,pmid,ti,ab,year,punchline_text,population,interventions,outcomes,population_mesh,interventions_mesh,outcomes_mesh,num_randomized,prob_low_rob,punchline_text,authors,journal,dois 0,32342496,Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial.,"AIM To assess the efficacy, safety, and tolerability of oromucosal nabiximols cannabinoid medicine as adjunct therapy for children with spasticity due to cerebral palsy/traumatic central nervous system injury with inadequate response to existing treatment. METHOD Overall, 72 patients (mean [SD] age 12y 4mo [3y 1mo], range 8-18y) were randomized at a ratio of 2:1 to receive nabiximols (n=47; 29 males, 18 females) or placebo (n=25; 15 males, 10 females) for 12 weeks (12 sprays/day max. based on clinical response/tolerability). The primary outcome was change from baseline in level of spasticity on a 0 to 10 Numerical Rating Scale (NRS), assessed by the primary caregiver at 12 weeks. Secondary outcomes included additional measures for spasticity, sleep quality, pain, health-related quality of life, comfort, depression, and safety. RESULTS There was no significant difference in the spasticity 0 to 10 NRS between nabiximols versus placebo groups after 12 weeks. No statistically significant differences were observed for any secondary endpoint. Adverse events were predominantly mild or moderate in severity; however, three cases of hallucinations were reported. INTERPRETATION Nabiximols was generally well tolerated; however, neuropsychiatric adverse events were observed. No significant reduction in spasticity with nabiximols treatment versus placebo was observed. WHAT THIS PAPER ADDS Oromucosal nabiximols is generally well tolerated by paediatric patients. However, three cases of hallucinations were observed, one of which involved auditory hallucinations and a suicide attempt. Oromucosal nabiximols versus placebo did not reduce cerebral palsy/central nervous system injury-related spasticity.",2020,There was no significant difference in the spasticity 0 to 10 NRS between nabiximols versus placebo groups after 12 weeks.,"['n=47; 29 males, 18 females) or', '72 patients (mean [SD] age 12y 4mo [3y 1mo], range 8-18y', 'paediatric patients', 'children with spasticity due to cerebral palsy/traumatic central nervous system injury', 'paediatric spasticity in cerebral palsy or traumatic brain injury']","['nabiximols cannabinoid medicine', 'nabiximols', 'oromucosal nabiximols cannabinoid medicine', 'placebo']","['spasticity 0', 'Adverse events', 'change from baseline in level of spasticity on a 0 to 10 Numerical Rating Scale (NRS', 'Efficacy and safety', 'spasticity', 'additional measures for spasticity, sleep quality, pain, health-related quality of life, comfort, depression, and safety', 'neuropsychiatric adverse events', 'cerebral palsy/central nervous system injury-related spasticity', 'efficacy, safety, and tolerability']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C1264238', 'cui_str': 'Injury of central nervous system'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}]","[{'cui': 'C2347556', 'cui_str': 'nabiximols'}, {'cui': 'C0006864', 'cui_str': 'cannabinoids'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1299004', 'cui_str': 'Oromucosal route'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C1264238', 'cui_str': 'Injury of central nervous system'}]",72.0,0.447635,There was no significant difference in the spasticity 0 to 10 NRS between nabiximols versus placebo groups after 12 weeks.,"[{'ForeName': 'Charlie', 'Initials': 'C', 'LastName': 'Fairhurst', 'Affiliation': ""Department of Paediatric Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Ram', 'Initials': 'R', 'LastName': 'Kumar', 'Affiliation': ""Department of Paediatric Neurology, Alder Hey Children's Hospital, Liverpool, UK.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Checketts', 'Affiliation': 'GW Research Ltd, Cambridge, UK.'}, {'ForeName': 'Bola', 'Initials': 'B', 'LastName': 'Tayo', 'Affiliation': 'GW Research Ltd, Cambridge, UK.'}, {'ForeName': 'Susie', 'Initials': 'S', 'LastName': 'Turner', 'Affiliation': ""Department of Paediatric Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.""}]",Developmental medicine and child neurology,['10.1111/dmcn.14548'] 1,32342846,Impact of Intermittent Mass Testing and Treatment on Incidence of Malaria Infection in a High Transmission Area of Western Kenya.,"Progress with malaria control in western Kenya has stagnated since 2007. Additional interventions to reduce the high burden of malaria in this region are urgently needed. We conducted a two-arm, community-based, cluster-randomized, controlled trial of active case detection and treatment of malaria infections in all residents mass testing and treatment (MTaT) of 10 village clusters (intervention clusters) for two consecutive years to measure differences in the incidence of clinical malaria disease and malaria infections compared with 20 control clusters where MTaT was not implemented. All residents of intervention clusters, irrespective of history of fever or other malaria-related symptoms, were tested three times per year before the peak malaria season using malaria rapid diagnostic tests. All positive cases were treated with dihydroartemisinin-piperaquine. The incidence of clinical malaria was measured through passive surveillance, whereas the cumulative incidence of malaria infection was measured using active surveillance in a cohort comprising randomly selected residents. The incidence of clinical malaria was 0.19 cases/person-year (p-y, 95% CI: 0.13-0.28) in the intervention arm and 0.24 cases/p-y (95% CI: 0.15-0.39) in the control arm (incidence rate ratio [IRR] 0.79, 95% CI: 0.61-1.02). The cumulative incidence of malaria infections was similar between the intervention (2.08 infections/p-y, 95% CI: 1.93-2.26) and control arms (2.19 infections/p-y, 95% CI: 2.02-2.37) with a crude IRR of 0.95 (95% CI: 0.87-1.04). Six rounds of MTaT over 2 years did not have a significant impact on the incidence of clinical malaria or the cumulative incidence of malaria infection in this area of high malaria transmission.",2020,"The cumulative incidence of malaria infections was similar between the intervention (2.08 infections/p-y, 95% CI: 1.93-2.26) and control arms (2.19 infections/p-y, 95% CI: 2.02-2.37) with a crude IRR of 0.95 (95% CI: 0.87-1.04).","['All residents of intervention clusters, irrespective of history of fever or other malaria-related symptoms', 'in a High Transmission Area of Western Kenya']",['dihydroartemisinin-piperaquine'],"['incidence of clinical malaria or the cumulative incidence of malaria infection', 'incidence rate ratio [IRR', 'Incidence of Malaria Infection', 'incidence of clinical malaria', 'cumulative incidence of malaria infection', 'cumulative incidence of malaria infections', 'incidence of clinical malaria disease and malaria infections']","[{'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0040722', 'cui_str': 'transmission'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}]","[{'cui': 'C0058108', 'cui_str': 'dihydroartemisinin'}, {'cui': 'C0071105', 'cui_str': 'piperaquine'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C4543807', 'cui_str': 'Clinical malaria'}, {'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0083017', 'cui_str': 'insulin receptor-related receptor'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",,0.204021,"The cumulative incidence of malaria infections was similar between the intervention (2.08 infections/p-y, 95% CI: 1.93-2.26) and control arms (2.19 infections/p-y, 95% CI: 2.02-2.37) with a crude IRR of 0.95 (95% CI: 0.87-1.04).","[{'ForeName': 'Meghna R', 'Initials': 'MR', 'LastName': 'Desai', 'Affiliation': 'Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.'}, {'ForeName': 'Aaron M', 'Initials': 'AM', 'LastName': 'Samuels', 'Affiliation': 'Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.'}, {'ForeName': 'Wycliffe', 'Initials': 'W', 'LastName': 'Odongo', 'Affiliation': 'Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Williamson', 'Affiliation': 'Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.'}, {'ForeName': 'Nobert Awino', 'Initials': 'NA', 'LastName': 'Odero', 'Affiliation': 'Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.'}, {'ForeName': 'Kephas', 'Initials': 'K', 'LastName': 'Otieno', 'Affiliation': 'Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.'}, {'ForeName': 'Ya Ping', 'Initials': 'YP', 'LastName': 'Shi', 'Affiliation': 'Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.'}, {'ForeName': 'Stephen Patrick', 'Initials': 'SP', 'LastName': 'Kachur', 'Affiliation': 'Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.'}, {'ForeName': 'Mary J', 'Initials': 'MJ', 'LastName': 'Hamel', 'Affiliation': 'Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Kariuki', 'Affiliation': 'Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.'}, {'ForeName': 'Kim A', 'Initials': 'KA', 'LastName': 'Lindblade', 'Affiliation': 'Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.19-0735'] 2,32342848,Safety and Immunogenicity of an AS03 B -Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study.,"Dengue disease and its causative agents, the dengue viruses (DENV-1-4), cause high morbidity in tropical and subtropical regions. We evaluated three dosing regimens of the investigational tetravalent AS03 B -adjuvanted dengue-purified inactivated vaccine (DPIV+AS03 B ). In this phase 1/2, observer-blind, placebo-controlled study (NCT02421367), 140 healthy adults were randomized 1:1:2 to receive DPIV+AS03 B according to the following regimens: 0-1 month (M), 0-1-6 M, or 0-3 M. Participants received DPIV+AS03 B or placebo at M0, M1, M3, and M6 according to their dosing schedule. Primary objectives were 1) to evaluate the safety of DPIV+AS03 B for 28 days (D) after each dose; 2) to demonstrate the added value of a booster dose (0-1-6 M versus 0-1 M) based on neutralizing antibody titers to each DENV type (DENV-1-4) at 28 D after the last dose; and, if this objective was met, 3) to demonstrate the benefit of a longer interval between the first and second doses (0-1 M versus 0-3 M). Adverse events (AEs) within 7 D after vaccination tended to be more frequent after DPIV+AS03 B doses than placebo; the number of grade 3 AEs was low (≤ 4.5% after DPIV+AS03 B ; ≤ 2.9% after placebo), with no obvious differences across groups. Within 28 D following each dose, the frequency of unsolicited AEs after DPIV+AS03 B appeared higher for three-dose (0-1-6 M) than two-dose (0-1 M and 0-3 M) regimens. No serious AEs were considered related to vaccination, and no potential immune-mediated diseases were reported during the study. All three schedules were well tolerated. Both primary immunogenicity objectives were demonstrated. The 0-3 M and 0-1-6 M regimens were more immunogenic than the 0-1 M regimen.",2020,"Adverse events (AEs) within 7 D after vaccination tended to be more frequent after DPIV + AS03 B doses than placebo; the number of grade 3 AEs was low (≤ 4.5% after DPIV + AS03 B ; ≤ 2.9% after placebo), with no obvious differences across groups.","['140 healthy adults', 'Healthy U.S. Adults']","['adjuvanted dengue-purified inactivated vaccine (DPIV + AS03 B ', 'DPIV + AS03', 'investigational tetravalent AS03 B', 'AS03 B -Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine', 'DPIV + AS03 B or placebo at M0, M1, M3, and M6 according to their dosing schedule', 'placebo']","['safety of DPIV + AS03 B for 28 days (D', 'Adverse events (AEs', 'tolerated', 'Safety and Immunogenicity']","[{'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0011311', 'cui_str': 'Dengue'}, {'cui': 'C0042212', 'cui_str': 'Vaccines, Killed'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0011315', 'cui_str': 'Dengue virus'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",140.0,0.149575,"Adverse events (AEs) within 7 D after vaccination tended to be more frequent after DPIV + AS03 B doses than placebo; the number of grade 3 AEs was low (≤ 4.5% after DPIV + AS03 B ; ≤ 2.9% after placebo), with no obvious differences across groups.","[{'ForeName': 'Leyi', 'Initials': 'L', 'LastName': 'Lin', 'Affiliation': 'Walter Reed Army Institute of Research, Silver Spring, Maryland.'}, {'ForeName': 'Kirsten E', 'Initials': 'KE', 'LastName': 'Lyke', 'Affiliation': 'Center for Vaccine Development and Global Health (CVD), University of Maryland, Baltimore, Maryland.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Koren', 'Affiliation': 'Walter Reed Army Institute of Research, Silver Spring, Maryland.'}, {'ForeName': 'Richard G', 'Initials': 'RG', 'LastName': 'Jarman', 'Affiliation': 'Walter Reed Army Institute of Research, Silver Spring, Maryland.'}, {'ForeName': 'Kenneth H', 'Initials': 'KH', 'LastName': 'Eckels', 'Affiliation': 'Walter Reed Army Institute of Research, Silver Spring, Maryland.'}, {'ForeName': 'Edith', 'Initials': 'E', 'LastName': 'Lepine', 'Affiliation': 'GSK, Rockville, Maryland.'}, {'ForeName': 'Monica A', 'Initials': 'MA', 'LastName': 'McArthur', 'Affiliation': 'Center for Vaccine Development and Global Health (CVD), University of Maryland, Baltimore, Maryland.'}, {'ForeName': 'Jeffrey R', 'Initials': 'JR', 'LastName': 'Currier', 'Affiliation': 'Walter Reed Army Institute of Research, Silver Spring, Maryland.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Friberg', 'Affiliation': 'Walter Reed Army Institute of Research, Silver Spring, Maryland.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Moris', 'Affiliation': 'GSK, Rixensart, Belgium.'}, {'ForeName': 'Paul B', 'Initials': 'PB', 'LastName': 'Keiser', 'Affiliation': 'Walter Reed Army Institute of Research, Silver Spring, Maryland.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'De La Barrera', 'Affiliation': 'Walter Reed Army Institute of Research, Silver Spring, Maryland.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Vaughn', 'Affiliation': 'GSK, Rockville, Maryland.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Paris', 'Affiliation': 'GSK, Rockville, Maryland.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Thomas', 'Affiliation': 'Walter Reed Army Institute of Research, Silver Spring, Maryland.'}, {'ForeName': 'Alexander C', 'Initials': 'AC', 'LastName': 'Schmidt', 'Affiliation': 'GSK, Rockville, Maryland.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.19-0738'] 3,32338931,Theory-specific patient change processes and mechanisms in different cognitive therapies for depression.,"OBJECTIVE This study aimed to identify differential patient change processes and mechanisms associated with long-term outcome in exposure-based cognitive therapy (EBCT) and cognitive-behavioral therapy (CBT) for depression. METHOD We drew on a randomized controlled trial in which 149 patients were randomly assigned to either EBCT or CBT, with the treatments showing comparable efficacy at 12-month follow-up (grosse Holtforth et al., 2019). Based on Doss's (2004) 4-step model of psychotherapy change and using sequential multilevel structural equation models, we tested putative theory-based change processes and mechanisms for both treatments. Specifically, we examined emotional processing and cognitive restructuring during treatment as hypothesized change processes of EBCT and CBT, respectively. Furthermore, as potential change mechanisms during follow-up, we examined theory-relevant mechanisms for each treatment, preselected via multilevel models. RESULTS Although the full serial mediational pathways were not supported, EBCT fostered greater during-treatment increases in emotional processing and higher self-efficacy during follow-up than CBT, both of which associated with better long-term depression outcome. Unexpectedly, cognitive restructuring change did not differ between EBCT and CBT. Across both CBT and EBCT, greater during-treatment increases in cognitive restructuring related to lower cognitive-behavioral avoidance and greater self-efficacy across follow-up, which associated with lower long-term depression. CONCLUSIONS Results suggest that therapists might improve long-term depression outcome by fostering both emotional processing (via emotion-focused techniques as included in EBCT) and cognitive restructuring (by using general CBT techniques included in both treatments), which operate either directly or through varied treatment-common mechanisms (e.g., greater self-efficacy and reduced cognitive-behavioral avoidance). (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"Although the full serial mediational pathways were not supported, EBCT fostered greater during-treatment increases in emotional processing and higher self-efficacy during follow-up than CBT, both of which associated with better long-term depression outcome.",['149 patients'],"['EBCT or CBT', 'exposure-based cognitive therapy (EBCT) and cognitive-behavioral therapy (CBT']","['cognitive-behavioral avoidance and greater self-efficacy', 'cognitive restructuring change', 'emotional processing and higher self-efficacy']","[{'cui': 'C5191071', 'cui_str': '149'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0150173', 'cui_str': 'Cognitive restructuring'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0205250', 'cui_str': 'High'}]",149.0,0.0333601,"Although the full serial mediational pathways were not supported, EBCT fostered greater during-treatment increases in emotional processing and higher self-efficacy during follow-up than CBT, both of which associated with better long-term depression outcome.","[{'ForeName': 'Juan Martín', 'Initials': 'JM', 'LastName': 'Gómez Penedo', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, University of Bern.'}, {'ForeName': 'Alice E', 'Initials': 'AE', 'LastName': 'Coyne', 'Affiliation': 'Department of Psychological and Brain Sciences, University of Massachusetts Amherst.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Constantino', 'Affiliation': 'Department of Psychological and Brain Sciences, University of Massachusetts Amherst.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Krieger', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, University of Bern.'}, {'ForeName': 'Adele M', 'Initials': 'AM', 'LastName': 'Hayes', 'Affiliation': 'Department of Psychological and Brain Sciences, University of Delaware.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Grosse Holtforth', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, University of Bern.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000502'] 4,32339169,Capacitive-resistive radiofrequency therapy to treat postpartum perineal pain: A randomized study.,"OBJECTIVE To evaluate the reduction of perineal pain after vaginal deliveries by capacitive resistive radiofrequency therapy (RF). METHODS We conducted a double-blind randomized study in University Hospital Centre in France. We included women presenting either perineal tears or an episiotomy after vaginal delivery (instrumental assisted or not). The participants were randomly assigned to RF or not at day 1 and day 2 postpartum. The primary outcome was pain evaluated as visual analog scale (VAS) score >4 at rest on day 2 after the treatment. Secondary outcomes included discomfort and pain while walking and seating two days after treatment, type of pain two days after treatment and analgesics intake two days after treatment, sexual intercourse retake and painful of intercourse were also assessed by phone call 30 days after delivery. We performed univariate analysis and multivariable regressions adjusting on the value of the outcome at baseline to improve precision of the estimated intervention effect. RESULTS Between June 1, 2017 and October 8, 2017, the RF group included 29 women compared with 31 women in the group without RF. There was no significant difference on VAS >4 between the two groups (13.8% vs. 9.7% p = 0.69; difference = 4.1%, 95%CI -12.2%- 20.4%); consumption of paracetamol was lower in the RF group (978.3 mg (sd = 804.5) vs 1703.7 mg (sd = 1381.6), p = 0.035; difference = -725.3 mg, 95%CI -1359.6 - -91.3). Multivariate analysis showed no association between RF and pain. Nevertheless, we found an association between RF and discomfort while walking (adjusted OR 0.24, 95% CI 0.07-0.90; p = 0.03). CONCLUSION VAS>4 at day 2 was not different in the experimental and the control groups but RF was associated with less perineal discomfort while walking and lower consumption of paracetamol after delivery. CLINICAL TRIAL REGISTRATIONS The study was registered in the Clinical Government trial (https://clinicaltrials.gov/ct2/show/NCT03172286?term=bretelle&rank=2) under the number NCT03172286.",2020,"VAS>4 at day 2 was not different in the experimental and the control groups but RF was associated with less perineal discomfort while walking and lower consumption of paracetamol after delivery. ","['University Hospital Centre in France', 'Between June 1, 2017 and October 8, 2017', 'women presenting either perineal tears or an episiotomy after vaginal delivery (instrumental assisted or not', 'postpartum perineal pain']","['capacitive resistive radiofrequency therapy (RF', 'Capacitive-resistive radiofrequency therapy']","['perineal discomfort while walking and lower consumption of paracetamol', 'VAS', 'VAS>4', 'discomfort and pain while walking and seating two days after treatment, type of pain two days after treatment and analgesics intake two days after treatment, sexual intercourse retake and painful of intercourse', 'RF and pain', 'pain evaluated as visual analog scale (VAS) score', 'consumption of paracetamol', 'perineal pain']","[{'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0240713', 'cui_str': 'Laceration of perineum'}, {'cui': 'C0014586', 'cui_str': 'Episiotomy'}, {'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0235641', 'cui_str': 'Pain in female perineum'}]","[{'cui': 'C4704842', 'cui_str': 'Radio-Frequency Therapy'}]","[{'cui': 'C0031066', 'cui_str': 'Perineal'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0277814', 'cui_str': 'Sitting position'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C4704842', 'cui_str': 'Radio-Frequency Therapy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0235641', 'cui_str': 'Pain in female perineum'}]",,0.29121,"VAS>4 at day 2 was not different in the experimental and the control groups but RF was associated with less perineal discomfort while walking and lower consumption of paracetamol after delivery. ","[{'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Bretelle', 'Affiliation': 'Department of Gynecology and Obstetrics, AP-HM, Assistance Publique-Hôpitaux de Marseille, Marseille, France.'}, {'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Fabre', 'Affiliation': 'Midwife school, Faculty of medical and paramedical sciences, Aix-Marseille University, Marseille, France.'}, {'ForeName': 'Marine', 'Initials': 'M', 'LastName': 'Golka', 'Affiliation': 'Midwife school, Faculty of medical and paramedical sciences, Aix-Marseille University, Marseille, France.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Pauly', 'Affiliation': 'Medical Evaluation, Department of Public Health, Assistance Publique-Hôpitaux de Marseille, AMU, Aix- Marseille Université, Marseille, France.'}, {'ForeName': 'Brimbelle', 'Initials': 'B', 'LastName': 'Roth', 'Affiliation': 'Medical Evaluation, Department of Public Health, Assistance Publique-Hôpitaux de Marseille, AMU, Aix- Marseille Université, Marseille, France.'}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Bechadergue', 'Affiliation': 'Department of Gynecology and Obstetrics, AP-HM, Assistance Publique-Hôpitaux de Marseille, Marseille, France.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Blanc', 'Affiliation': 'Department of Gynecology and Obstetrics, AP-HM, Assistance Publique-Hôpitaux de Marseille, Marseille, France.'}]",PloS one,['10.1371/journal.pone.0231869'] 5,32345685,A Triadic Intervention for Adolescent Sexual Health: A Randomized Clinical Trial.,"OBJECTIVES In this study, we evaluate the efficacy of Families Talking Together (FTT), a triadic intervention to reduce adolescent sexual risk behavior. METHODS Adolescents aged 11 to 14 and their female caregivers were recruited from a pediatric clinic; 900 families were enrolled; 84 declined. Families were randomly assigned to FTT or 1 of 2 control conditions. The FTT triadic intervention consisted of a 45-minute face-to-face session for mothers, health care provider endorsement of intervention content, printed materials for families, and a booster call for mothers. The primary outcomes were ever having had vaginal intercourse, sexual debut within the past 12 months, and condom use at last sexual intercourse. Assessments occurred at baseline, 3 months post baseline, and 12 months post baseline. RESULTS Of enrolled families, 73.4% identified as Hispanic, 20.4% as African American, and 6.2% as mixed race. Mean maternal age was 38.8 years, and mean adolescent grade was seventh grade. At the 12-month follow-up, 5.2% of adolescents in the experimental group reported having had sexual intercourse, compared with 18% of adolescents in the control groups ( P < .05). In the experimental group, 4.7% of adolescents reported sexual debut within the past 12 months, compared with 14.7% of adolescents in the control group ( P < .05). In the experimental group, 74.2% of sexually active adolescents indicated using a condom at last sexual intercourse, compared with 49.1% of adolescents in the control group ( P < .05). CONCLUSIONS This research suggests that the FTT triadic intervention is efficacious in delaying sexual debut and reducing sexual risk behavior among adolescents.",2020,This research suggests that the FTT triadic intervention is efficacious in delaying sexual debut and reducing sexual risk behavior among adolescents.,"['Mean maternal age was 38.8 years, and mean adolescent grade was seventh grade', 'Adolescent Sexual Health', 'Of enrolled families, 73.4% identified as Hispanic, 20.4% as African American, and 6.2% as mixed race', 'Adolescents aged 11 to 14 and their female caregivers were recruited from a pediatric clinic; 900 families were enrolled; 84 declined', 'adolescents']","['FTT triadic intervention', 'FTT', 'triadic intervention', 'Triadic Intervention', 'Families Talking Together']","['sexual intercourse', 'sexual debut', 'ever having had vaginal intercourse, sexual debut within the past 12 months, and condom use at last sexual intercourse', 'sexual risk behavior']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0024915', 'cui_str': 'Maternal age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0205441', 'cui_str': 'Seventh'}, {'cui': 'C2362326', 'cui_str': 'Sexual Health'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C4517820', 'cui_str': '6.2'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C3839701', 'cui_str': 'Pediatric clinic'}, {'cui': 'C4517900', 'cui_str': '900'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0086931', 'cui_str': 'Risk Behavior'}]",900.0,0.0590979,This research suggests that the FTT triadic intervention is efficacious in delaying sexual debut and reducing sexual risk behavior among adolescents.,"[{'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Guilamo-Ramos', 'Affiliation': 'Center for Latino Adolescent and Family Health, New York University, New York, New York; vincent.ramos@nyu.edu.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Benzekri', 'Affiliation': 'Center for Latino Adolescent and Family Health, New York University, New York, New York.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Thimm-Kaiser', 'Affiliation': 'Center for Latino Adolescent and Family Health, New York University, New York, New York.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Dittus', 'Affiliation': 'Division of Sexually Transmitted Disease Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.'}, {'ForeName': 'Yumary', 'Initials': 'Y', 'LastName': 'Ruiz', 'Affiliation': 'Center for Latino Adolescent and Family Health, New York University, New York, New York.'}, {'ForeName': 'Charles M', 'Initials': 'CM', 'LastName': 'Cleland', 'Affiliation': 'New York University Langone Health, New York, New York; and.'}, {'ForeName': 'Wanda', 'Initials': 'W', 'LastName': 'McCoy', 'Affiliation': 'Morris Heights Health Center, Bronx, New York.'}]",Pediatrics,['10.1542/peds.2019-2808'] 6,32346886,Predictors of genetic testing uptake in newly diagnosed breast cancer patients.,"BACKGROUND AND OBJECTIVES Many newly diagnosed breast cancer patients do not receive genetic counseling and testing at the time of diagnosis. We examined predictors of genetic testing (GT) in this population. METHODS Within a randomized controlled trial of proactive rapid genetic counseling and testing vs usual care, patients completed a baseline survey within 6 weeks of breast cancer diagnosis but before a definitive survey. We conducted a multinomial logistic regression to identify predictors of GT timing/uptake. RESULTS Having discussed GT with a surgeon was a dominant predictor (χ 2 (2, N = 320) = 70.13; P < .0001). Among those who discussed GT with a surgeon, patients who had made a final surgery decision were less likely to receive GT before surgery compared with postsurgically (OR [odds ratio] = 0.24; 95% confidence interval [CI] = 0.12-0.49) or no testing (OR = 0.28; 95% CI = 0.14-0.56). Older patients (OR = 0.95; 95% CI = 0.91-0.99) and participants enrolled in New York/New Jersey (OR = 0.22; 95% CI = 0.07-0.72) were less likely to be tested compared with receiving results before surgery. Those with higher perceived risk (OR = 1.02; 95% CI = 1.00-1.03) were more likely to receive results before surgery than to not be tested. CONCLUSIONS This study highlights the role of patient-physician communication about GT as well as patient-level factors that predict presurgical GT.",2020,"Those with higher perceived risk (OR = 1.02; 95% CI = 1.00-1.03) were more likely to receive results before surgery than to not be tested. ",['newly diagnosed breast cancer patients'],"['proactive rapid genetic counseling and testing vs usual care', 'genetic testing (GT']",['final surgery decision'],"[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0017382', 'cui_str': 'Genetic counseling'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0679560', 'cui_str': 'Genetic test'}]","[{'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",,0.139548,"Those with higher perceived risk (OR = 1.02; 95% CI = 1.00-1.03) were more likely to receive results before surgery than to not be tested. ","[{'ForeName': 'Mary K', 'Initials': 'MK', 'LastName': 'Ladd', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Beth N', 'Initials': 'BN', 'LastName': 'Peshkin', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Claudine', 'Initials': 'C', 'LastName': 'Isaacs', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Gillian', 'Initials': 'G', 'LastName': 'Hooker', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Shawna', 'Initials': 'S', 'LastName': 'Willey', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Heiddis', 'Initials': 'H', 'LastName': 'Valdimarsdottir', 'Affiliation': 'Department of Population Health Science and Policy, Center for Behavioral Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Tiffani', 'Initials': 'T', 'LastName': 'DeMarco', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': ""O'Neill"", 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Savannah', 'Initials': 'S', 'LastName': 'Binion', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'Marc D', 'Initials': 'MD', 'LastName': 'Schwartz', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of surgical oncology,['10.1002/jso.25956'] 7,32346896,Effects of virtual reality on moods in community older adults. A multicenter randomized controlled trial.,"INTRODUCTION Virtual reality (VR) technology is a potential method to use in cognitive intervention, but the use of VR in cognitive stimulation intervention for older adults has not been investigated. Therefore, the aim of this study was to investigate the mood change of older adults after participating in the VR cognitive stimulation activity. METHODS This is a multicenter randomized controlled, cross-over trial. The intervention was a VR cognitive stimulation activity, and the control was a paper-and-pencil activity. The participants were older adults with age over 60 and recruited in the elderly community centers. The Positive and Negative Affect Score (PANAS) was used to measure mood change. Mean difference (MD) with 95% confidence interval (95% CI) was calculated. The Simulator sickness questionnaire was used to measure adverse events. RESULTS A total of 236 participants from 19 community centers were recruited. After the VR activity, the participants had a significant increase in total PANAS positive affect score (MD = 2.09, 95% CI = 0.69 to 3.49), and a significant reduction in total negative affect score (MD = -1.99, 95% CI = -2.55 to -1.43). The reduction in negative affect score was significantly larger in VR activity than paper-and-pencil activity (MD = -0.48, 95% CI = -0.98 to 0.00). Besides, only three participants reported severe advance events after VR activity. CONCLUSIONS The use of VR technology is well accepted by older adults. Therefore, the use of VR technology through smartphone and a mobile app can be a potential method for future cognitive training interventions.",2020,"The reduction in negative affect score was significantly larger in VR activity than paper-and-pencil activity (MD = -0.48, 95% CI = -0.98 to 0.00).","['older adults', 'participants were older adults with age over 60 and recruited in the elderly community centres', 'Community Older Adults', 'older adults after participating in the VR cognitive stimulation activity', '236 participants from 19 community centres were recruited']","['Virtual-reality (VR) technology', 'Virtual Reality', 'VR technology']","['total PANAS positive affect score', 'Mean difference (MD', 'severe advance events', 'total negative affect score', 'VR activity']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0150174', 'cui_str': 'Cognitive stimulation'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0039421', 'cui_str': 'Technology'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",236.0,0.0575634,"The reduction in negative affect score was significantly larger in VR activity than paper-and-pencil activity (MD = -0.48, 95% CI = -0.98 to 0.00).","[{'ForeName': 'Joyce Y C', 'Initials': 'JYC', 'LastName': 'Chan', 'Affiliation': 'Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Tak Kit', 'Initials': 'TK', 'LastName': 'Chan', 'Affiliation': 'Stanley Ho Big Data Decision Analytics Research Centre, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Michael P F', 'Initials': 'MPF', 'LastName': 'Wong', 'Affiliation': 'Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Ruby S M', 'Initials': 'RSM', 'LastName': 'Cheung', 'Affiliation': 'Stanley Ho Big Data Decision Analytics Research Centre, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Karen K L', 'Initials': 'KKL', 'LastName': 'Yiu', 'Affiliation': 'Stanley Ho Big Data Decision Analytics Research Centre, The Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Kelvin K F', 'Initials': 'KKF', 'LastName': 'Tsoi', 'Affiliation': 'Stanley Ho Big Data Decision Analytics Research Centre, The Chinese University of Hong Kong, Shatin, Hong Kong.'}]",International journal of geriatric psychiatry,['10.1002/gps.5314'] 8,32347799,The Effect of Shame on Patients With Social Anxiety Disorder in Internet-Based Cognitive Behavioral Therapy: Randomized Controlled Trial.,"BACKGROUND Prior research has demonstrated the efficacy of internet-based cognitive behavioral therapy (ICBT) for social anxiety disorder (SAD). However, it is unclear how shame influences the efficacy of this treatment. OBJECTIVE This study aimed to investigate the role shame played in the ICBT treatment process for participants with SAD. METHODS A total of 104 Chinese participants (73 females; age: mean 24.92, SD 4.59 years) were randomly assigned to self-help ICBT, guided ICBT, or wait list control groups. For the guided ICBT group, half of the participants were assigned to the group at a time due to resource constraints. This led to a time difference among the three groups. Participants were assessed before and immediately after the intervention using the Social Interaction Anxiety Scale (SIAS), Social Phobia Scale (SPS), and Experience of Shame Scale (ESS). RESULTS Participants' social anxiety symptoms (self-help: differences between pre- and posttreatment SIAS=-12.71; Cohen d=1.01; 95% CI 9.08 to 16.32; P<.001 and differences between pre- and posttreatment SPS=11.13; Cohen d=0.89; 95% CI 6.98 to 15.28; P<.001; guided: SIAS=19.45; Cohen d=1.20; 95% CI 14.67 to 24.24; P<.001 and SPS=13.45; Cohen d=0.96; 95% CI 8.26 to 18.64; P<.001) and shame proneness (self-help: differences between pre- and posttreatment ESS=7.34; Cohen d=0.75; 95% CI 3.99 to 10.69; P<.001 and guided: differences between pre- and posttreatment ESS=9.97; Cohen d=0.88; 95% CI 5.36 to 14.57; P<.001) in both the self-help and guided ICBT groups reduced significantly after treatment, with no significant differences between the two intervention groups. Across all the ICBT sessions, the only significant predictors of reductions in shame proneness were the average number of words participants wrote in the exposure module (β=.222; SE 0.175; t 96 =2.317; P=.02) and gender (β=-.33; SE 0.002; t 77 =-3.13; P=.002). We also found a mediation effect, wherein reductions in shame fully mediated the relationship between the average number of words participants wrote in the exposure module and reductions in social anxiety symptoms (SIAS: β=-.0049; SE 0.0016; 95% CI -0.0085 to -0.0019 and SPS: β=-.0039; SE 0.0015; 95% CI -0.0075 to -0.0012). CONCLUSIONS The findings of this study suggest that participants' engagement in the exposure module in ICBT alleviates social anxiety symptoms by reducing the levels of shame proneness. Our study provides a new perspective for understanding the role of shame in the treatment of social anxiety. The possible mechanisms of the mediation effect and clinical implications are discussed. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR1900021952; http://www.chictr.org.cn/showproj.aspx?proj=36977.",2020,"Participants were assessed before and immediately after the intervention using Social Interaction Anxiety Scale (SIAS), Social Phobia Scale (SPS), and Experience of Shame Scale (ESS). ","['104 Chinese participants (73 females; age: mean 24.92 years, SD 4.59', 'Patients With Social Anxiety Disorder in Internet-Based', 'participants with SAD.\nMETHODS']","['ICBT', 'internet-based cognitive behavioral therapy (ICBT', 'Cognitive Behavioral Therapy']","['social anxiety symptoms', 'shame proneness', 'Social Interaction Anxiety Scale (SIAS), Social Phobia Scale (SPS), and Experience of Shame Scale (ESS', 'ICBT alleviates social anxiety symptoms']","[{'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031572', 'cui_str': 'Social phobia'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0036938', 'cui_str': 'Shame'}, {'cui': 'C0037420', 'cui_str': 'Interaction with others'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0031572', 'cui_str': 'Social phobia'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]",104.0,0.0369145,"Participants were assessed before and immediately after the intervention using Social Interaction Anxiety Scale (SIAS), Social Phobia Scale (SPS), and Experience of Shame Scale (ESS). ","[{'ForeName': 'Haoyu', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'School of Psychological and Cognitive Sciences, Peking University, Beijing, China.'}, {'ForeName': 'Qingxue', 'Initials': 'Q', 'LastName': 'Zhao', 'Affiliation': 'School of Psychological and Cognitive Sciences, Peking University, Beijing, China.'}, {'ForeName': 'Wenting', 'Initials': 'W', 'LastName': 'Mu', 'Affiliation': 'Center for the Treatment and Study of Anxiety, University of Pennsylvania, Pennsylvania, PA, United States.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Rodriguez', 'Affiliation': 'Department of Psychology, Pitzer College, California, CA, United States.'}, {'ForeName': 'Mingyi', 'Initials': 'M', 'LastName': 'Qian', 'Affiliation': 'School of Psychological and Cognitive Sciences, Peking University, Beijing, China.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Berger', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, University of Bern, Bern, Switzerland.'}]",JMIR mental health,['10.2196/15797'] 9,32347208,"Yoga improves balance, mobility, and perceived occupational performance in adults with chronic brain injury: A preliminary investigation.","BACKGROUND AND PURPOSE This was a preliminary investigation to investigate potential benefits of group yoga, as past work has indicated that one-on-one yoga can improve functional deficits in adults with brain injury. MATERIALS AND METHODS Participants served as their own controls. Nine participants with chronic brain injury were recruited, and seven (four female) completed the study. Performance measures of balance and mobility and self-reported measures of balance confidence, pain, and occupational performance and satisfaction were used. Data were collected 3 times: baseline (study onset), pre-yoga (after an 8-week no-contact period), and post-yoga (after 8 weeks of yoga). Group yoga was led by a yoga instructor/occupational therapist, and sessions lasted 1 h and occurred twice a week. RESULTS No participants withdrew due to adverse effects from yoga. There were no significant changes between baseline and pre-yoga. Significant improvement was observed post-yoga in balance (p = 0.05), mobility (p = 0.03), and self-reported occupational performance (p = 0.04). CONCLUSION We observed significant improvements in balance, mobility, and self-reported occupational performance in adults with chronic brain injury.",2020,"Significant improvement was observed post-yoga in balance (p = 0.05), mobility (p = 0.03), and self-reported occupational performance (p = 0.04). ","['Nine participants with chronic brain injury were recruited, and seven (four female) completed the study', 'adults with brain injury', 'Participants served as their own controls', 'adults with chronic brain injury']",[],"['self-reported occupational performance', 'balance confidence, pain, and occupational performance and satisfaction', 'balance, mobility, and perceived occupational performance', 'functional deficits', 'balance, mobility, and self-reported occupational performance', 'mobility']","[{'cui': 'C0751813', 'cui_str': 'Chronic Brain Injury'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],"[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0521127', 'cui_str': 'Occupational'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]",9.0,0.0225685,"Significant improvement was observed post-yoga in balance (p = 0.05), mobility (p = 0.03), and self-reported occupational performance (p = 0.04). ","[{'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Stephens', 'Affiliation': 'Colorado State University, Department of Occupational Therapy, USA. Electronic address: jaclyn.stephens@colostate.edu.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Van Puymbroeck', 'Affiliation': 'Clemson University, Recreational Therapy Program, USA.'}, {'ForeName': 'P L', 'Initials': 'PL', 'LastName': 'Sample', 'Affiliation': 'Colorado State University, Department of Occupational Therapy, USA. Electronic address: pat.sample@colostate.edu.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Schmid', 'Affiliation': 'Colorado State University, Department of Occupational Therapy, USA. Electronic address: arlene.schmid@colostate.edu.'}]",Complementary therapies in clinical practice,['10.1016/j.ctcp.2020.101172'] 10,32347209,"Evaluation of the effectiveness of self-healing training on self-compassion, body image concern, and recovery process in patients with skin cancer.","BACKGROUND AND PURPOSE The present study aimed to investigate the effect of self-healing training on self-compassion, body image concern, and recovery process in patients with skin cancer. MATERIALS AND METHODS The sample consisted of 34 volunteers who were purposefully selected and then randomly divided into experimental (n = 16) and control (n = 18) groups. The research instrument included the Self-Compassion Scale and Body Image Concern Inventory. The self-healing training intervention was then performed on the experimental group for twelve 90-min sessions. Finally, both groups underwent the post-test. Follow-up was performed two and four months after the post-test. RESULTS Self-healing training significantly increased self-compassion, including self-kindness, self-judgment, and sense of common humanity (p < 0.01), and decreased the level of body image concern, isolation, and over-identification (p < 0.05). CONCLUSION The self-healing is an appropriate intervention method to increase self-compassion and reduce body image concern and thus accelerate the process of skin cancer recovery.",2020,"RESULTS Self-healing training significantly increased self-compassion, including self-kindness, self-judgment, and sense of common humanity (p < 0.01), and decreased the level of body image concern, isolation, and over-identification (p < 0.05). ","['patients with skin cancer', '34 volunteers who were purposefully selected']",['self-healing training'],"['level of body image concern, isolation, and over-identification', 'self-compassion, including self-kindness, self-judgment, and sense of common humanity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007114', 'cui_str': 'Malignant neoplasm of skin'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0885003', 'cui_str': 'Xiakucao'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C0037421', 'cui_str': 'Social isolation'}, {'cui': 'C0020792', 'cui_str': 'Identification - mental defense mechanism'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0022423', 'cui_str': 'Judgement'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0020157', 'cui_str': 'Humanities'}]",34.0,0.00947867,"RESULTS Self-healing training significantly increased self-compassion, including self-kindness, self-judgment, and sense of common humanity (p < 0.01), and decreased the level of body image concern, isolation, and over-identification (p < 0.05). ","[{'ForeName': 'Zohreh', 'Initials': 'Z', 'LastName': 'Latifi', 'Affiliation': 'Department of Psychology, Payame Noor University, PO BOX 19395-4697, Tehran, Iran. Electronic address: latifizh@gmail.com.'}, {'ForeName': 'Mozhgan', 'Initials': 'M', 'LastName': 'Soltani', 'Affiliation': 'Department of Psychology, Payame Noor University, PO BOX 19395-4697, Tehran, Iran.'}, {'ForeName': 'Shokoufeh', 'Initials': 'S', 'LastName': 'Mousavi', 'Affiliation': 'Department of Psychology, Payame Noor University, PO BOX 19395-4697, Tehran, Iran.'}]",Complementary therapies in clinical practice,['10.1016/j.ctcp.2020.101180'] 11,32346804,Feasibility of using a computer-assisted working memory training program for healthy older women.,"Interventions for age-associated cognitive impairment are of increasing significance as populations age. Using N-back and memory strategy enhancement, the present study aimed to explore the feasibility of using, and outcomes of a working memory (WM) training program on visuospatial and verbal WM in older female adults. Older women from two comparable local health centers who scored 26 and higher on Mini-Mental State Examination were invited to participate. Women at one center (experimental group) received three sessions on memory enhancement techniques and a computerized training program with N-back. Women at the other center (control group) received three sessions on memory and aging and training on using various features of cellphones. All participants completed the Corsi Block Task and Digit Span Task at pre- and post-training. The experimental group showed significant improvements in their visuospatial and verbal WM compared to the control group. These findings support the brain's plasticity in the elderly. WM training for improving cognitive performance in older adults has potential and should be further investigated.",2020,The experimental group showed significant improvements in their visuospatial and verbal WM compared to the control group.,"['Older women from two comparable local health centers who scored 26 and higher on Mini-Mental State Examination were invited to participate', 'healthy older women', 'older adults', 'older female adults']","['working memory (WM) training program', 'computer-assisted working memory training program', 'three sessions on memory enhancement techniques and a computerized training program with N-back', 'WM training', 'three sessions on memory and aging and training']","['visuospatial and verbal WM', 'cognitive performance', 'Corsi Block Task and Digit Span Task']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}]",,0.0158536,The experimental group showed significant improvements in their visuospatial and verbal WM compared to the control group.,"[{'ForeName': 'Fahimeh', 'Initials': 'F', 'LastName': 'Ghavidel', 'Affiliation': 'Department of Psychology, Faculty of Education and Psychology, Ferdowsi University of Mashhad, 9177948991, Mashhad, Iran.'}, {'ForeName': 'Javad Salehi', 'Initials': 'JS', 'LastName': 'Fadardi', 'Affiliation': 'Department of Psychology, Faculty of Education and Psychology, Ferdowsi University of Mashhad, 9177948991, Mashhad, Iran. j.s.fadardi@um.ac.ir.'}, {'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'Gatto', 'Affiliation': 'Claremont Graduate University, Claremont, CA, USA.'}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Sedaghat', 'Affiliation': 'Sedaghat Cognitive Neuroscience Clinic, Mashhad, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Tabibi', 'Affiliation': 'Department of Psychology, Faculty of Education and Psychology, Ferdowsi University of Mashhad, 9177948991, Mashhad, Iran.'}]",Cognitive processing,['10.1007/s10339-020-00975-7'] 12,31270136,Automatic Measurement of Kidney and Liver Volumes from MR Images of Patients Affected by Autosomal Dominant Polycystic Kidney Disease.,"BACKGROUND The formation and growth of cysts in kidneys, and often liver, in autosomal dominant polycystic kidney disease (ADPKD) cause progressive increases in total kidney volume (TKV) and liver volume (TLV). Laborious and time-consuming manual tracing of kidneys and liver is the current gold standard. We developed a fully automated segmentation method for TKV and TLV measurement that uses a deep learning network optimized to perform semantic segmentation of kidneys and liver. METHODS We used 80% of a set of 440 abdominal magnetic resonance images (T2-weighted HASTE coronal sequences) from patients with ADPKD to train the network and the remaining 20% for validation. Both kidneys and liver were also segmented manually. To evaluate the method's performance, we used an additional test set of images from 100 patients, 45 of whom were also involved in longitudinal analyses. RESULTS TKV and TLV measured by the automated approach correlated highly with manually traced TKV and TLV (intraclass correlation coefficients, 0.998 and 0.996, respectively), with low bias and high precision (<0.1%±2.7% for TKV and -1.6%±3.1% for TLV); this was comparable with inter-reader variability of manual tracing (<0.1%±3.5% for TKV and -1.5%±4.8% for TLV). For longitudinal analysis, bias and precision were <0.1%±3.2% for TKV and 1.4%±2.9% for TLV growth. CONCLUSIONS These findings demonstrate a fully automated segmentation method that measures TKV, TLV, and changes in these parameters as accurately as manual tracing. This technique may facilitate future studies in which automated and reproducible TKV and TLV measurements are needed to assess disease severity, disease progression, and treatment response.",2019,"RESULTS TKV and TLV measured by the automated approach correlated highly with manually traced TKV and TLV (intraclass correlation coefficients, 0.998 and 0.996, respectively), with low bias and high precision (<0.1%±2.7% for TKV and -1.6%±3.1% for TLV); this was comparable with inter-reader variability of manual tracing (<0.1%±3.5% for TKV and -1.5%±4.8% for TLV).","['patients with ADPKD to train the network and the remaining 20% for validation', 'Patients Affected by Autosomal Dominant Polycystic Kidney Disease', '100 patients, 45 of whom were also involved in longitudinal analyses']",[],"['total kidney volume (TKV) and liver volume (TLV', 'Automatic Measurement of Kidney and Liver Volumes', 'TKV and TLV']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085413', 'cui_str': 'Autosomal dominant polycystic kidney disease'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0522476', 'cui_str': 'Patient affected'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]",[],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",,0.0219092,"RESULTS TKV and TLV measured by the automated approach correlated highly with manually traced TKV and TLV (intraclass correlation coefficients, 0.998 and 0.996, respectively), with low bias and high precision (<0.1%±2.7% for TKV and -1.6%±3.1% for TLV); this was comparable with inter-reader variability of manual tracing (<0.1%±3.5% for TKV and -1.5%±4.8% for TLV).","[{'ForeName': 'Maatje D A', 'Initials': 'MDA', 'LastName': 'van Gastel', 'Affiliation': 'Division of Nephrology and Hypertension, Department of Internal Medicine.'}, {'ForeName': 'Marie E', 'Initials': 'ME', 'LastName': 'Edwards', 'Affiliation': 'Division of Nephrology and Hypertension, Department of Internal Medicine.'}, {'ForeName': 'Vicente E', 'Initials': 'VE', 'LastName': 'Torres', 'Affiliation': 'Division of Nephrology and Hypertension, Department of Internal Medicine.'}, {'ForeName': 'Bradley J', 'Initials': 'BJ', 'LastName': 'Erickson', 'Affiliation': 'Department of Radiology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Ron T', 'Initials': 'RT', 'LastName': 'Gansevoort', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands and.'}, {'ForeName': 'Timothy L', 'Initials': 'TL', 'LastName': 'Kline', 'Affiliation': 'Division of Nephrology and Hypertension, Department of Internal Medicine; kline.timothy@mayo.edu.'}]",Journal of the American Society of Nephrology : JASN,['10.1681/ASN.2018090902'] 13,32342498,Efficacy of quadruple treatment on different types of pre-operative anaemia: secondary analysis of a randomised controlled trial.,"In patients with pre-operative anaemia undergoing cardiac surgery, combination treatment with intravenous iron, subcutaneous erythropoietin alpha, vitamin B12 and oral folic acid reduces allogeneic blood product transfusions. It is unclear if certain types of anaemia particularly benefit from this treatment. We performed a post-hoc analysis of anaemic patients from a randomised trial on the 'Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery'. We used linear regression analyses to examine the efficacy of a combination anaemia treatment compared with placebo on the following deficiencies, each representing a part of the combination treatment: ferritin and transferrin saturation; endogenous erythropoietin; holotranscobalamine; and folic acid in erythrocytes. Efficacy was defined as change in reticulocyte count from baseline to the first, third and fifth postoperative days and represented erythropoietic activity in the immediate peri-operative recovery phase. In all 253 anaemic patients, iron deficiency was the most common cause of anaemia. Treatment significantly increased reticulocyte count in all regression analyses on postoperative days 1, 3 and 5 (all p < 0.001). Baseline ferritin and endogenous erythropoietin were negatively associated with change in reticulocyte count on postoperative day 5, with an unstandardised regression coefficient B of -0.08 (95%CI -0.14 to -0.02) and -0.14 (95%CI -0.23 to -0.06), respectively. Quadruple anaemia treatment was effective regardless of the cause of anaemia and its effect manifested early in the peri-operative recovery phase. The more pronounced a deficiency was, the stronger the subsequent boost to erythropoiesis may have been.",2020,"Baseline ferritin and endogenous erythropoietin were negatively associated with change in reticulocyte count on postoperative day 5, with an unstandardised regression coefficient B of -0.08 (95%CI -0.14 to -0.02) and -0.14 (","['patients with pre-operative anaemia undergoing cardiac surgery, combination treatment with', '253 anaemic patients', 'patients with iron deficiency or anaemia undergoing cardiac surgery']","['intravenous iron, subcutaneous erythropoietin alpha, vitamin B12 and oral folic acid', 'ultra-short-term treatment', 'placebo']","['Efficacy', 'anaemia', 'erythropoietic activity', 'reticulocyte count', 'Baseline ferritin and endogenous erythropoietin']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0857322', 'cui_str': 'Anemic'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0014822', 'cui_str': 'erythropoietin'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0042845', 'cui_str': 'Vitamin B 12'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0206161', 'cui_str': 'Reticulocyte count'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0015879', 'cui_str': 'Ferritin'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C0014822', 'cui_str': 'erythropoietin'}]",253.0,0.192155,"Baseline ferritin and endogenous erythropoietin were negatively associated with change in reticulocyte count on postoperative day 5, with an unstandardised regression coefficient B of -0.08 (95%CI -0.14 to -0.02) and -0.14 (","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Rössler', 'Affiliation': 'Institute of Anesthesiology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Hegemann', 'Affiliation': 'Department of Medical Oncology and Haematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Schoenrath', 'Affiliation': 'Department of Cardiothoracic and Vascular Surgery, German Heart Centre Berlin, German Centre for Cardiovascular Research, Berlin, Germany.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Seifert', 'Affiliation': 'Department of Biostatistics, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Kaserer', 'Affiliation': 'Institute of Anesthesiology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'G H', 'Initials': 'GH', 'LastName': 'Spahn', 'Affiliation': 'Institute of Anesthesiology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Falk', 'Affiliation': 'Department of Cardiothoracic and Vascular Surgery, German Heart Centre Berlin, German Centre for Cardiovascular Research, Berlin, Germany.'}, {'ForeName': 'D R', 'Initials': 'DR', 'LastName': 'Spahn', 'Affiliation': 'Institute of Anesthesiology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.'}]",Anaesthesia,['10.1111/anae.15062'] 14,32340878,Pre-operative Patient Specific Flow Predictions to Improve Haemodialysis Arteriovenous Fistula Maturation (Shunt Simulation Study): A Randomised Controlled Trial.,"OBJECTIVE An arteriovenous fistula (AVF) needs to mature before it becomes suitable to cannulate for haemodialysis treatment. Maturation importantly depends on the post-operative flow increase. Unfortunately, 20-40% of AVFs fail to mature (FTM). A patient specific computational model that predicts immediate post-operative flow was developed, and it was hypothesised that providing information from this model for planning of fistula creation might reduce FTM rates. METHODS A multicentre, randomised controlled trial in nine Dutch hospitals was conducted in which patients with renal failure who were referred for AVF creation, were recruited. Patients were randomly assigned (1:1) to the control or computer simulation group. Both groups underwent a work up, with physical and duplex ultrasonography (DUS) examination. In the simulation group the data from the DUS examination were used for model simulations, and based on the immediate post-operative flow prediction, the ideal AVF configuration was recommended. The primary endpoint was AVF maturation defined as an AVF flow ≥500 mL/min and a vein inner diameter of ≥4 mm six weeks post-operatively. The secondary endpoint was model performance (i.e. comparisons between measured and predicted flows, and (multivariable) regression analysis for maturation probability with accompanying area under the receiver operator characteristic curve [AUC]). RESULTS A total of 236 patients were randomly assigned (116 in the control and 120 in the simulation group), of whom 205 (100 and 105 respectively) were analysed for the primary endpoint. There was no difference in FTM rates between the groups (29% and 32% respectively). Immediate post-operative flow prediction had an OR of 1.15 (1.06-1.26; p < .001) per 100 mL/min for maturation, and the accompanying AUC was 0.67 (0.59-0.75). CONCLUSION Providing pre-operative patient specific flow simulations during surgical planning does not result in improved maturation rates. Further study is needed to improve the predictive power of these simulations in order to render the computational model an adjunct to surgical planning.",2020,"Immediate post-operative flow prediction had an OR of 1.15 (1.06-1.26; p < .001) per 100 mL/min for maturation, and the accompanying AUC was 0.67 (0.59-0.75). ","['236 patients', 'Haemodialysis Arteriovenous Fistula Maturation (Shunt Simulation Study', 'nine Dutch hospitals was conducted in which patients with renal failure who were referred for AVF creation, were recruited']","['Pre-operative Patient Specific Flow Predictions', 'physical and duplex ultrasonography (DUS) examination', 'control or computer simulation group']","['AVF maturation defined as an AVF flow ≥500\xa0mL/min and a vein inner diameter', 'maturation rates', 'FTM rates', 'model performance (i.e. comparisons between measured and predicted flows, and (multivariable) regression analysis for maturation probability with accompanying area under the receiver operator characteristic curve [AUC']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0003855', 'cui_str': 'Arteriovenous fistula'}, {'cui': 'C0542331', 'cui_str': 'Shunt'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0035078', 'cui_str': 'Renal insufficiency'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0398221', 'cui_str': 'Arteriovenous fistulization'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0444916', 'cui_str': 'Duplex'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009609', 'cui_str': 'Models, Computer'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0003855', 'cui_str': 'Arteriovenous fistula'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0439445', 'cui_str': 'mL/min'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0205286', 'cui_str': 'Mature'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0034980', 'cui_str': 'Analysis, Regression'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}]",236.0,0.142999,"Immediate post-operative flow prediction had an OR of 1.15 (1.06-1.26; p < .001) per 100 mL/min for maturation, and the accompanying AUC was 0.67 (0.59-0.75). ","[{'ForeName': 'Niek', 'Initials': 'N', 'LastName': 'Zonnebeld', 'Affiliation': 'Department of Biomedical Engineering, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, the Netherlands; Department of Vascular Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands. Electronic address: niek.zonnebeld@mumc.nl.'}, {'ForeName': 'Jan H M', 'Initials': 'JHM', 'LastName': 'Tordoir', 'Affiliation': 'Department of Vascular Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Magda M', 'Initials': 'MM', 'LastName': 'van Loon', 'Affiliation': 'Department of Vascular Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'André A E A', 'Initials': 'AAEA', 'LastName': 'de Smet', 'Affiliation': 'Department of Surgery, Maasstad Hospital, Rotterdam, the Netherlands.'}, {'ForeName': 'Laurens C', 'Initials': 'LC', 'LastName': 'Huisman', 'Affiliation': 'Department of Surgery, Flevoziekenhuis, Almere, the Netherlands.'}, {'ForeName': 'Philippe W M', 'Initials': 'PWM', 'LastName': 'Cuypers', 'Affiliation': 'Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.'}, {'ForeName': 'Felix J V', 'Initials': 'FJV', 'LastName': 'Schlösser', 'Affiliation': 'Department of Surgery, Laurentius Hospital, Roermond, the Netherlands.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Lemson', 'Affiliation': 'Department of Surgery, Slingeland Hospital, Doetinchem, the Netherlands.'}, {'ForeName': 'Stefan G H', 'Initials': 'SGH', 'LastName': 'Heinen', 'Affiliation': 'Department of Surgery, St. Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'Lee H', 'Initials': 'LH', 'LastName': 'Bouwman', 'Affiliation': 'Department of Surgery, Zuyderland Medical Centre, Heerlen, the Netherlands.'}, {'ForeName': 'Raechel J', 'Initials': 'RJ', 'LastName': 'Toorop', 'Affiliation': 'Department of Surgery, University Medical Centre Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'Wouter', 'Initials': 'W', 'LastName': 'Huberts', 'Affiliation': 'Department of Biomedical Engineering, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Tammo', 'Initials': 'T', 'LastName': 'Delhaas', 'Affiliation': 'Department of Biomedical Engineering, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery,['10.1016/j.ejvs.2020.03.005'] 15,32390164,"Thiamidol containing treatment regimens in facial hyperpigmentation: An international multi-centre approach consisting of a double-blind, controlled, split-face study and of an open-label, real-world study.","OBJECTIVE Tyrosinase is the rate-limiting enzyme in melanogenesis. Thiamidol is the most potent inhibitor of human tyrosinase out of 50 000 tested compounds. In clinical studies, it was shown to improve facial hyperpigmentation, post-inflammatory hyperpigmentation and age spots significantly. To identify the optimal number of daily Thiamidol applications, we conducted a split-face study comparing the efficacy and tolerability of four-times with two-times daily application. Subsequently, we evaluated the efficacy and tolerability of a typical face care regimen containing Thiamidol in a real-world study. METHODS The split-face study was double-blind, randomized, controlled, including two Thiamidol containing products (serum and day care SPF 30). The serum was applied twice daily on one half of the face and the day care SPF30 twice-daily on the whole face. The real-world study was open-label, observational, including three Thiamidol containing products (day care SPF 30 in the morning, serum and night care in the evening). In both studies, subjects with mild-to-moderate facial hyperpigmentation applied the products over 12 weeks. Assessments included clinical and subjective grading of hyperpigmentation, skin condition, hemi-/modified MASI, chromameter and clinical photography. RESULTS In the split-face study (n = 34), hyperpigmentation, skin roughness and hMASI improved all significantly (P < 0.001) versus baseline, with first visible results after two weeks of twice-daily application. The four-times daily application led to significant improvement versus the two-times daily application. In the real-world study (n = 83), all evaluated parameters, including skin condition and chromametry (n = 30), improved significantly (P < 0.001) in comparison with baseline and the corresponding preceding visits. The subjects judged the cosmetic properties of the products positively. In both studies, the products were well tolerated. CONCLUSION Four-times daily Thiamidol improves facial hyperpigmentation significantly more than two-times daily and is well tolerated by the subjects. The real-world study with a typical face care regimen containing Thiamidol shows improvement of facial hyperpigmentation and confirms tolerability. Furthermore, the data provide evidence for the suitability of this three-product Thiamidol regimen for day-to-day life.",2020,"In clinical studies, it was shown to improve facial hyperpigmentation, post-inflammatory hyperpigmentation, and age spots significantly.","['subjects with mild-to-moderate facial hyperpigmentation', 'facial hyperpigmentation']",['Thiamidol'],"['tolerated', 'facial hyperpigmentation', 'facial hyperpigmentation, post-inflammatory hyperpigmentation', 'efficacy and tolerability', 'facial hyperpigmentation and confirms tolerability', 'clinical and subjective grading of hyperpigmentation, skin condition, hemi-/modified MASI, chromameter, and clinical photography', 'hyperpigmentation, skin roughness, and hMASI']","[{'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0162834', 'cui_str': 'Hyperpigmentation'}]",[],"[{'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0162834', 'cui_str': 'Hyperpigmentation'}, {'cui': 'C0333616', 'cui_str': 'Postinflammatory hyperpigmentation'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0037274', 'cui_str': 'Disorder of skin'}, {'cui': 'C1285521', 'cui_str': 'Hemi'}, {'cui': 'C0431056', 'cui_str': 'Photography of patient'}, {'cui': 'C0859038', 'cui_str': 'Skin roughness'}]",50000.0,0.0212795,"In clinical studies, it was shown to improve facial hyperpigmentation, post-inflammatory hyperpigmentation, and age spots significantly.","[{'ForeName': 'W G', 'Initials': 'WG', 'LastName': 'Philipp-Dormston', 'Affiliation': 'Hautzentrum Köln, Schillingsrotter Str. 39-41, Köln, 50996, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Vila Echagüe', 'Affiliation': 'Centro de Referencia en Tratamiento Laser, Av. Del Libertador 662, Piso 17, depto. 42, Buenos Aires, Argentina.'}, {'ForeName': 'S H', 'Initials': 'SH', 'LastName': 'Pérez Damonte', 'Affiliation': 'CLAIM, José Bonifacio 717, Buenos Aires, Argentina.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Riedel', 'Affiliation': 'BDF Argentina, Av Triunvirato 2902, Buenos Aires, C1427 AAP CABA, Argentina.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Filbry', 'Affiliation': 'BDF Argentina, Av Triunvirato 2902, Buenos Aires, C1427 AAP CABA, Argentina.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Warnke', 'Affiliation': 'BDF Argentina, Av Triunvirato 2902, Buenos Aires, C1427 AAP CABA, Argentina.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Lofrano', 'Affiliation': 'Beiersdorf AG, Unnastrasse 48, Hamburg, 20245, Germany.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Roggenkamp', 'Affiliation': 'BDF Argentina, Av Triunvirato 2902, Buenos Aires, C1427 AAP CABA, Argentina.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Nippel', 'Affiliation': 'BDF Argentina, Av Triunvirato 2902, Buenos Aires, C1427 AAP CABA, Argentina.'}]",International journal of cosmetic science,['10.1111/ics.12626'] 16,32345423,Escape the Drape Divide by Making Off-Service Rotations a Part of Surgery and Anesthesia Residencies.,"Unfortunately, the drape dividing the anesthesiologist from the surgeon is far too often a symbol of a greater divide in both communication and culture between the 2 specialties. When anesthesiologists and surgeons spend time rotating on each other's services, they develop a mutual respect for each other's clinical acumen and foster open communication channels for times of both routine clinical care and crisis. There is no better time than in residency, and no better way than cross-training, for anesthesia and surgical residents to hone these skills.",2020,"There is no better time than in residency, and no better way than cross-training, for anesthesia and surgical residents to hone these skills.",[],[],[],[],[],[],,0.0150846,"There is no better time than in residency, and no better way than cross-training, for anesthesia and surgical residents to hone these skills.","[{'ForeName': 'Aurelie', 'Initials': 'A', 'LastName': 'Merlo', 'Affiliation': 'Integrated cardiothoracic surgery resident at the University of North Carolina at Chapel Hill.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Haithcock', 'Affiliation': 'Professor of surgery in the Division of Cardiothoracic Surgery and program director of the Integrated Thoracic Surgery Residency Program at the University of North Carolina School of Medicine in Chapel Hill.'}]",AMA journal of ethics,['10.1001/amajethics.2020.305'] 17,32348638,Utilization trends of respiratory medication in premature infants discharged on home oxygen therapy.,"BACKGROUND Roughly half of all extremely preterm infants will be diagnosed with bronchopulmonary dysplasia (BPD), and a third will be discharged on home oxygen therapy (HOT). To date, there have been no studies that have examined the relationship between respiratory medication utilization in infants with BPD on HOT. METHODS The recorded home oximetry trial was a multicenter, randomized trial comparing two home oxygen management strategies in premature infants. Infants were enrolled at first outpatient pulmonary or neonatal intensive care unit (NICU) follow-up visit with a pulmonary component. Respiratory medication prescriptions and dosage were collected from time of enrollment through 6 months after HOT discontinuation. Patients were seen monthly while on HOT and at 1, 3, and 6 months after successful discontinuation. RESULTS During protocol visits, 174 (89%) infants had respiratory medications documented. Respiratory medication use was higher at initial follow-up visit compared with NICU discharge and decreased at the final 6-month follow-up visit. Infants who received inhaled steroids (IS) before weaning had mean HOT duration of 138 days (range: 24-562 days); infants who received IS after weaning had shorter mean HOT duration (55 days, range: 21-264). In time-to-event analysis the no IS group and the postwean group differed significantly (χ 2 1  = 8.1; P = .004). NICU clinics gave a total of 35 prescriptions to 43 patients, an average of 0.8 per patient, while the pulmonary clinics gave 837 prescriptions to 153 patients, or 5.5 per patient (P < .0001). CONCLUSION Respiratory prescribing patterns for infants on HOT are highly variable. Utilization of IS was not associated with shorter duration of HOT.",2020,In time-to-event analysis the no IS group and the postwean group differed significantly (χ 2 1  = 8.1; P = .004).,"['infants with BPD', 'Infants were enrolled at first outpatient pulmonary or neonatal intensive care unit (NICU) follow-up visit with a pulmonary component', 'premature infants', 'premature infants discharged on home oxygen therapy']",['inhaled steroids (IS'],"['mean HOT duration', 'shorter duration of HOT']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary dysplasia of newborn'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0589121', 'cui_str': 'Follow-up visit'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C1960973', 'cui_str': 'Home oxygen therapy'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1960973', 'cui_str': 'Home oxygen therapy'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0439593', 'cui_str': 'Short duration'}]",,0.10114,In time-to-event analysis the no IS group and the postwean group differed significantly (χ 2 1  = 8.1; P = .004).,"[{'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'White', 'Affiliation': 'Division of Neonatology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Berenson', 'Affiliation': 'School of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.'}, {'ForeName': 'Javed', 'Initials': 'J', 'LastName': 'Mannan', 'Affiliation': 'Division of Neonatology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.'}, {'ForeName': 'Henry A', 'Initials': 'HA', 'LastName': 'Feldman', 'Affiliation': ""Division of Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Rhein', 'Affiliation': 'Division of Neonatology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Pediatric pulmonology,['10.1002/ppul.24735'] 18,32350598,Comparison of aspirating pipettes and hysteroscopy with curettage.,"PURPOSE In this prospective study, endometrial biopsy by pipette was compared with hysteroscopy with curettage in patients with an abnormal uterine bleeding (ABU) (hypermenorrhea, intermediate bleeding, continuous bleeding, postmenopausal bleeding) and patients with a sonographically abnormal endometrium. METHODS 176 patients were included. The pipette samples were taken during the usual planned procedure under general anaesthesia. Thereafter, the planned hysteroscopy with curettage was completed. The study was performed as a double-blind study. The obtained histologies (of pipelle and curettage) were sent separately to the same pathologist. The pipelle material was encoded by a specific number without any patient data. RESULTS In 97% of the cases using the biopsy with pipette were obtained an adequate sample. The biopsy with pipette had a sensitivity and specificity of 100% in the diagnosis of endometrial carcinoma and atypical hyperplasia. Pipette showed a significantly lower accuracy with a sensitivity of 28% in the diagnosis of endometrial hyperplasia without atypia. Pipette showed the lowest sensitivity for polyps, myomas and atrophic endometrium. CONCLUSION The study shows that pipette sampling is a safe, accurate, low-cost ambulatory procedure with high sensitivity for the detection of atypical endometrial hyperplasia and endometrial carcinoma. In the case of sonographically definable findings (polyp, myoma), hysteroscopy with curettage is preferred.",2020,"The study shows that pipette sampling is a safe, accurate, low-cost ambulatory procedure with high sensitivity for the detection of atypical endometrial hyperplasia and endometrial carcinoma.","['176 patients were included', 'patients with an abnormal uterine bleeding (ABU) (hypermenorrhea, intermediate bleeding, continuous bleeding, postmenopausal bleeding) and patients with a sonographically abnormal endometrium']","['aspirating pipettes and hysteroscopy with curettage', 'hysteroscopy with curettage']","['sensitivity and specificity', 'lowest sensitivity for polyps, myomas and atrophic endometrium']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C3650625', 'cui_str': 'Abnormal uterine bleeding'}, {'cui': 'C0025323', 'cui_str': 'Menorrhagia'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C0014180', 'cui_str': 'Endometrial structure'}]","[{'cui': 'C0370199', 'cui_str': 'Specimen obtained by aspiration'}, {'cui': 'C0182301', 'cui_str': 'Micropipette'}, {'cui': 'C0020710', 'cui_str': 'Hysteroscopy'}, {'cui': 'C0010468', 'cui_str': 'Curettage'}]","[{'cui': 'C0036668', 'cui_str': 'Sensitivity and Specificity'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0032584', 'cui_str': 'Polyp'}, {'cui': 'C0027086', 'cui_str': 'Myoma'}, {'cui': 'C0334192', 'cui_str': 'Atrophic endometrium'}]",176.0,0.0205982,"The study shows that pipette sampling is a safe, accurate, low-cost ambulatory procedure with high sensitivity for the detection of atypical endometrial hyperplasia and endometrial carcinoma.","[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Piriyev', 'Affiliation': 'Clinic for Gynecology and Obstetrics of the Evangelical Hospital Cologne Weyertal Academic Teaching Hospital of the University of Cologne, Cologne, Germany. piriyev.elvins@gmail.com.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Mellin', 'Affiliation': 'Practice for Pathology and Cytology Cologne Weyertal, Cologne, Germany.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Römer', 'Affiliation': 'Clinic for Gynecology and Obstetrics of the Evangelical Hospital Cologne Weyertal Academic Teaching Hospital of the University of Cologne, Cologne, Germany.'}]",Archives of gynecology and obstetrics,['10.1007/s00404-020-05551-0'] 19,32290099,The Impact of Narrative Strategy on Promoting HPV Vaccination among College Students in Korea: The Role of Anticipated Regret.,"Human papillomavirus (HPV) vaccine hesitancy contributes to unsatisfactory vaccination coverage in Korea despite its high efficacy in preventing various diseases including cervical cancer. To enhance HPV vaccine uptake, effective communication with the public is key. To develop effective health promotion messages, this study examined the effects of message format on attitudes and intentions toward HPV vaccination, specifically focusing on anticipated action and inaction regrets. It employed a randomized experimental message design format (narrative versus didactic messages). A total of 222 Korean undergraduate students who had not received the HPV shot participated in the experiment. The results showed that didactic messages produce greater anticipated inaction regret, which further influences HPV vaccination attitudes and behaviors. Anticipated regret could potentially explain mixed narrative effects across health behaviors as described in existing literature.",2020,"The results showed that didactic messages produce greater anticipated inaction regret, which further influences HPV vaccination attitudes and behaviors.","['222 Korean undergraduate students who had not received the HPV shot participated in the experiment', 'College Students in Korea']",['Narrative Strategy'],"['inaction regret', 'HPV Vaccination', 'HPV vaccination attitudes and behaviors']","[{'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0022771', 'cui_str': 'Korea'}]","[{'cui': 'C1135957', 'cui_str': 'Narration'}]","[{'cui': 'C0080101', 'cui_str': 'Regret'}, {'cui': 'C1997921', 'cui_str': 'Vaccination for human papillomavirus'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",222.0,0.0172302,"The results showed that didactic messages produce greater anticipated inaction regret, which further influences HPV vaccination attitudes and behaviors.","[{'ForeName': 'Jarim', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Communication, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.'}]",Vaccines,['10.3390/vaccines8020176'] 20,32289841,Effects of Body Weight vs. Lean Body Mass on Wingate Anaerobic Test Performance in Endurance Athletes.,"The aim of this study was to determine the influence of body weight or lean body mass-based load on Wingate Anaerobic Test performance in male and female endurance trained individuals. Thirty-one participants (22 male cyclists and triathletes and 9 female triathletes) completed two randomized Wingate Anaerobic Test (body weight and lean body mass loads) in stationary start. There were no significant differences in power outputs variables between loads in any group. However, when comparing specific groups within the sample (e. g. cyclists vs cyclists) medium to large effect sizes were observed for Relative Mean Power Output (ES=0.53), Relative Lowest Power (ES=0.99) and Relative Power Muscle Mass (ES=0.54). Regarding gender differences, male cyclists and triathletes displayed higher relative and absolute power outputs (p<0.001) compared to female triathletes regardless of the protocol used. FI was lower in female triathletes compared to male triathletes and cyclists in body weight (p<0.001) and lean body mass (p<0.01) protocols. Body composition and anthropometric characteristics were similar in male cyclists and triathletes, but there were differences between genders. These results suggest that using either body weight-based or lean body mass-based load can be used interchangeably. However, there may be some practically relevant differences when evaluating this on an individual level.",2020,"Body composition and anthropometric characteristics were similar in male cyclists and triathletes, but there were differences between genders.","['Thirty-one participants (22 male cyclists and triathletes and 9 female triathletes', 'male and female endurance trained individuals', 'Endurance Athletes']","['body weight or lean body mass-based load', 'Body Weight vs. Lean Body Mass']",['Body composition and anthropometric characteristics'],"[{'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}]",31.0,0.070604,"Body composition and anthropometric characteristics were similar in male cyclists and triathletes, but there were differences between genders.","[{'ForeName': 'Miguel Ángel', 'Initials': 'MÁ', 'LastName': 'Galán-Rioja', 'Affiliation': 'Sport Training Lab., Faculty of Sport Sciences, University of Castilla-La Mancha, Campus of Toledo, Spain.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'González-Mohíno', 'Affiliation': 'Sport Training Lab., Faculty of Sport Sciences, University of Castilla-La Mancha, Campus of Toledo, Spain.'}, {'ForeName': 'Dajo', 'Initials': 'D', 'LastName': 'Sanders', 'Affiliation': 'Human Movement Science, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Mellado', 'Affiliation': 'Sport Training Lab., Faculty of Sport Sciences, University of Castilla-La Mancha, Campus of Toledo, Spain.'}, {'ForeName': 'José María', 'Initials': 'JM', 'LastName': 'González-Ravé', 'Affiliation': 'Sport Training Lab., Faculty of Sport Sciences, University of Castilla-La Mancha, Campus of Toledo, Spain.'}]",International journal of sports medicine,['10.1055/a-1114-6206'] 21,32349193,Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE).,"AIMS Little is known about the impact of sodium glucose co-transporter 2 (SGLT2) inhibitors on cardiac biomarkers, such as natriuretic peptides, in type 2 diabetes (T2D) patients with concomitant chronic heart failure (CHF). We compared the effect of canagliflozin with glimepiride, based on changes in N-terminal pro-brain natriuretic peptide (NT-proBNP), in that patient population. METHODS AND RESULTS Patients with T2D and stable CHF, randomized to receive canagliflozin 100 mg or glimepiride (starting-dose: 0.5 mg), were examined using the primary endpoint of non-inferiority of canagliflozin vs. glimepiride, defined as a margin of 1.1 in the upper limit of the two-sided 95% confidence interval (CI) for the group ratio of percentage change in NT-proBNP at 24 weeks. Data analysis of 233 patients showed mean left ventricular ejection fraction (LVEF) at randomization was 57.6 ± 14.6%, with 71% of patients having a preserved LVEF (≥50%). Ratio of NT-proBNP percentage change was 0.48 (95% CI, -0.13 to 1.59, P = 0.226) and therefore did not meet the prespecified non-inferiority margin. However, NT-proBNP levels did show a non-significant trend lower in the canagliflozin group [adjusted group difference; -74.7 pg/mL (95% CI, -159.3 to 10.9), P = 0.087] and also in the subgroup with preserved LVEF [-58.3 (95% CI, -127.6 to 11.0, P = 0.098]). CONCLUSIONS This study did not meet the predefined primary endpoint of changes in NT-proBNP levels, with 24 weeks of treatment with canagliflozin vs. glimepiride. Further research is warranted to determine whether patients with heart failure with preserved ejection fraction, regardless of diabetes status, could potentially benefit from treatment with SGLT2 inhibitors.",2020,Ratio of NT-proBNP percentage change was 0.48,"['type 2 diabetes (T2D) patients with concomitant chronic heart failure (CHF', 'Patients with T2D and stable CHF', 'patients with heart failure with preserved ejection fraction, regardless of diabetes status', 'patients with type 2 diabetes and chronic heart failure']","['canagliflozin', 'canagliflozin 100\xa0mg or glimepiride', 'canagliflozin vs. glimepiride', 'canagliflozin with glimepiride', 'sodium glucose co-transporter 2 (SGLT2) inhibitors']","['NT-proBNP levels', 'Ratio of NT-proBNP percentage change', 'mean left ventricular ejection fraction (LVEF']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C2960127', 'cui_str': 'Heart failure with normal ejection fraction'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0449438', 'cui_str': 'Status'}]","[{'cui': 'C2974540', 'cui_str': 'canagliflozin'}, {'cui': 'C3556569', 'cui_str': 'canagliflozin 100 MG [Invokana]'}, {'cui': 'C0061323', 'cui_str': 'glimepiride'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0598849', 'cui_str': 'Co-Transporters'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C1533071', 'cui_str': 'N terminal pro-brain natriuretic peptide level'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}]",233.0,0.223378,Ratio of NT-proBNP percentage change was 0.48,"[{'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Tanaka', 'Affiliation': 'Department of Cardiovascular Medicine, Saga University, Saga, Japan.'}, {'ForeName': 'Itaru', 'Initials': 'I', 'LastName': 'Hisauchi', 'Affiliation': 'Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan.'}, {'ForeName': 'Isao', 'Initials': 'I', 'LastName': 'Taguchi', 'Affiliation': 'Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Sezai', 'Affiliation': 'The Department of Cardiovascular Surgery, Nihon University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Shigeru', 'Initials': 'S', 'LastName': 'Toyoda', 'Affiliation': 'Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Mibu, Japan.'}, {'ForeName': 'Hirofumi', 'Initials': 'H', 'LastName': 'Tomiyama', 'Affiliation': 'Department of Cardiology, Tokyo Medical University, Tokyo, Japan.'}, {'ForeName': 'Masataka', 'Initials': 'M', 'LastName': 'Sata', 'Affiliation': 'Department of Cardiovascular Medicine, Tokushima University Graduate School, Tokushima, Japan.'}, {'ForeName': 'Shinichiro', 'Initials': 'S', 'LastName': 'Ueda', 'Affiliation': 'Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan.'}, {'ForeName': 'Jun-Ichi', 'Initials': 'JI', 'LastName': 'Oyama', 'Affiliation': 'Department of Cardiovascular Medicine, Saga University, Saga, Japan.'}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Kitakaze', 'Affiliation': 'Department of Clinical Medicine and Development, National Cerebral and Cardiovascular Center, Suita, Japan.'}, {'ForeName': 'Toyoaki', 'Initials': 'T', 'LastName': 'Murohara', 'Affiliation': 'Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Node', 'Affiliation': 'Department of Cardiovascular Medicine, Saga University, Saga, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",ESC heart failure,['10.1002/ehf2.12707'] 22,32291107,"Re: Nobuaki Matsubara, Kim N. Chi, Mustafa Özgüroğlu, et al. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. Eur Urol. 2020:77:494-500. https://doi.org/10.1016/j.eururo.2019.11.021.",,2020,,['Metastatic Castration-sensitive Prostate Cancer'],"['Androgen Deprivation Therapy', 'Abiraterone Acetate plus Prednisone or Placebos']",[],"[{'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C4302896', 'cui_str': 'Hormone sensitive prostate cancer'}]","[{'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C2607886', 'cui_str': 'Abiraterone acetate'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.0565058,,"[{'ForeName': 'B Andes', 'Initials': 'BA', 'LastName': 'Hess', 'Affiliation': 'Department of Chemistry, Vanderbilt University, Nashville, TN, 37235 USA. Electronic address: b.andes.hess@vanderbilt.edu.'}]",European urology,['10.1016/j.eururo.2020.03.018'] 23,32353535,High-Definition Chromoendoscopy Superior to High-Definition White-Light Endoscopy in Surveillance of Inflammatory Bowel Diseases in a Randomized Trial.,"BACKGROUND & AIMS There is debate over the optimal method for colonoscopic surveillance of patients with inflammatory bowel diseases. Guidelines recommend chromoendoscopy, but the value of chromoendoscopy in high-definition colonoscopy has not been proven. Furthermore, the value of random biopsies is controversial. METHODS We performed a prospective study of 305 patients with ulcerative colitis or Crohn's colitis referred for surveillance colonoscopy at a university hospital in Sweden, from March 2011 through April 2016. Patients randomly assigned to a group that received high-definition chromoendoscopy with indigo carmine (HD-CE; n = 152), collection of 32 random biopsies, and targeted biopsies or polypectomies or to a group that received high-definition white light endoscopy (HD-WLE; n = 153), collection of 32 random biopsies, and targeted biopsies or polypectomies. The primary endpoint was number of patients with dysplastic lesions. RESULTS Dysplastic lesions were detected in 17 patients with HD-CE and 7 patients with HD-WLE (P = .032). Dysplasias in random biopsies (n = 9760) were detected in 9 patients: 6 (3.9%) in the HD-CE group and 3 (2.0%) in the HD-WLE group (P = .72). Of the 9 patients with dysplasia, 3 patients (33%) had primary sclerosing cholangitis-only 18% of patients (54/305) included in the study had primary sclerosing cholangitis. The number of dysplastic lesions per 10 min of withdrawal time was 0.066 with HD-CE and 0.027 with HD-WLE (P = .056). CONCLUSIONS In a randomized trial, we found HD-CE with collection of random biopsies to be superior to HD-WLE with random biopsies for detection of dysplasia per colonoscopy. These results support the use of chromoendoscopy for surveillance of patients with inflammatory bowel diseases. ClinicalTrials.gov no: NCT01505842.",2020,"In a randomized trial, we found HD-CE with collection of random biopsies to be superior to HD-WLE with random biopsies for detection of dysplasia per colonoscopy.","['patients with inflammatory bowel diseases', '9 patients with dysplasia, 3 patients (33%) had primary sclerosing cholangitis-only 18% of patients (54/305) included in the study had primary sclerosing cholangitis', ""305 patients with ulcerative colitis or Crohn's colitis referred for surveillance colonoscopy at a university hospital in Sweden, from March 2011 through April 2016""]","['chromoendoscopy', 'High-definition Chromoendoscopy Superior to High-definition White-light Endoscopy', 'high-definition chromoendoscopy with indigo carmine (HD-CE, n=152), collection of 32 random biopsies, and targeted biopsies or polypectomies or to a group that received high-definition white light endoscopy (HD-WLE, n=153), collection of 32 random biopsies, and targeted biopsies or polypectomies']","['number of dysplastic lesions per 10 min of withdrawal time', 'Dysplastic lesions', 'number of patients with dysplastic lesions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021390', 'cui_str': 'Inflammatory bowel disease'}, {'cui': 'C0334044', 'cui_str': 'Dysplasia'}, {'cui': 'C0566602', 'cui_str': 'Primary sclerosing cholangitis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517703', 'cui_str': '305'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C0156147', 'cui_str': ""Crohn's disease of large bowel""}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0563228', 'cui_str': 'White light'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0021219', 'cui_str': 'indigo carmine'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0521210', 'cui_str': 'Resection of polyp'}, {'cui': 'C0441835', 'cui_str': 'Group A'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0334044', 'cui_str': 'Dysplasia'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",305.0,0.058605,"In a randomized trial, we found HD-CE with collection of random biopsies to be superior to HD-WLE with random biopsies for detection of dysplasia per colonoscopy.","[{'ForeName': 'Bjarki', 'Initials': 'B', 'LastName': 'Alexandersson', 'Affiliation': 'Department of Medicine Solna, Karolinska Institutet, Division of endoscopy, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Yousef', 'Initials': 'Y', 'LastName': 'Hamad', 'Affiliation': 'Department of Medicine Solna, Karolinska Institutet, Division of endoscopy, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Andreasson', 'Affiliation': 'Department of Medicine Solna, Karolinska Institutet, Division of endoscopy, Karolinska University Hospital, Stockholm, Sweden; Stress Research Institute, Stockholm University, Stockholm, Sweden; Department of Psychology, Macquarie University, Sydney, New South Wales, Australia.'}, {'ForeName': 'Carlos A', 'Initials': 'CA', 'LastName': 'Rubio', 'Affiliation': 'Department of Pathology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Yugo', 'Initials': 'Y', 'LastName': 'Ando', 'Affiliation': 'Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Kansai Medical University, Osaka, Japan.'}, {'ForeName': 'Kyosuke', 'Initials': 'K', 'LastName': 'Tanaka', 'Affiliation': 'Department of Endoscopy, Mie University Hospital, Tsu, Japan.'}, {'ForeName': 'Tamaki', 'Initials': 'T', 'LastName': 'Ichiya', 'Affiliation': 'Department of Medicine Solna, Karolinska Institutet, Division of endoscopy, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Rezaie', 'Affiliation': 'Department of Medicine Solna, Karolinska Institutet, Division of endoscopy, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Peter T', 'Initials': 'PT', 'LastName': 'Schmidt', 'Affiliation': 'Department of Medicine Solna, Karolinska Institutet, Division of endoscopy, Karolinska University Hospital, Stockholm, Sweden. Electronic address: peter.thelin.schmidt@ki.se.'}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2020.04.049'] 24,32353342,"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.","BACKGROUND Patients with HER2-positive breast cancer who have received two or more previous therapies for advanced disease have few effective treatment options. The monarcHER trial aimed to compare the efficacy of abemaciclib plus trastuzumab with or without fulvestrant with standard-of-care chemotherapy of physician's choice plus trastuzumab in women with advanced breast cancer. METHODS This phase 2, three-group, open-label trial was done across 75 hospitals, clinics, and medical centres in 14 countries. Eligible patients were women aged 18 years or older, who had hormone receptor-positive, HER2-positive advanced breast cancer with unresectable, locally advanced, recurrent or metastatic disease, Eastern Cooperative Oncology Group performance status of 0 or 1, and who had previously received at least two HER2-targeted therapies for advanced disease. Patients were randomly assigned 1:1:1 to the abemaciclib, trastuzumab, and fulvestrant (group A), abemaciclib and trastuzumab (group B), or standard-of-care chemotherapy and trastuzumab (group C). Oral abemaciclib 150 mg 12 hourly was administered on days 1-21 of a 21-day cycle, intravenous trastuzumab 8 mg/kg on cycle 1 day 1, followed by 6 mg/kg on day 1 of each subsequent 21-day cycle, and intramuscular fulvestrant 500 mg on days 1, 15, and 29 and once every 4 weeks thereafter. Standard-of-care chemotherapy was administered as specified by the product label. Randomisation was by a computer-generated random sequence by means of an interactive web-response system and stratified by number of previous systemic therapies for advanced breast cancer and measurable versus non-measurable disease. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population, first testing group A versus group C and, if this result was significant, then group B versus group C. Safety was assessed in all patients who had received at least one dose of study treatment. This trial is registered at ClinicalTrials.gov (NCT02675231) and is ongoing for long-term survival follow-up. FINDINGS Between May 31, 2016, and Feb 28, 2018, 325 patients were screened, of whom 237 eligible patients were enrolled and randomly assigned to groups A (n=79), B (n=79), and C (n=79). Median follow-up was 19·0 months (IQR 14·7-25·1). The study met its primary endpoint, showing a significant difference at the prespecified two-sided α of 0·2 in median progression-free survival between group A (8·3 months, 95% CI 5·9-12·6) and group C (5·7 months, 5·4-7·0; HR 0·67 [95% CI 0·45-1·00]; p=0·051). No difference was observed between median progression-free survival in group B (5·7 months, 95% CI 4·2-7·2) and group C (HR 0·94 [0·64-1·38]; p=0·77). The most common grade 3-4 treatment-emergent adverse event in groups A, B, and C was neutropenia (21 [27%] of 78 patients, 17 [22%] of 77, and 19 [26%] of 72). The most common serious adverse events were: in group A, pyrexia (three [4%]), diarrhoea (two [3%]), urinary tract infection (two [3%]), and acute kidney injury (two [3%]); in group B, diarrhoea (two [3%]) and pneumonitis (two [3%]); and in group C, neutropenia (four [6%]) and pleural effusion (two [3%]). Two deaths were attributed to treatment: one due to pulmonary fibrosis in group B and one due to febrile neutropenia in group C. INTERPRETATION The combination of abemaciclib, fulvestrant, and trastuzumab significantly improved progression-free survival versus standard-of-care chemotherapy plus trastuzumab while showing a tolerable safety profile. Our results suggest that a chemotherapy-free regimen might potentially be an alternative treatment option for patients with hormone receptor-positive, HER2-positive advanced breast cancer. FUNDING Eli Lilly and Company.",2020,"No difference was observed between median progression-free survival in group B (5·7 months, 95% CI 4·2-7·2) and group C (HR 0·94 [0·64-1·38]; p=0·77).","['women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER', '75 hospitals, clinics, and medical centres in 14 countries', 'patients with hormone receptor-positive, HER2-positive advanced breast cancer', 'Patients with HER2-positive breast cancer', 'Between May 31, 2016, and Feb 28, 2018, 325 patients were screened, of whom 237 eligible patients', 'women with advanced breast cancer', 'Eligible patients were women aged 18 years or older, who had hormone receptor-positive, HER2-positive advanced breast cancer with unresectable, locally advanced, recurrent or metastatic disease, Eastern Cooperative Oncology Group performance status of 0 or 1, and who had previously received at least two HER2-targeted therapies for advanced disease']","['Standard-of-care chemotherapy', ""abemaciclib plus trastuzumab with or without fulvestrant with standard-of-care chemotherapy of physician's choice plus trastuzumab"", 'Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy', 'Oral abemaciclib', 'abemaciclib, trastuzumab, and fulvestrant (group A), abemaciclib and trastuzumab (group B), or standard-of-care chemotherapy and trastuzumab']","['pneumonitis', 'febrile neutropenia', 'neutropenia', 'median progression-free survival', 'progression-free survival', 'acute kidney injury', 'diarrhoea', 'pyrexia', 'urinary tract infection', 'pleural effusion', 'investigator-assessed progression-free survival']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1960398', 'cui_str': 'HER2-positive carcinoma of breast'}, {'cui': 'C4517714', 'cui_str': '325'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C3852841', 'cui_str': 'abemaciclib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C0935916', 'cui_str': 'fulvestrant'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}]","[{'cui': 'C3714636', 'cui_str': 'Pneumonitis'}, {'cui': 'C0746883', 'cui_str': 'Febrile neutropenia'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0032227', 'cui_str': 'Pleural effusion'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}]",325.0,0.211064,"No difference was observed between median progression-free survival in group B (5·7 months, 95% CI 4·2-7·2) and group C (HR 0·94 [0·64-1·38]; p=0·77).","[{'ForeName': 'Sara M', 'Initials': 'SM', 'LastName': 'Tolaney', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: sara_tolaney@dfci.harvard.edu.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Wardley', 'Affiliation': 'The NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Zambelli', 'Affiliation': 'Istituto Di Ricovero e Cura a Carattere Scientifico, Ospedale San Raffaele, IRCCS, Milano, Italy.'}, {'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'Hilton', 'Affiliation': 'Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada.'}, {'ForeName': 'Tiffany A', 'Initials': 'TA', 'LastName': 'Troso-Sandoval', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Ricci', 'Affiliation': 'Institut Curie, PSL Research University, Department of Medical Oncology, Paris, France.'}, {'ForeName': 'Seock-Ah', 'Initials': 'SA', 'LastName': 'Im', 'Affiliation': 'Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Sung-Bae', 'Initials': 'SB', 'LastName': 'Kim', 'Affiliation': 'Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.'}, {'ForeName': 'Stephen Rd', 'Initials': 'SR', 'LastName': 'Johnston', 'Affiliation': 'Royal Marsden Hospital, London, UK.'}, {'ForeName': 'Arlene', 'Initials': 'A', 'LastName': 'Chan', 'Affiliation': 'Breast Cancer Research Centre-WA, Nedlands, WA, Australia; Curtin University, Nedlands, WA, Australia.'}, {'ForeName': 'Shom', 'Initials': 'S', 'LastName': 'Goel', 'Affiliation': 'Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Catron', 'Affiliation': 'Eli Lilly, Indianapolis, IN, USA.'}, {'ForeName': 'Sonya C', 'Initials': 'SC', 'LastName': 'Chapman', 'Affiliation': 'Eli Lilly, Windlesham, UK.'}, {'ForeName': 'Gregory L', 'Initials': 'GL', 'LastName': 'Price', 'Affiliation': 'Eli Lilly, Indianapolis, IN, USA.'}, {'ForeName': 'Zhengyu', 'Initials': 'Z', 'LastName': 'Yang', 'Affiliation': 'Eli Lilly, Indianapolis, IN, USA.'}, {'ForeName': 'M Corona', 'Initials': 'MC', 'LastName': 'Gainford', 'Affiliation': 'Eli Lilly, Indianapolis, IN, USA.'}, {'ForeName': 'Fabrice', 'Initials': 'F', 'LastName': 'André', 'Affiliation': 'Gustave Roussy, Université Paris Saclay, INSERM, Villejuif, France.'}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30112-1'] 25,32335270,"The effect of acute intragastric vs. intravenous alcohol administration on inflammation markers, blood lipids and gallbladder motility in healthy men.","Ethanol intake increases plasma concentrations of triglycerides and chronic ethanol use impairs lipid metabolism and causes chronic inflammation. The gut plays an important role in metabolic handling of nutrients, including lipids, and a leaky gut associated with alcohol intake, allowing inflammatory signals to the portal vein, has been proposed to constitute a mechanism by which ethanol induces hepatic inflammation. We compared the effects of enteral and parenteral administration of ethanol on a range of circulating inflammation markers (including soluble CD163, a marker of liver macrophage activation), lipids, cholecystokinin (CCK) and fibroblast growth factor 19 (FGF19) as well as gallbladder volume. On two separate and randomized study days, we subjected healthy men (n = 12) to double-blinded intragastric ethanol infusion (IGEI) and isoethanolemic intravenous ethanol infusion (IVEI). Blood was sampled and ultrasonographic evaluation of gallbladder volume was performed at frequent intervals for 4 h after initiation of ethanol administration on both days. Little or no effects were observed on plasma levels of inflammation markers during IGEI and IVEI, respectively. Circulating levels of total, low-density lipoprotein and high-density lipoprotein cholesterol decreased after ethanol administration independently of the administration form. Triglyceride and very low-density lipoprotein (VLDL) cholesterol concentrations increased more after IGEI compared to IVEI. IVEI had no effect on plasma CCK and caused an increased gallbladder volume whereas IGEI elicited a CCK response (P < 0.0001) without affecting gallbladder volume. Circulating FGF19 concentrations decreased equally in response to both ethanol administration forms. In conclusion, by evaluating a range of circulating inflammation markers during IGEI and IVEI we were not able to detect signs of systemic low-grade inflammation originating from the presence of ethanol in the gut. IVEI increased gallbladder volume whereas IGEI increased plasma CCK (with neutral effect on gallbladder volume), increased plasma VLDL cholesterol and triglyceride concentrations; indicating that the enteral route of administration may influence ethanol's effects on lipid metabolism.",2020,"Circulating levels of total, low-density lipoprotein and high-density lipoprotein cholesterol decreased after ethanol administration independently of the administration form.","['healthy men', 'subjected healthy men (n=12) to']","['double-blinded intragastric ethanol infusion (IGEI) and isoethanolemic intravenous ethanol infusion (IVEI', 'Ethanol intake', 'acute intragastric vs. intravenous alcohol', 'ethanol']","['Triglyceride and very low-density lipoprotein (VLDL) cholesterol concentrations', 'plasma VLDL cholesterol and triglyceride concentrations', 'inflammation markers, blood lipids and gallbladder motility', 'Circulating levels of total, low-density lipoprotein and high-density lipoprotein cholesterol', 'lipid metabolism', 'plasma levels of inflammation markers', 'IVEI increased gallbladder volume whereas IGEI increased plasma CCK', 'gallbladder volume', 'Circulating FGF19 concentrations', 'plasma CCK', 'circulating inflammation markers (including soluble CD163, a marker of liver macrophage activation), lipids, cholecystokinin (CCK) and fibroblast growth factor 19 (FGF19']","[{'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0442113', 'cui_str': 'Intragastric'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}]","[{'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023825', 'cui_str': 'Very low density lipoprotein'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0023826', 'cui_str': 'VLDL cholesterol'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0016976', 'cui_str': 'Gallbladder structure'}, {'cui': 'C0007608', 'cui_str': 'Motility, Cell'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0442113', 'cui_str': 'Intragastric'}, {'cui': 'C0008328', 'cui_str': 'Cholecystokinin'}, {'cui': 'C1431711', 'cui_str': 'FGF19 protein, human'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0251113', 'cui_str': 'CD163 antigen'}, {'cui': 'C0022801', 'cui_str': 'Kupffer cell'}]",,0.130521,"Circulating levels of total, low-density lipoprotein and high-density lipoprotein cholesterol decreased after ethanol administration independently of the administration form.","[{'ForeName': 'Amalie R', 'Initials': 'AR', 'LastName': 'Lanng', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Lærke S', 'Initials': 'LS', 'LastName': 'Gasbjerg', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Natasha C', 'Initials': 'NC', 'LastName': 'Bergmann', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.'}, {'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Gillum', 'Affiliation': 'Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jens F', 'Initials': 'JF', 'LastName': 'Rehfeld', 'Affiliation': 'Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Mads M', 'Initials': 'MM', 'LastName': 'Helsted', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.'}, {'ForeName': 'Holger J', 'Initials': 'HJ', 'LastName': 'Møller', 'Affiliation': 'Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Henning', 'Initials': 'H', 'LastName': 'Grønbæk', 'Affiliation': 'Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Vilsbøll', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Copenhagen, Denmark.'}, {'ForeName': 'Filip K', 'Initials': 'FK', 'LastName': 'Knop', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Copenhagen, Denmark. Electronic address: filipknop@dadlnet.dk.'}]","Alcohol (Fayetteville, N.Y.)",['10.1016/j.alcohol.2020.04.006'] 26,32354201,Immediate Effects of Ankle-Foot Orthosis Using Wire on Static Balance of Patients with Stroke with Foot Drop: A Cross-Over Study.,"The aim of this study was to investigate the immediate static balance effects of bare foot, UD-Flex ankle-foot orthosis (AFO), and AFO using wire (AOW) of patients with stroke with foot drop. Seventeen patients with stroke with foot drop (8 men and 9 women) were randomized to three conditions (bare foot, UD-Flex AFO, or AOW made with a flexible material). Static balance was assessed using the Zebris (Zebris GmbH, Isny, Germany) and BioRescue (RM Ingenierie, Rodez, France) pressure platform by a single examiner, who did not design the AOW. The order of testing with the equipment was random. The center of pressure path length (mm) measured using Zebris showed significant differences among the three conditions (bare foot, 484.47 ± 208.42; UD-Flex AFO, 414.59 ± 144.43; AOW, 318.29 ± 157.60) ( p < 0.05). The bare-foot condition was not significantly different from the UD-Flex AFO condition ( p > 0.05), but was significantly different from the AOW condition ( p < 0.05). The surface area ellipse (mm 2 ) measured using BioRescue showed significant differences among the three conditions (bare foot, 241.35 ± 153.76; UD-Flex AFO, 277.41 ± 381.83; AOW, 68.06 ± 48.98) ( p < 0.05). The bare-foot condition was not significantly different from the UD-Flex AFO condition ( p > 0.05), but the AOW condition was significantly different from the bare-foot ( p < 0.05) and from the UD-Flex AFO conditions ( p < 0.05). We suggest using the AOW made of flexible materials and wire instead of the UD-Flex AFO to improve immediate static balance of patients with stroke with foot drop after stroke. Further studies on the effects of dynamic balance and gait are required.",2020,"The bare-foot condition was not significantly different from the UD-Flex AFO condition ( p > 0.05), but the AOW condition was significantly different from the bare-foot ( p < 0.05) and from the UD-Flex AFO conditions ( p < 0.05).","['patients with stroke with foot drop', 'patients with stroke with foot drop after stroke', 'Patients with Stroke with Foot Drop', 'Seventeen patients with stroke with foot drop (8 men and 9 women']","['bare foot, UD-Flex ankle-foot orthosis (AFO), and AFO using wire (AOW', 'Ankle-Foot Orthosis Using Wire']","['immediate static balance', 'Static Balance', 'Static balance', 'AOW condition', 'pressure path length', 'Zebris (Zebris GmbH, Isny, Germany) and BioRescue (RM Ingenierie, Rodez, France) pressure platform']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0085684', 'cui_str': 'Foot-drop'}, {'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C1283250', 'cui_str': 'Foot orthosis'}, {'cui': 'C0005978', 'cui_str': 'Bone wire'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0005978', 'cui_str': 'Bone wire'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0016674', 'cui_str': 'France'}]",17.0,0.0428504,"The bare-foot condition was not significantly different from the UD-Flex AFO condition ( p > 0.05), but the AOW condition was significantly different from the bare-foot ( p < 0.05) and from the UD-Flex AFO conditions ( p < 0.05).","[{'ForeName': 'Jung-Hoon', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Therapy, College of Nursing, Healthcare Sciences and Human Ecology, Dong-Eui University, Busan 47340, Korea.'}, {'ForeName': 'Im-Rak', 'Initials': 'IR', 'LastName': 'Choi', 'Affiliation': 'Department of Rehabilitation Therapy Team, Sports Exercise Therapy Center, Good Samsun Hospital Busan 47007, Korea.'}, {'ForeName': 'Hyun-Su', 'Initials': 'HS', 'LastName': 'Choi', 'Affiliation': 'Department of Biomedical Health Science, Graduate School, Dong-Eui University, Busan 47340, Korea.'}]","Healthcare (Basel, Switzerland)",['10.3390/healthcare8020116'] 27,32361805,CycleGAN-based deep learning technique for artifact reduction in fundus photography.,"PURPOSE A low quality of fundus photograph with artifacts may lead to false diagnosis. Recently, a cycle-consistent generative adversarial network (CycleGAN) has been introduced as a tool to generate images without matching paired images. Therefore, herein, we present a deep learning technique that removes the artifacts automatically in a fundus photograph using a CycleGAN model. METHODS This study included a total of 2206 anonymized retinal images including 1146 with artifacts and 1060 without artifacts. In this experiment, we applied the CycleGAN model to color fundus photographs with a pixel resolution of 256 × 256 × 3. To apply the CycleGAN to an independent dataset, we randomly divided the data into training (90%) and test (10%) datasets. Additionally, we adopted the automated quality evaluation (AQE) to assess the retinal image quality. RESULTS From the results, we observed that the artifacts such as overall haze, edge haze, lashes, arcs, and uneven illumination were successfully reduced by the CycleGAN in the generated images, and the main information of the retina was essentially retained. Further, we observed that most of the generated images exhibited improved AQE grade values when compared with the original images with artifacts. CONCLUSION Thus, we could conclude that the CycleGAN technique can effectively reduce the artifacts and improve the quality of fundus photographs, and it may be beneficial for clinicians in analyzing the low-quality fundus photographs. Future studies should improve the quality and resolution of the generated image to provide a more detailed fundus photography.",2020,"Further, we observed that most of the generated images exhibited improved AQE grade values when compared with the original images with artifacts. ","['fundus photography', '2206 anonymized retinal images including 1146 with artifacts and 1060 without artifacts']",['CycleGAN-based deep learning technique'],"['AQE grade values', 'overall haze, edge haze, lashes, arcs, and uneven illumination']","[{'cui': 'C0200189', 'cui_str': 'Ocular fundus photography'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0085089', 'cui_str': 'Artifact'}]","[{'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4704761', 'cui_str': 'Hierarchical Learning'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0441799', 'cui_str': 'Grading values'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205154', 'cui_str': 'Along edge'}, {'cui': 'C0001857', 'cui_str': 'AIDS related complex'}, {'cui': 'C0023693', 'cui_str': 'Light'}]",2206.0,0.0244645,"Further, we observed that most of the generated images exhibited improved AQE grade values when compared with the original images with artifacts. ","[{'ForeName': 'Tae Keun', 'Initials': 'TK', 'LastName': 'Yoo', 'Affiliation': 'Department of Ophthalmology, Medical Research Center, Aerospace Medical Center, Republic of Korea Air Force, 635 Danjae-ro, Sangdang-gu, Cheongju, South Korea. eyetaekeunyoo@gmail.com.'}, {'ForeName': 'Joon Yul', 'Initials': 'JY', 'LastName': 'Choi', 'Affiliation': 'Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Hong Kyu', 'Initials': 'HK', 'LastName': 'Kim', 'Affiliation': 'Department of Ophthalmology, Dankook University Hospital, Dankook University College of Medicine, Cheonan, South Korea.'}]",Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,['10.1007/s00417-020-04709-5'] 28,32359666,Abstinence outcomes among women in reproductive health centers administered clinician or electronic brief interventions.,"Treatment of substance use in women seeking reproductive healthcare is crucial for the health of both women and their offspring. Although abstinence from all substance use during pregnancy is optimal, it is difficult to achieve. This secondary analysis reports abstinence outcomes from a randomized clinical trial of screening, brief intervention, and referral to treatment (SBIRT) for substance use among women seeking reproductive healthcare services. Women who screened positive for substance use were randomly assigned to either clinician-administered SBIRT, an electronically-administered brief intervention (e-SBIRT), or an enhanced usual care condition. At a 6-month follow-up assessment, compared to enhanced usual care, the clinician-administered SBIRT increased 1-month point prevalence of abstinence from the primary substance by 7.7%, and e-SBIRT increased abstinence by 12.8%. Both brief interventions were more useful than enhanced usual care and could increase substance use abstinence rates among women in reproductive healthcare clinics. The electronic brief intervention is particularly attractive given that it appears as efficacious as, but requires fewer resources than, clinician-delivered brief interventions.",2020,Both brief interventions were more useful than enhanced usual care and could increase substance use abstinence rates among women in reproductive healthcare clinics.,"['Women who screened positive for substance use', 'women in reproductive health centers administered clinician or electronic brief interventions', 'women seeking reproductive healthcare services', 'women in reproductive healthcare clinics', 'women seeking reproductive healthcare']","['clinician-administered SBIRT, an electronically-administered brief intervention (e-SBIRT), or an enhanced usual care condition', 'screening, brief intervention, and referral to treatment (SBIRT']","['Abstinence outcomes', 'substance use abstinence rates']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0242667', 'cui_str': 'Reproductive Health'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0035150', 'cui_str': 'Reproduction'}, {'cui': 'C0557829', 'cui_str': 'Healthcare services'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}]","[{'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}]",,0.0489737,Both brief interventions were more useful than enhanced usual care and could increase substance use abstinence rates among women in reproductive healthcare clinics.,"[{'ForeName': 'Kimberly A', 'Initials': 'KA', 'LastName': 'Yonkers', 'Affiliation': 'Department of Psychiatry, Yale School of Medicine, 300 George Street, New Haven, CT 06511, USA; Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA; Department of Epidemiology and Public Health, Yale School of Medicine, 60 College Street, New Haven, CT 06510, USA. Electronic address: Kimberly.Yonkers@yale.edu.'}, {'ForeName': 'Jason I', 'Initials': 'JI', 'LastName': 'Dailey', 'Affiliation': 'Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA. Electronic address: Jason.I.Dailey.mil@mail.mil.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Gilstad-Hayden', 'Affiliation': 'Department of Psychiatry, Yale School of Medicine, 300 George Street, New Haven, CT 06511, USA. Electronic address: Kathryn.Gilstad-Hayden@yale.edu.'}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Ondersma', 'Affiliation': 'Wayne State University, Merrill Palmer Skillman Institute, 71 E. Ferry Ave, Detroit, MI 48202, USA. Electronic address: s.ondersma@wayne.edu.'}, {'ForeName': 'Ariadna', 'Initials': 'A', 'LastName': 'Forray', 'Affiliation': 'Department of Psychiatry, Yale School of Medicine, 300 George Street, New Haven, CT 06511, USA. Electronic address: Ariadna.Forray@yale.edu.'}, {'ForeName': 'Todd A', 'Initials': 'TA', 'LastName': 'Olmstead', 'Affiliation': 'University of Texas at Austin, PO Box Y, Austin, TX 78713, USA. Electronic address: TOlmstead@austin.utexas.edu.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Martino', 'Affiliation': 'Department of Psychiatry, Yale School of Medicine, 300 George Street, New Haven, CT 06511, USA; VA Connecticut Healthcare System, 950 Campbell Avenue, West Haven, CT 06516, USA. Electronic address: Steve.Martino@yale.edu.'}]",Journal of substance abuse treatment,['10.1016/j.jsat.2020.02.012'] 29,32359702,"Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial.",,2020,,['Upper Tract Urothelial Carcinoma (the POUT Trial'],['Re: Adjuvant Chemotherapy'],[],"[{'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0007138', 'cui_str': 'Transitional cell carcinoma'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}]",[],,0.179276,,"[{'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Afferi', 'Affiliation': 'Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Moschini', 'Affiliation': 'Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy; Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.'}, {'ForeName': 'Agostino', 'Initials': 'A', 'LastName': 'Mattei', 'Affiliation': 'Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Montorsi', 'Affiliation': 'Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy; Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Briganti', 'Affiliation': 'Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy; Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Cathelineau', 'Affiliation': 'Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Sanchez-Salas', 'Affiliation': 'Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France. Electronic address: rafael.sanchez-salas@imm.fr.'}]",European urology,['10.1016/j.eururo.2020.04.006'] 30,32304911,"60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study.",,2020,,['Chinese patients with chronic coronary syndrome'],"['clopidogrel', 'ticagrelor']",['platelet inhibition'],"[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}]","[{'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}]","[{'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}]",,0.0257739,,"[{'ForeName': 'Meijiao', 'Initials': 'M', 'LastName': 'He', 'Affiliation': ""Cardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ""Cardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Yan', 'Affiliation': ""Cardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Guangzhong', 'Initials': 'G', 'LastName': 'Liu', 'Affiliation': ""Cardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Danghui', 'Initials': 'D', 'LastName': 'Sun', 'Affiliation': ""Cardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Yuan', 'Affiliation': ""Cardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': ""Cardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.""}, {'ForeName': 'Yihui', 'Initials': 'Y', 'LastName': 'Kong', 'Affiliation': ""Cardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China. Electronic address: kongyihui@126.com.""}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ""Cardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China; Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Harbin, People's Republic of China. Electronic address: ly99ly@vip.163.com.""}]",Thrombosis research,['10.1016/j.thromres.2020.03.014'] 31,32393498,Plasmodium falciparum Isolates Carrying pf k13 Polymorphisms Harbor the SVMNT Allele of pfcrt in Northwestern Indonesia.,"Artemisinin-based combination therapy (ACT) is the first-line antimalarial regimen in Indonesia. Susceptibility of Plasmodium falciparum to artemisinin is falling in the Greater Mekong subregion, but it is not known whether the efficacy of current combinations is also threatened in nearby Sumatera. We evaluated the genetic loci pfcrt, pfmdr1 , and pfk13 , considered to be under selection by artemisinin combination therapy, among 404 P. falciparum infections identified by PCR detection in a cross-sectional survey of 3,731 residents of three regencies. The pfcrt haplotype SVMNT (codons 72 to 76) was the most prevalent and displayed significant linkage disequilibrium with the pfmdr1 haplotype YY (codons 86 and 184) (odds ratio [OR] 26.7; 95% confidence interval [CI], 5.96 to 239.4; P <  0.001). This contrasts with Mekong countries, where the CVIET haplotype of pfcrt predominates. Among 231 evaluable isolates, only 9 (3.9%) showed any evidence of nonsynonymous gene variants in the propeller domain of pfk13 The Thr474Ala variant was seen in six individuals, and Cys580Tyr was identified with low confidence in only a single isolate from an asymptomatic individual. Among a subset of 117 symptomatic P. falciparum -infected individuals randomized to receive either dihydroartemisinin-piperaquine or artemether-lumefantrine, the treatment outcome was not associated with pretreatment genotype. However, submicroscopic persistent parasites at day 28 or day 42 of follow-up were significantly more likely to harbor the pfmdr1 haplotype NF (codons 86 and 184) than were pretreatment isolates ( P  < 0.001 for both treatment groups). Current ACT regimens appear to be effective in Sumatera, but evidence of persistent submicroscopic infection in some patients suggests further detailed studies of drug susceptibility should be undertaken.",2020,"Among 231 evaluable isolates, only nine (3.9%) showed any evidence of non-synonymous gene variants in the propeller domain of pfk13 ","['Plasmodium faciparum carrying pf k13 polymorphisms harbour the SVMNT allele of pfcrt in north-western Indonesia', '3,731 residents of three Regencies']","['dihydroartemisinin-piperaquine or artemether-lumefantrine', 'Artemisinin-based combination therapy']",[],"[{'cui': 'C0032148', 'cui_str': 'Plasmodium'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}, {'cui': 'C1673263', 'cui_str': 'KRT13 protein, human'}, {'cui': 'C0032529', 'cui_str': 'Genetic polymorphism'}, {'cui': 'C0475311', 'cui_str': 'Harbor'}, {'cui': 'C0002085', 'cui_str': 'Genetic alleles'}, {'cui': 'C0021247', 'cui_str': 'Indonesia'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}]","[{'cui': 'C0058108', 'cui_str': 'dihydroartemisinin'}, {'cui': 'C0071105', 'cui_str': 'piperaquine'}, {'cui': 'C0936150', 'cui_str': 'artemether and lumefantrine'}, {'cui': 'C0052430', 'cui_str': 'artemisinin'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}]",[],,0.0499095,"Among 231 evaluable isolates, only nine (3.9%) showed any evidence of non-synonymous gene variants in the propeller domain of pfk13 ","[{'ForeName': 'Inke N D', 'Initials': 'IND', 'LastName': 'Lubis', 'Affiliation': 'Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Hendri', 'Initials': 'H', 'LastName': 'Wijaya', 'Affiliation': 'Department of Paediatrics, University of Sumatera Utara, Medan, Indonesia.'}, {'ForeName': 'Munar', 'Initials': 'M', 'LastName': 'Lubis', 'Affiliation': 'Department of Paediatrics, University of Sumatera Utara, Medan, Indonesia.'}, {'ForeName': 'Chairuddin P', 'Initials': 'CP', 'LastName': 'Lubis', 'Affiliation': 'Department of Paediatrics, University of Sumatera Utara, Medan, Indonesia.'}, {'ForeName': 'Khalid B', 'Initials': 'KB', 'LastName': 'Beshir', 'Affiliation': 'Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Colin J', 'Initials': 'CJ', 'LastName': 'Sutherland', 'Affiliation': 'Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom colin.sutherland@lshtm.ac.uk.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.02539-19'] 32,32394089,Simulation Training in Neuroangiography: Transfer to Reality.,"PURPOSE Endovascular simulation is an established and validated training method, but there is still no proof of direct patient's benefit, defined as lower complication rate. In this study, the impact of such a training was investigated for rehearsal of patient-specific cases as well as for a structured simulation curriculum to teach angiographer novices. MATERIALS AND METHODS A total of 40 patients undergoing a diagnostic neuroangiography were randomized in a training and control group. In all training group patients, the angiographer received a patient-anatomy-specific rehearsal on a high-fidelity simulator prior to the real angiography. Radiation exposure, total duration, fluoroscopy time and amount of contrast agent of the real angiography were recorded. Silent cerebral ischemia was counted by magnetic resonance diffusion-weighted imaging (DWI). Additionally, the first 30 diagnostic neuroangiographies of six novices were compared (n total  = 180). Three novices had undergone a structured simulation curriculum; three had acquired angiographic skills without simulation. RESULTS No differences were found in the number of DWI lesions or in other quality measures of the angiographies performed with and without patient-specific rehearsal. A structured simulation curriculum for angiographer novices reduced fluoroscopy time significantly and radiation exposure. The curriculum had no influence on the total duration of the examination, the amount of contrast medium or the number of catheters used. CONCLUSION There was no measurable benefit of patient-anatomy-specific rehearsal for an unselected patient cohort. A structured simulation-based curriculum to teach angiographic skills resulted in a reduction of fluoroscopy time and radiation dose in the first real angiographies of novice angiographers. LEVEL OF EVIDENCE Level 4, part 1: randomized trial, part 2: historically controlled study.",2020,"A structured simulation-based curriculum to teach angiographic skills resulted in a reduction of fluoroscopy time and radiation dose in the first real angiographies of novice angiographers. ",['40 patients undergoing a diagnostic neuroangiography'],['patient-anatomy-specific rehearsal on a high-fidelity simulator prior to the real angiography'],"['number of DWI lesions', 'total duration of the examination, the amount of contrast medium or the number of catheters used', 'Radiation exposure, total duration, fluoroscopy time and amount of contrast agent of the real angiography', 'fluoroscopy time', 'patient-anatomy-specific rehearsal', 'Silent cerebral ischemia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002808', 'cui_str': 'Anatomy'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0449806', 'cui_str': 'Number of catheters'}, {'cui': 'C0015333', 'cui_str': 'Exposure to radiation'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002808', 'cui_str': 'Anatomy'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0443304', 'cui_str': 'Silent'}, {'cui': 'C0007785', 'cui_str': 'Cerebral infarction'}]",40.0,0.0386447,"A structured simulation-based curriculum to teach angiographic skills resulted in a reduction of fluoroscopy time and radiation dose in the first real angiographies of novice angiographers. ","[{'ForeName': 'Kornelia', 'Initials': 'K', 'LastName': 'Kreiser', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. kornelia.kreiser@tum.de.'}, {'ForeName': 'Kim G', 'Initials': 'KG', 'LastName': 'Gehling', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.'}, {'ForeName': 'Lea', 'Initials': 'L', 'LastName': 'Ströber', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Zimmer', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.'}, {'ForeName': 'Jan S', 'Initials': 'JS', 'LastName': 'Kirschke', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.'}]",Cardiovascular and interventional radiology,['10.1007/s00270-020-02479-5'] 33,32394851,[Antihypertensive and Vasoprotective Effects of Combined Pharmacotherapy in Patients with Arterial Hypertension and Prediabetes].,"Aim To evaluate effects of different types of combination drug therapy on indexes of 24-h blood pressure monitoring (24-h BPM), arterial stiffness, and central aortic pressure (CAP) in patients with arterial hypertension (AH) and prediabetes.Materials and methods The study included 120 patients with AH and prediabetes. After randomization using envelopes, three treatment groups were formed: group 1, patients receiving perindopril, indapamide SR, and metformin (n=40); group 2, patients receiving perindopril, moxonidin, and metformin (n=40); and group 3, patients receiving perindopril, indapamide SR, and amlodipine (n=40). 24-h BPM, determination of arterial stiffness, and measurement of CAP were performed for all patients.Results After 24 weeks of treatment, patients of all groups showed statistically significant improvements of most indexes of 24-h BPM, arterial stiffness, and CAP. In groups 2 and 3, the treatment was associated with significantly more pronounced beneficial changes in 24-BPM, arterial stiffness, and CAP compared to group 1. Antihypertensive and vasoprotective effects of the perindopril+moxonidin+metformin and perindopril+indopamide SR+amlodipine combinations were comparable.Conclusion The observed statistically significant antihypertensive and vasoprotective effects of the perindopril+moxonidin+metformin combination along with its known positive metabolic effect allow recommendation of this combination therapy to patients with AH and prediabetes as an effective strategy for BP control.",2020,"In groups 2 and 3, the treatment was associated with significantly more pronounced beneficial changes in 24-BPM, arterial stiffness, and CAP compared to group 1.","['Patients with Arterial Hypertension and Prediabetes', 'patients with arterial hypertension (AH) and prediabetes', '120 patients with AH and prediabetes']","['perindopril, indapamide SR, and metformin', 'Combined Pharmacotherapy', 'perindopril+moxonidin+metformin', 'perindopril, indapamide SR, and amlodipine', 'combination drug therapy', 'perindopril, moxonidin, and metformin', 'perindopril+moxonidin+metformin and perindopril+indopamide SR+amlodipine combinations']","['24-BPM, arterial stiffness, and CAP', '24-h blood pressure monitoring (24-h BPM), arterial stiffness, and central aortic pressure (CAP', '24-h BPM, arterial stiffness, and CAP', '24-h BPM, determination of arterial stiffness, and measurement of CAP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C4319550', 'cui_str': '120'}]","[{'cui': 'C0136123', 'cui_str': 'Perindopril'}, {'cui': 'C0021186', 'cui_str': 'Indapamide'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0051696', 'cui_str': 'Amlodipine'}, {'cui': 'C0013218', 'cui_str': 'Combination Drug Therapy'}, {'cui': 'C0066837', 'cui_str': 'moxonidine'}]","[{'cui': 'C0439385', 'cui_str': 'beats/min'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0456180', 'cui_str': 'Aortic pressure'}, {'cui': 'C0026426', 'cui_str': 'Blood pressure monitoring'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",120.0,0.0285572,"In groups 2 and 3, the treatment was associated with significantly more pronounced beneficial changes in 24-BPM, arterial stiffness, and CAP compared to group 1.","[{'ForeName': 'V V', 'Initials': 'VV', 'LastName': 'Skibitskiy', 'Affiliation': 'State Budget Educational Institution of Higher Professional Education ""Kuban State Medical University"" of the Ministry of Health of the Russian Federation.'}, {'ForeName': 'S R', 'Initials': 'SR', 'LastName': 'Gutova', 'Affiliation': 'State budgetary health institution of the Republic of Adygea ""Maykop City Clinical Hospital"".'}, {'ForeName': 'A V', 'Initials': 'AV', 'LastName': 'Fendrikova', 'Affiliation': 'State Budget Educational Institution of Higher Professional Education ""Kuban State Medical University"" of the Ministry of Health of the Russian Federation.'}, {'ForeName': 'A V', 'Initials': 'AV', 'LastName': 'Skibitskiy', 'Affiliation': 'State Budget Educational Institution of Higher Professional Education ""Kuban State Medical University"" of the Ministry of Health of the Russian Federation.'}]",Kardiologiia,['10.18087/cardio.2020.4.n1112'] 34,32394874,Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome TM ) and Short-Course Miltefosine in Comparison to Miltefosine Monotherapy.,"Visceral leishmaniasis (VL) is endemic in Asia, East and North Africa, South America, and Southern Europe, and is a major public health problem in the Indian subcontinent. Miltefosine received approval in 2002 to treat VL in India, and the Indian National Vector Borne Disease Control Programme later adopted a single dose (10 mg/kg) of liposomal amphotericin B. We report results of a randomized trial comparing the efficacy of combination therapy with an Indian preparation of liposomal amphotericin B (single dose of 7.5 mg/kg) and short-course miltefosine (2.5 mg/kg/day for 14 days; n = 66) in comparison to miltefosine monotherapy (2.5 mg/kg/day for 28 days; n = 78). Nine patients in the miltefosine group and three in the combination therapy group had to discontinue therapy because of serious adverse events. At the end of the therapy, the clinical and parasitological cure rate was 100% in both groups. By per-protocol analysis, by 6 months after completion of treatment, 12 of 69 patients in the miltefosine monotherapy arm (17.4%, 95% CI: 10.24-28%) and none in the combination therapy arm had relapse. Over 5 years of follow-up, 10 patients in the miltefosine monotherapy arm (all within 0.5-2 years after completing therapy) and none in the combination therapy arm experienced post-kala-azar dermal leishmaniasis. Combination therapy offered benefits over miltefosine monotherapy for VL in India.",2020,"At the end of the therapy, the clinical and parasitological cure rate was 100% in both groups.","['Visceral leishmaniasis (VL) is endemic in Asia, East and North Africa, South America, and Southern Europe']","['Miltefosine', 'miltefosine', 'liposomal amphotericin', 'miltefosine monotherapy', 'liposomal amphotericin B (single dose of 7.5 mg/kg) and short-course miltefosine', 'Liposomal Amphotericin B (Fungisome TM ) and Short-Course Miltefosine']","['relapse', 'discontinue therapy because of serious adverse events', 'clinical and parasitological cure rate']","[{'cui': 'C0023290', 'cui_str': 'Visceral leishmaniasis'}, {'cui': 'C0243130', 'cui_str': 'endemics'}, {'cui': 'C0003980', 'cui_str': 'Asia'}, {'cui': 'C0001745', 'cui_str': 'Northern Africa'}, {'cui': 'C0037713', 'cui_str': 'South America'}, {'cui': 'C0037724', 'cui_str': 'Southern Europe'}]","[{'cui': 'C0068006', 'cui_str': 'miltefosine'}, {'cui': 'C1145701', 'cui_str': 'amphotericin B liposomal'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0750729', 'cui_str': 'Courses'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205468', 'cui_str': 'Parasitologic'}]",,0.0417871,"At the end of the therapy, the clinical and parasitological cure rate was 100% in both groups.","[{'ForeName': 'Rama Prosad', 'Initials': 'RP', 'LastName': 'Goswami', 'Affiliation': 'Department of Tropical Medicine, School of Tropical Medicine, Kolkata, India.'}, {'ForeName': 'Mehebubar', 'Initials': 'M', 'LastName': 'Rahman', 'Affiliation': 'Department of Tropical Medicine, School of Tropical Medicine, Kolkata, India.'}, {'ForeName': 'Sukhen', 'Initials': 'S', 'LastName': 'Das', 'Affiliation': 'Department of Tropical Medicine, School of Tropical Medicine, Kolkata, India.'}, {'ForeName': 'Santanu Kumar', 'Initials': 'SK', 'LastName': 'Tripathi', 'Affiliation': 'Department of Clinical and Experimental Pharmacology, School of Tropical Medicine, Kolkata, India.'}, {'ForeName': 'Rudra Prosad', 'Initials': 'RP', 'LastName': 'Goswami', 'Affiliation': 'Department of Rheumatology, All India Institute of Medical Sciences, New Delhi, India.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.19-0931'] 35,32392699,Comparison of the Hemodynamic Performance of Two Neuromuscular Electrical Stimulation Devices Applied to the Lower Limb.,"Currently, 1% of the population of the Western world suffers from venous leg ulcers as a result of chronic venous insufficiency. Current treatment involves the use of moist wound healing, compression bandages, and intermittent pneumatic compression. Neuromuscular electrical stimulation is a novel potential new therapeutic method for the promotion of increased lower limb hemodynamics. The aim of this study was to measure the hemodynamic changes in the lower limb with the use of two neuromuscular electrical stimulation devices. Twelve healthy volunteers received two neuromuscular stimulation device interventions. The Geko TM and National University of Ireland (NUI) Galway neuromuscular electrical stimulation devices were randomized between dominant and non-dominant legs. Hemodynamic measurements of peak venous velocity (cm/s), the time average mean velocity (TAMEAN) (cm/s), and ejected volume (mL) of blood were recorded. Peak venous velocity was significantly increased by the Geko TM and the NUI Galway device compared to baseline blood flow ( p < 0.0001), while only the voluntary contraction produced significant increases in TAMEAN and ejected volume (both p < 0.05). Neuromuscular muscular electrical stimulation can produce adequate increases in lower limb hemodynamics sufficient to prevent venous stasis. Greater use of neuromuscular stimulation devices could be considered in the treatment of conditions related to chronic venous insufficiency but requires further research.",2020,"Peak venous velocity was significantly increased by the Geko TM and the NUI Galway device compared to baseline blood flow ( p < 0.0001), while only the voluntary contraction produced significant increases in TAMEAN and ejected volume (both p < 0.05).",['Twelve healthy volunteers'],"['neuromuscular electrical stimulation devices', 'neuromuscular stimulation device interventions', 'Neuromuscular electrical stimulation', 'Neuromuscular muscular electrical stimulation', 'Two Neuromuscular Electrical Stimulation Devices', 'neuromuscular stimulation devices']","['hemodynamic changes', 'Peak venous velocity', 'Hemodynamic measurements of peak venous velocity (cm/s), the time average mean velocity (TAMEAN']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0454448', 'cui_str': 'Neuromuscular stimulation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}]","[{'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0429871', 'cui_str': 'Venous velocity'}, {'cui': 'C0204901', 'cui_str': 'Hemodynamic measurements'}, {'cui': 'C0439392', 'cui_str': 'cm/s'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}]",12.0,0.0233083,"Peak venous velocity was significantly increased by the Geko TM and the NUI Galway device compared to baseline blood flow ( p < 0.0001), while only the voluntary contraction produced significant increases in TAMEAN and ejected volume (both p < 0.05).","[{'ForeName': 'Sahar', 'Initials': 'S', 'LastName': 'Avazzadeh', 'Affiliation': 'Physiology, School of Medicine, NUI Galway, University Road, Galway H91 TK33, Ireland.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': ""O'Farrell"", 'Affiliation': 'Physiology, School of Medicine, NUI Galway, University Road, Galway H91 TK33, Ireland.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Flaherty', 'Affiliation': 'Physiology, School of Medicine, NUI Galway, University Road, Galway H91 TK33, Ireland.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': ""O'Connell"", 'Affiliation': 'Physiology, School of Medicine, NUI Galway, University Road, Galway H91 TK33, Ireland.'}, {'ForeName': 'Gearóid', 'Initials': 'G', 'LastName': 'ÓLaighin', 'Affiliation': 'Electrical & Electronic Engineering, School of Engineering, NUI Galway, University Road, Galway H91 TK33, Ireland.'}, {'ForeName': 'Leo R', 'Initials': 'LR', 'LastName': 'Quinlan', 'Affiliation': 'Physiology, School of Medicine, NUI Galway, University Road, Galway H91 TK33, Ireland.'}]",Journal of personalized medicine,['10.3390/jpm10020036'] 36,32398024,Web-based exercise versus supervised exercise for decreasing visceral adipose tissue in older adults with central obesity: a randomized controlled trial.,"BACKGROUND Visceral adipose tissue (VAT) is a strong risk factor for cardiovascular disease and increases with age. While supervised exercise (SE) may be an effective approach, web-based exercise (WE) have other advantages such as being more readily accessible. Therefore, we evaluated the effects of WE on VAT, body composition and cardiometabolic risk markers in centrally obese older adults and compared the effects of WE to SE. We also explored the feasibility of WE. METHODS In a randomized controlled trial conducted in Umeå, Sweden during January 2018 - November 2018, N = 77, 70-year-old men and women with central obesity (> 1 kg VAT for women, > 2 kg for men) were randomized to an intervention group (n = 38) and a wait-list control group (n = 39). The intervention group received 10 weeks of SE while the wait-list control group lived as usual. Following a 10-week wash-out-period, the wait-list control group received 10 weeks of WE. The primary outcome was changes in VAT. Secondary outcomes included changes in fat mass (FM), lean body mass (LBM), blood lipids, fasting blood glucose. Additionally, we explored the feasibility of WE defined as adherence and participant experiences. RESULTS WE had no significant effect on VAT (P = 0.5), although it decreased FM by 450 g (95% confidence interval [CI], 37 to 836, P < 0.05). The adherence to WE was 85% and 87-97% of the participants rated aspects of the WE intervention > 4 on a scale of 1-5. Comparing SE to WE, there was no significant difference in decrease of VAT (Cohen's δ effect size [ES], 0.5, 95% CI, - 24 to 223, P = 0.11), although SE decreased FM by 619 g (ES, 0.5, 95% CI, 22 to 1215, P < 0.05) compared to WE. CONCLUSIONS Ten weeks of vigorous WE is insufficient to decrease VAT in centrally obese older adults, but sufficient to decrease FM while preserving LBM. The high adherence and positive experiences of the WE intervention implies that it could serve as an alternative exercise strategy for older adults with central obesity, with increased availability for a larger population. TRIAL REGISTRATION ClinicalTrials.gov (NCT03450655), retrospectively registered February 28, 2018.",2020,"WE had no significant effect on VAT (P = 0.5), although it decreased FM by 450 g (95% confidence interval [CI], 37 to 836, P < 0.05).","['older adults with central obesity', 'Umeå, Sweden during January 2018 - November 2018, N\u2009=\u200977, 70-year-old men and women with central obesity (>\u20091\u2009kg VAT for women, >\u20092\u2009kg for men', 'centrally obese older adults']","['Web-based exercise versus supervised exercise', 'wait-list control group', 'supervised exercise (SE', '10\u2009weeks of SE while the wait-list control group lived as usual']","['VAT', 'changes in fat mass (FM), lean body mass (LBM), blood lipids, fasting blood glucose', 'changes in VAT', 'VAT, body composition and cardiometabolic risk markers', 'SE decreased FM']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0311277', 'cui_str': 'Abdominal Obesity'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4280965', 'cui_str': 'Greater than one'}, {'cui': 'C1563740', 'cui_str': 'Abdominal Visceral Fat'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}]","[{'cui': 'C1563740', 'cui_str': 'Abdominal Visceral Fat'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}]",,0.245774,"WE had no significant effect on VAT (P = 0.5), although it decreased FM by 450 g (95% confidence interval [CI], 37 to 836, P < 0.05).","[{'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Ballin', 'Affiliation': 'Department of Community Medicine and Rehabilitation, Unit of Geriatric Medicine, Umeå University, 901 87, Umeå, Sweden. marcel.ballin@umu.se.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Hult', 'Affiliation': 'Department of Public Health and Clinical Medicine, Section of Sustainable Health, Umeå University, Umeå, Sweden.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Björk', 'Affiliation': 'Department of Public Health and Clinical Medicine, Section of Sustainable Health, Umeå University, Umeå, Sweden.'}, {'ForeName': 'Emmy', 'Initials': 'E', 'LastName': 'Lundberg', 'Affiliation': 'Department of Public Health and Clinical Medicine, Section of Sustainable Health, Umeå University, Umeå, Sweden.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Nordström', 'Affiliation': 'Department of Community Medicine and Rehabilitation, Unit of Geriatric Medicine, Umeå University, 901 87, Umeå, Sweden.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Nordström', 'Affiliation': 'Department of Public Health and Clinical Medicine, Section of Sustainable Health, Umeå University, Umeå, Sweden.'}]",BMC geriatrics,['10.1186/s12877-020-01577-w'] 37,32396535,"Proficiency based progression simulation training significantly reduces utility strikes; A prospective, randomized and blinded study.","OBJECTIVES We evaluated a simulation-based training curriculum with quantitatively defined performance benchmarks for utility workers location and excavation of utility services. BACKGROUND Damaging buried utilities is associated with considerable safety risks to workers and substantial cost to employers. METHODS In a prospective, randomized and blinded study we assessed the impact of Proficiency Based Progression (PBP) simulation training on the location and excavation of utility services work. RESULTS PBP simulation training reduced performance errors (33%, p = 0.006) in comparison a standard trained group. When implemented across all workers in the same division there was a 35-61% reduction in utility strikes (p = 0.028) and an estimated cost saving of £116,000 -£2,175,000 in the 12 months (47,000 work hours) studied. CONCLUSIONS The magnitude of the training benefit of PBP simulation training in the utilities sector appears to be the same as it is in surgery, cardiology and procedure-based medicine. APPLICATION Quality-assured utility worker simulation training significantly reduces utility damage and associated costs.",2020,"RESULTS PBP simulation training reduced performance errors (33%, p = 0.006) in comparison a standard trained group.",[],"['Proficiency based progression simulation training', 'PBP simulation training', 'Proficiency Based Progression (PBP) simulation training']","['performance errors', 'utility strikes']",[],"[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C4042947', 'cui_str': 'Simulation Training'}]","[{'cui': 'C0038452', 'cui_str': 'Employee Strikes'}]",,0.038472,"RESULTS PBP simulation training reduced performance errors (33%, p = 0.006) in comparison a standard trained group.","[{'ForeName': 'Anthony G', 'Initials': 'AG', 'LastName': 'Gallagher', 'Affiliation': 'Faculty of Life and Health Sciences, Ulster University, Magee Campus, Londonderry, Northern Ireland, United Kingdom.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hart', 'Affiliation': 'Group Training and Development Manager, ReachActive Unit 4B Lough Sheever Corporate Park, Mullingar, Co. Westmeath, Ireland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cleary', 'Affiliation': 'ReachActive, Mullingar, Co. Westmeath, Ireland.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Hamilton', 'Affiliation': 'ReachActive, Hertford, England, United Kingdom.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'McGlinchey', 'Affiliation': 'ReachActive, Mullingar, Co. Westmeath, Ireland.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Kiely', 'Affiliation': 'Flux Learning Ltd., Clonakilty, Co Cork, Ireland.'}, {'ForeName': 'Brendan P', 'Initials': 'BP', 'LastName': 'Bunting', 'Affiliation': 'School of Psychology, Coleraine, Co. Londonderry, Northern Ireland, United Kingdom.'}]",PloS one,['10.1371/journal.pone.0231979'] 38,32396564,The effect of monetary incentive on survey response for vulnerable children and youths: A randomized controlled trial.,"AIM In surveys non-responders may introduce bias and lower the validity of the studies. Ways to increase response rates are therefore important. The purpose of the study was to investigate if an unconditional monetary incentive can increase the response rate for vulnerable children and youths in a postal questionnaire survey. METHODS The study was designed as a randomized controlled trial. The study population consisted of 262 children and youth who participated in an established intervention study aimed at creating networks for different groups of vulnerable children and youths. The mean age of the participants was 16.7 years (range 11-28) and 67.9% were female. The questionnaire was adapted to three different age groups and covered different aspects of the participants' life situation, including the dimensions from the Strengths and Difficulties Questionnaire (SDQ). In the follow-up survey, participants were randomly allocated to two groups that either received a €15 voucher for a supermarket together with the questionnaire or only received the questionnaire. We used Poisson regression to estimate the differences in response rate (Rate Ratio RR) between the intervention group and the control group. RESULTS The response rate was 75.5% in the intervention group and 42.9% in the control group. The response rate in the intervention group was significantly higher than in the control group when adjusting for age and gender (Rate Ratio, RR 1.73; 95% CI 1.38-2.17). We did not find any significant differences in scales scores between the two groups for the five scales of the SDQ. In stratified analyses, we found the effect of the incentive to be higher for males (RR 2.81; 95% CI 1.61-4.91) than for females (1.43; 95% CI 1.12-1.84). CONCLUSIONS Monetary incentives can increase the response rate for vulnerable children and youths in surveys. TRIAL REGISTRATION The trial was retrospectively registered at ClinicalTrials.gov Identifier: NCT01741675.",2020,"The response rate in the intervention group was significantly higher than in the control group when adjusting for age and gender (Rate Ratio, RR 1.73; 95% CI 1.38-2.17).","['The mean age of the participants was 16.7 years (range 11-28) and 67.9% were female', 'vulnerable children and youths', '262 children and youth who participated in an established intervention study aimed at creating networks for different groups of vulnerable children and youths', 'vulnerable children and youths in a postal questionnaire survey', 'vulnerable children and youths in surveys']","['monetary incentive', '€15 voucher for a supermarket together with the questionnaire or only received the questionnaire']","['survey response', 'response rate', 'response rate (Rate Ratio RR', 'scales scores']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517590', 'cui_str': '16.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0425119', 'cui_str': 'Child at risk'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1096775', 'cui_str': 'Intervention Study'}, {'cui': 'C2744535', 'cui_str': 'CD69 protein, human'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]","[{'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0557778', 'cui_str': 'Supermarket'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",262.0,0.0763144,"The response rate in the intervention group was significantly higher than in the control group when adjusting for age and gender (Rate Ratio, RR 1.73; 95% CI 1.38-2.17).","[{'ForeName': 'Jan Hyld', 'Initials': 'JH', 'LastName': 'Pejtersen', 'Affiliation': 'VIVE-The Danish Center for Social Science Research, Copenhagen, Denmark.'}]",PloS one,['10.1371/journal.pone.0233025'] 39,32396578,Special footwear designed for pregnant women and its effect on kinematic gait parameters during pregnancy and postpartum period.,"During pregnancy, an array of changes occurs in women body to enable the growth and development of the future baby and the consequent delivery. These changes are reflected in the range of motion of trunk, pelvis, lower limbs and other body segments, affect the locomotion and some of these changes may persist to the postpartum period. The aim of this study was to describe the changes affecting the gait during pregnancy and to determine the effect of tested footwear on kinematic gait characteristics during pregnancy as previous studies indicate that special orthopaedic insoles and footwear might be useful in prevention of the common musculoskeletal pain and discomfort related to pregnancy. Participants from the control group (n = 18), without any intervention, and the experimental group (n = 23), which was wearing the tested shoes, were measured at their 14, 28 and 37 gestational weeks and 28 weeks postpartum to capture the complete pregnancy-related changes in gait. The gait 3D kinematic data were obtained using Simi Motion System. The differences between the control and experimental group at the first data collection session in most of the analysed variables, as well as relatively high standard deviations of analysed variables indicate large individual differences in the gait pattern. The effect of tested footwear on kinematic gait pattern changes may be explained by its preventive effect against the foot arches falling. In the control group, changes associated previously with the foot arches falling and hindfoot hyperpronation were observed during advanced phases of pregnancy and postpartum, e.g. increase in knee flexion or increase in spinal curvature. For the comprehensive evaluation of the tested footwear on pregnancy gait pattern, future studies combining the kinematic and dynamic plantographic methods are needed.",2020,"The differences between the control and experimental group at the first data collection session in most of the analysed variables, as well as relatively high standard deviations of analysed variables indicate large individual differences in the gait pattern.",['pregnant women'],[],"['knee flexion or increase in spinal curvature', 'kinematic gait parameters', 'foot arches falling and hindfoot hyperpronation']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}]",[],"[{'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0037932', 'cui_str': 'Curvature of spine'}, {'cui': 'C0600169', 'cui_str': 'Kinematics'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0230467', 'cui_str': 'Structure of arch of foot'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0230459', 'cui_str': 'Hindfoot'}]",,0.0341883,"The differences between the control and experimental group at the first data collection session in most of the analysed variables, as well as relatively high standard deviations of analysed variables indicate large individual differences in the gait pattern.","[{'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Gimunová', 'Affiliation': 'Department of Kinesiology, Faculty of Sports Studies, Masaryk University, Brno, Czech Republic.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Zvonař', 'Affiliation': 'Department of Kinesiology, Faculty of Sports Studies, Masaryk University, Brno, Czech Republic.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Sebera', 'Affiliation': 'Department of Kinesiology, Faculty of Sports Studies, Masaryk University, Brno, Czech Republic.'}, {'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Turčínek', 'Affiliation': 'Department of Informatics, Faculty of Business and Economics, Mendel University, Brno, Czech Republic.'}, {'ForeName': 'Kateřina', 'Initials': 'K', 'LastName': 'Kolářová', 'Affiliation': 'Department of Kinesiology, Faculty of Sports Studies, Masaryk University, Brno, Czech Republic.'}]",PloS one,['10.1371/journal.pone.0232901'] 40,32400321,Effectiveness trial of an online self-help intervention for sexual problems after cancer.,"Sexual dysfunction affects over 60% of cancer survivors. Internet interventions have improved sexual function, but with considerable clinician guidance, restricting scalability. This pragmatic trial evaluated an online, self-help intervention. As with many unguided digital interventions, attrition was high. Given low numbers in other groups, this paper focuses on 30% of female patient participants who completed 3-month questionnaires and visited the intervention site (N = 60). Benefits included increased sexually active individuals at follow-up (p < 0.001, Effect size = 0.54), improved sexual function (p < 0.001, Effect size = -0.76, N = 41), and increased use of sexual aids (p = 0.01, Effect size=-0.14, N = 58). The intervention has been revised to improve patient engagement.",2020,"Benefits included increased sexually active individuals at follow-up (p < 0.001, Effect size = 0.54), improved sexual function (p < 0.001, Effect size = -0.76, N = 41), and increased use of sexual aids (p = 0.01, Effect size=-0.14, N = 58).","['female patient participants who completed 3-month questionnaires and visited the intervention site (N\u2009=\u200960', 'sexual problems after cancer']",['online self-help intervention'],"['use of sexual aids', 'sexual function']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0856619', 'cui_str': 'Sexual problem'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}, {'cui': 'C0278092', 'cui_str': 'Sexual function'}]",,0.0573806,"Benefits included increased sexually active individuals at follow-up (p < 0.001, Effect size = 0.54), improved sexual function (p < 0.001, Effect size = -0.76, N = 41), and increased use of sexual aids (p = 0.01, Effect size=-0.14, N = 58).","[{'ForeName': 'Leslie R', 'Initials': 'LR', 'LastName': 'Schover', 'Affiliation': 'Will2Love, Houston, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Strollo', 'Affiliation': 'Behavioral and Epidemiology Research Group, American Cancer Society, Inc., Atlanta, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Stein', 'Affiliation': 'Department of Behavioral Sciences and Health Education, Rollins School of Public Health, Emory University, Atlanta, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Fallon', 'Affiliation': 'Behavioral and Epidemiology Research Group, American Cancer Society, Inc., Atlanta, USA.'}, {'ForeName': 'Tenbroeck', 'Initials': 'T', 'LastName': 'Smith', 'Affiliation': 'Behavioral and Epidemiology Research Group, American Cancer Society, Inc., Atlanta, USA.'}]",Journal of sex & marital therapy,['10.1080/0092623X.2020.1762813'] 41,32334592,"Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial.","BACKGROUND Exenatide, a glucagon like peptide 1 analog, has been suggested to reduce the cardiovascular disease risk factors, such as body weight, blood pressure and subclinical atherosclerosis in patients with type 2 diabetes mellitus (T2DM). This was the first randomized, open-label, controlled trial to compare the effects of exenatide versus insulin on subclinical atherosclerosis, as assessed by carotid-intima media thickness (CIMT), in patients with T2DM. METHODS A total of 66 patients with T2DM admitted from March 10, 2015 to June 20, 2017 in the Department of Endocrinology, Beijing Hospital were randomized to receive twice-daily exenatide or aspartate 70/30 insulin for 52 weeks. The primary endpoint was change from baseline in CIMT, and secondary endpoints included changes at week 52 from baseline in body weight, glycemic markers, lipid metabolism markers, blood pressure, C-reactive protein, fibrinogen, 8-hydroxydeoxyguanosine, irisin, and brain natriuretic peptide. RESULTS Exenatide more significantly reduced the CIMT from baseline compared with insulin after 52 weeks, with a mean difference of - 0.14 mm (95% interval confidence: - 0.25, - 0.02; P = 0.016). Weight and body mass index were both significantly reduced in the exenatide group over 52 weeks. Exenatide reduced total lipoprotein and low-density lipoprotein cholesterol levels more significantly than insulin at weeks 16 and 40. Correlation analyses showed that CIMT was positively correlated with low-density lipoprotein cholesterol. CONCLUSIONS Twice-daily exenatide could prevent atherosclerosis progression in patients with T2DM over a 52-week treatment period compared with insulin therapy. Trial registration Chinese Clinical Trial Registry ChiCTR-1800015658.",2020,Exenatide reduced total lipoprotein and low-density lipoprotein cholesterol levels more significantly than insulin at weeks 16 and 40.,"['type 2 diabetes mellitus patients', 'patients with T2DM', '66 patients with T2DM admitted from March 10, 2015 to June 20, 2017 in the Department of Endocrinology, Beijing Hospital', 'patients with type 2 diabetes mellitus (T2DM']","['exenatide versus insulin', 'exenatide', 'exenatide or aspartate 70/30 insulin', 'twice-daily exenatide and insulin', 'Exenatide']","['CIMT', 'atherosclerosis progression', 'Weight and body mass index', 'change from baseline in CIMT', 'body weight, glycemic markers, lipid metabolism markers, blood pressure, C-reactive protein, fibrinogen, 8-hydroxydeoxyguanosine, irisin, and brain natriuretic peptide', 'total lipoprotein and low-density lipoprotein cholesterol levels', 'carotid intima-media thickness', 'low-density lipoprotein cholesterol']","[{'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0014137', 'cui_str': 'Endocrinology'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0167117', 'cui_str': 'exenatide'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0085845', 'cui_str': 'Aspartate'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}]","[{'cui': 'C0162864', 'cui_str': 'Tunica intima'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0016006', 'cui_str': 'Fibrinogen'}, {'cui': 'C0050078', 'cui_str': '8-hydroxy-deoxyguanosine'}, {'cui': 'C0054015', 'cui_str': 'Nesiritide'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023820', 'cui_str': 'Lipoprotein'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}]",66.0,0.3004,Exenatide reduced total lipoprotein and low-density lipoprotein cholesterol levels more significantly than insulin at weeks 16 and 40.,"[{'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Endocrinology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical College, No. 1 Dahua Road, Dong Dan, Beijing, 100730, P. R. China.'}, {'ForeName': 'Tong-Zhang', 'Initials': 'TZ', 'LastName': 'Xian', 'Affiliation': 'Department of Endocrinology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua Road, Dong Dan, Beijing, 100730, P. R. China.'}, {'ForeName': 'Ming-Xiao', 'Initials': 'MX', 'LastName': 'Wu', 'Affiliation': 'Department of Ultrasound, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua Road, Dong Dan, Beijing, 100730, P. R. China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Ultrasound, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua Road, Dong Dan, Beijing, 100730, P. R. China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Pan', 'Affiliation': 'Department of Endocrinology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua Road, Dong Dan, Beijing, 100730, P. R. China. panqi621@126.com.'}, {'ForeName': 'Li-Xin', 'Initials': 'LX', 'LastName': 'Guo', 'Affiliation': 'Department of Endocrinology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical College, No. 1 Dahua Road, Dong Dan, Beijing, 100730, P. R. China. glx1218@163.com.'}]",Cardiovascular diabetology,['10.1186/s12933-020-01014-7'] 42,32294771,Preventing Diagnostic Errors in Ambulatory Care: An Electronic Notification Tool for Incomplete Radiology Tests.,"BACKGROUND Failure to complete recommended diagnostic tests may increase the risk of diagnostic errors. OBJECTIVES The aim of this study is to develop and evaluate an electronic monitoring tool that notifies the responsible clinician of incomplete imaging tests for their ambulatory patients. METHODS A results notification workflow engine was created at an academic medical center. It identified future appointments for imaging studies and notified the ordering physician of incomplete tests by secure email. To assess the impact of the intervention, the project team surveyed participating physicians and measured test completion rates within 90 days of the scheduled appointment. Analyses compared test completion rates among patients of intervention and usual care clinicians at baseline and follow-up. A multivariate logistic regression model was used to control for secular trends and differences between cohorts. RESULTS A total of 725 patients of 16 intervention physicians had 1,016 delayed imaging studies; 2,023 patients of 42 usual care clinicians had 2,697 delayed studies. In the first month, physicians indicated in 23/30 cases that they were unaware of the missed test prior to notification. The 90-day test completion rate was lower in the usual care than intervention group in the 6-month baseline period (18.8 vs. 22.1%, p  = 0.119). During the 12-month follow-up period, there was a significant improvement favoring the intervention group (20.9 vs. 25.5%, p  = 0.027). The change was driven by improved completion rates among patients referred for mammography (21.0 vs. 30.1%, p  = 0.003). Multivariate analyses showed no significant impact of the intervention. CONCLUSION There was a temporal association between email alerts to physicians about missed imaging tests and improved test completion at 90 days, although baseline differences in intervention and usual care groups limited the ability to draw definitive conclusions. Research is needed to understand the potential benefits and limitations of missed test notifications to reduce the risk of delayed diagnoses, particularly in vulnerable patient populations.",2020,"The 90-day test completion rate was lower in the usual care than intervention group in the 6-month baseline period (18.8 vs. 22.1%, p  = 0.119).","['their ambulatory patients', '725 patients of 16 intervention physicians had 1,016 delayed imaging studies; 2,023 patients of 42 usual care clinicians had 2,697 delayed studies', 'Ambulatory Care']",[],"['90-day test completion rate', 'completion rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0002423', 'cui_str': 'Outpatient Care'}]",[],"[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]",,0.0371544,"The 90-day test completion rate was lower in the usual care than intervention group in the 6-month baseline period (18.8 vs. 22.1%, p  = 0.119).","[{'ForeName': 'Saul N', 'Initials': 'SN', 'LastName': 'Weingart', 'Affiliation': 'Tufts Medical Center, Boston, Massachusetts, United States.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Yaghi', 'Affiliation': 'Tufts Medical Center, Boston, Massachusetts, United States.'}, {'ForeName': 'Liz', 'Initials': 'L', 'LastName': 'Barnhart', 'Affiliation': 'Tufts Medical Center, Boston, Massachusetts, United States.'}, {'ForeName': 'Sucharita', 'Initials': 'S', 'LastName': 'Kher', 'Affiliation': 'Tufts Medical Center, Boston, Massachusetts, United States.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Mazzullo', 'Affiliation': 'Tufts Medical Center, Boston, Massachusetts, United States.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Roberts', 'Affiliation': 'Tufts Medical Center, Boston, Massachusetts, United States.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Lominac', 'Affiliation': 'Tufts Medical Center, Boston, Massachusetts, United States.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Gittelson', 'Affiliation': 'Tufts Medical Center, Boston, Massachusetts, United States.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Argyris', 'Affiliation': 'Tufts Medical Center, Boston, Massachusetts, United States.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Harvey', 'Affiliation': 'Tufts Medical Center, Boston, Massachusetts, United States.'}]",Applied clinical informatics,['10.1055/s-0040-1708530'] 43,32358917,Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial.,"AIMS A multicentre trial, ICOS-ONE, showed increases above the upper limit of normality of cardiac troponin (cTn) in 27% of patients within 12 months after the end of cancer chemotherapy (CT) with anthracyclines, whether cardiac protection with enalapril was started at study entry in all (prevention arm) or only upon first occurrence on supra-normal cTn (troponin-triggered arm). The aims of the present post hoc analysis were (i) to assess whether anthracycline-based treatment could induce cardiotoxicity over 36 month follow-up and (ii) to describe the time course of three cardiovascular biomarkers (i.e. troponin I cTnI-Ultra, B-type natriuretic peptide BNP, and pentraxin 3 PTX3) and of left ventricular (LV) function up to 36 months. METHODS AND RESULTS Eligible patients were those prescribed first-in-life CT, without evidence of cardiovascular disease, normal cTn, LV ejection fraction (EF) >50%, not on renin-angiotensin aldosterone system antagonists. Patients underwent echocardiography and blood sampling at 24 and 36 months. No differences were observed in biomarker concentration between the two study arms, 'prevention' vs. 'troponin-triggered'. During additional follow-up 13 more deaths occurred, leading to a total of 23 (9.5%), all due to a non-cardiovascular cause. No new occurrences of LV-dysfunction were reported. Two additional patients were admitted to the hospital for cardiovascular causes, both for acute pulmonary embolism. No first onset of raised cTnI-Ultra was reported in the extended follow-up. BNP remained within normal range: at 36 months was 23.4 ng/L, higher (N.S.) than at baseline, 17.6 ng/L. PTX3 peaked at 5.2 ng/mL 1 month after CT and returned to baseline values thereafter. cTnI-Ultra peaked at 26 ng/L 1 month after CT and returned to 3 ng/L until the last measurement at 36 months. All echocardiographic variables remained stable during follow-up with a median LVEF of 63% and left atrial volume index about 24 mL/m 2 . CONCLUSIONS First-in-life CT with median cumulative dose of anthracyclines of 180 mg/m 2 does not seem to cause clinically significant cardiac injury, as assessed by circulating biomarkers and echocardiography, in patients aged 51 years (median), without pre-existing cardiac disease. This may suggest either a 100% efficacy of enalapril (given as preventive or troponin-triggered) or a reassuringly low absolute cardiovascular risk in this cohort of patients, which may not require intensive cardiologic follow-up.",2020,"All echocardiographic variables remained stable during follow-up with a median LVEF of 63% and left atrial volume index about 24 mL/m 2 . ","['27% of patients within 12\xa0months after the end of cancer chemotherapy (CT) with anthracyclines, whether cardiac protection with', 'Two additional patients were admitted to the hospital for cardiovascular causes, both for acute pulmonary embolism', 'Eligible patients were those prescribed first-in-life CT, without evidence of cardiovascular disease, normal cTn, LV ejection fraction (EF) >50%, not on renin-angiotensin aldosterone system antagonists', 'patients aged 51\xa0years (median), without pre-existing cardiac disease']","['anthracycline-based treatment', 'enalapril', 'cTnI', 'anthracyclines', 'troponin']","['biomarker concentration', 'LV-dysfunction', 'cardiotoxicity', 'Circulating biomarkers and cardiac function', 'BNP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0392920', 'cui_str': 'Antineoplastic chemotherapy regimen'}, {'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C2882221', 'cui_str': 'Acute pulmonary embolism'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C1096316', 'cui_str': 'Cardiac troponin'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0086907', 'cui_str': 'Renin-Angiotensin-Aldosterone System'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0018799', 'cui_str': 'Heart disease'}]","[{'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0014025', 'cui_str': 'Enalapril'}, {'cui': 'C0883409', 'cui_str': 'Cardiac troponin I'}, {'cui': 'C0041199', 'cui_str': 'Troponin'}]","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0242698', 'cui_str': 'Impaired left ventricular function'}, {'cui': 'C0876994', 'cui_str': 'Cardiotoxicity'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0054015', 'cui_str': 'Nesiritide'}]",,0.103054,"All echocardiographic variables remained stable during follow-up with a median LVEF of 63% and left atrial volume index about 24 mL/m 2 . ","[{'ForeName': 'Jennifer M T A', 'Initials': 'JMTA', 'LastName': 'Meessen', 'Affiliation': 'Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Cardinale', 'Affiliation': 'Cardioncology Unit, European Institute of Oncology, Milan, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Ciceri', 'Affiliation': 'Haematology/Transplant Unit, IRCCS Ospedale San Raffaele, Università Vita-Salute, Milan, Italy.'}, {'ForeName': 'Maria Teresa', 'Initials': 'MT', 'LastName': 'Sandri', 'Affiliation': 'Laboratory Medicine, Humanitas Clinical and Reseach Center - IRCCS - Rozzano, Milan, Italy.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Civelli', 'Affiliation': 'Department of Cardiology, European Institute of Oncology, Milan, Italy.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Bottazzi', 'Affiliation': 'Department of Immunology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.'}, {'ForeName': 'GianFranco', 'Initials': 'G', 'LastName': 'Cucchi', 'Affiliation': 'Department of Cardiology, Ospedale di Sondrio, Sondrio, Italy.'}, {'ForeName': 'Elisabetta', 'Initials': 'E', 'LastName': 'Menatti', 'Affiliation': 'Department of Oncology, Ospedale di Sondrio, Sondrio, Italy.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Mangiavacchi', 'Affiliation': 'Department of Cardiology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.'}, {'ForeName': 'Gianluigi', 'Initials': 'G', 'LastName': 'Condorelli', 'Affiliation': 'Department of Cardiology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Barbieri', 'Affiliation': 'Department of Cardiology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Italy.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Gori', 'Affiliation': 'Department of Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Colombo', 'Affiliation': 'Cardioncology Unit, European Institute of Oncology, Milan, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Curigliano', 'Affiliation': 'Division of Early Drug Development for Innovative Therapy, Department of Oncology and Hemato-Oncology, University of Milano, European Institute of Oncology, Milan, Italy.'}, {'ForeName': 'Michela', 'Initials': 'M', 'LastName': 'Salvatici', 'Affiliation': 'Laboratory Medicine, Humanitas Clinical and Reseach Center - IRCCS - Rozzano, Milan, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Pastori', 'Affiliation': 'Department of Cardiology, Ospedale di Vaio, Fidenza, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Ghisoni', 'Affiliation': 'Unità Operativa Complessa Cure Palliative, Ospedale di Vaio, Fidenza, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Bianchi', 'Affiliation': 'Department of Cardiology, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Falci', 'Affiliation': 'Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.'}, {'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Cortesi', 'Affiliation': 'Department of Cardiology, IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, Meldola, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Farolfi', 'Affiliation': 'Department of Oncology, IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, Meldola, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Monopoli', 'Affiliation': 'Department of Cardiology, Nuovo Ospedale San Giuseppe, Empoli, Italy.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Milandri', 'Affiliation': 'Department of Oncology, Nuovo Ospedale San Giuseppe, Empoli, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Bregni', 'Affiliation': 'Department of Oncology, Presidio Ospedaliero di Busto Arsizio, Busto Arsizio, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Malossi', 'Affiliation': 'Department of Oncology, Ospedale Regionale Umberto Parini, Aosta, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Nassiacos', 'Affiliation': 'Department of Cardiology, Presidio Ospedaliero di Saronno, Saronno, Italy.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Verusio', 'Affiliation': 'Department of Oncology, Presidio Ospedaliero di Saronno, Saronno, Italy.'}, {'ForeName': 'Lidia', 'Initials': 'L', 'LastName': 'Staszewsky', 'Affiliation': 'Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Leone', 'Affiliation': 'Department of Immunology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Novelli', 'Affiliation': 'Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Balconi', 'Affiliation': 'Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.'}, {'ForeName': 'Enrico B', 'Initials': 'EB', 'LastName': 'Nicolis', 'Affiliation': 'Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.'}, {'ForeName': 'Maria Grazia', 'Initials': 'MG', 'LastName': 'Franzosi', 'Affiliation': 'Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.'}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Masson', 'Affiliation': 'Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Garlanda', 'Affiliation': 'Department of Immunology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Mantovani', 'Affiliation': 'Department of Immunology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.'}, {'ForeName': 'Carlo M', 'Initials': 'CM', 'LastName': 'Cipolla', 'Affiliation': 'Department of Cardiology, European Institute of Oncology, Milan, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Latini', 'Affiliation': 'Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",ESC heart failure,['10.1002/ehf2.12695'] 44,32357152,Effects of antenatal hypnosis on maternal salivary cortisol during childbirth and six weeks postpartum-A randomized controlled trial.,"BACKGROUND Cortisol has been used to capture psychophysiological stress during childbirth and postpartum wellbeing. We explored the effect of a brief antenatal training course in self-hypnosis on salivary cortisol during childbirth and 6 weeks postpartum. METHODS In a randomized, controlled trial conducted at Aarhus University Hospital Skejby Denmark during the period January 2010 until October 2010, a total of 349 healthy nulliparous women were included. They were randomly allocated to a hypnosis group (n = 136) receiving three one-hour lessons in self-hypnosis with additional audio-recordings, a relaxation group (n = 134) receiving three one-hour lessons in various relaxation methods with audio-recordings for additional training, and a usual care group (n = 79) receiving ordinary antenatal care only. Salivary cortisol samples were collected during childbirth (at the beginning of the pushing state, 30 minutes, and 2 hours after childbirth), and 6 weeks postpartum (at wake up, 30 minutes after wake up, and evening). Cortisol concentrations were compared using a linear mixed-effects model. Correlations between cortisol concentrations and length of birth, experienced pain and calmness during birth were examined by a Spearman rank correlation test. FINDINGS During childbirth, week correlations were found between cortisol concentrations 30 minutes after childbirth and length of birth. In the beginning of the pushing state and 2 hours after childbirth, we found a tendency towards higher cortisol concentrations in the hypnosis group compared to the other two groups (hypnosis versus relaxation p = 0.02 and 0.03, hypnosis versus usual care p = 0.08 and 0.05). No differences were observed in cortisol concentrations between the groups 30 minutes after childbirth (hypnosis versus relaxation p = 0.08, hypnosis versus usual care 0.10) or 6 weeks postpartum (hypnosis versus relaxation: p = 0.85, 0.51, and 0.68, hypnosis versus usual care: p = 0.85, 0.93, and 0.96). CONCLUSION Antenatal hypnosis training may increase the release of cortisol during childbirth with no long-term consequences. Further research is needed to help interpret these findings.",2020,"No differences were observed in cortisol concentrations between the groups 30 minutes after childbirth (hypnosis versus relaxation p = 0.08, hypnosis versus usual care 0.10) or 6 weeks postpartum (hypnosis versus relaxation: p = 0.85, 0.51, and 0.68, hypnosis versus usual care: p = 0.85, 0.93, and 0.96). ","['at Aarhus University Hospital Skejby Denmark during the period January 2010 until October 2010, a total of 349 healthy nulliparous women were included']","['Antenatal hypnosis training', 'antenatal hypnosis', 'hypnosis group (n = 136) receiving three one-hour lessons in self-hypnosis with additional audio-recordings, a relaxation group (n = 134) receiving three one-hour lessons in various relaxation methods with audio-recordings for additional training, and a usual care group (n = 79) receiving ordinary antenatal care only']","['Salivary cortisol samples', 'cortisol concentrations and length of birth, experienced pain and calmness during birth', 'release of cortisol during childbirth', 'Cortisol concentrations', 'cortisol concentrations', 'maternal salivary cortisol']","[{'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0425979', 'cui_str': 'Nulliparous'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C2828394', 'cui_str': 'Antenatal'}, {'cui': 'C0020587', 'cui_str': 'Hypnotherapy'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}]","[{'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]",349.0,0.0956058,"No differences were observed in cortisol concentrations between the groups 30 minutes after childbirth (hypnosis versus relaxation p = 0.08, hypnosis versus usual care 0.10) or 6 weeks postpartum (hypnosis versus relaxation: p = 0.85, 0.51, and 0.68, hypnosis versus usual care: p = 0.85, 0.93, and 0.96). ","[{'ForeName': 'Anette', 'Initials': 'A', 'LastName': 'Werner', 'Affiliation': 'Institute of Clinical Research, Research Unit of Gynecology and Obstetrics, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Chunsen', 'Initials': 'C', 'LastName': 'Wu', 'Affiliation': 'Institute of Clinical Research, Research Unit of Gynecology and Obstetrics, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Zachariae', 'Affiliation': 'Department of Oncology, Unit for Psychooncology and Health Psychology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Ellen A', 'Initials': 'EA', 'LastName': 'Nohr', 'Affiliation': 'Institute of Clinical Research, Research Unit of Gynecology and Obstetrics, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Uldbjerg', 'Affiliation': 'Department of Gynecology and Obstetrics, Aarhus University Hospital Skejby, Aarhus, Denmark.'}, {'ForeName': 'Åse Marie', 'Initials': 'ÅM', 'LastName': 'Hansen', 'Affiliation': 'Department of Public Health, University of Copenhagen, Copenhagen, Denmark.'}]",PloS one,['10.1371/journal.pone.0230704'] 45,32367611,Accommodative dynamics and attention: the influence of manipulating attentional capacity on accommodative lag and variability.,"PURPOSE There is evidence that attention can modulate ocular dynamics, but its effects on accommodative dynamics have yet to be fully determined. We investigated the effects of manipulating the capacity to focus on task-relevant stimuli, using two levels of dual-tasking (arithmetic task) and auditory feedback, on the accommodative dynamics at three different target distances (500, 40 and 20 cm). METHODS The magnitude and variability of the accommodative response were objectively measured in 20 healthy young adults using the Grand Seiko WAM-5500 autorefractor. In randomised order, participants fixated on a Maltese cross while 1) performing an arithmetic task with two levels of complexity (low and high mental load); 2) being provided with two levels of auditory feedback (low and high feedback); and 3) without performing any mental task or receiving feedback (control). Accommodative and pupil dynamics were monitored for 90 seconds during each of the 15 trials (5 experimental conditions x 3 target distances). RESULTS The lag of accommodation was sensitive to the attentional state (p = 0.001), where a lower lag of accommodation was observed for the high feedback condition compared to the control (corrected p-value = 0.009). The imposition of mental load while fixating on a distant target led to a greater accommodative response (corrected p-value = 0.010), but no effects were found for the near targets. There was a main effect of the experimental manipulation on the accommodative variability (p < 0.001), with the use of auditory feedback improving the accuracy of the accommodative system. CONCLUSIONS Our data show that accommodative dynamics is affected by varying the capacity to focus on task-relevant stimuli, observing an improvement in accommodative stability and response with auditory feedback. These results highlight an association between attention and ocular dynamics and provide new insight into the control of accommodation.",2020,"The lag of accommodation was sensitive to the attentional state (p = 0.001), where a lower lag of accommodation was observed for the high feedback condition compared to the control (corrected p-value = 0.009).",['20 healthy young adults using the Grand Seiko WAM-5500 autorefractor'],['participants fixated on a Maltese cross while 1) performing an arithmetic task with two levels of complexity (low and high mental load); 2) being provided with two levels of auditory feedback (low and high feedback); and 3) without performing any mental task or receiving feedback (control'],"['accommodative stability and response with auditory feedback', 'lag of accommodation was sensitive to the attentional state', 'lag of accommodation', 'accommodative response', 'accommodative variability', 'dual-tasking (arithmetic task) and auditory feedback', 'Accommodative and pupil dynamics']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C1275634', 'cui_str': 'Automated infrared optometer'}]","[{'cui': 'C0324395', 'cui_str': 'Maltese dog'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0332324', 'cui_str': 'Sensitive'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C1827224', 'cui_str': 'Accommodative response'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0034121', 'cui_str': 'Pupil structure'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}]",20.0,0.0395495,"The lag of accommodation was sensitive to the attentional state (p = 0.001), where a lower lag of accommodation was observed for the high feedback condition compared to the control (corrected p-value = 0.009).","[{'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Redondo', 'Affiliation': 'Department of Optics, University of Granada, Granada, Spain.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Vera', 'Affiliation': 'Department of Optics, University of Granada, Granada, Spain.'}, {'ForeName': 'Rubén', 'Initials': 'R', 'LastName': 'Molina', 'Affiliation': 'Department of Optics, University of Granada, Granada, Spain.'}, {'ForeName': 'Leon N', 'Initials': 'LN', 'LastName': 'Davies', 'Affiliation': 'School of Optometry, Aston University, Birmingham, UK.'}, {'ForeName': 'Raimundo', 'Initials': 'R', 'LastName': 'Jiménez', 'Affiliation': 'Department of Optics, University of Granada, Granada, Spain.'}]",Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists),['10.1111/opo.12690'] 46,32361414,Neural correlates of NOS1 ex1f-VNTR allelic variation in panic disorder and agoraphobia during fear conditioning and extinction in fMRI.,"Neuronal nitric oxide synthase (NOS-I) impacts on fear/anxiety-like behavior in animals. In humans, the short (S) allele of a functional promotor polymorphism of NOS1 (NOS1 ex1f-VNTR) has been shown to be associated with higher anxiety and altered fear conditioning in healthy subjects in the amygdala and hippocampus (AMY/HIPP). Here, we explore the role of NOS1 ex1f-VNTR as a pathophysiological correlate of panic disorder and agoraphobia (PD/AG). In a sub-sample of a multicenter cognitive behavioral therapy (CBT) randomized controlled trial in patients with PD/AG (n = 48: S/S-genotype n=15, S/L-genotype n=21, L/L-genotype n=12) and healthy control subjects, HS (n = 34: S/S-genotype n=7, S/L-genotype n=17, L/L-genotype=10), a differential fear conditioning and extinction fMRI-paradigm was used to investigate how NOS1 ex1f-VNTR genotypes are associated with differential neural activation in AMY/HIPP. Prior to CBT, L/L-allele carriers showed higher activation than S/S-allele carriers in AMY/HIPP. A genotype × diagnosis interaction revealed that the S-allele in HS was associated with a pronounced deactivation in AMY/HIPP, while patients showed contrary effects. The interaction of genotype × stimulus type (CS+, conditioned stimulus associated with an aversive stimulus vs. CS-, unassociated) showed effects on differential learning in AMY/HIPP. All effects were predominately found during extinction. Genotype associated effects in patients were not altered after CBT. Low statistical power due to small sample size in each subgroup is a major limitation. However, our findings provide first preliminary evidence for dysfunctional neural fear conditioning/extinction associated with NOS1 ex1f-VNTR genotype in the context of PD/AG, shedding new light on the complex interaction between genetic risk, current psychopathology and treatment-related effects.",2020,Genotype associated effects in patients were not altered after CBT.,"['n\xa0=\xa048', 'healthy subjects', 'animals', 'patients with PD/AG', 'panic disorder and agoraphobia during fear conditioning and extinction in fMRI']",['cognitive behavioral therapy (CBT'],['Neuronal nitric oxide synthase (NOS-I) impacts on fear/anxiety-like behavior'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0003062', 'cui_str': 'Kingdom Animalia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030319', 'cui_str': 'Panic disorder'}, {'cui': 'C0001818', 'cui_str': 'Agoraphobia'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0015347', 'cui_str': 'Psychological Extinction'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0669368', 'cui_str': 'Nitric Oxide Synthase, Type I'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",,0.0249077,Genotype associated effects in patients were not altered after CBT.,"[{'ForeName': 'Isabelle C', 'Initials': 'IC', 'LastName': 'Ridderbusch', 'Affiliation': 'Department of Psychiatry and Psychotherapy & Center for Mind, Brain and Behavior - CMBB, Philipps-Universität Marburg, Marburg, Germany. Electronic address: isabelle.ridderbusch@med.uni-marburg.de.'}, {'ForeName': 'Yunbo', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Psychiatry and Psychotherapy & Center for Mind, Brain and Behavior - CMBB, Philipps-Universität Marburg, Marburg, Germany.'}, {'ForeName': 'Heike', 'Initials': 'H', 'LastName': 'Weber', 'Affiliation': 'Department of Psychiatry, Psychosomatics, and Psychotherapy, University Hospital of Würzburg, Würzburg, Germany; Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Reif', 'Affiliation': 'Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Herterich', 'Affiliation': 'Clinical Chemistry and Laboratory Medicine, University Hospital Würzburg, Würzburg, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Ströhle', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Pfleiderer', 'Affiliation': 'Medical Faculty, University of Münster and Department Clinical Radiology, University Hospital Münster, Münster, Germany.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Arolt', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital Münster, Münster, Germany.'}, {'ForeName': 'Hans-Ulrich', 'Initials': 'HU', 'LastName': 'Wittchen', 'Affiliation': 'Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität (LMU), München, Germany.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Lueken', 'Affiliation': 'Department of Psychology, Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Tilo', 'Initials': 'T', 'LastName': 'Kircher', 'Affiliation': 'Department of Psychiatry and Psychotherapy & Center for Mind, Brain and Behavior - CMBB, Philipps-Universität Marburg, Marburg, Germany.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Straube', 'Affiliation': 'Department of Psychiatry and Psychotherapy & Center for Mind, Brain and Behavior - CMBB, Philipps-Universität Marburg, Marburg, Germany.'}]",NeuroImage. Clinical,['10.1016/j.nicl.2020.102268'] 47,32366124,"Waiting for speech-language pathology services: A randomised controlled trial comparing therapy, advice and device.","Purpose: To compare children's speech, language and early literacy outcomes, and caregivers' empowerment and satisfaction following provision of 12 sessions of direct intervention (therapy), or face-to-face advice or a purpose-built website (device) while waiting for therapy. Method: A four-stage randomised controlled trial was undertaken involving three- to six-year-old children referred to speech-language pathology waiting lists at two Australian community health centres over eight months ( n  = 222). Stage 1 (screening): 149 were eligible to participate. Stage 2 (pre-assessment): 117 were assessed. Stage 3 (intervention): 110 were randomised to advice (33), device (39) or therapy (38). Stage 4 (post-assessment): 101 were re-assessed by a speech-language pathologist blinded to the intervention condition. Result: After controlling for baseline levels, children's speech (percentage of consonants correct) was significantly higher in the therapy group compared to the advice and device conditions. Caregivers' satisfaction was also significantly higher in the therapy condition compared to the device condition. There were no significant differences between the three conditions for children's intelligibility, language and early literacy or caregivers' empowerment. Conclusion: Therapy resulted in significantly higher speech outcomes than the advice and device conditions and was associated with significantly greater caregiver satisfaction. Provision of a website containing evidence-based material or a single session of advice may be a viable alternative while children wait for therapy targeting intelligibility, language and early literacy, and to empower caregivers.",2020,"There were no significant differences between the three conditions for children's intelligibility, language and early literacy or caregivers' empowerment.","['six-year-old children referred to speech-language pathology waiting lists at two Australian community health centres over eight months ( n \u2009=\u2009222', '149 were eligible to participate', 'Stage 1 (screening', 'Stage 3 (intervention', 'Waiting for speech-language pathology services']","['direct intervention (therapy), or face-to-face advice or a purpose-built website (device) while waiting for therapy']","['speech outcomes', ""children's intelligibility, language and early literacy or caregivers' empowerment"", ""Caregivers' satisfaction"", 'caregiver satisfaction', ""children's speech, language and early literacy outcomes""]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0037825', 'cui_str': 'Pathology, Speech-Language'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C5191071', 'cui_str': '149'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0542399', 'cui_str': 'Patient waiting for'}, {'cui': 'C0557854', 'cui_str': 'Services'}]","[{'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C1285529', 'cui_str': 'Purpose'}, {'cui': 'C0542399', 'cui_str': 'Patient waiting for'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0589416', 'cui_str': 'Intelligibility'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1319173', 'cui_str': 'Caregiver wellbeing status'}]",,0.116638,"There were no significant differences between the three conditions for children's intelligibility, language and early literacy or caregivers' empowerment.","[{'ForeName': 'Sharynne', 'Initials': 'S', 'LastName': 'McLeod', 'Affiliation': 'School of Teacher Education, Charles Sturt University, Bathurst, Australia.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Davis', 'Affiliation': 'Western NSW Local Health District, Bathurst, Australia.'}, {'ForeName': 'Katrina', 'Initials': 'K', 'LastName': 'Rohr', 'Affiliation': 'Western NSW Local Health District, Bathurst, Australia.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'McGill', 'Affiliation': 'School of Teacher Education, Charles Sturt University, Bathurst, Australia.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Miller', 'Affiliation': 'Western NSW Local Health District, Dubbo, Australia.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Roberts', 'Affiliation': 'Western NSW Local Health District, Bathurst, Australia.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Thornton', 'Affiliation': 'Western NSW Local Health District, Dubbo, Australia.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Ahio', 'Affiliation': 'Western NSW Local Health District, Dubbo, Australia.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Ivory', 'Affiliation': 'Faculty of Arts and Education, Charles Sturt University, Albury, Australia.'}]",International journal of speech-language pathology,['10.1080/17549507.2020.1731600'] 48,32366577,The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes.,"OBJECTIVE To examine whether low baseline diastolic blood pressure (DBP) modifies the effects of intensive systolic blood pressure (SBP) lowering on cardiovascular outcomes in type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS The Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial (ACCORD BP), a two-by-two factorial randomized controlled trial, examined effects of SBP (<120 vs. <140 mmHg) and glycemic (HbA 1c <6% vs. 7.0-7.9% [<42 vs. 53-63 mmol/mol]) control on cardiovascular events in T2DM ( N = 4,731). We examined whether effects of SBP control on cardiovascular composite were modified by baseline DBP and glycemic control. RESULTS Intensive SBP lowering decreased the risk of the cardiovascular composite (hazard ratio [HR] 0.76 [95% CI 0.59-0.98]) in the standard glycemic arm but not in the intensive glycemic arm (HR 1.06 [95% CI 0.81-1.40]). Spline regression models relating the effects of the intervention on the cardiovascular composite across the range of baseline DBP did not show evidence of effect modification by low baseline DBP for the cardiovascular composite in the standard or intensive glycemic arms. The relation between the effect of the intensive SBP intervention and baseline DBP was similar between glycemic arms for the cardiovascular composite three-way interaction ( P = 0.83). CONCLUSIONS In persons with T2DM, intensive SBP lowering decreased the risk of cardiovascular composite end point irrespective of baseline DBP in the setting of standard glycemic control. Hence, low baseline DBP should not be an impediment to intensive SBP lowering in patients with T2DM treated with guideline-recommended standard glycemic control.",2020,"The relation between the effect of the intensive SBP intervention and baseline DBP was similar between glycemic arms for the cardiovascular composite three-way interaction ( P = 0.83). ","['Type 2 Diabetes', 'type 2 diabetes mellitus (T2DM']","['low baseline diastolic blood pressure (DBP', 'Intensive Blood Pressure Lowering', 'intensive SBP intervention', 'intensive systolic blood pressure (SBP) lowering', 'SBP control', 'SBP']","['cardiovascular events', 'risk of the cardiovascular composite (hazard ratio [HR', 'risk of cardiovascular composite', 'cardiovascular outcomes']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C4274392', 'cui_str': 'Baseline diastolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0567952,"The relation between the effect of the intensive SBP intervention and baseline DBP was similar between glycemic arms for the cardiovascular composite three-way interaction ( P = 0.83). ","[{'ForeName': 'Olesya L', 'Initials': 'OL', 'LastName': 'Ilkun', 'Affiliation': 'Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Greene', 'Affiliation': 'Division of Biostatistics, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'Alfred K', 'Initials': 'AK', 'LastName': 'Cheung', 'Affiliation': 'Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'Paul K', 'Initials': 'PK', 'LastName': 'Whelton', 'Affiliation': 'Tulane University School of Public Health and Tropical Medicine, New Orleans, LA.'}, {'ForeName': 'Guo', 'Initials': 'G', 'LastName': 'Wei', 'Affiliation': 'Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Boucher', 'Affiliation': 'Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Ambrosius', 'Affiliation': 'Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC.'}, {'ForeName': 'Glenn M', 'Initials': 'GM', 'LastName': 'Chertow', 'Affiliation': 'Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA.'}, {'ForeName': 'Srinivasan', 'Initials': 'S', 'LastName': 'Beddhu', 'Affiliation': 'Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, UT srinivasan.beddhu@hsc.utah.edu.'}]",Diabetes care,['10.2337/dc19-2047'] 49,32303383,"Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.02.009.",,2020,,['Clinically Localized Prostate Cancer'],['Radical Prostatectomy or Observation'],[],"[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}]","[{'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}, {'cui': 'C0302523', 'cui_str': 'Observation'}]",[],,0.0184225,,"[{'ForeName': 'Roderick C N', 'Initials': 'RCN', 'LastName': 'van den Bergh', 'Affiliation': 'Department of Urology, Antonius Hospital, Soestwetering 1, Utrecht 3543 AZ, The Netherlands. Electronic address: roodvdb@hotmail.com.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Valerio', 'Affiliation': 'Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.'}, {'ForeName': 'Derya', 'Initials': 'D', 'LastName': 'Tilki', 'Affiliation': 'Department of Urology, University Hospital-Hamburg Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Gandaglia', 'Affiliation': 'Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European urology,['10.1016/j.eururo.2020.03.046'] 50,32363638,Comparison of gabapentin and hydroxyzine in the treatment of pruritus in patients on dialysis.,"BACKGROUND Pruritus is one of the most common problems in patients with chronic renal failure. Of all patients with end-stage renal disease (ESRD), 60-80% report pruritus during their life. AIM To compare the effect of gabapentin (GBP) and hydroxyzine (HYDZ) in treating pruritus in patients on dialysis. METHODS In a double-blind, randomized, crossover clinical trial, 32 patients on dialysis who reported pruritus were assigned randomly to receive either GBP or HYDZ for 6 weeks; the first group received GBP 100 mg/day orally and the second group received HYDZ 25 mg/day orally for 6 weeks. After this 6-week period (Period 1) there was a washout period of 2 weeks then patients were crossed over to the other drug (the first group receiving HYDZ and second group receiving GBP) and followed up for a further 6 weeks (Period 2). A visual analogue scale was used to measure pruritus intensity in the groups before and after the first and second period. RESULTS In Period 1, pruritus severity decreased from 7.1 ± 1.46 at baseline to 2.17 ± 1.82 at 6 weeks in the GBP group (P = 0.001) and from 6.83 ± 2.11 to 2.86 ± 1.67 in the HYDZ group (P = 0.001). In Period 2, pruritus severity decreased from 5.1 ± 1.61 at baseline to 1.56 ± 0.82 at 6 weeks in the GBP group (P < 0.01) and from 5.23 ± 2.11 to 2.1 ± 1.87 in the HYDZ group (P = 0.001). CONCLUSION Results showed that both HYDZ and GBP significantly improved and controlled pruritus in patients on dialysis, with no significant difference observed between the two drugs.",2020,"In the first six weeks, the severity of pruritus in Gabapentin group decreased from 7.1±1.46 at baseline to 2.17±1.82 at six weeks later (p=0.001) and in Hydroxyzine group decreased from 6.83±2.11 at baseline to 2.86±1.67 at six weeks later (p=0.001).","['patients suffering from chronic renal failure', 'dialysis patients', 'pruritus in dialysis patients', '32 dialysis patients with pruritus']","['Gabapentin capsule', 'Gabapentin or Hydroxyzine', 'Gabapentin', 'Hydroxyzine', 'Gabapentin and Hydroxyzine']","['severity of pruritus', 'controlled pruritus', 'Pruritus Scale questionnaire']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0033774', 'cui_str': 'Itching'}]","[{'cui': 'C0060926', 'cui_str': 'gabapentin'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0020404', 'cui_str': 'Hydroxyzine'}]","[{'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",32.0,0.135916,"In the first six weeks, the severity of pruritus in Gabapentin group decreased from 7.1±1.46 at baseline to 2.17±1.82 at six weeks later (p=0.001) and in Hydroxyzine group decreased from 6.83±2.11 at baseline to 2.86±1.67 at six weeks later (p=0.001).","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Mohammadi Kebar', 'Affiliation': 'Departments of, Departments of, Internal Medicine, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Sharghi', 'Affiliation': 'Department of, Community Medicine, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ghorghani', 'Affiliation': 'School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Hoseininia', 'Affiliation': 'Departments of, Departments of, Internal Medicine, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.'}]",Clinical and experimental dermatology,['10.1111/ced.14270'] 51,32372750,Assessment of the Feasibility and Acceptability of Using Water Pasteurization Indicators to Increase Access to Safe Drinking Water in the Peruvian Amazon.,"Approximately two billion people lack access to microbiologically safe drinking water globally. Boiling is the most popular household water treatment method and significantly reduces diarrheal disease, but is often practiced inconsistently or ineffectively. The use of low-cost technologies to improve boiling is one approach with potential for increasing access to safe drinking water. We conducted household trials to evaluate the feasibility and acceptability of water pasteurization indicators (WAPIs) in the Peruvian Amazon in 2015. A total of 28 randomly selected households were enrolled from a rural and a peri-urban community. All households trialed two WAPI designs, each for a 2-week period. Ninety-six percent of participants demonstrated the correct use of the WAPIs at the end of each trial, and 88% expressed satisfaction with both WAPI models. Ease of use, short treatment time, knowledge of the association between WAPI use and improved health, and the taste of treated water were among the key factors that influenced acceptability. Ease of use was the key factor that influenced design preference. Participants in both communities preferred a WAPI with a plastic box that floated on the water's surface compared with a WAPI with a wire that was dipped into the pot of drinking water while it was heating (77% versus 15%, P < 0.001); we selected the box design for a subsequent randomized trial of this intervention. The high feasibility and acceptability of the WAPIs in this study suggest that these interventions have potential to increase access to safe water in resource-limited settings.",2020,We conducted household trials to evaluate the feasibility and acceptability of water pasteurization indicators (WAPIs) in the Peruvian Amazon in 2015.,"['Peruvian Amazon in 2015', '28 randomly selected households were enrolled from a rural and a peri-urban community']",['water pasteurization indicators (WAPIs'],['diarrheal disease'],"[{'cui': 'C0325969', 'cui_str': 'Genus Amazona'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0597885', 'cui_str': 'Pasteurization'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}]","[{'cui': 'C1290807', 'cui_str': 'Diarrheal disorder'}]",28.0,0.026785,We conducted household trials to evaluate the feasibility and acceptability of water pasteurization indicators (WAPIs) in the Peruvian Amazon in 2015.,"[{'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Heitzinger', 'Affiliation': 'Innovacion Por la Salud Y el Desarollo (IPSYD), Asociación Benéfica Prisma, Lima, Peru.'}, {'ForeName': 'Stephen E', 'Initials': 'SE', 'LastName': 'Hawes', 'Affiliation': 'Department of Epidemiology, University of Washington, Seattle, Washington.'}, {'ForeName': 'Claudio A', 'Initials': 'CA', 'LastName': 'Rocha', 'Affiliation': 'U.S. Naval Medical Research Unit No. 6, Lima, Peru.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Alvarez', 'Affiliation': 'Regional Center for Disease Prevention and Control, Loreto Regional Ministry of Health, Iquitos, Peru.'}, {'ForeName': 'Carlton A', 'Initials': 'CA', 'LastName': 'Evans', 'Affiliation': 'IFHAD: Innovation for Health and Development, Laboratory of Research and Development, Universidad Peruana Cayetano Heredia, Lima, Peru.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.18-0963'] 52,32374527,A Secondary Data Analysis Examining Young Adults' Performance in an Internet Weight Loss Program with Financial Incentives.,"OBJECTIVE In traditional behavioral weight loss (BWL) programs, young adults fare worse than older adults with respect to engagement, retention, and weight loss, but money and use of technology have been cited as program factors that might improve outcomes for this population. This study evaluated young adult performance in internet-based BWL (IBWL) offering financial incentives for self-monitoring and weight loss. METHODS Participants (N = 180; BMI = 33.2 ± 6.0 kg/m 2 ) were randomly assigned to a 12-week IBWL or IBWL + incentives (IBWL + $) group. This secondary data analysis compared young adults (ages 18-35) in IBWL (n = 16) with young adults in IBWL + $ (n = 12) on percent weight loss, engagement, and retention. Young adults (n = 28) were also compared with older adults (ages 36-70; n = 152) on these outcomes. RESULTS Young adult weight loss was -2.8% ± 5.2% in IBWL and -5.4% ± 5.7% in IBWL + $ (P = 0.23, partial η 2  = 0.06). A greater proportion of young adults in IBWL + $ achieved a 10% weight loss compared with IBWL (42% vs. 6%, P = 0.02). Compared with older adults, young adults were less engaged, but there were no differences for retention or weight loss (P values > 0.05). CONCLUSIONS Findings suggest that technology-based BWL has the potential to eliminate weight loss disparities observed between young adults and older adults in in-person BWL trials. Moreover, adding financial incentives holds promise for promoting clinically meaningful weight loss for young adults.",2020,"Compared with older adults, young adults were less engaged, but there were no differences for retention or weight loss (P values > 0.05). ","['young adults', 'Participants (N\u2009=\u2009180; BMI\u2009=\u200933.2\u2009±\u20096.0 kg/m 2 ', 'young adults and older adults', 'young adults fare worse than older adults', 'Young adults (n\u2009=\u200928) were also compared with older adults (ages 36-70; n\u2009=\u2009152) on these outcomes', 'young adults (ages 18-35) in IBWL (n\u2009=\u200916) with young adults in IBWL\u2009+\u2009$ (n\u2009=\u200912) on percent weight loss, engagement, and retention']","['technology-based BWL', 'IBWL or IBWL\u2009+\u2009incentives (IBWL\u2009+\u2009$) group', 'traditional behavioral weight loss (BWL) programs']","['weight loss', 'retention or weight loss']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}]",,0.0386472,"Compared with older adults, young adults were less engaged, but there were no differences for retention or weight loss (P values > 0.05). ","[{'ForeName': 'Jessica Gokee', 'Initials': 'JG', 'LastName': 'LaRose', 'Affiliation': 'Department of Health Behavior and Policy, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.'}, {'ForeName': 'Tricia M', 'Initials': 'TM', 'LastName': 'Leahey', 'Affiliation': 'Department of Allied Health Services, University of Connecticut, Storrs, Connecticut, USA.'}, {'ForeName': 'Autumn', 'Initials': 'A', 'LastName': 'Lanoye', 'Affiliation': 'Department of Health Behavior and Policy, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Reading', 'Affiliation': 'Department of Health Behavior and Policy, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.'}, {'ForeName': 'Rena R', 'Initials': 'RR', 'LastName': 'Wing', 'Affiliation': 'Weight Control and Diabetes Research Center, Miriam Hospital, Providence, Rhode Island, USA.'}]","Obesity (Silver Spring, Md.)",['10.1002/oby.22797'] 53,32372290,Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.,"INTRODUCTION The aim of this analysis was to characterize the safety and tolerability of empagliflozin in patients with type 2 diabetes mellitus (T2DM) who were randomized to empagliflozin (10/25 mg) or placebo in clinical trials. METHODS Pooled data from 20 trials were analyzed for patients with T2DM treated with empagliflozin 10 mg (n = 4858), empagliflozin 25 mg (n = 5057), or placebo (n = 4904). The dataset comprised 15 randomized phase I-III trials, an extension trial and dose escalation studies. Adverse events (AEs) were assessed descriptively in participants who took ≥ 1 dose of study drug. AE incidence rates per 100 patient-years were calculated to adjust for differences in drug exposure between trials. RESULTS Total exposure was 16,480 and 7857 patient-years in the pooled empagliflozin 10/25 mg and placebo groups, respectively. The incidence of any AEs, AEs leading to treatment discontinuation, severe AEs, and serious AEs was similar across groups. The frequency of serious AEs requiring hospitalization was 18.6% for the empagliflozin 10/25 mg group and 21.3% for the placebo group. The empagliflozin 10/25 mg group was not associated with a higher rate of confirmed hypoglycemia versus placebo, except in patients co-administered insulin and/or a sulfonylurea (31.5% vs. 30.2%, respectively). The incidence of events consistent with urinary tract infections (UTI) was also similar for the empagliflozin 10/25 mg group versus placebo (9.27 vs. 9.70/100 patient-years, respectively). History of UTI was identified as a risk factor for UTI during treatment. Events consistent with genital infections occurred more frequently with empagliflozin 10/25 mg than placebo (3.54 vs. 0.95/100 patient-years, respectively). The frequency of AEs consistent with volume depletion was similar across groups, but higher with empagliflozin 10/25 mg than placebo in patients aged 75 to < 85 years and those on loop diuretics at baseline. CONCLUSION This comprehensive analysis confirms that both empagliflozin 10 mg and 25 mg are well tolerated in patients with T2DM, reinforcing the established clinical safety profile of empagliflozin.",2020,Events consistent with genital infections occurred more frequently with empagliflozin,"['10\xa0mg (n\u2009=\u20094858', 'Total exposure was 16,480 and 7857 patient-years in the pooled', 'Patients with Type 2 Diabetes Mellitus', 'patients with type 2 diabetes mellitus (T2DM', 'Pooled data from 20 trials were analyzed for patients with T2DM treated with', 'patients with T2DM']","['empagliflozin 25\xa0mg (n\u2009=\u20095057), or placebo', 'Empagliflozin', 'empagliflozin', 'placebo']","['AE incidence rates', 'genital infections', 'higher rate of confirmed hypoglycemia', 'safety and tolerability', 'incidence of any AEs, AEs leading to treatment discontinuation, severe AEs, and serious AEs', 'Adverse events (AEs', 'incidence of events consistent with urinary tract infections (UTI', 'frequency of AEs consistent with volume depletion', 'frequency of serious AEs requiring hospitalization']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0337051', 'cui_str': 'Pool'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C3848772', 'cui_str': 'empagliflozin 25 MG [Jardiance]'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0729552', 'cui_str': 'Genital infection'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0546884', 'cui_str': 'Hypovolemia'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",,0.314442,Events consistent with genital infections occurred more frequently with empagliflozin,"[{'ForeName': 'Ona', 'Initials': 'O', 'LastName': 'Kinduryte Schorling', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Clark', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Isabella', 'Initials': 'I', 'LastName': 'Zwiener', 'Affiliation': 'Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Kaspers', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Jisoo', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Hristo', 'Initials': 'H', 'LastName': 'Iliev', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany. hristo.iliev@boehringer-ingelheim.com.'}]",Advances in therapy,['10.1007/s12325-020-01329-7'] 54,32375151,Transoral Endoscopic Coblation Tongue Base Surgery in Obstructive Sleep Apnea: Resection versus Ablation.,"BACKGROUND A new transoral tongue base surgical procedure for the treatment of snoring and obstructive sleep apnea (OSA) is described. It is named ""Robo-Cob"" technique because it is similar to transoral robotic surgery (TORS) but it is performed by means of coblation technology in order to resect the tongue base in countries where TORS is not an available option for such benign conditions. METHODS In this prospective, randomized, controlled trial, the new Robo-Cob technique was carried out in 25 adult OSA patients with confirmed tongue base hypertrophy at preoperative drug-induced sedation endoscopy. The results of this procedure were compared with the coblation endoscopic lingual lightening (CELL) technique used to ablate (or minimally resect) the central part of the tongue base, in another 25 adult OSA patients with similar characteristics (age, sex, preoperative body mass index and Apnea-Hypopnea Index, AHI). The base of tongue surgery was part of multilevel surgery including also septoturbinoplasty and barbed reposition pharyngoplasty (with/without tonsillectomy). RESULTS In this study, the Robo-Cob technique is proved to be feasible and effective in all cases either alone or when combined with other procedures in multilevel surgical settings. No/minimal intraoperative or postoperative complications were observed. Postoperative pain as measured by visual analog scale ranged from 3 to 7. No tracheostomy was done in any patient. Objective clinical improvement was confirmed by a level 3 polygraphy performed 6 months after surgery. There was significant difference in operative time at the level of the tongue base between Robo-Cob and CELL techniques, with shorter times observed within the Robo-Cob group. Moreover, the Robo-Cob technique provided tongue base tissue specimens that allowed measurement of the volume that ranged from 5 to 17 cm3 (mean 11.64 ± 3.49 cm3). It was found that resection of at least 10 cm3 of tongue base tissue was associated with better outcomes in terms of postoperative AHI reduction. CONCLUSION In this study, the added values of using coblation for resection and not ablation appear to be the short surgical time, the low postoperative tissue edema, and the possibility of providing tissue specimens to measure resected volumes.",2020,"There was significant difference in operative time at the level of the tongue base between Robo-Cob and CELL techniques, with shorter times observed within the Robo-Cob group.","['Obstructive Sleep Apnea', 'snoring and obstructive sleep apnea (OSA', '25 adult OSA patients with similar characteristics (age, sex, preoperative body mass index and Apnea-Hypopnea Index, AHI', '25 adult OSA patients with confirmed tongue base hypertrophy at preoperative drug-induced sedation endoscopy']","['Transoral Endoscopic Coblation Tongue Base Surgery', 'coblation endoscopic lingual lightening (CELL) technique used to ablate (or minimally resect', 'transoral robotic surgery (TORS', 'multilevel surgery including also septoturbinoplasty and barbed reposition pharyngoplasty (with/without tonsillectomy']","['minimal intraoperative or postoperative complications', 'visual analog scale', 'operative time', 'Postoperative pain']","[{'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0037384', 'cui_str': 'Snoring'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0226958', 'cui_str': 'Structure of root of tongue'}, {'cui': 'C0020564', 'cui_str': 'Hypertrophy'}, {'cui': 'C0458082', 'cui_str': 'Drug-induced'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}]","[{'cui': 'C0442366', 'cui_str': 'Transoral approach'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0226958', 'cui_str': 'Structure of root of tongue'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040408', 'cui_str': 'Tongue structure'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0556030', 'cui_str': 'Repositioning'}, {'cui': 'C0192234', 'cui_str': 'Repair of pharynx'}, {'cui': 'C0040423', 'cui_str': 'Tonsillectomy'}]","[{'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}]",25.0,0.0183102,"There was significant difference in operative time at the level of the tongue base between Robo-Cob and CELL techniques, with shorter times observed within the Robo-Cob group.","[{'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Bahgat', 'Affiliation': 'Department of Otorhinolaryngology, Alexandria University, Alexandria, Egypt, ahmedyassinbahgat@gmail.com.'}, {'ForeName': 'Yassin', 'Initials': 'Y', 'LastName': 'Bahgat', 'Affiliation': 'Department of Otorhinolaryngology, Alexandria University, Alexandria, Egypt.'}, {'ForeName': 'Rajab', 'Initials': 'R', 'LastName': 'Alzahrani', 'Affiliation': 'Department of Surgery, ENT Division, Medical College, Albaha University, Albaha, Saudi Arabia.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Montevecchi', 'Affiliation': 'Department of Head-Neck Surgery, Otolaryngology, Head-Neck and Oral Surgery Unit, Morgagni Pierantoni Hospital, Azienda USL della Romagna, Forlì, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Cammaroto', 'Affiliation': 'Department of Head-Neck Surgery, Otolaryngology, Head-Neck and Oral Surgery Unit, Morgagni Pierantoni Hospital, Azienda USL della Romagna, Forlì, Italy.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Vicini', 'Affiliation': 'Department of Head-Neck Surgery, Otolaryngology, Head-Neck and Oral Surgery Unit, Morgagni Pierantoni Hospital, Azienda USL della Romagna, Forlì, Italy.'}]",ORL; journal for oto-rhino-laryngology and its related specialties,['10.1159/000506994'] 55,32376080,Resting State Functional Connectivity and Outcomes of Psychotherapies for Late-Life Depression.,"BACKGROUND Problem solving therapy (PST) and ""Engage,"" a reward-exposure"" based therapy, are important treatment options for late-life depression, given modest efficacy of antidepressants in this disorder. Abnormal function of the reward and default mode networks has been observed during depressive episodes. This study examined whether resting state functional connectivity (rsFC) of reward and DMN circuitries is associated with treatment outcomes. METHODS Thirty-two older adults with major depression (mean age = 72.7) were randomized to 9-weeks of either PST or ""Engage."" We assessed rsFC at baseline and week 6. We placed seeds in three a priori regions of interest: subgenual anterior cingulate cortex (sgACC), dorsal anterior cingulate cortex (dACC), and nucleus accumbens (NAcc). Outcome measures included the Hamilton Depression Rating Scale (HAMD) and the Behavioral Activation for Depression Scale (BADS). RESULTS In both PST and ""Engage,"" higher rsFC between the sgACC and middle temporal gyrus at baseline was associated with greater improvement in depression severity (HAMD). Preliminary findings suggested that in ""Engage"" treated participants, lower rsFC between the dACC and dorsomedial prefrontal cortex at baseline was associated with HAMD improvement. Finally, in Engage only, increased rsFC from baseline to week 6 between NAcc and Superior Parietal Cortex was associated with increased BADS scores. CONCLUSION The results suggest that patients who present with higher rsFC between the sgACC and a structure within the DMN may benefit from behavioral psychotherapies for late life depression. ""Engage"" may lead to increased rsFC within the reward system reflecting a reconditioning of the reward systems by reward exposure.",2020,"In both PST and ""Engage,"" higher rsFC between the sgACC and middle temporal gyrus at baseline was associated with greater improvement in depression severity (HAMD).",['Thirty-two older adults with major depression (mean age\u202f=\u202f72.7'],"['Problem solving therapy (PST', 'PST or ""Engage']","['BADS scores', 'anterior cingulate cortex (sgACC), dorsal anterior cingulate cortex (dACC), and nucleus accumbens (NAcc', 'depression severity (HAMD', 'Hamilton Depression Rating Scale (HAMD) and the Behavioral Activation for Depression Scale (BADS']","[{'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C1303140', 'cui_str': 'Problem solving therapy'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0007610', 'cui_str': 'Nucleus'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}]",32.0,0.0436281,"In both PST and ""Engage,"" higher rsFC between the sgACC and middle temporal gyrus at baseline was associated with greater improvement in depression severity (HAMD).","[{'ForeName': 'Nili', 'Initials': 'N', 'LastName': 'Solomonov', 'Affiliation': 'Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine (NS, LWV, LO, FMG, and GSA), White Plains, NY. Electronic address: nis2051@med.cornell.edu.'}, {'ForeName': 'Lindsay W', 'Initials': 'LW', 'LastName': 'Victoria', 'Affiliation': 'Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine (NS, LWV, LO, FMG, and GSA), White Plains, NY.'}, {'ForeName': 'Katharine', 'Initials': 'K', 'LastName': 'Dunlop', 'Affiliation': 'Feil Family Brain Mind Research Institute, Weill Cornell Medicine (KD and CL), New York, NY.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Respino', 'Affiliation': 'Rush University Medical Center (MR), Chicago, IL.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Hoptman', 'Affiliation': 'The Nathan S. Kline Institute for Psychiatric Research (MJH), Orangeburg, NY; New York University School of Medicine (MJH), New York, NY.'}, {'ForeName': 'Sigal', 'Initials': 'S', 'LastName': 'Zilcha-Mano', 'Affiliation': 'Columbia University (SZM), New York, NY; Haifa University (SZM), Haifa, Israel.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Oberlin', 'Affiliation': 'Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine (NS, LWV, LO, FMG, and GSA), White Plains, NY.'}, {'ForeName': 'Conor', 'Initials': 'C', 'LastName': 'Liston', 'Affiliation': 'Feil Family Brain Mind Research Institute, Weill Cornell Medicine (KD and CL), New York, NY.'}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Areán', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences (PAA), University of Washington School of Medicine, Seattle, WA.'}, {'ForeName': 'Faith M', 'Initials': 'FM', 'LastName': 'Gunning', 'Affiliation': 'Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine (NS, LWV, LO, FMG, and GSA), White Plains, NY.'}, {'ForeName': 'George S', 'Initials': 'GS', 'LastName': 'Alexopoulos', 'Affiliation': 'Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine (NS, LWV, LO, FMG, and GSA), White Plains, NY.'}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2020.04.008'] 56,32363608,Development and preliminary validation of the Meaningful and Enjoyable Activities Scale (MEAS) in mild dementia.,"BACKGROUND Engaging in meaningful activity is an important contributor to well-being in late life. This study aimed to develop a new measure of meaningful and enjoyable activities in people living with mild dementia. METHODS The study consisted of four phases: (a) a review of measures of meaningful activity in older people; (b) interviews with people with dementia and their carers (n = 32), (c) expert opinion; and (d) feasibility testing in a pilot randomised controlled trial (n = 63). RESULTS The development process resulted in a 20-item questionnaire. The Meaningful and Enjoyable Activities Scale (MEAS) evidenced appropriate levels of internal consistency (α = .79). Higher scores correlated with higher functional independence (r = -.605, P < .001), patient (r = .330, P = .010) and carer-rated patient quality of life (r = .505, P < .001). Multiple regression analyses showed that functional independence made a significant independent contribution in predicting higher levels of meaningful activity (F[7,45] = 6.75, P < .001, R 2 = .512; β = -.444, P = .001). Confirmatory factor analysis indicated that a revised three-factor 9-item model provided good fit for the data (X 2 = 22.74, P = .54, GFI = 0.93, RMSE = 0.00), with leisure-time physical activity, social engagement and mentally stimulating activities as the key dimensions. CONCLUSION Our study provides support for the construct of meaningful activity in people with mild dementia. Although we find preliminary evidence that the MEAS has adequate psychometric properties, future large scale studies are required to test its validity further and responsiveness to change.",2020,The Meaningful and Enjoyable Activities Scale (MEAS) evidenced appropriate levels of internal consistency (α = 0.79).,"['people with mild dementia', 'mild dementia', 'older people; 2) interviews with people with dementia and their carers (n\xa0=\xa032', 'people living with mild dementia']",['MEAS'],"['carer-rated patient quality of life', 'functional independence', 'Meaningful and Enjoyable Activities Scale (MEAS) evidenced appropriate levels of internal consistency', 'Meaningful and Enjoyable Activities Scale (MEAS', 'meaningful activity', 'leisure-time physical activity, social engagement and mentally stimulating activities']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3494623', 'cui_str': 'Mild dementia'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]","[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0086542', 'cui_str': 'Leisure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}]",,0.0439073,The Meaningful and Enjoyable Activities Scale (MEAS) evidenced appropriate levels of internal consistency (α = 0.79).,"[{'ForeName': 'Remco', 'Initials': 'R', 'LastName': 'Tuijt', 'Affiliation': 'Faculty of Brain Sciences, Division of Psychiatry, University College London, London, UK.'}, {'ForeName': 'Phuong', 'Initials': 'P', 'LastName': 'Leung', 'Affiliation': 'Faculty of Brain Sciences, Division of Psychiatry, University College London, London, UK.'}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Profyri', 'Affiliation': 'Faculty of Brain Sciences, Division of Psychiatry, University College London, London, UK.'}, {'ForeName': 'Vasiliki', 'Initials': 'V', 'LastName': 'Orgeta', 'Affiliation': 'Faculty of Brain Sciences, Division of Psychiatry, University College London, London, UK.'}]",International journal of geriatric psychiatry,['10.1002/gps.5316'] 57,32371759,Functional health and white matter hyperintensities as effect modifiers of blood pressure-lowering on cognitive function and vascular events in older Secondary Prevention of Small Subcortical Strokes trial participants.,"OBJECTIVE To determine whether cerebral small vessel disease or disability modify the effect of SBP treatment on cognitive and vascular outcomes in older patients with recent lacunar stroke. METHODS Participants aged at least 65 years of the Secondary Prevention of Small Subcortical Strokes Trial were randomized to a higher (130-149 mmHg) or lower (<130 mmHg) SBP target. The primary outcome was change in cognitive function (Cognitive Abilities Screening Instrument); secondary outcomes were incident mild cognitive impairment, stroke, major vascular events (all-stroke, myocardial infarction), and all-cause death. Results were stratified by severity of white matter hyperintensities (WMH; none/mild, moderate, severe) on baseline MRI, and by disability (no vs. at least one limitation in activities of daily living). RESULTS One thousand, two hundred and sixty-three participants (mean age 73.8 ± 5.9 years, 40% women) were included. Participants with severe WMH or disability had worse cognitive function at baseline and after a mean follow-up of 3.9 years. No significant interactions existed between treatment group and effect modifiers (WMH, disability) for change in cognitive function (P for interaction 0.42 and 0.66, respectively). A lower SBP target appeared more beneficial among those with worse WMH burden for vascular outcomes (P for interaction = 0.01 for stroke and 0.03 for major vascular events). CONCLUSION There was no difference in the effect of lowering SBP to less than 130 mmHg on cognitive function by cerebral small vessel disease or disability among older adults with a history of lacunar stroke. Those with evidence of small vessel disease may derive greater benefit from lower SBP on prevention of subsequent vascular events. TRIAL REGISTRATION Clinicaltrials.gov Identifier: NCT00059306.",2020,"No significant interactions existed between treatment group and effect modifiers (WMH, disability) for change in cognitive function (P for interaction 0.42 and 0.66, respectively).","['Participants aged at least 65 years of the Secondary Prevention of Small Subcortical Strokes Trial were randomized to a higher (130-149\u200ammHg) or lower (<130\u200ammHg) SBP target', 'One thousand, two hundred and sixty-three participants (mean age 73.8\u200a±\u200a5.9 years, 40% women) were included', 'older Secondary Prevention of Small Subcortical Strokes trial participants', 'Participants with severe WMH or disability had worse', 'older patients with recent lacunar stroke', 'older adults with a history of lacunar stroke']","['SBP treatment', 'blood pressure-lowering']","['cognitive and vascular outcomes', 'cognitive function', 'change in cognitive function (Cognitive Abilities Screening Instrument); secondary outcomes were incident mild cognitive impairment, stroke, major vascular events (all-stroke, myocardial infarction), and all-cause death', 'effect modifiers (WMH, disability', 'cognitive function by cerebral small vessel disease or disability', 'cognitive function and vascular events']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0679699', 'cui_str': 'Secondary prevention'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C5191071', 'cui_str': '149'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C4517671', 'cui_str': '263'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C3178801', 'cui_str': 'Lacunar stroke'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0262926', 'cui_str': 'History of'}]","[{'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]","[{'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C3542952', 'cui_str': 'Modifier'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C2733158', 'cui_str': 'Small vessel cerebrovascular disease'}]",1263.0,0.41933,"No significant interactions existed between treatment group and effect modifiers (WMH, disability) for change in cognitive function (P for interaction 0.42 and 0.66, respectively).","[{'ForeName': 'Manuel R', 'Initials': 'MR', 'LastName': 'Blum', 'Affiliation': 'aDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California, USA bDepartment of General Internal Medicine, Inselspital, Bern University Hospital cInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland dDivision of General Internal Medicine, Department of Medicine, San Francisco Veterans Affair Medical Center eKidney Health Research Collaborative, University of California fSan Francisco Veterans Affairs Medical Center, San Francisco, California, USA gSPS3 Coordinating Center hDivision of Neurology, Department of Medicine, Brain Research Center, University of British Columbia, Vancouver, Canada iDepartment of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania jDepartment of Medicine, Epidemiology and Biostatistics, University of California, San Francisco, California, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Scherzer', 'Affiliation': ''}, {'ForeName': 'Jesse C', 'Initials': 'JC', 'LastName': 'Ikeme', 'Affiliation': ''}, {'ForeName': 'Oscar R', 'Initials': 'OR', 'LastName': 'Benavente', 'Affiliation': ''}, {'ForeName': 'Leslie A', 'Initials': 'LA', 'LastName': 'McClure', 'Affiliation': ''}, {'ForeName': 'Carmen A', 'Initials': 'CA', 'LastName': 'Peralta', 'Affiliation': ''}, {'ForeName': 'Michelle C', 'Initials': 'MC', 'LastName': 'Odden', 'Affiliation': ''}]",Journal of hypertension,['10.1097/HJH.0000000000002440'] 58,32371767,Outcomes in adults with systolic blood pressure between 130 and 139 mmHg in Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial and Systolic Blood Pressure Intervention Trial.,"BACKGROUND Patients with stage 1 systolic hypertension have increased risk of cardiovascular disease (CVD) events. METHODS Using Cox models, we assess the effect of targeting an intensive SBP goal of less than 120 mmHg compared with standard SBP goal of less than 140 mmHg on the risk of CVD events in adults with stage 1 systolic hypertension with diabetes mellitus enrolled in Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial (ACCORD BP) (n = 1901) and without diabetes mellitus enrolled in Systolic Blood Pressure Intervention Trial (SPRINT) (n = 3484) that used identical SBP goal interventions. OUTCOMES In ACCORD BP, the primary composite CVD outcome was the first occurrence of myocardial infarction, stroke, or CVD mortality. In SPRINT, the primary composite CVD outcome was the first occurrence of myocardial infarction, other acute coronary syndrome, stroke, heart failure, or CVD mortality. RESULTS In SPRINT, targeting an intensive SBP goal significantly reduced the risk of the primary CVD outcome [hazard ratio 0.75 (95% confidence interval, 0.58-0.98); events 1.78 vs. 2.37%/year]. In ACCORD BP, the relationships of SBP goal with the primary CVD outcome was modified by the glycemia goal intervention (interaction P = 0.039). In the standard glycemia subgroup (A1c target 7-7.9%), intensive SBP goal significantly reduced the risk of the primary CVD outcome [hazard ratio 0.61 (0.40-0.94); events 1.63 vs. 2.56%/year]. In the intensive glycemia subgroup (A1c target <6%), the risk of the primary CVD outcome was not significantly different between groups [hazard ratio 1.20 (0.76-1.89); events 1.91 vs. 1.60%/year]. CONCLUSION Targeting an intensive SBP goal significantly reduced the risk of CVD events in patients with stage 1 systolic hypertension without diabetes and with diabetes on standard glycemia goal.",2020,"In SPRINT, the primary composite CVD outcome was the first occurrence of myocardial infarction, other acute coronary syndrome, stroke, heart failure, or CVD mortality. ","['n\u200a=\u200a1901) and without diabetes mellitus enrolled in Systolic Blood Pressure Intervention Trial (SPRINT) (n\u200a=\u200a3484) that used identical SBP goal interventions', 'adults with stage 1 systolic hypertension with diabetes mellitus enrolled in Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial (ACCORD BP', 'Patients with stage 1 systolic hypertension', 'patients with stage 1 systolic hypertension without diabetes and with diabetes on standard glycemia goal', 'adults with systolic blood pressure between 130 and 139\u200ammHg in Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial and Systolic Blood Pressure Intervention Trial']",['intensive SBP goal of less than 120\u200ammHg compared with standard SBP goal of less than 140\u200ammHg'],"['myocardial infarction, stroke, or CVD mortality', 'risk of the primary CVD outcome', 'myocardial infarction, other acute coronary syndrome, stroke, heart failure, or CVD mortality', 'risk of CVD events']","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0221155', 'cui_str': 'Systolic hypertension'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C5191072', 'cui_str': '139'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}]","[{'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C4319553', 'cui_str': '140'}]","[{'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",,0.207433,"In SPRINT, the primary composite CVD outcome was the first occurrence of myocardial infarction, other acute coronary syndrome, stroke, heart failure, or CVD mortality. ","[{'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Contreras', 'Affiliation': 'aUniversity of Miami Miller School of Medicine, Miami, Florida bWake Forest School of Medicine, Winston-Salem, North Carolina cMiami Veterans Affairs Healthcare System, Miami, Florida dGeorgetown University, Washington, District of Columbia eRutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey fMedical University of South Carolina gRalph H. Johnson VA Medical Center, Charleston, South Carolina hUniversity of Kentucky, Lexington, Kentucky iEmory University School of Medicine, Atlanta, Georgia jUniversity of Utah School of Medicine, Salt Lake City, Utah kGeisinger Medical Center, Danville, Pennsylvania lMemphis Veterans Affairs Medical Center mUniversity of Tennessee Health Science Center, Memphis, Tennessee, USA.'}, {'ForeName': 'Lingyi', 'Initials': 'L', 'LastName': 'Lu', 'Affiliation': ''}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Tamariz', 'Affiliation': ''}, {'ForeName': 'Michael V', 'Initials': 'MV', 'LastName': 'Rocco', 'Affiliation': ''}, {'ForeName': 'Vasilios', 'Initials': 'V', 'LastName': 'Papademetriou', 'Affiliation': ''}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Kostis', 'Affiliation': ''}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Pisoni', 'Affiliation': ''}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Glasser', 'Affiliation': ''}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Sweeney', 'Affiliation': ''}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Basile', 'Affiliation': ''}, {'ForeName': 'Lisa H', 'Initials': 'LH', 'LastName': 'Gren', 'Affiliation': ''}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Zamanian', 'Affiliation': ''}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Cushman', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of hypertension,['10.1097/HJH.0000000000002437'] 59,32374787,Anodal transcranial direct current stimulation reduces collinear lateral inhibition in normal peripheral vision.,"Collinear flanking stimuli can reduce the detectability of a Gabor target presented in peripheral vision. This phenomenon is called collinear lateral inhibition and it may contribute to crowding in peripheral vision. Perceptual learning can reduce collinear lateral inhibition in peripheral vision, however intensive training is required. Our aim was to assess whether modulation of collinear lateral inhibition can be achieved within a short time-frame using a single 20-minute session of primary visual cortex anodal transcranial direct current stimulation (a-tDCS). Thirteen observers with normal vision performed a 2AFC contrast detection task with collinear flankers positioned at a distance of 2λ from the target (lateral inhibition) or 6λ (control condition). The stimuli were presented 6° to the left of a central cross and fixation was monitored with an infra-red eye tracker. Participants each completed two randomly sequenced, single-masked stimulation sessions; real anodal tDCS and sham tDCS. For the 2λ separation condition, a-tDCS induced a significant reduction in detection threshold (reduced lateral inhibition). Sham stimulation had no effect. No effects of a-tDCS were observed for the 6λ separation condition. This result lays the foundation for future work investigating whether a-tDCS may be useful as a visual rehabilitation tool for individuals with central vision loss who are reliant on peripheral vision.",2020,"For the 2λ separation condition, a-tDCS induced a significant reduction in detection threshold (reduced lateral inhibition).","['individuals with central vision loss who are reliant on peripheral vision', 'normal peripheral vision']","['single-masked stimulation sessions; real anodal tDCS and sham tDCS', 'Perceptual learning', 'Anodal transcranial direct current stimulation']",['detection threshold (reduced lateral inhibition'],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0152191', 'cui_str': 'Central scotoma'}, {'cui': 'C0234628', 'cui_str': 'Peripheral vision'}, {'cui': 'C0278208', 'cui_str': 'Normal peripheral vision'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}]",13.0,0.0643383,"For the 2λ separation condition, a-tDCS induced a significant reduction in detection threshold (reduced lateral inhibition).","[{'ForeName': 'Rajkumar Nallour', 'Initials': 'RN', 'LastName': 'Raveendran', 'Affiliation': 'Envision Research Institute, Wichita, Kansas, United States of America.'}, {'ForeName': 'Katelyn', 'Initials': 'K', 'LastName': 'Tsang', 'Affiliation': 'School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada.'}, {'ForeName': 'Dilraj', 'Initials': 'D', 'LastName': 'Tiwana', 'Affiliation': 'School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Chow', 'Affiliation': 'School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Thompson', 'Affiliation': 'School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada.'}]",PloS one,['10.1371/journal.pone.0232276'] 60,32377822,Tear cytokines as potential biomarkers in non-infectious uveitis: post hoc analysis of a randomised clinical trial.,"PURPOSE The study aimed to evaluate cytokines in tears as potential biomarkers in non-infectious uveitis. METHODS Tear samples were obtained using Schirmer strips from 50 patients enrolled in a randomised controlled study of simvastatin in non-infectious uveitis and from a control group of 30 healthy participants. The concentrations of IL-6, IL-8, IL-10, and IFN-γ in tears were measured at the study's baseline and again after 8 weeks of treatment using commercial enzyme-linked immunosorbent assay kits. RESULTS The concentrations of tears IL-6 and IL-10 were increased in patients with non-infectious uveitis in comparison with the healthy participants. Longer disease duration was associated with elevated levels of IL-6. The concentrations of the studied cytokines in tears did not correlate with the extent of eye inflammation at baseline. No link between the changes in cytokine levels and changes in clinical parameters during treatment was observed. Baseline IL-10 concentrations independently predicted the development of the clinical response to treatment at weeks 4 and 8. CONCLUSION Although elevated in non-infectious uveitis patients, tear cytokine levels do not correlate with eye inflammation and are not sensitive to change after treatment. However, the level of IL-10 may be a predictive biomarker of response to the treatment of uveitis. TRIAL REGISTRATION NCT04183387.",2020,"The concentrations of IL-6, IL-8, IL-10, and IFN-γ in tears were measured at the study's baseline and again after 8 weeks of treatment using commercial enzyme-linked immunosorbent assay kits. ","['in non-infectious uveitis and from a control group of 30 healthy participants', 'non-infectious uveitis', 'Tear samples were obtained using Schirmer strips from 50 patients enrolled']","['simvastatin', 'commercial enzyme-linked immunosorbent assay kits']","['Baseline IL-10 concentrations', 'concentrations of tears IL-6', 'concentrations of IL-6, IL-8, IL-10, and IFN-γ in tears', 'cytokine levels', 'tear cytokine levels', 'elevated levels of IL-6', 'Longer disease duration']","[{'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0042164', 'cui_str': 'Uveitis'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C1611838', 'cui_str': 'Lacrimal fluid sample'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0493032', 'cui_str': 'Schirmer test paper strip'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0074554', 'cui_str': 'Simvastatin'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",50.0,0.175251,"The concentrations of IL-6, IL-8, IL-10, and IFN-γ in tears were measured at the study's baseline and again after 8 weeks of treatment using commercial enzyme-linked immunosorbent assay kits. ","[{'ForeName': 'Ivan V', 'Initials': 'IV', 'LastName': 'Shirinsky', 'Affiliation': 'Laboratory of Clinical Immunopharmacology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, 6 Zalesskogo str., Novosibirsk, 630099, Russia. ivan.shirinsky@gmail.com.'}, {'ForeName': 'Anastasia A', 'Initials': 'AA', 'LastName': 'Biryukova', 'Affiliation': 'S. N. Fyodorov Eye Microsurgery Complex, Novosibirsk Branch. 10 Kolhidskaya, Novosibirsk, 630071, Russia.'}, {'ForeName': 'Natalia Y', 'Initials': 'NY', 'LastName': 'Kalinovskaya', 'Affiliation': 'Laboratory of Clinical Immunopharmacology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, 6 Zalesskogo str., Novosibirsk, 630099, Russia.'}, {'ForeName': 'Valery S', 'Initials': 'VS', 'LastName': 'Shirinsky', 'Affiliation': 'Laboratory of Clinical Immunopharmacology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, 6 Zalesskogo str., Novosibirsk, 630099, Russia.'}]",Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,['10.1007/s00417-020-04707-7'] 61,32376732,"Oral nitrate supplementation to enhance pulmonary rehabilitation in COPD: ON-EPIC a multicentre, double-blind, placebo-controlled, randomised parallel group study.","RATIONALE Dietary nitrate supplementation has been proposed as a strategy to improve exercise performance, both in healthy individuals and in people with COPD. We aimed to assess whether it could enhance the effect of pulmonary rehabilitation (PR) in COPD. METHODS This double-blind, placebo-controlled, parallel group, randomised controlled study performed at four UK centres, enrolled adults with Global Initiative for Chronic Obstructive Lung Disease grade II-IV COPD and Medical Research Council dyspnoea score 3-5 or functional limitation to undertake a twice weekly 8-week PR programme. They were randomly assigned (1:1) to either 140 mL of nitrate-rich beetroot juice (BRJ) (12.9 mmol nitrate), or placebo nitrate-deplete BRJ, consumed 3 hours prior to undertaking each PR session. Allocation used computer-generated block randomisation. MEASUREMENTS The primary outcome was change in incremental shuttle walk test (ISWT) distance. Secondary outcomes included quality of life, physical activity level, endothelial function via flow-mediated dilatation, fat-free mass index and blood pressure parameters. RESULTS 165 participants were recruited, 78 randomised to nitrate-rich BRJ and 87 randomised to placebo. Exercise capacity increased more with active treatment (n=57) than placebo (n=65); median (IQR) change in ISWT distance +60 m (10, 85) vs +30 m (0, 70), estimated treatment effect 30 m (95% CI 10 to 40); p=0.027. Active treatment also impacted on systolic blood pressure: treatment group -5.0 mm Hg (-5.0, -3.0) versus control +6.0 mm Hg (-1.0, 15.5), estimated treatment effect -7 mm Hg (95% CI 7 to -20) (p<0.0005). No significant serious adverse events or side effects were reported. CONCLUSIONS Dietary nitrate supplementation appears to be a well-tolerated and effective strategy to augment the benefits of PR in COPD. TRIAL REGISTRATION NUMBER ISRCTN27860457.",2020,"Exercise capacity increased more with active treatment (n=57) than placebo (n=65); median (IQR) change in ISWT distance +60 m (10, 85) vs +30 m (0, 70), estimated treatment effect 30 m (95% CI 10 to 40); p=0.027.","['healthy individuals and in people with COPD', '165 participants were recruited, 78 randomised to', 'COPD', 'four UK centres, enrolled adults with Global Initiative for Chronic Obstructive Lung Disease grade II-IV COPD and Medical Research Council dyspnoea score 3-5 or functional limitation to undertake a twice weekly 8-week PR programme']","['placebo', 'nitrate-rich BRJ', 'Oral nitrate supplementation', '140\u2009mL of nitrate-rich beetroot juice (BRJ) (12.9\u2009mmol nitrate), or placebo nitrate-deplete BRJ', 'pulmonary rehabilitation (PR']","['serious adverse events or side effects', 'Exercise capacity', 'quality of life, physical activity level, endothelial function via flow-mediated dilatation, fat-free mass index and blood pressure parameters', 'systolic blood pressure', 'incremental shuttle walk test (ISWT) distance', 'median (IQR) change in ISWT distance', 'exercise performance']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0079816', 'cui_str': 'Research, Medical'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0442758', 'cui_str': '3/5'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0556985', 'cui_str': 'Twice weekly'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C1095905', 'cui_str': 'Beets preparation'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0002940', 'cui_str': 'Aneurysm'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C4280053', 'cui_str': 'Incremental Shuttle Walk Test'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",165.0,0.764259,"Exercise capacity increased more with active treatment (n=57) than placebo (n=65); median (IQR) change in ISWT distance +60 m (10, 85) vs +30 m (0, 70), estimated treatment effect 30 m (95% CI 10 to 40); p=0.027.","[{'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Pavitt', 'Affiliation': 'National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.'}, {'ForeName': 'Rebecca Jayne', 'Initials': 'RJ', 'LastName': 'Tanner', 'Affiliation': 'National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Lewis', 'Affiliation': 'National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Buttery', 'Affiliation': 'National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.'}, {'ForeName': 'Bhavin', 'Initials': 'B', 'LastName': 'Mehta', 'Affiliation': 'Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Jefford', 'Affiliation': 'Greenwich Adult Community Health Service, Oxleas NHS Foundation Trust, Dartford, Kent, UK.'}, {'ForeName': 'Katrina J', 'Initials': 'KJ', 'LastName': 'Curtis', 'Affiliation': 'National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.'}, {'ForeName': 'Winston A S', 'Initials': 'WAS', 'LastName': 'Banya', 'Affiliation': 'National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.'}, {'ForeName': 'Syed', 'Initials': 'S', 'LastName': 'Husain', 'Affiliation': 'Respiratory Medicine, Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, UK.'}, {'ForeName': 'Karnan', 'Initials': 'K', 'LastName': 'Satkunam', 'Affiliation': 'Greenwich Adult Community Health Service, Oxleas NHS Foundation Trust, Dartford, Kent, UK.'}, {'ForeName': 'Dinesh', 'Initials': 'D', 'LastName': 'Shrikrishna', 'Affiliation': 'Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, Somerset, UK.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Man', 'Affiliation': 'National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.'}, {'ForeName': 'Michael I', 'Initials': 'MI', 'LastName': 'Polkey', 'Affiliation': 'National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.'}, {'ForeName': 'Nicholas S', 'Initials': 'NS', 'LastName': 'Hopkinson', 'Affiliation': 'National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK n.hopkinson@ic.ac.uk.'}]",Thorax,['10.1136/thoraxjnl-2019-214278'] 62,32381925,[Effectiveness of L-Carnitine in the Treatment of Fatigue Associated with Chemotherapy in Patients with Gastric Cancer].,"AIM Low serum carnitine levels have been reported in patients with cancer receiving chemotherapy and are considered one of the factors causing fatigue associated with chemotherapy. We evaluated the effectiveness of L-carnitine in the treatment of fatigue associated with chemotherapy in patients with gastric cancer(GC). MATERIALS AND METHODS We performed a randomized controlled trial between December 2013 and December 2018. Untreated patients with advanced GC were included in the study; 1 patient developed an allergy after receiving the first chemotherapy and was excluded from the study. The primary endpoint was brief fatigue inventory(BFI). Patients were categorized into 2 groups: those who received L-carnitine oral supplements(group C)and those who did not receive L-carnitine oral supplements(group N). RESULTS The serum carnitine levels were improved significantly in group C compared with group N. BFIwas more aggravated in group N than group C; however, the difference was not significant. CONCLUSION We could not demonstrate the effectiveness of L-carnitine in the treatment of fatigue associated with chemotherapy in patients with GC.",2020,"The serum carnitine levels were improved significantly in group C compared with group N. BFIwas more aggravated in group N than group C; however, the difference was not significant. ","['Patients with Gastric Cancer', 'patients with GC', 'Untreated patients with advanced GC were included in the study; 1 patient developed an allergy after receiving the first chemotherapy and was excluded from the study', 'December 2013 and December 2018', 'patients with cancer receiving', 'patients with gastric cancer(GC']","['chemotherapy', 'L-carnitine oral supplements(group C)and those who did not receive L-carnitine oral supplements(group N', 'L-Carnitine', 'L-carnitine']","['serum carnitine levels', 'brief fatigue inventory(BFI']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0002111', 'cui_str': 'Allergy - specialty'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0087163', 'cui_str': 'Levocarnitine'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1299585', 'cui_str': 'Does not'}]","[{'cui': 'C0201937', 'cui_str': 'Carnitine measurement, serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",,0.0316508,"The serum carnitine levels were improved significantly in group C compared with group N. BFIwas more aggravated in group N than group C; however, the difference was not significant. ","[{'ForeName': 'Hayato', 'Initials': 'H', 'LastName': 'Watanabe', 'Affiliation': 'Dept. of Surgery, Gastroenterological Center, Yokohama City University Medical Center.'}, {'ForeName': 'Chikara', 'Initials': 'C', 'LastName': 'Kunisaki', 'Affiliation': ''}, {'ForeName': 'Yusaku', 'Initials': 'Y', 'LastName': 'Tanaka', 'Affiliation': ''}, {'ForeName': 'Sho', 'Initials': 'S', 'LastName': 'Sato', 'Affiliation': ''}, {'ForeName': 'Kei', 'Initials': 'K', 'LastName': 'Sato', 'Affiliation': ''}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Miyamoto', 'Affiliation': ''}, {'ForeName': 'Norio', 'Initials': 'N', 'LastName': 'Yukawa', 'Affiliation': ''}, {'ForeName': 'Ryuji', 'Initials': 'R', 'LastName': 'Kosaka', 'Affiliation': ''}, {'ForeName': 'Hirotoshi', 'Initials': 'H', 'LastName': 'Akiyama', 'Affiliation': ''}, {'ForeName': 'Munetaka', 'Initials': 'M', 'LastName': 'Masuda', 'Affiliation': ''}, {'ForeName': 'Itaru', 'Initials': 'I', 'LastName': 'Endo', 'Affiliation': ''}]",Gan to kagaku ryoho. Cancer & chemotherapy,[] 63,32383196,Efficacy and adverse events of 4% articaine compared with 2% lidocaine on primary molar extraction: A randomised controlled trial.,"BACKGROUND There is no consensus regarding the most effective anaesthetic solution for children; nerve block, especially mandibular, can be difficult for general dentists. Therefore, the study aims to compare the efficacy and the adverse events of articaine 4% with epinephrine 1:100 000 with lidocaine 2% with epinephrine 1:100 000 for primary molar extraction using buccal infiltration. METHODS These are data from a parallel triple-blind randomised controlled trial with a computer-generated allocation treatment. Forty-three children aged 6-10 years with a clinical and radiographic indication of primary molar extraction were enrolled. The intervention was local buccal infiltration with articaine 4% compared with lidocaine 2%. The main outcome was pain during anaesthetic injection and tooth extraction. Adverse events were examined as secondary outcomes. Children were treated in a University setting from April to June 2019. RESULTS Both solutions had similar anaesthetic efficacy in primary molar extraction when applied by the infiltrative technique (β -0.47; 95% CI -3.19 to 2.24; P = .76); however, children reported higher mean pain during articaine deposition (β 2.43; 95% CI 0.28-4.57; P = .02). The measured lidocaine pH was 3.19 (0.15) and articaine was 2.43 (0.00) (P = .04). Post-operative pain, oedema and nausea were observed without differences between the groups. CONCLUSIONS There was no difference in the efficacy of articaine compared to lidocaine for primary molar extraction. Articaine was more painful during the injection. PRACTICAL IMPLICATIONS Primary molar extractions can be performed with both articaine and lidocaine buccal infiltration.",2020,"Both solutions had similar anesthetic efficacy in primary molar extraction when applied by the infiltrative technique (β -0.47; 95% CI -3.19 to 2.24; p=0.76), however, children reported higher mean pain during articaine deposition (β 2.43; 95% CI 0.28 to 4.57; p=0.02).","['primary molars extraction using buccal infiltration', 'primary molars extraction', 'Forty-three children aged 6-10 years old with a clinical and radiographic indication of primary molar extraction were enrolled', 'Children were treated in a University setting from April to June 2019']","['Articaine', 'lidocaine', 'articaine', 'articaine and lidocaine buccal infiltration', 'epinephrine']","['anesthetic efficacy', 'pain during anesthetic injection and tooth extraction', 'Adverse events', 'mean pain', 'lidocaine pH', 'Postoperative pain, edema, and nausea', 'Efficacy and adverse events', 'local buccal infiltration']","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0450368', 'cui_str': '43'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C1608295', 'cui_str': 'Articaine'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}]","[{'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0040440', 'cui_str': 'Tooth extraction'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}]",43.0,0.201014,"Both solutions had similar anesthetic efficacy in primary molar extraction when applied by the infiltrative technique (β -0.47; 95% CI -3.19 to 2.24; p=0.76), however, children reported higher mean pain during articaine deposition (β 2.43; 95% CI 0.28 to 4.57; p=0.02).","[{'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Massignan', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Silveira Santos', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'ForeName': 'Mariane', 'Initials': 'M', 'LastName': 'Cardoso', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Bolan', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, Federal University of Santa Catarina, Florianópolis, Brazil.'}]",Journal of oral rehabilitation,['10.1111/joor.12989'] 64,32379777,Transplacental transfer of glyburide in women with gestational diabetes and neonatal hypoglycemia risk.,"BACKGROUND In pregnant women with gestational diabetes, glyburide can be an alternative to insulin despite concerns about its transplacental transfer. However, transplacental transfer of glyburide is poorly quantified and the relationship between cord blood glyburide concentration and hypoglycemia has not been studied. Our objective was to quantify the transplacental transfer of glyburide at delivery and to study the association between the cord blood glyburide concentration and the risk of neonatal hypoglycemia in patients with gestational diabetes treated with glyburide. METHODS AND FINDINGS INDAO was a multicenter, noninferiority, randomized trial conducted between May 2012 and November 2016 in 914 women with singleton pregnancies and gestational diabetes. An ancillary study was conducted in the 87 patients of the Bicêtre University Hospital Center. The sample consisted of 46 patients with utilizable assays at delivery. The relationships between glyburide concentration and the time since the last intake of glyburide and between fetal glyburide concentration and neonatal hypoglycemia were modeled with linear or logistic regressions using fractional polynomials. There was placental transfer of glyburide at a fetal to maternal ratio of 62% (95% CI [50; 74]). Umbilical cord blood glyburide concentration decreased steeply after the last maternal glyburide intake. After 24 hours, the mean umbilical cord blood concentration was less than 5 ng/mL. Neonatal hypoglycemia risk was increased with an odds ratio of hypoglycemia equal to 3.70 [1.40-9.77] for each 10 ng/mL increase in the cord blood glyburide concentration. However, no newborns were admitted to the NICU because of clinical signs of hypoglycemia or for treatment of hypoglycemia. CONCLUSION Considering that neonatal glyburide exposure may be limited by stopping treatment a sufficient time before labor, there may still be a place for glyburide in the management of gestational diabetes.",2020,"After 24 hours, the mean umbilical cord blood concentration was less than 5 ng/mL. Neonatal hypoglycemia risk was increased with an odds ratio of hypoglycemia equal to 3.70 [1.40-9.77] for each 10 ng/mL increase in the cord blood glyburide concentration.","['46 patients with utilizable assays at delivery', 'May 2012 and November 2016 in 914 women with singleton pregnancies and gestational diabetes', '87 patients of the Bicêtre University Hospital Center', 'pregnant women with gestational diabetes', 'patients with gestational diabetes treated with glyburide', 'women with gestational diabetes and neonatal hypoglycemia risk']",['glyburide'],"['fetal glyburide concentration and neonatal hypoglycemia', 'neonatal hypoglycemia', 'Umbilical cord blood glyburide concentration', 'mean umbilical cord blood concentration', 'Neonatal hypoglycemia risk', 'Transplacental transfer', 'placental transfer of glyburide', 'cord blood glyburide concentration']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0439671', 'cui_str': 'Gestational'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0017628', 'cui_str': 'Glyburide'}, {'cui': 'C0158986', 'cui_str': 'Neonatal hypoglycemia'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C0017628', 'cui_str': 'Glyburide'}]","[{'cui': 'C0015965', 'cui_str': 'Fetuses'}, {'cui': 'C0017628', 'cui_str': 'Glyburide'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0158986', 'cui_str': 'Neonatal hypoglycemia'}, {'cui': 'C0162371', 'cui_str': 'Cord blood'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0442375', 'cui_str': 'Transplacental approach'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0032043', 'cui_str': 'Placental structure'}]",914.0,0.0735579,"After 24 hours, the mean umbilical cord blood concentration was less than 5 ng/mL. Neonatal hypoglycemia risk was increased with an odds ratio of hypoglycemia equal to 3.70 [1.40-9.77] for each 10 ng/mL increase in the cord blood glyburide concentration.","[{'ForeName': 'Hanane', 'Initials': 'H', 'LastName': 'Bouchghoul', 'Affiliation': 'Department of Gynecology-Obstetrics, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France.'}, {'ForeName': 'Jean-Claude', 'Initials': 'JC', 'LastName': 'Alvarez', 'Affiliation': 'Département de Pharmacologie-Toxicologie, Assistance Publique-Hôpitaux de Paris, Hôpital Raymond Poincaré, MasSpecLab, Plateforme de spectrométrie de masse, Inserm U-1173, UFR PIFO, Université Versailles Saint Quentin-en-Yvelines, Garches, France.'}, {'ForeName': 'Céline', 'Initials': 'C', 'LastName': 'Verstuyft', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service de Génétique moléculaire, Pharmacogénétique et Hormonologie, Inserm U 1178 équipe Dépression, CESP, Université Paris-Sud, Le Kremlin-Bicêtre, France.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Bouyer', 'Affiliation': 'Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif, France.'}, {'ForeName': 'Marie-Victoire', 'Initials': 'MV', 'LastName': 'Senat', 'Affiliation': 'Department of Gynecology-Obstetrics, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France.'}]",PloS one,['10.1371/journal.pone.0232002'] 65,32381013,Assessing the Veterans Health Administration's response to intimate partner violence among women: protocol for a randomized hybrid type 2 implementation-effectiveness trial.,"BACKGROUND Intimate partner violence (IPV) against women in the United States (US) remains a complex public health crisis. Women who experience IPV are among the most vulnerable patients seen in primary care. Screening increases the detection of IPV and, when paired with appropriate response interventions, can mitigate the health effects of IPV. The Department of Veterans Affairs (VA) has encouraged evidence-based IPV screening programs since 2014, yet adoption is modest and questions remain regarding the optimal ways to implement these practices, which are not yet available within the majority of VA primary care clinics. METHODS/DESIGN This paper describes the planned evaluation of VA's nationwide implementation of IPV screening programs in primary care clinics through a randomized implementation-effectiveness hybrid type 2 trial. With the support of our VA operational partners, we propose a stepped wedge design to compare the impact of two implementation strategies of differing intensities (toolkit + implementation as usual vs. toolkit + implementation facilitation) and investigate the clinical effectiveness of IPV screening programs. Using balanced randomization, 16-20 VA Medical Centers will be assigned to receive implementation facilitation in one of three waves, with implementation support lasting 6 months. Implementation facilitation in this effort consists of the coordinated efforts of the two types of facilitators, external and internal. Implementation facilitation is compared to dissemination of a toolkit plus implementation as usual. We propose a mixed methods approach to collect quantitative (clinical records data) and qualitative (key informant interviews) implementation outcomes, as well as quantitative (clinical records data) clinical effectiveness outcomes. We will supplement these data collection methods with provider surveys to assess discrete implementation strategies used before, during, and following implementation facilitation. The integrated-Promoting Action on Research Implementation in Health Services (i-PARIHS) framework will guide the qualitative data collection and analysis. Summative data will be analyzed using the Reach Effectiveness Adoption Implementation Maintenance (RE-AIM) framework. DISCUSSION This research will advance national VHA efforts by identifying the practices and strategies useful for enhancing the implementation of IPV screening programs, thereby ultimately improving services for and health of women seen in primary care. TRIAL REGISTRATION NCT04106193. Registered on 23 September 2019.",2020,"This research will advance national VHA efforts by identifying the practices and strategies useful for enhancing the implementation of IPV screening programs, thereby ultimately improving services for and health of women seen in primary care. ","['Health Services', 'primary care clinics', 'Intimate partner violence (IPV) against women in the United States (US) remains a complex public health crisis', ""Veterans Health Administration's response to intimate partner violence among women""]",['IPV screening programs'],['detection of IPV'],"[{'cui': 'C0018747', 'cui_str': 'Services, Health'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0231224', 'cui_str': 'Crisis'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0178672', 'cui_str': 'Health administration'}]","[{'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}]",,0.0919335,"This research will advance national VHA efforts by identifying the practices and strategies useful for enhancing the implementation of IPV screening programs, thereby ultimately improving services for and health of women seen in primary care. ","[{'ForeName': 'Katherine M', 'Initials': 'KM', 'LastName': 'Iverson', 'Affiliation': ""Women's Health Sciences Division, National Center for PTSD, VA Boston Healthcare System, 150\u2009South Huntington Ave (116B-3), Boston, MA, 02130, USA. Katherine.Iverson@va.gov.""}, {'ForeName': 'Melissa E', 'Initials': 'ME', 'LastName': 'Dichter', 'Affiliation': 'VA Center for Health Equity Research and Promotion (CHERP), Corporal Michael J. Crescenz VA Medical Center, 3900 Woodland Ave, Philadelphia, 19104, PA, USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Stolzmann', 'Affiliation': 'Center for Healthcare Organization and Implementation Research (CHOIR), VA Boston Healthcare System, 150\u2009S. Huntington Ave (152\u2009M), Boston, MA, 02130, USA.'}, {'ForeName': 'Omonyêlé L', 'Initials': 'OL', 'LastName': 'Adjognon', 'Affiliation': 'Center for Healthcare Organization and Implementation Research (CHOIR), VA Boston Healthcare System, 150\u2009S. Huntington Ave (152\u2009M), Boston, MA, 02130, USA.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Lew', 'Affiliation': 'Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, 150\u2009S. Huntington Ave (152\u2009M), Boston, MA, 02130, USA.'}, {'ForeName': 'LeAnn E', 'Initials': 'LE', 'LastName': 'Bruce', 'Affiliation': 'Intimate Partner Violence Assistance Program, Care Management and Social Work, Department of Veterans Affairs, 810 Vermont Avenue, Washington, DC, 20420, USA.'}, {'ForeName': 'Megan R', 'Initials': 'MR', 'LastName': 'Gerber', 'Affiliation': ""Women's Health Center, VA Boston Healthcare System, 150\u2009S. Huntington Ave, Boston, MA, 02130, USA.""}, {'ForeName': 'Galina A', 'Initials': 'GA', 'LastName': 'Portnoy', 'Affiliation': 'Pain, Research, Informatics, Medical comorbidities, and Education (PRIME) Center, VA Conneticut Healthcare System, 950 Campbell Avenue, West Haven, CT, 06516, USA.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Miller', 'Affiliation': 'Center for Healthcare Organization and Implementation Research (CHOIR), VA Boston Healthcare System, 150\u2009S. Huntington Ave (152\u2009M), Boston, MA, 02130, USA.'}]",Implementation science : IS,['10.1186/s13012-020-0969-0'] 66,32384122,Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial.,"BACKGROUND In the primary analysis of a 12-month double-blind randomized active placebo-controlled trial, treatment of children with cystic fibrosis (CF) and pancreatic insufficiency (PI) with a readily absorbable structured lipid (Encala™, Envara Health, Wayne, PA) was safe, well-tolerated and improved dietary fat absorption (stool coefficient of fat absorption [CFA]), growth, and plasma fatty acids (FA). OBJECTIVE To determine if the Encala™ treatment effect varied by severity of baseline fat malabsorption. METHODS Subjects (n = 66, 10.5±3.0 yrs, 39% female) with baseline CFA who completed a three-month treatment with Encala™ or a calorie and macronutrient-matched placebo were included in this subgroup analysis. Subjects were categorized by median baseline CFA: low CFA (<88%) and high CFA (≥88%). At baseline and 3-month evaluations, CFA (72-hour stool, weighed food record) and height (HAZ), weight (WAZ) and BMI (BMIZ) Z-scores were calculated. Fasting plasma fatty acid (FA) concentrations were also measured. RESULTS Subjects in the low CFA subgroup had significantly improved CFA (+7.5±7.2%, mean 86.3±6.7, p = 0.002), and reduced stool fat loss (-5.7±7.2 g/24 hours) following three months of EncalaTM treatment. These subjects also had increased plasma linoleic acid (+20%), α-linolenic acid (+56%), and total FA (+20%) (p≤0.005 for all) concentrations and improvements in HAZ (0.06±0.08), WAZ (0.17±0.16), and BMIZ (0.20±0.25) (p≤0.002 for all). CFA and FA were unchanged with placebo in the low CFA group, with some WAZ increases (0.14±0.24, p = 0.02). High CFA subjects (both placebo and Encala™ groups) had improvements in WAZ and some FA. CONCLUSIONS Subjects with CF, PI and more severe fat malabsorption experienced greater improvements in CFA, FA and growth after three months of Encala™ treatment. Encala™ was safe, well-tolerated and efficacious in patients with CF and PI with residual fat malabsorption and improved dietary energy absorption, weight gain and FA status in this at-risk group.",2020,"Encala™ was safe, well-tolerated and efficacious in patients with CF and PI with residual fat malabsorption and improved dietary energy absorption, weight gain and FA status in this at-risk group.","['children with cystic fibrosis', 'children with cystic fibrosis (CF) and pancreatic insufficiency (PI', 'Subjects (n = 66, 10.5±3.0 yrs, 39% female) with baseline CFA who completed a three-month treatment with Encala™ or a']","['calorie and macronutrient-matched placebo', 'WAZ', 'placebo']","['residual fat malabsorption and growth', 'plasma linoleic acid', 'safe, well-tolerated and efficacious', 'Fasting plasma fatty acid (FA) concentrations', 'CFA', 'total FA', 'CFA and FA', 'CFA (72-hour stool, weighed food record) and height (HAZ), weight (WAZ) and BMI (BMIZ) Z-scores', 'concentrations and improvements in HAZ', 'dietary energy absorption, weight gain and FA status', 'stool fat loss', 'dietary fat absorption (stool coefficient of fat absorption [CFA]), growth, and plasma fatty acids (FA', 'CFA, FA and growth', 'α-linolenic acid']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0010674', 'cui_str': 'Cystic fibrosis'}, {'cui': 'C0030293', 'cui_str': 'Pancreatic insufficiency'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C4082119', 'cui_str': 'Three months'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0554103', 'cui_str': 'Intestinal malabsorption of fat'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0023749', 'cui_str': 'Linoleic acid'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0012171', 'cui_str': 'Dietary fat'}, {'cui': 'C0443214', 'cui_str': 'Fat absorption'}, {'cui': 'C0051405', 'cui_str': 'alpha-Linolenic Acid'}]",,0.119462,"Encala™ was safe, well-tolerated and efficacious in patients with CF and PI with residual fat malabsorption and improved dietary energy absorption, weight gain and FA status in this at-risk group.","[{'ForeName': 'Virginia A', 'Initials': 'VA', 'LastName': 'Stallings', 'Affiliation': ""Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, United States of America.""}, {'ForeName': 'Alyssa M', 'Initials': 'AM', 'LastName': 'Tindall', 'Affiliation': ""Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, United States of America.""}, {'ForeName': 'Maria R', 'Initials': 'MR', 'LastName': 'Mascarenhas', 'Affiliation': ""Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, United States of America.""}, {'ForeName': 'Asim', 'Initials': 'A', 'LastName': 'Maqbool', 'Affiliation': ""Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, United States of America.""}, {'ForeName': 'Joan I', 'Initials': 'JI', 'LastName': 'Schall', 'Affiliation': ""Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, United States of America.""}]",PloS one,['10.1371/journal.pone.0232685'] 67,32386810,Femtosecond Laser-Assisted Cataract Surgery Versus Phacoemulsification Cataract Surgery (FACT): A Randomized Noninferiority Trial.,"PURPOSE To report the 3-month results of a randomized trial (Femtosecond Laser-Assisted Cataract Trial [FACT]) comparing femtosecond laser-assisted cataract surgery (FLACS) with standard phacoemulsification cataract surgery (PCS). DESIGN Multicenter, randomized controlled trial funded by the UK National Institute of Health Research (HTA 13/04/46/). PARTICIPANTS Seven hundred eighty-five patients with age-related cataract. METHODS This trial took place in 3 hospitals in the UK National Health Service (NHS). Randomization (1:1) was stratified by site, surgeon, and 1 or both eyes eligible using a secure web-based system. Postoperative assessments were masked to the allocated intervention. The primary outcome was unaided distance visual acuity (UDVA) in the study eye at 3 months. Secondary outcomes included corrected distance visual acuity, complications, and patient-reported outcomes measures. The noninferiority margin was 0.1 logarithm of the minimum angle of resolution (logMAR). ISRCTN.com registry, number ISRCTN77602616. MAIN OUTCOME MEASURES We enrolled 785 participants between May 2015 and September 2017 and randomly assigned 392 to FLACS and 393 to PCS. At 3 months postoperatively, mean UDVA difference between treatment arms was -0.01 logMAR (-0.05 to 0.03), and mean corrected distance visual acuity difference was -0.01 logMAR (95% confidence interval [CI], -0.05 to 0.02). Seventy-one percent of both FLACS and PCS cases were within ±0.5 diopters (D) of the refractive target, and 93% of FLACS and 92% of PCS cases were within ±1.0 D. There were 2 posterior capsule tears in the PCS arm and none in the FLACS arm. There were no significant differences between arms for any secondary outcome. CONCLUSIONS Femtosecond laser-assisted cataract surgery is not inferior to conventional PCS surgery 3 months after surgery. Both methods are as good in terms of vision, patient-reported health, and safety outcomes at 3 months. Longer-term outcomes of the clinical effectiveness and cost-effectiveness are awaited.",2020,"There were no significant differences between arms for any secondary outcome. ","['Seven hundred eighty-five patients with age-related cataract', '785 participants between May 2015 and September 2017 and randomly assigned 392 to FLACS and 393 to PCS', '3 hospitals in the UK National Health Service (NHS']","['standard phacoemulsification cataract surgery (PCS', 'Femtosecond Laser-Assisted Cataract Surgery Versus Phacoemulsification Cataract Surgery (FACT', 'Femtosecond Laser-Assisted Cataract Trial [FACT', 'femtosecond laser-assisted cataract surgery (FLACS', 'Femtosecond laser-assisted cataract surgery']","['clinical effectiveness and cost-effectiveness', 'unaided distance visual acuity (UDVA', 'mean UDVA difference', 'corrected distance visual acuity, complications, and patient-reported outcomes measures', 'mean corrected distance visual acuity difference']","[{'cui': 'C4517862', 'cui_str': '700'}, {'cui': 'C4517892', 'cui_str': '85'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C1531960', 'cui_str': 'Femtosecond pulsed laser device'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C4517754', 'cui_str': '393'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027462', 'cui_str': 'National Health Services'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C1531960', 'cui_str': 'Femtosecond pulsed laser device'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C3850123', 'cui_str': 'Treatment Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0439846', 'cui_str': 'Unaided'}, {'cui': 'C0429537', 'cui_str': 'Distance visual acuity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",785.0,0.436528,"There were no significant differences between arms for any secondary outcome. ","[{'ForeName': 'Alexander C', 'Initials': 'AC', 'LastName': 'Day', 'Affiliation': 'The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; Moorfields Eye Hospital, London, United Kingdom; UCL Institute of Ophthalmology, London, United Kingdom. Electronic address: alex.day@ucl.ac.uk.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Burr', 'Affiliation': 'School of Medicine, University of St. Andrews, Fife, Scotland.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Bennett', 'Affiliation': 'UCL Comprehensive Clinical Trials Unit, London, United Kingdom.'}, {'ForeName': 'Catey', 'Initials': 'C', 'LastName': 'Bunce', 'Affiliation': ""Department of Primary Care & Public Health Sciences, King's College London, London, United Kingdom.""}, {'ForeName': 'Caroline J', 'Initials': 'CJ', 'LastName': 'Doré', 'Affiliation': 'UCL Comprehensive Clinical Trials Unit, London, United Kingdom.'}, {'ForeName': 'Gary S', 'Initials': 'GS', 'LastName': 'Rubin', 'Affiliation': 'UCL Institute of Ophthalmology, London, United Kingdom.'}, {'ForeName': 'Mayank A', 'Initials': 'MA', 'LastName': 'Nanavaty', 'Affiliation': 'Sussex Eye Hospital, Brighton & Sussex University Hospitals NHS Trust, Eastern Road, Brighton, United Kingdom.'}, {'ForeName': 'Kamaljit S', 'Initials': 'KS', 'LastName': 'Balaggan', 'Affiliation': 'Wolverhampton and Midlands Eye Infirmary, New Cross Hospital, Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, United Kingdom.'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Wilkins', 'Affiliation': 'The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; Moorfields Eye Hospital, London, United Kingdom.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Ophthalmology,['10.1016/j.ophtha.2020.02.028'] 68,32389808,Rationale and study design for lifestyle intervention in preparation for pregnancy (LIPP): A randomized controlled trial.,"INTRODUCTION Maternal obesity increases neonatal risk for obesity and metabolic syndrome later in life. Prior attempts to break this intergenerational obesity cycle by limiting excessive gestational weight gain have failed to reduce neonatal adiposity. Alternatively, pre-conception lifestyle interventions may improve the in utero metabolic milieu during early pregnancy leading to improved fetal outcomes. This randomized controlled trial (RCT) is evaluating whether a lifestyle intervention to reduce weight and improve maternal metabolism in preparation for pregnancy (LIPP) attenuates neonatal adiposity, compared to standard medical advice. MATERIAL AND METHODS Overweight/class 1 obese women after a previous pregnancy, ~12 weeks postpartum, preparing for a subsequent pregnancy, will be block randomized (1:1) to either LIPP or standard of care in a parallel design. Randomization is stratified by lactation status and overweight vs. class 1 obesity. The LIPP program consists of intensive short-term weight loss followed by weight maintenance until conception using supervised exercise and a low glycemic Mediterranean diet. PRIMARY OUTCOMES Group differences in neonatal adiposity at birth assessed by PEA POD and placental mitochondrial lipid metabolism. SECONDARY OUTCOMES Group differences in maternal pregravid and gestational body composition, insulin sensitivity, β-cell function, fasting metabolic and inflammatory biomarkers, and overall quality of life. Exploratory outcomes include umbilical cord blood insulin resistance, lipid profile and inflammation. DISCUSSION This RCT will determine the efficacy of maternal weight loss prior to pregnancy on reducing neonatal adiposity. Findings may change standard obstetrical care by providing Level 1 evidence on lifestyle interventions improving neonatal outcomes for women planning for pregnancy. CLINICAL TRIAL REGISTRATION NCT03146156.",2020,"Findings may change standard obstetrical care by providing Level 1 evidence on lifestyle interventions improving neonatal outcomes for women planning for pregnancy. ","['pregnancy (LIPP', 'Overweight/class 1 obese women after a previous pregnancy, ~12', 'women planning for pregnancy']","['LIPP', 'lifestyle intervention']","['umbilical cord blood insulin resistance, lipid profile and inflammation', 'maternal pregravid and gestational body composition, insulin sensitivity, β-cell function, fasting metabolic and inflammatory biomarkers, and overall quality of life', 'utero metabolic milieu', 'neonatal adiposity at birth assessed by PEA POD and placental mitochondrial lipid metabolism']","[{'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0441885', 'cui_str': 'Class 1'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0600457', 'cui_str': 'Gravida'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0162371', 'cui_str': 'Cord blood'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0439671', 'cui_str': 'Gestational'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0007613', 'cui_str': 'Physiology, Cell'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1744681', 'cui_str': 'Congenital'}, {'cui': 'C0030738', 'cui_str': 'Peas'}, {'cui': 'C0032043', 'cui_str': 'Placental structure'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}]",1.0,0.119724,"Findings may change standard obstetrical care by providing Level 1 evidence on lifestyle interventions improving neonatal outcomes for women planning for pregnancy. ","[{'ForeName': 'M L', 'Initials': 'ML', 'LastName': 'Erickson', 'Affiliation': 'Integrative Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, 6400 Perkins Rd, Baton Rouge, LA 70808, United States of America; Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, United States of America.'}, {'ForeName': 'J T', 'Initials': 'JT', 'LastName': 'Mey', 'Affiliation': 'Integrative Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, 6400 Perkins Rd, Baton Rouge, LA 70808, United States of America; Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, United States of America.'}, {'ForeName': 'C L', 'Initials': 'CL', 'LastName': 'Axelrod', 'Affiliation': 'Integrative Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, 6400 Perkins Rd, Baton Rouge, LA 70808, United States of America; Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, United States of America; Department of Translational Services, Pennington Biomedical Research Center, 6400 Perkins Rd, Baton Rouge, LA 70808, United States of America.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Paul', 'Affiliation': 'Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, United States of America.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Gordesky', 'Affiliation': 'Department of Reproductive Biology, Center for Reproductive Health, MetroHealth Medical, 2500 MetroHealth Dr, Cleveland, OH 44109, United States of America.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Russell', 'Affiliation': 'Mother Infant Research Institute, Tufts Medical Center, 800 Washington St, Boston, MA 02111, United States of America.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Barkoukis', 'Affiliation': 'Department of Nutrition, Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106, United States of America.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': ""O'Tierney-Ginn"", 'Affiliation': 'Department of Reproductive Biology, Center for Reproductive Health, MetroHealth Medical, 2500 MetroHealth Dr, Cleveland, OH 44109, United States of America; Mother Infant Research Institute, Tufts Medical Center, 800 Washington St, Boston, MA 02111, United States of America.'}, {'ForeName': 'R A', 'Initials': 'RA', 'LastName': 'Fielding', 'Affiliation': 'Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, 711 Washington St, Boston, MA 02111, United States of America.'}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Kirwan', 'Affiliation': 'Integrative Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, 6400 Perkins Rd, Baton Rouge, LA 70808, United States of America; Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, United States of America. Electronic address: John.Kirwan@pbrc.edu.'}, {'ForeName': 'P M', 'Initials': 'PM', 'LastName': 'Catalano', 'Affiliation': 'Department of Reproductive Biology, Center for Reproductive Health, MetroHealth Medical, 2500 MetroHealth Dr, Cleveland, OH 44109, United States of America; Mother Infant Research Institute, Tufts Medical Center, 800 Washington St, Boston, MA 02111, United States of America. Electronic address: pcatalano@tuftsmedicalcenter.org.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106024'] 69,32280035,Adolescent cognitive control and mediofrontal theta oscillations are disrupted by neglect: Associations with transdiagnostic risk for psychopathology in a randomized controlled trial.,"Children that have experienced psychosocial neglect display impairments in self-monitoring and controlling their behavior (cognitive control) and are at broad, transdiagnostic risk for psychopathology. However, the neural underpinnings of such effects remain unclear. Event-related mediofrontal theta oscillations reflect a neural process supporting cognitive control that may relate to transdiagnostic psychopathology risk. Recent work demonstrates reduced mediofrontal theta in rodent models of neglect; however, similar findings have not been reported in humans. Here, 136 children reared in Romanian institutions were randomly assigned to either a high-quality foster care intervention and placed with families or remained in institutions; 72 never-institutionalized children served as a comparison group. The intervention ended at 54 months; event-related mediofrontal theta and psychopathology were assessed at 12- and 16-year follow-up assessments. Institutional rearing (neglect) predicted reduced mediofrontal theta by age 16, which was linked to heightened transdiagnostic risk for psychopathology (P factor); no specific associations with internalizing/externalizing factors were present once transdiagnostic risk was accounted for. Earlier placement into foster care yielded greater mediofrontal activity by age 16. Moreover, foster care placement was associated with the developmental trajectory of mediofrontal theta across the adolescent period (ages 12-16), which was, in turn, associated with greater reductions in transdiagnostic risk across this same period. These data reflect the first experimental evidence that the development of mediofrontal theta is impacted by removal from situations of neglect in humans, and further characterizes the importance of studying developmental change in mediofrontal theta during the adolescent period.",2020,"Institutional rearing (neglect) predicted reduced mediofrontal theta by age 16, which was linked to heightened transdiagnostic risk for psychopathology (P factor); no specific associations with internalizing/externalizing factors were present once transdiagnostic risk was accounted for.",['136 children reared in Romanian institutions'],['high-quality foster care intervention and placed with families or remained in institutions; 72 never-institutionalized children served as a comparison group'],"['Adolescent cognitive control and mediofrontal theta oscillations', 'transdiagnostic risk', 'mediofrontal activity']","[{'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0035827', 'cui_str': 'Rumanian language'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0419195', 'cui_str': 'Foster care'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0562359', 'cui_str': 'Institutionalized'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",136.0,0.0417503,"Institutional rearing (neglect) predicted reduced mediofrontal theta by age 16, which was linked to heightened transdiagnostic risk for psychopathology (P factor); no specific associations with internalizing/externalizing factors were present once transdiagnostic risk was accounted for.","[{'ForeName': 'George A', 'Initials': 'GA', 'LastName': 'Buzzell', 'Affiliation': 'University of Maryland, College Park, MD, United States. Electronic address: gbuzzell@umd.edu.'}, {'ForeName': 'Sonya V', 'Initials': 'SV', 'LastName': 'Troller-Renfree', 'Affiliation': 'Teachers College, Columbia University, NY, United States.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Wade', 'Affiliation': 'University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Ranjan', 'Initials': 'R', 'LastName': 'Debnath', 'Affiliation': 'University of Maryland, College Park, MD, United States.'}, {'ForeName': 'Santiago', 'Initials': 'S', 'LastName': 'Morales', 'Affiliation': 'University of Maryland, College Park, MD, United States.'}, {'ForeName': 'Maureen E', 'Initials': 'ME', 'LastName': 'Bowers', 'Affiliation': 'University of Maryland, College Park, MD, United States.'}, {'ForeName': 'Charles H', 'Initials': 'CH', 'LastName': 'Zeanah', 'Affiliation': 'Tulane University School of Medicine, New Orleans, LA, United States.'}, {'ForeName': 'Charles A', 'Initials': 'CA', 'LastName': 'Nelson', 'Affiliation': ""Harvard Medical School, Boston, MA, United States; Boston Children's Hospital, Boston, MA, United States; Harvard Graduate School of Education, Boston, MA, United States.""}, {'ForeName': 'Nathan A', 'Initials': 'NA', 'LastName': 'Fox', 'Affiliation': 'University of Maryland, College Park, MD, United States.'}]",Developmental cognitive neuroscience,['10.1016/j.dcn.2020.100777'] 70,32343960,"JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection.","BACKGROUND & AIMS JNJ-56136379 (JNJ-6379), a capsid assembly modulator that blocks hepatitis B virus (HBV) replication, was well tolerated and demonstrated dose-proportional pharmacokinetics in healthy participants in part 1 of its first clinical trial. In part 2, we have evaluated the safety, pharmacokinetics, and antiviral activity of multiple doses of JNJ-6379 in patients with chronic HBV infection. METHODS We performed a double-blind study of 57 treatment-naïve patients with HB e antigen-positive or -negative (74%) chronic HBV infection without cirrhosis. Patients were randomly assigned to groups given JNJ-6379 at 25 mg (100 mg loading dose), 75 mg, 150 mg, or 250 mg or placebo daily for 4 weeks with an 8-week follow-up period. RESULTS Twenty-three (56%) of 41 patients given JNJ-6379 had at least 1 adverse event (AE) during treatment, compared with 10 (63%) of 16 patients given placebo. No serious AEs were reported during the treatment period. Three patients (7%) given JNJ-6379 vs none given placebo had grade 3 AEs; of these, 1 patient (150 mg) also had an isolated grade 4 increase in level of alanine aminotransferase that led to treatment discontinuation. JNJ-6379 exposure increased with dose, with time-linear pharmacokinetics. HBV-DNA and HBV-RNA decreased from baseline in patients receiving all doses of JNJ-6379, independently of viral genotype and HB e antigen status. On day 29, 13 (32%) of 41 patients had levels of HBV DNA below the lower limit of quantification. No clinically significant changes in levels of HB surface antigen were observed. CONCLUSIONS In a phase 1 study of treatment-naïve patients with chronic HBV infection, all doses tested of JNJ-6379 were well tolerated, showed dose-dependent pharmacokinetics, and had potent antiviral activity in patients with CHB. The findings support a phase 2a study to evaluate JNJ-6379 ± nucleos(t)ide analogs in patients with chronic HBV infection, which is under way. ClinicalTrials.gov identifier: NCT02662712.",2020,"HBV-DNA and HBV-RNA decreased from baseline in patients receiving all doses of JNJ-6379, independently of viral genotype and HB e antigen status.","['Patients with Chronic Infection', 'patients with CHB', 'patients with chronic HBV infection', 'healthy participants', '57 treatment-naïve patients with HB e antigen-positive or -negative (74%) chronic HBV infection without cirrhosis']","['JNJ-6379', 'placebo']","['levels of HBV DNA', 'level of alanine aminotransferase', 'HBV-DNA and HBV-RNA', 'safety, pharmacokinetics, and antiviral activity', 'levels of HB surface antigen']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0151317', 'cui_str': 'Chronic infectious disease'}, {'cui': 'C0151517', 'cui_str': 'Complete atrioventricular block'}, {'cui': 'C0524909', 'cui_str': 'Chronic type B viral hepatitis'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0019167', 'cui_str': 'Hepatitis B e antigen'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0369332', 'cui_str': 'Hepatitis B virus DNA'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0019169', 'cui_str': 'Hepatitis B Virus'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0003451', 'cui_str': 'Antiviral'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0003339', 'cui_str': 'Surface Antigens'}]",,0.0672743,"HBV-DNA and HBV-RNA decreased from baseline in patients receiving all doses of JNJ-6379, independently of viral genotype and HB e antigen status.","[{'ForeName': 'Fabien', 'Initials': 'F', 'LastName': 'Zoulim', 'Affiliation': 'Hepatology Unit, Hospices Civils de Lyon and Lyon University, Lyon, France; INSERM U1052-Cancer Research Institute of Lyon, Lyon, France. Electronic address: fabien.zoulim@chu-lyon.fr.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Lenz', 'Affiliation': 'Janssen Pharmaceuticals NV, Beerse, Belgium.'}, {'ForeName': 'Joris J', 'Initials': 'JJ', 'LastName': 'Vandenbossche', 'Affiliation': 'Janssen Pharmaceuticals NV, Beerse, Belgium.'}, {'ForeName': 'Willem', 'Initials': 'W', 'LastName': 'Talloen', 'Affiliation': 'Janssen Pharmaceuticals NV, Beerse, Belgium.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Verbinnen', 'Affiliation': 'Janssen Pharmaceuticals NV, Beerse, Belgium.'}, {'ForeName': 'Iurie', 'Initials': 'I', 'LastName': 'Moscalu', 'Affiliation': 'Spitalul Clinic Republican, ARENSIA EM, Chișinău, Moldova.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Streinu-Cercel', 'Affiliation': 'National Institute for Infectious Diseases ""Prof. Dr Matei Bals"", Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Bourgeois', 'Affiliation': 'ZNA Jan Palfijn, CPU, Antwerp, Belgium.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Buti', 'Affiliation': ""Hospital Universitario Vall d'Hebrón and CIBERHED del Instituto Carlos III, Barcelona, Spain.""}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Crespo', 'Affiliation': 'Hospital Universitario Marqués de Valdecilla, IDIVAL Santander, Spain.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Manuel Pascasio', 'Affiliation': 'Hospital Universitario Virgen del Rocio, Seville, Spain.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Sarrazin', 'Affiliation': 'Medizinische Klinik II, St. Josefs-Hospital, Weisbaden, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Vanwolleghem', 'Affiliation': 'Erasmus MC, University Medical Center, Rotterdam, Netherlands; Antwerp University Hospital, Antwerp, Belgium.'}, {'ForeName': 'Umesh', 'Initials': 'U', 'LastName': 'Shukla', 'Affiliation': 'Janssen Pharmaceuticals R&D, Titusville, New Jersey. Electronic address: UShukla@its.jnj.com.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Fry', 'Affiliation': 'Janssen Biopharma Inc., South San Francisco, California.'}, {'ForeName': 'Jeysen Z', 'Initials': 'JZ', 'LastName': 'Yogaratnam', 'Affiliation': 'Janssen Biopharma Inc., South San Francisco, California.'}]",Gastroenterology,['10.1053/j.gastro.2020.04.036'] 71,32383615,Effect of Aminophylline in Preventing Renal Dysfunction among Neonates with Prenatal Asphyxia: A Clinical Trial.,"BACKGROUND As there are different views on the effects of aminophylline on neonatal renal function, we intended to observe the effects of aminophylline on renal dysfunction in neonates with prenatal asphyxia. METHODS This randomized trial was conducted in the Obstetrics and Gynecology Hospital, Tehran, Iran, from June 2016 to May 2017, in neonates with moderate to severe asphyxia during birth. Fifty-six neonates were divided randomly into two groups. The intervention group received one dose of 5mg/kg slow intravenous aminophylline injection and the placebo group received 2 mL/kg of intravenous 10% solution of dextrose saline during the first hour of life. They were monitored and compared for renal functional indices, electrolytes, and complications of asphyxia during the three days of life. RESULTS The mean of Cr (37.9 ± 8.8 vs 38.5 ± 9.4 and 20.8 ± 4.8 vs 30.1 ± 5.2 μmol/L), GFR (21.55 ± 4.7 vs 20.25 ± 4.4 and 30.8 ± 7.1 vs 20.1 ± 6.5 mL/minute/1.73 m 2 ), Na (135.1 ± 12.4 vs134.5 ± 11.2 and 128.9 ± 11.5 vs 134.2 ± 10.9 mEq/L), and urine output (98.2 ± 25 vs 96.8 ± 23 and 148.7 ± 35 vs 108.8 ± 20 cc) were in the aminophylline treated and placebo group on the 1st and 3rd days, respectively. The mean difference of Cr (-9.3 (-8.9; -9.7) μmol/L); ( P = 0.02), GFR (10.7 (10.1; 11.3) mL/minute/1.73 m 2 ) ( P = 0.009), Na (-5.3 (-5.9; -4.7) mEq/L) ( P = 0.002), and urine volume (39.9 (24.9; 54.9) cc) ( P = 0.001) presented statistically significant differences on the third day between the intervention and placebo group. CONCLUSION Aminophylline was effective in preventing renal dysfunction in neonates with asphyxia. Neonates who received aminophylline indicated a significant improvement in GFR and urine output on the first day of life.",2020,"They were monitored and compared for renal functional indices, electrolytes, and complications of asphyxia during the three days of life. ","['Obstetrics and Gynecology Hospital, Tehran, Iran, from June 2016 to May 2017, in neonates with moderate to severe asphyxia during birth', 'Neonates with Prenatal Asphyxia', 'neonates with asphyxia', 'Fifty-six neonates', 'neonates with prenatal asphyxia']","['aminophylline', '4.7) mEq/L', 'aminophylline injection and the placebo group received 2 mL/kg of intravenous 10% solution of dextrose saline', 'Aminophylline', 'placebo']","['GFR', 'Renal Dysfunction', 'GFR and urine output', 'renal dysfunction', 'renal functional indices, electrolytes, and complications of asphyxia', 'urine volume']","[{'cui': 'C1274104', 'cui_str': 'Obstetrics and gynecology'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0004044', 'cui_str': 'Asphyxiation'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}]","[{'cui': 'C0002575', 'cui_str': 'Aminophylline'}, {'cui': 'C0439375', 'cui_str': 'mEq/L'}, {'cui': 'C4049912', 'cui_str': 'Aminophylline Injection'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1300574', 'cui_str': 'mL/kg'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C1565489', 'cui_str': 'Renal impairment'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0013832', 'cui_str': 'electrolytes'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0004044', 'cui_str': 'Asphyxiation'}]",56.0,0.303683,"They were monitored and compared for renal functional indices, electrolytes, and complications of asphyxia during the three days of life. ","[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Saboute', 'Affiliation': 'Department of Neonatology, Akbar Abadi Hospital, Iran University of Medical Sciences, (IUMS), Tehran, Iran.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Balasi', 'Affiliation': 'Department of Neonatology, Ali Asghar Hospital, Iran University of Medical Sciences, (IUMS), Tehran, Iran.'}, {'ForeName': 'Saleheh', 'Initials': 'S', 'LastName': 'Tajalli', 'Affiliation': 'School of Nursing and Midwifery, Iran University of Medical Sciences, (IUMS), Tehran, Iran.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Hajipour', 'Affiliation': 'Student Research Committee, Epidemiology Department, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Shaghayegh', 'Initials': 'S', 'LastName': 'Heshmat', 'Affiliation': 'Department of Neonatology, Ali Asghar Hospital, Iran University of Medical Sciences, (IUMS), Tehran, Iran.'}, {'ForeName': 'Nasrin', 'Initials': 'N', 'LastName': 'Khalesi', 'Affiliation': 'Department of Neonatology, Ali Asghar Hospital, Iran University of Medical Sciences, (IUMS), Tehran, Iran.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Allahqoli', 'Affiliation': 'Endometriosis Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.'}]",Archives of Iranian medicine,['10.34172/aim.2020.20'] 72,32380138,Reduced tactile acuity in chronic low back pain is linked with structural neuroplasticity in primary somatosensory cortex and is modulated by acupuncture therapy.,"Prior studies have shown that patients suffering from chronic Low Back Pain (cLBP) have impaired somatosensory processing including reduced tactile acuity, i.e. reduced ability to resolve fine spatial details with the perception of touch. The central mechanism(s) underlying reduced tactile acuity are unknown but may include changes in specific brain circuitries (e.g. neuroplasticity in the primary somatosensory cortex, S1). Furthermore, little is known about the linkage between changes in tactile acuity and the amelioration of cLBP by somatically-directed therapeutic interventions, such as acupuncture. In this longitudinal neuroimaging study, we evaluated healthy control adults (HC, N ​= ​50) and a large sample of cLBP patients (N ​= ​102) with structural brain imaging (T1-weighted MRI for Voxel-Based Morphometry, VBM; Diffusion Tensor Imaging, DTI) and tactile acuity testing using two-point discrimination threshold (2PDT) over the lower back (site of pain) and finger (control) locations. Patients were evaluated at baseline and following a 4-week course of acupuncture, with patients randomized to either verum acupuncture, two different forms of sham acupuncture (designed with or without somatosensory afference), or no-intervention usual care control. At baseline, cLBP patients demonstrated reduced acuity (greater 2PDT, P ​= ​0.01) over the low back, but not finger (P ​= ​0.29) locations compared to HC, suggesting that chronic pain affects tactile acuity specifically at body regions encoding the experience of clinical pain. At baseline, Gray Matter Volume (GMV) was elevated and Fractional Anisotropy (FA) was reduced, respectively, in the S1-back region of cLBP patients compared to controls (P ​< ​0.05). GMV in cLBP correlated with greater 2PDT-back scores (ρ ​= ​0.27, P ​= ​0.02). Following verum acupuncture, tactile acuity over the back was improved (reduced 2PDT) and greater improvements were associated with reduced S1-back GMV (ρ ​= ​0.52, P ​= ​0.03) and increased S1-back adjacent white matter FA (ρ ​= ​-0.56, P ​= ​0.01). These associations were not seen for non-verum control interventions. Thus, S1 neuroplasticity in cLBP is linked with deficits in tactile acuity and, following acupuncture therapy, may represent early mechanistic changes in somatosensory processing that track with improved tactile acuity.",2020,"At baseline, Gray Matter Volume (GMV) was elevated and Fractional Anisotropy (FA) was reduced, respectively, in the S1-back region of cLBP patients compared to controls (P<0.05).","['patients suffering from chronic Low Back Pain (cLBP', 'healthy control adults (HC, N=50) and a large sample of cLBP patients (N=102) with']","['acupuncture', 'structural brain imaging (T1-weighted MRI for Voxel Based Morphometry, VBM; Diffusion Tensor Imaging, DTI) and tactile acuity testing using two-point discrimination threshold (2PDT', 'verum acupuncture', 'sham acupuncture (designed with or without somatosensory afference), or no-intervention usual care control']","['tactile acuity', 'S1-back adjacent white matter FA', '2PDT-back scores', 'Fractional Anisotropy (FA', 'tactile acuity over the back was improved (reduced 2PDT', 'reduced S1-back GMV', 'reduced acuity', 'Gray Matter Volume (GMV']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0203860', 'cui_str': 'Imaging of brain'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C4523852', 'cui_str': 'Voxel-based morphometry'}, {'cui': 'C0078140', 'cui_str': 'VBM protocol'}, {'cui': 'C1537007', 'cui_str': 'Diffusion Tensor MRI'}, {'cui': 'C0439815', 'cui_str': 'Tactile'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0012632', 'cui_str': 'Cognitive discrimination'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439815', 'cui_str': 'Tactile'}, {'cui': 'C0205117', 'cui_str': 'Juxta-posed'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0085406', 'cui_str': 'Anisotropy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",102.0,0.102659,"At baseline, Gray Matter Volume (GMV) was elevated and Fractional Anisotropy (FA) was reduced, respectively, in the S1-back region of cLBP patients compared to controls (P<0.05).","[{'ForeName': 'Hyungjun', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA; Division of Clinical Medicine, Korea Institute of Oriental Medicine, Daejeon, 34054, South Korea.'}, {'ForeName': 'Ishtiaq', 'Initials': 'I', 'LastName': 'Mawla', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Jeungchan', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Gerber', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Walker', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Jieun', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA; Division of Clinical Medicine, Korea Institute of Oriental Medicine, Daejeon, 34054, South Korea.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Ortiz', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Suk-Tak', 'Initials': 'ST', 'LastName': 'Chan', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Marco L', 'Initials': 'ML', 'LastName': 'Loggia', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Ajay D', 'Initials': 'AD', 'LastName': 'Wasan', 'Affiliation': 'Department of Anesthesiology, Center for Pain Research, University of Pittsburgh, Pittsburgh, PA, 15261, USA.'}, {'ForeName': 'Robert R', 'Initials': 'RR', 'LastName': 'Edwards', 'Affiliation': ""Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.""}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Kong', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA; Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02215, USA.'}, {'ForeName': 'Ted J', 'Initials': 'TJ', 'LastName': 'Kaptchuk', 'Affiliation': 'Program in Placebo Studies & Therapeutic Encounter (PiPS), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.'}, {'ForeName': 'Randy L', 'Initials': 'RL', 'LastName': 'Gollub', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA; Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02215, USA.'}, {'ForeName': 'Bruce R', 'Initials': 'BR', 'LastName': 'Rosen', 'Affiliation': 'Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Vitaly', 'Initials': 'V', 'LastName': 'Napadow', 'Affiliation': ""Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA; Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. Electronic address: vitaly@mgh.harvard.edu.""}]",NeuroImage,['10.1016/j.neuroimage.2020.116899'] 73,32278820,The Impact of Preoperative Mindfulness-Based Stress Reduction on Postoperative Outcomes in Lumbar Spine Degenerative Disease: 3-Month and 12-Month Results of a Pilot Study.,"BACKGROUND We previously reported inpatient and 30-day postoperative patient-reported outcomes (PROs) of a controlled, noncrossover pilot study using preoperative mindfulness-based stress reduction (MBSR) training for lumbar spine surgery. Our goal here was to assess 3-month and 12-month postoperative PROs of preoperative MBSR in lumbar spine surgery for degenerative disease. METHODS Intervention group participants were prospectively enrolled in a preoperative online MBSR course. A comparison standard care only group was one-to-one matched retrospectively by age, sex, surgery type, and prescription opioid use. Three-month and 12-month postoperative PROs for pain, disability, quality of life, and opioid use were compared within and between groups. Regression models were used to assess whether MBSR use predicted outcomes. RESULTS Twenty-four participants were included in each group. At 3 months, follow-up was 87.5% and 95.8% in the comparison and intervention groups, respectively. In the intervention group, mean Patient-Reported Outcomes Measurement Information System-Physical Function (PROMIS-PF) was significantly higher, whereas mean Patient-Reported Outcomes Measurement Information System-Pain Interference (PROMIS-PI) and Oswestry Disability Index were significantly lower. The change from baseline in mean PROMIS-PF and PROMIS-PI was significantly greater than in the comparison group. At 12 months, follow-up was 58.3% and 83.3% in the comparison and intervention groups, respectively. In the intervention group, mean PROMIS-PI was significantly lower and change in mean PROMIS-PI from baseline was significantly greater. MBSR use was a significant predictor of change in PROMIS-PF at 3 months and in PROMIS-PI at 12 months. No adverse events were reported. CONCLUSIONS Three-month and 12-month results suggest that preoperative MBSR may have pain control benefits in lumbar spine surgery.",2020,MBSR use was a significant predictor of change in PROMIS-PF at 3 months and in PROMIS-PI at 12 months.,"['lumbar spine surgery for degenerative disease', 'lumbar spine surgery', 'Twenty-four participants were included in each group', 'Intervention group participants were prospectively enrolled in a preoperative online MBSR course', 'Lumbar Spine Degenerative Disease']","['preoperative mindfulness-based stress reduction (MBSR) training', 'Preoperative Mindfulness-Based Stress Reduction']","['mean Patient-Reported Outcomes Measurement Information System-Physical Function (PROMIS-PF', 'postoperative PROs for pain, disability, quality of life, and opioid use', 'adverse events', 'mean PROMIS-PI', 'Outcomes Measurement Information System-Pain Interference (PROMIS-PI) and Oswestry Disability Index', 'mean PROMIS-PF and PROMIS-PI']","[{'cui': 'C0408578', 'cui_str': 'Operation on lumbar spine'}, {'cui': 'C1285162', 'cui_str': 'Degenerative disorder'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0024091', 'cui_str': 'Bone structure of lumbar vertebra'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0021428', 'cui_str': 'Information system'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}]",24.0,0.0243929,MBSR use was a significant predictor of change in PROMIS-PF at 3 months and in PROMIS-PI at 12 months.,"[{'ForeName': 'Juneyoung L', 'Initials': 'JL', 'LastName': 'Chavez', 'Affiliation': 'Department of Neurosurgery, Clinical Neurosciences Center, University of Utah Health Sciences Center, Salt Lake City, Utah, USA. Electronic address: June.Yi@hsc.utah.edu.'}, {'ForeName': 'Christina A', 'Initials': 'CA', 'LastName': 'Porucznik', 'Affiliation': 'Division of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.'}, {'ForeName': 'Lisa H', 'Initials': 'LH', 'LastName': 'Gren', 'Affiliation': 'Division of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Guan', 'Affiliation': 'Department of Neurosurgery, Clinical Neurosciences Center, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.'}, {'ForeName': 'Evan', 'Initials': 'E', 'LastName': 'Joyce', 'Affiliation': 'Department of Neurosurgery, Clinical Neurosciences Center, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.'}, {'ForeName': 'Darrel S', 'Initials': 'DS', 'LastName': 'Brodke', 'Affiliation': 'Department of Orthopaedic Surgery, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.'}, {'ForeName': 'Andrew T', 'Initials': 'AT', 'LastName': 'Dailey', 'Affiliation': 'Department of Neurosurgery, Clinical Neurosciences Center, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Mahan', 'Affiliation': 'Department of Neurosurgery, Clinical Neurosciences Center, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Hood', 'Affiliation': 'Department of Neurosurgery, Clinical Neurosciences Center, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.'}, {'ForeName': 'Brandon D', 'Initials': 'BD', 'LastName': 'Lawrence', 'Affiliation': 'Department of Orthopaedic Surgery, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.'}, {'ForeName': 'William R', 'Initials': 'WR', 'LastName': 'Spiker', 'Affiliation': 'Department of Orthopaedic Surgery, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.'}, {'ForeName': 'Nicholas T', 'Initials': 'NT', 'LastName': 'Spina', 'Affiliation': 'Department of Orthopaedic Surgery, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.'}, {'ForeName': 'Erica F', 'Initials': 'EF', 'LastName': 'Bisson', 'Affiliation': 'Department of Neurosurgery, Clinical Neurosciences Center, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.'}]",World neurosurgery,['10.1016/j.wneu.2020.03.186'] 74,32384053,A Digital Intervention for Adolescent Depression (MoodHwb): Mixed Methods Feasibility Evaluation.,"BACKGROUND Treatment and prevention guidelines highlight the key role of health information and evidence-based psychosocial interventions for adolescent depression. Digital health technologies and psychoeducational interventions have been recommended to help engage young people and to provide accurate health information, enhance self-management skills, and promote social support. However, few digital psychoeducational interventions for adolescent depression have been robustly developed and evaluated in line with research guidance. OBJECTIVE We aimed to evaluate the feasibility, acceptability, and potential impact of a theory-informed, co-designed digital intervention program, MoodHwb. METHODS We used a mixed methods (quantitative and qualitative) approach to evaluate the program and the assessment process. Adolescents with or at elevated risk of depression and their parents and carers were recruited from mental health services, school counselors and nurses, and participants from a previous study. They completed a range of questionnaires before and after the program (related to the feasibility and acceptability of the program and evaluation process, and changes in mood, knowledge, attitudes, and behavior), and their Web usage was monitored. A subsample was also interviewed. A focus group was conducted with professionals from health, education, social, and youth services and charities. Interview and focus group transcripts were analyzed using thematic analysis with NVivo 10 (QSR International Pty Ltd). RESULTS A total of 44 young people and 31 parents or carers were recruited, of which 36 (82%) young people and 21 (68%) parents or carers completed follow-up questionnaires. In all, 19 young people and 12 parents or carers were interviewed. Overall, 13 professionals from a range of disciplines participated in the focus group. The key themes from the interviews and groups related to the design features, sections and content, and integration and context of the program in the young person's life. Overall, the participants found the intervention engaging, clear, user-friendly, and comprehensive, and stated that it could be integrated into existing services. Young people found the ""Self help"" section and ""Mood monitor"" particularly helpful. The findings provided initial support for the intervention program theory, for example, depression literacy improved after using the intervention (difference in mean literacy score: 1.7, 95% CI 0.8 to 2.6; P<.001 for young people; 1.3, 95% CI 0.4 to 2.2; P=.006 for parents and carers). CONCLUSIONS Findings from this early stage evaluation suggest that MoodHwb and the assessment process were feasible and acceptable, and that the intervention has the potential to be helpful for young people, families and carers as an early intervention program in health, education, social, and youth services and charities. A randomized controlled trial is needed to further evaluate the digital program.",2020,"The findings provided initial support for the intervention program theory, for example, depression literacy improved after using the intervention (difference in mean literacy score: 1.7, 95% CI 0.8 to 2.6; P<.001 for young people; 1.3, 95% CI 0.4 to 2.2; P=.006 for parents or carers). ","['Adolescents with or at elevated risk of depression and their parents and carers were recruited from mental health services, school counselors and nurses, and participants from a previous study', 'Adolescent Depression (MoodHwb', 'adolescent depression', '44 young people and 31 parents or carers were recruited, of which 36 (82%) young people and 21 (68%) parents or carers completed follow-up questionnaires', 'Young people', '19 young people and 12 parents or carers were interviewed']",['Digital Intervention'],[],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0025355', 'cui_str': 'Mental health service'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C1571885', 'cui_str': 'Professional counselor'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],44.0,0.0418669,"The findings provided initial support for the intervention program theory, for example, depression literacy improved after using the intervention (difference in mean literacy score: 1.7, 95% CI 0.8 to 2.6; P<.001 for young people; 1.3, 95% CI 0.4 to 2.2; P=.006 for parents or carers). ","[{'ForeName': 'Rhys', 'Initials': 'R', 'LastName': 'Bevan Jones', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, United Kingdom.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Thapar', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, United Kingdom.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Rice', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, United Kingdom.'}, {'ForeName': 'Becky', 'Initials': 'B', 'LastName': 'Mars', 'Affiliation': 'Population Health Sciences, University of Bristol, Bristol, England, United Kingdom.'}, {'ForeName': 'Sharifah Shameem', 'Initials': 'SS', 'LastName': 'Agha', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, United Kingdom.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Smith', 'Affiliation': 'Institute of Health and Wellbeing, University of Glasgow, Glasgow, Scotland, United Kingdom.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Merry', 'Affiliation': 'Faculty of Medical and Health Sciences, School of Medicine, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Stallard', 'Affiliation': 'Department for Health, University of Bath, Bath, England, United Kingdom.'}, {'ForeName': 'Ajay K', 'Initials': 'AK', 'LastName': 'Thapar', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, United Kingdom.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Jones', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, United Kingdom.'}, {'ForeName': 'Sharon A', 'Initials': 'SA', 'LastName': 'Simpson', 'Affiliation': 'Medical Research Council/Chief Scientist Office Social and Public Health Sciences Unit, Institute of Health and Wellbeing, University of Glasgow, Glasgow, Scotland, United Kingdom.'}]",JMIR mental health,['10.2196/14536'] 75,32390583,Comparing Training Techniques in Personal Protective Equipment Use.,"INTRODUCTION Physicians' management of hazardous material (HAZMAT) incidents requires personal protective equipment (PPE) utilization to ensure the safety of victims, facilities, and providers; therefore, providing effective and accessible training in its use is crucial. While an emphasis has been placed on the importance of PPE, there is debate about the most effective training methods. Circumstances may not allow for a traditional in-person demonstration; an accessible video training may provide a useful alternative. HYPOTHESIS Video training of Emergency Medicine (EM) residents in the donning and doffing of Level C PPE is more effective than in-person training. NULL HYPOTHESIS Video training of EM residents in the donning and doffing of Level C PPE is equally effective compared with in-person training. METHODS A randomized, controlled pilot trial was performed with 20 EM residents as part of their annual Emergency Preparedness training. Residents were divided into four groups, with Group 1 and Group 2 viewing a demonstration video developed by the Emergency Preparedness Team (EPT) and Group 3 and Group 4 receiving the standard in-person demonstration training by an EPT member. The groups then separately performed a donning and doffing simulation while blinded evaluators assessed critical tasks utilizing a prepared evaluation tool. At the drill's conclusion, all participants also completed a self-evaluation survey about their subjective interpretations of their respective trainings. RESULTS Both video and in-person training modalities showed significant overall improvement in participants' confidence in doffing and donning PPE equipment (P <.05). However, no statistically significant difference was found in the number of failed critical tasks in donning or doffing between the training modalities (P >.05). Based on these results, the null hypothesis cannot be rejected. However, these results were limited by the small sample size and the study was not sufficiently powered to show a difference between training modalities. CONCLUSION In this pilot study, video and in-person training were equally effective in training for donning and doffing Level C PPE, with similar error rates in both modalities. Further research into this subject with an appropriately powered study is warranted to determine whether this equivalence persists using a larger sample size.",2020,Both video and in-person training modalities showed significant overall improvement in participants' confidence in doffing and donning PPE equipment (P <.05).,['20 EM residents as part of their annual Emergency Preparedness training'],['Group 1 and Group 2 viewing a demonstration video developed by the Emergency Preparedness Team (EPT) and Group 3 and Group 4 receiving the standard in-person demonstration training by an EPT member'],['number of failed critical tasks'],"[{'cui': 'C0013964', 'cui_str': 'Emergency medicine'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C1956344', 'cui_str': 'Emergency Preparedness'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C1956344', 'cui_str': 'Emergency Preparedness'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0441876', 'cui_str': 'Group 4'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0680022', 'cui_str': 'Member of'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}]",,0.0356448,Both video and in-person training modalities showed significant overall improvement in participants' confidence in doffing and donning PPE equipment (P <.05).,"[{'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Salway', 'Affiliation': 'New York Health and Hospitals, Office of Quality and Safety, New York, New York, USA.'}, {'ForeName': 'Trenika', 'Initials': 'T', 'LastName': 'Williams', 'Affiliation': 'Geisel School of Medicine at Dartmouth, Hanover, New HampshireUSA.'}, {'ForeName': 'Camilo', 'Initials': 'C', 'LastName': 'Londono', 'Affiliation': 'SUNY Downstate College of Medicine, Brooklyn, New YorkUSA.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Roblin', 'Affiliation': 'SUNY Downstate College of Medicine, Brooklyn, New YorkUSA.'}, {'ForeName': 'Kristi', 'Initials': 'K', 'LastName': 'Koenig', 'Affiliation': 'Center for Disaster Medical Sciences, University of California - Irvine School of Medicine, Irvine, CaliforniaUSA.'}, {'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Arquilla', 'Affiliation': 'SUNY Downstate College of Medicine, Brooklyn, New YorkUSA.'}]",Prehospital and disaster medicine,['10.1017/S1049023X20000564'] 76,32387408,"A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.","INTRODUCTION Mometasone furoate (MF) is the inhaled corticosteroid (ICS) component in the long-acting β 2 -agonist (LABA)/ICS fixed-dose combination of indacaterol/MF, delivered via Breezhaler®, in development for asthma. MF at low (80 μg) and high (320 μg) doses delivered via Breezhaler® is expected to be comparable to MF at low (200 μg) and high (800 μg) doses respectively, delivered via Twisthaler®. METHODS This was a randomized, double-blind, double-dummy, four-week, parallel-group study of 739 adolescents and adults with persistent asthma. Eligible patients were receiving ICS treatment up to the maximum dose per day on a stable regimen for at least four weeks before screening. The study population was enriched for patients who were responsive to ICS therapy. The primary objective of the present study was to show non-inferiority of these doses, i.e. the low (80 μg) and high (320 μg) doses of MF delivered via Breezhaler® once daily, compared with the corresponding low (200 μg) and high (800 μg) doses of MF delivered via Twisthaler® once daily. The primary endpoint was 24 h post-dose trough forced expiratory volume in 1 s (FEV 1 ), after four weeks of treatment in patients with asthma. A secondary objective was to evaluate the efficacy of MF 80 μg and 320 μg delivered via Breezhaler®, and MF 200 μg and 800 μg delivered via Twisthaler® in terms of Asthma Control Questionnaire-5 (ACQ-5) after one, two, three and four weeks of treatment. RESULTS The LS mean difference in trough FEV 1 after four weeks of treatment between MF low dose 80 μg (Breezhaler®) and MF low dose 200 μg (Twisthaler®) was 27 mL (95% CI -34, 89); for MF high dose 320 μg (Breezhaler®) and MF high dose 800 μg (Twisthaler®) the difference was 0 mL (95% CI -60, 61). These differences were neither clinically nor statistically significant. All treatment arms provided similar clinically relevant improvements in ACQ-5 after four weeks of treatment compared with baseline. Both treatments showed a similar safety profile with a low incidence of adverse events. CONCLUSION The similarities in effects on lung function and ACQ after four weeks of treatment demonstrate the comparability of MF at low (80 μg) and high (320 μg) doses delivered with Breezhaler® with MF at low (200 μg) and high (800 μg) doses delivered with Twisthaler®, respectively. The study formally demonstrated that MF, delivered via Breezhaler®, is non-inferior to MF, delivered via Twisthaler® at corresponding ICS doses.",2020,"The study formally demonstrated that MF, delivered via Breezhaler®, is non-inferior to MF, delivered via Twisthaler® at corresponding ICS doses.","['739 adolescents and adults with persistent asthma', 'patients with asthma', 'patients who were responsive to ICS therapy']","['ICS', 'MF 80 μg and 320 μg delivered via Breezhaler®, and MF 200 μg and 800 μg delivered via Twisthaler®', 'Mometasone furoate (MF', 'MF high dose 800 μg (Twisthaler®', 'mometasone furoate delivered via Breezhaler® or Twisthaler®']","['ACQ-5', 'efficacy and safety', '24h post-dose trough forced expiratory volume in one second (FEV 1 ', 'lung function and ACQ']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3266628', 'cui_str': 'Persistent asthma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0205342', 'cui_str': 'Responsive'}, {'cui': 'C0149783', 'cui_str': 'Administration of steroid'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0066700', 'cui_str': 'Mometasone furoate'}, {'cui': 'C4517711', 'cui_str': '320'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0444956', 'cui_str': 'High dose'}]","[{'cui': 'C2919686', 'cui_str': 'Asthma control questionnaire'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439568', 'cui_str': 'Post-dose'}, {'cui': 'C0444506', 'cui_str': 'Trough'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}]",739.0,0.543909,"The study formally demonstrated that MF, delivered via Breezhaler®, is non-inferior to MF, delivered via Twisthaler® at corresponding ICS doses.","[{'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Buhl', 'Affiliation': 'Pulmonary Department, Johannes Gutenberg University Hospital, Mainz, Germany.'}, {'ForeName': 'Ana-Maria', 'Initials': 'AM', 'LastName': 'Tanase', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Motoi', 'Initials': 'M', 'LastName': 'Hosoe', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Weihua', 'Initials': 'W', 'LastName': 'Cao', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Demin', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Bartels', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Jauernig', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Ziegler', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Patalano', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Hederer', 'Affiliation': 'Novartis Institutes for Biomedical Research, Basel, Switzerland.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Kanniess', 'Affiliation': 'Gemeinschaftspraxis Reinfeld, Reinfeld, Germany.'}, {'ForeName': 'Hanns-Christian', 'Initials': 'HC', 'LastName': 'Tillmann', 'Affiliation': 'Novartis Institutes for Biomedical Research, Basel, Switzerland. Electronic address: hanns-christian.tillmann@novartis.com.'}]",Pulmonary pharmacology & therapeutics,['10.1016/j.pupt.2020.101919'] 77,32315869,Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN.,"BACKGROUND Direct oral anticoagulants (DOAC) and vitamin K antagonists (VKA) prevent thromboembolism in atrial fibrillation (AF). DOAC have a fixed dosing regimen and obviate INR monitoring. Therefore, DOAC presumably affect quality of life (QoL) less than VKA. However, some VKA users appreciate the monitoring. A high time in the therapeutic range (TTR) leads to a lower impact on QoL. We assessed the influence of switching from well-controlled VKA to a DOAC on QoL. METHODS In the GAInN study, 241 patients with AF, a TTR ≥ 70%, and neither bleeding nor thrombosis while on VKA were randomised to switching to DOAC (n = 121) or continuing VKA (n = 120). Health-related (SF-36) and anticoagulation-related QoL (PACT-Q) was assessed at baseline and after six and twelve months of follow-up. RESULTS AND CONCLUSION SF-36 development did not differ between groups. After one year, average PACT-Q Convenience improvement was 2.5 (0.3-4.7) higher on DOAC. DOAC users were 6percentage points (95%CI -4-16) more likely to improve >5 points on Convenience; 22 pp. (95%CI 1-43) in patients who scored <95/100 at baseline. The probability to meaningfully improve on PACT-Q Satisfaction was 12 pp. (95%CI 0-25) higher on DOAC. However, 5 (4.1%) and 4 (3.3%) DOAC users resumed VKA because of side-effects and patient preference. Switching from well-controlled VKA to DOAC for AF leads to a higher probability of improved PACT-Q convenience and satisfaction, but also to a higher risk of side-effects. Arguably only patients who are not satisfied with VKA should switch, because they have more to gain by switching.",2020,DOAC users were 6percentage points (95%CI -4-16) more likely to improve >5 points on Convenience; 22 pp.,"['241 patients with AF, a TTR\xa0≥\xa070%, and neither bleeding nor thrombosis while on VKA']","['vitamin K antagonist to direct oral anticoagulant', 'continuing VKA', 'Direct oral anticoagulants (DOAC) and vitamin K antagonists (VKA']","['Health-related (SF-36) and anticoagulation-related QoL (PACT-Q', 'average PACT-Q Convenience improvement', 'quality of life (QoL', 'Quality of life', 'probability to meaningfully improve on PACT-Q Satisfaction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0460097', 'cui_str': 'Within therapeutic range'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C1096489', 'cui_str': 'Vitamin K antagonist'}]","[{'cui': 'C1096489', 'cui_str': 'Vitamin K antagonist'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0238463', 'cui_str': 'Papillary thyroid carcinoma'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",241.0,0.12822,DOAC users were 6percentage points (95%CI -4-16) more likely to improve >5 points on Convenience; 22 pp.,"[{'ForeName': 'Jasper H A', 'Initials': 'JHA', 'LastName': 'van Miert', 'Affiliation': 'Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Certe Thrombosis Service, Groningen, the Netherlands. Electronic address: j.h.a.van.miert@umcg.nl.'}, {'ForeName': 'Hilde A M', 'Initials': 'HAM', 'LastName': 'Kooistra', 'Affiliation': 'Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Certe Thrombosis Service, Groningen, the Netherlands; Currently: Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Nic J G M', 'Initials': 'NJGM', 'LastName': 'Veeger', 'Affiliation': 'Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Annelies', 'Initials': 'A', 'LastName': 'Westerterp', 'Affiliation': 'Certe Thrombosis Service, Groningen, the Netherlands.'}, {'ForeName': 'Margriet', 'Initials': 'M', 'LastName': 'Piersma-Wichers', 'Affiliation': 'Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Certe Thrombosis Service, Groningen, the Netherlands.'}, {'ForeName': 'Karina', 'Initials': 'K', 'LastName': 'Meijer', 'Affiliation': 'Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}]",Thrombosis research,['10.1016/j.thromres.2020.04.007'] 78,32332339,Pattern of Marginal Local Failure in a Phase II Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy for Resectable and Borderline Resectable Pancreas Cancer: Erratum.,,2020,,['Resectable and Borderline Resectable Pancreas Cancer'],['Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy'],[],"[{'cui': 'C0235974', 'cui_str': 'Carcinoma of pancreas'}]","[{'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0729296', 'cui_str': 'Stereotactic'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]",[],,0.0138811,,[],American journal of clinical oncology,['10.1097/COC.0000000000000701'] 79,32350847,"Randomized, Double-blind Pilot Study of Nanocurcumin in Bladder Cancer Patients Receiving Induction Chemotherapy.","PURPOSE To evaluate the feasibility and potential efficacy of nanocurcumin supplementation in patients with localized muscle-invasive bladder cancer (MIBC) undergoing induction chemotherapy. MATERIALS AND METHODS In this double-blind, placebo-controlled trial, 26 MIBC patients were randomized to receive either nanocurcumin (180 mg/day) or placebo during the course of chemotherapy. All patients were followed up to four weeks after the end of treatment to assess the complete clinical response to the chemotherapy as primary endpoint. Secondary endpoints were the comparisons of chemotherapy?induced nephrotoxicity, hematologic nadirs, and toxicities between the two groups. Hematologic nadirs and toxicities were assessed during the treatment. RESULTS Nanocurcumin was well tolerated. The complete clinical response rates were 30.8 and 50% in the placebo and nanocurcumin groups, respectively. Although nanocurcumin was shown to be superior to placebo with respect to complete clinical response rates as the primary endpoint, there was no significant difference between the groups (p = 0.417). No significant difference was also found between the two groups with regard to grade 3/4 renal and hematologic toxicities as well as hematologic nadirs. CONCLUSION These preliminary data indicate the feasibility of nanocurcumin supplementation as a complementary therapy in MIBC patients and support further larger studies. Moreover, a substantial translational insight to fill the gap between the experiment and clinical practice in the field is provided.",2020,"No significant difference was also found between the two groups with regard to grade 3/4 renal and hematologic toxicities as well as hematologic nadirs. ","['Bladder Cancer Patients Receiving Induction Chemotherapy', 'patients with localized muscle-invasive bladder cancer (MIBC) undergoing induction chemotherapy', '26 MIBC patients']","['placebo', 'nanocurcumin', 'nanocurcumin supplementation', 'Nanocurcumin']","['grade 3/4 renal and hematologic toxicities', 'tolerated', 'chemotherapy?induced nephrotoxicity, hematologic nadirs, and toxicities', 'complete clinical response rates', 'hematologic nadirs', 'Hematologic nadirs and toxicities']","[{'cui': 'C0005684', 'cui_str': 'Malignant tumor of urinary bladder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3179010', 'cui_str': 'Induction chemotherapy'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1827293', 'cui_str': 'Carcinoma of urinary bladder, invasive'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0442757', 'cui_str': '3/4'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0018943', 'cui_str': 'Hematology'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0595916', 'cui_str': 'Toxic nephropathy'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",26.0,0.23094,"No significant difference was also found between the two groups with regard to grade 3/4 renal and hematologic toxicities as well as hematologic nadirs. ","[{'ForeName': 'Saleh', 'Initials': 'S', 'LastName': 'Sandoughdaran', 'Affiliation': 'Department of Radiation Oncology, Shohada-e-Tajrish Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Abolfazl', 'Initials': 'A', 'LastName': 'Razzaghdoust', 'Affiliation': 'Urology and Nephrology Research Center, Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Tabibi', 'Affiliation': 'Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Basiri', 'Affiliation': 'Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Nasser', 'Initials': 'N', 'LastName': 'Simforoosh', 'Affiliation': 'Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Bahram', 'Initials': 'B', 'LastName': 'Mofid', 'Affiliation': 'Department of Radiation Oncology, Shohada-e-Tajrish Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mofid429@sbmu.ac.ir.'}]",Urology journal,['10.22037/uj.v0i0.5719'] 80,32350915,"Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial.","BACKGROUND Cardiac troponin T (cTnT) and I (cTnI) concentrations provide strong prognostic information in anticoagulated patients with atrial fibrillation (AF). Whether the associations between cardiac troponin concentrations and mortality and morbidity differ by sex is not known. OBJECTIVES To assess whether men and women have different concentrations and prognostic value of cTnT and cTnI measurements in anticoagulated patients with AF. METHODS cTnT and cTnI concentrations were measured with high-sensitivity (hs) assays in EDTA plasma samples obtained from the multicentre ARISTOTLE trial, which randomized patients with AF and at least one risk factor for stroke or systemic embolic event to warfarin or apixaban. Patients were stratified according to sex and the associations between hs-troponin concentrations, and all-cause death, cardiac death, myocardial infarction, stroke or systemic embolic event and major bleeding were assessed in multivariable regression models. RESULTS We found higher cardiac troponin concentrations in men (n = 9649) compared to women (n = 5331), both for hs-cTnT (median 11.8 [Q1-3 8.1-18.0] vs. 9.6 [6.7-14.3] ng L -1 , P < 0.001) and hs-cTnI (5.8 [3.4-10.8] vs. 4.9 [3.1-8.8] ng L -1 , P < 0.001). Adjusting for baseline demographics, comorbidities and medications, men still had significantly higher hs-troponin concentrations than women. C-reactive protein and N-terminal pro-B-type natriuretic peptide concentrations were higher in female patients. Both hs-cTnT and hs-cTnI concentrations were associated with all clinical outcomes similarly in men and women (p-value for interaction >0.05 for all end-points). CONCLUSION Men have higher hs-troponin concentrations than women in AF. Regardless of sex, hs-troponin concentrations remain similarly associated with adverse clinical outcomes in anticoagulated patients with AF.",2020,"We found higher cardiac troponin concentrations in men (n=9649) compared to women (n=5331), both for hs-cTnT","['female patients', 'anticoagulated patients with atrial fibrillation (AF', 'men (n=9649) compared to women (n=5331), both for hs-cTnT', 'patients with AF and at least one risk factor for stroke or systemic embolic event to warfarin or apixaban', 'anticoagulated patients with AF', 'men and women with atrial fibrillation']","['cTnT', 'Cardiac troponin', 'Cardiac troponin T ']","['higher hs-troponin concentrations', 'cardiac troponin concentrations', 'troponin concentrations and all-cause death, cardiac death, myocardial infarction, stroke or systemic embolic event, and major bleeding', 'and cTnI concentrations', 'C-reactive protein and N-terminal pro-B-type natriuretic peptide concentrations', 'hs-troponin concentrations']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0523953', 'cui_str': 'Troponin T cardiac measurement'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C1831808', 'cui_str': 'apixaban'}]","[{'cui': 'C0523953', 'cui_str': 'Troponin T cardiac measurement'}, {'cui': 'C1096316', 'cui_str': 'Cardiac troponin'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0041199', 'cui_str': 'Troponin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1096316', 'cui_str': 'Cardiac troponin'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0376297', 'cui_str': 'Cardiac death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0883409', 'cui_str': 'Cardiac troponin I'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}]",,0.343636,"We found higher cardiac troponin concentrations in men (n=9649) compared to women (n=5331), both for hs-cTnT","[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Røsjø', 'Affiliation': 'Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Hijazi', 'Affiliation': 'Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Omland', 'Affiliation': 'Institute of Clinical Medicine, University of Oslo, Oslo, Norway.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Westerbergh', 'Affiliation': 'Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'M N', 'Initials': 'MN', 'LastName': 'Lyngbakken', 'Affiliation': 'Institute of Clinical Medicine, University of Oslo, Oslo, Norway.'}, {'ForeName': 'J H', 'Initials': 'JH', 'LastName': 'Alexander', 'Affiliation': 'Duke Clinical Research Institute, Duke Health, Durham, NC, USA.'}, {'ForeName': 'B J', 'Initials': 'BJ', 'LastName': 'Gersh', 'Affiliation': 'Mayo Clinic College of Medicine, Rochester, MN, USA.'}, {'ForeName': 'C B', 'Initials': 'CB', 'LastName': 'Granger', 'Affiliation': 'Duke Clinical Research Institute, Duke Health, Durham, NC, USA.'}, {'ForeName': 'E M', 'Initials': 'EM', 'LastName': 'Hylek', 'Affiliation': 'Boston University Medical Center, Boston, MA, USA.'}, {'ForeName': 'R D', 'Initials': 'RD', 'LastName': 'Lopes', 'Affiliation': 'Duke Clinical Research Institute, Duke Health, Durham, NC, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Siegbahn', 'Affiliation': 'Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Wallentin', 'Affiliation': 'Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.'}]",Journal of internal medicine,['10.1111/joim.13072'] 81,32363948,"The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double-blind, placebo-controlled, randomized clinical trials.","INTRODUCTION Peripheral neuropathic pain is a highly disabling condition for patients and a challenge for neurologists and pain physicians. Although many drugs have been assessed in scientific studies, few have demonstrated a clear clinical efficacy against neuropathic pain. Moreover, the paucity of data regarding their safety raised the question on the benefit-risk ratio when used in patients experiencing peripheral neuropathies. AREAS COVERED The authors conducted a review of double-blind, placebo-controlled, randomized clinical trials to assess the safety of medications used to treat neuropathic pain. This first review was focused on antidepressant and antiepileptic medications. The aim was to provide an overview of the treatment-emergent adverse events (≥10%) and the serious adverse effects described in clinical trials. EXPERT OPINION Among antiepileptics and antidepressants, duloxetine appeared to have the most detailed safety for the treatment of peripheral neuropathic pain. Over all studies, the most commonly reported adverse effects were dizziness, drowsiness, nausea, and constipation. Only 20.0% of the included studies (N = 90) presented a good description of adverse effects that included a statistical comparison vers us a placebo group. Important methodological improvements must be made to improve the assessment of medication safety in future clinical trials.",2020,"Over all studies, the most commonly reported adverse effects were dizziness, drowsiness, nausea, and constipation.","['patients and a challenge for neurologists and pain physicians', 'patients experiencing peripheral neuropathies']","['duloxetine', 'placebo']","['adverse effects', 'dizziness, drowsiness, nausea, and constipation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0237426', 'cui_str': 'Neurologist'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}]","[{'cui': 'C0245561', 'cui_str': 'duloxetine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}]",,0.468693,"Over all studies, the most commonly reported adverse effects were dizziness, drowsiness, nausea, and constipation.","[{'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Selvy', 'Affiliation': 'Université Clermont Auvergne, CHU Clermont-Ferrand, Service de chirurgie digestive, INSERM, NEURO-DOL , Clermont-Ferrand, France.'}, {'ForeName': 'Mélissa', 'Initials': 'M', 'LastName': 'Cuménal', 'Affiliation': 'Université Clermont Auvergne, INSERM NEURO-DOL , Clermont-Ferrand, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Kerckhove', 'Affiliation': 'Université Clermont Auvergne, CHU Clermont-Ferrand, Service de pharmacologie médicale, INSERMNEURO-DOL, Institut Analgesia , Clermont-Ferrand, France.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Courteix', 'Affiliation': 'Université Clermont Auvergne, INSERM NEURO-DOL , Clermont-Ferrand, France.'}, {'ForeName': 'Jérôme', 'Initials': 'J', 'LastName': 'Busserolles', 'Affiliation': 'Université Clermont Auvergne, INSERM NEURO-DOL , Clermont-Ferrand, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Balayssac', 'Affiliation': ""Université Clermont Auvergne, CHU Clermont-Ferrand, Délégation à la recherche clinique et à l'innovation, INSERM, NEURO-DOL , Clermont-Ferrand, France.""}]",Expert opinion on drug safety,['10.1080/14740338.2020.1764934'] 82,32305578,"Response to ""Effect of Aromatherapy Massage on Quality of Sleep in the Palliative Care Ward: Randomized Controlled Trial"".",,2020,,[],['Aromatherapy Massage'],['Quality of Sleep'],[],"[{'cui': 'C2585844', 'cui_str': 'Aromatherapy massage'}]","[{'cui': 'C0424563', 'cui_str': 'Quality of sleep'}]",,0.0879721,,"[{'ForeName': 'Masamitsu', 'Initials': 'M', 'LastName': 'Kobayashi', 'Affiliation': 'Faculty of Nursing, National Defense Medical College, Tokorozawa, Japan. Electronic address: masamitsu4k26@gmail.com.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Kako', 'Affiliation': 'Division of Nursing Science, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Kohei', 'Initials': 'K', 'LastName': 'Kajiwara', 'Affiliation': 'Japanese Red Cross Kyushu International College of Nursing, Fukuoka, Japan.'}, {'ForeName': 'Yasufumi', 'Initials': 'Y', 'LastName': 'Oosono', 'Affiliation': 'Faculty of Nursing, National Defense Medical College, Tokorozawa, Japan.'}, {'ForeName': 'Hiroko', 'Initials': 'H', 'LastName': 'Noto', 'Affiliation': 'Department of Health Sciences, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2020.04.007'] 83,32372387,Comparing the Potential for Irritation of a Ceramide-Based Moisturizer with a Urea-Based Moisturizer for Pediatric Atopic Dermatitis.,"INTRODUCTION Moisturizers are one of the mainstays of the topical treatment of atopic dermatitis (AD). One of the adverse effects of moisturizers is skin irritation, especially on excoriated AD skin. We compared the potential for irritation of two commercially available moisturizer products for the treatment of AD: a ceramide-based moisturizer (Ceradan ® Cream; Hyphens Pharma Pte Ltd, Singapore) and a urea 5% moisturizer (Aqurea Lite Cream; ICA Pharma Pte Ltd, Singapore). METHODS We performed a prospective single-blind randomized controlled study recruiting AD patients aged between 8 and 16 years with symmetrical or near symmetrical scratch marks (excoriations) of at least grade 2 to 3 severity score, according to the Eczema Area and Severity Index (EASI), over bilateral antecubital fossae. Subjects were randomized to receive the ceramide-based moisturizer to either the left or right antecubital fossa or urea 5% cream to the other antecubital fossa. Subjects were asked to grade the immediate skin irritation of both creams on a standard visual analogue scale (VAS) and which cream they would prefer to use as a daily moisturizer. Primary outcome was the mean irritant score of each cream, and secondary outcome was the subjects' preference of either cream as their daily moisturizer. RESULTS A total of 42 participants were enrolled with a mean age of 11 years 5 months. The ceramide-based cream had a significantly lower mean VAS score (mean 0.69, SD = 1.63) for irritation compared with urea 5% cream (1.43, SD = 1.64) (p = 0.035). More participants also preferred the ceramide-based cream over urea 5% cream (62% versus 38%) as their daily moisturizer, but this did not reach statistical significance (p = 0.164). CONCLUSIONS A ceramide-based moisturizer may be considered as a suitable choice for children to minimize irritation from moisturizer treatment for AD.",2020,"The ceramide-based cream had a significantly lower mean VAS score (mean 0.69, SD = 1.63) for irritation compared with urea 5% cream (1.43, SD = 1.64) (p = 0.035).","['Pediatric Atopic Dermatitis', 'AD patients aged between 8 and 16\xa0years with symmetrical or near symmetrical scratch marks (excoriations) of at least grade 2 to 3 severity score, according to the Eczema Area and Severity Index (EASI), over bilateral antecubital fossae', '42 participants were enrolled with a mean age of 11\xa0years 5\xa0months']","['ceramide-based moisturizer to either the left or right antecubital fossa or urea 5% cream to the other antecubital fossa', 'Ceramide-Based Moisturizer with a Urea-Based Moisturizer']","['standard visual analogue scale (VAS', 'mean irritant score of each cream', ""subjects' preference of either cream as their daily moisturizer"", 'mean VAS score']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332516', 'cui_str': 'Symmetrical'}, {'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C1384489', 'cui_str': 'Scratch marks'}, {'cui': 'C0475270', 'cui_str': 'G2 grade'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0013595', 'cui_str': 'Eczema'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0007745', 'cui_str': 'Ceramides'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0446523', 'cui_str': 'Antecubital fossa (surface region)'}, {'cui': 'C0041942', 'cui_str': 'Urea'}, {'cui': 'C0700385', 'cui_str': 'Cream'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0022108', 'cui_str': 'Irritant'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",42.0,0.0323502,"The ceramide-based cream had a significantly lower mean VAS score (mean 0.69, SD = 1.63) for irritation compared with urea 5% cream (1.43, SD = 1.64) (p = 0.035).","[{'ForeName': 'Valerie Pui Yoong', 'Initials': 'VPY', 'LastName': 'Ho', 'Affiliation': ""Dermatology Service, KK Women's and Children's Hospital, Singapore, Singapore. valerie.ho.p.y@singhealth.com.sg.""}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Ma', 'Affiliation': ""Dermatology Service, KK Women's and Children's Hospital, Singapore, Singapore.""}, {'ForeName': 'Hui Min', 'Initials': 'HM', 'LastName': 'Liew', 'Affiliation': ""Dermatology Service, KK Women's and Children's Hospital, Singapore, Singapore.""}, {'ForeName': 'Michelle Si Ying', 'Initials': 'MSY', 'LastName': 'Ng', 'Affiliation': ""Dermatology Service, KK Women's and Children's Hospital, Singapore, Singapore.""}, {'ForeName': 'Mark Jean Aan', 'Initials': 'MJA', 'LastName': 'Koh', 'Affiliation': ""Dermatology Service, KK Women's and Children's Hospital, Singapore, Singapore.""}]",Dermatology and therapy,['10.1007/s13555-020-00388-6'] 84,32379107,Effects of Auricular Acupressure in Patients on Hemodialysis.,"BACKGROUND Although studies on the effectiveness of self-management in limiting fluid intake in patients on hemodialysis have been conducted extensively, xerostomia, which is a powerful stimulus of fluid intake, has received scarce attention. PURPOSE The purpose of this study was to examine the effects of a 4-week auricular acupressure treatment on xerostomia, salivary flow rate, interdialytic weight gain, constipation, and diet-related quality of life in patients on hemodialysis in Korea. METHODS This was a randomized controlled trial. Sixty patients on hemodialysis were randomly assigned to either the experimental group (n = 30) or the control group (n = 30). The experimental group received an auricular acupressure intervention, which included the application of skin tape with a Semen vaccariae seed on the five auricular acupoints, including the large intestine (CO7), San Jiao (CO17), middle triangular fossa (TF3), spleen (CO13), and upper tragus (TG1), for 4 weeks. The control group received only the application of skin tape without a seed on the same auricular acupoints for the same period. The outcome variables were as follows: xerostomia, measured using the visual analog scale; salivary flow rate, measured using the unstimulated whole saliva absorbed in oral cotton; interdialytic weight gain; the constipation assessment scale score; and the Quality of Life Related to Dietary Change Questionnaire results. RESULTS The experimental group scored significantly better than the control group in terms of xerostomia (p = .004), salivary flow rate (p = .010), constipation (p = .009), and diet-related quality of life (p < .001). CONCLUSIONS/IMPLICATIONS FOR PRACTICE Auricular acupressure may be an important tool for alleviating the negative symptoms of xerostomia and for improving quality of life in patients on hemodialysis. Nurses caring for patients on hemodialysis with both xerostomia and constipation may teach auricular acupressure to help patients self-manage their discomfort.",2020,"The experimental group scored significantly better than the control group in terms of xerostomia (p = .004), salivary flow rate (p = .010), constipation (p = .009), and diet-related quality of life (p < .001). ","['Patients on Hemodialysis', 'Sixty patients on hemodialysis', 'Nurses caring for patients on hemodialysis with both xerostomia and constipation', 'patients on hemodialysis in Korea', 'patients on hemodialysis']","['skin tape without a seed on the same auricular acupoints', 'auricular acupressure treatment', 'Auricular Acupressure', 'auricular acupressure intervention, which included the application of skin tape with a Semen vaccariae seed on the five auricular acupoints, including the large intestine (CO7), San Jiao (CO17), middle triangular fossa (TF3), spleen (CO13), and upper tragus (TG1']","['visual analog scale; salivary flow rate', 'diet-related quality of life', 'constipation assessment scale score; and the Quality of Life Related to Dietary Change Questionnaire results', 'constipation', 'xerostomia, salivary flow rate, interdialytic weight gain, constipation, and diet-related quality of life', 'salivary flow rate', 'xerostomia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0043352', 'cui_str': 'Xerostomia'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0022771', 'cui_str': 'Korea'}]","[{'cui': 'C1721087', 'cui_str': 'Skin Tape'}, {'cui': 'C0036563', 'cui_str': 'Plant seeds'}, {'cui': 'C1522191', 'cui_str': 'Otic route'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C0282614', 'cui_str': 'Acupressure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0021851', 'cui_str': 'Structure of large intestine'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0205119', 'cui_str': 'Triangular'}, {'cui': 'C0325079', 'cui_str': 'Cryptoprocta ferox'}, {'cui': 'C0037993', 'cui_str': 'Splenic structure'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0229312', 'cui_str': 'Tragus structure'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0429177', 'cui_str': 'Salivary flow rate'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0043352', 'cui_str': 'Xerostomia'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}]",60.0,0.0268171,"The experimental group scored significantly better than the control group in terms of xerostomia (p = .004), salivary flow rate (p = .010), constipation (p = .009), and diet-related quality of life (p < .001). ","[{'ForeName': 'Eun Sook', 'Initials': 'ES', 'LastName': 'Jung', 'Affiliation': '1MSN, RN, Graduate School, Kyung Hee University, Seoul, Republic of Korea 2PhD, RN, Associate Professor, College of Nursing Science & East-West Nursing Research Institute, Kyung Hee University, Seoul, Republic of Korea.'}, {'ForeName': 'Ae Kyung', 'Initials': 'AK', 'LastName': 'Chang', 'Affiliation': ''}]",The journal of nursing research : JNR,['10.1097/jnr.0000000000000378'] 85,32388511,Randomized Controlled Trial of Nonsynchronized Nasal Intermittent Positive Pressure Ventilation versus Nasal CPAP after Extubation of VLBW Infants.,"BACKGROUND AND OBJECTIVES Nasal continuous positive airway pressure (NCPAP) is a useful method of respiratory support after extubation. However, some infants fail despite CPAP use and require reintubation. Some evidence suggests that synchronized nasal intermittent positive pressure ventilation (NIPPV) may decrease extubation failure in preterm infants. Nonsynchronized NIPPV (NS-NIPPV) is being widely used in preterm infants without conclusive evidence of its benefits and side effects. Our aim was to evaluate whether NS-NIPPV decreases extubation failure compared with NCPAP in ventilated very low birth weight infants (VLBWI) with respiratory distress syndrome (RDS). METHODS Randomized controlled trial of ventilated VLBWI being extubated for the first time. Before extubation, infants were randomized to receive NCPAP or NS-NIPPV. Primary outcome was the need for reintubation within 72 h. RESULTS 220 infants were included. The mean ± SD birth weight was 1,027 ± 256 g and gestational age 27.8 ± 1.9 weeks. Demographic and clinical characteristics were similar in both groups. Extubation failure was 32.4% for NCPAP versus 32.1% for NS-NIPPV, p = 0.98. The frequency of deaths, bronchopulmonary dysplasia, intraventricular hemorrhage, air leaks, necrotizing enterocolitis and duration of respiratory support did not differ between groups. CONCLUSIONS In this population of VLBWI, NS-NIPPV did not decrease extubation failure after RDS compared with NCPAP.",2020,"Extubation failure was 32.4% for NCPAP versus 32.1% for NS-NIPPV, p = 0.98.","['after Extubation of VLBW Infants', 'ventilated very low birth weight infants (VLBWI) with respiratory distress syndrome (RDS', 'preterm infants']","['Nonsynchronized NIPPV (NS-NIPPV', 'Nasal continuous positive airway pressure (NCPAP', 'NCPAP or NS-NIPPV', 'NS-NIPPV', 'Nonsynchronized Nasal Intermittent Positive Pressure Ventilation versus Nasal CPAP', 'ventilated VLBWI', 'NCPAP', 'synchronized nasal intermittent positive pressure ventilation (NIPPV']","['extubation failure', 'frequency of deaths, bronchopulmonary dysplasia, intraventricular hemorrhage, air leaks, necrotizing enterocolitis and duration of respiratory support', 'need for reintubation', 'mean ± SD birth weight', 'Extubation failure']","[{'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0282666', 'cui_str': 'Very Low Birth Weight'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0042491', 'cui_str': 'Ventilation'}, {'cui': 'C0282667', 'cui_str': 'Very low birth weight infant'}, {'cui': 'C0035220', 'cui_str': 'Respiratory distress syndrome in the newborn'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}]","[{'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0021778', 'cui_str': 'Intermittent positive pressure ventilation'}, {'cui': 'C1258045', 'cui_str': 'nCPAP Ventilation'}, {'cui': 'C3665969', 'cui_str': 'Nasal CPAP'}, {'cui': 'C0042491', 'cui_str': 'Ventilation'}, {'cui': 'C0282667', 'cui_str': 'Very low birth weight infant'}, {'cui': 'C0439580', 'cui_str': 'Synchronous'}]","[{'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary dysplasia of newborn'}, {'cui': 'C0240059', 'cui_str': 'Ventricular hemorrhage'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0332234', 'cui_str': 'Leaking'}, {'cui': 'C0014356', 'cui_str': 'Enterocolitis'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0860359', 'cui_str': 'Reintubate'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}]",220.0,0.490166,"Extubation failure was 32.4% for NCPAP versus 32.1% for NS-NIPPV, p = 0.98.","[{'ForeName': 'Alberto S', 'Initials': 'AS', 'LastName': 'Estay', 'Affiliation': 'Departamento de Neonatología, Pontificia Universidad Católica de Chile, Santiago, Chile, albertoestay@gmail.com.'}, {'ForeName': 'Gonzalo L', 'Initials': 'GL', 'LastName': 'Mariani', 'Affiliation': 'Instituto Universitario del Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.'}, {'ForeName': 'Claudio A', 'Initials': 'CA', 'LastName': 'Alvarez', 'Affiliation': 'Hospital Dr. Gustavo Fricke, Viña del Mar, Chile.'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Milet', 'Affiliation': 'Hospital Dr. Sotero del Río, Santiago, Chile.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Agost', 'Affiliation': 'Hospital Luis Carlos Lagomaggiore, Mendoza, Argentina.'}, {'ForeName': 'Claudia P', 'Initials': 'CP', 'LastName': 'Avila', 'Affiliation': 'Hospital San José, Santiago, Chile.'}, {'ForeName': 'Liliana', 'Initials': 'L', 'LastName': 'Roldan', 'Affiliation': 'Hospital Fernández, Buenos Aires, Argentina.'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Abdala', 'Affiliation': 'Hospital Español, Mendoza, Argentina.'}, {'ForeName': 'Rodolfo', 'Initials': 'R', 'LastName': 'Keller', 'Affiliation': 'Hospital Universitario Austral, Buenos Aires, Argentina.'}, {'ForeName': 'María F', 'Initials': 'MF', 'LastName': 'Galletti', 'Affiliation': 'Instituto Universitario del Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.'}, {'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'González', 'Affiliation': 'Departamento de Neonatología, Pontificia Universidad Católica de Chile, Santiago, Chile.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Neonatology,['10.1159/000506164'] 86,32392996,[Efficacy and safety of low-intensity pulsed ultrasound at different intervals by mechanical force in treating erectile dysfunction: a preliminary study].,"Objective: To study the efficacy and safety of low-intensity pulsed ultrasound (LIPUS) at different intervals by mechanical force in treating erectile dysfunction (ED). Method: Forty patients with mild to moderate ED were randomized in a 1∶1 ratio to receive 16-treatment sessions of LIPUS in group A and group B, applied 3 times per week and 2 times per week, respectively. End-point assessments were made at 8th week after treatment. Efficacy were evaluated using International Index of Erectile Function-Erectile Function domain score (IIEF-EF), Erectile Hardness Score (EHS), Self-Esteem and Relationship Questionnaire (SEAR), Sexual Encounter Profile (SEP), Global Assessment Question (GAQ), and pain were assessed by Visual Analogue Score (VAS).Treatment response was confirmed by a minimal clinically importance difference (MCID) at 8th week. Results: Compared with baseline, IIEF-EF score [(17.1±5.48 vs 23.4±3.75, P< 0.05) and (18.9±4.34 vs 24.1±4.32, P< 0.05)], proportion of EHS 4 [(0 vs 40%, P< 0.05) and (16.7% vs 55.6%, P< 0.05)], and Overall Relationship score [(50.6 vs 67.5, P< 0.05) and (44.4 vs 70.1, P< 0.05)] were significantly improved at 8th week in two groups, respectively. Compared with baseline, the positive responses to SEP-3 increased significantly at 8th week in two groups (50.0% vs 80.0%, P< 0.05) and (44.4% vs 88.9%, P< 0.05), respectively. The positive responses to GAQ-2 were 90.0% and 88.9% at 8th week in two groups, respectively. There were no significant differences in IIEF-EF, EHS, SEAR, SEP and GAQ at 8th week between two groups. There was no significant difference in treatment response using MCID between two groups at end-point (80.5% vs 77.5%). The treatment duration for full sessions were 2.5 weeks less in group A than group B. No adverse effects were reported in all cases. Conclusion: LIPUS at two different intervals is effective and safe for mild to moderate ED, and the regimen at 3 times per week can achieve quite good effect in relatively short duration,while the long-term effects is still be clarified in further study.",2020,"There were no significant differences in IIEF-EF, EHS, SEAR, SEP and GAQ at 8th week between two groups.","['treating erectile dysfunction', 'Forty patients with mild to moderate ED']","['low-intensity pulsed ultrasound (LIPUS', 'low-intensity pulsed ultrasound', 'LIPUS']","['positive responses to GAQ-2', 'IIEF-EF score', 'treatment response using MCID', 'proportion of EHS', 'positive responses to SEP-3', 'International Index of Erectile Function-Erectile Function domain score (IIEF-EF), Erectile Hardness Score (EHS), Self-Esteem and Relationship Questionnaire (SEAR), Sexual Encounter Profile (SEP), Global Assessment Question (GAQ), and pain were assessed by Visual Analogue Score', 'Overall Relationship score', 'IIEF-EF, EHS, SEAR, SEP and GAQ', 'adverse effects']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0242350', 'cui_str': 'Impotence'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}]","[{'cui': 'C4042796', 'cui_str': 'LIPUS'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C2960541', 'cui_str': 'International index of erectile function'}, {'cui': 'C0030847', 'cui_str': 'Penile erection'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0018599', 'cui_str': 'Hard'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",40.0,0.039409,"There were no significant differences in IIEF-EF, EHS, SEAR, SEP and GAQ at 8th week between two groups.","[{'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Xia', 'Affiliation': 'Urologic Medical Center, Institute of Urology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.'}, {'ForeName': 'H R', 'Initials': 'HR', 'LastName': 'Chen', 'Affiliation': 'Urologic Medical Center, Institute of Urology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Urologic Medical Center, Institute of Urology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.'}, {'ForeName': 'X C', 'Initials': 'XC', 'LastName': 'Li', 'Affiliation': 'Clinical Research Center, Shanghai General Hospital, Shanghai 200080, China.'}, {'ForeName': 'E L', 'Initials': 'EL', 'LastName': 'Zhi', 'Affiliation': 'Urologic Medical Center, Institute of Urology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.'}, {'ForeName': 'R H', 'Initials': 'RH', 'LastName': 'Tian', 'Affiliation': 'Urologic Medical Center, Institute of Urology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': 'Urologic Medical Center, Institute of Urology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.'}, {'ForeName': 'Y H', 'Initials': 'YH', 'LastName': 'Huang', 'Affiliation': 'Urologic Medical Center, Institute of Urology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.'}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Hu', 'Affiliation': 'Urologic Medical Center, Institute of Urology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Qiu', 'Affiliation': 'Clinical Research Center, Shanghai General Hospital, Shanghai 200080, China.'}]",Zhonghua yi xue za zhi,['10.3760/cma.j.cn112137-20191207-02679'] 87,31831847,Gait ability required to achieve therapeutic effect in gait and balance function with the voluntary driven exoskeleton in patients with chronic spinal cord injury: a clinical study.,"STUDY DESIGN A non-randomized open-label single-arm clinical trial. OBJECTIVES To analyze the effect of body weight supported treadmill training (BWSTT) with the voluntary driven exoskeleton (VDE) in persons with differing levels and completeness of spinal cord injury (SCI) and differing walking abilities. SETTING Keio University Hospital, Tokyo, Japan. METHODS Twenty individuals with chronic SCI (age, 43 ± 17 years) classified as American Spinal Injury Association Impairment Scale grade A (n = 2), B (n = 4), C (n = 8), or D (n = 6) who had reached a plateau in recovery. Participants underwent twenty 60 min sessions of BWSTT with the hybrid assisted limb. The speed, distance, and duration walked in every 60 min training session were recorded. The Walking Index for SCI Scale II (WISCI-II), 10 meters walk test (10MWT), 2 min walk test, timed up and go (TUG) test, Berg Balance Scale (BBS), lower extremity motor score (LEMS), Barthel Index, and Functional Independence Measure were evaluated at pre and post intervention. RESULTS There was a significant improvement in 10MWT, TUG, and BBS after the intervention. Walking ability significantly improved in participants with high walking ability at baseline (WISCI-II score 6-20; n = 12) but not in participants with low walking ability (WISCI-II score 0-3; n = 8). Significant improvement of BBS was also shown in participants with high walking ability at baseline. CONCLUSIONS Patients with high walking ability at baseline responded better to the training than those with low walking ability.",2020,Walking ability significantly improved in participants with high walking ability at baseline (WISCI-II score 6-20; n = 12) but not in participants with low walking ability (WISCI-II score 0-3; n = 8).,"['persons with differing levels and completeness of spinal cord injury (SCI) and differing walking abilities', 'patients with chronic spinal cord injury', 'Twenty individuals with chronic SCI (age, 43\u2009±\u200917 years) classified as American Spinal Injury Association Impairment Scale grade A (n\u2009=\u20092), B (n\u2009=\u20094), C (n\u2009=\u20098), or D (n\u2009=\u20096) who had reached a plateau in recovery', 'Keio University Hospital, Tokyo, Japan']","['voluntary driven exoskeleton', 'body weight supported treadmill training (BWSTT) with the voluntary driven exoskeleton (VDE']","['10MWT, TUG, and BBS', 'BBS', 'speed, distance, and duration walked', 'Walking ability', 'Walking Index for SCI Scale II (WISCI-II), 10 meters walk test (10MWT), 2\u2009min walk test, timed up and go (TUG) test, Berg Balance Scale (BBS), lower extremity motor score (LEMS), Barthel Index, and Functional Independence Measure']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439812', 'cui_str': 'Completeness'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C4720884', 'cui_str': 'American Spinal Injury Association impairment scale'}, {'cui': 'C0309195', 'cui_str': 'Grade A'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0040371', 'cui_str': 'Tokyo'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0441074', 'cui_str': 'Meters'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0559964', 'cui_str': 'Ability to walk'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C0451172', 'cui_str': 'Functional independence measure'}]",20.0,0.0297895,Walking ability significantly improved in participants with high walking ability at baseline (WISCI-II score 6-20; n = 12) but not in participants with low walking ability (WISCI-II score 0-3; n = 8).,"[{'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Okawara', 'Affiliation': 'Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Tomonori', 'Initials': 'T', 'LastName': 'Sawada', 'Affiliation': 'Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kohei', 'Initials': 'K', 'LastName': 'Matsubayashi', 'Affiliation': 'Department of Orthopaedic Surgery, National Hospital Organization, Murayama Medical Center, Tokyo, Japan.'}, {'ForeName': 'Keiko', 'Initials': 'K', 'LastName': 'Sugai', 'Affiliation': 'Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Osahiko', 'Initials': 'O', 'LastName': 'Tsuji', 'Affiliation': 'Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Narihito', 'Initials': 'N', 'LastName': 'Nagoshi', 'Affiliation': 'Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Morio', 'Initials': 'M', 'LastName': 'Matsumoto', 'Affiliation': 'Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Masaya', 'Initials': 'M', 'LastName': 'Nakamura', 'Affiliation': 'Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan. masa@a8.keio.jp.'}]",Spinal cord,['10.1038/s41393-019-0403-0'] 88,32397748,"Comparing the effects of multi-session anodal trans-cranial direct current stimulation of primary motor and dorsolateral prefrontal cortices on fatigue and quality of life in patients with multiple sclerosis: a double-blind, randomized, sham-controlled trial.","OBJECTIVE To compare the effects of anodal trans-cranial direct current stimulation (a-tDCS) over primary motor and dorsolateral prefrontal cortices on Fatigue Severity Scale and its lasting effect on fatigue reduction and improvement in quality of life in patients with multiple sclerosis. DESIGN A randomized, double-blinded, sham-controlled parallel clinical trial study. SETTING Neurological physiotherapy clinics. SUBJECTS Thirty-nine participants were randomly assigned to three groups: dorsolateral prefrontal cortex a-tDCS, primary motor a-tDCS (experimental groups) and sham a-tDCS. Finally, 36 participants completed the whole study ( n  = 12 in each group). INTERVENTIONS Participants in the experimental groups received six-session a-tDCS (1.5 mA, 20 minutes) during two weeks (three sessions per week). The sham group received six sessions of 20-minute sham stimulation. MAIN MEASURES The Fatigue Severity Scale and quality of life were assessed before, immediately and four weeks after the intervention. RESULTS Findings indicated a significant reduction in the Fatigue Severity Scale and a significant increase in the quality of life in both experimental groups, immediately after the intervention ( P  < 0.001), while Fatigue Severity Scale and quality of life changes were not significant in the sham a-tDCS group ( P  > 0.05). In addition, improvement of the variables remained four weeks after the intervention in dorsolateral prefrontal cortex a-tDCS (mean differences (95% confidence interval): 0.03 (-0.63 to 0.68) as compared to primary motor (-0.62 (-0.11 to -1.14) and sham a-tDCS groups (-0.47 (-1.37 to 0.43)). CONCLUSION Both primary motor and dorsolateral prefrontal cortex a-tDCS as compared to sham intervention can immediately improve fatigue and quality of life. However, the effects last up to four weeks only by the dorsolateral prefrontal cortex a-tDCS.",2020,Both primary motor and dorsolateral prefrontal cortex a-tDCS as compared to sham intervention can immediately improve fatigue and quality of life.,"['patients with multiple sclerosis', 'Neurological physiotherapy clinics', 'Thirty-nine participants', '36 participants completed the whole study ( n \u2009=\u200912 in each group']","['multi-session anodal trans-cranial direct current stimulation', 'dorsolateral prefrontal cortex a-tDCS, primary motor a-tDCS (experimental groups) and sham a-tDCS', 'anodal trans-cranial direct current stimulation (a-tDCS', 'six-session a-tDCS']","['quality of life', 'fatigue and quality of life', 'Fatigue Severity Scale', 'Fatigue Severity Scale and quality of life changes', 'dorsolateral prefrontal cortex a-tDCS', 'Fatigue Severity Scale and quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C4042764', 'cui_str': 'Neurophysiotherapy'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C3816447', 'cui_str': '39'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0037303', 'cui_str': 'Bone structure of cranium'}, {'cui': 'C0442831', 'cui_str': 'Direct current'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0037303', 'cui_str': 'Bone structure of cranium'}, {'cui': 'C0442831', 'cui_str': 'Direct current'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]",39.0,0.0917939,Both primary motor and dorsolateral prefrontal cortex a-tDCS as compared to sham intervention can immediately improve fatigue and quality of life.,"[{'ForeName': 'Marzieh', 'Initials': 'M', 'LastName': 'Mortezanejad', 'Affiliation': 'Neuromuscular Rehabilitation Research Centre, Semnan University of Medical Sciences, Semnan, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Ehsani', 'Affiliation': 'Neuromuscular Rehabilitation Research Centre, Semnan University of Medical Sciences, Semnan, Iran.'}, {'ForeName': 'Nooshin', 'Initials': 'N', 'LastName': 'Masoudian', 'Affiliation': 'Neurology Ward, Department of Internal Medicine, Kosar Hospital, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Zoghi', 'Affiliation': 'Discipline of Physiotherapy, Department of Rehabilitation, Nutrition and Sport, School of Allied Health, La Trobe University, Melbourne, VIC, Australia.'}, {'ForeName': 'Shapour', 'Initials': 'S', 'LastName': 'Jaberzadeh', 'Affiliation': 'Department of Physiotherapy, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.'}]",Clinical rehabilitation,['10.1177/0269215520921506'] 89,32398578,"The Effect of Semirecumbent and Right Lateral Positions on the Gastric Residual Volume of Mechanically Ventilated, Critically Ill Patients.","BACKGROUND Delay in stomach discharge is a challenge for patients who are tube fed and may result in serious side effects such as pneumonia and malnutrition. PURPOSE This study was designed to determine the respective effects of the semirecumbent (SR) supine and right lateral (RL) with a flatbed positions on the gastric residual volume (GRV) of mechanically ventilated, critically ill adult patients. METHODS A randomized, crossover clinical trial design was used to investigate GRV in 36 critically ill, ventilated adult patients who were hospitalized in the intensive care unit. GRV was measured at 3 hours after three consecutive feedings. GRV was first measured in all of the participants in the supine position; after which, participants were randomly assigned into one of two therapeutic positioning groups (Group A: assessment in the SR position and then the RL position; Group B: assessment in the RL position and then the SR position). RESULTS GRV was significantly lower in both the SR and RL positions than in the supine position. GRV in the SR and RL positions did not vary significantly. The in-group measurements for GRV did not significantly differ for any of the three positions. In Group A, GRV was significantly lower at each subsequent measurement point. CONCLUSION/IMPLICATIONS FOR PRACTICE Positioning patients in the RL and SR positions rather than in the supine position is an effective strategy to reduce GRV. Furthermore, placing patients in either the RL or SR position is an effective intervention to promote faster digestion and feedings.",2020,The in-group measurements for GRV did not significantly differ for any of the three positions.,"['mechanically ventilated, critically ill adult patients', 'Mechanically Ventilated, Critically Ill Patients', '36 critically ill, ventilated adult patients who were hospitalized in the intensive care unit']","['semirecumbent (SR) supine and right lateral (RL) with a flatbed positions', 'Semirecumbent and Right Lateral Positions']","['GRV', 'gastric residual volume (GRV']","[{'cui': 'C0042491', 'cui_str': 'Ventilation'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}]","[{'cui': 'C0038846', 'cui_str': 'Supine body position'}, {'cui': 'C0450415', 'cui_str': 'Lateral to the right'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0559228', 'cui_str': 'Right lateral decubitus position'}]","[{'cui': 'C3665864', 'cui_str': 'Gastric residual assessment'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",36.0,0.0318326,The in-group measurements for GRV did not significantly differ for any of the three positions.,"[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Farsi', 'Affiliation': ""1PhD, Associate Professor, Faculty of Nursing, Research Department and Community Health Department, Aja University of Medical Sciences, Tehran, Iran 2MSc, Researcher, Student Research Committee, Faculty of Nursing, Aja University of Medical Sciences, Tehran, Iran 3PhD, Assistant Professor, Harvard Medical School and Boston Children's Hospital, Boston, Massachusetts, USA 4PhD, Associate Professor, Faculty of Nursing, Community Health Department, Aja University of Medical Sciences, Tehran, Iran.""}, {'ForeName': 'Maaʼsoumeh', 'Initials': 'M', 'LastName': 'Kamali', 'Affiliation': ''}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Butler', 'Affiliation': ''}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Zareiyan', 'Affiliation': ''}]",The journal of nursing research : JNR,['10.1097/jnr.0000000000000377'] 90,32399253,"Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.","Objective SLE is a chronic inflammatory autoimmune disease characterised by the excessive production of autoantibodies, immune complexes and proinflammatory cytokines. Repository corticotropin injection (RCI) is a naturally sourced complex mixture of adrenocorticotropic hormone analogues and other pituitary peptides. RCI is approved by the US Food and Drug Administration for use during an exacerbation or as maintenance therapy in select cases of SLE. This paper discusses the design and baseline characteristics of a multicentre, double-blind, randomised, placebo-controlled, 24-week clinical trial evaluating the effect of RCI in reducing disease activity for patients with persistently active SLE despite moderate-dose corticosteroid use. Methods Efficacy will be evaluated using the SLE Responder Index-4 (SRI-4), SLE Disease Activity Index-2000 (SLEDAI-2K), British Isles Lupus Assessment Group-2004 (BILAG-2004) and Physician's Global Assessment (PGA). The primary efficacy endpoint will be the proportion of SRI-4 responders at week 16. Secondary and exploratory endpoints will include changes in disease activity scores over time, prednisone dose and biomarkers of inflammation and bone turnover. The safety and tolerability profile of RCI will also be evaluated through adverse event profiles, physical examination, clinical laboratory tests and serum cortisol levels. Results Target enrolment for this global study is 270 patients, and as of 15 November 2019, the modified intent-to-treat population included 169 patients. The study cohort had 91.7% women, had a mean age of 39.7 years, mean SLEDAI-2K total score of 9.9, mean BILAG-2004 total score of 18.1, mean PGA of 59.7 and mean prednisone or equivalent daily dose of 11.1 mg. A total of 79.3% and 64.5% of patients were receiving concomitant antimalarial or immunosuppressive therapy, respectively. Conclusions Data from this study will provide valuable insights into the therapeutic role of RCI in refractory SLE, as well as important information regarding its safety profile.",2020,"Methods Efficacy will be evaluated using the SLE Responder Index-4 (SRI-4), SLE Disease Activity Index-2000 (SLEDAI-2K), British Isles Lupus Assessment Group-2004 (BILAG-2004) and Physician's Global Assessment (PGA).","['patients with persistently active SLE despite moderate-dose corticosteroid use', '270 patients, and as of 15 November 2019, the modified intent-to-treat population included 169 patients', 'The study cohort had 91.7% women, had a mean age of 39.7 years, mean SLEDAI-2K total score of 9.9, mean BILAG-2004 total score of 18.1, mean PGA of 59.7 and mean prednisone or equivalent daily dose of 11.1\u2009mg']","['Repository corticotropin injection (RCI', 'RCI', 'Acthar Gel (repository corticotropin injection', 'placebo']","['proportion of SRI-4 responders', 'disease activity', 'safety and tolerability profile of RCI', ""SLE Responder Index-4 (SRI-4), SLE Disease Activity Index-2000 (SLEDAI-2K), British Isles Lupus Assessment Group-2004 (BILAG-2004) and Physician's Global Assessment (PGA"", 'disease activity scores over time, prednisone dose and biomarkers of inflammation and bone turnover']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0024141', 'cui_str': 'Systemic lupus erythematosus'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C4319603', 'cui_str': '270'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0451528', 'cui_str': 'Systemic lupus erythematosus disease activity index'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0020750', 'cui_str': 'Iceland'}, {'cui': 'C0024131', 'cui_str': 'Lupus vulgaris'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0001655', 'cui_str': 'Corticotropin'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0718234', 'cui_str': 'Acthar'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0024141', 'cui_str': 'Systemic lupus erythematosus'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0001655', 'cui_str': 'Corticotropin'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0451528', 'cui_str': 'Systemic lupus erythematosus disease activity index'}, {'cui': 'C0020750', 'cui_str': 'Iceland'}, {'cui': 'C0024131', 'cui_str': 'Lupus vulgaris'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0085268', 'cui_str': 'Bone remodeling'}]",,0.466664,"Methods Efficacy will be evaluated using the SLE Responder Index-4 (SRI-4), SLE Disease Activity Index-2000 (SLEDAI-2K), British Isles Lupus Assessment Group-2004 (BILAG-2004) and Physician's Global Assessment (PGA).","[{'ForeName': 'Anca D', 'Initials': 'AD', 'LastName': 'Askanase', 'Affiliation': 'Columbia University Medical Center, New York, New York, USA.'}, {'ForeName': 'Enxu', 'Initials': 'E', 'LastName': 'Zhao', 'Affiliation': 'Mallinckrodt Pharmaceuticals, Bedminster, New Jersey, USA.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Zhu', 'Affiliation': 'Mallinckrodt Pharmaceuticals, Bedminster, New Jersey, USA.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Connolly-Strong', 'Affiliation': 'Mallinckrodt Pharmaceuticals, Bedminster, New Jersey, USA.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Furie', 'Affiliation': 'Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.'}]",Lupus science & medicine,['10.1136/lupus-2020-000383'] 91,32397013,Comparison of Steroid Treatment with and without Hyperbaric Oxygen Therapy for Idiopathic Sudden Sensorineural Hearing Loss.,"BACKGROUND AND OBJECTIVES In this study, we compared the outcomes of patients with idiopathic sudden sensorineural hearing loss who underwent steroid treatment with or without hyperbaric oxygen (HBO) therapy and were followed-up in our clinic. SUBJECTS AND METHODS Patients were divided into two groups according to their treatment regimen. Steroid group received intravenous 1 mg/kg methylprednisolone which was due to be completed in 2-3 weeks with decreasing doses, and five doses of 0.5 mL intratympanic dexamethasone. Steroid+HBO group received the same steroid treatment with the addition of HBO therapy. The audiologic results of both treatment groups were compared after considering the patients' risk factors. RESULTS There was no significant difference between the steroid and Steroid+HBO groups in terms of hearing gain and degree of recovery, both at all degrees of hearing loss, and in severe and profound hearing loss. Hearing gain was similar when evaluated by audiogram type and admission time in both treatment groups. CONCLUSIONS We found that the addition of HBO therapy to systemic plus intratympanic steroid treatment did not affect hearing gain at all degrees of hearing loss in this study. Furthermore, audiogram type and admission time did not affect hearing gain between the two groups.",2020,"There was no significant difference between the steroid and Steroid+HBO groups in terms of hearing gain and degree of recovery, both at all degrees of hearing loss, and in severe and profound hearing loss.","['Idiopathic Sudden Sensorineural Hearing Loss', 'Subjects and Methods\n\n\nPatients', 'patients with idiopathic sudden sensorineural hearing loss who underwent']","['steroid treatment with or without hyperbaric oxygen (HBO) therapy', 'dexamethasone', 'Steroid+HBO', 'Steroid Treatment with and without Hyperbaric Oxygen Therapy', 'intravenous 1 mg/kg methylprednisolone']","['audiogram type and admission time', 'Furthermore, audiogram type and admission time', 'hearing gain and degree of recovery, both at all degrees of hearing loss, and in severe and profound hearing loss', 'Hearing gain', 'hearing gain', 'hearing loss']","[{'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C4275242', 'cui_str': 'Sudden sensorineural hearing loss'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0149783', 'cui_str': 'Administration of steroid'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0020431', 'cui_str': 'Hyperbaric oxygen therapy'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}]","[{'cui': 'C0018786', 'cui_str': 'Hearing examination'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0439808', 'cui_str': 'Profound'}, {'cui': 'C0011053', 'cui_str': 'Deafness'}]",,0.0292978,"There was no significant difference between the steroid and Steroid+HBO groups in terms of hearing gain and degree of recovery, both at all degrees of hearing loss, and in severe and profound hearing loss.","[{'ForeName': 'Abitter', 'Initials': 'A', 'LastName': 'Yücel', 'Affiliation': 'Department of Otorhinolaryngology Head and Neck Surgery, Konya Health Application and Research Center, University of Health Sciences Turkey, Konya, Turkey.'}, {'ForeName': 'Yaşar', 'Initials': 'Y', 'LastName': 'Özbuğday', 'Affiliation': 'Department of Otorhinolaryngology Head and Neck Surgery, Konya Training and Research Hospital, University of Health Sciences Turkey, Konya, Turkey.'}]",Journal of audiology & otology,['10.7874/jao.2019.00486'] 92,32334033,Acute Toxicity and Quality of Life of Hypofractionated Radiation Therapy for Breast Cancer.,"PURPOSE To assess the acute toxicity and quality of life (QOL) of hypofractionation compared with conventional fractionation for whole breast irradiation (WBI) after breast-conserving surgery. METHODS AND MATERIALS Women with node-negative breast cancer who had undergone breast-conserving surgery with clear margins were randomly assigned to conventional WBI of 5000 cGy in 25 fractions over 35 days or hypofractionated WBI of 4256 cGy in 16 fractions over 22 days. Acute skin toxicity and QOL were assessed at baseline and 2, 4, 6, and 8 weeks from the start of treatment for a subgroup of patients. QOL was assessed at baseline and 4 weeks posttreatment for all patients. In the acute toxicity substudy, repeated measures modeling was used to investigate treatment by time interactions over the 8-week period for acute toxicity and QOL mean change score. QOL mean change score from baseline to 4 weeks posttreatment was compared for all patients. RESULTS In the acute toxicity substudy, 161 patients participated. In the main trial, 1152 patients participated. Acute skin toxicity was initially similar between groups but was less with hypofractionation compared with conventional fractionation toward the end of the 8-week period (P < .001). QOL at 6 weeks from the start of treatment was improved with hypofractionation for the skin side effects, breast side effects, fatigue, attractiveness, and convenience domains (all P < .05). In the main trial, hypofractionation resulted in improved overall QOL and QOL attributed to skin side effects, breast side effects, and attractiveness (all P < .01). CONCLUSIONS Hypofractionated WBI compared with conventional WBI resulted in less acute toxicity and improved QOL. This further supports the benefits of hypofractionation.",2020,"QOL at 6 weeks from the start of treatment was improved with hypofractionation for the skin side effects, breast side effects, fatigue, attractiveness and convenience domains (all p < 0.05).","['1152 patients participated', 'Breast Cancer', 'Women with node negative breast cancer who had undergone BCS with clear margins']","['Hypofractionated Radiotherapy', 'conventional WBI', 'conventional fractionation for whole breast irradiation (WBI) following breast conserving surgery (BCS', 'conventional WBI of 5000 cGy in 25 fractions over 35 days or hypofractionated WBI']","['skin side effects, breast side effects, fatigue, attractiveness and convenience domains', 'acute toxicity and improved QOL', 'acute toxicity and QOL mean change score', 'QOL mean change score', 'Acute skin toxicity', 'QOL attributed to skin side effects, breast side effects, and attractiveness', 'QOL', 'Acute Toxicity and Quality of Life', 'Acute skin toxicity and QOL', 'overall QOL', 'acute toxicity and quality of life (QOL']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3160889', 'cui_str': 'Node-negative breast cancer'}, {'cui': 'C0917927', 'cui_str': 'Breast conserving surgery'}, {'cui': 'C1709157', 'cui_str': 'Tumor-Free Margins'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0457102', 'cui_str': 'Whole breast'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0524811', 'cui_str': 'Dose Fractionation, Radiotherapy'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0917927', 'cui_str': 'Breast conserving surgery'}, {'cui': 'C4319610', 'cui_str': '5000'}, {'cui': 'C0556645', 'cui_str': 'cGy'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1167791', 'cui_str': 'Skin toxicity'}, {'cui': 'C0449234', 'cui_str': 'Attribute'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",1152.0,0.104901,"QOL at 6 weeks from the start of treatment was improved with hypofractionation for the skin side effects, breast side effects, fatigue, attractiveness and convenience domains (all p < 0.05).","[{'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Arsenault', 'Affiliation': 'Department of Radiation Oncology, Dr. Léon Richard Oncology Centre, Moncton, New Brunswick, Canada.'}, {'ForeName': 'Sameer', 'Initials': 'S', 'LastName': 'Parpia', 'Affiliation': 'Department of Oncology, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Mira', 'Initials': 'M', 'LastName': 'Goldberg', 'Affiliation': 'Division of Radiation Oncology, Juravinski Cancer Centre, Hamilton, Ontario, Canada.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Rakovitch', 'Affiliation': 'Department of Radiation Oncology, University of Toronto and Odette Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Harold', 'Initials': 'H', 'LastName': 'Reiter', 'Affiliation': 'Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, Ontario, Canada.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Doherty', 'Affiliation': 'Department of Radiation Oncology, University of Toronto and Odette Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Himu', 'Initials': 'H', 'LastName': 'Lukka', 'Affiliation': 'Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, Ontario, Canada.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Sussman', 'Affiliation': 'Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, Ontario, Canada.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Wright', 'Affiliation': 'Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, Ontario, Canada.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Julian', 'Affiliation': 'Department of Oncology, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Whelan', 'Affiliation': 'Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, Ontario, Canada. Electronic address: twhelan@hhsc.ca.'}]","International journal of radiation oncology, biology, physics",['10.1016/j.ijrobp.2020.03.049'] 93,32333897,"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.","BACKGROUND Azathioprine is used as a first-line treatment to prevent relapses of neuromyelitis optica spectrum disorder (NMOSD). Tocilizumab has been reported to reduce NMOSD disease activity in retrospective case reports. We aimed to compare the safety and efficacy of tocilizumab and azathioprine in patients with highly relapsing NMOSD. METHODS We did an open-label, multicentre, randomised, phase 2 trial at six hospitals in China. We recruited adult patients (aged ≥18 years) with highly relapsing NMOSD diagnosed according to 2015 International Panel for Neuromyelitis Optica Diagnosis criteria, who had an Expanded Disability Status Scale (EDSS) score of 7·5 or lower, and had a history of at least two clinical relapses during the previous 12 months or three relapses during the previous 24 months with at least one relapse within the previous 12 months. Patients were randomly assigned (1:1) to intravenous tocilizumab (8 mg/kg every 4 weeks) or oral azathioprine (2-3 mg/kg per day) by an independent statistician using computer-generated randomisation software with permuted blocks of four. The central review committee, EDSS raters, laboratory personnel, and radiologists were masked to the treatment assignment, but investigators and patients were aware of treatment allocation. The minimum planned duration of treatment was 60 weeks following randomisation. The primary outcome was time to first relapse in the full analysis set, which included all randomly assigned patients who received at least one dose of study drug, and the per-protocol population, which included all patients who used azathioprine or tocilizumab as monotherapy. For the analyses of the primary outcome, the patients were prespecified into two subgroups according to concomitant autoimmune disease status. Safety was assessed in the full analysis set. This study is registered with ClinicalTrials.gov, NCT03350633. FINDINGS Between Nov 1, 2017, and Aug 3, 2018, we enrolled 118 patients, of whom 59 were randomly assigned to tocilizumab and 59 were randomly assigned to azathioprine. All 118 patients received one dose of study drug and were included in the full analysis set. 108 participants were included in the per-protocol analysis (56 in the tocilizumab group and 52 in the azathioprine group). In the full analysis set, median time to the first relapse was longer in the tocilizumab group than the azathioprine group (78·9 weeks [IQR 58·3-90·6] vs 56·7 [32·9-81·7] weeks; p=0·0026). Eight (14%) of 59 patients in the tocilizumab group and 28 (47%) of 59 patients in the azathioprine group had a relapse at the end of the study (hazard ratio [HR] 0·236 [95% CI 0·107-0·518]; p<0·0001). In the per-protocol analysis, 50 (89%) of 56 patients in the tocilizumab group were relapse-free compared with 29 (56%) of 52 patients in the azathioprine group at the end of the study (HR 0·188 [95% CI 0·076-0·463]; p<0·0001); the median time to first relapse was also longer in the tocilizumab group than the azathioprine group (67·2 weeks [IQR 47·9-77·9] vs 38·0 [23·6-64·9]; p<0·0001). In the prespecified subgroup analysis of the full analysis set stratified by concomitant autoimmune diseases, among patients without concomitant autoimmune diseases, three (9%) of 34 patients in the tocilizumab group and 13 (35%) of 37 patients in the azathioprine group had relapsed by the end of the study. Among patients with concomitant autoimmune diseases, a lower proportion of patients in the tocilizumab group had a relapse than in the azathioprine group (five [20%] of 25 patients vs 15 [68%] of 22 patients; HR 0·192 [95% CI 0·070-0·531]; p=0·0004). 57 (97%) of 59 patients in the tocilizumab group and 56 (95%) of 59 patients in the azathioprine group had adverse events. Treatment-associated adverse events occurred in 36 (61%) of 59 tocilizumab-treated patients and 49 (83%) of 59 azathioprine-treated patients. One death (2%) occurred in the tocilizumab group and one (2%) in the azathioprine group, but neither of the deaths were treatment-related. INTERPRETATION Tocilizumab significantly reduced the risk of a subsequent NMOSD relapse compared with azathioprine. Tocilizumab might therefore be another safe and effective treatment to prevent relapses in patients with NMOSD. FUNDING Tianjin Medical University, Advanced Innovation Center for Human Brain Protection, National Key Research and Development Program of China, National Science Foundation of China.",2020,Treatment-associated adverse events occurred in 36 (61%) of 59 tocilizumab-treated patients and 49 (83%) of 59 azathioprine-treated patients.,"['Between Nov 1, 2017, and Aug 3, 2018, we enrolled 118 patients, of whom 59 were randomly assigned to', 'patients with highly relapsing NMOSD', 'adult patients (aged ≥18 years) with highly relapsing NMOSD diagnosed according to 2015 International Panel for Neuromyelitis Optica', '108 participants were included in the per-protocol analysis (56 in the tocilizumab group and 52 in the azathioprine group', '0·236', 'six hospitals in China', 'highly relapsing neuromyelitis optica spectrum disorder (TANGO', 'patients with NMOSD', 'All 118 patients received one dose of study drug and were included in the full analysis set']","['oral azathioprine', 'Azathioprine', 'Tocilizumab', 'tocilizumab', 'azathioprine', 'intravenous tocilizumab', 'tocilizumab and azathioprine', 'azathioprine or tocilizumab as monotherapy']","['median time to first relapse', 'adverse events', 'Safety', 'risk of a subsequent NMOSD relapse', 'Expanded Disability Status Scale (EDSS) score', 'time to first relapse', 'Safety and efficacy', 'relapse-free', 'safety and efficacy', 'relapse', 'median time to the first relapse']","[{'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0027873', 'cui_str': 'Neuromyelitis optica'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1609165', 'cui_str': 'tocilizumab'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0004482', 'cui_str': 'Azathioprine'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0013175', 'cui_str': 'Clinical drug trial'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0004482', 'cui_str': 'Azathioprine'}, {'cui': 'C1609165', 'cui_str': 'tocilizumab'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C4087551', 'cui_str': 'Neuromyelitis optica spectrum disorder relapse'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0332296', 'cui_str': 'Free of'}]",118.0,0.235391,Treatment-associated adverse events occurred in 36 (61%) of 59 tocilizumab-treated patients and 49 (83%) of 59 azathioprine-treated patients.,"[{'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': 'Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China; China National Clinical Research Center for Neurological Diseases, Advanced Innovation Center for Human Brain Protection, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Meini', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Department of Neurology, First Hospital of Shanxi Medical University, Taiyuan, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Qiu', 'Affiliation': 'Department of Neurology, Third Hospital of Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Hongshan', 'Initials': 'H', 'LastName': 'Ma', 'Affiliation': ""The Third People's Hospital of Datong, School of Clinical Medicine, Shanxi Medical University, Datong, China.""}, {'ForeName': 'Xinghu', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'China National Clinical Research Center for Neurological Diseases, Advanced Innovation Center for Human Brain Protection, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Zilong', 'Initials': 'Z', 'LastName': 'Zhu', 'Affiliation': 'Department of Neurology, Huanhu Hospital, Tianjin, China.'}, {'ForeName': 'Chun-Sheng', 'Initials': 'CS', 'LastName': 'Yang', 'Affiliation': 'Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Dongmei', 'Initials': 'D', 'LastName': 'Jia', 'Affiliation': 'Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Tian-Xiang', 'Initials': 'TX', 'LastName': 'Zhang', 'Affiliation': 'Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Yuan', 'Affiliation': 'Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Feng', 'Affiliation': 'Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Wenli', 'Initials': 'W', 'LastName': 'Lu', 'Affiliation': 'School of Public Health, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Chunshui', 'Initials': 'C', 'LastName': 'Yu', 'Affiliation': 'Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China; School of Radiology, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Jeffrey L', 'Initials': 'JL', 'LastName': 'Bennett', 'Affiliation': 'Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado, Denver School of Medicine, Aurora, CO, USA.'}, {'ForeName': 'Fu-Dong', 'Initials': 'FD', 'LastName': 'Shi', 'Affiliation': 'Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China; China National Clinical Research Center for Neurological Diseases, Advanced Innovation Center for Human Brain Protection, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Electronic address: fshi@tmu.edu.cn.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Neurology,['10.1016/S1474-4422(20)30070-3'] 94,32333898,"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.","BACKGROUND Satralizumab, a humanised monoclonal antibody targeting the interleukin-6 receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) when added to immunosuppressant therapy. This study assessed the safety and efficacy of satralizumab monotherapy in patients with the disorder. METHODS In this phase 3, double-blind, placebo-controlled, parallel-group trial, we enrolled adults aged 18-74 years with aquaporin-4 antibody seropositive or seronegative NMOSD at 44 investigational sites in 13 countries. Eligible participants had experienced at least one documented NMOSD attack or relapse in the past 12 months and had a score of 6·5 or less on the Expanded Disability Status Scale. Exclusion criteria included clinical relapse 30 days or fewer before baseline. Participants were randomly assigned (2:1) to receive satralizumab 120 mg or visually matched placebo subcutaneously at weeks 0, 2, 4, and every 4 weeks thereafter. Taking immunosuppressants concomitantly was prohibited. The primary endpoint was time to the first protocol-defined relapse, based on the intention-to-treat population and analysed with stratification for two randomisation factors (previous therapy for prevention of attacks and nature of the most recent attack). Safety was assessed in all participants who received at least one dose of satralizumab or placebo. The double-blind phase was due to last until 44 protocol-defined relapses occurred or 1·5 years after random assignment of the last patient enrolled, whichever occurred first; participants could enter an open-label phase after the occurrence of a protocol-defined relapse or at the end of the double-blind phase. The study is registered with ClinicalTrials.gov, NCT02073279. FINDINGS 95 (57%) of 168 screened participants were randomly assigned to treatment (63 to satralizumab; 32 to placebo) between Aug 5, 2014, and April 2, 2017. Protocol-defined relapses occurred in 19 (30%) patients receiving satralizumab and 16 (50%) receiving placebo (hazard ratio 0·45, 95% CI 0·23-0·89; p=0·018). 473·9 adverse events per 100 patient-years occurred in the satralizumab group, as did 495·2 per 100 patient-years in the placebo group; the incidence of serious adverse events and adverse events leading to withdrawal was similar between groups. INTERPRETATION Satralizumab monotherapy reduced the rate of NMOSD relapse compared with placebo in the overall trial population, with a favourable safety profile. The patient population included a ratio of aquaporin-4 antibody seropositive and seronegative patients that was reflective of clinical practice. Satralizumab has the potential to become a valuable treatment option for patients with NMOSD. FUNDING Chugai Pharmaceutical (Roche).",2020,"BACKGROUND Satralizumab, a humanised monoclonal antibody targeting the interleukin-6 receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) when added to immunosuppressant therapy.","['enrolled adults aged 18-74 years with aquaporin-4 antibody seropositive or seronegative NMOSD at 44 investigational sites in 13 countries', 'patients with neuromyelitis optica spectrum disorder (NMOSD', 'neuromyelitis optica spectrum disorder', 'patients with the disorder', '95 (57%) of 168 screened participants', 'patients with NMOSD']","['placebo', 'satralizumab or placebo', 'Satralizumab', 'satralizumab monotherapy', 'satralizumab 120 mg or visually matched placebo']","['473·9 adverse events', 'Expanded Disability Status Scale', 'rate of NMOSD relapse', 'Safety', 'Protocol-defined relapses', 'Safety and efficacy', 'NMOSD attack or relapse', 'safety and efficacy', 'incidence of serious adverse events and adverse events leading to withdrawal', 'time to the first protocol-defined relapse, based on the intention-to-treat population']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C2919772', 'cui_str': 'Aquaporin-4 antibody'}, {'cui': 'C0521143', 'cui_str': 'Seropositive'}, {'cui': 'C0521144', 'cui_str': 'Seronegative'}, {'cui': 'C0027873', 'cui_str': 'Neuromyelitis optica'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C4319556', 'cui_str': '168'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale'}, {'cui': 'C4087551', 'cui_str': 'Neuromyelitis optica spectrum disorder relapse'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C4087481', 'cui_str': 'Neuromyelitis optica spectrum disorder attack'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}]",,0.694031,"BACKGROUND Satralizumab, a humanised monoclonal antibody targeting the interleukin-6 receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) when added to immunosuppressant therapy.","[{'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Traboulsee', 'Affiliation': 'Department of Neurology, University of British Columbia, Vancouver, BC, Canada. Electronic address: t.traboulsee@ubc.ca.'}, {'ForeName': 'Benjamin M', 'Initials': 'BM', 'LastName': 'Greenberg', 'Affiliation': 'Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Jeffrey L', 'Initials': 'JL', 'LastName': 'Bennett', 'Affiliation': 'Departments of Neurology and Ophthalmology, University of Colorado School of Medicine, Aurora, CO, USA.'}, {'ForeName': 'Lech', 'Initials': 'L', 'LastName': 'Szczechowski', 'Affiliation': 'Silesian Centre of Neurology, Medical University of Silesia, Katowice, Poland.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Fox', 'Affiliation': 'Central Texas Neurology Consultants, Round Rock, TX, USA.'}, {'ForeName': 'Svitlana', 'Initials': 'S', 'LastName': 'Shkrobot', 'Affiliation': 'Department of Neurology, Psychiatry, Narcology and Medical Psychology, Ternopil State Medical University, Ternopil, Ukraine.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Yamamura', 'Affiliation': 'Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Terada', 'Affiliation': 'Chugai Pharmaceutical, Tokyo, Japan.'}, {'ForeName': 'Yuichi', 'Initials': 'Y', 'LastName': 'Kawata', 'Affiliation': 'Chugai Pharmaceutical, Tokyo, Japan.'}, {'ForeName': 'Padraig', 'Initials': 'P', 'LastName': 'Wright', 'Affiliation': 'Chugai Pharma Europe, London, UK.'}, {'ForeName': 'Athos', 'Initials': 'A', 'LastName': 'Gianella-Borradori', 'Affiliation': 'Servier Laboratories, Suresnes, Paris, France.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Garren', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Brian G', 'Initials': 'BG', 'LastName': 'Weinshenker', 'Affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}]",The Lancet. Neurology,['10.1016/S1474-4422(20)30078-8'] 95,32334332,The effects of consecutive sessions of anodal transcranial direct current stimulation over the primary motor cortex on hand function in healthy older adults.,"BACKGROUND With advancing age, changes in the central nervous system may lead to motor functional deficits. Non-invasive brain stimulation techniques are suggested to help modifying brain function. OBJECTIVES The aim of the current study was to investigate the effect of using multi session anodal transcranial Direct Current Stimulation (a-tDCS) over the primary motor cortex (M1) on the hand function in healthy older adults. METHOD In this randomized, double-blinded, sham-controlled study 32 participants received active or sham a-tDCS (1 mA, 20 min, for five consecutive days) and performed the Purdue Pegboard Test (PPT) on the first day before tDCS application, immediately (T1), 30 min (T2), and one week after the last session (5th day) (T3) of the stimulation. RESULTS There was a significant improvement for PPT (p < 0.05) in a-tDCS group at all post-test values except for PPT for left hand (PPTL) at T1. Compared to the sham group, the results indicated significant improvement in all PPT subtests (P < 0.05), except for PPTL at T1, PPT for both hands at T2 and PPT assembly at T3 in a-tDCS group. CONCLUSION The current findings suggest a-tDCS can be considered as a promising stand-alone technique in the intervention of the age-related decline of manual dexterity for improving hand function.",2020,"Compared to the sham group, the results indicated significant improvement in all PPT subtests (P < 0.05), except for PPTL at T1, PPT for both hands at T2 and PPT assembly at T3 in a-tDCS group. ","['32 participants received', 'healthy older adults']","['multi session anodal transcranial Direct Current Stimulation (a-tDCS', 'active or sham a-tDCS', 'anodal transcranial direct current stimulation']","['PPT', 'PPT subtests']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0204462', 'cui_str': 'Purdue pegboard test'}]",32.0,0.0611213,"Compared to the sham group, the results indicated significant improvement in all PPT subtests (P < 0.05), except for PPTL at T1, PPT for both hands at T2 and PPT assembly at T3 in a-tDCS group. ","[{'ForeName': 'Mohamad', 'Initials': 'M', 'LastName': 'Rostami', 'Affiliation': 'Research Center on Aging, Department of Physiotherapy, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Mosallanezhad', 'Affiliation': 'Research Center on Aging, Department of Physiotherapy, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. Electronic address: zmosallanezhad@yahoo.com.'}, {'ForeName': 'Sepideh', 'Initials': 'S', 'LastName': 'Ansari', 'Affiliation': 'Musculoskeletal Rehabilitation Research Center, Speech Therapy Department, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran.'}, {'ForeName': 'Dawson', 'Initials': 'D', 'LastName': 'Kidgell', 'Affiliation': 'Department of Physiotherapy, School of Primary Health Care, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia.'}, {'ForeName': 'Tahere', 'Initials': 'T', 'LastName': 'Rezaeian', 'Affiliation': 'Research Center on Aging, Department of Physiotherapy, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.'}, {'ForeName': 'Enayatollah', 'Initials': 'E', 'LastName': 'Bakhshi', 'Affiliation': 'Department of Biostatistics, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Ghodrati', 'Affiliation': 'Health and Rehabilitation Sciences Program, University of Western Ontario, London, Canada.'}, {'ForeName': 'Shapour', 'Initials': 'S', 'LastName': 'Jaberzadeh', 'Affiliation': 'Department of Physiotherapy, School of Primary Health Care, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia.'}]",Archives of gerontology and geriatrics,['10.1016/j.archger.2020.104063'] 96,32305531,Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) procedure for colorectal liver metastasis.,"Since first described, Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) has garnered boisterous praise and fervent criticism. Its rapid adoption and employment for a variety of indications resulted in high perioperative morbidity and mortality. However recent risk stratification, refinement of technique to reduce the impact of stage I and progression along the learning curve have resulted in improved outcomes. The first randomized trial comparing ALPPS to two stage hepatectomy (TSH) for colorectal liver metastases (CRLM) was recently published demonstrating comparable perioperative morbidity and mortality with improved resectability and survival following ALPPS. In this review, as ALPPS enters the thirteenth year since conception, the current status of this contentious two stage technique is presented and best practices for deployment in the treatment of CRLM is codified.",2020,The first randomized trial comparing ALPPS to two stage hepatectomy (TSH) for colorectal liver metastases (CRLM) was recently published demonstrating comparable perioperative morbidity and mortality with improved resectability following ALPPS.,['colorectal liver metastases (CRLM'],"['Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS', 'stage hepatectomy (TSH', 'ALPPS', 'Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Procedure']",[],"[{'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C0494165', 'cui_str': 'Secondary malignant neoplasm of liver'}]","[{'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0032718', 'cui_str': 'Portal vein structure'}, {'cui': 'C0023690', 'cui_str': 'Ligation'}, {'cui': 'C0019144', 'cui_str': 'Liver excision'}, {'cui': 'C0301811', 'cui_str': 'Alkaline phosphatase isoenzyme, placental fraction'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0025664', 'cui_str': 'methods'}]",[],,0.0558555,The first randomized trial comparing ALPPS to two stage hepatectomy (TSH) for colorectal liver metastases (CRLM) was recently published demonstrating comparable perioperative morbidity and mortality with improved resectability following ALPPS.,"[{'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Hernandez-Alejandro', 'Affiliation': 'Department of Surgery and Division of Abdominal Transplantation and Hepatobiliary Surgery, University of Rochester Medical Center, Rochester, USA. Electronic address: Roberto_Hernandez@urmc.rochester.edu.'}, {'ForeName': 'Luis I', 'Initials': 'LI', 'LastName': 'Ruffolo', 'Affiliation': 'Department of Surgery and Division of Abdominal Transplantation and Hepatobiliary Surgery, University of Rochester Medical Center, Rochester, USA.'}, {'ForeName': 'Ruslan', 'Initials': 'R', 'LastName': 'Alikhanov', 'Affiliation': 'Department of Liver and Pancreatic Surgery, Clinical Research Center of Moscow, Moscow, Russia.'}, {'ForeName': 'Bergthor', 'Initials': 'B', 'LastName': 'Björnsson', 'Affiliation': 'Department of Surgery in Linköping, And Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Orlando Jorge M', 'Initials': 'OJM', 'LastName': 'Torres', 'Affiliation': 'Department of Gastrointestinal Surgery, Hepatopancreatobiliary Unit, University Hospital and School of Medicine, Federal University of Maranhão, São Luís, Brazil.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Serrablo', 'Affiliation': 'Division of Surgery, Miguel Servet University Hospital and University of Zaragoza School of Medicine, Zaragoza, Spain.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2020.04.009'] 97,32354661,How continuum beliefs can reduce stigma of schizophrenia: The role of perceived similarities.,"Growing evidence has shown continuum beliefs as a promising tool to reduce psychiatric stigma in the general population, but data still lack regarding mechanisms underlying this effect. This study aims at testing the hypothesis that continuum beliefs affect public stigma and self-stigma by increasing perceived similarities between oneself and people with schizophrenia. Perceiving such similarities may reduce public stigma and increase self-stigma in the general population. The current study was preregistered on OSF. Data were collected via an on-line survey (N = 565). Participants were randomly assigned to one of the three experimental conditions. Continuum beliefs were induced with short videos supporting either a continuum viewpoint of schizophrenia, a categorial viewpoint of schizophrenia, or a neutral video. A scale of Perceived similarities between oneself and people with schizophrenia was administered. Public stigma was measured with an Essentialism scale and Self-stigma with a scale of self-stereotype association. Mediation analyses showed that the effects of categorial and continuum beliefs on essentialism and self-stereotype association were mediated by perceived similarities. Our results suggest that continuum beliefs about schizophrenia act as a recategorization mechanism, by enhancing perceived similarities with the stereotyped group.",2020,Mediation analyses showed that the effects of categorial and continuum beliefs on essentialism and self-stereotype association were mediated by perceived similarities.,[],[],"['essentialism and self-stereotype association', 'public stigma and increase self-stigma', 'public stigma and self-stigma', 'Public stigma', 'stigma of schizophrenia']",[],[],"[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0038272', 'cui_str': 'Stereotyping'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0277787', 'cui_str': 'Stigma'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}]",565.0,0.0332623,Mediation analyses showed that the effects of categorial and continuum beliefs on essentialism and self-stereotype association were mediated by perceived similarities.,"[{'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'Violeau', 'Affiliation': 'Laboratory of Psychology EA 4139, University of Bordeaux, France. Electronic address: louis.violeau-beaugendre@u-bordeaux.fr.'}, {'ForeName': 'Kevin-Marc', 'Initials': 'KM', 'LastName': 'Valery', 'Affiliation': 'Laboratory of Psychology EA 4139, University of Bordeaux, France; Adult Psychiatric Hospital of Jonzac, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Fournier', 'Affiliation': 'Laboratory of Psychology EA 4139, University of Bordeaux, France; Adult Psychiatric Hospital of Jonzac, France.'}, {'ForeName': 'Antoinette', 'Initials': 'A', 'LastName': 'Prouteau', 'Affiliation': 'Laboratory of Psychology EA 4139, University of Bordeaux, France; Adult Psychiatric Hospital of Jonzac, France.'}]",Schizophrenia research,['10.1016/j.schres.2020.04.014'] 98,32357088,"Are Low-Income, Diverse Mothers Able to Meet Breastfeeding Intentions After 2 Months of Breastfeeding?","Background: Little is known about intended breastfeeding duration of women who initiate breastfeeding. We describe the association between intended and actual breastfeeding duration among low-income, diverse mothers who report maintaining breastfeeding for the first 2 months postpartum. Materials and Methods: We included mothers (64% Hispanic, 17% non-Hispanic black) participating in Greenlight, a cluster randomized childhood obesity prevention trial, who were providing breast milk at the 2-month preventive service visit and reported intended breastfeeding duration at this visit. Breastfeeding status was assessed at subsequent visits, up to 24 months. Poisson regression with a robust variance estimator was used to estimate risk ratios and 95% confidence intervals for meeting breastfeeding intentions. Covariates included race/ethnicity, income, receiving benefits from the Special Supplemental Nutrition Assistance Program for Women, Infants and Children (WIC), education, age, employment, depression, maternal obesity, U.S. born, whether infant was first born, and study site. Results: Median intended breastfeeding duration was 11.5 months (interquartile range [IQR]: 6-12) and median actual breastfeeding duration was 8.6 months (IQR: 4-14) ( n  = 349). Approximately half (49%) met intended breastfeeding duration. Breastfeeding duration differed based on milk type provided at the 2-month visit in that mothers providing mostly or only breast milk had increased likelihood of meeting breastfeeding intentions. Regardless of milk type provided at 2 months, the longer a mother intended to breastfeed, the less likely she was to meet her breastfeeding intentions. Conclusions: In this diverse sample of women less than half met breastfeeding intentions despite maintaining breastfeeding for 2 months. Understanding factors that prevent mothers from attaining intended breastfeeding duration is critical to improving breastfeeding outcomes, especially in low income and ethnic minority populations.",2020,"Regardless of milk type provided at 2 months, the longer a mother intended to breastfeed, the less likely she was to meet her breastfeeding intentions. ","['mothers (64% Hispanic, 17% non-Hispanic black) participating in Greenlight, a cluster randomized childhood obesity prevention trial, who were providing breast milk at the 2-month preventive service visit and reported intended breastfeeding duration at this visit', 'low-income, diverse mothers who report maintaining breastfeeding for the first 2 months postpartum', 'for Women, Infants and Children (WIC), education, age, employment, depression, maternal obesity, U.S. born, whether infant was first born, and study site']",['Special Supplemental Nutrition Assistance Program'],"['Median intended breastfeeding duration', 'Breastfeeding status', 'median actual breastfeeding duration', 'Breastfeeding duration', 'likelihood of meeting breastfeeding intentions']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C2362324', 'cui_str': 'Childhood obesity'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0199175', 'cui_str': 'Preventive service'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0746977', 'cui_str': 'Maternal Obesity'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205145', 'cui_str': 'Site'}]","[{'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C3494397', 'cui_str': 'SNAP Program'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]",,0.0397174,"Regardless of milk type provided at 2 months, the longer a mother intended to breastfeed, the less likely she was to meet her breastfeeding intentions. ","[{'ForeName': 'Melissa C', 'Initials': 'MC', 'LastName': 'Kay', 'Affiliation': 'Duke University, Durham, North Carolina, USA.'}, {'ForeName': 'Rushina', 'Initials': 'R', 'LastName': 'Cholera', 'Affiliation': 'Duke University, Durham, North Carolina, USA.'}, {'ForeName': 'Kori B', 'Initials': 'KB', 'LastName': 'Flower', 'Affiliation': 'University of North Carolina, Chapel Hill, North Carolina, USA.'}, {'ForeName': 'H Shonna', 'Initials': 'HS', 'LastName': 'Yin', 'Affiliation': 'New York University School of Medicine, New York, New York, USA.'}, {'ForeName': 'Russell L', 'Initials': 'RL', 'LastName': 'Rothman', 'Affiliation': 'Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Lee M', 'Initials': 'LM', 'LastName': 'Sanders', 'Affiliation': 'Stanford University, Stanford, California, USA.'}, {'ForeName': 'Alan M', 'Initials': 'AM', 'LastName': 'Delamater', 'Affiliation': 'University of Miami School of Medicine, Miami, Florida, USA.'}, {'ForeName': 'Eliana M', 'Initials': 'EM', 'LastName': 'Perrin', 'Affiliation': 'Duke University, Durham, North Carolina, USA.'}]",Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine,['10.1089/bfm.2020.0025'] 99,32367393,Comparison of the standard and triple airway maneuvering techniques for i-gel™ placement in patients undergoing elective surgery: a randomized controlled study.,"PURPOSE The i-gel is a supraglottic airway device with non-inflatable cuff which can suffer insertion failure if its standard placement technique is implemented. The aim of this study was to compare the placement technique proposed by the manufacturer of i-gel with the triple airway maneuver in terms of successful device insertion time and first-attempt success. METHODS After ethics committee approval, 103 ASA I-III patients were randomly allocated to the standard or triple airway maneuver groups. In the standard Group, the i-gel was inserted in the sniffing position while, in the triple group, it was inserted using the triple airway maneuver consisting of head tilt, jaw thrust, and open mouth. The time taken for successful insertion, first-attempt success rate, i-gel position, airway complications, and hemodynamic responses were assessed. RESULTS Between the two groups patient characteristics were similar. Time for successful insertion was significantly shorter in the triple group (20 ± 7 s) than with the standard technique (32 ± 11 s; p < 0.001). Successful insertion at the first attempt was 78% and 92% for the standard and triple group, respectively (p = 0.092). The i-gel position, airway complications, and hemodynamic responses were similar in both groups. CONCLUSION The triple airway maneuver required less i-gel insertion time as compared with the standard placement technique. First-attempt success rates were similar with both techniques, although the triple airway maneuver was superior to the standard method as a rescue technique in failed insertions. We therefore recommend use of the triple airway maneuver in i-gel insertion.",2020,"First-attempt success rates were similar with both techniques, although the triple airway maneuver was superior to the standard method as a rescue technique in failed insertions.","['patients undergoing elective surgery', '103 ASA I-III patients']",['standard and triple airway maneuvering techniques'],"['time taken for successful insertion, first-attempt success rate, i-gel position, airway complications, and hemodynamic responses', 'Time for successful insertion', 'airway complications, and hemodynamic responses']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}]",103.0,0.0395813,"First-attempt success rates were similar with both techniques, although the triple airway maneuver was superior to the standard method as a rescue technique in failed insertions.","[{'ForeName': 'İlkay', 'Initials': 'İ', 'LastName': 'Baran Akkuş', 'Affiliation': 'Department of Anesthesiology and Reanimation, University of Health Sciences, Diskapi Yildirim Beyazit Trainig and Research Hospital, Sehit Ömer Halisdemir Str, 06110, Dıskapı- Altındag, Ankara, Turkey. ilkayb@hotmail.com.'}, {'ForeName': 'Fatma', 'Initials': 'F', 'LastName': 'Kavak Akelma', 'Affiliation': 'Department of Anesthesiology and Reanimation, University of Health Sciences, Diskapi Yildirim Beyazit Trainig and Research Hospital, Sehit Ömer Halisdemir Str, 06110, Dıskapı- Altındag, Ankara, Turkey.'}, {'ForeName': 'Merve', 'Initials': 'M', 'LastName': 'Emlek', 'Affiliation': 'Department of Anesthesiology and Reanimation, University of Health Sciences, Diskapi Yildirim Beyazit Trainig and Research Hospital, Sehit Ömer Halisdemir Str, 06110, Dıskapı- Altındag, Ankara, Turkey.'}, {'ForeName': 'Derya', 'Initials': 'D', 'LastName': 'Özkan', 'Affiliation': 'Department of Anesthesiology and Reanimation, University of Health Sciences, Diskapi Yildirim Beyazit Trainig and Research Hospital, Sehit Ömer Halisdemir Str, 06110, Dıskapı- Altındag, Ankara, Turkey.'}, {'ForeName': 'Jülide', 'Initials': 'J', 'LastName': 'Ergil', 'Affiliation': 'Department of Anesthesiology and Reanimation, University of Health Sciences, Diskapi Yildirim Beyazit Trainig and Research Hospital, Sehit Ömer Halisdemir Str, 06110, Dıskapı- Altındag, Ankara, Turkey.'}, {'ForeName': 'Reyhan', 'Initials': 'R', 'LastName': 'Polat', 'Affiliation': 'Department of Anesthesiology and Reanimation, University of Health Sciences, Diskapi Yildirim Beyazit Trainig and Research Hospital, Sehit Ömer Halisdemir Str, 06110, Dıskapı- Altındag, Ankara, Turkey.'}]",Journal of anesthesia,['10.1007/s00540-020-02780-0'] 100,32367400,Length Polymorphisms in the Angiotensin I-Converting Enzyme Gene and the Serotonin-Transporter-Linked Polymorphic Region Constitute a Risk Haplotype for Depression in Patients with Coronary Artery Disease.,"Genetic variations affecting the course of depressive symptoms in patients with coronary artery disease (CAD) have not yet been well studied. Therefore, we set out to investigate whether distinct haplotypes of the two insertion/deletion polymorphisms in the serotonin-transporter-linked polymorphic region (5-HTTLPR) and the angiotensin I-converting enzyme (ACE) gene located on chromosome 17 can be identified as risk factors for trajectories of depression. Clinical and genotyping data were derived from 507 depressed CAD patients participating in the randomized, controlled, multicenter Stepwise Psychotherapy Intervention for Reducing Risk in Coronary Artery Disease (SPIRR-CAD) trial, of whom the majority had an acute cardiac event before study inclusion. Depression scores on the Hospital Anxiety and Depression Scale (HADS) were assessed at baseline and at five follow-up time points up to 2 years after study entrance. At baseline, depression scores did not significantly differ between patients carrying the risk haplotype ACE D/D, 5-HTTLPR I/I (n = 46) and the non-risk haplotypes (n = 461, 10.9 ± 2.7 versus 10.4 ± 2.5, p = 0.254). HADS-depression scores declined from study inclusion during the first year irrespective of the genotype. At each follow-up time point, HADS-depression scores were significantly higher in ACE D/D, 5-HTTLPR I/I carriers than in their counterparts. Two years after study inclusion, the mean HADS depression score remained 1.8 points higher in patients with the risk haplotype as compared to subjects not carrying this haplotype (9.9 ± 4.2 versus 8.1 ± 4.0, p = 0.009). In summary, the presence of the ACE D/D, 5-HTTLPR I/I haplotype may be a vulnerability factor for comorbid depressive symptoms in CAD patients.",2020,"At baseline, depression scores did not significantly differ between patients carrying the risk haplotype ACE D/D, 5-HTTLPR","['Patients with Coronary Artery Disease', '507 depressed CAD patients participating', 'CAD patients', 'patients with coronary artery disease (CAD']","['Psychotherapy Intervention', '5-HTTLPR']","['Depression scores', 'depression scores', 'HADS-depression scores', 'mean HADS depression score', 'Hospital Anxiety and Depression Scale (HADS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0450381', 'cui_str': '507'}, {'cui': 'C0344315', 'cui_str': 'Depressed mood'}]","[{'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",507.0,0.0420776,"At baseline, depression scores did not significantly differ between patients carrying the risk haplotype ACE D/D, 5-HTTLPR","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Meyer', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center and German Center for Cardiovascular Research, Partner Site Göttingen, Göttingen, Germany. thomas.meyer@med.uni-goettingen.de.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Rothe', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center and German Center for Cardiovascular Research, Partner Site Göttingen, Göttingen, Germany.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Staab', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center and German Center for Cardiovascular Research, Partner Site Göttingen, Göttingen, Germany.'}, {'ForeName': 'Hans-Christian', 'Initials': 'HC', 'LastName': 'Deter', 'Affiliation': 'Department of Psychosomatics and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Stella V', 'Initials': 'SV', 'LastName': 'Fangauf', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center and German Center for Cardiovascular Research, Partner Site Göttingen, Göttingen, Germany.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Hamacher', 'Affiliation': 'Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hellmich', 'Affiliation': 'Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Jünger', 'Affiliation': 'The German National Institute for State Examinations in Medicine, Pharmacy and Psychotherapy, Mainz, Germany.'}, {'ForeName': 'Karl-Heinz', 'Initials': 'KH', 'LastName': 'Ladwig', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Michal', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Petrowski', 'Affiliation': 'Department of Psychotherapy and Psychosomatics, Technical University of Dresden, Dresden, Germany.'}, {'ForeName': 'Joram', 'Initials': 'J', 'LastName': 'Ronel', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Clinic Barmelweid, Barmelweid, Switzerland.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Söllner', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany.'}, {'ForeName': 'Cora', 'Initials': 'C', 'LastName': 'Weber', 'Affiliation': 'Department of Psychosomatics and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'de Zwaan', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Redford B', 'Initials': 'RB', 'LastName': 'Williams', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Albus', 'Affiliation': 'Department of Psychosomatics and Psychotherapy, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Herrmann-Lingen', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center and German Center for Cardiovascular Research, Partner Site Göttingen, Göttingen, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Biochemical genetics,['10.1007/s10528-020-09967-w'] 101,32298839,Progress of the ALIFE2 study: A dynamic road towards more evidence.,"Investigator-initiated studies are invaluable, especially in fields that are not particularly of interest for the pharmaceutical industry because they are either less profitable or concern special patient groups such as pregnant women. However, designing, conducting, and completing an investigator-initiated randomised controlled trial is challenging. Patients and physicians' preferences, ethics requirements, (international) legislation and funding are all areas where such challenges are encountered. The Anticoagulants for LIving FEtuses (ALIFE)2 study (NTR3361) is an example of an investigator initiated international multicenter trial that progresses slowly, at least initially, as many challenges had to be overcome. Here, we discuss the challenges we faced during the course of the ALIFE2 study up till now and we explain how some of these challenges can be tackled or even avoided.",2020,The Anticoagulants for LIving FEtuses,"['pregnant women', 'LIving FEtuses']",[],[],"[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0015965', 'cui_str': 'Fetuses'}]",[],[],,0.0353679,The Anticoagulants for LIving FEtuses,"[{'ForeName': 'Eva N', 'Initials': 'EN', 'LastName': 'Hamulyák', 'Affiliation': 'Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: e.n.hamulyak@amsterdamumc.nl.'}, {'ForeName': 'Paulien G', 'Initials': 'PG', 'LastName': 'de Jong', 'Affiliation': 'Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Luuk J J', 'Initials': 'LJJ', 'LastName': 'Scheres', 'Affiliation': 'Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Lauren J', 'Initials': 'LJ', 'LastName': 'Ewington', 'Affiliation': 'Warwick Medical School, University Hospitals Coventry and Warwickshire NHS trust, Coventry, United Kingdom.'}, {'ForeName': 'Saskia', 'Initials': 'S', 'LastName': 'Middeldorp', 'Affiliation': 'Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Siobhan', 'Initials': 'S', 'LastName': 'Quenby', 'Affiliation': 'Warwick Medical School, University Hospitals Coventry and Warwickshire NHS trust, Coventry, United Kingdom.'}, {'ForeName': 'Mariëtte', 'Initials': 'M', 'LastName': 'Goddijn', 'Affiliation': 'Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}]",Thrombosis research,['10.1016/j.thromres.2020.03.015'] 102,32361755,Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir.,"BACKGROUND Cabotegravir is an HIV integrase inhibitor in clinical development with both oral and long-acting (LA) injectable formulations. Cabotegravir is primarily metabolized by uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A1, a known polymorphic enzyme with functional variants that can affect drug metabolism and exposure. OBJECTIVES To investigate the pharmacogenetic effects of the reduced-function alleles UGT1A1*6, UGT1A1*28 and/or UGT1A1*37 on steady-state pharmacokinetics (PK) and safety of oral cabotegravir (30 mg/day) and intramuscular cabotegravir LA (400 mg every 4 weeks or 600 mg every 8 weeks). METHODS Plasma cabotegravir PK was assessed in 346 UGT-genotyped participants with and without UGT1A1 functional variants across six studies (four Phase I and two Phase II) of oral cabotegravir, including 215 HIV-infected participants who received oral cabotegravir followed by cabotegravir LA. Changes from baseline in total bilirubin and ALT were assessed in one study (LATTE; NCT01641809). RESULTS Statistically significant (P < 0.05) associations were observed between UGT1A1 genotype and plasma cabotegravir PK parameters, with 28%-50% increases following oral cabotegravir [plasma cabotegravir concentration at the end of the dosing interval (Ctau), 1.50-fold; AUCtau, 1.41-fold; and Cmax, 1.28-fold] and 16%-24% increases following cabotegravir LA administration (48 week Ctau, 1.24-fold; AUCtau, 1.16-fold; and Cmax, 1.18-fold) among those with low-versus-normal genetically predicted UGT1A1 activity. A statistically significant (P < 10-5) association between predicted UGT1A1 activity and maximum change in total bilirubin was also observed (2.45-fold asymptomatic increase for low versus normal) without a corresponding change in ALT. CONCLUSIONS This modest increase in oral and parenteral cabotegravir exposure associated with a reduced function of UGT1A1 is not considered clinically relevant based on accumulated safety data; no dose adjustment is required.",2020,"RESULTS Statistically significant (P < 0.05) associations were observed between UGT1A1 genotype and plasma cabotegravir PK parameters, with 28%-50% increases following oral cabotegravir [plasma cabotegravir concentration at the end of the dosing interval (Ctau), 1.50-fold; AUCtau, 1.41-fold; and Cmax, 1.28-fold] and 16%-24% increases following cabotegravir LA administration (48 week Ctau, 1.24-fold; AUCtau, 1.16-fold; and Cmax, 1.18-fold) among those with low-versus-normal genetically predicted UGT1A1 activity.","['346 UGT-genotyped participants with and without UGT1A1 functional variants across six studies (four Phase I and two Phase II) of oral cabotegravir, including 215 HIV-infected participants who received']","['UGT1A1', 'oral cabotegravir followed by cabotegravir LA', 'oral cabotegravir (30\u2009mg/day) and intramuscular cabotegravir LA (400\u2009mg']","['oral cabotegravir [plasma cabotegravir concentration', 'UGT1A1 activity and maximum change in total bilirubin', 'steady-state pharmacokinetics (PK) and safety', 'UGT1A1 genotype and plasma cabotegravir PK parameters', 'total bilirubin and ALT']","[{'cui': 'C0643869', 'cui_str': ""uridine 5'-(phosphoimidazolate)""}, {'cui': 'C0041560', 'cui_str': 'Glucuronosyltransferase'}, {'cui': 'C1567723', 'cui_str': 'UGT1A1 protein, human'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0205419', 'cui_str': 'Variant'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4709308', 'cui_str': '215'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}]","[{'cui': 'C1567723', 'cui_str': 'UGT1A1 protein, human'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C3816746', 'cui_str': '400'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1567723', 'cui_str': 'UGT1A1 protein, human'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin'}, {'cui': 'C0205361', 'cui_str': 'Steady'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}]",,0.115334,"RESULTS Statistically significant (P < 0.05) associations were observed between UGT1A1 genotype and plasma cabotegravir PK parameters, with 28%-50% increases following oral cabotegravir [plasma cabotegravir concentration at the end of the dosing interval (Ctau), 1.50-fold; AUCtau, 1.41-fold; and Cmax, 1.28-fold] and 16%-24% increases following cabotegravir LA administration (48 week Ctau, 1.24-fold; AUCtau, 1.16-fold; and Cmax, 1.18-fold) among those with low-versus-normal genetically predicted UGT1A1 activity.","[{'ForeName': 'Parul', 'Initials': 'P', 'LastName': 'Patel', 'Affiliation': 'ViiV Healthcare, Research Triangle Park, NC, USA.'}, {'ForeName': 'Zhengyu', 'Initials': 'Z', 'LastName': 'Xue', 'Affiliation': 'PAREXEL International, Durham, NC, USA.'}, {'ForeName': 'Karen S', 'Initials': 'KS', 'LastName': 'King', 'Affiliation': 'GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Parham', 'Affiliation': 'PAREXEL International, Durham, NC, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Ford', 'Affiliation': 'GlaxoSmithKline, Research Triangle Park, NC, USA.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Lou', 'Affiliation': 'GlaxoSmithKline, Research Triangle Park, NC, USA.'}, {'ForeName': 'Kalpana K', 'Initials': 'KK', 'LastName': 'Bakshi', 'Affiliation': 'GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Sutton', 'Affiliation': 'ViiV Healthcare, Research Triangle Park, NC, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Margolis', 'Affiliation': 'ViiV Healthcare, Research Triangle Park, NC, USA.'}, {'ForeName': 'Arlene R', 'Initials': 'AR', 'LastName': 'Hughes', 'Affiliation': 'PAREXEL International, Durham, NC, USA.'}, {'ForeName': 'William R', 'Initials': 'WR', 'LastName': 'Spreen', 'Affiliation': 'ViiV Healthcare, Research Triangle Park, NC, USA.'}]",The Journal of antimicrobial chemotherapy,['10.1093/jac/dkaa147'] 103,32361959,A multicentre randomized controlled follow-up study of the effects of the underwater traction therapy in chronic low back pain.,"Low back pain (LBP) is one of the most costly diseases in the developed world. This study aimed to investigate the effects of underwater traction therapy on chronic low back pain. The primary objective was to prove that underwater traction therapy has favorable effects on LBP. Our secondary objective was to evaluate whether it also leads to improvement in the quality of life. This is a prospective, multicenter, follow-up study. A total of 176 patients with more than 3 months of low back pain enrolled from outpatient clinics were randomized into three groups: underwater weight bath traction therapy and non-steroidal anti-inflammatory drugs (NSAIDs); weight bath; and only NSAIDs. The following parameters were measured before, right after, and 9 weeks after the 3-week therapy: levels of low back pain in rest and during activity were tested using the visual analogue scale (VAS), the Oswestry Low Back Disability Questionnaire, and the EuroQol-5D-5L Questionnaire.The VAS levels improved significantly (p < 0.05) in both underwater weight bath traction therapy groups by the end of the treatment, whereas the improvement in the third group was not statistically significant. Furthermore, the improvements measured in the groups receiving traction therapy were persistent during the follow-up period. There were no significant changes in the Oswestry Index or the EuroQol-5D-5L without VAS parameters in any of the groups.Based on our results, for patients suffering from LBP pain who underwent underwater weight bath traction therapy, there were favorable impacts on the pain levels at rest or during activity. Clinical trial registration ID: NCT03488498, April 5, 2018.",2020,There were no significant changes in the Oswestry Index or the EuroQol-5D-5L without VAS parameters in any of the groups.,"['patients suffering from LBP pain who underwent', '176 patients with more than 3\xa0months of low back pain enrolled from outpatient clinics', 'chronic low back pain']","['underwater weight bath traction therapy', 'underwater weight bath traction therapy and non-steroidal anti-inflammatory drugs (NSAIDs); weight bath; and only NSAIDs', 'underwater traction therapy']","['quality of life', 'pain levels', 'chronic low back pain', 'visual analogue scale (VAS), the Oswestry Low Back Disability Questionnaire, and the EuroQol-5D-5L Questionnaire', 'low back pain in rest and during activity', 'VAS levels', 'Oswestry Index or the EuroQol-5D-5L without VAS parameters']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0040597', 'cui_str': 'Traction'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",176.0,0.0250049,There were no significant changes in the Oswestry Index or the EuroQol-5D-5L without VAS parameters in any of the groups.,"[{'ForeName': 'Tamás', 'Initials': 'T', 'LastName': 'Gáti', 'Affiliation': 'Rheumatology Department, Polyclinic of The Hospitaller Brothers of St John of God, Árpád fejedelem út 7, Budapest, 1027, Hungary. tomgati@gmail.com.'}, {'ForeName': 'Éva', 'Initials': 'É', 'LastName': 'Czímer', 'Affiliation': 'Aquarius Experience Bath, Sóstó, Fürdőház tér 2, Nyíregyháza, 4431, Hungary.'}, {'ForeName': 'Györgyi', 'Initials': 'G', 'LastName': 'Cserháti', 'Affiliation': 'Medical Department of Bath, Kenézy Gyula University Hospital, Debrecen, Hungary.'}, {'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Fehér', 'Affiliation': 'Hungarospa Hajdúszoboszló Private Limited Company, Hajdúszoboszló, Hungary.'}, {'ForeName': 'Mihály', 'Initials': 'M', 'LastName': 'Oláh', 'Affiliation': 'Hungarospa Hajdúszoboszló Private Limited Company, Hajdúszoboszló, Hungary.'}, {'ForeName': 'Ágota', 'Initials': 'Á', 'LastName': 'Kulisch', 'Affiliation': 'St. Andrew Hospital for Rheumatic Diseases, Hévíz, Hungary.'}, {'ForeName': 'Zsuzsanna', 'Initials': 'Z', 'LastName': 'Mándó', 'Affiliation': 'St. Andrew Hospital for Rheumatic Diseases, Hévíz, Hungary.'}, {'ForeName': 'Tamás', 'Initials': 'T', 'LastName': 'Bender', 'Affiliation': 'Rheumatology Department, Polyclinic of The Hospitaller Brothers of St John of God, Árpád fejedelem út 7, Budapest, 1027, Hungary.'}]",International journal of biometeorology,['10.1007/s00484-020-01919-8'] 104,32365109,The influence of an induced negative emotional state on autobiographical memory coherence.,"Individuals who experience difficulty constructing coherent narratives about significant personal experiences generally report less psychological well-being and more depressive symptoms. It remains, however, unclear whether a negative emotional state, one of the core symptoms of depression, causes this impairment in autobiographical memory coherence. The current study aimed to examine the causal relation between mood and memory coherence by means of a mood induction paradigm. A group of 165 students were randomly allocated to one of three mood groups: negative, positive, and neutral. We hypothesized that memory coherence would decrease following a negative mood induction. In addition, working memory capacity was expected to mediate the association between mood and memory coherence. Contrary to predictions, memory coherence increased following a negative mood induction. This increase was likewise observed in the positive mood group, though memory coherence remained consistent in the neutral mood group. This effect of mood on memory coherence was solely observed in female participants and not in the small male subsample. Results provided no support for the hypothesis that working memory capacity functioned as an underlying mechanism. Different theoretical explanations are discussed.",2020,"This increase was likewise observed in the positive mood group, though memory coherence remained consistent in the neutral mood group.","['A group of 165 students', 'female participants and not in the small male subsample']",[],"['memory coherence', 'autobiographical memory coherence']","[{'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0086582', 'cui_str': 'Male'}]",[],"[{'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}]",165.0,0.0311399,"This increase was likewise observed in the positive mood group, though memory coherence remained consistent in the neutral mood group.","[{'ForeName': 'Elien', 'Initials': 'E', 'LastName': 'Vanderveren', 'Affiliation': 'Center for the Psychology of Learning and Experimental Psychopathology, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Loes', 'Initials': 'L', 'LastName': 'Aerts', 'Affiliation': 'Undergraduate students clinical and health psychology, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Sofie', 'Initials': 'S', 'LastName': 'Rousseaux', 'Affiliation': 'Undergraduate students clinical and health psychology, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Bijttebier', 'Affiliation': 'School Psychology and Development in Context, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Hermans', 'Affiliation': 'Center for the Psychology of Learning and Experimental Psychopathology, KU Leuven, Leuven, Belgium.'}]",PloS one,['10.1371/journal.pone.0232495'] 105,32365932,Mobile X-ray Outside the Hospital vs. X-ray at the Hospital Challenges Exposed in an Explorative RCT Study.,"BACKGROUND For frail patients, it may sometimes be preferable to carry out X-ray examinations at the patients' own home. The general state of such patients may worsen due to transport and change of environment when transported for examination at the hospital. OBJECTIVE The aim of the randomized controlled trial (RCT) was to investigate if mobile X-ray improves healthcare for fragile patients. The primary outcome was the number of hospitalizations. DATA SOURCES We collected all data using questionnaires and data from the Electronic Patient Record (ER). PARTICIPANTS Patients referred to a mobile X-ray examination living in nursing homes and homes for the elderly in the Aarhus Municipality (Denmark). INTERVENTION mobile X-ray examinations compared to those at the hospital. Study appraisal: Data were collected and stored using the computer programme Redcap. Stata was used for statistical calculations. One hundred and thirty-six patients were included in the RCT. We did not find significant differences between mobile X-ray (intervention) and X-ray at the hospital (control) concerning hospitalizations and number of hospital days. Challenges: We met several challenges when carrying out RCT in the planned study population. Doctors often withdraw the referral when they found out that their patient should go to the hospital instead of mobile X-ray. The nursing home staff often considered the patient too frail to allow the test person to ask questions post X-ray. We also met challenges in the randomization method resulting in bias in the first data collection, so we had to adjust the randomization method. CONCLUSIONS For the fragile patients in the present explorative study, mobile X-ray did not significantly reduce the number of hospitalizations compared to X-ray at the hospital. Yet, mobile X-ray may be a new important diagnostic tool for more precise treatment to the frailest patients for whom transportation to the hospital is too exhausting. We need studies with focus on this aspect. We also recommend future RCT studies in a population for which mobile X-ray has not yet been a possibility.",2020,"For the fragile patients in the present explorative study, mobile X-ray did not significantly reduce the number of hospitalizations compared to X-ray at the hospital.","['One hundred and thirty-six patients were included in the RCT', 'frail patients', 'fragile patients', 'Patients referred to a mobile X-ray examination living in nursing homes and homes for the elderly in the Aarhus Municipality (Denmark']",['mobile X-ray'],['number of hospitalizations'],"[{'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0425205', 'cui_str': 'Lives in a nursing home'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}]","[{'cui': 'C0034571', 'cui_str': 'radiography'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",136.0,0.0884358,"For the fragile patients in the present explorative study, mobile X-ray did not significantly reduce the number of hospitalizations compared to X-ray at the hospital.","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Toppenberg', 'Affiliation': 'The Department of Radiology, Aarhus University Hospital, 8200 Aarhus, Denmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Christiansen', 'Affiliation': 'The Department of Radiology, Aarhus University Hospital, 8200 Aarhus, Denmark.'}, {'ForeName': 'Finn', 'Initials': 'F', 'LastName': 'Rasmussen', 'Affiliation': 'The Department of Radiology, Aarhus University Hospital, 8200 Aarhus, Denmark.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Nielsen', 'Affiliation': 'DEFACTUM, Social and Health Services and Labour Market, 8200 Aarhus, Denmark.'}, {'ForeName': 'Else Marie', 'Initials': 'EM', 'LastName': 'Damsgaard', 'Affiliation': 'Department of Geriatrics, Aarhus University Hospital, 8200 Aarhus, Denmark.'}]","Healthcare (Basel, Switzerland)",['10.3390/healthcare8020118'] 106,32381562,Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.,"BACKGROUND The best strategy for maintaining clinical remission in patients with axial spondyloarthritis (axSpA) has not been defined. C-OPTIMISE compared dose continuation, reduction and withdrawal of the tumour necrosis factor inhibitor certolizumab pegol (CZP) following achievement of sustained remission in patients with early axSpA. METHODS C-OPTIMISE was a two-part, multicentre phase 3b study in adults with early active axSpA (radiographic or non-radiographic). During the 48-week open-label induction period, patients received CZP 200 mg every 2 weeks (Q2W). At Week 48, patients in sustained remission (Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3 at Weeks 32/36 and 48) were randomised to double-blind CZP 200 mg Q2W (full maintenance dose), CZP 200 mg every 4 weeks (Q4W; reduced maintenance dose) or placebo (withdrawal) for a further 48 weeks. The primary endpoint was remaining flare-free (flare: ASDAS ≥2.1 at two consecutive visits or ASDAS >3.5 at any time point) during the double-blind period. RESULTS At Week 48, 43.9% (323/736) patients achieved sustained remission, of whom 313 were randomised to CZP full maintenance dose, CZP reduced maintenance dose or placebo. During Weeks 48 to 96, 83.7% (87/104), 79.0% (83/105) and 20.2% (21/104) of patients receiving the full maintenance dose, reduced maintenance dose or placebo, respectively, were flare-free (p<0.001 vs placebo in both CZP groups). Responses in radiographic and non-radiographic axSpA patients were comparable. CONCLUSIONS Patients with early axSpA who achieve sustained remission at 48 weeks can reduce their CZP maintenance dose; however, treatment should not be completely discontinued due to the high risk of flare following CZP withdrawal. TRIAL REGISTRATION NUMBER NCT02505542, ClinicalTrials.gov.",2020,"At Week 48, 43.9% (323/736) patients achieved sustained remission, of whom 313 were randomised to CZP full maintenance dose, CZP reduced maintenance dose or placebo.","['ASDAS) <1.3 at Weeks 32/36 and 48', 'patients with early axSpA.\nMETHODS', 'patients with axial spondyloarthritis (axSpA', 'adults with early active axSpA (radiographic or non-radiographic']","['CZP 200\u2009mg every 2 weeks (Q2W', 'CZP 200\u2009mg every 4 weeks (Q4W; reduced maintenance dose) or placebo', 'CZP 200\u2009mg Q2W', 'placebo']","['remaining flare-free (flare: ASDAS', 'sustained remission (Ankylosing Spondylitis Disease Activity Score', 'sustained remission', 'flare-free']","[{'cui': 'C4517499', 'cui_str': '1.3'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3203547', 'cui_str': 'Axial spondyloarthritis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}]","[{'cui': 'C4026841', 'cui_str': 'certolizumab pegol 200 MG'}, {'cui': 'C0585332', 'cui_str': 'Biweekly'}, {'cui': 'C1275555', 'cui_str': 'Every four weeks'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C3714445', 'cui_str': 'Maintenance dose'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0038013', 'cui_str': 'Ankylosing spondylitis'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}]",,0.666024,"At Week 48, 43.9% (323/736) patients achieved sustained remission, of whom 313 were randomised to CZP full maintenance dose, CZP reduced maintenance dose or placebo.","[{'ForeName': 'Robert Bm', 'Initials': 'RB', 'LastName': 'Landewé', 'Affiliation': 'Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, The Netherlands landewe@rlandewe.nl.'}, {'ForeName': 'Désirée', 'Initials': 'D', 'LastName': 'van der Heijde', 'Affiliation': 'Depertment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Maxime', 'Initials': 'M', 'LastName': 'Dougados', 'Affiliation': 'Hopital Cochin, Rheumatology, Université Paris Descartes, Paris, France.'}, {'ForeName': 'Xenofon', 'Initials': 'X', 'LastName': 'Baraliakos', 'Affiliation': 'Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Bochum, Herne, Germany.'}, {'ForeName': 'Filip E', 'Initials': 'FE', 'LastName': 'Van den Bosch', 'Affiliation': 'Department of Internal Medicine and Pediatrics, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Karl', 'Initials': 'K', 'LastName': 'Gaffney', 'Affiliation': 'Rheumatology Department, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Bauer', 'Affiliation': 'UCB Pharma, Monheim am Rhein, Germany.'}, {'ForeName': 'Bengt', 'Initials': 'B', 'LastName': 'Hoepken', 'Affiliation': 'UCB Pharma, Monheim am Rhein, Germany.'}, {'ForeName': 'Owen R', 'Initials': 'OR', 'LastName': 'Davies', 'Affiliation': 'UCB Pharma, Slough, UK.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'de Peyrecave', 'Affiliation': 'UCB Pharma, Brussels, Belgium.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Thomas', 'Affiliation': 'UCB Pharma, Monheim am Rhein, Germany.'}, {'ForeName': 'Lianne', 'Initials': 'LS', 'LastName': 'Gensler', 'Affiliation': 'University of California San Francisco, San Francisco, California, USA.'}]",Annals of the rheumatic diseases,['10.1136/annrheumdis-2019-216839'] 107,32381629,"Correction: First use of cenerimod, a selective S1P 1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study.",,2020,,[],['placebo'],[],[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.29762,,[],Lupus science & medicine,['10.1136/lupus-2019-000354corr1'] 108,32384364,Effectiveness of the virtual reality on cognitive function of children with hemiplegic cerebral palsy: a single-blind randomized controlled trial - Erratum.,,2020,,['children with hemiplegic cerebral palsy'],['virtual reality'],['cognitive function'],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0270805', 'cui_str': 'Hemiplegic cerebral palsy'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",,0.130281,,[],International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation,['10.1097/MRR.0000000000000414'] 109,32385846,A Randomized Controlled Trial with a Medical Device Containing Sodium Hyaluronate and Nicotinic Acid to Increase the Efficacy of Ultraviolet Phototherapy in Psoriasis.,"INTRODUCTION The dry and scaly skin of psoriatic patients decreases the efficacy of ultraviolet B (UVB) phototherapy. Different agents are used to facilitate the transmission of light, but most of these preparations are cosmetically unfavorable. We have tested a novel preparation containing sodium hyaluronate and nicotinic acid (UV Fotogel®; Pernix Ltd.) with the double aim to improve the efficacy of UVB phototherapy and assess the cosmetic acceptability of the preparation. METHODS Ninety patients with plaque psoriasis were enrolled in the study, of whom 44 received narrow-band UVB (NB-UVB) phototherapy. Prior to phototherapy, one side of the patient's body was treated with UV Fotogel while the other side served as a control. The other 46 patients used the preparation at their homes before regular sunbathing. The Local Psoriasis Severity Index (L-PSI), cosmetic acceptability and tolerability were recorded. The median values with the 25th and 75th percentiles (25p and 75p, respectively) were determined for the UV Fotogel-treated and control sites and then compared. RESULTS The sides of the body to which UV Fotogel was applied prior to NB-UVB phototherapy had a significantly lower median L-PSI score than the non-treated control sides at the end of the treatment (1.0 [25p-75p: 0.0-2.0] vs. 2.0 [1.0-3.0], respectively). The application of UV Fotogel prior to sunbathing also led to a significant decrease in L-PSI score. There was a significant reduction in the median L-PSI score of patients at the final visit compared to baseline (2.5 [25p-75p: 1.5-3.5] vs. 6.0 [6.0-7.0], respectively). Use of the preparation was not accompanied by considerable adverse effects, and the patients found it cosmetically acceptable. Application of UV Fotogel prior to sunbathing was well tolerated by the patients, and the cosmetic acceptability was also good. CONCLUSION UV Fotogel is potentially a useful device for enhancement of the efficacy of phototherapy in patients with psoriasis.",2020,The application of UV Fotogel prior to sunbathing also led to a significant decrease in L-PSI score.,"['patients with psoriasis', '46 patients used the preparation at their homes before regular sunbathing', 'Ninety patients with plaque psoriasis were enrolled in the study, of whom 44 received', 'psoriatic patients', 'Psoriasis']","['narrow-band UVB (NB-UVB) phototherapy', 'ultraviolet B (UVB) phototherapy', 'Ultraviolet Phototherapy', 'UVB phototherapy', 'Medical Device Containing Sodium Hyaluronate and Nicotinic Acid']","['median L-PSI score', 'cosmetic acceptability', 'Local Psoriasis Severity Index (L-PSI), cosmetic acceptability and tolerability', 'L-PSI score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0038813', 'cui_str': 'Sunbathing'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0406317', 'cui_str': 'Chronic small plaque psoriasis'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0332463', 'cui_str': 'Narrowed structure'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C1532472', 'cui_str': 'Ultra-violet'}, {'cui': 'C0031765', 'cui_str': 'Light therapy'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0087000', 'cui_str': 'Hyaluronate sodium'}, {'cui': 'C0027996', 'cui_str': 'Niacin'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",90.0,0.0219961,The application of UV Fotogel prior to sunbathing also led to a significant decrease in L-PSI score.,"[{'ForeName': 'Balázs', 'Initials': 'B', 'LastName': 'Bende', 'Affiliation': 'Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.'}, {'ForeName': 'Róbert', 'Initials': 'R', 'LastName': 'Kui', 'Affiliation': 'Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.'}, {'ForeName': 'Annamária', 'Initials': 'A', 'LastName': 'Németh', 'Affiliation': 'Clinical Research Coordination Centre, University of Szeged, Szeged, Hungary.'}, {'ForeName': 'Mariann', 'Initials': 'M', 'LastName': 'Borsos', 'Affiliation': 'Adware Research Ltd., Balatonfüred, Hungary.'}, {'ForeName': 'Zoltán', 'Initials': 'Z', 'LastName': 'Tóbiás', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, University of Szeged, Szeged, Hungary.'}, {'ForeName': 'Gábor', 'Initials': 'G', 'LastName': 'Erős', 'Affiliation': 'Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary. eros.gabor@med.u-szeged.hu.'}, {'ForeName': 'Lajos', 'Initials': 'L', 'LastName': 'Kemény', 'Affiliation': 'Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.'}, {'ForeName': 'Eszter', 'Initials': 'E', 'LastName': 'Baltás', 'Affiliation': 'Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.'}]",Dermatology and therapy,['10.1007/s13555-020-00385-9'] 110,32324444,Revisiting Reliability: Using Sampling Utterances and Grammatical Analysis Revised (SUGAR) to Compare 25- and 50-Utterance Language Samples.,"Purpose The goal of this study was to determine whether the results obtained from a 25-utterance conversational language sample were as reliable as those obtained from a 50-utterance sample. Method Robust conversational language samples from 220 children with typically developing language (106 boys, 114 girls) ranging in age from 3;2 to 7;10 (years;months) were collected. The language samples were randomly assigned to one of two conditions: a 25-utterance condition and a 50-utterance condition. Transcripts were examined for three metrics, including mean length of utterance SUGAR , words per sentence, and clauses per sentence. Results Data were analyzed using two methods. A linear mixed-model analysis was used to assess absolute and relative reliability, and the Bland-Altman procedure was used to assess absolute reliability and clinical acceptability. Results of the mixed-model analysis indicated that mean length of utterance SUGAR and words per sentence demonstrated relative reliability; however, none of the metrics demonstrated absolute reliability. In contrast, results of the Bland-Altman scatter plots indicated that all three metrics demonstrated absolute reliability because 94%-96% of participants' scores fell within the limits of agreement. Taken together, the results suggested that the statistically significant differences indicated by the mixed-model analysis were not clinically significant. Conclusion These results highlighted the importance of using different methods of analysis in studies of reliability. The findings indicated that reliable language sample results can be obtained from 25-utterance samples. Furthermore, by including practices already in use (e.g., collecting samples ≤ 50 utterances) and including only minimal changes to current practices, the methods used in this study are feasible for school-based clinicians, could be easily integrated into clinical practice, and could increase the use of evidence-based assessment practices in schools.",2020,"Results of the mixed-model analysis indicated that mean length of utterance SUGAR and words per sentence demonstrated relative reliability; however, none of the metrics demonstrated absolute reliability.","['220 children with typically developing language (106 boys, 114 girls) ranging in age from 3;2 to 7;10 (years;months) were collected']",['Sampling Utterances and Grammatical Analysis Revised (SUGAR'],"['absolute reliability and clinical acceptability', 'mean length of utterance SUGAR and words per sentence demonstrated relative reliability', 'mean length of utterance SUGAR , words per sentence, and clauses per sentence']","[{'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0080103', 'cui_str': 'Relative'}]",220.0,0.047942,"Results of the mixed-model analysis indicated that mean length of utterance SUGAR and words per sentence demonstrated relative reliability; however, none of the metrics demonstrated absolute reliability.","[{'ForeName': 'Stacey L', 'Initials': 'SL', 'LastName': 'Pavelko', 'Affiliation': 'Master of Science for Speech-Language Pathology Program, University of St. Augustine for Health Sciences, Dallas, TX.'}, {'ForeName': 'Larry R', 'Initials': 'LR', 'LastName': 'Price', 'Affiliation': 'Methodology, Measurement and Statistical Analysis, Office of Research and Sponsored Programs, Texas State University, San Marcos.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Owens', 'Affiliation': 'Department of Communication Sciences and Disorders, The College of Saint Rose, Albany, NY.'}]","Language, speech, and hearing services in schools",['10.1044/2020_LSHSS-19-00026'] 111,32305871,"Pharmacokinetics of maslinic and oleanolic acids from olive oil - Effects on endothelial function in healthy adults. A randomized, controlled, dose-response study.","To date, pharmacokinetics of maslinic (MA) and oleanolic (OA) acids, at normal dietary intakes in humans, have not been evaluated, and data concerning their bioactive effects are scarce. We assessed MA and OA pharmacokinetics after ingestion of olive oils (OOs) with high and low triterpenic acid contents, and specifically the effect of triterpenes on endothelial function. We performed a double-blind, dose-response, randomized, cross-over nutritional intervention in healthy adults, and observed that MA and OA increased in biological fluids in a dose-dependent manner. MA bioavailability was greater than that of OA, and consumption of pentacyclic triterpenes was associated with improved endothelial function. To the best of our knowledge, this is the first time MA pharmacokinetics, and effects on endothelial function in vivo, have been reported in humans.",2020,"MA bioavailability was greater than that of OA, and consumption of pentacyclic triterpenes was associated with improved endothelial function.",['healthy adults'],"['maslinic and oleanolic acids from olive oil ', 'maslinic (MA) and oleanolic (OA) acids', 'olive oils (OOs']","['MA and OA pharmacokinetics', 'endothelial function', 'MA bioavailability', 'MA and OA increased in biological fluids']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0028925', 'cui_str': 'Oleanol'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}]",,0.11831,"MA bioavailability was greater than that of OA, and consumption of pentacyclic triterpenes was associated with improved endothelial function.","[{'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'de la Torre', 'Affiliation': 'Integrative Pharmacology and Systems Neuroscience Research Group, IMIM (Hospital del Mar Research Institute), Dr. Aiguader 88, 08003 Barcelona, Spain; UniversitatPompeuFabra (CEXS-UPF), Dr. Aiguader 88, 08003 Barcelona, Spain; CIBER de Fisiopatología Obesidad y Nutrición (CIBEROBN), Santiago de Compostela 15706, Spain. Electronic address: rtorre@imim.es.'}, {'ForeName': 'Marceli', 'Initials': 'M', 'LastName': 'Carbó', 'Affiliation': 'UniversitatPompeuFabra (CEXS-UPF), Dr. Aiguader 88, 08003 Barcelona, Spain. Electronic address: marcelli.carbo@upf.edu.'}, {'ForeName': 'Mitona', 'Initials': 'M', 'LastName': 'Pujadas', 'Affiliation': 'Integrative Pharmacology and Systems Neuroscience Research Group, IMIM (Hospital del Mar Research Institute), Dr. Aiguader 88, 08003 Barcelona, Spain; CIBER de Fisiopatología Obesidad y Nutrición (CIBEROBN), Santiago de Compostela 15706, Spain. Electronic address: mpujadas@imim.es.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Biel', 'Affiliation': 'Fundación Pública Andaluza para la Investigación Biosanitaria de Andalucía Oriental ""Alejandro Otero"" (FIBAO), Granada, Spain. Electronic address: sbiel@fibao.es.'}, {'ForeName': 'María-Dolores', 'Initials': 'MD', 'LastName': 'Mesa', 'Affiliation': 'Department of Biochemistry and Molecular Biology II, Institute of Nutrition and Food Technology ""José Mataix"", Biomedical Research Center, Health Science Technological Park, University of Granada, Avenida del Conocimiento s/n. 18100 Armilla, Granada, Spain; Instituto de Investigación Biosanitariaibs GRANADA, Complejo Hospitalario Universitario de Granada, Granada 18014, Spain. Electronic address: mdmesa@ugr.es.'}, {'ForeName': 'María-Isabel', 'Initials': 'MI', 'LastName': 'Covas', 'Affiliation': 'CIBER de Fisiopatología Obesidad y Nutrición (CIBEROBN), Santiago de Compostela 15706, Spain; NUPROAS (Nutritional Project Assessment), Handesbolag (NUPROAS HB), Nacka, Sweden.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Expósito', 'Affiliation': 'Fundación Pública Andaluza para la Investigación Biosanitaria de Andalucía Oriental ""Alejandro Otero"" (FIBAO), Granada, Spain. Electronic address: manuela.exposito.ruiz.exts@juntadeandalucia.es.'}, {'ForeName': 'Juan-Antonio', 'Initials': 'JA', 'LastName': 'Espejo', 'Affiliation': 'Instituto para la Calidad y Seguridad Alimentaria (ICSA), Granada, Spain.'}, {'ForeName': 'Estefanía', 'Initials': 'E', 'LastName': 'Sanchez-Rodriguez', 'Affiliation': 'Department of Biochemistry and Molecular Biology II, Institute of Nutrition and Food Technology ""José Mataix"", Biomedical Research Center, Health Science Technological Park, University of Granada, Avenida del Conocimiento s/n. 18100 Armilla, Granada, Spain.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Díaz-Pellicer', 'Affiliation': 'Integrative Pharmacology and Systems Neuroscience Research Group, IMIM (Hospital del Mar Research Institute), Dr. Aiguader 88, 08003 Barcelona, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Jimenez-Valladares', 'Affiliation': 'Cooperativa San Francisco de Asís. Montefrío. Granada, Spain. Electronic address: jvalladares@aceitesmontevilla.com.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Rosa', 'Affiliation': 'Fundación Pública Andaluza para la Investigación Biosanitaria de Andalucía Oriental ""Alejandro Otero"" (FIBAO), Granada, Spain. Electronic address: crosa@fibao.es.'}, {'ForeName': 'Oscar', 'Initials': 'O', 'LastName': 'Pozo', 'Affiliation': 'Integrative Pharmacology and Systems Neuroscience Research Group, IMIM (Hospital del Mar Research Institute), Dr. Aiguader 88, 08003 Barcelona, Spain. Electronic address: opozo@imim.es.'}, {'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Fitó', 'Affiliation': 'CIBER de Fisiopatología Obesidad y Nutrición (CIBEROBN), Santiago de Compostela 15706, Spain; Cardiovascular Risk and Nutrition Research Group, IMIM (Hospital del Mar Research Institute), Dr. Aiguader 88, 08003 Barcelona, Spain. Electronic address: mfito@imim.es.'}]",Food chemistry,['10.1016/j.foodchem.2020.126676'] 112,32334632,"The Balanced Opioid Initiative: protocol for a clustered, sequential, multiple-assignment randomized trial to construct an adaptive implementation strategy to improve guideline-concordant opioid prescribing in primary care.","BACKGROUND Rates of opioid prescribing tripled in the USA between 1999 and 2015 and were associated with significant increases in opioid misuse and overdose death. Roughly half of all opioids are prescribed in primary care. Although clinical guidelines describe recommended opioid prescribing practices, implementing these guidelines in a way that balances safety and effectiveness vs. risk remains a challenge. The literature offers little help about which implementation strategies work best in different clinical settings or how strategies could be tailored to optimize their effectiveness in different contexts. Systems consultation consists of (1) educational/engagement meetings with audit and feedback reports, (2) practice facilitation, and (3) prescriber peer consulting. The study is designed to discover the most cost-effective sequence and combination of strategies for improving opioid prescribing practices in diverse primary care clinics. METHODS/DESIGN The study is a hybrid type 3 clustered, sequential, multiple-assignment randomized trial (SMART) that randomizes clinics from two health systems at two points, months 3 and 9, of a 21-month intervention. Clinics are provided one of four sequences of implementation strategies: a condition consisting of educational/engagement meetings and audit and feedback alone (EM/AF), EM/AF plus practice facilitation (PF), EM/AF + prescriber peer consulting (PPC), and EM/AF + PF + PPC. The study's primary outcome is morphine-milligram equivalent (MME) dose by prescribing clinicians within clinics. The study's primary aim is the comparison of EM/AF + PF + PPC versus EM/AF alone on change in MME from month 3 to month 21. The secondary aim is to derive cost estimates for each of the four sequences and compare them. The exploratory aim is to examine four tailoring variables that can be used to construct an adaptive implementation strategy to meet the needs of different primary care clinics. DISCUSSION Systems consultation is a practical blend of implementation strategies used in this case to improve opioid prescribing practices in primary care. The blend offers a range of strategies in sequences from minimally to substantially intensive. The results of this study promise to help us understand how to cost effectively improve the implementation of evidence-based practices. TRIAL REGISTRATION NCT04044521 (ClinicalTrials.gov). Registered 05 August 2019.",2020,"BACKGROUND Rates of opioid prescribing tripled in the USA between 1999 and 2015 and were associated with significant increases in opioid misuse and overdose death.","['primary care', 'diverse primary care clinics']","['EM/AF + PF + PPC versus EM/AF alone', 'educational/engagement meetings and audit and feedback alone (EM/AF), EM/AF plus practice facilitation (PF), EM/AF + prescriber peer consulting (PPC), and EM/AF + PF + PPC']","['opioid misuse and overdose death', 'morphine-milligram equivalent (MME) dose by prescribing clinicians within clinics']","[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic'}]","[{'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0037415', 'cui_str': 'Social Facilitation'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0029944', 'cui_str': 'Drug overdose'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0439210', 'cui_str': 'mg'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}]",,0.0591709,"BACKGROUND Rates of opioid prescribing tripled in the USA between 1999 and 2015 and were associated with significant increases in opioid misuse and overdose death.","[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Quanbeck', 'Affiliation': 'Department of Family Medicine and Community Health, University of Wisconsin-Madison, 800 University Bay Drive, Suite 210, Madison, WI, 53705-2278, USA. arquanbe@wisc.edu.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Almirall', 'Affiliation': 'Department of Statistics and Institute for Social Research, University of Michigan, 2448 Institute for Social Research, 426 Thompson St., Ann Arbor, MI, 48104-2321, USA.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Jacobson', 'Affiliation': 'Institute for Clinical and Translational Research and School of Nursing, University of Wisconsin, Madison, 5130 Signe Skott Cooper Hall, 701 Highland Ave, Madison, WI, 53705-2202, USA.'}, {'ForeName': 'Randall T', 'Initials': 'RT', 'LastName': 'Brown', 'Affiliation': 'Department of Family Medicine and Community Health, University of Wisconsin-Madison, 1100 Delaplaine Ct, Madison, WI, 53705-1840, USA.'}, {'ForeName': 'Jillian K', 'Initials': 'JK', 'LastName': 'Landeck', 'Affiliation': 'Department of Family Medicine and Community Health, University of Wisconsin-Madison, 1100 Delaplaine Ct, Madison, WI, 53705-1840, USA.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Madden', 'Affiliation': 'APT Foundation, 1 Long Wharf Drive, Suite 321, New Haven, CT, 06511-5991, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Cohen', 'Affiliation': 'Bellin Health Systems, Inc., 744 S. Webster Ave, Green Bay, WI, 54305, USA.'}, {'ForeName': 'Brienna M F', 'Initials': 'BMF', 'LastName': 'Deyo', 'Affiliation': 'Department of Family Medicine and Community Health, University of Wisconsin-Madison, 1100 Delaplaine Ct, Madison, WI, 53705-1840, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Robinson', 'Affiliation': 'Forward Data Analytic Services, LLC, 6700 Cross Country Road, Verona, WI, 53593, USA.'}, {'ForeName': 'Roberta A', 'Initials': 'RA', 'LastName': 'Johnson', 'Affiliation': 'Department of Family Medicine and Community Health, University of Wisconsin-Madison, 800 University Bay Drive, Suite 210, Madison, WI, 53705-2278, USA.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Schumacher', 'Affiliation': 'Department of Family Medicine and Community Health, University of Wisconsin-Madison, 800 University Bay Drive, Suite 210, Madison, WI, 53705-2278, USA.'}]",Implementation science : IS,['10.1186/s13012-020-00990-4'] 113,32332545,Computer-Aided Design and Manufacturing Cutting and Drilling Guides with Prebent Titanium Plates Improve Surgical Accuracy of Skeletal Class III Malocclusion.,"BACKGROUND The aim of this study was to evaluate the effects of the use of computer-aided design and manufacturing cutting and drilling guides with prebent titanium plates for the correction of skeletal class III malocclusion. METHODS In this prospective, randomized, controlled clinical trial, 46 patients with skeletal class III malocclusion were randomly assigned into two groups. The patients underwent bimaxillary surgery with computer-aided design and manufacturing cutting and drilling guides with prebent titanium plates (experimental group) or computer-aided design and manufacturing splints (control group). Preoperative and postoperative imaging data were collected and then analyzed using Mimics Research 19.0, Geomagic Studio, and IBM SPSS Version 21.0. RESULTS Deformity evaluation and posttreatment assessment were performed for all patients. The experimental group had fewer postoperative complications. Comparison of the linear and angular differences to facial reference planes revealed more accurate repositioning of the mandible and condyles in the experimental group, although the position of several landmarks still requires small adjustments. CONCLUSION Computer-aided design and manufacturing cutting and drilling guides with prebent titanium plates effectively corrected skeletal class III malocclusion, providing positional control of segments with reasonable surgical accuracy. CLINICAL QUESTION/LEVEL OF EVIDENCE Therapeutic, II.",2020,The experimental group had fewer postoperative complications.,['46 patients with skeletal class III malocclusion'],"['Computer-Aided Design and Manufacturing Cutting and Drilling Guides with Prebent Titanium Plates', 'computer-aided design and manufacturing cutting and drilling guides with prebent titanium plates', 'bimaxillary surgery with computer-aided design and manufacturing cutting and drilling guides with prebent titanium plates (experimental group) or computer-aided design and manufacturing splints (control group']",['postoperative complications'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0399526', 'cui_str': 'Malocclusion, Angle class III'}]","[{'cui': 'C0162517', 'cui_str': 'Computer-Assisted Design'}, {'cui': 'C0337279', 'cui_str': 'Drilling - action'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0040302', 'cui_str': 'Titanium'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038009', 'cui_str': 'Splint'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0032787', 'cui_str': 'Postoperative complication'}]",46.0,0.0218564,The experimental group had fewer postoperative complications.,"[{'ForeName': 'Kehan', 'Initials': 'K', 'LastName': 'Li', 'Affiliation': ""Chengdu and Shanghai, People's Republic of China From the Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University; and the Department of Oral and Maxillofacial Surgery, Shanghai Stomatological Hospital, Fudan University.""}, {'ForeName': 'Jiayang', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Du', 'Affiliation': ''}, {'ForeName': 'Chunwei', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': ''}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Ye', 'Affiliation': ''}, {'ForeName': 'En', 'Initials': 'E', 'LastName': 'Luo', 'Affiliation': ''}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000006794'] 114,32249950,"Efficacy of electrical stimulation of denervated muscle: A multicenter, double-blind, randomized clinical trial.","BACKGROUND This was a multicenter, double-blind, randomized clinical trial to investigate the efficacy of electrical stimulation of denervated muscle (ESDM) on recovery of patients with peripheral nerve injuries. METHODS We enrolled 38 patients with traumatic peripheral nerve injuries with axonal damage and clinical impairment of two muscles, who were randomly treated with real or sham electrical stimulation (ES). Clinical and neurophysiological examinations were performed before treatment, at the end of treatment, and 3 mo posttreatment, by the same physician who was blinded to the ES allocation. RESULTS All patients improved but there was no significant beneficial effect of ESDM compared with sham treatment. CONCLUSIONS This study failed to demonstrate the efficacy of ESDM for peripheral nerve injuries. However, given the large number of variables related to ES and the heterogeneity in disease etiologies and clinical manifestations, future studies on homogeneous populations using different stimulation protocols may be useful.",2020,"All patients improved but there was no significant beneficial effect of ESDM compared to sham treatment. ","['denervated muscle', 'patients with peripheral nerve injuries', '38 patients with traumatic peripheral nerve injuries with axonal damage and clinical impairment of two muscles, who were randomly treated with']","['ESDM', 'electrical stimulation', 'electrical stimulation of denervated muscle (ESDM', 'real or sham electrical stimulation (ES']",[],"[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0262593', 'cui_str': 'Injury of peripheral nerve'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]",[],38.0,0.408084,"All patients improved but there was no significant beneficial effect of ESDM compared to sham treatment. ","[{'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Piccinini', 'Affiliation': 'Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Cuccagna', 'Affiliation': 'Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy.'}, {'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Caliandro', 'Affiliation': 'Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Coraci', 'Affiliation': 'Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Germanotta', 'Affiliation': 'IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.'}, {'ForeName': 'Cristiano', 'Initials': 'C', 'LastName': 'Pecchioli', 'Affiliation': 'IRCCS Fondazione Don Carlo Gnocchi, Milan, Taly.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Padua', 'Affiliation': 'Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy.'}]",Muscle & nerve,['10.1002/mus.26880'] 115,32330925,Effects of serotonin and dopamine depletion on neural prediction computations during social learning.,"We have previously shown that individuals with high depression scores demonstrate impaired behavioral and neural responses during social learning. Given that depression is associated with altered dopamine (DA) and serotonin (5-HT) functioning, the current study aimed to elucidate the role of these neurotransmitters in the social learning process using a dietary depletion manipulation. In a double-blind design, 70 healthy volunteers were randomly allocated to a 5-HT depletion (N = 24), DA depletion (N = 24), or placebo (N = 22) group. Participants performed a social learning task during fMRI scanning, as part of which they learned associations between name cues and rewarding (happy faces) or aversive (fearful faces) social outcomes. Behaviorally, 5-HT depleted subjects demonstrated impaired social reward learning compared to placebo controls, with a marginal effect in the same direction in the DA depletion group. On the neural level, computational modeling-based fMRI analyses revealed that 5-HT depletion altered social reward prediction signals in the insula, temporal lobe, and prefrontal cortex, while DA depletion affected social reward prediction encoding only in the prefrontal cortex. These results indicate that 5-HT depletion impairs learning from social rewards, on both the behavioral and the neural level, while DA depletion has a less extensive effect. Interestingly, the behavioral and neural responses observed after 5-HT depletion in the current study closely resemble our previous findings in individuals with high depression scores using the same task. It may thus be the case that decreased 5-HT levels contribute to social learning deficits in depression.",2020,"Behaviorally, 5-HT depleted subjects demonstrated impaired social reward learning compared to placebo controls, with a marginal effect in the same direction in the DA depletion group.","['70 healthy volunteers', 'individuals with high depression scores', 'neural prediction computations during social learning']","['5-HT depletion (N\u2009=\u200924), DA depletion (N\u2009=\u200924), or placebo', 'serotonin and dopamine depletion', 'social learning task during fMRI scanning, as part of which they learned associations between name cues and rewarding (happy faces) or aversive (fearful faces) social outcomes']",['social reward learning'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0679082', 'cui_str': 'Social Learning'}]","[{'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0333668', 'cui_str': 'Depletion'}, {'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0679082', 'cui_str': 'Social Learning'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C1274040', 'cui_str': 'Result'}]","[{'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0013621', 'cui_str': 'Education'}]",70.0,0.0161143,"Behaviorally, 5-HT depleted subjects demonstrated impaired social reward learning compared to placebo controls, with a marginal effect in the same direction in the DA depletion group.","[{'ForeName': 'Anna-Lena', 'Initials': 'AL', 'LastName': 'Frey', 'Affiliation': 'School of Psychology and Clinical Language Sciences, University of Reading, Reading, UK.'}, {'ForeName': 'Ciara', 'Initials': 'C', 'LastName': 'McCabe', 'Affiliation': 'School of Psychology and Clinical Language Sciences, University of Reading, Reading, UK. c.mccabe@reading.ac.uk.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0678-z'] 116,31863227,A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.,"BACKGROUND Nivolumab showed improvement in overall survival (OS) in ATTRACTION-2, the first phase 3 study in patients with gastric/gastroesophageal junction (G/GEJ) cancer treated with ≥ 2 chemotherapy regimens. The 2-year follow-up results of ATTRACTION-2 are presented herein. METHODS ATTRACTION-2 was a randomized, double-blind, placebo-controlled, phase 3 trial (49 sites; Japan, South Korea, and Taiwan). The median (min-max) follow-up period was 27.3 (24.1-36.3) months. The primary endpoint was OS. A subanalysis of OS was performed based on best overall response and tumor-programmed death ligand-1 (PD-L1) expression status. RESULTS Overall, 493 of 601 screened patients were randomized (2:1) to receive nivolumab (330) or placebo (163). OS (median [95% confidence interval; CI]) was significantly longer in the nivolumab group (5.26 [4.60-6.37] vs 4.14 [3.42-4.86] months in placebo group) at the 2-year follow-up (hazard ratio [95% CI], 0.62 [0.51-0.76]; P < 0.0001). A higher OS rate was observed in the nivolumab vs placebo group at 1 (27.3% vs 11.6%) and 2 years (10.6% vs 3.2%). The OS benefit was observed regardless of tumor PD-L1 expression. Among patients with a complete or partial response (CR or PR) in the nivolumab group, the median OS (95% CI) was 26.6 (21.65-not applicable) months; the OS rates at 1 and 2 years were 87.1% and 61.3%, respectively. No new safety signals were identified. CONCLUSIONS Nivolumab treatment resulted in clinically meaningful long-term improvements in OS in patients with previously treated G/GEJ cancer. The long-term survival benefit of nivolumab was most evident in patients with a CR or PR.",2020,"CONCLUSIONS Nivolumab treatment resulted in clinically meaningful long-term improvements in OS in patients with previously treated G/GEJ cancer.","['previously treated advanced gastric or gastroesophageal junction cancer', 'phase 3 trial (49 sites; Japan, South Korea, and Taiwan', 'patients with gastric/gastroesophageal junction (G/GEJ) cancer treated with\u2009≥\u20092 chemotherapy regimens', 'patients with previously treated G/GEJ cancer', '493 of 601 screened patients', 'patients with a CR or PR']","['placebo', 'nivolumab', 'nivolumab (330) or placebo']","['partial response (CR or PR', 'median OS', 'OS rate', 'clinically meaningful long-term improvements in OS', 'OS rates', 'overall survival (OS', 'OS']","[{'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C0014871', 'cui_str': 'Gastroesophageal Junction'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0439561', 'cui_str': 'Phase 3 (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0022773', 'cui_str': 'South Korea'}, {'cui': 'C0039260', 'cui_str': 'Formosa'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3657270', 'cui_str': 'nivolumab'}]","[{'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",,0.491092,"CONCLUSIONS Nivolumab treatment resulted in clinically meaningful long-term improvements in OS in patients with previously treated G/GEJ cancer.","[{'ForeName': 'Li-Tzong', 'Initials': 'LT', 'LastName': 'Chen', 'Affiliation': 'National Institute of Cancer Research, National Health Research Institutes, National Cheng Kung University, Tainan, Taiwan.'}, {'ForeName': 'Taroh', 'Initials': 'T', 'LastName': 'Satoh', 'Affiliation': 'Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan.'}, {'ForeName': 'Min-Hee', 'Initials': 'MH', 'LastName': 'Ryu', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Yee', 'Initials': 'Y', 'LastName': 'Chao', 'Affiliation': 'Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Kato', 'Affiliation': 'Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.'}, {'ForeName': 'Hyun Cheol', 'Initials': 'HC', 'LastName': 'Chung', 'Affiliation': 'Division of Medical Oncology, Yonsei Cancer Center, Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea.'}, {'ForeName': 'Jen-Shi', 'Initials': 'JS', 'LastName': 'Chen', 'Affiliation': 'Division of Hematology and Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.'}, {'ForeName': 'Kei', 'Initials': 'K', 'LastName': 'Muro', 'Affiliation': 'Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'Won Ki', 'Initials': 'WK', 'LastName': 'Kang', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Kun-Huei', 'Initials': 'KH', 'LastName': 'Yeh', 'Affiliation': 'National Taiwan University Cancer Center, Taipei, Taiwan.'}, {'ForeName': 'Takaki', 'Initials': 'T', 'LastName': 'Yoshikawa', 'Affiliation': 'Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.'}, {'ForeName': 'Sang Cheul', 'Initials': 'SC', 'LastName': 'Oh', 'Affiliation': 'Division of Hematology and Oncology, Department of Internal Medicine, College of Medicine, Korea University, Seoul, South Korea.'}, {'ForeName': 'Li-Yuan', 'Initials': 'LY', 'LastName': 'Bai', 'Affiliation': 'Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.'}, {'ForeName': 'Takao', 'Initials': 'T', 'LastName': 'Tamura', 'Affiliation': 'Department of Medical Oncology, Faculty of Medicine, Kindai University, Osakasayama, Japan.'}, {'ForeName': 'Keun-Wook', 'Initials': 'KW', 'LastName': 'Lee', 'Affiliation': 'Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Hamamoto', 'Affiliation': 'Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Jong Gwang', 'Initials': 'JG', 'LastName': 'Kim', 'Affiliation': 'Kyungpook National University School of Medicine, Daegu, South Korea.'}, {'ForeName': 'Keisho', 'Initials': 'K', 'LastName': 'Chin', 'Affiliation': 'Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.'}, {'ForeName': 'Do-Youn', 'Initials': 'DY', 'LastName': 'Oh', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.'}, {'ForeName': 'Keiko', 'Initials': 'K', 'LastName': 'Minashi', 'Affiliation': 'Clinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan.'}, {'ForeName': 'Jae Yong', 'Initials': 'JY', 'LastName': 'Cho', 'Affiliation': 'Department of Medical Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Tsuda', 'Affiliation': 'Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Sameshima', 'Affiliation': 'Medical Oncology, Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka, Japan.'}, {'ForeName': 'Yoon-Koo', 'Initials': 'YK', 'LastName': 'Kang', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Narikazu', 'Initials': 'N', 'LastName': 'Boku', 'Affiliation': 'Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. nboku@ncc.go.jp.'}]",Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association,['10.1007/s10120-019-01034-7'] 117,32217922,The Design of a Prospective Trial to Evaluate the Role of Preoperative Frailty Assessment in Older Women Undergoing Surgery for the Treatment of Pelvic Organ Prolapse: The FASt Supplemental Trial.,"OBJECTIVE We present the rationale for and the design of a prospective trial to evaluate the role of preoperative frailty and mobility assessments in older women undergoing surgery for the treatment of pelvic organ prolapse (POP) as a planned prospective supplemental trial to the ASPIRe (Apical Suspension Repair for Vault Prolapse In a Three-Arm Randomized Trial Design) trial. The Frailty ASPIRe Study (FASt) examines the impact of preoperative frailty and mobility on surgical outcomes in older women (≥65 years) participating in the ASPIRe trial. The primary objective of FASt is to determine the impact of preoperative age, multimorbidity, frailty, and decreased mobility on postoperative outcomes in older women (≥65 years old) undergoing surgery for POP. METHODS The selection of the preoperative assessments, primary outcome measures, and participant inclusion is described. Frailty and mobility measurements will be collected at the preoperative visit and include the 6 Robinson frailty measurements and the Timed Up and Go mobility test. The main outcome measure in the FASt supplemental study will be moderate to severe postoperative adverse events according to the Clavien-Dindo Severity Classification. CONCLUSIONS This trial will assess impact of preoperative age, multimorbidity, frailty, and decreased mobility on postoperative outcomes in older women (≥65 years old) undergoing surgical procedures for the correction of apical POP. Information from this trial may help both primary care providers and surgeons better advise/inform women on their individual risks of surgical complications and provide more comprehensive postoperative care to women at highest risk of complications.",2020,The Frailty ASPIRe Study (FASt) examines the impact of preoperative frailty and mobility on surgical outcomes in older women (≥65 years) participating in the ASPIRe trial.,"['older women (≥65 years old) undergoing surgery for POP', 'older women undergoing surgery for the treatment of pelvic organ prolapse (POP', 'Older Women Undergoing Surgery for the Treatment of Pelvic Organ Prolapse', 'older women (≥65 years) participating in the ASPIRe trial', 'older women (≥65 years old) undergoing surgical procedures for the correction of apical POP']","['FASt', 'Preoperative Frailty Assessment', 'ASPIRe (Apical Suspension Repair for Vault Prolapse']","['Frailty and mobility measurements', 'moderate to severe postoperative adverse events according to the Clavien-Dindo Severity Classification']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0439820', 'cui_str': 'Popping sensation quality'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877015', 'cui_str': 'Urogenital Prolapse'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0205111', 'cui_str': 'Apical (qualifier value)'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0205111', 'cui_str': 'Apical (qualifier value)'}, {'cui': 'C1382107', 'cui_str': 'Suspension'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C0033377', 'cui_str': 'Prolapse'}]","[{'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0008903', 'cui_str': 'taxonomy'}]",,0.0665108,The Frailty ASPIRe Study (FASt) examines the impact of preoperative frailty and mobility on surgical outcomes in older women (≥65 years) participating in the ASPIRe trial.,"[{'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Erekson', 'Affiliation': 'From the Department of Obstetrics and Gynecology, The Geisel School of Medicine at Dartmouth, Hanover, NH.'}, {'ForeName': 'Shawn', 'Initials': 'S', 'LastName': 'Menefee', 'Affiliation': 'University of California, San Diego, and Kaiser Permanente, San Diego, CA.'}, {'ForeName': 'Ryan E', 'Initials': 'RE', 'LastName': 'Whitworth', 'Affiliation': 'RTI International, Research Triangle Park.'}, {'ForeName': 'Cindy L', 'Initials': 'CL', 'LastName': 'Amundsen', 'Affiliation': 'Duke University Medical Center, Durham, NC.'}, {'ForeName': 'Lily A', 'Initials': 'LA', 'LastName': 'Arya', 'Affiliation': 'University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Yuko M', 'Initials': 'YM', 'LastName': 'Komesu', 'Affiliation': 'University of New Mexico Health Sciences Center, Albuquerque, NM.'}, {'ForeName': 'Cecile A', 'Initials': 'CA', 'LastName': 'Ferrando', 'Affiliation': ""Department of Obstetrics, Gynecology & Women's Health Institute, Cleveland Clinic, Cleveland, OH.""}, {'ForeName': 'Halina M', 'Initials': 'HM', 'LastName': 'Zyczynski', 'Affiliation': 'The Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Magee-Womens Research Institute, Pittsburgh, PA.'}, {'ForeName': 'Vivian W', 'Initials': 'VW', 'LastName': 'Sung', 'Affiliation': 'Alpert Medical School of Brown University, Providence, RI.'}, {'ForeName': 'David D', 'Initials': 'DD', 'LastName': 'Rahn', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'Jasmine', 'Initials': 'J', 'LastName': 'Tan-Kim', 'Affiliation': 'University of California, San Diego, and Kaiser Permanente, San Diego, CA.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Mazloomdoost', 'Affiliation': 'The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD.'}, {'ForeName': 'Marie G', 'Initials': 'MG', 'LastName': 'Gantz', 'Affiliation': 'RTI International, Research Triangle Park.'}, {'ForeName': 'Holly E', 'Initials': 'HE', 'LastName': 'Richter', 'Affiliation': 'University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Female pelvic medicine & reconstructive surgery,['10.1097/SPV.0000000000000833'] 118,29384426,Korean clergy for healthy families: online intervention for preventing intimate partner violence.,"BACKGROUND Intimate partner violence (IPV) among immigrant women is a serious public health problem. Churches and clergy play a fundamental role in their lives, as a form of social organization and alternative to community services. PURPOSE To describe the implementation and evaluation of an intervention for Korean American faith leaders designed to increase knowledge about IPV and about resources to handle IPV, strengthen attitudes that do not support IPV, enhance self-efficacy to handle IPV, and increase prevention and intervention behaviors about IPV. METHODS Korean American faith leaders in a Southeastern state of the USA were invited to participate in the study ( n = 55). Participants completed two online assessments: baseline and a 3-month follow-up. After the baseline assessment, participants were randomized to either the intervention ( n = 27) or the control ( n = 28) group. The intervention consisted of three online modules, each taking approximately 30-45 min to complete. Modules were developed based on the researchers' work with Korean American faith leaders. Assessments and interventions were available in Korean and English. RESULTS Compared to the control group, the intervention group significantly improved their knowledge of resources and enhanced attitudes against IPV. The intervention group increased their self-efficacy and behaviors to prevent IPV more than the control group, but these changes were not statistically significant. CONCLUSIONS The online training provided a safe and convenient environment for the Korean American clergy, for whom anonymity and convenient access were important. Results are promising, but highlight the need to include more specific training of skills, which could be incorporated into the online modules in the form of an avatar. This online training could serve as a template to be adapted for other immigrant groups.",2019,"The intervention group increased their self-efficacy and behaviors to prevent IPV more than the control group, but these changes were not statistically significant. ","['immigrant women', 'intimate partner violence', 'Korean American faith leaders in a Southeastern state of the USA were invited to participate in the study ( n = 55', 'healthy families', 'Korean American faith leaders']",[],"['knowledge of resources and enhanced attitudes against IPV', 'self-efficacy and behaviors to prevent IPV']","[{'cui': 'C0282163', 'cui_str': 'Immigrants'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0597921', 'cui_str': 'Korean Americans'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0015576', 'cui_str': 'Family'}]",[],"[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0276240', 'cui_str': 'Infectious pustular vulvovaginitis (disorder)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}]",55.0,0.0305382,"The intervention group increased their self-efficacy and behaviors to prevent IPV more than the control group, but these changes were not statistically significant. ","[{'ForeName': 'Y Joon', 'Initials': 'YJ', 'LastName': 'Choi', 'Affiliation': 'University of Georgia, School of Social Work, Athens, GA, USA.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Orpinas', 'Affiliation': 'University of Georgia, Health Promotion and Behavior, Athens, GA, USA.'}, {'ForeName': 'Irang', 'Initials': 'I', 'LastName': 'Kim', 'Affiliation': 'Northwestern State University of Louisiana, Department of Social Work, Natchitoches, LA, USA.'}, {'ForeName': 'Kyung Soon', 'Initials': 'KS', 'LastName': 'Ko', 'Affiliation': ""Seoul Women's University, Korea.""}]",Global health promotion,['10.1177/1757975917747878'] 119,30773970,Accounts of Family Conflict in Home Hospice Care: The Central Role of Autonomy for Informal Caregiver Resilience.,"End-of-life caregiving is a highly stressful experience often fraught with conflict and tension. However, little is known about the ways family conflict manifests for informal caregivers of home hospice patients (IHCs). Framed by relational dialectics theory, the purpose of this study was to provide nurses and other health care professionals with an empirical understanding of how IHCs experience family conflict and tensions associated with caregiving. A second aim was to determine what strategies IHCs use to manage these family conflicts. Data used in this qualitative secondary analysis were originally collected as part of a randomized clinical trial of an IHC support intervention. Based on thematic analysis of data from 25 IHCs who reported family conflict, a conceptual model of caregiver resilience was developed from the themes and categories that emerged during the coding stage. Autonomy was identified as a central tension. IHCs used several strategies to address family conflict including communication, formal support, and emotional self-care.",2019,"However, little is known about the ways family conflict manifests for informal caregivers of home hospice patients (IHCs).",['informal caregivers of home hospice patients (IHCs'],[],[],"[{'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0019947', 'cui_str': 'Hospices'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]",[],[],,0.0238546,"However, little is known about the ways family conflict manifests for informal caregivers of home hospice patients (IHCs).","[{'ForeName': 'Jacquelyn J', 'Initials': 'JJ', 'LastName': 'Benson', 'Affiliation': '1 University of Missouri, Columbia, USA.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Parker Oliver', 'Affiliation': '1 University of Missouri, Columbia, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Demiris', 'Affiliation': '2 University of Pennsylvania, Philadelphia, USA.'}, {'ForeName': 'Karla', 'Initials': 'K', 'LastName': 'Washington', 'Affiliation': '1 University of Missouri, Columbia, USA.'}]",Journal of family nursing,['10.1177/1074840719828091'] 120,30820571,An Experimental Study of Nicotine Warning Statements in E-cigarette Tweets.,"INTRODUCTION It is unclear whether warnings on electronic cigarette (e-cigarette) advertisements required by the US Food and Drug Administration (FDA) will apply to social media. Given the key role of social media in marketing e-cigarettes, we seek to inform FDA decision making by exploring how warnings on various tweet content influence perceived healthiness, nicotine harm, likelihood to try e-cigarettes, and warning recall. METHODS In this 2 × 4 between-subjects experiment participants viewed a tweet from a fictitious e-cigarette brand. Four tweet content versions (e-cigarette product, e-cigarette use, e-cigarette in social context, unrelated content) were crossed with two warning versions (absent, present). Adult e-cigarette users (N = 994) were recruited via social media ads to complete a survey and randomized to view one of eight tweets. Multivariable regressions explored effects of tweet content and warning on perceived healthiness, perceived harm, and likelihood to try e-cigarettes, and tweet content on warning recall. Covariates were tobacco and social media use and demographics. RESULTS Tweets with warnings elicited more negative health perceptions of the e-cigarette brand than tweets without warnings (p < .05). Tweets featuring e-cigarette products (p < .05) or use (p < .001) elicited higher warning recall than tweets featuring unrelated content. CONCLUSIONS This is the first study to examine warning effects on perceptions of e-cigarette social media marketing. Warnings led to more negative e-cigarette health perceptions, but no effect on perceived nicotine harm or likelihood to try e-cigarettes. There were differences in warning recall by tweet content. Research should explore how varying warning content (text, size, placement) on tweets from e-cigarette brands influences health risk perceptions. IMPLICATIONS FDA's 2016 ruling requires warnings on advertisements for nicotine-containing e-cigarettes, but does not specify whether this applies to social media. This study is the first to examine how e-cigarette warnings in tweets influence perceived healthiness and harm of e-cigarettes, which is important because e-cigarette brands are voluntarily including warnings on Twitter and Instagram. Warnings influenced perceived healthiness of the e-cigarette brand, but not perceived nicotine harm or likelihood to try e-cigarettes. We also saw higher recall of warning statements for tweets featuring e-cigarettes. Findings suggest that expanding warning requirements to e-cigarette social media marketing warrants further exploration and FDA consideration.",2020,"Tweets featuring ecigarette products (p< 0.05) or use (p< 0.001) elicited higher warning recall than tweets featuring unrelated content. ","['n this 2x4 between-subjects experiment participants viewed a tweet from a fictitious e-cigarette brand', 'Adult ecigarette users (n=\xa0994) were recruited via social media ads to complete a survey and randomized to view one of 8 tweets']",['nicotine'],"['negative health perceptions', 'perceived healthiness, perceived harm, and likelihood to try e-cigarettes and tweet content on warning recall', 'warning recall']","[{'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C3849993', 'cui_str': 'Electronic Cigarettes'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3179065', 'cui_str': 'Social Media'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]","[{'cui': 'C0028040', 'cui_str': 'Nicotine'}]","[{'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C3849993', 'cui_str': 'Electronic Cigarettes'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}]",994.0,0.0105378,"Tweets featuring ecigarette products (p< 0.05) or use (p< 0.001) elicited higher warning recall than tweets featuring unrelated content. ","[{'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Guillory', 'Affiliation': 'Prime Affect Research, Dublin, Ireland.'}, {'ForeName': 'Annice E', 'Initials': 'AE', 'LastName': 'Kim', 'Affiliation': 'Center for Health Policy Science and Tobacco Research, RTI International, Research Triangle Park, NC.'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Fiacco', 'Affiliation': 'Center for Health Policy Science and Tobacco Research, RTI International, Research Triangle Park, NC.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Cress', 'Affiliation': 'Center for Health Policy Science and Tobacco Research, RTI International, Research Triangle Park, NC.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Pepper', 'Affiliation': 'Center for Health Policy Science and Tobacco Research, RTI International, Research Triangle Park, NC.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Nonnemaker', 'Affiliation': 'Center for Health Policy Science and Tobacco Research, RTI International, Research Triangle Park, NC.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntz029'] 121,31853727,Making Internet-delivered cognitive behaviour therapy scalable for cancer survivors: a randomized non-inferiority trial of self-guided and technician-guided therapy.,"PURPOSE To compare the effectiveness and acceptability of two low-intensity methods of offering a transdiagnostic Internet-delivered cognitive behaviour therapy (ICBT) intervention for treating symptoms of anxiety and depression among cancer survivors. METHODS Cancer survivors with symptoms of anxiety or depression (n = 86) were randomly assigned to receive a transdiagnostic ICBT programme (Wellbeing After Cancer) that was either guided by a technician (n = 42) or self-guided (n = 44). Measures of anxiety, depression, fear of cancer recurrence, and quality of life were completed at pre-treatment, post-treatment, and 4 weeks following treatment completion. RESULTS Large within-group effect sizes were observed on measures of depression, anxiety, and mental health-related quality of life (d range, 0.98-1.86) at post-treatment. Medium effects were found for reductions in fear of cancer recurrence (d range, 0.65-0.78). Non-inferiority was established for the primary outcome measures of anxiety and depression. All participants reported high satisfaction ratings of the programme; however, technician-guided participants were slightly more satisfied with their level of support (d = 0.57, p = .014). CONCLUSIONS The Wellbeing After Cancer Course was associated with improved levels of anxiety, depression, fear of cancer recurrence, and quality of life, regardless of how ICBT was offered. IMPLICATIONS FOR CANCER SURVIVORS ICBT is emerging as an accessible and effective treatment for depression, anxiety, and fear of cancer recurrence in cancer survivors. The success of non-therapist-guided options increases the potential scalability of ICBT, which is particularly valuable for cancer survivors from rural areas who have less access to mental health services.",2020,"Medium effects were found for reductions in fear of cancer recurrence (d range, 0.65-0.78).","['FOR CANCER SURVIVORS', 'cancer survivors', 'Cancer survivors with symptoms of anxiety or depression (n = 86']","['ICBT', 'transdiagnostic Internet-delivered cognitive behaviour therapy (ICBT) intervention', 'transdiagnostic ICBT programme (Wellbeing After Cancer) that was either guided by a technician (n = 42) or self-guided', 'self-guided and technician-guided therapy', 'Making Internet-delivered cognitive behaviour therapy scalable']","['high satisfaction ratings', 'levels of anxiety, depression, fear of cancer recurrence, and quality of life, regardless of how ICBT', 'fear of cancer recurrence', 'anxiety, depression, fear of cancer recurrence, and quality of life', 'effectiveness and acceptability', 'anxiety and depression', 'depression, anxiety, and mental health-related quality of life']","[{'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety (observable entity)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0233705', 'cui_str': 'Fear of getting cancer (finding)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0034380'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}]",,0.136007,"Medium effects were found for reductions in fear of cancer recurrence (d range, 0.65-0.78).","[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Dirkse', 'Affiliation': 'Department of Clinical Health Psychology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, PZ 350 - 771 Bannatyne Avenue, Winnipeg, MB, R3E 3N4, Canada. ddirkse@hsc.mb.ca.'}, {'ForeName': 'H D', 'Initials': 'HD', 'LastName': 'Hadjistavropoulos', 'Affiliation': 'Department of Psychology, University of Regina, 3737 Wascana Parkway, Regina, SK, S4S 0A2, Canada.'}, {'ForeName': 'N A', 'Initials': 'NA', 'LastName': 'Alberts', 'Affiliation': ""Department of Psychology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-3678, USA.""}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Karin', 'Affiliation': 'eCentreClinic, Department of Psychology, Macquarie University, Sydney, Australia.'}, {'ForeName': 'L H', 'Initials': 'LH', 'LastName': 'Schneider', 'Affiliation': 'Department of Psychology, University of Regina, 3737 Wascana Parkway, Regina, SK, S4S 0A2, Canada.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Titov', 'Affiliation': 'eCentreClinic, Department of Psychology, Macquarie University, Sydney, Australia.'}, {'ForeName': 'B F', 'Initials': 'BF', 'LastName': 'Dear', 'Affiliation': 'eCentreClinic, Department of Psychology, Macquarie University, Sydney, Australia.'}]",Journal of cancer survivorship : research and practice,['10.1007/s11764-019-00810-9'] 122,32139254,Consumption of a diet high in dairy leads to higher 15:0 in cholesteryl esters of healthy people when compared to diets high in meat and grain.,"BACKGROUND AND AIMS A higher dairy product intake has been associated to higher blood concentrations of 15:0 (pentadecanoic acid), 17:0 (margaric acid), and 14:0 (myristic acid). This study investigates whether a diet high in dairy products influences cholesteryl ester fatty acid concentrations of these specific fatty acids (FA). METHODS AND RESULTS In a randomized multiple cross-over study, 13 men and 17 women aged 22 ± 4 years with a BMI of 21.6 ± 2.2 kg/m 2 received 3 isocaloric intervention diets (dairy, meat or grain) in random order. For this post-hoc analysis, FA in plasma cholesteryl esters were measured using gas chromatography. We performed a linear mixed model per centered log-ratio transformed FA, adjusting for period, and the interaction between diet and period. Consumed total fat intake per controlled intervention diet was 31.0 ± 0.9 en%/day (dairy), 31.5 ± 0.6 en%/day (meat), and 28.4 ± 1.2 en%/day (grain), respectively. The dairy diet led to higher relative concentrations of 15:0 when compared to diets high in meat and grain, (β; 0.27, 95%CI: 0.18,0.37; p = 1.2 × 10 -5 , and β: 0.15; 95%CI: 0.06,0.24; p = 1.2 × 10 -2 , respectively). The dairy diet also led to higher 14:0 when compared to the meat diet (β: 0.34; 95%CI: 0.21,0.46; p = 6.0 × 10 -5 ), but not when compared to the grain diet. 17:0 did not differ between diets. CONCLUSION The plasma cholesteryl ester fraction after a diet high in dairy was characterized by higher 15:0 levels. Concentrations of 14:0 were only higher when comparing the FA profile after a diet high in dairy when compared to a diet high in meat. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT01314040.",2020,"The dairy diet also led to higher 14:0 when compared to the meat diet (β: 0.34; 95%CI: 0.21,0.46; p = ",['13 men and 17 women aged 22\xa0±\xa04 years with a BMI of 21.6\xa0±\xa02.2'],"['isocaloric intervention diets (dairy, meat or grain']","['plasma cholesteryl ester fraction', 'plasma cholesteryl esters']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517629', 'cui_str': '2.2'}]","[{'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0025017', 'cui_str': 'Meat'}, {'cui': 'C0086369', 'cui_str': 'Grain (substance)'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0008387', 'cui_str': 'Cholesteryl Esters'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}]",13.0,0.0405382,"The dairy diet also led to higher 14:0 when compared to the meat diet (β: 0.34; 95%CI: 0.21,0.46; p = ","[{'ForeName': 'Linda E T', 'Initials': 'LET', 'LastName': 'Vissers', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. Electronic address: l.e.t.vissers@umcutrecht.nl.'}, {'ForeName': 'Sabita S', 'Initials': 'SS', 'LastName': 'Soedamah-Muthu', 'Affiliation': 'Division of Human Nutrition and Health, Wageningen University, Wageningen, the Netherlands; Center of Research on Psychological and Somatic Disorders (CORPS), Department of Medical and Clinical Psychology, Tilburg University, the Netherlands; Institute for Food, Nutrition and Health, University of Reading, Reading, UK.'}, {'ForeName': 'Yvonne T', 'Initials': 'YT', 'LastName': 'van der Schouw', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Nicolaas P A', 'Initials': 'NPA', 'LastName': 'Zuithoff', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Johanna M', 'Initials': 'JM', 'LastName': 'Geleijnse', 'Affiliation': 'Division of Human Nutrition and Health, Wageningen University, Wageningen, the Netherlands.'}, {'ForeName': 'Ivonne', 'Initials': 'I', 'LastName': 'Sluijs', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. Electronic address: I.Sluijs-2@umcutrecht.nl.'}]","Nutrition, metabolism, and cardiovascular diseases : NMCD",['10.1016/j.numecd.2020.01.006'] 123,32127336,Impact of body mass index on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: Insights from the ELDERLY ACS 2 trial.,"BACKGROUND AND AIM Elderly patients are at increased risk of hemorrhagic and thrombotic complications after an acute coronary syndrome (ACS). Frailty, comorbidities and low body weight have emerged as conditioning the prognostic impact of dual antiplatelet therapy (DAPT). The aim of the present study was to investigate the prognostic impact of body mass index (BMI) on clinical outcome among patients included in the Elderly-ACS 2 trial, a randomized, open-label, blinded endpoint study comparing low-dose (5 mg) prasugrel vs clopidogrel among elderly patients with ACS. METHODS AND RESULTS Our population is represented by 1408 patients enrolled in the Elderly-ACS 2 trial. BMI was calculated at admission. The primary endpoint of this analysis was cardiovascular (CV) mortality. Secondary endpoints were all-cause death, recurrent MI, Bleeding Academic Research Consortium (BARC) type 2 or 3 bleeding, and re-hospitalization for cardiovascular reasons or stent thrombosis within 12 months after index admission. Patients were grouped according to median values of BMI ( = 16, with high distress (assessed using the GHQ-28), and actively help-seeking, individually randomised, and assessed online. Primary outcome was relatives' distress (GHQ-28) at 24 weeks. Secondary outcomes were wellbeing, support, costs and user feedback. RESULTS We recruited 800 relatives (REACT = 399; RD only = 401) with high distress at baseline (GHQ-28 REACT mean 40.3, SD 14.6; RD only mean 40.0, SD 14.0). Median time spent online on REACT was 50.8 min (IQR 12.4-172.1) versus 0.5 min (IQR 0-1.6) on RD only. Retention to primary follow-up (24 weeks) was 75% (REACT n = 292 (73.2%); RD-only n = 307 (76.6%)). Distress decreased in both groups by 24 weeks, with no significant difference between the two groups (- 1.39, 95% CI -3.60, 0.83, p = 0.22). Estimated cost of delivering REACT was £62.27 per person and users reported finding it safe, acceptable and convenient. There were no adverse events or reported side effects. CONCLUSIONS REACT is an inexpensive, acceptable, and safe way to deliver NICE-recommended support for relatives. However, for highly distressed relatives it is no more effective in reducing distress (GHQ-28) than a comprehensive online resource directory. TRIAL REGISTRATION ISRCTN72019945 prospectively registered 19/11/2015.",2020,"BACKGROUND The Relatives Education And Coping Toolkit (REACT) is an online supported self-management toolkit for relatives of people with psychosis or bipolar designed to improve access to NICE recommended information and emotional support. ","['We recruited 800 relatives (REACT\u2009=\u2009399; RD only\u2009=\u2009401) with high distress at baseline (GHQ-28 REACT mean 40.3, SD 14.6; RD only mean 40.0, SD 14.0', 'relatives of people with psychosis or bipolar (REACT', 'Participants were UK relatives aged >\u2009=\u200916, with high distress (assessed using the GHQ-28), and actively help-seeking']","['REACT', 'Coping Toolkit (REACT', 'web-based peer-supported self-management intervention']","['Estimated cost of delivering REACT', 'wellbeing, support, costs and user feedback', ""relatives' distress (GHQ-28"", 'Distress', 'Median time spent online on REACT']","[{'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0282426', 'cui_str': 'Directories'}, {'cui': 'C0205171', 'cui_str': 'Singular'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0443156', 'cui_str': 'Bipolar'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0439091', 'cui_str': '>='}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}]","[{'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",800.0,0.28686,"BACKGROUND The Relatives Education And Coping Toolkit (REACT) is an online supported self-management toolkit for relatives of people with psychosis or bipolar designed to improve access to NICE recommended information and emotional support. ","[{'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Lobban', 'Affiliation': 'Spectrum Centre for Mental Health Research, Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK. f.lobban@lancaster.ac.uk.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Akers', 'Affiliation': 'Spectrum Centre for Mental Health Research, Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Duncan', 'Initials': 'D', 'LastName': 'Appelbe', 'Affiliation': 'Clinical Trials Research Centre, Institute of Child Health, Alder Hey, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Lesley', 'Initials': 'L', 'LastName': 'Chapman', 'Affiliation': 'Spectrum Centre for Mental Health Research, Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Lizzi', 'Initials': 'L', 'LastName': 'Collinge', 'Affiliation': 'Spectrum Centre for Mental Health Research, Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Dodd', 'Affiliation': 'Clinical Trials Research Centre, Institute of Child Health, Alder Hey, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Flowers', 'Affiliation': 'Spectrum Centre for Mental Health Research, Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Hollingsworth', 'Affiliation': 'Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Johnson', 'Affiliation': 'University College London, Maple House, 149 Tottenham Court Road, London, W1T 7NF, UK.'}, {'ForeName': 'Steven H', 'Initials': 'SH', 'LastName': 'Jones', 'Affiliation': 'Spectrum Centre for Mental Health Research, Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Ceu', 'Initials': 'C', 'LastName': 'Mateus', 'Affiliation': 'Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Mezes', 'Affiliation': 'Spectrum Centre for Mental Health Research, Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Murray', 'Affiliation': 'e-Health and Primary Care, Primary Care & Population Health Institute of Epidemiology & Health, Faculty of Pop Health Sciences, University College London, London, UK.'}, {'ForeName': 'Katerina', 'Initials': 'K', 'LastName': 'Panagaki', 'Affiliation': 'Spectrum Centre for Mental Health Research, Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Rainford', 'Affiliation': 'Clinical Trials Research Centre, Institute of Child Health, Alder Hey, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Robinson', 'Affiliation': 'Spectrum Centre for Mental Health Research, Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Rosala-Hallas', 'Affiliation': 'Clinical Trials Research Centre, Institute of Child Health, Alder Hey, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Sellwood', 'Affiliation': 'Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Walker', 'Affiliation': 'Spectrum Centre for Mental Health Research, Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Williamson', 'Affiliation': 'Clinical Trials Research Centre, Institute of Child Health, Alder Hey, University of Liverpool, Liverpool, UK.'}]",BMC psychiatry,['10.1186/s12888-020-02545-9'] 150,32054896,"Instability Resistance Training improves Working Memory, Processing Speed and Response Inhibition in Healthy Older Adults: A Double-Blinded Randomised Controlled Trial.","Aging is associated with declines in physical and cognitive performance. While there is no doubt about beneficial effects of physical exercise on proxies of strength and balance, the overall evidence for positive effects of resistance and balance training on executive functions is rather inconsistent. Whether the simultaneous exercising of strength and balance, i.e., instability resistance training, promotes executive functions in older adults is unknown. In the present trial, we tested the effects of unstable vs. stable resistance training on executive functions. Sixty-eight healthy older adults aged 65-79 years were randomly assigned to either an instability free-weight resistance training or one of two stable machine-based resistance training programs. Each group exercised twice a week on non-consecutive days for 10 weeks. Four tests to evaluate specific domains of executive functions were administered prior and following training: working memory, processing speed, response inhibition and set-shifting. The instability resistance training group improved working memory, processing speed and response inhibition from pre to post-test. In contrast, we found no improvements in executive functions for both stable resistance training groups. Our results demonstrate that 10 weeks of instability resistance training suffice to improve executive functions in older adults.",2020,Sixty-eight healthy older adults aged 65-79 years were randomly assigned to either an instability free-weight resistance training or one of two stable machine-based resistance training programs.,"['Healthy Older Adults', 'older adults', 'Sixty-eight healthy older adults aged 65-79 years']","['Instability Resistance Training', 'physical exercise', 'unstable vs. stable resistance training', 'instability free-weight resistance training or one of two stable machine-based resistance training programs']","['physical and cognitive performance', 'executive functions', 'working memory, processing speed and response inhibition', 'Working Memory, Processing Speed and Response Inhibition']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0450387', 'cui_str': '68 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C1444783', 'cui_str': 'Instability'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0443343', 'cui_str': 'Unstable status (qualifier value)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0336779', 'cui_str': 'Machine, device (physical object)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0582591', 'cui_str': 'Processing speed (observable entity)'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}]",68.0,0.0361629,Sixty-eight healthy older adults aged 65-79 years were randomly assigned to either an instability free-weight resistance training or one of two stable machine-based resistance training programs.,"[{'ForeName': 'Nils', 'Initials': 'N', 'LastName': 'Eckardt', 'Affiliation': 'University of Kassel, Institute of Sports and Sport Science, Department of Training and Movement Science, Kassel, 34121, Germany. nils.eckardt@uol.de.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Braun', 'Affiliation': 'University of Kassel, Institute of Sports and Sport Science, Department of Training and Movement Science, Kassel, 34121, Germany.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Kibele', 'Affiliation': 'University of Kassel, Institute of Sports and Sport Science, Department of Training and Movement Science, Kassel, 34121, Germany.'}]",Scientific reports,['10.1038/s41598-020-59105-0'] 151,32316864,Amazake made from sake cake and rice koji suppresses sebum content in differentiated hamster sebocytes and improves skin properties in humans.,"Amazake is a traditional Japanese health drink. Here, we examined the effects of amazake on skin in cells and humans. Treatment with sake cake or rice koji suppressed intracellular lipid accumulation in differentiated hamster sebocytes, likely through the reduced expression of peroxisome proliferator-activated receptor-gamma (PPARγ) mRNA. In double-blind, placebo-controlled trial, seventeen Japanese women ingested either amazake or placebo for 4 weeks. Ingestion of the amazake decreased the sebum content compared to the placebo. The questionnaires showed improvements in ""face color,"" ""dark circles under the eyes,"" ""glossy hair,"" and ""waking up well"", only in the amazake. In accordance with the questionnaires, additional analysis revealed the change in the L* values under the eyes was statistically increased in the amazake compared to the placebo. These results indicate that amazake may decrease sebum content in cells and humans and increase the L* values under the eyes, with some additional beneficial effects in humans.",2020,Ingestion of the amazake decreased the sebum content compared to the placebo.,['seventeen Japanese women ingested either'],"['amazake', 'amazake or placebo', 'sake cake or rice koji', 'placebo']","['skin properties', 'sebum content', 'intracellular lipid accumulation', 'face color,"" ""dark circles under the eyes,"" ""glossy hair,"" and ""waking up well']","[{'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0452597', 'cui_str': 'Cake'}, {'cui': 'C0035567', 'cui_str': 'Rice'}]","[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0036511', 'cui_str': 'Sebum'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0175996', 'cui_str': 'Protoplasm'}, {'cui': 'C0333574', 'cui_str': 'Fatty deposition'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0332582', 'cui_str': 'Dark color'}, {'cui': 'C0231706', 'cui_str': 'Circling gait'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0442696', 'cui_str': 'Waking'}]",17.0,0.0923512,Ingestion of the amazake decreased the sebum content compared to the placebo.,"[{'ForeName': 'Hiroko', 'Initials': 'H', 'LastName': 'Maruki-Uchida', 'Affiliation': 'Health Science Research Center, R&D Institute, Morinaga and Company Limited , Yokohama, Japan.'}, {'ForeName': 'Masahiko', 'Initials': 'M', 'LastName': 'Sai', 'Affiliation': 'Health Science Research Center, R&D Institute, Morinaga and Company Limited , Yokohama, Japan.'}, {'ForeName': 'Shoichiro', 'Initials': 'S', 'LastName': 'Yano', 'Affiliation': 'Yaesu Nihonbashi Skin Clinic , Tokyo, Japan.'}, {'ForeName': 'Minoru', 'Initials': 'M', 'LastName': 'Morita', 'Affiliation': 'Health Science Research Center, R&D Institute, Morinaga and Company Limited , Yokohama, Japan.'}, {'ForeName': 'Kazuhisa', 'Initials': 'K', 'LastName': 'Maeda', 'Affiliation': 'School of Bioscience and Biotechnology, Tokyo University of Technology , Hachioji, Tokyo, Japan.'}]","Bioscience, biotechnology, and biochemistry",['10.1080/09168451.2020.1756734'] 152,32310145,Effectiveness of a Web-Based Intervention to Support Medication Adherence Among People Living With HIV: Web-Based Randomized Controlled Trial.,"BACKGROUND Taking antiretroviral therapy (ART) is part of the daily life of people living with HIV. Different electronic health (eHealth) initiatives adjunctive to usual care have been proposed to support optimal medication adherence. A web-based intervention called HIV Treatment, Virtual Nursing Assistance, and Education or VIH-TAVIE (from its French version Virus de l'immunodéficience humaine-Traitement assistance virtuelle infirmière et enseignement) was developed to empower people living with HIV to manage their ART and symptoms optimally. OBJECTIVE We aimed to evaluate the effectiveness of VIH-TAVIE in a web-based randomized controlled trial (RCT). METHODS This RCT was entirely web-based, including recruitment, consent granting, questionnaire completion, and intervention exposure (consultation with VIH-TAVIE [experimental group] or websites [control group]). To be eligible for the study, people living with HIV had to be 18 years or older, be on ART for at least 6 months, have internet access, and have internet literacy. Participants were randomly assigned to either the experimental group (n=45) or control group (n=43). The primary outcome was ART adherence. The secondary outcomes included self-efficacy regarding medication intake, symptom-related discomfort, skills and strategies, and social support. All outcomes were measured with a self-administered web-based questionnaire at the following three time points: baseline and 3 and 6 months later. A generalized linear mixed model was built to assess the evolution of ART adherence over time in both groups. RESULTS The sample included 88 participants, and of these, 73 (83%) were men. The median age of the participants was 42 years. Participants had been diagnosed with HIV a median of 7 years earlier (IQR 3-17) and had been on ART for a median of 5 years (IQR 2-12). The proportion of treatment-adherent participants at baseline was high in both groups (34/41, 83% in the experimental group and 30/39, 77% in the control group). Participants also reported high treatment adherence, high self-efficacy, and high skills; perceived good social support; and experienced low discomfort from symptoms. Analyses revealed no intergroup difference regarding ART adherence (OR 1.9, 95% CI 0.6-6.4). CONCLUSIONS This study highlights the challenges and lessons learned from conducting an entirely web-based RCT among people living with HIV. The challenges were related to the engagement of people living with HIV on the following three levels: starting the web-based study (recruitment), completing the web-based intervention (engagement), and continuing the study (retention). The results contribute to the existing body of knowledge regarding how to conduct web-based evaluation studies of eHealth interventions aimed at developing and strengthening personal skills and abilities. TRIAL REGISTRATION ClinicalTrials.gov NCT01510340; https://clinicaltrials.gov/ct2/show/NCT01510340.",2020,"The secondary outcomes included self-efficacy regarding medication intake, symptom-related discomfort, skills and strategies, and social support.","['people living with HIV', 'The sample included 88 participants, and of these, 73 (83%) were men', 'Participants had been diagnosed with HIV a median of 7 years earlier (IQR 3-17) and had been on ART for a median of 5 years (IQR 2-12', 'people living with HIV had to be 18 years or older, be on ART for at least 6 months, have internet access, and have internet literacy', 'People Living With HIV']","['Web-Based Intervention', 'VIH-TAVIE', 'antiretroviral therapy (ART']","['self-efficacy regarding medication intake, symptom-related discomfort, skills and strategies, and social support', 'ART adherence']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C4704731', 'cui_str': 'Internet Access'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}]","[{'cui': 'C3898714', 'cui_str': 'Internet Intervention'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",88.0,0.218067,"The secondary outcomes included self-efficacy regarding medication intake, symptom-related discomfort, skills and strategies, and social support.","[{'ForeName': 'José', 'Initials': 'J', 'LastName': 'Côté', 'Affiliation': ""Research Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Geneviève', 'Initials': 'G', 'LastName': 'Rouleau', 'Affiliation': ""Research Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Maria Pilar', 'Initials': 'MP', 'LastName': 'Ramirez-Garcia', 'Affiliation': ""Research Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Auger', 'Affiliation': ""Research Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Réjean', 'Initials': 'R', 'LastName': 'Thomas', 'Affiliation': ""Clinique médicale l'Actuel, Montreal, QC, Canada.""}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Leblanc', 'Affiliation': ""Research Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}]",JMIR public health and surveillance,['10.2196/17733'] 153,32281159,Intensive control of hypertension and risk of Alzheimer's dementia in older adults with depression.,"OBJECTIVES Intensive control of hypertension has been reported to decrease risk of cognitive decline. However, the effect of this in older adults with hypertension and comorbid depression is not well understood. We aim to identify whether intensive control of systolic blood pressure (BP) is associated with reduced risk of Alzheimer's dementia (AD) in a clinical population. METHODS Using data from the National Alzheimer's Coordinating Center, we conducted survival analyses in older adults with normal cognition at baseline and treated hypertension. We also examined those with comorbid depression, to determine if intensive control of systolic BP (≤120 mmHg) was associated with reduced risk of AD. RESULTS In all older adults with treated hypertension (n = 4505), 298 (6.6%) developed AD during a median follow-up duration of 4.2 years. In the comorbid depression subgroup (n = 1327), 152 (11.5%) developed AD. Intensive control of systolic BP was not significantly associated with reduced risk of AD in the overall sample (HR 1.13, 95%, 0.79-1.64). However, in the comorbid depression subgroup, intensive control of systolic BP (≤120 mmHg) was associated with increased risk of AD (HR 1.49, 95%, 1.03-2.15) compared to standard control (121-139 mmHg). CONCLUSIONS In a clinical population of older adults with hypertension and comorbid depression, we found that an intensive systolic BP target of ≤120 mmHg was associated with increased risk of AD. While these findings are preliminary, they suggest that a more cautious approach to hypertension treatment may be warranted in this vulnerable subgroup.",2020,"Intensive control of systolic BP was not significantly associated with reduced risk of AD in the overall sample (HR 1.13, 95%, 0.79-1.64).","[""Using data from the National Alzheimer's Coordinating Center, we conducted survival analyses in older adults with normal cognition at baseline and treated hypertension"", 'older adults with hypertension and comorbid depression', 'older adults with depression', 'older adults with treated hypertension (n = 4505), 298 (6.6%) developed AD during a median follow-up duration of 4.2\u2009years']",['intensive control of systolic blood pressure (BP'],"['risk of AD', 'intensive control of systolic BP']","[{'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0427184', 'cui_str': 'No incoordination'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0038953', 'cui_str': 'Analysis, Survival'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2712133', 'cui_str': 'Normal cognition'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C4517823', 'cui_str': '6.6'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C4517758', 'cui_str': '4.2'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",4505.0,0.143044,"Intensive control of systolic BP was not significantly associated with reduced risk of AD in the overall sample (HR 1.13, 95%, 0.79-1.64).","[{'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Yeung', 'Affiliation': 'Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Kiss', 'Affiliation': 'Evaluative Clinical Sciences, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.'}, {'ForeName': 'Damien', 'Initials': 'D', 'LastName': 'Gallagher', 'Affiliation': 'Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.'}]",International journal of geriatric psychiatry,['10.1002/gps.5309'] 154,32317591,Potential for Lung Recruitment and Ventilation-Perfusion Mismatch in Patients With the Acute Respiratory Distress Syndrome From Coronavirus Disease 2019.,"OBJECTIVES Severe cases of coronavirus disease 2019 develop the acute respiratory distress syndrome, requiring admission to the ICU. This study aimed to describe specific pathophysiological characteristics of acute respiratory distress syndrome from coronavirus disease 2019. DESIGN Prospective crossover physiologic study. SETTING ICU of a university-affiliated hospital from northern Italy dedicated to care of patients with confirmed diagnosis of coronavirus disease 2019. PATIENTS Ten intubated patients with acute respiratory distress syndrome and confirmed diagnosis of coronavirus disease 2019. INTERVENTIONS We performed a two-step positive end-expiratory pressure trial with change of 10 cm H2O in random order. MEASUREMENTS AND MAIN RESULTS At each positive end-expiratory pressure level, we assessed arterial blood gases, respiratory mechanics, ventilation inhomogeneity, and potential for lung recruitment by electrical impedance tomography. Potential for lung recruitment was assessed by the recently described recruitment to inflation ratio. In a subgroup of seven paralyzed patients, we also measured ventilation-perfusion mismatch at lower positive end-expiratory pressure by electrical impedance tomography. At higher positive end-expiratory pressure, respiratory mechanics did not change significantly: compliance remained relatively high with low driving pressure. Oxygenation and ventilation inhomogeneity improved but arterial CO2 increased despite unchanged respiratory rate and tidal volume. The recruitment to inflation ratio presented median value higher than previously reported in acute respiratory distress syndrome patients but with large variability (median, 0.79 [0.53-1.08]; range, 0.16-1.40). The FIO2 needed to obtain viable oxygenation at lower positive end-expiratory pressure was significantly correlated with the recruitment to inflation ratio (r = 0.603; p = 0.05). The ventilation-perfusion mismatch was elevated (median, 34% [32-45%] of lung units) and, in six out of seven patients, ventilated nonperfused units represented a much larger proportion than perfused nonventilated ones. CONCLUSIONS In patients with acute respiratory distress syndrome from coronavirus disease 2019, potential for lung recruitment presents large variability, while elevated dead space fraction may be a specific pathophysiological trait. These findings may guide selection of personalized mechanical ventilation settings.",2020,"At higher positive end-expiratory pressure, respiratory mechanics did not change significantly: compliance remained relatively high with low driving pressure.","['Patients With the Acute Respiratory Distress Syndrome From Coronavirus Disease 2019', 'patients with acute respiratory distress syndrome', 'acute respiratory distress syndrome from coronavirus disease 2019', 'ICU of a university-affiliated hospital from northern Italy dedicated to care of patients with confirmed diagnosis of coronavirus disease 2019', 'Ten intubated patients with acute respiratory distress syndrome and confirmed diagnosis of coronavirus disease 2019', 'Severe cases of coronavirus disease 2019 develop the acute respiratory distress syndrome, requiring admission to the ICU']",['Lung Recruitment and Ventilation-Perfusion Mismatch'],"['arterial blood gases, respiratory mechanics, ventilation inhomogeneity, and potential for lung recruitment by electrical impedance tomography', 'respiratory rate and tidal volume', 'ventilation-perfusion mismatch']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C2721740', 'cui_str': 'Ventilation perfusion mismatch'}]","[{'cui': 'C0150411', 'cui_str': 'Analysis of arterial blood gases and pH'}, {'cui': 'C0035230', 'cui_str': 'Breathing Mechanics'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0162537', 'cui_str': 'Impedance'}, {'cui': 'C0040395', 'cui_str': 'Diagnostic tomography'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C2721740', 'cui_str': 'Ventilation perfusion mismatch'}]",10.0,0.127794,"At higher positive end-expiratory pressure, respiratory mechanics did not change significantly: compliance remained relatively high with low driving pressure.","[{'ForeName': 'Tommaso', 'Initials': 'T', 'LastName': 'Mauri', 'Affiliation': ""Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Spinelli', 'Affiliation': ""Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Scotti', 'Affiliation': ""Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Colussi', 'Affiliation': ""Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Maria Cristina', 'Initials': 'MC', 'LastName': 'Basile', 'Affiliation': ""Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Crotti', 'Affiliation': ""Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Tubiolo', 'Affiliation': ""Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Tagliabue', 'Affiliation': ""Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Zanella', 'Affiliation': ""Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Grasselli', 'Affiliation': ""Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Pesenti', 'Affiliation': ""Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}]",Critical care medicine,['10.1097/CCM.0000000000004386'] 155,32311466,Reduction in Post-Discharge Return to Acute Care in Hepatopancreatobiliary Surgery: Results of a Quality Improvement Initiative.,"BACKGROUND Postoperative returns to acute care represent fragmented care, are costly, and often evolve into readmission. Reduction of postoperative readmissions and emergency department visits represents an opportunity to improve quality of care and decrease resource use. The aim of this study was to assess the impact of 2 failure modes and effects analysis-guided quality improvement interventions on return to acute care within 30 days postoperatively. METHODS An American College of Surgeons NSQIP database analysis of adult patients treated by a single hepatopancreatobiliary surgeon at a quaternary academic center was performed. Two failure modes and effects analysis-guided quality improvement interventions were assessed in a staged fashion, including a post-discharge phone call follow-up, and a preoperative clinic visit to discuss plans of care. The primary end point of interest was return to acute care (readmission or emergency department use) within 30 days from postoperative discharge. RESULTS During the 4-year study period, 684 patients underwent a hepatopancreatobiliary operation. After the implementation of the failure modes and effects analysis interventions, the baseline 30-day readmission rate was reduced by 48% post intervention (13.5% vs 6.9%; p = 0.011). This impact was sustained, with a readmission rate below the lowest baseline in 5 of 6 postintervention quarters. Short-stay readmissions were reduced by > 76% after the interventions (28.5% vs 6.6%). Post-discharge emergency department visits were also reduced by nearly 40% after initiation of both failure modes and effects analysis-guided quality improvement interventions (11.3% vs 6.9%; p = 0.125), which showed similar sustained response. CONCLUSIONS The results from this study can be used to help identify, develop, and test interventions to optimize emergency department use and readmission to reduce healthcare costs and improve patient quality of life.",2020,"This impact was sustained, with a readmission rate below the lowest baseline in 5 of 6 post-intervention quarters.","['684 patients underwent an HPB operation', 'Hepatopancreatobiliary Surgery', 'return to acute care within 30 days postoperatively', 'adult patients treated by a single hepatopancreatobiliary surgeon at a quaternary academic center was performed']",['FMEA-guided quality improvement (FQI) interventions'],"['return to acute care (readmission or ED utilization', 'patient quality of life', 'readmission rate', 'Post-discharge emergency department visits', 'Short-stay readmissions', 'baseline 30-day readmission rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C2936612', 'cui_str': 'Quality Improvement'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0030700', 'cui_str': 'Thirty Day Readmission'}]",684.0,0.0355843,"This impact was sustained, with a readmission rate below the lowest baseline in 5 of 6 post-intervention quarters.","[{'ForeName': 'Brendan P', 'Initials': 'BP', 'LastName': 'Lovasik', 'Affiliation': 'Department of Surgery, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Catherine M', 'Initials': 'CM', 'LastName': 'Blair', 'Affiliation': 'Department of Surgery, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Lori A', 'Initials': 'LA', 'LastName': 'Little', 'Affiliation': 'Department of Surgery, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Marty', 'Initials': 'M', 'LastName': 'Sellers', 'Affiliation': 'Department of Surgery, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'Sweeney', 'Affiliation': 'Department of Surgery, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Juan M', 'Initials': 'JM', 'LastName': 'Sarmiento', 'Affiliation': 'Department of Surgery, Emory University School of Medicine, Atlanta, GA. Electronic address: jmsarmie@emory.edu.'}]",Journal of the American College of Surgeons,['10.1016/j.jamcollsurg.2020.03.034'] 156,32312606,"Classification-Specific Treatment Improves Pain, Disability, Fear-Avoidance Beliefs, and Erector Spinae Muscle Activity During Walking in Patients With Low Back Pain Exhibiting Lumbar Extension-Rotation Pattern: A Randomized Controlled Trial.","OBJECTIVE Low back pain (LBP) has commonly been managed via classification-specific interventions in homogeneous groups. However, it is largely unknown whether treatment tailored to specific classifications is more effective than generic treatment. The purpose of this study was to evaluate the effects of classification-specific treatment on the self-reported responses and erector spinae (ES) activity of patients with LBP exhibiting a lumbar extension-rotation (ExtRot) pattern. METHODS In total, 39 patients exhibiting the lumbar ExtRot pattern were randomized to an experimental (n = 19) group and a control (n = 20) group. Participants in the experimental group received classification-specific treatment, which included exercise to control or prevent lumbopelvic motion during lower-extremity movement. Participants in the control group were encouraged to perform general exercises and were educated about LBP. Patient-reported pain intensity, disability, and fear-avoidance belief and ES muscle activity during walking were assessed prior to and after the intervention. Two-way analysis of covariance was used to examine the effects of classification-specific treatment. RESULTS After 6-week intervention, significant time-by-group interaction effects were demonstrated on pain intensity, disability, fear-avoidance beliefs-physical activity score, and ES muscle activity during walking. There were significant effects of group on pain, disability, and fear-avoidance beliefs-physical activity score after intervention. After the 6-week intervention, the ES muscle activity significantly decreased in the experimental group during walking, but does not represent an all-events decrease. CONCLUSION Classification-specific treatment may be effective in patients with LBP exhibiting the lumbar ExtRot pattern, reducing pain intensity, disability, fear-avoidance beliefs, and ES muscle activity during walking.",2020,"After 6-week intervention, significant time-by-group interaction effects were demonstrated on pain intensity, disability, fear-avoidance beliefs-physical activity score, and ES muscle activity during walking.","['patients with LBP exhibiting the lumbar ExtRot pattern', '39 patients exhibiting the lumbar ExtRot pattern', 'patients with LBP exhibiting a lumbar extension-rotation (ExtRot) pattern', 'Patients With Low Back Pain Exhibiting Lumbar Extension-Rotation Pattern']","['classification-specific treatment, which included exercise to control or prevent lumbopelvic motion during lower-extremity movement']","['Pain, Disability, Fear-Avoidance Beliefs, and Erector Spinae Muscle Activity', 'ES muscle activity', 'pain intensity, disability, fear-avoidance beliefs, and ES muscle activity', 'pain, disability, and fear-avoidance beliefs-physical activity score', 'pain intensity, disability, fear-avoidance beliefs-physical activity score, and ES muscle activity during walking', 'pain intensity, disability, and fear-avoidance belief and ES muscle activity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0015272', 'cui_str': 'Exhibits as Topic'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}]","[{'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0026649', 'cui_str': 'Movement'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0224301', 'cui_str': 'Structure of erector spinae muscle'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",39.0,0.0328917,"After 6-week intervention, significant time-by-group interaction effects were demonstrated on pain intensity, disability, fear-avoidance beliefs-physical activity score, and ES muscle activity during walking.","[{'ForeName': 'Si-Hyun', 'Initials': 'SH', 'LastName': 'Kim', 'Affiliation': 'Department of Physical Therapy, Sangji University, Wonju-si, Gangwon-do, South Korea.'}, {'ForeName': 'Kyue-Nam', 'Initials': 'KN', 'LastName': 'Park', 'Affiliation': 'Department of Physical Therapy, Jeonju University, Jeonju-si, Jeonrabuk-do, South Korea.'}, {'ForeName': 'Oh-Yun', 'Initials': 'OY', 'LastName': 'Kwon', 'Affiliation': 'Department of Physical Therapy, Yonsei University, Wonju-si, Gangwon-Do, South Korea. Electronic address: kwonoy@yonsei.ac.kr.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2019.04.004'] 157,32312607,Changes in Vertebral Arterial Blood Flow During Premanipulative Tests in Participants With Upper Cervical Spine Motion Restriction.,"OBJECTIVE The purpose of the present study was to measure changes in blood flow velocity and volume flow rate (VFR) in the contralateral vertebral artery (VA) during end-range rotation and pre-manipulative hold at C1-C2 and to compare these measurements between participants with and without C1-C2 range of motion (ROM) restriction. METHODS This research was approached as an exploratory study and designed as a parallel noninterventional controlled trial with intentionally equal allocation, for studying diagnostic tests. Fifteen women and 13 men (mean age 44) were recruited (volunteer sample) in physiotherapy clinics. No participant had any current neurologic or vertebrobasilar insufficiency symptoms. The measurements of 13 participants with a limited ROM C1-C2 and 15 with no limitation were compared. Blood flow velocity and VFR in the contralateral VA were measured using color duplex Doppler imaging in 3 neck positions: neutral, maximal rotation, and pre-manipulative hold of C1-C2. RESULTS Pre-manipulative hold significantly (P < .01) decreased all blood flow velocity parameters and VFR, mainly in the left VA. End-range rotation showed a significant (P < .05) decrease in the peak systolic velocity in the left VA. No significant differences were found between participants grouped by the presence or absence of a C1-C2 ROM restriction. CONCLUSION A C1-C2 rotational ROM restriction does not appear associated with change in a significantly reduced VA blood flow due to the neck position.",2020,"RESULTS Pre-manipulative hold significantly (P < .01) decreased all blood flow velocity parameters and VFR, mainly in the left VA.","['participants with and without C1-C2 range of motion (ROM) restriction', '13 participants with a limited ROM C1-C2 and 15 with no limitation were compared', 'Participants With Upper Cervical Spine Motion Restriction', 'Fifteen women and 13 men (mean age 44) were recruited (volunteer sample) in physiotherapy clinics']",[],"['peak systolic velocity', 'Vertebral Arterial Blood Flow', 'blood flow velocity parameters and VFR', 'blood flow velocity and volume flow rate (VFR', 'Blood flow velocity and VFR', 'current neurologic or vertebrobasilar insufficiency symptoms']","[{'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0231589', 'cui_str': 'Limitation of joint movement'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0728985', 'cui_str': 'Structure of cervical vertebral column'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C3839152', 'cui_str': 'Physiotherapy clinic'}]",[],"[{'cui': 'C0442710', 'cui_str': 'Peak systolic'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0549207', 'cui_str': 'Bone structure of spine'}, {'cui': 'C0229665', 'cui_str': 'Arterial blood'}, {'cui': 'C0005798', 'cui_str': 'Blood Flow Velocity'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0042568', 'cui_str': 'Vertebrobasilar artery syndrome'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",15.0,0.0371664,"RESULTS Pre-manipulative hold significantly (P < .01) decreased all blood flow velocity parameters and VFR, mainly in the left VA.","[{'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Leenaerts', 'Affiliation': 'Paramedisch Instituut Scheepjeshof, Veenendaal, The Netherlands. Electronic address: a.e.r.leenaerts@live.nl.'}, {'ForeName': 'Wouter', 'Initials': 'W', 'LastName': 'Molenaar', 'Affiliation': 'Fysiogroep Waterland, Monnickendam, The Netherlands.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Cattrysse', 'Affiliation': 'Experimental Anatomy research group, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2019.10.002'] 158,32291802,A pilot randomized controlled trial of hearing aids to improve mood and cognition in older adults.,"OBJECTIVES Age-related hearing loss (ARHL) is a prevalent condition associated with increased risk for depression and cognitive decline. This 12-week prospective, double-blind pilot randomized controlled trial (RCT) of hearing aids (HAs) for depressed older adults with ARHL evaluated the feasibility of a novel research design. METHODS/DESIGN N = 13 individuals aged ≥60 years with Major Depressive Disorder or Persistent Depressive Disorder and at least mild hearing loss (pure tone average ≥ 30 dB) were randomized to receive full- (active) vs low-amplification (sham) HAs added to psychiatric treatment as usual. Duration of HA use in hours/day, adverse events frequency, attrition rate, and maintenance of the study blinding were the primary outcome measures. RESULTS Compliance with HAs was excellent (>9 hours/day for both groups) and rates of adverse events and drop-outs did not differ between groups. Preliminary data demonstrated differential improvement for active vs sham HAs on hearing functioning (Hearing Handicap Inventory for the Elderly [nonparametric effect size (np-ES) = 0.62]), depressive symptoms (Inventory for Depressive Symptomatology [np-ES = 0.31]), cognition (Repeatable Battery for the Assessment of Neuropsychological Status Immediate Memory [np-ES = 0.25]), and general functioning (World Health Organization Disability Assessment Schedule [np-ES = 0.53]). Significantly greater than 50% of both groups correctly guessed their treatment assignment, indicating incomplete concealment of treatment allocation. CONCLUSIONS This pilot RCT for ARHL and late-life depression was feasible to execute and showed clinical promise, but improved methods of blinding the experimental treatments are needed. Larger studies should investigate whether hearing remediation may be an effective preventative and/or therapeutic strategy for late-life depression and cognitive decline.",2020,"Preliminary data demonstrated differential improvement for active vs. sham HAs on hearing functioning (Hearing Handicap Inventory for the Elderly [nonparametric effect size (np-ES) =.62]), depressive symptoms (Inventory for Depressive Symptomatology [np-ES=.31]), cognition (Repeatable Battery for the Assessment of Neuropsychological Status Immediate Memory [np-ES=.25]), and general functioning (World Health Organization Disability Assessment Schedule [np-ES=.53]).","['depressed older adults with ARHL', 'N=13 individuals aged ≥60\u2009years with Major Depressive Disorder or Persistent Depressive Disorder and at least mild hearing loss (pure tone average ≥30dB', 'Older Adults']","['Hearing Aids', 'full', 'hearing aids (HAs']","['hearing functioning (Hearing Handicap Inventory', 'rates of adverse events', 'Duration of HA use in hours/day, adverse events frequency, attrition rate, and maintenance of the study blinding', 'depressive symptoms', 'Mood and Cognition']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0013415', 'cui_str': 'Dysthymia'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}]","[{'cui': 'C0018768', 'cui_str': 'Hearing aid'}]","[{'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0231172', 'cui_str': 'Handicap'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0556974', 'cui_str': 'hours/day'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",13.0,0.294852,"Preliminary data demonstrated differential improvement for active vs. sham HAs on hearing functioning (Hearing Handicap Inventory for the Elderly [nonparametric effect size (np-ES) =.62]), depressive symptoms (Inventory for Depressive Symptomatology [np-ES=.31]), cognition (Repeatable Battery for the Assessment of Neuropsychological Status Immediate Memory [np-ES=.25]), and general functioning (World Health Organization Disability Assessment Schedule [np-ES=.53]).","[{'ForeName': 'Katharine K', 'Initials': 'KK', 'LastName': 'Brewster', 'Affiliation': 'Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Pavlicova', 'Affiliation': 'Columbia University Mailman School of Public Health, New York, New York, USA.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Stein', 'Affiliation': 'Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': 'New York State Psychiatric Institute, New York, New York, USA.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'New York State Psychiatric Institute, New York, New York, USA.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Brown', 'Affiliation': 'Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA.'}, {'ForeName': 'Steven P', 'Initials': 'SP', 'LastName': 'Roose', 'Affiliation': 'Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA.'}, {'ForeName': 'Ana H', 'Initials': 'AH', 'LastName': 'Kim', 'Affiliation': 'Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA.'}, {'ForeName': 'Justin S', 'Initials': 'JS', 'LastName': 'Golub', 'Affiliation': 'Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Brickman', 'Affiliation': 'Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Galatioto', 'Affiliation': 'Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Kuhlmey', 'Affiliation': 'Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA.'}, {'ForeName': 'Bret R', 'Initials': 'BR', 'LastName': 'Rutherford', 'Affiliation': 'Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA.'}]",International journal of geriatric psychiatry,['10.1002/gps.5311'] 159,29946115,"Red palm olein supplementation on cytokines, endothelial function and lipid profile in centrally overweight individuals: a randomised controlled trial.","BACKGROUND/OBJECTIVES The consumption of antioxidant-rich cooking oil such as red palm olein may be cardioprotective from the perspective of subclinical inflammation and endothelial function. SUBJECTS/METHODS Using a crossover design, we conducted a randomised controlled trial in 53 free-living high-risk abdominally overweight subjects, comparing the effects of incorporating red palm olein (with palm olein as control) in a supervised isocaloric 2100 kcal diet of 30% en fat, two-thirds (45 g/day) of which were derived from the test oil for a period of 6 weeks each. RESULTS We did not observe a significant change in interleukin-6 (IL-6), in parallel with other pro-inflammatory (tumour necrosis factor-β, interleukin-1β, IL-1β, high sensitivity C-reactive protein, hsCRP) and endothelial function (soluble intercellular adhesion molecules, sICAM, soluble intravascular adhesion molecules, sVCAM) parameters. Interestingly, we observed a significant reduction in oxidised LDL levels (P < 0.0386) while on the red palm olein diet, together with the increase in plasma alpha tocopherol (P < 0.0002), alpha carotene (P < 0.0001) and beta carotene (P < 0.0001) concentrations compared with palm olein diet. CONCLUSION Red palm olein did not improve subclinical inflammation and endothelial function despite profound increase in antioxidant levels. The positive improvement in oxidised LDL merits further attention in this group of subjects at risk of developing cardiovascular disease.",2019,"Interestingly, we observed a significant reduction in oxidised LDL levels (P < 0.0386) while on the red palm olein diet, together with the increase in plasma alpha tocopherol (P < 0.0002), alpha carotene (P < 0.0001) and beta carotene (P < 0.0001) concentrations compared with palm olein diet. ","['53 free-living high-risk abdominally overweight subjects', 'centrally overweight individuals']","['red palm olein (with palm olein as control', 'Red palm olein supplementation']","['subclinical inflammation and endothelial function', 'beta carotene', 'antioxidant levels', 'alpha carotene', 'cytokines, endothelial function and lipid profile', 'plasma alpha tocopherol', 'interleukin-6 (IL-6', 'oxidised LDL levels']","[{'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0332575', 'cui_str': 'Red color (finding)'}, {'cui': 'C0230373', 'cui_str': 'Palm of hand (surface region)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0205211', 'cui_str': 'Subclinical (qualifier value)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0053396', 'cui_str': 'betacarotene'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0051336', 'cui_str': 'alpha-carotene'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0969677', 'cui_str': 'd-alpha tocopherol'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C3539166', 'cui_str': 'Oxidised LDL'}]",53.0,0.102017,"Interestingly, we observed a significant reduction in oxidised LDL levels (P < 0.0386) while on the red palm olein diet, together with the increase in plasma alpha tocopherol (P < 0.0002), alpha carotene (P < 0.0001) and beta carotene (P < 0.0001) concentrations compared with palm olein diet. ","[{'ForeName': 'Radhika', 'Initials': 'R', 'LastName': 'Loganathan', 'Affiliation': 'Malaysian Palm Oil Board, Bandar Baru Bangi, Kajang, Selangor, 43000, Malaysia.'}, {'ForeName': 'Shireene Ratna', 'Initials': 'SR', 'LastName': 'Vethakkan', 'Affiliation': 'Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia.'}, {'ForeName': 'Ammu K', 'Initials': 'AK', 'LastName': 'Radhakrishnan', 'Affiliation': 'Pathology Division, Faculty of Medicine and Health, International Medical University, 126, Jalan Jalil Perkasa 19, Bukit Jalil, Kuala Lumpur, 57000, Malaysia.'}, {'ForeName': 'Ghazali Abd', 'Initials': 'GA', 'LastName': 'Razak', 'Affiliation': 'Malaysian Palm Oil Board, Bandar Baru Bangi, Kajang, Selangor, 43000, Malaysia.'}, {'ForeName': 'Teng', 'Initials': 'T', 'LastName': 'Kim-Tiu', 'Affiliation': 'Malaysian Palm Oil Board, Bandar Baru Bangi, Kajang, Selangor, 43000, Malaysia. kt.teng@gmail.com.'}]",European journal of clinical nutrition,['10.1038/s41430-018-0236-5'] 160,32320773,"Surgery versus combined treatment with curettage and imiquimod for nodular basal cell carcinoma: One-year results of a noninferiority, randomized, controlled trial.","PURPOSE Nodular basal cell carcinoma (nBCC) is mostly treated with surgical excision. Interest in minimally invasive treatment of these low-risk tumors is increasing. We assessed the effectiveness of nBCC treatment with curettage and imiquimod cream compared with surgical excision. METHODS Patients with nBCC included in this randomized, controlled noninferiority trial were randomly assigned to either a curettage and imiquimod cream group or a surgical excision group. The primary endpoint was the proportion of patients free from treatment failure 1 year after the end of treatment. A prespecified noninferiority margin of 8% was used. A modified intention-to-treat and a per-protocol analysis was performed (ClinicalTrials.gov identifier NCT02242929). RESULTS One hundred forty-five patients were randomized: 73 to the curettage and imiquimod cream group and 72 to the surgical excision group. The proportion of patients free of recurrence after 12 months was 86.3% (63/73) for the curettage and imiquimod group and 100% (72/72) for the surgical excision group. The difference in efficacy was -13.7% (95% confidence interval -21.6% to -5.8%; 1-sided P = .0004) favoring surgical excision. CONCLUSION Noninferiority of curettage and imiquimod cream cannot be concluded. Given the still high efficacy of curettage and imiquimod cream and the indolent growth pattern of nBCC, curettage and imiquimod could still be a valuable treatment option with the possibility to prevent overuse of excisions. However, it cannot replace surgical excision.",2020,Proportion of patients free of recurrence after 12 months was 86.3% for curettage and imiquimod (63/73) and 100% for excision (72/72).,"['Nodular basal cell carcinoma (nBCC', '145 patients were randomized; 73 to', 'Patients with nodular BCC', 'Nodular basal cell carcinoma (SCIN']","['imiquimod cream', 'curettage and imiquimod cream and 72 to surgical excision', 'imiquimod', 'Surgery versus combined treatment with Curettage and Imiquimod', 'nBCC', 'curettage and imiquimod cream or surgical excision', 'curettage and imiquimod cream']","['efficacy', 'proportion of patients free from treatment failure one 1 year']","[{'cui': 'C1304300', 'cui_str': 'Nodular basal cell carcinoma of skin'}, {'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205297', 'cui_str': 'Nodular'}, {'cui': 'C4721806', 'cui_str': 'Basal cell carcinoma of skin'}]","[{'cui': 'C1252977', 'cui_str': 'imiquimod Topical Cream'}, {'cui': 'C0010468', 'cui_str': 'Curettage'}, {'cui': 'C0728940', 'cui_str': 'Excision'}, {'cui': 'C0165032', 'cui_str': 'imiquimod'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1304300', 'cui_str': 'Nodular basal cell carcinoma of skin'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0439234', 'cui_str': 'year'}]",145.0,0.0800048,Proportion of patients free of recurrence after 12 months was 86.3% for curettage and imiquimod (63/73) and 100% for excision (72/72).,"[{'ForeName': 'Kelly A E', 'Initials': 'KAE', 'LastName': 'Sinx', 'Affiliation': 'Department of Dermatology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. Electronic address: kelly.sinx@mumc.nl.'}, {'ForeName': 'Patty J', 'Initials': 'PJ', 'LastName': 'Nelemans', 'Affiliation': 'Department of Epidemiology, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Nicole W J', 'Initials': 'NWJ', 'LastName': 'Kelleners-Smeets', 'Affiliation': 'Department of Dermatology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Veronique J L', 'Initials': 'VJL', 'LastName': 'Winnepenninckx', 'Affiliation': 'Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Aimee H M M', 'Initials': 'AHMM', 'LastName': 'Arits', 'Affiliation': 'Department of Dermatology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands; Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands; Department of Dermatology, Catharina Hospital, Eindhoven, The Netherlands.'}, {'ForeName': 'Klara', 'Initials': 'K', 'LastName': 'Mosterd', 'Affiliation': 'Department of Dermatology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.04.053'] 161,32293363,"Internet-guided cognitive, behavioral and chronobiological interventions in depression-prone insomnia subtypes: protocol of a randomized controlled prevention trial.","BACKGROUND Major depressive disorder is among the most burdening and costly chronic health hazards. Since its prognosis is poor and treatment effectiveness is moderate at best, prevention would be the strategy of first choice. Insomnia may be the best modifiable risk factor. Insomnia is highly prevalent (4-10%) and meta-analysis estimates ±13% of people with insomnia to develop depression within a year. Among people with insomnia, recent work identified three subtypes with a particularly high lifetime risk of depression. The current randomized controlled trial (RCT) evaluates the effects of internet-guided Cognitive Behavioral Therapy for Insomnia (CBT-I), Chronobiological Therapy (CT), and their combination on insomnia and the development of depressive symptoms. METHODS We aim to include 120 participants with Insomnia Disorder (ID) of one of the three subtypes that are more prone to develop depression. In a two by two factorial repeated measures design, participants will be randomized to CBT-I, CT, CBT-I + CT or treatment as usual, and followed up for one year. The primary outcome is the change, relative to baseline, of the severity of depressive symptoms integrated over four follow-ups spanning one year. Secondary outcome measures include a diagnosis of major depressive disorder, insomnia severity, sleep diaries, actigraphy, cost-effectiveness, and brain structure and function. DISCUSSION Pre-selection of three high-risk insomnia subtypes allows for a sensitive assessment of the possibility to prevent the development and worsening of depressive symptoms through interventions targeting insomnia. TRIAL REGISTRATION Netherlands Trial Register (NL7359). Registered on 19 October 2018.",2020,"The primary outcome is the change, relative to baseline, of the severity of depressive symptoms integrated over four follow-ups spanning one year.","['120 participants with Insomnia Disorder (ID) of one of the three subtypes that are more prone to develop depression', 'depression-prone insomnia subtypes', 'people with insomnia']","['internet-guided Cognitive Behavioral Therapy', 'Chronobiological Therapy (CT', 'CT, CBT-I\u2009+\u2009CT', 'Internet-guided cognitive, behavioral and chronobiological interventions']","['change, relative to baseline, of the severity of depressive symptoms integrated', 'diagnosis of major depressive disorder, insomnia severity, sleep diaries, actigraphy, cost-effectiveness, and brain structure and function', 'Insomnia']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0449560', 'cui_str': 'Subtype'}, {'cui': 'C0033422', 'cui_str': 'Prone body position'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",120.0,0.133192,"The primary outcome is the change, relative to baseline, of the severity of depressive symptoms integrated over four follow-ups spanning one year.","[{'ForeName': 'Jeanne', 'Initials': 'J', 'LastName': 'Leerssen', 'Affiliation': 'Department of Sleep and Cognition, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105, BA, Amsterdam, The Netherlands. j.leerssen@vu.nl.'}, {'ForeName': 'Jessica C', 'Initials': 'JC', 'LastName': 'Foster-Dingley', 'Affiliation': 'Department of Sleep and Cognition, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105, BA, Amsterdam, The Netherlands.'}, {'ForeName': 'Oti', 'Initials': 'O', 'LastName': 'Lakbila-Kamal', 'Affiliation': 'Department of Sleep and Cognition, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105, BA, Amsterdam, The Netherlands.'}, {'ForeName': 'Laura M S', 'Initials': 'LMS', 'LastName': 'Dekkers', 'Affiliation': 'Department of Sleep and Cognition, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105, BA, Amsterdam, The Netherlands.'}, {'ForeName': 'Anne C W', 'Initials': 'ACW', 'LastName': 'Albers', 'Affiliation': 'Department of Sleep and Cognition, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105, BA, Amsterdam, The Netherlands.'}, {'ForeName': 'Savannah L C', 'Initials': 'SLC', 'LastName': 'Ikelaar', 'Affiliation': 'Department of Sleep and Cognition, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105, BA, Amsterdam, The Netherlands.'}, {'ForeName': 'Teodora', 'Initials': 'T', 'LastName': 'Maksimovic', 'Affiliation': 'Department of Sleep and Cognition, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105, BA, Amsterdam, The Netherlands.'}, {'ForeName': 'Rick', 'Initials': 'R', 'LastName': 'Wassing', 'Affiliation': 'Department of Sleep and Cognition, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105, BA, Amsterdam, The Netherlands.'}, {'ForeName': 'Simon J', 'Initials': 'SJ', 'LastName': 'Houtman', 'Affiliation': 'Department of Sleep and Cognition, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105, BA, Amsterdam, The Netherlands.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Bresser', 'Affiliation': 'Department of Sleep and Cognition, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105, BA, Amsterdam, The Netherlands.'}, {'ForeName': 'Tessa F', 'Initials': 'TF', 'LastName': 'Blanken', 'Affiliation': 'Department of Sleep and Cognition, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105, BA, Amsterdam, The Netherlands.'}, {'ForeName': 'Bart', 'Initials': 'B', 'LastName': 'Te Lindert', 'Affiliation': 'Department of Sleep and Cognition, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105, BA, Amsterdam, The Netherlands.'}, {'ForeName': 'Jennifer R', 'Initials': 'JR', 'LastName': 'Ramautar', 'Affiliation': 'Department of Sleep and Cognition, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105, BA, Amsterdam, The Netherlands.'}, {'ForeName': 'Eus J W', 'Initials': 'EJW', 'LastName': 'Van Someren', 'Affiliation': 'Department of Sleep and Cognition, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105, BA, Amsterdam, The Netherlands.'}]",BMC psychiatry,['10.1186/s12888-020-02554-8'] 162,31914971,"A randomized controlled efficacy trial of an electronic screening and brief intervention for alcohol misuse in adolescents and young adults vulnerable to HIV infection: step up, test up study protocol.","BACKGROUND Young people account for more than a quarter of new HIV infections in the US, with the majority of cases among young men who have sex with men; young transgender women are also vulnerable to infection. Substance use, particularly alcohol misuse, is a driver of sexual transmission and a potential barrier to engagement in the HIV prevention and care continuum, however vulnerable youth are difficult to reach for substance use services due, in part, to complex social and structural factors and limited access to health care. The Community Prevention Services Task Force recommends electronic screening and brief intervention as an evidence-based intervention for the prevention of excessive alcohol consumption; however, no prior studies have extended this model to community-based populations of youth that are susceptible to HIV infection. This paper describes the study protocol for an electronic screening and brief intervention to reduce alcohol misuse among adolescents and young adults vulnerable to HIV infection in community-based settings. METHODS This study, Step Up, Test Up, is a randomized controlled trial of an electronic alcohol screening and brief intervention among youth, ages 16-25, who are vulnerable to HIV infection. Individuals who present for HIV testing at one of three community-based locations are recruited for study participation. Eligibility includes those aged 16-25 years, HIV-negative or unknown HIV status, male or trans female with a history of sex with men, and English-speaking. Participants who screen at moderate to high risk for alcohol misuse on the Alcohol Use Disorders Identification Test (AUDIT) are randomized (1:1) to either an electronic brief intervention to reduce alcohol misuse or a time-and attention-matched control. The primary outcome is change in the frequency/quantity of recent alcohol use at 1, 3, 6 and 12-month follow-up. DISCUSSION Testing of evidence-based interventions to reduce alcohol misuse among youth vulnerable to HIV infection are needed. This study will provide evidence to determine feasibility and efficacy of a brief electronically-delivered intervention to reduce alcohol misuse for this population. TRIAL REGISTRATION ClinicalTrials.gov number, NCT02703116, registered March 9, 2016.",2020,"Test Up, is a randomized controlled trial of an electronic alcohol screening and brief intervention among youth, ages 16-25, who are vulnerable to HIV infection.","['adolescents and young adults vulnerable to HIV infection', 'Individuals who present for HIV testing at one of three community-based locations are recruited for study participation', 'Eligibility includes those aged 16-25\u2009years, HIV-negative or unknown HIV status, male or trans female with a history of sex with men, and English-speaking', 'adolescents and young adults vulnerable to HIV infection in community-based settings', 'youth, ages 16-25, who are vulnerable to HIV infection', 'Participants who screen at moderate to high risk for alcohol misuse on the Alcohol Use Disorders Identification Test (AUDIT', 'young men who have sex with men; young transgender women']","['electronic alcohol screening and brief intervention', 'electronic brief intervention to reduce alcohol misuse or a time-and attention-matched control', 'electronic screening and brief intervention']","['frequency/quantity of recent alcohol use at 1, 3, 6 and 12-month follow-up']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0019693', 'cui_str': 'T-Lymphotropic Virus Type III Infections, Human'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0450429', 'cui_str': 'Location (attribute)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0481430', 'cui_str': 'HTLV-3 antibody negative'}, {'cui': 'C0439673', 'cui_str': 'Unknown (qualifier value)'}, {'cui': 'C0458074', 'cui_str': 'HIV status'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test (assessment scale)'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C1319927', 'cui_str': 'Male-to-female transsexual'}]","[{'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C1265611', 'cui_str': 'Quantity finding'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]",,0.0471683,"Test Up, is a randomized controlled trial of an electronic alcohol screening and brief intervention among youth, ages 16-25, who are vulnerable to HIV infection.","[{'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Kuhns', 'Affiliation': ""The Potocsnak Family Division of Adolescent and Young Adult Medicine, Ann & Robert H. Lurie Children's Hospital, 225 E. Chicago Avenue, Box 161, Chicago, IL, 60611, USA. lkuhns@luriechildrens.org.""}, {'ForeName': 'Niranjan', 'Initials': 'N', 'LastName': 'Karnik', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Rush Medical College, Rush University, Chicago, IL, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Hotton', 'Affiliation': 'Chicago Center for HIV Elimination, University of Chicago Medicine, Chicago, IL, USA.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Muldoon', 'Affiliation': ""The Potocsnak Family Division of Adolescent and Young Adult Medicine, Ann & Robert H. Lurie Children's Hospital, 225 E. Chicago Avenue, Box 161, Chicago, IL, 60611, USA.""}, {'ForeName': 'Geri', 'Initials': 'G', 'LastName': 'Donenberg', 'Affiliation': 'Department of Medicine, University of Illinois at Chicago, Center for Dissemination and Implementation Science, Chicago, IL, USA.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Keglovitz', 'Affiliation': 'Howard Brown Health, Chicago, IL, USA.'}, {'ForeName': 'Moira', 'Initials': 'M', 'LastName': 'McNulty', 'Affiliation': 'Chicago Center for HIV Elimination, University of Chicago Medicine, Chicago, IL, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Schneider', 'Affiliation': 'Chicago Center for HIV Elimination, University of Chicago Medicine, Chicago, IL, USA.'}, {'ForeName': 'Faith', 'Initials': 'F', 'LastName': 'Summersett-Williams', 'Affiliation': ""The Potocsnak Family Division of Adolescent and Young Adult Medicine, Ann & Robert H. Lurie Children's Hospital, 225 E. Chicago Avenue, Box 161, Chicago, IL, 60611, USA.""}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Garofalo', 'Affiliation': ""The Potocsnak Family Division of Adolescent and Young Adult Medicine, Ann & Robert H. Lurie Children's Hospital, 225 E. Chicago Avenue, Box 161, Chicago, IL, 60611, USA.""}]",BMC public health,['10.1186/s12889-020-8154-6'] 163,32315362,Variability in engagement and progress in efficacious integrated collaborative care for primary care patients with obesity and depression: Within-treatment analysis in the RAINBOW trial.,"INTRODUCTION The RAINBOW randomized clinical trial validated the efficacy of an integrated collaborative care intervention for obesity and depression in primary care, although the effect was modest. To inform intervention optimization, this study investigated within-treatment variability in participant engagement and progress. METHODS Data were collected in 2014-2017 and analyzed post hoc in 2018. Cluster analysis evaluated patterns of change in weekly self-monitored weight from week 6 up to week 52 and depression scores on the Patient Health Questionnaire-9 (PHQ-9) from up to 15 individual sessions during the 12-month intervention. Chi-square tests and ANOVA compared weight loss and depression outcomes objectively measured by blinded assessors to validate differences among categories of treatment engagement and progress defined based on cluster analysis results. RESULTS Among 204 intervention participants (50.9 [SD, 12.2] years, 71% female, 72% non-Hispanic White, BMI 36.7 [6.9], PHQ-9 14.1 [3.2]), 31% (n = 63) had poor engagement, on average completing self-monitored weight in <3 of 46 weeks and <5 of 15 sessions. Among them, 50 (79%) discontinued the intervention by session 6 (week 8). Engaged participants (n = 141; 69%) self-monitored weight for 11-22 weeks, attended almost all 15 sessions, but showed variable treatment progress based on patterns of change in self-monitored weight and PHQ-9 scores over 12 months. Three patterns of weight change (%) represented minimal weight loss (n = 50, linear β1 = -0.06, quadratic β2 = 0.001), moderate weight loss (n = 61, β1 = -0.28, β2 = 0.002), and substantial weight loss (n = 12, β1 = -0.53, β2 = 0.005). Three patterns of change in PHQ-9 scores represented moderate depression without treatment progress (n = 40, intercept β0 = 11.05, β1 = -0.11, β2 = 0.002), moderate depression with treatment progress (n = 20, β0 = 12.90, β1 = -0.42, β2 = 0.006), and milder depression with treatment progress (n = 81, β0 = 7.41, β1 = -0.23, β2 = 0.003). The patterns diverged within 6-8 weeks and persisted throughout the intervention. Objectively measured weight loss and depression outcomes were significantly worse among participants with poor engagement or poor progress on either weight or PHQ-9 than those showing progress on both. CONCLUSIONS Participants demonstrating poor engagement or poor progress could be identified early during the intervention and were more likely to fail treatment at the end of the intervention. This insight could inform individualized and timely optimization to enhance treatment efficacy. TRIAL REGISTRATION ClinicalTrials.gov# NCT02246413.",2020,"Objectively measured weight loss and depression outcomes were significantly worse among participants with poor engagement or poor progress on either weight or PHQ-9 than those showing progress on both. ","['primary care patients with obesity and depression', '204 intervention participants (50.9 [SD, 12.2] years, 71% female, 72% non-Hispanic White, BMI 36.7 [6.9], PHQ-9 14.1 [3.2]), 31% (n = 63) had poor engagement, on average completing self-monitored weight in <3 of 46 weeks and <5 of 15 sessions', 'Engaged participants (n = 141; 69', 'Data were collected in 2014-2017 and analyzed post hoc in 2018']",['integrated collaborative care intervention'],"['milder depression', 'weight loss and depression outcomes', 'weight change', 'moderate weight loss', 'self-monitored weight', 'substantial weight loss', 'moderate depression', 'self-monitored weight and PHQ-9 scores', 'minimal weight loss']","[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517826', 'cui_str': '6.9'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C4517687', 'cui_str': '3.2'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0687676', 'cui_str': 'After values'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0588007', 'cui_str': 'Moderate depression'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}]",,0.0287906,"Objectively measured weight loss and depression outcomes were significantly worse among participants with poor engagement or poor progress on either weight or PHQ-9 than those showing progress on both. ","[{'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Lv', 'Affiliation': 'Institute of Health Research and Policy, University of Illinois at Chicago, Chicago, Illinois, United States of America.'}, {'ForeName': 'Lan', 'Initials': 'L', 'LastName': 'Xiao', 'Affiliation': 'Department of Medicine, Stanford University, Palo Alto, California, United States of America.'}, {'ForeName': 'Marzieh', 'Initials': 'M', 'LastName': 'Majd', 'Affiliation': 'Department of Biobehavioral Health, Pennsylvania State University, University Park, Pennsylvania, United States of America.'}, {'ForeName': 'Philip W', 'Initials': 'PW', 'LastName': 'Lavori', 'Affiliation': 'Department of Biomedical Data Science, Stanford University, Stanford, California, United States of America.'}, {'ForeName': 'Joshua M', 'Initials': 'JM', 'LastName': 'Smyth', 'Affiliation': 'Department of Biobehavioral Health, Pennsylvania State University, University Park, Pennsylvania, United States of America.'}, {'ForeName': 'Lisa G', 'Initials': 'LG', 'LastName': 'Rosas', 'Affiliation': 'Department of Health Research and Policy and Medicine, Stanford University, Palo Alto, California, United States of America.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Venditti', 'Affiliation': 'Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.'}, {'ForeName': 'Mark B', 'Initials': 'MB', 'LastName': 'Snowden', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, United States of America.'}, {'ForeName': 'Megan A', 'Initials': 'MA', 'LastName': 'Lewis', 'Affiliation': 'Center for Communications Science, RTI International, Seattle, Washington, United States of America.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Ward', 'Affiliation': 'Pacific Coast Psychiatric Associates, San Francisco, California, United States of America.'}, {'ForeName': 'Lenard', 'Initials': 'L', 'LastName': 'Lesser', 'Affiliation': 'One Medical, San Francisco, California, United States of America.'}, {'ForeName': 'Leanne M', 'Initials': 'LM', 'LastName': 'Williams', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, United States of America.'}, {'ForeName': 'Kristen M J', 'Initials': 'KMJ', 'LastName': 'Azar', 'Affiliation': 'Sutter Health Research Enterprise, Center for Health Systems Research, Walnut Creek, California, United States of America.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'Institute of Health Research and Policy, University of Illinois at Chicago, Chicago, Illinois, United States of America.'}]",PloS one,['10.1371/journal.pone.0231743'] 164,32317109,Treatment of Neck Pain With Myofascial Therapies: A Single Blind Randomized Controlled Trial.,"OBJECTIVE This study aimed to investigate the effects of myofascial release therapy vs a standard physical therapy program in patients with neck pain (NP). METHODS This was a randomized controlled trial in which 54 participants with mechanical NP were randomly assigned into an experimental group (EG) or a comparison group (CG). The EG group (n = 27) received 5 therapy sessions of myofascial release therapy while the CG group (n = 27) received 10 sessions of massage, ultrasound therapy, and transcutaneous electric nerve stimulation over a 2-week period. Outcome measures were the numerical pain rating scale (NPRS), pressure pain thresholds (PPTs) and range of motion at the end of treatment and at 1-month follow-up. RESULTS At 1-month follow-up, between-group differences in change scores were found in the NPRS (mean = -1.56, 95% confidence interval [CI] [-2.30 to -0.81]; P < .001), in the right thoracic PPT (mean = 0.35, 95% CI [0.03-0.66]; P = .031), and in both left (mean = 0.34, 95% CI [0.08-0.61]; P = .012) and right (mean = 0.29, 95% CI [0.04-0.54]; P = .026) suboccipital PPTs. The success rate was 63.0% in the CG and 92.6% in the EG. The number needed to treat was 3.38 (95% CI = 1.99-11.23). CONCLUSIONS Myofascial release therapy could be better than a standard physical therapy program for improving pain and suboccipital PPTs in patients with NP. However, the difference between both treatments is less than the minimum detectable change of the NPRS.",2020,"The number needed to treat was 3.38 (95% CI = 1.99-11.23). ","['patients with NP', 'patients with neck pain (NP', '54 participants with mechanical NP']","['5 therapy sessions of myofascial release therapy while the CG group (n\u202f=\u202f27) received 10 sessions of massage, ultrasound therapy, and transcutaneous electric nerve stimulation', 'standard physical therapy program', 'myofascial release therapy']","['change scores', 'numerical pain rating scale (NPRS), pressure pain thresholds (PPTs) and range of motion at the end of treatment and at 1-month follow-up', 'number needed to treat', 'right thoracic PPT', 'success rate', 'pain and suboccipital PPTs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0695600', 'cui_str': 'Myofascial release'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0041620', 'cui_str': 'Therapeutic ultrasound'}, {'cui': 'C0040654', 'cui_str': 'Percutaneous electrical nerve stimulation'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C3179138', 'cui_str': 'Numbers Needed To Treat'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0032334', 'cui_str': 'podofilox'}, {'cui': 'C0442187', 'cui_str': 'Suboccipital approach'}]",54.0,0.107912,"The number needed to treat was 3.38 (95% CI = 1.99-11.23). ","[{'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Rodríguez-Huguet', 'Affiliation': 'Department of Nursing and Physiotherapy, University of Cádiz, Cádiz, Andalusia, Spain. Electronic address: manuel.rodriguez@uca.es.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Rodríguez-Almagro', 'Affiliation': 'Department of Health Sciences, University of Jaén, Jaén, Andalusia, Spain.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Rodríguez-Huguet', 'Affiliation': 'Department of Traumatology and Orthopedic Surgery, Jerez de la Frontera Hospital, Jeréz de la Frontera, Andalusia, Spain.'}, {'ForeName': 'Rocío', 'Initials': 'R', 'LastName': 'Martín-Valero', 'Affiliation': 'Department of Physiotherapy, University of Málaga, Málaga, Andalusia, Spain.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Lomas-Vega', 'Affiliation': 'Department of Health Sciences, University of Jaén, Jaén, Andalusia, Spain.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2019.12.001'] 165,32171768,Frequency of Mass Azithromycin Distribution for Ocular Chlamydia in a Trachoma Endemic Region of Ethiopia: A Cluster Randomized Trial.,"PURPOSE Annual mass azithromycin distribution significantly reduces the prevalence of ocular Chlamydia trachomatis, the causative organism of trachoma. However, in some areas a decade or more of treatment has not controlled infection. Here, we compared multiple treatment arms from a community-randomized trial to evaluate whether increasing frequency of azithromycin distribution decreases prevalence in the short term. METHODS Seventy-two communities in Goncha Siso Enesie woreda in the Amhara region of Northern Ethiopia were randomized to 1 of 6 azithromycin distribution strategies: (1) delayed, (2) annual, (3) biannual, (4) quarterly to children only, (5) biennial, or (6) biennial plus latrine promotion. We analyzed data from the 60 communities in the delayed, annual, biannual, quarterly, and biennial distribution arms at the 12-month study visit. Communities in the annual and biennial distribution arm were combined, as they each had a single distribution before any 12-month retreatment. We assessed the effect of increased frequency of azithromycin distribution on ocular chlamydia prevalence. RESULTS Ocular chlamydia prevalence was significantly different across azithromycin distribution frequency in children (P < .0001) and adults (P < .0001), with lower prevalence associated with higher frequency. Among children, quarterly azithromycin distribution led to a significantly greater reduction in ocular chlamydia prevalence than the World Health Organization-recommended annual treatment prevalence (mean difference -11.4%, 95% confidence interval -19.5 to -3.3%, P = .007). CONCLUSIONS Increased frequency of azithromycin distribution leads to decreased ocular chlamydia prevalence over a short-term period. In some regions with high levels of ocular chlamydia prevalence, additional azithromycin distributions may help achieve local elimination of infection.",2020,"RESULTS Ocular chlamydia prevalence was significantly different across azithromycin distribution frequency in children (P<0.0001) and adults (P<0.0001), with lower prevalence associated with higher frequency.","['Seventy-two communities in Goncha Seso Enesie Woreda in the Amhara Region of Northern Ethiopia', '60 communities in the delayed, annual, biannual, quarterly, and biennial distribution arms at the 12-month study visit', 'ocular chlamydia in a trachoma endemic region of Ethiopia']","['azithromycin', 'azithromycin distribution strategies: 1) delayed, 2) annual, 3) biannual, 4) quarterly to children only, 5) biennial, or 6) biennial plus latrine promotion', 'azithromycin distribution']","['ocular chlamydia prevalence', 'Ocular chlamydia prevalence']","[{'cui': 'C4319632', 'cui_str': 'Seventy-two'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0015024', 'cui_str': 'Federal Democratic Republic of Ethiopia'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0332179', 'cui_str': 'q3mo'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4521296', 'cui_str': 'Ocular (intended site)'}, {'cui': 'C0008148', 'cui_str': 'Chlamydia'}, {'cui': 'C0040592', 'cui_str': 'Egyptian Ophthalmia'}, {'cui': 'C0243130', 'cui_str': 'endemics'}]","[{'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0332179', 'cui_str': 'q3mo'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0023124', 'cui_str': 'Latrines'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}]","[{'cui': 'C4521296', 'cui_str': 'Ocular (intended site)'}, {'cui': 'C0008148', 'cui_str': 'Chlamydia'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}]",,0.0495108,"RESULTS Ocular chlamydia prevalence was significantly different across azithromycin distribution frequency in children (P<0.0001) and adults (P<0.0001), with lower prevalence associated with higher frequency.","[{'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Lietman', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA; Department of Ophthalmology, University of California, San Francisco, San Francisco, California, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA. Electronic address: tom.lietman@ucsf.edu.'}, {'ForeName': 'Berhan', 'Initials': 'B', 'LastName': 'Ayele', 'Affiliation': 'The Carter Center Ethiopia, Addis Ababa, Ethiopia.'}, {'ForeName': 'Teshome', 'Initials': 'T', 'LastName': 'Gebre', 'Affiliation': 'International Trachoma Initiative, Addis Ababa, Ethiopia.'}, {'ForeName': 'Mulat', 'Initials': 'M', 'LastName': 'Zerihun', 'Affiliation': 'The Carter Center Ethiopia, Addis Ababa, Ethiopia.'}, {'ForeName': 'Zerihun', 'Initials': 'Z', 'LastName': 'Tadesse', 'Affiliation': 'The Carter Center Ethiopia, Addis Ababa, Ethiopia.'}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Emerson', 'Affiliation': 'International Trachoma Initiative, Atlanta, Georgia, USA.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Nash', 'Affiliation': 'The Carter Center, Atlanta, Georgia, USA.'}, {'ForeName': 'Travis C', 'Initials': 'TC', 'LastName': 'Porco', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA; Department of Ophthalmology, University of California, San Francisco, San Francisco, California, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Jeremy D', 'Initials': 'JD', 'LastName': 'Keenan', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA; Department of Ophthalmology, University of California, San Francisco, San Francisco, California, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Catherine E', 'Initials': 'CE', 'LastName': 'Oldenburg', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA; Department of Ophthalmology, University of California, San Francisco, San Francisco, California, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.'}]",American journal of ophthalmology,['10.1016/j.ajo.2020.02.019'] 166,30897999,Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease.,"Background Vascular risk factors have been associated with differences in cognitive performance in epidemiological studies, but evidence in patients with coronary heart disease is more limited. Methods and Results The Montreal Cognitive Assessment score obtained 3.2±0.37 years after randomization to darapladib, a reversible inhibitor of lipoprotein phospholipase A 2 or placebo was evaluated for 10 634 patients with coronary heart disease from 38 countries in the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial. The Montreal Cognitive Assessment scores for darapladib and placebo groups were similar (mean± SD , 25.3±3.84 versus 25.4±3.73, respectively; P=0.27) and the adjusted odds ratio ( OR ) for mild cognitive impairment (Montreal Cognitive Assessment score <26) was 1.00 (95% CI , 0.93-1.09). Mild cognitive impairment was more likely with increasing age ( OR , 1.33 [1.27-1.41], +5 years after 65). For other baseline clinical characteristics, the strongest independent predictors of cognitive impairment were education (≤8 years versus college/university, OR , 2.95 [2.60-3.35]; >8 years/trade school versus college/university, OR , 1.38 [1.25-1.52] and geographic grouping). Cardiovascular risk factors independently associated with cognitive impairment were history of stroke ( OR , 1.43 [1.20-1.71]); <2.5 hours of moderate or vigorous intensity exercise/week ( OR , 1.19 [1.04-1.37]); high-density lipoprotein cholesterol <1.16 mmol/L ( OR , 1.19 [1.04-1.37]); diabetes mellitus requiring treatment ( OR , yes versus no: 1.15 [1.05-1.26]); and history of hypertension ( OR , 1.12 [1.02-1.23]). Conclusions In patients with stable coronary heart disease, cognitive performance was associated with modifiable cardiovascular risk factors, educational level, and global region, but was not influenced by darapladib. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00799903.",2019,"The Montreal Cognitive Assessment score obtained 3.2±0.37 years after randomization to darapladib, a reversible inhibitor of lipoprotein phospholipase","['634 patients with coronary heart disease from 38 countries in the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial', 'patients with coronary heart disease', 'Patients With Stable Coronary Heart Disease', 'patients with stable coronary heart disease', '8\xa0years/trade school versus college/university, OR , 1.38 [1.25-1.52] and geographic grouping']","['placebo', 'lipoprotein phospholipase']","['history of hypertension', 'Cardiovascular and Lifestyle Risk Factors and Cognitive Function', 'Montreal Cognitive Assessment scores', 'modifiable cardiovascular risk factors, educational level, and global region', 'Montreal Cognitive Assessment score', 'Mild cognitive impairment', 'density lipoprotein cholesterol', 'adjusted odds ratio ( OR ) for mild cognitive impairment (Montreal Cognitive Assessment score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0010068', 'cui_str': 'Coronary Disease'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C2936350', 'cui_str': 'Plaque, Atherosclerotic'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation (observable entity)'}, {'cui': 'C2348075', 'cui_str': 'darapladib'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C4517497', 'cui_str': '1.25 (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0031671', 'cui_str': 'Lecithinases'}]","[{'cui': 'C0455527', 'cui_str': 'H/O: hypertension'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C4721272', 'cui_str': 'Montreal cognitive assessment score'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0065055', 'cui_str': 'lipoprotein cholesterol'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}]",10634.0,0.311222,"The Montreal Cognitive Assessment score obtained 3.2±0.37 years after randomization to darapladib, a reversible inhibitor of lipoprotein phospholipase","[{'ForeName': 'Ralph A H', 'Initials': 'RAH', 'LastName': 'Stewart', 'Affiliation': '1 Green Lane Cardiovascular Service Auckland City Hospital Auckland New Zealand.'}, {'ForeName': 'Claes', 'Initials': 'C', 'LastName': 'Held', 'Affiliation': '3 Department of Medical Sciences Cardiology Uppsala University Uppsala Sweden.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Krug-Gourley', 'Affiliation': '5 Metabolic Pathways and Cardiovascular Medicine Delivery Unit GlaxoSmithKline Research and Development Collegeville PA.'}, {'ForeName': 'Dawn', 'Initials': 'D', 'LastName': 'Waterworth', 'Affiliation': '6 Department of Genetics GlaxoSmithKline Medicines Research Centre Upper Merion Philadelphia PA.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Stebbins', 'Affiliation': '7 Duke Clinical Research Institute Durham NC.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Chiswell', 'Affiliation': '7 Duke Clinical Research Institute Durham NC.'}, {'ForeName': 'Emil', 'Initials': 'E', 'LastName': 'Hagstrom', 'Affiliation': '3 Department of Medical Sciences Cardiology Uppsala University Uppsala Sweden.'}, {'ForeName': 'Paul W', 'Initials': 'PW', 'LastName': 'Armstrong', 'Affiliation': '8 Canadian VIGOUR Centre University of Alberta Edmonton Canada.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Wallentin', 'Affiliation': '3 Department of Medical Sciences Cardiology Uppsala University Uppsala Sweden.'}, {'ForeName': 'Harvey', 'Initials': 'H', 'LastName': 'White', 'Affiliation': '1 Green Lane Cardiovascular Service Auckland City Hospital Auckland New Zealand.'}]",Journal of the American Heart Association,['10.1161/JAHA.118.010641'] 167,31713262,Impact of an intervention to support hearing and vision in dementia: The SENSE-Cog Field Trial.,"OBJECTIVES Hearing, vision, and cognitive impairment commonly co-occur in older adults. Improving sensory function may positively impact outcomes in people with dementia (PwD). We developed a ""sensory intervention"" (SI) to support hearing and vision in PwD. Here, we report the findings of an international open-label field trial, and nested case series, to explore the impact of the SI on dementia-related outcomes. METHODS This was a home-based trial conducted in France, England, and Cyprus. Participants were people with mild-to-moderate dementia and hearing and/or vision impairment (n = 19) and their study partners (unpaid carers; n = 19). The ""basic"" SI included a hearing and vision assessment and provision of glasses and/or hearing aids. A subsample received the ""extended"" SI with additional weekly visits from a sensory support therapist (SST). Exploratory analyses of dementia-related, health utility and resource utilisation outcomes were performed. RESULTS Quality of life (QoL) and sensory functional ability improved. Change in QoL exceeded the threshold for a minimum clinically important difference. There was a modest improvement (in absolute terms) post intervention in behavioural disturbance, self-efficacy, and relationship satisfaction. Study partner time assisting instrumental activities of daily living (iADL) and supervision decreased by about 22 and 38 hours per month, respectively, although time for personal ADL support increased. Qualitative data supported effectiveness of the intervention: PwD were more socially engaged, less isolated, less dependent on study partners, and had improved functional ability and communication. CONCLUSIONS These findings support the need for a definitive randomised controlled trial (RCT) to evaluate the effectiveness of the intervention.",2020,"Qualitative data supported effectiveness of the intervention: PwD were more socially engaged, less isolated, less dependent on study partners, and had improved functional ability and communication. ","['in dementia', 'Participants were people with mild-to-moderate dementia and hearing and/or vision impairment (n=19), and their study partners (unpaid carers; n=19', 'older adults', 'people with dementia (PwD']","[""extended' SI with additional weekly visits from a sensory support therapist (SST"", 'intervention to support hearing and vision', ""Sensory Intervention' (SI) to support hearing and vision in PwD""]","['hearing and vision assessment and provision of glasses and/or hearing aids', 'Study partner time assisting instrumental activities of daily living (iADL) and supervision', 'Change in QoL', 'behavioural disturbance, self-efficacy and relationship satisfaction', 'Quality of life (QoL) and sensory functional ability']","[{'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C1305660', 'cui_str': 'Carer (occupation)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0445254', 'cui_str': 'Sensory (qualifier value)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0042789', 'cui_str': 'Vision'}]","[{'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0017596', 'cui_str': 'Glass'}, {'cui': 'C0018767', 'cui_str': 'Audition'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C1290928', 'cui_str': 'Instrumental activity of daily living (observable entity)'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0034380'}, {'cui': 'C0445254', 'cui_str': 'Sensory (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",,0.113663,"Qualitative data supported effectiveness of the intervention: PwD were more socially engaged, less isolated, less dependent on study partners, and had improved functional ability and communication. ","[{'ForeName': 'Iracema', 'Initials': 'I', 'LastName': 'Leroi', 'Affiliation': 'Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Simkin', 'Affiliation': 'Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Hooper', 'Affiliation': 'Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Wolski', 'Affiliation': 'Institute of Applied Research, Development and Further Education, Catholic University of Applied Sciences Freiburg, Freiburg, Germany.'}, {'ForeName': 'Harvey', 'Initials': 'H', 'LastName': 'Abrams', 'Affiliation': 'Department of Communication Sciences and Disorders, University of South Florida, Tampa, FL.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Armitage', 'Affiliation': 'Division of Psychology and Mental Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Camacho', 'Affiliation': 'Manchester Centre for Health Economics, University of Manchester, Manchester, UK.'}, {'ForeName': 'Anna Pavlina', 'Initials': 'AP', 'LastName': 'Charalambous', 'Affiliation': 'Department of Health Sciences, European University Cyprus, Nicosia, Cyprus.'}, {'ForeName': 'Fideline', 'Initials': 'F', 'LastName': 'Collin', 'Affiliation': 'INSERM, EUCLID/F-CRIN Clinical Trials Platform, University of Bordeaux, Talence, Aquitaine, France.'}, {'ForeName': 'Fofi', 'Initials': 'F', 'LastName': 'Constantinidou', 'Affiliation': 'Centre for Applied Neurosciences, University of Cyprus, Nicosia, Cyprus.'}, {'ForeName': 'Piers', 'Initials': 'P', 'LastName': 'Dawes', 'Affiliation': 'Manchester Centre for Audiology and Deafness, University of Manchester, Manchester, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Elliott', 'Affiliation': 'Manchester Centre for Health Economics, University of Manchester, Manchester, UK.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Falkingham', 'Affiliation': 'Department of Audiology, Starkey Hearing Technologies, Stockport, UK.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Frison', 'Affiliation': 'INSERM, EUCLID/F-CRIN Clinical Trials Platform, University of Bordeaux, Talence, Aquitaine, France.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Hann', 'Affiliation': 'Centre for Biostatistics, University of Manchester, Manchester, UK.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Helmer', 'Affiliation': 'INSERM, Bordeaux Population Health Research Center, Team LEHA, University of Bordeaux, Talence, Aquitaine, France.'}, {'ForeName': 'Ines', 'Initials': 'I', 'LastName': 'Himmelsbach', 'Affiliation': 'Institute of Applied Research, Development and Further Education, Catholic University of Applied Sciences Freiburg, Freiburg, Germany.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Hussain', 'Affiliation': 'Manchester Centre for Health Economics, University of Manchester, Manchester, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Marié', 'Affiliation': 'Research and Development, Essilor International, Paris, France.'}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Montecelo', 'Affiliation': 'Research and Development, Essilor International, Paris, France.'}, {'ForeName': 'Chryssoula', 'Initials': 'C', 'LastName': 'Thodi', 'Affiliation': 'Department of Health Sciences, European University Cyprus, Nicosia, Cyprus.'}, {'ForeName': 'Wai Kent', 'Initials': 'WK', 'LastName': 'Yeung', 'Affiliation': 'Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.'}]",International journal of geriatric psychiatry,['10.1002/gps.5231'] 168,32295565,"Minocycline as adjunctive treatment for treatment-resistant depression: study protocol for a double blind, placebo-controlled, randomized trial (MINDEP2).","BACKGROUND Available evidence suggests that adjunctive treatment with immunomodulatory medications may be effective in the treatment of major depressive disorder (MDD). A pilot trial of the tetracycline minocycline as adjunctive treatment in treatment-resistant depression (TRD), produced promising results, however, a larger scale trial is needed to confirm the antidepressant actions of this drug. METHODS This is a 12-week double blind, placebo-controlled, randomized trial of minocycline as an add-on to standard antidepressants for adults (age > 18) with DSM-5 major depressive episode, who have failed to respond to at least two adequate trials of antidepressant treatment. It is a parallel-arm study with 50 participants in each group. The primary outcome measure is change in 17-item Hamilton Depression Rating Scale (HRSD-17) total scores from baseline to week 12. Secondary measures include the Clinical Global Impression (CGI) scale, World Health Organization Quality of Life Short Version (WHOQOL-BREF) and the Generalized Anxiety Disorder scale (GAD-7). Peripheral inflammatory biomarkers will be collected at baseline, week 6 and 12. DISCUSSION If minocycline is well tolerated and effective in reducing depressive symptoms in patients with TRD, it would warrant genuine consideration as a treatment option for TRD. Additionally, if results demonstrate that minocycline has antidepressant properties, and that changes in inflammatory status are associated with its antidepressant action, it will inform the development of individualized treatment for a subset of patients with MDD. TRIAL REGISTRATION Clinicaltrials.gov identifier: NCT03947827. Registered 13th May, 2019.",2020,"Secondary measures include the Clinical Global Impression (CGI) scale, World Health Organization Quality of Life Short Version (WHOQOL-BREF) and the Generalized Anxiety Disorder scale (GAD-7).","['treatment-resistant depression (TRD', '50 participants in each group', 'patients with TRD', 'adults (age\xa0>\xa018) with DSM-5 major depressive episode, who have failed to respond to at least two adequate trials of antidepressant treatment']","['Minocycline', 'minocycline', 'tetracycline minocycline', 'placebo']","['Clinical Global Impression (CGI) scale, World Health Organization Quality of Life Short Version (WHOQOL-BREF) and the Generalized Anxiety Disorder scale (GAD-7', 'change in 17-item Hamilton Depression Rating Scale (HRSD-17) total scores', 'depressive symptoms', 'Peripheral inflammatory biomarkers']","[{'cui': 'C2063866', 'cui_str': 'Therapy-Resistant Depression'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C0024517', 'cui_str': 'Major depression, single episode'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0026187', 'cui_str': 'Minocycline'}, {'cui': 'C0039644', 'cui_str': 'Tetracycline'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C3641330', 'cui_str': 'GAD-7'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",,0.0905107,"Secondary measures include the Clinical Global Impression (CGI) scale, World Health Organization Quality of Life Short Version (WHOQOL-BREF) and the Generalized Anxiety Disorder scale (GAD-7).","[{'ForeName': 'Muhammad Ishrat', 'Initials': 'MI', 'LastName': 'Husain', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada. ishrat.husain@camh.ca.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Cullen', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Madeha', 'Initials': 'M', 'LastName': 'Umer', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Andre F', 'Initials': 'AF', 'LastName': 'Carvalho', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Kloiber', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Jeffrey H', 'Initials': 'JH', 'LastName': 'Meyer', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Ortiz', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Yuliya', 'Initials': 'Y', 'LastName': 'Knyahnytska', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'M Omair', 'Initials': 'MO', 'LastName': 'Husain', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Justine', 'Initials': 'J', 'LastName': 'Giddens', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Breno S', 'Initials': 'BS', 'LastName': 'Diniz', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Allan H', 'Initials': 'AH', 'LastName': 'Young', 'Affiliation': 'Kings College London, London, UK.'}, {'ForeName': 'Benoit H', 'Initials': 'BH', 'LastName': 'Mulsant', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Zafiris J', 'Initials': 'ZJ', 'LastName': 'Daskalakis', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}]",BMC psychiatry,['10.1186/s12888-020-02553-9'] 169,32320537,The effectiveness of a mobile high-frequency chest wall oscillation (HFCWO) device for airway clearance.,"INTRODUCTION High-frequency chest wall oscillation (HFCWO) is a commonly prescribed airway clearance technique (ACT) for patients whose ability to expectorate sputum is compromised. This study aimed to assess the effectiveness of a newly developed mobile ACT device (mHFCWO-The Monarch Airway Clearance System) in patients with cystic fibrosis (CF). A standard nonmobile HFCWO device (sHFCWO) was used as a comparator. METHODOLOGY This was a randomized, open-label, crossover pilot study. CF patients were treated with each device. Sputum was collected during and after each therapy session, while spirometry tests, Brody score assessment and functional respiratory imaging were performed before and after treatments. RESULTS Wet weight of sputum collected during and after treatment was similar for mHFCWO and sHFCWO (6.53 ± 8.55 vs 5.80 ± 5.82; P = .777). Interestingly, the mHFCWO treatment led to a significant decrease in specific airway volume (9.55 ± 9.96 vs 8.74 ± 9.70 mL/L; P < .001), while increasing specific airway resistance (0.10 ± 0.16 vs 0.16 ± 0.23 KPA*S; P < .001). These changes were heterogeneously-distributed throughout the lung tissue and were greater in the distal areas, suggesting a shift of mucus. Changes were accompanied by an overall improvement in the Brody index (57.71 ± 16.55 vs 55.20 ± 16.98; P = .001). CONCLUSION The newly developed mobile device provides airway clearance for CF patients comparable to a nonmobile sHFCWO device, yielding a change in airway geometry and patency by the shift of mucus from the more peripheral regions to the central airways.",2020,"The newly developed mobile device provides airway clearance for CF patients comparable to a nonmobile sHFCWO device, yielding a change in airway geometry and patency by the shift of mucus from the more peripheral regions to the central airways.",['patients with cystic fibrosis (CF'],"['mobile high-frequency chest wall oscillation (HFCWO) device', 'mobile ACT device (mHFCWO-The Monarch Airway Clearance System', 'High-frequency chest wall oscillation (HFCWO', 'standard nonmobile HFCWO device (sHFCWO']","['specific airway resistance', 'specific airway volume', 'Brody index']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010674', 'cui_str': 'Cystic fibrosis'}]","[{'cui': 'C1136075', 'cui_str': 'High-Frequency Chest Compression'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0001884', 'cui_str': 'Airway Resistance'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.0447732,"The newly developed mobile device provides airway clearance for CF patients comparable to a nonmobile sHFCWO device, yielding a change in airway geometry and patency by the shift of mucus from the more peripheral regions to the central airways.","[{'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Leemans', 'Affiliation': 'Department of Rehabilitation Sciences and Physiotherapy, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'Belmans', 'Affiliation': 'Fluidda nv, Kontich, Belgium.'}, {'ForeName': 'Cedric', 'Initials': 'C', 'LastName': 'Van Holsbeke', 'Affiliation': 'Fluidda nv, Kontich, Belgium.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Becker', 'Affiliation': 'Department of Medical Affairs, Hillrom Company Inc., St. Paul, Minnesota.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Vissers', 'Affiliation': 'Department of Rehabilitation Sciences and Physiotherapy, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Kris', 'Initials': 'K', 'LastName': 'Ides', 'Affiliation': 'Department of Rehabilitation Sciences and Physiotherapy, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Stijn', 'Initials': 'S', 'LastName': 'Verhulst', 'Affiliation': 'Department of Rehabilitation Sciences and Physiotherapy, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Van Hoorenbeeck', 'Affiliation': 'Department of Rehabilitation Sciences and Physiotherapy, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.'}]",Pediatric pulmonology,['10.1002/ppul.24784'] 170,32293383,"Clinical and cost effectiveness of staff training in the delivery of Positive Behaviour Support (PBS) for adults with intellectual disabilities, autism spectrum disorder and challenging behaviour - randomised trial.","BACKGROUND Although Positive Behaviour Support (PBS) is a widely used intervention for ameliorating challenging behaviour (CB), evidence for its use in adults with intellectual disability (ID) and comorbid autism (ASD) is lacking. We report a planned subsidiary analysis of adults with both ASD and ID who participated in a randomised trial of PBS delivered by health professionals. METHODS The study was a multicentre, cluster randomised trial conducted in 23 community ID services in England, participants were randomly allocated to either the delivery of PBS (n = 11 clusters) or to treatment as usual (TAU; n = 12). One-hundred and thirteen participants (46% of all participants in the trial) had a diagnosis of ID, autism spectrum disorder and CB (ASD+); (47 allocated to the intervention arm, and 66 to the control). CB (primary outcome) was measured with the Aberrant Behaviour Checklist total score (ABC-CT). Secondary outcomes included mental health status, psychotropic medication use, health and social care costs and quality adjusted life years (QALYs) over 12 months. RESULTS There were no statistically significant differences in ABC-CT between ASD+ groups randomised to the two arms over 12 months (adjusted mean difference = - 2.10, 95% CI: - 11.3 7.13, p = 0.655) or other measures. The mean incremental cost of the intervention per participant was £628 (95% CI -£1004 to £2013). There was a difference of 0.039 (95% CI - 0.028 to 0.103) for QALYs and a cost per QALY gained of £16,080. CONCLUSIONS Results suggest lack of clinical effectiveness for PBS delivered by specialist ID clinical teams. Further evidence is needed from larger trials, and development of improved interventions. TRIAL REGISTRATION ClinicalTrials.gov: NCT01680276.",2020,"There were no statistically significant differences in ABC-CT between ASD+ groups randomised to the two arms over 12 months (adjusted mean difference = - 2.10, 95% CI: - 11.3 7.13, p = 0.655) or other measures.","['adults with intellectual disability (ID) and comorbid autism (ASD', '23 community ID services in England, participants', 'One-hundred and thirteen participants (46% of all participants in the trial) had a diagnosis of ID, autism spectrum disorder and CB (ASD', 'adults with intellectual disabilities, autism spectrum disorder and challenging behaviour - randomised trial', 'adults with both ASD and ID who participated in a randomised trial of PBS delivered by health professionals']","['Positive Behaviour Support (PBS', 'PBS', 'staff training']","['mean incremental cost', 'mental health status, psychotropic medication use, health and social care costs and quality adjusted life years (QALYs', 'Aberrant Behaviour Checklist total score (ABC-CT', 'ABC-CT']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3714756', 'cui_str': 'Intellectual disability'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}, {'cui': 'C0018817', 'cui_str': 'Atrial septal defect'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0474414', 'cui_str': 'Challenging behavior'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0033978', 'cui_str': 'Psychotherapeutic agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0419189', 'cui_str': 'Social care'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0443127', 'cui_str': 'Aberrant'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",23.0,0.32936,"There were no statistically significant differences in ABC-CT between ASD+ groups randomised to the two arms over 12 months (adjusted mean difference = - 2.10, 95% CI: - 11.3 7.13, p = 0.655) or other measures.","[{'ForeName': 'Andre', 'Initials': 'A', 'LastName': 'Strydom', 'Affiliation': ""Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry Psychology and Neuroscience, King's College London, 16 De Crespigny Park, London, SE5 8AF, UK. andre.strydom@kcl.ac.uk.""}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Bosco', 'Affiliation': 'Institute of Mental Health, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Vickerstaff', 'Affiliation': ""Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry Psychology and Neuroscience, King's College London, 16 De Crespigny Park, London, SE5 8AF, UK.""}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Hunter', 'Affiliation': 'Research Department of Primary Care and Population Health, University College London, London, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Hassiotis', 'Affiliation': 'Division of Psychiatry, University College London, London, UK.'}]",BMC psychiatry,['10.1186/s12888-020-02577-1'] 171,31927219,Influencing college students' normative perceptions of protective behavioral strategies: A pilot randomized trial.,"INTRODUCTION Personalized feedback interventions (PFIs) are associated with small but reliable decreases in alcohol consumption among college students. While they often include information regarding protective behavioral strategies (PBS), PFIs do not typically include feedback aimed to modify normative perceptions of PBS. This study aimed to enhance the efficacy of existing PFIs among college students by incorporating normative feedback on participants' use of PBS. METHODS Students enrolled in undergraduate courses (N = 268) completed baseline and 1-month follow-up assessments of past-month use of PBS, normative perceptions of PBS use, alcohol consumption, and alcohol-related consequences. Participants were randomized to one of three conditions: typical feedback on PBS (typical strategies PFI), descriptive normative feedback on PBS (strategy norms PFI), or assessment-only control (AOC). Participants in the typical strategies PFI and strategy norms PFI conditions received web-based personalized feedback profiles. RESULTS Compared to AOC, both the strategy norms PFI and typical strategies PFI were effective in correcting participants' perceptions of other students' engagement in PBS (p = .01) but did not differ significantly from one another. No statistically significant differences were observed between conditions in terms of actual PBS use, alcohol consumption, or alcohol-related consequences at 1-month follow-up (p > .05). DISCUSSION The strategy norms and typical strategies PFIs were both successful in increasing normative perceptions of PBS use, indicating that general (rather than normative) feedback regarding PBS use may be sufficient for changing perceptions of PBS use.",2020,"No statistically significant differences were observed between conditions in terms of actual PBS use, alcohol consumption, or alcohol-related consequences at 1-month follow-up (p > .05). ","['college students', 'Students enrolled in undergraduate courses (N\xa0=\xa0268']","['Personalized feedback interventions (PFIs', 'typical feedback on PBS (typical strategies PFI), descriptive normative feedback on PBS (strategy norms PFI), or assessment-only control (AOC']","['actual PBS use, alcohol consumption, or alcohol-related consequences']","[{'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C4517673', 'cui_str': '268'}]","[{'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}]",,0.0309089,"No statistically significant differences were observed between conditions in terms of actual PBS use, alcohol consumption, or alcohol-related consequences at 1-month follow-up (p > .05). ","[{'ForeName': 'Eleanor L S', 'Initials': 'ELS', 'LastName': 'Leavens', 'Affiliation': 'Department of Psychology, Oklahoma State University, Stillwater, OK, United States.'}, {'ForeName': 'Mary Beth', 'Initials': 'MB', 'LastName': 'Miller', 'Affiliation': 'Department of Psychiatry, University of Missouri, Columbia, MO, United States.'}, {'ForeName': 'Emma I', 'Initials': 'EI', 'LastName': 'Brett', 'Affiliation': 'Department of Psychology, Oklahoma State University, Stillwater, OK, United States.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Baraldi', 'Affiliation': 'Department of Psychology, Oklahoma State University, Stillwater, OK, United States.'}, {'ForeName': 'Thad R', 'Initials': 'TR', 'LastName': 'Leffingwell', 'Affiliation': 'Department of Psychology, Oklahoma State University, Stillwater, OK, United States. Electronic address: leavens@okstate.edu.'}]",Addictive behaviors,['10.1016/j.addbeh.2019.106256'] 172,31675674,"Chromosomal stability in buccal cells was linked to age but not affected by exercise and nutrients - Vienna Active Ageing Study (VAAS), a randomized controlled trial.","The purpose of this study was to investigate the effect of six months strength training with or without supplementing protein and vitamins, on chromosomal integrity of buccal cells in institutionalized elderly. One hundred seventeen women and men (65-98 years) performed either resistance training (RT), RT combined with a nutritional supplement (RTS) or cognitive training (CT) twice per week for six months. Participants' fitness was measured using the 6 min walking, the chair rise, and the handgrip strength test. Genotoxicity and cytotoxicity parameters were investigated with the Buccal Micronucleus Cytome (BMcyt) assay. Six minutes walking and chair rise performance improved significantly, however, no changes of the parameters of the BMcyt were detected. Age and micronuclei (MN) frequency correlated significantly, for both women (r = 0.597, p = 0.000) and men (r = 0.508, p = 0.000). Squared regressions revealed a significant increase in the MN frequency of buccal cells with age (R 2  = 0.466, p = 0.000). Interestingly and contrary to what was shown in blood lymphocytes, chromosomal damage in buccal cells increases until very old age, which might qualify them as a valid biomarker for aging. Unexpectedly, in this group of institutionalized elderly, resistance training using elastic bands had no effect on chromosomal damage in buccal cells.",2020,"Six minutes walking and chair rise performance improved significantly, however, no changes of the parameters of the BMcyt were detected.","['institutionalized elderly', 'One hundred seventeen women and men (65-98 years) performed either']","['six months strength training with or without supplementing protein and vitamins', 'resistance training (RT), RT combined with a nutritional supplement (RTS) or cognitive training (CT']","['Six minutes walking and chair rise performance', 'MN frequency of buccal cells', 'Genotoxicity and cytotoxicity parameters', 'chromosomal damage in buccal cells', 'blood lymphocytes, chromosomal damage in buccal cells', 'Age and micronuclei (MN) frequency', 'Chromosomal stability in buccal cells', 'Buccal Micronucleus Cytome (BMcyt) assay']","[{'cui': 'C0562359', 'cui_str': 'Institutionalized (finding)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0450331', 'cui_str': '17 (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0042890', 'cui_str': 'Vitamins'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0242295', 'cui_str': 'Dietary Supplementations'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0179847', 'cui_str': 'Chair (physical object)'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0442010', 'cui_str': 'Buccal (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0598309', 'cui_str': 'Genotoxicity'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0010957', 'cui_str': 'Damage (morphologic abnormality)'}, {'cui': 'C0005768'}, {'cui': 'C4018897', 'cui_str': 'Lymphocyte component of blood'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1257826', 'cui_str': 'Chromosomal Stability'}, {'cui': 'C0026004', 'cui_str': 'Micronucleus (morphologic abnormality)'}, {'cui': 'C1510438', 'cui_str': 'Assay technique (qualifier value)'}]",117.0,0.026009,"Six minutes walking and chair rise performance improved significantly, however, no changes of the parameters of the BMcyt were detected.","[{'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Franzke', 'Affiliation': 'University of Vienna, Research Platform Active Ageing, Althanstraße 14, 1090, Vienna, Austria. Electronic address: bernhard.franzke@univie.ac.at.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Schober-Halper', 'Affiliation': 'University of Vienna, Research Platform Active Ageing, Althanstraße 14, 1090, Vienna, Austria.'}, {'ForeName': 'Marlene', 'Initials': 'M', 'LastName': 'Hofmann', 'Affiliation': 'University of Vienna, Research Platform Active Ageing, Althanstraße 14, 1090, Vienna, Austria.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Oesen', 'Affiliation': 'University of Vienna, Research Platform Active Ageing, Althanstraße 14, 1090, Vienna, Austria.'}, {'ForeName': 'Anela', 'Initials': 'A', 'LastName': 'Tosevska', 'Affiliation': 'University of Vienna, Research Platform Active Ageing, Althanstraße 14, 1090, Vienna, Austria; Department of Molecular, Cell and Developmental Biology, UCLA, 610 Charles E. Young Drive East, Los Angeles, CA, 90095, USA.'}, {'ForeName': 'Armen', 'Initials': 'A', 'LastName': 'Nersesyan', 'Affiliation': 'Medical University of Vienna, Institute of Cancer Research, Department of Internal Medicine I, Borschkegasse 8a, 1090, Vienna, Austria.'}, {'ForeName': 'Siegfried', 'Initials': 'S', 'LastName': 'Knasmüller', 'Affiliation': 'Medical University of Vienna, Institute of Cancer Research, Department of Internal Medicine I, Borschkegasse 8a, 1090, Vienna, Austria.'}, {'ForeName': 'Eva-Maria', 'Initials': 'EM', 'LastName': 'Strasser', 'Affiliation': 'Karl Landsteiner Institute for Remobilization and Functional Health/ Institute for Physical Medicine and Rehabilitation, Kaiser Franz Joseph Spital, SMZ-Süd, Kundratstraße 3, 1100, Vienna, Austria.'}, {'ForeName': 'Marlies', 'Initials': 'M', 'LastName': 'Wallner', 'Affiliation': 'University of Applied Sciences FH JOANNEUM, Eggenberger Allee 11, 8020, Graz, Austria.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Wessner', 'Affiliation': 'University of Vienna, Research Platform Active Ageing, Althanstraße 14, 1090, Vienna, Austria; University of Vienna, Centre for Sport Science and University Sports, Department of Sport and Exercise Physiology, Auf der Schmelz 6, 1150, Vienna, Austria.'}, {'ForeName': 'Karl-Heinz', 'Initials': 'KH', 'LastName': 'Wagner', 'Affiliation': 'University of Vienna, Research Platform Active Ageing, Althanstraße 14, 1090, Vienna, Austria; University of Vienna, Faculty of Life Sciences, Department of Nutritional Sciences, Althanstraße 14, 1090, Vienna, Austria.'}]",Redox biology,['10.1016/j.redox.2019.101362'] 173,30409751,Smartphone-based Healthy Weight Management Intervention for Chinese American Adolescents: Short-term Efficacy and Factors Associated With Decreased Weight.,"PURPOSE This study aimed to examine the short-term efficacy of a smartphone-based intervention for Chinese American adolescents who are overweight or obese and to explore factors associated with decreased body mass index (BMI). METHODS A randomized controlled study design was used. Intervention group received culturally appropriate and tailored educational program for weight management while control group received general health information. Anthropometrics, blood pressure, levels of physical and sedentary activity, diet, self-efficacy, and quality of life were assessed at baseline, 3 months, and 6 months. Linear mixed-effects models and regression models were used to analyze outcomes. RESULTS The study included 40 adolescent participants. Adolescents in the intervention reduced their BMI (z = -4.89, p < .001), BMI z score (z = -4.72, p < .001), sugary beverage (z = -.44, P = .001), and TV and computer time (z = -.51, p < .001) and increasing in self-efficacy in nutrition and physical activity significantly more than those in the control group. BMI reduction was significantly correlated with decreased fast food consumption and increased physical activity (F = 6.99, p = .007, r2 = .40). Being female and decreased sugary beverage consumption were related to decreased BMI z score (F = 8.38, p = .003, r2 = .511). CONCLUSIONS A culturally appropriate smartphone-based intervention has great potential to reduce obesity and improve adherence to a healthy lifestyle. Reducing sugary beverages and fast food intake and decreasing sedentary time are associated with decreased BMI among adolescents who are overweight or obese.",2019,BMI reduction was significantly correlated with decreased fast food consumption and increased physical activity,"['Chinese American Adolescents', 'adolescents who are overweight or obese', 'Chinese American adolescents who are overweight or obese', '40 adolescent participants']","['Smartphone-based Healthy Weight Management Intervention', 'culturally appropriate and tailored educational program for weight management while control group received general health information', 'smartphone-based intervention']","['BMI z score', 'BMI', 'TV and computer time', 'BMI reduction', 'self-efficacy in nutrition and physical activity', 'sugary beverage', 'physical activity', 'Anthropometrics, blood pressure, levels of physical and sedentary activity, diet, self-efficacy, and quality of life', 'sugary beverage consumption']","[{'cui': 'C0008121', 'cui_str': 'Chinese Americans'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0005329', 'cui_str': 'Beverages'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0034380'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]",40.0,0.0363706,BMI reduction was significantly correlated with decreased fast food consumption and increased physical activity,"[{'ForeName': 'Jyu-Lin', 'Initials': 'JL', 'LastName': 'Chen', 'Affiliation': 'University of California San Francisco, San Francisco, California. Electronic address: jyu-lin.chen@ucsf.edu.'}, {'ForeName': 'Claudia Maria', 'Initials': 'CM', 'LastName': 'Guedes', 'Affiliation': 'Department of Kinesiology, San Francisco State University, San Francisco, California.'}, {'ForeName': 'Audrey E', 'Initials': 'AE', 'LastName': 'Lung', 'Affiliation': 'North East Medical Services, San Francisco, California.'}]",The Journal of adolescent health : official publication of the Society for Adolescent Medicine,['10.1016/j.jadohealth.2018.08.022'] 174,30836804,"""Worth the Walk"": Culturally Tailored Stroke Risk Factor Reduction Intervention in Community Senior Centers.","Background Racial/ethnic minority older adults have worse stroke burden than non-Hispanic white and younger counterparts. Our academic-community partner team tested a culturally tailored 1-month (8-session) intervention to increase walking and stroke knowledge among Latino, Korean, Chinese, and black seniors. Methods and Results We conducted a randomized wait-list controlled trial of 233 adults aged 60 years and older, with a history of hypertension, recruited from senior centers. Outcomes were measured at baseline (T0), immediately after the 1-month intervention (T1), and 2 months later (T2). The primary outcome was pedometer-measured change in steps. Secondary outcomes included stroke knowledge (eg, intention to call 911 for stroke symptoms) and other self-reported and clinical measures of health. Mean age of participants was 74 years; 90% completed T2. Intervention participants had better daily walking change scores than control participants at T1 (489 versus -398 steps; mean difference in change=887; 97.5% CI, 137-1636), but not T2 after adjusting for multiple comparisons (233 versus -714; mean difference in change=947; 97.5% CI, -108 to 2002). The intervention increased the percent of stroke symptoms for which participants would call 911 (from 49% to 68%); the control group did not change (mean difference in change T0-T1=22%; 99.9% CI, 9-34%). This effect persisted at T2. The intervention did not affect measures of health (eg, blood pressure). Conclusions This community-partnered intervention did not succeed in increasing and sustaining meaningful improvements in walking levels among minority seniors, but it caused large, sustained improvements in stroke preparedness. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 02181062.",2019,"This community-partnered intervention did not succeed in increasing and sustaining meaningful improvements in walking levels among minority seniors, but it caused large, sustained improvements in stroke preparedness.","['233 adults aged 60\xa0years and older, with a history of hypertension, recruited from senior centers', 'Community Senior Centers', 'minority seniors', 'Mean age of participants was 74\xa0years; 90% completed T2', 'Latino, Korean, Chinese, and black seniors']","['culturally tailored 1-month (8-session) intervention', 'Walk"": Culturally Tailored Stroke Risk Factor Reduction Intervention']","['pedometer-measured change in steps', 'percent of stroke symptoms', 'stroke knowledge (eg, intention to call 911 for stroke symptoms) and other self-reported and clinical measures of health', 'health (eg, blood pressure', 'daily walking change scores']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0455527', 'cui_str': 'H/O: hypertension'}, {'cui': 'C3658240', 'cui_str': 'Centers for the Aged'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C1556095', 'cui_str': 'Koreans'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}]","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C1277291', 'cui_str': 'Stroke risk'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]","[{'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",233.0,0.162508,"This community-partnered intervention did not succeed in increasing and sustaining meaningful improvements in walking levels among minority seniors, but it caused large, sustained improvements in stroke preparedness.","[{'ForeName': 'Josephine A', 'Initials': 'JA', 'LastName': 'Menkin', 'Affiliation': '1 David Geffen School of Medicine at UCLA Los Angeles CA.'}, {'ForeName': 'Heather E', 'Initials': 'HE', 'LastName': 'McCreath', 'Affiliation': '1 David Geffen School of Medicine at UCLA Los Angeles CA.'}, {'ForeName': 'Sarah Y', 'Initials': 'SY', 'LastName': 'Song', 'Affiliation': '2 Rush University Medical Center Chicago IL.'}, {'ForeName': 'Carmen A', 'Initials': 'CA', 'LastName': 'Carrillo', 'Affiliation': '1 David Geffen School of Medicine at UCLA Los Angeles CA.'}, {'ForeName': 'Carmen E', 'Initials': 'CE', 'LastName': 'Reyes', 'Affiliation': '1 David Geffen School of Medicine at UCLA Los Angeles CA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Trejo', 'Affiliation': '3 City of Los Angeles Department of Aging Los Angeles CA.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Choi', 'Affiliation': '4 UCLA School of Nursing Los Angeles CA.'}, {'ForeName': 'Phyllis', 'Initials': 'P', 'LastName': 'Willis', 'Affiliation': '5 Watts Labor Community Action Committee Los Angeles CA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Jimenez', 'Affiliation': '6 Mexican American Opportunity Foundation Montebello CA.'}, {'ForeName': 'Sina', 'Initials': 'S', 'LastName': 'Ma', 'Affiliation': '7 Chinatown Service Center Los Angeles CA.'}, {'ForeName': 'Emiley', 'Initials': 'E', 'LastName': 'Chang', 'Affiliation': '1 David Geffen School of Medicine at UCLA Los Angeles CA.'}, {'ForeName': 'Honghu', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': '1 David Geffen School of Medicine at UCLA Los Angeles CA.'}, {'ForeName': 'Ivy', 'Initials': 'I', 'LastName': 'Kwon', 'Affiliation': '8 Science 37 Los Angeles CA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Kotick', 'Affiliation': '9 The Kotick Network Los Angeles CA.'}, {'ForeName': 'Catherine A', 'Initials': 'CA', 'LastName': 'Sarkisian', 'Affiliation': '1 David Geffen School of Medicine at UCLA Los Angeles CA.'}]",Journal of the American Heart Association,['10.1161/JAHA.118.011088'] 175,31041545,Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).,"BACKGROUND The risk:benefit ratio of concomitant use of thiopurines with scheduled adalimumab (ADA) maintenance therapy for Crohn's disease is controversial. The aim of this study is to identify the influence of withdrawal of thiopurines in patients in remission with combination therapy in an open-label, randomised, controlled trial (DIAMOND2; UMIN000009596). METHODS Patients in corticosteroid-free clinical remission (CFCR) for ≥ 6 months with ADA (40 mg, s.c., every other week) scheduled maintenance combined with thiopurines were randomised into two groups, ""continue"" (Con) or ""discontinue"" (Dis) group of thiopurines, whereas all other patients kept receiving scheduled ADA maintenance therapy for 52 weeks. The primary endpoint was the proportion of patients in CFCR at week 52. Secondary endpoints were endoscopic remission (ER), trough levels of ADA in serum, and safety. RESULTS Fifty patients were randomised to Con or Dis groups. Characteristics of patients were not significantly different between the groups. CFCR and ER prevalence at week 52 were not significantly different between groups (log rank, P = 0.704, P = 1.000, respectively). Trough levels of ADA were not significantly different between groups (P = 0.515). The proportion of patients with AAA positivity at week 52 was not significantly different (P = 0.437). ER at week 0 was involved in ER and triple remission at week 52. No serious adverse effects were observed in either group. CONCLUSION Continuation of thiopurines > 6 months offers no clear benefit over scheduled ADA monotherapy. CFCR, ER, and ADA trough level at week 52 were not significantly different between groups. ER at week 0 may be involved in better long-term clinical outcomes.",2019,"CFCR and ER prevalence at week 52 were not significantly different between groups (log rank, P = 0.704, P = 1.000, respectively).","['patients in remission with combination therapy in an open-label', 'Fifty patients', ""Crohn's disease treated with scheduled adalimumab maintenance"", 'Patients in corticosteroid-free clinical remission (CFCR) for\u2009≥']","['continue"" (Con) or ""discontinue"" (Dis) group of thiopurines, whereas all other patients kept receiving scheduled ADA maintenance therapy', 'thiopurines with scheduled adalimumab (ADA) maintenance therapy', 'thiopurines', 'ADA', 'Withdrawal of thiopurines']","['serious adverse effects', 'CFCR and ER prevalence', 'Trough levels of ADA', 'proportion of patients in CFCR', 'CFCR, ER, and ADA trough level', 'proportion of patients with AAA positivity', 'endoscopic remission (ER), trough levels of ADA in serum, and safety']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0556895', 'cui_str': 'Combination therapy (regime/therapy)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0156147', 'cui_str': 'Colitis, Granulomatous'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C1122087', 'cui_str': 'adalimumab'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}]","[{'cui': 'C1706472', 'cui_str': 'Discontinue - dosing instruction imperative'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}, {'cui': 'C1122087', 'cui_str': 'adalimumab'}]","[{'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0444506', 'cui_str': 'Trough (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",50.0,0.167078,"CFCR and ER prevalence at week 52 were not significantly different between groups (log rank, P = 0.704, P = 1.000, respectively).","[{'ForeName': 'Tadakazu', 'Initials': 'T', 'LastName': 'Hisamatsu', 'Affiliation': 'Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, 181-8611, Japan. thisamatsu@ks.kyorin-u.ac.jp.'}, {'ForeName': 'Shingo', 'Initials': 'S', 'LastName': 'Kato', 'Affiliation': 'Department of Gastroenterology and Hepatology, Saitama Medical Centre, Saitama Medical University, Saitama, Japan.'}, {'ForeName': 'Reiko', 'Initials': 'R', 'LastName': 'Kunisaki', 'Affiliation': 'Inflammatory Bowel Disease Centre, Yokohama City University Medical Center, Kanagawa, Japan.'}, {'ForeName': 'Minoru', 'Initials': 'M', 'LastName': 'Matsuura', 'Affiliation': 'Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Masakazu', 'Initials': 'M', 'LastName': 'Nagahori', 'Affiliation': 'Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Motoya', 'Affiliation': 'Inflammatory Bowel Disease Center, Sapporo Kosei General Hospital, Sapporo, Japan.'}, {'ForeName': 'Motohiro', 'Initials': 'M', 'LastName': 'Esaki', 'Affiliation': 'Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.'}, {'ForeName': 'Norimasa', 'Initials': 'N', 'LastName': 'Fukata', 'Affiliation': 'Third Department of Internal Medicine, Kansai Medical University, Osaka, Japan.'}, {'ForeName': 'Satoko', 'Initials': 'S', 'LastName': 'Inoue', 'Affiliation': 'Departments of Gastroenterology, Kobe City Medical Center General Hospital, Hyogo, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Sugaya', 'Affiliation': 'Department of Internal Medicine, Japan Red Cross Ashikaga Hospital, Tochigi, Japan.'}, {'ForeName': 'Hirotake', 'Initials': 'H', 'LastName': 'Sakuraba', 'Affiliation': 'Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.'}, {'ForeName': 'Fumihito', 'Initials': 'F', 'LastName': 'Hirai', 'Affiliation': 'Inflammatory Bowel Disease Center, Fukuoka University Chikushi Hospital, Chikushino, Japan.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Watanabe', 'Affiliation': 'Division of Gastroenterology, Osaka City General Hospital, Osaka, Japan.'}, {'ForeName': 'Takanori', 'Initials': 'T', 'LastName': 'Kanai', 'Affiliation': 'Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Naganuma', 'Affiliation': 'Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Nakase', 'Affiliation': 'Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Suzuki', 'Affiliation': 'Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan.'}, {'ForeName': 'Mamoru', 'Initials': 'M', 'LastName': 'Watanabe', 'Affiliation': 'Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.'}, {'ForeName': 'Toshifumi', 'Initials': 'T', 'LastName': 'Hibi', 'Affiliation': 'Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.'}, {'ForeName': 'Masanori', 'Initials': 'M', 'LastName': 'Nojima', 'Affiliation': 'Center for Translational Research, Institute of Medical Science Hospital, University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Matsumoto', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, Iwate Medical University, Morioka, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of gastroenterology,['10.1007/s00535-019-01582-w'] 176,30514652,Efficacy of a Family-Based Intervention on Parent-Adolescent Discrepancies in Positive Parenting and Substance Use Among Hispanic Youth.,"PURPOSE The research literature shows that discrepancies in positive parenting between parent and adolescent represents maladaptive parent-adolescent relationships, which are in turn positively linked to later substance use in Hispanic youth. However, questions remain about for whom interventions work and by what mechanisms they work to prevent discrepancies in positive parenting. The current study investigated the moderating and mediating roles of positive parenting discrepancy trajectories on the association between condition effect (i.e., a family-based intervention vs. prevention as usual condition) and substance use among Hispanic youth. METHODS Eigth grade Hispanic adolescents (mean age = 13.86) and their primary caregivers (mean age = 42.32) were randomly assigned to two conditions: Familias Unidas (n = 376) or prevention as usual (n = 370). Participants were assessed at baseline and at 6, 18, and 30 months postbaseline. Using structural equation modeling, moderated mediation analyses were conducted to test whether the relationship between condition and past 90-day substance use at 30 months was mediated by discrepancy trajectories in positive parenting and whether direct and indirect relationships between condition and substance use were moderated by positive parenting discrepancies at baseline. RESULTS The results showed that, relative to prevention as usual, Familias Unidas reduced positive parenting discrepancies across time, when parent reports were higher than adolescent reports at baseline; this in turn, predicted substance use at 30 months postbaseline. CONCLUSIONS The findings provide important evidence supporting the need to collect multiple informant reports on positive parenting and examining the directionality of these reports among Hispanic families.",2019,"The results showed that, relative to prevention as usual, Familias Unidas reduced positive parenting discrepancies across time, when parent reports were higher than adolescent reports at baseline; this in turn, predicted substance use at 30 months postbaseline. ","['Eigth grade Hispanic adolescents ', 'Hispanic youth', 'mean age\u202f=\u202f13.86) and their primary caregivers (mean age\u202f=\u202f42.32', 'Hispanic Youth']",['Family-Based Intervention'],[],"[{'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0178499', 'cui_str': 'Base'}]",[],,0.046566,"The results showed that, relative to prevention as usual, Familias Unidas reduced positive parenting discrepancies across time, when parent reports were higher than adolescent reports at baseline; this in turn, predicted substance use at 30 months postbaseline. ","[{'ForeName': 'Tae Kyoung', 'Initials': 'TK', 'LastName': 'Lee', 'Affiliation': 'Department of Public Health Sciences, University of Miami, Miller School of Medicine, Miami, Florida. Electronic address: txl371@med.miami.edu.'}, {'ForeName': 'Yannine', 'Initials': 'Y', 'LastName': 'Estrada', 'Affiliation': 'Department of Public Health Sciences, University of Miami, Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Mary H', 'Initials': 'MH', 'LastName': 'Soares', 'Affiliation': 'Department of Public Health Sciences, University of Miami, Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'Sánchez Ahumada', 'Affiliation': 'Fundación San Carlos de Maipo, Región Metropolitana, Chile.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Correa Molina', 'Affiliation': 'Fundación San Carlos de Maipo, Región Metropolitana, Chile.'}, {'ForeName': 'Monica M', 'Initials': 'MM', 'LastName': 'Bahamon', 'Affiliation': 'Department of Public Health Sciences, University of Miami, Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Prado', 'Affiliation': 'Department of Public Health Sciences, University of Miami, Miller School of Medicine, Miami, Florida.'}]",The Journal of adolescent health : official publication of the Society for Adolescent Medicine,['10.1016/j.jadohealth.2018.10.002'] 177,32303884,"Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial.","PURPOSE Remimazolam, an ultra-short-acting benzodiazepine sedative is equally effective as propofol in induction and maintenance of general anesthesia with improved hemodynamic stability in American Society of Anesthesiologists (ASA) Class I and II patients. This trial investigated remimazolam's efficacy and safety in vulnerable patients (ASA Class III) undergoing elective general surgery. METHODS A multicenter, randomized, double-blind, parallel-group trial in 67 adult surgical patients undergoing general anesthesia with two remimazolam induction doses (6 mg kg -1  h -1 -group A and 12 mg kg -1  h -1 -group B) has been conducted in 6 trials sites in Japan. Remimazolam was infused up to 2 mg kg -1  h -1 for maintenance of anesthesia in both groups. RESULTS The functional anesthetic capability of the investigated drug was 100% in both arms. The mean time to loss of consciousness (LoC) was significantly shorter in group B (81.7 s) compared to group A (97.2 s), p = 0.0139. The mean bispectral index (BIS) value during maintenance of anesthesia ranged from 46.0 to 68.0 and from 44.7 to 67.5 in group A and B, respectively. There was no statistically significant difference between the remimazolam arms concerning the incidence of blood pressure (BP) decrease (67.7% in group B vs. 54.8% in group A), recovery profile or the incidence or severity of adverse events (AEs) or adverse drug reactions (ADRs). CONCLUSION Both induction regimens (6 and 12 mg kg -1  h -1 ) were equally efficacious and safe in surgical patients ASA Class III. A significantly shorter time to LoC was observed with the higher remimazolam dosage. Clinical trial registration This trial is registered with the Japan Pharmaceutical Information Center-Clinical Trials Information (JapicCTI). JapicCTI number: 121977.",2020,"There was no statistically significant difference between the remimazolam arms concerning the incidence of blood pressure (BP) decrease (67.7% in group B vs. 54.8% in group A), recovery profile or the incidence or severity of adverse events (AEs) or adverse drug reactions (ADRs). ","['vulnerable patients (ASA Class III) undergoing elective general surgery', '67 adult surgical patients undergoing general anesthesia with two', 'high-risk surgical patients (ASA Class III', 'American Society of Anesthesiologists (ASA', 'surgical patients ASA Class III', '6 trials sites in Japan']","['remimazolam induction doses (6\xa0mg\xa0kg', 'Remimazolam', '1 \xa0h -1 -group A and 12\xa0mg', 'benzodiazepine sedative', 'remimazolam']","['recovery profile or the incidence or severity of adverse events (AEs) or adverse drug reactions (ADRs', 'Safety and efficacy', 'mean time to loss of consciousness (LoC', 'mean bispectral index (BIS) value', 'blood pressure (BP) decrease', 'functional anesthetic capability', 'shorter time to LoC']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0441887', 'cui_str': 'Class 3'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C1274039', 'cui_str': 'General surgery'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C3179470', 'cui_str': 'remimazolam'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0700308', 'cui_str': 'Protium'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0360114', 'cui_str': 'Benzodiazepine sedative'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0041755', 'cui_str': 'Adverse reaction to drug'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0041657', 'cui_str': 'Loss of consciousness'}, {'cui': 'C1301882', 'cui_str': 'Bispectral index'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}]",67.0,0.332376,"There was no statistically significant difference between the remimazolam arms concerning the incidence of blood pressure (BP) decrease (67.7% in group B vs. 54.8% in group A), recovery profile or the incidence or severity of adverse events (AEs) or adverse drug reactions (ADRs). ","[{'ForeName': 'Matsuyuki', 'Initials': 'M', 'LastName': 'Doi', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Hamamatsu University Hospital, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan. matsuyuki_doi@nifty.com.'}, {'ForeName': 'Naoyuki', 'Initials': 'N', 'LastName': 'Hirata', 'Affiliation': 'Department of Anesthesiology, Sapporo Medical University School of Medicine, Sapporo, Japan.'}, {'ForeName': 'Toshiyasu', 'Initials': 'T', 'LastName': 'Suzuki', 'Affiliation': 'Department of Anesthesiology, Tokai University of Medicine, Isehara, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Morisaki', 'Affiliation': 'Department of Anesthesiology, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Morimatsu', 'Affiliation': 'Department of Anesthesiology and Resuscitology, Okayama University Hospital, Okayama, Japan.'}, {'ForeName': 'Atsuhiro', 'Initials': 'A', 'LastName': 'Sakamoto', 'Affiliation': 'Department of Anesthesiology, Nippon Medical School, Tokyo, Japan.'}]",Journal of anesthesia,['10.1007/s00540-020-02776-w'] 178,32276003,The beneficial role of FeNO in association with GINA guidelines for titration of inhaled corticosteroids in adult asthma: A randomized study.,"PURPOSE This study aimed to demonstrate the role of fractional concentration of exhaled nitric oxide (FeNO) in association with Global Initiative for Asthma (GINA) guidelines for treatment of adult patients with asthma. METHODS It was a prospective and randomized study. The symptomatic asthmatic patients were randomly divided into two groups: GINA group (followed GINA guidelines; N = 86) or GINA + FeNO group (followed GINA guidelines + FeNO for titration of inhaled corticosteroids - ICS; N = 90). They were followed-up for 9 months. RESULTS In GINA group, 37.2% patients had no treatment and 62.8% patients discontinued treatment vs. 40.0% and 60.0% in GINA + FeNO, respectively. After 3, 6 and 9 months of treatment, the percentage of mild, moderate and severe asthma showed no significant difference between the two groups. At 9th month, Δ moderate asthma (reduction) in GINA + FeNO group was significantly higher than in the GINA group (-22.0% vs. -11.6%; P = 0.018). The improvement of asthma control test (ACT) score was not different between the groups at 9th month (12 ± 6 vs. 10 ± 5; P > 0.05); the level of FeNO reduction in GINA + FeNO group was significantly higher than that in GINA group (-42 ± 11 vs. -35 ± 9; P = 0.022). The daily dose of ICS in GINA + FeNO group was significantly lower than that in GINA group (397 ± 171 vs. 482 ± 240 mcg and 375 ± 203 vs. 424 ± 221 mcg; respectively) at the end of 6 and 9 months. CONCLUSION The use of FeNO in association with GINA guidelines has a beneficial role for accurate daily dose of ICS in adult patients with asthma.",2020,"After 3, 6 and 9 months of treatment, the percentage of mild, moderate and severe asthma showed no significant difference between the two groups.","['symptomatic asthmatic patients', 'adult asthma', 'adult patients with asthma']","['GINA group (followed GINA guidelines; N\xa0=\xa086) or GINA\xa0+\xa0FeNO group (followed GINA guidelines\xa0+\xa0FeNO for titration of inhaled corticosteroids - ICS; N\xa0=\xa090', 'exhaled nitric oxide (FeNO', 'GINA']","['percentage of mild, moderate and severe asthma', 'level of FeNO reduction', 'improvement of asthma control test (ACT) score']","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0162621', 'cui_str': 'Titration method'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0581126', 'cui_str': 'Severe asthma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C2733224', 'cui_str': 'Asthma control test score'}]",,0.0308658,"After 3, 6 and 9 months of treatment, the percentage of mild, moderate and severe asthma showed no significant difference between the two groups.","[{'ForeName': 'Tung', 'Initials': 'T', 'LastName': 'Truong-Thanh', 'Affiliation': 'Department of Internal Medicine, Thanh Hoa General Hospital, Thanh Hoa City, Vietnam.'}, {'ForeName': 'Anh', 'Initials': 'A', 'LastName': 'Vo-Thi-Kim', 'Affiliation': 'Department of Public Health, Thang Long University, Hanoi City, Vietnam.'}, {'ForeName': 'Thuc', 'Initials': 'T', 'LastName': 'Vu-Minh', 'Affiliation': 'Department of Airway Diseases, ENT Institute, Hanoi City, Vietnam.'}, {'ForeName': 'Dung', 'Initials': 'D', 'LastName': 'Truong-Viet', 'Affiliation': 'Department of Public Health, Thang Long University, Hanoi City, Vietnam.'}, {'ForeName': 'Huong', 'Initials': 'H', 'LastName': 'Tran-Van', 'Affiliation': 'Department of Public Health, Thang Long University, Hanoi City, Vietnam.'}, {'ForeName': 'Sy', 'Initials': 'S', 'LastName': 'Duong-Quy', 'Affiliation': 'Department of Respiratory Diseases, Lam Dong Medical College, Dalat City, Vietnam; Department of Immuno-Allergology, Penn State Medical College, Hershey, USA. Electronic address: sduongquy.jfvp@gmail.com.'}]",Advances in medical sciences,['10.1016/j.advms.2020.03.001'] 179,32037269,Comparison of Antiplatelet Therapies for Prevention of Patent Foramen Ovale-Associated Stroke.,"AIMS The REDUCE study demonstrated a reduction in the risk of recurrent stroke with patent foramen ovale closure and antiplatelet therapy compared to antiplatelet therapy alone. The clinicians were allowed to choose among aspirin, clopidogrel, or aspirin/dipyridamole with the expectation that all antiplatelet therapies would have similar efficacy in this population. We tested that presumption by comparing recurrent stroke rates among antiplatelet agents within the control arm of the trial. METHODS We evaluated patients in REDUCE study who were randomized to the medical arm. The primary endpoint for this analysis was freedom from clinical ischemic stroke through at least 2 years of follow-up, to a maximum of 5 years. In the primary analysis, antiplatelet treatment was defined as the agent during the week prior to a recurrent stroke or last known contact. RESULTS Of 223 patients in the medical treatment arm, the initial agent was aspirin 52%, clopidogrel 30%, and aspirin/dipyridamole 12%. Patients treated with aspirin were similar to those treated with alternatives, but were more likely to be enrolled in the United States. The last reported agent was aspirin alone in 55%, clopidogrel alone in 31%, aspirin/dipyridamole in 7%, and other/nothing/missing in 7%. Recurrent stroke rates were similar for all 3 antiplatelet regimens in unadjusted and adjusted analyses, with no overall difference among agents (P= .17). CONCLUSIONS Among patients with patent foramen ovale-associated stroke who were managed medically, there were no differences among antiplatelet agents in the risk of recurrent stroke, though confidence intervals were wide.",2020,"Among patients with patent foramen ovale-associated stroke who were managed medically, there were no differences among antiplatelet agents in the risk of recurrent stroke, though confidence intervals were wide.","['223 patients in the medical treatment arm, the initial agent was']","['antiplatelet therapy alone', 'aspirin, clopidogrel, or aspirin/dipyridamole', 'clopidogrel', 'aspirin/dipyridamole', 'aspirin']","['recurrent stroke rates', 'freedom from clinical ischemic stroke', 'Recurrent stroke rates']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}]","[{'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0732279', 'cui_str': 'Aspirin / Dipyridamole'}]","[{'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}]",,0.0296037,"Among patients with patent foramen ovale-associated stroke who were managed medically, there were no differences among antiplatelet agents in the risk of recurrent stroke, though confidence intervals were wide.","[{'ForeName': 'Scott E', 'Initials': 'SE', 'LastName': 'Kasner', 'Affiliation': 'University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: kasner@mail.med.upenn.edu.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Randall', 'Affiliation': 'WL Gore and Associates, Flagstaff, Arizona.'}, {'ForeName': 'Grethe', 'Initials': 'G', 'LastName': 'Andersen', 'Affiliation': 'Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Helle K', 'Initials': 'HK', 'LastName': 'Iversen', 'Affiliation': 'University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Risto O', 'Initials': 'RO', 'LastName': 'Roine', 'Affiliation': 'Turku University Hospital and University of Turku, Turku, Finland.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Sjostrand', 'Affiliation': 'Karolinska Instituet, Stockholm, Sweden.'}, {'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'Rhodes', 'Affiliation': 'Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Søndergaard', 'Affiliation': 'Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association,['10.1016/j.jstrokecerebrovasdis.2019.104632'] 180,31171039,Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.,"BACKGROUND Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients with unresectable stage IIIB-IVM1c melanoma. METHODS Patients were randomized 2:1 to receive intratumoral talimogene laherparepvec or subcutaneous recombinant GM-CSF. In addition to overall survival (OS), durable response rate (DRR), objective response rate (ORR), complete responses (CR), and safety are also reported. All final analyses are considered to be descriptive and treatment responses were assessed by the investigators. RESULTS Of 436 patients in the intent-to-treat population, 295 were allocated to talimogene laherparepvec and 141 to GM-CSF. Median follow-up in the final OS analysis was 49 months. Median OS was 23.3 months (95% confidence interval [CI], 19.5-29.6) and 18.9 months (95% CI, 16.0-23.7) in the talimogene laherparepvec and GM-CSF arms, respectively (unstratified hazard ratio, 0.79; 95% CI, 0.62-1.00; p = 0.0494 [descriptive]). DRR was 19.0 and 1.4% (unadjusted odds ratio, 16.6; 95% CI, 4.0-69.2; p < 0.0001); ORR was 31.5 and 6.4%. Fifty (16.9%) and 1 (0.7%) patient in the talimogene laherparepvec and GM-CSF arms, respectively, achieved CR. In talimogene laherparepvec-treated patients, median time to CR was 8.6 months; median CR duration was not reached. Among patients with a CR, 88.5% were estimated to survive at a 5-year landmark analysis. Talimogene laherparepvec efficacy was more pronounced in stage IIIB-IVM1a melanoma as already described in the primary analysis. The safety reporting was consistent with the primary OPTiM analysis. CONCLUSIONS In this final planned OPTiM analysis, talimogene laherparepvec continued to result in improved longer-term efficacy versus GM-CSF and remained well tolerated. The final analysis also confirms that talimogene laherparepvec was associated with durable CRs that were associated with prolonged survival. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT00769704 .",2019,"Median OS was 23.3 months (95% confidence interval [CI], 19.5-29.6) and 18.9 months (95% CI, 16.0-23.7) in the talimogene laherparepvec and GM-CSF arms, respectively (unstratified hazard ratio, 0.79; 95% CI, 0.62-1.00; p = 0.0494 [descriptive]).","['Patients', 'patients with unresectable stage IIIB-IVM1c melanoma', '436 patients in the intent-to-treat population', 'unresectable stage III-IV melanoma']","['intratumoral talimogene laherparepvec or subcutaneous recombinant GM-CSF', 'talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor']","['ORR', 'tolerated', 'median time to CR', 'Median OS', 'median CR duration', 'Talimogene laherparepvec efficacy', 'overall survival (OS), durable response rate (DRR), objective response rate (ORR), complete responses (CR), and safety', 'DRR', 'prolonged survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0456599', 'cui_str': 'Stage 3B (qualifier value)'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3 (qualifier value)'}]","[{'cui': 'C1831828', 'cui_str': 'TALIMOGENE LAHERPAREPVEC'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C0079460', 'cui_str': 'Tumor-Cell Human GM Colony-Stimulating Factor'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1831828', 'cui_str': 'TALIMOGENE LAHERPAREPVEC'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}]",,0.333489,"Median OS was 23.3 months (95% confidence interval [CI], 19.5-29.6) and 18.9 months (95% CI, 16.0-23.7) in the talimogene laherparepvec and GM-CSF arms, respectively (unstratified hazard ratio, 0.79; 95% CI, 0.62-1.00; p = 0.0494 [descriptive]).","[{'ForeName': 'Robert H I', 'Initials': 'RHI', 'LastName': 'Andtbacka', 'Affiliation': 'Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Collichio', 'Affiliation': 'University of North Carolina Medical Center, Chapel Hill, NC, USA.'}, {'ForeName': 'Kevin J', 'Initials': 'KJ', 'LastName': 'Harrington', 'Affiliation': 'The Institute of Cancer Research/The Royal Marsden Hospital NIHR Biomedical Research Centre, London, SW3 6JB, UK. Kevin.Harrington@icr.ac.uk.'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Middleton', 'Affiliation': 'NIHR Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'Downey', 'Affiliation': 'Global Biostatistical Science, Amgen Ltd, Cambridge, UK.'}, {'ForeName': 'Katarina', 'Initials': 'K', 'LastName': 'Ӧhrling', 'Affiliation': 'Medical development, Amgen (Europe) GmbH, Zug, Switzerland.'}, {'ForeName': 'Howard L', 'Initials': 'HL', 'LastName': 'Kaufman', 'Affiliation': 'Massachusetts General Hospital, Boston, MA, USA.'}]",Journal for immunotherapy of cancer,['10.1186/s40425-019-0623-z'] 181,32282842,Yoga in school sports improves functioning of autonomic nervous system in young adults: A non-randomized controlled pilot study.,"BACKGROUND Yoga in school is a beneficial tool to promote the good health and well-being of students by changing the way they react to stress. The positive effects of yoga-taught in schools-on children, youth and young adults have been demonstrated in former studies using mostly subjective psychometric data. AIM The present trial aims to evaluate the potential effects of yoga on autonomic regulation in young adults by analyzing heart rate variability (HRV). METHODS This study is a non-randomized, explorative, two-arm-pilot study with an active control group. Fourteen healthy young adults took part in a 10-week yoga program (90 min once a week) in school and were compared to a control group of 11 students who participated in conventional school sports (90 min once a week over 10 weeks). 24-hour electrocardiograms (ECGs) were recorded at baseline and following the 10-week intervention. From 20-minute of nocturnal sleep phases, HRV parameters were calculated from linear (time and frequency domain) and nonlinear dynamics (such as symbolic dynamics and Poincaré plot analysis). Analyses of variance (ANOVA) followed by t-tests as post-hoc tests estimating both statistical significance and effect size were used to compare pre-post-intervention for the two groups. RESULTS The statistical analysis of the interaction effects did not reveal a significant group and time interaction for the individual nocturnal HRV indices. Almost all indices revealed medium and large effects regarding the time main effects. The changes in the HRV indices following the intervention were more dramatic for the yoga group than for the control group which is reflected in predominantly higher significances and stronger effect sizes in the yoga group. CONCLUSION In this explorative pilot trial, an increase of HRV (more parasympathetic dominance and overall higher HRV) after ten weeks of yoga in school in comparison to regular school sports was demonstrated, showing an improved self-regulation of the autonomic nervous system.",2020,"The changes in the HRV indices following the intervention were more dramatic for the yoga group than for the control group which is reflected in predominantly higher significances and stronger effect sizes in the yoga group. ","['schools-on children, youth and young adults', 'Fourteen healthy young adults', 'young adults', '11 students who participated in']","['conventional school sports', 'school sports', 'yoga program', 'yoga-taught']","['functioning of autonomic nervous system', 'HRV (more parasympathetic dominance and overall higher HRV', 'HRV indices', 'autonomic regulation', '24-hour electrocardiograms (ECGs']","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0039401', 'cui_str': 'Education'}]","[{'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C1287621', 'cui_str': 'Eye dominance - finding'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0430461', 'cui_str': '24 Hour ECG'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}]",14.0,0.0330619,"The changes in the HRV indices following the intervention were more dramatic for the yoga group than for the control group which is reflected in predominantly higher significances and stronger effect sizes in the yoga group. ","[{'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Frank', 'Affiliation': 'Department of Pediatrics, Jena University Hospital, Jena, Germany.'}, {'ForeName': 'Georg', 'Initials': 'G', 'LastName': 'Seifert', 'Affiliation': 'Department of Pediatrics, Division of Oncology and Hematology, Charité - Universitätsmedizin, Berlin, Germany.'}, {'ForeName': 'Rico', 'Initials': 'R', 'LastName': 'Schroeder', 'Affiliation': 'Institute of Innovative Health Technologies IGHT, Ernst-Abbe-Hochschule Jena, Jena, Germany.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Gruhn', 'Affiliation': 'Department of Pediatrics, Jena University Hospital, Jena, Germany.'}, {'ForeName': 'Wiebke', 'Initials': 'W', 'LastName': 'Stritter', 'Affiliation': 'Department of Pediatrics, Division of Oncology and Hematology, Charité - Universitätsmedizin, Berlin, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Jeitler', 'Affiliation': 'Institute for Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin, Berlin, Germany.'}, {'ForeName': 'Nico', 'Initials': 'N', 'LastName': 'Steckhan', 'Affiliation': 'Institute for Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin, Berlin, Germany.'}, {'ForeName': 'Christian S', 'Initials': 'CS', 'LastName': 'Kessler', 'Affiliation': 'Institute for Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin, Berlin, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Michalsen', 'Affiliation': 'Institute for Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin, Berlin, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Voss', 'Affiliation': 'Institute of Innovative Health Technologies IGHT, Ernst-Abbe-Hochschule Jena, Jena, Germany.'}]",PloS one,['10.1371/journal.pone.0231299'] 182,32300002,Cognitive-behavioral therapy-based intervention to treat symptoms of anxiety in pregnancy in a prenatal clinic using non-specialist providers in Pakistan: design of a randomised trial.,"INTRODUCTION Prenatal anxiety is a prevalent condition that is harmful for women and a strong predictor of postpartum depression. This trial assesses an intervention initiated in early pregnancy to mid pregnancy among women with clinical or subclinical symptoms of anxiety in Pakistan. METHODS AND ANALYSIS: Happy Mother, Healthy Baby (HMHB) is a phase three, two-arm, single-blind, individual randomised clinical trial conducted in the outpatient department of Holy Family Hospital, a large public tertiary care facility affiliated with Rawalpindi Medical University (RMU). Pregnant women (enrolled at ≤22 weeks of gestation) receive six individual HMHB sessions based on cognitive-behavioral therapy (CBT) and relaxation techniques that are administered by non-specialist providers and tailored to address anxiety symptoms. Two to six booster sessions are given between the fifth consecutive weekly core session and the sixth core session that occurs in the third trimester. Apart from baseline data, data are collected in the third trimester, at birth and at 6-weeks postpartum. Primary outcomes include diagnoses of postpartum common mental disorders. Secondary outcomes include symptoms of anxiety and of depression, and birth outcomes including small-for-gestational age, low birth weight and preterm birth. An economic analysis will determine the cost effectiveness of the intervention. ETHICS Ethics approval was obtained from the Johns Hopkins Bloomberg School of Health Institutional Review Board (Baltimore, USA), the Human Development Research Foundation Ethics Committee (Islamabad, Pakistan), the RMU Institutional Research Forum (Rawalpindi, Pakistan) and the National Institute of Mental Health-appointed Global Mental Health Data Safety and Monitoring Board. DISSEMINATION Results from this trial will build evidence for the efficacy of a CBT-based intervention for pregnant women delivered by non-specialised providers. Identification of an evidence-based intervention for anxiety starting in early pregnancy to mid pregnancy may be transferable for use and scale-up in other low-income and middle-income countries. TRIAL REGISTRATION NUMBER NCT03880032.",2020,Pregnant women (enrolled at ≤22 weeks of gestation) receive six individual HMHB sessions based on cognitive-behavioral therapy (CBT) and relaxation techniques that are administered by non-specialist providers and tailored to address anxiety symptoms.,"['anxiety in pregnancy in a prenatal clinic using non-specialist providers in Pakistan', 'women with clinical or subclinical symptoms of anxiety in Pakistan', 'outpatient department of Holy Family Hospital, a large public tertiary care facility affiliated with Rawalpindi Medical University (RMU', 'pregnant women delivered by non-specialised providers', 'Pregnant women (enrolled at ≤22 weeks of gestation) receive']","['Happy Mother, Healthy Baby (HMHB', 'six individual HMHB sessions based on cognitive-behavioral therapy (CBT) and relaxation techniques that are administered by non-specialist providers and tailored to address anxiety symptoms', 'Cognitive-behavioral therapy-based intervention', 'CBT-based intervention']","['diagnoses of postpartum common mental disorders', 'symptoms of anxiety and of depression, and birth outcomes including small-for-gestational age, low birth weight and preterm birth']","[{'cui': 'C4543692', 'cui_str': 'Anxiety in pregnancy'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0030211', 'cui_str': 'Pakistan'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205211', 'cui_str': 'Subclinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0035029', 'cui_str': 'Relaxation technique'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C1286282', 'cui_str': 'Birth outcome'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0235991', 'cui_str': 'Small for gestational age'}, {'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}]",,0.279811,Pregnant women (enrolled at ≤22 weeks of gestation) receive six individual HMHB sessions based on cognitive-behavioral therapy (CBT) and relaxation techniques that are administered by non-specialist providers and tailored to address anxiety symptoms.,"[{'ForeName': 'Pamela J', 'Initials': 'PJ', 'LastName': 'Surkan', 'Affiliation': 'Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA psurkan@jhu.edu.'}, {'ForeName': 'Syed Usman', 'Initials': 'SU', 'LastName': 'Hamdani', 'Affiliation': 'Human Development Research Foundation, Rawalpindi, Pakistan.'}, {'ForeName': 'Zill-E', 'Initials': 'ZE', 'LastName': 'Huma', 'Affiliation': 'Human Development Research Foundation, Rawalpindi, Pakistan.'}, {'ForeName': 'Huma', 'Initials': 'H', 'LastName': 'Nazir', 'Affiliation': 'Human Development Research Foundation, Rawalpindi, Pakistan.'}, {'ForeName': 'Najia', 'Initials': 'N', 'LastName': 'Atif', 'Affiliation': 'Human Development Research Foundation, Rawalpindi, Pakistan.'}, {'ForeName': 'Armaan A', 'Initials': 'AA', 'LastName': 'Rowther', 'Affiliation': 'Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Rizwana', 'Initials': 'R', 'LastName': 'Chaudhri', 'Affiliation': 'Department of Gynaecology and Obstetrics, Holy Family Hospital, Rawalpindi Medical University, Rawalpindi, Pakistan.'}, {'ForeName': 'Shamsa', 'Initials': 'S', 'LastName': 'Zafar', 'Affiliation': 'Human Development Research Foundation, Rawalpindi, Pakistan.'}, {'ForeName': 'Luke C', 'Initials': 'LC', 'LastName': 'Mullany', 'Affiliation': 'Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Abid', 'Initials': 'A', 'LastName': 'Malik', 'Affiliation': 'Human Development Research Foundation, Rawalpindi, Pakistan.'}, {'ForeName': 'Atif', 'Initials': 'A', 'LastName': 'Rahman', 'Affiliation': 'Department of Psychological Sciences, University of Liverpool, Liverpool, UK.'}]",BMJ open,['10.1136/bmjopen-2020-037590'] 183,32300013,"Asking young children to ""do science"" instead of ""be scientists"" increases science engagement in a randomized field experiment.","Subtle features of common language can imply to young children that scientists are a special and distinct kind of person-a way of thinking that can interfere with the development of children's own engagement with science. We conducted a large field experiment (involving 45 prekindergarten schools, 130 teachers, and over 1,100 children) to test if targeting subtle properties of language can increase science engagement in children's daily lives. Despite strong tendencies to describe scientists as a special kind of person (in a baseline control condition), brief video-based training changed the language that teachers used to introduce science to their students. These changes in language were powerful enough to predict children's science interest and behavior days later. Thus, subtle features of language shape children's beliefs and behaviors as they unfold in real world environments. Harnessing these mechanisms could promote science engagement in early childhood.",2020,"Despite strong tendencies to describe scientists as a special kind of person (in a baseline control condition), brief video-based training changed the language that teachers used to introduce science to their students.","[""children's daily lives"", '45 prekindergarten schools, 130 teachers, and over 1,100 children']",[],[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}]",[],[],1100.0,0.0458692,"Despite strong tendencies to describe scientists as a special kind of person (in a baseline control condition), brief video-based training changed the language that teachers used to introduce science to their students.","[{'ForeName': 'Marjorie', 'Initials': 'M', 'LastName': 'Rhodes', 'Affiliation': 'Department of Psychology, New York University, New York, NY 10003; marjorie.rhodes@nyu.edu.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Cardarelli', 'Affiliation': 'Department of Psychology, New York University, New York, NY 10003.'}, {'ForeName': 'Sarah-Jane', 'Initials': 'SJ', 'LastName': 'Leslie', 'Affiliation': 'Department of Philosophy, Princeton University, Princeton, NJ 08544.'}]",Proceedings of the National Academy of Sciences of the United States of America,['10.1073/pnas.1919646117'] 184,31314569,Minimizing the Relationship Between Early Formula Use and Breastfeeding Cessation by Limiting Formula Volume.,"Objective: Early exposure to formula can interfere with successful long-term breastfeeding. The objective of this study was to determine whether limiting the volume of formula used in the first month attenuates formula's detrimental impact on long-term breastfeeding success. Materials and Methods: Using detailed data on dietary intake from a randomized clinical trial, we conducted a secondary analysis of the association between volume of formula received in the first month and breastfeeding cessation before 6 and 12 months of age. We used descriptive statistics and multivariable logistic regression, respectively, to explore this association without and with adjustment for demographic and clinical predictors of infant feeding. Results: Among 199 breastfeeding infants, 80 (40%) received formula daily at 1 month of age, and breastfeeding cessation before 6 and 12 months of age was higher for these infants (46% and 67%) than for those breastfed exclusively (6% and 27%) ( p  < 0.0005 for each). The risk of cessation did not differ between those who received ≤4 fl oz daily in the first month (11%) and those who did not receive formula in the first month (6%) ( p  = 0.42). Adjusting for gestational age, race/ethnicity, income, and intention to breastfeed exclusively, the odds ratio for the outcome of cessation before 6 months was 1.15 (95% confidence interval = 0.20-6.67) for infants who received ≤4 fl oz daily compared with those who breastfed exclusively. Conclusion: Limiting formula volumes to ≤4 fl oz daily may attenuate the deleterious association between early formula use and subsequent successful breastfeeding.",2019,The risk of cessation did not differ between those who received ≤4 fl oz daily in the first month (11%) and those who did not receive formula in the first month (6%) ( p  = 0.42).,[],[],['risk of cessation'],[],[],"[{'cui': 'C0035647', 'cui_str': 'Risk'}]",199.0,0.0383321,The risk of cessation did not differ between those who received ≤4 fl oz daily in the first month (11%) and those who did not receive formula in the first month (6%) ( p  = 0.42).,"[{'ForeName': 'Valerie J', 'Initials': 'VJ', 'LastName': 'Flaherman', 'Affiliation': 'Department of Pediatrics, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'McKean', 'Affiliation': 'Department of Pediatrics, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Braunreuther', 'Affiliation': 'School of Medicine, New York Medical College, Valhalla, New York.'}, {'ForeName': 'Laura R', 'Initials': 'LR', 'LastName': 'Kair', 'Affiliation': 'Department of Pediatrics, University of California Davis, Davis, California.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Cabana', 'Affiliation': 'Department of Pediatrics, University of California San Francisco, San Francisco, California.'}]",Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine,['10.1089/bfm.2019.0055'] 185,31320735,Intravitreal dexamethasone implant as an alternative to systemic steroids as prophylaxis for uveitic cataract surgery: a randomized trial.,"PURPOSE To determine the utility of the dexamethasone implant (IVD) as an alternative to systemic steroids as prophylaxis against cystoid macular edema (CMO) in patients with chronic, recurrent CMO associated intermediate or posterior uveitis (IU/PU), and cataract undergoing cataract surgery. METHODS This was a randomized, parallel design, and clinical trial. Patients with IU/PU and cataract scheduled for cataract surgery were randomly assigned to receive the IVD concurrently with cataract surgery (Group 1: 20 patients) or systemic steroids (Group 2: 23 patients) tapered over 4-6 weeks along with uneventful cataract surgery and routine postoperative care. Patients with glaucoma/contraindications to steroids were excluded. All patients were followed up for 6 months. OUTCOME MEASURE Primary-incidence of postoperative CMO. Secondary-the change in BCVA (corrected distance visual acuity) and Central Subfield thickness (CST) and complications. Appropriate statistical analysis was done. RESULTS The median age was 47.3 ± 4.23 years (group 1) and 49.12 ± 5.32 years (Group 2). One patient (Group 1) and two (Group 2) developed CMO. The BCVA improved significantly in both groups (p = 0.013). The CST change was insignificant. Four patients (Group 1) required intraocular pressure (IOP) lowering medications. Three patients (Group 2) required early steroid taper. CONCLUSIONS IVD is a good alternative as prophylaxis in IU/PU and cataract in preventing postoperative CMO.",2020,The BCVA improved significantly in both groups (p = 0.013).,"['uveitic cataract surgery', 'Patients with IU/PU and cataract scheduled for cataract surgery', 'The median age was 47.3\u2009±\u20094.23 years (group 1) and 49.12\u2009±\u20095.32 years (Group 2', 'Patients with glaucoma/contraindications to steroids were excluded', 'patients with chronic, recurrent CMO associated intermediate or posterior uveitis (IU/PU), and cataract undergoing cataract surgery']","['dexamethasone implant (IVD', 'IVD concurrently with cataract surgery', 'systemic steroids (Group 2: 23 patients) tapered over 4-6 weeks along with uneventful cataract surgery and routine postoperative care', 'Intravitreal dexamethasone implant']","['CMO', 'BCVA', 'postoperative CMO', 'BCVA (corrected distance visual acuity) and Central Subfield thickness (CST) and complications', 'intraocular pressure (IOP) lowering medications']","[{'cui': 'C2004600', 'cui_str': 'Cataract surgery specialty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0856347', 'cui_str': 'Right cataract'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C2242746', 'cui_str': 'Glaucoma (SMQ)'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to (contextual qualifier) (qualifier value)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0042167', 'cui_str': 'Uveitis, Posterior'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C2004600', 'cui_str': 'Cataract surgery specialty'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0032786', 'cui_str': 'Postoperative Care'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0429537', 'cui_str': 'Distance visual acuity (observable entity)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0021888', 'cui_str': 'Ocular Tension'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}]",,0.0567074,The BCVA improved significantly in both groups (p = 0.013).,"[{'ForeName': 'Aditya', 'Initials': 'A', 'LastName': 'Sudhalkar', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India. adityasudhalkar@yahoo.com.'}, {'ForeName': 'Abhay', 'Initials': 'A', 'LastName': 'Vasavada', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}, {'ForeName': 'Deepak', 'Initials': 'D', 'LastName': 'Bhojwani', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}, {'ForeName': 'Viraj', 'Initials': 'V', 'LastName': 'Vasavada', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}, {'ForeName': 'Shail', 'Initials': 'S', 'LastName': 'Vasavada', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}, {'ForeName': 'Vaishali', 'Initials': 'V', 'LastName': 'Vasavada', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}, {'ForeName': 'Samaresh', 'Initials': 'S', 'LastName': 'Srivastava', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}]","Eye (London, England)",['10.1038/s41433-019-0534-8'] 186,31320738,Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data.,"BACKGROUND/OBJECTIVES This post hoc analysis explores the relationship between residual oedema exposure after ranibizumab treatment initiation and long-term visual acuity outcome in eyes with centre-involved diabetic macular oedema (DMO). SUBJECTS/METHODS Eyes randomised to the ranibizumab + prompt or deferred laser treatment arms in the Protocol I trial and with observed central retinal thickness (CRT) readings at baseline and ≥1 follow-up visits (n = 367) were stratified by 1) oedema duration (number of study visits with CRT ≥ 250 µm during the first 52 weeks of ranibizumab treatment); and 2) oedema extent (amount of excess CRT [≥ 250 µm] at each study visit, averaged over the first 52 weeks). Associations between measures of residual oedema and best-corrected visual acuity (BCVA) were assessed in multiple regression analyses. RESULTS Oedema duration and oedema extent during the first 52 weeks of ranibizumab treatment showed significant negative associations with BCVA improvement at weeks 52, 104 and 156. Eyes with the most persistent oedema gained (mean) 4.4 (95% CI 0.1─8.7) fewer Early Treatment Diabetic Retinopathy Study (ETDRS) letters at week 156 than eyes with the least persistent oedema (P = 0.044). Eyes with the greatest amount of oedema gained (mean) 9.3 (95% CI 4.0─14.5) fewer ETDRS letters at week 156 than eyes with the least amount of oedema (P < 0.001). CONCLUSIONS Macular oedema exposure over the first 52 weeks of ranibizumab treatment is a negative prognostic factor for long-term visual acuity improvement in centre-involved DMO.",2020,"Oedema duration and oedema extent during the first 52 weeks of ranibizumab treatment showed significant negative associations with BCVA improvement at weeks 52, 104 and 156.","['diabetic macular oedema', 'eyes with centre-involved diabetic macular oedema (DMO']","['ranibizumab + prompt or deferred laser treatment', 'ranibizumab']","['oedema and visual acuity outcome', 'residual oedema and best-corrected visual acuity (BCVA', 'Oedema duration and oedema extent', 'ETDRS letters']","[{'cui': 'C0730285', 'cui_str': 'Diabetic macular edema'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0013604', 'cui_str': 'Hydrops'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C1690532', 'cui_str': 'Best corrected visual acuity'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0439792', 'cui_str': 'Extents (qualifier value)'}, {'cui': 'C1096774', 'cui_str': 'Letter'}]",367.0,0.11728,"Oedema duration and oedema extent during the first 52 weeks of ranibizumab treatment showed significant negative associations with BCVA improvement at weeks 52, 104 and 156.","[{'ForeName': 'Srinivas R', 'Initials': 'SR', 'LastName': 'Sadda', 'Affiliation': 'Doheny Eye Institute, Los Angeles, CA, USA. SSadda@doheny.org.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Campbell', 'Affiliation': 'Allergan plc, Irvine, CA, USA.'}, {'ForeName': 'Pravin U', 'Initials': 'PU', 'LastName': 'Dugel', 'Affiliation': 'Retinal Consultants of Arizona, Phoenix, AZ, USA.'}, {'ForeName': 'Nancy M', 'Initials': 'NM', 'LastName': 'Holekamp', 'Affiliation': 'Pepose Vision Institute and Washington University School of Medicine, St. Louis, MO, USA.'}, {'ForeName': 'Szilárd', 'Initials': 'S', 'LastName': 'Kiss', 'Affiliation': 'Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Anat', 'Initials': 'A', 'LastName': 'Loewenstein', 'Affiliation': 'Department of Ophthalmology, Tel Aviv Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Albert J', 'Initials': 'AJ', 'LastName': 'Augustin', 'Affiliation': 'Department of Ophthalmology, Staedtisches Klinikum Karlsruhe, Karlsruhe, Germany.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Shih', 'Affiliation': 'Allergan plc, Irvine, CA, USA.'}, {'ForeName': 'Xiaoshu', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': 'Allergan plc, Irvine, CA, USA.'}, {'ForeName': 'Charles C', 'Initials': 'CC', 'LastName': 'Wykoff', 'Affiliation': 'Retina Consultants of Houston, Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USA.'}, {'ForeName': 'Scott M', 'Initials': 'SM', 'LastName': 'Whitcup', 'Affiliation': 'Jules Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}]","Eye (London, England)",['10.1038/s41433-019-0522-z'] 187,31358922,Progression and new onset of macular retinoschisis in myopic choroidal neovascularization eyes after Conbercept therapy: a post-hoc analysis.,"OBJECTIVES The objective of this study is to evaluate the progression and new onset of macular retinoschisis (MRS) in the patients treated with intravitreal Conbercept injections for myopic choroidal neovascularization (mCNV). METHODS Post-hoc analysis of 160 mCNV patients included in SHINY study was performed to evaluate the impact of Conbercept injection on MRS in patients with mCNV undergoing intravitreal Conbercept injections. The patients were 3:1 randomized to the study group (three loading dose and thereafter pro re nata [PRN]) and the control group (3 months' sham injection, then one Conbercept injection at month 4 and thereafter PRN). MRS was assessed with optical coherence tomography by masked graders. RESULTS At baseline, 28 of 122 eyes in study group and 10 of 38 eyes in control group had MRS. At month 3, two patients showed MRS progression and one patient had new onset MRS in study group. No MRS progression nor new onset MRS was found in the control group. At final visit, the cumulative incidence of MRS was 1.3% (2/160). Both Spearman's correlation and multiple logistic regression demonstrated no association between the progression and new onset of MRS and intravitreal injection frequency (correlation coefficient = 0.017, P = 0.851 and odds ratio = 0.996, P = 0.982). In addition, baseline vitreoretinal adhesion was the most likely potential risk factor resulting in MRS progression (odds ratio = 4.566, P = 0.027). Furthermore, MRS progression was more likely to take place in outer retinal layers. CONCLUSIONS The progression and new onset of MRS was not associated with the frequency of intravitreal Conbercept injections.",2020,No MRS progression nor new onset MRS was found in the control group.,"['myopic choroidal neovascularization eyes after Conbercept therapy', '160 mCNV patients included in SHINY study', 'for myopic choroidal neovascularization (mCNV', 'patients with mCNV undergoing intravitreal Conbercept injections']","['Conbercept injection on MRS', 'intravitreal Conbercept injections']","['MRS', 'cumulative incidence of MRS', 'progression and new onset of MRS and intravitreal injection frequency', 'MRS progression nor new\xa0onset MRS', 'MRS progression', 'new onset MRS']","[{'cui': 'C3665926', 'cui_str': 'Myopic choroidal neovascularization'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C2352201', 'cui_str': 'KH902 fusion protein'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]","[{'cui': 'C2352201', 'cui_str': 'KH902 fusion protein'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0332162', 'cui_str': 'Onset of (contextual qualifier) (qualifier value)'}, {'cui': 'C1554888', 'cui_str': 'Intravitreal Injections'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}]",,0.0474506,No MRS progression nor new onset MRS was found in the control group.,"[{'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Shiqi', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Yuanzhi', 'Initials': 'Y', 'LastName': 'Yuan', 'Affiliation': 'Department of Ophthalmology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Minlu', 'Initials': 'M', 'LastName': 'Song', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Fenglei', 'Initials': 'F', 'LastName': 'Kuang', 'Affiliation': 'R&D Center, Chengdu Kanghong Biotech Ltd., Sichuan, China.'}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Liu', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Zhang', 'Affiliation': 'Department of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Peking, China.'}, {'ForeName': 'Fenghua', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China. shretina@sjtu.edu.cn.""}, {'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Sun', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China. xdsun@sjtu.edu.cn.""}]","Eye (London, England)",['10.1038/s41433-019-0516-x'] 188,30922146,Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.,"Background Inability to tolerate statins because of muscle symptoms contributes to uncontrolled cholesterol levels and insufficient cardiovascular risk reduction. Bempedoic acid, a prodrug that is activated by a hepatic enzyme not present in skeletal muscle, inhibits ATP -citrate lyase, an enzyme upstream of β-hydroxy β-methylglutaryl-coenzyme A reductase in the cholesterol biosynthesis pathway. Methods and Results The phase 3, double-blind, placebo-controlled CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen) Serenity study randomized 345 patients with hypercholesterolemia and a history of intolerance to at least 2 statins (1 at the lowest available dose) 2:1 to bempedoic acid 180 mg or placebo once daily for 24 weeks. The primary end point was mean percent change from baseline to week 12 in low-density lipoprotein cholesterol. The mean age was 65.2 years, mean baseline low-density lipoprotein cholesterol was 157.6 mg/dL, and 93% of patients reported a history of statin-associated muscle symptoms. Bempedoic acid treatment significantly reduced low-density lipoprotein cholesterol from baseline to week 12 (placebo-corrected difference, -21.4% [95% CI, -25.1% to -17.7%]; P<0.001). Significant reductions with bempedoic acid versus placebo were also observed in non-high-density lipoprotein cholesterol (-17.9%), total cholesterol (-14.8%), apolipoprotein B (-15.0%), and high-sensitivity C-reactive protein (-24.3%; P<0.001 for all comparisons). Bempedoic acid was safe and well tolerated. The most common muscle-related adverse event, myalgia, occurred in 4.7% and 7.2% of patients who received bempedoic acid or placebo, respectively. Conclusions Bempedoic acid offers a safe and effective oral therapeutic option for lipid lowering in patients who cannot tolerate statins. Clinical Trial Registration URL : https://www.clinicaltrials.gov . Unique identifier: NCT 02988115.",2019,"Bempedoic acid treatment significantly reduced low-density lipoprotein cholesterol from baseline to week 12 (placebo-corrected difference, -21.4% [95% CI, -25.1% to -17.7%]; P<0.001).","['Patients With Hypercholesterolemia and Statin Intolerance', '345 patients with hypercholesterolemia and a history of intolerance to at least 2 statins (1 at the lowest available dose) 2:1 to', 'patients who cannot tolerate statins']","['placebo', 'bempedoic acid 180\xa0mg or placebo', 'bempedoic acid or placebo', 'Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen', 'Bempedoic acid', 'Bempedoic Acid', 'placebo-controlled CLEAR ']","['safe and well tolerated', 'mean baseline low-density lipoprotein cholesterol', 'total cholesterol', 'non-high-density lipoprotein cholesterol', 'low-density lipoprotein cholesterol', 'apolipoprotein B', 'high-sensitivity C-reactive protein']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0020443', 'cui_str': 'High Cholesterol Levels'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0231199', 'cui_str': 'Intolerance, function (observable entity)'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3659310', 'cui_str': '8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C2963144', 'cui_str': 'Clear (qualifier value)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0729627', 'cui_str': 'Non-HDL cholesterol'}, {'cui': 'C0003593', 'cui_str': 'ApoB'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}]",345.0,0.387448,"Bempedoic acid treatment significantly reduced low-density lipoprotein cholesterol from baseline to week 12 (placebo-corrected difference, -21.4% [95% CI, -25.1% to -17.7%]; P<0.001).","[{'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Laufs', 'Affiliation': '1 Klinik und Poliklinik für Kardiologie Universitätsklinikum Leipzig Leipzig Germany.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Banach', 'Affiliation': '2 Department of Hypertension Medical University of Lodz Poland.'}, {'ForeName': 'G B John', 'Initials': 'GBJ', 'LastName': 'Mancini', 'Affiliation': '3 Division of Cardiology University of British Columbia Vancouver British Columbia Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Gaudet', 'Affiliation': '4 Lipidology Unit, Community Genomic Medicine Centre and ECOGENE-21 Department of Medicine Université de Montréal Saguenay Quebec Canada.'}, {'ForeName': 'LeAnne T', 'Initials': 'LT', 'LastName': 'Bloedon', 'Affiliation': '5 Esperion Therapeutics, Inc. Ann Arbor MI.'}, {'ForeName': 'Lulu Ren', 'Initials': 'LR', 'LastName': 'Sterling', 'Affiliation': '5 Esperion Therapeutics, Inc. Ann Arbor MI.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Kelly', 'Affiliation': '5 Esperion Therapeutics, Inc. Ann Arbor MI.'}, {'ForeName': 'Erik S G', 'Initials': 'ESG', 'LastName': 'Stroes', 'Affiliation': '6 Department of Vascular Medicine Academic Medical Center of Amsterdam Netherlands.'}]",Journal of the American Heart Association,['10.1161/JAHA.118.011662'] 189,32314466,Use of an emollient-containing diaper and pH-buffered wipe regimen restores skin pH and reduces residual enzymatic activity.,"BACKGROUND/OBJECTIVES Diaper dermatitis is one of the most frequent skin conditions affecting infants and is associated with elevated skin pH, exposure to urine and feces, and increased fecal protease and lipase activity, resulting in stratum corneum barrier damage and increased risk of infection. The study aim was to determine the impact of two diaper and wipe regimens on newborn infant skin pH and residual enzyme activity after stool cleaning. METHODS Two diaper and wipe regimens were compared in a randomized, single-blinded crossover study. Regimen A paired an emollient-containing diaper with an acidic, pH-buffered wipe. Regimen B was a non-emollient diaper and wipe with limited buffering capacity. A 3-day washout period preceded each 3-day regimen use period. Skin pH at the perianal/buttocks interface (PBI), genital region, and undiapered chest control were measured at baseline and day 3. Skin swabs were collected for residual enzyme activity after a stool cleaning event. RESULTS Diapered skin pH at the PBI was similar to undiapered skin after 3 days of use for Regimen A, while PBI pH for Regimen B was elevated versus control. PBI pH was lower for Regimen A versus Regimen B. After a stool cleaning, PBI skin pH for Regimen A was lower immediately and had lower residual enzyme activity versus Regimen B (P < .05), and the pH-lowering effect was sustained up to 60 minutes. CONCLUSIONS These results suggest that the use of an emollient-containing diaper with a pH-buffered wipe creates conditions favorable to optimum diapered skin health.",2020,"After a stool cleaning, PBI skin pH for Regimen A was lower immediately and had lower residual enzyme activity versus Regimen B (P < .05), and the pH-lowering effect was sustained up to 60 minutes. ",['Two diaper and wipe regimens'],"['emollient-containing diaper with an acidic, pH-buffered wipe']","['Diapered skin pH', 'PBI pH', 'Skin pH at the perianal/buttocks interface (PBI), genital region, and undiapered chest control', 'residual enzyme activity', 'newborn infant skin pH and residual enzyme activity', 'residual enzymatic activity']","[{'cui': 'C0180416', 'cui_str': 'Diaper'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]","[{'cui': 'C0013983', 'cui_str': 'Emollient'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0180416', 'cui_str': 'Diaper'}, {'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0006353', 'cui_str': 'Buffers'}]","[{'cui': 'C0232445', 'cui_str': 'Acid mantle'}, {'cui': 'C0442158', 'cui_str': 'Perianal'}, {'cui': 'C0006497', 'cui_str': 'Buttock structure'}, {'cui': 'C0446509', 'cui_str': 'Genital region'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0243102', 'cui_str': 'enzyme activity'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",,0.033102,"After a stool cleaning, PBI skin pH for Regimen A was lower immediately and had lower residual enzyme activity versus Regimen B (P < .05), and the pH-lowering effect was sustained up to 60 minutes. ","[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Gustin', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Bohman', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Ogle', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}, {'ForeName': 'Tanuja', 'Initials': 'T', 'LastName': 'Chaudhary', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}, {'ForeName': 'Lijuan', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}, {'ForeName': 'Gina', 'Initials': 'G', 'LastName': 'Fadayel', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'Mitchell', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}, {'ForeName': 'Vivek', 'Initials': 'V', 'LastName': 'Narendran', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Marty O', 'Initials': 'MO', 'LastName': 'Visscher', 'Affiliation': 'James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA.'}, {'ForeName': 'Andrew N', 'Initials': 'AN', 'LastName': 'Carr', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}]",Pediatric dermatology,['10.1111/pde.14169'] 190,30202873,Influenza Hemagglutination-inhibition Antibody Titer as a Mediator of Vaccine-induced Protection for Influenza B.,"BACKGROUND The hemagglutination inhibition (HAI) assay is an established correlate of protection for the inactivated influenza vaccine. However, the proportion of vaccine-induced protection that is mediated by the post-vaccination HAI titer has not been assessed. METHODS We used data from a randomized, placebo-controlled trial of a split-virion inactivated influenza vaccine in children aged 6-17 years. Sera were collected before and 30 days after receipt of vaccination or placebo and tested by the HAI assay against B/Brisbane/60/2008-like (B/Victoria lineage). We fitted Cox proportional hazards models to the time to laboratory-confirmed influenza B. We used causal mediation analysis to estimate the proportion of the total effect of vaccination that was mediated by higher HAI titers. RESULTS We estimated that vaccine efficacy against confirmed B/Victoria infection was 68% (95% confidence interval, 33%, 88%), and post-vaccination HAI titers explained 57% of the effect of vaccination on protection. CONCLUSIONS The majority of the effect of inactivated influenza vaccination in children is mediated by the increased HAI titer after vaccination; however, other components of the immune response to vaccination may also play a role in protection and should be further explored. Causal mediation analysis provides a framework to quantify the role of various mediators of protection.",2019,"The hemagglutination inhibition (HAI) assay is an established correlate of protection for the inactivated influenza vaccine, but the proportion of vaccine-induced protection that is mediated by the post-vaccination HAI titer has not been assessed. ",['children 6-17 years of age'],"['split-virion inactivated influenza vaccine', 'placebo, and tested by the HAI assay against B', 'placebo']","['HAI titer', 'vaccine efficacy against confirmed B/Victoria infection']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0042760', 'cui_str': 'Viral Particles'}, {'cui': 'C0021403', 'cui_str': 'Influenza Vaccines'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C1510438', 'cui_str': 'Assay technique (qualifier value)'}]","[{'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0042645', 'cui_str': 'Victoria'}, {'cui': 'C3714514', 'cui_str': 'Infection'}]",,0.206448,"The hemagglutination inhibition (HAI) assay is an established correlate of protection for the inactivated influenza vaccine, but the proportion of vaccine-induced protection that is mediated by the post-vaccination HAI titer has not been assessed. ","[{'ForeName': 'Benjamin J', 'Initials': 'BJ', 'LastName': 'Cowling', 'Affiliation': 'World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'Wey Wen', 'Initials': 'WW', 'LastName': 'Lim', 'Affiliation': 'World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'Ranawaka A P M', 'Initials': 'RAPM', 'LastName': 'Perera', 'Affiliation': 'World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'Vicky J', 'Initials': 'VJ', 'LastName': 'Fang', 'Affiliation': 'World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'Gabriel M', 'Initials': 'GM', 'LastName': 'Leung', 'Affiliation': 'World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'J S Malik', 'Initials': 'JSM', 'LastName': 'Peiris', 'Affiliation': 'World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'Eric J', 'Initials': 'EJ', 'LastName': 'Tchetgen Tchetgen', 'Affiliation': 'Statistics Department, Wharton School, University of Pennsylvania, Philadelphia.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciy759'] 191,31236796,Effects of whole-body vibration under hypoxic exposure on muscle mass and functional mobility in older adults.,"BACKGROUND Ageing is accompanied by a loss of muscle mass and function, which are associated with decrease of functional capacity. Combination of WBV training with normobaric hypoxic exposure could augment the beneficial effects due to synergic effects of both treatments. AIMS The purpose of this study was to examine the effects of 36 sessions of the combined WBV training and normobaric hypoxic exposure on muscle mass and functional mobility in older adults. METHODS Nineteen elderly people were randomly assigned to a: vibration normoxic exposure group (NWBV; n = 10; 20.9% FiO 2 ) and vibration hypoxic exposure group (HWBV; n = 9). Participants developed 36 sessions of WBV training along 18 weeks, which included 4 bouts of 30 s (12.6 Hz in frequency and 4 mm in amplitude) with 60 s of rest between bouts, inside a hypoxic chamber for the HWBV. The ""Timed Up and Go Test"" evaluated functional mobility. Percentages of lean mass were obtained with dual-energy X-ray absorptiometry. RESULTS Neither statistically significant within group variations nor statistically significant differences between both groups were detected to any parameter. DISCUSSION Baseline characteristics of population, training protocol and the level of hypoxia employed could cause different adaptations on muscle mass and function. CONCLUSIONS The combination of WBV training and hypoxic exposure did not cause any effect on either legs lean mass or functional mobility of older adults.",2020,The combination of WBV training and hypoxic exposure did not cause any effect on either legs lean mass or functional mobility of older adults.,"['Nineteen elderly people', 'older adults']","['vibration normoxic exposure group (NWBV; n\u2009=\u200910; 20.9% FiO 2 ) and vibration hypoxic exposure', 'WBV training', 'whole-body vibration under hypoxic exposure', 'combined WBV training and normobaric hypoxic exposure']",['muscle mass and functional mobility'],"[{'cui': 'C0450337', 'cui_str': '19 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0459800', 'cui_str': 'Vibration'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0240417', 'cui_str': 'Form of muscle (finding)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}]",19.0,0.0245262,The combination of WBV training and hypoxic exposure did not cause any effect on either legs lean mass or functional mobility of older adults.,"[{'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Camacho-Cardenosa', 'Affiliation': 'Facultad Ciencias del Deporte, Universidad de Extremadura, Av. Universidad, s/n (Faculty of Sport Science), Cáceres, Spain. mcamachocardenosa@unex.es.'}, {'ForeName': 'Alba', 'Initials': 'A', 'LastName': 'Camacho-Cardenosa', 'Affiliation': 'Facultad Ciencias del Deporte, Universidad de Extremadura, Av. Universidad, s/n (Faculty of Sport Science), Cáceres, Spain.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Tomas-Carus', 'Affiliation': 'Departamento de Desporto e Saúde, Escola de Ciências e Tecnologia, Universidade de Évora, Évora, Portugal.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Olcina', 'Affiliation': 'Facultad Ciencias del Deporte, Universidad de Extremadura, Av. Universidad, s/n (Faculty of Sport Science), Cáceres, Spain.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Timón', 'Affiliation': 'Facultad Ciencias del Deporte, Universidad de Extremadura, Av. Universidad, s/n (Faculty of Sport Science), Cáceres, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Brazo-Sayavera', 'Affiliation': 'Instituto Superior de Educación Física, Rivera, Uruguay.'}]",Aging clinical and experimental research,['10.1007/s40520-019-01246-y'] 192,31469677,The Use of Tai-Chi to Reduce Anxiety Among Nursing Students Undergoing Simulation.,"This study sought to examine tai-chi as an anxiety-reducing method to increase self-efficacy and improve performance among baccalaureate nursing students experiencing a patient care simulation. The sample included 63 nursing students enrolled in a traditional or second-degree nursing program. The study used a randomized control group pretest-posttest design. Students in the experimental group experienced significant reductions in cognitive and somatic anxiety, along with an increase in self-efficacy and improved performance. Tai-chi can be an effective technique to reduce anxiety and improve self-efficacy and performance among nursing students in simulations.",2020,"Students in the experimental group experienced significant reductions in cognitive and somatic anxiety, along with an increase in self-efficacy and improved performance.","['Nursing Students Undergoing Simulation', 'nursing students in simulations', '63 nursing students enrolled in a traditional or second-degree nursing program', 'baccalaureate nursing students experiencing a patient care simulation']",['Tai-Chi'],"['self-efficacy and improved performance', 'Anxiety', 'cognitive and somatic anxiety', 'anxiety and improve self-efficacy and performance']","[{'cui': 'C0038496', 'cui_str': 'Pupil Nurses'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0443298', 'cui_str': 'Second degree (qualifier value)'}, {'cui': 'C0028678', 'cui_str': 'nursing care'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0017313'}]","[{'cui': 'C0376403', 'cui_str': 'Taiji'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",,0.0181443,"Students in the experimental group experienced significant reductions in cognitive and somatic anxiety, along with an increase in self-efficacy and improved performance.","[{'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Mulcahy', 'Affiliation': 'About the Authors Angela Mulcahy, PhD, RN, CMSRN, CHSE, is a clinical assistant professor at Texas A&M University College of Nursing, Bryan, Texas. Brian Holland, PhD, RN, is associate dean for academic affairs at the University of Florida College of Nursing. Kevin Gosselin, PhD, is director, Academics and Biostatistics, HonorHealth Research Institute, Scottsdale, Arizona. Alison Pittman, PhD, RN, CPN, CNE, is a clinical assistant professor, Texas A&M University College of Nursing. For more information, contact Dr. Mulcahy at mulcahy@tamhsc.edu.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Holland', 'Affiliation': ''}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Gosselin', 'Affiliation': ''}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Pittman', 'Affiliation': ''}]",Nursing education perspectives,['10.1097/01.NEP.0000000000000495'] 193,32308200,Effectiveness of an exercise training programme COPD in primary care: A randomized controlled trial.,"BACKGROUND Pulmonary rehabilitation is very effective in improving exercise capacity, dyspnea and quality of life in the small group of patients with moderate to severe COPD. Given that little is known about exercise training in the large group of patients with mild to moderate COPD, we assessed the effectiveness of an exercise training programme in primary care. METHODS In this RCT, 90 patients with mild to moderate COPD (FEV 1 74.2 ± 13.5%pred) participated in a 4-month exercise training programme or control treatment. Primary outcome was improvement in functional exercise capacity, assessed by the 6-min walking distance (6MWD). Secondary outcomes were breathlessness (MRC dyspnoea score), disease-specific quality of life (CCQ, CRQ), muscle strength and objective daily physical activity. There was a follow-up measurement at 6 months. RESULTS At 4 months, we found a statistically and clinically relevant between-group difference in 6MWD of +26.6 m (95% CI: 4,3-49.0, p = 0.020). Shoulder strength significantly improved with a between-group difference of 23.9 Nm (p = 0.0350). At 6 months, there was a significant improvement in handgrip force and CRQ sub score mastery of respectively 1.9 KgF (p = 0.028) and 0.5 (p = 0.035). There were no significant between-group differences in breathlessness, quality of life, knee strength and daily physical activity. CONCLUSION The results indicate that exercise training in primary care is particularly effective in improving physical fitness (exercise capacity and strength), but not in breathlessness, health-related quality of life and daily physical activity. A broader assessment for COPD patients in primary care might be a necessary condition to offer the most effective intervention.",2020,Shoulder strength significantly improved with a between-group difference of 23.9 Nm (p = 0.0350).,"['COPD patients in primary care', 'primary care', '90 patients with mild to moderate COPD (FEV 1 74.2\xa0±\xa013.5%pred) participated in a 4-month', 'patients with mild to moderate COPD', 'patients with moderate to severe COPD']","['exercise training programme or control treatment', 'exercise training', 'exercise training programme COPD', 'exercise training programme']","['6MWD', 'functional exercise capacity, assessed by the 6-min walking distance (6MWD', 'Shoulder strength', 'physical fitness (exercise capacity and strength', 'handgrip force and CRQ sub score mastery', 'exercise capacity, dyspnea and quality of life', 'breathlessness (MRC dyspnoea score), disease-specific quality of life (CCQ, CRQ), muscle strength and objective daily physical activity', 'breathlessness, health-related quality of life and daily physical activity', 'breathlessness, quality of life, knee strength and daily physical activity']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}]","[{'cui': 'C0454284', 'cui_str': 'Functional exercises'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}]",90.0,0.0614354,Shoulder strength significantly improved with a between-group difference of 23.9 Nm (p = 0.0350).,"[{'ForeName': 'Annemieke', 'Initials': 'A', 'LastName': 'Fastenau', 'Affiliation': 'Dept of Family Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands. Electronic address: annemieke.fastenau@maastrichtuniversity.nl.'}, {'ForeName': 'Onno Cp', 'Initials': 'OC', 'LastName': 'van Schayck', 'Affiliation': 'Dept of Family Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Bjorn', 'Initials': 'B', 'LastName': 'Winkens', 'Affiliation': 'Dept of Methodology and Statistics, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Aretz', 'Affiliation': 'Dept of Family Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Rik', 'Initials': 'R', 'LastName': 'Gosselink', 'Affiliation': 'KU Leuven, Faculty of Kinesiology and Rehabilitation Sciences, Leuven, Belgium.'}, {'ForeName': 'Jean Wm', 'Initials': 'JW', 'LastName': 'Muris', 'Affiliation': 'Dept of Family Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.'}]",Respiratory medicine,['10.1016/j.rmed.2020.105943'] 194,32308204,"Randomised, placebo-controlled trial of dexamethasone for quality of life in pulmonary sarcoidosis.","BACKGROUND Many patients with pulmonary sarcoidosis experience reduced quality of life. Although oral corticosteroids are the most common agents used in sarcoidosis, very little is known on the effects on quality of life. METHODS In this double-blind, placebo-controlled trial, newly diagnosed patients without an indication for high dose immunosuppressive therapy were randomised to once-daily dexamethasone 1 mg (6.5 mg prednisone equivalent) or placebo for 6 months. The primary study parameter was the subscale physical functioning of the 36-item Short Form health survey (SF-36). Secondary parameters included five other patient reported outcome measures, disease activity markers and plasma cytokine profiles. RESULTS A total of 16 patients was randomised to dexamethasone (n = 7) and placebo (n = 9). During follow-up no significant difference for physical functioning was measured (p = 0.18). Dexamethasone treated patients showed a decrease in fatigue score (Checklist Individual Strength) from 106 (baseline) to 88 (3 months; p = 0.03); 86 (6 months; p = 0.05); 79 (9 months; p = 0.04); 90 (12 months; p = 0.03). Placebo treated patients showed no change: 96 (baseline) to 105 (3 months; p = 0.16); 91 (6 months; p = 0.48); 92 (9 months; p = 0.61); 95 (12 months; p = 0.90). During treatment with dexamethasone significant improvements in the SF-36 subscales vitality and pain, and a significant reduction in serum angiotensin-converting enzyme, soluble interleukin 2 receptor levels and serum cytokines and chemokines were measured. CONCLUSIONS Low-dose dexamethasone results in a reduction of the inflammatory profile and has the potential to improve quality of life parameters and fatigue.",2020,Placebo treated patients showed no change: 96 (baseline) to 105 (3 months; p = 0.16); 91 (6 months; p = 0.48); 92 (9 months; p = 0.61); 95 (12 months; p = 0.90).,"['newly diagnosed patients without an indication for high dose immunosuppressive therapy', '16 patients', 'pulmonary sarcoidosis']","['dexamethasone', 'Dexamethasone', 'placebo', 'Placebo']","['subscale physical functioning of the 36-item Short Form health survey (SF-36', 'fatigue score (Checklist Individual Strength', 'serum angiotensin-converting enzyme, soluble interleukin 2 receptor levels and serum cytokines and chemokines', 'disease activity markers and plasma cytokine profiles', 'SF-36 subscales vitality and pain', 'quality of life parameters and fatigue', 'physical functioning', 'quality of life']","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0021079', 'cui_str': 'Immunosuppressive therapy'}, {'cui': 'C0036205', 'cui_str': 'Pulmonary sarcoidosis'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0022709', 'cui_str': 'Dipeptidyl carboxypeptidase I'}, {'cui': 'C0487019', 'cui_str': 'Interleukin 2 receptor, soluble'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0282554', 'cui_str': 'Cytokines, Chemotactic'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",16.0,0.401844,Placebo treated patients showed no change: 96 (baseline) to 105 (3 months; p = 0.16); 91 (6 months; p = 0.48); 92 (9 months; p = 0.61); 95 (12 months; p = 0.90).,"[{'ForeName': 'Roeland', 'Initials': 'R', 'LastName': 'Vis', 'Affiliation': 'Dept of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, the Netherlands. Electronic address: r.vis@antoniusziekenhuis.nl.'}, {'ForeName': 'Ewoudt M W', 'Initials': 'EMW', 'LastName': 'van de Garde', 'Affiliation': 'Dept of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'Bob', 'Initials': 'B', 'LastName': 'Meek', 'Affiliation': 'Dept of Medical Microbiology and Immunology, St Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'Ingrid H E', 'Initials': 'IHE', 'LastName': 'Korenromp', 'Affiliation': 'Interstitial Lung Diseases Centre of Excellence, Dept of Pulmonology, St Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'Jan C', 'Initials': 'JC', 'LastName': 'Grutters', 'Affiliation': 'Interstitial Lung Diseases Centre of Excellence, Dept of Pulmonology, St Antonius Hospital, Nieuwegein, the Netherlands; Division of Heart & Lungs, University Medical Center Utrecht, Utrecht, the Netherlands.'}]",Respiratory medicine,['10.1016/j.rmed.2020.105936'] 195,32305124,Effects of Different Immunosuppressive Drugs on Incretins in Renal Transplant Patients.,"BACKGROUND Immunosuppressive drugs used in transplantation patients, may contribute to the development of post-transplant diabetes mellitus through their possible adverse effects on incretins. We aimed to compare the effects of different immunosuppressive drugs used in renal transplantation patients on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels. PATIENTS AND METHODS Forty five subjects were enrolled in the study (cyclosporine-treated 15 and tacrolimus-treated renal transplant patients 15, and healthy volunteers as a control group 15). Oral glucose tolerance test with 75 gr glucose was performed. GLP-1 and GIP levels were measured at 0 (baseline), 30, 60, 90, 120 min using ELISA method. RESULTS A statistically significant level of difference was detected in GLP-1 levels at the baseline, 30th and 120th minutes among all three groups (p < 0,001, p = 0,026 and p = 0,022, respectively). Baseline GLP-1 levels in cyclosporine-treated renal transplant patients were higher than in both tacrolimus-treated renal transplant patients (p = 0,016) and control groups (p < 0,001). GLP-1 levels at the 30th minute were higher in tacrolimus-treated renal transplant patients when compared to the cyclosporine-treated renal transplant patients (p = 0,024). GLP-1 levels at the 120th minute were higher in tacrolimus-treated renal transplant patients than the control group (p = 0,024). The areas under the curve of GLP-1 was higher in tacrolimus-treated renal transplant patients when compared to the control group (p = 0,018). GIP levels at 120th was lower in cyclosporine-treated renal transplant patients when compared to control group (p = 0,003). CONCLUSION These findings showed a temporally affected incretin hormones in renal transplant patients, a preserved GLP-1 response to an oral glucose load in renal transplant patients on cyclosporine and increased GLP -1 response to an oral glucose load in those on tacrolimus.",2020,"GLP-1 levels at the 120th minute were higher in tacrolimus-treated renal transplant patients than the control group (p = 0,024).","['treated renal transplant patients', 'Renal Transplant Patients', 'transplantation patients', 'renal transplant patients', 'renal transplantation patients on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels', 'treated renal transplant patients 15, and healthy volunteers as a control group 15', 'Forty five subjects were enrolled in the study ']","['cyclosporine', 'Immunosuppressive Drugs', 'cyclosporine-treated 15 and tacrolimus']","['GLP-1 and GIP levels', 'GLP -1 response', 'GIP levels', 'Oral glucose tolerance test', 'Baseline GLP-1 levels', 'curve of GLP-1', 'GLP-1 levels']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0017132', 'cui_str': 'Gastric inhibitory polypeptide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0010592', 'cui_str': 'Cyclosporine'}, {'cui': 'C0021081', 'cui_str': 'Immunosuppressant agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}]","[{'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0017132', 'cui_str': 'Gastric inhibitory polypeptide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205134', 'cui_str': 'Curved'}]",45.0,0.0200643,"GLP-1 levels at the 120th minute were higher in tacrolimus-treated renal transplant patients than the control group (p = 0,024).","[{'ForeName': 'Nusret', 'Initials': 'N', 'LastName': 'Yilmaz', 'Affiliation': 'Akdeniz University, School of Medicine, Division of Endocrinology, Antalya, Turkey.'}, {'ForeName': 'Ramazan', 'Initials': 'R', 'LastName': 'Sari', 'Affiliation': 'Akdeniz University, School of Medicine, Division of Endocrinology, Antalya, Turkey. Electronic address: drsari@hotmail.com.'}, {'ForeName': 'Gultekin', 'Initials': 'G', 'LastName': 'Suleymanlar', 'Affiliation': 'Akdeniz University, School of Medicine, Division of Nephrology, Antalya, Turkey.'}, {'ForeName': 'Sebahat', 'Initials': 'S', 'LastName': 'Ozdem', 'Affiliation': 'Akdeniz University, School of Medicine, Department of Biochemistry, Antalya, Turkey.'}]",Journal of the National Medical Association,['10.1016/j.jnma.2020.03.012'] 196,32108274,Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials.,"Outcomes in economic evaluations, such as health utilities and costs, are products of multiple variables, often requiring complete item responses to questionnaires. Therefore, missing data are very common in cost-effectiveness analyses. Multiple imputations (MI) are predominately recommended and could be made either for individual items or at the aggregate level. We, therefore, aimed to assess the precision of both MI approaches (the item imputation vs. aggregate imputation) on the cost-effectiveness results. The original data set came from a cluster-randomized, controlled trial and was used to describe the missing data pattern and compare the differences in the cost-effectiveness results between the two imputation approaches. A simulation study with different missing data scenarios generated based on a complete data set was used to assess the precision of both imputation approaches. For health utility and cost, patients more often had a partial (9% vs. 23%, respectively) rather than complete missing (4% vs. 0%). The imputation approaches differed in the cost-effectiveness results (the item imputation: - 61,079€/QALY vs. the aggregate imputation: 15,399€/QALY). Within the simulation study mean relative bias (< 5% vs. < 10%) and range of bias (< 38% vs. < 83%) to the true incremental cost and incremental QALYs were lower for the item imputation compared to the aggregate imputation. Even when 40% of data were missing, relative bias to true cost-effectiveness curves was less than 16% using the item imputation, but up to 39% for the aggregate imputation. Thus, the imputation strategies could have a significant impact on the cost-effectiveness conclusions when more than 20% of data are missing. The item imputation approach has better precision than the imputation at the aggregate level.",2020,"For health utility and cost, patients more often had a partial (9% vs. 23%, respectively) rather than complete missing (4% vs. 0%).",[],[],"['true incremental cost and incremental QALYs', 'health utilities and costs, are products of multiple variables, often requiring complete item responses to questionnaires', 'cost-effectiveness conclusions']",[],[],"[{'cui': 'C0205238', 'cui_str': 'True (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0080071', 'cui_str': 'QALY'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",,0.0336039,"For health utility and cost, patients more often had a partial (9% vs. 23%, respectively) rather than complete missing (4% vs. 0%).","[{'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Michalowsky', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Ellernholzstrasse 1-2, 17487, Greifswald, Germany. bernhard.michalowsky@dzne.de.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Hoffmann', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Ellernholzstrasse 1-2, 17487, Greifswald, Germany.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Kennedy', 'Affiliation': 'Department of Health Research Methods, Evidence and Impact (Formerly Clinical Epidemiology and Biostatistics), McMaster University, 1280 Main Street West, Hamilton, Canada.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Xie', 'Affiliation': 'Department of Health Research Methods, Evidence and Impact (Formerly Clinical Epidemiology and Biostatistics), McMaster University, 1280 Main Street West, Hamilton, Canada.'}]",The European journal of health economics : HEPAC : health economics in prevention and care,['10.1007/s10198-020-01166-z'] 197,30585371,Mood impairment is stronger in young than in older adults after sleep deprivation.,"Sleep deprivation commonly impairs affective regulation and causes worse mood. However, the majority of previous research concerns young adults. Because susceptibility to sleep deprivation and emotion regulation change distinctively across adult age, we tested here the hypothesis that the effect of sleep deprivation on mood is stronger in young than in older adults. In an experimental design, young (18-30 years) and older adults (60-72 years) participated in either a sleep control (young, n = 63; older, n = 47) or a total sleep deprivation condition (young, n = 61; older, n = 47). Sleepiness, mood and common symptoms of sleep deprivation were measured using established questionnaires and ratings. Sleep-deprived participants felt more sleepy, stressed and cold, and reported lower vigour and positive affect, regardless of age. All the other outcome measures (negative affect, depression, confusion, tension, anger, fatigue, total mood disturbance, hunger, cognitive attenuation, irritability) showed a weaker response to sleep deprivation in the older group, as indicated by age*sleep deprivation interactions (ps < 0.05). The results show that older adults are emotionally less affected by sleep deprivation than young adults. This tolerance was mainly related to an attenuated increase in negative mood. This could possibly be related to the well-known positivity effect, which suggests that older adults prioritize regulating their emotions to optimize well-being. The results also highlight that caution is warranted when generalizing results from sleep deprivation studies across the adult lifespan.",2019,"Sleep-deprived participants felt more sleepy, stressed and cold, and reported lower vigour and positive affect, regardless of age.","['young (18-30\xa0years) and older adults (60-72\xa0years) participated in either a sleep control (young, n\xa0=\xa063; older, n\xa0=\xa047) or a total sleep deprivation condition (young, n\xa0=\xa061; older, n\xa0=\xa047', 'young than in older adults', 'older adults']",[],"['depression, confusion, tension, anger, fatigue, total mood disturbance, hunger, cognitive attenuation, irritability', 'sleep deprivation', 'negative mood', 'Sleepiness, mood and common symptoms of sleep deprivation', 'Mood impairment']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0037316', 'cui_str': 'Sleep Deprivation'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]",[],"[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0009676', 'cui_str': 'Confusional State'}, {'cui': 'C0233494', 'cui_str': 'Tension (finding)'}, {'cui': 'C0002957', 'cui_str': 'Anger'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0020175', 'cui_str': 'Hunger'}, {'cui': 'C0022107', 'cui_str': 'Irritable Mood'}, {'cui': 'C0037316', 'cui_str': 'Sleep Deprivation'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C2830004', 'cui_str': 'Somnolence'}, {'cui': 'C0205214', 'cui_str': 'Common (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}]",,0.0283327,"Sleep-deprived participants felt more sleepy, stressed and cold, and reported lower vigour and positive affect, regardless of age.","[{'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Schwarz', 'Affiliation': 'Stress Research Institute, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Axelsson', 'Affiliation': 'Stress Research Institute, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Gerhardsson', 'Affiliation': 'Department of Psychology, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Tamm', 'Affiliation': 'Stress Research Institute, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Håkan', 'Initials': 'H', 'LastName': 'Fischer', 'Affiliation': 'Department of Psychology, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Göran', 'Initials': 'G', 'LastName': 'Kecklund', 'Affiliation': 'Stress Research Institute, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Torbjörn', 'Initials': 'T', 'LastName': 'Åkerstedt', 'Affiliation': 'Stress Research Institute, Stockholm University, Stockholm, Sweden.'}]",Journal of sleep research,['10.1111/jsr.12801'] 198,30857452,Prognostic Importance of Defibrillator-Appropriate Shocks and Antitachycardia Pacing in Patients With Mild Heart Failure.,"Background Patients with heart failure and an implantable cardioverter-defibrillator ( ICD ) for primary prevention are at increased mortality risk after receiving shock therapy. We sought to determine the prognostic significance of ICD therapies, both shock and antitachycardia pacing, delivered for different ventricular arrhythmia ( VA ) rates. Methods and Results We evaluated mortality risk among 1790 ICD -implanted patients from MADIT -CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). For the first analysis, patients were divided into mutually exclusive groups by the rate of treated VA only: slow VA (<200 beats per minute) and fast VA (≥200 beats per minute or ventricular fibrillation). In a secondary analysis, both the type of ICD therapy and VA rate were used. The reference group was always patients who had no ICD therapy. ICD therapy for fast VA was associated with increased mortality risk (hazard ratio [ HR] , 2.27; 95% CI , 1.48-3.48; P<0.001). However, mortality risk after ICD therapy for slow VA was similar to the risk related to no ICD therapy ( HR , 1.45; 95% CI , 0.86-2.44; P=0.162). Consistently, shocks ( HR , 2.96; 95% CI , 1.91-4.60; P<0.001) and antitachycardia pacing ( HR , 2.22; 95% CI , 0.96-5.14; P=0.063) for fast VA were both associated with increased mortality risk. Shocks and antitachycardia pacing for slow VA were not significantly associated with increased mortality risk ( HR , 1.43 [95% CI , 0.52-3.92; P=0.489]; and HR , 1.43 [95% CI, 0.80-2.56; P=0.232], respectively). Conclusions In patients with mild heart failure receiving ICD for primary prevention, mortality is associated with the rate of underlying VA rather than the type of therapy. These findings suggest that fast VA is a marker for increased mortality rather than shock therapy directly contributing to increased risk. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00180271.",2019,"Shocks and antitachycardia pacing for slow VA were not significantly associated with increased mortality risk ( HR , 1.43 [95% CI , 0.52-3.92; P=0.489]; and HR , 1.43 [95% CI, 0.80-2.56; P=0.232], respectively).","['patients who had no ICD therapy', '1790 ICD -implanted patients from', ' Patients with heart failure and an', 'patients with mild heart failure receiving', 'Patients With Mild Heart Failure']","['Defibrillator-Appropriate Shocks and Antitachycardia Pacing', 'MADIT -CRT', 'implantable cardioverter-defibrillator ( ICD ', 'ICD']","['mortality risk', 'antitachycardia pacing']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}]","[{'cui': 'C0180307', 'cui_str': 'Defibrillators'}, {'cui': 'C1869063', 'cui_str': 'Shock (SMQ)'}, {'cui': 'C0562458', 'cui_str': 'Pacing up and down (finding)'}, {'cui': 'C0162589', 'cui_str': 'Implantable Cardioverter-Defibrillators'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0562458', 'cui_str': 'Pacing up and down (finding)'}]",,0.162152,"Shocks and antitachycardia pacing for slow VA were not significantly associated with increased mortality risk ( HR , 1.43 [95% CI , 0.52-3.92; P=0.489]; and HR , 1.43 [95% CI, 0.80-2.56; P=0.232], respectively).","[{'ForeName': 'Yitschak', 'Initials': 'Y', 'LastName': 'Biton', 'Affiliation': '1 Heart Research Follow-Up Program Division of Cardiology Department of Medicine University of Rochester Medical Center Rochester NY.'}, {'ForeName': 'Usama A', 'Initials': 'UA', 'LastName': 'Daimee', 'Affiliation': '1 Heart Research Follow-Up Program Division of Cardiology Department of Medicine University of Rochester Medical Center Rochester NY.'}, {'ForeName': 'Jayson R', 'Initials': 'JR', 'LastName': 'Baman', 'Affiliation': '1 Heart Research Follow-Up Program Division of Cardiology Department of Medicine University of Rochester Medical Center Rochester NY.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Kutyifa', 'Affiliation': '1 Heart Research Follow-Up Program Division of Cardiology Department of Medicine University of Rochester Medical Center Rochester NY.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'McNitt', 'Affiliation': '1 Heart Research Follow-Up Program Division of Cardiology Department of Medicine University of Rochester Medical Center Rochester NY.'}, {'ForeName': 'Bronislava', 'Initials': 'B', 'LastName': 'Polonsky', 'Affiliation': '1 Heart Research Follow-Up Program Division of Cardiology Department of Medicine University of Rochester Medical Center Rochester NY.'}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Zareba', 'Affiliation': '1 Heart Research Follow-Up Program Division of Cardiology Department of Medicine University of Rochester Medical Center Rochester NY.'}, {'ForeName': 'Ilan', 'Initials': 'I', 'LastName': 'Goldenberg', 'Affiliation': '1 Heart Research Follow-Up Program Division of Cardiology Department of Medicine University of Rochester Medical Center Rochester NY.'}]",Journal of the American Heart Association,['10.1161/JAHA.118.010346'] 199,30857464,Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y 12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial.,"Background There are limited data on how the combination of diabetes mellitus ( DM ) and chronic kidney disease ( CKD ) affects cardiovascular outcomes as well as response to different P2Y 12 receptor antagonists, which represented the aim of the present investigation. Methods and Results In this post hoc analysis of the PLATO (Platelet Inhibition and Patient Outcomes) trial, which randomized acute coronary syndrome patients to ticagrelor versus clopidogrel, patients (n=15 108) with available DM and CKD status were classified into 4 groups: DM +/ CKD + (n=1058), DM +/ CKD - (n=2748), DM -/ CKD + (n=2160), and DM -/ CKD - (n=9142). The primary efficacy end point was a composite of cardiovascular death, myocardial infarction, or stroke at 12 months. The primary safety end point was PLATO major bleeding. DM +/ CKD + patients had a higher incidence of the primary end point compared with DM -/ CKD - patients (23.3% versus 7.1%; adjusted hazard ratio 2.22; 95% CI 1.88-2.63; P<0.001). Patients with DM +/ CKD - and DM -/ CKD + had an intermediate risk profile. The same trend was shown for the individual components of the primary end point and for major bleeding. Compared with clopidogrel, ticagrelor reduced the incidence of the primary end point consistently across subgroups ( P-interaction=0.264), but with an increased absolute risk reduction in DM +/ CKD +. The effects on major bleeding were also consistent across subgroups ( P-interaction=0.288). Conclusions In acute coronary syndrome patients, a gradient of risk was observed according to the presence or absence of DM and CKD , with patients having both risk factors at the highest risk. Although the ischemic benefit of ticagrelor over clopidogrel was consistent in all subgroups, the absolute risk reduction was greatest in patients with both DM and CKD . Clinical Trial Registration URL : http://www.clinicatrials.gov . Unique identifier: NCT 00391872.",2019,"Compared with clopidogrel, ticagrelor reduced the incidence of the primary end point consistently across subgroups ( P-interaction=0.264), but with an increased absolute risk reduction in DM +/ CKD +.","['Patients With Acute Coronary Syndromes', 'acute coronary syndrome patients']","['DM +/ CKD', 'clopidogrel, ticagrelor', 'DM +/ CKD ', 'ticagrelor', 'ticagrelor versus clopidogrel']","['major bleeding', 'composite of cardiovascular death, myocardial infarction, or stroke at 12\xa0months', 'absolute risk reduction']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0948089', 'cui_str': 'Acute Coronary Syndrome'}]","[{'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C3179139', 'cui_str': 'Absolute Risk Reduction'}]",,0.0449121,"Compared with clopidogrel, ticagrelor reduced the incidence of the primary end point consistently across subgroups ( P-interaction=0.264), but with an increased absolute risk reduction in DM +/ CKD +.","[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Franchi', 'Affiliation': '1 University of Florida, College of Medicine-Jacksonville Jacksonville FL.'}, {'ForeName': 'Stefan K', 'Initials': 'SK', 'LastName': 'James', 'Affiliation': '2 Department of Medical Sciences Cardiology Uppsala University Uppsala Sweden.'}, {'ForeName': 'Tatevik', 'Initials': 'T', 'LastName': 'Ghukasyan Lakic', 'Affiliation': '3 Uppsala Clinical Research Center Uppsala University Uppsala Sweden.'}, {'ForeName': 'Andrzej J', 'Initials': 'AJ', 'LastName': 'Budaj', 'Affiliation': '4 Postgraduate Medical School Grochowski Hospital Warsaw Poland.'}, {'ForeName': 'Jan H', 'Initials': 'JH', 'LastName': 'Cornel', 'Affiliation': '5 Department of Cardiology Noordwest Ziekenhuisgroep Alkmaar Netherlands.'}, {'ForeName': 'Hugo A', 'Initials': 'HA', 'LastName': 'Katus', 'Affiliation': '6 Medizinishe Klinik Universitätsklinikum Heidelberg Heidelberg Germany.'}, {'ForeName': 'Matyas', 'Initials': 'M', 'LastName': 'Keltai', 'Affiliation': '7 Hungarian Institute of Cardiology Semmelweis University Budapest Hungary.'}, {'ForeName': 'Frederic', 'Initials': 'F', 'LastName': 'Kontny', 'Affiliation': '8 Department of Cardiology Stavanger University Hospital Stavanger Norway.'}, {'ForeName': 'Basil S', 'Initials': 'BS', 'LastName': 'Lewis', 'Affiliation': '9 Lady Davis Carmel Medical Center Haifa Israel.'}, {'ForeName': 'Robert F', 'Initials': 'RF', 'LastName': 'Storey', 'Affiliation': '10 Department of Infection, Immunity and Cardiovascular Disease University of Sheffield United Kingdom.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Himmelmann', 'Affiliation': '11 AstraZeneca, Research and Development Gothenburg Sweden.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Wallentin', 'Affiliation': '2 Department of Medical Sciences Cardiology Uppsala University Uppsala Sweden.'}, {'ForeName': 'Dominick J', 'Initials': 'DJ', 'LastName': 'Angiolillo', 'Affiliation': '1 University of Florida, College of Medicine-Jacksonville Jacksonville FL.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of the American Heart Association,['10.1161/JAHA.118.011139'] 200,31102328,High vs. low oxygen therapy in patients with acute heart failure: HiLo-HF pilot trial.,"AIMS Most patients with acute heart failure (AHF) are treated with supplemental oxygen during hospitalization. In this study, we investigated the effect of oxygen titrated to high vs. low pulse oximetry targets in patients hospitalized with AHF. METHODS AND RESULTS In a pilot, open-label randomized controlled trial (RCT), 50 patients who were admitted with AHF were randomized to either high (≥96%) or low (90-92%) SpO 2 targets. Oxygen was manually titrated to the assigned target ranges for 72 h. The primary endpoint was the change in N-terminal pro-brain-type natriuretic peptide (NT-proBNP) from randomization to 72 h, and secondary endpoints included patient-reported dyspnoea by visual analogue scale (VAS), patient global assessment (PGA), peak expiratory flow (PEF) within 72 h, and clinical outcomes up to 30 days following hospital discharge. The median age was 73.5 years, and 42% were women. The change in NT-proBNP was -6963 (-13 345, -1253) pg/mL in the high SpO 2 group and -2093 (-5692, -353) pg/mL in the low SpO 2 group (P = 0.46), and the 72 h to baseline NT-proBNP ratio was similar between groups (0.7 vs. 0.6, P = 0.51). There were no differences between arms in change in dyspnoea VAS (P = 0.86), PGA (P = 0.91), PEF (P = 0.52), in-hospital mortality (4.0% vs. 8.0%, P = 0.50), or 30 day heart failure readmission rates (20.8% vs. 8.7%, P = 0.22). CONCLUSIONS In this study, no differences were observed in the primary or secondary outcomes for patients randomized to high vs. low SpO 2 targets. Further RCTs with larger sample sizes are warranted to determine the efficacy and safety of oxygen therapy in patients with AHF.",2019,"There were no differences between arms in change in dyspnoea VAS (P = 0.86), PGA (P = 0.91), PEF (P = 0.52), in-hospital mortality (4.0% vs. 8.0%, P = 0.50), or 30 day heart failure readmission rates (20.8% vs. 8.7%, P = 0.22). ","['50 patients who were admitted with AHF', 'The median age was 73.5\xa0years, and 42% were women', 'patients with AHF', 'patients with acute heart failure (AHF', 'patients with acute heart failure', 'patients hospitalized with AHF']","['High vs. low oxygen therapy', 'oxygen titrated to high vs. low pulse oximetry targets', 'supplemental oxygen']","['change in N-terminal pro-brain-type natriuretic peptide (NT-proBNP', 'dyspnoea VAS', 'PEF', 'hospital mortality', 'PGA', 'baseline NT-proBNP ratio', 'patient-reported dyspnoea by visual analogue scale (VAS), patient global assessment (PGA), peak expiratory flow (PEF) within 72\xa0h, and clinical outcomes', 'heart failure readmission rates']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0015506', 'cui_str': 'coagulation factor VIII'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0264714', 'cui_str': 'Acute heart failure (disorder)'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0184633', 'cui_str': 'Oxygen Inhalation Therapy'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0034108', 'cui_str': 'Oximetry, Pulse'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C1144709', 'cui_str': 'Natriuretic Peptides'}, {'cui': 'C1963813', 'cui_str': 'NT-proBNP'}, {'cui': 'C0013404', 'cui_str': 'Breathlessness'}, {'cui': 'C0085556', 'cui_str': 'Mortalities, In-house'}, {'cui': 'C0085409', 'cui_str': 'Polyendocrinopathies, Autoimmune'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}]",,0.375931,"There were no differences between arms in change in dyspnoea VAS (P = 0.86), PGA (P = 0.91), PEF (P = 0.52), in-hospital mortality (4.0% vs. 8.0%, P = 0.50), or 30 day heart failure readmission rates (20.8% vs. 8.7%, P = 0.22). ","[{'ForeName': 'Nariman', 'Initials': 'N', 'LastName': 'Sepehrvand', 'Affiliation': 'Canadian VIGOUR Centre, University of Alberta, 2-132 Li Ka Shing Centre for Health Research Innovation, Edmonton, Alberta, Canada, T6G 2E1.'}, {'ForeName': 'Wendimagegn', 'Initials': 'W', 'LastName': 'Alemayehu', 'Affiliation': 'Canadian VIGOUR Centre, University of Alberta, 2-132 Li Ka Shing Centre for Health Research Innovation, Edmonton, Alberta, Canada, T6G 2E1.'}, {'ForeName': 'Brian H', 'Initials': 'BH', 'LastName': 'Rowe', 'Affiliation': 'Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Finlay A', 'Initials': 'FA', 'LastName': 'McAlister', 'Affiliation': 'Canadian VIGOUR Centre, University of Alberta, 2-132 Li Ka Shing Centre for Health Research Innovation, Edmonton, Alberta, Canada, T6G 2E1.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'van Diepen', 'Affiliation': 'Canadian VIGOUR Centre, University of Alberta, 2-132 Li Ka Shing Centre for Health Research Innovation, Edmonton, Alberta, Canada, T6G 2E1.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Stickland', 'Affiliation': 'Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Justin A', 'Initials': 'JA', 'LastName': 'Ezekowitz', 'Affiliation': 'Canadian VIGOUR Centre, University of Alberta, 2-132 Li Ka Shing Centre for Health Research Innovation, Edmonton, Alberta, Canada, T6G 2E1.'}]",ESC heart failure,['10.1002/ehf2.12448'] 201,32297875,"An Internet-Based, Peer-Delivered Messaging Intervention for HIV Testing and Condom Use Among Men Who Have Sex With Men in India (CHALO!): Pilot Randomized Comparative Trial.","BACKGROUND Leveraging internet-based communication tools (eg, messaging apps, SMS text messaging, and email) may be an effective avenue for delivery of HIV prevention messages to men who have sex with men (MSM) in India, but there are limited models for such internet-based interventions. OBJECTIVE The CHALO! pilot was an online educational and behavioral intervention aimed to determine the feasibility, acceptability, and preliminary impact of a peer-delivered, internet-based messaging intervention for HIV testing and consistent condom use for MSM in India. The messages addressed barriers to HIV testing and condom use and were theoretically based on the information-motivation-behavioral skills model. METHODS Between February and March 2015, we recruited, enrolled, and randomized 244 participants via online advertisements on mobile dating apps and Facebook. Eligible men (18 years or older, sexually active with other men, and self-reported HIV-negative or unknown status) were randomized to receive educational and motivational messages framed as either approach (ie, a desirable outcome to be achieved) or avoidance (an undesirable outcome to be avoided) over 12 weeks via internet-based messaging platforms. Participants completed online surveys at baseline and immediately postintervention. RESULTS Participants were similar across arms with respect to sociodemographic and behavioral characteristics. Over 82.0% (200/244) of participants were retained (ie, viewed final messages), and 52.3% (130/244) of them completed the follow-up survey. Of those completing the follow-up survey, 82.3% (107/130) liked or strongly liked participating in CHALO!. The results showed a significant increase in self-reported HIV testing in the past 6 months from baseline to follow-up (41/130, 31.5% to 57/130, 43.8%; P=.04). When including those who reported intentions to test, this percentage increased from 44.6% (58/130) at baseline to 65.4% (85/130) at follow-up (P<.01). When examining intentions to test among those without prior HIV testing, intentions increased from 32% (16/50) of the sample at baseline to 56% (28/50) of the sample at follow-up (P=.02). Condom use during anal sex did not significantly change from baseline to follow-up. HIV testing and condom use did not significantly differ between approach and avoidance conditions at follow-up. CONCLUSIONS As one of the first studies of an online HIV prevention intervention for Indian MSM, CHALO! was feasible to implement by a community-based organization, was acceptable to participants, and demonstrated potential to improve HIV testing rates.",2020,"The results showed a significant increase in self-reported HIV testing in the past 6 months from baseline to follow-up (41/130, 31.5% to 57/130, 43.8%; P=.04).","['Men', 'Eligible men (18 years or older, sexually active with other men, and self-reported HIV-negative or unknown status', 'Who Have Sex With Men in India', 'Between February and March 2015, we recruited, enrolled, and randomized 244 participants via online advertisements on mobile dating apps and Facebook', 'men who have sex with men (MSM) in India']","['CHALO', 'Peer-Delivered Messaging Intervention for HIV Testing and Condom Use', 'educational and motivational messages framed as either approach (ie, a desirable outcome to be achieved) or avoidance', 'peer-delivered, internet-based messaging intervention for HIV testing and consistent condom use for MSM']",['self-reported HIV testing'],"[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0241028', 'cui_str': 'Sexually active'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0481430', 'cui_str': 'HIV negative'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C4517660', 'cui_str': '244'}, {'cui': 'C0949214', 'cui_str': 'Advertisements'}, {'cui': 'C0011008', 'cui_str': 'Date'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0080089', 'cui_str': 'Reading Frames'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}]",244.0,0.165018,"The results showed a significant increase in self-reported HIV testing in the past 6 months from baseline to follow-up (41/130, 31.5% to 57/130, 43.8%; P=.04).","[{'ForeName': 'Viraj V', 'Initials': 'VV', 'LastName': 'Patel', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, Montefiore Health System, Bronx, NY, United States.'}, {'ForeName': 'Shruta', 'Initials': 'S', 'LastName': 'Rawat', 'Affiliation': 'The Humsafar Trust, Mumbai, India.'}, {'ForeName': 'Alpana', 'Initials': 'A', 'LastName': 'Dange', 'Affiliation': 'The Humsafar Trust, Mumbai, India.'}, {'ForeName': 'Corina', 'Initials': 'C', 'LastName': 'Lelutiu-Weinberger', 'Affiliation': 'François-Xavier Bagnoud Center, School of Nursing, Rutgers Biomedical and Health Sciences, Newark, NJ, United States.'}, {'ForeName': 'Sarit A', 'Initials': 'SA', 'LastName': 'Golub', 'Affiliation': 'Department of Psychology, Hunter College, City University of New York, New York, NY, United States.'}]",JMIR public health and surveillance,['10.2196/16494'] 202,32303386,"Reply to Roderick C.N. van den Bergh, Massimo Valerio, Derya Tilki, and Giorgio Gandaglia's Letter to the Editor re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2020.02.009.",,2020,,['Clinically Localized Prostate Cancer'],['Radical Prostatectomy or Observation'],[],"[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}]","[{'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}, {'cui': 'C0302523', 'cui_str': 'Observation'}]",[],,0.0166434,,"[{'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'Wilt', 'Affiliation': 'Minneapolis VA Center for Care Delivery and Outcomes Research, Minneapolis, MN, USA; Section of General Medicine, University of Minnesota School of Medicine, Minneapolis, MN, USA. Electronic address: tim.wilt@va.gov.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Dahm', 'Affiliation': 'Minneapolis VA Section of Urology, Minneapolis, MN, USA; Department of Urology, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Brawer', 'Affiliation': 'MDx Health, Irvine, CA, USA; Nanospectra Biosciences, Houston, TX, USA.'}]",European urology,['10.1016/j.eururo.2020.03.047'] 203,30879375,"Acute Effects of Heat-Not-Burn, Electronic Vaping, and Traditional Tobacco Combustion Cigarettes: The Sapienza University of Rome-Vascular Assessment of Proatherosclerotic Effects of Smoking ( SUR - VAPES ) 2 Randomized Trial.","Background Little clinical research on new-generation heat-not-burn cigarettes ( HNBC ) in comparison with electronic vaping cigarettes ( EVC ) and traditional tobacco combustion cigarettes ( TC ) has been reported. We aimed to appraise the acute effects of single use of HNBC , EVC, and TC in healthy smokers. Methods and Results This was an independent, cross-over, randomized trial in 20 TC smokers, with allocation to different cycles of HNBC , EVC , and TC . All participants used all types of products, with an intercycle washout of 1 week. End points were oxidative stress, antioxidant reserve, platelet activation, flow-mediated dilation, blood pressure, and satisfaction scores. Single use of any product led to an adverse impact on oxidative stress, antioxidant reserve, platelet function, flow-mediated dilation, and blood pressure. HNBC had less impact than EVC and TC on soluble Nox2-derived peptide (respectively, P=0.004 and 0.001), 8-iso-prostaglandin F2α- III ( P=0.004 and <0.001), and vitamin E ( P=0.018 and 0.044). HNBC and EVC were equally less impactful than TCs on flow-mediated dilation ( P=0.872 for HNBC versus EVC ), H 2 O 2 ( P=0.522), H 2 O 2 breakdown activity ( P=0.091), soluble CD 40 ligand ( P=0.849), and soluble P-selectin ( P=0.821). The effect of HNBC and, to a lesser extent EVC , on blood pressure was less evident than that of TC , whereas HNBC appeared more satisfying than EVC (all P<0.05). Conclusions Acute effects of HNBC , EVC, and TC are different on several oxidative stress, antioxidant reserve, platelet function, cardiovascular, and satisfaction dimensions, with TCs showing the most detrimental changes in clinically relevant features. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 03301129.",2019,"HNBC and EVC were equally less impactful than TCs on flow-mediated dilation ( P=0.872 for HNBC versus EVC ), H 2 O 2 ( P=0.522), H 2 O 2 breakdown activity ( P=0.091), soluble CD 40 ligand ( P=0.849), and soluble P-selectin ( P=0.821).","['20 TC smokers', 'healthy smokers']","['Heat-Not-Burn, Electronic Vaping, and Traditional Tobacco Combustion Cigarettes', 'electronic vaping cigarettes ( EVC ) and traditional tobacco combustion cigarettes ( TC ', 'HNBC', 'HNBC , EVC, and TC']","['blood pressure', '8-iso-prostaglandin F2α- III', 'oxidative stress, antioxidant reserve, platelet activation, flow-mediated dilation, blood pressure, and satisfaction scores', 'soluble Nox2-derived peptide', 'flow-mediated dilation', 'oxidative stress, antioxidant reserve, platelet function, flow-mediated dilation, and blood pressure', 'HNBC and EVC', 'several oxidative stress, antioxidant reserve, platelet function, cardiovascular, and satisfaction dimensions', 'vitamin E']","[{'cui': 'C0337664', 'cui_str': 'Smoker'}]","[{'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0006434', 'cui_str': 'Burns'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}]","[{'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0911936', 'cui_str': 'iso(VL)'}, {'cui': 'C0356622', 'cui_str': 'Prostaglandins, oxytocics'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0032173', 'cui_str': 'Platelet Activation'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030956', 'cui_str': 'Peptides'}, {'cui': 'C1254881', 'cui_str': 'Platelet function'}, {'cui': 'C0439534', 'cui_str': 'Dimensions (qualifier value)'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}]",20.0,0.125354,"HNBC and EVC were equally less impactful than TCs on flow-mediated dilation ( P=0.872 for HNBC versus EVC ), H 2 O 2 ( P=0.522), H 2 O 2 breakdown activity ( P=0.091), soluble CD 40 ligand ( P=0.849), and soluble P-selectin ( P=0.821).","[{'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Biondi-Zoccai', 'Affiliation': '1 Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome Latina Italy.'}, {'ForeName': 'Sebastiano', 'Initials': 'S', 'LastName': 'Sciarretta', 'Affiliation': '1 Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome Latina Italy.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Bullen', 'Affiliation': '3 National Institute for Health Innovation School of Population Health Faculty of Medical and Health Sciences The University of Auckland New Zealand.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Nocella', 'Affiliation': '2 IRCCS NEUROMED Pozzilli Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Violi', 'Affiliation': '4 Department of Internal Medicine and Medical Specialties Sapienza University of Rome Italy.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Loffredo', 'Affiliation': '4 Department of Internal Medicine and Medical Specialties Sapienza University of Rome Italy.'}, {'ForeName': 'Pasquale', 'Initials': 'P', 'LastName': 'Pignatelli', 'Affiliation': '4 Department of Internal Medicine and Medical Specialties Sapienza University of Rome Italy.'}, {'ForeName': 'Ludovica', 'Initials': 'L', 'LastName': 'Perri', 'Affiliation': '4 Department of Internal Medicine and Medical Specialties Sapienza University of Rome Italy.'}, {'ForeName': 'Mariangela', 'Initials': 'M', 'LastName': 'Peruzzi', 'Affiliation': '1 Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome Latina Italy.'}, {'ForeName': 'Antonino G M', 'Initials': 'AGM', 'LastName': 'Marullo', 'Affiliation': '1 Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome Latina Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'De Falco', 'Affiliation': '1 Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome Latina Italy.'}, {'ForeName': 'Isotta', 'Initials': 'I', 'LastName': 'Chimenti', 'Affiliation': '1 Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome Latina Italy.'}, {'ForeName': 'Vittoria', 'Initials': 'V', 'LastName': 'Cammisotto', 'Affiliation': '4 Department of Internal Medicine and Medical Specialties Sapienza University of Rome Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Valenti', 'Affiliation': '1 Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome Latina Italy.'}, {'ForeName': 'Flaminia', 'Initials': 'F', 'LastName': 'Coluzzi', 'Affiliation': '1 Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome Latina Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Cavarretta', 'Affiliation': '1 Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome Latina Italy.'}, {'ForeName': 'Albino', 'Initials': 'A', 'LastName': 'Carrizzo', 'Affiliation': '2 IRCCS NEUROMED Pozzilli Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Prati', 'Affiliation': '5 Division of Cardiology San Giovanni Addolorata Hospital Rome Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Carnevale', 'Affiliation': '1 Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome Latina Italy.'}, {'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Frati', 'Affiliation': '2 IRCCS NEUROMED Pozzilli Italy.'}]",Journal of the American Heart Association,['10.1161/JAHA.118.010455'] 204,30943824,Using mH ealth Tools to Improve Access and Coverage of People With Public Health Insurance and High Cardiovascular Disease Risk in Argentina: A Pragmatic Cluster Randomized Trial.,"Background Control of cardiovascular disease ( CVD ) risk factors is suboptimal in Argentina, despite the government's provision of free blood pressure and cholesterol-lowering medications for people without private insurance. We assessed whether community health workers' use of an integrated mH ealth tool encourages patients to attend visits at primary care clinics to improve CVD risk management in 2 provinces of Argentina. Methods and Results We conducted a pragmatic cluster randomized trial, with primary care clinics randomly assigned to intervention or control. Eligible people were aged 40 to 79 years, lived in the catchment area of primary care clinics, possessed a mobile phone for personal use, had public health coverage, and a 10-year CVD risk ≥10%. In the control arm, community health workers screened for CVD risk using a paper-based tool and encouraged high-risk people to present to the primary care clinics for care. In the intervention arm, community health workers used the mH ealth tool to calculate CVD risk and confirm a scheduled physician appointment. Primary outcomes were the proportion of participants who attended a baseline visit and completed at least 1 follow-up, respectively. We enrolled 755 people (376 interventions; 379 controls). Intervention participants were significantly more likely to complete baseline visits (49.4% versus 13.5%, P value 0.0008) and follow-up visits (31.9% versus 7.7%; P value 0.0041). The use of chronic medication and current smoking were significant predictors of primary outcomes. Conclusions Use of mH ealth tools identifies patients at high CVD risk in their home, increases the likelihood of participating in chronic CVD risk factor management, and strengthens referrals. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 02913339.",2019,"Intervention participants were significantly more likely to complete baseline visits (49.4% versus 13.5%, P value 0.0008) and follow-up visits (31.9% versus 7.7%; P value 0.0041).","['We enrolled 755 people (376 interventions; 379 controls', 'Eligible people were aged 40 to 79 years, lived in the catchment area of primary care clinics, possessed a mobile phone for personal use, had public health coverage, and a 10-year CVD risk ≥10', 'encourages patients to attend visits at primary care clinics to improve CVD risk management in 2 provinces of Argentina', 'People With Public Health Insurance and High Cardiovascular Disease Risk in Argentina']","['intervention or control', 'integrated mH ealth tool']",['complete baseline visits'],"[{'cui': 'C4517872', 'cui_str': 'Seven hundred and fifty-five'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0007403', 'cui_str': 'Health Service Area'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic (environment)'}, {'cui': 'C1136360', 'cui_str': 'Mobile Phone'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0052080', 'cui_str': '3-((phenylacetyl)amino)-2,6-piperidinedione'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0035649', 'cui_str': 'Risk Management'}, {'cui': 'C0003761', 'cui_str': 'Argentina'}, {'cui': 'C0021672', 'cui_str': 'Insurance'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}]","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]",755.0,0.0872107,"Intervention participants were significantly more likely to complete baseline visits (49.4% versus 13.5%, P value 0.0008) and follow-up visits (31.9% versus 7.7%; P value 0.0041).","[{'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Beratarrechea', 'Affiliation': '1 Department of Chronic Diseases South American Center of Excellence for Cardiovascular Health (CESCAS) Institute for Clinical Effectiveness and Health Policy (IECS) Buenos Aires Argentina.'}, {'ForeName': 'Shafika', 'Initials': 'S', 'LastName': 'Abrahams-Gessel', 'Affiliation': '2 Center for Health Decision Science Harvard T.H. Chan School of Public Health Boston MA.'}, {'ForeName': 'Vilma', 'Initials': 'V', 'LastName': 'Irazola', 'Affiliation': '1 Department of Chronic Diseases South American Center of Excellence for Cardiovascular Health (CESCAS) Institute for Clinical Effectiveness and Health Policy (IECS) Buenos Aires Argentina.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Gutierrez', 'Affiliation': '1 Department of Chronic Diseases South American Center of Excellence for Cardiovascular Health (CESCAS) Institute for Clinical Effectiveness and Health Policy (IECS) Buenos Aires Argentina.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Moyano', 'Affiliation': '1 Department of Chronic Diseases South American Center of Excellence for Cardiovascular Health (CESCAS) Institute for Clinical Effectiveness and Health Policy (IECS) Buenos Aires Argentina.'}, {'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Gaziano', 'Affiliation': '2 Center for Health Decision Science Harvard T.H. Chan School of Public Health Boston MA.'}]",Journal of the American Heart Association,['10.1161/JAHA.118.011799'] 205,30943832,Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.,"Background Hypertension is a known risk factor for heart failure ( HF ), possibly via the mechanism of cardiac remodeling and left ventricular hypertrophy ( LVH ). We studied the extent to which blood pressure ( BP ) change and evolving LVH contribute to the effect that lisinopril, doxazosin, and amlodipine have on HF compared with chlorthalidone. Methods and Results We conducted causal mediation analysis of ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) data (1994-2002; in-trial follow-up). ALLHAT participants with available serial ECG s and BP measurements were included (n=29 892; mean age 67±4 years; 32% black; 56% men): 11 008 were randomized to chlorthalidone, 5967 to doxazosin, 6593 to amlodipine, and 6324 to lisinopril. Evolving ECG LVH and BP lowering served as mediators. Incident symptomatic HF was the primary outcome. Linear regression (for mediator) and logistic regression (for outcome) models were adjusted for mediator-outcome confounders (demographic and clinical characteristics known to be associated both with both LVH /hypertension and HF ). A large majority of participants (96%) had ECG LVH status unchanged, but 4% developed evolving ECG LVH . On average, BP decreased by 11/7 mm Hg. In adjusted Cox regression analyses, progressing ECG LVH (hazard ratio [ HR ] 1.78 [95% CI 1.43-2.22]), resolving ECG LVH ( HR 1.33 [95% CI 1.03-1.70]), and baseline ECG LVH (1.17 [95% CI 1.04-1.31]) carried risk of incident HF . After full adjustment, evolving ECG LVH mediated 4% of the effect of doxazosin on HF . Systolic BP lowering mediated 12% of the effect of doxazosin, and diastolic BP lowering mediated 10% of the effect of doxazosin, 7% of the effect of amlodipine, and borderline 9% of the effect of lisinopril on HF . Conclusions Evolving ECG LVH and BP change account for 4% to 13% of the mechanism by which antihypertensive medications prevent HF . Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00000542.",2019,"A large majority of participants (96%) had ECG LVH status unchanged, but 4% developed evolving ECG LVH .","['n=29\xa0892; mean age 67±4\xa0years; 32% black; 56% men', 'ALLHAT participants with available serial ECG s and BP measurements were included ']","['ALLHAT (Antihypertensive and Lipid-Lowering Treatment', 'lisinopril', 'chlorthalidone', 'doxazosin', 'amlodipine', 'lisinopril, doxazosin, and amlodipine']","['baseline ECG LVH', 'progressing ECG LVH (hazard ratio [ HR ', 'blood pressure ( BP ) change', 'BP', 'Systolic BP', 'ECG LVH status', 'diastolic BP lowering', 'resolving ECG LVH']","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C1623258', 'cui_str': 'ECG'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0003364', 'cui_str': 'Anti-Hypertensive Drugs'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0065374', 'cui_str': 'Lisinopril'}, {'cui': 'C0008294', 'cui_str': 'Chlorthalidone'}, {'cui': 'C0114873', 'cui_str': 'Doxazosin'}, {'cui': 'C0051696', 'cui_str': 'Amlodipine'}]","[{'cui': 'C1623258', 'cui_str': 'ECG'}, {'cui': 'C0149721', 'cui_str': 'Left Ventricular Hypertrophy'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C3714811', 'cui_str': 'Resolved (qualifier value)'}]",,0.24169,"A large majority of participants (96%) had ECG LVH status unchanged, but 4% developed evolving ECG LVH .","[{'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Johnson', 'Affiliation': '1 The Knight Cardiovascular Institute Oregon Health & Science University Portland OR.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Oparil', 'Affiliation': '2 Department of Medicine School of Medicine University of Alabama at Birmingham AL.'}, {'ForeName': 'Barry R', 'Initials': 'BR', 'LastName': 'Davis', 'Affiliation': '3 University of Texas School of Public Health Houston TX.'}, {'ForeName': 'Larisa G', 'Initials': 'LG', 'LastName': 'Tereshchenko', 'Affiliation': '1 The Knight Cardiovascular Institute Oregon Health & Science University Portland OR.'}]",Journal of the American Heart Association,['10.1161/JAHA.119.011961'] 206,32314290,The effect of Zataria multiflora on inflammatory cytokine and respiratory symptoms in veterans exposed to sulfur mustard.,"The effect of Zataria multiflora (Z. multiflora) on serum cytokine, chemokines, and respiratory symptoms in the veterans exposed to sulfur mustard (SM) more than two decades (27-30 years) ago was conducted in 2018. Thirty-four patients were randomly assigned to the placebo group (P, mean age (54.40 ± 5.51)) and two treated groups with Z. multiflora extract 5 and 10 mg/kg/day (Z5 and 10; mean age, 58.50 ± 3.60 and 55.18 ± 4.11, respectively). Serum levels of tumor necrosis factor (TNF-α), monocyte chemotactic protein 1 (MCP-1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), forced expiratory volume-one second (FEV 1 ), and respiratory symptoms including chest wheeze (CW), night wheeze (NW), night cough (NC), and cough and wheeze during exercise (ECW) were assessed at the baseline (phase 0), 1 and 2 months after starting treatment (phase I and II, respectively). The value of FEV 1 was significantly increased in Z10 in phase I and II compared with that in phase 0 (p < 0.01 for both) and in Z5 in phase II compared with phase I and 0 (p < 0.001for both). All respiratory symptoms significantly decreased in Z5 and 10 in phase I and II compared with those in phase 0 (p < 0.05 to p < 0.001). Serum levels of TNF-α and VEGF were decreased in Z5 and 10 in phase I and II compared with those in phase 0 (p < 0.05 to p < 0.001). Serum levels of MCP-1 and EGF were decreased in Z10 in phase I and II compared with those in phase 0 (p < 0.05 to p < 0.001). The percent change of respiratory symptoms, serum levels of cytokines during the treatment period, was significantly improved in the treated groups compared with that in the placebo group. Two months' of treatment with Z. multiflora improved cytokine levels, respiratory symptom, and FEV 1 values in SM-exposed patients.",2020,"Serum levels of tumor necrosis factor (TNF-α), monocyte chemotactic protein 1 (MCP-1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), forced expiratory volume-one second (FEV 1 ), and respiratory symptoms including chest wheeze (CW), night wheeze (NW), night cough (NC), and cough and wheeze during exercise (ECW) were assessed at the baseline (phase 0), 1 and 2 months after starting treatment (phase I and II, respectively).","['veterans exposed to sulfur mustard (SM) more than two decades (27-30\xa0years) ago was conducted in 2018', 'Thirty-four patients', 'veterans exposed to sulfur mustard']","['Zataria multiflora', 'Zataria multiflora (Z. multiflora', 'placebo']","['value of FEV 1', 'cytokine levels, respiratory symptom, and FEV 1 values', 'respiratory symptoms, serum levels of cytokines', 'inflammatory cytokine and respiratory symptoms', 'serum cytokine, chemokines, and respiratory symptoms', 'All respiratory symptoms', 'Serum levels of TNF-α and VEGF', 'Serum levels of MCP-1 and EGF', 'Serum levels of tumor necrosis factor (TNF-α), monocyte chemotactic protein 1 (MCP-1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), forced expiratory volume-one second (FEV 1 ), and respiratory symptoms including chest wheeze (CW), night wheeze (NW), night cough (NC), and cough and wheeze during exercise (ECW']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0026874', 'cui_str': 'Mustard gas'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0003023', 'cui_str': 'Angola'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0037090', 'cui_str': 'Respiratory symptom'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0282554', 'cui_str': 'Cytokines, Chemotactic'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0128897', 'cui_str': 'Monocyte Chemoattractant Protein-1'}, {'cui': 'C0242275', 'cui_str': 'Epidermal Growth Factor'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0043144', 'cui_str': 'Wheezing'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0587107', 'cui_str': 'During exercise'}]",34.0,0.0320334,"Serum levels of tumor necrosis factor (TNF-α), monocyte chemotactic protein 1 (MCP-1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), forced expiratory volume-one second (FEV 1 ), and respiratory symptoms including chest wheeze (CW), night wheeze (NW), night cough (NC), and cough and wheeze during exercise (ECW) were assessed at the baseline (phase 0), 1 and 2 months after starting treatment (phase I and II, respectively).","[{'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Khazdair', 'Affiliation': 'Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.'}, {'ForeName': 'Fariba', 'Initials': 'F', 'LastName': 'Rezaeetalab', 'Affiliation': 'COPD Research Center, Department of Internal Medicine, Imam-Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Houshang', 'Initials': 'H', 'LastName': 'Rafatpanah', 'Affiliation': 'Department of Immunology, Immunology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mohammad Hossein', 'Initials': 'MH', 'LastName': 'Boskabady', 'Affiliation': 'Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran. boskabadymh@mums.ac.ir.'}]",Environmental science and pollution research international,['10.1007/s11356-020-08855-5'] 207,31183750,"Strength training and protein supplementation improve muscle mass, strength, and function in mobility-limited older adults: a randomized controlled trial.","BACKGROUND Adaptation to strength training in very old mobility-limited individuals is not fully characterized. Therefore, the aim of this study was to perform a thorough investigation of the adaptation to a lower body strength training regime in this population, with particular emphasis on the relationship between changes in selected variables. METHODS Twenty-two mobility-limited older men and women (85 ± 6 years) were randomized to either a group performing 30 min of heavy-load strength training three times a week, with daily protein supplementation, for 10 weeks (ST), or a control group. End points were leg lean mass assessed by DXA, muscle thickness assessed by ultrasound, isometric and dynamic strength, rate of torque development, and functional capacity. RESULTS Leg lean mass increased from baseline in ST (0.7 ± 0.3 kg), along with increased thickness of vastus lateralis (4.4 ± 3.2%), rectus femoris (6.7 ± 5.1%), and vastus intermedius (5.8 ± 5.9%). The hypertrophy was accompanied by improved knee extensor strength (20-23%) and functional performance (7-11%). In ST, neither the change in leg lean mass nor muscle thickness correlated with changes in muscle strength. However, a strong correlation was observed between the change in isometric strength and gait velocity (r = 0.70). CONCLUSIONS The mismatch between gains in muscle size and strength suggests that muscle quality-related adaptations contributed to the increases in strength. The correlations observed between improvements in strength and function suggests that interventions eliciting large improvements in strength may also be superior in terms of functional gains in this population.",2020,The hypertrophy was accompanied by improved knee extensor strength (20-23%) and functional performance (7-11%).,"['mobility-limited older adults', 'Twenty-two mobility-limited older men and women (85\u2009±\u20096\xa0years']","['Strength training and protein supplementation', 'group performing 30\xa0min of heavy-load strength training three times a week, with daily protein supplementation, for 10\xa0weeks (ST), or a control group', 'strength training']","['knee extensor strength', 'leg lean mass assessed by DXA, muscle thickness assessed by ultrasound, isometric and dynamic strength, rate of torque development, and functional capacity', 'functional performance', 'thickness of vastus lateralis', 'Leg lean mass', 'isometric strength and gait velocity', 'leg lean mass nor muscle thickness', 'muscle mass, strength, and function']","[{'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0439801', 'cui_str': 'Limited (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4284772', 'cui_str': '22 (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0770246', 'cui_str': 'Protein supplement'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0376590', 'cui_str': 'Torque'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C3853978'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle (finding)'}, {'cui': 'C0031843', 'cui_str': 'function'}]",,0.0248789,The hypertrophy was accompanied by improved knee extensor strength (20-23%) and functional performance (7-11%).,"[{'ForeName': 'Sigve Nyvik', 'Initials': 'SN', 'LastName': 'Aas', 'Affiliation': 'Department of Physical Performance, Norwegian School of Sport Sciences, Oslo, Norway. s.n.aas@nih.no.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Seynnes', 'Affiliation': 'Department of Physical Performance, Norwegian School of Sport Sciences, Oslo, Norway.'}, {'ForeName': 'Haakon B', 'Initials': 'HB', 'LastName': 'Benestad', 'Affiliation': 'Section of Anatomy, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Truls', 'Initials': 'T', 'LastName': 'Raastad', 'Affiliation': 'Department of Physical Performance, Norwegian School of Sport Sciences, Oslo, Norway.'}]",Aging clinical and experimental research,['10.1007/s40520-019-01234-2'] 208,32251729,The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design.,"OBJECTIVE Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colchicine in COVID-19 complications prevention. METHODS Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) and clinical picture that involves temperature >37.5 oC and at least two out of the: i. sustained coughing, ii. sustained throat pain, iii. Anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2<95 mmHg will be included. Patients will be randomised (1:1) in colchicine or control group. RESULTS Trial results will be disseminated through peer-reviewed publications and conference presentations. CONCLUSION GRECCO-19 trial aims to identify whether colchicine may positively intervene in the clinical course of COVID-19. (ClinicalTrials.gov Identifier: NCT04326790).",2020,"Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) and clinical picture that involves temperature >37.5 oC and at least two out of the: i. sustained coughing, ii. sustained throat pain, iii.",['Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR'],"['colchicine', 'Colchicine']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0599161', 'cui_str': 'Polymerase Chain Reaction, Reverse Transcriptase'}]","[{'cui': 'C0009262', 'cui_str': 'Colchicine'}]",[],,0.120551,"Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) and clinical picture that involves temperature >37.5 oC and at least two out of the: i. sustained coughing, ii. sustained throat pain, iii.","[{'ForeName': 'Spyridon G', 'Initials': 'SG', 'LastName': 'Deftereos', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece. Electronic address: spdeftereos@gmail.com.'}, {'ForeName': 'Gerasimos', 'Initials': 'G', 'LastName': 'Siasos', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Giannopoulos', 'Affiliation': 'General Hospital of Athens ""G.Gennimatas"" Hospital, Athens, Greece.'}, {'ForeName': 'Dimitrios A', 'Initials': 'DA', 'LastName': 'Vrachatis', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece; Humanitas Clinical and Research Institute, Rozzano, Milan, Italy.'}, {'ForeName': 'Christos', 'Initials': 'C', 'LastName': 'Angelidis', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Sotiria G', 'Initials': 'SG', 'LastName': 'Giotaki', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Panagiotis', 'Initials': 'P', 'LastName': 'Gargalianos', 'Affiliation': 'Athens Medical Center, Athens, Greece.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Giamarellou', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece; Therapeutirion Hygeia, Athens, Greece.'}, {'ForeName': 'Charalampos', 'Initials': 'C', 'LastName': 'Gogos', 'Affiliation': 'Medical School, University of Patras, Patra, Greece.'}, {'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Daikos', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece; Mitera Hospital, Athens, Greece.'}, {'ForeName': 'Marios', 'Initials': 'M', 'LastName': 'Lazanas', 'Affiliation': 'Metropolitan General Hospital, Athens, Greece.'}, {'ForeName': 'Pagona', 'Initials': 'P', 'LastName': 'Lagiou', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Saroglou', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece; Metropolitan Hospital, Athens, Greece.'}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Sipsas', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Sotirios', 'Initials': 'S', 'LastName': 'Tsiodras', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Dimitrios', 'Initials': 'D', 'LastName': 'Chatzigeorgiou', 'Affiliation': 'Hellenic Air Force General Staff.'}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Moussas', 'Affiliation': 'Athens Medical Center, Athens, Greece.'}, {'ForeName': 'Anastasia', 'Initials': 'A', 'LastName': 'Kotanidou', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Koulouris', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Evangelos', 'Initials': 'E', 'LastName': 'Oikonomou', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Kaoukis', 'Affiliation': 'General Hospital of Athens ""G.Gennimatas"" Hospital, Athens, Greece.'}, {'ForeName': 'Charalampos', 'Initials': 'C', 'LastName': 'Kossyvakis', 'Affiliation': 'General Hospital of Athens ""G.Gennimatas"" Hospital, Athens, Greece.'}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Raisakis', 'Affiliation': 'General Hospital of Athens ""G.Gennimatas"" Hospital, Athens, Greece.'}, {'ForeName': 'Katerina', 'Initials': 'K', 'LastName': 'Fountoulaki', 'Affiliation': 'General Hospital of Elefsina ""Thriasio"", Elefsina, Greece.'}, {'ForeName': 'Mihalis', 'Initials': 'M', 'LastName': 'Comis', 'Affiliation': 'General Hospital of Elefsina ""Thriasio"", Elefsina, Greece.'}, {'ForeName': 'Dimitrios', 'Initials': 'D', 'LastName': 'Tsiachris', 'Affiliation': 'Athens Medical Center, Athens, Greece.'}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Sarri', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Theodorakis', 'Affiliation': 'Missolonghi General Hospital ""Chatzikosta"", Missolonghi, Greece.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Martinez-Dolz', 'Affiliation': 'Hospital Universitario y Politécnico La Fe, Valencia, Spain.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Sanz-Sánchez', 'Affiliation': 'Humanitas Clinical and Research Institute, Rozzano, Milan, Italy; Hospital Universitario y Politécnico La Fe, Valencia, Spain.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Reimers', 'Affiliation': 'Humanitas Clinical and Research Institute, Rozzano, Milan, Italy.'}, {'ForeName': 'Giulio G', 'Initials': 'GG', 'LastName': 'Stefanini', 'Affiliation': 'Humanitas Clinical and Research Institute, Rozzano, Milan, Italy.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Cleman', 'Affiliation': 'Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Dimitrios', 'Initials': 'D', 'LastName': 'Filippou', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Christoforos D', 'Initials': 'CD', 'LastName': 'Olympios', 'Affiliation': 'General Hospital of Elefsina ""Thriasio"", Elefsina, Greece.'}, {'ForeName': 'Vlasios N', 'Initials': 'VN', 'LastName': 'Pyrgakis', 'Affiliation': 'General Hospital of Athens ""G.Gennimatas"" Hospital, Athens, Greece.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Goudevenos', 'Affiliation': 'University of Ioannina, Ioannina, Greece.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Hahalis', 'Affiliation': 'Medical School, University of Patras, Patra, Greece.'}, {'ForeName': 'Theofilos M', 'Initials': 'TM', 'LastName': 'Kolettis', 'Affiliation': 'University of Ioannina, Ioannina, Greece.'}, {'ForeName': 'Efstathios', 'Initials': 'E', 'LastName': 'Iliodromitis', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Dimitrios', 'Initials': 'D', 'LastName': 'Tousoulis', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Christodoulos', 'Initials': 'C', 'LastName': 'Stefanadis', 'Affiliation': 'Medical School, National & Kapodistrian University of Athens, Athens, Greece; Athens Medical Center, Athens, Greece.'}]",Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese,['10.1016/j.hjc.2020.03.002'] 209,32302261,The Effects of Different Sources of Stuttering Disclosure on the Perceptions of a Child Who Stutters.,"Purpose This study measured between-group differences in perceived speech skills and personality characteristics of a 12-year-old boy who stutters as a function of a factual stuttering disclosure statement, delivered by the boy who stutters, his ""mother,"" or his ""teacher."" Method Two hundred seventeen college-aged adults were randomly assigned to one of four groups, including a control group (no stuttering disclosure) and three experimental groups (child disclosure, mother disclosure, and teacher disclosure). Participants in the control condition viewed a brief video of a 12-year-old boy who stutters. For the experimental conditions, participants viewed a brief factual stuttering disclosure video (delivered by the child, mother, or teacher), followed by the same minute-long video of a boy who stutters used in the control condition. Following the videos, participants completed surveys relative to their perception of the boy's speech skills and personality characteristics. Results Results support previous research citing benefits of stuttering disclosure. Significant between-group differences in both perceived speech skills and personality characteristics were observed when stuttering was disclosed by not only the child who stutters but also his teacher. When stuttering was disclosed by the mother, limited positive attitudinal differences were observed in speech skills; as a matter of fact, a number of personality characteristics were perceived more negatively as a function of stuttering disclosure by the mother. Conclusions While results were generally most positive when the boy disclosed his own stuttering, data from this study support the efficacy of verbal stuttering disclosure provided by a teacher as a means of improving perceptions associated with stuttering. Accordingly, data support the notion that children who stutter will experience an improved quality of life when taught effective self-disclosure strategies by both parents and professionals, and that professionals (but not necessarily parents) can effectively disclose their clients' stuttering during this mentorship and self-advocacy process.",2020,Significant between-group differences in both perceived speech skills and personality characteristics were observed when stuttering was disclosed by not only the child who stutters but also his teacher.,"['12-year-old boy who stutters as a function of a factual stuttering disclosure statement, delivered by the boy who stutters, his ""mother,"" or his ""teacher', 'Participants in the control condition viewed a brief video of a 12-year-old boy who stutters', 'Method Two hundred seventeen college-aged adults']","['control group (no stuttering disclosure) and three experimental groups (child disclosure, mother disclosure, and teacher disclosure']","['speech skills', 'quality of life', 'perceived speech skills and personality characteristics']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0038506', 'cui_str': 'Stuttering'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0012625', 'cui_str': 'Information Disclosure'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038506', 'cui_str': 'Stuttering'}, {'cui': 'C0012625', 'cui_str': 'Information Disclosure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}]","[{'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0233849', 'cui_str': 'Character trait finding'}]",217.0,0.026744,Significant between-group differences in both perceived speech skills and personality characteristics were observed when stuttering was disclosed by not only the child who stutters but also his teacher.,"[{'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Snyder', 'Affiliation': 'Department of Communication Sciences & Disorders, The University of Mississippi, University.'}, {'ForeName': 'Molly Grace', 'Initials': 'MG', 'LastName': 'Williams', 'Affiliation': 'Department of Communication Sciences & Disorders, The University of Mississippi, University.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Adams', 'Affiliation': 'School of Behavioral and Brain Sciences, The University of Texas at Dallas, Richardson.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Blanchet', 'Affiliation': 'Department of Communication Sciences and Disorders, Baylor University, Waco, TX.'}]","Language, speech, and hearing services in schools",['10.1044/2020_LSHSS-19-00059'] 210,32272923,The impact of motivational interviewing on relapse to substance use among women in Iran: a randomized clinical trial.,"BACKGROUND Women in Iran are in great need of effective substance abuse services. The current study was conducted to investigate the effectiveness of motivational interviewing (MI) for women in treatment for drug use in Iran. METHOD The sample (N = 60) included women in a drug treatment center in Qazvin (Iran) from August to December of 2017. The research sample included 60 female drug users randomly assigned to MI or Standard Care (SC). Prior to randomization women completed a baseline questionnaire and the Relapse Prediction Scale (RPS), which measures desire (urge) to use and probability of using/not using in risky situations (self-efficacy). MI consisted of eight 60-min group sessions over a 1-month period, twice weekly. At 2-months follow-up, data were gathered using a questionnaire similar to baseline. Mixed Model Analysis were used to determine group differences. RESULTS Mean age of participants was 30 years and average addiction duration was 7 years. Although the scores of the desire to use and the probability of drug use were not significant before the intervention, after the intervention, scores on desire to use and probability of use improved about 81.1% (F: 2230.15, P < 0.001, degrees of freedom: 63, 15) and 81.9%, (F: 749.39, P < 0.001, degrees of freedom: 79, 77), respectively, compared to those of control group. CONCLUSION The results showed that motivational interviewing could decrease desire to use and probability of use among female drug users. Motivational interviewing could play an important role in improving women's health in Iran. TRIAL REGISTRATION IRCT registration number: IRCT20140907019077N4 Registration date: 2017-12-12, 1396/09/21 Registration timing: registered_while_recruiting Last update: 2017-12-12, 1396/09/21.",2020,"The current study was conducted to investigate the effectiveness of motivational interviewing (MI) for women in treatment for drug use in Iran. ","['2017-12-12, 1396/09/21', 'women in Iran', 'women in treatment for drug use in Iran', 'The sample (N\u2009=\u200960) included women in a drug treatment center in Qazvin (Iran) from August to December of 2017', '60 female drug users randomly assigned to', ""women's health in Iran"", 'IRCT registration number', 'Mean age of participants was 30\u2009years and average addiction duration was 7\u2009years', 'Women in Iran']","['motivational interviewing', 'Motivational interviewing', 'MI or Standard Care (SC', 'motivational interviewing (MI']","['Relapse Prediction Scale (RPS), which measures desire (urge) to use and probability of using/not using in risky situations (self-efficacy', 'desire to use and probability of use among female drug users', 'scores on desire to use and probability of use']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0449889', 'cui_str': 'Drug used'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1510463', 'cui_str': 'Drug Rehabilitation Centers'}, {'cui': 'C0338666', 'cui_str': 'Misuses drugs'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0080339', 'cui_str': ""Woman's Health""}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0085281', 'cui_str': 'Addiction'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]","[{'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0445107', 'cui_str': 'Not used'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0338666', 'cui_str': 'Misuses drugs'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",60.0,0.0475721,"The current study was conducted to investigate the effectiveness of motivational interviewing (MI) for women in treatment for drug use in Iran. ","[{'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Oveisi', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Metabolic Disease Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.'}, {'ForeName': 'L A R', 'Initials': 'LAR', 'LastName': 'Stein', 'Affiliation': 'Psychology Department, University of RI, Kingston, RI, USA.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Babaeepour', 'Affiliation': 'Department of Midwifery, Faculty of Nursing and Midwifery, Qazvin University of Medical Sciences, Qazvin, Iran.'}, {'ForeName': 'Marzieh', 'Initials': 'M', 'LastName': 'Araban', 'Affiliation': 'Department of Health Education and Promotion, Public Health School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. arabanm@ajums.ac.ir.'}]",BMC psychiatry,['10.1186/s12888-020-02561-9'] 211,31087455,Efficacy of antepartum administration of hepatitis B immunoglobulin in preventing mother-to-child transmission of hepatitis B virus.,"The aim of this study was to investigate the efficacy of antepartum administration of three doses of hepatitis B immunoglobulin (HBIG) in interrupting mother-to-child transmission (MTCT) of hepatitis B virus (HBV). In this trial, a total of 728 HBeAg-positive pregnant women with chronic HBV infection who had an HBV DNA level higher than 6log 10  copies/mL were enrolled. They were divided into three groups based on individual preference. Subjects in group A and group B received 200 IU (unit) HBIG and 400 IU (unit) HBIG intramuscularly once a month at the third, second and first month before delivery, respectively. Subjects in the control group (C) received no special treatment. All the infants received passive-active immunoprophylaxis. The HBsAg-positive rate of all infants at 7-12 months of age was 5.1% (37/728). Specifically, the HBsAg-positive rate of infants was comparable in all three groups (5.3% vs 5.1% vs 5%, P = 0.988). No significant difference was found in anti-HBs levels between the infants aged 7-12 months in the three groups (P = 0.469). HBV DNA levels of the umbilical cord blood in the HBV-infected group were higher than those in the uninfected group (5.2 vs 3.4log 10  copies/mL, P < 0.001), and these with family history of HBV infection were also higher (45.9% vs 28.5%, P = 0.034). To conclude, administration of passive-active immunoprophylaxis to infants contributed to effective prevention of the MTCT of HBV; extra antepartum administration of HBIG during pregnancy could not decrease the rate of MTCT or increase the anti-HBs levels of infants born to HBsAg-positive mothers with HBV DNA higher than 6log 10  copies/mL.",2019,No significant difference was found in anti-HBs levels between the infants aged 7-12 months in the three groups (P = 0.469).,"['interrupting mother-to-child transmission (MTCT) of hepatitis B virus (HBV', '728 HBeAg-positive pregnant women with chronic HBV infection who had an HBV DNA level higher than 6log 10 \xa0copies/mL were enrolled', 'mother-to-child transmission of hepatitis B virus']","['HBIG and 400\xa0IU (unit) HBIG', 'hepatitis B immunoglobulin', 'hepatitis B immunoglobulin (HBIG', 'passive-active immunoprophylaxis', 'no special treatment', '200\xa0IU (unit']","['family history of HBV infection', 'HBV DNA levels of the umbilical cord blood', 'HBsAg-positive rate', 'rate of MTCT', 'anti-HBs levels']","[{'cui': 'C0443239', 'cui_str': 'Interrupted (qualifier value)'}, {'cui': 'C0282474', 'cui_str': 'Mother-to-Child Transmission'}, {'cui': 'C0019169', 'cui_str': 'Hepatitis B Virus'}, {'cui': 'C0019167', 'cui_str': 'e Antigens'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]","[{'cui': 'C0062525', 'cui_str': 'hepatitis B immunoglobin'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0205555', 'cui_str': 'Special (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}]","[{'cui': 'C0241889', 'cui_str': 'Family Medical History'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0162371', 'cui_str': 'Cord Blood'}, {'cui': 'C0149709', 'cui_str': 'HBsAg positive'}, {'cui': 'C0369334', 'cui_str': 'Antibody to hepatitis B surface antigen (substance)'}]",,0.030232,No significant difference was found in anti-HBs levels between the infants aged 7-12 months in the three groups (P = 0.469).,"[{'ForeName': 'Mengyu', 'Initials': 'M', 'LastName': 'Zhao', 'Affiliation': 'Difficult & Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Huaibin', 'Initials': 'H', 'LastName': 'Zou', 'Affiliation': 'Difficult & Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Difficult & Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Sujun', 'Initials': 'S', 'LastName': 'Zheng', 'Affiliation': 'Difficult & Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Zhongping', 'Initials': 'Z', 'LastName': 'Duan', 'Affiliation': 'Difficult & Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.'}]",Journal of viral hepatitis,['10.1111/jvh.13123'] 212,32239737,"Meralgia paresthetica: Nerve stimulator-guided injection with methylprednisolone/lidocaine, a double-blind randomized placebo-controlled study.","BACKGROUND Meralgia paresthetica is a mononeuropathy of the lateral femoral cutaneous nerve. A common therapy is injection with corticosteroids. The goal of this study was to analyze the effect of injection with methylprednisolone/lidocaine vs placebo. METHODS After randomization, 10 patients received a nerve stimulator-guided injection with methylprednisolone/lidocaine, and 10 patients received saline. The primary outcome measure was pain (visual analogue scale, VAS). RESULTS In the placebo group, there was a significant pain reduction (baseline VAS, 6.8; VAS week 12, 4.3; P = .014). The VAS score in the methylprednisolone group did not show a significant reduction (baseline VAS, 7.4; VAS week 12, 4.8; P = .053). There was no significant difference in pain reduction between the groups. CONCLUSIONS We found no objective evidence for benefit from nerve stimulator-guided injection with corticosteroids in meralgia paresthetica, although this study is limited by a small sample size. Future placebo-controlled studies using ultrasound-guided injection are warranted.",2020,"We found no objective evidence for benefit from nerve stimulator-guided injection with corticosteroids in meralgia paraesthetica, although this study is limited by a small sample size.",[],"['methylprednisolone', 'placebo', 'methylprednisolone/lidocaine', 'saline', 'nerve stimulator-guided injection with methylprednisolone/lidocaine']","['VAS score', 'pain (visual analogue scale, VAS', 'pain reduction']",[],"[{'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0582124', 'cui_str': 'Neurostimulator'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",,0.599475,"We found no objective evidence for benefit from nerve stimulator-guided injection with corticosteroids in meralgia paraesthetica, although this study is limited by a small sample size.","[{'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Kloosterziel', 'Affiliation': 'Department of Neurology, Haga Hospital, The Hague, The Netherlands.'}, {'ForeName': 'Dénes L J', 'Initials': 'DLJ', 'LastName': 'Tavy', 'Affiliation': 'Department of Neurology, Haga Hospital, The Hague, The Netherlands.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Arends', 'Affiliation': 'Department of Neurology, Haga Hospital, The Hague, The Netherlands.'}, {'ForeName': 'Joyce M', 'Initials': 'JM', 'LastName': 'Zijdewind', 'Affiliation': 'Department of Neurology, Haga Hospital, The Hague, The Netherlands.'}, {'ForeName': 'Erik W', 'Initials': 'EW', 'LastName': 'van Zwet', 'Affiliation': 'Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands.'}, {'ForeName': 'Paul W', 'Initials': 'PW', 'LastName': 'Wirtz', 'Affiliation': 'Department of Neurology, Haga Hospital, The Hague, The Netherlands.'}]",Muscle & nerve,['10.1002/mus.26877'] 213,31659803,"A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma.","BACKGROUND GB001 is an oral antagonist of the prostaglandin D2 receptor that may inhibit recruitment and activation of airway eosinophils, reducing airway inflammation. OBJECTIVE To assess GB001 safety, efficacy and pharmacokinetics from a Phase 2 study and explore the association between type 2 biomarkers (fractional exhaled nitric oxide and blood eosinophils) and asthma control markers following GB001 administration. METHODS A randomized, placebo-controlled, double-blind study evaluating 36 patients with mild-to-moderate atopic asthma. Patients receiving fluticasone propionate ≤500 mcg/day or equivalent were randomized (2:1) to GB001 (30 mg) or placebo once daily for 28 days. Safety, pharmacokinetics, forced expiratory volume in 1 second, asthma control questionnaire and rescue medication use were assessed. Clinical outcomes were analysed post hoc by baseline fractional exhaled nitric oxide (<35 and ≥35 ppb) and blood eosinophil (<250 and ≥250 cells/µL) subgroups. RESULTS GB001 was well tolerated and rapidly absorbed with a 14.5-hour terminal half-life. Overall, GB001 demonstrated greater improvement relative to placebo in forced expiratory volume in 1 second at Day 28 (102 mL [95% CI: -110, 314]). Greater effects on forced expiratory volume in 1 second were observed in the high baseline fractional exhaled nitric oxide and blood eosinophil subgroups (207 mL [95% CI: -283, 698];133 mL [95% CI: -422, 687], respectively). These effects were observed as early as Day 2 (229 mL [95% CI: -170, 628]; 163 mL [95% CI: -223, 550] for the high baseline fractional exhaled nitric oxide and blood eosinophil subgroups, respectively) and were sustained through treatment completion. CONCLUSION AND CLINICAL RELEVANCE GB001 was well tolerated, with the estimated half-life supporting once-daily (QD) dosing. GB001 may have a rapid and sustained effect on lung function, particularly in patients with type 2 phenotype. Further studies are needed to confirm these findings.",2020,"Overall, GB001 demonstrated greater improvement relative to placebo in forced expiratory volume in 1 second at Day 28 (102 ml [95% CI: -110, 314]).","['Mild to Moderate Asthma', 'patients with Type 2 phenotype', '36 patients with mild to moderate atopic asthma']","['placebo', 'GB001 (30 mg) or placebo', 'DP2 Antagonist GB001', 'fluticasone propionate']","['forced expiratory volume', 'Safety, pharmacokinetics, forced expiratory volume in 1 second, asthma control questionnaire, and rescue medication use', 'GB001 safety, efficacy and pharmacokinetics', 'blood eosinophils']","[{'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1314763', 'cui_str': 'Phenotyping (qualifier value)'}, {'cui': 'C0155877', 'cui_str': 'Allergic asthma (disorder)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}, {'cui': 'C0117996', 'cui_str': 'Fluticasone propionate'}]","[{'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C2919686', 'cui_str': 'Asthma control questionnaire'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil, segmented (cell)'}]",687.0,0.459935,"Overall, GB001 demonstrated greater improvement relative to placebo in forced expiratory volume in 1 second at Day 28 (102 ml [95% CI: -110, 314]).","[{'ForeName': 'Hector', 'Initials': 'H', 'LastName': 'Ortega', 'Affiliation': 'Gossamer Bio Inc, San Diego, CA, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Fitzgerald', 'Affiliation': 'Pieris Pharmaceuticals, Boston, MA, USA.'}, {'ForeName': 'Kartik', 'Initials': 'K', 'LastName': 'Raghupathi', 'Affiliation': 'Gossamer Bio Inc, San Diego, CA, USA.'}, {'ForeName': 'Cindy-Ann', 'Initials': 'CA', 'LastName': 'Tompkins', 'Affiliation': 'Gossamer Bio Inc, San Diego, CA, USA.'}, {'ForeName': 'Jinshan', 'Initials': 'J', 'LastName': 'Shen', 'Affiliation': 'Gossamer Bio Inc, San Diego, CA, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Dittrich', 'Affiliation': 'Gossamer Bio Inc, San Diego, CA, USA.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Pattwell', 'Affiliation': 'Medicines Evaluation Unit, Manchester University Hospital Trust, Manchester, UK.'}, {'ForeName': 'Dave', 'Initials': 'D', 'LastName': 'Singh', 'Affiliation': 'Medicines Evaluation Unit, Manchester University Hospital Trust, Manchester, UK.'}]",Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,['10.1111/cea.13524'] 214,31846558,The effect of three-dimensional visualisation on performance in endoscopic sinus surgery: A clinical training study using surgical navigation for movement analysis in a randomised crossover design.,"OBJECTIVES Endoscopic imaging techniques and endoscopic endonasal surgery (EES) expertise have evolved rapidly. Only few studies have assessed the effect of three-dimensional (3D) endoscopy on endoscopic sinus surgery (ESS). The present study aimed to objectively and subjectively assess the additional value of 3D high-definition (HD) endoscopy in ESS. DESIGN A randomized crossover study of endoscopic surgery performance, using five ESS tasks of varying complexity, performed on Thiel embalmed human specimens. SETTING Simulated surgical environment. PARTICIPANTS Thirty participants, inexperienced in ESS. MAIN OUTCOME MEASURES Performance was assessed using video imaging, surgical navigation and questionnaires. Main outcome measures were as follows: efficiency (defined by time to task completion), distance covered inside the nose, average velocity towards target, accuracy (measured by error rate), and subjective assessment of endoscope characteristics. RESULTS During ESS tasks, both efficiency and accuracy did not differ significantly between 2D HD and 3D HD endoscopy. Subjectively, imaging characteristics of the 3D HD endoscope were rated significantly better. CONCLUSIONS ESS performance of inexperienced participants was not significantly improved by the use of 3D HD endoscopy during ESS tasks, although imaging characteristics of the 3D HD endoscope were rated significantly better. Surgical field characteristics and surgical techniques are likely to influence any additional value of 3D HD endoscopy.",2020,"During endoscopic sinus surgery tasks, both efficiency and accuracy did not differ significantly between 2D HD and 3D HD endoscopy.","['Thirty participants, inexperienced in endoscopic endonasal surgery']","['3D high-definition (HD) endoscopy', 'endoscopic endonasal surgery', 'Endoscopic imaging techniques and endoscopic endonasal surgery (EES', 'three-dimensional visualization', 'endoscopic surgery performance']","['efficiency and accuracy', 'video imaging, surgical navigation and questionnaires, with the main outcome measures being efficiency (defined by time to task completion), distance covered inside the nose, average velocity towards target, accuracy (measured by error rate), and subjective assessment of endoscope characteristics', 'Subjectively, imaging characteristics of the 3D HD endoscope']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C3539107', 'cui_str': 'Definition (core metadata concept)'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0079595', 'cui_str': 'Imaging technique (qualifier value)'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional (qualifier value)'}, {'cui': 'C0282493', 'cui_str': 'Surgical Procedures, Endoscopic'}]","[{'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C1299527', 'cui_str': 'Video imaging'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205225', 'cui_str': 'Principal (qualifier value)'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0439844', 'cui_str': 'Covered (qualifier value)'}, {'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}, {'cui': 'C0028429', 'cui_str': 'Nose'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0014243', 'cui_str': 'Endoscopes'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}]",30.0,0.134157,"During endoscopic sinus surgery tasks, both efficiency and accuracy did not differ significantly between 2D HD and 3D HD endoscopy.","[{'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Ten Dam', 'Affiliation': 'Department of Otorhinolaryngology/Head and Neck Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Herman M', 'Initials': 'HM', 'LastName': 'Helder', 'Affiliation': 'Department of Otorhinolaryngology/Head and Neck Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Bernard F A M', 'Initials': 'BFAM', 'LastName': 'van der Laan', 'Affiliation': 'Department of Otorhinolaryngology/Head and Neck Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Feijen', 'Affiliation': 'Department of Otorhinolaryngology/Head and Neck Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Astrid G W', 'Initials': 'AGW', 'LastName': 'Korsten-Meijer', 'Affiliation': 'Department of Otorhinolaryngology/Head and Neck Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}]",Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery,['10.1111/coa.13494'] 215,30957675,Dynamic Volumetric Computed Tomography Angiography Is a Preferred Method for Unclassified Endoleaks by Conventional Computed Tomography Angiography After Endovascular Aortic Repair.,"Background The aim of this study was to assess the feasibility and safety of dynamic volumetric computed tomography angiography ( DV - CTA ) for endoleaks detected but not classified by conventional CTA in patients after endovascular aortic repair. Methods and Results From January 2016 to October 2017, 24 patients with endoleaks with aneurysm sac enlargement detected but not classified by conventional CTA were randomly assigned to the conventional CTA group and the DV - CTA group for further evaluation. The amount of contrast agent, radiation dosage, and changes in creatinine during the operation were compared between the 2 groups. Reintervention was performed according to the endoleak classification followed by the 6- and 12-month follow-up. The accuracy of classifying endoleaks by DV - CTA was comparable to that by digital subtraction angiography. Additionally, the total amount of contrast agent and the radiation dosage in the DV - CTA group during the operation were diminished by 14.0% ( P=0.007) and 12.1% ( P=0.004), respectively, compared with those in the conventional CTA group. No contrast-induced nephropathy was observed. All endoleaks were treated instantly after identification. No endoleaks were found in any of the patients during follow-up. Conclusions DV - CTA could replace digital subtraction angiography as an alternative method for the classification of endoleaks that cannot be differentiated by conventional CTA . Additionally, the amount of contrast agent and the total radiation dosage were substantially reduced, which improved safety among operators and patients.",2019,No endoleaks were found in any of the patients during follow-up.,"['From January 2016 to October 2017, 24 patients with endoleaks with aneurysm sac enlargement detected but not classified by conventional CTA', 'patients after endovascular aortic repair']","['Conventional Computed Tomography Angiography', 'conventional CTA group and the DV - CTA', 'Dynamic Volumetric Computed Tomography Angiography', 'dynamic volumetric computed tomography angiography ( DV - CTA ']","['total amount of contrast agent and the radiation dosage', 'total radiation dosage']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1504464', 'cui_str': 'Perigraft Leak'}, {'cui': 'C0002940', 'cui_str': 'Aneurysm'}, {'cui': 'C1293134', 'cui_str': 'Enlargement procedure'}, {'cui': 'C0442726', 'cui_str': 'Detected (qualifier value)'}, {'cui': 'C0008902', 'cui_str': 'Systematics'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0003483', 'cui_str': 'Aorta'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0040395', 'cui_str': 'Tomographic imaging'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0445383', 'cui_str': 'Volumetric (qualifier value)'}, {'cui': 'C1536105', 'cui_str': 'Angiography, CT'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0009924', 'cui_str': 'Contrast Agents'}, {'cui': 'C0034524', 'cui_str': 'Radiation Dosage'}]",24.0,0.0141469,No endoleaks were found in any of the patients during follow-up.,"[{'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Hou', 'Affiliation': '1 Department of Radiology Shanghai Institute of Medical Imaging Zhongshan Hospital Fudan University Shanghai China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Zhu', 'Affiliation': '2 Department of Vascular Surgery Zhongshan Hospital Fudan University Shanghai China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': '3 Department of Biostatistics School of Public Health Fudan University Shanghai China.'}, {'ForeName': 'Mengsu', 'Initials': 'M', 'LastName': 'Zeng', 'Affiliation': '1 Department of Radiology Shanghai Institute of Medical Imaging Zhongshan Hospital Fudan University Shanghai China.'}, {'ForeName': 'Daqiao', 'Initials': 'D', 'LastName': 'Guo', 'Affiliation': '2 Department of Vascular Surgery Zhongshan Hospital Fudan University Shanghai China.'}, {'ForeName': 'Weiguo', 'Initials': 'W', 'LastName': 'Fu', 'Affiliation': '2 Department of Vascular Surgery Zhongshan Hospital Fudan University Shanghai China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Si', 'Affiliation': '2 Department of Vascular Surgery Zhongshan Hospital Fudan University Shanghai China.'}]",Journal of the American Heart Association,['10.1161/JAHA.119.012011'] 216,32314514,"Randomized clinical trial: Effects of Aloe barbadensis Mill. extract on symptoms, fecal microbiota and fecal metabolite profiles in patients with irritable bowel syndrome.","BACKGROUND Aloe barbadensis Mill. (Aloe) with potential prebiotic effects has been suggested to reduce symptoms in patients with irritable bowel syndrome (IBS). We therefore aimed to determine the effects of an Aloe extract on symptoms of IBS, and evaluate whether effects may be mediated by fecal microbiota and metabolites in a randomized, double-blind, controlled trial. METHODS Patient with IBS diagnosed according to the ROME III criteria (all subtypes), received Aloe or control treatment (inulin) for 4 weeks. IBS Symptom Severity Score (IBS-SSS) was assessed, and fecal samples collected before and at end of treatment. Fecal microbiota composition and metabolomic profile were determined. KEY RESULTS In total, 160 IBS patients completed the study. The overall severity of IBS symptoms was reduced in both Aloe and control treatment groups (P < .001, both groups, comparing baseline vs end of treatment), without difference between groups (P = .62). The frequency of responders (IBS-SSS reduction ≥ 50) did not differ between Aloe treatment (n = 33, 39%) and control (n = 34, 45%) (P = .49). However, fecal microbiota and metabolite profiles differed between Aloe, but not control treatment responders and non-responders both before and after treatment. CONCLUSION In a mixed group of IBS patients, Aloe was not superior to control treatment, although it showed potential to reduce IBS symptom severity in subsets of IBS patients which could be predicted by fecal microbiota and metabolite profiles. ClinicalTrials.gov no: NCT01400048.",2020,"The overall severity of IBS symptoms was reduced in both Aloe and control treatment groups (P < .001, both groups, comparing baseline vs end of treatment), without difference between groups (P = .62).","['patients with irritable bowel syndrome (IBS', 'patients with irritable bowel syndrome', '160 IBS patients completed the study', 'Patient with IBS diagnosed according to the ROME III criteria (all subtypes), received']","['Aloe extract', 'Aloe barbadensis Mill', 'Aloe or control treatment (inulin']","['IBS Symptom Severity Score (IBS-SSS', 'Fecal microbiota composition and metabolomic profile', 'symptoms, fecal microbiota and fecal metabolite profiles', 'overall severity of IBS symptoms', 'IBS symptom severity', 'fecal microbiota and metabolite profiles']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0035831', 'cui_str': 'Rome'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0449560', 'cui_str': 'Subtype'}]","[{'cui': 'C0304554', 'cui_str': 'Aloe Extract'}, {'cui': 'C0718405', 'cui_str': 'Aloe vera'}, {'cui': 'C0599997', 'cui_str': 'Mill'}, {'cui': 'C0002168', 'cui_str': 'Aloe'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0021936', 'cui_str': 'Inulin'}]","[{'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0037052', 'cui_str': 'Sick sinus syndrome'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C1328813', 'cui_str': 'Metabolomics'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",160.0,0.1365,"The overall severity of IBS symptoms was reduced in both Aloe and control treatment groups (P < .001, both groups, comparing baseline vs end of treatment), without difference between groups (P = .62).","[{'ForeName': 'Bani', 'Initials': 'B', 'LastName': 'Ahluwalia', 'Affiliation': 'Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Maria K', 'Initials': 'MK', 'LastName': 'Magnusson', 'Affiliation': 'Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Böhn', 'Affiliation': 'Calmino Group AB, Gothenburg, Sweden.'}, {'ForeName': 'Stine', 'Initials': 'S', 'LastName': 'Störsrud', 'Affiliation': 'Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Fredrik', 'Initials': 'F', 'LastName': 'Larsson', 'Affiliation': 'Calmino Group AB, Gothenburg, Sweden.'}, {'ForeName': 'Otto', 'Initials': 'O', 'LastName': 'Savolainen', 'Affiliation': 'Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden.'}, {'ForeName': 'Alastair', 'Initials': 'A', 'LastName': 'Ross', 'Affiliation': 'Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Simrén', 'Affiliation': 'Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Öhman', 'Affiliation': 'Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.'}]",Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,['10.1111/nmo.13860'] 217,32223044,"Monomeric Flavanols Are More Efficient Substrates for Gut Microbiota Conversion to Hydroxyphenyl-γ-Valerolactone Metabolites Than Oligomeric Procyanidins: A Randomized, Placebo-Controlled Human Intervention Trial.","SCOPE The majority of ingested flavanols reach the colon where they are catabolized by the microbiota to form hydroxyphenyl-γ-valerolactones (HGVLs). It is not known if the HGVLs are catabolic products of monomeric (epi)catechins (EPC), oligomeric procyanidins (OPCs), or both. Using data from a randomized, double-blind, placebo-controlled crossover trial the relative contributions of catechins and OPC to the bioavailable pool of HGVLs are estimated. METHODS AND RESULTS Participants ingested an apple extract once daily for 28 days that delivered the following: i) 70 mg EPC and 65 mg OPC (low dose EPC), ii) 140 mg EPC and 130 mg OPC (high dose EPC), iii) 6 mg EPC and 130 mg OPC (OPC), and iv) a placebo control. Urine is collected over a 24-h period before and after treatments. The median urinary excretion of HGVLs after ingestion of the high dose EPC is tenfold higher than that excreted after ingestion of the OPC that provided an equivalent dose of PC. Approximately 22% of catechins are converted to HGVLs in contrast to PC, for which there is limited conversion. CONCLUSION Monomeric catechins are efficiently converted to derived HGVLs that are absorbed and excreted in human urine, whereas oligomeric PCs are much less efficiently converted.",2020,The median urinary excretion of HGVL metabolites after ingestion of the high dose EPC was 10-fold higher than that excreted after ingestion of the OPC that provided an equivalent dose of PC.,['Participants ingested an apple extract once daily for 28-d that delivered the following: (i) 70\xa0mg'],"['catechins and 65\xa0mg PC (Low dose EPC', 'Placebo', 'placebo']",['median urinary excretion of HGVL metabolites'],"[{'cui': 'C3257517', 'cui_str': 'Apple extract'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}]","[{'cui': 'C0007404', 'cui_str': 'Catechin'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0169014', 'cui_str': 'erucylphosphocholine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}]",,0.455696,The median urinary excretion of HGVL metabolites after ingestion of the high dose EPC was 10-fold higher than that excreted after ingestion of the OPC that provided an equivalent dose of PC.,"[{'ForeName': 'Wendy J', 'Initials': 'WJ', 'LastName': 'Hollands', 'Affiliation': 'Food Innovation and Health Programme, Quadram Institute Bioscience, Norwich, NR4 7UQ, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Philo', 'Affiliation': 'Food Innovation and Health Programme, Quadram Institute Bioscience, Norwich, NR4 7UQ, UK.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Perez-Moral', 'Affiliation': 'Food Innovation and Health Programme, Quadram Institute Bioscience, Norwich, NR4 7UQ, UK.'}, {'ForeName': 'Paul W', 'Initials': 'PW', 'LastName': 'Needs', 'Affiliation': 'Food Innovation and Health Programme, Quadram Institute Bioscience, Norwich, NR4 7UQ, UK.'}, {'ForeName': 'George M', 'Initials': 'GM', 'LastName': 'Savva', 'Affiliation': 'Core Research Services, Quadram Institute Bioscience, Norwich, NR4 7UQ, UK.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Kroon', 'Affiliation': 'Food Innovation and Health Programme, Quadram Institute Bioscience, Norwich, NR4 7UQ, UK.'}]",Molecular nutrition & food research,['10.1002/mnfr.201901135'] 218,32290739,The clinical outcomes of rituximab biosimilar CT-P10 (Truxima ® ) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience.,"We evaluated real-world effectiveness and safety of CT-P10 (Truxima ® ) compared with originator rituximab in diffuse large B-cell lymphoma (DLBCL) treatment. Before and after the introduction of CT-P10 to our institute (November 2017), 221 newly-diagnosed DLBCL patients received rituximab with standard cyclophosphamide, vincristine, doxorubicin and prednisone. Patients received originator rituximab throughout ( n  = 95), switched from originator rituximab to CT-P10 ( n  = 36), or received CT-P10 throughout ( n  = 90). There were no significant differences between groups in overall response rate (91.6% vs 94.4% vs 96.7%, respectively; p  = 0.403) or complete response rate (84.2% vs 77.8% vs 86.7%, respectively; p  = 0.467). Kaplan-Meier survival curves also showed no significant differences in progression-free survival and overall survival between groups (log-rank p  = 0.794 and p  = 0.955, respectively). Safety profiles were comparable between treatment groups. These data support the ability of CT-P10 to successfully replace originator rituximab in DLBCL treatment and, given the lowered financial barrier, to improve the overall prognosis for DLBCL patients.",2020,"Kaplan-Meier survival curves also showed no significant differences in progression-free survival and overall survival between groups (log-rank p  = 0.794 and p  = 0.955, respectively).","['diffuse large B-cell lymphoma (DLBCL) treatment', 'patients with diffuse large B-cell lymphoma']","['rituximab biosimilar CT-P10 (Truxima ® ) with CHOP', 'rituximab with standard cyclophosphamide, vincristine, doxorubicin and prednisone', 'CT-P10 (Truxima ® ', 'originator rituximab', 'originator rituximab to CT-P10']","['progression-free survival and overall survival', 'overall response rate', 'Safety profiles', 'complete response rate']","[{'cui': 'C0079744', 'cui_str': 'Malignant lymphoma, large B-cell, diffuse'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4287770', 'cui_str': 'CT-P10'}, {'cui': 'C4741331', 'cui_str': 'Truxima'}, {'cui': 'C0055598', 'cui_str': 'CHOP protocol'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}]",,0.0288692,"Kaplan-Meier survival curves also showed no significant differences in progression-free survival and overall survival between groups (log-rank p  = 0.794 and p  = 0.955, respectively).","[{'ForeName': 'Kyoungmin', 'Initials': 'K', 'LastName': 'Lee', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Joo Young', 'Initials': 'JY', 'LastName': 'Ha', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Ah Ra', 'Initials': 'AR', 'LastName': 'Jung', 'Affiliation': 'Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Yoon Sei', 'Initials': 'YS', 'LastName': 'Lee', 'Affiliation': 'Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Sang-Wook', 'Initials': 'SW', 'LastName': 'Lee', 'Affiliation': 'Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jin-Sook', 'Initials': 'JS', 'LastName': 'Ryu', 'Affiliation': 'Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Eun Jin', 'Initials': 'EJ', 'LastName': 'Chae', 'Affiliation': 'Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Kyung Won', 'Initials': 'KW', 'LastName': 'Kim', 'Affiliation': 'Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jooryung', 'Initials': 'J', 'LastName': 'Huh', 'Affiliation': 'Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Chan-Sik', 'Initials': 'CS', 'LastName': 'Park', 'Affiliation': 'Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Dok Hyun', 'Initials': 'DH', 'LastName': 'Yoon', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Cheolwon', 'Initials': 'C', 'LastName': 'Suh', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}]",Leukemia & lymphoma,['10.1080/10428194.2020.1742906'] 219,32298870,The effects of transcranial direct current stimulation on within- and cross-paradigm transfer following multi-session backward recall training.,"Transcranial direct current stimulation (tDCS) has been shown to enhance the efficacy and generalisation of working memory (WM) training, but there has been little systematic investigation into how coupling task-specific WM training with stimulation impacts more specifically on transfer to untrained tasks. This randomised controlled trial investigated the boundary conditions to transfer by testing firstly whether the benefits of training on backward digit recall (BDR) extend to untrained backward recall tasks and n-back tasks with different materials, and secondly which, if any, form of transfer is enhanced by tDCS. Forty-eight participants were allocated to one of three conditions: BDR training with anodal (10 min, 1 mA) or sham tDCS, or visual search training with sham tDCS, applied over the left dorsolateral prefrontal cortex. Transfer was assessed on within- (backward recall with digits, letters, and spatial locations) and cross-paradigm (n-back with digits and letters) transfer tests following three sessions of training and stimulation. On-task training gains were found, with transfer to other backward span but not n-back tasks. There was little evidence that tDCS enhanced on-task training or transfer. These findings indicate that training enhances paradigm-specific processes within WM, but that tDCS does not enhance these gains.",2020,"Transcranial direct current stimulation (tDCS) has been shown to enhance the efficacy and generalisation of working memory (WM) training, but there has been little systematic investigation into how coupling task-specific WM training with stimulation impacts more specifically on transfer to untrained tasks.",['Forty-eight participants'],"['transcranial direct current stimulation', 'Transcranial direct current stimulation (tDCS', 'BDR training with anodal (10\u202fmin, 1\u202fmA) or sham tDCS, or visual search training with sham tDCS']","['backward digit recall (BDR', 'tDCS enhanced on-task training or transfer']","[{'cui': 'C4319608', 'cui_str': '48'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0439781', 'cui_str': 'Backward'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C1172076', 'cui_str': '1-(1-phenylethyl)-2-methyleneaziridine'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0234621', 'cui_str': 'Visual'}]","[{'cui': 'C0439781', 'cui_str': 'Backward'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}]",48.0,0.0236361,"Transcranial direct current stimulation (tDCS) has been shown to enhance the efficacy and generalisation of working memory (WM) training, but there has been little systematic investigation into how coupling task-specific WM training with stimulation impacts more specifically on transfer to untrained tasks.","[{'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Byrne', 'Affiliation': 'MRC Cognition and Brain Sciences Unit, 15 Chaucer Road, University of Cambridge, Cambridge CB2 7EF, UK. Electronic address: emb72@cam.ac.uk.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Ewbank', 'Affiliation': 'MRC Cognition and Brain Sciences Unit, 15 Chaucer Road, University of Cambridge, Cambridge CB2 7EF, UK. Electronic address: m.ewbank@iesohealth.com.'}, {'ForeName': 'Susan E', 'Initials': 'SE', 'LastName': 'Gathercole', 'Affiliation': 'Department of Psychiatry, Douglas House, 18b Trumpington Road, University of Cambridge, Cambridge CB2 8AH, UK. Electronic address: seg57@cam.ac.uk.'}, {'ForeName': 'Joni', 'Initials': 'J', 'LastName': 'Holmes', 'Affiliation': 'MRC Cognition and Brain Sciences Unit, 15 Chaucer Road, University of Cambridge, Cambridge CB2 7EF, UK. Electronic address: joni.holmes@mrc-cbu.cam.ac.uk.'}]",Brain and cognition,['10.1016/j.bandc.2020.105552'] 220,32306076,"Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial.","BACKGROUND Adoptive tumor-infiltrating lymphocytes (TIL) therapy and interleukin-2 (IL-2) have been investigated in melanoma. AIM To confirm previously observed preventive effects of TIL + IL2 in a subgroup of patients with relapsing metastatic stage III melanoma. METHODOLOGY Open-label, randomized two-group, multicenter five-year trial in adult stage III melanoma patients with only one invaded lymph node after complete resection. Patients received TIL + IL2 or abstention. TIL + IL2 was administered within 8 weeks after lymph node resection and 4 weeks after. Disease-free survival was assessed every 2 months up to month 18, every 3 months up to month 36 and every 4 months up to 5 years. A once-a-year follow-up was scheduled beyond the five-year follow-up. Safety was assessed throughout the trial. RESULTS Overall, 49 patients accounted for the modified intent-to-treat and 47 for the PP. Slightly more male than female patients participated; mean age was 57.7 ± 11.4 years in the TIL + IL2 group and 53.5 ± 13.0 years in the abstention group. After 5 years of follow-up, 11/26 patients in the TIL + IL2 group and 13/23 in the abstention group had relapsed. There was no statistical difference between the groups (HR: 0.63 CI 95% [0.28-1.41], p = 0.258), nine patients in the TIL + IL2 and 11 in the abstention group died with no significant difference between the two groups (HR: 0.65 CI95% [0.27 - 1.59], p = 0.34). Safety was good. CONCLUSION We did not confirm results of a previous trial. However, ulceration of the primary melanoma may be considered predictive of the efficacy of TIL in melanoma in adjuvant setting, in a manner similar to interferon α.",2020,"There was no statistical difference between the groups (HR: 0.63 CI 95% [0.28-1.41], p = 0.258), nine patients in the TIL + IL2 and 11 in the abstention group died with no significant difference between the two groups (HR: 0.65 CI95% [0.27 - 1.59], p = 0.34).","['stage III melanoma patients with only one invaded lymph node after complete resection', 'patients with relapsing metastatic stage III melanoma', 'Slightly more male than female patients participated; mean age was 57.7\u2009±\u200911.4\xa0years in the TIL\u2009+\u2009IL2 group and 53.5\u2009±', 'adult stage III melanoma patients with only one invaded lymph node after complete resection']","['Adoptive tumor-infiltrating lymphocytes (TIL) therapy and interleukin-2 (IL-2', 'TIL\u2009+\u2009IL2', 'TIL\u2009', 'TIL\u2009+\u2009IL2 or abstention']","['Disease-free survival', 'Safety']","[{'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024204', 'cui_str': 'Structure of lymph node'}, {'cui': 'C0015250', 'cui_str': 'Complete excision'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0750482', 'cui_str': 'Slightly'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517533', 'cui_str': '11.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0079722', 'cui_str': 'Tumor-Infiltrating Lymphocytes'}, {'cui': 'C0021756', 'cui_str': 'Interleukin-2'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0079722', 'cui_str': 'Tumor-Infiltrating Lymphocytes'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0021756', 'cui_str': 'Interleukin-2'}]","[{'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.119467,"There was no statistical difference between the groups (HR: 0.63 CI 95% [0.28-1.41], p = 0.258), nine patients in the TIL + IL2 and 11 in the abstention group died with no significant difference between the two groups (HR: 0.65 CI95% [0.27 - 1.59], p = 0.34).","[{'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Khammari', 'Affiliation': 'Dermato-cancérology Department, CHU Nantes, CIC 1413, CRCINA, INSERM, University of Nantes, CHU Nantes-Hôtel-Dieu, 1 Place Alexis Ricordeau, 44093, Nantes Cedex 01, France.'}, {'ForeName': 'Jean-Michel', 'Initials': 'JM', 'LastName': 'Nguyen', 'Affiliation': 'SEME, PHU11, Saint-Jacques Hospital, CRCINA, INSERM, University of Nantes, Nantes, France.'}, {'ForeName': 'Marie-Thérèse', 'Initials': 'MT', 'LastName': 'Leccia', 'Affiliation': 'Department of Dermatology, Allergology and Photobiology, CHU A Michallon, Grenoble, France.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Guillot', 'Affiliation': 'Département of Dermatology, University of Montpellier, CHU de Montpellier, Montpellier, France.'}, {'ForeName': 'Soraya', 'Initials': 'S', 'LastName': 'Saiagh', 'Affiliation': 'UTCG, CHU Nantes, Nantes, France.'}, {'ForeName': 'Marie-Christine', 'Initials': 'MC', 'LastName': 'Pandolfino', 'Affiliation': 'UTCG, CHU Nantes, Nantes, France.'}, {'ForeName': 'Anne-Chantal', 'Initials': 'AC', 'LastName': 'Knol', 'Affiliation': 'CRCINA, INSERM, University of Angers, University of Nantes, Nantes, France.'}, {'ForeName': 'Gaëlle', 'Initials': 'G', 'LastName': 'Quéreux', 'Affiliation': 'Dermato-cancérology Department, CHU Nantes, CIC 1413, CRCINA, INSERM, University of Nantes, CHU Nantes-Hôtel-Dieu, 1 Place Alexis Ricordeau, 44093, Nantes Cedex 01, France.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Chiffolettau', 'Affiliation': 'Pharmacovigilance Department, CHU Nantes, Nantes, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Labarrière', 'Affiliation': 'CRCINA, INSERM, University of Angers, University of Nantes, Nantes, France.'}, {'ForeName': 'Brigitte', 'Initials': 'B', 'LastName': 'Dréno', 'Affiliation': 'Dermato-cancérology Department, CHU Nantes, CIC 1413, CRCINA, INSERM, University of Nantes, CHU Nantes-Hôtel-Dieu, 1 Place Alexis Ricordeau, 44093, Nantes Cedex 01, France. brigitte.dreno@atlanmed.fr.'}]","Cancer immunology, immunotherapy : CII",['10.1007/s00262-020-02572-1'] 221,31804285,A Randomized Trial of Multiple-Patient Simulation Preparation to Improve Novice Nurses' Competence and Self-Efficacy.,"AIM The purpose of the study was to determine best practices for multiple-patient simulation (MPS) preparation and frequency to improve behavioral performance in nursing students. BACKGROUND MPS provides a safe environment for novice nurses to practice priority setting, delegation, and multitasking, but evidence for best practices is needed. METHOD A multisite, blinded, randomized trial was conducted to evaluate the effect of three simulation preparation methods (expert modeling, voice-over PowerPoint, and reading assignments) on students' competence and self-efficacy for providing care to multiple patients in the simulation lab. Participants (n = 73) were enrolled in capstone clinical courses at two schools of nursing. RESULTS Though there was no difference in raw change in competence score among the study groups, there was a statistically significant difference in pretest and posttest scores. The change in self-efficacy did not correlate with the change in competence. CONCLUSION These findings will help educators understand how novice nurses benefit from repeated MPS activities.",2020,"Though there was no difference in raw change in competence score among the study groups, there was a statistically significant difference in pretest and posttest scores.","['nursing students', 'Participants (n = 73) were enrolled in capstone clinical courses at two schools of nursing']","['Multiple-Patient Simulation Preparation', 'three simulation preparation methods (expert modeling, voice-over PowerPoint, and reading assignments']","['behavioral performance', ""students' competence and self-efficacy"", ""Novice Nurses' Competence and Self-Efficacy"", 'raw change in competence score', 'self-efficacy']","[{'cui': 'C0038496', 'cui_str': 'Pupil Nurses'}, {'cui': 'C0449259', 'cui_str': 'Clinical course (attribute)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0028678', 'cui_str': 'nursing care'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0085137', 'cui_str': 'Patient Simulation'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0034754', 'cui_str': 'Reading'}]","[{'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0710283,"Though there was no difference in raw change in competence score among the study groups, there was a statistically significant difference in pretest and posttest scores.","[{'ForeName': 'Ashley E', 'Initials': 'AE', 'LastName': 'Franklin', 'Affiliation': 'About the Authors Ashley E. Franklin, PhD, RN, CNE, CHSE, is an assistant professor, Texas Christian University, Fort Worth, Texas. Stephanie Sideras, PhD, RN, is an assistant professor, Oregon Health & Science University, Portland, Oregon. Caitlin Dodd, MSN, RN, is an assistant professor of professional practice, Texas Christian University. Jeremy Hutson, MSN, RN, is an instructor, Clackamas Community College, Portland, Oregon. This research was made possible by funding from the National League for Nursing Foundation for Nursing Joyce Griffin-Sobel Research Award and from Texas Christian University (Alma and Robert D. Moreton Research Award). For more information, contact Dr. Franklin at a.b.edge@tcu.edu.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Sideras', 'Affiliation': ''}, {'ForeName': 'Caitlin', 'Initials': 'C', 'LastName': 'Dodd', 'Affiliation': ''}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Hutson', 'Affiliation': ''}]",Nursing education perspectives,['10.1097/01.NEP.0000000000000593'] 222,32113011,Effects of dance intervention on frailty among older adults.,"OBJECTIVE The aims of this study were to examine the effects of dance intervention on frailty in pre-frail and frail older persons. DESIGN This is a quasi-experimental, two-group trial. SETTING Older adults living nursing home. PARTICIPANTS Participants aged ≥ 60 years with low physical activity (mean age was 81.8 years; 71 % were female) (N = 66). METHODS Participants allocated to the dance group attended 40 min dance sessions in a nursing home, three times a week for 12-weeks. Participants allocated to the control group maintained their normal daily activities. Assessments were conducted at baseline, 6 weeks, and 12 weeks by researchers blinded to the allocation. Frailty was measured based on Fried criteria. Estimates of frailty between groups over time were calculated using the generalized estimating equations (GEE) and mixed effects models. RESULTS The prevalence of frailty decreased over time in the dance group compared to the control group (P = 0.002). The mean frailty scores decreased 0.69 at 6 weeks and 1.06 at 12 weeks. Compared to the control group, the prevalence of slowness (p = 0.002), weakness (p = 0.005), and low physical activity (p < 0.001) significantly decreased in the dance group. CONCLUSIONS Dance intervention may reduce the presence and severity of frailty in older adults. Slowness and low physical activity improve following 12 weeks of dance intervention.",2020,The prevalence of frailty decreased over time in the dance group compared to the control group (P = 0.002).,"['Participants aged ≥ 60 years with low physical activity (mean age was 81.8 years; 71 % were female', 'Older adults living nursing home', 'older adults', 'pre-frail and frail older persons']","['dance intervention', 'control group maintained their normal daily activities', 'dance group attended 40 min dance sessions']","['prevalence of frailty', 'Slowness and low physical activity', 'prevalence of slowness', 'weakness', 'low physical activity', 'mean frailty scores']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028688', 'cui_str': 'Nursing Homes'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}]","[{'cui': 'C0010963', 'cui_str': 'Dancing'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}]","[{'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C3714552', 'cui_str': 'Weakness - general'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0268148,The prevalence of frailty decreased over time in the dance group compared to the control group (P = 0.002).,"[{'ForeName': 'Xiangfei', 'Initials': 'X', 'LastName': 'Meng', 'Affiliation': 'School of Nursing, Jilin University, Changchun, China.'}, {'ForeName': 'Guichen', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'School of Nursing, Jilin University, Changchun, China.'}, {'ForeName': 'Guangwei', 'Initials': 'G', 'LastName': 'Zhang', 'Affiliation': 'Respiratory Department of the First Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Huiru', 'Initials': 'H', 'LastName': 'Yin', 'Affiliation': 'School of Nursing, Jilin University, Changchun, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Jia', 'Affiliation': 'School of Nursing, Jilin University, Changchun, China.'}, {'ForeName': 'Shuo', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'School of Nursing, Jilin University, Changchun, China.'}, {'ForeName': 'Binghan', 'Initials': 'B', 'LastName': 'Shang', 'Affiliation': 'School of Nursing, Jilin University, Changchun, China.'}, {'ForeName': 'Chunyan', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'The First Hospital of Jilin University, Changchun, China. Electronic address: fengshe738@sohu.com.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'School of Nursing, Jilin University, Changchun, China; Department of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, China. Electronic address: chen_care@126.com.'}]",Archives of gerontology and geriatrics,['10.1016/j.archger.2019.104001'] 223,31443102,Colonization by B. infantis EVC001 modulates enteric inflammation in exclusively breastfed infants.,"BACKGROUND Infant gut dysbiosis, often associated with low abundance of bifidobacteria, is linked to impaired immune development and inflammation-a risk factor for increased incidence of several childhood diseases. We investigated the impact of B. infantis EVC001 colonization on enteric inflammation in a subset of exclusively breastfed term infants from a larger clinical study. METHODS Stool samples (n = 120) were collected from infants randomly selected to receive either 1.8 × 10 10 CFU B. infantis EVC001 daily for 21 days (EVC001) or breast milk alone (controls), starting at day 7 postnatal. The fecal microbiome was analyzed using 16S ribosomal RNA, proinflammatory cytokines using multiplexed immunoassay, and fecal calprotectin using ELISA at three time points: days 6 (Baseline), 40, and 60 postnatal. RESULTS Fecal calprotectin concentration negatively correlated with Bifidobacterium abundance (P < 0.0001; ρ = -0.72), and proinflammatory cytokines correlated with Clostridiaceae and Enterobacteriaceae, yet negatively correlated with Bifidobacteriaceae abundance. Proinflammatory cytokines were significantly lower in EVC001-fed infants on days 40 and 60 postnatally compared to baseline and compared to control infants. CONCLUSION Our findings indicate that gut dysbiosis (absence of B. infantis) is associated with increased intestinal inflammation. Early addition of EVC001 to diet represents a novel strategy to prevent enteric inflammation during a critical developmental phase.",2019,"Proinflammatory cytokines were significantly lower in EVC001-fed infants on days 40 and 60 postnatally compared to baseline and compared to control infants. ","['exclusively breastfed infants', 'Stool samples (n\u2009=\u2009120']","['CFU B. infantis EVC001 daily for 21 days (EVC001) or breast milk alone (controls), starting at day 7 postnatal']","['Proinflammatory cytokines', 'intestinal inflammation', 'fecal microbiome', 'Fecal calprotectin concentration', 'enteric inflammation', 'proinflammatory cytokines']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1550661', 'cui_str': 'Feces specimen'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0026140', 'cui_str': 'Breast Milk'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0443281', 'cui_str': 'Postnatal (qualifier value)'}]","[{'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C3889047', 'cui_str': 'Intestinal inflammation'}, {'cui': 'C1956108', 'cui_str': 'Microbiome'}, {'cui': 'C1964053', 'cui_str': 'Faecal calprotectin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",1010.0,0.0603489,"Proinflammatory cytokines were significantly lower in EVC001-fed infants on days 40 and 60 postnatally compared to baseline and compared to control infants. ","[{'ForeName': 'Bethany M', 'Initials': 'BM', 'LastName': 'Henrick', 'Affiliation': 'Evolve Biosystems, Inc, Davis, CA, USA. bhenrick2@unl.edu.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Chew', 'Affiliation': 'Evolve Biosystems, Inc, Davis, CA, USA.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Casaburi', 'Affiliation': 'Evolve Biosystems, Inc, Davis, CA, USA.'}, {'ForeName': 'Heather K', 'Initials': 'HK', 'LastName': 'Brown', 'Affiliation': 'Evolve Biosystems, Inc, Davis, CA, USA.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Frese', 'Affiliation': 'Evolve Biosystems, Inc, Davis, CA, USA.'}, {'ForeName': 'You', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Morrison Microscopy Core Research Facility, University of Nebraska, Lincoln, NE, USA.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Underwood', 'Affiliation': 'Foods for Health Institute, University of California Davis, Davis, CA, USA.'}, {'ForeName': 'Jennifer T', 'Initials': 'JT', 'LastName': 'Smilowitz', 'Affiliation': 'Foods for Health Institute, University of California Davis, Davis, CA, USA.'}]",Pediatric research,['10.1038/s41390-019-0533-2'] 224,31735487,"Effects of Cognitive Rehabilitation on Cognition, Apathy, Quality of Life, and Subjective Complaints in the Elderly: A Randomized Controlled Trial.","OBJECTIVE To determine the efficacy of a new-generation integrative cognitive rehabilitation (CR) program (Rehacop) on cognition, clinical symptoms, quality of life (QoL), and subjective complaints in the elderly. DESIGN A randomized controlled trial study with a cohort of elderly people over 55 years of age. SETTING Communities of the Basque Country (Spain). PARTICIPANTS A total of 124 elderly participants (aged 79.00 ± 8.85 years) were randomized in the Rehacop group (RG) (n = 62) and control group (CG) (n = 62). INTERVENTION The RG attended 39 CR sessions for 3 months (3 sessions/week, 60-minute/session) with the Rehacop program. The CG performed occupational tasks with the same frequency and duration as the RG. METHODS Participants underwent a neuropsychological assessment at baseline and post-treatment which included cognitive, clinical, and functional tests. In addition, participants and their formal caregivers completed a subjective complaints questionnaire. The data were analyzed according to the intention to treat analysis and with participants who completed the study. This study was registered at clinicaltrials.gov (NCT03435029). RESULTS The RG showed significant improvements compared to the CG in neurocognition (ANCOVA timexgroup interaction effect size (η p 2 )=0.05, 90% confidence interval (CI) = 0.00-0.12). The RG also reduced apathy (η p 2 =0.06, 90% CI = 0.01-0.15) and participants' subjective complaints (η p 2 =0.11, 90% CI = 0.03-0.21) and improved QoL (η p 2 =0.08, 90% CI = 0.01-0.17). CONCLUSIONS Participants who attended the intervention improved their cognition, QoL, and reduced apathy and subjective complaints after treatment. These findings provide a new understanding of the benefits of CR in the elderly.",2020,"The RG showed significant improvements compared to the CG in neurocognition (ANCOVA timexgroup interaction effect size (η p 2 )=0.05, 90% confidence interval (CI) = 0.00-0.12).","['Elderly', 'A total of 124 elderly participants (aged 79.00\xa0±\xa08.85 years', 'elderly people over 55 years of age', 'Participants underwent a neuropsychological assessment at baseline and post-treatment which included cognitive, clinical, and functional tests', 'Communities of the Basque Country (Spain']","['Rehacop group (RG) (n\u202f=\u202f62) and control group (CG', 'new-generation integrative cognitive rehabilitation (CR) program (Rehacop', 'Cognitive Rehabilitation']","['CG in neurocognition (ANCOVA timexgroup interaction effect size', 'QoL', 'cognition, QoL, and reduced apathy and subjective complaints', 'cognition, clinical symptoms, quality of life (QoL), and subjective complaints', 'Cognition, Apathy, Quality of Life, and Subjective Complaints', 'subjective complaints questionnaire', 'subjective complaints']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0337796', 'cui_str': 'Basques (ethnic group)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0037747', 'cui_str': 'Spain'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0687133', 'cui_str': 'Drug Interactions'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0085632', 'cui_str': 'Apathy'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0277786', 'cui_str': 'Presenting complaint'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034380'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",124.0,0.0448712,"The RG showed significant improvements compared to the CG in neurocognition (ANCOVA timexgroup interaction effect size (η p 2 )=0.05, 90% confidence interval (CI) = 0.00-0.12).","[{'ForeName': 'Genoveva', 'Initials': 'G', 'LastName': 'Montoya-Murillo', 'Affiliation': 'Department of Methods and Experimental Psychology, Faculty of Psychology and Education, University of Deusto, Bilbao, Spain.'}, {'ForeName': 'Naroa', 'Initials': 'N', 'LastName': 'Ibarretxe-Bilbao', 'Affiliation': 'Department of Methods and Experimental Psychology, Faculty of Psychology and Education, University of Deusto, Bilbao, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Peña', 'Affiliation': 'Department of Methods and Experimental Psychology, Faculty of Psychology and Education, University of Deusto, Bilbao, Spain.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Ojeda', 'Affiliation': 'Department of Methods and Experimental Psychology, Faculty of Psychology and Education, University of Deusto, Bilbao, Spain. Electronic address: nojeda@deusto.es.'}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2019.10.011'] 225,30963721,Motivational interviewing can support physical activity in elderly patients with diastolic heart failure: results from a pilot study.,"AIMS Patients suffering from heart failure with preserved ejection fraction (HFpEF) report similar symptoms and reduction in quality of life to those with reduced ejection fraction but remain largely untreated. We conducted a preliminary evaluation of the acceptance, feasibility, and efficacy of a motivational interviewing (MI) intervention to support elderly patients suffering from HFpEF in maintaining or starting physical activity. METHODS AND RESULTS At the conclusion of the exercise training in diastolic heart failure parent trial that examined the effects of supervised exercise, patients with HFpEF were offered participation in a two-group pilot study. Based on their preference, consenting patients were assigned to either a 6 month MI intervention group (n = 19) or their physicians' usual care (n = 20). To support participants in increasing and/or maintaining their physical activity, counsellors delivered a mean of 6.5 MI sessions (face to face and via telephone) and also provided a physical activity diary as self-management tool. At baseline and 6 months, we assessed participants' physical activity motivation (Sportbezogene Selbstkonkordanz Scale) and their physical improvements with the 6 min walk test and a cardiopulmonary exercise test. Of the entire sample (N = 39), 46% were female, their mean age was 73, 90% were in New York Heart Association Class II, and the mean ejection fraction was 61.4%. The majority of MI participants rated the intervention as acceptable, 90% perceived MI as helpful in setting specific exercise goals and overcoming barriers concerning physical activity, and 58% considered the physical activity diary as very helpful. Three-quarters of MI participants (79%) reported an increase in their physical activity compared with the previous year. Intervention participants showed a greater increase in median peak VO 2 from baseline to 6 months (baseline: 18.4 mL/kg/min; 6 months: 20.4 mL/kg/min) compared with the control group (baseline: 20.0 mL/kg/min; 6 months: 19.2 mL/kg/min; P = 0.015). There was no significant change in motivation on the Sportbezogene Selbstkonkordanz Scale for either group (MI: 1.7 vs. 3, P = 0.55; control: 4.7 vs. 4, P = 0.26) nor did patients show any significant improvements in the 6 min walk test (MI: 549 vs. 540 m, P = 0.80; control: 572 vs. 580 m, P = 0.37). Counsellors rated the implementation of the MI intervention as feasible. CONCLUSIONS The results from this pilot study suggest that our MI intervention was well accepted by participants and deemed feasible. It also appears to be an effective treatment to increase and maintain physical activity and exercise capacity in patients suffering from HFpEF. Our findings need to be confirmed in a randomized clinical trial with larger and unselected patient cohorts.",2019,"There was no significant change in motivation on the Sportbezogene Selbstkonkordanz Scale for either group (MI: 1.7 vs. 3, P = 0.55; control: 4.7 vs. 4, P = 0.26) nor did patients show any significant improvements in the 6 min walk test (MI: 549 vs. 540 m, P = 0.80; control: 572 vs. 580 m, P = 0.37).","['patients with HFpEF', 'Of the entire sample (N\xa0=\xa039), 46% were female, their mean age was 73, 90% were in New York Heart Association Class II, and the mean ejection fraction was 61.4', 'elderly patients suffering from HFpEF in maintaining or starting physical activity', 'Patients suffering from heart failure with preserved ejection fraction (HFpEF', 'patients suffering from HFpEF', 'elderly patients with diastolic heart failure']","['exercise training', ""MI intervention group (n\xa0=\xa019) or their physicians' usual care"", 'motivational interviewing (MI) intervention', 'Motivational interviewing']","['motivation on the Sportbezogene Selbstkonkordanz Scale', 'physical activity', 'physical activity motivation (Sportbezogene Selbstkonkordanz Scale) and their physical improvements with the 6\xa0min walk test and a cardiopulmonary exercise test', 'median peak VO']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439751', 'cui_str': 'Entire (qualifier value)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0441886', 'cui_str': 'Class 2 (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0728887', 'cui_str': 'Preserving (attribute)'}, {'cui': 'C1135196', 'cui_str': 'Heart Failure, Diastolic'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0683474', 'cui_str': 'Motivational Interviewing'}]","[{'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0222045'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary Exercise Test'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}]",,0.0305356,"There was no significant change in motivation on the Sportbezogene Selbstkonkordanz Scale for either group (MI: 1.7 vs. 3, P = 0.55; control: 4.7 vs. 4, P = 0.26) nor did patients show any significant improvements in the 6 min walk test (MI: 549 vs. 540 m, P = 0.80; control: 572 vs. 580 m, P = 0.37).","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Schertz', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center, Von-Siebold-Str. 5, D-37075, Göttingen, Germany.'}, {'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Herbeck Belnap', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center, Von-Siebold-Str. 5, D-37075, Göttingen, Germany.'}, {'ForeName': 'Mira-Lynn', 'Initials': 'ML', 'LastName': 'Chavanon', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center, Von-Siebold-Str. 5, D-37075, Göttingen, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Edelmann', 'Affiliation': 'Department of Internal Medicine and Cardiology, Universitätsmedizin Berlin (Charité), Berlin, Germany.'}, {'ForeName': 'Rolf', 'Initials': 'R', 'LastName': 'Wachter', 'Affiliation': 'German Centre for Cardiovascular Research (DZHK), Göttingen, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Herrmann-Lingen', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center, Von-Siebold-Str. 5, D-37075, Göttingen, Germany.'}]",ESC heart failure,['10.1002/ehf2.12436'] 226,31148411,Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy.,"AIMS Iron deficiency worsens symptoms, quality of life, and exercise capacity in chronic heart failure (CHF) and might do so by promoting fluid retention. We assessed whether iron repletion improved congestion in CHF and appraised the prognostic utility of calculated plasma volume status (PVS), a novel index of congestion, in the FAIR-HF data set. METHODS AND RESULTS In FAIR-HF, 459 iron deficient CHF patients were randomized to intravenous ferric carboxymaltose (FCM) or saline and assessed at 4, 12, and 24 weeks. Using weight and haematocrit, we calculated PVS in 436 patients. At baseline, PVS and weight were -5.5 ± 7.7% and 76.9 ± 14.3 kg, with peripheral oedema evident in 35% of subjects. Higher PVS values correlated to other congestion surrogates such as lower serum albumin. At 4 weeks, FCM was associated with greater reductions in weight (0.02) and PVS (P < 0.0001), and a trend for improved peripheral oedema at 24 weeks (0.07). Irrespective of treatment allocation, patients with a decrease in PVS from baseline to week 24 had higher increments in 6 min walking distance (61.4 m vs. 43.5 m, 0.02) and were more likely to improve their NYHA class (33.3% vs. 15.5%, 0.001). A PVS > -4% at baseline predicted worse outcomes even after adjustment for treatment assignment (hazard ratio 1.88, 95% confidence interval 1.01-3.51, 0.046). CONCLUSIONS Intravenous iron therapy with FCM is associated with early reductions in PVS and weight, implying that decongestion might be one mechanism via which iron repletion aids CHF patients. Calculated PVS is of prognostic utility in this cohort.",2019,"At 4 weeks, FCM was associated with greater reductions in weight (0.02) and PVS (P < 0.0001), and a trend for improved peripheral oedema at 24 weeks (0.07).","['436 patients', 'chronic heart failure (CHF']","['FCM', 'ferric carboxymaltose', 'intravenous ferric carboxymaltose (FCM) or saline']","['quality of life, and exercise capacity', 'calculated plasma volume status and clinical congestion', 'peripheral oedema', 'PVS', 'weight (0.02) and PVS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0264716', 'cui_str': 'Chronic heart failure (disorder)'}]","[{'cui': 'C2001867', 'cui_str': 'ferric carboxymaltose'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}]","[{'cui': 'C0034380'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0032127', 'cui_str': 'Blood Plasma Volume'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0700148', 'cui_str': 'Congestion (morphologic abnormality)'}, {'cui': 'C0085649', 'cui_str': 'Peripheral edema (morphologic abnormality)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C4517398', 'cui_str': '0.02'}]",,0.144281,"At 4 weeks, FCM was associated with greater reductions in weight (0.02) and PVS (P < 0.0001), and a trend for improved peripheral oedema at 24 weeks (0.07).","[{'ForeName': 'Darlington O', 'Initials': 'DO', 'LastName': 'Okonko', 'Affiliation': ""School of Cardiovascular Medicine and Sciences, James Black Centre, King's College London British Heart Foundation Centre of Excellence, London, UK.""}, {'ForeName': 'Fadi', 'Initials': 'F', 'LastName': 'Jouhra', 'Affiliation': ""King's College Hospital, London, UK.""}, {'ForeName': 'Huda', 'Initials': 'H', 'LastName': 'Abu-Own', 'Affiliation': ""King's College Hospital, London, UK.""}, {'ForeName': 'Gerasimos', 'Initials': 'G', 'LastName': 'Filippatos', 'Affiliation': 'National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.'}, {'ForeName': 'Josep Comin', 'Initials': 'JC', 'LastName': 'Colet', 'Affiliation': 'Hospital del Mar (Parc de Salut Mar), Barcelona, Spain.'}, {'ForeName': 'Chainey', 'Initials': 'C', 'LastName': 'Suki', 'Affiliation': 'Vifor Pharma Ltd, Glattbrugg, Switzerland.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Mori', 'Affiliation': 'Vifor Pharma Ltd, Glattbrugg, Switzerland.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Ponikowski', 'Affiliation': 'Medical University, Wroclaw, Poland.'}, {'ForeName': 'Stefan D', 'Initials': 'SD', 'LastName': 'Anker', 'Affiliation': 'Division of Cardiology and Metabolism-Heart Failure, Cachexia & Sarcopenia, Department of Cardiology (CVK); and Berlin-Brandenburg Center for Regenerative Therapies (BCRT); Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",ESC heart failure,['10.1002/ehf2.12462'] 227,30471871,Can High Schools Be an Effective Setting to Promote Healthy Lifestyles? Effects of a Multiple Behavior Change Intervention in Adolescents.,"PURPOSE The main aim was to examine the effects of a school-based intervention on multiple health behaviors in adolescents, such as 24-hour movement behaviors (i.e., physical activity, sedentary time, and sleep duration), diet, and substance consumption (i.e., alcohol and tobacco). Another aim was to examine intragender differences in the effectiveness of the programme. METHODS A quasi-experimental design was carried out in two secondary schools throughout one academic year. A final sample of 210 students participated: 105 in the control (Mage = 13.07 ± 0.63) and 105 in the experimental school (Mage = 13.05 ± 0.59). A multicomponent school-based intervention was conducted by teachers in the experimental school via curricular (i.e., tutorial action plan, interdisciplinary project, and school break) and extracurricular (i.e., family involvement, institutional and noncurricular activities, and dissemination of health information and events) actions to promote adolescents' healthy lifestyles. Physical activity and sedentary time were measured by accelerometers, and the rest of health behaviors by using self-reported scales. RESULTS Experimental school students showed a significant improvement in meeting specific and general combinations of 24-hour movement guidelines, sedentary screen time levels, nap duration, (un)healthy diet scores, breakfast intake, and soft drink consumption compared to both control school students and their baseline values (p >.05). Active commuting and substance consumption rates only showed a significant improvement compared to control school students (p >.05). Although the intervention programme was effective in improving health-related behaviors in both genders, a large effect size was observed in boys. CONCLUSIONS Conducting multiple health behavior interventions becomes essential to improve adolescents' healthy lifestyles.",2019,Active commuting and substance consumption rates only showed a significant improvement compared to control school students (p >.05).,"['A quasi-experimental design was carried out in two secondary schools throughout one academic year', 'Experimental school students', ""adolescents' healthy lifestyles"", 'Adolescents', '210 students participated: 105 in the control (Mage\u202f=\u202f13.07 ± 0.63) and 105 in the experimental school (Mage\u202f=\u202f13.05 ± 0.59']","['multicomponent school-based intervention', 'school-based intervention', 'Multiple Behavior Change Intervention']","['meeting specific and general combinations of 24-hour movement guidelines, sedentary screen time levels, nap duration, (un)healthy diet scores, breakfast intake, and soft drink consumption', 'Active commuting and substance consumption rates', 'Physical activity and sedentary time', 'multiple health behaviors', '24-hour movement behaviors (i.e., physical activity, sedentary time, and sleep duration), diet, and substance consumption (i.e., alcohol and tobacco', 'health-related behaviors']","[{'cui': 'C0015320', 'cui_str': 'Experimental Design'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}, {'cui': 'C0036530', 'cui_str': 'Schools, Secondary'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C4277664', 'cui_str': 'Healthy Life Styles'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4517468', 'cui_str': '0.63'}, {'cui': 'C4517465', 'cui_str': 'Zero point five nine'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]","[{'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0220845', 'cui_str': 'guidelines'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C4704787', 'cui_str': 'Screen Time'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0067518', 'cui_str': 'NAPS'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0452415', 'cui_str': 'Healthy Diet'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4553621', 'cui_str': 'With breakfast'}, {'cui': 'C3489624', 'cui_str': 'Soft Drinks'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0439861', 'cui_str': 'Substance (substance)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0018687'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}]",210.0,0.0168737,Active commuting and substance consumption rates only showed a significant improvement compared to control school students (p >.05).,"[{'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Sevil', 'Affiliation': 'Department of Didactics of the Musical Plastic and Corporal Expression, Faculty of Health and Sport Sciences, , University of Zaragoza, Huesca, Spain. Electronic address: jsevils@unizar.es.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'García-González', 'Affiliation': 'Department of Didactics of the Musical Plastic and Corporal Expression, Faculty of Health and Sport Sciences, , University of Zaragoza, Huesca, Spain.'}, {'ForeName': 'Ángel', 'Initials': 'Á', 'LastName': 'Abós', 'Affiliation': 'Department of Didactics of the Musical Plastic and Corporal Expression, Faculty of Health and Sport Sciences, , University of Zaragoza, Huesca, Spain.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Generelo', 'Affiliation': 'Department of Didactics of the Musical Plastic and Corporal Expression, Faculty of Health and Sport Sciences, , University of Zaragoza, Huesca, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Aibar', 'Affiliation': 'Department of Didactics of the Musical, Plastic and Corporal Expression, Faculty of Social Sciences and Humanities, University of Zaragoza, Huesca, Spain.'}]",The Journal of adolescent health : official publication of the Society for Adolescent Medicine,['10.1016/j.jadohealth.2018.09.027'] 228,30612807,Gender Differences in Depression Literacy and Stigma After a Randomized Controlled Evaluation of a Universal Depression Education Program.,"PURPOSE Depression is a debilitating illness with frequent onset during adolescence. Depression affects women more often than men; men are more likely to complete suicide and less likely to seek treatment. The Adolescent Depression Awareness Program (ADAP) is a school-based depression intervention that educates adolescents about depression symptoms and addresses accompanying stigma. The study aims examined gender differences in the ADAP's impact on depression literacy and stigma. METHODS Data came from a randomized trial (2012-2015). Six thousand six hundred seventy-nine students from 54 schools in several states were matched into pairs and randomized to the intervention or wait-list control. Teachers delivered the ADAP as part of the health curriculum. Depression literacy and stigma outcomes were measured before intervention, 6 weeks later, and at 4 months. Multilevel models evaluated whether gender moderated the effect of ADAP on depression literacy and stigma. RESULTS At 4 months, there was a main effect of the ADAP on depression literacy (odds ratio [OR] = 3.3, p = .001) with intervention students achieving depression literacy at higher rates than controls. Gender exhibited a main effect, with women showing greater rates of depression literacy than men (OR = 1.51, p = .001). There was no significant intervention × gender interaction. The ADAP did not exhibit a significant main effect on stigma. There was a main effect for gender, with women demonstrating less stigma than men (OR = .65, p = .001). There was no significant interaction between the intervention and gender on stigma. CONCLUSIONS The ADAP demonstrates effectiveness for increasing rates of depression literacy among high school students. In this study, gender was not associated with ADAP's effectiveness.",2019,"Gender exhibited a main effect, with women showing greater rates of depression literacy than men (OR = 1.51, p = .001).","['Six thousand six hundred seventy-nine students from 54 schools in several states', 'Data came from a randomized trial (2012-2015', 'high school students']","['school-based depression intervention', 'intervention or wait-list control', 'ADAP', 'Adolescent Depression Awareness Program (ADAP']","['stigma', 'depression literacy', 'rates of depression literacy', 'depression literacy and stigma', 'Depression literacy and stigma outcomes']","[{'cui': 'C3842326', 'cui_str': 'Six thousand'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0960273', 'cui_str': 'CAME'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0004448', 'cui_str': 'Situational Awareness'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0277787', 'cui_str': 'Stigma (finding)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}]",6679.0,0.1019,"Gender exhibited a main effect, with women showing greater rates of depression literacy than men (OR = 1.51, p = .001).","[{'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Townsend', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland; Kennedy Krieger Institute, Baltimore, Maryland. Electronic address: ltownsend01@msn.com.'}, {'ForeName': 'Rashelle', 'Initials': 'R', 'LastName': 'Musci', 'Affiliation': 'Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Stuart', 'Affiliation': 'Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland; Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore Maryland; Department of Health, Policy, and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Heley', 'Affiliation': 'Department of Health, Policy, and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Mary Beth', 'Initials': 'MB', 'LastName': 'Beaudry', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Schweizer', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Ruble', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Swartz', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Holly', 'Initials': 'H', 'LastName': 'Wilcox', 'Affiliation': 'Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.'}]",The Journal of adolescent health : official publication of the Society for Adolescent Medicine,['10.1016/j.jadohealth.2018.10.298'] 229,31016887,Muscle wasting and function after muscle activation and early protocol-based physiotherapy: an explorative trial.,"BACKGROUND Early mobilization improves physical independency of critically ill patients at hospital discharge in a general intensive care unit (ICU)-cohort. We aimed to investigate clinical and molecular benefits or detriments of early mobilization and muscle activating measures in a high-risk ICU-acquired weakness cohort. METHODS Fifty patients with a SOFA score ≥9 within 72 h after ICU admission were randomized to muscle activating measures such as neuromuscular electrical stimulation or whole-body vibration in addition to early protocol-based physiotherapy (intervention) or early protocol-based physiotherapy alone (control). Muscle strength and function were assessed by Medical Research Council (MRC) score, handgrip strength and Functional Independence Measure at first awakening, ICU discharge, and 12 month follow-up. Patients underwent open surgical muscle biopsy on day 15. We investigated the impact of muscle activating measures in addition to early protocol-based physiotherapy on muscle strength and function as well as on muscle wasting, morphology, and homeostasis in patients with sepsis and ICU-acquired weakness. We compared the data with patients treated with common physiotherapeutic practice (CPP) earlier. RESULTS ICU-acquired weakness occurs within the entire cohort, and muscle activating measures did not improve muscle strength or function at first awakening (MRC median [IQR]: CPP 3.3 [3.0-4.3]; control 3.0 [2.7-3.4]; intervention 3.0 [2.1-3.8]; P > 0.05 for all), ICU discharge (MRC median [IQR]: CPP 3.8 [3.4-4.4]; control 3.9 [3.3-4.0]; intervention 3.6 [2.8-4.0]; P > 0.05 for all), and 12 month follow-up (MRC median [IQR]: control 5.0 [4.3-5.0]; intervention 4.8 [4.3-5.0]; P = 0.342 for all). No signs of necrosis or inflammatory infiltration were present in the histological analysis. Myocyte cross-sectional area in the intervention group was significantly larger in comparison with the control group (type I +10%; type IIa +13%; type IIb +3%; P < 0.001 for all) and CPP (type I +36%; type IIa +49%; type IIb +65%; P < 0.001 for all). This increase was accompanied by an up-regulated gene expression for myosin heavy chains (fold change median [IQR]: MYH1 2.3 [1.1-2.7]; MYH2 0.7 [0.2-1.8]; MYH4 5.1 [2.2-15.3]) and an unaffected gene expression for TRIM63, TRIM62, and FBXO32. CONCLUSIONS In our patients with sepsis syndrome at high risk for ICU-acquired weakness muscle activating measures in addition to early protocol-based physiotherapy did not improve muscle strength or function at first awakening, ICU discharge, or 12 month follow-up. Yet it prevented muscle atrophy.",2019,Myocyte cross-sectional area in the intervention group was significantly larger in comparison with the control group (type I +10%; type IIa +13%; type IIb +3%; P < 0.001 for all) and CPP (type I +36%; type IIa +49%; type IIb +65%; P < 0.001 for all).,"['Fifty patients with a SOFA score ≥9 within 72\xa0h after ICU admission', 'patients treated with common physiotherapeutic practice (CPP) earlier', 'patients with sepsis and ICU-acquired weakness', 'critically ill patients at hospital discharge in a general intensive care unit (ICU)-cohort']","['muscle activation and early protocol-based physiotherapy', 'muscle activating measures such as neuromuscular electrical stimulation or whole-body vibration in addition to early protocol-based physiotherapy (intervention) or early protocol-based physiotherapy alone (control', 'open surgical muscle biopsy']","['Muscle strength and function', 'Myocyte cross-sectional area', 'unaffected gene expression for TRIM63, TRIM62, and FBXO32', 'muscle strength or function', 'Medical Research Council (MRC) score, handgrip strength and Functional Independence Measure at first awakening, ICU discharge', 'necrosis or inflammatory infiltration', 'ICU discharge']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0205214', 'cui_str': 'Common (qualifier value)'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C4087120', 'cui_str': 'Intensive care unit acquired weakness'}, {'cui': 'C0010340', 'cui_str': 'Critically Ill'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0013786', 'cui_str': 'Electrical Stimulation'}, {'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}, {'cui': 'C0459800', 'cui_str': 'Vibration'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0185283', 'cui_str': 'Biopsy of muscle (procedure)'}]","[{'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0596981', 'cui_str': 'Myocytes'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0205155', 'cui_str': 'Sectional (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C0079816', 'cui_str': 'Medical Research'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451172', 'cui_str': 'Functional independence measure (assessment scale)'}, {'cui': 'C1720052', 'cui_str': 'Awakening'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0027540', 'cui_str': 'Necrosis'}, {'cui': 'C0302158', 'cui_str': 'Inflammatory infiltration'}]",50.0,0.064542,Myocyte cross-sectional area in the intervention group was significantly larger in comparison with the control group (type I +10%; type IIa +13%; type IIb +3%; P < 0.001 for all) and CPP (type I +36%; type IIa +49%; type IIb +65%; P < 0.001 for all).,"[{'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Wollersheim', 'Affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Julius J', 'Initials': 'JJ', 'LastName': 'Grunow', 'Affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Niklas M', 'Initials': 'NM', 'LastName': 'Carbon', 'Affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Haas', 'Affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Malleike', 'Affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Sara F', 'Initials': 'SF', 'LastName': 'Ramme', 'Affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Schneider', 'Affiliation': 'Berlin Institute of Health (BIH), Berlin, Germany.'}, {'ForeName': 'Claudia D', 'Initials': 'CD', 'LastName': 'Spies', 'Affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Märdian', 'Affiliation': 'Center for Musculoskeletal Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Knut', 'Initials': 'K', 'LastName': 'Mai', 'Affiliation': 'Berlin Institute of Health (BIH), Berlin, Germany.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Spuler', 'Affiliation': 'Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Experimental and Clinical Research Center (ECRC), Berlin, Germany.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Fielitz', 'Affiliation': 'Berlin Institute of Health (BIH), Berlin, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Weber-Carstens', 'Affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}]","Journal of cachexia, sarcopenia and muscle",['10.1002/jcsm.12428'] 230,31016897,Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus.,"BACKGROUND Type 2 diabetes, a highly prevalent chronic disease, is associated with increasing frailty and functional decline in older people. We aimed to evaluate the effectiveness of a multimodal intervention on functional performance in frail and pre-frail participants aged ≥70 years with type 2 diabetes mellitus. METHODS The MID-Frail study was a cluster-randomized multicenter clinical trial conducted in 74 trial sites across seven European countries. The trial recruited 964 participants who were aged >70 years [mean age in intervention group, 78.4 (SD 5.6) years, 49.2% male and 77.6 (SD 5.29) years, 52.4% male in usual care group], with type diabetes mellitus and determined to be frail or pre-frail using Fried's frailty phenotype. Participants were allocated by trial site to follow either usual care (UCG) or intervention procedures (IG). Intervention group participants received a multimodal intervention composed of (i) an individualized and progressive resistance exercise programme for 16 weeks; (ii) a structured diabetes and nutritional educational programme over seven sessions; and (iii) Investigator-linked training to ensure optimal diabetes care. Short Physical Performance Battery (SPPB) scores were used to assess change in functional performance at 12 months between the groups. An analysis of the cost-effectiveness of the intervention was undertaken using the incremental cost-effectiveness ratio (ICER). Secondary outcomes included mortality, hospitalization, institutionalization, quality of life, burden on caregivers, the frequency and severity of hypoglycaemia episodes, and the cost-effectiveness of the intervention. RESULTS After 12 months, IG participants had mean SPPB scores 0.85 points higher than those in the UCG (95% CI, 0.44 to 1.26, P < 0.0001). Dropouts were higher in frail participants and in the intervention group, but significant differences in SPPB between treatment groups remained consistent after sensitivity analysis. Estimates suggest a mean saving following intervention of 428.02 EUR (2016) per patient per year, with ICER analysis indicating a consistent benefit of the described health care intervention over usual care. No statistically significant differences between groups were detected in any of the other secondary outcomes. CONCLUSIONS We have demonstrated that a 12 month structured multimodal intervention programme across several clinical settings in different European countries leads to a clinically relevant and cost-effective improvement in the functional status of older frail and pre-frail participants with type 2 diabetes mellitus.",2019,"Dropouts were higher in frail participants and in the intervention group, but significant differences in SPPB between treatment groups remained consistent after sensitivity analysis.","['older frail and pre-frail participants with type 2 diabetes mellitus', 'older people with type 2 diabetes mellitus', 'frail and pre-frail participants aged ≥70\xa0years with type 2 diabetes mellitus', ""964 participants who were aged >70\xa0years [mean age in intervention group, 78.4 (SD 5.6)\xa0years, 49.2% male and 77.6 (SD 5.29)\xa0years, 52.4% male in usual care group], with type diabetes mellitus and determined to be frail or pre-frail using Fried's frailty phenotype"", '74 trial sites across seven European countries']","['usual care (UCG) or intervention procedures (IG', 'multimodal intervention composed of (i) an individualized and progressive resistance exercise programme for 16\xa0weeks; (ii) a structured diabetes and nutritional educational programme over seven sessions; and (iii) Investigator-linked training to ensure optimal diabetes care', 'multimodal intervention programme', 'multimodal intervention']","['incremental cost-effectiveness ratio (ICER', 'mortality, hospitalization, institutionalization, quality of life, burden on caregivers, the frequency and severity of hypoglycaemia episodes, and the cost-effectiveness of the intervention', 'SPPB', 'functional performance', 'Short Physical Performance Battery (SPPB) scores', 'mean SPPB scores']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517794', 'cui_str': '5.6 (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C1510451', 'cui_str': 'Fries'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C1314763', 'cui_str': 'Phenotyping (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0454713', 'cui_str': 'European country (geographic location)'}]","[{'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0021629', 'cui_str': 'Institutionalization'}, {'cui': 'C0034380'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C3853978'}, {'cui': 'C4075289', 'cui_str': 'Short Physical Performance Battery score (observable entity)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",964.0,0.128605,"Dropouts were higher in frail participants and in the intervention group, but significant differences in SPPB between treatment groups remained consistent after sensitivity analysis.","[{'ForeName': 'Leocadio', 'Initials': 'L', 'LastName': 'Rodriguez-Mañas', 'Affiliation': 'Servicio de Geriatría, Hospital Universitario de Getafe, Madrid, Spain.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Laosa', 'Affiliation': 'Foundation for Biomedical Research-Hospital Universitario de Getafe, Madrid, Spain.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Vellas', 'Affiliation': 'Centre Hospitalier Universitaire de Toulouse, Toulouse, France.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Paolisso', 'Affiliation': 'University of Campania-Luigi Vanvitelli, Naples, Italy.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Topinkova', 'Affiliation': 'First Faculty of Medicine, Charles University, Prague, Czech Republic.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Oliva-Moreno', 'Affiliation': 'University Castilla La Mancha University, Toledo, Spain.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Bourdel-Marchasson', 'Affiliation': 'Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.'}, {'ForeName': 'Mikel', 'Initials': 'M', 'LastName': 'Izquierdo', 'Affiliation': 'IdiSNA, Navarra Institute for Health Research, Public University of Navarra, Pamplona, Spain.'}, {'ForeName': 'Kerry', 'Initials': 'K', 'LastName': 'Hood', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Andrej', 'Initials': 'A', 'LastName': 'Zeyfang', 'Affiliation': 'Ulm University, Ulm, Germany.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Gambassi', 'Affiliation': 'Università Cattolica Sacro Cuore, Rome, Italy.'}, {'ForeName': 'Mirko', 'Initials': 'M', 'LastName': 'Petrovic', 'Affiliation': 'Department of Geriatrics, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Tim C', 'Initials': 'TC', 'LastName': 'Hardman', 'Affiliation': 'Niche Science & Technology Ltd, Richmond, UK.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Kelson', 'Affiliation': 'Department of Mathematics, University of Exeter, Exeter, UK.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Bautmans', 'Affiliation': 'Gerontology Department, Vrije Universiteit Brussel, Brussels, Belgium.'}, {'ForeName': 'Gabor', 'Initials': 'G', 'LastName': 'Abellan', 'Affiliation': 'Centre Hospitalier Universitaire de Toulouse, Toulouse, France.'}, {'ForeName': 'Michelangela', 'Initials': 'M', 'LastName': 'Barbieri', 'Affiliation': 'University of Campania-Luigi Vanvitelli, Naples, Italy.'}, {'ForeName': 'Luz M', 'Initials': 'LM', 'LastName': 'Peña-Longobardo', 'Affiliation': 'University Castilla La Mancha University, Toledo, Spain.'}, {'ForeName': 'Sophie C', 'Initials': 'SC', 'LastName': 'Regueme', 'Affiliation': 'Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Calvani', 'Affiliation': 'Università Cattolica Sacro Cuore, Rome, Italy.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'De Buyser', 'Affiliation': 'Department of Geriatrics, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Alan J', 'Initials': 'AJ', 'LastName': 'Sinclair', 'Affiliation': 'Foundation for Diabetes Research in Older People, Diabetes Frail Ltd, Luton, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Journal of cachexia, sarcopenia and muscle",['10.1002/jcsm.12432'] 231,31074178,Appetite and food intake results from phase I studies of anamorelin.,"BACKGROUND Loss of appetite and body weight are potentially devastating, highly prevalent cancer complications. The ghrelin receptor is a mediator of appetite and metabolism, and anamorelin is a novel, orally administered ghrelin receptor agonist. Effects on appetite and food intake may influence body-weight gain but can be difficult to measure in multi-site studies. Here, we summarize two single-centre trials. METHODS Both trials were phase I, randomized, double-blind, placebo-controlled, partly/wholly crossover studies of healthy young adults. Study 102 tested single anamorelin doses of 1-20 mg. Assessments included post-dose self-ratings on 100 mm visual analogue scales for hunger, anticipated eating pleasure, and anticipated quantity of food consumption. Study 101 tested single 10, 25, and 50 mg doses. Assessments included the same scales plus caloric intake beginning 4 h post-dose. RESULTS Study 102 treated 16 male subjects (mean age, 26.3 years). Mean hunger scores generally increased after all treatments, with significant differences from placebo (P < 0.05) in the 5 mg anamorelin group at 0.5 and 1 h post-dose (+8.2 and +13.2 mm). Results for other scales were similar. Study 101 treated nine male subjects (mean age, 26.3 years). Pooled findings for anamorelin 25 and 50 mg vs. placebo showed significant mean increases in hunger scores at all but 1 pre-prandial time point, including the first assessment, 0.5 h post-dose (+10.9 vs. +0.7 mm, P = 0.0077), and the last assessment, 4 h post-dose (+32.7 vs. +7.0 mm, P = 0.0170), with a significant mean 18.4% increase vs. placebo in caloric intake (P = 0.0148). CONCLUSIONS In single-centre studies of healthy adults, single anamorelin doses of 1-20 mg elicited modest increases in hunger, and single doses of 25 and 50 mg achieved significant increases in hunger and caloric intake. The findings are consistent with dose-related weight gain reported in a prior phase I study as well as multi-centre findings in cachectic cancer patients and expand the evidence supporting anamorelin as a potential intervention.",2019,"Mean hunger scores generally increased after all treatments, with significant differences from placebo (P < 0.05) in the 5 mg anamorelin group at 0.5 and 1 h post-dose (+8.2 and +13.2 mm).","['cachectic cancer patients', 'Study 102 treated 16 male subjects (mean age, 26.3 years', 'Study 101 treated nine male subjects (mean age, 26.3 years', 'healthy adults', 'healthy young adults']",['placebo'],"['post-dose self-ratings on 100 mm visual analogue scales for hunger, anticipated eating pleasure, and anticipated quantity of food consumption', 'hunger and caloric intake', 'caloric intake', 'Mean hunger scores', 'hunger scores', 'weight gain']","[{'cui': 'C0006625', 'cui_str': 'Cachexia'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517668', 'cui_str': 'Twenty-six point three'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0439568', 'cui_str': 'Post-dose (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0020175', 'cui_str': 'Hunger'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0679105', 'cui_str': 'Pleasure'}, {'cui': 'C1265611', 'cui_str': 'Quantity finding'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}]",9.0,0.375845,"Mean hunger scores generally increased after all treatments, with significant differences from placebo (P < 0.05) in the 5 mg anamorelin group at 0.5 and 1 h post-dose (+8.2 and +13.2 mm).","[{'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Blum', 'Affiliation': 'Buffalo Clinical Research Center, LLC, Buffalo, NY, USA.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Mair', 'Affiliation': 'Formerly, Inveresk Research, Edinburgh, UK.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Duus', 'Affiliation': 'Formerly, Helsinn Therapeutics (US), Incorporated, Iselin, NJ, USA.'}]","Journal of cachexia, sarcopenia and muscle",['10.1002/jcsm.12439'] 232,31751466,Dopamine-Induced Dysconnectivity Between Salience Network and Auditory Cortex in Subjects With Psychotic-like Experiences: A Randomized Double-Blind Placebo-Controlled Study.,"Dopamine is involved in the pathophysiology of schizophrenia. Disrupted salience processing by the salience network (SN) may be a central link between dysregulated dopamine function and psychotic symptoms. However, dopaminergic influence on the SN and its presumed influence on psychotic and subpsychotic symptoms or psychotic-like experiences in healthy individuals remain unclear. Therefore, we investigated dopamine-induced changes in functional connectivity of the right anterior insula (rAI), a central SN hub, and their association with psychotic-like experiences. We enrolled 54 healthy, right-handed male subjects in a randomized, double-blind, cross-sectional placebo-controlled experiment. Psychotic-like experiences were assessed using the revised Exceptional Experiences Questionnaire (PAGE-R). They then received either placebo (n = 32) or 200 mg L-DOPA (n = 33), a dopamine precursor, orally and underwent resting-state functional magnetic resonance imaging. In a seed-to-voxel approach, we analyzed dopamine-induced changes in functional connectivity of the rAI and assessed the relationship between functional connectivity changes and PAGE-R score. L-DOPA reduced functional connectivity between the rAI and the left auditory cortex planum polare. In the placebo group, we found a strong negative correlation between PAGE-R score and rAI to planum polare functional connectivity; in the L-DOPA group, there was a strong positive correlation between PAGE-R score and functional connectivity between rAI and planum polare. The PAGE-R score explained about 30% of the functional connectivity variation between rAI and planum polare in the two groups. Our findings suggest that psychotic-like experiences are associated with dopamine-induced disruption of auditory input to the SN, which may lead to aberrant attribution of salience.",2020,L-DOPA reduced functional connectivity between the rAI and the left auditory cortex planum polare.,"['54 healthy, right-handed male subjects', 'Subjects With Psychotic-like Experiences']","['Dopamine-Induced Dysconnectivity Between Salience Network and Auditory Cortex', 'Placebo', 'placebo', 'Dopamine', 'dopamine precursor, orally and underwent resting-state functional magnetic resonance imaging']","['PAGE-R score and rAI to planum polare functional connectivity', 'Psychotic-like experiences', 'PAGE-R score and functional connectivity', 'functional connectivity']","[{'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}]","[{'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0004302', 'cui_str': 'Temporal Auditory Area'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3498719', 'cui_str': 'Planum Polare'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}]",54.0,0.185893,L-DOPA reduced functional connectivity between the rAI and the left auditory cortex planum polare.,"[{'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Rössler', 'Affiliation': 'Collegium Helveticum, University of Zurich and ETH Zurich, Zurich, Switzerland.'}, {'ForeName': 'Wulf', 'Initials': 'W', 'LastName': 'Rössler', 'Affiliation': 'Collegium Helveticum, University of Zurich and ETH Zurich, Zurich, Switzerland.'}, {'ForeName': 'Erich', 'Initials': 'E', 'LastName': 'Seifritz', 'Affiliation': 'Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Lui', 'Initials': 'L', 'LastName': 'Unterrassner', 'Affiliation': 'Collegium Helveticum, University of Zurich and ETH Zurich, Zurich, Switzerland.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Wyss', 'Affiliation': 'Collegium Helveticum, University of Zurich and ETH Zurich, Zurich, Switzerland.'}, {'ForeName': 'Helene', 'Initials': 'H', 'LastName': 'Haker', 'Affiliation': 'Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Wotruba', 'Affiliation': 'Collegium Helveticum, University of Zurich and ETH Zurich, Zurich, Switzerland.'}]",Schizophrenia bulletin,['10.1093/schbul/sbz110'] 233,32297162,"Lidocaine as an element of multimodal analgesic therapy in major spine surgical procedures in children: a prospective, randomized, double-blind study.","BACKGROUND Introducing the principles of multimodal analgesic therapy is necessary to provide appropriate comfort for the patient after surgery. The main objective of the study was evaluating the influence of perioperative intravenous (i.v.) lidocaine infusion on postoperative morphine requirements during the first 48 h postoperatively in children undergoing major spine surgery. MATERIALS AND METHODS Prospective, randomized, double-blind study: 41 children, qualified to multilevel spine surgery, were randomly divided into two treatment groups: lidocaine and placebo (control). The lidocaine group received lidocaine as a bolus of 1.5 mg/kg over 30 minutes, followed by a continuous infusion at 1 mg/kg/h to 6 hours after surgery. The protocol of perioperative management was identical for all patients. MEASUREMENTS morphine demand, intensity of postoperative pain (the Numerical Rating Scale), oral feeding initiation time, first attempts at assuming erect position, postoperative quality of life (the Acute Short-form /SF-12/ health survey). RESULTS Patient data did not differ demographically. Compared to the control group, lidocaine treatment reduced the demand for morphine during the first 24h [95% CI 0.13 (0.11-0.28) mg/kg, p = 0.0122], 48h [95% CI 0.46 (0.22-0.52) mg/kg, p = 0.0299] after surgery and entire hospitalization [95% CI 0.58 (0.19-0.78) mg/kg, p = 0.04]; postoperative pain intensity; nutritional withdrawal period [introduction of liquid diet (p = 0.024) and solid diet (p = 0.012)], and accelerated the adoption of an upright position [sitting (p = 0.048); walking (p = 0.049)]. The SF-12 generic health survey did not differ between groups before operation, 2 months and 4 years after surgery. CONCLUSIONS Perioperative lidocaine administration, as a part of the applied analgesic therapy regimen, may decrease postoperative opioid demand and accelerates convalescence of children undergoing major surgery.",2020,"Compared to the control group, lidocaine treatment reduced the demand for morphine during the first 24h [95% CI 0.13 (0.11-0.28) mg/kg, p = 0.0122], 48h [95% CI 0.46 (0.22-0.52) mg/kg, p = 0.0299] after surgery and entire hospitalization","['children undergoing major surgery', '41 children, qualified to multilevel spine surgery', 'major spine surgical procedures in children', 'children undergoing major spine surgery']","['Lidocaine', 'lidocaine', 'lidocaine and placebo (control']","['demand for morphine', 'postoperative morphine requirements', 'entire hospitalization', 'postoperative pain intensity; nutritional withdrawal period [introduction of liquid diet', 'SF-12 generic health survey', 'morphine demand, intensity of postoperative pain (the Numerical Rating Scale), oral feeding initiation time, first attempts at assuming erect position, postoperative quality of life (the Acute Short-form /SF-12/ health survey', 'adoption of an upright position [sitting']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0920347', 'cui_str': 'Procedure on spinal cord'}, {'cui': 'C0037949', 'cui_str': 'Structure of vertebral column'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0439751', 'cui_str': 'Entire'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0001593', 'cui_str': 'Adoption'}, {'cui': 'C0037216', 'cui_str': 'SITS'}]",41.0,0.143157,"Compared to the control group, lidocaine treatment reduced the demand for morphine during the first 24h [95% CI 0.13 (0.11-0.28) mg/kg, p = 0.0122], 48h [95% CI 0.46 (0.22-0.52) mg/kg, p = 0.0299] after surgery and entire hospitalization","[{'ForeName': 'Ilona', 'Initials': 'I', 'LastName': 'Batko', 'Affiliation': ""Department of Anesthesiology and Intensive Care, University Children's Hospital, 265 Wielicka St, 30-663, Cracow, Poland. ilona.batko@poczta.onet.pl.""}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Kościelniak-Merak', 'Affiliation': ""Department of Clinical Biochemistry, University Children's Hospital, Jagiellonian University Medical College, Cracow, Poland.""}, {'ForeName': 'Przemysław J', 'Initials': 'PJ', 'LastName': 'Tomasik', 'Affiliation': ""Department of Clinical Biochemistry, University Children's Hospital, Jagiellonian University Medical College, Cracow, Poland.""}, {'ForeName': 'Krzysztof', 'Initials': 'K', 'LastName': 'Kobylarz', 'Affiliation': ""Department of Anesthesiology and Intensive Care, University Children's Hospital, 265 Wielicka St, 30-663, Cracow, Poland.""}, {'ForeName': 'Jerzy', 'Initials': 'J', 'LastName': 'Wordliczek', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Jagiellonian University Medical College, Cracow, Poland.'}]",Pharmacological reports : PR,['10.1007/s43440-020-00100-7'] 234,32297703,"Safety and efficacy of intrarenal arterial autologous CD34+ cell transfusion in patients with chronic kidney disease: A randomized, open-label, controlled phase II clinical trial.","BACKGROUND This was a randomized, open-label, controlled phase II clinical trial to investigate the safety, efficacy, and outcomes of intrarenal artery infusion of autologous peripheral-blood-derived CD34+ cells for patients with chronic kidney disease (CKD; ie, stage III or IV). MATERIALS AND METHODS Between October 2016 and July 2018, 52 consecutive patients with CKD at stage III or IV were randomly allocated into a treatment group (TG; 2.5 × 10 7 cells for each intrarenal artery; n = 26) and a control group (CG; standardized pharmacotherapy only; n = 26). The primary endpoints included safety and change of creatinine level/creatinine clearance. The secondary endpoints were 12-month combined unfavorable clinical outcomes (defined as dialysis or death), improvement in proteinuria, and CD34+ cell-related adverse events. RESULTS All patients were uneventfully discharged after CD34+ cell therapy. The baseline endothelial progenitor cell (EPC) populations did not differ between TG and CG (P > .5). Flow cytometric analysis showed increases in circulating EPC (ie, CD34+KDR+CD45 dim / CD34+CD133+CD45 dim /CD31+CD133+CD45 dim /CD34+CD133+KDR+/CD133+) and hematopoietic stem cell (CD34+) populations after granulocyte-colony stimulating factor treatment (all P < .001). Besides, Matrigel assay of angiogenesis was also significantly enhanced (all P < .001). Renal-venous blood samplings (ie, at 0, 5, 10, and 30 minutes after CD34+ cell infusion) demonstrated significant progressive increases in EPC level (P for trend <.001) among the TG patients. One-year combined unfavorable clinical outcomes were significantly lower in TG than those in CG (0% [0] vs 13.3% [4], P = .038). By 12 months after CD34+ cell therapy, circulating creatinine level, ratio of urine protein to urine creatinine, and creatinine clearance showed no difference between TG and CG (all P > .1). CONCLUSION CD34+ cell therapy was safe and improved 1-year outcome.",2020,The baseline endothelial progenitor cell (EPC) populations did not differ between TG and CG (P > .5).,"['Between October 2016 and July 2018, 52 consecutive patients with CKD at stage III or IV', 'patients with chronic kidney disease (CKD; ie, stage III or IV', 'patients with chronic kidney disease']","['CD31+CD133+CD45', 'control group (CG; standardized pharmacotherapy', 'intrarenal arterial autologous CD34+ cell transfusion', 'CD34+CD133+KDR+/CD133', 'CD34+ cell therapy', 'intrarenal artery infusion of autologous peripheral-blood-derived CD34+ cells']","['Safety and efficacy', 'safety and change of creatinine level/creatinine clearance', 'circulating EPC', 'Renal-venous blood samplings', '12-month combined unfavorable clinical outcomes (defined as dialysis or death), improvement in proteinuria, and CD34+ cell-related adverse events', 'EPC level', 'baseline endothelial progenitor cell (EPC) populations', 'Matrigel assay of angiogenesis', 'circulating creatinine level, ratio of urine protein to urine creatinine, and creatinine clearance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0882849', 'cui_str': 'Cell positive for CD34 antigen'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0201975', 'cui_str': 'Creatinine measurement'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine'}, {'cui': 'C3850017', 'cui_str': 'Circulating Endothelial Progenitor Cells'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0190979', 'cui_str': 'Phlebotomy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0882849', 'cui_str': 'Cell positive for CD34 antigen'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0065749', 'cui_str': 'matrigel'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0262923', 'cui_str': 'Urine protein test'}, {'cui': 'C1318439', 'cui_str': 'Creatinine measurement, urine'}]",52.0,0.0442942,The baseline endothelial progenitor cell (EPC) populations did not differ between TG and CG (P > .5).,"[{'ForeName': 'Chih-Chao', 'Initials': 'CC', 'LastName': 'Yang', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.'}, {'ForeName': 'Pei-Hsun', 'Initials': 'PH', 'LastName': 'Sung', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.'}, {'ForeName': 'Ben-Chung', 'Initials': 'BC', 'LastName': 'Cheng', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.'}, {'ForeName': 'Yi-Chen', 'Initials': 'YC', 'LastName': 'Li', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.'}, {'ForeName': 'Yi-Ling', 'Initials': 'YL', 'LastName': 'Chen', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.'}, {'ForeName': 'Mel S', 'Initials': 'MS', 'LastName': 'Lee', 'Affiliation': 'Department of Orthopedics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.'}, {'ForeName': 'Hon-Kan', 'Initials': 'HK', 'LastName': 'Yip', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.'}]",Stem cells translational medicine,['10.1002/sctm.19-0409'] 235,31315612,"Intensive virtual reality and robotic based upper limb training compared to usual care, and associated cortical reorganization, in the acute and early sub-acute periods post-stroke: a feasibility study.","BACKGROUND There is conflict regarding the benefits of greater amounts of intensive upper limb rehabilitation in the early period post-stroke. This study was conducted to test the feasibility of providing intensive therapy during the early period post-stroke and to develop a randomized control trial that is currently in process. Specifically, the study investigated whether an additional 8 h of specialized, intensive (200-300 separate hand or arm movements per hour) virtual reality (VR)/robotic based upper limb training introduced within 1-month post-stroke resulted in greater improvement in impairment and behavior, and distinct changes in cortical reorganization measured via Transcranial Magnetic Stimulation (TMS), compared to that of a control group. METHODS Seven subjects received 8-1 h sessions of upper limb VR/robotic training in addition to their inpatient therapy (PT, OT, ST). Six subjects only received their inpatient therapy. All were tested on measures of impairment [Upper Extremity Fugl-Meyer Assessment (UEFMA), Wrist AROM, Maximum Pinch Force], behavior [Wolf Motor Function Test (WMFT)], and also received TMS mapping until 6 months post training. ANOVAs were conducted to measure differences between groups across time for all outcome measures. Associations between changes in ipsilesional cortical maps during the early period of enhanced neuroplasticity and long-term changes in upper limb impairment and behavior measures were evaluated. RESULTS The VR/robotic group made significantly greater improvements on UEFMA and Wrist AROM scores compared to the usual care group. There was also less variability in the association between changes in the First Dorsal Interosseus (FDI) muscle map area and WMFT and Maximum Force change scores for the VR/robotic group. CONCLUSIONS An additional 8 h of intensive VR/robotic based upper limb training initiated within the first month post-stroke may promote greater gains in impairment compared to usual care alone. Importantly, the data presented demonstrated the feasibility of conducting this intervention and multiple outcome measures (impairment, behavioral, neurophysiological) in the early period post-stroke.",2019,The VR/robotic group made significantly greater improvements on UEFMA and Wrist AROM scores compared to the usual care group.,['Seven subjects received'],"['8-1\u2009h sessions of upper limb VR/robotic training in addition to their inpatient therapy (PT, OT, ST', 'intensive therapy', 'intensive VR/robotic based upper limb training', 'additional 8\u2009h of specialized, intensive (200-300 separate hand or arm movements per hour) virtual reality (VR)/robotic based upper limb training', 'Intensive virtual reality and robotic based upper limb training compared to usual care, and associated cortical reorganization']","['UEFMA and Wrist AROM scores', 'impairment [Upper Extremity Fugl-Meyer Assessment (UEFMA), Wrist AROM, Maximum Pinch Force], behavior [Wolf Motor Function Test (WMFT', 'impairment and behavior, and distinct changes in cortical reorganization measured via Transcranial Magnetic Stimulation (TMS', 'First Dorsal Interosseus (FDI) muscle map area and WMFT and Maximum Force change scores']","[{'cui': 'C0205453', 'cui_str': '7'}]","[{'cui': 'C0700308', 'cui_str': 'Protium (substance)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0556501', 'cui_str': 'Upper limb training (procedure)'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0443299', 'cui_str': 'Separate (qualifier value)'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0564385', 'cui_str': 'per hour'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}]","[{'cui': 'C0043262', 'cui_str': 'Wrist'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0418416', 'cui_str': 'Pinched (event)'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0325001', 'cui_str': 'Wolves'}, {'cui': 'C0234130', 'cui_str': 'Motor function (observable entity)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation (procedure)'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0024779', 'cui_str': 'Map'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",300.0,0.0240431,The VR/robotic group made significantly greater improvements on UEFMA and Wrist AROM scores compared to the usual care group.,"[{'ForeName': 'Jigna', 'Initials': 'J', 'LastName': 'Patel', 'Affiliation': 'Department of Rehabilitation and Movement Sciences, School of Health Professions, Rutgers University, The State University of New Jersey, 65 Bergen Street, Newark, NJ, 07107, USA. patel421@shp.rutgers.edu.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Fluet', 'Affiliation': 'Department of Rehabilitation and Movement Sciences, School of Health Professions, Rutgers University, The State University of New Jersey, 65 Bergen Street, Newark, NJ, 07107, USA.'}, {'ForeName': 'Qinyin', 'Initials': 'Q', 'LastName': 'Qiu', 'Affiliation': 'Department of Rehabilitation and Movement Sciences, School of Health Professions, Rutgers University, The State University of New Jersey, 65 Bergen Street, Newark, NJ, 07107, USA.'}, {'ForeName': 'Mathew', 'Initials': 'M', 'LastName': 'Yarossi', 'Affiliation': 'Movement Neuroscience Laboratory, Department of Physical Therapy, Bouve College of Health Sciences, Movement and Rehabilitation Science, Northeastern University, 308C Robinson Hall - 360 Huntington Avenue, Boston, MA, 02115, USA.'}, {'ForeName': 'Alma', 'Initials': 'A', 'LastName': 'Merians', 'Affiliation': 'Department of Rehabilitation and Movement Sciences, School of Health Professions, Rutgers University, The State University of New Jersey, 65 Bergen Street, Newark, NJ, 07107, USA.'}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Tunik', 'Affiliation': 'Movement Neuroscience Laboratory, Department of Physical Therapy, Bouve College of Health Sciences, Movement and Rehabilitation Science, Northeastern University, 308C Robinson Hall - 360 Huntington Avenue, Boston, MA, 02115, USA.'}, {'ForeName': 'Sergei', 'Initials': 'S', 'LastName': 'Adamovich', 'Affiliation': 'Department of Biomedical Engineering, New Jersey Institute of Technology, 616 Fenster Hall - 323 Dr. MLK Jr. BLVD, Newark, NJ, 07102, USA.'}]",Journal of neuroengineering and rehabilitation,['10.1186/s12984-019-0563-3'] 236,31403327,Considering anticipated regret may reduce colorectal cancer screening intentions: a randomised controlled trial.,"Objective: Regular screening for colorectal cancer (CRC) can substantially improve outcomes. This study investigated how measuring regret expected from failing to screen might lead to stronger screening intentions. Five potential moderators were evaluated: perceived threat, psychological reactance, prior screening participation, concurrently measuring faecal aversion (FA) and anticipated regret (AR). Design: A 2 (AR measured pre/post intention) × 2 (FA measured pre/post intention) single blind parallel randomised controlled trial was used. Australians aged 45 and over completed an online survey measuring AR, FA, intention, theory of planned behaviour variables and potential moderators. Main outcome measures: The primary outcome was CRC screening intention. Results: Eight hundred and three participants were randomised, with 666 analysed. Measuring AR prior to intention unexpectedly resulted in a significantly lower intention to screen ( d  = 0.18, 95% CI [0.03, 0.33]) compared to measuring after intention. Trait reactance predicted a significantly lower intention when it was at least 0.52 SD above the mean; other moderators were not supported. Conclusion: The processes underlying anticipated regret manipulations must be better understood in order to have practical value in health promotion. More research is required to determine how to minimise or avoid the apparent negative effects of psychological reactance in CRC screening communication. Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12618001098224 http://www.ANZCTR.org.au/ACTRN12618001098224.aspx.",2020,Trait reactance predicted a significantly lower intention when it was at least 0.52 SD above the mean; other moderators were not supported. ,"['Eight hundred and three participants were randomised, with 666 analysed', 'colorectal cancer (CRC']",['Regular screening'],"['threat, psychological reactance, prior screening participation, concurrently measuring faecal aversion (FA) and anticipated regret (AR', 'colorectal cancer screening intentions', 'CRC screening intention', 'Trait reactance']","[{'cui': 'C3844106', 'cui_str': 'Eight hundred'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0170127', 'cui_str': 'Calcibiotic Root Canal Sealer'}]","[{'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}]","[{'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0233496', 'cui_str': 'Aversion (finding)'}, {'cui': 'C0080101', 'cui_str': 'Regret'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0170127', 'cui_str': 'Calcibiotic Root Canal Sealer'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}]",803.0,0.174368,Trait reactance predicted a significantly lower intention when it was at least 0.52 SD above the mean; other moderators were not supported. ,"[{'ForeName': 'Hugh', 'Initials': 'H', 'LastName': 'Hunkin', 'Affiliation': 'School of Psychology, University of Adelaide, Adelaide, SA, Australia.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Turnbull', 'Affiliation': 'School of Psychology, University of Adelaide, Adelaide, SA, Australia.'}, {'ForeName': 'Ian T', 'Initials': 'IT', 'LastName': 'Zajac', 'Affiliation': 'School of Psychology, University of Adelaide, Adelaide, SA, Australia.'}]",Psychology & health,['10.1080/08870446.2019.1649407'] 237,31595302,"Oxytocin Enhances an Amygdala Circuit Associated With Negative Symptoms in Schizophrenia: A Single-Dose, Placebo-Controlled, Crossover, Randomized Control Trial.","Negative symptoms are core contributors to vocational and social deficits in schizophrenia (SZ). Available antipsychotic medications typically fail to reduce these symptoms. The neurohormone oxytocin (OT) is a promising treatment for negative symptoms, given its role in complex social behaviors mediated by the amygdala. In sample 1, we used a double-blind, placebo-controlled, crossover design to test the effects of a single dose of intranasal OT on amygdala resting-state functional connectivity (rsFC) in SZ (n = 22) and healthy controls (HC, n = 24) using a whole-brain corrected approach: we identified regions for which OT modulated SZ amygdala rsFC, assessed whether OT-modulated circuits were abnormal in SZ relative to HC on placebo, and evaluated whether connectivity on placebo and OT-induced connectivity changes correlated with baseline negative symptoms in SZ. Given our modest sample size, we used a second SZ (n = 183) and HC (n = 178) sample to replicate any symptom correlations. In sample 1, OT increased rsFC between the amygdala and left middle temporal gyrus, superior temporal sulcus, and angular gyrus (MTG/STS/AngG) in SZ compared to HC. Further, SZ had hypo-connectivity in this circuit compared to HC on placebo. More severe negative symptoms correlated with less amygdala-to-left-MTG/STS/AngG connectivity on placebo and with greater OT-induced connectivity increases. In sample 2, we replicated the correlation between amygdala-left-MTG/STS/AngG hypo-connectivity and negative symptoms, finding a specific association with expressive negative symptoms. These data suggest intranasal OT can normalize functional connectivity in an amygdala-to-left-MTG/STS/AngG circuit that contributes to negative symptoms in SZ.",2020,More severe negative symptoms correlated with less amygdala-to-left-MTG/STS/AngG connectivity on placebo and with greater OT-induced connectivity increases.,"['SZ (n = 22) and healthy controls (HC, n = 24', 'Schizophrenia']","['Placebo', 'SZ', 'placebo', 'intranasal OT', 'Oxytocin', 'neurohormone oxytocin (OT']","['hypo-connectivity', 'severe negative symptoms', 'amygdala resting-state functional connectivity (rsFC']","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0597049', 'cui_str': 'Neurohormones'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid Body'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}]",,0.133066,More severe negative symptoms correlated with less amygdala-to-left-MTG/STS/AngG connectivity on placebo and with greater OT-induced connectivity increases.,"[{'ForeName': 'Samantha V', 'Initials': 'SV', 'LastName': 'Abram', 'Affiliation': 'Sierra Pacific Mental Illness Research Education and Clinical Centers, San Francisco VA Medical Center, and the University of California, San Francisco, CA.'}, {'ForeName': 'Lize', 'Initials': 'L', 'LastName': 'De Coster', 'Affiliation': 'Department of Computer Science, Universidad Carlos III de Madrid, Madrid, Spain.'}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Roach', 'Affiliation': 'Mental Health Service, San Francisco Veterans Affairs Medical Center, San Francisco, CA.'}, {'ForeName': 'Bryon A', 'Initials': 'BA', 'LastName': 'Mueller', 'Affiliation': 'Department of Psychiatry, University of Minnesota, Minneapolis, MN.'}, {'ForeName': 'Theo G M', 'Initials': 'TGM', 'LastName': 'van Erp', 'Affiliation': 'Clinical Translational Neuroscience Laboratory, Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, CA, USA.'}, {'ForeName': 'Vince D', 'Initials': 'VD', 'LastName': 'Calhoun', 'Affiliation': 'The Mind Research Network, Albuquerque, NM.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Preda', 'Affiliation': 'Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, CA, USA.'}, {'ForeName': 'Kelvin O', 'Initials': 'KO', 'LastName': 'Lim', 'Affiliation': 'Department of Psychiatry, University of Minnesota, Minneapolis, MN.'}, {'ForeName': 'Jessica A', 'Initials': 'JA', 'LastName': 'Turner', 'Affiliation': 'Department of Psychology, Georgia State University, Atlanta, GA.'}, {'ForeName': 'Judith M', 'Initials': 'JM', 'LastName': 'Ford', 'Affiliation': 'Mental Health Service, San Francisco Veterans Affairs Medical Center, San Francisco, CA.'}, {'ForeName': 'Daniel H', 'Initials': 'DH', 'LastName': 'Mathalon', 'Affiliation': 'Mental Health Service, San Francisco Veterans Affairs Medical Center, San Francisco, CA.'}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Woolley', 'Affiliation': 'Mental Health Service, San Francisco Veterans Affairs Medical Center, San Francisco, CA.'}]",Schizophrenia bulletin,['10.1093/schbul/sbz091'] 238,31612956,Cannabis and Alcohol Co-Use in a Smoking Cessation Pharmacotherapy Trial for Adolescents and Emerging Adults.,"INTRODUCTION The co-use of cannabis and alcohol among tobacco-using youth is common. Alcohol co-use is associated with worse tobacco cessation outcomes, but results are mixed regarding the impact of cannabis on tobacco outcomes and if co-use leads to increased use of non-treated substances. This secondary analysis from a youth smoking cessation trial aimed to (1) evaluate the impact of cannabis or alcohol co-use on smoking cessation, (2) examine changes in co-use during the trial, and (3) explore secondary effects of varenicline on co-use. METHODS The parent study was a 12-week, randomized clinical trial of varenicline for smoking cessation among youth (ages 14-21, N = 157; Mage = 19, 40% female; 76% White). Daily cigarette, cannabis, and alcohol use data were collected via daily diaries during treatment and Timeline Follow-back for 14 weeks post-treatment. RESULTS Baseline cannabis co-users (68%) had double the odds of continued cigarette smoking throughout the trial compared with noncannabis users, which was pronounced in males and frequent cannabis users. Continued smoking during treatment was associated with higher probability of concurrent cannabis use. Baseline alcohol co-users (80%) did not have worse smoking outcomes compared with nonalcohol users, but continued smoking was associated with higher probability of concurrent drinking. Varenicline did not affect co-use. CONCLUSIONS Inconsistent with prior literature, results showed that alcohol co-users did not differ in smoking cessation, whereas cannabis co-users had poorer cessation outcomes. Youth tobacco treatment would benefit from added focus on substance co-use, particularly cannabis, but may need to be tailored appropriately to promote cessation. IMPLICATIONS Among youth cigarette smokers enrolled in a pharmacotherapy evaluation clinical trial, alcohol and/or cannabis co-use was prevalent. The co-use of cannabis affected smoking cessation outcomes, but more so for males and frequent cannabis users, whereas alcohol co-use did not affect smoking cessation. Reductions in smoking were accompanied by concurrent reductions in alcohol or cannabis use. Substance co-use does not appear to affect all youth smokers in the same manner and treatment strategies may need to be tailored appropriately for those with lower odds of smoking cessation.",2020,"The co-use of cannabis affected smoking cessation outcomes, but more so for males and frequent cannabis users, whereas alcohol co-use did not affect smoking cessation.","['youth cigarette smokers', 'Adolescents and Emerging Adults', 'smoking cessation among youth (ages 14-21, N = 157; Mage = 19, 40% female; 76% White']","['varenicline', 'cannabis or alcohol co-use', 'Varenicline']",['cigarette smoking'],"[{'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0337667', 'cui_str': 'Cigarette smoker (finding)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0043157', 'cui_str': 'Whites'}]","[{'cui': 'C1569608', 'cui_str': 'varenicline'}, {'cui': 'C0678449', 'cui_str': 'Cannabis'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C1947944', 'cui_str': 'Use'}]","[{'cui': 'C0700219', 'cui_str': 'Cigarette Smoking'}]",,0.0318818,"The co-use of cannabis affected smoking cessation outcomes, but more so for males and frequent cannabis users, whereas alcohol co-use did not affect smoking cessation.","[{'ForeName': 'Erin A', 'Initials': 'EA', 'LastName': 'McClure', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Nathaniel L', 'Initials': 'NL', 'LastName': 'Baker', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Caitlyn O', 'Initials': 'CO', 'LastName': 'Hood', 'Affiliation': 'Department of Psychology, University of Kentucky, Lexington, KY.'}, {'ForeName': 'Rachel L', 'Initials': 'RL', 'LastName': 'Tomko', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Lindsay M', 'Initials': 'LM', 'LastName': 'Squeglia', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Julianne C', 'Initials': 'JC', 'LastName': 'Flanagan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Carpenter', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'Gray', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntz170'] 239,32291702,Randomized Controlled Trial Comparing the Outcomes of Enhanced Recovery After Surgery and Standard Recovery Pathways in Laparoscopic Sleeve Gastrectomy.,"PURPOSE The enhanced recovery after surgery (ERAS) pathway is an evidence-based perioperative pathway that results in less pain, earlier recovery, and lower complication rates. Studies to prove their efficacy over standard recovery pathways in the Indian population are scarce. Our study intends to compare the outcomes of these pathways in the Indian community focusing on hospital stay, postoperative pain, and time for rescue analgesia. MATERIALS AND METHODS This is a single-blinded RCT involving 112 patients who underwent laparoscopic sleeve gastrectomy (LSG). The groups were divided into ERAS and standard pathway arms by closed envelope technique. The primary outcome was the length of hospital stay, while the secondary outcomes included pain score; postoperative nausea, and vomiting (PONV); time for rescue analgesia; and ambulation. RESULTS Of 112 patients included, 56 were allocated in the ERAS group, and the remaining 56 were included in the standard pathway group. We found no significant differences in the baseline characteristics between the two groups. Mean hospital stay was significantly lower in the ERAS group compared to the standard group (p = 0.003). In comparison to the standard group, ERAS patients were ambulated early, and the difference was highly significant (p < 0.001). Pain scores between the two groups showed a significant difference during the 4th hour and 8th hour. We also found a significant variation between the time for first rescue analgesia and the two groups (p < 0.001). CONCLUSION Patients who followed ERAS protocol were found to have shortened hospital stay, decreased pain, early ambulation, and reduced need for rescue analgesia. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03191318.",2020,Mean hospital stay was significantly lower in the ERAS group compared to the standard group (p = 0.003).,"['Of 112 patients included, 56 were allocated in the ERAS group, and the remaining 56 were included in the standard pathway group', '112 patients who underwent']","['ERAS', 'ERAS and standard pathway arms by closed envelope technique', 'laparoscopic sleeve gastrectomy (LSG', 'Laparoscopic Sleeve Gastrectomy']","['length of hospital stay', 'pain score; postoperative nausea, and vomiting (PONV); time for rescue analgesia; and ambulation', 'Pain scores', 'Mean hospital stay', 'shortened hospital stay, decreased pain, early ambulation, and reduced need for rescue analgesia', 'hospital stay, postoperative pain, and time for rescue analgesia']","[{'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C5197734', 'cui_str': 'Enhanced Postsurgical Recovery'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}]","[{'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0520904', 'cui_str': 'Postoperative nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0013457', 'cui_str': 'Ambulation, Early'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}]",112.0,0.0908106,Mean hospital stay was significantly lower in the ERAS group compared to the standard group (p = 0.003).,"[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Prabhakaran', 'Affiliation': 'Department of Bariatric and Metabolic Surgery, GEM Hospital & Research Center, Coimbatore, Tamil Nadu, 641045, India.'}, {'ForeName': 'Shivanshu', 'Initials': 'S', 'LastName': 'Misra', 'Affiliation': 'Department of Bariatric and Metabolic Surgery, GEM Hospital & Research Center, Coimbatore, Tamil Nadu, 641045, India.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Magila', 'Affiliation': 'Department of Bariatric and Metabolic Surgery, GEM Hospital & Research Center, Coimbatore, Tamil Nadu, 641045, India.'}, {'ForeName': 'S Saravana', 'Initials': 'SS', 'LastName': 'Kumar', 'Affiliation': 'Department of Bariatric and Metabolic Surgery, GEM Hospital & Research Center, Coimbatore, Tamil Nadu, 641045, India.'}, {'ForeName': 'Sudarsan', 'Initials': 'S', 'LastName': 'Kasthuri', 'Affiliation': 'Department of Bariatric and Metabolic Surgery, GEM Hospital & Research Center, Coimbatore, Tamil Nadu, 641045, India.'}, {'ForeName': 'Chinnusamy', 'Initials': 'C', 'LastName': 'Palanivelu', 'Affiliation': 'Department of Bariatric and Metabolic Surgery, GEM Hospital & Research Center, Coimbatore, Tamil Nadu, 641045, India.'}, {'ForeName': 'P Praveen', 'Initials': 'PP', 'LastName': 'Raj', 'Affiliation': 'Department of Bariatric and Metabolic Surgery, GEM Hospital & Research Center, Coimbatore, Tamil Nadu, 641045, India. praveenraj@me.com.'}]",Obesity surgery,['10.1007/s11695-020-04585-2'] 240,31944221,Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.,"Importance A randomized clinical trial is needed to determine whether the second-generation Abl-tyrosine kinase inhibitor dasatinib is more effective than the first-generation inhibitor imatinib mesylate for childhood Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Objective To determine whether dasatinib given at a daily dosage of 80 mg/m2 is more effective than imatinib mesylate at a daily dosage of 300 mg/m2 to improve event-free survival of children with Philadelphia chromosome-positive ALL in the context of intensive chemotherapy without prophylactic cranial irradiation. Design, Setting, and Participants This open-label, phase 3 randomized clinical trial was conducted at 20 hospitals in China. Enrollment occurred from January 1, 2015, through September 18, 2018, and randomization was stopped on October 4, 2018, when the early stopping criterion of the trial was met. Patients aged 0 to 18 years were recruited. Of the 225 patients with the diagnosis, 35 declined participation and 1 died before treatment, leaving 189 patients available for analysis. Data were analyzed from January 1 through August 4, 2019. Interventions Patients were randomized to receive daily dasatinib (n = 92) or imatinib (n = 97) continuously for the entire duration of ALL therapy from the time of diagnosis made during remission induction to the end of continuation therapy. Main Outcomes and Measures The primary outcome was event-free survival, analyzed based on intention to treat. The secondary outcomes were relapse, death due to toxic effects, and overall survival. Results Among the 189 participants (136 male [72.0%]; median age, 7.8 [interquartile range (IQR), 5.2-11.3] years) and a median follow-up of 26.4 (IQR, 16.3-34.1) months, the 4-year event-free survival and overall survival rates were 71.0% (95% CI, 56.2%-89.6%) and 88.4% (95% CI, 81.3%-96.1%), respectively, in the dasatinib group and 48.9% (95% CI, 32.0%-74.5%; P = .005, log-rank test) and 69.2% (95% CI, 55.6%-86.2%; P = .04, log-rank test), respectively, in the imatinib group. The 4-year cumulative risk of any relapse was 19.8% (95% CI, 4.2%-35.4%) in the dasatinib group and 34.4% (95% CI, 15.6%-53.2%) in the imatinib group (P = .01, Gray test), whereas the 4-year cumulative risk of an isolated central nervous system relapse was 2.7% (95% CI, 0.0%-8.1%) in the dasatinib group and 8.4% (95% CI, 1.2%-15.6%) in the imatinib group (P = .06, Gray test). There were no significant differences in the frequency of severe toxic effects between the 2 treatment groups. Conclusions and Relevance Intensive chemotherapy including dasatinib at a dosage of 80 mg/m2 per day yielded superior results in the treatment of Philadelphia chromosome-positive ALL compared with imatinib mesylate at a dosage of 300 mg/m2 per day and provided excellent control of central nervous system leukemia without the use of prophylactic cranial irradiation. Trial Registration Chinese Clinical Trial Registry: ChiCTR-IPR-14005706.",2020,"There were no significant differences in the frequency of severe toxic effects between the 2 treatment groups. ","['20 hospitals in China', '225 patients with the diagnosis, 35 declined participation and 1 died before treatment, leaving 189 patients available for analysis', 'Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia', 'childhood Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL', 'children with Philadelphia chromosome-positive ALL in the context of intensive chemotherapy without prophylactic cranial irradiation', '189 participants (136 male [72.0%]; median age, 7.8 [interquartile range (IQR), 5.2-11.3] years', 'Patients aged 0 to 18 years were recruited']","['Dasatinib vs Imatinib', 'daily dasatinib (n\u2009=\u200992) or imatinib', 'imatinib mesylate']","['frequency of severe toxic effects', 'event-free survival', '4-year event-free survival and overall survival rates', '4-year cumulative risk of any relapse', '4-year cumulative risk of an isolated central nervous system relapse', 'relapse, death due to toxic effects, and overall survival']","[{'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C4517652', 'cui_str': '225 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C1709527', 'cui_str': 'Ph+ acute lymphoblastic leukemia'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0856536', 'cui_str': 'Philadelphia chromosome positive'}, {'cui': 'C0449255', 'cui_str': 'Context (attribute)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}, {'cui': 'C0079172', 'cui_str': 'Cranial Irradiation'}, {'cui': 'C4517568', 'cui_str': 'One hundred and thirty-six'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C4517790', 'cui_str': '5.2 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C1455147', 'cui_str': 'dasatinib'}, {'cui': 'C0935989', 'cui_str': 'imatinib'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0939537', 'cui_str': 'Imatinib mesylate'}]","[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",189.0,0.392935,"There were no significant differences in the frequency of severe toxic effects between the 2 treatment groups. ","[{'ForeName': 'Shuhong', 'Initials': 'S', 'LastName': 'Shen', 'Affiliation': ""National Children's Medical Center, Department of Hematology/Oncology, Key Laboratory of Pediatric Hematology and Oncology of China Ministry of Health, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Xiaojuan', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'State Key Laboratory of Experimental Hematology and Division of Pediatric Blood Diseases Center, Institute of Hematology and Blood Diseases Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Tianjin, China.'}, {'ForeName': 'Jiaoyang', 'Initials': 'J', 'LastName': 'Cai', 'Affiliation': ""National Children's Medical Center, Department of Hematology/Oncology, Key Laboratory of Pediatric Hematology and Oncology of China Ministry of Health, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': ""Department of Hematology/Oncology, Chongqing Medical University Affiliated Children's Hospital, Chongqing, China.""}, {'ForeName': 'Ju', 'Initials': 'J', 'LastName': 'Gao', 'Affiliation': 'Department of Pediatrics, Key Laboratory of Birth Defects and Related Disease of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Shaoyan', 'Initials': 'S', 'LastName': 'Hu', 'Affiliation': ""Department of Hematology/Oncology, Children's Hospital of Soochow University, Suzhou, China.""}, {'ForeName': 'Xiaowen', 'Initials': 'X', 'LastName': 'Zhai', 'Affiliation': ""Department of Hematology/Oncology, Children's Hospital of Fudan University, Shanghai, China.""}, {'ForeName': 'Changda', 'Initials': 'C', 'LastName': 'Liang', 'Affiliation': ""Department of Hematology/Oncology, Jiangxi Provincial Children's Hospital, Nanchang, China.""}, {'ForeName': 'Xiuli', 'Initials': 'X', 'LastName': 'Ju', 'Affiliation': 'Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, China.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Jiang', 'Affiliation': ""Department of Hematology/Oncology, Guangzhou Women and Children's Medical Center, Guangzhou, China.""}, {'ForeName': 'Runming', 'Initials': 'R', 'LastName': 'Jin', 'Affiliation': 'Department of Pediatrics, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Xuedong', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Ningling', 'Initials': 'N', 'LastName': 'Wang', 'Affiliation': 'Department of Pediatrics, Anhui Medical University Second Affiliated Hospital, Anhui, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Tian', 'Affiliation': ""Department of Hematology/Oncology, Kunming Children's Hospital, Kunming, China.""}, {'ForeName': 'Kaili', 'Initials': 'K', 'LastName': 'Pan', 'Affiliation': ""Department of Hematology/Oncology, Xi'an Northwest Women and Children Hospital, Xi'an, China.""}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Jiang', 'Affiliation': ""Department of Hematology/Oncology, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, China.""}, {'ForeName': 'Lirong', 'Initials': 'L', 'LastName': 'Sun', 'Affiliation': 'Department of Pediatrics, Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Yongjun', 'Initials': 'Y', 'LastName': 'Fang', 'Affiliation': ""Department of Hematology/Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China.""}, {'ForeName': 'Chi-Kong', 'Initials': 'CK', 'LastName': 'Li', 'Affiliation': ""Department of Pediatrics, Hong Kong Children's Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.""}, {'ForeName': 'Qun', 'Initials': 'Q', 'LastName': 'Hu', 'Affiliation': 'Department of Pediatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Minghua', 'Initials': 'M', 'LastName': 'Yang', 'Affiliation': 'Department of Pediatrics, Xiangya Hospital Central South University, Changsha, China.'}, {'ForeName': 'Yiping', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'Department of Pediatrics, Key Laboratory of Birth Defects and Related Disease of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': ""Department of Hematology/Oncology, Guangzhou Women and Children's Medical Center, Guangzhou, China.""}, {'ForeName': 'Chunfu', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Deqing', 'Initials': 'D', 'LastName': 'Pei', 'Affiliation': ""Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee.""}, {'ForeName': 'Sima', 'Initials': 'S', 'LastName': 'Jeha', 'Affiliation': ""Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee.""}, {'ForeName': 'Jun J', 'Initials': 'JJ', 'LastName': 'Yang', 'Affiliation': ""Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee.""}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Cheng', 'Affiliation': ""Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee.""}, {'ForeName': 'Jingyan', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': ""National Children's Medical Center, Department of Hematology/Oncology, Key Laboratory of Pediatric Hematology and Oncology of China Ministry of Health, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Xiaofan', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'State Key Laboratory of Experimental Hematology and Division of Pediatric Blood Diseases Center, Institute of Hematology and Blood Diseases Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Tianjin, China.'}, {'ForeName': 'Ching-Hon', 'Initials': 'CH', 'LastName': 'Pui', 'Affiliation': ""Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee.""}]",JAMA oncology,['10.1001/jamaoncol.2019.5868'] 241,32291095,"A randomized half-body, double blind, controlled trial on the effects of a pH-modified moisturizer vs. standard moisturizer in mild to moderate atopic dermatitis.","BACKGROUND Higher skin pH in atopic dermatitis contributes to impaired epidermal barrier. A moisturizer compatible with physiological pH could improve atopic dermatitis. OBJECTIVE To determine the effect of a physiologically compatible pH moisturizer in atopic dermatitis. METHODS A randomized half body, double blind, controlled trial involving patients with stable atopic dermatitis was performed. pH-modified moisturizer and standard moisturizer were applied to half body for 6 weeks. RESULTS A total of 6 (16.7%) males and 30 (83.3%) females participated. Skin pH reductions from week 0, week 2 and 6 were significant at the forearms (5.315 [0.98] to 4.85 [0.54] to 5.04 [0.78], p=0.02) and abdomen (5.25 [1.01], 4.82 [0.64], 5.01 [0.59], p=0.00) but not at the shins (5.01 [0.80], 4.76 [0.49], 4.85 [0.79], p=0.09) with pH-modified moisturizer. Transepidermal water loss (TEWL) at the forearms decreased (4.60 [2.55] to 3.70 [3.10] to 3.00 [3.55], p=0.00), abdomen (3.90 [2.90] to 2.40 [3.45] to 2.70 [2.25], p=0.046). SCORAD improved from 14.1±12.75 to 10.5±13.25 to 7±12.25, p=0.00. In standard moisturizer group, pH reductions were significant at the forearms (5.29 [0.94] to 4.84 [0.55] to 5.02 [0.70], p=0.00) and abdomen (5.25 [1.09], 4.91 [0.63], 5.12 [0.66], p=0.00). TEWL at the forearm were (4.80 [2.95], 4.10 [2.15], 4.60 [3.40], p=0.67), shins (3.80 [1.40], 3.50 [2.35], 4.00 [2.50], p=0.91) and abdomen (3.70 [2.45], 4.10 [3.60], 3.40 [2.95], p=0.80). SCORAD improved from 14.2±9.1 to 10.9±10.65 to 10.5±11, p=0.00. Reduction in pH was observed with both moisturizers while TEWL significantly improved with pH-modified moisturizer. pH-modified moisturizer resulted in greater pH, TEWL and SCORAD improvements however the differences were not significant from standard moisturizer. STUDY LIMITATION Skin hydration was not evaluated. CONCLUSION Moisturization is beneficial for atopic dermatitis; use of physiologically compatible pH moisturizer is promising.",2020,"pH-modified moisturizer resulted in greater pH, TEWL and SCORAD improvements however the differences were not significant from standard moisturizer. ","['patients with stable atopic dermatitis', 'atopic dermatitis', 'mild to moderate atopic dermatitis', 'A total of 6 (16.7%) males and 30 (83.3%) females participated']","['Moisturization', 'pH-modified moisturizer vs. standard moisturizer', 'pH-modified moisturizer and standard moisturizer']","['greater pH, TEWL and SCORAD improvements', 'Reduction in pH', 'pH reductions', 'SCORAD', 'atopic dermatitis', 'Transepidermal water loss (TEWL', 'Skin pH reductions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517590', 'cui_str': '16.7'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C0232445', 'cui_str': 'Acid mantle'}]",,0.11098,"pH-modified moisturizer resulted in greater pH, TEWL and SCORAD improvements however the differences were not significant from standard moisturizer. ","[{'ForeName': 'Siew Wen', 'Initials': 'SW', 'LastName': 'Goh', 'Affiliation': 'Dermatology Unit, Medical Department, University Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia; Dermatology Unit, Department of Medicine, University Kebangsaan Malaysia Medical Center, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Adawiyah', 'Initials': 'A', 'LastName': 'Jamil', 'Affiliation': 'Department of Medicine, University Kebangsaan Malaysia Medical Center, Kuala Lumpur, Malaysia; Dermatology Unit, Department of Medicine, University Kebangsaan Malaysia Medical Center, Kuala Lumpur, Malaysia. Electronic address: adda_jamil@yahoo.com.'}, {'ForeName': 'Nazarudin', 'Initials': 'N', 'LastName': 'Safian', 'Affiliation': 'Department of Community Health, Faculty of Medicine, University Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Norazirah', 'Initials': 'N', 'LastName': 'Md Nor', 'Affiliation': 'Dermatology Unit, Medical Department, University Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia; Dermatology Unit, Department of Medicine, University Kebangsaan Malaysia Medical Center, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Norliza', 'Initials': 'N', 'LastName': 'Muhammad', 'Affiliation': 'Department of Pharmacology, Faculty of Medicine, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Nur Liyana', 'Initials': 'NL', 'LastName': 'Saharudin', 'Affiliation': 'Department of Pharmacy, University Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.'}]",Anais brasileiros de dermatologia,['10.1016/j.abd.2019.11.007'] 242,31337807,Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants.,"Altogether, 20-30% of women receive intrapartum antibiotic prophylaxis (IAP) to prevent sepsis in infants and 2-5% of newborn infants receive antibiotics due to suspected sepsis. Caesarean section has a long-term impact on the intestinal microbiome but the effects of perinatal antibiotics on gut microbiome in vaginally delivered infants are not well known. We compared the impact of IAP, postnatal antibiotics, or their combination on the gut microbiome and emergence of antimicrobial resistance in a controlled study of 149 newborn infants recruited within 24 hours after birth. We collected 659 fecal samples, including 426 daily samples from infants before discharge from the hospital and 111 follow-up samples at six months. Penicillin was mostly used for IAP and the combination of penicillin and aminoglycoside for postnatal treatment. Postnatal antibiotic groups received Lactobacillus reuteri probiotic. Newborn gut colonization differed in both IAP and postnatal antibiotics groups as compared to that in control group. The effect size of IAP was comparable to that caused by postnatal antibiotics. The observed differences were still present at six months and not prevented by lactobacilli consumption. Given the present clinical results, the impact of perinatal antibiotics on the subsequent health of newborn infants should be further evaluated.",2019,Newborn gut colonization differed in both IAP and postnatal antibiotics groups as compared to that in control group.,"['149 newborn infants recruited within 24\u2009hours after birth', 'We collected 659 fecal samples, including 426 daily samples from infants before discharge from the hospital and 111 follow-up samples at six months', 'newborn infants', 'infants']","['intrapartum antibiotic prophylaxis (IAP', 'Penicillin', 'intrapartum and postnatal antibiotics', 'Lactobacillus reuteri probiotic', 'penicillin and aminoglycoside']",['Newborn gut colonization'],"[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0456337', 'cui_str': 'Intrapartum (qualifier value)'}, {'cui': 'C0282638', 'cui_str': 'Premedication, Antibiotic'}, {'cui': 'C0030842', 'cui_str': 'Antibiotics, Penicillin'}, {'cui': 'C0443281', 'cui_str': 'Postnatal (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0317625', 'cui_str': 'Lactobacillus reuteri'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}, {'cui': 'C0002556', 'cui_str': 'Aminoglycosides'}]","[{'cui': 'C0021289', 'cui_str': 'Newborns'}]",659.0,0.0366165,Newborn gut colonization differed in both IAP and postnatal antibiotics groups as compared to that in control group.,"[{'ForeName': 'Terhi', 'Initials': 'T', 'LastName': 'Tapiainen', 'Affiliation': 'Department of Pediatrics and Adolescence, Oulu University Hospital, 90029, Oulu, Finland. terhi.tapiainen@oulu.fi.'}, {'ForeName': 'Pirjo', 'Initials': 'P', 'LastName': 'Koivusaari', 'Affiliation': 'Ecology and Genetics, Faculty of Science, University of Oulu, Oulu, 90014, Finland.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Brinkac', 'Affiliation': 'J. Craig Venter Institute, Rockville, MD, 28050, USA. lbrinkac@jcvi.org.'}, {'ForeName': 'Hernan A', 'Initials': 'HA', 'LastName': 'Lorenzi', 'Affiliation': 'J. Craig Venter Institute, Rockville, MD, 28050, USA.'}, {'ForeName': 'Jarmo', 'Initials': 'J', 'LastName': 'Salo', 'Affiliation': 'Department of Pediatrics and Adolescence, Oulu University Hospital, 90029, Oulu, Finland.'}, {'ForeName': 'Marjo', 'Initials': 'M', 'LastName': 'Renko', 'Affiliation': 'Department of Pediatrics and Adolescence, Oulu University Hospital, 90029, Oulu, Finland.'}, {'ForeName': 'Hannele', 'Initials': 'H', 'LastName': 'Pruikkonen', 'Affiliation': 'PEDEGO Research Unit and Medical Research Center Oulu, University of Oulu, Oulu, 90014, Finland.'}, {'ForeName': 'Tytti', 'Initials': 'T', 'LastName': 'Pokka', 'Affiliation': 'Department of Pediatrics and Adolescence, Oulu University Hospital, 90029, Oulu, Finland.'}, {'ForeName': 'Weizhong', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'J. Craig Venter Institute, La Jolla, CA, 92037, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Nelson', 'Affiliation': 'J. Craig Venter Institute, Rockville, MD, 28050, USA.'}, {'ForeName': 'Anna Maria', 'Initials': 'AM', 'LastName': 'Pirttilä', 'Affiliation': 'J. Craig Venter Institute, Rockville, MD, 28050, USA.'}, {'ForeName': 'Mysore V', 'Initials': 'MV', 'LastName': 'Tejesvi', 'Affiliation': 'Ecology and Genetics, Faculty of Science, University of Oulu, Oulu, 90014, Finland.'}]",Scientific reports,['10.1038/s41598-019-46964-5'] 243,32289474,"5-Year Update of a Multi-Institution, Prospective Phase 2 Hypofractionated Postmastectomy Radiation Therapy Trial.","PURPOSE Hypofractionation in the setting of postmastectomy radiation (PMRT) is not currently the standard of care in most countries. Here we present a 5-year update of our multi-institutional, phase 2 prospective trial evaluating a novel 15-day hypofractionated PMRT regimen. METHODS AND MATERIALS Patients were enrolled to receive 3.33 Gy daily to the chest wall (or reconstructed breast) and regional lymphatics in 11 fractions with an optional 4-fraction mastectomy scar boost. The primary endpoint was freedom from grade 3 or higher late non-reconstruction-related radiation toxicities. Toxicities were scored using Common Terminology Criteria for Adverse Events v4.0. Secondary endpoints included local and locoregional recurrence rates, cosmesis, and reconstruction complications. RESULTS After enrolling 69 patients with stage II-IIIa breast cancer, 67 women were eligible for analysis. At a median follow up of 54 months, there were no acute or late grade 3 and 4 nonreconstruction reported toxicities. The grade 2 or greater late toxicity rate was only 12% and comprised grade 2 pain, fatigue, and lymphedema that persisted beyond 6 months after completion of radiation therapy. Only 3 women (4.6%) experienced a chest wall or nodal recurrence as a first site of relapse. Freedom from local failure, including local failure after distant relapse, was 92% at 5 years, and the 5-year overall survival was 90%. CONCLUSIONS This is the first prospective trial conducted in the United States to demonstrate the safe and effective use of hypofractionated PMRT. We have demonstrated a low complication rate while achieving excellent local control. Toxicity was better than anticipated based on previously published series of PMRT toxicities. Although our fractionation was novel, the radiobiological equivalent dose is similar to other hypofractionation schedules. This trial was the basis for the creation of Alliance A221505 (RT CHARM), which is currently accruing patients in a phase 3 randomized design.",2020,"Freedom from local failure, including local failure after distant relapse was 92% at 5 years and the 5-year overall survival was 90%. ","['Patients were enrolled to receive 3.33 Gray (Gy) daily to the', '69 patients with stage II-IIIa breast cancer, 67 women were eligible for analysis']","['post mastectomy radiation (PMRT', 'chest wall (or reconstructed breast) and regional lymphatics in 11 fractions with an optional 4 fraction mastectomy scar boost', 'Alliance Axxxxx (xxxxx', 'hypofractionated PMRT']","['late toxicity rate', 'low complication rate', 'toxicities', 'local failure after distant relapse', 'chest wall or nodal recurrence', 'Toxicities', 'Toxicity', 'freedom from grade 3 or higher late non-reconstruction related radiation toxicities', 'pain, fatigue and lymphedema', 'local and locoregional recurrence rates, cosmesis and reconstruction complications', '5-year overall survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517690', 'cui_str': '3.33'}, {'cui': 'C0556636', 'cui_str': 'Gy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0024881', 'cui_str': 'Mastectomy'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0205076', 'cui_str': 'Chest wall structure'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0024235', 'cui_str': 'Structure of lymphatic system'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}]","[{'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0443203', 'cui_str': 'Distant'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0205076', 'cui_str': 'Chest wall structure'}, {'cui': 'C0443268', 'cui_str': 'Nodal'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C1510432', 'cui_str': 'Radiation sickness'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0024236', 'cui_str': 'Lymphedema'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",69.0,0.105768,"Freedom from local failure, including local failure after distant relapse was 92% at 5 years and the 5-year overall survival was 90%. ","[{'ForeName': 'Matthew M', 'Initials': 'MM', 'LastName': 'Poppe', 'Affiliation': 'Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah. Electronic address: matthew.poppe@hci.utah.edu.'}, {'ForeName': 'Zeinab A', 'Initials': 'ZA', 'LastName': 'Yehia', 'Affiliation': 'Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Baker', 'Affiliation': 'Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah.'}, {'ForeName': 'Sharad', 'Initials': 'S', 'LastName': 'Goyal', 'Affiliation': 'George Washington University, Washington, DC.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Toppmeyer', 'Affiliation': 'Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.'}, {'ForeName': 'Laurie', 'Initials': 'L', 'LastName': 'Kirstein', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York City, New York.'}, {'ForeName': 'Chunxia', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Rutgers School of Public Health, Piscataway, New Jersey.'}, {'ForeName': 'D F', 'Initials': 'DF', 'LastName': 'Moore', 'Affiliation': 'Rutgers School of Public Health, Piscataway, New Jersey.'}, {'ForeName': 'Bruce G', 'Initials': 'BG', 'LastName': 'Haffty', 'Affiliation': 'Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.'}, {'ForeName': 'Atif J', 'Initials': 'AJ', 'LastName': 'Khan', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York City, New York.'}]","International journal of radiation oncology, biology, physics",['10.1016/j.ijrobp.2020.03.020'] 244,31400333,Impact of Aortic Atherosclerosis Burden on Outcomes of Surgical Aortic Valve Replacement.,"BACKGROUND Epiaortic ultrasound detects and localizes ascending aortic atherosclerosis. In this analysis we investigated the association between epiaortic ultrasound-based atheroma grade during surgical aortic valve replacement (SAVR) and perioperative adverse outcomes. METHODS SAVR patients in a randomized trial of 2 embolic protection devices underwent a protocol-defined 5-view epiaortic ultrasound read at a core laboratory. Aortic atherosclerosis was quantified with the Katz atheroma grade, and patients were categorized as mild (grade I-II) or moderate/severe (grade III-V). Multivariable logistic regression was used to estimate associations between atheroma grade and adverse outcomes, including death, clinically apparent stroke, cerebral infarction on diffusion-weighted magnetic resonance imaging, delirium, and acute kidney injury (AKI) by 7 and 30 days. RESULTS Precannulation epiaortic ultrasound data were available for 326 of 383 randomized patients (85.1%). Of these, 106 (32.5%) had moderate/severe Katz atheroma grade at any segment of the ascending aorta. Although differences in the composite of death, stroke, or cerebral infarction on diffusion-weighted magnetic resonance imaging by 7 days were not statistically significant, moderate/severe atheroma grade was associated with a greater risk of AKI by 7 days (adjusted odds ratio, 2.63; 95% confidence interval, 1.24-5.58; P = .01). At 30 days, patients with moderate/severe atheroma grade had a greater risk of death, stroke, or AKI (adjusted odds ratio, 1.97; 95% confidence interval, 1.04-3.71; P = .04). CONCLUSIONS Moderate/severe aortic atherosclerosis was associated with an increased risk of adverse events after SAVR. Epiaortic ultrasound may serve as a useful adjunct for identifying patients who may benefit from strategies to reduce atheroembolic complications during SAVR.",2020,"While there were no significant differences in the composite of death, stroke or cerebral infarction on DW-MRI by 7 days, moderate/severe atheroma grade was associated with a greater risk of AKI by 7 days (adjusted odds ratio [OR]: 2.63; 95% confidence interval [CI]: 1.24-5.58; p=0.01).","['SAVR patients', 'Of the 383 randomized patients, 326 (85.1%) had pre-cannulation epiaortic ultrasound data available']","['embolic protection devices underwent a protocol-defined 5-view epiaortic ultrasound read at a core-laboratory', 'Surgical Aortic Valve Replacement']","['risk of adverse events', 'severe aortic atherosclerosis', 'atheroma grade and adverse outcomes including death, clinically apparent stroke, cerebral infarction on diffusion-weighted magnetic resonance imaging (DW-MRI), delirium, and acute kidney injury (AKI', 'risk of death, stroke or AKI', 'composite of death, stroke or cerebral infarction on DW-MRI by 7 days, moderate/severe atheroma grade', 'Aortic atherosclerosis', 'moderate/severe Katz atheroma grade']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}]","[{'cui': 'C2936200', 'cui_str': 'Emboli Protection Devices'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve (procedure)'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0155733', 'cui_str': 'Atherosclerosis of aorta (disorder)'}, {'cui': 'C0264956', 'cui_str': 'Atheromatous Plaques'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0007785', 'cui_str': 'Cerebral Infarction'}, {'cui': 'C0598801', 'cui_str': 'Diffusion weighted magnetic resonance imaging'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C2609414', 'cui_str': 'Acute Renal Injury'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}]",383.0,0.312698,"While there were no significant differences in the composite of death, stroke or cerebral infarction on DW-MRI by 7 days, moderate/severe atheroma grade was associated with a greater risk of AKI by 7 days (adjusted odds ratio [OR]: 2.63; 95% confidence interval [CI]: 1.24-5.58; p=0.01).","[{'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Iribarne', 'Affiliation': 'Section of Cardiac Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Pan', 'Affiliation': 'Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Jock N', 'Initials': 'JN', 'LastName': 'McCullough', 'Affiliation': 'Section of Cardiac Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'Mathew', 'Affiliation': 'Division of Cardiothoracic Anesthesiology, Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Hung', 'Affiliation': 'Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Zeng', 'Affiliation': 'Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Voisine', 'Affiliation': 'Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec, Québec, Canada.'}, {'ForeName': 'Patrick T', 'Initials': 'PT', 'LastName': ""O'Gara"", 'Affiliation': ""Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Nancy M', 'Initials': 'NM', 'LastName': 'Sledz', 'Affiliation': 'Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Annetine C', 'Initials': 'AC', 'LastName': 'Gelijns', 'Affiliation': 'Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: annetine.gelijns@mssm.edu.'}, {'ForeName': 'Wendy C', 'Initials': 'WC', 'LastName': 'Taddei-Peters', 'Affiliation': 'Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland.'}, {'ForeName': 'Steven R', 'Initials': 'SR', 'LastName': 'Messé', 'Affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Alan J', 'Initials': 'AJ', 'LastName': 'Moskowitz', 'Affiliation': 'Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Vinod H', 'Initials': 'VH', 'LastName': 'Thourani', 'Affiliation': 'Department of Cardiac Surgery, MedStar Heart and Vascular Institute, Washington, DC.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Argenziano', 'Affiliation': 'Division of Cardiothoracic Surgery, Department of Surgery, New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Groh', 'Affiliation': 'Cardiovascular and Thoracic Surgery, Mission Health and Hospitals, Asheville, North Carolina.'}, {'ForeName': 'Gennaro', 'Initials': 'G', 'LastName': 'Giustino', 'Affiliation': 'Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Jessica R', 'Initials': 'JR', 'LastName': 'Overbey', 'Affiliation': 'Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'J Michael', 'Initials': 'JM', 'LastName': 'DiMaio', 'Affiliation': 'Department of Cardiothoracic Surgery, The Heart Hospital Baylor Plano, Baylor Scott & White Health, Plano, Texas.'}, {'ForeName': 'Peter K', 'Initials': 'PK', 'LastName': 'Smith', 'Affiliation': 'Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina.'}]",The Annals of thoracic surgery,['10.1016/j.athoracsur.2019.06.037'] 245,32291360,The Effect of an Anti-Bullying Intervention on Male Students' Bullying-victimization Behaviors and Social Competence: A Randomized Controlled Trial in Deprived Urban Areas.,"BACKGROUND Violence among adolescents is a global public health concern. There is limited evidence on the effectiveness of anti-bullying interventions in Iran. Weaimed to examine the effectiveness of social cognitive theory (SCT)-based intervention on reducing bullying and victimization in elementary school students. STUDY DESIGN A randomized controlled trial. METHODS Eight elementary schools (consisted of 280 students in 5th and 6th grade) from deprived and semi-deprived areas of Kermanshah (west of Iran) were randomly assigned to intervention and control group from 2018 to 2019. Anti-bullying training content appropriate for SCT and sociocultural characteristics were provided to the intervention group including students, parents, teachers and school staff. The measures included SCT constructs, bullying, victimization, and social competence of students. RESULTS At baseline participants of two groups were homogenous in terms of demographic factors except for the type of living with the parent (P=0.040) and outcome variables including SCT constructs and bullying behaviors. The interventions significantly improved SCT constructs, reduced bullying and victimization and increased social competence in the intervention group compared to the control group (P<0.001). The difference between outcome expectations in both groups was not significant (P=0.137). CONCLUSION Interventions based on sociocultural characteristics and focuses on SCT theory reduce bullying and victimization behavior. Given the effectiveness and feasibility of these interventions, this theory can be effective to break the bullying cycle and improve social competence.",2019,"The interventions significantly improved SCT constructs, reduced bullying and victimization and increased social competence in the intervention group compared to the control group (P<0.001).","['elementary school students', 'Eight elementary schools (consisted of 280 students in 5th and 6th grade) from deprived and semi-deprived areas of Kermanshah (west of Iran', 'Deprived Urban Areas', ""Male Students' Bullying-victimization Behaviors and Social Competence""]","['Anti-Bullying Intervention', 'social cognitive theory (SCT)-based intervention']","['SCT constructs, reduced bullying and victimization and increased social competence', 'SCT constructs and bullying behaviors', 'SCT constructs, bullying, victimization, and social competence of students']","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0205439', 'cui_str': 'Fifth'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0037769', 'cui_str': 'West syndrome'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0424318', 'cui_str': 'Bullying'}, {'cui': 'C0376695', 'cui_str': 'Victimization'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0679005', 'cui_str': 'Social Abilities'}]","[{'cui': 'C0424318', 'cui_str': 'Bullying'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0012931', 'cui_str': 'Recombinant DNA'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0424318', 'cui_str': 'Bullying'}, {'cui': 'C0376695', 'cui_str': 'Victimization'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0679005', 'cui_str': 'Social Abilities'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0038492', 'cui_str': 'Student'}]",,0.0410674,"The interventions significantly improved SCT constructs, reduced bullying and victimization and increased social competence in the intervention group compared to the control group (P<0.001).","[{'ForeName': 'Nooshin', 'Initials': 'N', 'LastName': 'Salimi', 'Affiliation': 'Department of Public Health, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.'}, {'ForeName': 'Akram', 'Initials': 'A', 'LastName': 'Karimi-Shahanjarini', 'Affiliation': 'Department of Public Health, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran. karimi.a@umsha.ac.ir.'}, {'ForeName': 'Forouzan', 'Initials': 'F', 'LastName': 'Rezapur-Shahkolai', 'Affiliation': 'Department of Public Health, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.'}, {'ForeName': 'Behrooz', 'Initials': 'B', 'LastName': 'Hamzeh', 'Affiliation': 'Research Center for Environmental Determinants of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Ghodratollah', 'Initials': 'G', 'LastName': 'Roshanaei', 'Affiliation': 'Department of Biostatistics, Modeling of Noncommunicable Disease Research Canter, Hamadan University of Medical Sciences, Hamadan, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Babamiri', 'Affiliation': 'Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.'}]",Journal of research in health sciences,[] 246,31960045,"Commentary: Efficacy and Safety of Minimally Invasive Surgery With Thrombolysis in Intracerebral Haemorrhage Evacuation (MISTIE III): A Randomized, Controlled, Open-Label, Blinded Endpoint Phase 3 Trial.",,2020,,['Intracerebral Haemorrhage Evacuation (MISTIE III'],['Minimally Invasive Surgery'],[],"[{'cui': 'C2937358', 'cui_str': 'Intracerebral Hemorrhage'}, {'cui': 'C1282573', 'cui_str': 'Evacuation procedure'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C0282624', 'cui_str': 'Minimal Surgical Procedures'}]",[],,0.154348,,"[{'ForeName': 'Mithun G', 'Initials': 'MG', 'LastName': 'Sattur', 'Affiliation': 'Department of Neurosurgery, Division of Neuroendovascular Surgery, Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Alejandro M', 'Initials': 'AM', 'LastName': 'Spiotta', 'Affiliation': 'Department of Neurosurgery, Division of Neuroendovascular Surgery, Medical University of South Carolina, Charleston, South Carolina.'}]",Neurosurgery,['10.1093/neuros/nyz551'] 247,32286685,A randomized controlled trial of a tablet-based intervention to address predonation fears among high school donors.,"BACKGROUND Prior studies have shown donation-related fear to be associated with decreased donor confidence and an increased risk for vasovagal reactions. This study examined the effects of a predonation intervention that provided fearful donors with suggestions for coping. STUDY DESIGN AND METHODS Using a tablet-based application, high school donors (49.4% female) answered a question regarding their fear of having blood drawn. Those who reported fear were randomly assigned to either a control (n = 930) or an intervention (n = 911) group. Donors in the control group rated their confidence in dealing with their fear and then donated as usual. Donors in the intervention group received a brief audiovisual presentation on coping strategies, rated their confidence, and then donated as usual. RESULTS A higher proportion of fearful versus nonfearful donors experienced a vasovagal reaction, even after controlling for other demographic and health predictors (OR, 2.3; 95% CI, 1.655-3.185, p < 0.001). Fearful donors who received the intervention reported greater confidence than controls, but the proportion of vasovagal reactions did not differ significantly between the intervention (6.1%) and control (6.8%) groups. CONCLUSION Although the current tablet-based intervention may have some psychological benefit in that it was associated with greater donor confidence, the observed effect was small and did not translate into a lower risk for vasovagal reactions. However, greater confidence among young donors may lead to an increased willingness to donate again-a potential outcome that we will revisit among these donors as part of a planned 2-year follow-up.",2020,"Fearful donors who received the intervention reported greater confidence than controls, but the proportion of vasovagal reactions did not differ significantly between the intervention (6.1%) and control (6.8%) groups. ","['Using a tablet-based application, high school donors (49.4% female) answered a question regarding their fear of having blood drawn', 'high school donors']","['predonation intervention', 'tablet-based intervention', 'brief audiovisual presentation']","['vasovagal reaction', 'proportion of vasovagal reactions']","[{'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0005834', 'cui_str': 'Collection of blood specimen for laboratory'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}]","[{'cui': 'C0042420', 'cui_str': 'Vasovagal syncope'}]",,0.0370992,"Fearful donors who received the intervention reported greater confidence than controls, but the proportion of vasovagal reactions did not differ significantly between the intervention (6.1%) and control (6.8%) groups. ","[{'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'France', 'Affiliation': 'Department of Psychology, Ohio University, Athens, Ohio, USA.'}, {'ForeName': 'Janis L', 'Initials': 'JL', 'LastName': 'France', 'Affiliation': 'Department of Psychology, Ohio University, Athens, Ohio, USA.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Kowalsky', 'Affiliation': 'Department of Psychology, Ohio State University Newark, Newark, Ohio, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Conatser', 'Affiliation': 'Department of Psychology, Ohio University, Athens, Ohio, USA.'}, {'ForeName': 'Louisa', 'Initials': 'L', 'LastName': 'Duffy', 'Affiliation': 'New York Blood Center Enterprises, New York, New York, USA.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Barnofsky', 'Affiliation': 'New York Blood Center Enterprises, New York, New York, USA.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Kessler', 'Affiliation': 'New York Blood Center Enterprises, New York, New York, USA.'}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Shaz', 'Affiliation': 'New York Blood Center Enterprises, New York, New York, USA.'}]",Transfusion,['10.1111/trf.15790'] 248,31876451,Effect of transcutaneous electrical nerve stimulation on jaw movement-evoked pain in patients with TMJ disc displacement without reduction and healthy controls.,"Objective: Transcutaneous electrical nerve stimulation (TENS) may serve as non-invasive intervention for painful temporomandibular disorders (TMD) to improve jaw motor function, but its efficacy is still debated. This parallel study evaluated the effect of TENS on pain and movement patterns after repeated jaw movements in patients with painful temporomandibular joints (TMJ) and disc displacement without reduction (DDwoR), and compared with healthy controls. Material and Methods: 20 patients with TMJ pain and DDwoR and 20 age- and gender-matched healthy volunteers were randomly assigned to TENS/sham TENS (sTENS) intervention groups in a block design (10 in each group). Participants performed 20 repeated jaw movements (4 x 5 sessions), and reported pain intensity on a 0-10 Numerical Rating Scale (NRS) subsequently both before and after the intervention. Data were tested by repeated measures analysis of variance (ANOVA). Results: Significant increase of pain intensity and reduction of opening range were shown within repeated jaw movements in TMJ pain patients in contrast to healthy participants ( p  ≤ .001). Pain was significantly reduced during repeated open-close ( p  = .007), fast open-close ( p  = .016) and horizontal movements ( p  = .023), accompanied with increased opening range ( p  = .033) and open-close velocity ( p  = .019) with TENS intervention when compared with sTENS group ( p  > .05) in TMJ pain patients. Conclusions: This study indicated that movement-evoked pain was reduced either spontaneously or by sTENS in TMJ pain patients with DDwoR, and interestingly, that TENS could attenuate movement-evoked pain and improve jaw motor function during repeated jaw movements. The findings may have implications for TENS treatment in TMJ pain patients with DDwoR.",2020,Significant increase of pain intensity and reduction of opening range were shown within repeated jaw movements in TMJ pain patients in contrast to healthy participants ( p  ≤ .001).,"['20 patients with TMJ pain and DDwoR and 20 age- and gender-matched healthy volunteers', 'patients with TMJ disc displacement without reduction and healthy controls', 'TMJ pain patients with DDwoR', 'painful temporomandibular disorders (TMD', 'patients with painful temporomandibular joints (TMJ) and disc displacement without reduction (DDwoR), and compared with healthy controls']","['Transcutaneous electrical nerve stimulation (TENS', 'TENS', 'sTENS', 'TENS/sham TENS (sTENS) intervention', 'transcutaneous electrical nerve stimulation']","['open-close velocity', 'Pain', 'jaw movement-evoked pain', 'opening range', 'movement-evoked pain', 'pain intensity', 'pain and movement patterns', 'horizontal movements', 'jaw motor function', 'pain intensity and reduction of opening range']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0039493', 'cui_str': 'TMJ'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C1705370', 'cui_str': 'Disc - unit of product usage'}, {'cui': 'C0456080', 'cui_str': 'Displacement (attribute)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0039494', 'cui_str': 'TMJ Diseases'}]","[{'cui': 'C0040654', 'cui_str': 'Electric Stimulation, Transcutaneous'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0587267', 'cui_str': 'Closed (qualifier value)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0022359', 'cui_str': 'Jaw'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C1444748', 'cui_str': 'Provoked by (attribute)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0205126', 'cui_str': 'Horizontal (qualifier value)'}, {'cui': 'C0234130', 'cui_str': 'Motor function (observable entity)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]",20.0,0.0623832,Significant increase of pain intensity and reduction of opening range were shown within repeated jaw movements in TMJ pain patients in contrast to healthy participants ( p  ≤ .001).,"[{'ForeName': 'Yuanxiu', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Jinglu', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Kelun', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Orofacial Pain & TMD Research Unit, Institute of Stomatology, Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Svensson', 'Affiliation': 'Section of Orofacial Pain and Jaw Function, Department of Dentistry and Oral Health, Aarhus University, Aarhus, Denmark.'}]",Acta odontologica Scandinavica,['10.1080/00016357.2019.1707868'] 249,31627041,Levetiracetam in genetic generalized epilepsy: A prospective unblinded active-controlled trial.,"PURPOSE To compare the efficacy and tolerability of levetiracetam (LEV) versus valproate (VPA) monotherapy in adults with genetic generalized tonic-clonic seizures alone (GTCS) and juvenile myoclonic epilepsy (JME). METHODS This study was an open-label, active-controlled trial with a two-parallel-group design. Outcome measures including withdrawal rate and seizure freedom rate at 26th weeks and time to withdrawal, and time to first seizure were compared between LEV and VPA groups. Furthermore, tolerability and development of adverse events (AEs) were investigated and analyzed. RESULTS One hundred and three patients enrolled the study. 71.1% of patients in LEV group and 29.3% in VPA group were female. By the end of 26 th week, seizure freedom rate and withdrawal rate were 88.9% and 8.9% in LEV group and 86.2% and 10.3% in VPA group with no significant difference. Time to first seizure was longer in VPA group (p = 0.32) and time to withdrawal favored LEV (p = 0.51). At least one AE was reported in 37.7% of patients in LEV group and 55.1% in VPA group. The most common AEs were psychiatric symptoms and dizziness in those on LEV and weight gain and dyspepsia in VPA group. CONCLUSION LEV has similar efficacy and acceptable safety in comparison to VPA in short-term treatment of patients with genetic GTCS and JME, and it could be considered as an alternative to VPA particularly in women of reproductive age.",2019,Time to first seizure was longer in VPA group (p = 0.32) and time to withdrawal favored LEV (p = 0.51).,"['One hundred and three patients enrolled the study', 'adults with genetic generalized tonic-clonic seizures alone (GTCS) and juvenile myoclonic epilepsy (JME', 'genetic generalized epilepsy']","['levetiracetam (LEV', 'valproate (VPA) monotherapy', 'LEV', 'VPA', 'Levetiracetam']","['efficacy and tolerability', 'weight gain and dyspepsia', 'withdrawal rate and seizure freedom rate at 26th weeks and time to withdrawal, and time to first seizure', 'Time to first seizure', 'tolerability and development of adverse events (AEs', 'seizure freedom rate and withdrawal rate', 'psychiatric symptoms and dizziness']","[{'cui': 'C4517526', 'cui_str': 'One hundred and three'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0017399', 'cui_str': 'genetics'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0494475', 'cui_str': 'Generalized Tonic-Clonic Seizures'}, {'cui': 'C0270853', 'cui_str': 'JME (Juvenile Myoclonic Epilepsy)'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}]","[{'cui': 'C0377265', 'cui_str': 'Levetiracetam'}, {'cui': 'C0080356', 'cui_str': 'Valproate'}]","[{'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0013395', 'cui_str': 'Indigestion'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0233401', 'cui_str': 'Psychiatric symptom (finding)'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}]",103.0,0.0356111,Time to first seizure was longer in VPA group (p = 0.32) and time to withdrawal favored LEV (p = 0.51).,"[{'ForeName': 'Nasim', 'Initials': 'N', 'LastName': 'Tabrizi', 'Affiliation': 'Neurology department, Mazandaran University of medical sciences, Sari, Iran. Electronic address: nasimtabrizi@gmail.com.'}, {'ForeName': 'Ashraf', 'Initials': 'A', 'LastName': 'Zarvani', 'Affiliation': 'Neurology department, Mazandaran University of medical sciences, Sari, Iran.'}, {'ForeName': 'Parisa', 'Initials': 'P', 'LastName': 'Rezaei', 'Affiliation': 'Neurology department, Mazandaran University of medical sciences, Sari, Iran.'}, {'ForeName': 'Hamed', 'Initials': 'H', 'LastName': 'Cheraghmakani', 'Affiliation': 'Neurology department, Mazandaran University of medical sciences, Sari, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Alizadeh-Navaei', 'Affiliation': 'Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran.'}]",Epilepsy research,['10.1016/j.eplepsyres.2019.106214'] 250,31677583,Ethnicity and health outcomes among people with epilepsy participating in an epilepsy self-management RCT.,"People with epilepsy (PWE) may experience negative health events (NHEs) such as seizures, emergency room visits, and hospitalizations, with ethnic and racial minorities disproportionately affected. Epilepsy self-management may reduce NHEs; however, few reports examine self-management outcomes in racial minorities. Using data from a longitudinal 6-month randomized controlled trial (RCT) of 120 PWE, this analysis compared African-American and Whites at baseline, 10 weeks and 24 weeks after receiving the ""Self-management for people with epilepsy (SMART) and a history of NHEs"" self-management program. The primary RCT outcome was number of NHEs. At baseline, compared to Whites, African-Americans had less education (p = 0.02) and greater depressive severity (p = 0.04). Both African-American and Whites generally improved with SMART, and there were no racial differences in NHE counts or other outcomes' responses. Given known racial disparities in epilepsy care, it may be particularly important to reach out to minority PWE with self-management programs.",2019,"Both African-American and Whites generally improved with SMART, and there were no racial differences in NHE counts or other outcomes' responses.","['African-American and Whites at baseline, 10\u202fweeks and 24\u202fweeks after receiving the ""Self-management for people with epilepsy (SMART) and a history of NHEs"" self-management program', 'People with epilepsy (PWE', 'people with epilepsy participating in an epilepsy self-management RCT']",[],"['number of NHEs', 'Ethnicity and health outcomes', 'depressive severity']","[{'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]",[],"[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0243103', 'cui_str': 'ethnicity'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",,0.0414492,"Both African-American and Whites generally improved with SMART, and there were no racial differences in NHE counts or other outcomes' responses.","[{'ForeName': 'Neha', 'Initials': 'N', 'LastName': 'Kumar', 'Affiliation': 'Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Aebi', 'Affiliation': 'Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'Lu', 'Affiliation': 'Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Burant', 'Affiliation': 'Case Western Reserve University, Frances Payne Bolton School of Nursing, Cleveland, Ohio, USA.'}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Sajatovic', 'Affiliation': 'Department of Psychiatry and of Neurology, Neurological & Behavioral Outcomes Center, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. Electronic address: Martha.Sajatovic@uhhospitals.org.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2019.106469'] 251,32281222,Learning of the mental nerve block technique with dental anaesthesia simulation models builds motor skills and confidence in dental students.,"INTRODUCTION We compared the motor learning, self-confidence whilst performing an anaesthesia technique and the perception of confidence between a group of students trained (G1) with two distinct dental anaesthesia simulation models (DASM) and a group of students (G2) not trained with DASM. MATERIALS AND METHODS The G1 students (n = 22) were trained with a learning protocol including a DASM for simulating a puncture and a DASM for simulating an injection of dental anaesthesia. The G2 students (n = 22) received no such training. Both groups performed the mental nerve block (MNB) in a clinical setting, after which the average working time (motor learning), number of times help was requested for performing the MNB (self-confidence) and the scores of a Likert Scale questionnaire (perception of confidence) between the groups were compared with a t test. RESULTS Compared with G2, the G1 students showed a shorter average working time (G1, 7:30 ± 0:54 min; G2, 9:06 ± 2:27 min; P = .017). Hence, G1 students had better motor skills. They also requested help when performing the MNB fewer times than the G2 students (G1, 2.2 ± 0.5 times; G2, 4.6 ± 1.95 times; P < .001). On the other hand, the G1 students demonstrated better perception of confidence (Likert Scale questionnaire) when performing the MNB compared with the G2 students (P = .007). CONCLUSION The learning protocol with two different DASMs had a positive effect on the motor skills and the confidence of dental students performing the mental nerve block.",2020,"On the other hand, the G1 students demonstrated better perception of confidence (Likert Scale questionnaire) when performing the MNB compared with the G2 students (P = .007). ","['The G1 students (n\xa0=\xa022', 'G2 students (n\xa0=\xa022) received', 'dental students']","['students trained (G1) with two distinct dental anaesthesia simulation models (DASM) and a group of students (G2) not trained with DASM', 'no such training', 'learning protocol including a DASM for simulating a puncture and a DASM for simulating an injection of dental anaesthesia']","['motor skills and the confidence of dental students performing the mental nerve block', 'motor skills', 'perception of confidence (Likert Scale questionnaire', 'Likert Scale questionnaire (perception of confidence', 'shorter average working time (G1, 7:30\xa0±', 'mental nerve block (MNB']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0038493', 'cui_str': 'Dental Student'}]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0026612', 'cui_str': 'Motor Skills'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0038493', 'cui_str': 'Dental Student'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0394808', 'cui_str': 'Local anesthetic mental nerve block'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0451267', 'cui_str': 'Likert scale'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",22.0,0.0343301,"On the other hand, the G1 students demonstrated better perception of confidence (Likert Scale questionnaire) when performing the MNB compared with the G2 students (P = .007). ","[{'ForeName': 'María J', 'Initials': 'MJ', 'LastName': 'Reyes-Acuca', 'Affiliation': 'School of Dentistry, Universidad Veracruzana, Rio Blanco, México.'}, {'ForeName': 'Zayra S', 'Initials': 'ZS', 'LastName': 'Sánchez-Lezama', 'Affiliation': 'School of Dentistry, Universidad Veracruzana, Rio Blanco, México.'}, {'ForeName': 'Berenice', 'Initials': 'B', 'LastName': 'Capistrán-Sarmiento', 'Affiliation': 'School of Dentistry, Universidad Veracruzana, Rio Blanco, México.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Teodoro-Isneros', 'Affiliation': 'School of Dentistry, Universidad Veracruzana, Rio Blanco, México.'}, {'ForeName': 'José L', 'Initials': 'JL', 'LastName': 'Suárez-Franco', 'Affiliation': 'School of Dentistry, Universidad Veracruzana, Rio Blanco, México.'}, {'ForeName': 'Bernardino I', 'Initials': 'BI', 'LastName': 'Cerda-Cristerna', 'Affiliation': 'School of Dentistry, Universidad Veracruzana, Rio Blanco, México.'}]",European journal of dental education : official journal of the Association for Dental Education in Europe,['10.1111/eje.12527'] 252,32043980,Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial.,"BACKGROUND GRECCAR 2 was the first multicentre, randomised trial to compare local excision with total mesorectal excision in downstaged low rectal cancer. Encouraging oncological results were noted at 3 years' follow-up but needed to be corroborated with longer follow-up. In this study, we aimed to report the 5-year oncological outcomes, including local recurrence, metastatic disease, and survival. METHODS Patients age 18 years and older with T2T3 low rectal cancer, of maximum size 4 cm, who were clinically good responders after chemoradiotherapy (residual tumour ≤2 cm) were randomly assigned before surgery to either local excision or total mesorectal excision. Randomisation was centralised and not stratified and used permuted blocks of size eight. In the local excision group, a completion total mesorectal excision was performed if pathological tumour stage was ypT2-3. The primary objective of this study was to assess the 5-year oncological outcomes of local recurrence, metastatic disease, disease-free survival, overall survival, and cancer-specific mortality, which were the secondary endpoints of GRECCAR 2. We used Kaplan-Meier estimates and Cox modelling to estimate and compare recurrence and survival in modified intention-to-treat and as-treated populations. This trial was registered with ClinicalTrials.gov, number NCT00427375. FINDINGS Between March 1, 2007, and Sept 24, 2012, 148 patients who were good clinical responders were randomly assigned to treatment, three patients were excluded after randomisation (because they had metastatic disease, tumour >8 cm from anal verge, or withdrew consent), leaving 145 for analysis: 74 in the local excision group and 71 in the total mesorectal excision group. Median follow-up was 60 months (IQR 58-60) in the local excision group and 60 months (57-60) in the total mesorectal excision group. 23 patients died and five were lost to follow-up. In the local excision group, 26 had a completion total mesorectal excision for ypT2-3 tumour. In the modified intention-to-treat analysis, there was no difference between the local excision and total mesorectal excision groups in 5-year local recurrence (7% [95% CI 3-16] vs 7% [3-16]; adjusted hazard ratio [HR] 0·71 [95% CI 0·19-2·58]; p=0·60), metastatic disease (18% [CI 11-30] vs 19% [11-31]; 0·86 [0·36-2·06]; p=0·73), overall survival (84% [73-91] vs 82% [71-90]; 0·92 [0·38-2·22]; p=0·85), disease-free survival (70% [58-79] vs 72% [60-82]; 0·87 [0·44-1·72]; p=0·68), or cancer-specific mortality (7% [3-17] vs 10% [5-20]; 0·65 [0·17-2·49]; p=0·53). INTERPRETATION The 5-year results of this multicentre randomised trial corroborate the 3-year results, providing no evidence of difference in oncological outcomes between local excision and total mesorectal excision. Local excision can be proposed in selected patients having a small T2T3 low rectal cancer with a good clinical response after chemoradiotherapy. FUNDING National Cancer Institute of France.",2020,"Local excision can be proposed in selected patients having a small T2T3 low rectal cancer with a good clinical response after chemoradiotherapy. ","['Patients age 18 years and older with T2T3 low rectal cancer, of maximum size 4 cm, who were clinically good responders after chemoradiotherapy (residual tumour ≤2 cm', '148 patients who were good clinical responders were randomly assigned to treatment, three patients were excluded after randomisation (because they had metastatic disease, tumour >8 cm from anal verge, or withdrew consent), leaving 145 for analysis: 74 in the local excision group and 71 in the total mesorectal excision group', '0·65', 'rectal cancer', 'downstaged low rectal cancer', '23 patients died and five were lost to follow-up', 'selected patients having a small T2T3 low rectal cancer with a good clinical response after chemoradiotherapy']","['local excision with total mesorectal excision', 'completion total mesorectal excision', 'local excision and total mesorectal excision', 'chemoradiotherapy plus local excision', 'Local excision', 'local excision or total mesorectal excision']","['disease-free survival', 'local excision and total mesorectal excision groups in 5-year local recurrence', 'cancer-specific mortality', '5-year oncological outcomes of local recurrence, metastatic disease, disease-free survival, overall survival, and cancer-specific mortality', 'completion total mesorectal excision', 'metastatic disease', '5-year oncological outcomes', 'overall survival', 'local recurrence, metastatic disease, and survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0007113', 'cui_str': 'Cancer of Rectum'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0543478', 'cui_str': 'Residual Tumor'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C2939420', 'cui_str': 'Metastatic disease'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0227423', 'cui_str': 'Structure of transition zone of anal mucous membrane'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}, {'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0278259', 'cui_str': 'Local resection'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C1273428', 'cui_str': 'Total mesorectal excision'}, {'cui': 'C1306577', 'cui_str': 'On examination - dead (finding)'}, {'cui': 'C1302313', 'cui_str': 'Lost to Follow-Up'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}]","[{'cui': 'C0278259', 'cui_str': 'Local resection'}, {'cui': 'C1273428', 'cui_str': 'Total mesorectal excision'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0242793', 'cui_str': 'Disease-Free Survival'}, {'cui': 'C0278259', 'cui_str': 'Local resection'}, {'cui': 'C1273428', 'cui_str': 'Total mesorectal excision'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C2939420', 'cui_str': 'Metastatic disease'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",3.0,0.510846,"Local excision can be proposed in selected patients having a small T2T3 low rectal cancer with a good clinical response after chemoradiotherapy. ","[{'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Rullier', 'Affiliation': 'Department of Colorectal Surgery, Haut-Lévèque Hospital, CHU Bordeaux, France. Electronic address: eric.rullier@chu-bordeaux.fr.'}, {'ForeName': 'Véronique', 'Initials': 'V', 'LastName': 'Vendrely', 'Affiliation': 'Radiotherapy Department, Haut-Lévèque Hospital, CHU Bordeaux, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Asselineau', 'Affiliation': ""INSERM CIC1401-EC, Bordeaux, France; CHU Bordeaux, Service d'information médicale, Bordeaux, France.""}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Rouanet', 'Affiliation': ""Département de Chirurgie Oncologique, ICM Val d'Aurelle, Montpellier, France.""}, {'ForeName': 'Jean-Jacques', 'Initials': 'JJ', 'LastName': 'Tuech', 'Affiliation': 'Service de Chirurgie Digestive, CHU Charles Nicolle, Rouen, France.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Valverde', 'Affiliation': 'Service de Chirurgie Digestive, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.'}, {'ForeName': 'Cecile', 'Initials': 'C', 'LastName': 'de Chaisemartin', 'Affiliation': 'Département de Chirurgie Oncologique, Institut Paoli Calmette, Marseille, France.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Rivoire', 'Affiliation': 'Département de Chirurgie Oncologique, Centre Léon Bérard, Lyon, France.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Trilling', 'Affiliation': 'Service de Chirurgie Digestive, Hôpital A. Michallon, La Tronche, France.'}, {'ForeName': 'Mehrdad', 'Initials': 'M', 'LastName': 'Jafari', 'Affiliation': 'Département de Chirurgie Oncologique, Centre Oscar Lambret, Lille, France.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Portier', 'Affiliation': 'Service de Chirurgie Digestive, Hôpital Purpan, Toulouse, France.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Meunier', 'Affiliation': 'Service de Chirurgie Viscérale, CHU Pontchaillou, Rennes, France.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Sieleznieff', 'Affiliation': 'Service de Chirurgie Digestive, CHU Timone, Marseille, France.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Bertrand', 'Affiliation': 'Département de Chirurgie Digestive et de Cancérologie Digestive, Hôpital Universitaire Carémeau, Nimes, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Marchal', 'Affiliation': 'Département de Chirurgie Oncologique, Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Dubois', 'Affiliation': 'Service de Chirurgie Générale et Digestive, Hôtel Dieu, Clermont-Ferrand, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Pocard', 'Affiliation': 'Département Médico-Chirurgical de Pathologie Digestive, Hôpital Lariboisière, Paris, France.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Rullier', 'Affiliation': ""Service d'Anatomopathologie, Hôpital Pellegrin, Bordeaux, CHU Bordeaux, France.""}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Smith', 'Affiliation': ""Service d'Oncologie médicale, Haut-Lévèque Hospital, CHU Bordeaux, France.""}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Frulio', 'Affiliation': 'Service de Radiologie, Haut-Lévèque Hospital, CHU Bordeaux, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Frison', 'Affiliation': ""INSERM CIC1401-EC, Bordeaux, France; CHU Bordeaux, Service d'information médicale, Bordeaux, France.""}, {'ForeName': 'Quentin', 'Initials': 'Q', 'LastName': 'Denost', 'Affiliation': 'Department of Colorectal Surgery, Haut-Lévèque Hospital, CHU Bordeaux, France.'}]",The lancet. Gastroenterology & hepatology,['10.1016/S2468-1253(19)30410-8'] 253,32171439,Effect of Physical Exercise Training in Patients With Chagas Heart Disease (from the PEACH STUDY).,"Chagas heart disease (HD) is a chronic fibrosing myocarditis with high mortality. The PEACH study aimed to evaluate if exercise training can improve the functional capacity of Chagas HD patients with left ventricular dysfunction and/or heart failure. The PEACH study was a single center, parallel-group, clinical trial that randomized 30 clinical stable Chagas HD patients with left ventricular ejection fraction <45% or heart failure symptoms to either supervised exercise training 3 times/week for 6 months or a control group. Both groups had the same monthly pharmaceutical and nutritional counseling and usual care. Primary end point was functional capacity assessed by peak exercise oxygen consumption (peak VO 2 ) obtained by cardiopulmonary exercise test. Secondary end points included other cardiopulmonary exercise test variables, cardiac function by echocardiography, body composition, muscle respiratory strength, and metabolic biomarkers. Peak VO 2 increased among patients in exercise group from 17.60 ± 4.65 mlO 2 kg -1 min -1 to 19.40 ± 5.51 mlO 2 kg -1 min -1 while decreased in controls from 15.40 ± 6.30 mlO 2 kg -1 min -1 to 12.96 ± 4.50 mlO 2 kg -1 min -1 , resulting in significant difference in change in peak VO 2 between groups after 6 months (β = +4.6, p = 0.004). There were significant differences between groups in changes in anaerobic threshold (β = 3.7, p = 0.05), peak oxygen pulse (β = +2.7, p = 0.032) and maximum minute ventilation (β = +13.9, p < 0.0001) after 6 months of intervention. In conclusion, exercise training improved functional capacity of chronic Chagas HD patients with left ventricular dysfunction and/or heart failure.",2020,"There were significant differences between groups in changes in anaerobic threshold (β = 3.7, p = 0.05), peak oxygen pulse (β = +2.7, p = 0.032) and maximum minute ventilation (β = +13.9, p < 0.0001) after 6 months of intervention.","['Chagas HD patients with left ventricular dysfunction and/or heart failure', 'chronic Chagas HD patients with left ventricular dysfunction and/or heart failure', '30 clinical stable Chagas HD patients with left ventricular ejection fraction <45% or heart failure symptoms to either', 'Patients With Chagas Heart Disease (from the PEACH STUDY']","['exercise training', 'supervised exercise training', 'Physical Exercise Training', '1 min -1']","['peak oxygen pulse', 'Peak VO 2', 'anaerobic threshold', 'functional capacity assessed by peak exercise oxygen consumption (peak VO 2 ) obtained by cardiopulmonary exercise test', 'functional capacity', 'cardiopulmonary exercise test variables, cardiac function by echocardiography, body composition, muscle respiratory strength, and metabolic biomarkers', 'maximum minute ventilation', 'peak VO']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0242973', 'cui_str': 'Ventricular Dysfunction'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0018799', 'cui_str': 'Cardiac Diseases'}, {'cui': 'C0949824', 'cui_str': 'Peach'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1301862', 'cui_str': 'Min 1'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0002749', 'cui_str': 'Anaerobic Threshold'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1305742', 'cui_str': 'Oxygen consumption'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary Exercise Test'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function (observable entity)'}, {'cui': 'C0013516', 'cui_str': 'Transthoracic Echocardiography'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1301655', 'cui_str': 'Minute ventilation'}]",30.0,0.0301918,"There were significant differences between groups in changes in anaerobic threshold (β = 3.7, p = 0.05), peak oxygen pulse (β = +2.7, p = 0.032) and maximum minute ventilation (β = +13.9, p < 0.0001) after 6 months of intervention.","[{'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'de Souza Nogueira Sardinha Mendes', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil. Electronic address: fernanda.sardinha@ini.fiocruz.br.'}, {'ForeName': 'Mauro Felippe Felix', 'Initials': 'MFF', 'LastName': 'Mediano', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil; National Institute of Cardiology, Laranjeiras, Rio de Janeiro, Brazil.'}, {'ForeName': 'Fernando Cesar', 'Initials': 'FC', 'LastName': 'de Castro E Souza', 'Affiliation': 'National Institute of Cardiology, Laranjeiras, Rio de Janeiro, Brazil.'}, {'ForeName': 'Paula Simplício', 'Initials': 'PS', 'LastName': 'da Silva', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil.'}, {'ForeName': 'Fernanda Martins', 'Initials': 'FM', 'LastName': 'Carneiro', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil.'}, {'ForeName': 'Marcelo Teixeira', 'Initials': 'MT', 'LastName': 'de Holanda', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil.'}, {'ForeName': 'Roberto Magalhães', 'Initials': 'RM', 'LastName': 'Saraiva', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil.'}, {'ForeName': 'Sergio Salles', 'Initials': 'SS', 'LastName': 'Xavier', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil.'}, {'ForeName': 'Pedro Emmanuel Alvarenga', 'Initials': 'PEA', 'LastName': 'Americano do Brasil', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil.'}, {'ForeName': 'Andréa Silvestre', 'Initials': 'AS', 'LastName': 'de Sousa', 'Affiliation': 'Evandro Chagas National Institute of Infectious Diseases, Fiocruz Foundation, Manguinhos, Rio de Janeiro, Brazil.'}]",The American journal of cardiology,['10.1016/j.amjcard.2020.01.035'] 254,32184100,Dissociable effects of tDCS polarity on latent decision processes are associated with individual differences in neurochemical concentrations and cortical morphology.,"Applying a weak electrical current to the cortex has the potential to modulate neural functioning and behaviour. The most common stimulation technique, transcranial direct current stimulation (tDCS), has been used for causal investigations of brain and cognitive functioning, and to treat psychiatric conditions such as depression. However, the efficacy of tDCS in modulating behaviour varies across individuals. Moreover, despite being associated with different neural effects, the two polarities of electrical stimulation - anodal and cathodal - can result in similar behavioural outcomes. Here we employed a previously replicated behavioural paradigm that has been associated with polarity non-specific disruption of training effects in a simple decision-making task. We then used the linear ballistic accumulator model to quantify latent components of the decision-making task. In addition, magnetic resonance imaging measures were acquired prior to tDCS sessions to quantify cortical morphology and local neurochemical concentrations. Both anodal and cathodal stimulation disrupted learning-related task improvement relative to sham (placebo) stimulation, but the two polarities of stimulation had distinct effects on latent task components. Whereas anodal stimulation tended to affect decision thresholds for the behavioural task, cathodal stimulation altered evidence accumulation rates. Moreover, performance variability with anodal stimulation was related to cortical thickness of the inferior frontal gyrus, whereas performance variability with cathodal stimulation was related to cortical thickness in the inferior precentral sulcus, as well as to prefrontal neurochemical excitability. Our findings demonstrate that both cortical morphology and local neurochemical balance are important determinants of individual differences in behavioural responses to electrical brain stimulation.",2020,"Both anodal and cathodal stimulation disrupted learning-related task improvement relative to sham (placebo) stimulation, but the two polarities of stimulation had distinct effects on latent task components.",[],"['sham (placebo', 'tDCS', 'transcranial direct current stimulation (tDCS']",[],[],"[{'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}]",[],,0.0548698,"Both anodal and cathodal stimulation disrupted learning-related task improvement relative to sham (placebo) stimulation, but the two polarities of stimulation had distinct effects on latent task components.","[{'ForeName': 'Hannah L', 'Initials': 'HL', 'LastName': 'Filmer', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Australia. Electronic address: h.l.filmer@gmail.com.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Ballard', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Australia.'}, {'ForeName': 'Shane E', 'Initials': 'SE', 'LastName': 'Ehrhardt', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Australia.'}, {'ForeName': 'Saskia', 'Initials': 'S', 'LastName': 'Bollmann', 'Affiliation': 'Centre for Advanced Imaging, The University of Queensland, St Lucia, Australia.'}, {'ForeName': 'Thomas B', 'Initials': 'TB', 'LastName': 'Shaw', 'Affiliation': 'Centre for Advanced Imaging, The University of Queensland, St Lucia, Australia.'}, {'ForeName': 'Jason B', 'Initials': 'JB', 'LastName': 'Mattingley', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Australia; Queensland Brain Institute, The University of Queensland, St Lucia, Australia; Canadian Institute for Advanced Research (CIFAR), Toronto, Canada.'}, {'ForeName': 'Paul E', 'Initials': 'PE', 'LastName': 'Dux', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Australia.'}]",Neuropsychologia,['10.1016/j.neuropsychologia.2020.107433'] 255,31423939,Evaluation of agomelatine for the treatment of sleep problems in adults with autism spectrum disorder and co-morbid intellectual disability.,"PURPOSE Intellectual disability (ID) and autism spectrum disorder (ASD) are common, co-occurring developmental disorders and are frequently associated with sleep problems. This study aimed to assess the effectiveness and tolerability of agomelatine as a pharmacotherapy for sleep problems in ASD adults with ID. METHOD A randomised, crossover, triple-blind, placebo-controlled clinical trial, with two three-month periods of treatment starting with either agomelatine or placebo and a washout period of two weeks. Ambulatory circadian monitoring (24 hours/7 days) evaluated total sleep time (TST) as the primary outcome variable. RESULTS Participants ( N =23; 35±12 years old; 83% male) had a median of three (interquartile range (IQR) 1-4) co-morbidities and were taking a median of five (IQR 2-7) prescribed drugs. Before agomelatine or placebo treatment, all subjects presented with insomnia symptoms, including sleep latency (100% abnormal, 55±23 minutes) or TST (55% abnormal, 449±177 minutes), and 66% had circadian rhythm sleep-wake abnormalities with rhythm phase advancements according to the M5 sleep phase marker values. During the three-month agomelatine treatment, night TST significantly increased by a mean of 83 minutes (16% abnormal, 532±121 minutes), together with a phase correction (M5 1:45±2:28 hours vs. 3:15±2:20 hours), improving sleep stability in wrist temperature rhythm (0.43±0.29 vs. 0.52±0.18 AU). Adverse events were mild and transient. CONCLUSIONS Agomelatine was effective and well tolerated for treating insomnia and circadian rhythm sleep problems present in adults with ASD and ID.",2019,"CONCLUSIONS Agomelatine was effective and well tolerated for treating insomnia and circadian rhythm sleep problems present in adults with ASD and ID.","['Intellectual disability (ID) and autism spectrum disorder (ASD', 'adults with autism spectrum disorder and co-morbid intellectual disability', 'Participants ( N =23; 35±12 years old; 83% male', 'ASD adults with ID']","['Agomelatine', 'placebo', 'agomelatine or placebo', 'agomelatine']","['Adverse events', 'insomnia symptoms, including sleep latency', 'total sleep time (TST', 'sleep problems', 'night TST', 'sleep stability in wrist temperature rhythm', 'effectiveness and tolerability', 'circadian rhythm sleep-wake abnormalities with rhythm phase advancements according to the M5 sleep phase marker values']","[{'cui': 'C3714756', 'cui_str': 'Intellectual Development Disorder'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0971637', 'cui_str': 'Agomelatine product'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C4505222', 'cui_str': 'REM Sleep Latency'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnias'}, {'cui': 'C0043262', 'cui_str': 'Wrist'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0008810', 'cui_str': 'Nycthemeral Rhythm'}, {'cui': 'C0442696', 'cui_str': 'Waking (observable entity)'}, {'cui': 'C0000769', 'cui_str': 'anomalies'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0441478', 'cui_str': 'Surgical advancement - action'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.115211,"CONCLUSIONS Agomelatine was effective and well tolerated for treating insomnia and circadian rhythm sleep problems present in adults with ASD and ID.","[{'ForeName': 'Pura', 'Initials': 'P', 'LastName': 'Ballester', 'Affiliation': 'Neuropharmacology on Pain (NED), Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain.'}, {'ForeName': 'María José', 'Initials': 'MJ', 'LastName': 'Martínez', 'Affiliation': 'Chronobiology Lab, Department of Physiology, College of Biology, University of Murcia, Mare Nostrum Campus, Murcia Spain.'}, {'ForeName': 'María-Del-Mar', 'Initials': 'MD', 'LastName': 'Inda', 'Affiliation': 'Neuropharmacology on Pain (NED), Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain.'}, {'ForeName': 'Auxiliadora', 'Initials': 'A', 'LastName': 'Javaloyes', 'Affiliation': 'Education Centre for Children and Adolescents with Autism, Mental Health Problems and Behavioural Disorders (EDUCATEA), Alicante, Spain.'}, {'ForeName': 'Amanda L', 'Initials': 'AL', 'LastName': 'Richdale', 'Affiliation': 'Olga Tennison Autism Research Centre, School of Psychology and Public Health, La Trobe University, Melbourne, VIC, Australia.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Muriel', 'Affiliation': 'Neuropharmacology on Pain (NED), Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain.'}, {'ForeName': 'César', 'Initials': 'C', 'LastName': 'Belda', 'Affiliation': 'Infanta Leonor Autism Centre, Alicante, Spain.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Toral', 'Affiliation': 'San Rafael Resources Centre, Santa Faz, Spain.'}, {'ForeName': 'Domingo', 'Initials': 'D', 'LastName': 'Morales', 'Affiliation': 'Operations Research Centre, Miguel Hernández University of Elche, Elche, Spain.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Fernández', 'Affiliation': 'Bioengineering Institute, Miguel Hernández University of Elche, Elche, Spain.'}, {'ForeName': 'Ana M', 'Initials': 'AM', 'LastName': 'Peiró', 'Affiliation': 'Neuropharmacology on Pain (NED), Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881119864968'] 256,31575326,"Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.","BACKGROUND About 50% of obsessive-compulsive disorder patients still suffer significant symptoms even after the recommended first-line therapy. This demonstrates the necessity to investigate strategies to improve alleviation of symptoms. OBJECTIVE The main objective of this study was to investigate the efficacy of a 5-hydroxytryptophan 3 receptor antagonist, tropisetron, as an adjuvant therapy to selective serotonin reuptake inhibitors, in ameliorating obsessive-compulsive disorder symptoms. METHODS Men and women between the ages of 18-60 years diagnosed with obsessive-compulsive disorder, based on DSM5, who had a Yale-Brown obsessive compulsive scale score of more than 21 were recruited in a double-blinded, parallel-group, placebo-controlled, clinical trial of 10 weeks to receive either tropisetron (5 mg twice daily) and fluvoxamine (100 mg daily initially followed by 200 mg daily after week 4) or placebo and fluvoxamine. The primary outcome of interest in this study was the Yale-Brown obsessive compulsive scale total score decrease from baseline. RESULTS One hundred and eight participants were equally randomized into two groups; 48 participants in each group finished the trial. The Yale-Brown obsessive compulsive total score significantly dropped in both groups while the tropisetron group participants experienced a significantly higher decrease in their scores (Greenhouse-Geisser F (1.53-65.87)=3.516, p -value=0.04). No major adverse effect was observed in any of the groups. CONCLUSION This trial showed a significant efficacy for tropisetron over placebo in treatment of obsessive-compulsive disorder symptoms when added to fluvoxamine.",2019,"The Yale-Brown obsessive compulsive total score significantly dropped in both groups while the tropisetron group participants experienced a significantly higher decrease in their scores (Greenhouse-Geisser F (1.53-65.87)=3.516, p -value=0.04).","['One hundred and eight participants were equally randomized into two groups; 48 participants in each group finished the trial', 'Men and women between the ages of 18-60 years diagnosed with obsessive-compulsive disorder, based on DSM5, who had a Yale-Brown obsessive compulsive scale score of more than 21', 'obsessive-compulsive disorder patients']","['5-hydroxytryptophan 3 receptor antagonist, tropisetron', 'fluvoxamine', 'Fluvoxamine combination therapy with tropisetron', 'placebo', 'tropisetron', 'placebo and fluvoxamine']","['Yale-Brown obsessive compulsive total score', 'Yale-Brown obsessive compulsive scale total score decrease from baseline', 'obsessive-compulsive disorder symptoms', 'adverse effect']","[{'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1706059', 'cui_str': 'Finish - dosing instruction imperative'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0028768', 'cui_str': 'Anankastic Personality'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0678579', 'cui_str': 'Brown'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0000578', 'cui_str': '5-Hydroxytryptophan'}, {'cui': 'C4543207', 'cui_str': 'Receptor antagonist'}, {'cui': 'C0063322', 'cui_str': 'tropisetron'}, {'cui': 'C0085228', 'cui_str': 'Fluvoxamine'}, {'cui': 'C0556895', 'cui_str': 'Combination therapy (regime/therapy)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0678579', 'cui_str': 'Brown'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0028768', 'cui_str': 'Anankastic Personality'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0001688', 'cui_str': 'side effects'}]",108.0,0.421309,"The Yale-Brown obsessive compulsive total score significantly dropped in both groups while the tropisetron group participants experienced a significantly higher decrease in their scores (Greenhouse-Geisser F (1.53-65.87)=3.516, p -value=0.04).","[{'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Shalbafan', 'Affiliation': 'Mental Health Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Farzaneh', 'Initials': 'F', 'LastName': 'Malekpour', 'Affiliation': 'Mental Health Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Borna', 'Initials': 'B', 'LastName': 'Tadayon Najafabadi', 'Affiliation': 'Psychiatric Research Center, Tehran University of Medical, Tehran, Iran.'}, {'ForeName': 'Kiandokht', 'Initials': 'K', 'LastName': 'Ghamari', 'Affiliation': 'Psychiatric Research Center, Tehran University of Medical, Tehran, Iran.'}, {'ForeName': 'Seyed-Ali', 'Initials': 'SA', 'LastName': 'Dastgheib', 'Affiliation': 'Substance Abuse Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Arash', 'Initials': 'A', 'LastName': 'Mowla', 'Affiliation': 'Substance Abuse Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Shirazi', 'Affiliation': 'Mental Health Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mehrdad', 'Initials': 'M', 'LastName': 'Eftekhar Ardebili', 'Affiliation': 'Mental Health Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Ghazizadeh-Hashemi', 'Affiliation': 'Mental Health Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Shahin', 'Initials': 'S', 'LastName': 'Akhondzadeh', 'Affiliation': 'Psychiatric Research Center, Tehran University of Medical, Tehran, Iran.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881119878177'] 257,32278858,A dose-response evaluation of purified anthocyanins on inflammatory and oxidative biomarkers and metabolic risk factors in healthy young adults: A randomized controlled trial.,"OBJECTIVES Anthocyanins derived from different plant sources have been found to possess a variety of health-promoting effects, including antiinflammatory properties and protection from oxidative stress. The aim of this study was to investigate the dose-response relationship between anthocyanins and metabolic risk factors as well as inflammatory and oxidative biomarkers in healthy adult volunteers. METHODS We conducted a randomized, double-blind, placebo-controlled trial, which included an increasing dosing schedule of 20, 40, 80, 160, and 320 mg of purified anthocyanins or placebo. Participants (n = 111) were administered either agent for 14 consecutive days. RESULTS No significant differences in either baseline characteristics or daily intake of dietary nutrients were detected between the experimental and control groups. After anthocyanin supplementation, there was a significant difference in adjusted fasting plasma glucose levels. The group receiving 80 mg/d of anthocyanin had the lowest baseline-adjusted fasting plasma glucose when compared with placebo (F = 3.556, P = 0.007). Logarithmically adjusted plasma interleukin-10 levels were negatively correlated with increasing anthocyanin dose (F = 2.738, P = 0.025). Similarly, 8-iso-prostaglandin F2α levels decreased with increasing anthocyanins dose (F = 3.513, P = 0.009). CONCLUSIONS Taken together, our results suggest that anthocyanin supplementation at a dose greater than 80 mg/d is an effective antioxidant and antiinflammatory agent in healthy young adults.",2020,"The group receiving 80 mg/d of anthocyanin had the lowest baseline-adjusted fasting plasma glucose when compared with placebo (F = 3.556, P = 0.007).","['healthy adult volunteers', 'healthy young adults']","['purified anthocyanins or placebo', 'anthocyanin', 'placebo', 'purified anthocyanins', 'anthocyanin supplementation']","['baseline characteristics or daily intake of dietary nutrients', '8-iso-prostaglandin F2α levels', 'inflammatory and oxidative biomarkers and metabolic risk factors', 'adjusted fasting plasma glucose levels', 'fasting plasma glucose', 'Logarithmically adjusted plasma interleukin-10 levels']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0003161', 'cui_str': 'Anthocyanin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0911936', 'cui_str': 'isovaleronitrile'}, {'cui': 'C0033554', 'cui_str': 'Prostaglandin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}]",111.0,0.500311,"The group receiving 80 mg/d of anthocyanin had the lowest baseline-adjusted fasting plasma glucose when compared with placebo (F = 3.556, P = 0.007).","[{'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Department of Nutrition, School of Public Health, Guangdong Medical University, Dongguan, China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of Nutrition, School of Public Health, Sun Yat-Sen University, Guangzhou, China.'}, {'ForeName': 'Peiwen', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'Department of Nutrition, School of Public Health, Guangdong Medical University, Dongguan, China.'}, {'ForeName': 'Yongji', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Nutrition, Henry Fok School of Food Science and Engineering, Shaoguan University, Shaoguan, China.'}, {'ForeName': 'Longying', 'Initials': 'L', 'LastName': 'Zha', 'Affiliation': 'Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Nutrition and Food Hygiene, School of Public Health, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Wenhua', 'Initials': 'W', 'LastName': 'Ling', 'Affiliation': 'Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of Nutrition, School of Public Health, Sun Yat-Sen University, Guangzhou, China.'}, {'ForeName': 'Honghui', 'Initials': 'H', 'LastName': 'Guo', 'Affiliation': 'Department of Nutrition, School of Public Health, Guangdong Medical University, Dongguan, China; Department of Nutrition, Henry Fok School of Food Science and Engineering, Shaoguan University, Shaoguan, China. Electronic address: guohh1999@hotmail.com.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110745'] 258,32273122,Surface dissolution and transesterification of thermoset dimethacrylate polymer by dimethacrylate adhesive resin and organic catalyst-alcohol solution.,"OBJECTIVES To evaluate transesterification based dissolution of dimethacrylate and epoxy polymers, the former containing ester groups. Polymer substrates were treated with an adhesive resin (Stick™ Resin) and an organic catalyst-alcohol solution (ethylene glycol and triazabicyclodecene). The surface was chemically and nanomechanically analyzed with Fourier Transform-Infrared (FTIR) spectroscopy, surface profile peak (R p ) and nanohardness and modulus of elasticity. METHODS A total of 100 specimens each of light-cured dimethacrylate polymer and heat-cured diepoxy polymer were prepared. 20 specimens were randomly selected and used as control group (0s). The remaining specimens were randomly divided into 40 each for treatment with an Stick™ resin and ethylene glycol+triazabicyclodecene. Within each group the 40 specimens were randomly subdivided into 20 each for treatment at 5min and 24h, with 10 specimens for FTIR and nanohardness and modulus of elasticity, and the other 10 for SEM and surface R p analyses. RESULTS Dimethacrylate polymer showed a reduction in the nanohardness and modulus of elasticity, R p values and SEM also showed significant topographical changes after being treated with either Stick™ resin or ethylene glycol+triazabicyclodecene, whereas epoxy resin substrate did not. FTIR analyses affirmed changes in the intensity of ester groups. SIGNIFICANCE Ester group containing dimethacrylate polymer showed a reduction in NMP within 5min of exposure to the treatment agents with softening by solution ethylene glycol+triazabicyclodecene associated to the reduction of ester groups in the polymer structure by transesterification. Epoxy polymer without ester groups was not affected by surface softening with treatment agents. Adhesive resin caused surface swelling.",2020,"RESULTS Dimethacrylate polymer showed a reduction in the nanohardness and modulus of elasticity, R p values and SEM also showed significant topographical changes after being treated with either Stick™ resin or ethylene glycol+triazabicyclodecene, whereas epoxy resin substrate did not.","['A total of 100 specimens each of light-cured dimethacrylate polymer and heat-cured diepoxy polymer', '20 specimens']","['Ester group containing dimethacrylate polymer', 'adhesive resin (Stick™ Resin) and an organic catalyst-alcohol solution (ethylene glycol and triazabicyclodecene', 'Stick™ resin and ethylene glycol+triazabicyclodecene']","['Fourier Transform-Infrared (FTIR) spectroscopy, surface profile peak (R p ) and nanohardness and modulus of elasticity', 'NMP', 'surface swelling', 'nanohardness and modulus of elasticity, R p values and SEM']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0440254', 'cui_str': 'Dimethacrylate'}, {'cui': 'C0032521', 'cui_str': 'Polymer'}, {'cui': 'C0018837', 'cui_str': 'Heat'}]","[{'cui': 'C0014898', 'cui_str': 'Ester'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0440254', 'cui_str': 'Dimethacrylate'}, {'cui': 'C0032521', 'cui_str': 'Polymer'}, {'cui': 'C0001516', 'cui_str': 'Adhesive'}, {'cui': 'C0035191', 'cui_str': 'Resins, Plant'}, {'cui': 'C1706582', 'cui_str': 'Stick'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0015083', 'cui_str': 'ethylene glycol'}, {'cui': 'C2351312', 'cui_str': 'triazabicyclodecene'}, {'cui': 'C0015075', 'cui_str': 'Ethylene'}]","[{'cui': 'C0282183', 'cui_str': 'Fourier Transform'}, {'cui': 'C1532326', 'cui_str': 'Infra-red'}, {'cui': 'C0037812', 'cui_str': 'Analysis, Spectrum'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C2350289', 'cui_str': 'Young Modulus'}, {'cui': 'C0044438', 'cui_str': '1-methyl-2-pyrrolidinone'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0262878', 'cui_str': 'Scanning electron microscope'}]",20.0,0.0141781,"RESULTS Dimethacrylate polymer showed a reduction in the nanohardness and modulus of elasticity, R p values and SEM also showed significant topographical changes after being treated with either Stick™ resin or ethylene glycol+triazabicyclodecene, whereas epoxy resin substrate did not.","[{'ForeName': 'Santhosh', 'Initials': 'S', 'LastName': 'Basavarajappa', 'Affiliation': 'Dental Biomaterial Research Chair, Dental Health Department, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Saudi Arabia. Electronic address: sbasavarajappa@ksu.edu.sa.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Perea-Lowery', 'Affiliation': 'Institute of Dentistry, Department of Biomaterials Science, University of Turku, FI-20520 Turku, Finland.'}, {'ForeName': 'Abdullah Maghram', 'Initials': 'AM', 'LastName': 'Alshehri', 'Affiliation': 'Dental Biomaterial Research Chair, Dental Health Department, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Saudi Arabia.'}, {'ForeName': 'Abdul Aziz Abdullah', 'Initials': 'AAA', 'LastName': 'Al-Kheraif', 'Affiliation': 'Dental Biomaterial Research Chair, Dental Health Department, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Saudi Arabia.'}, {'ForeName': 'Jukka P', 'Initials': 'JP', 'LastName': 'Matinlinna', 'Affiliation': 'Faculty of Dentistry, The University of Hong Kong, Applied Oral Sciences & Community Dental Care, Dental Materials Science, Hong Kong SAR, PR China.'}, {'ForeName': 'Pekka K', 'Initials': 'PK', 'LastName': 'Vallittu', 'Affiliation': 'Professor and Chair of Biomaterials Science and Turku Clinical Biomaterials Centre - TCBC, Institute of Dentistry, University of Turku and City of Turku Welfare Division, Oral Health Care, FI-20520 Turku, Finland.'}]",Dental materials : official publication of the Academy of Dental Materials,['10.1016/j.dental.2020.03.005'] 259,31289334,The effects of exercise session timing on weight loss and components of energy balance: midwest exercise trial 2.,"BACKGROUND/OBJECTIVES Circadian physiology has been linked to body weight regulation and obesity. To date, few studies have assessed the association between exercise timing and weight related outcomes. The aim of this secondary analysis was to explore the impact of exercise timing (i.e., 24 h clock time of exercise session) on weight loss and components of energy balance. SUBJECTS/METHODS Overweight/obese (BMI 25.0-39.9 kg/m 2 ), physically inactive, young adults (~51% female) completed a 10-month supervised exercise program (400 or 600 kcal/session for 5 days/week) or served as non-exercise controls (CON). Participants were categorized based on the time of day in which they completed exercise sessions (Early-Ex: >50% of sessions completed between 7:00 and 11:59 am; (n = 21), Late-Ex: >50% of sessions completed between 3:00 and 7:00 pm; (n = 25), Sporadic-Ex: <50% of sessions completed in any time category; (n = 24), and CON; (n = 18)). Body weight, energy intake (EI; digital photography), and non-exercise physical activity (NEPA; accelerometer) were assessed at baseline, 3.5, 7, and 10 months. Total daily energy expenditure (TDEE; doubly labeled water), was assessed at baseline and 10 months. RESULTS At month 10, weight loss was significantly greater in both Early-EX (-7.2 ± 1.2%; p < 0.001) and Sporadic-EX (- 5.5 ± 1.2%; p = 0.01) vs CON (+0.5 ± 1.0%), and Early-EX vs Late-EX (-2.1 ± 1.0%; p < 0.001). There were no between group differences for change in TDEE, EI, and non-exercise energy expenditure (P > 0.05). A significant group × time interaction (p = 0.02) was observed for NEPA (counts/min), however, after adjusting for multiple comparisons, group effects were no longer significant. CONCLUSIONS Despite minimal differences in components of energy balance, Early-EX lost significantly more weight compared with Late-Ex. Although the mechanisms are unclear, the timing of exercise may be important for body weight regulation.",2020,"A significant group × time interaction (p = 0.02) was observed for NEPA (counts/min), however, after adjusting for multiple comparisons, group effects were no longer significant. ","['Overweight/obese (BMI 25.0-39.9\u2009kg/m 2 ), physically inactive, young adults (~51% female']","['exercise session', 'supervised exercise program (400 or 600\u2009kcal/session for 5 days/week) or served as non-exercise controls (CON', 'CON']","['Total daily energy expenditure (TDEE; doubly labeled water', 'time interaction', 'weight loss', 'Body weight, energy intake (EI; digital photography), and non-exercise physical activity (NEPA; accelerometer', 'change in TDEE, EI, and non-exercise energy expenditure', 'weight loss and components of energy balance']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0439259', 'cui_str': 'kilocalorie'}, {'cui': 'C0677547', 'cui_str': 'days/week (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0014272', 'cui_str': 'Energy Expenditure'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray (qualifier value)'}, {'cui': 'C0031749', 'cui_str': 'Photography'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}]",,0.0725595,"A significant group × time interaction (p = 0.02) was observed for NEPA (counts/min), however, after adjusting for multiple comparisons, group effects were no longer significant. ","[{'ForeName': 'Erik A', 'Initials': 'EA', 'LastName': 'Willis', 'Affiliation': 'Center for Health Promotion and Disease Prevention, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA. erik.willis@unc.edu.'}, {'ForeName': 'Seth A', 'Initials': 'SA', 'LastName': 'Creasy', 'Affiliation': 'Division of Endocrinology, Metabolism, and Diabetes, Anschutz Medical Campus, University of Colorado Aurora, Aurora, CO, USA.'}, {'ForeName': 'Jeffery J', 'Initials': 'JJ', 'LastName': 'Honas', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Edward L', 'Initials': 'EL', 'LastName': 'Melanson', 'Affiliation': 'Division of Endocrinology, Metabolism, and Diabetes, Anschutz Medical Campus, University of Colorado Aurora, Aurora, CO, USA.'}, {'ForeName': 'Joseph E', 'Initials': 'JE', 'LastName': 'Donnelly', 'Affiliation': 'Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS, USA.'}]",International journal of obesity (2005),['10.1038/s41366-019-0409-x'] 260,31292531,One-year postpartum anthropometric outcomes in mothers and children in the LIFE-Moms lifestyle intervention clinical trials.,"BACKGROUND/OBJECTIVES Excess gestational weight gain (GWG) is a risk factor for maternal postpartum weight retention and excessive neonatal adiposity, especially in women with overweight or obesity. Whether lifestyle interventions to reduce excess GWG also reduce 12-month maternal postpartum weight retention and infant weight-for-length z score is unknown. Randomized controlled trials from the LIFE-Moms consortium investigated lifestyle interventions that began in pregnancy and tested whether there was benefit through 12 months on maternal postpartum weight retention (i.e., the difference in weight from early pregnancy to 12 months) and infant-weight-for-length z scores. SUBJECTS/METHODS In LIFE-Moms, women (N = 1150; 14.1 weeks gestation at enrollment) with overweight or obesity were randomized within each of seven trials to lifestyle intervention or standard care. Individual participant data were combined and analyzed using generalized linear mixed models with trial entered as a random effect. The 12-month assessment was completed by 83% (959/1150) of women and 84% (961/1150) of infants. RESULTS Compared with standard care, lifestyle intervention reduced postpartum weight retention (2.2 ± 7.0 vs. 0.7 ± 6.2 kg, respectively; difference of -1.6 kg (95% CI -2.5, -0.7; p = 0.0003); the intervention effect was mediated by reduction in excess GWG, which explained 22% of the effect on postpartum weight retention. Lifestyle intervention also significantly increased the odds (OR = 1.68 (95% CI, 1.26, 2.24)) and percentage of mothers (48.2% vs. 36.2%) at or below baseline weight at 12 months postpartum (yes/no) compared with standard care. There was no statistically significant treatment group effect on infant anthropometric outcomes at 12 months. CONCLUSIONS Compared with standard care, lifestyle interventions initiated in pregnancy and focused on healthy eating, increased physical activity, and other behavioral strategies resulted in significantly less weight retention but similar infant anthropometric outcomes at 12 months postpartum in a large, diverse US population of women with overweight and obesity.",2020,"Lifestyle intervention also significantly increased the odds (OR = 1.68 (95% CI, 1.26, 2.24)) and percentage of mothers (48.2% vs. 36.2%) at or below baseline weight at 12 months postpartum (yes/no) compared with standard care.","['women (N\u2009=\u20091150; 14.1 weeks gestation at enrollment) with overweight or obesity', 'mothers and children in the LIFE-Moms lifestyle intervention clinical trials', 'women with overweight or obesity']","['lifestyle intervention or standard care', 'LIFE-Moms consortium investigated lifestyle interventions']","['maternal postpartum weight retention and infant weight-for-length z score', 'infant anthropometric outcomes', 'weight retention', 'infant-weight-for-length z scores', 'postpartum weight retention', 'maternal postpartum weight retention']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C1442163', 'cui_str': 'Multiple of the median'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}]","[{'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C1442163', 'cui_str': 'Multiple of the median'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}]","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C4704811', 'cui_str': 'Postpartum Weight Retention'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0035280', 'cui_str': 'Retention'}]",1150.0,0.182381,"Lifestyle intervention also significantly increased the odds (OR = 1.68 (95% CI, 1.26, 2.24)) and percentage of mothers (48.2% vs. 36.2%) at or below baseline weight at 12 months postpartum (yes/no) compared with standard care.","[{'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Phelan', 'Affiliation': 'Department of Kinesiology & Public Health, California Polytechnic State University, San Luis Obispo, CA, USA. sphelan@calpoly.edu.'}, {'ForeName': 'Rebecca G', 'Initials': 'RG', 'LastName': 'Clifton', 'Affiliation': 'The Biostatistics Center, George Washington University, Washington, DC, USA.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Haire-Joshu', 'Affiliation': 'Center for Diabetes Translation Research, Washington University in St. Louis, St. Louis, MO, USA.'}, {'ForeName': 'Leanne M', 'Initials': 'LM', 'LastName': 'Redman', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Van Horn', 'Affiliation': 'Department of Preventive Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Evans', 'Affiliation': 'The National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.'}, {'ForeName': 'Kaumudi', 'Initials': 'K', 'LastName': 'Joshipura', 'Affiliation': 'Center for Clinical Research and Health Promotion, School of Dental Medicine, Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico.'}, {'ForeName': 'Kimberly A', 'Initials': 'KA', 'LastName': 'Couch', 'Affiliation': 'Phoenix Indian Medical Center, Indian Health Service, Phoenix, AZ, USA.'}, {'ForeName': 'S Sonia', 'Initials': 'SS', 'LastName': 'Arteaga', 'Affiliation': 'The National Heart, Lung, and Blood Institute, Bethesda, MD, USA.'}, {'ForeName': 'Alison G', 'Initials': 'AG', 'LastName': 'Cahill', 'Affiliation': 'Department of Obstetrics and Gynecology, Washington University in St. Louis, St. Louis, MO, USA.'}, {'ForeName': 'Kimberly L', 'Initials': 'KL', 'LastName': 'Drews', 'Affiliation': 'The Biostatistics Center, George Washington University, Washington, DC, USA.'}, {'ForeName': 'Paul W', 'Initials': 'PW', 'LastName': 'Franks', 'Affiliation': 'Department of Nutrition, Harvard T.H. Chan Public Health School, Harvard University, Boston, MA, USA.'}, {'ForeName': 'Dympna', 'Initials': 'D', 'LastName': 'Gallagher', 'Affiliation': 'New York Obesity Research Center, Dept. of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.'}, {'ForeName': 'Jami L', 'Initials': 'JL', 'LastName': 'Josefson', 'Affiliation': 'Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Klein', 'Affiliation': 'Center for Human Nutrition, Washington University in St. Louis, St. Louis, MO, USA.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Knowler', 'Affiliation': 'Diabetes Epidemiology and Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ, USA.'}, {'ForeName': 'Corby K', 'Initials': 'CK', 'LastName': 'Martin', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA, USA.'}, {'ForeName': 'Alan M', 'Initials': 'AM', 'LastName': 'Peaceman', 'Affiliation': 'Department of Obstetrics and Gynecology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Thom', 'Affiliation': 'The Biostatistics Center, George Washington University, Washington, DC, USA.'}, {'ForeName': 'Rena R', 'Initials': 'RR', 'LastName': 'Wing', 'Affiliation': 'The Miriam Hospital and the Department of Psychiatry and Human Behavior, Warren Alpert Medical School at Brown University, Providence, RI, USA.'}, {'ForeName': 'Susan Z', 'Initials': 'SZ', 'LastName': 'Yanovski', 'Affiliation': 'The National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Pi-Sunyer', 'Affiliation': 'New York Obesity Research Center, Dept. of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",International journal of obesity (2005),['10.1038/s41366-019-0410-4'] 261,32243051,Effect of augmented reality simulation on administration of local anaesthesia in paediatric patients.,"BACKGROUND Augmented reality (AR) is a simulation of a three-dimensional environment created using hardware and software that provides the user with realistic experiences and ability to interact. The aim of the study was to evaluate the impact of AR simulator on the perception of learning and acute stress level in students administering local anaesthesia to paediatric patients relative to standard teaching methods. MATERIAL AND METHODS The prospective study included 21 fourth- and fifth-year students enrolled in 5-year dental programme. In addition to conventional training, the students of the study group used the augmented reality simulator in a dental office 2 hours weekly in 2 weeks. The level of salivary cortisol was measured before and after the anaesthetic procedure as one of the indicators of acute stress. RESULTS A statistically significant shorter time to perform infiltrative anaesthesia technique for the anterior superior alveolar nerve was observed in students using the AR technique (28.91 ± 9.06 seconds in the study group and 39.80 ± 9.29 seconds in the control group). The level of cortisol before and after anaesthesia was statistically significant in all subjects (cortisol concentration was 0.53 μg/dL before anaesthesia and 2.44 μg/dL after the procedure); however, there was no statistically significant difference between the groups. CONCLUSION The AR concept may influence better manipulation and control of the syringe in students administering their first anaesthetic injection to paediatric patients, but may not reduce acute stress.",2020,"A statistically significant shorter time to perform infiltrative anesthesia technique for the anterior superior alveolar nerve was observed in students using the AR technique (28,91±9,06 seconds in the Study group and 39,80±9,29 seconds in the Control group).","['students administering local anesthesia to pediatric patients relative to standard teaching methods', '21 fourth- and fifth-year students enrolled in 5-year-dental program', 'pediatric patients']","['AR simulator', 'Augmented Reality (AR', 'Augmented Reality simulation']","['cortisol concentration', 'level of salivary cortisol', 'level of cortisol']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0039403', 'cui_str': 'Teaching Methods'}, {'cui': 'C0205438', 'cui_str': 'Fourth'}, {'cui': 'C0205439', 'cui_str': 'Fifth'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C5197824', 'cui_str': 'Mixed Reality'}]","[{'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}]",21.0,0.0412944,"A statistically significant shorter time to perform infiltrative anesthesia technique for the anterior superior alveolar nerve was observed in students using the AR technique (28,91±9,06 seconds in the Study group and 39,80±9,29 seconds in the Control group).","[{'ForeName': 'Rasa', 'Initials': 'R', 'LastName': 'Mladenovic', 'Affiliation': 'Faculty of Medicine, Department for Dentistry, University in Pristina, Kosovska Mitrovica, Serbia.'}, {'ForeName': 'Dragana', 'Initials': 'D', 'LastName': 'Dakovic', 'Affiliation': 'Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia.'}, {'ForeName': 'Leandro', 'Initials': 'L', 'LastName': 'Pereira', 'Affiliation': 'Blantus Endodontic Center, Campinas, Brazil.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Matvijenko', 'Affiliation': 'Faculty of Medicine, Department for Dentistry, University in Pristina, Kosovska Mitrovica, Serbia.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Mladenovic', 'Affiliation': 'Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.'}]",European journal of dental education : official journal of the Association for Dental Education in Europe,['10.1111/eje.12529'] 262,32248795,Efficacy of a self-applied online program to promote resilience and coping skills in university students in four Spanish-speaking countries: study protocol for a randomized controlled trial.,"BACKGROUND There is evidence of a high prevalence of depression and anxiety in university students. Therefore, college time is a key period where prevention of mental disorders through interventions that promote resilience and mental health can be relevant. Currently, there are interventions available, but these are insufficient for those who need them. Online interventions are tools that can facilitate global accessibility and are easy for young people to use. CORE (Cultivating Our Resilience) is a self-administered online program, based on Ryff's psychological well-being model, to promote resilience and coping skills in university students at risk of developing symptoms of depression or anxiety. The objective is to evaluate the effectiveness of this intervention protocol in comparison with an active control condition targeting healthy lifestyle, and a waiting list control condition. The study will be conducted in four populations of Spanish-speaking university students (Spain, Argentina, Colombia, and Mexico). METHODS The study design is a randomized controlled trial (RCT). At least 324 university students will be randomly assigned to three conditions: 1) CORE, a 6-week training program to improve resilience; 2) HLP, a 6-week training to promote a healthy lifestyle; and 3) WL, waiting list control condition. The primary outcome measure will be the Connor-Davidson resilience scale. Additionally, measures of anxiety, depression, quality of life and socio-demographic variables (age, sex, incomes, marital status, among others) will be collected. Participants will be evaluated at pre-treatment, after each module, 6 weeks after allocation, and at 3-month follow-up. Intention-to-treat and per-protocol analyses will be performed. DISCUSSION The results of this study will contribute to research on Internet-administered interventions and the implementation of a protocol that includes a series of components designed to improve resilience and coping skills, increase psychological well-being, and prevent depression and anxiety disorders in Spanish-speaking university students. In addition, avenues will be opened up for new research on the effectiveness of these interventions focused on the prevention and promotion of mental health in Spanish-speaking countries. TRIAL REGISTRATION Registered at ClinicalTrials.gov NCT03903978 on April 2, 2019.",2020,"CORE (Cultivating Our Resilience) is a self-administered online program, based on Ryff's psychological well-being model, to promote resilience and coping skills in university students at risk of developing symptoms of depression or anxiety.","['At least 324 university students', 'university students in four Spanish-speaking countries', 'Spanish-speaking university students', 'four populations of Spanish-speaking university students (Spain, Argentina, Colombia, and Mexico', 'university students at risk of developing symptoms of depression or anxiety', 'university students']","['self-applied online program', 'CORE, a 6-week training program to improve resilience; 2) HLP, a 6-week training to promote a healthy lifestyle; and 3) WL, waiting list control condition']","['Connor-Davidson resilience scale', 'anxiety, depression, quality of life and socio-demographic variables (age, sex, incomes, marital status, among others', 'resilience and coping skills']","[{'cui': 'C4517713', 'cui_str': '324'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0234856', 'cui_str': 'Speaking'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0003761', 'cui_str': 'Argentina'}, {'cui': 'C3245499', 'cui_str': 'Colombia'}, {'cui': 'C0025885', 'cui_str': 'Mexico'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0263420', 'cui_str': 'Hyperkeratosis lenticularis perstans'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C4277664', 'cui_str': 'Healthy Lifestyles'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0024819', 'cui_str': 'Marital status'}, {'cui': 'C0086059', 'cui_str': 'Coping Skills'}]",,0.114054,"CORE (Cultivating Our Resilience) is a self-administered online program, based on Ryff's psychological well-being model, to promote resilience and coping skills in university students at risk of developing symptoms of depression or anxiety.","[{'ForeName': 'Araceli', 'Initials': 'A', 'LastName': 'Palma-Gómez', 'Affiliation': 'Universitat Jaume I, Castellón, Spain.'}, {'ForeName': 'Rocío', 'Initials': 'R', 'LastName': 'Herrero', 'Affiliation': 'CIBER of Physiopathology of Obesity and Nutrition (CB06/03) Instituto Salud Carlos III, Madrid, Spain. rherrero@uji.es.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Baños', 'Affiliation': 'CIBER of Physiopathology of Obesity and Nutrition (CB06/03) Instituto Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'Azucena', 'Initials': 'A', 'LastName': 'García-Palacios', 'Affiliation': 'Universitat Jaume I, Castellón, Spain.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Castañeiras', 'Affiliation': 'Universidad Nacional de Mar del Plata, Mar del Plata, Argentina.'}, {'ForeName': 'Gabriela Lidia', 'Initials': 'GL', 'LastName': 'Fernandez', 'Affiliation': 'Universidad de Buenos Aires, Buenos Aires, Argentina.'}, {'ForeName': 'Dario Martín', 'Initials': 'DM', 'LastName': 'Llull', 'Affiliation': 'Universidad Nacional de Mar del Plata, Mar del Plata, Argentina.'}, {'ForeName': 'Lorena Cudris', 'Initials': 'LC', 'LastName': 'Torres', 'Affiliation': 'Universidad Popular del Cesar, Valledupar, Colombia.'}, {'ForeName': 'Libia Alvis', 'Initials': 'LA', 'LastName': 'Barranco', 'Affiliation': 'Universidad Popular del Cesar, Valledupar, Colombia.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Cárdenas-Gómez', 'Affiliation': 'Universidad Politécnica de Tecámac, Tecámac de Felipe Villanueva, Mexico.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Botella', 'Affiliation': 'Universitat Jaume I, Castellón, Spain.'}]",BMC psychiatry,['10.1186/s12888-020-02536-w'] 263,31821059,"Anaesthetic efficacy of 2% lidocaine with different concentrations of epinephrine (1:80,000 and 1:200,000) in intraligamentary injection after a failed primary inferior alveolar nerve block: a randomized double-blind study.","Introduction: The present study evaluated the anaesthetic efficacy of 2% lidocaine with 1:80,000 epinephrine vs. 2% lidocaine with 1:200,000 given as supplemental intraligamentary injections after a failed inferior alveolar nerve block (IANB) in patients with symptomatic irreversible pulpitis. The effect of these solutions on the heart rate was also evaluated. Methods: One-hundred-eighteen adult patients with symptomatic irreversible pulpits in a mandibular first or second molar, received an initial IANB with 2% lidocaine with 1:80,000 epinephrine. Pain during the endodontic treatment was assessed using a visual analogue scale (Heft-Parker VAS). Eighty-eight patients with unsuccessful anaesthesia were randomly allocated to one of the two treatment groups: one group received 0.6 mL/root of supplementary intraligamentary injection of 2% lidocaine with 1:80,000 epinephrine; while the second group received 2% lidocaine with 1:200,000 epinephrine. Endodontic treatment was re-initiated. Success after primary injection or supplementary injection was defined as no or mild pain (pain score ≤54 mm on HP VAS) during access preparation and root canal instrumentation. Heart rate was monitored using a finger pulse oximeter. The anaesthetic success rates were analyzed with the Pearson chi-square test at 5% significance levels. The heart rate changes were analyzed using the t-test. Results: The anaesthetic success rate in patients receiving supplementary intraligamentary injections in 1:80,000 epinephrine group was 82%, while the intraligamentary injections with 2% lidocaine with 1:200,000 epinephrine were successful in 57% of cases. The difference was statistically significant (χ 2 =6.4, p  = .011). There was no significant effect of both the anaesthetic agents on the mean heart rate. Conclusions: Both 2% lidocaine with 1:80,000 epinephrine and 2% lidocaine with 1:200,000 epinephrine improved the success rates after a failed primary anaesthetic injection. The 1:80,000 epinephrine group was significantly more successful.",2020,"The anaesthetic success rate in patients receiving supplementary intraligamentary injections in 1:80,000 epinephrine group was 82%, while the intraligamentary injections with 2% lidocaine with 1:200,000 epinephrine were successful in 57% of cases.","['One-hundred-eighteen adult patients with symptomatic irreversible pulpits in a mandibular first or second molar, received an initial IANB with 2', 'Eighty-eight patients with unsuccessful anaesthesia', 'patients with symptomatic irreversible pulpitis', 'intraligamentary injection after a failed primary inferior alveolar nerve block']","['epinephrine', 'lidocaine', 'lidocaine with 1:200,000 epinephrine', 'lidocaine with 1:80,000 epinephrine', 'epinephrine vs. 2% lidocaine']","['anaesthetic success rate', 'anaesthetic efficacy', 'Pain', 'Anaesthetic efficacy', 'anaesthetic success rates', 'successful', 'heart rate changes', 'mean heart rate', 'success rates', 'heart rate', 'Heart rate']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C4517898', 'cui_str': '88'}, {'cui': 'C1272705', 'cui_str': 'Unsuccessful'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0394801', 'cui_str': 'Local anesthetic inferior alveolar nerve block'}]","[{'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}]","[{'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0232189', 'cui_str': 'Alteration in heart rate'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}]",118.0,0.211607,"The anaesthetic success rate in patients receiving supplementary intraligamentary injections in 1:80,000 epinephrine group was 82%, while the intraligamentary injections with 2% lidocaine with 1:200,000 epinephrine were successful in 57% of cases.","[{'ForeName': 'Vivek', 'Initials': 'V', 'LastName': 'Aggarwal', 'Affiliation': 'Department of Conservative Dentistry and Endodontics, Faculty of Dentistry, Jamia Millia Islamia, New Delhi, India.'}, {'ForeName': 'Mamta', 'Initials': 'M', 'LastName': 'Singla', 'Affiliation': 'Department of Conservative Dentistry and Endodontics, SGT Dental College, Gurgaon, Haryana, India.'}, {'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Saatchi', 'Affiliation': 'Professor of Endodontics, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Mukesh', 'Initials': 'M', 'LastName': 'Hasija', 'Affiliation': 'Department of Conservative Dentistry and Endodontics, Faculty of Dentistry, Jamia Millia Islamia, New Delhi, India.'}]",Acta odontologica Scandinavica,['10.1080/00016357.2019.1700302'] 264,31475623,"Efficacy of a standardised saffron extract (affron®) as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults: A randomised, double-blind, placebo-controlled study.","BACKGROUND As a stand-alone intervention, saffron has efficacy for the treatment of mild-to-moderate depression. However, research as an adjunct agent is limited. AIMS The effects of saffron as an adjunct to pharmaceutical antidepressants in adults with persistent depression was investigated. METHODS In this eight-week, randomised, double-blind, placebo-controlled study, adults with persistent depression, currently taking a pharmaceutical antidepressant were given a placebo or a saffron extract (affron®, 14 mg b.i.d.). Primary outcome measures included the clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS) and self-rated MADRS (MADRS-S). Secondary outcome measures included the Antidepressant Side-Effect Checklist (ASEC) and Short Form-36 Health Survey (SF-36). RESULTS Of the 160 participants enrolled, 139 provided usable data. Based on the MADRS, depressive symptoms decreased more in participants taking saffron compared with a placebo, with reductions of 41 and 21%, respectively ( p = 0.001). However, scores on the MADRS-S decreased 27 and 26% in the saffron and placebo conditions, respectively ( p = 0.831). Saffron was associated with a greater reduction in adverse effects of antidepressants ( p = 0.019), although this was non-significant after covarying for baseline values ( p = 0.449). Quality of life improved in both groups with no significant between-group differences ( p = 0.638). CONCLUSION Adjunctive administration of a standardised saffron extract (affron®) for eight weeks was associated with a greater improvement in depressive symptoms as measured by the clinician-rated MADRS but not the self-report MADRS-S. Given the conflicting results, further research is needed to clarify the clinical benefits of saffron as an adjunctive treatment for adults with persistent depressive symptoms despite antidepressant drug treatment.",2019,"Saffron was associated with a greater reduction in adverse effects of antidepressants ( p = 0.019), although this was non-significant after covarying for baseline values ( p = 0.449).","['adults with persistent depression, currently taking a pharmaceutical antidepressant were given a', 'persistent depressive symptoms in adults', 'adults with persistent depressive symptoms despite antidepressant drug treatment', '160 participants enrolled, 139 provided usable data', 'adults with persistent depression was investigated']","['placebo or a saffron extract', 'saffron', 'placebo', 'standardised saffron extract (affron®']","['Quality of life', 'depressive symptoms', 'Antidepressant Side-Effect Checklist (ASEC) and Short Form-36 Health Survey (SF-36', 'MADRS-S', 'MADRS, depressive symptoms', 'adverse effects of antidepressants', 'clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS) and self-rated MADRS (MADRS-S']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant Drugs'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3696061', 'cui_str': 'Saffron Extract'}, {'cui': 'C2348128', 'cui_str': 'Saffron'}]","[{'cui': 'C0034380'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant Drugs'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}, {'cui': 'C0036588', 'cui_str': 'Self'}]",160.0,0.413651,"Saffron was associated with a greater reduction in adverse effects of antidepressants ( p = 0.019), although this was non-significant after covarying for baseline values ( p = 0.449).","[{'ForeName': 'Adrian L', 'Initials': 'AL', 'LastName': 'Lopresti', 'Affiliation': 'College of Science, Health, Engineering and Education, Murdoch University, Perth, WA, Australia.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Smith', 'Affiliation': 'College of Science, Health, Engineering and Education, Murdoch University, Perth, WA, Australia.'}, {'ForeName': 'Sean D', 'Initials': 'SD', 'LastName': 'Hood', 'Affiliation': 'Division of Psychiatry, UWA Medical School, University of Western Australia, Perth, WA, Australia.'}, {'ForeName': 'Peter D', 'Initials': 'PD', 'LastName': 'Drummond', 'Affiliation': 'College of Science, Health, Engineering and Education, Murdoch University, Perth, WA, Australia.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881119867703'] 265,31547761,No evidence for the involvement of serotonin or the 5-HTTLPR genotype in intertemporal choice in a larger community sample.,"BACKGROUND Serotonin has been implicated in impulsive behaviours such as temporal discounting. While animal studies and theoretical approaches suggest that reduced tonic serotonin levels increase temporal discounting rates and vice versa, evidence from human studies is scarce and inconclusive. Furthermore, an important modulator of serotonin signalling, a genetic variation in the promoter region of the serotonin transporter gene ( 5-HTTLPR ), has not been investigated for temporal discounting so far. OBJECTIVE First, the purpose of this study was to test for a significant association between 5-HTTLPR and temporal discounting. Second, we wished to investigate the effect of high/low tonic serotonin levels on intertemporal choice and blood oxygen-level-dependent response, controlling for 5-HTTLPR. METHODS We tested the association of 5-HTTLPR with temporal discounting rates using an intertemporal choice task in 611 individuals. We then manipulated tonic serotonin levels with acute tryptophan interventions (depletion, loading, balanced) in a subsample of 45 short (S)-allele and 45 long (L)/L-allele carriers in a randomised double-blind crossover design using functional magnetic resonance imaging and an intertemporal choice task. RESULTS Overall, we did not find any effect of serotonin and 5-HTTLPR on temporal discounting rates or the brain networks associated with valuation and cognitive control. CONCLUSION Our findings indicate that serotonin may not be directly involved in choices including delays on longer timescales such as days, weeks or months. We speculate that serotonin plays a stronger role in dynamic intertemporal choice tasks where the delays are on a timescale of seconds and hence are therefore directly experienced during the experiment.",2019,"Overall, we did not find any effect of serotonin and 5-HTTLPR on temporal discounting rates or the brain networks associated with valuation and cognitive control. ",['611 individuals'],"['serotonin', 'functional magnetic resonance imaging and an intertemporal choice task', 'acute tryptophan interventions (depletion, loading, balanced) in a subsample of 45 short (S)-allele and 45 long (L)/L-allele carriers']","['intertemporal choice and blood oxygen-level-dependent response, controlling for 5-HTTLPR']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0041249', 'cui_str': 'L-tryptophan'}, {'cui': 'C0333668', 'cui_str': 'Depletion (morphologic abnormality)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0002085', 'cui_str': 'Allelomorphs'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0560175', 'cui_str': 'Carrier State'}]","[{'cui': 'C0005768'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",611.0,0.202027,"Overall, we did not find any effect of serotonin and 5-HTTLPR on temporal discounting rates or the brain networks associated with valuation and cognitive control. ","[{'ForeName': 'Philipp T', 'Initials': 'PT', 'LastName': 'Neukam', 'Affiliation': 'Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Yacila I', 'Initials': 'YI', 'LastName': 'Deza-Araujo', 'Affiliation': 'Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Marxen', 'Affiliation': 'Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Shakoor', 'Initials': 'S', 'LastName': 'Pooseh', 'Affiliation': 'Freiburg Center for Data Analysis and Modeling, Freiburg, Germany.'}, {'ForeName': 'Marcella', 'Initials': 'M', 'LastName': 'Rietschel', 'Affiliation': 'Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Schwarzenbolz', 'Affiliation': 'Institute of Food Chemistry, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Michael N', 'Initials': 'MN', 'LastName': 'Smolka', 'Affiliation': 'Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881119874417'] 266,32242355,Timing of Endoscopy for Acute Upper Gastrointestinal Bleeding.,"BACKGROUND It is recommended that patients with acute upper gastrointestinal bleeding undergo endoscopy within 24 hours after gastroenterologic consultation. The role of endoscopy performed within time frames shorter than 24 hours has not been adequately defined. METHODS To evaluate whether urgent endoscopy improves outcomes in patients predicted to be at high risk for further bleeding or death, we randomly assigned patients with overt signs of acute upper gastrointestinal bleeding and a Glasgow-Blatchford score of 12 or higher (scores range from 0 to 23, with higher scores indicating a higher risk of further bleeding or death) to undergo endoscopy within 6 hours (urgent-endoscopy group) or between 6 and 24 hours (early-endoscopy group) after gastroenterologic consultation. The primary end point was death from any cause within 30 days after randomization. RESULTS A total of 516 patients were enrolled. The 30-day mortality was 8.9% (23 of 258 patients) in the urgent-endoscopy group and 6.6% (17 of 258) in the early-endoscopy group (difference, 2.3 percentage points; 95% confidence interval [CI], -2.3 to 6.9). Further bleeding within 30 days occurred in 28 patients (10.9%) in the urgent-endoscopy group and in 20 (7.8%) in the early-endoscopy group (difference, 3.1 percentage points; 95% CI, -1.9 to 8.1). Ulcers with active bleeding or visible vessels were found on initial endoscopy in 105 of the 158 patients (66.4%) with peptic ulcers in the urgent-endoscopy group and in 76 of 159 (47.8%) in the early-endoscopy group. Endoscopic hemostatic treatment was administered at initial endoscopy for 155 patients (60.1%) in the urgent-endoscopy group and for 125 (48.4%) in the early-endoscopy group. CONCLUSIONS In patients with acute upper gastrointestinal bleeding who were at high risk for further bleeding or death, endoscopy performed within 6 hours after gastroenterologic consultation was not associated with lower 30-day mortality than endoscopy performed between 6 and 24 hours after consultation. (Funded by the Health and Medical Fund of the Food and Health Bureau, Government of Hong Kong Special Administrative Region; ClinicalTrials.gov number, NCT01675856.).",2020,"Endoscopic hemostatic treatment was administered at initial endoscopy for 155 patients (60.1%) in the urgent-endoscopy group and for 125 (48.4%) in the early-endoscopy group. ","['patients with acute upper gastrointestinal bleeding undergo endoscopy within 24 hours after gastroenterologic consultation', 'patients predicted to be at high risk for further bleeding or death, we randomly assigned patients with overt signs of acute upper gastrointestinal bleeding and a Glasgow-Blatchford score of 12 or higher (scores range from 0 to 23, with higher scores indicating a higher risk of further bleeding or death) to undergo endoscopy within 6 hours (urgent-endoscopy group) or between 6 and 24 hours (early-endoscopy group) after gastroenterologic consultation', '516 patients were enrolled']",['Endoscopic hemostatic treatment'],"['death', 'peptic ulcers', 'Ulcers with active bleeding or visible vessels', '30-day mortality', 'Further bleeding']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0266809', 'cui_str': 'Acute upper gastrointestinal hemorrhage'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C1292428', 'cui_str': '6 hours'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0030920', 'cui_str': 'Peptic ulcer'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205379', 'cui_str': 'Visible'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",516.0,0.0981341,"Endoscopic hemostatic treatment was administered at initial endoscopy for 155 patients (60.1%) in the urgent-endoscopy group and for 125 (48.4%) in the early-endoscopy group. ","[{'ForeName': 'James Y W', 'Initials': 'JYW', 'LastName': 'Lau', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Raymond S Y', 'Initials': 'RSY', 'LastName': 'Tang', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Heyson C H', 'Initials': 'HCH', 'LastName': 'Chan', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Hon-Chi', 'Initials': 'HC', 'LastName': 'Yip', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Shannon M', 'Initials': 'SM', 'LastName': 'Chan', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Sally W Y', 'Initials': 'SWY', 'LastName': 'Luk', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Sunny H', 'Initials': 'SH', 'LastName': 'Wong', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Louis H S', 'Initials': 'LHS', 'LastName': 'Lau', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Rashid N', 'Initials': 'RN', 'LastName': 'Lui', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Ting T', 'Initials': 'TT', 'LastName': 'Chan', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Joyce W Y', 'Initials': 'JWY', 'LastName': 'Mak', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Francis K L', 'Initials': 'FKL', 'LastName': 'Chan', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Joseph J Y', 'Initials': 'JJY', 'LastName': 'Sung', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}]",The New England journal of medicine,['10.1056/NEJMoa1912484'] 267,31591483,Role of appetitive phenotype trajectory groups on child body weight during a family-based treatment for children with overweight or obesity.,"OBJECTIVE Emerging evidence suggests that individual appetitive traits may usefully explain patterns of weight loss in behavioral weight loss treatments for children. The objective of this study was to identify trajectories of child appetitive traits and the impact on child weight changes over time. METHODS Secondary data analyses of a randomized noninferiority trial conducted between 2011 and 2015 evaluated children's appetitive traits and weight loss. Children with overweight and obesity (mean age = 10.4; mean BMI z = 2.0; 67% girls; 32% Hispanic) and their parent (mean age = 42.9; mean BMI = 31.9; 87% women; 31% Hispanic) participated in weight loss programs and completed assessments at baseline, 3, 6,12, and 24 months. Repeated assessments of child appetitive traits, including satiety responsiveness, food responsiveness and emotional eating, were used to identify parsimonious grouping of change trajectories. Linear mixed-effects models were used to identify the impact of group trajectory on child BMIz change over time. RESULTS One hundred fifty children and their parent enrolled in the study. The three-group trajectory model was the most parsimonious and included a high satiety responsive group (HighSR; 47.4%), a high food responsive group (HighFR; 34.6%), and a high emotional eating group (HighEE; 18.0%). Children in all trajectories lost weight at approximately the same rate during treatment, however, only the HighSR group maintained their weight loss during follow-ups, while the HighFR and HighEE groups regained weight (adjusted p-value < 0.05). CONCLUSIONS Distinct trajectories of child appetitive traits were associated with differential weight loss maintenance. Identified high-risk subgroups may suggest opportunities for targeted intervention and maintenance programs.",2019,"Repeated assessments of child appetitive traits, including satiety responsiveness, food responsiveness and emotional eating, were used to identify parsimonious grouping of change trajectories.","['children', 'children with overweight or obesity', 'Children with overweight and obesity (mean age\u2009', 'One hundred fifty children and their parent enrolled in the study', ""2011 and 2015 evaluated children's appetitive traits and weight loss""]",['appetitive phenotype trajectory'],"['child body weight', 'differential weight loss maintenance', 'child BMIz change over time', 'weight loss', 'child appetitive traits, including satiety responsiveness, food responsiveness and emotional eating']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}]","[{'cui': 'C1314763', 'cui_str': 'Phenotyping (qualifier value)'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0443199', 'cui_str': 'Differential (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0036239', 'cui_str': 'Satiations'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}]",150.0,0.0200187,"Repeated assessments of child appetitive traits, including satiety responsiveness, food responsiveness and emotional eating, were used to identify parsimonious grouping of change trajectories.","[{'ForeName': 'Kerri N', 'Initials': 'KN', 'LastName': 'Boutelle', 'Affiliation': 'Department of Pediatrics, UC San Diego, La Jolla, CA, USA. kboutelle@ucsd.edu.'}, {'ForeName': 'D Eastern', 'Initials': 'DE', 'LastName': 'Kang Sim', 'Affiliation': 'Department of Pediatrics, UC San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Manzano', 'Affiliation': 'Department of Pediatrics, UC San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Kyung E', 'Initials': 'KE', 'LastName': 'Rhee', 'Affiliation': 'Department of Pediatrics, UC San Diego, La Jolla, CA, USA.'}, {'ForeName': 'Scott J', 'Initials': 'SJ', 'LastName': 'Crow', 'Affiliation': 'Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Strong', 'Affiliation': 'Department of Family Medicine and Public Health, UC San Diego, La Jolla, CA, USA.'}]",International journal of obesity (2005),['10.1038/s41366-019-0463-4'] 268,30756115,Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease.,"BACKGROUND Randomized placebo-controlled trials in the development of disease-modifying treatments for Alzheimer's disease are typically of short duration (12-18 months), and health economic modeling requires extrapolation of treatment effects beyond the trial period. OBJECTIVES To investigate whether observational data can be used to extrapolate data from open-label trials, we compared outcomes (cognition, function, behavior) over 36 months for patients with mild Alzheimer's disease dementia in the GERAS observational study (proxy for placebo control) with those of the mild Alzheimer's disease population on active treatment (solanezumab) in two 18-month randomized placebo-controlled trials (EXPEDITION and EXPEDITION2) and the additional 18-month open-label extension study (EXPEDITION-EXT). DESIGN AND SETTING Analysis of longitudinal data from patients with mild Alzheimer's disease dementia in the GERAS observational study (conducted in France, Germany and the United Kingdom) and the EXPEDITION program (conducted in Europe, North America, South America, Asia and Australia). PARTICIPANTS European and North American community-living patients, aged ≥55 years, with probable Alzheimer's disease dementia and their caregivers. Mild Alzheimer's disease dementia was defined as a Mini-Mental State Examination score of 20-26 in EXPEDITION and 21-26 in GERAS. INTERVENTION Active treatment in both randomized placebo-controlled trials and the open-label extension study was intravenous solanezumab 400 mg every 4 weeks. Patients in GERAS were receiving treatment as part of standard care. MEASUREMENTS Between-group differences for changes from baseline over 36 months in cognitive function, ability to perform activities of daily living, and behavioral and psychological symptoms of dementia were assessed using models stratified by propensity score. RESULTS At baseline, patients and caregivers participating in GERAS were significantly older than those in the EXPEDITION studies, and the GERAS patient cohort had fewer years of education and a shorter time since diagnosis of Alzheimer's disease. The baseline mean Mini-Mental State Examination score of the GERAS cohort was significantly higher (indicating better cognition) than that of patients receiving placebo or active treatment in the pooled EXPEDITION studies Baseline functional ability scores were significantly lower for the GERAS cohort, indicating poorer functioning. Propensity score stratification achieved a good balance in the baseline variables between GERAS and the two EXPEDITION arms. Over 18 months, least squares mean changes from baseline in outcome measures were similar in the GERAS cohort and the pooled placebo groups from the randomized controlled trials. Also, the 18-month results for the comparison between the GERAS cohort and the pooled active treatment groups from the randomized controlled trials were generally similar to those reported for the comparison with the control group in the randomized trial. Comparison of active treatment (EXPEDITION-EXT) and observational study (GERAS, as proxy control) results over 36 months of the open-label trial showed a significantly smaller decline in activities of daily living (instrumental and basic) in the active treatment group, reflecting better functioning, but no between-group differences at 36 months for cognitive function or behavioral and psychological symptoms of dementia. CONCLUSIONS Comparing results from clinical trials and observational studies (real-world data) may be a useful methodological approach for informing long-term outcomes in Alzheimer's disease drug development and could be used to inform health economic modeling. Further research using this methodological approach is needed.",2019,"The baseline mean Mini-Mental State Examination score of the GERAS cohort was significantly higher (indicating better cognition) than that of patients receiving placebo or active treatment in the pooled EXPEDITION studies Baseline functional ability scores were significantly lower for the GERAS cohort, indicating poorer functioning.","[""European and North American community-living patients, aged ≥55 years, with probable Alzheimer's disease dementia and their caregivers"", ""patients with mild Alzheimer's disease dementia in the GERAS observational study (conducted in France, Germany and the United Kingdom) and the EXPEDITION program (conducted in Europe, North America, South America, Asia and Australia"", ""patients with mild Alzheimer's disease dementia in the GERAS observational study (proxy for placebo control) with those of the mild Alzheimer's disease population on active treatment (solanezumab) in two 18-month randomized""]","['solanezumab', 'placebo']","[""Mild Alzheimer's disease dementia"", 'cognitive function, ability to perform activities of daily living, and behavioral and psychological symptoms of dementia', 'activities of daily living (instrumental and basic', 'cognitive function or behavioral and psychological symptoms of dementia', 'baseline mean Mini-Mental State Examination score', 'Baseline functional ability scores']","[{'cui': 'C0239307', 'cui_str': 'European (ethnic group)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C1518527', 'cui_str': 'Observational Study'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom'}, {'cui': 'C0015315', 'cui_str': 'Expeditions'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0037713', 'cui_str': 'South America'}, {'cui': 'C0003980', 'cui_str': 'Asia'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0600420', 'cui_str': 'Proxy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C2935150', 'cui_str': 'solanezumab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0001288', 'cui_str': 'ADL'}, {'cui': 'C4285807', 'cui_str': 'Neuropsychiatric symptoms'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C2960235', 'cui_str': 'Mini-mental state examination score (observable entity)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.283246,"The baseline mean Mini-Mental State Examination score of the GERAS cohort was significantly higher (indicating better cognition) than that of patients receiving placebo or active treatment in the pooled EXPEDITION studies Baseline functional ability scores were significantly lower for the GERAS cohort, indicating poorer functioning.","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Reed', 'Affiliation': 'Catherine Reed, Eli Lilly and Company, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK, Phone: 0044 (0) 1276 483243; Fax: 0044 (0) 1276 483192; Email: reed_catherine@lilly.com.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Happich', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Raskin', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Tockhorn-Heidenreich', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Belger', 'Affiliation': ''}]",The journal of prevention of Alzheimer's disease,['10.14283/jpad.2019.4'] 269,32272756,"""JUMPing into Diabetes Control"": A Group-Setting Self-Empowerment Lifestyle Intervention among Diabetes Patients.","We examined the impact of a group-based self-empowerment intervention among diabetes patients, which uses multidisciplinary education, collaborative learning, peer support, and development of diabetes-specific social capital to improve glycemic control and weight management. Thirty-five patients who had primary care established at the Prisma Health Upstate, Internal Medicine Resident clinic and held the diagnosis of diabetes for longer than one year were recruited for our single-arm pilot intervention. Each group intervention session involved one to two internal medicine resident physician facilitators, a clinical diabetic educator, and 5-10 patients. Each session had a framework facilitated by the resident, with most of the discussion being patient-led, aiming to provide a collaborative learning environment and create a support group atmosphere to encourage self-empowerment. Patients' hemoglobin A1c level and body mass index (BMI) before the intervention and 3 to 6 months after completion were collected from the laboratory results obtained in the participants' routine clinic visits. All graduates from this three-week intervention were invited to attend monthly maintenance sessions, and we tracked the HgbA1c measures of 29 JUMP graduates one year after the intervention, even though 13 of the 29 chose not to participate in the monthly maintenance sessions. The pre-intervention HgbA1c level averaged 8.84%, whereas the post-intervention HgbA1c level averaged 7.81%. A paired t test showed that this pre-post difference of 1.03 percentage points was statistically significant ( p = 0.0007). For BMI, there was an average decline of 0.78 from the pre-intervention mean value of 40.56 to the post-intervention mean value of 39.78 ( p = 0.03). Among the 29 participants who agreed to participate in our follow-up measure of their HgbA1c status one year after the intervention, a paired t test showed that there was no significant difference between the post-JUMP measure and the follow-up measure ( p = 0.808). There was no statistically significant difference between the HgbA1c level of those participating in the maintenance program and that of those not participating (post-intervention t test of between-group difference: p = 0.271; follow-up t test of between-group difference: p = 0.457). Our single-arm, pilot study of the three-week group intervention of self-empowerment shows promising results in glycemic control and weight loss. The short duration and small number of sessions expected could make it more feasible for implementation and dissemination as compared with popular intervention protocols that require much longer periods of attendance, if the effectiveness of this patient group-based self-empowerment approach can be further established by randomized controlled studies in the future.",2020,There was no statistically significant difference between the HgbA1c level of those participating in the maintenance program and that of those not participating (post-intervention t test of between-group difference: p = 0.271; follow-up t test of between-group difference: ,"['Thirty-five patients who had primary care established at the Prisma Health Upstate, Internal Medicine Resident clinic and held the diagnosis of diabetes for longer than one year were recruited for our single-arm pilot intervention', 'Diabetes Patients', 'diabetes patients']","['JUMPing', 'group-based self-empowerment intervention']","['HgbA1c level', 'glycemic control and weight loss', 'hemoglobin A1c level and body mass index (BMI']","[{'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0138404', 'cui_str': 'prisma'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0021782', 'cui_str': 'Internal medicine'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0675390', 'cui_str': 'ARID1A protein, human'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0474680', 'cui_str': 'Hemoglobin A1c measurement'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",35.0,0.0177479,There was no statistically significant difference between the HgbA1c level of those participating in the maintenance program and that of those not participating (post-intervention t test of between-group difference: p = 0.271; follow-up t test of between-group difference: ,"[{'ForeName': 'Sheena', 'Initials': 'S', 'LastName': 'Henry', 'Affiliation': 'Department of Medicine, University of Missouri, 1 Hospital Dr, Columbia, MO 65212, USA.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Shi', 'Affiliation': 'Department of Public Health Sciences, Clemson University, 507 Edwards Hall, Clemson, SC 29634, USA.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Alexander', 'Affiliation': 'Internal Medicine Clinic, Prisma Health, 876 West Faris Rd, Greenville, SC 29605-5601, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': ""O'Neal"", 'Affiliation': 'Department of Medicine, University of Kentucky, 800 Rose Street MN 150, Lexington, KY 40506, USA.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Carey', 'Affiliation': 'Atrium Healthcare, 1000 Blythe Blvd. Charlotte, NC 28203, USA.'}, {'ForeName': 'Hugh D', 'Initials': 'HD', 'LastName': 'Spitler', 'Affiliation': 'Department of Public Health Sciences, Clemson University, 507 Edwards Hall, Clemson, SC 29634, USA.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Leonard', 'Affiliation': 'Internal Medicine Clinic, Prisma Health, 876 West Faris Rd, Greenville, SC 29605-5601, USA.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Chastain', 'Affiliation': 'Internal Medicine Clinic, Prisma Health, 876 West Faris Rd, Greenville, SC 29605-5601, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Hassan', 'Affiliation': 'Mayo Clinic, 4500 San Pablo RD S\u2002Jacksonville, FL 32224, USA.'}, {'ForeName': 'Meenu', 'Initials': 'M', 'LastName': 'Jindal', 'Affiliation': 'Internal Medicine Clinic, Prisma Health, 876 West Faris Rd, Greenville, SC 29605-5601, USA.'}]","Healthcare (Basel, Switzerland)",['10.3390/healthcare8020090'] 270,32100192,InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design.,"INTRODUCTION Suboptimal glycaemic control among people with type 1 diabetes (T1D) is known to lead to long-term micro- and macrovascular complications and, unfortunately, it is still prevalent even in the most affluent societies. Although glycated haemoglobin monitoring is considered to be the gold standard for assessing glycaemic control, such monitoring is unable to reliably measure acute glycaemic excursions. Continuous glucose monitoring (CGM) has been shown to improve glucose control and reduce the incidence of hypoglycaemia, and also allow a more complete assessment of overall glycaemic control and hyper- and hypoglycaemic excursions. The use of CGM has led to time-in-range, which is the time that a patient is within the glycaemic range of 70 to 180 mg/dL, to be adopted as a treatment target. To date, only limited data comparing the second-generation insulins glargine 300 U/mL (Gla-300) and degludec 100 U/mL (IDeg-100) in people with T1D are available, and there is no CGM literature on comparisons of the use of CGM results to assess primary, secondary and tertiary endpoints. The aim of the InRange study was to address this unmet need. METHODS InRange is a multicentre, randomised, active-controlled, parallel-group, 12-week, open-label, phase 4, comparative study. Adults with T1D will be randomised to receive once-daily Gla-300 or IDeg-100 by subcutaneous injection in the morning. Following an 8-week titration period, CGM data will be collected over 20 consecutive days. PLANNED OUTCOMES The primary objective is to demonstrate that Gla-300 is noninferior to IDeg-100 in terms of glycaemic control [time-in-range ≥ 70 to ≤ 180 mg/dL (≥ 3.9 to ≤ 10 mmol/L)] and variability, as assessed using CGM, in adults with T1D. The results are expected to help confirm the utility of CGM in clinical practice in this population and provide insight into its application as an outcome measure in clinical practice. TRIAL REGISTRATION NCT04075513.",2020,"Continuous glucose monitoring (CGM) has been shown to improve glucose control and reduce the incidence of hypoglycaemia, and also allow a more complete assessment of overall glycaemic control and hyper- and hypoglycaemic excursions.","['Adults with T1D', 'adults with T1D', 'Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design', 'people with type 1 diabetes (T1D']","['CGM', 'Gla-300', 'U/mL', 'Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL', 'Continuous glucose monitoring (CGM']",[],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C2945590', 'cui_str': 'unit/mL'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C3491971', 'cui_str': 'insulin degludec'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}]",[],,0.065702,"Continuous glucose monitoring (CGM) has been shown to improve glucose control and reduce the incidence of hypoglycaemia, and also allow a more complete assessment of overall glycaemic control and hyper- and hypoglycaemic excursions.","[{'ForeName': 'Tadej', 'Initials': 'T', 'LastName': 'Battelino', 'Affiliation': ""UMC-University Children's Hospital, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. tadej.battelino@mf.uni-lj.si.""}, {'ForeName': 'Zsolt', 'Initials': 'Z', 'LastName': 'Bosnyak', 'Affiliation': 'Sanofi S.A., Paris, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Danne', 'Affiliation': 'Diabetes Centre for Children and Adolescents, Children\'s and Youth Hospital ""Auf Der Bult"", Hannover, Germany.'}, {'ForeName': 'Bhaswati', 'Initials': 'B', 'LastName': 'Mukherjee', 'Affiliation': 'Sanofi S.A., Paris, France.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Edelman', 'Affiliation': 'University of California, San Diego, CA, USA.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Pilorget', 'Affiliation': 'Sanofi S.A., Paris, France.'}, {'ForeName': 'Pratik', 'Initials': 'P', 'LastName': 'Choudhary', 'Affiliation': ""King's College Hospital NHS Foundation Trust, London, UK.""}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Renard', 'Affiliation': 'Department of Endocrinology, Diabetes and Nutrition, Montpellier University Hospital, University of Montpellier, Montpellier, France.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Bergenstal', 'Affiliation': 'International Diabetes Center at Park Nicollet, Minneapolis, USA.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00781-6'] 271,32234652,Gut microbiota composition after diet and probiotics in overweight breast cancer survivors: a randomized open-label pilot intervention trial.,"OBJECTIVES Breast cancer (BC) is the most diagnosed cancer in women. Increasing survival rates shift attention to preventive strategies. Obesity and intestinal microbiota composition may be associated with BC. A Mediterranean diet (MD) proved to be protective. The aim of this study was to assess the efficacy of probiotics in addition to an MD versus diet alone in influencing gut microbiota and metabolic profile in overweight BC survivors. METHODS A total of 34 BC survivors were randomly assigned to an MD for 4 mo plus 1 sachet/d of probiotics (Bifidobacterium longum BB536, Lactobacillus rhamnosus HN001) for the first 2 mo (intervention group, n = 16) or an MD alone for 4 mo (control group, n = 18). Anthropometric and nutritional assessments, adherence to the MD, compliance with physical activity, and metabolic parameters dosage were performed at baseline (T0), at 2 mo (T2), and at 4 mo (T4). Intestinal microbiota analysis was performed at T0 and T2. RESULTS After 2 mo of probiotic administration the number of bacterial species (P = 0.01) and the bacterial diversity assessed with the Chao1 index (P = 0.004) significantly increased; no significant variations were detected after diet alone. The Bacteroidetes-to-Firmicutes ratio significantly decreased in the intervention group and increased in controls (P = 0.004). Significant reductions of body weight, body mass index, fasting glucose, and homeostasis model assessment of insulin resistance were identified at T4 in both groups; in the intervention group waist circumference (P = 0.012), waist-to-hip ratio (P = 0.045), and fasting insulin (P = 0.017) also significantly decreased. CONCLUSIONS Probiotics in addition to an MD positively influence gut microbiota and improve metabolic and anthropometric parameters compared with an MD alone.",2020,After 2 mo of probiotic administration the number of bacterial species (P = 0.01) and the bacterial diversity assessed with the Chao1 index (P = 0.004) significantly increased; no significant variations were detected after diet alone.,"['diagnosed cancer in women', '34 BC survivors', 'overweight BC survivors', 'overweight breast cancer survivors']","['MD for 4 mo plus 1 sachet/d of probiotics (Bifidobacterium longum BB536, Lactobacillus rhamnosus HN001', 'Mediterranean diet (MD', 'MD alone', 'MD versus diet alone']","['gut microbiota and metabolic profile', 'Obesity and intestinal microbiota composition', 'number of bacterial species', 'fasting insulin', 'bacterial diversity assessed with the Chao1 index', 'Bacteroidetes-to-Firmicutes ratio', 'body weight, body mass index, fasting glucose, and homeostasis model assessment of insulin resistance', 'waist-to-hip ratio', 'Anthropometric and nutritional assessments, adherence to the MD, compliance with physical activity, and metabolic parameters dosage', 'Gut microbiota composition', 'metabolic and anthropometric parameters', 'Intestinal microbiota analysis']","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}]","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2348127', 'cui_str': 'Sachet - unit of product usage'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0314977', 'cui_str': 'Bifidobacterium longum'}, {'cui': 'C0317597', 'cui_str': 'Lactobacillus casei rhamnosus'}, {'cui': 'C1138412', 'cui_str': 'Mediterranean Diet'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C1328813', 'cui_str': 'Metabolomics'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C1829779', 'cui_str': 'Homeostasis model assessment'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0205682', 'cui_str': 'Waist/hip ratio'}, {'cui': 'C0028708', 'cui_str': 'Assessment of nutritional status'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]",34.0,0.0359041,After 2 mo of probiotic administration the number of bacterial species (P = 0.01) and the bacterial diversity assessed with the Chao1 index (P = 0.004) significantly increased; no significant variations were detected after diet alone.,"[{'ForeName': 'Marianna', 'Initials': 'M', 'LastName': 'Pellegrini', 'Affiliation': 'Department of Clinical Nutrition, Città della Salute e della Scienza, Turin, Italy.'}, {'ForeName': 'Mirko', 'Initials': 'M', 'LastName': 'Ippolito', 'Affiliation': 'Department of Clinical Nutrition, Città della Salute e della Scienza, Turin, Italy.'}, {'ForeName': 'Taira', 'Initials': 'T', 'LastName': 'Monge', 'Affiliation': 'Department of Clinical Nutrition, Città della Salute e della Scienza, Turin, Italy.'}, {'ForeName': 'Rossella', 'Initials': 'R', 'LastName': 'Violi', 'Affiliation': 'Department of Clinical Nutrition, Città della Salute e della Scienza, Turin, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Cappello', 'Affiliation': 'CeRMS Labortory of Tumor Immunology, University of Turin, Italy.'}, {'ForeName': 'Ilario', 'Initials': 'I', 'LastName': 'Ferrocino', 'Affiliation': 'Department of Agricultural, Forest and Food Sciences, University of Turin, Italy.'}, {'ForeName': 'Luca Simone', 'Initials': 'LS', 'LastName': 'Cocolin', 'Affiliation': 'Department of Agricultural, Forest and Food Sciences, University of Turin, Italy.'}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'De Francesco', 'Affiliation': 'Department of Clinical Nutrition, Città della Salute e della Scienza, Turin, Italy.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Bo', 'Affiliation': 'Department of Medical Science, University of Turin, Italy.'}, {'ForeName': 'Concetta', 'Initials': 'C', 'LastName': 'Finocchiaro', 'Affiliation': 'Department of Clinical Nutrition, Città della Salute e della Scienza, Turin, Italy. Electronic address: cfinocchiaro@cittadellasalute.to.it.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110749'] 272,32234653,Adequacy and safety of α-lactalbumin-enriched low-protein infant formula: A randomized controlled trial.,"OBJECTIVES The aim of this study was to demonstrate suitability and safety of an infant formula enriched with α-lactalbumin with a reduced protein content of 1.89 g protein/100 kcal. METHODS This was a randomized, double-blind controlled trial with 80 healthy newborn infants who were assigned to receive either an isocaloric low- or high-protein content formula (1.89 versus 2.1 g/100 kcal). The low-protein content formula was enriched with α-lactalbumin. A breast-fed reference group of 40 infants was studied concurrently. Anthropometric measures were taken at inclusion, after 6 and 12 wk as well as after 6 and 12 mo of follow-up. Primary outcome was weight gain in g/d between study inclusion to 12 wk. Secondary outcomes included anthropometric measures expressed in Z-scores, mean formula consumption, and caloric intake as well as food tolerance. RESULTS Fifty-two infants in the formula group (low protein: 26, high protein: 26) and 32 in the breast-fed reference group completed the 3-mo intervention period. There was no difference in weight gain among feeding groups at the end of the intervention period. Mean weight gain in g/d was 32 in the low-protein, 31 in the high-protein, and 33 in the breast-fed reference group. No significant difference was found between study groups in Z-scores for weight, length, head circumference, weight-for-length, or body mass index nor for fat percentage at end of intervention and after follow-up. CONCLUSION α-lactalbumin-enriched formula with a protein content of 1.89 g protein/100 kcal is safe and supports adequate growth.",2020,"No significant difference was found between study groups in Z-scores for weight, length, head circumference, weight-for-length, or body mass index nor for fat percentage at end of intervention and after follow-up. ","['Fifty-two infants in the formula group (low protein: 26, high protein: 26) and 32 in the breast-fed reference group completed the 3-mo intervention period', '80 healthy newborn infants']","['α-lactalbumin', 'isocaloric low- or high-protein content formula', 'α-lactalbumin-enriched low-protein infant formula']","['weight gain', 'Z-scores for weight, length, head circumference, weight-for-length, or body mass index nor for fat percentage', 'anthropometric measures expressed in Z-scores, mean formula consumption, and caloric intake as well as food tolerance', 'Mean weight gain']","[{'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0242972', 'cui_str': 'Low protein diet'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0578757', 'cui_str': 'Good neonatal condition at birth'}]","[{'cui': 'C0022912', 'cui_str': 'Lactalbumin'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0242972', 'cui_str': 'Low protein diet'}, {'cui': 'C0150589', 'cui_str': 'Infant formula'}]","[{'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0262499', 'cui_str': 'Head circumference'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}]",80.0,0.177549,"No significant difference was found between study groups in Z-scores for weight, length, head circumference, weight-for-length, or body mass index nor for fat percentage at end of intervention and after follow-up. ","[{'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Petersen', 'Affiliation': 'Department of Pediatrics, Evangelisches Waldkrankenhaus Spandau, Berlin, Germany. Electronic address: Hanna.Petersen@jsd.de.'}, {'ForeName': 'Antonia', 'Initials': 'A', 'LastName': 'Nomayo', 'Affiliation': 'Department of Pediatrics, Evangelisches Waldkrankenhaus Spandau, Berlin, Germany.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Zelenka', 'Affiliation': 'DMK Baby GmbH, Bremen, Germany.'}, {'ForeName': 'Janine', 'Initials': 'J', 'LastName': 'Foster', 'Affiliation': 'Department of Pediatrics, Evangelisches Waldkrankenhaus Spandau, Berlin, Germany.'}, {'ForeName': 'Josef', 'Initials': 'J', 'LastName': 'Tvrdík', 'Affiliation': 'Department of Computer Sciences, University of Ostrava, Czech Republic.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Jochum', 'Affiliation': 'Department of Pediatrics, Evangelisches Waldkrankenhaus Spandau, Berlin, Germany.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110728'] 273,32286894,Effects of Cacao By-Products and a Modest Weight Loss Intervention on the Concentration of Serum Triglycerides in Overweight Subjects: Proof of Concept.,"Therapeutic approaches to decrease serum triglyceride (TG) concentrations are not successful mainly due to poor adherence or adverse effects of therapies. In consequence, the search for new low-cost and safer therapeutic alternatives is mandatory. Dark chocolate and cacao have shown promising results improving lipid profiles. Recently, using cacao by-products to reduce elevated cardiometabolic risk markers in an animal model of obesity induced by a high-fat diet and fructose, we showed that TGs, low-density lipoprotein cholesterol, and the TG/high-density lipoprotein (HDL) ratio decreased, suggesting that cacao by-products improved the metabolic function of obese animals. Based on these results, as a proof of concept, a blinded placebo-controlled study was implemented to explore the effects of cacao by-products on anthropometric and biochemical variables in a group of overweight subjects participating in a program composed of reduced-calorie-diet counseling plus a simple aerobic exercise plan. The results showed that counseling induced weight and abdominal circumference reductions in both groups. TGs did not change in the control group; however, TG decreased significantly by 54.9 mg/dL (27.9%) in the experimental group. The TG/HDL cholesterol ratio changed markedly (1.5) in the experimental group. The results reported suggest the use of cacao by-products as an alternative for the treatment of hypertriglyceridemia.",2020,"TGs did not change in the control group; however, TG decreased significantly by 54.9 mg/dL (27.9%) in the experimental group.","['Overweight Subjects', 'overweight subjects participating in a program composed of']","['Cacao By-Products and a Modest Weight Loss Intervention', 'reduced-calorie-diet counseling plus a simple aerobic exercise plan']","['elevated cardiometabolic risk markers', 'weight and abdominal circumference reductions', 'Concentration of Serum Triglycerides', 'serum triglyceride (TG) concentrations', 'TGs, low-density lipoprotein cholesterol, and the TG/high-density lipoprotein (HDL) ratio', 'TG', 'TG/HDL cholesterol ratio', 'lipid profiles']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0006622', 'cui_str': 'Theobroma cacao'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0301589', 'cui_str': 'Calorie diet'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1300813', 'cui_str': 'Abdominal circumference'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0542495', 'cui_str': 'Measurement of serum triglyceride level'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}]",,0.0224022,"TGs did not change in the control group; however, TG decreased significantly by 54.9 mg/dL (27.9%) in the experimental group.","[{'ForeName': 'Perla', 'Initials': 'P', 'LastName': 'León-Flores', 'Affiliation': 'Integral Caardiometabolic Research Laboratory, Research and Posgraduate Studies Section, School of Medicine, National Polytechnique Institute, Mexico City, Mexico.'}, {'ForeName': 'Nayelli', 'Initials': 'N', 'LastName': 'Nájera', 'Affiliation': 'Integral Caardiometabolic Research Laboratory, Research and Posgraduate Studies Section, School of Medicine, National Polytechnique Institute, Mexico City, Mexico.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Pérez', 'Affiliation': 'Unit of Metabolism and Nutritional Support, Hospital Juarez, Mexico City, Mexico.'}, {'ForeName': 'Blanca', 'Initials': 'B', 'LastName': 'Pardo', 'Affiliation': 'Unit of Metabolism and Nutritional Support, Hospital Juarez, Mexico City, Mexico.'}, {'ForeName': 'Fiacro', 'Initials': 'F', 'LastName': 'Jimenez', 'Affiliation': 'Health Norms Direction, ISSSTE, Mexico City, Mexico.'}, {'ForeName': 'Dylan', 'Initials': 'D', 'LastName': 'Diaz-Chiguer', 'Affiliation': 'Health Norms Direction, ISSSTE, Mexico City, Mexico.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Villarreal', 'Affiliation': 'School of Medicine, University of California, San Diego, California, USA.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Hidalgo', 'Affiliation': 'Integral Caardiometabolic Research Laboratory, Research and Posgraduate Studies Section, School of Medicine, National Polytechnique Institute, Mexico City, Mexico.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Ceballos', 'Affiliation': 'Integral Caardiometabolic Research Laboratory, Research and Posgraduate Studies Section, School of Medicine, National Polytechnique Institute, Mexico City, Mexico.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Meaney', 'Affiliation': 'Integral Caardiometabolic Research Laboratory, Research and Posgraduate Studies Section, School of Medicine, National Polytechnique Institute, Mexico City, Mexico.'}]",Journal of medicinal food,['10.1089/jmf.2019.0201'] 274,30417636,Cost-effectiveness of the SQ HDM SLIT-tablet for the treatment of allergic asthma in three Eastern European Countries.,"Summary Background. The SQ® house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet (ACARIZAX®, ALK-Abelló A/S, Hørsholm, Denmark) is an allergy immunotherapy tablet for people with allergic respiratory disease. This analysis aims to assess the cost-effectiveness of the SQ HDM SLIT-tablet from the perspective of three Eastern European countries: Czech Republic, Poland and Slovakia. Methods. A cost-utility model per country was developed, which compared the SQ HDM SLIT-tablet as add-on to pharmacotherapy with pharmacotherapy alone in patients with HDM allergic asthma (AA) over a five year time horizon. The effectiveness of the two interventions was based on the results from a large-scale randomised controlled trial. In the models, annual costs and quality-adjusted life year (QALY) scores from the trial were extrapolated over a five year period, and the incremental cost-effectiveness ratios (ICERs) were estimated. One-way deterministic sensitivity and scenario analyses were undertaken. Results. The SQ HDM SLIT-tablet is cost-effective in all three markets over the five year time horizon (ICERs of less than € 10,000 per additional QALY). Treatment with the SQ HDM SLIT-tablet improves patient outcomes, with QALY gains of 0.35, versus pharmacotherapy only. In all three countries, the SQ HDM SLIT-tablet also incurs increased costs compared to pharma-cotherapy treatment only. The sensitivity analysis identified utility values from the clinical trial as the main driver of the model results. Conclusion. The SQ HDM SLIT-tablet is a cost-effective treatment option for people with HDM AA in three different health care settings in Eastern Europe.",2019,The SQ HDM SLIT-tablet is cost-effective in all three markets over the five year time horizon,"['patients with HDM allergic asthma (AA', 'allergic asthma in three Eastern European Countries', 'people with allergic respiratory disease', 'people with HDM AA in three different health care settings in Eastern Europe']","['SQ HDM SLIT-tablet', 'SQ® house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet (ACARIZAX®, ALK-Abelló A/S, Hørsholm, Denmark']","['cost-effectiveness', 'incremental cost-effectiveness ratios (ICERs', 'annual costs and quality-adjusted life year (QALY) scores', 'Cost-effectiveness']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0155877', 'cui_str': 'Allergic asthma (disorder)'}, {'cui': 'C0454713', 'cui_str': 'European country (geographic location)'}, {'cui': 'C1504369', 'cui_str': 'Respiratory system allergy'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C0015177', 'cui_str': 'Europe, Eastern'}]","[{'cui': 'C0184904', 'cui_str': 'Slitting (procedure)'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C3539110', 'cui_str': 'house dust mites'}, {'cui': 'C3658366', 'cui_str': 'Sublingual Immunotherapy'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0080071', 'cui_str': 'QALY'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0415523,The SQ HDM SLIT-tablet is cost-effective in all three markets over the five year time horizon,"[{'ForeName': 'W', 'Initials': 'W', 'LastName': 'Green', 'Affiliation': 'York Health Economics Consortium, Enterprise House, Innovation Way, University of York, Heslington, York, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'McMaster', 'Affiliation': 'York Health Economics Consortium, Enterprise House, Innovation Way, University of York, Heslington, York, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Babela', 'Affiliation': 'St. Elisabeth University, Institute of Healthcare Disciplines, Bratislava, Slovakia. ALK-Abelló, Denmark.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Buchs', 'Affiliation': 'ALK-Abelló, Denmark.'}]",European annals of allergy and clinical immunology,['10.23822/EurAnnACI.1764-1489.78'] 275,31326978,Associations of Hearing Loss and Menopausal Hormone Therapy With Change in Global Cognition and Incident Cognitive Impairment Among Postmenopausal Women.,"BACKGROUND Hearing loss (HL) and menopausal hormone therapy (conjugated equine estrogens [CEE] and/or medroxyprogesterone acetate [MPA]) are separately associated with cognitive decline and increased risk of incident cognitive impairment. Joint effects of HL and HT could be associated with additive or synergistic decline in global cognition and risk of incident cognitive impairment among postmenopausal women. METHODS Using the Women's Health Initiative (WHI) Memory Study, 7,220 postmenopausal women with measures of HL, global cognition (Modified Mini-Mental State Examination score), and cognitive impairment (centrally adjudicated diagnoses of mild cognitive impairment and dementia) from 1996 to 2009. Multivariable linear mixed-effects models were used to analyze rate of change in global cognition. Accelerated failure time models were used to evaluate time to incident cognitive impairment, stratified by HT. RESULTS Within the CEE-Alone trial, observed adverse effects of CEE-Alone on change in global cognition did not differ by HL, and estimated joint effects of HL and CEE-Alone were not associated with incident cognitive impairment. Within the CEE+MPA trial, while HL did not independently accelerate time to cognitive impairment, the adverse effect of CEE+MPA on global cognition was heightened in older women with HL. Older women on CEE+MPA either with HL (time ratio [TR] = 0.82, 95% confidence interval [CI]: 0.71, 0.94) or with normal hearing (TR = 0.86, 95% CI: 0.76, 0.97) had faster time to cognitive impairment than those with normal hearing and placebo. CONCLUSIONS HL may accentuate the adverse effect of CEE+MPA, not CEE-Alone, on global cognitive decline, not incident cognitive impairment, among postmenopausal women on HT.",2020,"Joint effects of HL and HT could be associated with additive or synergistic decline in global cognition and risk of incident cognitive impairment among postmenopausal women. ","['postmenopausal women', '7,220 postmenopausal women with measures of HL, global cognition (Modified Mini- Mental State Examination score), and cognitive impairment (centrally-adjudicated diagnoses of mild cognitive impairment and dementia) from 1996-2009', 'Postmenopausal Women', 'postmenopausal women on HT', 'older women with HL', 'Older women on']","['HL and HT', 'Menopausal Hormone Therapy', 'medroxyprogesterone acetate [MPA', 'CEE+MPA']","['incident cognitive impairment', 'normal hearing', 'rate of change in global cognition', 'global cognition', 'faster time to cognitive impairment']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C4304091', 'cui_str': '3MS (Modified Mini-Mental State) Examination score'}, {'cui': 'C0338656', 'cui_str': 'Cognitive Dysfunction'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C0025320', 'cui_str': 'Change of Life, Female'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy (procedure)'}, {'cui': 'C0065864', 'cui_str': 'medroxyprogesterone acetate'}]","[{'cui': 'C0338656', 'cui_str': 'Cognitive Dysfunction'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",,0.094197,"Joint effects of HL and HT could be associated with additive or synergistic decline in global cognition and risk of incident cognitive impairment among postmenopausal women. ","[{'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'Armstrong', 'Affiliation': 'Laboratory of Behavioral Neuroscience, National Institute of Aging, Baltimore, Maryland.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Espeland', 'Affiliation': 'Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Jiu-Chiuan', 'Initials': 'JC', 'LastName': 'Chen', 'Affiliation': 'Department of Preventive Medicine and Neurology, Keck School of Medicine of University of Southern California, Los Angeles, California.'}, {'ForeName': 'Kamal', 'Initials': 'K', 'LastName': 'Masaki', 'Affiliation': 'Department of Geriatric Medicine, John A. Burns School of Medicine, University of Hawai`i Manoa, Honolulu, Hawaii.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Wactawski-Wende', 'Affiliation': 'Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University of Buffalo, New York.'}, {'ForeName': 'Wenjun', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.'}, {'ForeName': 'Margery L S', 'Initials': 'MLS', 'LastName': 'Gass', 'Affiliation': 'Department of Obstetrics & Gynecology, University of Cincinnati, Cincinnati, Ohio.'}, {'ForeName': 'Marcia L', 'Initials': 'ML', 'LastName': 'Stefanick', 'Affiliation': 'Department of Medicine, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': 'Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Jennifer A', 'Initials': 'JA', 'LastName': 'Deal', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Stephen R', 'Initials': 'SR', 'LastName': 'Rapp', 'Affiliation': 'Department of Psychiatry and Behavioral Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Frank R', 'Initials': 'FR', 'LastName': 'Lin', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Resnick', 'Affiliation': 'Laboratory of Behavioral Neuroscience, National Institute of Aging, Baltimore, Maryland.'}]","The journals of gerontology. Series A, Biological sciences and medical sciences",['10.1093/gerona/glz173'] 276,32235930,Effects of underfeeding and oral vancomycin on gut microbiome and nutrient absorption in humans.,"Direct evidence in humans for the impact of the microbiome on nutrient absorption is lacking. We conducted an extended inpatient study using two interventions that we hypothesized would alter the gut microbiome and nutrient absorption. In each, stool calorie loss, a direct proxy of nutrient absorption, was measured. The first phase was a randomized cross-over dietary intervention in which all participants underwent in random order 3 d of over- and underfeeding. The second was a randomized, double-blind, placebo-controlled pharmacologic intervention using oral vancomycin or matching placebo (NCT02037295). Twenty-seven volunteers (17 men and 10 women, age 35.1 ± 7.3, BMI 32.3 ± 8.0), who were healthy other than having impaired glucose tolerance and obesity, were enrolled and 25 completed the entire trial. The primary endpoints were the effects of dietary and pharmacological intervention on stool calorie loss. We hypothesized that stool calories expressed as percentage of caloric intake would increase with underfeeding compared with overfeeding and increase during oral vancomycin treatment. Both primary endpoints were met. Greater stool calorie loss was observed during underfeeding relative to overfeeding and during vancomycin treatment compared with placebo. Key secondary endpoints were to evaluate the changes in gut microbial community structure as evidenced by amplicon sequencing and metagenomics. We observed only a modest perturbation of gut microbial community structure with under- versus overfeeding but a more widespread change in community structure with reduced diversity with oral vancomycin. Increase in Akkermansia muciniphila was common to both interventions that resulted in greater stool calorie loss. These results indicate that nutrient absorption is sensitive to environmental perturbations and support the translational relevance of preclinical models demonstrating a possible causal role for the gut microbiome in dietary energy harvest.",2020,Greater stool calorie loss was observed during underfeeding relative to overfeeding and during vancomycin treatment compared with placebo.,"['humans', 'Twenty-seven volunteers (17 men and 10 women, age 35.1\u2009±\u20097.3, BMI 32.3\u2009±\u20098.0), who were healthy other than having impaired glucose tolerance and obesity, were enrolled and 25 completed the entire trial']","['placebo', 'underfeeding and oral vancomycin', 'dietary and pharmacological intervention', 'vancomycin or matching placebo', 'vancomycin', 'dietary intervention']","['gut microbiome and nutrient absorption', 'gut microbial community structure as evidenced by amplicon sequencing and metagenomics', 'stool calorie loss', 'caloric intake']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439751', 'cui_str': 'Entire'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0360373', 'cui_str': 'Vancomycin-containing product in oral dose form'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0042313', 'cui_str': 'Vancomycin'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}]","[{'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C4704957', 'cui_str': 'Microbial Community Structure'}, {'cui': 'C0162801', 'cui_str': 'Analysis, Sequence'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}]",27.0,0.138031,Greater stool calorie loss was observed during underfeeding relative to overfeeding and during vancomycin treatment compared with placebo.,"[{'ForeName': 'Alessio', 'Initials': 'A', 'LastName': 'Basolo', 'Affiliation': 'Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, AZ, USA. alessio.basolo@nih.gov.'}, {'ForeName': 'Maximilian', 'Initials': 'M', 'LastName': 'Hohenadel', 'Affiliation': 'Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, AZ, USA.'}, {'ForeName': 'Qi Yan', 'Initials': 'QY', 'LastName': 'Ang', 'Affiliation': 'Department of Microbiology and Immunology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Piaggi', 'Affiliation': 'Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, AZ, USA.'}, {'ForeName': 'Sascha', 'Initials': 'S', 'LastName': 'Heinitz', 'Affiliation': 'Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, AZ, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Walter', 'Affiliation': 'Clinical Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Walter', 'Affiliation': 'Clinical Mass Spectrometry Core, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Parrington', 'Affiliation': 'Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, AZ, USA.'}, {'ForeName': 'Donovan D', 'Initials': 'DD', 'LastName': 'Trinidad', 'Affiliation': 'Department of Microbiology and Immunology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Reiner Jumpertz', 'Initials': 'RJ', 'LastName': 'von Schwartzenberg', 'Affiliation': 'Department of Endocrinology and Metabolic Diseases, Charité University Medicine, Berlin, Germany.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Turnbaugh', 'Affiliation': 'Department of Microbiology and Immunology, University of California, San Francisco, CA, USA. peter.turnbaugh@ucsf.edu.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Krakoff', 'Affiliation': 'Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, AZ, USA. jkrakoff@mail.nih.gov.'}]",Nature medicine,['10.1038/s41591-020-0801-z'] 277,32280979,"On ""Comparative Effectiveness of mHealth-Supported Exercise Compared With Exercise Alone for People With Parkinson Disease: Randomized Controlled Pilot Study."" Ellis TD, Cavanaugh JT, DeAngelis T, Hendron K, Thomas CA, Saint-Hilaire M, Pencina K, Latham NK. Phys Ther. 2019; 99:203-216.",,2020,,['People With Parkinson Disease'],['mHealth-Supported Exercise Compared With Exercise Alone'],"['Ellis TD, Cavanaugh, JT, DeAngelis, T, Hendron, K, Thomas, CA, Saint-Hilaire, M, Pencina, K, Latham, NK']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}]","[{'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0242823', 'cui_str': 'Saints'}]",,0.0311955,,"[{'ForeName': 'Fulvio', 'Initials': 'F', 'LastName': 'Scorza', 'Affiliation': 'Disciplina de Neurociência, Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM), São Paulo, Brazil.'}, {'ForeName': 'Laís', 'Initials': 'L', 'LastName': 'Rodrigues', 'Affiliation': 'Disciplina de Neurociência, Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM).'}, {'ForeName': 'Leandro', 'Initials': 'L', 'LastName': 'Oliveira', 'Affiliation': 'Disciplina de Neurociência, Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM).'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Andersen', 'Affiliation': 'Departamento de Psicobiologia, Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM).'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Tufik', 'Affiliation': 'Departamento de Psicobiologia, Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM).'}, {'ForeName': 'Josef', 'Initials': 'J', 'LastName': 'Finsterer', 'Affiliation': 'Krankenanstalt Rudolfstiftung, Vienna, Messerli Institute, Veterinary University of Vienna, Vienna, Austria.'}]",Physical therapy,['10.1093/ptj/pzaa061'] 278,32087795,"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.","BACKGROUND Treatment with tenofovir disoproxil fumarate has been associated with renal toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis B virus (HBV) infection. Tenofovir alafenamide is a tenofovir prodrug with high intrahepatic concentrations of active drug and reduced systemic tenofovir exposures compared with tenofovir disoproxil fumarate. In patients with chronic HBV, tenofovir alafenamide has shown efficacy non-inferior to that of tenofovir disoproxil fumarate with improved renal and bone safety. With this non-inferiority study, we aimed to evaluate the efficacy and safety of tenofovir alafenamide in patients with HBV infection switching from tenofovir disoproxil fumarate who are virally suppressed. METHODS Patients with chronic HBV infection who had been receiving tenofovir disoproxil fumarate for 48 weeks or more and who had HBV DNA less than the lower limit of quantification (LLOQ) for at least 12 weeks were recruited to this randomised, multicentre, double-blind, phase 3 non-inferiority study. Patients were randomly assigned in a 1:1 ratio to receive tenofovir alafenamide 25 mg once a day or to continue tenofovir disoproxil fumarate 300 mg once a day. The primary efficacy endpoint was loss of virological control, defined as the proportion of patients who received at least one dose of study drug who had HBV DNA of at least 20 IU/mL at week 48 by the modified US Food and Drug Administration (FDA) snapshot algorithm. Key safety endpoints were changes in hip and spine bone mineral density, estimated creatinine clearance by Cockcroft-Gault, and markers of bone turnover and renal tubular function. The study was powered for non-inferiority in efficacy of tenofovir alafenamide versus tenofovir disoproxil fumarate with a 4% margin. Investigators and patients were unaware of treatment allocation and on-treatment results. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT02979613. FINDINGS Participants in this study were enrolled between Dec 29, 2016, and Oct 20, 2017. 541 patients were screened and 490 patients were randomly assigned to switch to tenofovir alafenamide or to stay on tenofovir disoproxil fumarate. Two patients assigned to receive tenofovir alafenamide did not receive treatment; thus the full analysis set for efficacy and safety analyses consisted of 243 patients in the tenofovir alafenamide group and 245 in the tenofovir disoproxil fumarate group. At week 48, one patient from each treatment group (both <1%) had HBV DNA of at least 20 IU/mL (difference in proportion 0·0%, 95% CI -1·9 to 2·0), thereby showing non-inferior efficacy of tenofovir alafenamide to tenofovir disoproxil fumarate. Patients who received tenofovir alafenamide had significantly increased bone mineral density at hip (mean change 0·66% [SD 2·08] vs -0·51% [SD 1·91]; difference in least square means 1·17% [95% CI 0·80 to 1·54; p<0·0001]) and at spine (mean change 1·74% [3·46] vs -0·11% [3·13]; difference in least square means 1·85% [1·24 to 2·46; p<0·0001]), creatinine clearance by Cockcroft-Gault relative to tenofovir disoproxil fumarate (median change 0·94 mL/min [IQR -4·47 to 6·24] vs -2·74 mL/min [-7·89 to 1·88]; p <0·0001), and improved markers of bone turnover and tubular function at week 48. The most common treatment-emergent adverse events were upper respiratory tract infection (18 [7%] of 243 patients in the tenofovir alafenamide group and 16 [7%] of 245 patients in the tenofovir disoproxil fumarate group) and nasopharyngitis (13 [5%] of 243 patients in the tenofovir alafenamide group and 12 [5%] of 245 patients in the tenofovir disoproxil fumarate group). The incidence of grade 3 and above adverse events and serious adverse events was low and similar between groups. No viral resistance was observed in patients who qualified for viral sequencing. INTERPRETATION These findings suggest that tenofovir alafenamide can be substituted for tenofovir disoproxil fumarate in patients with HBV infection for improved safety without a loss of efficacy. FUNDING Gilead Sciences.",2020,"Patients who received tenofovir alafenamide had significantly increased bone mineral density at hip (mean change 0·66% [SD 2·08] vs -0·51% [SD 1·91]; difference in least square means 1·17% [95% CI 0·80 to 1·54; p<0·0001]) and at spine (mean change 1·74% [3·46] vs -0·11% [3·13]; difference in least square means 1·85% [1·24 to 2·46; p<0·0001]), creatinine clearance by Cockcroft-Gault relative to tenofovir disoproxil fumarate (median change 0·94 mL/min [IQR -4·47 to 6·24] vs -2·74 mL/min [-7·89 to 1·88]; p <0·0001), and improved markers of bone turnover and tubular function at week 48.","['patients with HBV infection switching from tenofovir disoproxil fumarate who are virally suppressed', 'Participants in this study were enrolled between Dec 29, 2016, and Oct 20, 2017', 'for 48 weeks or more and who had HBV DNA less than the lower limit of quantification (LLOQ) for at least 12 weeks', 'patients with chronic hepatitis B virus (HBV) infection', 'patients who qualified for viral sequencing', 'patients with HBV infection', 'Patients with chronic HBV infection who had been receiving', '541 patients were screened and 490 patients', 'virologically suppressed patients with chronic hepatitis B']","['tenofovir disoproxil fumarate', 'tenofovir disoproxil fumarate to tenofovir alafenamide', 'tenofovir alafenamide to tenofovir disoproxil fumarate', 'tenofovir alafenamide versus tenofovir disoproxil fumarate', 'tenofovir alafenamide', 'tenofovir alafenamide group and 245 in the tenofovir disoproxil fumarate group', 'Tenofovir alafenamide', 'tenofovir alafenamide or to stay on tenofovir disoproxil fumarate', 'tenofovir alafenamide 25 mg once a day or to continue tenofovir disoproxil fumarate']","['HBV DNA', 'efficacy and safety', 'hip and spine bone mineral density, estimated creatinine clearance by Cockcroft-Gault, and markers of bone turnover and renal tubular function', 'bone mineral density', 'viral resistance', 'loss of virological control', 'nasopharyngitis', 'markers of bone turnover and tubular function', 'incidence of grade 3 and above adverse events and serious adverse events', 'renal and bone safety', 'creatinine clearance by Cockcroft-Gault relative to tenofovir disoproxil fumarate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C1260953', 'cui_str': 'Suppressed (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0439801', 'cui_str': 'Limited (qualifier value)'}, {'cui': 'C0524909', 'cui_str': 'Chronic Hepatitis B Virus Infection'}, {'cui': 'C0487717', 'cui_str': 'Viral Sequencing'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}]","[{'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C3713958', 'cui_str': 'tenofovir alafenamide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517661', 'cui_str': '245'}, {'cui': 'C4293420', 'cui_str': 'tenofovir alafenamide 25 MG [Vemlidy]'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}]","[{'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0037949', 'cui_str': 'Spinal Column'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine (procedure)'}, {'cui': 'C0085268', 'cui_str': 'Bone Turnover'}, {'cui': 'C0332208', 'cui_str': 'Tubular (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0520989', 'cui_str': 'Viral resistance, function (observable entity)'}, {'cui': 'C0205466', 'cui_str': 'virology'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C3875154', 'cui_str': 'Relative to (attribute)'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}]",541.0,0.207175,"Patients who received tenofovir alafenamide had significantly increased bone mineral density at hip (mean change 0·66% [SD 2·08] vs -0·51% [SD 1·91]; difference in least square means 1·17% [95% CI 0·80 to 1·54; p<0·0001]) and at spine (mean change 1·74% [3·46] vs -0·11% [3·13]; difference in least square means 1·85% [1·24 to 2·46; p<0·0001]), creatinine clearance by Cockcroft-Gault relative to tenofovir disoproxil fumarate (median change 0·94 mL/min [IQR -4·47 to 6·24] vs -2·74 mL/min [-7·89 to 1·88]; p <0·0001), and improved markers of bone turnover and tubular function at week 48.","[{'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Lampertico', 'Affiliation': 'CRC ""A M and A Migliavacca"" Center for Liver Disease, Division of Gastroenterology and Hepatology, Foundation IRCCS Cà Granda Ospedale, Maggiore Policlinico, University of Milan, Milan, Italy. Electronic address: pietro.lampertico@unimi.it.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Buti', 'Affiliation': ""Hospital General Universitari Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Fung', 'Affiliation': 'Toronto General Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'Sang Hoon', 'Initials': 'SH', 'LastName': 'Ahn', 'Affiliation': 'Yongsei University, Severance Hospital, Seoul, South Korea.'}, {'ForeName': 'Wan-Long', 'Initials': 'WL', 'LastName': 'Chuang', 'Affiliation': 'Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.'}, {'ForeName': 'Won Young', 'Initials': 'WY', 'LastName': 'Tak', 'Affiliation': 'School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea.'}, {'ForeName': 'Alnoor', 'Initials': 'A', 'LastName': 'Ramji', 'Affiliation': 'Gastrointestinal Research Institute, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Chi-Yi', 'Initials': 'CY', 'LastName': 'Chen', 'Affiliation': 'Chiayi Christian Hospital, Chiayi City, Taiwan.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Tam', 'Affiliation': 'LAIR Centre, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Ho', 'Initials': 'H', 'LastName': 'Bae', 'Affiliation': 'Asian Pacific Liver Center, Los Angeles, CA, USA.'}, {'ForeName': 'Xiaoli', 'Initials': 'X', 'LastName': 'Ma', 'Affiliation': 'Hahnemann University Hospital, Philadelphia, PA, USA.'}, {'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'Flaherty', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Anuj', 'Initials': 'A', 'LastName': 'Gaggar', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Lau', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Wu', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Vithika', 'Initials': 'V', 'LastName': 'Suri', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Susanna K', 'Initials': 'SK', 'LastName': 'Tan', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'G Mani', 'Initials': 'GM', 'LastName': 'Subramanian', 'Affiliation': 'Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Huy', 'Initials': 'H', 'LastName': 'Trinh', 'Affiliation': 'Silicon Valley Research Institute, San Jose, CA, USA.'}, {'ForeName': 'Seung-Kew', 'Initials': 'SK', 'LastName': 'Yoon', 'Affiliation': 'Catholic University of Korea, Seoul, South Korea.'}, {'ForeName': 'Kosh', 'Initials': 'K', 'LastName': 'Agarwal', 'Affiliation': 'Kings College Hospital, London, UK.'}, {'ForeName': 'Young-Suk', 'Initials': 'YS', 'LastName': 'Lim', 'Affiliation': 'Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Henry L Y', 'Initials': 'HLY', 'LastName': 'Chan', 'Affiliation': 'The Chinese University of Hong Kong, China.'}]",The lancet. Gastroenterology & hepatology,['10.1016/S2468-1253(19)30421-2'] 279,32248838,Effectiveness of biological nurturing on early breastfeeding problems: a randomized controlled trial.,"BACKGROUND Biological nurturing is a neurobehavioral approach to breastfeeding support that encourages women to breastfed in a relaxed, laidback position. This approach has the potential to reduce breast problems (e.g., sore nipples), making good latch easier and thus facilitating the initiation of exclusive breastfeeding. However, its effects have not been adequately investigated in a real-life situation. The aim of this randomized controlled trial was to assess the effectiveness of biological nurturing, compared to usual hospital practices, on the frequency of breast problems and on the prevalence of exclusive breastfeeding at discharge from the maternity ward, after 1 week, and at one and 4 months. METHODS Open randomized parallel controlled trial carried out in a third level maternity ward (IRCCS Burlo Garofolo, Trieste, Italy) between March and December 2018. Two-hundred eight women who planned to give birth at the hospital and who expressed the intention to breastfeed were enrolled during pregnancy and randomized to receive breastfeeding support following either the biological nurturing approach or the usual care protocol based on the WHO/UNICEF 20-h course, in use at the hospital. The primary study outcome was the incidence of breast problems during hospital stay, defined as the presence of one or more of the following outcomes, collected separately: sore nipples, cracked nipples, engorgement and mastitis. The primary analysis was performed by intention to treat. The follow up lasted 4 months. RESULTS One hundred eighty eight out of 208 women (90.3%) were included in the analysis, 90 allocated to the biological nurturing group and 98 to the usual care group. At discharge from the maternity ward, biological nurturing significantly reduced the risk of breast problems (Relative risk [RR] 0.56, 95% Confidence Interval [CI] 0.40, 0.79), including cracked (RR 0.42, 95% CI 0.24, 0.74) and sore nipples (RR 0.59, 95% CI 0.40, 0.88). No statistically significant difference was observed for exclusive breastfeeding at discharge and up to 4 months. No adverse events occurred. CONCLUSIONS The biological nurturing approach applied in the real-life situation of a third level hospital was effective in preventing breast problems. TRIAL REGISTRATION Clinicaltrials.gov NCT03503500. Date of First Submission: 28 March 2018.",2020,"The biological nurturing approach applied in the real-life situation of a third level hospital was effective in preventing breast problems. ","['early breastfeeding problems', 'One hundred eighty eight out of 208 women (90.3%) were included in the analysis, 90 allocated to the biological nurturing group and 98 to the usual care group', 'Two-hundred eight women who planned to give birth at the hospital and who expressed the intention to breastfeed were enrolled during pregnancy and randomized to receive', 'a third level maternity ward (IRCCS Burlo Garofolo, Trieste, Italy) between March and December 2018']","['biological nurturing', 'breastfeeding support following either the biological nurturing approach or the usual care protocol based on the WHO/UNICEF 20-h course']","['risk of breast problems', 'adverse events', 'sore nipples', 'incidence of breast problems during hospital stay, defined as the presence of one or more of the following outcomes, collected separately: sore nipples, cracked nipples, engorgement and mastitis']","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4517898', 'cui_str': '88'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C1171181', 'cui_str': 'Breastfeeding support'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0250336', 'cui_str': 'CARE protocol'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0041682', 'cui_str': ""United Nations Children's Fund""}, {'cui': 'C0750729', 'cui_str': 'Courses'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0567499', 'cui_str': 'Breast problem'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0423637', 'cui_str': 'Sore nipple'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0152453', 'cui_str': 'Fissure of nipple'}, {'cui': 'C0020452', 'cui_str': 'Hyperemia'}, {'cui': 'C0024894', 'cui_str': 'Mastitis'}]",208.0,0.136205,"The biological nurturing approach applied in the real-life situation of a third level hospital was effective in preventing breast problems. ","[{'ForeName': 'Mariarosa', 'Initials': 'M', 'LastName': 'Milinco', 'Affiliation': 'Clinical Epidemiology and Public Health Research Unit, Institute for Maternal and Child Health - IRCCS ""Burlo Garofolo"", Trieste, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Travan', 'Affiliation': 'Neonatal Intensive Care Unit, Institute for Maternal and Child Health - IRCCS ""Burlo Garofolo"", Trieste, Italy.'}, {'ForeName': 'Adriano', 'Initials': 'A', 'LastName': 'Cattaneo', 'Affiliation': 'Clinical Epidemiology and Public Health Research Unit, Institute for Maternal and Child Health - IRCCS ""Burlo Garofolo"", Trieste, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Knowles', 'Affiliation': 'Clinical Epidemiology and Public Health Research Unit, Institute for Maternal and Child Health - IRCCS ""Burlo Garofolo"", Trieste, Italy.'}, {'ForeName': 'Maria Vittoria', 'Initials': 'MV', 'LastName': 'Sola', 'Affiliation': 'Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI), Trieste, Italy.'}, {'ForeName': 'Enrica', 'Initials': 'E', 'LastName': 'Causin', 'Affiliation': 'Neonatal Intensive Care Unit, Institute for Maternal and Child Health - IRCCS ""Burlo Garofolo"", Trieste, Italy.'}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Cortivo', 'Affiliation': 'Obstetrics and Gynecology Department, Institute for Maternal and Child Health - IRCCS ""Burlo Garofolo"", Trieste, Italy.'}, {'ForeName': 'Maura', 'Initials': 'M', 'LastName': 'Degrassi', 'Affiliation': 'Obstetrics and Gynecology Department, Institute for Maternal and Child Health - IRCCS ""Burlo Garofolo"", Trieste, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Di Tommaso', 'Affiliation': 'Obstetrics and Gynecology Department, Institute for Maternal and Child Health - IRCCS ""Burlo Garofolo"", Trieste, Italy.'}, {'ForeName': 'Giuseppa', 'Initials': 'G', 'LastName': 'Verardi', 'Affiliation': 'Obstetrics and Gynecology Department, Institute for Maternal and Child Health - IRCCS ""Burlo Garofolo"", Trieste, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Dipietro', 'Affiliation': 'Obstetrics and Gynecology Department, Institute for Maternal and Child Health - IRCCS ""Burlo Garofolo"", Trieste, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Piazza', 'Affiliation': 'Obstetrics and Gynecology Department, Institute for Maternal and Child Health - IRCCS ""Burlo Garofolo"", Trieste, Italy.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Scolz', 'Affiliation': 'Neonatal Intensive Care Unit, Institute for Maternal and Child Health - IRCCS ""Burlo Garofolo"", Trieste, Italy.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Rossetto', 'Affiliation': 'Life and Health Sciences Department, University of Trieste, Trieste, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Ronfani', 'Affiliation': 'Clinical Epidemiology and Public Health Research Unit, Institute for Maternal and Child Health - IRCCS ""Burlo Garofolo"", Trieste, Italy. luca.ronfani@burlo.trieste.it.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",International breastfeeding journal,['10.1186/s13006-020-00261-4'] 280,31686095,Comparing the Standard and Electronic Versions of the Alzheimer's Disease Assessment Scale - Cognitive Subscale: A Validation Study.,"The Alzheimer's Disease Assessment Scale (ADAS-Cog) has become the de facto gold-standard for assessing the efficacy of putative anti-dementia treatments. There has been an increasing interest in providing greater standardization, automation, and administration consistency to the scale. Recently, electronic versions of the ADAS-Cog (eADAS-Cog) have been utilized in clinical trials and demonstrated significant reductions in frequency of rater error as compared to paper. In order to establish validity of the electronic version (eADAS-Cog), 20 subjects who had received a diagnosis of probable Alzheimer's disease (AD) at a private US Memory Clinic completed a single-center, randomized, counterbalanced, prospective trial comparing a version of the eADAS-Cog to the standard paper scale. Interclass Correlation Coefficient on total scores and Kappa analysis on domain scores yielded high agreement (0.88 - 0.99). Effects of order and mode of administration on ADAS-Cog total scores did not demonstrate a significant main effect. Overall, this study establishes adequate concurrent validity between the ADAS-Cog and eADAS-Cog among an adult population with diagnosed AD.",2019,Effects of order and mode of administration on ADAS-Cog total scores did not demonstrate a significant main effect.,"[""20 subjects who had received a diagnosis of probable Alzheimer's disease (AD) at a private US Memory Clinic completed a single-center""]",['electronic version (eADAS-Cog'],"[""Alzheimer's Disease Assessment Scale - Cognitive Subscale"", 'ADAS-Cog total scores']","[{'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C4521534', 'cui_str': 'US Military enlisted E1'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}]","[{'cui': 'C0450989', 'cui_str': ""Alzheimer's disease assessment scale (assessment scale)""}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",20.0,0.0580983,Effects of order and mode of administration on ADAS-Cog total scores did not demonstrate a significant main effect.,"[{'ForeName': 'T M', 'Initials': 'TM', 'LastName': 'Solomon', 'Affiliation': 'Todd M. Solomon, Bracket, 575 E Swedesford Road, Wayne, PA 19087. E-mail: Todd.Solomon@bracketglobal.com.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Barbone', 'Affiliation': ''}, {'ForeName': 'H T', 'Initials': 'HT', 'LastName': 'Feaster', 'Affiliation': ''}, {'ForeName': 'D S', 'Initials': 'DS', 'LastName': 'Miller', 'Affiliation': ''}, {'ForeName': 'G B', 'Initials': 'GB', 'LastName': 'deBros', 'Affiliation': ''}, {'ForeName': 'C A', 'Initials': 'CA', 'LastName': 'Murphy', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Michalczuk', 'Affiliation': ''}]",The journal of prevention of Alzheimer's disease,['10.14283/jpad.2019.27'] 281,32065359,Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study.,"INTRODUCTION Ezetimibe/statin combination therapy has been reported to provide additional cardioprotective effects compared to statin monotherapy. The apolipoprotein B/A1 (apoB/A1) ratio is an effective predictor of cardiovascular diseases. The aim of this study was to compare the efficacy and safety of rosuvastatin/ezetimibe combination therapy versus rosuvastatin monotherapy using the apoB/A1 ratio in patients with diabetes and hypercholesterolemia. METHODS In this randomized, multicenter, open-label, parallel-group study, patients were randomly assigned to receive the combination therapy of rosuvastatin 5 mg/ezetimibe 10 mg once daily (n = 68) or monotherapy with rosuvastatin 10 mg once daily (n = 68), for 8 weeks. RESULTS After the 8-week treatment, percentage change (least-square means ± standard error) in the apoB/A1 ratio in the rosuvastatin/ezetimibe group was significantly decreased compared to the rosuvastatin group (- 46.14 ± 1.58% vs.  - 41.30 ± 1.58%, respectively; P = 0.03). In addition, the proportion of patients achieving > 50% reduction in low-density lipoprotein-cholesterol (LDL-C) and in the comprehensive lipid target (LDL-C < 70 mg/dL, non-HDL-cholesterol [non-HDL-C] < 100 mg/dL, and apoB < 80 mg/dL) was significantly different between the two groups (76.5 and 73.5% in the rosuvastatin/ezetimibe group and 47.1 and 45.6% in the rosuvastatin group, respectively; P < 0.001). The reduction in total cholesterol, non-HDL-C, LDL-C, and apoB were greater in the rosuvastatin/ezetimibe group than in the rosuvastatin group. Both treatments were well tolerated, and no between-group differences in drug-related adverse events were observed. CONCLUSION The apoB/A1 ratio was significantly reduced in patients receiving combination therapy with ezetimibe and rosuvastatin compared to those receiving rosuvastatin monotherapy. Both treatments were well tolerated in patients with type 2 diabetes and hypercholesterolemia. TRIAL REGISTRATION NCT03446261.",2020,"The reduction in total cholesterol, non-HDL-C, LDL-C, and apoB were greater in the rosuvastatin/ezetimibe group than in the rosuvastatin group.","['Patients With Type 2 Diabetes', 'patients with diabetes and hypercholesterolemia', 'patients with type 2 diabetes and hypercholesterolemia']","['monotherapy with rosuvastatin', 'rosuvastatin 5\xa0mg/ezetimibe', 'Ezetimibe/statin combination therapy', 'ezetimibe and rosuvastatin', 'rosuvastatin/ezetimibe combination therapy versus rosuvastatin monotherapy', 'Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy', 'rosuvastatin/ezetimibe', 'rosuvastatin', 'rosuvastatin monotherapy']","['drug-related adverse events', 'efficacy and safety', 'tolerated', 'apoB/A1 ratio', 'total cholesterol, non-HDL-C, LDL-C, and apoB', 'low-density lipoprotein-cholesterol (LDL-C']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0020443', 'cui_str': 'High Cholesterol Levels'}]","[{'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C1142985', 'cui_str': 'ezetimibe'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0556895', 'cui_str': 'Combination therapy (regime/therapy)'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0003593', 'cui_str': 'ApoB'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}]",,0.0149835,"The reduction in total cholesterol, non-HDL-C, LDL-C, and apoB were greater in the rosuvastatin/ezetimibe group than in the rosuvastatin group.","[{'ForeName': 'Jiwoo', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.'}, {'ForeName': 'You-Cheol', 'Initials': 'YC', 'LastName': 'Hwang', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, 892, Dongnam-ro, Gangdong-gu, Seoul, 05278, Korea.'}, {'ForeName': 'Woo Je', 'Initials': 'WJ', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.'}, {'ForeName': 'Jong Chul', 'Initials': 'JC', 'LastName': 'Won', 'Affiliation': 'Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, 1342, Dongil-ro, Nowon-gu, Seoul, 01757, Korea.'}, {'ForeName': 'Kee-Ho', 'Initials': 'KH', 'LastName': 'Song', 'Affiliation': 'Division of Endocrinology and Metabolism, Konkuk University Medical Center, Konkuk University School of Medicine, 120, Neungdong-ro, Gwangjin-gu, Seoul, 05029, Korea.'}, {'ForeName': 'Cheol-Young', 'Initials': 'CY', 'LastName': 'Park', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29, Saemunan-ro, Jongno-gu, Seoul, 03181, Korea.'}, {'ForeName': 'Kyu Jeung', 'Initials': 'KJ', 'LastName': 'Ahn', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, 892, Dongnam-ro, Gangdong-gu, Seoul, 05278, Korea. ahnkj@khu.ac.kr.'}, {'ForeName': 'Joong-Yeol', 'Initials': 'JY', 'LastName': 'Park', 'Affiliation': 'Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. jypark@amc.seoul.kr.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00778-1'] 282,31781890,Prospective comparison of indwelling cannulas drain and needle aspiration for symptomatic seroma after mastectomy in breast cancer patients.,"AIMS Postoperative seroma is the most frequent sequelae after mastectomy and axillary surgery with no optimal regimens for seroma resolution recommended in routine clinical. Indwelling cannulas with needle and catheter have been widely used in long-term medication therapies, but evidence of indwelling cannulas in seroma management after mastectomy is lacking. The purpose of this study is to evaluate the feasibility of indwelling cannulas in seroma management after mastectomy. METHODS Patients who underwent modified radical mastectomy (MRM) and developed symptomatic seroma after removal of the drains between August 2017 and December 2018, were randomized into two groups either indwelling cannulas drain of seroma (Group A) or needle aspiration of seroma (Group B). We prospectively compared the number of visits for seroma, the time from removal of the drain to the final seroma resolution and the cost between the methods. RESULTS A total of 860 patients underwent MRM between August 2017 and December 2018, among which 86 patients who developed symptomatic seroma after removal of the drains, were randomized into two groups either Group A or Group B. The number of visits for seroma in Group A was 2.35 ± 0.69 times, which was less than those in Group B (4.86 ± 1.06 times). Similarly, the time of drain removal to final seroma resolution in Group A was 4.65 ± 0.78 days, which was shorter than 7.09 ± 1.54 in Group B. In Group A, the total mean cost per patient (25.81 ± 7.71 RMB) was less than the total mean cost per patient (49.30 ± 9.85 RMB) in Group B. Cost savings were noted with using indwelling cannulas in seroma management. CONCLUSION It is feasible to drain indwelling cannulas drain for postmastectomy seroma, with less visits for patients, rapid seroma resolution and less cost. Indwelling cannulas can be an efficient, cost effective solution to treat symptomatic seroma after breast surgery.",2020,"In Group A, the total mean cost per patient (25.81 ± 7.71 RMB) was less than the total mean cost per patient (49.30 ± 9.85 RMB) in Group B. Cost savings were noted with using indwelling cannulas in seroma management. ","['and developed symptomatic seroma after removal of the drains between August 2017 and December 2018', 'breast cancer patients', '860 patients underwent MRM between August 2017 and December 2018, among which 86 patients who developed symptomatic seroma after removal of the drains', 'Patients who underwent']","['indwelling cannulas drain and needle aspiration', 'indwelling cannulas', 'Indwelling cannulas with needle and catheter', 'indwelling cannulas drain of seroma (Group A) or needle aspiration of seroma', 'modified radical mastectomy (MRM']","['number of visits for seroma', 'time of drain removal to final seroma resolution', 'total mean cost']","[{'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0262627', 'cui_str': 'Seroma'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0180499', 'cui_str': 'Drain, device (physical object)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0439848', 'cui_str': 'Indwelling (qualifier value)'}, {'cui': 'C0180499', 'cui_str': 'Drain, device (physical object)'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}, {'cui': 'C0349707', 'cui_str': 'Aspiration - action (qualifier value)'}, {'cui': 'C0520453', 'cui_str': 'Cannula'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C0262627', 'cui_str': 'Seroma'}, {'cui': 'C0441835', 'cui_str': 'Group A (qualifier value)'}, {'cui': 'C0024883', 'cui_str': 'Modified Mastectomy'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1704447', 'cui_str': 'Patient visit for (contextual qualifier) (qualifier value)'}, {'cui': 'C0262627', 'cui_str': 'Seroma'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0411815', 'cui_str': 'Removal of drain (procedure)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",860.0,0.0147319,"In Group A, the total mean cost per patient (25.81 ± 7.71 RMB) was less than the total mean cost per patient (49.30 ± 9.85 RMB) in Group B. Cost savings were noted with using indwelling cannulas in seroma management. ","[{'ForeName': 'Xiufeng', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': ""Department of Breast Surgical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, No. 420 Fu Ma Road, Fuzhou, 350014, Fujian, People's Republic of China. wxf200104@hotmail.com.""}, {'ForeName': 'Yiping', 'Initials': 'Y', 'LastName': 'Luo', 'Affiliation': ""Department of Anesthesiology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, 350014, Fujian, People's Republic of China.""}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Zeng', 'Affiliation': ""Department of Breast Surgical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, No. 420 Fu Ma Road, Fuzhou, 350014, Fujian, People's Republic of China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Peng', 'Affiliation': ""Department of Clinical Laboratory, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, 350014, Fujian, People's Republic of China.""}, {'ForeName': 'Zhaoming', 'Initials': 'Z', 'LastName': 'Zhong', 'Affiliation': ""Department of Ultrasound, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, 350014, Fujian, People's Republic of China.""}]",Archives of gynecology and obstetrics,['10.1007/s00404-019-05396-2'] 283,32267989,Postoperative Infections Associated With Prolonged Spinal Cord Stimulation Trial Duration (PROMISE RCT).,"INTRODUCTION In the PROMISE study, a multinational randomized controlled trial (RCT) of the effectiveness of spinal cord stimulation (SCS) with multicolumn surgical leads as a treatment of low back pain, clinicians followed their usual practice. An early, unplanned safety analysis revealed that the infection rate in Belgium (5/23), where trial duration was a median 21.5 days, was significantly higher than the 1/64 rate observed in the other study countries (median 5.8 days, p < 0.01). This report reviews infections observed in the PROMISE study after study completion. MATERIALS AND METHODS For all infections related to SCS, we used descriptive statistics and tests of independent variables to analyze potentially contributing factors (age, sex, coexisting medical conditions, tobacco use, lead type, and trial duration) between subjects with infections versus those without. Cumulative incidence curves were created using the Kaplan-Meier method and compared between the two strata using a log-rank test. RESULTS Among nine (5.2%) infections in 174 subjects trialed, the only significant contributing factor to infection was trial duration: median 21 days (range 3-56) for those with infection vs. six days (1-41) for those without (p = 0.001; Wilcoxon rank-sum test). The cumulative incidence of infection for subjects trialed >10 days was 24.1% vs. 1.4% for subjects trialed ≤10 days (p < 0.001). After the protocol was amended to limit trial duration to 10 days, 14 infection-free trials were performed in Belgium. CONCLUSIONS Although not part of the preplanned analysis, our observation supports the hypothesis of a cause-effect relationship between trial duration and the risk of infection and the conclusion that prolonged SCS trials should be avoided.",2020,The cumulative incidence of infection for subjects trialed >10 days was 24.1% vs. 1.4% for subjects trialed ≤10 days (p < 0.001).,[],['spinal cord stimulation (SCS'],"['infection rate in Belgium', 'cumulative incidence of infection', 'Postoperative Infections', 'Cumulative incidence curves']",[],"[{'cui': 'C0394477', 'cui_str': 'Neurostimulation of spinal cord tissue'}, {'cui': 'C0175699', 'cui_str': 'Saethre-Chotzen syndrome'}]","[{'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0004950', 'cui_str': 'Belgium'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0392618', 'cui_str': 'Postoperative infection'}, {'cui': 'C0205134', 'cui_str': 'Curved'}]",174.0,0.115943,The cumulative incidence of infection for subjects trialed >10 days was 24.1% vs. 1.4% for subjects trialed ≤10 days (p < 0.001).,"[{'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'North', 'Affiliation': 'The Neuromodulation Foundation, Inc., Baltimore, MD, USA.'}, {'ForeName': 'Mehul J', 'Initials': 'MJ', 'LastName': 'Desai', 'Affiliation': 'International Spine, Pain & Performance Center and George Washington University Medical Center, Washington, DC, USA.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Vangeneugden', 'Affiliation': 'Department of Neurosurgery, Sint Maarten General Hospital, Duffel, Belgium.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Raftopoulos', 'Affiliation': 'Department of Neurosurgery, University Hospital St-Luc (UCL), Brussels, Belgium.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Van Havenbergh', 'Affiliation': 'Department of Neurosurgery, GZA - Sint Augustinus Hospital, Wilrijk, Belgium.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Deruytter', 'Affiliation': 'Department of Neurosurgery, AZ Delta Hospital, Roeselare, Belgium.'}, {'ForeName': 'Jean-Michel', 'Initials': 'JM', 'LastName': 'Remacle', 'Affiliation': 'Department of Neurosurgery, La Citadelle Regional Hospital, Liège, Belgium.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Shipley', 'Affiliation': 'The Neuromodulation Foundation, Inc., Baltimore, MD, USA.'}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Tan', 'Affiliation': 'Department of Clinical Research, Medtronic, Minneapolis, MN, USA.'}, {'ForeName': 'Mary Jo', 'Initials': 'MJ', 'LastName': 'Johnson', 'Affiliation': 'Department of Clinical Research, Medtronic, Minneapolis, MN, USA.'}, {'ForeName': 'Carine', 'Initials': 'C', 'LastName': 'Van den Abeele', 'Affiliation': 'Department of Clinical Research, Medtronic International Trading Sàrl, Tolochenaz, Switzerland.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Rigoard', 'Affiliation': 'Department of Neurosurgery, Poitiers University Hospital, Poitiers, France, PRISMATICS Lab, Faculty of Medicine, University of Poitiers, Poitiers, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Neuromodulation : journal of the International Neuromodulation Society,['10.1111/ner.13141'] 284,32165347,Combined Heart-Kidney Transplant Versus Sequential Kidney Transplant in Heart Transplant Recipients.,"OBJECTIVES In patients with reduced kidney function there are no established guidelines to suggest combined heart-kidney transplant (HKTx) versus sequential kidney transplant (SKTx) using preoperative value of estimated glomerular filtration (eGFR). METHODS The United Network for Organ Sharing database was queried from 2000 to 2015 to evaluate survival of HKTx and SKTx population stratified by preoperative eGFR rate <45 mL/min. Aim of the study was to assess the eGFR rate that is most beneficial to perform a concomitant or a SKTx at time of transplant evaluation. RESULTS In our analysis, patients who required SKTx are recipients that, after heart transplantation, developed or worsened kidney insufficiency due to calcineurin inhibitor nephrotoxicity. In recipients with eGFR <30 or dialysis, a total of 545 received HKTx and 80 received SKTx. The median waiting time between heart and kidney transplant in SKTx group was 6 years. The overall post-transplant survival was 81% and 80% and 75% and 59% at 5 and 1 years for the HKTx and SKTx groups, respectively (P = .04). In recipients with eGFR from 30 to 44, a total of 107 received HKTx and 112 received SKTx. The median waiting time between heart and kidney transplant in SKTx group was 4 years. Overall post-transplant survival showed no statistically significant differences in HKTx group (n=107) compared with SKTx group (n=112) and was 90% and 95% at 1 year and 74% and 52% at 5 years, respectively (P = .4) . CONCLUSIONS To optimize organ and patient survival, eGFR value can be utilized to discern between HKTx versus SKTx in patients with decreased renal function at the time of heart transplantation. Patients with eGFR<30 or in dialysis presented better survival with HKTx, while both SKTx and HKTx are suitable for patients with eGFR between 30 and 45.",2020,"Overall post transplant survival showed no statistically significant differences in HKTx group (n=107) compared to SKTx group (n=112) and was 90% and 95% at 1 year and 74% and 52% at 5 years, respectively (p=0.4) . ","['Heart Transplant Recipients', 'The United Network for Organ Sharing database was queried from 2000 to 2015 to evaluate survival of HKTx and SKTX population stratified by preoperative eGFR rate < 45ml/min', 'recipients with eGFR <30 or dialysis, a total of 545 received HKTx and 80 received', 'recipients with eGFR from 30 to 44, a total of 107 received HKTx and 112 received']","['SKTx', 'Combined Heart-Kidney Transplant versus Sequential Kidney Transplant']","['overall post transplant survival', 'median waiting time', 'renal function', 'eGFR rate', 'Overall post transplant survival']","[{'cui': 'C2029943', 'cui_str': 'Transplanted heart present'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C3543841', 'cui_str': 'Query'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C4551529', 'cui_str': 'Renal Dialysis'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4517809', 'cui_str': 'Five hundred and forty-five'}, {'cui': 'C4517529', 'cui_str': 'One hundred and seven'}, {'cui': 'C4319548', 'cui_str': '112'}]","[{'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0022671', 'cui_str': 'Grafting, Kidney'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0332835', 'cui_str': 'Grafts'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}]",,0.0316457,"Overall post transplant survival showed no statistically significant differences in HKTx group (n=107) compared to SKTx group (n=112) and was 90% and 95% at 1 year and 74% and 52% at 5 years, respectively (p=0.4) . ","[{'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Gallo', 'Affiliation': 'Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, Kentucky.'}, {'ForeName': 'Jaimin R', 'Initials': 'JR', 'LastName': 'Trivedi', 'Affiliation': 'Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, Kentucky.'}, {'ForeName': 'Erin M', 'Initials': 'EM', 'LastName': 'Schumer', 'Affiliation': 'Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, Kentucky.'}, {'ForeName': 'Mark S', 'Initials': 'MS', 'LastName': 'Slaughter', 'Affiliation': 'Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, Kentucky. Electronic address: mark.slaughter@louisville.edu.'}]",Journal of cardiac failure,['10.1016/j.cardfail.2020.03.002'] 285,28853979,"The Effect of Atorvastatin on Vascular Function and Structure in Young Adult Survivors of Childhood Cancer: A Randomized, Placebo-Controlled Pilot Clinical Trial.","Purpose: Many adult survivors of childhood cancer are at high-risk of developing cardiovascular disease. Cancer therapy may cause damage to the vascular endothelium, thereby initiating atherosclerosis. Atorvastatin has been shown to improve endothelial function independent of reducing cholesterol, as well as reduce/slow arterial stiffness and thickening, yet has never been studied in childhood cancer survivors (CCS). Methods: Twenty-seven young adult (age 26.8 ± 6.2 years) survivors of childhood acute lymphoblastic leukemia or Non-Hodgkin's lymphoma were randomly assigned (1:1) 40 mg/day of atorvastatin or placebo for 6 months. Brachial artery flow-mediated dilation (FMD), small artery reactive hyperemia index (RHI), arterial stiffness, and carotid artery elasticity/thickness were assessed. Results: Fifteen participants completed the trial. No significant treatment effect for any vascular outcomes was observed at 6 months; however, a significant decrease in peak FMD (-3.0 [95% confidence interval [CI]: -5.3, -0.7]) and a trending significant decrease in RHI (-0.3 [95% CI: -0.62, 0.01]) was observed in the placebo group, resulting in a trend toward a treatment effects ( p  < 0.10). No effect on arterial stiffness, carotid arterial elasticity, or thickness was observed. Conclusion: Six months of atorvastatin treatment did not improve endothelial function or arterial stiffness in young adult CCS. While a trend toward an improvement in endothelial function was present, findings should be interpreted with caution owing to the small number of evaluable participants and subsequent lack of sufficient power. Further research in a larger sample size is needed to fully elucidate the effects of atorvastatin on vascular function. Trial registered at clinicaltrials.gov as NCT01733953.",2019,"No significant treatment effect for any vascular outcomes was observed at 6 months; however, a significant decrease in peak FMD (-3.0 [95% confidence interval [CI]:","['Fifteen participants completed the trial', 'Twenty-seven young adult (age 26.8\u2009±\u20096.2 years', 'young adult CCS', ""survivors of childhood acute lymphoblastic leukemia or Non-Hodgkin's lymphoma"", 'childhood cancer survivors (CCS', 'Young Adult Survivors of Childhood Cancer']","['Placebo', 'Atorvastatin', 'atorvastatin', 'atorvastatin or placebo']","['Brachial artery flow-mediated dilation (FMD), small artery reactive hyperemia index (RHI), arterial stiffness, and carotid artery elasticity/thickness', 'endothelial function', 'arterial stiffness, carotid arterial elasticity, or thickness', 'Vascular Function and Structure', 'endothelial function or arterial stiffness', 'vascular outcomes', 'RHI', 'peak FMD']","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517820', 'cui_str': '6.2'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C1961102', 'cui_str': 'Lymphocytic Leukemia, Acute'}, {'cui': 'C0024305', 'cui_str': ""Lymphoma, Nonhodgkin's""}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0286651', 'cui_str': 'atorvastatin'}]","[{'cui': 'C0006087', 'cui_str': 'Brachial Artery'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0226001', 'cui_str': 'Structure of small artery'}, {'cui': 'C0178824', 'cui_str': 'Reactive Hyperemia'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0599949', 'cui_str': 'Arterial Stiffness'}, {'cui': 'C0007272', 'cui_str': 'Carotid Arteries'}, {'cui': 'C0013764'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}]",27.0,0.289083,"No significant treatment effect for any vascular outcomes was observed at 6 months; however, a significant decrease in peak FMD (-3.0 [95% confidence interval [CI]:","[{'ForeName': 'Kara L', 'Initials': 'KL', 'LastName': 'Marlatt', 'Affiliation': '1Pennington Biomedical Research Center, Baton Rouge, Louisiana.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Steinberger', 'Affiliation': '2Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota.'}, {'ForeName': 'Kyle D', 'Initials': 'KD', 'LastName': 'Rudser', 'Affiliation': '3Division of Biostatistics, School of Public Health, and Clinical and Translational Science Institute, University of Minnesota, Minneapolis, Minnesota.'}, {'ForeName': 'Donald R', 'Initials': 'DR', 'LastName': 'Dengel', 'Affiliation': '2Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota.'}, {'ForeName': 'Karim T', 'Initials': 'KT', 'LastName': 'Sadak', 'Affiliation': '2Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota.'}, {'ForeName': 'Jill L', 'Initials': 'JL', 'LastName': 'Lee', 'Affiliation': '2Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota.'}, {'ForeName': 'Anne H', 'Initials': 'AH', 'LastName': 'Blaes', 'Affiliation': ""5Cancer and Blood Disorders Program, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota.""}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Duprez', 'Affiliation': '6Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.'}, {'ForeName': 'Joanna L', 'Initials': 'JL', 'LastName': 'Perkins', 'Affiliation': ""5Cancer and Blood Disorders Program, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota.""}, {'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Ross', 'Affiliation': '2Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota.'}, {'ForeName': 'Aaron S', 'Initials': 'AS', 'LastName': 'Kelly', 'Affiliation': '2Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota.'}]",Journal of adolescent and young adult oncology,['10.1089/jayao.2017.0075'] 286,32266730,Gamification improves melanoma visual identification among high school students: Results from a randomized study.,"Identification of melanoma or worrisome moles is often taught as an important part of routine skin checks. We sought to evaluate the efficacy of gamified education vs. traditional ABCDEs education on melanoma identification and self-confidence in identifying worrisome moles. We report that in our cohort (n = 271), participants randomized to the gamified intervention were more likely to correctly identify melanoma and non-melanoma skin lesions than those randomized to the ABCDE control cohort (74.2% vs 63.5% correct, P < .0001) and perceived confidence in self-identifying worrisome lesions was slightly higher in the gamified group than the traditional group, though the trend was not significant. These novel findings have significant implications on improved ways to educate young patients on the visual identification of melanoma and worrisome moles.",2020,"< .0001) and perceived confidence in self-identifying worrisome lesions was slightly higher in the gamified group than the traditional group, though the trend was not significant.",['high school students'],['gamified education vs. traditional ABCDEs education'],"['melanoma identification and self-confidence', 'correctly identify melanoma and non-melanoma skin lesions', 'melanoma visual identification', 'perceived confidence in self-identifying worrisome lesions']","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}]","[{'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0020792', 'cui_str': 'Identification - mental defense mechanism'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0151779', 'cui_str': 'Malignant melanoma of skin'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0036588', 'cui_str': 'Self'}]",271.0,0.0582645,"< .0001) and perceived confidence in self-identifying worrisome lesions was slightly higher in the gamified group than the traditional group, though the trend was not significant.","[{'ForeName': 'Justin L', 'Initials': 'JL', 'LastName': 'Jia', 'Affiliation': 'Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Shen', 'Affiliation': 'Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Mika M', 'Initials': 'MM', 'LastName': 'Tabata', 'Affiliation': 'Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Kavita Y', 'Initials': 'KY', 'LastName': 'Sarin', 'Affiliation': 'Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.'}]",Pediatric dermatology,['10.1111/pde.14158'] 287,32265346,Subomohyoid Anterior Suprascapular Block versus Interscalene Block for Arthroscopic Shoulder Surgery: A Multicenter Randomized Trial: Erratum.,,2020,,['Arthroscopic Shoulder Surgery'],['Subomohyoid Anterior Suprascapular Block versus Interscalene Block'],[],"[{'cui': 'C0186321', 'cui_str': 'Operative procedure on shoulder'}]","[{'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0394698', 'cui_str': 'Brachial plexus block by interscalene approach'}]",[],,0.0942267,,[],Anesthesiology,['10.1097/ALN.0000000000003314'] 288,32278637,Editor's Choice - Role of Compression After Radiofrequency Ablation of Varicose Veins: A Randomised Controlled Trial ☆ .,"OBJECTIVE Post-procedure limb compression, hitherto routine following open varicose vein surgery, has been extended to endovenous procedures. However, no robust evidence exists to support this practice. Most of the previous studies have focused on the ideal duration of compression. This study evaluates the clinical and patient reported outcomes with and without post-procedure leg compression following radiofrequency ablation (RFA). METHODS This single centre, prospective, non-inferiority randomised controlled trial recruited adult patients, into two groups (A: RFA with compression stocking for two weeks, B: RFA alone). The primary outcome was ultrasound determined target vein obliteration at 12 weeks. Secondary outcome measures included a Quality of Life (QoL) score [Aberdeen Varicose Vein Severity Score (AVSS) and Revised Venous Clinical Severity Score (RVCSS)], patient satisfaction, pain score, and complications. RESULTS In total, 100 consecutive patients were recruited (A: 51; B: 49) classified as clinical class C2-C6 of the Clinical-Etiological-Anatomical-Pathophysiological (CEAP) classification. At 12 weeks the occlusion rate of the target vein was similar in both groups at 98% (n = 47) and 98% (n = 45), respectively (p = 1.0). There was no statistically significant difference in mean AVSS 6 vs. 5.0 (mean difference -1, 95% CI -2 - 3, p = .57) and mean RVCSS 3 vs. 4 (mean difference 1, 95% CI -1 - 2, p = .46) scores at 12 weeks. Comparable patient satisfaction scores were observed (p = .72) and pain score 2.0 vs. 2.0 (p = .92) were achieved in both groups. Two patients in each group developed deep vein thrombosis at two weeks follow up (p = 1.0 for above the knee and p = 1.0 for below the knee). CONCLUSION The clinical and patient reported outcomes following RFA without compression are no worse than with compression. This trial supports the conclusion that the widely practised use of compression after RFA adds no clinical benefit for the patients. However, a much larger study, preferably a multicentre trial, may be required to confirm this conclusion.",2020,"At 12 weeks the occlusion rate of the target vein was similar in both groups at 98% (n = 47) and 98% (n = 45), respectively (p = 1.0).","['Varicose Veins', '100 consecutive patients were recruited (A: 51; B: 49) classified as clinical class C2-C6 of the Clinical-Etiological-Anatomical-Pathophysiological (CEAP) classification']","['Radiofrequency Ablation', 'Compression', 'radiofrequency ablation (RFA']","['deep vein thrombosis', 'ultrasound determined target vein obliteration', 'occlusion rate of the target vein', 'mean AVSS', 'Quality of Life (QoL) score [Aberdeen Varicose Vein Severity Score (AVSS) and Revised Venous Clinical Severity Score (RVCSS)], patient satisfaction, pain score, and complications', 'pain score', 'patient satisfaction scores']","[{'cui': 'C0042345', 'cui_str': 'Phlebectasia'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0220784', 'cui_str': 'Anatomic'}]","[{'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C0332459', 'cui_str': 'Compression'}]","[{'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0332465', 'cui_str': 'Obliteration'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0042345', 'cui_str': 'Phlebectasia'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0451370', 'cui_str': 'Patient satisfaction score'}]",100.0,0.282396,"At 12 weeks the occlusion rate of the target vein was similar in both groups at 98% (n = 47) and 98% (n = 45), respectively (p = 1.0).","[{'ForeName': 'Madu', 'Initials': 'M', 'LastName': 'Onwudike', 'Affiliation': 'Vascular Surgery, Manchester University NHS Foundation Trust, Manchester, UK; Vascular Surgery, Bolton Hospitals NHS Foundation Trust, Bolton, UK. Electronic address: madu@doctors.org.uk.'}, {'ForeName': 'Kazim', 'Initials': 'K', 'LastName': 'Abbas', 'Affiliation': 'Vascular Surgery, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Thompson', 'Affiliation': 'Vascular Surgery, Bolton Hospitals NHS Foundation Trust, Bolton, UK.'}, {'ForeName': 'Damien M', 'Initials': 'DM', 'LastName': 'McElvenny', 'Affiliation': 'Division of Population Health, Health Services Research & Primary Care, University of Manchester, UK.'}]",European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery,['10.1016/j.ejvs.2020.03.014'] 289,32095887,[Exergames for patients with complex regional pain syndrome : A feasibility study].,"BACKGROUND Complex regional pain syndrome (CRPS) is a disease of the limbs composed of various disorders and defined by the cardinal symptom of pain. So-called exergames with a combination of physical activity and fun are increasingly being offered as part of treatment. Exergame therapy could also provide CRPS patients with repetitive training, reward and motivation. METHOD In this study 10 adult patients with CRPS of the hand (50% acute) received a 30 min therapy session using MindMotion™GO. MindMotion™GO is a software that enables control of the integrated games through visual feedback. Outcomes were the subjectively perceived workload (National Aeronautics and Space Administration-task load index, NASA-TLX), user-friendliness (system usability scale, SUS) and pain (numeric rating scale, NRS). RESULTS The CRPS patients rated the average workload as appropriate with a total score of 50.9 points (SD ± 18.13). The user-friendliness of the system was judged to be acceptable with an average total score of 89.5 ± 7.53 points. There were no significant changes in pain intensity after the exergames. The subgroup analysis (acute versus chronic) showed differences in the assessment of the individual dimensions of the workload. CONCLUSION In this study the use of exergames proved to be a suitable tool for rehabilitation of the hand in adult CRPS patients. Whether exergames represent an effective rehabilitation strategy should be examined by means of functional and activity-related target criteria in a representative sample in a randomized controlled study.",2020,The user-friendliness of the system was judged to be acceptable with an average total score of 89.5 ± 7.53 points.,"['10\xa0adult patients with CRPS of the hand (50% acute) received a\xa030', 'adult CRPS patients', 'patients with complex regional pain syndrome ']",[],"['subjectively perceived workload (National Aeronautics and Space Administration-task load index, NASA-TLX), user-friendliness (system usability scale, SUS) and pain (numeric rating scale, NRS', 'pain intensity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0458219', 'cui_str': 'CRPS (Complex Regional Pain Syndromes)'}]",[],"[{'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0242776', 'cui_str': 'NASA'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0222045'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",,0.0423382,The user-friendliness of the system was judged to be acceptable with an average total score of 89.5 ± 7.53 points.,"[{'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Storz', 'Affiliation': 'Klinik und Poliklinik für Orthopädie, Physikalische Medizin und Rehabilitation, Klinikum der Universität München, LMU München, München, Deutschland. claudia.storz@med.uni-muenchen.de.'}, {'ForeName': 'Heike', 'Initials': 'H', 'LastName': 'Schulte-Göcking', 'Affiliation': 'Klinik und Poliklinik für Orthopädie, Physikalische Medizin und Rehabilitation, Klinikum der Universität München, LMU München, München, Deutschland.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Woiczinski', 'Affiliation': 'Klinik und Poliklinik für Orthopädie, Physikalische Medizin und Rehabilitation, Klinikum der Universität München, LMU München, München, Deutschland.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Azqueta-Gavaldon', 'Affiliation': 'Klinik und Poliklinik für Orthopädie, Physikalische Medizin und Rehabilitation, Klinikum der Universität München, LMU München, München, Deutschland.'}, {'ForeName': 'Shahnaz Christina', 'Initials': 'SC', 'LastName': 'Azad', 'Affiliation': 'Interdisziplinäre Schmerzambulanz, Campus Großhadern, Klinikum der Universität München, LMU München, München, Deutschland.'}, {'ForeName': 'Eduard', 'Initials': 'E', 'LastName': 'Kraft', 'Affiliation': 'Klinik und Poliklinik für Orthopädie, Physikalische Medizin und Rehabilitation, Klinikum der Universität München, LMU München, München, Deutschland.'}]","Schmerz (Berlin, Germany)",['10.1007/s00482-019-00436-x'] 290,31700147,The effects of local cooling rates on perfusion of sacral skin under externally applied pressure in people with spinal cord injury: an exploratory study.,"STUDY DESIGN Experimental before-after design. OBJECTIVES The objectives of this study were to explore the effects of local cooling rates on perfusion of sacral skin under externally applied pressure in people with spinal cord injury (SCI). SETTING Research laboratory. METHODS Seventeen participants, including seven wheelchair users with SCI and ten able-bodied (AB) controls. Each participant underwent seven protocols, including pressure (60 mmHg) with local cooling (∆t = -10 °C) for 20 min at three cooling rates (-0.5, -4, -10 °C/min), pressure with local cooling for 40 min, pressure with local heating (∆t = +10 °C), local cooling without pressure, and pressure without temperature changes. Each protocol included a 10-min baseline, a 20-min (or 40-min) loading period and a 20-min recovery. A compound sensor head consisting of laser Doppler and heating and cooling probes was used to measure sacral skin blood flow and temperature in the prone position. Blood flow responses were characterized by peak blood flow, recovery time, and total blood flow in the recovery period. RESULTS The results demonstrated that the cooling rate at -10 °C/min resulted in smaller skin blood flow response compared with -0.5 °C/min (p < 0.05) but were not significantly different to the cooling rate at -4 °C/min. There was a significant difference in the recovery time between the 20-min cooling compared with the 40-min cooling for the SCI group (p < 0.05). CONCLUSIONS Our findings provide initial evidence that local cooling rates affect skin blood flow responses under externally applied pressure in people with SCI.",2020,C/min resulted in smaller skin blood flow response compared with -0.5 °C/min (p < 0.05) but were not significantly different to the cooling rate at -4 °C/min.,"['people with spinal cord injury', 'people with spinal cord injury (SCI', 'people with SCI', 'Seventeen participants, including seven wheelchair users with SCI and ten able-bodied (AB) controls']","['laser Doppler and heating and cooling probes', 'local cooling rates']","['peak blood flow, recovery time, and total blood flow', 'cooling rate at -10', 'smaller skin blood flow response', 'cooling rate', 'sacral skin blood flow and temperature', 'recovery time', 'Blood flow responses']","[{'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0450331', 'cui_str': '17 (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0853966', 'cui_str': 'Wheelchair user'}, {'cui': 'C1299581', 'cui_str': 'Able'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0430489', 'cui_str': 'Laser doppler (procedure)'}, {'cui': 'C0018851', 'cui_str': 'Heating'}, {'cui': 'C3179165', 'cui_str': 'Probe (methazole)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0591126', 'cui_str': 'AT 10'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}]",17.0,0.0858534,C/min resulted in smaller skin blood flow response compared with -0.5 °C/min (p < 0.05) but were not significantly different to the cooling rate at -4 °C/min.,"[{'ForeName': 'Yih-Kuen', 'Initials': 'YK', 'LastName': 'Jan', 'Affiliation': 'Rehabilitation Engineering Lab, Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Champaign, IL, USA. yjan@illinois.edu.'}]",Spinal cord,['10.1038/s41393-019-0378-x'] 291,31883044,Cross-linked hyaluronan gel to improve pregnancy rate of women patients with moderate to severe intrauterine adhesion treated with IVF: a randomized controlled trial.,"PURPOSE To evaluate whether the cross-linked hyaluronan (cHA) gel can improve the clinical pregnancy rate of patients with moderate to severe intrauterine adhesion (IUA) who underwent operative hysteroscopy followed by embryo transfer. METHODS Women with moderate to severe IUA desiring to undergo embryo transfer were recruited in this randomized controlled trial. The patients were randomized on the day of receiving hysteroscopy. The control group received standard hysteroscopy, while cHA gel was applied to the treatment group at the end of hysteroscopy and 5-7 days after operation. All patients were expected to undergo in vitro fertilization (IVF)/intracytoplasmic sperm injection and frozen-thawed embryo transfer (FET). RESULTS A total of 306 patients were enrolled in this study, of which 202 were assigned to the treatment group and 104 to the control group. Both the clinical pregnancy rate (26.3% [49/186] vs. 15.3% [13/85], P = 0.045), the implantation rate (17.7% [57/322] vs. 9.8% [15/153], P = 0.025), and the endometrial thickness on the day of embryo transfer (7.97 ± 1.37 vs. 7.50 ± 0.60 mm, P < 0.001) were significantly higher in the treatment group compared to the control group. In addition, histological assessment of the paired endometrial tissues collected before and after operation revealed a relatively higher number of tubular glands after operation (15.1 ± 13.2 vs. 28.8 ± 30.4, P = 0.166). CONCLUSIONS To conclude, the application of cHA gel in patients with moderate to severe IUA during hysteroscopy can improve the quality of endometrium and uterine receptivity and consequently enhance the clinical pregnancy rate after IVF/CSI and FET.",2020,"Both the clinical pregnancy rate (26.3% [49/186] vs. 15.3% [13/85], P = 0.045), the implantation rate (17.7% [57/322] vs. 9.8% [15/153], P = 0.025), and the endometrial thickness on the day of embryo transfer (7.97 ± 1.37 vs. 7.50 ± 0.60 mm, P < 0.001) were significantly higher in the treatment group compared to the control group.","['patients with moderate to severe intrauterine adhesion (IUA) who underwent operative hysteroscopy followed by embryo transfer', 'women patients with moderate to severe intrauterine adhesion treated with', 'A total of 306 patients were enrolled in this study, of which 202 were assigned to the treatment group and 104 to the control group', 'Women with moderate to severe IUA desiring to undergo embryo transfer']","['cHA gel', 'Cross-linked hyaluronan gel', 'IVF', 'cross-linked hyaluronan (cHA) gel', 'hysteroscopy', 'standard hysteroscopy, while cHA gel']","['quality of endometrium and uterine receptivity', 'pregnancy rate', 'clinical pregnancy rate', 'vitro fertilization (IVF)/intracytoplasmic sperm injection and frozen-thawed embryo transfer (FET', 'number of tubular glands', 'endometrial thickness on the day of embryo transfer', 'implantation rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C1704274', 'cui_str': 'Intrauterine adhesions (disorder)'}, {'cui': 'C0020710', 'cui_str': 'Uterine Endoscopy'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0013938', 'cui_str': 'Embryo Transfer'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0813622', 'cui_str': 'Hyaluronan'}, {'cui': 'C0015915', 'cui_str': 'Test-Tube Fertilization'}, {'cui': 'C0020710', 'cui_str': 'Uterine Endoscopy'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0014180', 'cui_str': 'Endometrium'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rate'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0015914', 'cui_str': 'Fertilization'}, {'cui': 'C0037868', 'cui_str': 'Sperm'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0677542', 'cui_str': 'Frozen (qualifier value)'}, {'cui': 'C0013938', 'cui_str': 'Embryo Transfer'}, {'cui': 'C0643582', 'cui_str': 'FETS'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0332208', 'cui_str': 'Tubular (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0021107', 'cui_str': 'Insertion procedure'}]",202.0,0.0613867,"Both the clinical pregnancy rate (26.3% [49/186] vs. 15.3% [13/85], P = 0.045), the implantation rate (17.7% [57/322] vs. 9.8% [15/153], P = 0.025), and the endometrial thickness on the day of embryo transfer (7.97 ± 1.37 vs. 7.50 ± 0.60 mm, P < 0.001) were significantly higher in the treatment group compared to the control group.","[{'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Mao', 'Affiliation': ""Department of Assisted Reproduction, The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Tao', 'Affiliation': ""Department of Assisted Reproduction, The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Renfei', 'Initials': 'R', 'LastName': 'Cai', 'Affiliation': ""Department of Assisted Reproduction, The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Assisted Reproduction, The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Hongyuan', 'Initials': 'H', 'LastName': 'Gao', 'Affiliation': ""Department of Assisted Reproduction, The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Qiuju', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': ""Department of Assisted Reproduction, The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Kuang', 'Affiliation': ""Department of Assisted Reproduction, The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Shaozhen', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': ""Department of Assisted Reproduction, The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, China. 15001867500@163.com.""}]",Archives of gynecology and obstetrics,['10.1007/s00404-019-05368-6'] 292,32274986,"Use, Acceptability, Performance, and Health Impact of Hollow Fiber Ultrafilters for Water Treatment in Rural Kenyan Households, 2009-2011.","Diarrheal illness remains a leading cause of morbidity and mortality in children < 5 years in developing countries, and contaminated water contributes to diarrhea risk. To address this problem, a novel hollow fiber ultrafilter (HFU) was developed for household water treatment. To test its impact on water quality and infant health, we conducted a cluster-randomized longitudinal evaluation in 10 intervention and 10 comparison villages in Kenya, attempting to enroll all households with infants (< 12 months old). We conducted a baseline survey, distributed HFUs to intervention households, made biweekly home visits for 1 year to assess water treatment practices and diarrhea in infants, and tested water samples from both groups every 2 months for Escherichia coli . We enrolled 92 infants from intervention households and 74 from comparison households. During the 1-year study period, 45.7% of intervention households and 97.3% of comparison households had at least one stored water sample test positive for E. coli . Compared with comparison households, the odds of E. coli contamination in stored water was lower for intervention households (odds ratio [OR]: 0.42, 95% CI: 0.24, 0.74), but there was no difference in the odds of reported diarrhea in infants, adjusting for covariates (OR: 1.19, 95% CI: 0.74, 1.90). Although nearly all water samples obtained from unprotected sources and filtered by the HFU were free of E. coli contamination, HFUs alone were not effective at reducing diarrhea in infants.",2020,"Compared with comparison households, the odds of E. coli contamination in stored water was lower for intervention households (OR: 0.42, 95% CI: 0.24, 0.74), but there was no difference in the odds of reported diarrhea in infants, adjusting for covariates (OR: 1.19, 95% CI: 0.74, 1.90).","['92 infants from intervention households and 74 from comparison households', 'children < 5 years in developing countries', '10 intervention and 10 comparison villages in Kenya, attempting to enroll all households with infants (< 12 months old', 'Rural Kenyan Households, 2009-2011']",[],"['Use, Acceptability, Performance, and Health Impact of Hollow Fiber Ultrafilters', 'diarrhea', 'water quality and infant health']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011750', 'cui_str': 'Less-Developed Countries'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0337839', 'cui_str': 'Kenyans'}]",[],"[{'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0332484', 'cui_str': 'Hollow shape'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0597680', 'cui_str': 'Water Quality'}, {'cui': 'C0205806', 'cui_str': 'Baby Health'}]",92.0,0.0801791,"Compared with comparison households, the odds of E. coli contamination in stored water was lower for intervention households (OR: 0.42, 95% CI: 0.24, 0.74), but there was no difference in the odds of reported diarrhea in infants, adjusting for covariates (OR: 1.19, 95% CI: 0.74, 1.90).","[{'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Fagerli', 'Affiliation': 'Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Gieraltowski', 'Affiliation': 'Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Nygren', 'Affiliation': 'Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Foote', 'Affiliation': 'Emory University, Atlanta, Georgia.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Gaines', 'Affiliation': 'Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia.'}, {'ForeName': 'Jared', 'Initials': 'J', 'LastName': 'Oremo', 'Affiliation': 'Safe Water and AIDS Project, Kisumu, Kenya.'}, {'ForeName': 'Aloyce', 'Initials': 'A', 'LastName': 'Odhiambo', 'Affiliation': 'Safe Water and AIDS Project, Kisumu, Kenya.'}, {'ForeName': 'Sunkyung', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Quick', 'Affiliation': 'Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.19-0862'] 293,32100275,Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern.,"Linzagolix is a novel, oral GnRH receptor antagonist developed for the treatment of endometriosis and uterine fibroids. We assessed high-dose linzagolix safety and bleeding pattern effects in healthy women using combined versus delayed hormonal add-back therapy (ABT). This was a single-center, open-label, parallel-group study in 32 premenopausal women, who were randomized to daily linzagolix (200 mg)/ABT for 10 weeks (""Combined-ABT"") or linzagolix (200 mg) for 4 weeks followed by linzagolix (200 mg)/ABT for 6 weeks (""Delayed-ABT""). Main outcome measures included bleeding records, trough estradiol (E2) concentrations and adverse events. Linzagolix alone promptly reduced bleeding, leading to amenorrhea in all women by week 5. When combined ABT was started (week 5), spotting (≤ 0.80 days/week/subject) and bleeding (≤ 0.53 days/week/subject) occurred; bleeding was markedly more frequent than after ABT start in the ""Combined-ABT"" group. In the ""Combined-ABT"" group, spotting (≤ 0.69 days/week/subject) and occasional bleeding (≤ 0.25 days/week/subject) occurred during the first half of treatment with a tendency to further decrease during the second half. Linzagolix alone rapidly reduced E2 reaching median week 4 levels of 4.1 pg/mL. Median E2 after combined linzagolix/ABT ranged between 35 and 42 pg/mL for the ""Delayed-ABT"" group (weeks 5-10) and between 24 and 32 pg/mL for the ""Combined-ABT"" group (weeks 1-10). Linzagolix was well tolerated. Most frequently reported adverse events were headache (32/156) and hot flushes (19/156). Hot flushes exclusively occurred in the ""Delayed-ABT"" group. In this study, treatment start with a combined linzagolix/ABT regimen resulted in better bleeding control, no hot flushes, and lower median E2 levels than a ""Delayed-ABT"" regimen. These results may help defining the linzagolix/ABT regimen to be adopted when treating sex-hormone-dependent diseases. Clinical Trial Registration Number-EudraCT Number: 2017-003822-34.",2020,"Linzagolix alone rapidly reduced E2 reaching median week 4 levels of 4.1 pg/mL. Median E2 after combined linzagolix/ABT ranged between 35 and 42 pg/mL for the ""Delayed-ABT"" group (weeks 5-10) and between 24 and 32 pg/mL for the ""Combined-ABT"" group (weeks 1-10).","['32 premenopausal women', 'healthy women using']","['linzagolix', 'combined GnRH receptor antagonist linzagolix and hormonal add-back therapy', 'Linzagolix', 'combined linzagolix/ABT', 'combined versus delayed hormonal add-back therapy (ABT']","['occasional bleeding', 'bleeding', 'tolerated', 'bleeding control, no hot flushes, and lower median E2 levels', 'bleeding records, trough estradiol (E2) concentrations and adverse events', 'linzagolix safety and bleeding pattern effects', 'bleeding, leading to amenorrhea', 'Hot flushes']","[{'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0034811', 'cui_str': 'Receptors, GnRH'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}, {'cui': 'C0458083', 'cui_str': 'Hormonal (qualifier value)'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0521114', 'cui_str': 'Infrequent (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0600142', 'cui_str': 'Hot Flashes'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0444506', 'cui_str': 'Trough (qualifier value)'}, {'cui': 'C1700235', 'cui_str': '(11BAPOP2) estradiol'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0002453', 'cui_str': 'Amenorrhea'}]",32.0,0.0496312,"Linzagolix alone rapidly reduced E2 reaching median week 4 levels of 4.1 pg/mL. Median E2 after combined linzagolix/ABT ranged between 35 and 42 pg/mL for the ""Delayed-ABT"" group (weeks 5-10) and between 24 and 32 pg/mL for the ""Combined-ABT"" group (weeks 1-10).","[{'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Pohl', 'Affiliation': 'ObsEva SA, Chemin des Aulx 12, 1228, Plan-les-Ouates, Geneva, Switzerland. oliver.pohl@obseva.ch.'}, {'ForeName': 'Line', 'Initials': 'L', 'LastName': 'Marchand', 'Affiliation': 'ObsEva SA, Chemin des Aulx 12, 1228, Plan-les-Ouates, Geneva, Switzerland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Bell', 'Affiliation': 'Celerion Ltd, Belfast, BT9 6AD, UK.'}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Gotteland', 'Affiliation': 'ObsEva SA, Chemin des Aulx 12, 1228, Plan-les-Ouates, Geneva, Switzerland.'}]","Reproductive sciences (Thousand Oaks, Calif.)",['10.1007/s43032-020-00172-z'] 294,32222582,"Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: A proof-of-concept, single-arm, open-label clinical trial.","OBJECTIVES A very low-calorie ketogenic diet (VLCKD) has been associated with a significant reduction in visceral adipose tissue and ketone bodies that likely possess antiinflammatory properties. We evaluated the efficacy of an aggressive weight-loss (WL) program with a ketogenic induction phase as first-line treatment for chronic plaque psoriasis. METHODS Adult patients who were overweight or obese and drug-naïve (i.e., never treated, excluding the use of topical emollients; n = 37; 30% men; age: 43.1 ± 13.8 y) with stable chronic plaque psoriasis underwent a 10-wk, 2-phase WL program consisting of a 4-wk protein-sparing, VLCKD (<500 kcal/d; 1.2 g of protein/kg of ideal body weight/d) and 6-wk balanced, hypocaloric (25-30 kcal/kg of ideal body weight/d), Mediterranean-like diet. The primary endpoint was the reduction in Psoriasis Area and Severity Index (PASI) score at wk 10. Major secondary endpoints included PASI score responses of ≥50% and ≥75%, reduction in body surface area involved, improvement in itch severity (visual analogue scale), and Dermatology Life Quality Index score at wk 10. RESULTS With a mean body weight reduction of 12.0% (-10.6 kg), the dietary intervention resulted in a significant reduction in PASI (baseline score: 13.8 ± 6.9; range, 7-32), with a mean change of -10.6 (95% confidence interval, -12.8 to -8.4; P < 0.001). PASI score responses of ≥50% and ≥75% were recorded in 36 patients (97.3%) and 24 patients (64.9%), respectively. Treatment also resulted in a significant reduction (P < 0.001) in the body surface area involved (-17.4%) and an improvement in itch severity (-33.2 points) and Dermatology Life Quality Index score (-13.4 points). CONCLUSIONS In drug-naïve adult overweight patients with stable chronic plaque psoriasis, an aggressive dietary WL program consisting of a VLCKD, followed by a balanced, hypocaloric, Mediterranean-like diet, appeared to be an effective first-line strategy to reduce disease severity.",2020,"PASI score responses of ≥50% and ≥75% were recorded in 36 patients (97.3%) and 24 patients (64.9%), respectively.","['chronic plaque psoriasis', 'drug-naïve adult overweight patients with stable chronic plaque psoriasis', 'Adult patients who were overweight or obese and drug-naïve (i.e., never treated, excluding the use of topical emollients; n\xa0=\xa037; 30% men; age: 43.1 ± 13.8 y) with stable chronic plaque psoriasis underwent a 10-wk, 2-phase']","['aggressive weight-loss (WL) program', 'Mediterranean-like diet', '4-wk protein-sparing, VLCKD', 'Aggressive weight-loss program with a ketogenic induction phase', 'calorie ketogenic diet (VLCKD']","['itch severity', 'PASI score responses of ≥50% and ≥75%, reduction in body surface area involved, improvement in itch severity (visual analogue scale), and Dermatology Life Quality Index score', 'reduction in Psoriasis Area and Severity Index (PASI) score', 'PASI score responses', 'PASI', 'mean body weight reduction', 'Dermatology Life Quality Index score', 'body surface area']","[{'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0406317', 'cui_str': 'Plaque psoriasis (disorder)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0013983', 'cui_str': 'Emollients'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517561', 'cui_str': '13.8 (qualifier value)'}, {'cui': 'C0052080', 'cui_str': '3-((phenylacetyl)amino)-2,6-piperidinedione'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}]","[{'cui': 'C3179079', 'cui_str': 'Weight Loss Programs'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C0259972', 'cui_str': 'Ketogenic Diet'}]","[{'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0005902', 'cui_str': 'Body Surface Area'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C4706308', 'cui_str': 'Dermatology Life Quality Index score'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}]",,0.0345302,"PASI score responses of ≥50% and ≥75% were recorded in 36 patients (97.3%) and 24 patients (64.9%), respectively.","[{'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Castaldo', 'Affiliation': 'Nutriketo Lab A.O.R.N. San Giuseppe Moscati, Contrada Amoretta, Avellino, Italy; University of Salerno, Salerno, Italy. Electronic address: lavoronep@yahoo.it.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Rastrelli', 'Affiliation': 'Department of Pharmacy, Faculty of Pharmacy, University of Salerno, Fisciano, Salerno, Italy.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Galdo', 'Affiliation': 'Oncologic Dermatology Unit, IRCCS-CROB, Rionero in Vulture, Potenza, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Molettieri', 'Affiliation': 'Nutriketo Lab A.O.R.N. San Giuseppe Moscati, Contrada Amoretta, Avellino, Italy.'}, {'ForeName': 'Felice', 'Initials': 'F', 'LastName': 'Rotondi Aufiero', 'Affiliation': 'Dermatology and Dermatosurgery Unit, A.O.R.N. San Giuseppe Moscati, Avellino, Italy.'}, {'ForeName': 'Emanuele', 'Initials': 'E', 'LastName': 'Cereda', 'Affiliation': 'Clinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110757'] 295,30908853,Comparative Responsiveness of Outcome Measures for the Assessment of Pain and Function in Osteoarthritis of the First Metatarsophalangeal Joint.,"OBJECTIVE The present study was undertaken to assess the comparative responsiveness of outcome measures used for the assessment of pain and function in individuals with osteoarthritis (OA) of the first metatarsophalangeal (MTP) joint. METHODS Eighty-eight patients (mean ± SD age 57.2 ± 10.2 years) with OA of the first MTP joint who participated in a randomized trial completed the Foot Health Status Questionnaire (FHSQ), the Foot Function Index Revised Short Form (FFI-RS), and 100-mm visual analog scales (VAS) of pain and stiffness at baseline and 12 weeks. Responsiveness of the subscales for each outcome measure was determined using paired t-tests, Cohen's d coefficient, the standardized response mean (SRM), and the Guyatt index (GI). Sample size estimations were calculated based on minimal important differences (MIDs). RESULTS All outcome measures were sensitive to change and demonstrated at least medium effect sizes. Three outcome measures exhibited large or very large effect sizes for Cohen's d coefficient, the SRM, and the GI: the FHSQ pain subscale (d = 1.03; SRM 1.10, GI score 1.30), the FFI-RS pain subscale (d = 1.09; SRM 1.05, GI score 1.73), and the 100-mm VAS of pain severity while walking (d = 1.22; SRM 1.07, GI score 1.78). Sample size calculations indicated that between 20 and 33 participants per group would be required to detect MIDs using these measures. CONCLUSION The FHSQ pain subscale, FFI-RS pain subscale, and the 100-mm VAS of pain severity while walking are the most responsive outcome measures for the assessment of pain and function in individuals with OA of the first MTP joint. These findings provide useful information to guide researchers in selecting appropriate outcome measures for use in future clinical trials.",2020,"Three outcome measures exhibited large or very large effect sizes for Cohen's d, SRM, and GI: the FHSQ pain subscale (d=1.03; SRM=1.10, GI=1.30), the FFI-R pain subscale (d=1.09; SRM=1.05, GI=1.73), and the 100 mm VAS of pain severity while walking (d=1.22; SRM=1.07, GI=1.78).","['individuals with first metatarsophalangeal joint osteoarthritis (1 st MTPJ OA', 'mean age [SD] 57.2 [10.2] years) with 1 st MTPJ OA who participated', 'First Metatarsophalangeal Joint Osteoarthritis', 'Eighty-eight people ']",[],"['FFI-R pain subscale', 'standardised response mean (SRM), and the Guyatt index (GI', ""large or very large effect sizes for Cohen's d, SRM, and GI: the FHSQ pain subscale"", 'FHSQ pain subscale, FFI-RS pain subscale', 'Foot Health Status Questionnaire (FHSQ), the Foot Function Index Revised Short Form (FFI-RS), and 100 mm visual analog scales (VAS) of pain and stiffness', 'Pain and Function']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0025589', 'cui_str': 'Metatarsophalangeal Joint'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517898', 'cui_str': '88 (qualifier value)'}]",[],"[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0450093', 'cui_str': 'Very large (qualifier value)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0016504', 'cui_str': 'Foot'}, {'cui': 'C0018759', 'cui_str': 'Level of Health'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C4706287', 'cui_str': 'Foot Function Index (assessment scale)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0427008', 'cui_str': 'Stiffness (finding)'}, {'cui': 'C0031843', 'cui_str': 'function'}]",,0.0452557,"Three outcome measures exhibited large or very large effect sizes for Cohen's d, SRM, and GI: the FHSQ pain subscale (d=1.03; SRM=1.10, GI=1.30), the FFI-R pain subscale (d=1.09; SRM=1.05, GI=1.73), and the 100 mm VAS of pain severity while walking (d=1.22; SRM=1.07, GI=1.78).","[{'ForeName': 'Hylton B', 'Initials': 'HB', 'LastName': 'Menz', 'Affiliation': 'La Trobe University, Melbourne, Victoria, Australia, and Arthritis Research UK Primary Care Centre, Keele University, Staffordshire, UK.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Auhl', 'Affiliation': 'La Trobe University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Jade M', 'Initials': 'JM', 'LastName': 'Tan', 'Affiliation': 'La Trobe University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Pazit', 'Initials': 'P', 'LastName': 'Levinger', 'Affiliation': 'La Trobe University and National Ageing Research Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Roddy', 'Affiliation': 'Arthritis Research UK Primary Care Centre, Keele University, Staffordshire, UK, and Academic Rheumatology Centre, Midlands Partnership NHS Trust, Stoke-on-Trent, UK.'}, {'ForeName': 'Shannon E', 'Initials': 'SE', 'LastName': 'Munteanu', 'Affiliation': 'La Trobe University, Melbourne, Victoria, Australia.'}]",Arthritis care & research,['10.1002/acr.23883'] 296,30908867,Feasibility and Preliminary Outcomes of a Physical Therapist-Administered Physical Activity Intervention After Total Knee Replacement.,"OBJECTIVE To explore the feasibility, fidelity, safety, and preliminary outcomes of a physical therapist-administered physical activity (PA) intervention after total knee replacement (TKR). METHODS People who had undergone a unilateral TKR and were receiving outpatient physical therapy (PT) were randomized to a control or intervention group. Both groups received standard PT for TKR. The intervention included being provided with a Fitbit Zip, step goals, and 1 phone call a month for 6 months after discharge from PT. Feasibility was measured by rates of recruitment and retention, safety was measured by the frequency of adverse events, and fidelity was measured by adherence to the weekly steps/day goal created by the physical therapist and participant monitoring of steps/day. An Actigraph GT3X measured PA, which was quantified as steps/day and minutes/week of engaging in moderate-to-vigorous PA. Our preliminary outcome was the difference in PA 6 months after discharge from PT between the control and intervention groups. RESULTS Of the 43 individuals who were enrolled, 53.4% were women, the mean ± SD age was 67.0 ± 7.0 years, and the mean ± SD body mass index was 31.5 ± 5.9 kg/m 2 . For both the control and intervention groups, the recruitment and retention rates were 64% and 83.7%, respectively, and adherence to the intervention ranged from 45% to 60%. No study-related adverse events occurred. The patients in the intervention group accumulated a mean 1,798 more steps/day (95% confidence interval [95% CI] 240, 3,355) and spent 73.4 more minutes/week (95% CI -14.1, 160.9) engaging in moderate-to-vigorous PA at 6 months than those in the control group. CONCLUSION A physical therapist-administered PA intervention is feasible and safe, demonstrates treatment fidelity, and may increase PA after TKR. Future research is needed to establish the effectiveness of the intervention.",2020,"the recruitment and retention rates were 64% and 83.7%, respectively, no study-related adverse events occurred, and adherence to the intervention ranged from 45-60%.","['total knee replacement', '43 people enrolled (mean(SD) age = 67.0 (7.0), BMI = 31.5 (5.9), 53.4% women', 'People with a unilateral TKR in outpatient PT']","['physical therapist-administered PA intervention', 'standard PT for TKR', 'physical therapist-administered physical activity intervention', 'physical therapist-administered physical activity (PA) intervention after total knee replacement (TKR']","['rates of recruitment and retention, safety by the frequency of adverse events, and fidelity of the intervention by adherence', 'adverse events', 'retention rates']","[{'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}]","[{'cui': 'C2362565', 'cui_str': 'Physiotherapists'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}]","[{'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.0423838,"the recruitment and retention rates were 64% and 83.7%, respectively, no study-related adverse events occurred, and adherence to the intervention ranged from 45-60%.","[{'ForeName': 'Meredith B', 'Initials': 'MB', 'LastName': 'Christiansen', 'Affiliation': 'University of Delaware, Newark.'}, {'ForeName': 'Louise M', 'Initials': 'LM', 'LastName': 'Thoma', 'Affiliation': 'University of Delaware, Newark.'}, {'ForeName': 'Hiral', 'Initials': 'H', 'LastName': 'Master', 'Affiliation': 'University of Delaware, Newark.'}, {'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'Voinier', 'Affiliation': 'University of Delaware, Newark.'}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Schmitt', 'Affiliation': 'University of Delaware, Newark.'}, {'ForeName': 'Melissa L', 'Initials': 'ML', 'LastName': 'Ziegler', 'Affiliation': 'University of Delaware, Newark.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'LaValley', 'Affiliation': 'Boston University, Boston, Massachusetts.'}, {'ForeName': 'Daniel K', 'Initials': 'DK', 'LastName': 'White', 'Affiliation': 'University of Delaware, Newark.'}]",Arthritis care & research,['10.1002/acr.23882'] 297,32270636,[Effect of jiaotong qiaomai needling technique of acupuncture on the morphology of lower limb muscle based on muscle-skeleton ultrasound measurement in patients with post-stroke strephenopodia].,"OBJECTIVE To evaluate the therapeutic effect on post-stroke strephenopodia treated with jiaotong qiaomai (harmonizing the heel vessel) needling technique of acupuncture. METHODS A total of 64 patients were randomized into an observation group (30 cases included, 2 cases dropped off) and a control group (30 cases included, 2 cases dropped off). In the control group, the routine needling technique of acupuncture and rehabilitation exercise were provided. In the observation group, on the base of the therapeutic regimen as the control group, the jiaotong qiaomai needling technique of acupuncture was added. Fengchi (GB 20), Rangu (KI 2), Zhaohai (KI 6) on the affected side and Fengfu (GV 16) were selected. The treatment was given once daily, 5 times a week, for 4 weeks totally in either group. Separately, before treatment, in 2 weeks and 4 weeks of treatment, the strephenopodia angle was measured and Holden functional ambulation classification (FAC) was evaluated in the patients. Additionally, before treatment and in 4 weeks of treatment, the muscle-skeleton ultrasound was adopted to measure the thickness of anterior tibia muscle and posterior tibia muscle in the resting state of the patients. RESULTS The strephenopodia angle and Holden FAC were all improved after 4-week treatment in the two groups as compared with those before treatment ( P <0.01, P <0.05), and the results in the observation group were better than those in the control group ( P <0.01, P <0.05). Before treatment, the thickness of anterior tibia muscle and posterior tibia muscle on the healthy side was higher than that on the affected side in the patients of the two groups ( P <0.05). After treatment, the thickness of anterior tibia muscle and posterior tibia muscle on the affected side was increased as compared with that before treatment in the two groups ( P <0.01, P <0.05). The thickness on the healthy side was similar before and after treatment in the observation group ( P >0.05), and it was increased on the healthy side after treatment as compared with that before treatment in the control group ( P <0.05). After treatment, the thickness of anterior tibia muscle and posterior tibia muscle on the affected side was similar to that on the healthy side in the two groups ( P >0.05), and the thickness on the affected side in the observation group was higher than that in the control group after treatment ( P <0.05). CONCLUSION The jiaotong qiaomai needling technique of acupuncture effectively improves the strephenopodia angle and ambulation function, as well as the morphology of anterior tibia muscle and posterior tibia muscle in the patients with post-stroke strephenopodia.",2020,"The thickness on the healthy side was similar before and after treatment in the observation group ( P >0.05), and it was increased on the healthy side after treatment as compared with that before treatment in the control group ( P <0.05).","['patients with post-stroke strephenopodia', '64 patients']","['acupuncture', 'acupuncture and rehabilitation exercise', 'jiaotong qiaomai needling technique of acupuncture']","['strephenopodia angle and ambulation function', 'thickness on the healthy side', 'Fengchi (GB 20), Rangu (KI 2), Zhaohai (KI 6', 'healthy side', 'strephenopodia angle and Holden FAC', 'morphology of anterior tibia muscle and posterior tibia muscle', 'thickness of anterior tibia muscle and posterior tibia muscle on the affected side', 'Holden functional ambulation classification (FAC', 'thickness of anterior tibia muscle and posterior tibia muscle on the healthy side', 'thickness of anterior tibia muscle and posterior tibia muscle']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0054427', 'cui_str': 'CAF protocol'}, {'cui': 'C0332437', 'cui_str': 'Associated morphology'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0392760', 'cui_str': 'Affecting'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0008902', 'cui_str': 'Classification'}]",64.0,0.0166496,"The thickness on the healthy side was similar before and after treatment in the observation group ( P >0.05), and it was increased on the healthy side after treatment as compared with that before treatment in the control group ( P <0.05).","[{'ForeName': 'Chuan-Liang', 'Initials': 'CL', 'LastName': 'Ruan', 'Affiliation': 'Department of Acupuncture and Moxibustion, Quanzhou TCM Hospital, Quanzhou 362000, Fujian Province, China.'}, {'ForeName': 'Ruo-Lan', 'Initials': 'RL', 'LastName': 'Chen', 'Affiliation': 'Department of Acupuncture and Moxibustion, Quanzhou TCM Hospital, Quanzhou 362000, Fujian Province, China.'}, {'ForeName': 'Zi-Han', 'Initials': 'ZH', 'LastName': 'Lin', 'Affiliation': 'Department of Acupuncture and Moxibustion, Quanzhou TCM Hospital, Quanzhou 362000, Fujian Province, China.'}, {'ForeName': 'Hai-Li', 'Initials': 'HL', 'LastName': 'Lin', 'Affiliation': 'Department of Acupuncture and Moxibustion, Quanzhou TCM Hospital, Quanzhou 362000, Fujian Province, China.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190416-k0004'] 298,32270637,[Acupuncture combined with opioid drugs on moderate and severe cancer pain: a randomized controlled trial].,"OBJECTIVE To explore the clinical therapeutic effect of acupuncture combined with opioid drugs on moderate and severe cancer pain. METHODS A total of 60 patients with cancer were randomized into an observation group and a control group, 30 cases in each group. Oxycodonehydrochloride prolonged-release tablet was taken orally in the control group. On the basis of the control group, acupuncture was applied at Hegu (LI 4), Neiguan (PC 6), Zusanli (ST 36), Sanyinjiao (SP 6), etc. Corresponding back- shu points, xi -cleft points and ashi points were selected additionally according to primary viscera and pain sites in the observation group. The treatment was given once a day for 2 weeks. Symptomatic and supportive treatment were implanted, and no other antalgic measures were given during the trial. The daily dosage of opioid drug and the adverse reactions were recorded in both groups. Karnofsky performance status (KPS) and quality of life (QOL) scale scores were compared before and after treatment. Numerical rating scale (NRS) score was calculated to evaluate the clinical therapeutic effect. RESULTS Compared before treatment, the daily dosage of opioid drugs after treatment was obviously reduced in the observation group ( P <0.01), and was obviously increased in the control group ( P <0.05). The dosage of opioid drugs after treatment in the observation group was much less than the control group ( P <0.01). After treatment, the KPS and QOL scores were increased in both groups ( P <0.01), and the scores in the observation group were superior to the control group ( P <0.01, P <0.05). The analgesic effective rate was 90.0% (27/30) in the observation group, which was superior to 76.7% (23/30) in the control group ( P <0.05). The adverse reactions rate in the observation group was lower than the control group ( P <0.01). CONCLUSION Acupuncture combined with opioid drugs can effectively relieve the cancer pain, improve the performance status and quality of life in cancer patients, reduce the dosage of opioid drugs and adverse reactions rate.",2020,"After treatment, the KPS and QOL scores were increased in both groups ( P <0.01), and the scores in the observation group were superior to the control group ( P <0.01, P <0.05).","['60 patients with cancer', 'cancer patients', 'moderate and severe cancer pain']","['acupuncture', 'Acupuncture combined with opioid drugs', 'Oxycodonehydrochloride', 'acupuncture combined with opioid drugs']","['performance status and quality of life', 'Karnofsky performance status (KPS) and quality of life (QOL) scale scores', 'adverse reactions', 'moderate and severe cancer pain', 'KPS and QOL scores', 'analgesic effective rate', 'Numerical rating scale (NRS) score', 'cancer pain', 'adverse reactions rate', 'cleft points and ashi']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0596240', 'cui_str': 'Cancer pain'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0206065', 'cui_str': 'Karnofsky performance status'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0596240', 'cui_str': 'Cancer pain'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205242', 'cui_str': 'Cleaved'}]",60.0,0.0380471,"After treatment, the KPS and QOL scores were increased in both groups ( P <0.01), and the scores in the observation group were superior to the control group ( P <0.01, P <0.05).","[{'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Guoyitang Department of Anhui University of CM, Hefei 230038, China.'}, {'ForeName': 'Rui-Rui', 'Initials': 'RR', 'LastName': 'Sun', 'Affiliation': 'Third Affiliated Hospital of Anhui University of CM.'}, {'ForeName': 'Qing-Ling', 'Initials': 'QL', 'LastName': 'Li', 'Affiliation': 'Graduate School of Anhui University of CM.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Ma', 'Affiliation': 'Graduate School of Anhui University of CM.'}, {'ForeName': 'Yong-Lei', 'Initials': 'YL', 'LastName': 'Zeng', 'Affiliation': 'Second Affiliated Hospital of Anhui University of CM.'}, {'ForeName': 'Xue-Zhao', 'Initials': 'XZ', 'LastName': 'Jia', 'Affiliation': 'College of TCM, Anhui University of CM, Hefei 230038.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'College of TCM, Anhui University of CM, Hefei 230038.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190311-k0001'] 299,32270638,[Pelvic-sacral tendon-regulation needling technique of acupuncture combined with manipulative reduction in treatment of postpartum pelvic girdle pain: a randomized controlled trial].,"OBJECTIVE To observe the effect on postpartum pelvic girdle pain treated with the combined therapy of pelvic-sacral tendon-regulation needling technique of acupuncture and manipulative reduction and the simple manipulative therapy. METHODS A total of 80 patients with postpartum pelvic girdle pain were randomized into an observation group and a control group, 40 cases in each one. In the control group, the manipulative reduction was simply adopted. In the observation group, on the base of the treatment as the control group, the pelvic-sacral tendon-regulation needling technique of acupuncture was applied at Mingmen (GV 4), Dachangshu (BL 25), Yaoyangguan (GV 3), Ciliao (BL 32), Zhongliao (BL 33), Huantiao (GB 30) and Yanglingquan (GB 34). In either group, the treatment was given once every two days, three times a week and 3 treatments taken as one course. Totally, 3 courses of treatment were required. The clinical therapeutic effect was compared in the patients between the two groups. The changes in the scores of the pain visual analogue scale (VAS), Oswestry dysfunction index (ODI) and Japanese Orthopaedic Association (JOA), as well as the pelvic floor distress inventory - short form 20 (PFDI-20), the pelvic floor impact questionnaire (PFIQ-7) and the sex life index (the frequency of intercourse and orgasm) were recorded in the patients of the two groups before and after treatment. RESULTS The total effective rate was 95.0% (38/40) in the observation group, higher than 77.5% (31/40) in the control group ( P <0.01). After treatment, the scores of VAS, ODI, PFDI-20 and PFIQ-7 were lower than those before treatment respectively in the patients of the two groups ( P <0.01). JOA score and the sex life index were increased after treatment as compared with those before treatment in the two groups ( P <0.01). The difference value of each of the above indexes in the observation group was higher than the control group ( P <0.01). CONCLUSION The combined therapy of pelvic-sacral tendon-regulation needling technique of acupuncture and manipulative reduction effectively alleviates pain and improves the muscle strength of pelvic floor muscle fibers in the patients with postpartum pelvic girdle pain. Its therapeutic effect is better than that of the simple manipulative therapy.",2020,"The changes in the scores of the pain visual analogue scale (VAS), Oswestry dysfunction index (ODI) and Japanese Orthopaedic Association (JOA), as well as the pelvic floor distress inventory - short form 20 (PFDI-20), the pelvic floor impact questionnaire (PFIQ-7) and the sex life index (the frequency of intercourse and orgasm) were recorded in the patients of the two groups before and after treatment. ","['postpartum pelvic girdle pain', '80 patients with postpartum pelvic girdle pain', 'patients with postpartum pelvic girdle pain']","['Pelvic-sacral tendon-regulation needling technique of acupuncture combined with manipulative reduction', 'pelvic-sacral tendon-regulation needling technique of acupuncture and manipulative reduction', 'pelvic-sacral tendon-regulation needling technique of acupuncture and manipulative reduction and the simple manipulative therapy', 'pelvic-sacral tendon-regulation needling technique of acupuncture']","['clinical therapeutic effect', 'scores of VAS, ODI, PFDI-20 and PFIQ-7', 'pain visual analogue scale (VAS), Oswestry dysfunction index (ODI) and Japanese Orthopaedic Association (JOA), as well as the pelvic floor distress inventory - short form 20 (PFDI-20), the pelvic floor impact questionnaire (PFIQ-7) and the sex life index (the frequency of intercourse and orgasm', 'total effective rate', 'JOA score and the sex life index']","[{'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0240682', 'cui_str': 'Pelvic girdle pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0030797', 'cui_str': 'Pelvic'}, {'cui': 'C0036037', 'cui_str': 'Bone structure of sacrum'}, {'cui': 'C0039508', 'cui_str': 'Tendon structure'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0949742', 'cui_str': 'Therapy, Manipulation'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0029260', 'cui_str': 'Sexual orgasm'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",80.0,0.0256599,"The changes in the scores of the pain visual analogue scale (VAS), Oswestry dysfunction index (ODI) and Japanese Orthopaedic Association (JOA), as well as the pelvic floor distress inventory - short form 20 (PFDI-20), the pelvic floor impact questionnaire (PFIQ-7) and the sex life index (the frequency of intercourse and orgasm) were recorded in the patients of the two groups before and after treatment. ","[{'ForeName': 'Jia-Man', 'Initials': 'JM', 'LastName': 'Wu', 'Affiliation': 'Department of TCM, Shenzhen Maternity and Children Healthcare Hospital Affiliated to Southern Medical University, Shenzhen 518028, Guangdong Province, China.'}, {'ForeName': 'Yuan-Yuan', 'Initials': 'YY', 'LastName': 'Zhuo', 'Affiliation': 'Department of Acupuncture and Moxibustion, Shenzhen TCM Hospital.'}, {'ForeName': 'Xiao-Ling', 'Initials': 'XL', 'LastName': 'Qin', 'Affiliation': 'Department of TCM, Shenzhen Maternity and Children Healthcare Hospital Affiliated to Southern Medical University, Shenzhen 518028, Guangdong Province, China.'}, {'ForeName': 'Xiao-Ying', 'Initials': 'XY', 'LastName': 'Yu', 'Affiliation': 'Department of TCM, Shenzhen Maternity and Children Healthcare Hospital Affiliated to Southern Medical University, Shenzhen 518028, Guangdong Province, China.'}, {'ForeName': 'Shan', 'Initials': 'S', 'LastName': 'Hu', 'Affiliation': 'Department of TCM, Shenzhen Maternity and Children Healthcare Hospital Affiliated to Southern Medical University, Shenzhen 518028, Guangdong Province, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Ning', 'Affiliation': 'Department of TCM, Shenzhen Maternity and Children Healthcare Hospital Affiliated to Southern Medical University, Shenzhen 518028, Guangdong Province, China.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190313-k0002'] 300,32270639,"[Therapeutic effect on mild perimenopausal depression treated with acupuncture at the ""thirteen ghost points"" and kaixin powder].","OBJECTIVE To compare the clinical therapeutic effect on perimenopausal depression between the combined treatment with acupuncture at the ""thirteen ghost points"" and kaixin powder and the single application of kaixin powder. METHODS A total of 60 patients with mild perimenopausal depression were randomized into a Chinese medication group (30 cases, 2 cases dropped off) and a combined treatment group (acupuncture and Chinese medication, 30 cases). In the Chinese medication group, the modified kaixin powder was administered, one dose a day, taking in the morning and the evening separately. In the combined treatment group, on the base of the treatment as the Chinese medication group, acupuncture was applied to the ""thirteen ghost points"" invented by SUN Si-miao , e.g. Shuigou (GV 26), Shaoshang (LU 11), Yinbai (SP 1), Daling (PC 7), Shenmai (BL 62), Jiache (ST 6), Chengjiang (CV 24), Laogong (PC 8), Shangxing (GV 23), etc. The needles were withdrawed after the qi was acquired, and acupuncture was given once every two days, 3 times a week. In both of the groups, the consecutive treatment for 12 weeks was required. Separately, before treatment, after treatment and in 1-month follow-up visit, the score of the Hamilton depression scale (HAMD), the score of the self-rating depression scale (SDS) and the score of the perimenopausal Kupperman were observed in the two groups. In 12 weeks of treatment, the clinical therapeutic effect was compared between the two groups. RESULTS After treatment and during the follow-up, HAMD, SDS and Kupperman scores were all reduced obviously as compared with those before treatment in the two groups ( P <0.05). These scores in the combined treatment group were all lower than those in the Chinese medication group ( P <0.05). The total effective rate was 90.0% (27/30) in the combined treatment group, better than 78.6% (22/28) in the Chinese medication group ( P <0.05). CONCLUSION Either the combined treatment with acupuncture at the ""thirteen ghost points"" and kaixin powder or the single application of kaixin powder is effective on perimenopausal depression. The therapeutic effect of the combined treatment of acupuncture and Chinese medication is superior to the simple application of kaixin powder.",2020,These scores in the combined treatment group were all lower than those in the Chinese medication group ( P <0.05).,"['60 patients with mild perimenopausal depression', 'mild perimenopausal depression treated with']","['acupuncture', 'acupuncture and Chinese medication', 'combined treatment group (acupuncture and Chinese medication', 'acupuncture was applied to the ""thirteen ghost points"" invented by SUN Si-miao , e.g. Shuigou (GV 26), Shaoshang (LU 11), Yinbai (SP 1), Daling (PC 7), Shenmai (BL 62), Jiache (ST 6), Chengjiang (CV 24), Laogong (PC 8), Shangxing', 'Chinese medication']","['perimenopausal depression', 'clinical therapeutic effect', 'HAMD, SDS and Kupperman scores', 'total effective rate', 'Hamilton depression scale (HAMD), the score of the self-rating depression scale (SDS) and the score of the perimenopausal Kupperman']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C3839366', 'cui_str': 'Perimenopausal state'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0014776', 'cui_str': 'Erythrocyte Ghost'}, {'cui': 'C0038817', 'cui_str': 'Sunlight'}, {'cui': 'C0381529', 'cui_str': 'syringopeptin SP(SC)-1'}, {'cui': 'C0646427', 'cui_str': 'DALES'}, {'cui': 'C0603925', 'cui_str': 'fructus schizandrae, radix ginseng, radix ophiopogonis drug combination'}]","[{'cui': 'C3839366', 'cui_str': 'Perimenopausal state'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0037506', 'cui_str': 'Sodium lauryl sulfate'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0036588', 'cui_str': 'Self'}]",60.0,0.0225889,These scores in the combined treatment group were all lower than those in the Chinese medication group ( P <0.05).,"[{'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Gu', 'Affiliation': 'School of Acupuncture- Moxibustion and Tuina, Shaanxi University of CM, Xianyang 712046, China.'}, {'ForeName': 'Rui-Hui', 'Initials': 'RH', 'LastName': 'Wang', 'Affiliation': 'School of Acupuncture- Moxibustion and Tuina, Shaanxi University of CM, Xianyang 712046, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Wu', 'Affiliation': 'Department of Dermatology, Second Affiliated Hospital of Shaanxi University of CM.'}, {'ForeName': 'Zeng-Hui', 'Initials': 'ZH', 'LastName': 'Ke', 'Affiliation': 'School of Acupuncture- Moxibustion and Tuina, Shaanxi University of CM, Xianyang 712046, China.'}, {'ForeName': 'Huan', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'School of Acupuncture- Moxibustion and Tuina, Shaanxi University of CM, Xianyang 712046, China.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'School of Acupuncture- Moxibustion and Tuina, Shaanxi University of CM, Xianyang 712046, China.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190308-0005'] 301,30816331,"Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group.","Children's Cancer Group CCG-1882 improved outcome for 1-21-year old with high risk acute lymphoblastic leukemia and Induction Day 8 marrow blasts ≥25% (slow early responders, SER) with longer and stronger post induction intensification (PII). This CCG-1961 explored alternative PII strategies. We report 10-year follow-up for patients with rapid early response (RER) and for the first time details our experience for SER patients. A total of 2057 patients were enrolled, and 1299 RER patients were randomized to 1 of 4 PII regimens: standard vs. augmented intensity and standard vs. increased length. At the end of interim maintenance, 447 SER patients were randomized to idarubicin/cyclophosphamide or weekly doxorubicin in the delayed intensification phases. The 10-year EFS for RER were 79.4 ± 2.4% and 70.9 ± 2.6% (hazard ratio = 0.65, 95% CI 0.52-0.82, p < 0.001) for augmented and standard strength PII; the 10-year OS rates were 87.2 ± 2.0% and 81.0 ± 2.2% (hazard ratio = 0.64, 95% CI 0.48-0.86, p = 0.003). Outcomes remain similar for standard and longer PII, and for SER patients assigned to idarubicin/cyclophosphamide and weekly doxorubicin. The EFS and OS advantage of augmented PII is sustained at 10 years for RER patients. Longer PII for RER patients and sequential idarubicin/cyclophosphamide for SER patients offered no advantage. CCG-1961 is the platform for subsequent COG studies.",2019,"Outcomes remain similar for standard and longer PII, and for SER patients assigned to idarubicin/cyclophosphamide and weekly doxorubicin.","['patients with rapid early response (RER) and for the first time\xa0details our experience for SER patients', '447 SER patients', '2057 patients were enrolled, and 1299 RER patients']","['idarubicin/cyclophosphamide and weekly doxorubicin', 'idarubicin/cyclophosphamide or weekly doxorubicin', 'idarubicin/cyclophosphamide', 'CCG-1961']","['10-year OS rates', '10-year EFS for RER']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}]","[{'cui': 'C0020789', 'cui_str': 'Idarubicin'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",2057.0,0.0559644,"Outcomes remain similar for standard and longer PII, and for SER patients assigned to idarubicin/cyclophosphamide and weekly doxorubicin.","[{'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Steinherz', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, USA. steinhep@mskcc.org.'}, {'ForeName': 'Nita L', 'Initials': 'NL', 'LastName': 'Seibel', 'Affiliation': ""Children's National Health System, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.""}, {'ForeName': 'Harland', 'Initials': 'H', 'LastName': 'Sather', 'Affiliation': ""Children's Oncology Group, Los Angeles, CA, USA.""}, {'ForeName': 'Lingyun', 'Initials': 'L', 'LastName': 'Ji', 'Affiliation': 'Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Xinxin', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': ""Children's Oncology Group, Los Angeles, CA, USA.""}, {'ForeName': 'Meenakshi', 'Initials': 'M', 'LastName': 'Devidas', 'Affiliation': 'Department of Biostatistics, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Paul S', 'Initials': 'PS', 'LastName': 'Gaynon', 'Affiliation': ""Children's Hospital of Los Angeles, Los Angeles, CA, USA.""}]",Leukemia,['10.1038/s41375-019-0422-z'] 302,31454829,Acute kidney injury risk-based screening in pediatric inpatients: a pragmatic randomized trial.,"BACKGROUND Pediatric acute kidney injury (AKI) is common and associated with increased morbidity, mortality, and length of stay. We performed a pragmatic randomized trial testing the hypothesis that AKI risk alerts increase AKI screening. METHODS All intensive care and ward admissions of children aged 28 days through 21 years without chronic kidney disease from 12/6/2016 to 11/1/2017 were included. The intervention alert displayed if calculated AKI risk was > 50% and no serum creatinine (SCr) was ordered within 24 h. The primary outcome was SCr testing within 48 h of AKI risk > 50%. RESULTS Among intensive care admissions, 973/1909 (51%) were randomized to the intervention. Among those at risk, more SCr tests were ordered for the intervention group than for controls (418/606, 69% vs. 361/597, 60%, p = 0.002). AKI incidence and severity were the same in intervention and control groups. Among ward admissions, 5492/10997 (50%) were randomized to the intervention, and there were no differences between groups in SCr testing, AKI incidence, or severity of AKI. CONCLUSIONS Alerts based on real-time prediction of AKI risk increased screening rates in intensive care but not pediatric ward settings. Pragmatic clinical trials provide the opportunity to assess clinical decision support and potentially eliminate ineffective alerts.",2020,AKI incidence and severity were the same in intervention and control groups.,"['pediatric inpatients', 'All intensive care and ward admissions of children aged 28 days through 21 years without chronic kidney disease from 12/6/2016 to 11/1/2017 were included']",[],"['serum creatinine (SCr', 'SCr tests', 'AKI incidence and severity', 'morbidity, mortality, and length of stay', 'SCr testing within 48\u2009h of AKI risk', 'SCr testing, AKI incidence, or severity of AKI', 'calculated AKI risk']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0085559'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]",[],"[{'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",,0.192399,AKI incidence and severity were the same in intervention and control groups.,"[{'ForeName': 'Sara L', 'Initials': 'SL', 'LastName': 'Van Driest', 'Affiliation': 'Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA. sara.van.driest@vumc.org.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Michael F', 'Initials': 'MF', 'LastName': 'McLemore', 'Affiliation': 'Health Information Technology, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Brian C', 'Initials': 'BC', 'LastName': 'Bridges', 'Affiliation': 'Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Geoffrey M', 'Initials': 'GM', 'LastName': 'Fleming', 'Affiliation': 'Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Tracy L', 'Initials': 'TL', 'LastName': 'McGregor', 'Affiliation': 'Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Deborah P', 'Initials': 'DP', 'LastName': 'Jones', 'Affiliation': 'Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Shirey-Rice', 'Affiliation': 'Institute for Clinical and Translational Research, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Cheryl L', 'Initials': 'CL', 'LastName': 'Gatto', 'Affiliation': 'Institute for Clinical and Translational Research, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'James C', 'Initials': 'JC', 'LastName': 'Gay', 'Affiliation': 'Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Daniel W', 'Initials': 'DW', 'LastName': 'Byrne', 'Affiliation': 'Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Asli', 'Initials': 'A', 'LastName': 'Weitkamp', 'Affiliation': 'Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Dan M', 'Initials': 'DM', 'LastName': 'Roden', 'Affiliation': 'Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Bernard', 'Affiliation': 'Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.'}]",Pediatric research,['10.1038/s41390-019-0550-1'] 303,31609296,Salt Loading Blunts Central and Peripheral Postexercise Hypotension.,"INTRODUCTION High salt intake is a widespread cardiovascular risk factor with systemic effects. These effects include an expansion of plasma volume, which may interfere with postexercise hypotension (PEH). However, the effects of high salt intake on central and peripheral indices of PEH remain unknown. We tested the hypothesis that high salt intake would attenuate central and peripheral PEH. METHODS Nineteen healthy adults (7 female/12 male; age, 25 ± 4 yr; body mass index, 23.3 ± 2.2 kg·m; V[Combining Dot Above]O2peak, 41.6 ± 8.7 mL·min·kg; systolic blood pressure (BP), 112 ± 9 mm Hg; diastolic BP, 65 ± 9 mm Hg) participated in this double-blind, randomized, placebo-controlled crossover study. Participants were asked to maintain a 2300 mg·d sodium diet for 10 d on two occasions separated by ≥2 wk. Total salt intake was manipulated via ingestion of capsules containing either table salt (3900 mg·d) or placebo (dextrose) during each diet. On the 10th day, participants completed 50 min of cycling at 60% V[Combining Dot Above]O2peak. A subset of participants (n = 8) completed 60 min of seated rest (sham trial). Beat-to-beat BP was measured in-laboratory for 60 min after exercise via finger photoplethysmography. Brachial and central BPs were measured for 24 h after exercise via ambulatory BP monitor. RESULTS Ten days of high salt intake increased urinary sodium excretion (134 ± 70 (dextrose) vs 284 ± 74 mmol per 24 h (salt), P < 0.001), expanded plasma volume (7.2% ± 10.8%), and abolished PEH during in-laboratory BP monitoring (main effect of diet, P < 0.001). Ambulatory systolic BPs were higher for 12 h after exercise during the salt and sham trials compared with the dextrose trial (average change, 3.6 ± 2.1 mm Hg (dextrose), 9.9 ± 1.4 mm Hg (salt), 9.8 ± 2.5 mm Hg (sham); P = 0.01). Ambulatory central systolic BP was also higher during the salt trial compared with dextrose trial. CONCLUSION High salt intake attenuates peripheral and central PEH, potentially reducing the beneficial cardiovascular effects of acute aerobic exercise.",2020,"Ten days of high salt intake increased urinary sodium excretion (dextrose=134±70 vs. salt=284±74 mmol•24H, p<0.001), expanded plasma volume (7.2±10.8%), and abolished PEH during in-lab BP monitoring (main effect of diet: p<0.001).","['Nineteen healthy adults (7F/12M, age=25±4 yrs; BMI=23.3±2.2 kg•m; VO2peak=41.6±8.7 mL•min•kg; SBP=112±9 mmHg; DBP=65±9 mmHg) participated']","['placebo', 'placebo (dextrose']","['Salt Loading Blunts Central and Peripheral Postexercise Hypotension', 'Ambulatory central systolic BP', 'expanded plasma volume', 'Ambulatory systolic BPs', 'urinary sodium excretion', 'Total salt intake', 'Brachial and central BP', 'Beat-to-beat blood pressure (BP']","[{'cui': 'C0450337', 'cui_str': '19 (qualifier value)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0439475', 'cui_str': 'torr (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0017725', 'cui_str': 'dextrose'}]","[{'cui': 'C0036140', 'cui_str': 'Salts'}, {'cui': 'C1997138', 'cui_str': 'Blunted'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C2936233', 'cui_str': 'Postexercise Hypotension'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0205229', 'cui_str': 'Expanding (qualifier value)'}, {'cui': 'C0032127', 'cui_str': 'Blood Plasma Volume'}, {'cui': 'C3541959', 'cui_str': 'Sodium supplement (substance)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0445456', 'cui_str': 'Brachial (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}]",19.0,0.540888,"Ten days of high salt intake increased urinary sodium excretion (dextrose=134±70 vs. salt=284±74 mmol•24H, p<0.001), expanded plasma volume (7.2±10.8%), and abolished PEH during in-lab BP monitoring (main effect of diet: p<0.001).","[{'ForeName': 'Matthew C', 'Initials': 'MC', 'LastName': 'Babcock', 'Affiliation': 'Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE.'}, {'ForeName': 'Austin T', 'Initials': 'AT', 'LastName': 'Robinson', 'Affiliation': 'Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE.'}, {'ForeName': 'Joseph C', 'Initials': 'JC', 'LastName': 'Watso', 'Affiliation': 'Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE.'}, {'ForeName': 'Kamila U', 'Initials': 'KU', 'LastName': 'Migdal', 'Affiliation': 'Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE.'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Martens', 'Affiliation': 'Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE.'}, {'ForeName': 'David G', 'Initials': 'DG', 'LastName': 'Edwards', 'Affiliation': 'Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE.'}, {'ForeName': 'Linda S', 'Initials': 'LS', 'LastName': 'Pescatello', 'Affiliation': 'Department of Kinesiology, University of Connecticut, Storrs, CT.'}, {'ForeName': 'William B', 'Initials': 'WB', 'LastName': 'Farquhar', 'Affiliation': 'Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002187'] 304,32070246,Neurodevelopmental Outcomes at 42 Months After Thyroxine Supplementation in Infants Below 28 Weeks' Gestation: A Randomized Controlled Trial.,"Background: Infants below 28 weeks' gestation have low thyroid hormone plasma levels compared with more mature infants and this may contribute to their risk of developmental disability. We aimed at determining the effect of supplementation with levothyroxine (LT4) for extremely premature infants born below 28 weeks' gestations on neurodevelopmental outcomes at 42 months. Methods: An explanatory double-blind, randomized, placebo-controlled trial consecutively recruited 153 infants below 28 weeks' gestation from 5 neonatal units in the United Kingdom. Infants were either supplemented with LT4 started intravenously during the first 5 days after birth and then changed to oral LT4 when enteral feeds were fully established (8 μg/kg birthweight/day as a single daily dose) or given placebo until 32 weeks' corrected gestational age. Neurodevelopmental outcomes at 42 months (range 40-43) were evaluated in 59 of these infants (30 LT4-supplemented, 29 placebo) by using Bayley III Mental and Psychomotor Developmental Indices. Cognition outcomes was correlated with plasma free thyroxine (fT4) level at 36 weeks and diffusion tensor imaging (DTI) markers. Results: The LT4 supplemented group performed significantly better in motor, language, and cognitive function domains. The mean of the difference between each group (95% confidence intervals [CI], p -value) was motor domain 6.96 ([0.55-13.38], p  = 0.034); language domain 8.93 ([0.16-17.70], p  = 0.041); and cognition domain 6.35 ([0.14-12.55], p  = 0.045). Neurodevelopmental outcome at 42 months had some associations with the trial's primary outcome (subarachnoid space width and motor outcome, p  = 0.03), plasma fT4 level at 36 weeks (fT4 and cognition outcome, p  = 0.01), and DTI at 36 weeks with cognition outcomes ( p  > 0.05). Conclusion: Our data suggest that early supplementation with LT4 may improve long-term neurodevelopment in infants born below 28 weeks' gestation, but larger trials are warranted as the current reported improvements shown are not strong enough to warrant a change in practice.",2020,"language domain 8.93 (0.16-17.70, p=0.041); cognition domain 6.35 (0.14-12.55, p=0.045).","[""extremely premature infants born below 28 weeks' gestations on neurodevelopmental outcomes at 42 months"", ""153 infants below 28 weeks' gestation from five neonatal units in the United Kingdom"", ""infants below 28 weeks' gestation""]","['placebo', 'levothyroxine (LT4', 'thyroxine supplementation', 'LT4']","['subarachnoid space width and motor outcome, p=0.03), plasma free thyroxine level at 36 weeks (FT4 and cognition outcome, p=0.01) and Diffusion Tensor Imaging (DTI', 'Bayley III Mental and Psychomotor Developmental Indices', 'motor, language and cognitive function domains', 'plasma free thyroxine level', 'Neurodevelopmental outcome']","[{'cui': 'C3494262', 'cui_str': 'Extremely Preterm Infants'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1881373', 'cui_str': ""L-3,5,3',5'-Tetraiodothyronine""}, {'cui': 'C0202231', 'cui_str': 'Thyroxine measurement (procedure)'}]","[{'cui': 'C0038527', 'cui_str': 'Subarachnoid Space'}, {'cui': 'C0487742', 'cui_str': 'Width (qualifier value)'}, {'cui': 'C1269635', 'cui_str': 'Plasma free thyroxine level'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C1537007', 'cui_str': 'Diffusion Tensor MRI'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0458003', 'cui_str': 'Developmental (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0023008', 'cui_str': 'Languages'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}]",153.0,0.456237,"language domain 8.93 (0.16-17.70, p=0.041); cognition domain 6.35 (0.14-12.55, p=0.045).","[{'ForeName': 'Sze May', 'Initials': 'SM', 'LastName': 'Ng', 'Affiliation': ""Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.""}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Turner', 'Affiliation': ""Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.""}, {'ForeName': 'A Michael', 'Initials': 'AM', 'LastName': 'Weindling', 'Affiliation': ""Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.""}]",Thyroid : official journal of the American Thyroid Association,['10.1089/thy.2019.0293'] 305,32259266,Effectiveness of Iodophor vs Chlorhexidine Solutions for Surgical Site Infections and Unplanned Reoperations for Patients Who Underwent Fracture Repair: The PREP-IT Master Protocol.,"Importance The risk of developing a surgical site infection after extremity fracture repair is nearly 5 times greater than in most elective orthopedic surgical procedures. For all surgical procedures, it is standard practice to prepare the operative site with an antiseptic solution; however, there is limited evidence to guide the choice of solution used for orthopedic fracture repair. Objective To compare the effectiveness of iodophor vs chlorhexidine solutions to reduce surgical site infections and unplanned fracture-related reoperations for patients who underwent fracture repair. Design, Setting, and Participants The PREP-IT (Program of Randomized Trials to Evaluate Pre-operative Antiseptic Skin Solutions in Orthopaedic Trauma) master protocol will be followed to conduct 2 multicenter pragmatic cluster randomized crossover trials, Aqueous-PREP (Pragmatic Randomized Trial Evaluating Pre-Operative Aqueous Antiseptic Skin Solution in Open Fractures) and PREPARE (Pragmatic Randomized Trial Evaluating Pre-Operative Alcohol Skin Solutions in Fractured Extremities). The Aqueous-PREP trial will compare 4% aqueous chlorhexidine vs 10% povidone-iodine for patients with open extremity fractures. The PREPARE trial will compare 2% chlorhexidine in 70% isopropyl alcohol vs 0.7% iodine povacrylex in 74% isopropyl alcohol for patients with open extremity fractures and patients with closed lower extremity or pelvic fractures. Both trials will share key aspects of study design and trial infrastructure. The studies will follow a pragmatic cluster randomized crossover design with alternating treatment periods of approximately 2 months. The primary outcome will be surgical site infection and the secondary outcome will be unplanned fracture-related reoperations within 12 months. The Aqueous-PREP trial will enroll a minimum of 1540 patients with open extremity fractures from at least 12 hospitals; PREPARE will enroll a minimum of 1540 patients with open extremity fractures and 6280 patients with closed lower extremity and pelvic fractures from at least 18 hospitals. The primary analyses will adhere to the intention-to-treat principle and account for potential between-cluster and between-period variability. The patient-centered design, implementation, and dissemination of results are guided by a multidisciplinary team that includes 3 patients and other relevant stakeholders. Discussion The PREP-IT master protocol increases efficiency through shared trial infrastructure and study design components. Because prophylactic skin antisepsis is used prior to all surgical procedures and the application, cost, and availability of all study solutions are similar, the results of the PREP-IT trials are poised to inform clinical guidelines and bring about an immediate change in clinical practice. Trial Registration ClinicalTrials.gov Identifiers: NCT03385304 and NCT03523962.",2020,"To compare the effectiveness of iodophor vs chlorhexidine solutions to reduce surgical site infections and unplanned fracture-related reoperations for patients who underwent fracture repair. ","['patients who underwent fracture repair', '1540 patients with open extremity fractures from at least 12 hospitals', 'patients with open extremity fractures and patients with closed lower extremity or pelvic fractures', 'patients with open extremity fractures', '1540 patients with open extremity fractures and 6280 patients with closed lower extremity and pelvic fractures from at least 18 hospitals', 'Patients', 'Open Fractures', 'Fractured Extremities']","['Pre-Operative Aqueous Antiseptic Skin Solution', 'isopropyl alcohol', 'chlorhexidine', 'Fracture Repair', 'Iodophor vs Chlorhexidine Solutions', 'iodophor vs chlorhexidine solutions', 'isopropyl alcohol vs 0.7% iodine povacrylex', 'povidone-iodine']","['surgical site infection', 'unplanned fracture-related reoperations', 'surgical site infections and unplanned fracture-related reoperations', 'Surgical Site Infections and Unplanned Reoperations']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3805218', 'cui_str': 'Fracture repair'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0149531', 'cui_str': 'Fracture of pelvis'}, {'cui': 'C0016662', 'cui_str': 'Fracture, open'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0003205', 'cui_str': 'Antiseptic agent'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0022237', 'cui_str': 'Isopropyl Alcohol'}, {'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C3805218', 'cui_str': 'Fracture repair'}, {'cui': 'C0021988', 'cui_str': 'Iodophors'}, {'cui': 'C4517474', 'cui_str': '0.7'}, {'cui': 'C1876049', 'cui_str': 'iodine povacrylex'}, {'cui': 'C0032857', 'cui_str': 'Povidone-Iodine'}]","[{'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}]",6280.0,0.141164,"To compare the effectiveness of iodophor vs chlorhexidine solutions to reduce surgical site infections and unplanned fracture-related reoperations for patients who underwent fracture repair. ","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Gerard P', 'Initials': 'GP', 'LastName': 'Slobogean', 'Affiliation': 'Department of Orthopaedics, University of Maryland School of Medicine, Baltimore.'}, {'ForeName': 'Sheila', 'Initials': 'S', 'LastName': 'Sprague', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Wells', 'Affiliation': 'Trauma Survivors Network, Falls Church, Virginia.'}, {'ForeName': 'Mohit', 'Initials': 'M', 'LastName': 'Bhandari', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Alejandra', 'Initials': 'A', 'LastName': 'Rojas', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Alisha', 'Initials': 'A', 'LastName': 'Garibaldi', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Amber', 'Initials': 'A', 'LastName': 'Wood', 'Affiliation': 'Association of periOperative Registered Nurses, Denver, Colorado.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Howe', 'Affiliation': 'Department of Orthopaedics, University of Maryland School of Medicine, Baltimore.'}, {'ForeName': 'Anthony D', 'Initials': 'AD', 'LastName': 'Harris', 'Affiliation': 'Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore.'}, {'ForeName': 'Bradley A', 'Initials': 'BA', 'LastName': 'Petrisor', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Daniel C', 'Initials': 'DC', 'LastName': 'Mullins', 'Affiliation': 'Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Pogorzelski', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Marvel', 'Affiliation': 'Patient Advisor, Baltimore, Maryland.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Heels-Ansdell', 'Affiliation': 'Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Franca', 'Initials': 'F', 'LastName': 'Mossuto', 'Affiliation': 'Hamilton Health Science, Hamilton, Ontario, Canada.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Grissom', 'Affiliation': 'Trauma Survivor Network, Baltimore, Maryland.'}, {'ForeName': 'Gina', 'Initials': 'G', 'LastName': 'Del Fabbro', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Gordon H', 'Initials': 'GH', 'LastName': 'Guyatt', 'Affiliation': 'Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Gregory J', 'Initials': 'GJ', 'LastName': 'Della Rocca', 'Affiliation': 'Department of Orthopaedic Surgery, University of Missouri, Columbia.'}, {'ForeName': 'Haley K', 'Initials': 'HK', 'LastName': 'Demyanovich', 'Affiliation': 'Department of Orthopaedics, University of Maryland School of Medicine, Baltimore.'}, {'ForeName': 'I Leah', 'Initials': 'IL', 'LastName': 'Gitajn', 'Affiliation': 'Department of Orthopaedics, Dartmouth University, Hanover, New Hampshire.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Palmer', 'Affiliation': 'Patient Advisor, Baltimore, Maryland.'}, {'ForeName': 'Jean-Claude', 'Initials': 'JC', 'LastName': ""D'Alleyrand"", 'Affiliation': 'Department of Orthopaedic Surgery, Walter Reed National Military Medical Center, Bethesda, Maryland.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Friedrich', 'Affiliation': 'Washington, DC.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Rivera', 'Affiliation': 'Department of Orthopaedic Surgery, San Antonio Military Medical Center, San Antonio, Texas.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Hebden', 'Affiliation': 'Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Rudnicki', 'Affiliation': 'Department of Orthopaedics, University of Maryland School of Medicine, Baltimore.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Fowler', 'Affiliation': 'Department of Orthopaedic Surgery, San Antonio Military Medical Center, San Antonio, Texas.'}, {'ForeName': 'Kyle J', 'Initials': 'KJ', 'LastName': 'Jeray', 'Affiliation': 'Department of Orthopaedic Surgery, Greenville Health System, Greenville, South Carolina.'}, {'ForeName': 'Lehana', 'Initials': 'L', 'LastName': 'Thabane', 'Affiliation': 'Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Marchand', 'Affiliation': 'Department of Orthopaedic Surgery, University of Utah, Salt Lake City.'}, {'ForeName': 'Lyndsay M', 'Initials': 'LM', 'LastName': ""O'Hara"", 'Affiliation': 'Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore.'}, {'ForeName': 'Manjari G', 'Initials': 'MG', 'LastName': 'Joshi', 'Affiliation': 'Department of Medicine, University of Maryland School of Medicine, Baltimore.'}, {'ForeName': 'Max', 'Initials': 'M', 'LastName': 'Talbot', 'Affiliation': 'Canadian Armed Forces, Montreal, Qubec, Canada.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Camara', 'Affiliation': 'Department of Orthopaedics, University of Maryland School of Medicine, Baltimore.'}, {'ForeName': 'Olivia Paige', 'Initials': 'OP', 'LastName': 'Szasz', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Nathan N', 'Initials': 'NN', 'LastName': ""O'Hara"", 'Affiliation': 'Department of Orthopaedics, University of Maryland School of Medicine, Baltimore.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'McKay', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'P J', 'Initials': 'PJ', 'LastName': 'Devereaux', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Robert V', 'Initials': 'RV', 'LastName': ""O'Toole"", 'Affiliation': 'Department of Orthopaedics, University of Maryland School of Medicine, Baltimore.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Zura', 'Affiliation': 'Department of Orthopaedics, Louisiana State University Health, New Orleans.'}, {'ForeName': 'Saam', 'Initials': 'S', 'LastName': 'Morshed', 'Affiliation': 'Department of Orthopaedic Surgery, University of California, San Francisco.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Dodds', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Stephanie L', 'Initials': 'SL', 'LastName': 'Tanner', 'Affiliation': 'Department of Orthopaedic Surgery, Greenville Health System, Greenville, South Carolina.'}, {'ForeName': 'Taryn', 'Initials': 'T', 'LastName': 'Scott', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Uyen', 'Initials': 'U', 'LastName': 'Nguyen', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.'}]",JAMA network open,['10.1001/jamanetworkopen.2020.2215'] 306,32270631,[Transcutaneous electrical acupoint stimulation for early enteral nutrition tolerance in patients with sepsis of gastrointestinal dysfunction: a multi-center randomized controlled trial].,"OBJECTIVE To compare the therapeutic effect of transcutaneous electrical acupoint stimulation (TEAS) combined with conventional western medicine and western medicine alone on early enteral nutrition tolerance in patients with sepsis. METHODS Forty-nine patients with sepsis were randomly divided into an observation group (24 cases) and a control group (25 cases). The control group was treated with conventional western medicine, including limited fluid resuscitation, anti-infection and maintenance of hemodynamics, and enteral nutrition was provided when the hemodynamics became stable and the dosage of vasoactive drugs was reduced. The observation group, on the basis of the treatment of the control group, was treated with TEAS at Tianshu (ST 25), Shangjuxu (ST 37), Jiexi (ST 41), Diji (SP 8), Zusanli (ST 36), Zhongwan (CV 12) and Daheng (SP 15) when the enteral nutrition was provided (dilatational wave, 2 Hz/10 Hz, twice a day, 30 min each time), and the TEAS stopped when enteral nutrition was normal. The antral motility index (MI) was evaluated by ultrasonography on the first, third and fifth day into treatment in the two groups, and the duration from providing enteral nutrition to normal enteral nutrition was recorded. The acute gastrointestinal injury (AGI) classification, admission time of intensive care unit (ICU) and hospitalization time were compared. RESULTS The antral MI on the third and fifth day into treatment in the observation group was significantly higher than that in the control group ( P <0.05). The duration from providing enteral nutrition to normal enteral nutrition was (5.08±0.65) days in the observation group, which was shorter than (5.56±0.65) days in the control group ( P <0.05). The improvement of AGI classification after treatment in the observation group was significantly superior to the control group ( P <0.05). The hospitalization time in the observation group was shorter than that in the control group ( P <0.05). CONCLUSION TEAS combined with conventional western medicine treatment could significantly promote gastrointestinal peristalsis, improve the early intestinal nutrition tolerance in patients with sepsis, so as to shorten the time of reaching the standard of enteral nutrition and hospitalization time, which is better than conventional western medicine treatment alone.",2020,The improvement of AGI classification after treatment in the observation group was significantly superior to the control group ( P <0.05).,"['patients with sepsis', 'patients with sepsis of gastrointestinal dysfunction', 'Forty-nine patients with sepsis']","['TEAS at Tianshu (ST 25), Shangjuxu (ST 37), Jiexi (ST 41), Diji (SP 8), Zusanli (ST 36), Zhongwan (CV 12) and Daheng (SP 15', 'conventional western medicine', 'TEAS', 'Transcutaneous electrical acupoint stimulation', 'transcutaneous electrical acupoint stimulation (TEAS) combined with conventional western medicine and western medicine alone']","['antral motility index (MI', 'AGI classification', 'hospitalization time', 'antral MI', 'early enteral nutrition tolerance', 'acute gastrointestinal injury (AGI) classification, admission time of intensive care unit (ICU) and hospitalization time', 'early intestinal nutrition tolerance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}]","[{'cui': 'C4721445', 'cui_str': 'Teasing'}, {'cui': 'C1813433', 'cui_str': 'ST-37'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0293352', 'cui_str': 'Antral'}, {'cui': 'C0007608', 'cui_str': 'Motility, Cell'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1299007', 'cui_str': 'Alpha-glucosidase inhibitor'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0160345', 'cui_str': 'Injury of gastrointestinal tract'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}]",49.0,0.0194602,The improvement of AGI classification after treatment in the observation group was significantly superior to the control group ( P <0.05).,"[{'ForeName': 'Huan', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Third Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Zhu', 'Affiliation': 'Third Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China.'}, {'ForeName': 'Hai-Bin', 'Initials': 'HB', 'LastName': 'Ni', 'Affiliation': 'Department of Emergency and Critical Medicine, Affiliated Hospital of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine.'}, {'ForeName': 'Xing-Xing', 'Initials': 'XX', 'LastName': 'Hu', 'Affiliation': 'Department of Emergency, Lishui District Hospital of TCM, Nanjing 211200, Jiangsu Province.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190426-0003'] 307,31126825,One-year follow-up of a remotely delivered epilepsy self-management program in high-risk people with epilepsy.,"OBJECTIVE ""Self-management for people with epilepsy and a history of negative health events"" (SMART) is a novel group-format epilepsy self-management intervention demonstrated to reduce negative health events (NHEs) such as accidents, emergency department visits, and seizures in adults with epilepsy in a 6-month prospective randomized controlled trial (RCT); SMART also reduced depressive symptoms and improved health functioning and quality of life. This report describes the longer-term (12-month) post-efficacy RCT outcomes in adults with epilepsy who received SMART. METHODS After completing a 6-month, prospective RCT that demonstrated efficacy of SMART vs 6-month waitlist control (WL), adults ≥18 years of age with epilepsy were followed for an additional 12 months. Individuals originally randomized to WL received the 8-week SMART intervention immediately following the conclusion of the RCT. For this long-term extension analysis, assessments were conducted at 24 weeks (the 6-month primary outcome time-point of the efficacy RCT), at 32 weeks for individuals originally randomized to WL, and at 48 weeks and 72 weeks for all individuals. Outcomes assessed included past 6-month NHE counts, depressive symptoms assessed with the 9-item Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS), and quality of life assessed with the 10-item Quality of Life in Epilepsy (QOLIE-10). RESULTS At the beginning of this long-term observational period (24-week follow-up time point for the original RCT), there were 50 individuals in the group originally randomized to SMART and 52 originally randomized to WL. Mean age was 41.4 years, 70% women (N = 71), 64% (N = 65) African-American, and 8% Hispanic (N = 8). Study attrition from week 24 to week 72 was 8% in the arm originally randomized to SMART and 17% in the arm originally randomized to WL. During the 12-month observation period (24 weeks to 72 weeks), there were a total of 44 serious adverse events and 4 deaths, none related to study participation. There was no significant change in total past 6-month NHE counts in the group originally randomized to SMART, although the group had significantly reduced 6-month seizure counts. The group originally randomized to WL, who received SMART during this observational period, had a reduction in total NHE counts. The group originally randomized to SMART had relatively stable levels on other outcome variables except for a trend for improved MADRS (p = 0.08). In the group originally randomized to WL, there were significant improvements in PHQ-9 (p = 0.01), MADRS (p ≤ 0.01), and QOLIE-10 (p = 0.004). CONCLUSIONS This post-RCT extension study suggests that adults with epilepsy who participate in the SMART intervention sustain clinical effects at 1-year follow-up and may have incremental improvements in seizure frequency and mood. Future research needs to identify opportunities for scale-up and outreach to other high-risk groups with epilepsy.",2019,"In the group originally randomized to WL, there were significant improvements in PHQ-9 (p = 0.01), MADRS (p ≤ 0.01), and QOLIE-10 (p = 0.004). ","['adults ≥18\u202fyears of age with epilepsy', 'high-risk people with epilepsy', 'Mean age was 41.4\u202fyears, 70% women (N\u202f=\u202f71), 64% (N\u202f=\u202f65) African-American, and 8% Hispanic (N\u202f=\u202f8', 'people with epilepsy and a history of negative health events"" (SMART', 'adults with epilepsy who participate in the', 'adults with epilepsy']","['SMART intervention', 'epilepsy self-management program']","['health functioning and quality of life', 'PHQ-9', 'QOLIE-10', 'total NHE counts', 'past 6-month NHE counts, depressive symptoms assessed with the 9-item Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS), and quality of life assessed with the 10-item Quality of Life in Epilepsy (QOLIE-10', '6-month seizure counts', 'MADRS', 'total past 6-month NHE counts']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}]","[{'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0034380'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C1879301', 'cui_str': 'Patient Health Questionnaire'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}]",,0.104302,"In the group originally randomized to WL, there were significant improvements in PHQ-9 (p = 0.01), MADRS (p ≤ 0.01), and QOLIE-10 (p = 0.004). ","[{'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Sajatovic', 'Affiliation': 'Department of Neurology, Neurological & Behavioral Outcomes Center, Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Psychiatry, Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Cleveland, OH, USA. Electronic address: martha.sajatovic@uhhospitals.org.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Colon-Zimmermann', 'Affiliation': 'Department of Neurology, Neurological & Behavioral Outcomes Center, Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Psychiatry, Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Cleveland, OH, USA.'}, {'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Kahriman', 'Affiliation': 'Department of Neurology, Louis Stokes Cleveland VAMC, Case Western Reserve University School of Medicine, Cleveland, OH, USA.'}, {'ForeName': 'Edna', 'Initials': 'E', 'LastName': 'Fuentes-Casiano', 'Affiliation': 'Department of Psychiatry, Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Cleveland, OH, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Burant', 'Affiliation': 'Case Western Reserve University School of Nursing, Louis Stokes Cleveland VAMC, Cleveland, OH, USA.'}, {'ForeName': 'Michelle E', 'Initials': 'ME', 'LastName': 'Aebi', 'Affiliation': 'Department of Psychiatry, Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Cleveland, OH, USA.'}, {'ForeName': 'Kristin A', 'Initials': 'KA', 'LastName': 'Cassidy', 'Affiliation': 'Department of Neurology, Neurological & Behavioral Outcomes Center, Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Psychiatry, Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Cleveland, OH, USA.'}, {'ForeName': 'Samden', 'Initials': 'S', 'LastName': 'Lhatoo', 'Affiliation': 'Department of Neurology, University of Texas Houston, Houston, TX, USA.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Einstadter', 'Affiliation': 'Case Western Reserve University and Center for Health Care Research and Policy, MetroHealth Medical Center, Cleveland, OH, USA.'}, {'ForeName': 'Peijun', 'Initials': 'P', 'LastName': 'Chen', 'Affiliation': 'Department of Psychiatry, Louis Stokes Cleveland VAMC, Case Western Reserve University School of Medicine, Cleveland, OH, USA.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2019.04.034'] 308,30850442,Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial.,"OBJECTIVE Most suicidality literature in Huntington disease (HD) is based on natural history studies or retrospective reviews, but reports on risk factors from clinical trials are limited. METHODS We analyzed 609 participants from 2CARE, a randomized, double-blind, placebo-controlled clinical trial with up to 5 years of follow-up, for risk factors related to suicidality. The primary outcome variable was the time from randomization until the first occurrence of either suicidal ideation or attempt. We also considered time from randomization until the first suicide attempt as a secondary outcome variable. RESULTS Depression, anxiety, bipolar disorder, antidepressant or anxiolytic use, and prior suicide attempt at baseline were associated with time to ideation or attempt. Baseline employment status, marital status, CAG repeat length, tetrabenazine use, and treatment assignment (coenzyme Q 10 or placebo) were not associated with suicidality. Time-dependent variables from the Unified Huntington's Disease Rating Scale Behavioral Assessment were associated with time to suicidal ideation or attempt, driven mainly by items related to depressed mood, low self-esteem/guilt, anxiety, suicidal thoughts, irritability, and compulsions. Variables associated with time to suicide attempt alone were generally similar. CONCLUSION These data suggest psychiatric comorbidities in HD are predictive of suicidal behavior while participating in clinical trials, reinforcing the importance of clinical surveillance and treatment towards lessening risk during participation and perhaps beyond. Designing a composite algorithm for early prediction of suicide attempts in HD may be of value, particularly given anticipated trials aimed at disease modification are likely to be long-term. CLINICALTRIALSGOV IDENTIFIER NCT00608881.",2019,"Time-dependent variables from the Unified Huntington's Disease Rating Scale Behavioral Assessment were associated with time to suicidal ideation or attempt, driven mainly by items related to depressed mood, low self-esteem/guilt, anxiety, suicidal thoughts, irritability, and compulsions.","['Huntington disease', 'Huntington disease (HD', '609 participants from 2CARE']","['tetrabenazine', 'placebo', 'coenzyme Q 10 or placebo']","['time to suicide attempt alone', ""Unified Huntington's Disease Rating Scale Behavioral Assessment"", 'time to suicidal ideation or attempt, driven mainly by items related to depressed mood, low self-esteem/guilt, anxiety, suicidal thoughts, irritability, and compulsions', 'time from randomization until the first occurrence of either suicidal ideation or attempt', 'Depression, anxiety, bipolar disorder, antidepressant or anxiolytic use, and prior suicide attempt']","[{'cui': 'C0020179', 'cui_str': 'Progressive Chorea, Hereditary, Chronic (Huntington)'}]","[{'cui': 'C0039623', 'cui_str': 'Tetrabenazine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2242675', 'cui_str': 'Coenzyme Q'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0038663', 'cui_str': 'Suicide attempt (event)'}, {'cui': 'C0020179', 'cui_str': 'Progressive Chorea, Hereditary, Chronic (Huntington)'}, {'cui': 'C0222045'}, {'cui': 'C1160858', 'cui_str': 'Behavior care assessment'}, {'cui': 'C0424000', 'cui_str': 'Suicidal Ideation'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0344315', 'cui_str': 'Depressed'}, {'cui': 'C0679136', 'cui_str': 'Low self-esteem (finding)'}, {'cui': 'C0018379', 'cui_str': 'Guilt'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0022107', 'cui_str': 'Irritable Mood'}, {'cui': 'C0600104', 'cui_str': 'Compulsive Behavior'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0005586', 'cui_str': 'Psychosis, Manic-Depressive'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant Drugs'}, {'cui': 'C0040616', 'cui_str': 'Anti-Anxiety Drugs'}, {'cui': 'C1947944', 'cui_str': 'Use'}]",609.0,0.3254,"Time-dependent variables from the Unified Huntington's Disease Rating Scale Behavioral Assessment were associated with time to suicidal ideation or attempt, driven mainly by items related to depressed mood, low self-esteem/guilt, anxiety, suicidal thoughts, irritability, and compulsions.","[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'McGarry', 'Affiliation': 'From Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA. mcgarry-andrew@cooperhealth.edu.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'McDermott', 'Affiliation': 'From Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA.'}, {'ForeName': 'Karl', 'Initials': 'K', 'LastName': 'Kieburtz', 'Affiliation': 'From Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA.'}, {'ForeName': 'Wai Lun Alan', 'Initials': 'WLA', 'LastName': 'Fung', 'Affiliation': 'From Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'McCusker', 'Affiliation': 'From Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Peng', 'Affiliation': 'From Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA.'}, {'ForeName': 'Elisabeth A', 'Initials': 'EA', 'LastName': 'de Blieck', 'Affiliation': 'From Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA.'}, {'ForeName': 'Merit', 'Initials': 'M', 'LastName': 'Cudkowicz', 'Affiliation': 'From Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.P.M., K.K., E.A.d.B.), NY; North York General Hospital (W.L.A.F.), University of Toronto, Canada; Westmead Hospital (E.M.), Australia; The Ohio State University (J.P.), Columbus; and Harvard Medical School (M.C.), Boston, MA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Neurology,['10.1212/WNL.0000000000007244'] 309,30192928,Anticholinergic Amnesia is Mediated by Alterations in Human Network Connectivity Architecture.,"Disrupted cholinergic neurotransmission plays a central role in Alzheimer's disease, medication-induced memory impairment, and delirium. At the systems level, this suggests anticholinergic drugs may alter the activity and interplay of anatomically distributed neural networks critical for memory function. Using a network-sensitive imaging technique (functional connectivity MRI) and a double-blind, crossover design, we examined the consequences of anticholinergic drug administration on episodic memory and functional network architecture in a group of clinically normal elderly. We observed that low-dose scopolamine (0.2 mg IV) decreased episodic memory performance and selectively decreased connectivity strength in 3 of 7 cortical networks. Both memory and connectivity effects were independent of β-amyloid burden. Drug-induced connectivity changes within the Default and Salience networks, as well as reductions in the strength of anticorrelation between these 2 networks, were sufficient to fully statistically mediate the effects of scopolamine on memory performance. These results provide experimental support for the importance of the Default and Salience networks to memory performance and suggest scopolamine-induced amnesia is underpinned by disrupted connectivity within and between these 2 networks. More broadly, these results support the potential utility of fcMRI as tool examine the systems-level pharmacology of psychoactive drugs.",2019,We observed that low-dose scopolamine (0.2 mg IV) decreased episodic memory performance and selectively decreased connectivity strength in 3 of 7 cortical networks.,['a group of clinically normal elderly'],"['network-sensitive imaging technique (functional connectivity MRI', 'anticholinergic drug administration', 'scopolamine']","['episodic memory performance', 'connectivity strength', 'episodic memory and functional network architecture', 'memory performance']","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0332324', 'cui_str': 'Sensitive (qualifier value)'}, {'cui': 'C0079595', 'cui_str': 'Imaging technique (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0242896', 'cui_str': 'Anticholinergic Agents'}, {'cui': 'C0150270', 'cui_str': 'Medication administration case management'}, {'cui': 'C0036442', 'cui_str': 'Scopolamine'}]","[{'cui': 'C0561843', 'cui_str': 'Autobiographical Memory'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0003737', 'cui_str': 'Architecture'}, {'cui': 'C1285654', 'cui_str': 'Ability to remember'}]",7.0,0.0446424,We observed that low-dose scopolamine (0.2 mg IV) decreased episodic memory performance and selectively decreased connectivity strength in 3 of 7 cortical networks.,"[{'ForeName': 'Jasmeer P', 'Initials': 'JP', 'LastName': 'Chhatwal', 'Affiliation': 'Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Aaron P', 'Initials': 'AP', 'LastName': 'Schultz', 'Affiliation': 'Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Trey', 'Initials': 'T', 'LastName': 'Hedden', 'Affiliation': 'Harvard Medical School, Boston, MA 02115, USA.'}, {'ForeName': 'Brendon P', 'Initials': 'BP', 'LastName': 'Boot', 'Affiliation': ""Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Wigman', 'Affiliation': 'Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Dorene', 'Initials': 'D', 'LastName': 'Rentz', 'Affiliation': 'Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Keith A', 'Initials': 'KA', 'LastName': 'Johnson', 'Affiliation': 'Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Reisa A', 'Initials': 'RA', 'LastName': 'Sperling', 'Affiliation': 'Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.'}]","Cerebral cortex (New York, N.Y. : 1991)",['10.1093/cercor/bhy214'] 310,29893790,"Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.","Background The activity of palbociclib as a single agent in advanced breast cancer has not been extensively studied, with the only available clinical data limited to heavily pretreated patients. Preclinical data suggests palbociclib may partially reverse endocrine resistance, though this hypothesis has not been evaluated in previous clinical studies. This phase II, open-label, multicenter study examined the activity of palbociclib monotherapy, as well as palbociclib given in combination with the same endocrine therapy (ET) that was received prior to disease progression, in postmenopausal women with moderately pretreated, estrogen receptor-positive, HER2 negative advanced breast cancer. Patients and methods Eligible women with advanced disease which had progressed on one or two prior ETs were randomized 1 : 1 to receive either palbociclib alone, or palbociclib in combination with the ET as previously received. Primary end point was clinical benefit rate (CBR); secondary end points included progression-free survival (PFS). Results Between October 2012 and July 2016, a total of 115 patients were randomized. The CBR was 54% [95% confidence interval (CI): 41.5-63.7] for combination therapy, and 60% (95% CI: 47.8-72.9) for monotherapy. Median PFS was 10.8 months (95% CI: 5.6-12.7) for combination therapy, and 6.5 months (95% CI: 5.4-8.5) for monotherapy [hazard ratio (HR) 0.69; 95% CI: 0.4-1.1, exploratory P-value = 0.12]. Exploratory analyses revealed the PFS advantage for combination therapy was seen in the subgroup of patients who received prior ET for >6 months (HR 0.53; 95% CI: 0.3-0.9, exploratory P-value = 0.02), but not in those who received prior ET for ≤6 months. Conclusion Palbociclib has clinical activity as a single agent in women with moderately pretreated, oestrogen receptor-positive, HER2-negative advanced breast cancer. Palbociclib may have potential to reverse endocrine resistance in patients with a history of previous durable response to ET. Clinical trial information NCT02549430.",2018,"Median PFS was 10.8 months (95% CI: 5.6-12.7) for combination therapy, and 6.5 months (95% CI: 5.4-8.5) for monotherapy [hazard ratio (HR) 0.69; 95% CI: 0.4-1.1, exploratory P-value = 0.12].","['women with moderately pretreated, oestrogen receptor-positive, HER2-negative advanced breast cancer', 'Results\n\n\nBetween October 2012 and July 2016, a total of 115 patients were randomized', 'advanced breast cancer', 'postmenopausal women with moderately pretreated, estrogen receptor-positive, HER2 negative advanced breast cancer', 'patients with a history of previous durable response to ET', 'Patients and methods\n\n\nEligible women with advanced disease which had progressed on one or two prior ETs']","['palbociclib alone, or palbociclib in combination with the ET', 'endocrine therapy', 'palbociclib given in combination with the same endocrine therapy (ET']","['Median PFS', 'CBR', 'PFS advantage for combination therapy', 'clinical benefit rate (CBR); secondary end points included progression-free survival (PFS']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0202006', 'cui_str': 'Estrogen measurement (procedure)'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C4087376', 'cui_str': 'HER2 negative'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4517540', 'cui_str': '115 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0034804', 'cui_str': 'Estrogen Receptors'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C3853822', 'cui_str': 'palbociclib'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy (procedure)'}, {'cui': 'C1947971', 'cui_str': 'Give'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0556895', 'cui_str': 'Combination therapy (regime/therapy)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",115.0,0.0669645,"Median PFS was 10.8 months (95% CI: 5.6-12.7) for combination therapy, and 6.5 months (95% CI: 5.4-8.5) for monotherapy [hazard ratio (HR) 0.69; 95% CI: 0.4-1.1, exploratory P-value = 0.12].","[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Malorni', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy. Electronic address: luca.malorni@uslcentro.toscana.it.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Curigliano', 'Affiliation': 'Division of Early Drug Development, Department of Haematology and Haemato-Oncology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Minisini', 'Affiliation': 'Department of Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Cinieri', 'Affiliation': 'Medical Oncology Department, ASL Brindisi, Brindisi, Italy.'}, {'ForeName': 'C A', 'Initials': 'CA', 'LastName': 'Tondini', 'Affiliation': 'Hospital Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': ""D'Hollander"", 'Affiliation': 'International Drug Development Institute, Louvain-La-Neuve, Belgium.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Arpino', 'Affiliation': 'Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Bernardo', 'Affiliation': 'Medical Oncology Department, ICS Maugeri IRCCS, Pavia, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Martignetti', 'Affiliation': ""Oncology Department, Azienda USL Toscana Sud Est, Hospital Alta Val D'Elsa, Poggibonsi Siena, Italy.""}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Criscitiello', 'Affiliation': 'Division of Early Drug Development, Istituto Europeo di Oncologia, Milan, Italy.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Puglisi', 'Affiliation': 'Medical Oncology and Cancer Prevention Unit, IRCCS, CRO National Cancer Institute, Aviano; Department of Medicine, University of Udine, Udine, Italy.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Pestrin', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Sanna', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Moretti', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Risi', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Biagioni', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'McCartney', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Boni', 'Affiliation': 'Clinical Trial Coordinating Center, AOU Careggi, Istituto Toscano Tumori, Florence, Italy.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Buyse', 'Affiliation': 'International Drug Development Institute, San Francisco, USA.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Migliaccio', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Biganzoli', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Di Leo', 'Affiliation': '""Sandro Pitigliani"" Medical Oncology Department, Hospital of Prato, Prato, Italy.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdy214'] 311,32172239,Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.,"BACKGROUND Chronic kidney disease (CKD) risk is elevated in patients with type 2 diabetes mellitus (T2DM). Disease management in these patients has been generally focused on glycemic control and controlling other renal and cardiac risk factors as, historically, few protective therapies have been available. The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation -(CREDENCE) trial of canagliflozin was the first study to demonstrate renal protection with a sodium glucose co-transporter 2 inhibitor in patients with T2DM and CKD, and these results could have important implications for clinical practice. SUMMARY In CREDENCE, participants with T2DM and estimated glomerular filtration rate 30-<90 mL/min/1.73 m2 and urinary albumin-creatinine ratio >300-5,000 mg/g who were treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker for ≥4 weeks prior to randomization at either the maximum labeled or tolerated dose were randomized to receive either canagliflozin 100 mg or placebo. Canagliflozin significantly reduced the risk of the primary composite outcome of doubling of serum creatinine, end-stage kidney disease, or renal or cardiovascular (CV) death compared with placebo (hazard ratio 0.70, 95% CI 0.59-0.82; p = 0.00001). Canagliflozin also reduced the risk of secondary renal and CV outcomes. The safety profile of canagliflozin in CREDENCE was generally similar to previous studies of canagliflozin. No imbalances were observed between canagliflozin and placebo in the risk of amputation or fracture in the CREDENCE population. Key Messages: The positive renal and CV effects of canagliflozin observed in the -CREDENCE trial could have a substantial impact on improving outcomes for patients with T2DM and CKD.",2020,No imbalances were observed between canagliflozin and placebo in the risk of amputation or fracture in the CREDENCE population.,"['Patients with Type 2 Diabetes and Chronic Kidney Disease', 'participants with T2DM and estimated glomerular filtration rate 30-<90 mL/min/1.73 m2 and urinary albumin-creatinine ratio', 'patients with T2DM and CKD', 'patients with type 2 diabetes mellitus (T2DM', 'Diabetes with Established Nephropathy Clinical Evaluation']","['canagliflozin 100\xa0mg or placebo', 'canagliflozin and placebo', 'Sodium Glucose Co-Transporter 2 Inhibitors', 'canagliflozin', 'angiotensin-converting enzyme inhibitor or angiotensin receptor blocker', 'sodium glucose co-transporter 2 inhibitor', 'Canagliflozin']","['risk of amputation or fracture', 'risk of secondary renal and CV outcomes', 'serum creatinine, end-stage kidney disease, or renal or cardiovascular (CV) death']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C3811844'}, {'cui': 'C0439087', 'cui_str': '<90 (qualifier value)'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C0022658', 'cui_str': 'Kidney Diseases'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C3556805', 'cui_str': 'canagliflozin 100 MG'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2974540', 'cui_str': 'canagliflozin'}, {'cui': 'C4301634', 'cui_str': 'Sodium-glucose co-transporter 2 (SGLT2) inhibitors'}, {'cui': 'C0003015', 'cui_str': 'ACE Inhibitors'}, {'cui': 'C0815017', 'cui_str': 'Angiotensin Receptor Blockers'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0022661', 'cui_str': 'End-Stage Kidney Disease'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",,0.0507764,No imbalances were observed between canagliflozin and placebo in the risk of amputation or fracture in the CREDENCE population.,"[{'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Weir', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA, Mweir@som.umaryland.edu.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'McCullough', 'Affiliation': 'Baylor University Medical Center, Baylor Heart and Vascular Hospital, Baylor Heart and Vascular Institute, Dallas, Texas, USA.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Buse', 'Affiliation': 'University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Anderson', 'Affiliation': 'The Frist Clinic, Nashville, Tennessee, USA.'}]",American journal of nephrology,['10.1159/000506533'] 312,32166619,"Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus.","INTRODUCTION Sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors inhibit the reabsorption of glucose from the kidneys and increase urinary glucose excretion (UGE), thereby lowering the blood glucose concentration in people suffering from type 1 and type 2 diabetes mellitus (T2DM). In a previous study, we reported a pharmacokinetics/pharmacodynamics model to estimate individual change in UGE (ΔUGE), which is a direct pharmacological effect of SGLT2 inhibitors. In this study, we report our enhancement of the previous model to predict the long-term effects of ipragliflozin on clinical outcomes in patients with T2DM. METHODS The time course of fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) in patients with T2DM following ipragliflozin treatment that had been observed in earlier clinical trials was modeled using empirical models combined with the maximum drug effect (E max ) model and disease progression model. As a predictive factor of drug effect, estimated ΔUGE was introduced into the E max model, instead of ipragliflozin exposure. The developed models were used to simulate the time course of FPG and HbA1c following once-daily treatment with placebo or ipragliflozin at doses of 12.5, 25, 50 and 100 mg, and the changes at 52 weeks at the approved dose of 50 mg were summarized by renal function category. RESULTS The developed models that included UGE as a dependent variable of response were found to well describe observed time courses in FPG and HbA1c. Baseline blood glucose level and renal function had significant effects on the glucose-lowering effect of ipragliflozin, and these models enabled quantification of these impacts on clinical outcomes. Simulated median changes in HbA1c in T2DM patients with mild and moderate renal impairment were 25 and 63% lower, respectively, than those in T2DM patients with normal renal function. These results are consistent with the observed clinical data from a previous renal impairment study. CONCLUSIONS Empirical models established based on the effect of UGE well predicted the renal function-dependent long-term glucose-lowering effects of ipragliflozin in patients with T2DM.",2020,"Baseline blood glucose level and renal function had significant effects on the glucose-lowering effect of ipragliflozin, and these models enabled quantification of these impacts on clinical outcomes.","['patients with T2DM', 'Patients with Type 2 Diabetes Mellitus', 'patients with T2DM following', 'people suffering from type 1 and type 2 diabetes mellitus (T2DM']","['Sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors', 'ipragliflozin', 'placebo or ipragliflozin', 'Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2']","['Baseline blood glucose level and renal function', 'time course of fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c', 'moderate renal impairment']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}, {'cui': 'C0011860', 'cui_str': 'Diabetes Mellitus, Type 2'}]","[{'cui': 'C3541959', 'cui_str': 'Sodium supplement (substance)'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C3492889', 'cui_str': 'ipragliflozin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0017739', 'cui_str': 'Sodium-Glucose Transport Proteins'}]","[{'cui': 'C0428554', 'cui_str': 'Blood glucose result - finding'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0449247', 'cui_str': 'Time course (attribute)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4521595', 'cui_str': 'Lcpl'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C1565489', 'cui_str': 'Renal Insufficiency'}]",,0.036441,"Baseline blood glucose level and renal function had significant effects on the glucose-lowering effect of ipragliflozin, and these models enabled quantification of these impacts on clinical outcomes.","[{'ForeName': 'Masako', 'Initials': 'M', 'LastName': 'Saito', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan. masako.saito@astellas.com.'}, {'ForeName': 'Atsunori', 'Initials': 'A', 'LastName': 'Kaibara', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Kadokura', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Junko', 'Initials': 'J', 'LastName': 'Toyoshima', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Yoshida', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Kazuta', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Eiji', 'Initials': 'E', 'LastName': 'Ueyama', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00785-2'] 313,31767947,Clinical recommendations for use of lidocaine lubricant during bowel care after spinal cord injury prolong care routines and worsen autonomic dysreflexia: results from a randomised clinical trial.,"STUDY DESIGN Clinical trial. OBJECTIVE Spinal cord injury (SCI) impacts autonomic function and bowel management. Bowel care is a potential trigger for autonomic dysreflexia (AD; paroxysmal hypertension elicited by sensory stimuli below the level of lesion). AD can be life threatening so strategies to minimise AD are prioritised after SCI. Lidocaine lubricant is recommended during bowel care with the rationale to minimise the sensory stimulus, reducing AD. The objective of this study was to assess whether lidocaine lubricant (Xylocaine 2%) ameliorates AD during at-home bowel care compared with standard lubricant (placebo). SETTING Community. METHOD Participants (n = 13; age 44.0 ± 3.3 years) with high-level SCI (C3-T4) performed their normal at-home bowel care on two days, each time using a different lubricant, with continuous non-invasive cardiovascular monitoring. Injury to spinal autonomic (sympathetic) nerves was determined from low-frequency systolic arterial pressure (LF SAP) variability. RESULTS Participants displayed reduced autonomic function (LF SAP 3.02 ± 0.84 mmHg 2 ), suggesting impaired autonomic control. Bowel care duration was increased with lidocaine (79.1 ± 10.0 min) compared to placebo (57.7 ± 6.3 min; p = 0.018). All participants experienced AD on both days, but maximum SAP was higher with lidocaine (214.3 ± 10.5 mmHg) than placebo (196.7 ± 10.0 mmHg; p = 0.046). Overall, SAP was higher for longer with lidocaine (6.5 × 10 5  ± 0.9 × 10 5  mmHg • beat) than placebo (4.4 × 10 5  ± 0.6 × 10 5  mmHg • beat; p = 0.018) indicating a higher burden of AD. Heart rate and rhythm disturbances were increased during AD, particularly with lidocaine use. CONCLUSIONS At-home bowel care was a potent trigger for AD. Our findings contradict recommendations for lidocaine use during bowel care, suggesting that anaesthetic lubricants impair reflex bowel emptying, resulting in longer care routines with an increased burden of AD.",2020,"RESULTS Participants displayed reduced autonomic function (LF SAP 3.02 ± 0.84 mmHg 2 ), suggesting impaired autonomic control.","['Participants (n\u2009=\u200913; age 44.0\u2009±\u20093.3\xa0years) with high-level SCI (C3-T4) performed their normal at-home bowel care on two days, each time using a different lubricant, with continuous non-invasive cardiovascular monitoring', 'during bowel care after spinal cord injury prolong care routines and worsen autonomic dysreflexia', 'Community']","['lidocaine', 'standard lubricant (placebo', 'placebo', 'lidocaine lubricant', 'lidocaine lubricant (Xylocaine 2%) ameliorates AD', 'Lidocaine lubricant']","['autonomic function', 'Overall, SAP', 'maximum SAP', 'Heart rate and rhythm disturbances', 'Bowel care duration', 'low-frequency systolic arterial pressure (LF SAP) variability']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517688', 'cui_str': '3.3 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0150155', 'cui_str': 'Bowel management'}, {'cui': 'C1457900', 'cui_str': 'Each'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0282222', 'cui_str': 'Lubrication Agents'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive (qualifier value)'}, {'cui': 'C0161959', 'cui_str': 'Cardiovascular monitoring (regime/therapy)'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0238015', 'cui_str': 'Spinal Autonomic Dysreflexia'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0282222', 'cui_str': 'Lubrication Agents'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0699094', 'cui_str': 'Xylocaine'}]","[{'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0150155', 'cui_str': 'Bowel management'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0205213', 'cui_str': 'Low frequency (qualifier value)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}]",,0.186011,"RESULTS Participants displayed reduced autonomic function (LF SAP 3.02 ± 0.84 mmHg 2 ), suggesting impaired autonomic control.","[{'ForeName': 'Vera-Ellen M', 'Initials': 'VM', 'LastName': 'Lucci', 'Affiliation': 'Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.'}, {'ForeName': 'Maureen S', 'Initials': 'MS', 'LastName': 'McGrath', 'Affiliation': 'Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.'}, {'ForeName': 'Jessica A', 'Initials': 'JA', 'LastName': 'Inskip', 'Affiliation': 'Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.'}, {'ForeName': 'Shirromi', 'Initials': 'S', 'LastName': 'Sarveswaran', 'Affiliation': 'Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.'}, {'ForeName': 'Rhonda', 'Initials': 'R', 'LastName': 'Willms', 'Affiliation': 'International Collaboration on Repair and Discoveries (ICORD), University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Victoria E', 'Initials': 'VE', 'LastName': 'Claydon', 'Affiliation': 'Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada. victoria_claydon@sfu.ca.'}]",Spinal cord,['10.1038/s41393-019-0381-2'] 314,31769342,Enhancement of role modelling in clinical educators: A randomized controlled trial.,"Introduction: Role models have an important impact on the professional behavior of medical students. Previous investigations help us understand how to improve role modelling. However, studies aiming at enhancing role modelling among clinical educators are very limited and generally lack comprehensive evaluations of the designed programs. We intended to gather robust evidence on the effectiveness of a longitudinal program for enhancing role modelling. Methods: Clinical educators were divided into intervention and control groups. The longitudinal program, developed based on the exposure phase of the 'Positive Doctor Role Modelling' framework, was delivered during three months of onsite and online sessions. The effectiveness of the program was assessed in three levels of reaction, learning, and behavior. Results: In the intervention group ( N  = 18), the mean score of satisfaction was 4.7 ( SD  = 0.5), and the learning (awareness about role modelling) improved significantly after the program (3.33-4.34), comparing to the control group (3.53-3.63). There was no significant difference in terms of behavior improvement between the two groups, before and after the program. Conclusions: Our findings indicate that our longitudinal faculty development program on role modelling was highly appreciated by clinical educators, and improved their awareness and deliberate role modelling.",2020,"There was no significant difference in terms of behavior improvement between the two groups, before and after the program.","['medical students', 'clinical educators']",[],"['reaction, learning, and behavior', 'behavior improvement', 'mean score of satisfaction']","[{'cui': 'C0038495', 'cui_str': 'Students, Medical'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}]",[],"[{'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",,0.0186865,"There was no significant difference in terms of behavior improvement between the two groups, before and after the program.","[{'ForeName': 'Elaheh', 'Initials': 'E', 'LastName': 'Mohammadi', 'Affiliation': 'Department of Medical Education, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Azim', 'Initials': 'A', 'LastName': 'Mirzazadeh', 'Affiliation': 'Department of Medical Education, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Amir Ali', 'Initials': 'AA', 'LastName': 'Sohrabpour', 'Affiliation': 'Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hooman', 'Initials': 'H', 'LastName': 'Shahsavari', 'Affiliation': 'Medical-Surgical Department, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Yaseri', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Mortaz Hejri', 'Affiliation': 'Department of Medical Education, Tehran University of Medical Sciences, Tehran, Iran.'}]",Medical teacher,['10.1080/0142159X.2019.1691720'] 315,32269170,"Correction: Regular, sustained-release morphine for chronic breathlessness: a multicentre, double-blind, randomised, placebo-controlled trial .",,2020,,['chronic breathlessness'],"['placebo', 'Correction: Regular, sustained-release morphine']",[],"[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]",[],,0.761976,,[],Thorax,['10.1136/thoraxjnl-2019-213681corr1'] 316,32200266,Efficacy and safety of immediate oral intake in patients with mild acute pancreatitis: A randomized controlled trial.,"OBJECTIVES Early enteral nutrition is recommended for patients with severe acute pancreatitis (AP); however, nutritional management strategies for patients with mild AP have not been established. The aim of this study was to evaluate the benefits and safety of immediate oral intake of low-fat solid food in patients with mild AP who were allowed to take opioid analgesics. METHODS In this single-center randomized study, the immediate feeding (IMF) group was permitted immediate oral intake of low-fat (15 g/d) solid food. In the standard food (STF) group, patients received gradually increasing amounts of dietary fat. Twenty-six patients were randomized, with 13 allocated to each group. The primary outcome was the period between diagnosis and recovery from AP. The cost and rate of progression to severe disease were evaluated as secondary outcomes. RESULTS The IMF group (mean recovery days: 2 ± 1) recovered significantly earlier (mean difference in recovery days: 6.3; 95% confidence interval [CI], 4.8-7.9; P < 0.001) than the STF group (mean recovery days: 8.3 ± 2.3), with a lower overall treatment cost (mean difference in costs: -$460; 95% CI, -$880 to -$40; P = 0.034). The IMF group showed a lower rate of progression to severe AP (IMF, 0%; STF, 15.3%; P = 0.48). CONCLUSION The initial treatment strategy for mild AP should be altered from the gradual introduction of oral feeding upon the absence of pain to immediate oral nutrition with opioid analgesics, to improve treatment efficacy and reduce treatment cost.",2020,"The IMF group showed a lower rate of progression to severe AP (IMF, 0%; STF, 15.3%; P = 0.48). ","['patients with mild AP who were allowed to take opioid analgesics', 'Twenty-six patients', 'patients with severe acute pancreatitis (AP', 'patients with mild acute pancreatitis']","['immediate oral intake', 'IMF', 'immediate feeding (IMF', 'standard food (STF']","['period between diagnosis and recovery from AP', 'Efficacy and safety', 'rate of progression to severe AP', 'cost and rate of progression to severe disease']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0002772', 'cui_str': 'Analgesics, Opioid'}, {'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0001339', 'cui_str': 'Acute pancreatitis (disorder)'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0016452', 'cui_str': 'Food'}]","[{'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",26.0,0.141563,"The IMF group showed a lower rate of progression to severe AP (IMF, 0%; STF, 15.3%; P = 0.48). ","[{'ForeName': 'Masayasu', 'Initials': 'M', 'LastName': 'Horibe', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Eisuke', 'Initials': 'E', 'LastName': 'Iwasaki', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Atsuo', 'Initials': 'A', 'LastName': 'Nakagawa', 'Affiliation': 'Clinical and Translational Research Center, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Juntaro', 'Initials': 'J', 'LastName': 'Matsuzaki', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kazuhiro', 'Initials': 'K', 'LastName': 'Minami', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Yujiro', 'Initials': 'Y', 'LastName': 'Machida', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Tamagawa', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Yoichi', 'Initials': 'Y', 'LastName': 'Takimoto', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Ueda', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Tadashi', 'Initials': 'T', 'LastName': 'Katayama', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Shintaro', 'Initials': 'S', 'LastName': 'Kawasaki', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Misako', 'Initials': 'M', 'LastName': 'Matsushita', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Seino', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Seiichiro', 'Initials': 'S', 'LastName': 'Fukuhara', 'Affiliation': 'Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Takanori', 'Initials': 'T', 'LastName': 'Kanai', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address: takagast@z2.keio.jp.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110724'] 317,32270208,Invited Response on: Mastopexy with Autologous Augmentation in Women After Massive Weight Loss-A Randomized Clinical Trial.,,2020,,['Women'],['Mastopexy with Autologous Augmentation'],[],"[{'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0191918', 'cui_str': 'Fixation of pendulous breast'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}]",[],,0.0942726,,"[{'ForeName': 'Peder', 'Initials': 'P', 'LastName': 'Ikander', 'Affiliation': 'Research Unit for Plastic Surgery, Odense University Hospital, Odense, Denmark. peder.ikander@gmail.com.'}, {'ForeName': 'Jens A', 'Initials': 'JA', 'LastName': 'Sørensen', 'Affiliation': 'Research Unit for Plastic Surgery, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Jørn B', 'Initials': 'JB', 'LastName': 'Thomsen', 'Affiliation': 'Research Unit for Plastic Surgery, Odense University Hospital, Odense, Denmark.'}]",Aesthetic plastic surgery,['10.1007/s00266-020-01697-z'] 318,30911113,"Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.","Telomere length in chronic lymphocytic leukemia (CLL) has been shown to be of prognostic importance, but the analyses have largely been executed on heterogeneous patient cohorts outside of clinical trials. In the present study, we performed a comprehensive analysis of telomere length associations in the well characterized CLL8 trial (n = 620) of the German CLL study group, with validation in a representative cohort of the CLL4 trial (n = 293). Absolute telomere length was analyzed using quantitative-PCR. Apart from identifying associations of short telomere length with adverse prognostic factors and survival, the study identified cases with 17p- and 11q- associated with TP53 and ATM loss, respectively, to have the shortest telomeres, even when these aberrations were present in small subclones. Thus, telomere shortening may precede acquisition of the high-risk aberrations, contributing to disease evolution. In line with this, telomere shortening was associated with an increase in genomic complexity as well as clonal evolution, highlighting its importance as a biomarker especially in monitoring disease progression in non-high-risk CLL.",2019,"In line with this, telomere shortening was associated with an increase in genomic complexity as well as clonal evolution, highlighting its importance as a biomarker especially in monitoring disease progression in non-high-risk CLL.","['well characterized CLL8 trial (n\u2009=\u2009620) of the German CLL study group, with validation in a representative cohort of the CLL4 trial (n\u2009=\u2009293', 'chronic lymphocytic leukemia (CLL', 'chronic lymphocytic leukemia']",[],"['TP53 and ATM loss', 'Absolute telomere length', 'genomic complexity']","[{'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C4708788', 'cui_str': '620'}, {'cui': 'C1556085', 'cui_str': 'Germans (ethnic group)'}, {'cui': 'C0023434', 'cui_str': 'Lymphoma, Small Lymphocytic'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]",[],"[{'cui': 'C0678214', 'cui_str': 'atmosphere (qualifier value)'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0085187'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0887950', 'cui_str': 'Genomics'}]",,0.0234911,"In line with this, telomere shortening was associated with an increase in genomic complexity as well as clonal evolution, highlighting its importance as a biomarker especially in monitoring disease progression in non-high-risk CLL.","[{'ForeName': 'Billy Michael Chelliah', 'Initials': 'BMC', 'LastName': 'Jebaraj', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany.'}, {'ForeName': 'Eugen', 'Initials': 'E', 'LastName': 'Tausch', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany.'}, {'ForeName': 'Dan A', 'Initials': 'DA', 'LastName': 'Landau', 'Affiliation': 'Department of Medicine, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Jasmin', 'Initials': 'J', 'LastName': 'Bahlo', 'Affiliation': 'Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Robrecht', 'Affiliation': 'Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Amaro N', 'Initials': 'AN', 'LastName': 'Taylor-Weiner', 'Affiliation': 'Broad Institute, Cambridge, MA, USA.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Bloehdorn', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany.'}, {'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Scheffold', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Mertens', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Böttcher', 'Affiliation': 'Department II of Internal Medicine, University Hospital of Schleswig-Holstein, Kiel, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kneba', 'Affiliation': 'Department II of Internal Medicine, University Hospital of Schleswig-Holstein, Kiel, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Jäger', 'Affiliation': 'Department of Medicine I, Division of Hematology and Hemostaeology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Thorsten', 'Initials': 'T', 'LastName': 'Zenz', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Wenger', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Guenter', 'Initials': 'G', 'LastName': 'Fingerle-Rowson', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Clemens', 'Initials': 'C', 'LastName': 'Wendtner', 'Affiliation': 'Klinikum Schwabing, Academic Teaching Hospital of University of Munich, Munich, Germany.'}, {'ForeName': 'Anna-Maria', 'Initials': 'AM', 'LastName': 'Fink', 'Affiliation': 'Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Catherine J', 'Initials': 'CJ', 'LastName': 'Wu', 'Affiliation': 'Broad Institute, Cambridge, MA, USA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Eichhorst', 'Affiliation': 'Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Fischer', 'Affiliation': 'Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hallek', 'Affiliation': 'Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Döhner', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Stilgenbauer', 'Affiliation': 'Department of Internal Medicine III, Ulm University, Ulm, Germany. stephan.stilgenbauer@uniklinik-ulm.de.'}]",Leukemia,['10.1038/s41375-019-0446-4'] 319,31238370,Effects of Sustained Inflation or Positive Pressure Ventilation on the Release of Adrenomedullin in Preterm Infants with Respiratory Failure at Birth.,"OBJECTIVE Delivery room (DR) management may play an important role in the development and prevention of lung injury. Therefore, in a cohort of low birth weight infants (LBW), we investigated the effects of two different lung recruitment maneuvers, such as positive pressure ventilation (PPV) and sustained inflation (SI) on adrenomedullin (AM), a well-established lung-specific vasoactive agent. STUDY DESIGN This is a prospective case-control randomized study in 44 LBW infants spontaneously breathing with respiratory failure at birth requiring respiratory support. LBW were randomized to receive PPV ( n  = 22) or SI ( n  = 22) support. AM was measured from blood in samples collected at birth from arterial artery (BLT0) and at 1-hour (BLT1) and at 24-hour (BLT2) from peripheral venous site. AM assessment in urine samples was performed at 1-hour (URT1) and at 24-hour (URT2). RESULTS No significant differences in AM ( p  > 0.05) blood (T0-T2) and urine (T1, T2) levels were observed between groups. CONCLUSION The present data, showing the absence of any differences in AM blood and urine levels, suggest that PPV and SI are both feasible and equally effective DR maneuvers. The findings open the way to further studies evaluating the effects of PPV and SI on short-/long-term respiratory outcome through biomarkers assessment.",2019,"No significant differences in AM ( p  > 0.05) blood (T0-T2) and urine (T1, T2) levels were observed between groups. ","['44 LBW infants spontaneously breathing with respiratory failure at birth requiring respiratory support', 'low birth weight infants (LBW', 'Preterm Infants with Respiratory Failure at Birth']","['PPV and SI', 'PPV', 'Sustained Inflation or Positive Pressure Ventilation']","['positive pressure ventilation (PPV) and sustained inflation (SI) on adrenomedullin (AM', 'blood (T0-T2) and urine (T1, T2) levels', 'AM', 'AM blood and urine levels']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C3889105', 'cui_str': 'Respiratory failure (SMQ)'}, {'cui': 'C1744681', 'cui_str': 'Congenital (qualifier value)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0021288', 'cui_str': 'Low Birth Weight Infant'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}]","[{'cui': 'C1318493', 'cui_str': 'Inflation'}, {'cui': 'C3266857', 'cui_str': 'Positive-Pressure Ventilation'}]","[{'cui': 'C3266857', 'cui_str': 'Positive-Pressure Ventilation'}, {'cui': 'C0443318', 'cui_str': 'Sustained (qualifier value)'}, {'cui': 'C1318493', 'cui_str': 'Inflation'}, {'cui': 'C0215825', 'cui_str': 'Adrenomedullin (1-52)'}, {'cui': 'C0005768'}, {'cui': 'C0042037'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",44.0,0.0347267,"No significant differences in AM ( p  > 0.05) blood (T0-T2) and urine (T1, T2) levels were observed between groups. ","[{'ForeName': 'Azzurra', 'Initials': 'A', 'LastName': 'La Verde', 'Affiliation': ""Neonatal Intensive Care Unit, V. Buzzi Children's Hospital, ASST-FBF-Sacco, Milan, Italy.""}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Franchini', 'Affiliation': ""Neonatal Intensive Care Unit, G. D'Annunzio University of Chieti, Chieti, Italy.""}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Lapergola', 'Affiliation': ""Neonatal Intensive Care Unit, G. D'Annunzio University of Chieti, Chieti, Italy.""}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Lista', 'Affiliation': ""Neonatal Intensive Care Unit, V. Buzzi Children's Hospital, ASST-FBF-Sacco, Milan, Italy.""}, {'ForeName': 'Ignazio', 'Initials': 'I', 'LastName': 'Barbagallo', 'Affiliation': 'Department of Biomedical and Biotechnological Sciences Section of Biochemistry, University of Catania, Catania, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Livolti', 'Affiliation': 'Department of Biomedical and Biotechnological Sciences Section of Biochemistry, University of Catania, Catania, Italy.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Gazzolo', 'Affiliation': ""Neonatal Intensive Care Unit, G. D'Annunzio University of Chieti, Chieti, Italy.""}]",American journal of perinatology,['10.1055/s-0039-1692133'] 320,31994767,"Construction and evaluation of multidomain attention training to improve alertness attention, sustained attention, and visual-spatial attention in older adults with mild cognitive impairment: A randomized controlled trial.","OBJECTIVES We aimed to analyze the effects of multidomain attention training on alertness, sustained attention, and visual-spatial attention in older adults with mild cognitive impairment (MCI). DESIGN The design used in this study was a two-arm, parallel group, double-blind randomized controlled trial. SETTING AND PARTICIPANTS The participants of the study were seventy-eight older adults with MCI (mean age: 79.5 ± 7.9 years) from retirement centers and community housing for the elderly. INTERVENTION The participants were randomly assigned to an experimental group (multidomain attention training, n = 39) or an active control group (n = 39). Both groups underwent training sessions for 45 minutes three times per week for 6 weeks (18 sessions in total). MEASURES The main efficacy indicator was alertness (Trail Making Test Part B), sustained attention (Digit Vigilance Test), and visual-spatial attention (Trail Making Test Part A). The secondary outcome indicators were other cognitive functions (Mini-Mental State Examination [MMSE] and Montreal Cognitive Assessment [MoCA] subscales). Measurements were obtained at pretest, posttest, and 3 and 6 months after training. RESULTS The results were analyzed by a generalized estimating equation (GEE), which indicated that attention outcomes (alertness, sustained attention, and visual-spatial attention) of the experimental group did not improve after training. However, the experimental group displayed a significant improvement in the attention, memory, and orientation of MMSE and MoCA subscales over a period of 6 months and also showed superior results compared with the control group. CONCLUSIONS Multidomain attention training demonstrated improved alertness and visual-spatial attention for posttest after 6 months. We also outline potential future advances in attention training for improving attention in older adults with MCI.",2020,"However, the experimental group displayed a significant improvement in the attention, memory, and orientation of MMSE and MoCA subscales over a period of 6 months and also showed superior results compared to the control group. ","['older adults with MCI', 'Older Adults with Mild Cognitive Impairment', 'older adults with mild cognitive impairment (MCI', 'Seventy-eight older adults with MCI (mean age: 79.5 ±\u20097.9\u2009years) from retirement centers and community housing for the elderly']","['multi-domain attention training', 'Multi-domain Attention Training', 'experimental group (multi-domain attention training, n\xa0=\xa039) or an active control group']","['alertness and visual-spatial attention', 'attention outcomes (alertness, sustained attention and visual-spatial attention', 'Alertness Attention, Sustained Attention, and Visual-Spatial Attention', 'alertness, sustained attention, and visual-spatial attention', 'alertness (Trail Making Test Part B), sustained attention (Digit Vigilance Test), and visual-spatial attention (Trail Making Test Part A', 'cognitive functions (MMSE and MoCA subscale', 'attention, memory, and orientation of MMSE and MoCA subscales']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0560005', 'cui_str': 'millicurie'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0338046', 'cui_str': 'Residential home (environment)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0085378', 'cui_str': 'Housing for the Elderly'}]","[{'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0556509', 'cui_str': 'Attention training (regime/therapy)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0589099', 'cui_str': 'Sustained attention, function (observable entity)'}, {'cui': 'C0040604', 'cui_str': 'Trail Making Test'}, {'cui': 'C0582802', 'cui_str': 'Digit'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0029266', 'cui_str': 'Cognitive Orientation'}]",78.0,0.111278,"However, the experimental group displayed a significant improvement in the attention, memory, and orientation of MMSE and MoCA subscales over a period of 6 months and also showed superior results compared to the control group. ","[{'ForeName': 'Hui-Ling', 'Initials': 'HL', 'LastName': 'Yang', 'Affiliation': 'Post-Baccalaureate Program in Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Hsin', 'Initials': 'H', 'LastName': 'Chu', 'Affiliation': 'Institute of Aerospace and Undersea Medicine, School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Ching-Chiu', 'Initials': 'CC', 'LastName': 'Kao', 'Affiliation': 'School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Nae-Fang', 'Initials': 'NF', 'LastName': 'Miao', 'Affiliation': 'Post-Baccalaureate Program in Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Pi-Chen', 'Initials': 'PC', 'LastName': 'Chang', 'Affiliation': 'School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Tseng', 'Affiliation': 'Graduate Institute of Humanities in Medicine, Taipei Medical University, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Anthony Paul', 'Initials': 'AP', 'LastName': ""O'Brien"", 'Affiliation': 'School of Nursing and Midwifery, Faculty of Health and Medicine, The University of Newcastle (UoN), Newcastle, New South Wales, Australia.'}, {'ForeName': 'Kuei-Ru', 'Initials': 'KR', 'LastName': 'Chou', 'Affiliation': 'School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan, Republic of China.'}]",International journal of geriatric psychiatry,['10.1002/gps.5269'] 321,32105715,Prior and Perioperative Revascularization Does Not Affect Survival in Lung Transplant Patients.,"BACKGROUND Coronary artery disease is common in lung transplant patients and has historically been viewed as a contraindication to the procedure. Although this mindset is changing, the effect of prior or perioperative revascularization on lung transplant survival outcomes is not adequately established. METHODS We performed a single-center retrospective analysis of all single and double lung transplant patients from 2012 to 2018 (n = 468). Patients were split into 4 groups: (1) patients who received a preoperative percutaneous coronary intervention (n = 34), (2) those who received coronary artery bypass grafting (CABG) before transplantation (n = 25), (3) those that received concomitant CABG during transplantation (n = 29), and (4) those who had lung transplantation with no need for revascularization (n = 380). Groups were compared for demographics, surgical procedure, and survival outcomes. RESULTS The no-revascularization group was statistically younger than the rest (P = .001). The lung allocation score trended toward being higher in the concomitant coronary artery bypass group (P = .03). All groups were predominantly diagnosed with idiopathic pulmonary fibrosis. The proportion of patients with chronic obstructive pulmonary disease was greatest in the group not requiring revascularization (P = .001). Patients with previous CABG were more likely to receive a single lung transplant than a double one (21 versus 4; P = .054). Length of stay, posttransplant survival, and postoperative adverse events were similar among all groups. CONCLUSIONS Results suggest that preoperative or intraoperative revascularization does not negatively affect survival in lung transplant patients; lung recipients with coronary artery disease have comparable survival when adequately revascularized.",2020,The proportion of patients with COPD was greatest in the group not requiring revascularization (p=0.001).,"['Patients with previous coronary artery bypass grafting', 'lung transplant patients', 'n=25), 3) patients that received', 'lung transplant patients; lung recipients with coronary artery disease', 'n=34), 2) patients that received', 'n=29), and 4) patients that had lung transplantation with no need for revascularization (n=380', 'lung transplant patients from 2012-2018 (n=468']","['concomitant coronary artery bypass grafting during transplantation', 'coronary artery bypass grafting prior to transplantation', 'pre-operative PCI']","['proportion of patients with COPD', 'demographics, surgical procedure, and survival outcomes', 'Length of stay, post-transplant survival, and postoperative adverse events', 'lung allocation score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0010055', 'cui_str': 'Coronary Artery Bypass Grafting'}, {'cui': 'C0024128', 'cui_str': 'Grafting, Lung'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C1956346', 'cui_str': 'Coronary Artery Disease'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}]","[{'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0010055', 'cui_str': 'Coronary Artery Bypass Grafting'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0332835', 'cui_str': 'Grafts'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4720844', 'cui_str': 'Lung allocation score'}]",2.0,0.0365361,The proportion of patients with COPD was greatest in the group not requiring revascularization (p=0.001).,"[{'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Kanaparthi', 'Affiliation': 'Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania; Division of Cardiothoracic Surgery, University of Kentucky, Lexington, Kentucky.'}, {'ForeName': 'Mohammed A', 'Initials': 'MA', 'LastName': 'Kashem', 'Affiliation': 'Division of Cardiovascular Surgery, Temple University Medical Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Manish', 'Initials': 'M', 'LastName': 'Suryapalam', 'Affiliation': 'Department of Biology, Temple University, Philadelphia, Pennsylvania.'}, {'ForeName': 'Huaqing', 'Initials': 'H', 'LastName': 'Zhao', 'Affiliation': 'Division of Cardiovascular Surgery, Temple University Medical Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Stacey', 'Initials': 'S', 'LastName': 'Brann', 'Affiliation': 'Division of Cardiovascular Surgery, Temple University Medical Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Eros', 'Initials': 'E', 'LastName': 'Leotta', 'Affiliation': 'Division of Cardiovascular Surgery, Temple University Medical Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Minakata', 'Affiliation': 'Division of Cardiovascular Surgery, Temple University Medical Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Suresh', 'Initials': 'S', 'LastName': 'Keshavamurthy', 'Affiliation': 'Division of Cardiothoracic Surgery, University of Kentucky, Lexington, Kentucky.'}, {'ForeName': 'Norihisa', 'Initials': 'N', 'LastName': 'Shigemura', 'Affiliation': 'Division of Cardiovascular Surgery, Temple University Medical Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Yoshiya', 'Initials': 'Y', 'LastName': 'Toyoda', 'Affiliation': 'Division of Cardiovascular Surgery, Temple University Medical Center, Philadelphia, Pennsylvania. Electronic address: yoshiya.toyoda@tuhs.temple.edu.'}]",The Annals of thoracic surgery,['10.1016/j.athoracsur.2020.01.016'] 322,32270632,[Midnight-noon ebb-flow acupuncture combined with rehabilitation therapy for severe craniocerebral trauma patients with vegetative state: a randomized controlled trial].,"OBJECTIVE To compare the clinical therapeutic effect of midnight-noon ebb-flow acupuncture combined with rehabilitation therapy and simple rehabilitation therapy in severe craniocerebral trauma patients with vegetative state. METHODS A total of 100 patients were randomized into an observation group and a control group, 50 cases in each one. Basic treatment of medication, hyperbaric oxygen therapy and specialized nursing were given in both groups. In the control group, rehabilitation therapy was adopted for 30 min each time, once a day. On the basis of the control group, midnight-noon ebb-flow acupuncture was applied in the observation group, the needles were sustained for 30 min, once a day, 5 times a week. The treatment was for 30 days in both groups. Before treatment and after 10, 20, 30 days of treatment, scores of Glasgow coma scale (GCS) and coma recovery scale-revised (CRS-R) were observed, and the conscious rate after treatment was calculated in both groups. RESULTS Compared before treatment, the GCS and CRS-R scores after 10, 20, 30 days of treatment were increased in both groups ( P <0.01), and the scores in the observation group were superior to those in the control group ( P <0.01). After treatment, the conscious rate was 20.0% (10/50) in the observation group, which was superior to 12.0% (6/50) in the control group ( P <0.01). CONCLUSION Midnight-noon ebb-flow acupuncture combined with rehabilitation therapy can effectively treat the severe craniocerebral trauma patients with vegetative state, improve the consciousness level, and have superior therapeutic effect compared with simple rehabilitation therapy.",2020,"Compared before treatment, the GCS and CRS-R scores after 10, 20, 30 days of treatment were increased in both groups ( P <0.01), and the scores in the observation group were superior to those in the control group ( P <0.01).","['100 patients', 'severe craniocerebral trauma patients with vegetative state']","['rehabilitation therapy', 'hyperbaric oxygen therapy and specialized nursing', 'Midnight-noon ebb-flow acupuncture combined with rehabilitation therapy', 'midnight-noon ebb-flow acupuncture combined with rehabilitation therapy and simple rehabilitation therapy']","['conscious rate', 'scores of Glasgow coma scale (GCS) and coma recovery scale-revised (CRS-R', 'GCS and CRS-R scores']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018674', 'cui_str': 'Injury of head'}, {'cui': 'C0917808', 'cui_str': 'Vegetative State'}]","[{'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0020431', 'cui_str': 'Hyperbaric oxygen therapy'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0332172', 'cui_str': 'Midnight'}, {'cui': 'C0585020', 'cui_str': 'Noon'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205352', 'cui_str': 'Simple'}]","[{'cui': 'C0234421', 'cui_str': 'Consciousness'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0017594', 'cui_str': 'Glasgow coma scale'}, {'cui': 'C0009421', 'cui_str': 'Coma'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0010278', 'cui_str': 'Craniosynostosis syndrome'}, {'cui': 'C1522376', 'cui_str': 'GCLC protein, human'}]",100.0,0.0397452,"Compared before treatment, the GCS and CRS-R scores after 10, 20, 30 days of treatment were increased in both groups ( P <0.01), and the scores in the observation group were superior to those in the control group ( P <0.01).","[{'ForeName': 'Ying-Cun', 'Initials': 'YC', 'LastName': 'Bao', 'Affiliation': 'Department of Rehabilitation, Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Zhang', 'Affiliation': 'Department of Rehabilitation, Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China.'}, {'ForeName': 'Qun', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Rehabilitation, Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': 'Department of Rehabilitation, Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China.'}, {'ForeName': 'Xiao-Rong', 'Initials': 'XR', 'LastName': 'Cheng', 'Affiliation': 'Department of Rehabilitation, Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China.'}, {'ForeName': 'Yi-Bao', 'Initials': 'YB', 'LastName': 'Zhang', 'Affiliation': 'Department of Rehabilitation, Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Qiu', 'Affiliation': 'Department of Rehabilitation, Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20191028-k0001'] 323,32270633,[Effect of electroacupuncture on diaphragmatic function in patients with post-stroke tracheotomy].,"OBJECTIVE To observe the effect of electroacupuncture (EA) on diaphragmatic function based on conventional treatment in patients with post - stroke tracheotomy tube. METHODS A total of 70 patients were randomized into an observation group (35 cases) and a control group (34 cases, 1 case dropped off). Internal medical basic treatment and breathing training were given in both groups. Besides, Xingnao Kaiqiao acupuncture was applied at Neiguan (PC 6), Shuigou (GV 26), Sanyinjiao (SP 6), Jiquan (HT 1), Chize (LU 5) and Weizhong (BL 40) in the control group, the needles were sustained for 30 min. On the basis of treatment in the control group, EA was applied at Tianding (LI 17), Fengchi (GB 20) and Jiaji (EX - B 2, C 3 -C 5 ) in the observation group, with continuous wave, 10-20 Hz, 30 min each time. The treatment was given once a day, 6 times a week for 4 weeks in both groups. Before and after treatment, the diaphragmatic motility was measured by SonoSite ultrasound system (M-Turbo) in the two groups. RESULTS Compared before treatment, the diaphragmatic motility after treatment was increased in both groups ( P <0.01), and the improvement in the observation group was superior to the control group ( P <0.01). CONCLUSION Electroacupuncture can promote the recovery of diaphragmatic function in patients with post-stroke tracheotomy tube.",2020,"Compared before treatment, the diaphragmatic motility after treatment was increased in both groups ( P <0.01), and the improvement in the observation group was superior to the control group ( P <0.01). ","['patients with post - stroke tracheotomy tube', 'patients with post-stroke tracheotomy', 'patients with post-stroke tracheotomy tube', '70 patients']","['Internal medical basic treatment and breathing training', 'electroacupuncture (EA', 'electroacupuncture', 'Electroacupuncture']","['diaphragmatic motility', 'recovery of diaphragmatic function', 'diaphragmatic function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0040590', 'cui_str': 'Tracheostomy'}, {'cui': 'C0175730', 'cui_str': 'Tube'}]","[{'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}]","[{'cui': 'C0011980', 'cui_str': 'Diaphragm structure'}, {'cui': 'C0007608', 'cui_str': 'Motility, Cell'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",70.0,0.0162401,"Compared before treatment, the diaphragmatic motility after treatment was increased in both groups ( P <0.01), and the improvement in the observation group was superior to the control group ( P <0.01). ","[{'ForeName': 'Ming-Yue', 'Initials': 'MY', 'LastName': 'Zhu', 'Affiliation': 'Fifth Clinical Medical College, Guangzhou University of CM, Guangzhou 510095, Guangdong Province, China.'}, {'ForeName': 'Xing-Qing', 'Initials': 'XQ', 'LastName': 'Chen', 'Affiliation': 'Fifth Clinical Medical College, Guangzhou University of CM, Guangzhou 510095, Guangdong Province, China.'}, {'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Huang', 'Affiliation': 'Department of Acupuncture-Moxibustion and Rehabilitation, Guangdong Second TCM Hospital, Guangzhou 510095.'}, {'ForeName': 'Yan-Xia', 'Initials': 'YX', 'LastName': 'Peng', 'Affiliation': 'Fifth Clinical Medical College, Guangzhou University of CM, Guangzhou 510095, Guangdong Province, China.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190408-0005'] 324,32270634,[Effect of transcutaneous electrical acupoint stimulation on postoperative olfactory memory disorder and plasma melatonin in patients with general anesthesia of sevoflurane].,"OBJECTIVE To observe the effect of transcutaneous electrical acupoint stimulation (TEAS) on postoperative olfactory memory disorder in patients with general anesthesia of sevoflurane and to explore its possible mechanism. METHODS Forty patients who were scheduled to have gynecological and urological procedures under general anesthesia were randomly divided into an observation group and a control group, 20 cases in each group. The patients in the observation group were treated with TEAS (dilatational wave, 2 Hz/100 Hz) at Yingxiang (LI 20) and Yintang (GV 29) 10 min before anesthesia induction until the end of operation; the patients in the control group received general anesthesia directly. The changes of mean arterial pressure (MAP), heart rate (HR) and blood oxygen saturation (SpO 2 ) were recorded before treatment, 30 min after operation and at the end of operation; smell identification score was measured by Connecticut Chemosensory Clinical Research Center (CCCRC) olfactory test before treatment (T 0 ) and when Aldrete recovery score reached 10 points at the end of anesthesia (T 1 ); the concentration of melatonin in plasma was measured by ELISA method in the two groups. RESULTS The between-group differences and within-group differences of MAP, HR and SpO 2 were not significant at each time point ( P >0.05). Compared with T 0 , the score of smell identification and plasma concentration of melatonin were not significantly different at T 1 in the observation group ( P >0.05), however, the score of smell identification and plasma concentration of melatonin were reduced in the control group ( P <0.05). At T 1 , the score of smell identification and plasma concentration of melatonin in the observation group were higher than those in the control group ( P <0.05). CONCLUSION TEAS could improve the postoperative olfactory memory disorder in patients with general anesthesia of sevoflurane, and its mechanism may be related to the increase of plasma concentration of melatonin.",2020,"Compared with T 0 , the score of smell identification and plasma concentration of melatonin were not significantly different at T 1 in the observation group ( P >0.05), however, the score of smell identification and plasma concentration of melatonin were reduced in the control group ( P <0.05).","['patients with general anesthesia of sevoflurane', 'patients with general anesthesia of', 'Forty patients who were scheduled to have gynecological and urological procedures under general anesthesia']","['transcutaneous electrical acupoint stimulation (TEAS', 'TEAS (dilatational wave, 2 Hz/100 Hz) at Yingxiang (LI 20) and Yintang (GV 29) 10 min before anesthesia induction until the end of operation; the patients in the control group received general anesthesia directly', 'transcutaneous electrical acupoint stimulation', 'TEAS', 'sevoflurane']","['score of smell identification and plasma concentration of melatonin', 'postoperative olfactory memory disorder', 'MAP, HR and SpO 2', 'concentration of melatonin in plasma', 'mean arterial pressure (MAP), heart rate (HR) and blood oxygen saturation (SpO 2 ', 'Connecticut Chemosensory Clinical Research Center (CCCRC) olfactory test']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0018417', 'cui_str': 'Gynecology'}, {'cui': 'C3653764', 'cui_str': 'UROLOGICALS'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}]","[{'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0039400', 'cui_str': 'Tea'}, {'cui': 'C4721445', 'cui_str': 'Teasing'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0450834', 'cui_str': 'Yintang'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0473960', 'cui_str': 'Induction of general anesthesia'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0037361', 'cui_str': 'Sense of smell, function'}, {'cui': 'C0020792', 'cui_str': 'Identification - mental defense mechanism'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0025261', 'cui_str': 'Retention Disorders, Cognitive'}, {'cui': 'C0024779', 'cui_str': 'Maps'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0428174', 'cui_str': 'Hemoglobin saturation with oxygen'}, {'cui': 'C0009778', 'cui_str': 'Connecticut'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0430621', 'cui_str': 'Olfaction test'}]",40.0,0.0410453,"Compared with T 0 , the score of smell identification and plasma concentration of melatonin were not significantly different at T 1 in the observation group ( P >0.05), however, the score of smell identification and plasma concentration of melatonin were reduced in the control group ( P <0.05).","[{'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': ""Department of Anesthesiology, Third People's Hospital of Guizhou Province, Guiyang 550008, China.""}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Gao', 'Affiliation': 'Department of Anesthesiology, Third Affiliated Hospital of Guizhou Medical University, Duyun 558000.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Cao', 'Affiliation': ""Department of Anesthesiology, Second People's Hospital of Guiyang City.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, Third Affiliated Hospital of Guizhou Medical University, Duyun 558000.'}, {'ForeName': 'Yi-Min', 'Initials': 'YM', 'LastName': 'Ren', 'Affiliation': 'Department of Anesthesiology, Third Affiliated Hospital of Guizhou Medical University, Duyun 558000.'}, {'ForeName': 'Te', 'Initials': 'T', 'LastName': 'Xi', 'Affiliation': ""Department of Anesthesiology, Third People's Hospital of Guizhou Province, Guiyang 550008, China.""}, {'ForeName': 'Hua-Lin', 'Initials': 'HL', 'LastName': 'Gao', 'Affiliation': ""Department of Anesthesiology, Third People's Hospital of Guizhou Province, Guiyang 550008, China.""}, {'ForeName': 'An-Qi', 'Initials': 'AQ', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology, Third People's Hospital of Guizhou Province, Guiyang 550008, China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, Third Affiliated Hospital of Guizhou Medical University, Duyun 558000.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190326-k0010'] 325,32270635,[Stiletto needle combined with massotherapy for pain in patients with knee osteoarthritis].,"OBJECTIVE To compare the clinical effect between Stiletto needle combined with massotherapy and articular injection of sodium hyaluronate for pain in patients with knee osteoarthritis (KOA). METHODS A total of 156 patients with KOA were randomly divided into an observation group and a control group, 78 cases in each group. The patients in the observation group were treated with Stiletto needle (once a week) combined with massotherapy (twice a week); the patients in the control group were treated with articular injection of sodium hyaluronate (once a week). The treatment period were 5 weeks in total. The visual analogue scale (VAS) score, local tenderness value, knee joint activity and Lysholm knee joint score were recorded before treatment, 3 weeks and 5 weeks of treatment. RESULTS Compared before treatment, the VAS score, local tenderness value, knee joint activity and Lysholm knee joint score in the two groups were improved 5 weeks of treatment ( P <0.05). After 5 weeks of treatment, The local tenderness value and Lysholm knee joint score in the observation group were significantly improved compared with the control group ( P <0.05), but the knee joint activity in the control group was superior to that in the observation group ( P <0.05). CONCLUSION The Stiletto needle combined with massotherapy are superior to articular injection of sodium hyaluronate in relieving pain and improving knee joint function in patients with early-to-moderate KOA, but its effect on joint activity is inferior to sodium hyaluronate.",2020,"The Stiletto needle combined with massotherapy are superior to articular injection of sodium hyaluronate in relieving pain and improving knee joint function in patients with early-to-moderate KOA, but its effect on joint activity is inferior to sodium hyaluronate.","['patients with knee osteoarthritis (KOA', 'patients with knee osteoarthritis', 'patients with early-to-moderate KOA', '156 patients with KOA']","['articular injection of sodium hyaluronate', 'Stiletto needle (once a week) combined with massotherapy', 'sodium hyaluronate', 'Stiletto needle combined with massotherapy and articular injection of sodium hyaluronate', 'Stiletto needle combined with massotherapy']","['knee joint function', 'knee joint activity', 'visual analogue scale (VAS) score, local tenderness value, knee joint activity and Lysholm knee joint score', 'local tenderness value and Lysholm knee joint score', 'VAS score, local tenderness value, knee joint activity and Lysholm knee joint score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}]","[{'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0087000', 'cui_str': 'Hyaluronate sodium'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0558293', 'cui_str': 'Once a week'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0022745', 'cui_str': 'Knee joint structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0234233', 'cui_str': 'Soreness'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",156.0,0.0118812,"The Stiletto needle combined with massotherapy are superior to articular injection of sodium hyaluronate in relieving pain and improving knee joint function in patients with early-to-moderate KOA, but its effect on joint activity is inferior to sodium hyaluronate.","[{'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Department of Orthopedics, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Wu', 'Affiliation': 'Department of Orthopedics, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China.'}, {'ForeName': 'Yan-Fei', 'Initials': 'YF', 'LastName': 'Chen', 'Affiliation': ""Department of Orthopedics, Honghui Hospital of Xi'an Jiaotong University, Xi'an 710054, Shaanxi Province.""}, {'ForeName': 'Wei-Kai', 'Initials': 'WK', 'LastName': 'Qin', 'Affiliation': 'Department of Orthopedics, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China.'}, {'ForeName': 'Yuan-Hao', 'Initials': 'YH', 'LastName': 'Li', 'Affiliation': 'Department of Orthopedics, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China.'}, {'ForeName': 'Jun-Yu', 'Initials': 'JY', 'LastName': 'Wei', 'Affiliation': 'Department of Orthopedics, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China.'}, {'ForeName': 'Cheng-Zhi', 'Initials': 'CZ', 'LastName': 'Hou', 'Affiliation': 'Department of Orthopedics, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China.'}, {'ForeName': 'Yong-Li', 'Initials': 'YL', 'LastName': 'Dong', 'Affiliation': 'Department of Orthopedics, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190225-0005'] 326,31679677,"Acute Achilles Tendon Ruptures: Efficacy of Conservative and Surgical (Percutaneous, Open) Treatment-A Randomized, Controlled, Clinical Trial.","There is controversy regarding the best treatment for acute ruptures of the Achilles tendon. Multiple treatments present good results in the short and long term, none being superior to the other if a protocol of rehabilitation with full early weightbearing rehabilitation is followed. The objective of this study was to provide evidence on the efficacy and safety of conservative or surgical (percutaneous or open) treatment for acute Achilles tendon rupture. A randomized, controlled, parallel-groups, pilot clinical trial was performed in patients aged ≥18 years who arrived at the emergency room of our center experiencing acute Achilles tendon rupture. Patients were randomized via a computer-generated list to receive 1 of 3 treatments (conservative, percutaneous surgery, or open surgery). All patients followed the same protocol of rehabilitation with early weightbearing. A responder (i.e., successful treatment) was defined as capable of standing heelrise mono- and bipodally for 3 seconds, having a pain score ≤2 (verbal numerical rating scale) after walking, and having returned to active previous life (sport) at 1-year follow-up. From 2014 to 2017, 34 consecutive patients (median age, 41 years [range 18 to 59]; 32 male [94%]) were included: 11 conservative treatment, 11 percutaneous surgery, and 12 open surgery. At 1-year follow-up, the proportion of responders was 100% (11/11, 95% confidence interval [CI] 74% to 100%), 82% (9/11, 95% CI 52% to 95%), and 83% (10/12, 95% CI 55% to 95%), respectively. There was no case of total rerupture. Similar efficacy was found for conservative, percutaneous, and open surgery treatments for acute Achilles tendon rupture at 1-year follow-up with an early weightbearing rehabilitation program.",2019,"Similar efficacy was found for conservative, percutaneous, and open surgery treatments for acute Achilles tendon rupture at 1-year follow-up with an early weightbearing rehabilitation program.","['patients aged ≥18 years who arrived at the emergency room of our center experiencing acute Achilles tendon rupture', 'acute Achilles tendon rupture', 'Acute Achilles Tendon Ruptures', 'From 2014 to 2017, 34 consecutive patients (median age, 41 years [range 18 to 59]; 32 male [94%]) were included: 11 conservative treatment, 11 percutaneous surgery, and 12 open surgery']","['computer-generated list to receive 1 of 3 treatments (conservative, percutaneous surgery, or open surgery', 'conservative or surgical (percutaneous or open) treatment', 'Conservative and Surgical (Percutaneous, Open']","['efficacy and safety', 'total rerupture', 'pain score ≤2 (verbal numerical rating scale']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0263970', 'cui_str': 'Rupture of Achilles tendon'}, {'cui': 'C0151937', 'cui_str': 'Traumatic rupture of tendon'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0459914', 'cui_str': 'Conservative Management'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach - access (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0348025', 'cui_str': 'Open approach - access (qualifier value)'}]","[{'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach - access (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0348025', 'cui_str': 'Open approach - access (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0222045'}]",34.0,0.106292,"Similar efficacy was found for conservative, percutaneous, and open surgery treatments for acute Achilles tendon rupture at 1-year follow-up with an early weightbearing rehabilitation program.","[{'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Manent', 'Affiliation': 'Surgeon, Orthopaedic and Trauma Surgery Department, Hospital Consorci Sanitari Integral, Sant Joan Despí, Barcelona, Catalonia, Spain. Electronic address: amanentm@gmail.com.'}, {'ForeName': 'Laia', 'Initials': 'L', 'LastName': 'López', 'Affiliation': 'Surgeon, Orthopaedic and Trauma Surgery Department, Hospital Consorci Sanitari Integral, Sant Joan Despí, Barcelona, Catalonia, Spain.'}, {'ForeName': 'Hèctor', 'Initials': 'H', 'LastName': 'Corominas', 'Affiliation': 'Medical Doctor, Rheumatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Santamaría', 'Affiliation': 'Surgeon, Orthopaedic and Trauma Surgery Department, Hospital Consorci Sanitari Integral, Sant Joan Despí, Barcelona, Catalonia, Spain.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Domínguez', 'Affiliation': 'Surgeon, Orthopaedic and Trauma Surgery Department, Hospital Consorci Sanitari Integral, Sant Joan Despí, Barcelona, Catalonia, Spain.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Llorens', 'Affiliation': 'Surgeon, Orthopaedic and Trauma Surgery Department, Hospital Consorci Sanitari Integral, Sant Joan Despí, Barcelona, Catalonia, Spain.'}, {'ForeName': 'Miquel', 'Initials': 'M', 'LastName': 'Sales', 'Affiliation': 'Surgeon, Orthopaedic and Trauma Surgery Department, Hospital Consorci Sanitari Integral, Sant Joan Despí, Barcelona, Catalonia, Spain.'}, {'ForeName': 'Sebastián', 'Initials': 'S', 'LastName': 'Videla', 'Affiliation': ""Associate, Clinical Research Support Unit, Clinical Pharmacology Department, Bellvitge University Hospital/Bellvitge Biomedical Research Institute/University of Barcelona, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.""}]",The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons,['10.1053/j.jfas.2019.02.002'] 327,31688650,Association of Fish Oil and Physical Activity on Mobility Disability in Older Adults.,"PURPOSE This study aimed to examine whether long-term fish oil (FO) supplementation is associated with a lower risk of mobility disability and enhances benefits of physical activity (PA). METHODS A total of 1635 sedentary adults age 70 to 89 yr from the Lifestyle Interventions and Independence for Elders single-blinded randomized, multicenter clinical trial, which compared a structured PA program to a health education program. Primary outcome was incident major mobility disability (MMD), defined by loss of ability to walk 400 m, measured every 6 months for an average of 2.6 yr. Secondary outcomes included persistent mobility disability, Short Physical Performance Battery, 400-m walk speed, and grip strength. RESULTS A third of participants reported using FO at baseline (456 (28%); mean age, 78.5 yr; 70.5% women). MMD was experienced by 131 participants (28.7%) in the FO group and 405 (34.4%) participants in the nonuser group. After adjusting for confounders, FO supplementation was associated with a lower risk (HR, 0.78; 95% confidence interval (CI), 0.64-0.96) of incident MMD. However, there was no interaction (P = 0.19) between FO supplementation and PA intervention for MMD. For the secondary outcome of persistent mobility disability, the intervention association differed by supplementation (P = 0.002) with PA intervention associations of (HR, 1.36; 95% CI, 0.83-2.23) for users and (HR, 0.61; 95% CI, 0.46-0.81) for nonusers. Changes in physical performance outcomes were not modified by baseline FO supplementation or combination with PA. CONCLUSIONS FO supplementation was associated with a lower risk of MMD in low to moderate functioning older adults. However, supplementation did not enhance the benefit of PA on risk of mobility disability. These results are hypothesis generating and need to be confirmed in randomized trials.",2020,"For the secondary outcome of PMD, the intervention association differed by supplementation (P= .002) with PA intervention associations of (HR, 1.36; 95% CI, 0.83-2.23) for users and (HR, 0.61; 95% CI, 0.46-0.81) for nonusers.","['1635 sedentary adults aged 70 to 89 years from the Lifestyle Interventions and Independence for Elders (LIFE) single-blinded randomized, multi-center clinical trial', 'Older Adults']","['long-term fish oil (FO) supplementation', 'FO supplementation', 'Fish Oil and Physical Activity', 'structured physical activity (PA) program to a health education (HE) program']","['Mobility Disability', 'MMD', 'persistent mobility disability (PMD), Short Physical Performance Battery (SPPB), 400m walk speed, and grip strength', 'incident major mobility disability (MMD), defined by loss of ability to walk 400m', 'physical performance outcomes', 'lower risk of major mobility disability']","[{'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0016157', 'cui_str': 'Fish Oils'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0018701'}]","[{'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C4075461', 'cui_str': 'Short Physical Performance Battery'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C2009910', 'cui_str': 'Gait Speed'}, {'cui': 'C0429271', 'cui_str': 'Grip strength (observable entity)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0559964', 'cui_str': 'Ambulation ability'}, {'cui': 'C2607857'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}]",1635.0,0.262862,"For the secondary outcome of PMD, the intervention association differed by supplementation (P= .002) with PA intervention associations of (HR, 1.36; 95% CI, 0.83-2.23) for users and (HR, 0.61; 95% CI, 0.46-0.81) for nonusers.","[{'ForeName': 'Anoop', 'Initials': 'A', 'LastName': 'Balachandran', 'Affiliation': 'Department of Aging and Geriatric Research, College of Medicine, University of Florida, Gainesville, FL.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Gundermann', 'Affiliation': 'Department of Aging and Geriatric Research, College of Medicine, University of Florida, Gainesville, FL.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Walkup', 'Affiliation': 'Department of Biostatistical Sciences, School of Medicine, Wake Forest University, Winston-Salem, NC.'}, {'ForeName': 'Abby C', 'Initials': 'AC', 'LastName': 'King', 'Affiliation': 'School of Medicine, Stanford University, Stanford, CA.'}, {'ForeName': 'Walter T', 'Initials': 'WT', 'LastName': 'Ambrosius', 'Affiliation': 'Department of Biostatistical Sciences, School of Medicine, Wake Forest University, Winston-Salem, NC.'}, {'ForeName': 'Stephen B', 'Initials': 'SB', 'LastName': 'Kritchevsky', 'Affiliation': ""Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, Sticht Center for Healthy Aging and Alzheimer's Prevention, School of Medicine, Wake Forest University, Winston-Salem, NC.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Pahor', 'Affiliation': 'Department of Aging and Geriatric Research, College of Medicine, University of Florida, Gainesville, FL.'}, {'ForeName': 'Anne B', 'Initials': 'AB', 'LastName': 'Newman', 'Affiliation': 'Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Todd M', 'Initials': 'TM', 'LastName': 'Manini', 'Affiliation': 'Department of Aging and Geriatric Research, College of Medicine, University of Florida, Gainesville, FL.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002195'] 328,32253263,Effect of State Immunization Information System Centralized Reminder and Recall on HPV Vaccination Rates.,"BACKGROUND Although autodialer centralized reminder and recall (C-R/R) from state immunization information systems (IISs) has been shown to raise childhood vaccination rates, its impact on human papillomavirus (HPV) vaccination rates is unclear. METHODS In a 4-arm pragmatic randomized controlled trial across 2 states, we randomly selected practices representative of the specialty (pediatrics, family medicine, and health center) where children received care. Within each practice, patients 11 to 17.9 years old who had not completed their HPV vaccine series (NY: N = 30 616 in 123 practices; CO: N = 31 502 in 80 practices) were randomly assigned to receive 0, 1, 2, or 3 IIS C-R/R autodialer messages per vaccine dose. We assessed HPV vaccine receipt via the IIS, calculated intervention costs, and compared HPV vaccine series initiation and completion rates across study arms. RESULTS In New York, HPV vaccine initiation rates ranged from 37.0% to 37.4%, and completion rates were between 29.1% and 30.1%, with no significant differences across study arms. In Colorado, HPV vaccine initiation rates ranged from 31.2% to 33.5% and were slightly higher for 1 reminder compared with none, but vaccine completion rates, ranging from 27.0% to 27.8%, were similar. On adjusted analyses in Colorado, vaccine initiation rates were slightly higher for 1 and 3 C-R/R messages (adjusted risk ratios 1.07 and 1.04, respectively); completion rates were slightly higher for 1 and 3 C-R/R messages (adjusted risk ratios 1.02 and 1.03, respectively). CONCLUSIONS IIS-based C-R/R for HPV vaccination did not improve HPV vaccination rates in New York and increased vaccination rates slightly in Colorado.",2020,"In Colorado, HPV vaccine initiation rates ranged from 31.2% to 33.5% and were slightly higher for 1 reminder compared with none, but vaccine completion rates, ranging from 27.0% to 27.8%, were similar.","['2 states, we randomly selected practices representative of the specialty (pediatrics, family medicine, and health center) where children received care', 'patients 11 to 17.9 years old who had not completed their HPV vaccine series (NY: N ', '30\u2009616 in 123 practices', 'N = 31\u2009502 in 80 practices']",[],"['Colorado, vaccine initiation rates', 'completion rates', 'HPV vaccination rates', 'vaccination rates', 'HPV vaccine initiation rates', 'HPV Vaccination Rates']","[{'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0015607', 'cui_str': 'Family practice'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1444661', 'cui_str': 'Stopped before completion'}, {'cui': 'C1512511', 'cui_str': 'Human papillomavirus vaccine'}, {'cui': 'C0205549', 'cui_str': 'Series'}]",[],"[{'cui': 'C0009399', 'cui_str': 'Colorado'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C1512511', 'cui_str': 'Human papillomavirus vaccine'}]",,0.434936,"In Colorado, HPV vaccine initiation rates ranged from 31.2% to 33.5% and were slightly higher for 1 reminder compared with none, but vaccine completion rates, ranging from 27.0% to 27.8%, were similar.","[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Szilagyi', 'Affiliation': 'Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California; pszilagyi@mednet.ucla.edu.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Albertin', 'Affiliation': 'Department of Pediatrics, School of Medicine and Dentistry, University of Rochester, Rochester, New York.'}, {'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'Gurfinkel', 'Affiliation': 'Adult and Child Consortium for Health Outcomes Research and Delivery Science, School of Medicine and.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Beaty', 'Affiliation': 'Adult and Child Consortium for Health Outcomes Research and Delivery Science, School of Medicine and.'}, {'ForeName': 'Xinkai', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'Statistics Core and.'}, {'ForeName': 'Sitaram', 'Initials': 'S', 'LastName': 'Vangala', 'Affiliation': 'Statistics Core and.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Rice', 'Affiliation': 'Adult and Child Consortium for Health Outcomes Research and Delivery Science, School of Medicine and.'}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Campbell', 'Affiliation': 'Clinical Pharmacy and.'}, {'ForeName': 'Melanie D', 'Initials': 'MD', 'LastName': 'Whittington', 'Affiliation': 'Clinical Pharmacy and.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Valderrama', 'Affiliation': 'Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Breck', 'Affiliation': 'Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Roth', 'Affiliation': 'Colorado Immunization Information System, Colorado Department of Public Health and Environment, Denver, Colorado.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Meldrum', 'Affiliation': 'New York State Immunization Information System, New York State Department of Health, Albany, New York; and.'}, {'ForeName': 'Chi-Hong', 'Initials': 'CH', 'LastName': 'Tseng', 'Affiliation': 'Statistics Core and.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Rand', 'Affiliation': 'Department of Pediatrics, School of Medicine and Dentistry, University of Rochester, Rochester, New York.'}, {'ForeName': 'Sharon G', 'Initials': 'SG', 'LastName': 'Humiston', 'Affiliation': ""Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri.""}, {'ForeName': 'Stanley', 'Initials': 'S', 'LastName': 'Schaffer', 'Affiliation': 'Department of Pediatrics, School of Medicine and Dentistry, University of Rochester, Rochester, New York.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Kempe', 'Affiliation': 'Departments of Pediatrics and.'}]",Pediatrics,['10.1542/peds.2019-2689'] 329,32149863,Learning mechanisms in nocebo hyperalgesia: the role of conditioning and extinction processes.,"Nocebo hyperalgesia is a clinically relevant phenomenon and may be formed as a result of associative learning, implemented by classical conditioning. This study explored for the first time distinct nocebo conditioning methods and their consequences for nocebo attenuation methods. Healthy participants (N = 140) were recruited and randomized to the following nocebo hyperalgesia induction groups: conditioning with continuous reinforcement (CRF), conditioning with partial reinforcement (PRF), and a sham-conditioning control group. In the attenuation phase, counterconditioning was compared with extinction. During induction, participants experienced increased thermal pain in 100% of nocebo trials in the CRF groups, while in only 70% of nocebo trials in the PRF groups. During evocation, pain stimulation was equivalent across all trials. During attenuation, pain stimulation was decreased on nocebo trials relative to control trials for the counterconditioning groups, while pain remained equivalent across all trials for the extinction groups. Results showed that both PRF and CRF significantly induced nocebo hyperalgesia, but CRF was a more potent nocebo induction method, as compared to PRF. Counterconditioning was more effective than extinction in attenuating nocebo hyperalgesia. Neither CRF nor PRF resulted in resistance to extinction. However, compared with CRF, conditioning with PRF resulted in more resistance to counterconditioning. These findings demonstrate that the more ambiguous learning method of PRF can induce nocebo hyperalgesia and may potentially explain the treatment resistance and chronification seen in clinical practice. Further research is required to establish whether attenuation with counterconditioning is generalizable to clinical settings.",2020,"During attenuation, pain stimulation was decreased on nocebo trials relative to control trials for the counterconditioning groups, while pain remained equivalent across all trials for the extinction groups.","['Healthy participants (N = 140', 'nocebo hyperalgesia']","['nocebo hyperalgesia induction groups: conditioning with continuous reinforcement (CRF), conditioning with partial reinforcement (PRF), and a sham-conditioning control group', 'PRF and CRF']","['nocebo hyperalgesia', 'pain stimulation', 'thermal pain']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C3658218', 'cui_str': 'Nocebo'}, {'cui': 'C0020429', 'cui_str': 'Hyperalgesic Sensations'}]","[{'cui': 'C3658218', 'cui_str': 'Nocebo'}, {'cui': 'C0020429', 'cui_str': 'Hyperalgesic Sensations'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0035007', 'cui_str': 'Reinforcement'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0033374', 'cui_str': 'Prolactin-Releasing Peptide'}, {'cui': 'C0010132', 'cui_str': 'corticorelin'}]","[{'cui': 'C3658218', 'cui_str': 'Nocebo'}, {'cui': 'C0020429', 'cui_str': 'Hyperalgesic Sensations'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}]",140.0,0.0465884,"During attenuation, pain stimulation was decreased on nocebo trials relative to control trials for the counterconditioning groups, while pain remained equivalent across all trials for the extinction groups.","[{'ForeName': 'Mia Athina', 'Initials': 'MA', 'LastName': 'Thomaidou', 'Affiliation': 'Health, Medical and Neuropsychology Unit, Leiden University, Leiden, the Netherlands.'}, {'ForeName': 'Dieuwke Swaantje', 'Initials': 'DS', 'LastName': 'Veldhuijzen', 'Affiliation': 'Health, Medical and Neuropsychology Unit, Leiden University, Leiden, the Netherlands.'}, {'ForeName': 'Kaya Joanne', 'Initials': 'KJ', 'LastName': 'Peerdeman', 'Affiliation': 'Health, Medical and Neuropsychology Unit, Leiden University, Leiden, the Netherlands.'}, {'ForeName': 'Naomi Zoë Sifra', 'Initials': 'NZS', 'LastName': 'Wiebing', 'Affiliation': 'Health, Medical and Neuropsychology Unit, Leiden University, Leiden, the Netherlands.'}, {'ForeName': 'Joseph Sullivan', 'Initials': 'JS', 'LastName': 'Blythe', 'Affiliation': 'Health, Medical and Neuropsychology Unit, Leiden University, Leiden, the Netherlands.'}, {'ForeName': 'Andrea Walbruga Maria', 'Initials': 'AWM', 'LastName': 'Evers', 'Affiliation': 'Health, Medical and Neuropsychology Unit, Leiden University, Leiden, the Netherlands.'}]",Pain,['10.1097/j.pain.0000000000001861'] 330,29878040,nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.,"Background Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity evaluated the efficacy and safety of first-line nab-paclitaxel plus carboplatin (nab-P/C), nab-paclitaxel plus gemcitabine (nab-P/G), and gemcitabine plus carboplatin (G/C) in patients with mTNBC. Patients and methods Patients with pathologically confirmed mTNBC and no prior chemotherapy for metastatic BC received (1 : 1 : 1) nab-P 125 mg/m2 plus C AUC 2, nab-P 125 mg/m2 plus G 1000 mg/m2, or G 1000 mg/m2 plus C AUC 2, all on days 1, 8 q3w. Phase II primary end point: investigator-assessed progression-free survival (PFS); secondary end points included overall response rate (ORR), overall survival (OS), percentage of patients initiating cycle 6 with doublet therapy, and safety. Results In total, 191 patients were enrolled (nab-P/C, n = 64; nab-P/G, n = 61; G/C, n = 66). PFS was significantly longer with nab-P/C versus nab-P/G [median, 8.3 versus 5.5 months; hazard ratio (HR), 0.59 [95% CI, 0.38-0.92]; P = 0.02] or G/C (median, 8.3 versus 6.0 months; HR, 0.58 [95% CI, 0.37-0.90]; P = 0.02). OS was numerically longer with nab-P/C versus nab-P/G (median, 16.8 versus 12.1 months; HR, 0.73 [95% CI, 0.47-1.13]; P = 0.16) or G/C (median, 16.8 versus 12.6 months; HR, 0.80 [95% CI, 0.52-1.22]; P = 0.29). ORR was 73%, 39%, and 44%, respectively. In the nab-P/C, nab-P/G, and G/C groups, 64%, 56%, and 50% of patients initiated cycle 6 with a doublet. Grade ≥3 adverse events were mainly hematologic. Conclusions First-line nab-P/C was active in mTNBC and resulted in a significantly longer PFS and improved risk/benefit profile versus nab-P/G or G/C.",2018,"PFS was significantly longer with nab-P/C versus nab-P/G [median, 8.3 versus 5.5 months; hazard ratio (HR), 0.59 [95% CI, 0.38-0.92]; P = 0.02] or G/C (median, 8.3 versus 6.0 months; HR, 0.58 [95% CI, 0.37-0.90]; P = 0.02).","['patients with triple-negative metastatic breast cancer', '191 patients were enrolled (nab-P/C, n\u2009=\u200964; nab-P/G, n\u2009=\u200961; G/C, n\u2009=\u200966', 'Patients and methods\n\n\nPatients with pathologically confirmed mTNBC and no prior chemotherapy for metastatic BC received (1 : 1 : 1', 'patients with mTNBC']","['first-line nab-paclitaxel plus carboplatin (nab-P/C), nab-paclitaxel plus gemcitabine (nab-P/G), and gemcitabine plus carboplatin (G/C', '\n\n\nMetastatic triple-negative breast cancer (mTNBC', 'nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin', 'nab-P 125\u2009mg/m2 plus C AUC 2, nab-P 125\u2009mg/m2 plus G 1000\u2009mg/m2, or G 1000\u2009mg/m2 plus C AUC']","['Grade ≥3 adverse events', 'OS', 'investigator-assessed progression-free survival (PFS', 'overall response rate (ORR), overall survival (OS), percentage of patients initiating cycle 6 with doublet therapy, and safety', 'PFS', 'efficacy and safety', 'ORR']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer metastatic'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}]","[{'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C3539878', 'cui_str': 'Triple Negative Breast Cancer'}, {'cui': 'C4319551', 'cui_str': 'One hundred and twenty-five'}, {'cui': 'C1319266', 'cui_str': 'mg/sq.m'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}]","[{'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",191.0,0.131626,"PFS was significantly longer with nab-P/C versus nab-P/G [median, 8.3 versus 5.5 months; hazard ratio (HR), 0.59 [95% CI, 0.38-0.92]; P = 0.02] or G/C (median, 8.3 versus 6.0 months; HR, 0.58 [95% CI, 0.37-0.90]; P = 0.02).","[{'ForeName': 'D A', 'Initials': 'DA', 'LastName': 'Yardley', 'Affiliation': 'Sarah Cannon Research Institute and Tennessee Oncology PLLC, Medical Oncology, Nashville, USA. Electronic address: dyardley@tnonc.com.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Coleman', 'Affiliation': 'Department of Oncology and Metabolism, Weston Park Hospital, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Conte', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology, University of Padova and Medical Oncology 2, Istituto Oncologico Veneto, Padova, Italy.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Cortes', 'Affiliation': ""Medical Oncology, Ramon y Cajal University Hospital, Madrid; Vall d'Hebron Institute of Oncology, Barcelona, Spain.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Brufsky', 'Affiliation': 'Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Shtivelband', 'Affiliation': 'Medical Oncology, Ironwood Physicians, PC, Chandler, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Young', 'Affiliation': 'Medical Oncology, The Center for Cancer and Blood Disorders, Fort Worth, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Bengala', 'Affiliation': 'Medical Oncology, Misericordia General Hospital, Grosseto, Italy.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Ali', 'Affiliation': 'Medical Oncology, Henry Ford Health System, Detroit, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Eakel', 'Affiliation': 'Hematology and Oncology, Florida Cancer Specialists, Sarasota, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Schneeweiss', 'Affiliation': 'Gynecology and Medical Oncology, Heidelberg University Hospital, Heidelberg, Germany.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'de la Cruz-Merino', 'Affiliation': 'Clinical Oncology, Hospital Universitario Virgen Macarena, Seville, Spain.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Wilks', 'Affiliation': 'Hematology and Medical Oncology, Texas Oncology, San Antonio, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': ""O'Shaughnessy"", 'Affiliation': 'Hematology, Medical Oncology, Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Glück', 'Affiliation': 'GMA Early Assets, Celgene Corporation, Summit, USA.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Biostatistics, Celgene Corporation, Summit, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Miller', 'Affiliation': 'Clinical Research and Development, Hematology/Oncology, Celgene Corporation, Summit, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Barton', 'Affiliation': 'Clinical Research and Development, Hematology/Oncology, Celgene Corporation, Summit, USA.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Harbeck', 'Affiliation': 'Breast Cancer Center, University of Munich, Munich, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdy201'] 331,31894600,Neuroticism predicts fear of falling after hip fracture.,"OBJECTIVES Fear of falling (FoF) is common and associated with poorer functional outcomes after hip fracture. We sought to differentiate patterns of FoF at 4 and 12 weeks after surgical repair for hip fracture and examine predictors of FoF. METHODS/DESIGN Secondary analysis of existing data from a 52-week prospective study examining recovery after hip fracture. Participants (N = 263) were aged 60 and older with recent hip fracture recruited from eight hospitals. FoF was measured 4 and 12 weeks postfracture with the Short Falls Efficacy Scale-International. Latent class mixed models were constructed to identify distinct patterns of FoF from 4 to 12 weeks postfracture and predictors of FoF. Predictors examined included age, gender, neuroticism, depression, negative affect, perceived social support, medical comorbidity, functional ability, cognition, and pain. RESULTS Three latent classes of FoF were identified: a group with minimal FoF at weeks 4 and 12 (72%), a group with high FoF that decreased (17%), and a group with high FoF that increased from week 4 to 12 (11%). In a multivariate model, higher neuroticism was associated with greater risk for high FoF (increasing or decreasing), whereas higher premorbid medical comorbidity was associated with increasing FoF, poorer premorbid functional ability was associated with decreasing FoF, and social support was not significantly associated. CONCLUSIONS Older adults with higher neuroticism are more likely to have FoF in the first 12 weeks after a hip fracture. Screening for neuroticism in health care settings might identify individuals who would benefit from interventions to improve outcomes during recovery.",2020,"In a multivariate model, higher neuroticism was associated with greater risk for high FoF (increasing or decreasing), whereas higher premorbid medical comorbidity was associated with increasing FoF, poorer premorbid functional ability was associated with decreasing FoF, and social support was not significantly associated. ","['Participants (N = 263) were aged 60 and older with recent hip fracture recruited from eight hospitals', 'Older adults with higher neuroticism']",[],"['social support, medical comorbidity, functional ability, cognition, and pain', 'FoF, and social support', 'premorbid medical comorbidity']","[{'cui': 'C4517671', 'cui_str': '263'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0019557', 'cui_str': 'Hip Fractures'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1842981', 'cui_str': 'Neuroticism Traits'}]",[],"[{'cui': 'C0037438'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",263.0,0.0172056,"In a multivariate model, higher neuroticism was associated with greater risk for high FoF (increasing or decreasing), whereas higher premorbid medical comorbidity was associated with increasing FoF, poorer premorbid functional ability was associated with decreasing FoF, and social support was not significantly associated. ","[{'ForeName': 'Emily S', 'Initials': 'ES', 'LastName': 'Bower', 'Affiliation': 'SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, California.'}, {'ForeName': 'Julie L', 'Initials': 'JL', 'LastName': 'Wetherell', 'Affiliation': 'VA San Diego Healthcare System, University of California, San Diego, California.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Petkus', 'Affiliation': 'Department of Neurology, University of Southern California, Los Angeles, California.'}, {'ForeName': 'Eric J', 'Initials': 'EJ', 'LastName': 'Lenze', 'Affiliation': 'Healthy Mind Lab, Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri.'}]",International journal of geriatric psychiatry,['10.1002/gps.5261'] 332,31483448,Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.,"Importance The patterns of disease recurrence after resection of pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear. Objective To define patterns of recurrence after adjuvant chemotherapy and the association with survival. Design, Setting, and Participants Prospectively collected data from the phase 3 European Study Group for Pancreatic Cancer 4 adjuvant clinical trial, an international multicenter study. The study included 730 patients who had resection and adjuvant chemotherapy for pancreatic cancer. Data were analyzed between July 2017 and May 2019. Interventions Randomization to adjuvant gemcitabine or gemcitabine plus capecitabine. Main Outcomes and Measures Overall survival, recurrence, and sites of recurrence. Results Of the 730 patients, median age was 65 years (range 37-81 years), 414 were men (57%), and 316 were women (43%). The median follow-up time from randomization was 43.2 months (95% CI, 39.7-45.5 months), with overall survival from time of surgery of 27.9 months (95% CI, 24.8-29.9 months) with gemcitabine and 30.2 months (95% CI, 25.8-33.5 months) with the combination (HR, 0.81; 95% CI, 0.68-0.98; P = .03). The 5-year survival estimates were 17.1% (95% CI, 11.6%-23.5%) and 28.0% (22.0%-34.3%), respectively. Recurrence occurred in 479 patients (65.6%); another 78 patients (10.7%) died without recurrence. Local recurrence occurred at a median of 11.63 months (95% CI, 10.05-12.19 months), significantly different from those with distant recurrence with a median of 9.49 months (95% CI, 8.44-10.71 months) (HR, 1.21; 95% CI, 1.01-1.45; P = .04). Following recurrence, the median survival was 9.36 months (95% CI, 8.08-10.48 months) for local recurrence and 8.94 months (95% CI, 7.82-11.17 months) with distant recurrence (HR, 0.89; 95% CI, 0.73-1.09; P = .27). The median overall survival of patients with distant-only recurrence (23.03 months; 95% CI, 19.55-25.85 months) or local with distant recurrence (23.82 months; 95% CI, 17.48-28.32 months) was not significantly different from those with only local recurrence (24.83 months; 95% CI, 22.96-27.63 months) (P = .85 and P = .35, respectively). Gemcitabine plus capecitabine had a 21% reduction of death following recurrence compared with monotherapy (HR, 0.79; 95% CI, 0.64-0.98; P = .03). Conclusions and Relevance There were no significant differences between the time to recurrence and subsequent and overall survival between local and distant recurrence. Pancreatic cancer behaves as a systemic disease requiring effective systemic therapy after resection. Trial Registration ClinicalTrials.gov identifier: NCT00058201, EudraCT 2007-004299-38, and ISRCTN 96397434.",2019,"Conclusions and Relevance There were no significant differences between the time to recurrence and subsequent and overall survival between local and distant recurrence.","[' median age was 65 years (range 37-81 years), 414 were men (57%), and 316 were women (43', '730 patients who had resection and adjuvant chemotherapy for pancreatic cancer', 'Pancreatic Ductal Adenocarcinoma', '730 patients']","['Gemcitabine plus capecitabine', 'gemcitabine', 'gemcitabine or gemcitabine plus capecitabine']","['local recurrence', 'median overall survival', 'Measures\n\n\nOverall survival, recurrence, and sites of recurrence', 'overall survival', 'median survival', 'death following recurrence', 'local with distant recurrence', 'time to recurrence and subsequent and overall survival', 'Recurrence', 'distant recurrence', 'median follow-up time', 'Local recurrence', '5-year survival estimates']","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C4517771', 'cui_str': 'Four hundred and fourteen'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0450356', 'cui_str': '316'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0346647', 'cui_str': 'Cancer of Pancreas'}, {'cui': 'C0001418', 'cui_str': 'Adenoma, Malignant'}]","[{'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}]","[{'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C2945843', 'cui_str': 'Site of (attribute)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0443203', 'cui_str': 'Distant (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}]",730.0,0.440122,"Conclusions and Relevance There were no significant differences between the time to recurrence and subsequent and overall survival between local and distant recurrence.","[{'ForeName': 'Robert P', 'Initials': 'RP', 'LastName': 'Jones', 'Affiliation': 'The Royal Liverpool University Hospital, Liverpool, England.'}, {'ForeName': 'Eftychia-Eirini', 'Initials': 'EE', 'LastName': 'Psarelli', 'Affiliation': 'University of Liverpool, Liverpool, England.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Jackson', 'Affiliation': 'University of Liverpool, Liverpool, England.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Ghaneh', 'Affiliation': 'The Royal Liverpool University Hospital, Liverpool, England.'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Halloran', 'Affiliation': 'The Royal Liverpool University Hospital, Liverpool, England.'}, {'ForeName': 'Daniel H', 'Initials': 'DH', 'LastName': 'Palmer', 'Affiliation': 'University of Liverpool, Liverpool, England.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Campbell', 'Affiliation': 'The Royal Liverpool University Hospital, Liverpool, England.'}, {'ForeName': 'Juan W', 'Initials': 'JW', 'LastName': 'Valle', 'Affiliation': 'University of Manchester/The Christie, Manchester, England.'}, {'ForeName': 'Olusola', 'Initials': 'O', 'LastName': 'Faluyi', 'Affiliation': 'The Clatterbridge Cancer Centre, Wirral, England.'}, {'ForeName': 'Derek A', 'Initials': 'DA', 'LastName': ""O'Reilly"", 'Affiliation': 'Manchester University Foundation Trust, Manchester, England.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cunningham', 'Affiliation': 'Royal Marsden Hospital, London, England.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Wadsley', 'Affiliation': 'Weston Park Hospital, Sheffield, England.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Darby', 'Affiliation': 'Weston Park Hospital, Sheffield, England.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Meyer', 'Affiliation': 'Royal Free Hospital, London, England.'}, {'ForeName': 'Roopinder', 'Initials': 'R', 'LastName': 'Gillmore', 'Affiliation': 'Royal Free Hospital, London, England.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Anthoney', 'Affiliation': ""St. James's University Hospital, Leeds, England.""}, {'ForeName': 'Pehr', 'Initials': 'P', 'LastName': 'Lind', 'Affiliation': 'Clinical Research Sörmland, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Bengt', 'Initials': 'B', 'LastName': 'Glimelius', 'Affiliation': 'Clinical Research Sörmland, University of Uppsala, Uppsala, Sweden.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Falk', 'Affiliation': 'Bristol Haematology and Oncology Centre, Bristol, England.'}, {'ForeName': 'Jakob R', 'Initials': 'JR', 'LastName': 'Izbicki', 'Affiliation': 'University of Hamburg Medical Institutions UKE, Hamburg, Germany.'}, {'ForeName': 'Gary William', 'Initials': 'GW', 'LastName': 'Middleton', 'Affiliation': 'Royal Surrey County Hospital, Guildford, England.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Cummins', 'Affiliation': 'Royal Surrey County Hospital, Guildford, England.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Ross', 'Affiliation': ""Guy's Hospital, London, England.""}, {'ForeName': 'Harpreet', 'Initials': 'H', 'LastName': 'Wasan', 'Affiliation': 'Hammersmith Hospital, London, England.'}, {'ForeName': 'Alec', 'Initials': 'A', 'LastName': 'McDonald', 'Affiliation': 'The Beatson West of Scotland Cancer Centre, Glasgow, Scotland.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Crosby', 'Affiliation': 'Velindre Hospital, Cardiff, Wales.'}, {'ForeName': 'Yuk', 'Initials': 'Y', 'LastName': 'Ting', 'Affiliation': 'Queen Elizabeth Hospital, Birmingham, England.'}, {'ForeName': 'Kinnari', 'Initials': 'K', 'LastName': 'Patel', 'Affiliation': 'Churchill Hospital, Oxford, England.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Sherriff', 'Affiliation': 'Derriford Hospital, Plymouth, England.'}, {'ForeName': 'Rubin', 'Initials': 'R', 'LastName': 'Soomal', 'Affiliation': 'Jersey General Hospital, Jersey, England.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Borg', 'Affiliation': 'Skåne University Hospital, Lund, Sweden.'}, {'ForeName': 'Sharmila', 'Initials': 'S', 'LastName': 'Sothi', 'Affiliation': 'University Hospital Coventry, Coventry, England.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Hammel', 'Affiliation': 'Hôpital Beaujon, Clichy, France.'}, {'ForeName': 'Markus M', 'Initials': 'MM', 'LastName': 'Lerch', 'Affiliation': 'Greifswald University, Medicine, Greifswald, Germany.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Mayerle', 'Affiliation': 'Greifswald University, Medicine, Greifswald, Germany.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Tjaden', 'Affiliation': 'University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Strobel', 'Affiliation': 'University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Thilo', 'Initials': 'T', 'LastName': 'Hackert', 'Affiliation': 'University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Markus W', 'Initials': 'MW', 'LastName': 'Büchler', 'Affiliation': 'University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Neoptolemos', 'Affiliation': 'University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA surgery,['10.1001/jamasurg.2019.3337'] 333,31277077,Cardiorespiratory behavior of preterm infants receiving continuous positive airway pressure and high flow nasal cannula post extubation: randomized crossover study.,"BACKGROUND Nasal continuous positive airway pressure (NCPAP) and high flow nasal cannula (HFNC) are modes of non-invasive respiratory support commonly used after extubation in extremely preterm infants. However, the cardiorespiratory physiology of these infants on each mode is unknown. METHODS Prospective, randomized crossover study in infants with birth weight ≤1250 g undergoing their first extubation attempt. NCPAP and HFNC were applied randomly for 45 min each, while ribcage and abdominal movements, electrocardiogram, oxygen saturation, and fraction of inspired oxygen (FiO 2 ) were recorded. Respiratory signals were analyzed using an automated method, and differences between NCPAP and HFNC features and changes in FiO 2 were analyzed. RESULTS A total of 30 infants with median [interquartile range] gestational age of 27 weeks [25.7, 27.9] and birth weight of 930 g [780, 1090] were studied. Infants were extubated at 5 days [2, 13] of life with 973 g [880, 1170] and three failed (10%). No differences in cardiorespiratory behavior were noted, except for longer respiratory pauses (9.2 s [5.0, 11.5] vs. 7.3 s [4.6, 9.3]; p = 0.04) and higher FiO 2 levels (p = 0.02) during HFNC compared to NCPAP. CONCLUSIONS In extremely preterm infants studied shortly after extubation, the use of HFNC was associated with longer respiratory pauses and higher FiO 2 requirements.",2020,"No differences in cardiorespiratory behavior were noted, except for longer respiratory pauses (9.2 s [5.0, 11.5] vs. 7.3 s [4.6, 9.3]; p = 0.04) and higher FiO 2 levels (p = 0.02) during HFNC compared to NCPAP. ","['extremely preterm infants', 'infants with birth weight ≤1250', 'preterm infants receiving continuous positive airway pressure and high flow nasal cannula post extubation', '30 infants with median [interquartile range] gestational age of 27 weeks [25.7, 27.9] and birth weight of 930\u2009g [780, 1090']","['HFNC', 'NCPAP and HFNC', 'Nasal continuous positive airway pressure (NCPAP) and high flow nasal cannula (HFNC']","['longer respiratory pauses', 'ribcage and abdominal movements, electrocardiogram, oxygen saturation, and fraction of inspired oxygen (FiO 2 ', 'cardiorespiratory behavior']","[{'cui': 'C3494262', 'cui_str': 'Extremely Preterm Infants'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannula'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C1258045', 'cui_str': 'Nasal Continuous Positive Airway Pressure'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannula'}]","[{'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0222762', 'cui_str': 'Thoracic Cage'}, {'cui': 'C1286159', 'cui_str': 'Movement of abdomen'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0428167', 'cui_str': 'FIO2'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]",30.0,0.118465,"No differences in cardiorespiratory behavior were noted, except for longer respiratory pauses (9.2 s [5.0, 11.5] vs. 7.3 s [4.6, 9.3]; p = 0.04) and higher FiO 2 levels (p = 0.02) during HFNC compared to NCPAP. ","[{'ForeName': 'Lara J', 'Initials': 'LJ', 'LastName': 'Kanbar', 'Affiliation': 'Department of Biomedical Engineering, Montreal, QC, Canada.'}, {'ForeName': 'Wissam', 'Initials': 'W', 'LastName': 'Shalish', 'Affiliation': 'Department of Pediatrics, Neonatal Division, Montreal, QC, Canada.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Latremouille', 'Affiliation': 'Department of Pediatrics, Neonatal Division, Montreal, QC, Canada.'}, {'ForeName': 'Smita', 'Initials': 'S', 'LastName': 'Rao', 'Affiliation': 'Department of Pediatrics, Neonatal Division, Montreal, QC, Canada.'}, {'ForeName': 'Karen A', 'Initials': 'KA', 'LastName': 'Brown', 'Affiliation': 'Department of Anesthesia, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Kearney', 'Affiliation': 'Department of Biomedical Engineering, Montreal, QC, Canada.'}, {'ForeName': 'Guilherme M', 'Initials': 'GM', 'LastName': ""Sant'Anna"", 'Affiliation': 'Department of Pediatrics, Neonatal Division, Montreal, QC, Canada. guilherme.santanna@mcgill.ca.'}]",Pediatric research,['10.1038/s41390-019-0494-5'] 334,30137262,Analgesic Effects Evoked by Real and Imagined Acupuncture: A Neuroimaging Study.,"Acupuncture can provide therapeutic analgesic benefits but is limited by its cost and scheduling difficulties. Guided imagery is a commonly used method for treating many disorders, such as chronic pain. The present study examined a novel intervention for pain relief that integrates acupuncture with imagery called video-guided acupuncture imagery treatment (VGAIT). A total of 27 healthy subjects were recruited for a crossover-design study that included 5 sessions administered in a randomized order (i.e., baseline and 4 different interventions). We investigated changes in pain threshold and fMRI signals modulated by: 1) VGAIT, watching a video of acupuncture previously administered on the participant's own body at baseline while imagining it being concurrently applied; 2) a VGAIT control condition, watching a video of a cotton swab touching the skin; 3) real acupuncture; and 4) sham acupuncture. Results demonstrated that real acupuncture and VGAIT significantly increased pain threshold compared with respective control groups. Imaging showed that real acupuncture produced greater activation of the insula compared with VGAIT. VGAIT produced greater deactivation at the rostral anterior cingulate cortex. Our findings demonstrate that VGAIT holds potential clinical value for pain management.",2019,VGAIT produced greater deactivation at the rostral anterior cingulate cortex.,['27 healthy subjects'],"['Acupuncture', 'VGAIT', 'real acupuncture and VGAIT', 'acupuncture with imagery called video-guided acupuncture imagery treatment (VGAIT', 'Real and Imagined Acupuncture', 'VGAIT control condition, watching a video of a cotton swab touching the skin; 3) real acupuncture; and 4) sham acupuncture']","['pain threshold', 'pain relief']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0150627', 'cui_str': 'Imagery'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C1095832', 'cui_str': 'Cotton - textile'}, {'cui': 'C1261188', 'cui_str': 'Swab (physical object)'}, {'cui': 'C0152054', 'cui_str': 'Therapeutic Touch'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C0162703', 'cui_str': 'Pain Threshold'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}]",27.0,0.157563,VGAIT produced greater deactivation at the rostral anterior cingulate cortex.,"[{'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Cao', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.'}, {'ForeName': 'Yiheng', 'Initials': 'Y', 'LastName': 'Tu', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.'}, {'ForeName': 'Scott P', 'Initials': 'SP', 'LastName': 'Orr', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.'}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Lang', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Vangel', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesia, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.'}, {'ForeName': 'Randy', 'Initials': 'R', 'LastName': 'Gollub', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Kong', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.'}]","Cerebral cortex (New York, N.Y. : 1991)",['10.1093/cercor/bhy190'] 335,31712987,Preventing acute kidney injury and improving outcome in critically ill patients utilizing risk prediction score (PRAIOC-RISKS) study. A prospective controlled trial of AKI prevention.,"BACKGROUND Acute kidney injury (AKI) has significant impact on mortality and morbidity in critically ill patients. METHODS A prospective controlled interventional pilot study composed of observation and intervention arms was run at two different Intensive care unit (ICU) sites. A recently validated risk prediction score was used to predict the AKI in critically ill patients at high risk of developing AKI. All patients with established AKI at the time of recruitment were excluded from the study. A package of early preventive measures, including an early nephrology review was applied to high risk patients in the intervention arm to prevent AKI development. RESULTS We have recruited 108 patients at the intervention site and 98 patients at the observation site. The primary outcome measure was the AKI incidence. AKI incidence was significantly lower in the intervention arm than its incidence in the observation arm (11% vs 26%, p = 0.002). The median Time till recovery of AKI episodes was significantly lower in the intervention arm (3(1) vs. 5(2) days, p = 0.014) 0.30 day mortality was lower in the intervention arm, however, not statistically significant. CONCLUSION Our pilot study showed that it was feasible to apply a simple risk score to implement early preventive measures to high risk patients, consequently, mitigating the risk of AKI development and reducing the time till recovery of AKI episodes. Multicentre studies are needed to confirm this favourable effect.",2020,"AKI incidence was significantly lower in the intervention arm than its incidence in the observation arm (11% vs 26%, p = 0.002).","['All patients with established AKI at the time of recruitment were excluded from the study', 'critically ill patients at high risk of developing AKI', 'critically ill patients', 'critically ill patients utilizing risk prediction score (PRAIOC-RISKS) study', '108 patients at the intervention site and 98 patients at the observation site']",[],"['AKI incidence', 'median Time till recovery of AKI episodes', 'mortality and morbidity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0010340', 'cui_str': 'Critically Ill'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0302523', 'cui_str': 'Observation'}]",[],"[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}]",108.0,0.102574,"AKI incidence was significantly lower in the intervention arm than its incidence in the observation arm (11% vs 26%, p = 0.002).","[{'ForeName': 'Tarek Samy', 'Initials': 'TS', 'LastName': 'Abdelaziz', 'Affiliation': 'Department of Internal Medicine, KasrAlainy Hospitals, Cairo University Hospitals, Cairo, Egypt. taroukah5070@kasralainy.edu.eg.'}, {'ForeName': 'Ragai', 'Initials': 'R', 'LastName': 'Fouda', 'Affiliation': 'Medical ICU, KasrAlainy Hospitals, Cairo University Hospitals, Cairo, Egypt.'}, {'ForeName': 'Wessam M', 'Initials': 'WM', 'LastName': 'Hussin', 'Affiliation': 'Department of Internal Medicine, KasrAlainy Hospitals, Cairo University Hospitals, Cairo, Egypt.'}, {'ForeName': 'Mohamed S', 'Initials': 'MS', 'LastName': 'Elyamny', 'Affiliation': 'Department of Internal Medicine, KasrAlainy Hospitals, Cairo University Hospitals, Cairo, Egypt.'}, {'ForeName': 'Yasser M', 'Initials': 'YM', 'LastName': 'Abdelhamid', 'Affiliation': 'Department of Internal Medicine, KasrAlainy Hospitals, Cairo University Hospitals, Cairo, Egypt.'}]",Journal of nephrology,['10.1007/s40620-019-00671-6'] 336,32087340,"The OaSiS trial: A hybrid type II, national cluster randomized trial to implement smoking cessation during CT screening for lung cancer.","INTRODUCTION When the Centers for Medicare and Medicaid Services announced coverage for low dose CT lung cancer screening, they also mandated that imaging centers offer smoking cessation services. We designed the Optimizing Lung Screening (OaSiS) trial to evaluate strategies to implement the Public Health Service Guidelines for Treating Tobacco Use and Dependence during CT screening for lung cancer. METHODS AND DESIGN OaSiS was implemented using a pragmatic effectiveness-implementation hybrid design in 26 imaging clinics across the United States affiliated with the National Cancer Institute's National Community Oncology Research Program (NCORP). The 26 sites selected for participation in the OaSiS trial were randomized to receive either a compendium of implementation strategies to add or enhance smoking cessation services during lung screening or to usual care. Usual care sites were given the option to receive the full compendium of implementation strategies at the conclusion of data collection. We have evaluated both the effectiveness of the implementation strategies to improve smoking cessation at six months among patients undergoing LDCT screening as well as the adoption and sustainability of evidence-based tobacco cessation strategies in imaging clinics. DISCUSSION The OaSiS trial was designed to identify opportunities for implementing evidence-based smoking cessation into LDCT lung cancer screening imaging facilities and to establish the effectiveness of these services. We report our study design and evaluation, including strengths of the pragmatic design and the inclusion of a diverse range of screening programs. Establishing these tobacco cessation services will be critical to reducing smoking related morbidity and mortality.",2020,"We have evaluated both the effectiveness of the implementation strategies to improve smoking cessation at six months among patients undergoing LDCT screening as well as the adoption and sustainability of evidence-based tobacco cessation strategies in imaging clinics. ","['patients undergoing LDCT screening', ""26 imaging clinics across the United States affiliated with the National Cancer Institute's National Community Oncology Research Program (NCORP"", '26 sites selected for participation in the OaSiS trial', 'for lung cancer']","['compendium of implementation strategies to add or enhance smoking cessation services during lung screening or to usual care', 'smoking cessation during CT screening']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C1513882', 'cui_str': 'National Cancer Institute'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0035168'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0766345', 'cui_str': 'OASIS'}, {'cui': 'C1306460', 'cui_str': 'Primary malignant neoplasm of lung'}]","[{'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0220908', 'cui_str': 'Screening'}]",[],26.0,0.0444411,"We have evaluated both the effectiveness of the implementation strategies to improve smoking cessation at six months among patients undergoing LDCT screening as well as the adoption and sustainability of evidence-based tobacco cessation strategies in imaging clinics. ","[{'ForeName': 'Kristie Long', 'Initials': 'KL', 'LastName': 'Foley', 'Affiliation': 'Wake Forest School of Medicine, Department of Implementation Science, Medical Center Blvd., Winston-Salem, NC 27157, United States of America. Electronic address: kfoley@wakehealth.edu.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Miller', 'Affiliation': 'Wake Forest School of Medicine, Department of Implementation Science, Medical Center Blvd., Winston-Salem, NC 27157, United States of America; Internal Medicine, Medical Center Blvd., Winston-Salem, NC 27157, United States of America.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Weaver', 'Affiliation': 'Wake Forest School of Medicine, Department of Implementation Science, Medical Center Blvd., Winston-Salem, NC 27157, United States of America; Social Sciences and Health Policy, Medical Center Blvd., Winston-Salem, NC 27157, United States of America.'}, {'ForeName': 'Erin L', 'Initials': 'EL', 'LastName': 'Sutfin', 'Affiliation': 'Social Sciences and Health Policy, Medical Center Blvd., Winston-Salem, NC 27157, United States of America.'}, {'ForeName': 'W Jeffrey', 'Initials': 'WJ', 'LastName': 'Petty', 'Affiliation': 'Hematology and Oncology, Medical Center Blvd., Winston-Salem, NC 27157, United States of America.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Bellinger', 'Affiliation': 'Pulmonology and Critical Care, Medical Center Blvd., Winston-Salem, NC 27157, United States of America.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Spangler', 'Affiliation': 'Family and Community Medicine, Medical Center Blvd., Winston-Salem, NC 27157, United States of America.'}, {'ForeName': 'Rebecca J', 'Initials': 'RJ', 'LastName': 'Stone', 'Affiliation': 'Wake Forest School of Medicine, Department of Implementation Science, Medical Center Blvd., Winston-Salem, NC 27157, United States of America.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Lawler', 'Affiliation': 'Wake Forest School of Medicine, Department of Implementation Science, Medical Center Blvd., Winston-Salem, NC 27157, United States of America.'}, {'ForeName': 'Whitney', 'Initials': 'W', 'LastName': 'Davis', 'Affiliation': 'Wake Forest School of Medicine, Department of Implementation Science, Medical Center Blvd., Winston-Salem, NC 27157, United States of America.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Dressler', 'Affiliation': 'Biostatistics and Data Science, Medical Center Blvd., Winston-Salem, NC 27157, United States of America.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Lesser', 'Affiliation': 'Internal Medicine, Medical Center Blvd., Winston-Salem, NC 27157, United States of America; Hematology and Oncology, Medical Center Blvd., Winston-Salem, NC 27157, United States of America.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Chiles', 'Affiliation': 'Radiology, Medical Center Blvd., Winston-Salem, NC 27157, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.105963'] 337,30010756,Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.,"Background Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence. Patients and methods Patients with resected AJCC stage IIB, IIC and III cutaneous melanoma were randomised to receive either adjuvant bevacizumab (7.5 mg/kg i.v. 3 weekly for 1 year) or standard observation. The primary end point was detection of an 8% difference in 5-year overall survival (OS) rate; secondary end points included disease-free interval (DFI) and distant metastasis-free interval (DMFI). Tumour and blood were analysed for prognostic and predictive markers. Results Patients (n=1343) recruited between 2007 and 2012 were predominantly stage III (73%), with median age 56 years (range 18-88 years). With 6.4-year median follow-up, 515 (38%) patients had died [254 (38%) bevacizumab; 261 (39%) observation]; 707 (53%) patients had disease recurrence [336 (50%) bevacizumab, 371 (55%) observation]. OS at 5 years was 64% for both groups [hazard ratio (HR) 0.98; 95% confidence interval (CI) 0.82-1.16, P = 0.78). At 5 years, 51% were disease free on bevacizumab versus 45% on observation (HR 0.85; 95% CI 0.74-0.99, P = 0.03), 58% were distant metastasis free on bevacizumab versus 54% on observation (HR 0.91; 95% CI 0.78-1.07, P = 0.25). Forty four percent of 682 melanomas assessed had a BRAFV600 mutation. In the observation arm, BRAF mutant patients had a trend towards poorer OS compared with BRAF wild-type patients (P = 0.06). BRAF mutation positivity trended towards better OS with bevacizumab (P = 0.21). Conclusions Adjuvant bevacizumab after resection of high-risk melanoma improves DFI, but not OS. BRAF mutation status may predict for poorer OS untreated and potential benefit from bevacizumab. Clinical Trial Information ISRCTN 81261306; EudraCT Number: 2006-005505-64.",2018,"OS at 5 years was 64% for both groups [hazard ratio (HR) 0.98; 95% confidence interval (CI) 0.82-1.16, P = 0.78).","['81261306; EudraCT Number: 2006-005505-64', 'Forty four percent of 682 melanomas assessed had a BRAFV600 mutation', 'Results\n\n\nPatients (n=1343) recruited between 2007 and 2012 were predominantly stage III (73%), with median age 56\u2009years (range 18-88\u2009years', 'melanoma patients at high risk of recurrence', 'Patients and methods\n\n\nPatients with resected AJCC stage IIB, IIC and III cutaneous melanoma']","['Adjuvant bevacizumab', 'adjuvant bevacizumab', 'bevacizumab', 'Bevacizumab']","['poorer OS', 'disease recurrence', '5-year overall survival (OS) rate; secondary end points included disease-free interval (DFI) and distant metastasis-free interval (DMFI', 'distant metastasis free', 'BRAF mutation positivity']","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3 (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0441915', 'cui_str': 'AJCC'}, {'cui': 'C0441769', 'cui_str': 'Stage 2B (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C4521174', 'cui_str': 'Cutaneous'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}]","[{'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C0679254', 'cui_str': 'Disease recurrence'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C1269798', 'cui_str': 'pM category'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}]",,0.751936,"OS at 5 years was 64% for both groups [hazard ratio (HR) 0.98; 95% confidence interval (CI) 0.82-1.16, P = 0.78).","[{'ForeName': 'P G', 'Initials': 'PG', 'LastName': 'Corrie', 'Affiliation': 'Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. Electronic address: pippa.corrie@addenbrookes.nhs.uk.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Marshall', 'Affiliation': 'Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'P D', 'Initials': 'PD', 'LastName': 'Nathan', 'Affiliation': 'Medical Oncology, Mount Vernon Hospital, Northwood, UK.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Lorigan', 'Affiliation': 'Department of Medical Oncology, Christie Hospital, Manchester, UK.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gore', 'Affiliation': 'Royal Marsden Hospital NHS Trust, London, UK.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Tahir', 'Affiliation': 'Oncology Research, Broomfield Hospital, Chelmsford, UK.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Faust', 'Affiliation': 'Oncology Department, Leicester Royal Infirmary, Leicester, UK.'}, {'ForeName': 'C G', 'Initials': 'CG', 'LastName': 'Kelly', 'Affiliation': 'Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, Newcastle upon Tyne, UK.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Marples', 'Affiliation': ""Leeds Cancer Centre, St James's University Hospital, Leeds, UK.""}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Danson', 'Affiliation': 'Weston Park Hospital, Academic Unit of Clinical Oncology, Sheffield, UK.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Marshall', 'Affiliation': ""Cancer & Palliative Care, St. Helen's Hospital, St. Helens, UK.""}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Houston', 'Affiliation': 'Oncology Department, Royal Surrey County Hospital, Guildford, UK.'}, {'ForeName': 'R E', 'Initials': 'RE', 'LastName': 'Board', 'Affiliation': 'Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Waterston', 'Affiliation': 'Clinical Trials Unit, Beatson WOS Cancer Centre, Glasgow, UK.'}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Nobes', 'Affiliation': 'Department of Clinical Oncology, Norfolk & Norwich University Hospital, Norwich, UK.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Harries', 'Affiliation': ""Guy's & St. Thomas' Hospital, Guy's Cancer Centre, London, UK.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Kumar', 'Affiliation': 'Velindre Cancer Centre, Cardiff, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Goodman', 'Affiliation': 'Exeter Oncology Centre, Royal Devon and Exeter Hospital, Exeter, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Dalgleish', 'Affiliation': ""St George's Hospital, Cancer Centre, London, UK.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Martin-Clavijo', 'Affiliation': 'Cancer Centre, Queen Elizabeth Hospital, Birmingham, UK.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Westwell', 'Affiliation': 'Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Casasola', 'Affiliation': 'Cancer Centre, Ninewells Hospital, Dundee, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Chao', 'Affiliation': 'Royal Free Hospital, London, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Maraveyas', 'Affiliation': 'Castle Hill Hospital, Cottingham, UK.'}, {'ForeName': 'P M', 'Initials': 'PM', 'LastName': 'Patel', 'Affiliation': 'Academic Unit of Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK.'}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Ottensmeier', 'Affiliation': 'CRUK and NIHR Southampton Experimental Cancer Medicine Centre, Southampton University Hospitals NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Farrugia', 'Affiliation': 'Oncology Centre, Cheltenham General Hospital, Cheltenham, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Humphreys', 'Affiliation': 'Oncology Department, James Cook University Hospital, Middlesbrough, UK.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Eccles', 'Affiliation': 'Oncology Department, Poole Hospital, Dorset, UK.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Young', 'Affiliation': 'Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'E O', 'Initials': 'EO', 'LastName': 'Barker', 'Affiliation': 'Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Harman', 'Affiliation': 'Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Weiss', 'Affiliation': 'Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'K A', 'Initials': 'KA', 'LastName': 'Myers', 'Affiliation': 'Department of Oncology, University of Oxford, Oxford, UK; Experimental Cancer Medicine Centre, Oxford, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Chhabra', 'Affiliation': 'Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'S H', 'Initials': 'SH', 'LastName': 'Rodwell', 'Affiliation': 'Melanoma Focus, Cambridge, UK.'}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Dunn', 'Affiliation': 'Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'M R', 'Initials': 'MR', 'LastName': 'Middleton', 'Affiliation': 'Oxford NIHR Biomedical Research Centre, Oxford, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Nathan', 'Affiliation': ''}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Lorigan', 'Affiliation': ''}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Dziewulski', 'Affiliation': ''}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Holikova', 'Affiliation': ''}, {'ForeName': 'Udaiveer', 'Initials': 'U', 'LastName': 'Panwar', 'Affiliation': ''}, {'ForeName': 'Saad', 'Initials': 'S', 'LastName': 'Tahir', 'Affiliation': ''}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Faust', 'Affiliation': ''}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Thomas', 'Affiliation': ''}, {'ForeName': 'Pippa', 'Initials': 'P', 'LastName': 'Corrie', 'Affiliation': ''}, {'ForeName': 'Bhawna', 'Initials': 'B', 'LastName': 'Sirohi', 'Affiliation': ''}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Kelly', 'Affiliation': ''}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Middleton', 'Affiliation': ''}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Marples', 'Affiliation': ''}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Danson', 'Affiliation': ''}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Lester', 'Affiliation': ''}, {'ForeName': 'Ernest', 'Initials': 'E', 'LastName': 'Marshall', 'Affiliation': ''}, {'ForeName': 'Mazhar', 'Initials': 'M', 'LastName': 'Ajaz', 'Affiliation': ''}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Houston', 'Affiliation': ''}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Board', 'Affiliation': ''}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Eaton', 'Affiliation': ''}, {'ForeName': 'Ashita', 'Initials': 'A', 'LastName': 'Waterston', 'Affiliation': ''}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Nobes', 'Affiliation': ''}, {'ForeName': 'Suat', 'Initials': 'S', 'LastName': 'Loo', 'Affiliation': ''}, {'ForeName': 'Gill', 'Initials': 'G', 'LastName': 'Gray', 'Affiliation': ''}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Stubbings', 'Affiliation': ''}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Gore', 'Affiliation': ''}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Harries', 'Affiliation': ''}, {'ForeName': 'Satish', 'Initials': 'S', 'LastName': 'Kumar', 'Affiliation': ''}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Goodman', 'Affiliation': ''}, {'ForeName': 'Angus', 'Initials': 'A', 'LastName': 'Dalgleish', 'Affiliation': ''}, {'ForeName': 'Agustin', 'Initials': 'A', 'LastName': 'Martin-Clavijo', 'Affiliation': ''}, {'ForeName': 'Jerry', 'Initials': 'J', 'LastName': 'Marsden', 'Affiliation': ''}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Westwell', 'Affiliation': ''}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Casasola', 'Affiliation': ''}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Chao', 'Affiliation': ''}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Maraveyas', 'Affiliation': ''}, {'ForeName': 'Ernest', 'Initials': 'E', 'LastName': 'Marshall', 'Affiliation': ''}, {'ForeName': 'Poulam', 'Initials': 'P', 'LastName': 'Patel', 'Affiliation': ''}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Ottensmeier', 'Affiliation': ''}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Farrugia', 'Affiliation': ''}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Humphreys', 'Affiliation': ''}, {'ForeName': 'Bryony', 'Initials': 'B', 'LastName': 'Eccles', 'Affiliation': ''}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Dega', 'Affiliation': ''}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Herbert', 'Affiliation': ''}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Price', 'Affiliation': ''}, {'ForeName': 'Murray', 'Initials': 'M', 'LastName': 'Brunt', 'Affiliation': ''}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Scott-Brown', 'Affiliation': ''}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Hamilton', 'Affiliation': ''}, {'ForeName': 'Richard Larry', 'Initials': 'RL', 'LastName': 'Hayward', 'Affiliation': ''}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Smyth', 'Affiliation': ''}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Woodings', 'Affiliation': ''}, {'ForeName': 'Neena', 'Initials': 'N', 'LastName': 'Nayak', 'Affiliation': ''}, {'ForeName': 'Lorna', 'Initials': 'L', 'LastName': 'Burrows', 'Affiliation': ''}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Wolstenholme', 'Affiliation': ''}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Wagstaff', 'Affiliation': ''}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Nicolson', 'Affiliation': ''}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Wilson', 'Affiliation': ''}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Barlow', 'Affiliation': ''}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Scrase', 'Affiliation': ''}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Podd', 'Affiliation': ''}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Gonzalez', 'Affiliation': ''}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Stewart', 'Affiliation': ''}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Highley', 'Affiliation': ''}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Wolstenholme', 'Affiliation': ''}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Grumett', 'Affiliation': ''}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Goodman', 'Affiliation': ''}, {'ForeName': 'Toby', 'Initials': 'T', 'LastName': 'Talbot', 'Affiliation': ''}, {'ForeName': 'Kannon', 'Initials': 'K', 'LastName': 'Nathan', 'Affiliation': ''}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Coltart', 'Affiliation': ''}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Gee', 'Affiliation': ''}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Gore', 'Affiliation': ''}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Farrugia', 'Affiliation': ''}, {'ForeName': 'Agustin', 'Initials': 'A', 'LastName': 'Martin-Clavijo', 'Affiliation': ''}, {'ForeName': 'Jerry', 'Initials': 'J', 'LastName': 'Marsden', 'Affiliation': ''}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Price', 'Affiliation': ''}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Farrugia', 'Affiliation': ''}, {'ForeName': 'Kannon', 'Initials': 'K', 'LastName': 'Nathan', 'Affiliation': ''}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Coltart', 'Affiliation': ''}, {'ForeName': 'Kannon', 'Initials': 'K', 'LastName': 'Nathan', 'Affiliation': ''}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Coltart', 'Affiliation': ''}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdy229'] 338,31744312,Reconsidering Dexmedetomidine for Sedation in the Critically Ill: Implications of the SPICE III Trial.,"Dexmedetomidine is a sedative agent that has gained popularity for use in the intensive care unit over the past 20 years. Guidelines recommend dexmedetomidine as a first-line agent to achieve light sedation in mechanically ventilated adults. Recently, the SPICE III (Sedation Practice in Intensive Care Evaluation III) trial was published. This was a randomized controlled trial comparing initial sedation with dexmedetomidine with usual care sedation in adult patients receiving mechanical ventilation. The results of this trial have both validated and contradicted previous findings about dexmedetomidine. This editorial examines the merits of the SPICE III trial and the role of dexmedetomidine in practice following its publication.",2020,This was a randomized controlled trial comparing initial sedation with dexmedetomidine with usual care sedation in adult patients receiving mechanical ventilation.,"['mechanically ventilated adults', 'adult patients receiving mechanical ventilation', 'Sedation in the Critically Ill']","['Reconsidering Dexmedetomidine', 'dexmedetomidine', 'Dexmedetomidine']",[],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0010340', 'cui_str': 'Critically Ill'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}]",[],,0.0709695,This was a randomized controlled trial comparing initial sedation with dexmedetomidine with usual care sedation in adult patients receiving mechanical ventilation.,"[{'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Farina', 'Affiliation': 'Michigan Medicine, Ann Arbor, MI, USA.'}, {'ForeName': 'Cesar', 'Initials': 'C', 'LastName': 'Alaniz', 'Affiliation': 'Michigan Medicine, Ann Arbor, MI, USA.'}]",The Annals of pharmacotherapy,['10.1177/1060028019890672'] 339,32011785,The effects of mindfulness-based intervention on quality of life and poststroke depression in patients with spontaneous intracerebral hemorrhage in China.,"OBJECTIVE Spontaneous intracerebral hemorrhage (sICH) is a devastating disease that can lead to poststroke depression (PSD) and greatest impact on the quality of life (QOL) of patients. Mindfulness meditation was viewed as one of the effective ways to reduce PSD in patients with cancer. The present study tried to investigate whether mindfulness meditation has potential benefits in PSD and QOL for sICH patients in China. METHODS Two hundred and two patients in West China Hospital, Sichuan University, enrolled from January 2017 to December 2018 were included in a randomized controlled trial. After removing missing values, there were 67 in control group and 67 in intervention group. Patients in intervention group received 2-month mindfulness-based cognitive therapy, and patients in control group received stress management education (ie, an active control). RESULTS The results suggested that the significant differences of depression, trait mindfulness, social well-being, emotional well-being, and total score of QOL were found in intervention group from time 1 to time 2. Physical well-being and the score of NIH stroke scale experienced significant changes in both control group and intervention group over time. CONCLUSIONS Mindfulness-based intervention has positive effects on sICH patients' depression, social well-being, and emotional well-being. However, the change of trait mindfulness over time could not explain these positive effects. Future studies could explore the mechanism of mindfulness-based intervention on sICH patients' depression and QOL and clarify the boundaries of the positive effects of mindfulness-based intervention.",2020,"Physical well-being and the score of NIH stroke scale (NIHSS) experienced significant changes in both control group and intervention group over time. ","['sICH patients in China', 'patients with cancer', 'patients with spontaneous intracerebral hemorrhage in China', 'Two hundred and two patients in West China Hospital Sichuan University enrolled from January, 2017 to December, 2018']","['month mindfulness-based cognitive therapy, patients in control group received stress management education (ie, an active control', 'mindfulness meditation', 'Mindfulness meditation', 'mindfulness-based intervention']","['quality of life (QOL', 'depression, trait mindfulness, social well-being, emotional well-being, and total score of QOL', 'quality of life and post-stroke depression', 'Physical well-being and the score of NIH stroke scale (NIHSS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C2937358', 'cui_str': 'Intracerebral Hemorrhage'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}]","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1444245', 'cui_str': 'Stress control education (procedure)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0150277'}]","[{'cui': 'C0034380'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C2938940', 'cui_str': 'Post stroke depression'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C1697238', 'cui_str': 'NIH stroke scale'}]",,0.0251754,"Physical well-being and the score of NIH stroke scale (NIHSS) experienced significant changes in both control group and intervention group over time. ","[{'ForeName': 'Xiaoyu', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Junyi', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'School of Psychology, Sichuan Normal University, Chengdu, China.'}, {'ForeName': 'Chengwei', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Integrated Traditional and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Jianqin', 'Initials': 'J', 'LastName': 'Lv', 'Affiliation': 'Department of Integrated Traditional and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.'}]",International journal of geriatric psychiatry,['10.1002/gps.5273'] 340,31431654,Lack of social support as measured by the Family Resource Scale screening tool is associated with early adverse cognitive outcome in extremely low birth weight children.,"OBJECTIVE Extremely low birth weight children are at high risk for cognitive impairment. STUDY DESIGN Cognitive outcome of extremely low birth weight children participating in a Neonatal Research Network, randomized trial was evaluated at 18 and 30 months corrected age using the Bayley Scales of Infant Development, 2nd ed. Family resources and social support were assessed using a Family Resource Scale parent questionnaire. Regression analysis was used to determine independent demographic, medical, and family resource factors influencing longitudinal cognitive outcome. RESULT Higher Family Resource Scale scores at 18 months were associated with greater improvement in cognitive scores between 18 and 30 months. Cognitive outcome was most adversely affected in children whose families had the least resources and social support. The adverse effect of poor social support was independent of family income. CONCLUSION Poor interpersonal social support has an independent, adverse impact on cognitive outcomes of extremely low birth weight infants.",2019,Cognitive outcome was most adversely affected in children whose families had the least resources and social support.,"['extremely low birth weight infants', 'extremely low birth weight children participating in a Neonatal Research Network, randomized trial was evaluated at 18 and 30 months corrected age using the Bayley Scales of Infant Development, 2nd ed', 'extremely low birth weight children']",[],"['Cognitive outcome', 'Higher Family Resource Scale scores', 'cognitive scores']","[{'cui': 'C0456065', 'cui_str': 'Infant, Extremely Low Birth Weight'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0035168'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0451021', 'cui_str': 'Bayley scale of infant development (assessment scale)'}, {'cui': 'C0205436', 'cui_str': 'Second - ordinal'}]",[],"[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0599714,Cognitive outcome was most adversely affected in children whose families had the least resources and social support.,"[{'ForeName': 'Martha G', 'Initials': 'MG', 'LastName': 'Fuller', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, University of California San Diego, San Diego, CA, USA. mfuller@sandiego.edu.'}, {'ForeName': 'Yvonne E', 'Initials': 'YE', 'LastName': 'Vaucher', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, University of California San Diego, San Diego, CA, USA.'}, {'ForeName': 'Carla M', 'Initials': 'CM', 'LastName': 'Bann', 'Affiliation': 'RTI International, Research Triangle Park, North Carolina, NC, USA.'}, {'ForeName': 'Abhik', 'Initials': 'A', 'LastName': 'Das', 'Affiliation': 'RTI International, Research Triangle Park, North Carolina, NC, USA.'}, {'ForeName': 'Betty R', 'Initials': 'BR', 'LastName': 'Vohr', 'Affiliation': 'Department of Pediatrics, Women, and Infants Hospital, Brown University, Providence, RI, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-019-0462-2'] 341,32132641,Impact of change in bedtime variability on body composition and inflammation: secondary findings from the Go Red for Women Strategically Focused Research Network.,"Variability in daily sleep patterns is an emerging factor linked to metabolic syndrome. However, whether reducing bedtime variability improves markers of disease risk has not been tested. Here, we assessed whether body composition and inflammation were impacted by changes in bedtime variability over a 6-week period, during which, women were instructed to maintain healthy, habitual sleep (HS) patterns (one arm of a randomized trial). Data were available for 37 women (age 34.9 ± 12.4 years, BMI 24.7 ± 2.9 kg/m 2 , sleep duration 7.58 ± 0.49 h/night). Body composition and leukocyte platelet aggregates (LPA) were measured at baseline and endpoint using magnetic resonance imaging and flow cytometry, respectively. Sleep data were collected daily using wrist actigraphy. Change in bedtime variability was calculated as the difference in the standard deviation (SD) of bedtimes measured during the 2-week screening period and the 6-week intervention period. Results showed that women who reduced their bedtime variability (n = 29) during the intervention had reductions in total (P < 0.001) and subcutaneous adipose tissue (P < 0.001) relative to women who increased/maintained (n = 8) bedtime variability. Similar effects were observed for LPA levels between women who reduced vs increased/maintained bedtime variability (P = 0.011). Thus, reducing bedtime variability, without changing sleep duration, could improve cardiometabolic health by reducing adiposity and inflammation.",2020,Similar effects were observed for LPA levels between women who reduced vs increased/maintained bedtime variability (P = 0.011).,"['37 women (age 34.9\u2009±\u200912.4\u2009years, BMI 24.7\u2009±\u20092.9\u2009kg/m 2 , sleep duration 7.58\u2009±\u20090.49\u2009h/night']",[],"['Change in bedtime variability', 'LPA levels', 'maintained bedtime variability', 'cardiometabolic health', 'Body composition and leukocyte platelet aggregates (LPA', 'Sleep data', 'body composition and inflammation', 'bedtime variability', 'subcutaneous adipose tissue']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517543', 'cui_str': '12.4 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517641', 'cui_str': '2.9 (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}]",[],"[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0521112', 'cui_str': 'Bedtime (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0023516', 'cui_str': 'Blood Corpuscles, White'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0205418', 'cui_str': 'Aggregate (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0222331', 'cui_str': 'Subcutaneous Fat'}]",37.0,0.140356,Similar effects were observed for LPA levels between women who reduced vs increased/maintained bedtime variability (P = 0.011).,"[{'ForeName': 'Marie-Pierre', 'Initials': 'MP', 'LastName': 'St-Onge', 'Affiliation': 'Sleep center of excellence, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA. ms2554@cumc.columbia.edu.'}, {'ForeName': 'Ayanna', 'Initials': 'A', 'LastName': 'Campbell', 'Affiliation': 'Sleep center of excellence, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA.'}, {'ForeName': 'Faris', 'Initials': 'F', 'LastName': 'Zuraikat', 'Affiliation': 'Sleep center of excellence, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Cheng', 'Affiliation': 'Department of Biostatistics, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, 10032, USA.'}, {'ForeName': 'Riddhi', 'Initials': 'R', 'LastName': 'Shah', 'Affiliation': 'Sleep center of excellence, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Berger', 'Affiliation': 'Center for the Prevention of Cardiovascular Disease; Department of Medicine, New York University Langone Health, New York, NY, 10010, USA.'}, {'ForeName': 'Rosemary V', 'Initials': 'RV', 'LastName': 'Sampogna', 'Affiliation': 'Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA.'}, {'ForeName': 'Sanja', 'Initials': 'S', 'LastName': 'Jelic', 'Affiliation': 'Sleep center of excellence, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA.'}]",International journal of obesity (2005),['10.1038/s41366-020-0555-1'] 342,31995035,Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study.,"BACKGROUND Anthracycline‑induced cardiotoxicity (AIC) remains the main long‑term irreversible side effect in malignancy survivors. Cardiotoxicity prevention is one of the most reasonable approaches. AIMS In this prospective randomized open‑label study, we aimed to verify whether ramipril protects from early‑onset AIC in women with breast cancer (BC). METHODS We analyzed data from 96 women (median age, 47 years) with BC after breast surgery, without significant cardiovascular diseases, who were eligible for adjuvant anthracyclines. They were randomized to a ramipril or control arm. Cardiotoxicity was estimated with repeat echocardiography and themeasurement of troponin I and N‑terminal fragment of the prohormone brain natriuretic peptide (NT‑proBNP) levels over 1‑year follow‑up. Anthracycline‑induced cardiotoxicity was defined as a decrease in left ventricular ejection fraction (LVEF), elevated biomarker levels, and/or occurrence of heart failure (HF) or cardiac death. RESULTS A decrease in LVEF above 10‑percent points occurred in 6.3% of ramipril patients and 18.5% ofcontrols (P = 0.15). No cases of HF, cardiac death, or LVEF decline below 50% were reported. The percentage of patients with elevated NT‑proBNP levels increased with time in controls (P = 0.003) and remained unchanged in the ramipril arm. At the end of follow‑up, an increase in NT‑proBNP levels was more common and decline was less common in the control than ramipril arm (P = 0.01). No significant differences in troponin levels were found between the study arms. Ramipril was well tolerated in normotensive women. CONCLUSIONS In relatively young women with BC without serious comorbidities, who received anthracyclines, 1‑year treatment with ramipril exerts potentially protective effects on cardiotoxicity assessed with NT‑proBNP levels.",2020,"Cardiotoxicity was estimated with repeated echocardiography, troponin I and NT-proBNP levels over one-year follow-up.","['normotensive women', 'Women with breast cancer (BC', '96 women, median age 47 years, without significant cardiovascular diseases, post-breast surgery and eligible for adjuvant anthracyclines, was analyzed', 'low-risk breast cancer women']","['angiotensin-converting enzyme inhibitor ramipril', 'ramipril', 'ramipril (RA) or control arm (CA', 'Ramipril', 'Anthracycline', 'anthracycline therapy']","['left ventricular ejection fraction (LVEF) and/or biomarkers elevation and/or occurrence of heart failure (HF) or cardiac death', 'NT-proBNP elevation increased with time in CA', 'HF, cardiac death or LVEF decline', 'repeated echocardiography, troponin I and NT-proBNP levels', 'troponin levels', 'NTproBNP increase and fewer NT-proBNP decline', 'Cardiotoxicity']","[{'cui': 'C2712122', 'cui_str': 'Normal blood pressure (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0851312', 'cui_str': 'Breast surgery'}, {'cui': 'C0282564', 'cui_str': 'Anthracyclines'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}]","[{'cui': 'C0003015', 'cui_str': 'ACE Inhibitors'}, {'cui': 'C0072973', 'cui_str': 'Ramipril'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0282564', 'cui_str': 'Anthracyclines'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0376297', 'cui_str': 'Cardiac Death'}, {'cui': 'C1963813', 'cui_str': 'NT-proBNP'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0332311', 'cui_str': 'With time (qualifier value)'}, {'cui': 'C0013516', 'cui_str': 'Transthoracic Echocardiography'}, {'cui': 'C0920210', 'cui_str': 'Troponin I measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0523952', 'cui_str': 'Troponin measurement'}, {'cui': 'C0669479', 'cui_str': 'NT-BNP'}, {'cui': 'C0205388', 'cui_str': 'Few (qualifier value)'}, {'cui': 'C0876994', 'cui_str': 'Cardiac Toxicity'}]",96.0,0.0850916,"Cardiotoxicity was estimated with repeated echocardiography, troponin I and NT-proBNP levels over one-year follow-up.","[{'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Słowik', 'Affiliation': 'Department of Oncology, Jagiellonian University Medical College, Kraków, Poland'}, {'ForeName': 'Paweł', 'Initials': 'P', 'LastName': 'Jagielski', 'Affiliation': 'Human Nutrition Department,Faculty of Health Science, Jagiellonian University Medical College, Kraków, Poland'}, {'ForeName': 'Paweł', 'Initials': 'P', 'LastName': 'Potocki', 'Affiliation': 'Department of Oncology, Jagiellonian University Medical College, Kraków, Poland'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Streb', 'Affiliation': 'Department of Oncology, Jagiellonian University Medical College, Kraków, Poland'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Ochenduszko', 'Affiliation': 'Department of Medical Oncology, Dr. Peset University Hospital, Valencia, Spain'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Wysocki', 'Affiliation': 'Department of Oncology, Jagiellonian University Medical College, Kraków, Poland'}, {'ForeName': 'Grzegorz', 'Initials': 'G', 'LastName': 'Gajos', 'Affiliation': 'Department of Coronary Disease and Heart Failure, Jagiellonian University Medical College, Kraków, Poland; Institute of Cardiology, John Paul II Hospital, Kraków, Poland'}, {'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Konduracka', 'Affiliation': 'Department of Coronary Disease and Heart Failure, Jagiellonian University Medical College, Kraków, Poland; Institute of Cardiology, John Paul II Hospital, Kraków, Poland. ekonduracka@interia.eu'}]",Kardiologia polska,['10.33963/KP.15163'] 343,31633896,Metoprolol for the Prevention of Acute Exacerbations of COPD.,"BACKGROUND Observational studies suggest that beta-blockers may reduce the risk of exacerbations and death in patients with moderate or severe chronic obstructive pulmonary disease (COPD), but these findings have not been confirmed in randomized trials. METHODS In this prospective, randomized trial, we assigned patients between the ages of 40 and 85 years who had COPD to receive either a beta-blocker (extended-release metoprolol) or placebo. All the patients had a clinical history of COPD, along with moderate airflow limitation and an increased risk of exacerbations, as evidenced by a history of exacerbations during the previous year or the prescribed use of supplemental oxygen. We excluded patients who were already taking a beta-blocker or who had an established indication for the use of such drugs. The primary end point was the time until the first exacerbation of COPD during the treatment period, which ranged from 336 to 350 days, depending on the adjusted dose of metoprolol. RESULTS A total of 532 patients underwent randomization. The mean (±SD) age of the patients was 65.0±7.8 years; the mean forced expiratory volume in 1 second (FEV 1 ) was 41.1±16.3% of the predicted value. The trial was stopped early because of futility with respect to the primary end point and safety concerns. There was no significant between-group difference in the median time until the first exacerbation, which was 202 days in the metoprolol group and 222 days in the placebo group (hazard ratio for metoprolol vs. placebo, 1.05; 95% confidence interval [CI], 0.84 to 1.32; P = 0.66). Metoprolol was associated with a higher risk of exacerbation leading to hospitalization (hazard ratio, 1.91; 95% CI, 1.29 to 2.83). The frequency of side effects that were possibly related to metoprolol was similar in the two groups, as was the overall rate of nonrespiratory serious adverse events. During the treatment period, there were 11 deaths in the metoprolol group and 5 in the placebo group. CONCLUSIONS Among patients with moderate or severe COPD who did not have an established indication for beta-blocker use, the time until the first COPD exacerbation was similar in the metoprolol group and the placebo group. Hospitalization for exacerbation was more common among the patients treated with metoprolol. (Funded by the Department of Defense; BLOCK COPD ClinicalTrials.gov number, NCT02587351.).",2019,"Metoprolol was associated with a higher risk of exacerbation leading to hospitalization (hazard ratio, 1.91; 95% CI, 1.29 to 2.83).","['532 patients underwent randomization', 'patients between the ages of 40 and 85 years who had COPD to receive either a', 'patients who were already taking a beta-blocker or who had an established indication for the use of such drugs', 'patients with moderate or severe chronic obstructive pulmonary disease (COPD', 'Acute Exacerbations of COPD', 'patients with moderate or severe COPD']","['beta-blocker (extended-release metoprolol) or placebo', 'beta-blockers', 'placebo', 'metoprolol', 'metoprolol vs. placebo', 'Metoprolol']","['median time until the first exacerbation', 'frequency of side effects', 'time until the first COPD exacerbation', 'risk of exacerbations', 'time until the first exacerbation of COPD', 'Hospitalization for exacerbation', 'overall rate of nonrespiratory serious adverse events', 'mean forced expiratory volume']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C0392360', 'cui_str': 'Reason for (attribute)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0730607', 'cui_str': 'Severe chronic obstructive pulmonary disease (disorder)'}, {'cui': 'C0340044', 'cui_str': 'Acute exacerbation of chronic obstructive airways disease (disorder)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}]","[{'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C0025859', 'cui_str': 'Metoprolol'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0740304', 'cui_str': 'COPD exacerbation'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}]",532.0,0.447618,"Metoprolol was associated with a higher risk of exacerbation leading to hospitalization (hazard ratio, 1.91; 95% CI, 1.29 to 2.83).","[{'ForeName': 'Mark T', 'Initials': 'MT', 'LastName': 'Dransfield', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Voelker', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Surya P', 'Initials': 'SP', 'LastName': 'Bhatt', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Brenner', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Casaburi', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Carolyn E', 'Initials': 'CE', 'LastName': 'Come', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'J Allen D', 'Initials': 'JAD', 'LastName': 'Cooper', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Gerard J', 'Initials': 'GJ', 'LastName': 'Criner', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Jeffrey L', 'Initials': 'JL', 'LastName': 'Curtis', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'MeiLan K', 'Initials': 'MK', 'LastName': 'Han', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Umur', 'Initials': 'U', 'LastName': 'Hatipoğlu', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Erika S', 'Initials': 'ES', 'LastName': 'Helgeson', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Vipul V', 'Initials': 'VV', 'LastName': 'Jain', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Kalhan', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kaminsky', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Kaner', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Ken M', 'Initials': 'KM', 'LastName': 'Kunisaki', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Allison A', 'Initials': 'AA', 'LastName': 'Lambert', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Lammi', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Lindberg', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Barry J', 'Initials': 'BJ', 'LastName': 'Make', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Fernando J', 'Initials': 'FJ', 'LastName': 'Martinez', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Charlene', 'Initials': 'C', 'LastName': 'McEvoy', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Ralph J', 'Initials': 'RJ', 'LastName': 'Panos', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Reed', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Scanlon', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Frank C', 'Initials': 'FC', 'LastName': 'Sciurba', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Smith', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Peruvemba S', 'Initials': 'PS', 'LastName': 'Sriram', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'William W', 'Initials': 'WW', 'LastName': 'Stringer', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Jeremy A', 'Initials': 'JA', 'LastName': 'Weingarten', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'J Michael', 'Initials': 'JM', 'LastName': 'Wells', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Westfall', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'Stephen C', 'Initials': 'SC', 'LastName': 'Lazarus', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Connett', 'Affiliation': ""From the Lung Health Center, University of Alabama at Birmingham (M.T.D., S.P.B., J.M.W., E.W.), and Birmingham Veterans Affairs (VA) Medical Center (M.T.D., J.A.D.C., J.M.W.) - both in Birmingham; the University of Minnesota (H.V., E.S.H., S.L., J.E.C.) and the Minneapolis VA Medical Center (K.M.K.), Minneapolis, HealthPartners Minnesota, Bloomington (C.M.), and Mayo Clinic, Rochester (P.D.S.) - all in Minnesota; New York-Presbyterian (NYP)-Columbia University Medical Center (K.B.), NYP-Weill Cornell Medical Center (R. Kaner, F.J.M.), NYP-Queens Medical Center (A.S.), and NYP-Brooklyn Methodist Medical Center (J.A.W.) - all in New York; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles (R.C., W.W.S.), the University of California, San Francisco-Fresno, Fresno (V.V.J.), and the University of California, San Francisco, San Francisco (S.C.L.) - all in California; Brigham and Women's Hospital, Boston (C.E.C.); Temple University School of Medicine, Philadelphia (G.J.C.); the Ann Arbor VA Medical Center (J.L.C.) and the University of Michigan Health System (M.K.H.) - both in Ann Arbor; the Cleveland Clinic, Cleveland (U.H.); Northwestern University, Chicago (R. Kalhan); the University of Vermont, Burlington (D.K.); the University of Washington, Seattle (A.A.L.); Louisiana State University, New Orleans (M.R.L.); National Jewish Health, Denver (B.J.M.); the Cincinnati VA Medical Center, Cincinnati (R.J.P.); the University of Maryland, Baltimore (R.M.R.); the University of Pittsburgh, Pittsburgh (F.C.S.); and North Florida-South Georgia Veterans Health System, Gainesville (P.S.S.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1908142'] 344,31652245,Exercise Effects on Mitochondrial Function and Lipid Metabolism during Energy Balance.,"INTRODUCTION/PURPOSE Aerobic exercise training (AET) has been shown to improve mitochondrial bioenergetics and upregulate proteins related to lipid metabolism. However, it remains to be determined if these alterations associated with AET persist when measured in energy balance (EB) in the days after the last bout of training. The purpose of the study was to test the hypothesis that improvements in skeletal muscle mitochondrial function induced by AET observed in previous literature would persist when measured after restoring EB conditions 72 h removed from the last exercise bout. METHODS Participants were 14 premenopausal women (age = 31.2 ± 6.7 yr, BMI = 26.6 ± 5.1 kg·m). The AET program required three monitored training sessions per week for 8-16 wk. Skeletal muscle biopsies were obtained at baseline and after 8-16 wk of AET (≥72 h after the last exercise bout). All food was provided for 72 h before biopsies, and EB was managed 24 h before testing within ±100 kcal of measured energy requirements using a whole-room calorimeter. Mitochondrial oxidative capacity was quantified in permeabilized muscle fibers from the vastus lateralis. RESULTS We found that AET increased coupled respiration (154%) and uncoupled respiration (90%) rates using a fatty acid substrate (palmitoyl carnitine) (P < 0.05). However, when rates were normalized to complex IV activity (a marker of mitochondrial content), no significant differences were observed. In addition, there were no changes in proteins known to mediate mitochondrial biogenesis or lipid transport and metabolism after AET. CONCLUSION Eight to 16 wk of AET improved mitochondrial capacity under fatty acid substrate when assessed in EB, which appears to be due to mitochondrial biogenesis.",2020,"However, when rates were normalized to complex IV activity (a marker of mitochondrial content), no significant differences were observed.","['Participants were 14 premenopausal women (age = 31.2 ± 6.7 years, BMI = 26.6 ± 5.1 kg/m']","['AET', 'Aerobic exercise training (AET']","['complex IV activity', 'mitochondrial capacity under fatty acid substrate', 'Mitochondrial Function and Lipid Metabolism', 'Skeletal muscle biopsies', 'Mitochondrial oxidative capacity', 'coupled respiration']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0629582', 'cui_str': 'AETS'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0015684', 'cui_str': 'Fatty Acids'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0242692', 'cui_str': 'Muscle, Voluntary'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}]",,0.0528183,"However, when rates were normalized to complex IV activity (a marker of mitochondrial content), no significant differences were observed.","[{'ForeName': 'Jonathan L', 'Initials': 'JL', 'LastName': 'Warren', 'Affiliation': 'Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Gary R', 'Initials': 'GR', 'LastName': 'Hunter', 'Affiliation': 'Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Gower', 'Affiliation': 'Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Marcas M', 'Initials': 'MM', 'LastName': 'Bamman', 'Affiliation': 'Department of Cell Development and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Samuel T', 'Initials': 'ST', 'LastName': 'Windham', 'Affiliation': 'Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Douglas R', 'Initials': 'DR', 'LastName': 'Moellering', 'Affiliation': 'Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Fisher', 'Affiliation': 'Department of Human Studies, University of Alabama at Birmingham, Birmingham, AL.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002190'] 345,32241751,Effects of an extrinsic motivator on the evaluation of cognitive and daily living functions in patients with schizophrenia.,"We investigated the effect of an extrinsic motivator on the MATRICS Consensus Cognitive Battery (MCCB) and UCSD Performance-Based Skills Assessment (UPSA) scores, which assess cognitive and daily living functions, in patients with schizophrenia. We enrolled 60 clinically stable patients with schizophrenia and allocated them to the motivator or control group. We conducted baseline assessments of cognitive function using the MCCB, daily living function using the UPSA, clinical symptoms, and psychosocial characteristics in both groups. In the retrial, we initially evaluated clinical symptoms. Next, we assigned an extrinsic motivator to the motivator group and again assessed cognitive function and daily living function using the MCCB and UPSA. Statistical analyses were performed using t-tests, Chi-square tests, Fisher's exact test, repeated measures analysis of variance, and logistic regression analysis. We found significant time × group interactions in processing speed, verbal learning, visual learning, and composite scores of MCCB. There were no significant interactions in UPSA scores. The meaningful change rates of social cognition and composite scores in MCCB were significantly higher in the motivator group than in the control group. After adjusting for additional variables, the extrinsic motivator had a significant effect on the meaningful MCCB composite score change. Conclusively, our findings suggest beneficial effects of extrinsic motivator on the MCCB score in patients with schizophrenia. In the future, the implementation and interpretation of the MCCB considering the motivation is necessary.",2020,"We found significant time × group interactions in processing speed, verbal learning, visual learning, and composite scores of MCCB.","['enrolled 60 clinically stable patients with schizophrenia and allocated them to the motivator or control group', 'patients with schizophrenia']",['extrinsic motivator'],"['meaningful MCCB composite score change', 'processing speed, verbal learning, visual learning, and composite scores of MCCB', 'Consensus Cognitive Battery (MCCB) and UCSD Performance-Based Skills Assessment (UPSA) scores', 'evaluation of cognitive and daily living functions', 'UPSA scores', 'MCCB score', 'social cognition and composite scores in MCCB', 'cognitive function and daily living function']","[{'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205101', 'cui_str': 'External'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0582591', 'cui_str': 'Processing speed'}, {'cui': 'C0042531', 'cui_str': 'Verbal learning'}, {'cui': 'C0582587', 'cui_str': 'Visual learning'}, {'cui': 'C0376298', 'cui_str': 'Consensus'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",60.0,0.0185012,"We found significant time × group interactions in processing speed, verbal learning, visual learning, and composite scores of MCCB.","[{'ForeName': 'Sung-Jin', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Department of Psychiatry, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.'}, {'ForeName': 'Do-Un', 'Initials': 'DU', 'LastName': 'Jung', 'Affiliation': 'Department of Psychiatry, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea. Electronic address: gabriel.jdu@gmail.com.'}, {'ForeName': 'Jung-Joon', 'Initials': 'JJ', 'LastName': 'Moon', 'Affiliation': 'Department of Psychiatry, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.'}, {'ForeName': 'Dong-Wook', 'Initials': 'DW', 'LastName': 'Jeon', 'Affiliation': 'Department of Psychiatry, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.'}, {'ForeName': 'Young-Soo', 'Initials': 'YS', 'LastName': 'Seo', 'Affiliation': 'Department of Psychiatry, Sharing and Happiness Hospital, Busan, Republic of Korea.'}, {'ForeName': 'Sung-Soo', 'Initials': 'SS', 'LastName': 'Jung', 'Affiliation': 'Department of Psychiatry, Sharing and Happiness Hospital, Busan, Republic of Korea.'}, {'ForeName': 'Yoo-Chul', 'Initials': 'YC', 'LastName': 'Lee', 'Affiliation': 'Department of Psychiatry, Busan Metropolitan Mental Hospital, Busan, Republic of Korea.'}, {'ForeName': 'Jeong-Eun', 'Initials': 'JE', 'LastName': 'Kim', 'Affiliation': 'Department of Psychiatry, Busan Metropolitan Mental Hospital, Busan, Republic of Korea.'}]",Schizophrenia research,['10.1016/j.schres.2020.03.036'] 346,31978354,"Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study.","BACKGROUND Influenza is an important public health problem and existing vaccines are not completely protective. New vaccines that protect by alternative mechanisms are needed to improve efficacy of influenza vaccines. In 2015, we did a phase 1 trial of an oral influenza vaccine, VXA-A1.1. A favourable safety profile and robust immunogenicity results in that trial supported progression of the vaccine to the current phase 2 trial. The aim of this study was to evaluate efficacy of the vaccine in a human influenza challenge model. METHODS We did a single-site, placebo-controlled and active-controlled, phase 2 study at WCCT Global, Costa Mesa, CA, USA. Eligible individuals had an initial A/California/H1N1 haemagglutination inhibition titre of less than 20 and were aged 18-49 years and in good health. Individuals were randomly assigned (2:2:1) to receive a single immunisation of either 10 11 infectious units of VXA-A1.1 (a monovalent tablet vaccine) orally, a full human dose of quadrivalent inactivated influenza vaccine (IIV) via intramuscular injection, or matched placebo. Randomisation was done by computer-generated assignments with block size of five. An unmasked pharmacist provided the appropriate vaccines and placebos to the administrating nurse. Individuals receiving the treatments, investigators, and staff were all masked to group assignments. 90 days after immunisation, individuals without clinically significant symptoms or signs of influenza, an oral temperature of higher than 37·9°C, a positive result for respiratory viral shedding on a Biofire test, and any investigator-assessed contraindications were challenged intranasally with 0·5 mL wild-type A/CA/like(H1N1)pdm09 influenza virus. The primary outcomes were safety, which was assessed in all immunised participants through 365 days, and influenza-positive illness after viral challenge, which was assessed in individuals that received the viral challenge and the required number of assessments post viral challenge. This trial is registered with ClinicalTrials.gov, number NCT02918006. RESULTS Between Aug 31, 2016, and Jan 23, 2017, 374 individuals were assessed for eligibility, of whom 179 were randomly assigned to receive either VXA-A1.1 (n=71 [one individual did not provide a diary card, thus the solicited events were assessed in 70 individuals]), IIV (n=72), or placebo (n=36). Between Dec 2, 2016, and April 26, 2017, 143 eligible individuals (58 in the VXA-A1.1 group, 54 in the IIV group, and 31 in the placebo group) were challenged with influenza virus. VXA-A1.1 was well tolerated with no serious or medically significant adverse events. The most prevalent solicited adverse events for each of the treatment groups after immunisation were headache in the VXA-A1.1 (in five [7%] of 70 participants) and placebo (in seven [19%] of 36 participants) groups and tenderness at injection site in the IIV group (in 19 [26%] of 72 participants) Influenza-positive illness after challenge was detected in 17 (29%) of 58 individuals in the VXA-A1.1 group, 19 (35%) of 54 in the IIV group, and 15 (48%) of 31 in the placebo group. INTERPRETATION Orally administered VXA-A1.1 was well tolerated and generated protective immunity against virus shedding, similar to a licensed intramuscular IIV. These results represent a major step forward in developing a safe and effective oral influenza vaccine. FUNDING Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, and Biomedical Advanced Research and Development Authority.",2020,The most prevalent solicited adverse events for each of the treatment groups after immunisation were headache in the VXA-A1.1,"['143 eligible individuals (58 in the VXA-A1.1 group, 54 in the IIV group, and 31 in the placebo group) were challenged with influenza virus', 'Between Aug 31, 2016, and Jan 23, 2017, 374 individuals were assessed for eligibility, of whom 179', 'Eligible individuals had an initial A/California/H1N1 haemagglutination inhibition titre of less than 20 and were aged 18-49 years and in good health']","['oral influenza vaccine', 'vaccine', 'placebo', 'oral influenza vaccine, VXA-A1.1', 'VXA-A1.1 (a monovalent tablet vaccine) orally, a full human dose of quadrivalent inactivated influenza vaccine (IIV) via intramuscular injection, or matched placebo', 'VXA-A1.1']","['headache', 'Efficacy, immunogenicity, and safety', 'Influenza-positive illness', 'tenderness at injection site']","[{'cui': 'C4517573', 'cui_str': 'One hundred and forty-three'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4316910', 'cui_str': 'Influenzavirus'}, {'cui': 'C4517609', 'cui_str': '179 (qualifier value)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0580264', 'cui_str': 'H1N1'}, {'cui': 'C0018904', 'cui_str': 'Hemagglutination Inhibition Tests'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0021403', 'cui_str': 'Influenza Vaccines'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0021492', 'cui_str': 'Intramuscular injection (procedure)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]","[{'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0021400', 'cui_str': 'Influenza, Human'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0234233', 'cui_str': 'Tenderness (finding)'}, {'cui': 'C0221208', 'cui_str': 'Injection site (morphologic abnormality)'}]",374.0,0.340586,The most prevalent solicited adverse events for each of the treatment groups after immunisation were headache in the VXA-A1.1,"[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Liebowitz', 'Affiliation': 'Vaxart, South San Francisco, CA, USA.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Gottlieb', 'Affiliation': 'Vaxart, South San Francisco, CA, USA.'}, {'ForeName': 'Nikita S', 'Initials': 'NS', 'LastName': 'Kolhatkar', 'Affiliation': 'Vaxart, South San Francisco, CA, USA.'}, {'ForeName': 'Shaily J', 'Initials': 'SJ', 'LastName': 'Garg', 'Affiliation': 'Vaxart, South San Francisco, CA, USA.'}, {'ForeName': 'Jason M', 'Initials': 'JM', 'LastName': 'Asher', 'Affiliation': 'Biomedical Advanced Research and Development Authority, Washington, DC, USA.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Nazareno', 'Affiliation': 'Vaxart, South San Francisco, CA, USA.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Kim', 'Affiliation': 'Ark Clinical Research, Long Beach, CA, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'McIlwain', 'Affiliation': 'WCCT Global, Costa Mesa, CA, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Sean N', 'Initials': 'SN', 'LastName': 'Tucker', 'Affiliation': 'Vaxart, South San Francisco, CA, USA. Electronic address: sean_tucker@mac.com.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(19)30584-5'] 347,32237995,Attending After-School Physical Activity Club 2 Days a Week Attenuated an Increase in Percentage Body Fat and a Decrease in Fitness Among Adolescent Girls at Risk for Obesity.,"PURPOSE To evaluate the effect of a 17-week intervention, including an after-school physical activity (PA) club 3 d/wk, on moderate-to-vigorous physical activity (MVPA), body mass index (BMI) z score, percentage body fat (%BF), and cardiorespiratory fitness (CRF) among fifth to eighth grade girls having a BMI z score ≥0, and explore whether intervention outcomes varied by club attendance (1 vs 2 vs 3 d/wk). DESIGN Secondary analysis of data from a group randomized controlled trial (N = 1519, 10- to 15-year-old girls: n = 753 intervention; n = 766 control). SETTING Twenty-four Midwestern US schools (n = 12 intervention; n = 12 control). SAMPLE Subsample (n = 1194 girls) from trial's intervention (n = 593 girls) and control (n = 601 girls) groups having BMI z scores ≥0. MEASURES Moderate-to-vigorous physical activity (min/h), BMI z score, %BF, and CRF ( V ˙ O 2max : mL/kg/min) were estimated at baseline and postintervention. ANALYSIS Linear mixed-effect models. RESULTS Intervention group gained less %BF ( B = -0.35, P = .016), and their CRF decreased less ( B = 0.22, P = . 010) than the control. Marginally significant findings showed girls attending the club an average of 1 d/wk had greater increases in %BF ( B = 0.33, P = .087) and MVPA ( B = 0.20, P = . 083) and a greater decrease in CRF ( B = -0.20, P = . 061) than girls attending 3 d/wk. No differences occurred between girls who attended 2 versus 3 d/wk for any outcomes. CONCLUSIONS The intervention attenuated an increase in %BF and a decrease in CRF among girls at risk for obesity from baseline to postintervention. Offering the after-school PA club 2 d/wk may be adequate for achieving outcomes.",2020,"RESULTS Intervention group gained less %BF ( B = -0.35, P = .016), and their CRF decreased less ( B = 0.22, P = .","['Adolescent Girls at Risk for Obesity', ""SAMPLE\n\n\nSubsample (n = 1194 girls) from trial's intervention (n = 593 girls) and"", 'N = 1519, 10- to 15-year-old girls: n = 753 intervention; n = 766 control', 'control (n = 601 girls) groups having BMI z scores ≥0', 'Twenty-four Midwestern US schools (n = 12 intervention; n = 12 control']",[],"['Percentage Body Fat', 'Fitness', 'Moderate-to-vigorous physical activity (min/h), BMI z score, %BF, and CRF ( V', 'BF', 'CRF', 'MVPA', 'moderate-to-vigorous physical activity (MVPA), body mass index (BMI) z score, percentage body fat (%BF), and cardiorespiratory fitness (CRF']","[{'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0036375', 'cui_str': 'School'}]",[],"[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0010132', 'cui_str': 'Corticotropin-Releasing Hormone'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}]",,0.0252926,"RESULTS Intervention group gained less %BF ( B = -0.35, P = .016), and their CRF decreased less ( B = 0.22, P = .","[{'ForeName': 'Lorraine B', 'Initials': 'LB', 'LastName': 'Robbins', 'Affiliation': 'College of Nursing, Michigan State University, East Lansing, MI, USA.'}, {'ForeName': 'Jiying', 'Initials': 'J', 'LastName': 'Ling', 'Affiliation': 'College of Nursing, Michigan State University, East Lansing, MI, USA.'}, {'ForeName': 'Fujun', 'Initials': 'F', 'LastName': 'Wen', 'Affiliation': 'Center for Family Health, Jackson, MI, USA.'}]",American journal of health promotion : AJHP,['10.1177/0890117120915679'] 348,32234275,"Does Telehealth Delivery of a Dyadic Dementia Care Program Provide a Noninferior Alternative to Face-To-Face Delivery of the Same Program? A Randomized, Controlled Trial.","OBJECTIVE This study aimed to determine whether delivery of a dyadic intervention using telehealth was noninferior to delivery of the same program using traditional face-to-face delivery through home visits. DESIGN We conducted a noninferiority randomized controlled trial. PARTICIPANTS Participants had a diagnosis of dementia, were living in the community, and had an informal caregiver who reported difficulties in managing activities of daily living or behavioral symptoms. INTERVENTION Participants were randomized to receive either telehealth or home visit delivery of the same intervention program. MEASUREMENTS The primary outcome was the Caregiving Mastery Index, secondary outcomes included caregiver's perceptions of change, activities of daily living function, and type and frequency of behavioral symptoms of persons living with dementia. Therapists delivering the intervention recorded the time spent delivering the intervention as well as travel time. RESULTS Sixty-three dyads were recruited and randomized. Both groups reported improvements for the primary outcome, however, these were not statistically significant. There were no significant differences between groups for the primary outcome (mean difference 0.09 (95% confidence interval -1.26 to 1.45) or the secondary outcomes at 4 months. Both groups reported significant improvements in caregiver's perceptions of change. The amount of time spent delivering the content of the program was similar between groups, however offering the intervention via telehealth significantly reduced travel time (mean 255.9 minutes versus mean 77.2 minutes, p <0.0001). CONCLUSION It is feasible to offer dyadic interventions via telehealth and doing so reduces travel time and results in similar benefits for families.",2020,"The amount of time spent delivering the content of the program was similar between groups, however offering the intervention via telehealth significantly reduced travel time (mean 255.9 minutes versus mean 77.2 minutes, p <0.0001). ","['Participants had a diagnosis of dementia, were living in the community, and had an informal caregiver who reported difficulties in managing activities of daily living or behavioral symptoms', 'Sixty-three dyads were recruited and randomized']",['telehealth or home visit delivery of the same intervention program'],"['travel time', ""Caregiving Mastery Index, secondary outcomes included caregiver's perceptions of change, activities of daily living function, and type and frequency of behavioral symptoms of persons living with dementia""]","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1319882', 'cui_str': 'Informal caregiver'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C1269688', 'cui_str': 'Activities of daily living management'}, {'cui': 'C0004941', 'cui_str': 'Behavioral Symptoms'}, {'cui': 'C4319614', 'cui_str': '63'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]","[{'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0040802', 'cui_str': 'Travel'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0004941', 'cui_str': 'Behavioral Symptoms'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}]",63.0,0.213133,"The amount of time spent delivering the content of the program was similar between groups, however offering the intervention via telehealth significantly reduced travel time (mean 255.9 minutes versus mean 77.2 minutes, p <0.0001). ","[{'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Laver', 'Affiliation': 'College of Medicine and Public Health (KL, EL, OD, MC), Flinders University, Adelaide, South Australia, Australia. Electronic address: Kate.Laver@flinders.edu.au.'}, {'ForeName': 'Enwu', 'Initials': 'E', 'LastName': 'Liu', 'Affiliation': 'College of Medicine and Public Health (KL, EL, OD, MC), Flinders University, Adelaide, South Australia, Australia.'}, {'ForeName': 'Lindy', 'Initials': 'L', 'LastName': 'Clemson', 'Affiliation': 'University of Sydney (LC), Sydney, New South Wales, Australia.'}, {'ForeName': 'Owen', 'Initials': 'O', 'LastName': 'Davies', 'Affiliation': 'College of Medicine and Public Health (KL, EL, OD, MC), Flinders University, Adelaide, South Australia, Australia.'}, {'ForeName': 'Len', 'Initials': 'L', 'LastName': 'Gray', 'Affiliation': 'University of Queensland (LG), Queensland, Australia.'}, {'ForeName': 'Laura N', 'Initials': 'LN', 'LastName': 'Gitlin', 'Affiliation': 'Drexel University (LNG), Philadelphia, PA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Crotty', 'Affiliation': 'College of Medicine and Public Health (KL, EL, OD, MC), Flinders University, Adelaide, South Australia, Australia.'}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2020.02.009'] 349,32234329,"Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.","BACKGROUND & AIMS Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT) that has been hypothesized to improve non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake and stimulating hepatic bile acid production. We studied the safety, tolerability and efficacy of volixibat in patients with NASH. METHODS In this double-blind, phase II dose-finding study, adults with ≥5% steatosis and NASH without cirrhosis (N = 197) were randomized to receive volixibat (5, 10 or 20 mg) or placebo once daily for 48 weeks. The endpoints of a predefined interim analysis (n = 80), at week 24, were: ≥5% reduction in MRI-proton density fat fraction and ≥20% reduction in serum alanine aminotransferase levels. The primary endpoint was a ≥2-point reduction in non-alcoholic fatty liver disease activity score without worsening fibrosis at week 48. RESULTS Volixibat did not meet either interim endpoint; the study was terminated owing to lack of efficacy. In participants receiving any volixibat dose, mean serum 7-alpha-hydroxy-4-cholesten-3-one (C4; a biomarker of bile acid synthesis) increased from baseline to week 24 (+38.5 ng/ml [SD 53.18]), with concomitant decreases in serum total cholesterol (-14.5 mg/dl [SD 28.32]) and low-density lipoprotein cholesterol (-16.1 mg/dl [SD 25.31]). These changes were generally dose-dependent. On histological analysis, a greater proportion of participants receiving placebo (38.5%, n = 5/13) than volixibat (30.0%, n = 9/30) met the primary endpoint. Treatment-emergent adverse events (TEAEs) were mainly mild or moderate. No serious TEAEs were related to volixibat. Diarrhoea was the most common TEAE overall and the most common TEAE leading to discontinuation. CONCLUSIONS Increased serum C4 and decreased serum cholesterol levels provide evidence of target engagement. However, inhibition of ASBT by volixibat did not elicit a liver-related therapeutic benefit in adults with NASH. LAY SUMMARY A medicine called volixibat has previously been shown to reduce cholesterol levels in the blood. This study investigated whether volixibat could reduce the amount of fat in the liver and reduce liver injury in adults with an advanced form of non-alcoholic fatty liver disease. Volixibat did not reduce the amount of fat in the liver, nor did it have any other beneficial effect on liver injury. Participants in the study generally tolerated the side effects of volixibat and, as in previous studies, the main side effect was diarrhoea. These results show that volixibat is not an effective treatment for people with fatty liver disease. CLINICAL TRIAL IDENTIFIER NCT02787304.",2020,A predefined interim analysis (n = 80) at week 24 had endpoints of ≥5% reduction in magnetic resonance imaging-proton density fat fraction and ≥20% reduction in serum alanine aminotransferase levels.,"['Adults with ≥5% steatosis and NASH without cirrhosis (N = 197', 'adults with non-alcoholic steatohepatitis']",['placebo'],"['Diarrhoea', 'serum total cholesterol', 'serum cholesterol levels', 'low-density lipoprotein cholesterol', 'mean serum 7-alpha-hydroxy-4-cholesten-3-one (C4; a biomarker of bile acid synthesis', 'serum alanine aminotransferase levels', '≥2-point reduction in non-alcoholic fatty liver disease activity score without worsening fibrosis']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0152254', 'cui_str': 'Fatty degeneration'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}, {'cui': 'C3241937', 'cui_str': 'Nonalcoholic steatohepatitis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0587184', 'cui_str': 'Serum cholesterol measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0049730', 'cui_str': '7 alpha-hydroxy-4-cholesten-3-one'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005390', 'cui_str': 'Bile acid'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}]",197.0,0.566627,A predefined interim analysis (n = 80) at week 24 had endpoints of ≥5% reduction in magnetic resonance imaging-proton density fat fraction and ≥20% reduction in serum alanine aminotransferase levels.,"[{'ForeName': 'Philip N', 'Initials': 'PN', 'LastName': 'Newsome', 'Affiliation': 'National Institute for Health Research, Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. Electronic address: p.n.newsome@bham.ac.uk.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Palmer', 'Affiliation': 'Shire Plc, a Takeda company, Lexington, MA, USA.'}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Freilich', 'Affiliation': 'Kansas City Research Institute, Kansas City, MO, USA.'}, {'ForeName': 'Muhammad Y', 'Initials': 'MY', 'LastName': 'Sheikh', 'Affiliation': 'Fresno Clinical Research Center, Fresno, CA, USA.'}, {'ForeName': 'Aasim', 'Initials': 'A', 'LastName': 'Sheikh', 'Affiliation': 'GI Specialists of Georgia, Marietta, GA, USA.'}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'Sarles', 'Affiliation': 'DHAT Research Institute, Garland, TX, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Herring', 'Affiliation': 'Quality Medical Research, PLLC, Nashville, TN, USA.'}, {'ForeName': 'Parvez', 'Initials': 'P', 'LastName': 'Mantry', 'Affiliation': 'Methodist Health System Clinical Research Institute, Dallas, TX, USA.'}, {'ForeName': 'Zeid', 'Initials': 'Z', 'LastName': 'Kayali', 'Affiliation': 'Inland Empire Liver Foundation, Rialto, CA, USA.'}, {'ForeName': 'Tarek', 'Initials': 'T', 'LastName': 'Hassanein', 'Affiliation': 'Southern California Research Center, Coronado, CA, USA.'}, {'ForeName': 'Hak-Myung', 'Initials': 'HM', 'LastName': 'Lee', 'Affiliation': 'Shire Plc, a Takeda company, Lexington, MA, USA.'}, {'ForeName': 'Guruprasad P', 'Initials': 'GP', 'LastName': 'Aithal', 'Affiliation': 'National Institute for Health Research, Nottingham Biomedical Research Centre at the Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK; Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of hepatology,['10.1016/j.jhep.2020.03.024'] 350,30789027,Consumer directed care in residential aged care: an evaluation of a staff training program.,"Objectives: The advent of Consumer-Directed Care (CDC, or individualized care) in Residential Aged Care Facilities (RACFs, or residential care) will require a paradigm shift in service delivery. This article evaluated the six-session Resident at the Centre of Care (RCC) staff training program designed to equip staff to implement a CDC model of care among residents. Method: There were two experimental conditions: RCC training program alone, RCC training program plus support, and a 'care as usual' condition. Outcome measures were resident quality of life (QoL) and resident working relationships with staff at 3-month follow-up. At Time 1, 92 residents from RACFs participated in the program. The RCC is six sessions that focus on the development of staff skills in communicating with residents, as well as the organizational change and transformational leadership that is needed for the implementation of CDC. Results: There were significant improvements in resident QoL. There was no major difference between the RCC Program plus support condition compared to the RCC Program alone condition, but both were associated with more positive changes in resident QoL than the 'care as usual' condition. Conclusion: This study demonstrates that training staff in strategies to implement CDC in RACFs can lead to an improvement in the wellbeing of many residents, and that additional support to assist staff to implement the strategies may not be required to produce such improvements. Longer term follow-up is necessary to determine if the improvements in resident QoL are sustained.",2020,"There was no major difference between the RCC Program plus support condition compared to the RCC Program alone condition, but both were associated with more positive changes in resident QoL than the 'care as usual' condition. ","['residential aged care', 'Residential Aged Care Facilities (RACFs, or residential care', 'six-session Resident at the Centre of Care (RCC) staff training program designed to equip staff to implement a CDC model of care among residents', '92 residents from RACFs participated in the program']","[""RCC training program alone, RCC training program plus support, and a 'care as usual' condition"", 'Consumer-Directed Care (CDC, or individualized care']","['resident quality of life (QoL) and resident working relationships with staff', 'resident QoL']","[{'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0007670', 'cui_str': 'CDC'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0007670', 'cui_str': 'CDC'}]","[{'cui': 'C0034380'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}]",,0.0179643,"There was no major difference between the RCC Program plus support condition compared to the RCC Program alone condition, but both were associated with more positive changes in resident QoL than the 'care as usual' condition. ","[{'ForeName': 'Marita P', 'Initials': 'MP', 'LastName': 'McCabe', 'Affiliation': 'School of Health Sciences, Swinburne University of Technology, Hawthorn, Australia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Beattie', 'Affiliation': 'Dementia Centre for Research Collaboration, Queensland University of Technology, Brisbane, Australia.'}, {'ForeName': 'Gery', 'Initials': 'G', 'LastName': 'Karantzas', 'Affiliation': 'School of Psychology, Deakin University, Burwood, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Mellor', 'Affiliation': 'School of Psychology, Deakin University, Burwood, Australia.'}, {'ForeName': 'Kerrie', 'Initials': 'K', 'LastName': 'Sanders', 'Affiliation': 'Department of Medicine, University of Melbourne and Western Health, Sunshine Hospital, Melbourne, Australia.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Busija', 'Affiliation': 'School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.'}, {'ForeName': 'Belinda', 'Initials': 'B', 'LastName': 'Goodenough', 'Affiliation': 'Dementia Training Australia, University of Wollongong, Wollongong, Australia.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Bennett', 'Affiliation': 'School of Allied Health, Australian Catholic University, Sydney, Australia.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'von Treuer', 'Affiliation': 'Cairnmillar Institute, Melbourne, Australia.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Byers', 'Affiliation': 'School of Health Sciences, Swinburne University of Technology, Hawthorn, Australia.'}]",Aging & mental health,['10.1080/13607863.2019.1574711'] 351,32045773,Comparison of hemocoagulase atrox versus tranexamic acid used in primary total knee arthroplasty: A randomized controlled trial.,"BACKGROUND Total knee arthroplasty (TKA) has been considered as an effective choice for end-stage osteoarthritis or rheumatic arthritis. Tranexamic acid (TXA) has been widely used to prevent excessive blood loss perioperatively. Similarly, hemocoagulase atrox can significantly diminish blood loss and transfusion requirements in surgeries, however, it was rarely used in TKA. The purpose of this study is to identify whether hemocoagulase atrox is equal to TXA in reducing blood loss and transfusion rates following TKA, and compare clinical outcomes and complications between the two groups. METHODS 74 patients were randomized to receive TXA (1.5 g intra-articular combined with 1.5 g intravenous), or hemocoagulase atrox (1 U intra-articular combined with 1 U intravenous). The primary outcome was total blood loss. The secondary outcomes included reduction of hemoglobin concentration, clinical outcomes, blood coagulation values, thromboembolic complications, and transfusion rates. RESULTS The mean total blood loss was 431.7 mL in the TXA group compared with 644.6 mL in the hemocoagulase atrox group, with statistical significance (P < 0.05). There were significant differences in reduction of hemoglobin level (P < 0.05). The rate of deep vein thrombosis (DVT) in patients given TXA was higher than those given hemocoagulase atrox, however, there were no significant differences. No transfusions were required in either group, and no significant differences were found in the length of hospital stay and clinical outcomes. CONCLUSIONS Although the blood loss was significantly greater in the hemocoagulase atrox group, no transfusions were required and no significant differences were observed for any other outcomes measured. Meanwhile, the rate of DVT in the hemocoagulase atrox group tends to be lower than those in TXA group. We concluded that hemocoagulase atrox was not superior to TXA in reducing perioperative blood loss. Further studies are warranted to evaluate if hemocoagulase atrox use could improve perioperative blood loss in patients with high thrombotic risk undergoing TKA.",2020,"No transfusions were required in either group, and no significant differences were found in the length of hospital stay and clinical outcomes. ","['primary total knee arthroplasty', '74 patients', 'patients with high thrombotic risk undergoing TKA']","['TXA', 'Tranexamic acid (TXA', 'Total knee arthroplasty (TKA', 'TXA (1.5\xa0g intra-articular combined with 1.5\xa0g intravenous), or hemocoagulase atrox (1\xa0U intra-articular combined with 1\xa0U intravenous', 'hemocoagulase atrox versus tranexamic acid']","['total blood loss', 'rate of DVT', 'reduction of hemoglobin concentration, clinical outcomes, blood coagulation values, thromboembolic complications, and transfusion rates', 'blood loss and transfusion requirements', 'rate of deep vein thrombosis (DVT', 'length of hospital stay and clinical outcomes', 'perioperative blood loss', 'blood loss and transfusion rates', 'blood loss', 'reduction of hemoglobin level', 'mean total blood loss']","[{'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0442108', 'cui_str': 'Intra-articular (qualifier value)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0917789', 'cui_str': 'Hemocoagulase'}, {'cui': 'C1100331', 'cui_str': '1-(tBuS)-(DHMRP)U'}]","[{'cui': 'C0232100', 'cui_str': 'Exsanguinating Hemorrhage'}, {'cui': 'C0149871', 'cui_str': 'Deep Vein Thrombosis'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C1318517', 'cui_str': 'Hemoglobin concentration, dipstick - finding'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0005778', 'cui_str': 'Blood Clotting'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0199960', 'cui_str': 'Transfusion - action (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",74.0,0.0637642,"No transfusions were required in either group, and no significant differences were found in the length of hospital stay and clinical outcomes. ","[{'ForeName': 'Ji-Zheng', 'Initials': 'JZ', 'LastName': 'Qin', 'Affiliation': 'Zhongshan Hospital, Xiamen University, Fujian 361004, China.'}, {'ForeName': 'Shao-Jie', 'Initials': 'SJ', 'LastName': 'Wang', 'Affiliation': 'Zhongshan Hospital, Xiamen University, Fujian 361004, China.'}, {'ForeName': 'Xin-Peng', 'Initials': 'XP', 'LastName': 'Zheng', 'Affiliation': 'Zhongshan Hospital, Xiamen University, Fujian 361004, China.'}, {'ForeName': 'Hong-Hai', 'Initials': 'HH', 'LastName': 'Zhao', 'Affiliation': 'Zhongshan Hospital, Xiamen University, Fujian 361004, China.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Lin', 'Affiliation': 'Zhongshan Hospital, Xiamen University, Fujian 361004, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Shi', 'Affiliation': 'Zhongshan Hospital, Xiamen University, Fujian 361004, China.'}, {'ForeName': 'Chun', 'Initials': 'C', 'LastName': 'Xia', 'Affiliation': 'Zhongshan Hospital, Xiamen University, Fujian 361004, China. Electronic address: chunxia99@aliyun.com.'}]",Thrombosis research,['10.1016/j.thromres.2020.02.001'] 352,32027842,"Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study.","BACKGROUND The monoclonal antibody m102.4 is a potent, fully human antibody that neutralises Hendra and Nipah viruses in vitro and in vivo. We aimed to investigate the safety, tolerability, pharmacokinetics, and immunogenicity of m102.4 in healthy adults. METHODS In this double-blind, placebo-controlled, single-centre, dose-escalation, phase 1 trial of m102.4, we randomly assigned healthy adults aged 18-50 years with a body-mass index of 18·0-35·0 kg/m 2 to one of five cohorts. A sentinel pair for each cohort was randomly assigned to either m102.4 or placebo. The remaining participants in each cohort were randomly assigned (5:1) to receive m102.4 or placebo. Cohorts 1-4 received a single intravenous infusion of m102.4 at doses of 1 mg/kg (cohort 1), 3 mg/kg (cohort 2), 10 mg/kg (cohort 3), and 20 mg/kg (cohort 4), and were monitored for 113 days. Cohort 5 received two infusions of 20 mg/kg 72 h apart and were monitored for 123 days. The primary outcomes were safety and tolerability. Secondary outcomes were pharmacokinetics and immunogenicity. Analyses were completed according to protocol. The study was registered on the Australian New Zealand Clinical Trials Registry, ACTRN12615000395538. FINDINGS Between March 27, 2015, and June 16, 2016, 40 (52%) of 77 healthy screened adults were enrolled in the study. Eight participants were assigned to each cohort (six received m102.4 and two received placebo). 86 treatment-emergent adverse events were reported, with similar rates between placebo and treatment groups. The most common treatment-related event was headache (12 [40%] of 30 participants in the combined m102.4 group, and three [30%] of ten participants in the pooled placebo group). No deaths or severe adverse events leading to study discontinuation occurred. Pharmacokinetics based on those receiving m102.4 (n=30) were linear, with a median half-life of 663·3 h (range 474·3-735·1) for cohort 1, 466·3 h (382·8-522·3) for cohort 2, 397·0 h (333·9-491·8) for cohort 3, and 466·7 h (351·0-889·6) for cohort 4. The elimination kinetics of those receiving repeated dosing (cohort 5) were similar to those of single-dose recipients (median elimination half-time 472·0 [385·6-592·0]). Anti-m102.4 antibodies were not detected at any time-point during the study. INTERPRETATION Single and repeated dosing of m102.4 were well tolerated and safe, displayed linear pharmacokinetics, and showed no evidence of an immunogenic response. This study will inform future dosing regimens for m102.4 to achieve prolonged exposure for systemic efficacy to prevent and treat henipavirus infections. FUNDING Queensland Department of Health, the National Health and Medical Research Council, and the National Hendra Virus Research Program.",2020,"BACKGROUND The monoclonal antibody m102.4 is a potent, fully human antibody that neutralises Hendra and Nipah viruses in vitro and in vivo.","['Between March 27, 2015, and June 16, 2016, 40 (52%) of 77 healthy screened adults were enrolled in the study', 'healthy adults', 'healthy adults aged 18-50 years with a body-mass index of 18·0-35·0 kg/m 2 to one of five cohorts']","['human monoclonal antibody targeting the G glycoprotein', 'placebo']","['pharmacokinetics and immunogenicity', 'safety and tolerability', 'headache', 'tolerated and safe', 'Safety, tolerability, pharmacokinetics, and immunogenicity', 'elimination kinetics', 'safety, tolerability, pharmacokinetics, and immunogenicity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C3542957', 'cui_str': 'Antineoplastic MAbs'}, {'cui': 'C0017968', 'cui_str': 'Glycoproteins'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}]",8.0,0.485018,"BACKGROUND The monoclonal antibody m102.4 is a potent, fully human antibody that neutralises Hendra and Nipah viruses in vitro and in vivo.","[{'ForeName': 'Elliott Geoffrey', 'Initials': 'EG', 'LastName': 'Playford', 'Affiliation': 'Infection Management Services, Princess Alexandra Hospital, Brisbane, QLD, Australia; School of Medicine, University of Queensland Brisbane, QLD, Australia. Electronic address: geoffrey.Playford@health.qld.gov.au.'}, {'ForeName': 'Trent', 'Initials': 'T', 'LastName': 'Munro', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Stephen M', 'Initials': 'SM', 'LastName': 'Mahler', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia; ARC Training Centre for Biopharmaceutical Innovation, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Elliott', 'Affiliation': 'Q-Pharm, Clive Berghofer Cancer Research Centre, Herston, QLD, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Gerometta', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Kym L', 'Initials': 'KL', 'LastName': 'Hoger', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Martina L', 'Initials': 'ML', 'LastName': 'Jones', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia; ARC Training Centre for Biopharmaceutical Innovation, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Griffin', 'Affiliation': 'Q-Pharm, Clive Berghofer Cancer Research Centre, Herston, QLD, Australia; Clinical Tropical Medicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.'}, {'ForeName': 'Kathleen D', 'Initials': 'KD', 'LastName': 'Lynch', 'Affiliation': 'Child Health Research Centre, Faculty of Medicine, University of Queensland Brisbane, QLD, Australia; Communicable Disease Branch, Prevention Division, Queensland Health, Brisbane, QLD, Australia.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Carroll', 'Affiliation': 'Communicable Disease Branch, Prevention Division, Queensland Health, Brisbane, QLD, Australia.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'El Saadi', 'Affiliation': 'Communicable Disease Branch, Prevention Division, Queensland Health, Brisbane, QLD, Australia.'}, {'ForeName': 'Margaret E', 'Initials': 'ME', 'LastName': 'Gilmour', 'Affiliation': 'Q-Pharm, Clive Berghofer Cancer Research Centre, Herston, QLD, Australia.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Hughes', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Hughes', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Edwin', 'Initials': 'E', 'LastName': 'Huang', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'de Bakker', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Reuben', 'Initials': 'R', 'LastName': 'Klein', 'Affiliation': 'Health and Biosecurity Business Unit, CSIRO Australian Animal Health Laboratory, Geelong, VIC, Australia.'}, {'ForeName': 'Mark G', 'Initials': 'MG', 'LastName': 'Scher', 'Affiliation': 'Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.'}, {'ForeName': 'Ina L', 'Initials': 'IL', 'LastName': 'Smith', 'Affiliation': 'Health and Biosecurity Business Unit, CSIRO Australian Animal Health Laboratory, Geelong, VIC, Australia.'}, {'ForeName': 'Lin-Fa', 'Initials': 'LF', 'LastName': 'Wang', 'Affiliation': 'Health and Biosecurity Business Unit, CSIRO Australian Animal Health Laboratory, Geelong, VIC, Australia; Programme in Emerging Infectious Diseases, Duke-National University Medical School, Singapore.'}, {'ForeName': 'Stephen B', 'Initials': 'SB', 'LastName': 'Lambert', 'Affiliation': 'Child Health Research Centre, Faculty of Medicine, University of Queensland Brisbane, QLD, Australia; Communicable Disease Branch, Prevention Division, Queensland Health, Brisbane, QLD, Australia.'}, {'ForeName': 'Dimiter S', 'Initials': 'DS', 'LastName': 'Dimitrov', 'Affiliation': 'Center for Antibody Therapeutics, University of Pittsburgh Medical School, Pittsburgh, PA, USA.'}, {'ForeName': 'Peter P', 'Initials': 'PP', 'LastName': 'Gray', 'Affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia; ARC Training Centre for Biopharmaceutical Innovation, University of Queensland Brisbane, QLD, Australia.'}, {'ForeName': 'Christopher C', 'Initials': 'CC', 'LastName': 'Broder', 'Affiliation': 'Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(19)30634-6'] 353,30088982,Morning impairment in vascular function is unrelated to overnight sleep or the inactivity that accompanies sleep.,"Adverse cardiovascular events, such as myocardial infarction and sudden cardiac death, occur more frequently in the morning. Prior studies have shown that vascular endothelial function (VEF), a marker of cardiovascular disease, is attenuated during physical inactivity and declines across the night. We sought to determine whether a morning attenuation in VEF is a result of prior sleep or the inactivity that inevitably accompanies sleep. After 1 wk of a rigorously controlled sleep-wake schedule and behaviors, 10 healthy participants completed a randomized crossover protocol in dim light and constant conditions, incorporating a night of 6 h of sleep opportunity and a night of immobility while they were supine and awake. VEF was measured in the dominant brachial artery as flow mediated dilation (FMD) before and after each 6-h trial. To avoid disturbing sleep and posture of the participants, blood was drawn using a 12-ft catheter from an adjoining laboratory room before, during, and after each 6-h trial, and plasma was analyzed for markers of oxidative stress [malondialdehyde adducts (MDA)], and endothelin-1. Contrary to expectation, both nocturnal sleep and nocturnal inactivity significantly increased FMD ( P < 0.05). There was no significant change in MDA or endothelin-1 within and between trials. Contrary to expectations based on prior studies, we found that overnight sleep or the inactivity that accompanies sleep did not result in attenuation in VEF in the morning hours in healthy people. Thus, it is plausible that the endogenous circadian system, a remaining factor not studied here, is responsible for the commonly observed decline in VEF across the night.",2018,"Contrary to expectation, both nocturnal sleep and nocturnal inactivity significantly increased FMD ( P < 0.05).",['10 healthy participants'],[],"['oxidative stress [malondialdehyde adducts (MDA)], and endothelin-1', 'VEF', 'MDA or endothelin-1', 'nocturnal sleep and nocturnal inactivity significantly increased FMD', 'Adverse cardiovascular events, such as myocardial infarction and sudden cardiac death']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]",[],"[{'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0079281', 'cui_str': 'Endothelin Type 1'}, {'cui': 'C0000379', 'cui_str': '1,3-Benzodioxole-5-ethanamine, alpha-methyl-'}, {'cui': 'C0240526', 'cui_str': 'Night time (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0085298', 'cui_str': 'Sudden Cardiac Death'}]",10.0,0.0712327,"Contrary to expectation, both nocturnal sleep and nocturnal inactivity significantly increased FMD ( P < 0.05).","[{'ForeName': 'Saurabh S', 'Initials': 'SS', 'LastName': 'Thosar', 'Affiliation': 'Oregon Institute of Occupational Health Sciences, Oregon Health & Science University , Portland, Oregon.'}, {'ForeName': 'Alec M', 'Initials': 'AM', 'LastName': 'Berman', 'Affiliation': 'Oregon Institute of Occupational Health Sciences, Oregon Health & Science University , Portland, Oregon.'}, {'ForeName': 'Maya X', 'Initials': 'MX', 'LastName': 'Herzig', 'Affiliation': 'Oregon Institute of Occupational Health Sciences, Oregon Health & Science University , Portland, Oregon.'}, {'ForeName': 'Sally A', 'Initials': 'SA', 'LastName': 'Roberts', 'Affiliation': 'Oregon Institute of Occupational Health Sciences, Oregon Health & Science University , Portland, Oregon.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Lasarev', 'Affiliation': 'Oregon Institute of Occupational Health Sciences, Oregon Health & Science University , Portland, Oregon.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Shea', 'Affiliation': 'Oregon Institute of Occupational Health Sciences, Oregon Health & Science University , Portland, Oregon.'}]","American journal of physiology. Regulatory, integrative and comparative physiology",['10.1152/ajpregu.00143.2018'] 354,32238297,Improving Social Connectedness for Homebound Older Adults: Randomized Controlled Trial of Tele-Delivered Behavioral Activation Versus Tele-Delivered Friendly Visits.,"OBJECTIVE To test the acceptability and effectiveness of a lay-coach-facilitated, videoconferenced, short-term behavioral activation (Tele-BA) intervention for improving social connectedness among homebound older adults. METHODS We employed a two-site, participant-randomized controlled trial with 89 older adults (averaging 74 years old) who were recipients of, and initially screened by, home-delivered meals programs. All participants reported loneliness; many reported being socially isolated and/or dissatisfaction with social support. Participants received five weekly videoconference sessions of either Tele-BA or Tele-FV (friendly visits; active control). Three primary outcomes were social interaction (Duke Social Support Index [DSSI] Social Interaction Subscale), subjective loneliness (PROMIS Social Isolation Scale), and DSSI Satisfaction with Social Support Subscale. Depression severity (PHQ-9) and disability (WHODAS 2.0) were secondary outcomes. Mixed-effects regression models were fit to evaluate outcomes at 6- and 12-weeks follow-up. RESULTS Compared to Tele-FV participants, Tele-BA participants had greater increase in social interaction (t [81] = 2.42, p = 0.018) and satisfaction with social support (t [82] = 2.00, p = 0.049) and decrease in loneliness (t [81] = -3.08, p = 0.003), depression (t [82] = -3.46, p = 0.001), and disability (t [81] = -2.29, p = 0.025). CONCLUSION A short-term, lay-coach-facilitated Tele-BA is a promising intervention for the growing numbers of homebound older adults lacking social connectedness. The intervention holds promise for scalability in programs that already serve homebound older adults. More research is needed to solidify the clinical evidence base, cost-effectiveness and sustainability of Tele-BA delivered by lay coaches for homebound and other older adults.",2020,"Compared to Tele-FV participants, Tele-BA participants had greater increase in social interaction (t [81] = 2.42, p = 0.018) and satisfaction with social support (t [82] = 2.00, p = 0.049) and decrease in loneliness (t [81] = -3.08, p = 0.003), depression (t [82] = -3.46, p = 0.001), and disability (t [81] = -2.29, p = 0.025). ","['89 older adults (averaging 74 years old) who were recipients of, and initially screened by, home-delivered meals programs', 'homebound older adults', 'Homebound Older Adults']","['lay-coach-facilitated, videoconferenced, short-term behavioral activation (Tele-BA) intervention', 'videoconference sessions of either Tele-BA or Tele-FV (friendly visits; active control', 'Tele-Delivered Behavioral Activation Versus Tele-Delivered Friendly Visits', 'lay-coach-facilitated Tele-BA']","['Depression severity (PHQ-9) and disability', 'depression', 'social interaction (Duke Social Support Index [DSSI] Social Interaction Subscale), subjective loneliness (PROMIS Social Isolation Scale), and DSSI Satisfaction with Social Support Subscale', 'disability', 'loneliness', 'satisfaction with social support', 'social interaction']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0242798', 'cui_str': 'Home-Bound Persons'}]","[{'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C1450049', 'cui_str': 'Videoconference'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1515258', 'cui_str': 'Telephone number (property)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0037420', 'cui_str': 'Interaction with others'}, {'cui': 'C1512090', 'cui_str': 'Dukes staging system'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0023974', 'cui_str': 'Feeling lonely'}, {'cui': 'C0037421', 'cui_str': 'Social isolation'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",89.0,0.0496621,"Compared to Tele-FV participants, Tele-BA participants had greater increase in social interaction (t [81] = 2.42, p = 0.018) and satisfaction with social support (t [82] = 2.00, p = 0.049) and decrease in loneliness (t [81] = -3.08, p = 0.003), depression (t [82] = -3.46, p = 0.001), and disability (t [81] = -2.29, p = 0.025). ","[{'ForeName': 'Namkee G', 'Initials': 'NG', 'LastName': 'Choi', 'Affiliation': 'The University of Texas at Austin, Steve Hicks School of Social Work (NGC, CNM), Austin, TX. Electronic address: nchoi@austin.utexas.edu.'}, {'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Pepin', 'Affiliation': 'Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Health (RP, CJS, MLB), Hanover, NH.'}, {'ForeName': 'C Nathan', 'Initials': 'CN', 'LastName': 'Marti', 'Affiliation': 'The University of Texas at Austin, Steve Hicks School of Social Work (NGC, CNM), Austin, TX.'}, {'ForeName': 'Courtney J', 'Initials': 'CJ', 'LastName': 'Stevens', 'Affiliation': 'Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Health (RP, CJS, MLB), Hanover, NH.'}, {'ForeName': 'Martha L', 'Initials': 'ML', 'LastName': 'Bruce', 'Affiliation': 'Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Health (RP, CJS, MLB), Hanover, NH.'}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2020.02.008'] 355,31206595,Validation of a questionnaire algorithm based on repeated open application testing with the constituents of fragrance mix I.,"BACKGROUND In a European study on contact allergy in the general population, it was hypothesized that the combination of contact allergy to a fragrance together with a history indicating dermatitis at exposure, and thereafter subsequent avoidance of scented products, implied a diagnosis of allergic contact dermatitis. OBJECTIVES The primary aim of this study was to validate this hypothesis and algorithm. The secondary aim was to investigate whether there was any association between the outcome of the repeated open application test (ROAT) and the patch test reactivity. METHODS In total, 109 patients with and without contact allergy to fragrance mix (FM) I were recruited. Volunteers from six European dermatology clinics participated in the study including a patch test and a ROAT. RESULTS Positive ROAT reactions were noted in 26 of the 44 volunteers with contact allergy to FM I. None of the volunteers reacted to the vehicle (P < 0·001). More individuals with a positive algorithm had positive ROATs than those with a negative algorithm. However, the difference was not statistically significant. The lower the patch test concentration eliciting a positive test reaction, the more likely a positive ROAT and the more likely that the positive ROAT appeared early during the investigative period. CONCLUSIONS The algorithm used in this study was not substantiated in this ROAT set-up. The stronger the patch test reactivity the more likely was a positive ROAT and the more likely it was that the positive ROAT appeared early during the application period. What's already known about this topic? To the best of our knowledge, a scientifically designed and conducted repeated open application test (ROAT) has never been performed before to validate a diagnosis of allergic contact dermatitis partly based on a questionnaire. What does this study add? This is the largest controlled, randomized and blinded ROAT performed to date. Higher patch test reactivity to fragrance mix I indicated a greater likelihood of a positive ROAT. What are the clinical implications of this work? Further refinement of the questions is required in order to diagnose allergic contact dermatitis from fragrances based on a questionnaire.",2020,Higher patch test reactivity to fragrance mix,"['Volunteers from six European dermatology clinics participated in the study including a patch test and a ROAT', '109 patients with and without contact allergy to fragrance mix (FM']","['fragrance mix', 'repeated open application test (ROAT']",['Positive ROAT reactions'],"[{'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0239307', 'cui_str': 'European (ethnic group)'}, {'cui': 'C3812390', 'cui_str': 'Dermatology clinic (environment)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0030646', 'cui_str': 'Patch Tests'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0002111', 'cui_str': 'Allergy Specialty'}, {'cui': 'C0440059', 'cui_str': 'Fragrance mix (product)'}]","[{'cui': 'C0440059', 'cui_str': 'Fragrance mix (product)'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]","[{'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}]",109.0,0.0341232,Higher patch test reactivity to fragrance mix,"[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bruze', 'Affiliation': 'Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Engfeldt', 'Affiliation': 'Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Ofenloch', 'Affiliation': 'Department of Clinical Social Medicine, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Elsner', 'Affiliation': 'Department of Dermatology, University Hospital Jena, Jena, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Goncalo', 'Affiliation': 'Department of Dermatology, University Hospital and Faculty of Medicine, University of Coimbra, Coimbra, Portugal.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Isaksson', 'Affiliation': 'Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Naldi', 'Affiliation': 'Centro Studi GISED - FROM Presidio Ospedaliero Matteo Rota, Bergamo, Italy.'}, {'ForeName': 'M-L', 'Initials': 'ML', 'LastName': 'Schuttelaar', 'Affiliation': 'Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Å', 'Initials': 'Å', 'LastName': 'Svensson', 'Affiliation': 'Department of Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Diepgen', 'Affiliation': 'Department of Clinical Social Medicine, University Hospital Heidelberg, Heidelberg, Germany.'}]",The British journal of dermatology,['10.1111/bjd.18224'] 356,32232781,Longitudinal resident coaching in the outpatient setting: A novel intervention to improve ambulatory consultation skills.,"BACKGROUND Direct observation with feedback to learners should be a mainstay in resident education, yet it is infrequently done and its impact on consultation skills has rarely been assessed. APPROACH This project presents the framework and implementation of a longitudinal low-frequency, high-intensity direct observation and coaching intervention, and elaborates on insights learned. Internal medicine interns at one residency training program were randomized to an ambulatory coaching intervention or usual precepting. Over one year, coached interns had three complete primary care visits directly observed by a faculty clinician-coach who provided feedback informed by a behavior checklist. Immediately after each of the coached patient encounters, interns completed a structured self-assessment and coaches led a 30-minute feedback session informed by intern self-reflection and checklist items. Interns with usual precepting had two mini-CEX observations over the course of the year without other formal direct observation in the ambulatory setting. EVALUATION As part of the post-intervention assessment, senior faculty members blinded to intervention and control group assignments evaluated videotaped encounters. Coached interns completed an average of 21/23 behaviors from the checklist, while interns from the control group completed 18 (p < 0.05). The median overall grade for coached interns was B+, compared to B-/C+ for controls (p < 0.05). REFLECTION Coaching interns longitudinally using a behavior checklist is feasible and associated with improved consultation performance. Direct observation of complete clinical encounters followed by systematic coaching is educationally valuable, but time and resource intensive.",2020,"Coached interns completed an average of 21/23 behaviors from the checklist, while interns from the control group completed 18 (p < 0.05).",['Internal medicine interns at one residency training program'],['ambulatory coaching intervention or usual precepting'],['median overall grade'],"[{'cui': 'C0021782', 'cui_str': 'Internal Medicine'}, {'cui': 'C0035182', 'cui_str': 'Residency'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0557773', 'cui_str': 'Coach (physical object)'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}]",,0.0156887,"Coached interns completed an average of 21/23 behaviors from the checklist, while interns from the control group completed 18 (p < 0.05).","[{'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Graddy', 'Affiliation': 'Division of Addiction Medicine, Department of Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ryan.graddy@gmail.com.'}, {'ForeName': 'Stasia S', 'Initials': 'SS', 'LastName': 'Reynolds', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Scott M', 'Initials': 'SM', 'LastName': 'Wright', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}]",Perspectives on medical education,['10.1007/s40037-020-00573-5'] 357,32089064,Effects of Maternal Vitamin D3 Supplementation on Offspring Epigenetic Clock of Gestational Age at Birth: A Post-hoc Analysis of a Randomized Controlled Trial.,"Vitamin D could be beneficial for healthy ageing in humans. We previously found that vitamin D supplementation may slow down epigenetic ageing in young African American adults. We tested new epigenetic clocks developed for neonates among a multiethnic population, and tested the hypothesis that maternal vitamin D supplementation would slow down the epigenetic gestational age acceleration (GAA) in newborn babies. Ninety-two pregnant women (aged 29.6 ± 4.8 y; 21% African Americans, 28% Hispanics) were randomized to receive 4000 IU/day vitamin D 3 or placebo, plus prenatal vitamins containing 400 IU vitamin D 3 during pregnancy in a randomized controlled trial (RCT). Cord blood genome-wide methylation analysis was performed on the Illumina Infinium MethylationEPIC Beadchip. DNA methylation gestational age was calculated based on two calculations developed by Knight and Bohlin. DNA methylation gestational ages calculated by Knight's clock and Bohlin' clock were highly correlated with the gestational age in the placebo group (correlation coefficients = 0.88, p s< 0.001, respectively). GAA was associated with higher birth weight ( p = 0.039). In the entire cohort, vitamin D 3 supplementation was not associated with GAA ( p > 0.05). However, vitamin D 3 supplementation decreased GAA by both Knight's clock (β = -0.89, p = 0.047) and Bohlin's clock (β = -0.71, p = 0.005) in the African American participants. Maternal vitamin D 3 supplementation may slow down the epigenetic gestational ageing process in African American neonates. Long-term follow-up studies are warranted to determine the role of epigenetic age acceleration in the growth and development of offspring.",2020,"However, vitamin D 3 supplementation decreased GAA by both Knight's clock (β=-0.89, p =0.047) and Bohlin's clock (β=-0.71, p =0.005) in the African American participants.","['Ninety-two pregnant women (aged 29.6±4.8 years; 21% African Americans, 28% Hispanics', 'African American participants', 'healthy aging in humans', 'neonates among a multiethnic population', 'newborn babies', 'Offspring Epigenetic Clock of Gestational Age at Birth', 'African American neonates', 'young African American adults']","['GAA', 'Vitamin D 3 supplementation', 'vitamin D supplementation', '4000 IU/day vitamin D 3 or placebo, plus prenatal vitamins containing 400 IU vitamin D 3', 'Vitamin D', 'Maternal Vitamin D 3 Supplementation']","[""DNA methylation gestational ages calculated by Knight's clock and Bohlin' clock"", 'GAA', 'higher birth weight']","[{'cui': 'C3816959', 'cui_str': 'Ninety'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1655731', 'cui_str': 'Epigenetics'}, {'cui': 'C0456129', 'cui_str': 'Length of gestation at birth'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C3842327', 'cui_str': '4000 (qualifier value)'}, {'cui': 'C0439465', 'cui_str': 'IU/day'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0772413', 'cui_str': 'Prenatal vitamin'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}]","[{'cui': 'C0376452', 'cui_str': 'DNA Methylation'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0444686', 'cui_str': 'Calculated (qualifier value)'}, {'cui': 'C0349482', 'cui_str': 'High birth weight baby'}]",92.0,0.512595,"However, vitamin D 3 supplementation decreased GAA by both Knight's clock (β=-0.89, p =0.047) and Bohlin's clock (β=-0.71, p =0.005) in the African American participants.","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Georgia Prevention Institute, Department of Medicine, Medical College of Georgia, Augusta University , Augusta, GA, USA.'}, {'ForeName': 'Carol L', 'Initials': 'CL', 'LastName': 'Wagner', 'Affiliation': 'Department of Pediatrics, Medical University of South Carolina ,SC, USA.'}, {'ForeName': 'Yanbin', 'Initials': 'Y', 'LastName': 'Dong', 'Affiliation': 'Georgia Prevention Institute, Department of Medicine, Medical College of Georgia, Augusta University , Augusta, GA, USA.'}, {'ForeName': 'Xiaoling', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Georgia Prevention Institute, Department of Medicine, Medical College of Georgia, Augusta University , Augusta, GA, USA.'}, {'ForeName': 'Judith R', 'Initials': 'JR', 'LastName': 'Shary', 'Affiliation': 'Department of Pediatrics, Medical University of South Carolina ,SC, USA.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'Georgia Prevention Institute, Department of Medicine, Medical College of Georgia, Augusta University , Augusta, GA, USA.'}, {'ForeName': 'Bruce W', 'Initials': 'BW', 'LastName': 'Hollis', 'Affiliation': 'Department of Pediatrics, Medical University of South Carolina ,SC, USA.'}, {'ForeName': 'Haidong', 'Initials': 'H', 'LastName': 'Zhu', 'Affiliation': 'Georgia Prevention Institute, Department of Medicine, Medical College of Georgia, Augusta University , Augusta, GA, USA.'}]",Epigenetics,['10.1080/15592294.2020.1734148'] 358,31948767,Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study.,"BACKGROUND Ivermectin is a potential new vector control tool to reduce malaria transmission. Mosquitoes feeding on a bloodmeal containing ivermectin have a reduced lifespan, meaning they are less likely to live long enough to complete sporogony and become infectious. We aimed to estimate the effect of ivermectin on malaria transmission in various scenarios of use. METHODS We validated an existing population-level mathematical model of the effect of ivermectin mass drug administration (MDA) on the mosquito population and malaria transmission against two datasets: clinical data from a cluster- randomised trial done in Burkina Faso in 2015 wherein ivermectin was given to individuals taller than 90 cm and entomological data from a study of mosquito outcomes after ivermectin MDA for onchocerciasis or lymphatic filariasis in Burkina Faso, Senegal, and Liberia between 2008 and 2013. We extended the existing model to include a range of complementary malaria interventions (seasonal malaria chemoprevention and MDA with dihydroartemisinin-piperaquine) and to incorporate new data on higher doses of ivermectin with a longer mosquitocidal effect. We consider two ivermectin regimens: a single dose of 400 μg/kg (1 × 400 μg/kg) and three consecutive daily doses of 300 μg/kg per day (3 × 300 μg/kg). We simulated the effect of these two doses in a range of usage scenarios in different transmission settings (highly seasonal, seasonal, and perennial). We report percentage reductions in clinical incidence and slide prevalence. FINDINGS We estimate that MDA with ivermectin will reduce prevalence and incidence and is most effective in areas with highly seasonal transmission. In a highly seasonal moderate transmission setting, three rounds of ivermectin only MDA at 3 × 300 μg/kg (rounds spaced 1 month apart) and 70% coverage is predicted to reduce clinical incidence by 71% and prevalence by 34%. We predict that adding ivermectin MDA to seasonal malaria chemoprevention in this setting would reduce clinical incidence by an additional 77% in children younger than 5 years compared with seasonal malaria chemoprevention alone; adding ivermectin MDA to MDA with dihydroartemisinin-piperaquine in this setting would reduce incidence by an additional 75% and prevalence by an additional 64% (all ages) compared with MDA with dihydroartemisinin-piperaquine alone. INTERPRETATION Our modelling predictions suggest that ivermectin could be a valuable addition to the malaria control toolbox, both in areas with persistently high transmission where existing interventions are insufficient and in areas approaching elimination to prevent resurgence. FUNDING Imperial College Junior Research Fellowship.",2020,"Mosquitoes feeding on a bloodmeal containing ivermectin have a reduced lifespan, meaning they are less likely to live long enough to complete sporogony and become infectious.","['for onchocerciasis or lymphatic filariasis in Burkina Faso, Senegal, and Liberia between 2008 and 2013']","['Ivermectin', 'malaria interventions (seasonal malaria chemoprevention and MDA with dihydroartemisinin-piperaquine', 'ivermectin mass drug administration (MDA', 'ivermectin MDA', 'ivermectin']",['clinical incidence'],"[{'cui': 'C0029001', 'cui_str': 'Onchocerciasis'}, {'cui': 'C0013884', 'cui_str': 'Bancroftian Elephantiasis'}, {'cui': 'C0006409', 'cui_str': 'Upper Volta'}, {'cui': 'C0036644', 'cui_str': 'Republic of Senegal'}, {'cui': 'C0023617', 'cui_str': 'Republic of Liberia'}]","[{'cui': 'C0022322', 'cui_str': 'Ivermectin'}, {'cui': 'C0024530', 'cui_str': 'Plasmodium Infections'}, {'cui': 'C0439601', 'cui_str': 'Seasonal course (qualifier value)'}, {'cui': 'C0282515', 'cui_str': 'Chemoprophylaxis'}, {'cui': 'C0000379', 'cui_str': '1,3-Benzodioxole-5-ethanamine, alpha-methyl-'}, {'cui': 'C0058108', 'cui_str': 'quinghaosu, dihydro-'}, {'cui': 'C0071105', 'cui_str': ""Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-)""}, {'cui': 'C4505223', 'cui_str': 'Mass Drug Administration'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}]",,0.376561,"Mosquitoes feeding on a bloodmeal containing ivermectin have a reduced lifespan, meaning they are less likely to live long enough to complete sporogony and become infectious.","[{'ForeName': 'Hannah C', 'Initials': 'HC', 'LastName': 'Slater', 'Affiliation': 'MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK. Electronic address: hslater@path.org.'}, {'ForeName': 'Brian D', 'Initials': 'BD', 'LastName': 'Foy', 'Affiliation': 'Arthropod-borne and Infectious Diseases Laboratory, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Kobylinski', 'Affiliation': 'Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Chaccour', 'Affiliation': 'ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Instituto de Salud Tropical, Universidad de Navarra, Pamplona, Spain; Ifakara Health Institute, Ifakara, Tanzania.'}, {'ForeName': 'Oliver J', 'Initials': 'OJ', 'LastName': 'Watson', 'Affiliation': 'MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Hellewell', 'Affiliation': 'MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK.'}, {'ForeName': 'Ghaith', 'Initials': 'G', 'LastName': 'Aljayyoussi', 'Affiliation': 'Liverpool School of Tropical Medicine, Liverpool, UK.'}, {'ForeName': 'Teun', 'Initials': 'T', 'LastName': 'Bousema', 'Affiliation': 'Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, London, UK; Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, Netherlands.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Burrows', 'Affiliation': 'Medicines for Malaria Venture, Geneva, Switzerland.'}, {'ForeName': 'Umberto', 'Initials': 'U', 'LastName': ""D'Alessandro"", 'Affiliation': 'MRC Unit The Gambia at LSHTM, Fajara, Banjul, Gambia.'}, {'ForeName': 'Haoues', 'Initials': 'H', 'LastName': 'Alout', 'Affiliation': 'ASTRE unit (UMR117), INRA-CIRAD, Montpellier, France.'}, {'ForeName': 'Feiko O', 'Initials': 'FO', 'LastName': 'Ter Kuile', 'Affiliation': 'Liverpool School of Tropical Medicine, Liverpool, UK.'}, {'ForeName': 'Patrick G T', 'Initials': 'PGT', 'LastName': 'Walker', 'Affiliation': 'MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK.'}, {'ForeName': 'Azra C', 'Initials': 'AC', 'LastName': 'Ghani', 'Affiliation': 'MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK.'}, {'ForeName': 'Menno R', 'Initials': 'MR', 'LastName': 'Smit', 'Affiliation': 'Liverpool School of Tropical Medicine, Liverpool, UK.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(19)30633-4'] 359,31802559,The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis.,"BACKGROUND AND AIMS Curcumin has anti-inflammatory properties. The aim of this study was to evaluate the effect of curcumin on improvement of the disease activity in ulcerative colitis (UC). METHODS In this randomized double-blind clinical trial, 70 patients with mild-to-moderate UC were randomly assigned to curcumin (1,500 mg/day) or placebo intake for 8 weeks. Disease clinical activity, quality of life, serum levels of tumor necrosis factor alpha (TNF-α), high-sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR) values, and complete blood count were measured. RESULTS Changes in Simple Clinical Colitis Activity Index score were significantly higher in the curcumin than the placebo group (-5.9 ± 2.08 vs. -2.1 ± 2.6; p = .001). The scores of Inflammatory Bowel Disease Questionnaire-9 and quality of life were significantly higher in the intervention group compared to the control group (p = .006). Furthermore, the curcumin supplementation reduced the serum hs-CRP concentration (-6.3 ± 13.6 vs. 3.7 ± 11.6 μg/ml; p = .01) and ESR levels significantly (-1.6 ± 2.7 vs. -0.09 ± 2.4 mm/hr; p = .02) in comparison with the control group. No significant changes were observed in the TNF-α levels of both groups. CONCLUSIONS Consumption of the curcumin supplement, along with drug therapy, is associated with significant improvement of the clinical outcomes, quality of life, hs-CRP, and ESR in patients with mild-to-moderate UC.",2020,The scores of Inflammatory Bowel Disease Questionnaire-9 and quality of life were significantly higher in the intervention group compared to the control group (p = .006).,"['ulcerative colitis (UC', 'patients with ulcerative colitis', '70 patients with mild-to-moderate UC']","['placebo', 'curcumin', 'curcumin supplementation']","['Disease clinical activity, quality of life, serum levels of tumor necrosis factor alpha (TNF-α), high-sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR) values, and complete blood count', 'Simple Clinical Colitis Activity Index score', 'clinical outcomes and inflammatory markers', 'serum hs-CRP concentration', 'scores of Inflammatory Bowel Disease Questionnaire-9 and quality of life', 'ESR levels', 'clinical outcomes, quality of life, hs-CRP, and ESR', 'TNF-α levels']","[{'cui': 'C0009324', 'cui_str': 'Inflammatory Bowel Disease, Ulcerative Colitis Type'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0010467', 'cui_str': 'Curcumin'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0034380'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0009555', 'cui_str': 'Complete Blood Count'}, {'cui': 'C0205352', 'cui_str': 'Simple (qualifier value)'}, {'cui': 'C0009319', 'cui_str': 'Colitis'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0021390', 'cui_str': 'Inflammatory Bowel Diseases'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",70.0,0.241526,The scores of Inflammatory Bowel Disease Questionnaire-9 and quality of life were significantly higher in the intervention group compared to the control group (p = .006).,"[{'ForeName': 'Narges', 'Initials': 'N', 'LastName': 'Sadeghi', 'Affiliation': 'Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Anahita', 'Initials': 'A', 'LastName': 'Mansoori', 'Affiliation': 'Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Aliakbar', 'Initials': 'A', 'LastName': 'Shayesteh', 'Affiliation': 'Alimentary Tract Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Seyed Jalal', 'Initials': 'SJ', 'LastName': 'Hashemi', 'Affiliation': 'Alimentary Tract Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.6581'] 360,30965384,Benefits of a brief psychological intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: 12-month follow-up results of a randomized controlled trial.,"BACKGROUND People with melanoma want and need effective interventions for living with fear of cancer recurrence (FCR). OBJECTIVES This study reports the 12-month outcomes of a brief, psychological intervention designed to reduce FCR in people at high risk of developing another primary melanoma compared with usual care. METHODS In this two-arm randomized controlled trial, adults previously diagnosed with stage 0, I or II melanoma were randomly allocated to the intervention (n = 80) or control (usual care) arm (n = 84). The trial was registered with the Australian and New Zealand Clinical Trials Registry on 19 March 2013 (registration: ACTRN12613000304730). The intervention comprised a 76-page psychoeducational resource and three individually tailored, telephone-based sessions with a psychologist, scheduled at specific time points around participants' dermatological appointments. The primary outcome was the level of self-reported fear of new or recurrent melanoma assessed at 12 months postintervention using the severity subscale of the Fear of Cancer Recurrence Inventory. RESULTS Compared with the control arm, the intervention group reported significantly lower FCR at 12 months postintervention; the between-group mean difference was -1·41 for FCR severity [95% confidence interval (CI) -2·6 to -0·2; P = 0·02] and -1·32 for FCR triggers (95% CI -2·6 to -0·02; P = 0·04). The odds ratio for FCR severity scores ≥13 (54% intervention, 63% control) was 0·59 (95% CI 0·30-1·14, P = 0·12). There were no differences between groups in secondary outcomes, such as anxiety, depression or health-related quality of life. CONCLUSIONS The previously reported 6-month benefits of this brief, patient-centred psychological intervention in reducing FCR were found to continue 12 months postintervention, with no known adverse effects, supporting implementation as part of routine melanoma care.",2020,"The odds ratio for FCR severity scores ≥13 (54% intervention, 63% control) was 0.59 (95% CI 0.30 to 1.14, p=0.12).","['people at high risk of developing another melanoma', 'people at high risk of developing another primary melanoma', 'adults previously diagnosed with Stage 0, I or II melanoma']","['patient-centered psychological intervention', 'psychological intervention', ""76-page psycho-educational resource and three individually-tailored, telephone-based sessions with a psychologist, scheduled at specific time-points around participants' dermatological appointments""]","['Severity subscale of the Fear of Cancer Recurrence Inventory (FCRI', 'fear of cancer recurrence', 'anxiety, depression or health-related quality of life', 'level of self-reported fear of new or recurrent melanoma', 'FCR', 'FCR severity', 'odds ratio for FCR severity scores', 'cancer recurrence']","[{'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0441763', 'cui_str': 'Stage 0 (qualifier value)'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0033908', 'cui_str': 'Psychologist'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0011625', 'cui_str': 'Agent, Dermatological'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}]","[{'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0233705', 'cui_str': 'Fear of getting cancer (finding)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C0457451', 'cui_str': 'Severity score (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}]",,0.3899,"The odds ratio for FCR severity scores ≥13 (54% intervention, 63% control) was 0.59 (95% CI 0.30 to 1.14, p=0.12).","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Dieng', 'Affiliation': 'NHMRC Clinical Trials Centre, The University of Sydney, NSW, Australia.'}, {'ForeName': 'R L', 'Initials': 'RL', 'LastName': 'Morton', 'Affiliation': 'NHMRC Clinical Trials Centre, The University of Sydney, NSW, Australia.'}, {'ForeName': 'D S J', 'Initials': 'DSJ', 'LastName': 'Costa', 'Affiliation': 'Pain Management Research Institute, University of Sydney at Royal North Shore Hospital, NSW, Australia.'}, {'ForeName': 'P N', 'Initials': 'PN', 'LastName': 'Butow', 'Affiliation': 'Psycho-oncology Co-operative Research Group, School of Psychology, The University of Sydney, NSW, Australia.'}, {'ForeName': 'S W', 'Initials': 'SW', 'LastName': 'Menzies', 'Affiliation': 'Discipline of Dermatology, Sydney Medical School, The University of Sydney, NSW, Australia.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Lo', 'Affiliation': 'Melanoma Institute Australia, The University of Sydney, NSW, Australia.'}, {'ForeName': 'G J', 'Initials': 'GJ', 'LastName': 'Mann', 'Affiliation': 'Melanoma Institute Australia, The University of Sydney, NSW, Australia.'}, {'ForeName': 'A E', 'Initials': 'AE', 'LastName': 'Cust', 'Affiliation': 'Cancer Epidemiology and Prevention Research, Sydney School of Public Health, The University of Sydney, NSW, Australia.'}, {'ForeName': 'N A', 'Initials': 'NA', 'LastName': 'Kasparian', 'Affiliation': 'Melanoma Institute Australia, The University of Sydney, NSW, Australia.'}]",The British journal of dermatology,['10.1111/bjd.17990'] 361,32054791,Bladder training for urinary tract symptoms in Parkinson disease: A randomized controlled trial.,"OBJECTIVE To assess the feasibility and efficacy of bladder training for troublesome lower urinary tract symptoms (LUTS) in Parkinson disease (PD). METHODS In this single-center, single-blinded, randomized controlled trial, participants with a history of PD and LUTS were randomized to a 12-week bladder training program (BT) or conservative advice (CA). Outcome measures included a 3-day volume frequency diary, International Consultation on Incontinence Questionnaire (ICIQ)-Overactive Bladder Module, and ICIQ-Quality of Life Module. Co-primary endpoints were (1) patient perception of change and (2) change in number of urgency episodes at 12 weeks. Secondary endpoints included change in ICIQ scores, number of micturitions, and volume voided. RESULTS Thirty-eight participants were randomized (18 to CA, 20 to BT). Both CA and BT were associated with significant improvements in volume voided, number of micturitions, symptom severity scores, and measures of quality of life (all p < 0.05). At 12 weeks, compared to CA, BT was associated with significant superiority on patient perception of improvement ( p = 0.001), significantly greater reductions in number of voids in 24 hours (mean decrease 2.3 ± 0.8 voids vs 0.3 ± 0.5 [ p < 0.05]), and greater reductions in interference with daily life (2.1 ± 0.8 point improvement vs 0.3 ± 0.7 point deterioration [ p < 0.05]). BT was not associated with change in urgency episodes (mean change 2.4 ± 1.5 urgency episodes vs 3.5 ± 1.5 [ p NS]). At 20 weeks, BT remained associated with greater improvement in interference in daily life. Loss of significance in other measures may reflect loss of power from loss to follow-up. CONCLUSION This controlled trial demonstrated the potential benefits of BT for LUTS in PD. CLASSIFICATION OF EVIDENCE This study provides Class III evidence that for patients with PD and LUTS, BT significantly increased patient perception of improvement but did not significantly reduce urgency episodes.",2020,"Both CA and BT were associated with significant improvements in volume voided, number of micturitions, symptom severity scores, and measures of quality of life (all p < 0.05).","['Parkinson disease (PD', 'participants with a history of PD and LUTS', 'urinary tract symptoms in PD']","['bladder training program (BT) or conservative advice (CA', 'Bladder training', 'bladder training']","['number of voids', 'patient perception of improvement', 'change in ICIQ scores, number of micturitions, and volume voided', 'interference with daily life', 'patient perception of change and (2) change in number of urgency episodes', 'volume voided, number of micturitions, symptom severity scores, and measures of quality of life', 'interference in daily life', 'urgency episodes', '3-day volume frequency diary, International Consultation on Incontinence Questionnaire (ICIQ)-Overactive Bladder Module, and ICIQ-Quality of Life Module']","[{'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0042027'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0150474', 'cui_str': 'Urinary bladder training'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0042034', 'cui_str': 'Micturition'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0439609', 'cui_str': 'Urgency (qualifier value)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0034380'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0376660', 'cui_str': 'Diary'}, {'cui': 'C2711460', 'cui_str': 'International consultation on incontinence questionnaire (assessment scale)'}, {'cui': 'C0878773', 'cui_str': 'Overactive Bladder'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}]",38.0,0.229963,"Both CA and BT were associated with significant improvements in volume voided, number of micturitions, symptom severity scores, and measures of quality of life (all p < 0.05).","[{'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'McDonald', 'Affiliation': 'From Gateshead Health (C.M.) and Newcastle Upon Tyne Hospitals (J.R., J.L.N.), NHS Foundation Trust; Faculty of Medical Sciences (C.M., J.L.N., D.J.B.), Newcastle University, UK; and Zealand University Hospital (K.W.), Roskilde, Denmark. claire.mcdonald@ncl.ac.uk.'}, {'ForeName': 'Jackie', 'Initials': 'J', 'LastName': 'Rees', 'Affiliation': 'From Gateshead Health (C.M.) and Newcastle Upon Tyne Hospitals (J.R., J.L.N.), NHS Foundation Trust; Faculty of Medical Sciences (C.M., J.L.N., D.J.B.), Newcastle University, UK; and Zealand University Hospital (K.W.), Roskilde, Denmark.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Winge', 'Affiliation': 'From Gateshead Health (C.M.) and Newcastle Upon Tyne Hospitals (J.R., J.L.N.), NHS Foundation Trust; Faculty of Medical Sciences (C.M., J.L.N., D.J.B.), Newcastle University, UK; and Zealand University Hospital (K.W.), Roskilde, Denmark.'}, {'ForeName': 'Julia L', 'Initials': 'JL', 'LastName': 'Newton', 'Affiliation': 'From Gateshead Health (C.M.) and Newcastle Upon Tyne Hospitals (J.R., J.L.N.), NHS Foundation Trust; Faculty of Medical Sciences (C.M., J.L.N., D.J.B.), Newcastle University, UK; and Zealand University Hospital (K.W.), Roskilde, Denmark.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Burn', 'Affiliation': 'From Gateshead Health (C.M.) and Newcastle Upon Tyne Hospitals (J.R., J.L.N.), NHS Foundation Trust; Faculty of Medical Sciences (C.M., J.L.N., D.J.B.), Newcastle University, UK; and Zealand University Hospital (K.W.), Roskilde, Denmark.'}]",Neurology,['10.1212/WNL.0000000000008931'] 362,31988481,Effectiveness and cost-effectiveness of The Daily Mile on childhood weight outcomes and wellbeing: a cluster randomised controlled trial.,"BACKGROUND The Daily Mile is designed to increase physical activity levels with children running or walking around school grounds for 15-min daily. It has been adopted by schools worldwide and endorsed as a solution to tackle obesity, despite no robust evidence of its benefits. We conducted a cluster randomised controlled trial to determine its clinical and cost-effectiveness. METHODS Forty schools were randomly assigned (1:1) to either the Daily Mile intervention or control group in which only the usual school health and wellbeing activities were implemented. The primary outcome was BMI z-score (BMIz) at 12 months follow-up from baseline, with planned subgroup analysis to examine differential effects. Primary economic analysis outcome was incremental cost per Quality-Adjusted-Life-Year (QALY) gained. RESULTS Using a constrained randomisation approach, balanced on school size, baseline BMIz and proportion of pupils eligible for free school meals, 20 schools were allocated to intervention (n = 1,153 participants) and 20 to control (n = 1,127); 3 schools withdrew (2 intervention, 1 control). At 12 months, BMIz data were available for 18 intervention schools (n = 850) and 19 control schools (n = 820 participants). Using intention-to-treat analysis the adjusted mean difference (MD) in BMIz (intervention - control) was -0.036 (95% CI: -0.085 to 0.013, p = 0.146). Pre-specified subgroup analysis showed a significant interaction with sex (p = 0.001) suggesting a moderate size benefit of The Daily Mile in girls (MD -0.097, 95% CI -0.156 to -0.037). This was consistent with the exploratory economic results that showed The Daily Mile to be highly cost-effective in girls (£2,492 per QALY), but not in boys, and overall to have a 76% chance of cost-effectiveness for the whole sample, at the commonly applied UK threshold of £20,000 per QALY. CONCLUSIONS Overall the Daily Mile had a small but non-significant effect on BMIz, however, it had a greater effect in girls suggesting that it might be considered as a cost-effective component of a system-wide approach to childhood obesity prevention.",2020,"Overall the Daily Mile had a small but non-significant effect on BMIz, however, it had a greater effect in girls suggesting that it might be considered as a cost-effective component of a system-wide approach to childhood obesity prevention.","['pupils eligible for free school meals, 20 schools', 'Forty schools']","['Daily Mile', 'Daily Mile intervention or control group in which only the usual school health and wellbeing activities were implemented']","['Effectiveness and cost-effectiveness', 'physical activity levels', 'childhood weight outcomes and wellbeing', 'BMI z-score (BMIz', 'BMIz', 'incremental cost per Quality-Adjusted-Life-Year (QALY) gained']","[{'cui': 'C0034121', 'cui_str': 'Pupil'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0331865', 'cui_str': 'Mile (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0080071', 'cui_str': 'QALY'}]",40.0,0.246083,"Overall the Daily Mile had a small but non-significant effect on BMIz, however, it had a greater effect in girls suggesting that it might be considered as a cost-effective component of a system-wide approach to childhood obesity prevention.","[{'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Breheny', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Passmore', 'Affiliation': 'Services for Education, Birmingham, B7 4AX, UK.'}, {'ForeName': 'Peymane', 'Initials': 'P', 'LastName': 'Adab', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK. p.adab@bham.ac.uk.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Martin', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK.'}, {'ForeName': 'Karla', 'Initials': 'K', 'LastName': 'Hemming', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK.'}, {'ForeName': 'Emma R', 'Initials': 'ER', 'LastName': 'Lancashire', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Frew', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK. e.frew@bham.ac.uk.'}]",International journal of obesity (2005),['10.1038/s41366-019-0511-0'] 363,30705390,Screening and brief intervention for obesity in primary care: cost-effectiveness analysis in the BWeL trial.,"BACKGROUND The Brief Intervention for Weight Loss Trial enrolled 1882 consecutively attending primary care patients who were obese and participants were randomised to physicians opportunistically endorsing, offering, and facilitating a referral to a weight loss programme (support) or recommending weight loss (advice). After one year, the support group lost 1.4 kg more (95%CI 0.9 to 2.0): 2.4 kg versus 1.0 kg. We use a cohort simulation to predict effects on disease incidence, quality of life, and healthcare costs over 20 years. METHODS Randomly sampling from the trial population, we created a virtual cohort of 20 million adults and assigned baseline morbidity. We applied the weight loss observed in the trial and assumed weight regain over four years. Using epidemiological data, we assigned the incidence of 12 weight-related diseases depending on baseline disease status, age, gender, body mass index. From a healthcare perspective, we calculated the quality adjusted life years (QALYs) accruing and calculated the incremental difference between trial arms in costs expended in delivering the intervention and healthcare costs accruing. We discounted future costs and benefits at 1.5% over 20 years. RESULTS Compared with advice, the support intervention reduced the cumulative incidence of weight-related disease by 722/100,000 people, 0.33% of all weight-related disease. The incremental cost of support over advice was £2.01million/100,000. However, the support intervention reduced health service costs by £5.86 million/100,000 leading to a net saving of £3.85 million/100,000. The support intervention produced 992 QALYs/100,000 people relative to advice. CONCLUSIONS A brief intervention in which physicians opportunistically endorse, offer, and facilitate a referral to a behavioural weight management service to patients with a BMI of at least 30 kg/m 2 reduces healthcare costs and improves health more than advising weight loss.",2019,"Compared with advice, the support intervention reduced the cumulative incidence of weight-related disease by 722/100,000 people, 0.33% of all weight-related disease.","['Randomly sampling from the trial population, we created a virtual cohort of 20 million adults and assigned baseline morbidity', 'patients with a BMI of at least 30\u2009kg/m 2 reduces healthcare costs and improves health more than advising weight loss', '1882 consecutively attending primary care patients who were obese and participants']","['physicians opportunistically endorsing, offering, and facilitating a referral to a weight loss programme (support) or recommending weight loss (advice']","['disease incidence, quality of life, and healthcare costs', 'cumulative incidence of weight-related disease', 'weight loss', 'health service costs']","[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0085552', 'cui_str': 'Healthcare Costs'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0034380'}, {'cui': 'C0085552', 'cui_str': 'Healthcare Costs'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0018747', 'cui_str': 'Health Services'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",1882.0,0.159942,"Compared with advice, the support intervention reduced the cumulative incidence of weight-related disease by 722/100,000 people, 0.33% of all weight-related disease.","[{'ForeName': 'Lise', 'Initials': 'L', 'LastName': 'Retat', 'Affiliation': 'UK Health Forum, Fleetbank House, 2-6 Salisbury Square, London, EC4Y 8JX, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Pimpin', 'Affiliation': 'UK Health Forum, Fleetbank House, 2-6 Salisbury Square, London, EC4Y 8JX, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Webber', 'Affiliation': 'UK Health Forum, Fleetbank House, 2-6 Salisbury Square, London, EC4Y 8JX, UK.'}, {'ForeName': 'Abbygail', 'Initials': 'A', 'LastName': 'Jaccard', 'Affiliation': 'UK Health Forum, Fleetbank House, 2-6 Salisbury Square, London, EC4Y 8JX, UK.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Lewis', 'Affiliation': 'Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Tearne', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Hood', 'Affiliation': 'Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Christian-Brown', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.'}, {'ForeName': 'Peymane', 'Initials': 'P', 'LastName': 'Adab', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, West Midlands, B15 2TT, UK.'}, {'ForeName': 'Rachna', 'Initials': 'R', 'LastName': 'Begh', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Jolly', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, West Midlands, B15 2TT, UK.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Daley', 'Affiliation': 'School of Sport, Exercise and Health Sciences, Loughborough University, Ashby Road, Loughborough, Leicestershire, LE11 3TU, UK.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Farley', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, West Midlands, B15 2TT, UK.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Lycett', 'Affiliation': 'Faculty of Health and Life Sciences, Coventry University, Priory Street, Coventry, CV1 5FB, UK.'}, {'ForeName': 'Alecia', 'Initials': 'A', 'LastName': 'Nickless', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.'}, {'ForeName': 'Ly-Mee', 'Initials': 'LM', 'LastName': 'Yu', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Jebb', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Aveyard', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK. paul.aveyard@phc.ox.ac.uk.'}]",International journal of obesity (2005),['10.1038/s41366-018-0295-7'] 364,32217288,Cardiopulmonary exercise test indices of respiratory buffering before and after aerobic exercise training in women with pulmonary hypertension: Differentiation by magnitudes of change in six-minute walk test performance.,"While aerobic exercise training (AET) has generally been shown to improve 6-min walk test (6MWT) distance (6MWD) in patients with pulmonary hypertension (PH), a substantial number of patients appear to adapt differently, with minimal or even negative changes in 6MWT distance being reported. PURPOSE To compare post-aerobic exercise training adaptations in cardiorespiratory functional capacity across three groups of patients with PH: those with high (HI), low (LI) and negative (NEG) post-training increases in 6MWD. METHODS Participants were 25 females (age 54 ± 11 years; BMI 31 ± 7 kg/m 2 ) who completed a vigorous, 10-week, thrice weekly, supervised treadmill walking exercise program. Cardiopulmonary exercise tests (CPET) and 6MWT were completed before and after training. Ten of the 25 participants were classified as HI (range = 47-143 m), 11 were classified as LI (range = 4-37 m) and 4 were classified as NEG (range = -17 to -53 m). RESULTS Peak CPET duration, WR and time to anaerobic threshold (AT) were significantly higher (p < 0.05) after training in both the LI and HI groups but not in the NEG group. There was a significant improvement in VE/VCO 2 (p = 0.042), PETCO 2 (p = 0.011) and TV (p = 0.050) in the HI group after training, but not in the NEG or LI group. CONCLUSION These findings suggest that sustained ventilatory inefficiency and restricted respiratory buffering may mediate exercise intolerance and impede the ability to adapt to exercise training in some patients with PH.",2020,"There was a significant improvement in VE/VCO 2 (p = 0.042), PETCO 2 (p = 0.011) and TV (p = 0.050) in the HI group after training, but not in the NEG or LI group. ","['Ten of the 25 participants were classified as HI (range\xa0=\xa047-143\xa0m), 11 were classified as LI (range\xa0=\xa04-37\xa0m) and 4 were classified as NEG (range\xa0', 'patients with PH: those with high (HI), low (LI) and negative (NEG) post-training increases in 6MWD', 'women with pulmonary hypertension', 'patients with pulmonary hypertension (PH', 'Participants were 25 females (age 54\xa0±\xa011 years; BMI 31\xa0±\xa07\xa0kg/m 2 ']","['aerobic exercise training adaptations', 'supervised treadmill walking exercise program', 'aerobic exercise training (AET', 'aerobic exercise training', 'Cardiopulmonary exercise', 'Cardiopulmonary exercise tests (CPET) and 6MWT']","['Peak CPET duration, WR and time to anaerobic threshold (AT', '6-min walk test (6MWT) distance (6MWD', 'VE/VCO 2', 'cardiorespiratory functional capacity']","[{'cui': 'C0008902', 'cui_str': 'Systematics'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C4517573', 'cui_str': 'One hundred and forty-three'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1963999', 'cui_str': 'Pulmonary hypertension (SMQ)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0392673', 'cui_str': 'Adaptation, function (observable entity)'}, {'cui': 'C0184069', 'cui_str': 'Treadmill, device (physical object)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0629582', 'cui_str': 'AETS'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary Exercise Test'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0055954', 'cui_str': 'CPET'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0002749', 'cui_str': 'Anaerobic Threshold'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}]",25.0,0.0299208,"There was a significant improvement in VE/VCO 2 (p = 0.042), PETCO 2 (p = 0.011) and TV (p = 0.050) in the HI group after training, but not in the NEG or LI group. ","[{'ForeName': 'Z V', 'Initials': 'ZV', 'LastName': 'Morris', 'Affiliation': 'Department of Rehabilitation Science, George Mason University, Fairfax, VA, USA; Rehabilitation Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA.'}, {'ForeName': 'L M K', 'Initials': 'LMK', 'LastName': 'Chin', 'Affiliation': 'Rehabilitation Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Chan', 'Affiliation': 'Rehabilitation Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Guccione', 'Affiliation': 'Department of Rehabilitation Science, George Mason University, Fairfax, VA, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ahmad', 'Affiliation': 'Rehabilitation Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA.'}, {'ForeName': 'R E', 'Initials': 'RE', 'LastName': 'Keyser', 'Affiliation': 'Department of Rehabilitation Science, George Mason University, Fairfax, VA, USA; Rehabilitation Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA. Electronic address: rkeyser@gmu.edu.'}]",Respiratory medicine,['10.1016/j.rmed.2020.105900'] 365,31952923,"Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.","BACKGROUND The safety and immunogenicity of a highly attenuated recombinant vesicular stomatitis virus (rVSV) expressing HIV-1 gag (rVSVN4CT1-HIV-1gag1) was shown in previous phase 1 clinical studies. An rVSV vector expressing Ebola virus glycoprotein (EBOV-GP) in place of HIV-1 gag (rVSVN4CT1-EBOVGP1) showed single-dose protection from lethal challenge with low passage Ebola virus in non-human primates. We aimed to evaluate the safety and immunogenicity of the rVSVN4CT1-EBOVGP1 vaccine in healthy adults. METHODS We did a randomised double-blind, placebo-controlled, phase 1 dose-escalation study at a single clinical site (Optimal Research) in Melbourne, FL, USA. Eligible participants were healthy men and non-pregnant women aged 18-60 years, with a body-mass index (BMI) of less than 40 kg/m 2 , no history of filovirus infection, VSV infection, or receipt of rVSV in previous studies, and who had not visited regions where Ebola virus outbreaks have occurred. Three cohorts were enrolled to assess a low (2·5 × 10 4 plaque forming units [PFU]), intermediate (2 × 10 5 PFU), or high dose (1·8 × 10 6 PFU) of the vaccine. Participants within each cohort were randomly allocated (10:3) to receive vaccine or placebo by intramuscular injection in a homologous prime and boost regimen, with 4 weeks between doses. All syringes were masked with syringe sleeves; participants and study site staff were not blinded to dose level but were blinded to active vaccine and placebo. The primary outcomes were safety and tolerability; immunogenicity, assessed as GP-specific humoral immune response (at 2 weeks after each dose) and cellular immune response (at 1 and 2 weeks after each dose), was a secondary outcome. All randomised participants were included in primary and safety analyses. This trial is registered with ClinicalTrials.gov, NCT02718469. FINDINGS Between Dec 22, 2015, and Sept 15, 2016, 39 individuals (18 [46%] men and 21 [54%] women, mean age 51 years [SD 10]) were enrolled, with ten participants receiving the vaccine and three participants receiving placebo in each of three cohorts. One participant in the intermediate dose cohort was withdrawn from the study because of a diagnosis of invasive ductal breast carcinoma 24 days after the first vaccination, which was considered unrelated to the vaccine. No severe adverse events were observed. Solicited local adverse events occurred in ten (26%) of 39 participants after the first dose and nine (24%) of 38 participants after the second dose; the events lasted 3 days or less, were predominantly injection site tenderness (17 events) and injection site pain (ten events), and were either mild (19 events) or moderate (ten events) in intensity. Systemic adverse events occurred in 13 (33%) of 39 participants after the first dose and eight (21%) of 38 participants after the second dose; the events were mild (45 events) or moderate (11 events) in severity, and the most common events were malaise or fatigue (13 events) and headache (12 events). Arthritis and maculopapular, vesicular, or purpuric rash distal to the vaccination site(s) were not reported. A GP-specific IgG response was detected in all vaccine recipients after two doses (and IgG response frequency was 100% after a single high dose), and an Ebola virus neutralising response was detected in 100% of participants in the high-dose cohort. INTERPRETATION The rVSVN4CT1-EBOVGP1 vaccine was well tolerated at all dose levels tested and was immunogenic despite a high degree of attenuation. The combined safety and immunogenicity profile of the rVSVN4CT1-EBOVGP1 vaccine vector support phase 1-2 clinical evaluation. FUNDING US Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense: Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical.",2020,"A GP-specific IgG response was detected in all vaccine recipients after two doses (and IgG response frequency was 100% after a single high dose), and an Ebola virus neutralising response was detected in 100% of participants in the high-dose cohort. ","['Eligible participants were healthy men and non-pregnant women aged 18-60 years, with a body-mass index (BMI) of less than 40 kg/m 2 , no history of filovirus infection, VSV infection, or receipt of rVSV in previous studies, and who had not visited regions where Ebola virus outbreaks have occurred', 'Participants within each cohort', 'Between Dec 22, 2015, and Sept 15, 2016, 39 individuals (18 [46%] men and 21 [54%] women, mean age 51 years [SD 10]) were enrolled, with ten participants receiving the vaccine and three participants receiving', 'healthy adults', 'Three cohorts were enrolled to assess a low (2·5\u2008×\u200810 4 plaque forming units [PFU]), intermediate (2\u2008×\u200810 5 PFU), or high dose']","['placebo', 'rVSVN4CT1-EBOVGP1 Ebola virus vaccine', 'rVSVN4CT1-EBOVGP1 vaccine', 'rVSVN4CT1-EBOVGP1 vaccine vector', 'vaccine or placebo', 'vaccine', 'rVSV vector expressing Ebola virus glycoprotein (EBOV-GP', 'recombinant vesicular stomatitis virus (rVSV) expressing HIV-1 gag (rVSVN4CT1-HIV-1gag1']","['safety and immunogenicity', 'safety and tolerability; immunogenicity, assessed as GP-specific humoral immune response', 'injection site pain', 'severe adverse events', 'Ebola virus neutralising response', 'Systemic adverse events', 'Safety and immunogenicity', 'cellular immune response', 'Solicited local adverse events', 'malaise or fatigue (13 events) and headache']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0332122', 'cui_str': 'No history of (contextual qualifier) (qualifier value)'}, {'cui': 'C0242917', 'cui_str': 'Filovirus Infections'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0949892', 'cui_str': 'Ebola Virus'}, {'cui': 'C0220888', 'cui_str': 'outbreaks'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1449556', 'cui_str': 'Ebola Vaccines'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0442335', 'cui_str': 'Vectors (qualifier value)'}, {'cui': 'C0949892', 'cui_str': 'Ebola Virus'}, {'cui': 'C0017968', 'cui_str': 'Glycoproteins'}, {'cui': 'C1623048', 'cui_str': 'Vesicular stomatitis virus (organism)'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0328767', 'cui_str': 'Mycteroperca microlepis (organism)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C1155229'}, {'cui': 'C0151828', 'cui_str': 'Injection site pain (disorder)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0949892', 'cui_str': 'Ebola Virus'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C1817908', 'cui_str': 'Cellular Immune Response'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0231218', 'cui_str': 'Undifferentiated illness: Vague ill health'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}]",39.0,0.56335,"A GP-specific IgG response was detected in all vaccine recipients after two doses (and IgG response frequency was 100% after a single high dose), and an Ebola virus neutralising response was detected in 100% of participants in the high-dose cohort. ","[{'ForeName': 'David K', 'Initials': 'DK', 'LastName': 'Clarke', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA. Electronic address: dclarke@profectusbiosciences.com.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Xu', 'Affiliation': 'Department of Immunology, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Demetrius', 'Initials': 'D', 'LastName': 'Matassov', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Theresa E', 'Initials': 'TE', 'LastName': 'Latham', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Ayuko', 'Initials': 'A', 'LastName': 'Ota-Setlik', 'Affiliation': 'Department of Immunology, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Cheryl S', 'Initials': 'CS', 'LastName': 'Gerardi', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Amara', 'Initials': 'A', 'LastName': 'Luckay', 'Affiliation': 'Department of Immunology, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Susan E', 'Initials': 'SE', 'LastName': 'Witko', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Luz', 'Initials': 'L', 'LastName': 'Hermida', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Terry', 'Initials': 'T', 'LastName': 'Higgins', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Tremblay', 'Affiliation': 'Department of Quality Assurance, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Sciotto-Brown', 'Affiliation': 'Department of Regulatory Affairs, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Chen', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Egan', 'Affiliation': 'Bill and Melinda Gates Medical Research Institute, Cambridge, MA, USA.'}, {'ForeName': 'Janice M', 'Initials': 'JM', 'LastName': 'Rusnak', 'Affiliation': 'Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical, Fort Detrick, MD, USA.'}, {'ForeName': 'Lucy A', 'Initials': 'LA', 'LastName': 'Ward', 'Affiliation': 'Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical, Fort Detrick, MD, USA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Eldridge', 'Affiliation': 'Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA; Department of Immunology, Profectus BioSciences, Pearl River, NY, USA.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(19)30614-0'] 366,32219623,"Cost-effectiveness of a non-pharmacological treatment vs. ""care as usual"" in day care centers for community-dwelling older people with cognitive impairment: results from the German randomized controlled DeTaMAKS-trial.","BACKGROUND Cognitive impairment in older adults causes a high economic and societal burden. This study assesses the cost-effectiveness of the multicomponent, non-pharmacological MAKS treatment vs. ""care as usual"" in German day care centers (DCCs) for community-dwelling people with mild cognitive impairment (MCI) or mild to moderate dementia over 6 months. METHODS The analysis was conducted from the societal perspective alongside the cluster-randomized controlled, multicenter, prospective DeTaMAKS-trial with waitlist group design. Outcomes were Mini-Mental Status Examination (MMSE) and Erlangen Test of Activities of Daily Living in Persons with Mild Dementia or Mild Cognitive Impairment (ETAM) of 433 individuals in 32 DCCs. Incremental differences in MMSE and ETAM were calculated via a Gaussian-distributed and incremental cost difference via a Gamma-distributed Generalized Linear Model. Cost-effectiveness was assessed via cost-effectiveness planes and cost-effectiveness acceptability curves (CEAC). RESULTS At 6 months, MMSE (adjusted mean difference = 0.92; 95% confidence interval (CI): 0.17 to 1.67; p = 0.02) and ETAM (adjusted mean difference = 1.00; CI: 0.14 to 1.85; p = 0.02) were significantly better in the intervention group. The adjusted cost difference was - €938.50 (CI: - 2733.65 to 763.13; p = 0.31). Given the CEAC, MAKS was cost-effective for 78.0% of MMSE and 77.4% for ETAM without a need for additional costs to payers. CONCLUSIONS MAKS is a cost-effective treatment to stabilize the ability to perform activities of daily living and cognitive abilities of people with MCI or mild to moderate dementia in German DCCs. Thus, MAKS should be implemented in DCCs.",2020,"At 6 months, MMSE (adjusted mean difference = 0.92; 95% confidence interval (CI):","['community-dwelling older people with cognitive impairment', 'German day care centers (DCCs) for community-dwelling people with mild cognitive impairment (MCI) or mild to moderate dementia over 6\xa0months', 'older adults', 'Persons with Mild Dementia or Mild Cognitive Impairment (ETAM) of 433 individuals in 32 DCCs']","['ETAM', 'non-pharmacological treatment vs. ""care', 'multicomponent, non-pharmacological MAKS treatment vs. ""care']","['Cost-effectiveness', 'cost-effectiveness planes and cost-effectiveness acceptability curves (CEAC', 'cost-effectiveness', 'Mini-Mental Status Examination (MMSE) and Erlangen Test of Activities of Daily Living']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0338656', 'cui_str': 'Cognitive Dysfunction'}, {'cui': 'C1556085', 'cui_str': 'Germans (ethnic group)'}, {'cui': 'C0175952', 'cui_str': 'Day care center (environment)'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C3494623', 'cui_str': 'Mild dementia'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0205464', 'cui_str': 'Pharmacologic (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0001288', 'cui_str': 'ADL'}]",,0.179057,"At 6 months, MMSE (adjusted mean difference = 0.92; 95% confidence interval (CI):","[{'ForeName': 'Kathrin', 'Initials': 'K', 'LastName': 'Steinbeisser', 'Affiliation': 'Institute of Health Economics and Health Care Management, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764, Neuherberg, Germany.'}, {'ForeName': 'Larissa', 'Initials': 'L', 'LastName': 'Schwarzkopf', 'Affiliation': 'Institute of Health Economics and Health Care Management, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764, Neuherberg, Germany.'}, {'ForeName': 'Elmar', 'Initials': 'E', 'LastName': 'Graessel', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Center for Health Service Research in Medicine, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Schwabachanlage 6, 91054, Erlangen, Germany. elmar.graessel@uk-erlangen.de.'}, {'ForeName': 'Hildegard', 'Initials': 'H', 'LastName': 'Seidl', 'Affiliation': 'Institute of Health Economics and Health Care Management, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764, Neuherberg, Germany.'}]",The European journal of health economics : HEPAC : health economics in prevention and care,['10.1007/s10198-020-01175-y'] 367,32219705,Does quality of life feedback promote seeking help for undiagnosed cancer?,"PURPOSE Diagnosing cancer early is an imperative, as help-seeking delays affect survival. Quality of life (QoL) deteriorates after diagnosis, but decline may start when cancer is suspected at the earliest stage of the pathway to treatment. This study examined whether offering guided feedback about personal QoL to adults with potential cancer symptoms, living in deprived communities, changes QoL and promotes help-seeking in primary care. METHODS Visitors to a CRUK mobile cancer roadshow were recruited in 43 sites. A prospective longitudinal (2 × 2) repeated-measures design was applied. Where they presented a potential cancer symptom, and were 'signposted' to a GP, they were allocated to a symptom condition, or a lifestyle condition, if seeking cancer risk advice. Randomisation was to an Intervention group, who received feedback about personal QoL results (WHOQOL-BREF and WHOQOL importance measures), or a Control group who assessed QoL without feedback. Depression was screened. RESULTS Of 107 participants, the mean age was 53; 50% were women, 57% were without tertiary education, 66% were unemployed and 45% were currently ill. Over 10 weeks, 54% of all those with symptoms sought help from a medical source and 42% specifically from a GP. Thirty-one completed all three assessments. With symptoms present, psychological, social and environmental QoL were poor, becoming poorer over time. When the symptoms group received feedback, psychological QoL increased, but GP visits were unaffected. However, feedback increased help-seeking from informal social contacts. Lifestyle groups reported consistently good psychological and social QoL. CONCLUSION This early cancer research offers practical and theoretical implications for QoL interventions in deprived communities.",2020,"When the symptoms group received feedback, psychological QoL increased, but GP visits were unaffected.","['Visitors to a CRUK mobile cancer roadshow were recruited in 43 sites', 'adults with potential cancer symptoms, living in deprived communities, changes QoL and promotes help-seeking in primary care', '107 participants', 'mean age was 53; 50% were women, 57% were without tertiary education, 66% were unemployed and 45% were currently ill']","['guided feedback about personal QoL', 'feedback about personal QoL results (WHOQOL-BREF and WHOQOL importance measures), or a Control group who assessed QoL without feedback']","['good psychological and social QoL', 'Quality of life (QoL) deteriorates', 'feedback, psychological QoL increased, but GP visits', 'psychological, social and environmental QoL']","[{'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C4517529', 'cui_str': 'One hundred and seven'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0041674', 'cui_str': 'Unemployment'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}]","[{'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}]",107.0,0.0221673,"When the symptoms group received feedback, psychological QoL increased, but GP visits were unaffected.","[{'ForeName': 'Suzanne M', 'Initials': 'SM', 'LastName': 'Skevington', 'Affiliation': 'Division of Psychology and Mental Health, Faculty of Biology, Medicine and Health, International Hub for Quality of Life Research, Manchester Centre for Health Psychology, University of Manchester, Manchester, M13 9PL, UK. suzanne.skevington@manchester.ac.uk.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Long', 'Affiliation': 'Division of Psychology and Mental Health, Faculty of Biology, Medicine and Health, International Hub for Quality of Life Research, Manchester Centre for Health Psychology, University of Manchester, Manchester, M13 9PL, UK.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Gartland', 'Affiliation': 'Division of Psychology and Mental Health, Faculty of Biology, Medicine and Health, International Hub for Quality of Life Research, Manchester Centre for Health Psychology, University of Manchester, Manchester, M13 9PL, UK.'}]","Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation",['10.1007/s11136-020-02431-7'] 368,32213642,Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.,"OBJECTIVE To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals. METHODS Aspirin in Reducing Events in the Elderly (ASPREE) was a double-blind, placebo-controlled trial of low-dose aspirin. In the United States and Australia, community-dwelling individuals aged ≥70 years (US minorities ≥65 years) and free of cardiovascular disease, physical disability, and diagnosed dementia were enrolled. Participants were randomized 1:1-100 mg daily aspirin or placebo. The Modified Mini-Mental State Examination, Hopkins Verbal Learning Test-Revised, Symbol Digit Modalities Test, and Controlled Oral Word Association Test assessed cognition at baseline and over follow-up. Additional cognitive testing was performed in participants with suspected dementia (""trigger"") based on within-study assessments or clinical history. Dementia was adjudicated according to DSM-IV criteria. National Institute on Aging-Alzheimer's Association criteria were used for AD and MCI subclassification. RESULTS A total of 19,114 participants were followed over a median 4.7 years and 964 triggered further dementia assessments. There were 575 adjudicated dementia cases, and 41% were classified as clinically probable AD. There was no substantial difference in the risk of all dementia triggers (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.91-1.17), probable AD (HR, 0.96; 95% CI, 0.74-1.24), or MCI (HR, 1.12; 95% CI, 0.92-1.37) between aspirin and placebo. Cognitive change over time was similar in the aspirin and placebo groups. CONCLUSIONS There was no evidence that aspirin was effective in reducing risk of dementia, MCI, or cognitive decline. Follow-up of these outcomes after initial exposure is ongoing. CLASSIFICATION OF EVIDENCE This study provides Class II evidence that for healthy older individuals, low-dose aspirin does not significantly reduce the incidence of dementia, probable AD, MCI, or cognitive decline. CLINICALTRIALSGOV IDENTIFIER NCT01038583.",2020,"There was no substantial difference in the risk of all dementia triggers (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.91-1.17), probable AD (HR, 0.96; 95% CI, 0.74-1.24), or MCI (HR, 1.12; 95% CI, 0.92-1.37) between aspirin and placebo.","['incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals', 'healthy older individuals', 'A total of 19,114 participants were followed over a median 4.7 years and 964 triggered further dementia assessments', 'United States and Australia, community-dwelling individuals aged ≥70 years (US minorities ≥65 years) and free of cardiovascular disease, physical disability, and diagnosed dementia were enrolled', 'participants with suspected dementia (""trigger"") based on within-study assessments or clinical history']","['aspirin', 'Aspirin', 'placebo', 'aspirin or placebo', 'aspirin vs placebo']","['risk of all dementia triggers', 'Modified Mini-Mental State Examination, Hopkins Verbal Learning Test-Revised, Symbol Digit Modalities Test, and Controlled Oral Word Association Test assessed cognition', 'dementia and cognitive decline', 'Cognitive change over time', 'incidence of dementia, probable AD, MCI, or cognitive decline', 'risk of dementia, MCI, or cognitive decline']","[{'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0234985', 'cui_str': 'Cognitive Decline'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1444748', 'cui_str': 'Provoked by (attribute)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C4045975', 'cui_str': 'Community Dwelling'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0332296', 'cui_str': 'Free of (attribute)'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0520817', 'cui_str': 'Physical handicap (finding)'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}]","[{'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C1444748', 'cui_str': 'Provoked by (attribute)'}, {'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}, {'cui': 'C0042531', 'cui_str': 'Verbal Learning'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0451522', 'cui_str': 'Symbol Digit Modalities Test'}, {'cui': 'C3827022', 'cui_str': 'Controlled Oral Word Association Test'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0234985', 'cui_str': 'Cognitive Decline'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C0560005', 'cui_str': 'millicurie'}]",19114.0,0.630076,"There was no substantial difference in the risk of all dementia triggers (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.91-1.17), probable AD (HR, 0.96; 95% CI, 0.74-1.24), or MCI (HR, 1.12; 95% CI, 0.92-1.37) between aspirin and placebo.","[{'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Ryan', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL. elsdon.storey@monash.edu joanne.ryan@monash.edu.""}, {'ForeName': 'Elsdon', 'Initials': 'E', 'LastName': 'Storey', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL. elsdon.storey@monash.edu joanne.ryan@monash.edu.""}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Murray', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': 'Robyn L', 'Initials': 'RL', 'LastName': 'Woods', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': 'Rory', 'Initials': 'R', 'LastName': 'Wolfe', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Reid', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Nelson', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': 'Trevor T J', 'Initials': 'TTJ', 'LastName': 'Chong', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': 'Jeff D', 'Initials': 'JD', 'LastName': 'Williamson', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': 'Stephanie A', 'Initials': 'SA', 'LastName': 'Ward', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': 'Jessica E', 'Initials': 'JE', 'LastName': 'Lockery', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': 'Suzanne G', 'Initials': 'SG', 'LastName': 'Orchard', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Trevaks', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Kirpach', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': 'Anne B', 'Initials': 'AB', 'LastName': 'Newman', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Ernst', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': 'John J', 'Initials': 'JJ', 'LastName': 'McNeil', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': 'Raj C', 'Initials': 'RC', 'LastName': 'Shah', 'Affiliation': ""From the School of Public Health and Preventive Medicine (J.R., E.S., R.L.W., R.W., C.M.R., S.A.W., J.E.L., S.G.O., R.T., J.J.M.) and the Turner Institute for Brain and Mental Health (T.T.J.C.), Monash University, Melbourne, Australia; Berman Center for Outcomes and Clinical Research (A.M.M., B.K.), Hennepin Health Research Institute; Division of Geriatrics, Department of Medicine (A.M.M., B.K.), Hennepin Healthcare, Minneapolis, MN; School of Public Health (C.M.R.), Curtin University, Perth; Menzies Institute for Medical Research (M.R.N.), University of Tasmania, Hobart, Australia; Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine (J.D.W.), Wake Forest School of Medicine, Winston-Salem, NC; Center for Aging and Population Health (A.B.N.), University of Pittsburgh, PA; Department of Pharmacy Practice and Science, College of Pharmacy, and the Department of Family Medicine, Carver College of Medicine (M.E.E.), University of Iowa, Iowa City; and Department of Family Medicine and Rush Alzheimer's Disease Center (R.C.S.), Rush University Medical Center, Chicago, IL.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Neurology,['10.1212/WNL.0000000000009277'] 369,31376153,"A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment.","BACKGROUND Interleukin-17 antagonists have received a first-line label for moderate-to-severe plaque psoriasis. OBJECTIVES We conducted the first head-to-head trial between the two most commonly used first-line therapies in Germany, fumaric acid esters (FAEs) and methotrexate, and the interleukin-17A antagonist, ixekizumab. METHODS Systemic-naive patients were randomized in this parallel-group, active-comparator, open-label, rater-blinded trial (each group n = 54). The primary outcome was the proportion of patients achieving ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) at 24 weeks. Key secondary outcomes included 24-week PASI 90 and 100, static Physician's Global Assessment (sPGA) score of 0 or 1, and Dermatology Life Quality Index (DLQI) score of 0 or 1. Safety events at week 24 were analysed using Fisher's exact test. Missing data were imputed using nonresponder imputation. The trial was registered at ClinicalTrials.gov (NCT02634801) and EudraCT (2015-002649-69). RESULTS At week 24, more ixekizumab-treated patients achieved PASI 75 [91% vs. 22% FAEs (P < 0·001) and 70% methotrexate (P = 0·014)], PASI 90 [80% vs. 9% FAEs (P < 0·001) and 39% methotrexate (P < 0·001)] and PASI 100 [41% vs. 4% FAEs (P < 0·001) and 13% methotrexate (P = 0·0041)], as well as sPGA (0,1) and DLQI (0,1). CONCLUSIONS Ixekizumab was superior in inducing PASI 75/90/100, sPGA (0,1) and DLQI (0,1) responses at week 24 compared with methotrexate and FAEs. Safety profiles for all treatments were consistent with prior studies.",2020,"At week 24, more ixekizumab-treated patients achieved PASI 75 (90·7% vs. 22·2% FAE [p<0·0001] and 70·4% methotrexate [p=0·0137]); PASI 90 (79·6% vs. 9·3% FAE [p<0·0001] and 38·9% methotrexate [p<0·0001]); PASI 100 (40·7% vs. 3·7% FAE [p<0·0001] and 13·0% methotrexate [p=0·0020]), as well as sPGA(0,1) and DLQI(0,1) rates. CONCLUSIONS Ixekizumab was superior in inducing PASI 75/90/100, sPGA(0,1), and DLQI(0,1) responses at week 24 compared to methotrexate and FAE.","['Systemic-naïve patients', 'patients with moderate-to-severe plaque psoriasis naïve to systemic treatment']",['ixekizumab to fumaric acid esters and methotrexate'],"[""24-week PASI 90/100, static Physician's Global Assessment (sPGA)(0,1), and Dermatology Life Quality Index (DLQI)(0,1) measurements"", 'proportion of patients achieving Psoriasis Area and Severity Index (PASI', 'Safety events']","[{'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0406317', 'cui_str': 'Plaque psoriasis (disorder)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C3489764', 'cui_str': 'ixekizumab'}, {'cui': 'C1959568', 'cui_str': 'Fumarate Esters'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}]","[{'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0441463', 'cui_str': 'Static (qualifier value)'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0451112', 'cui_str': 'Dermatology life quality index (assessment scale)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}]",,0.141496,"At week 24, more ixekizumab-treated patients achieved PASI 75 (90·7% vs. 22·2% FAE [p<0·0001] and 70·4% methotrexate [p=0·0137]); PASI 90 (79·6% vs. 9·3% FAE [p<0·0001] and 38·9% methotrexate [p<0·0001]); PASI 100 (40·7% vs. 3·7% FAE [p<0·0001] and 13·0% methotrexate [p=0·0020]), as well as sPGA(0,1) and DLQI(0,1) rates. CONCLUSIONS Ixekizumab was superior in inducing PASI 75/90/100, sPGA(0,1), and DLQI(0,1) responses at week 24 compared to methotrexate and FAE.","[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Reich', 'Affiliation': 'Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Augustin', 'Affiliation': 'Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Thaçi', 'Affiliation': 'Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Pinter', 'Affiliation': 'Department of Dermatology, University Clinic of Frankfurt am Main, Frankfurt am Main, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Leutz', 'Affiliation': 'Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN, U.S.A.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Henneges', 'Affiliation': 'Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN, U.S.A.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Schneider', 'Affiliation': 'Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN, U.S.A.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Schacht', 'Affiliation': 'Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN, U.S.A.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Dossenbach', 'Affiliation': 'Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN, U.S.A.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Mrowietz', 'Affiliation': 'Psoriasis Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.'}]",The British journal of dermatology,['10.1111/bjd.18384'] 370,31793731,"Efficacy and safety of Sophora alopecuroides var. alopecuroides seed extract for opioid detoxification: A randomized, double-blind, and placebo-controlled clinical trial.","The seeds of Sophora alopecuroides L. var. alopecuroides (S. alopecuroides) have alleviated morphine withdrawal in mice. Therefore, in this study, the alkaloid composition of S. alopecuroides extract was determined by gas chromatography (GC) and gas chromatography-mass spectrometry (GC-MS) analysis. Moreover, 50 abstinent opium addicts consumed three 400 mg extract capsules once daily and 50 other patients took placebo for 8 days. At the baseline and days 3 and 8, the clinical opiate withdrawal scale (COWS) was used to assess withdrawal symptoms. At the baseline and Day 8, the patients' blood levels of serum glutamate oxaloacetate transferase; serum glutamate pyruvate transferase; alkaline phosphatase; total, direct, and indirect bilirubins; creatinine and blood urea nitrogen; complete blood count; and prothrombine time were measured. The groups' parameter values were also compared. Sophocarpine, matrine, and sophoramine were the major alkaloids constituting, respectively, 32.85, 26.55, and 6.91% of the extract. The extract decreased the COWS score at Days 3 and 8 significantly compared with the placebo (p < .001). The extract did not significantly affect the blood parameters' values compared with the placebo (p > .05). There was no adverse drug effect. In conclusion, the extract reduces the acute opioid withdrawal symptoms and seems to have good safety and tolerability.",2020,The extract decreased the COWS score at Days 3 and 8 significantly compared with the placebo (p < .001).,"['50 abstinent opium addicts', 'opioid detoxification']","['placebo', 'Sophora alopecuroides var']","['blood levels of serum glutamate oxaloacetate transferase; serum glutamate pyruvate transferase; alkaline phosphatase; total, direct, and indirect bilirubins; creatinine and blood urea nitrogen; complete blood count; and prothrombine time', ""blood parameters' values"", 'Efficacy and safety', 'clinical opiate withdrawal scale (COWS', 'acute opioid withdrawal symptoms', 'COWS score', 'good safety and tolerability']","[{'cui': 'C0457801', 'cui_str': 'Current non-drinker of alcohol (finding)'}, {'cui': 'C0029112', 'cui_str': 'Opium'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0150543', 'cui_str': 'Detoxification therapy (regime/therapy)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0330796', 'cui_str': 'Sophora'}]","[{'cui': 'C0005768'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0220839', 'cui_str': 'Glutamate'}, {'cui': 'C0220889', 'cui_str': 'oxaloacetate'}, {'cui': 'C0040676', 'cui_str': 'Transferase'}, {'cui': 'C0244104', 'cui_str': 'Pyruvate'}, {'cui': 'C0002059', 'cui_str': 'Orthophosphoric-monoester phosphohydrolase (alkaline optimum)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0301719', 'cui_str': 'Indirect reacting bilirubin (substance)'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0600137', 'cui_str': 'Blood urea nitrogen (substance)'}, {'cui': 'C0009555', 'cui_str': 'Complete Blood Count'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3472219', 'cui_str': 'Clinical opiate withdrawal scale (assessment scale)'}, {'cui': 'C0029104', 'cui_str': 'Opioid withdrawal (disorder)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}]",,0.265822,The extract decreased the COWS score at Days 3 and 8 significantly compared with the placebo (p < .001).,"[{'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Kianbakht', 'Affiliation': 'Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Hajiaghaee', 'Affiliation': 'Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran.'}, {'ForeName': 'Shahin', 'Initials': 'S', 'LastName': 'Akhondzadeh', 'Affiliation': 'Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.6578'] 371,31797473,"Effects of crocin and saffron aqueous extract on gene expression of SIRT1, AMPK, LOX1, NF-κB, and MCP-1 in patients with coronary artery disease: A randomized placebo-controlled clinical trial.","This trial evaluated the potential impacts of saffron aqueous extract (SAE) and its main carotenoid on some of the atherosclerosis-related gene expression and serum levels of oxidized low-density cholesterol (ox-LDL) and Monocyte chemoattractant protein 1 (MCP-1) in patients with coronary artery disease (CAD). Participants of this randomized controlled trial included 84 CAD patients who categorized into three groups: Group 1 received crocin (30 mg/day), Group 2 SAE (30 mg/day), and Group 3 placebo for 8 weeks. Gene expression of Sirtuin 1 (SIRT1), 5'-adenosine monophosphate-activated protein kinase (AMPK), Lectin-like oxidized LDL receptor 1 (LOX1), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and MCP-1 in peripheral blood mononuclear cells assessed by real-time PCR. Furthermore, serum ox-LDL and MCP-1 levels measured at the beginning and end of the intervention. Compared with the placebo group, gene expression of SIRT1 and AMPK increased significantly in the crocin group (p = .001), and the expression of LOX1 and NF-κB decreased significantly (p = .016 and .004, respectively). Serum ox-LDL levels decreased significantly in the crocin group after the intervention (p = .002) while MCP-1 levels decreased both in crocin and SAE groups (p = .001). Crocin may have beneficial effects on CAD patients by increasing the gene expression of SIRT1 and AMPK and decreasing the expression of LOX1 and NF-κB.",2020,"Gene expression of Sirtuin 1 (SIRT1), 5'-adenosine monophosphate-activated protein kinase (AMPK), Lectin-like oxidized LDL receptor 1 (LOX1), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and MCP-1 in peripheral blood mononuclear cells assessed by real-time PCR.","['84 CAD patients who categorized into three groups: Group 1 received', 'patients with coronary artery disease', 'patients with coronary artery disease (CAD']","['placebo', 'saffron aqueous extract (SAE', 'crocin and saffron aqueous extract', 'crocin']","[""Gene expression of Sirtuin 1 (SIRT1), 5'-adenosine monophosphate-activated protein kinase (AMPK), Lectin-like oxidized LDL receptor 1 (LOX1), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB"", 'MCP-1 levels', 'gene expression of SIRT1, AMPK, LOX1, NF-κB, and MCP-1', 'Serum ox-LDL levels', 'gene expression of SIRT1 and AMPK', 'Furthermore, serum ox-LDL and MCP-1 levels', 'expression of LOX1 and NF-κB']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C1956346', 'cui_str': 'Coronary Artery Disease'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2348128', 'cui_str': 'Saffron'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C0056503', 'cui_str': 'crocin'}]","[{'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C2720167', 'cui_str': 'Sirt1'}, {'cui': 'C0631470', 'cui_str': ""5'-(sulfonylbenzoyl)adenosine""}, {'cui': 'C0033681', 'cui_str': 'Tyrosylprotein Kinase'}, {'cui': 'C0023206', 'cui_str': 'Lectin (substance)'}, {'cui': 'C0536243', 'cui_str': 'Receptors, Oxidized LDL'}, {'cui': 'C0021036', 'cui_str': 'Immunoglobulin kappa-Chains'}, {'cui': 'C0004561', 'cui_str': 'B-Cells'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0348035', 'cui_str': 'oxidized low density lipoprotein'}, {'cui': 'C3854321', 'cui_str': 'Expression'}]",84.0,0.048982,"Gene expression of Sirtuin 1 (SIRT1), 5'-adenosine monophosphate-activated protein kinase (AMPK), Lectin-like oxidized LDL receptor 1 (LOX1), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and MCP-1 in peripheral blood mononuclear cells assessed by real-time PCR.","[{'ForeName': 'Nasim', 'Initials': 'N', 'LastName': 'Abedimanesh', 'Affiliation': 'Department of Nutrition, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.'}, {'ForeName': 'Behrooz', 'Initials': 'B', 'LastName': 'Motlagh', 'Affiliation': 'Department of Clinical Biochemistry, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.'}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Abedimanesh', 'Affiliation': 'Faculty of Medical Sciences, Department of Clinical Biochemistry, Tarbiat Modares University, Tehran, Iran.'}, {'ForeName': 'S Zahra', 'Initials': 'SZ', 'LastName': 'Bathaie', 'Affiliation': 'Faculty of Medical Sciences, Department of Clinical Biochemistry, Tarbiat Modares University, Tehran, Iran.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Separham', 'Affiliation': 'Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Ostadrahimi', 'Affiliation': 'Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.6580'] 372,30664661,Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis.,"BACKGROUND/OBJECTIVES Prolonged-release (PR) naltrexone 32 mg/bupropion 360 mg (NB) is approved for chronic weight management as an adjunct to reduced-calorie diet and increased physical activity. Central nervous system-active medications have the potential to affect mood; therefore, post hoc analysis of clinical trial data was conducted to evaluate psychiatric adverse events (PAEs) and effects on mood of NB therapy versus placebo. SUBJECTS/METHODS Data were pooled from 5 prospective, double-blind, randomized, placebo-controlled clinical trials (duration range, 24-56 weeks) of NB in subjects with overweight or obesity. PAEs were collected via AE preferred terms, organized into major subtopics (e.g., anxiety, depression, sleep disorders), and divided into category terms (e.g., anxiety, potential anxiety symptoms). Additionally, the Inventory of Depressive Symptomatology Self Report (IDS-SR; score range 0-84) and the Columbia Classification Algorithm of Suicide Assessment (C-CASA) evaluated treatment-emergent depressive/anxiety symptoms and suicidal behavior/ideation, respectively. RESULTS Baseline characteristics and comorbidities were comparable for placebo (n = 1515) and NB (n = 2545). Most common PAEs in the NB group (using category grouping; NB vs placebo) were sleep disorders (12.7 vs 7.9%, P < 0.001), anxiety (5.4 vs 3.3%, P = 0.029), and depression (1.8 vs 2.7%, P = 0.014); PAEs were more frequent during dose escalation and generally mild or moderate. Mean (SD) changes in IDS-SR total score from baseline to endpoint were small in both groups: 0.13 (5.83) for NB and -0.45 (5.65) for placebo. Retrospective AE categorization via C-CASA confirmed no completed suicides, suicide attempts, or preparatory acts toward imminent suicidal behavior. CONCLUSIONS This large pooled analysis of 5 clinical trials provides additional safety information about the NB PAE profile. Anxiety and sleep disorder-related PAEs were more frequent with NB versus placebo but were mostly mild to moderate and generally occurred early. Depression-related PAEs were less common with NB than placebo, and NB was not associated with suicidal ideation or behavior in this patient population.",2019,"Depression-related PAEs were less common with NB than placebo, and NB was not associated with suicidal ideation or behavior in this patient population.",['subjects with overweight or obesity'],"['naltrexone/bupropion combination therapy', 'bupropion 360\u2009mg (NB', 'placebo']","['Depression-related PAEs', 'depression', 'suicidal ideation or behavior', 'Inventory of Depressive Symptomatology Self Report (IDS-SR; score range 0-84) and the Columbia Classification Algorithm of Suicide Assessment (C-CASA) evaluated treatment-emergent depressive/anxiety symptoms and suicidal behavior/ideation, respectively', 'Psychiatric adverse events', 'Mean (SD) changes in IDS-SR total score', 'Anxiety and sleep disorder-related PAEs', 'anxiety', 'sleep disorders']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C0085208', 'cui_str': 'Bupropion'}, {'cui': 'C0556895', 'cui_str': 'Combination therapy (regime/therapy)'}, {'cui': 'C4319607', 'cui_str': '360 (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0424000', 'cui_str': 'Suicidal Ideation'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0008903', 'cui_str': 'taxonomy'}, {'cui': 'C0002045'}, {'cui': 'C3494753', 'cui_str': 'Suicide evaluation'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C1760428', 'cui_str': 'Suicidal behavior (finding)'}, {'cui': 'C0392348', 'cui_str': 'Ideation, function (observable entity)'}, {'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0851578', 'cui_str': 'Sleep Disorders'}]",,0.497082,"Depression-related PAEs were less common with NB than placebo, and NB was not associated with suicidal ideation or behavior in this patient population.","[{'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Pi-Sunyer', 'Affiliation': 'Columbia University Medical Center, New York, NY, USA.'}, {'ForeName': 'Caroline M', 'Initials': 'CM', 'LastName': 'Apovian', 'Affiliation': 'Boston University School of Medicine and Department of Medicine Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center, Boston, MA, USA.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'McElroy', 'Affiliation': 'Lindner Center of HOPE, Mason, and Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Dunayevich', 'Affiliation': 'Annexon Biosciences, South San Francisco, CA, USA.'}, {'ForeName': 'Lisette M', 'Initials': 'LM', 'LastName': 'Acevedo', 'Affiliation': 'Nalpropion Pharmaceuticals, Inc, La Jolla, CA, USA.'}, {'ForeName': 'Frank L', 'Initials': 'FL', 'LastName': 'Greenway', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA. frank.greenway@pbrc.edu.'}]",International journal of obesity (2005),['10.1038/s41366-018-0302-z'] 373,32229495,"Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers.","Contezolid (MRX-I), a new oxazolidinone, is an antibiotic in development for treating complicated skin and soft tissue infections caused by resistant Gram-positive bacteria. This was a thorough QT study conducted in 52 healthy subjects who were administered oral contezolid at a therapeutic (800 mg) dose, a supratherapeutic (1,600 mg) dose, placebo, and oral moxifloxacin at 400 mg in four separate treatment periods. The pharmacokinetic profile of contezolid was also evaluated. Time point analysis indicated that the upper bounds of the two-sided 90% confidence interval (CI) for placebo-corrected change-from-baseline QTc (ΔΔQTc) were <10 ms for the contezolid therapeutic dose at each time point. The upper bound of the 90% CI for ΔΔQTc was slightly more than 10 ms with the contezolid supratherapeutic dose at 3 and 4 h postdose, and the prolongation effect on the QT/QTc interval was less than that of the positive control, moxifloxacin, at 400 mg. At 3 and 4 h after the moxifloxacin dose, the moxifloxacin group met the assay sensitivity criteria outlined in ICH Guidance E14 by having a lower confidence bound of ≥5 ms. The results of a linear exposure-response model which were similar to that of a time point analysis demonstrated a slightly positive relationship between contezolid plasma levels and ΔQTcF interval with a slope of 0.227 ms per mg/liter (90% CI, 0.188 to 0.266). In summary, contezolid did not prolong the QT interval at a therapeutic dose and may have a slight effect on QT interval prolongation at a supratherapeutic dose.",2020,Time-point analysis indicated that the upper bounds of the two-sided 90% confidence interval (CI) for placebo-corrected change-from-baseline QTc (ΔΔQTc) were <10 ms for the contezolid therapeutic dose at each time point.,"['52 healthy subjects who were administered', 'healthy Chinese volunteers']","['placebo', 'placebo, and oral moxifloxacin', 'moxifloxacin', 'oral contezolid', 'supratherapeutic', 'contezolid (MRX-I']","['QT interval prolongation', 'contezolid plasma levels and ΔQTcF interval', 'QT interval']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}]","[{'cui': 'C0429028', 'cui_str': 'QT interval feature'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1272706', 'cui_str': 'Interval'}]",52.0,0.16154,Time-point analysis indicated that the upper bounds of the two-sided 90% confidence interval (CI) for placebo-corrected change-from-baseline QTc (ΔΔQTc) were <10 ms for the contezolid therapeutic dose at each time point.,"[{'ForeName': 'Junzhen', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Guoying', 'Initials': 'G', 'LastName': 'Cao', 'Affiliation': 'Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China.'}, {'ForeName': 'Hailan', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Yuancheng', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China.'}, {'ForeName': 'Beining', 'Initials': 'B', 'LastName': 'Guo', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Xiaojie', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China.'}, {'ForeName': 'Jicheng', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China.'}, {'ForeName': 'Kanhong', 'Initials': 'K', 'LastName': 'Ni', 'Affiliation': 'Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Qian', 'Affiliation': 'Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jufang', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Yuan', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China zhangj_fudan@aliyun.com xiyuewen@medmail.com.cn.'}, {'ForeName': 'Yuewen', 'Initials': 'Y', 'LastName': 'Xi', 'Affiliation': 'Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China zhangj_fudan@aliyun.com xiyuewen@medmail.com.cn.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.02158-19'] 374,32229636,Author response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.,,2020,,[],['naproxen'],[],[],"[{'cui': 'C0027396', 'cui_str': 'Naproxen'}]",[],,0.0875124,,"[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Breitner', 'Affiliation': '(Montreal).'}, {'ForeName': 'Pierre-Francois', 'Initials': 'PF', 'LastName': 'Meyer', 'Affiliation': '(Montreal).'}]",Neurology,['10.1212/WNL.0000000000009185'] 375,32229635,Reader response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.,,2020,,[],['naproxen'],[],[],"[{'cui': 'C0027396', 'cui_str': 'Naproxen'}]",[],,0.0995455,,"[{'ForeName': 'J Wesson', 'Initials': 'JW', 'LastName': 'Ashford', 'Affiliation': '(Palo Alto, CA).'}]",Neurology,['10.1212/WNL.0000000000009184'] 376,32209650,Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.,"OBJECTIVE To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM). METHODS The Prevention of Migraine via Intravenous ALD403 Safety and Efficacy-2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with CM were randomly assigned to receive IV eptinezumab 100 mg, eptinezumab 300 mg, or placebo administered on day 0 and week 12. The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1 to 12. RESULTS Among treated participants (n = 1,072), baseline mean number of MMDs was ≈16.1 across groups. Treatment with eptinezumab 100 and 300 mg was associated with significant reductions in MMDs across weeks 1 to 12 compared with placebo (placebo -5.6, 100 mg -7.7, p < 0.0001 vs placebo; 300 mg -8.2, p < 0.0001 vs placebo). Treatment-emergent adverse events (TEAEs) were reported by 43.5% (100 mg), 52.0% (300 mg), and 46.7% (placebo) of patients. Nasopharyngitis was the only TEAE reported for >2% of eptinezumab-treated patients at an incidence of >2% over placebo; it occurred in the 300 mg eptinezumab arm (eptinezumab 9.4%, placebo 6.0%). CONCLUSION In patients with CM, eptinezumab 100 and 300 mg was associated with a significant reduction in MMDs from the day after IV administration through week 12, was well tolerated, and demonstrated an acceptable safety profile. CLASSIFICATION OF EVIDENCE This study provides Class I evidence that for patients with CM, a single dose of eptinezumab reduces MMDs over 12 weeks of treatment. CLINICALTRIALSGOV IDENTIFIER NCT02974153.",2020,"Treatment with eptinezumab 100 and 300 mg was associated with significant reductions in MMDs across weeks 1 to 12 compared with placebo (placebo -5.6, 100 mg -7.7, p < 0.0001 vs placebo; 300 mg -8.2, p < 0.0001 vs placebo).","['patients with CM', 'chronic migraine (CM', 'Adults with CM', 'patients with chronic migraine']","['IV eptinezumab 100 mg, eptinezumab 300 mg, or placebo', 'eptinezumab', 'placebo (placebo', 'placebo']","['Efficacy and safety', 'mean monthly migraine days (MMDs', 'baseline mean number of MMDs', 'acceptable safety profile', 'MMDs', 'Nasopharyngitis']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1960870', 'cui_str': 'Chronic migraine'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}]",1072.0,0.62084,"Treatment with eptinezumab 100 and 300 mg was associated with significant reductions in MMDs across weeks 1 to 12 compared with placebo (placebo -5.6, 100 mg -7.7, p < 0.0001 vs placebo; 300 mg -8.2, p < 0.0001 vs placebo).","[{'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Lipton', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ. richard.lipton@einsteinmed.org.""}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Goadsby', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Smith', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Schaeffler', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Biondi', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'Hirman', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Pederson', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}, {'ForeName': 'Brent', 'Initials': 'B', 'LastName': 'Allan', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Cady', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}]",Neurology,['10.1212/WNL.0000000000009169'] 377,32224129,Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.,"BACKGROUND & AIMS We investigated the effects of inducing deep remission in patients with early Crohn's disease (CD). METHODS We collected follow-up data from 122 patients (mean age, 31.2 ± 11.3 y) with early, moderate to severe CD (median duration, 0.2 years; interquartile range, 0.1-0.5) who participated in the Effect of Tight Control Management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population. Fifty percent of patients (n = 61) were randomly assigned to a tight control strategy (increased therapy based on fecal level of calprotectin, serum level of C-reactive protein, and symptoms), and 50% were assigned to conventional management. We categorized patients as those who were vs were not in deep remission (CD endoscopic index of severity scores below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median, 3.02 years; range, 0.05-6.26 years). The primary outcome was a composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD. Kaplan-Meier and penalized Cox regression with bootstrapping were used to compare composite rates between patients who achieved or did not achieve remission at the end of the follow-up period. RESULTS Major adverse outcomes were reported for 34 patients (27.9%) during the follow-up period. Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P = .01). When we adjusted for potential confounders, deep remission (adjusted hazard ratio, 0.19; 95% confidence interval, 0.07-0.31) was significantly associated with a lower risk of major adverse outcome. CONCLUSIONS In an analysis of follow-up data from the CALM study, we associated induction of deep remission in early, moderate to severe CD with decreased risk of disease progression over a median time of 3 years, regardless of tight control or conventional management strategy.",2020,Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P=.01).,"['Fifty percent of patients (n=61', ""patients with early Crohn's disease (CD"", 'below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median 3.02 y; range, 0.05-6.26 y', '122 patients (mean age, 31.2±11.3 y) with early, moderate to severe CD (median duration 0.2 y; interquartile range, 0.1-0.5 y) who participated in the effect of tight control management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population']",['tight control strategy (increased therapy'],"['composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD', 'Deep Remission', 'deep remission', 'major adverse outcomes', 'composite rates', 'deep remission (CD endoscopic index of severity scores']","[{'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0156147', 'cui_str': 'Colitis, Granulomatous'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C3887532', 'cui_str': 'Ulceration (qualifier value)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C4517411', 'cui_str': '0.05'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C4517420', 'cui_str': 'Zero point one'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0453911', 'cui_str': 'Tights (physical object)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0205313', 'cui_str': 'Original (qualifier value)'}, {'cui': 'C0150157', 'cui_str': 'Calming'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0453911', 'cui_str': 'Tights (physical object)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0333330', 'cui_str': 'Internal fistula (morphologic abnormality)'}, {'cui': 'C0000833', 'cui_str': 'Abscess'}, {'cui': 'C1261287', 'cui_str': 'Stenosis'}, {'cui': 'C0267561', 'cui_str': 'Fistula of perianal skin'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0457451', 'cui_str': 'Severity score (qualifier value)'}]",122.0,0.0825621,Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P=.01).,"[{'ForeName': 'Ryan C', 'Initials': 'RC', 'LastName': 'Ungaro', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Yzet', 'Affiliation': 'Amiens University Hospital, Department of Gastroenterology, Amiens, France.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Bossuyt', 'Affiliation': 'Imelda Gastroenterology Clinical Research Center, Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium.'}, {'ForeName': 'Filip J', 'Initials': 'FJ', 'LastName': 'Baert', 'Affiliation': 'AZ Delta Roeselare, Roeselare, Belgium.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Vanasek', 'Affiliation': 'Second Department of Internal Medicine, University Hospital Hradec Králové, Hradec Králové, Czech Republic.'}, {'ForeName': 'Geert R', 'Initials': 'GR', 'LastName': ""D'Haens"", 'Affiliation': 'Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Vincent Wilhelmus', 'Initials': 'VW', 'LastName': 'Joustra', 'Affiliation': 'Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Remo', 'Initials': 'R', 'LastName': 'Panaccione', 'Affiliation': 'Inflammatory Bowel Disease Unit, University of Calgary, Calgary, Canada.'}, {'ForeName': 'Gottfried', 'Initials': 'G', 'LastName': 'Novacek', 'Affiliation': 'Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Reinisch', 'Affiliation': 'Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Armuzzi', 'Affiliation': 'Inflammatory Bowel Disease Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS-Università Cattolica del Sacro Cuore, Rome, Italy.'}, {'ForeName': 'Oleksandr', 'Initials': 'O', 'LastName': 'Golovchenko', 'Affiliation': 'Medical Clinical Investigational Center of Medical Center Health Clinic LLC, Vinnytsia, Ukraine.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Prymak', 'Affiliation': 'Medical Clinical Investigational Center of Medical Center Health Clinic LLC, Vinnytsia, Ukraine.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Goldis', 'Affiliation': 'Universitatea de Medicina si Farmacie, Timisoara, Romania.'}, {'ForeName': 'Simon P', 'Initials': 'SP', 'LastName': 'Travis', 'Affiliation': 'Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Hébuterne', 'Affiliation': 'Gastroenterology and Clinical Nutrition Department, Centre Hospitalier Universitaire of Nice, University of Nice Sophia-Antipolis, Nice, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Ferrante', 'Affiliation': 'University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Rogler', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Mathurin', 'Initials': 'M', 'LastName': 'Fumery', 'Affiliation': 'Amiens University Hospital, Department of Gastroenterology, Amiens, France.'}, {'ForeName': 'Silvio', 'Initials': 'S', 'LastName': 'Danese', 'Affiliation': 'Humanitas University, Istituto Clinico Humanitas, Milan, Italy.'}, {'ForeName': 'Grazyna', 'Initials': 'G', 'LastName': 'Rydzewska', 'Affiliation': 'Central Clinical Hospital of Ministry of Interior and Administration in Warsaw, Warsaw, Poland.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Pariente', 'Affiliation': 'Claude Huriez Hospital, Lille University, Lille, France.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Hertervig', 'Affiliation': 'Skane University Hospital, Lund, Sweden.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Stanciu', 'Affiliation': 'Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Serrero', 'Affiliation': 'Hepato-Gastroenterology Department, North Hospital, University of Mediterranean, Marseille, France.'}, {'ForeName': 'Mircea', 'Initials': 'M', 'LastName': 'Diculescu', 'Affiliation': 'University of Medicine and Pharmacy ""Carol Davila,"" Bucharest, Romania.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Peyrin-Biroulet', 'Affiliation': 'Hépato Gastro-Entérologie, Hôpital de Brabois, Nancy, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Laharie', 'Affiliation': ""Service d'Hépato-gastroentérologie et Oncologie Digestive, Hôpital Haut-Lévêque, Bordeaux, France.""}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Wright', 'Affiliation': 'Kingsbury Hospital, Cape Town, South Africa.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Gomollón', 'Affiliation': 'Hospital Clínico de Zaragoza, IIS Aragón, Zaragoza, Spain.'}, {'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Gubonina', 'Affiliation': 'Military Medical Academy named after S.M. Kirov, Saint Petersburg, Russian Federation.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Schreiber', 'Affiliation': 'Department of Internal Medicine I, Kiel University, Kiel, Germany.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Motoya', 'Affiliation': 'Inflammatory Bowel Disease Center, Sapporo Kosei General Hospital, Sapporo, Japan.'}, {'ForeName': 'Per M', 'Initials': 'PM', 'LastName': 'Hellström', 'Affiliation': 'Uppsala University Hospital, Uppsala, Sweden.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Halfvarson', 'Affiliation': 'Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.'}, {'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'Butler', 'Affiliation': 'AbbVie, Inc, North Chicago, Illinois.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Petersson', 'Affiliation': 'AbbVie, Inc, North Chicago, Illinois.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Petralia', 'Affiliation': 'Department of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Jean-Frederic', 'Initials': 'JF', 'LastName': 'Colombel', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.'}]",Gastroenterology,['10.1053/j.gastro.2020.03.039'] 378,32044505,Prostaglandin E1 effects on CD62p and PAC-1 in patients with sudden sensorineural hearing loss.,"PERSPECTIVES To evaluate the treatment outcome of vasodilator prostaglandin E1 (PGE1) in treating sudden sensorineural hearing loss (SSNHL) and to determine its effects on platelet activation, as reflected by changes in CD62p and PAC-1. METHODS We prospectively enrolled 60 patients with confirmed SSNHL and randomly divided them into two groups: the SSNHL group received regular therapy, and the SSNHL-PGE1 group received additional intravenous injection of PGE1. After 14 days of treatment, we measured clinical improvement and CD62p-positive and PAC-1-positive platelets. 30 healthy medical staff members were included as a control group. RESULTS The SSNHL patients had significantly higher levels of CD62p-positive or PAC-1 positive platelets than the healthy subjects. The ratios of CD62p positive or PAC-1 positive platelets significantly decreased after the two treatments. The average pure tone (PTA) hearing thresholds decreased to 26.51 ± 12.65 dB in SSNHL-PGE1 group after treatment, which was significantly lower than that of the SSNHL group (34.46 ± 10.35 dB). Patients with initial severe or profound hearing loss (PTA ≥ 71 dB) had better hearing improvement on PGE1 than on the regular treatment. Patients in the SSNHL-PGE1 treatment group had significantly lower CD62p and PAC-1 levels than those in the SSNHL group. Patients with higher initial positive CD62p and PAC-1 ratios tended to have higher potential of clinical improvement and hearing gains after PGE1 treatment. Initial CD62p and PAC-1 levels were significantly correlated with hearing thresholds in patients with SSNHL. CONCLUSION PGE1 application could improve treatment efficacy and suppress excessive platelet activation in patients with SSNHL.",2020,Patients with higher initial positive CD62p and PAC-1 ratios tended to have higher potential of clinical improvement and hearing gains after PGE1 treatment.,"['patients with sudden sensorineural hearing loss', '60 patients with confirmed SSNHL', 'Patients with initial severe or profound hearing loss (PTA\xa0≥\xa071\xa0dB', '30 healthy medical staff members were included as a control group', 'patients with SSNHL']","['vasodilator prostaglandin E1 (PGE1', 'SSNHL group received regular therapy, and the SSNHL-PGE1 group received additional intravenous injection of PGE1']","['Initial CD62p and PAC-1 levels', 'hearing improvement on PGE1', 'hearing gains', 'average pure tone (PTA) hearing thresholds', 'excessive platelet activation', 'clinical improvement and CD62p-positive and PAC-1-positive platelets', 'ratios of CD62p positive or PAC-1 positive platelets', 'levels of CD62p-positive or PAC-1 positive platelets', 'CD62p and PAC-1 levels']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4275242', 'cui_str': 'Sudden sensorineural hearing loss (disorder)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0439808', 'cui_str': 'Profundis'}, {'cui': 'C0015522', 'cui_str': 'Factor Eleven'}, {'cui': 'C0025106', 'cui_str': 'Medical Staff'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0042402', 'cui_str': 'Vasodilator Drugs'}, {'cui': 'C0002335', 'cui_str': 'Alprostadil'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0021494', 'cui_str': 'Intravenous Injections'}]","[{'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0182281', 'cui_str': 'Picture Archiving and Communication Systems'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0018767', 'cui_str': 'Audition'}, {'cui': 'C0002335', 'cui_str': 'Alprostadil'}, {'cui': 'C0449864', 'cui_str': 'Threshold (property) (qualifier value)'}, {'cui': 'C0442802', 'cui_str': 'Excessive (qualifier value)'}, {'cui': 'C0032173', 'cui_str': 'Platelet Activation'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",60.0,0.0157721,Patients with higher initial positive CD62p and PAC-1 ratios tended to have higher potential of clinical improvement and hearing gains after PGE1 treatment.,"[{'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Xi', 'Affiliation': ""Otorhinolaryngology Head and Neck Surgery, Shaanxi Provincial People's Hospital, The Third Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710068, Shaanxi, China.""}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': ""Otorhinolaryngology Head and Neck Surgery, Shaanxi Provincial People's Hospital, Medical Research School of Northwestern Polytechnical University, 710068, Shaanxi, China. Electronic address: hui_liu555@163.com.""}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ""Otorhinolaryngology Head and Neck Surgery, Shaanxi Provincial People's Hospital, Xi'an 710068, Shaanxi, China.""}]",Thrombosis research,['10.1016/j.thromres.2020.01.023'] 379,31708806,Hypnotic Discontinuation Using a Blinded (Masked) Tapering Approach: A Case Series.,"Chronic use of hypnotic medications such as benzodiazepines is associated with adverse consequences including increased risk of falls. Efforts to help patients discontinue these medications have had varying levels of success. We developed a blinded (masked) tapering protocol to help patients taper off hypnotics. In this blinded protocol, patients consented to a drug taper but agreed to forego knowledge about the specific tapering schedule or the actual dose each night until the end of the taper. Blinded tapering aims to reduce negative expectancies for withdrawal effects that may impair a patient's successful discontinuation of hypnotics. In preparation for a randomized trial, we tested the feasibility of adding a blinded tapering component to current best evidence practice [supervised hypnotic taper combined with cognitive behavioral therapy for insomnia (CBTI)] in 5 adult patients recruited from an outpatient mental health practice in Oregon. A compounding pharmacy prepared the blinded capsules for each patient. During the gradual blinded taper, each participant completed CBTI. Measures collected included feasibility/process (e.g., recruitment barriers), hypnotic use, the Dysfunctional Beliefs and Attitudes about Sleep Scale, Insomnia Severity Index, Epworth Sleepiness Scale, and Patient Health Questionnaire-9 (depressive symptoms). The intervention was feasible, and participants reported high satisfaction with the protocol and willingness to follow the same treatment again. All five participants successfully discontinued their hypnotic medication use post-treatment. Dysfunctional beliefs/attitudes about sleep and insomnia severity improved. Blinded tapering is a promising new method for improving hypnotic discontinuation among patients treated with a combination of hypnotic tapering plus CBTI.",2019,Blinded tapering is a promising new method for improving hypnotic discontinuation among patients treated with a combination of hypnotic tapering plus CBTI.,"['patients treated with a combination of hypnotic tapering plus CBTI', '5 adult patients recruited from an outpatient mental health practice in Oregon']","['benzodiazepines', 'hypnotic taper combined with cognitive behavioral therapy']","['feasibility/process (e.g., recruitment barriers), hypnotic use, the Dysfunctional Beliefs and Attitudes about Sleep Scale, Insomnia Severity Index, Epworth Sleepiness Scale, and Patient Health Questionnaire-9 (depressive symptoms', 'Dysfunctional beliefs/attitudes about sleep and insomnia severity', 'insomnia (CBTI']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0020591', 'cui_str': 'Hypnotics'}, {'cui': 'C0441640', 'cui_str': 'Tapering - action (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0029195', 'cui_str': 'Oregon'}]","[{'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C0020591', 'cui_str': 'Hypnotics'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]","[{'cui': 'C4521054', 'cui_str': 'Process (qualifier value)'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0020591', 'cui_str': 'Hypnotics'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0222045'}, {'cui': 'C4520529', 'cui_str': 'Insomnia severity index (assessment scale)'}, {'cui': 'C3541276', 'cui_str': 'ESS - Epworth Sleepiness Scale'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",,0.131677,Blinded tapering is a promising new method for improving hypnotic discontinuation among patients treated with a combination of hypnotic tapering plus CBTI.,"[{'ForeName': 'Constance H', 'Initials': 'CH', 'LastName': 'Fung', 'Affiliation': 'Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, North Hills, CA, United States.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Martin', 'Affiliation': 'Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, North Hills, CA, United States.'}, {'ForeName': 'Cathy', 'Initials': 'C', 'LastName': 'Alessi', 'Affiliation': 'Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, North Hills, CA, United States.'}, {'ForeName': 'Joseph M', 'Initials': 'JM', 'LastName': 'Dzierzewski', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, Richmond, VA, United States.'}, {'ForeName': 'Ian A', 'Initials': 'IA', 'LastName': 'Cook', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, United States.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Moore', 'Affiliation': 'Department of Medicine, University of California, San Diego School of Medicine, La Jolla, CA, United States.'}, {'ForeName': 'Austin', 'Initials': 'A', 'LastName': 'Grinberg', 'Affiliation': 'Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, North Hills, CA, United States.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Zeidler', 'Affiliation': 'Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, North Hills, CA, United States.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Kierlin', 'Affiliation': 'Northwest Sleep and Behavior, Lake Oswego, OR, United States.'}]",Frontiers in psychiatry,['10.3389/fpsyt.2019.00717'] 380,30538282,Prefronto-cerebellar neuromodulation affects appetite in obesity.,"Human neuroimaging studies have consistently reported changes in cerebellar function and integrity in association with obesity. To date, however, the nature of this link has not been studied directly. Emerging evidence suggests a role for the cerebellum in higher cognitive functions through reciprocal connections with the prefrontal cortex. The purpose of this exploratory study was to examine appetite changes associated with noninvasive prefronto-cerebellar neuromodulation in obesity. Totally, 12 subjects with class I obesity (mean body mass index 32.9 kg/m 2 ) underwent a randomized, single-blinded, sham-controlled, crossover study, during which they received transcranial direct current stimulation ((tDCS); active/sham) aimed at simultaneously enhancing the activity of the prefrontal cortex and decreasing the activity of the cerebellum. Changes in appetite (state and food-cue-triggered) and performance in a food-modified working memory task were evaluated. We found that active tDCS caused an increase in hunger and desire to eat following food-cue exposure. In line with these data, subjects also tended to make more errors during the working memory task. No changes in basic motor performance occurred. This study represents the first demonstration that prefronto-cerebellar neuromodulation can influence appetite in individuals with obesity. While preliminary, our findings support a potential role for prefronto-cerebellar pathways in the behavioral manifestations of obesity.",2019,Changes in appetite (state and food-cue-triggered) and performance in a food-modified working memory task were evaluated.,"['individuals with obesity', '12 subjects with class']","['transcranial direct current stimulation ((tDCS); active/sham', 'active tDCS', 'prefronto-cerebellar neuromodulation', 'Prefronto-cerebellar neuromodulation']","['basic motor performance', 'appetite (state and food-cue-triggered) and performance', 'hunger and desire to eat']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C1444748', 'cui_str': 'Provoked by (attribute)'}, {'cui': 'C0020175', 'cui_str': 'Hunger'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}]",12.0,0.0223505,Changes in appetite (state and food-cue-triggered) and performance in a food-modified working memory task were evaluated.,"[{'ForeName': 'Elena M', 'Initials': 'EM', 'LastName': 'Marron', 'Affiliation': 'Cognitive NeuroLab, Faculty of Health Sciences, Universitat Oberta de Catalunya (UOC), Barcelona, Spain. emunozmarr@uoc.edu.'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Viejo-Sobera', 'Affiliation': 'Cognitive NeuroLab, Faculty of Health Sciences, Universitat Oberta de Catalunya (UOC), Barcelona, Spain.'}, {'ForeName': 'Guillem', 'Initials': 'G', 'LastName': 'Cuatrecasas', 'Affiliation': 'Endocrinology Department, Clínica Sagrada Familia. Faculty of Health Sciences, Universitat Oberta de Catalunya (UOC), Barcelona, Spain.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Redolar-Ripoll', 'Affiliation': 'Cognitive NeuroLab, Faculty of Health Sciences, Universitat Oberta de Catalunya (UOC), Barcelona, Spain.'}, {'ForeName': 'Pilar García', 'Initials': 'PG', 'LastName': 'Lorda', 'Affiliation': 'Cognitive NeuroLab, Faculty of Health Sciences, Universitat Oberta de Catalunya (UOC), Barcelona, Spain.'}, {'ForeName': 'Abhishek', 'Initials': 'A', 'LastName': 'Datta', 'Affiliation': 'Soterix Medical, New York City, NY, USA.'}, {'ForeName': 'Marom', 'Initials': 'M', 'LastName': 'Bikson', 'Affiliation': 'Department of Biomedical Engineering, City College of New York (CCNY), New York, NY, USA.'}, {'ForeName': 'Greta', 'Initials': 'G', 'LastName': 'Magerowski', 'Affiliation': 'Laboratory of Bariatric and Nutritional Neuroscience, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Alonso-Alonso', 'Affiliation': 'Laboratory of Bariatric and Nutritional Neuroscience, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. malonso@bidmc.harvard.edu.'}]",International journal of obesity (2005),['10.1038/s41366-018-0278-8'] 381,30568260,Personalized nutrition: pretreatment glucose metabolism determines individual long-term weight loss responsiveness in individuals with obesity on low-carbohydrate versus low-fat diet.,"BACKGROUND/OBJECTIVES The interaction between fasting plasma glucose (FPG) and fasting insulin (FI) concentrations and diets with different carbohydrate content were studied as prognostic markers of weight loss as recent studies up to 6 months of duration have suggested the importance of these biomarkers. SUBJECTS/METHODS This was a retrospective analysis of a clinical trial where participants with obesity were randomized to an ad libitum low-carbohydrate diet or a low-fat diet with low energy content (1200-1800 kcal/day [≈ 5.0-7.5 MJ/d]; ≤ 30% calories from fat) for 24 months. Participants were categorized (pretreatment) as normoglycemic (FPG < 5.6 mmol/L) or prediabetic (FPG ≥ 5.6-6.9 mmol/L) and further stratified by median FI. Linear mixed models were used to examine outcomes by FPG and FI values. RESULTS After 2 years, participants with prediabetes and high FI lost 7.2  kg (95% CI 2.1;12.2, P = 0.005) more with the low-fat than low-carbohydrate diet, whereas those with prediabetes and low FI tended to lose 6.2  kg (95% CI -0.9;13.3, P = 0.088) more on the low-carbohydrate diet than low-fat diet [mean difference: 13.3 kg (95% CI 4.6;22.0, P = 0.003)]. No differences between diets were found among participants with normoglycemia and either high or low FI (both P ≥ 0.16). CONCLUSIONS Fasting plasma glucose and insulin are strong predictors of the weight loss response to diets with different macronutrient composition and might be a useful approach for personalized weight management.",2019,"No differences between diets were found among participants with normoglycemia and either high or low FI (both P ≥ 0.16). ","['Participants were categorized (pretreatment) as normoglycemic (FPG\u2009<\u20095.6\u2009mmol/L) or prediabetic (FPG\u2009≥\u20095.6-6.9\u2009mmol/L) and further stratified by median FI', 'individuals with obesity on low-carbohydrate versus low-fat diet', 'participants with obesity']",['ad libitum low-carbohydrate diet or a low-fat diet with low energy content'],['fasting plasma glucose (FPG) and fasting insulin (FI) concentrations'],"[{'cui': 'C0580545', 'cui_str': 'Blood glucose normal (finding)'}, {'cui': 'C4517794', 'cui_str': '5.6 (qualifier value)'}, {'cui': 'C1532563', 'cui_str': 'umol/mL'}, {'cui': 'C4517826', 'cui_str': 'Six point nine'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0242970', 'cui_str': 'Fat-Restricted Diet'}]","[{'cui': 'C0259836', 'cui_str': 'Diet, Carbohydrate-Restricted'}, {'cui': 'C0242970', 'cui_str': 'Fat-Restricted Diet'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",,0.0200382,"No differences between diets were found among participants with normoglycemia and either high or low FI (both P ≥ 0.16). ","[{'ForeName': 'Mads F', 'Initials': 'MF', 'LastName': 'Hjorth', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Sciences, University of Copenhagen, Copenhagen, Denmark. madsfiil@nexs.ku.dk.'}, {'ForeName': 'Arne', 'Initials': 'A', 'LastName': 'Astrup', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Yishai', 'Initials': 'Y', 'LastName': 'Zohar', 'Affiliation': 'Gelesis, Boston, MA, USA.'}, {'ForeName': 'Lorien E', 'Initials': 'LE', 'LastName': 'Urban', 'Affiliation': 'Gelesis, Boston, MA, USA.'}, {'ForeName': 'R Drew', 'Initials': 'RD', 'LastName': 'Sayer', 'Affiliation': 'University of Colorado Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'Bruce W', 'Initials': 'BW', 'LastName': 'Patterson', 'Affiliation': 'Washington University School of Medicine, St. Louis, MO, USA.'}, {'ForeName': 'Sharon J', 'Initials': 'SJ', 'LastName': 'Herring', 'Affiliation': 'Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Klein', 'Affiliation': 'Washington University School of Medicine, St. Louis, MO, USA.'}, {'ForeName': 'Babette S', 'Initials': 'BS', 'LastName': 'Zemel', 'Affiliation': 'University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Gary D', 'Initials': 'GD', 'LastName': 'Foster', 'Affiliation': 'University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Holly R', 'Initials': 'HR', 'LastName': 'Wyatt', 'Affiliation': 'University of Colorado Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'James O', 'Initials': 'JO', 'LastName': 'Hill', 'Affiliation': 'University of Colorado Anschutz Medical Campus, Aurora, CO, USA.'}]",International journal of obesity (2005),['10.1038/s41366-018-0298-4'] 382,32236553,A randomized trial comparing the effects of sternal band and plate fixation of the sternum with that of figure-of-8 wires on sternal edge motion and quality of recovery after cardiac surgery.,"OBJECTIVES We sought to compare the effects of conventional wire cerclage with that of the band and plate fixation of the sternum. METHODS A parallel randomized open-label trial with 1:1 allocation ratio compared healing after adult cardiac surgery using 'figure-of-8' stainless steel wire cerclage or a band and plate system (plates). The primary end point was maximal sternal edge displacement during active coughing of ≥2 mm in ≥2 of 4 sites measured with ultrasound by 2 assessors blinded to the other at 6 weeks postoperatively. Secondary end points at 12 weeks included ultrasound assessment, computed tomography (CT) scan and multidimensional assessment of quality of recovery using the Postoperative Quality of Recovery Scale. RESULTS Of 50 patients, 26 received plates and 24 wires. Two patients died and 1 withdrew consent leaving 25 plates and 22 wires for primary end point analysis. Operations included 37 coronary, 5 valve and 8 combined coronary and valve procedures. At 6 weeks, less sternal movement was observed in patients with plates than those with wires, 4% (1/25) vs 32% (7/22), P = 0.018. Agreement between observers was high, kappa = 0.850. At 12 weeks, less ultrasound motion was seen in patients with plates, 0% (0/23) than those with wires, 25% (5/20), P = 0.014. Recovery from pain was higher for patients with plates 92% (22/24) than those with wires 67% (14/21), P = 0.004. CT bone edge separation was less for plates 38% (9/24) than wires 71% (15/21), P = 0.036. CT mild bone synthesis or greater was similar between patients with plates 21% (5/24) and wires 14% (3/21), P = 0.71. CONCLUSIONS Patients receiving the band and plate system had significantly less sternal edge motion than those receiving wires, 6 and 12 weeks after cardiac surgery and experienced less pain. CLINICAL TRIAL REGISTRATION clinicaltrials.gov NCT03282578.",2020,"CT bone edge separation was less for plates 38% (9/24) than wires 71% (15/21), P = 0.036.","['Of 50 patients, 26 received plates and 24 wires', 'Operations included 37 coronary, 5 valve and 8 combined coronary and valve procedures']","[""1:1 allocation ratio compared healing after adult cardiac surgery using 'figure-of-8' stainless steel wire cerclage or a band and plate system (plates"", 'conventional wire cerclage', 'sternal band and plate fixation']","['maximal sternal edge displacement during active coughing of ≥2\u2009mm in ≥2 of 4 sites measured with ultrasound', 'ultrasound assessment, computed tomography (CT) scan and multidimensional assessment of quality of recovery using the Postoperative Quality of Recovery Scale', 'sternal movement', 'ultrasound motion', 'CT bone edge separation', 'CT mild bone synthesis', 'pain', 'sternal edge motion', 'sternal edge motion and quality of recovery', 'Recovery from pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0005978', 'cui_str': 'Bone wire'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0038126', 'cui_str': 'Stainless steel material'}, {'cui': 'C0005978', 'cui_str': 'Bone wire'}, {'cui': 'C1292825', 'cui_str': 'Cerclage'}, {'cui': 'C0230715', 'cui_str': 'A band'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0205154', 'cui_str': 'Along edge'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0036679', 'cui_str': 'Separation'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.0795619,"CT bone edge separation was less for plates 38% (9/24) than wires 71% (15/21), P = 0.036.","[{'ForeName': 'Alistair G', 'Initials': 'AG', 'LastName': 'Royse', 'Affiliation': 'Department of Surgery, The University of Melbourne, Parkville, VIC, Australia.'}, {'ForeName': 'Doa', 'Initials': 'D', 'LastName': 'El-Ansary', 'Affiliation': 'Department of Surgery, The University of Melbourne, Parkville, VIC, Australia.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Hoang', 'Affiliation': 'Department of Surgery, The Royal Melbourne Hospital, Melbourne, VIC, Australia.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'Lui', 'Affiliation': 'Department of Radiology, The University of Melbourne, Parkville, VIC, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'McCusker', 'Affiliation': 'Department of Radiology, The University of Melbourne, Parkville, VIC, Australia.'}, {'ForeName': 'Lynda', 'Initials': 'L', 'LastName': 'Tivendale', 'Affiliation': 'Department of Surgery, The University of Melbourne, Parkville, VIC, Australia.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Surgery, The University of Melbourne, Parkville, VIC, Australia.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Canty', 'Affiliation': 'Department of Surgery, The University of Melbourne, Parkville, VIC, Australia.'}, {'ForeName': 'Colin F', 'Initials': 'CF', 'LastName': 'Royse', 'Affiliation': 'Department of Surgery, The University of Melbourne, Parkville, VIC, Australia.'}]",Interactive cardiovascular and thoracic surgery,['10.1093/icvts/ivaa040'] 383,31276189,Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials.,"BACKGROUND Obesity is associated with psoriasis and negatively affects response to therapy. OBJECTIVES To evaluate the efficacy and safety of brodalumab in nonobese vs. obese patients with psoriasis. METHODS This is a post hoc analysis of the prospective, phase III, multicentre, randomized, placebo- and active-comparator-controlled AMAGINE-2 and AMAGINE-3 trials, in which patients were randomized to treatment with brodalumab 210 mg every 2 weeks, ustekinumab or placebo for a 12-week induction phase. At week 12, patients who received brodalumab 210 mg every 2 weeks continued brodalumab, those treated with ustekinumab continued ustekinumab, and those who received placebo switched to brodalumab 210 mg every 2 weeks. Patients were categorized by body mass index (BMI) category (< 30 or ≥ 30 kg m -2 ) and efficacy was evaluated using the physician-rated Psoriasis Area and Severity Index and static Physician's Global Assessment instruments. RESULTS In total, 281 of 687 patients (40·9%) were obese. Skin clearance was comparable across BMI subgroups in brodalumab-treated patients. Psoriasis Area and Severity Index 100% improvement rates in nonobese and obese patients at week 12 were 54·1% and 49·5%, respectively, and at week 52 they were 72·6% and 64·8%, respectively. Week 12 ustekinumab responses were lower than brodalumab responses and were 6-17% lower in obese than in nonobese patients. No appreciable differences in overall safety were observed between nonobese and obese patients. CONCLUSIONS The efficacy and safety of brodalumab did not differ between patients with moderate-to-severe psoriasis who had a BMI < 30 kg m -2 or a BMI ≥ 30 kg m -2 .",2020,"Psoriasis area and severity index 100% improvement rates in non-obese and obese patients at week 12 were 54.1% and 49.5%, respectively, and at week 52 were 72.6% and 64.8%, respectively.","['patients with moderate-to-severe psoriasis who had a BMI <30 kg/m 2 and a BMI ≥30 kg/m 2 ', 'non-obese vs obese patients with psoriasis', 'In total, 281 of 687 patients (40.9%) were obese', ""Patients were categorized by body mass index (BMI) category (<30 kg/m 2 or ≥30 kg/m 2 ) and efficacy was evaluated using the physician-rated psoriasis area and severity index and static physician's global assessment instruments"", 'Obese and Non-Obese Patients With Psoriasis']","['placebo switched to brodalumab', 'placebo', 'brodalumab 210 mg Q2W continued brodalumab', 'brodalumab 210 mg every 2 weeks, ustekinumab, or placebo', 'Brodalumab', 'brodalumab']","['Psoriasis area and severity index 100% improvement rates', 'overall safety', 'Skin clearance', 'efficacy and safety']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0441463', 'cui_str': 'Static (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C4551823', 'cui_str': 'instruments'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3491331', 'cui_str': 'brodalumab'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1608841', 'cui_str': 'ustekinumab'}]","[{'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}]",,0.16127,"Psoriasis area and severity index 100% improvement rates in non-obese and obese patients at week 12 were 54.1% and 49.5%, respectively, and at week 52 were 72.6% and 64.8%, respectively.","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Hsu', 'Affiliation': 'Temple University Lewis Katz School of Medicine, Philadelphia, PA, U.S.A.'}, {'ForeName': 'L J', 'Initials': 'LJ', 'LastName': 'Green', 'Affiliation': 'George Washington University School of Medicine & Health Sciences, Washington, DC, U.S.A.'}, {'ForeName': 'M G', 'Initials': 'MG', 'LastName': 'Lebwohl', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.'}, {'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Wu', 'Affiliation': 'Dermatology Research and Education Foundation, Irvine, CA, U.S.A.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Blauvelt', 'Affiliation': 'Oregon Medical Research Center, Portland, OR, U.S.A.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Jacobson', 'Affiliation': 'Ortho Dermatologics, Bridgewater, NJ, U.S.A.'}]",The British journal of dermatology,['10.1111/bjd.18327'] 384,31286480,"Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial.","BACKGROUND Secukinumab has shown sustained efficacy and safety in several manifestations of psoriasis. OBJECTIVES GESTURE investigated the long-term (2·5-year) safety and efficacy of 150 mg and 300 mg subcutaneous secukinumab in 205 patients with moderate-to-severe palmoplantar psoriasis. METHODS GESTURE was a randomized, double-blind, placebo-controlled, multicentre, phase IIIb trial conducted across 15 countries. The study was 140 weeks long and consisted of four periods: screening (up to 4 weeks), treatment period 1 (16 weeks), treatment period 2 (116 weeks) and post-treatment follow-up (8 weeks). Eligible patients were aged ≥ 18 years with moderate-to-severe palmoplantar psoriasis and at least one plaque outside of the palms and soles. Efficacy was assessed via a palmoplantar Investigator's Global Assessment (ppIGA) and the palmoplantar Psoriasis Area and Severity Index (PASI). RESULTS The primary end point, a ppIGA score of 0 or 1, was met at week 16. The effect was sustained over 2·5 years with 59% [95% confidence interval (CI) 43·5-74·1] and 53% (95% CI 35·1-69·6) of patients in the secukinumab 300 mg and 150 mg groups, respectively, achieving clear or almost clear palms and soles (ppIGA 0 or 1). At 2·5 years, the mean palmoplantar PASI percentage was reduced in both the secukinumab 300 mg group (-74·7%) and the secukinumab 150 mg group (-61·6%). A total of 17% (secukinumab 300 mg group) and 18% (secukinumab 150 mg group) of patients experienced no difficulty in hands and feet functionality, as indicated by the palmoplantar quality of life instrument overall scores. The safety profile was favourable. CONCLUSIONS GESTURE revealed that secukinumab provides a strong and sustained response over 2·5 years in challenging-to-treat palmoplantar psoriasis.",2020,"At 2·5 years, the mean palmoplantar Psoriasis Area and Severity Index % was reduced with both secukinumab 300 (-74·7%) and 150 mg (-61·6%).","['Subjects with Moderate-to-Severe Palmoplantar Psoriasis', '205 subjects with moderate-to-severe palmoplantar psoriasis (ppPsO']","['Placebo', 'subcutaneous secukinumab', 'Secukinumab']","['Palmoplantar Quality of Life Instrument overall scores', 'mean palmoplantar Psoriasis Area and Severity Index ', ""palmoplantar Investigator's Global Assessment (ppIGA""]","[{'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C3179547', 'cui_str': 'secukinumab'}]","[{'cui': 'C0034380'}, {'cui': 'C4551823', 'cui_str': 'instruments'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",,0.56875,"At 2·5 years, the mean palmoplantar Psoriasis Area and Severity Index % was reduced with both secukinumab 300 (-74·7%) and 150 mg (-61·6%).","[{'ForeName': 'A B', 'Initials': 'AB', 'LastName': 'Gottlieb', 'Affiliation': 'Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Kubanov', 'Affiliation': 'State Scientific Center of Dermatology, Venereology and Cosmetology, Moscow, Russia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'van Doorn', 'Affiliation': 'Department of Dermatology, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Sullivan', 'Affiliation': 'Kingsway Dermatology & Aesthetics, Miranda, Australia.'}, {'ForeName': 'K A', 'Initials': 'KA', 'LastName': 'Papp', 'Affiliation': 'K. Papp Research and Probity Medical Research, Inc., Waterloo, ON, Canada.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'You', 'Affiliation': 'China Novartis Institutes for BioMedical Research, Shanghai, China.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Regnault', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Frueh', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}]",The British journal of dermatology,['10.1111/bjd.18331'] 385,31941795,Randomized controlled trial of N -acetylcysteine therapy for RYR1 -related myopathies.,"OBJECTIVE To investigate the efficacy of N -acetylcysteine (NAC) for decreasing elevated oxidative stress and increasing physical endurance in individuals with ryanodine receptor 1-related myopathies ( RYR1 -RM). METHODS In this 6-month natural history assessment (n = 37) followed by a randomized, double-blinded, placebo-controlled trial, 33 eligible participants were block-randomized (1:1) to receive NAC (n = 16) or placebo (n = 17), orally for 6 months (adult dose 2,700 mg/d; pediatric dose 30 mg/kg/d). The primary endpoint was urine 15-F2t isoprostane concentration and the clinically meaningful co-primary endpoint was 6-minute walk test (6MWT) distance. RESULTS When compared to the general population, participants had elevated baseline 15-F2t isoprostane concentrations and most had a decreased 6MWT distance (mean ± SD 3.2 ± 1.5 vs 1.1 ± 1.7 ng/mg creatinine and 468 ± 134 vs 600 ± 58 m, respectively, both p < 0.001). 15-F2t isoprostane concentration and 6MWT distance did not change over the 6-month natural history assessment ( p = 0.98 and p = 0.61, respectively). NAC treatment did not improve 15-F2t isoprostane concentration (least squares means difference 0.1 [95% confidence interval [CI] -1.4 to 1.6] ng/mg creatinine, p = 0.88) or 6MWT distance (least squares means difference 24 [95% CI -5.5 to 53.4] m, p = 0.11). NAC was safe and well-tolerated at the doses administered in this study. CONCLUSION In ambulatory RYR1 -RM-affected individuals, we observed stable disease course, and corroborated preclinical reports of elevated oxidative stress and decreased physical endurance. NAC treatment did not decrease elevated oxidative stress, as measured by 15-F2t isoprostane. CLASSIFICATION OF EVIDENCE This study provides Class I evidence that, for people with RYR1 -RM, treatment with oral NAC does not decrease oxidative stress as measured by 15-F2t isoprostane. CLINICALTRIALSGOV IDENTIFIER NCT02362425.",2020,"15-F2t isoprostane concentration and 6MWT distance did not change over the 6-month natural history assessment ( p = 0.98 and p = 0.61, respectively).","['RYR1 -related myopathies', 'individuals with ryanodine receptor 1-related myopathies ( RYR1 -RM', '33 eligible participants were block-randomized (1:1) to receive']","['N -acetylcysteine therapy', 'placebo', 'NAC', 'N -acetylcysteine (NAC', 'oral NAC']","['15-F2t isoprostane concentration', '6MWT distance', 'safe and well-tolerated', '15-F2t isoprostane concentration and 6MWT distance', 'oxidative stress', 'elevated oxidative stress', 'urine 15-F2t isoprostane concentration and the clinically meaningful co-primary endpoint was 6-minute walk test (6MWT) distance']","[{'cui': 'C0524965', 'cui_str': 'RyR1'}, {'cui': 'C0026848', 'cui_str': 'Muscle Disorders'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}]","[{'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0295541', 'cui_str': '8-isoprostaglandin F2alpha'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0042037'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0444858', 'cui_str': 'AM 6 (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}]",33.0,0.628661,"15-F2t isoprostane concentration and 6MWT distance did not change over the 6-month natural history assessment ( p = 0.98 and p = 0.61, respectively).","[{'ForeName': 'Joshua J', 'Initials': 'JJ', 'LastName': 'Todd', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Tokunbor A', 'Initials': 'TA', 'LastName': 'Lawal', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Jessica W', 'Initials': 'JW', 'LastName': 'Witherspoon', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Irene C', 'Initials': 'IC', 'LastName': 'Chrismer', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Muslima S', 'Initials': 'MS', 'LastName': 'Razaqyar', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Monal', 'Initials': 'M', 'LastName': 'Punjabi', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Elliott', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Fatoumata', 'Initials': 'F', 'LastName': 'Tounkara', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Kuo', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Monique O', 'Initials': 'MO', 'LastName': 'Shelton', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Allen', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Mary M', 'Initials': 'MM', 'LastName': 'Cosgrove', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Melody', 'Initials': 'M', 'LastName': 'Linton', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Darren', 'Initials': 'D', 'LastName': 'Michael', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Minal S', 'Initials': 'MS', 'LastName': 'Jain', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Waite', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Bart', 'Initials': 'B', 'LastName': 'Drinkard', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Paul G', 'Initials': 'PG', 'LastName': 'Wakim', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'James J', 'Initials': 'JJ', 'LastName': 'Dowling', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Carsten G', 'Initials': 'CG', 'LastName': 'Bönnemann', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Magalie', 'Initials': 'M', 'LastName': 'Emile-Backer', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Katherine G', 'Initials': 'KG', 'LastName': 'Meilleur', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada. meilleurk@mail.nih.gov.'}]",Neurology,['10.1212/WNL.0000000000008872'] 386,30877090,Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study.,"OBJECTIVE We examined the effects of metformin on diabetes prevention and the subgroups that benefited most over 15 years in the Diabetes Prevention Program (DPP) and its follow-up, the Diabetes Prevention Program Outcomes Study (DPPOS). RESEARCH DESIGN AND METHODS During the DPP (1996-2001), adults at high risk of developing diabetes were randomly assigned to masked placebo ( n = 1,082) or metformin 850 mg twice daily ( n = 1,073). Participants originally assigned to metformin continued to receive metformin, unmasked, in the DPPOS (2002-present). Ascertainment of diabetes development was based on fasting or 2-h glucose levels after an oral glucose tolerance test or on HbA 1c . Reduction in diabetes incidence with metformin was compared with placebo in subgroups by hazard ratio (HR) and rate differences (RDs). RESULTS During 15 years of postrandomization follow-up, metformin reduced the incidence (by HR) of diabetes compared to placebo by 17% or 36% based on glucose or HbA 1c levels, respectively. Metformin's effect on the development of glucose-defined diabetes was greater for women with a history of prior gestational diabetes mellitus (GDM) (HR 0.59, RD -4.57 cases/100 person-years) compared with parous women without GDM (HR 0.94, RD -0.38 cases/100 person-years [interaction P = 0.03 for HR, P = 0.01 for RD]). Metformin also had greater effects, by HR and RD, at higher baseline fasting glucose levels. With diabetes development based on HbA 1c , metformin was more effective in subjects with higher baseline HbA 1c by RD, with metformin RD -1.03 cases/100 person-years with baseline HbA 1c <6.0% (42 mmol/mol) and -3.88 cases/100 person-years with 6.0-6.4% ( P = 0.0001). CONCLUSIONS Metformin reduces the development of diabetes over 15 years. The subsets that benefitted the most include subjects with higher baseline fasting glucose or HbA 1c and women with a history of GDM.",2019,"Metformin's effect on the development of glucose-defined diabetes was greater for women with a history of prior gestational diabetes mellitus (GDM) (HR 0.59, RD -4.57 cases/100 person-years) compared with parous women without GDM (HR 0.94, RD -0.38 cases/100","['diabetes prevention and the subgroups that benefited most over 15 years in the Diabetes Prevention Program (DPP) and its follow-up, the Diabetes Prevention Program Outcomes Study (DPPOS', 'women with a history of prior gestational diabetes mellitus (GDM', 'Diabetes', '1996-2001), adults at high risk of developing diabetes']","['placebo', 'metformin', 'metformin RD', 'DPP', 'masked placebo', 'Metformin']","['hazard ratio (HR) and rate differences (RDs', 'diabetes incidence', 'HR and RD', 'development of glucose-defined diabetes']","[{'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0085207', 'cui_str': 'Diabetes, Pregnancy-Induced'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0058353', 'cui_str': 'DPPS'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]",,0.012261,"Metformin's effect on the development of glucose-defined diabetes was greater for women with a history of prior gestational diabetes mellitus (GDM) (HR 0.59, RD -4.57 cases/100 person-years) compared with parous women without GDM (HR 0.94, RD -0.38 cases/100","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes care,['10.2337/dc18-1970'] 387,32105790,"Mindfulness-Based Cognitive Therapy for Psychological Distress, Fear of Cancer Recurrence, Fatigue, Spiritual Well-Being, and Quality of Life in Patients With Breast Cancer-A Randomized Controlled Trial.","CONTEXT Mindfulness-based interventions have been receiving growing attention in cancer care. OBJECTIVES The purpose of this randomized controlled trial is to examine the effectiveness of mindfulness-based cognitive therapy (MBCT) for psychological distress (anxiety and depression), fear of cancer recurrence (FCR), fatigue, spiritual well-being, and quality of life (QOL) in Japanese ambulatory patients with Stage I-III breast cancer. METHODS A total of 74 patients were randomly assigned to either an eight-week MBCT intervention group (n = 38) or a wait-list control group (n = 36). The primary outcome was psychological distress, measured on Hospital Anxiety and Depression Scale. The secondary outcomes were FCR (Concerns About Recurrence Scale-overall anxiety subscale), fatigue (Brief Fatigue Inventory), spiritual well-being (Functional Assessment of Chronic Illness Therapy-Spiritual), QOL (Functional Assessment of Cancer Therapy-General), and mindfulness skills (Five Facet Mindfulness Questionnaire). The participants were assessed at baseline (T0), Week 8 (T1), and Week 12 (T2). The results were analyzed using a intention-to-treat linear mixed model. RESULTS The participants in the MBCT group experienced significantly better outcomes in their psychological distress (Cohen's d = 1.17; P < 0.001), FCR (d = 0.43; P < 0.05), fatigue (d = 0.66; P < 0.01), spiritual well-being (d = 0.98; P < 0.001), and QOL (d = 0.79; P < 0.001) compared with the control group. The difference remained significant at T2 (four weeks after completion of the intervention). CONCLUSION MBCT was demonstrated to improve well-being that encompasses psychological, physical, and spiritual domains in Japanese patients with nonmetastatic breast cancer. The favorable effect was maintained up to four weeks after the completion of the intervention.",2020,"The secondary outcomes were FCR (Concerns About Recurrence Scale - overall anxiety subscale), fatigue (Brief Fatigue Inventory), spiritual well-being (Functional Assessment of Chronic Illness Therapy-Spiritual), QOL (Functional Assessment of Cancer Therapy-General) and mindfulness skills (Five Facet Mindfulness Questionnaire).","['Japanese ambulatory patients with stage I to III breast cancer', 'Patients with Breast Cancer ', '74 patients', 'Japanese patients with nonmetastatic breast cancer']","['MBCT intervention', 'Mindfulness-based Cognitive Therapy', 'mindfulness-based cognitive therapy (MBCT', 'MBCT', 'wait-list control group']","['psychological distress, measured on Hospital Anxiety and Depression Scale', 'FCR (Concerns About Recurrence Scale - overall anxiety subscale), fatigue (Brief Fatigue Inventory), spiritual well-being (Functional Assessment of Chronic Illness Therapy-Spiritual), QOL (Functional Assessment of Cancer Therapy-General) and mindfulness skills (Five Facet Mindfulness Questionnaire', 'Psychological Distress, Fear of Cancer Recurrence, Fatigue, Spiritual Wellbeing and Quality of Life', 'FCR', 'spiritual wellbeing', 'QOL', 'fatigue', 'psychological distress', 'psychological distress (anxiety and depression), fear of cancer recurrence (FCR), fatigue, spiritual wellbeing and quality of life (QOL']","[{'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1 (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}]","[{'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0222045'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0008679', 'cui_str': 'Chronic Illness'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0222679', 'cui_str': 'Structure of articular surface of bone'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0233705', 'cui_str': 'Fear of getting cancer (finding)'}, {'cui': 'C3697375', 'cui_str': 'Spiritual wellbeing (observable entity)'}, {'cui': 'C0034380'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]",74.0,0.0567975,"The secondary outcomes were FCR (Concerns About Recurrence Scale - overall anxiety subscale), fatigue (Brief Fatigue Inventory), spiritual well-being (Functional Assessment of Chronic Illness Therapy-Spiritual), QOL (Functional Assessment of Cancer Therapy-General) and mindfulness skills (Five Facet Mindfulness Questionnaire).","[{'ForeName': 'Sunre', 'Initials': 'S', 'LastName': 'Park', 'Affiliation': 'Faculty of Nursing and Medical Care, Keio University, Shinjuku-ku, Tokyo, Japan. Electronic address: spark@keio.jp.'}, {'ForeName': 'Yasuko', 'Initials': 'Y', 'LastName': 'Sato', 'Affiliation': 'Department of Nursing, National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan.'}, {'ForeName': 'Yuka', 'Initials': 'Y', 'LastName': 'Takita', 'Affiliation': 'Faculty of Nursing and Medical Care, Keio University, Shinjuku-ku, Tokyo, Japan; Department of Nursing, Faculty of Health Sciences, Tokyo Kasei University, Itabashi-ku, Tokyo, Japan.'}, {'ForeName': 'Noriko', 'Initials': 'N', 'LastName': 'Tamura', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Ninomiya', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.'}, {'ForeName': 'Teppei', 'Initials': 'T', 'LastName': 'Kosugi', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.'}, {'ForeName': 'Mitsuhiro', 'Initials': 'M', 'LastName': 'Sado', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.'}, {'ForeName': 'Atsuo', 'Initials': 'A', 'LastName': 'Nakagawa', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan; Clinical and Translational Research Center, Keio University Hospital, Shinjuku-ku, Tokyo, Japan.'}, {'ForeName': 'Maiko', 'Initials': 'M', 'LastName': 'Takahashi', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.'}, {'ForeName': 'Tetsu', 'Initials': 'T', 'LastName': 'Hayashida', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Fujisawa', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan; Division of Patient Safety, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2020.02.017'] 388,32212856,Augmenting Computerized Cognitive Training With Vortioxetine for Age-Related Cognitive Decline: A Randomized Controlled Trial.,"OBJECTIVE Age-related cognitive decline, the deterioration in functions such as memory and executive function, is faced by most older adults and affects function and quality of life. No approved treatments exist for age-related cognitive decline. Computerized cognitive training has been shown to provide consistent albeit modest improvements in cognitive function as measured by neuropsychological testing. Vortioxetine, an antidepressant medication, has putative procognitive and proneuroplastic properties and therefore may be able to augment cognitive training. In this placebo-controlled study, the authors tested the cognitive benefits of vortioxetine added to cognitive training for adults age 65 or older with age-related cognitive decline. METHODS After a 2-week lead-in period of cognitive training, 100 participants were randomly assigned to receive either vortioxetine or placebo in addition to cognitive training for 26 weeks. The primary outcome measure was global cognitive performance, assessed by the NIH Toolbox Cognition Battery Fluid Cognition Composite. The secondary outcome measure was functional cognition, assessed by the UCSD Performance-Based Skills Assessment. All participants received motivational messaging and support from study staff to maximize adherence to the training. RESULTS Participants who received vortioxetine with cognitive training showed a greater increase in global cognitive performance compared with those who received placebo with cognitive training. This separation was significant at week 12 but not at other assessment time points. Both groups showed improvement in the secondary outcome measure of functional cognition, with no significant difference between groups. CONCLUSIONS Vortioxetine may be beneficial for age-related cognitive decline when combined with cognitive training. These findings provide new treatment directions for combating cognitive decline in older adults.",2020,"RESULTS Participants who received vortioxetine with cognitive training showed a greater increase in global cognitive performance compared with those who received placebo with cognitive training.","['adults age 65 or older with age-related cognitive decline', '100 participants', 'Age-Related Cognitive Decline', 'older adults']","['vortioxetine added to cognitive training', 'Computerized cognitive training', 'Computerized Cognitive Training With Vortioxetine', 'placebo', 'motivational messaging', 'vortioxetine or placebo', 'vortioxetine with cognitive training', 'Vortioxetine']","['cognitive function', 'global cognitive performance, assessed by the NIH Toolbox Cognition Battery Fluid Cognition Composite', 'global cognitive performance', 'functional cognition', 'functional cognition, assessed by the UCSD Performance-Based Skills Assessment']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0236848', 'cui_str': 'Age-related cognitive decline (finding)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]","[{'cui': 'C3661282', 'cui_str': 'vortioxetine'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0729447', 'cui_str': 'Battery fluid (substance)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",100.0,0.154771,"RESULTS Participants who received vortioxetine with cognitive training showed a greater increase in global cognitive performance compared with those who received placebo with cognitive training.","[{'ForeName': 'Eric J', 'Initials': 'EJ', 'LastName': 'Lenze', 'Affiliation': ""Healthy Mind Lab, Department of Psychiatry (Lenze, Stevens, Pham, Haddad), Department of Radiology (Shimony), and Division of Biostatistics (Miller), Washington University School of Medicine, St. Louis; Department of Psychology, St. Louis University, St. Louis (Waring); and Department of Psychology, Queen's University, Kingston, Ontario (Bowie).""}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Stevens', 'Affiliation': ""Healthy Mind Lab, Department of Psychiatry (Lenze, Stevens, Pham, Haddad), Department of Radiology (Shimony), and Division of Biostatistics (Miller), Washington University School of Medicine, St. Louis; Department of Psychology, St. Louis University, St. Louis (Waring); and Department of Psychology, Queen's University, Kingston, Ontario (Bowie).""}, {'ForeName': 'Jill D', 'Initials': 'JD', 'LastName': 'Waring', 'Affiliation': ""Healthy Mind Lab, Department of Psychiatry (Lenze, Stevens, Pham, Haddad), Department of Radiology (Shimony), and Division of Biostatistics (Miller), Washington University School of Medicine, St. Louis; Department of Psychology, St. Louis University, St. Louis (Waring); and Department of Psychology, Queen's University, Kingston, Ontario (Bowie).""}, {'ForeName': 'Vy T', 'Initials': 'VT', 'LastName': 'Pham', 'Affiliation': ""Healthy Mind Lab, Department of Psychiatry (Lenze, Stevens, Pham, Haddad), Department of Radiology (Shimony), and Division of Biostatistics (Miller), Washington University School of Medicine, St. Louis; Department of Psychology, St. Louis University, St. Louis (Waring); and Department of Psychology, Queen's University, Kingston, Ontario (Bowie).""}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Haddad', 'Affiliation': ""Healthy Mind Lab, Department of Psychiatry (Lenze, Stevens, Pham, Haddad), Department of Radiology (Shimony), and Division of Biostatistics (Miller), Washington University School of Medicine, St. Louis; Department of Psychology, St. Louis University, St. Louis (Waring); and Department of Psychology, Queen's University, Kingston, Ontario (Bowie).""}, {'ForeName': 'Josh', 'Initials': 'J', 'LastName': 'Shimony', 'Affiliation': ""Healthy Mind Lab, Department of Psychiatry (Lenze, Stevens, Pham, Haddad), Department of Radiology (Shimony), and Division of Biostatistics (Miller), Washington University School of Medicine, St. Louis; Department of Psychology, St. Louis University, St. Louis (Waring); and Department of Psychology, Queen's University, Kingston, Ontario (Bowie).""}, {'ForeName': 'J Philip', 'Initials': 'JP', 'LastName': 'Miller', 'Affiliation': ""Healthy Mind Lab, Department of Psychiatry (Lenze, Stevens, Pham, Haddad), Department of Radiology (Shimony), and Division of Biostatistics (Miller), Washington University School of Medicine, St. Louis; Department of Psychology, St. Louis University, St. Louis (Waring); and Department of Psychology, Queen's University, Kingston, Ontario (Bowie).""}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Bowie', 'Affiliation': ""Healthy Mind Lab, Department of Psychiatry (Lenze, Stevens, Pham, Haddad), Department of Radiology (Shimony), and Division of Biostatistics (Miller), Washington University School of Medicine, St. Louis; Department of Psychology, St. Louis University, St. Louis (Waring); and Department of Psychology, Queen's University, Kingston, Ontario (Bowie).""}]",The American journal of psychiatry,['10.1176/appi.ajp.2019.19050561'] 389,31944823,The effect of anaemia on normal tissue toxicity and survival outcomes in prostate cancer treated with radical radiotherapy and neo-adjuvant androgen deprivation.,"OBJECTIVE It has been established that survival and toxicity outcomes in some cancer types could be influenced by haemoglobin (Hb) levels. This study aims to determine if pre-treatment Hb is associated with late toxicity or survival outcomes in prostate cancer. METHODS Data from one Phase III randomised controlled trial and one single arm translational trial were analysed. Patients had localized prostate cancer and received ≥70 Gy radiotherapy and neo-adjuvant androgen deprivation between 1997 and 2013. RESULTS 302 males were included. Median follow-up was 6.8 years for toxicity and 10.3 years for survival outcomes. Patients with Hb below the reference range were more likely to experience Grade 2-3 late gastrointestinal toxicity than patients with Hb within the range ( p = 0.050). Neither late genitourinary toxicity, erectile function toxicity, prostate-specific antigen relapse free survival nor overall survival of patients were statistically significantly different between groups. CONCLUSION Anaemia in prostate cancer is found in the minority of patients and is usually mild. Prostate cancer patients undergoing radiotherapy with low Hb were more likely to experience Grade 2-3 late gastrointestinal toxicity. ADVANCES IN KNOWLEDGE This study is one of the first in the published literature to investigate the role of Hb in prostate cancer toxicity and survival. We have found an association between Hb below the reference range and late GI toxicity. Consideration should be given to further investigating patients with iron deficiency anaemia to guide management options and outrule underlying GI pathology before proceeding with radiotherapy treatment.",2020,"Neither late genitourinary toxicity, erectile function toxicity, PSA relapse free survival nor overall survival of patients were statistically significantly different between groups. ","['Prostate cancer patients undergoing', 'Three hundred and two males were included', 'prostate cancer', 'prostate cancer treated with', 'Patients had localized prostate cancer and received ≥70\u2009Gy radiotherapy and neo-adjuvant androgen deprivation between 1997 and 2013']","['radiotherapy', 'radical radiotherapy and neo-adjuvant androgen deprivation']","['late toxicity or survival outcomes', 'survival and toxicity outcomes', 'experience Grade 2-3 late gastrointestinal toxicity', 'late genitourinary toxicity, erectile function toxicity, PSA relapse free survival nor overall survival', 'normal tissue toxicity and survival outcomes']","[{'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0392752', 'cui_str': 'Localized (qualifier value)'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C0002844', 'cui_str': 'Androgenic Compounds'}, {'cui': 'C0730225', 'cui_str': '1997 (qualifier value)'}]","[{'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C0439807', 'cui_str': 'Radical - extent'}, {'cui': 'C0002844', 'cui_str': 'Androgenic Compounds'}]","[{'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C1142499', 'cui_str': 'Gastrointestinal toxicity'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0201544', 'cui_str': 'Prostate specific antigen measurement (procedure)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0332441', 'cui_str': 'Normal tissue (finding)'}]",302.0,0.160658,"Neither late genitourinary toxicity, erectile function toxicity, PSA relapse free survival nor overall survival of patients were statistically significantly different between groups. ","[{'ForeName': 'Lorna G', 'Initials': 'LG', 'LastName': 'Keenan', 'Affiliation': 'Cancer Trials Ireland (formally All-Ireland Cooperative Oncology Research Group, ICORG), Dublin, Ireland.'}, {'ForeName': 'Nazir', 'Initials': 'N', 'LastName': 'Ibrahim', 'Affiliation': 'St Lukes Radiation Oncology Network, Oakland Drive, Highfield Road, Rathgar, Dublin, Ireland.'}, {'ForeName': 'Mary T', 'Initials': 'MT', 'LastName': 'Dunne', 'Affiliation': 'Cancer Trials Ireland (formally All-Ireland Cooperative Oncology Research Group, ICORG), Dublin, Ireland.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Finn', 'Affiliation': 'St Lukes Radiation Oncology Network, Oakland Drive, Highfield Road, Rathgar, Dublin, Ireland.'}, {'ForeName': 'John G', 'Initials': 'JG', 'LastName': 'Armstrong', 'Affiliation': 'Cancer Trials Ireland (formally All-Ireland Cooperative Oncology Research Group, ICORG), Dublin, Ireland.'}]",The British journal of radiology,['10.1259/bjr.20190577'] 390,31498030,Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.,"PURPOSE Outcome measures that comprehensively capture attributes of immuno-oncology agents, including prolonged treatment-free time and persistent treatment-related adverse events (TRAEs), are needed to complement conventional survival end points. METHODS We pooled data from the CheckMate 067 and 069 clinical trials of nivolumab and ipilimumab, as monotherapies or in combination, for patients with advanced melanoma. Treatment-free survival (TFS) was defined as the area between Kaplan-Meier curves for two conventional time-to-event end points, each defined from random assignment: time to immune checkpoint inhibitor (ICI) protocol therapy cessation and time to subsequent systemic therapy initiation or death. TFS was partitioned as time with and without toxicity by a third end point, time to cessation of both ICI therapy and toxicity. Toxicity included persistent and late-onset grade 3 or higher TRAEs. The area under each Kaplan-Meier curve was estimated by the 36-month restricted mean time. RESULTS At 36 months, many of the 1,077 patients who initiated ICI therapy were surviving free of subsequent therapy initiation (47% nivolumab plus ipilimumab, 37% nivolumab, 15% ipilimumab). The restricted mean TFS was longer for nivolumab plus ipilimumab (11.1 months) compared with nivolumab (4.6 months; difference, 6.5 months; 95% CI, 5.0 to 8.0 months) or ipilimumab (8.7 months; difference, 2.4 months; 95% CI, 0.8 to 4.1 months); restricted mean TFS represented 31% (3% with and 28% without toxicity), 13% (1% and 11%), and 24% (less than 1% and 23%) of the 36-month period, respectively, in the three treatment groups. TFS without toxicity was longer for nivolumab plus ipilimumab than nivolumab (difference, 6.0 months) or ipilimumab (difference, 1.7 months). CONCLUSION The analysis of TFS between ICI cessation and subsequent therapy initiation revealed longer TFS without toxicity for patients with advanced melanoma who received nivolumab plus ipilimumab compared with nivolumab or ipilimumab. Regardless of treatment, a small proportion of the TFS involved grade 3 or higher TRAEs.",2019,"TFS without toxicity was longer for nivolumab plus ipilimumab than nivolumab (difference, 6.0 months) or ipilimumab (difference, 1.7 months). ","['Patients With Advanced Melanoma', 'patients with advanced melanoma']","['nivolumab plus ipilimumab', 'Immune Checkpoint Inhibition', 'ipilimumab', 'nivolumab or ipilimumab', 'nivolumab and ipilimumab', 'TFS']","['Treatment-free survival (TFS', 'TFS without toxicity', 'surviving free of subsequent therapy initiation', 'mean TFS', 'Treatment-Free Survival', 'Toxicity included persistent and late-onset grade 3 or higher TRAEs']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}]","[{'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C0439662', 'cui_str': 'Immune (qualifier value)'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0332296', 'cui_str': 'Free of (attribute)'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation (observable entity)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]",1077.0,0.196501,"TFS without toxicity was longer for nivolumab plus ipilimumab than nivolumab (difference, 6.0 months) or ipilimumab (difference, 1.7 months). ","[{'ForeName': 'Meredith M', 'Initials': 'MM', 'LastName': 'Regan', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Lillian', 'Initials': 'L', 'LastName': 'Werner', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Sumati', 'Initials': 'S', 'LastName': 'Rao', 'Affiliation': 'Bristol-Myers Squibb, Princeton, NJ.'}, {'ForeName': 'Komal', 'Initials': 'K', 'LastName': 'Gupte-Singh', 'Affiliation': 'Bristol-Myers Squibb, Princeton, NJ.'}, {'ForeName': 'F Stephen', 'Initials': 'FS', 'LastName': 'Hodi', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Kirkwood', 'Affiliation': 'University of Pittsburgh Cancer Institute, Pittsburgh, PA.'}, {'ForeName': 'Harriet M', 'Initials': 'HM', 'LastName': 'Kluger', 'Affiliation': 'Yale Cancer Center, New Haven, CT.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Larkin', 'Affiliation': 'The Royal Marsden NHS Foundation Trust, London, United Kingdom.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Postow', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Corey', 'Initials': 'C', 'LastName': 'Ritchings', 'Affiliation': 'Bristol-Myers Squibb, Princeton, NJ.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Sznol', 'Affiliation': 'Yale University School of Medicine, New Haven, CT.'}, {'ForeName': 'Ahmad A', 'Initials': 'AA', 'LastName': 'Tarhini', 'Affiliation': 'Emory University and Winship Comprehensive Cancer Center, Atlanta, GA.'}, {'ForeName': 'Jedd D', 'Initials': 'JD', 'LastName': 'Wolchok', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Michael B', 'Initials': 'MB', 'LastName': 'Atkins', 'Affiliation': 'Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.'}, {'ForeName': 'David F', 'Initials': 'DF', 'LastName': 'McDermott', 'Affiliation': 'Harvard Medical School, Boston, MA.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.00345'] 391,31216226,Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.,"PURPOSE We report the final, protocol-specified analysis of overall survival (OS) in GOG-0218, a phase III, randomized trial of bevacizumab in women with newly diagnosed ovarian, fallopian tube, or primary peritoneal carcinoma. METHODS A total of 1,873 women with incompletely resected stage III to IV disease were randomly assigned 1:1:1 to six 21-day cycles of intravenous carboplatin (area under the concentration v time curve 6) and paclitaxel (175 mg/m 2 ) versus chemotherapy plus concurrent bevacizumab (15 mg/kg, cycles 2 to 6) versus chemotherapy plus concurrent and maintenance bevacizumab (cycles 2 to 22). Inclusion criteria included a Gynecologic Oncology Group performance status of 0 to 2 and no history of clinically significant vascular events or evidence of intestinal obstruction. OS was analyzed in the intention-to-treat population. A total of 1,195 serum and/or tumor specimens were sequenced for BRCA1/2 and damaging mutations in homologous recombination repair (HRR) genes. Intratumoral microvessel density was studied using CD31 immunohistochemistry. RESULTS Median follow-up was 102.9 months. Relative to control (n = 625), for patients receiving bevacizumab-concurrent (n = 625), the hazard ratio (HR) of death was 1.06 (95% CI, 0.94 to 1.20); for bevacizumab-concurrent plus maintenance (n = 623), the HR was 0.96 (95% CI, 0.85 to 1.09). Disease-specific survival was not improved in any arm. No survival advantage was observed after censoring patients who received bevacizumab at crossover or as second line. Median OS for stage IV bevacizumab-concurrent plus maintenance was 42.8 v 32.6 months for stage IV control (HR, 0.75; 95% CI, 0.59 to 0.95). Relative to wild type, the HR for death for BRCA1/2 mutated carcinomas was 0.62 (95% CI, 0.52 to 0.73), and for non- BRCA1/2 HRR, the HR was 0.65 (95% CI, 0.51 to 0.85). BRCA1/2 , HRR, and CD31 were not predictive of bevacizumab activity. CONCLUSION No survival differences were observed for patients who received bevacizumab compared with chemotherapy alone. Testing for BRCA1/2 mutations and homologous recombination deficiency is essential.",2019,Disease-specific survival was not improved in any arm.,"['women with newly diagnosed ovarian, fallopian tube, or primary peritoneal carcinoma', '1,873 women with incompletely resected stage III to IV disease', 'Ovarian Cancer']","['intravenous carboplatin (area under the concentration v time curve 6) and paclitaxel', 'bevacizumab', 'Bevacizumab', 'chemotherapy plus concurrent and maintenance bevacizumab', 'bevacizumab-concurrent', 'chemotherapy plus concurrent bevacizumab']","['hazard ratio (HR) of death', 'survival differences', 'Disease-specific survival', 'survival advantage', 'Median OS', 'Intratumoral microvessel density', 'BRCA1/2 , HRR, and CD31', 'vascular events or evidence of intestinal obstruction']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0015560', 'cui_str': 'Oviducts, Mammalian'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0948303', 'cui_str': 'Peritoneal carcinoma'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3 (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1140680', 'cui_str': 'Ovary Cancer'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0205420', 'cui_str': 'Concurrent (qualifier value)'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2350570', 'cui_str': 'Microvessels'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0332120', 'cui_str': 'Evidence of (contextual qualifier) (qualifier value)'}, {'cui': 'C0021843', 'cui_str': 'Intestinal Obstruction'}]",1873.0,0.353929,Disease-specific survival was not improved in any arm.,"[{'ForeName': 'Krishnansu S', 'Initials': 'KS', 'LastName': 'Tewari', 'Affiliation': 'University of California, Irvine, Medical Center, Orange, CA.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Burger', 'Affiliation': 'University of Pennsylvania Abramson Cancer Center, Philadelphia, PA.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Enserro', 'Affiliation': 'Roswell Park Cancer Institute, Buffalo, NY.'}, {'ForeName': 'Barbara M', 'Initials': 'BM', 'LastName': 'Norquist', 'Affiliation': 'University of Washington, Seattle, WA.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Swisher', 'Affiliation': 'University of Washington, Seattle, WA.'}, {'ForeName': 'Mark F', 'Initials': 'MF', 'LastName': 'Brady', 'Affiliation': 'Roswell Park Cancer Institute, Buffalo, NY.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Bookman', 'Affiliation': 'Permanente Medical Group, San Francisco, CA.'}, {'ForeName': 'Gini F', 'Initials': 'GF', 'LastName': 'Fleming', 'Affiliation': 'The University of Chicago, Chicago, IL.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Huang', 'Affiliation': 'Roswell Park Cancer Institute, Buffalo, NY.'}, {'ForeName': 'Howard D', 'Initials': 'HD', 'LastName': 'Homesley', 'Affiliation': 'Indiana University Medical Center, Indianapolis, IN.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Fowler', 'Affiliation': 'The Ohio State University James Cancer Hospital, Columbus, OH.'}, {'ForeName': 'Benjamin E', 'Initials': 'BE', 'LastName': 'Greer', 'Affiliation': 'University of Washington, Seattle, WA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Boente', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Sharon X', 'Initials': 'SX', 'LastName': 'Liang', 'Affiliation': 'Western Pennsylvania Hospital, Pittsburgh, PA.'}, {'ForeName': 'Chenglin', 'Initials': 'C', 'LastName': 'Ye', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Bais', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Leslie M', 'Initials': 'LM', 'LastName': 'Randall', 'Affiliation': 'University of California, Irvine, Medical Center, Orange, CA.'}, {'ForeName': 'John K', 'Initials': 'JK', 'LastName': 'Chan', 'Affiliation': 'California Pacific Medical Center Research Institute, San Francisco, CA.'}, {'ForeName': 'J Stuart', 'Initials': 'JS', 'LastName': 'Ferriss', 'Affiliation': 'Dell Seton Medical Center at The University of Texas, Austin, TX.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Coleman', 'Affiliation': 'MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Aghajanian', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Herzog', 'Affiliation': 'University of Cincinnati Cancer Institute, Cincinnati, OH.'}, {'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'DiSaia', 'Affiliation': 'University of California, Irvine, Medical Center, Orange, CA.'}, {'ForeName': 'Larry J', 'Initials': 'LJ', 'LastName': 'Copeland', 'Affiliation': 'The Ohio State University James Cancer Hospital, Columbus, OH.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Mannel', 'Affiliation': 'University of Oklahoma Health Sciences Center, Oklahoma City, OK.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Birrer', 'Affiliation': 'University of Alabama, Birmingham, AL.'}, {'ForeName': 'Bradley J', 'Initials': 'BJ', 'LastName': 'Monk', 'Affiliation': 'University of Arizona and Creighton University, Phoenix, AZ.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.01009'] 392,31504596,Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial.,"CONTEXT Prostate-specific antigen (PSA) changes during testosterone treatment of older hypogonadal men have not been rigorously evaluated. DESIGN Double-blinded, placebo-controlled trial. SETTING Twelve US academic medical centers. PARTICIPANTS Seven hundred ninety hypogonadal men ≥65 years of age with average testosterone levels ≤275 ng/dL. Men at high risk for prostate cancer were excluded. INTERVENTIONS Testosterone or placebo gel for 12 months. MAIN OUTCOMES Percentile changes in PSA during testosterone treatment of 12 months. RESULTS Testosterone treatment that increased testosterone levels from 232 ± 63 ng/dL to midnormal was associated with a small but substantially greater increase (P < 0.001) in PSA levels than placebo treatment. Serum PSA levels increased from 1.14 ± 0.86 ng/mL (mean ± SD) at baseline by 0.47 ± 1.1 ng/mL at 12 months in the testosterone group and from 1.25 ± 0.86 ng/mL by 0.06 ± 0.72 ng/mL in the placebo group. Five percent of men treated with testosterone had an increase ≥1.7 ng/mL and 2.5% of men had an increase of ≥3.4 ng/mL. A confirmed absolute PSA >4.0 ng/mL at 12 months was observed in 1.9% of men in the testosterone group and 0.3% in the placebo group. Four men were diagnosed with prostate cancer; two were Gleason 8. CONCLUSIONS When hypogonadal older men with normal baseline PSA are treated with testosterone, 5% had an increase in PSA ≥1.7 ng/mL, and 2.5% had an increase ≥3.4 ng/mL.",2019,Serum PSA levels increased from 1.14±0.86 ng/mL (mean ±SD) at baseline by 0.47±1.1 ng/mL at 12 months in the testosterone group and from 1.25±0.86 ng/mL by 0.06±0.72 ng/mL in the placebo group.,"['790 hypogonadal men ≥65 years with average testosterone levels ≤275 ng/dL. Men at high risk for prostate cancer were excluded', 'older hypogonadal men', 'Four men were diagnosed with prostate cancer', 'Twelve United States academic medical centers', 'Hypogonadal Older Men']","['placebo', 'testosterone', 'Testosterone', 'Testosterone or placebo gel']","['testosterone levels', 'PSA levels', 'Serum PSA levels']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0523912', 'cui_str': 'Testosterone measurement (procedure)'}, {'cui': 'C0439274', 'cui_str': 'ng/dL'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0000872', 'cui_str': 'University Medical Centers'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0523912', 'cui_str': 'Testosterone measurement (procedure)'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}]","[{'cui': 'C0523912', 'cui_str': 'Testosterone measurement (procedure)'}, {'cui': 'C0201544', 'cui_str': 'Prostate specific antigen measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",790.0,0.749418,Serum PSA levels increased from 1.14±0.86 ng/mL (mean ±SD) at baseline by 0.47±1.1 ng/mL at 12 months in the testosterone group and from 1.25±0.86 ng/mL by 0.06±0.72 ng/mL in the placebo group.,"[{'ForeName': 'Glenn R', 'Initials': 'GR', 'LastName': 'Cunningham', 'Affiliation': ""Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Baylor St. Luke's Medical Center, Houston, Texas.""}, {'ForeName': 'Susan S', 'Initials': 'SS', 'LastName': 'Ellenberg', 'Affiliation': 'Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Shalender', 'Initials': 'S', 'LastName': 'Bhasin', 'Affiliation': ""Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Alvin M', 'Initials': 'AM', 'LastName': 'Matsumoto', 'Affiliation': 'Geriatric Research, Education, and Clinical Center, Department of Veterans Affairs Puget Sound Health Care System, Seattle, Washington.'}, {'ForeName': 'J Kellogg', 'Initials': 'JK', 'LastName': 'Parsons', 'Affiliation': 'Department of Urology, Moores Comprehensive Cancer Center, University of California San Diego, San Diego, California.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Preston', 'Affiliation': 'Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Jane A', 'Initials': 'JA', 'LastName': 'Cauley', 'Affiliation': 'Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Gill', 'Affiliation': 'Division of Geriatric Medicine, Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Ronald S', 'Initials': 'RS', 'LastName': 'Swerdloff', 'Affiliation': 'Division of Endocrinology, Harbor-University of California at Los Angeles Medical Center, Torrance, California.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Division of Endocrinology, Harbor-University of California at Los Angeles Medical Center, Torrance, California.'}, {'ForeName': 'Kristine E', 'Initials': 'KE', 'LastName': 'Ensrud', 'Affiliation': 'Department of Medicine, Division of Epidemiology & Community Health, University of Minnesota, Minneapolis, Minnesota.'}, {'ForeName': 'Cora E', 'Initials': 'CE', 'LastName': 'Lewis', 'Affiliation': 'Department of Epidemiology, School of Public Health at UAB, Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Pahor', 'Affiliation': 'Department of Aging & Geriatric Research, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Jill P', 'Initials': 'JP', 'LastName': 'Crandall', 'Affiliation': 'Divisions of Endocrinology and Geriatrics, Albert Einstein College of Medicine, Bronx, New York.'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Molitch', 'Affiliation': 'Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Cifelli', 'Affiliation': 'Center for Clinical Epidemiology & Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Shehzad', 'Initials': 'S', 'LastName': 'Basaria', 'Affiliation': ""Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Susan J', 'Initials': 'SJ', 'LastName': 'Diem', 'Affiliation': 'Department of Medicine, Division of Epidemiology & Community Health, University of Minnesota, Minneapolis, Minnesota.'}, {'ForeName': 'Alisa J', 'Initials': 'AJ', 'LastName': 'Stephens-Shields', 'Affiliation': 'Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Xiaoling', 'Initials': 'X', 'LastName': 'Hou', 'Affiliation': 'Center for Clinical Epidemiology & Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Snyder', 'Affiliation': 'Division of Endocrinology, Diabetes, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/jc.2019-00806'] 393,32209647,"A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9).","OBJECTIVE To evaluate the efficacy and safety of fast-acting insulin aspart (faster aspart) compared with insulin aspart (IAsp), both with insulin degludec with or without metformin, in adults with type 2 diabetes not optimally controlled with a basal-bolus regimen. RESEARCH DESIGN AND METHODS This multicenter, double-blind, treat-to-target trial randomized participants to faster aspart ( n = 546) or IAsp ( n = 545). All available information, regardless of treatment discontinuation or use of ancillary treatment, was used for evaluation of effect. RESULTS Noninferiority for the change from baseline in HbA 1c 16 weeks after randomization (primary end point) was confirmed for faster aspart versus IAsp (estimated treatment difference [ETD] -0.04% [95% CI -0.11; 0.03]; -0.39 mmol/mol [-1.15; 0.37]; P < 0.001). Faster aspart was superior to IAsp for change from baseline in 1-h postprandial glucose (PPG) increment using a meal test (ETD -0.40 mmol/L [-0.66; -0.14]; -7.23 mg/dL [-11.92; -2.55]; P = 0.001 for superiority). Change from baseline in self-measured 1-h PPG increment for the mean over all meals favored faster aspart (ETD -0.25 mmol/L [-0.42; -0.09]); -4.58 mg/dL [-7.59; -1.57]; P = 0.003). The overall rate of treatment-emergent severe or blood glucose (BG)-confirmed hypoglycemia was statistically significantly lower for faster aspart versus IAsp (estimated treatment ratio 0.81 [95% CI 0.68; 0.97]). CONCLUSIONS In combination with insulin degludec, faster aspart provided effective overall glycemic control, superior PPG control, and a lower rate of severe or BG-confirmed hypoglycemia versus IAsp in adults with type 2 diabetes not optimally controlled with a basal-bolus regimen.",2020,Faster aspart was superior to IAsp for change from baseline in 1-h postprandial glucose (PPG) increment using a meal test (ETD -0.40 mmol/L [-0.66; -0.14]; -7.23 mg/dL,"['Adults With Type 2 Diabetes (Onset 9', 'adults with type 2 diabetes not optimally controlled with a basal-bolus regimen', ' n = 546) or IAsp ( n = 545']","['faster aspart', 'Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin', 'insulin aspart (IAsp), both with insulin degludec with or without metformin', 'fast-acting insulin aspart (faster aspart']","['overall rate of treatment-emergent severe or blood glucose (BG)-confirmed hypoglycemia', 'efficacy and safety']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C4517809', 'cui_str': 'Five hundred and forty-five'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0123677', 'cui_str': 'Insulin, Aspart, Human'}, {'cui': 'C3491971', 'cui_str': 'insulin degludec'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0980293,Faster aspart was superior to IAsp for change from baseline in 1-h postprandial glucose (PPG) increment using a meal test (ETD -0.40 mmol/L [-0.66; -0.14]; -7.23 mg/dL,"[{'ForeName': 'Wendy S', 'Initials': 'WS', 'LastName': 'Lane', 'Affiliation': 'Mountain Diabetes and Endocrine Centre, Asheville, NC mountaindiabetes@msn.com.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Favaro', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Naveen', 'Initials': 'N', 'LastName': 'Rathor', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Hak C', 'Initials': 'HC', 'LastName': 'Jang', 'Affiliation': 'Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, South Korea.'}, {'ForeName': 'Maiken I S', 'Initials': 'MIS', 'LastName': 'Kjærsgaard', 'Affiliation': 'Novo Nordisk A/S, Aalborg, Denmark.'}, {'ForeName': 'Alejandra', 'Initials': 'A', 'LastName': 'Oviedo', 'Affiliation': 'Santojanni Hospital and CENUDIAB, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina.'}, {'ForeName': 'Ludger', 'Initials': 'L', 'LastName': 'Rose', 'Affiliation': 'Institute of Diabetes Research, Münster, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Senior', 'Affiliation': 'Division of Endocrinology and Metabolism, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Sesti', 'Affiliation': 'Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Soto Gonzalez', 'Affiliation': 'Service of Endocrinology and Nutrition, University Hospital of A Coruña, La Coruña, Spain.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Franek', 'Affiliation': 'Mossakowski Clinical Research Center, Polish Academy of Sciences, and Department of Endocrinology and Diabetology, Central Clinical Hospital of the MSWiA, Warsaw, Poland.'}]",Diabetes care,['10.2337/dc19-2232'] 394,30918320,Effects of propofol on the inflammatory response during robot-assisted laparoscopic radical prostatectomy: a prospective randomized controlled study.,"Robot-assisted laparoscopic radical prostatectomy (RALRP) is a minimally invasive procedure; however, some amount of surgical trauma that can trigger systemic inflammation remains. Moreover, pneumoperitoneum during RALRP induces ischemia-reperfusion injury (IRI). Propofol, an anesthetic, is known to have anti-inflammatory and antioxidant properties. In the present study, we compared the effects of propofol with those of desflurane on inflammation and IRI during RALRP via measurements of different biomarkers and evaluation of perioperative renal function. Fifty patients were randomized to receive either desflurane (n = 25) or propofol (n = 25) with remifentanil during RALRP. Serum levels of interleukin (IL)-6 (IL-6), tumor necrosis factor alpha, C-reactive protein, and nitric oxide were measured 10 min after anesthesia induction (T1), 100 min after carbon dioxide (CO 2 ) insufflation (T2), and 10 min after CO 2 deflation (T3). Perioperative urine outputs and the serum creatinine level at 24 h after surgery were also recorded. We found that IL-6 levels at T2 and T3 were higher than those at T1 in both groups, although the increases were significant attenuated only in the propofol group. The other parameters showed no differences among the three time points in both groups. The intraoperative urine output was significantly higher in the propofol group than in the desflurane group, while the creatinine level showed no significant changes in either group. Our findings suggest that propofol can not only attenuate the inflammatory response during and after pneumoperitoneum in patients undergoing RALRP but also prevent oliguria during pneumoperitoneum.",2019,"Serum levels of interleukin (IL)-6 (IL-6), tumor necrosis factor alpha, C-reactive protein, and nitric oxide were measured 10 min after anesthesia induction (T1), 100 min after carbon dioxide (CO 2 ) insufflation (T2), and 10 min after CO 2 deflation (T3).",['Fifty patients'],"['robot-assisted laparoscopic radical prostatectomy', 'propofol', 'desflurane', 'Robot-assisted laparoscopic radical prostatectomy (RALRP', 'remifentanil during RALRP', 'Propofol']","['Perioperative urine outputs and the serum creatinine level', 'ischemia-reperfusion injury (IRI', 'Serum levels of interleukin (IL)-6 (IL-6), tumor necrosis factor alpha, C-reactive protein, and nitric oxide', 'intraoperative urine output', 'IL-6 levels', 'oliguria', 'inflammatory response']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C4039115', 'cui_str': 'Robot assisted laparoscopic radical prostatectomy'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0063252', 'cui_str': 'desflurane'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}]","[{'cui': 'C1287298', 'cui_str': 'UO - Urine output'}, {'cui': 'C0600061', 'cui_str': 'Serum creatinine level - finding'}, {'cui': 'C0035126', 'cui_str': 'Ischemia-Reperfusion Injury'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0028961', 'cui_str': 'Oligurias'}]",50.0,0.0542383,"Serum levels of interleukin (IL)-6 (IL-6), tumor necrosis factor alpha, C-reactive protein, and nitric oxide were measured 10 min after anesthesia induction (T1), 100 min after carbon dioxide (CO 2 ) insufflation (T2), and 10 min after CO 2 deflation (T3).","[{'ForeName': 'Go Un', 'Initials': 'GU', 'LastName': 'Roh', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, CHA Bundang Medical Center, CHA University School of Medicine, 59 Yatap-ro, Bundang-gu, Seongnami-si, Gyeonggi-do, 13496, Korea.'}, {'ForeName': 'Young', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, 211 Eonju-ro, Gangnam-gu, Seoul, 06273, Korea.'}, {'ForeName': 'Junbeom', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, CHA Bundang Medical Center, CHA University School of Medicine, 59 Yatap-ro, Bundang-gu, Seongnami-si, Gyeonggi-do, 13496, Korea.'}, {'ForeName': 'Yu Min', 'Initials': 'YM', 'LastName': 'Ki', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, CHA Bundang Medical Center, CHA University School of Medicine, 59 Yatap-ro, Bundang-gu, Seongnami-si, Gyeonggi-do, 13496, Korea.'}, {'ForeName': 'Dong Woo', 'Initials': 'DW', 'LastName': 'Han', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, 211 Eonju-ro, Gangnam-gu, Seoul, 06273, Korea. hanesth@yuhs.ac.'}]",Scientific reports,['10.1038/s41598-019-41708-x'] 395,32210365,Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial.,"BACKGROUND The cancer vaccine Vx-001, which targets the universal tumour antigen TElomerase Reverse Transcriptase (TERT), can mount specific Vx-001/TERT 572 CD8 + cytotoxic T cells; this immune response is associated with improved overall survival (OS) in patients with advanced/metastatic non-small cell lung cancer (NSCLC). METHODS A randomised, double blind, phase 2b trial, in HLA-A*201-positive patients with metastatic, TERT-expressing NSCLC, who did not progress after first-line platinum-based chemotherapy were randomised to receive either Vx-001 or placebo. The primary endpoint of the trial was OS. RESULTS Two hundred and twenty-one patients were randomised and 190 (101 and 89 patients in the placebo and the Vx-001 arm, respectively) were analysed for efficacy. There was not treatment-related toxicity >grade 2. The study did not meet its primary endpoint (median OS 11.3 and 14.3 months for the placebo and the Vx-001, respectively; p = 0.86) whereas the median Time to Treatment Failure (TTF) was 3.5 and 3.6 months, respectively. Disease control for >6months was observed in 30 (33.7%) and 26 (25.7%) patients treated with Vx-001 and placebo, respectively. There was no documented objective CR or PR. Long lasting TERT-specific immune response was observed in 29.2% of vaccinated patients who experienced a significantly longer OS compared to non-responders (21.3 and 13.4 months, respectively; p = 0.004). CONCLUSION Vx-001 could induce specific CD8 + immune response but failed to meet its primary endpoint. Subsequent studies have to be focused on the identification and treatment of subgroups of patients able to mount an effective immunological response to Vx-001. CLINICAL TRIAL REGISTRATION NCT01935154.",2020,"Long lasting TERT-specific immune response was observed in 29.2% of vaccinated patients who experienced a significantly longer OS compared to non-responders (21.3 and 13.4 months, respectively; p = 0.004). ","['patients with advanced/metastatic non-small cell lung cancer (NSCLC', 'patients with stage IV non-small cell lung cancer', 'Two hundred and twenty-one patients were randomised and 190 (101 and 89 patients in the', 'A*201-positive patients with metastatic, TERT-expressing NSCLC, who did not progress after first-line platinum-based chemotherapy']","['htert (vx-001) cancer vaccine', 'HLA', 'placebo', 'Vx-001 or placebo', 'chemotherapy maintenance immunotherapy']","['objective CR or PR', 'overall survival (OS', 'median Time to Treatment Failure (TTF', 'specific CD8 + immune response', 'Long lasting TERT-specific immune response']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0278987', 'cui_str': 'Metastatic non-small cell lung cancer (disorder)'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4 (qualifier value)'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}, {'cui': 'C4517650', 'cui_str': '220 (qualifier value)'}, {'cui': 'C4517622', 'cui_str': 'One hundred and ninety'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C1098768', 'cui_str': '(diethylenetriamine)-platinum(II)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C1958472', 'cui_str': 'Vx001 cpd'}, {'cui': 'C0376659', 'cui_str': 'Vaccines, Tumor'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0021083', 'cui_str': 'Immunotherapy'}]","[{'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3494202', 'cui_str': 'Time-to-Treatment'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0301872', 'cui_str': 'Immune response, function (observable entity)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}]",221.0,0.621622,"Long lasting TERT-specific immune response was observed in 29.2% of vaccinated patients who experienced a significantly longer OS compared to non-responders (21.3 and 13.4 months, respectively; p = 0.004). ","[{'ForeName': 'Cesare', 'Initials': 'C', 'LastName': 'Gridelli', 'Affiliation': 'S.G. Moscati Hospital, Avellino, Italy. cgridelli@libero.it.'}, {'ForeName': 'Tudor', 'Initials': 'T', 'LastName': 'Ciuleanu', 'Affiliation': 'Institutui, Oncologic I. Chircuta, Cluz-Napoca, Romania.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Domine', 'Affiliation': 'Fundacion Jimenez Diaz, Madrid, Spain.'}, {'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Szczesna', 'Affiliation': 'Mazowieckie Centrum, Otwock, Poland.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Bover', 'Affiliation': 'Son Llatzer Hospital, Palma de Mallorca, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Cobo', 'Affiliation': 'Hospital Regional Universitario Málaga, Instituto de Investigaciones Biomédicas (IBIMA), Málaga, Spain.'}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Kentepozidis', 'Affiliation': '251 General Airforce Hospital, Athens, Greece.'}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Zarogoulidis', 'Affiliation': 'Papanikolaou General Hospital, Exohi, Greece.'}, {'ForeName': 'Charalabos', 'Initials': 'C', 'LastName': 'Kalofonos', 'Affiliation': 'University Hospital of Patras, Rio, Greece.'}, {'ForeName': 'Andrzej', 'Initials': 'A', 'LastName': 'Kazarnowisz', 'Affiliation': 'Oddzial Onkologiiz Pododdziatem, Olsztyn, Poland.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Korozan', 'Affiliation': 'Hospicjum Dutkiewicza SAC, Gdansk, Poland.'}, {'ForeName': 'Ramon', 'Initials': 'R', 'LastName': 'de Las Penas', 'Affiliation': 'Hospital Provincial de Castellon, Castellon, Spain.'}, {'ForeName': 'Margarita', 'Initials': 'M', 'LastName': 'Majem', 'Affiliation': 'Hospital de la Santa Creui Sant Pau, Barcelona, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Chella', 'Affiliation': 'A.O.U. di Pisa Hospital, Pisa, Italy.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Griesinger', 'Affiliation': 'Pius Hospital, Oldenburg, Germany.'}, {'ForeName': 'Evangelos', 'Initials': 'E', 'LastName': 'Bournakis', 'Affiliation': 'University Hospital ""Aretaieion"", Athens, Greece.'}, {'ForeName': 'Parvis', 'Initials': 'P', 'LastName': 'Sadjadian', 'Affiliation': 'Johannes Wesling Klinikum, Minden, Germany.'}, {'ForeName': 'Athanasios', 'Initials': 'A', 'LastName': 'Kotsakis', 'Affiliation': 'Dpt of Medical Oncology, University General Hospital of Larissa, Larissa, Greece.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Chinet', 'Affiliation': 'Hopital Ambroise Paré, Boulogne-Billancourt, France.'}, {'ForeName': 'Kostantinos N', 'Initials': 'KN', 'LastName': 'Syrigos', 'Affiliation': 'General Hospital of Thoracic Diseases \'\'Sotiria"", Athens, Greece.'}, {'ForeName': 'Pierpaolo', 'Initials': 'P', 'LastName': 'Correale', 'Affiliation': 'University Hospital of Siena, Siena, Italy.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Gallou', 'Affiliation': 'Vaxon-Biotech, Paris, France.'}, {'ForeName': 'Jeanne- Menez', 'Initials': 'JM', 'LastName': 'Jamet', 'Affiliation': 'Vaxon-Biotech, Paris, France.'}, {'ForeName': 'Eleni- Kyriaki', 'Initials': 'EK', 'LastName': 'Vetsika', 'Affiliation': 'University General Hospital of Heraklion, Heraklion, Crete, Greece.'}, {'ForeName': 'Kostas', 'Initials': 'K', 'LastName': 'Kosmatopoulos', 'Affiliation': 'Vaxon-Biotech, Paris, France.'}, {'ForeName': 'Vassilis', 'Initials': 'V', 'LastName': 'Georgoulias', 'Affiliation': 'University General Hospital of Heraklion, Heraklion, Crete, Greece.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",British journal of cancer,['10.1038/s41416-020-0785-y'] 396,32201443,"Comparison of midazolam and low-dose dexmedetomidine in flexible bronchoscopy: A prospective, randomized, double-blinded study.","BACKGROUND Dexmedetomidine is a clinically useful drug for providing sedation, but concern regarding its cardiovascular side effect profile can limit its widespread use during routine diagnostic flexible bronchoscopy (FB). MATERIALS AND METHODS Patients between 18 and 65 years of age, who required diagnostic FB, were screened. Eligible patients were randomized to either receive 0.5 μg/kg intravenous dexmedetomidine over 10 min or intravenous midazolam 0.035 mg/kg over 1 min. If required, rescue medication (intravenous midazolam 0.5 mg bolus) was administered. The primary outcome measure was the composite score. Other parameters observed were numerical rating scale, hemodynamic variables, oxygen saturation, number of doses of rescue medication, visual analog scale score for cough, ease of bronchoscopy, Ramsay Sedation Score, and postprocedure patient response after 24 h of bronchoscopy. RESULTS A total of 54 patients were enrolled, 27 in each group. Total composite score (mean ± standard deviation) in dexmedetomidine and midazolam group at nasopharynx was 7.04 ± 2.19 and 6.59 ± 1.55 ( P = 0.387), respectively. The corresponding values at the level of trachea were 9.22 ± 3.69 and 8.63 ± 2.13 ( P = 0.475). In the dexmedetomidine group, patient response after 24 h of bronchoscopy showed the quality of sedation to be excellent in three patients, good in 10, fair in 11, and poor in 3 and discomfort to be nil in 14, mild 7, moderate in 3, and severe in 3. The corresponding values in the midazolam group for the quality of sedation were 0, 9, 18, 0 and for discomfort 10, 16, 1, 0. Other parameters did not reveal any statistically significant difference. CONCLUSION Dexmedetomidine at a dose of 0.5 μg/kg may provide clinically useful conscious sedation, comparable to midazolam.",2020,"Other parameters did not reveal any statistically significant difference. ","['Eligible patients', '54 patients were enrolled, 27 in each group', 'Patients between 18 and 65 years of age, who required diagnostic FB, were screened', 'flexible bronchoscopy']","['midazolam', 'dexmedetomidine', 'dexmedetomidine and midazolam', 'midazolam and low-dose dexmedetomidine', 'Dexmedetomidine']","['quality of sedation', 'numerical rating scale, hemodynamic variables, oxygen saturation, number of doses of rescue medication, visual analog scale score for cough, ease of bronchoscopy, Ramsay Sedation Score, and postprocedure patient response after 24 h of bronchoscopy', 'Total composite score (mean ± standard deviation', 'composite score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0443220', 'cui_str': 'Flexible (qualifier value)'}, {'cui': 'C0006290', 'cui_str': 'Bronchoscopy'}]","[{'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}]","[{'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0222045'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0006290', 'cui_str': 'Bronchoscopy'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}]",54.0,0.390527,"Other parameters did not reveal any statistically significant difference. ","[{'ForeName': 'Rahul', 'Initials': 'R', 'LastName': 'Magazine', 'Affiliation': 'Department of Respiratory Medicine, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.'}, {'ForeName': 'Shivaraj Kumar', 'Initials': 'SK', 'LastName': 'Venkatachala', 'Affiliation': 'Department of Respiratory Medicine, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.'}, {'ForeName': 'Umesh', 'Initials': 'U', 'LastName': 'Goneppanavar', 'Affiliation': 'Department of Anaesthesia, Dharwad Institute of Mental Health and Neurosciences, Dharwad and Karnataka Institute of Medical Sciences, Hubballi, Karnataka, India.'}, {'ForeName': 'Vyshak Uddur', 'Initials': 'VU', 'LastName': 'Surendra', 'Affiliation': 'Department of Respiratory Medicine, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.'}, {'ForeName': 'Vasudeva', 'Initials': 'V', 'LastName': 'Guddattu', 'Affiliation': 'Department of Data Science, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka, India.'}, {'ForeName': 'Bharti', 'Initials': 'B', 'LastName': 'Chogtu', 'Affiliation': 'Department of Pharmacology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.'}]",Indian journal of pharmacology,['10.4103/ijp.IJP_287_19'] 397,32212129,Which stent to use for the management of pancreatic pseudocysts? Time for randomized controlled studies.,,2020,,[],[],[],[],[],[],,0.0368287,,"[{'ForeName': 'Gianenrico', 'Initials': 'G', 'LastName': 'Rizzatti', 'Affiliation': 'Digestive Endoscopy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.'}, {'ForeName': 'Mihai', 'Initials': 'M', 'LastName': 'Rimbaș', 'Affiliation': 'Digestive Endoscopy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Larghi', 'Affiliation': 'Digestive Endoscopy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.'}]",Endoscopy,['10.1055/a-1103-1938'] 398,32201441,A 12-week prospective randomized controlled comparative trial of vilazodone and sertraline in Indian patients with depression.,"BACKGROUND Depressive disorders are considered to be one of the leading causes of morbidity and mortality accounting for 4.3% of total disability-adjusted life years. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors have greater efficacy and lesser side effects; at the same time, these drugs cause sexual dysfunction and weight gain. Vilazodone was supposed to have better efficacy and less sexual dysfunction and weight gain. AIM OF THE STUDY The aim is to compare efficacy (in terms of Hamilton Depression Rating Scale [HDRS]), sexual dysfunction (in terms of Arizona Sexual Experience Scale [ASEX]), and weight gain caused due to vilazodone and sertraline. MATERIALS AND METHODS This is a randomized controlled study; 60 patients diagnosed with depressive episode were divided into two groups of 30 each; using block randomization technique, one group was prescribed vilazodone and another sertraline. The groups were compared on the basis of efficacy, weight gain, and sexual dysfunction using HDRS and ASEX at baseline, 4-week, and 12-week intervals. Statistical analysis was done by applying Chi-square test, Fisher's exact test, t -test, and repeated measures ANOVA using Wilks' lambda test. RESULTS On comparing both vilazodone and sertraline, it was observed that both molecules have equal efficacy in terms of HDRS, but vilazodone does not cause weight gain and sexual dysfunction in terms of ASEX, and these findings are statistically very highly significant. CONCLUSIONS Our study shows that vilazodone has similar efficacy but can be a better antidepressant due to lesser weight gain and sexual dysfunction compared to sertraline.",2020,"The groups were compared on the basis of efficacy, weight gain, and sexual dysfunction using HDRS and ASEX at baseline, 4-week, and 12-week intervals.","['Indian patients with depression', '60 patients diagnosed with depressive episode']","['vilazodone and sertraline', 'vilazodone', 'Vilazodone', 'sertraline', 'vilazodone and another sertraline']","['efficacy, weight gain, and sexual dysfunction using HDRS and ASEX', 'Hamilton Depression Rating Scale [HDRS]), sexual dysfunction (in terms of Arizona Sexual Experience Scale [ASEX]), and weight gain', 'weight gain and sexual dysfunction', 'sexual dysfunction and weight gain']","[{'cui': 'C1524069', 'cui_str': 'Indian (racial group)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0349217', 'cui_str': 'Depressive episode'}]","[{'cui': 'C1530072', 'cui_str': 'vilazodone'}, {'cui': 'C0074393', 'cui_str': 'Sertraline'}]","[{'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0549622', 'cui_str': 'Sexual disorder (disorder)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C0003787', 'cui_str': 'Arizona'}]",60.0,0.027511,"The groups were compared on the basis of efficacy, weight gain, and sexual dysfunction using HDRS and ASEX at baseline, 4-week, and 12-week intervals.","[{'ForeName': 'Manish', 'Initials': 'M', 'LastName': 'Bathla', 'Affiliation': 'Department of Psychiatry, MM Institute of Medical Sciences and Research, Ambala, Haryana, India.'}, {'ForeName': 'Shazia', 'Initials': 'S', 'LastName': 'Anjum', 'Affiliation': 'Department of Psychiatry, MM Institute of Medical Sciences and Research, Ambala, Haryana, India.'}]",Indian journal of pharmacology,['10.4103/ijp.IJP_618_18'] 399,32201442,"The evaluation of efficacy and safety of methotrexate and pioglitazone in psoriasis patients: A randomized, open-labeled, active-controlled clinical trial.","OBJECTIVES Psoriasis is a chronic inflammatory disease showing co-existence with metabolic syndrome (MS), as has been confirmed by numerous epidemiologic studies in recent times. In this study, the aim was to ascertain the beneficial effects of pioglitazone in psoriasis, simultaneously targeting the improvement of MS parameters. MATERIALS AND METHODS We conducted a prospective randomized open-labeled parallel-group interventional study in patients of moderate-to-severe chronic plaque psoriasis. A total of 90 patients were inducted in study and divided into three groups of standard treatment (methotrexate 7.5 mg/week for 12 weeks), active treatment (pioglitazone 15 mg tablets once daily for 12 weeks), and their combination. Primary outcome was taken as percentage Psoriasis Area and Severity Index (PASI) improvement from baseline; secondary outcomes were PASI-75, safety profile, and MS parameters. RESULTS Intergroup evaluation of PASI score showed that standard treatment methotrexate and active treatment pioglitazone were comparable. Combination of methotrexate and pioglitazone proved superior in efficacy from both standard and active treatment in 8 and 12 weeks. Adverse drug reactions were mild and treated symptomatically. Pioglitazone and combination group also demonstrated beneficial efficacy in parameter of MS hence establishing it as a potential therapy in psoriasis with MS. CONCLUSIONS Pioglitazone alone or in combination with standard treatment may be a safe alternative drug for psoriasis coexisting with MS proving beneficial for both.",2020,"RESULTS Intergroup evaluation of PASI score showed that standard treatment methotrexate and active treatment pioglitazone were comparable.","['patients of moderate-to-severe chronic plaque psoriasis', 'psoriasis patients', 'A total of 90 patients']","['pioglitazone', 'standard treatment (methotrexate 7.5 mg/week for 12 weeks), active treatment (pioglitazone', 'methotrexate and pioglitazone', 'Pioglitazone']","['PASI score', 'beneficial efficacy', 'efficacy and safety', 'PASI-75, safety profile, and MS parameters', 'percentage Psoriasis Area and Severity Index (PASI', 'Adverse drug reactions']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0406317', 'cui_str': 'Plaque psoriasis (disorder)'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]","[{'cui': 'C0071097', 'cui_str': 'pioglitazone'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1128686', 'cui_str': 'Methotrexate 7.5 MG'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0041755', 'cui_str': 'Drug Side Effects'}]",90.0,0.0309169,"RESULTS Intergroup evaluation of PASI score showed that standard treatment methotrexate and active treatment pioglitazone were comparable.","[{'ForeName': 'Afroz', 'Initials': 'A', 'LastName': 'Abidi', 'Affiliation': ""Department of Pharmacology, Era's Lucknow Medical College, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Dilshad Ali', 'Initials': 'DA', 'LastName': 'Rizvi', 'Affiliation': ""Department of Pharmacology, Era's Lucknow Medical College, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Kshitij', 'Initials': 'K', 'LastName': 'Saxena', 'Affiliation': ""Department of Dermatology, Era's Lucknow Medical College, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Savita', 'Initials': 'S', 'LastName': 'Chaudhary', 'Affiliation': ""Department of Dermatology, Era's Lucknow Medical College, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ahmad', 'Affiliation': ""Department of Pharmacology, Era's Lucknow Medical College, Lucknow, Uttar Pradesh, India.""}]",Indian journal of pharmacology,['10.4103/ijp.IJP_88_19'] 400,32126576,Endoscopic ultrasonography-guided deployment of embolization coils and cyanoacrylate injection in gastric varices versus coiling alone: a randomized trial.,"BACKGROUND Gastric variceal bleeding is a life-threating condition with challenging management. We aimed to compare the efficacy and safety of endoscopic ultrasonography (EUS)-guided coil embolization and cyanoacrylate injection versus EUS-guided coil embolization alone in the management of gastric varices. METHODS A single-center, parallel-randomized controlled trial involving 60 participants with gastric varices (GOV II and IGV I) who were randomly allocated to EUS-guided coil embolization and cyanoacrylate injection (n = 30) or EUS-guided coil embolization alone (n = 30). The primary end points were the technical and clinical success rates of both procedures. The secondary end points were the reappearance of gastric varices during follow-up, along with rebleeding, the need for reintervention, and complication and survival rates. RESULTS The technical success rate was 100 % in both groups. Immediate disappearance of varices was observed in 86.7 % of patients treated with coils and cyanoacrylate, versus 13.3 % of patients treated with coils alone ( P  < 0.001). Median survival time was 16.4 months with coils and cyanoacrylate versus 14.2 months with coils alone ( P  = 0.90). Rebleeding occurred in 3.3 % of patients treated with combined treatment and 20 % of those treated with coils alone ( P  = 0.04). With combined treatment, 83.3 % of patients were free from reintervention versus 60 % with coils alone (hazard ratio 0.27; 95 % confidence interval 0.095 - 0.797; P  = 0.01). CONCLUSIONS EUS-guided coil embolization with cyanoacrylate injection achieved excellent clinical success, with lower rates of rebleeding and reintervention than coil treatment alone. Multicenter studies are required to define the most appropriate technique for gastric variceal obliteration.",2020,"Immediate disappearance of varices was observed in 86.7 % of patients treated with coils and cyanoacrylate, versus 13.3 % of patients treated with coils alone ( P  < 0.001).",['60 participants with gastric varices (GOV II and IGV I'],"['coils alone', 'cyanoacrylate', 'Endoscopic ultrasonography-guided deployment of embolization coils and cyanoacrylate injection', 'coiling alone', 'endoscopic ultrasonography (EUS)-guided coil embolization and cyanoacrylate injection versus EUS-guided coil embolization alone', 'EUS-guided coil embolization and cyanoacrylate injection (n\u200a=\u200a30) or EUS-guided coil embolization alone']","['Median survival time', 'efficacy and safety', 'Rebleeding', 'technical and clinical success rates of both procedures', 'technical success rate', 'reappearance of gastric varices', 'Immediate disappearance of varices', 'rebleeding and reintervention', 'excellent clinical success', 'rebleeding, the need for reintervention, and complication and survival rates']","[{'cui': 'C0017145', 'cui_str': 'Gastric Varix'}]","[{'cui': 'C0419518', 'cui_str': 'Contraceptive coil (physical object)'}, {'cui': 'C0010507', 'cui_str': 'Cyanoacrylates'}, {'cui': 'C0376443', 'cui_str': 'Ultrasonography, Endoscopic'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0522644', 'cui_str': 'Embolization coil, device (physical object)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0013931', 'cui_str': 'Embolotherapy'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2919552', 'cui_str': 'Survival time'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0017145', 'cui_str': 'Gastric Varix'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0042345', 'cui_str': 'Varices'}, {'cui': 'C1961136', 'cui_str': 'Excellent (qualifier value)'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",60.0,0.0756777,"Immediate disappearance of varices was observed in 86.7 % of patients treated with coils and cyanoacrylate, versus 13.3 % of patients treated with coils alone ( P  < 0.001).","[{'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Robles-Medranda', 'Affiliation': 'Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Guayaquil, Ecuador.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Oleas', 'Affiliation': 'Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Guayaquil, Ecuador.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Valero', 'Affiliation': 'Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Guayaquil, Ecuador.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Puga-Tejada', 'Affiliation': 'Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Guayaquil, Ecuador.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Baquerizo-Burgos', 'Affiliation': 'Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Guayaquil, Ecuador.'}, {'ForeName': 'Jesenia', 'Initials': 'J', 'LastName': 'Ospina', 'Affiliation': 'Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Guayaquil, Ecuador.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Pitanga-Lukashok', 'Affiliation': 'Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Guayaquil, Ecuador.'}]",Endoscopy,['10.1055/a-1123-9054'] 401,31209602,Determining changes in bone metabolism after bariatric surgery in postmenopausal women.,"BACKGROUND Accelerated bone loss is a known complication after bariatric surgery. Bone mineral density has been shown to decrease significantly after Laparoscopic Roux-en-Y gastric bypass (RYGB). Laparoscopic sleeve gastrectomy (SG) effects on bone density are largely unknown. This should be considered for those with increased preoperative risk for bone loss, such as postmenopausal females. METHODS This prospective clinical trial included postmenopausal patients, with BMI ≥ 35 k/m 2 , being evaluated for either RYGB or SG. Patients with history of osteoporosis, estrogen hormone replacement therapy, active smoking, glucocorticoid use, or weight > 295 lb were excluded. Patients underwent DEXA scans preoperatively and 1 year postoperatively with measurement of total body bone mineral density (BMD) and bone mineral content (BMC) as well as regional site-specific BMD and BMC. RESULTS A total of 28 patients were enrolled. 16 (57.1%) patients underwent RYGB and 12 (42.9%) patients underwent SG. Median preoperative BMI was 44.2 k/m 2 (IQR 39.9, 46.6). Median change in BMI at 12 months was - 11.3 k/m 2 (IQR - 12.8, - 7.9). A significant reduction in total body BMC was seen when comparing preoperative measurements to postoperative measurements (2358.32 vs 2280.68 grams; p = 0.002). Regional site BMC and BMD significantly decreased in the ribs and spine postoperatively (p = < 0.02) representing the greatest loss in the axial skeleton. Comparing those who underwent RYGB to SG there was no significant difference between the two groups when evaluating changes in total or regional site BMD. CONCLUSION Postmenopausal women were found to have decreased BMD and BMC after RYGB and SG, suggesting that high-risk women may benefit from postoperative DEXA screening. Further study is needed to determine the clinical significance of these findings. It is unknown if these changes in BMD are due to modifiable factors (Vitamin D level, activity level, hormone status, etc.), and whether BMD and BMC is recovered beyond 1 year.",2020,Regional site BMC and BMD significantly decreased in the ribs and spine postoperatively (p = < 0.02) representing the greatest loss in the axial skeleton.,"['postmenopausal women', '28 patients were enrolled', '295\xa0lb were excluded', 'postmenopausal patients, with BMI\u2009≥\u200935\xa0k/m 2 , being evaluated for either RYGB or SG', 'Patients with history of osteoporosis, estrogen hormone replacement therapy, active smoking, glucocorticoid use, or weight\u2009', 'Postmenopausal women']",['Laparoscopic sleeve gastrectomy (SG'],"['Median preoperative BMI', 'Median change in BMI', 'total or regional site BMD', 'total body BMC', 'Regional site BMC and BMD', 'total body bone mineral density (BMD) and bone mineral content (BMC', 'bone metabolism', 'BMD and BMC']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C3532614', 'cui_str': 'History of osteoporosis (situation)'}, {'cui': 'C3537250', 'cui_str': 'ESTROGENS'}, {'cui': 'C0282402', 'cui_str': 'Hormone replacement therapy (procedure)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C3540778', 'cui_str': 'Glucocorticoids'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}]","[{'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0005963', 'cui_str': 'Bone Mineral Content'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}]",28.0,0.0387213,Regional site BMC and BMD significantly decreased in the ribs and spine postoperatively (p = < 0.02) representing the greatest loss in the axial skeleton.,"[{'ForeName': 'Andrew R', 'Initials': 'AR', 'LastName': 'Luhrs', 'Affiliation': 'Department of Surgery, Duke University Medical Center, 407 Crutchfield St, Durham, NC, 27704, USA.'}, {'ForeName': 'Gerardo', 'Initials': 'G', 'LastName': 'Davalos', 'Affiliation': 'Department of Surgery, Duke University Medical Center, 407 Crutchfield St, Durham, NC, 27704, USA.'}, {'ForeName': 'Reginald', 'Initials': 'R', 'LastName': 'Lerebours', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Yoo', 'Affiliation': 'Department of Surgery, Duke University Medical Center, 407 Crutchfield St, Durham, NC, 27704, USA.'}, {'ForeName': 'Chan', 'Initials': 'C', 'LastName': 'Park', 'Affiliation': 'Department of Surgery, Tripler Army Medical Center, Honolulu, HI, USA.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Tabone', 'Affiliation': 'Department of Surgery, West Virginia University, Morgantown, WV, USA.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Omotosho', 'Affiliation': 'Department of Surgery, Rush University, Chicago, IL, USA.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Torquati', 'Affiliation': 'Department of Surgery, Rush University, Chicago, IL, USA.'}, {'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'Portenier', 'Affiliation': 'Department of Surgery, Duke University Medical Center, 407 Crutchfield St, Durham, NC, 27704, USA.'}, {'ForeName': 'Alfredo D', 'Initials': 'AD', 'LastName': 'Guerron', 'Affiliation': 'Department of Surgery, Duke University Medical Center, 407 Crutchfield St, Durham, NC, 27704, USA. alfredo.guerron-cruz@duke.edu.'}]",Surgical endoscopy,['10.1007/s00464-019-06922-8'] 402,32206812,Collaborative Home-Visit Program for Young Children With Motor Delays in Rural Taiwan: A Pilot Randomized Controlled Trial.,"BACKGROUND Caregiver engagement and collaborative team early childhood intervention (ECI) services are international trends; however, relevant evidence of collaborative home-visiting ECI in rural areas is as yet undetermined. OBJECTIVE The study aimed to investigate the effectiveness of a collaborative ECI program in a rural area of Taiwan. DESIGN The study was a pilot randomized control led trial. METHODS Children aged 6 to 33 months experiencing motor delays and their caregivers were enrolled in Taitung, Taiwan. Using stratified randomization, 24 participants were allocated to either experimental or control groups, and both received 5 home visits within 3 months. The experimental group received ECI services based on the International Classification of Functioning, Disability and Health framework and family-centered approaches. The control group received regular home visits by local social workers. Child outcomes included Pediatric Evaluation of Disability Inventory Chinese Version and Peabody Developmental Motor Scale, 2nd edition. Family outcomes included the Disability-Adapted Infant-Toddler version of Home Observation for Measurement, and Chinese versions of the Knowledge of Infant Development Inventory and Parental Stress Index-Short Form. A tester blinded to the study conducted assessments at baseline, postintervention, and 3-month follow-up. Two-way mixed analysis of variance was used with α = .05 (2-tailed). RESULTS The experimental group improved scores on the Disability-Adapted Infant-Toddler version of Home Observation for Measurement significantly more than the control group with an effect size of 0.64 at follow-up. In other outcomes, both groups showed no significant differences. The follow-up rate was 69%, and adherence to the ECI program was acceptable. LIMITATIONS A limitation of the study was the heterogeneity of the sample. CONCLUSIONS This pilot study revealed possible effectiveness in implementing collaborative ECI programs based on family-centered approaches and the International Classification of Functioning, Disability and Health in rural areas. Larger field studies are needed to confirm our findings.",2020,The experimental group improved scores on the DA-IT-HOME significantly more than the control group with ESf of 0.64 at follow-up.,"['Children aged 6 to 33 months experiencing motor delays and their caregivers were enrolled in Taitung, Taiwan', 'rural area of Taiwan', 'rural areas', 'Young Children With Motor Delays in Rural Taiwan']","['regular home visits by local social workers', 'collaborative ECI program', 'Collaborative Home-Visit Program', 'ECI services based on the International Classification of Functioning, Disability and Health (ICF) framework and family-centered approaches', 'Caregiver engagement and collaborative team early childhood intervention']","['Pediatric Evaluation of Disability Inventory Chinese Version and Peabody Developmental Motor Scale, 2nd Edition', 'Disability-Adapted Infant-Toddler version of Home Observation for Measurement', 'scores on the DA-IT-HOME']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0520947', 'cui_str': 'Clumsy child (finding)'}, {'cui': 'C0039260', 'cui_str': 'Formosa'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}]","[{'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0020043', 'cui_str': 'Home Visits'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0037444', 'cui_str': 'Social worker (occupation)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2370861', 'cui_str': 'International Classification of Functioning, Disability and Health'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0599196', 'cui_str': 'Early childhood'}]","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0458003', 'cui_str': 'Developmental (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0205436', 'cui_str': 'Second - ordinal'}, {'cui': 'C0441792', 'cui_str': 'Editions (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0682053', 'cui_str': 'Toddler (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",24.0,0.0651495,The experimental group improved scores on the DA-IT-HOME significantly more than the control group with ESf of 0.64 at follow-up.,"[{'ForeName': 'Yu-Hsin', 'Initials': 'YH', 'LastName': 'Hsieh', 'Affiliation': 'Department of Special Education, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Hua-Fang', 'Initials': 'HF', 'LastName': 'Liao', 'Affiliation': 'Academic Committee, Taiwan Society of ICF, 5th Floor, No. 166, Dayei Road, Baitou District, New Taipei City, Taiwan; and School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University, Taipei, Taiwan.'}, {'ForeName': 'Suh-Fang', 'Initials': 'SF', 'LastName': 'Jeng', 'Affiliation': 'School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University.'}, {'ForeName': 'Mei-Hui', 'Initials': 'MH', 'LastName': 'Tseng', 'Affiliation': 'School and Graduate Institute of Occupational Therapy, College of Medicine, National Taiwan University.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Schiariti', 'Affiliation': 'Division of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada.'}, {'ForeName': 'Mei-Yan', 'Initials': 'MY', 'LastName': 'Tsai', 'Affiliation': 'Taiwan Social Welfare Action Alliance, Taitung, Taiwan.'}, {'ForeName': 'Sheh-Chia', 'Initials': 'SC', 'LastName': 'Sun', 'Affiliation': 'Department of Early Childhood Education, Teachers College, National Taitung University, Taitung County, Taiwan.'}]",Physical therapy,['10.1093/ptj/pzaa033'] 403,32206861,Mastopexy with Autologous Augmentation in Women After Massive Weight Loss: A Randomized Clinical Trial.,,2020,,"['After Massive Weight Loss', 'Women']",['Mastopexy with Autologous Augmentation'],[],"[{'cui': 'C0522501', 'cui_str': 'Massive (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0191918', 'cui_str': 'Fixation of pendulous breast (procedure)'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C1293122', 'cui_str': 'Augmentation procedure'}]",[],,0.134257,,"[{'ForeName': 'Xiaoyu', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ""Department of Aesthetic and Reconstructive Breast Surgery, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 33 Badachu Road, Shijingshan District, Beijing, 100144, People's Republic of China.""}, {'ForeName': 'Dali', 'Initials': 'D', 'LastName': 'Mu', 'Affiliation': ""Department of Aesthetic and Reconstructive Breast Surgery, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 33 Badachu Road, Shijingshan District, Beijing, 100144, People's Republic of China. doctormudali@hotmail.com.""}]",Aesthetic plastic surgery,['10.1007/s00266-020-01688-0'] 404,32405701,Intraocular pressure increases during dynamic resistance training exercises according to the exercise phase in healthy young adults.,"PURPOSE To determine the intraocular pressure (IOP) changes caused by the execution of lower body and upper body resistance training exercises leading to muscular failure depending on the exercise phase (concentric vs. eccentric). We also assessed the influence of the exercise type (back squat vs. biceps curl) and level of effort on the IOP response. METHODS Nineteen physically active young adults performed four sets (2 exercise type × 2 exercise phase) of 10 repetitions leading to muscular failure while adopting a normal breathing pattern. IOP was measured by rebound tonometry at baseline, after each of the ten repetitions, and after 1 min of recovery. RESULTS There was a main effect of the exercise phase (p < 0.001, η 2 = 0.56), observing greater IOP values in the eccentric condition of the back squat and concentric condition of the biceps curl. Also, greater IOP values were obtained for the back squat in comparison with the biceps curl (p < 0.001, η 2 = 0.61), and IOP progressively increases with the level of accumulated effort (p < 0.001, η 2 = 0.88; Pearson r = 0.97-0.98). CONCLUSIONS IOP fluctuates during the different phases of the repetition in dynamic resistance training exercises, being greater IOP values observed during the more physically demanding phases of the exercise (eccentric phase of the back squat and concentric phase of the biceps curl). A heightened IOP response is positively associated with muscle size (back squat > biceps curl) and with the level of effort (number of accumulated repetitions). Based on these findings, highly demanding dynamic resistance training should be avoided when maintaining stable IOP levels is desirable.",2020,"There was a main effect of the exercise phase (p < 0.001, η 2 = 0.56), observing greater IOP values in the eccentric condition of the back squat and concentric condition of the biceps curl.","['Nineteen physically active young adults', 'healthy young adults']","['dynamic resistance training exercises', 'exercise type × 2 exercise phase) of 10 repetitions leading to muscular failure while adopting a normal breathing pattern']","['greater IOP values', 'IOP', 'IOP response', 'Intraocular pressure', 'IOP values', 'intraocular pressure (IOP) changes']","[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0556453', 'cui_str': 'Physically active'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0425382', 'cui_str': 'Adopted'}, {'cui': 'C0231795', 'cui_str': 'Normal respiratory function'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}]","[{'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",19.0,0.0291437,"There was a main effect of the exercise phase (p < 0.001, η 2 = 0.56), observing greater IOP values in the eccentric condition of the back squat and concentric condition of the biceps curl.","[{'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Vera', 'Affiliation': 'Department of Optics, Faculty of Sciences, University of Granada, Campus Fuentenueva, 18071, Granada, Spain.'}, {'ForeName': 'Beatríz', 'Initials': 'B', 'LastName': 'Redondo', 'Affiliation': 'Department of Optics, Faculty of Sciences, University of Granada, Campus Fuentenueva, 18071, Granada, Spain.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Perez-Castilla', 'Affiliation': 'Department of Physical Education and Sport, Faculty of Sport Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Raimundo', 'Initials': 'R', 'LastName': 'Jiménez', 'Affiliation': 'Department of Optics, Faculty of Sciences, University of Granada, Campus Fuentenueva, 18071, Granada, Spain. raimundo@ugr.es.'}, {'ForeName': 'Amador', 'Initials': 'A', 'LastName': 'García-Ramos', 'Affiliation': 'Department of Physical Education and Sport, Faculty of Sport Sciences, University of Granada, Granada, Spain.'}]",Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,['10.1007/s00417-020-04736-2'] 405,32200610,Comparison of two methods of continuous femoral nerve block with elastomeric pump after total knee arthroplasty.,"BACKGROUND The best method of continuous femoral nerve block (CFNB) after total knee arthroplasty (TKA) has not been determined. The study aimed to assess the effectiveness of CFNB based on patient-controlled regional analgesia (PCRA) with basal infusion of local anesthetic in decreasing pain and providing functional restoration after TKA and to compare it with the method of basal infusion only. METHODS The prospective randomized controlled trial included 90 patients who were divided into three groups. Group I: control group with basal morphine infusion, without CFNB. Group II: CFNB with continuous infusion of ropivacaine. Group III: CFNB with basal infusion of ropivacaine plus boluses. Intensity of pain, morphine consumption, patient satisfaction, adverse effects, the effect on range of motion (ROM) in the knee joint, as well as using the measure of a distance were analyzed. RESULTS A lower level of pain was observed (P < 0.005), as was reduced opioid consumption (P < 0.005), a greater ROM (P < 0.005), a longer distance covered (P < 0.005), and a smaller incidence of nausea in group III when compared with group II. No statistically significant difference was noted between the groups in terms of other side effects. There was higher satisfaction between group II and group III on days 1 and 2 (P < 0.08). CONCLUSIONS It was demonstrated that CFNB with continuous infusion of 5 mL h-1 of 0.2% ropivacaine plus 5 mL as a bolus causes a greater reduction in pain intensity and opioid consumption; it also shortens the time of functional restoration in comparison to perineural infusion of 5mL h-1 only during the first 4 days after TKA and constitutes an effective and safe alternative to using an electronic pump.",2020,"A lower level of pain was observed (P < 0.005), as was reduced opioid consumption (P < 0.005), a greater ROM (P < 0.005), a longer distance covered (P < 0.005), and a smaller incidence of nausea in group III when compared with group II.","['after total knee arthroplasty', '90 patients who were divided into three groups']","['continuous femoral nerve block (CFNB', 'ropivacaine', 'continuous femoral nerve block with elastomeric pump', 'local anesthetic', 'ropivacaine plus boluses', 'CFNB', 'control group with basal morphine infusion, without CFNB', 'total knee arthroplasty (TKA']","['Intensity of pain, morphine consumption, patient satisfaction, adverse effects, the effect on range of motion (ROM', 'higher satisfaction', 'greater ROM', 'opioid consumption', 'pain intensity and opioid consumption', 'pain and providing functional restoration', 'level of pain', 'nausea']","[{'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0394739', 'cui_str': 'Local anesthetic femoral nerve block (procedure)'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0444925', 'cui_str': 'elastomeric'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia (procedure)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}]","[{'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0080078', 'cui_str': 'Range of Motion'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration (attribute)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",90.0,0.0787619,"A lower level of pain was observed (P < 0.005), as was reduced opioid consumption (P < 0.005), a greater ROM (P < 0.005), a longer distance covered (P < 0.005), and a smaller incidence of nausea in group III when compared with group II.","[{'ForeName': 'Bulat', 'Initials': 'B', 'LastName': 'Tuyakov', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.'}, {'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Mieszkowski', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.'}, {'ForeName': 'Dariusz', 'Initials': 'D', 'LastName': 'Onichimowski', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.'}, {'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Mayzner-Zawadzka', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.'}]",Anaesthesiology intensive therapy,['10.5114/ait.2020.93710'] 406,32037784,Postactivation potentiation attenuates resistance exercise performance decrements following aerobic exercise in trained men.,"BACKGROUND The purpose of this study was to investigate if a post-activation potentiation (PAP) protocol may attenuate the acute interference induced by high-intensity intermittent exercise (HIIE) and on subsequent strength exercise performance in recreationally trained men. METHODS Eleven resistance-trained men (age: 25.7±3.7 y) randomly completed three experimental trials: strength exercise (SE) only (4 sets of maximal number of repetitions at 70% on the 45º leg press); concurrent exercise (CE) comprised 5000-m of HIIE at maximal aerobic speed (1:1 effort and pause ratio) followed by SE protocol; CE with post-activation potentiation (CE-PAP), comprised the same CE protocol preceded by one set of 2 repetitions at 90% of 1RM on the 45° leg-press before strength exercise. The number of repetitions performed was recorded for each set and total weight lifted was calculated. RESULTS The CE condition induced a greater decrement in volume for the leg press compared to SE and CE-PAP in sets 1 (24±21%; 18±25%), 2 (20±21%; 22±22%), and 3 (19±20%; 25±15%), respectively. Total weight lifted was greater after SE (8,795±2,581 kg) and CE-PAP (8.809±2.655 kg) conditions compared to CE (7.049±2.822 kg) (SE vs. CE: P=0.020) and (CE-PAP vs. CE: P=0.010) but there was no significant difference between SE and CE-PAP (P=1.00). CONCLUSIONS PAP using a heavy load attenuated acute interference (total volume during lower-body strength) generated by HIIE protocol, but did not enhance volume compared to SE alone.",2020,"The CE condition induced a greater decrement in volume for the leg press compared to SE and CE-PAP in sets 1 (24±21%; 18±25%), 2 (20±21%; 22±22%), and 3 (19±20%; 25±15%), respectively.","['Eleven resistance-trained men (age: 25.7±3.7 y) randomly completed three experimental trials', 'trained men', 'recreationally trained men']","['Strength Exercise (SE) only (4 sets of maximal number of repetitions at 70% on the 45o leg press); Concurrent Exercise (CE) comprised 5000-m of HIIE at maximal aerobic speed (1:1 effort and pause ratio) followed by SE protocol; Concurrent Exercise with post-activation potentiation (CE- PAP), comprised the same CE protocol preceded by one set of 2 repetitions at 90% of 1RM on the 45° leg-press before strength exercise', 'Postactivation potentiation', 'aerobic exercise', 'post-activation potentiation (PAP) protocol', 'high- intensity intermittent exercise (HIIE']",['Total weight lifted'],"[{'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0205420', 'cui_str': 'Concurrent (qualifier value)'}, {'cui': 'C4319610', 'cui_str': '5000 (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0429387', 'cui_str': 'Post-activation (tetanic) potentiation - finding'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C4277545', 'cui_str': 'High-Intensity Intermittent Exercise'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0181620', 'cui_str': 'Lift'}]",,0.0247124,"The CE condition induced a greater decrement in volume for the leg press compared to SE and CE-PAP in sets 1 (24±21%; 18±25%), 2 (20±21%; 22±22%), and 3 (19±20%; 25±15%), respectively.","[{'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'Conrado de Freitas', 'Affiliation': 'Skeletal Muscle Assessment Laboratory (LABSIM), Department of Physical Education, School of Technology and Sciences, São Paulo State University (UNESP), Presidente Prudente, Brazil - marceloconrado013@gmail.com.'}, {'ForeName': 'Valéria L', 'Initials': 'VL', 'LastName': 'Panissa', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Jason M', 'Initials': 'JM', 'LastName': 'Cholewa', 'Affiliation': 'Department of Kinesiology, Coastal Carolina University, Conway, South Carolina, SC, USA.'}, {'ForeName': 'Emerson', 'Initials': 'E', 'LastName': 'Franchini', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Luís A', 'Initials': 'LA', 'LastName': 'Gobbo', 'Affiliation': 'Skeletal Muscle Assessment Laboratory (LABSIM), Department of Physical Education, School of Technology and Sciences, São Paulo State University (UNESP), Presidente Prudente, Brazil.'}, {'ForeName': 'Fabricio E', 'Initials': 'FE', 'LastName': 'Rossi', 'Affiliation': 'Immunometabolism of Skeletal Muscle and Exercise Research Group, Federal University of Piauí (UFPI), Teresina, Brazil.'}]",The Journal of sports medicine and physical fitness,['10.23736/S0022-4707.20.10227-5'] 407,31361714,Effects of Lifestyle Physical Activity on Vascular Function in Asymptomatic Peripheral Arterial Disease.,"PURPOSE The purpose of this study was to examine the effects of a 12-wk in-home self-monitored physical activity (PA) program targeting a combination of lifestyle PA program on changes in endothelial reactivity, arterial stiffness, sedentary behaviors, and upright and stepping activities in individuals with asymptomatic peripheral arterial disease (APAD). METHODS Participants (n = 38) with APAD (ages 52-87 yr) were randomized to attention control (AC) or a PA sedentary reduction (PASR) group using an interactive online 3-month program focusing on increasing lifestyle PA and decreasing sedentary behaviors. The ActivPal™ PA monitor was used to measure postural and stepping parameters. Endothelial reactivity (peripheral arterial tone-reactive hyperemia index [PAT-RHI]) and augmentation index (AIx) were measured using the EndoPAT™ system at baseline and 3 months. RESULTS The PASR group significantly decreased daily sit/lie hours (-0.80 ± 0.87 vs 0.18 ± 0.77 P = 0.001), increased sit-to-stand transitions per day (7.1 ± 10.5 vs -1.4 ± 5.71, P < 0.001), and increased daily step counts (2814 ± 1753 vs 742 ± 1321, P < 0.001). The PASR group also increased steps per day accumulated within specific cadence bands 61-80 steps per minute (1252 ± 447 vs 177 ± 359, P < 0.001), 81-100 steps per minute band (919 ± 511 vs -98 ± 697, P < 0.001), and within the 101-120 steps per minute band (415 ± 625 vs -327 ± 467, P < 0.001) versus the AC group. PAT-RHI significantly increased in the PASR group (0.179 ± 0.180 vs 0.0.044 ± 0.101, P = 0.019), whereas no significant changes were observed in PAT-AIx. CONCLUSIONS Modest improvements in microvascular reactivity, PA, sedentary behavior, but not arterial stiffness were demonstrated after a 12-wk intervention targeting sedentary behavior reduction and increased lifestyle PA in individuals with APAD.",2020,"The PASR group significantly decreased daily sit/lie hours (-0.80 ± 0.87 vs. 0.18 ± 0.77 p= 0.001), increased sit to stand transitions/day (7.1 ±10.5 vs. -1.4 ± 5.71, p<0.001) and increased daily step counts (2814 ± 1753 vs. 742 ± 1321, p <0.001).","['individuals with APAD', 'individuals with asymptomatic peripheral arterial disease (APAD', 'Participants (n = 38) with APAD (ages 52-87', 'Asymptomatic Peripheral Arterial Disease']","['attention control, (AC) or a PA and sedentary reduction (PASR) group employing an interactive online 3-month program focusing on increasing lifestyle PA and decreasing sedentary behaviors', 'home self-monitored physical activity (PA) program targeting a combination of lifestyle physical activity program', 'Lifestyle Physical Activity']","['daily step counts', 'Endothelial reactivity (PAT-RHI) and augmentation index (AIx', 'PAT-AIx', 'endothelial reactivity, arterial stiffness, sedentary behaviors, upright and stepping activities', 'lifestyle PA', 'microvascular reactivity, physical activity, sedentary behavior', 'PAT-RHI']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0047196', 'cui_str': 'APADH'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic (finding)'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Artery Disease'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0557351', 'cui_str': 'Employed (finding)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C1532253', 'cui_str': 'Sedentary Behavior'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0030587', 'cui_str': 'Paroxysmal atrial tachycardia (disorder)'}, {'cui': 'C1293122', 'cui_str': 'Augmentation procedure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0999177', 'cui_str': 'Genus Aix (organism)'}, {'cui': 'C0599949', 'cui_str': 'Arterial Stiffness'}, {'cui': 'C1532253', 'cui_str': 'Sedentary Behavior'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0443258', 'cui_str': 'Microvascular (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]",120.0,0.0497261,"The PASR group significantly decreased daily sit/lie hours (-0.80 ± 0.87 vs. 0.18 ± 0.77 p= 0.001), increased sit to stand transitions/day (7.1 ±10.5 vs. -1.4 ± 5.71, p<0.001) and increased daily step counts (2814 ± 1753 vs. 742 ± 1321, p <0.001).","[{'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Laslovich', 'Affiliation': 'University of St. Augustine for Health Sciences, San Marcos, CA.'}, {'ForeName': 'Brent A', 'Initials': 'BA', 'LastName': 'Alvar', 'Affiliation': 'Point Loma Nazarene University, Point Loma, CA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Allison', 'Affiliation': 'Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA.'}, {'ForeName': 'Mitchell J', 'Initials': 'MJ', 'LastName': 'Rauh', 'Affiliation': 'Doctor of Physical Therapy Program, School of Exercise and Nutritional Sciences, San Diego State University, San Diego, CA.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002109'] 408,31385912,Acute Exercise Effects Predict Training Change in Cognition and Connectivity.,"PURPOSE Previous studies report memory and functional connectivity of memory systems improve acutely after a single aerobic exercise session or with training, suggesting that the acute effects of aerobic exercise may reflect initial changes that adapt over time. In this trial, for the first time, we test the proof-of-concept of whether the acute and training effects of aerobic exercise on working memory and brain network connectivity are related in the same participants. METHODS Cognitively normal older participants (N = 34) were enrolled in a randomized clinical trial (NCT02453178). Participants completed fMRI resting state and a face working memory N-back task acutely after light- and moderate-intensity exercises and after a 12-wk aerobic training intervention. RESULTS Functional connectivity did not change more after moderate-intensity training compared with light-intensity training. However, both training groups showed similar changes in cardiorespiratory fitness (CRF) (maximal exercise oxygen uptake, V˙O2peak), limiting group-level comparisons. Acute effects of moderate-intensity aerobic exercise on connections primarily in the default network predicted training enhancements in the same connections. Working memory also improved acutely, especially after moderate-intensity, and greater acute improvements predicted greater working memory improvement with training. Exercise effects on functional connectivity of right lateralized frontoparietal connections were related to both acute and training gains in working memory. CONCLUSIONS Our data support the concept of acute aerobic exercise effects on functional brain systems and performance as an activity-evoked biomarker for exercise training benefits in the same outcomes. These findings may lead to new insights and methods for improving memory outcomes with aerobic exercise training.",2020,"Exercise effects on functional connectivity of right lateralized fronto-parietal connections were related to both acute and training gains in working memory. ","['Cognitively normal older participants (N=34', 'same participants']","['aerobic exercise', 'fMRI resting state and a face working memory N-back task acutely after light and moderate intensity exercise and after a 12-week aerobic training intervention', 'moderate intensity aerobic exercise', 'aerobic exercise training']","['hippocampal-cortical connections', 'cardiorespiratory fitness (maximal exercise oxygen uptake, VO2peak', 'working memory and brain network connectivity', 'functional connectivity of right lateralized fronto-parietal connections', 'Cognition and Connectivity']","[{'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0449379', 'cui_str': 'Connection (attribute)'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake (observable entity)'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0442030', 'cui_str': 'Parietal (qualifier value)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",,0.0718148,"Exercise effects on functional connectivity of right lateralized fronto-parietal connections were related to both acute and training gains in working memory. ","[{'ForeName': 'Michelle W', 'Initials': 'MW', 'LastName': 'Voss', 'Affiliation': 'Department of Psychological and Brain Sciences, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Timothy B', 'Initials': 'TB', 'LastName': 'Weng', 'Affiliation': 'Department of Psychological and Brain Sciences, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Krithika', 'Initials': 'K', 'LastName': 'Narayana-Kumanan', 'Affiliation': 'Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Rachel C', 'Initials': 'RC', 'LastName': 'Cole', 'Affiliation': 'Interdisciplinary Graduate Program in Neuroscience, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Conner', 'Initials': 'C', 'LastName': 'Wharff', 'Affiliation': 'Department of Psychological and Brain Sciences, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Reist', 'Affiliation': 'Department of Psychological and Brain Sciences, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Lyndsey', 'Initials': 'L', 'LastName': 'Dubose', 'Affiliation': 'Department of Health and Human Physiology, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Gardar', 'Initials': 'G', 'LastName': 'Sigurdsson', 'Affiliation': 'Department of Internal Medicine, University of Iowa, Iowa City, IA.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Mills', 'Affiliation': 'Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Jeffrey D', 'Initials': 'JD', 'LastName': 'Long', 'Affiliation': 'Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Vincent A', 'Initials': 'VA', 'LastName': 'Magnotta', 'Affiliation': 'Department of Radiology, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Gary L', 'Initials': 'GL', 'LastName': 'Pierce', 'Affiliation': 'Department of Health and Human Physiology, University of Iowa, Iowa City, IA.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002115'] 409,31818059,High-velocity elastic-band training improves hamstring muscle activation and strength in basketball players.,"BACKGROUND The aim of this study was use surface EMG activity to assess changes in co-activation of knee flexors and extensors muscle groups during elastic-band exercise after 5 weeks of high-velocity elastic-band training in basketball players. METHODS College male basketball players (N.=18) were randomly divided into one of two groups: 1) the elastic-band training group performed low-load and high-velocity - lying prone - hamstring curls training three times per week; 2) the control group did not do any training. Pre- and post- training assessment included concentric knee extension and flexion at 60°/s and 240°/s, and the frequency of knee flexion and extension with elastic bands in the prone position. The EMG of the rectus femoris, semitendinosus muscles and the long head of the biceps femoris were assessed during these activities, and 30-m sprint running speed was measured from a stationary start and a running start. RESULTS It was shown that high-velocity elastic-band training was 1) feasible, 2) increased movement velocity and 3) muscle strength, 4) altered neural control such that excessive lengthening of the hamstring muscle, and hence strain-injuries, may be prevented and 5) improved sprint performance in basketball players. CONCLUSIONS These results suggest that high-velocity elastic-band training may be a tool to prevent hamstring strain-injuries in basketball players.",2020,"The EMG of the rectus femoris, semitendinosus muscles and the long head of the biceps femoris were assessed during these activities, and 30-m sprint running speed was measured from a stationary start and a running start. ","['College male basketball players (N.=18', 'basketball players']","['Pre- and post- training assessment included concentric knee extension and flexion at 60°/s and 240°', 'High-velocity elastic-band training', 'elastic-band training group performed low-load and high-velocity - lying prone - hamstring curls training three times per week; 2) the control group did not do any training']","['sprint performance', 'movement velocity and 3) muscle strength, 4) altered neural control', 'hamstring muscle activation and strength']","[{'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0004818', 'cui_str': 'Basketball'}]","[{'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439744', 'cui_str': 'Concentric (qualifier value)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0231452', 'cui_str': 'Flexion, function (observable entity)'}, {'cui': 'C4319600', 'cui_str': '240 (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0185014', 'cui_str': 'Banding'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0033422', 'cui_str': 'Prone Position'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}]","[{'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}]",,0.0166939,"The EMG of the rectus femoris, semitendinosus muscles and the long head of the biceps femoris were assessed during these activities, and 30-m sprint running speed was measured from a stationary start and a running start. ","[{'ForeName': 'Sigitas', 'Initials': 'S', 'LastName': 'Kamandulis', 'Affiliation': 'Lithuanian Sports University, Kaunas, Lithuania.'}, {'ForeName': 'Donatas', 'Initials': 'D', 'LastName': 'Janusevicius', 'Affiliation': 'Lithuanian Sports University, Kaunas, Lithuania.'}, {'ForeName': 'Audrius', 'Initials': 'A', 'LastName': 'Snieckus', 'Affiliation': 'Lithuanian Sports University, Kaunas, Lithuania - audrius.snieckus@lsu.lt.'}, {'ForeName': 'Danguole', 'Initials': 'D', 'LastName': 'Satkunskienė', 'Affiliation': 'Lithuanian Sports University, Kaunas, Lithuania.'}, {'ForeName': 'Albertas', 'Initials': 'A', 'LastName': 'Skurvydas', 'Affiliation': 'Lithuanian Sports University, Kaunas, Lithuania.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Degens', 'Affiliation': 'Lithuanian Sports University, Kaunas, Lithuania.'}]",The Journal of sports medicine and physical fitness,['10.23736/S0022-4707.19.10244-7'] 410,31524046,Responsiveness of different dynamic contrast-enhanced magnetic resonance imaging approaches: a post-hoc analysis of a randomized controlled trial of certolizumab pegol in rheumatoid arthritis.,"Objective : The aim was to explore dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as an early marker of therapeutic response in patients with rheumatoid arthritis (RA) starting treatment with certolizumab pegol (CZP). Method : In 40 RA patients initiating CZP (27 patients) or 2 weeks of placebo (PCB) followed by CZP (13 patients), DCE-MRI of the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints was performed at weeks 0, 1, 2, 4, 8, and 16. Using semi-automated software, three methods for drawing volume regions of interest (ROIs) in MCP2-5 and PIP2-5 were applied: 'Standard' (slices: all; joints: MCP2-5 together and PIP2-5 together), 'Detailed' (slices: slices with high-quality visualization; joints: as Standard), and 'Single-joint' (slices: as Detailed; joints: each joint separately). The number of enhancing voxels (Nvoxel), initial rate of enhancement (IRE), and maximum enhancement (ME) were extracted and analysed for each method. Results : Nvoxel in MCP2-5, and IRE and ME in PIP2-5 decreased statistically significantly (Wilcoxon rank-sum test, p < 0.02-0.03) after 16 weeks of treatment for the Standard method. Nvoxel and ME decreased significantly more in the CZP group than in the PCB group after 1 week of treatment, but not at later time-points. There were no significant changes for DCE-MRI parameters for the Detailed and Single-joint methods. Conclusions : Certain DCE-MRI parameters detected decreased inflammation during CZP treatment in RA patients. Using specific criteria for ROIs, as in the Detailed and Single-joint methods, decreased the statistical power and could not show any changes over time.",2020,"Nvoxel and ME decreased significantly more in the CZP group than in the PCB group after 1 week of treatment, but not at later time-points.","['RA patients', 'rheumatoid arthritis', '40 RA patients initiating', 'patients with rheumatoid arthritis (RA) starting treatment with certolizumab pegol (CZP']","['dynamic contrast-enhanced magnetic resonance imaging approaches', 'certolizumab pegol', 'placebo (PCB) followed by CZP', 'PCB', 'dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI', 'CZP']","['DCE-MRI parameters', 'Nvoxel and ME', 'number of enhancing voxels (Nvoxel), initial rate of enhancement (IRE), and maximum enhancement (ME']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid Arthritis'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1872109', 'cui_str': 'certolizumab pegol'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C1872109', 'cui_str': 'certolizumab pegol'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0032447', 'cui_str': 'PCBs'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}]","[{'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}]",,0.0889267,"Nvoxel and ME decreased significantly more in the CZP group than in the PCB group after 1 week of treatment, but not at later time-points.","[{'ForeName': 'M B', 'Initials': 'MB', 'LastName': 'Axelsen', 'Affiliation': 'Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Boesen', 'Affiliation': 'Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Bliddal', 'Affiliation': 'The Parker Institute, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Lth', 'Initials': 'L', 'LastName': 'Jacobsson', 'Affiliation': 'Department of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Hansen', 'Affiliation': 'Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte, Denmark.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Østergaard', 'Affiliation': 'Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark.'}]",Scandinavian journal of rheumatology,['10.1080/03009742.2019.1639820'] 411,30953222,A prospective randomized comparison of airway seal using the novel vision-guided insertion of LMA-Supreme® and LMA-Protector®.,"The laryngeal mask airways supreme (LMA-Supreme™) and protector (LMA-Protector™) are generally placed blindly, often resulting in a less than optimal position and vision-guided placement has been recommended. This prospective, randomized controlled study compared the efficacy of airway seal by measuring the oropharyngeal leak pressure in 100 surgical patients who underwent a variety of non-thoracic surgery under general anaesthesia, suitable with a supraglottic airway device. Patients were allocated to either the LMA-Supreme (n = 50) or LMA-Protector (n = 50) group. All insertions were performed under vision of a videolaryngoscope using an 'insert-detect-correct-as-you-go' technique with standardized corrective measures. Our primary endpoint, mean oropharyngeal leak pressure, was significantly higher in the LMA-Protector (31.7 ± 2.9 cm H 2 O) compared to the LMA-Supreme (27.7 ± 3.5 cm H 2 O) group (mean difference 4.0 cm H 2 O, 95% confidence interval (CI) 2.7-5.3 cm H 2 O, p < 0.001) after achieving a near-optimal fibreoptic position in the LMA-Protector (94%) and LMA-Supreme (96%) groups. No statistically significant differences were shown for secondary outcomes of alignment, number of insertion attempts and malpositions, and final anatomical position as scored by fibreoptic evaluation. Corrective manoeuvres were required in virtually all patients to obtain a correct anatomically positioned LMA. Position outcomes of the two devices were similar except for the proportion of procedures with folds in the proximal cuff (90% LMA-Supreme vs. 2% LMA-Protector, p < 0.001), the need for intracuff pressure adjustments (80% LMA-Supreme vs. 48% LMA-Protector, p = 0.001) and size correction (18% LMA-Supreme vs. 4% LMA-Protector, p = 0.025). In conclusion, a higher oropharyngeal leak pressure can be achieved with LMA-Protector compared to LMA-Supreme with optimal anatomical position when insertion is vision-guided.",2020,"No statistically significant differences were shown for secondary outcomes of alignment, number of insertion attempts and malpositions, and final anatomical position as scored by fibreoptic evaluation.","['100 surgical patients who underwent a variety of non-thoracic surgery under general anaesthesia, suitable with a supraglottic airway device']","['airway seal using the novel vision-guided insertion of LMA-Supreme® and LMA-Protector®', 'LMA-Supreme (n\u2009=\u200950) or LMA-Protector', ""videolaryngoscope using an 'insert-detect-correct-as-you-go' technique with standardized corrective measures"", 'LMA-Protector', 'airway seal', 'laryngeal mask airways supreme (LMA-Supreme™) and protector (LMA-Protector™']","['size correction', 'secondary outcomes of alignment, number of insertion attempts and malpositions, and final anatomical position as scored by fibreoptic evaluation', 'need for intracuff pressure adjustments', 'mean oropharyngeal leak pressure', 'proportion of procedures with folds in the proximal cuff']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0039986', 'cui_str': 'Thoracic Surgery'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C4076036', 'cui_str': 'Supraglottic airway (physical object)'}, {'cui': 'C0220819', 'cui_str': 'devices'}]","[{'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}, {'cui': 'C0036492', 'cui_str': 'Seal (organism)'}, {'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C3282376', 'cui_str': 'Supreme'}, {'cui': 'C3164607', 'cui_str': 'Videolaryngoscope (physical object)'}, {'cui': 'C1881217', 'cui_str': 'Insert - unit of product usage'}, {'cui': 'C0442726', 'cui_str': 'Detected (qualifier value)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0162645', 'cui_str': 'Laryngeal Mask Airway'}]","[{'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0333042', 'cui_str': 'Malposition (morphologic abnormality)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0277809', 'cui_str': 'Anatomical position (finding)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0456081', 'cui_str': 'Adjustment (procedure)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1522409', 'cui_str': 'Oropharyngeal route (qualifier value)'}, {'cui': 'C0332234', 'cui_str': 'Leaking (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0185026', 'cui_str': 'Plication - action (qualifier value)'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}]",100.0,0.0798499,"No statistically significant differences were shown for secondary outcomes of alignment, number of insertion attempts and malpositions, and final anatomical position as scored by fibreoptic evaluation.","[{'ForeName': 'André A J', 'Initials': 'AAJ', 'LastName': 'van Zundert', 'Affiliation': ""Department of Anaesthesia and Perioperative Medicine, Royal Brisbane and Women's Hospital, The University of Queensland, Brisbane, QLD, Australia. vanzundertandre@gmail.com.""}, {'ForeName': 'Kerstin H', 'Initials': 'KH', 'LastName': 'Wyssusek', 'Affiliation': ""Department of Anaesthesia and Perioperative Medicine, Royal Brisbane and Women's Hospital, The University of Queensland, Brisbane, QLD, Australia.""}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Pelecanos', 'Affiliation': 'Statistics Unit, QIMR Berghofer Medical Research Institute, The University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Roets', 'Affiliation': ""Department of Anaesthesia and Perioperative Medicine, Royal Brisbane and Women's Hospital, The University of Queensland, Brisbane, QLD, Australia.""}, {'ForeName': 'Chandra M', 'Initials': 'CM', 'LastName': 'Kumar', 'Affiliation': 'Department of Anaesthesia, Khoo Teck Puat Hospital, Yishun Central, Singapore.'}]",Journal of clinical monitoring and computing,['10.1007/s10877-019-00301-3'] 412,30968326,Comparison of LM-Supreme™ and endotracheal tube in patients undergoing gynecological laparoscopic surgery.,"While laryngeal mask is widely used for laparoscopic interventions in some countries, concerns exist regarding pulmonary aspiration and inadequate ventilation. We compared the LM-Supreme™ (LM-S) with the endotracheal tube (ETT) for laparoscopic gynecological interventions in terms of ventilation parameters and gastric distention. This prospective randomized and double-blind study. The patients were divided into two groups: ETT (n = 50) and LM-S group (n = 50). All patients in the LM-S and ETT groups recieved total intravenous general anaesthesia and standard ventilation protocols. Ventilation parameters (airway peak pressure, mean airway pressure, end-tidal carbon dioxide, total volume, oropharyngeal leak pressure) and perioperative laryngopharyngeal morbidity were recorded before peritoneal insufflation, during and after the peroperative period. The mean airway pressure values in the ETT group 2 min after airway device insertion were significantly higher. The gastric distension after the laparoscope entered the abdomen in the LM-S group was found to be significantly lower. In the first hour postoperative sore throat, disphonia and dysphagia were statistically significantly higher in the ETT group. In our study we concluded that LM-S provides reliable endotracheal intubation in ASA I & II patients undergoing laparoscopic gynecological surgery under positive pressure ventilation.ClinicalTrials.gov ID NCT02127632.",2020,"In the first hour postoperative sore throat, disphonia and dysphagia were statistically significantly higher in the ETT group.","['patients undergoing laparoscopic gynecological surgery under positive pressure ventilation', 'patients undergoing gynecological laparoscopic surgery']","['LM-S', 'LM-Supreme™ (LM-S) with the endotracheal tube (ETT', 'LM-Supreme™ and endotracheal tube']","['gastric distension', 'Ventilation parameters (airway peak pressure, mean airway pressure, end-tidal carbon dioxide, total volume, oropharyngeal leak pressure) and perioperative laryngopharyngeal morbidity', 'postoperative sore throat, disphonia and dysphagia', 'mean airway pressure values']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0038902', 'cui_str': 'Gynecological Surgical Procedure'}, {'cui': 'C3266857', 'cui_str': 'Positive-Pressure Ventilation'}, {'cui': 'C0751429', 'cui_str': 'Surgical Procedures, Laparoscopic'}]","[{'cui': 'C3282376', 'cui_str': 'Supreme'}, {'cui': 'C0336630', 'cui_str': 'Endotracheal tube, device (physical object)'}]","[{'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C3714614', 'cui_str': 'Distention'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C3267120', 'cui_str': 'Airway peak pressure'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C1522409', 'cui_str': 'Oropharyngeal route (qualifier value)'}, {'cui': 'C0332234', 'cui_str': 'Leaking (qualifier value)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0242429', 'cui_str': 'Sore Throat'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.0378748,"In the first hour postoperative sore throat, disphonia and dysphagia were statistically significantly higher in the ETT group.","[{'ForeName': 'Bahar', 'Initials': 'B', 'LastName': 'Kuvaki', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Dokuz Eylul University, İzmir, Turkey.'}, {'ForeName': 'Şule', 'Initials': 'Ş', 'LastName': 'Özbilgin', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Dokuz Eylul University, İzmir, Turkey. ozbilginsule@gmail.com.'}, {'ForeName': 'Sakize Ferim', 'Initials': 'SF', 'LastName': 'Günenç', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Dokuz Eylul University, İzmir, Turkey.'}, {'ForeName': 'Burcu Ataseven', 'Initials': 'BA', 'LastName': 'Küçük', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Dokuz Eylul University, İzmir, Turkey.'}]",Journal of clinical monitoring and computing,['10.1007/s10877-019-00310-2'] 413,32145041,"Dose-dependent naloxone-induced morphine withdrawal symptoms in opioid-dependent males-a double-blinded, randomized study.","AIMS Oral opioid preparations combined with naloxone are intended to induce a transient acute withdrawal syndrome to avoid intravenous misuse. This trial aimed to establish an appropriate morphine-naloxone dose ratio for an abuse-deterrent oral opioid formulation. METHODS In a randomized, double-blinded, 2 × 2 cross-over trial, 43 patients with opioid use disorder were challenged with intravenous morphine HCl Ph.Eur. (75 mg; [morphine mono]) or morphine HCl Ph.Eur. and naloxone HCl Ph.Eur. at ratios of 100:1 (75 mg: 0.75 mg; [morphine-naloxone 100:1]) or 200:1 (75 mg: 0.375 mg; [morphine-naloxone 200:1]). Acute naloxone-induced opioid withdrawal was evaluated using subjective (Short Opiate Withdrawal Scale-German [SOWS-G]) and observer-rated (Objective Opiate Withdrawal Scale [OOWS], Wang scale) questionnaires, and physiological parameters. For statistical analysis, the area under the curve between baseline and 20 minutes after drug administration of the outcome variables was calculated. RESULTS Intravenous morphine-naloxone caused rapid withdrawal symptoms. Coadministration of naloxone dose-dependently (morphine-naloxone 100:1 > morphine-naloxone 200:1) increased SOWS-G, OOWS and Wang Scale area under the curve when compared to morphine mono, respectively (all P < .0001). A similar response was detectable for changes of pupil diameter. Blood pressure and respiratory rate changed heterogeneously, and heart rate was unaltered by morphine without or with naloxone. CONCLUSION Morphine-naloxone 100:1 effectively suppresses the pleasurable effects of intravenous morphine and results in an aversive withdrawal reaction. A lower naloxone concentration as used in morphine-naloxone 200:1 does not appear to be appropriate to prevent intravenous morphine misuse.",2020,"Coadministration of naloxone dose-dependently (morphine-naloxone 100:1 > morphine-naloxone 200:1) increased SOWS-G, OOWS and Wang Scale area under the curve when compared to morphine mono, respectively (all P < .0001).","['43 patients with opioid use disorder', 'withdrawal symptoms in opioid-dependent males']","['Morphine-naloxone', 'naloxone', 'naloxone dose-dependently (morphine-naloxone 100:1 > morphine-naloxone', 'morphine-naloxone', 'morphine HCl Ph.Eur. and naloxone HCl Ph.Eur', 'intravenous morphine HCl Ph.Eur', 'morphine', 'naloxone-induced morphine', 'Acute naloxone']","['Blood pressure and respiratory rate changed heterogeneously, and heart rate', 'aversive withdrawal reaction', 'SOWS-G, OOWS and Wang Scale area under the curve', 'rapid withdrawal symptoms', 'subjective (Short Opiate Withdrawal Scale-German [SOWS-G]) and observer-rated (Objective Opiate Withdrawal Scale [OOWS], Wang scale) questionnaires, and physiological parameters']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0087169', 'cui_str': 'Withdrawal Symptoms'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0027358', 'cui_str': 'Naloxone'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0443985', 'cui_str': 'Flinders medical center-7 marker (substance)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}]","[{'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0231832', 'cui_str': 'Respiration Rate'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0857405', 'cui_str': 'Withdrawal reaction'}, {'cui': 'C0222045'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0087169', 'cui_str': 'Withdrawal Symptoms'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0242401', 'cui_str': 'Opiates'}, {'cui': 'C1556085', 'cui_str': 'Germans (ethnic group)'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",43.0,0.270251,"Coadministration of naloxone dose-dependently (morphine-naloxone 100:1 > morphine-naloxone 200:1) increased SOWS-G, OOWS and Wang Scale area under the curve when compared to morphine mono, respectively (all P < .0001).","[{'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Weisshaar', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Brandt', 'Affiliation': 'Department of Applied Psychology: Work, Education & Economy, Faculty of Psychology, University of Vienna, Vienna, Austria.'}, {'ForeName': 'Brigitte', 'Initials': 'B', 'LastName': 'Litschauer', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Safoura', 'Initials': 'S', 'LastName': 'Sheik-Rezaei', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Moser', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Günther', 'Initials': 'G', 'LastName': 'Nirnberger', 'Affiliation': 'Bioconsult GmbH, Breitenfurt, Austria.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Kühberger', 'Affiliation': 'G. L. Pharma GmbH, Lannach, Austria.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Bauer', 'Affiliation': 'G. L. Pharma GmbH, Lannach, Austria.'}, {'ForeName': 'Christa', 'Initials': 'C', 'LastName': 'Firbas', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Ghazaleh', 'Initials': 'G', 'LastName': 'Gouya', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Wolzt', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Fischer', 'Affiliation': 'Center for Public Health, Medical University of Vienna, Vienna, Austria.'}]",British journal of clinical pharmacology,['10.1111/bcp.14271'] 414,32205785,Isolated Central Nervous System Relapse Following Treatment Reduction in Low-risk Acute Lymphoblastic Leukemia at the Children's Cancer Center of Lebanon.,"The aim of this trial was to decrease the incidence of life-threatening infections by decreasing the dose and the duration of dexamethasone treatment during maintenance therapy. This was a prospective, nonrandomized trial of low-risk acute lymphoblastic leukemia patients 1 to 18 years of age who were treated at the Children's Cancer Center of Lebanon (CCCL). Patients consecutively diagnosed between 2002 and 2013 were divided into groups 1 and 2 receiving total dexamethasone doses of 1144 and 618 mg/m, respectively. A total of 84 patients were assigned to group 1 and 33 patients to group 2. The 5-year cumulative incidence of isolated central nervous system relapse increased from (n=0% [95% confidence interval: 0%-4.4%]) in group 1 to 9.1% [95% confidence interval: 3%-23%]; P=0.021) in group 2. Decreasing cumulative dose of dexamethasone for low-risk childhood acute lymphoblastic leukemia patients aiming to avoid serious viral infections led to a significant increase in isolated central nervous system relapse.",2020,The 5-year cumulative incidence of isolated central nervous system relapse increased from (n=0% [95% confidence interval: 0%-4.4%]) in group 1 to 9.1%,"['Patients consecutively diagnosed between 2002 and 2013', ""low-risk acute lymphoblastic leukemia patients aged 1 to 18 years who were treated at the Children's Cancer Center of Lebanon (CCCL"", ""Low-risk Acute Lymphoblastic Leukemia at the Children's Cancer Center of Lebanon"", 'low-risk childhood acute lymphoblastic leukemia patients', '84 patients were assigned to group 1 and 33 patients to group 2']","['total dexamethasone', 'dexamethasone']","['incidence of life-threatening infections', '5-year cumulative incidence of isolated central nervous system relapse']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}, {'cui': 'C1961102', 'cui_str': 'Lymphocytic Leukemia, Acute'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0023190', 'cui_str': 'Lebanese Republic'}, {'cui': 'C0231537', 'cui_str': 'Cathodal closure clonus (finding)'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}]",84.0,0.0521006,The 5-year cumulative incidence of isolated central nervous system relapse increased from (n=0% [95% confidence interval: 0%-4.4%]) in group 1 to 9.1%,"[{'ForeName': 'Habib', 'Initials': 'H', 'LastName': 'El-Khoury', 'Affiliation': 'Faculty of Medicine.'}, {'ForeName': 'Mohamad', 'Initials': 'M', 'LastName': 'Chahrour', 'Affiliation': 'Faculty of Medicine.'}, {'ForeName': 'Khaled M', 'Initials': 'KM', 'LastName': 'Ghanem', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine.'}, {'ForeName': 'Omran', 'Initials': 'O', 'LastName': 'Saifi', 'Affiliation': 'Faculty of Medicine.'}, {'ForeName': 'Hani', 'Initials': 'H', 'LastName': 'Tamim', 'Affiliation': 'Clinical Research Institute, American University of Beirut, Beirut, Lebanon.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'El-Solh', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine.'}, {'ForeName': 'Dima', 'Initials': 'D', 'LastName': 'Hamideh', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine.'}, {'ForeName': 'Nidale', 'Initials': 'N', 'LastName': 'Tarek', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine.'}, {'ForeName': 'Raya', 'Initials': 'R', 'LastName': 'Saab', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine.'}, {'ForeName': 'Miguel R', 'Initials': 'MR', 'LastName': 'Abboud', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine.'}, {'ForeName': 'Samar A', 'Initials': 'SA', 'LastName': 'Muwakkit', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine.'}]",Journal of pediatric hematology/oncology,['10.1097/MPH.0000000000001785'] 415,32404035,Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.,"Background and Purpose- The RE-SPECT ESUS trial (Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source) tested the hypothesis that dabigatran would be superior to aspirin for the prevention of recurrent stroke in patients with embolic stroke of undetermined source. This exploratory subgroup analysis investigates the impact of age, renal function (both predefined), and dabigatran dose (post hoc) on the rates of recurrent stroke and major bleeding. Methods- RE-SPECT ESUS was a multicenter, randomized, double-blind trial of dabigatran 150 or 110 mg (for patients aged ≥75 years and/or with creatinine clearance 30 to <50 mL/minute) twice daily compared with aspirin 100 mg once daily. The primary outcome was recurrent stroke. Results- The trial, which enrolled 5390 patients from December 2014 to January 2018, did not demonstrate superiority of dabigatran versus aspirin for prevention of recurrent stroke in patients with embolic stroke of undetermined source. However, among the population qualifying for the lower dabigatran dose, the rate of recurrent stroke was reduced with dabigatran versus aspirin (7.4% versus 13.0%; hazard ratio, 0.57 [95% CI, 0.39-0.82]; interaction P =0.01). This was driven mainly by the subgroup aged ≥75 years (7.8% versus 12.4%; hazard ratio, 0.63 [95% CI, 0.43-0.94]; interaction P =0.10). Stroke rates tended to be lower with dabigatran versus aspirin with declining renal function. Risks for major bleeding were similar between treatments, irrespective of renal function, but with a trend for lower bleeding rates with dabigatran versus aspirin in older patients. Conclusions- In subgroup analyses of RE-SPECT ESUS, dabigatran reduced the rate of recurrent stroke compared with aspirin in patients qualifying for the lower dose of dabigatran. These results are hypothesis-generating. Aspirin remains the standard antithrombotic treatment for patients with embolic stroke of undetermined source. Registration- URL: https://www.clinicaltrials.gov; Unique identifier: NCT02239120.",2020,"Risks for major bleeding were similar between treatments, irrespective of renal function, but with a trend for lower bleeding rates with dabigatran versus aspirin in older patients.","['patients aged ≥75 years and/or with creatinine clearance 30 to <50 mL/minute) twice daily compared with', 'older patients', 'patients with embolic stroke of undetermined source', 'Patients With Embolic Stroke of Undetermined Source', '5390 patients from December 2014 to January 2018']","['Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid', 'aspirin 100 mg once daily', 'Methods- RE-SPECT ESUS', 'Aspirin', ' and Purpose', 'dabigatran versus aspirin', 'aspirin', 'Conclusions', 'dabigatran']","['Stroke rates', 'Risks for major bleeding', 'recurrent stroke', 'rates of recurrent stroke and major bleeding', 'rate of recurrent stroke', 'bleeding rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C3888970', 'cui_str': 'Embolic stroke of undetermined source'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0040018', 'cui_str': 'Thrombin'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C1571583', 'cui_str': 'dabigatran etexilate'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C1124475', 'cui_str': 'Aspirin 100 MG'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0040399', 'cui_str': 'Single photon emission computerized tomography'}, {'cui': 'C1285529', 'cui_str': 'Purpose'}, {'cui': 'C2348066', 'cui_str': 'dabigatran'}]","[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1836785', 'cui_str': 'Recurrent stroke'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]",5390.0,0.375563,"Risks for major bleeding were similar between treatments, irrespective of renal function, but with a trend for lower bleeding rates with dabigatran versus aspirin in older patients.","[{'ForeName': 'Hans-Christoph', 'Initials': 'HC', 'LastName': 'Diener', 'Affiliation': 'From the Faculty of Medicine, Institute for Medical Informatics, Biometry and Epidemiology, University Duisburg-Essen, Germany (H.-C.D.).'}, {'ForeName': 'Ralph L', 'Initials': 'RL', 'LastName': 'Sacco', 'Affiliation': 'Clinical and Translational Science, Miller School of Medicine, University of Miami, FL (R.L.S.).'}, {'ForeName': 'J Donald', 'Initials': 'JD', 'LastName': 'Easton', 'Affiliation': 'Department of Neurology, University of California, San Francisco (J.D.E.).'}, {'ForeName': 'Christopher B', 'Initials': 'CB', 'LastName': 'Granger', 'Affiliation': 'Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (C.B.G.).'}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Bar', 'Affiliation': 'Department of Neurology, University Hospital Ostrava, Ostrava-Poruba-Poruba, Czech Republic (M. Bar).'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Bernstein', 'Affiliation': 'Department of Neurology, Northwestern University, Chicago, IL (R.A.B.).'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Brainin', 'Affiliation': 'Department of Neurosciences and Preventive Medicine, Danube University Krems, Krems an der Donau, Austria (M. Brainin).'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Brueckmann', 'Affiliation': 'Metabolism Medicine, Boehringer Ingelheim International GmbH, Germany (M. Brueckmann).'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Cronin', 'Affiliation': 'Cardiometabolic Medicine, Boehringer Ingelheim Ltd, Burlington, ON, Canada (L.C.).'}, {'ForeName': 'Geoffrey', 'Initials': 'G', 'LastName': 'Donnan', 'Affiliation': 'Department of Neurology, Melbourne Brain Centre, University of Melbourne, Parkville, VIC, Australia (G.D.).'}, {'ForeName': 'Zuzana', 'Initials': 'Z', 'LastName': 'Gdovinová', 'Affiliation': 'Department of Neurology, Pavol Jozef Šafárik University in Košice, University Hospital L. Pasteur, Košice, Slovak Republic (Z.G.).'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Grauer', 'Affiliation': 'Clinical Operations Global, Boehringer Ingelheim Pharma GmbH & Co. K.G., Biberach, Germany (C.G.).'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Kleine', 'Affiliation': 'Biostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co. K.G., Ingelheim, Germany (E.K.).'}, {'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'Kleinig', 'Affiliation': 'Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia (T.J.K.).'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Lyrer', 'Affiliation': 'Division of Neurology, Stroke Center, University Hospital Basel, Switzerland (P.L.).'}, {'ForeName': 'Sheila', 'Initials': 'S', 'LastName': 'Martins', 'Affiliation': 'Neurology Service, Hospital de Clínicas de Porto Alegre, Brazil (S.M.).'}, {'ForeName': 'Juliane', 'Initials': 'J', 'LastName': 'Meyerhoff', 'Affiliation': 'Cardiology Medicine, Boehringer Ingelheim International GmbH, Germany (J.M.).'}, {'ForeName': 'Truman', 'Initials': 'T', 'LastName': 'Milling', 'Affiliation': 'Department of Neurology, Department of Surgery and Perioperative Care, Seton Dell Medical School Stroke Institute, Austin, TX (T.M.).'}, {'ForeName': 'Waltraud', 'Initials': 'W', 'LastName': 'Pfeilschifter', 'Affiliation': 'Center of Neurology and Neurosurgery, Goethe University Frankfurt, Frankfurt am Main, Germany (W.P.).'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Poli', 'Affiliation': 'Department of Neurology with Focus on Neurovascular Diseases and Neurooncology, University of Tübingen, and Hertie Institute for Clinical Brain Research, Germany (S.P.).'}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Reif', 'Affiliation': 'Department of Neurology, Cerebrovaskulární ambulance s.r.o., Brno, Czech Republic (M.R.).'}, {'ForeName': 'David Z', 'Initials': 'DZ', 'LastName': 'Rose', 'Affiliation': 'Department of Neurology, Morsani College of Medicine, University of South Florida, Tampa (D.Z.R.).'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Šaňák', 'Affiliation': 'Comprehensive Stroke Center, Department of Neurology, Palacky University, Olomouc, Czech Republic (D.S.).'}, {'ForeName': 'Wolf-Rüdiger', 'Initials': 'WR', 'LastName': 'Schäbitz', 'Affiliation': 'Department of Neurology, Evangelisches Klinikum Bethel, Bielefeld, Germany (W.-R.S.).'}]",Stroke,['10.1161/STROKEAHA.119.028643'] 416,32402060,Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial.,"AIMS The association of body weight and weight change with mortality and cardiovascular (CV) outcome in patients with diabetes mellitus (DM) is not clearly established. We assessed the relationship between weight, weight change, and outcomes in patients with established CV risk factors and type 2 DM or pre-diabetes. METHODS AND RESULTS A total of 12 521 participants from the ORIGIN trial were grouped in BMI categories of low body weight [body mass index (BMI) < 22 kg/m2] normal (22-24.9), overweight (25-29.9), obesity Grades 1-3 (30-34.9, 35-39.9, ≥40 kg/m2, respectively). Outcome variables included total and CV mortality and composite outcomes of CV death, non-fatal stroke, or myocardial infarction plus revascularization or heart failure hospitalization. Follow-up was 6.2 years (interquartile range 5.8-6.7 years). After multivariable adjustment, lowest risks were seen in patients with overweight and mild obesity for total mortality [overweight: hazard ratio (HR) 0.80 (95% confidence interval (CI) 0.69-0.91); obesity Grade 1: HR 0.82 (0.71-0.95), both P < 0.01)] and CV mortality [overweight: HR 0.79 (0.66-0.94); obesity Grade 1: 0.79 (0.65-0.95), all compared to patients with normal BMI, P < 0.05]. Obesity of any severity was not associated with higher mortality. Low body weight was related to higher mortality [HR 1.28 (1.02-1.61); CV mortality: HR 1.34 (1.01-1.79), P < 0.05]. A continued 2-year weight loss was associated with higher risk of mortality [HR 1.32 (1.18-1.46), P < 0.0001] and CV mortality [HR 1.18 (1.02-1.35), compared to patients without weight loss, P < 0.05]. In turn, weight gain was not related to any adverse outcome. CONCLUSION Obesity in patients with DM or pre-diabetes and CV risk profile was not associated with higher mortality or adverse CV outcome. The lowest mortality risk was seen in patients with overweight and moderate obesity (BMI 25-35 kg/m2). Weight loss was an independent risk factor for higher mortality compared to no weight loss.",2020,The lowest mortality risk was seen in patients with overweight and moderate obesity (BMI 25-35 kg/m2).,"['patients with diabetes mellitus (DM', 'A total of 12 521 participants from the ORIGIN trial were grouped in BMI categories of low body weight [body mass index (BMI)\u2009<\u200922 kg/m2] normal (22-24.9), overweight (25-29.9), obesity Grades 1-3 (30-34.9, 35-39.9, ≥40\u2009kg/m2, respectively', 'patients with established CV risk factors and type 2 DM or pre-diabetes']",[],"['body weight and weight change with mortality and cardiovascular (CV) outcome', 'Weight loss', '2-year weight loss', 'weight gain', 'Obesity and weight loss', 'CV mortality', 'total and CV mortality and composite outcomes of CV death, non-fatal stroke, or myocardial infarction plus revascularization or heart failure hospitalization', 'mortality or adverse CV outcome', 'Low body weight', 'lowest mortality risk']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]",[],"[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",12521.0,0.0708303,The lowest mortality risk was seen in patients with overweight and moderate obesity (BMI 25-35 kg/m2).,"[{'ForeName': 'Wolfram', 'Initials': 'W', 'LastName': 'Doehner', 'Affiliation': 'Berlin Institute of Health Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, 13353 Berlin, Germany.'}, {'ForeName': 'Hertzel C', 'Initials': 'HC', 'LastName': 'Gerstein', 'Affiliation': 'Population Health Research Institute, McMaster University, Hamilton Health Sciences, L8S 4K1 Hamilton, ON, Canada.'}, {'ForeName': 'Janina', 'Initials': 'J', 'LastName': 'Ried', 'Affiliation': 'Sanofi-Aventis Deutschland GmbH, Research & Development, 65926 Frankfurt, Germany.'}, {'ForeName': 'Hyejung', 'Initials': 'H', 'LastName': 'Jung', 'Affiliation': 'Population Health Research Institute, McMaster University, Hamilton Health Sciences, L8S 4K1 Hamilton, ON, Canada.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Asbrand', 'Affiliation': 'Sanofi-Aventis Deutschland GmbH, Research & Development, 65926 Frankfurt, Germany.'}, {'ForeName': 'Sibylle', 'Initials': 'S', 'LastName': 'Hess', 'Affiliation': 'Sanofi-Aventis Deutschland GmbH, Research & Development, 65926 Frankfurt, Germany.'}, {'ForeName': 'Stefan D', 'Initials': 'SD', 'LastName': 'Anker', 'Affiliation': 'Berlin Institute of Health Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, 13353 Berlin, Germany.'}]",European heart journal,['10.1093/eurheartj/ehaa293'] 417,32068442,"Responses of gut and pancreatic hormones, bile acids, and fibroblast growth factor-21 differ to glucose, protein, and fat ingestion after gastric bypass surgery.","Postprandial gut hormone responses change after Roux-en-Y gastric bypass (RYGB), and we investigated the impact of glucose, protein, and fat (with and without pancreas lipase inhibition) on plasma responses of gut and pancreas hormones, bile acids, and fibroblast growth factor 21 (FGF-21) after RYGB and in nonoperated control subjects. In a randomized, crossover study 10 RYGB operated and 8 healthy weight-matched control subjects were administered 4 different 4-h isocaloric (200 kcal) liquid meal tests containing >90 energy (E)% of either glucose, protein (whey protein), or fat (butter with and without orlistat). The primary outcome was glucagon-like peptide-1 (GLP-1) secretion (area under the curve above baseline). Secondary outcomes included responses of peptide YY (PYY), glucose-dependent insulinotropic polypeptide (GIP), cholecystokinin (CCK), glicentin, neurotensin, ghrelin, insulin, glucagon, bile acids, and FGF-21. In the RYGB group the responses of GLP-1, GIP, glicentin, FGF-21, and C-peptide were increased after glucose compared with the other meals. The neurotensin and bile acids responses were greater after fat, while the glucagon and CCK responses were greater after protein ingestion. Furthermore, compared with control subjects, RYGB subjects had greater responses of total PYY after glucose, glucagon after glucose and fat, glicentin after glucose and protein, and GLP-1 and neurotensin after all meals, while GIP and CCK responses were lower after fat. Ghrelin responses did not differ between meals or between groups. Orlistat reduced all hormone responses to fat ingestion, except for ghrelin in the RYGB group. In conclusion, after RYGB glucose is a more potent stimulator of most gut hormones, especially for the marked increased secretion of GLP-1 compared with fat and protein. NEW & NOTEWORTHY We investigated the impact of glucose, protein, and fat meals on intestinal and pancreatic hormones, bile acid, and fibroblast growth factor 21 (FGF-21) secretion in gastric bypass-operated patients compared with matched nonoperated individuals. The fat meal was administered with and without a pancreas lipase inhibitor. We found that the impact of the different meals on gut hormones, bile, and FGF 21 secretion differ and was different from the responses observed in nonoperated control subjects.",2020,"The neurotensin and bile acids responses were greater after fat, while the glucagon and CCK responses were greater after protein ingestion.",['eight healthy weight-matched control subjects'],"['glucose, protein and fat (with and without pancreas lipase inhibition', 'Orlistat®', '4-hour isocaloric (200 kcal) liquid meal-tests containing >90E% of either glucose, protein (whey protein) or fat (butter with and without orlistat®', 'Roux-en-Y gastric bypass (RYGB']","['responses of total PYY after glucose, glucagon after glucose and fat, glicentin after glucose and protein, and GLP-1 and neurotensin after all meals, while GIP and CCK responses', 'responses of GLP-1, GIP, glicentin, FGF-21 and C-peptide', 'Responses of gut and pancreatic hormones, bile acids and fibroblast growth', 'glucagon and CCK responses', 'plasma responses of gut and pancreas hormones, bile acids and FGF-21', 'neurotensin and bile acids responses', 'responses of PYY, GIP, CCK, glicentin, neurotensin, insulin, glucagon, bile acids and FGF 21', 'GLP-1 secretion (area under the curve above baseline']","[{'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0023764', 'cui_str': 'Lipase'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}, {'cui': 'C0076275', 'cui_str': 'orlistat'}, {'cui': 'C1292426', 'cui_str': '4 hours (qualifier value)'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439259', 'cui_str': 'kilocalorie'}, {'cui': 'C1304698', 'cui_str': 'Liquid - descriptor'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0006494', 'cui_str': 'Butter'}, {'cui': 'C0585179', 'cui_str': 'Roux-en-Y Gastric Bypass'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0070358', 'cui_str': 'PYY Peptide'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0876232', 'cui_str': 'glucagon recombinant'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0061309', 'cui_str': 'Glicentine'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-Like Peptide 1'}, {'cui': 'C0027930', 'cui_str': 'Neurotensin'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C1702020', 'cui_str': '37-epsilon-palmitoyl-Lys-GIP'}, {'cui': 'C1505513', 'cui_str': 'CCK(58)(ns)'}, {'cui': 'C0972232', 'cui_str': 'fibroblast growth factor 21'}, {'cui': 'C0006558', 'cui_str': 'Proinsulin C-Peptide'}, {'cui': 'C0005390', 'cui_str': 'Bile Acids'}, {'cui': 'C0016030', 'cui_str': 'Fibroblasts'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0005388', 'cui_str': 'Bile'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0036537', 'cui_str': 'Secretions'}, {'cui': 'C0376690', 'cui_str': 'AUC'}]",,0.0143719,"The neurotensin and bile acids responses were greater after fat, while the glucagon and CCK responses were greater after protein ingestion.","[{'ForeName': 'Christian Zinck', 'Initials': 'CZ', 'LastName': 'Jensen', 'Affiliation': 'Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.'}, {'ForeName': 'Kirstine N', 'Initials': 'KN', 'LastName': 'Bojsen-Møller', 'Affiliation': 'Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.'}, {'ForeName': 'Maria S', 'Initials': 'MS', 'LastName': 'Svane', 'Affiliation': 'Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.'}, {'ForeName': 'Line M', 'Initials': 'LM', 'LastName': 'Holst', 'Affiliation': 'Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.'}, {'ForeName': 'Kjeld', 'Initials': 'K', 'LastName': 'Hermansen', 'Affiliation': 'Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Bolette', 'Initials': 'B', 'LastName': 'Hartmann', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Nicolai Jacob', 'Initials': 'NJ', 'LastName': 'Wewer Albrechtsen', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Rune Ehrenreich', 'Initials': 'RE', 'LastName': 'Kuhre', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Viggo B', 'Initials': 'VB', 'LastName': 'Kristiansen', 'Affiliation': 'Department of surgical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark.'}, {'ForeName': 'Jens Frederik', 'Initials': 'JF', 'LastName': 'Rehfeld', 'Affiliation': 'Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Trine R', 'Initials': 'TR', 'LastName': 'Clausen', 'Affiliation': 'Department of Diabetes and Obesity Biology, Novo Nordisk A/S, Maaloev, Denmark.'}, {'ForeName': 'Jens J', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Sten', 'Initials': 'S', 'LastName': 'Madsbad', 'Affiliation': 'Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.'}]",American journal of physiology. Gastrointestinal and liver physiology,['10.1152/ajpgi.00265.2019'] 418,31062131,Influence of different PEEP levels on electrical impedance tomography findings in patients under general anesthesia ventilated in the lateral decubitus position.,"To determine the effect of various PEEP levels on electrical impedance tomography (EIT) measured differences in regional ventilation, hemodynamics, lung mechanics and parameters of alveolar gas exchange. Thirty three patients scheduled for elective urologic surgery in general anesthesia in lateral decubitus position were randomized into three groups-PEEP 0, 5 and 10 mbar. EIT recording, arterial blood gas analysis and hemodynamic parameters were captured at three timepoints-before induction (T0), 5 min after lateral positioning (T1) and 90 min after positioning (T2). Dynamic compliance (Cdyn) was measured at T1 and T2. Offline EIT data analysis was performed to calculate EIT derived parameters of ventilation distribution. Patients ventilated with PEEP of 10 mbar had a significantly lower A-a (alveolo arterial) gradient over measurements and symmetrical distribution of ventilation measured by EIT. There was no significant difference in Cdyn, center of ventilation indices and inhomogeneity index between groups. There was no difference of mean arterial pressure, cardiac index and heart rate between groups. Patients with 5 mbar of PEEP had higher stroke volume index compared to 0 and 10 mbar at baseline and over measurements. Nondependent/dependent TV ratio as well as global inhomogeneity index were correlated with A-a gradient. Dynamic compliance showed no correlation to A-a gradient. In our study, a PEEP level of 10 mbar improved alveolar gas exchange without compromising hemodynamic stability in patients mechanically ventilated in the lateral decubitus position. EIT measured parameters may be used to determine optimal ventilation parameters in these patients with inhomogeneous lung mechanics. Further studies are needed in patients with various lung pathologies.",2020,"There was no significant difference in Cdyn, center of ventilation indices and inhomogeneity index between groups.","['patients mechanically ventilated in the lateral decubitus position', 'patients under general anesthesia ventilated in the lateral decubitus position', 'patients with various lung pathologies', 'Thirty three patients scheduled for elective urologic surgery in general anesthesia in lateral decubitus position', 'Patients with 5\xa0mbar of', 'patients with inhomogeneous lung mechanics']",['PEEP'],"['Dynamic compliance (Cdyn', 'mean arterial pressure, cardiac index and heart rate', 'lower A-a (alveolo arterial) gradient over measurements and symmetrical distribution of ventilation measured by EIT', 'EIT recording, arterial blood gas analysis and hemodynamic parameters', 'stroke volume index', 'global inhomogeneity index', 'Cdyn, center of ventilation indices and inhomogeneity index', 'regional ventilation, hemodynamics, lung mechanics and parameters of alveolar gas exchange']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444379', 'cui_str': 'Lateral decubitus position (finding)'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0450358', 'cui_str': '33 (qualifier value)'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0042077', 'cui_str': 'Urology'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0002915', 'cui_str': 'General Anesthesia'}, {'cui': 'C0376706', 'cui_str': 'Mechanics'}]","[{'cui': 'C0863179', 'cui_str': 'Peeping'}]","[{'cui': 'C0429680', 'cui_str': 'Dynamic compliance (observable entity)'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C0428776', 'cui_str': 'Cardiac index (observable entity)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0332516', 'cui_str': 'Symmetry'}, {'cui': 'C0231933', 'cui_str': 'Distribution of ventilation, function (observable entity)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0150411', 'cui_str': 'Blood gases, arterial measurement (procedure)'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0038455', 'cui_str': 'Stroke Volume'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0376706', 'cui_str': 'Mechanics'}, {'cui': 'C0596601', 'cui_str': 'Gas'}]",33.0,0.0457474,"There was no significant difference in Cdyn, center of ventilation indices and inhomogeneity index between groups.","[{'ForeName': 'Andrej', 'Initials': 'A', 'LastName': 'Šribar', 'Affiliation': 'Clinical Department of Anesthesiology, Resuscitation and Intensive Care Medicine, University Hospital Dubrava, Av. Gojka Šuška 6, 10000, Zagreb, Croatia. andrej.sribar@gmail.com.'}, {'ForeName': 'Vlasta', 'Initials': 'V', 'LastName': 'Merc', 'Affiliation': 'Clinical Department of Anesthesiology, Resuscitation and Intensive Care Medicine, University Hospital Dubrava, Av. Gojka Šuška 6, 10000, Zagreb, Croatia.'}, {'ForeName': 'Zoran', 'Initials': 'Z', 'LastName': 'Peršec', 'Affiliation': 'Department of Urology, University Hospital Dubrava, Zagreb, Croatia.'}, {'ForeName': 'Jasminka', 'Initials': 'J', 'LastName': 'Peršec', 'Affiliation': 'Clinical Department of Anesthesiology, Resuscitation and Intensive Care Medicine, University Hospital Dubrava, Av. Gojka Šuška 6, 10000, Zagreb, Croatia.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Milas', 'Affiliation': 'Clinical Department of Urology, University Hospital Center Zagreb, Zagreb, Croatia.'}, {'ForeName': 'Sanja', 'Initials': 'S', 'LastName': 'Husedžinović', 'Affiliation': 'Zagreb Dental Polyclinic, Zagreb, Croatia.'}]",Journal of clinical monitoring and computing,['10.1007/s10877-019-00318-8'] 419,32109422,"Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.","BACKGROUND An urgent need to reduce the metabolic side-effects of glucocorticoid overexposure has been recognised, as glucocorticoid excess can lead to Cushing's syndrome, which is associated with high morbidity. We aimed to evaluate the potential of metformin to reverse such effects while sparing the anti-inflammatory benefits of glucocorticoids. METHODS We did a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial involving four hospitals in the UK. Patients without diabetes were eligible if they were between the ages of 18 and 75 years with an inflammatory disease treated with continuous prednisolone (≥20 mg/day for ≥4 weeks and remaining on ≥10 mg/day for the subsequent 12 weeks, or its cumulative dose-equivalent). Eligible patients were randomly allocated (1:1) to either the metformin or placebo groups, using a computer-generated randomisation table stratified according to age and BMI. Metformin and placebo were administered orally for 12 weeks in escalating doses: 850 mg/day for the first 5 days, 850 mg twice a day for the next 5 days, and 850 mg three times a day subsequently. The primary outcome was the between-group difference in visceral-to-subcutaneous fat area ratio over 12 weeks, assessed by CT. Secondary outcomes included changes in metabolic, bone, cardiovascular, and inflammatory parameters over 12 weeks. Our analysis followed a modified intention-to-treat principle for the primary outcome. This study is registered with ClinicalTrials.gov, NCT01319994. FINDINGS Between July 17, 2012, and Jan 14, 2014, 849 patients were assessed for study eligibility, of which 53 were randomly assigned to receive either metformin (n=26) or placebo (n=27) for 12 weeks. 19 patients in the metformin group and 21 in the placebo group were eligible for the primary outcome analysis. Both groups received an equivalent cumulative dose of glucocorticoids (1860 mg prednisolone-equivalent [IQR 1060-2810] in the metformin group vs 1770 mg [1020-2356] in the placebo group); p=0·76). No change in the visceral-to-subcutaneous fat area ratio between the treatment groups was observed (0·11, 95% CI -0·02 to 0·24; p=0·09), but patients in the metformin group lost truncal subcutaneous fat compared with the placebo group (-3835 mm 2 , 95% CI -6781 to -888; p=0·01). Improvements in markers of carbohydrate, lipid, liver, and bone metabolism were observed in the metformin group compared with the placebo group. Additionally, those in the metformin group had improved fibrinolysis, carotid intima-media thickness, inflammatory parameters, and clinical markers of disease activity. The frequency of pneumonia (one event in the metformin group vs seven in the placebo group; p=0·01), overall rate of moderate-to-severe infections (two vs 11; p=0·001), and all-cause hospital admissions due to adverse events (one vs nine; p=0·001) were lower in the metformin group than in the placebo group. Patients in the metformin group had more events of diarrhoea than the placebo group (18 events vs eight; p=0·01). INTERPRETATION No significant changes in the visceral-to-subcutaneous fat area ratio between the treatment groups were observed; however, metformin administration did improve some of the metabolic profile and clinical outcomes for glucocorticoid-treated patients with inflammatory disease, which warrants further investigation. FUNDING Barts Charity and Merck Serono.",2020,"Improvements in markers of carbohydrate, lipid, liver, and bone metabolism were observed in the metformin group compared with the placebo group.","['four hospitals in the UK', 'Patients without diabetes were eligible if they were between the ages of 18 and 75 years with an inflammatory disease treated with', 'patients on systemic glucocorticoid therapy', 'Eligible patients', 'Between July 17, 2012, and Jan 14, 2014, 849 patients were assessed for study eligibility, of which 53', '19 patients in the']","['metformin', 'placebo', 'Metformin', 'glucocorticoids', 'Metformin and placebo', 'prednisolone-equivalent [IQR 1060-2810] in the metformin', 'metformin or placebo', 'continuous prednisolone']","['metabolic profile and clinical outcomes', 'overall rate of moderate-to-severe infections', 'events of diarrhoea', 'fibrinolysis, carotid intima-media thickness, inflammatory parameters, and clinical markers of disease activity', 'visceral-to-subcutaneous fat area ratio', 'metabolic complications and inflammation', 'markers of carbohydrate, lipid, liver, and bone metabolism', 'changes in metabolic, bone, cardiovascular, and inflammatory parameters', 'frequency of pneumonia', 'truncal subcutaneous fat']","[{'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1290884', 'cui_str': 'Inflammatory disorder'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C3540777', 'cui_str': 'Glucocorticoids, Systemic'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3540778', 'cui_str': 'Glucocorticoids'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}]","[{'cui': 'C3853758', 'cui_str': 'Metabolic Profile'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C1305868', 'cui_str': 'Fibrinolysis'}, {'cui': 'C0162864', 'cui_str': 'Vascular Intima'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0008963', 'cui_str': 'Markers, Clinical'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0442045', 'cui_str': 'Visceral (qualifier value)'}, {'cui': 'C0222331', 'cui_str': 'Subcutaneous Fat'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}]",849.0,0.523472,"Improvements in markers of carbohydrate, lipid, liver, and bone metabolism were observed in the metformin group compared with the placebo group.","[{'ForeName': 'Ida', 'Initials': 'I', 'LastName': 'Pernicova', 'Affiliation': 'Centre for Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Endocrinology and Metabolic Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Kelly', 'Affiliation': 'Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Ajodha', 'Affiliation': 'Centre for Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'Anju', 'Initials': 'A', 'LastName': 'Sahdev', 'Affiliation': 'Department of Radiology, Barts Health NHS Trust, London, UK.'}, {'ForeName': 'Jonathan P', 'Initials': 'JP', 'LastName': 'Bestwick', 'Affiliation': 'Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'Plamena', 'Initials': 'P', 'LastName': 'Gabrovska', 'Affiliation': 'Centre for Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'Olufunso', 'Initials': 'O', 'LastName': 'Akanle', 'Affiliation': 'Department of Radiology, Barts Health NHS Trust, London, UK.'}, {'ForeName': 'Ramzi', 'Initials': 'R', 'LastName': 'Ajjan', 'Affiliation': 'Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.'}, {'ForeName': 'Blerina', 'Initials': 'B', 'LastName': 'Kola', 'Affiliation': 'Centre for Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'Marietta', 'Initials': 'M', 'LastName': 'Stadler', 'Affiliation': ""Centre for Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Faculty of Life Sciences and Medicine, Department of Diabetes, King's College London, London, UK.""}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Fraser', 'Affiliation': 'Department of Medicine, University of East Anglia, Norwich, UK.'}, {'ForeName': 'Mirjam', 'Initials': 'M', 'LastName': 'Christ-Crain', 'Affiliation': 'Centre for Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Division of Endocrinology, Diabetes & Metabolism, Department of Internal Medicine and Department of Clinical Research, University Hospital, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Ashley B', 'Initials': 'AB', 'LastName': 'Grossman', 'Affiliation': 'Centre for Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'Costantino', 'Initials': 'C', 'LastName': 'Pitzalis', 'Affiliation': 'Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'Márta', 'Initials': 'M', 'LastName': 'Korbonits', 'Affiliation': 'Centre for Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. Electronic address: m.korbonits@qmul.ac.uk.'}]",The lancet. Diabetes & endocrinology,['10.1016/S2213-8587(20)30021-8'] 420,31590688,An electronic family health history tool to identify and manage patients at increased risk for colorectal cancer: protocol for a randomized controlled trial.,"BACKGROUND Colorectal cancer is the fourth most commonly diagnosed cancer in the United States. Approximately 3-10% of the population has an increased risk for colorectal cancer due to family history and warrants more frequent or intensive screening. Yet, < 50% of that high-risk population receives guideline-concordant care. Systematic collection of family health history and decision support may improve guideline-concordant screening for patients at increased risk of colorectal cancer. We seek to test the effectiveness of a web-based, systematic family health history collection tool and decision support platform (MeTree) to improve risk assessment and appropriate management of colorectal cancer risk among patients in the Department of Veterans Affairs primary care practices. METHODS In this ongoing randomized controlled trial, primary care providers at the Durham Veterans Affairs Health Care System and the Madison VA Medical Center are randomized to immediate intervention or wait-list control. Veterans are eligible if assigned to enrolled providers, have an upcoming primary care appointment, and have no conditions that would place them at increased risk for colorectal cancer (such as personal history, adenomatous polyps, or inflammatory bowel disease). Those with a recent lower endoscopy (e.g. colonoscopy, sigmoidoscopy) are excluded. Immediate intervention patients put their family health history information into a web-based platform, MeTree, which provides both patient- and provider-facing decision support reports. Wait-list control patients access MeTree 12 months post-consent. The primary outcome is the risk-concordant colorectal cancer screening referral rate obtained via chart review. Secondary outcomes include patient completion of risk management recommendations (e.g. colonoscopy) and referral for genetic consultation. We will also conduct an economic analysis and an assessment of providers' experience with MeTree clinical decision support recommendations to inform future implementation efforts if the intervention is found to be effective. DISCUSSION This trial will assess the feasibility and effectiveness of patient-collected family health history linked to decision support to promote risk-appropriate screening in a large healthcare system such as the Department of Veterans Affairs. TRIAL REGISTRATION ClinicalTrials.gov, NCT02247336 . Registered on 25 September 2014.",2019,Approximately 3-10% of the population has an increased risk for colorectal cancer due to family history and warrants more frequent or intensive screening.,"['colorectal cancer risk among patients in the Department of Veterans Affairs primary care practices', 'primary care providers at the Durham Veterans Affairs Health Care System and the Madison VA Medical Center', 'patients at increased risk of colorectal cancer', 'Veterans are eligible if assigned to enrolled providers, have an upcoming primary care appointment, and have no conditions that would place them at increased risk for colorectal cancer (such as personal history, adenomatous polyps, or inflammatory bowel disease']","['web-based, systematic family health history collection tool and decision support platform (MeTree', 'immediate intervention or wait-list control']","['patient completion of risk management recommendations (e.g. colonoscopy) and referral for genetic consultation', 'risk-concordant colorectal cancer screening referral rate obtained via chart review']","[{'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C2735026', 'cui_str': 'Primary care provider (occupation)'}, {'cui': 'C0454851', 'cui_str': 'Durham (geographic location)'}, {'cui': 'C0018696', 'cui_str': 'Health Care Systems'}, {'cui': 'C0565990', 'cui_str': 'Medical center (environment)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0424945', 'cui_str': 'Social / personal history observable'}, {'cui': 'C0206677', 'cui_str': 'Adenomatous Polyps'}, {'cui': 'C0021390', 'cui_str': 'Inflammatory Bowel Diseases'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0220922', 'cui_str': 'systematics'}, {'cui': 'C0241889', 'cui_str': 'Family Medical History'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0035649', 'cui_str': 'Risk Management'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}, {'cui': 'C2585524', 'cui_str': 'Referral for'}, {'cui': 'C0017399', 'cui_str': 'genetics'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C0541653', 'cui_str': 'Chart review'}]",,0.144353,Approximately 3-10% of the population has an increased risk for colorectal cancer due to family history and warrants more frequent or intensive screening.,"[{'ForeName': 'Karen M', 'Initials': 'KM', 'LastName': 'Goldstein', 'Affiliation': 'Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, 508 Fulton Street, Durham, NC, 27705, USA. karen.goldstein@duke.edu.'}, {'ForeName': 'Deborah A', 'Initials': 'DA', 'LastName': 'Fisher', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'R Ryanne', 'Initials': 'RR', 'LastName': 'Wu', 'Affiliation': 'Division of General Internal Medicine, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Lori A', 'Initials': 'LA', 'LastName': 'Orlando', 'Affiliation': 'Division of General Internal Medicine, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Cynthia J', 'Initials': 'CJ', 'LastName': 'Coffman', 'Affiliation': 'Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, 508 Fulton Street, Durham, NC, 27705, USA.'}, {'ForeName': 'Janet M', 'Initials': 'JM', 'LastName': 'Grubber', 'Affiliation': 'Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, 508 Fulton Street, Durham, NC, 27705, USA.'}, {'ForeName': 'Tejinder', 'Initials': 'T', 'LastName': 'Rakhra-Burris', 'Affiliation': 'Center for Applied Genomics and Precision Medicine, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Wang', 'Affiliation': 'Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, 508 Fulton Street, Durham, NC, 27705, USA.'}, {'ForeName': 'Maren T', 'Initials': 'MT', 'LastName': 'Scheuner', 'Affiliation': 'Division of Medical Genetics, University of California at San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Sperber', 'Affiliation': 'Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, 508 Fulton Street, Durham, NC, 27705, USA.'}, {'ForeName': 'Santanu K', 'Initials': 'SK', 'LastName': 'Datta', 'Affiliation': 'Division of General Internal Medicine, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Nelson', 'Affiliation': 'IDEAS Center, VA Salt Lake City Healthcare System, Salt Lake City, UT, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Strawbridge', 'Affiliation': 'Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, 508 Fulton Street, Durham, NC, 27705, USA.'}, {'ForeName': 'Dawn', 'Initials': 'D', 'LastName': 'Provenzale', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Hauser', 'Affiliation': 'Durham Cooperative Studies Program Epidemiology Center, Durham Veterans Affairs Health Care System, Durham, NC, USA.'}, {'ForeName': 'Corrine I', 'Initials': 'CI', 'LastName': 'Voils', 'Affiliation': 'William S Middleton Memorial Veterans Hospital, Madison, WI, USA.'}]",Trials,['10.1186/s13063-019-3659-y'] 421,32205563,Deficiency of cysteinyl cathepsin K suppresses the development of experimental intimal hyperplasia in response to chronic stress.,"BACKGROUND Chronic psychological stress (CPS) is linked to cardiovascular disease initiation and progression. Given that cysteinyl cathepsin K (CatK) participates in vascular remodeling and atherosclerotic plaque growth in several animal models, we investigated the role of CatK in the development of experimental neointimal hyperplasia in response to chronic stress. METHODS AND RESULTS At first, male wild-type (CatK) mice that underwent carotid ligation injury were subjected to chronic immobilization stress. On postoperative and stressed day 14, the results demonstrated that stress accelerated injury-induced neointima hyperplasia. On day 4, stressed mice showed following: increased levels of monocyte chemoattractant protein-1, gp91phox, toll-like receptor-2 (TLR2), TLR4, and CatK mRNAs or/and proteins, oxidative stress production, aorta-derived smooth muscle cell (SMC) migration, and macrophage infiltration as well as targeted intracellular proliferating-related molecules. Stressed mice showed increased matrix metalloproteinase-2 (MMP-2) and MMP-9 mRNA expressions and activities and elastin disruption in the injured carotid arteries. Second, CatK and CatK deficiency (CatK) mice received ligation injury and stress to explore the role of CatK. The stress-induced harmful changes were prevented by CatK. Finally, CatK mice that had undergone ligation surgery were randomly assigned to one of two groups and administered vehicle or CatK inhibitor for 14 days. Pharmacological CatK intervention produced a vascular benefit. CONCLUSION These data indicate that CatK deletion protects against the development of experimental neointimal hyperplasia via the attenuation of inflammatory overaction, oxidative stress production, and VSMC proliferation, suggesting that CatK is a novel therapeutic target for the management of CPS-related restenosis after intravascular intervention therapies.",2020,"On day 4, stressed mice showed following: increased levels of monocyte chemoattractant protein-1, gp91phox, toll-like receptor-2 (TLR2), TLR4, and CatK mRNAs or/and proteins, oxidative stress production, aorta-derived smooth muscle cell (SMC) migration, and macrophage infiltration as well as targeted intracellular proliferating-related molecules.",['CatK mice that had undergone ligation surgery'],"['Pharmacological CatK intervention', 'cysteinyl cathepsin K', 'cysteinyl cathepsin K (CatK', 'vehicle or CatK inhibitor']","['monocyte chemoattractant protein-1, gp91phox, toll-like receptor-2 (TLR2), TLR4, and CatK mRNAs or/and proteins, oxidative stress production, aorta-derived smooth muscle cell (SMC) migration, and macrophage infiltration', 'stress accelerated injury-induced neointima hyperplasia', 'matrix metalloproteinase-2 (MMP-2) and MMP-9 mRNA expressions and activities and elastin disruption']","[{'cui': 'C0026809', 'cui_str': 'Mice'}, {'cui': 'C0023690', 'cui_str': 'Ligation'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0205464', 'cui_str': 'Pharmacologic (qualifier value)'}, {'cui': 'C0284930', 'cui_str': 'Cathepsin X'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle (substance)'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0128897', 'cui_str': 'Chemokine (C-C Motif) Ligand 2'}, {'cui': 'C0754728', 'cui_str': 'Toll-Like Receptor 2'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0033268'}, {'cui': 'C0003483', 'cui_str': 'Aorta'}, {'cui': 'C1135918', 'cui_str': 'Smooth Muscle Cells'}, {'cui': 'C1533574', 'cui_str': 'Migration, function (observable entity)'}, {'cui': 'C0024432', 'cui_str': 'Monocyte-Derived Macrophages'}, {'cui': 'C3669041', 'cui_str': 'Spread by direct extension (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0521110', 'cui_str': 'Accelerated (contextual qualifier) (qualifier value)'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C2936380', 'cui_str': 'Neointima'}, {'cui': 'C0020507', 'cui_str': 'Hyperplasia'}, {'cui': 'C0172537', 'cui_str': '72-kDa Type IV Collagenase'}, {'cui': 'C0623362', 'cui_str': 'MMPs'}, {'cui': 'C0035696', 'cui_str': 'mRNA'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0013765', 'cui_str': 'Elastin'}, {'cui': 'C0332453', 'cui_str': 'Disruption (morphologic abnormality)'}]",,0.029322,"On day 4, stressed mice showed following: increased levels of monocyte chemoattractant protein-1, gp91phox, toll-like receptor-2 (TLR2), TLR4, and CatK mRNAs or/and proteins, oxidative stress production, aorta-derived smooth muscle cell (SMC) migration, and macrophage infiltration as well as targeted intracellular proliferating-related molecules.","[{'ForeName': 'Xiangkun', 'Initials': 'X', 'LastName': 'Meng', 'Affiliation': ""aDepartment of Cardiology and Hypertension, Yanbian University Hospital, Yanjin, Jilin, China bDepartment of Community Health & Geriatrics cInstitute of Innovation for Future Society, Nagoya University Graduate School of Medicine, Nagoya, Japan dDepartment of Physiology and Pathophysiology, Jiaxing University Medical College, Jiaxing, Zhejiang, China eDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya fDepartment of Anatomy and Neuroscience, Hamamatsu University School of Medicine, Hamamatsu, Japan gDepartment of Public Health, Guilin Medical College, Guangxi hShanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China iDepartment of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan jDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Limei', 'Initials': 'L', 'LastName': 'Piao', 'Affiliation': ''}, {'ForeName': 'Hailong', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Aiko', 'Initials': 'A', 'LastName': 'Inoue', 'Affiliation': ''}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Haiying', 'Initials': 'H', 'LastName': 'Jiang', 'Affiliation': ''}, {'ForeName': 'Kae', 'Initials': 'K', 'LastName': 'Nakamura', 'Affiliation': ''}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Sasaki', 'Affiliation': ''}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Wenhu', 'Initials': 'W', 'LastName': 'Xu', 'Affiliation': ''}, {'ForeName': 'Chenglin', 'Initials': 'C', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Hu', 'Affiliation': ''}, {'ForeName': 'Hongxian', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Toyoaki', 'Initials': 'T', 'LastName': 'Murohara', 'Affiliation': ''}, {'ForeName': 'Guo-Ping', 'Initials': 'GP', 'LastName': 'Shi', 'Affiliation': ''}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Kuzuya', 'Affiliation': ''}, {'ForeName': 'Xian Wu', 'Initials': 'XW', 'LastName': 'Cheng', 'Affiliation': ''}]",Journal of hypertension,['10.1097/HJH.0000000000002424'] 422,32203207,Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.,"BACKGROUND Cardiotoxicity is the most significant adverse event associated with trastuzumab (T), the main component of HER2-positive breast cancer (BC) treatment. Less is known about the cardiotoxicity of dual HER2 blockade with T plus lapatinib (L), although this regimen is used in the metastatic setting. METHODS This is a sub-analysis of the ALTTO trial comparing adjuvant treatment options for patients with early HER2-positive BC. Patients randomised to either T or concomitant T + L were eligible. Cardiac events (CEs) rates were compared according to treatment arm. RESULTS With 6.9 years of median follow-up (FU) and 4190 patients, CE were observed in 363 (8.6%): 166 (7.9%) of patient in T + L arm vs. 197 (9.3%) in T arm (OR = 0.85 [95% CI, 0.68-1.05]). During anti-HER2 treatment 270 CE (6.4%) occurred while 93 (2.2%) were during FU (median time to onset = 6.6 months [IQR = 3.4-11.7]). While 265 CEs were asymptomatic (73%), 94 were symptomatic (26%) and four were cardiac deaths (1%). Recovery was observed in 301 cases (83.8%). Identified cardiac risk factors were: baseline LVEF < 55% (vs > 64%, OR 3.1 [95% CI 1.54-6.25]), diabetes mellitus (OR 1.85 [95% CI 1.25-2.75]), BMI > 30 kg/m 2 (vs < 25 mg/kg 2 , OR 2.21 [95% CI 1.40-3.49]), cumulative dose of doxorubicin ≥240 mg/m 2 (OR 1.36 [95% CI 1.01-1.82]) and of epirubicin≥ 480 mg/m 2 (OR 2.33 [95% CI 1.55-3.51]). CONCLUSIONS Dual HER2 blockade with T + L is a safe regimen from a cardiac perspective, but cardiac-focused history for proper patient selection is crucial. TRIAL REGISTRATION NUMBER ClinicalTrials.gov Identifier: NCT00490139 (registration date: 22/06/2007); EudraCT Number: 2006-000562-36 (registration date: 04/05/2007); Sponsor Protocol Number: BIG2-06 /EGF106708/N063D.",2020,"Cardiac events (CEs) rates were compared according to treatment arm. ","['patients with early HER2-positive BC', 'patients with HER2-positive breast cancer treated in the']","['trastuzumab (T', 'adjuvant lapatinib', 'T or concomitant T\u2009+\u2009L', 'doxorubicin']","['diabetes mellitus', 'Cardiac events (CEs) rates', 'Recovery', 'cardiac deaths']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C1292734', 'cui_str': 'Treats'}]","[{'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C1506770', 'cui_str': 'lapatinib'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}]","[{'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0376297', 'cui_str': 'Cardiac Death'}]",,0.264623,"Cardiac events (CEs) rates were compared according to treatment arm. ","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Eiger', 'Affiliation': ""Institut Jules Bordet Institute and L'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.""}, {'ForeName': 'Noam F', 'Initials': 'NF', 'LastName': 'Pondé', 'Affiliation': ""Institut Jules Bordet Institute and L'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.""}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Agbor-Tarh', 'Affiliation': 'Frontier Science, Kingussie, United Kingdom.'}, {'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Moreno-Aspitia', 'Affiliation': 'Mayo Clinic, Jacksonville, FL, USA.'}, {'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'Piccart', 'Affiliation': ""Institut Jules Bordet Institute and L'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.""}, {'ForeName': 'Florentine S', 'Initials': 'FS', 'LastName': 'Hilbers', 'Affiliation': 'Breast International Group (BIG), Brussels, Belgium.'}, {'ForeName': 'Olena', 'Initials': 'O', 'LastName': 'Werner', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Saranya', 'Initials': 'S', 'LastName': 'Chumsri', 'Affiliation': 'Mayo Clinic, Jacksonville, FL, USA.'}, {'ForeName': 'Amylou', 'Initials': 'A', 'LastName': 'Dueck', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Scottsdale, AZ, USA.'}, {'ForeName': 'Judith R', 'Initials': 'JR', 'LastName': 'Kroep', 'Affiliation': 'Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Gomez', 'Affiliation': 'Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.'}, {'ForeName': 'István', 'Initials': 'I', 'LastName': 'Láng', 'Affiliation': 'Istenhegyi Géndiagnosztika Private Health Center, Oncology Clinic, Budapest, Hungary.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Rodeheffer', 'Affiliation': 'Cardiovascular Department, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Ewer', 'Affiliation': 'MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Suter', 'Affiliation': 'Department of Cardiology, lnselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Evandro', 'Initials': 'E', 'LastName': 'de Azambuja', 'Affiliation': ""Institut Jules Bordet Institute and L'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. evandro.azambuja@bordet.be.""}]",British journal of cancer,['10.1038/s41416-020-0786-x'] 423,32404353,Costimulation Blockade Disrupts CD4 + T Cell Memory Pathways and Uncouples Their Link to Decline in β-Cell Function in Type 1 Diabetes.,"We previously reported that costimulation blockade by abatacept limits the decline of β-cell function and the frequency of circulating CD4 + central memory T cells (T CM ) (CD45RO + CD62L + ) in new-onset type 1 diabetes. In human subjects receiving placebo, we found a significant association between an increase in CD4 + T CM cells and the decline of β-cell function. To extend and refine these findings, we examined changes in human CD4 + and CD8 + naive and memory T cell subsets at greater resolution using polychromatic flow and mass cytometry. In the placebo group, we successfully reproduced the original finding of a significant association between T CM and β-cell function and extended this to other T cell subsets. Furthermore, we show that abatacept treatment significantly alters the frequencies of a majority of CD4 + conventional and regulatory T cell subsets; in general, Ag-naive subsets increase and Ag-experienced subsets decrease, whereas CD8 + T cell subsets are relatively resistant to drug effects, indicating a lesser reliance on CD28-mediated costimulation. Importantly, abatacept uncouples the relationship between changes in T cell subsets and β-cell function that is a component of the natural history of the disease. Although these data suggest immunological markers for predicting change in β-cell function in type 1 diabetes, the finding that abatacept blunts this relationship renders the biomarkers nonpredictive for this type of therapy. In sum, our findings point to a novel mechanism of action for this successful immunotherapy that may guide other disease-modifying approaches for type 1 diabetes.",2020,"In the placebo group, we successfully reproduced the original finding of a significant association between T CM and β-cell function and extended this to other T cell subsets.",[],['placebo'],"['T CM and β-cell function', 'CD4 + T CM cells and the decline of β-cell function', 'human CD4 + and CD8 + naive and memory T cell subsets', 'frequencies of a majority of CD4 + conventional and regulatory T cell subsets', 'frequency of circulating CD4 + central memory T cells (T CM ) (CD45RO + CD62L + ']",[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0007613', 'cui_str': 'Physiology, Cell'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0080202', 'cui_str': 'T-Cell Subsets'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0039198', 'cui_str': 'Regulatory T-Lymphocytes'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0162833', 'cui_str': 'Lymphocyte antigen CD45RO'}, {'cui': 'C0125090', 'cui_str': 'Lymphocyte antigen CD62L'}]",,0.0502345,"In the placebo group, we successfully reproduced the original finding of a significant association between T CM and β-cell function and extended this to other T cell subsets.","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Eichmann', 'Affiliation': ""Peter Gorer Department of Immunobiology, Faculty of Life Sciences and Medicine, King's College London, London SE1 9RT, United Kingdom; martin.eichmann@kcl.ac.uk.""}, {'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Baptista', 'Affiliation': ""Peter Gorer Department of Immunobiology, Faculty of Life Sciences and Medicine, King's College London, London SE1 9RT, United Kingdom.""}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Ellis', 'Affiliation': ""Biomedical Research Centre at Guy's and St Thomas' Hospitals and King's College London, London SE1 9RT, United Kingdom.""}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Heck', 'Affiliation': ""Biomedical Research Centre at Guy's and St Thomas' Hospitals and King's College London, London SE1 9RT, United Kingdom.""}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Peakman', 'Affiliation': ""Peter Gorer Department of Immunobiology, Faculty of Life Sciences and Medicine, King's College London, London SE1 9RT, United Kingdom.""}, {'ForeName': 'Craig A', 'Initials': 'CA', 'LastName': 'Beam', 'Affiliation': 'Department of Biomedical Sciences, Homer Stryker M.D. School of Medicine, Western Michigan University, Kalamazoo, MI 49008.'}]","Journal of immunology (Baltimore, Md. : 1950)",['10.4049/jimmunol.1901439'] 424,32406989,Diarrhoeal disease knowledge among diarrhoea patient housholds: findings from the randomised controlled trial of the Cholera-Hospital-Based-Intervention-for-7-days (CHoBI7) mobile health program.,"OBJECTIVE The objective of this study was to evaluate the impact of the Cholera-Hospital-Based-Intervention-for-7-days (CHoBI7) handwashing with soap and water treatment mobile health (mHealth) program on diarrhoeal disease knowledge among diarrhoea patients and their household members in urban Dhaka, Bangladesh. METHODS A cluster-randomised controlled trial of the CHoBI7 mHealth program was conducted among diarrhoea patient households in Dhaka, Bangladesh. Patients were randomised to three arms: standard recommendation on oral rehydration solution use; health facility delivery of CHoBI7 plus mHealth (weekly voice and text messages) (no home visits); and health facility delivery of CHoBI7 plus two home visits and mHealth. An open-ended questionnaire was administered to 1468 participants 12 years of age or older on diarrhoeal disease transmission and prevention. These items were combined to form a diarrhoeal disease knowledge score measured at baseline and at a 1 week, 6 month and 12 month follow-up. RESULTS At baseline, when participants were asked to report three ways diarrhoeal diseases were spread 37% (546/1468) of participants reported by water, 13% (187/1468) by lack of handwashing and 4% (53/1468) by food not being covered properly. At baseline when asked to name three ways diarrhoeal diseases could be prevented, 35% (515/1468) of participants reported safe water, and 16% (228/1468) reported handwashing with soap. At the 12-month follow-up, the overall diarrhoeal disease knowledge score was significantly higher in the mHealth with no home visits arm (score coefficient: 0.69, 95% Confidence Interval: 0.36, 1.01, P < 0.0001) and the mHealth with two home visits arm (score coefficient: 1.18, 95% CI: 0.87, 1.49, P < 0.0001) compared with the standard recommendation arm. CONCLUSION The CHoBI7 mHealth program significantly increased knowledge of diarrhoeal disease transmission and prevention among diarrhoea patients and their household members 12 months after in-person visits for program delivery were conducted.",2020,"At the 12 month follow-up, the overall diarrhea knowledge score was significantly higher in mHealth with no home visits arm (score coefficient: 0.69, 95% Confidence Interval: 0.36, 1.01, p<0.0001) and the mHealth with two home visits arm (score coefficient:","['diarrhea patients and their household members in urban Dhaka', 'diarrhea patient households in Dhaka, Bangladesh', 'diarrhea patient households', 'Household Members of Diarrhea Patients', '1468 participants 12 years of age or older on diarrheal disease transmission and prevention']","['CHoBI7 mHealth program', 'Cholera-Hospital-Based-Intervention-for-7 Days (CHoBI7) Mobile Health Program', 'Cholera-Hospital-Based-Intervention-for-7-days (CHoBI7) handwashing with soap and water treatment mobile health (mHealth) program', 'standard recommendation on oral rehydration solution use; health facility delivery of CHoBI7 plus mHealth (no home visits); and health facility delivery of CHoBI7 plus two home visits and mHealth']","['diarrheal disease knowledge', 'overall diarrhea knowledge score', 'diarrheal disease knowledge score']","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1290807', 'cui_str': 'Diarrheal disorder'}, {'cui': 'C0040722', 'cui_str': 'transmission'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]","[{'cui': 'C0008354', 'cui_str': 'Cholera'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0037392', 'cui_str': 'Soap'}, {'cui': 'C0597684', 'cui_str': 'Water Treatment'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0078516', 'cui_str': 'World Health Organization oral rehydration solution'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}]","[{'cui': 'C1290807', 'cui_str': 'Diarrheal disorder'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.131471,"At the 12 month follow-up, the overall diarrhea knowledge score was significantly higher in mHealth with no home visits arm (score coefficient: 0.69, 95% Confidence Interval: 0.36, 1.01, p<0.0001) and the mHealth with two home visits arm (score coefficient:","[{'ForeName': 'Jahed', 'Initials': 'J', 'LastName': 'Masud', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Md Sazzadul', 'Initials': 'MS', 'LastName': 'Islam Bhuyian', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Shwapon', 'Initials': 'S', 'LastName': 'Kumar Biswas', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Fatema', 'Initials': 'F', 'LastName': 'Zohura', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Perin', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Nowshin', 'Initials': 'N', 'LastName': 'Papri', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Fahmida', 'Initials': 'F', 'LastName': 'Dil Farzana', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Tahmina', 'Initials': 'T', 'LastName': 'Parvin', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Shirajum', 'Initials': 'S', 'LastName': 'Monira', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Munirul', 'Initials': 'M', 'LastName': 'Alam', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Marie George', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}]",Tropical medicine & international health : TM & IH,['10.1111/tmi.13415'] 425,32183769,Optimizing internet-delivered cognitive behaviour therapy for alcohol misuse: a study protocol for a randomized factorial trial examining the effects of a pre-treatment assessment interview and health educator guidance.,"BACKGROUND Alcohol misuse is a common, disabling, and costly issue worldwide, but the vast majority of people with alcohol misuse never access treatment for varying reasons. Internet-delivered cognitive behaviour therapy (ICBT) may be an attractive treatment alternative for individuals with alcohol misuse who are reluctant to seek help due to stigma, or who live in rural communities with little access to face-to-face treatment. With the growing development of ICBT treatment clinics, investigating ways to optimize its delivery within routine clinic settings becomes a crucial avenue of research. Some studies in the alcohol treatment literature suggest that assessment interviews conducted pre-treatment may improve short- and long-term drinking outcomes but no experimental evaluation of this has been conducted. Further, research on internet interventions for alcohol misuse suggests that guidance from a therapist or coach improves outcomes, but more research on the benefits of guidance in ICBT is still needed. METHODS This study is a 2X2 factorial randomized controlled trial where all of the expected 300 participants receive access to the Alcohol Change Course, an eight-week ICBT program. A comprehensive pre-treatment assessment interview represents factor 1, and guidance from a health educator represents factor 2. All participants will be asked to respond to measures at screening, pre-treatment, mid-treatment, post-treatment and 3, 6 and 12 months after treatment completion. DISCUSSION This study will provide valuable information on optimization of ICBT for alcohol misuse within routine clinic settings. TRIAL REGISTRATION ClinicalTrials.gov, registered June 13th 2019, NCT03984786.",2020,"Internet-delivered cognitive behaviour therapy (ICBT) may be an attractive treatment alternative for individuals with alcohol misuse who are reluctant to seek help due to stigma, or who live in rural communities with little access to face-to-face treatment.","['300 participants receive access to the Alcohol Change Course, an eight-week ICBT program', 'individuals with alcohol misuse']","['Optimizing internet-delivered cognitive behaviour therapy', 'Internet-delivered cognitive behaviour therapy (ICBT']",[],"[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]",[],,0.0341452,"Internet-delivered cognitive behaviour therapy (ICBT) may be an attractive treatment alternative for individuals with alcohol misuse who are reluctant to seek help due to stigma, or who live in rural communities with little access to face-to-face treatment.","[{'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Sundström', 'Affiliation': 'Department of Psychology, University of Regina, 3737 Wascana Parkway, Regina, Saskatchewan, S4S 0A2, Canada. Christopher.sundstrom@ki.se.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Hadjistavropoulos', 'Affiliation': 'Department of Psychology, University of Regina, 3737 Wascana Parkway, Regina, Saskatchewan, S4S 0A2, Canada.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Wilhelms', 'Affiliation': 'Department of Psychology, University of Regina, 3737 Wascana Parkway, Regina, Saskatchewan, S4S 0A2, Canada.'}, {'ForeName': 'Matt', 'Initials': 'M', 'LastName': 'Keough', 'Affiliation': 'Department of Psychology, York University, Toronto, Ontario, Canada.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schaub', 'Affiliation': 'Swiss Research Institute for Public Health and Addiction, University of Zurich, Zurich, Switzerland.'}]",BMC psychiatry,['10.1186/s12888-020-02506-2'] 426,32183772,COPe-support - a multi-component digital intervention for family carers for people affected by psychosis: study protocol for a randomized controlled trial.,"BACKGROUND Psychosis often causes significant distress and impacts not only in the individuals, but also those close to them. Many relatives and friends ('carers') provide long-term support and need resources to assist them. We have co-produced a digital mental health intervention called COPe-support (Carers fOr People with Psychosis e-support) to provide carers with flexible access to high quality psychoeducation and interactive support from experts and peers. This study evaluates the effectiveness of COPe-support to promote mental wellbeing and caregiving experiences in carers. METHODS This study is a single-blind, parallel arm, individually randomized controlled trial (RCT) comparing COPe-support, with attention control. Both groups continue to receive usual care. COPe-support provides interactive web-based psychoeducation on psychosis-related issues, wellbeing-promotion and network support through forums. The attention-control is a non-interactive online information resource pack. Carers living in England are eligible if they provide at least weekly support to a family member or close friend affected by psychosis, and use internet communication (including emails) daily. All trial procedures are run online, including collection of outcome measurements which participants will directly input into our secure platform. Following baseline assessment, a web-based randomization system will be used to allocate 360 carers to either arm. Participants have unlimited access to the allocated condition for 40 weeks. Data collection is at three time points (10, 20, and 40 weeks after randomization). Analyses will be conducted by trial statisticians blinded to allocation. The primary outcome is mental wellbeing measured by Warwick Edinburgh Mental Wellbeing Scale (WEMWBS), at 20 weeks. As well as an intention-to-treat analysis, a complier average causal effect (CACE) analysis will be conducted to estimate the intervention effect in participants who have accessed COPe-support content twice or more. The secondary objectives and analysis will examine other health and caregiving-related outcomes and explore mechanisms. In a process evaluation, we will interview 20% of the intervention arm participants regarding the acceptability of COPe-support. We will explore in detail participants' usage patterns. DISCUSSION The results of this trial will provide valuable information about the effectiveness of COPe-support in promoting wellbeing and caregiving experiences in carers. TRIAL REGISTRATION The RCT is registered with the Current Controlled Trials registration (ISRCTN 89563420, registration date: 02/03/2018).",2020,We have co-produced a digital mental health intervention called COPe-support (Carers fOr People with Psychosis e-support) to provide carers with flexible access to high quality psychoeducation and interactive support from experts and peers.,"['family carers for people affected by psychosis', 'participants who have accessed COPe-support content twice or more', 'carers']","['COPe-support provides interactive web-based psychoeducation', 'COPe-support', 'digital mental health intervention called COPe-support (Carers', 'COPe-support - a multi-component digital intervention']",['mental wellbeing measured by Warwick Edinburgh Mental Wellbeing Scale (WEMWBS'],"[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C1305660', 'cui_str': 'Carer (occupation)'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0150181', 'cui_str': 'Coping support'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C1720725', 'cui_str': 'Twice'}]","[{'cui': 'C0150181', 'cui_str': 'Coping support'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0871175', 'cui_str': 'Psycho-education'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray (qualifier value)'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C1305660', 'cui_str': 'Carer (occupation)'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}]","[{'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0222045'}]",,0.369844,We have co-produced a digital mental health intervention called COPe-support (Carers fOr People with Psychosis e-support) to provide carers with flexible access to high quality psychoeducation and interactive support from experts and peers.,"[{'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Sin', 'Affiliation': ""Population Health Research Institute, St George's, University of London, Cranmer Terrace, London, SW17 0RE, England, UK. jasin@sgul.ac.uk.""}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Henderson', 'Affiliation': ""Health Service & Population Research Department, King's College London, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, London, SE5 8AF, England, UK.""}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Cornelius', 'Affiliation': 'Imperial Clinical Trials Unit, School of Public Health, Imperial College London, Stadium House, 68 Wood Lane, London, England, W12 7RH, UK.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Chen', 'Affiliation': 'Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, England, UK.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Elkes', 'Affiliation': 'Imperial Clinical Trials Unit, School of Public Health, Imperial College London, Stadium House, 68 Wood Lane, London, England, W12 7RH, UK.'}, {'ForeName': 'Luke A', 'Initials': 'LA', 'LastName': 'Woodham', 'Affiliation': ""Institute of Medical and Biomedical Education, St George's, University of London, Cranmer Terrace, London, SW17 0RE, England, UK.""}, {'ForeName': 'Aurora Sesé', 'Initials': 'AS', 'LastName': 'Hernández', 'Affiliation': ""Institute of Medical and Biomedical Education, St George's, University of London, Cranmer Terrace, London, SW17 0RE, England, UK.""}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Spence-Polin', 'Affiliation': ""Institute of Medical and Biomedical Education, St George's, University of London, Cranmer Terrace, London, SW17 0RE, England, UK.""}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Batchelor', 'Affiliation': ""Population Health Research Institute, St George's, University of London, Cranmer Terrace, London, SW17 0RE, England, UK.""}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Gillard', 'Affiliation': ""Population Health Research Institute, St George's, University of London, Cranmer Terrace, London, SW17 0RE, England, UK.""}]",BMC psychiatry,['10.1186/s12888-020-02528-w'] 427,31403611,Short Sprints Accumulated at School Modulate Postprandial Metabolism in Boys.,"INTRODUCTION This study examined the efficacy of maximal sprint running accumulated during a typical school day to modulate postprandial metabolism in adolescent boys. METHODS Nineteen adolescent boys completed three 2-d experimental conditions: a standard-practice control (CON), an accumulated in-school sprint running (ACC), and a single block of afterschool sprint running (BLO). On day 1, a fasting capillary blood sample was taken at 0735 h in the school. Three subsequent postprandial blood samples were taken at predetermined times after consumption of standardized breakfast and lunch. During ACC, participants accumulated four sets of 10 × 30-m maximal-intensity sprint runs across natural breaks in lessons. During BLO, participants performed the same number of sprints (40) in a single after-school exercise session. The blood samples from day 1 were replicated on the day after exercise (day 2). RESULTS On day 1, no significant differences in total area under the plasma triacylglycerol concentration versus time curve (TAUC-TAG) were observed between conditions (P = 0.126). However, TAUC-insulin was lower in ACC compared with BLO (-26%, effect size [ES] = 0.86, P = 0.001) and CON (-22%, ES = 0.72, P = 0.010). On day 2, TAUC-TAG was 12% lower after ACC (ES = 0.49; P = 0.002) and 10% lower after BLO (ES = 0.37; P = 0.019) compared with CON. No significant differences were observed between conditions on day 2 for postprandial insulin or glucose (P ≥ 0.738). CONCLUSION Four sets of 10 × 30-m sprints, accumulated in four separate bouts (<5 min) during the school day, reduced postprandial triacylglycerol and insulin concentrations in adolescent boys and may represent an effective in-school exercise strategy to promote metabolic health.",2020,"No significant differences were observed between conditions on Day 2 for postprandial insulin or glucose (P ≥ 0.738). ","['adolescent boys', 'Nineteen adolescent boys', 'Boys']","['maximal sprint running', '2-day experimental conditions; a standard-practice control (CON); accumulated in-school sprint running (ACC); and a single block of afterschool sprint running (BLO']","['postprandial blood samples', 'postprandial insulin or glucose', 'total area under the plasma triacylglycerol concentration versus time curve (TAUC-TAG', 'CON', 'TAUC-insulin', 'postprandial triacylglycerol and insulin concentrations']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0450337', 'cui_str': '19 (qualifier value)'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}]","[{'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0037293', 'cui_str': 'Tag (morphologic abnormality)'}]",19.0,0.0348249,"No significant differences were observed between conditions on Day 2 for postprandial insulin or glucose (P ≥ 0.738). ","[{'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'Smallcombe', 'Affiliation': 'School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UNITED KINGDOM.'}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Barrett', 'Affiliation': 'School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UNITED KINGDOM.'}, {'ForeName': 'Lauren B', 'Initials': 'LB', 'LastName': 'Sherar', 'Affiliation': 'School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UNITED KINGDOM.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Sedgwick', 'Affiliation': 'School of Social and Health Sciences, Leeds Trinity University, Leeds, UNITED KINGDOM.'}, {'ForeName': 'Tommy', 'Initials': 'T', 'LastName': 'Slater', 'Affiliation': 'School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UNITED KINGDOM.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Tolfrey', 'Affiliation': 'School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UNITED KINGDOM.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002121'] 428,32209570,CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.,"PURPOSE In patients with ovarian cancer receiving neoadjuvant chemotherapy, the first-line treatment success will depend on both the tumor-primary chemosensitivity and the completeness of interval debulking surgery (IDS). The modeled CA-125 ELIMination rate constant K (KELIM), calculated with the CA-125 longitudinal kinetics during the first 100 chemotherapy days, is a validated early marker of tumor chemosensitivity. The objective was to investigate the role of the chemosensitivity relative to the success of first-line medical-surgical treatment. EXPERIMENTAL DESIGN The CA-125 concentrations were prospectively measured in the randomized phase II trial CHIVA (NCT01583322, carboplatin-paclitaxel regimen ± nintedanib, and IDS, n = 188 patients). The KELIM predictive value regarding the tumor response rate, likelihood of complete IDS, risk of subsequent platinum-resistant relapse (PtRR), progression-free survival (PFS), and overall survival (OS) was assessed using univariate and multivariate tests. RESULTS The data from 134 patients were analyzed. KELIM was an independent and major predictor of subsequent PtRR risk, and of survivals. The final logistic regression model, including KELIM [OR = 0.13; 95% confidence interval (CI), 0.03-0.49] and complete IDS (no vs. yes, OR = 0.30; 95% CI, 0.11-0.76) highlights the preponderant role of chemosensitivity on the success of the first-line treatment. In patients with highly chemosensitive diseases, the patient prognosis was driven more by the chemotherapy-induced antitumor effects than by the surgery. CONCLUSIONS The tumor-primary chemosensitivity, assessed by the modeled CA-125 KELIM calculated during neoadjuvant chemotherapy (http://www.biomarker-kinetics.org/CA-125-neo), may be a major parameter to consider for decision-making regarding IDS attempt, and selecting patients for treatments meant to reverse the primary chemoresistance.",2020,"KELIM was an independent and major predictor of subsequent PtRR risk, and of survivals.","['patients with highly chemosensitive diseases', 'ovarian cancer patients receiving', 'Patients With Ovarian Cancer', '134 patients were analysed']","['neoadjuvant chemotherapy', 'carboplatin-paclitaxel regimen ']","['complete IDS', 'subsequent PtRR risk, and of survivals', 'CA-125 ELIMination rate constant K (KELIM', 'platinum-resistant relapse (PtRR); progression-free survival (PFS); and overall survival (OS', 'modeled CA-125 ELIMination rate constant K (KELIM), calculated with the CA-125 longitudinal kinetics']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1140680', 'cui_str': 'Ovary Cancer'}, {'cui': 'C4517565', 'cui_str': 'One hundred and thirty-four'}]","[{'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}]","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0201549', 'cui_str': 'CA 125 measurement (procedure)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C1098768', 'cui_str': '(diethylenetriamine)-platinum(II)'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0444686', 'cui_str': 'Calculated (qualifier value)'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal (qualifier value)'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}]",188.0,0.0383071,"KELIM was an independent and major predictor of subsequent PtRR risk, and of survivals.","[{'ForeName': 'Benoit', 'Initials': 'B', 'LastName': 'You', 'Affiliation': 'Univ Lyon, Université Claude Bernard Lyon 1, Faculté de médecine Lyon-Sud, Lyon, France. benoit.you@chu-lyon.fr.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Robelin', 'Affiliation': 'Univ Lyon, Université Claude Bernard Lyon 1, Faculté de médecine Lyon-Sud, Lyon, France.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Tod', 'Affiliation': 'Univ Lyon, Université Claude Bernard Lyon 1, Faculté de médecine Lyon-Sud, Lyon, France.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Louvet', 'Affiliation': ""L'Institut Mutualiste Montsouris, Service d'oncologie, GINECO, Paris, France.""}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Lotz', 'Affiliation': 'HÔPITAL TENON Oncologie médicale, GINECO, Paris, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Abadie-Lacourtoisie', 'Affiliation': ""Institut de Cancérologie de l'Ouest - ICO - Site Paul Papin, Oncologie médicale gynécologique, Angers, GINECO, Paris, France.""}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Fabbro', 'Affiliation': ""ICM Val d'Aurelle Parc Euromedecine, Oncologie médicale, Montpellier, GINECO, Paris, France.""}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Desauw', 'Affiliation': 'Centre Hospitalier Régional Universitaire de Lille, Oncologie médicale, Lille Cedex, GINECO, Paris, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Bonichon-Lamichhane', 'Affiliation': ""Clinique Tivoli, service d'oncologie, BORDEAUX, GINECO, Paris, France.""}, {'ForeName': 'Jean-Emmanuel', 'Initials': 'JE', 'LastName': 'Kurtz', 'Affiliation': ""Hôpitaux Universitaires de Strasbourg, Service d'Oncologie et d'Hématologie, Strasbourg, France.""}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Follana', 'Affiliation': ""CLCC Antoine Lacassagne, Département d'Hématologie - Oncologie médicale, NICE CEDEX 2, GINECO, Paris, France.""}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Leheurteur', 'Affiliation': 'CRCL Henri Becquerel, cancérologie Médicale, Rouen, GINECO, Paris, France.'}, {'ForeName': 'Francesco Del', 'Initials': 'FD', 'LastName': 'Piano', 'Affiliation': 'Hôpitaux de LEMAN, Chirurgie Gynécologique, THONON LES BAINS, GINECO, Paris, France.'}, {'ForeName': 'Gwénael', 'Initials': 'G', 'LastName': 'Ferron', 'Affiliation': 'Institut Claudius Regaud, Département de Chirurgie Oncologique, TOULOUSE, France.'}, {'ForeName': 'Gaëtan', 'Initials': 'G', 'LastName': 'De Rauglaudre', 'Affiliation': 'Institut Sainte-Catherine, Oncologie radiothérapie, Avignon, GINECO, Paris, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Ray-Coquard', 'Affiliation': 'Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, & Université Claude Bernard Lyon, Lyon, GINECO, Paris, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Combe', 'Affiliation': 'Hôpital Européen Georges Pompidou, Oncologie Médicale, GINECO, Paris, France.'}, {'ForeName': 'Annick', 'Initials': 'A', 'LastName': 'Chevalier-Place', 'Affiliation': 'Centre Oscar Lambret, cancérologie gynécologique, GINECO, Paris, France.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Joly', 'Affiliation': 'Centre François Baclesse, Oncologie Médicale, GINECO, Paris, France.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Leary', 'Affiliation': 'Institut Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Pujade-Lauraine', 'Affiliation': 'ARCAGY-GINECO, GINECO, GINEGEPS, Paris, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Freyer', 'Affiliation': 'Univ Lyon, Université Claude Bernard Lyon 1, Faculté de médecine Lyon-Sud, Lyon, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Colomban', 'Affiliation': 'Univ Lyon, Université Claude Bernard Lyon 1, Faculté de médecine Lyon-Sud, Lyon, France.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-0054'] 429,31915153,Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors.,"Sodium-glucose cotransport 2 inhibitors (SGLT2i) lower plasma glucose but stimulate endogenous glucose production (EGP). The current study examined the effect of dapagliflozin on EGP while clamping plasma glucose, insulin, and glucagon concentrations at their fasting level. Thirty-eight patients with type 2 diabetes received an 8-h measurement of EGP ([3- 3 H]-glucose) on three occasions. After a 3-h tracer equilibration, subjects received 1 ) dapagliflozin 10 mg ( n = 26) or placebo ( n = 12); 2 ) repeat EGP measurement with the plasma glucose concentration clamped at the fasting level; and 3 ) repeat EGP measurement with inhibition of insulin and glucagon secretion with somatostatin infusion and replacement of basal plasma insulin and glucagon concentrations. In study 1, the change in EGP (baseline to last hour of EGP measurement) in subjects receiving dapagliflozin was 22% greater (+0.66 ± 0.11 mg/kg/min, P < 0.05) than in subjects receiving placebo, and it was associated with a significant increase in plasma glucagon and a decrease in the plasma insulin concentration compared with placebo. Under glucose clamp conditions (study 2), the change in plasma insulin and glucagon concentrations was comparable in subjects receiving dapagliflozin and placebo, yet the difference in EGP between dapagliflozin and placebo persisted (+0.71 ± 0.13 mg/kg/min, P < 0.01). Under pancreatic clamp conditions (study 3), dapagliflozin produced an initial large decrease in EGP (8% below placebo), followed by a progressive increase in EGP that was 10.6% greater than placebo during the last hour. Collectively, these results indicate that 1 ) the changes in plasma insulin and glucagon concentration after SGLT2i administration are secondary to the decrease in plasma glucose concentration, and 2 ) the dapagliflozin-induced increase in EGP cannot be explained by the increase in plasma glucagon or decrease in plasma insulin or glucose concentrations.",2020,"Under glucose clamp conditions (Study 2), the change in plasma insulin and glucagon concentrations was comparable in subjects receiving dapagliflozin and placebo, yet the difference in EGP between dapagliflozin and placebo persisted (+0.71 ±0.13 mg/kg.min, p<0.01).",['38 T2DM patients'],"['dapagliflozin and placebo', 'dapagliflozin', 'placebo', '8-hour measurement of EGP', 'placebo (n=12); (ii) repeat EGP measurement with plasma glucose concentration clamped at the fasting level; (iii) repeat EGP measurement with inhibition of insulin and glucagon secretion with somatostatin infusion and replacement of basal plasma insulin and glucagon concentrations']","['plasma glucose concentration', 'EGP', 'change in EGP', 'progressive increase in EGP', 'change in plasma insulin and glucagon concentrations', 'plasma insulin and glucagon concentration', 'plasma insulin or glucose concentrations', 'EGP while clamping plasma glucose, insulin and glucagon concentrations', 'Plasma Insulin and Glucagon Concentrations', 'plasma insulin concentration', 'plasma glucagon']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1292429', 'cui_str': '8 hours (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C2584434', 'cui_str': 'Plasma glucose concentration'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0876232', 'cui_str': 'glucagon recombinant'}, {'cui': 'C0036537', 'cui_str': 'Secretions'}, {'cui': 'C0037659', 'cui_str': 'Somatostatin'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]","[{'cui': 'C2584434', 'cui_str': 'Plasma glucose concentration'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0876232', 'cui_str': 'glucagon recombinant'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1287281', 'cui_str': 'Finding of glucose concentration, dipstick (finding)'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C1278023', 'cui_str': 'Plasma glucagon measurement'}]",38.0,0.0926784,"Under glucose clamp conditions (Study 2), the change in plasma insulin and glucagon concentrations was comparable in subjects receiving dapagliflozin and placebo, yet the difference in EGP between dapagliflozin and placebo persisted (+0.71 ±0.13 mg/kg.min, p<0.01).","[{'ForeName': 'Mariam', 'Initials': 'M', 'LastName': 'Alatrach', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Nitchakarn', 'Initials': 'N', 'LastName': 'Laichuthai', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Martinez', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Agyin', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Ali Muhammed', 'Initials': 'AM', 'LastName': 'Ali', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Hussein', 'Initials': 'H', 'LastName': 'Al-Jobori', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Lavynenko', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Adams', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Curtis', 'Initials': 'C', 'LastName': 'Triplitt', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Ralph', 'Initials': 'R', 'LastName': 'DeFronzo', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX albarado@uthscsa.edu.'}, {'ForeName': 'Eugenio', 'Initials': 'E', 'LastName': 'Cersosimo', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}, {'ForeName': 'Muhammad', 'Initials': 'M', 'LastName': 'Abdul-Ghani', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.'}]",Diabetes,['10.2337/db19-0770'] 430,32207051,Venetoclax monotherapy induced rapid and sustained response in a frail patient with refractory AL amyloidosis: Less is more?,"Immunoglobulin light chain amyloidosis (AL) is a plasma cell disorder characterized by accumulation of misfolded proteins, which can induce organ damage. Venetoclax is active in multiple myeloma patients, in particular those with t(11;14) translocation. t(11;14) translocation is the most common cytogenetic abnormality in AL patients; venetoclax may thus be a useful additional treatment option for this disease. However, a recent trial in multiple myeloma patients (BELLINI) reported increased mortality associated with venetoclax versus placebo in combination with bortezomib and dexamethasone. In this report, we describe an AL patient who had suffered from recurrent infection during previous treatment, but who responded to and tolerated well single-agent venetoclax for more than 1 year. The present report indicates that venetoclax monotherapy may be active and safe for refractory AL amyloidosis.",2020,"Venetoclax is active in multiple myeloma patients, in particular those with t(11;14) translocation.","['frail patient with refractory AL amyloidosis', 'AL patient who had suffered from recurrent infection during previous treatment, but who responded to and tolerated well single-agent venetoclax for more than 1 year']","['venetoclax monotherapy', 'Venetoclax', 'Immunoglobulin light chain amyloidosis (AL', 'placebo', 'Venetoclax monotherapy', 'bortezomib and dexamethasone']",['mortality'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0268381', 'cui_str': 'AL Amyloidosis'}, {'cui': 'C0239998', 'cui_str': 'Recurrent infectious disease'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C4079830', 'cui_str': 'venetoclax'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C4079830', 'cui_str': 'venetoclax'}, {'cui': 'C0268381', 'cui_str': 'AL Amyloidosis'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}]",,0.0532864,"Venetoclax is active in multiple myeloma patients, in particular those with t(11;14) translocation.","[{'ForeName': 'Pui-Lun', 'Initials': 'PL', 'LastName': 'Yip', 'Affiliation': 'Department of Medicine, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong, SAR. ypl741@ha.org.hk.'}, {'ForeName': 'June S M', 'Initials': 'JSM', 'LastName': 'Lau', 'Affiliation': 'Department of Medicine, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong, SAR.'}, {'ForeName': 'Ching-Pong', 'Initials': 'CP', 'LastName': 'Lam', 'Affiliation': 'Department of Medicine, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong, SAR.'}]",International journal of hematology,['10.1007/s12185-020-02857-2'] 431,32207359,Oxytocin and vasopressin modulation of prisoner's dilemma strategies.,"BACKGROUND The neuropeptides oxytocin and vasopressin have been repeatedly implicated in social decision making by enhancing social salience and, generally, cooperation. The iterated and sequential version of the prisoner's dilemma (PD) game is a social dilemma paradigm eliciting strategies of cooperation versus competition. AIMS We aimed to characterise the role of PD players' sex, game partner type (computer vs. human) and oxytocin or vasopressin inhalation on the player's strategy preference. METHODS Participants (153 men; 151 women) were randomised to intranasal 24 IU oxytocin, 20 IU vasopressin or placebo, double-blind, and played the PD. We examined main and interactive effects of sex, drug and partner type on strategy preference. RESULTS We found a pervasive preference for a tit-for-tat strategy (i.e. general sensitivity to the partner's choices) over unconditional cooperation, particularly when against a human rather than a computer partner. Oxytocin doubled this sensitivity in women (i.e. the preference for tit-for-tat over unconditional cooperation strategies) when playing against computers, which suggests a tendency to anthropomorphise them, and doubled women's unconditional cooperation preference when playing against humans. Vasopressin doubled sensitivity to the partner's previous choices (i.e. for tit-for-tat over unconditional cooperation) across sexes and partner types. CONCLUSIONS These findings suggest that women may be more sensitive to oxytocin's social effects of anthropomorphism of non-humans and of unconditional cooperation with humans, which may be consistent with evolutionary pressures for maternal care, and that vasopressin, irrespective of sex and partner type, may be generally sensitising humans to others' behaviour.",2020,"The iterated and sequential version of the prisoner's dilemma (PD) game is a social dilemma paradigm eliciting strategies of cooperation versus competition. ",['Participants (153 men; 151 women'],"['oxytocin or vasopressin inhalation', 'intranasal 24\u2009IU oxytocin, 20\u2009IU vasopressin or placebo, double-blind, and played the PD', 'Oxytocin', 'Vasopressin']",[],"[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0201849', 'cui_str': 'Antidiuretic hormone measurement (procedure)'}, {'cui': 'C1705211', 'cui_str': 'Inhalation - unit of product usage'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0032214', 'cui_str': 'Play'}]",[],153.0,0.0510137,"The iterated and sequential version of the prisoner's dilemma (PD) game is a social dilemma paradigm eliciting strategies of cooperation versus competition. ","[{'ForeName': 'Maria Leonor', 'Initials': 'ML', 'LastName': 'Neto', 'Affiliation': 'Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Marília', 'Initials': 'M', 'LastName': 'Antunes', 'Affiliation': 'Centro de Estatística e Aplicações e Departamento de Estatística e Investigação Operacional, Faculdade de Ciências, Universidade de Lisboa, Lisbon, Portugal.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Lopes', 'Affiliation': 'INESC-ID, Instituto Superior Técnico, Lisbon, Portugal.'}, {'ForeName': 'Duarte', 'Initials': 'D', 'LastName': 'Ferreira', 'Affiliation': 'Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Rilling', 'Affiliation': 'Department of Anthropology, Emory University, Atlanta, USA.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Prata', 'Affiliation': ""Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881120913145'] 432,32403341,Measuring the Development of Therapeutic-Decision-Making Skills by Practicing Pharmacists Undertaking a University-Based Postgraduate Clinical Qualification at Distance.,"(1) Background: The processes and skills required to make decisions about drug therapy have been termed ""therapeutic decision-making"" in pharmacy practice. The aim of this study was to evaluate a tool constructed to measure the development of therapeutic-decision-making skills by practicing pharmacists undertaking a university-based continuing professional development program. (2) Methods: A pre- and post-intervention crossover study design was used to investigate the qualitative and quantitative features of practicing pharmacists' responses to two clinical vignettes designed to measure the development of therapeutic-decision-making skills. The vignettes were assigned a score using a five-point scale and compared pre- and post-intervention. (3) Results: There was a median increase in score of 2 units on the five-point scale in the post-intervention scores compared to pre-intervention ( p < 0.0001). (4) Conclusions: The results were interpreted to suggest that the participants' responses to the vignettes are a reasonable measure of student learning. Therefore, we infer that the teaching and learning intervention successfully enabled the development of therapeutic-decision-making skills by practicing pharmacists.",2020,There was a median increase in score of 2 units on the five-point scale in the post-intervention scores compared to pre-intervention ( p < 0.0001).,['practicing pharmacists undertaking a university-based continuing professional development program'],[],[],"[{'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0033333', 'cui_str': 'Program development'}]",[],[],,0.0271971,There was a median increase in score of 2 units on the five-point scale in the post-intervention scores compared to pre-intervention ( p < 0.0001).,"[{'ForeName': 'Daniel F B', 'Initials': 'DFB', 'LastName': 'Wright', 'Affiliation': 'School of Pharmacy, University of Otago, Dunedin 9054, New Zealand.'}, {'ForeName': 'Stephen B', 'Initials': 'SB', 'LastName': 'Duffull', 'Affiliation': 'School of Pharmacy, University of Otago, Dunedin 9054, New Zealand.'}, {'ForeName': 'Kyle J', 'Initials': 'KJ', 'LastName': 'Wilby', 'Affiliation': 'School of Pharmacy, University of Otago, Dunedin 9054, New Zealand.'}, {'ForeName': 'Aynsley K', 'Initials': 'AK', 'LastName': 'Peterson', 'Affiliation': 'School of Pharmacy, University of Otago, Dunedin 9054, New Zealand.'}, {'ForeName': 'Megan G', 'Initials': 'MG', 'LastName': 'Anakin', 'Affiliation': 'Education Unit, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.'}]","Pharmacy (Basel, Switzerland)",['10.3390/pharmacy8020083'] 433,32046418,An Integrated Efficacy and Safety Analysis of Single-Dose Secnidazole 2 g in the Treatment of Bacterial Vaginosis.,"Bacterial vaginosis (BV) is the most common gynecologic infection in women aged 14 to 49 years. Currently recommended treatments require extended dosing and are thus associated with poor adherence. A single-dose oral granule formulation of secnidazole 2 g (SOLOSEC™ [secnidazole], Symbiomix Therapeutics, a Lupin company, Baltimore, MD), a 5-nitroimidazole antibiotic with antimicrobial activity, has been approved by the US Food and Drug Administration for the treatment of BV in adult women. As part of the US registration package, two randomized, double-blind, placebo-controlled clinical studies were conducted to confirm the efficacy and safety of a novel single-dose oral formulation of secnidazole 2 g. This is an integrated analysis of efficacy and safety results from these studies, pivotal study 1 and pivotal study 2. By combining the results of the two studies, relevant information is presented especially when considering the effect of secnidazole on patients with recurrent episodes of BV and the difference in effect on patients of black race. Single-dose secnidazole 2 g was statistically superior to placebo on all primary and secondary efficacy outcomes in both trials, including clinical outcome responder rate (P < 0.001), achievement of Nugent scores in the normal range of 0 to 3 (P < 0.001), greater numbers of patients as therapeutic outcome responders at the test of cure/end of study visit on days 21-30 (P < 0.001), and fewer patients requiring additional treatment at the test of cure/end of study visit (P < 0.001), supporting the role for single oral dose secnidazole 2 g granules as treatment for women with BV.",2020,"g was statistically superior to placebo on all primary and secondary efficacy outcomes in both trials, including clinical outcome responder rate (P < 0.001), achievement of Nugent scores in the normal range of 0 to 3 (P < 0.001), greater numbers of patients as therapeutic outcome responders at the test of cure/end of study visit on days 21-30 (P < 0.001), and fewer patients requiring additional treatment at the test of cure/end of study visit (P < 0.001), supporting the role for single oral dose secnidazole 2 g granules as treatment for women with BV.","['women aged 14 to 49\xa0years', 'Bacterial Vaginosis', 'women with BV', 'adult women']","['placebo', 'secnidazole 2', 'Single-Dose Secnidazole', 'secnidazole']","['Bacterial vaginosis (BV', 'achievement of Nugent scores', 'clinical outcome responder rate', 'efficacy and safety']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0085166', 'cui_str': 'Vaginitis, Nonspecific'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0074246', 'cui_str': 'secnidazole'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C0085166', 'cui_str': 'Vaginitis, Nonspecific'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.140457,"g was statistically superior to placebo on all primary and secondary efficacy outcomes in both trials, including clinical outcome responder rate (P < 0.001), achievement of Nugent scores in the normal range of 0 to 3 (P < 0.001), greater numbers of patients as therapeutic outcome responders at the test of cure/end of study visit on days 21-30 (P < 0.001), and fewer patients requiring additional treatment at the test of cure/end of study visit (P < 0.001), supporting the role for single oral dose secnidazole 2 g granules as treatment for women with BV.","[{'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Pentikis', 'Affiliation': 'Symbiomix Therapeutics, LLC, 1101 E 33rd St, Suite E306, Baltimore, MD, 21218, USA. helenpentikis@lupin.com.'}, {'ForeName': 'Nikki', 'Initials': 'N', 'LastName': 'Adetoro', 'Affiliation': 'Symbiomix Therapeutics, LLC, 1101 E 33rd St, Suite E306, Baltimore, MD, 21218, USA.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Tipping', 'Affiliation': 'Prosoft Clinical, Wayne, PA, USA.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Levy', 'Affiliation': 'Prosoft Clinical, Wayne, PA, USA.'}]","Reproductive sciences (Thousand Oaks, Calif.)",['10.1007/s43032-019-00048-x'] 434,32183793,The effect of dialectical behaviour therapy in autism spectrum patients with suicidality and/ or self-destructive behaviour (DIASS): study protocol for a multicentre randomised controlled trial.,"BACKGROUND Many persons with autism spectrum disorder (ASD) are treated in long-term specialised care. In this population, suicidal behaviour troubles patients, families, and specialists in the field because it is difficult to treat. At present, there is no documented effective therapy for suicidal behaviour in ASD (Autism Research 7:507-521, 2014; Crisis 35:301-309, 2014). Dialectical Behaviour Therapy (DBT) is an efficacious treatment programme for chronically suicidal and/or self-harm behaviour in patients with Borderline Personality Disorder (J Psychiatry 166:1365-1374, 2014; Linehan MM. Cognitive behavioural therapy of borderline personality disorder. 1993). This study will evaluate the efficacy of DBT in persons with ASD and suicidal/ self- destructive behaviour in a multicentre randomised controlled clinical trial. METHOD One hundred twenty-eight persons with autism and suicidal and/or self-harming behaviour will be recruited from specialised mental healthcare services and randomised into two conditions: 1) the DBT condition in which the participants have weekly individual cognitive behavioural therapy sessions and a 2.5 h skills training group session twice per week during 6 months, and 2) the treatment as usual condition which consists of weekly individual therapy sessions of 30-45 min with a psychotherapist or social worker. Assessments will take place at baseline, at post-treatment (6 months), and after a follow-up period of 12 months. The mediators will also be assessed at 3 months. The primary outcome is the level of suicidal ideation and behaviour. The secondary outcomes are anxiety and social performance, depression, core symptoms of ASD, quality of life, and cost-utility. Emotion regulation and therapeutic alliance are hypothesised to mediate the effects on the primary outcome. DISCUSSION The results from this study will provide an evaluation of the efficacy of DBT treatment in persons with ASD on suicidal and self-harming behaviour. The study is conducted in routine mental health services which enhances the generalisability of the study results to clinical practice. TRIAL REGISTRATION ISRCTN96632579. Registered 1 May 2019. Retrospectively registered.",2020,Dialectical Behaviour Therapy (DBT) is an efficacious treatment programme for chronically suicidal and/or self-harm behaviour in patients with Borderline Personality Disorder (J Psychiatry,"['persons with ASD on suicidal and self-harming behaviour', 'patients with Borderline Personality Disorder (J Psychiatry', 'One hundred twenty-eight persons with autism and suicidal and/or self-harming behaviour will be recruited from specialised mental healthcare services and randomised into two conditions: 1) the DBT condition in which the participants have weekly', 'borderline personality disorder', 'autism spectrum patients with suicidality and/ or self-destructive behaviour (DIASS', 'persons with ASD', 'persons with autism spectrum disorder (ASD']","['individual cognitive behavioural therapy sessions and a 2.5\u2009h skills training group session twice per week during 6 months, and 2) the treatment as usual condition which consists of weekly individual therapy sessions of 30-45\u2009min with a psychotherapist or social worker', 'dialectical behaviour therapy', 'DBT', 'Cognitive behavioural therapy', 'Dialectical Behaviour Therapy (DBT']","['level of suicidal ideation and behaviour', 'anxiety and social performance, depression, core symptoms of ASD, quality of life, and cost-utility']","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0438696', 'cui_str': 'Suicidal (finding)'}, {'cui': 'C0085271', 'cui_str': 'Self-Injury'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0006012', 'cui_str': 'Borderline Personality Disorder'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0557829', 'cui_str': 'Healthcare services (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}]","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0559197', 'cui_str': 'Skills training (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0557555', 'cui_str': 'Psychotherapists'}, {'cui': 'C0037444', 'cui_str': 'Social worker (occupation)'}, {'cui': 'C1321145', 'cui_str': 'Dialectical Behavior Therapy'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0424000', 'cui_str': 'Suicidal Ideation'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034380'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",128.0,0.0928603,Dialectical Behaviour Therapy (DBT) is an efficacious treatment programme for chronically suicidal and/or self-harm behaviour in patients with Borderline Personality Disorder (J Psychiatry,"[{'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Huntjens', 'Affiliation': 'Parnassia Psychiatric Institute, The Hague, The Netherlands. a.huntjens@parnassia.nl.'}, {'ForeName': 'L M C Wies', 'Initials': 'LMCW', 'LastName': 'van den Bosch', 'Affiliation': 'Dialexis, Nijmegen; Synthis, Deventer, The Netherlands.'}, {'ForeName': 'Bram', 'Initials': 'B', 'LastName': 'Sizoo', 'Affiliation': 'Centre for Developmental Disorders, Dimence Institute of Mental Health, Deventer, The Netherlands.'}, {'ForeName': 'Ad', 'Initials': 'A', 'LastName': 'Kerkhof', 'Affiliation': 'Department of Clinical Psychology, VU University, Amsterdam, The Netherlands.'}, {'ForeName': 'Marcus J H', 'Initials': 'MJH', 'LastName': 'Huibers', 'Affiliation': 'Department of Clinical Psychology, VU University, Amsterdam, The Netherlands.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'van der Gaag', 'Affiliation': 'Parnassia Psychiatric Institute, The Hague, The Netherlands.'}]",BMC psychiatry,['10.1186/s12888-020-02531-1'] 435,32100943,Microbial contamination and plaque scores of nanogold-coated toothbrush.,"OBJECTIVE The study aimed to evaluate the microbial contamination and plaque scores of nanogold-coated and uncoated toothbrushes. METHODS This study was designed as a single-centre, parallel, examiner-blinded, randomized, two-group clinical trial. Eighty-four participants were enrolled and randomly assigned to receive either a nanogold or uncoated toothbrush. Basic periodontal therapy was performed for all the recruited subjects, and plaque scores of zero were considered baseline values. All participants were instructed to follow a twice-daily brushing regimen without dentifrice and to refrain from other oral hygiene care during the one-week study period. Plaque levels were assessed after one week using the Turesky modification of the Quigley-Hein Plaque Index (TMQHPI). The bristles were tested for microbial contamination by viable cell counting. The recorded data were statistically analysed, and a P-value of <.05 was accepted as statistically significant. RESULTS After one week of brushing without using toothpaste, the mean plaque index scores were 0.37 ± 0.07 in the nanogold group and 0.58 ± 0.10 in the uncoated group. A significant difference in the mean plaque scores was observed between the groups (P < .001). The mean colony-forming unit (CFU) was 21 ± 48.8 for the nanogold-coated group and 100 ± 128.4 for the uncoated group. The difference in the mean CFUs observed between the groups was significant (P = .014). CONCLUSION The use of a nanogold-coated toothbrush demonstrated significantly lower bristle contamination and lower plaque scores after one week compared with uncoated toothbrushes without using dentifrice.",2020,The use of a nano-gold coated toothbrush demonstrated significantly lower bristle contamination and lower plaque scores after one week compared with uncoated toothbrushes without using dentifrice.,['Eighty-four participants'],['nano-gold or uncoated toothbrush'],"['mean plaque index scores', 'Microbial contamination and plaque scores', 'microbial contamination and plaque scores', 'mean colony-forming unit (CFU', 'Plaque levels', 'mean plaque scores', 'mean CFUs', 'bristle contamination and lower plaque scores']","[{'cui': 'C4319623', 'cui_str': '84 (qualifier value)'}]","[{'cui': 'C0018026', 'cui_str': 'Gold'}, {'cui': 'C0183975', 'cui_str': 'Toothbrush, device (physical object)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0553561', 'cui_str': 'colony-forming unit (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}]",84.0,0.0277366,The use of a nano-gold coated toothbrush demonstrated significantly lower bristle contamination and lower plaque scores after one week compared with uncoated toothbrushes without using dentifrice.,"[{'ForeName': 'Pavithra', 'Initials': 'P', 'LastName': 'Durgesh', 'Affiliation': 'Department of Periodontology and Oral implantology, Bangalore Institute of Dental Sciences and Research Centre, Bangalore, India.'}, {'ForeName': 'Srirangarajan', 'Initials': 'S', 'LastName': 'Sridharan', 'Affiliation': 'Department of Periodontology and Oral implantology, Bangalore Institute of Dental Sciences and Research Centre, Bangalore, India.'}, {'ForeName': 'Srikumar K', 'Initials': 'SK', 'LastName': 'Prabhu', 'Affiliation': 'Department of Periodontology and Oral implantology, Bangalore Institute of Dental Sciences and Research Centre, Bangalore, India.'}, {'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Rao', 'Affiliation': 'Department of Periodontology and Oral implantology, Bangalore Institute of Dental Sciences and Research Centre, Bangalore, India.'}, {'ForeName': 'Vinaya', 'Initials': 'V', 'LastName': 'Rudresh', 'Affiliation': 'Department of Periodontology and Oral implantology, Bangalore Institute of Dental Sciences and Research Centre, Bangalore, India.'}, {'ForeName': 'Durgesh', 'Initials': 'D', 'LastName': 'H Bangalore', 'Affiliation': 'Dental Health Department, College of Applied Medical Sciences, King Saud University, Riyadh, Kingdom of Saudi Arabia.'}]",International journal of dental hygiene,['10.1111/idh.12433'] 436,31343517,"Acute Soy Supplementation Improves 20-km Time Trial Performance, Power, and Speed.","INTRODUCTION Isoflavones, a chemical class of phytoestrogens found in soybeans and soy products, may have biological functions similar to estradiol. After binding with ERβ or perhaps independently of estrogen receptors, isoflavones may augment vascular endothelial relaxation, contributing to improved limb blood flow. PURPOSE To determine if acute fermented soy extract supplementation influences 20-km time trial cycling performance and cardiac hemodynamics compared with a placebo. METHODS Subjects included 25 cyclists and triathletes (31 ± 8 yr, V˙O2peak: 55.1 ± 8.4 mL·kg·min). Each subject completed a V˙O2peak assessment, familiarization, and two 20-km time trials in randomized order after ingestion of a fermented soy extract supplement or placebo. The fermented soy extract consisted of 30 g powdered supplement in 16 fl. ounces of water. The placebo contained the same quantities of organic cocoa powder and water. Each trial consisted of 60 min of rest, 30 min at 55% Wpeak, and a self-paced 20-km time trial. RESULTS Soy supplementation elicited a faster time to 20-km completion (-0.22 ± 0.51 min; -13 s), lower average HR (-5 ± 7 bpm), and significantly greater power (7 ± 3 W) and speed (0.42 ± 0.16 km·h) during the last 5 km of the time trial compared with placebo. Analysis of the results by relative fitness level (<57 vs ≥ 57 mL⋅kg⋅min) indicated that those with a higher level of fitness reaped the largest performance improvement alongside a reduced HR (-5 ± 7 bpm). CONCLUSIONS Ingestion of a fermented soy extract supplement improved sprint-distance performance through improvements in both power and speed. For those with great aerobic fitness, soy supplementation may help to decrease cardiac demand alongside performance improvement.",2020,"RESULTS Soy supplementation elicited a faster time to 20km completion (-0.22 ± 0.10 min; -37 s), lower average heart rate (-5 ± 1 bpm), and significantly greater power (7 ± 3 W) and speed (0.42 ± 0.16 km•h) during the last 5 km of the time trial compared to placebo.","['Subjects included twenty-five cyclists and triathletes (31 ± 8 y, VO2peak: 55.1 ± 8.4 mL·kg·min']","['Acute Soy Supplementation', 'soy extract supplementation', 'placebo', 'fermented soy extract supplement', 'fermented soy extract supplement or placebo']","['20-km time trial cycling performance and cardiac hemodynamics', 'limb blood flow', 'heart rate', 'sprint-distance performance', 'faster time to 20km completion', 'lower average heart rate', '20-km Time Trial Performance, Power, and Speed']","[{'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C4517876', 'cui_str': '8.4'}]","[{'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0015385', 'cui_str': 'Limbs'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}]",,0.380526,"RESULTS Soy supplementation elicited a faster time to 20km completion (-0.22 ± 0.10 min; -37 s), lower average heart rate (-5 ± 1 bpm), and significantly greater power (7 ± 3 W) and speed (0.42 ± 0.16 km•h) during the last 5 km of the time trial compared to placebo.","[{'ForeName': 'Afton D', 'Initials': 'AD', 'LastName': 'Seeley', 'Affiliation': 'Laboratory of Clinical and Applied Physiology, University of Miami, Coral Gables, FL.'}, {'ForeName': 'Kevin A', 'Initials': 'KA', 'LastName': 'Jacobs', 'Affiliation': 'Laboratory of Clinical and Applied Physiology, University of Miami, Coral Gables, FL.'}, {'ForeName': 'Joseph F', 'Initials': 'JF', 'LastName': 'Signorile', 'Affiliation': 'Laboratory of Neuromuscular Research and Active Aging, University of Miami, Coral Gables, FL.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002102'] 437,31343518,Athlete-Opponent Interdependency Alters Pacing and Information-Seeking Behavior.,"PURPOSE The influence of interdependency between competitors on pacing decision-making and information-seeking behavior has been explored. This has been done by only altering instructions, and thereby action possibilities, while controlling environment (i.e., competitor behavior) and exercise task. METHODS Twelve participants performed a 4-km time trial on a Velotron cycle ergometer in a randomized, counterbalanced order alone with no virtual opponent (NO), against a virtual opponent with no restrictions (low athlete-opponent interdependency [OP-IND]), or against a virtual opponent who the participant was permitted to overtake only once during the trial (high athlete-opponent interdependency [OP-DEP]). Information-seeking behavior was evaluated using an SMI eye tracker. Differences in pacing, performance, and information-seeking behavior were examined using repeated-measures ANOVA (P < 0.05). RESULTS Neither mean power output (NO, 298 ± 35 W; OP-IND, 297 ± 38 W; OP-DEP, 296 ± 37 W) nor finishing time (NO, 377.7 ± 17.4 s; OP-IND, 379.3 ± 19.5 s; OP-DEP, 378.5 ± 17.7 s) differed between experimental conditions. However, power output was lower in the first kilometer of OP-DEP compared with the other experimental conditions (NO, 332 ± 59 W; OP-IND, 325 ± 62 W; OP-DEP, 316 ± 58 W; both P < 0.05), and participants decided to wait longer before they overtook their opponent (OP-IND, 137 ± 130 s; OP-DEP, 255 ± 107 s; P = 0.040). Moreover, total fixation time spent on the avatar of the virtual opponent increased when participants were only allowed to overtake once (OP-IND, 23.3 ± 16.6 s; OP-DEP, 55.8 ± 32.7 s; P = 0.002). CONCLUSION A higher interdependency between athlete and opponent altered pacing behavior in terms of in-race adaptations based on opponent's behavior, and it induced an increased attentional focus on the virtual opponent. Thus, in the context of exercise regulation, attentional cues are likely to be used in an adaptive way according to their availability and situational relevance, consistent with a decision-making framework based on the interdependence of perception and action.",2020,"Differences in pacing, performance and information-seeking behavior were examined using repeated-measures ANOVA (p<0.05). ",['Twelve participants performed a 4-km time-trial on a'],"['counterbalanced order alone with no virtual opponent (NO), against a virtual opponent with no restrictions (low athlete-opponent interdependency; OP-IND), or against a virtual opponent who the participant was permitted to overtake only once during the trial (high athlete-opponent interdependency; OP-DEP', 'Velotron cycle ergometer']","['power output', 'total fixation time spent on the avatar of the virtual opponent', 'pacing, performance and information-seeking behavior']","[{'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C1632851', 'cui_str': 'Times'}]","[{'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0023636', 'cui_str': 'Permits'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0057472', 'cui_str': '1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride'}]","[{'cui': 'C0445194', 'cui_str': 'Power output (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0562458', 'cui_str': 'Pacing up and down (finding)'}, {'cui': 'C0596775', 'cui_str': 'Information Seeking Behavior'}]",12.0,0.0165217,"Differences in pacing, performance and information-seeking behavior were examined using repeated-measures ANOVA (p<0.05). ","[{'ForeName': 'Marco J', 'Initials': 'MJ', 'LastName': 'Konings', 'Affiliation': 'School of Sport, Rehabilitation and Exercise Sciences, University of Essex, Colchester, UNITED KINGDOM.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Foulsham', 'Affiliation': 'Department of Psychology, University of Essex, Colchester, UNITED KINGDOM.'}, {'ForeName': 'Dominic', 'Initials': 'D', 'LastName': 'Micklewright', 'Affiliation': 'School of Sport, Rehabilitation and Exercise Sciences, University of Essex, Colchester, UNITED KINGDOM.'}, {'ForeName': 'Florentina J', 'Initials': 'FJ', 'LastName': 'Hettinga', 'Affiliation': 'School of Sport, Rehabilitation and Exercise Sciences, University of Essex, Colchester, UNITED KINGDOM.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002101'] 438,31343521,Low-Frequency HIIT Improves Body Composition and Aerobic Capacity in Overweight Men.,"BACKGROUND The relationship between the frequency of high-intensity interval training (HIIT) and the resultant adaptations is largely unclear. PURPOSE This study compared the effects of different frequencies of HIIT with those of moderate-intensity continuous training (MICT) on body composition in overweight or obese adults. METHODS Fifty-six overweight or obese (body mass index = 26.4 ± 2.9) men between 18 and 30 yr old (age = 22.8 ± 3.1 yr) were randomly assigned to the following groups: no-intervention control (CON; n = 14), MICT performed thrice weekly (MICT×3/wk; n = 9), HIIT performed thrice weekly (HIIT×3/wk; n = 14), HIIT performed twice weekly (HIIT×2/wk; n = 10), and HIIT performed once weekly (HIIT×1/wk; n = 9). Each HIIT session consisted of 12 × 1-min bouts at 90% heart rate reserve, interspersed with 11 × 1-min bouts at 70% heart rate reserve. Aerobic capacity, body composition, resting heart rate, vascular function, insulin resistance, and biomarkers of metabolic syndrome risk factor were examined at baseline, after 4 wk, and after 8 wk of intervention. RESULTS Aerobic capacity and percent fat-free mass significantly increased in all exercise groups compared with those in the CON group (CON vs all exercise groups, P < 0.05), whereas body fat mass and systolic blood pressure significantly decreased after 8 wk of intervention in all exercise groups compared with those in the CON group (CON vs all exercise groups, P < 0.05). Body fat mass significantly decreased after 4 wk in all HIIT groups compared with those in the CON group (CON vs all HIIT groups, P < 0.05) but not in the MICT×3/wk group. CONCLUSION These novel results demonstrated that performing HIIT once weekly, even with a lower weekly volume of exercise, improved cardiorespiratory fitness, body composition, and blood pressure in overweight/obese adults. Low-frequency HIIT might be a feasible and effective strategy for the prescription of an initial exercise program for inactive, overweight, or obese young men.",2020,"RESULTS Aerobic capacity and percent fat-free mass significantly increased in all exercise groups compared with those in the CON group (CON vs. all exercise groups: p<0.05), whereas body fat mass and systolic blood pressure significantly decreased after 8 weeks of intervention in all exercise groups compared with those in the CON group (CON vs. all exercise groups: p<0.05).","['overweight or obese', 'overweight/obese adults', 'BMI: 26.4±2.9) men aged between 18 and 30 years (age: 22.8±3.1', 'obese young men', 'overweight or obese adults', 'Fifty-six', 'Overweight Men']","['no-intervention control (CON; n=14), MICT', 'high-intensity interval training (HIIT', 'moderate-intensity continuous training (MICT', 'CON']","['cardiorespiratory fitness, body composition, and blood pressure', 'body composition', 'Body Composition and Aerobic Capacity', 'Aerobic capacity, body composition, resting heart rate, vascular function, insulin resistance, and biomarkers of metabolic syndrome risk factor', 'Body fat mass', 'Aerobic capacity and percent fat-free mass', 'body fat mass and systolic blood pressure']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4277545', 'cui_str': 'High-Intensity Intermittent Exercise'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C1821417', 'cui_str': 'Resting heart rate (observable entity)'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0524620', 'cui_str': 'Metabolic Syndrome X'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass (observable entity)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}]",56.0,0.0266858,"RESULTS Aerobic capacity and percent fat-free mass significantly increased in all exercise groups compared with those in the CON group (CON vs. all exercise groups: p<0.05), whereas body fat mass and systolic blood pressure significantly decreased after 8 weeks of intervention in all exercise groups compared with those in the CON group (CON vs. all exercise groups: p<0.05).","[{'ForeName': 'Edwin C', 'Initials': 'EC', 'LastName': 'Chin', 'Affiliation': 'Division of Kinesiology, School of Public Health, The University of Hong Kong, Pokfulam, HONG KONG.'}, {'ForeName': 'Angus P', 'Initials': 'AP', 'LastName': 'Yu', 'Affiliation': 'Division of Kinesiology, School of Public Health, The University of Hong Kong, Pokfulam, HONG KONG.'}, {'ForeName': 'Christopher W', 'Initials': 'CW', 'LastName': 'Lai', 'Affiliation': 'Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, HONG KONG.'}, {'ForeName': 'Daniel Y', 'Initials': 'DY', 'LastName': 'Fong', 'Affiliation': 'School of Nursing, The University of Hong Kong, Pokfulam, HONG KONG.'}, {'ForeName': 'Derwin K', 'Initials': 'DK', 'LastName': 'Chan', 'Affiliation': 'Division of Kinesiology, School of Public Health, The University of Hong Kong, Pokfulam, HONG KONG.'}, {'ForeName': 'Stephen H', 'Initials': 'SH', 'LastName': 'Wong', 'Affiliation': 'Department of Sports Science and Physical Education, The Chinese University of Hong Kong, Pokfulam, HONG KONG.'}, {'ForeName': 'Fenghua', 'Initials': 'F', 'LastName': 'Sun', 'Affiliation': 'Department of Health and Physical Education, The Education University of Hong Kong, Pokfulam, HONG KONG.'}, {'ForeName': 'Heidi H', 'Initials': 'HH', 'LastName': 'Ngai', 'Affiliation': 'Dietitic Clinic, School of Professional and Continuing Education, The University of Hong Kong, Pokfulam, HONG KONG.'}, {'ForeName': 'Patrick S H', 'Initials': 'PSH', 'LastName': 'Yung', 'Affiliation': 'Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Pokfulam, HONG KONG.'}, {'ForeName': 'Parco M', 'Initials': 'PM', 'LastName': 'Siu', 'Affiliation': 'Division of Kinesiology, School of Public Health, The University of Hong Kong, Pokfulam, HONG KONG.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002097'] 439,31834251,Physical Activity Is Higher in Patients with Left Ventricular Assist Device Compared with Chronic Heart Failure.,"PURPOSE Left ventricular assist devices (LVAD) are associated with an increased aerobic capacity in patients with chronic heart failure (CHF). However, studies evaluating the impact of LVAD implantation on physical activity (PA) are lacking. The aim of this study was to compare daily PA levels in participants with LVAD with well-matched CHF participants. METHODS Sixteen participants with an LVAD (age, 59.1 ± 10.8 yr) were case-matched to 16 participants with advanced CHF (age, 58.3 ± 8.7 yr), who were listed or being considered for cardiac transplantation. Participants underwent a cardiopulmonary exercise test to determine peak oxygen consumption (V˙O2 peak). Physical activity was monitored continuously for seven consecutive days with an Actiheart monitor. RESULTS V˙O2 peak in the CHF group (12.3 ± 3.5 mL·kg·min) was not significantly different to the LVAD group before LVAD implantation (10.4 ± 2.1 mL·kg·min), but was lower than in the LVAD group after implantation (15.8 ± 4.3 mL·kg·min; P < 0.05). Physical activity was higher in the LVAD (19.7 ± 6.4 kJ·kg·d) compared with the CHF group (11.6 ± 6.9 kJ·kg·d; P = 0.001). The LVAD participants spent more time performing moderate-intensity PA than their CHF counterparts (median, 26 min·d; interquartile range, 24-40 min·d vs median, 12 min·d; interquartile range, 9-16 min·d; P < 0.001). Physical activity was correlated with V˙O2 peak (r = 0.582; P = 0.001) across participants in the CHF and LVAD groups. CONCLUSIONS Higher levels of PA were observed in participants with LVAD compared with patients with advanced CHF. This may be due to a higher V˙O2 peak, resulting in an improved capacity to perform activities of daily living with less symptoms.",2020,Physical activity was higher in the LVAD (19.7 ± 6.4 kJ·kg·d) compared with the CHF group (11.6 ± 6.9 kJ·kg·d; P = 0.001).,"['patients with chronic heart failure (CHF', 'participants with LVAD with well-matched CHF participants', 'Sixteen participants with an LVAD (age, 59.1 ± 10.8 yr) were case-matched to 16 participants with advanced CHF (age, 58.3 ± 8.7 yr), who were listed or being considered for cardiac transplantation']","['LVAD', 'cardiopulmonary exercise test', 'Left ventricular assist devices (LVAD', 'LVAD implantation']","['peak oxygen consumption (V˙O2 peak', 'Physical activity', 'aerobic capacity', 'time performing moderate-intensity PA', 'V˙O2 peak', 'Physical Activity', 'daily PA levels']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0264716', 'cui_str': 'Chronic heart failure (disorder)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517523', 'cui_str': '10.8'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C4517880', 'cui_str': '8.7 (qualifier value)'}, {'cui': 'C0018823', 'cui_str': 'Transplantation, Cardiac'}]","[{'cui': 'C2959886', 'cui_str': 'Cardiopulmonary Exercise Test'}, {'cui': 'C0181598', 'cui_str': 'Left ventricular assist device'}, {'cui': 'C0021107', 'cui_str': 'Insertion procedure'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C1305742', 'cui_str': 'Oxygen consumption'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",16.0,0.08397,Physical activity was higher in the LVAD (19.7 ± 6.4 kJ·kg·d) compared with the CHF group (11.6 ± 6.9 kJ·kg·d; P = 0.001).,"[{'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Moreno-Suarez', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, AUSTRALIA.'}, {'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Liew', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, AUSTRALIA.'}, {'ForeName': 'Lawrence G', 'Initials': 'LG', 'LastName': 'Dembo', 'Affiliation': 'Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Murdoch, AUSTRALIA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Larbalestier', 'Affiliation': 'Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Murdoch, AUSTRALIA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Maiorana', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, AUSTRALIA.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002104'] 440,31834252,Effects of Exercise Training and Statin Use in People Living with Human Immunodeficiency Virus with Dyslipidemia.,"PURPOSE To evaluate the effects of the combination of exercise training (ET) and statins in people living with human immunodeficiency virus. METHODS This was a randomized, double-blind, placebo-controlled clinical trial. Eighty-three people living with human immunodeficiency virus were assigned to either placebo (PL), statins (STA), PL + ET (PLET) or STA + ET (STAET) groups. Volunteers assigned to STA and STAET groups were administered 10 mg of rosuvastatin, whereas the PL and PLET groups were administered a placebo. The PLET and STAET groups performed ET three times a week. Before and after the 12-wk follow-up, the volunteers underwent to anthropometric assessment and blood collection to evaluate lipid profile, cardiovascular markers, inflammatory profile; a Doppler ultrasound examination, muscle strength (MS) and cardiorespiratory fitness (CF) tests were performed. RESULTS There was a decrease in total cholesterol, triglycerides, low-density lipoprotein, C-reactive protein, fibrinogen, interleukin (IL)-1β and right carotid intima-media thickness in the STA, PLET, and STAET groups compared with PL group (P < 0.001). Furthermore, there was a decrease in total cholesterol, triglycerides, low-density lipoprotein, IL-1β, IL-6, and IL-8 levels and in left and right carotid intima-media thickness and an increase in HDL-c levels in the STAET groups compared with the STA (P ≤ 0.001) and PLET groups (P ≤ 0.001). There was an increase in IL-10 levels, peak-systolic velocity, end-diastolic velocity, wall shear rate in the PLET and STAET groups compared with the PL (P ≤ 0.001) and STA groups (P ≤ 0.001). The PLET and STAET groups reduced body fat mass, body fat percentage and increased lean body mass, MS and CF compared with PL (P ≤ 0.001) and STA (P ≤ 0.001) groups. CONCLUSIONS The combination of ET and statins is useful to enhance lipid and inflammatory profiles, reduce cardiovascular disease markers, and improve Doppler ultrasound findings, MS and CF in people living with HIV.",2020,"There was a decrease in total cholesterol, triglycerides, low-density lipoprotein, C-reactive protein, fibrinogen, interleukin (IL)-1β and right carotid intima-media thickness in the STA, PLET, and STAET groups compared with PL group (P < 0.001).","['People Living with Human Immunodeficiency Virus with Dyslipidemia', 'people living with human immunodeficiency virus', 'people living with HIV', 'Eighty-three people living with human immunodeficiency virus']","['STA', 'placebo', 'exercise training (ET) and statins', 'rosuvastatin', 'placebo (PL), statins (STA), PL + ET (PLET) or STA + ET (STAET', 'Exercise Training and Statin Use']","['IL-10 levels, peak-systolic velocity, end-diastolic velocity, wall shear rate', 'total cholesterol, triglycerides, low-density lipoprotein, C-reactive protein, fibrinogen, interleukin (IL)-1β and right carotid intima-media thickness', 'total cholesterol, triglycerides, low-density lipoprotein, IL-1β, IL-6, and IL-8 levels and in left and right carotid intima-media thickness', 'lipid profile, cardiovascular markers, inflammatory profile; a Doppler ultrasound examination, muscle strength (MS) and cardiorespiratory fitness (CF) tests', 'HDL-c levels', 'body fat mass, body fat percentage and increased lean body mass, MS and CF']","[{'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemias'}, {'cui': 'C4517888', 'cui_str': '83'}]","[{'cui': 'C1529286', 'cui_str': 'stas'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C1947944', 'cui_str': 'Use'}]","[{'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0442710', 'cui_str': 'Peak systolic, function (observable entity)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0205380', 'cui_str': 'Walled (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0982156', 'cui_str': 'fibrinogen (125I)'}, {'cui': 'C0021764', 'cui_str': 'Interleukins'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0162864', 'cui_str': 'Vascular Intima'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0162481', 'cui_str': 'Doppler Ultrasound'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass (observable entity)'}]",83.0,0.140864,"There was a decrease in total cholesterol, triglycerides, low-density lipoprotein, C-reactive protein, fibrinogen, interleukin (IL)-1β and right carotid intima-media thickness in the STA, PLET, and STAET groups compared with PL group (P < 0.001).","[{'ForeName': 'Hugo Ribeiro', 'Initials': 'HR', 'LastName': 'Zanetti', 'Affiliation': 'Postgraduate Program in Health Science, Faculty of Medicine, Federal University of Uberlândia, Uberlândia/MG, BRAZIL.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Gonçalves', 'Affiliation': 'Master Institute of Education President Antônio Carlos, Araguari/MG, BRAZIL.'}, {'ForeName': 'Leandro', 'Initials': 'L', 'LastName': 'Teixeira Paranhos Lopes', 'Affiliation': 'Department of Medicine, Brazil University, Fernandópolis/SP, BRAZIL.'}, {'ForeName': 'Edmar Lacerda', 'Initials': 'EL', 'LastName': 'Mendes', 'Affiliation': 'Institute of Health Sciences, Department of Sport Sciences, Federal University of Triângulo Mineiro, Uberaba/MG, BRAZIL.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Roever', 'Affiliation': 'Postgraduate Program in Health Science, Faculty of Medicine, Federal University of Uberlândia, Uberlândia/MG, BRAZIL.'}, {'ForeName': 'Mário Leon', 'Initials': 'ML', 'LastName': 'Silva-Vergara', 'Affiliation': 'Institute of Health Sciences, Department of Medical Clinics, Clinics Hospital, Federal University of Triângulo Mineiro, Uberaba/MG, BRAZIL.'}, {'ForeName': 'Fernando Freitas', 'Initials': 'FF', 'LastName': 'Neves', 'Affiliation': 'Institute of Health Sciences, Department of Medical Clinics, Clinics Hospital, Federal University of Triângulo Mineiro, Uberaba/MG, BRAZIL.'}, {'ForeName': 'Elmiro Santos', 'Initials': 'ES', 'LastName': 'Resende', 'Affiliation': 'Postgraduate Program in Health Science, Faculty of Medicine, Federal University of Uberlândia, Uberlândia/MG, BRAZIL.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002120'] 441,32198638,When Testosterone Needs to be Contrasted: A Preliminary Study of Scar Prevention in Transmen Top Surgery with an Innovative Galenic Preparation.,"BACKGROUND Transmen are individuals who live a marked incongruence between the assigned gender and the experienced gender. Crucial and life-changing steps in their transition are testosterone treatment and mastectomy to remove the stigma of feminine identity. After surgery, patients' attention turns to the scars, often not aesthetically pleasant. We thus created an innovative galenic preparation for scar treatment after surgery composed by spironolactone, alfa bisabolol and silicone gel. Functional outcomes, side effects and satisfaction were assessed. METHODS For the present prospective randomized controlled study, 30 patients with similar demographic characteristics who underwent double incision mastectomy with NA grafts between February 2014 and June 2019 were selected. The treatment Group A (n = 15) was treated for 12 months with ""Top Surgery Scar go,"" the control Group B (n = 15) with silicon gel. Statistical analysis including Wilcoxon test and Kruskal-Wallis test per variable was performed. To assess satisfaction, a second Wilcoxon test was applied. RESULTS The differences between Group A and Group B were statistically significant, especially at T12 with very low p values. Satisfaction was greater in Group A (p value = 3e-4). No major side effects were noticed in Group A. CONCLUSIONS TSSgo scar innovative treatment showed long-term efficacy in comparison with silicon gel in terms of improved scar tissue texture, pigmentation, pliability and height. It is easy to set up, cost-effective and safe. Further studies are necessary to better assess efficacy and validity of TSSgo, but it appears to be promising as the new treatment of reference for scar management after top surgery in transmen. LEVEL OF EVIDENCE IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.",2020,"TSSgo scar innovative treatment showed long-term efficacy in comparison with silicon gel in terms of improved scar tissue texture, pigmentation, pliability and height.",['30 patients with similar demographic characteristics who underwent double incision mastectomy with NA grafts between February 2014 and June 2019 were selected'],"['IV', 'Top Surgery Scar go,"" the control Group B (n\u2009=\u200915) with silicon gel', 'spironolactone, alfa bisabolol and silicone gel']","['scar tissue texture, pigmentation, pliability and height', 'Functional outcomes, side effects and satisfaction', 'cost-effective and safe', 'Wilcoxon test and Kruskal-Wallis test', 'Satisfaction']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0184898', 'cui_str': 'Incision - attribute'}, {'cui': 'C0024886', 'cui_str': 'Total Mastectomy'}, {'cui': 'C1527362', 'cui_str': 'grafts'}]","[{'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0008767', 'cui_str': 'Cicatrization'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037107', 'cui_str': 'Silicon'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C0037982', 'cui_str': 'Spironolactone'}, {'cui': 'C0053774', 'cui_str': 'bisabolol'}, {'cui': 'C0599034', 'cui_str': 'Silicone Gels'}]","[{'cui': 'C2004491', 'cui_str': 'Scars'}, {'cui': 'C0449582', 'cui_str': 'With texture (attribute)'}, {'cui': 'C0031911', 'cui_str': 'Pigmentation'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",30.0,0.0507789,"TSSgo scar innovative treatment showed long-term efficacy in comparison with silicon gel in terms of improved scar tissue texture, pigmentation, pliability and height.","[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Tanini', 'Affiliation': 'Department of Plastic and Reconstructive Microsurgery, Careggi University Hospital, Florence, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Calabrese', 'Affiliation': 'Department of Plastic and Reconstructive Microsurgery, Careggi University Hospital, Florence, Italy.'}, {'ForeName': 'Alessandra D', 'Initials': 'AD', 'LastName': 'Fisher', 'Affiliation': 'Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, Florence, Italy.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Maggi', 'Affiliation': 'Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, Florence, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Lo Russo', 'Affiliation': 'Department of Plastic and Reconstructive Microsurgery, Careggi University Hospital, Florence, Italy. giulialorusso70@gmail.com.'}]",Aesthetic plastic surgery,['10.1007/s00266-020-01678-2'] 442,31974142,PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid.,"The cardiovascular benefits of fibrates have been shown to be heterogeneous and to depend on the presence of atherogenic dyslipidemia. We investigated whether genetic variability in the PPARA gene, coding for the pharmacological target of fibrates (PPAR-α), could be used to improve the selection of patients with type 2 diabetes who may derive cardiovascular benefit from addition of this treatment to statins. We identified a common variant at the PPARA locus (rs6008845, C/T) displaying a study-wide significant influence on the effect of fenofibrate on major cardiovascular events (MACE) among 3,065 self-reported white subjects treated with simvastatin and randomized to fenofibrate or placebo in the ACCORD-Lipid trial. T/T homozygotes (36% of participants) experienced a 51% MACE reduction in response to fenofibrate (hazard ratio 0.49; 95% CI 0.34-0.72), whereas no benefit was observed for other genotypes ( P interaction = 3.7 × 10 -4 ). The rs6008845-by-fenofibrate interaction on MACE was replicated in African Americans from ACCORD ( N = 585, P = 0.02) and in external cohorts (ACCORD-BP, ORIGIN, and TRIUMPH, total N = 3059, P = 0.005). Remarkably, rs6008845 T/T homozygotes experienced a cardiovascular benefit from fibrate even in the absence of atherogenic dyslipidemia. Among these individuals, but not among carriers of other genotypes, fenofibrate treatment was associated with lower circulating levels of CCL11-a proinflammatory and atherogenic chemokine also known as eotaxin ( P for rs6008845-by-fenofibrate interaction = 0.003). The GTEx data set revealed regulatory functions of rs6008845 on PPARA expression in many tissues. In summary, we have found a common PPARA regulatory variant that influences the cardiovascular effects of fenofibrate and that could be used to identify patients with type 2 diabetes who would derive benefit from fenofibrate treatment, in addition to those with atherogenic dyslipidemia.",2020,T/T homozygotes (36% of participants) experienced a 51% MACE reduction in response to fenofibrate (HR=0.49; 95%C.I. 0.34-0.72) whereas no benefit was observed for other genotypes (p for interaction=3.7x10 -4 ).,"['Type 2 Diabetes', '3,065 self-reported White subjects treated with', 'patients with type 2 diabetes']","['Fenofibrate', 'simvastatin', 'fenofibrate', 'fenofibrate or placebo']","['circulating levels of CCL11 - a pro-inflammatory and atherogenic chemokine', 'major cardiovascular events (MACE']","[{'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0033228', 'cui_str': 'Fenofibrate'}, {'cui': 'C0074554', 'cui_str': 'Simvastatin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0282554', 'cui_str': 'Cytokines, Chemotactic'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0349381', 'cui_str': 'Mace (substance)'}]",,0.0503884,T/T homozygotes (36% of participants) experienced a 51% MACE reduction in response to fenofibrate (HR=0.49; 95%C.I. 0.34-0.72) whereas no benefit was observed for other genotypes (p for interaction=3.7x10 -4 ).,"[{'ForeName': 'Mario Luca', 'Initials': 'ML', 'LastName': 'Morieri', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA.'}, {'ForeName': 'Hetal S', 'Initials': 'HS', 'LastName': 'Shah', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Sjaarda', 'Affiliation': 'McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada.'}, {'ForeName': 'Petra A', 'Initials': 'PA', 'LastName': 'Lenzini', 'Affiliation': 'Department of Genetics, Washington University School of Medicine, St. Louis, MO.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Campbell', 'Affiliation': 'Department of Genetics, Washington University School of Medicine, St. Louis, MO.'}, {'ForeName': 'Alison A', 'Initials': 'AA', 'LastName': 'Motsinger-Reif', 'Affiliation': 'Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Durham, NC.'}, {'ForeName': 'He', 'Initials': 'H', 'LastName': 'Gao', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Lovato', 'Affiliation': 'Wake Forest School of Medicine, Winston Salem, NC.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Prudente', 'Affiliation': 'Research Unit of Metabolic and Cardiovascular Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.'}, {'ForeName': 'Assunta', 'Initials': 'A', 'LastName': 'Pandolfi', 'Affiliation': 'Department of Medical, Oral and Biotechnological Sciences, University ""G. d\'Annunzio,"" Chieti, Italy.'}, {'ForeName': 'Marcus G', 'Initials': 'MG', 'LastName': 'Pezzolesi', 'Affiliation': 'Division of Nephrology and Hypertension and Diabetes and Metabolism Center, University of Utah, Salt Lake City, UT.'}, {'ForeName': 'Ronald J', 'Initials': 'RJ', 'LastName': 'Sigal', 'Affiliation': 'Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Cumming School of Medicine, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Paré', 'Affiliation': 'McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada.'}, {'ForeName': 'Santica M', 'Initials': 'SM', 'LastName': 'Marcovina', 'Affiliation': 'Department of Medicine, University of Washington, and Northwest Lipid Metabolism and Diabetes Research Laboratories, Seattle, WA.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Rotroff', 'Affiliation': 'Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.'}, {'ForeName': 'Elisabetta', 'Initials': 'E', 'LastName': 'Patorno', 'Affiliation': ""Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.""}, {'ForeName': 'Luana', 'Initials': 'L', 'LastName': 'Mercuri', 'Affiliation': 'Research Unit of Metabolic and Cardiovascular Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.'}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Trischitta', 'Affiliation': 'Research Unit of Metabolic and Cardiovascular Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.'}, {'ForeName': 'Emily Y', 'Initials': 'EY', 'LastName': 'Chew', 'Affiliation': 'Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Kraft', 'Affiliation': 'Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Buse', 'Affiliation': 'Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Wagner', 'Affiliation': 'Center for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Cresci', 'Affiliation': 'Department of Genetics, Washington University School of Medicine, St. Louis, MO.'}, {'ForeName': 'Hertzel C', 'Initials': 'HC', 'LastName': 'Gerstein', 'Affiliation': 'McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada.'}, {'ForeName': 'Henry N', 'Initials': 'HN', 'LastName': 'Ginsberg', 'Affiliation': 'Irving Institute for Clinical and Translational Research, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY.'}, {'ForeName': 'Josyf C', 'Initials': 'JC', 'LastName': 'Mychaleckyj', 'Affiliation': 'Center for Public Health Genomics, University of Virginia, Charlottesville, VA.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Doria', 'Affiliation': 'Research Division, Joslin Diabetes Center, Boston, MA alessandro.doria@joslin.harvard.edu.'}]",Diabetes,['10.2337/db19-0973'] 443,32207137,Comparison of the Efficacy of Local Anesthesia Methods and Caudal Regional Anesthesia in Prostate Biopsy Applied Under Transrectal Ultrasonography: A Randomized Controlled Study.,"PURPOSE To evaluate the efficacy of caudal regional anesthesia and local anesthesia methods in prostate biopsy applied under transrectal ultrasonography.Matherials and Methods: This prospective study included a total of 160 patients randomly separated into 4 equal groups as intrarectal local anesthesia (IRLA), periprostatic local anesthesia (PPLA), combined local anesthesia (IRLA+PPLA), and caudal regional anesthesia (CRA). The patients were evaluated using the pain scores on a visual analog scale. RESULTS The pain score during anesthesia induction was significantly higher in the CRA group than in the IRLA and IRLA+PPLA groups (p<0.001). The pain score during entry of the probe to the rectum and movement was significantly lower in the CRA group than the IRLA groups (p=0.014). The pain score on penetration of the needle to the prostate and at 30 mins after the biopsy was significantly higher in the IRLA group (p<0.001). At 2 hours after the biopsy, the pain score in the CRA group was significantly lower than IRLA groups (p=0.015). CONCLUSION The PPLA alone can be applied more quickly than CRA, causes less pain during the application, and has similar efficacy in reducing pain during and after the prostate biopsy procedure.",2020,The pain score during entry of the probe to the rectum and movement was significantly lower in the CRA group than the IRLA groups (p=0.014).,"['160 patients randomly separated into 4 equal groups as', 'Prostate Biopsy Applied Under Transrectal Ultrasonography', 'prostate biopsy applied under transrectal ultrasonography']","['IRLA+PPLA', 'caudal regional anesthesia and local anesthesia methods', 'Local Anesthesia Methods and Caudal Regional Anesthesia', 'IRLA', 'intrarectal local anesthesia (IRLA), periprostatic local anesthesia (PPLA), combined local anesthesia (IRLA+PPLA), and caudal regional anesthesia (CRA', 'CRA', 'Matherials and Methods']","['pain score on penetration of the needle to the prostate', 'pain score', 'pain score during anesthesia induction', 'pain scores on a visual analog scale']","[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0443299', 'cui_str': 'Separate (qualifier value)'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0205518', 'cui_str': 'Transrectal approach (qualifier value)'}, {'cui': 'C0041618', 'cui_str': 'Echotomography'}]","[{'cui': 'C0205097', 'cui_str': 'Caudal (qualifier value)'}, {'cui': 'C0002911', 'cui_str': 'Anesthesia, Regional'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia (procedure)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0473960', 'cui_str': 'Induction of general anesthesia (procedure)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",160.0,0.0256807,The pain score during entry of the probe to the rectum and movement was significantly lower in the CRA group than the IRLA groups (p=0.014).,"[{'ForeName': 'Sahin', 'Initials': 'S', 'LastName': 'Pasali', 'Affiliation': 'Ankara Numune Training and Research Hospital, Department of Urology, Ankara, Turkey. sahinpasali@gmail.com.'}, {'ForeName': 'Cuneyt', 'Initials': 'C', 'LastName': 'Ozden', 'Affiliation': 'Ankara Numune Training and Research Hospital, Department of Urology, Ankara, Turkey.'}, {'ForeName': 'Yalcin', 'Initials': 'Y', 'LastName': 'Kizilkan', 'Affiliation': 'Ankara Numune Training and Research Hospital, Department of Urology, Ankara, Turkey.'}, {'ForeName': 'Suleyman', 'Initials': 'S', 'LastName': 'Camgoz', 'Affiliation': 'Ankara Numune Training and Research Hospital, Department of Anesthesiology, Ankara, Turkey.'}, {'ForeName': 'Semih', 'Initials': 'S', 'LastName': 'Baskan', 'Affiliation': 'Ankara Numune Training and Research Hospital, Department of Anesthesiology, Ankara, Turkey.'}, {'ForeName': 'Samet', 'Initials': 'S', 'LastName': 'Senel', 'Affiliation': 'Ankara Numune Training and Research Hospital, Department of Urology, Ankara, Turkey.'}, {'ForeName': 'Doruk', 'Initials': 'D', 'LastName': 'Demirel', 'Affiliation': 'Ankara Numune Training and Research Hospital, Department of Urology, Ankara, Turkey.'}, {'ForeName': 'Cevdet Serkan', 'Initials': 'CS', 'LastName': 'Gokkaya', 'Affiliation': 'Ankara Numune Training and Research Hospital, Department of Urology, Ankara, Turkey.'}]",Urology journal,['10.22037/uj.v0i0.5503'] 444,32207140,Cost-effectiveness of Medical Expulsive Therapy with Alpha-blockers for Large Distal Ureteral Stones in China.,"PURPOSE To assess the cost-effectiveness of medical expulsive therapy (MET) versus observation for large distal ureteral stones in China and provide preliminary evidence for the determination of the course of MET by mathematical estimation. MATERIALS AND METHODS With linear success rate assumptions, a decision tree was constructed by TreeAge Pro 2011 software. The stones passage rates after observation or receiving 0.4 mg daily tamsulosin were estimated according to a large randomized clinical trial (RCT). The costs of ureteroscopy, drugs and examinations were estimated according to related price from pharmacies or hospitals, or the guidance price published by the government. MET was also compared with observation by the sensitivity analysis. The effectiveness of MET or observation was presented by quality-adjusted life-day. Mathematical estimation of stone expulsion time was made by using a decision-analytic Markov model under the assumption that the daily stone expulsion probability is constant. RESULTS In China, the MET was associated with a $295.1 cost advantage over observation. The cost of ureteroscopy has to decrease to $77.8 to reach cost equivalence between observation and MET. Observation is cost-effective only if ureteroscopy is very cheap or the difference of stone expulsion rates is insignificant. The estimated expulsion time was much longer than those reported in above mentioned RCT. CONCLUSION Due to the high cost of ureteroscopy, MET showed a cost advantage over observation in treating distal ureteral stones in China. The daily stone passage rate was inconstant. More studies are needed to find the appropriate duration of MET.",2020,The daily stone passage rate was inconstant.,['Large Distal Ureteral Stones in China'],"['tamsulosin', 'medical expulsive therapy (MET', 'Medical Expulsive Therapy']","['daily stone passage rate', 'stone expulsion rates', 'cost-effectiveness', 'stones passage rates', 'costs of ureteroscopy, drugs and examinations', 'estimated expulsion time']","[{'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}, {'cui': 'C0041952', 'cui_str': 'Ureterolithiasis'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}]","[{'cui': 'C0257343', 'cui_str': 'tamsulosin'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0006736', 'cui_str': 'Biliary or Urinary Stones'}, {'cui': 'C1293107', 'cui_str': 'Expulsion (procedure)'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0194261', 'cui_str': 'Ureteroscopy'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",,0.033047,The daily stone passage rate was inconstant.,"[{'ForeName': 'Yucong', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Ouyang', 'Affiliation': 'Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'ForeName': 'Heng', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'ForeName': 'Haoran', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Yuan', 'Affiliation': 'Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'ForeName': 'Hongyan', 'Initials': 'H', 'LastName': 'Lu', 'Affiliation': 'Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'ForeName': 'Xifeng', 'Initials': 'X', 'LastName': 'Sun', 'Affiliation': 'Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'ForeName': 'Zhangqun', 'Initials': 'Z', 'LastName': 'Ye', 'Affiliation': 'Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'ForeName': 'Jinchun', 'Initials': 'J', 'LastName': 'Xing', 'Affiliation': 'Department of Urology, The first affiliated hospital of Xiamen University, Xiamen, China.'}, {'ForeName': 'Zhiqiang', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Xu', 'Affiliation': 'Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}]",Urology journal,['10.22037/uj.v0i0.5433'] 445,32187610,Measuring the impact of the French version of The Whiplash Book on both treatment approach and fear-avoidance beliefs among emergency physicians. A cluster randomized controlled trial.,"BACKGROUND Whiplash-associated disorders have been the subject of much attention in the scientific literature and remain a major public health problem. OBJECTIVE Measure the impact of a validated information booklet on the fear-avoidance beliefs of emergency physicians and their approach to management regarding the treatment of whiplash-associated disorders. METHODS A prospective cluster randomized controlled study conducted with a sample of emergency medicine physicians. Fear-avoidance beliefs were measured using The Whiplash Belief Questionnaire (WBQ) and Fear-Avoidance Beliefs Questionnaire (FABQ). We assessed the approach to management based on the prescription of pharmacological and non-pharmacological treatments based on the advice given to patients. The validated information booklet was the French version of The Whiplash Book. A set of questionnaires was sent to participants pre- and post-intervention. The experimental intervention was the provision of The Whiplash Book. The control arm did not receive any training or information. RESULTS Mean fears and beliefs scores on inclusion were high: WBQ = 19.09 (± 4.06); physical activity FABQ = 11.45 (± 4.73); work FABQ = 13.85 (± 6.70). Improvement in fear-avoidance beliefs scores being greater in the intervention group was further confirmed by the variation in WBQ (-20 [-32; -6] vs. -6 [-16; 9]; p = 0.06), physical activity FABQ (-70 [-86; -50] vs. -15 [-40; 11]; p < 0.001), and work FABQ (-40 [-71; 0] vs. 0 [-31; 50]; p = 0.02). The emergency physicians' initial approach to management was not consistent with current guidelines. Reading the French version of The Whiplash Book could contribute to changing their approach to management in several areas on intra-group analysis. CONCLUSION The French version of The Whiplash Book positively influenced fear-avoidance beliefs among emergency physicians.",2020,Fear-avoidance beliefs were measured using The Whiplash Belief Questionnaire (WBQ) and Fear-Avoidance Beliefs Questionnaire (FABQ).,"['emergency physicians', 'whiplash-associated disorders', 'sample of emergency medicine physicians']","['validated information booklet', 'control arm did not receive any training or information']","['physical activity FABQ', 'Whiplash Belief Questionnaire (WBQ) and Fear-Avoidance Beliefs Questionnaire (FABQ', 'Fear-avoidance beliefs', 'fear-avoidance beliefs', 'work FABQ', 'fear-avoidance beliefs scores', 'Mean fears and beliefs scores']","[{'cui': 'C0175673', 'cui_str': 'Emergency (qualifier value)'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0013964', 'cui_str': 'Emergency Medicine'}]","[{'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",,0.0406218,Fear-avoidance beliefs were measured using The Whiplash Belief Questionnaire (WBQ) and Fear-Avoidance Beliefs Questionnaire (FABQ).,"[{'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Lanhers', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.'}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Poizat', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Pereira', 'Affiliation': 'Innovation and Clinical Research, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.'}, {'ForeName': 'Candy', 'Initials': 'C', 'LastName': 'Auclair', 'Affiliation': 'Department of Public Health, Biostatistics Unit, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Perrier', 'Affiliation': 'Emergency Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.'}, {'ForeName': 'Jeannot', 'Initials': 'J', 'LastName': 'Schmidt', 'Affiliation': 'Clermont-Ferrand Auvergne University, Clermont-Ferrand, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Gerbaud', 'Affiliation': 'Clermont-Ferrand Auvergne University, Clermont-Ferrand, France.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Coudeyre', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.'}]",PloS one,['10.1371/journal.pone.0229849'] 446,32201440,A comparative study of alpha-1a blockers (tamsulosin) versus estrogens in the treatment of lower urinary tract symptoms in perimenopausal females.,"OBJECTIVE Lower urinary tract symptoms (LUTS) in perimenopausal females are very common. It can be treated with alpha-blockers or application of topical oestrogen. The purpose of this study is to compare the efficacy of alpha-blockers versus topical estrogen in the treatment of LUTS in perimenopausal females. MATERIALS AND METHODS All perimenopausal females between the age group of 45 and 60 years who present with the symptom of voiding LUTS were divided into two groups. Acute urinary retention patients were excluded from the study. The first group was given alpha-blocker (tamsulosin) and other group was given topical estrogen application (0.5%-1%) in the periurethral region. Patients were followed up clinically by voiding components of the International Prostate Symptom Score and objectively by uroflowmetry and postvoid residual (PVR) urine estimation (ultrasonography). RESULTS Alpha-blocker group had 40 females and topical estrogen group had 40 females. During the 6-week period, 8 patients of the first group and 6 patients of the estrogen group discontinued the treatment. In the first group, pretreatment mean Qmax (maximum flow rate) of patients was 7.2 ml/s and posttreatment Qmax was 18.4. In the second group, the values were 7.4 ml/s and 10.2, respectively. This difference was statistically significant ( P < 0.0001). In the first group, pretreatment PVR urine was significant, which became insignificant after the treatment, whereas in the second group, PVR was significant posttreatment also. CONCLUSION Alpha-1a blockers should be used as the first-line medical management in perimenopausal females with symptoms of LUTS, as they have a clear advantage over topical estrogens.",2020,"In the first group, pretreatment mean Qmax (maximum flow rate) of patients was 7.2 ml/s and posttreatment Qmax was 18.4.","['perimenopausal females with symptoms of LUTS', 'All perimenopausal females between the age group of 45 and 60 years who present with the symptom of voiding LUTS', 'Acute urinary retention patients', 'perimenopausal females']","['alpha-blockers versus topical estrogen', 'alpha-blocker (tamsulosin', 'alpha-1a blockers (tamsulosin', 'Alpha-1a blockers', 'topical estrogen application']","['PVR', 'pretreatment PVR urine', 'pretreatment mean Qmax (maximum flow rate', 'voiding components of the International Prostate Symptom Score and objectively by uroflowmetry and postvoid residual (PVR) urine estimation (ultrasonography']","[{'cui': 'C3839366', 'cui_str': 'Perimenopausal state (finding)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0341742', 'cui_str': 'Acute retention of urine (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C3537250', 'cui_str': 'ESTROGENS'}, {'cui': 'C0257343', 'cui_str': 'tamsulosin'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}]","[{'cui': 'C0042037'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C1998280', 'cui_str': 'International prostate symptom score (assessment scale)'}, {'cui': 'C0200008', 'cui_str': 'Uroflowmetry (procedure)'}, {'cui': 'C0278024', 'cui_str': 'Residual urine'}, {'cui': 'C0041618', 'cui_str': 'Echotomography'}]",,0.0157466,"In the first group, pretreatment mean Qmax (maximum flow rate) of patients was 7.2 ml/s and posttreatment Qmax was 18.4.","[{'ForeName': 'Krishnendu', 'Initials': 'K', 'LastName': 'Maiti', 'Affiliation': 'Department of Urology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.'}, {'ForeName': 'Alankar', 'Initials': 'A', 'LastName': 'Jaiswal', 'Affiliation': 'Department of Urology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.'}, {'ForeName': 'Dilip Kumar', 'Initials': 'DK', 'LastName': 'Pal', 'Affiliation': 'Department of Urology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.'}]",Indian journal of pharmacology,['10.4103/ijp.IJP_545_18'] 447,31684705,"The effectiveness of three different recovery methods on blood lactate, acute muscle performance, and delayed-onset muscle soreness: a randomized comparative study.","BACKGROUND Recovery from exercise is important in sports and rehabilitation for preventing exercise-induced injuries and recovery of performance. This study aimed to compare active recovery (AR), neuromuscular electrical stimulation (NMES), and foam rolling (FR) in terms of blood lactate (Bla) removal, reduction in delayed-onset muscle soreness (DOMS), and restoration of muscle strength, endurance, and flexibility in healthy young individuals. METHODS Forty-five subjects aged 20-25 years were assigned to AR, FR, and NMES groups. The subjects performed a single bout of circuit-based high-intensity training (CBHIT) at 85% of the heart rate reserve (HRR). The subjects in the AR group walked at 40% of the HRR, whereas those in the FR group self-massaged the tight muscles. In the NMES group, electrical stimulation was applied to the hamstrings and quadriceps. All recovery methods took 15 minutes. The sit-and-reach performance, quadriceps and hamstring strength, and squat endurance of the subjects were measured prior to CBHIT and after recovery. Bla concentrations were measured before CBHIT and at 0, 5, and 20 minutes of recovery. The DOMS were evaluated for 3 days. RESULTS After recovery, no significant differences were found between the groups in terms of quadriceps (right, P=0.82; left, P=0.772) and hamstring (right, P=0.41; left, P=0.30) strength, sit-and-reach performance (P=0.55), squat endurance (P=0.18), Bla concentration at each time point (P=0.94), and DOMS (P=0.31). CONCLUSIONS This study showed that AR, NMES, and FR have similar effects on Bla removal, performance recovery, and DOMS reduction in healthy young individuals.",2020,"After recovery, no significant differences were found between the groups in terms of quadriceps (right, p=0.82; left, p=0.772) and hamstring (right, p=0.41; left, p=0.30) strength, sit-and-reach performance (p=0.55), squat endurance (p=0.18), Bla concentration at each time point (p=0.94), and DOMS (p=0.31). ","['healthy young individuals', 'Forty-five subjects aged 20-25 years']","['active recovery (AR), neuromuscular electrical stimulation (NMES), and foam rolling (FR', 'single bout of circuit-based high-intensity training (CBHIT', 'NMES']","['strength, sit-and-reach performance (p=0.55), squat endurance', 'blood lactate, acute muscle performance, and delayed-onset muscle soreness', 'blood lactate (Bla) removal, reduction in delayed-onset muscle soreness (DOMS), and restoration of muscle strength, endurance, and flexibility', 'Bla concentration', 'Bla concentrations', 'sit-and-reach performance, quadriceps and hamstring strength, and squat endurance', 'Bla removal, performance recovery, and DOMS reduction']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0013786', 'cui_str': 'Electrical Stimulation'}, {'cui': 'C0991510', 'cui_str': 'Foam (basic dose form)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}, {'cui': 'C0241236', 'cui_str': 'Does squat (finding)'}, {'cui': 'C0518031', 'cui_str': 'Endurance capacity'}, {'cui': 'C0005768'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0231528', 'cui_str': 'Muscle Pain'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration (attribute)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0013007', 'cui_str': '1-(2,5-Dimethoxy-4-Methylphenyl)-2-Aminopropane'}]",45.0,0.0266475,"After recovery, no significant differences were found between the groups in terms of quadriceps (right, p=0.82; left, p=0.772) and hamstring (right, p=0.41; left, p=0.30) strength, sit-and-reach performance (p=0.55), squat endurance (p=0.18), Bla concentration at each time point (p=0.94), and DOMS (p=0.31). ","[{'ForeName': 'Buket', 'Initials': 'B', 'LastName': 'Akinci', 'Affiliation': 'Division of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Biruni University, Istanbul, Turkey - barbuket@hotmail.com.'}, {'ForeName': 'Yonca', 'Initials': 'Y', 'LastName': 'Zenginler Yazgan', 'Affiliation': 'Division of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Istanbul University-Cerrahpasa, Istanbul, Turkey.'}, {'ForeName': 'Tulin', 'Initials': 'T', 'LastName': 'Altinoluk', 'Affiliation': 'Department of Physiology, Institute of Health Science, Marmara University, Istanbul, Turkey.'}]",The Journal of sports medicine and physical fitness,['10.23736/S0022-4707.19.10142-9'] 448,32129892,Myasthenia gravis patient and physician opinions about immunosuppressant reduction.,"INTRODUCTION To reduce myasthenia gravis (MG) patient risk of immunosuppressant (IS) exposure adverse events (AEs), such as infections and malignancies, and to reduce treatment burden, international guidelines recommend decreasing IS dose in stable MG patients. METHODS Online surveys were conducted of self-identified MG patients and MG physician experts about the importance of IS dose reduction for MG patients who achieve prolonged periods of disease stability. RESULTS Eighty-four percent of MG patients (n = 283) and 100% of physicians (n = 45) were concerned about long-term IS-associated AEs. Although both groups favored attempting IS reduction, they raised concerns including MG relapse, hospitalization, and uncertainty about the future. Presented with an estimated 12% significant relapse rate with IS dose reduction, 76% of patients would be willing to enroll in a randomized IS dose reduction trial. DISCUSSION Patients and physicians favor considering IS dose reduction but are also concerned about potential negative sequelae.",2020,"Although both groups favored attempting IS reduction, they raised concerns including: MG relapse, hospitalization, and uncertainty about the future.","['Myasthenia Gravis Patient and Physician Opinions', 'Online surveys were conducted of self-identified MG patients and MG physician experts about the importance of IS dose reduction for MG patients who achieve prolonged periods of disease stability']",[],['relapse rate'],"[{'cui': 'C0947912'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0871010', 'cui_str': 'Opinions'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0425945', 'cui_str': 'Prolonged periods (finding)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",[],"[{'cui': 'C0035020', 'cui_str': 'Relapse'}]",45.0,0.025263,"Although both groups favored attempting IS reduction, they raised concerns including: MG relapse, hospitalization, and uncertainty about the future.","[{'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Hehir', 'Affiliation': 'The Robert Larner M.D. College of Medicine, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Anna Rostedt', 'Initials': 'AR', 'LastName': 'Punga', 'Affiliation': 'Department of Neuroscience Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Ciafaloni', 'Affiliation': 'University of Rochester School of Medicine, Rochester, New York, USA.'}]",Muscle & nerve,['10.1002/mus.26850'] 449,32160891,"Study protocol of a multicenter randomized controlled trial of mindfulness-based intervention versus relaxation to reduce emotional exhaustion in medical students in France: the ""Must prevent"" study.","BACKGROUND Medical students are exposed to an emotionally exhausting training/work environment and to stressful academic demands. Consequently, psychopathologies, burnout and suicidal ideation are frequent in this population. These factors can also affect their empathy and quality of care. Therefore, the development and implementation of programs to promote resilience to stress specifically in medical students and the evaluation of their efficiency are a priority. Here, we describe the protocol of the first French study to assess the long-term effectiveness and acceptability of a mindfulness-based intervention (MBI) compared with relaxation training (RT) to reduce emotional exhaustion in medical students. METHODS This multicenter randomized controlled trial (""Must prevent"") plans to enroll 612 students in the fourth and fifth year of medical studies from nine French universities. After inclusion, they will be assigned randomly to the MBI or RT group. Both interventions are structured around an 8-week program that includes one group class per week and daily at-home exercises. The primary endpoint is the emotional exhaustion score assessed with the Maslach Burnout Inventory at month 12 of the follow-up. Secondary endpoints include anxiety-depressive symptomatology, suicidality, psychoactive substance use, depersonalization, psychological and physical pain, empathy, emotional regulation, self-compassion, mindfulness, quality of life, and program acceptability. Evaluations will be done before and immediately after the 8-week intervention, and at month 6 and 12 of the post-intervention follow-up. DISCUSSION If the proposed interventions are well accepted and useful to decrease negative emotions and/or increase wellbeing among medical students, they should be disseminated among this population and even included as part of the training on emotional skills needed for the routine medical practice. TRIAL REGISTRATION This trial is registered under the number NCT04026594 (July 18, 2019).",2020,"If the proposed interventions are well accepted and useful to decrease negative emotions and/or increase wellbeing among medical students, they should be disseminated among this population and even included as part of the training on emotional skills needed for the routine medical practice. ","['medical students in France', 'medical students', '612 students in the fourth and fifth year of medical studies from nine French universities']","['mindfulness-based intervention versus relaxation', 'mindfulness-based intervention (MBI', 'relaxation training (RT']","['emotional exhaustion', 'anxiety-depressive symptomatology, suicidality, psychoactive substance use, depersonalization, psychological and physical pain, empathy, emotional regulation, self-compassion, mindfulness, quality of life, and program acceptability', 'emotional exhaustion score assessed with the Maslach Burnout Inventory', 'empathy and quality of care']","[{'cui': 'C0038495', 'cui_str': 'Students, Medical'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C4517834', 'cui_str': '612 (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0205438', 'cui_str': 'Fourth (qualifier value)'}, {'cui': 'C0205439', 'cui_str': 'Fifth (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1556084', 'cui_str': 'French (ethnic group)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}]","[{'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0282333', 'cui_str': 'Relaxation Therapy'}]","[{'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion (finding)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0682880', 'cui_str': 'Psychoactive substance'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0011551', 'cui_str': 'Depersonalization'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0034380'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state (disorder)'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0034379', 'cui_str': 'Quality of Care'}]",,0.0444885,"If the proposed interventions are well accepted and useful to decrease negative emotions and/or increase wellbeing among medical students, they should be disseminated among this population and even included as part of the training on emotional skills needed for the routine medical practice. ","[{'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Baeza-Velasco', 'Affiliation': 'Department of Emergency Psychiatry and Acute Care, CHU Montpellier, France. 191 Av du Doyen Gaston Giraud, 34090, Montpellier, France. carolina.baeza-velasco@u-paris.fr.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Genty', 'Affiliation': 'Department of Emergency Psychiatry and Acute Care, CHU Montpellier, France. 191 Av du Doyen Gaston Giraud, 34090, Montpellier, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Jaussent', 'Affiliation': 'PSNREC, University of Montpellier, INSERM, Montpellier, France.'}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Benramdane', 'Affiliation': 'Department of Emergency Psychiatry and Acute Care, CHU Montpellier, France. 191 Av du Doyen Gaston Giraud, 34090, Montpellier, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Courtet', 'Affiliation': 'Department of Emergency Psychiatry and Acute Care, CHU Montpellier, France. 191 Av du Doyen Gaston Giraud, 34090, Montpellier, France.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Olié', 'Affiliation': 'Department of Emergency Psychiatry and Acute Care, CHU Montpellier, France. 191 Av du Doyen Gaston Giraud, 34090, Montpellier, France.'}]",BMC psychiatry,['10.1186/s12888-020-02529-9'] 450,31809409,Energy Deficit Required for Exercise-induced Improvements in Glycemia the Next Day.,"PURPOSE This study determined the impact of an exercise-induced energy deficit on postprandial and 24 h glycemic control the day after a session of exercise. METHODS Fifteen healthy participants (m/f = 5/10, 27 ± 6 yr, body mass index = 24 ± 3 kg·m, peak oxygen consumption [V˙O2peak] = 36 ± 9 mL·kg·min) completed two separate 5-d experimental trials performed under ""free-living"" conditions. On day 1 of each trial, participants were fitted with a continuous glucose monitor and abstained from exercise. Day 2 served as a nonexercise control (NoEx). On day 3, participants exercised at 3:00 PM (65% V˙O2peak) until they expended 350 kcals (~45 min). The diet during both experimental trials was identical with the exception of meals after this exercise session. During one trial, the dinner after exercise did not replenish the 350 kcal expended during exercise, thereby establishing an exercise energy deficit (ExDEF). During the other experimental trial, the dinner after exercise contained an additional 350 kcal to compensate for the energy expended during exercise, and thereby maintained energy balance after exercise (ExBAL). Free-living glycemia was measured the day before exercise (NoEx) and the day after exercise under ExDEF and ExBAL conditions. RESULTS The day after exercise, 3 h postprandial area under the curve was lower after breakfast in ExDEF compared with ExBAL (16.0 ± 1.8 vs 17.0 ± 1.6 mmol·L·h per 3 h, P = 0.01), but did not differ between groups after lunch (P = 0.24), dinner (P = 0.39), or evening snack (P = 0.45). Despite differences in the glycemic response to breakfast, 24 h glycemia did not differ between ExDEF and ExBAL (area under the curve = 128 ± 10 vs 131 ± 10 mmol·L·h per 24 h, respectively; P = 0.54). CONCLUSIONS An exercise-induced energy deficit lowered the glycemic response to breakfast the next day-but this energy deficit did not impact total 24 h glycemia, the day after exercise in metabolically healthy adults.",2020,An exercise-induced energy deficit lowered the glycemic response to breakfast the next day - but this energy deficit did not impact total 24h glycemia the day after exercise in metabolically healthy adults.,"['metabolically healthy adults', 'Fifteen healthy participants (m/f=5/10, 27±6 yrs, BMI=24±3 kg·m, VO2peak=36±9 mL·kg·min) completed two separate 5-day experimental trials performed under ""free-living"" conditions']","['exercise-induced energy deficit', 'Day 2 served as a non-exercise control (NoEx', 'dinner after exercise did not replenish the 350 kcals expended during exercise, thereby establishing an exercise energy deficit (ExDEF', 'continuous glucose monitor (CGM) and abstained from exercise']","['postprandial area under curve (AUC', 'Free-living glycemia', 'glycemic response to breakfast, 24h glycemia']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0443299', 'cui_str': 'Separate (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4552592', 'cui_str': 'With dinner'}, {'cui': 'C1979962', 'cui_str': 'After exercise (qualifier value)'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C4517735', 'cui_str': '350'}, {'cui': 'C0439259', 'cui_str': 'kilocalorie'}, {'cui': 'C0587107', 'cui_str': 'During exercise (qualifier value)'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}]","[{'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C4553621', 'cui_str': 'With breakfast'}]",15.0,0.0604915,An exercise-induced energy deficit lowered the glycemic response to breakfast the next day - but this energy deficit did not impact total 24h glycemia the day after exercise in metabolically healthy adults.,"[{'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Schleh', 'Affiliation': 'Substrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Pitchford', 'Affiliation': 'Substrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Jenna B', 'Initials': 'JB', 'LastName': 'Gillen', 'Affiliation': 'Substrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Jeffrey F', 'Initials': 'JF', 'LastName': 'Horowitz', 'Affiliation': 'Substrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, MI.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002211'] 451,32186106,Effects of Gua Sha therapy on weightlifting training: a randomized trial.,"OBJECTIVE To evaluate the effect of Gua Sha therapy on weightlifting training. METHODS The sample size was calculated by conducting a pilot study. A total of 44 male weightlifters were randomly assigned to either the Gua Sha group (n = 15), sham scraping group (n = 14), or control group (n = 14). The participants in the Gua Sha group and sham scraping group received 16 sessions of Gua Sha therapy during normal weightlifting training for 8 weeks. No treatment was applied to participants in the control group. The effectiveness of Gua Sha therapy was evaluated by measuring weightlifting ability, the rating of perceived exertion (RPE) of snatch and clean and jerk (85% of 1 repetition maximum), and creatinine kinase (CK), blood urea nitrogen (BUN), and immunoglobulin A levels. RESULTS Gua Sha therapy treatment significantly increased weightlifting ability in participants in the Gua Sha group (P < 0.01). The RPE values of snatch and clean and jerk were significantly lower in the Gua Sha group and sham scraping groups compared with the control group (P < 0.05). CK levels were lower and immunoglobulin A levels were significantly higher in the Gua Sha group compared with sham scraping group and control group (both P < 0.05). BUN levels tended to be reduced only in the Gua Sha group. A close correlation between CK levels and the RPE was found in the Gua Sha group. CONCLUSION Gua Sha therapy can facilitate weightlifting ability, reduce the RPE, and inhibit muscle injury by promoting recovery from fatigue caused by normal weightlifting training. Gua Sha therapy could be an effective treatment to complement normal weightlifting training.",2019,CK levels were lower and immunoglobulin A levels were significantly higher in the Gua Sha group compared with sham scraping group and control group (both P < 0.05).,"['weightlifting training', '44 male weightlifters']","['Gua Sha therapy', 'sham scraping group']","['CK levels and the RPE', 'weightlifting ability', 'weightlifting ability, the rating of perceived exertion (RPE) of snatch and clean and jerk (85% of 1 repetition maximum), and creatinine kinase (CK), blood urea nitrogen (BUN), and immunoglobulin A levels', 'BUN levels', 'CK levels', 'RPE values of snatch and clean and jerk']","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0184933', 'cui_str': 'Scraping (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0445208', 'cui_str': 'RPE'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0015264', 'cui_str': 'Exertion, function (observable entity)'}, {'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C1704276', 'cui_str': 'Spasmodic movement (finding)'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C4521566', 'cui_str': 'Kinase'}, {'cui': 'C0600137', 'cui_str': 'Blood urea nitrogen (substance)'}, {'cui': 'C0202083', 'cui_str': 'Immunoglobulin A measurement (procedure)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",44.0,0.0392475,CK levels were lower and immunoglobulin A levels were significantly higher in the Gua Sha group compared with sham scraping group and control group (both P < 0.05).,"[{'ForeName': 'Xingze', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'School of Physical Education and Training, Shanghai University of Sport, Shanghai, 200438, China.'}, {'ForeName': 'Baohui', 'Initials': 'B', 'LastName': 'Jia', 'Affiliation': ""Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.""}, {'ForeName': 'Houyong', 'Initials': 'H', 'LastName': 'Zhong', 'Affiliation': 'Research Center of Physical Education and Health Education in Gannan Normal University, Ganzhou City, Jiangxi Province 341000, China.'}, {'ForeName': 'Xingyu', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Research Center of Physical Education and Health Education in Gannan Normal University, Ganzhou City, Jiangxi Province 341000, China.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Chen', 'Affiliation': 'Department of Internal Medicine, The 8th Medical Center of Chinese PLA General Hospital Xiao Xitian Clinic, Beijing 100082, China.'}, {'ForeName': 'Jinsheng', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.'}]",Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan,[] 452,32186107,Effect of adjuvant therapy with electroacupuncture on bone turnover markers and interleukin 17 in patients with rheumatoid arthritis.,"OBJECTIVE To evaluate the effect of electroacupuncture as an adjuvant treatment with first-line medications on bone metabolism biomarkers and interleukin-17 (IL-17) in the peripheral blood of patients with rheumatoid arthritis (RA). METHODS Sixty RA patients were randomized into three groups. The control group was treated with methotrexate plus leflunomide (MTX+LEF), the acupuncture group was treated with simple needling plus MTX + LEF, and the patients in the electroacupuncture (EA) group were treated with EA plus MTX + LEF. EA or acupuncture was applied every other day for a total of 10 times over a treatment period of 8 weeks. RESULTS In all three treatment groups, serum levels of the bone metabolism markers PICP, N-MID, and B-ALP were elevated and the concentrations of the inflammatory markers β-CTx, IL-17, CRP, and TRACP-5b were reduced after treatment. These differences were significant for the EA group but not the other groups (P < 0.05). CONCLUSION EA could effectively reduce the suffering and improve the quality of life of RA patients. It is a promising adjuvant therapy for enhancing the effectiveness of clinical therapeutics.",2019,"In all three treatment groups, serum levels of the bone metabolism markers PICP, N-MID, and B-ALP were elevated and the concentrations of the inflammatory markers β-CTx, IL-17, CRP, and TRACP-5b were reduced after treatment.","['patients with rheumatoid arthritis (RA', 'Sixty RA patients', 'patients with rheumatoid arthritis']","['methotrexate plus leflunomide (MTX+LEF', 'EA', 'acupuncture', 'EA plus MTX + LEF', 'electroacupuncture', 'EA or acupuncture', 'electroacupuncture (EA', 'simple needling plus MTX + LEF']","['bone turnover markers', 'bone metabolism biomarkers and interleukin-17 (IL-17', 'quality of life', 'concentrations of the inflammatory markers β-CTx, IL-17, CRP, and TRACP-5b', 'serum levels of the bone metabolism markers PICP, N-MID, and B-ALP']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid Arthritis'}]","[{'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0063041', 'cui_str': 'leflunomide'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0205352', 'cui_str': 'Simple (qualifier value)'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}]","[{'cui': 'C0085268', 'cui_str': 'Bone Turnover'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0384648', 'cui_str': 'IL-17'}, {'cui': 'C0034380'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0297331', 'cui_str': 'TRAcP'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0072052', 'cui_str': 'CPP-I'}, {'cui': 'C0444598', 'cui_str': 'Mid (qualifier value)'}]",60.0,0.0620938,"In all three treatment groups, serum levels of the bone metabolism markers PICP, N-MID, and B-ALP were elevated and the concentrations of the inflammatory markers β-CTx, IL-17, CRP, and TRACP-5b were reduced after treatment.","[{'ForeName': 'Chuang', 'Initials': 'C', 'LastName': 'Zeng', 'Affiliation': 'Department of Traditional Chinese Medicine Integrated TCM and Western Medicine, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.'}, {'ForeName': 'Xuejing', 'Initials': 'X', 'LastName': 'Bai', 'Affiliation': 'Department of Traditional Chinese Medicine Integrated TCM and Western Medicine, Yunyang Hospital, Chongqing, 404500, China.'}, {'ForeName': 'Heping', 'Initials': 'H', 'LastName': 'Qin', 'Affiliation': 'Department of Traditional Chinese Medicine Integrated TCM and Western Medicine, Yunyang Hospital, Chongqing, 404500, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Traditional Chinese Medicine Integrated TCM and Western Medicine, Yunyang Hospital, Chongqing, 404500, China.'}, {'ForeName': 'Xiaofeng', 'Initials': 'X', 'LastName': 'Rong', 'Affiliation': 'Department of Traditional Chinese Medicine Integrated TCM and Western Medicine, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Yan', 'Affiliation': 'Department of Traditional Chinese Medicine Integrated TCM and Western Medicine, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.'}]",Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan,[] 453,32186108,Effect of hand-ear acupuncture on chronic low-back pain: a randomized controlled trial.,"OBJECTIVE To evaluate the effect of hand-ear acupuncture on chronic low-back pain (cLBP). METHODS This was an open, randomized and controlled trial in The General Hospital of Western Theater Command, Sichuan Province. The trial was registered with ClinicalTrials.gov, NCT02260284. All the 152 participates with cLBP were randomly assigned to hand-ear acupuncture (n = 54), standard acupuncture (n = 50), or usual care groups (n = 48). Eighteen treatments were provided over 7 weeks. Back-related dysfunction and symptom severity were assessed by the Roland-Morris Disability Questionnaire (RMDQ) and the Visual Analogue Scale (VAS), which were collected at baseline, 2 months and 6 months post to the treatment. RESULTS At 6 months, the RMDQ scores improved by 7.74 points of hand-ear acupuncture group. Significant improvement of VAS and RMDQ was observed in hand-ear acupuncture group (P < 0.001), but no significant changes of RMDQ were observed in both standard acupuncture group and usual care group. We also observed an overall efficacy rate of 88.89% in hand-ear acupuncture group, as evaluated by Diagnosis and Curative Effect Standard for Symptom pattern of Traditional Chinese Medicine, which was much higher than 45.84% in the usual care group (H = 16.000, P < 0.001). CONCLUSION Both of the hand-ear acupuncture and standard acupuncture modes have beneficial and persistent effectiveness against cLBP compared with the usual care. Furthermore, hand-ear acupuncture is significantly more effective than the standardized acupuncture, especially in the long term.",2019,"Significant improvement of VAS and RMDQ was observed in hand-ear acupuncture group (P < 0.001), but no significant changes of RMDQ were observed in both standard acupuncture group and usual care group.","['General Hospital of Western Theater Command, Sichuan Province', '152 participates with cLBP', 'chronic low-back pain']","['standard acupuncture', 'hand-ear acupuncture']","['RMDQ scores', 'Roland-Morris Disability Questionnaire (RMDQ) and the Visual Analogue Scale (VAS', 'overall efficacy rate', 'Back-related dysfunction and symptom severity', 'chronic low-back pain (cLBP', 'RMDQ', 'VAS and RMDQ']","[{'cui': 'C0020008', 'cui_str': 'Hospitals, General'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain (finding)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0752217', 'cui_str': 'Auricular Acupuncture'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain (finding)'}]",152.0,0.128255,"Significant improvement of VAS and RMDQ was observed in hand-ear acupuncture group (P < 0.001), but no significant changes of RMDQ were observed in both standard acupuncture group and usual care group.","[{'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Luo', 'Affiliation': ""Graduate College, The People's Liberation Army Naval Medical University, Shanghai 200433, China.""}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Yang', 'Affiliation': 'Traditional Chinese Medicine Department, The General Hospital of Western Theater Command, Chengdu 610083, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Liu', 'Affiliation': 'Traditional Chinese Medicine Department, The General Hospital of Western Theater Command, Chengdu 610083, China.'}, {'ForeName': 'Xiaolong', 'Initials': 'X', 'LastName': 'Zhong', 'Affiliation': 'Traditional Chinese Medicine Department, The General Hospital of Western Theater Command, Chengdu 610083, China.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Tang', 'Affiliation': ""The People's Liberation Army 32357 troops, Chengdu 611630, China.""}, {'ForeName': 'Mingyang', 'Initials': 'M', 'LastName': 'Guo', 'Affiliation': 'Traditional Chinese Medicine Department, The General Hospital of Western Theater Command, Chengdu 610083, China.'}, {'ForeName': 'Yonghe', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Traditional Chinese Medicine Department, The General Hospital of Western Theater Command, Chengdu 610083, China.'}]",Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan,[] 454,32096571,"Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance.","AIMS To examine the effects of a sodium-glucose co-transporter 2 (SGLT2) inhibitor, tofogliflozin, on resting heart rate by exploring baseline factors that independently influenced changes in the resting heart rate. METHODS Data on 419 participants in tofogliflozin phase 2/3 trials were analysed. Changes in resting heart rate from baseline to week 24 were analysed using an analysis of covariance (ANCOVA) model with groups (tofogliflozin/placebo) as a fixed effect and baseline values as covariates. The antilipolytic effect was evaluated as adipose tissue insulin resistance (Adipo-IR) and was calculated as the product of fasting insulin and free fatty acid. Multivariate analysis evaluated independent factors for changes in resting heart rate from baseline to week 24. RESULTS Of the participants, 58% were men, and mean age, HbA 1c , BMI and resting heart rate were 57.6 years, 65 mmol/mol (8.1%), 25.5 kg/m 2 and 66 bpm, respectively. At week 24, adjusted mean difference vs. placebo in the change from baseline was -2.3 bpm [95% confidence interval (CI) -4.6, -0.1] with tofogliflozin. Changes in resting heart rate were positively correlated with changes in Adipo-IR, whereas reductions in HbA 1c , body weight and blood pressure were similar independent of changes in resting heart among quartiles of resting heart rate change. On multivariate analysis, higher baseline resting heart rates and Adipo-IR values were significantly associated with greater reductions in resting heart rate. CONCLUSIONS Tofogliflozin corrected resting heart rate levels in accordance with baseline levels. Correction of high resting heart rates may be attributed to improved adipose tissue insulin resistance, leading to correction of hyperinsulinaemia.",2020,"At week 24, adjusted mean difference vs. placebo in the change from baseline was -2.3 bpm [95% confidence interval (CI) -4.6, -0.1] with tofogliflozin.","[' 58% were men, and mean age, HbA 1c , BMI and resting heart rate were 57.6 years, 65 mmol/mol (8.1%), 25.5 kg/m 2 and 66 bpm, respectively', 'Data on 419 participants in tofogliflozin phase 2/3 trials were analysed']","['Tofogliflozin', 'tofogliflozin/placebo', 'placebo', 'sodium-glucose co-transporter 2 (SGLT2) inhibitor, tofogliflozin', 'SGLT2 inhibitor, tofogliflozin']","['antilipolytic effect', 'HbA 1c , body weight and blood pressure', 'resting heart rate', 'adipose tissue insulin resistance (Adipo-IR']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C1821417', 'cui_str': 'Resting heart rate (observable entity)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mole - unit'}, {'cui': 'C4517875', 'cui_str': '8.1 (qualifier value)'}, {'cui': 'C4517663', 'cui_str': 'Twenty-five point five'}, {'cui': 'C3501434'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}]","[{'cui': 'C3501434'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4301634', 'cui_str': 'Sodium-glucose co-transporter 2 (SGLT2) inhibitors'}, {'cui': 'C3273807', 'cui_str': 'Gliflozins'}]","[{'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C1821417', 'cui_str': 'Resting heart rate (observable entity)'}, {'cui': 'C0001527', 'cui_str': 'Fatty Tissue'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}]",419.0,0.0414319,"At week 24, adjusted mean difference vs. placebo in the change from baseline was -2.3 bpm [95% confidence interval (CI) -4.6, -0.1] with tofogliflozin.","[{'ForeName': 'T', 'Initials': 'T', 'LastName': 'Nojima', 'Affiliation': 'Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Matsubayashi', 'Affiliation': 'Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Yoshida', 'Affiliation': 'Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Suganami', 'Affiliation': 'Clinical Data Science Department, Kowa Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Abe', 'Affiliation': 'Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ishizawa', 'Affiliation': 'Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Fujihara', 'Affiliation': 'Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Tanaka', 'Affiliation': 'Department of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Kaku', 'Affiliation': 'Kawasaki Medical School, Okayama, Japan.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Sone', 'Affiliation': 'Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.'}]",Diabetic medicine : a journal of the British Diabetic Association,['10.1111/dme.14279'] 455,31688645,Planned Aerobic Exercise Increases Energy Intake at the Preceding Meal.,"PURPOSE Effects of exercise on subsequent energy intake are well documented, but whether preexercise energy intake is affected by future planned exercise is unknown. This study investigated the effect of planned late-afternoon exercise on appetite and energy intake before (breakfast and lunch) and after (evening meal/snacks) exercise. METHODS Twenty healthy, active participants (10 male; age, 23 ± 5 yr; body mass index 23.7 ± 3.2 kg·m; V˙O2peak, 44.1 ± 5.4 mL·kg··min) completed randomized, counterbalanced exercise (EX) and resting (REST) trials. After trial notification, participants were provided ad libitum breakfast (0800 h) and lunch (1200 h) in the laboratory, before completing 1-h exercise (30-min cycling, 30-min running) at 75%-80% maximal HR (EX, 2661 ± 783 kJ) or 1-h supine rest (REST, 310 ± 58 kJ) 3 h after lunch. Participants were provided a food pack (pasta meal/snacks) for consumption after exercise (outside laboratory). Appetite was measured regularly, and meal and 24-h energy intake were quantified. RESULTS Ad libitum energy intake was greater during EX at lunch (EX, 3450 ± 1049 kJ; REST, 3103 ± 927 kJ; P = 0.004), but similar between trials at breakfast (EX, 2656 ± 1291 kJ; REST, 2484 ± 1156 kJ; P = 0.648) and dinner (EX, 6249 ± 2216 kJ; REST, 6240 ± 2585 kJ; P = 0.784). Total 24-h energy intake was similar between trials (P = 0.388), meaning that relative energy intake (24-h energy intake minus EX/REST energy expenditure) was reduced during EX (EX, 9694 ± 3313 kJ; REST, 11,517 ± 4023 kJ; P = 0.004). CONCLUSION Energy intake seems to be increased in anticipation of, rather than in response to, aerobic exercise, but the increase was insufficient to compensate for energy expended during exercise, meaning that aerobic exercise reduced energy balance relative to rest.",2020,"Total 24-hour energy intake was similar between trials (P=0.388), meaning relative energy intake (24-h energy intake minus EX/REST energy expenditure), was reduced during EX (EX 9694 ± 3313 kJ; REST 11517 ± 4023 kJ; P=0.004). ","['Twenty healthy, active participants (10 male; age 23 ± 5 y, BMI 23.7 ± 3.2 kg/m, VO2peak 44.1 ± 5.4 ml/kg/min']","['planned late-afternoon exercise', 'Planned Aerobic Exercise', 'counterbalanced exercise (EX) and resting (REST', 'exercise', 'food pack (pasta meal/snacks) for consumption post-exercise (outside laboratory']","['Energy Intake', 'Appetite', 'Total 24-hour energy intake', 'meaning relative energy intake (24-h energy intake minus EX/REST energy expenditure', 'appetite and energy intake']","[{'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517687', 'cui_str': '3.2'}, {'cui': 'C4517792', 'cui_str': 'Five point four'}, {'cui': 'C0439402', 'cui_str': 'mL/min/kg'}]","[{'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0439550', 'cui_str': 'Afternoon (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C1968515', 'cui_str': 'Pack (physical object)'}, {'cui': 'C0452694', 'cui_str': 'Pasta (substance)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C3494314', 'cui_str': 'Snacking'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1979962', 'cui_str': 'After exercise (qualifier value)'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}]","[{'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0332288', 'cui_str': 'Without (attribute)'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0014272', 'cui_str': 'Energy Expenditure'}]",20.0,0.25516,"Total 24-hour energy intake was similar between trials (P=0.388), meaning relative energy intake (24-h energy intake minus EX/REST energy expenditure), was reduced during EX (EX 9694 ± 3313 kJ; REST 11517 ± 4023 kJ; P=0.004). ","[{'ForeName': 'Asya', 'Initials': 'A', 'LastName': 'Barutcu', 'Affiliation': 'School of Sport, Exercise and Health Sciences, Loughborough University, Leicestershire, UNITED KINGDOM.'}, {'ForeName': 'Shelley', 'Initials': 'S', 'LastName': 'Taylor', 'Affiliation': ''}, {'ForeName': 'Chris J', 'Initials': 'CJ', 'LastName': 'McLeod', 'Affiliation': ''}, {'ForeName': 'Gemma L', 'Initials': 'GL', 'LastName': 'Witcomb', 'Affiliation': ''}, {'ForeName': 'Lewis J', 'Initials': 'LJ', 'LastName': 'James', 'Affiliation': ''}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002199'] 456,31688648,Baseline and Exercise Predictors of V˙O2peak in Systolic Heart Failure Patients: Results from SMARTEX-HF.,"PURPOSE This study aimed to investigate baseline, exercise testing, and exercise training-mediated predictors of change in peak oxygen uptake (V˙O2peak) from baseline to 12-wk follow-up (ΔV˙O2peak) in a post hoc analysis from the SMARTEX Heart Failure trial. METHODS We studied 215 patients with heart failure with left ventricular ejection fraction (LVEF) ≤35%, and New York Heart Association (NYHA) classes II-III who were randomized to either supervised high-intensity interval training with exercise target intensity of 90%-95% of peak heart rate (HRpeak) or supervised moderate continuous training (MCT) with target intensity of 60%-70% of HRpeak, or who received a recommendation of regular exercise on their own. Predictors of ΔV˙O2peak were assessed in two models: a logistic regression model comparing highest and lowest tertiles (baseline parameters) and a multivariate linear regression model (test/training/clinical parameters). RESULTS The change in V˙O2peak in response to the interventions (ΔV˙O2peak) varied substantially, from -8.50 to +11.30 mL·kg·min. Baseline NYHA (class II gave higher odds vs III; odds ratio (OR), 7.1 (2.0-24.9); P = 0.002), LVEF (OR per percent, 1.1 (1.0-1.2); P = 0.005), and age (OR per 10 yr, 0.5 (0.3-0.8); P = 0.003) were associated with ΔV˙O2peak.In the multivariate linear regression, 34% of the variability in ΔV˙O2peak was explained by the increase in exercise training workload, ΔHRpeak between baseline and 12-wk posttesting, age, and ever having smoked. CONCLUSION Exercise training response (ΔV˙O2peak) correlated negatively with age, LVEF, and NYHA class. The ability to increase workload during the training period and increased ΔHRpeak between baseline and the 12-wk test were associated with a positive outcome.",2020,"Baseline NYHA (class II gave higher odds vs III, odds ratio (OR) 7.1 (2.0, 24.9), p=0.002), LVEF OR per % 1.1 (1.0, 1.2), p = 0.005), age (OR per 10 years 0.5 (0.3, 0.8)), p=0.003) were associated with ΔVO2peak.","['215 patients with heart failure with left ventricular ejection fraction (LVEF) <35%, and NYHA class II-III', 'Systolic Heart Failure Patients']","['supervised high intensity interval training (HIIT) with exercise target intensity 90-95% of peak heart rate (HRpeak), supervised moderate continuous training (MCT) with target intensity 60-70% of HRpeak, or who received a recommendation of regular exercise on their own (RRE']",['peak oxygen uptake (VO2peak'],"[{'cui': 'C4709308', 'cui_str': '215 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0441886', 'cui_str': 'Class 2 (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C1135191', 'cui_str': 'Heart Failure, Systolic'}]","[{'cui': 'C4277545', 'cui_str': 'High-Intensity Intermittent Exercise'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0582191', 'cui_str': 'Regular exercise (observable entity)'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake (observable entity)'}]",215.0,0.0707408,"Baseline NYHA (class II gave higher odds vs III, odds ratio (OR) 7.1 (2.0, 24.9), p=0.002), LVEF OR per % 1.1 (1.0, 1.2), p = 0.005), age (OR per 10 years 0.5 (0.3, 0.8)), p=0.003) were associated with ΔVO2peak.","[{'ForeName': 'Trine', 'Initials': 'T', 'LastName': 'Karlsen', 'Affiliation': 'Faculty of Nursing and Health Sciences, Nord University, Bodø, NORWAY.'}, {'ForeName': 'Vibeke', 'Initials': 'V', 'LastName': 'Videm', 'Affiliation': 'Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, Trondheim, NORWAY.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Halle', 'Affiliation': 'Department of Prevention, Rehabilitation and Sports Medicine, Technische Universität München, Klinikum rechts der Isar, Munich, GERMANY.'}, {'ForeName': 'Øyvind', 'Initials': 'Ø', 'LastName': 'Ellingsen', 'Affiliation': 'Clinic of Cardiology, St. Olavs University Hospital, Trondheim, NORWAY.'}, {'ForeName': 'Asbjørn', 'Initials': 'A', 'LastName': 'Støylen', 'Affiliation': 'Clinic of Cardiology, St. Olavs University Hospital, Trondheim, NORWAY.'}, {'ForeName': 'Håvard', 'Initials': 'H', 'LastName': 'Dalen', 'Affiliation': 'Clinic of Cardiology, St. Olavs University Hospital, Trondheim, NORWAY.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Delagardelle', 'Affiliation': 'Department of Cardiology, Centre Hospitalier de Luxembourg, LUXEMBOURG.'}, {'ForeName': 'Alf Inge', 'Initials': 'AI', 'LastName': 'Larsen', 'Affiliation': 'Department of Cardiology, Stavanger University Hospital, Stavanger, NORWAY.'}, {'ForeName': 'Torstein', 'Initials': 'T', 'LastName': 'Hole', 'Affiliation': 'Department of Circulation and Medical Imaging, NTNU - Norwegian University of Science and Technology, Trondheim, NORWAY.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Mezzani', 'Affiliation': 'Cardiac Rehabilitation Division, Salvatore Maugeri Foundation IRCCS, Scientific Institute of Veruno, Veruno, ITALY.'}, {'ForeName': 'Emeline M', 'Initials': 'EM', 'LastName': 'VAN Craenenbroeck', 'Affiliation': 'Department of Cardiology, Antwerp University Hospital, Edegem, BELGIUM.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Beckers', 'Affiliation': 'Department of Cardiology, Antwerp University Hospital, Edegem, BELGIUM.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Pressler', 'Affiliation': 'Department of Prevention, Rehabilitation and Sports Medicine, Technische Universität München, Klinikum rechts der Isar, Munich, GERMANY.'}, {'ForeName': 'Jeffrey W', 'Initials': 'JW', 'LastName': 'Christle', 'Affiliation': 'Department of Prevention, Rehabilitation and Sports Medicine, Technische Universität München, Klinikum rechts der Isar, Munich, GERMANY.'}, {'ForeName': 'Ephraim B', 'Initials': 'EB', 'LastName': 'Winzer', 'Affiliation': 'Heart Center Dresden, University Hospital at the Technical University of Dresden, Dresden, GERMANY.'}, {'ForeName': 'Norman', 'Initials': 'N', 'LastName': 'Mangner', 'Affiliation': 'Heart Center Dresden, University Hospital at the Technical University of Dresden, Dresden, GERMANY.'}, {'ForeName': 'Felix J', 'Initials': 'FJ', 'LastName': 'Woitek', 'Affiliation': 'Heart Center Dresden, University Hospital at the Technical University of Dresden, Dresden, GERMANY.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Höllriegel', 'Affiliation': 'Heart Center Dresden, University Hospital at the Technical University of Dresden, Dresden, GERMANY.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Snoer', 'Affiliation': 'Department of Cardiology, Zeeland University Hospital, Roskilde, DENMARK.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Feiereisen', 'Affiliation': 'Department of Cardiology, Centre Hospitalier de Luxembourg, LUXEMBOURG.'}, {'ForeName': 'Torstein', 'Initials': 'T', 'LastName': 'Valborgland', 'Affiliation': 'Department of Cardiology, Stavanger University Hospital, Stavanger, NORWAY.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Linke', 'Affiliation': 'Heart Center Dresden, University Hospital at the Technical University of Dresden, Dresden, GERMANY.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Prescott', 'Affiliation': 'Department of Cardiology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, DENMARK.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002193'] 457,31915189,Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men.,"OBJECTIVE Disrupted sleep increases CSF levels of tau and β-amyloid (Aβ) and is associated with an increased risk of Alzheimer disease (AD). Our aim was to determine whether acute sleep loss alters diurnal profiles of plasma-based AD-associated biomarkers. METHODS In a 2-condition crossover study, 15 healthy young men participated in 2 standardized sedentary in-laboratory conditions in randomized order: normal sleep vs overnight sleep loss. Plasma levels of total tau (t-tau), Aβ40, Aβ42, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were assessed using ultrasensitive single molecule array assays or ELISAs, in the fasted state in the evening prior to, and in the morning after, each intervention. RESULTS In response to sleep loss (+17.2%), compared with normal sleep (+1.8%), the evening to morning ratio was increased for t-tau ( p = 0.035). No changes between the sleep conditions were seen for levels of Aβ40, Aβ42, NfL, or GFAP (all p > 0.10). The AD risk genotype rs4420638 did not significantly interact with sleep loss-related diurnal changes in plasma levels of Aβ40 or Aβ42 ( p > 0.10). Plasma levels of Aβ42 (-17.1%) and GFAP (-12.1%) exhibited an evening to morning decrease across conditions ( p < 0.05). CONCLUSIONS Our exploratory study suggests that acute sleep loss results in increased blood levels of t-tau. These changes provide further evidence that sleep loss may have detrimental effects on brain health even in younger individuals. Larger cohorts are warranted to delineate sleep vs circadian mechanisms, implications for long-term recurrent conditions (e.g., in shift workers), as well as interactions with other lifestyle and genetic factors.",2020,"No changes between the sleep conditions were seen for levels of Aβ40, Aβ42, NfL, or GFAP (all p > 0.10).","['15 healthy young men participated in 2 standardized sedentary in-laboratory conditions in randomized order', 'young men']",['normal sleep vs overnight sleep loss'],"['levels of Aβ40, Aβ42, NfL, or GFAP', 'evening to morning ratio', 'blood levels', 'normal sleep', 'sleep loss', 'Plasma levels of Aβ42', 'CSF levels of tau and β-amyloid ', 'risk of Alzheimer disease (AD', 'diurnal plasma dynamics of CNS health biomarkers', 'Plasma levels of total tau (t-tau), Aβ40, Aβ42, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP', 'GFAP']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}]","[{'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0439583', 'cui_str': 'Overnight (qualifier value)'}, {'cui': 'C0235161', 'cui_str': 'Sleep loss'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0017626', 'cui_str': 'Glial Intermediate Filament Protein'}, {'cui': 'C0587117', 'cui_str': 'Evening (qualifier value)'}, {'cui': 'C0332170', 'cui_str': 'Morning (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0005768'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0235161', 'cui_str': 'Sleep loss'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C1720655', 'cui_str': 'Tau'}, {'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C0332169', 'cui_str': 'Daytime (qualifier value)'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C0337112', 'cui_str': 'Chain, device (physical object)'}]",15.0,0.110715,"No changes between the sleep conditions were seen for levels of Aβ40, Aβ42, NfL, or GFAP (all p > 0.10).","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Benedict', 'Affiliation': 'From the Departments of Neuroscience (C.B., J.C.) and Medical Sciences (J.C.), Uppsala University; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London, UK.'}, {'ForeName': 'Kaj', 'Initials': 'K', 'LastName': 'Blennow', 'Affiliation': 'From the Departments of Neuroscience (C.B., J.C.) and Medical Sciences (J.C.), Uppsala University; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London, UK.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Zetterberg', 'Affiliation': 'From the Departments of Neuroscience (C.B., J.C.) and Medical Sciences (J.C.), Uppsala University; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Cedernaes', 'Affiliation': 'From the Departments of Neuroscience (C.B., J.C.) and Medical Sciences (J.C.), Uppsala University; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London, UK. jonathan.cedernaes@medsci.uu.se.'}]",Neurology,['10.1212/WNL.0000000000008866'] 458,31932513,Interaction of serum vitamin B 12 and folate with MTHFR genotypes on risk of ischemic stroke.,"OBJECTIVE We evaluated the interaction of serum folate and vitamin B 12 with methylenetetrahydrofolate reductase ( MTHFR ) C677T genotypes on the risk of first ischemic stroke and on the efficacy of folic acid treatment in prevention of first ischemic stroke. METHODS A total of 20,702 hypertensive adults were randomized to a double-blind treatment of daily enalapril 10 mg and folic acid 0.8 mg or enalapril 10 mg alone. Participants were followed up every 3 months. RESULTS Median values of folate and B 12 concentrations at baseline were 8.1 ng/mL and 280.2 pmol/L, respectively. Over a median of 4.5 years, among those not receiving folic acid, participants with baseline serum B 12 or serum folate above the median had a significantly lower risk of first ischemic stroke (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.57-0.96), especially in those with MTHFR 677 CC genotype (wild-type) (HR, 0.49; 95% CI, 0.31-0.78). Folic acid treatment significantly reduced the risk of first ischemic stroke in participants with both folate and B 12 below the median (2.3% in enalapril-folic acid group vs 3.6% in enalapril-only group; HR, 0.62; 95% CI, 0.46-0.86), particularly in MTHFR 677 CC carriers (1.6% vs 4.9%; HR, 0.24; 95% CI, 0.11-0.55). However, TT homozygotes responded better with both folate and B 12 levels above the median (HR, 0.28; 95% CI, 0.10-0.75). CONCLUSIONS The risk of first ischemic stroke was significantly higher in hypertensive patients with low levels of both folate and B 12 . Effect of folic acid treatment was greatest in patients with low folate and B 12 with the CC genotype, and with high folate and B 12 with the TT genotype.",2020,"Folic acid treatment significantly reduced the risk of first ischemic stroke in participants with both folate and B 12 below the median (2.3% in enalapril-folic acid group vs 3.6% in enalapril-only group; HR, 0.62; 95% CI, 0.46-0.86), particularly in MTHFR 677 CC carriers (1.6% vs 4.9%; HR, 0.24; 95% CI, 0.11-0.55).","['20,702 hypertensive adults', 'hypertensive patients', 'patients with low folate and B 12 with the CC genotype, and with high folate and B 12 with the TT genotype']","['serum folate and vitamin B 12 with methylenetetrahydrofolate reductase ( MTHFR ) C677T genotypes', 'Folic acid', 'folic acid', 'daily enalapril 10 mg and folic acid 0.8 mg or enalapril 10 mg alone', 'enalapril', 'enalapril-folic acid', 'folic acid treatment', 'serum vitamin B 12 and folate with MTHFR genotypes']","['Median values of folate and B 12 concentrations', 'risk of first ischemic stroke']","[{'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0178638', 'cui_str': 'Folate'}, {'cui': 'C1285573', 'cui_str': 'Genotype determination'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0178638', 'cui_str': 'Folate'}, {'cui': 'C0042845', 'cui_str': 'cyanocobalamin'}, {'cui': 'C0066357', 'cui_str': 'Methylenetetrahydrofolate Reductase (NADPH2)'}, {'cui': 'C1285573', 'cui_str': 'Genotype determination'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0014025', 'cui_str': 'Enalapril'}, {'cui': 'C0986173', 'cui_str': 'Folic Acid 0.8 MG'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0178638', 'cui_str': 'Folate'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}]",677.0,0.0550573,"Folic acid treatment significantly reduced the risk of first ischemic stroke in participants with both folate and B 12 below the median (2.3% in enalapril-folic acid group vs 3.6% in enalapril-only group; HR, 0.62; 95% CI, 0.46-0.86), particularly in MTHFR 677 CC carriers (1.6% vs 4.9%; HR, 0.24; 95% CI, 0.11-0.55).","[{'ForeName': 'Xianhui', 'Initials': 'X', 'LastName': 'Qin', 'Affiliation': ""From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.""}, {'ForeName': 'J David', 'Initials': 'JD', 'LastName': 'Spence', 'Affiliation': ""From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.""}, {'ForeName': 'Jianping', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ""From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ""From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.""}, {'ForeName': 'Youbao', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ""From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.""}, {'ForeName': 'Ningling', 'Initials': 'N', 'LastName': 'Sun', 'Affiliation': ""From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.""}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Liang', 'Affiliation': ""From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.""}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': ""From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.""}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ""From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.""}, {'ForeName': 'Binyan', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': ""From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.""}, {'ForeName': 'Xiaoshu', 'Initials': 'X', 'LastName': 'Cheng', 'Affiliation': ""From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.""}, {'ForeName': 'Lianyou', 'Initials': 'L', 'LastName': 'Zhao', 'Affiliation': ""From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.""}, {'ForeName': 'Xiaobin', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ""From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.""}, {'ForeName': 'Xiping', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': ""From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD. huoyong@263.net.cn xipingxu126@126.com.""}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Huo', 'Affiliation': ""From Renal Division (X.Q., Y.L., M.L., Y.Z., X.X.), Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease (X.Q., Y.L., M.L., Y.Z., X.X.); State Key Laboratory for Organ Failure Research (X.Q., Y.L., M.L., Y.Z., X.X.), Guangzhou, China; Stroke Prevention and Atherosclerosis Research Centre (J.D.S.), Robarts Research Institute, University of Western Ontario, London, Canada; Department of Cardiology (J.L., Y.Z., Y.H.), Peking University First Hospital; Department of Cardiology (N.S.), Peking University People's Hospital; Beijing Advanced Innovation Center for Food Nutrition and Human Health (Y.S.), Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing; Institute for Biomedicine (B.W.), Anhui Medical University, Hefei; Department of Cardiology (X.C.), Second Affiliated Hospital, Nanchang University; Department of Cardiology (L.Z.), Tangdu Hospital, the Fourth Military Medical University, Xi'an, China; and Department of Population, Family and Reproductive Health (X.W.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD. huoyong@263.net.cn xipingxu126@126.com.""}]",Neurology,['10.1212/WNL.0000000000008932'] 459,32131865,Mobile phone support to sustain exclusive breastfeeding in the community after hospital delivery and counseling: a quasi-experimental study.,"BACKGROUND Rapid increases in hospital and cesarean deliveries threaten an already falling exclusive breastfeeding rate (EBR) in Bangladesh. There is neither a sustained Baby-Friendly Hospital Initiative (BFHI) nor any community support for breastfeeding mothers. Our aim was to find out whether breastfeeding support after hospital delivery and subsequently by mobile phone at home is effective in improving EBR in infants under six-months of age. METHODS A quasi-experimental study was carried out in 2010 at the Centre for Woman and Child Health (CWCH), Savar, Bangladesh. A total of 129 mothers delivered at CWCH were recruited in pre-intervention phase and their infants followed up between 0 and 5 months of age in the community for exclusive breastfeeding (EBF), anthropometry and illness. An intervention package was then implemented with postpartum support for first hour breastfeeding initiation, correction of position and attachment and face-to-face counseling in hospital followed by mobile phone support by two trained Research Assistants once every 15 days after discharge up to six months of age. During the intervention phase, 164 pregnant women delivered at CWCH were recruited and followed up as in the pre-intervention phase. RESULTS In the pre-intervention phase among 114 infants, 66 (58%) were found to be exclusively breastfed. In the intervention phase among 151 infants, 118 (78%) were exclusively breastfed (p = 0.000). In the pre-intervention phase EBR at less than one month and five months were 85 and 42% as in the intervention phase these EBR were 89 and 71% respectively. Wasting (weight-for-height Z-score < - 2.00), stunting (height-for-age Z-score < - 2.00), and underweight (weight-for-age Z-score < - 2.00) was 17 (15%), 7 (6%), and 14 (13%) respectively in the pre-intervention phase. In the intervention phase wasting, stunting, and underweight was 16 (11%), 16 (11%), and 15 (10%) respectively. Therefore, there was no statistically significant differences in nutritional status of the infants in the two phases. There was also no significant differences in child morbidity (pneumonia and diarrhea) between the two phases. CONCLUSION A combination of hospital support and mobile phone counseling in the community sustained higher rates of EBF in the community after hospital delivery.",2020,"In the intervention phase among 151 infants, 118 (78%) were exclusively breastfed (p = 0.000).","['A quasi-experimental study was carried out in 2010 at the Centre for Woman and Child Health (CWCH), Savar, Bangladesh', 'Wasting (weight-for-height Z-score\u2009<\u2009-\u20092.00), stunting (height-for-age Z-score\u2009<\u2009-\u20092.00), and underweight', 'infants under six-months of age', 'hospital and cesarean deliveries threaten an already falling exclusive breastfeeding rate (EBR) in Bangladesh', '129 mothers delivered at CWCH\xa0were recruited in pre-intervention phase and their infants\xa0followed up between 0 and 5\u2009months of age in the community for exclusive breastfeeding (EBF), anthropometry and illness', '164 pregnant women\xa0delivered at CWCH were recruited and followed up as in the pre-intervention phase', '114 infants, 66 (58%) were found to be exclusively breastfed']","['Mobile phone support to sustain exclusive breastfeeding', 'hospital support and mobile phone counseling']","['child morbidity (pneumonia and diarrhea', 'wasting, stunting, and underweight', 'sustained Baby-Friendly Hospital Initiative (BFHI', 'nutritional status']","[{'cui': 'C2985410', 'cui_str': 'Clinical Trials, Nonrandomized'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0008078', 'cui_str': 'Childrens Health'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C0235394', 'cui_str': 'Wasting'}, {'cui': 'C0424670', 'cui_str': 'Weight for height (observable entity)'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0018273', 'cui_str': 'Stunting'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C1384674', 'cui_str': 'Deliveries by cesarean (finding)'}, {'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C0242205', 'cui_str': 'Breast Feeding, Exclusive'}, {'cui': 'C0566687', 'cui_str': 'Mother delivered (finding)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C4708785', 'cui_str': 'One hundred and fourteen'}]","[{'cui': 'C1136360', 'cui_str': 'Mobile Phone'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0443318', 'cui_str': 'Sustained (qualifier value)'}, {'cui': 'C0242205', 'cui_str': 'Breast Feeding, Exclusive'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0235394', 'cui_str': 'Wasting'}, {'cui': 'C0018273', 'cui_str': 'Stunting'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0424093', 'cui_str': 'Initiative (observable entity)'}, {'cui': 'C0392209', 'cui_str': 'Nutrition Status'}]",164.0,0.0259962,"In the intervention phase among 151 infants, 118 (78%) were exclusively breastfed (p = 0.000).","[{'ForeName': 'Iftia', 'Initials': 'I', 'LastName': 'Jerin', 'Affiliation': 'Centre for Woman and Child Health (CWCH), Savar, Dhaka, 1349, Bangladesh.'}, {'ForeName': 'Monira', 'Initials': 'M', 'LastName': 'Akter', 'Affiliation': 'Centre for Woman and Child Health (CWCH), Savar, Dhaka, 1349, Bangladesh. monira.akter03@yahoo.com.'}, {'ForeName': 'Khurshid', 'Initials': 'K', 'LastName': 'Talukder', 'Affiliation': 'Centre for Woman and Child Health (CWCH), Savar, Dhaka, 1349, Bangladesh.'}, {'ForeName': 'Muhammad Qudrat E Khuda', 'Initials': 'MQEK', 'LastName': 'Talukder', 'Affiliation': 'Centre for Woman and Child Health (CWCH), Savar, Dhaka, 1349, Bangladesh.'}, {'ForeName': 'Mohammad Abdur', 'Initials': 'MA', 'LastName': 'Rahman', 'Affiliation': 'Department of Public Health and Informatics, Jahangirnagar University, Savar, Dhaka, 1342, Bangladesh.'}]",International breastfeeding journal,['10.1186/s13006-020-00258-z'] 460,32187788,Longitudinal effects of a novel advanced pneumatic compression device on patient-reported outcomes in the management of cancer-related head and neck lymphedema: A preliminary report.,"BACKGROUND Head and neck cancer (HNC) survivors experience head and neck lymphedema (HNL), which requires treatment to prevent morbidity. We explore the self-reported outcomes and satisfaction of patients with HNC receiving treatment for HNL with an advanced pneumatic compression device (APCD). METHODS HNC survivors (n = 205) prescribed with an at-home Flexitouch head and neck APCD completed pretreatment and posttreatment self-reported assessments addressing efficacy, function, and symptoms. Participant average age was 60 years with 74% male. Pre-post responses for ≥25 days of use were assessed via the non-parametric Wilcoxon Signed Rank test. RESULTS Analysis revealed statistically significant improvement in all symptoms and all function items (P < 0.00001). Compliance with prescribed therapy (at least 30 minutes daily) was high with 71% of participants reporting daily use and 87% reporting overall satisfaction. CONCLUSIONS The reported improvements in function and symptoms, and high compliance rate, provide a rationale for a subsequent randomized controlled trial.",2020,"RESULTS Analysis revealed statistically significant improvement in all symptoms and all function items (P < 0.00001).","['Head and neck cancer (HNC) survivors experience head and neck lymphedema (HNL', 'HNC survivors (n = 205) prescribed with an at-home Flexitouch head and neck APCD completed pretreatment and posttreatment self-reported assessments addressing efficacy, function, and symptoms', 'cancer-related head and neck lymphedema', 'Participant average age was 60\u2009years with 74% male. Pre-post responses for ≥25\u2009days of use were assessed via the non-parametric Wilcoxon Signed Rank test', 'patients with HNC receiving treatment for HNL with an advanced pneumatic compression device (APCD']",['novel advanced pneumatic compression device'],"['function and symptoms, and high compliance rate', 'all symptoms and all function items']","[{'cui': 'C0278996', 'cui_str': 'Cancer of Head and Neck'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0027536', 'cui_str': 'Necking (finding)'}, {'cui': 'C0024236', 'cui_str': 'Lymphedema'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0376649', 'cui_str': 'Address'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C0699794', 'cui_str': 'Rank (attribute)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0220819', 'cui_str': 'devices'}]","[{'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0220819', 'cui_str': 'devices'}]","[{'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}]",,0.0888776,"RESULTS Analysis revealed statistically significant improvement in all symptoms and all function items (P < 0.00001).","[{'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Gutiérrez', 'Affiliation': 'Department of Physical Medicine & Rehabilitation, The University of Texas Health Science Center / McGovern Medical School, Houston, Texas.'}, {'ForeName': 'Harvey N', 'Initials': 'HN', 'LastName': 'Mayrovitz', 'Affiliation': 'Division of Physiology, Department of Medical Education, Nova Southeastern University, Dr. Kiran C. Patel College of Allopathic Medicine, Fort Lauderdale, Florida.'}, {'ForeName': 'Syed Hassan Shiraz', 'Initials': 'SHS', 'LastName': 'Naqvi', 'Affiliation': 'Department of Otorhinolaryngology - Head & Neck Surgery, The University of Texas Health Science Center / McGovern Medical School, Houston, Texas.'}, {'ForeName': 'Ron J', 'Initials': 'RJ', 'LastName': 'Karni', 'Affiliation': 'Division of Head & Neck Surgical Oncology, Department of Otorhinolaryngology - Head & Neck Surgery Division of Medical Oncology, The University of Texas Health Science Center / McGovern Medical School, Houston, Texas.'}]",Head & neck,['10.1002/hed.26110'] 461,32186013,"Jiawei Xiaoyao capsule treatment for mild to moderate major depression with anxiety symptoms: a randomized, double-blind, double-dummy, controlled, multicenter, parallel-treatment trial.","OBJECTIVE To assess the efficacy and safety of Jiawei Xiaoyao (JWXY) capsules on mild to moderate depression with anxiety symptoms, a randomized, double-blind, double-dummy controlled, multicenter, parallel-treatment trial was carried out among 210 outpatients with mild to moderate depression and anxiety symptoms from three hospitals in Beijing China. METHODS Participants were randomized into the JWXY group or the sertraline group. Each group received JWXY treatment and sertraline placebo, or sertraline and JWXY placebo for 8 weeks. Main outcomes were measured using the Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Rating Scale (HAMA) and the Clinical Global Impression Scale. RESULTS JWXY and sertraline had the equivalent effect on HAMD at every interview point. JWXY was more effective at reducing the HAMA scores at the 2nd and 12th week, HAMD sleep disturbance subscale scores at the 8th and 12th week, and HAMA somatic anxiety subscale scores at the 12th week. The rate of adverse events in the two groups was the same. CONCLUSION For mild to moderate depression with anxiety symptoms, JWXY could be as effective as sertraline in alleviating depressive symptoms. For anxiety symptoms, JWXY may be effective more quickly and with longer lasting effects than sertraline. In particular, it may also improve quality of sleep and somatic anxiety symptoms. JWXY is safe and cheaper than conventional antidepressants, and may be the first alternative choice for depression with anxiety symptoms.",2019,"JWXY was more effective at reducing the HAMA scores at the 2nd and 12th week, HAMD sleep disturbance subscale scores at the 8th and 12th week, and HAMA somatic anxiety subscale scores at the 12th week.","['mild to moderate major depression with anxiety symptoms', '210 outpatients with mild to moderate depression and anxiety symptoms from three hospitals in Beijing China', 'mild to moderate depression with anxiety symptoms', 'Participants']","['Jiawei Xiaoyao (JWXY) capsules', 'sertraline', 'JWXY', 'Jiawei Xiaoyao capsule treatment', 'JWXY treatment and sertraline placebo, or sertraline and JWXY placebo']","['HAMA scores', 'Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Rating Scale (HAMA) and the Clinical Global Impression Scale', 'HAMD sleep disturbance subscale scores', 'HAMA somatic anxiety subscale scores', 'quality of sleep and somatic anxiety symptoms', 'rate of adverse events']","[{'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}]","[{'cui': 'C1869284', 'cui_str': 'xiao-yao'}, {'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C3639708', 'cui_str': 'Clinical global impression scale'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnias'}, {'cui': 'C0459443', 'cui_str': 'Subscale score (qualifier value)'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep (observable entity)'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",210.0,0.369208,"JWXY was more effective at reducing the HAMA scores at the 2nd and 12th week, HAMD sleep disturbance subscale scores at the 8th and 12th week, and HAMA somatic anxiety subscale scores at the 12th week.","[{'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Su', 'Affiliation': 'Department of Scientific Research, Beijing Hospital of Traditional Chinese Medicine,Capital Medical University, Beijing 100010, China.'}, {'ForeName': 'Jiping', 'Initials': 'J', 'LastName': 'Fan', 'Affiliation': 'China Press of Traditional Chinese Medicine, Beijing 100013, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Li', 'Affiliation': 'Department of Neurology, Guang An Men Hospital, China Academy of Chinese Medical Sciences Beijing 100053, China.'}, {'ForeName': 'Xindong', 'Initials': 'X', 'LastName': 'Cao', 'Affiliation': 'Department of Chinese Medicine, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': 'Department of Neurology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China.'}, {'ForeName': 'Zhenyun', 'Initials': 'Z', 'LastName': 'Han', 'Affiliation': 'Department of Neurology, Dongfang Hospital of BeijingUniversity of Chinese Medicine, Beijing 100029, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': 'Department of Pathophysiology and Allergy Research Vienna General Hospital, Vienna A-1090, Austria.'}]",Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan,[] 462,32186016,"Effect of electrically stimulating acupoint, Zusanli (ST 36), on patient's recovery after laparoscopic colorectal cancer resection: a randomized controlled trial.","OBJECTIVE To investigate the effect of transcutaneous electrical acupoint stimulation (TEAS) on enhanced recovery after surgery (ERAS) in laparoscopic colorectal cancer resection and its clinical significance. METHODS Sixty-four patients undergoing laparoscopic colorectal resection were randomly divided into two groups, the control group (group A) and the TEAS group (group B). Patients in the TEAS group received electroacupuncture stimulation of bilateral Zusanli (ST 36) at 30 min before anesthesia to the end of surgery. The patients in the control group were not given the stimulation. Perioperative anesthesia management of the two groups were performed according to the ERAS guidelines, and postoperative patient-controlled intravenous analgesia (PCIA) was used. The amount of remifentanil used in the two groups was observed and recorded, and the visual analogue scale (VAS) of the 4, 12, 24 and 48 h after surgery in the two groups was recorded. Moreover, postoperative anal exhaust time, postoperative feeding time, postoperative first ambulation time and postoperative hospital stay length were compared between the two groups. RESULTS Compared with group A, the VAS score of group B decreased significantly at 48 h after operation (P < 0.05). The postoperative anal exhaust time in group B was significantly shorter than that of group A (P < 0.05). There was no significant difference between the two groups with regards to remifentanil consumption, postoperative feeding time, postoperative first ambulation time and postoperative hospital stay (all P > 0.05). CONCLUSION TEAS can promote the recovery of postoperative gastrointestinal function and reduce the pain intensity 48 h after surgery, thus satisfying the need of early postoperative analgesia.",2019,The postoperative anal exhaust time in group B was significantly shorter than that of group A (P < 0.05).,"['Sixty-four patients undergoing laparoscopic colorectal resection', ""patient's recovery after laparoscopic colorectal cancer resection"", 'laparoscopic colorectal cancer resection']","['surgery (ERAS', 'electrically stimulating acupoint, Zusanli (ST 36', 'remifentanil', 'electroacupuncture stimulation of bilateral Zusanli', 'TEAS', 'transcutaneous electrical acupoint stimulation (TEAS']","['postoperative anal exhaust time, postoperative feeding time, postoperative first ambulation time and postoperative hospital stay length', 'VAS score', 'postoperative anal exhaust time', 'pain intensity', 'remifentanil consumption, postoperative feeding time, postoperative first ambulation time and postoperative hospital stay', 'recovery of postoperative gastrointestinal function', 'visual analogue scale (VAS']","[{'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0555952', 'cui_str': 'Colorectal (qualifier value)'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}]","[{'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0001302', 'cui_str': 'Acupoints'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0442828', 'cui_str': 'Electrical (qualifier value)'}, {'cui': 'C0039400', 'cui_str': 'Tea'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C2939124', 'cui_str': 'Anal (qualifier value)'}, {'cui': 'C0231226', 'cui_str': 'Exhausting (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0945826', 'cui_str': 'Ambulation'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",64.0,0.0177849,The postoperative anal exhaust time in group B was significantly shorter than that of group A (P < 0.05).,"[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Huang', 'Affiliation': 'Department of Anesthesiology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510000, China.'}, {'ForeName': 'Wenfei', 'Initials': 'W', 'LastName': 'Long', 'Affiliation': 'Department of Anesthesiology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510000, China.'}, {'ForeName': 'Jianbin', 'Initials': 'J', 'LastName': 'Xiao', 'Affiliation': 'Department of Anesthesiology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510000, China.'}, {'ForeName': 'Gaofeng', 'Initials': 'G', 'LastName': 'Zhao', 'Affiliation': 'Department of Anesthesiology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510000, China.'}, {'ForeName': 'Tingyu', 'Initials': 'T', 'LastName': 'Yu', 'Affiliation': 'Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510000, China.'}]",Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan,[] 463,32186395,A Prospective Randomized Clinical Trial of Combination Therapy with Proton Pump Inhibitors and Mucolytics in Patients with Laryngopharyngeal Reflux.,"OBJECTIVES To identify whether combination therapy with mucolytics and proton pump inhibitors (PPIs) leads to faster and more effective symptomatic relief in patients with laryngopharyngeal reflux (LPR). METHODS Patients diagnosed as LPR with a reflux symptom index (RSI) ≥ 13 and a reflux finding score (RFS) ≥ 7 were enrolled in this prospective study. Patients were randomly allocated to control (PPI only) or experimental (PPI + mucolytics) groups and changes in RSI and RFS values were assessed at 1- and 3-month follow-up. RESULTS One hundred sixteen patients were randomly allocated into either the control group ( n = 59) or the experimental group ( n = 57). The RSI and RFS scores significantly decreased in both groups (all P < .001) after 1 month of treatment; however, there was no significant difference in RSI change between groups ( P = .223). After 3 months of treatment, there remained no significant difference in RSI change between groups ( P = .592). CONCLUSIONS Combination therapy with mucolytics and PPI compared to PPI alone did not lead to faster or more effective symptomatic relief in LPR patients.",2020,"The RSI and RFS scores significantly decreased in both groups (all P < .001) after 1 month of treatment; however, there was no significant difference in RSI change between groups ( P = .223).","['patients with laryngopharyngeal reflux (LPR', 'Patients diagnosed as LPR with a reflux symptom index (RSI) ≥ 13 and a reflux finding score (RFS) ≥ 7 were enrolled', 'LPR patients', 'Patients with Laryngopharyngeal Reflux', 'One hundred sixteen patients']","['mucolytics and proton pump inhibitors (PPIs', 'control (PPI only) or experimental (PPI + mucolytics', 'Proton Pump Inhibitors and Mucolytics']","['effective symptomatic relief', 'RSI and RFS values', 'RSI change', 'RSI and RFS scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1168250', 'cui_str': 'Laryngopharyngeal Reflux'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0303134', 'cui_str': '7Be radioisotope'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3715157', 'cui_str': '16'}]","[{'cui': 'C4521480', 'cui_str': 'Hydrogen/potassium adenosine triphosphatase enzyme system inhibitor (disposition)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0026698', 'cui_str': 'Mucolytics'}]","[{'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C1301676', 'cui_str': 'Relieves (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",116.0,0.0204404,"The RSI and RFS scores significantly decreased in both groups (all P < .001) after 1 month of treatment; however, there was no significant difference in RSI change between groups ( P = .223).","[{'ForeName': 'Minsuk', 'Initials': 'M', 'LastName': 'Chae', 'Affiliation': 'Department of Otorhinolaryngology, Eulji University School of Medicine, Eulji Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Dong Hyuk', 'Initials': 'DH', 'LastName': 'Jang', 'Affiliation': 'Department of Otorhinolaryngology, Eulji University School of Medicine, Eulji Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Ho Chan', 'Initials': 'HC', 'LastName': 'Kim', 'Affiliation': 'Department of Otorhinolaryngology, Eulji University School of Medicine, Eulji Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Minsu', 'Initials': 'M', 'LastName': 'Kwon', 'Affiliation': 'Korea University Hospital, Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Seoul, Republic of Korea.'}]","The Annals of otology, rhinology, and laryngology",['10.1177/0003489420913592'] 464,32179526,Significant Efficacy of a Single Low Dose of Primaquine Compared to Stand-Alone Artemisinin Combination Therapy in Reducing Gametocyte Carriage in Cambodian Patients with Uncomplicated Multidrug-Resistant Plasmodium falciparum Malaria.,"Since 2012, a single low dose of primaquine (SLDPQ; 0.25 mg/kg of body weight) with artemisinin-based combination therapies has been recommended as the first-line treatment of acute uncomplicated Plasmodium falciparum malaria to interrupt its transmission, especially in low-transmission settings of multidrug resistance, including artemisinin resistance. Policy makers in Cambodia have been reluctant to implement this recommendation due to primaquine safety concerns and a lack of data on its efficacy. In this randomized controlled trial, 109 Cambodians with acute uncomplicated P. falciparum malaria received dihydroartemisinin-piperaquine (DP) alone or combined with SLDPQ on the first treatment day. The transmission-blocking efficacy of SLDPQ was evaluated on days 0, 1, 2, 3, 7, 14, 21, and 28, and recrudescence by reverse transcriptase PCR (RT-PCR) (gametocyte prevalence) and membrane feeding assays with Anopheles minimus mosquitoes (gametocyte infectivity). Without the influence of recrudescent infections, DP-SLDPQ reduced gametocyte carriage 3-fold compared to that achieved with DP. Of 48 patients tested on day 0, only 3 patients were infectious to mosquitoes (∼6%). Posttreatment, three patients were infectious on day 14 (3.5%, 1/29) and on the 1st and 7th days of recrudescence (8.3%, 1/12 for each); this overall low infectivity precluded our ability to assess its transmission-blocking efficacy. Our study confirms the effective gametocyte clearance of SLDPQ when combined with DP in multidrug-resistant P. falciparum infections and the negative impact of recrudescent infections due to poor DP efficacy. Artesunate-mefloquine (ASMQ) has replaced DP, and ASMQ-SLDPQ has been deployed to treat all patients with symptomatic P. falciparum infections to further support the elimination of multidrug-resistant P. falciparum in Cambodia. (This study has been registered at ClinicalTrials.gov under identifier NCT02434952.).",2020,"Without the influence of recrudescent infections, DP+SLDPQ reduced gametocyte carriage 3 fold compared to DP.","['109 Cambodians with acute uncomplicated P. falciparum malaria received', 'Cambodian patients with uncomplicated multidrug resistant Plasmodium falciparum malaria']","['primaquine', 'stand alone artemisinin combination therapy', 'SLDPQ', 'primaquine (SLDPQ', 'Artesunate-mefloquine (ASMQ', 'dihydroartemisinin-piperaquine (DP) alone or combined with SLDPQ']","['gametocyte carriage', 'transcriptase polymerase chain reaction (RT-PCR) (gametocyte prevalence) and membrane-feeding assays with Anopheles minimus mosquitoes (gametocyte infectivity']","[{'cui': 'C1553323', 'cui_str': 'Cambodians'}, {'cui': 'C0024535', 'cui_str': 'Plasmodium falciparum Malaria'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}]","[{'cui': 'C0033126', 'cui_str': 'Primaquine'}, {'cui': 'C0560204', 'cui_str': 'Does stand alone (finding)'}, {'cui': 'C1136174', 'cui_str': 'Artemisinins'}, {'cui': 'C0556895', 'cui_str': 'Combination therapy (regime/therapy)'}, {'cui': 'C0052432', 'cui_str': 'artesunate'}, {'cui': 'C0025153', 'cui_str': 'Mefloquine'}, {'cui': 'C0058108', 'cui_str': 'quinghaosu, dihydro-'}, {'cui': 'C0071105', 'cui_str': ""Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-)""}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0686869', 'cui_str': 'Gametocyte'}, {'cui': 'C0035681', 'cui_str': 'RNA Polymerases'}, {'cui': 'C0032520', 'cui_str': 'PCR'}, {'cui': 'C3853643', 'cui_str': 'Probe with target amplification technique (qualifier value)'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0025255', 'cui_str': 'Membranes'}, {'cui': 'C2987508', 'cui_str': 'Feeding (observable entity)'}, {'cui': 'C1510438', 'cui_str': 'Assay technique (qualifier value)'}, {'cui': 'C0322934', 'cui_str': 'Anopheles minimus (organism)'}, {'cui': 'C0026584', 'cui_str': 'Mosquitoes'}, {'cui': 'C0030657', 'cui_str': 'infectivity'}]",109.0,0.0456092,"Without the influence of recrudescent infections, DP+SLDPQ reduced gametocyte carriage 3 fold compared to DP.","[{'ForeName': 'Amélie', 'Initials': 'A', 'LastName': 'Vantaux', 'Affiliation': 'Malaria Molecular Epidemiology Unit, Institut Pasteur of Cambodia, Phnom Penh, Cambodia amelie.vantaux@gmail.com.'}, {'ForeName': 'Saorin', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Malaria Molecular Epidemiology Unit, Institut Pasteur of Cambodia, Phnom Penh, Cambodia.'}, {'ForeName': 'Eakpor', 'Initials': 'E', 'LastName': 'Piv', 'Affiliation': 'Malaria Molecular Epidemiology Unit, Institut Pasteur of Cambodia, Phnom Penh, Cambodia.'}, {'ForeName': 'Sophy', 'Initials': 'S', 'LastName': 'Chy', 'Affiliation': 'Malaria Molecular Epidemiology Unit, Institut Pasteur of Cambodia, Phnom Penh, Cambodia.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Berne', 'Affiliation': 'Malaria Molecular Epidemiology Unit, Institut Pasteur of Cambodia, Phnom Penh, Cambodia.'}, {'ForeName': 'Nimol', 'Initials': 'N', 'LastName': 'Khim', 'Affiliation': 'Malaria Molecular Epidemiology Unit, Institut Pasteur of Cambodia, Phnom Penh, Cambodia.'}, {'ForeName': 'Dysoley', 'Initials': 'D', 'LastName': 'Lek', 'Affiliation': 'National Center for Parasitology, Entomology and Malaria Control Program, Phnom Penh, Cambodia.'}, {'ForeName': 'Sovannaroth', 'Initials': 'S', 'LastName': 'Siv', 'Affiliation': 'National Center for Parasitology, Entomology and Malaria Control Program, Phnom Penh, Cambodia.'}, {'ForeName': 'Mavuto', 'Initials': 'M', 'LastName': 'Mukaka', 'Affiliation': 'Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand.'}, {'ForeName': 'Walter R', 'Initials': 'WR', 'LastName': 'Taylor', 'Affiliation': 'Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand.'}, {'ForeName': 'Didier', 'Initials': 'D', 'LastName': 'Ménard', 'Affiliation': 'Malaria Molecular Epidemiology Unit, Institut Pasteur of Cambodia, Phnom Penh, Cambodia.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.02108-19'] 465,31348529,Vitamin D supplementation for women during pregnancy.,"BACKGROUND Vitamin D supplementation during pregnancy may be needed to protect against adverse pregnancy outcomes. This is an update of a review that was first published in 2012 and then in 2016. OBJECTIVES To examine whether vitamin D supplementation alone or in combination with calcium or other vitamins and minerals given to women during pregnancy can safely improve maternal and neonatal outcomes. SEARCH METHODS For this update, we searched Cochrane Pregnancy and Childbirth's Trials Register (12 July 2018), contacted relevant organisations (15 May 2018), reference lists of retrieved trials and registries at clinicaltrials.gov and WHO International Clinical Trials Registry Platform (12 July 2018). Abstracts were included if they had enough information to extract the data. SELECTION CRITERIA Randomised and quasi-randomised trials evaluating the effect of supplementation with vitamin D alone or in combination with other micronutrients for women during pregnancy in comparison to placebo or no intervention. DATA COLLECTION AND ANALYSIS Two review authors independently i) assessed the eligibility of trials against the inclusion criteria, ii) extracted data from included trials, and iii) assessed the risk of bias of the included trials. The certainty of the evidence was assessed using the GRADE approach. MAIN RESULTS We included 30 trials (7033 women), excluded 60 trials, identified six as ongoing/unpublished trials and two trials are awaiting assessments.Supplementation with vitamin D alone versus placebo/no interventionA total of 22 trials involving 3725 pregnant women were included in this comparison; 19 trials were assessed as having low-to-moderate risk of bias for most domains and three trials were assessed as having high risk of bias for most domains. Supplementation with vitamin D alone during pregnancy probably reduces the risk of pre-eclampsia (risk ratio (RR) 0.48, 95% confidence interval (CI) 0.30 to 0.79; 4 trials, 499 women, moderate-certainty evidence) and gestational diabetes (RR 0.51, 95% CI 0.27 to 0.97; 4 trials, 446 women, moderate-certainty evidence); and probably reduces the risk of having a baby with low birthweight (less than 2500 g) (RR 0.55, 95% CI 0.35 to 0.87; 5 trials, 697 women, moderate-certainty evidence) compared to women who received placebo or no intervention. Vitamin D supplementation may make little or no difference in the risk of having a preterm birth < 37 weeks compared to no intervention or placebo (RR 0.66, 95% CI 0.34 to 1.30; 7 trials, 1640 women, low-certainty evidence). In terms of maternal adverse events, vitamin D supplementation may reduce the risk of severe postpartum haemorrhage (RR 0.68, 95% CI 0.51 to 0.91; 1 trial, 1134 women, low-certainty evidence). There were no cases of hypercalcaemia (1 trial, 1134 women, low-certainty evidence), and we are very uncertain as to whether vitamin D increases or decreases the risk of nephritic syndrome (RR 0.17, 95% CI 0.01 to 4.06; 1 trial, 135 women, very low-certainty evidence). However, given the scarcity of data in general for maternal adverse events, no firm conclusions can be drawn.Supplementation with vitamin D and calcium versus placebo/no interventionNine trials involving 1916 pregnant women were included in this comparison; three trials were assessed as having low risk of bias for allocation and blinding, four trials were assessed as having high risk of bias and two had some components having a low risk, high risk, or unclear risk. Supplementation with vitamin D and calcium during pregnancy probably reduces the risk of pre-eclampsia (RR 0.50, 95% CI 0.32 to 0.78; 4 trials, 1174 women, moderate-certainty evidence). The effect of the intervention is uncertain on gestational diabetes (RR 0.33,% CI 0.01 to 7.84; 1 trial, 54 women, very low-certainty evidence); and low birthweight (less than 2500 g) (RR 0.68, 95% CI 0.10 to 4.55; 2 trials, 110 women, very low-certainty evidence) compared to women who received placebo or no intervention. Supplementation with vitamin D and calcium during pregnancy may increase the risk of preterm birth < 37 weeks in comparison to women who received placebo or no intervention (RR 1.52, 95% CI 1.01 to 2.28; 5 trials, 942 women, low-certainty evidence). No trial in this comparison reported on maternal adverse events.Supplementation with vitamin D + calcium + other vitamins and minerals versus calcium + other vitamins and minerals (but no vitamin D)One trial in 1300 participants was included in this comparison; it was assessed as having low risk of bias. Pre-eclampsia was not assessed. Supplementation with vitamin D + other nutrients may make little or no difference in the risk of preterm birth < 37 weeks (RR 1.04, 95% CI 0.68 to 1.59; 1 trial, 1298 women, low-certainty evidence); or low birthweight (less than 2500 g) (RR 1.12, 95% CI 0.82 to 1.51; 1 trial, 1298 women, low-certainty evidence). It is unclear whether it makes any difference to the risk of gestational diabetes (RR 0.42, 95% CI 0.10 to 1.73) or maternal adverse events (hypercalcaemia no events; hypercalciuria RR 0.25, 95% CI 0.02 to 3.97; 1 trial, 1298 women,) because the certainty of the evidence for both outcomes was found to be very low. AUTHORS' CONCLUSIONS We included 30 trials (7033 women) across three separate comparisons. Our GRADE assessments ranged from moderate to very low, with downgrading decisions based on limitations in study design, imprecision and indirectness.Supplementing pregnant women with vitamin D alone probably reduces the risk of pre-eclampsia, gestational diabetes, low birthweight and may reduce the risk of severe postpartum haemorrhage. It may make little or no difference in the risk of having a preterm birth < 37 weeks' gestation. Supplementing pregnant women with vitamin D and calcium probably reduces the risk of pre-eclampsia but may increase the risk of preterm births < 37 weeks (these findings warrant further research). Supplementing pregnant women with vitamin D and other nutrients may make little or no difference in the risk of preterm birth < 37 weeks' gestation or low birthweight (less than 2500 g). Additional rigorous high quality and larger randomised trials are required to evaluate the effects of vitamin D supplementation in pregnancy, particularly in relation to the risk of maternal adverse events.",2019,"Vitamin D supplementation may make little or no difference in the risk of having a preterm birth < 37 weeks compared to no intervention or placebo (RR 0.66, 95% CI 0.34 to 1.30; 7 trials, 1640 women, low-certainty evidence).","['30 trials (7033 women) across three separate comparisons', 'women during pregnancy in comparison to placebo or no intervention', '1916 pregnant women', 'gestational diabetes (RR 0.33', 'women during pregnancy', '3725 pregnant women', 'Supplementing pregnant women with', '1300 participants', '30 trials (7033 women), excluded 60 trials, identified six as ongoing/unpublished trials and two trials are awaiting assessments']","['vitamin D alone versus placebo', 'vitamin D supplementation', 'vitamin D and calcium', 'vitamin D + calcium + other vitamins and minerals versus calcium + other vitamins and minerals', 'placebo', 'supplementation with vitamin D alone or in\xa0combination\xa0with other\xa0micronutrients', 'vitamin D', 'vitamin D supplementation alone or in combination with calcium or other vitamins and minerals', 'vitamin D ', 'vitamin D and calcium versus placebo/no interventionNine', 'Vitamin D supplementation']","['risk of nephritic syndrome', 'risk of gestational diabetes', 'gestational diabetes', 'risk of pre-eclampsia, gestational diabetes, low birthweight', 'eclampsia', 'maternal adverse events', 'risk of preterm birth', 'risk of pre-eclampsia', 'risk of severe postpartum haemorrhage', 'risk of having a baby with low birthweight']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0443299', 'cui_str': 'Separate (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0439671', 'cui_str': 'Gestational (qualifier value)'}, {'cui': 'C4517449', 'cui_str': 'Zero point three three'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0042890', 'cui_str': 'Vitamins'}, {'cui': 'C0026162', 'cui_str': 'Minerals'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0268732', 'cui_str': 'Nephritic syndrome (disorder)'}, {'cui': 'C0439671', 'cui_str': 'Gestational (qualifier value)'}, {'cui': 'C0032914', 'cui_str': 'EPH Toxemias'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0013537', 'cui_str': 'Eclampsia'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0151526', 'cui_str': 'Premature Birth'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0032797', 'cui_str': 'Postpartum Hemorrhage'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]",1300.0,0.758436,"Vitamin D supplementation may make little or no difference in the risk of having a preterm birth < 37 weeks compared to no intervention or placebo (RR 0.66, 95% CI 0.34 to 1.30; 7 trials, 1640 women, low-certainty evidence).","[{'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Palacios', 'Affiliation': 'Department of Dietetics and Nutrition, Robert Stempel College of Public Health and Social Work, Florida International University, 11200 SW 8th Street, AHC 5 - 323, Miami, Florida, USA, 33199.'}, {'ForeName': 'Lia K', 'Initials': 'LK', 'LastName': 'Kostiuk', 'Affiliation': ''}, {'ForeName': 'Juan Pablo', 'Initials': 'JP', 'LastName': 'Peña-Rosas', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD008873.pub4'] 466,32122315,"A protocol for a multicentre, parallel-group, pragmatic randomised controlled trial to evaluate the NEVERMIND system in preventing and treating depression in patients with severe somatic conditions.","BACKGROUND Depressive symptoms are common in individuals suffering from severe somatic conditions. There is a lack of interventions and evidence-based interventions aiming to reduce depressive symptoms in patients with severe somatic conditions. The aim of the NEVERMIND project is to address these issues and provide evidence by testing the NEVERMIND system, designed to reduce and prevent depressive symptoms in comparison to treatment as usual. METHODS The NEVERMIND study is a parallel-groups, pragmatic randomised controlled trial to assess the effectiveness of the NEVERMIND system in reducing depressive symptoms among individuals with severe somatic conditions. The NEVERMIND system comprises a smart shirt and a user interface, in the form of a mobile application. The system is a real-time decision support system, aiming to predict the severity and onset of depressive symptoms by modelling the well-being condition of patients based on physiological data, body movement, and the recurrence of social interactions. The study includes 330 patients who have a diagnosis of myocardial infarction, breast cancer, prostate cancer, kidney failure, or lower limb amputation. Participants are randomised in blocks of ten to either the NEVERMIND intervention or treatment as usual as the control group. Clinical interviews and structured questionnaires are administered at baseline, at 12 weeks, and 24 weeks to assess whether the NEVERMIND system is superior to treatment as usual. The endpoint of primary interest is Beck Depression Inventory II (BDI-II) at 12 weeks defined as (i) the severity of depressive symptoms as measured by the BDI-II. Secondary outcomes include prevention of the onset of depressive symptoms, changes in quality of life, perceived stigma, and self-efficacy. DISCUSSION There is a lack of evidence-based interventions aiming to reduce and prevent depressive symptoms in patients with severe somatic conditions. If the NEVERMIND system is effective, it will provide healthcare systems with a novel and innovative method to attend to depressive symptoms in patients with severe somatic conditions. TRIAL REGISTRATION DRKS00013391. Registered 23 November 2017.",2020,"The system is a real-time decision support system, aiming to predict the severity and onset of depressive symptoms by modelling the well-being condition of patients based on physiological data, body movement, and the recurrence of social interactions.","['330 patients who have a diagnosis of myocardial infarction, breast cancer, prostate cancer, kidney failure, or lower limb amputation', 'individuals suffering from severe somatic conditions', 'patients with severe somatic conditions', 'individuals with severe somatic conditions']",[],"['prevention of the onset of depressive symptoms, changes in quality of life, perceived stigma, and self-efficacy', 'depressive symptoms', 'Beck Depression Inventory II (BDI-II) at 12\u2009weeks defined as (i) the severity of depressive symptoms']","[{'cui': 'C4517719', 'cui_str': '330 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}, {'cui': 'C0035078', 'cui_str': 'Kidney Failure'}, {'cui': 'C0337308', 'cui_str': 'Amputation of lower limb (procedure)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]",[],"[{'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0332162', 'cui_str': 'Onset of (contextual qualifier) (qualifier value)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0034380'}, {'cui': 'C0277787', 'cui_str': 'Stigma (finding)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory (assessment scale)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",,0.197858,"The system is a real-time decision support system, aiming to predict the severity and onset of depressive symptoms by modelling the well-being condition of patients based on physiological data, body movement, and the recurrence of social interactions.","[{'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Carli', 'Affiliation': 'National Centre for Suicide Research and Prevention of Mental Ill-Health, Karolinska Institutet, Stockholm, Sweden. Vladimir.carli@ki.se.'}, {'ForeName': 'Danuta', 'Initials': 'D', 'LastName': 'Wasserman', 'Affiliation': 'National Centre for Suicide Research and Prevention of Mental Ill-Health, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Gergö', 'Initials': 'G', 'LastName': 'Hadlaczky', 'Affiliation': 'National Centre for Suicide Research and Prevention of Mental Ill-Health, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Nuhamin Gebrewold', 'Initials': 'NG', 'LastName': 'Petros', 'Affiliation': 'National Centre for Suicide Research and Prevention of Mental Ill-Health, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Carletto', 'Affiliation': 'Department of Neuroscience ""Rita Levi Montalcini"", Università degli Studi di Torino, Turin, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Citi', 'Affiliation': 'School of Computer Science and Electronic Engineering, University of Essex, Colchester, UK.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Dinis', 'Affiliation': 'Faculdade de Medicina and CCUL, Universidade de Lisboa, Lisbon, Portugal.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Gentili', 'Affiliation': 'General Psychology Department, Università degli Studi di Padova, Padua, Italy.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Gonzalez-Martinez', 'Affiliation': 'Life Supporting Technologies, Universidad Politécnica de Madrid, Madrid, Spain.'}, {'ForeName': '', 'Initials': '', 'LastName': 'Aldo De Leonibus', 'Affiliation': 'Inventya LTD, Daresbury, UK.'}, {'ForeName': 'Björn', 'Initials': 'B', 'LastName': 'Meyer', 'Affiliation': 'GAIA AG, Hamburg, Germany.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Ostacoli', 'Affiliation': 'Department of Clinical and Biological Sciences, Università degli studi di Torino, Turin, Italy.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Ottaviano', 'Affiliation': 'Life Supporting Technologies, Universidad Politécnica de Madrid, Madrid, Spain.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Ouakinin', 'Affiliation': 'Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Paradiso', 'Affiliation': 'Smartex, Pisa, Italy.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Poli', 'Affiliation': 'School of Computer Science and Electronic Engineering, University of Essex, Colchester, UK.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Rocha', 'Affiliation': 'Faculdade de Medicina and CCUL, Universidade de Lisboa, Lisbon, Portugal.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Settanta', 'Affiliation': 'Department of Clinical and Biological Sciences, Università degli studi di Torino, Turin, Italy.'}, {'ForeName': 'Maria Teresa Arredondo', 'Initials': 'MTA', 'LastName': 'Waldmeyer', 'Affiliation': 'Life Supporting Technologies, Universidad Politécnica de Madrid, Madrid, Spain.'}, {'ForeName': 'Gaetano', 'Initials': 'G', 'LastName': 'Valenza', 'Affiliation': 'Research Center ""E.Piaggio"" and Department of Information Engineering, School of Engineering, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Enzo Pasquale', 'Initials': 'EP', 'LastName': 'Scilingo', 'Affiliation': 'Research Center ""E.Piaggio"" and Department of Information Engineering, School of Engineering, University of Pisa, Pisa, Italy.'}]",BMC psychiatry,['10.1186/s12888-020-02494-3'] 467,32196826,Altered fractionation diminishes importance of tumor volume in oropharyngeal cancer: Subgroup analysis of ARTSCAN-trial.,"BACKGROUND A large tumor volume negatively impacts the outcome of radiation therapy (RT). Altered fractionation (AF) can improve local control (LC) compared with conventional fractionation (CF). The aim of the present study was to investigate if response to AF differs with tumor volume in oropharyngeal cancer. METHODS Three hundred and twenty four patients with oropharyngeal cancer treated in a randomized, phase III trial comparing CF (2 Gy/d, 5 d/wk, 7 weeks, total dose 68 Gy) to AF (1.1 Gy + 2 Gy/d, 5 d/wk, 4.5 weeks, total dose 68 Gy) were analyzed. RESULTS Tumor volume had less impact on LC for patients treated with AF. There was an interaction between tumor volume and fractionation schedule (P = .039). This differential response was in favor of CF for small tumors and of AF for large tumors. CONCLUSION AF diminishes the importance of tumor volume for local tumor control in oropharyngeal cancer.",2020,There was an interaction between tumor volume and fractionation schedule (P = .039).,"['oropharyngeal cancer', 'Three hundred and twenty four patients with oropharyngeal cancer']","['AF (1.1 Gy\u2009', 'radiation therapy (RT', 'Altered fractionation (AF', 'conventional fractionation (CF', 'CF']",[],"[{'cui': 'C2349952', 'cui_str': 'Cancer of Oropharnyx'}, {'cui': 'C4517713', 'cui_str': '324'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C4517491', 'cui_str': 'One point one'}, {'cui': 'C0034619', 'cui_str': 'radiation therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]",[],324.0,0.0619599,There was an interaction between tumor volume and fractionation schedule (P = .039).,"[{'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Adrian', 'Affiliation': 'Department of Clinical Sciences Lund, Oncology, Skåne University Hospital, Lund University, Lund, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Gebre-Medhin', 'Affiliation': 'Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Kjellén', 'Affiliation': 'Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden.'}, {'ForeName': 'Elinore', 'Initials': 'E', 'LastName': 'Wieslander', 'Affiliation': 'Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden.'}, {'ForeName': 'Björn', 'Initials': 'B', 'LastName': 'Zackrisson', 'Affiliation': 'Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Nilsson', 'Affiliation': 'Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden.'}]",Head & neck,['10.1002/hed.26142'] 468,31764462,Sleep Deprivation: Cytokine and Neuroendocrine Effects on Perception of Effort.,"INTRODUCTION An increased perception of effort and subjective fatigue are thought to be central to decreased exercise performance observed after disrupted sleep. However, there is limited understanding of mechanisms that underpin these phenomena. We investigated the role of interleukin-6 (IL-6), the soluble IL-6 receptor, and neuroendocrine factors (cortisol, adrenaline, noradrenaline, and brain-derived neurotropic factor) in mediating these responses at rest and during exercise. METHODS In a randomized order, 10 healthy active men completed three experimental trials following different sleep conditions: a single night of sleep deprivation, partial sleep deprivation equivalent to 4 h of sleep, and normal sleep. The experimental sessions consisted of physiological and perceptual measurements of exercise intensity throughout 45-min moderate intensity and 15-min maximal effort cycling. Cytokine and neuroendocrine factors were assessed at rest and in response to exercise. RESULTS Sleep deprivation resulted in increased resting IL-6, lower blood glucose, increased perceived fatigue and perception of effort, lower free-living energy expenditure, and reduced maximal exercise performance. In contrast, sleep deprivation did not alter physiological, cytokine, or neuroendocrine responses to exercise. Variations in the resting concentration of IL-6 were associated with lowered blood glucose, an increased perception of effort, and impaired exercise performance. Resting concentrations of cortisol, adrenaline, noradrenaline, and BNDF showed subtle interactions with specific aspects of mood status and performance but were not affected by sleep deprivation. There were minimal effects of partial sleep deprivation. CONCLUSIONS These findings demonstrate that cytokine and neuroendocrine responses to exercise are not altered by sleep deprivation but that changes in the resting concentration of IL-6 may play a role in altered perception of effort in this context.",2020,"RESULTS Sleep deprivation resulted in increased resting IL-6, lower blood glucose, increased perceived fatigue and perception of effort, lower free-living energy expenditure, and reduced maximal exercise performance.",['ten healthy active males'],"['single night of sleep deprivation (DEP), partial sleep deprivation equivalent to 4-hrs of sleep (PART) and normal sleep (CON']","['resting IL-6, lower blood glucose, increased perceived fatigue and perception of effort, lower free-living energy expenditure, and reduced maximal exercise performance', 'interleukin-6 (IL-6), the soluble interleukin-6 receptor (sIL-6R) and neuroendocrine factors (cortisol, adrenaline, noradrenaline and brain derived neurotropic factor (BDNF', 'partial sleep deprivation', 'perception of effort and subjective fatigue', 'Cytokine and neuroendocrine factors', 'perception of effort, and impaired exercise performance', 'exercise performance']","[{'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0037316', 'cui_str': 'Sleep Deprivation'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}]","[{'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0014272', 'cui_str': 'Energy Expenditure'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0063717', 'cui_str': 'Receptors, IL-6'}, {'cui': 'C0333873', 'cui_str': 'Squamous intraepithelial lesion'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0037316', 'cui_str': 'Sleep Deprivation'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}]",10.0,0.0458212,"RESULTS Sleep deprivation resulted in increased resting IL-6, lower blood glucose, increased perceived fatigue and perception of effort, lower free-living energy expenditure, and reduced maximal exercise performance.","[{'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Cullen', 'Affiliation': 'Centre for Sport Exercise and Life Sciences, Coventry University, Priory Street, Coventry, UNITED KINGDOM.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Thomas', 'Affiliation': 'School of Sport and Exercise Science, University of Worcester, Henwick Grove, Worcester, UNITED KINGDOM.'}, {'ForeName': 'Alex J', 'Initials': 'AJ', 'LastName': 'Wadley', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UNITED KINGDOM.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002207'] 469,32180155,"Comparison of the efficacy of intramuscular botulinum toxin type-A injection into the pectoralis major and the teres major muscles and suprascapular nerve block for hemiplegic shoulder pain: a prospective, double-blind, randomized, controlled trial.","INTRODUCTION This study aims to investigate the effect of botulinum toxin-A (BoNT-A) injection into pectoralis major and teres major muscles and suprascapular nerve block (SSNB) on pain, range of motion (ROM), and upper extremity function for (hemiplegic shoulder pain) HSP, and to compare the effectiveness of these two methods. MATERIALS AND METHODS Sixty patients with HSP were randomly assigned into 2 groups. The Group 1 (n = 30) received BoNT-A injection into the pectoralis major and teres major, and the Group 2 (n = 30) received SSSB. Patients were evaluated just before the start of the study, and 2 and 6 weeks after the start of the study with visual analog scale (VAS), Modified Ashworth Scale (MASH), the passive ROM, and the Fugl-Meyer Scale (FMS) arm section. RESULTS In Group 1, statistically significant improvement was found in all evaluation parameters on 2th and 6th week. Group 2 showed significant improvement in all parameters on week 2 (p < 0.05), and significant improvement was observed in MASH and pain in abduction in the 6th week (p < 0.05). When the groups were compared with each other, a statistically significant difference was observed in MASH, ROM, and FMS parameters on week 2 in favor of Group 1; in all evaluation parameters, there was a statistically significant difference in favor of Group 1 on week 6 (p < 0.05). CONCLUSION We concluded that BoNT-A injection into the pectoralis major and teres major muscles for HSP was equal in the short term and more effective in the middle term compared with SSNB treatment in improving pain, ROM, and function.",2020,"When the groups were compared with each other, a statistically significant difference was observed in MASH, ROM, and FMS parameters on week 2 in favor of Group 1; in all evaluation parameters, there was a statistically significant difference in favor of Group 1 on week 6 (p < 0.05). ","['hemiplegic shoulder pain', 'Sixty patients with HSP']","['intramuscular botulinum toxin type-A injection', 'SSSB', 'SSNB', 'botulinum toxin-A (BoNT-A) injection']","['pain, ROM, and function', 'MASH and pain in abduction', 'visual analog scale (VAS), Modified Ashworth Scale (MASH), the passive ROM, and the Fugl-Meyer Scale (FMS) arm section', 'pain, range of motion (ROM), and upper extremity function', 'MASH, ROM, and FMS parameters']","[{'cui': 'C0037011', 'cui_str': 'Shoulder Pain'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0442117', 'cui_str': 'Intramuscular (qualifier value)'}, {'cui': 'C4060200', 'cui_str': 'Botulinum Toxin Type A Injection [Botox]'}, {'cui': 'C0006055', 'cui_str': 'Botulin'}, {'cui': 'C2930113', 'cui_str': 'incobotulinumtoxinA'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0231456', 'cui_str': 'Abduction, function (observable entity)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C4707572', 'cui_str': 'Modified Ashworth Scale (assessment scale)'}, {'cui': 'C0222045'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0080078', 'cui_str': 'Range of Motion'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",60.0,0.0291965,"When the groups were compared with each other, a statistically significant difference was observed in MASH, ROM, and FMS parameters on week 2 in favor of Group 1; in all evaluation parameters, there was a statistically significant difference in favor of Group 1 on week 6 (p < 0.05). ","[{'ForeName': 'Meliha', 'Initials': 'M', 'LastName': 'Kasapoğlu-Aksoy', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, University of Health Sciences Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey. melihakasapoglu@hotmail.com.'}, {'ForeName': 'İlknur', 'Initials': 'İ', 'LastName': 'Aykurt-Karlıbel', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, University of Health Sciences Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey.'}, {'ForeName': 'Lale', 'Initials': 'L', 'LastName': 'Altan', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Uludağ University Medicine Faculty, Bursa, Turkey.'}]",Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,['10.1007/s10072-020-04334-4'] 470,32170259,Blended learning as an adjunct to tutor-led seminars in undergraduate orthodontics: a randomised controlled trial.,"Aims To describe the use of blended learning as a method of undergraduate orthodontic teaching delivery and to assess its effectiveness in terms of knowledge gain.Design Randomised controlled trial.Setting Queen Mary University of London.Materials and methods Seventy dental undergraduate students in their fifth year were randomly allocated to receive orthodontic seminar-based teaching either using a blended approach based on an e-learning resource or with no prior teaching. All students were asked to complete tests both before (T0) and after (T1) the study period.Results The mean post-test score in the intervention group was 98.3% (a 19% improvement on baseline), while the mean score in the control group was 97.2% with intra-group improvements being statistically significant in both groups (P <0.001). However, no significant difference in terms of improvement in knowledge was found between the two groups (P = 0.36). In terms of satisfaction, 82% of the blended group and 74% in the control group rated the teaching as 'very good'.Conclusions An undergraduate orthodontic-oral surgery e-learning adjunct to traditional teaching was successfully developed. Blending and traditional seminar teaching appear to be equally effective in terms of short-term knowledge gain, with high levels of learner satisfaction common to both approaches.",2020,"However, no significant difference in terms of improvement in knowledge was found between the two groups (P = 0.36).","['Materials and methods Seventy dental undergraduate students in their fifth year', 'Setting Queen Mary University of London', 'undergraduate orthodontics']","['blended learning', 'Blended learning', 'orthodontic seminar-based teaching either using a blended approach based on an e-learning resource or with no prior teaching']","['knowledge', 'mean score', 'mean post-test score']","[{'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0023973', 'cui_str': 'London'}, {'cui': 'C0029335', 'cui_str': 'Orthodontics'}]","[{'cui': 'C0029335', 'cui_str': 'Orthodontics'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0035201', 'cui_str': 'Resources'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",70.0,0.0693456,"However, no significant difference in terms of improvement in knowledge was found between the two groups (P = 0.36).","[{'ForeName': 'Sri', 'Initials': 'S', 'LastName': 'Jeganathan', 'Affiliation': 'Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'Padhraig S', 'Initials': 'PS', 'LastName': 'Fleming', 'Affiliation': 'Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. padhraig.fleming@qmul.ac.uk.'}]",British dental journal,['10.1038/s41415-020-1332-1'] 471,31011944,Pilot randomised controlled trial of a brief mindfulness-based intervention for those with persistent pain.,"A pilot-randomised controlled trial (RCT) examined the effects of a brief mindfulness-based intervention (MBI) on persistent pain patients and assessed the feasibility of conducting a definitive RCT. A brief (15 min) mindfulness body-scan audio was compared with an active control administered in a clinic and then used independently over 1 month. Immediate effects of the intervention were assessed with brief measures of pain severity, distraction and distress. Assessments at baseline, 1 week and 1 month included pain severity and interference, mood, pain-catastrophizing, mindfulness, self-efficacy, quality of life and intervention acceptability. Of 220 referred patients, 147 were randomised and 71 completed all assessments. There were no significant immediate intervention effects. There were significant positive effects for ratings of intervention 'usefulness' at 1 week (p = 0.044), and pain self-efficacy at 1 month (p = 0.039) for the MBI group compared with control. Evidently, it is feasible to recruit persistent pain patients to a brief MBI study. Strategies are needed to maximise retention of participants.Trial registration Current controlled trials ISRCTN61538090. Registered 20 April 2015.",2019,"There were significant positive effects for ratings of intervention 'usefulness' at 1 week (p = 0.044), and pain self-efficacy at 1 month (p = 0.039) for the MBI group compared with control.","['those with persistent pain', 'persistent pain patients', 'Of 220 referred patients, 147 were randomised and 71 completed all assessments']","['brief mindfulness-based intervention (MBI', 'brief mindfulness-based intervention']","['pain self-efficacy', 'pain severity, distraction and distress', 'pain severity and interference, mood, pain-catastrophizing, mindfulness, self-efficacy, quality of life and intervention acceptability']","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517650', 'cui_str': '220 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C1369038', 'cui_str': 'Distraction (procedure)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0034380'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",,0.0956365,"There were significant positive effects for ratings of intervention 'usefulness' at 1 week (p = 0.044), and pain self-efficacy at 1 month (p = 0.039) for the MBI group compared with control.","[{'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Howarth', 'Affiliation': ""Population Health Research Institute, St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK. p1306542@sgul.ac.uk.""}, {'ForeName': 'Muhammad', 'Initials': 'M', 'LastName': 'Riaz', 'Affiliation': ""Population Health Research Institute, St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK.""}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Perkins-Porras', 'Affiliation': ""Institute of Medical and Biomedical Education, St George's, University of London, London, UK.""}, {'ForeName': 'Jared G', 'Initials': 'JG', 'LastName': 'Smith', 'Affiliation': ""Population Health Research Institute, St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK.""}, {'ForeName': 'Jeevakan', 'Initials': 'J', 'LastName': 'Subramaniam', 'Affiliation': ""Population Health Research Institute, St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK.""}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Copland', 'Affiliation': ""Persistent Pain Service, St George's Hospital, London, UK.""}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Hurley', 'Affiliation': ""Faculty of Health, Social Care and Education, Kingston University and St George's, University of London, London, UK.""}, {'ForeName': 'Iain', 'Initials': 'I', 'LastName': 'Beith', 'Affiliation': ""Faculty of Health, Social Care and Education, Kingston University and St George's, University of London, London, UK.""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Ussher', 'Affiliation': ""Population Health Research Institute, St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK.""}]",Journal of behavioral medicine,['10.1007/s10865-019-00040-5'] 472,32185497,"Invited Discussion on: A Randomized, Controlled Study Comparing Subbrow Blepharoplasty and Subbrow Blepharoplasty Combined with Periorbital Muscle Manipulation for Periorbital Aging Rejuvenation in Asians.",,2020,,['Periorbital Aging Rejuvenation in Asians'],['Subbrow Blepharoplasty and Subbrow Blepharoplasty Combined with Periorbital Muscle Manipulation'],[],"[{'cui': 'C0230064', 'cui_str': 'Periorbital region structure'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0035016', 'cui_str': 'Rejuvenation'}]","[{'cui': 'C0197213', 'cui_str': 'Blepharoplasty'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0230064', 'cui_str': 'Periorbital region structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0947647', 'cui_str': 'Manipulation - action (qualifier value)'}]",[],,0.0241604,,"[{'ForeName': 'Min-Hee', 'Initials': 'MH', 'LastName': 'Ryu', 'Affiliation': 'Division of Plastic and Aesthetic Surgery, The Affiliated Friendship Plastic Surgery Hospital of Nanjing Medical University, No. 109 Nongguangli, Chaoyang District, Beijing City, 100021, China. psryuminhee@gmail.com.'}]",Aesthetic plastic surgery,['10.1007/s00266-020-01669-3'] 473,32185595,"A prospective randomized trial comparing corifollitropin-α late-start (day 4) versus standard administration (day 2) in expected poor, normal, and high responders undergoing controlled ovarian stimulation for IVF.","OBJECTIVE To assess whether corifollitropin-α (CFα) late-start administration (day 4) and standard administration (day 2) can obtain similar oocyte yield and live birth rate. STUDY DESIGN A randomized controlled trial. SETTING University Hospital IVF Unit. PATIENTS One hundred thirteen women undergoing IVF. INTERVENTIONS Patients distributed in three subgroups (expected poor, normal, or high responders to FSH) were randomized into two treatment arms: (a) CFα late-start: CFα on day 4 + GnRH antagonist from day 8 + (when needed) recFSH from day 11; (b) CFα standard start: CFα on day 2 + GnRH antagonist from day 6 + (when needed) recFSH from day 9. IVF or ICSI was performed as indicated. RESULTS Considering the whole study group, the late-start regimen obtained comparable oocyte yield (8.9 ± 5.6 vs. 8.8 ± 6.2; p = n.s.), cPR/started cycle (25% vs. 31.6%, p = n.s.), and cumulative live birth rate (LBR)/ovum pickup (OPU) (29.2% vs. 37.7%, p = n.s.) than the standard regimen. The outcome of the two regimens was comparable in the two subgroups of high and normal responders. Differently, in poor responders, oocyte yield was similar, but LBR/OPU was significantly lower with late-start CFα administration that caused 40% cancellation rate due to monofollicular response. ROC curves showed that the threshold AMH levels associated with cycle cancellation were 0.6 ng/ml for late-start regimen and 0.2 ng/ml for standard regimen. CONCLUSION CFα may be administered on either day 2 or day 4 to patients with expected high or normal response to FSH without compromising oocyte yield and/or live birth rate. Differently, late-start administration is not advisable for expected poor responders with AMH ≤ 0.6 ng/ml. TRIAL REGISTRATION NCT03816670.",2020,The outcome of the two regimens was comparable in the two subgroups of high and normal responders.,"['One hundred thirteen women undergoing IVF', 'University Hospital IVF Unit']","['IVF or ICSI', 'corifollitropin-α late-start (day 4) versus standard administration', 'corifollitropin-α (CFα) late-start administration (day 4) and standard administration', 'CFα late-start: CFα on day 4 + GnRH antagonist from day 8 + (when needed) recFSH']","['oocyte yield', 'LBR/OPU', 'cumulative live birth rate (LBR)/ovum pickup (OPU', 'cPR/started cycle']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0015915', 'cui_str': 'Test-Tube Fertilization'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}]","[{'cui': 'C0015915', 'cui_str': 'Test-Tube Fertilization'}, {'cui': 'C0455164', 'cui_str': 'ICSI'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0023610', 'cui_str': 'Gonadorelin'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}, {'cui': 'C0027552', 'cui_str': 'Needs'}]","[{'cui': 'C0029045', 'cui_str': 'Ovocytes'}, {'cui': 'C0481667', 'cui_str': 'Live Birth'}, {'cui': 'C0007203', 'cui_str': 'Cardio-Pulmonary Resuscitation'}, {'cui': 'C1272689', 'cui_str': 'Started'}]",113.0,0.17166,The outcome of the two regimens was comparable in the two subgroups of high and normal responders.,"[{'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Revelli', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy. alberto.revelli@unito.it.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Gennarelli', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Sestero', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Canosa', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Carosso', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Salvagno', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Pittatore', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Filippini', 'Affiliation': 'Clinical Statistics, Department of Surgical Sciences, University of Torino, Corso Bramante 88, Turin, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Benedetto', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}]",Journal of assisted reproduction and genetics,['10.1007/s10815-020-01742-5'] 474,32096451,Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.,"Purpose: To investigate the efficacy and sustainability of drug-coated balloon (DCB) treatment of femoropopliteal in-stent restenosis (ISR). Materials and Methods: An investigator-initiated, prospective, multicenter, 1:1 randomized study enrolled 88 patients for treatment of ISR with DCB (n=47; mean age 68.3±9.6 years; 26 men) or uncoated balloon (n=41; mean age 67.6±10.2 years; 26 men) angioplasty ( ClinicalTrials.gov identifier NCT01594684). Additionally, the protocol provided for an observational arm composed of patients from either randomized arm who experienced recurrent ISR ≥30 days after the index treatment. Redo treatment consisted of 2 DCBs sequentially inflated at the same location (double dose therapy). The majority of patients (66, 78%) had Rutherford category 3 ischemia. The mean lesion length was 140 mm; a third (27, 31%) were total occlusions. The primary endpoint was angiographic late lumen loss (LLL) at 6 months evaluated by an independent core laboratory. Results: Twenty-two patients (7 DCB +15 uncoated) were treated for recurrence with fully overlapping double DCB angioplasty. Six-month LLL was lower after DCB (0.34±1.12 mm) treatment than after angioplasty with an uncoated balloon (1.58±1.10 mm, p<0.001). At the 12-month follow-up, target lesion revascularization (TLR) was performed in 18 (49%) of 37 patients in the uncoated group, 6 (14%) of 43 patients in the single-dose DCB group (p=0.001), and no patients from the recurrent ISR group. At ~2 years after treatment, a remarkable number (14/27, 52%) of TLRs were recorded in the single-dose DCB group. Conclusion: Treatment with DCBs resulted in significantly less 6-month LLL and fewer TLRs up to 24 months than treatment with uncoated balloons. The double dose for treating recurrent ISR did not cause recognizable adverse events or require TLR up to 24 months.",2020,"Six-month LLL was lower after DCB (0.34±1.12 mm) treatment than after angioplasty with an uncoated balloon (1.58±1.00 mm, p<0.001).","['88 patients for treatment of ISR with DCB (n=47; mean age 68.3±9.6 years; 26 men) or uncoated balloon (n=41; mean age 67.6±10.2 years; 26 men) angioplasty ( ClinicalTrials.gov identifier NCT01594684', 'Superficial Femoral and Popliteal Arteries']","['drug-coated balloon (DCB', 'Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty']","['mean lesion length', '6-month LLL and fewer TLRs', 'TLRs', 'total occlusions', 'target lesion revascularization (TLR', 'angiographic late lumen loss (LLL']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft (physical object)'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty'}, {'cui': 'C0205124', 'cui_str': 'Superficial (qualifier value)'}, {'cui': 'C0015811', 'cui_str': 'Femur'}, {'cui': 'C0032649', 'cui_str': 'Popliteal Artery'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0453946', 'cui_str': 'Coat (physical object)'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft (physical object)'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0002996', 'cui_str': 'Dilation, Transluminal Arterial'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205388', 'cui_str': 'Few (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0441597', 'cui_str': 'Occlusion - action (qualifier value)'}, {'cui': 'C0014742', 'cui_str': 'Erythema Multiforme'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}]",88.0,0.0822507,"Six-month LLL was lower after DCB (0.34±1.12 mm) treatment than after angioplasty with an uncoated balloon (1.58±1.00 mm, p<0.001).","[{'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Tepe', 'Affiliation': 'Department of Radiology, RoMed Klinikum Rosenheim, Germany.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Schroeder', 'Affiliation': 'Center for Diagnostic Radiology & Minimally Invasive Therapy, The Jewish Hospital, Berlin, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Albrecht', 'Affiliation': 'Department of Radiology and Interventional Radiology, Vivantes Hospital Berlin Neukölln, Berlin, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Reimer', 'Affiliation': 'Institute for Diagnostic and Interventional Radiology, Klinikum Karlsruhe, Germany.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Diehm', 'Affiliation': 'Zentrum für Gefäßmedizin, Aarau, Switzerland.'}, {'ForeName': 'Jean-Luc', 'Initials': 'JL', 'LastName': 'Baeriswyl', 'Affiliation': 'Clinlogix LLC, Lower Gwynedd, PA, USA.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Brechtel', 'Affiliation': 'Franziskus Krankenhaus, Berlin, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Speck', 'Affiliation': 'Charité-Universitätsmedizin Berlin, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Zeller', 'Affiliation': 'Clinic of Cardiology and Angiology II, Universitäts-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany.'}]",Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists,['10.1177/1526602820907917'] 475,31997715,ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.,"Purpose: To report the 12-month results of a multicenter, prospective, randomized controlled trial to determine if the ZILVER PTX paclitaxel-eluting stent was noninferior in terms of safety and efficacy compared with surgical bypass. Materials and Methods: This is a study in symptomatic TransAtlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions comparing endovascular ZILVER PTX stenting vs surgical bypass surgery using a prosthetic graft ( ClinicalTrials.gov identifier NCT01952457). Between October 2013 and July 2017, 220 patients (mean age 68.6±10.5 years; 159 men) were enrolled and randomized to the ZILVER PTX treatment group (113, 51.4%) or the bypass treatment group (107, 48.6%). Most of the lesions were occlusions (208, 94.5%); the mean lesion length was 247.1±69.3 mm. The primary outcome measure was primary patency at 12 months, defined as no evidence of binary restenosis or occlusion within the target lesion or bypass graft based on a duplex-derived peak systolic velocity ratio <2.4 and no clinically-driven target lesion revascularization (TLR) in endovascular cases or reintervention to restore flow in the bypass. Results: The estimated 12-month primary patency rate was 74.5% (95% CI 66.3% to 82.7%) for the ZILVER PTX group vs 72.5% (95% CI 63.7% to 81.3%) for the bypass arm (p=0.998). Freedom from TLR at 12 months was 80.9% (95% CI 73.3% to 88.5%) for the ZILVER PTX group vs 76.2% (95% CI 68.0% to 84.4%) for the bypass group (p=0.471). The 30-day complication rate was significantly lower in the ZILVER PTX group (4.4% vs 11.3%, p=0.004). Also, procedure time and hospital stay were significantly shorter in the ZILVER PTX group (p<0.001 for both). Conclusion: With noninferior patency results, a lower complication rate, and shorter procedures and hospital stays, paclitaxel-eluting stenting might become a recommended treatment for long TASC C and D femoropopliteal lesions.",2020,"Also, procedure time and hospital stay were significantly shorter in the ZILVER PTX group (p<0.001 for both). ","['Femoropopliteal Lesions', 'Between October 2013 and July 2017, 220 patients (mean age 68.6±10.5 years; 159 men']","['ZILVER PTX Stent vs Bypass Surgery', 'endovascular ZILVER PTX stenting vs surgical bypass surgery', 'ZILVER PTX paclitaxel-eluting stent', 'ZILVER PTX']","['30-day complication rate', 'estimated 12-month primary patency rate', 'lower complication rate, and shorter procedures and hospital stays, paclitaxel-eluting stenting', 'primary patency at 12 months, defined as no evidence of binary restenosis or occlusion within the target lesion or bypass graft based on a duplex-derived peak systolic velocity ratio <2.4 and no clinically-driven target lesion revascularization (TLR', 'safety and efficacy', 'procedure time and hospital stay', 'mean lesion length']","[{'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C4517650', 'cui_str': '220 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C1536078', 'cui_str': 'Bypass surgery'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}]","[{'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0332125', 'cui_str': 'No evidence of (contextual qualifier) (qualifier value)'}, {'cui': 'C0333186', 'cui_str': 'Restenosis'}, {'cui': 'C0441597', 'cui_str': 'Occlusion - action (qualifier value)'}, {'cui': 'C0014742', 'cui_str': 'Erythema Multiforme'}, {'cui': 'C0185098', 'cui_str': 'Bypass graft'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0444916', 'cui_str': 'Duplex (qualifier value)'}, {'cui': 'C0442710', 'cui_str': 'Peak systolic, function (observable entity)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C4517631', 'cui_str': '2.4 (qualifier value)'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}]",,0.0869478,"Also, procedure time and hospital stay were significantly shorter in the ZILVER PTX group (p<0.001 for both). ","[{'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Bosiers', 'Affiliation': 'A.Z. Sint-Blasius Hospital, Dendermonde, Belgium.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Setacci', 'Affiliation': 'University of Siena, Italy.'}, {'ForeName': 'Gianmarco', 'Initials': 'G', 'LastName': 'De Donato', 'Affiliation': 'University of Siena, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Torsello', 'Affiliation': 'St. Franziskus Hospital Münster, Germany.'}, {'ForeName': 'Pierre Galvagni', 'Initials': 'PG', 'LastName': 'Silveira', 'Affiliation': 'UFSC University Hospital Santa Catarina, Florianópolis, SC, Brazil.'}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'Deloose', 'Affiliation': 'A.Z. Sint-Blasius Hospital, Dendermonde, Belgium.'}, {'ForeName': 'Dierk', 'Initials': 'D', 'LastName': 'Scheinert', 'Affiliation': 'University Hospital of Leipzig, Germany.'}, {'ForeName': 'Pierfrancesco', 'Initials': 'P', 'LastName': 'Veroux', 'Affiliation': 'University Hospital of Catania, Italy.'}, {'ForeName': 'Jeroen', 'Initials': 'J', 'LastName': 'Hendriks', 'Affiliation': 'University Hospital of Antwerp, Edegem, Belgium.'}, {'ForeName': 'Lieven', 'Initials': 'L', 'LastName': 'Maene', 'Affiliation': 'OLV Hospital Aalst, Belgium.'}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'Keirse', 'Affiliation': 'RZ Heilig Hart Tienen, Belgium.'}, {'ForeName': 'Tulio', 'Initials': 'T', 'LastName': 'Navarro', 'Affiliation': 'Federal University of Minas Gerais, Brazil.'}, {'ForeName': 'Joren', 'Initials': 'J', 'LastName': 'Callaert', 'Affiliation': 'A.Z. Sint-Blasius Hospital, Dendermonde, Belgium.'}, {'ForeName': 'Hans-Henning', 'Initials': 'HH', 'LastName': 'Eckstein', 'Affiliation': 'Klinikum rechts der Isar, Munich, Germany.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Teβarek', 'Affiliation': 'St. Bonifatius Hospital Lingen, Lingen, Niedersachsen, Germany.'}, {'ForeName': 'Alessia', 'Initials': 'A', 'LastName': 'Giaquinta', 'Affiliation': 'UFSC University Hospital Santa Catarina, Florianópolis, SC, Brazil.'}, {'ForeName': 'Jeroen', 'Initials': 'J', 'LastName': 'Wauters', 'Affiliation': 'Flanders Medical Research Program, Dendermonde, Belgium.'}]",Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists,['10.1177/1526602820902014'] 476,31764465,Metabolic Effects of Three Different Activity Bouts during Sitting in Inactive Adults.,"PURPOSE This study aimed to determine whether interrupting prolonged sitting with three different walking-bout schedules improves glycemic metabolism relative to continuous prolonged sitting in sedentary adults. METHODS In a randomized, crossover trial, 16 inactive healthy adults (7 men, 24 ± 3 yr old) completed four 26-h laboratory sessions, including 22.5 h in an energy expenditure (EE)-testing calorimeter chamber. The four 9-h intervention periods were as follows: 9-h uninterrupted sitting (SIT), 30-min sitting/3-min brisk (60% V˙O2max) treadmill walk (WALK3), 45-min sitting/5-min (WALK5), or 60-min sitting/8-min (WALK8). Coprimary outcomes included the difference in the mean interstitial glucose concentration, total area under the curve (tAUC), and incremental area under the curve (iAUC) for the entire 26 and 9 h (intervention period) during three activity-bout conditions compared with SIT. RESULTS Compared with SIT, the 26-h mean glucose concentration was attenuated in WALK8 (Δmean -0.22 mmol·L [95% confidence interval = -0.43 to -0.001], P = 0.048) without adjustment for EE and attenuated in WALK3 (Δ-0.47 mmol·L [-0.75 to -0.10]), WALK5 (Δ-0.47 mmol·L [-0.83 to -0.10]), and WALK8 (Δ-0.53 mmol·L [-0.92 to -0.13]) after adjustment for EE (all P < 0.01). The 26-h tAUC was reduced in WALK3 (Δ-11.18 mmol·L per 26 h [-20.07 to -2.29]), WALK5 (2.12.67 mmol·L per 26 h [-22.54 to -2.79]), and WALK8 (Δ-13.85 mmol·L per 26 h [-24.60 to -3.10]) (all P < 0.01), as well as the iAUC (all P < 0.05), only after adjustment for EE. The 9-h mean glucose concentration, tAUC, and iAUC decreased in the three activity-break conditions regardless of EE adjustment (all P < 0.05). CONCLUSIONS All three walking-bout conditions improved glycemic metabolism compared with SIT, independent of EE, in inactive, healthy adults.",2020,"Compared with SIT, the 26-h mean glucose concentration was attenuated in WALK8 (Δmean -0.22 mmol·L [95% CI -0.43--0.001], p= 0.048) without adjustment for EE and attenuated in WALK3 (","['16 inactive healthy adults (7 men, 24±3 years old) completed four 26-h laboratory sessions, including 22.5 h in an energy expenditure (EE)-testing calorimeter chamber', 'sedentary adults', 'Inactive Adults']","['WALK3', '30-min sitting/3-min brisk (60% VO2max) treadmill walk (WALK3); 45-min sitting/5-min (WALK5); or 60-min sitting/8-min (WALK8', 'WALK8', '9-h uninterrupted sitting (SIT', 'WALK5', 'prolonged sitting with 3 different walking-bout schedules']","['9-h mean glucose concentration, tAUC, and iAUC', 'glycemic metabolism', 'mean glucose concentration', 'mean interstitial glucose concentration, total areas under the curve (tAUC), and incremental AUC (iAUC']","[{'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C4517649', 'cui_str': 'Twenty-two point five'}, {'cui': 'C0014272', 'cui_str': 'Energy Expenditure'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0443162', 'cui_str': 'Brisk (qualifier value)'}, {'cui': 'C0184069', 'cui_str': 'Treadmill, device (physical object)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1287281', 'cui_str': 'Finding of glucose concentration, dipstick (finding)'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}]",,0.0375696,"Compared with SIT, the 26-h mean glucose concentration was attenuated in WALK8 (Δmean -0.22 mmol·L [95% CI -0.43--0.001], p= 0.048) without adjustment for EE and attenuated in WALK3 (","[{'ForeName': 'Sheng-Xia', 'Initials': 'SX', 'LastName': 'Ma', 'Affiliation': 'School of Kinesiology, Shanghai University of Sport, Shanghai, CHINA.'}, {'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Zhu', 'Affiliation': ''}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Xiao-Mei', 'Initials': 'XM', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Yan-Yu', 'Initials': 'YY', 'LastName': 'Lin', 'Affiliation': ''}, {'ForeName': 'Zhen-Bo', 'Initials': 'ZB', 'LastName': 'Cao', 'Affiliation': ''}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002212'] 477,31764466,Exercise Training Reduces Reward for High-Fat Food in Adults with Overweight/Obesity.,"PURPOSE There is increasing evidence that exercise training may facilitate weight management via improvements in homeostatic appetite control, but little is known about how exercise training affects food reward and susceptibility to overeating. METHODS This study examined changes in food reward and eating behavior traits after a supervised 12-wk exercise intervention (10.5 MJ·wk) in inactive individuals with overweight/obesity (exercisers; n = 46, 16 men/30 women; mean (SD) body mass index, 30.6 (3.8) kg·m; and mean (SD) age, 43.2 (7.5) yr) compared with nonexercising controls (n = 15; 6 men/9 women; mean (SD) body mass index, 31.4 (3.7) kg·m; and mean (SD) age, 41.4 (10.7) yr). Liking and wanting scores for high-fat relative to low-fat foods were assessed with the Leeds Food Preference Questionnaire before and after consumption of an isoenergetic high-fat or high-carbohydrate lunch. Eating behavior traits were assessed using the Three-Factor Eating Questionnaire and Binge Eating Scale. RESULTS A week-group interaction indicated that wanting scores decreased from baseline to postintervention in exercisers only (M[INCREMENT]Pre-Post = -4.1, P = 0.03, ηp = 0.09, 95% confidence interval [CI], -7.8 to -0.4), but there was no exercise effect on liking. There was also a week-group interaction for binge eating, which decreased in exercisers only (M[INCREMENT]Pre-Post = -1.5, P = 0.01, ηp = 0.11; 95% CI, -2.7 to -0.4). A small reduction in disinhibition was also apparent in exercisers (M[INCREMENT]Pre-Post = -0.7, P = 0.02, ηp = 0.10; 95% CI, -1.3 to -0.1). CONCLUSIONS This study showed that 12 wk of exercise training reduced wanting scores for high-fat foods and trait markers of overeating in individuals with overweight/obesity compared with nonexercising controls. Further research is needed to elucidate the mechanisms behind these exercise-induced changes in food reward.",2020,This study showed that 12 weeks of exercise training reduced wanting scores for high-fat foods and trait markers of overeating in individuals with overweight/obesity compared to non-exercising Controls.,"['inactive individuals with overweight/obesity (Exercisers; n=46, 16 males/30 females; BMI=30.6 (SD 3.8) kg/m and age=43.2 (SD 7.5) years compared to non-exercising Controls (n=15; 6 males/9 females; BMI=31.4 (SD 3.7) kg/m and age=41.4 (SD 10.7) years', 'individuals with overweight/obesity']",['exercise training'],"['food reward and eating behavior traits', 'Factor Eating Questionnaire and Binge Eating Scale', 'liking', 'disinhibition', 'Eating behavior traits', 'binge eating', 'Liking and wanting scores', 'wanting scores']","[{'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0180776', 'cui_str': 'Exerciser'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C4517859', 'cui_str': 'Seven point five'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4517696', 'cui_str': '3.7 (qualifier value)'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}]","[{'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0015745', 'cui_str': 'Eating Behavior'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0596170', 'cui_str': 'Binge overeating'}, {'cui': 'C0222045'}, {'cui': 'C0234410', 'cui_str': 'Disinhibition, function (observable entity)'}, {'cui': 'C1444647', 'cui_str': 'Wanted'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.120453,This study showed that 12 weeks of exercise training reduced wanting scores for high-fat foods and trait markers of overeating in individuals with overweight/obesity compared to non-exercising Controls.,"[{'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Beaulieu', 'Affiliation': 'School of Psychology, Faculty of Medicine and Health, University of Leeds, Leeds, UNITED KINGDOM.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Hopkins', 'Affiliation': 'School of Food Science and Nutrition, Faculty of Mathematics and Physical Sciences, University of Leeds, Leeds, UNITED KINGDOM.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Gibbons', 'Affiliation': 'School of Psychology, Faculty of Medicine and Health, University of Leeds, Leeds, UNITED KINGDOM.'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Oustric', 'Affiliation': 'School of Psychology, Faculty of Medicine and Health, University of Leeds, Leeds, UNITED KINGDOM.'}, {'ForeName': 'Phillipa', 'Initials': 'P', 'LastName': 'Caudwell', 'Affiliation': 'Novo Nordisk A/S, Bagsværd, DENMARK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Blundell', 'Affiliation': 'School of Psychology, Faculty of Medicine and Health, University of Leeds, Leeds, UNITED KINGDOM.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Finlayson', 'Affiliation': 'School of Psychology, Faculty of Medicine and Health, University of Leeds, Leeds, UNITED KINGDOM.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002205'] 478,30597537,Acceptance and treatment effects of an internet-delivered cognitive-behavioral intervention for family caregivers of people with dementia: A randomized-controlled trial.,"OBJECTIVES The study evaluated the efficacy of an internet-delivered cognitive-behavioral intervention for caregivers of people with dementia and examined acceptance of program characteristics. METHOD Thirty-nine caregivers (M age  = 62.11 ± 9.67, 78.4% female) were enrolled in a 2 × 3 randomized-controlled trial (RCT) that compared an intervention and wait-list control group. A cognitive-behavioral intervention program was adapted for delivery via an internet platform. Participants exchanged eight weekly messages with a therapist. RESULTS Treatment satisfaction and acceptance of the program were high. Well-being increased over the intervention duration and intervention group participants were better able to cope with the anticipated death of the care recipient and utilized more psychosocial resources after the intervention ended. Effects were not maintained until follow-up and there were no treatment effects for depression and burden of care. CONCLUSIONS Internet-delivered cognitive-behavioral interventions are suitable for caregivers. A larger RCT needs to investigate possible combinations of classic and internet-delivered programs and confirm efficacy.",2019,Well-being increased over the intervention duration and intervention group,"['caregivers of people with dementia and examined acceptance of program characteristics', 'Thirty-nine caregivers (M age \u2009=\u200962.11\u2009±\u20099.67, 78.4% female', 'family caregivers of people with dementia']","['intervention and wait-list control group', 'internet-delivered cognitive-behavioral intervention']",['depression and burden of care'],"[{'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C3816447', 'cui_str': '39 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086279', 'cui_str': 'Family Caregivers'}]","[{'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}]","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]",39.0,0.0865557,Well-being increased over the intervention duration and intervention group,"[{'ForeName': 'Franziska', 'Initials': 'F', 'LastName': 'Meichsner', 'Affiliation': 'Department of Counseling and Clinical Intervention, Institute of Psychology, Friedrich Schiller University Jena, Jena, Germany.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Theurer', 'Affiliation': 'Department of Counseling and Clinical Intervention, Institute of Psychology, Friedrich Schiller University Jena, Jena, Germany.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Wilz', 'Affiliation': 'Department of Counseling and Clinical Intervention, Institute of Psychology, Friedrich Schiller University Jena, Jena, Germany.'}]",Journal of clinical psychology,['10.1002/jclp.22739'] 479,30597551,"Guided internet CBT versus ""gold standard"" depression treatments: An individual patient analysis.","OBJECTIVE Guided, computerized cognitive behavioral therapy delivered over the internet (iCBT) is a promising treatment for depression. However, comparisons to ""gold standard"" treatments and comparators, such as structured psychotherapy, medications, or pill placebo are rare. We compare the results of an 8-week trial of guided iCBT to outcomes from two trials of depression treatment, Penn-Vandy and U. Washington, using individual patient data. METHOD We adjusted for sample differences by restricting the iCBT sample to randomised controlled trial (RCT) inclusion criteria and using propensity scores. Three separate samples were included in analyses: iCBT trial (N = 89), Penn-Vandy (N = 240), and U. Washington (N = 241). Continuous outcomes were analyzed with linear-mixed models and noninferiority analyses were conducted for iCBT versus the psychotherapy conditions. The primary outcomes were attrition, remission, and the Hamilton Rating Scale for Depression. RESULTS Dropout was greater in iCBT than in CT, medications, placebo (Penn-Vandy), and CT and BA (U. Washington), but the rates of remission were similar. In continuous analyses, iCBT was superior to placebo in both RCTs and most analyses indicated no difference between iCBT and the active treatments. CONCLUSIONS Guided iCBT appears not inferior to ""gold standard"" treatments for depression and is superior to placebo. Weaknesses include a lack of randomization, unblinded assessments, and a shorter ""frame of treatment"" in the iCBT sample.",2019,"In continuous analyses, iCBT was superior to placebo in both RCTs and most analyses indicated no difference between iCBT and the active treatments. ",[],"['guided iCBT', 'computerized cognitive behavioral therapy delivered over the internet (iCBT', 'placebo', 'Guided internet CBT']","['attrition, remission, and the Hamilton Rating Scale for Depression', 'rates of remission']",[],"[{'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C1998288', 'cui_str': 'Computerized cognitive behavioral therapy'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression (assessment scale)'}]",,0.245023,"In continuous analyses, iCBT was superior to placebo in both RCTs and most analyses indicated no difference between iCBT and the active treatments. ","[{'ForeName': 'Nicholas R', 'Initials': 'NR', 'LastName': 'Forand', 'Affiliation': 'Department of Psychiatry, Donald and Barbara School of Medicine at Hofstra/Northwell, Glen Oaks, New York.'}, {'ForeName': 'Jason E', 'Initials': 'JE', 'LastName': 'Feinberg', 'Affiliation': 'Department of Psychology, George Mason University, Fairfax, Virginia.'}, {'ForeName': 'Jeffrey G', 'Initials': 'JG', 'LastName': 'Barnett', 'Affiliation': 'Department of Psychiatry, Donald and Barbara School of Medicine at Hofstra/Northwell, Glen Oaks, New York.'}, {'ForeName': 'Daniel R', 'Initials': 'DR', 'LastName': 'Strunk', 'Affiliation': 'Department of Psychology, The Ohio State University, Columbus, Ohio.'}]",Journal of clinical psychology,['10.1002/jclp.22733'] 480,32167957,Adding Contralaterally Controlled Electrical Stimulation of the Triceps to Contralaterally Controlled Functional Electrical Stimulation of the Finger Extensors Reduces Upper Limb Impairment and Improves Reachable Workspace but not Dexterity: A Randomized Controlled Trial.,"OBJECTIVE Different methods of neuromuscular electrical stimulation may be used for poststroke upper limb rehabilitation. This study evaluated the effects of contralaterally controlled functional electrical stimulation of the triceps and finger extensors. DESIGN This is a randomized controlled trial of 67 participants who were less than 2 yrs poststroke and assigned to the following: (a) arm + hand contralaterally controlled functional electrical stimulation, (b) hand contralaterally controlled functional electrical stimulation, or (c) arm + hand cyclic neuromuscular electrical stimulation. Participants were prescribed 10 sessions/week of assigned electrical stimulation at home plus 24 sessions of functional task practice in the laboratory for 12 wks. The primary outcome measure was the Box and Blocks Test. Secondary measures included reachable workspace, Upper Extremity Fugl-Meyer, Stroke Upper Limb Capacity Scale, Arm Motor Abilities Test, and Motor Activity Log. RESULTS There were no significant between-group differences on the Box and Blocks Test. At 6 mos after treatment, arm + hand contralaterally controlled functional electrical stimulation improved reachable workspace more than hand contralaterally controlled functional electrical stimulation, between-group difference of 264 (95% confidence interval = 28-500) cm and more than arm + hand cyclic neuromuscular electrical stimulation, between-group difference of 281 (95% confidence interval = 22-540) cm. Arm + hand contralaterally controlled functional electrical stimulation improved Upper Extremity Fugl-Meyer score more than hand contralaterally controlled functional electrical stimulation, between-group difference of 6.7 (95% confidence interval = 0.6-12.7). The between-group differences on the Stroke Upper Limb Capacity Scale and Arm Motor Abilities Test were not significant. CONCLUSIONS Adding contralaterally controlled elbow extension to hand contralaterally controlled functional electrical stimulation does not improve on gains in hand dexterity, but it further reduces upper limb impairment and improves reachable workspace measured in the laboratory. However, these additional benefits may not be large enough to be perceived by stroke survivors when they are performing activities of daily living at home.",2020,"CCFES improved UEFM score more than Hand CCFES, between-group difference of 6.7 (95% CI, 0.6-12.7).",['67 participants <2 years post-stroke assigned to'],"['neuromuscular electrical stimulation (NMES', 'contralaterally controlled functional electrical stimulation (CCFES']","['theSULCS and AMAT', 'Box and Blocks Test (BBT', 'reachable workspace', 'UEFM score', 'Reachable Workspace (RW), Upper Extremity Fugl-Meyer (UEFM), Stroke Upper Limb Capacity Scale (SULCS), and Arm Motor Abilities Test (AMAT), and Motor Activity Log (MAL', 'BBT']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}]","[{'cui': 'C0013786', 'cui_str': 'Electrical Stimulation'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}]","[{'cui': 'C1638312', 'cui_str': 'Boxes'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0222045'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0026606', 'cui_str': 'Motor Activity'}]",67.0,0.175681,"CCFES improved UEFM score more than Hand CCFES, between-group difference of 6.7 (95% CI, 0.6-12.7).","[{'ForeName': 'Jayme S', 'Initials': 'JS', 'LastName': 'Knutson', 'Affiliation': 'From the Department of Physical Medicine and Rehabilitation, MetroHealth Rehabilitation Institute (JSK, NSM, MYH, TZH, RDW, JC), and the Center for Healthcare Research and Policy (DDG), The MetroHealth System, Cleveland, Ohio; Cleveland Functional Electrical Stimulation Center, Cleveland, Ohio (JSK, NSM, MYH, TZH, RDW, JC); and Departments of Physical Medicine and Rehabilitation (JSK, NSM, RDW, JC), Medicine (DDG), and Biomedical Engineering (JC), Case Western Reserve University, Cleveland, Ohio.'}, {'ForeName': 'Nathaniel S', 'Initials': 'NS', 'LastName': 'Makowski', 'Affiliation': ''}, {'ForeName': 'Mary Y', 'Initials': 'MY', 'LastName': 'Harley', 'Affiliation': ''}, {'ForeName': 'Terri Z', 'Initials': 'TZ', 'LastName': 'Hisel', 'Affiliation': ''}, {'ForeName': 'Douglas D', 'Initials': 'DD', 'LastName': 'Gunzler', 'Affiliation': ''}, {'ForeName': 'Richard D', 'Initials': 'RD', 'LastName': 'Wilson', 'Affiliation': ''}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Chae', 'Affiliation': ''}]",American journal of physical medicine & rehabilitation,['10.1097/PHM.0000000000001363'] 481,31549334,Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis.,"BACKGROUND Small intestinal bacterial overgrowth (SIBO) affects up to 60% of patients with systemic sclerosis (SSc), and it improves with antibiotics. The addition of probiotics could lead to better results. AIMS To evaluate the efficacy and safety of Saccharomyces boulardii (SB) versus metronidazole (M) versus M + SB for 2 months, to reduce gastrointestinal symptoms and SIBO assessed with hydrogen breath test in SSc. METHODS An open pilot clinical trial performed in forty patients with SIBO and SSc (ACR-EULAR 2013) who signed informed consent. Three groups were assigned: M, SB, and M + SB, for 2 months. Hydrogen was measured in parts per million with a hydrogen breath test to evaluate SIBO. The National Institutes of Health Patient-Reported Outcomes Measurement Information System (NIH-PROMIS) questionnaire was applied to quantify gastrointestinal symptoms with a raw score of eight symptoms. This study is registered in ClinicalTrials.gov with the following ID: NCT03692299. RESULTS Baseline characteristics were similar between groups. The average age was 53.2 ± 9.3 years, and the evolution of SSc was 13.5 (1-34) years. After 2 months of treatment, SIBO was eradicated in 55% of the M + SB group: 33% of SB, and 25% of M. The SB and M + SB groups had decreased diarrhea, abdominal pain, and gas/bloating/flatulence, but M remained unchanged. Reductions in expired hydrogen at 45 to 60 min were as follows: M + SB 48% and 44%, M 18% and 20%, and SB 53% and 60% at the first and second months, respectively (p < 0.01). Adverse effects were epigastric burning and constipation in M (53%) and M + SB (36%), and flatulence/diarrhea in SB (22%). CONCLUSIONS Metronidazole treatment is partially effective in SIBO, but S. boulardii in monotherapy or in combination improves the gastrointestinal outcomes in SSc.",2020,"Adverse effects were epigastric burning and constipation in M (53%) and M + SB (36%), and flatulence/diarrhea in SB (22%). ","['patients with systemic sclerosis (SSc', 'forty patients with SIBO and SSc (ACR-EULAR 2013) who signed informed consent', 'The average age was 53.2\u2009±\u20099.3\xa0years, and the evolution of SSc was 13.5 (1-34) years', 'Small Intestinal Bacterial Overgrowth in Systemic Sclerosis']","['Saccharomyces boulardii and Metronidazole', 'Metronidazole', 'Saccharomyces boulardii (SB) versus metronidazole (M) versus M\u2009+\u2009SB']","['SIBO', 'flatulence/diarrhea', 'gastrointestinal outcomes', 'diarrhea, abdominal pain, and gas/bloating/flatulence', 'epigastric burning and constipation']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036421', 'cui_str': 'Systemic Scleroderma'}, {'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517559', 'cui_str': '13.5 (qualifier value)'}, {'cui': 'C3160854', 'cui_str': 'Small intestinal bacterial overgrowth'}]","[{'cui': 'C0772093', 'cui_str': 'Saccharomyces boulardii'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}]","[{'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C0596601', 'cui_str': 'Gas'}, {'cui': 'C0541938', 'cui_str': 'Epigastric burning'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}]",,0.126581,"Adverse effects were epigastric burning and constipation in M (53%) and M + SB (36%), and flatulence/diarrhea in SB (22%). ","[{'ForeName': 'Grettel', 'Initials': 'G', 'LastName': 'García-Collinot', 'Affiliation': ""Research Division, Clinical Research Training Center, Hospital de Especialidades Centro Medico 'La Raza', Instituto Mexicano del Seguro Social, Mexico City, Mexico.""}, {'ForeName': 'Eduardo Osiris', 'Initials': 'EO', 'LastName': 'Madrigal-Santillán', 'Affiliation': 'Conservation Medicine Laboratory, Escuela Superior de Medicina (ESM), Instituto Politecnico Nacional, Mexico City, Mexico.'}, {'ForeName': 'Michel A', 'Initials': 'MA', 'LastName': 'Martínez-Bencomo', 'Affiliation': ""Research Division, Hospital de Especialidades Centro Medico 'La Raza', Instituto Mexicano del Seguro Social, Seris y Zaachila SN, Colonia La Raza, Azcapotzalco, Mexico City, Mexico.""}, {'ForeName': 'Rosa A', 'Initials': 'RA', 'LastName': 'Carranza-Muleiro', 'Affiliation': 'Postgraduate Section, Escuela Superior de Medicina (ESM), Instituto Politecnico Nacional, Mexico City, Mexico.'}, {'ForeName': 'Luis J', 'Initials': 'LJ', 'LastName': 'Jara', 'Affiliation': ""Direction of Education and Research, Hospital de Especialidades Centro Medico 'La Raza', Instituto Mexicano del Seguro Social, Mexico City, Mexico.""}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Vera-Lastra', 'Affiliation': ""Internal Medicine Department, Hospital de Especialidades Centro Medico, 'La Raza', Instituto Mexicano del Seguro Social, Mexico City, Mexico.""}, {'ForeName': 'Daniel H', 'Initials': 'DH', 'LastName': 'Montes-Cortes', 'Affiliation': ""Emergency Department, Hospital General Centro Medico 'La Raza', Instituto Mexicano del Seguro Social, Mexico City, Mexico.""}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Medina', 'Affiliation': ""Translational Research Unit, Hospital de Especialidades Centro Medico 'La Raza', Instituto Mexicano del Seguro Social, Mexico City, Mexico.""}, {'ForeName': 'María Pilar', 'Initials': 'MP', 'LastName': 'Cruz-Domínguez', 'Affiliation': ""Research Division, Hospital de Especialidades Centro Medico 'La Raza', Instituto Mexicano del Seguro Social, Seris y Zaachila SN, Colonia La Raza, Azcapotzalco, Mexico City, Mexico. drapilarcd@live.com.mx.""}]",Digestive diseases and sciences,['10.1007/s10620-019-05830-0'] 482,32171637,Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial.,"Neurocognitive impairments are well established in both ultra-high risk (UHR) for psychosis and major depressive disorder (MDD). Despite this understanding, investigation of neurocognitive deficits in UHR individuals with MDD and its association with MDD within this population, has been scarce. Hence, this study aimed to examine any differences in neurocognition at baseline between those with MDD at baseline and those with no history of MDD, as well as determine whether neurocognitive variables are significantly associated with meeting criteria for MDD at follow-up, while controlling for relevant clinical variables, within a UHR cohort. Data analysis was conducted on 207 participants whose baseline neurocognition was assessed using Brief Assessment of Cognition for Schizophrenia, as part of a trial of omega-3 fatty acids (NEURAPRO) for UHR individuals. While baseline MDD was the strongest predictor, poorer verbal memory and higher verbal fluency were significantly associated with MDD at 12 months (p = .04 and 0.026, respectively). Further, higher processing speed was significantly associated with MDD at medium-term follow-up (p = .047). These findings outline that neurocognitive skills were independently associated with meeting criteria for MDD at follow-up within UHR individuals, with novel findings of better verbal fluency and processing speed being linked to MDD outcomes. Hence, neurocognitive performance should be considered as a marker of risk for MDD outcomes and a target for management of MDD in UHR.",2020,"Further, higher processing speed was significantly associated with MDD at medium-term follow-up (p = .047).","['207 participants whose baseline neurocognition was assessed using Brief Assessment of Cognition for Schizophrenia, as part of a trial of', 'UHR individuals with MDD', 'psychosis individuals with and without depression']","['NEURAPRO', 'omega-3 fatty acids (NEURAPRO']","['higher processing speed', 'poorer verbal memory and higher verbal fluency', 'Cognitive functioning']","[{'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C1292711', 'cui_str': 'Part of (attribute)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]","[{'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0582591', 'cui_str': 'Processing speed (observable entity)'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}]",207.0,0.109403,"Further, higher processing speed was significantly associated with MDD at medium-term follow-up (p = .047).","[{'ForeName': 'Sumudu Rasangi', 'Initials': 'SR', 'LastName': 'Mallawaarachchi', 'Affiliation': 'Orygen, Parkville, Australia; The Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia. Electronic address: sumudu.mallawaarachchi@orygen.org.au.'}, {'ForeName': 'G Paul', 'Initials': 'GP', 'LastName': 'Amminger', 'Affiliation': 'Orygen, Parkville, Australia; The Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia; Department of Psychiatry and Psychotherapy, Clinical Division of Social Psychiatry, Medical University Vienna, Vienna, Austria. Electronic address: paul.amminger@orygen.org.au.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Farhall', 'Affiliation': 'Department of Psychology and Counselling, La Trobe University, Bundoora, Australia. Electronic address: j.farhall@latrobe.edu.au.'}, {'ForeName': 'Luke K', 'Initials': 'LK', 'LastName': 'Bolt', 'Affiliation': 'Department of Psychology and Counselling, La Trobe University, Bundoora, Australia.'}, {'ForeName': 'Barnaby', 'Initials': 'B', 'LastName': 'Nelson', 'Affiliation': 'The Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia. Electronic address: barnaby.nelson@orygen.org.au.'}, {'ForeName': 'Hok Pan', 'Initials': 'HP', 'LastName': 'Yuen', 'Affiliation': 'Orygen, Parkville, Australia; The Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia. Electronic address: hokpan.yuen@orygen.org.au.'}, {'ForeName': 'Patrick D', 'Initials': 'PD', 'LastName': 'McGorry', 'Affiliation': 'Orygen, Parkville, Australia; The Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia. Electronic address: pat.mcgorry@orygen.org.au.'}, {'ForeName': 'Connie', 'Initials': 'C', 'LastName': 'Markulev', 'Affiliation': 'Orygen, Parkville, Australia; The Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia. Electronic address: connie.markulev@orygen.org.au.'}, {'ForeName': 'Miriam R', 'Initials': 'MR', 'LastName': 'Schäfer', 'Affiliation': 'The Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia; Department of Psychiatry and Psychotherapy, Clinical Division of Social Psychiatry, Medical University Vienna, Vienna, Austria.'}, {'ForeName': 'Nilufar', 'Initials': 'N', 'LastName': 'Mossaheb', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Clinical Division of Social Psychiatry, Medical University Vienna, Vienna, Austria. Electronic address: nilufar.mossaheb@meduniwien.ac.at.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Schlögelhofer', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Clinical Division of Social Psychiatry, Medical University Vienna, Vienna, Austria. Electronic address: monika.schloegelhofer@meduniwien.ac.at.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Smesny', 'Affiliation': 'Department of Psychiatry, University Hospital Jena, Jena, Germany. Electronic address: stefan.smesny@med.uni-jena.de.'}, {'ForeName': 'Ian B', 'Initials': 'IB', 'LastName': 'Hickie', 'Affiliation': 'Brain and Mind Centre, University of Sydney, Sydney, Australia. Electronic address: Ian.hickie@sydney.edu.au.'}, {'ForeName': 'Gregor Emanuel', 'Initials': 'GE', 'LastName': 'Berger', 'Affiliation': 'Child and Adolescent Psychiatric Service of the Canton of Zurich, Zurich, Switzerland. Electronic address: gregor.berger@puk.zh.ch.'}, {'ForeName': 'Eric Y H', 'Initials': 'EYH', 'LastName': 'Chen', 'Affiliation': 'Department of Psychiatry, University of Hong Kong, Hong Kong. Electronic address: eyhchen@hkusua.hku.hk.'}, {'ForeName': 'Lieuwe', 'Initials': 'L', 'LastName': 'de Haan', 'Affiliation': 'Department of Psychiatry, Amsterdam University Medical Centers, the Netherlands. Electronic address: l.dehaan@amc.uva.nl.'}, {'ForeName': 'Dorien H', 'Initials': 'DH', 'LastName': 'Nieman', 'Affiliation': 'Department of Psychiatry, Amsterdam University Medical Centers, the Netherlands. Electronic address: d.h.nieman@amc.uva.nl.'}, {'ForeName': 'Merete', 'Initials': 'M', 'LastName': 'Nordentoft', 'Affiliation': 'Psychiatric Centre Bispebjerg, Copenhagen, Denmark. Electronic address: merete.nordentoft@regionh.dk.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Riecher-Rössler', 'Affiliation': 'University of Basel, Basel, Switzerland. Electronic address: anita.riecher@unibas.ch.'}, {'ForeName': 'Swapna', 'Initials': 'S', 'LastName': 'Verma', 'Affiliation': 'Institute of Mental Health, Singapore, Singapore. Electronic address: swapna_verma@imh.com.sg.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Thompson', 'Affiliation': 'Orygen, Parkville, Australia; The Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia; Division of Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, England, United Kingdom; North Warwickshire Early Intervention in Psychosis Service, Coventry and Warwickshire National Health Service Partnership Trust, Coventry, England, United Kingdom. Electronic address: andrew.thompson@orygen.org.au.'}, {'ForeName': 'Alison Ruth', 'Initials': 'AR', 'LastName': 'Yung', 'Affiliation': 'Orygen, Parkville, Australia; The Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia; Division of Psychology and Mental Health, University of Manchester, Manchester, England, United Kingdom; Greater Manchester Mental Health NHS Foundation Trust, Manchester, England, United Kingdom. Electronic address: alison.yung@orygen.org.au.'}, {'ForeName': 'Kelly A', 'Initials': 'KA', 'LastName': 'Allott', 'Affiliation': 'Orygen, Parkville, Australia; The Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia. Electronic address: kelly.allott@orygen.org.au.'}]",Schizophrenia research,['10.1016/j.schres.2020.03.008'] 483,30891657,Computerized neurocognitive training for improving dietary health and facilitating weight loss.,"Nearly 70% of Americans are overweight, in large part because of overconsumption of high-calorie foods such as sweets. Reducing sweets is difficult because powerful drives toward reward overwhelm inhibitory control (i.e., the ability to withhold a prepotent response) capacities. Computerized inhibitory control trainings (ICTs) have shown positive outcomes, but impact on real-world health behavior has been variable, potentially because of limitations inherent in existing paradigms, e.g., low in frequency, intrinsic enjoyment, personalization, and ability to adapt to increasing ability. The present study aimed to assess the feasibility, acceptability, and efficacy of a gamified and non-gamified, daily, personalized, and adaptive ICT designed to facilitate weight loss by targeting consumption of sweets. Participants (N = 106) were randomized to one of four conditions in a 2 (gamified vs. non-gamified) by 2 (ICT vs. sham) factorial design. Participants were prescribed a no-added-sugar diet and completed 42 daily, at-home trainings, followed by two weekly booster trainings. Results indicated that the ICTs were feasible and acceptable. Surprisingly, compliance to the 44 trainings was excellent (88.8%) and equivalent across both gamified and non-gamified conditions. As hypothesized, the impact of ICT on weight loss was moderated by implicit preference for sweet foods [F(1,95) = 6.17, p = .02] such that only those with higher-than-average implicit preference benefited (8-week weight losses for ICT were 3.1% vs. 2.2% for sham). A marginally significant effect was observed for gamification to reduce the impact of ICT. Implications of findings for continued development of ICTs to impact health behavior are discussed.",2019,"Surprisingly, compliance to the 44 trainings was excellent (88.8%) and equivalent across both gamified and non-gamified conditions.",['Participants (N\u2009=\u2009106'],"['gamified and non-gamified, daily, personalized, and adaptive ICT', 'Computerized neurocognitive training', 'Computerized inhibitory control trainings (ICTs']","['dietary health and facilitating weight loss', 'feasibility, acceptability, and efficacy', 'weight loss']",[],"[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",106.0,0.0424756,"Surprisingly, compliance to the 44 trainings was excellent (88.8%) and equivalent across both gamified and non-gamified conditions.","[{'ForeName': 'Evan M', 'Initials': 'EM', 'LastName': 'Forman', 'Affiliation': 'Drexel University, Philadelphia, USA. emf27@drexel.edu.'}, {'ForeName': 'Stephanie M', 'Initials': 'SM', 'LastName': 'Manasse', 'Affiliation': 'Drexel University, Philadelphia, USA.'}, {'ForeName': 'Diane H', 'Initials': 'DH', 'LastName': 'Dallal', 'Affiliation': 'Drexel University, Philadelphia, USA.'}, {'ForeName': 'Rebecca J', 'Initials': 'RJ', 'LastName': 'Crochiere', 'Affiliation': 'Drexel University, Philadelphia, USA.'}, {'ForeName': 'Caitlin M', 'Initials': 'CM', 'LastName': 'Loyka', 'Affiliation': 'Drexel University, Philadelphia, USA.'}, {'ForeName': 'Meghan L', 'Initials': 'ML', 'LastName': 'Butryn', 'Affiliation': 'Drexel University, Philadelphia, USA.'}, {'ForeName': 'Adrienne S', 'Initials': 'AS', 'LastName': 'Juarascio', 'Affiliation': 'Drexel University, Philadelphia, USA.'}, {'ForeName': 'Katrijn', 'Initials': 'K', 'LastName': 'Houben', 'Affiliation': 'Maastricht University, Maastricht, The Netherlands.'}]",Journal of behavioral medicine,['10.1007/s10865-019-00024-5'] 484,30903442,Adapting a self-affirmation intervention for use in a mobile application for smokers.,"Self-affirmation interventions can reduce defensive responses to threats to the self, but have had limited reach to the general population. We sought to create an effective and feasible version of the Kindness Questionnaire self-affirmation intervention for use on a mobile device outside the traditional university laboratory setting and by non-student participants. In an online experiment, 603 cigarette smokers (M age = 37.5 years, SD = 10.2) were randomly assigned to one of six conditions in a 2 (Self-Affirmation: Self-Affirmation, No Self-Affirmation Control) × 3 (Example Type: Written, Imagined, No Examples) fully-crossed design. Participants read a message about the health harms of smoking. None of the self-affirmation variations were effective or feasible: the self-affirmation showed null effects on the primary outcomes of message acceptance, perceived message effectiveness, and reactance. It also backfired by reducing intentions to quit smoking and risk perceptions. Participants spent little time reading the health message, and those in the written self-affirmation condition infrequently provided detailed responses. Translating interventions developed and tested for efficacy in laboratory settings to ""real-world"" settings is necessary but challenging.",2019,"None of the self-affirmation variations were effective or feasible: the self-affirmation showed null effects on the primary outcomes of message acceptance, perceived message effectiveness, and reactance.","['37.5\xa0years, SD\u2009=\u200910.2', '603 cigarette smokers (M age ', 'smokers', 'mobile device outside the traditional university laboratory setting and by non-student participants']",['Kindness Questionnaire self-affirmation intervention'],"['message acceptance, perceived message effectiveness, and reactance']","[{'cui': 'C4517742', 'cui_str': '37.5 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0337667', 'cui_str': 'Cigarette smoker (finding)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}]","[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0036588', 'cui_str': 'Self'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}]",603.0,0.0144147,"None of the self-affirmation variations were effective or feasible: the self-affirmation showed null effects on the primary outcomes of message acceptance, perceived message effectiveness, and reactance.","[{'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Taber', 'Affiliation': 'Department of Psychological Sciences, Kent State University, Kent, OH, 44242-0001, USA. jtaber1@kent.edu.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'McQueen', 'Affiliation': 'School of Medicine, Washington University in Saint Louis, Saint Louis, MO, 63110, USA.'}, {'ForeName': 'Nicolle', 'Initials': 'N', 'LastName': 'Simonovic', 'Affiliation': 'Department of Psychological Sciences, Kent State University, Kent, OH, 44242-0001, USA.'}, {'ForeName': 'Erika A', 'Initials': 'EA', 'LastName': 'Waters', 'Affiliation': 'School of Medicine, Washington University in Saint Louis, Saint Louis, MO, 63110, USA.'}]",Journal of behavioral medicine,['10.1007/s10865-019-00028-1'] 485,31398726,A Technology-based Intervention to Increase Reading Comprehension of Morphosyntax Structures.,"The purpose of this study was to examine the effectiveness of a technology-based intervention (LanguageLinks: Syntax Assessment and Intervention®; Laureate Learning Systems, Inc., 2013) to improve reading comprehension for d/Deaf and hard of hearing (DHH) elementary students. The intervention was a self-paced, interactive program designed to scaffold learning of morphosyntax structures. Participants included 37 DHH students with moderate to profound hearing levels, 7-12 years of age, in Grades 2-6. Assessment data were collected pre- and post- an 8-week intervention using a randomized control trial methodology. Findings indicate the intervention did not appear to be effective in improving performance, and 17 out of 36 morphosyntax structures were found difficult to comprehend for participants in the treatment group. These difficult structures included aspects of pronominalization, the verbal system, and number in nouns. Results are compared to previous research, with recommendations for future areas of research related to increasing knowledge of morphosyntax for learners who are DHH.",2020,"Findings indicate the intervention did not appear to be effective in improving performance, and 17 out of 36 morphosyntax structures were found difficult to comprehend for participants in the treatment group.","['Participants included 37 DHH students with moderate to profound hearing levels, 7-12 years of age, in Grades 2-6', 'd/Deaf and hard of hearing (DHH) elementary students']",['technology-based intervention (LanguageLinks: Syntax Assessment and Intervention®'],[],"[{'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0041711', 'cui_str': 'United States Department of Health and Human Services'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0439808', 'cui_str': 'Profundis'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0525064', 'cui_str': 'Hearing Impaired Persons'}, {'cui': 'C0018599', 'cui_str': 'Hardness'}, {'cui': 'C0018767', 'cui_str': 'Audition'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",[],,0.0153675,"Findings indicate the intervention did not appear to be effective in improving performance, and 17 out of 36 morphosyntax structures were found difficult to comprehend for participants in the treatment group.","[{'ForeName': 'Joanna E', 'Initials': 'JE', 'LastName': 'Cannon', 'Affiliation': 'University of British Columbia.'}, {'ForeName': 'Anita M', 'Initials': 'AM', 'LastName': 'Hubley', 'Affiliation': 'University of British Columbia.'}, {'ForeName': 'Julia I', 'Initials': 'JI', 'LastName': ""O'Loughlin"", 'Affiliation': 'University of British Columbia.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Phelan', 'Affiliation': 'University of British Columbia.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Norman', 'Affiliation': 'Kwantlen Polytechnic University.'}, {'ForeName': 'Alayna', 'Initials': 'A', 'LastName': 'Finley', 'Affiliation': 'Vancouver Community College.'}]",Journal of deaf studies and deaf education,['10.1093/deafed/enz029'] 486,32173478,"Effects of Blended (Yellow) vs Forced Coagulation (Blue) Currents on Adverse Events, Complete Resection, or Polyp Recurrence After Polypectomy in a Large Randomized Trial.","BACKGROUND & AIMS There is debate over the type of electrosurgical setting that should be used for polyp resection. Some endoscopists use a type of blended current (yellow), whereas others prefer coagulation (blue). We performed a single-blinded, randomized trial to determine whether type of electrosurgical setting affects risk of adverse events or recurrence. METHODS Patients undergoing endoscopic mucosal resection of nonpedunculated colorectal polyps 20 mm or larger (n = 928) were randomly assigned, in a 2 × 2 design, to groups that received clip closure or no clip closure of the resection defect (primary intervention) and then to either a blended current (Endocut Q) or coagulation current (forced coagulation) (Erbe Inc) (secondary intervention and focus of the study). The study was performed at multiple centers, from April 2013 through October 2017. Patients were evaluated 30 days after the procedure (n = 919), and 675 patients underwent a surveillance colonoscopy at a median of 6 months after the procedure. The primary outcome was any severe adverse event in a per patient analysis. Secondary outcomes were complete resection and recurrence at first surveillance colonoscopy in a per polyp analysis. RESULTS Serious adverse events occurred in 7.2% of patients in the Endocut group and 7.9% of patients in the forced coagulation group, with no significant differences in the occurrence of types of events. There were no significant differences between groups in proportions of polyps that were completely removed (96% in the Endocut group vs 95% in the forced coagulation group) or the proportion of polyps found to have recurred at surveillance colonoscopy (17% and 17%, respectively). Procedural characteristics were comparable, except that 17% of patients in the Endocut group had immediate bleeding that required an intervention, compared with 11% in the forced coagulation group (P = .006). CONCLUSIONS In a randomized trial to compare 2 commonly used electrosurgical settings for the resection of large colorectal polyps (Endocut vs forced coagulation), we found no difference in risk of serious adverse events, complete resection rate, or polyp recurrence. Electrosurgical settings can therefore be selected based on endoscopist expertise and preference. Clinicaltrials.gov ID NCT01936948.",2020,There were no significant differences between groups in proportions of polyps that were completely removed (96% in the in the Endocut group vs 95% in the forced coagulation group) or the proportion of polyps found to have recurred at surveillance colonoscopy (17% and 17%).,"['multiple centers, from April 2013 through October 2017', 'Patients were evaluated 30 days after the procedure (n=919), and 675 patients underwent a', 'Patients undergoing endoscopic mucosal resection of non-pedunculated colorectal polyps 20 mm or larger (n=928']","['clip closure or no clip closure of the resection defect (primary intervention) and then to either a blended current (Endocut Q) or coagulation current (forced coagulation; Erbe Inc.) (secondary intervention', 'electrosurgical setting', 'Blended (Yellow) vs Forced Coagulation (Blue) Currents', 'surveillance colonoscopy']","['adverse events', 'Adverse Events, Complete Resection, or Polyp Recurrence', 'immediate bleeding', 'proportions of polyps', 'risk of serious adverse events, complete resection rate, or polyp recurrence', 'severe adverse event', 'occurrence of types of events', 'complete resection and recurrence at first surveillance colonoscopy in a per polyp analysis']","[{'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C4517854', 'cui_str': '675 (qualifier value)'}, {'cui': 'C1700928', 'cui_str': 'Endoscopic Mucous Membrane Resection'}, {'cui': 'C0555952', 'cui_str': 'Colorectal (qualifier value)'}, {'cui': 'C0032584', 'cui_str': 'Polyp (morphologic abnormality)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}]","[{'cui': 'C0175722', 'cui_str': 'Clip'}, {'cui': 'C0185003', 'cui_str': 'Reparative closure (procedure)'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0441509', 'cui_str': 'Coagulation - action (qualifier value)'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0733511', 'cui_str': 'Surveillance (regime/therapy)'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0032584', 'cui_str': 'Polyp (morphologic abnormality)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0733511', 'cui_str': 'Surveillance (regime/therapy)'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}, {'cui': 'C1524024', 'cui_str': 'analysis'}]",,0.159884,There were no significant differences between groups in proportions of polyps that were completely removed (96% in the in the Endocut group vs 95% in the forced coagulation group) or the proportion of polyps found to have recurred at surveillance colonoscopy (17% and 17%).,"[{'ForeName': 'Heiko', 'Initials': 'H', 'LastName': 'Pohl', 'Affiliation': 'Dartmouth Geisel School of Medicine, Hanover, New Hampshire; Section of Gastroenterology and Hepatology, Veterans Affairs Medical Center White River Junction, Vermont. Electronic address: Heiko.pohl@dartmouth.edu.'}, {'ForeName': 'Ian S', 'Initials': 'IS', 'LastName': 'Grimm', 'Affiliation': 'Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.'}, {'ForeName': 'Matthew T', 'Initials': 'MT', 'LastName': 'Moyer', 'Affiliation': 'Matthew T. Moyer, Division of Gastroenterology and Hepatology, Penn State Hershey Medical Center, Hershey, Pennsylvania.'}, {'ForeName': 'Muhammad K', 'Initials': 'MK', 'LastName': 'Hasan', 'Affiliation': 'Muhammad K. Hasan, Center for Interventional Endoscopy, Florida Hospital, Orlando, Florida.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Pleskow', 'Affiliation': 'Douglas Pleskow, Division of Gastroenterology Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'B Joseph', 'Initials': 'BJ', 'LastName': 'Elmunzer', 'Affiliation': 'Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Mouen A', 'Initials': 'MA', 'LastName': 'Khashab', 'Affiliation': 'Mouen A. Khashab, Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, Maryland.'}, {'ForeName': 'Omid', 'Initials': 'O', 'LastName': 'Sanaei', 'Affiliation': 'Mouen A. Khashab, Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, Maryland.'}, {'ForeName': 'Firas H', 'Initials': 'FH', 'LastName': 'Al-Kawas', 'Affiliation': 'Mouen A. Khashab, Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, Maryland; Sibley Memorial Hospital, Washington, DC.'}, {'ForeName': 'Stuart R', 'Initials': 'SR', 'LastName': 'Gordon', 'Affiliation': 'Dartmouth Geisel School of Medicine, Hanover, New Hampshire; Department of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.'}, {'ForeName': 'Abraham', 'Initials': 'A', 'LastName': 'Mathew', 'Affiliation': 'Matthew T. Moyer, Division of Gastroenterology and Hepatology, Penn State Hershey Medical Center, Hershey, Pennsylvania.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Levenick', 'Affiliation': 'Matthew T. Moyer, Division of Gastroenterology and Hepatology, Penn State Hershey Medical Center, Hershey, Pennsylvania.'}, {'ForeName': 'Harry R', 'Initials': 'HR', 'LastName': 'Aslanian', 'Affiliation': 'Section of Digestive Diseases, Yale-New Haven Hospital, New Haven, Connecticut.'}, {'ForeName': 'Fadi', 'Initials': 'F', 'LastName': 'Antaki', 'Affiliation': 'Division of Gastroenterology, John D. Dingell Veterans Affairs Medical Center and Wayne State University, Detroit, Michigan.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'von Renteln', 'Affiliation': 'Division of Gastroenterology, University of Montreal Medical Center and Research Center, Montreal, Quebec, Canada.'}, {'ForeName': 'Seth D', 'Initials': 'SD', 'LastName': 'Crockett', 'Affiliation': 'Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Rastogi', 'Affiliation': 'Division of Gastroenterology, Hepatology and Motility, University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Gill', 'Affiliation': 'Division of Gastroenterology James A. Haley Veterans Affairs Medical Center, University of South Florida, Tampa, Florida.'}, {'ForeName': 'Ryan J', 'Initials': 'RJ', 'LastName': 'Law', 'Affiliation': 'Division of Gastroenterology and Hepatology University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Pooja A', 'Initials': 'PA', 'LastName': 'Elias', 'Affiliation': 'Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Pellise', 'Affiliation': 'Gastroenterology Department, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Todd A', 'Initials': 'TA', 'LastName': 'Mackenzie', 'Affiliation': 'The Dartmouth Institute, Department for Biomedical Data Science, Lebanon, New Hampshire.'}, {'ForeName': 'Douglas K', 'Initials': 'DK', 'LastName': 'Rex', 'Affiliation': 'Indiana University School of Medicine, Indianapolis, Indiana.'}]",Gastroenterology,['10.1053/j.gastro.2020.03.014'] 487,32166842,"Comparison of Paresthesia Mapping to Anatomical Placement in Burst Spinal Cord Stimulation: Initial Trial Results of the Prospective, Multicenter, Randomized, Double-Blinded, Crossover, CRISP Study.","INTRODUCTION In this prospective, multicenter, double-blinded, randomized, crossover study, we compared the therapeutic efficacy of burst SCS delivered using a lead implanted with the paresthesia mapping approach to a lead implanted with an anatomic placement approach. MATERIALS AND METHODS Subjects with chronic low back pain were implanted with two leads, one using paresthesia-mapping approach (PM) and the second using anatomical placement procedure (AP). Stimulation contacts were chosen using the standard intraoperative paresthesia-testing procedure for the paresthesia-mapped lead or an activated bipole overlapping the T9-T10 junction for the anatomical lead. Amplitude for either lead was selected such that no sensory percepts were generated. Subjects were assessed at baseline and after a trial period during which they tested each lead for two weeks in random order. Eligible subjects had the option to receive permanent implants using their preferred AP or PM approach at end-of-trial. RESULTS Of the 53 subjects who completed both trial periods, 43 (81.1%) experienced at least 50% back pain relief with at least one lead. Nearly half of these (20; 46.5%) were profound responders who experienced at least 80% back pain relief with either leads. Primary and secondary outcomes, at the end of trial, showed significant improvements for both AP and PM leads from baseline yet were not significantly different from each other. DISCUSSION The trial results of this study suggest that similar clinical outcomes can be achieved in burst SCS when performing lead placement either using paresthesia mapping or anatomical placement with imaging references.",2020,"Primary and secondary outcomes, at the end of trial, showed significant improvements for both AP and PM leads from baseline yet were not significantly different from each other. ","['Subjects with chronic low back pain', 'Eligible subjects had the option to receive permanent implants using their preferred AP or PM approach at end-of-trial']","['burst SCS', 'Paresthesia Mapping to Anatomical Placement', 'paresthesia-mapping approach (PM) and the second using anatomical placement procedure (AP']","['back pain relief', 'AP and PM leads']","[{'cui': 'C0457949', 'cui_str': 'Chronic low back pain (finding)'}, {'cui': 'C0205355', 'cui_str': 'Permanent (qualifier value)'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}]","[{'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C0220784', 'cui_str': 'Anatomic (qualifier value)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0589567', 'cui_str': 'Placement procedure (procedure)'}]","[{'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C1301676', 'cui_str': 'Relieves (qualifier value)'}, {'cui': 'C0023175', 'cui_str': 'Lead'}]",,0.260349,"Primary and secondary outcomes, at the end of trial, showed significant improvements for both AP and PM leads from baseline yet were not significantly different from each other. ","[{'ForeName': 'Adnan', 'Initials': 'A', 'LastName': 'Al-Kaisy', 'Affiliation': ""Guy's & St. Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Ganesan', 'Initials': 'G', 'LastName': 'Baranidharan', 'Affiliation': 'Leeds Teaching Hospitals NHS Trust, Leeds, UK.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Palmisani', 'Affiliation': ""Guy's & St. Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Pang', 'Affiliation': ""Guy's & St. Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Onita', 'Initials': 'O', 'LastName': 'Will', 'Affiliation': ""Guy's & St. Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Wesley', 'Affiliation': ""Guy's & St. Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Tracey', 'Initials': 'T', 'LastName': 'Crowther', 'Affiliation': 'Leeds Teaching Hospitals NHS Trust, Leeds, UK.'}, {'ForeName': 'Karl', 'Initials': 'K', 'LastName': 'Ward', 'Affiliation': 'Leeds Teaching Hospitals NHS Trust, Leeds, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Castino', 'Affiliation': 'Leeds Teaching Hospitals NHS Trust, Leeds, UK.'}, {'ForeName': 'Adil', 'Initials': 'A', 'LastName': 'Raza', 'Affiliation': 'Abbott, Plano, TX, USA.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Agnesi', 'Affiliation': 'Abbott, Plano, TX, USA.'}]",Neuromodulation : journal of the International Neuromodulation Society,['10.1111/ner.13104'] 488,32158971,The role of antibiotic prophylaxis in mild to moderate isolated hydronephrosis detected in antenatal screening.,"Purpose To determine whether continuous antibiotic prophylaxis (CAP) could prevent urinary tract infection (UTI) in mild to moderate antenatal isolated hydronephrosis (IH), characterized by hydronephrosis without ureter and bladder abnormalities, and anteroposterior renal pelvis diameter <16 mm and the Society for Fetal Urology grade <4, in neonatal renal ultrasound. Materials and Methods Eighty neonates aged 7 to 30 days, with antenatal hydronephrosis and mild to moderate IH on neonatal renal ultrasound, were recruited from August 2015 to December 2016. Neonates were randomly assigned to CAP until hydronephrosis resolution or aged 12 months (CAP group, n=40) or to watchful observation (control group, n=40). The primary outcome was UTI. The probability of UTI was compared between the randomized groups using the Kaplan-Meier method and the log-rank test. Results Nonadherence occurred in 6/40 parents in the CAP arm (15.0%). Thus, only 34 patients received CAP. UTI occurred in 5/34 patients in the CAP group (14.7%) and in 4/40 controls (10.0%). The probability of UTI was increased in the CAP group (hazard ratio, 1.38; 95% confidence interval, 0.37-5.16; p=0.63). UTI caused by cotrimoxazole resistant bacteria was four times higher in the CAP group than in controls (relative risk, 4.0; 95% confidence interval, 1.2-13.5; p=0.02). The trial was prematurely terminated due to the negative impact of CAP on bacterial sensitivity. Conclusions The benefits of CAP in infants with mild to moderate IH were inconclusive. CAP conferred a high risk of resistant bacterial organisms when UTI occurs.",2020,"The probability of UTI was increased in the CAP group (hazard ratio, 1.38; 95% confidence interval, 0.37-5.16; p=0.63).","['Eighty neonates aged 7 to 30 days, with antenatal hydronephrosis and mild to moderate IH on neonatal renal ultrasound, were recruited from August 2015 to December 2016', 'mild to moderate antenatal isolated hydronephrosis (IH), characterized by hydronephrosis without ureter and bladder abnormalities, and anteroposterior renal pelvis diameter <16 mm and the Society for Fetal Urology grade <4, in neonatal renal ultrasound', 'mild to moderate isolated hydronephrosis detected in antenatal screening', 'infants with mild to moderate IH']","['CAP', 'continuous antibiotic prophylaxis (CAP', 'CAP until hydronephrosis resolution or aged 12 months (CAP group, n=40) or to watchful observation (control', 'antibiotic prophylaxis']","['urinary tract infection (UTI', 'cotrimoxazole resistant bacteria', 'UTI', 'probability of UTI']","[{'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C2828394', 'cui_str': 'Antenatal (qualifier value)'}, {'cui': 'C0020295', 'cui_str': 'Hydronephrosis'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C0041951', 'cui_str': 'Ureter'}, {'cui': 'C0005682', 'cui_str': 'Bladder'}, {'cui': 'C0000769', 'cui_str': 'anomalies'}, {'cui': 'C1301886', 'cui_str': 'Diameter (qualifier value)'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0042077', 'cui_str': 'Urology'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0442726', 'cui_str': 'Detected (qualifier value)'}, {'cui': 'C0260591', 'cui_str': 'Antenatal screening, unspecified'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0179586', 'cui_str': 'Cap (physical object)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0282638', 'cui_str': 'Premedication, Antibiotic'}, {'cui': 'C0020295', 'cui_str': 'Hydronephrosis'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C0041044', 'cui_str': 'Sulfamethoxazole / Trimethoprim'}, {'cui': 'C1444090', 'cui_str': 'Resistant bacteria'}, {'cui': 'C0033204', 'cui_str': 'Probability'}]",80.0,0.288283,"The probability of UTI was increased in the CAP group (hazard ratio, 1.38; 95% confidence interval, 0.37-5.16; p=0.63).","[{'ForeName': 'Pornpimol', 'Initials': 'P', 'LastName': 'Rianthavorn', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Suratsawadi', 'Initials': 'S', 'LastName': 'Phithaklimnuwong', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}]",Investigative and clinical urology,['10.4111/icu.2020.61.2.200'] 489,30683710,Randomized Trial of a Tailored Cognitive-Behavioral Therapy Mobile Application for Anxiety in Patients with Incurable Cancer.,"BACKGROUND The aim of this study was to test the efficacy of a tailored cognitive-behavioral therapy (CBT) mobile application (app) to treat anxiety in patients with incurable cancer. MATERIALS AND METHODS Patients with incurable cancers ( n = 145) who reported elevated anxiety symptoms at two cancer centers were randomized to receive either the CBT mobile app for anxiety or a mobile health education program (control) delivered via tablet computers, which patients self-administered over 12 weeks. To assess anxiety, depression symptoms, and quality of life (QOL), we used the Hamilton Anxiety Rating Scale (HAM-A, primary outcome), Clinical Global Impression Scale, Hospital Anxiety and Depression Scale (HADS), Patient Health Questionnaire-9, and Functional Assessment of Cancer Therapy-General at baseline and 12 weeks. Analysis of covariance models were calculated to assess intervention effects on patient outcomes. RESULTS Patients (73.8% female; 91.0% white; mean age = 56.45 years, SD = 11.30) in both study groups reported improvements in anxiety, depression symptoms, and QOL from baseline to postassessment, with no significant differences in any outcome measure between groups. Secondary analyses showed that, among the subgroup of patients with severe baseline anxiety, those randomized to the CBT app had greater improvements on the HAM-A (Mean Difference = 7.44, standard error [SE] = 3.35, p = .037) and HADS-Anxiety Subscale (Mean Difference = 4.44, SE = 1.60, p = .010) compared with the control group. CONCLUSION Both the tailored CBT app for anxiety and the health education program were associated with improvements in anxiety, mood, and QOL, but these outcomes did not differ between study groups. The CBT app was more beneficial than health education for patients with severe baseline anxiety. IMPLICATIONS FOR PRACTICE A cognitive-behavioral therapy mobile application tailored to treat anxiety in patients with advanced cancer helps improve access to evidence-based supportive care in a convenient, private, and timely manner.",2019,"Both the tailored CBT app for anxiety and the health education program were associated with improvements in anxiety, mood, and QOL, but these outcomes did not differ between study groups.","['Patients with Incurable Cancer', 'patients with severe baseline anxiety', 'patients with incurable cancer', 'patients with advanced cancer', 'Patients with incurable cancers ( n = 145) who reported elevated anxiety symptoms at two cancer centers']","['Tailored Cognitive-Behavioral Therapy Mobile Application', 'CBT', 'CBT mobile app for anxiety or a mobile health education program (control) delivered via tablet computers', 'tailored cognitive-behavioral therapy (CBT) mobile application (app']","['HADS-Anxiety Subscale', 'anxiety, depression symptoms, and QOL', 'anxiety, depression symptoms, and quality of life (QOL', 'anxiety, mood, and QOL', 'Hamilton Anxiety Rating Scale (HAM-A, primary outcome), Clinical Global Impression Scale, Hospital Anxiety and Depression Scale (HADS), Patient Health Questionnaire-9, and Functional Assessment of Cancer Therapy-General', 'HAM-A', 'severe baseline anxiety']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0729314', 'cui_str': 'Education provision (procedure)'}, {'cui': 'C4045980', 'cui_str': 'Tablet Computers'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034380'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0222045'}, {'cui': 'C3853311', 'cui_str': 'Ham'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C3639708', 'cui_str': 'Clinical global impression scale'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}]",,0.0803484,"Both the tailored CBT app for anxiety and the health education program were associated with improvements in anxiety, mood, and QOL, but these outcomes did not differ between study groups.","[{'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'Greer', 'Affiliation': 'Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA jgreer2@mgh.harvard.edu.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Jacobs', 'Affiliation': 'Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Pensak', 'Affiliation': 'University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'James J', 'Initials': 'JJ', 'LastName': 'MacDonald', 'Affiliation': 'University of California, Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Charn-Xin', 'Initials': 'CX', 'LastName': 'Fuh', 'Affiliation': 'Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Giselle K', 'Initials': 'GK', 'LastName': 'Perez', 'Affiliation': 'Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Ward', 'Affiliation': 'Lee Memorial Health System, Fort Myers, Florida, USA.'}, {'ForeName': 'Colleen', 'Initials': 'C', 'LastName': 'Tallen', 'Affiliation': 'Lee Memorial Health System, Fort Myers, Florida, USA.'}, {'ForeName': 'Alona', 'Initials': 'A', 'LastName': 'Muzikansky', 'Affiliation': 'Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Traeger', 'Affiliation': 'Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Frank J', 'Initials': 'FJ', 'LastName': 'Penedo', 'Affiliation': 'Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Areej', 'Initials': 'A', 'LastName': 'El-Jawahri', 'Affiliation': 'Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Safren', 'Affiliation': 'University of Miami, Coral Gables, Florida, USA.'}, {'ForeName': 'William F', 'Initials': 'WF', 'LastName': 'Pirl', 'Affiliation': 'Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Temel', 'Affiliation': 'Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.'}]",The oncologist,['10.1634/theoncologist.2018-0536'] 490,30980223,A web-based physical activity intervention benefits persons with low self-efficacy in COPD: results from a randomized controlled trial.,"Promoting physical activity (PA) is of top priority in chronic obstructive pulmonary disease (COPD). This study examines the influence of an internet-delivered intervention on the relationship between exercise self-efficacy and changes in PA, physical health, and exercise capacity in COPD. 112 U.S. Veterans with COPD were randomized to either a comparison (pedometer alone) or an intervention group (pedometer plus access to an internet-mediated PA intervention). There was a significant interaction between baseline exercise self-efficacy and randomization group on change in PA. In the comparison group, there was a significant relationship between higher baseline exercise self-efficacy and greater change in PA, whereas in the intervention group, improvements in PA were independent of level of baseline self-efficacy. Similar patterns were found with physical health and exercise capacity as outcomes. The use of an internet-mediated intervention significantly benefited persons with COPD who had low baseline self-efficacy to increase PA and physical health.Clinical trial registration The randomized clinical trial was registered on ClinicalTrials.gov (NCT01772082).",2019,The use of an internet-mediated intervention significantly benefited persons with COPD who had low baseline self-efficacy to increase PA and physical health.,"['chronic obstructive pulmonary disease (COPD', 'persons with COPD who had low baseline self-efficacy to increase PA and physical health', 'benefits persons with low self-efficacy in COPD', '112 U.S. Veterans with COPD']","['A web-based physical activity intervention', 'internet-mediated intervention', 'internet-delivered intervention', 'comparison (pedometer alone) or an intervention group (pedometer plus access to an internet-mediated PA intervention']",['higher baseline exercise self-efficacy and greater change in PA'],"[{'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}]",,0.0817305,The use of an internet-mediated intervention significantly benefited persons with COPD who had low baseline self-efficacy to increase PA and physical health.,"[{'ForeName': 'Stephanie A', 'Initials': 'SA', 'LastName': 'Robinson', 'Affiliation': 'Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, USA. stephanie.robinson5@va.gov.'}, {'ForeName': 'Stephanie L', 'Initials': 'SL', 'LastName': 'Shimada', 'Affiliation': 'Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, USA.'}, {'ForeName': 'Karen S', 'Initials': 'KS', 'LastName': 'Quigley', 'Affiliation': 'Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, USA.'}, {'ForeName': 'Marilyn L', 'Initials': 'ML', 'LastName': 'Moy', 'Affiliation': 'VA Boston Healthcare System, Boston, MA, USA.'}]",Journal of behavioral medicine,['10.1007/s10865-019-00042-3'] 491,32160422,"Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.","OBJECTIVE Alcohol use disorder (AUD) is a common comorbidity of schizophrenia. No effective pharmacologic treatment is available for both disorders to date. METHODS In a phase 2, double-blind study, patients with schizophrenia and AUD experiencing ≥ 10 drinking and ≥ 2 heavy-drinking days in the previous month and recent (≤ 6 mo) disease symptom exacerbation were recruited between June 2014 and March 2017. DSM-IV-TR and DSM-5 criteria were used to assign the diagnoses of schizophrenia and AUD, respectively. After a 6-week lead-in period, 234 eligible patients were randomized (1:1) to olanzapine + 10 mg samidorphan tablets (OLZ/SAM) or olanzapine + placebo tablets (olanzapine) for 36-60 weeks of treatment. The primary outcome of time to the first event of exacerbation of disease symptoms (EEDS) was evaluated using the log rank test for treatment comparison, and the Cox proportional-hazards model was used to estimate hazard ratio. Safety was assessed as adverse events and laboratory measures. RESULTS No significant difference was observed between groups in the time to first EEDS (hazard ratio = 0.91; 95% CI, 0.53-1.56; P = .746). Patients treated with OLZ/SAM vs olanzapine had numerically lower rates in 6 of 8 criteria to evaluate EEDS. Change from baseline in percentage of heavy-drinking days during the double-blind treatment period was similar in OLZ/SAM- vs olanzapine-treated patients. OLZ/SAM was generally well tolerated with a safety profile similar to olanzapine. CONCLUSIONS OLZ/SAM was not superior to olanzapine in the time to EEDS and was well tolerated in patients with schizophrenia and AUD. Further research is needed to identify effective treatments for this difficult-to-treat population. TRIAL REGISTRATIONS ClinicalTrials.gov identifier: NCT02161718; EudraCT number: 2014-001211-39 ​.",2020,Patients treated with OLZ/SAM vs olanzapine had numerically lower rates in 6 of 8 criteria to evaluate EEDS.,"['ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder', 'patients with schizophrenia and AUD experiencing ≥ 10 drinking and ≥ 2 heavy-drinking days in the previous month and recent (≤ 6 mo) disease symptom exacerbation were recruited between June 2014 and March 2017', 'patients with schizophrenia and AUD', '234 eligible patients']","['olanzapine + 10 mg samidorphan tablets (OLZ/SAM) or olanzapine + placebo tablets (olanzapine', 'OLZ/SAM vs olanzapine', 'OLZ/SAM', 'Olanzapine Plus Samidorphan', 'olanzapine']","['adverse events and laboratory measures', 'time to first EEDS', 'time to the first event of exacerbation of disease symptoms (EEDS']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0001956', 'cui_str': 'Alcohol Use Disorder'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C4277369', 'cui_str': '3-carboxamido-4-hydroxynaltrexone'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C1563296', 'cui_str': 'Systolic anterior movement of mitral valve'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0235874', 'cui_str': 'Disease Exacerbation'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",234.0,0.0925487,Patients treated with OLZ/SAM vs olanzapine had numerically lower rates in 6 of 8 criteria to evaluate EEDS.,"[{'ForeName': 'Mary F', 'Initials': 'MF', 'LastName': 'Brunette', 'Affiliation': 'Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756. Mary.F.Brunette@hitchcock.org.'}, {'ForeName': 'Christoph U', 'Initials': 'CU', 'LastName': 'Correll', 'Affiliation': 'Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, New York, USA.'}, {'ForeName': 'Stephanie S', 'Initials': 'SS', 'LastName': ""O'Malley"", 'Affiliation': 'Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'McDonnell', 'Affiliation': 'Alkermes Pharma Ireland Limited, Dublin, Ireland.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'DiPetrillo', 'Affiliation': 'Alkermes, Inc, Waltham, Massachusetts, USA.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': 'Alkermes, Inc, Waltham, Massachusetts, USA.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Simmons', 'Affiliation': 'Alkermes, Inc, Waltham, Massachusetts, USA.'}, {'ForeName': 'Bernard L', 'Initials': 'BL', 'LastName': 'Silverman', 'Affiliation': 'Alkermes, Inc, Waltham, Massachusetts, USA.'}, {'ForeName': 'Leslie', 'Initials': 'L', 'LastName': 'Citrome', 'Affiliation': 'New York Medical College, Valhalla, New York, USA.'}, {'ForeName': 'Alan I', 'Initials': 'AI', 'LastName': 'Green', 'Affiliation': 'Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.'}]",The Journal of clinical psychiatry,['10.4088/JCP.19m12786'] 492,31958993,Initial Findings of a Multicomponent School Health Intervention in Rural Appalachia: The Greenbrier CHOICES Project.,"Background . Schools are an important setting for health promotion because they afford children and adolescents numerous opportunities to accumulate the recommended physical activity (PA) minutes and make other health-related decisions, including healthy eating. Unfortunately, there is little evidence of coordinated school-based health interventions in rural Appalachia. The Greenbrier Children's Health Opportunities Involving Coordinated Efforts in Schools Project was a federally funded, 3-year, multicomponent school-based health intervention focused on PA, healthy eating, and weight management. Aims . The purpose of this study was to evaluate the impact of Greenbrier Children's Health Opportunities Involving Coordinated Efforts in Schools on adolescent PA, dietary behaviors, and weight status. Method . Measures of PA, dietary behaviors, and body mass index were collected across 14 data points throughout the intervention (including a baseline in Year 1). Results . Participants included 4,633 randomly selected middle school students ( M = 2,289, F = 2,344) across the intervention. Baseline to Year 3 findings revealed a 12.8 percentage point increase in students achieving 60 minutes of daily PA. There were no significant differences in either dietary behavior or body mass index. Discussion . Findings provide evidence of the positive impact comprehensive school-based health interventions can have on middle school student health-related behaviors. Conclusion . Schools remain an ideal setting for health promotion. Initiatives targeting more than one level of influence on health-related behaviors are more likely to succeed.",2020,There were no significant differences in either dietary behavior or body mass index. ,"['Rural Appalachia', 'Participants included 4,633 randomly selected middle school students ( M = 2,289, F = 2,344) across the intervention']",['Multicomponent School Health Intervention'],"['PA, dietary behaviors, and body mass index', 'dietary behavior or body mass index']","[{'cui': 'C0003609', 'cui_str': 'Appalachia'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557797', 'cui_str': 'Middle school (environment)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",4633.0,0.019366,There were no significant differences in either dietary behavior or body mass index. ,"[{'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Jones', 'Affiliation': 'Illinois State University, Normal, IL, USA.'}, {'ForeName': 'Luciana', 'Initials': 'L', 'LastName': 'Zuest', 'Affiliation': 'California State University Chico, Chico, CA, USA.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Bulger', 'Affiliation': 'West Virginia University, Morgantown, WV, USA.'}, {'ForeName': 'Eloise', 'Initials': 'E', 'LastName': 'Elliott', 'Affiliation': 'West Virginia University, Morgantown, WV, USA.'}, {'ForeName': 'Kibum', 'Initials': 'K', 'LastName': 'Cho', 'Affiliation': 'Hanyang University, Seoul, South Korea.'}, {'ForeName': 'Christa', 'Initials': 'C', 'LastName': 'Lilly', 'Affiliation': 'West Virginia University, Morgantown, WV, USA.'}]",Health education & behavior : the official publication of the Society for Public Health Education,['10.1177/1090198119897612'] 493,31877968,Comparison of the Effects of Brazil Nut Oil and Soybean Oil on the Cardiometabolic Parameters of Patients with Metabolic Syndrome: A Randomized Trial.,"Recent evidence suggests that replacing saturated fat with unsaturated fat is beneficial for cardiovascular health. This study compared the effects of Brazil nut oil (BNO) and soybean oil (SO) supplementation for 30 days on anthropometric, blood pressure, biochemical, and oxidative parameters in patients with metabolic syndrome (MS). Thirty-one patients with MS were randomly allocated to receive 30 sachets with 10 mL each of either BNO ( n = 15) or SO ( n = 16) for daily supplementation. Variables were measured at the beginning of the study and after 30 days of intervention. No change in anthropometric and blood pressure variables were observed ( p > 0.05). Total ( p = 0.0253) and low-density lipoprotein ( p = 0.0437) cholesterol increased in the SO group. High-density lipoprotein cholesterol decreased ( p = 0.0087) and triglycerides increased ( p = 0.0045) in the BNO group. Malondialdehyde levels decreased in the BNO group ( p = 0.0296) and total antioxidant capacity improved in the SO group ( p = 0.0110). Although the addition of oils without lifestyle interventions did not affect anthropometric findings or blood pressure and promoted undesirable results in the lipid profile in both groups, daily supplementation of BNO for 30 days decreased lipid peroxidation, contributing to oxidative stress reduction.",2019,Malondialdehyde levels decreased in the BNO group ( p = 0.0296) and total antioxidant capacity improved in the SO group ( p = 0.0110).,"['Thirty-one patients with MS', 'Patients with Metabolic Syndrome', 'patients with metabolic syndrome (MS']","['Brazil nut oil (BNO) and soybean oil (SO) supplementation', 'Brazil Nut Oil and Soybean Oil', '30 sachets with 10 mL each of either BNO']","['High-density lipoprotein cholesterol', 'Malondialdehyde levels', 'anthropometric, blood pressure, biochemical, and oxidative parameters', 'low-density lipoprotein', 'Cardiometabolic Parameters', 'anthropometric and blood pressure variables', 'triglycerides', 'total antioxidant capacity', 'lipid peroxidation', 'blood pressure', 'cholesterol']","[{'cui': 'C0450355', 'cui_str': '31 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0524620', 'cui_str': 'Metabolic Syndrome X'}]","[{'cui': 'C3256204', 'cui_str': 'BRAZIL NUT OIL'}, {'cui': 'C0037732', 'cui_str': 'Soybean Oil'}, {'cui': 'C4319662', 'cui_str': 'Sachet'}]","[{'cui': 'C0023822', 'cui_str': 'High Density Lipoprotein Cholesterol'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0205474', 'cui_str': 'Biochemical (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0023775', 'cui_str': 'Lipid Peroxidation'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}]",31.0,0.151239,Malondialdehyde levels decreased in the BNO group ( p = 0.0296) and total antioxidant capacity improved in the SO group ( p = 0.0110).,"[{'ForeName': 'Lívia Martins', 'Initials': 'LM', 'LastName': 'Costa E Silva', 'Affiliation': 'LAMEFI-Laboratory of Physical Measures, Postgraduate Program in Food Science and Technology, Federal University of Para, Belém Pará 66075-900, Brazil.'}, {'ForeName': 'Maria Luisa', 'Initials': 'ML', 'LastName': 'Pereira de Melo', 'Affiliation': ""Academic Master's Degree in Nutrition and Health, State University of Ceará, Fortaleza 60.714.903, Brazil.""}, {'ForeName': 'Fernando Vinicius', 'Initials': 'FV', 'LastName': 'Faro Reis', 'Affiliation': 'Institute of Health Sciences, Federal University of Para, Belém Pará 66075-900, Brazil.'}, {'ForeName': 'Marta Chagas', 'Initials': 'MC', 'LastName': 'Monteiro', 'Affiliation': 'Postgraduate Program in Pharmaceutical Sciences, Federal University of Para, Belém Pará 66075-900, Brazil.'}, {'ForeName': 'Savio Monteiro', 'Initials': 'SM', 'LastName': 'Dos Santos', 'Affiliation': 'Postgraduate Program in Pharmaceutical Sciences, Federal University of Para, Belém Pará 66075-900, Brazil.'}, {'ForeName': 'Bruno Alexandre', 'Initials': 'BA', 'LastName': 'Quadros Gomes', 'Affiliation': 'Neuroscience and Cellular Biology Postgraduation Program, Biological Science Institute, Federal University of Para, Belém Pará 66075-900, Brazil.'}, {'ForeName': 'Luiza Helena', 'Initials': 'LH', 'LastName': 'Meller da Silva', 'Affiliation': 'LAMEFI-Laboratory of Physical Measures, Postgraduate Program in Food Science and Technology, Federal University of Para, Belém Pará 66075-900, Brazil.'}]",Nutrients,['10.3390/nu12010046'] 494,32195857,The Wrist and Radius Injury Surgical Trial: 12-Month Outcomes from a Multicenter International Randomized Clinical Trial.,"BACKGROUND Optimal treatment for distal radius fractures in older adults remains uncertain. No randomized trials comparing the most frequently used treatments in this population have been conducted. Surgical treatment rates vary widely, and the sustained benefits of surgery are uncertain. METHODS The Wrist and Radius Injury Surgical Trial, a randomized, multicenter trial, enrolled 304 adults aged 60 years and older with isolated, unstable distal radius fractures at 24 institutions. Patients who wanted surgery (n = 187) were randomized to internal fixation, external fixation, or percutaneous pinning; patients who preferred conservative management (n = 117) received casting. The primary outcome was the 12-month Michigan Hand Outcomes Questionnaire (MHQ) summary score. RESULTS At 12 months, there were no differences by treatment in primary outcome. Twelve-month MHQ summary scores differed between internal fixation and external fixation by 3 points (97.5 percent CI, 6.0 to 11.5) and between internal fixation and pinning by -0.14 (97.5 percent CI, -9.2 to 8.9). However, at 6 weeks, the mean MHQ summary score for internal fixation was greater than for external fixation by 19 (p < 0.001), pinning by 11 (p < 0.001), and casting by 7 (p = 0.03). Internal fixation participants demonstrated significantly better radiologic alignment throughout the follow-up period. Malunion was experienced by 48 percent of casting participants. CONCLUSIONS Recovery was fastest for internal fixation and slowest for external fixation according to most measures, but by 12 months there were no meaningful differences in outcomes. Casting participants experienced satisfactory results despite loss of radiologic alignment. CLINICAL QUESTION/LEVEL OF EVIDENCE Therapeutic, II.",2020,"Twelve-month MHQ Summary scores differed between VLPS and EFP by 3 points (97.5% CL: -6.0, 11.5) and between VLPS and pinning by -0.14(-9.2,8.9).","['distal radius fractures (DRFs) in older adults', 'Patients who wanted surgery (n=187', 'enrolled 304 adults age 60 years and older with isolated, unstable DRFs at 24 institutions']","['VLPS', 'internal fixation with volar plate (VLPS), external fixation (EFP), or percutaneous pinning; patients who preferred conservative management (n=117) received casting']","['12-month Michigan Hand Outcomes Questionnaire (MHQ) Summary score', 'radiologic alignment', 'mean MHQ Summary score for VLPS', 'MHQ domain scores and radiographic parameters']","[{'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius (body structure)'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1444647', 'cui_str': 'Wanted'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0443343', 'cui_str': 'Unstable status (qualifier value)'}, {'cui': 'C1272753', 'cui_str': 'Institution'}]","[{'cui': 'C0016642', 'cui_str': 'Osteosynthesis, Fracture'}, {'cui': 'C0443349', 'cui_str': 'Volar (qualifier value)'}, {'cui': 'C0407295', 'cui_str': 'Fixation of fracture using plate (procedure)'}, {'cui': 'C0407333', 'cui_str': 'Fixation of fracture using external fixator (procedure)'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach - access (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3543840', 'cui_str': 'Preferred'}, {'cui': 'C0459914', 'cui_str': 'Conservative Management'}, {'cui': 'C0302143', 'cui_str': 'Casts (qualifier value)'}]","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0025939', 'cui_str': 'Michigan'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205483', 'cui_str': 'Radiologic (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",304.0,0.137787,"Twelve-month MHQ Summary scores differed between VLPS and EFP by 3 points (97.5% CL: -6.0, 11.5) and between VLPS and pinning by -0.14(-9.2,8.9).","[{'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Chung', 'Affiliation': 'Ann Arbor, Mich. From the Section of Plastic Surgery, Department of Surgery, University of Michigan Medical School; and the Center for Statistical Consulting and Research, University of Michigan.'}, {'ForeName': 'H Myra', 'Initials': 'HM', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Sunitha', 'Initials': 'S', 'LastName': 'Malay', 'Affiliation': ''}, {'ForeName': 'Melissa J', 'Initials': 'MJ', 'LastName': 'Shauver', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000006829'] 495,32195858,"The Effect of Surgical Video on Resident Performance of Carpal Tunnel Release: A Cadaveric Simulation-Based, Prospective, Randomized, Blinded Pilot Study.","BACKGROUND Surgical videos are increasingly common, although their role in residency curricula remains unclear. The aim of this study was to evaluate the impact of an educational surgical video on resident performance of an open carpal tunnel release through an Objective Structured Assessment of Technical Skills and serial questionnaires. METHODS Twenty-two residents representing six postgraduate years were randomized to receive text-based materials with or without a surgical video before performing a carpal tunnel release on human cadavers. Procedures were video recorded, anonymized, and independently evaluated by three hand surgeons using the Objective Structured Assessment of Technical Skills global rating scale, a procedure-specific technical rating scale, a record of operative errors, and pass/fail designation. Residents completed questionnaires before and after the procedure to track confidence in their technical skills. RESULTS Residents in their first and second postgraduate years (n = 10) who watched the surgical video committed fewer operative errors (median, 4 versus 1.3; p = 0.043) and were more confident in their abilities following the procedure (median, 75 versus 32; p = 0.043) than those receiving text resources alone. There were no significant differences in Objective Structured Assessment of Technical Skills performance or questionnaire responses among more senior residents (n = 12). The technical rating scale was internally consistent (Cronbach α = 0.95; 95 percent CI, 0.91 to 0.98), reliable (intraclass correlation coefficient, 0.73; 95 percent CI, 0.40 to 0.88), and correlated with surgical experience (Spearman ρ = 0.57; p = 0.006). CONCLUSION Watching an educational surgical video to prepare for a cadaveric procedure significantly reduced operative errors and improved confidence among junior trainees performing a carpal tunnel release.",2020,Watching an educational surgical video to prepare for a cadaveric procedure significantly reduced operative errors and improved confidence among junior trainees performing a carpal tunnel release.,"['Twenty-two residents representing six postgraduate years', 'Carpal Tunnel Release']","['educational surgical video', 'text-based materials with or without a surgical video before performing a carpal tunnel release on human cadavers', 'Surgical Video']","['OSATS global rating scale, a procedure-specific technical rating scale, a record of operative errors, and pass/fail designation', 'technical rating scale', 'operative errors', 'OSATS performance or questionnaire responses']","[{'cui': 'C4284772', 'cui_str': '22 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0196576', 'cui_str': 'Carpal tunnel decompression'}]","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C3541382', 'cui_str': 'Text'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0196576', 'cui_str': 'Carpal tunnel decompression'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0006629', 'cui_str': 'Corpse'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C2355580', 'cui_str': 'Record of (contextual qualifier) (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.0372309,Watching an educational surgical video to prepare for a cadaveric procedure significantly reduced operative errors and improved confidence among junior trainees performing a carpal tunnel release.,"[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Yee', 'Affiliation': 'St. Louis, Mo.; and Utrecht, The Netherlands From the Division of Plastic and Reconstructive Surgery, Department of Surgery, Washington University School of Medicine; and the Department of Plastic, Reconstructive and Hand Surgery, Utrecht University Medical Center.'}, {'ForeName': 'William M', 'Initials': 'WM', 'LastName': 'Padovano', 'Affiliation': ''}, {'ForeName': 'Amanda G', 'Initials': 'AG', 'LastName': 'Rowe', 'Affiliation': ''}, {'ForeName': 'Elspeth J R', 'Initials': 'EJR', 'LastName': 'Hill', 'Affiliation': ''}, {'ForeName': 'Ida K', 'Initials': 'IK', 'LastName': 'Fox', 'Affiliation': ''}, {'ForeName': 'Amy M', 'Initials': 'AM', 'LastName': 'Moore', 'Affiliation': ''}, {'ForeName': 'J Henk', 'Initials': 'JH', 'LastName': 'Coert', 'Affiliation': ''}, {'ForeName': 'Susan E', 'Initials': 'SE', 'LastName': 'Mackinnon', 'Affiliation': ''}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000006817'] 496,32195861,Postoperative Antibiotic Prophylaxis in Reduction Mammaplasty: A Randomized Controlled Trial.,"BACKGROUND Reduction mammaplasty is a well-established procedure. Studies have shown benefits of using antibiotics in this procedure. Nevertheless, there is no solid evidence to support postoperative antibiotic prophylaxis. The authors evaluated the influence of postoperative antibiotic delivery on infection rates after reduction mammaplasty. METHODS The authors conducted a randomized trial of noninferiority, with two parallel groups, with triple blinding. The participants were 124 women with breast hypertrophy, with reduction mammaplasty already scheduled, selected consecutively. All patients underwent reduction mammaplasty, performed by the same surgical team, using the superomedial pedicle technique for ascending the nipple-areola complex. All patients received cephalothin (1 g) intravenously at the anesthetic induction and every 6 hours for 24 hours. At hospital discharge, they were assigned randomly to either the placebo (n = 62) or antibiotic group (n = 62) and were instructed to take identical capsules containing 500 mg of cephalexin or placebo, respectively, every 6 hours, for 7 days. Patients were assessed weekly, for 4 weeks, regarding the occurrence of surgical-site infection, by a surgeon who was unaware of the allocation. The criteria and definitions of the Centers for Disease Control and Prevention were adopted. RESULTS There was no statistical difference between groups regarding age, body mass index, or resected breast tissue weight. The overall surgical-site infection rate was 0.81 percent. Only one patient, allocated to the antibiotic, presented infection, classified as superficial incisional (p = 1.00). In the placebo group, surgery time was higher (p = 0.003). CONCLUSION The maintenance of antibiotics in the postoperative period of reduction mammaplasty did not influence the rates of surgical-site infection. CLINICAL QUESTION/LEVEL OF EVIDENCE Therapeutic, I.",2020,"Only one patient, allocated to AG, presented infection, classified as superficial incisional (p=1.00).","['124 women with breast hypertrophy, with reduction mammaplasty already scheduled, selected consecutively', 'reduction mammaplasty']","['Postoperative antibiotic prophylaxis', 'placebo', 'antibiotic', 'cephalothin', 'cephalexin or placebo']","['infection rates', 'surgery time', 'overall surgical site infection rate', 'rates of surgical site infection']","[{'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C0020564', 'cui_str': 'Hypertrophy'}, {'cui': 'C0191922', 'cui_str': 'Breast reduction'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0282638', 'cui_str': 'Premedication, Antibiotic'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0007735', 'cui_str': 'cefalotin'}, {'cui': 'C0007716', 'cui_str': 'Cephalexin'}]","[{'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038941', 'cui_str': 'Postoperative Wound Infection'}]",124.0,0.159188,"Only one patient, allocated to AG, presented infection, classified as superficial incisional (p=1.00).","[{'ForeName': 'Edgard S', 'Initials': 'ES', 'LastName': 'Garcia', 'Affiliation': 'São Paulo and Pouso Alegre, Brazil From the Graduate Program in Translational Surgery, Universidade Federal de São Paulo; the Division of Plastic Surgery and the Department of Bioestatistics, Universidade do Vale do Sapucaí; and Universidade de Santo.'}, {'ForeName': 'Daniela F', 'Initials': 'DF', 'LastName': 'Veiga', 'Affiliation': ''}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Veiga-Filho', 'Affiliation': ''}, {'ForeName': 'Isaías V', 'Initials': 'IV', 'LastName': 'Cabral', 'Affiliation': ''}, {'ForeName': 'Natália L L', 'Initials': 'NLL', 'LastName': 'Pinto', 'Affiliation': ''}, {'ForeName': 'Neil F', 'Initials': 'NF', 'LastName': 'Novo', 'Affiliation': ''}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Sabino-Neto', 'Affiliation': ''}, {'ForeName': 'Lydia M', 'Initials': 'LM', 'LastName': 'Ferreira', 'Affiliation': ''}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000006809'] 497,32180059,"Counting fast or slow, aloud or silently? A comparison of adult stutterers and non-stutterers.","This study assesses factors influencing the capacity to maintain a steady rhythm during explicit counting activities. There are three counting paces (count every 800, 1200, or 1600 ms) and three experimental conditions (count silently, aloud and aloud in the presence of someone). The study also assesses the effect of a speech disorder, namely stuttering, on this counting ability by comparing the performance of a group of adult stutterers (n = 21) to that of a group of adult non-stutterers (n = 24). For temporal variability, in addition to replicating the fact that counting more slowly leads to lower performance, the results show that there are benefits to expect when participants count aloud instead of silently. There is no main effect of group, but the interaction between the experimental condition, the counting pace, and the group is significant. Adult non-stutterers are better than adult stutterers in the silent and long time-interval conditions (1600 ms). The significantly higher variability at 1600 ms indicates a loss of efficiency in the capacity to keep time constant when counting is slow, and it is in this condition that stutterers will gain the most benefits from counting aloud instead of silently.",2020,Adult non-stutterers are better than adult stutterers in the silent and long time-interval conditions (1600 ms).,['group of adult stutterers (n\u2009=\u200921) to that of a group of adult non-stutterers (n\u2009=\u200924'],[],[],"[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]",[],[],,0.0368474,Adult non-stutterers are better than adult stutterers in the silent and long time-interval conditions (1600 ms).,"[{'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Plamondon', 'Affiliation': 'École de Psychologie, Université Laval, 2325 Rue des Bibliothèques, Quebec, QC, G1V 0A6, Canada.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Grondin', 'Affiliation': 'École de Psychologie, Université Laval, 2325 Rue des Bibliothèques, Quebec, QC, G1V 0A6, Canada. simon.grondin@psy.ulaval.ca.'}]",Cognitive processing,['10.1007/s10339-020-00955-x'] 498,32173114,Small-Incision Lenticule Extraction (SMILE) for the Correction of Myopia with Astigmatism: Outcomes of the United States Food and Drug Administration Premarket Approval Clinical Trial.,"PURPOSE To present outcomes of the United States Food and Drug Administration premarket approval clinical trial of small-incision lenticule extraction (SMILE) for the correction of myopia and astigmatism. DESIGN Prospective, multicenter clinical trial. PARTICIPANTS The study included 357 eyes of 357 patients treated with SMILE (50 for myopia and 307 for myopia with astigmatism). Preoperative sphere ranged between -1.00 and -10.00 diopters (D), with manifest spherical equivalent (MSE) of up to -11.50 D and refractive cylinder of up to -3.00 D. METHODS -Participants were followed up for 12 months. Corrected distance visual acuity (CDVA) and uncorrected distance visual acuity (UDVA), stability of the manifest refraction, and vector analysis of refractive cylinder are presented for the 307 eyes treated for myopia with astigmatism. Adverse events (AEs) are presented for all 357 eyes. MAIN OUTCOME MEASURES Corrected distance visual acuity, uncorrected distance visual acuity, manifest refraction, astigmatic outcomes, and adverse events. RESULTS Of the 307 astigmatic eyes enrolled in the study, 304 were treated successfully. In 3 eyes, the procedure was aborted because of intraoperative suction loss. The mean MSE reduced from -5.39±2.30 D at baseline to -0.01±0.24 D at 12 months. Of all eyes, 95.3% were within 0.50 D of emmetropia at 12 months. The percentage of eyes with UDVA of 20/20 or better was 89.0%. No loss of 2 or more lines of CDVA was observed at the 12-month visit. The refractive cylinder reduced from -1.53±0.70 D at baseline to -0.18±0.31 D at 12 months. The mean correction ratio of refractive cylinder was 0.96±0.16 and a slight undercorrection was apparent for higher attempted corrections of astigmatism. Three intraoperative AEs associated with difficult lenticule removal and resultant cap tear occurred, and all resolved without sequelae at postoperative day 1. During the postoperative period, 8 AEs were recorded, but none of them had significant consequences. CONCLUSIONS Small-incision lenticule extraction for the treatment of myopia and astigmatism was safe and effective, and the reported AEs had no significant impact on visual acuity. Slight undercorrection of refractive cylinder requires further attention.",2020,The mean correction ratio of refractive cylinder was 0.96±0.16 and a slight undercorrection was apparent for higher attempted corrections of astigmatism.,"['307 astigmatic eyes enrolled in the study', 'The study included 357 eyes of 357 patients treated with SMILE (50 for myopia and 307 for myopia with astigmatism']","['small-incision lenticule extraction (SMILE', 'Small-Incision Lenticule Extraction']","['mean MSE', 'Corrected distance visual acuity, uncorrected distance visual acuity, manifest refraction, astigmatic outcomes, and adverse events', 'refractive cylinder', 'mean correction ratio of refractive cylinder', 'No loss of 2 or more lines of CDVA', 'Corrected distance visual acuity (CDVA) and uncorrected distance visual acuity (UDVA), stability of the manifest refraction, and vector analysis of refractive cylinder', 'visual acuity']","[{'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0037363', 'cui_str': 'Smilings'}, {'cui': 'C0027092', 'cui_str': 'Nearsightedness'}, {'cui': 'C0004106', 'cui_str': 'Astigmatism'}]","[{'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0184898', 'cui_str': 'Incision - attribute'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C0037363', 'cui_str': 'Smilings'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0429537', 'cui_str': 'Distance visual acuity (observable entity)'}, {'cui': 'C1301318', 'cui_str': 'M-Manifest refraction'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4319645', 'cui_str': 'Cylinder (unit of presentation)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0442335', 'cui_str': 'Vectors (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}]",357.0,0.300165,The mean correction ratio of refractive cylinder was 0.96±0.16 and a slight undercorrection was apparent for higher attempted corrections of astigmatism.,"[{'ForeName': 'Jon G', 'Initials': 'JG', 'LastName': 'Dishler', 'Affiliation': 'Dishler Laser Institute, Greenwood Village, Colorado. Electronic address: jond@dishler.com.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Slade', 'Affiliation': 'Slade & Baker Vision Center, Houston, Texas.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Seifert', 'Affiliation': 'Carl Zeiss Meditec AG, Jena, Germany.'}, {'ForeName': 'Steven C', 'Initials': 'SC', 'LastName': 'Schallhorn', 'Affiliation': 'Department of Ophthalmology, University of California, San Francisco, San Francisco, California; Carl Zeiss Meditec, Inc, Dublin, California; Optical Express, Glasgow, United Kingdom.'}]",Ophthalmology,['10.1016/j.ophtha.2020.01.010'] 499,30853042,Effects of a Workplace-Based Sleep Health Program on Sleep in Members of the German Armed Forces.,"STUDY OBJECTIVES To develop and evaluate a brief manual-based sleep health program within the workplace health promotion of the German Armed Forces. METHODS The sleep health program comprised four weekly group sessions. Sixty-three members (48 males) were randomly allocated to either a treatment group or a waiting control group matching for age, sex, and baseline Pittsburgh Sleep Quality Index (PSQI). The control group had to wait before participating in the sleep health program until the treatment group finished the intervention. Sleep was assessed by ambulatory polysomnography (PSG) as well as with evening and morning protocols at baseline (t0), directly after the treatment group participated in the sleep health program (t1), and after the control group finished participation (t2). The PSQI, the Insomnia Severity Index (ISI), and the Epworth Sleepiness Scale (ESS) were applied at the same three time points, and during a 3-month follow-up evaluation (t3). RESULTS Fifty-seven out of the 63 randomized individuals (42 males, mean age = 40.6 years; complete PSG data: n = 36; complete questionnaire data: n = 39) participated in the sleep health program. Objective wake after sleep onset, sleep efficiency, latency to persistent sleep, self-reported sleep latency, restfulness, PSQI, and ISI scores improved with medium or large effects in both groups. ESS scores decreased with moderate effects in the treatment group only. CONCLUSIONS The sleep health program had a positive and stable effect on objective and self-reported sleep parameters, and it is suitable as a preventive measure in members of the German Armed Forces. CLINICAL TRIAL REGISTRATION Registry: ClinicalTrials.gov; Title: Development and Evaluation of a Sleep-coaching Program; Identifier: NCT02896062; URL: https://clinicaltrials.gov/ct2/show/record/NCT02896062.",2019,"The PSQI, the Insomnia Severity Index (ISI), and the Epworth Sleepiness Scale (ESS) were applied at the same three time points, and during a 3-month follow-up evaluation (t3). ","[' complete PSG data: n = 36; complete questionnaire data: n = 39) participated in the sleep health program', 'Fifty-seven out of the 63 randomized individuals (42 males, mean age = 40.6 years', 'Sixty-three members (48 males', 'Sleep in Members of the German Armed Forces']","['waiting control group matching for age, sex, and baseline Pittsburgh Sleep Quality Index (PSQI', 'Workplace-Based Sleep Health Program', 'brief manual-based sleep health program']","['PSQI, the Insomnia Severity Index (ISI), and the Epworth Sleepiness Scale (ESS', 'Sleep', 'Objective wake after sleep onset, sleep efficiency, latency to persistent sleep, self-reported sleep latency, restfulness, PSQI, and ISI scores', 'ambulatory polysomnography (PSG', 'ESS scores']","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C4517815', 'cui_str': '57'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4319614', 'cui_str': '63 (qualifier value)'}, {'cui': 'C0680022', 'cui_str': 'Member of (attribute)'}, {'cui': 'C1556085', 'cui_str': 'Germans (ethnic group)'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C3697468', 'cui_str': 'PSQI - Pittsburgh sleep quality index'}, {'cui': 'C0162579', 'cui_str': 'Job Site'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}]","[{'cui': 'C4520529', 'cui_str': 'Insomnia severity index (assessment scale)'}, {'cui': 'C3541276', 'cui_str': 'ESS - Epworth Sleepiness Scale'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0442696', 'cui_str': 'Waking (observable entity)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C4505222', 'cui_str': 'REM Sleep Latency'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0162701', 'cui_str': 'Monitoring, Sleep'}]",39.0,0.0196773,"The PSQI, the Insomnia Severity Index (ISI), and the Epworth Sleepiness Scale (ESS) were applied at the same three time points, and during a 3-month follow-up evaluation (t3). ","[{'ForeName': 'Cornelia', 'Initials': 'C', 'LastName': 'Sauter', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Competence Center of Sleep Medicine at Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Jens T', 'Initials': 'JT', 'LastName': 'Kowalski', 'Affiliation': 'German Armed Forces Office, Applied Military Psychology and Research Group, Hamburg, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Stein', 'Affiliation': 'German Armed Forces Office, Applied Military Psychology and Research Group, Hamburg, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Röttger', 'Affiliation': 'German Armed Forces Office, Applied Military Psychology and Research Group, Hamburg, Germany.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Danker-Hopfe', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Competence Center of Sleep Medicine at Campus Benjamin Franklin, Berlin, Germany.'}]",Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine,['10.5664/jcsm.7666'] 500,31584766,Effects of high-intensity interval training compared to moderate-intensity continuous training on maximal oxygen consumption and blood pressure in healthy men: A randomized controlled trial,"INTRODUCTION Aerobic exercise generates increased cardiorespiratory fitness, which results in a protective factor for cardiovascular disease. High-intensity interval training (HIIT) might produce higher increases on cardiorespiratory fitness in comparison with moderate-intensity continuous training (MICT); however, current evidence is not conclusive. OBJECTIVE To compare the effects of a low-volume HIIT and a MICT on maximal oxygen consumption (VO2max), systolic blood pressure, and diastolic blood pressure during eight weeks in healthy men between 18 and 44 years of age. MATERIALS AND METHODS We conducted a randomized controlled trial. Forty-four volunteers were randomized to HIIT (n=22) or MICT (n=22). Both groups performed 24 sessions on a treadmill. The HIIT group completed 15 bouts of 30 seconds (90-95%, maximal heart rate, HRmax), while the MICT group completed 40 minutes of continuous exercise (65-75% HRmax).  Results: Intra-group analysis showed an increase in VO2max of 3.5 ml/kg/min [95% confidence interval (CI) 2.02 to 4.93; p=0.0001] in HIIT and 1.9 ml/kg/min (95% CI -0.98 to 4.82; p=0.18) in MICT. However, the difference between the two groups was not statistically significant (1.01 ml/kg/min. 95% CI -2.16 to 4.18, p=0.52). MICT generated a greater reduction in systolic blood pressure compared to HIIT (median 8 mm Hg; p<0.001). No statistically significant differences were found between the groups for DBP. CONCLUSIONS Results indicated no significant change in VO2max with a low-volume HIIT protocol versus MICT after 24 sessions. In contrast, MICT provided a greater reduction in systolic blood pressure compared to HIIT. The study is registered as a clinical trial via clinicaltrials.gov with identifier number: NCT02288403.",2019,MICT generated a greater reduction in systolic blood pressure compared to HIIT (median 8 mm Hg; p<0.001).,"['healthy men between 18 and 44 years of age', 'healthy men', 'Forty-four volunteers were randomized to HIIT (n=22) or']","['high-intensity interval training', 'MICT', 'MICT group completed 40 minutes of continuous exercise (65-75% HRmax', 'low-volume HIIT and a MICT', 'moderate-intensity continuous training', 'Aerobic exercise', 'High-intensity interval training (HIIT']","['cardiorespiratory fitness', 'VO2max', 'maximal oxygen consumption (VO2max), systolic blood pressure, and diastolic blood pressure', 'maximal oxygen consumption and blood pressure', 'systolic blood pressure']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C4277545', 'cui_str': 'High-Intensity Intermittent Exercise'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}]","[{'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C1305742', 'cui_str': 'Oxygen consumption'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}]",44.0,0.170748,MICT generated a greater reduction in systolic blood pressure compared to HIIT (median 8 mm Hg; p<0.001).,"[{'ForeName': 'Víctor Hugo', 'Initials': 'VH', 'LastName': 'Arboleda-Serna', 'Affiliation': 'Grupo de Investigación en Actividad Física para la Salud, Instituto de Educación Física, Universidad de Antioquia, Medellín, Colombia. victor.arboleda@udea.edu.co.'}, {'ForeName': 'Yuri', 'Initials': 'Y', 'LastName': 'Feito', 'Affiliation': ''}, {'ForeName': 'Fredy Alonso', 'Initials': 'FA', 'LastName': 'Patiño-Villada', 'Affiliation': ''}, {'ForeName': 'Astrid Viviana', 'Initials': 'AV', 'LastName': 'Vargas-Romero', 'Affiliation': ''}, {'ForeName': 'Elkin Fernando', 'Initials': 'EF', 'LastName': 'Arango-Vélez', 'Affiliation': ''}]",Biomedica : revista del Instituto Nacional de Salud,['10.7705/biomedica.4451'] 501,31752544,Block the light and sleep well: Evening blue light filtration as a part of cognitive behavioral therapy for insomnia.,"The objective of the present study was to assess the effect of combining CBT-I with wearing blue-light blocking glasses 90 min prior to bedtime on subjective and objective sleep parameters and daily symptoms (anxiety, depression, hyperarousal). Thirty patients (mean age 48.1 ± 16.13 years, range 21-71, 15 men/15 women) completed a CBT-I group therapy program, with groups randomly assigned to either ""active"" (blue-light filtering glasses) condition or ""placebo"" (glasses without filtering properties) condition. Patients were continually monitored by wristwatch actigraphy, kept their sleep diaries and completed a standard questionnaire battery at admission and after the end of the program. Statistical analyses showed a greater reduction of BAI score in ""active"" (4.33 ± 4.58) versus ""placebo"" (-0.92 ± 3.68) groups of patients [F = 6.389, p = .019, Cohen's d = 1.26] and significant prolongation of subjective total sleep time in ""active"" (-36.88 ± 48.68 min.) versus ""placebo"" (7.04 ± 47.50 min.) [F = 8.56, p < .01, d = 0.91] group. When pre- and post-treatment results were compared in both groups separately, using paired-samples t-tests, significant differences were observed also in the active group for BDI-II score (t = 3.66, p = .003, Cohen's d = 0.95) and HAS score (t = 2.90, p = .012, Cohen's d = 0.75). No significant differences were found in the placebo group. In active group, there was also a significant reduction of subjective sleep latency (t = 2.65, p = .021, d = 0.73) and an increase of subjective total sleep time (t = -2.73, p = .018, d = -0.76) without change in objective sleep duration which was significantly shortened in the placebo group. We provide further evidence that blocking short-wavelength light in the evening hours may be beneficial for patients suffering from insomnia.",2020,"In active group, there was also a significant reduction of subjective sleep latency (t = 2.65, p = .021, d = 0.73) and an increase of subjective total sleep time (t = -2.73, p = .018, d = -0.76) without change in objective sleep duration which was significantly shortened in the placebo group.","['patients suffering from insomnia', 'Thirty patients (mean age 48.1 ± 16.13 years, range 21-71, 15 men/15 women']","['placebo', 'CBT-I group therapy program', 'active"" (blue-light filtering glasses) condition or ""placebo"" (glasses without filtering properties) condition', 'CBT-I with wearing blue-light blocking glasses']","['BDI-II score', 'objective sleep duration', 'HAS score', 'subjective total sleep time', 'BAI score', 'subjective sleep latency', 'subjective and objective sleep parameters and daily symptoms (anxiety, depression, hyperarousal']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1527374', 'cui_str': 'Group Therapy'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0303896', 'cui_str': 'Blue light (physical force)'}, {'cui': 'C0180860', 'cui_str': 'Filter, device (physical object)'}, {'cui': 'C0017596', 'cui_str': 'Glass'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0871161', 'cui_str': 'Property (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C4505222', 'cui_str': 'REM Sleep Latency'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C4552570', 'cui_str': 'Hyperarousal'}]",90.0,0.0796097,"In active group, there was also a significant reduction of subjective sleep latency (t = 2.65, p = .021, d = 0.73) and an increase of subjective total sleep time (t = -2.73, p = .018, d = -0.76) without change in objective sleep duration which was significantly shortened in the placebo group.","[{'ForeName': 'Karolina', 'Initials': 'K', 'LastName': 'Janků', 'Affiliation': 'Sleep Medicine and Chronobiology, National Institute of Mental Health, Klecany, Czech Republic.'}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Šmotek', 'Affiliation': 'Sleep Medicine and Chronobiology, National Institute of Mental Health, Klecany, Czech Republic.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Fárková', 'Affiliation': 'Sleep Medicine and Chronobiology, National Institute of Mental Health, Klecany, Czech Republic.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Kopřivová', 'Affiliation': 'Sleep Medicine and Chronobiology, National Institute of Mental Health, Klecany, Czech Republic.'}]",Chronobiology international,['10.1080/07420528.2019.1692859'] 502,31259767,HIV stigma and viral load among African-American women receiving treatment for HIV.,"OBJECTIVE African-American women are more likely than other women in the United States to experience poor HIV-related health; HIV stigma may contribute to these outcomes. This study assessed the relationship between HIV stigma and viral load, over time, among a sample of African-American women receiving treatment for HIV, and explored social support and depressive symptoms as mediators. DESIGN Secondary analysis of longitudinal data. METHODS Data came from a randomized trial of an intervention to reduce HIV stigma among African-American women in HIV care in Chicago, Illinois and Birmingham, Alabama. Sociodemographic and psychosocial data were collected at up to six study visits over 14 months. Viral loads were extracted from medical records during the study period. Generalized linear mixed effects models were used to estimate associations among overall, internalized, and enacted HIV stigma and viral load over time. Mediation analyses were used to estimate indirect effects via social support and depressive symptoms. RESULTS Data from 234 women were analyzed. Overall HIV stigma was significantly associated with subsequent viral load (adjusted β = 0.24, P = 0.005). Both between-subject (adjusted β = 0.74, P < 0.001) and within-subject (adjusted β = 0.34, P = 0.005) differences in enacted stigma were associated with viral load. Neither social support nor depressive symptoms were statistically significant mediators. CONCLUSION Ongoing experiences of HIV stigmatization may contribute to increased viral load among African-American women in primary HIV care. Interventions should aim to alleviate the consequences of stigma experienced by patients and prevent future stigmatization.",2019,"Overall HIV stigma was significantly associated with subsequent viral load (adjusted β = 0.24, P = 0.005).","['African-American women in HIV care in Chicago, Illinois and Birmingham, Alabama', 'African-American women', 'African-American women in primary HIV care', '234 women were analyzed', 'African-American women receiving treatment for HIV', 'African-American women receiving treatment for HIV, and explored social support and depressive symptoms as mediators']",[],"['Overall HIV stigma', 'enacted stigma', 'Sociodemographic and psychosocial data', 'depressive symptoms', 'HIV stigma', 'overall, internalized, and enacted HIV stigma and viral load over time', 'Viral loads', 'HIV stigma and viral load']","[{'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0008044', 'cui_str': 'Chicago'}, {'cui': 'C0001895', 'cui_str': 'Alabama'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0037438'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}]",[],"[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0277787', 'cui_str': 'Stigma (finding)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",234.0,0.0469557,"Overall HIV stigma was significantly associated with subsequent viral load (adjusted β = 0.24, P = 0.005).","[{'ForeName': 'Christopher G', 'Initials': 'CG', 'LastName': 'Kemp', 'Affiliation': 'Department of Global Health.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Lipira', 'Affiliation': 'Department of Health Services.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Huh', 'Affiliation': 'School of Social Work.'}, {'ForeName': 'Paul E', 'Initials': 'PE', 'LastName': 'Nevin', 'Affiliation': 'Department of Global Health.'}, {'ForeName': 'Janet M', 'Initials': 'JM', 'LastName': 'Turan', 'Affiliation': 'School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Jane M', 'Initials': 'JM', 'LastName': 'Simoni', 'Affiliation': 'Department of Global Health.'}, {'ForeName': 'Susan E', 'Initials': 'SE', 'LastName': 'Cohn', 'Affiliation': 'Division of Infectious Diseases, Northwestern University Feinberg School of Medicine.'}, {'ForeName': 'Mieoak', 'Initials': 'M', 'LastName': 'Bahk', 'Affiliation': 'Ruth M. Rothstein CORE Center, Chicago, Illinois.'}, {'ForeName': 'Baiba', 'Initials': 'B', 'LastName': 'Berzins', 'Affiliation': 'Division of Infectious Diseases, Northwestern University Feinberg School of Medicine.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Andrasik', 'Affiliation': 'Department of Global Health.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Mugavero', 'Affiliation': 'Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Deepa', 'Initials': 'D', 'LastName': 'Rao', 'Affiliation': 'Department of Global Health.'}]","AIDS (London, England)",['10.1097/QAD.0000000000002212'] 503,32155662,First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients.,"OBJECTIVES The German-speaking Myeloma Multicenter Group (GMMG) conducted this trial to investigate efficacy and safety of the three-drug combination bendamustine/prednisone/bortezomib (BPV) as first-line therapy for elderly patients with multiple myeloma (MM). METHODS Elderly MM patients requiring first-line therapy and not eligible for intensive treatment were enrolled in this phase IIb multicenter study. Patients were treated with BPV regimen for a maximum of nine cycles. RESULTS Forty-six patients were included in the trial with a median age of 76 years. Nineteen patients had renal impairment at baseline. The ORR was 78.8% for patients treated with 3 and more BPV cycles and 71.1% for all evaluable patients. The median progression-free survival was 25 months, and overall survival at 24 months was 83.3%. The clinical benefit rate including MR was 91.2%. In patients with renal impairment at baseline, a renal response was observed in 11 pts. with complete recovery of the renal function in six patients. The most frequent CTC grade 3/4 AEs experienced by patients were hematological (17.5%) and infectious (9.8%) complications. No new safety signals were observed for the study drugs under investigation. CONCLUSIONS Bendamustine/prednisone/bortezomib may serve as a first-line regimen for transplant-ineligible elderly MM patients in particular for patients with renal impairment requiring a fast and durable renal response.",2020,"The ORR was 76.5%, the median progression free survival 25 months and overall survival at 24 month 83.3%.","['elderly patients with multiple myeloma (MM', 'non-transplant eligible symptomatic multiple myeloma patients', '6 patients', '19 patients had renal impairment at baseline', 'Elderly MM patients requiring first-line therapy and not eligible for intensive treatment were enrolled in this phase IIb multicenter study', 'transplant ineligible elderly MM patients in particular for patients with renal impairment requiring a fast and durable renal response', '46 patients were included into the trial with a median age of 76 years']","['3-drug-combination bendamustine/prednisone/bortezomib (BPV', 'BPV', 'Bendamustine/Prednisone/Bortezomib (BPV) ']","['renal response', 'renal function', 'clinical benefit rate (CBR) including MR', 'ORR', 'median progression free survival 25 months and overall survival']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0026764', 'cui_str': 'Myelomatosis'}, {'cui': 'C0332835', 'cui_str': 'Grafts'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C1565489', 'cui_str': 'Renal Insufficiency'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C1096776', 'cui_str': 'Multicenter Study'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0013162', 'cui_str': 'Drug Combinations'}, {'cui': 'C0525079', 'cui_str': 'bendamustine'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C0531207', 'cui_str': 'bpV(phen)'}]","[{'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",46.0,0.0301331,"The ORR was 76.5%, the median progression free survival 25 months and overall survival at 24 month 83.3%.","[{'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Knauf', 'Affiliation': 'Centrum Haematologie & Onkologie Bethanien, Frankfurt, Germany.'}, {'ForeName': 'Gerrit', 'Initials': 'G', 'LastName': 'Dingeldein', 'Affiliation': 'Onkologische Schwerpunktpraxis, Darmstadt, Germany.'}, {'ForeName': 'Rudolf', 'Initials': 'R', 'LastName': 'Schlag', 'Affiliation': 'Hämatologisch-Onkologische Schwerpunktpraxis, Würzburg, Germany.'}, {'ForeName': 'Manfred', 'Initials': 'M', 'LastName': 'Welslau', 'Affiliation': 'Onkologische Praxis, Aschaffenburg, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Moehler', 'Affiliation': 'IQVIA, Frankfurt, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Terzer', 'Affiliation': 'Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Walter', 'Affiliation': 'Koordinierungszentrum für klinische Studien Heidelberg, FRG, Heidelberg, Germany.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Habermehl', 'Affiliation': 'Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Kunz', 'Affiliation': 'Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Goldschmidt', 'Affiliation': 'Department of Medicine V, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Marc-Steffen', 'Initials': 'MS', 'LastName': 'Raab', 'Affiliation': 'Department of Medicine V, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of haematology,['10.1111/ejh.13409'] 504,30136637,Impact of Low-Level Blast Exposure on Brain Function after a One-Day Tactile Training and the Ameliorating Effect of a Jugular Vein Compression Neck Collar Device.,"Special Weapons and Tactics (SWAT) personnel who conduct breacher exercises are at risk for blast-related head trauma. We aimed to investigate the potential impact of low-level blast exposure during breacher training on the neural functioning of working memory and auditory network connectivity. We also aimed to evaluate the effects of a jugular vein compression collar, designed to internally mitigate slosh energy absorption, preserving neural functioning and connectivity, following blast exposure. A total of 23 SWAT personnel were recruited and randomly assigned to a non-collar (n = 11) and collar group (n = 12). All participants completed a 1-day breacher training with multiple blast exposure. Prior to and following training, 18 participants (non-collar, n = 8; collar, n = 10) completed functional magnetic resonance imaging (fMRI) of working memory using N-Back task; 20 participants (non-collar, n = 10; collar, n = 12) completed resting-state fMRI. Key findings from the working memory analysis include significantly increased fMRI brain activation in the right insular, right superior temporal pole, right inferior frontal gyrus, and pars orbitalis post-training for the non-collar group (p < 0.05, threshold-free cluster enhancement corrected), but no changes were noted for the collar group. The elevation in fMRI activation in the non-collar group was found to correlate significantly (n = 7, r = 0.943, p = 0.001) with average peak impulse amplitude experienced during the training. In the resting-state fMRI analysis, significant pre- to post-training increase in connectivity between the auditory network and two discrete regions (left middle frontal gyrus and left superior lateral occipital/angular gyri) was found in the non-collar group, while no change was observed in the collar group. These data provided initial evidence of the impact of low-level blast on working memory and auditory network connectivity as well as the protective effect of collar on brain function following blast exposure, and is congruent with previous collar findings in sport-related traumatic brain injury.",2019,"Key findings from the working memory analysis include significantly increased fMRI brain activation in the right insular, right superior temporal pole, right inferior frontal gyrus, and pars orbitalis post-training for the non-collar group (p < 0.05, threshold-free cluster enhancement corrected), but no changes were noted for the collar group.","['18 participants (non-collar, n\u2009=\u20098; collar, n\u2009=\u200910) completed', 'A total of 23 SWAT personnel']","['jugular vein compression collar', 'Low-Level Blast Exposure', 'low-level blast exposure during breacher training', 'functional magnetic resonance imaging (fMRI) of working memory using N-Back task; 20 participants (non-collar, n\u2009=\u200910; collar, n\u2009=\u200912) completed resting-state fMRI']","['right superior temporal pole, right inferior frontal gyrus, and pars orbitalis post-training', 'fMRI brain activation', 'neural functioning of working memory and auditory network connectivity', 'elevation in fMRI activation', 'Brain Function']","[{'cui': 'C0175751', 'cui_str': 'Cervical collar, device (physical object)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]","[{'cui': 'C0022427', 'cui_str': 'Jugular Veins'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0175751', 'cui_str': 'Cervical collar, device (physical object)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0337091', 'cui_str': 'Blasting (qualifier value)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}]","[{'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0149552', 'cui_str': 'Structure of temporal pole'}, {'cui': 'C0152298', 'cui_str': 'Gyrus Frontalis Inferior'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0031843', 'cui_str': 'function'}]",23.0,0.0420043,"Key findings from the working memory analysis include significantly increased fMRI brain activation in the right insular, right superior temporal pole, right inferior frontal gyrus, and pars orbitalis post-training for the non-collar group (p < 0.05, threshold-free cluster enhancement corrected), but no changes were noted for the collar group.","[{'ForeName': 'Weihong', 'Initials': 'W', 'LastName': 'Yuan', 'Affiliation': ""1 Pediatric Neuroimaging Research Consortium, Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio.""}, {'ForeName': 'Kim D', 'Initials': 'KD', 'LastName': 'Barber Foss', 'Affiliation': ""2 The SPORT Center, Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio.""}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Dudley', 'Affiliation': ""1 Pediatric Neuroimaging Research Consortium, Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio.""}, {'ForeName': 'Staci', 'Initials': 'S', 'LastName': 'Thomas', 'Affiliation': ""2 The SPORT Center, Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio.""}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Galloway', 'Affiliation': ""2 The SPORT Center, Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio.""}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'DiCesare', 'Affiliation': ""2 The SPORT Center, Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio.""}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Leach', 'Affiliation': ""3 Division of Radiology, Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio.""}, {'ForeName': 'Pete', 'Initials': 'P', 'LastName': 'Scheifele', 'Affiliation': '4 Department of Communication Sciences and Disorders, University of Cincinnati , Ohio.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Farina', 'Affiliation': '4 Department of Communication Sciences and Disorders, University of Cincinnati , Ohio.'}, {'ForeName': 'Gloria', 'Initials': 'G', 'LastName': 'Valencia', 'Affiliation': '4 Department of Communication Sciences and Disorders, University of Cincinnati , Ohio.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Smith', 'Affiliation': ""2 The SPORT Center, Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio.""}, {'ForeName': 'Mekibib', 'Initials': 'M', 'LastName': 'Altaye', 'Affiliation': ""5 Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio.""}, {'ForeName': 'Christopher K', 'Initials': 'CK', 'LastName': 'Rhea', 'Affiliation': '6 Department of Kinesiology, University of North Carolina at Greensboro , Greensboro, North Carolina.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Talavage', 'Affiliation': '7 School of Electrical and Computer Engineering, Purdue University , West Lafayette, Indiana.'}, {'ForeName': 'Gregory D', 'Initials': 'GD', 'LastName': 'Myer', 'Affiliation': ""2 The SPORT Center, Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio.""}]",Journal of neurotrauma,['10.1089/neu.2018.5737'] 505,31940457,Boosting attachment security to cope with threats: Behavioral and ERPs findings.,"Attachment security describes a sense of safety and security felt by individuals and promotes mental health. The mechanism by which attachment security buffers against psychological threat remains unclear, however. Here, we explored how attachment security attenuates the response to threatening information using a signal detection theory (SDT) and event-related potentials (ERPs) approach. Participants were assigned to an attachment security priming condition or a control condition. After a priming procedure, behavioral data and electroencephalography (EEG) signals were recorded while participants categorized threatening and neutral pictures. Our behavioral results revealed that attachment security biased participant responses to categorizing the two types of pictures; participants in the control condition exhibited a tendency to categorize stimuli as threatening, whereas those in the attachment security condition tended to categorize stimuli as neutral. Meanwhile, attachment security priming modulated early attention processes, reflected by an increased P200. The findings reported here suggest that attachment security buffers against external threats by modulating individual response preferences, the effects of which manifest in the early stages of attentional processing.",2020,"Our behavioral results revealed that attachment security biased participant responses to categorizing the two types of pictures; participants in the control condition exhibited a tendency to categorize stimuli as threatening, whereas those in the attachment security condition tended to categorize stimuli as neutral.",[],['attachment security priming condition or a control condition'],['behavioral data and electroencephalography (EEG) signals'],[],"[{'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0013819', 'cui_str': 'EEG'}]",,0.0310038,"Our behavioral results revealed that attachment security biased participant responses to categorizing the two types of pictures; participants in the control condition exhibited a tendency to categorize stimuli as threatening, whereas those in the attachment security condition tended to categorize stimuli as neutral.","[{'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Wu', 'Affiliation': 'CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China; University of Chinese Academy of Sciences, Beijing, China. Electronic address: wull@psych.ac.cn.'}, {'ForeName': 'Ruolei', 'Initials': 'R', 'LastName': 'Gu', 'Affiliation': 'CAS Key Laboratory of Behavioral Science, Institute of Psychology, Chinese Academy of Sciences, Beijing, China; University of Chinese Academy of Sciences, Beijing, China.'}, {'ForeName': 'Xiaoxuan', 'Initials': 'X', 'LastName': 'Shi', 'Affiliation': 'CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China; University of Chinese Academy of Sciences, Beijing, China.'}, {'ForeName': 'Beiyi', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': 'CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China; University of Chinese Academy of Sciences, Beijing, China.'}, {'ForeName': 'Jianxin', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China. Electronic address: zhangjx@psych.ac.cn.'}]",International journal of psychophysiology : official journal of the International Organization of Psychophysiology,['10.1016/j.ijpsycho.2020.01.003'] 506,31740368,Colchicine's effects on lipoprotein particle concentrations in adults with metabolic syndrome: A secondary analysis of a randomized controlled trial.,"BACKGROUND Colchicine has received renewed interest for its potential beneficial effects in secondary prevention of cardiovascular disease. This was presumed to be primarily because of its anti-inflammatory effects; however, limited data exist regarding colchicine's impact on other cardiovascular risk factors. OBJECTIVE The aim of this study was to examine if colchicine's anti-inflammatory actions would lead to reduced circulating concentrations of oxidized low-density lipoprotein (oxLDL) in metabolically unhealthy individuals. We also examined if colchicine would improve concentrations of other atherogenic lipoprotein subfractions. METHODS This is a secondary analysis of a double-blind, randomized, placebo-controlled pilot study in which 40 adults with metabolic syndrome were randomized to colchicine 0.6 mg or placebo twice daily for 3 months. Blood samples were collected in the fasted state. OxLDL was measured using enzyme-linked immunosorbent assay. Nuclear magnetic resonance spectroscopy was used to measure other lipoprotein particle subfraction concentrations. RESULTS Compared with placebo, colchicine reduced markers of inflammation, including C-reactive protein, erythrocyte sedimentation rate, and GlycA (P < .01). Concentrations of oxLDL (P = .019) and small LDL (P = .022) appeared significantly increased in the colchicine arm. Colchicine had no significant effect on other lipoprotein subfractions or lipoprotein particle sizes (all P > .05). CONCLUSION Although colchicine may have benefit in secondary prevention of cardiovascular disease in at-risk individuals, we found no evidence that these effects are because of improvements in circulating atherogenic lipoprotein particle concentrations. Further studies are needed to confirm whether colchicine increases circulating oxLDL and small LDL levels in adults with metabolic syndrome. If true, additional research is warranted to elucidate the mechanisms underlying these associations.",2019,"Colchicine had no significant effect on other lipoprotein subfractions or lipoprotein particle sizes (all P > .05). ","['adults with metabolic syndrome', '40 adults with metabolic syndrome', 'metabolically unhealthy individuals']","[""Colchicine's"", 'colchicine 0.6\xa0mg or placebo', 'Colchicine', 'placebo, colchicine', 'oxLDL', 'placebo', 'colchicine']","['lipoprotein particle concentrations', 'circulating atherogenic lipoprotein particle concentrations', 'Blood samples', 'lipoprotein subfractions or lipoprotein particle sizes', 'small LDL', 'markers of inflammation, including C-reactive protein, erythrocyte sedimentation rate, and GlycA (P']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0524620', 'cui_str': 'Metabolic Syndrome X'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0009262', 'cui_str': 'Colchicine'}, {'cui': 'C2718493', 'cui_str': 'Colchicine 0.6 MG [Colcrys]'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0348035', 'cui_str': 'oxidized low density lipoprotein'}]","[{'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0030608', 'cui_str': 'Particle Size'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}]",40.0,0.656291,"Colchicine had no significant effect on other lipoprotein subfractions or lipoprotein particle sizes (all P > .05). ","[{'ForeName': 'Andrew P', 'Initials': 'AP', 'LastName': 'Demidowich', 'Affiliation': 'Section on Growth and Obesity, Division of Intramural Research (DIR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA; Johns Hopkins Community Physicians at Howard County General Hospital, Johns Hopkins Medicine, Columbia, MD, USA; Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins School of Medicine, Baltimore, MD, USA. Electronic address: ademido1@jhmi.edu.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Wolska', 'Affiliation': 'Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.'}, {'ForeName': 'Sierra R', 'Initials': 'SR', 'LastName': 'Wilson', 'Affiliation': 'Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.'}, {'ForeName': 'Jordan A', 'Initials': 'JA', 'LastName': 'Levine', 'Affiliation': 'Section on Growth and Obesity, Division of Intramural Research (DIR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA.'}, {'ForeName': 'Alexander V', 'Initials': 'AV', 'LastName': 'Sorokin', 'Affiliation': 'Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.'}, {'ForeName': 'Sheila M', 'Initials': 'SM', 'LastName': 'Brady', 'Affiliation': 'Section on Growth and Obesity, Division of Intramural Research (DIR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA.'}, {'ForeName': 'Alan T', 'Initials': 'AT', 'LastName': 'Remaley', 'Affiliation': 'Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.'}, {'ForeName': 'Jack A', 'Initials': 'JA', 'LastName': 'Yanovski', 'Affiliation': 'Section on Growth and Obesity, Division of Intramural Research (DIR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA.'}]",Journal of clinical lipidology,['10.1016/j.jacl.2019.10.011'] 507,31727580,"Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial.","BACKGROUND Tuberculosis, which is often undiagnosed, is the major cause of death among HIV-positive people. We aimed to test whether the use of a clinical algorithm enabling the initiation of empirical tuberculosis treatment by nurses in primary health-care clinics would reduce mortality compared with standard of care for adults with advanced HIV disease. METHODS In this open-label cluster-randomised controlled trial, we recruited individuals from 24 primary health-care clinics in South Africa. The clinics were randomly assigned (1:1) to either deliver an intervention or routine care (control) using computer-generated random numbers. Eligible participants were HIV-positive adults (aged ≥18 years) with CD4 counts of 150 cells per μL or less, who had not had antiretroviral therapy (ART) in the past 6 months or tuberculosis treatment in the past 3 months, and did not require urgent hospital referral. In intervention clinics, study nurses assessed participants on the basis of tuberculosis symptoms, body-mass index, point-of-care haemoglobin concentrations, and urine lipoarabinomannan assay results. Participants classified by a study algorithm as having high probability of tuberculosis (positive urine lipoarabinomannan assay, body-mass index <18·5 kg/m 2 , or haemoglobin concentration <100 g/L) were recommended to start tuberculosis treatment immediately followed by ART 2 weeks later; participants classified as medium probability (tuberculosis symptoms, no high probability criteria) were recommended to have symptom-guided investigation; and participants classified as low probability (no tuberculosis symptoms or high probability criteria) were recommended to start ART immediately. In standard-of-care clinics, participants received treatment in accordance with South African guidelines. Investigators and participants were aware of treatment allocation. The primary outcome was all-cause mortality at 6 months, assessed in the intention-to-treat population. Safety was also analysed in the intention-to treat population. This trial is registered with the ISRCTN registry, ISRCTN35344604, and the South African National Clinical Trials Register, DOH-27-0812-3902. FINDINGS Between Dec 19, 2012, and Dec 18, 2014, 3091 individuals were screened for eligibility, of whom 3053 were recruited, and 3022 (1507 participants in the intervention group and 1515 participants in the control group) were analysed for the primary outcome. 930 (61·7%) of 1507 participants in the intervention group versus 172 (11·4%) of 1515 participants in the control group had started tuberculosis treatment by 2 months. At 6 months, the mortality rate was 19·0 deaths per 100 person-years for the intervention group versus 21·6 deaths per 100 person-years in the control group (unadjusted hazard ratio [HR] 0·92, 95% CI 0·67-1·26, p=0·58; adjusted HR 0·87, 0·61-1·24, p=0·41). 28 (1·9%) of 1507 participants in the intervention group and ten (0·7%) of 1515 participants in the control group reported serious or severe adverse events. Grade 3 or 4 nausea and vomiting was the most common adverse event (ten participants in the intervention group and four participants in the control group). Among participants with adverse events, eight participants (six participants in the intervention group and two participants in the control group) died; none of the six deaths in the intervention group were attributed to the study intervention. INTERPRETATION Our intervention substantially increased coverage of tuberculosis treatment in this high-risk population, but did not reduce mortality. FUNDING Joint Global Health Trials (Medical Research Council, Department for International Development, Wellcome Trust).",2020,The clinics were randomly assigned (1:1) to either deliver an intervention or routine care (control) using computer-generated random numbers.,"['adults with advanced HIV disease', 'Between Dec 19, 2012, and Dec 18, 2014, 3091 individuals were screened for eligibility, of whom 3053 were recruited, and 3022 (1507 participants in the intervention group and 1515 participants in the control group', 'people with advanced HIV (TB Fast Track', '930 (61·7%) of 1507 participants in the intervention group versus 172 (11·4%) of 1515 participants in the control group had started tuberculosis treatment by 2 months', 'nurses in primary health-care clinics', 'Participants classified by a study algorithm as having high probability of tuberculosis (positive urine lipoarabinomannan assay, body-mass index', 'Eligible participants were HIV-positive adults (aged ≥18 years) with CD4 counts of 150 cells per μL or less, who had not had antiretroviral therapy (ART) in the past 6 months or tuberculosis treatment in the past 3 months, and did not require urgent hospital referral', 'recruited individuals from 24 primary health-care clinics in South Africa']","['Algorithm-guided empirical tuberculosis treatment', 'intervention or routine care (control) using computer-generated random numbers']","['serious or severe adverse events', 'mortality rate', 'Safety', 'cause mortality', 'Grade 3 or 4 nausea and vomiting']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0019693', 'cui_str': 'T-Lymphotropic Virus Type III Infections, Human'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C4517601', 'cui_str': '172 (qualifier value)'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0041296', 'cui_str': 'Mycobacterium tuberculosis Infection'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0008902', 'cui_str': 'Systematics'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0002045'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0042037'}, {'cui': 'C0065041', 'cui_str': 'lipoarabinomannan'}, {'cui': 'C1510438', 'cui_str': 'Assay technique (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0439609', 'cui_str': 'Urgency (qualifier value)'}, {'cui': 'C0019982', 'cui_str': 'Hospital Referral'}, {'cui': 'C0037712', 'cui_str': 'Union of South Africa'}]","[{'cui': 'C0002045'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0041296', 'cui_str': 'Mycobacterium tuberculosis Infection'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting (disorder)'}]",1507.0,0.295803,The clinics were randomly assigned (1:1) to either deliver an intervention or routine care (control) using computer-generated random numbers.,"[{'ForeName': 'Alison D', 'Initials': 'AD', 'LastName': 'Grant', 'Affiliation': 'TB Centre, London School of Hygiene & Tropical Medicine, London, UK; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK; Africa Health Research Institute, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa; School of Public Health, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: alison.grant@lshtm.ac.uk.'}, {'ForeName': 'Salome', 'Initials': 'S', 'LastName': 'Charalambous', 'Affiliation': 'School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; The Aurum Institute, Johannesburg, South Africa.'}, {'ForeName': 'Mpho', 'Initials': 'M', 'LastName': 'Tlali', 'Affiliation': 'The Aurum Institute, Johannesburg, South Africa.'}, {'ForeName': 'Aaron S', 'Initials': 'AS', 'LastName': 'Karat', 'Affiliation': 'TB Centre, London School of Hygiene & Tropical Medicine, London, UK; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Susan E', 'Initials': 'SE', 'LastName': 'Dorman', 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Hoffmann', 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Johnson', 'Affiliation': 'Foundation for Professional Development, Pretoria, South Africa.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Vassall', 'Affiliation': 'TB Centre, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Gavin J', 'Initials': 'GJ', 'LastName': 'Churchyard', 'Affiliation': 'TB Centre, London School of Hygiene & Tropical Medicine, London, UK; School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; The Aurum Institute, Johannesburg, South Africa; Advancing Care and Treatment for TB/HIV, South African Medical Research Council, Johannesburg, South Africa.'}, {'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Fielding', 'Affiliation': 'TB Centre, London School of Hygiene & Tropical Medicine, London, UK; School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.'}]",The lancet. HIV,['10.1016/S2352-3018(19)30266-8'] 508,31419610,Moment-by-Moment in Women's Recovery (MMWR): Mindfulness-based intervention effects on residential substance use disorder treatment retention in a randomized controlled trial.,"In this study we test the efficacy of Moment-by-Moment in Women's Recovery (MMWR), a mindfulness-based intervention adapted to support women with substance use disorder (SUD) while in residential treatment. We use a parallel-group randomized controlled trial with a time-matched psychoeducation control to test MMWR effects on residential treatment retention. We used clinical staff-determined residential site discharge status and discharge date from the SUD treatment site record to determine retention. We tested for study group differences in retention defined as time to treatment non-completion without improvement (i.e., patient left treatment before completion of the treatment plan and made little or no progress toward achieving treatment goals based on clinical team determination), as well as differences in self-report of study intervention mechanisms of action (i.e., mindfulness, perceived stress, distress tolerance, emotion regulation, distress, affect, and drug and alcohol craving). The analytic timeframe for the survival analysis was from study intervention start date to 150 days later. The sample (N = 200) was female, majority amphetamine/methamphetamine users (76%), Hispanic (58%), with a history of incarceration (62%). By the 150-day analytic endpoint, the sample had 74 (37%) treatment Completers, 42 (21%) still In-residence, 26 (13%) Non-completers with satisfactory progress, and 58 (29%) Non-completers without satisfactory progress. Survival analysis of the intent-to-treat sample showed the risk of non-completion without improvement was lower in MMWR as compared to the control group (adjusted hazard ratio = 0.42, 95% CI: 0.16-1.08, p = .07). Both groups improved on select self-reported mechanism measure scores at immediate post-intervention, but only in the MMWR group did class attendance (dosage) have a large-size correlation with improved mindfulness (r = .61, p < .01), distress tolerance (r = 0.55, p < .01) and positive affect (r = 0.52, p < .01) scores. The hazard ratio for retention was of medium-to-large effect size, suggesting the clinical relevance of adding MMWR to an all-women's, ethnoracially diverse, SUD residential treatment center. An extended curriculum may be helpful considering the protective benefits of class attendance on psychological health indicators.",2019,"Both groups improved on select self-reported mechanism measure scores at immediate post-intervention, but only in the MMWR group did class attendance (dosage) have a large-size correlation with improved mindfulness (r = .61, p < .01), distress tolerance (r = 0.55, p < .01) and positive affect (r = 0.52, p < .01) scores.","[""Women's Recovery (MMWR), a mindfulness-based intervention adapted to support women with substance use disorder (SUD) while in residential treatment"", 'The sample (N\u202f=\u202f200) was female, majority amphetamine/methamphetamine users (76%), Hispanic (58%), with a history of incarceration (62']",[],"['Survival analysis', 'select self-reported mechanism measure scores', 'MMWR', 'hazard ratio for retention', 'action (i.e., mindfulness, perceived stress, distress tolerance, emotion regulation, distress, affect, and drug and alcohol craving', 'distress tolerance']","[{'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0038586', 'cui_str': 'Substance Use Disorders'}, {'cui': 'C0035189', 'cui_str': 'Residential Treatment'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0002658', 'cui_str': 'Amphetamine'}, {'cui': 'C0025611', 'cui_str': 'metamfetamine'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0205255', 'cui_str': 'Imprisonment (finding)'}]",[],"[{'cui': 'C0038953', 'cui_str': 'Survival Analysis'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0441472', 'cui_str': 'Action (qualifier value)'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0013987', 'cui_str': 'Emotions'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0556385', 'cui_str': 'Craving for alcohol (finding)'}]",,0.166546,"Both groups improved on select self-reported mechanism measure scores at immediate post-intervention, but only in the MMWR group did class attendance (dosage) have a large-size correlation with improved mindfulness (r = .61, p < .01), distress tolerance (r = 0.55, p < .01) and positive affect (r = 0.52, p < .01) scores.","[{'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Black', 'Affiliation': 'Department of Preventive Medicine, Keck School of Medicine, University of Southern California, USA. Electronic address: davidbla@usc.edu.'}, {'ForeName': 'Hortensia', 'Initials': 'H', 'LastName': 'Amaro', 'Affiliation': 'Herbert Wertheim College of Medicine and Robert Stempel College of Public Health and Social Work, Florida International University, USA.'}]",Behaviour research and therapy,['10.1016/j.brat.2019.103437'] 509,31843338,Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.,"BACKGROUND BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer, demonstrated improvement of local control and bladder cancer-specific survival from the addition of concomitant 5-fluorouracil and mitomycin C to radiotherapy. OBJECTIVE To determine the impact of treatment on the health-related quality of life (HRQoL) of BC2001 participants. DESIGN, SETTING, AND PARTICIPANTS 458 UK patients with T2-T4a N0 M0 transitional cell carcinoma of the bladder. INTERVENTION Patients were randomised to the chemotherapy comparison (radiotherapy, 178, or chemoradiotherapy, 182); and/or to the radiotherapy comparison (standard, 108, or reduced high-dose volume radiotherapy, 111). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Patients completed Functional Assessment of Cancer Therapy-Bladder (FACT-BL) questionnaires at baseline, end of treatment (EoT), and 6, 12, 24, 36, 48, and 60 months after radiotherapy. The primary endpoint was change from baseline in the bladder cancer subscale (BLCS) at 12 months. RESULTS AND LIMITATIONS Data were available for 331 (92%) and 204 (93%) participants at baseline and for 192 (54%) and 114 (52%) at 12 months for the chemotherapy and radiotherapy comparisons, respectively. HRQoL declined at EoT (BLCS -5.06 [99% confidence interval: -6.12 to -4.00, p< 0.001]; overall FACT-B TOTAL score -8.22 [-10.76 to -5.68, p< 0.01]), recovering to baseline at 6 months and remaining similar to baseline subsequently. There was no significant difference between randomised groups at any time point. CONCLUSIONS Immediately following (chemo)radiotherapy, a significant proportion of patients report declines in HRQoL, which improve to baseline after 6 months. Two-thirds of patients report stable or improved HRQoL on long-term follow-up. There is no evidence of impairment in HRQoL resulting from the addition of chemotherapy. PATIENT SUMMARY Quality of life of bladder cancer patients treated with radiotherapy±chemotherapy deteriorates during treatment, but improves to at least pretreatment levels within 6 months. Addition of chemotherapy to radiotherapy does not affect patient-reported quality of life.",2020,"There was no significant difference between randomised groups at any time point. ","['458 UK patients with T2-T4a N0 M0 transitional cell carcinoma of the bladder', 'muscle-invasive bladder cancer', 'Patients Treated for Muscle-invasive Bladder Cancer with', 'bladder cancer patients treated with', ' 178, or chemoradiotherapy, 182']","['bladder-sparing treatment', 'chemotherapy to radiotherapy', 'radiotherapy±chemotherapy deteriorates', 'Radiotherapy ± Chemotherapy', '5-fluorouracil and mitomycin C to radiotherapy', 'chemotherapy comparison (radiotherapy']","['bladder cancer subscale (BLCS', 'Quality of Life Outcomes', 'Quality of life', 'HRQoL', 'local control and bladder cancer-specific survival', 'quality of life', 'Functional Assessment of Cancer Therapy-Bladder (FACT-BL) questionnaires']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0007138', 'cui_str': 'Carcinoma, Transitional Cell'}, {'cui': 'C0005682', 'cui_str': 'Bladder'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C1827293', 'cui_str': 'Invasive bladder cancer'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for (contextual qualifier) (qualifier value)'}, {'cui': 'C0005684', 'cui_str': 'Malignant Tumor of Urinary Bladder'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}]","[{'cui': 'C0005682', 'cui_str': 'Bladder'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0002475', 'cui_str': 'Mitomycin'}]","[{'cui': 'C0005684', 'cui_str': 'Malignant Tumor of Urinary Bladder'}, {'cui': 'C0034380'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0005682', 'cui_str': 'Bladder'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",458.0,0.462282,"There was no significant difference between randomised groups at any time point. ","[{'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Huddart', 'Affiliation': 'The Institute of Cancer Research, London, UK; Royal Marsden NHS Foundation Trust, London, UK. Electronic address: Robert.Huddart@icr.ac.uk.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Hall', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Lewis', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Porta', 'Affiliation': 'The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Malcolm', 'Initials': 'M', 'LastName': 'Crundwell', 'Affiliation': 'Royal Devon & Exeter NHS Foundation Trust, Exeter, UK.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Jenkins', 'Affiliation': 'Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, UK.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Rawlings', 'Affiliation': 'Torbay and South Devon NHS Foundation Trust, Torquay, UK.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Tremlett', 'Affiliation': 'Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Campani', 'Affiliation': 'University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Carey', 'Initials': 'C', 'LastName': 'Hendron', 'Affiliation': 'University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Syed A', 'Initials': 'SA', 'LastName': 'Hussain', 'Affiliation': 'Academic unit of Oncology, Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Nicholas D', 'Initials': 'ND', 'LastName': 'James', 'Affiliation': 'University of Birmingham, Birmingham, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European urology,['10.1016/j.eururo.2019.11.001'] 510,31754962,"Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study.","BACKGROUND LATITUDE was the first phase 3 trial examining the survival benefit of adding abiraterone acetate (AA) + prednisone (P) to androgen-deprivation therapy (ADT) in newly diagnosed metastatic, castration-sensitive prostate cancer (mCSPC). Due to significant improvement in overall survival after the first interim analysis, patients in the placebos + ADT arm could switch to AA + P + ADT during an open-label extension. As in other studies where switching is allowed, statistical adjustments are needed to assess the real benefit of new drugs. PATIENTS AND METHODS This was a post hoc analysis to estimate the true survival benefit of AA + P + ADT in patients with newly diagnosed mCSPC by applying statistical adjustments commonly used to adjust for treatment switching. RESULTS Of 112 patients still receiving placebos + ADT at the first interim analysis, 72 switched to AA + P + ADT during the open-label extension. Final analysis was conducted after median follow-up of 51.8 months. Compared to the placebos + ADT arm, the risk of death in the AA + P + ADT arm was 34% lower [hazard ratio (HR) = 0.663 (95% confidence interval 0.566-0.778)] by unadjusted intent-to-treat analysis, 37% lower [HR = 0.629 (95% confidence interval 0.526-0.753)] by rank preserving structure failure time modeling, and 38% lower [HR = 0.616 (95% confidence interval 0.524-0.724)] by inverse probability of censoring weights. CONCLUSIONS Analyses adjusting for treatment switching using two different statistical approaches confirm the improved survival benefit of adding AA + P to ADT in patients with newly diagnosed mCSPC. TRIAL REGISTRATION ClinicalTrials.gov identifier NCT01715285.",2019,"Compared to the placebos + ADT arm, the risk of death in the AA + P + ADT arm was 34% lower [hazard ratio (HR) = 0.663 (95% confidence interval 0.566-0.778)] by unadjusted intent-to-treat analysis, 37% lower [HR = 0.629 (95% confidence interval 0.526-0.753)] by rank preserving structure failure time modeling, and 38% lower [HR = 0.616 (95% confidence interval 0.524-0.724)] by inverse probability of censoring weights. ","['112 patients still receiving', 'patients with newly diagnosed mCSPC', 'newly diagnosed metastatic, castration-sensitive prostate cancer (mCSPC']","['AA\u2009+\u2009P\u2009+\u2009ADT', 'placebos\u2009+\u2009ADT', 'abiraterone acetate (AA)\u2009+\u2009prednisone (P) to androgen-deprivation therapy (ADT']","['risk of death', 'survival benefit', 'overall survival']","[{'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C4302896', 'cui_str': 'Hormone sensitive prostate cancer (disorder)'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2607886', 'cui_str': 'abiraterone acetate'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy (procedure)'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",112.0,0.296385,"Compared to the placebos + ADT arm, the risk of death in the AA + P + ADT arm was 34% lower [hazard ratio (HR) = 0.663 (95% confidence interval 0.566-0.778)] by unadjusted intent-to-treat analysis, 37% lower [HR = 0.629 (95% confidence interval 0.526-0.753)] by rank preserving structure failure time modeling, and 38% lower [HR = 0.616 (95% confidence interval 0.524-0.724)] by inverse probability of censoring weights. ","[{'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Feyerabend', 'Affiliation': 'Urologic Oncology, Studienpraxis Urologie, Nürtingen, Germany.'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Saad', 'Affiliation': ""Urologic Oncology, Centre Hospitalier de L'Université de Montréal/CRCHUM, Montréal, QC, Canada.""}, {'ForeName': 'Nolen Joy', 'Initials': 'NJ', 'LastName': 'Perualila', 'Affiliation': 'Health Economics and Market Access EMEA, Janssen, Beerse, Belgium. NPeruali@its.jnj.com.'}, {'ForeName': 'Suzy', 'Initials': 'S', 'LastName': 'Van Sanden', 'Affiliation': 'Health Economics and Market Access EMEA, Janssen, Beerse, Belgium.'}, {'ForeName': 'Joris', 'Initials': 'J', 'LastName': 'Diels', 'Affiliation': 'Health Economics and Market Access EMEA, Janssen, Beerse, Belgium.'}, {'ForeName': 'Tetsuro', 'Initials': 'T', 'LastName': 'Ito', 'Affiliation': 'Health Economics and Market Access EMEA, Janssen, High Wycombe, Buckinghamshire, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'De Porre', 'Affiliation': 'Clinical Oncology, Janssen Research & Development BE, Spring House, USA.'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Fizazi', 'Affiliation': 'Gustave Roussy, University of Paris Sud, Paris, France.'}]",Targeted oncology,['10.1007/s11523-019-00685-x'] 511,31397551,Attentional bias modification is associated with fMRI response toward negative stimuli in individuals with residual depression: a randomized controlled trial,"Background Attentional bias modification (ABM) may lead to more adaptive emotion perception and emotion regulation. Understanding the neural basis of these effects may lead to greater precision for the development of future treatments. Task-related functional MRI (fMRI) after ABM training has not been investigated in depression so far. The main aim of this randomized controlled trial was to explore differences in brain activity after ABM training, in response to emotional stimuli. Methods A total of 134 people with previous depression, who had been treated for depression and had various degrees of residual symptoms, were randomized to 14 days of active ABM or a closely matched placebo training, followed by an fMRI emotion regulation task. The training procedure was a classical dot–probe task with emotional face stimuli. In the active ABM condition, the probes replaced the more positively valenced face of a given pair. As participants implicitly learned to predict the probe location, this would be likely to induce a more positive attentional bias. The placebo condition was identical, except for the contingency of the probe, which appeared equally behind positive and negative stimuli. We compared depression symptoms and subjective ratings of perceived negativity during fMRI between the training groups. We explored brain activation in predefined regions of interest and across the whole brain. We explored activation in areas associated with changes in attentional bias and degree of depression. Results Compared with the placebo group, the ABM group showed reduced activation in the amygdala and the anterior cingulate cortex when passively viewing negative images. We found no group differences in predefined regions of interest associated with emotion regulation strategies. Response in the temporal cortices was associated with the degree of change in attentional bias and the degree of depressive symptoms in ABM versus placebo. Limitations These findings should be replicated in other samples of patients with depression, and in studies using fMRI designs that allow analyses of within-group variability from baseline to follow-up. Conclusion Attentional bias modification training has an effect on brain function in the circuitry associated with emotional appraisal and the generation of affective states. Clinicaltrials.gov identifier NCT02931487",2020,"Compared with the placebo group, the ABM group showed reduced activation in the amygdala and the anterior cingulate cortex when passively viewing negative images.","['134 people with previous depression, who had been treated for depression and had various degrees of residual symptoms', 'individuals with residual depression']","['\n\n\nAttentional bias modification (ABM', 'ABM training', 'placebo', 'ABM', 'active ABM or a closely matched placebo training, followed by an fMRI emotion regulation task']","['brain activity', 'attentional bias\nand degree of depression', 'attentional bias and the degree of depressive symptoms', 'adaptive emotion perception and emotion regulation', 'brain function']","[{'cui': 'C4517565', 'cui_str': 'One hundred and thirty-four'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for (contextual qualifier) (qualifier value)'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C4277667', 'cui_str': 'Attentional Bias'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0013987', 'cui_str': 'Emotions'}, {'cui': 'C0220905', 'cui_str': 'regulations'}]","[{'cui': 'C0443158', 'cui_str': 'Brain activity (observable entity)'}, {'cui': 'C4277667', 'cui_str': 'Attentional Bias'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0013987', 'cui_str': 'Emotions'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0031843', 'cui_str': 'function'}]",134.0,0.262416,"Compared with the placebo group, the ABM group showed reduced activation in the amygdala and the anterior cingulate cortex when passively viewing negative images.","[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Hilland', 'Affiliation': 'From the Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway (Hilland, Landrø, Harmer, Maglanoc, Jonassen); the Division of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway (Hilland, Landrø); the Psychopharmacology and Emotional Research Lab, University Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Harmer); the Computational Psychiatry Laboratory, Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Browning); the Oxford Health NHS Trust, Oxford, United Kingdom (Browning); the NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway (Maglanoc); and the Division of Psychiatry, Akerhus University Hospital, Oslo, Norway (Jonassen).'}, {'ForeName': 'Nils I.', 'Initials': 'NI', 'LastName': 'Landrø', 'Affiliation': 'From the Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway (Hilland, Landrø, Harmer, Maglanoc, Jonassen); the Division of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway (Hilland, Landrø); the Psychopharmacology and Emotional Research Lab, University Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Harmer); the Computational Psychiatry Laboratory, Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Browning); the Oxford Health NHS Trust, Oxford, United Kingdom (Browning); the NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway (Maglanoc); and the Division of Psychiatry, Akerhus University Hospital, Oslo, Norway (Jonassen).'}, {'ForeName': 'Catherine J.', 'Initials': 'CJ', 'LastName': 'Harmer', 'Affiliation': 'From the Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway (Hilland, Landrø, Harmer, Maglanoc, Jonassen); the Division of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway (Hilland, Landrø); the Psychopharmacology and Emotional Research Lab, University Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Harmer); the Computational Psychiatry Laboratory, Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Browning); the Oxford Health NHS Trust, Oxford, United Kingdom (Browning); the NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway (Maglanoc); and the Division of Psychiatry, Akerhus University Hospital, Oslo, Norway (Jonassen).'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Browning', 'Affiliation': 'From the Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway (Hilland, Landrø, Harmer, Maglanoc, Jonassen); the Division of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway (Hilland, Landrø); the Psychopharmacology and Emotional Research Lab, University Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Harmer); the Computational Psychiatry Laboratory, Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Browning); the Oxford Health NHS Trust, Oxford, United Kingdom (Browning); the NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway (Maglanoc); and the Division of Psychiatry, Akerhus University Hospital, Oslo, Norway (Jonassen).'}, {'ForeName': 'Luigi A.', 'Initials': 'LA', 'LastName': 'Maglanoc', 'Affiliation': 'From the Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway (Hilland, Landrø, Harmer, Maglanoc, Jonassen); the Division of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway (Hilland, Landrø); the Psychopharmacology and Emotional Research Lab, University Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Harmer); the Computational Psychiatry Laboratory, Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Browning); the Oxford Health NHS Trust, Oxford, United Kingdom (Browning); the NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway (Maglanoc); and the Division of Psychiatry, Akerhus University Hospital, Oslo, Norway (Jonassen).'}, {'ForeName': 'Rune', 'Initials': 'R', 'LastName': 'Jonassen', 'Affiliation': 'From the Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway (Hilland, Landrø, Harmer, Maglanoc, Jonassen); the Division of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway (Hilland, Landrø); the Psychopharmacology and Emotional Research Lab, University Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Harmer); the Computational Psychiatry Laboratory, Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Browning); the Oxford Health NHS Trust, Oxford, United Kingdom (Browning); the NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway (Maglanoc); and the Division of Psychiatry, Akerhus University Hospital, Oslo, Norway (Jonassen).'}]",Journal of psychiatry & neuroscience : JPN,['10.1503/jpn.180118'] 512,31350248,A multicentre randomised feasibility STUdy evaluating the impact of a prognostic model for Management of BLunt chest wall trauma patients: STUMBL Trial.,"OBJECTIVE A new prognostic model has been developed and externally validated, the aim of which is to assist in the management of the blunt chest wall trauma patient in the emergency department (ED). The aim of this trial is to assess the feasibility and acceptability of a definitive impact trial investigating the clinical and cost-effectiveness of a new prognostic model for the management of patients with blunt chest wall trauma in the ED. DESIGN Stepped wedge feasibility trial. SETTING Four EDs in England and Wales. PARTICIPANTS Adult blunt chest wall trauma patients presenting to the ED with no concurrent, life-threatening injuries. INTERVENTION A prognostic model (the STUMBL score) to guide clinical decision-making. OUTCOME MEASURES Primary: participant recruitment rate and clinicians' use of the STUMBL score. Secondary: composite outcome measure (mortality, pulmonary complications, delayed upgrade in care, unplanned representations to the ED), physical and mental components of quality of life, clinician feedback and health economic data gathering methodology for healthcare resource utilisation. RESULTS Quantitative data were analysed using the intention-to-treat principle. 176 patients were recruited; recruitment targets were achieved at all sites. Clinicians used the model in 96% of intervention cases. All feasibility criteria were fully or partially met. After adjusting for predefined covariates, there were no statistically significant differences between the control and intervention periods. Qualitative analysis highlighted that STUMBL was well-received and clinicians would support a definitive trial. Collecting data on intervention costs, health-related quality of life and healthcare resource use was feasible. DISCUSSION We have demonstrated that a fully powered randomised clinical trial of the STUMBL score is feasible and desirable to clinicians. Minor methodological modifications will be made for the full trial. TRIAL REGISTRATION NUMBER ISRCTN95571506; Post-results.",2019,"After adjusting for predefined covariates, there were no statistically significant differences between the control and intervention periods.","['Adult blunt chest wall trauma patients presenting to the ED with no concurrent, life-threatening injuries', 'Four EDs in England and Wales', 'BLunt chest wall trauma patients', 'patients with blunt chest wall trauma in the ED', '176 patients were recruited; recruitment targets were achieved at all sites']",[],"[""recruitment rate and clinicians' use of the STUMBL score"", 'mortality, pulmonary complications, delayed upgrade in care, unplanned representations to the ED), physical and mental components of quality of life, clinician feedback and health economic data gathering methodology for healthcare resource utilisation', 'feasibility and acceptability']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1997138', 'cui_str': 'Blunted'}, {'cui': 'C0205076', 'cui_str': 'Chest Wall'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0205420', 'cui_str': 'Concurrent (qualifier value)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}]",[],"[{'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0580931', 'cui_str': 'In care (finding)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0034380'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013557', 'cui_str': 'economics'}, {'cui': 'C0969625', 'cui_str': 'methodology'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",176.0,0.12586,"After adjusting for predefined covariates, there were no statistically significant differences between the control and intervention periods.","[{'ForeName': 'Ceri', 'Initials': 'C', 'LastName': 'Battle', 'Affiliation': 'Emergency Department, Welsh Centre for Emergency Medicine Research, Swansea, UK.'}, {'ForeName': 'Hayley A', 'Initials': 'HA', 'LastName': 'Hutchings', 'Affiliation': 'Swansea Trials Unit, Swansea University Medical School, Swansea, UK.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Driscoll', 'Affiliation': 'Swansea Trials Unit, Swansea University Medical School, Swansea, UK.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': ""O'Neill"", 'Affiliation': 'Swansea Trials Unit, Swansea University Medical School, Swansea, UK.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Groves', 'Affiliation': 'Swansea University College of Human and Health Sciences, Swansea, UK.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Watkins', 'Affiliation': 'Swansea Trials Unit, Swansea University Medical School, Swansea, UK.'}, {'ForeName': 'Fiona Elizabeth', 'Initials': 'FE', 'LastName': 'Lecky', 'Affiliation': 'Health Services Research, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Jones', 'Affiliation': 'Emergency Department, Royal Gwent Hospital, Aneurin Bevan University Health Board, Newport, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Gagg', 'Affiliation': 'Emergency Department, Musgrove Park Hospital, Taunton, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Body', 'Affiliation': 'Division of Cardiovascular Sciences, The University of Manchester, Manchester.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Abbott', 'Affiliation': 'Swansea Trials Unit, Swansea University Medical School, Swansea, UK.'}, {'ForeName': 'Phillip A', 'Initials': 'PA', 'LastName': 'Evans', 'Affiliation': 'Emergency Department, Welsh Centre for Emergency Medicine Research, Swansea, UK.'}]",BMJ open,['10.1136/bmjopen-2019-029187'] 513,31350391,Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans.,"Several vaccines are approved in the United States for seasonal influenza vaccination every year. Here we compare the impact of repeat influenza vaccination on hemagglutination inhibition (HI) titers, antibody binding and affinity maturation to individual hemagglutinin (HA) domains, HA1 and HA2, across vaccine platforms. Fold change in HI and antibody binding to HA1 trends higher for H1N1pdm09 and H3N2 but not against B strains in groups vaccinated with FluBlok compared with FluCelvax and Fluzone. Antibody-affinity maturation occurs against HA1 domain of H1N1pdm09, H3N2 and B following vaccination with all vaccine platforms, but not against H1N1pdm09-HA2. Importantly, prior year vaccination of subjects receiving repeat vaccinations demonstrated reduced antibody-affinity maturation to HA1 of all three influenza virus strains irrespective of the vaccine platform. This study identifies an important impact of repeat vaccination on antibody-affinity maturation following vaccination, which may contribute to lower vaccine effectiveness of seasonal influenza vaccines in humans.",2019,Fold change in HI and antibody binding to HA1 trends higher for H1N1pdm09 and H3N2 but not against B strains in groups vaccinated with FluBlok compared with FluCelvax and Fluzone.,['humans'],"['influenza vaccination', 'FluCelvax and Fluzone']","['hemagglutination inhibition (HI) titers, antibody binding and affinity maturation to individual hemagglutinin (HA) domains, HA1 and HA2']","[{'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0042200', 'cui_str': 'Influenza vaccination (procedure)'}]","[{'cui': 'C0018904', 'cui_str': 'Hemagglutination Inhibition Tests'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0018909', 'cui_str': 'Hemagglutinin'}, {'cui': 'C3541951', 'cui_str': 'Domain'}]",,0.0305576,Fold change in HI and antibody binding to HA1 trends higher for H1N1pdm09 and H3N2 but not against B strains in groups vaccinated with FluBlok compared with FluCelvax and Fluzone.,"[{'ForeName': 'Surender', 'Initials': 'S', 'LastName': 'Khurana', 'Affiliation': 'Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, 20993, USA. Surender.Khurana@fda.hhs.gov.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Hahn', 'Affiliation': 'Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, 20993, USA.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Coyle', 'Affiliation': 'Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, 20993, USA.'}, {'ForeName': 'Lisa R', 'Initials': 'LR', 'LastName': 'King', 'Affiliation': 'Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, 20993, USA.'}, {'ForeName': 'Tsai-Lien', 'Initials': 'TL', 'LastName': 'Lin', 'Affiliation': 'Division of Biostatistics, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, 20993, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Treanor', 'Affiliation': 'University of Rochester Medical Center, Rochester, NY, 14642, USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Sant', 'Affiliation': 'University of Rochester Medical Center, Rochester, NY, 14642, USA.'}, {'ForeName': 'Hana', 'Initials': 'H', 'LastName': 'Golding', 'Affiliation': 'Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, 20993, USA.'}]",Nature communications,['10.1038/s41467-019-11296-5'] 514,30321315,Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection.,"BACKGROUND Desirability of outcome ranking (DOOR) is an innovative approach in clinical trials to evaluate the global benefits and risks of an intervention. We developed and validated a DOOR endpoint for Staphylococcus aureus bloodstream infection (BSI) through a survey to infectious diseases clinicians and secondary analysis of trial data. METHODS We administered a survey of 20 cases of S. aureus BSI, asking respondents to rank outcomes by global desirability. Correlations and percentage of pairwise agreement among rankings were estimated to inform development of a DOOR endpoint, which was applied to 2 prior S. aureus BSI trials. The probability that a patient randomly assigned to experimental treatment would have a better DOOR ranking than if assigned to control was estimated. Results were also analyzed using partial credit, which is analogous to scoring an academic test, assigning 100% to the most desirable outcome, 0% to the least, and ""partial credit"" to intermediate ranks. RESULTS Forty-two recipients (97%) completed the survey. The DOOR endpoint fitting these rankings (r = 0.89; 95% confidence interval, 0.67 to 0.94) incorporated survival plus cumulative occurrence of adverse events, cure, infectious complications, and ongoing symptoms. Tailored versions of this endpoint were applied to 2 S. aureus BSI trials, and both demonstrated no benefit of the experimental treatment using DOOR and partial credit analysis. CONCLUSIONS Using S. aureus BSI as an exemplar, we developed a DOOR endpoint that can be used as a template for development of DOOR endpoints for other diseases. Future trials can incorporate DOOR to allow for global assessment of patient experience.",2019,"The DOOR endpoint fitting these rankings (r = 0.89; 95% confidence interval, 0.67 to 0.94) incorporated survival plus cumulative occurrence of adverse events, cure, infectious complications, and ongoing symptoms.",[],[],"['survival plus cumulative occurrence of adverse events, cure, infectious complications, and ongoing symptoms']",[],[],"[{'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.116771,"The DOOR endpoint fitting these rankings (r = 0.89; 95% confidence interval, 0.67 to 0.94) incorporated survival plus cumulative occurrence of adverse events, cure, infectious complications, and ongoing symptoms.","[{'ForeName': 'Sarah B', 'Initials': 'SB', 'LastName': 'Doernberg', 'Affiliation': 'Department of Internal Medicine, Division of Infectious Diseases, University of California, San Francisco.'}, {'ForeName': 'Thuy Tien Tram', 'Initials': 'TTT', 'LastName': 'Tran', 'Affiliation': 'Biostatistics Center, Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University, D.C.'}, {'ForeName': 'Steven Y C', 'Initials': 'SYC', 'LastName': 'Tong', 'Affiliation': 'Victorian Infectious Disease Service, the Royal Melbourne Hospital, and the University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.'}, {'ForeName': 'Mical', 'Initials': 'M', 'LastName': 'Paul', 'Affiliation': 'Institute of Infectious Diseases, Rambam Health Care Campus.'}, {'ForeName': 'Dafna', 'Initials': 'D', 'LastName': 'Yahav', 'Affiliation': 'Unit of Infectious Diseases, Rabin Medical Center, Beilinson Hospital, Petah Tikva.'}, {'ForeName': 'Joshua S', 'Initials': 'JS', 'LastName': 'Davis', 'Affiliation': 'Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Northern Territory, Australia.'}, {'ForeName': 'Leonard', 'Initials': 'L', 'LastName': 'Leibovici', 'Affiliation': 'Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.'}, {'ForeName': 'Helen W', 'Initials': 'HW', 'LastName': 'Boucher', 'Affiliation': 'Tufts Medical Center, Infectious Diseases, Boston, Massachusetts.'}, {'ForeName': 'G Ralph', 'Initials': 'GR', 'LastName': 'Corey', 'Affiliation': 'Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Sara E', 'Initials': 'SE', 'LastName': 'Cosgrove', 'Affiliation': 'Department of Antimicrobial Stewardship, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Henry F', 'Initials': 'HF', 'LastName': 'Chambers', 'Affiliation': 'Department of Internal Medicine, Division of Infectious Diseases, University of California, San Francisco.'}, {'ForeName': 'Vance G', 'Initials': 'VG', 'LastName': 'Fowler', 'Affiliation': 'Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Scott R', 'Initials': 'SR', 'LastName': 'Evans', 'Affiliation': 'Biostatistics Center, Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University, D.C.'}, {'ForeName': 'Thomas L', 'Initials': 'TL', 'LastName': 'Holland', 'Affiliation': 'Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciy766'] 515,30521366,Separate and interacting effects of the endogenous circadian system and behaviors on plasma aldosterone in humans.,"Measurements of aldosterone for diagnosis of primary aldosteronism are usually made from blood sampled in the morning when aldosterone typically peaks. We tested the relative contributions and interacting influences of the circadian system, ongoing behaviors, and prior sleep to this morning peak in aldosterone. To determine circadian rhythmicity and separate effects of behaviors on aldosterone, 16 healthy participants completed a 5-day protocol in dim light while all behaviors ranging from sleep to exercise were standardized and scheduled evenly across the 24-h circadian period. In another experiment, to test the separate effects of prior nocturnal sleep or the inactivity that accompanies sleep on aldosterone, 10 healthy participants were studied across 2 nights: 1 with sleep and 1 with maintained wakefulness (randomized order). Plasma aldosterone was measured repeatedly in each experiment. Aldosterone had a significant endogenous rhythm ( P < 0.001), rising across the circadian night and peaking in the morning (~8 AM). Activity, including exercise, increased aldosterone, and different behaviors modulated aldosterone differently across the circadian cycle (circadian phase × behavior interaction; P < 0.001). In the second experiment, prior nocturnal sleep and prior rested wakefulness both increased plasma aldosterone ( P < 0.001) in the morning, to the same extent as the change in circadian phases between evening and morning. The morning increase in aldosterone is due to effects of the circadian system plus increased morning activities and not prior sleep or the inactivity accompanying sleep. These findings have implications for the time of and behaviors preceding measurement of aldosterone, especially under conditions of shift work and jet lag.",2019,"In the second experiment, prior nocturnal sleep and prior rested wakefulness both increased plasma aldosterone ( P < 0.001) in the morning, to the same extent as the change in circadian phases between evening and morning.","['humans', '10 healthy participants were studied across 2 nights: 1 with sleep and 1 with maintained wakefulness (randomized order', '16 healthy participants completed a 5-day protocol in dim light while all behaviors ranging from sleep to exercise were standardized and scheduled evenly across the 24-h circadian period']","['aldosterone', 'Aldosterone']","['endogenous rhythm', 'morning activities and not prior sleep or the inactivity accompanying sleep', 'Plasma aldosterone', 'Activity, including exercise, increased aldosterone, and different behaviors modulated aldosterone', 'prior nocturnal sleep and prior rested wakefulness both increased plasma aldosterone']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C0043012', 'cui_str': 'Wakefulnesses'}, {'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}]","[{'cui': 'C0373535', 'cui_str': 'Aldosterone measurement (procedure)'}]","[{'cui': 'C0205227', 'cui_str': 'Endogenous (qualifier value)'}, {'cui': 'C0332170', 'cui_str': 'Morning (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0857639', 'cui_str': 'Plasma aldosterone'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0373535', 'cui_str': 'Aldosterone measurement (procedure)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0443264', 'cui_str': 'Modulated (qualifier value)'}, {'cui': 'C0240526', 'cui_str': 'Night time (qualifier value)'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0043012', 'cui_str': 'Wakefulnesses'}]",16.0,0.0323653,"In the second experiment, prior nocturnal sleep and prior rested wakefulness both increased plasma aldosterone ( P < 0.001) in the morning, to the same extent as the change in circadian phases between evening and morning.","[{'ForeName': 'Saurabh S', 'Initials': 'SS', 'LastName': 'Thosar', 'Affiliation': 'Oregon Institute of Occupational Health Sciences, Oregon Health & Science University , Portland, Oregon.'}, {'ForeName': 'Jose F', 'Initials': 'JF', 'LastName': 'Rueda', 'Affiliation': 'Division of Nephrology and Hypertension, School of Medicine, Oregon Health & Science University , Portland, Oregon.'}, {'ForeName': 'Alec M', 'Initials': 'AM', 'LastName': 'Berman', 'Affiliation': 'Oregon Institute of Occupational Health Sciences, Oregon Health & Science University , Portland, Oregon.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Lasarev', 'Affiliation': 'Oregon Institute of Occupational Health Sciences, Oregon Health & Science University , Portland, Oregon.'}, {'ForeName': 'Maya X', 'Initials': 'MX', 'LastName': 'Herzig', 'Affiliation': 'Oregon Institute of Occupational Health Sciences, Oregon Health & Science University , Portland, Oregon.'}, {'ForeName': 'Noal A', 'Initials': 'NA', 'LastName': 'Clemons', 'Affiliation': 'Oregon Institute of Occupational Health Sciences, Oregon Health & Science University , Portland, Oregon.'}, {'ForeName': 'Sally A', 'Initials': 'SA', 'LastName': 'Roberts', 'Affiliation': 'Oregon Institute of Occupational Health Sciences, Oregon Health & Science University , Portland, Oregon.'}, {'ForeName': 'Nicole P', 'Initials': 'NP', 'LastName': 'Bowles', 'Affiliation': 'Oregon Institute of Occupational Health Sciences, Oregon Health & Science University , Portland, Oregon.'}, {'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Emens', 'Affiliation': 'Portland Veterans Affairs Medical Center , Portland, Oregon.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Ellison', 'Affiliation': 'Division of Nephrology and Hypertension, School of Medicine, Oregon Health & Science University , Portland, Oregon.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Shea', 'Affiliation': 'Oregon Institute of Occupational Health Sciences, Oregon Health & Science University , Portland, Oregon.'}]","American journal of physiology. Regulatory, integrative and comparative physiology",['10.1152/ajpregu.00314.2018'] 516,32143221,Effects of Modified Constraint-Induced Movement Therapy in Real-World Arm Use in Young Children with Unilateral Cerebral Palsy: A Single-Blind Randomized Trial.,"OBJECTIVE To determine whether modified constraint-induced movement therapy (mCIMT) with continuous restraint is feasible and effective in improving the use of the paretic arm in the real world among infants and toddlers with unilateral cerebral palsy (CP). DESIGN Single-blind randomized controlled trial. SETTING Tertiary hospital. PARTICIPANTS Children aged 7 to 36 months with unilateral CP ( N  = 24; 16 boys, 8 girls). INTERVENTION The experimental group received 2-hour clinic-based mCIMT sessions (5 days per week for 3 weeks), and a continuous restraint was applied. MAIN OUTCOME MEASURES Standardized assessments were conducted. Peabody Developmental Motor Scales-2 (PDMS-2), Gross Motor Function Measure-66, Pediatric Motor Activity Log (PMAL), and Pediatric Evaluation of Disability Inventory were measured pre- and postintervention. Children who agreed to participate in the accelerometer study additionally wore accelerometers on both their wrists for 3 days before and after the intervention. RESULTS The mCIMT group exhibited greater improvement in PMAL-how often ( p  = 0.048; ηp 2  = 0.173), PMAL-how well ( p  = 0.008; ηp 2  = 0.289), and PDMS-2 visual motor integration ( p  = 0.014; ηp 2  = 0.256) posttreatment than the control group. The percentage of time in moderate-to-vigorous physical activity ( z  = -2.24; p  = 0.03) and vector magnitude average counts ( z  = -2.52; p  = 0.01) significantly increased in children in who wore accelerometers ( N  = 8) after the 3-week mCIMT protocol. CONCLUSION mCIMT with continuous restraint applied to infants and toddlers with unilateral CP appeared to have a positive effect on paretic hand use in the real world. CLINICAL TRIAL REGISTRATION NUMBER NCT03418519.",2020,"The percentage of time in moderate-to-vigorous physical activity ( z  = -2.24; p  = 0.03) and vector magnitude average counts ( z  = -2.52; p  = 0.01) significantly increased in children in who wore accelerometers ( N  = 8) after the 3-week mCIMT protocol. ","['Young Children with Unilateral Cerebral Palsy', 'infants and toddlers with unilateral cerebral palsy (CP', 'Children aged 7 to 36 months with unilateral CP ( N \u2009=\u200924; 16 boys, 8 girls', 'Tertiary hospital']","['Modified Constraint-Induced Movement Therapy', '2-hour clinic-based mCIMT sessions', 'modified constraint-induced movement therapy (mCIMT) with continuous restraint', 'mCIMT with continuous restraint']","['percentage of time in moderate-to-vigorous physical activity', 'PMAL', 'Peabody Developmental Motor Scales-2 (PDMS-2), Gross Motor Function Measure-66', 'PDMS-2 visual motor integration', 'Pediatric Motor Activity Log (PMAL), and Pediatric Evaluation of Disability Inventory']","[{'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0007789', 'cui_str': 'CP (Cerebral Palsy)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0682053', 'cui_str': 'Toddler (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0587437', 'cui_str': 'Tertiary Hospital'}]","[{'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0454279', 'cui_str': 'Movement therapy (regime/therapy)'}, {'cui': 'C1292425', 'cui_str': '2 hours (qualifier value)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0458003', 'cui_str': 'Developmental (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0677549', 'cui_str': 'Gross motor functions (observable entity)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0026606', 'cui_str': 'Motor Activity'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",,0.0791907,"The percentage of time in moderate-to-vigorous physical activity ( z  = -2.24; p  = 0.03) and vector magnitude average counts ( z  = -2.52; p  = 0.01) significantly increased in children in who wore accelerometers ( N  = 8) after the 3-week mCIMT protocol. ","[{'ForeName': 'Young Sub', 'Initials': 'YS', 'LastName': 'Hwang', 'Affiliation': 'Department of Physical and Rehabilitation Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Jeong-Yi', 'Initials': 'JY', 'LastName': 'Kwon', 'Affiliation': 'Department of Physical and Rehabilitation Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.'}]",Neuropediatrics,['10.1055/s-0040-1702220'] 517,31980342,Experiential negative symptoms are more predictive of real-life functional outcome than expressive negative symptoms in clinical high-risk states.,"BACKGROUND Negative symptoms are key features of psychosis-spectrum disorders linked to psychosis development and functional impairments. This study investigated the predictive strength of negative symptoms domains on multiple aspects of real-life functional outcome in individuals at clinical high-risk (CHR) for psychosis. METHODS A total of 146 UHR individuals were enrolled in a randomized, clinical trial (RCT), with this being analyses secondary to the RCT. The participants were assessed at baseline with the Scale for the Assessment of Negative Symptoms (SANS) encompassing the four domains of affect, alogia, avolition, and anhedonia. Functioning measures, encompassing overall-, social-, and role functioning, self-report social functioning, and quality of life, were obtained at 12-month follow-up. Regression analyses elucidated on the relationship between the four negative symptom domains and functional outcomes. RESULTS Anhedonia and avolition were the aspects of negative symptoms most predictive of real-life functioning at 12-month follow-up explaining 7-20% of the variance on the outcome measures. Alogia was predictive of social functioning. These findings were maintained when controlling for the effect of neurocognition, antipsychotic medication, and depressive symptoms. DISCUSSION Our findings show experiential negative symptoms to predict multiple areas of real-life functioning and quality of life, while expressive negative symptoms exert a modest influence on the functional prognosis of CHR individuals. Experiential negative symptoms may therefore constitute an important treatment target in intervention approaches aimed at enhancing the functional outcome of CHR individuals.",2020,"RESULTS Anhedonia and avolition were the aspects of negative symptoms most predictive of real-life functioning at 12-month follow-up explaining 7-20% of the variance on the outcome measures.","['146 UHR individuals', 'individuals at clinical high-risk (CHR) for psychosis']",[],"['alogia, avolition, and anhedonia', 'Functioning measures, encompassing overall-, social-, and role functioning, self-report social functioning, and quality of life']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}]",[],"[{'cui': 'C0003537', 'cui_str': 'Anepia'}, {'cui': 'C3495892', 'cui_str': 'Avolition'}, {'cui': 'C0178417', 'cui_str': 'Anhedonia'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0034380'}]",146.0,0.0758566,"RESULTS Anhedonia and avolition were the aspects of negative symptoms most predictive of real-life functioning at 12-month follow-up explaining 7-20% of the variance on the outcome measures.","[{'ForeName': 'Louise Birkedal', 'Initials': 'LB', 'LastName': 'Glenthøj', 'Affiliation': 'Copenhagen Research Centre for Mental Health (CORE), Copenhagen University Hospital, DK-2900 Hellerup, Denmark; Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, DK-2600 Glostrup, Denmark. Electronic address: louise.birkedal.glenthoej@regionh.dk.'}, {'ForeName': 'Tina Dam', 'Initials': 'TD', 'LastName': 'Kristensen', 'Affiliation': 'Copenhagen Research Centre for Mental Health (CORE), Copenhagen University Hospital, DK-2900 Hellerup, Denmark; Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, DK-2600 Glostrup, Denmark.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Wenneberg', 'Affiliation': 'Copenhagen Research Centre for Mental Health (CORE), Copenhagen University Hospital, DK-2900 Hellerup, Denmark; Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, DK-2600 Glostrup, Denmark.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Hjorthøj', 'Affiliation': 'Copenhagen Research Centre for Mental Health (CORE), Copenhagen University Hospital, DK-2900 Hellerup, Denmark; University of Copenhagen, Department of Public Health, Section of Epidemiology, Denmark.'}, {'ForeName': 'Merete', 'Initials': 'M', 'LastName': 'Nordentoft', 'Affiliation': 'Copenhagen Research Centre for Mental Health (CORE), Copenhagen University Hospital, DK-2900 Hellerup, Denmark; Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, DK-2600 Glostrup, Denmark.'}]",Schizophrenia research,['10.1016/j.schres.2020.01.012'] 518,31852385,Compassion meditation increases optimism towards a transgressor.,"Past research reveals important connections between meditative practices and compassion. Most studies, however, focus on the effects of one type of meditation (vs. a no-intervention control) on a single expression of compassion (e.g. offering a seat) towards a relatable target (e.g. a person on crutches), without exploring possible mechanisms. Hence, few studies include different types of meditation, active controls, multiple ways to express compassion, unrelatable targets, and potential mediators. To this end, the present study compared the effects of mindfulness meditation with those of compassion meditation on different expressions of compassion towards a convicted murderer. Seventy-four participants were randomly assigned to a mindfulness meditation, compassion meditation, or active control class, or a no-class control. After an 8-week programme, we assessed compassion by giving participants the option of fulfilling a murderer's request that they write him and then coding those letters for empathy, sympathy, forgiveness, and optimism. Participants in the compassion meditation class wrote more optimistic letters compared to participants in the other three conditions, in part because they valued positivity more. No statistically significant differences emerged for the other expressions of compassion. We discuss the implications of these findings for our understanding of how meditation increases compassion towards unrelatable targets.",2020,"Participants in the compassion meditation class wrote more optimistic letters compared to participants in the other three conditions, in part because they valued positivity more.",['Seventy-four participants'],"['Compassion meditation', 'mindfulness meditation with those of compassion meditation', 'mindfulness meditation, compassion meditation, or active control class, or a no-class control']","['expressions of compassion', 'optimistic letters']","[{'cui': 'C4517867', 'cui_str': 'Seventy-four'}]","[{'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0150277'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}]","[{'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0564470', 'cui_str': 'Optimistic (finding)'}, {'cui': 'C1096774', 'cui_str': 'Letter'}]",74.0,0.0293982,"Participants in the compassion meditation class wrote more optimistic letters compared to participants in the other three conditions, in part because they valued positivity more.","[{'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Koopmann-Holm', 'Affiliation': 'Department of Psychology, Santa Clara University, Santa Clara, CA, USA.'}, {'ForeName': 'Jocelyn', 'Initials': 'J', 'LastName': 'Sze', 'Affiliation': 'Department of Psychology, University of California Berkeley, Berkeley, CA, USA.'}, {'ForeName': 'Thupten', 'Initials': 'T', 'LastName': 'Jinpa', 'Affiliation': 'Department of Religious Studies, McGill University, Montreal, Canada.'}, {'ForeName': 'Jeanne L', 'Initials': 'JL', 'LastName': 'Tsai', 'Affiliation': 'Department of Psychology, Stanford University, Stanford, CA, USA.'}]",Cognition & emotion,['10.1080/02699931.2019.1703648'] 519,31796677,Cerebral White Matter Integrity in Amnestic Mild Cognitive Impairment: A 1-Year Randomized Controlled Trial of Aerobic Exercise Training.,"Cerebral white matter (WM) represents the structural substrate of neuronal communications which is damaged by Alzheimer's disease (AD). Aerobic exercise training (AET) may improve WM integrity in cognitively normal older adults, but its efficacy remains unknown in patients with amnestic mild cognitive impairment (MCI), a prodromal phase of AD dementia. Therefore, we conducted a proof-of-concept study that randomized 70 amnestic MCI patients to a 1-year program of AET or a non-aerobic stretching and toning (SAT), active control group. Thirty-six patients completed both baseline and follow-up MRI scans, and cerebral WM integrity was measured by WM lesion volume and diffusion characteristics using fluid-attenuated-inversion-recovery and diffusion tensor imaging respectively. Peak oxygen uptake (VO2peak) and neuropsychological function were also measured. At baseline and 1-year follow-up, WM lesion volume and diffusion characteristics were similar between the AET and SAT groups, although VO2peak significantly improved after AET. The AET group showed slight improvement in neuropsychological performance. When analyzing individual data, tract-based spatial statistics demonstrated that VO2peak improvements are associated with attenuated elevations in mean and axial diffusivities, particularly the anterior WM fiber tracts (e.g., genu of corpus callosum). In patients with amnestic MCI, we found that although AET intervention did not improve WM integrity at group level analysis, individual cardiorespiratory fitness gains were associated with improved WM tract integrity of the prefrontal cortex.",2020,"At baseline and 1-year follow-up, WM lesion volume and diffusion characteristics were similar between the AET and SAT groups, although VO2peak significantly improved after AET.","['patients with amnestic MCI', 'Amnestic Mild Cognitive Impairment', 'cognitively normal older adults', 'patients with amnestic mild cognitive impairment (MCI), a prodromal phase of AD dementia', '70 amnestic MCI patients to a 1-year program of AET or a non-aerobic stretching and toning (SAT), active control group']","['Aerobic Exercise Training', 'Aerobic exercise training (AET']","['WM integrity', 'WM tract integrity of the prefrontal cortex', 'neuropsychological performance', 'Peak oxygen uptake (VO2peak) and neuropsychological function', 'cerebral WM integrity', 'WM lesion volume and diffusion characteristics']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0560005', 'cui_str': 'millicurie'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0565928', 'cui_str': 'Prodromal phase (qualifier value)'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0629582', 'cui_str': 'AETS'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0629582', 'cui_str': 'AETS'}]","[{'cui': 'C1947912', 'cui_str': 'Integrity (attribute)'}, {'cui': 'C0205266', 'cui_str': 'Intact (qualifier value)'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake (observable entity)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}]",70.0,0.0839437,"At baseline and 1-year follow-up, WM lesion volume and diffusion characteristics were similar between the AET and SAT groups, although VO2peak significantly improved after AET.","[{'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Tarumi', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, TX, USA.'}, {'ForeName': 'Binu P', 'Initials': 'BP', 'LastName': 'Thomas', 'Affiliation': 'Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Benjamin Y', 'Initials': 'BY', 'LastName': 'Tseng', 'Affiliation': 'Department of Health and Kinesiology, The University of Texas at Tyler, Tyler, TX, USA.'}, {'ForeName': 'Ciwen', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, TX, USA.'}, {'ForeName': 'Kyle B', 'Initials': 'KB', 'LastName': 'Womack', 'Affiliation': 'Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Hynan', 'Affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Hanzhang', 'Initials': 'H', 'LastName': 'Lu', 'Affiliation': 'Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'C Munro', 'Initials': 'CM', 'LastName': 'Cullum', 'Affiliation': 'Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Zhang', 'Affiliation': 'Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, TX, USA.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-190875'] 520,30078335,A Randomized Trial to Test Personalized Environmental Report Back to Reduce Lung Cancer Risk.,"BACKGROUND More radon-related lung cancers occur among those exposed to tobacco smoke. OBJECTIVES To test the effects of a personalized environmental report back intervention on change in stage of action for air nicotine testing and adopting a smoke-free home and radon testing and mitigation from baseline to 3 months postintervention. METHODS The study design used a two-arm parallel groups randomized controlled trial with stratified quota sampling. The treatment group received free air nicotine and radon home test kits and a brief problem-solving phone intervention; the control group received a coupon for free test kits. A sample of 515 homeowners were enrolled; 319 completed the 3-month follow-up. Stage of action to test and remediate the home was measured consistent with the precaution adoption process model. Linear mixed modeling assessed whether the main and interaction effects of treatment and time were associated with the testing and remediation outcomes; multiple covariates were included in the models. RESULTS The models for the four stages of action outcomes (testing and remediating for radon and secondhand smoke) each had a significant treatment-by-time effect. The general pattern was an increase in stage of action from baseline to 3 months. The degree of change was generally larger among the treatment group participants relative to the controls, indicating that those in the treatment group were more ready to take action. For all the models, participants with higher self-efficacy for radon/air nicotine testing and radon/secondhand smoke remediation were more ready to take action to test and remediate. Synergistic risk perception was associated with stage of action for radon mitigation. CONCLUSIONS Homeowners who were provided free radon and air nicotine test kits, given their results, and engaged in a brief telephonic problem-solving consultation tended to show a greater increase in readiness to take action to test and remediate by 3 months compared with those who received standard public health practice. Both groups showed an increase in stage of action for all four outcomes over time.",2019,"For all the models, participants with higher self-efficacy for radon/air nicotine testing and radon/secondhand smoke remediation were more ready to take action to test and remediate.",['A sample of 515 homeowners were enrolled; 319 completed the 3-month follow-up'],"['free air nicotine and radon home test kits and a brief problem-solving phone intervention; the control group received a coupon for free test kits', 'personalized environmental report back intervention']","['stage of action', 'Synergistic risk perception', 'Lung Cancer Risk']","[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0578827', 'cui_str': 'Owns own home (finding)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]","[{'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0034629', 'cui_str': 'Radon'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C1272835', 'cui_str': 'Test kit'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C3669643', 'cui_str': 'Problem solving (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0684224', 'cui_str': 'Report'}]","[{'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0441472', 'cui_str': 'Action (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1306460', 'cui_str': 'Primary malignant neoplasm of lung'}]",515.0,0.0219912,"For all the models, participants with higher self-efficacy for radon/air nicotine testing and radon/secondhand smoke remediation were more ready to take action to test and remediate.","[{'ForeName': 'Ellen J', 'Initials': 'EJ', 'LastName': 'Hahn', 'Affiliation': '1 University of Kentucky, Lexington, KY, USA.'}, {'ForeName': 'Luz', 'Initials': 'L', 'LastName': 'Huntington-Moskos', 'Affiliation': '2 University of Louisville, Louisville, KY, USA.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Mundy', 'Affiliation': '1 University of Kentucky, Lexington, KY, USA.'}, {'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Rademacher', 'Affiliation': '1 University of Kentucky, Lexington, KY, USA.'}, {'ForeName': 'Amanda T', 'Initials': 'AT', 'LastName': 'Wiggins', 'Affiliation': '1 University of Kentucky, Lexington, KY, USA.'}, {'ForeName': 'Mary Kay', 'Initials': 'MK', 'LastName': 'Rayens', 'Affiliation': '1 University of Kentucky, Lexington, KY, USA.'}, {'ForeName': 'Jamie L', 'Initials': 'JL', 'LastName': 'Studts', 'Affiliation': '1 University of Kentucky, Lexington, KY, USA.'}, {'ForeName': 'Karen M', 'Initials': 'KM', 'LastName': 'Butler', 'Affiliation': '1 University of Kentucky, Lexington, KY, USA.'}]",Health education & behavior : the official publication of the Society for Public Health Education,['10.1177/1090198118788602'] 521,31961417,Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial.,"Importance A prior pilot study demonstrated the systemic absorption of 4 sunscreen active ingredients; additional studies are needed to determine the systemic absorption of additional active ingredients and how quickly systemic exposure exceeds 0.5 ng/mL as recommended by the US Food and Drug Administration (FDA). Objective To assess the systemic absorption and pharmacokinetics of the 6 active ingredients (avobenzone, oxybenzone, octocrylene, homosalate, octisalate, and octinoxate) in 4 sunscreen products under single- and maximal-use conditions. Design, Setting, and Participants Randomized clinical trial at a clinical pharmacology unit (West Bend, Wisconsin) was conducted in 48 healthy participants. The study was conducted between January and February 2019. Interventions Participants were randomized to 1 of 4 sunscreen products, formulated as lotion (n = 12), aerosol spray (n = 12), nonaerosol spray (n = 12), and pump spray (n = 12). Sunscreen product was applied at 2 mg/cm2 to 75% of body surface area at 0 hours on day 1 and 4 times on day 2 through day 4 at 2-hour intervals, and 34 blood samples were collected over 21 days from each participant. Main Outcomes and Measures The primary outcome was the maximum plasma concentration of avobenzone over days 1 through 21. Secondary outcomes were the maximum plasma concentrations of oxybenzone, octocrylene, homosalate, octisalate, and octinoxate over days 1 through 21. Results Among 48 randomized participants (mean [SD] age, 38.7 [13.2] years; 24 women [50%]; 23 white [48%], 23 African American [48%], 1 Asian [2%], and 1 of unknown race/ethnicity [2%]), 44 (92%) completed the trial. Geometric mean maximum plasma concentrations of all 6 active ingredients were greater than 0.5 ng/mL, and this threshold was surpassed on day 1 after a single application for all active ingredients. For avobenzone, the overall maximum plasma concentrations were 7.1 ng/mL (coefficient of variation [CV], 73.9%) for lotion, 3.5 ng/mL (CV, 70.9%) for aerosol spray, 3.5 ng/mL (CV, 73.0%) for nonaerosol spray, and 3.3 ng/mL (CV, 47.8%) for pump spray. For oxybenzone, the concentrations were 258.1 ng/mL (CV, 53.0%) for lotion and 180.1 ng/mL (CV, 57.3%) for aerosol spray. For octocrylene, the concentrations were 7.8 ng/mL (CV, 87.1%) for lotion, 6.6 ng/mL (CV, 78.1%) for aerosol spray, and 6.6 ng/mL (CV, 103.9%) for nonaerosol spray. For homosalate, concentrations were 23.1 ng/mL (CV, 68.0%) for aerosol spray, 17.9 ng/mL (CV, 61.7%) for nonaerosol spray, and 13.9 ng/mL (CV, 70.2%) for pump spray. For octisalate, concentrations were 5.1 ng/mL (CV, 81.6%) for aerosol spray, 5.8 ng/mL (CV, 77.4%) for nonaerosol spray, and 4.6 ng/mL (CV, 97.6%) for pump spray. For octinoxate, concentrations were 7.9 ng/mL (CV, 86.5%) for nonaerosol spray and 5.2 ng/mL (CV, 68.2%) for pump spray. The most common adverse event was rash, which developed in 14 participants. Conclusions and Relevance In this study conducted in a clinical pharmacology unit and examining sunscreen application among healthy participants, all 6 of the tested active ingredients administered in 4 different sunscreen formulations were systemically absorbed and had plasma concentrations that surpassed the FDA threshold for potentially waiving some of the additional safety studies for sunscreens. These findings do not indicate that individuals should refrain from the use of sunscreen. Trial Registration ClinicalTrials.gov Identifier: NCT03582215.",2020,"For octisalate, concentrations were 5.1 ng/mL (CV, 81.6%) for aerosol spray, 5.8 ng/mL (CV, 77.4%) for nonaerosol spray, and 4.6 ng/mL","['48 randomized participants (mean [SD] age', 'January and February 2019', '48 healthy participants', '38.7 [13.2] years; 24 women [50%]; 23 white [48%], 23 African American [48%], 1 Asian [2%], and 1 of unknown race/ethnicity [2%]), 44 (92%) completed the trial', 'healthy participants']","['sunscreen products, formulated as lotion (n\u2009=\u200912), aerosol spray (n\u2009=\u200912), nonaerosol spray (n\u2009=\u200912), and pump spray', 'Sunscreen Application', '6 active ingredients (avobenzone, oxybenzone, octocrylene, homosalate, octisalate, and octinoxate']","['Geometric mean maximum plasma concentrations', 'maximum plasma concentration of avobenzone', 'overall maximum plasma concentrations', 'maximum plasma concentrations of oxybenzone, octocrylene, homosalate, octisalate, and octinoxate over days 1 through 21', 'Plasma Concentration of Sunscreen Active Ingredients']","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C0439673', 'cui_str': 'Unknown (qualifier value)'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}, {'cui': 'C0243103', 'cui_str': 'ethnicity'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0038818', 'cui_str': 'Sunscreens'}, {'cui': 'C0544341', 'cui_str': 'Lotion (basic dose form)'}, {'cui': 'C1706745', 'cui_str': 'Aerosol spray (qualifier value)'}, {'cui': 'C4521772', 'cui_str': 'Spray'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0097513', 'cui_str': 'avobenzone'}, {'cui': 'C0069803', 'cui_str': 'oxybenzone'}, {'cui': 'C0257715', 'cui_str': 'octocrylene'}, {'cui': 'C0304631', 'cui_str': 'homosalate'}, {'cui': 'C0304632', 'cui_str': 'octisalate'}, {'cui': 'C0046100', 'cui_str': 'Octinoxate'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0097513', 'cui_str': 'avobenzone'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0069803', 'cui_str': 'oxybenzone'}, {'cui': 'C0257715', 'cui_str': 'octocrylene'}, {'cui': 'C0304631', 'cui_str': 'homosalate'}, {'cui': 'C0304632', 'cui_str': 'octisalate'}, {'cui': 'C0046100', 'cui_str': 'Octinoxate'}, {'cui': 'C0585022', 'cui_str': 'During day (qualifier value)'}, {'cui': 'C0038818', 'cui_str': 'Sunscreens'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}]",48.0,0.539163,"For octisalate, concentrations were 5.1 ng/mL (CV, 81.6%) for aerosol spray, 5.8 ng/mL (CV, 77.4%) for nonaerosol spray, and 4.6 ng/mL","[{'ForeName': 'Murali K', 'Initials': 'MK', 'LastName': 'Matta', 'Affiliation': 'Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Jeffry', 'Initials': 'J', 'LastName': 'Florian', 'Affiliation': 'Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Robbert', 'Initials': 'R', 'LastName': 'Zusterzeel', 'Affiliation': 'Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Nageswara R', 'Initials': 'NR', 'LastName': 'Pilli', 'Affiliation': 'Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Vikram', 'Initials': 'V', 'LastName': 'Patel', 'Affiliation': 'Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Donna A', 'Initials': 'DA', 'LastName': 'Volpe', 'Affiliation': 'Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Division of Pharmaceutical Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Oh', 'Affiliation': 'Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Bashaw', 'Affiliation': 'Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Issam', 'Initials': 'I', 'LastName': 'Zineh', 'Affiliation': 'Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Sanabria', 'Affiliation': 'Spaulding Clinical Research, West Bend, Wisconsin.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Kemp', 'Affiliation': 'Spaulding Clinical Research, West Bend, Wisconsin.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Godfrey', 'Affiliation': 'Spaulding Clinical Research, West Bend, Wisconsin.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Adah', 'Affiliation': 'Division of Nonprescription Drug Products, Office of Drug Evaluation IV, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Coelho', 'Affiliation': 'Division of Nonprescription Drug Products, Office of Drug Evaluation IV, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Office of Drug Evaluation IV, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Lesley-Anne', 'Initials': 'LA', 'LastName': 'Furlong', 'Affiliation': 'Office of Drug Evaluation IV, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Ganley', 'Affiliation': 'Office of Drug Evaluation IV, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Michele', 'Affiliation': 'Division of Nonprescription Drug Products, Office of Drug Evaluation IV, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'David G', 'Initials': 'DG', 'LastName': 'Strauss', 'Affiliation': 'Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.'}]",JAMA,['10.1001/jama.2019.20747'] 522,31022003,Feasibility and Outcomes of an Exercise Intervention for Chemotherapy-Induced Heart Failure.,"PURPOSE Cancer treatment-related heart failure (HF) is an emerging health concern, as the number of survivors is increasing rapidly, and cardiac health issues are a leading cause of mortality in this population. While there is general evidence for the efficacy of exercise rehabilitation interventions, more research is needed on exercise rehabilitation interventions for patients specifically with treatment-induced HF and whether such interventions are safe and well-accepted. This study provides feasibility and health outcomes of a pilot exercise intervention for cancer survivors with chemotherapy-induced HF. METHODS Twenty-five participants were randomized to a clinic-based exercise intervention or a wait-list control group or, alternatively, allowed to enroll in a home-based exercise intervention if they declined the randomized study. For purposes of analysis, both types of exercise programs were combined into a single intervention group. Repeated-measures analysis of variance was conducted to assess for significant time and treatment group main effects separately and time × treatment group interaction effects. RESULTS Significant improvements in maximum oxygen uptake ((Equation is included in full-text article.)O2max) were observed in the intervention group. Intervention satisfaction and adherence were high for both clinic- and home-based interventions, with no reported serious adverse events. Enrollment was initially low for the clinic-based intervention, necessitating the addition of the home-based program as an intervention alternative. CONCLUSIONS Results suggest that exercise rehabilitation interventions are feasible in terms of safety, retention, and satisfaction and have the potential to improve (Equation is included in full-text article.)O2max. To maximize adherence and benefits while minimizing participant burden, an ideal intervention may incorporate elements of both clinic-based supervised exercise sessions and a home-based program.",2019,"Intervention satisfaction and adherence were high for both clinic- and home-based interventions, with no reported serious adverse events.","['Twenty-five participants', 'cancer survivors with chemotherapy-induced HF']","['pilot exercise intervention', 'clinic-based exercise intervention or a wait-list control group or, alternatively, allowed to enroll in a home-based exercise intervention', 'exercise rehabilitation interventions', 'Exercise Intervention']","['safety, retention, and satisfaction', 'maximum oxygen uptake', 'Intervention satisfaction and adherence']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}]","[{'cui': 'C0473169', 'cui_str': 'Aviators'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0429693', 'cui_str': 'Maximum oxygen uptake (observable entity)'}]",25.0,0.063477,"Intervention satisfaction and adherence were high for both clinic- and home-based interventions, with no reported serious adverse events.","[{'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Tsai', 'Affiliation': 'Department of Health Promotion & Behavioral Sciences, The University of Texas School of Public Health, Houston (Mr Tsai); Department of Behavioral Science (Mr Tsai, Ms Harrison, and Dr Basen-Engquist), Department of Cardiology, Division of Internal Medicine (Drs Mouhayar and Durand), Department of Biostatistics (Dr Song), Department of Nursing (Dr Fadol), and Clinical Research Support Center (Ms Massey), The University of Texas MD Anderson Cancer Center, Houston; and Cardiovascular Division, Washington University School of Medicine in St Louis, St Louis, Missouri (Dr Lenihan).'}, {'ForeName': 'Elie', 'Initials': 'E', 'LastName': 'Mouhayar', 'Affiliation': ''}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Lenihan', 'Affiliation': ''}, {'ForeName': 'Jaejoon', 'Initials': 'J', 'LastName': 'Song', 'Affiliation': ''}, {'ForeName': 'Jean-Bernard', 'Initials': 'JB', 'LastName': 'Durand', 'Affiliation': ''}, {'ForeName': 'Anecita', 'Initials': 'A', 'LastName': 'Fadol', 'Affiliation': ''}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Massey', 'Affiliation': ''}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Harrison', 'Affiliation': ''}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Basen-Engquist', 'Affiliation': ''}]",Journal of cardiopulmonary rehabilitation and prevention,['10.1097/HCR.0000000000000388'] 523,31811950,Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer.,"BACKGROUND & AIMS Many genetic variants have been associated with colorectal cancer risk, although few have been associated with survival times of patients. Identification of genetic variants associated with survival times might improve our understanding of disease progression and aid in outcome prediction. We performed a genome-wide association study to identify variants associated with colon cancer survival time. METHODS We performed a post hoc analysis of data from NCCTG N0147 (Alliance), a randomized phase 3 trial of patients with resected stage III colon cancer, and from NSABP C-08 (NRG), a phase 3 trial that compared therapy regimens for patients with resected stage II or III colon cancer. Genotype analyses were performed on DNA from blood samples from 4974 patients. We used Cox proportional hazards regression to evaluate the association of each single nucleotide polymorphism with times of overall survival and disease-free survival, adjusting for age at diagnosis, sex, treatment group, and principal components of genetic ancestry. We performed the analysis for studies N0147 and C-08 separately, and results were combined in a fixed-effects meta-analysis. RESULTS A locus on chromosome 7p15.2 was significantly associated with overall survival time (P ≤ 5x10 -08 ). The most significant variant at this locus, rs76766811 (P = 1.6x10 -08 ), is common among African Americans (minor allele frequency, approximately 18%) but rare in European Americans (minor allele frequency <0.1%). Within strata of self-reported ancestry, this variant was associated with times of overall survival and disease-free survival in only African Americans (hazard ratio for overall survival, 2.82; 95% CI, 1.88-4.23; P = 5.0x10 -07 and hazard ratio for disease-free survival, 2.27; 95% CI, 1.62-3.18; P = 1.8x10 -06 ). CONCLUSIONS In an analysis of data from 2 trials of patients with stage II or III colon cancer, we identified rs76766811 as a potential prognostic variant in African American patients. This finding should be confirmed in additional study populations. ClinicalTrials.gov Identifiers: NCT00096278 (NSABP C-08) and NCT00079274 (NCCTG N0147).",2019,A locus on chromosome 7p15.2 was significantly associated with overall survival time (P≤5x10 -08 ).,"['African American patients', '4974 patients', 'patients with resected stage III colon cancer, and from NSABP C-08 (NRG), a phase 3 trial that compared therapy regimens for patients with resected stage II or III colon cancer', 'patients with stage II or III colon cancer', 'Patients with Stage II-III Colon Cancer']",[],"['overall survival time', 'overall survival and disease-free survival', 'colon cancer survival time']","[{'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3 (qualifier value)'}, {'cui': 'C0007102', 'cui_str': 'Cancer of Colon'}, {'cui': 'C0439561', 'cui_str': 'Phase 3 (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2 (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}]",[],"[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C2919552', 'cui_str': 'Survival time'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0242793', 'cui_str': 'Disease-Free Survival'}, {'cui': 'C0007102', 'cui_str': 'Cancer of Colon'}]",4974.0,0.294248,A locus on chromosome 7p15.2 was significantly associated with overall survival time (P≤5x10 -08 ).,"[{'ForeName': 'Kathryn L', 'Initials': 'KL', 'LastName': 'Penney', 'Affiliation': ""Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.""}, {'ForeName': 'Barbara L', 'Initials': 'BL', 'LastName': 'Banbury', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Bien', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Tabitha A', 'Initials': 'TA', 'LastName': 'Harrison', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Xinwei', 'Initials': 'X', 'LastName': 'Hua', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, Washington; University of Washington, Seattle, Washington.'}, {'ForeName': 'Amanda I', 'Initials': 'AI', 'LastName': 'Phipps', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, Washington; University of Washington, Seattle, Washington.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Sun', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Mingyang', 'Initials': 'M', 'LastName': 'Song', 'Affiliation': 'Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Amit D', 'Initials': 'AD', 'LastName': 'Joshi', 'Affiliation': 'Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Steven R', 'Initials': 'SR', 'LastName': 'Alberts', 'Affiliation': 'Department of Health Science Research, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Carmen J', 'Initials': 'CJ', 'LastName': 'Allegra', 'Affiliation': 'University of Florida, Gainesville, Florida; NRG Oncology, Pittsburgh, Pennsylvania.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Atkins', 'Affiliation': 'NRG Oncology, Pittsburgh, Pennsylvania; Southeast Clinical Oncology Research (SCOR) Consortium NCORP, Winston-Salem, North Carolina.'}, {'ForeName': 'Linda H', 'Initials': 'LH', 'LastName': 'Colangelo', 'Affiliation': 'NRG Oncology, Pittsburgh, Pennsylvania; University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'George', 'Affiliation': 'University of Florida, Gainesville, Florida; NRG Oncology, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Goldberg', 'Affiliation': 'NRG Oncology, Pittsburgh, Pennsylvania; West Virginia University Cancer Institute, Morgantown, West Virginia.'}, {'ForeName': 'Peter C', 'Initials': 'PC', 'LastName': 'Lucas', 'Affiliation': 'NRG Oncology, Pittsburgh, Pennsylvania; University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Suresh G', 'Initials': 'SG', 'LastName': 'Nair', 'Affiliation': 'Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Shi', 'Affiliation': 'Department of Health Science Research, Mayo Clinic, Rochester, Minnesota; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Frank A', 'Initials': 'FA', 'LastName': 'Sinicrope', 'Affiliation': 'Department of Health Science Research, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Norman', 'Initials': 'N', 'LastName': 'Wolmark', 'Affiliation': 'NRG Oncology, Pittsburgh, Pennsylvania; Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Yothers', 'Affiliation': 'NRG Oncology, Pittsburgh, Pennsylvania; University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Peters', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, Washington; University of Washington, Seattle, Washington.'}, {'ForeName': 'Polly A', 'Initials': 'PA', 'LastName': 'Newcomb', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, Washington; University of Washington, Seattle, Washington.'}, {'ForeName': 'Andrew T', 'Initials': 'AT', 'LastName': 'Chan', 'Affiliation': ""Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: achan@mgh.harvard.edu.""}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2019.11.046'] 524,31971595,Decrease in Resting Heart Rate Measured Using Smartphone Apps to Verify Abstinence From Smoking: An Exploratory Study.,"INTRODUCTION Verifying self-reports of smoking abstinence is challenging in studies that involve remote data collection. Resting heart rate (HR) decreases during smoking abstinence. This study assessed whether a decrease in resting HR measured using freely available smartphone apps could potentially be used to verify smoking abstinence. METHODS This study involved a repeated measures experimental design, with data collection in natural setting. Participants were 18 adult, daily smokers. They recorded resting HR in beats per minute (bpm) using freely available smartphone apps during five timepoints (two in the morning and three postnoon) on each of 3 days. The outcome measure was the mean of the postnoon HR recordings. The experimental condition for each of the 3 days (counterbalanced order) was as follows: (1) smoking as usual, (2) not smoking without nicotine replacement therapy (NRT), or (3) not smoking but using NRT. Abstinence was verified using expired-air carbon monoxide (CO) concentration. RESULTS Compared with the smoking as usual condition, mean HR was 13.4 bpm lower (95% confidence interval [CI] = 5.4 to 21.4, p = .001) in the not smoking without NRT condition and 10.4 bpm lower (95% CI = 3.1 to 17.8, p = 0.004) in the not smoking with NRT condition. There was no statistically significant difference in HR between the two not smoking conditions (p = .39). Abstinence during not smoking days without and with NRT was CO-verified in 18/18 and in 16/18 cases, respectively. CONCLUSIONS Self-recording of resting HR in natural setting using smartphone apps shows a reliable decrease in response to smoking abstinence and may provide a basis for remote verification in smoking cessation studies. IMPLICATIONS Remote verification of self-reported abstinence in smoking cessation studies remains challenging. Smoking abstinence has been shown to decrease resting HR under laboratory conditions. This study demonstrated that self-recording using freely available smartphone apps shows reliable decreases in resting HR during smoking abstinence and may provide a basis for inexpensive remote verification of smoking abstinence.",2020,There was no statistically significant difference in HR between the two not smoking conditions (p=0.39).,"['Participants were 18 adult, daily smokers']","['smoking as usual, 2) not smoking without nicotine replacement therapy (NRT), or 3) not smoking but using NRT']","['HR', 'resting HR', 'expired-air carbon monoxide (CO) concentration', 'mean of the post-noon HR recordings', 'resting heart rate', 'Resting heart rate (HR']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}]","[{'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C1278444', 'cui_str': 'Nicotine replacement therapy'}]","[{'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0585020', 'cui_str': 'Noon (qualifier value)'}, {'cui': 'C1821417', 'cui_str': 'Resting heart rate (observable entity)'}]",18.0,0.0368632,There was no statistically significant difference in HR between the two not smoking conditions (p=0.39).,"[{'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Herbec', 'Affiliation': 'Department of Behavioural Science and Health, University College London, London, UK.'}, {'ForeName': 'Ella', 'Initials': 'E', 'LastName': 'Parker', 'Affiliation': 'Department of Clinical, Educational and Health Psychology, University College London, London, UK.'}, {'ForeName': 'Harveen Kaur', 'Initials': 'HK', 'LastName': 'Ubhi', 'Affiliation': 'Department of Behavioural Science and Health, University College London, London, UK.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Raupach', 'Affiliation': 'The Centre for Behaviour Change, Department of Clinical, Educational and Health Psychology, University College London, London, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'West', 'Affiliation': 'Department of Behavioural Science and Health, University College London, London, UK.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntaa021'] 525,31125276,"Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study.","PURPOSE In PALOMA-2, palbociclib plus letrozole significantly improved progression-free survival (PFS) as initial treatment of estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. We assessed the benefit of palbociclib plus letrozole in Asians. PATIENTS AND METHODS Of 666 enrolled postmenopausal women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (no prior treatment of advanced disease), 95 were Asian. Patients were randomly assigned 2:1 to receive palbociclib plus letrozole or placebo plus letrozole. The primary end point was investigator-assessed PFS. Secondary end points were overall survival, objective response, patient-reported outcomes, pharmacokinetics, and safety. RESULTS Median PFS was significantly longer in Asian patients who received palbociclib plus letrozole versus placebo plus letrozole (25.7 months [95% CI, 19.2 months to not estimable] v 13.9 months [95% CI, 7.4 to 22.0 months]; hazard ratio, 0.49; 95% CI, 0.27 to 0.87; P = .007). The most common toxicities with palbociclib were hematologic and more frequent among Asians versus non-Asians: neutropenia (any grade, 95.4% v 76.8%; grade 3/4, 89.2% v 62.5%), leukopenia (43.1% v 38.3%; 32.3% v 23.5%), and thrombocytopenia (27.7% v 13.5%; 4.6% v 1.1%). No Asians had febrile neutropenia. Discontinuation rates as a result of adverse events were similar among Asian and non-Asian patients who received palbociclib plus letrozole (10.8% and 9.5%). In Asians, quality of life (QOL) was maintained with no significant differences observed between treatments from baseline in breast cancer-specific QOL and general health status scores. Change from baseline in EuroQol five dimensions index scores was significantly higher with palbociclib plus letrozole (0.013 v -0.069; P = .0132). Geometric mean palbociclib trough concentration values were higher in Asians versus non-Asians (93.8 v 61.7 ng/mL). CONCLUSION Consistent with the overall study population, the addition of palbociclib to letrozole significantly improved PFS in Asians. Hematologic toxicities were more frequent in Asians versus non-Asians but manageable with early dose modifications while maintaining QOL.",2019,Change from baseline in EuroQol five dimensions index scores was significantly higher with palbociclib plus letrozole (0.013 v -0.069; P = .0132).,"['Asians', 'Of 666 enrolled postmenopausal women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (no prior treatment of advanced disease), 95 were Asian', 'Postmenopausal Asian Women With Metastatic Breast Cancer']","['placebo plus letrozole', 'palbociclib plus letrozole', 'palbociclib plus letrozole or placebo plus letrozole', 'Palbociclib Plus Letrozole', 'PALOMA-2, palbociclib plus letrozole', 'letrozole']","['leukopenia', 'progression-free survival (PFS', 'febrile neutropenia', 'Hematologic toxicities', 'overall survival, objective response, patient-reported outcomes, pharmacokinetics, and safety', 'Discontinuation rates', 'adverse events', 'Geometric mean palbociclib trough concentration values', 'investigator-assessed PFS', 'EuroQol five dimensions index scores', 'breast cancer-specific QOL and general health status scores', 'quality of life (QOL', 'thrombocytopenia', 'Median PFS']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0034804', 'cui_str': 'Estrogen Receptors'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C3496586', 'cui_str': 'epidermal growth factor receptor 2, human'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer metastatic'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C3853822', 'cui_str': 'palbociclib'}]","[{'cui': 'C0750394', 'cui_str': 'Decreased blood leukocyte number (finding)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0746883', 'cui_str': 'Febrile Neutropenia'}, {'cui': 'C0205488', 'cui_str': 'Hematologic (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3853822', 'cui_str': 'palbociclib'}, {'cui': 'C0444506', 'cui_str': 'Trough (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0018759', 'cui_str': 'Level of Health'}, {'cui': 'C0034380'}, {'cui': 'C0040034', 'cui_str': 'Thrombopenia'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",666.0,0.149505,Change from baseline in EuroQol five dimensions index scores was significantly higher with palbociclib plus letrozole (0.013 v -0.069; P = .0132).,"[{'ForeName': 'Seock-Ah', 'Initials': 'SA', 'LastName': 'Im', 'Affiliation': 'Seoul National Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Hirofumi', 'Initials': 'H', 'LastName': 'Mukai', 'Affiliation': 'National Cancer Center Hospital East, Chiba, Japan.'}, {'ForeName': 'In Hae', 'Initials': 'IH', 'LastName': 'Park', 'Affiliation': 'National Cancer Center, Gyeonggi-do, South Korea.'}, {'ForeName': 'Norikazu', 'Initials': 'N', 'LastName': 'Masuda', 'Affiliation': 'National Hospital Organization Osaka National Hospital, Osaka, Japan.'}, {'ForeName': 'Chikako', 'Initials': 'C', 'LastName': 'Shimizu', 'Affiliation': 'National Center for Global Health and Medicine, Tokyo, Japan.'}, {'ForeName': 'Sung-Bae', 'Initials': 'SB', 'LastName': 'Kim', 'Affiliation': 'University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Young-Hyuck', 'Initials': 'YH', 'LastName': 'Im', 'Affiliation': 'Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Shoichiro', 'Initials': 'S', 'LastName': 'Ohtani', 'Affiliation': 'Hiroshima City Hospital, Hiroshima, Japan.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Huang Bartlett', 'Affiliation': 'Pfizer, Collegeville, PA.'}, {'ForeName': 'Dongrui R', 'Initials': 'DR', 'LastName': 'Lu', 'Affiliation': 'Pfizer, La Jolla, CA.'}, {'ForeName': 'Shrividya', 'Initials': 'S', 'LastName': 'Iyer', 'Affiliation': 'Pfizer, New York, NY.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Mori', 'Affiliation': 'Pfizer Japan, Tokyo, Japan.'}, {'ForeName': 'Ave', 'Initials': 'A', 'LastName': 'Mori', 'Affiliation': 'Pfizer Srl, Milan, Italy.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Gauthier', 'Affiliation': 'Pfizer, San Francisco, CA.'}, {'ForeName': 'Richard S', 'Initials': 'RS', 'LastName': 'Finn', 'Affiliation': 'David Geffen School of Medicine, Los Angeles, CA.'}, {'ForeName': 'Masakazu', 'Initials': 'M', 'LastName': 'Toi', 'Affiliation': 'Kyoto University, Kyoto, Japan.'}]",Journal of global oncology,['10.1200/JGO.18.00173'] 526,31910028,"Effect of acute and short-term dietary fat ingestion on postprandial skeletal muscle protein synthesis rates in middle-aged, overweight, and obese men.","Muscle anabolic resistance to dietary protein is associated with obesity and insulin resistance. However, the contribution of excess consumption of fat to anabolic resistance is not well studied. The aim of these studies was to test the hypothesis that acute and short-term dietary fat overload will impair the skeletal muscle protein synthetic response to dietary protein ingestion. Eight overweight/obese men [46.4 ± 1.4 yr, body mass index (BMI) 32.3 ± 5.4 kg/m 2 ] participated in the acute feeding study, which consisted of two randomized crossover trials. On each occasion, subjects ingested an oral meal (with and without fat emulsion), 4 h before the coingestion of milk protein, intrinsically labeled with [1- 13 C]phenylalanine, and dextrose. Nine overweight/obese men (44.0 ± 1.7 yr, BMI 30.1 ± 1.1 kg/m 2 ) participated in the chronic study, which consisted of a baseline, 1-wk isocaloric diet, followed by a 2-wk high-fat diet (+25% energy excess). Acutely, incorporation of dietary amino acids into the skeletal muscle was twofold higher ( P < 0.05) in the lipid trial compared with control. There was no effect of prior lipid ingestion on indices of insulin sensitivity (muscle glucose uptake, pyruvate dehydrogenase complex activity, and Akt phosphorylation) in response to the protein/dextrose drink. Fat overfeeding had no effect on muscle protein synthesis or glucose disposal in response to whey protein ingestion, despite increased muscle diacylglycerol C16:0 ( P = 0.06) and ceramide C16:0 ( P < 0.01) levels. Neither acute nor short-term dietary fat overload has a detrimental effect on the skeletal muscle protein synthetic response to dietary protein ingestion in overweight/obese men, suggesting that dietary-induced accumulation of intramuscular lipids per se is not associated with anabolic resistance.",2020,"Acutely, incorporation of dietary amino acids into the skeletal muscle was 2-fold higher (P<0.05) in the lipid trial compared to control.","['overweight/obese men', 'Eight overweight/obese males [46.4±1.4 years, BMI 32.3±5.4 kg/m 2 ] participated in the acute feeding study', 'Nine overweight/obese males [44.0±1.7 years, BMI 30.1±1.1 kg/m 2 ] participated in the chronic study', 'middle-aged, overweight and obese men']","['lipid ingestion', 'oral meal (with and without fat emulsion) 4h before the coingestion of milk protein, intrinsically labelled with [1- 13 C]phenylalanine, and dextrose', 'acute and short-term dietary fat ingestion']","['muscle protein synthesis or glucose disposal', 'postprandial skeletal muscle protein synthesis rates', 'incorporation of dietary amino acids into the skeletal muscle', 'insulin sensitivity (muscle glucose uptake, PDC activity and Akt phosphorylation', 'muscle DAG C16:0']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0205847', 'cui_str': 'Middle Aged'}]","[{'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0304483', 'cui_str': 'Fat emulsion (substance)'}, {'cui': 'C0026138', 'cui_str': 'Milk Proteins'}, {'cui': 'C0017725', 'cui_str': 'dextrose'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0012171', 'cui_str': 'Dietary Fats'}]","[{'cui': 'C0026832', 'cui_str': 'Muscle Proteins'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0242692', 'cui_str': 'Muscle, Voluntary'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0243126', 'cui_str': 'incorporation'}, {'cui': 'C3539946', 'cui_str': 'Amino acids'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0031715', 'cui_str': 'Phosphorylation'}]",,0.0276175,"Acutely, incorporation of dietary amino acids into the skeletal muscle was 2-fold higher (P<0.05) in the lipid trial compared to control.","[{'ForeName': 'Kostas', 'Initials': 'K', 'LastName': 'Tsintzas', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Jones', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Pardeep', 'Initials': 'P', 'LastName': 'Pabla', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Mallinson', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Barrett', 'Affiliation': 'Centre for Analytical Bioscience, Advanced Materials and Healthcare Technologies Division, School of Pharmacy, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Dong-Hyun', 'Initials': 'DH', 'LastName': 'Kim', 'Affiliation': 'Centre for Analytical Bioscience, Advanced Materials and Healthcare Technologies Division, School of Pharmacy, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Cooper', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Davies', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Tariq', 'Initials': 'T', 'LastName': 'Taylor', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Chee', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Gaffney', 'Affiliation': 'MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, United Kingdom.'}, {'ForeName': 'Luc J C', 'Initials': 'LJC', 'LastName': 'van Loon', 'Affiliation': 'Department of Human Movement Sciences, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Francis B', 'Initials': 'FB', 'LastName': 'Stephens', 'Affiliation': 'School of Sport and Health Sciences, University of Exeter, Exeter, United Kingdom.'}]",American journal of physiology. Endocrinology and metabolism,['10.1152/ajpendo.00344.2019'] 527,31734069,Thermal ablation versus cryotherapy or loop excision to treat women positive for cervical precancer on visual inspection with acetic acid test: pilot phase of a randomised controlled trial.,"BACKGROUND Cryotherapy is standard practice for treating patients with cervical precancer in see-and-treat programmes in low-income and middle-income countries (LMICs). Because of logistical difficulties with cryotherapy (eg, the necessity, costs, and supply chain difficulties of refrigerant gas; equipment failure; and treatment duration >10 min), a battery-operated thermal ablator that is lightweight and portable has been developed. We aimed to compare thermal ablation using the new device with cryotherapy. METHODS We report the pilot phase of a randomised controlled trial in routine screen-and-treat clinics providing cervical screening using visual inspection with acetic acid (VIA) in Lusaka, Zambia. We recruited non-pregnant women, aged 25 years or older, who were eligible for ablative therapy. We randomly assigned participants (1:1:1) to thermal ablation, cryotherapy, or large loop excision of the transformation zone (LLETZ), using computer-generated allocation. The randomisation was concealed but the nurses providing treatment and the participants were unmasked. Thermal ablation was achieved using the Liger thermal ablator (using 1-5 overlapping applications of the probe heated to 100°C, each application lasting for 40 s), cryotherapy was carried out using the double-freeze technique (freeze for 3 min, thaw for 5 min, and freeze again for 3 min), and LLETZ (using a large loop driven by an electro-surgical unit to excise the transformation zone) was done under local anaesthesia. The primary endpoint was treatment success, defined as either human papillomavirus (HPV) type-specific clearance among participants who were positive for the same HPV type at baseline, or a negative VIA test at 6-month follow-up, if the baseline HPV test was negative. Per protocol analyses were done. Enrolment for the full trial is ongoing. Here, we present findings from a prespecified pilot phase of the full trial. The final analysis of the full trial will assess non-inferiority of the groups for the primary efficacy endpoint. The study is registered with ClinicalTrials.gov, number NCT02956239. FINDINGS Between Aug 2, 2017, and Jan 15, 2019, 750 participants were randomly assigned (250 per group). 206 (84%) participants in the cryotherapy group, 197 (81%) in the thermal ablation group, and 204 (84%) in the LLETZ group attended the 6-month follow-up examination. Treatment success was reported in 120 (60%) of 200 participants in the cryotherapy group, 123 (64%) of 192 in the thermal ablation group, and 134 (67%) of 199 in the LLETZ group (p=0·31). Few participants complained of moderate to severe pain in any group immediately after the procedure (six [2%] of 250 in the cryotherapy group, four [2%] of 250 in the thermal ablation group, and five [2%] of 250 in the LLETZ group) and 2 weeks after the procedure (one [<1%] of 241 in the cryotherapy group, none of 242 in the thermal ablation group, and two [<1%] of 237 in the LLETZ group). None of the participants reported any complication requiring medical consultation or admission to hospital. INTERPRETATION Results from this pilot study preliminarily suggest that thermal ablation has similar treatment success to cryotherapy, without the practical disadvantages of providing cryotherapy in an LMIC. However, the study was not powered to establish the similarity between the techniques, and results from the ongoing randomised controlled trial are need to confirm these results. FUNDING US National Institutes of Health.",2020,"Treatment success was reported in 120 (60%) of 200 participants in the cryotherapy group, 123 (64%) of 192 in the thermal ablation group, and 134 (67%) of 199 in the LLETZ group (p=0·31).","['Between Aug 2, 2017, and Jan 15, 2019', '750 participants', 'recruited non-pregnant women, aged 25 years or older, who were eligible for ablative therapy', 'patients with cervical precancer in see-and-treat programmes in low-income and middle-income countries (LMICs']","['Thermal ablation versus cryotherapy or loop excision', 'thermal ablation, cryotherapy, or large loop excision of the transformation zone (LLETZ), using computer-generated allocation', 'routine screen-and-treat clinics providing cervical screening using visual inspection with acetic acid (VIA', 'LLETZ']","['treatment success, defined as either human papillomavirus (HPV) type-specific clearance', 'severe pain', 'complication requiring medical consultation or admission to hospital', 'Treatment success']","[{'cui': 'C4517868', 'cui_str': '750 (qualifier value)'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205064', 'cui_str': 'Cervical (qualifier value)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0444598', 'cui_str': 'Mid (qualifier value)'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}]","[{'cui': 'C0677798', 'cui_str': 'Thermal ablation'}, {'cui': 'C4551716', 'cui_str': 'Cryotherapy'}, {'cui': 'C0445022', 'cui_str': 'Loop (qualifier value)'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C3714584', 'cui_str': 'Transformation, function (observable entity)'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0205064', 'cui_str': 'Cervical (qualifier value)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0199219', 'cui_str': 'Visual observation'}, {'cui': 'C0766298', 'cui_str': '(methylsulfanyl)acetic acid'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0278140', 'cui_str': 'Severe pain (finding)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission (procedure)'}]",750.0,0.164652,"Treatment success was reported in 120 (60%) of 200 participants in the cryotherapy group, 123 (64%) of 192 in the thermal ablation group, and 134 (67%) of 199 in the LLETZ group (p=0·31).","[{'ForeName': 'Leeya F', 'Initials': 'LF', 'LastName': 'Pinder', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA; Obstetrics and Gynecology, University of Zambia, Lusaka, Zambia.'}, {'ForeName': 'Groesbeck P', 'Initials': 'GP', 'LastName': 'Parham', 'Affiliation': 'Obstetrics and Gynecology, University of Zambia, Lusaka, Zambia; Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'Partha', 'Initials': 'P', 'LastName': 'Basu', 'Affiliation': 'Screening Group, Early Detection and Prevention Section, International Agency for Research on Cancer, WHO, Lyon, France. Electronic address: basup@iarc.fr.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Muwonge', 'Affiliation': 'Screening Group, Early Detection and Prevention Section, International Agency for Research on Cancer, WHO, Lyon, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Lucas', 'Affiliation': 'Screening Group, Early Detection and Prevention Section, International Agency for Research on Cancer, WHO, Lyon, France.'}, {'ForeName': 'Namakau', 'Initials': 'N', 'LastName': 'Nyambe', 'Affiliation': 'UNC Global Project-Zambia, Lusaka, Zambia.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Sauvaget', 'Affiliation': 'Screening Group, Early Detection and Prevention Section, International Agency for Research on Cancer, WHO, Lyon, France.'}, {'ForeName': 'Mulindi H', 'Initials': 'MH', 'LastName': 'Mwanahamuntu', 'Affiliation': 'Department of Obstetrics and Gynecology, Women and Newborn Hospital, University of Zambia, Lusaka, Zambia.'}, {'ForeName': 'Rengaswamy', 'Initials': 'R', 'LastName': 'Sankaranarayanan', 'Affiliation': 'Research Triangle Institute, International-India, Commercial Tower, Pullman Hotel Aerocity, New Delhi, India.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Prendiville', 'Affiliation': 'Screening Group, Early Detection and Prevention Section, International Agency for Research on Cancer, WHO, Lyon, France.'}]",The Lancet. Oncology,['10.1016/S1470-2045(19)30635-7'] 528,32153038,Conservative therapies to treat pain and anxiety associated with temporomandibular disorders: a randomized clinical trial.,"INTRODUCTION Temporomandibular dysfunction (TMD) is a condition that affects the stomatognathic system. OBJECTIVE To determine the effect of treatment with an occlusal splint (OS), manual therapy (MT), counselling (CS) and the combination of an occlusal splint and counselling (OSCS) on pain and anxiety in patients with TMD. MATERIALS AND METHODS A randomised clinical trial was conducted with 89 patients diagnosed with TMD through RDC/TMD (Research Diagnostic Criteria for Temporomandibular Disorders) and divided into four groups of treatment: OSCS (n = 25); OS (n = 24); MT (n = 21); and CS (n = 19). Participants were assessed before and after 1 month of therapy for pain, anxiety and TMD diagnosis. Pain was measured by a visual analogue scale. To assess anxiety, Hospital Anxiety and Depression Scale (HADS), Beck Anxiety Inventory (BAI) and the State-Trait Anxiety Inventory (STAI-S and T) were used. The data were analysed using SPSS (Statistical Package for Social Science) 22.0. RESULTS The four groups obtained a significant reduction (P < 0.001) in the pain after 1 month of treatment. Treatment in all groups promoted a significant reduction in anxiety symptoms 1 month after completion, HADS (P < 0.001), BAI (P < 0.001), STAI-T (P = 0.006). Thus, no group was superior to the other in reducing the studied variables. CONCLUSION The therapies used were effective in reducing pain and anxiety in patients diagnosed with TMD. However, no treatment was superior to the other in reducing the studied variables.",2020,The four groups obtained a significant reduction (P < 0.001) in the pain after 1 month of treatment.,"['patients diagnosed with TMD', 'pain and anxiety associated with temporomandibular disorders', '89 patients diagnosed with TMD through RDC/TMD (Research Diagnostic Criteria for Temporomandibular Disorders', 'patients with TMD']","['occlusal splint (OS), manual therapy (MT), counselling (CS) and the combination of an occlusal splint and counselling (OSCS', 'OSCS', 'Conservative therapies']","['pain and anxiety', 'anxiety symptoms', 'Pain', 'BAI', 'pain', 'pain, anxiety and TMD diagnosis', 'anxiety, Hospital Anxiety and Depression Scale (HADS), Beck Anxiety Inventory (BAI) and the State-Trait Anxiety Inventory (STAI-S and T']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0039494', 'cui_str': 'TMJ Diseases'}, {'cui': 'C0035168'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0162528', 'cui_str': 'Occlusal Splints'}, {'cui': 'C0454525', 'cui_str': 'Manual Therapies'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0459914', 'cui_str': 'Conservative Management'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory (assessment scale)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",89.0,0.0715685,The four groups obtained a significant reduction (P < 0.001) in the pain after 1 month of treatment.,"[{'ForeName': 'Rafaela Albuquerque', 'Initials': 'RA', 'LastName': 'Melo', 'Affiliation': 'Department of Dentistry, Universidade Federal, do Rio Grande do Norte (UFRN), Natal, Brazil.'}, {'ForeName': 'Camila Maria Bastos Machado', 'Initials': 'CMBM', 'LastName': 'de Resende', 'Affiliation': 'Department of Dentistry, Universidade Federal, do Rio Grande do Norte (UFRN), Natal, Brazil.'}, {'ForeName': 'Cássia Renata de Figueirêdo', 'Initials': 'CRF', 'LastName': 'Rêgo', 'Affiliation': 'Department of Dentistry, Universidade Federal, do Rio Grande do Norte (UFRN), Natal, Brazil.'}, {'ForeName': 'Andressa de Sousa Leite', 'Initials': 'ASL', 'LastName': 'Bispo', 'Affiliation': 'Department of Dentistry, Universidade Federal, do Rio Grande do Norte (UFRN), Natal, Brazil.'}, {'ForeName': 'Gustavo Augusto Seabra', 'Initials': 'GAS', 'LastName': 'Barbosa', 'Affiliation': 'Department of Dentistry, Universidade Federal, do Rio Grande do Norte (UFRN), Natal, Brazil.'}, {'ForeName': 'Erika Oliveira', 'Initials': 'EO', 'LastName': 'de Almeida', 'Affiliation': 'Department of Dentistry, Universidade Federal, do Rio Grande do Norte (UFRN), Natal, Brazil.'}]",International dental journal,['10.1111/idj.12546'] 529,31326936,Cuff Leak Test and Airway Obstruction in Mechanically Ventilated ICU Patients (COMIC): a pilot randomised controlled trial protocol.,"INTRODUCTION Endotracheal intubation and invasive mechanical ventilation are lifesaving interventions that are commonly performed in the intensive care unit (ICU). Laryngeal oedema is a known complication of intubation that may cause airway obstruction in a patient on extubation. To date, the only test available to predict this complication is the cuff leak test (CLT); however, its diagnostic accuracy and utility remains uncertain. Herein, we report the protocol for the CuffLeak and AirwayObstruction in MechanicallyVentilated ICU Patients (COMIC) pilottrial. METHODS AND ANALYSIS This will be a multicentred, pragmatic, pilot randomised controlled trial (RCT). We will enrol 100 mechanically ventilated patients in the ICU who are deemed ready for extubation. We will exclude patients at a high risk of laryngeal oedema. All enrolled patients will have a CLT done before extubation. In the intervention arm, the results of the CLT will be communicated to the bedside physician, and decision to extubate will be left to the treating team. In the control arm, respiratory therapist will not communicate the results of the CLT to the treating physician, and the patient will be extubated regardless of the CLT result. Randomisation will be done in a 1:1 allocation ratio, stratified by size of the endotracheal tube and duration of invasive mechanical ventilation.Although we will examine all clinical outcomes relevant for the future COMIC RCT, the primary outcomes of the COMIC pilottrial will be feasibility outcomes including: consent rate, recruitment rate and protocol adherence. Clinical outcomes include postextubation stridor, reintubation, emergency surgical airway, ICU mortality, in hospital mortality, duration of mechanical ventilation and ICU length of stay in days. ETHICS AND DISSEMINATION The Hamilton Integrated Research Ethics Board, Imam Abdulrahman Bin Faisal University Institutional Review Board and Bioethical Commission of the Jagiellonian University approved this study. The trial results will be disseminated via publication in peer-reviewed journals. TRIAL REGISTRATION NUMBER NCT03372707.",2019,"Clinical outcomes include postextubation stridor, reintubation, emergency surgical airway, ICU mortality, in hospital mortality, duration of mechanical ventilation and ICU length of stay in days. ","['100 mechanically ventilated patients in the ICU who are deemed ready for extubation', 'patients at a high risk of laryngeal oedema', 'MechanicallyVentilated ICU Patients (COMIC) pilottrial', 'Mechanically Ventilated ICU Patients (COMIC']",['Endotracheal intubation and invasive mechanical ventilation'],"['Cuff Leak Test and Airway Obstruction', 'postextubation stridor, reintubation, emergency surgical airway, ICU mortality, in hospital mortality, duration of mechanical ventilation and ICU length of stay in days']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0023052', 'cui_str': 'Laryngeal Edema'}]","[{'cui': 'C0021932', 'cui_str': 'Intubation, Endotracheal'}, {'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}]","[{'cui': 'C0332234', 'cui_str': 'Leaking (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0001883', 'cui_str': 'Airway Obstruction'}, {'cui': 'C0038450', 'cui_str': 'Stridor'}, {'cui': 'C0175673', 'cui_str': 'Emergency (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0085556', 'cui_str': 'Mortalities, In-house'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]",100.0,0.163439,"Clinical outcomes include postextubation stridor, reintubation, emergency surgical airway, ICU mortality, in hospital mortality, duration of mechanical ventilation and ICU length of stay in days. ","[{'ForeName': 'Kimberley', 'Initials': 'K', 'LastName': 'Lewis', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Culgin', 'Affiliation': ""The Research Institute of St. Joseph's Healthcare Hamilton, St Joseph's Healthcare, Hamilton, Ontario, Canada.""}, {'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Jaeschke', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Perri', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Corry', 'Initials': 'C', 'LastName': 'Marchildon', 'Affiliation': ""St. Joseph's Healthcare, Hamilton, Ontario, Canada.""}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Hassall', 'Affiliation': ""St. Joseph's Healthcare, Hamilton, Ontario, Canada.""}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Piraino', 'Affiliation': ""Department of Critical Care, St Michael's Hospital, Toronto, Ontario, Canada.""}, {'ForeName': 'Lehana', 'Initials': 'L', 'LastName': 'Thabane', 'Affiliation': ""The Research Institute of St. Joseph's Healthcare Hamilton, St Joseph's Healthcare, Hamilton, Ontario, Canada.""}, {'ForeName': 'Yousef', 'Initials': 'Y', 'LastName': 'Almubarak', 'Affiliation': 'Department of Critical Care, Imam Abdulrahman Ben Faisal University, Dammam, Saudi Arabia.'}, {'ForeName': 'Mohammed S', 'Initials': 'MS', 'LastName': 'Alshahrani', 'Affiliation': 'Department of Emergency and Critical Care, Imam Abdulrahman Ben Faisal University, Dammam, Saudi Arabia.'}, {'ForeName': 'Bram', 'Initials': 'B', 'LastName': 'Rochwerg', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Bandar', 'Initials': 'B', 'LastName': 'Baw', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Szczeklik', 'Affiliation': 'Department of Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, Krakow, Poland.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Karachi', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Waleed', 'Initials': 'W', 'LastName': 'Alhazzani', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2019-029394'] 530,31270121,Efficacy of vibrotactile device DentalVibe in reducing injection pain and anxiety during local anaesthesia in paediatric dental patients: a study protocol for a randomised controlled clinical trial.,"INTRODUCTION A current non-pharmacological mean for attaining painless local anaesthesia (LA) is presented by vibrotactile devices. Their concept is to reduce injection pain due to distraction by applying physical stimuli which interfere with pain signals. The aim of this study is to determine the efficacy of the DentalVibe (DV) device in reducing pain and anxiety associated with LA in paediatric patients. METHODS AND ANALYSIS The proposed study is a randomised controlled clinical trial with split-mouth design. Included are positive patients aged 8-12 years, requiring buccal infiltration for extraction of two bilateral primary maxillary molars. After dental fear measurement, eligible patients undergo two single-visit treatments with DV device allocated to either first or second LA via computer-generated randomisation sequence. Outcome measures will be self-reported pain felt during LA on Visual Analogue Scale; self-reported anxiety on Facial Image Scale; pain-related behaviour according to Faces, Legs, Activity, Cry, Consolability Scale; heart rate; patient preference to LA technique.Data will be analysed with intention-to-treat concept by Student's t-test for paired samples, Wilcoxon signed-rank test, p<0.05. Pretest on 20 subjects resulted in n=41 patients sample size. ETHICS AND DISSEMINATION This study protocol has been approved by the Committee for Scientific Research Ethics, Medical University - Plovdiv, Bulgaria (Reference number P-8604, Protocol of approval No. 6/23.11.2017) and registered on a publicly accessible database. This research received institutional funding from the Medical University - Plovdiv, Bulgaria, under project SPD-03/2017. Findings will be reported in scientific publications and at research conferences, and in project summary papers for participants. TRIAL REGISTRATION NUMBER NCT03445182; Pre-results.",2019,"Outcome measures will be self-reported pain felt during LA on Visual Analogue Scale; self-reported anxiety on Facial Image Scale; pain-related behaviour according to Faces, Legs, Activity, Cry, Consolability Scale; heart rate; patient preference to LA technique.","['eligible patients undergo two single-visit treatments with DV device allocated to either first or second LA via computer-generated randomisation sequence', 'positive patients aged 8-12 years, requiring buccal infiltration for extraction of two bilateral primary maxillary molars', 'paediatric dental patients', '20 subjects resulted in n=41 patients sample size', 'paediatric patients']","['vibrotactile device DentalVibe', 'DentalVibe (DV) device']","['pain and anxiety', 'self-reported pain felt during LA on Visual Analogue Scale; self-reported anxiety on Facial Image Scale; pain-related behaviour according to Faces, Legs, Activity, Cry, Consolability Scale; heart rate; patient preference to LA technique', 'injection pain and anxiety']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0442010', 'cui_str': 'Buccal (qualifier value)'}, {'cui': 'C3669041', 'cui_str': 'Spread by direct extension (qualifier value)'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0026367', 'cui_str': 'Molar'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0332294', 'cui_str': 'Resulting in (attribute)'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}]","[{'cui': 'C0220819', 'cui_str': 'devices'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0222045'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0010399', 'cui_str': 'Cryings'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0376409', 'cui_str': 'Patient Preference'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]",,0.217524,"Outcome measures will be self-reported pain felt during LA on Visual Analogue Scale; self-reported anxiety on Facial Image Scale; pain-related behaviour according to Faces, Legs, Activity, Cry, Consolability Scale; heart rate; patient preference to LA technique.","[{'ForeName': 'Elitsa', 'Initials': 'E', 'LastName': 'Veneva', 'Affiliation': 'Department of Pediatric Dentistry, Faculty of Dental Medicine, Medical University - Plovdiv, Plovdiv, Bulgaria.'}, {'ForeName': 'Radka', 'Initials': 'R', 'LastName': 'Cholakova', 'Affiliation': 'Department of Oral Surgery, Faculty of Dental Medicine, Medical University - Plovdiv, Plovdiv, Bulgaria.'}, {'ForeName': 'Ralitsa', 'Initials': 'R', 'LastName': 'Raycheva', 'Affiliation': 'Department of Social Medicine and Public Health, Faculty of Public Health, Medical University - Plovdiv, Plovdiv, Bulgaria.'}, {'ForeName': 'Ani', 'Initials': 'A', 'LastName': 'Belcheva', 'Affiliation': 'Department of Pediatric Dentistry, Faculty of Dental Medicine, Medical University - Plovdiv, Plovdiv, Bulgaria.'}]",BMJ open,['10.1136/bmjopen-2019-029460'] 531,30139835,Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.,"BACKGROUND The VeriStrat test provides accurate predictions of outcomes in all lines of therapy for patients with non-small cell lung cancer (NSCLC). We investigated the predictive and prognostic role of VeriStrat in patients enrolled on the MARQUEE phase III trial of tivantinib plus erlotinib (T+E) versus placebo plus erlotinib (P+E) in previously treated patients with advanced NSCLC. METHODS Pretreatment plasma samples were available for 996 patients and were analyzed by matrix-assisted laser desorption/ionization-time of flight mass spectrometry to generate VeriStrat labels (good, VS-G, or poor, VS-P). RESULTS Overall, no significant benefit in overall survival (OS) and progression-free survival (PFS) were observed for the addition of tivantinib to erlotinib. Regardless of treatment arm, patients who were classified as VS-G had significantly longer PFS (3.8 mo for T+E arm, 2.0 mo for P+E arm) and OS (11.6 mo for T+E, 10.2 mo for P+E arm) than patients classified as VS-P (PFS: 1.9 mo for both arms, hazard ratio [HR], 0.584; 95% confidence interval [CI], 0.468-0.733; p < .0001 for T+E, HR, 0.686; 95% CI, 0.546-0.870; p = .0015 for P+E; OS: 4.0 mo for both arms, HR, 0.333; 95% CI, 0.264-0.422; p < .0001 for T+E; HR, 0.449; 95% CI, 0.353-0.576; p < .0001 for P+E). The VS-G population had higher OS than the VS-P population within Eastern Cooperative Oncology Group (ECOG) performance score (PS) categories. VS-G patients on the T+E arm had longer PFS, but not OS, than VS-G patients on the P+E arm ( p = .0108). Among EGFR mutation-positive patients, those with VS-G status had a median OS more than twice that of any other group (OS: 31.6 mo for T+E and 22.8 mo for P+E), whereas VS-P patients had similar survival rates as VS-G, EGFR-wild type patients (OS: 13.7 mo for T+E and 6.5 mo for P+E). CONCLUSION In these analyses, VeriStrat showed a prognostic role within EGOC PS categories and regardless of treatment arm and EGFR status, suggesting that VeriStrat could be used to identify EGFR mutation-positive patients who will have a poor response to EGFR tyrosine kinase inhibitors. IMPLICATIONS FOR PRACTICE This study suggests that VeriStrat testing could enhance the prognostic role of performance status and smoking status and replicates findings from other trials that showed that the VeriStrat test identifies EGFR mutation-positive patients likely to have a poor response to EGFR tyrosine kinase inhibitors (TKIs). Although these findings should be confirmed in other populations, VeriStrat use could be considered in EGFR mutation-positive patients as an additional prognostic tool, and these results suggest that EGFR mutation-positive patients with VeriStrat ""poor"" classification could benefit from other therapeutic agents given in conjunction with TKI monotherapy.",2019,"VS-G patients on the T+E arm had longer PFS, but not OS, than VS-G patients on the P+E arm ( p = .0108).","['patients with non-small cell lung cancer (NSCLC', 'Previously Treated Patients with Advanced Non-Small Cell Lung Cancer', 'Pretreatment plasma samples were available for 996 patients and were analyzed by matrix-assisted laser desorption/ionization-time of flight mass spectrometry to generate VeriStrat labels (good, VS-G, or poor, VS-P', 'previously treated patients with advanced NSCLC', 'patients enrolled on the MARQUEE phase III trial of']","['Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE', 'tivantinib plus erlotinib (T+E) versus placebo plus erlotinib (P+E']","['overall survival (OS) and progression-free survival (PFS', 'survival rates', 'median OS', 'PFS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0444263', 'cui_str': 'Plasma specimen'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C4319583', 'cui_str': 'Matrix'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0037813', 'cui_str': 'Spectrum Analysis, Mass'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C1135135', 'cui_str': 'erlotinib'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2987651'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",996.0,0.222257,"VS-G patients on the T+E arm had longer PFS, but not OS, than VS-G patients on the P+E arm ( p = .0108).","[{'ForeName': 'Consuelo', 'Initials': 'C', 'LastName': 'Buttigliero', 'Affiliation': 'Division of Medical Oncology, Department of Oncology, University of Torino at San Luigi Gonzaga Hospital, Turin, Italy.'}, {'ForeName': 'Frances A', 'Initials': 'FA', 'LastName': 'Shepherd', 'Affiliation': 'Princess Margaret Cancer Centre, Toronto, Canada.'}, {'ForeName': 'Fabrice', 'Initials': 'F', 'LastName': 'Barlesi', 'Affiliation': 'Aix-Marseille University, Marseille, France.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Schwartz', 'Affiliation': 'Arqule, Inc., Woburn, Massachusetts, USA.'}, {'ForeName': 'Sergey', 'Initials': 'S', 'LastName': 'Orlov', 'Affiliation': 'St. Petersburg State Medical University, St. Petersburg, Russian Federation.'}, {'ForeName': 'Adolfo G', 'Initials': 'AG', 'LastName': 'Favaretto', 'Affiliation': 'Instituto Oncologico Veneto, Padova, Italy.'}, {'ForeName': 'Armando', 'Initials': 'A', 'LastName': 'Santoro', 'Affiliation': 'Instituto Clinico Humanitas, Milan, Italy.'}, {'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Hirsh', 'Affiliation': 'McGill University Health Centre, Montreal, Canada.'}, {'ForeName': 'Rodryg', 'Initials': 'R', 'LastName': 'Ramlau', 'Affiliation': 'Oncology Department, Poznan University of Medical Sciences, Poznan, Poland.'}, {'ForeName': 'Adele R', 'Initials': 'AR', 'LastName': 'Blackler', 'Affiliation': 'Biodesix Inc., Boulder, Colorado, USA.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Roder', 'Affiliation': 'Biodesix Inc., Boulder, Colorado, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Spigel', 'Affiliation': 'Tennessee Oncology Associates, Nashville, Tennessee, USA.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Novello', 'Affiliation': 'Division of Medical Oncology, Department of Oncology, University of Torino at San Luigi Gonzaga Hospital, Turin, Italy.'}, {'ForeName': 'Wallace', 'Initials': 'W', 'LastName': 'Akerley', 'Affiliation': 'Huntsman Cancer Institute, Salt Lake City, Utah, USA.'}, {'ForeName': 'Giorgio V', 'Initials': 'GV', 'LastName': 'Scagliotti', 'Affiliation': 'Division of Medical Oncology, Department of Oncology, University of Torino at San Luigi Gonzaga Hospital, Turin, Italy giorgio.scagliotti@unito.it.'}]",The oncologist,['10.1634/theoncologist.2018-0089'] 532,29794557,Does the Neuroimmune Modulator Ibudilast Alter Food Craving? Results in a Sample With Alcohol Use Disorder.,"OBJECTIVE Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor. A randomized, placebo-control, crossover human laboratory trial advanced IBUD development for alcohol use disorder and found that IBUD reduced tonic levels of alcohol craving. Given the importance of considering medication effects on other appetitive behavior, the present study tested the effect of IBUD (50 mg bid) on food craving. METHOD The present study was a secondary data analysis of the trial of IBUD in non-treatment seekers with alcohol use disorder (N = 19). High-fat/high-sugar food craving was measured daily. Moreover, because substantial literatures show that small alcohol doses and psychological stress increase eating of high-fat/high-sugar food, craving for high-fat/high-sugar food was measured after alcohol infusion and stress reactivity. RESULTS Results indicated that IBUD did not alter tonic high-fat/high-sugar food craving. Alcohol infusion did not generally increase high-fat/high-sugar food craving but psychological stress did. Likewise, IBUD did not affect high-fat/high-sugar food craving after alcohol infusion but IBUD did increase high-fat/high-sugar food craving after psychological stress. Follow-up analyses revealed that, among individuals with lower depressive symptomatology, IBUD compared to placebo heightened the effect of psychological stress on high-fat/high-sugar food craving. CONCLUSIONS These results advance the development of IBUD for addiction indications by demonstrating that IBUD compared to placebo does not suppress other appetitive responses, namely craving for high-fat/high-sugar food among individuals with alcohol use disorder.",2018,"Follow-up analyses revealed that, among individuals with lower depressive symptomatology, IBUD compared to placebo heightened the effect of psychological stress on high-fat/high-sugar food craving. ",['non-treatment seekers with alcohol use disorder (N\u200a=\u200a19'],"['Alcohol infusion', 'placebo']","['food craving', 'tonic high-fat/high-sugar food craving']","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0001956', 'cui_str': 'Alcohol Use Disorder'}]","[{'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0872380', 'cui_str': 'Food craving'}, {'cui': 'C3543842', 'cui_str': 'TONICS'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0453865', 'cui_str': 'Sweet food (substance)'}, {'cui': 'C0870371', 'cui_str': 'Craving'}]",,0.0379759,"Follow-up analyses revealed that, among individuals with lower depressive symptomatology, IBUD compared to placebo heightened the effect of psychological stress on high-fat/high-sugar food craving. ","[{'ForeName': 'Jenna R', 'Initials': 'JR', 'LastName': 'Cummings', 'Affiliation': 'Department of Psychology (JRC, AJT, LAR); and Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA (LAR).'}, {'ForeName': 'A Janet', 'Initials': 'AJ', 'LastName': 'Tomiyama', 'Affiliation': ''}, {'ForeName': 'Lara A', 'Initials': 'LA', 'LastName': 'Ray', 'Affiliation': ''}]",Journal of addiction medicine,['10.1097/ADM.0000000000000416'] 533,31985558,Effects of Art and Reminiscence Therapy on Agitated Behaviors Among Older Adults With Dementia.,"BACKGROUND Cognitive degeneration and agitated behavior symptoms of dementia in older adults are the main causes of disability and inability and increase the cost of medical care. Agitated behavior symptoms of dementia are the main causes of early institutionalization and make caregivers exhausted. PURPOSE The aim of this study was to examine the effects of art therapy and reminiscence therapy on the alleviation of agitated behaviors in older adults with dementia. METHODS An experimental research design with two experimental groups and one comparison group was conducted to examine the effects for each group on agitated behaviors. Participants were recruited from two dementia care centers in central and northern Taiwan. The study included 54 older individuals who met the sampling criteria and completed the data collection process. The participants were randomly allocated into the art therapy group (n = 24), the reminiscence therapy group (n = 22), and the comparison group (n = 8). The intervention consisted of 50-minute sessions conducted weekly for 12 weeks. Regular activities were continued in the comparison group. The structured questionnaires were completed, and observations of agitated behaviors were collected before the intervention and at 1 and 6 weeks after the intervention. RESULTS Significant differences were found in agitated behavior symptoms at the three time points in the art therapy group, whereas reminiscence therapy was found to have had a clear and immediate effect on decreasing agitated behavior. The generalized estimating equation exchange model test revealed a significant and sustained, postintervention effect of art therapy on agitated behavior. In contrast, no significant and sustained effect on agitated behavior was observed in the reminiscence therapy group. CONCLUSIONS The findings of this study support that art therapy may have a positive effect on dementia-associated agitated behaviors in institutionalized older adults. Reminiscence therapy activities conducted weekly for 50 minutes each session did not reach statistically significant implications. It is suggested that future studies consider conducting art and reminiscence therapies for a 16-week duration with two weekly sessions to evaluate the effectiveness of the therapy. The duration of follow-up should be extended as well in future studies.",2020,"The generalized estimating equation exchange model test revealed a significant and sustained, postintervention effect of art therapy on agitated behavior.","['institutionalized older adults', 'older adults with dementia', 'Participants were recruited from two dementia care centers in central and northern Taiwan', 'older adults', 'Older Adults With Dementia', '54 older individuals who met the sampling criteria and completed the data collection process']","['art therapy and reminiscence therapy', 'Art and Reminiscence Therapy', 'reminiscence therapy']","['Regular activities', 'agitated behavior', 'Agitated Behaviors', 'agitated behavior symptoms']","[{'cui': 'C0562359', 'cui_str': 'Institutionalized (finding)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0039260', 'cui_str': 'Formosa'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0010995', 'cui_str': 'Data Collection'}, {'cui': 'C4521054', 'cui_str': 'Process (qualifier value)'}]","[{'cui': 'C0003827', 'cui_str': 'Art Therapy'}, {'cui': 'C0150321', 'cui_str': 'Rt - reminiscence therapy'}, {'cui': 'C0003826', 'cui_str': 'Arts'}]","[{'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated (finding)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",54.0,0.051653,"The generalized estimating equation exchange model test revealed a significant and sustained, postintervention effect of art therapy on agitated behavior.","[{'ForeName': 'Chiu-Yueh', 'Initials': 'CY', 'LastName': 'Hsiao', 'Affiliation': '1PhD, RN, Assistant Professor, College of Nursing, Hungkuang University, Taiwan, ROC 2PhD, RN, CNE, NEA-BC, Professor, College of Nursing, Hungkuang University, Taiwan, ROC 3PhD, RN, Adjunct Assistant Professor, Department of Nursing, National Taichung University of Science and Technology, and Adjunct Assistant Professor, Department of Gerontic Technology and Service Management, Nan Kai University of Technology, Taiwan, ROC 4MSN, RN, Supervisor, Department of Nursing, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Taiwan, ROC 5PhD, ANP, RN, Professor, Institute of Long-Term Care, Mackay Medical College, Taiwan, ROC.'}, {'ForeName': 'Shu-Li', 'Initials': 'SL', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Yu-Shuang', 'Initials': 'YS', 'LastName': 'Hsiao', 'Affiliation': ''}, {'ForeName': 'Hsiu-Yun', 'Initials': 'HY', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Shu-Hui', 'Initials': 'SH', 'LastName': 'Yeh', 'Affiliation': ''}]",The journal of nursing research : JNR,['10.1097/jnr.0000000000000373'] 534,31969201,[ 18 F]FDDNP PET binding predicts change in executive function in a pilot clinical trial of geriatric depression.,"OBJECTIVES Geriatric depression often presents with memory and cognitive complaints that are associated with increased risk for Alzheimer's disease (AD). In a parent clinical trial of escitalopram combined with memantine or placebo for geriatric depression and subjective memory complaints, we found that memantine improved executive function and delayed recall performance at 12 months (NCT01902004). In this report, we used positron emission tomography (PET) to assess the relationship between in-vivo amyloid and tau brain biomarkers and clinical and cognitive treatment response. DESIGN In a randomized double-blind placebo-controlled trial, we measured 2-(1-{6-[(2-[F18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene) malononitrile ([18F]FDDNP) binding at baseline and assessed mood and cognitive performance at baseline, posttreatment (6 months), and naturalistic follow-up (12 months). PARTICIPANTS Twenty-two older adults with major depressive disorder and subjective memory complaints completed PET scans and were included in this report. RESULTS Across both treatment groups, higher frontal lobe [18F]FDDNP binding at baseline was associated with improvement in executive function at 6 months (corrected p = .045). This effect was no longer significant at 12 months (corrected p = .12). There was no association of regional [18F]FDDNP binding with change in mood symptoms (corrected p = .2). CONCLUSIONS [18F]FDDNP binding may predict cognitive response to antidepressant treatment. Larger trials are required to further test the value of [18F]FDDNP binding as a biomarker for cognitive improvement with antidepressant treatment in geriatric depression.",2020,"There was no association of regional [18F]FDDNP binding with change in mood symptoms (corrected p = .2). ",['Twenty-two older adults with major depressive disorder and subjective memory complaints completed PET scans and were included in this report'],"['placebo', 'memantine or placebo', '2-(1-{6-[(2-[F18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene) malononitrile ([18F]FDDNP', 'positron emission tomography (PET']","['mood symptoms', 'cognitive response', 'executive function and delayed recall performance', 'executive function', 'geriatric depression and subjective memory complaints']","[{'cui': 'C4284772', 'cui_str': '22 (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0277786', 'cui_str': 'Presenting complaint'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0032743', 'cui_str': 'Positron-Emission Tomography'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0684224', 'cui_str': 'Report'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0025242', 'cui_str': 'Memantine'}, {'cui': 'C0057889', 'cui_str': 'dicyanomethane'}, {'cui': 'C1100805', 'cui_str': '2-(1-(6-((2-((18)F)fluoroethyl)(methyl)amino)-2-naphthyl)ethylidene)malononitrile'}, {'cui': 'C0032743', 'cui_str': 'Positron-Emission Tomography'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}]","[{'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0017469', 'cui_str': 'Geriatrics'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0277786', 'cui_str': 'Presenting complaint'}]",22.0,0.314821,"There was no association of regional [18F]FDDNP binding with change in mood symptoms (corrected p = .2). ","[{'ForeName': 'Beatrix', 'Initials': 'B', 'LastName': 'Krause-Sorio', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095, USA.'}, {'ForeName': 'Prabha', 'Initials': 'P', 'LastName': 'Siddarth', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095, USA.'}, {'ForeName': 'Kelsey T', 'Initials': 'KT', 'LastName': 'Laird', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Ercoli', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095, USA.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Narr', 'Affiliation': 'Brain Research Institute, Los Angeles, CA 90095, USA.'}, {'ForeName': 'Jorge R', 'Initials': 'JR', 'LastName': 'Barrio', 'Affiliation': 'Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Small', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095, USA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Lavretsky', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095, USA.'}]",International psychogeriatrics,['10.1017/S1041610219002047'] 535,31912937,Long-term functional results after excisional haemorrhoidectomy.,"AIM The aim of this work was to perform a long-term evaluation of a randomized trial focusing on functional aspects after excisional haemorrhoidectomy with a minimum follow-up of 9 years. METHOD A questionnaire-based study including patients operated on for haemorrhoids in Sweden between 1999 and 2003. A total of 225 patients were randomized to Milligan's or Ferguson's operation. Twenty-six patients had died and 151 (76%) participated after a median follow-up of 10.7 years (range 9.2-12.6 years). RESULTS Seventy-seven patients were in the Milligan group and 74 in the Ferguson group. Forty-eight (32%) reported recurrence. Anal bleeding was reported in 80% at baseline but in 28% at long-term follow-up (P < 0.0001). At baseline, 49% had spontaneous anal pain and 25% pain at defaecation. At follow-up, these figures were 17% and 11%. At follow-up, 19% described a sense of anal stenosis. At baseline, soiling was reported in 51% but in 20% at long-term follow-up (P < 0.001). Nineteen per cent used pads preoperatively and 6% at follow-up (P < 0.0001). Straining at defaecation was reported by 35% at baseline. At follow-up, this figure was 25% (P = 0.055). CONCLUSION Symptoms associated with haemorrhoids were reduced at long-term follow-up. The most common problems were perceived recurrence and a sense of anal stenosis.",2020,Anal bleeding was reported in 80% at baseline but in 28% at long-term follow-up (p<0.0001).,"['Twenty-six patients had died and 151 (76%) participated after a median follow-up of 10.7 years (range 9.2 - 12.6', '225 patients', 'Seventy-seven were in the Milligan group and 74 in the Ferguson group', 'Questionnaire-based study including patients operated on for haemorrhoids in Sweden, 1999-2003']","[""Milligan's or Ferguson's operation"", 'excisional haemorrhoidectomy']","['soiling', 'recurrence and a sense of anal stenosis', 'recurrence', 'Anal bleeding', 'spontaneous anal pain and 25% pain at defecation']","[{'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C4517545', 'cui_str': 'Twelve point six'}, {'cui': 'C4517652', 'cui_str': '225 (qualifier value)'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0019112', 'cui_str': 'Hemorrhoids'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}]","[{'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C0019108', 'cui_str': 'Hemorrhoidectomy'}]","[{'cui': 'C0349450', 'cui_str': 'Soiling (finding)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0262374', 'cui_str': 'Stricture of anus (disorder)'}, {'cui': 'C0426747', 'cui_str': 'Bleeding from anus (disorder)'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C0238637', 'cui_str': 'Anal pain (finding)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}]",77.0,0.0625345,Anal bleeding was reported in 80% at baseline but in 28% at long-term follow-up (p<0.0001).,"[{'ForeName': 'J-P', 'Initials': 'JP', 'LastName': 'Lehmann', 'Affiliation': 'Department of Surgery, Östersunds Hospital, Östersund, Sweden.'}, {'ForeName': 'H Ö', 'Initials': 'HÖ', 'LastName': 'Johansson', 'Affiliation': 'Department of Surgery, Falu Hospital, Falun, Sweden.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Graf', 'Affiliation': 'Department of Surgical Sciences, Akademiska Sjukhuset Uppsala, Uppsala University, Uppsala, Sweden.'}]",Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland,['10.1111/codi.14954'] 536,29996689,Theoretical Mediators of RealConsent: A Web-Based Sexual Violence Prevention and Bystander Education Program.,"This study examined the process by which a web-based sexual violence (SV) prevention program (i.e., RealConsent) prevents SV perpetration and increases bystander behaviors. Data from 743 college men who participated in a randomized controlled trial were analyzed. Simple and multiple-mediation models were estimated, using several theoretical constructs to assess the mechanisms through which RealConsent produced significant effects on SV perpetration and prosocial bystander or intervening behaviors. The results indicated that knowledge of effective consent for sex, hostility toward women, date rape attitudes, and hyper-gender male ideology significantly mediated the effects of RealConsent on SV perpetration in the multiple-mediator model. Furthermore, intentions to intervene significantly mediated the effects of RealConsent on prosocial bystander behaviors in the multiple-mediator model. The results show that the RealConsent program works to prevent SV perpetration and prosocial bystander behaviors via several theoretically proposed mediators central to the development and content of the program. The results also provide strong evidence that SV and bystander education for college men may benefit from including an explicit focus on decreasing negative norms related to women (e.g., hostility, date rape attitudes, hyper-gender ideology) and through increasing college men's knowledge of consent and intentions to intervene.",2019,"The results indicated that knowledge of effective consent for sex, hostility toward women, date rape attitudes, and hyper-gender male ideology significantly mediated the effects of RealConsent on SV perpetration in the multiple-mediator model.","['college men', '743 college men who participated']","['web-based sexual violence (SV) prevention program (i.e., RealConsent', 'RealConsent']","['prosocial bystander behaviors', 'SV perpetration and prosocial bystander or intervening behaviors', 'bystander behaviors', 'SV perpetration and prosocial bystander behaviors']","[{'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C3489576', 'cui_str': 'Sexual Violence'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior'}]",743.0,0.0209311,"The results indicated that knowledge of effective consent for sex, hostility toward women, date rape attitudes, and hyper-gender male ideology significantly mediated the effects of RealConsent on SV perpetration in the multiple-mediator model.","[{'ForeName': 'Laura F', 'Initials': 'LF', 'LastName': 'Salazar', 'Affiliation': '1 Georgia State University, Atlanta, GA, USA.'}, {'ForeName': 'Alana', 'Initials': 'A', 'LastName': 'Vivolo-Kantor', 'Affiliation': '1 Georgia State University, Atlanta, GA, USA.'}, {'ForeName': 'Anne Marie', 'Initials': 'AM', 'LastName': 'Schipani-McLaughlin', 'Affiliation': '1 Georgia State University, Atlanta, GA, USA.'}]",Health education & behavior : the official publication of the Society for Public Health Education,['10.1177/1090198118779126'] 537,31978010,Efficacy and Safety of Sodium Benzoate in The Management of Hyperammonemia in Decompensated Chronic Liver Disease of the Childhood-A Double-blind Randomized Controlled Trial.,"OBJECTIVE The objective was to evaluate the efficacy and safety of sodium benzoate in the management of hyperammonemia and hepatic encephalopathy (HE) in decompensated chronic liver disease. METHODS It was a prospective, interventional, double-blinded randomized controlled trial conducted from August 2017 to December 2018. Children with decompensated chronic liver disease and hyperammonemia were included in the study. Those with ammonia >400 μg/dL, already receiving sodium benzoate or with grade III ascites were excluded. Group A received sodium benzoate (400 mg/kg loading dose followed by 200 mg · kg · daymaintenance for 5 days) along with the standard medical therapy. Group B received standard medical therapy with placebo. RESULTS A total of 108 episodes of hyperammonemia occurred in 86 patients of whom 16 were excluded. The final analysis included 46 episodes in each group. The median decrease in ammonia from baseline to day 5 was 52 μg/dL in group A versus 42 μg/dL in group B (P = 0.321). There was a significant decrease in ammonia on days 1 and 2 in group A as compared to group B, but not on subsequent days. There was no significant difference in the resolution of HE (57.1% vs 50%; P = 1), but there was higher, albeit insignificant increase in ascites in group A (15.9% vs 4.5%). CONCLUSIONS Addition of sodium benzoate significantly reduced the ammonia levels on the first 2 days of therapy but the effect was not sustained till day 5. The effect of sodium benzoate would probably be more sustained, if higher dosage (400 mg · kg · day) could be used under monitoring of benzoate levels. There was no effect on resolution of HE. Sodium benzoate caused an increasing trend of adverse events with no effect on short-term survival.",2020,"There was no significant difference in the resolution of HE (57.1% vs 50%; P = 1), but there was higher, albeit insignificant increase in ascites in group A (15.9% vs 4.5%). ","['August 2017 to December 2018', 'A total of 108 episodes of hyperammonemia occurred in 86 patients of whom 16 were excluded', 'Children with decompensated chronic liver disease and hyperammonemia', 'decompensated chronic liver disease']","['sodium benzoate', 'sodium benzoate (400\u200amg/kg loading dose followed by 200\u200amg\u200a·\u200akg\u200a·\u200adaymaintenance for 5 days) along with the standard medical therapy', 'standard medical therapy with placebo', 'Sodium Benzoate']","['ammonia', 'Efficacy and Safety', 'resolution of HE', 'ammonia levels', 'median decrease in ammonia', 'adverse events', 'ascites']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0220994', 'cui_str': 'Hyperammonemia'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0341439', 'cui_str': 'Chronic liver disease (disorder)'}]","[{'cui': 'C0142805', 'cui_str': 'Sodium Benzoate'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C3714444', 'cui_str': 'Loading dose'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy (procedure)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0002607', 'cui_str': 'Ammonia'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0201879', 'cui_str': 'Ammonia measurement (procedure)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0003962', 'cui_str': 'Ascites'}]",,0.418311,"There was no significant difference in the resolution of HE (57.1% vs 50%; P = 1), but there was higher, albeit insignificant increase in ascites in group A (15.9% vs 4.5%). ","[{'ForeName': 'Pandey', 'Initials': 'P', 'LastName': 'Snehavardhan', 'Affiliation': 'Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.'}, {'ForeName': 'Bikrant B', 'Initials': 'BB', 'LastName': 'Lal', 'Affiliation': ''}, {'ForeName': 'Vikrant', 'Initials': 'V', 'LastName': 'Sood', 'Affiliation': ''}, {'ForeName': 'Rajeev', 'Initials': 'R', 'LastName': 'Khanna', 'Affiliation': ''}, {'ForeName': 'Seema', 'Initials': 'S', 'LastName': 'Alam', 'Affiliation': ''}]",Journal of pediatric gastroenterology and nutrition,['10.1097/MPG.0000000000002521'] 538,31962346,[Effectiveness of Biofeedback for Primary Headache - A Randomized Controlled Study].,"BACKGROUND Biofeedback-treatment for primary headache is highly recommended. Its expenses are mostly not or not completely covered by health funds, hindering the implementation in the care system. This randomized controlled study aimed at evaluating the efficacy of a biofeedback-treatment for primary headache in the outpatient care system all over Germany. METHODS The participants were divided into a direct treatment-group (n=41) and a waiting control-group (n=29). The treatment was carried out for 8-11 sessions with vasoconstriction-/vasodilation training for migraine, with electromyography training for headache of the tension type (diagnosis according to the criteria of the International Headache Association). Headache characteristics (frequency, duration, intensity) were collected via headache-diary before, during and after the treatment and headache specific disability using the Pain Disability Index before and after the treatment. The waiting group stated additional information of the questionnaires about 3 months before and again ultimately before the start of the treatment. Measurement of the headache specific self-efficacy (Headache Management Self-efficacy Scale) took place every second session. For the collected parameters the effect sizes f 2 or r were computed before in comparison to after the treatment and comparing the treatment-group to the waiting-group. RESULTS Headache characteristics decreased during the time of the study significantly linearly with medium to strong effects (frequency f 2 =0.302, p<0.001, duration f 2 =0.186, p<0.001, mean intensity f 2 =0.502, p<0.001, maximal intensity f 2 =0.546, p<0.001). Using biofeedback the self-efficacy rose significantly (p<0.001, r=0.782), even compared to the waiting time (p<0.001, r=0.604). Additionally the handling of pain, the psychological disability and the disability in everyday life improved significantly. DISCUSSION AND CONCLUSION Overall the effects were comparable to already existing studies. Therefore biofeedback turned out to be efficient against migraine and tension-type headache in the out-patient care setting. By that a better integration in the care system seems to be qualified.",2020,"Using biofeedback the self-efficacy rose significantly (p<0.001, r=0.782), even compared to the waiting time (p<0.001, r=0.604).",['primary headache in the outpatient care system all over Germany'],"['biofeedback-treatment', 'Biofeedback', 'waiting control-group', 'vasoconstriction-/vasodilation training for migraine, with electromyography training']","['Headache characteristics', 'waiting time', 'handling of pain, the psychological disability and the disability in everyday life', 'headache specific self-efficacy (Headache Management Self-efficacy Scale', 'headache specific disability using the Pain Disability Index', 'Headache characteristics (frequency, duration, intensity']","[{'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0002423', 'cui_str': 'Outpatient Care'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0017480', 'cui_str': 'Germany'}]","[{'cui': 'C0678663', 'cui_str': 'Biofeedback, function (observable entity)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1456863', 'cui_str': 'Vasoconstriction'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}]","[{'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0018578', 'cui_str': 'Handling'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0222045'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}]",,0.0172543,"Using biofeedback the self-efficacy rose significantly (p<0.001, r=0.782), even compared to the waiting time (p<0.001, r=0.604).","[{'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Kolbe', 'Affiliation': 'Psychosomatische Medizin, Universitätsklinikum Regensburg.'}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Eberhardt', 'Affiliation': 'Psychosomatische Medizin, Universitätsklinikum Regensburg.'}, {'ForeName': 'Beate', 'Initials': 'B', 'LastName': 'Leinberger', 'Affiliation': 'Psychosomatische Medizin, Universitätsklinikum Regensburg.'}, {'ForeName': 'Thilo', 'Initials': 'T', 'LastName': 'Hinterberger', 'Affiliation': 'Psychosomatische Medizin, Universitätsklinikum Regensburg.'}]","Psychotherapie, Psychosomatik, medizinische Psychologie",['10.1055/a-1059-9356'] 539,31300493,Is the apparently protective effect of maternal nicotine replacement therapy (NRT) used in pregnancy on infant development explained by smoking cessation?: secondary analyses of a randomised controlled trial.,"OBJECTIVE To investigate relationships between maternal smoking status in pregnancy and infant development. The largest randomised controlled trial of nicotine replacement therapy (NRT) for smoking cessation in pregnancy, the smoking, nicotine and pregnancy (SNAP) trial, found that at 1 month after randomisation, smoking cessation rates were doubled in the NRT group compared with the placebo group. At delivery, there was no significant difference in cessation rates between groups. Surprisingly, infants born to women randomised to NRT were more likely to have unimpaired development at 2 years. We hypothesised that this apparently protective effect was due to smoking cessation caused by NRT and so, investigate this relationship using the same cohort. DESIGN Secondary analysis of a randomised controlled trial. SETTING Seven antenatal hospitals in the Midlands and North-West England. PARTICIPANTS Eight hundred and eighty-four pregnant smokers randomised to receive either NRT patches or visually-identical placebo in the SNAP trial. Participants' smoking behaviour were recorded at randomisation, 1 month after their target quit date and at delivery. METHODS Using logistic regression models, we investigated associations between participants' smoking measures and infant development (assessed using the Ages and Stages questionnaire) at 2 years. MAIN OUTCOME MEASURES 2 year infant development. RESULTS Developmental impairment was reported for 12.7% of study 2 year olds. Maternal heaviness of smoking at randomisation (OR: 1.26, 95% CI: 0.82 to 1.96, p=0.091), validated smoking abstinence recorded at 1 month after a quit date (OR: 1.02, 95% CI: 0.60 to 1.74, p=0.914) and validated smoking abstinence recorded at both 1 month after a quit date and at the end of pregnancy (OR: 1.52, 95% CI: 0.81 to 2.85, p=0.795) were not independently associated with infant developmental impairment at 2 years. CONCLUSION We found no evidence that NRT treatment improved infants' developmental outcomes through smoking cessation. TRIAL REGISTRATION NUMBER CTA03057/0002/001-0001; Post-results.",2019,"Maternal heaviness of smoking at randomisation (OR: 1.26, 95% CI: 0.82 to 1.96, p=0.091), validated smoking abstinence recorded at 1 month after a quit date (OR: 1.02, 95% CI: 0.60 to 1.74, p=0.914) and validated smoking abstinence recorded at both 1 month after a quit date and at the end of pregnancy (OR: 1.52, 95% CI: 0.81 to 2.85, p=0.795) were not independently associated with infant developmental impairment at 2 years. ","['Seven antenatal hospitals in the Midlands and North-West England', 'Eight hundred and eighty-four pregnant smokers']","['nicotine replacement therapy (NRT', 'placebo', 'NRT patches or visually-identical placebo', 'maternal nicotine replacement therapy (NRT', 'NRT']","['cessation rates', 'validated smoking abstinence', 'Maternal heaviness of smoking', 'smoking behaviour', 'smoking cessation rates']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C2828394', 'cui_str': 'Antenatal (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C3844106', 'cui_str': 'Eight hundred'}, {'cui': 'C4319623', 'cui_str': '84 (qualifier value)'}, {'cui': 'C0549206', 'cui_str': 'Pregnancy not delivered'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}]","[{'cui': 'C1278444', 'cui_str': 'Nicotine replacement therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0445403', 'cui_str': 'Human patch'}, {'cui': 'C0205280', 'cui_str': 'Identical (qualifier value)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}]","[{'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}]",884.0,0.202215,"Maternal heaviness of smoking at randomisation (OR: 1.26, 95% CI: 0.82 to 1.96, p=0.091), validated smoking abstinence recorded at 1 month after a quit date (OR: 1.02, 95% CI: 0.60 to 1.74, p=0.914) and validated smoking abstinence recorded at both 1 month after a quit date and at the end of pregnancy (OR: 1.52, 95% CI: 0.81 to 2.85, p=0.795) were not independently associated with infant developmental impairment at 2 years. ","[{'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Iyen', 'Affiliation': 'Division of Primary Care, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Luis R', 'Initials': 'LR', 'LastName': 'Vaz', 'Affiliation': 'Division of Primary Care, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Jaspal', 'Initials': 'J', 'LastName': 'Taggar', 'Affiliation': 'Division of Primary Care, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Cooper', 'Affiliation': 'Division of Primary Care, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Lewis', 'Affiliation': 'Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Coleman', 'Affiliation': 'Division of Primary Care, University of Nottingham, Nottingham, UK.'}]",BMJ open,['10.1136/bmjopen-2018-024923'] 540,31944893,Dental RECUR Randomized Trial to Prevent Caries Recurrence in Children.,"The purpose of this study was to determine the efficacy of a dental nurse-delivered intervention-the Dental RECUR Brief Negotiated Interview for Oral Health (DR-BNI)-in reducing the recurrence of dental caries in children who have a primary tooth extracted. It was based on a 2-arm multicenter randomized controlled trial with blinded outcome assessment. Participants were 5- to 7-y-old children ( n = 241) scheduled to have primary teeth extracted in 12 UK centers. Test intervention parents ( n = 119) received DR-BNI led by trained dental nurses. DR-BNI is a 30-min structured conversation informed by motivational interviewing with a forward focus to prevent future caries. Preventive goals are agreed, and a review appointment is made with child's general dental practitioner, who is advised to treat the child as being at high caries risk. The control intervention ( n = 122) was a parent-nurse conversation about child's future tooth eruption, with advice given to visit a general dental practitioner as usual. At baseline, the DR-BNI group's mean dmft was 6.8, and the control group's was 6.3. A median of 5 teeth were extracted, mainly under general anesthesia. Final dental assessments were conducted by a single examiner visiting 189 schools 2 y after intervention; 193 (80%) of 241 children were examined. In the control group, 62% developed new caries in teeth that were caries-free or unerupted at baseline, as compared with 44% in the test group, a significant reduction ( P = 0.021). The odds of new caries experience occurring were reduced by 51% in the DR-BNI group as compared with control. There was a 29% decrease in the relative risk of new caries experience in the DR-BNI group as compared with control. This single low-cost, low-intensity intervention was successful in significantly reducing the risk of recurrence of dental caries in children. This trial has implications for changing pediatric dental practice internationally. Training in and implementation of a motivational interviewing-informed brief intervention provides opportunities for dental nurses to facilitate behavior change improving the oral health of children at high caries risk (ISRCTN 24958829).",2020,The odds of new caries experience occurring were reduced by 51% in the DR-BNI group as compared with control.,"['children', 'children who have a primary tooth extracted', 'children at high caries risk (ISRCTN 24958829', 'Children', 'Participants were 5- to 7-y-old children ( n = 241) scheduled to have primary teeth extracted in 12 UK centers']","['DR-BNI led by trained dental nurses', 'motivational interviewing-informed brief intervention', 'control intervention', 'dental nurse-delivered intervention-the Dental RECUR Brief Negotiated Interview for Oral Health (DR-BNI)-in']","['risk of recurrence of dental caries', 'new caries', 'relative risk of new caries experience']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C3266841', 'cui_str': 'Baby Teeth'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0969259', 'cui_str': ""bis(O,O'-di-p-tolyldithiophosphato-S,S')(1,10-phenanthroline-N,N')nickel(II)""}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0011327', 'cui_str': 'Nurses, Dental'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0700287', 'cui_str': 'Informing (procedure)'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0680727', 'cui_str': 'Negotiation'}, {'cui': 'C0029162'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0011334', 'cui_str': 'Dental Decay'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}]",241.0,0.049632,The odds of new caries experience occurring were reduced by 51% in the DR-BNI group as compared with control.,"[{'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Pine', 'Affiliation': 'Research and Innovation, Salford Royal NHS Foundation Trust, Northern Care Alliance NHS Group, Summerfield House, Salford, UK.'}, {'ForeName': 'P M', 'Initials': 'PM', 'LastName': 'Adair', 'Affiliation': ""Centre for Improving Health-Related Quality of Life, School of Psychology, Queen's University, Belfast, UK.""}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Burnside', 'Affiliation': 'Department of Biostatistics, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Brennan', 'Affiliation': 'Health Education North West, Regatta Place, Liverpool, UK.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Sutton', 'Affiliation': 'Department of Biostatistics, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'R T', 'Initials': 'RT', 'LastName': 'Edwards', 'Affiliation': 'Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Ezeofor', 'Affiliation': 'Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Albadri', 'Affiliation': 'Paediatric Dentistry, School of Dentistry, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Curnow', 'Affiliation': 'Public Dental Service, Broxden Dental Centre, NHS Tayside, Perth, UK.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Deery', 'Affiliation': 'School of Clinical Dentistry, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'M T', 'Initials': 'MT', 'LastName': 'Hosey', 'Affiliation': 'Paediatric Dentistry, Centre of Oral, Clinical and Translational Science, Faculty of Dentistry, Oral and Craniofacial Sciences, Kings College London, London, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Willis-Lake', 'Affiliation': 'Kent Community Health NHS Foundation Trust, Maidstone, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Lynn', 'Affiliation': 'Community Dental Service, Arches Health and Care Centre, Belfast Health and Social Care Trust, Belfast, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Parry', 'Affiliation': 'Special Care Dental Service, Sussex Community NHS Foundation Trust, Brighton, UK.'}, {'ForeName': 'F S L', 'Initials': 'FSL', 'LastName': 'Wong', 'Affiliation': 'Barts and the London Schools of Medicine and Dentistry, Institute of Dentistry, Queen Mary University of London, London, UK.'}]",Journal of dental research,['10.1177/0022034519886808'] 541,30952794,INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.,"OBJECTIVE To evaluate the safety and efficacy of low-dose naproxen for prevention of progression in presymptomatic Alzheimer disease (AD) among cognitively intact persons at risk. METHODS Investigation of Naproxen Treatment Effects in Pre-symptomatic Alzheimer's Disease (INTREPAD), a 2-year double-masked pharmaco-prevention trial, enrolled 195 AD family history-positive elderly (mean age 63 years) participants screened carefully to exclude cognitive disorder (NCT-02702817). These were randomized 1:1 to naproxen sodium 220 mg twice daily or placebo. Multimodal imaging, neurosensory, cognitive, and (in ∼50%) CSF biomarker evaluations were performed at baseline, 3, 12, and 24 months. A modified intent-to-treat analysis considered 160 participants who remained on-treatment through their first follow-up examination. The primary outcome was rate of change in a multimodal composite presymptomatic Alzheimer Progression Score (APS). RESULTS Naproxen-treated individuals showed a clear excess of adverse events. Among treatment groups combined, the APS increased by 0.102 points/year (SE 0.014; p < 10 -12 ), but rate of change showed little difference by treatment assignment (0.019 points/year). The treatment-related rate ratio of 1.16 (95% confidence interval 0.64-1.96) suggested that naproxen does not reduce the rate of APS progression by more than 36%. Secondary analyses revealed no notable treatment effects on individual CSF, cognitive, or neurosensory biomarker indicators of progressive presymptomatic AD. CONCLUSIONS In cognitively intact individuals at risk, sustained treatment with naproxen sodium 220 mg twice daily increases frequency of adverse health effects but does not reduce apparent progression of presymptomatic AD. CLASSIFICATION OF EVIDENCE This study provides Class I evidence that, for people who are cognitively intact, low-dose naproxen does not significantly reduce progression of a composite indicator of presymptomatic AD.",2019,"Among treatment groups combined, the APS increased by 0.102 points/year (SE 0.014; p < 10 -12 ), but rate of change showed little difference by treatment assignment (0.019 points/year).","[""Pre-symptomatic Alzheimer's Disease (INTREPAD), a 2-year double-masked pharmaco-prevention trial, enrolled 195 AD family history-positive elderly (mean age 63 years) participants screened carefully to exclude cognitive disorder (NCT-02702817"", '160 participants who remained on-treatment through their first follow-up examination', 'cognitively intact persons at risk']","['naproxen', 'Naproxen', 'low-dose naproxen', 'naproxen sodium', 'INTREPAD', 'naproxen sodium 220 mg twice daily or placebo']","['safety and efficacy', 'APS', 'rate of APS progression', 'frequency of adverse health effects', 'adverse events', 'rate of change in a multimodal composite presymptomatic Alzheimer Progression Score (APS', 'CSF biomarker evaluations', 'individual CSF, cognitive, or neurosensory biomarker indicators of progressive presymptomatic AD']","[{'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0024861', 'cui_str': 'Masks'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0009241', 'cui_str': 'Cognition Disorders'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C0205266', 'cui_str': 'Intact (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C1444641', 'cui_str': 'At risk'}]","[{'cui': 'C0027396', 'cui_str': 'Naproxen'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0546873', 'cui_str': 'Naproxen sodium'}, {'cui': 'C2684571', 'cui_str': 'Naproxen sodium 220 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0085409', 'cui_str': 'Polyendocrinopathies, Autoimmune'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}]",195.0,0.478065,"Among treatment groups combined, the APS increased by 0.102 points/year (SE 0.014; p < 10 -12 ), but rate of change showed little difference by treatment assignment (0.019 points/year).","[{'ForeName': 'Pierre-François', 'Initials': 'PF', 'LastName': 'Meyer', 'Affiliation': 'From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montréal, Canada; and John Hopkins University (J.L.), Baltimore, MD.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Tremblay-Mercier', 'Affiliation': 'From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montréal, Canada; and John Hopkins University (J.L.), Baltimore, MD.'}, {'ForeName': 'Jeannie', 'Initials': 'J', 'LastName': 'Leoutsakos', 'Affiliation': 'From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montréal, Canada; and John Hopkins University (J.L.), Baltimore, MD.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Madjar', 'Affiliation': 'From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montréal, Canada; and John Hopkins University (J.L.), Baltimore, MD.'}, {'ForeName': 'Marie-Élyse', 'Initials': 'MÉ', 'LastName': 'Lafaille-Maignan', 'Affiliation': 'From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montréal, Canada; and John Hopkins University (J.L.), Baltimore, MD.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Savard', 'Affiliation': 'From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montréal, Canada; and John Hopkins University (J.L.), Baltimore, MD.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Rosa-Neto', 'Affiliation': 'From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montréal, Canada; and John Hopkins University (J.L.), Baltimore, MD.'}, {'ForeName': 'Judes', 'Initials': 'J', 'LastName': 'Poirier', 'Affiliation': 'From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montréal, Canada; and John Hopkins University (J.L.), Baltimore, MD.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Etienne', 'Affiliation': 'From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montréal, Canada; and John Hopkins University (J.L.), Baltimore, MD.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Breitner', 'Affiliation': 'From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montréal, Canada; and John Hopkins University (J.L.), Baltimore, MD. john.breitner@mcgill.ca.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Neurology,['10.1212/WNL.0000000000007232'] 542,31082267,Impact of a Lung Cancer Screening Information Film on Informed Decision-making: A Randomized Trial.,"Rationale: Lung cancer screening has the potential to save lives, but it also carries a risk of potential harms. Explaining the benefits and harms of screening in a way that is balanced and comprehensible to individuals with various levels of education is essential. Although a shared decision-making approach is mandated by the Centers for Medicare & Medicaid Services, there have been no randomized studies to evaluate the impact of different forms of lung screening information. Objectives: To evaluate the impact of a novel information film on informed decision-making in individuals considering participating in lung cancer screening. Methods: A subset of participants from LSUT (Lung Screen Uptake Trial) were randomly allocated either to view the information film and receive a written information booklet or to receive the booklet alone. The primary outcome was the objective knowledge score after intervention. Secondary outcomes included subjective knowledge, decisional conflict, final screening participation, and acceptability of the materials. Univariate and multivariate analyses were performed to determine differences in pre- and postintervention knowledge scores in both groups and between groups for the primary and secondary outcomes. Results: In the final analysis of 229 participants, both groups showed significantly improved subjective and objective knowledge scores after intervention. This improvement was greatest in the film + booklet group, where mean objective knowledge improved by 2.16 points (standard deviation [SD] 1.8) compared with 1.84 points (SD 1.9) in the booklet-alone group (β coefficient 0.62; confidence interval, 0.17-1.08; P = 0.007 in the multivariable analysis). Mean subjective knowledge increased by 0.92 points (SD 1.0) in the film + booklet group and 0.55 points (SD 1.1) in the booklet-alone group (β coefficient 0.32; CI, 0.05-0.58; P = 0.02 in the multivariable analysis). Decisional certainty was higher in the film + booklet (mean 8.5/9 points [SD 1.3], group than in the booklet-alone group (mean 8.2/9 points [SD 1.5]). Both information materials were well accepted, and there were no differences in final screening participation rates between groups. Conclusions: The information film improved knowledge and reduced decisional conflict without affecting lung-screening uptake. Clinical trial registered with clinicaltrials.gov (NCT02558101).",2019,Univariate and multivariate analyses were performed to determine differences in pre- and postintervention knowledge scores in both groups and between groups for the primary and secondary outcomes. ,"['participants from LSUT (Lung Screen Uptake Trial', 'individuals considering participating in lung cancer screening']","['view the information film and receive a written information booklet or to receive the booklet alone', 'Lung Cancer Screening Information Film']","['objective knowledge score', 'mean objective knowledge', 'Mean subjective knowledge', 'pre- and postintervention knowledge scores', 'subjective knowledge, decisional conflict, final screening participation, and acceptability of the materials', 'Decisional certainty', 'subjective and objective knowledge scores']","[{'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0281477', 'cui_str': 'Lung cancer screening (procedure)'}]","[{'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C4319646', 'cui_str': 'Film'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0281477', 'cui_str': 'Lung cancer screening (procedure)'}]","[{'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0231394', 'cui_str': 'Decisional conflict (finding)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0439543', 'cui_str': 'Certainties (qualifier value)'}]",229.0,0.114202,Univariate and multivariate analyses were performed to determine differences in pre- and postintervention knowledge scores in both groups and between groups for the primary and secondary outcomes. ,"[{'ForeName': 'Mamta', 'Initials': 'M', 'LastName': 'Ruparel', 'Affiliation': '1 Lungs for Living Research Centre, UCL Respiratory, and.'}, {'ForeName': 'Samantha L', 'Initials': 'SL', 'LastName': 'Quaife', 'Affiliation': '2 Research Department of Behavioural Science and Health, University College London, London, United Kingdom.'}, {'ForeName': 'Bhagabati', 'Initials': 'B', 'LastName': 'Ghimire', 'Affiliation': '3 Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, United Kingdom.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Dickson', 'Affiliation': '1 Lungs for Living Research Centre, UCL Respiratory, and.'}, {'ForeName': 'Angshu', 'Initials': 'A', 'LastName': 'Bhowmik', 'Affiliation': '4 Department of Thoracic Medicine, Homerton University Hospital, London, United Kingdom.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Navani', 'Affiliation': '1 Lungs for Living Research Centre, UCL Respiratory, and.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Baldwin', 'Affiliation': '6 Respiratory Medicine Unit, David Evans Research Centre, Nottingham University Hospitals, Nottingham, United Kingdom.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Duffy', 'Affiliation': '3 Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, United Kingdom.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Waller', 'Affiliation': '2 Research Department of Behavioural Science and Health, University College London, London, United Kingdom.'}, {'ForeName': 'Sam M', 'Initials': 'SM', 'LastName': 'Janes', 'Affiliation': '1 Lungs for Living Research Centre, UCL Respiratory, and.'}]",Annals of the American Thoracic Society,['10.1513/AnnalsATS.201811-841OC'] 543,29893246,The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agents.,"Tenofovir disoproxil fumarate combined with emtricitabine is a highly effective oral pre-exposure prophylaxis (PrEP) agent for preventing the acquisition of HIV. This effectiveness has consequences for the design and analysis of trials assessing experimental PrEP regimens, which now generally include an active-control tenofovir disoproxil fumarate plus emtricitabine group, rather than a placebo group, as a comparator. Herein, we describe major problems in the interpretation of the primary measure of effectiveness proposed for these trials, namely the ratio of HIV incidence in the experimental agent group to that in the active-control group. We argue that valid interpretation requires an assumption about one of two parameters: either the incidence among trial participants had they not received PrEP or the effectiveness of tenofovir disoproxil fumarate plus emtricitabine within the trial. However, neither parameter is directly observed because of the absence of a no-treatment group, thus requiring the use of external evidence or subjective judgment. We propose an alternative measure of effectiveness based on the concept of averted infections, which incorporates one of these parameters. The measure is simple to interpret, has clinical and public health relevance, and is a natural preservation-of-effect criterion for assessing statistical non-inferiority. Its adoption could also allow the use of smaller sample sizes, currently a major barrier to the assessment of experimental PrEP regimens.",2018,"The measure is simple to interpret, has clinical and public health relevance, and is a natural preservation-of-effect criterion for assessing statistical non-inferiority.",[],"['Tenofovir disoproxil fumarate combined with emtricitabine', 'tenofovir disoproxil fumarate plus emtricitabine', 'placebo']",[],[],"[{'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]",[],,0.040053,"The measure is simple to interpret, has clinical and public health relevance, and is a natural preservation-of-effect criterion for assessing statistical non-inferiority.","[{'ForeName': 'David T', 'Initials': 'DT', 'LastName': 'Dunn', 'Affiliation': 'Medical Research Council Clinical Trials Unit, University College London, London, UK; Institute for Global Health, University College London, London, UK. Electronic address: d.dunn@ucl.ac.uk.'}, {'ForeName': 'David V', 'Initials': 'DV', 'LastName': 'Glidden', 'Affiliation': 'Division of Biostatistics, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Oliver T', 'Initials': 'OT', 'LastName': 'Stirrup', 'Affiliation': 'Institute for Global Health, University College London, London, UK.'}, {'ForeName': 'Sheena', 'Initials': 'S', 'LastName': 'McCormack', 'Affiliation': 'Medical Research Council Clinical Trials Unit, University College London, London, UK.'}]",The lancet. HIV,['10.1016/S2352-3018(18)30045-6'] 544,31971419,Context and craving among individuals with alcohol use disorder attempting to moderate their drinking.,"Many individuals with alcohol use disorder (AUD) prefer a goal of moderation, because they do not see their drinking as causing severe enough consequences to merit abstinence. Given that individuals attempting to moderate will continue to put themselves in contexts where drinking occurs, understanding how distinct external alcohol cues prompt craving is important for implementing the optimal treatments for individuals with AUD. Using data from a randomized controlled trial of stepped care brief interventions for AUD, this study explored the relationship between drinking contexts and craving in individuals attempting to moderate their drinking using ecological momentary assessment (EMA). At baseline, participants were asked to prospectively identify drinking contexts that were particularly likely to elicit intense craving and heavy drinking, called highly valued drinking contexts (HVCs). During EMA, participants were asked to report three times a day (morning, afternoon, evening) on their non-mutually exclusive contexts and their level of craving. Using multilevel modeling, all drinking contexts were tested as concurrent predictors of craving across the 84 days of the study. Next, AUD severity was tested as a moderator of HVC on craving. Results demonstrated that being in an HVC corresponded to greater reports of any craving and intensity of craving, over and above the influences of several other contextual factors (e.g., negative affect and already drinking). AUD severity significantly moderated HVC's impact on any craving, such that greater AUD severity potentiated HVC's already high odds of any craving. Implications for treatments for individuals with AUD are discussed. (PsycINFO Database Record (c) 2020 APA, all rights reserved).",2020,"AUD severity significantly moderated HVC's impact on any craving, such that greater AUD severity potentiated HVC's already high odds of any craving.","['individuals with AUD', 'Many individuals with alcohol use disorder (AUD', 'individuals attempting to moderate their drinking using ecological momentary assessment (EMA', 'individuals with alcohol use disorder attempting to moderate their drinking']",[],['craving and intensity of craving'],"[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0001956', 'cui_str': 'Alcohol Use Disorder'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C4277684', 'cui_str': 'Ecological Momentary Assessment'}, {'cui': 'C0268596', 'cui_str': 'Glutaric Acidemia, Type 2'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}]",[],"[{'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}]",,0.0153291,"AUD severity significantly moderated HVC's impact on any craving, such that greater AUD severity potentiated HVC's already high odds of any craving.","[{'ForeName': 'Alexis N', 'Initials': 'AN', 'LastName': 'Kuerbis', 'Affiliation': 'Silberman School of Social Work.'}, {'ForeName': 'Sijing', 'Initials': 'S', 'LastName': 'Shao', 'Affiliation': 'Center for Addiction Services and Psychotherapy Research.'}, {'ForeName': 'Hayley', 'Initials': 'H', 'LastName': 'Treloar Padovano', 'Affiliation': 'Department of Psychiatry and Human Behavior.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Jadanova', 'Affiliation': 'Center for Addiction Services and Psychotherapy Research.'}, {'ForeName': 'Danusha', 'Initials': 'D', 'LastName': 'Selva Kumar', 'Affiliation': 'Center for Addiction Services and Psychotherapy Research.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Vitale', 'Affiliation': 'Center for Addiction Services and Psychotherapy Research.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Nitzburg', 'Affiliation': 'Center for Addiction Services and Psychotherapy Research.'}, {'ForeName': 'Nehal P', 'Initials': 'NP', 'LastName': 'Vadhan', 'Affiliation': 'Center for Addiction Services and Psychotherapy Research.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Morgenstern', 'Affiliation': 'Center for Addiction Services and Psychotherapy Research.'}]",Experimental and clinical psychopharmacology,['10.1037/pha0000349'] 545,31969687,Co-development of a physiotherapist-delivered physical activity intervention for adults with spinal cord injury.,"STUDY DESIGNS Cross-sectional survey, semi-structured interview, and randomized-controlled trial. OBJECTIVES Optimal spinal cord injury (SCI)-specific PA intervention strategies appropriate for the physiotherapist setting are unknown. The purpose of this paper is to describe the rigorous co-development process of a theory-based, physiotherapist-led PA intervention for people with SCI and assess its feasibility for implementation in the rehabilitation setting. SETTING Community. METHODS Co-development of the intervention included (1) a review of the literature; (2) key informant interviews with people with SCI (n = 26); (3) a national online survey of physiotherapists' barriers, needs, and preferences (n = 239); (4) a review of the evidence and recommendations for the intervention from a stakeholder expert panel (n = 13); and (5) a randomized controlled trial of intervention training and its effects on implementation determinants amongst physiotherapists (n = 20). RESULTS Almost 300 people with SCI and physiotherapists were engaged in the intervention development process. Optimal intervention delivery should be tailored and include (1) education on safety, PA guidelines, and behaviour change techniques, (2) referral to other peers, local programmes, and health professionals, and (3) adapted exercise prescriptions. Following intervention implementation training, physiotherapists demonstrated stronger tested and perceived knowledge, skills, resources, and confidence for promoting PA to people with SCI, ps < 0.05. CONCLUSIONS This development process serves as an example methodology for using theory to co-create a leisure-time physical activity behaviour change intervention tailored for people with SCI.",2020,"Following intervention implementation training, physiotherapists demonstrated stronger tested and perceived knowledge, skills, resources, and confidence for promoting PA to people with SCI, ps < 0.05. ","[""Co-development of the intervention included (1) a review of the literature; (2) key informant interviews with people with SCI (n\u2009=\u200926); (3) a national online survey of physiotherapists' barriers, needs, and preferences (n\u2009=\u2009239); (4"", '300 people with SCI and physiotherapists', 'people with SCI', 'adults with spinal cord injury', 'Community']","['physiotherapist-led PA intervention', 'physiotherapist-delivered physical activity intervention', 'intervention training']",[],"[{'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0699752', 'cui_str': 'Review of (contextual qualifier) (qualifier value)'}, {'cui': 'C0023866', 'cui_str': 'Literature'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapists'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0558295', 'cui_str': 'Preferences (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C2362565', 'cui_str': 'Physiotherapists'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]",[],,0.107125,"Following intervention implementation training, physiotherapists demonstrated stronger tested and perceived knowledge, skills, resources, and confidence for promoting PA to people with SCI, ps < 0.05. ","[{'ForeName': 'Jasmin K', 'Initials': 'JK', 'LastName': 'Ma', 'Affiliation': 'School of Health and Exercise Sciences, University of British Columbia, Kelowna, BC, Canada. Jasmin.ma@ubc.ca.'}, {'ForeName': 'Oren', 'Initials': 'O', 'LastName': 'Cheifetz', 'Affiliation': 'Hematology/Oncology Program, Hamilton Health Sciences, Hamilton, ON, Canada.'}, {'ForeName': 'Kendra R', 'Initials': 'KR', 'LastName': 'Todd', 'Affiliation': 'School of Health and Exercise Sciences, University of British Columbia, Kelowna, BC, Canada.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Chebaro', 'Affiliation': 'Neurocore Physiotherapy & Pilates Centre, Richmond Hill, ON, Canada.'}, {'ForeName': 'Sen Hoong', 'Initials': 'SH', 'LastName': 'Phang', 'Affiliation': 'Propel Physiotherapy, Toronto, ON, Canada.'}, {'ForeName': 'Robert B', 'Initials': 'RB', 'LastName': 'Shaw', 'Affiliation': 'School of Health and Exercise Sciences, University of British Columbia, Kelowna, BC, Canada.'}, {'ForeName': 'Kyle J', 'Initials': 'KJ', 'LastName': 'Whaley', 'Affiliation': 'Propel Physiotherapy, Toronto, ON, Canada.'}, {'ForeName': 'Kathleen A', 'Initials': 'KA', 'LastName': 'Martin Ginis', 'Affiliation': 'School of Health and Exercise Sciences, University of British Columbia, Kelowna, BC, Canada.'}]",Spinal cord,['10.1038/s41393-020-0422-x'] 546,31868666,Comparative Cognitive Effects of Choreographed Exercise and Multimodal Physical Therapy in Older Adults with Amnestic Mild Cognitive Impairment: Randomized Clinical Trial.,"BACKGROUND Recent research on mild cognitive impairment (MCI) has primarily focused on searching for measures to prevent or delay the progression of MCI to dementia. Physical exercise has shown to be effective in the prevention of age-related cognitive decline in elderly adults with MCI. However, the most effective type and dose of exercise for the improvement of cognition are yet to be determined. OBJECTIVE To compare the cognitive effects of choreographed exercise (Choreography group) with a multimodal physical therapy program (Physical Therapy group) in elderly adults with amnestic MCI, a population with an increased risk of developing dementia. METHODS We conducted a randomized clinical trial with two parallel groups under allocation concealment and assessor blinding. Participants were allocated into Choreography or Physical Therapy group and performed exercises twice per week in 60-minute sessions during 12 weeks. RESULTS Thirty-six participants with amnestic MCI, ages 65 to 85, were assessed at baseline and after 12 weeks of intervention, by comprehensive validated neuropsychological and physical assessments. A Repeated measures General Lineal Model showed statistically significant differences in cognitive and physical outcomes. Both groups significantly improved in visual delayed recall. The Choreography group exhibited significantly more benefits on verbal recognition memory than the Physical Therapy group. CONCLUSION Greater cognitive benefits were achieved in the choreographic intervention than in the multimodal physical therapy, mainly in those functions more related to the risk of conversion to dementia. Additional studies are needed to confirm whether the observed effects are related to delayed onset of Alzheimer's disease in elderly adults with amnestic MCI.",2020,"CONCLUSION Greater cognitive benefits were achieved in the choreographic intervention than in the multimodal physical therapy, mainly in those functions more related to the risk of conversion to dementia.","['elderly adults with MCI', 'elderly adults with amnestic MCI', 'Older Adults with Amnestic Mild Cognitive Impairment', 'mild cognitive impairment (MCI', 'elderly adults with amnestic MCI, a population with an increased risk of developing dementia']","['Choreography or Physical Therapy group and performed exercises', 'choreographic intervention', 'Choreographed Exercise and Multimodal Physical Therapy', 'choreographed exercise (Choreography group) with a multimodal physical therapy program (Physical Therapy group', 'Physical exercise']","['cognitive benefits', 'visual delayed recall', 'verbal recognition memory', 'cognitive and physical outcomes']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0560005', 'cui_str': 'millicurie'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}]","[{'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0524637', 'cui_str': 'Recognition (Psychology)'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}]",36.0,0.0546262,"CONCLUSION Greater cognitive benefits were achieved in the choreographic intervention than in the multimodal physical therapy, mainly in those functions more related to the risk of conversion to dementia.","[{'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Bisbe', 'Affiliation': 'Department of Physical Therapy and Nursing of Blanquerna School of Health Sciences, Ramon Llull University, Barcelona, Spain.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Fuente-Vidal', 'Affiliation': 'Research Group on Methodology, Methods, Models and Outcomes of Health and Social Sciences (M3O), University of Vic, Barcelona, Spain.'}, {'ForeName': 'Elisabet', 'Initials': 'E', 'LastName': 'López', 'Affiliation': 'Department of Psychology of Blanquerna Faculty of Psychology, Education and Sports Sciences, Ramon Llull University, Barcelona, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Moreno', 'Affiliation': 'Physical Therapy Ambulatory Service, Barcelona, Spain.'}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Naya', 'Affiliation': 'Physical Therapy Ambulatory Service, Barcelona, Spain.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'de Benetti', 'Affiliation': 'Physical Therapy Ambulatory Service, Barcelona, Spain.'}, {'ForeName': 'Raimon', 'Initials': 'R', 'LastName': 'Milà', 'Affiliation': 'Department of Physical Therapy and Nursing of Blanquerna School of Health Sciences, Ramon Llull University, Barcelona, Spain.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Bruna', 'Affiliation': 'Department of Psychology of Blanquerna Faculty of Psychology, Education and Sports Sciences, Ramon Llull University, Barcelona, Spain.'}, {'ForeName': 'Mercè', 'Initials': 'M', 'LastName': 'Boada', 'Affiliation': 'Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades. Universitat Internacional de Catalunya, Barcelona, Spain.'}, {'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Alegret', 'Affiliation': 'Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades. Universitat Internacional de Catalunya, Barcelona, Spain.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-190552'] 547,31388720,Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease.,"PURPOSE To compare the incremental diagnostic value of amyloid-PET and CSF (Aβ42, tau, and phospho-tau) in AD diagnosis in patients with mild cognitive impairment (MCI) or mild dementia, in order to improve the definition of diagnostic algorithm. METHODS Two independent dementia experts provided etiological diagnosis and relative diagnostic confidence in 71 patients on 3 rounds, based on (1) clinical, neuropsychological, and structural MRI information alone; (2) adding one biomarker (CSF amyloid and tau levels or amyloid-PET with a balanced randomized design); and (3) adding the other biomarker. RESULTS Among patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P = 0.028) and 3 (CSF 0%; PET 78%, P < 0.001); PET induced a diagnostic confidence increase significantly higher than CSF on both rounds 2 and 3. CONCLUSIONS Amyloid-PET should be prioritized over CSF biomarkers in the diagnostic workup of patients investigated for suspected AD, as it provides greater changes in diagnosis and diagnostic confidence. TRIAL REGISTRATION EudraCT no.: 2014-005389-31.",2020,"Among patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P = 0.028) and 3 (CSF 0%; PET 78%, P < 0.001); PET induced a diagnostic confidence increase significantly higher than CSF on both rounds 2 and 3. CONCLUSIONS Amyloid-PET should be prioritized over CSF biomarkers in the diagnostic workup of patients investigated for suspected AD, as it provides greater changes in diagnosis and diagnostic confidence. ","['Two independent dementia experts provided etiological diagnosis and relative diagnostic confidence in 71 patients on 3 rounds, based on (1) clinical, neuropsychological, and structural MRI information alone; (2) adding one biomarker (CSF amyloid and tau levels or amyloid-PET with a balanced randomized design); and (3) adding the other biomarker', 'patients with mild cognitive impairment (MCI) or mild dementia']","['EudraCT', 'amyloid-PET and CSF (Aβ42, tau, and phospho-tau', 'amyloid-PET versus CSF']","['diagnostic confidence', 'diagnostic changes']","[{'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C1720655', 'cui_str': 'Tau'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C3494623', 'cui_str': 'Mild dementia'}]","[{'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}, {'cui': 'C1720655', 'cui_str': 'Tau'}]","[{'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",,0.0645688,"Among patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P = 0.028) and 3 (CSF 0%; PET 78%, P < 0.001); PET induced a diagnostic confidence increase significantly higher than CSF on both rounds 2 and 3. CONCLUSIONS Amyloid-PET should be prioritized over CSF biomarkers in the diagnostic workup of patients investigated for suspected AD, as it provides greater changes in diagnosis and diagnostic confidence. ","[{'ForeName': 'Matteo Cotta', 'Initials': 'MC', 'LastName': 'Ramusino', 'Affiliation': 'Memory Clinic and LANVIE -Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Chemin du Petit Bel-Air 2, Bâtiment Voirons, CH1225, Geneva, Switzerland. matteo.cottaramusino01@universitadipavia.it.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Garibotto', 'Affiliation': 'NIMTlab, Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, CH1205, Geneva, Switzerland.'}, {'ForeName': 'Ruggero', 'Initials': 'R', 'LastName': 'Bacchin', 'Affiliation': 'Memory Clinic and LANVIE -Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Chemin du Petit Bel-Air 2, Bâtiment Voirons, CH1225, Geneva, Switzerland.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Altomare', 'Affiliation': 'Memory Clinic and LANVIE -Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Chemin du Petit Bel-Air 2, Bâtiment Voirons, CH1225, Geneva, Switzerland.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Dodich', 'Affiliation': 'NIMTlab, Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, CH1205, Geneva, Switzerland.'}, {'ForeName': 'Frederic', 'Initials': 'F', 'LastName': 'Assal', 'Affiliation': 'Memory Clinic and LANVIE -Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Chemin du Petit Bel-Air 2, Bâtiment Voirons, CH1225, Geneva, Switzerland.'}, {'ForeName': 'Aline', 'Initials': 'A', 'LastName': 'Mendes', 'Affiliation': 'Memory Clinic and LANVIE -Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Chemin du Petit Bel-Air 2, Bâtiment Voirons, CH1225, Geneva, Switzerland.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Costa', 'Affiliation': 'Center for Cognitive and Behavioral Disorders, IRCCS Mondino Foundation and Dept of Brain and Behavior, University of Pavia, 27100, Pavia, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Tinazzi', 'Affiliation': 'Dept of Neurosciences, Biomedicine and Movement Sciences, Section of Neurology, University of Verona, 34134, Verona, Italy.'}, {'ForeName': 'Silvia D', 'Initials': 'SD', 'LastName': 'Morbelli', 'Affiliation': 'Nuclear Medicine, Dept of Health Sciences (DISSAL), University of Genoa and IRCCS AOU San Martino-IST, 16132, Genoa, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Bauckneht', 'Affiliation': 'Nuclear Medicine, Dept of Health Sciences (DISSAL), University of Genoa and IRCCS AOU San Martino-IST, 16132, Genoa, Italy.'}, {'ForeName': 'Agnese', 'Initials': 'A', 'LastName': 'Picco', 'Affiliation': 'Clinical Neurology, Dept. of Neuroscience (DINOGMI), University of Genoa, 16126, Genoa, Italy.'}, {'ForeName': 'Massimo E', 'Initials': 'ME', 'LastName': 'Dottorini', 'Affiliation': 'Nuclear Medicine Division, ""S. Maria della Misericordia"" Hospital, 06129, Perugia, Italy.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Tranfaglia', 'Affiliation': 'Nuclear Medicine Division, ""S. Maria della Misericordia"" Hospital, 06129, Perugia, Italy.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Farotti', 'Affiliation': 'Center for Memory Disturbances, Laboratory of Clinical Neurochemistry, University of Perugia, 06123, Perugia, Italy.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Salvadori', 'Affiliation': 'Center for Memory Disturbances, Laboratory of Clinical Neurochemistry, University of Perugia, 06123, Perugia, Italy.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Moretti', 'Affiliation': ""Alzheimer's Disease Operative Unit, IRCCS S, Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.""}, {'ForeName': 'Giordano', 'Initials': 'G', 'LastName': 'Savelli', 'Affiliation': 'Nuclear Medicine Division, Fondazione Poliambulanza Istituto Ospedaliero, 25124, Brescia, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Tarallo', 'Affiliation': ""LANE-Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.""}, {'ForeName': 'Flavio', 'Initials': 'F', 'LastName': 'Nobili', 'Affiliation': 'Clinical Neurology, Dept. of Neuroscience (DINOGMI), University of Genoa, 16126, Genoa, Italy.'}, {'ForeName': 'Maura', 'Initials': 'M', 'LastName': 'Parapini', 'Affiliation': 'Memory Clinic and LANVIE -Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Chemin du Petit Bel-Air 2, Bâtiment Voirons, CH1225, Geneva, Switzerland.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Cavaliere', 'Affiliation': 'IRCCS SDN, 80143, Naples, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Salvatore', 'Affiliation': 'University of Naples ""Federico II"", 80131, Naples, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Salvatore', 'Affiliation': 'IRCCS SDN, 80143, Naples, Italy.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Boccardi', 'Affiliation': 'Memory Clinic and LANVIE -Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Chemin du Petit Bel-Air 2, Bâtiment Voirons, CH1225, Geneva, Switzerland.'}, {'ForeName': 'Giovanni B', 'Initials': 'GB', 'LastName': 'Frisoni', 'Affiliation': 'Memory Clinic and LANVIE -Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Chemin du Petit Bel-Air 2, Bâtiment Voirons, CH1225, Geneva, Switzerland.'}]",European journal of nuclear medicine and molecular imaging,['10.1007/s00259-019-04466-6'] 548,30239552,Limited appearance of apocarotenoids is observed in plasma after consumption of tomato juices: a randomized human clinical trial.,"Background Nonvitamin A apocarotenoids occur in foods. Some function as retinoic acid receptor antagonists in vitro, though it is unclear if apocarotenoids are absorbed or accumulate to levels needed to elicit biological function. Objective The aim of this study was to quantify carotenoids and apocarotenoids (β-apo-8'-, -10'-, -12'-, and -14'-carotenal, apo-6'-, -8'-, -10'-, -12'-, and -14'-lycopenal, retinal, acycloretinal, β-apo-13-carotenone, and apo-13-lycopenone) in human plasma after controlled consumption of carotenoid-rich tomato juices. Design Healthy subjects (n = 35) consumed a low-carotenoid diet for 2 wk, then consumed 360 mL of high-β-carotene tomato juice (30.4 mg of β-carotene, 34.5 μg total β-apocarotenoids/d), high-lycopene tomato juice (42.5 mg of lycopene, 119.2 μg total apolycopenoids/d), or a carotenoid-free control (cucumber juice) per day for 4 wk. Plasma was sampled at baseline (after washout) and after 2 and 4 wk, and analyzed for carotenoids and apocarotenoids using high-pressure liquid chromatography (HPLC) and HPLC-tandem mass spectrometry, respectively. The methods used to analyze the apocarotenoids had limits of detection of ∼ 100 pmol/L. Results Apocarotenoids are present in tomato juices at 0.1-0.5% of the parent carotenoids. Plasma lycopene and β-carotene increased (P < 0.001) after consuming high-lycopene and β-carotene tomato juices, respectively, while retinol remained unchanged. β-Apo-13-carotenone was found in the blood of all subjects at every visit, although elevated (P < 0.001) after consuming β-carotene tomato juice for 4 wk (1.01 ± 0.27 nmol/L) compared with both baseline (0.37 ± 0.17 nmol/L) and control (0.46 ± 0.11 nmol/L). Apo-6'-lycopenal was detected or quantifiable in 29 subjects, while β-apo-10'- and 12'-carotenal were detected in 6 and 2 subjects, respectively. No other apolycopenoids or apocarotenoids were detected. Conclusions β-Apo-13-carotenone was the only apocarotenoid that was quantifiable in all subjects, and was elevated in those consuming high-β-carotene tomato juice. Levels were similar to previous reports of all-trans-retinoic acid. Other apocarotenoids are either poorly absorbed or rapidly metabolized or cleared, and so are absent or limited in blood. β-Apo-13-carotenone may form from vitamin A and its presence warrants further investigation. This trial was registered at clinicaltrials.gov as NCT02550483.",2018,"Plasma lycopene and β-carotene increased (P < 0.001) after consuming high-lycopene and β-carotene tomato juices, respectively, while retinol remained unchanged.",['Healthy subjects (n\xa0=\xa035'],"['β-Apo-13-carotenone', ""carotenoids and apocarotenoids (β-apo-8'-, -10'-, -12'-, and -14'-carotenal, apo-6'-, -8'-, -10'-, -12'-, and -14'-lycopenal, retinal, acycloretinal, β-apo-13-carotenone, and apo-13-lycopenone"", 'low-carotenoid diet for 2 wk, then consumed 360 mL of high-β-carotene tomato juice (30.4 mg of β-carotene, 34.5 μg total β-apocarotenoids/d), high-lycopene tomato juice (42.5 mg of lycopene, 119.2 μg total apolycopenoids/d), or a carotenoid-free control (cucumber juice']","['Plasma lycopene and β-carotene', 'Plasma']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0007271', 'cui_str': 'Carotenes and Carotenoids'}, {'cui': 'C0035331', 'cui_str': 'Retinal'}, {'cui': 'C0968442', 'cui_str': 'acycloretinal'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C4319607', 'cui_str': '360 (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0373568', 'cui_str': 'Carotene measurement (procedure)'}, {'cui': 'C0452460', 'cui_str': 'tomato juice'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0065331', 'cui_str': 'lycopene'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C3256210', 'cui_str': 'cucumber juice'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0065331', 'cui_str': 'lycopene'}, {'cui': 'C0373568', 'cui_str': 'Carotene measurement (procedure)'}]",,0.0505027,"Plasma lycopene and β-carotene increased (P < 0.001) after consuming high-lycopene and β-carotene tomato juices, respectively, while retinol remained unchanged.","[{'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Cooperstone', 'Affiliation': 'Horticulture and Crop Sciences, The Ohio State University, Columbus, OH.'}, {'ForeName': 'Janet A', 'Initials': 'JA', 'LastName': 'Novotny', 'Affiliation': 'USDA Agricultural Research Service, Beltsville Human Nutrition Research Center, Beltsville, MD.'}, {'ForeName': 'Ken M', 'Initials': 'KM', 'LastName': 'Riedl', 'Affiliation': 'Food Science and Technology, The Ohio State University, Columbus, OH.'}, {'ForeName': 'Morgan J', 'Initials': 'MJ', 'LastName': 'Cichon', 'Affiliation': 'Food Science and Technology, The Ohio State University, Columbus, OH.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Francis', 'Affiliation': 'Horticulture and Crop Sciences, The Ohio State University, Columbus, OH.'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Curley', 'Affiliation': 'Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, OH.'}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Schwartz', 'Affiliation': 'Food Science and Technology, The Ohio State University, Columbus, OH.'}, {'ForeName': 'Earl H', 'Initials': 'EH', 'LastName': 'Harrison', 'Affiliation': 'Human Sciences, Human Nutrition, The Ohio State University, Columbus, OH.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqy177'] 549,31958976,Evaluating the Feasibility of Implementing an HIV Prevention Intervention for Incarcerated African American Men: Lessons Learned From a Pilot Study.,"This pilot study evaluated the feasibility of implementing an evidence-based, culturally adapted HIV intervention with substance-using African American men in a prison setting. We recruited 60, soon-to-be released African American male prisoners from a larger study ( N = 211) to be randomly selected for participation in the group-based HIV intervention, Real Men Are Safe-Culturally Adapted (REMAS-CA). Participants who were not selected for participation in the intervention received standard Centers for Disease Control and Prevention HIV prevention counseling education, provided during participant assessment in the larger study. Nearly all of the participants who were selected to participate (87%) completed the REMAS-CA intervention. To examine feasibility, data were collected about any revisions made to the HIV intervention components for the prison setting, time needed to implement the program in full, details of implementing the intervention to ensure participation and maintain retention, and participant perception of the intervention. Revisions to the intervention included reducing the number of sessions from five to three, modifying the protocol language based on the setting, and removing six activities deemed inappropriate and/or unallowable by the prison officials. The cultural considerations and intervention, overall, were well received by the participants. However, several revisions made specific to the prison and its administration could affect the potential effectiveness of the intervention. Future research is needed to determine the effectiveness of REMAS-CA among this community.",2020,"This pilot study evaluated the feasibility of implementing an evidence-based, culturally adapted HIV intervention with substance-using African American men in a prison setting.","['We recruited 60, soon-to-be released African American male prisoners from a larger study ( N = 211', 'African American men in a prison setting', 'Participants who were not selected for participation in the intervention received', 'Incarcerated African American Men']","['standard Centers for Disease Control and Prevention HIV prevention counseling education', 'HIV Prevention Intervention', 'HIV intervention, Real Men Are Safe-Culturally Adapted (REMAS-CA', 'REMAS-CA intervention']",[],"[{'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0033167', 'cui_str': 'Prisoners'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0033168', 'cui_str': 'Prisons'}, {'cui': 'C0036849', 'cui_str': 'Set'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0007670', 'cui_str': 'CDC'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]",[],,0.0185619,"This pilot study evaluated the feasibility of implementing an evidence-based, culturally adapted HIV intervention with substance-using African American men in a prison setting.","[{'ForeName': 'Carlos C', 'Initials': 'CC', 'LastName': 'Mahaffey', 'Affiliation': 'Oklahoma State University, Stillwater, OK, USA.'}, {'ForeName': 'Danelle', 'Initials': 'D', 'LastName': 'Stevens-Watkins', 'Affiliation': 'University of Kentucky, Lexington, KY, USA.'}, {'ForeName': 'A Kathleen', 'Initials': 'AK', 'LastName': 'Burlew', 'Affiliation': 'University of Cincinnati, Cincinnati, OH, USA.'}, {'ForeName': 'Myles D', 'Initials': 'MD', 'LastName': 'Moody', 'Affiliation': 'University of Kentucky, Lexington, KY, USA.'}, {'ForeName': 'Paris B', 'Initials': 'PB', 'LastName': 'Wheeler', 'Affiliation': 'University of Kentucky, Lexington, KY, USA.'}, {'ForeName': 'Shawndaya', 'Initials': 'S', 'LastName': 'Thrasher', 'Affiliation': 'University of Kentucky, Lexington, KY, USA.'}]",Health promotion practice,['10.1177/1524839919896786'] 550,31954998,Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.,"OBJECTIVE This post hoc analysis of six randomized, double-blind, Phase II and III studies evaluated efficacy and safety of adjunctive perampanel (2-12 mg/day) in adolescent patients (aged ≥12 to ≤17 years) with uncontrolled partial-onset seizures, with or without secondarily generalized (SG) seizures, or primary generalized tonic-clonic (PGTC) seizures. METHODS Adolescent patients from Studies 304 (NCT00699972), 305 (NCT00699582), 306 (NCT00700310), 335 (NCT01618695), 235 (NCT01161524), and 332 (NCT01393743) were included. Efficacy assessments (split by seizure type) included median percent change in seizure frequency per 28 days from baseline and seizure-freedom rates. Safety assessments (all seizure types combined) included monitoring of treatment-emergent adverse events (TEAEs). RESULTS The Safety Analysis Set included 372 adolescent patients (placebo, n = 114; perampanel, n = 258); the Full Analysis Set included 346 patients with partial-onset seizures (placebo, n = 103; perampanel, n = 243), of whom 125 experienced SG seizures during baseline (placebo, n = 37; perampanel, n = 88), and 22 with PGTC seizures (placebo, n = 9; perampanel, n = 13). Compared with placebo, perampanel 8 and 12 mg/day conferred greater median percent reductions in seizure frequency per 28 days for partial-onset seizures (18.0% vs 35.9% and 53.8% [both P < 0.01]) and SG seizures (24.4% vs 72.8% [P < 0.001] and 57.8% [P < 0.01]), and greater seizure-freedom rates (partial-onset: 7.8% vs 13.2% and 11.8% [not statistically significant]; SG: 8.1% vs 40.7% [P < 0.001] and 41.7% [P < 0.01]). For PGTC seizures, and compared with placebo, perampanel 8 mg/day was also associated with greater median percent reductions in seizure frequency per 28 days (29.8% vs 88.0%) and greater seizure-freedom rates (11.1% vs 23.1%). Treatment-emergent adverse events were reported in 76 (66.7%) placebo- and 192 (74.4%) perampanel-treated patients (most common: dizziness, somnolence, headache, and nasopharyngitis). Serious TEAEs occurred in 5 (4.4%) placebo- and 11 (4.3%) perampanel-treated patients. CONCLUSIONS Adjunctive perampanel was efficacious and generally well tolerated in adolescent patients with partial-onset, SG, or PGTC seizures and represents a potentially beneficial treatment option for adolescents with uncontrolled epilepsy.",2020,"Compared with placebo, perampanel 8 and 12 mg/day conferred greater median percent reductions in seizure frequency per 28 days for partial-onset seizures (18.0% vs 35.9% and 53.8% [both P < 0.01]) and SG seizures (24.4% vs 72.8% [P < 0.001] and 57.8% [P < 0.01]), and greater seizure-freedom rates (partial-onset: 7.8% vs 13.2% and 11.8% [not statistically significant]; SG: 8.1% vs 40.7% [P < 0.001] and 41.7% [P ","['adolescents with uncontrolled epilepsy', 'adolescent patients (aged ≥12 to ≤17\u202fyears) with uncontrolled partial-onset seizures, with or without secondarily generalized (SG) seizures, or primary generalized tonic-clonic (PGTC) seizures', 'adolescent patients with partial-onset, SG, or PGTC seizures', 'Adolescent patients from Studies 304 (NCT00699972), 305 (NCT00699582), 306 (NCT00700310), 335 (NCT01618695), 235 (NCT01161524), and 332 (NCT01393743) were included', 'adolescent patients with epilepsy', '372 adolescent patients (placebo, n\u202f=\u202f114; perampanel, n\u202f=\u202f258); the Full Analysis Set included 346 patients with partial-onset seizures (placebo, n\u202f=\u202f103; perampanel, n\u202f=\u202f243), of whom 125 experienced SG seizures during baseline (placebo, n\u202f=\u202f37; perampanel, n\u202f=\u202f88), and 22 with']","['placebo', 'perampanel', 'PGTC seizures (placebo, n\u202f=\u202f9; perampanel', 'placebo, perampanel', 'adjunctive perampanel']","['partial-onset seizures', 'Treatment-emergent adverse events', 'monitoring of treatment-emergent adverse events (TEAEs', 'Efficacy and safety', 'Serious TEAEs', 'seizure frequency', 'SG seizures', 'seizure-freedom rates', 'dizziness, somnolence, headache, and nasopharyngitis']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0270838', 'cui_str': 'Secondarily generalized seizures'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0494475', 'cui_str': 'Generalized Tonic-Clonic Seizures'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4517703', 'cui_str': 'Three hundred and five'}, {'cui': 'C4709307', 'cui_str': '335'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4708785', 'cui_str': 'One hundred and fourteen'}, {'cui': 'C2698764', 'cui_str': 'perampanel'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C4517526', 'cui_str': 'One hundred and three'}, {'cui': 'C4319551', 'cui_str': 'One hundred and twenty-five'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2698764', 'cui_str': 'perampanel'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}]","[{'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C2830004', 'cui_str': 'Somnolence'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}]",372.0,0.745167,"Compared with placebo, perampanel 8 and 12 mg/day conferred greater median percent reductions in seizure frequency per 28 days for partial-onset seizures (18.0% vs 35.9% and 53.8% [both P < 0.01]) and SG seizures (24.4% vs 72.8% [P < 0.001] and 57.8% [P < 0.01]), and greater seizure-freedom rates (partial-onset: 7.8% vs 13.2% and 11.8% [not statistically significant]; SG: 8.1% vs 40.7% [P < 0.001] and 41.7% [P ","[{'ForeName': 'J Eric', 'Initials': 'JE', 'LastName': 'Piña-Garza', 'Affiliation': ""The Children's Hospital at TriStar Centennial, 330 23rd Avenue North, Suite 580, Nashville, TN 37203, USA. Electronic address: jesus.pinagarza@hcahealthcare.com.""}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Rosenfeld', 'Affiliation': 'Comprehensive Epilepsy Care Center for Children and Adults, 11134 Conway Road, St. Louis, MO 63131, USA. Electronic address: werosenfeld@msn.com.'}, {'ForeName': 'Kazunori', 'Initials': 'K', 'LastName': 'Saeki', 'Affiliation': 'Eisai Co., Ltd., 4-6-10, Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan. Electronic address: k-saeki@hhc.eisai.co.jp.'}, {'ForeName': 'Vicente', 'Initials': 'V', 'LastName': 'Villanueva', 'Affiliation': 'Hospital Universitario y Politécnico La Fe, Avinguda de Fernando Abril Martorell 106, 46026, Valencia, Spain. Electronic address: vevillanuevah@yahoo.es.'}, {'ForeName': 'Harumi', 'Initials': 'H', 'LastName': 'Yoshinaga', 'Affiliation': 'National Hospital Organization, Minami-Okayama Medical Center, 4066 Hayashimacho Hayashima, Tsukubo-gun, Okayama 701-0304, Japan. Electronic address: magenta@md.okayama-u.ac.jp.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Patten', 'Affiliation': 'Eisai Ltd., Mosquito Way, Hatfield, Hertfordshire AL10 9SN, UK. Electronic address: Anna_Patten@eisai.net.'}, {'ForeName': 'Betsy', 'Initials': 'B', 'LastName': 'Williams', 'Affiliation': 'Formerly: Eisai Inc., 100 Tice Blvd, Woodcliff Lake, NJ 07677, USA. Electronic address: betsy.williams@iqvia.com.'}, {'ForeName': 'Manoj', 'Initials': 'M', 'LastName': 'Malhotra', 'Affiliation': 'Eisai Inc., 100 Tice Blvd, Woodcliff Lake, NJ 07677, USA. Electronic address: manoj_malhotra@eisai.com.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2019.106876'] 551,31292183,"Thiamine dose response in human milk with supplementation among lactating women in Cambodia: study protocol for a double-blind, four-parallel arm randomised controlled trial.","INTRODUCTION Thiamine (vitamin B1) deficiency remains a concern in Cambodia where women with low thiamine intake produce thiamine-poor milk, putting their breastfed infants at risk of impaired cognitive development and potentially fatal infantile beriberi. Thiamine fortification of salt is a potentially low-cost, passive means of combating thiamine deficiency; however, both the dose of thiamine required to optimise milk thiamine concentrations as well as usual salt intake of lactating women are unknown. METHODS AND ANALYSIS In this community-based randomised controlled trial, 320 lactating women from Kampong Thom, Cambodia will be randomised to one of four groups to consume one capsule daily containing 0, 1.2, 2.4 or 10 mg thiamine as thiamine hydrochloride, between 2 and 24 weeks postnatal. The primary objective is to estimate the dose where additional maternal intake of thiamine no longer meaningfully increases infant thiamine diphosphate concentrations 24 weeks postnatally. At 2, 12 and 24 weeks, we will collect sociodemographic, nutrition and health information, a battery of cognitive assessments, maternal (2 and 24 weeks) and infant (24 weeks only) venous blood samples (biomarkers: ThDP and transketolase activity) and human milk samples (also at 4 weeks; biomarker: milk thiamine concentrations). All participants and their families will consume study-provided salt ad libitum throughout the trial, and we will measure salt disappearance each fortnight. Repeat weighed salt intakes and urinary sodium concentrations will be measured among a subset of 100 participants. Parameters of E max dose-response curves will be estimated using non-linear least squares models with both 'intention to treat' and a secondary 'per-protocol' (capsule compliance ≥80%) analyses. ETHICS AND DISSEMINATION Ethical approval was obtained in Cambodia (National Ethics Committee for Health Research 112/250NECHR), Canada (Mount Saint Vincent University Research Ethics Board 2017-141) and the USA (University of Oregon Institutional Review Board 07052018.008). Results will be shared with participants' communities, as well as relevant government and scientific stakeholders via presentations, academic manuscripts and consultations. TRIAL REGISTRATION NUMBER NCT03616288.",2019,"Ethical approval was obtained in Cambodia (National Ethics Committee for Health Research 112/250NECHR), Canada (Mount Saint Vincent University Research Ethics Board 2017-141) and the USA (University of Oregon Institutional Review Board 07052018.008).","['human milk with supplementation among lactating women in Cambodia', '320 lactating women from Kampong Thom, Cambodia']","['thiamine as thiamine hydrochloride', 'Thiamine', 'Thiamine fortification of salt']",[],"[{'cui': 'C0026140', 'cui_str': 'Breast Milk'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0006797', 'cui_str': 'Khmer Republic'}, {'cui': 'C4517711', 'cui_str': '320 (qualifier value)'}]","[{'cui': 'C0373727', 'cui_str': 'Vitamin B-1 measurement'}, {'cui': 'C0770309', 'cui_str': 'Thiamine hydrochloride'}, {'cui': 'C0036140', 'cui_str': 'Salts'}]",[],100.0,0.319086,"Ethical approval was obtained in Cambodia (National Ethics Committee for Health Research 112/250NECHR), Canada (Mount Saint Vincent University Research Ethics Board 2017-141) and the USA (University of Oregon Institutional Review Board 07052018.008).","[{'ForeName': 'Kyly C', 'Initials': 'KC', 'LastName': 'Whitfield', 'Affiliation': 'Mount Saint Vincent University, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Hou', 'Initials': 'H', 'LastName': 'Kroeun', 'Affiliation': 'Helen Keller International Cambodia, Phnom Penh, Cambodia.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Green', 'Affiliation': 'South Australian Health & Medical Research Institute, Adelaide, Australia.'}, {'ForeName': 'Frank T', 'Initials': 'FT', 'LastName': 'Wieringa', 'Affiliation': 'UMR-204 Nutripass, Institut de Recherche pour le Développement, UM/IRD/Supagro, Montpellier, France.'}, {'ForeName': 'Mam', 'Initials': 'M', 'LastName': 'Borath', 'Affiliation': 'National Sub-Committee for Food Fortification, Cambodia Ministry of Planning, Phnom Penh, Cambodia.'}, {'ForeName': 'Prak', 'Initials': 'P', 'LastName': 'Sophonneary', 'Affiliation': 'National Nutrition Programme, Maternal and Child Health Centre, Cambodia Ministry of Health, Phnom Penh, Cambodia.'}, {'ForeName': 'Jeffrey R', 'Initials': 'JR', 'LastName': 'Measelle', 'Affiliation': 'Department of Psychology, University of Oregon, Eugene, Oregon, USA.'}, {'ForeName': 'Dare', 'Initials': 'D', 'LastName': 'Baldwin', 'Affiliation': 'Department of Psychology, University of Oregon, Eugene, Oregon, USA.'}, {'ForeName': 'Lisa N', 'Initials': 'LN', 'LastName': 'Yelland', 'Affiliation': 'South Australian Health & Medical Research Institute, Adelaide, Australia.'}, {'ForeName': 'Shalem', 'Initials': 'S', 'LastName': 'Leemaqz', 'Affiliation': 'South Australian Health & Medical Research Institute, Adelaide, Australia.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Chan', 'Affiliation': 'Mount Saint Vincent University, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Jelisa', 'Initials': 'J', 'LastName': 'Gallant', 'Affiliation': 'Mount Saint Vincent University, Halifax, Nova Scotia, Canada.'}]",BMJ open,['10.1136/bmjopen-2019-029255'] 552,31780589,Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction).,"INTRODUCTION Antipsychotic medication is effective in reducing acute symptoms of psychosis, but it has a range of potentially serious and debilitating adverse effects and is often disliked by patients. It is therefore essential it is only used when benefits outweigh harms. Although multiple trials conducted with people with schizophrenia indicate an increased risk of relapse in the short-term following abrupt antipsychotic discontinuation, there is little evidence about the long-term outcome of a gradual process of reduction and discontinuation on social functioning, relapse and other outcomes. METHODS AND ANALYSIS This is a multicentre, randomised controlled trial involving people with schizophrenia and related disorders who have had more than one episode. Participants are randomised to have a clinically-supervised, gradual reduction of antipsychotic medication, leading to discontinuation when possible, or to continue with maintenance treatment. Blinded follow-up assessments are conducted at 6, 12 and 24 months and the primary outcome is social functioning, measured by the Social Functioning Scale at 24 months. A minimum of 134 evaluable participants provides 90% power to detect a five-point difference, and 206 to detect a four-point difference. Secondary outcomes include severe relapse (admission to hospital) and the study is also intended to detect a minimum 10% difference in severe relapse, which requires 402 participants, assuming a 15% loss to follow-up. Other secondary outcomes include all relapses, as identified by an independent and blinded endpoint committee, symptoms measured by the Positive and Negative Syndrome Scale, quality of life, adverse effects, self-rated recovery and neuropsychological measures. Enrolment started in 2016. The trial is scheduled to finish in June 2022. ETHICS AND DISSEMINATION Ethical approval was initially obtained on 27 October 2016 (UK Research Ethics Committee reference 16/LO/1507). Results will be published in peer-reviewed journals and disseminated to the public. TRIAL REGISTRATION NUMBER ISRCTN90298520. EudraCT: 2016-000709-36. Pre-results.",2019,"Although multiple trials conducted with people with schizophrenia indicate an increased risk of relapse in the short-term following abrupt antipsychotic discontinuation, there is little evidence about the long-term outcome of a gradual process of reduction and discontinuation on social functioning, relapse and other outcomes. ","['people with schizophrenia and related disorders', 'people with schizophrenia and related disorders who have had more than one episode', '134 evaluable participants']","['EudraCT', 'Antipsychotic medication', 'gradual antipsychotic reduction and discontinuation']","['social functioning, measured by the Social Functioning Scale', 'severe relapse', 'all relapses, as identified by an independent and blinded endpoint committee, symptoms measured by the Positive and Negative Syndrome Scale, quality of life, adverse effects, self-rated recovery and neuropsychological measures', 'severe relapse (admission to hospital', 'risk of relapse']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C4517565', 'cui_str': 'One hundred and thirty-four'}]","[{'cui': 'C0040615', 'cui_str': 'Antipsychotic Drugs'}, {'cui': 'C0439833', 'cui_str': 'Gradual (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]","[{'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C2585826', 'cui_str': 'Social functioning scale (assessment scale)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale (assessment scale)'}, {'cui': 'C0034380'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission (procedure)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",402.0,0.166369,"Although multiple trials conducted with people with schizophrenia indicate an increased risk of relapse in the short-term following abrupt antipsychotic discontinuation, there is little evidence about the long-term outcome of a gradual process of reduction and discontinuation on social functioning, relapse and other outcomes. ","[{'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Moncrieff', 'Affiliation': 'Division of Psychiatry, University College London and North East London NHS Foundation Trust, London, UK j.moncrieff@ucl.ac.uk.'}, {'ForeName': 'Glyn', 'Initials': 'G', 'LastName': 'Lewis', 'Affiliation': 'Division of Psychiatry, University College London, London, UK.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Freemantle', 'Affiliation': 'Institute for Clinical Trials and Methodology, University College London, London, UK.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Johnson', 'Affiliation': 'Division of Psychiatry, University College London, London, UK.'}, {'ForeName': 'Thomas R E', 'Initials': 'TRE', 'LastName': 'Barnes', 'Affiliation': 'Division of Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Morant', 'Affiliation': 'Division of Psychiatry, University College London, London, UK.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Pinfold', 'Affiliation': 'McPin Foundation, London, UK.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Hunter', 'Affiliation': 'Research Department of Primary Care and Population Health, University College London, London, UK.'}, {'ForeName': 'Lyn J', 'Initials': 'LJ', 'LastName': 'Kent', 'Affiliation': 'Independent consultant, Brentwood, UK.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Smith', 'Affiliation': 'Independent consultant, Brighton, UK.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Darton', 'Affiliation': 'Independent consultant, London, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Horne', 'Affiliation': 'School of Pharmacy, University College London, London, UK.'}, {'ForeName': 'Nadia E', 'Initials': 'NE', 'LastName': 'Crellin', 'Affiliation': 'Division of Psychiatry, University College London, London, UK.'}, {'ForeName': 'Ruth E', 'Initials': 'RE', 'LastName': 'Cooper', 'Affiliation': 'Unit for Social and Community Psychiatry, Queen Mary University of London, London, UK.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Priebe', 'Affiliation': 'Unit for Social and Community Psychiatry, Queen Mary University of London, London, UK.'}]",BMJ open,['10.1136/bmjopen-2019-030912'] 553,30932360,Early Magnetic Resonance Imaging-Based Changes in Patients With Meniscal Tear and Osteoarthritis: Eighteen-Month Data From a Randomized Controlled Trial of Arthroscopic Partial Meniscectomy Versus Physical Therapy.,"OBJECTIVE The present study was undertaken to evaluate changes in knee magnetic resonance imaging (MRI) findings over the course of 18 months in subjects with osteoarthritic change and meniscal tear treated with arthroscopic partial meniscectomy (APM) or nonoperatively with physical therapy (PT). METHODS We used 18-month follow-up data from the Meniscal Tear in Osteoarthritis Research Trial. MRI results were read with reference to the MRI Osteoarthritis Knee Score. We focused on 18-month change in bone marrow lesions (BMLs), cartilage thickness, cartilage surface area, osteophyte size, effusion-synovitis, and Hoffa-synovitis. We used multinomial logistic regression to assess associations between MRI-based changes in each feature and treatment type. RESULTS A total of 351 subjects were randomized, and 225 had both baseline and 18-month MRI results. In both treatment groups, patients experienced substantial changes in several MRI-based markers. In 60% of the APM group, versus 33% of the PT group, cartilage surface area damage advanced in ≥2 subregions (adjusted odds ratio 4.2 [95% confidence interval 2.0-9.0). Patients who underwent APM also had greater advancement in scores for osteophytes and effusion-synovitis. We did not find significant associations between treatment type and change in cartilage thickness, BMLs, or Hoffa-synovitis. CONCLUSION This cohort of patients with meniscal tear and osteoarthritis showed marked advancement in MRI-based features over 18 months. Patients treated with APM showed more advancement in some features compared to those treated nonoperatively. The clinical relevance of these early findings is unknown and requires further study.",2020,"We did not find significant associations between treatment type and change in cartilage thickness, BMLs, or Hoffa-synovitis. ","['Patients with Meniscal Tear and Osteoarthritis', '351 subjects were randomized and 225 had both baseline and 18-month MRI', 'subjects with osteoarthritic change (OA) and meniscal tear (MT) treated with']","['arthroscopic partial meniscectomy (APM) or non-operatively with physical therapy (PT', 'APM']","['cartilage thickness, BMLs, or Hoffa-synovitis', 'cartilage surface area damage advanced in ≥2 subregions', 'MRI OA Knee Score (MOAKS', 'bone marrow lesions (BMLs), cartilage thickness, cartilage surface area, osteophytes size, effusion-synovitis, and Hoffa-synovitis']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}, {'cui': 'C4517652', 'cui_str': '225 (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0187901', 'cui_str': 'Meniscal Resection'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}]","[{'cui': 'C0007301', 'cui_str': 'Cartilage'}, {'cui': 'C0039103', 'cui_str': 'Synovitis'}, {'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0010957', 'cui_str': 'Damage (morphologic abnormality)'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis, Knee'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0005953', 'cui_str': 'Bone Marrow'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C1956089', 'cui_str': 'Bone Spur'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0013687', 'cui_str': 'Effusion (morphologic abnormality)'}]",351.0,0.0360848,"We did not find significant associations between treatment type and change in cartilage thickness, BMLs, or Hoffa-synovitis. ","[{'ForeName': 'Jamie E', 'Initials': 'JE', 'LastName': 'Collins', 'Affiliation': ""Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Losina', 'Affiliation': ""Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Marx', 'Affiliation': 'Weill Cornell Medicine, Hospital for Special Surgery, New York, New York.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Guermazi', 'Affiliation': 'Boston University School of Medicine, Boston, Massachusetts.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Jarraya', 'Affiliation': 'Boston University School of Medicine, Boston, Massachusetts, and Mercy Catholic Medical Center, Darby, Pennsylvania.'}, {'ForeName': 'Morgan H', 'Initials': 'MH', 'LastName': 'Jones', 'Affiliation': 'Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Bruce A', 'Initials': 'BA', 'LastName': 'Levy', 'Affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Mandl', 'Affiliation': 'Weill Cornell Medicine, Hospital for Special Surgery, New York, New York.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Martin', 'Affiliation': 'Massachusetts General Hospital, Boston.'}, {'ForeName': 'Rick W', 'Initials': 'RW', 'LastName': 'Wright', 'Affiliation': 'Washington University School of Medicine, St. Louis, Missouri.'}, {'ForeName': 'Kurt P', 'Initials': 'KP', 'LastName': 'Spindler', 'Affiliation': 'Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Jeffrey N', 'Initials': 'JN', 'LastName': 'Katz', 'Affiliation': ""Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Arthritis care & research,['10.1002/acr.23891'] 554,31112737,Mindfulness-based group intervention in adolescents at-risk for excess weight gain: A randomized controlled pilot study.,"OBJECTIVES To assess feasibility/acceptability of a mindfulness-based approach to excess weight prevention in adolescents at-risk for excess weight gain. To pilot test efficacy of a mindfulness-based intervention for improving food reward sensitivity, stress-eating, executive function (EF), and BMI/adiposity. METHODS A pilot randomized controlled trial was conducted with 12-17y adolescents at-risk for excess weight gain based on above-average weight (body mass index [BMI]≥70%ile) or parental history of obesity (BMI≥30 kg/m 2 ). Adolescents were randomized to a mindfulness-based (n = 29) or health education control group (n = 25) that met for six weekly one-hour sessions. Feasibility/acceptability were determined from attendance and acceptability survey ratings. At baseline, six-week and six-month follow-up, adolescents' perceived stress was measured with the Perceived Stress Scale, food reward sensitivity with a behavioral task, stress-eating during a laboratory test meal, and EF with the parent-reported Behavior Rating Inventory of Executive Function and NIH Toolbox. At the same intervals, BMI indices and body fat by air displacement plethysmography were assessed in a fasted state. RESULTS Median session attendance was 6:6 sessions in both conditions; program acceptability ratings were above-average. Compared to health education, adolescents in mindfulness had lower food reward sensitivity at six-months (Cohen's d = 0.64, p = .01). There were no between-condition differences in BMI (mindfulness vs. health education Δsix-months 95%CI 0.20, 1.52 kg/m 2 vs. 0.21, 1.62 kg/m 2 ) or adiposity (-3.64, -0.61% vs. -4.31, -1.04%) changes. CONCLUSIONS A mindfulness-based group intervention is feasible/acceptable among adolescents at-risk for excess weight. In this pilot sample, mindfulness and health education were equivocal for BMI/adiposity outcomes. Future trials with a larger, adequately-powered sample and longer-term follow-up are necessary to test efficacy of a mindfulness-based intervention for food reward sensitivity, stress-eating, EF, and stabilizing growth trajectories in youth at-risk for adult obesity.",2019,"Compared to health education, adolescents in mindfulness had lower food reward sensitivity at six-months (Cohen's d = 0.64, p = .01).","['adolescents at-risk for excess weight gain', 'youth at-risk for adult obesity', '12-17y adolescents at-risk for excess weight gain based on above-average weight (body mass index [BMI]≥70%ile) or parental history of obesity (BMI≥30\u202fkg/m 2 ', 'Adolescents']","['Mindfulness-based group intervention', 'mindfulness-based intervention', 'mindfulness-based (n\u202f=\u202f29) or health education control group', 'mindfulness-based approach to excess weight prevention']","['Perceived Stress Scale, food reward sensitivity with a behavioral task, stress-eating during a laboratory test meal, and EF with the parent-reported Behavior Rating Inventory of Executive Function and NIH Toolbox', 'BMI', 'adiposity', 'food reward sensitivity', 'food reward sensitivity, stress-eating, executive function (EF), and BMI/adiposity', 'Feasibility/acceptability', 'BMI indices and body fat by air displacement plethysmography']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0455493', 'cui_str': 'H/O: obesity'}]","[{'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0018701'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}]","[{'cui': 'C0582653', 'cui_str': 'Perceived stress scale (assessment scale)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0022885', 'cui_str': 'Laboratory test (procedure)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C1563743', 'cui_str': 'Adiposis'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0456080', 'cui_str': 'Displacement (attribute)'}, {'cui': 'C0032221', 'cui_str': 'Plethysmography'}]",,0.0646146,"Compared to health education, adolescents in mindfulness had lower food reward sensitivity at six-months (Cohen's d = 0.64, p = .01).","[{'ForeName': 'Lauren B', 'Initials': 'LB', 'LastName': 'Shomaker', 'Affiliation': 'Human Development & Family Studies, Colorado State University, 1570 Campus Delivery, Fort Collins, CO, 80523, United States; Community & Behavioral Health, Colorado School of Public Health, 13001 E. 17th Pl, Aurora, CO, 80045, United States. Electronic address: lauren.shomaker@colostate.edu.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Berman', 'Affiliation': 'Human Development & Family Studies, Colorado State University, 1570 Campus Delivery, Fort Collins, CO, 80523, United States.'}, {'ForeName': 'Morgan', 'Initials': 'M', 'LastName': 'Burke', 'Affiliation': 'Human Development & Family Studies, Colorado State University, 1570 Campus Delivery, Fort Collins, CO, 80523, United States.'}, {'ForeName': 'Shelly K', 'Initials': 'SK', 'LastName': 'Annameier', 'Affiliation': 'Human Development & Family Studies, Colorado State University, 1570 Campus Delivery, Fort Collins, CO, 80523, United States.'}, {'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'Pivarunas', 'Affiliation': 'Human Development & Family Studies, Colorado State University, 1570 Campus Delivery, Fort Collins, CO, 80523, United States.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Sanchez', 'Affiliation': 'Community & Behavioral Health, Colorado School of Public Health, 13001 E. 17th Pl, Aurora, CO, 80045, United States.'}, {'ForeName': 'Amy D', 'Initials': 'AD', 'LastName': 'Smith', 'Affiliation': 'Human Development & Family Studies, Colorado State University, 1570 Campus Delivery, Fort Collins, CO, 80523, United States.'}, {'ForeName': 'Silas', 'Initials': 'S', 'LastName': 'Hendrich', 'Affiliation': 'Human Development & Family Studies, Colorado State University, 1570 Campus Delivery, Fort Collins, CO, 80523, United States.'}, {'ForeName': 'Nathaniel R', 'Initials': 'NR', 'LastName': 'Riggs', 'Affiliation': 'Human Development & Family Studies, Colorado State University, 1570 Campus Delivery, Fort Collins, CO, 80523, United States.'}, {'ForeName': 'Kristina T', 'Initials': 'KT', 'LastName': 'Legget', 'Affiliation': 'Psychiatry, School of Medicine, Anschutz Medical Campus, University of Colorado, 13001 E. 17th Pl, Aurora, CO, 80045, United States.'}, {'ForeName': 'Marc-Andre', 'Initials': 'MA', 'LastName': 'Cornier', 'Affiliation': 'Division of Endocrinology, Metabolism & Diabetes, Department of Medicine, School of Medicine, Anschutz Medical Campus, University of Colorado, 13001 E. 17th Pl, Aurora, CO, 80045, Aurora, CO, United States.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Melby', 'Affiliation': 'Food Science & Human Nutrition, Colorado State University, 1571 Campus Delivery, Fort Collins, CO, 80523, United States.'}, {'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'Johnson', 'Affiliation': 'Food Science & Human Nutrition, Colorado State University, 1571 Campus Delivery, Fort Collins, CO, 80523, United States.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Lucas-Thompson', 'Affiliation': 'Human Development & Family Studies, Colorado State University, 1570 Campus Delivery, Fort Collins, CO, 80523, United States.'}]",Appetite,['10.1016/j.appet.2019.05.022'] 555,31015317,"Beliefs About Advanced Cancer Curability in Older Patients, Their Caregivers, and Oncologists.","BACKGROUND Ensuring older patients with advanced cancer and their oncologists have similar beliefs about curability is important. We investigated discordance in beliefs about curability in patient-oncologist and caregiver-oncologist dyads. MATERIALS AND METHODS We used baseline data from a cluster randomized trial assessing whether geriatric assessment improves communication and quality of life in older patients with advanced cancer and their caregivers. Patients were aged ≥70 years with incurable cancer from community oncology practices. Patients, caregivers, and oncologists were asked: ""What do you believe are the chances the cancer will go away and never come back with treatment?"" Options were 100%, >50%, 50/50, <50%, and 0% (5-point scale). Discordance in beliefs about curability was defined as any difference in scale scores (≥3 points were severe). We used multivariate logistic regressions to describe correlates of discordance. RESULTS Discordance was present in 60% (15% severe) of the 336 patient-oncologist dyads and 52% (16% severe) of the 245 caregiver-oncologist dyads. Discordance was less common in patient-oncologist dyads when oncologists practiced longer (adjusted odds ratio [AOR] 0.90, 95% confidence interval [CI] 0.84-0.97) and more common in non-Hispanic white patients (AOR 5.77, CI 1.90-17.50) and when patients had lung (AOR 1.95, CI 1.29-2.94) or gastrointestinal (AOR 1.55, CI 1.09-2.21) compared with breast cancer. Severe discordance was more common when patients were non-Hispanic white, had lower income, and had impaired social support. Caregiver-oncologist discordance was more common when caregivers were non-Hispanic white (AOR 3.32, CI 1.01-10.94) and reported lower physical health (AOR 0.88, CI 0.78-1.00). Severe discordance was more common when caregivers had lower income and lower anxiety level. CONCLUSION Discordance in beliefs about curability is common, occasionally severe, and correlated with patient, caregiver, and oncologist characteristics. IMPLICATIONS FOR PRACTICE Ensuring older patients with advanced cancer and their caregivers have similar beliefs about curability as the oncologist is important. This study investigated discordance in beliefs about curability in patient-oncologist (PO) and caregiver-oncologist (CO) dyads. It found that discordance was present in 60% (15% severe) of PO dyads and 52% (16% severe) of CO dyads, raising serious questions about the process by which patients consent to treatment. This study supports the need for interventions targeted at the oncologist, patient, caregiver, and societal levels to improve the delivery of prognostic information and patients'/caregivers' understanding and acceptance of prognosis.",2019,"Discordance was less common in patient-oncologist dyads when oncologists practiced longer (adjusted odds ratio [AOR] 0.90, 95% confidence interval [CI] 0.84-0.97) and more common in non-Hispanic white patients (AOR 5.77, CI 1.90-17.50) and when patients had lung (AOR 1.95, CI 1.29-2.94) or gastrointestinal (AOR 1.55, CI 1.09-2.21) compared with breast cancer.","['older patients with advanced cancer', 'patient-oncologist and caregiver-oncologist dyads', 'older patients with advanced cancer and', 'older patients with advanced cancer and their caregivers', 'patient-oncologist (PO) and caregiver-oncologist (CO) dyads', 'Patients were aged ≥70 years with incurable cancer from community oncology practices']",['geriatric assessment'],"['Caregiver-oncologist discordance', 'physical health', 'Severe discordance', 'communication and quality of life']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0259990', 'cui_str': 'Oncologists'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0017463', 'cui_str': 'Geriatric Assessment'}]","[{'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0259990', 'cui_str': 'Oncologists'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0034380'}]",,0.106975,"Discordance was less common in patient-oncologist dyads when oncologists practiced longer (adjusted odds ratio [AOR] 0.90, 95% confidence interval [CI] 0.84-0.97) and more common in non-Hispanic white patients (AOR 5.77, CI 1.90-17.50) and when patients had lung (AOR 1.95, CI 1.29-2.94) or gastrointestinal (AOR 1.55, CI 1.09-2.21) compared with breast cancer.","[{'ForeName': 'Kah Poh', 'Initials': 'KP', 'LastName': 'Loh', 'Affiliation': 'James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA kahpoh_loh@urmc.rochester.edu.'}, {'ForeName': 'Supriya G', 'Initials': 'SG', 'LastName': 'Mohile', 'Affiliation': 'James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Lund', 'Affiliation': 'University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Epstein', 'Affiliation': 'James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Lianlian', 'Initials': 'L', 'LastName': 'Lei', 'Affiliation': 'Department of Public Health Services, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Culakova', 'Affiliation': 'James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'McHugh', 'Affiliation': 'James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Wells', 'Affiliation': 'James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Nikesha', 'Initials': 'N', 'LastName': 'Gilmore', 'Affiliation': 'James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Mostafa R', 'Initials': 'MR', 'LastName': 'Mohamed', 'Affiliation': 'James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Kamen', 'Affiliation': 'James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Aarne', 'Affiliation': 'James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Conlin', 'Affiliation': 'Pacific Cancer Research Consortium NCORP, Seattle, Washington, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Bearden', 'Affiliation': 'Southeast Clinical Oncology Research Consortium NCORP, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Adedayo', 'Initials': 'A', 'LastName': 'Onitilo', 'Affiliation': 'Wisconsin NCORP, Weston, Wisconsin, USA.'}, {'ForeName': 'Marsha', 'Initials': 'M', 'LastName': 'Wittink', 'Affiliation': 'Department of Psychiatry, Palliative Care, University of Rochester Medical Center, Rochester, New York, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Dale', 'Affiliation': 'City of Hope National Medical Center, Duarte, California, USA.'}, {'ForeName': 'Arti', 'Initials': 'A', 'LastName': 'Hurria', 'Affiliation': 'City of Hope National Medical Center, Duarte, California, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Duberstein', 'Affiliation': 'Department of Psychiatry, Palliative Care, University of Rochester Medical Center, Rochester, New York, USA.'}]",The oncologist,['10.1634/theoncologist.2018-0890'] 556,30403772,Metabolic Effects of Breaking Prolonged Sitting With Standing or Light Walking in Older South Asians and White Europeans: A Randomized Acute Study.,"BACKGROUND Prolonged sitting is common in older adults and is associated with insulin resistance and poor cardiometabolic health. We investigate whether breaking prolonged sitting with regular short bouts of standing or light walking improves postprandial metabolism in older white European and South Asian adults and whether effects are modified by ethnic group. METHODS Thirty South Asian (15 women) and 30 white European (14 women) older adults (aged 65-79 years) undertook three experimental conditions in random order. (a) Prolonged sitting: continuous sitting during an observation period if 7.5 hours consuming two standardized mixed meals. (b) Standing breaks: sitting interrupted with 5 minutes of standing every 30 minutes (accumulating 60 minutes of standing over the observation period). (c) Walking breaks: sitting interrupted with 5 minutes of self-paced light walking every 30 minutes (accumulating 60 minutes of walking). Blood samples (glucose, insulin, triglycerides) and blood pressure were sampled regularly throughout each condition. RESULTS Compared with prolonged sitting, walking breaks lowered postprandial insulin by 16.3 mU/L, (95% CI: 19.7, 22.0) with greater reductions (p = .029) seen in South Asians (22.4 mU/L; 12.4, 32.4) than white Europeans (10.3 mU/L; 5.9, 14.7). Glucose (0.3 mmol/L; 0.1, 0.5) and blood pressure (4 mm Hg; 2, 6), but not triglycerides, were lower with walking breaks, with no ethnic differences. Standing breaks did not improve any outcome. CONCLUSIONS Breaking prolonged sitting with short bouts of light walking, but not standing, resulted in clinically meaningful improvements in markers of metabolic health in older adults, with South Asians gaining a greater reduction in postprandial insulin. TRIAL REGISTRATION NCT02453204.",2020,"Compared with prolonged sitting, walking breaks lowered postprandial insulin by 16.3 mU/l, (95% CI 19.7, 22.0) with greater reductions (p = 0.029) seen in South Asians (22.4 mU/l; 12.4, 32.4) than White Europeans (10.3 mU/l; 5.9, 14.7).","['Methods\n\n\nThirty South Asian (15 women) and 30 white European (14 women', 'older white European and South Asian adults', 'older adults', 'older adults (65-79 years) undertook three experimental conditions in random order', 'older South Asians and White Europeans']","['breaking prolonged sitting with standing or light walking', 'Walking Breaks: sitting interrupted with 5 mins of self-paced light walking every 30 mins (accumulating 60 mins of walking', 'Prolonged sitting', 'breaking prolonged sitting with regular short bouts of standing or light walking']","['postprandial insulin', 'postprandial metabolism', 'Blood samples (glucose, insulin, triglycerides) and blood pressure', 'blood pressure']","[{'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0239307', 'cui_str': 'European (ethnic group)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0041666', 'cui_str': 'Undertaking'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}]","[{'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0443239', 'cui_str': 'Interrupted (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}]","[{'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}]",30.0,0.0605649,"Compared with prolonged sitting, walking breaks lowered postprandial insulin by 16.3 mU/l, (95% CI 19.7, 22.0) with greater reductions (p = 0.029) seen in South Asians (22.4 mU/l; 12.4, 32.4) than White Europeans (10.3 mU/l; 5.9, 14.7).","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Yates', 'Affiliation': 'Diabetes Research Centre, College of Life Sciences, University of Leicester, Australia.'}, {'ForeName': 'Charlotte L', 'Initials': 'CL', 'LastName': 'Edwardson', 'Affiliation': 'Diabetes Research Centre, College of Life Sciences, University of Leicester, Australia.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Celis-Morales', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Australia.'}, {'ForeName': 'Stuart J H', 'Initials': 'SJH', 'LastName': 'Biddle', 'Affiliation': 'Institute for Resilient Regions, University of Southern Queensland, Springfield Central, Australia.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Bodicoat', 'Affiliation': 'Diabetes Research Centre, College of Life Sciences, University of Leicester, Australia.'}, {'ForeName': 'Melanie J', 'Initials': 'MJ', 'LastName': 'Davies', 'Affiliation': 'Diabetes Research Centre, College of Life Sciences, University of Leicester, Australia.'}, {'ForeName': 'Dale', 'Initials': 'D', 'LastName': 'Esliger', 'Affiliation': 'School of Sport, Exercise, and Health Sciences, Loughborough University, Birmingham.'}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'Henson', 'Affiliation': 'Diabetes Research Centre, College of Life Sciences, University of Leicester, Australia.'}, {'ForeName': 'Aadil', 'Initials': 'A', 'LastName': 'Kazi', 'Affiliation': 'Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Diabetes Frail Ltd and University of Aston, Birmingham.'}, {'ForeName': 'Kamesh', 'Initials': 'K', 'LastName': 'Khunti', 'Affiliation': 'Diabetes Research Centre, College of Life Sciences, University of Leicester, Australia.'}, {'ForeName': 'Naveed', 'Initials': 'N', 'LastName': 'Sattar', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Australia.'}, {'ForeName': 'Alan J', 'Initials': 'AJ', 'LastName': 'Sinclair', 'Affiliation': 'Foundation for Diabetes Research in Older People, Diabetes Frail Ltd and University of Aston, Birmingham.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Rowlands', 'Affiliation': 'Diabetes Research Centre, College of Life Sciences, University of Leicester, Australia.'}, {'ForeName': 'Latha', 'Initials': 'L', 'LastName': 'Velayudhan', 'Affiliation': ""Institute of Psychiatry, Psychology and Neurosciences, King's College London.""}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Zaccardi', 'Affiliation': 'Diabetes Research Centre, College of Life Sciences, University of Leicester, Australia.'}, {'ForeName': 'Jason M R', 'Initials': 'JMR', 'LastName': 'Gill', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Australia.'}]","The journals of gerontology. Series A, Biological sciences and medical sciences",['10.1093/gerona/gly252'] 557,30205231,Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study.,"We evaluated the feasibility of ruxolitinib therapy followed by a reduced-intensity conditioning (RIC) regimen for patients with myelofibrosis (MF) undergoing transplantation in a 2-stage Simon phase II trial. The aims were to decrease the incidence of graft failure (GF) and nonrelapse mortality (NRM) compared with data from the previous Myeloproliferative Disorders Research Consortium 101 Study. The plan was to enroll 11 patients each in related donor (RD) and unrelated donor (URD) arms, with trial termination if ≥3 failures (GF or death by day +100 post-transplant) occurred in the RD arm or ≥6 failures occurred in the URD. A total of 21 patients were enrolled, including 7 in the RD arm and 14 in the URD arm. The RD arm did not meet the predetermined criteria for proceeding to stage II. Although the URD arm met the criteria for stage II, the study was terminated owing to poor accrual and a significant number of failures. In all 19 transplant recipients, ruxolitinib was tapered successfully without significant side effects, and 9 patients (47%) had a significant decrease in symptom burden. The cumulative incidences of GF, NRM, acute graft-versus-host disease (GVHD), and chronic GVHD at 24 months were 16%, 28%, 64%, and 76%, respectively. On an intention-to-treat basis, the 2-year overall survival was 61% for the RD arm and 70% for the URD arm. Ruxolitinib can be integrated as pretransplantation treatment for patients with MF, and a tapering strategy before transplantation is safe, allowing patients to commence conditioning therapy with a reduced symptom burden. However, GF and NRM remain significant.",2019,The aims were to decrease the incidence of graft failure (GF) and nonrelapse mortality (NRM) compared with data from the previous Myeloproliferative Disorders Research Consortium 101 Study.,"['A total of 21 patients were enrolled, including 7 in the RD arm and 14 in the URD arm', 'patients with myelofibrosis (MF) undergoing transplantation in a 2-stage Simon phase II trial', 'patients with MF']","['Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning', 'ruxolitinib therapy followed by a reduced-intensity conditioning (RIC) regimen']","['2-year overall survival', 'symptom burden', 'incidence of graft failure (GF) and nonrelapse mortality (NRM', 'cumulative incidences of GF, NRM, acute graft-versus-host disease (GVHD), and chronic GVHD']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0001815', 'cui_str': 'Idiopathic Myelofibrosis'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0443058', 'cui_str': 'Simon (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}]","[{'cui': 'C2931926', 'cui_str': 'ruxolitinib'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1262018', 'cui_str': 'Transplant failure'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0856825', 'cui_str': 'Acute graft-versus-host disease (disorder)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0018133', 'cui_str': 'Homologous Wasting Disease'}]",21.0,0.060239,The aims were to decrease the incidence of graft failure (GF) and nonrelapse mortality (NRM) compared with data from the previous Myeloproliferative Disorders Research Consortium 101 Study.,"[{'ForeName': 'Vikas', 'Initials': 'V', 'LastName': 'Gupta', 'Affiliation': 'MPN Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. Electronic address: vikas.gupta@uhn.ca.'}, {'ForeName': 'Heidi E', 'Initials': 'HE', 'LastName': 'Kosiorek', 'Affiliation': 'Mayo Clinic Cancer Center, Phoenix, Arizona.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Mead', 'Affiliation': 'MRC Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, BRC Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Rebecca B', 'Initials': 'RB', 'LastName': 'Klisovic', 'Affiliation': 'Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Galvin', 'Affiliation': 'Feinberg School of Medicine, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Dmitriy', 'Initials': 'D', 'LastName': 'Berenzon', 'Affiliation': 'Comprehensive Cancer Center, Wake Forest School of Medicine, Winston Salem, North Carolina.'}, {'ForeName': 'Abdulraheem', 'Initials': 'A', 'LastName': 'Yacoub', 'Affiliation': 'University of Kansas Medical Hospital, Westwood, Kansas.'}, {'ForeName': 'Auro', 'Initials': 'A', 'LastName': 'Viswabandya', 'Affiliation': 'MPN Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Ruben A', 'Initials': 'RA', 'LastName': 'Mesa', 'Affiliation': 'Mayo Clinic Cancer Center, Phoenix, Arizona.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Goldberg', 'Affiliation': 'New York University School of Medicine, New York, New York.'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Price', 'Affiliation': 'New York University School of Medicine, New York, New York.'}, {'ForeName': 'Mohamed E', 'Initials': 'ME', 'LastName': 'Salama', 'Affiliation': 'Department of Pathology, University of Utah, Salt Lake City, Utah.'}, {'ForeName': 'Rona Singer', 'Initials': 'RS', 'LastName': 'Weinberg', 'Affiliation': 'New York Blood Center, New York, New York.'}, {'ForeName': 'Raajit', 'Initials': 'R', 'LastName': 'Rampal', 'Affiliation': 'Memorial Sloan-Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Noushin', 'Initials': 'N', 'LastName': 'Farnoud', 'Affiliation': 'Memorial Sloan-Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Amylou C', 'Initials': 'AC', 'LastName': 'Dueck', 'Affiliation': 'Mayo Clinic Cancer Center, Phoenix, Arizona.'}, {'ForeName': 'John O', 'Initials': 'JO', 'LastName': 'Mascarenhas', 'Affiliation': 'Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Hoffman', 'Affiliation': 'Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}]",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,['10.1016/j.bbmt.2018.09.001'] 558,31420412,TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).,"BACKGROUND Primary cytoreductive surgery followed by chemotherapy has been considered standard management for patients with advanced ovarian cancer over decades. An alternative approach of interval debulking surgery following neoadjuvant chemotherapy was subsequently reported by two randomized phase III trials (EORTC-GCG, CHORUS), which were criticized owing to important limitations, especially regarding the rate of complete resection. PRIMARY OBJECTIVE To clarify the optimal timing of surgical therapy in advanced ovarian cancer. STUDY HYPOTHESIS Primary cytoreductive surgery is superior to interval cytoreductive surgery following neoadjuvant chemotherapy for overall survival in patients with advanced ovarian cancer. TRIAL DESIGN TRUST is an international open, randomized, controlled multi-center trial investigating overall survival after primary cytoreductive surgery versus neoadjuvant chemotherapy and subsequent interval cytoreductive surgery in patients with FIGO stage IIIB-IVB ovarian, tubal, and peritoneal carcinoma. To guarantee adequate surgical quality, participating centers need to fulfill specific quality assurance criteria (eg, ≥50% complete resection rate in upfront surgery for FIGO IIIB-IVB patients, ≥36 debulking-surgeries/year) and agree to independent audits by TRUST quality committee delegates. Patients in the primary cytoreductive surgery arm undergo surgery followed by 6 cycles of platinum-based chemotherapy, whereas patients in the interval cytoreductive surgery arm undergo 3 cycles of neoadjuvant chemotherapy after histologic confirmation of the disease, followed by interval cytoreductive surgery and subsequently, 3 cycles of platinum-based chemotherapy. The intention of surgery for both groups is complete tumor resection according to guideline recommendations. MAJOR INCLUSION/EXCLUSION CRITERIA Major inclusion criteria are suspected or histologically confirmed, newly diagnosed invasive epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma FIGO stage IIIB-IVB (IV only if resectable metastasis). Major exclusion criteria are non-epithelial ovarian malignancies and borderline tumors; prior chemotherapy for ovarian cancer; or abdominal/pelvic radiotherapy. PRIMARY ENDPOINT Overall survival. SAMPLE SIZE 772 patients. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS Accrual completion approximately mid-2019, results are expected after 5 years' follow-up in 2024. TRIAL REGISTRATION NCT02828618.",2019,"Primary cytoreductive surgery is superior to interval cytoreductive surgery following neoadjuvant chemotherapy for overall survival in patients with advanced ovarian cancer. ","['772 patients', 'advanced ovarian cancer', 'advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7', 'Major inclusion criteria are suspected or histologically confirmed, newly diagnosed invasive epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma FIGO stage IIIB-IVB (IV only if resectable metastasis', 'patients with advanced ovarian cancer', 'patients with FIGO stage IIIB-IVB ovarian, tubal, and peritoneal carcinoma']","['Radical Upfront Surgical Therapy', 'interval cytoreductive surgery arm undergo 3 cycles of neoadjuvant chemotherapy', 'platinum-based chemotherapy', 'primary cytoreductive surgery arm undergo surgery followed by 6 cycles of platinum-based chemotherapy', 'interval debulking surgery following neoadjuvant chemotherapy', 'primary cytoreductive surgery versus neoadjuvant chemotherapy and subsequent interval cytoreductive surgery', 'interval cytoreductive surgery', 'neoadjuvant chemotherapy', 'surgical therapy', 'TRUST']","['Overall survival', 'overall survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1140680', 'cui_str': 'Ovary Cancer'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C0677886', 'cui_str': 'Carcinoma, Ovarian Epithelial'}, {'cui': 'C0015560', 'cui_str': 'Oviducts, Mammalian'}, {'cui': 'C0007097', 'cui_str': 'Epithelioma'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0948303', 'cui_str': 'Peritoneal carcinoma'}, {'cui': 'C0450454', 'cui_str': 'FIGO Stage'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}]","[{'cui': 'C0439807', 'cui_str': 'Radical - extent'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C3850079', 'cui_str': 'Cytoreductive Surgery'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1098768', 'cui_str': '(diethylenetriamine)-platinum(II)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C1706406', 'cui_str': 'Interventional debulking surgery (procedure)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0237935', 'cui_str': 'Trust'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",772.0,0.3548,"Primary cytoreductive surgery is superior to interval cytoreductive surgery following neoadjuvant chemotherapy for overall survival in patients with advanced ovarian cancer. ","[{'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Reuss', 'Affiliation': 'AGO Study Group and Coordinating Centre for Clinical Trials, Philipps-Universität Marburg, Marburg, Germany alexander.reuss@kks.uni-marburg.de.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'du Bois', 'Affiliation': 'AGO Study Group and Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte Evangelische Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Harter', 'Affiliation': 'AGO Study Group and Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte Evangelische Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Fotopoulou', 'Affiliation': 'AGO Study Group and West London Gynecological Cancer Centre; Imperial College Healthcare NHS Trust, London, UK.'}, {'ForeName': 'Jalid', 'Initials': 'J', 'LastName': 'Sehouli', 'Affiliation': 'AGO Study Group and Department of Gynecologic Oncology, Charite Comprehensive Cancer Center Berlin, Berlin, Germany.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Aletti', 'Affiliation': 'MANGO and Department of Gynecology, Istituto Europeo di Oncologia, Milano, Italy.'}, {'ForeName': 'Frederic', 'Initials': 'F', 'LastName': 'Guyon', 'Affiliation': 'GINECO and Institut Bergonie, Bordeaux, France.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Greggi', 'Affiliation': 'Department of Gynecologic Oncology Surgery, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.'}, {'ForeName': 'Berit Jul', 'Initials': 'BJ', 'LastName': 'Mosgaard', 'Affiliation': 'NSGO and Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Reinthaller', 'Affiliation': 'Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Hilpert', 'Affiliation': 'AGO Study Group and Mammazentrum am Krankenhaus Jerusalem, Hamburg, Germany.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Schade-Brittinger', 'Affiliation': 'AGO Study Group and Coordinating Centre for Clinical Trials, Philipps-Universität Marburg, Marburg, Germany.'}, {'ForeName': 'Dennis S', 'Initials': 'DS', 'LastName': 'Chi', 'Affiliation': 'AGO Study Group and Gynecology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Mahner', 'Affiliation': 'AGO Study Group and Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University Munich, Munich, Bayern, Germany.'}]",International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,['10.1136/ijgc-2019-000682'] 559,31980932,Tolvaptan can limit postoperative paroxysmal atrial fibrillation occurrence after open-heart surgery.,"PURPOSE Tolvaptan administration in the early postoperative period after cardiac surgery rapidly treats fluid retention without affecting the renal function. Tolvaptan also has the benefit of not stimulating the renin-angiotensin and sympathetic nervous systems, which are risk factors for postoperative paroxysmal atrial fibrillation. In this study, we examined the hypothesis that tolvaptan administration reduces postoperative paroxysmal atrial fibrillation and worsening of the renal function incidence in patients who have undergone open-heart surgery. METHODS From our previous randomized study, we selected 166 open-heart surgery patients, divided them into 2 groups [tolvaptan group, 83 patients; control (non-tolvaptan) group, 83 patients], and compared the incidence of postoperative paroxysmal atrial fibrillation and worsening of the renal function in the postoperative period between the groups. RESULTS The incidence of worsening of the renal function was significantly lower in the tolvaptan group than in the control group (4.8% vs. 15.7%; P = 0.04). The incidence of postoperative paroxysmal atrial fibrillation within 14 days was also significantly lower in the tolvaptan group than in the control group (26.5% vs. 42.2%; P = 0.011). CONCLUSION Tolvaptan administration in the early postoperative period after open-heart surgery may reduce the incidence of postoperative paroxysmal atrial fibrillation and worsening of the renal function.",2020,The incidence of worsening of the renal function was significantly lower in the tolvaptan group than in the control group (4.8% vs. 15.7%; P = 0.04).,"['166 open-heart surgery patients, divided them into 2 groups [tolvaptan group, 83 patients', 'patients who have undergone open-heart surgery']","['control (non-tolvaptan', 'Tolvaptan', 'tolvaptan']","['postoperative paroxysmal atrial fibrillation and worsening of the renal function', 'incidence of postoperative paroxysmal atrial fibrillation', 'incidence of postoperative paroxysmal atrial fibrillation and worsening of the renal function', 'incidence of worsening of the renal function', 'postoperative paroxysmal atrial fibrillation and worsening of the renal function incidence']","[{'cui': 'C0189745', 'cui_str': 'Open heart surgery (procedure)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1176308', 'cui_str': 'tolvaptan'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1176308', 'cui_str': 'tolvaptan'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0235480', 'cui_str': 'Paroxysmal atrial fibrillation (disorder)'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}]",,0.0198718,The incidence of worsening of the renal function was significantly lower in the tolvaptan group than in the control group (4.8% vs. 15.7%; P = 0.04).,"[{'ForeName': 'Yoshinobu', 'Initials': 'Y', 'LastName': 'Nakamura', 'Affiliation': 'Department of Cardiovascular Surgery, Tottori University Faculty of Medicine, Tottori University Hospital, 36-1 Nishi-cho, Yonago, 683-8504, Japan. ynobu@xf7.so-net.ne.jp.'}, {'ForeName': 'Yuichirou', 'Initials': 'Y', 'LastName': 'Kishimoto', 'Affiliation': 'Department of Cardiovascular Surgery, Tottori University Faculty of Medicine, Tottori University Hospital, 36-1 Nishi-cho, Yonago, 683-8504, Japan.'}, {'ForeName': 'Shingo', 'Initials': 'S', 'LastName': 'Harada', 'Affiliation': 'Department of Cardiovascular Surgery, Tottori University Faculty of Medicine, Tottori University Hospital, 36-1 Nishi-cho, Yonago, 683-8504, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Onohara', 'Affiliation': 'Department of Cardiovascular Surgery, Tottori University Faculty of Medicine, Tottori University Hospital, 36-1 Nishi-cho, Yonago, 683-8504, Japan.'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Otsuki', 'Affiliation': 'Department of Cardiovascular Surgery, Tottori University Faculty of Medicine, Tottori University Hospital, 36-1 Nishi-cho, Yonago, 683-8504, Japan.'}, {'ForeName': 'Hiromu', 'Initials': 'H', 'LastName': 'Horie', 'Affiliation': 'Department of Cardiovascular Surgery, Tottori University Faculty of Medicine, Tottori University Hospital, 36-1 Nishi-cho, Yonago, 683-8504, Japan.'}, {'ForeName': 'Motonobu', 'Initials': 'M', 'LastName': 'Nishimura', 'Affiliation': 'Department of Cardiovascular Surgery, Tottori University Faculty of Medicine, Tottori University Hospital, 36-1 Nishi-cho, Yonago, 683-8504, Japan.'}]",Surgery today,['10.1007/s00595-020-01962-3'] 560,31980933,Prophylactic ligation of the thoracic duct branch prevents chylothorax after pulmonary resection for right lung cancer.,"PURPOSE Chylothorax is a rare and challenging complication of thoracic surgery. Whereas most current studies focus on postoperative treatment and preventative measures for esophageal cancer surgery, the current study investigates the impact of prophylactic ligation of the thoracic duct branch on postoperative chylothorax after pulmonary resection for right lung cancer. METHODS The subjects of this retrospective study were 1165 patients who underwent right pulmonary resection and mediastinal lymph-node dissection in our department between January 2015 and August 2019. Those who underwent prophylactic ligation of the thoracic duct branch after 4R lymph-node dissection were assigned to group A (n = 475), and those who did not were assigned to group B (n = 690). The incidence of postoperative chylothorax, the success rate of conservative treatment, the postoperative hospital stay, and the chest drainage volume were recorded and compared statistically between the two groups. RESULTS The incidence of postoperative chylothorax was significantly lower in group A than in group B (0.84% vs. 2.90%, p = 0.015). Patients who had a chylothorax in group A had a significantly shorter postoperative hospital stay, less mean drainage volume per day, and less total drainage than those in group B (7.25 ± 0.50 days vs. 11.00 ± 2.81 days, p = 0.003; 0.64 ± 0.04 L vs. 0.80 ± 0.09 L, p = 0.003; 4.64 ± 0.40 L vs. 8.82 ± 2.84 L; p = 0.002). The success rate of conservative treatment was higher in group A than in group B, but the difference was not significant (100% vs. 75.0%, p = 0.544). CONCLUSION Performing prophylactic ligation of the thoracic duct branch during right pulmonary resection and mediastinal lymph-node dissection is an effective and safe method of preventing postoperative chylothorax.",2020,"Patients who had a chylothorax in group A had a significantly shorter postoperative hospital stay, less mean drainage volume per day, and less total drainage than those in group B (7.25 ± 0.50 days vs. 11.00 ± 2.81 days, p = 0.003; 0.64 ± 0.04 L vs. 0.80 ± 0.09 L, p = 0.003; 4.64 ± 0.40 L vs. 8.82 ± 2.84 L; p = 0.002).","['right lung cancer', '1165 patients who underwent right pulmonary resection and mediastinal lymph-node dissection in our department between January 2015 and August 2019']",['prophylactic ligation of the thoracic duct branch after 4R lymph-node dissection'],"['success rate of conservative treatment', 'total drainage', 'postoperative hospital stay', 'incidence of postoperative chylothorax, the success rate of conservative treatment, the postoperative hospital stay, and the chest drainage volume', 'incidence of postoperative chylothorax', 'mean drainage volume']","[{'cui': 'C0225706', 'cui_str': 'Right lung structure'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0396565', 'cui_str': 'Lung excision'}, {'cui': 'C0588055', 'cui_str': 'Mediastinal lymph node structure (body structure)'}, {'cui': 'C0012737', 'cui_str': 'Dissection'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}]","[{'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}, {'cui': 'C0193907', 'cui_str': 'Ligation of thoracic duct (procedure)'}, {'cui': 'C0205384', 'cui_str': 'Branching (qualifier value)'}, {'cui': 'C0242382', 'cui_str': 'Lymph Node Dissection'}]","[{'cui': 'C0459914', 'cui_str': 'Conservative Management'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0013103', 'cui_str': 'Drainage'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0008733', 'cui_str': 'Chylothorax'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",1165.0,0.0335261,"Patients who had a chylothorax in group A had a significantly shorter postoperative hospital stay, less mean drainage volume per day, and less total drainage than those in group B (7.25 ± 0.50 days vs. 11.00 ± 2.81 days, p = 0.003; 0.64 ± 0.04 L vs. 0.80 ± 0.09 L, p = 0.003; 4.64 ± 0.40 L vs. 8.82 ± 2.84 L; p = 0.002).","[{'ForeName': 'Zixu', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuannanli No 17, Chaoyang District, Beijing, 100021, China.'}, {'ForeName': 'Minjun', 'Initials': 'M', 'LastName': 'Du', 'Affiliation': 'Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuannanli No 17, Chaoyang District, Beijing, 100021, China.'}, {'ForeName': 'Yicheng', 'Initials': 'Y', 'LastName': 'Liang', 'Affiliation': 'Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuannanli No 17, Chaoyang District, Beijing, 100021, China.'}, {'ForeName': 'Shaolong', 'Initials': 'S', 'LastName': 'Ju', 'Affiliation': 'Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuannanli No 17, Chaoyang District, Beijing, 100021, China.'}, {'ForeName': 'Xingkai', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuannanli No 17, Chaoyang District, Beijing, 100021, China.'}, {'ForeName': 'Yushun', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': 'Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuannanli No 17, Chaoyang District, Beijing, 100021, China. bjgaoyushun@163.com.'}]",Surgery today,['10.1007/s00595-020-01969-w'] 561,31310929,Bringing light into darkness: A multiple baseline mixed methods case series evaluation of Augmented Depression Therapy (ADepT).,"Two core features of depression are elevations in negative valence system (NVS) functioning and reductions in positive valence system (PVS) functioning. Existing psychological treatments have focused on the NVS and neglected the PVS, which may contribute to sub-optimal outcomes. The present mixed methods multiple randomised baseline case series preliminarily evaluates Augmented Depression Therapy (ADepT), a novel depression treatment targeting PVS and NVS disturbance, that aims both to reduce depression and enhance wellbeing. Eleven clinically depressed participants were recruited. Intensive time series analyses showed that 7/11 participants improved on both wellbeing and depression. Reliable and clinically significant improvement was observed for 9/11 participants on at least one of these outcomes (and also across a range of other PVS and NVS outcomes). Group level analyses showed significant pre to post change on all outcomes. Benchmarking analyses indicated these effect sizes were at least comparable (and for some PVS outcomes superior) to existing treatments. Gains were largely sustained over one-year follow-up. Qualitative interviews indicated ADepT was feasible and acceptable. These findings provide preliminary support for ADepT as a novel depression treatment. Further evaluation, directly comparing ADepT to existing treatments using randomised controlled trial designs, is now required.",2019,Reliable and clinically significant improvement was observed for 9/11 participants on at least one of these outcomes (and also across a range of other PVS and NVS outcomes).,['Eleven clinically depressed participants were recruited'],['Augmented Depression Therapy (ADepT'],"['negative valence system (NVS) functioning and reductions in positive valence system (PVS) functioning', 'wellbeing and depression']","[{'cui': 'C0344315', 'cui_str': 'Depressed'}]","[{'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]",11.0,0.0481897,Reliable and clinically significant improvement was observed for 9/11 participants on at least one of these outcomes (and also across a range of other PVS and NVS outcomes).,"[{'ForeName': 'Barnaby D', 'Initials': 'BD', 'LastName': 'Dunn', 'Affiliation': 'Mood Disorders Centre, University of Exeter, UK. Electronic address: b.d.dunn@exeter.ac.uk.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Widnall', 'Affiliation': 'Mood Disorders Centre, University of Exeter, UK.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Reed', 'Affiliation': 'Mood Disorders Centre, University of Exeter, UK.'}, {'ForeName': 'Christabel', 'Initials': 'C', 'LastName': 'Owens', 'Affiliation': 'College of Medicine and Health, University of Exeter, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Campbell', 'Affiliation': 'College of Medicine and Health, University of Exeter, UK.'}, {'ForeName': 'Willem', 'Initials': 'W', 'LastName': 'Kuyken', 'Affiliation': 'Department of Psychiatry, University of Oxford, UK.'}]",Behaviour research and therapy,['10.1016/j.brat.2019.103418'] 562,31670808,"Gentamicin, azithromycin and ceftriaxone in the treatment of gonorrhoea: the relationship between antibiotic MIC and clinical outcome.","OBJECTIVES To investigate the relationship between MIC and clinical outcome in a randomized controlled trial that compared gentamicin 240 mg plus azithromycin 1 g with ceftriaxone 500 mg plus azithromycin 1 g. MIC analysis was performed on Neisseria gonorrhoeae isolates from all participants who were culture positive before they received treatment. METHODS Viable gonococcal cultures were available from 279 participants, of whom 145 received ceftriaxone/azithromycin and 134 received gentamicin/azithromycin. Four participants (6 isolates) and 14 participants (17 isolates) did not clear infection in the ceftriaxone/azithromycin and gentamicin/azithromycin arms, respectively. MICs were determined by Etest on GC agar base with 1% Vitox. The geometric mean MICs of azithromycin, ceftriaxone and gentamicin were compared using logistic and linear regression according to treatment received and N. gonorrhoeae clearance. RESULTS As the azithromycin MIC increased, gentamicin/azithromycin treatment was less effective than ceftriaxone/azithromycin at clearing N. gonorrhoeae. There was a higher geometric mean MIC of azithromycin for isolates from participants who had received gentamicin/azithromycin and did not clear infection compared with those who did clear infection [ratio 1.95 (95% CI 1.28-2.97)], but the use of categorical MIC breakpoints did not accurately predict the treatment response. The geometric mean MIC of azithromycin was higher in isolates from the pharynx compared with genital isolates. CONCLUSIONS We found that categorical resistance to azithromycin or ceftriaxone in vitro, and higher gentamicin MICs in the absence of breakpoints, were poorly predictive of treatment failure.",2020,"There was a higher geometric mean MIC of azithromycin for isolates from participants who had received gentamicin/azithromycin and did not clear infection compared with those who did clear infection [ratio 1.95 (95% CI 1.28-2.97)], but the use of categorical MIC breakpoints did not accurately predict the treatment response.","['gonorrhoea', 'Viable gonococcal cultures were available from 279 participants, of whom 145 received', 'Neisseria gonorrhoeae isolates from all participants who were culture positive before they received treatment']","['azithromycin, ceftriaxone and gentamicin', 'Gentamicin, azithromycin and ceftriaxone', 'azithromycin MIC', 'gentamicin 240\u2009mg plus azithromycin', 'azithromycin', 'ceftriaxone/azithromycin and gentamicin/azithromycin', 'ceftriaxone/azithromycin', 'gentamicin/azithromycin', 'azithromycin or ceftriaxone', 'ceftriaxone 500\u2009mg plus azithromycin']","['geometric mean MIC of azithromycin', 'geometric mean MIC']","[{'cui': 'C0018081', 'cui_str': 'Neisseria gonorrhoeae Infection'}, {'cui': 'C0443348', 'cui_str': 'Viable (qualifier value)'}, {'cui': 'C0220814', 'cui_str': 'culture'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C0027573', 'cui_str': 'Gonococcus'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C0159125', 'cui_str': 'Culture positive'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0007561', 'cui_str': 'Ceftriaxone'}, {'cui': 'C0017436', 'cui_str': 'Gentamicins'}, {'cui': 'C0427978', 'cui_str': 'Minimum Inhibitory Concentration'}, {'cui': 'C4319600', 'cui_str': '240 (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C4050978', 'cui_str': 'Ceftriaxone 500 MG'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0427978', 'cui_str': 'Minimum Inhibitory Concentration'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}]",279.0,0.0826859,"There was a higher geometric mean MIC of azithromycin for isolates from participants who had received gentamicin/azithromycin and did not clear infection compared with those who did clear infection [ratio 1.95 (95% CI 1.28-2.97)], but the use of categorical MIC breakpoints did not accurately predict the treatment response.","[{'ForeName': 'Michelle J', 'Initials': 'MJ', 'LastName': 'Cole', 'Affiliation': 'National Infection Service, PHE, London, UK.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Tan', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Fifer', 'Affiliation': 'National Infection Service, PHE, London, UK.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Brittain', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Lelia', 'Initials': 'L', 'LastName': 'Duley', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Trish', 'Initials': 'T', 'LastName': 'Hepburn', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Tessa', 'Initials': 'T', 'LastName': 'Lawrence', 'Affiliation': 'University Hospitals Birmingham NHS Foundation Trust, Whittall Street Clinic, Birmingham, UK.'}, {'ForeName': 'Alan A', 'Initials': 'AA', 'LastName': 'Montgomery', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Kirsty', 'Initials': 'K', 'LastName': 'Sprange', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Sukhwinder', 'Initials': 'S', 'LastName': 'Thandi', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Churchward', 'Affiliation': 'National Infection Service, PHE, London, UK.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Tripodo', 'Affiliation': 'National Infection Service, PHE, London, UK.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Woodford', 'Affiliation': 'National Infection Service, PHE, London, UK.'}, {'ForeName': 'Jonathan D C', 'Initials': 'JDC', 'LastName': 'Ross', 'Affiliation': 'University Hospitals Birmingham NHS Foundation Trust, Whittall Street Clinic, Birmingham, UK.'}]",The Journal of antimicrobial chemotherapy,['10.1093/jac/dkz436'] 563,30768397,Changes in General and Specific Psychopathology Factors Over a Psychosocial Intervention.,"OBJECTIVE Recent research suggests that comorbidity in child and adolescent psychiatric symptoms can be summarized by a single latent dimension known as the p factor and more specific factors summarizing clusters of symptoms. This study investigated within- and between-person changes in general and specific psychopathology factors over a psychosocial intervention. METHOD A secondary analysis was conducted of the Systemic Therapy for At-Risk Teens study, a pragmatic randomized controlled trial that compared the effects of multisystemic therapy with those of management as usual for decreasing antisocial behavior in 684 adolescents (82% boys; 11-18 years old at baseline) over an 18-month period. The general p factor and specific antisocial, attention, anxiety, and mood factors were estimated from a symptom-level analysis of a set of narrowband symptom scales measured repeatedly during the study. General and specific psychopathology factors were assessed for reliability, validity, and within- and between-person change using a parallel process multilevel growth model. RESULTS A revised bi-factor model that included a general p factor and specific anxiety, mood, antisocial, and attention factors with cross-loadings fit the data best. Although the factor structure was multidimensional, the p factor accounted for most of the variance in total scores. The p factor, anxiety, and antisocial factors predicted within-person variation in external outcomes. Furthermore, the p factor and antisocial factors showed within-person declines, whereas anxiety showed within-person increases, over time. Despite individual variation in baseline factor scores, adolescents showed similar rates of change. CONCLUSION The bi-factor model is useful for teasing apart general and specific therapeutic changes that are conflated in standard analyses of symptom scores. CLINICAL TRIAL REGISTRATION INFORMATION START (Systemic Therapy for At Risk Teens): A National Randomised Controlled Trial to Evaluate Multisystemic Therapy in the UK Context; http://www.isrctn.com; ISRCTN77132214.",2019,"Despite individual variation in baseline factor scores, adolescents showed similar rates of change. ","['At Risk Teens', '684 adolescents (82% boys; 11-18 years old at baseline) over an 18-month period']",['multisystemic therapy'],"['general p factor and specific antisocial, attention, anxiety, and mood factors']","[{'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C1521910', 'cui_str': 'Teens'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C3840203', 'cui_str': 'Multisystemic therapy (regime/therapy)'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0026516', 'cui_str': 'Mood'}]",684.0,0.113647,"Despite individual variation in baseline factor scores, adolescents showed similar rates of change. ","[{'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Constantinou', 'Affiliation': 'Division of Psychology and Language Sciences, University College London, UK. Electronic address: matthew.constantinou.13@ucl.ac.uk.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Goodyer', 'Affiliation': 'University of Cambridge, UK.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Eisler', 'Affiliation': ""Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK; South London and Maudsley NHS Foundation Trust, University College London, UK.""}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Butler', 'Affiliation': 'University of Prince Edward Island, Charlottetown, Canada.'}, {'ForeName': 'Abdullah', 'Initials': 'A', 'LastName': 'Kraam', 'Affiliation': 'University of Leeds and Leeds Community Healthcare NHS Trust, Leeds, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Scott', 'Affiliation': ""Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK.""}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Pilling', 'Affiliation': 'Division of Psychology and Language Sciences, University College London, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Simes', 'Affiliation': 'Division of Psychology and Language Sciences, University College London, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Ellison', 'Affiliation': 'Division of Psychology and Language Sciences, University College London, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Allison', 'Affiliation': 'Division of Psychology and Language Sciences, University College London, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Fonagy', 'Affiliation': 'Division of Psychology and Language Sciences, University College London, UK.'}]",Journal of the American Academy of Child and Adolescent Psychiatry,['10.1016/j.jaac.2018.11.011'] 564,32000099,Who is willing to participate in research? A screening model for an anxiety and depression trial in the epilepsy clinic.,"OBJECTIVE Anxiety and depression in epilepsy are prevalent, associated with poor outcomes, underrecognized, undertreated, and thus a key area of need for treatment research. The objective of this study was to assess factors associated with research participation among epilepsy clinic patients who screened positive for anxiety or depression. This was accomplished by characterizing clinical and psychiatric factors among patients seen in an epilepsy clinic and evaluating which factors were associated with consent for potential research participation, via a combined clinical and research screening model. METHODS In a pragmatic trial of anxiety and depression treatment in epilepsy, individuals with a positive screen for anxiety and/or depression at a routine epilepsy clinic visit were invited to opt-in (via brief electronic consent) to further eligibility assessment for a randomized treatment study. Information on psychiatric symptoms and treatment characteristics were collected for dual clinical care and research screening purposes. Cross-sectional association of demographic, clinical, and psychiatric factors with opting-in to research was analyzed by multiple logistic regression. RESULTS Among N = 199 unique adults with a first positive screen for anxiety and/or depression among 786 total screening events, 154 (77.4%) opted-in to further potential research assessment. Higher depression scores and current treatment with an antidepressant were independently associated with opting-in to research (depression odds ratio (OR) = 1.13 per 1-point increase in Neurological Disorders Depression Inventory-Epilepsy (NDDI-E) score, p = 0.028, 95% confidence interval (CI): 1.01-1.26; antidepressant OR = 2.37, p = 0.041, CI: 1.04-5.41). Nearly half of the 199 individuals (43.7%) with anxiety and/or depression symptoms were already being treated with an antidepressant, and 46.7% were receiving neither antidepressant therapy nor mental health specialty care. One-quarter (24.1%) reported a past psychiatric hospitalization, yet only half of these individuals were receiving mental health specialty care. SIGNIFICANCE Our results demonstrate a high willingness to participate in research using a brief electronic consent approach at a routine clinic visit. Adults with persistent anxiety or depression symptoms despite antidepressant therapy and those with higher depression scores were more willing to consider a randomized treatment study. This has implications for future study design, as individuals already on treatment or those with more severe symptoms are often excluded from traditional research designs. We also found a high burden of psychiatric disease and high prevalence of persistent symptoms despite ongoing antidepressant treatment.",2020,Nearly half of the 199 individuals (43.7%) with anxiety,"['Among N\u202f=\u202f199 unique adults with a first positive screen for anxiety and/or depression among 786 total screening events, 154 (77.4%) opted-in to further potential research assessment', 'epilepsy clinic patients who screened positive for anxiety or depression', 'epilepsy, individuals with a positive screen for anxiety and/or depression at a routine epilepsy clinic visit', '199 individuals (43.7%) with anxiety', 'Adults with persistent anxiety or depression symptoms despite antidepressant therapy and those with higher depression scores']",[],"['past psychiatric hospitalization', 'Neurological Disorders Depression Inventory-Epilepsy (NDDI-E) score', 'Higher depression scores']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0035168'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0008952', 'cui_str': 'Clinic Visits'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1096649', 'cui_str': 'Antidepressant therapy'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",[],"[{'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0027765', 'cui_str': 'Neurologic Disorders'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]",,0.0539495,Nearly half of the 199 individuals (43.7%) with anxiety,"[{'ForeName': 'Heidi M', 'Initials': 'HM', 'LastName': 'Munger Clary', 'Affiliation': 'Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: hmungerc@wakehealth.edu.'}, {'ForeName': 'Rachel D', 'Initials': 'RD', 'LastName': 'Croxton', 'Affiliation': 'Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: croxrd13@alumni.wfu.edu.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Allan', 'Affiliation': 'Department of Psychiatry, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: jallan@wakehealth.edu.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Lovato', 'Affiliation': 'Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: jlovato@wakehealth.edu.'}, {'ForeName': 'Gretchen', 'Initials': 'G', 'LastName': 'Brenes', 'Affiliation': 'Department of Internal Medicine, Section of Geriatrics, Wake Forest University, Winston-Salem, NC, USA. Electronic address: gbrenes@wakehealth.edu.'}, {'ForeName': 'Beverly M', 'Initials': 'BM', 'LastName': 'Snively', 'Affiliation': 'Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: bmellen@wakehealth.edu.'}, {'ForeName': 'Mingyu', 'Initials': 'M', 'LastName': 'Wan', 'Affiliation': 'Neuroscience Graduate Program, Wake Forest University, Winston-Salem, NC, USA. Electronic address: miwan@wakehealth.edu.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Kimball', 'Affiliation': 'Department of Psychiatry, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'ForeName': 'Matthew H', 'Initials': 'MH', 'LastName': 'Wong', 'Affiliation': 'Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'ForeName': 'Cormac A', 'Initials': 'CA', 'LastName': ""O'Donovan"", 'Affiliation': 'Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: odonovan@wakehealth.edu.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Conner', 'Affiliation': 'Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: kconner@wakehealth.edu.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Jones', 'Affiliation': 'Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Duncan', 'Affiliation': 'Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: pduncan@wakehealth.edu.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2020.106907'] 565,31144648,A Method to Detect Presence of Chest Compressions During Resuscitation Using Transthoracic Impedance.,"OBJECTIVE Interruptions in chest compressions during treatment of out-of-hospital cardiac arrest are associated with lower likelihood of successful resuscitation. Real-time automated detection of chest compressions may improve CPR administration during resuscitation, and could facilitate application of next-generation ECG algorithms that employ different parameters depending on compression state. In contrast to accelerometer sensors, transthoracic impedance (TTI) is commonly acquired by defibrillators. We sought to develop and evaluate the performance of a TTI-based algorithm to automatically detect chest compressions. METHODS Five-second TTI segments were collected from patients with out-of-hospital cardiac arrest treated by one of four defibrillator models. Segments with and without chest compressions were collected prior to each of the first four defibrillation shocks (when available) from each case. Patients were divided randomly into 40% training and 60% validation groups. From the training segments, we identified spectral and time-domain features of the TTI associated with compressions. We used logistic regression to predict compression state from these features. Performance was measured by sensitivity and specificity in the validation set. The relationship between performance and TTI segment length was also evaluated. RESULTS The algorithm was trained using 1859 segments from 460 training patients. Validation sensitivity and specificity were >98% using 2727 segments from 691 validation patients. Validation performance was significantly reduced using segments shorter than 3.2 s. CONCLUSIONS A novel method can reliably detect the presence of chest compressions using TTI. These results suggest potential to provide real-time feedback in order to improve CPR performance or facilitate next-generation ECG rhythm algorithms during resuscitation.",2020,"Validation performance was significantly reduced using segments shorter than 3.2 s. CONCLUSIONS ",['Five-second TTI segments were collected from patients with out-of-hospital cardiac arrest treated by one of four defibrillator models'],[],"['performance and TTI segment length', 'sensitivity and specificity', 'Validation sensitivity and specificity', 'Validation performance', 'CPR performance']","[{'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0761034', 'cui_str': 'tsetse thrombin inhibitor'}, {'cui': 'C0441635', 'cui_str': 'Segment (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2936490', 'cui_str': 'Out-of-Hospital Heart Arrest'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0180307', 'cui_str': 'Defibrillators'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}]",[],"[{'cui': 'C0761034', 'cui_str': 'tsetse thrombin inhibitor'}, {'cui': 'C0441635', 'cui_str': 'Segment (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0036668', 'cui_str': 'Sensitivity and Specificity'}, {'cui': 'C0007203', 'cui_str': 'Cardio-Pulmonary Resuscitation'}]",,0.0151684,"Validation performance was significantly reduced using segments shorter than 3.2 s. CONCLUSIONS ","[{'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Coult', 'Affiliation': ''}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Blackwood', 'Affiliation': ''}, {'ForeName': 'Thomas D', 'Initials': 'TD', 'LastName': 'Rea', 'Affiliation': ''}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Kudenchuk', 'Affiliation': ''}, {'ForeName': 'Heemun', 'Initials': 'H', 'LastName': 'Kwok', 'Affiliation': ''}]",IEEE journal of biomedical and health informatics,['10.1109/JBHI.2019.2918790'] 566,30607527,"Associations Among Job Role, Training Type, and Staff Turnover in a Large-Scale Implementation Initiative.","Staff turnover is problematic for behavioral health agencies implementing evidence-based practices (EBPs), which are costly and time-consuming. The current study examined the association between EBP training methods and turnover and explored predictors of turnover for different types of staff. Participants (100 clinicians, 50 supervisors, 50 administrators) were randomized to one of three training conditions for an EBP. Results indicated low annual rates of turnover for clinicians, supervisors, and administrators. However, contrary to hypothesis, no statistically significant differences were found in rates of turnover across training conditions. Partially consistent with prior research, organizational climate was a significant predictor of supervisor and administrator turnover at 24 months, but was not a significant predictor of clinician turnover. Implications and future directions for research are discussed.",2019,The current study examined the association between EBP training methods and turnover and explored predictors of turnover for different types of staff.,"['Participants (100 clinicians, 50 supervisors, 50 administrators']",[],"['low annual rates of turnover for clinicians, supervisors, and administrators']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0403172', 'cui_str': 'Supervisor (occupation)'}, {'cui': 'C0085751', 'cui_str': 'Administrators'}]",[],"[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0443331', 'cui_str': 'Turnover technique (qualifier value)'}, {'cui': 'C0403172', 'cui_str': 'Supervisor (occupation)'}, {'cui': 'C0085751', 'cui_str': 'Administrators'}]",,0.0197243,The current study examined the association between EBP training methods and turnover and explored predictors of turnover for different types of staff.,"[{'ForeName': 'Laurel A', 'Initials': 'LA', 'LastName': 'Brabson', 'Affiliation': 'Department of Psychology, West Virginia University, 1124 Life Sciences Building, P.O. Box 6040, Morgantown, WV, 26506-6040, USA. labrabson@mix.wvu.edu.'}, {'ForeName': 'Amy D', 'Initials': 'AD', 'LastName': 'Herschell', 'Affiliation': 'Department of Psychology, West Virginia University, 1124 Life Sciences Building, P.O. Box 6040, Morgantown, WV, 26506-6040, USA.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Kolko', 'Affiliation': 'Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, USA.'}, {'ForeName': 'Stanley J', 'Initials': 'SJ', 'LastName': 'Mrozowski', 'Affiliation': ''}]",The journal of behavioral health services & research,['10.1007/s11414-018-09645-1'] 567,31916007,Age and gender differences in financial distress among hematopoietic cell transplant survivors.,"PURPOSE Cancer has long-term financial consequences. Adolescent and young adult (AYA) and middle-aged cancer survivors may experience more financial toxicity than older adults. This study examined age differences in financial distress in hematopoietic cell transplant survivors and whether these differences result from measurement bias, more financial barriers to care, or an overall higher level of distress. METHODS Hematologic malignancy survivors (n = 1135, 2-10 years post-transplant) completed the Cancer and Treatment Distress Scale (CTXD) and demographics as part of the baseline assessment for a randomized clinical trial. The CTXD has seven subscales, but for this study, we examined the financial distress subscale and the overall score. Item response theory analyses tested for bias by age and gender. Multivariate linear regression tested the association of age and gender with the CTXD scores while controlling for financial barriers to care. RESULTS No bias was found on the CTXD. AYA (p < 0.01) and middle-aged adults (p < 0.001) reported more financial and overall distress than older (age 65+) adults. The same association of age and financial distress was observed in women (p < 0.01). However, only middle-aged men (p < 0.01) reported more financial and overall distress than older men; AYA men did not (p > 0.18). Financial barriers to care were not associated with financial or overall distress. CONCLUSIONS Part of the increase in financial distress with younger age may be due to a higher risk of general distress. Policy initiatives to control cancer costs should consider life stage and the unique financial challenges at different ages for men and women.",2020,"However, only middle-aged men (p < 0.01) reported more financial and overall distress than older men; AYA men did not (p > 0.18).","['Hematologic malignancy survivors (n\u2009=\u20091135, 2-10\xa0years post-transplant) completed the Cancer and Treatment Distress Scale (CTXD) and demographics as part of the baseline assessment for a randomized clinical trial', 'Adolescent and young adult (AYA) and middle-aged cancer survivors', 'older adults', 'hematopoietic cell transplant survivors']",[],"['financial distress', 'age and financial distress', 'financial and overall distress', 'financial distress subscale']","[{'cui': 'C0376545', 'cui_str': 'Hematological Neoplasms'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0332835', 'cui_str': 'Grafts'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0222045'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C1292711', 'cui_str': 'Part of (attribute)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0205847', 'cui_str': 'Middle Aged'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0206152', 'cui_str': 'Cell Transplants'}]",[],"[{'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.0320963,"However, only middle-aged men (p < 0.01) reported more financial and overall distress than older men; AYA men did not (p > 0.18).","[{'ForeName': 'Salene M W', 'Initials': 'SMW', 'LastName': 'Jones', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Jean C', 'Initials': 'JC', 'LastName': 'Yi', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Heather S L', 'Initials': 'HSL', 'LastName': 'Jim', 'Affiliation': 'Moffitt Cancer Center, Tampa, FL, USA.'}, {'ForeName': 'Alison W', 'Initials': 'AW', 'LastName': 'Loren', 'Affiliation': 'University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Navneet S', 'Initials': 'NS', 'LastName': 'Majhail', 'Affiliation': 'Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Uberti', 'Affiliation': 'Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Whalen', 'Affiliation': 'University of Nebraska, Omaha, NB, USA.'}, {'ForeName': 'Wendy M', 'Initials': 'WM', 'LastName': 'Leisenring', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Mary E D', 'Initials': 'MED', 'LastName': 'Flowers', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Stephanie J', 'Initials': 'SJ', 'LastName': 'Lee', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Karen L', 'Initials': 'KL', 'LastName': 'Syrjala', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ksyrjala@fredhutch.org.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-019-05291-1'] 568,31315873,Novel ACT-based eHealth psychoeducational intervention for students with mental distress: a study protocol for a mixed-methodology pilot trial.,"INTRODUCTION Recent studies have revealed a high prevalence of depression, anxiety and stress symptoms among university students, highlighting an urgent need for preventative measures at low cost to better support often overwhelmed support services. OBJECTIVE Here we propose a protocol for assessing the feasibility of a randomised controlled trial (RCT) for an online transdiagnostic psychoeducational intervention called 'A Bite of ACT' compared with a waitlist control. METHODS AND ANALYSIS This is an RCT with crossover design involving baseline assessments and two follow-up periods. The primary outcome measure will be the Acceptance Checklist for Clinical Effectiveness Pilot Trials (ACCEPT) for measuring the feasibility of the trial design and methods. Secondary outcomes include measures of well-being, social connectedness, quality of life (EuroQol Five Dimensions), depression, anxiety and stress (Depression Anxiety Stress Scales-21), as well as the process measures: psychological flexibility (Acceptance and Action Questionnaire-Second Version and the Mindful Attention Awareness Scale) and heart rate variability. Analysis will involve calculating descriptive statistics, examining trial feasibility outcomes through ACCEPT, and determining effect size measures to determine the sample size needed in a future trial (if indicated). Qualitative interviews and preliminary health economics analysis will provide additional insights into the feasibility of the intervention and trial methods. ETHICS AND DISSEMINATION This study has been approved by the Department of Psychology Research Ethics Committee in the College of Human and Health Sciences at Swansea University. Dissemination will involve publication in international peer-reviewed journals, presentation of findings at relevant local, national and international conferences, and promotion of study outcomes using social media and other channels for disseminating findings to the wider community. TRIAL REGISTRATION NUMBER NCT03810131; Pre-results.",2019,"Here we propose a protocol for assessing the feasibility of a randomised controlled trial (RCT) for an online transdiagnostic psychoeducational intervention called 'A Bite of ACT' compared with a waitlist control. ","['university students', 'students with mental distress', 'College of Human and Health Sciences at Swansea University']","['ACCEPT', 'Novel ACT-based eHealth psychoeducational intervention']","['Acceptance Checklist for Clinical Effectiveness Pilot Trials (ACCEPT', 'measures of well-being, social connectedness, quality of life (EuroQol Five Dimensions), depression, anxiety and stress (Depression Anxiety Stress Scales-21), as well as the process measures: psychological flexibility (Acceptance and Action Questionnaire-Second Version and the Mindful Attention Awareness Scale) and heart rate variability']","[{'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0235109', 'cui_str': 'Mental distress (finding)'}, {'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1328956', 'cui_str': 'eHealth'}]","[{'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C3850123', 'cui_str': 'Treatment Effectiveness'}, {'cui': 'C0473169', 'cui_str': 'Aviators'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0034380'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0222045'}, {'cui': 'C0086850', 'cui_str': 'Process Measures'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0441472', 'cui_str': 'Action (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0004448', 'cui_str': 'Situational Awareness'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}]",,0.147825,"Here we propose a protocol for assessing the feasibility of a randomised controlled trial (RCT) for an online transdiagnostic psychoeducational intervention called 'A Bite of ACT' compared with a waitlist control. ","[{'ForeName': 'Darren J', 'Initials': 'DJ', 'LastName': 'Edwards', 'Affiliation': 'Department of Public Health, Policy and Social Sciences, Swansea University, Swansea, UK.'}, {'ForeName': 'Elinor', 'Initials': 'E', 'LastName': 'Rainey', 'Affiliation': 'Department of Psychology, Swansea University, Swansea, UK.'}, {'ForeName': 'Vasiliki', 'Initials': 'V', 'LastName': 'Boukouvala', 'Affiliation': 'Department of Psychology, Swansea University, Swansea, UK.'}, {'ForeName': 'Yasmin', 'Initials': 'Y', 'LastName': 'Wells', 'Affiliation': 'Department of Psychology, Swansea University, Swansea, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Bennett', 'Affiliation': 'Department of Psychology, Swansea University, Swansea, UK.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Tree', 'Affiliation': 'Department of Psychology, Swansea University, Swansea, UK.'}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Kemp', 'Affiliation': 'Department of Psychology, Swansea University, Swansea, UK.'}]",BMJ open,['10.1136/bmjopen-2019-029411'] 569,30888034,Rationale and Study Design of a Randomized Clinical Trial of Metformin to Prevent Frailty in Older Adults With Prediabetes.,"BACKGROUND Frailty is a geriatric syndrome that leads to poor health outcomes with aging. Previous studies have demonstrated that insulin resistance and inflammation predict frailty onset. Metformin is a widely used, well-tolerated drug that improves insulin sensitivity and displays anti-inflammatory properties. It is also known to prevent diabetes onset in adults with prediabetes. We hypothesize that metformin in older adults with prediabetes will promote healthy aging and prevent frailty. Here we describe an ongoing placebo-controlled, double-blinded clinical trial of metformin for the prevention of frailty in older adults with prediabetes. METHODS Older adults aged more than 65 years are randomized to metformin or placebo and are followed for 2 years. Prediabetes, required for inclusion, is assessed by 2-hour oral glucose tolerance test. Exclusion criteria are baseline frailty (Fried criteria), diabetes, dementia, untreated depression, active malignancy, or severe cardiovascular, pulmonary, and neurologic diseases. Primary outcome is frailty; secondary outcomes are physical function (Short Physical Performance Battery), systemic and skeletal muscle tissue inflammation, muscle insulin signaling, insulin sensitivity (insulin clamp), glucose tolerance (oral glucose tolerance test), and body composition (dual-energy x-ray absorptiometry). Subjects are followed every 3 months for safety assessments and every 6 months for frailty assessment (Fried criteria) and oral glucose tolerance test, and every 12 or 24 months for secondary outcomes. Enrollment of 120 subjects (completers) will take place over a 2-year period. CONCLUSION Metformin is being examined in this study as a potential therapeutic agent to prevent frailty in older adults with prediabetes. Findings from this trial may have future implications for the screening and potential treatment of prediabetes in older patients with metformin for the prevention of frailty.",2020,Findings from this trial may have future implications for the screening and potential treatment of pre-diabetes in older patients with metformin for the prevention of frailty.,"['older adults with pre-diabetes', 'adults with pre-diabetes', '120 subjects (completers) will take place over a 2 year period', 'older patients with', 'Older adults aged 65+ years', 'Older Adults with Pre-Diabetes']","['Metformin', 'placebo', 'metformin or placebo', 'metformin']","['physical function (short physical performance battery), systemic and skeletal muscle tissue inflammation, muscle insulin signaling, insulin sensitivity (insulin clamp), glucose tolerance (OGTT), and body composition (dual-energy x-ray absorptiometry']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C4075461', 'cui_str': 'Short Physical Performance Battery'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C1959759', 'cui_str': 'Skeletal muscle tissue (body structure)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C1510486', 'cui_str': 'Dual X-Ray Absorptiometry'}]",,0.124901,Findings from this trial may have future implications for the screening and potential treatment of pre-diabetes in older patients with metformin for the prevention of frailty.,"[{'ForeName': 'Sara E', 'Initials': 'SE', 'LastName': 'Espinoza', 'Affiliation': 'Division of Geriatrics, Gerontology, and Palliative Medicine, Department of Medicine, University of Texas Health Science Center at San Antonio, Texas.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Musi', 'Affiliation': 'Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, Texas.'}, {'ForeName': 'Chen-Pin', 'Initials': 'CP', 'LastName': 'Wang', 'Affiliation': 'Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, Texas.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Michalek', 'Affiliation': 'Department of Epidemiology and Biostatistics, Texas.'}, {'ForeName': 'Beverly', 'Initials': 'B', 'LastName': 'Orsak', 'Affiliation': 'Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, Texas.'}, {'ForeName': 'Terry', 'Initials': 'T', 'LastName': 'Romo', 'Affiliation': 'Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, Texas.'}, {'ForeName': 'Becky', 'Initials': 'B', 'LastName': 'Powers', 'Affiliation': 'Division of Geriatrics, Gerontology, and Palliative Medicine, Department of Medicine, University of Texas Health Science Center at San Antonio, Texas.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Conde', 'Affiliation': 'Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, Texas.'}, {'ForeName': 'Melody', 'Initials': 'M', 'LastName': 'Moris', 'Affiliation': 'Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, Texas.'}, {'ForeName': 'Darcy', 'Initials': 'D', 'LastName': 'Bair-Kelps', 'Affiliation': 'Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, Texas.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, Texas.'}, {'ForeName': 'Vinutha', 'Initials': 'V', 'LastName': 'Ganapathy', 'Affiliation': 'Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, Texas.'}, {'ForeName': 'Tyson E', 'Initials': 'TE', 'LastName': 'Jergensen', 'Affiliation': 'Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, Texas.'}, {'ForeName': 'Lauri C', 'Initials': 'LC', 'LastName': 'Kelly', 'Affiliation': 'Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, Texas.'}, {'ForeName': 'Rozmin', 'Initials': 'R', 'LastName': 'Jiwani', 'Affiliation': 'Geriatric Research, Education, and Clinical Center, South Texas Veterans Health Care System, San Antonio, Texas.'}]","The journals of gerontology. Series A, Biological sciences and medical sciences",['10.1093/gerona/glz078'] 570,30716528,"Home use of a compact, 12‑lead ECG recording system for newborns.","BACKGROUND An easy-to-operate ECG recorder should be useful for newborn screening for heart conditions, by health care workers - or parents. We developed a one-piece electrode strip and a compact, 12‑lead ECG recorder for newborns. METHOD We enrolled 2582 newborns in a trial to assess abilities of parents to record a 12‑lead ECG on their infants (2-4 weeks-old). Newborns were randomized to recordings by parents (1290) or our staff (1292 controls). Educational backgrounds of parents varied, including 64% with no more than a high school diploma. RESULTS For newborns randomized to parent recorded ECGs, 94% of parents completed a 10-minute recording. However, 42.6% asked for verbal help, and 12.7% needed physical help. ECG quality was the same for recordings by parents versus staff. CONCLUSIONS By use of a one-piece electrode strip and a compact recorder, 87% of parents recorded diagnostic quality ECGs on their newborn infants, with minimal assistance.",2019,"ECG quality was the same for recordings by parents versus staff. ","['2582 newborns in a trial to assess abilities of parents to record a 12‑lead ECG on their infants (2-4\u202fweeks-old', 'newborn screening for heart conditions, by health care workers - or parents', 'Educational backgrounds of parents varied, including 64% with no more than a high school diploma', 'Newborns', 'newborns']",[],"['diagnostic quality ECGs', 'ECG quality']","[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C1623258', 'cui_str': 'ECG'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}]",[],"[{'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C1623258', 'cui_str': 'ECG'}]",2582.0,0.0393571,"ECG quality was the same for recordings by parents versus staff. ","[{'ForeName': 'Henry J', 'Initials': 'HJ', 'LastName': 'Lin', 'Affiliation': 'Division of Medical Genetics, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, USA; Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: hlin@labiomed.org.'}, {'ForeName': 'Yueh-Tze', 'Initials': 'YT', 'LastName': 'Lan', 'Affiliation': 'Division of Pediatric Cardiology, Department of Pediatrics, Santa Clara Valley Medical Center, San Jose, CA, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Silka', 'Affiliation': ""Division of Cardiology, Children's Hospital Los Angeles, Department of Pediatrics, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.""}, {'ForeName': 'Nancy J', 'Initials': 'NJ', 'LastName': 'Halnon', 'Affiliation': 'Division of Pediatric Cardiology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Villa-Lopez', 'Affiliation': 'Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.'}, {'ForeName': 'Nataly', 'Initials': 'N', 'LastName': 'Arenas', 'Affiliation': 'Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.'}, {'ForeName': 'Fabian', 'Initials': 'F', 'LastName': 'Escobedo', 'Affiliation': 'Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Montoya', 'Affiliation': 'Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Valdez', 'Affiliation': 'Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.'}, {'ForeName': 'Omid', 'Initials': 'O', 'LastName': 'Rajabi Shishvan', 'Affiliation': 'Department of Electrical and Computer Engineering, University at Albany, State University of New York, Albany, NY, USA.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Sedano', 'Affiliation': 'Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.'}, {'ForeName': 'Emily H', 'Initials': 'EH', 'LastName': 'Marr', 'Affiliation': 'Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Lauzon', 'Affiliation': 'Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.'}, {'ForeName': 'A S', 'Initials': 'AS', 'LastName': 'Moosa', 'Affiliation': 'St. Francis Medical Center, Lynwood, CA, USA.'}, {'ForeName': 'Kimberly J', 'Initials': 'KJ', 'LastName': 'Ko', 'Affiliation': 'Division of Hospitalist Medicine, Department of Pediatrics, Harbor-UCLA Medical Center, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Elaine C', 'Initials': 'EC', 'LastName': 'Shoji', 'Affiliation': 'Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Pediatrics, Providence Little Company of Mary Medical Center, Torrance, CA, USA.'}, {'ForeName': 'Alexandra M', 'Initials': 'AM', 'LastName': 'Clark', 'Affiliation': 'Department of Pediatrics, Riverside University Health System - Medical Center, Moreno Valley, CA, USA; Department of Pediatrics, Loma Linda University Medical Center, Loma Linda, CA, USA.'}, {'ForeName': 'Lynne M', 'Initials': 'LM', 'LastName': 'Smith', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, Harbor-UCLA Medical Center, Los Angeles Biomedical Research Institute, Torrance, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'John Michael', 'Initials': 'JM', 'LastName': 'Criley', 'Affiliation': 'Division of Cardiology, Department of Medicine, Harbor-UCLA Medical Center, Los Angeles Biomedical Research Institute, Torrance, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Wayne W', 'Initials': 'WW', 'LastName': 'Grody', 'Affiliation': 'Departments of Pathology and Laboratory Medicine, Pediatrics, and Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Yii-Der Ida', 'Initials': 'YI', 'LastName': 'Chen', 'Affiliation': 'Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA; Division of Genomic Outcomes, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, USA; Departments of Medicine and Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Kent D', 'Initials': 'KD', 'LastName': 'Taylor', 'Affiliation': 'Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA; Division of Genomic Outcomes, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Xiuqing', 'Initials': 'X', 'LastName': 'Guo', 'Affiliation': 'Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA; Division of Genomic Outcomes, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Tolga', 'Initials': 'T', 'LastName': 'Soyata', 'Affiliation': 'Department of Electrical and Computer Engineering, University at Albany, State University of New York, Albany, NY, USA.'}, {'ForeName': 'Jerome I', 'Initials': 'JI', 'LastName': 'Rotter', 'Affiliation': 'Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA; Division of Genomic Outcomes, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, USA; Departments of Human Genetics, Medicine, and Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Tingchou', 'Initials': 'T', 'LastName': 'Chien', 'Affiliation': 'Department of Electrical Engineering and Computer Science, The Henry Samueli School of Engineering, University of California, Irvine, CA, USA.'}, {'ForeName': 'Pai', 'Initials': 'P', 'LastName': 'Chou', 'Affiliation': 'Department of Electrical Engineering and Computer Science, The Henry Samueli School of Engineering, University of California, Irvine, CA, USA.'}, {'ForeName': 'Ruey-Kang', 'Initials': 'RK', 'LastName': 'Chang', 'Affiliation': 'Division of Pediatric Cardiology, Department of Pediatrics, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}]",Journal of electrocardiology,['10.1016/j.jelectrocard.2019.01.086'] 571,30383097,"Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial.","Importance Young mouse plasma restores memory in aged mice, but, to our knowledge, the effects are unknown in patients with Alzheimer disease (AD). Objective To assess the safety, tolerability, and feasibility of infusions of young fresh frozen plasma (yFFP) from donors age 18 to 30 years in patients with AD. Design, Setting, and Participants The Plasma for Alzheimer Symptom Amelioration (PLASMA) study randomized 9 patients under a double-blind crossover protocol to receive 4 once-weekly infusions of either 1 unit (approximately 250 mL) of yFFP from male donors or 250 mL of saline, followed by a 6-week washout and crossover to 4 once-weekly infusions of an alternate treatment. Patients and informants were masked to treatment and subjective measurements. After an open-label amendment, 9 patients received 4 weekly yFFP infusions only and their subjective measurements were unmasked. Patients were enrolled solely at Stanford University, a tertiary academic medical center, from September 2014 to December 2016, when enrollment reached its target. Eighteen consecutive patients with probable mild to moderate AD dementia, a Mini-Mental State Examination (score of 12 to 24 inclusive), and an age of 50 to 90 years were enrolled. Thirty-one patients were screened and 13 were excluded: 11 failed the inclusion criteria and 2 declined to participate. Interventions One unit of yFFP from male donors/placebo infused once weekly for 4 weeks. Main Outcome and Measures The primary outcomes were the safety, tolerability, and feasibility of 4 weekly yFFP infusions. Safety end point analyses included all patients who received the study drug/placebo. Results There was no difference in the age (mean [SD], 74.17 [7.96] years), sex (12 women [67%]), or baseline Mini-Mental State Examination score (mean [SD], 19.39 [3.24]) between the crossover (n = 9) and open-label groups (n = 9). There were no related serious adverse events. One patient discontinued participation because of urticaria and another because of an unrelated stroke. There was no statistically significant difference between the plasma (17 [94.4%]) and placebo (9 [100.0%]) cohorts for other adverse events, which were mild to moderate in severity. The most common adverse events in the plasma group included hypertension (3 [16.7%]), dizziness (2 [11.1%]), sinus bradycardia (3 [16.7%]), headache (3 [16.7%]), and sinus tachycardia (3 [16.7%]). The mean visit adherence (n = 18) was 86% (interquartile range, 87%-100%) and adherence, accounting for a reduction in the total visit requirement due to early patient discontinuation, was 96% (interquartile range, 89%-100%). Conclusions and Relevance The yFFP treatment was safe, well tolerated, and feasible. The study's limitations were the small sample size, short duration, and change in study design. The results warrant further exploration in larger, double-blinded placebo-controlled clinical trials. Trial Registration ClinicalTrials.gov Identifier: NCT02256306.",2019,There were no related serious adverse events.,"['patients with Alzheimer disease (AD', 'Eighteen consecutive patients with probable mild to moderate AD dementia, a Mini-Mental State Examination (score of 12 to 24 inclusive), and an age of 50 to 90 years were enrolled', 'donors age 18 to 30 years in patients with AD', 'Thirty-one patients were screened and 13 were excluded: 11 failed the inclusion criteria and 2 declined to participate', 'Patients were enrolled solely at Stanford University, a tertiary academic medical center, from September 2014 to December 2016, when enrollment reached its target', 'aged mice', 'Alzheimer Symptom Amelioration Study']","['yFFP from male donors or 250 mL of saline', 'yFFP', 'placebo', 'young fresh frozen plasma (yFFP', 'Young Plasma Infusion']","['sinus tachycardia', 'baseline Mini-Mental State Examination score', 'safety, tolerability, and feasibility of 4 weekly yFFP infusions', 'hypertension', 'headache', 'Safety, Tolerability, and Feasibility', 'safety, tolerability', 'total visit requirement due to early patient discontinuation', 'safe, well tolerated, and feasible', 'mean visit adherence', 'serious adverse events', 'dizziness', 'sinus bradycardia']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0450355', 'cui_str': '31 (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0000872', 'cui_str': 'University Medical Centers'}, {'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}, {'cui': 'C0026809', 'cui_str': 'Mice'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0016709', 'cui_str': 'Fresh frozen plasma (product)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}]","[{'cui': 'C0039239', 'cui_str': 'Sinus Tachycardia'}, {'cui': 'C2960235', 'cui_str': 'Mini-mental state examination score (observable entity)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0085610', 'cui_str': 'Sinus bradycardia (disorder)'}]",9.0,0.241668,There were no related serious adverse events.,"[{'ForeName': 'Sharon J', 'Initials': 'SJ', 'LastName': 'Sha', 'Affiliation': 'Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.'}, {'ForeName': 'Gayle K', 'Initials': 'GK', 'LastName': 'Deutsch', 'Affiliation': 'Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Tian', 'Affiliation': 'Department of Health Research and Policy, Stanford University, Stanford, California.'}, {'ForeName': 'Kara', 'Initials': 'K', 'LastName': 'Richardson', 'Affiliation': 'Science37, San Francisco, California.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Coburn', 'Affiliation': 'Department of Neurosurgery, Stanford University, Stanford, California.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Gaudioso', 'Affiliation': 'Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.'}, {'ForeName': 'Tatiana', 'Initials': 'T', 'LastName': 'Marcal', 'Affiliation': 'Department of Pediatrics, Stanford University, Stanford, California.'}, {'ForeName': 'Ethan', 'Initials': 'E', 'LastName': 'Solomon', 'Affiliation': ""Alzheimer's Therapeutic Research Institute, University of Southern California, Los Angeles.""}, {'ForeName': 'Athanasia', 'Initials': 'A', 'LastName': 'Boumis', 'Affiliation': 'Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Bet', 'Affiliation': 'Department of Neurosurgery, Stanford University, Stanford, California.'}, {'ForeName': 'Maarten', 'Initials': 'M', 'LastName': 'Mennes', 'Affiliation': 'SBGneuro Ltd, Oxford, England.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'van Oort', 'Affiliation': 'SBGneuro Ltd, Oxford, England.'}, {'ForeName': 'Christian F', 'Initials': 'CF', 'LastName': 'Beckmann', 'Affiliation': 'SBGneuro Ltd, Oxford, England.'}, {'ForeName': 'Steven P', 'Initials': 'SP', 'LastName': 'Braithwaite', 'Affiliation': 'Alkahest, San Carlos, California.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Jackson', 'Affiliation': 'Alkahest, San Carlos, California.'}, {'ForeName': 'Karoly', 'Initials': 'K', 'LastName': 'Nikolich', 'Affiliation': 'Alkahest, San Carlos, California.'}, {'ForeName': 'Darby', 'Initials': 'D', 'LastName': 'Stephens', 'Affiliation': 'Alkahest, San Carlos, California.'}, {'ForeName': 'Geoffrey A', 'Initials': 'GA', 'LastName': 'Kerchner', 'Affiliation': 'Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Wyss-Coray', 'Affiliation': 'Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.'}]",JAMA neurology,['10.1001/jamaneurol.2018.3288'] 572,29600288,Diffusion Tensor Cardiac Magnetic Resonance Reveals Exosomes From Cardiosphere-Derived Cells Preserve Myocardial Fiber Architecture After Myocardial Infarction.,"The object of the study was to reveal the fiber microstructural response with diffusion tensor cardiac magnetic resonance after intramyocardial exosomes secreted by cardiosphere-derived cells (CDC EXO ) in chronic porcine myocardial infarction. Porcine with myocardial infarction underwent intramyocardial delivery of human CDC EXO and placebo in a randomized placebo-controlled study. Four weeks after injection, viability improved in the CDC EXO group, whereas myocardial fiber architecture and cardiac function were preserved. In the placebo group, fiber architecture and cardiac function declined. Myocardial regeneration by CDC EXO is not tumor-like; instead, details of tissue architecture are faithfully preserved, which may foster physiological excitation and contraction.",2018,"Four weeks after injection, viability improved in the CDC EXO group, whereas myocardial fiber architecture and cardiac function were preserved.",['chronic porcine myocardial infarction'],"['human CDC EXO and placebo', 'placebo', 'cardiosphere-derived cells (CDC EXO ']","['myocardial fiber architecture and cardiac function', 'viability', 'fiber architecture and cardiac function']","[{'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}]","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0007670', 'cui_str': 'CDC'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0007634', 'cui_str': 'Cells'}]","[{'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C0003737', 'cui_str': 'Architecture'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function (observable entity)'}]",,0.126923,"Four weeks after injection, viability improved in the CDC EXO group, whereas myocardial fiber architecture and cardiac function were preserved.","[{'ForeName': 'Christopher T', 'Initials': 'CT', 'LastName': 'Nguyen', 'Affiliation': 'Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Dawkins', 'Affiliation': 'Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Xiaoming', 'Initials': 'X', 'LastName': 'Bi', 'Affiliation': 'MR R&D, Siemens Healthcare, Los Angeles, California.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Marbán', 'Affiliation': 'Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Debiao', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.'}]",JACC. Basic to translational science,['10.1016/j.jacbts.2017.09.005'] 573,31919404,"Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial.","BACKGROUND No standard treatment is available for advanced biliary tract cancer (BTC) after first-line therapy with gemcitabine plus cisplatin (GEMCIS). The objective of this study was to evaluate safety and anti-tumour activity of fluorouracil, leucovorin, irinotecan plus oxaliplatin (FOLFIRINOX) as salvage treatment in patients with previously treated advanced BTC. METHODS In this two-stage phase 2 study, patients with advanced BTC who had disease progression or unacceptable toxicity after ≥3 cycles of GEMCIS were eligible. Primary endpoints were safety and efficacy (defined as objective response rate, ORR). In stage one, ten patients were treated with FOLFIRINOX every 2 weeks. In stage two, an additional 20 patients were enrolled at a starting dose as defined in stage one, provided that in stage ≥1 objective response or ≥2 stable diseases were observed and ≤3 patients had serious adverse events (SAEs) within the first 6 weeks of treatment. Secondary endpoints were progression-free survival (PFS) and overall survival (OS). RESULTS Forty patients were screened for eligibility and 30 patients were enrolled. In stage one, one patient had a partial response and five patients had stable disease. One patient had a SAE during the first 6 weeks of treatment, and five patients required a dose reduction due to adverse events. The most common grade 3-4 adverse events in stage one were neutropaenia, mucositis and diarrhoea. Stage two was initiated with FOLFIRINOX in an adapted dose. In stage two, grade 3-4 neutropaenia, diarrhoea, nausea and vomiting were the most common adverse events. The ORR, median PFS and OS in all patients were 10%, 6.2 and 10.7 months, respectively. CONCLUSIONS In patients with advanced BTC who progressed after or were intolerant to GEMCIS, FOLFIRINOX can be administered safely and could be considered as an option for salvage treatment in these patients. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov Identifier NCT02456714.",2020,"In stage two, grade 3-4 neutropaenia, diarrhoea, nausea and vomiting were the most common adverse events.","['advanced biliary tract cancer', 'Forty patients were screened for eligibility and 30 patients were enrolled', 'patients with advanced BTC who progressed after or were intolerant to', 'patients with previously treated advanced BTC', 'patients with advanced BTC who had disease progression or unacceptable toxicity after ≥3 cycles of GEMCIS were eligible']","['fluorouracil, leucovorin, irinotecan plus oxaliplatin (FOLFIRINOX', 'gemcitabine plus cisplatin (GEMCIS', 'GEMCIS']","['neutropaenia, mucositis and diarrhoea', 'neutropaenia, diarrhoea, nausea and vomiting', 'ORR, median PFS and OS', 'Efficacy and safety', 'serious adverse events (SAEs', 'safety and efficacy (defined as objective response rate, ORR', 'adverse events', 'progression-free survival (PFS) and overall survival (OS']","[{'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0750952', 'cui_str': 'Biliary Tract Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0242656', 'cui_str': 'Disease Progression'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}]","[{'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C2721771', 'cui_str': 'levoleucovorin'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}]","[{'cui': 'C0333355', 'cui_str': 'Mucositis'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting (disorder)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",40.0,0.171873,"In stage two, grade 3-4 neutropaenia, diarrhoea, nausea and vomiting were the most common adverse events.","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Belkouz', 'Affiliation': 'Amsterdam UMC, Department of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'de Vos-Geelen', 'Affiliation': 'Maastricht UMC+, GROW - School for Oncology and Developmental Biology, Department Of Internal Medicine Division of Medical, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands.'}, {'ForeName': 'Ron A A', 'Initials': 'RAA', 'LastName': 'Mathôt', 'Affiliation': 'Amsterdam UMC, Department of Pharmacy, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'Ferry A L M', 'Initials': 'FALM', 'LastName': 'Eskens', 'Affiliation': 'Erasmus MC, Department of Medical Oncology, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'van Gulik', 'Affiliation': 'Amsterdam UMC, Department of Surgery, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'Martijn G H', 'Initials': 'MGH', 'LastName': 'van Oijen', 'Affiliation': 'Amsterdam UMC, Department of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'Cornelis J A', 'Initials': 'CJA', 'LastName': 'Punt', 'Affiliation': 'Amsterdam UMC, Department of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'Johanna W', 'Initials': 'JW', 'LastName': 'Wilmink', 'Affiliation': 'Amsterdam UMC, Department of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'Heinz-Josef', 'Initials': 'HJ', 'LastName': 'Klümpen', 'Affiliation': 'Amsterdam UMC, Department of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. h.klumpen@amsterdamumc.nl.'}]",British journal of cancer,['10.1038/s41416-019-0698-9'] 574,31910903,"Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels.","BACKGROUND Despite increased atherothrombotic risk in type 2 diabetes mellitus, (T2DM) the best preventative antithrombotic strategy remains undetermined. We defined the effects of three antiplatelet agents on functional readout and biomarker kinetics in platelet activation and coagulation in patients with T2DM. MATERIALS AND METHODS 56 patients with T2DM were randomised to antiplatelet monotherapy with aspirin 75 mg once daily (OD), clopidogrel 75 mg OD or prasugrel 10 mg OD during three periods of a crossover study. Platelet aggregation (PA) was determined by light-transmittance aggregometry and P-selectin expression by flow cytometry. Markers of fibrin clot dynamics, inflammation and coagulation were measured. Plasma levels of 14 miRNA were assessed by quantitative polymerase chain reactions. RESULTS Of the 56 patients, 24 (43%) were receiving aspirin for primary prevention of ischaemic events and 32 (57%) for secondary prevention. Prasugrel was the strongest inhibitor of ADP-induced PA (mean ± SD maximum response to 20μmol/L ADP 77.6 ± 8.4% [aspirin] vs. 57.7 ± 17.6% [clopidogrel] vs. 34.1 ± 14.1% [prasugrel], p < 0.001), P-selectin expression (30 μmol/L ADP; 45.1 ± 21.4% vs. 27.1 ± 19.0% vs. 14.1 ± 14.9%, p < 0.001) and collagen-induced PA (2 μg/mL; 62.1 ± 19.4% vs. 72.3 ± 18.2% vs. 60.2 ± 18.5%, p < 0.001). Fibrin clot dynamics and levels of coagulation and inflammatory proteins were similar. Lower levels of miR-24 (p = 0.004), miR-191 (p = 0.019), miR-197 (p = 0.009) and miR-223 (p = 0.014) were demonstrated during prasugrel-therapy vs. aspirin. Circulating miR-197 was lower in those cardiovascular disease during therapy with aspirin (p = 0.039) or prasugrel (p = 0.0083). CONCLUSIONS Prasugrel monotherapy in T2DM provided potent platelet inhibition and reduced levels of a number of platelet-associated miRNAs. miR-197 is a potential marker of cardiovascular disease in this population. Clinical outcome studies investigating prasugrel monotherapy are warranted in individuals with T2DM. Trial registration EudraCT, 2009-011907-22. Registered 15 March 2010, https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011907-22/GB.",2020,"Lower levels of miR-24 (p = 0.004), miR-191 (p = 0.019), miR-197 (p = 0.009) and miR-223 (p = 0.014) were demonstrated during prasugrel-therapy vs. aspirin.","['Of the 56 patients, 24 (43%) were receiving', 'individuals with T2DM', '56 patients with T2DM', 'patients with type 2 diabetes mellitus', 'patients with T2DM']","['prasugrel-therapy vs. aspirin', 'Prasugrel', 'aspirin', 'Aspirin, clopidogrel and prasugrel monotherapy', 'antiplatelet monotherapy with aspirin 75\xa0mg once daily (OD), clopidogrel 75\xa0mg OD or prasugrel 10\xa0mg OD']","['Lower levels of miR-24', 'miR-191', 'ischaemic events', 'Circulating miR-197', 'Platelet aggregation (PA', 'P-selectin expression', 'fibrin clot dynamics, inflammation and coagulation', 'miR-223', 'miR-197', 'Plasma levels', 'atherothrombotic risk', 'Fibrin clot dynamics and levels of coagulation and inflammatory proteins']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]","[{'cui': 'C1620287', 'cui_str': 'prasugrel'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0983879', 'cui_str': 'Aspirin 75 MG'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C1124675', 'cui_str': 'clopidogrel 75 MG'}, {'cui': 'C2710121', 'cui_str': 'prasugrel 10 MG [Effient]'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0677599', 'cui_str': 'Platelet aggregation'}, {'cui': 'C0134835', 'cui_str': 'Platelet alpha-Granule Membrane Protein'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0015982', 'cui_str': 'Fibrin'}, {'cui': 'C0302148', 'cui_str': 'Blood coagulum'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0441509', 'cui_str': 'Coagulation - action (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}]",56.0,0.259153,"Lower levels of miR-24 (p = 0.004), miR-191 (p = 0.019), miR-197 (p = 0.009) and miR-223 (p = 0.014) were demonstrated during prasugrel-therapy vs. aspirin.","[{'ForeName': 'William A E', 'Initials': 'WAE', 'LastName': 'Parker', 'Affiliation': 'Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Schulte', 'Affiliation': ""King's British Heart Foundation Centre, King's College London, London, UK.""}, {'ForeName': 'Temo', 'Initials': 'T', 'LastName': 'Barwari', 'Affiliation': ""King's British Heart Foundation Centre, King's College London, London, UK.""}, {'ForeName': 'Fladia', 'Initials': 'F', 'LastName': 'Phoenix', 'Affiliation': 'Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.'}, {'ForeName': 'Sam M', 'Initials': 'SM', 'LastName': 'Pearson', 'Affiliation': 'Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Mayr', 'Affiliation': ""King's British Heart Foundation Centre, King's College London, London, UK.""}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Grant', 'Affiliation': 'Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.'}, {'ForeName': 'Robert F', 'Initials': 'RF', 'LastName': 'Storey', 'Affiliation': 'Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Ramzi A', 'Initials': 'RA', 'LastName': 'Ajjan', 'Affiliation': 'Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. R.Ajjan@leeds.ac.uk.'}]",Cardiovascular diabetology,['10.1186/s12933-019-0981-3'] 575,31939347,Effect of nurse-led food exchange intervention for patients undergoing peritoneal dialysis
.,"AIM We aimed to apply nurse-led food exchange model intervention to peritoneal dialysis (PD) patients and verify its effectiveness. BACKGROUND Protein-energy malnutrition is a prominent problem in patients on PD, and it has been estimated that 40% of PD patients suffer from malnutrition to some extent. INTRODUCTION The rate of malnutrition among PD patients has been relatively high in recent years. Although a lot of effort has been made to alter the situation, an effective method has yet to be implemented. MATERIALS AND METHODS We recruited 142 patients according to the inclusion and exclusion criteria and divided them into study group (n = 71) and control group (n = 71) using a random-number table generated by SPSS22.0. The control group received routine dietary guidance and instruction while the study group received nurse-led food exchange intervention. The subjective global assessment (SGA) scale scores, nutrition parameter, and dialysis efficacy indicators between the two groups were compared at baseline and after 12 months of intervention. RESULTS There were no significant differences between the two groups in all dimensions at the baseline measures (p > 0.05). However, after 12 months of intervention, the study group represented a higher score of SGA while the control group declined, which was significantly different (p = 0.022). The study group had an improved level of body mass index, triceps skinfold thickness, middle-arm muscle circumference, serum albumin, prealbumin, and normalized protein catabolic rate, while the control group showed decreased levels, and these results were significantly different (p = 0.001, p = 0.019, p = 0.001, p < 0.001, p = 0.043, respectively). Moreover, blood urea nitrogen declined in the study group and increased in the control group, which was significantly different (p = 0.004). CONCLUSION Nurse-led food exchange model intervention improved nutrition condition of PD patients dramatically. Implications for nursing and/or health policy: Our study provides a basis for health policy designers to develop nutrition programs and encourage clinical nurses to participate in PD patients' diet management.",2020,"The study group had an improved level of body mass index, triceps skinfold thickness, middle-arm muscle circumference, serum albumin, prealbumin, and normalized protein catabolic rate, while the control group showed decreased levels, and these results were significantly different (p = 0.001, p = 0.019, p = 0.001,","['patients undergoing peritoneal dialysis\u2029', 'We recruited 142 patients according to the inclusion and exclusion criteria and divided them into study group (n\xa0=\xa071) and control group (n\xa0=\xa071) using a', 'nursing and/or health policy']","['Nurse-led food exchange model intervention', 'routine dietary guidance and instruction while the study group received nurse-led food exchange intervention', 'nurse-led food exchange model intervention to peritoneal dialysis (PD', 'nurse-led food exchange intervention', 'random-number table generated by SPSS22.0']","['higher score of SGA', 'level of body mass index, triceps skinfold thickness, middle-arm muscle circumference, serum albumin, prealbumin, and normalized protein catabolic rate', 'rate of malnutrition', 'subjective global assessment (SGA) scale scores, nutrition parameter, and dialysis efficacy indicators', 'nutrition condition', 'blood urea nitrogen']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0031139', 'cui_str': 'Peritoneal Dialysis'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332286', 'cui_str': 'Into (attribute)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0028678', 'cui_str': 'nursing care'}, {'cui': 'C0018735', 'cui_str': 'Health Policy'}]","[{'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0031139', 'cui_str': 'Peritoneal Dialysis'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1706074', 'cui_str': 'Table'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0037302', 'cui_str': 'Skinfold Thickness'}, {'cui': 'C0444598', 'cui_str': 'Mid (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0523465', 'cui_str': 'Albumin measurement, serum (procedure)'}, {'cui': 'C0032923', 'cui_str': 'Transthyretin'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0162429', 'cui_str': 'Malnutrition'}, {'cui': 'C0451514', 'cui_str': 'Subjective global assessment (assessment scale)'}, {'cui': 'C0222045'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C4551529', 'cui_str': 'Renal Dialysis'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0600137', 'cui_str': 'Blood urea nitrogen (substance)'}]",142.0,0.0314102,"The study group had an improved level of body mass index, triceps skinfold thickness, middle-arm muscle circumference, serum albumin, prealbumin, and normalized protein catabolic rate, while the control group showed decreased levels, and these results were significantly different (p = 0.001, p = 0.019, p = 0.001,","[{'ForeName': 'Yixin', 'Initials': 'Y', 'LastName': 'Luo', 'Affiliation': ''}, {'ForeName': 'Yanlin', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Yongsheng', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Xiang', 'Affiliation': ''}, {'ForeName': 'Qiaoyuan', 'Initials': 'Q', 'LastName': 'Wu', 'Affiliation': ''}]",Clinical nephrology,['10.5414/CN109898'] 576,31957558,Prenatal docosahexaenoic acid supplementation has long-term effects on childhood behavioral and brain responses during performance on an inhibitory task.,"Introduction: Offsprings from a prenatal docosahexaenoic acid (DHA) supplementation trial, in which pregnant women were assigned to placebo or 600mg DHA/day, were followed to determine the effect of prenatal DHA supplementation on the behavior and brain function at 5.5 years (n=81 placebo, n=86 supplemented). Methods: Event-related potentials (ERP) were recorded during a visual task requiring a button press (Go) to frequent target stimuli and response inhibition to the rare stimuli (No-Go). Univariate ANOVAs were used to test differences between group and sex for behavioral measures. ERP differences were tested using a three-way mixed-design multivariate analysis of variance (MANOVA). Results: There was a significant sex × group interaction for hit rate and errors of omission; there was no difference between males and females in the placebo group, but DHA males outperformed DHA females. Males overall and the placebo group made more errors requiring response inhibition; DHA females were significantly better than placebo females and DHA males. ERP P2 amplitude was larger in the DHA group. A significant N2 amplitude condition effect was observed in females and DHA group males, but not in placebo group males. Discussion: Prenatal DHA supplementation improved inhibitory performance overall, especially for females in the DHA group, possibly accounting for their conservative behavior during Go trials. Development of brain regions responsible for visual processing may be sensitive to maternal DHA status, evidenced by greater P2 amplitude. Males may benefit more from maternal DHA supplementation, indicated by the N2 condition effect seen only in males in the DHA group.",2020,Males overall and the placebo group made more errors requiring response inhibition; DHA females were significantly better than placebo females and DHA males.,['pregnant women'],"['placebo', 'Prenatal docosahexaenoic acid supplementation', 'prenatal DHA supplementation', 'Prenatal DHA supplementation', 'prenatal docosahexaenoic acid (DHA) supplementation']","['errors requiring response inhibition; DHA females', 'hit rate and errors of omission', 'N2 amplitude condition effect', 'Event-related potentials (ERP', 'ERP P2 amplitude', 'childhood behavioral and brain responses']","[{'cui': 'C0033011', 'cui_str': 'Pregnant Women'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0556102', 'cui_str': 'DHA - Docosahexaenoic acid supplementation'}]","[{'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0596020', 'cui_str': 'Does hit (finding)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0282171', 'cui_str': 'Potentials, Event-Related'}, {'cui': 'C0337380', 'cui_str': 'Endoscopic retrograde pancreatography (procedure)'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}]",86.0,0.176488,Males overall and the placebo group made more errors requiring response inhibition; DHA females were significantly better than placebo females and DHA males.,"[{'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Gustafson', 'Affiliation': 'Department of Neurology, University of Kansas Medical Center (KUMC), Kansas City, KS, USA.'}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Liao', 'Affiliation': 'Hoglund Brain Imaging Center, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Nicole B', 'Initials': 'NB', 'LastName': 'Mathis', 'Affiliation': 'Department of Neurology, University of Kansas Medical Center (KUMC), Kansas City, KS, USA.'}, {'ForeName': 'D Jill', 'Initials': 'DJ', 'LastName': 'Shaddy', 'Affiliation': 'Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Elizabeth H', 'Initials': 'EH', 'LastName': 'Kerling', 'Affiliation': 'Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Danielle N', 'Initials': 'DN', 'LastName': 'Christifano', 'Affiliation': 'Hoglund Brain Imaging Center, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Colombo', 'Affiliation': 'Department of Psychology/Schiefelbusch Institute for Life Span Studies, University of Kansas (KU), Lawrence, KS, USA.'}, {'ForeName': 'Susan E', 'Initials': 'SE', 'LastName': 'Carlson', 'Affiliation': 'Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, KS, USA.'}]",Nutritional neuroscience,['10.1080/1028415X.2020.1712535'] 577,31957654,Long-term effects of cardiac rehabilitation on sleep apnea severity in patients with coronary artery disease.,"STUDY OBJECTIVES Sleep apnea (SA) is prevalent among patients with coronary artery disease (CAD) and increases cardiovascular risk. A previous study showed that 1 month of cardiac rehabilitation (CR) reduced severity of SA in patients with CAD by reducing fluid accumulation in the legs during the day and the amount of fluid shifting rostrally into the neck overnight. The aim of this study was to evaluate whether CR will lead to longer-term attenuation of SA in patients with CAD. METHODS Fifteen patients with CAD and SA who had participated in a 1-month randomized trial of the effects of exercise training on SA were followed up until they completed 6 months of CR (age: 65 ± 10 years; body mass index: 27.0 ± 3.9 kg/m²; apnea-hypopnea index [AHI]: 39.0 ± 16.7). The AHI was evaluated at baseline by polysomnography and then at 6 months by portable monitoring at home. Cardiorespiratory fitness (VO 2peak ) was evaluated via a graded cardiopulmonary exercise test at baseline and 6 months later. The 6-month CR program included once weekly, 90-minute, in-facility exercise sessions, and 4 days per week at-home exercise sessions. RESULTS After 6 months of CR, there was a 54% reduction in the AHI (30.5 ± 15.2 to 14.1 ± 7.5, P < .001). Body mass index remained unchanged, but VO 2peak increased by 27% (20.0 ± 6.1 to 26.0 ± 8.9 mL/kg/min, P = .04). CONCLUSIONS Participation in CR is associated with a significant long-term decrease in the severity of SA. This finding suggests that attenuation of SA by exercise could be a mechanism underlying reduced mortality following participation in CR in patients with CAD and SA. CLINICAL TRIAL REGISTRATION This study is registered at www.controlled-trials.com with identifier number ISRCTN50108373.",2020,"Body mass index remained unchanged, but VO 2peak increased by 27% (20.0 ± 6.1 to 26.0 ± 8.9 mL/kg/min, P = .04). ","['patients with coronary artery disease (CAD) and increases cardiovascular risk', 'patients with CAD', 'patients with coronary artery disease', 'patients with CAD and SA', 'Fifteen patients with CAD and SA who had participated']","['exercise training', 'cardiac rehabilitation', 'cardiac rehabilitation (CR']","['Body mass index', 'sleep apnea severity', 'Cardiorespiratory fitness (VO 2peak ', 'VO 2peak']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1956346', 'cui_str': 'Coronary Artery Disease'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0700431', 'cui_str': 'Cardiovascular Rehabilitation'}]","[{'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0037315', 'cui_str': 'Sleep Hypopnea'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}]",,0.0969035,"Body mass index remained unchanged, but VO 2peak increased by 27% (20.0 ± 6.1 to 26.0 ± 8.9 mL/kg/min, P = .04). ","[{'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Mendelson', 'Affiliation': 'Sleep Research Laboratory, University Health Network Toronto Rehabilitation Institute, Toronto, Canada.'}, {'ForeName': 'Toru', 'Initials': 'T', 'LastName': 'Inami', 'Affiliation': 'Sleep Research Laboratory, University Health Network Toronto Rehabilitation Institute, Toronto, Canada.'}, {'ForeName': 'Owen', 'Initials': 'O', 'LastName': 'Lyons', 'Affiliation': 'Sleep Research Laboratory, University Health Network Toronto Rehabilitation Institute, Toronto, Canada.'}, {'ForeName': 'Hisham', 'Initials': 'H', 'LastName': 'Alshaer', 'Affiliation': 'Sleep Research Laboratory, University Health Network Toronto Rehabilitation Institute, Toronto, Canada.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Marzolini', 'Affiliation': 'Cardiac Rehabilitation and Prevention, University Health Network Toronto Rehabilitation Institute, Toronto, Canada.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Oh', 'Affiliation': 'Cardiac Rehabilitation and Prevention, University Health Network Toronto Rehabilitation Institute, Toronto, Canada.'}, {'ForeName': 'T Douglas', 'Initials': 'TD', 'LastName': 'Bradley', 'Affiliation': 'Sleep Research Laboratory, University Health Network Toronto Rehabilitation Institute, Toronto, Canada.'}]",Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine,['10.5664/jcsm.8124'] 578,31835476,"Effect of Fibre-Enriched Orange Juice on Postprandial Glycaemic Response and Satiety in Healthy Individuals: An Acute, Randomised, Placebo-Controlled, Double-Blind, Crossover Study.","Background : Consumption of fibre-enriched orange juice may be an appropriate way to supplement daily fibre intake and achieve beneficial effects on metabolic health. The present study aimed to assess the short-term effects of fibre-enriched orange juice on postprandial metabolism and satiety in a healthy adult population. Methods : In this double-blind, randomised, placebo-controlled, crossover study 10 healthy subjects underwent two one-day trials in which they consumed an orange juice beverage containing 1.4 g/100 mL of citrus fibre (29.3% soluble and 41.9% insoluble) or a placebo (regular orange juice without added fibre). Postprandial glucose, insulin, gut hormones (GLP1, GIP and ghrelin), leptin and qualitative appetite/satiety assessment were measured every 15 or 30 min over the 120 min test period. Results : The fibre-enriched orange juice decreased postprandial serum glucose and circulating insulin levels at 15 min compared with the placebo. In addition, after intake of the fibre-enriched juice, a significant effect on qualitative feelings of satiety and fullness was observed at 15 and 120 min, and was accompanied by a significant decrease in GLP1 response at 15 min. No significant changes were observed in leptin, GIP and ghrelin after juice intake. Conclusions : In healthy individuals, a single acute consumption of fibre-enriched orange juice has short-term beneficial effects on postprandial glycaemia, circulating insulin levels and satiety through GLP1 secretion.",2019,"Postprandial glucose, insulin, gut hormones (GLP1, GIP and ghrelin), leptin and qualitative appetite/satiety assessment were measured every 15 or 30 min over the 120 min test period. ","['healthy adult population', 'healthy individuals', '10 healthy subjects underwent two one-day trials in which they consumed an orange juice beverage containing 1.4 g/100 mL of citrus fibre (29.3% soluble and 41.9% insoluble) or a', 'Healthy Individuals']","['placebo', 'Placebo', 'Fibre-Enriched Orange Juice', 'fibre-enriched orange juice', 'placebo (regular orange juice without added fibre']","['GLP1 response', 'qualitative feelings of satiety and fullness', 'Postprandial Glycaemic Response and Satiety', 'postprandial serum glucose and circulating insulin levels', 'postprandial metabolism and satiety', 'leptin, GIP and ghrelin after juice intake', 'Postprandial glucose, insulin, gut hormones (GLP1, GIP and ghrelin), leptin and qualitative appetite/satiety assessment']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0452458', 'cui_str': 'Orange juice'}, {'cui': 'C0005329', 'cui_str': 'Beverages'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C4517503', 'cui_str': '1.4 (qualifier value)'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C0452458', 'cui_str': 'Orange juice'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}]","[{'cui': 'C0205556', 'cui_str': 'Qualitative (qualifier value)'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0036239', 'cui_str': 'Satiations'}, {'cui': 'C0439650', 'cui_str': 'Fullness (qualifier value)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0202041', 'cui_str': 'Glucose measurement, serum (procedure)'}, {'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C1702020', 'cui_str': '37-epsilon-palmitoyl-Lys-GIP'}, {'cui': 'C0911014', 'cui_str': 'Ghrelin (substance)'}, {'cui': 'C1268568', 'cui_str': 'Juice'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",10.0,0.364156,"Postprandial glucose, insulin, gut hormones (GLP1, GIP and ghrelin), leptin and qualitative appetite/satiety assessment were measured every 15 or 30 min over the 120 min test period. ","[{'ForeName': 'Neus', 'Initials': 'N', 'LastName': 'Bosch-Sierra', 'Affiliation': 'Service of Endocrinology, University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avda Gaspar Aguilar 90, 46017 Valencia, Spain.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Marqués-Cardete', 'Affiliation': 'Zumos Valencianos del Mediterraneo S.A., Calle del Pollancar (Pol Industrial Parc Sagunt I) S/N, 46520 Puerto de Sagunto, Valencia, Spain.'}, {'ForeName': 'Aránzazu', 'Initials': 'A', 'LastName': 'Gurrea-Martínez', 'Affiliation': 'Zumos Valencianos del Mediterraneo S.A., Calle del Pollancar (Pol Industrial Parc Sagunt I) S/N, 46520 Puerto de Sagunto, Valencia, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Grau-Del Valle', 'Affiliation': 'Service of Endocrinology, University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avda Gaspar Aguilar 90, 46017 Valencia, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Morillas', 'Affiliation': 'Service of Endocrinology, University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avda Gaspar Aguilar 90, 46017 Valencia, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Hernández-Mijares', 'Affiliation': 'Service of Endocrinology, University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avda Gaspar Aguilar 90, 46017 Valencia, Spain.'}, {'ForeName': 'Celia', 'Initials': 'C', 'LastName': 'Bañuls', 'Affiliation': 'Service of Endocrinology, University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avda Gaspar Aguilar 90, 46017 Valencia, Spain.'}]",Nutrients,['10.3390/nu11123014'] 579,31928846,Clinical and MRI Predictors of Conversion From Mild Behavioural Impairment to Dementia.,"OBJECTIVE As an analogy with mild cognitive impairment (MCI), the mild behavioral impairment (MBI) construct has been proposed as a diagnostic label for those presenting late-onset behavioral symptoms. To date, however, the clinical, cognitive, and structural imaging features associated with an increased risk of conversion from MBI to dementia are poorly understood. METHODS We retrospectively analyzed the cognitive performance and structural brain MRI of 113 subjects, with a clinical follow-up of at least 4 years available. Subjects were randomly assigned to a Group A (56 subjects; age: 65.4 ± 7.9 years, 15 females, MMSE score: 28.4 ± 2.3)) or to a Group B (57 subjects, age: 66.6 ± 6.4, 17 females, MMSE score: 28.0 ± 1.4). In the Group A, cognitive and structural variables were compared between converters (at 4 years) and nonconverters and then verified in the Group B group. RESULTS In the Group A, 14 patients converted to behavioral-variant of frontotemporal dementia (bv-FTD) and 4 to Alzheimer's Disease (AD). Converters presented at baseline lower executive function scores and total Theory of Mind (ToM scores), as well as more severe focal frontal atrophy. In the Group B, 13 subjects converted to bv-FTD and none to AD. The combination of the variables identified in the Group A significantly (p <0.001) discriminated between converters and nonconverters in the Group B with a sensitivity of 0.615 and a specificity of 1 (total accuracy 91.22%). CONCLUSION The combined presence of executive deficit, impaired ToM, and presence of isolated frontal atrophy was associated with risk of progression from MBI to a clinically evident neurodegenerative condition, mainly bv-FTD, over a 4-year period.",2020,"The combination of the variables identified in the Group A significantly (p <0.001) discriminated between converters and nonconverters in the Group B with a sensitivity of 0.615 and a specificity of 1 (total accuracy 91.22%). ","['113 subjects, with a clinical follow-up of at least 4 years available', 'Subjects were randomly assigned to a Group A (56 subjects; age: 65.4 ± 7.9 years, 15 females, MMSE score: 28.4 ± 2.3)) or to a Group B (57 subjects, age: 66.6 ± 6.4, 17 females, MMSE score: 28.0 ± 1.4', ""14 patients converted to behavioral-variant of frontotemporal dementia (bv-FTD) and 4 to Alzheimer's Disease (AD""]",[],"['severe focal frontal atrophy', 'executive function scores and total Theory of Mind (ToM scores']","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0441835', 'cui_str': 'Group A (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0441836', 'cui_str': 'Group B (qualifier value)'}, {'cui': 'C4517822', 'cui_str': '6.4 (qualifier value)'}, {'cui': 'C4517503', 'cui_str': '1.4 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4011788', 'cui_str': 'Behavioral variant of frontotemporal dementia (disorder)'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}]",[],"[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205234', 'cui_str': 'Focal (qualifier value)'}, {'cui': 'C0205123', 'cui_str': 'Coronal (qualifier value)'}, {'cui': 'C0333641', 'cui_str': 'Atrophy'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0935573', 'cui_str': 'Mentalizing'}]",113.0,0.0375881,"The combination of the variables identified in the Group A significantly (p <0.001) discriminated between converters and nonconverters in the Group B with a sensitivity of 0.615 and a specificity of 1 (total accuracy 91.22%). ","[{'ForeName': 'B', 'Initials': 'B', 'LastName': 'Orso', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa (Beatrice Orso, Dario Arnaldi, Federico Massa, Gianluca Serafini, Elisa Doglione, Flavio Nobili, Matteo Pardini), Italy.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Mattei', 'Affiliation': 'Bozen Civic Hospital (Chiara Mattei), Bozen, Italy.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Arnaldi', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa (Beatrice Orso, Dario Arnaldi, Federico Massa, Gianluca Serafini, Elisa Doglione, Flavio Nobili, Matteo Pardini), Italy; Policlinico S. Martino IRCCS (Dario Arnaldi, Gianluca Serafini, Flavio Nobili, Matteo Pardini), Genova, Italy.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Massa', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa (Beatrice Orso, Dario Arnaldi, Federico Massa, Gianluca Serafini, Elisa Doglione, Flavio Nobili, Matteo Pardini), Italy.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Serafini', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa (Beatrice Orso, Dario Arnaldi, Federico Massa, Gianluca Serafini, Elisa Doglione, Flavio Nobili, Matteo Pardini), Italy; Policlinico S. Martino IRCCS (Dario Arnaldi, Gianluca Serafini, Flavio Nobili, Matteo Pardini), Genova, Italy.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Plantone', 'Affiliation': 'Neurology Unit, Di Venere Hospital (Domenico Plantone), Bari, Italy.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Doglione', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa (Beatrice Orso, Dario Arnaldi, Federico Massa, Gianluca Serafini, Elisa Doglione, Flavio Nobili, Matteo Pardini), Italy.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Grafman', 'Affiliation': 'Cognitive Neuroscience Laboratory, Shirley Ryan Ability Lab (Jordan Grafman), Chicago, IL.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Nobili', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa (Beatrice Orso, Dario Arnaldi, Federico Massa, Gianluca Serafini, Elisa Doglione, Flavio Nobili, Matteo Pardini), Italy; Policlinico S. Martino IRCCS (Dario Arnaldi, Gianluca Serafini, Flavio Nobili, Matteo Pardini), Genova, Italy.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Pardini', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa (Beatrice Orso, Dario Arnaldi, Federico Massa, Gianluca Serafini, Elisa Doglione, Flavio Nobili, Matteo Pardini), Italy; Policlinico S. Martino IRCCS (Dario Arnaldi, Gianluca Serafini, Flavio Nobili, Matteo Pardini), Genova, Italy. Electronic address: matteo.pardini@unige.it.'}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2019.12.007'] 580,31954158,Patient-centered change in the day-to-day impact of postmenopausal vaginal symptoms: results from a multicenter randomized trial.,"BACKGROUND Vulvovaginal symptoms, which include dryness, irritation, and pain with intercourse, are common among postmenopausal women and are associated with impaired sexual functioning and quality of life. Previous assessment of treatment strategies for these symptoms has been limited by a lack of sensitive patient-centered outcome measures that assess symptom impact on functional and quality-of-life domains. OBJECTIVE We aimed to (1) examine change in the impact of postmenopausal vulvovaginal symptoms on multiple aspects of well-being and functioning in relation to vaginal estradiol and moisturizer treatment and (2) guide meaningful interpretation of scores on a structured-item questionnaire measure of condition-specific impact. STUDY DESIGN Data were drawn from postmenopausal women who were enrolled in the Menopause Strategies: Finding Lasting Answers for Symptoms and Health Vaginal Health Trial (a 12-week, double-blind, placebo-controlled randomized trial of treatment for vulvovaginal symptoms) who were assigned to vaginal 10-μg estradiol tablet plus placebo gel (n=98), vaginal moisturizer plus placebo tablet (n=97), or dual placebo (n=94). At baseline and 12-week follow up, participants completed the Day-to-Day Impact of Vaginal Aging questionnaire to assess the impact of vaginal symptoms on 4 domains (activities of daily living, emotional well-being, sexual functioning, and body image), each on a 0-4 point scale. Day-to-Day Impact of Vaginal Aging sensitivity to change was assessed by the examination of the associations between change in Day-to-Day Impact of Vaginal Aging domain scores and vulvovaginal symptom severity from baseline to 12 weeks with analysis of covariance. Within-woman and between-group minimal clinically important improvement was assessed with the use of an anchor-based approach that relates change in Day-to-Day Impact of Vaginal Aging domain scores with self-reported benefit from treatment. RESULTS Participants in all treatment arms (n=289) demonstrated reduced impact of vulvovaginal symptoms on all domains of well-being and functioning as assessed by Day-to-Day Impact of Vaginal Aging at 12-week follow up, with no significant differences in improvement between women who were assigned to either estradiol tablet or vaginal moisturizer compared with placebo. For all Day-to-Day Impact of Vaginal Aging domains, mean impact scores were reduced when participants reported symptom improvement (-0.3 to -0.8 point change in Day-to-Day Impact of Vaginal Aging scores for <2-point symptom severity change vs -0.4 to -1.6 point change in Day-to-Day Impact of Vaginal Aging scores for 2+ point symptom severity change; all P<.001). Minimal clinically important change in Day-to-Day Impact of Vaginal Aging domain scale scores, which are anchored to self-reported meaningful benefit from treatment at 12 weeks, ranged from -0.4 to -1.3 (within-woman) and -0.2 to -0.7 (between-group). Observed change and minimal clinically important difference were largest for the sexual functioning domain. CONCLUSION The impact of vulvovaginal symptoms on day-to-day activities, sexual function, emotional well-being, and body image may be improved with low-dose vaginal estradiol, moisturizer, or topical placebo. The Day-to-Day Impact of Vaginal Aging questionnaire demonstrates sensitivity to change with treatment of vulvovaginal symptoms, particularly Day-to-Day Impact of Vaginal Aging scales that focus on symptom impact on sexual functioning and body image. Minimal clinically important improvement in the impact of vulvovaginal symptoms as measured by the Day-to-Day Impact of Vaginal Aging can be defined with the use of these measures.",2020,,['Postmenopausal Vaginal Symptoms'],[],[],"[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",[],[],,0.0982499,,"[{'ForeName': 'Carolyn J', 'Initials': 'CJ', 'LastName': 'Gibson', 'Affiliation': 'San Francisco VA Health Care System, San Francisco, CA; Department of Psychiatry, University of California, San Francisco, CA. Electronic address: Carolyn.Gibson2@va.gov.'}, {'ForeName': 'Alison J', 'Initials': 'AJ', 'LastName': 'Huang', 'Affiliation': 'Department of Medicine, University of California, San Francisco, CA.'}, {'ForeName': 'Joseph C', 'Initials': 'JC', 'LastName': 'Larson', 'Affiliation': 'Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Mitchell', 'Affiliation': 'Vincent Obstetrics and Gynecology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Diem', 'Affiliation': 'Department of Medicine and Epidemiology and Community Health, University of Minnesota, Minneapolis, MN; Department of Medicine, Minneapolis VA Health Care System, Minneapolis, MN.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'LaCroix', 'Affiliation': 'Department of Family Medicine and Public Health, University of California, San Diego, CA.'}, {'ForeName': 'Katherine M', 'Initials': 'KM', 'LastName': 'Newton', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute, Seattle, WA.'}, {'ForeName': 'Susan D', 'Initials': 'SD', 'LastName': 'Reed', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Washington, Seattle, WA.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Guthrie', 'Affiliation': 'Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2019.12.270'] 581,31953482,"Effect of probiotics on multi-resistant organism colonisation in persons with spinal cord injury: secondary outcome of ProSCIUTTU, a randomised placebo-controlled trial.","STUDY DESIGN Randomised double-blind placebo-controlled trial. OBJECTIVES Multi-resistant organism (MRO) colonisation is common in people with SCI. We aimed to determine whether Lactobacillus reuteri RC-14 + Lactobacillus GR-1 (RC14-GR1) and/or Lactobacillus rhamnosus GG + Bifidobacterium BB-12 (LGG-BB12) are effective in preventing or clearing MRO colonisation. SETTING New South Wales, Australia. METHODS The 207 SCI participants were randomised to one of four arms: (i) RC14-GR1 + LGG-BB12, (ii) RC14-GR1 + placebo, (iii) LGG-BB12 + placebo or (iv) double placebos for 6 months. Microbiological samples of nose, groin, urine and bowel were taken at baseline, 3 and 6 months. Analysis was conducted for the presence of methicillin-resistant Staphylococcus aureus (MRSA), multi-resistant gram-negative organisms (MRGNs) and vancomycin-resistant enterococcus (VRE). The outcomes were clearance of, or new colonisation with MRSA, MRGN, VRE or MROs and whether participants remained free of MRSA, MRGN, VRE or MROs throughout the study. Risk factors associated with an outcome were adjusted for using nominal or binary logistic regression. RESULTS There was a significant reduction in new MRGN colonisation compared with placebo for participants treated with RC14-GR1 (OR 0.10, 95% CI, 0.01-0.88, P = 0.04), after allowing that inpatients were more likely to be newly colonised (OR 21.41, 95% CI, 3.98-115.13, P < 0.0001). Participants who intermittent self-catheterised (IMC) were more likely to remain MRO-free than those utilising SPC or IDCs (OR 2.80, 95% CI, 1.41-5.54, P = 0.009). CONCLUSIONS Probiotics are ineffective at clearing MROs in people with SCI. However, RC14-GR1 is effective at preventing new colonisation with MRGNs. The use of IMC significantly improves the chance of remaining MRO-free.",2020,"There was a significant reduction in new MRGN colonisation compared with placebo for participants treated with RC14-GR1 (OR 0.10, 95% CI, 0.01-0.88, P = 0.04), after allowing that inpatients were more likely to be newly colonised (OR 21.41, 95% CI, 3.98-115.13, P < 0.0001).","['persons with spinal cord injury', '207 SCI participants', 'New South Wales, Australia', 'people with SCI']","['placebo', 'probiotics', 'IMC', 'RC14-GR1\u2009+\u2009LGG-BB12, (ii) RC14-GR1\u2009+\u2009placebo, (iii) LGG-BB12\u2009+\u2009placebo or (iv) double placebos', 'vancomycin-resistant enterococcus (VRE', 'Lactobacillus reuteri RC-14\u2009+\u2009Lactobacillus GR-1 (RC14-GR1) and/or Lactobacillus rhamnosus GG\u2009+\u2009Bifidobacterium BB-12 (LGG-BB12', 'RC14-GR1']","['new MRGN colonisation', 'clearance of, or new colonisation with MRSA, MRGN, VRE or MROs and whether participants remained free of MRSA, MRGN, VRE or MROs', 'Microbiological samples of nose, groin, urine and bowel']","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1265175', 'cui_str': 'Vancomycin-Resistant Enterococci'}, {'cui': 'C0317625', 'cui_str': 'Lactobacillus reuteri'}, {'cui': 'C0022938', 'cui_str': 'Lactobacillus'}, {'cui': 'C1629836', 'cui_str': 'Lactobacillus rhamnosus GG'}, {'cui': 'C4280067', 'cui_str': 'Bifidobacterium BB-12'}]","[{'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C1265292', 'cui_str': 'MRSA'}, {'cui': 'C1265175', 'cui_str': 'Vancomycin-Resistant Enterococci'}, {'cui': 'C0332296', 'cui_str': 'Free of (attribute)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0028429', 'cui_str': 'Nose'}, {'cui': 'C0018246', 'cui_str': 'Groin'}, {'cui': 'C0042037'}, {'cui': 'C0021853', 'cui_str': 'Intestines'}]",207.0,0.653716,"There was a significant reduction in new MRGN colonisation compared with placebo for participants treated with RC14-GR1 (OR 0.10, 95% CI, 0.01-0.88, P = 0.04), after allowing that inpatients were more likely to be newly colonised (OR 21.41, 95% CI, 3.98-115.13, P < 0.0001).","[{'ForeName': 'Swee-Ling', 'Initials': 'SL', 'LastName': 'Toh', 'Affiliation': 'Department of Spinal and Rehabilitation Medicine, Prince of Wales Hospital, Sydney, NSW, Australia. SweeLing.Toh@health.nsw.gov.au.'}, {'ForeName': 'Bonsan Bonne', 'Initials': 'BB', 'LastName': 'Lee', 'Affiliation': 'Department of Spinal and Rehabilitation Medicine, Prince of Wales Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Judy M', 'Initials': 'JM', 'LastName': 'Simpson', 'Affiliation': 'Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Scott A', 'Initials': 'SA', 'LastName': 'Rice', 'Affiliation': 'Singapore Centre for Environmental Life Sciences Engineering and the School of Biological Sciences, Nanyang Technological University, Nanyang, Singapore.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Kotsiou', 'Affiliation': 'Department of Infectious Diseases and Microbiology, NSW Health Pathology, Royal North Shore Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Obaydullah', 'Initials': 'O', 'LastName': 'Marial', 'Affiliation': 'Neuroscience Research Australia (NeuRA) and UNSW Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Ryan', 'Affiliation': 'Neuroscience Research Australia (NeuRA) and UNSW Sydney, Sydney, NSW, Australia.'}]",Spinal cord,['10.1038/s41393-020-0420-z'] 582,31806235,[Comparison of volume-controlled and pressure-controlled ventilation on respiratory mechanics in laparoscopic bariatric surgery: randomized clinical trial].,"BACKGROUND It is not clear which mechanical ventilation mode should be used in bariatric surgery, one of the treatment options for patients with obesity. OBJECTIVES To compare volume-controlled ventilation and pressure-controlled ventilation in terms of respiratory mechanics and arterial blood gas values in patients undergoing laparoscopic bariatric surgery. METHODS Sixty-two patients with morbid obesity scheduled for gastric bypass were included in this study. Their ideal body weights were calculated during preoperative visits, and patients were divided into two groups, volume-controlled ventilation and pressure-controlled ventilation. The patients were ventilated in accordance with a previously determined algorithm. Mechanical ventilation parameters and arterial blood gas analysis were recorded 5 minutes after induction, 30 minutes after pneumoperitoneum, and at the end of surgery. Also, the dynamic compliance, inspired O 2 pressure/fractional O 2 ratio, and alveolar-arterial oxygen gradient pressure were calculated. RESULTS Peak airway pressures were lower in patients ventilated in pressure-controlled ventilation mode at the end of surgery (p = 0.011). Otherwise, there was no difference between groups in terms of intraoperative respiratory parameters and arterial blood gas analyses. CONCLUSIONS Pressure-controlled ventilation mode is not superior to volume-controlled ventilation mode in patients with laparoscopic bariatric surgery.",2019,"RESULTS Peak airway pressures were lower in patients ventilated in pressure-controlled ventilation mode at the end of surgery (p = 0.011).","['patients with obesity', 'patients undergoing laparoscopic bariatric surgery', 'laparoscopic bariatric surgery', 'Sixty-two patients with morbid obesity scheduled for gastric bypass', 'patients with laparoscopic bariatric surgery']","['volume-controlled and pressure-controlled ventilation', 'volume-controlled ventilation and pressure-controlled ventilation']","['dynamic compliance, inspired O 2 pressure/fractional O 2 ratio, and alveolar-arterial oxygen gradient pressure', 'intraoperative respiratory parameters and arterial blood gas analyses', 'Peak airway pressures', 'Mechanical ventilation parameters and arterial blood gas analysis']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1456587', 'cui_str': 'Bariatric Surgery'}, {'cui': 'C4517835', 'cui_str': '62 (qualifier value)'}, {'cui': 'C0028756', 'cui_str': 'Obesity, Severe'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0017125', 'cui_str': 'Gastric Bypass'}]","[{'cui': 'C0449972', 'cui_str': 'Volume control (attribute)'}, {'cui': 'C0564626', 'cui_str': 'Pressure controlled ventilation (procedure)'}, {'cui': 'C1320708', 'cui_str': 'Volume controlled ventilation'}]","[{'cui': 'C0429680', 'cui_str': 'Dynamic compliance (observable entity)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C3203470', 'cui_str': 'Alveolar-arterial oxygen gradient'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0150411', 'cui_str': 'Blood gases, arterial measurement (procedure)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}]",62.0,0.0285601,"RESULTS Peak airway pressures were lower in patients ventilated in pressure-controlled ventilation mode at the end of surgery (p = 0.011).","[{'ForeName': 'Erhan', 'Initials': 'E', 'LastName': 'Ozyurt', 'Affiliation': 'University of Health Sciences, Antalya Training and Research Hospital, Department of Anesthesiology and Reanimation, Antália, Turquia. Electronic address: eozyurt@hotmail.com.'}, {'ForeName': 'Ali Sait', 'Initials': 'AS', 'LastName': 'Kavakli', 'Affiliation': 'University of Health Sciences, Antalya Training and Research Hospital, Department of Anesthesiology and Reanimation, Antália, Turquia.'}, {'ForeName': 'Nilgun Kavrut', 'Initials': 'NK', 'LastName': 'Ozturk', 'Affiliation': 'University of Health Sciences, Antalya Training and Research Hospital, Department of Anesthesiology and Reanimation, Antália, Turquia.'}]",Revista brasileira de anestesiologia,['10.1016/j.bjan.2019.08.005'] 583,31822353,[Efficacy of ultrasound-guided erector spinae plane block for analgesia after laparoscopic cholecystectomy: a randomized controlled trial].,"BACKGROUND AND OBJECTIVES The primary aim of this study is to assess the effect of ultrasoung-guided erector spinae block on postoperative opioid consumption after laparoscopic cholecystectomy. The secondary aims are to assess the effects of erector spinae plane block on intraoperative fentanyl need and postoperative pain scores. METHODS Patients between 18-70 years old, ASA I-II were included in the study and randomly allocated into two groups. In Group ESP, patients received bilateral US-ESP with 40ml of 0.25% bupivacaine at the level of T7, while in Group Control, they received bilateral US-ESP with 40ml of saline before the induction of anesthesia. Then a standard general anesthesia procedure was conducted in both groups. NRS scores at the postoperative 15th, 30th, 60th minutes, 12th and 24th hours, intraoperative fentanyl need and total postoperative tramadol consumption were recorded. RESULTS There were 21 patients in Group ESP and 20 patients in Group Control. Mean postoperative tramadol consumption was 100±19.2mg in Group ESP, while it was 143±18.6mg in Group Control (p<0.001). The mean intraoperative fentanyl need was significantly lower in Group ESP (p=0.022). NRS scores at the postoperative 15th, 30th min, 12th hour and 24th hour were significantly lower in ESP group (p<0.05). According to repeated measures analysis, NRS score variation over time was significantly varied between two groups (F[1,39]=24.061, p< 0.0005). CONCLUSIONS Bilateral US-ESP block provided significant reduction in postoperative opioid consumption, intraoperative fentanyl need and postoperative pain scores of patients undergoing laparoscopic cholecystectomy.",2019,The mean intraoperative fentanyl need was significantly lower in Group ESP (p=0.022).,"['Patients between 18-70 years old, ASA I-II', 'after laparoscopic cholecystectomy', 'patients undergoing laparoscopic cholecystectomy', 'analgesia after laparoscopic cholecystectomy']","['erector spinae plane block', 'bilateral US-ESP with 40ml of 0.25% bupivacaine', 'ultrasoung-guided erector spinae block', 'ESP', 'ultrasound-guided erector spinae plane block']","['NRS score variation over time', 'mean intraoperative fentanyl need', 'Mean postoperative tramadol consumption', 'NRS scores', 'postoperative opioid consumption, intraoperative fentanyl need and postoperative pain scores', 'intraoperative fentanyl need and total postoperative tramadol consumption', 'postoperative opioid consumption']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0162522', 'cui_str': 'Cholecystectomy, Celioscopic'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}]","[{'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0015373', 'cui_str': 'Extrasensory Perception'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",,0.151715,The mean intraoperative fentanyl need was significantly lower in Group ESP (p=0.022).,"[{'ForeName': 'Basak', 'Initials': 'B', 'LastName': 'Altiparmak', 'Affiliation': 'Muğla Sıtkı Koçman University, Muğla Sıtkı Koçman Üniversitesi Egitim Arastırma Hastanesi, Department of Anesthesiology and Reanimation, Muğla, Turquia. Electronic address: basakugurlu@me.com.'}, {'ForeName': 'Melike Korkmaz', 'Initials': 'MK', 'LastName': 'Toker', 'Affiliation': 'Muğla Sıtkı Koçman University Training and Research Hospital, Department of Anesthesiology and Reanimation, Muğla, Turquia.'}, {'ForeName': 'Ali İhsan', 'Initials': 'Aİ', 'LastName': 'Uysal', 'Affiliation': 'Muğla Sıtkı Koçman University Training and Research Hospital, Department of Anesthesiology and Reanimation, Muğla, Turquia.'}, {'ForeName': 'Yağmur', 'Initials': 'Y', 'LastName': 'Kuşçu', 'Affiliation': 'Muğla Sıtkı Koçman University Training and Research Hospital, Department of Anesthesiology and Reanimation, Muğla, Turquia.'}, {'ForeName': 'Semra Gümüş', 'Initials': 'SG', 'LastName': 'Demirbilek', 'Affiliation': 'Muğla Sıtkı Koçman University Training and Research Hospital, Department of Anesthesiology and Reanimation, Muğla, Turquia.'}]",Revista brasileira de anestesiologia,['10.1016/j.bjan.2019.09.001'] 584,31836201,[Comparison of pressure-controlled volume-guaranteed ventilation and volume-controlled ventilation in obese patients during gynecologic laparoscopic surgery in the Trendelenburg position].,"BACKGROUND AND OBJECTIVES The aim of this study was to investigate the efficacy of the pressure-controlled, volume-guaranteed (PCV-VG) and volume-controlled ventilation (VCV) modes for maintaining adequate airway pressures, lung compliance and oxygenation in obese patients undergoing laparoscopic hysterectomy in the Trendelenburg position. METHODS Patients (104) who underwent laparoscopic gynecologic surgery with a body mass index between 30 and 40kg.m -2 were randomized to receive either VCV or PCV-VG ventilation. The tidal volume was set at 8mL.kg -1 , with an inspired oxygen concentration of 0.4 with a Positive End-Expiratory Pressure (PEEP) of 5mmHg. The peak inspiratory pressure, mean inspiratory pressure, plateau pressure, driving pressure, dynamic compliance, respiratory rate, exhaled tidal volume, etCO 2 , arterial blood gas analysis, heart rate and mean arterial pressure at 5minutes after induction of anesthesia in the and at 5, 30 and 60minutes, respectively, after pneumoperitoneum in the Trendelenburg position were recorded. RESULTS The PCV-VG group had significantly decreased peak inspiratory pressure, mean inspiratory pressur, plateau pressure, driving pressure and increased dynamic compliance compared to the VCV group. Mean PaO 2 levels were significantly higher in the PCV-VG group than in the VCV group at every time point after pneumoperitoneum in the Trendelenburg position. CONCLUSIONS The PCV-VG mode of ventilation limited the peak inspiratory pressure, decreased the driving pressure and increased the dynamic compliance compared to VCV in obese patients undergoing laparoscopic hysterectomy. PCV-VG may be a preferable modality to prevent barotrauma during laparoscopic surgeries in obese patients.",2019,"Mean PaO 2 levels were significantly higher in the PCV-VG group than in the VCV group at every time point after pneumoperitoneum in the Trendelenburg position. ","['obese patients during gynecologic laparoscopic surgery in the Trendelenburg position', 'obese patients', 'obese patients undergoing laparoscopic hysterectomy', 'Patients (104) who underwent laparoscopic gynecologic surgery with a body mass index between 30 and 40kg.m -2', 'obese patients undergoing laparoscopic hysterectomy in the Trendelenburg position']","['PCV-VG', 'VCV', 'VCV or PCV-VG ventilation', 'pressure-controlled volume-guaranteed ventilation and volume-controlled ventilation', 'volume-guaranteed (PCV-VG) and volume-controlled ventilation (VCV) modes']","['peak inspiratory pressure, mean inspiratory pressure, plateau pressure, driving pressure, dynamic compliance, respiratory rate, exhaled tidal volume, etCO 2 , arterial blood gas analysis, heart rate and mean arterial pressure at 5minutes after induction of anesthesia', 'driving pressure', 'tidal volume', 'peak inspiratory pressure, mean inspiratory pressur, plateau pressure, driving pressure and increased dynamic compliance', 'Mean PaO 2 levels']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205480', 'cui_str': 'Gynecologic (qualifier value)'}, {'cui': 'C0751429', 'cui_str': 'Surgical Procedures, Laparoscopic'}, {'cui': 'C0277812', 'cui_str': 'Trendelenburg Position'}, {'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy (procedure)'}, {'cui': 'C0038902', 'cui_str': 'Gynecological Surgical Procedure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0018935', 'cui_str': 'Erythrocyte Volume, Packed'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C1320708', 'cui_str': 'Volume controlled ventilation'}]","[{'cui': 'C0232021', 'cui_str': 'Maximum inspiratory pressure (observable entity)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0445176', 'cui_str': 'Plateau pressure (qualifier value)'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0429680', 'cui_str': 'Dynamic compliance (observable entity)'}, {'cui': 'C0231832', 'cui_str': 'Respiration Rate'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0040210', 'cui_str': 'Tidal Volume'}, {'cui': 'C0150411', 'cui_str': 'Blood gases, arterial measurement (procedure)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C0853212', 'cui_str': 'Induction of anesthesia'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output (observable entity)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",,0.0489141,"Mean PaO 2 levels were significantly higher in the PCV-VG group than in the VCV group at every time point after pneumoperitoneum in the Trendelenburg position. ","[{'ForeName': 'Melike Korkmaz', 'Initials': 'MK', 'LastName': 'Toker', 'Affiliation': 'Mugla Sıtkı Kocman University, Research and Training Hospital, Department of Anesthesiology and Reanimation, Mugla, Turquia. Electronic address: meltoker@gmail.com.'}, {'ForeName': 'Basak', 'Initials': 'B', 'LastName': 'Altıparmak', 'Affiliation': 'Mugla Sıtkı Kocman University, Department of Anesthesiology and Reanimation, Mugla, Turquia.'}, {'ForeName': 'Ali İhsan', 'Initials': 'Aİ', 'LastName': 'Uysal', 'Affiliation': 'Mugla Sıtkı Kocman University, Research and Training Hospital, Department of Anesthesiology and Reanimation, Mugla, Turquia.'}, {'ForeName': 'Semra Gumus', 'Initials': 'SG', 'LastName': 'Demirbilek', 'Affiliation': 'Mugla Sıtkı Kocman University, Department of Anesthesiology and Reanimation, Mugla, Turquia.'}]",Revista brasileira de anestesiologia,['10.1016/j.bjan.2019.09.003'] 585,31335201,Satisfaction with the Use of Different Technologies for Insulin Delivery and Glucose Monitoring Among Adults with Long-Standing Type 1 Diabetes and Problematic Hypoglycemia: 2-Year Follow-Up in the HypoCOMPaSS Randomized Clinical Trial.,"Background: In the HypoCOMPaSS trial, adults with long-standing type 1 diabetes and problematic hypoglycemia were randomized to compare insulin pump (continuous subcutaneous insulin infusion; CSII) with multiple daily injections (MDI) and real-time continuous glucose monitoring (RT-CGM) with conventional self-monitoring of blood glucose (SMBG). Our aim was to investigate participants' satisfaction with these technologies at 6-month randomized, controlled trial (RCT) endpoint and at 2-year follow-up. Methods: Participants completed the Insulin Treatment Satisfaction Questionnaire subscales ""device delivery"" and ""hypoglycemia control""; and Glucose Monitoring Experience Questionnaire, assessing ""convenience"", ""effectiveness"", ""intrusiveness"", and ""total satisfaction."" We assessed change over time and between-group differences by insulin and monitoring modalities. Results: Participants ( N  = 96) were 64% women, aged 49 ± 12 years, with a diabetes duration of 29 ± 12 years. At 6 months, participants reported improvements compared with baseline (all P  < 0.001) in satisfaction with insulin ""delivery device"" ( r =  0.39) and ""hypoglycemia control"" ( r  = 0.52), and trends toward significance in perceived ""effectiveness"" ( r =  0.42) and ""intrusiveness"" ( r  = 0.27) of monitoring device (but not ""convenience"", P  = 0.139). All improvements were sustained at 2 years. At 6 months, the only difference between arms was that greater satisfaction with insulin ""delivery device"" was reported in the CSII group compared with MDI ( P  < 0.001, r  = 0.40). No between-group differences were observed at 2 years. Conclusions: Overall, significant improvements in participant satisfaction with diabetes technologies were observed over the 6-month RCT, in all domains except ""convenience,"" and maintained at 2 years. Although HypoCOMPaSS demonstrated noninferiority of SMBG versus CGM, and MDI versus CSII in terms of biomedical outcomes, detailed assessments confirm that participants' satisfaction with delivery device was greater in those allocated to CSII than MDI.",2019,"At 6 months, participants reported improvements compared to baseline (all p<0.001) in satisfaction with insulin 'delivery device' (r=0.39) and 'hypoglycaemia control' (r=0.52), and trends towards significance in perceived 'effectiveness' (r=0.42) and 'intrusiveness' (r=0.27) of monitoring device (but not 'convenience', p=0.139).","['Results Participants (N=96) were: 64% women, aged 49±12 years, diabetes duration 29±12 years', 'adults with long-standing type 1 diabetes and problematic hypoglycaemia']",['insulin pump (CSII) vs multiple daily injections (MDI) and real-time continuous glucose monitoring (RT-CGM) vs conventional self-monitoring (SMBG'],"['participant satisfaction with diabetes technologies', ""satisfaction with insulin 'delivery device"", ""perceived 'effectiveness' (r=0.42) and 'intrusiveness"", 'satisfaction with delivery device', ""satisfaction with insulin 'delivery device' (r=0.39) and 'hypoglycaemia control"", ""Insulin Treatment Satisfaction Questionnaire (ITSQ) subscales 'device delivery' and 'hypoglycaemia control'; and Glucose Monitoring Experience Questionnaire (GME-Q), assessing 'convenience', 'effectiveness', 'intrusiveness' and 'total satisfaction""]","[{'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}]","[{'cui': 'C1140609', 'cui_str': 'Insulin pump'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0588436', 'cui_str': 'Self-monitoring (regime/therapy)'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",,0.116608,"At 6 months, participants reported improvements compared to baseline (all p<0.001) in satisfaction with insulin 'delivery device' (r=0.39) and 'hypoglycaemia control' (r=0.52), and trends towards significance in perceived 'effectiveness' (r=0.42) and 'intrusiveness' (r=0.27) of monitoring device (but not 'convenience', p=0.139).","[{'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Speight', 'Affiliation': 'School of Psychology, Deakin University, Geelong, Australia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Holmes-Truscott', 'Affiliation': 'School of Psychology, Deakin University, Geelong, Australia.'}, {'ForeName': 'Stuart A', 'Initials': 'SA', 'LastName': 'Little', 'Affiliation': 'Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom.'}, {'ForeName': 'Lalantha', 'Initials': 'L', 'LastName': 'Leelarathna', 'Affiliation': 'Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Walkinshaw', 'Affiliation': 'School of Medicine and Biomedical Science, Sheffield University, Sheffield, United Kingdom.'}, {'ForeName': 'Horn Kai', 'Initials': 'HK', 'LastName': 'Tan', 'Affiliation': 'Peninsula College of Medicine and Dentistry, Plymouth, United Kingdom.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Bowes', 'Affiliation': 'Poole Diabetes Centre, Poole Hospital NHS Foundation Trust, Poole, United Kingdom.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kerr', 'Affiliation': 'Sansum Diabetes Research Institute, Santa Barbara, California.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Flanagan', 'Affiliation': 'Peninsula College of Medicine and Dentistry, Plymouth, United Kingdom.'}, {'ForeName': 'Simon R', 'Initials': 'SR', 'LastName': 'Heller', 'Affiliation': 'School of Medicine and Biomedical Science, Sheffield University, Sheffield, United Kingdom.'}, {'ForeName': 'Mark L', 'Initials': 'ML', 'LastName': 'Evans', 'Affiliation': 'Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'James A M', 'Initials': 'JAM', 'LastName': 'Shaw', 'Affiliation': 'Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom.'}]",Diabetes technology & therapeutics,['10.1089/dia.2019.0152'] 586,31356703,Guilt in the Treatment of Posttraumatic Stress Disorder Among Active Duty Military Personnel.,"The current study examined the role of trauma-related guilt on posttraumatic stress disorder (PTSD) symptom change during prolonged exposure therapy (PE) as well as the efficacy of PE in reducing three dimensions of guilt (responsibility, wrongdoing, and lack of justification) during treatment. Participants were 331 active duty U.S. military personnel seeking treatment for PTSD who were randomized to one of four groups: massed PE (10 sessions delivered over 2 weeks), spaced PE (10 sessions delivered over 8 weeks), present-centered therapy (PCT; 10 sessions delivered over 8 weeks), or minimal contact control (MCC; weekly therapist phone check-in for 4 weeks). The results showed that baseline guilt did not predict reductions in PTSD symptoms for spaced PE or for PCT, ps = .178-.387, ds = -0.02-0.07. Treatment condition (massed PE vs. MCC; spaced PE vs. PCT) did not moderate reductions in guilt for spaced PE versus PCT. Guilt decreased significantly over treatment in all groups, p < .001 to p = .038, ds = -0.19 to -0.42, except concerning justification in the spaced PE and PCT groups, p = .140, d = -0.10. The findings suggest that guilt may be reduced significantly following active PTSD treatment and attention control and that PTSD recovery is not impacted by baseline levels of trauma-related guilt in military personnel with PTSD, although reported levels of guilt were low to moderate in this sample.",2019,"Guilt decreased significantly over treatment in all groups, p < .001 to p = .038, ds = -0.19 to -0.42, except concerning justification in the spaced PE and PCT groups, p = .140, d = -0.10.",['Participants were 331 active duty U.S. military personnel seeking treatment for PTSD'],"['massed PE (10 sessions delivered over 2 weeks), spaced PE (10 sessions delivered over 8 weeks), present-centered therapy (PCT; 10 sessions delivered over 8 weeks), or minimal contact control (MCC; weekly therapist phone check-in for 4 weeks', 'prolonged exposure therapy (PE']","['Guilt', 'PTSD symptoms']","[{'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0026126', 'cui_str': 'Armed Forces Personnel'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}]","[{'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0162566', 'cui_str': 'Porphyria Cutanea Tarda'}, {'cui': 'C0547040', 'cui_str': 'Minimal (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}]","[{'cui': 'C0018379', 'cui_str': 'Guilt'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",331.0,0.0237805,"Guilt decreased significantly over treatment in all groups, p < .001 to p = .038, ds = -0.19 to -0.42, except concerning justification in the spaced PE and PCT groups, p = .140, d = -0.10.","[{'ForeName': 'Carmen P', 'Initials': 'CP', 'LastName': 'McLean', 'Affiliation': 'National Center for PTSD, VA Palo Alto Health Care System, Menlo Park, California, USA.'}, {'ForeName': 'Laurie', 'Initials': 'L', 'LastName': 'Zandberg', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Lily', 'Initials': 'L', 'LastName': 'Brown', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Yinyin', 'Initials': 'Y', 'LastName': 'Zang', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Benhamou', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Dondanville', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Yarvis', 'Affiliation': 'Department of Behavioral Health, Carl R. Darnall Army Medical Center, Fort Hood, Texas, USA.'}, {'ForeName': 'Brett T', 'Initials': 'BT', 'LastName': 'Litz', 'Affiliation': 'Massachusetts Veterans Epidemiological Research and Information Center, VA Boston Healthcare System, Boston, Massachusetts, USA.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Mintz', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.'}, {'ForeName': 'Stacey', 'Initials': 'S', 'LastName': 'Young-McCaughan', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.'}, {'ForeName': 'Alan L', 'Initials': 'AL', 'LastName': 'Peterson', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.'}, {'ForeName': 'Edna B', 'Initials': 'EB', 'LastName': 'Foa', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of traumatic stress,['10.1002/jts.22416'] 587,31429979,Effectiveness of the Intent to Complete and Intent to Attend Intervention to Predict and Prevent Posttraumatic Stress Disorder Treatment Drop Out Among Soldiers.,"Active duty military service members have high dropout rates for trauma-focused treatment in both clinical practice and research settings. Measuring patients' intent to complete (ITC) and intent to attend (ITA) treatment have been suggested as methods to reduce dropout, but no studies have examined the effectiveness of such measures. In an attempt to reduce high dropout rates, measures of ITC and ITA were included in a randomized controlled trial evaluating prolonged exposure (PE) and virtual reality exposure (VRE) in active duty soldiers with posttraumatic stress disorder (PTSD). Participants (N = 108) were randomized to either PE or VRE, and the last 49 to enroll were administered a measure of ITC at enrollment and a measure of ITA at the end of every session. A score of 7 or below triggered a problem-solving discussion with the individual's therapist. The results revealed that the ITA assessment predicted treatment dropout after controlling for mental health stigma, PTSD symptoms, and age, odds ratio (OR) = 0.24, p = .023. Additionally, participants who completed the ITA assessment were less likely to drop out than those who were not administered the ITA, OR = 0.29 p = .002. The ITC did not predict treatment dropout OR = 0.98, p = .402. These findings suggest that assessing ITA throughout trauma-focused therapy may reduce treatment dropout rather than solely measuring ITC prior to starting psychotherapy. Based on these preliminary findings, future research should randomize the measurement of ITA in clinical trials to evaluate its impact on treatment dropout.",2019,"The ITC did not predict treatment dropout OR = 0.98, p = .402.","['Participants (N = 108', 'active duty soldiers with posttraumatic stress disorder (PTSD', 'Active duty military service members']","['PE or VRE', 'prolonged exposure (PE) and virtual reality exposure (VRE']","['mental health stigma, PTSD symptoms, and age, odds ratio (OR) ']","[{'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0524647', 'cui_str': 'Soldiers'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C3831794', 'cui_str': 'Active duty military'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}]","[{'cui': 'C1265175', 'cui_str': 'Vancomycin-Resistant Enterococci'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0277787', 'cui_str': 'Stigma (finding)'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}]",,0.0401713,"The ITC did not predict treatment dropout OR = 0.98, p = .402.","[{'ForeName': 'Grant P', 'Initials': 'GP', 'LastName': 'Shulman', 'Affiliation': 'VA Puget Sound Health Care System, Tacoma, Washington, USA.'}, {'ForeName': 'Benjamin E', 'Initials': 'BE', 'LastName': 'Buck', 'Affiliation': 'VA Puget Sound Health Care System, Tacoma, Washington, USA.'}, {'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Gahm', 'Affiliation': 'National Center for Telehealth and Technology, Tacoma, Washington, USA.'}, {'ForeName': 'Greg M', 'Initials': 'GM', 'LastName': 'Reger', 'Affiliation': 'VA Puget Sound Health Care System, Tacoma, Washington, USA.'}, {'ForeName': 'Aaron M', 'Initials': 'AM', 'LastName': 'Norr', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Washington, School of Medicine, Seattle, Washington, USA.'}]",Journal of traumatic stress,['10.1002/jts.22427'] 588,31943293,Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.,"BACKGROUND AND AIMS Cenicriviroc (CVC) is a C-C chemokine receptors type 2 and 5 dual antagonist under evaluation for treating liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). Year 1 primary analysis of the 2-year CENTAUR study showed that CVC had an antifibrotic effect without impacting steatohepatitis. Herein, we report the final data from year 2 exploratory analyses. APPROACH AND RESULTS This was a randomized, controlled study of adults with NASH, nonalcoholic fatty liver disease activity score ≥4, and NASH Clinical Research Network stage 1-3 fibrosis. Participants in arms A and C received CVC 150 mg or placebo, respectively, for 2 years; arm B received placebo in year 1 and switched to CVC in year 2. Liver biopsy was performed at baseline, year 1, and year 2. Of 289 randomized participants, 242 entered year 2. At year 2, 24% of patients who switched to CVC and 17% who remained on placebo achieved ≥1-stage fibrosis improvement and no worsening of NASH (P = 0.37). Twice the proportion on CVC who achieved fibrosis response at year 1 maintained benefit at year 2 (60% arm A versus 30% arm C), including 86% on CVC who had stage 3 fibrosis at baseline. Over 2 years, a similar proportion on CVC or placebo achieved ≥1-stage fibrosis improvement and no worsening of NASH (15% arm A versus 17% arm C). In patients with fibrosis responses, we observed consistent reductions in levels of N-terminal type 3 collagen propeptide and enhanced liver fibrosis scores, while increases in aspartate aminotransferase-to-platelet ratio index and Fibrosis-4 scores were consistently observed in nonresponders. Safety profile was comparable across groups. CONCLUSIONS CVC was well tolerated, and year 2 data corroborate antifibrotic findings from year 1. The majority on CVC who achieved fibrosis response at year 1 maintained it at year 2, with greater effect in advanced fibrosis. ClinicalTrials.gov number, NCT02217475 (CENTAUR).",2020,Safety profile was comparable across groups.,"['Adults with Nonalcoholic Steatohepatitis and Fibrosis', 'adults with nonalcoholic steatohepatitis (NASH', 'Of 289 randomized, 242 participants entered Year 2', 'adults with NASH, nonalcoholic fatty liver disease activity score ≥4, and NASH CRN stage 1-3 fibrosis']","['placebo', 'Cenicriviroc (CVC', 'Cenicriviroc Treatment', 'CVC', 'CVC 150 mg or placebo']","['antifibrotic effect without impacting steatohepatitis', 'Safety profile', 'APRI and FIB-4 scores', '≥1-stage fibrosis improvement AND no worsening of NASH', 'PRO-C3 levels and ELF scores', 'fibrosis response']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3241937', 'cui_str': 'Nonalcoholic Steatohepatitis'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0400966', 'cui_str': 'NAFLD'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1 (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4279622'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}]","[{'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C2711227', 'cui_str': 'Liver Steatosis'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0071997', 'cui_str': 'C3 Precursor'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",289.0,0.211356,Safety profile was comparable across groups.,"[{'ForeName': 'Vlad', 'Initials': 'V', 'LastName': 'Ratziu', 'Affiliation': 'Hôpital Pitié Salpêtrière and Sorbonne Université, Paris, France.'}, {'ForeName': 'Arun', 'Initials': 'A', 'LastName': 'Sanyal', 'Affiliation': 'Department of Gastroenterology, Virginia Commonwealth University, Richmond, VA.'}, {'ForeName': 'Stephen A', 'Initials': 'SA', 'LastName': 'Harrison', 'Affiliation': 'Pinnacle Clinical Research, San Antonio, TX.'}, {'ForeName': 'Vincent Wai-Sun', 'Initials': 'VW', 'LastName': 'Wong', 'Affiliation': ""Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong, People's Republic of China.""}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Francque', 'Affiliation': 'Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Zachary', 'Initials': 'Z', 'LastName': 'Goodman', 'Affiliation': 'Center for Liver Diseases, Inova Fairfax Medical Campus, Falls Church, VA.'}, {'ForeName': 'Guruprasad P', 'Initials': 'GP', 'LastName': 'Aithal', 'Affiliation': 'NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Kris V', 'Initials': 'KV', 'LastName': 'Kowdley', 'Affiliation': 'Liver Care Network, Swedish Medical Center, Seattle, WA.'}, {'ForeName': 'Star', 'Initials': 'S', 'LastName': 'Seyedkazemi', 'Affiliation': 'Allergan plc, South San Francisco, CA.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Fischer', 'Affiliation': 'Allergan plc, South San Francisco, CA.'}, {'ForeName': 'Rohit', 'Initials': 'R', 'LastName': 'Loomba', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA.'}, {'ForeName': 'Manal F', 'Initials': 'MF', 'LastName': 'Abdelmalek', 'Affiliation': 'Division of Gastroenterology & Hepatology, Department of Medicine, Duke University, Durham, NC.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Tacke', 'Affiliation': 'Department of Medicine III, University Hospital Aachen, Aachen, Germany.'}]","Hepatology (Baltimore, Md.)",['10.1002/hep.31108'] 589,31951260,Effectiveness of an Evidence-Based Amputee Rehabilitation Program: A Pilot Randomized Controlled Trial.,"BACKGROUND Despite the prevalence of lower limb amputation (LLA), only a small percentage of people with LLA actually receive physical therapy post amputation and are rehabilitated to their full potential level of function. There is a need for the development of a rehabilitation program that targets impairments and limitations specific to people with LLA. OBJECTIVE The objective of this study was to determine whether the Evidence-Based Amputee Rehabilitation program would improve functional mobility of people with unilateral transtibial amputation (TTA) who have already completed physical therapy and prosthetic training. DESIGN This study was a randomized, wait-list control, single-blinded pilot clinical trial. SETTING This study researched participants who had received postamputation rehabilitation to varying degrees, either in an inpatient and/or outpatient settings. PARTICIPANTS The participants in this study included veterans and nonveterans with unilateral TTA due to dysvascular disease and trauma. INTERVENTION This study included a prescription-based rehabilitation program for people with amputations. MEASUREMENTS Results were measured with The Amputee Mobility Predictor with (AMPPro) and without a prosthesis (AMPnoPro) and 6-Minute Walk Test (6MWT) at baseline and at the end of the 8-week intervention. RESULTS The intervention group improved on the AMPPro scores (36.4 to 41.7), AMPnoro scores (23.2 to 27.1), and 6MWT distance (313.6 to 387.7 m). The effect size for the intervention was very large (1.32). In contrast, the wait-list control group demonstrated no change in AMPPro scores (35.3 to 35.6), AMPnoPro scores (24.7 to 25.0), and 6MWT distance (262.6 m to 268.8 m). LIMITATIONS The sample size was small. A total 326 potential candidates were screened with 306 unable to meet inclusion criteria or unwilling to participate. CONCLUSION People with unilateral TTA who received Evidence-Based Amputee Rehabilitation program demonstrated significant improvement in functional mobility, with most participants (66.7%) improved at least 1 K-level (58.3%) and greater than the minimal detectable change (66.7%).",2020,"The intervention group improved on the AMPPro scores (36.4 to 41.7), AMPnoro scores (23.2 to 27.1), and 6MWT distance (313.6 to 387.7 m).The effect size for the intervention was very large (1.32).","['participants who had received post amputation rehabilitation to varying degrees, either in an inpatient and/or outpatient settings', 'people with unilateral transtibial amputation (TTA) who have already completed physical therapy and prosthetic training', 'Three-hundred twenty-six potential candidates were screened with 306 unable to meet inclusion criteria or unwilling to participate', 'The participants in this study included veterans and non-veterans with unilateral TTA due to dysvascular disease and trauma', 'people with amputations']","['prescription-based rehabilitation program', 'Evidence-Based Amputee Rehabilitation (EBAR) program', 'EBAR program', 'Evidence-Based Amputee Rehabilitation (EBAR) Program']","['6MWT distance', 'functional mobility', 'AMPnoPro scores', 'Amputee Mobility Predictor with (AMPPro) and without a prosthesis (AMPnoPro) and 6-minute Walk Test (6MWT', 'AMPnoro scores', 'AMPPro scores']","[{'cui': 'C0204095', 'cui_str': 'Post-amputation rehabilitation (regime/therapy)'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C1299582', 'cui_str': 'Unable'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0558080', 'cui_str': 'Unwilling (finding)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C1627773', 'cui_str': 'Tissue texture abnormality'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}]","[{'cui': 'C0033080', 'cui_str': 'Prescriptions'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0002695', 'cui_str': 'Amputees'}]","[{'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0002695', 'cui_str': 'Amputees'}, {'cui': 'C0175649', 'cui_str': 'Prosthesis'}, {'cui': 'C0430515', 'cui_str': '6-Minute Walk Test'}]",306.0,0.112927,"The intervention group improved on the AMPPro scores (36.4 to 41.7), AMPnoro scores (23.2 to 27.1), and 6MWT distance (313.6 to 387.7 m).The effect size for the intervention was very large (1.32).","[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Gailey', 'Affiliation': 'Department of Physical Therapy, University of Miami Miller School of Medicine, 5915 Ponce de Leon Boulevard, 5th Floor, Coral Gables, FL 33146 USA.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Gaunaurd', 'Affiliation': 'Department of Physical Therapy, University of Miami Miller School of Medicine, 5915 Ponce de Leon Boulevard, 5th Floor, Coral Gables, FL 33146 USA.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Raya', 'Affiliation': 'Department of Physical Therapy, University of Miami Miller School of Medicine, 5915 Ponce de Leon Boulevard, 5th Floor, Coral Gables, FL 33146 USA.'}, {'ForeName': 'Neva', 'Initials': 'N', 'LastName': 'Kirk-Sanchez', 'Affiliation': 'Department of Physical Therapy, University of Miami Miller School of Medicine, 5915 Ponce de Leon Boulevard, 5th Floor, Coral Gables, FL 33146 USA.'}, {'ForeName': 'Luz M', 'Initials': 'LM', 'LastName': 'Prieto-Sanchez', 'Affiliation': 'North Florida Regional Thyroid Center, Tallahassee, Florida.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Roach', 'Affiliation': 'Department of Physical Therapy, University of Miami Miller School of Medicine, 5915 Ponce de Leon Boulevard, 5th Floor, Coral Gables, FL 33146 USA.'}]",Physical therapy,['10.1093/ptj/pzaa008'] 590,31411762,Dexmedetomidine Alleviates Postpartum Depressive Symptoms following Cesarean Section in Chinese Women: A Randomized Placebo-Controlled Study.,"OBJECTIVES Few studies have investigated the prophylactic efficacy of dexmedetomidine (DEX) in postpartum depressive symptoms (PDS). A randomized double-blind placebo-controlled trial was conducted to investigate whether the administration of DEX, immediately after delivery and for patient-controlled intravenous analgesia (PCIA), can attenuate PDS. METHODS A total of 600 parturients scheduled for elective cesarean delivery under spinal anesthesia were randomly allocated into the control group (infusion with 0.9% normal saline after delivery and PCIA with sufentanil) and the DEX group (DEX infusion 0.5 μg/kg after delivery and PCIA with DEX plus sufentanil). The prevalence of postpartum depressive disorders was indicated by the Edinburgh Postnatal Depression Scale (EPDS). Postoperative analgesia, sedation, and sleep quality of parturients were also assessed. RESULTS Postpartum blues and PDS prevalence in the DEX, versus control, group were significantly lower (5.0% vs 14.1%, p<0.001; 5.7% vs 16.3%, p<0.001, respectively), especially in parturients with antenatal depression or moderate stress during pregnancy. Compared with the control group, the EPDS score at postpartum days 7 and 42 in the DEX group was significantly lower (4.23 ± 4.37 vs 1.93 ± 3.36, p<0.001; 4.68 ± 4.78 vs 1.99 ± 3.18, p<0.001, respectively), as was the incidence of postpartum self-harm ideation at postpartum days 7 and 42 in the DEX group versus the control group (1.1% vs 4.0%, p=0.03; 0.4% vs 2.9%, p=0.04, respectively). The pain score and the sleep quality in the DEX group were better than that in the control group (p<0.001). CONCLUSION The application of DEX in the early postpartum period can significantly attenuate the incidence of postpartum depressive disorders.",2019,"The pain score and the sleep quality in the DEX group was better than that in the Control group (p<0.001). ","['postpartum depressive symptoms (PDS', 'Six hundred parturients scheduled for elective caesarean delivery under spinal anesthesia', 'parturients with antenatal depression or moderate pressure during pregnancy', 'Cesarean Section in Chinese Women']","['DEX', 'Control group (infusion with 0.9%normal saline after delivery and PCIA with sufentanil', 'placebo', 'dexmedetomidine (DEX', 'Dexmedetomidine', 'DEX group (DEX infusion 0.5ug.kg -1 after delivery and PCIA with DEX', 'Placebo']","['pain score and the sleep quality', 'Postoperative analgesia, sedation, and sleep quality', 'incidence of postpartum self-harm ideation', 'Edinburgh Postnatal Depression Scale (EPDS) score', 'Postpartum blues and PDS prevalence']","[{'cui': 'C0086839', 'cui_str': 'Postpartum Period'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}, {'cui': 'C0002928', 'cui_str': 'Spinal Anesthesia'}, {'cui': 'C2828394', 'cui_str': 'Antenatal (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0007876', 'cui_str': 'C-Section (OB)'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0086839', 'cui_str': 'Postpartum Period'}, {'cui': 'C0085271', 'cui_str': 'Self-Injury'}, {'cui': 'C0392348', 'cui_str': 'Ideation, function (observable entity)'}, {'cui': 'C3472185', 'cui_str': 'Edinburgh postnatal depression scale score (observable entity)'}, {'cui': 'C1260957', 'cui_str': 'Blue color (qualifier value)'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}]",600.0,0.290007,"The pain score and the sleep quality in the DEX group was better than that in the Control group (p<0.001). ","[{'ForeName': 'He-Ya', 'Initials': 'HY', 'LastName': 'Yu', 'Affiliation': 'Department of Anesthesiology, Third Xiangya Hospital of Central South University, Changsha, China.'}, {'ForeName': 'Sai-Ying', 'Initials': 'SY', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Third Xiangya Hospital of Central South University, Changsha, China.'}, {'ForeName': 'Cheng-Xuan', 'Initials': 'CX', 'LastName': 'Quan', 'Affiliation': 'Department of Anesthesiology, Third Xiangya Hospital of Central South University, Changsha, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Fang', 'Affiliation': 'Department of Anesthesiology, Third Xiangya Hospital of Central South University, Changsha, China.'}, {'ForeName': 'Shi-Chao', 'Initials': 'SC', 'LastName': 'Luo', 'Affiliation': 'Department of Anesthesiology, Third Xiangya Hospital of Central South University, Changsha, China.'}, {'ForeName': 'Dan-Yang', 'Initials': 'DY', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Third Xiangya Hospital of Central South University, Changsha, China.'}, {'ForeName': 'Shan-Shan', 'Initials': 'SS', 'LastName': 'Zhen', 'Affiliation': 'Department of Anesthesiology, Third Xiangya Hospital of Central South University, Changsha, China.'}, {'ForeName': 'Jia-Hui', 'Initials': 'JH', 'LastName': 'Ma', 'Affiliation': 'Department of Anesthesiology, Third Xiangya Hospital of Central South University, Changsha, China.'}, {'ForeName': 'Kai-Ming', 'Initials': 'KM', 'LastName': 'Duan', 'Affiliation': 'Department of Anesthesiology, Third Xiangya Hospital of Central South University, Changsha, China.'}]",Pharmacotherapy,['10.1002/phar.2320'] 591,31971061,Dynamic Assessment for Identifying Spanish-Speaking English Learners' Risk for Mathematics Disabilities: Does Language of Administration Matter?,"We examined dynamic assessment's (DA's) added value over traditional assessments for identifying Spanish-speaking English learners' (ELs) risk for developing mathematics disabilities, as a function of the language of test administration (English vs. Spanish), type of math outcome, and EL's language dominance. At the start of first grade, ELs ( N = 368) were randomly assigned to English-DA or Spanish-DA conditions, were assessed on static mathematics measures and domain-general (language, reasoning) measures in English, and completed DA in their assigned language condition. At year's end, they were assessed on calculation and word-problem solving outcomes in English. Results from multigroup path models indicated that Spanish-DA mitigates the impact of ELs' language dominance on DA performance. Moreover, ELs' language dominance moderated DA's predictive validity differentially depending on DA language and type of outcome. Spanish-DA showed higher predictive validity in Spanish-dominant ELs than English-dominant ELs when predicting calculations but not word-problem solving. English-DA was predictive for both outcomes, regardless of ELs' language dominance.",2020,Spanish-DA showed higher predictive validity in Spanish-dominant ELs than English-dominant ELs when predicting calculations but not word-problem solving.,['Mathematics Disabilities'],[],"['static mathematics measures and domain-general (language, reasoning) measures in English, and completed DA']","[{'cui': 'C0024934', 'cui_str': 'Mathematics'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}]",[],"[{'cui': 'C0441463', 'cui_str': 'Static (qualifier value)'}, {'cui': 'C0024934', 'cui_str': 'Mathematics'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0023008', 'cui_str': 'Languages'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]",368.0,0.0353739,Spanish-DA showed higher predictive validity in Spanish-dominant ELs than English-dominant ELs when predicting calculations but not word-problem solving.,"[{'ForeName': 'Eunsoo', 'Initials': 'E', 'LastName': 'Cho', 'Affiliation': 'Michigan State University, East Lansing, USA.'}, {'ForeName': 'Lynn S', 'Initials': 'LS', 'LastName': 'Fuchs', 'Affiliation': 'Vanderbilt University, Nashville, TN, USA.'}, {'ForeName': 'Pamela M', 'Initials': 'PM', 'LastName': 'Seethaler', 'Affiliation': 'Vanderbilt University, Nashville, TN, USA.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Fuchs', 'Affiliation': 'Vanderbilt University, Nashville, TN, USA.'}, {'ForeName': 'Donald L', 'Initials': 'DL', 'LastName': 'Compton', 'Affiliation': 'Florida State University, Tallahassee, USA.'}]",Journal of learning disabilities,['10.1177/0022219419898887'] 592,31835620,"The Acute and Chronic Cognitive and Cerebral Blood-Flow Effects of Nepalese Pepper ( Zanthoxylum armatum DC.) Extract-A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Humans.","Background : Zanthoxylum armatum DC. (ZA) is a traditional Asian culinary spice and medicinal compound, which is rich in monoterpenes and hydroxy α-sanshool. Mechanistic interactions with the monoamine, cholinergic and cannabinoid neurotransmission systems, as well as transient receptor potential (TRP) and potassium ion channels, may predispose ZA to modulate human brain function. Objectives : To investigate the effects of a single dose and 56-days supplementation with a lipid extract of ZA on cognitive function, mood and cerebral blood-flow (CBF) parameters in the pre-frontal cortex during cognitive task performance. Design : Double-blind, randomized, parallel groups study with N = 82 healthy males and females between the ages of 30 and 55 years. Assessments were undertaken pre-dose and at 1, 3 and 5 hours post-dose on the first (Day 1) and last (Day 56) days of supplementation. Results : A single dose of ZA (Day 1) resulted in acute improvements on a 'Speed of Attention' factor and the Rapid Visual Information Processing (RVIP) task, in comparison to placebo. However, following ZA participants were less accurate on the name-to-face recall task. After 56 days of ZA consumption (Day 56), speed was enhanced on a global 'Speed of Performance' measure, comprising data from all of the timed tasks in the computerized battery. Participants also completed more correct Serial 3s Subtractions at the 3 hours assessment and were less mentally fatigued throughout the day than participants consuming placebo. These effects were complemented on both Day 1 and Day 56 by modulation of CBF parameters, as assessed by Near Infrared Spectroscopy (NIRS). The primary finding here was a reduced hemodynamic response during the RVIP task. Conclusion : ZA improves aspects of cognitive performance, in particular the speed of performing tasks, in healthy humans and results in concomitant reductions in hemodynamic responses in the frontal cortex during task performance. The findings suggest an increase in neural efficiency following ZA.",2019,"These effects were complemented on both Day 1 and Day 56 by modulation of CBF parameters, as assessed by Near Infrared Spectroscopy (NIRS).","['Healthy Humans', '82 healthy males and females between the ages of 30 and 55 years']","['Placebo', 'Nepalese Pepper ( Zanthoxylum armatum DC', '56-days supplementation with a lipid extract of ZA', 'placebo', 'ZA']","['cognitive function, mood and cerebral blood-flow (CBF) parameters', 'hemodynamic response', 'neural efficiency', ""acute improvements on a 'Speed of Attention' factor and the Rapid Visual Information Processing (RVIP) task"", 'cognitive performance']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0453397', 'cui_str': 'Piper nigrum'}, {'cui': 'C1026724', 'cui_str': 'Zanthoxylum'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}]","[{'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0428714', 'cui_str': 'Cerebral Blood Flow'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0021420', 'cui_str': 'Information Processing'}]",82.0,0.172104,"These effects were complemented on both Day 1 and Day 56 by modulation of CBF parameters, as assessed by Near Infrared Spectroscopy (NIRS).","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kennedy', 'Affiliation': 'Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle-upon-Tyne NE1 8ST, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Wightman', 'Affiliation': 'Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle-upon-Tyne NE1 8ST, UK.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Khan', 'Affiliation': 'Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle-upon-Tyne NE1 8ST, UK.'}, {'ForeName': 'Torsten', 'Initials': 'T', 'LastName': 'Grothe', 'Affiliation': 'Mibelle Group Biochemistry, Bolimattstrasse 1, CH-5033, Buchs, Switzerland.'}, {'ForeName': 'Philippa', 'Initials': 'P', 'LastName': 'Jackson', 'Affiliation': 'Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle-upon-Tyne NE1 8ST, UK.'}]",Nutrients,['10.3390/nu11123022'] 593,31910101,Effects of Supplemental Vitamin D on Muscle Performance and Quality of Life in Graves' Disease: A Randomized Clinical Trial.,"Background: Vitamin D deficiency has been proposed to have a role in the development and course of Graves' disease (GD). Muscle weakness and quality of life (QoL) impairments are shared features of GD and vitamin D deficiency. We aimed at investigating whether vitamin D supplementation would improve restoration of muscle performance and thyroid-related QoL in GD and at describing the effect of anti-thyroid medication (ATD) on these outcomes. Methods: In a double-blinded clinical trial, hyperthyroid patients with a first-time diagnosis of GD were randomized to vitamin D 70 μg (2800 IU)/day or matching placebo as add-on to standard ATD. At baseline and after 3 and 9 months of intervention, we assessed isometric muscle strength, muscle function tests, postural stability, body composition, and QoL-impairment by using the ThyPRO questionnaire. Linear mixed modeling was used to analyze between-group differences. (The DAGMAR study clinicaltrials.gov ID NCT02384668). Results: Nine months of vitamin D supplementation caused an attenuation of muscle strength increment in all muscle measures investigated, significant at knee extension 60° where the increase was 24% lower ( p  = 0.04) in the vitamin D group compared with placebo. Compared with placebo, vitamin D supplementation tended to reduce gain of lean body mass (-24%, p  = 0.08). Vitamin D supplementation significantly impeded alleviation of Composite QoL and the same trend was observed for the Overall QoL-Impact and Impaired Daily Life scales. In response to ATD, all measures improved significantly. The increase in muscle strength ranged from 25% to 40% ( p all < 0.001), and increment of lean body mass was 10% ( p  < 0.001). Large changes were observed in all QoL scales. Conclusions: Nine months of vitamin D supplementation caused unfavorable effects on restoration of muscle performance. In contrast, ATD treatment was associated with marked improvement in all measures of muscle performance and thyroid-related QoL. In patients with newly diagnosed GD, high-dose vitamin D supplementation should not be recommended to improve muscle function, but ATD is of major importance to alleviate muscle impairment.",2020,"Nine months of vitamin D supplementation caused an attenuation of muscle strength increment in all muscle groups investigated, significant at knee extension 60° where the increase was 24% smaller (p=0.04) in the vitamin D group compared with placebo.","['hyperthyroid patients with a first time diagnosis of GD', ""Graves' disease""]","['anti-thyroid medication (ATD', 'placebo, vitamin D supplementation', 'vitamin D 70 mcg (2800 IU)/day or matching placebo', 'Vitamin D supplementation', 'vitamin D supplementation', 'supplemental vitamin D', 'placebo', ' Vitamin D deficiency', 'vitamin D']","['lean body mass', 'Muscle weakness and quality of life (QoL) impairments', 'gain of lean body mass', 'alleviation of Composite QoL', 'Overall QoL-Impact and Impaired Daily Life scales', 'muscle performance and thyroid-related QoL', 'muscle strength', 'attenuation of muscle strength increment', 'muscle performance and quality of life', 'restoration of muscle performance', 'restoration of muscle performance and thyroid-related QoL in GD', 'isometric muscle strength, muscle function tests, postural stability, body composition, and QoL-impairment using ThyPRO']","[{'cui': 'C0020550', 'cui_str': 'Hyperthyroid'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0018213', 'cui_str': 'Graves Disease'}]","[{'cui': 'C0040134', 'cui_str': 'thyroid (USP)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0439211', 'cui_str': 'microgram'}, {'cui': 'C4517680', 'cui_str': 'Two thousand eight hundred'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0042870', 'cui_str': 'Vitamin D Deficiency'}]","[{'cui': 'C0424678', 'cui_str': 'Lean body mass (observable entity)'}, {'cui': 'C0151786', 'cui_str': 'Muscular Weakness'}, {'cui': 'C0034380'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0222045'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0040134', 'cui_str': 'thyroid (USP)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration (attribute)'}, {'cui': 'C0231484', 'cui_str': 'Muscular activity'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0205278', 'cui_str': 'Postural (qualifier value)'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}]",,0.389076,"Nine months of vitamin D supplementation caused an attenuation of muscle strength increment in all muscle groups investigated, significant at knee extension 60° where the increase was 24% smaller (p=0.04) in the vitamin D group compared with placebo.","[{'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Grove-Laugesen', 'Affiliation': 'Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Per Karkov', 'Initials': 'PK', 'LastName': 'Cramon', 'Affiliation': 'Department of Endocrinology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Sofie', 'Initials': 'S', 'LastName': 'Malmstroem', 'Affiliation': 'Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Ebbehoj', 'Affiliation': 'Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Torquil', 'Initials': 'T', 'LastName': 'Watt', 'Affiliation': 'Department of Internal Medicine, Gentofte and Herlev Hospital, Herlev, Denmark.'}, {'ForeName': 'Klavs Würgler', 'Initials': 'KW', 'LastName': 'Hansen', 'Affiliation': 'Medical Department, Regional Hospital Silkeborg, Silkeborg, Denmark.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Rejnmark', 'Affiliation': 'Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.'}]",Thyroid : official journal of the American Thyroid Association,['10.1089/thy.2019.0634'] 594,31917907,A Clinical Trial of a Psychoeducation Group Intervention for Patients With Borderline Personality Disorder.,"OBJECTIVE The objective of this study was to assess the impact of a 6-session psychoeducational group (PEG) intervention for borderline personality disorder (BPD) in an underserved community-based outpatient setting. METHODS The study was conducted between July 2015 and January 2017. Of 96 outpatients who met DSM-IV criteria for BPD, the first 48 received the experimental treatment, whereas the next 48 were assigned to a wait list. All received non-intensive treatment as usual. The primary outcome measure, the Zanarini Rating Scale for DSM-IV Borderline Personality Disorder (ZAN-BPD), was administered at baseline, at the end of treatment, and 2 months after the end of treatment. RESULTS The PEG intervention was associated with a significant improvement on all sectors of BPD (P < .001). Improvements were greater for the PEG on all sectors except impulsivity. Benefits remained stable during 2-month follow-up. The PEG intervention had a large effect size (Cohen d = -1.16), whereas the wait list effect size was small (Cohen d = -0.18). The between-arms effect size was 0.80 after treatment and 0.90 at follow-up. With full response defined as a decrease of ≥ 50% from baseline in ZAN-BPD total score, 22 patients (46%) in the psychoeducation group and 3 (6%) in the wait list group were considered full responders. CONCLUSIONS This study shows that a PEG intervention can be an effective treatment for patients with BPD. The overall cost benefits of group interventions and the the applicability of a PEG intervention to underserved patients demonstrate its potential to address significant public health needs.",2019,The PEG intervention was associated with a significant improvement on all sectors of BPD (P < .001).,"['96 outpatients who met DSM-IV criteria for BPD, the first 48 received the experimental treatment, whereas the next 48 were assigned to a wait list', 'patients with BPD', 'borderline personality disorder (BPD) in an underserved community-based outpatient setting', 'Patients With Borderline Personality Disorder', 'July 2015 and January 2017']","['6-session psychoeducational group (PEG) intervention', 'Psychoeducation Group Intervention', 'PEG intervention']","['Zanarini Rating Scale for DSM-IV Borderline Personality Disorder (ZAN-BPD', 'wait list effect size', 'all sectors of BPD']","[{'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0220952', 'cui_str': 'DSM-IV'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0006012', 'cui_str': 'Borderline Personality Disorder'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0871175', 'cui_str': 'Psycho-education'}]","[{'cui': 'C0222045'}, {'cui': 'C0220952', 'cui_str': 'DSM-IV'}, {'cui': 'C0006012', 'cui_str': 'Borderline Personality Disorder'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}]",96.0,0.0347258,The PEG intervention was associated with a significant improvement on all sectors of BPD (P < .001).,"[{'ForeName': 'Maria Elena', 'Initials': 'ME', 'LastName': 'Ridolfi', 'Affiliation': ""Fano Outpatients' Services, DSM AV1, Via Guarnieri 16, 61032, Fano, Italy. mariaelena.ridolfi@gmail.com.""}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Rossi', 'Affiliation': 'Unit of Psychiatry, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.'}, {'ForeName': 'Giorgia', 'Initials': 'G', 'LastName': 'Occhialini', 'Affiliation': ""Fano Outpatients' Services, DSM AV1, Fano, Italy.""}, {'ForeName': 'John G', 'Initials': 'JG', 'LastName': 'Gunderson', 'Affiliation': 'McLean Hospital, Belmont, Massachusetts, USA.'}]",The Journal of clinical psychiatry,['10.4088/JCP.19m12753'] 595,31912474,"Tamsulosin And Sodium Diclofenac as An Effective Therapy To Reduce Pain After Ureteral Stent Removal: A Prospective, Double Blinded Randomized Placebo Controlled Trial Study.","PURPOSE This study was conducted to determine the effects of tamsulosin and diclofenac sodium use on patients' pain perception after ureteral stents removal. MATERIALS AND METHODS This study was a randomized control trial with double-blinded design. Eighty patients who underwent ureteral stent removal surgery at Kardinah Hospital, Tegal during January to March 2017 were divided into four groups. The experimental group was administered by analgesic for two days, (A) placebo tid, or (B) diclofenac sodium 50 mg bid, or (C) tamsulosin 0.2 mg sid, or (D) combination of tamsulosin and diclofenac sodium. Analgesic effects were assessed with the Visual Analog Scale (VAS). Relationships among variables were assessed using one-way ANOVA and post hoc tests. RESULTS The surgical procedure for ureteral stent removal consisted of 48 (60%) male and 32 (40%) female. The average age of group A, B, C, and D were 51.0, 51.9, 47.6, and 47.3 years, and the average stent dwell times was 6.3 weeks. VAS values of the entire experimental group were lower than the control group on the first day until the second day after the stent removal procedure (p <0.05). In the experimental group, there was no difference between group B and C (p> 0.05). Group D showed better analgesic effects than group B and C (p <0.05). There were no severe side effects found in whole cases. CONCLUSION The result shows that combination therapy of diclofenac sodium and tamsulosin is better in reducing the pain after ureteral stent removal compared to the admission of a single placebo, tamsulosin, and diclofenac sodium therapy.",2020,Group D showed better analgesic effects than group B and C (p <0.05).,"['Eighty patients who underwent ureteral stent removal surgery at Kardinah Hospital, Tegal during January to March 2017', ""patients' pain perception after ureteral stents removal"", 'ureteral stent removal consisted of 48 (60%) male and 32 (40%) female']","['diclofenac sodium therapy', 'tamsulosin and diclofenac sodium', 'Placebo', 'placebo tid, or (B) diclofenac sodium 50 mg bid, or (C) tamsulosin 0.2 mg sid, or (D) combination of tamsulosin and diclofenac sodium', 'placebo, tamsulosin', 'diclofenac sodium and tamsulosin', 'Tamsulosin And Sodium Diclofenac']","['Pain', 'Analgesic effects', 'Visual Analog Scale (VAS', 'pain', 'analgesic effects', 'VAS values', 'severe side effects']","[{'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1278795', 'cui_str': 'Removal of ureteral stent (procedure)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C3714605', 'cui_str': 'Pain Perception'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0700583', 'cui_str': 'Diclofenac Sodium'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0257343', 'cui_str': 'tamsulosin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0908863', 'cui_str': 'TIDS'}, {'cui': 'C2710094', 'cui_str': 'Diclofenac Sodium 50 MG'}, {'cui': 'C0048106', 'cui_str': 'BIDS'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0038644', 'cui_str': 'SIDS'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}]",80.0,0.0909805,Group D showed better analgesic effects than group B and C (p <0.05).,"[{'ForeName': 'Exsa', 'Initials': 'E', 'LastName': 'Hadibrata', 'Affiliation': 'Department of Urology, Faculty of Medicine Universitas Lampung/ Abdul Moeloek General Hospital, Lampung, Indonesia. exsa.hadibrata@gmail.com.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Farishal', 'Affiliation': 'Medical Doctor Departmet Of Urology, Faculty Of Medicine Universitas Lampung, Lampung, Indonesia.'}, {'ForeName': 'Zulfikar', 'Initials': 'Z', 'LastName': 'Ali', 'Affiliation': 'Department of Surgery, Kardinah Hospital, Tegal, Central Java, Indonesia. Yogyakarta, Indonesia.'}, {'ForeName': 'Raden', 'Initials': 'R', 'LastName': 'Danarto', 'Affiliation': 'Department of Surgery, Faculty of Medicine Universitas Gadjah Mada/Dr Sardjito General Hospital.'}]",Urology journal,['10.22037/uj.v0i0.5190'] 596,31785175,The effect of deep inhalation on mannitol responsiveness.,"BACKGROUND Mannitol inhalation testing is specific for asthmatics with eosinophilic airway inflammation, a factor that has been negatively correlated with the development of deep inhalation bronchoprotection. OBJECTIVE To evaluate the effect of deep inhalations on responsiveness to inhaled mannitol in correlation with the degree of airway inflammation. METHODS Twenty participants with stable asthma completed this randomized, crossover study. A screening visit assessed responsiveness to methacholine and airway inflammation through fractional exhaled nitric oxide (FeNO) measures and sputum induction. Participants next completed two mannitol challenges, one with deep inhalations (standard method) and one with inhalations to half of total lung capacity, and two methacholine challenges, one with tidal breathing (standard method) and one with deep inhalations. Only the inhalation technique for dose administration differed between repeat mannitol or methacholine challenges. RESULTS Deep inhalations did not significantly influence the provocative dose of mannitol causing a 15% fall in forced expiratory volume in 1 second ((P = .73; n = 7) or the mannitol dose-response slope (P = .26; n = 20). Deep inhalations produced significant bronchoprotection against methacholine (P = .03; n = 20). FeNO levels were significantly correlated to sputum eosinophilia (P = .02; n = 15), responsiveness to deep inhalation methacholine (P = .005; n = 20), the dose-response slopes from deep inhalation mannitol (P = .01; n = 20), and the dose-response slope from non-deep inhalation mannitol (P = .005; n = 20). CONCLUSIONS AND CLINICAL RELEVANCE Deep inhalations did not produce significant bronchoprotection against inhaled mannitol. This result is in agreement with past findings linking airway inflammation with loss of deep inhalation bronchoprotection. CLINICAL TRIAL REGISTRATION This study was prospectively registered on clinicaltrials.gov (NCT03505489).",2020,Deep inhalations produced significant bronchoprotection against methacholine (p=0.03; n=20).,"['asthmatics with eosinophilic airway inflammation', 'Twenty participants with stable asthma']","['Deep Inhalation', 'deep inhalations (standard method) and one with inhalations to half of total lung capacity, and two methacholine challenges, one with tidal breathing (standard method) and one with deep inhalations']","['FeNO levels', 'forced expiratory volume', 'Mannitol Responsiveness', 'sputum eosinophilia']","[{'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}]","[{'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C1705211', 'cui_str': 'Inhalation - unit of product usage'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0040509', 'cui_str': 'Total Lung Capacity'}, {'cui': 'C0430567', 'cui_str': 'Methacholine challenge (procedure)'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}]","[{'cui': 'C4523905', 'cui_str': 'Fractional exhaled nitric oxide'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0887166', 'cui_str': '(L)-Mannitol'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C2240374', 'cui_str': 'Eosinophil count raised (finding)'}]",20.0,0.0455423,Deep inhalations produced significant bronchoprotection against methacholine (p=0.03; n=20).,"[{'ForeName': 'Christianne M', 'Initials': 'CM', 'LastName': 'Blais', 'Affiliation': 'Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.'}, {'ForeName': 'Beth E', 'Initials': 'BE', 'LastName': 'Davis', 'Affiliation': 'Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.'}, {'ForeName': 'Donald W', 'Initials': 'DW', 'LastName': 'Cockcroft', 'Affiliation': 'Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.'}]",Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,['10.1111/cea.13543'] 597,31758735,"Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age.","BACKGROUND & AIMS Treatment of children aged 3-6 genotype 4 is still limited by the interferon side effects. We aimed in this study to evaluate the effectiveness and safety of sofosbuvir/ledipasvir in children (3-6 years) genotype 4 chronic HCV-infected patients. METHODS In total, 22 consecutive chronic HCV-infected patients (mean age 4.8 ± 0.9years, 19 males) were included in this prospective study. All patients received sofosbuvir 200 mg/ledipasvir 45 mg in a single oral daily dose. Patients were randomly subdivided into two groups according the duration of treatment into 8 and 12 weeks. All the clinical and laboratory data were collected. All the side effects were recorded from the patients or their parents. Follow-up were made at Week 4, 8 and 12 and 12 weeks after the end of treatment (SVR12). RESULTS The overall SVR12 rate was 100%. At Week 4, 9/11 patients in the 12-week group (81.8%; 95% CI: 52.3%-94.7%) achieved virologic negativity, vs 10/11 (90.9%; 95% CI: 62.3%-98.4%) in the 8-week group. At Week 8, 10/11 (90.8%; 95% CI: 62.3%-98.4%) in the 12-week group vs 11/11 (100%; 95% CI: 74.1%-100%) in the 8-week group were virologically negative. The reported side effects were cough, abdominal pain, nausea, vomiting and diarrhoea especially early in the treatment. The main complaint was difficulty in swallowing the tablets in the youngest patient at the beginning of the course of treatment. All patients were compliant to treatment. CONCLUSION Sofosbuvir/ledipasvir combination is safe and tolerable in the chronic infected HCV genotype 4 infected children (3-6 years). The 8-week treatment duration is similarly effective as the 12-week duration.",2020,"At Week 8, 10/11 (90.8%; 95%CI: 62.3%-98.4%) in the 12-week group versus 11/11 (100%; 95%CI: 74.1%-100%) in the 8-weeks group were virologically negative.","['22 consecutive chronic HCV infected patients (mean age 4.8±0.9years, 19 males', 'in total', 'children aged 3-6 genotype-4', 'chronic hepatitis C virus genotype 4, infected children of 3 to 6 years of age', 'children (3-6 years) genotype-4 chronic HCV infected patients']","['Sofosbuvir/ledipasvir therapy', 'Sofosbuvir/ledipasvir combination', 'sofosbuvir/ledipasvir', 'sofosbuvir 200mg /ledipasvir45mg']","['virologic negativity', 'safe and tolerable', 'overall SVR12 rate', 'cough, abdominal pain, nausea, vomiting and diarrhea']","[{'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1285573', 'cui_str': 'Genotype determination'}, {'cui': 'C0524910', 'cui_str': 'Hepatitis C, Chronic'}, {'cui': 'C0042776', 'cui_str': 'Virus'}, {'cui': 'C0680063', 'cui_str': 'Child of (finding)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C2976303', 'cui_str': 'sofosbuvir'}, {'cui': 'C3851350', 'cui_str': 'ledipasvir'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4319558', 'cui_str': '200'}]","[{'cui': 'C0205466', 'cui_str': 'virology'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C0151791', 'cui_str': 'Nausea, vomiting and diarrhea (disorder)'}]",22.0,0.027026,"At Week 8, 10/11 (90.8%; 95%CI: 62.3%-98.4%) in the 12-week group versus 11/11 (100%; 95%CI: 74.1%-100%) in the 8-weeks group were virologically negative.","[{'ForeName': 'Enas M', 'Initials': 'EM', 'LastName': 'Kamal', 'Affiliation': 'Department of Gastroenterology, Hepatology and Endemic Medicine, Minia University Hospitals, El Minia, Egypt.'}, {'ForeName': 'Mortada', 'Initials': 'M', 'LastName': 'El-Shabrawi', 'Affiliation': 'Pediatric and Pediatrics Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Hisham', 'Initials': 'H', 'LastName': 'El-Khayat', 'Affiliation': 'Department of Gastroenterology, Hepatology and Endemic Medicine, Theodore Bilharz Research Institute, Giza, Egypt.'}, {'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Yakoot', 'Affiliation': 'Green Clinic Research Centre, Alexandria, Egypt.'}, {'ForeName': 'Yehia', 'Initials': 'Y', 'LastName': 'Sameh', 'Affiliation': 'Department of Hepatology, Gastroenterology and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni-suef, Egypt.'}, {'ForeName': 'Yasser', 'Initials': 'Y', 'LastName': 'Fouad', 'Affiliation': 'Department of Gastroenterology, Hepatology and Endemic Medicine, Minia University Hospitals, El Minia, Egypt.'}, {'ForeName': 'Dina', 'Initials': 'D', 'LastName': 'Attia', 'Affiliation': 'Department of Hepatology, Gastroenterology and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni-suef, Egypt.'}]",Liver international : official journal of the International Association for the Study of the Liver,['10.1111/liv.14308'] 598,31449914,Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.,"BACKGROUND Nemolizumab targets the IL-31 receptor α subunit involved in atopic dermatitis (AD) pathogenesis. OBJECTIVE We sought to evaluate a new dosing strategy of nemolizumab in patients with AD. METHODS We performed a 24-week, randomized, double-blind, multicenter study of nemolizumab (10, 30, and 90 mg) subcutaneous injections every 4 weeks versus placebo, with topical corticosteroids in adults with moderate-to-severe AD, severe pruritus, and inadequate control with topical treatment (n = 226). The Eczema Area and Severity Index (EASI), the peak pruritus (PP) numeric rating scale (NRS), and the Investigator's Global Assessment (IGA) were assessed. Standard safety assessments were performed. RESULTS Nemolizumab improved EASI, IGA, and/or NRS-itch scores, with the 30-mg dose being most effective. Nemolizumab (30 mg) reduced EASI scores versus placebo at week 24 (-68.8% vs -52.1%, P = .016); significant differences were observed by week 8 (P ≤ .01). With significant improvement (P = .028) as early as week 4, IGA 0/1 rates were higher for 30 mg of nemolizumab versus placebo at week 16 (33.3% vs 12.3%, P = .008) but not week 24 because of an increased placebo/topical corticosteroid effect (36.8% vs 21.1%, P = .06). PP-NRS scores were improved for 30 mg of nemolizumab versus placebo at week 16 (-68.6% vs -34.3%, P < .0001) and week 24 (-67.3% vs -35.8%, P < .0001), with a difference by week 1 (P < .001). NRS response rates (≥4-point decrease) were greater for 30 mg of nemolizumab versus placebo at week 16 (P ≤ .001) and week 24 (P ≤ .01). Nemolizumab was safe and well tolerated. The most common adverse events were nasopharyngitis and upper respiratory tract infection. CONCLUSIONS Nemolizumab resulted in rapid and sustained improvements in cutaneous signs of inflammation and pruritus in patients with AD, with maximal efficacy observed at 30 mg. Nemolizumab had an acceptable safety profile.",2020,NRS response rates (≥4-point decrease) were higher for nemolizumab 30 mg vs placebo at wk-16 (p≤0.001) and wk-24 (p≤0.01).,"['adults with moderate-to-severe AD, severe pruritus and inadequate control with topical treatment (n=226', '10, 30, 90 mg', 'Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus']","['nemolizumab 30 mg vs placebo', 'Nemolizumab', 'topical corticosteroid', 'placebo', 'Nemolizumab 30 mg reduced EASI vs placebo', 'nemolizumab', 'SC injections q 4 weeks vs placebo']","['safe and well-tolerated', 'NRS response rates', 'EASI, IGA and/or NRS-itch', 'cutaneous signs of inflammation and pruritus', ""Eczema Area and Severity Index (EASI), peak-pruritus numeric rating score (PP-NRS), and Investigator's Global Assessment (IGA"", 'PP NRS', 'placebo/TCS effect']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C0205412', 'cui_str': 'Inadequate (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0011615', 'cui_str': 'Neurodermatitis, Disseminated'}]","[{'cui': 'C4505530', 'cui_str': 'nemolizumab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0240291', 'cui_str': 'Mg reduced'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C4521174', 'cui_str': 'Cutaneous'}, {'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0013595', 'cui_str': 'Dermatitis, Eczematous'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}]",,0.357643,NRS response rates (≥4-point decrease) were higher for nemolizumab 30 mg vs placebo at wk-16 (p≤0.001) and wk-24 (p≤0.01).,"[{'ForeName': 'Jonathan I', 'Initials': 'JI', 'LastName': 'Silverberg', 'Affiliation': 'Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Ill. Electronic address: jonathanisilverberg@gmail.com.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Pinter', 'Affiliation': 'Department of Dermatology, Venereology, and Allergology, Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany.'}, {'ForeName': 'Grazyna', 'Initials': 'G', 'LastName': 'Pulka', 'Affiliation': 'School of Medicine, Jagiellonian University Medical College, Krakow, Poland.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Poulin', 'Affiliation': 'Department of Medicine, Université Laval, Quebec City, Quebec, Canada.'}, {'ForeName': 'Jean-David', 'Initials': 'JD', 'LastName': 'Bouaziz', 'Affiliation': 'Department of Dermatology, Paris VII Sorbonne Paris Cité University Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Wollenberg', 'Affiliation': 'Department of Dermatology and Allergology, Ludwig-Maximilians-Universität, Munich, Germany.'}, {'ForeName': 'Dédée F', 'Initials': 'DF', 'LastName': 'Murrell', 'Affiliation': 'Department of Dermatology, St George Clinical School, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Alexis', 'Affiliation': 'Department of Dermatology, Icahn School of Medicine, Mount Sinai, New York, NY.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Lindsey', 'Affiliation': 'Galderma Laboratories, Fort Worth, Tex.'}, {'ForeName': 'Faiz', 'Initials': 'F', 'LastName': 'Ahmad', 'Affiliation': 'Galderma Laboratories, Fort Worth, Tex.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Piketty', 'Affiliation': 'Galderma R&D, Lausanne, Switzerland.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Clucas', 'Affiliation': 'Retired, Sophia Antipolis, France.'}]",The Journal of allergy and clinical immunology,['10.1016/j.jaci.2019.08.013'] 599,30097652,Predictors for misreporting sodium and potassium intakes by overweight and obese participants in a food-based clinical trial: implications for practice.,"This study compared self-reported sodium and potassium intakes with urinary biomarkers and identified predictive factors. Secondary analysis of the 3-month intensive phase of the HealthTrack study with control (C), interdisciplinary intervention (I), intervention plus 30 g walnuts/day (IW) arms (n = 149). Dietary data was derived from diet history (DH) interviews and biomarker measures from urine. Urine-derived sodium (all, p = 0.000) and potassium (C: p = 0.011; I: p = 0.000; IW: p = 0.004) measures were significantly greater than self-reported intakes over the three months. Multiple linear regression showed body weight at baseline, body mass index (BMI) at baseline, and combined BMI at baseline and DH interviewer significantly negatively predicted the differences in sodium intake and excretion for C (β = -21.226, p = 0.016), I (β = -106.140, p = 0.002) and IW (F (9.530, 2df), p = 0.000), respectively. Where intakes of sodium and potassium are of interest in a trial, both reported intake and urinary biomarker measures are recommended.",2020,"Urine-derived sodium (all, p = 0.000) and potassium (C:",[],['potassium (C'],"['body weight at baseline, body mass index (BMI', 'sodium intake and excretion for C (β']",[],"[{'cui': 'C0304475', 'cui_str': 'Potassium supplement'}]","[{'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C3541959', 'cui_str': 'Sodium supplement (substance)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}]",,0.0238138,"Urine-derived sodium (all, p = 0.000) and potassium (C:","[{'ForeName': 'Vivienne X', 'Initials': 'VX', 'LastName': 'Guan', 'Affiliation': 'School of Medicine, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia. xg885@uowmail.edu.au.'}, {'ForeName': 'Yasmine C', 'Initials': 'YC', 'LastName': 'Probst', 'Affiliation': 'School of Medicine, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia.'}, {'ForeName': 'Elizabeth P', 'Initials': 'EP', 'LastName': 'Neale', 'Affiliation': 'School of Medicine, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia.'}, {'ForeName': 'Linda C', 'Initials': 'LC', 'LastName': 'Tapsell', 'Affiliation': 'School of Medicine, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia.'}]",European journal of clinical nutrition,['10.1038/s41430-018-0283-y'] 600,31024091,Factors associated with plasma n-3 and n-6 polyunsaturated fatty acid levels in Tanzanian infants.,"BACKGROUND/OBJECTIVES To identify factors associated with plasma polyunsaturated fatty acid (PUFA) levels among 3-month-old Tanzanian infants. SUBJECTS/METHODS Infants (n = 238) and mothers (n = 193) randomly selected from participants in the neonatal vitamin A supplementation randomized controlled trial. A cross-sectional study of maternal-infant pairs at 3 months postpartum. RESULTS All infant total, n-3, n-6, and individual PUFA levels were correlated with maternal levels. Infant plasma n-3 PUFA levels were higher when maternal n-3 PUFA levels were higher (mean difference in infant % fatty acid per unit increase in maternal levels ± standard error: 0.79 ± 0.08; P < 0.01). Infant plasma docosahexaenoic acid (DHA) levels were positively associated with maternal DHA levels (0.77 ± 0.09; P < 0.01) but were lower for twin births (-0.55 ± 0.27; P = 0.03). Greater birth weight in kilograms (1.00 ± 0.43; P = 0.02) and higher maternal n-6 PUFA levels (0.20 ± 0.07; P < 0.01) were positively associated with higher infant n-6 PUFA levels, whereas maternal mono-unsaturated fatty acid (MUFA) levels (-0.26 ± 0.08; P < 0.01), maternal mid upper arm circumference (MUAC) (-0.22 ± 0.11; P = 0.04), and male sex (-0.99 ± 0.45; P = 0.03) were associated with lower infant plasma n-6 PUFA levels. Infant plasma arachidonic acid (AA) levels were positively associated with maternal plasma AA levels (0.38 ± 0.09; P < 0.01), but inversely associated with twin births (-1.37 ± 0.67; P = 0.04). CONCLUSIONS Greater birth weight and higher maternal plasma PUFA levels at 3 months postpartum were significantly associated with higher infant plasma PUFA levels at 3 months age. Twin births, male sex, and higher maternal MUFA levels were associated with lower infant plasma PUFA levels. Nutrition counseling for optimal intake of PUFA-rich foods, to lactating mothers in resource-limited settings may be beneficial for improved infant health.",2020,Infant plasma n-3 PUFA levels were higher when maternal n-3 PUFA levels were higher (mean difference in infant % fatty acid per unit increase in maternal levels ± standard error: 0.79 ± 0.08; P < 0.01).,"['maternal-infant pairs at 3 months postpartum', 'Tanzanian infants', 'Infants (n\u2009=\u2009238) and mothers (n\u2009=\u2009193) randomly selected from participants in the', '3-month-old Tanzanian infants']","['neonatal vitamin', 'Nutrition counseling']","['All infant total, n-3, n-6, and individual PUFA levels', 'lower infant plasma n-6 PUFA levels', 'maternal DHA levels', 'Infant plasma arachidonic acid (AA) levels', 'maternal plasma AA levels', 'infant plasma PUFA levels', 'maternal MUFA levels', 'Infant plasma n-3 PUFA levels', 'higher infant n-6 PUFA levels', 'plasma polyunsaturated fatty acid (PUFA) levels', 'plasma n-3 and n-6 polyunsaturated fatty acid levels', 'birth weight and higher maternal plasma PUFA levels', 'maternal n-6 PUFA levels', 'maternal n-3 PUFA levels', 'maternal mid upper arm circumference (MUAC', 'maternal mono-unsaturated fatty acid (MUFA) levels', 'Greater birth weight in kilograms', 'Infant plasma docosahexaenoic acid (DHA) levels']","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0086839', 'cui_str': 'Postpartum Period'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0042890', 'cui_str': 'Vitamins'}, {'cui': 'C3714365', 'cui_str': 'Counseling about nutrition'}]","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C1278199', 'cui_str': 'Plasma arachidonic acid measurement'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0032615', 'cui_str': 'Polyunsaturated Fatty Acids'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}, {'cui': 'C0562351', 'cui_str': 'Mid upper arm circumference (observable entity)'}, {'cui': 'C0540173', 'cui_str': 'MonoS'}, {'cui': 'C1281901', 'cui_str': 'Fatty acid measurement'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0556150', 'cui_str': 'docosahexaenoic acid'}]",,0.0880946,Infant plasma n-3 PUFA levels were higher when maternal n-3 PUFA levels were higher (mean difference in infant % fatty acid per unit increase in maternal levels ± standard error: 0.79 ± 0.08; P < 0.01).,"[{'ForeName': 'Pili', 'Initials': 'P', 'LastName': 'Kamenju', 'Affiliation': 'Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA. pillie6@yahoo.co.uk.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Hertzmark', 'Affiliation': 'Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Edmond K', 'Initials': 'EK', 'LastName': 'Kabagambe', 'Affiliation': 'Division of Epidemiology, Departments of Medicine and Otolaryngology, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Emily R', 'Initials': 'ER', 'LastName': 'Smith', 'Affiliation': 'Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Alfa', 'Initials': 'A', 'LastName': 'Muhihi', 'Affiliation': 'Africa Academy for Public Health, Dar es Salaam, Tanzania.'}, {'ForeName': 'Ramadhani A', 'Initials': 'RA', 'LastName': 'Noor', 'Affiliation': 'Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Salum', 'Initials': 'S', 'LastName': 'Mshamu', 'Affiliation': 'Africa Academy for Public Health, Dar es Salaam, Tanzania.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Briegleb', 'Affiliation': 'Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Sudfeld', 'Affiliation': 'Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Honorati', 'Initials': 'H', 'LastName': 'Masanja', 'Affiliation': 'Ifakara Health Institute, Dar es Salaam, Tanzania.'}, {'ForeName': 'Wafaie W', 'Initials': 'WW', 'LastName': 'Fawzi', 'Affiliation': 'Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}]",European journal of clinical nutrition,['10.1038/s41430-019-0428-7'] 601,30312541,Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression.,"Cardiac allograft vasculopathy (CAV) causes heart failure after heart transplantation (HTx), but its pathogenesis is incompletely understood. Notch signaling, possibly modulated by everolimus (EVR), is essential for processes involved in CAV. We hypothesized that circulating Notch ligands would be dysregulated after HTx. We studied circulating delta-like Notch ligand 1 (DLL1) and periostin (POSTN) and CAV in de novo HTx recipients (n = 70) randomized to standard or EVR-based, calcineurin inhibitor-free immunosuppression and in maintenance HTx recipients (n = 41). Compared to healthy controls, plasma DLL1 and POSTN were elevated in de novo (P < .01; P < .001) and maintenance HTx recipients (P < .001; P < .01). Use of EVR was associated with a treatment effect for DLL1. For de novo HTx recipients, a change in DLL1 correlated with a change in CAV at 1 (P = .021) and 3 years (P = .005). In vitro, activation of T cells increased DLL1 secretion, attenuated by EVR. In vitro data suggest that also endothelial cells and vascular smooth muscle cells (VSMCs) could contribute to circulating DLL1. Immunostaining of myocardial specimens showed colocalization of DLL1 with T cells, endothelial cells, and VSMCs. Our findings suggest a role of DLL1 in CAV progression, and that the beneficial effect of EVR on CAV could reflect a suppressive effect on DLL1. Trial registration numbers-SCHEDULE trial: ClinicalTrials.gov NCT01266148; NOCTET trial: ClinicalTrials.gov NCT00377962.",2019,"Compared to healthy controls, plasma DLL1 and POSTN were elevated in de novo (P ","['heart transplant recipients on everolimus-based immunosuppression', 'Cardiac allograft vasculopathy (CAV) causes heart failure after heart transplantation (HTx', 'de novo HTx recipients (n\xa0=\xa070) randomized to']","['standard or EVR-based, calcineurin inhibitor-free immunosuppression', 'circulating delta-like Notch ligand 1 (DLL1) and periostin (POSTN) and CAV']","['colocalization of DLL1 with T cells, endothelial cells, and VSMCs', 'plasma DLL1 and POSTN', 'DLL1 secretion']","[{'cui': 'C2029943', 'cui_str': 'Transplanted heart present'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0021080', 'cui_str': 'Immunosuppression (Physiology)'}, {'cui': 'C0564471', 'cui_str': 'Allograft heart (substance)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0018823', 'cui_str': 'Transplantation, Cardiac'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C4521884', 'cui_str': 'Calcineurin inhibitor (disposition)'}, {'cui': 'C0021080', 'cui_str': 'Immunosuppression (Physiology)'}, {'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0205316', 'cui_str': 'Notched (qualifier value)'}, {'cui': 'C0023688', 'cui_str': 'Ligands'}, {'cui': 'C0206179', 'cui_str': 'Chicken Anemia Agent'}]","[{'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0225336', 'cui_str': 'Endothelial Cells'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0036537', 'cui_str': 'Secretions'}]",70.0,0.0506602,"Compared to healthy controls, plasma DLL1 and POSTN were elevated in de novo (P ","[{'ForeName': 'Hilde M', 'Initials': 'HM', 'LastName': 'Norum', 'Affiliation': 'Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Annika E', 'Initials': 'AE', 'LastName': 'Michelsen', 'Affiliation': 'Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Tove', 'Initials': 'T', 'LastName': 'Lekva', 'Affiliation': 'Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Satish', 'Initials': 'S', 'LastName': 'Arora', 'Affiliation': 'Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Otterdal', 'Affiliation': 'Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Maria Belland', 'Initials': 'MB', 'LastName': 'Olsen', 'Affiliation': 'Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Xiang Yi', 'Initials': 'XY', 'LastName': 'Kong', 'Affiliation': 'Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Einar', 'Initials': 'E', 'LastName': 'Gude', 'Affiliation': 'Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Arne K', 'Initials': 'AK', 'LastName': 'Andreassen', 'Affiliation': 'Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Dag', 'Initials': 'D', 'LastName': 'Solbu', 'Affiliation': 'Novartis Norge AS, Oslo, Norway.'}, {'ForeName': 'Kristjan', 'Initials': 'K', 'LastName': 'Karason', 'Affiliation': 'Sahlgrenska University Hospital, Transplant Institute, Gothenburg, Sweden.'}, {'ForeName': 'Göran', 'Initials': 'G', 'LastName': 'Dellgren', 'Affiliation': 'Sahlgrenska University Hospital, Transplant Institute, Gothenburg, Sweden.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Gullestad', 'Affiliation': 'Institute of Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Pål', 'Initials': 'P', 'LastName': 'Aukrust', 'Affiliation': 'Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Thor', 'Initials': 'T', 'LastName': 'Ueland', 'Affiliation': 'Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.'}]",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,['10.1111/ajt.15141'] 602,31296936,Anaemia and iron deficiency in pregnancy and adverse perinatal outcomes in Southern India.,"BACKGROUND/OBJECTIVES We examined the prevalence of anaemia, iron deficiency, and inflammation during pregnancy and their associations with adverse pregnancy and infant outcomes in India. SUBJECTS/METHODS Three hundred and sixty-six women participating in a randomised trial of vitamin B 12 supplementation were monitored to assess haemoglobin (Hb), serum ferritin (SF), hepcidin, C-reactive protein (CRP), and alpha-1-acid glycoprotein (AGP) during pregnancy. Women received vitamin B 12 supplementation (50 µg per day) or placebo daily; all women received daily prenatal iron-folic acid supplementation. Binomial and linear regression models were used to examine the associations of maternal iron biomarkers with pregnancy and infant outcomes. RESULTS Thirty percent of women were anaemic (Hb < 11.0 g/dl), 48% were iron deficient (SF < 15.0 µg/l), and 23% had iron deficiency anaemia at their first prenatal visit. The prevalence of inflammation (CRP > 5.0 mg/l: 17%; AGP > 1.0 g/l: 11%) and anaemia of inflammation (Hb < 11.0 g/dl, SF > 15.0 µg/l, plus CRP > 5.0 mg/l or AGP > 1.0 g/l: 2%) were low. Infants born to anaemic women had a twofold higher risk of low birth weight (<2500 g; risk ratio [RR]: 2.15, 95%CI: 1.20-3.84, p = 0.01), preterm delivery (RR: 2.67 (1.43-5.00); p = 0.002), underweight (WAZ < -2; RR: 2.20, 95%CI: 1.16-4.15, p = 0.02), and lower MUAC (β(SE): -0.94 (0.45)cm, p = 0.03). Similarly, maternal Hb concentrations predicted higher infant birth weight (p = 0.02) and greater gestational age at delivery (β(SE): 0.28 (0.08) weeks, p = 0.001), lower risk of preterm delivery (<37 weeks; RR: 0.76, 95%CI: 0.66-86, p < 0.0001); and higher infant MUAC (β(SE): 0.36 (0.13) cm, p = 0.006). Maternal SF concentrations were associated with greater birth length (β(SE): 0.44 (0.20) cm, p < 0.03). Findings were similar after adjusting SF concentrations for inflammation. IDA was associated with higher risk of low birth weight (RR: 1.99 (1.08-3.68); p = 0.03) and preterm birth (RR: 3.46 (1.81-6.61); p = 0.0002); and lower birth weight (p = 0.02), gestational age at birth (p = 0.0002), and infant WAZ scores (p = 0.02). CONCLUSIONS The prevalence of anaemia and iron deficiency was high early in pregnancy and associated with increased risk of adverse pregnancy and infant outcomes. A comprehensive approach to prevent anaemia is needed in women of reproductive age, to enhance haematological status and improve maternal and child health outcomes.",2020,"Similarly, maternal Hb concentrations predicted higher infant birth weight (p = 0.02) and greater gestational age at delivery (β(SE): 0.28 (0.08) weeks, p = 0.001), lower risk of preterm delivery (<37 weeks; RR: 0.76, 95%CI: 0.66-86, p < 0.0001); and higher infant MUAC (β(SE): 0.36 (0.13) cm, p = 0.006).","['Southern India', 'Infants born to anaemic women', 'Three hundred and sixty-six women participating']","['l', 'vitamin B 12 supplementation', 'IDA', 'placebo daily; all women received daily prenatal iron-folic acid supplementation']","['haemoglobin (Hb), serum ferritin (SF), hepcidin, C-reactive protein (CRP), and alpha-1-acid glycoprotein (AGP', 'lower risk of preterm delivery', 'iron deficiency anaemia', 'Maternal SF concentrations', 'infant birth weight', 'prevalence of anaemia and iron deficiency', 'Anaemia and iron deficiency in pregnancy and adverse perinatal outcomes', 'higher risk of low birth weight', 'infant WAZ scores', 'risk of low birth weight', 'lower birth weight', 'anaemia of inflammation', 'preterm birth', 'preterm delivery']","[{'cui': 'C0021201', 'cui_str': 'Republic of India'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0857322', 'cui_str': 'Anemic'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4319607', 'cui_str': '360 (qualifier value)'}]","[{'cui': 'C0042845', 'cui_str': 'cyanocobalamin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C0556110', 'cui_str': 'Folic acid supplementation (product)'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0696113', 'cui_str': 'Serum ferritin measurement'}, {'cui': 'C0966897', 'cui_str': 'Liver-Expressed Antimicrobial Peptide'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0029297', 'cui_str': 'alpha 1-Acid Glycoprotein'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}, {'cui': 'C0151526', 'cui_str': 'Premature Birth'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia (disorder)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0240066', 'cui_str': 'Iron deficiency (disorder)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",366.0,0.459335,"Similarly, maternal Hb concentrations predicted higher infant birth weight (p = 0.02) and greater gestational age at delivery (β(SE): 0.28 (0.08) weeks, p = 0.001), lower risk of preterm delivery (<37 weeks; RR: 0.76, 95%CI: 0.66-86, p < 0.0001); and higher infant MUAC (β(SE): 0.36 (0.13) cm, p = 0.006).","[{'ForeName': 'Julia L', 'Initials': 'JL', 'LastName': 'Finkelstein', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA. jfinkelstein@cornell.edu.'}, {'ForeName': 'Anura V', 'Initials': 'AV', 'LastName': 'Kurpad', 'Affiliation': ""St. John's Research Institute, Bangalore, India.""}, {'ForeName': 'Beena', 'Initials': 'B', 'LastName': 'Bose', 'Affiliation': ""St. John's Research Institute, Bangalore, India.""}, {'ForeName': 'Tinku', 'Initials': 'T', 'LastName': 'Thomas', 'Affiliation': ""St. John's Research Institute, Bangalore, India.""}, {'ForeName': 'Krishnamachari', 'Initials': 'K', 'LastName': 'Srinivasan', 'Affiliation': ""St. John's Medical College, Bangalore, India.""}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Duggan', 'Affiliation': ""St. John's Research Institute, Bangalore, India. Christopher.duggan@childrens.harvard.edu.""}]",European journal of clinical nutrition,['10.1038/s41430-019-0464-3'] 603,31905354,Comparison of Two Telemedicine Delivery Modes for Neonatal Resuscitation Support: A Simulation-Based Randomized Trial.,"INTRODUCTION Previous research has described technical aspects of telemedicine and the clinical impact of provider-to-patient telemedicine; however, little is known about provider-to-provider telemedical interventions. OBJECTIVE The primary aim of this study was to compare two telemedicine delivery modes on the quality of a simulated neonatal resuscitation. Our secondary aim was to evaluate the providers' task load. METHODS This was a prospective, single-center, randomized, simulation-based trial comparing a remote neonatal team leader (""teleleader"") versus a remote consultant (""teleconsultant""). Participants resuscitated a simulated, apneic, and bradycardic neonate. Performance was assessed by video review and task load was measured by the self-reported NASA task load index (NASA-TLX) tool. In the teleleader group, one remote neonatal specialist assumed the role of team leader in the resuscitation. In the teleconsultant group, the same remote specialist assumed the role of teleconsultant. RESULTS Twenty-two participants were included in the analyses. The teleleader group was associated with a higher overall checklist score compared to teleconsultants (median score 68%, interquartile range [IQR]: 66-69 vs. 58%, IQR: 42-62; p = 0.016). No significant difference was seen in overall subjective workload as measured by the NASA-TLX tool. However, mental demand and frustration were significantly greater with teleconsultants compared to teleleaders (mean mental demand: 14.1 vs. 17.0 out of 21; frustration: 7.9 vs. 14.7 out of 21). CONCLUSIONS Simulated neonates randomized to teams with teleleaders received significantly better resuscitative care compared to those randomized to teams with teleconsultants. Mental demand and frustration were higher for providers in the teleconsultant compared to teleleader teams.",2020,"The teleleader group was associated with a higher overall checklist score compared to teleconsultants (median score 68%, interquartile range [IQR]: 66-69 vs. 58%, IQR: 42-62; p = 0.016).","['Neonatal Resuscitation Support', 'Twenty-two participants were included in the analyses', 'Participants resuscitated a simulated, apneic, and bradycardic neonate']","['remote neonatal team leader (""teleleader"") versus a remote consultant (""teleconsultant']","['overall checklist score', 'Mental demand and frustration', 'video review and task load', 'mental demand and frustration', 'overall subjective workload']","[{'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0035273', 'cui_str': 'Resuscitation'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C4284772', 'cui_str': '22 (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C2587207', 'cui_str': 'Resuscitate'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}]","[{'cui': 'C0205157', 'cui_str': 'Remote (qualifier value)'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0009817', 'cui_str': 'Consultant'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0016770', 'cui_str': 'Frustration'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}]",22.0,0.0473408,"The teleleader group was associated with a higher overall checklist score compared to teleconsultants (median score 68%, interquartile range [IQR]: 66-69 vs. 58%, IQR: 42-62; p = 0.016).","[{'ForeName': 'Isabel T', 'Initials': 'IT', 'LastName': 'Gross', 'Affiliation': 'Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA, isabel.t.gross@gmail.com.'}, {'ForeName': 'Travis', 'Initials': 'T', 'LastName': 'Whitfill', 'Affiliation': 'Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.'}, {'ForeName': 'Brooke', 'Initials': 'B', 'LastName': 'Redmond', 'Affiliation': 'Department of Neonatology, Yale University School of Medicine, New Haven, Connecticut, USA.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Couturier', 'Affiliation': 'Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.'}, {'ForeName': 'Ambika', 'Initials': 'A', 'LastName': 'Bhatnagar', 'Affiliation': 'Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Joseph', 'Affiliation': 'Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Joseph', 'Affiliation': 'Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Ray', 'Affiliation': 'Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Wagner', 'Affiliation': 'Department of Pediatrics, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Auerbach', 'Affiliation': 'Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.'}]",Neonatology,['10.1159/000504853'] 604,31915996,Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial.,"BACKGROUND In ENSURE-AF study, edoxaban had similar efficacy and safety profile versus enoxaparin-warfarin (enox-warf) in patients undergoing electrical cardioversion of non-valvular atrial fibrillation. OBJECTIVES To evaluate the efficacy and safety of edoxaban versus enox-warf in patients who were vitamin K antagonists (VKA) naïve or experienced at time of randomisation into ENSURE-AF trial. METHODS The primary efficacy endpoint was a composite of stroke, systemic embolic event, myocardial infarction, and cardiovascular death during the overall study period, 28 days on study drug after cardioversion and 30 days follow-up. The primary safety endpoint was the composite of major and clinically relevant nonmajor bleeding during the on-medication period from time of first dose to last dose of study drug taken + 3 days. RESULTS Of 2199 patients enrolled in ENSURE-AF, 1095 were randomised to edoxaban and 1104 to enox-warf. There were numerically fewer primary efficacy endpoint events with edoxaban than enox-warf irrespective of whether VKA experienced or naïve (0.5% vs. 0.9%, 0.3% vs. 1.4%, respectively). There were no significant differences in the primary safety endpoint [odds ratio (OR) 2.09, 95% confidence interval (CI) 0.72-6.81 in anticoagulant experienced patients, OR 0.77, 95% CI 0.15-3.60 in anticoagulant naïve patients] and in major bleeding rates regardless of treatment or VKA experience (OR 0.69, 95%CI 0.06-6.04, OR 0.48, 95% CI 0.01-9.25, respectively). CONCLUSIONS Edoxaban had comparable efficacy and safety to optimized anticoagulation with enox-warf. The primary efficacy and safety endpoint outcomes were broadly similar between VKA experienced or naïve patients.",2020,"There were numerically fewer primary efficacy endpoint events with edoxaban than enox-warf irrespective of whether VKA experienced or naïve (0.5% vs. 0.9%, 0.3% vs. 1.4%, respectively).","['patients undergoing electrical cardioversion of non-valvular atrial fibrillation', '2199 patients enrolled in ENSURE-AF, 1095 were randomised to', 'patients who were vitamin K antagonists (VKA) naïve or experienced at time of randomisation into ENSURE-AF trial', 'subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF']","['Edoxaban versus warfarin', 'edoxaban', 'edoxaban versus warfarin', 'Edoxaban', 'enoxaparin-warfarin (enox-warf']","['composite of major and clinically relevant nonmajor bleeding during the on-medication period from time of first dose to last dose of study drug taken\u2009+\u20093\xa0days', 'composite of stroke, systemic embolic event, myocardial infarction, and cardiovascular death', 'efficacy and safety']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0013778', 'cui_str': 'Electrical Cardioversion'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}, {'cui': 'C3653316', 'cui_str': 'Vitamin K antagonists'}, {'cui': 'C1632851', 'cui_str': 'Times'}]","[{'cui': 'C2975435', 'cui_str': 'edoxaban'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0206460', 'cui_str': 'Enoxaparin'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",2199.0,0.152552,"There were numerically fewer primary efficacy endpoint events with edoxaban than enox-warf irrespective of whether VKA experienced or naïve (0.5% vs. 0.9%, 0.3% vs. 1.4%, respectively).","[{'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Kozieł', 'Affiliation': 'Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, William Henry Duncan Building, 6 West Derby Street, Liverpool, L78TX, UK.'}, {'ForeName': 'Naab', 'Initials': 'N', 'LastName': 'Al-Saady', 'Affiliation': 'Covance Inc, Cardiovascular/Metabolic, Maidenshead, UK.'}, {'ForeName': 'Søren P', 'Initials': 'SP', 'LastName': 'Hjortshøj', 'Affiliation': 'Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.'}, {'ForeName': 'Assen', 'Initials': 'A', 'LastName': 'Goudev', 'Affiliation': 'Queen Giovanna University Hospital, Sofia, Bulgaria.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Huber', 'Affiliation': '3rd Medical Department, Cardiology and Intensive Care Medicine, Medcial School, Wilhelminenhospital, and Sigmund Freud University, Vienna, Austria.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Cohen', 'Affiliation': 'Hôpital Saint Antoine, Hôpital Tenon; Université Pierre Et Marie Curie (Paris VI), Paris, France.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Jin', 'Affiliation': 'Daiichi Sankyo Pharma Development, Basking Ridge, New York, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Melino', 'Affiliation': 'Daiichi Sankyo, Basking Ridge, New York, USA.'}, {'ForeName': 'Shannon M', 'Initials': 'SM', 'LastName': 'Winters', 'Affiliation': 'Daiichi Sankyo, Basking Ridge, New York, USA.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Goette', 'Affiliation': 'St. Vincenz-Hospital, Paderborn, Germany.'}, {'ForeName': 'Gregory Y H', 'Initials': 'GYH', 'LastName': 'Lip', 'Affiliation': 'Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, William Henry Duncan Building, 6 West Derby Street, Liverpool, L78TX, UK. gregory.lip@liverpool.ac.uk.'}]",Clinical research in cardiology : official journal of the German Cardiac Society,['10.1007/s00392-019-01594-9'] 605,31632709,Efficacy of water spray for evaporative cooling in athletes with spinal cord injury.,"Study design Interventional crossover study. Objective Spinal cord injury (SCI) disrupts afferent input to the hypothalamus and impairs efferent vaso- and sudomotor output, especially in lesions above the sympathetic chain (T1-L2). In consequence, persons with SCI under heat stress experience impairment in the ability to dissipate heat proportional to the lesion level. Thermoregulatory dysfunction places an individual at high risk of hyperthermia, which can be life threatening, especially for athletes with SCI during exercise. Current evidence on therapeutic cooling techniques in athletes with SCI is limited, but basic physiologic and research data suggest water spray (WS) might be efficacious, particularly in athletes with tetraplegia (TP), who are most impaired in thermoregulation. The aim of this study was to evaluate the effect of WS on core temperature (Tc) during exercise in athletes with SCI. Setting Texas, USA. Methods Eleven individuals with SCI: seven with TP, four with paraplegia (PP); and sixteen able-bodied (AB) controls underwent a wheelchair intermittent sprint exercise for 90 min under two conditions: (1) WS application every 15 min and (2) control (C), without WS. Tc was measured every 15 min and was analyzed for the effect of group (TP, PP, and AB) and time. Change in Tc (ΔTc) was also compared between groups. Results ΔTc was significantly higher in TP vs. PP ( p  < 0.0001) and TP vs. AB ( p  < 0.0001) groups under C treatment. WS significantly attenuated ΔTc in TP ( p  = 0.001), but did not change ΔTc in PP or AB. Conclusion WS effectively attenuated Tc elevation during exercise in athletes with TP. Sponsorship Texas chapter of the Paralyzed Veterans of America.",2019,"WS significantly attenuated ΔTc in TP ( p  = 0.001), but did not change ΔTc in PP or AB. Conclusion WS effectively attenuated Tc elevation during exercise in athletes with TP. ","['athletes with spinal cord injury', 'athletes with tetraplegia (TP', 'Sponsorship\n\n\nTexas chapter of the Paralyzed Veterans of America', 'Eleven individuals with SCI: seven with TP, four with paraplegia (PP); and sixteen able-bodied (AB) controls underwent a', 'athletes with SCI']","['water spray', 'wheelchair intermittent sprint exercise for 90\u2009min under two conditions: (1) WS application every 15\u2009min and (2) control (C), without WS']","['Change in Tc (ΔTc', 'Tc elevation', 'core temperature (Tc', 'TP vs. PP']","[{'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0034372', 'cui_str': 'Tetraplegia'}, {'cui': 'C0039711', 'cui_str': 'Texas'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0002454', 'cui_str': 'Americas'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0030486', 'cui_str': 'Paralysis, Legs'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C1299581', 'cui_str': 'Able'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C4521772', 'cui_str': 'Spray'}, {'cui': 'C0043143', 'cui_str': 'Wheel Chairs'}, {'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}]",11.0,0.0318801,"WS significantly attenuated ΔTc in TP ( p  = 0.001), but did not change ΔTc in PP or AB. Conclusion WS effectively attenuated Tc elevation during exercise in athletes with TP. ","[{'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Trbovich', 'Affiliation': '1Department of Rehabilitation Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX USA.'}, {'ForeName': 'Wouter', 'Initials': 'W', 'LastName': 'Koek', 'Affiliation': '2Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX USA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Ortega', 'Affiliation': '3School of Health Professions, Physical Therapy Department, University of Texas Health Science Center at San Antonio, San Antonio, TX USA.'}]",Spinal cord series and cases,['10.1038/s41394-019-0194-8'] 606,31914437,One-Year Results of Treatment of Diabetic Macular Edema with Aflibercept Using the Treat-and-Extend Dosing Regimen: the VIBIM Study.,"INTRODUCTION The purpose of this study was to report the one-year results of treatment of diabetic macular edema (DME) with aflibercept using a treat-and-extend regimen (TER). METHODS This was a prospective, multicenter, single-arm study planned for 2 years. The eyes received 5 consecutive intravitreal injections of 2 mg of aflibercept every 4 weeks, and the interval between injections was then adjusted by 2 weeks based on changes in the central subfield macular thickness (CSMT). If the CSMT was worse, stable, or better, the interval was shortened, extended, or maintained, respectively. The primary outcome measure was the change in best-corrected visual acuity (BCVA) from baseline to 104 weeks, and the secondary outcome was the change in BCVA from baseline to 52 weeks. RESULTS Of the 48 patients enrolled, 46 completed a 1-year visit. BCVA improved significantly by 9.1 letters (95% confidence interval: 5.3-13.0 letters) from 56.2 letters at baseline (p < 0.001), and CSMT decreased by -171.7 μm from 489.4 to 317.7 μm (p < 0.001). The proportion of eyes having 20/40 or better vision increased from 17.4 to 41.3%, and the proportion of eyes that gained ≥15 letters was 28.3%. The mean number of injections was 8.5 times for 52 weeks. Worsening of macular edema did not occur in 76.1% of eyes during the extension period, and the interval between injections was extended to 12 weeks in 73.9% of eyes at 52 weeks. CONCLUSIONS The TER showed 1-year efficacy comparable to that of the fixed dosing regimen of pivotal trials, and its flexible dosing would prevent overtreatment.",2020,"BCVA improved significantly by 9.1 letters (95% confidence interval: 5.3-13.0 letters) from 56.2 letters at baseline (p < 0.001), and CSMT decreased by -171.7 μm from 489.4 to 317.7 μm (p < 0.001).","['diabetic macular edema (DME', '48 patients enrolled']","['aflibercept', 'Aflibercept']","['mean number of injections', 'change in best-corrected visual acuity (BCVA', 'BCVA', '1-year efficacy', 'proportion of eyes having 20/40 or better vision', 'CSMT', 'Worsening of macular edema']","[{'cui': 'C0730285', 'cui_str': 'Diabetic macular edema'}, {'cui': 'C0641456', 'cui_str': 'DMES'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1134659', 'cui_str': 'aflibercept'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C1690532', 'cui_str': 'Best corrected visual acuity'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0271051', 'cui_str': 'Macular Edema'}]",46.0,0.0839918,"BCVA improved significantly by 9.1 letters (95% confidence interval: 5.3-13.0 letters) from 56.2 letters at baseline (p < 0.001), and CSMT decreased by -171.7 μm from 489.4 to 317.7 μm (p < 0.001).","[{'ForeName': 'Kang Yeun', 'Initials': 'KY', 'LastName': 'Pak', 'Affiliation': 'Department of Ophthalmology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.'}, {'ForeName': 'Jae Pil', 'Initials': 'JP', 'LastName': 'Shin', 'Affiliation': 'Department of Ophthalmology, Kyungpook National University School of Medicine, Deagu, Republic of Korea.'}, {'ForeName': 'Hyun Woong', 'Initials': 'HW', 'LastName': 'Kim', 'Affiliation': 'Department of Ophthalmology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Sagong', 'Affiliation': 'Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, Republic of Korea.'}, {'ForeName': 'Yu Cheol', 'Initials': 'YC', 'LastName': 'Kim', 'Affiliation': 'Department of Ophthalmology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea.'}, {'ForeName': 'Sang Joon', 'Initials': 'SJ', 'LastName': 'Lee', 'Affiliation': 'Department of Ophthalmology, Kosin University College of Medicine, Busan, Republic of Korea.'}, {'ForeName': 'In Young', 'Initials': 'IY', 'LastName': 'Chung', 'Affiliation': 'Department of Ophthalmology, Gyeongsang National University School of Medicine, Jinju, Republic of Korea.'}, {'ForeName': 'Sung Who', 'Initials': 'SW', 'LastName': 'Park', 'Affiliation': 'Department of Ophthalmology, Pusan National University, College of Medicine, Yangsan, Republic of Korea.'}, {'ForeName': 'Ji Eun', 'Initials': 'JE', 'LastName': 'Lee', 'Affiliation': 'Department of Ophthalmology, Pusan National University, College of Medicine, Yangsan, Republic of Korea, jlee@pusan.ac.kr.'}]",Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde,['10.1159/000504753'] 607,31815677,Effectiveness of Smartphone App-Based Interactive Management on Glycemic Control in Chinese Patients With Poorly Controlled Diabetes: Randomized Controlled Trial.,"BACKGROUND In recent years, the rapid development of mobile medical technology has provided multiple ways for the long-term management of chronic diseases, especially diabetes. As a new type of management model, smartphone apps are global, convenient, cheap, and interactive. Although apps were proved to be more effective at glycemic control, compared with traditional computer- and Web-based telemedicine technologies, how to gain a further and sustained improvement is still being explored. OBJECTIVE The objective of this study was to investigate the effectiveness of an app-based interactive management model by a professional health care team on glycemic control in Chinese patients with poorly controlled diabetes. METHODS This study was a 6-month long, single-center, prospective randomized controlled trial. A total of 276 type 1 or type 2 diabetes patients were enrolled and randomized to the control group (group A), app self-management group (group B), and app interactive management group (group C) in a 1:1:1 ratio. The primary outcome was the change in glycated hemoglobin (HbA 1c ) level. Missing data were handled by multiple imputation. RESULTS At months 3 and 6, all 3 groups showed significant decreases in HbA 1c levels (all P<.05). Patients in the app interactive management group had a significantly lower HbA 1c level than those in the app self-management group at 6 months (P=.04). The average HbA 1c reduction in the app interactive management group was larger than that in the app self-management and control groups at both months 3 and 6 (all P<.05). However, no differences in HbA 1c reduction were observed between the app self-management and control groups at both months 3 and 6 (both P>.05). Multivariate line regression analyses also showed that the app interactive management group was associated with the larger reduction of HbA 1c compared with groups A and B at both months 3 and 6 (all P>.05). In addition, the app interactive management group had better control of triglyceride and high-density lipoprotein cholesterol levels at both months 3 and 6 compared with baseline (both P<.05). CONCLUSIONS In Chinese patients with poorly controlled diabetes, it was difficult to achieve long-term effective glucose improvement by using app self-management alone, but combining it with interactive management can help achieve rapid and sustained glycemic control. TRIAL REGISTRATION ClinicalTrials.gov NCT02589730; https://clinicaltrials.gov/ct2/show/NCT02589730.",2019,Patients in the app interactive management group had a significantly lower HbA 1c level than those in the app self-management group at 6 months (P=.04).,"['Chinese patients with poorly controlled diabetes', 'Chinese Patients With Poorly Controlled Diabetes', 'A total of 276 type 1 or type 2 diabetes patients']","['app self-management group (group B), and app interactive management group', 'Smartphone App-Based Interactive Management', 'app-based interactive management model by a professional health care team']","['change in glycated hemoglobin (HbA 1c ) level', 'control of triglyceride and high-density lipoprotein cholesterol levels', 'HbA 1c level', 'HbA 1c levels', 'HbA 1c reduction', 'average HbA 1c reduction']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}]","[{'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0441836', 'cui_str': 'Group B (qualifier value)'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C0086390', 'cui_str': 'Medical Care Team'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0017853', 'cui_str': 'Hemoglobin, Glycosylated'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]",276.0,0.0298292,Patients in the app interactive management group had a significantly lower HbA 1c level than those in the app self-management group at 6 months (P=.04).,"[{'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Xingxing', 'Initials': 'X', 'LastName': 'He', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Shen', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Haoyong', 'Initials': 'H', 'LastName': 'Yu', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Jiemin', 'Initials': 'J', 'LastName': 'Pan', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Zhu', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Yuqian', 'Initials': 'Y', 'LastName': 'Bao', 'Affiliation': ""Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}]",Journal of medical Internet research,['10.2196/15401'] 608,31688306,"Distinct patterns of short-chain fatty acids during flare in patients with ulcerative colitis under treatment with mesalamine or a herbal combination of myrrh, chamomile flowers, and coffee charcoal: secondary analysis of a randomized controlled trial.","OBJECTIVES Short-chain fatty acids are involved in the regulation of the gut immune system. In ulcerative colitis, short-chain fatty acids are often reduced, especially during flare. This study evaluated exploratively the pattern of butyrate and total short-chain fatty acids in patients with ulcerative colitis during flare treated either with mesalamine or a herbal preparation consisting of myrrh, chamomile flowers, and coffee charcoal which showed promising results in maintaining remission in a randomized double-blind, double-dummy, controlled clinical trial (EudraCT-Number 2007-007928-18). METHODS Patients were treated with the herbal preparation or mesalamine. Clinical activity was monitored by Clinical Colitis Activity Index. Using gas chromatography, we analyzed fecal samples of 38 patients who experienced a flare during treatment. RESULTS Paired t-test showed a significant decline of total short-chain fatty acids [M before = 66.12, SD = 39.59; M after = 29.83, SD = 15.05; 95% bootstrap confidence interval (20.53-55.30); P = 0.01) and of butyrate [M before 11.35, SD = 7.56; M after = 6.50, SD = 3.55; 95% bootstrap confidence interval (2.06-8.11); P = 0.02] in the event of a flare for patients treated with mesalamine but not for patients treated with the herbal preparation. CONCLUSION Patients who received the herbal preparation did not show a significant decline of total short-chain fatty acids in the event of a flare. Since a decline of short-chain fatty acids might lead to unfavorable health impairments, a combination of the two treatments should be further investigated.",2020,"RESULTS Paired t-test showed a significant decline of total short-chain fatty acids [M before = 66.12, SD = 39.59; M after = 29.83, SD = 15.05; 95% bootstrap confidence interval (20.53-55.30); P = 0.01) and of butyrate [M before 11.35, SD = 7.56; M after = 6.50, SD = 3.55; 95% bootstrap confidence interval (2.06-8.11); P = 0.02] in the event of a flare for patients treated with mesalamine but not for patients treated with the herbal preparation. ","['Patients were treated with the', 'patients with ulcerative colitis during flare treated either with', '38 patients who experienced a flare during treatment', 'patients with ulcerative colitis under treatment with']","['butyrate and total short-chain fatty acids', 'herbal combination of myrrh, chamomile flowers, and coffee charcoal', 'herbal preparation or mesalamine', 'mesalamine or a herbal preparation consisting of myrrh, chamomile flowers, and coffee charcoal', 'mesalamine', 'short-chain fatty acids']","['Clinical activity', 'total short-chain fatty acids', 'Clinical Colitis Activity Index']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0009324', 'cui_str': 'Inflammatory Bowel Disease, Ulcerative Colitis Type'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0006521', 'cui_str': 'Butyrates'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0015691', 'cui_str': 'Fatty Acids, Short-Chain'}, {'cui': 'C0376667', 'cui_str': 'Herbal'}, {'cui': 'C0207011', 'cui_str': 'Myrrh extract'}, {'cui': 'C0725584', 'cui_str': 'CHAMOMILE FLOWERS'}, {'cui': 'C0009237', 'cui_str': 'Coffee'}, {'cui': 'C0007955', 'cui_str': 'Charcoal'}, {'cui': 'C0949854', 'cui_str': 'Herbal Preparations'}, {'cui': 'C0127615', 'cui_str': 'mesalazine'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0015691', 'cui_str': 'Fatty Acids, Short-Chain'}, {'cui': 'C0009319', 'cui_str': 'Colitis'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.502744,"RESULTS Paired t-test showed a significant decline of total short-chain fatty acids [M before = 66.12, SD = 39.59; M after = 29.83, SD = 15.05; 95% bootstrap confidence interval (20.53-55.30); P = 0.01) and of butyrate [M before 11.35, SD = 7.56; M after = 6.50, SD = 3.55; 95% bootstrap confidence interval (2.06-8.11); P = 0.02] in the event of a flare for patients treated with mesalamine but not for patients treated with the herbal preparation. ","[{'ForeName': 'Jost', 'Initials': 'J', 'LastName': 'Langhorst', 'Affiliation': 'Integrative Gastroenterology, University of Duisburg-Essen, Kliniken-Essen-Mitte, Essen.'}, {'ForeName': 'Anna K', 'Initials': 'AK', 'LastName': 'Koch', 'Affiliation': 'Integrative Gastroenterology, University of Duisburg-Essen, Kliniken-Essen-Mitte, Essen.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Voiss', 'Affiliation': 'Department for Internal and Integrative Medicine, Social Foundation Bamberg, Clinic Bamberg, Bamberg.'}, {'ForeName': 'Gustav J', 'Initials': 'GJ', 'LastName': 'Dobos', 'Affiliation': 'Department for Internal and Integrative Medicine, Social Foundation Bamberg, Clinic Bamberg, Bamberg.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Rueffer', 'Affiliation': 'Labor LS SE & Co. KG/Enterosan, Bad Bocklet-Großenbrach, Germany.'}]",European journal of gastroenterology & hepatology,['10.1097/MEG.0000000000001582'] 609,31877362,Beneficial Effects of Listening to Classical Music in Patients With Heart Failure: A Randomized Controlled Trial.,"BACKGROUND Practical recommendations on nonpharmacologic non-device/surgical interventions in patients with heart failure (HF) are well known. Although complementary treatments may have beneficial effects, there is no evidence that these on their own improve mortality, morbidity, or quality of life. We examined the effects of listening to recorded classical music on HF-specific quality of life (QOL), generic QOL, sleep quality, anxiety, depression, and cognitive state in patients with HF in the home-care setting. METHODS AND RESULTS Multicenter randomized controlled trial. One hundred fifty-nine patients with HF were randomized on a 1:1 basis in 2 groups: experimental (music) and control. Patients were evaluated after 30, 60, 90 days (experimental period) and at 6 months. Patients randomized to the music group listened to music from a large preselected playlist, at least 30 minutes per day, for 3 months on an MP3 player. Patients in the control group received standard care. HF-specific QOL, generic QOL, self-care, somatic perception of HF symptoms, sleep quality, anxiety and depression, and cognitive abilities were assessed throughout the use of specific scales. On average, patients in the music group showed greater improvements in terms of HF-specific QOL (P < .001), generic-QOL (P = .005), quality of sleep (P = .007), anxiety and depression levels (P < .001 for both), and cognitive performances (P = .003). CONCLUSIONS Listening to recorded classical music is a feasible, noninvasive, safe, and inexpensive intervention, able to improve QOL in patients with HF in the home-care setting.",2020,"On average, patients in the music group showed greater improvements in terms of HF-specific QOL (P<0.001), generic-QOL (P=0.005), quality of sleep (P=0.007), anxiety and depression levels (P<0.001 for both), and cognitive performances (P=0.003). ","['patients with heart failure', 'patients with heart failure (HF', 'patients with HF in the home-care setting', 'One hundred fifty-nine patients with HF']","['listening to recorded classical music', 'music group listened to music from a large preselected playlist', 'standard care', 'listening to classical music', 'Listening to recorded classical music']","['cognitive performances', 'HF-specific QOL, generic QOL, self-care, somatic perception of HF symptoms, sleep quality, anxiety and depression, and cognitive abilities', 'quality of sleep', 'generic-QOL', 'HF-specific quality of life (QOL), generic QOL, sleep quality, anxiety, depression, and cognitive state', 'mortality, morbidity or quality of life', 'HF-specific QOL', 'anxiety and depression levels']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0204977', 'cui_str': 'Home Care'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3830128', 'cui_str': '59 (qualifier value)'}]","[{'cui': 'C0004339', 'cui_str': 'Auscultation'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0681251', 'cui_str': 'Classical Music'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0036592', 'cui_str': 'Self Care'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep (observable entity)'}, {'cui': 'C0034380'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C1319226', 'cui_str': 'Level of depression'}]",159.0,0.0734823,"On average, patients in the music group showed greater improvements in terms of HF-specific QOL (P<0.001), generic-QOL (P=0.005), quality of sleep (P=0.007), anxiety and depression levels (P<0.001 for both), and cognitive performances (P=0.003). ","[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Burrai', 'Affiliation': 'Educational and Research, ATS Sardegna-ASSL Sassari, 07100 Sassari, Italy.'}, {'ForeName': 'Giuseppe D', 'Initials': 'GD', 'LastName': 'Sanna', 'Affiliation': 'Clinical and Interventional Cardiology, Sassari University Hospital, 07100 Sassari, Italy. Electronic address: giuseppe.sanna@aousassari.it.'}, {'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Moccia', 'Affiliation': 'Clinical and Interventional Cardiology, Sassari University Hospital, 07100 Sassari, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Morlando', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milano, 20138 Milano, Italy.'}, {'ForeName': 'Eugenio R', 'Initials': 'ER', 'LastName': 'Cosentino', 'Affiliation': 'Department of Internal Medicine, University of Bologna, 40138 Bologna, Italy.'}, {'ForeName': 'Virna', 'Initials': 'V', 'LastName': 'Bui', 'Affiliation': 'Department of Internal Medicine, University of Bologna, 40138 Bologna, Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Micheluzzi', 'Affiliation': 'Clinical and Interventional Cardiology, Sassari University Hospital, 07100 Sassari, Italy.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Borghi', 'Affiliation': 'Department of Internal Medicine, University of Bologna, 40138 Bologna, Italy.'}, {'ForeName': 'Guido', 'Initials': 'G', 'LastName': 'Parodi', 'Affiliation': 'Clinical and Interventional Cardiology, Sassari University Hospital, 07100 Sassari, Italy.'}]",Journal of cardiac failure,['10.1016/j.cardfail.2019.12.005'] 610,31348731,Immunogenicity and safety of a meningococcal serogroups A and C tetanus toxoid conjugate vaccine (MenAC-TT): two immune schedules in toddles aged 12-23 months in China.,"Background : This exploratory study aimed to assess the immunogenicity and safety of 1 and 2 doses of meningococcal serogroups A and C tetanus toxoid-conjugate vaccine (MenAC-TT) in toddles. Methods : Healthy participants aged 12-23 months were randomized into two groups to receive 1 or 2 doses of the tested vaccine. The interval was 28 days between two doses. Blood samples were collected at day 0 before the immunization and day 28 post-each dose. Safety observation was conducted during 28 days after each vaccination. Serious adverse event (SAE) was conducted throughout 6 month observation period. Results : Overall 301 toddles were vaccinated. Twenty-eight days post full-course vaccination, ≥97.20% toddles had titers ≥1:8 and ≥81.48% had titers ≥1:128 for MenA and MenC in the two schedules groups. There were no significant differences between the two schedule groups for each titer thresholds and serogroups. Up to month 12 post the first dose, titers ≥1:8 and 1:128 were declined to 71.32-80.83% and 26.67-57.85% for each meningococcal serogroups. Most adverse reactions (ARs) were mild or moderate, and the incidence of grade 3 ARs was below 3.33%. The incidence of redness was significantly higher in the two doses group than that in the one dose group, in terms of grade 1 and grade 2 were higher. No SAEs were considered causally related to vaccination. Conclusion : The MenAC-TT showed similarly safety and immunogenicity profile in toddles with two schedules. It will be more important to provide the data for formulating appropriate immunization strategies in different age groups in China.",2019,"The incidence of redness was significantly higher in the two doses group than that in the one dose group, in terms of grade 1 and grade 2 were higher.","['Healthy participants aged 12-23\xa0months', 'toddles aged 12-23 months in China', 'different age groups in China']","[' ', 'meningococcal serogroups A and C tetanus toxoid-conjugate vaccine (MenAC-TT', 'meningococcal serogroups A and C tetanus toxoid conjugate vaccine (MenAC-TT']","['Blood samples', 'Immunogenicity and safety', 'Serious adverse event (SAE', 'safety and immunogenicity profile', 'immunogenicity and safety', 'incidence of redness']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}]","[{'cui': 'C0449543', 'cui_str': 'Serogroup'}, {'cui': 'C0305062', 'cui_str': 'Clostridium tetani toxoid antigen, inactivated'}, {'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}]","[{'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0332575', 'cui_str': 'Red color (finding)'}]",28.0,0.132365,"The incidence of redness was significantly higher in the two doses group than that in the one dose group, in terms of grade 1 and grade 2 were higher.","[{'ForeName': 'Jialei', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': 'Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, China.'}, {'ForeName': 'Hongguang', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Public Health, Southeast University, Nanjing, China.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Chu', 'Affiliation': 'Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Liang', 'Affiliation': 'Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, China.'}, {'ForeName': 'Jingxin', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Luo', 'Affiliation': 'OLYMVAX biopharmaceutical Co., LTD., Chengdu, China.'}, {'ForeName': 'Yuemei', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, China.'}, {'ForeName': 'Fanyue', 'Initials': 'F', 'LastName': 'Meng', 'Affiliation': 'Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, China.'}, {'ForeName': 'Fengcai', 'Initials': 'F', 'LastName': 'Zhu', 'Affiliation': 'Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, China.'}]",Human vaccines & immunotherapeutics,['10.1080/21645515.2019.1627816'] 611,30600961,Therapeutic effects of anterolateral thigh flap transfer in repairing oral and maxillofacial defects after ablative surgery of neoplasms.,"BACKGROUND To investigate the therapeutic effects of anterolateral thigh flap transfer in repairing oral and maxillofacial defects after ablative surgery of neoplasms and to discuss perioperative psychological care. METHODS A total of 80 patients who received oral and maxillofacial surgery for tumor resection in Nanfang Hospital from October 2014 to August 2016 were selected. Patients were randomly divided into control group and observation group, 40 patients in each group. Patients in control group received forearm flap transfer, while patients in observation group were treated with anterolateral thigh flap transfer. RESULTS The survival rate of flap, food intake ability, quality of life and incidence of complication were compared between groups. There was no significant difference in survival rate of the flaps between two groups (P>0.05). No significant difference in food intake was found between groups at 3 months after operation (P>0.05). The UW-QOL scores of the two groups at 1 year after operation were significantly higher than those before operation (P<0.05), and no significant differences in UW-QOL scores were found between two groups at 1 year after operation (P>0.05). Incidence of temporary dysfunction, hyperplastic scar, permanent dysfunction, pigmentation and pruritus was significantly lower in observation group than in control group (P<0.05). There was no significant difference in the incidence of necrosis between two groups (P>0.05). CONCLUSIONS The results showed that anterolateral thigh flap transfer has similar therapeutic effects to those of forearm flap transfer in repairing oral and maxillofacial defects after ablative surgery of neoplasms and improving food intake and quality of life. But Anterolateral thigh flap transfer can reduce the incidence of postoperative complications, so this treatment should be popularized.",2019,"Incidence of temporary dysfunction, hyperplastic scar, permanent dysfunction, pigmentation and pruritus was significantly lower in observation group than in control group (p<0.05).","['80 patients who received oral and maxillofacial surgery for tumor resection in Nanfang Hospital from October 2014 to August 2016 were selected', 'ablative surgery of neoplasms']",['anterolateral thigh flap transfer'],"['survival rate', 'incidence of necrosis', 'forearm flap transfer', 'Incidence of temporary dysfunction, hyperplastic scar, permanent dysfunction, pigmentation and pruritus', 'food intake', 'survival rate of flap, food intake ability, quality of life and incidence of complication', 'food intake and quality of life', 'UW-QOL scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0812928', 'cui_str': 'Oral and maxillofacial surgery'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0332194', 'cui_str': 'Anterolateral (qualifier value)'}, {'cui': 'C0440992', 'cui_str': 'Thigh flap (substance)'}, {'cui': 'C0040671', 'cui_str': 'Transfer'}]","[{'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0027540', 'cui_str': 'Necrosis'}, {'cui': 'C0440931', 'cui_str': 'Forearm flap (substance)'}, {'cui': 'C0040671', 'cui_str': 'Transfer'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C0334162', 'cui_str': 'Hyperplastic scar (morphologic abnormality)'}, {'cui': 'C0205355', 'cui_str': 'Permanent (qualifier value)'}, {'cui': 'C0031911', 'cui_str': 'Pigmentation'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0038925', 'cui_str': 'Surgical Flaps'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0034380'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",80.0,0.0239741,"Incidence of temporary dysfunction, hyperplastic scar, permanent dysfunction, pigmentation and pruritus was significantly lower in observation group than in control group (p<0.05).","[{'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Zhao', 'Affiliation': 'Department of Stomatology, Nanfang Hospital (The First School of Clinical Medicine), Southern Medical University, Guangzhou, China - zhaof2283041@163.com.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': 'Department of Obstetrics and Gynecology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zhao', 'Affiliation': 'Department of Blood Transfusion, Nanfang Hospital (The First School of Clinical Medicine), Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Hongxia', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Stomatology, Nanfang Hospital (The First School of Clinical Medicine), Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Zhifeng', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Department of Stomatology, Nanfang Hospital (The First School of Clinical Medicine), Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Yuling', 'Initials': 'Y', 'LastName': 'Luo', 'Affiliation': 'Department of Oncology, Nanfang Hospital (The First School of Clinical Medicine), Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Chen', 'Affiliation': 'Department of Nephrology, Nanfang Hospital (The First School of Clinical Medicine), Southern Medical University, Guangzhou, China.'}]",Minerva chirurgica,['10.23736/S0026-4733.18.07820-3'] 612,31122997,"'Reducing Delays In Vaccination' (REDIVAC) trial: a protocol for a randomised controlled trial of a web-based, individually tailored, educational intervention to improve timeliness of infant vaccination.","INTRODUCTION Increasing numbers of children are failing to receive many recommended vaccines, which has led to significant outbreaks of vaccine-preventable diseases in the USA and worldwide. A major driver of undervaccination is parental vaccine hesitance. Prior research demonstrates that mothers are the primary decision maker for infant vaccination, and that their vaccination attitudes form primarily during pregnancy and early in their infant's life. METHODS AND ANALYSIS This manuscript describes the protocol for an ongoing three-armed randomised controlled trial done at Kaiser Permanente Colorado (KPCO). The trial aims to test the efficacy of provided tailored, individualised information via the Internet to pregnant and new mothers versus untailored information versus usual care on the timeliness of infant vaccination. The primary outcome to be assessed is vaccination status, which is a dichotomous outcome (up to date vs not) assessed at age 200 days, reflecting the time when infants should have completed the first set of vaccine provided (at age 2, 4 and 6 months). Infants with one or more age-appropriate recommended vaccines at least 30 days delayed are categorised as not up to date whereas all other infants are considered up to date. Secondary outcomes include vaccination status at age 489 days, reflecting receipt of recommended vaccines at age 12-15 months, as well as vaccination attitudes, hesitancy and intention. Vaccination data will be derived from the electronic medical record and the state immunisation registry. Other secondary outcomes will be assessed by online surveys. ETHICS AND DISSEMINATION The study activities were approved by the Institutional Review Boards of the University of Colorado, KPCO and the University of Michigan. Results will be disseminated through peer-reviewed manuscripts and conference presentations. TRIAL REGISTRATION NUMBER NCT02665013; Pre-results.",2019,"The trial aims to test the efficacy of provided tailored, individualised information via the Internet to pregnant and new mothers versus untailored information versus usual care on the timeliness of infant vaccination.",['Kaiser Permanente Colorado (KPCO'],['educational intervention'],"['Reducing Delays', 'timeliness of infant vaccination', 'vaccination status at age 489 days, reflecting receipt of recommended vaccines at age 12-15 months, as well as vaccination attitudes, hesitancy and intention']","[{'cui': 'C0009399', 'cui_str': 'Colorado'}]",[],"[{'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C1443394', 'cui_str': 'Vaccination status'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0558058', 'cui_str': 'Reflecting (finding)'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0152032', 'cui_str': 'Delay when starting to pass urine (finding)'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]",,0.200583,"The trial aims to test the efficacy of provided tailored, individualised information via the Internet to pregnant and new mothers versus untailored information versus usual care on the timeliness of infant vaccination.","[{'ForeName': 'Amanda F', 'Initials': 'AF', 'LastName': 'Dempsey', 'Affiliation': 'Department of Pediatrics, University of Colorado Denver, Denver, Colorado, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Wagner', 'Affiliation': 'Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado, USA.'}, {'ForeName': 'Komal', 'Initials': 'K', 'LastName': 'Narwaney', 'Affiliation': 'Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Pyrzanowski', 'Affiliation': 'Department of Pediatrics, University of Colorado Denver, Denver, Colorado, USA.'}, {'ForeName': 'Bethany M', 'Initials': 'BM', 'LastName': 'Kwan', 'Affiliation': 'Department of Family Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.'}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Kraus', 'Affiliation': 'Institute for Health Research, Kaiser Permanente, Denver, Colorado, USA.'}, {'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Gleason', 'Affiliation': 'Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado, USA.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Resnicow', 'Affiliation': 'Health Education and Health Behavior, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Carter', 'Initials': 'C', 'LastName': 'Sevick', 'Affiliation': 'Department of Pediatrics, University of Colorado Denver, Denver, Colorado, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Cataldi', 'Affiliation': 'Department of Pediatrics, University of Colorado Denver, Denver, Colorado, USA.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Brewer', 'Affiliation': 'Department of Pediatrics, University of Colorado Denver, Denver, Colorado, USA.'}, {'ForeName': 'Jason M', 'Initials': 'JM', 'LastName': 'Glanz', 'Affiliation': 'Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado, USA.'}]",BMJ open,['10.1136/bmjopen-2018-027968'] 613,31473464,Engaging Youth (Adolescents and Young Adults) to Change Frequent Marijuana Use: Motivational Enhancement Therapy (MET) in Primary Care.,"PURPOSE To characterize information elicited from adolescent/young adults with frequent cannabis use in Motivational Enhancement Therapy (MET), and determine whether differences exist across stages of change (SOC) for reducing use. DESIGN AND METHODS Primary care patients 15-24 years old using cannabis ≥3 times/week enrolled in a pilot randomized intervention trial. All youth were offered two 1-hour MET sessions. Content analysis was used to code and categorize main reasons for use, alternative behaviors, goals, values, pros and cons of change, and compared results between youth in Pre-Contemplation vs. Contemplation SOC. RESULTS Fifty-six youth completed MET session 1, 46 completed session 2. Most reported their main reason for use was related to emotional coping, negative feelings were a top-3 trigger, and distraction was an alternative way to meet their needs. Youth most frequently described progress in education or career/job as 1-year goals. More than half identified family as a very important value. They most frequently reported pros of using less related to achieving goals, self-improving, and saving money, and a con related to stress/coping. Compared to youth in Pre-Contemplation SOC, those in Contemplation were more likely to identify relationships as both a pro and con of using less cannabis. CONCLUSIONS MET can reveal developmentally appropriate goals, healthy values, and ambivalence about cannabis use that can be used to facilitate movement along the stages of behavior change toward reduction/cessation. PRACTICE IMPLICATIONS Brief motivational therapy can be used in primary care to gather information important in helping youth to reduce cannabis use.",2019,"Compared to youth in Pre-Contemplation SOC, those in Contemplation were more likely to identify relationships as both a pro and con of using less cannabis. ","['Engaging youth (adolescents and young adults', 'adolescent/young adults with frequent cannabis use in', 'Primary care patients 15-24\u202fyears old using cannabis ≥3 times/week enrolled']",['Motivational Enhancement Therapy (MET'],[],"[{'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}, {'cui': 'C3160814', 'cui_str': 'Cannabis use'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0678449', 'cui_str': 'Cannabis'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",[],56.0,0.0207139,"Compared to youth in Pre-Contemplation SOC, those in Contemplation were more likely to identify relationships as both a pro and con of using less cannabis. ","[{'ForeName': 'Meredith', 'Initials': 'M', 'LastName': 'Kells', 'Affiliation': ""Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, United States of America. Electronic address: Meredith.kells@childrens.harvard.edu.""}, {'ForeName': 'Pamela J', 'Initials': 'PJ', 'LastName': 'Burke', 'Affiliation': ""Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, United States of America; Northeastern University Bouve College of Health Sciences, School of Nursing, United States of America.""}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Parker', 'Affiliation': ""Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, United States of America; Northeastern University Bouve College of Health Sciences, School of Nursing, United States of America.""}, {'ForeName': 'Cassandra', 'Initials': 'C', 'LastName': 'Jonestrask', 'Affiliation': ""Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, United States of America.""}, {'ForeName': 'Lydia A', 'Initials': 'LA', 'LastName': 'Shrier', 'Affiliation': ""Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, United States of America; Department of Pediatrics, Harvard Medical School, United States of America.""}]",Journal of pediatric nursing,['10.1016/j.pedn.2019.08.011'] 614,30887671,First bathing time of newborn infants after birth: A comparative analysis.,"PURPOSE The study was designed as an experimental study to describe the effect of the first bathing time on the body temperature and skin moisture of a newborn after birth. DESIGN AND METHODS The study population consisted of term newborns between January and June 2016 in the Istanbul University, Cerrahpaşa Medical Faculty Hospital at Istanbul. The sample group was randomly divided into two groups according to different bathing times. The first group (39 infants) was given a bath 24 hr after birth, and the second group (34 infants) was given a bath 48 hr after birth. The infants in both the groups were dried with the first towel and then wrapped in a second dry towel, and a cap put to prevent hypothermia and to minimize any minor fluid loss. The body temperature and skin moisture level were measured before the bath, after the bath, and 10 min after the bath. RESULTS It was determined that the 10th-minute body temperatures of the infants with the first bathing time 48 hr after birth were significantly higher compared with the infants with the first bath time 24 hr after birth (Z = -2.654; p = .008). PRACTICAL IMPLICATIONS Postponing of the first bathing time of newborns to 48 hr after birth was effective in preserving the body temperature of the infant. Postponing the bath to the 48th hr improved moisture, which may improve skin integrity and aid with skin development.",2019,Postponing of the first bathing time of newborns to 48 hr after birth was effective in preserving the body temperature of the infant.,"['term newborns between January and June 2016 in the Istanbul University, Cerrahpaşa Medical Faculty Hospital at Istanbul', 'newborn infants after birth']",[],"['body temperature and skin moisture', 'body temperature and skin moisture level', 'skin integrity and aid with skin development']","[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0015537', 'cui_str': 'Faculty, Medical'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0005615', 'cui_str': 'Birth'}]",[],"[{'cui': 'C0886414', 'cui_str': 'Body temperature'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1947912', 'cui_str': 'Integrity (attribute)'}, {'cui': 'C0449435', 'cui_str': 'Aid (attribute)'}, {'cui': 'C0243107', 'cui_str': 'development'}]",,0.0150953,Postponing of the first bathing time of newborns to 48 hr after birth was effective in preserving the body temperature of the infant.,"[{'ForeName': 'Duygu', 'Initials': 'D', 'LastName': 'Gözen', 'Affiliation': 'Department of Pediatric Nursing, Istanbul University-Cerrahpaşa, Florence Nightingale Faculty of Nursing, Istanbul, Turkey.'}, {'ForeName': 'Sinem Y', 'Initials': 'SY', 'LastName': 'Çaka', 'Affiliation': 'Department of Pediatric Nursing, Sakarya University, Faculty of Health Science, Sakarya, Turkey.'}, {'ForeName': 'Selda A', 'Initials': 'SA', 'LastName': 'Beşirik', 'Affiliation': 'Department of Pediatric Nursing, Karamanoğlu Mehmet Bey University, Faculty of Health Science, Konya, Turkey.'}, {'ForeName': 'Yıldız', 'Initials': 'Y', 'LastName': 'Perk', 'Affiliation': 'Neonatology Unit, Department of Pediatric, Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospital, Istanbul, Turkey.'}]",Journal for specialists in pediatric nursing : JSPN,['10.1111/jspn.12239'] 615,31158271,"IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.","BACKGROUND AND AIMS Following induction/maintenance treatment in the UNITI/IM-UNITI studies of ustekinumab for Crohn's disease, patients entered a long-term extension for up to 5 years from induction. Efficacy through 152 and safety through 156 weeks are reported. METHODS At IM-UNITI Week 44, 567 ustekinumab-treated patients entered the long-term extension and continued to receive blinded subcutaneous ustekinumab on their assigned dose interval, without any subsequent dose adjustment. Placebo-treated patients discontinued after study unblinding [after IM-UNITI Week 44 analyses]. Efficacy data in the long-term extension [LTE] were collected every 12 weeks [q12w] before unblinding and then at q12w/q8w dosing visits. RESULTS Through Week 156, 29.6% of ustekinumab-treated patients discontinued. In an intent-to-treat analysis of randomised patients from IM-UNITI Weeks 0-152, 38.0% of ustekinumab induction responders receiving the drug q12w and 43.0% q8w were in remission at Week 152. Among patients entering the long-term extension in their original randomised groups, 61.9% of q12w and 69.5% of q8w patients were in remission at Week 152. Across all ustekinumab-treated patients [randomised and non-randomised] entering the long-term extension, remission rates at Week 152 were 56.3% and 55.1% for q12w and q8w, respectively. Safety events [per 100 patient-years] were similar among all ustekinumab-treated patients entering the long-term extension and placebo [overall adverse events 389.70 vs 444.17; serious adverse events, 18.97 vs 19.54; serious infections, 4.21 vs 3.97]. Rates of antibodies to ustekinumab through Week 156 remained low, 4.6% in all randomised ustekinumab-treated patients; lowest among patients in the original randomised q8w group [2/82, 2.4%]. CONCLUSIONS Continued treatment with subcutaneous ustekinumab maintained clinical response and remission through 3 years in a majority of patients who responded to induction therapy and was well-tolerated. ClinicalTrials.gov number NCT01369355.",2020,"CONCLUSION Continued treatment with subcutaneous ustekinumab maintained clinical response and remission through 3 years in a majority of patients who responded to induction therapy and was well-tolerated.","[""Crohn's Disease""]","['Placebo', 'IM-UNITI']","['3 Year Efficacy, Safety, and Immunogenicity', 'remission rates']","[{'cui': 'C0156147', 'cui_str': 'Colitis, Granulomatous'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}]",,0.381981,"CONCLUSION Continued treatment with subcutaneous ustekinumab maintained clinical response and remission through 3 years in a majority of patients who responded to induction therapy and was well-tolerated.","[{'ForeName': 'Stephen B', 'Initials': 'SB', 'LastName': 'Hanauer', 'Affiliation': 'Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Sandborn', 'Affiliation': 'University of California San Diego, La Jolla, CA USA.'}, {'ForeName': 'Brian G', 'Initials': 'BG', 'LastName': 'Feagan', 'Affiliation': 'Robarts Clinical Trials, Western University, London, ON, Canada.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Gasink', 'Affiliation': 'Janssen Scientific Affairs, LLC, Horsham, PA, USA.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Jacobstein', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Zou', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Jewel', 'Initials': 'J', 'LastName': 'Johanns', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Omoniyi J', 'Initials': 'OJ', 'LastName': 'Adedokun', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Bruce E', 'Initials': 'BE', 'LastName': 'Sands', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Rutgeerts', 'Affiliation': 'University Hospital, Gasthuisberg, Leuven, Belgium.'}, {'ForeName': 'Willem J S', 'Initials': 'WJS', 'LastName': 'de Villiers', 'Affiliation': 'Stellenbosch University, Stellenbosch, South Africa.'}, {'ForeName': 'Jean-Frédéric', 'Initials': 'JF', 'LastName': 'Colombel', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Subrata', 'Initials': 'S', 'LastName': 'Ghosh', 'Affiliation': 'NIHR Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK.'}]",Journal of Crohn's & colitis,['10.1093/ecco-jcc/jjz110'] 616,31869312,Effects of a Cardiac Rehabilitation Program Versus Usual Care on Cardiopulmonary Function in Patients With Cardiac Syndrome X.,"PURPOSE Because of uncertainty in the pathophysiological process, the treatment of cardiac syndrome X (CSX) is still under study. Addressing the effects of cardiac rehabilitation (CR) can help promote the prescription of this modality as an adjuvant therapy for these patients. METHODS This study was performed on 30 patients with effort-induced angina pectoris using a positive exercise test and/or myocardial perfusion scan in the absence of obvious stenosis or a stenosis of <50% on coronary angiography. The patients were divided into the CR and usual care (UC) groups and underwent cardiopulmonary exercise testing with gas exchange analysis before and after the study. The Duke Treadmill Score was used to compare prognosis and survival estimates of patients. RESULTS An increase in peak oxygen uptake ((Equation is included in full-text article.)O2) was significantly higher in the CR group than in the control group (P = .017). Resting (Equation is included in full-text article.)O2 was also increased in the CR group, but its difference with the UC group was not statistically significant. Resting O2 pulse was increased in the CR group, which significantly differed between groups (P = .041). Exercise test duration and the Duke Treadmill Score significantly increased in the CR group as compared with the UC group (P = .003 and P = .002, respectively). Also, recovery heart rate in the first minute was significantly improved in CR group. CONCLUSION Adding a 4-wk course of CR to UC for patients with CSX not only increased the Duke Treadmill Score and exercise test duration but also improved the resting O2 pulse, peak (Equation is included in full-text article.)O2, and first-minute recovery heart rate.",2020,"Resting O2 pulse was increased in the CR group, which significantly differed between groups (P = .041).","['Patients With Cardiac Syndrome X', '30 patients with effort-induced angina pectoris using a positive exercise test and/or myocardial perfusion scan in the absence of obvious stenosis or a stenosis of <50% on coronary angiography']","['cardiac rehabilitation (CR', 'Cardiac Rehabilitation Program Versus Usual Care', 'CR and usual care (UC) groups and underwent cardiopulmonary exercise testing with gas exchange analysis']","['resting O2 pulse, peak (Equation', 'peak oxygen uptake', 'Duke Treadmill Score and exercise test duration', 'Exercise test duration and the Duke Treadmill Score', 'Cardiopulmonary Function', 'Duke Treadmill Score', 'recovery heart rate', 'Resting O2 pulse']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0206064', 'cui_str': 'Microvascular Angina'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0002962', 'cui_str': 'Stenocardia'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0015260', 'cui_str': 'Exercise Test'}, {'cui': 'C0430471', 'cui_str': 'Myocardial perfusion scan'}, {'cui': 'C0332197', 'cui_str': 'Absent (qualifier value)'}, {'cui': 'C1261287', 'cui_str': 'Stenosis'}, {'cui': 'C0085532', 'cui_str': 'Angiography of coronary arteries'}]","[{'cui': 'C0700431', 'cui_str': 'Cardiovascular Rehabilitation'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary Exercise Test'}, {'cui': 'C0596601', 'cui_str': 'Gas'}, {'cui': 'C1524024', 'cui_str': 'analysis'}]","[{'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake (observable entity)'}, {'cui': 'C0582804', 'cui_str': ""Duke's coronary artery disease score (assessment scale)""}, {'cui': 'C0015260', 'cui_str': 'Exercise Test'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}]",,0.0276866,"Resting O2 pulse was increased in the CR group, which significantly differed between groups (P = .041).","[{'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Rahmani', 'Affiliation': 'Cardiovascular Section, Sports Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran (Drs Rahmani, Sobh-Rakhshankhah, Mazaheri, Hashemi, Niyazi, and Khoddami-Vishteh); and Heart Failure Unit, Cardiology University Department, University of Milan, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy (Dr Guazzi).'}, {'ForeName': 'Sepideh', 'Initials': 'S', 'LastName': 'Niyazi', 'Affiliation': ''}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Sobh-Rakhshankhah', 'Affiliation': ''}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Guazzi', 'Affiliation': ''}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Mazaheri', 'Affiliation': ''}, {'ForeName': 'Naeimeh', 'Initials': 'N', 'LastName': 'Hashemi', 'Affiliation': ''}, {'ForeName': 'Hamid-Reza', 'Initials': 'HR', 'LastName': 'Khoddami-Vishteh', 'Affiliation': ''}]",Journal of cardiopulmonary rehabilitation and prevention,['10.1097/HCR.0000000000000439'] 617,31714393,Effect of Home-Based Cardiac Rehabilitation in a Lower-Middle Income Country: RESULTS FROM A CONTROLLED TRIAL.,"PURPOSE Cardiovascular disease is the leading cause of mortality and morbidity in lower-middle income countries (LMICs), including Bangladesh. Cardiac rehabilitation (CR) as part of secondary prevention of cardiovascular disease has been shown to reduce mortality and morbidity and improve quality of life and exercise capacity. However, to date, very few controlled trials of CR have been conducted in LMICs. METHODS A quasi-randomized controlled trial comparing home-based CR plus usual care with usual care alone was undertaken with patients following coronary artery bypass graft surgery. Participants in the CR group received an in-hospital CR class and were introduced to a locally developed educational booklet with details of a home-based exercise program and then received monthly telephone calls for 12 mo. Primary outcomes were coronary heart disease (CHD) risk factors, health-related quality of life (HRQOL), and mental well-being. Maximal oxygen uptake as a measure of exercise capacity was a secondary outcome. RESULTS In total, 142 of 148 eligible participants took part in the trial (96%); 71 in each group. At 12-mo follow-up, 61 patients (86%) in the CR group and 40 (56%) in the usual care group provided complete outcome data. Greater reductions in CHD risk factors and improvements in HRQOL, mental well-being, and exercise capacity were seen for the CR group compared with the usual care group. CONCLUSIONS In the context of a single-center LMIC setting, this study demonstrated the feasibility of home-based CR programs and offers a model of service delivery that could be replicated on a larger scale.",2020,"Greater reductions in CHD risk factors and improvements in HRQOL, mental well-being, and exercise capacity were seen for the CR group compared with the usual care group. ","['lower-middle income countries (LMICs), including Bangladesh', 'a Lower-Middle Income Country', 'In total, 142 of 148 eligible participants took part in the trial (96%); 71 in each group']","['hospital CR class and were introduced to a locally developed educational booklet with details of a home-based exercise program and then received monthly telephone calls', 'coronary artery bypass graft surgery', 'Home-Based Cardiac Rehabilitation', 'home-based CR plus usual care with usual care alone', 'Cardiac rehabilitation (CR']","['CHD risk factors and improvements in HRQOL, mental well-being, and exercise capacity', 'Maximal oxygen uptake', 'mortality and morbidity and improve quality of life and exercise capacity', 'coronary heart disease (CHD) risk factors, health-related quality of life (HRQOL), and mental well-being']","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0444598', 'cui_str': 'Mid (qualifier value)'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C1292748', 'cui_str': 'Introduces'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0010055', 'cui_str': 'Coronary Artery Bypass Grafting'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0700431', 'cui_str': 'Cardiovascular Rehabilitation'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0424578', 'cui_str': 'Sense of well-being'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake (observable entity)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C1277690', 'cui_str': 'Coronary heart disease risk'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}]",148.0,0.113643,"Greater reductions in CHD risk factors and improvements in HRQOL, mental well-being, and exercise capacity were seen for the CR group compared with the usual care group. ","[{'ForeName': 'Jamal', 'Initials': 'J', 'LastName': 'Uddin', 'Affiliation': 'Physiotherapy Unit, Department of Cardiac Surgery (Mr Jamal Uddin), Department of Cardiac Surgery (Drs Siraj and Jalal Uddin), and Department of Cardiology (Drs Rashid and Karim) Ibrahim Cardiac Hospital & Research Institute, Shagbag, Dhaka, Bangladesh; Danish Knowledge Centre for Rehabilitation and Palliative Care (REHPA), Odense University Hospital and University of Southern Denmark, Copenhagen, Denmark (Messrs Jamal Uddin and Joshi, Ms Rossau, and Drs Taylor and Zwisler); Department of Noncommunicable Disease, Bangladesh University of Health Sciences (BUHS), Dhaka, Bangladesh (Mr Moniruzzaman and Dr Jalal Uddin); Institute of Health Research, University of Exeter Medical School, Exeter, United Kingdom (Dr Taylor); and Institute of Health and Well Being, University of Glasgow, Glasgow, United Kingdom (Dr Taylor).'}, {'ForeName': 'Vicky L', 'Initials': 'VL', 'LastName': 'Joshi', 'Affiliation': ''}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Moniruzzaman', 'Affiliation': ''}, {'ForeName': 'Rezaul', 'Initials': 'R', 'LastName': 'Karim', 'Affiliation': ''}, {'ForeName': 'Jalal', 'Initials': 'J', 'LastName': 'Uddin', 'Affiliation': ''}, {'ForeName': 'Masoom', 'Initials': 'M', 'LastName': 'Siraj', 'Affiliation': ''}, {'ForeName': 'Mohammad Abdur', 'Initials': 'MA', 'LastName': 'Rashid', 'Affiliation': ''}, {'ForeName': 'Henriette Knold', 'Initials': 'HK', 'LastName': 'Rossau', 'Affiliation': ''}, {'ForeName': 'Rod S', 'Initials': 'RS', 'LastName': 'Taylor', 'Affiliation': ''}, {'ForeName': 'Ann-Dorthe', 'Initials': 'AD', 'LastName': 'Zwisler', 'Affiliation': ''}]",Journal of cardiopulmonary rehabilitation and prevention,['10.1097/HCR.0000000000000471'] 618,31630923,Effects of Church-Based Parent-Child Abstinence-Only Interventions on Adolescents' Sexual Behaviors.,"PURPOSE The aim of the study was to evaluate the efficacy of faith-based and nonfaith-based parent-child abstinence-only interventions in reducing sexual risk behavior among young African American adolescents. METHODS Randomized controlled trial recruiting 613 African American parent-adolescent dyads from urban African American Baptist churches and randomizing them to one of three parent-child interventions: faith-based abstinence-only intervention emphasizing delaying or reducing sexual intercourse drawing on Biblical scriptures; nonfaith-based abstinence-only emphasizing intervention delaying or reducing sexual intercourse without referencing scriptures; or attention-matched control intervention targeting health issues unrelated to sexual behavior. Primary outcome was the self-reported frequency of condomless sexual intercourse in the past 3 months assessed periodically through 18 months postintervention. Secondary outcomes were frequency of sexual intercourse, number of sexual partners, consistent condom use and, among sexually inexperienced adolescents, sexual debut. RESULTS Generalized estimating equations analyses revealed that nonfaith-based abstinence-only intervention reduced the frequency of condomless sexual intercourse, frequency of sexual intercourse, and number of sexual partners compared with the attention-matched control intervention, whereas faith-based abstinence-only intervention did not. Neither intervention affected consistent condom use or sexual debut. CONCLUSIONS Parent-child abstinence-only interventions can reduce condomless sexual intercourse among young African American adolescents in church settings. Linking the abstinence message to Biblical scriptures may not be efficacious.",2020,"RESULTS Generalized estimating equations analyses revealed that nonfaith-based abstinence-only intervention reduced the frequency of condomless sexual intercourse, frequency of sexual intercourse, and number of sexual partners compared with the attention-matched control intervention, whereas faith-based abstinence-only intervention did not.","['613 African American parent-adolescent dyads from urban African American Baptist churches and randomizing them to one of three parent', 'young African American adolescents in church settings', 'young African American adolescents', ""Adolescents' Sexual Behaviors""]","['faith-based and nonfaith-based parent-child abstinence-only interventions', 'Church-Based Parent-Child Abstinence-Only Interventions', 'child interventions: faith-based abstinence-only intervention emphasizing delaying or reducing sexual intercourse drawing on Biblical scriptures; nonfaith-based abstinence-only emphasizing intervention delaying or reducing sexual intercourse without referencing scriptures; or attention-matched control intervention targeting health issues unrelated to sexual behavior']","['self-reported frequency of condomless sexual intercourse', 'frequency of sexual intercourse, number of sexual partners, consistent condom use and, among sexually inexperienced adolescents, sexual debut', 'condom use or sexual debut', 'frequency of condomless sexual intercourse, frequency of sexual intercourse, and number of sexual partners', 'condomless sexual intercourse', 'sexual risk behavior']","[{'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0337728', 'cui_str': 'Baptists'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0562324', 'cui_str': 'Church (environment)'}, {'cui': 'C0036864', 'cui_str': 'Sexual Behavior'}]","[{'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0562324', 'cui_str': 'Church (environment)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0009253', 'cui_str': 'Sexual Intercourse'}, {'cui': 'C0013113', 'cui_str': 'Drawing'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445356', 'cui_str': 'Unrelated (finding)'}, {'cui': 'C0036864', 'cui_str': 'Sexual Behavior'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0009253', 'cui_str': 'Sexual Intercourse'}, {'cui': 'C0278108', 'cui_str': 'Frequency of sexual intercourse (observable entity)'}, {'cui': 'C0556463', 'cui_str': 'Number of sexual partners (observable entity)'}, {'cui': 'C0009653', 'cui_str': 'Condoms'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0086931', 'cui_str': 'Risk Behavior'}]",613.0,0.0467737,"RESULTS Generalized estimating equations analyses revealed that nonfaith-based abstinence-only intervention reduced the frequency of condomless sexual intercourse, frequency of sexual intercourse, and number of sexual partners compared with the attention-matched control intervention, whereas faith-based abstinence-only intervention did not.","[{'ForeName': 'Loretta S', 'Initials': 'LS', 'LastName': 'Jemmott', 'Affiliation': 'College of Nursing and Health Professions, Drexel University, Philadelphia, Pennsylvania. Electronic address: jemmott@drexel.edu.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Jemmott', 'Affiliation': 'Department of Psychiatry, Annenberg School for Communication and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Larry D', 'Initials': 'LD', 'LastName': 'Icard', 'Affiliation': 'School of Social Work, College of Public Health, Temple University, Philadelphia, Pennsylvania.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Hsu', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania, Philadelphia, Pennsylvania.'}]",The Journal of adolescent health : official publication of the Society for Adolescent Medicine,['10.1016/j.jadohealth.2019.07.021'] 619,31744798,Twenty-four-month outcomes of inflammatory choroidal neovascularisation treated with intravitreal anti-vascular endothelial growth factors: a comparison between two treatment regimens.,"BACKGROUND AND AIM There is still no established treatment regimen for eyes with inflammatory choroidal neovascularisation (iCNV) treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections. This study compared the 24-month outcomes of two treatment regimens of anti-VEGF injections in eyes with iCNV. METHODS Eyes with iCNV treated with anti-VEGF injections were divided into two groups: eyes treated with a loading phase of 3 monthly injections and then re-treated as needed (LOADING group) and eyes treated as needed from the beginning (PRN group). Visual acuity (VA), number of injections and iCNV recurrences at 24 months were compared between the groups. RESULTS Eighty-two eyes were included, 42 in the LOADING and 40 in the PRN group. Baseline VA (mean(SD)) was 57.3 (15.8) letters in the LOADING vs 60.7 (15.6) letters in the PRN group (p=0.32). The VA (mean (95% CI)) increased at 3 months (+14.8 (10.6 to 18.9) and +11.2 (6.4 to 16) letters in the LOADING and PRN group, respectively) and remained significantly higher than baseline over the entire follow-up in both groups (all p<0.001). At 24 months, there was no difference in VA between the LOADING and PRN group (72.3 (14.0) vs 74.7 (11.3) letters, p=0.36) but the LOADING group received significantly more injections (median (Q1-Q3)) than the PRN (4.5 (3-7) vs 2.5 (2-3.2), p<0.0001). The iCNV recurrences were similar in both groups. CONCLUSIONS iCNV responded well to anti-VEGF with significant and sustained VA improvement. The loading phase did not confer any advantage in terms of outcomes. PRN regimen from the beginning was as effective as more intensive treatment.",2020,"At 24 months, there was no difference in VA between the LOADING and PRN group (87.8 (13.8) vs 90.3 (11.3) letters, p=0.36) but the LOADING group received significantly more injections (median (Q1-Q3)) than the PRN (4.5 (3-7) vs 2.5 (2-3.2), p<0.0001).","['eyes with iCNV', 'Eighty-two eyes were included, 42 in the LOADING and 40 in the PRN group', 'Eyes with iCNV treated with anti-VEGF injections', 'eyes with inflammatory choroidal neovascularisation (iCNV) treated with']","['intravitreal anti-vascular endothelial growth factors', 'anti-VEGF injections', 'intravitreal anti-vascular endothelial growth factor (VEGF) injections']","['Baseline VA (mean(SD', 'iCNV recurrences', 'VA', 'Visual acuity (VA), number of injections and iCNV recurrences']","[{'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0558288', 'cui_str': 'prn'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0078058', 'cui_str': 'Vascular Endothelial Growth Factor A'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0600518', 'cui_str': 'Neovascularization, Choroid'}]","[{'cui': 'C0078058', 'cui_str': 'Vascular Endothelial Growth Factor A'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]","[{'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}]",,0.0355067,"At 24 months, there was no difference in VA between the LOADING and PRN group (87.8 (13.8) vs 90.3 (11.3) letters, p=0.36) but the LOADING group received significantly more injections (median (Q1-Q3)) than the PRN (4.5 (3-7) vs 2.5 (2-3.2), p<0.0001).","[{'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Invernizzi', 'Affiliation': 'Eye Clinic, Department of Biomedical and Clinical Science ""L. Sacco"", Luigi Sacco Hospital, University of Milan, Milan, Italy alessandro.invernizzi@gmail.com.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Pichi', 'Affiliation': 'Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Symes', 'Affiliation': 'Save Sight Institute, The University of Sydney, Faculty of Health and Medicine, Sydney, New South Wales, Australia.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Zagora', 'Affiliation': 'Save Sight Institute, The University of Sydney, Faculty of Health and Medicine, Sydney, New South Wales, Australia.'}, {'ForeName': 'Aniruddha Kishandutt', 'Initials': 'AK', 'LastName': 'Agarwal', 'Affiliation': 'Department of Ophthalmology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Phuc', 'Initials': 'P', 'LastName': 'Nguyen', 'Affiliation': 'Save Sight Institute, The University of Sydney, Faculty of Health and Medicine, Sydney, New South Wales, Australia.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Erba', 'Affiliation': 'Eye Clinic, Department of Biomedical and Clinical Science ""L. Sacco"", Luigi Sacco Hospital, University of Milan, Milan, Italy.'}, {'ForeName': 'Alba', 'Initials': 'A', 'LastName': 'Xhepa', 'Affiliation': 'Eye Clinic, Department of Biomedical and Clinical Science ""L. Sacco"", Luigi Sacco Hospital, University of Milan, Milan, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'De Simone', 'Affiliation': 'Ocular Immunology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Cimino', 'Affiliation': 'Ocular Immunology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.'}, {'ForeName': 'Mark C', 'Initials': 'MC', 'LastName': 'Gillies', 'Affiliation': 'Save Sight Institute, The University of Sydney, Faculty of Health and Medicine, Sydney, New South Wales, Australia.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'McCluskey', 'Affiliation': 'Save Sight Institute, The University of Sydney, Faculty of Health and Medicine, Sydney, New South Wales, Australia.'}]",The British journal of ophthalmology,['10.1136/bjophthalmol-2019-315257'] 620,31113310,Tailored feedback reduced prolonged sitting time and improved the health of housewives: a single-blind randomized controlled pilot study.,"Reducing sitting time, independent of physical activity, is important for health. However, few reports have been published regarding physical activity of housewives compared to that of employed women. We examined strategies to shorten housewives' sitting time using a single-blind randomized controlled trial. Forty-eight housewives (38.0 ± 4.5 years old) were randomly assigned to one of three groups: pamphlet, self-feedback, and tailored feedback groups. All participants received a pamphlet describing the risks of prolonged sitting. The self-feedback and tailored feedback groups were also given feedback on sitting time by a smartphone application. The tailored feedback group received individual suggestions regarding lifestyle to shorten sitting time. We measured physical activity using an accelerometer and health-related quality of life using the Short-Form 8. The longest prolonged sitting time significantly decreased over time, a significant reduction was observed after the intervention only in the tailored feedback group. Vitality, mental health, and role emotional components of health-related quality of life showed a significant improvement with time but no significant differences were observed among the study groups. We suggested an easy approach to shortening prolonged sitting time in housewives using a pamphlet and feedback by smartphone. However, tailored consulting was necessary to yield a more effective result.",2020,"Vitality, mental health, and role emotional components of health-related quality of life showed a significant improvement with time but no significant differences were observed among the study groups.",['Forty-eight housewives (38.0 ± 4.5 years old'],"['pamphlet, self-feedback, and tailored feedback groups', 'individual suggestions regarding lifestyle to shorten sitting time']","['physical activity using an accelerometer and health-related quality of life', 'health of housewives', 'sitting time', 'Reducing sitting time', 'longest prolonged sitting time', 'Vitality, mental health, and role emotional components of health-related quality of life']","[{'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C3844009', 'cui_str': 'Four point five'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0038659', 'cui_str': 'Suggestion'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C1282927', 'cui_str': 'Shortened (qualifier value)'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C1632851', 'cui_str': 'Times'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}]",48.0,0.0167612,"Vitality, mental health, and role emotional components of health-related quality of life showed a significant improvement with time but no significant differences were observed among the study groups.","[{'ForeName': 'Tomomi', 'Initials': 'T', 'LastName': 'Kitagawa', 'Affiliation': 'Graduate School of Comprehensive Rehabilitation, Osaka Prefecture University, Habikino City, Osaka, Japan.'}, {'ForeName': 'Yumi', 'Initials': 'Y', 'LastName': 'Higuchi', 'Affiliation': 'Graduate School of Comprehensive Rehabilitation, Osaka Prefecture University, Habikino City, Osaka, Japan.'}, {'ForeName': 'Emiko', 'Initials': 'E', 'LastName': 'Todo', 'Affiliation': 'Graduate School of Comprehensive Rehabilitation, Osaka Prefecture University, Habikino City, Osaka, Japan.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Ueda', 'Affiliation': 'Graduate School of Comprehensive Rehabilitation, Osaka Prefecture University, Habikino City, Osaka, Japan.'}, {'ForeName': 'Suguru', 'Initials': 'S', 'LastName': 'Ando', 'Affiliation': 'Graduate School of Comprehensive Rehabilitation, Osaka Prefecture University, Habikino City, Osaka, Japan.'}, {'ForeName': 'Tatsunori', 'Initials': 'T', 'LastName': 'Murakami', 'Affiliation': 'Graduate School of Comprehensive Rehabilitation, Osaka Prefecture University, Habikino City, Osaka, Japan.'}]",Women & health,['10.1080/03630242.2019.1616043'] 621,31881852,"Leukocyte telomere length and serum polyunsaturated fatty acids, dietary habits, cardiovascular risk factors and features of myocardial infarction in elderly patients.","BACKGROUND Telomeres are non-coding sequences at the end of eukaryote chromosomes, which in complex with associated proteins serve to protect subtelomeric DNA. Telomeres shorten with each cell division, are regarded as a biomarker for aging and have also been suggested to play a role in atherosclerosis and cardiovascular disease (CVD). The aim of the present study was to explore the associations between leukocyte telomere length and serum polyunsaturated fatty acids, diet, cardiovascular risk factors and features of myocardial infarction (MI) in elderly patients. METHODS The material is based upon the first 299 included patients in the OMEMI trial, where patients aged 70-82 years of age are randomized to receive omega-3 supplements or corn oil (placebo) after MI. Patients were included 2-8 weeks after the index MI. DNA was extracted from whole blood, and leukocyte telomere length (LTL) was analyzed by qPCR and reported as a number relative to a reference gene. Serum long chain polyunsaturated fatty acid (LCPUFA) content was analyzed by gas chromatography. Diet was evaluated with the validated SmartDiet food frequency questionnaire. Medical records, patient interviews and clinical examination provided previous medical history and anthropometric data. Non-parametric statistical tests were used. RESULTS Median (25, 75 percentile) LTL was 0.55 (0.42, 0.72). Patients had a median age of 75 years, 70.2% were male and 45.2% used omega-3 supplements. There was a weak, but significant correlation between LTL and linoleic acid (r = 0.139, p = 0.017), but not with other LCPUFAs. There was a trend towards longer telomeres with a healthier diet, but this did not reach statistical significance (p = 0.073). No associations were found between LTL and CVD risk factors or features of MI. CONCLUSIONS In our population of elderly with a recent myocardial infarction LTL was associated with linoleic acid concentrations, but not with other LCPUFAs. Patients with a healthy diet tended to have longer telomeres. The limited associations may be due to age and the narrow age-span in our population. Further studies, designed to detect longitudinal changes should be performed to explore the role of telomeres in cardiovascular aging. TRIAL REGISTRATION Clinical trials no. NCT01841944, registration date April 29, 2013.",2019,"There was a trend towards longer telomeres with a healthier diet, but this did not reach statistical significance (p = 0.073).","['Median (25, 75 percentile', 'Patients had a median age of 75\u2009years, 70.2% were male and 45.2% used omega-3 supplements', 'elderly patients', '299 included patients in the OMEMI trial, where patients aged 70-82\u2009years of age']",['omega-3 supplements or corn oil (placebo'],"['LTL and CVD risk factors or features of MI', 'Serum long chain polyunsaturated fatty acid (LCPUFA) content', 'Leukocyte telomere length and serum polyunsaturated fatty acids, dietary habits, cardiovascular risk factors and features of myocardial infarction', 'LTL and linoleic acid', 'leukocyte telomere length and serum polyunsaturated fatty acids, diet, cardiovascular risk factors and features of myocardial infarction (MI']","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C1719844', 'cui_str': 'Greek letter omega'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C1719844', 'cui_str': 'Greek letter omega'}, {'cui': 'C0010029', 'cui_str': 'Corn Oil'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0337112', 'cui_str': 'Chain, device (physical object)'}, {'cui': 'C0032615', 'cui_str': 'Polyunsaturated Fatty Acids'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0023516', 'cui_str': 'Blood Corpuscles, White'}, {'cui': 'C0085187'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0086152', 'cui_str': 'Diet Habits'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0023750', 'cui_str': 'Linoleic Acids'}, {'cui': 'C0012155', 'cui_str': 'Diet'}]",75.0,0.044887,"There was a trend towards longer telomeres with a healthier diet, but this did not reach statistical significance (p = 0.073).","[{'ForeName': 'Are A', 'Initials': 'AA', 'LastName': 'Kalstad', 'Affiliation': 'Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevål, Postboks 4956 Nydalen, 0424, Oslo, Norway. areaka@medisin.uio.no.'}, {'ForeName': 'Sjur', 'Initials': 'S', 'LastName': 'Tveit', 'Affiliation': 'Faculty of Medicine, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Peder L', 'Initials': 'PL', 'LastName': 'Myhre', 'Affiliation': 'Department of Cardiology, Akershus University Hospital HF, Lørenskog, Norway.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Laake', 'Affiliation': 'Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevål, Postboks 4956 Nydalen, 0424, Oslo, Norway.'}, {'ForeName': 'Trine B', 'Initials': 'TB', 'LastName': 'Opstad', 'Affiliation': 'Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevål, Postboks 4956 Nydalen, 0424, Oslo, Norway.'}, {'ForeName': 'Arnljot', 'Initials': 'A', 'LastName': 'Tveit', 'Affiliation': 'Faculty of Medicine, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Erik B', 'Initials': 'EB', 'LastName': 'Schmidt', 'Affiliation': 'Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Svein', 'Initials': 'S', 'LastName': 'Solheim', 'Affiliation': 'Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevål, Postboks 4956 Nydalen, 0424, Oslo, Norway.'}, {'ForeName': 'Harald', 'Initials': 'H', 'LastName': 'Arnesen', 'Affiliation': 'Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevål, Postboks 4956 Nydalen, 0424, Oslo, Norway.'}, {'ForeName': 'Ingebjørg', 'Initials': 'I', 'LastName': 'Seljeflot', 'Affiliation': 'Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevål, Postboks 4956 Nydalen, 0424, Oslo, Norway.'}]",BMC geriatrics,['10.1186/s12877-019-1383-9'] 622,31337877,Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.,"BACKGROUND Retrospective studies suggest that low molecular weight heparin may delay the development of metastasis in patients with resected NSCLC. METHODS Multicentre phase 3 study with patients with completely resected NSCLC who were randomised after surgery to receive chemotherapy with or without nadroparin. The main exclusion criteria were R1/2 and wedge/segmental resection. FDG-PET was required. The primary endpoint was recurrence-free survival (RFS). RESULTS Among 235 registered patients, 202 were randomised (nadroparin: n = 100; control n = 102). Slow accrual enabled a decrease in the number of patients needed from 600 to 202, providing 80% power to compare RFS with 94 events (α = 0.05; 2-sided). There were no differences in bleeding events between the two groups. The median RFS was 65.2 months (95% CI, 36-NA) in the nadroparin arm and 37.7 months (95% CI, 22.7-NA) in the control arm (HR 0.77 (95% CI, 0.53-1.13, P = 0.19). FDG-PET SUVmax ≥10 predicted a greater likelihood of recurrence in the first year (HR 0.48, 95% CI 0.22-0.9, P = 0.05). CONCLUSIONS Adjuvant nadroparin did not improve RFS in patients with resected NSCLC. In this study, a high SUVmax predicted a greater likelihood of recurrence in the first year. CLINICAL TRIAL REGISTRATION Netherlands Trial registry: NTR1250/1217.",2019,"FDG-PET SUVmax ≥10 predicted a greater likelihood of recurrence in the first year (HR 0.48, 95% CI 0.22-0.9, P = 0.05). ","['patients with completely resected non-small-cell lung cancer', '235 registered patients, 202 were randomised (nadroparin: n\u2009=\u2009100; control n\u2009=\u2009102', 'patients with resected NSCLC', 'patients with resected NSCLC.\nMETHODS\n\n\nMulticentre phase 3 study with patients with completely resected NSCLC who were randomised after surgery to receive']","['adjuvant chemotherapy with or without nadroparin', 'chemotherapy with or without nadroparin']","['median RFS', 'RFS', 'recurrence-free survival (RFS', 'bleeding events', 'likelihood of recurrence']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4554154', 'cui_str': 'Completely - dosing instruction fragment (qualifier value)'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0206232', 'cui_str': 'Nadroparin'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439561', 'cui_str': 'Phase 3 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}]","[{'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0206232', 'cui_str': 'Nadroparin'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease (finding)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}]",202.0,0.512985,"FDG-PET SUVmax ≥10 predicted a greater likelihood of recurrence in the first year (HR 0.48, 95% CI 0.22-0.9, P = 0.05). ","[{'ForeName': 'Harry J M', 'Initials': 'HJM', 'LastName': 'Groen', 'Affiliation': 'Department of Pulmonary Disease, University of Groningen and University Medical Center Groningen, Hanzeplein 1, Box 30.001, 9700 RB, Groningen, Netherlands. h.j.m.groen@umcg.nl.'}, {'ForeName': 'Erik H F M', 'Initials': 'EHFM', 'LastName': 'van der Heijden', 'Affiliation': 'Department of Pulmonary Diseases, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, Netherlands.'}, {'ForeName': 'Theo J', 'Initials': 'TJ', 'LastName': 'Klinkenberg', 'Affiliation': 'Department of Cardiothoracic Surgery, University of Groningen and University Medical Center Groningen, Hanzeplein 1, Box 30.001, 9700 RB, Groningen, Netherlands.'}, {'ForeName': 'Bonne', 'Initials': 'B', 'LastName': 'Biesma', 'Affiliation': ""Department of Pulmonary Diseases, Jeroen Bosch Hospital, Henri Dunantstraat 1, 5223 GZ, 's-Hertogenbosch, Netherlands.""}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Aerts', 'Affiliation': 'Department of Pulmonary Diseases, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD, Rotterdam, Netherlands.'}, {'ForeName': 'Ad', 'Initials': 'A', 'LastName': 'Verhagen', 'Affiliation': 'Department of Cardiothoracic Surgery, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, Netherlands.'}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Kloosterziel', 'Affiliation': 'Department of Pulmonary Diseases, Isala Hospital, Dokter van Heesweg 2, 8025 AB, Zwolle, Netherlands.'}, {'ForeName': 'Remge', 'Initials': 'R', 'LastName': 'Pieterman', 'Affiliation': 'Department of Pulmonary Diseases, Ommelander Hospital Group, Pastorieweg 1, 9679 BJ, Scheemda, Netherlands.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'van den Borne', 'Affiliation': 'Department of Pulmonary Diseases, Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, Netherlands.'}, {'ForeName': 'Hans J M', 'Initials': 'HJM', 'LastName': 'Smit', 'Affiliation': 'Department of Pulmonary Diseases, Rijnstate Hospital, Wagnerlaan 55, 6815 AD, Arnhem, Netherlands.'}, {'ForeName': 'Otto', 'Initials': 'O', 'LastName': 'Hoekstra', 'Affiliation': 'Department of Nuclear Medicine, Amsterdam University Medical Center, De Boelelaan 1117, 1081, HVAmsterdam, Netherlands.'}, {'ForeName': 'Frans M N H', 'Initials': 'FMNH', 'LastName': 'Schramel', 'Affiliation': 'Department of Pulmonary Diseases, St Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, Netherlands.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'van der Noort', 'Affiliation': 'Department of Biometrics, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands.'}, {'ForeName': 'Harm', 'Initials': 'H', 'LastName': 'van Tinteren', 'Affiliation': 'Department of Biometrics, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands.'}, {'ForeName': 'Egbert F', 'Initials': 'EF', 'LastName': 'Smit', 'Affiliation': 'Department of Thoracic Oncology, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands.'}, {'ForeName': 'Anne-Marie C', 'Initials': 'AC', 'LastName': 'Dingemans', 'Affiliation': 'Department of Pulmonary Diseases, Maastricht University Medical Center, P. Debijelaan 25, 6229 HX, Maastricht, Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",British journal of cancer,['10.1038/s41416-019-0533-3'] 623,28029485,Shenfu injection for improving cellular immunity and clinical outcome in patients with sepsis or septic shock.,"PURPOSE To assess the efficacy of Shenfu injection (SFI) for enhancing cellular immunity and improving the clinical outcomes of patients with septic shock. METHODS Patients with sepsis were randomly assigned to receive either SFI at a dose of 100mL every 24hours for 7 consecutive days or a placebo in addition to conventional therapy. The immunologic parameters were collected on days 1, 3, and 7 after the above treatments, and the clinical outcomes were updated for 28days. RESULTS Of these160 patients, 3 were excluded from the analysis due to protocol violation and withdrawal of consent; thus, 157 completed the study (78 in the SFI group and 79 in the placebo group). We found that SFI increased both CD4 + and CD8 + T cells in peripheral blood and up-regulated HLA-DR expression in monocytes (P<.05). Furthermore, SFI was also found to restore ex vivo monocytic tumor necrosis factor α and interleukin 6 proinflammatory cytokine release in response to the endotoxin (P<.05). Importantly, the SFI group showed better clinical outcomes than did the placebo group in terms of the duration of vasopressor use (P=.008), Acute Physiology and Chronic Health Evaluation II score (P=.034), Marshall score (P=.01), and length of intensive care unit stay (10.5±3.2 vs 12.2±2.8days; P=.012). However, the 28-day mortality rate was not significantly different between the SFI (20.5%; 16/78) and placebo groups (27.8%; -22/79; P=.28). CONCLUSION These findings suggest that SFI can enhance the cellular immunity of patients with septic shock and could be a promising adjunctive treatment for patients with septic shock.",2017,"Furthermore, SFI was also found to restore ex vivo monocytic tumor necrosis factor α and interleukin 6 proinflammatory cytokine release in response to the endotoxin (P<.05).","['Patients with sepsis', 'patients with septic shock', 'patients with sepsis or septic shock']","['Shenfu injection (SFI', 'placebo', 'Shenfu injection', 'placebo in addition to conventional therapy', 'SFI']","['clinical outcomes', 'duration of vasopressor use', 'Marshall score (P=.01), and length of intensive care unit stay', 'SFI increased both CD4 + and CD8 + T cells in peripheral blood and up-regulated HLA-DR expression', 'Acute Physiology and Chronic Health Evaluation II score', '28-day mortality rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C0036983', 'cui_str': 'Septic Shock'}]","[{'cui': 'C1528398', 'cui_str': 'Shen-Fu'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood (substance)'}, {'cui': 'C0019764', 'cui_str': 'HLA-DR'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0243028', 'cui_str': 'APACHE II'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}]",,0.17881,"Furthermore, SFI was also found to restore ex vivo monocytic tumor necrosis factor α and interleukin 6 proinflammatory cytokine release in response to the endotoxin (P<.05).","[{'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Zhang', 'Affiliation': ""Department of Critical Care Medicine, The Sixth Affiliated Hospital of Wenzhou Medical College, Lishui People's Hospital, Lishui, Zhejiang 323000,China.""}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Department of Medical Statistics, Zhoupu Hospital Affiliated to Shanghai University of Medicine & Health Sciences, Shanghai 201318, China.'}, {'ForeName': 'Zeliang', 'Initials': 'Z', 'LastName': 'Qiu', 'Affiliation': ""Department of Critical Care Medicine, The Sixth Affiliated Hospital of Wenzhou Medical College, Lishui People's Hospital, Lishui, Zhejiang 323000,China; Department of Critical Care Medicine, Zhoupu Hospital Affiliated to Shanghai University of Medicine & Health Sciences, Shanghai 201318, China. Electronic address: 1201zeliang_qiu@tongji.edu.cn.""}, {'ForeName': 'Yiping', 'Initials': 'Y', 'LastName': 'Ye', 'Affiliation': ""Department of Traditional Chinese Medicine, The Sixth Affiliated Hospital of Wenzhou Medical College, Lishui People's Hospital, Lishui, Zhejiang,China.""}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Critical Care Medicine, The Sixth Affiliated Hospital of Wenzhou Medical College, Lishui People's Hospital, Lishui, Zhejiang 323000,China.""}, {'ForeName': 'Tianzheng', 'Initials': 'T', 'LastName': 'Lou', 'Affiliation': ""Department of Critical Care Medicine, The Sixth Affiliated Hospital of Wenzhou Medical College, Lishui People's Hospital, Lishui, Zhejiang 323000,China.""}]",The American journal of emergency medicine,['10.1016/j.ajem.2016.09.008'] 624,31847602,Effects of circadian restricted feeding on parameters of metabolic syndrome among healthy subjects.,"Experimental studies indicate that energy homeostasis to the circadian clock at the behavioral, physiological, and molecular levels, emphasize that timing of food intake may play a significant role in the development of obesity and central obesity. Therefore, resetting the circadian clock by circadian energy restriction via food intake in the morning or evening, may be used as a new approach for prevention of obesity, metabolic syndrome and related diseases. After ethical clearance and written, informed consent, free living subjects were included if they volunteered to take most of the total daily meals (approximately 2000 Kcal./day) in the evening (4 weeks) or morning (4 weeks). Of 22 adults, half were randomly selected by computer generated numbers to eat in the morning and the other half in the evening, after 8.00 PM. The eating pattern was changed after 4 weeks of intervention and a 4-week washout period, those who ate in the morning were advised to eat in the evening and vice versa. Validated questionnaires were used to assess food intakes, physical activity, and intake of alcohol and tobacco. Physical examination included measurement of body weight, height, and blood pressure (BP) by sphygmomanometer. Data were regularly recorded blindly, in all subjects at start of study and during follow-up. Blood samples were collected after an overnight fast for analysis of blood glucose and Hb1c. Feeding in the evening was associated with significant increase in body weight by 0.80 kg ( P < .001), body mass index (BMI) by 0.30 kg/m 2 ( P < .001) and waist circumference by 1.13 cm ( P < .05). Feeding the same amount of energy in the morning was not associated with any significant change in weight, BMI or waist circumference ( P > .500). Lesser increases in all three variables were associated with AM versus PM feeding ( P < .05). Systolic BP slightly increased on PM and decreased on AM feeding, with a difference between the two responses of 1.55 mmHg ( P < .05). Fasting blood glucose was lower on AM than on PM feeding (74.86 vs. 77.95 mg/dl, paired t = 4.220, P < .001). Hb1C increased on PM feeding by 0.28 (from 4.45 to 4.73; t = 9.176, P < .001), but decreased on AM feeding by 0.077 (from 4.53 to 4.45; t = -6.859, P < .001). The difference in Hb1C response between AM and PM feeding is also statistically significant (t = -11.599, P < .001). Eating in the evening can predispose to obesity, central obesity and increases in fasting blood glucose and Hb1c that are indicators of the metabolic syndrome. By contrast, eating in the morning can decrease Hb1c and systolic BP, indicating that it may be protective against the metabolic syndrome.",2020,"Feeding the same amount of energy in the morning was not associated with any significant change in weight, BMI or waist circumference ( P > .500).","['Of 22 adults', 'healthy subjects']",['circadian restricted feeding'],"['body weight', 'metabolic syndrome', 'food intakes, physical activity, and intake of alcohol and tobacco', 'Hb1C increased on PM feeding', 'waist circumference', 'AM feeding', 'Hb1c and systolic BP', 'body weight, height, and blood pressure (BP', 'Systolic BP', 'eating pattern', 'fasting blood glucose', 'weight, BMI or waist circumference', 'body mass index (BMI', 'Fasting blood glucose', 'Hb1C response']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0443288', 'cui_str': 'Restricted (qualifier value)'}, {'cui': 'C2987508', 'cui_str': 'Feeding (observable entity)'}]","[{'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0524620', 'cui_str': 'Metabolic Syndrome X'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C2987508', 'cui_str': 'Feeding (observable entity)'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",22.0,0.0169736,"Feeding the same amount of energy in the morning was not associated with any significant change in weight, BMI or waist circumference ( P > .500).","[{'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Singh', 'Affiliation': 'Halberg Hospital and Research Institute, Moradabad, India.'}, {'ForeName': 'Germaine', 'Initials': 'G', 'LastName': 'Cornelissen', 'Affiliation': 'Halberg Chronobiology Center, University of Minnesota Medical School, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Viliam', 'Initials': 'V', 'LastName': 'Mojto', 'Affiliation': 'Department of Internal Medicine, Comenius University, Bratislava, Slovakia.'}, {'ForeName': 'Ghizal', 'Initials': 'G', 'LastName': 'Fatima', 'Affiliation': 'Department of Molecular Medicine, Era medical College, Lucknow, India.'}, {'ForeName': 'Sanit', 'Initials': 'S', 'LastName': 'Wichansawakun', 'Affiliation': 'Department of Internal Medicine, Faculty of Medicine, Thammasat University, Bangkok, Thailand.'}, {'ForeName': 'Mukta', 'Initials': 'M', 'LastName': 'Singh', 'Affiliation': 'Department of Home Science, MMV, BHU, Varanasi, India.'}, {'ForeName': 'Kumar', 'Initials': 'K', 'LastName': 'Kartikey', 'Affiliation': 'Halberg Hospital and Research Institute, Moradabad, India.'}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Sharma', 'Affiliation': 'Halberg Hospital and Research Institute, Moradabad, India.'}, {'ForeName': 'V I', 'Initials': 'VI', 'LastName': 'Torshin', 'Affiliation': 'Department of Physiology, RUDN University, Moscow, Russia.'}, {'ForeName': 'Sergey', 'Initials': 'S', 'LastName': 'Chibisov', 'Affiliation': 'Department of Physiology, RUDN University, Moscow, Russia.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Kharlitskaya', 'Affiliation': 'Department of Physiology, RUDN University, Moscow, Russia.'}, {'ForeName': 'O A', 'Initials': 'OA', 'LastName': 'Al-Bawareed', 'Affiliation': 'Department of Physiology, RUDN, Moscow, Russia.'}]",Chronobiology international,['10.1080/07420528.2019.1701817'] 625,31333058,Quantitative Assessment of Effectiveness of Ultrasonic Propulsion of Kidney Stones.,"Purpose: Ultrasonic propulsion is an investigative modality to noninvasively image and reposition urinary stones. Our goals were to test safety and effectiveness of new acoustic exposure conditions from a new transducer, and to use simultaneous ureteroscopic and ultrasonic observation to quantify stone repositioning. Materials and Methods: During operation, ultrasonic propulsion was applied transcutaneously, whereas stone targets were visualized ureteroscopically. Exposures were 350 kHz frequency, ≤200 W/cm 2 focal intensity, and ≤3-second bursts per push. Ureteroscope and ultrasound (US) videos were recorded. Video clips with and without stone motion were randomized and scored for motion ≥3 mm by independent reviewers blinded to the exposures. Subjects were followed with telephone calls, imaging, and chart review for adverse events. Results: The investigative treatment was used in 18 subjects and 19 kidneys. A total of 62 stone targets were treated ranging in size from a collection of ""dust"" to 15 mm. Subjects received an average of 17 ± 14 propulsion bursts (per kidney) for a total average exposure time of 40 ± 40 seconds. Independent reviewers scored at least one stone movement ≥3 mm in 18 of 19 kidneys (95%) from the ureteroscope videos and in 15 of 19 kidneys (79%) from the US videos. This difference was probably because of motion out of the US imaging plane. Treatment repositioned stones in two cases that would have otherwise required basket repositioning. No serious adverse events were observed with the device or procedure. Conclusions: Ultrasonic propulsion was shown to be safe, and it effectively repositioned stones in 95% of kidneys despite positioning and access restrictions caused by working in an operating room on anesthetized subjects.",2019,"CONCLUSIONS Ultrasonic propulsion was shown to be safe, and it effectively repositioned stones in 95% of kidneys despite positioning and access restrictions caused by working in an operating room on anesthetized subjects.",['18 subjects and 19 kidneys'],"['ultrasonic propulsion of kidney stones', 'Ultrasonic propulsion', 'Video clips with and without stone motion']","['Ureteroscope and ultrasound (US) videos', 'serious adverse events']","[{'cui': 'C0022646', 'cui_str': 'Kidney'}]","[{'cui': 'C1456803', 'cui_str': 'Ultrasonics'}, {'cui': 'C0022650', 'cui_str': 'Kidney Stones'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0175722', 'cui_str': 'Clip'}, {'cui': 'C0006736', 'cui_str': 'Biliary or Urinary Stones'}, {'cui': 'C0687704', 'cui_str': 'Motions (qualifier value)'}]","[{'cui': 'C0184213', 'cui_str': 'Ureteroscopes'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",62.0,0.0458556,"CONCLUSIONS Ultrasonic propulsion was shown to be safe, and it effectively repositioned stones in 95% of kidneys despite positioning and access restrictions caused by working in an operating room on anesthetized subjects.","[{'ForeName': 'Jessica C', 'Initials': 'JC', 'LastName': 'Dai', 'Affiliation': 'Department of Urology, University of Washington, Seattle, Washington.'}, {'ForeName': 'Mathew D', 'Initials': 'MD', 'LastName': 'Sorensen', 'Affiliation': 'Department of Urology, University of Washington, Seattle, Washington.'}, {'ForeName': 'Helena C', 'Initials': 'HC', 'LastName': 'Chang', 'Affiliation': 'Department of Urology, University of Washington, Seattle, Washington.'}, {'ForeName': 'Patrick C', 'Initials': 'PC', 'LastName': 'Samson', 'Affiliation': 'Department of Urology, University of Washington, Seattle, Washington.'}, {'ForeName': 'Barbrina', 'Initials': 'B', 'LastName': 'Dunmire', 'Affiliation': 'Center for Industrial and Medical Ultrasound, Applied physics Laboratory, University of Washington, Seattle, Washington.'}, {'ForeName': 'Bryan W', 'Initials': 'BW', 'LastName': 'Cunitz', 'Affiliation': 'Center for Industrial and Medical Ultrasound, Applied physics Laboratory, University of Washington, Seattle, Washington.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Thiel', 'Affiliation': 'Center for Industrial and Medical Ultrasound, Applied physics Laboratory, University of Washington, Seattle, Washington.'}, {'ForeName': 'Ziyue', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of Biostatistics, Indiana University, Indianapolis, Indiana.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Bailey', 'Affiliation': 'Department of Urology, University of Washington, Seattle, Washington.'}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Harper', 'Affiliation': 'Department of Urology, University of Washington, Seattle, Washington.'}]",Journal of endourology,['10.1089/end.2019.0340'] 626,31339055,A Multidisciplinary Intervention to Improve Care for High-Risk COPD Patients.,"Chronic obstructive pulmonary disease (COPD) exacerbations contribute to both costs and patient morbidity. The authors designed a quality project to improve care for high-risk COPD patients admitted with an exacerbation. An electronic medical record report was used to target admitted high-risk COPD patients for an intervention that included pulmonary and respiratory therapy consults, post-discharge phone calls from a patient navigator, referrals to palliative services when appropriate, and bedside delivery of medications. The control population was a similar group of patients at a community partner hospital who received usual care. In all, 157 unique patients were enrolled over 16 months; referrals to palliative care services increased and rates of outpatient follow-up improved. There was no difference in readmissions or emergency department visits between the 2 groups. Better coordination of outpatient care and attention to psychosocial burdens were identified as possible targets for future interventions.",2020,There was no difference in readmissions or emergency department visits between the 2 groups.,"['high-risk COPD patients admitted with an exacerbation', 'admitted high-risk COPD patients', 'Chronic obstructive pulmonary disease (COPD) exacerbations', '157 unique patients were enrolled over 16 months; referrals to palliative care services increased and rates of outpatient follow-up improved', 'High-Risk COPD Patients', 'patients at a community partner hospital who received usual care']",['Multidisciplinary Intervention'],['readmissions or emergency department visits'],"[{'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3508933', 'cui_str': 'Chronic obstructive pulmonary disease exacerbation'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0584096', 'cui_str': 'Referral to palliative care service (procedure)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}]",[],"[{'cui': 'C0562508', 'cui_str': 'Emergency Room'}]",,0.0223049,There was no difference in readmissions or emergency department visits between the 2 groups.,"[{'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Gay', 'Affiliation': ""Brigham and Women's Hospital, Boston, MA.""}, {'ForeName': 'Sonali', 'Initials': 'S', 'LastName': 'Desai', 'Affiliation': ""Brigham and Women's Hospital, Boston, MA.""}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'McNeil', 'Affiliation': ""Brigham and Women's Hospital, Boston, MA.""}]",American journal of medical quality : the official journal of the American College of Medical Quality,['10.1177/1062860619865329'] 627,32409778,A pragmatic randomized controlled trial testing the effects of the international scientific SCI exercise guidelines on SCI chronic pain: protocol for the EPIC-SCI trial.,"STUDY DESIGN Protocol for a pragmatic randomized controlled trial (the Exercise guideline Promotion and Implementation in Chronic SCI [EPIC-SCI] Trial). PRIMARY OBJECTIVES To test if home-/community-based exercise, prescribed according to the international SCI exercise guidelines, significantly reduces chronic bodily pain in adults with SCI. SECONDARY OBJECTIVES To investigate: (1) the effects of exercise on musculoskeletal and neuropathic chronic pain; (2) if reduced inflammation and increased descending inhibitory control are viable pathways by which exercise reduces pain; (3) the effects of chronic pain reductions on subjective well-being; and (4) efficiency of a home-/community-based exercise intervention. SETTING Exercise in home-/community-based settings; assessments in university-based laboratories in British Columbia, Canada. METHOD Eighty-four adults with chronic SCI, reporting chronic musculoskeletal or neuropathic pain, and not meeting the current SCI exercise guidelines, will be recruited and randomized to a 6-month Exercise or Wait-List Control condition. Exercise will occur in home/community settings and will be supported through behavioral counseling. All measures will be taken at baseline, 3-months and 6-months. Analyses will consist of linear mixed effect models, multiple regression analyses and a cost-utility analysis. The economic evaluation will examine the incremental costs and health benefits generated by the intervention compared with usual care. ETHICS AND DISSEMINATION The University of British Columbia Clinical Research Ethics Board approved the protocol (#H19-01650). Using an integrated knowledge translation approach, stakeholders will be engaged throughout the trial and will co-create and disseminate evidence-based recommendations and messages regarding the use of exercise to manage SCI chronic pain.",2020,"Using an integrated knowledge translation approach, stakeholders will be engaged throughout the trial and will co-create and disseminate evidence-based recommendations and messages regarding the use of exercise to manage SCI chronic pain.","['adults with SCI', 'Exercise in home-/community-based settings; assessments in university-based laboratories in British Columbia, Canada', 'Eighty-four adults with chronic SCI, reporting chronic musculoskeletal or neuropathic pain, and not meeting the current SCI exercise guidelines']","['home-/community-based exercise intervention', 'international scientific SCI exercise guidelines', '6-month Exercise or Wait-List Control condition', 'exercise']","['chronic bodily pain', 'musculoskeletal and neuropathic chronic pain', 'SCI chronic pain']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0006193', 'cui_str': 'British Columbia'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0027796', 'cui_str': 'Neuralgia'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}]",84.0,0.155033,"Using an integrated knowledge translation approach, stakeholders will be engaged throughout the trial and will co-create and disseminate evidence-based recommendations and messages regarding the use of exercise to manage SCI chronic pain.","[{'ForeName': 'Kathleen A', 'Initials': 'KA', 'LastName': 'Martin Ginis', 'Affiliation': 'Department of Medicine, Division of Physical Medicine and Rehabilitation, University of British Columbia, Vancouver, BC, Canada. kathleen_martin.ginis@ubc.ca.'}, {'ForeName': 'Jan W', 'Initials': 'JW', 'LastName': 'van der Scheer', 'Affiliation': 'Department of Medicine, Division of Physical Medicine and Rehabilitation, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Kendra R', 'Initials': 'KR', 'LastName': 'Todd', 'Affiliation': 'School of Health and Exercise Sciences, University of British Columbia, Kelowna, BC, Canada.'}, {'ForeName': 'Jennifer C', 'Initials': 'JC', 'LastName': 'Davis', 'Affiliation': 'Centre for Chronic Disease Prevention and Management, University of British Columbia, Kelowna, BC, Canada.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Gaudet', 'Affiliation': 'Spinal Cord Injury British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Femke', 'Initials': 'F', 'LastName': 'Hoekstra', 'Affiliation': 'School of Health and Exercise Sciences, University of British Columbia, Kelowna, BC, Canada.'}, {'ForeName': 'Mohammad Ehsanul', 'Initials': 'ME', 'LastName': 'Karim', 'Affiliation': 'School of Population and Public Health and Centre for Health Evaluation and Outcome Sciences, Providence Health Care, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'John L K', 'Initials': 'JLK', 'LastName': 'Kramer', 'Affiliation': 'International Collaboration on Repair Discoveries (ICORD), University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Jonathan Peter', 'Initials': 'JP', 'LastName': 'Little', 'Affiliation': 'School of Health and Exercise Sciences, University of British Columbia, Kelowna, BC, Canada.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Singer', 'Affiliation': 'School of Population and Public Health, UBC; Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Townson', 'Affiliation': 'Department of Medicine, Division of Physical Medicine and Rehabilitation, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'West', 'Affiliation': 'International Collaboration on Repair Discoveries (ICORD), University of British Columbia, Vancouver, BC, Canada.'}]",Spinal cord,['10.1038/s41393-020-0478-7'] 628,31335204,The Beneficial Effect of the Mobile Application Euglyca in Children and Adolescents with Type 1 Diabetes Mellitus: A Randomized Controlled Trial.,"Background: Euglyca ® is a mobile application which we developed for children and adolescents suffering type 1 diabetes mellitus (T1DM) for calculation of the appropriate insulin bolus dose by importing in the equation carbohydrates, lipids, glucose levels, and personalized parameters. Aim of this study is to evaluate the efficacy of this application on patients' glycemic control and satisfaction. Subjects and Methods: Eighty children and adolescents (aged 13.5 ± 2.8 years old, mean ± standard deviation) with T1DM were included in the study and were randomly and equally assigned in two groups. Patients were asked to use Euglyca for the calculation of the bolus insulin dose in the E group and to pursue their routine calculations in the C group (controls). At baseline and at 3, 6, and 12 months following the initial visit, glycated hemoglobin (HbA1c) values, percentages of hypoglycemias, hyperglycemias, and normoglycemias were determined for each patient, while Diabetes Treatment Satisfaction Questionnaire (DTSQ) was used to assess patients' treatment satisfaction at baseline and at 6 and 12 months. Results: Children and adolescents in the E group had a statistically significant decrease in HbA1c values and increase in percentages of normoglycemias and DTSQ scores, in comparison to children and adolescents in the C group. In the E group, a statistically significant positive linear correlation was found between DTSQ score and percentages of normoglycemias and a statistically significant negative correlation between changes in percentages of normoglycemias (Δnormoglycemias) and changes in HbA1c (ΔHbA1c). Conclusions: The use of the mobile application Euglyca contributes to the improvement of glycemic control and treatment satisfaction of children and adolescents with T1DM.",2019,"RESULTS Children and adolescents in the E group had a statistically significant decrease in HbA1c values and increase in percentages of normoglycemias and DTSQ scores, in comparison to children and adolescents in the C group.","['children and adolescents suffering diabetes mellitus type 1 (T1DM', 'Children and Adolescents with Diabetes Mellitus Type 1', 'children and adolescents with T1DM', 'Eighty children and adolescents (aged 13.5 ± 2.8 years old, mean ± SD) with T1DM were included in the study', ""patients' glycemic control and satisfaction""]",['mobile application Euglyca®'],"['percentages of normoglycemias (Δnormoglycemias) and changes in HbA1c (ΔHbA1c', 'normoglycemias and DTSQ scores', 'DTSQs score and percentages of normoglycemias', 'Diabetes Treatment Satisfaction questionnaire (DTSQ', 'HbA1c values', 'glycated hemoglobin (HbA1c) values, percentages of hypoglycemias, hyperglycemias and normoglycemias']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}, {'cui': 'C0011854', 'cui_str': 'Diabetes Mellitus, Type 1'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C4517559', 'cui_str': '13.5 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]","[{'cui': 'C3658310', 'cui_str': 'Mobile Apps'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451116', 'cui_str': 'Diabetes treatment satisfaction questionnaire (assessment scale)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}]",80.0,0.0509393,"RESULTS Children and adolescents in the E group had a statistically significant decrease in HbA1c values and increase in percentages of normoglycemias and DTSQ scores, in comparison to children and adolescents in the C group.","[{'ForeName': 'Christos', 'Initials': 'C', 'LastName': 'Chatzakis', 'Affiliation': 'Endocrine Unit of 3rd Pediatric Department of Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.'}, {'ForeName': 'Dimitrios', 'Initials': 'D', 'LastName': 'Floros', 'Affiliation': 'Department of Electrical Engineering of Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Papagianni', 'Affiliation': 'Endocrine Unit of 3rd Pediatric Department of Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.'}, {'ForeName': 'Kyriaki', 'Initials': 'K', 'LastName': 'Tsiroukidou', 'Affiliation': 'Endocrine Unit of 3rd Pediatric Department of Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.'}, {'ForeName': 'Konstantina', 'Initials': 'K', 'LastName': 'Kosta', 'Affiliation': 'Endocrine Unit of 3rd Pediatric Department of Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.'}, {'ForeName': 'Anastasios', 'Initials': 'A', 'LastName': 'Vamvakis', 'Affiliation': 'Endocrine Unit of 3rd Pediatric Department of Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.'}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Koletsos', 'Affiliation': 'Endocrine Unit of 3rd Pediatric Department of Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.'}, {'ForeName': 'Elpida', 'Initials': 'E', 'LastName': 'Hatziagorou', 'Affiliation': 'Endocrine Unit of 3rd Pediatric Department of Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.'}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Tsanakas', 'Affiliation': 'Endocrine Unit of 3rd Pediatric Department of Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Mastorakos', 'Affiliation': 'Endocrine Unit of Aretaieion Hospital, University of Athens Medical School, Athens, Greece.'}]",Diabetes technology & therapeutics,['10.1089/dia.2019.0170'] 629,31307856,NASA Mission X Program for Healthy Eating and Active Living among Taiwanese Elementary School Students.,"PURPOSE This study assessed the effects of an intervention program adapted from the NASA Mission X (MX) program on children's Healthy Eating Active Living (HEAL) knowledge and behaviors and anthropometry. METHODS This clustered randomized control trial recruited 8 elementary schools in remote rural areas of Northern Taiwan. The intervention was the 8-week MX program. All the 3rd and 4th graders were invited to the study (n = 245). Children's weight, height, HEAL knowledge and behaviors were measured pre- and post-intervention. RESULTS The intervention group had significantly more improvements than control group in physical activity knowledge score (+0.91 vs. +0.25, p = 0.002), diet knowledge score (+0.62 vs. +0.17, p = 0.044), and score of interests in NASA and space exploration (+0.34 vs. -0.07, p < 0.0001). BMI increased from 18.4 to 18.6 (p < 0.05) for the control group but did not change for the intervention group. The changes in BMI between groups did not differ significantly. CONCLUSION AND PRACTICE IMPLICATIONS This randomized controlled trial showed that the NASA MX program was feasible and acceptable among children in Taiwan, and improved children's HEAL knowledge. (ClinicalTrials.gov registration: NCT03355131).",2019,BMI increased from 18.4 to 18.6 (p < 0.05) for the control group but did not change for the intervention group.,"[""children in Taiwan, and improved children's HEAL knowledge"", 'healthy eating and active living among Taiwanese elementary school students', '8 elementary schools in remote rural areas of Northern Taiwan', ""children's Healthy Eating Active Living (HEAL) knowledge and behaviors and anthropometry""]","['NASA Mission X program', 'NASA MX program', 'NASA Mission X (MX) program']","['physical activity knowledge score', 'changes in BMI', 'BMI', ""Children's weight, height, HEAL knowledge and behaviors"", 'diet knowledge score', 'score of interests in NASA and space exploration']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0039260', 'cui_str': 'Formosa'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0205249', 'cui_str': 'Healed (qualifier value)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0452415', 'cui_str': 'Healthy Diet'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C1556096', 'cui_str': 'Taiwanese (ethnic group)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0205157', 'cui_str': 'Remote (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}]","[{'cui': 'C0242776', 'cui_str': 'NASA'}, {'cui': 'C0026219', 'cui_str': 'Missions'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0205249', 'cui_str': 'Healed (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0242776', 'cui_str': 'NASA'}, {'cui': 'C0242504', 'cui_str': 'Space Exploration'}]",,0.0294804,BMI increased from 18.4 to 18.6 (p < 0.05) for the control group but did not change for the intervention group.,"[{'ForeName': 'Yu-Chun', 'Initials': 'YC', 'LastName': 'Lin', 'Affiliation': 'Institute of Public Health, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Hsin-Jen', 'Initials': 'HJ', 'LastName': 'Chen', 'Affiliation': 'Institute of Public Health, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Youfa', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Fisher Institute of Health and Well-being, Department of Nutrition and Health Sciences, College of Health, Ball State University, Muncie, IN, USA.'}, {'ForeName': 'Jungwon', 'Initials': 'J', 'LastName': 'Min', 'Affiliation': 'Fisher Institute of Health and Well-being, Department of Nutrition and Health Sciences, College of Health, Ball State University, Muncie, IN, USA.'}, {'ForeName': 'Hui-Chao', 'Initials': 'HC', 'LastName': 'Wu', 'Affiliation': 'Department of Nursing, Mackay Medical College, New Taipei City, Taiwan.'}, {'ForeName': 'Nubia A', 'Initials': 'NA', 'LastName': 'Carvajal', 'Affiliation': 'MORI Associates, NASA Communications, Outreach, Multimedia and Information Technology (COMIT) Contract, TX, USA.'}, {'ForeName': 'Hsing-Yu', 'Initials': 'HY', 'LastName': 'Yang', 'Affiliation': 'Department of Nursing, Mackay Medical College, New Taipei City, Taiwan. Electronic address: hyyang@mmc.edu.tw.'}]",Journal of pediatric nursing,['10.1016/j.pedn.2019.06.016'] 630,31299247,"A Randomized Trial of Nebulized Lignocaine, Lignocaine Spray, or Their Combination for Topical Anesthesia During Diagnostic Flexible Bronchoscopy.","BACKGROUND The optimal mode of delivering topical anesthesia during flexible bronchoscopy remains unknown. This article compares the efficacy and safety of nebulized lignocaine, lignocaine oropharyngeal spray, or their combination. METHODS Consecutive subjects were randomized 1:1:1 to receive nebulized lignocaine (2.5 mL of 4% solution, group A), oropharyngeal spray (10 actuations of 10% lignocaine, group B), or nebulization (2.5 mL, 4% lignocaine) and two actuations of 10% lignocaine spray (group C). The primary outcome was the subject-rated severity of cough according to a visual analog scale. The secondary outcomes included bronchoscopist-rated severity of cough and overall procedural satisfaction on a visual analog scale, total lignocaine dose, subject's willingness to undergo a repeat procedure, adverse reactions to lignocaine, and others. RESULTS A total of 1,050 subjects (median age, 51 years; 64.8% men) were included. The median (interquartile range) score for subject-rated cough severity was significantly lower in group B compared to group C or group A (4 [1-10] vs 11 [4-24] vs 13 [5-30], respectively; P < .001). The bronchoscopist-rated severity of cough was also the least (P < .001), and the overall satisfaction was highest in group B (P < .001). The cumulative lignocaine dose administered was the least in group B (P < .001). A significantly higher proportion of subjects (P < .001) were willing to undergo a repeat bronchoscopy in group B (73.7%) than in groups A (49.1%) and C (59.4%). No lignocaine-related adverse events were observed. CONCLUSIONS Ten actuations of 10% lignocaine oropharyngeal spray were superior to nebulized lignocaine or their combination for topical anesthesia during diagnostic flexible bronchoscopy. TRIAL REGISTRY ClinicalTrials.gov; No.: NCT03109392; URL: www.clinicaltrials.gov.",2020,A significantly higher proportion of subjects (P < .001) were willing to undergo a repeat bronchoscopy in group B (73.7%) than in groups A (49.1%) and C (59.4%).,"['1,050 subjects (median age, 51 years; 64.8%\xa0men', 'Consecutive subjects']","['Nebulized Lignocaine, Lignocaine Spray, or Their Combination for Topical Anesthesia', 'nebulized lignocaine', 'lignocaine spray', 'lignocaine', 'nebulized lignocaine, lignocaine oropharyngeal spray, or their combination', 'oropharyngeal spray (10 actuations of 10%\xa0lignocaine, group B), or nebulization (2.5\xa0mL, 4%\xa0lignocaine']","['bronchoscopist-rated severity of cough', 'adverse events', ""bronchoscopist-rated severity of cough and overall procedural satisfaction on a visual analog scale, total lignocaine dose, subject's willingness to undergo a repeat procedure, adverse reactions to lignocaine, and others"", 'subject-rated severity of cough according to a visual analog scale', 'efficacy and safety', 'overall satisfaction', 'median (interquartile range) score for subject-rated cough severity']","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C4521772', 'cui_str': 'Spray'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C1522409', 'cui_str': 'Oropharyngeal route (qualifier value)'}, {'cui': 'C4319628', 'cui_str': 'Actuation (unit of presentation)'}, {'cui': 'C0441836', 'cui_str': 'Group B (qualifier value)'}, {'cui': 'C3844011', 'cui_str': '2.5'}]","[{'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",1050.0,0.072135,A significantly higher proportion of subjects (P < .001) were willing to undergo a repeat bronchoscopy in group B (73.7%) than in groups A (49.1%) and C (59.4%).,"[{'ForeName': 'Sahajal', 'Initials': 'S', 'LastName': 'Dhooria', 'Affiliation': 'Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Shivani', 'Initials': 'S', 'LastName': 'Chaudhary', 'Affiliation': 'Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Babu', 'Initials': 'B', 'LastName': 'Ram', 'Affiliation': 'Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Inderpaul Singh', 'Initials': 'IS', 'LastName': 'Sehgal', 'Affiliation': 'Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Valliappan', 'Initials': 'V', 'LastName': 'Muthu', 'Affiliation': 'Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Kuruswamy Thurai', 'Initials': 'KT', 'LastName': 'Prasad', 'Affiliation': 'Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Ashutosh N', 'Initials': 'AN', 'LastName': 'Aggarwal', 'Affiliation': 'Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Ritesh', 'Initials': 'R', 'LastName': 'Agarwal', 'Affiliation': 'Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: agarwal.ritesh@outlook.in.'}]",Chest,['10.1016/j.chest.2019.06.018'] 631,30358116,A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study).,"OBJECTIVE The aim of this study was to examine the long-term efficacy of combination of tamsulosin 0.2 mg + dutasteride 0.5 mg + imidafenacin 0.2 mg (TDI) therapy compared with tamsulosin + dutasteride (TD) therapy for 52 weeks in benign prostatic hyperplasia (BPH) patients with a prostate volume (PV) ≥30 mL and remaining overactive bladder (OAB) symptoms after having received tamsulosin for ≥8 weeks. Previously, we reported that the improvement in OAB symptoms at 24 weeks was significantly greater in the TDI than TD group. METHODS BPH patients with OAB symptoms after ≥8 weeks tamsulosin were randomly assigned to the TDI or TD group in a ratio of 1:1 ratio, and followed-up for 52 weeks. Changes in the OAB Symptom Score (OABSS), International Prostate Symptom Score (IPSS), and post-void residual (PVR) were evaluated. RESULTS In all, 163 patients were randomized, and 125 patients (76.7%) completed 52 weeks of treatment. At Week 52, there were significant decreases in the OABSS and IPSS storage subscore compared with baseline in the TDI versus TD group, but the change in the total IPSS did not differ significantly between the two groups. There was no change in PVR from Week 24 to Week 52 in either group. CONCLUSIONS For BPH patients with PVR ≥30 mL and remaining storage symptoms despite tamsulosin monotherapy, TDI treatment showed better results in terms of improved OAB symptoms than TD treatment up to 52 weeks.",2019,"At Week 52, there were significant decreases in the OABSS and IPSS storage subscore compared with baseline in the TDI versus TD group, but the change in the total IPSS did not differ significantly between the two groups.","['52\u2009weeks in benign prostatic hyperplasia (BPH) patients with a prostate volume (PV) ≥30\u2009mL and remaining overactive bladder (OAB) symptoms after having received tamsulosin for ≥8 weeks', '163 patients were randomized, and 125 patients (76.7%) completed 52\u2009weeks of treatment', 'patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study', 'BPH patients with OAB symptoms after ≥8 weeks']","['tamsulosin monotherapy', 'TDI or TD', 'tamsulosin 0.2 mg\u2009+\u2009dutasteride 0.5 mg\u2009+\u2009imidafenacin 0.2 mg (TDI) therapy', 'tamsulosin + dutasteride (TD) therapy', 'dutasteride and imidafenacin to tamsulosin', 'tamsulosin']","['OAB Symptom Score (OABSS), International Prostate Symptom Score (IPSS), and post-void residual (PVR', 'total IPSS', 'OAB symptoms', 'OABSS and IPSS storage subscore', 'efficacy and safety', 'PVR']","[{'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1704272', 'cui_str': 'Benign Prostatic Hyperplasia'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0878773', 'cui_str': 'Overactive Bladder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0257343', 'cui_str': 'tamsulosin'}, {'cui': 'C4319551', 'cui_str': 'One hundred and twenty-five'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0005001', 'cui_str': 'Benign enlargement of prostate'}]","[{'cui': 'C0257343', 'cui_str': 'tamsulosin'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C1593561', 'cui_str': 'Dutasteride 0.5 MG [Avodart]'}, {'cui': 'C1876226', 'cui_str': 'imidafenacin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0754659', 'cui_str': 'Dutasteride'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1998280', 'cui_str': 'International prostate symptom score (assessment scale)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1698986', 'cui_str': 'Storage (procedure)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",163.0,0.0623427,"At Week 52, there were significant decreases in the OABSS and IPSS storage subscore compared with baseline in the TDI versus TD group, but the change in the total IPSS did not differ significantly between the two groups.","[{'ForeName': 'Tomonori', 'Initials': 'T', 'LastName': 'Yamanishi', 'Affiliation': 'Department of Urology, Continence Center, Dokkyo Medical University, Tochigi, Japan.'}, {'ForeName': 'Hirotaka', 'Initials': 'H', 'LastName': 'Asakura', 'Affiliation': 'Department of Urology, Saitama Medical University Hospital, Saitama, Japan.'}, {'ForeName': 'Narihito', 'Initials': 'N', 'LastName': 'Seki', 'Affiliation': 'Department of Urology, Kyushu Central Hospital, Fukuoka, Japan.'}, {'ForeName': 'Shoji', 'Initials': 'S', 'LastName': 'Tokunaga', 'Affiliation': 'Medical Information Center, Kyushu University Hospital, Fukuoka, Japan.'}]",Lower urinary tract symptoms,['10.1111/luts.12243'] 632,24381222,"Changes in soluble transferrin receptor and hemoglobin concentrations in Malawian mothers are associated with those values in their exclusively breastfed, HIV-exposed infants.","Infant iron status at birth is influenced by maternal iron status during pregnancy; however, there are limited data on the extent to which maternal iron status is associated with infant iron status during exclusive breastfeeding. We evaluated how maternal and infant hemoglobin and iron status [soluble transferrin receptors (TfR) and ferritin] were related during exclusive breastfeeding in HIV-infected women and their infants. The Breastfeeding, Antiretrovirals, and Nutrition Study was a randomized controlled trial in Lilongwe, Malawi, in which HIV-infected women were assigned with a 2 × 3 factorial design to a lipid-based nutrient supplement (LNS), or no LNS, and maternal, infant, or no antiretroviral drug, and followed for 24 wk. Longitudinal models were used to relate postpartum maternal hemoglobin (n = 1926) to concurrently measured infant hemoglobin, adjusting for initial infant hemoglobin values. In a subsample, change in infant iron status (hemoglobin, log ferritin, log TfR) between 2 (n = 352) or 6 wk (n = 167) and 24 wk (n = 519) was regressed on corresponding change in the maternal indicator, adjusting for 2 or 6 wk values. A 1 g/L higher maternal hemoglobin at 12, 18, and 24 wk was associated with a 0.06 g/L (P = 0.01), 0.10 g/L (P < 0.001), and 0.06 g/L (P = 0.01), respectively, higher infant hemoglobin. In the subsample, a reduction in maternal log TfR and an increase in hemoglobin from initial measurement to 24 wk were associated with the same pattern in infant values (log TfR β = -0.18 mg/L, P < 0.001; hemoglobin β = 0.13 g/L, P = 0.01). Given the observed influence of maternal and initial infant values, optimizing maternal iron status in pregnancy and postpartum is important to protect infant iron status. This trial was registered at clinicaltrials.gov as NCT00164736.",2014,"A 1 g/L higher maternal hemoglobin at 12, 18, and 24 wk was associated with a 0.06 g/L (P = 0.01), 0.10 g/L (P < 0.001), and 0.06 g/L (P = 0.01), respectively, higher infant hemoglobin.","['HIV-infected women and their infants', 'HIV-infected women', 'Malawian mothers']","['lipid-based nutrient supplement (LNS), or no LNS, and maternal, infant, or no antiretroviral drug, and followed for 24 wk']","['maternal and infant hemoglobin and iron status [soluble transferrin receptors (TfR) and ferritin', 'maternal hemoglobin', 'maternal log TfR', 'soluble transferrin receptor and hemoglobin concentrations', 'infant iron status (hemoglobin, log ferritin, log TfR', 'hemoglobin']","[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}]","[{'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0599685', 'cui_str': 'Anti-Retroviral Agents'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}]","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C1116139', 'cui_str': 'Transferrin receptor, soluble (substance)'}, {'cui': 'C0373607', 'cui_str': 'Ferritin measurement (procedure)'}, {'cui': 'C1318517', 'cui_str': 'Hemoglobin concentration, dipstick - finding'}]",,0.066039,"A 1 g/L higher maternal hemoglobin at 12, 18, and 24 wk was associated with a 0.06 g/L (P = 0.01), 0.10 g/L (P < 0.001), and 0.06 g/L (P = 0.01), respectively, higher infant hemoglobin.","[{'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Widen', 'Affiliation': 'Institute of Human Nutrition and Department of Epidemiology, Columbia University, New York, NY;'}, {'ForeName': 'Margaret E', 'Initials': 'ME', 'LastName': 'Bentley', 'Affiliation': ''}, {'ForeName': 'Dumbani', 'Initials': 'D', 'LastName': 'Kayira', 'Affiliation': ''}, {'ForeName': 'Charles S', 'Initials': 'CS', 'LastName': 'Chasela', 'Affiliation': ''}, {'ForeName': 'Eric J', 'Initials': 'EJ', 'LastName': 'Daza', 'Affiliation': ''}, {'ForeName': 'Zebrone K', 'Initials': 'ZK', 'LastName': 'Kacheche', 'Affiliation': ''}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'Tegha', 'Affiliation': ''}, {'ForeName': 'Denise J', 'Initials': 'DJ', 'LastName': 'Jamieson', 'Affiliation': ''}, {'ForeName': 'Athena P', 'Initials': 'AP', 'LastName': 'Kourtis', 'Affiliation': ''}, {'ForeName': 'Charles M', 'Initials': 'CM', 'LastName': 'van der Horst', 'Affiliation': ''}, {'ForeName': 'Lindsay H', 'Initials': 'LH', 'LastName': 'Allen', 'Affiliation': ''}, {'ForeName': 'Setareh', 'Initials': 'S', 'LastName': 'Shahab-Ferdows', 'Affiliation': ''}, {'ForeName': 'Linda S', 'Initials': 'LS', 'LastName': 'Adair', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Journal of nutrition,['10.3945/jn.113.177915'] 633,31839555,Comparison of cognitive adverse effects and efficacy of 2 pulse widths (0.5 ms and 1.5 ms) of brief pulse bilateral electroconvulsive therapy in patients with schizophrenia - A randomized single blind controlled trial.,,2020,,['patients with schizophrenia '],['2 pulse widths (0.5\xa0ms and 1.5\xa0ms) of brief pulse bilateral electroconvulsive therapy'],[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}]","[{'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0487742', 'cui_str': 'Width (qualifier value)'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0444804', 'cui_str': 'Brief pulse (qualifier value)'}, {'cui': 'C0562343', 'cui_str': 'Bilateral electroconvulsive therapy (procedure)'}]",[],,0.097881,,"[{'ForeName': 'Dhruva', 'Initials': 'D', 'LastName': 'Ithal', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bangalore, India.'}, {'ForeName': 'Shyam Sundar', 'Initials': 'SS', 'LastName': 'Arumugham', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bangalore, India.'}, {'ForeName': 'Channaveerachari Naveen', 'Initials': 'CN', 'LastName': 'Kumar', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bangalore, India.'}, {'ForeName': 'Ramesh J', 'Initials': 'RJ', 'LastName': 'Venkatapura', 'Affiliation': 'Department of Neuro-anesthesia, National Institute of Mental Health and Neuro Sciences, Bangalore, India.'}, {'ForeName': 'Jagadisha', 'Initials': 'J', 'LastName': 'Thirthalli', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bangalore, India. Electronic address: jagatth@yahoo.com.'}, {'ForeName': 'Bangalore N', 'Initials': 'BN', 'LastName': 'Gangadhar', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bangalore, India.'}]",Schizophrenia research,['10.1016/j.schres.2019.11.062'] 634,31839571,"Effects of a high protein/low carbohydrate low-calorie diet versus a standard low-calorie diet on anthropometric parameters and cardiovascular risk factors, role of polymorphism rs3123554 in the cannabinoid receptor gene type 2 (CB2R).","BACKGROUND CB2R receptors has been referred to as the peripheral cannabinoid receptor isoform, and regulate inflammatory response in various settings. CB2R gene variants could play a role on metabolic changes after weight loss with different interventions. OBJECTIVE To assess the effect of the genetic variant (rs3123554) of the CB2R gene on anthropometric and biochemical changes after weight loss secondary to a high protein/low carbohydrate diet vs. a standard low-calorie diet during 9 months. DESIGN 268 obese subjects were randomly allocated to one of two diets for 9 months, Diet HP (high protein-low carbohydrate low-calorie diet) and Diet S (standard protein low-calorie diet). Biochemical and anthropometric parameters were measured at baseline and at 3 and 9 months. RESULTS Ninety-four patients (35.1%) had genotype GG and 174 (64.9%) subjects had the following genotypes; GA (115 patients, 42.9%) or AA (59 study subjects, 18.0%) (second group). After both diets, body mass index (BMI), fat mass, weight, waist circumference, and systolic blood pressure improved in both genotypes with no difference between diets. Before and after both low-calorie diets, body weight, BMI, fat mass, and waist circumference were higher in A allele carriers than in non-A allele carriers. After both diets (HP and S), levels of glucose, insulin, HOMA-IR, triglycerides, total cholesterol, and LDL cholesterol decreased in non-A allele carriers. These parameters remained unchanged in A allele carriers. Leptin levels decreased after HP and S diets in both genotypes. CONCLUSION Non-A allele carriers showed a better response of total cholesterol, LDL cholesterol, triglycerides, glucose, HOMA-IR, and insulin levels than allele A carriers with both low-calorie diets and with the same weight loss.",2020,"A allele carriers showed a better response of total cholesterol, LDL cholesterol, triglycerides, glucose, HOMA-IR, and insulin levels than allele A carriers with both low-calorie diets and with the same weight loss.",['268 obese subjects'],"['high protein/low carbohydrate diet vs. a standard low-calorie diet', 'Diet HP (high protein-low carbohydrate low-calorie diet) and Diet S (standard protein low-calorie diet', 'high protein/low carbohydrate low-calorie diet versus a standard low-calorie diet', 'genetic variant (rs3123554']","['Biochemical and anthropometric parameters', 'body mass index (BMI), fat mass, weight, waist circumference, and systolic blood pressure', 'total cholesterol, LDL cholesterol, triglycerides, glucose, HOMA-IR, and insulin levels', 'levels of glucose, insulin, HOMA-IR, triglycerides, total cholesterol, and LDL cholesterol', 'Leptin levels', 'body weight, BMI, fat mass, and waist circumference', 'anthropometric parameters and cardiovascular risk factors']","[{'cui': 'C4517673', 'cui_str': '268'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0259836', 'cui_str': 'Diet, Carbohydrate-Restricted'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2930544', 'cui_str': 'Low-Calorie Diet'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0017399', 'cui_str': 'genetics'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}]","[{'cui': 'C0205474', 'cui_str': 'Biochemical (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}]",268.0,0.0171706,"A allele carriers showed a better response of total cholesterol, LDL cholesterol, triglycerides, glucose, HOMA-IR, and insulin levels than allele A carriers with both low-calorie diets and with the same weight loss.","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Primo', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición, Escuela de Medicina y Departamento dee Endocrinología y Nutrición, Hospital Clínico Universitario, Universidad de Valladolid, Valladolid, España.'}, {'ForeName': 'Olatz', 'Initials': 'O', 'LastName': 'Izaola', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición, Escuela de Medicina y Departamento dee Endocrinología y Nutrición, Hospital Clínico Universitario, Universidad de Valladolid, Valladolid, España.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'de Luis', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición, Escuela de Medicina y Departamento dee Endocrinología y Nutrición, Hospital Clínico Universitario, Universidad de Valladolid, Valladolid, España. Electronic address: dadluis@yahoo.es.'}]","Endocrinologia, diabetes y nutricion",['10.1016/j.endinu.2019.09.010'] 635,31329246,Effect of a Community Health Worker-Delivered Parental Education and Counseling Intervention on Anemia Cure Rates in Rural Indian Children: A Pragmatic Cluster Randomized Clinical Trial.,"Importance Iron deficiency anemia, the largest cause of anemia worldwide, adversely affects cognitive development in children. Moreover, the imperceptible childhood anemia prevalence reduction in response to anemia control measures is associated with tremendous social and economic cost. Objective To evaluate the effects of community-based parental education/counseling when combined with usual treatment on children's anemia cure rate. Design, Setting, and Participants A pragmatic cluster randomized clinical trial in children aged 12 to 59 months from 55 villages from the rural Chamrajnagar district in southern India was conducted between November 2014 and July 2015; 6-month follow-up ended in January 2016. Villages were randomly assigned to either usual treatment (n = 27) or to the intervention (n = 28). Among 1144 participating children, 534 were diagnosed as having anemia (hemoglobin levels <11g/dL and >7.9g/dL; to convert to grams per liter, multiply by 10) and constituted the study sample in this analysis. Data were analyzed between July 2016 and September 2017. Interventions Iron and folic acid (IFA), 20 mg/d, 5 times daily per week, for 5 months (usual treatment) or health worker-delivered education/counseling combined with usual treatment (intervention). Main Outcomes and Measures The primary outcome was anemia cure rate defined as hemoglobin level at or greater than 11 g/dL during follow-up. Results Of the children included in the study, the mean age was 30 months, with a slightly higher ratio of boys to girls. Of 534 children with anemia (intervention n = 303; usual treatment n = 231), 517 were reassessed after 6 months (intervention n = 298; usual treatment n = 219) while 17 were lost to follow-up (intervention n = 5 and usual treatment n = 12). Anemia cure rate was higher in children in the intervention group compared with children receiving usual treatment (55.7% [n = 166 of 298] vs 41.4% [n = 90 of 219]). The risk ratio derived through multilevel logistic regression was 1.37 (95% CI, 1.04-1.70); the model-estimated risk difference was 15.1% (95% CI, 3.9-26.3). Intervention-group children demonstrated larger mean hemoglobin increments (difference, intervention vs control: 0.25 g/dL; 95% CI, 0.07-0.44 g/dL) and improved IFA adherence (61.7%; 95% CI, 56.2-67.3 vs 48.4%; 95% CI, 41.7-55.1 consumed >75% of tablets provided). Adverse events were mild (intervention: 26.8%; 95% CI, 21.8-31.9 vs usual treatment: 21%; 95% CI, 15.6-26.4). To cure 1 child with anemia, 7 mothers needed to be counseled (number needed to treat: 7; 95% CI, 4-26). Conclusions and Relevance Parental education and counseling by a community health worker achieved perceivable gains in curing childhood anemia. Policy makers should consider this approach to enhance population level anemia control. Trial Registration ISRCTN identifier: ISRCTN68413407.",2019,"Adverse events were mild (intervention: 26.8%; 95% CI, 21.8-31.9 vs usual treatment: 21%; 95% CI, 15.6-26.4).","['children', 'children aged 12 to 59 months from 55 villages from the rural Chamrajnagar district in southern India was conducted between November 2014 and July 2015; 6-month follow-up ended in January 2016', '1144 participating children, 534 were diagnosed as having anemia (hemoglobin levels <11g/dL and ', '534 children with anemia (intervention n\u2009=\u2009303; usual treatment n\u2009=\u2009231), 517 were', 'Rural Indian Children']","['health worker-delivered education/counseling combined with usual treatment (intervention', 'reassessed after 6 months (intervention n\u2009=\u2009298; usual treatment n\u2009=\u2009219) while 17 were lost to follow-up (intervention n\u2009=\u20095 and usual treatment n\u2009=\u200912', 'community-based parental education/counseling', 'Community Health Worker-Delivered Parental Education and Counseling Intervention', 'Interventions\n\n\nIron and folic acid (IFA']","['Anemia Cure Rates', 'IFA adherence', ""children's anemia cure rate"", 'Adverse events', 'anemia cure rate defined as hemoglobin level', 'larger mean hemoglobin increments', 'Anemia cure rate', 'risk ratio derived through multilevel logistic regression']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0562518', 'cui_str': 'Village environment (environment)'}, {'cui': 'C0021201', 'cui_str': 'Republic of India'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1524069', 'cui_str': 'Indian (racial group)'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C4517648', 'cui_str': '219 (qualifier value)'}, {'cui': 'C1302313', 'cui_str': 'Lost to Follow-Up'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}]","[{'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C0206031', 'cui_str': 'Logistic Regression'}]",534.0,0.181575,"Adverse events were mild (intervention: 26.8%; 95% CI, 21.8-31.9 vs usual treatment: 21%; 95% CI, 15.6-26.4).","[{'ForeName': 'Arun S', 'Initials': 'AS', 'LastName': 'Shet', 'Affiliation': 'Department of Hematology/Medical Oncology, St Johns Medical College and Hospital, Bangalore, India.'}, {'ForeName': 'Merrick', 'Initials': 'M', 'LastName': 'Zwarenstein', 'Affiliation': 'Department of Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.'}, {'ForeName': 'Abha', 'Initials': 'A', 'LastName': 'Rao', 'Affiliation': 'Department of Hematology/Medical Oncology, St Johns Medical College and Hospital, Bangalore, India.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Jebaraj', 'Affiliation': 'Department of Hematology/Medical Oncology, St Johns Medical College and Hospital, Bangalore, India.'}, {'ForeName': 'Karthika', 'Initials': 'K', 'LastName': 'Arumugam', 'Affiliation': 'Department of Hematology/Medical Oncology, St Johns Medical College and Hospital, Bangalore, India.'}, {'ForeName': 'Salla', 'Initials': 'S', 'LastName': 'Atkins', 'Affiliation': 'Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Mascarenhas', 'Affiliation': 'MYRADA, Bangalore, India.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Klar', 'Affiliation': 'Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.'}, {'ForeName': 'Maria Rosaria', 'Initials': 'MR', 'LastName': 'Galanti', 'Affiliation': 'Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.'}]",JAMA pediatrics,['10.1001/jamapediatrics.2019.2087'] 636,31275816,Accuracy of wearable heart rate monitors in cardiac rehabilitation.,"Background To assess the accuracy of four wearable heart rate (HR) monitors in patients with established cardiovascular disease enrolled in phase II or III cardiac rehabilitation (CR). Methods Eighty adult patients enrolled in phase II or III CR were monitored during a CR session that included exercise on a treadmill and/or stationary cycle. Participants underwent HR monitoring with standard ECG limb leads, an electrocardiographic (ECG) chest strap monitor (Polar H7), and two randomly assigned wrist-worn HR monitors (Apple Watch, Fitbit Blaze, Garmin Forerunner 235, TomTom Spark Cardio), one on each wrist. HR was recorded at rest and at 3, 5, and 7 minutes of steady-state exercise on the treadmill and stationary cycle. Results Across all exercise conditions, the chest strap monitor (Polar H7) had the best agreement with ECG (r c =0.99) followed by the Apple Watch (r c =0.80), Fitbit Blaze (r c =0.78), TomTom Spark (r c =0.76) and Garmin Forerunner (r c =0.52). There was variability in accuracy under different exercise conditions. On the treadmill, only the Fitbit Blaze performed well (r c =0.76), while on the stationary cycle, Apple Watch (r c =0.89) and TomTom Spark (r c =0.85) were most accurate. Conclusions In cardiac patients, the accuracy of wearable, optically based HR monitors varies, and none of those tested was as accurate as an electrode-containing chest monitor. This observation has implications for in-home CR, as electrode-containing chest monitors should be used when accurate HR measurement is imperative.",2019,"Results Across all exercise conditions, the chest strap monitor (Polar H7) had the best agreement with ECG (r c =0.99) followed by the Apple Watch (r c =0.80), Fitbit Blaze (r c =0.78), TomTom Spark (r c =0.76) and Garmin Forerunner (r c =0.52).","['cardiac rehabilitation', 'patients with established cardiovascular disease enrolled in phase II or III cardiac rehabilitation (CR', 'Eighty adult patients enrolled in phase II or III CR']","['HR monitoring with standard ECG limb leads, an electrocardiographic (ECG) chest strap monitor (Polar H7), and two randomly assigned wrist-worn HR monitors (Apple Watch, Fitbit Blaze, Garmin Forerunner 235, TomTom Spark Cardio']","['accuracy of four wearable heart rate (HR) monitors', 'Fitbit Blaze']","[{'cui': 'C0700431', 'cui_str': 'Cardiovascular Rehabilitation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C0542504', 'cui_str': 'Standard ECG'}, {'cui': 'C0441100', 'cui_str': 'Limb lead (physical object)'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0183631', 'cui_str': 'Strap, device (physical object)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0043262', 'cui_str': 'Wrist'}, {'cui': 'C1095830', 'cui_str': 'Apple'}]","[{'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}]",80.0,0.0238733,"Results Across all exercise conditions, the chest strap monitor (Polar H7) had the best agreement with ECG (r c =0.99) followed by the Apple Watch (r c =0.80), Fitbit Blaze (r c =0.78), TomTom Spark (r c =0.76) and Garmin Forerunner (r c =0.52).","[{'ForeName': 'Muhammad', 'Initials': 'M', 'LastName': 'Etiwy', 'Affiliation': 'Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'ForeName': 'Zade', 'Initials': 'Z', 'LastName': 'Akhrass', 'Affiliation': 'Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Gillinov', 'Affiliation': 'Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'ForeName': 'Alaa', 'Initials': 'A', 'LastName': 'Alashi', 'Affiliation': 'Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Wang', 'Affiliation': 'Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Blackburn', 'Affiliation': 'Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'ForeName': 'Stephen M', 'Initials': 'SM', 'LastName': 'Gillinov', 'Affiliation': 'Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'ForeName': 'Dermot', 'Initials': 'D', 'LastName': 'Phelan', 'Affiliation': 'Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'ForeName': 'A Marc', 'Initials': 'AM', 'LastName': 'Gillinov', 'Affiliation': 'Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'ForeName': 'Penny L', 'Initials': 'PL', 'LastName': 'Houghtaling', 'Affiliation': 'Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'ForeName': 'Hoda', 'Initials': 'H', 'LastName': 'Javadikasgari', 'Affiliation': 'Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'ForeName': 'Milind Y', 'Initials': 'MY', 'LastName': 'Desai', 'Affiliation': 'Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.'}]",Cardiovascular diagnosis and therapy,['10.21037/cdt.2019.04.08'] 637,31315150,A pilot randomized controlled trial of a gratitude intervention for adolescents with Type 1 diabetes.,"AIM Cost-effective psychosocial interventions that can feasibly be implemented into busy clinical settings are needed to improve psychological and physical health outcomes in adolescents with Type 1 diabetes. We examined the efficacy of a gratitude journalling intervention to improve psychological well-being and glycaemic control in adolescents aged 10-16 years with Type 1 diabetes. METHODS Eighty adolescents were randomized to the 8-week gratitude intervention (N = 40) or standard care (N = 40). Self-reported measures of stress, quality of life, self-care, depression and gratitude were assessed at baseline and 8 weeks after baseline. Glycaemic control (HbA 1c ) was assessed at baseline and 12 weeks after baseline. A per-protocol analysis was conducted with the adolescents who completed all questionnaires (N = 60). Analysis of covariance (ANCOVA) was used to examine differences between treatment arms at follow-up adjusting for baseline scores. RESULTS There was no evidence of any between-group differences in the psychological or behavioural measures at follow-up (all P-values > 0.05). Glycaemic control slightly increased in the control group while remaining stable in the gratitude group, with a between-group difference of 6.1 mmol/mol [95% confidence interval (CI) -2.6 to 14.7; 0.6%, 95% CI -0.2 to 1.3] at 12 weeks after baseline. After adjusting for baseline HbA 1c , this between-group difference was significant (P = 0.048). CONCLUSIONS This is the first randomized trial of a gratitude journalling intervention for adolescents with Type 1 diabetes. Gratitude journalling interventions represent a clinically usable approach. If and how it helps to stabilise glycaemic control in adolescents with Type 1 diabetes remains to be confirmed in future research.",2020,There was no evidence of any between-group differences in the psychological or behavioural measures at follow-up (all P-values > 0.05).,"['Eighty adolescents', 'adolescents with Type 1 diabetes', 'adolescents aged 10-16 years with Type 1 diabetes']","['gratitude intervention', 'gratitude journalling intervention', 'gratitude intervention (N\xa0=\xa040) or standard care']","['Glycaemic control slightly', 'stress, quality of life, self-care, depression and gratitude', 'psychological or behavioural measures', 'Glycaemic control (HbA 1c ']","[{'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0750482', 'cui_str': 'Slightly (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0034380'}, {'cui': 'C0036592', 'cui_str': 'Self Care'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}]",80.0,0.0876569,There was no evidence of any between-group differences in the psychological or behavioural measures at follow-up (all P-values > 0.05).,"[{'ForeName': 'K R', 'Initials': 'KR', 'LastName': 'Schache', 'Affiliation': 'Department of Psychological Medicine, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'P L', 'Initials': 'PL', 'LastName': 'Hofman', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'A S', 'Initials': 'AS', 'LastName': 'Serlachius', 'Affiliation': 'Department of Psychological Medicine, University of Auckland, Auckland, New Zealand.'}]",Diabetic medicine : a journal of the British Diabetic Association,['10.1111/dme.14078'] 638,29875101,"Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3 -ITD-mutated, relapsed or refractory AML.","This randomized, open-label, phase 2b study (NCT01565668) evaluated the efficacy and safety of 2 dosing regimens of quizartinib monotherapy in patients with relapsed/refractory (R/R) FLT3 -internal tandem duplication (ITD)-mutated acute myeloid leukemia (AML) who previously underwent transplant or 1 second-line salvage therapy. Patients (N = 76) were randomly assigned to 30- or 60-mg/day doses (escalations to 60 or 90 mg/day, respectively, permitted for lack/loss of response) of single-agent oral quizartinib dihydrochloride. Allelic frequency of at least 10% was defined as FLT3 -ITD-mutated disease. Coprimary endpoints were composite complete remission (CRc) rates and incidence of QT interval corrected by Fridericia's formula (QTcF) of more than 480 ms (grade 2 or greater). Secondary endpoints included overall survival (OS), duration of CRc, bridge to transplant, and safety. CRc rates were 47% in both groups, similar to earlier reports with higher quizartinib doses. Incidence of QTcF above 480 ms was 11% and 17%, and QTcF above 500 ms was 5% and 3% in the 30- and 60-mg groups, respectively, which is less than earlier reports with higher doses of quizartinib. Median OS (20.9 and 27.3 weeks), duration of CRc (4.2 and 9.1 weeks), and bridge to transplant rates (32% and 42%) were higher in the 60-mg groups than in the 30-mg group. Dose escalation occurred in 61% and 14% of patients in the 30- and 60-mg groups, respectively. This high clinical activity of quizartinib at the evaluated doses is consistent with previous reports with an improved safety profile. Need to dose-escalate more than half of patients who received quizartinib 30 mg also supports further investigation of treatment with quizartinib 60 mg/day.",2018,"Dose escalation occurred in 61% and 14% of patients in the 30- and 60-mg groups, respectively.","['in FLT3 -ITD-mutated, relapsed or refractory AML', 'Patients (N = 76', 'patients with relapsed/refractory (R/R) FLT3 -internal tandem duplication (ITD)-mutated acute myeloid leukemia (AML) who previously underwent transplant or 1 second-line salvage therapy']","['single-agent oral quizartinib dihydrochloride', 'quizartinib monotherapy']","['bridge to transplant rates', ""composite complete remission (CRc) rates and incidence of QT interval corrected by Fridericia's formula (QTcF"", 'overall survival (OS), duration of CRc, bridge to transplant, and safety', 'Incidence of QTcF', 'CRc rates', 'Allelic frequency', 'Median OS', 'efficacy and safety', 'Dose escalation', 'duration of CRc']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}, {'cui': 'C0075804', 'cui_str': 'TANDEM'}, {'cui': 'C0332597', 'cui_str': 'Duplication (finding)'}, {'cui': 'C0023467', 'cui_str': 'Nonlymphoblastic Leukemia, Acute'}, {'cui': 'C0332835', 'cui_str': 'Grafts'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0085405', 'cui_str': 'Salvage Treatment'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C2980091', 'cui_str': 'AC220 compound'}]","[{'cui': 'C0456378', 'cui_str': 'Type of bridge (attribute)'}, {'cui': 'C0332835', 'cui_str': 'Grafts'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0429028', 'cui_str': 'QT interval feature'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0170127', 'cui_str': 'Calcibiotic Root Canal Sealer'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]",76.0,0.0207431,"Dose escalation occurred in 61% and 14% of patients in the 30- and 60-mg groups, respectively.","[{'ForeName': 'Jorge E', 'Initials': 'JE', 'LastName': 'Cortes', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Martin S', 'Initials': 'MS', 'LastName': 'Tallman', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Gary J', 'Initials': 'GJ', 'LastName': 'Schiller', 'Affiliation': 'David Geffen School of Medicine at UCLA, Los Angeles, CA.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Trone', 'Affiliation': 'Daiichi Sankyo Pharma Development, San Diego, CA.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Gammon', 'Affiliation': 'Daiichi Sankyo Pharma Development, San Diego, CA.'}, {'ForeName': 'Stuart L', 'Initials': 'SL', 'LastName': 'Goldberg', 'Affiliation': 'Hackensack University Medical Center, Hackensack, NJ.'}, {'ForeName': 'Alexander E', 'Initials': 'AE', 'LastName': 'Perl', 'Affiliation': 'Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Marie', 'Affiliation': 'Saint-Antoine Hospital, AH-HP-University Paris 6, Paris, France.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Martinelli', 'Affiliation': 'University of Bologna, Bologna, Italy; and.'}, {'ForeName': 'Hagop M', 'Initials': 'HM', 'LastName': 'Kantarjian', 'Affiliation': 'Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Levis', 'Affiliation': 'Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.'}]",Blood,['10.1182/blood-2018-01-821629'] 639,31943513,Improving postoperative analgesia in after mastectomy: Is now the time for an international randomized controlled trial?,,2020,,[],[],['postoperative analgesia'],[],[],"[{'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}]",,0.209462,,"[{'ForeName': 'Mansoor Syed', 'Initials': 'MS', 'LastName': 'Yousuf', 'Affiliation': 'County Durham and Darlington NHS Foundation Trust, Durham, UK.'}, {'ForeName': 'Irfan', 'Initials': 'I', 'LastName': 'Sohail', 'Affiliation': 'County Durham and Darlington NHS Foundation Trust, Durham, UK.'}, {'ForeName': 'Sumbal', 'Initials': 'S', 'LastName': 'Bhatti', 'Affiliation': 'Norwich Medical School, University of East Anglia, Norwich, UK.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Cox', 'Affiliation': 'Department of Radiology, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.'}]",The breast journal,['10.1111/tbj.13732'] 640,31326732,Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia.,"BACKGROUND Impaired illness awareness or insight into illness (IIA) is a common feature of schizophrenia that contributes to medication nonadherence and poor clinical outcomes. Neuroimaging studies suggest IIA may arise from interhemispheric imbalance in frontoparietal regions, particularly in the posterior parietal area (PPA) and the dorsolateral prefrontal cortex (dlPFC). In this pilot study, we examined the effects of transcranial direct current stimulation (tDCS) on brain regions implicated in IIA. METHODS Eleven patients with schizophrenia with IIA (≥3 PANSS G12) and 10 healthy controls were included. A crossover design was employed where all participants received single-session bi-frontal, bi-parietal, and sham stimulation in random order. For each condition, we measured (i) blood oxygen level-dependent (BOLD) response to an illness awareness task pre- and post-stimulation, (ii) regional cerebral blood-flow (rCBF) prior to and during stimulation, and (iii) changes in illness awareness. RESULTS At baseline, patients with schizophrenia showed higher BOLD-response to an illness awareness task in the left-PPA compared to healthy controls. Bi-parietal stimulation reduced the interhemispheric imbalance in the PPA compared to sham stimulation. Relatedly, bi-parietal stimulation increased rCBF beneath the anode (21% increase in the right-PPA), but not beneath the cathode (5.6% increase in the left-PPA). Bi-frontal stimulation did not induce changes in rCBF. We found no changes in illness awareness. CONCLUSION Although single-session tDCS did not improve illness awareness, this pilot study provides mechanistic justification for future investigations to determine if multi-session bi-parietal tDCS can induce sustained changes in brain activity in the PPA in association with improved illness awareness.",2019,"At baseline, patients with schizophrenia showed higher BOLD-response to an illness awareness task in the left-PPA compared to healthy controls.","['schizophrenia', 'Eleven patients with schizophrenia with IIA (≥3 PANSS G12) and 10 healthy controls were included']","['transcranial direct current stimulation', 'transcranial direct current stimulation (tDCS']","['measured (i) blood oxygen level-dependent (BOLD) response to an illness awareness task pre- and post-stimulation, (ii) regional cerebral blood-flow (rCBF) prior to and during stimulation, and (iii) changes in illness awareness', 'BOLD-response', 'rCBF', 'interhemispheric imbalance']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C0005768'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0004448', 'cui_str': 'Situational Awareness'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0428714', 'cui_str': 'Cerebral Blood Flow'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}]",,0.0292784,"At baseline, patients with schizophrenia showed higher BOLD-response to an illness awareness task in the left-PPA compared to healthy controls.","[{'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, (CAMH), University of Toronto, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Plitman', 'Affiliation': 'Cerebral Imaging Centre, Douglas Mental Health University Institute, McGill University, Montreal, Quebec, Canada; Department of Psychiatry, McGill University, Montreal, Quebec, Canada.'}, {'ForeName': 'Shinichiro', 'Initials': 'S', 'LastName': 'Nakajima', 'Affiliation': 'Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, (CAMH), University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Geriatric Mental Health Division, CAMH, University of Toronto, Toronto, Ontario, Canada; Department of Neuropsychiatry, Keio University, Tokyo, Japan.'}, {'ForeName': 'Youssef', 'Initials': 'Y', 'LastName': 'Alshehri', 'Affiliation': 'Geriatric Mental Health Division, CAMH, University of Toronto, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, CAMH, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Iwata', 'Affiliation': 'Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, (CAMH), University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Jun Ku', 'Initials': 'JK', 'LastName': 'Chung', 'Affiliation': 'Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, (CAMH), University of Toronto, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Caravaggio', 'Affiliation': 'Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, (CAMH), University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Mahesh', 'Initials': 'M', 'LastName': 'Menon', 'Affiliation': 'University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Blumberger', 'Affiliation': 'Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Geriatric Mental Health Division, CAMH, University of Toronto, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, CAMH, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Bruce G', 'Initials': 'BG', 'LastName': 'Pollock', 'Affiliation': 'Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Geriatric Mental Health Division, CAMH, University of Toronto, Toronto, Ontario, Canada; Department of Neuropsychiatry, Keio University, Tokyo, Japan.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Remington', 'Affiliation': 'Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Geriatric Mental Health Division, CAMH, University of Toronto, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, CAMH, University of Toronto, Toronto, Ontario, Canada; Schizophrenia Division, CAMH, Toronto, Ontario, Canada.'}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'De Luca', 'Affiliation': 'Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Geriatric Mental Health Division, CAMH, University of Toronto, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, CAMH, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Graff-Guerrero', 'Affiliation': 'Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, (CAMH), University of Toronto, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Geriatric Mental Health Division, CAMH, University of Toronto, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, CAMH, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Gerretsen', 'Affiliation': 'Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, (CAMH), University of Toronto, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Geriatric Mental Health Division, CAMH, University of Toronto, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, CAMH, University of Toronto, Toronto, Ontario, Canada. Electronic address: philgerretsen@yahoo.com.'}]",European psychiatry : the journal of the Association of European Psychiatrists,['10.1016/j.eurpsy.2019.06.007'] 641,31250477,'MusiMath' and 'Academic Music' - Two music-based intervention programs for fractions learning in fourth grade students.,"Music and mathematics require abstract thinking and using symbolic notations. Controversy exists regarding transfer from musical training to math achievements. The current study examined the effect of two integrated intervention programs representing holistic versus acoustic approaches, on fraction knowledge. Three classes of fourth graders attended 12 lessons on fractions: One class attended the 'MusiMath' holistic program (n = 30) focusing on rhythm within the melody. Another class attended the 'Academic Music' acoustic program (Courey et al., Educ Stud Math 81:251, 2012) (n = 25) which uses rhythm only. The third class received regular fraction lessons (comparison group, n = 22). Students in both music programs learned to write musical notes and perform rhythmic patterns through clapping and drumming as part of their fraction lessons. They worked toward adding musical notes to produce a number (fraction), and created addition/subtraction problems with musical notes. The music programs used a 4/4 time signature with whole, half, quarter and eighth notes. In the math lessons, the students learned the analogy between musical durations and 1 2 , 1 4 , 1 8 fractions, but also practiced fractions other than 1 2 , 1 4 , 1 8 . Music and math were assessed before, immediately following, and 3- and 6-months post-intervention. Pre- to post-intervention analyses indicated that only the 'MusiMath' group showed greater transfer to intervention-trained and untrained fractions than the comparison group. The 'Academic Music' group showed a trend on trained fractions. Although both music groups outperformed the comparison group 3- and 6-months post-intervention on trained fractions, only the 'MusiMath' group demonstrated greater gains in untrained fractions. Gains were more evident in trained than in untrained fractions. A video abstract of this article can be viewed at https://youtu.be/uJ_KWWDO624.",2020,"Although both music groups outperformed the comparison group 3- and 6-months post-intervention on trained fractions, only the 'MusiMath' group demonstrated greater gains in untrained fractions.","['fourth grade students', 'Three classes of fourth graders attended 12 lessons on fractions']",['regular fraction lessons'],['Music and math'],"[{'cui': 'C0205438', 'cui_str': 'Fourth (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}]","[{'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}]","[{'cui': 'C0026867', 'cui_str': 'Music'}]",,0.0207043,"Although both music groups outperformed the comparison group 3- and 6-months post-intervention on trained fractions, only the 'MusiMath' group demonstrated greater gains in untrained fractions.","[{'ForeName': 'Libby', 'Initials': 'L', 'LastName': 'Azaryahu', 'Affiliation': 'School of Education, Bar-Ilan University, Ramat Gan, Israel.'}, {'ForeName': 'Susan Joan', 'Initials': 'SJ', 'LastName': 'Courey', 'Affiliation': 'Graduate School of Education, Touro College, New York, New York.'}, {'ForeName': 'Rivka', 'Initials': 'R', 'LastName': 'Elkoshi', 'Affiliation': 'Faculty of Music Education, Levinsky College of Education, Tel Aviv, Israel.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Adi-Japha', 'Affiliation': 'School of Education, Bar-Ilan University, Ramat Gan, Israel.'}]",Developmental science,['10.1111/desc.12882'] 642,31286426,"Effect of hand hygiene intervention on the absenteeism of pre-school children in Klang Valley, Malaysia: a quasi-experimental study.","BACKGROUND Absenteeism amongst pre-school children is often due to illnesses such as hand, foot, and mouth disease, acute gastroenteritis, cold and flu, which are easily spread amongst them. This is because of weak immunity and lack of knowledge on proper hand hygiene. This quasi-experimental study assessed the efficacy of an intervention consisting of a hand hygiene education programme, along with digital tools in bringing about a change in behaviour and health conditions amongst pre-school children in Klang Valley, Malaysia. METHODS A total of 377 school children, male and female, aged 5-6 years old, participated and were assigned to either the intervention or a control group. During the 2 months intervention period, children in the test group were trained on proper hand hygiene practices and techniques with the aid of the interactive android-based tablets. The numbers of absent days of all the children were recorded for 2 months before the intervention and during the intervention. RESULTS In the test group, there was a 25% increase in the total number of absent days from the pre-intervention period to the intervention period, a much lesser increment observed as compared to that of control group in which the increase was much higher at 89%. Results showed a significant difference (P < 0·05) between the absenteeism rates for the test and control group during the intervention period. CONCLUSION These results suggest that proper education and intervention increase hand hygiene compliance, which may help decrease school absenteeism due to illness; however, a longer study duration may be necessary to evaluate the benefit further.",2020,"Results showed a significant difference (P < 0·05) between the absenteeism rates for the test and control group during the intervention period. ","['pre-school children in Klang Valley, Malaysia', 'Absenteeism amongst pre-school children', 'absenteeism of pre-school children in Klang Valley, Malaysia', '377 school children, male and female, aged 5-6\xa0years old']","['trained on proper hand hygiene practices and techniques with the aid of the interactive android-based tablets', 'hand hygiene intervention']","['absenteeism rates', 'total number of absent days']","[{'cui': 'C0424930', 'cui_str': 'Pre-school (environment)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0563004', 'cui_str': 'Valley (environment)'}, {'cui': 'C0024552', 'cui_str': 'Federation of Malaya'}, {'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C0260267', 'cui_str': 'School child (occupation)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C3494474', 'cui_str': 'Hand Hygiene'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0449435', 'cui_str': 'Aid (attribute)'}, {'cui': 'C0718532', 'cui_str': 'Android'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}]","[{'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0332197', 'cui_str': 'Absent (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]",377.0,0.0238952,"Results showed a significant difference (P < 0·05) between the absenteeism rates for the test and control group during the intervention period. ","[{'ForeName': 'Nurul Azmawati', 'Initials': 'NA', 'LastName': 'Mohamed', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia. drnurul@usim.edu.my.'}, {'ForeName': 'Mohd Dzulkhairi', 'Initials': 'MD', 'LastName': 'Mohd Rani', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Tengku Zetty Maztura', 'Initials': 'TZM', 'LastName': 'Tengku Jamaluddin', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia.'}, {'ForeName': 'Zarini', 'Initials': 'Z', 'LastName': 'Ismail', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Shalinawati', 'Initials': 'S', 'LastName': 'Ramli', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Habibah', 'Initials': 'H', 'LastName': 'Faroque', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Farisha Nur', 'Initials': 'FN', 'LastName': 'Abd Samad', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Abdul Rashid', 'Initials': 'AR', 'LastName': 'Ariffien', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Aisyah Ar Redha', 'Initials': 'AAR', 'LastName': 'Che Amir Farid', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Ilina', 'Initials': 'I', 'LastName': 'Isahak', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}]",World journal of pediatrics : WJP,['10.1007/s12519-019-00283-x'] 643,31280941,Comparison between new modified external rotation method and external rotation method for reduction of ASD.,"INTRODUCTION Dislocation of the shoulder joint is common and is mainly anterior. Several reduction methods have been described and the external reduction method (ERM) is one of the newest. We modified the ERM by making some additions in hopes to develop a less painful, quick and simple method. The aim of this study was to compare the new modified external rotation reduction method (MERM) with ERM in acute anterior shoulder dislocations (ASD). METHODS A total of 62 patients with ASD were classified randomly into 2 groups. The reduction was performed with MERM in one group and with ERM in the other group and the results were compared. Patients' pain scores, reduction time, success rate of the reduction methods, age, sex, dislocation side, dislocation time, previous dislocations history, injury mechanism, any complications, reduction time and neurovascular examination were collected. Parametric and nonparametric analyses were used to compare MERM and ERM. RESULTS The study cohort consisted of 62 patients (52 males, 10 females; mean age, 35 years; age range, 18-73 years) who were randomly assigned to treatment with the MERM (n = 32) or the ERM (n = 30). There was a statistically significant difference between the two methods in terms of time, and the MERM can be applied much faster than ERM (1.34 ± 1.41 min vs 3.05 ± 1.93 min; p < 0.001). The intra-reduction VAS pain score was not significantly in patients who were treated with MERM (85.31 ± 10.39 vs. 78.33 ± 16.54; p = 0.122). CONCLUSION MERM can be an alternate method compared to the ERM for the reduction of ASD.",2020,"There was a statistically significant difference between the two methods in terms of time, and the MERM can be applied much faster than ERM (1.34 ± 1.41 min vs 3.05 ± 1.93 min; p < 0.001).","['acute anterior shoulder dislocations (ASD', '62 patients with ASD', '62 patients (52 males, 10 females; mean age, 35\u202fyears; age range, 18-73\u202fyears']","['ERM', 'new modified external rotation reduction method (MERM) with ERM', 'new modified external rotation method and external rotation method', 'MERM']","['intra-reduction VAS pain score', 'pain scores, reduction time, success rate of the reduction methods, age, sex, dislocation side, dislocation time, previous dislocations history, injury mechanism, any complications, reduction time and neurovascular examination']","[{'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0037005', 'cui_str': 'Glenohumeral Dislocation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}]","[{'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0231462', 'cui_str': 'Lateral rotation - action (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0238395', 'cui_str': 'Male Pseudohermaphroditism'}]","[{'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0012691', 'cui_str': 'Joint Dislocations'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}]",62.0,0.020717,"There was a statistically significant difference between the two methods in terms of time, and the MERM can be applied much faster than ERM (1.34 ± 1.41 min vs 3.05 ± 1.93 min; p < 0.001).","[{'ForeName': 'Mehmet', 'Initials': 'M', 'LastName': 'Akcimen', 'Affiliation': 'Health Science University Antalya Training and Research Hospital, Department of Emergency Medicine, Antalya, Turkey.'}, {'ForeName': 'Cihan', 'Initials': 'C', 'LastName': 'Bedel', 'Affiliation': 'Health Science University Antalya Training and Research Hospital, Department of Emergency Medicine, Antalya, Turkey. Electronic address: cihanbedel@hotmail.com.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.07.001'] 644,31199180,Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.,"Objectives: To assess the effects of belimumab on disease activity across multiple organ domains in Japanese patients from the Phase 3 randomized, double-blind, North-East Asia study, BEL113750 (NCT01345253). Methods: Patients, aged ≥18 years, with American College of Rheumatology-defined systemic lupus erythematosus (SLE) and a Safety of Estrogen in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) score ≥8 at screening, on stable SLE treatment, were randomized 2:1 to receive intravenous belimumab 10 mg/kg or placebo, plus standard of care, on Days 0, 14, and 28, then 4-weekly until Week 48. Patients were assessed for SELENA-SLEDAI and British Isles Lupus Assessment Group (BILAG) organ system improvement/worsening between baseline and Week 52. Results: Sixty patients (belimumab, n  = 39; placebo, n  = 21) were enrolled in Japan. Improvement was seen in a greater proportion of belimumab patients, compared with placebo, in most SELENA-SLEDAI and BILAG domains (significant for the mucocutaneous domain). Worsening occurred in SELENA-SLEDAI hematologic and renal systems (<7% both treatments) and in a number of BILAG systems: <11% (placebo) and <8% (belimumab), although the small sample size should be noted. Conclusion: Organ system improvements were seen in more Japanese belimumab-treated than placebo-treated patients, providing further evidence supporting belimumab use in Japanese patients with SLE.",2020,"Improvement was seen in a greater proportion of belimumab patients, compared with placebo, in most SELENA-SLEDAI and BILAG domains (significant for the mucocutaneous domain).","['Japanese patients with systemic lupus erythematosus treated with', 'Japanese patients with SLE', 'Japanese patients', 'Methods: Patients, aged ≥18 years, with American College of Rheumatology-defined systemic lupus erythematosus (SLE) and a', 'Sixty patients (belimumab, n \u2009=\u200939; placebo, n \u2009=\u200921) were enrolled in Japan']","['intravenous belimumab 10\u2009mg/kg or placebo', 'belimumab', 'placebo']",['Safety of Estrogen in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI'],"[{'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0024141', 'cui_str': 'Lupus Erythematosus Disseminatus'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C1141000', 'cui_str': 'Sled, device (physical object)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0035452', 'cui_str': 'Rheumatology'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C1723401', 'cui_str': 'belimumab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C1723401', 'cui_str': 'belimumab'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3537250', 'cui_str': 'ESTROGENS'}, {'cui': 'C0409974', 'cui_str': 'Lupus erythematosus (disorder)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1141000', 'cui_str': 'Sled, device (physical object)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",60.0,0.595781,"Improvement was seen in a greater proportion of belimumab patients, compared with placebo, in most SELENA-SLEDAI and BILAG domains (significant for the mucocutaneous domain).","[{'ForeName': 'Yoshiya', 'Initials': 'Y', 'LastName': 'Tanaka', 'Affiliation': 'The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan.'}, {'ForeName': 'Damon', 'Initials': 'D', 'LastName': 'Bass', 'Affiliation': 'Immuno-Inflammation, GSK, Philadelphia, PA, USA.'}, {'ForeName': 'Myron', 'Initials': 'M', 'LastName': 'Chu', 'Affiliation': 'Immuno-Inflammation, GSK, Philadelphia, PA, USA.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Egginton', 'Affiliation': 'Biostatistics, GSK, Stevenage, UK.'}, {'ForeName': 'Beulah', 'Initials': 'B', 'LastName': 'Ji', 'Affiliation': 'R&D Clinical Development, GSK, Uxbridge, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Roth', 'Affiliation': 'Immuno-Inflammation, GSK, Philadelphia, PA, USA.'}]",Modern rheumatology,['10.1080/14397595.2019.1630897'] 645,31767518,Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.,"BACKGROUND Familial hypercholesterolemia is characterized by high levels of low-density lipoprotein cholesterol (LDL-C), and causes of familial hypercholesterolemia include apolipoprotein B (APOB) loss-of-function mutations (LOFm) and proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutations (GOFm). OBJECTIVE The aim of this study was to compare the pharmacokinetics and pharmacodynamics of alirocumab between patients with APOB LOFm vs PCSK9 GOFm. METHODS Patients (6 APOB LOFm and 17 PCSK9 GOFm carriers) with LDL-C ≥70 mg/dL on maximally tolerated lipid-lowering therapies received alirocumab 150 mg at Weeks 0, 2, 4, and 6, placebo at Week 8, alirocumab at Week 10, placebo at Weeks 12 and 14, then completed a follow-up period at Week 22. RESULTS At Week 8, mean ± standard error (SE) alirocumab concentration was lower in APOB LOFm carriers compared with PCSK9 GOFm carriers (12.12 ± 1.81 vs 16.74 ± 2.53 mg/L). APOB LOFm carriers had higher mean ± SE total PCSK9 (6.56 ± 0.73 mg/L) and lower mean ± SE free PCSK9 (0.025 ± 0.016 mg/L) at Week 8 compared with PCSK9 GOFm carriers (4.21 ± 0.35 and 0.11 ± 0.035 mg/L for total and free PCSK9, respectively). Despite this observed greater PCSK9 suppression, mean ± SE percent LDL-C reduction was lower in APOB LOFm (55.3 ± 1.0%) compared with PCSK9 GOFm carriers (73.1 ± 0.9%). Treatment-emergent adverse events occurred in 16 patients (94.1%) in the PCSK9 GOFm group and 5 patients (83.3%) in the APOB LOFm group. CONCLUSIONS Overall, PCSK9 inhibition with alirocumab results in clinically meaningful reductions in LDL-C in both APOB LOFm and PCSK9 GOFm carriers, although reductions were greater in the PCSK9 GOFm carriers. The results indicate a possible underlying contributor to hypercholesterolemia other than PCSK9 in patients with APOB LOFm. CLINICAL TRIAL REGISTRATION NCT01604824; clinicaltrials.gov.",2019,"Treatment-emergent adverse events occurred in 16 patients (94.1%) in the PCSK9 GOFm group and 5 patients (83.3%) in the APOB LOFm group. ","['patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations', 'patients with APOB LOFm vs PCSK9 GOFm', 'Patients (6 APOB LOFm and 17 PCSK9 GOFm carriers) with LDL-C ≥70', 'patients with APOB LOFm']","['placebo', 'PCSK9 GOFm', 'alirocumab', 'alirocumab at Week 10, placebo']","['PCSK9 suppression, mean\xa0±\xa0SE percent LDL-C reduction', 'SE total PCSK9', 'Treatment-emergent adverse events', 'APOB LOFm', 'mean\xa0±\xa0standard error (SE) alirocumab concentration']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0020445', 'cui_str': 'Hyperbetalipoproteinemia'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C1100660', 'cui_str': 'Proprotein Convertases'}, {'cui': 'C0038601', 'cui_str': 'Subtilisins'}, {'cui': 'C0165249', 'cui_str': 'kexin protein, S cerevisiae'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0003593', 'cui_str': 'ApoB'}, {'cui': 'C4505106', 'cui_str': 'Loss of Function Mutation'}, {'cui': 'C0560175', 'cui_str': 'Carrier State'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3491162', 'cui_str': 'alirocumab'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0221103', 'cui_str': 'Binocular vision suppression (disorder)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0003593', 'cui_str': 'ApoB'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3491162', 'cui_str': 'alirocumab'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",,0.10362,"Treatment-emergent adverse events occurred in 16 patients (94.1%) in the PCSK9 GOFm group and 5 patients (83.3%) in the APOB LOFm group. ","[{'ForeName': 'Paul N', 'Initials': 'PN', 'LastName': 'Hopkins', 'Affiliation': 'School of Medicine, University of Utah, Salt Lake City, UT, USA. Electronic address: paul.hopkins@utah.edu.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Krempf', 'Affiliation': 'CHU de Nantes - Hôpital Nord Laennec, Saint-Herblain, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Bruckert', 'Affiliation': 'Hôpital de la Pitié-Salpêtrière, Paris, France.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Donahue', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Yang', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'A Thomas', 'Initials': 'AT', 'LastName': 'DiCioccio', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}]",Journal of clinical lipidology,['10.1016/j.jacl.2019.10.007'] 646,29800584,Who is studied in de novo fear conditioning paradigms? An examination of demographic and stimulus characteristics predicting fear learning.,"A common challenge in fear conditioning studies is that a relatively large proportion of individuals fail to acquire a differential conditioned skin conductance response (SCR). Researchers have identified demographic factors associated with poorer fear learning and explored the use of different fear conditioning paradigms across various populations. However, few studies have strategically aimed to enhance acquisition by manipulating the unconditioned stimulus (UCS). In the current manuscript, we examined whether demographic factors predicted failure to condition (n = 274) and explored whether modifications to the UCS enhanced fear learning (n = 143). Results indicated that race, but not age, education, or gender, predicted failure to condition. Stepwise logistic regression demonstrated that race was the most influential of these predictors; African Americans were less likely to acquire a conditioned SCR, compared to non-African Americans. Also, use of a compound UCS (i.e., electric shock combined with a scream noise) led to nearly double the rate of acquisition of a conditioned SCR. Hence, use of a compound UCS may provide a way to reduce the number of excluded individuals in studies of fear-conditioned SCR and thereby improve the representativeness of research samples.",2018,"Stepwise logistic regression demonstrated that race was the most influential of these predictors; African Americans were less likely to acquire a conditioned SCR, compared to non-African Americans.",[],"['compound UCS (i.e., electric shock combined with a scream noise']",[],[],"[{'cui': 'C0205198', 'cui_str': 'Compound (qualifier value)'}, {'cui': 'C0013781', 'cui_str': 'Exposure to electric current, with passage of current through tissue (event)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0521008', 'cui_str': 'Screaming (finding)'}, {'cui': 'C0028263', 'cui_str': 'Noise'}]",[],,0.0318228,"Stepwise logistic regression demonstrated that race was the most influential of these predictors; African Americans were less likely to acquire a conditioned SCR, compared to non-African Americans.","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Alexandra Kredlow', 'Affiliation': 'Department of Psychological & Brain Sciences, Boston University, 648 Beacon Street, 5th Floor, Boston, MA 02215, United States. Electronic address: kredlow@bu.edu.'}, {'ForeName': 'Scott P', 'Initials': 'SP', 'LastName': 'Orr', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, East Building 120, 2nd Avenue, Charlestown, MA 02129, United States. Electronic address: scott_orr@hms.harvard.edu.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Otto', 'Affiliation': 'Department of Psychological & Brain Sciences, Boston University, 648 Beacon Street, 5th Floor, Boston, MA 02215, United States. Electronic address: mwotto@bu.edu.'}]",International journal of psychophysiology : official journal of the International Organization of Psychophysiology,['10.1016/j.ijpsycho.2018.05.008'] 647,31759938,"Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study.","BACKGROUND Lipoprotein apheresis (LA) can effectively lower lipoproteins but is an invasive procedure. OBJECTIVE The objective of this study was to evaluate whether evolocumab can reduce LA requirement in patients undergoing chronic LA. METHODS Patients on regular weekly or every-2-week LA and moderate- to high-intensity statin (if tolerated) with pre-LA low-density lipoprotein cholesterol (LDL-C) levels ≥2.6 mmol/L (100 mg/dL) to ≤4.9 mmol/L (190 mg/dL) were randomized to continue the same LA frequency, or discontinue LA and receive evolocumab 140 mg every-2-weeks subcutaneously for 6 weeks. At week 6, all patients received only open-label evolocumab for 18 weeks. The primary endpoint was LA avoidance at the end of 6 weeks based on achieving pre-LA LDL-C <2.6 mmol/L at week 4. RESULTS Thirty-nine patients (mean [SD] age 62 [10] years, 59% male, 82% with familial hypercholesterolemia) were randomized (evolocumab, n = 19; LA, n = 20). At the end of 6 weeks, more patients receiving evolocumab avoided LA than those receiving LA (84% vs 10%; treatment difference, 74% [95% CI: 45, 87]; P < .0001). Thirty patients (77%) did not require LA at 24 weeks. Evolocumab reduced pre-LA LDL-C by 50% from the baseline to week 4 compared with a 3% increase in the LA arm. Pre-LA LDL-C <1.8 mmol/L (70 mg/dL) was achieved by 10 patients (53%) receiving evolocumab and none receiving LA (week 4). Safety was comparable between arms. CONCLUSION Evolocumab treatment significantly reduced LA requirement in patients undergoing chronic LA. In addition, >50% of patients achieved LDL-C <1.8 mmol/L on evolocumab alone, demonstrating that in patients with pre-LA LDL-C ≤4.9 mmol/L, evolocumab may replace LA.",2019,Evolocumab reduced pre-LA LDL-C by 50% from the baseline to week 4 compared with a 3% increase in the LA arm.,"['Thirty-nine patients (mean [SD] age 62 [10] years, 59% male, 82% with familial hypercholesterolemia', 'patients undergoing chronic LA', 'patients undergoing chronic LA.\nMETHODS\n\n\nPatients on regular weekly or every-2-week LA and moderate- to high-intensity statin (if tolerated) with pre-LA low-density lipoprotein cholesterol (LDL-C) levels']","['discontinue LA and receive evolocumab 140\xa0mg every-2-weeks subcutaneously for 6\xa0weeks', 'Lipoprotein apheresis (LA', 'Evolocumab', 'evolocumab avoided LA', 'Pre-LA LDL-C', 'evolocumab']","['Safety', 'LA requirement', 'LA avoidance', 'lipoprotein apheresis requirement and lipid levels', 'Evolocumab reduced pre-LA LDL-C']","[{'cui': 'C3816447', 'cui_str': '39 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0020445', 'cui_str': 'Hyperbetalipoproteinemia'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]","[{'cui': 'C1706472', 'cui_str': 'Discontinue - dosing instruction imperative'}, {'cui': 'C3529352', 'cui_str': 'evolocumab'}, {'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0005791', 'cui_str': 'Pheresis'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0005791', 'cui_str': 'Pheresis'}, {'cui': 'C0428460', 'cui_str': 'Finding of lipid level (finding)'}, {'cui': 'C3529352', 'cui_str': 'evolocumab'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}]",39.0,0.0856299,Evolocumab reduced pre-LA LDL-C by 50% from the baseline to week 4 compared with a 3% increase in the LA arm.,"[{'ForeName': 'Seth J', 'Initials': 'SJ', 'LastName': 'Baum', 'Affiliation': 'Preventive Cardiology, Boca Raton, FL, USA. Electronic address: sjbaum@fpim.org.'}, {'ForeName': 'Tiziana', 'Initials': 'T', 'LastName': 'Sampietro', 'Affiliation': 'Lipoapheresis Unit, Fondazione CNR Toscana Gabriele Monasterio, Pisa, Italy.'}, {'ForeName': 'Dev', 'Initials': 'D', 'LastName': 'Datta', 'Affiliation': 'Lipid Unit, University Hospital Llandough, Penarth, Cardiff, United Kingdom.'}, {'ForeName': 'Patrick M', 'Initials': 'PM', 'LastName': 'Moriarty', 'Affiliation': 'Division of Clinical Pharmacology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Beat', 'Initials': 'B', 'LastName': 'Knusel', 'Affiliation': 'Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA.'}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Schneider', 'Affiliation': 'Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA.'}, {'ForeName': 'Ransi', 'Initials': 'R', 'LastName': 'Somaratne', 'Affiliation': 'Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Kurtz', 'Affiliation': 'Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Hohenstein', 'Affiliation': 'Nephrological Center Villingen-Schwenningen, Villingen-Schwenningen, Germany; Extracorporeal Treatment and Lipoprotein Apheresis Center, Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universitaet, Dresden, Germany.'}]",Journal of clinical lipidology,['10.1016/j.jacl.2019.10.003'] 648,31787586,National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.,"Representatives from the National Lipid Association (NLA) participated in the development of the 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol, which reaffirmed that lifestyle changes and statin treatment are therapeutic cornerstones for atherosclerotic cardiovascular disease (ASCVD) risk reduction. It also updated prior recommendations to incorporate newer data demonstrating ASCVD risk reduction with ezetimibe and proprotein convertase subtilisin kexin type 9 inhibitors as adjuncts to statin therapy for patients at high and very-high ASCVD risk. The 2018 Guideline was finalized shortly before full results were available from a randomized, placebo-controlled cardiovascular outcomes trial [Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT)] that examined the effects of icosapent ethyl (IPE) 4 g/d on major adverse cardiovascular events in selected high- or very high-risk, statin-treated patients with elevated triglycerides. The primary outcome variable of first major adverse cardiovascular event (cardiovascular death, myocardial infarction, stroke, coronary revascularization and hospitalization for unstable angina) was reduced by 25% (95% confidence interval 17%-32%, P < .001). REDUCE-IT served as the primary basis for the NLA's review of evidence for the use of IPE for ASCVD risk reduction. Based on this review, the NLA position is that for patients aged ≥45 years with clinical ASCVD, or aged ≥50 years with diabetes mellitus requiring medication plus ≥1 additional risk factor, with fasting triglycerides 135 to 499 mg/dL on high-intensity or maximally tolerated statin therapy (±ezetimibe), treatment with IPE is recommended for ASCVD risk reduction (evidence rating: class I; evidence level: B-R).",2019,IT served as the primary basis for the NLA's review of evidence for the use of IPE for ASCVD risk reduction.,"['patients at high and very-high ASCVD risk', 'statin-treated patients with elevated triglycerides and high or very-high ASCVD risk', 'patients aged ≥45\xa0years with clinical ASCVD, or aged ≥50\xa0years with diabetes mellitus requiring medication plus ≥1 additional risk factor, with fasting triglycerides 135 to 499\xa0mg/dL on high-intensity or maximally tolerated statin therapy (±ezetimibe), treatment with IPE is recommended for ASCVD risk reduction (evidence rating: class']","['placebo', 'icosapent ethyl (IPE) 4 g']","['first major adverse cardiovascular event (cardiovascular death, myocardial infarction, stroke, coronary revascularization and hospitalization for unstable angina']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0442804', 'cui_str': 'Very high (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1278454', 'cui_str': 'Statin prophylaxis'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0058978', 'cui_str': 'icosapent ethyl'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0002965', 'cui_str': 'Angina at Rest'}]",2018.0,0.0487982,IT served as the primary basis for the NLA's review of evidence for the use of IPE for ASCVD risk reduction.,"[{'ForeName': 'Carl E', 'Initials': 'CE', 'LastName': 'Orringer', 'Affiliation': 'Miller School of Medicine, Cardiovascular Division, University of Miami, Miami, FL, USA. Electronic address: ceo20@med.miami.edu.'}, {'ForeName': 'Terry A', 'Initials': 'TA', 'LastName': 'Jacobson', 'Affiliation': 'Department of Medicine, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Maki', 'Affiliation': 'School of Public Health, Department of Applied Health Science, Indiana University, Bloomington, IN, USA; Midwest Biomedical Research, Center for Metabolic and Cardiovascular Health, Addison, IL, USA.'}]",Journal of clinical lipidology,['10.1016/j.jacl.2019.10.014'] 649,31242506,"Effectiveness of two guided self-administered interventions for psychological distress among women with infertility: a three-armed, randomized controlled trial.","STUDY QUESTION What is the effect of two guided self-administered interventions on psychological distress in women undergoing IVF or ICSI? SUMMARY ANSWER A brief mindfulness intervention significantly reduced depression and improved sleep quality, while the gratitude journal intervention showed no significant effect on any outcome variables. WHAT IS KNOWN ALREADY Mindfulness and gratitude journal interventions have been found to be beneficial in reducing negative affect and improving well-being. However, there are very few mental health professionals who implement such interventions in low- and middle-income countries. Therefore, two guided self-administered interventions for women with infertility were designed to help them cope with their psychological distress. STUDY DESIGN, SIZE, DURATION A three-armed, randomized controlled trial was designed to evaluate the mindfulness and gratitude journal interventions for women undergoing IVF/ICSI. Between May 2016 and November 2017, at the reproductive center in a public hospital, 234 women were randomly assigned to the brief mindfulness group (BMG, n = 78), gratitude journal group (GJG, n = 78) or control group (CG, n = 78). The inclusion criteria were being a woman undergoing her first cycle of IVF, having at least junior middle school education and having no biological or adopted children. PARTICIPANTS/MATERIALS, SETTING, METHODS Female infertility patients (n = 346) were approached, and 112 did not meet the inclusion criteria. All three randomized groups completed questionnaires on the day of down-regulation (T1), the day before embryo(s) transfer (T2), and 3 days before the pregnancy test (T3). The BMG completed four sessions and listened to a 20-minute audio daily, including guided mindfulness breathing and body scan. The GJG completed four sessions and wrote three gratitude journals daily. The CG received routine care. A generalized estimating equation was used in an intention-to-treat analysis. The primary outcome was depression. Secondary outcomes were anxiety, sleep quality, infertility-related stress, mindfulness and gratitude. MAIN RESULTS AND THE ROLE OF CHANCE Participants of the BMG showed decreased depression (mean difference (MD) = -1.69, [-3.01, -0.37], d = 0.44) and improved sleep quality (MD = -1.24, [-1.95, -0.39], d = 0.43) compared to the CG, but the effect was not significant for anxiety, Fertility Problem Inventory totals, mindfulness, gratitude scores or pregnancy rates. The BMG showed a significant reduction in depression and improvement in sleep quality between T1 and T2, a continuous significant reduction between T1 and T3 and no reduction between T2 and T3. There were no significant effects on any of the variables for the GJG. LIMITATIONS, REASONS FOR CAUTION The inclusion criteria may result in bias because some participants with low education were excluded and only women with infertility were included. A low compliance rate occurred in the gratitude journals group. Moreover, men were not included in this study. Further research should consider including spouses of the target population. WIDER IMPLICATIONS OF THE FINDINGS The brief mindfulness intervention was beneficial in decreasing depression and improving sleep quality. Implementation of guided self-administered mindfulness could make the psychological counseling service more accessible for patients with infertility in resource-poor settings. The efficiency and feasibility of the gratitude journal intervention needs to be investigated further. STUDY FUNDING/COMPETING INTEREST(S) This study was funded by the National Social Science Foundation (17BSH054). The authors have no conflicts of interest. TRIAL REGISTRATION NUMBER ChiCTR-IOR-16008452. TRIAL REGISTRATION DATE 9 May 2016. DATE OF FIRST PATIENT’S ENROLMENT 15 May 2016.",2019,"The BMG showed a significant reduction in depression and improvement in sleep quality between T1 and T2, a continuous significant reduction between T1 and T3 and no reduction between T2 and T3.","['Female infertility patients (n\u2009=\u2009346) were approached, and 112 did not meet the inclusion criteria', 'patients with infertility in resource-poor settings', 'participants with low education were excluded and only women with infertility were included', 'Between May 2016 and November 2017, at the reproductive center in a public hospital, 234 women', 'women with infertility', 'woman undergoing her first cycle of IVF, having at least junior middle school education and having no biological or adopted children', 'women undergoing IVF/ICSI', 'women undergoing IVF or ICSI']","['guided mindfulness breathing and body scan', 'guided self-administered interventions', 'mindfulness intervention', 'brief mindfulness group (BMG, n\u2009=\u200978), gratitude journal group (GJG, n\u2009=\u200978) or control group (CG']","['compliance rate', 'psychological distress', 'anxiety, sleep quality, infertility-related stress, mindfulness and gratitude', 'depression', 'anxiety, Fertility Problem Inventory totals, mindfulness, gratitude scores or pregnancy rates', 'depression and improving sleep quality', 'sleep quality', 'depression and improved sleep quality']","[{'cui': 'C0021361', 'cui_str': 'Female infertility (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0021359', 'cui_str': 'Infertility'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0020022', 'cui_str': 'Hospitals, Public'}, {'cui': 'C0557797', 'cui_str': 'Middle school (environment)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0337541', 'cui_str': 'Adopted child (person)'}, {'cui': 'C0015915', 'cui_str': 'Test-Tube Fertilization'}, {'cui': 'C0455164', 'cui_str': 'ICSI'}]","[{'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}, {'cui': 'C0441633'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0021359', 'cui_str': 'Infertility'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0278048', 'cui_str': 'Fertility problem (finding)'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rate'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}]",234.0,0.130669,"The BMG showed a significant reduction in depression and improvement in sleep quality between T1 and T2, a continuous significant reduction between T1 and T3 and no reduction between T2 and T3.","[{'ForeName': 'Cai-Feng', 'Initials': 'CF', 'LastName': 'Bai', 'Affiliation': 'School of Nursing, Shandong University, No. 44 Wenhua Xi Road, Jinan 250012, China.'}, {'ForeName': 'Nai-Xue', 'Initials': 'NX', 'LastName': 'Cui', 'Affiliation': 'School of Nursing, Shandong University, No. 44 Wenhua Xi Road, Jinan 250012, China.'}, {'ForeName': 'Xian', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': 'Reproductive Medicine Center, General Hospital of Ningxia Medical University, 804 Sheng Li Street, Yinchuan 750004, China.'}, {'ForeName': 'Guang-Li', 'Initials': 'GL', 'LastName': 'Mi', 'Affiliation': 'Nursing Department, General Hospital of Ningxia Medical University, 804 Sheng Li Street, Yinchuan 750004, China.'}, {'ForeName': 'Ji-Wei', 'Initials': 'JW', 'LastName': 'Sun', 'Affiliation': 'School of Nursing, Shandong University, No. 44 Wenhua Xi Road, Jinan 250012, China.'}, {'ForeName': 'Di', 'Initials': 'D', 'LastName': 'Shao', 'Affiliation': 'School of Health Care Management, Shandong University, No. 44 Wenhua Xi Road, Jinan 250012, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'School of Nursing, Shandong University, No. 44 Wenhua Xi Road, Jinan 250012, China.'}, {'ForeName': 'Yin-Zhi', 'Initials': 'YZ', 'LastName': 'Jiang', 'Affiliation': 'Reproductive Medicine Center, General Hospital of Ningxia Medical University, 804 Sheng Li Street, Yinchuan 750004, China.'}, {'ForeName': 'Qian-Qian', 'Initials': 'QQ', 'LastName': 'Yang', 'Affiliation': 'School of Nursing, Shandong University, No. 44 Wenhua Xi Road, Jinan 250012, China.'}, {'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'School of Nursing, Shandong University, No. 44 Wenhua Xi Road, Jinan 250012, China.'}, {'ForeName': 'Feng-Lin', 'Initials': 'FL', 'LastName': 'Cao', 'Affiliation': 'School of Nursing, Shandong University, No. 44 Wenhua Xi Road, Jinan 250012, China.'}]","Human reproduction (Oxford, England)",['10.1093/humrep/dez066'] 650,31231758,A Single Dose of Dietary Nitrate Increases Maximal Knee Extensor Angular Velocity and Power in Healthy Older Men and Women.,"BACKGROUND Aging results in reductions in maximal muscular strength, speed, and power, which often lead to functional limitations highly predictive of disability, institutionalization, and mortality in elderly adults. This may be partially due to reduced nitric oxide (NO) bioavailability. We, therefore, hypothesized that dietary nitrate (NO3-), a source of NO via the NO3- → nitrite (NO2-) → NO enterosalivary pathway, could increase muscle contractile function in older subjects. METHODS Twelve healthy older (age 71 ± 5 years) men and women were studied using a randomized, double-blind, placebo-controlled, crossover design. After fasting overnight, subjects were tested 2 hours after ingesting beetroot juice containing or devoid of 13.4 ± 1.6 mmol NO3-. Plasma NO3- and NO2- and breath NO were measured periodically, and muscle function was determined using isokinetic dynamometry. RESULTS N O 3 - ingestion increased (p < .001) plasma NO3-, plasma NO2-, and breath NO by 1,051% ± 433%, 138% ± 149%, and 111% ± 115%, respectively. Maximal velocity of knee extension increased (p < .01) by 10.9% ± 12.1%. Maximal knee extensor power increased (p < .05) by 4.4% ± 7.8%. CONCLUSIONS Acute dietary NO3- intake improves maximal knee extensor angular velocity and power in older individuals. These findings may have important implications for this population, in whom diminished muscle function can lead to functional limitations, dependence, and even premature death.",2020,"RESULTS NO3- ingestion increased (P<0.001) plasma NO3-, plasma NO2 , and","['healthy older men and women', 'y) men and women', 'older subjects', 'Twelve healthy older (age 71±5', 'older individuals']","['dietary nitrate', 'dietary nitrate (NO3', 'Acute dietary NO3- intake', 'placebo']","['Plasma NO3- and NO2 and breath NO', 'maximal knee extensor angular velocity and power', 'Maximal knee extensor power', 'maximal knee extensor angular velocity', 'NO3- ingestion increased (P<0.001) plasma NO3-, plasma NO2 , and', 'nitric oxide (NO) bioavailability', 'Maximal velocity of knee extension']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0028125', 'cui_str': 'Nitrates'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0225386', 'cui_str': 'Breath (substance)'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0205143', 'cui_str': 'Angular (qualifier value)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}]",12.0,0.0826662,"RESULTS NO3- ingestion increased (P<0.001) plasma NO3-, plasma NO2 , and","[{'ForeName': 'Andrew R', 'Initials': 'AR', 'LastName': 'Coggan', 'Affiliation': 'Department of Kinesiology, Indiana University-Purdue University Indianapolis.'}, {'ForeName': 'Richard L', 'Initials': 'RL', 'LastName': 'Hoffman', 'Affiliation': 'Department of Kinesiology, Indiana University-Purdue University Indianapolis.'}, {'ForeName': 'Derrick A', 'Initials': 'DA', 'LastName': 'Gray', 'Affiliation': 'Department of Kinesiology, Indiana University-Purdue University Indianapolis.'}, {'ForeName': 'Ranjani N', 'Initials': 'RN', 'LastName': 'Moorthi', 'Affiliation': 'Department of Internal Medicine, Indiana University-Purdue University Indianapolis.'}, {'ForeName': 'Deepak P', 'Initials': 'DP', 'LastName': 'Thomas', 'Affiliation': 'Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.'}, {'ForeName': 'Joshua L', 'Initials': 'JL', 'LastName': 'Leibowitz', 'Affiliation': 'Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.'}, {'ForeName': 'Dakkota', 'Initials': 'D', 'LastName': 'Thies', 'Affiliation': 'Department of Radiology, Washington University School of Medicine, St. Louis, Missouri.'}, {'ForeName': 'Linda R', 'Initials': 'LR', 'LastName': 'Peterson', 'Affiliation': 'Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.'}]","The journals of gerontology. Series A, Biological sciences and medical sciences",['10.1093/gerona/glz156'] 651,31252090,"Moderators of Mindfulness Meditation, Cognitive Therapy, and Mindfulness-Based Cognitive Therapy for Chronic Low Back Pain: A Test of the Limit, Activate, and Enhance Model.","This study examined psychosocial pain treatment moderation in a secondary analysis of a trial that compared cognitive therapy (CT), mindfulness-meditation (MM), and mindfulness-based cognitive therapy (MBCT) for chronic low back pain (CLBP). The Limit, Activate, and Enhance (LA&E) model of moderation provided a framework for testing a priori hypotheses. Adult participants (N = 69) with CLBP completed a pretreatment assessment of hypothesized moderators: pain catastrophizing, brain state as assessed by electroencephalogram, mindful observing, and nonreactivity. Outcomes were pain interference, characteristic pain intensity, physical function, and depression, assessed at pre- and post-treatment. Moderation analyses found significant interaction effects, specifically: 1) higher and lower baseline pain catastrophizing was associated with greater improvement in pain intensity in MM and MBCT, respectively; 2) higher baseline theta power was associated with greater improvement in depression in MBCT and interfered with response to CT; 3) lower baseline nonreactivity was associated with greater improvement in physical function in MM while higher nonreactivity was associated with greater improvement in MBCT. The findings support the possibility that different patients are more or less likely to benefit from various treatments. Theory-driven moderation research has the capacity to inform the development of patient-treatment matching algorithms to optimize outcome. PERSPECTIVE: This study presents preliminary findings from theory-driven tests of the moderators of mindfulness meditation, cognitive therapy, and mindfulness-based cognitive therapy for chronic low back pain. The results of such analyses may inform the understanding of for whom various evidence-based psychosocial pain treatments may engender the most meaningful benefits.",2020,"Moderation analyses found significant interaction effects, specifically: (1) higher and lower baseline pain catastrophizing was associated with greater improvement in pain intensity in MM and MBCT, respectively; (2) higher baseline theta power was associated with greater improvement in depression in MBCT and interfered with response to CT; (3) lower baseline non-reactivity was associated with greater improvement in physical function in MM while higher non-reactivity was associated with greater improvement in MBCT.","['chronic low back pain (CLBP', 'Adult participants (N=69) with CLBP completed a pre-treatment assessment of hypothesized moderators: pain catastrophizing, brain state as assessed by electroencephalogram, mindful observing, and non-reactivity', 'chronic low back pain']","['cognitive therapy (CT), mindfulness-meditation (MM), and mindfulness-based cognitive therapy (MBCT', 'mindfulness meditation, cognitive therapy and mindfulness-based cognitive therapy', 'mindfulness meditation, cognitive therapy, and mindfulness-based cognitive therapy']","['physical function', 'MBCT', 'pain interference, characteristic pain intensity, physical function, and depression, assessed at pre- and post-treatment', 'depression in MBCT', 'pain intensity']","[{'cui': 'C0457949', 'cui_str': 'Chronic low back pain (finding)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C1527380', 'cui_str': 'Electroencephalogram'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0150277'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",69.0,0.0330779,"Moderation analyses found significant interaction effects, specifically: (1) higher and lower baseline pain catastrophizing was associated with greater improvement in pain intensity in MM and MBCT, respectively; (2) higher baseline theta power was associated with greater improvement in depression in MBCT and interfered with response to CT; (3) lower baseline non-reactivity was associated with greater improvement in physical function in MM while higher non-reactivity was associated with greater improvement in MBCT.","[{'ForeName': 'Melissa A', 'Initials': 'MA', 'LastName': 'Day', 'Affiliation': 'School of Psychology, University of Queensland, Brisbane, Queensland, Australia. Electronic address: m.day@uq.edu.au.'}, {'ForeName': 'Beverly E', 'Initials': 'BE', 'LastName': 'Thorn', 'Affiliation': 'Department of Psychology, University of Alabama, Tuscaloosa, Alabama.'}, {'ForeName': 'Dawn M', 'Initials': 'DM', 'LastName': 'Ehde', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington, Seattle, Washington.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Burns', 'Affiliation': 'Department of Behavioral Sciences, Rush University Medical Center, Chicago, Illinois.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Barnier', 'Affiliation': 'Department of Cognitive Science, Macquarie University, Sydney, New South Wales, Australia.'}, {'ForeName': 'Jason B', 'Initials': 'JB', 'LastName': 'Mattingley', 'Affiliation': 'School of Psychology, University of Queensland, Brisbane, Queensland, Australia; Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Matthews', 'Affiliation': 'School of Psychology, University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Mark P', 'Initials': 'MP', 'LastName': 'Jensen', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington, Seattle, Washington.'}]",The journal of pain : official journal of the American Pain Society,['10.1016/j.jpain.2019.06.006'] 652,31264055,Pilot randomized controlled trial of exercise training for older veterans with PTSD.,"Exercise training positively impacts mental health, yet remains untested in older adults with posttraumatic stress disorder (PTSD). We conducted a randomized controlled pilot trial to test the feasibility and acceptability of exercise training in older veterans with PTSD. Fifty-four veterans ≥ 60 years, with a DSM-V diagnosis of PTSD, were randomized to supervised exercise (n = 36) or wait-list (WL; n = 18). Primary outcomes included recruitment rates, attendance, satisfaction, and retention. Secondary outcomes included changes in PTSD symptoms, depression, health-related quality of life, and sleep quality; assessed at baseline and 12 weeks. There were no adverse events. Attrition was minimal (14%), and adherence to the exercise intervention was high (82%). Clinically significant improvements in PTSD and related conditions were observed following exercise (Cohen's d = 0.36-0.81). Exercise training is safe and acceptable in older adults with PTSD, may improve PTSD symptoms, and broadly impacts PTSD-related conditions. Future definitive trials are warranted.",2020,Clinically significant improvements in PTSD and related conditions were observed following exercise (Cohen's d = 0.36-0.81).,"['60\xa0years, with a DSM-V diagnosis of PTSD', 'Fifty-four veterans ≥', 'older veterans with PTSD', 'older adults with PTSD', 'older adults with posttraumatic stress disorder (PTSD']","['exercise training', 'supervised exercise', 'Exercise training']","['PTSD and related conditions', 'recruitment rates, attendance, satisfaction, and retention', 'Attrition', 'changes in PTSD symptoms, depression, health-related quality of life, and sleep quality']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C4517807', 'cui_str': 'Fifty-four'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0034380'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}]",,0.0384691,Clinically significant improvements in PTSD and related conditions were observed following exercise (Cohen's d = 0.36-0.81).,"[{'ForeName': 'Katherine S', 'Initials': 'KS', 'LastName': 'Hall', 'Affiliation': 'Geriatric Research, Education, and Clinical Center, VA Durham Healthcare System, 508 Fulton St., Durham, NC, 27705, USA. katherine.hall@duke.edu.'}, {'ForeName': 'Miriam C', 'Initials': 'MC', 'LastName': 'Morey', 'Affiliation': 'Geriatric Research, Education, and Clinical Center, VA Durham Healthcare System, 508 Fulton St., Durham, NC, 27705, USA.'}, {'ForeName': 'Hayden B', 'Initials': 'HB', 'LastName': 'Bosworth', 'Affiliation': 'Department of Medicine, Duke University, 3600 Duke Medicine Circle, Durham, NC, 27710, USA.'}, {'ForeName': 'Jean C', 'Initials': 'JC', 'LastName': 'Beckham', 'Affiliation': 'Mental Illness Research, Education, and Clinical Center, VA Durham Healthcare System, 508 Fulton St., Durham, NC, 27705, USA.'}, {'ForeName': 'Michelle M', 'Initials': 'MM', 'LastName': 'Pebole', 'Affiliation': 'Geriatric Research, Education, and Clinical Center, VA Durham Healthcare System, 508 Fulton St., Durham, NC, 27705, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Sloane', 'Affiliation': 'Geriatric Research, Education, and Clinical Center, VA Durham Healthcare System, 508 Fulton St., Durham, NC, 27705, USA.'}, {'ForeName': 'Carl F', 'Initials': 'CF', 'LastName': 'Pieper', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Duke University, 3600 Duke Medicine Circle, Durham, NC, 27710, USA.'}]",Journal of behavioral medicine,['10.1007/s10865-019-00073-w'] 653,31264269,The influence of orthokeratology compression factor on ocular higher-order aberrations.,"BACKGROUND To investigate the influence of compression factor upon changes in ocular higher-order aberrations (HOAs) in young myopic children undergoing orthokeratology treatment. METHODS Subjects aged between six and < 11 years, with low myopia (0.50-4.00 D inclusive), low astigmatism (≤ 1.25 D), and anisometropia (≤ 1.00 D), were randomly assigned to wear orthokeratology lenses of different compression factors in each eye (one eye 0.75 D and the fellow eye 1.75 D). HOAs were measured weekly over one month of lens wear. Wavefront analysis was conducted over a 5-mm pupil using a sixth order Zernike polynomial expansion. Linear mixed models were used to examine the individual Zernike co-efficients and specific root-mean-square (RMS) error (spherical, comatic, total HOAs) metrics and their changes between the two eyes during the study period. RESULTS Twenty-eight myopic (mean manifest spherical equivalent refraction: -2.10 ± 0.58 D) children (median [range] age: 9.3 [7.8-11.0] years) were analysed. Significant interocular differences in HOAs at baseline were observed for Z 6 - 6 and Z 6 - 4 only (both p < 0.05). During the lens wear period, eyes fitted with the increased compression factor showed greater changes in primary spherical aberration ( Z 4 0 , p = 0.04) and RMS values for spherical and total HOAs (both p < 0.01). Considering data from both eyes together, after adjusting for the paired nature of the data, some other Zernike terms ( Z 3 1 and Z 6 0 , both p < 0.01) and the RMS value of comatic aberrations (p < 0.001) significantly increased after one month of orthokeratology treatment. The increase in primary spherical aberration ( Z 4 0 ) was positively correlated with the reduction in spherical equivalent refractive error, but only in eyes fitted with the increased compression factor (r = 0.69, p < 0.001). CONCLUSIONS Increasing the orthokeratology compression factor by 1.00 D significantly altered some HOAs, particularly spherical aberration. Given the association between positive spherical aberration and eye growth in children, further research investigating the influence of orthokeratology compression factor on axial eye growth is warranted.",2020,"The increase in primary spherical aberration ( Z 4 0 ) was positively correlated with the reduction in spherical equivalent refractive error, but only in eyes fitted with the increased compression factor (r = 0.69, p < 0.001). ","['Subjects aged between six and < 11\u2009years, with low myopia (0.50-4.00 D inclusive), low astigmatism (≤ 1.25 D), and anisometropia (≤ 1.00 D', 'young myopic children undergoing orthokeratology treatment', 'children (median [range] age: 9.3 [7.8-11.0] years) were analysed', 'Twenty-eight myopic (mean manifest spherical equivalent refraction: -2.10\u2009±\u20090.58 D']",['orthokeratology compression factor'],"['HOAs', 'RMS value of comatic aberrations', 'individual Zernike co-efficients and specific root-mean-square (RMS) error (spherical, comatic, total HOAs) metrics', 'orthokeratology compression factor', 'compression factor', 'primary spherical aberration', 'RMS values for spherical and total HOAs']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0027092', 'cui_str': 'Nearsightedness'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0004106', 'cui_str': 'Astigmatism'}, {'cui': 'C4517497', 'cui_str': '1.25 (qualifier value)'}, {'cui': 'C0003081', 'cui_str': 'Anisometropia'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1533088', 'cui_str': 'Orthokeratology'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205319', 'cui_str': 'Manifest (qualifier value)'}, {'cui': 'C0332501', 'cui_str': 'Spherical shape (qualifier value)'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0430943', 'cui_str': 'Refraction'}, {'cui': 'C4517463', 'cui_str': '0.58'}]","[{'cui': 'C1533088', 'cui_str': 'Orthokeratology'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}]","[{'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0442799', 'cui_str': 'Efficient (qualifier value)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0563017', 'cui_str': 'Anal penetration using finger (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205120', 'cui_str': 'Square (qualifier value)'}, {'cui': 'C0332501', 'cui_str': 'Spherical shape (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0699680', 'cui_str': 'Metric'}, {'cui': 'C1533088', 'cui_str': 'Orthokeratology'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}]",,0.0196033,"The increase in primary spherical aberration ( Z 4 0 ) was positively correlated with the reduction in spherical equivalent refractive error, but only in eyes fitted with the increased compression factor (r = 0.69, p < 0.001). ","[{'ForeName': 'Jason K', 'Initials': 'JK', 'LastName': 'Lau', 'Affiliation': 'Centre for Myopia Research, School of Optometry, The Hong Kong Polytechnic University, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Vincent', 'Affiliation': 'Contact Lens and Visual Optics Laboratory, School of Optometry and Visual Science, Queensland University of Technology, Brisbane, Queensland, Australia.'}, {'ForeName': 'Sin-Wan', 'Initials': 'SW', 'LastName': 'Cheung', 'Affiliation': 'Centre for Myopia Research, School of Optometry, The Hong Kong Polytechnic University, Hong Kong Special Administrative Region, China.'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Cho', 'Affiliation': 'Centre for Myopia Research, School of Optometry, The Hong Kong Polytechnic University, Hong Kong Special Administrative Region, China.'}]",Clinical & experimental optometry,['10.1111/cxo.12933'] 654,31248731,The effect of multimedia-based nutrition education on parents' knowledge and body weight change in leukemia children.,"OBJECTIVES The present study aimed to identify the effect of multimedia-based education targeting the parents of children with leukemia on their knowledge about leukemia and on body weight changes in their children. METHODS A quasi-experimental design with non-equivalent pre- and post-test groups was used in this study. A total of 28 parents of children with leukemia were recruited using a consecutive sampling method and assigned into the intervention and control groups (n=14 each). Parents in the intervention group were given a 10-15-min multimedia video to watch before their children's chemotherapy sessions. RESULTS We found a significant improvement in parents' knowledge level after the multimedia-based education (p=0.001). However, there was no significant difference in the weight changes of the children in the intervention and control groups (p=1.00). CONCLUSIONS Multimedia-based education is associated with an increased knowledge level for the parents of children with leukemia.",2019,We found a significant improvement in parents' knowledge level after the multimedia-based education (p=0.001).,"['leukemia children', '28 parents of children with leukemia', 'parents of children with leukemia', 'parents of children with leukemia on their knowledge about leukemia and on body weight changes in their children']","[""10-15-min multimedia video to watch before their children's chemotherapy sessions"", 'multimedia-based education', 'multimedia-based nutrition education']","[""parents' knowledge level"", ""parents' knowledge and body weight change"", 'knowledge level', 'weight changes']","[{'cui': 'C0023418', 'cui_str': 'Leucocythaemia'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030551', 'cui_str': 'Parent of (observable entity)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0005911', 'cui_str': 'Body Weight Changes'}]","[{'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0376478', 'cui_str': 'Multimedium'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0204934', 'cui_str': 'Nutritional education'}]","[{'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0871796', 'cui_str': 'Knowledge level'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0005911', 'cui_str': 'Body Weight Changes'}]",28.0,0.0203789,We found a significant improvement in parents' knowledge level after the multimedia-based education (p=0.001).,"[{'ForeName': 'Fiorentina', 'Initials': 'F', 'LastName': 'Nova', 'Affiliation': 'Faculty of Nursing, Universitas Indonesia, Depok, West Java, Indonesia.'}, {'ForeName': 'Allenidekania', 'Initials': 'A', 'LastName': 'Allenidekania', 'Affiliation': 'Faculty of Nursing, Universitas Indonesia, Depok, West Java, Indonesia. Electronic address: alleni@ui.ac.id.'}, {'ForeName': 'Nur', 'Initials': 'N', 'LastName': 'Agustini', 'Affiliation': 'Faculty of Nursing, Universitas Indonesia, Depok, West Java, Indonesia.'}]",Enfermeria clinica,['10.1016/j.enfcli.2019.04.027'] 655,31254717,Reducing negative stimulus valence does not attenuate the return of fear: Two counterconditioning experiments.,"Exposure-based treatment for anxiety disorders is effective for many patients, but relapse is not uncommon. One predictor of the return of fear is the negative valence of fear-relevant stimuli. The aim of the current experiments was to examine whether counterconditioning with positive film clips reduces this negative stimulus valence as well as the return of fear, compared to standard extinction training and to an extinction training with non-contingent exposure to the positive film clips. Participants were 87 students in Experiment 1 (three-day paradigm), and 90 students in Experiment 2 (one-day paradigm). They first underwent a differential acquisition phase, in which one of three pictures was paired with an electric shock. They were then randomly allocated to one of the three intervention groups. Afterwards, they underwent a test phase in which pictures were presented without shock (to measure spontaneous recovery of fear), which was followed by unsignaled shocks to induce reinstatement of extinguished fear. Outcome variables were self-reported stimulus valence, shock expectancy, skin conductance, and fear-potentiated startle. In both experiments, counterconditioning decreased negative stimulus valence, relative to the other interventions, but it did not reduce spontaneous fear recovery or fear reinstatement. Overall, our findings do not support the notion that counterconditioning reduces return of fear.",2019,"In both experiments, counterconditioning decreased negative stimulus valence, relative to the other interventions, but it did not reduce spontaneous fear recovery or fear reinstatement.","['Participants were 87 students in Experiment 1 (three-day paradigm), and 90 students in Experiment 2 (one-day paradigm']","['standard extinction training and to an extinction training with non-contingent exposure to the positive film clips', 'counterconditioning with positive film clips']","['spontaneous fear recovery or fear reinstatement', 'self-reported stimulus valence, shock expectancy, skin conductance, and fear-potentiated startle', 'return of fear', 'negative stimulus valence']","[{'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0015347', 'cui_str': 'Extinction (Psychology)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C4319646', 'cui_str': 'Film'}, {'cui': 'C0175722', 'cui_str': 'Clip'}]","[{'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0234402', 'cui_str': 'Stimulus, function (observable entity)'}, {'cui': 'C1869063', 'cui_str': 'Shock (SMQ)'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}]",,0.0177551,"In both experiments, counterconditioning decreased negative stimulus valence, relative to the other interventions, but it did not reduce spontaneous fear recovery or fear reinstatement.","[{'ForeName': 'Eva A M', 'Initials': 'EAM', 'LastName': 'van Dis', 'Affiliation': 'Utrecht University, Department of Clinical Psychology, the Netherlands. Electronic address: e.a.m.vandis@uu.nl.'}, {'ForeName': 'Muriel A', 'Initials': 'MA', 'LastName': 'Hagenaars', 'Affiliation': 'Utrecht University, Department of Clinical Psychology, the Netherlands.'}, {'ForeName': 'Claudi L H', 'Initials': 'CLH', 'LastName': 'Bockting', 'Affiliation': 'Utrecht University, Department of Clinical Psychology, the Netherlands.'}, {'ForeName': 'Iris M', 'Initials': 'IM', 'LastName': 'Engelhard', 'Affiliation': 'Utrecht University, Department of Clinical Psychology, the Netherlands.'}]",Behaviour research and therapy,['10.1016/j.brat.2019.103416'] 656,31245901,Randomized clinical study to compare negative pressure wound therapy with simultaneous saline irrigation and traditional negative pressure wound therapy for complex foot infections.,"The aim of this study was to compare the efficacy of different negative pressure wound therapy (NPWT) devices and NPWT with and without simultaneous irrigation in patients admitted to hospital with moderate and severe foot infections. Ninety patients were randomized in a 12-week prospective, randomized noninferiority trial to compare wound healing in patients with moderate and severe infected foot wounds treated with NPWT after surgery. Inclusion criteria included ABI > 0.5 or toe pressures >30 PVR/mmHg, >18 years of age and exclusion included active Charcot arthropathy, collagen vascular disease, HIV, and hypercoagulable state. We compared two different traditional devices, NPWT-K (KCI, VAC Ulta) and NPWT-C (Cardinal, PRO), and NPWT-I with saline irrigation (Cardinal, PRO). All patients had therapy delivered at 125 mmHg continuous pressure. In patients who received simultaneous saline irrigation (NPWT-I), the administration rate was 15 ml per hour. The primary outcome was the proportion of healed wounds in 12 weeks. Secondary outcomes included surgical wound closure, number of surgeries, length of stay, and time to wound healing. Continuous data was presented as mean ± standard deviation. Analysis of variance was used to compare continuous variables and chi-square to compare dichotomous variables with an alpha of 0.05. There were no differences in outcomes among NPWT-I, NPWT-C, and NPWT-K groups in proportion of healed wounds (63.3%, 50.0%, 46.7% p = 0.39), surgical wound closure (83.3%, 80.0%, 63.3%, p = 0.15), number of surgeries (2.0 ± 0.49, 2.4 ± 0.77, 2.4 ± 0.68, p = 0.06), length of stay (16.3 ± 15.7, 14.7 ± 7.4, 15.3 ± 10.5 days, p = 0.87), time to wound healing (46.2 ± 22.8, 40.9 ± 18.8, 45.9 ± 28.3 days, p = 0.78). We did not identify any significant differences in clinical outcomes or adverse events between patients treated with different NPWT devices or NPWT with and without irrigation.",2020,We did not identify any significant differences in clinical outcomes or adverse events between patients treated with different NPWT devices or NPWT with and without irrigation.,"['Ninety patients', 'patients admitted to hospital with moderate and severe foot infections', 'patients with moderate and severe infected foot wounds treated with NPWT after surgery', 'Inclusion criteria included ABI\u2009>\u20090.5 or toe pressures >30 PVR/mmHg, >18\u2009years of age and exclusion included active Charcot arthropathy, collagen vascular disease, HIV, and hypercoagulable state', 'complex foot infections']","['simultaneous saline irrigation', 'negative pressure wound therapy with simultaneous saline irrigation and traditional negative pressure wound therapy', 'negative pressure wound therapy (NPWT) devices and NPWT with and without simultaneous irrigation', 'NPWT-I with saline irrigation (Cardinal, PRO']","['number of surgeries', 'healed wounds', 'clinical outcomes or adverse events', 'proportion of healed wounds', 'wound healing', 'time to wound healing', 'length of stay', 'surgical wound closure', 'surgical wound closure, number of surgeries, length of stay, and time to wound healing']","[{'cui': 'C3816959', 'cui_str': 'Ninety'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0555973', 'cui_str': 'Infection of foot'}, {'cui': 'C0016504', 'cui_str': 'Foot'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0040357', 'cui_str': 'Toes'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0439475', 'cui_str': 'torr (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0003892', 'cui_str': ""Charcot's Joint""}, {'cui': 'C0262428', 'cui_str': 'Collagen-vascular disease'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0398623', 'cui_str': 'Hypercoagulability'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}]","[{'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0022100', 'cui_str': 'Lavage'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0043187', 'cui_str': 'Wind'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C1956078', 'cui_str': 'Topical Negative-Pressure Therapy'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0326926', 'cui_str': 'Northern cardinal'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1265679', 'cui_str': 'Wound, healed'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0332803', 'cui_str': 'Surgical Incision'}, {'cui': 'C0185003', 'cui_str': 'Reparative closure (procedure)'}]",90.0,0.0948136,We did not identify any significant differences in clinical outcomes or adverse events between patients treated with different NPWT devices or NPWT with and without irrigation.,"[{'ForeName': 'Kathryn E', 'Initials': 'KE', 'LastName': 'Davis', 'Affiliation': 'Department of Plastic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'La Fontaine', 'Affiliation': 'Department of Plastic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Farrar', 'Affiliation': 'Department of Immunology and Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'Orhan K', 'Initials': 'OK', 'LastName': 'Oz', 'Affiliation': 'Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Crisologo', 'Affiliation': 'Department of Plastic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Berriman', 'Affiliation': 'Berriman Consulting, Princeton, New Jersey.'}, {'ForeName': 'Lawrence A', 'Initials': 'LA', 'LastName': 'Lavery', 'Affiliation': 'Department of Plastic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.'}]",Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society,['10.1111/wrr.12741'] 657,31233269,Effects of Message Framing on Patients' Perceptions and Willingness to Change to a Biosimilar in a Hypothetical Drug Switch.,"OBJECTIVE Patients often hold negative perceptions toward biosimilars that can create barriers to their uptake. Physicians also report uncertainty in how best to explain biosimilars. The aim of this study was to measure the effect of differently framed explanations on patients' perceptions of and willingness to change to a biosimilar in a hypothetical drug switch. METHODS Ninety-six patients with rheumatic diseases taking an originator biologic were randomized to receive 1 of 4 biosimilar explanations: positive framing with and without an analogy, and negative framing with and without an analogy. Willingness to switch to a biosimilar, perceptions about biosimilars, and the effectiveness of the explanation were measured after the information delivery. RESULTS Positive framing led to more participants being willing to switch (67%) than negative framing (46%). Framing significantly predicted willingness to switch to a biosimilar, with participants in the positive framing group being 2.36 times more willing to switch (P = 0.041). The positive framing group also reported significantly greater perceived efficacy of biosimilars (P = 0.046) and thought the explanation was more convincing (P = 0.030). The analogy did not enhance willingness to switch or increase understanding (P > 0.05). CONCLUSION Positive framing can improve perceptions of and willingness to switch to a biosimilar in patients currently taking biologic treatments.",2019,"The positive framing group also reported significantly greater perceived efficacy of biosimilars (P = 0.046), and thought the explanation was more convincing (P = 0.030).",['Ninety-six patients with rheumatic diseases taking an originator biologic'],"['biosimilar explanations - positive framing with and without an analogy, and negative framing with and without an analogy']",['efficacy of biosimilars'],"[{'cui': 'C4319625', 'cui_str': '96'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0035435', 'cui_str': 'Rheumatism'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C4553887', 'cui_str': 'Biologic Drugs'}]","[{'cui': 'C4045974', 'cui_str': 'Biosimilars'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}]","[{'cui': 'C4045974', 'cui_str': 'Biosimilars'}]",96.0,0.0527785,"The positive framing group also reported significantly greater perceived efficacy of biosimilars (P = 0.046), and thought the explanation was more convincing (P = 0.030).","[{'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Gasteiger', 'Affiliation': 'University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Annie S K', 'Initials': 'ASK', 'LastName': 'Jones', 'Affiliation': 'University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Kleinstäuber', 'Affiliation': 'University of Auckland, Auckland, and University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Lobo', 'Affiliation': 'Auckland District Health Board, Auckland, New Zealand.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'Horne', 'Affiliation': 'University College London, London, UK.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Dalbeth', 'Affiliation': 'Auckland District Health Board and University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Keith J', 'Initials': 'KJ', 'LastName': 'Petrie', 'Affiliation': 'University of Auckland, Auckland, New Zealand.'}]",Arthritis care & research,['10.1002/acr.24012'] 658,31697238,"A Technology-Assisted, Brief Mind-Body Intervention to Improve the Waiting Room Experience for Chemotherapy Patients: Randomized Quality Improvement Study.","BACKGROUND Patients waiting for chemotherapy can experience stress, anxiety, nausea, and pain. Acupressure and meditation have been shown to control such symptoms. OBJECTIVE This study aimed to evaluate the feasibility and effectiveness of an integrative medicine app to educate patients about these self-care tools in chemotherapy waiting rooms. METHODS We screened and enrolled cancer patients in chemotherapy waiting rooms at two Memorial Sloan Kettering Cancer Center locations. Patients were randomly assigned into an intervention arm in which subjects watched acupressure and meditation instructional videos or a control arm in which they watched a time- and attention-matched integrative oncology lecture video. Before and after watching the videos, we asked the patients to rate four key symptoms: stress, anxiety, nausea, and pain. We performed the analysis of covariance to detect differences between the two arms postintervention while controlling for baseline symptoms. RESULTS A total of 223 patients were enrolled in the study: 113 patients were enrolled in the intervention arm and 110 patients were enrolled in the control arm. In both groups, patients showed significant reductions in stress and anxiety from baseline (all P<.05), with the treatment arm reporting greater stress and anxiety reduction than the control arm (1.64 vs 1.15 in stress reduction; P=.01 and 1.39 vs 0.78 in anxiety reduction; P=.002). The majority of patients reported that the videos helped them pass time and that they would watch the videos again. CONCLUSIONS An integrative medicine self-care app in the waiting room improved patients' experiences and reduced anxiety and stress. Future research could focus on expanding this platform to other settings to improve patients' overall treatment experiences.",2019,"In both groups, patients showed significant reductions in stress and anxiety from baseline (all P<.05), with the treatment arm reporting greater stress and anxiety reduction than the control arm (1.64 vs 1.15 in stress reduction; P=.01 and 1.39 vs 0.78 in anxiety reduction; P=.002).","['enrolled cancer patients in chemotherapy waiting rooms at two Memorial Sloan Kettering Cancer Center locations', '223 patients were enrolled in the study', '113 patients were enrolled in the intervention arm and 110 patients were enrolled in the control arm', 'Chemotherapy Patients']","['acupressure and meditation instructional videos or a control arm in which they watched a time- and attention-matched integrative oncology lecture video', 'Acupressure and meditation', 'integrative medicine app']","['stress and anxiety', 'feasibility and effectiveness', 'stress and anxiety reduction', 'rate four key symptoms: stress, anxiety, nausea, and pain']","[{'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0450429', 'cui_str': 'Location (attribute)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0282614', 'cui_str': 'Acupressure'}, {'cui': 'C0150277'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C4505053', 'cui_str': 'Integrative Oncology'}, {'cui': 'C0376683', 'cui_str': 'Lecture'}, {'cui': 'C2350258', 'cui_str': 'Integrative Medicine'}]","[{'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0150135', 'cui_str': 'Reducing anxiety'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",223.0,0.0382051,"In both groups, patients showed significant reductions in stress and anxiety from baseline (all P<.05), with the treatment arm reporting greater stress and anxiety reduction than the control arm (1.64 vs 1.15 in stress reduction; P=.01 and 1.39 vs 0.78 in anxiety reduction; P=.002).","[{'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Bao', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Deng', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.'}, {'ForeName': 'Lauren A', 'Initials': 'LA', 'LastName': 'DeMarzo', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.'}, {'ForeName': 'W Iris', 'Initials': 'WI', 'LastName': 'Zhi', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.'}, {'ForeName': 'Janice L', 'Initials': 'JL', 'LastName': 'DeRito', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Blinder', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.'}, {'ForeName': 'Connie', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.'}, {'ForeName': 'Qing S', 'Initials': 'QS', 'LastName': 'Li', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Green', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Pendleton', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.'}, {'ForeName': 'Jun J', 'Initials': 'JJ', 'LastName': 'Mao', 'Affiliation': 'Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.'}]",JMIR cancer,['10.2196/13217'] 659,31230925,Short versus long axis ultrasound guided approach for internal jugular vein cannulations: A prospective randomized controlled trial.,"OBJECTIVES Ultrasound-guided internal jugular vein cannulation is a standard procedure performed in ICUs worldwide. According to the guidelines, the short-axis approach is recommended over the long-axis approach for IJV cannulation. Double-operator cannulation is more convenient for the said procedure. However, the guidelines favor single-operator cannulation due to limited trials. We hypothesized that double-operator long-axis cannulation will be faster and have fewer complications than double-operator short-axis cannulation. METHODS This was a prospective, randomized trial of patients who needed central venous catheterization in the intensive care unit. The eligible patients were randomized into two groups. In one group, the short-axis view by two operators was used for cannulation, and the long-axis view by 2 operators was used in the other group. The time elapsed from skin puncture to guide-wire insertion. RESULTS The central venous catheter was placed by ultrasound guidance in all 100 patients. No significant differences were observed in the patient characteristics between the two groups. The mean time of insertion was 74.2 ± 110.1 s with the short-axis approach compared with 70.3 ± 97.3 s with the long-axis approach. The frequency of complications was also significantly lower with the long-axis approach. DISCUSSION The long-axis view for IJV cannulation has similar insertion and procedure timings to the short-axis view. However, the complication rate and number of needle punctures required were less with the long-axis view than with those with the short-axis view.",2020,"However, the complication rate and number of needle punctures required were less with the long-axis view than with those with the short-axis view.",['patients who needed central venous catheterization in the intensive care unit'],"['Ultrasound-guided internal jugular vein cannulation', 'Short versus long axis ultrasound guided approach for internal jugular vein cannulations', 'double-operator long-axis cannulation', 'Double-operator cannulation']","['frequency of complications', 'mean time of insertion', 'complication rate and number of needle punctures']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0007435', 'cui_str': 'Central Catheterization'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}]","[{'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0226550', 'cui_str': 'Internal jugular vein structure'}, {'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0522487', 'cui_str': 'Long axis (qualifier value)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}]","[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}, {'cui': 'C0033119', 'cui_str': 'Puncture wound - injury (disorder)'}]",100.0,0.0343039,"However, the complication rate and number of needle punctures required were less with the long-axis view than with those with the short-axis view.","[{'ForeName': 'Arun', 'Initials': 'A', 'LastName': 'Rath', 'Affiliation': 'IMS and SUM Hospital, Bhubaneswar, Odisha 751014, India.'}, {'ForeName': 'Shakti Bedanta', 'Initials': 'SB', 'LastName': 'Mishra', 'Affiliation': 'Department of Anaesthesiology, IMS and SUM Hospital, Bhubaneswar, Odisha 751014, India. Electronic address: shaktibedantamishra@soauniversity.ac.in.'}, {'ForeName': 'Bhabani', 'Initials': 'B', 'LastName': 'Pati', 'Affiliation': 'IMS and SUM Hospital, Bhubaneswar, Odisha 751014, India.'}, {'ForeName': 'Sanjib Kumar', 'Initials': 'SK', 'LastName': 'Dhar', 'Affiliation': 'IMS and SUM Hospital, Bhubaneswar, Odisha 751014, India.'}, {'ForeName': 'Snigdha', 'Initials': 'S', 'LastName': 'Ipsita', 'Affiliation': 'IMS and SUM Hospital, Bhubaneswar, Odisha 751014, India.'}, {'ForeName': 'Samir', 'Initials': 'S', 'LastName': 'Samal', 'Affiliation': 'IMS and SUM Hospital, Bhubaneswar, Odisha 751014, India.'}, {'ForeName': 'Afzal', 'Initials': 'A', 'LastName': 'Azim', 'Affiliation': 'SGPGI, Lucknow 226014, India.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.06.010'] 660,32409493,Exercise-Induced Increases in Insulin Sensitivity After Bariatric Surgery Are Mediated By Muscle Extracellular Matrix Remodeling.,"Exercise seems to enhance the beneficial effect of bariatric (Roux-en-Y gastric bypass [RYGB]) surgery on insulin resistance. We hypothesized that skeletal muscle extracellular matrix (ECM) remodeling may underlie these benefits. Women were randomized to either a combined aerobic and resistance exercise training program following RYGB (RYGB + ET) or standard of care (RYGB). Insulin sensitivity was assessed by oral glucose tolerance test. Muscle biopsy specimens were obtained at baseline and 3 and 9 months after surgery and subjected to comprehensive phenotyping, transcriptome profiling, molecular pathway identification, and validation in vitro. Exercise training improved insulin sensitivity beyond surgery alone (e.g., Matsuda index: RYGB 123% vs. RYGB + ET 325%; P ≤ 0.0001). ECM remodeling was reduced by surgery alone, with an additive benefit of surgery and exercise training (e.g., collagen I: RYGB -41% vs. RYGB + ET -76%; P ≤ 0.0001). Exercise and RYGB had an additive effect on enhancing insulin sensitivity, but surgery alone did not resolve insulin resistance and ECM remodeling. We identified candidates modulated by exercise training that may become therapeutic targets for treating insulin resistance, in particular, the transforming growth factor-β1/SMAD 2/3 pathway and its antagonist follistatin. Exercise-induced increases in insulin sensitivity after bariatric surgery are at least partially mediated by muscle ECM remodeling.",2020,"Exercise and RYGB had an additive effect on enhancing insulin sensitivity, but surgery alone did not resolve insulin resistance and ECM remodeling.",[],"['surgery and exercise training ( e.g., collagen', 'combined aerobic and resistance exercise training program following RYGB or standard of care (RYGB', 'I - RYGB', 'exercise training']","['enhancing insulin sensitivity', 'ECM remodeling', 'insulin resistance and ECM remodeling', 'Insulin Sensitivity', 'insulin sensitivity', 'Insulin sensitivity']",[],"[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0015350', 'cui_str': 'Matrix, Extracellular'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}]",,0.0522588,"Exercise and RYGB had an additive effect on enhancing insulin sensitivity, but surgery alone did not resolve insulin resistance and ECM remodeling.","[{'ForeName': 'Wagner S', 'Initials': 'WS', 'LastName': 'Dantas', 'Affiliation': 'Integrated Physiology and Molecular Metabolism Laboratory, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA.'}, {'ForeName': 'Hamilton', 'Initials': 'H', 'LastName': 'Roschel', 'Affiliation': 'Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Laboratory of Assessment and Conditioning in Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Igor H', 'Initials': 'IH', 'LastName': 'Murai', 'Affiliation': 'Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Laboratory of Assessment and Conditioning in Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Saulo', 'Initials': 'S', 'LastName': 'Gil', 'Affiliation': 'Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Laboratory of Assessment and Conditioning in Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Gangarao', 'Initials': 'G', 'LastName': 'Davuluri', 'Affiliation': 'Integrated Physiology and Molecular Metabolism Laboratory, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA.'}, {'ForeName': 'Christopher L', 'Initials': 'CL', 'LastName': 'Axelrod', 'Affiliation': 'Integrated Physiology and Molecular Metabolism Laboratory, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA.'}, {'ForeName': 'Sujoy', 'Initials': 'S', 'LastName': 'Ghosh', 'Affiliation': 'Genomics Core, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA.'}, {'ForeName': 'Susan S', 'Initials': 'SS', 'LastName': 'Newman', 'Affiliation': 'Genomics Core, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Integrated Physiology and Molecular Metabolism Laboratory, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA.'}, {'ForeName': 'Samuel K', 'Initials': 'SK', 'LastName': 'Shinjo', 'Affiliation': 'Rheumatology Division, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Willian', 'Initials': 'W', 'LastName': 'das Neves', 'Affiliation': 'Clinical Oncology Service, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Merege-Filho', 'Affiliation': 'Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Laboratory of Assessment and Conditioning in Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Walcy R', 'Initials': 'WR', 'LastName': 'Teodoro', 'Affiliation': 'Rheumatology Division, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Vera L', 'Initials': 'VL', 'LastName': 'Capelozzi', 'Affiliation': 'Department of Pathology, School of Medicine, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Rosa Maria', 'Initials': 'RM', 'LastName': 'Pereira', 'Affiliation': 'Rheumatology Division, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Fabiana B', 'Initials': 'FB', 'LastName': 'Benatti', 'Affiliation': 'School of Applied Sciences, Universidade Estadual de Campinas, São Paulo, Brazil.'}, {'ForeName': 'Ana L', 'Initials': 'AL', 'LastName': 'de Sá-Pinto', 'Affiliation': 'Rheumatology Division, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'de Cleva', 'Affiliation': 'Department of Digestive Division, School of Medicine, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Marco A', 'Initials': 'MA', 'LastName': 'Santo', 'Affiliation': 'Department of Digestive Division, School of Medicine, Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Kirwan', 'Affiliation': 'Integrated Physiology and Molecular Metabolism Laboratory, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Gualano', 'Affiliation': 'Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Laboratory of Assessment and Conditioning in Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil gualano@usp.br.'}]",Diabetes,['10.2337/db19-1180'] 661,31774037,"A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation.","BACKGROUND Protease-activated receptor-1 antagonism by vorapaxar could facilitate arteriovenous fistula maturation but may increase bleeding risk. OBJECTIVE The primary objective of the Vorapaxar Study for Maturation of arteriovenous fistula for Hemodialysis Access (VorapAccess) was to determine if vorapaxar improves arteriovenous fistula functional maturation in patients with end-stage renal disease. METHODS VorapAccess was a randomized, placebo-controlled, double-blind pilot trial comparing 2.5 mg vorapaxar per day with placebo for twelve weeks starting on day two after arteriovenous fistula creation. The primary outcome was time to functional maturation defined as successful cannulation for six hemodialysis sessions within three weeks. The planned sample size was 50 participants. The study was terminated early after withdrawal of planned financial support. Given the small number of randomized patients, we performed descriptive analyses without inference testing. RESULTS A total of 13 participants were randomly allocated study drug (six vorapaxar and seven placebo). The median age was 56 years and seven participants (54%) were female. The median (minimum-maximum) days to functional maturation were 169 (77-287) days in the vorapaxar group and 145 (48-198) days in the placebo group. Six of the 13 (46%) participants had arteriovenous fistula functional maturation within 180 days; two of six (33%) in the vorapaxar group and four of seven (57%) in the placebo group. There was one bleeding event in the placebo group. CONCLUSION Fewer than half of participants had functional maturation within 180 days after surgery, suggesting a major need for agents or strategies that enhance arteriovenous fistula maturation.",2020,"There was one bleeding event in the placebo group. ","['A total of 13 participants', 'The median age was 56\u2009years and seven participants (54%) were female', 'patients with end-stage renal disease']","['placebo', 'vorapaxar', 'vorapaxar per day with placebo', 'vorapaxar and seven placebo']","['bleeding event', 'arteriovenous fistula maturation', 'functional maturation', 'arteriovenous fistula functional maturation', 'safety and efficacy', 'time to functional maturation defined as successful cannulation for six hemodialysis sessions']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0022661', 'cui_str': 'End-Stage Kidney Disease'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2974521', 'cui_str': 'vorapaxar'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C0205453', 'cui_str': '7'}]","[{'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0003855', 'cui_str': 'Arteriovenous fistula (morphologic abnormality)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]",50.0,0.719572,"There was one bleeding event in the placebo group. ","[{'ForeName': 'Christoph B', 'Initials': 'CB', 'LastName': 'Olivier', 'Affiliation': 'Stanford Center for Clinical Research (SCCR), Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Vandana', 'Initials': 'V', 'LastName': 'Sundaram', 'Affiliation': 'Quantitative Sciences Unit, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Glenn M', 'Initials': 'GM', 'LastName': 'Chertow', 'Affiliation': 'Division of Nephrology, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Sumana', 'Initials': 'S', 'LastName': 'Shashidhar', 'Affiliation': 'Stanford Center for Clinical Research (SCCR), Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Lori K', 'Initials': 'LK', 'LastName': 'McDonnell', 'Affiliation': 'Division of Vascular Surgery, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Victoria Y', 'Initials': 'VY', 'LastName': 'Ding', 'Affiliation': 'Quantitative Sciences Unit, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Manisha', 'Initials': 'M', 'LastName': 'Desai', 'Affiliation': 'Quantitative Sciences Unit, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Kenneth W', 'Initials': 'KW', 'LastName': 'Mahaffey', 'Affiliation': 'Stanford Center for Clinical Research (SCCR), Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Mell', 'Affiliation': 'Division of Vascular Surgery, School of Medicine, Stanford University, Stanford, CA, USA.'}]",The journal of vascular access,['10.1177/1129729819887269'] 662,31221941,Leukocytapheresis Therapy for Rheumatoid Arthritis: Results Compared with Control Trial.,"Context Rheumatoid arthritis (RA) is a chronic multisystem autoimmune disease, mainly characterized by synovitis and with symmetrical joint involvement. LCAP therapy for RA patients has been shown to be safe and efficacious in some developed countries for over a decade. Objective The study intended to evaluate the efficacy and safety of leukocytopheresis (LCAP) for treatment of rheumatoid arthritis (RA) and to study the influence of treatment on the levels of various serum cytokines. Design The study was a nonblinded, nonrandomized, controlled trial. Setting The study took place in the Department of Rheumatology and Immunology at Beijing Hospital at the National Center of Gerontology in Beijing, China. Participants Participants were 51 patients with RA at the hospital with a 28-joint disease activity score (DAS28) exceeding the 3.20 needed to fulfill the classification criteria of the American College of Rheumatology (ACR). Intervention Participants were divided into 2 groups. One group (intervention group) received LCAP therapy (n = 20), while the control group (n = 31) received disease-modifying antirheumatic drugs (DMARDs). Patients receiving the LCAP therapy were treated using a Cellsorba column every 5 days for a total of 5 treatments. Outcome Measures Clinical assessment of participants' symptoms included: (1) a tender-joint count, (2) a swollen-joint count, (3) erythrocyte sedimentation rates (ESR), (4) C-reactive protein levels (CRP), (5) a visual analog scale (VAS) for pain, (6) the DAS28 C-reactive protein (DAS28-CRP) scores, and the Health Assessment Questionnaire Disability Index (HAQ-DI). The study also evaluated participants' scores for the American College of Rheumatology (ACR) Core Data Set. Serum collected before and after therapy from both groups was analyzed for the levels of bradykinin, serotonin, heat shock protein 70, human CXC-chemokine ligand 16 (CXCL16), prostaglandin E2, and macrophage inflammation protein 1α. Results At week 4 for participants receiving the LCAP therapy, ACR20, ACR50, and ACR70 were observed in 55%, 30%, and 20% of patients, respectively, compared to 19.4%, 3.2%, and 0% for patients in the control group (P < .05). Also, at week 24 of LCAP therapy, ACR20, ACR50, and ACR70 were observed in 70%, 50%, and 30% of patients, respectively, which was significantly higher than the 25.8%, 12.9%, and 3.2% of patients in the control group (P < .05). The serum levels of CXCL16 and serotonin were significantly reduced in the LCAP group compared with control group. Conclusions This study indicated that LCAP therapy can significantly decrease RA disease activity and is a safe and effective alternative therapy. LCAP therapy significantly reduced serum CXCL16 and serotonin levels, offering a putative mechanism by which it improves the articular symptoms of RA.",2020,"LCAP therapy significantly reduced serum CXCL16 and serotonin levels, offering a putative mechanism by which it improves the articular symptoms of RA.","[""participants' scores for the American College of Rheumatology (ACR) Core Data Set"", 'rheumatoid arthritis (RA', 'Participants\n\n\nParticipants were 51 patients with RA at the hospital with a 28-joint disease activity score (DAS28) exceeding the 3.20 needed to fulfill the classification criteria of the American College of Rheumatology (ACR', 'Rheumatoid Arthritis', 'Department of Rheumatology and Immunology at Beijing Hospital at the National Center of Gerontology in Beijing, China']","['LCAP', 'disease-modifying antirheumatic drugs (DMARDs', 'leukocytopheresis (LCAP', 'Leukocytapheresis Therapy', 'LCAP therapy']","['ACR20, ACR50, and ACR70', ""Outcome Measures\n\n\nClinical assessment of participants' symptoms included: (1) a tender-joint count, (2) a swollen-joint count, (3) erythrocyte sedimentation rates (ESR), (4) C-reactive protein levels (CRP), (5) a visual analog scale (VAS) for pain, (6) the DAS28 C-reactive protein (DAS28-CRP) scores, and the Health Assessment Questionnaire Disability Index (HAQ-DI"", 'serum CXCL16 and serotonin levels', 'serum levels of CXCL16 and serotonin', 'RA disease activity']","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0035452', 'cui_str': 'Rheumatology'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0150098', 'cui_str': 'Data Set'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid Arthritis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0022408', 'cui_str': 'Arthropathy'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0008903', 'cui_str': 'taxonomy'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0152036', 'cui_str': 'Immunology'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0205767', 'cui_str': 'Gerontology'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}]","[{'cui': 'C0242708', 'cui_str': 'Antirheumatic Drugs, Disease-Modifying'}, {'cui': 'C0023416', 'cui_str': 'Leukocytapheresis'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0451530', 'cui_str': 'Tender joint count (assessment scale)'}, {'cui': 'C0451521', 'cui_str': 'Swollen joint count (assessment scale)'}, {'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451208', 'cui_str': 'Health assessment questionnaire (assessment scale)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0102923', 'cui_str': 'HAQ'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",51.0,0.0219527,"LCAP therapy significantly reduced serum CXCL16 and serotonin levels, offering a putative mechanism by which it improves the articular symptoms of RA.","[{'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Yongjing', 'Initials': 'Y', 'LastName': 'Cheng', 'Affiliation': ''}, {'ForeName': 'Yingjuan', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Gao', 'Affiliation': ''}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Bingyao', 'Initials': 'B', 'LastName': 'Mu', 'Affiliation': ''}, {'ForeName': 'Rongwei', 'Initials': 'R', 'LastName': 'Zhou', 'Affiliation': ''}, {'ForeName': 'Cibo', 'Initials': 'C', 'LastName': 'Huang', 'Affiliation': ''}]",Alternative therapies in health and medicine,[] 663,31210140,Comparing Written Versus Pictorial Asthma Action Plans to Improve Asthma Management and Health Outcomes Among Children and Adolescents: Protocol of a Pilot and Feasibility Randomized Controlled Trial.,"BACKGROUND Asthma is an important focus for pediatric health research as management of asthma symptoms is a significant challenge, and morbidity and mortality among youths with asthma remain prevalent. Treatment guidelines for asthma recommend a written asthma action plan (WAAP) that summarizes individualized instructions for daily medication use. However, WAAPs are typically written at a seventh- to ninth-grade reading level, which can be a barrier to young people in understanding their treatment, having confidence in using a WAAP, and engaging with asthma education. OBJECTIVE Utilizing a feasibility and pilot randomized controlled trial (RCT) design, the objective of the Take Action for Asthma Control study is to test a symptom-based, computer-generated pictorial asthma action plan (PAAP) in comparison with a standard WAAP and assess the feasibility and acceptability of the asthma action plan (AAP) intervention and study procedures. The study has 3 aims: (1) estimate the effect sizes of PAAPs compared with WAAPs on outcomes (eg, AAP knowledge and medication adherence), (2) evaluate feasibility and acceptability of AAP intervention and RCT procedures from the perspectives of key stakeholders, and (3) establish whether parent and youth literacy levels are associated with treatment outcomes. METHODS This feasibility and pilot RCT is a block randomized, 2-arm, parallel-group clinical trial, lasting 6 months in duration. At baseline, participants will be randomly assigned to receive a PAAP or WAAP generated for them and reviewed with them by their asthma physician. Study procedures will take place over 4 separate time points: a baseline clinic appointment, 1-month telephone follow-up, and 3- and 6-month clinic-based follow-ups. At each time point, data will be collected related to the main outcomes: AAP knowledge, AAP satisfaction, asthma control, pulmonary function, and adherence to daily asthma medication. A sample size of up to 60 participants (aged 8-17 years) will be recruited. Feasibility and acceptability data will be collected via one-to-one qualitative interviews with providers involved in the study and a subgroup of families that participate in the study. RESULTS Recruitment and data collection began in May 2017 and were completed in October 2018. CONCLUSIONS This pilot and feasibility study will test the potential efficacy, feasibility, and acceptability of an AAP intervention and study procedures. The findings will inform the design and delivery of a future definitive trial to assess the efficacy of PAAPs versus WAAPs in supporting asthma self-management among children and adolescents. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/11733.",2019,"The findings will inform the design and delivery of a future definitive trial to assess the efficacy of PAAPs versus WAAPs in supporting asthma self-management among children and adolescents. ","['youths with asthma remain prevalent', '60 participants (aged 8-17 years', 'Children and Adolescents', 'children and adolescents']","['PAAPs versus WAAPs', 'written asthma action plan (WAAP', 'PAAPs', 'AAP intervention and RCT procedures', 'computer-generated pictorial asthma action plan (PAAP', 'asthma action plan (AAP) intervention', 'WAAPs', 'AAP intervention', 'PAAP or WAAP', 'Pictorial Asthma Action Plans']","['potential efficacy, feasibility, and acceptability', 'AAP satisfaction, asthma control, pulmonary function, and adherence to daily asthma medication']","[{'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C1273866', 'cui_str': 'Action plan (community)'}, {'cui': 'C0051989', 'cui_str': 'Gly-Pro-HyPro-Gly-Ala-Gly'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0009622', 'cui_str': 'Computers'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0051989', 'cui_str': 'Gly-Pro-HyPro-Gly-Ala-Gly'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}]",,0.0912659,"The findings will inform the design and delivery of a future definitive trial to assess the efficacy of PAAPs versus WAAPs in supporting asthma self-management among children and adolescents. ","[{'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Hynes', 'Affiliation': 'Department of Psychology, West Virginia University, Morgantown, WV, United States.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Durkin', 'Affiliation': 'Department of Psychology, West Virginia University, Morgantown, WV, United States.'}, {'ForeName': 'Desireé N', 'Initials': 'DN', 'LastName': 'Williford', 'Affiliation': 'Department of Psychology, West Virginia University, Morgantown, WV, United States.'}, {'ForeName': 'Hope', 'Initials': 'H', 'LastName': 'Smith', 'Affiliation': 'Department of Psychology, West Virginia University, Morgantown, WV, United States.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Skoner', 'Affiliation': 'Department of Pediatrics, School of Medicine, West Virginia University, Morgantown, WV, United States.'}, {'ForeName': 'Christa', 'Initials': 'C', 'LastName': 'Lilly', 'Affiliation': 'Department of Biostatistics, School of Public Health, West Virginia University, Morgantown, WV, United States.'}, {'ForeName': 'Viral Dilip', 'Initials': 'VD', 'LastName': 'Kothari', 'Affiliation': 'Department of Pediatrics, School of Medicine, West Virginia University, Morgantown, WV, United States.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Mc Sharry', 'Affiliation': 'School of Psychology, National University of Ireland, Galway, Galway, Ireland.'}, {'ForeName': 'Christina L', 'Initials': 'CL', 'LastName': 'Duncan', 'Affiliation': 'Department of Psychology, West Virginia University, Morgantown, WV, United States.'}]",JMIR research protocols,['10.2196/11733'] 664,31789778,Enhancing the Patient Experience for Individuals Undergoing Endoscopic Procedures Using Virtual Reality.,"The results of medical procedures can often be difficult to translate into comprehensible and engaging information for patients. This randomized controlled trial evaluated the satisfaction and perceived value of a technology, called HealthVoyager, which creates a personalized virtual reality (VR) experience of a patient's endoscopy or colonoscopy findings in comparison to the standard practice (ie, reviewing printed reports). The platform allows gastroenterologists to create a customized VR patient report to help translate medical knowledge and procedural information to the patient. Forty-one patients (17 HealthVoyager [test]; 24 standard practice [control]) completed a self-report survey assessing their experience for receiving medical information. Results demonstrated that patients were significantly more satisfied in learning about their gastrointestinal condition and procedural results using HealthVoyager rather than with the standard of care. These results have implications for improving the knowledge translation of medical findings between healthcare providers and patients in various disease states and patient populations.",2020,Results demonstrated that patients were significantly more satisfied in learning about their gastrointestinal condition and procedural results using HealthVoyager rather than with the standard of care.,"['Forty-one patients (17 HealthVoyager [test]; 24 standard practice [control]) completed a self-report survey assessing their experience for receiving medical information', 'Individuals Undergoing Endoscopic Procedures Using Virtual Reality']",[],[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0282493', 'cui_str': 'Surgical Procedures, Endoscopic'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}]",[],[],41.0,0.0189646,Results demonstrated that patients were significantly more satisfied in learning about their gastrointestinal condition and procedural results using HealthVoyager rather than with the standard of care.,"[{'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Palanica', 'Affiliation': 'Labs Department, Klick Health, Klick Inc., Toronto, Ontario, Canada.'}, {'ForeName': 'McKenzie', 'Initials': 'M', 'LastName': 'Leier', 'Affiliation': ""Division of Gastroenterology, Boston Children's Hospital, Boston, MA.""}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Lee', 'Affiliation': 'Labs Department, Klick Health, Klick Inc., Toronto, Ontario, Canada.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Fossat', 'Affiliation': 'Labs Department, Klick Health, Klick Inc., Toronto, Ontario, Canada.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Docktor', 'Affiliation': ""Division of Gastroenterology, Boston Children's Hospital, Boston, MA.""}]",Journal of pediatric gastroenterology and nutrition,['10.1097/MPG.0000000000002577'] 665,31567714,"A randomized controlled trial of the effects of local tranexamic acid on mortality, rebleeding, and recurrent endoscopy need in patients with upper gastrointestinal hemorrhage.","OBJECTIVE Tranexamic acid (TXA) is an antifibrinolytic agent used to control bleeding in different circumstances. We conducted a randomized controlled trial to assess the efficacy and safety of locally administered TXA in upper gastrointestinal hemorrhage. METHODS This single-center, double-blind, randomized controlled trial was performed in a tertiary emergency department (ED) in patients presenting with upper gastrointestinal bleeding symptoms between 2016 and 2018. The patients received either 2000 mg of 5% TXA in 100 mL of isotonic saline solution or 100 mL isotonic saline (control group) via the nasogastric route. As a composite outcome, recurrent endoscopy need, rebleeding, surgery need, recurrent admission to the ED, and mortality parameters were evaluated at the end of a one-month period. RESULTS During the study period, 78 patients were randomized into the TXA group, and 79 patients were randomized into the isotonic saline group. The majority of the bleedings (61%) were in Forrest class 3, and the most frequent cause was peptic ulcer disease. The composite outcome occurred in 25 of the TXA patients (32.1%) and 23 of the isotonic saline patients (29.1%); no statistically significant difference was found between the groups (P = 0.690). In addition, no statistically significant differences were observed between the TXA and control groups regarding mortality (10.3 vs 12.7%; P = 0.637), recurrent ED admission (17.9 vs 12.7%; P = 0.357), or thromboembolic complications (3.8 vs 1.3%; P = 0.367). CONCLUSION Locally administered TXA confers no additional benefit over standard care in patients with upper gastrointestinal hemorrhage.",2020,The composite outcome occurred in 25 of the TXA patients (32.1%) and 23 of the isotonic saline patients (29.1%); no statistically significant difference was found between the groups (P = 0.690).,"['patients presenting with upper gastrointestinal bleeding symptoms between 2016 and 2018', 'patients with upper gastrointestinal hemorrhage', '78 patients were randomized into the TXA group, and 79 patients']","['isotonic saline', 'local tranexamic acid', 'Tranexamic acid (TXA', 'isotonic saline solution or 100 mL isotonic saline (control group) via the nasogastric route', 'TXA', '2000 mg of 5% TXA']","['mortality', 'recurrent endoscopy need, rebleeding, surgery need, recurrent admission to the ED, and mortality parameters', 'efficacy and safety', 'thromboembolic complications', 'mortality, rebleeding, and recurrent endoscopy need', 'recurrent ED admission']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0041909', 'cui_str': 'Upper gastrointestinal hemorrhage (disorder)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0694637', 'cui_str': 'Nasogastric use'}, {'cui': 'C0470277', 'cui_str': '2000'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",78.0,0.123375,The composite outcome occurred in 25 of the TXA patients (32.1%) and 23 of the isotonic saline patients (29.1%); no statistically significant difference was found between the groups (P = 0.690).,"[{'ForeName': 'Adnan', 'Initials': 'A', 'LastName': 'Karadaş', 'Affiliation': 'Department of Emergency Medicine, Balikesir Atatürk City Hospital, Balikesir.'}, {'ForeName': 'Nurettin Özgür', 'Initials': 'NÖ', 'LastName': 'Doğan', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Kocaeli University, Kocaeli.'}, {'ForeName': 'Seda Güney', 'Initials': 'SG', 'LastName': 'Pinar', 'Affiliation': 'Department of Emergency Medicine, Zonguldak Atatürk State Hospital, Zonguldak.'}, {'ForeName': 'Olcay', 'Initials': 'O', 'LastName': 'Yeşil', 'Affiliation': 'Department of Emergency Medicine, Kars Harakani State Hospital, Kars, Turkey.'}, {'ForeName': 'Murat', 'Initials': 'M', 'LastName': 'Pekdemir', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Kocaeli University, Kocaeli.'}, {'ForeName': 'Serkan', 'Initials': 'S', 'LastName': 'Yilmaz', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Kocaeli University, Kocaeli.'}, {'ForeName': 'Elif', 'Initials': 'E', 'LastName': 'Yaka', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Kocaeli University, Kocaeli.'}]",European journal of gastroenterology & hepatology,['10.1097/MEG.0000000000001555'] 666,31775668,Save the children by treating their mothers (PriVileG-M-study) - study protocol: a sequentially randomized controlled trial of individualized psychotherapy and telemedicine to reduce mental stress in pregnant women and young mothers and to improve Child's health.,"BACKGROUND As early as pregnancy, maternal mental stress impinges on the child's development and health. Thus, this may cause enhanced risk for premature birth, lowered fetal growth, and lower fetal birth weight as well as enhanced levels of the stress hormone cortisol and lowered levels of the bonding hormone oxytocin. Maternal stress further reduces maternal sensitivity for the child's needs which impairs the mother-child-interaction and bonding. Therefore, prevention and intervention studies on mental stress are necessary, beginning prenatally and applying rigorous research methodology, such as randomized controlled trials, to ensure high validity. METHODS A randomized controlled trial is used to assess the impact of psychotherapy and telemedicine on maternal mental stress and the child's mental and physical health. Mentally stressed pregnant women are randomized to an intervention (IG) and a not intervened control group. The IG receives an individualized psychotherapy starting prenatal and lasting for 10 months. Afterwards, a second randomization is used to investigate whether the use of telemedicine can stabilize the therapeutic effects. Using ecological momentary assessments and video recordings, the transfer into daily life, maternal sensitivity and mother-child-bonding are assessed. Psycho-biologically, the synchronicity of cortisol and oxytocin levels between mother and child are assessed as well as the peptidome of the colostrum and breast milk, which are assumed to be essential for the adaptation to the extra-uterine environment. All assessments are compared to an additional control group of healthy women. Finally, the results of the study will lead to the development of a qualification measure for health professionals to detect mental stress, to treat it with low-level interventions and to refer those women with high stress levels to mental health professionals. DISCUSSION The study aims to prevent the transgenerational transfer of psychiatric and somatic disorders from the mother to her child. The effects of the psychotherapy will be stabilized through telemedicine and long-term impacts on the child's and mothers' mental health are enhanced. The combination of psychotherapy, telemedicine and methodologies of ecological momentary assessment, video recording and bio banking are new in content-related and methodological manner. TRIAL REGISTRATION German Clinical Trials Register: DRKS00017065. Registered 02 May 2019. World Health Organization, Universal Trial Number: U1111-1230-9826. Registered 01 April 2019.",2019,"Using ecological momentary assessments and video recordings, the transfer into daily life, maternal sensitivity and mother-child-bonding are assessed.","['psychiatric and somatic disorders from the mother to her child', ""pregnant women and young mothers and to improve Child's health"", 'Mentally stressed pregnant women']","['psychotherapy, telemedicine and methodologies of ecological momentary assessment, video recording and bio banking', 'telemedicine', 'individualized psychotherapy and telemedicine', 'psychotherapy', 'psychotherapy and telemedicine', 'intervention (IG) and a not intervened control group']","['mental stress', ""maternal mental stress and the child's mental and physical health"", 'maternal sensitivity', 'transfer into daily life, maternal sensitivity and mother-child-bonding', 'synchronicity of cortisol and oxytocin levels']","[{'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0008078', 'cui_str': 'Childrens Health'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}]","[{'cui': 'C1273567', 'cui_str': 'Psychotherapy (specialty)'}, {'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0969625', 'cui_str': 'methodology'}, {'cui': 'C4277684', 'cui_str': 'Ecological Momentary Assessment'}, {'cui': 'C0042650', 'cui_str': 'Audiovisual Recording'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0040671', 'cui_str': 'Transfer'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0028758', 'cui_str': 'Object Relationship'}, {'cui': 'C0439579', 'cui_str': 'Synchronicities (qualifier value)'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",,0.0739938,"Using ecological momentary assessments and video recordings, the transfer into daily life, maternal sensitivity and mother-child-bonding are assessed.","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bischoff', 'Affiliation': 'Department of Health and Prevention, Institute of Psychology, University Greifswald, Greifswald, Germany. marie.bischoff1@uni-greifswald.de.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Howland', 'Affiliation': 'Department of Neonatology and Paediatric Intensive Care, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Klinger-König', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Tomczyk', 'Affiliation': 'Department of Health and Prevention, Institute of Psychology, University Greifswald, Greifswald, Germany.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Schmidt', 'Affiliation': 'Department of Health and Prevention, Institute of Psychology, University Greifswald, Greifswald, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Zygmunt', 'Affiliation': 'Clinic and Polyclinic for Obstetrics and Gynecology, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Heckmann', 'Affiliation': 'Department of Neonatology and Paediatric Intensive Care, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'van den Berg', 'Affiliation': 'Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Bethke', 'Affiliation': 'Department of Health, Nursing and Administration, University of Applied Sciences Neubrandenburg, Neubrandenburg, Germany.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Corleis', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Günther', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Liutkus', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Stentzel', 'Affiliation': 'Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Neumann', 'Affiliation': 'Department of Health, Nursing and Administration, University of Applied Sciences Neubrandenburg, Neubrandenburg, Germany.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Penndorf', 'Affiliation': 'Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Ludwig', 'Affiliation': 'Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Hammer', 'Affiliation': 'Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Winter', 'Affiliation': 'Integrated Research Biobank, University Medicine Greifswald, Greifswald, Germany.'}, {'ForeName': 'H J', 'Initials': 'HJ', 'LastName': 'Grabe', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany.'}]",BMC psychiatry,['10.1186/s12888-019-2279-0'] 667,30720034,Influence of daily fresh pear consumption on biomarkers of cardiometabolic health in middle-aged/older adults with metabolic syndrome: a randomized controlled trial.,"Previous research suggests potential for fresh pears as a functional food for promoting cardiometabolic health. The purpose of this randomized, open-label, placebo-controlled, crossover clinical trial was to evaluate the influence of daily fresh pear consumption on blood pressure (primary outcome) and other biomarkers of cardiometabolic health in middle-aged/older adults with metabolic syndrome (MetS). Forty men and women aged 45-65 years with MetS were included and randomly assigned to receive either two medium-sized fresh pears (Pear) or a calorie-matched control drink (Control) per day for each 12-week treatment period, each separated by a 4-week washout period. After 12 weeks of daily fresh pear consumption, systolic blood pressure tended to be reduced (130 ± 2 mmHg vs. 134 ± 2 mmHg at baseline, P = 0.07) and pulse pressure was significantly reduced (51 ± 1 vs. 54 ± 1 at baseline, P < 0.05). At 12 weeks, leptin concentrations were lower in the Pear group than Control (52.5 [7.6, 120.5] ng dL-1vs. 53.4 [5.0, 120.5] ng dL-1, respectively, P < 0.05), and there was a significant group by time interaction (P < 0.05). Leptin concentrations were significantly reduced at 12 weeks compared to baseline in the Pear group (52.5 [7.6, 120.5] ng dL-1vs. 54.8 [6.4, 120.5] ng dL-1 at baseline, P < 0.05) but not in the Control group. Waist circumference was significantly reduced at 12 weeks in the Pear group (107.7 ± 2.0 cm vs. 108.4 ± 2 cm at baseline, P < 0.05) with a trend for a group by time interaction (P < 0.1), and significantly lower in the Pear group than Control (108.1 ± 2.0 cm vs. 108.8 ± 2 cm, P < 0.05) at 6 weeks with a significant group by time interaction (P < 0.05). Conversely, values were significantly increased at 6 weeks (108.8 ± 2 cm vs. 108.3 ± 2.0 cm at baseline, P < 0.05) in the Control group and sustained at 12 weeks. Waist-to-hip ratio was significantly reduced (0.92 ± 0.01 vs. 0.93 ± 0.01 at baseline, P < 0.05) at 12 weeks in the Pear group, and significantly lower than Control at 6 weeks (0.93 ± 0.01 vs. 0.93 ± 0.01, respectively, P < 0.05) and 12 weeks (0.92 ± 0.01 vs. 0.93 ± 0.01, P < 0.05). These findings suggest that daily fresh pear consumption may promote modest improvements in cardiometabolic health in middle-aged/older adults with MetS. This trial was registered at clinicaltrials.gov as NCT02228837.",2019,"Leptin concentrations were significantly reduced at 12 weeks compared to baseline in the Pear group (52.5 [7.6, 120.5]","['middle-aged/older adults with MetS', 'middle-aged/older adults with metabolic syndrome (MetS', '54.8 [6.4, 120.5', 'Forty men and women aged 45-65 years with MetS', '53.4 [5.0, 120.5', 'middle-aged/older adults with metabolic syndrome']","['daily fresh pear consumption', 'two medium-sized fresh pears (Pear) or a calorie-matched control drink (Control', 'placebo']","['blood pressure', 'cardiometabolic health', 'Waist-to-hip ratio', 'leptin concentrations', 'Waist circumference', 'systolic blood pressure', 'Leptin concentrations', 'pulse pressure']","[{'cui': 'C0205847', 'cui_str': 'Middle Aged'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0524620', 'cui_str': 'Metabolic Syndrome X'}, {'cui': 'C4517822', 'cui_str': '6.4 (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0443224', 'cui_str': 'Fresh (qualifier value)'}, {'cui': 'C1138601', 'cui_str': 'Pears'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}, {'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205682', 'cui_str': 'Waist-Hip Ratio'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0949236', 'cui_str': 'Pulse Pressure'}]",,0.110933,"Leptin concentrations were significantly reduced at 12 weeks compared to baseline in the Pear group (52.5 [7.6, 120.5]","[{'ForeName': 'Negin', 'Initials': 'N', 'LastName': 'Navaei', 'Affiliation': 'Department of Nutrition, Food, and Exercise Sciences, Florida State University, Tallahassee, FL, USA.'}, {'ForeName': 'Shirin', 'Initials': 'S', 'LastName': 'Pourafshar', 'Affiliation': ''}, {'ForeName': 'Neda S', 'Initials': 'NS', 'LastName': 'Akhavan', 'Affiliation': ''}, {'ForeName': 'Nicole S', 'Initials': 'NS', 'LastName': 'Litwin', 'Affiliation': ''}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Foley', 'Affiliation': ''}, {'ForeName': 'Kelli S', 'Initials': 'KS', 'LastName': 'George', 'Affiliation': ''}, {'ForeName': 'Shannon C', 'Initials': 'SC', 'LastName': 'Hartley', 'Affiliation': ''}, {'ForeName': 'Marcus L', 'Initials': 'ML', 'LastName': 'Elam', 'Affiliation': ''}, {'ForeName': 'Sangeeta', 'Initials': 'S', 'LastName': 'Rao', 'Affiliation': ''}, {'ForeName': 'Bahram H', 'Initials': 'BH', 'LastName': 'Arjmandi', 'Affiliation': ''}, {'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'Johnson', 'Affiliation': ''}]",Food & function,['10.1039/c8fo01890a'] 668,30132265,The Effect of Fatigue-Related Education on Pediatric Oncology Patients' Fatigue and Quality of Life.,"The identification of cancer-related fatigue as a clinical problem in pediatric oncology is an important phenomenon, and there are limited number of studies about raising the awareness of pediatric oncology patients and their parents. Fatigue-related education for patients and their parents before and during cancer treatment reduces the fatigue levels of patients. This study aims to analyze the effect of fatigue-related education for pediatric oncology patients aged 7-12 and their parents on their fatigue and quality of life. This study was conducted with 80 children with cancer and their parents who were assigned to either the control group (n = 40) or the experimental group (n = 40). The experimental group received a fatigue-related educational program. The data were collected three times: prior to the program, 3 months later, and 6 months afterwards. Multidimensional variance analysis, the Bonferroni adjusted t test and regression analysis were used to analyze the data. A significant difference was found among the experimental and the control group for total mean scores and the mean scores of subdimensions of the Scale for the Assessment of Fatigue-Child Form in terms of the interactions of group, time, and group*time (p < 0.05). Significant differences were found among the experimental and control groups' mean scores on the Scale for the Quality of Life-Child and Parents Form in terms of the interactions of group, time, and group*time (p < 0.05). Fatigue-related education is an effective education model as a way to reduce fatigue and increase the quality of life of children with cancer. The use of fatigue-related education by nurses in pediatric oncology clinics will have positive effects on children and their parents.",2019,"Significant differences were found among the experimental and control groups' mean scores on the Scale for the Quality of Life-Child and Parents Form in terms of the interactions of group, time, and group*time (p < 0.05).","['children and their parents', '80 children with cancer and their parents who were assigned to either the control group (n\u2009=\u200940) or the experimental group (n\u2009=\u200940', 'Pediatric Oncology Patients', 'pediatric oncology patients aged 7-12 and their parents on their', 'children with cancer']","['Fatigue-Related Education', 'fatigue-related educational program']","['Fatigue-related education', 'fatigue and quality of life', 'fatigue levels', 'Fatigue and Quality of Life', 'total mean scores']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0043237', 'cui_str': 'WHO'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1518931', 'cui_str': 'Pediatric oncology (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0034380'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",80.0,0.0207193,"Significant differences were found among the experimental and control groups' mean scores on the Scale for the Quality of Life-Child and Parents Form in terms of the interactions of group, time, and group*time (p < 0.05).","[{'ForeName': 'Aslı Akdeniz', 'Initials': 'AA', 'LastName': 'Kudubes', 'Affiliation': 'Department of Pediatric Nursing, Dokuz Eylul University Faculty of Nursing, Inciralti, 35340, Izmir, Turkey. asliakdeniz@hotmail.com.'}, {'ForeName': 'Murat', 'Initials': 'M', 'LastName': 'Bektas', 'Affiliation': 'Department of Pediatric Nursing, Dokuz Eylul University Faculty of Nursing, Inciralti, 35340, Izmir, Turkey.'}, {'ForeName': 'Kamer', 'Initials': 'K', 'LastName': 'Mutafoğlu', 'Affiliation': 'Department of Pediatrics, Izmir University of Economics Faculty of Medicine, Izmir, Turkey.'}]",Journal of cancer education : the official journal of the American Association for Cancer Education,['10.1007/s13187-018-1419-4'] 669,30244403,Effect of Educational Intervention Based on the Health Belief Model and Self-Efficacy in Promoting Preventive Behaviors in a Cholangiocarcinoma Screening Group.,"Cholangiocarcinoma (CCA) is a neoplasm known as one of the most common causes of cancer-related deaths in Southeast Asia, particularly in Thailand, Laos, and Cambodia. Prevention and health education are required. Therefore, this study aimed to determine the effectiveness of an educational intervention to prevent CCA among a rural population in Thailand based on the health belief model (HBM) and self-efficacy frameworks. In this quasi-experimental study, 60 participants (30 participants in the experimental group and 30 participants in the control group) were selected in 2017. The educational intervention for the experimental group consisted of seven training sessions (introduction to CCA, risk factors, complications, benefits and barriers to proper consumption of cooked fish, carcinogenic agents, behavioral protection, and self-efficacy in applying preventive behaviors). A questionnaire that consisted of demographic information, knowledge, and HBM constructs (perceived susceptibility, severity, benefits, barriers, cues to action, and self-efficacy) was used to measure CCA preventive behaviors before and 3 months after the intervention. Data were analyzed using SPSS-22 via chi-squared, paired t-tests, and independent samples t tests at a significance level of 0.5. Three months after the intervention, the experimental group showed a significant increase in the knowledge, perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cues to action, self-efficacy, and CCA preventive behaviors compared to the control group. This study showed the effectiveness of the intervention based on the HBM constructs and self-efficacy in the adoption of CCA preventive behaviors 3 months post intervention in the risk group. Thus, these models may serve as a framework for designing and implementing educational interventions for the prevention of CCA.",2019,"Three months after the intervention, the experimental group showed a significant increase in the knowledge, perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cues to action, self-efficacy, and CCA preventive behaviors compared to the control group.","['rural population in Thailand based on the health belief model (HBM) and self-efficacy frameworks', '60 participants (30 participants in the experimental group and 30 participants in the control group) were selected in 2017']","['Educational Intervention', 'educational intervention', 'Cholangiocarcinoma (CCA']","['knowledge, perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cues to action, self-efficacy, and CCA preventive behaviors', 'CCA preventive behaviors', 'demographic information, knowledge, and HBM constructs (perceived susceptibility, severity, benefits, barriers, cues to action, and self-efficacy']","[{'cui': 'C0035962', 'cui_str': 'Rural Population'}, {'cui': 'C0039725', 'cui_str': 'Kingdom of Thailand'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C3714363', 'cui_str': 'Health belief model (qualifier value)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0206698', 'cui_str': 'Cholangiocellular Carcinoma'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C1264642', 'cui_str': 'Susceptibility (property) (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0441472', 'cui_str': 'Action (qualifier value)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C1456501', 'cui_str': 'Preventive'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}]",60.0,0.0317671,"Three months after the intervention, the experimental group showed a significant increase in the knowledge, perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cues to action, self-efficacy, and CCA preventive behaviors compared to the control group.","[{'ForeName': 'Wirangrong', 'Initials': 'W', 'LastName': 'Srithongklang', 'Affiliation': 'Parasitic Disease Research Center, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand.'}, {'ForeName': 'Benchapan', 'Initials': 'B', 'LastName': 'Panithanang', 'Affiliation': 'Parasitic Disease Research Center, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand.'}, {'ForeName': 'Pontip', 'Initials': 'P', 'LastName': 'Kompor', 'Affiliation': 'Parasitic Disease Research Center, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand.'}, {'ForeName': 'Prasit', 'Initials': 'P', 'LastName': 'Pengsaa', 'Affiliation': 'Parasitic Disease Research Center, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand.'}, {'ForeName': 'Natthawut', 'Initials': 'N', 'LastName': 'Kaewpitoon', 'Affiliation': 'Parasitic Disease Research Center, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand. natthawut.ka@sut.ac.th.'}, {'ForeName': 'Parichart', 'Initials': 'P', 'LastName': 'Wakkhuwatapong', 'Affiliation': 'Parasitic Disease Research Center, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand.'}, {'ForeName': 'Soraya J', 'Initials': 'SJ', 'LastName': 'Kaewpitoon', 'Affiliation': 'Parasitic Disease Research Center, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand.'}]",Journal of cancer education : the official journal of the American Association for Cancer Education,['10.1007/s13187-018-1424-7'] 670,31770296,"Preemptive Pregabalin in Children and Adolescents Undergoing Posterior Instrumented Spinal Fusion: A Double-Blinded, Placebo-Controlled, Randomized Clinical Trial.","BACKGROUND Pregabalin as part of a multimodal pain-management regimen has been shown to reduce opioid consumption after spinal surgery in adults but it is unclear whether this is also true in adolescents. Pregabalin has been found to have neuroprotective effects and therefore could have a positive impact on pain after spinal deformity surgery. We conducted a randomized, double-blinded, placebo-controlled clinical trial of adolescent patients undergoing spinal fusion to evaluate the short-term effects of pregabalin on postoperative pain and opioid consumption. METHODS Adolescents with adolescent idiopathic scoliosis, Scheuermann kyphosis, or spondylolisthesis who were scheduled for posterior spinal fusion with all-pedicle-screw instrumentation were randomized to receive either pregabalin (2 mg/kg twice daily) or placebo preoperatively and for 5 days after surgery. The patients ranged from 10 to 21 years of age. The primary outcome was total opioid consumption as measured with use of patient-controlled analgesia. Postoperative pain scores and opioid-related adverse effects were evaluated. RESULTS Sixty-three of 77 eligible patients were included and analyzed. Cumulative oxycodone consumption per kilogram did not differ between the study groups during the first 48 hours postoperatively, with a median of 1.44 mg/kg (95% confidence interval [CI],1.32 to 1.67 mg/kg) in the pregabalin group and 1.50 mg/kg (95% CI, 1.39 to 1.79 mg/kg) in the placebo group (p = 0.433). A subgroup analysis of 51 patients with adolescent idiopathic scoliosis showed the same result, with a mean of 1.45 mg/kg (95% CI, 1.24 to 1.65 mg/kg) in the pregabalin group and 1.59 mg/kg (95% CI, 1.37 to 1.82 mg/kg) in the placebo group (p = 0.289). Total oxycodone consumption per hour (mg/kg/hr) was not different between the groups over the time points (p = 0.752). The postoperative pain scores did not differ significantly between the groups (p = 0.196). CONCLUSIONS The use of perioperative pregabalin does not reduce the postoperative opioid consumption or pain scores in adolescents after posterior spinal fusion surgery. LEVEL OF EVIDENCE Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.",2020,"The use of perioperative pregabalin does not reduce the postoperative opioid consumption or pain scores in adolescents after posterior spinal fusion surgery. ","['adolescents after posterior spinal fusion surgery', '51 patients with adolescent idiopathic scoliosis', 'Sixty-three of 77 eligible patients were included and analyzed', 'adolescent patients undergoing spinal fusion', 'Adolescents with adolescent idiopathic scoliosis, Scheuermann kyphosis, or spondylolisthesis who were scheduled for posterior spinal fusion with all-pedicle-screw instrumentation', 'Children and Adolescents Undergoing Posterior']","['pregabalin', 'Placebo', 'Instrumented Spinal Fusion', 'placebo', 'Preemptive Pregabalin', 'perioperative pregabalin', 'Pregabalin']","['opioid consumption', 'Postoperative pain scores and opioid-related adverse effects', 'postoperative pain scores', 'postoperative opioid consumption or pain scores', 'Cumulative oxycodone consumption per kilogram', 'Total oxycodone consumption', 'total opioid consumption as measured with use of patient-controlled analgesia']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0919636', 'cui_str': 'Operative spinal fusion'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0410702', 'cui_str': 'Adolescent idiopathic scoliosis (disorder)'}, {'cui': 'C4319614', 'cui_str': '63 (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0037935', 'cui_str': 'Spinal Fusion'}, {'cui': 'C0036310', 'cui_str': 'Scheuermann Kyphosis'}, {'cui': 'C0038016', 'cui_str': 'Spondylisthesis'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C1961768', 'cui_str': 'Pedicle Screws'}, {'cui': 'C0021632', 'cui_str': 'instrumentation'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0657912', 'cui_str': 'pregabalin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4551823', 'cui_str': 'instruments'}, {'cui': 'C0037935', 'cui_str': 'Spinal Fusion'}]","[{'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0030049', 'cui_str': 'Oxycodone'}, {'cui': 'C0439209', 'cui_str': 'kg'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0078944', 'cui_str': 'Patient-Controlled Analgesia'}]",77.0,0.746358,"The use of perioperative pregabalin does not reduce the postoperative opioid consumption or pain scores in adolescents after posterior spinal fusion surgery. ","[{'ForeName': 'Linda L', 'Initials': 'LL', 'LastName': 'Helenius', 'Affiliation': 'Departments of Anaesthesiology and Intensive Care (L.L.H. and T.M.) and Paediatric Orthopaedic Surgery (L.L.H., H.O., M.L., O.P., and I.J.H.), University of Turku and Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Oksanen', 'Affiliation': 'Departments of Anaesthesiology and Intensive Care (L.L.H. and T.M.) and Paediatric Orthopaedic Surgery (L.L.H., H.O., M.L., O.P., and I.J.H.), University of Turku and Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Lastikka', 'Affiliation': 'Departments of Anaesthesiology and Intensive Care (L.L.H. and T.M.) and Paediatric Orthopaedic Surgery (L.L.H., H.O., M.L., O.P., and I.J.H.), University of Turku and Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Olli', 'Initials': 'O', 'LastName': 'Pajulo', 'Affiliation': 'Departments of Anaesthesiology and Intensive Care (L.L.H. and T.M.) and Paediatric Orthopaedic Surgery (L.L.H., H.O., M.L., O.P., and I.J.H.), University of Turku and Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Eliisa', 'Initials': 'E', 'LastName': 'Löyttyniemi', 'Affiliation': 'Department of Biostatistics, University of Turku, Turku, Finland.'}, {'ForeName': 'Tuula', 'Initials': 'T', 'LastName': 'Manner', 'Affiliation': 'Departments of Anaesthesiology and Intensive Care (L.L.H. and T.M.) and Paediatric Orthopaedic Surgery (L.L.H., H.O., M.L., O.P., and I.J.H.), University of Turku and Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Ilkka J', 'Initials': 'IJ', 'LastName': 'Helenius', 'Affiliation': 'Departments of Anaesthesiology and Intensive Care (L.L.H. and T.M.) and Paediatric Orthopaedic Surgery (L.L.H., H.O., M.L., O.P., and I.J.H.), University of Turku and Turku University Hospital, Turku, Finland.'}]",The Journal of bone and joint surgery. American volume,['10.2106/JBJS.19.00650'] 671,31739206,"Comparison of the effect of nocturnal use of commercial versus custom-made wrist orthoses, in addition to gliding exercises, in the function and symptoms of carpal tunnel syndrome: A pilot randomized trial.","BACKGROUND Conservative treatment for carpal tunnel syndrome (CTS) often includes wrist orthosis. However, there is no consensus on whether commercial or custom-made wrist orthosis is better for the treatment. PURPOSE To assess feasibility of a study comparing nocturnal use of commercial versus custom-made wrist orthosis in the treatment of mild/moderate CTS and estimate their potential effects on function and symptoms. STUDY DESIGN Randomized clinical trial. METHODS Twenty-four individuals with mild/moderate CTS were randomized to wear either a commercial orthosis (n = 12) or a custom-made orthosis (n = 12). Participants used the assigned orthosis at night for 45 days and performed gliding exercises at home/work. We collected data on access to eligible population and feasibility of protocol. Data on use of orthosis, performance of exercises, and symptoms were collected through a dairy filled by the participant. Outcomes were pain (using Numeric Pain Rating Scale), symptom severity and functional status (using Boston Questionnaire), pinch strength (by dynamometry), and electromyographic activity of forearm muscles (sampled during a reach-to-grasp task). Outcomes were measured before and after the intervention. RESULTS There were no loses to follow-up in either intervention group. After treatment, we found increased tripod pinch strength and better symptoms and function in both orthosis groups, with better outcomes for the custom-made orthosis, although the differences were not statistically significant. CONCLUSIONS The preliminary results showed a potential for better outcomes from the custom-made orthosis. We established that a larger study would be feasible and could be designed and conducted based on the estimates provided by this study. TRIAL REGISTRATION Brazilian Registry of Clinical Trials (ReBEC) - registration number: RBR-74rqnz.",2020,"After treatment, we found increased tripod pinch strength and better symptoms and function in both orthosis groups, with better outcomes for the custom-made orthosis, although the differences were not statistically significant. ","['Twenty-four individuals with mild/moderate CTS', 'carpal tunnel syndrome (CTS', 'carpal tunnel syndrome']","['commercial orthosis (n\u202f=\u202f12) or a custom-made orthosis', 'nocturnal use of commercial versus custom-made wrist orthoses']","['tripod pinch strength and better symptoms and function', 'pain (using Numeric Pain Rating Scale), symptom severity and functional status (using Boston Questionnaire), pinch strength (by dynamometry), and electromyographic activity of forearm muscles (sampled during a reach-to-grasp task']","[{'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0007286', 'cui_str': 'Amyotrophy, Thenar, Of Carpal Origin'}]","[{'cui': 'C0162343', 'cui_str': 'Customs'}, {'cui': 'C0240526', 'cui_str': 'Night time (qualifier value)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0043262', 'cui_str': 'Wrist'}, {'cui': 'C0029365', 'cui_str': 'Orthose'}]","[{'cui': 'C0454273', 'cui_str': 'Tripod (physical object)'}, {'cui': 'C1720876', 'cui_str': 'Pinch Strength'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0222045'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0006037', 'cui_str': 'Boston'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0016536', 'cui_str': 'Antebrachiums'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}, {'cui': 'C0220843', 'cui_str': 'Grip'}]",24.0,0.0927797,"After treatment, we found increased tripod pinch strength and better symptoms and function in both orthosis groups, with better outcomes for the custom-made orthosis, although the differences were not statistically significant. ","[{'ForeName': 'Danielle Soares', 'Initials': 'DS', 'LastName': 'Figueiredo', 'Affiliation': 'Department of Human Movement Science, Universidade Federal de São Paulo, Santos, Brazil; Rua Silva Jardim, nº 136, Vila Mathias, Santos, São Paulo, CEP 11015-020, Brazil. Electronic address: dani.figueiredo16@yahoo.com.br.'}, {'ForeName': 'Marcia Aparecida', 'Initials': 'MA', 'LastName': 'Ciol', 'Affiliation': 'Department of Rehabilitation Medicine, School of Medicine, University of Washington, Seattle, USA; 1959 NE Pacific St, UW Box, 356490, Seattle, WA, 98195-6490, USA. Electronic address: marciac@uw.edu.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'da Conceição Dos Santos', 'Affiliation': 'Department of Human Movement Science, Universidade Federal de São Paulo, Santos, Brazil; Rua Silva Jardim, nº 136, Vila Mathias, Santos, São Paulo, CEP 11015-020, Brazil. Electronic address: mariasantosto@uol.com.br.'}, {'ForeName': 'Letícia', 'Initials': 'L', 'LastName': 'de Araújo Silva', 'Affiliation': 'Department of Human Movement Science, Universidade Federal de São Paulo, Santos, Brazil; Rua Silva Jardim, nº 136, Vila Mathias, Santos, São Paulo, CEP 11015-020, Brazil. Electronic address: leticiaaraujos@hotmail.com.'}, {'ForeName': 'Joseph Bruno', 'Initials': 'JB', 'LastName': 'Bidin Brooks', 'Affiliation': 'Faculty of Medicine, Universidade Metropolitana de Santos, Santos, Brazil; Rua da Constituição, nº 374, Vila Nova, Santos, São Paulo, CEP 11015-470, Brazil. Electronic address: joseph3b@gmail.com.'}, {'ForeName': 'Roger Amorim', 'Initials': 'RA', 'LastName': 'Santos Diniz', 'Affiliation': 'Faculty of Medicine, Universidade Metropolitana de Santos, Santos, Brazil; Rua da Constituição, nº 374, Vila Nova, Santos, São Paulo, CEP 11015-470, Brazil. Electronic address: rod.diniz@uol.com.br.'}, {'ForeName': 'Helga Tatiana', 'Initials': 'HT', 'LastName': 'Tucci', 'Affiliation': 'Department of Human Movement Science, Universidade Federal de São Paulo, Santos, Brazil; Rua Silva Jardim, nº 136, Vila Mathias, Santos, São Paulo, CEP 11015-020, Brazil. Electronic address: helgatucci@gmail.com.'}]",Musculoskeletal science & practice,['10.1016/j.msksp.2019.102089'] 672,31784929,"Evaluation of bradykinin, VEGF, and EGF biomarkers in gingival crevicular fluid and comparison of PhotoBioModulation with conventional techniques in periodontitis: a split-mouth randomized clinical trial.","Periodontal disease is a chronic progressive inflammatory process leading to damage of tooth-supporting tissues. This comparative study assessed the effect of PhotoBioModulation (PBM) versus conventional therapy, and investigated biomarkers involved in the healing process. The test group comprised twenty systemically-healthy non-smoking subjects with chronic periodontitis with the presence of two matched contro-lateral premolar sites (probing depth > 5 mm); twenty subjects without chronic periodontitis (CP) served as control group. Patients were treated at baseline, either with scaling and root planing (SRP group) or with a procedure entailing SRP supported by PBM (PBM group). The laser used was a diode laser operating at 645 nm wavelength, 10 J/cm2, and 0.5 W/cm2 with a 600 μm fiber optic. Crevicular fluid levels of bradykinin (BK), vascular endothelial growth factor (VEGF), and epidermal growth factor z (EGF) were determined at both sites. Crevicular fluid specimens from both groups were analyzed with the ELISA TEST. Clinical differences in analyzed outcomes were observed in favor of PBM treatment. Taking average values as 100%, the reduction in BK concentration was 47.68% with SRP and 68.43% with PBM on day 3; the VEGF concentration decreased by 35.73% with SRP and 48.59% with PBM on day 7; the EGF concentration increased by 55.58% with SRP and by 58.11% with PBM on day 21.Clinical parameters improved significantly in both groups (pooled mean values of probing depth decreased from 5.6 to 4.5 mm; gingival index from 1.92 to 1.1; and bleeding on probing from 49.67 to 23.23) but did not vary significantly between the PBM and the SRP group. The results confirmed that PBM have beneficial effects in the early phases of the healing process playing a role in modulation of BK, EGF, and VEGF in gingival crevicular fluid levels; both groups had significant clinical improvement over control but there was no significant difference between them, only a trend for PBM group. The overall results of the study suggest a potential benefit of PBM in conjunction with SRP in treating chronic periodontitis.",2020,Clinical differences in analyzed outcomes were observed in favor of PBM treatment.,"['periodontitis', 'twenty systemically-healthy non-smoking subjects with chronic periodontitis with the presence of two matched contro-lateral premolar sites (probing depth > 5 mm); twenty subjects without chronic periodontitis (CP) served as control group']","['scaling and root planing (SRP group) or with a procedure entailing SRP supported by PBM (PBM group', 'bradykinin, VEGF, and EGF biomarkers', 'PBM', 'PhotoBioModulation (PBM']","['VEGF concentration', 'EGF concentration', 'gingival index', 'Crevicular fluid levels of bradykinin (BK), vascular endothelial growth factor (VEGF), and epidermal growth factor z (EGF', 'probing depth', 'BK concentration']","[{'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0266929', 'cui_str': 'Adult Periodontitis'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0205093', 'cui_str': 'Lateral (qualifier value)'}, {'cui': 'C1704302', 'cui_str': 'Premolar'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C3179165', 'cui_str': 'Probe (methazole)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0439084', 'cui_str': '>5 (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0085287', 'cui_str': 'Root Planings'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0071006', 'cui_str': 'phytobacteriomycin'}, {'cui': 'C0006100', 'cui_str': 'Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg'}, {'cui': 'C0078058', 'cui_str': 'Vascular Endothelial Growth Factor A'}, {'cui': 'C0242275', 'cui_str': 'Epidermal Growth Factor'}]","[{'cui': 'C0078058', 'cui_str': 'Vascular Endothelial Growth Factor A'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0242275', 'cui_str': 'Epidermal Growth Factor'}, {'cui': 'C0017569', 'cui_str': 'Gingival Index'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0006100', 'cui_str': 'Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg'}, {'cui': 'C3179165', 'cui_str': 'Probe (methazole)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}]",20.0,0.0273185,Clinical differences in analyzed outcomes were observed in favor of PBM treatment.,"[{'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Angiero', 'Affiliation': 'Department of Medical Sciences and Diagnostic Integrated, University of Genoa, Genova, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Ugolini', 'Affiliation': 'Department of Medical Sciences and Diagnostic Integrated, University of Genoa, Genova, Italy. Alessandro.ugolini@unige.it.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Cattoni', 'Affiliation': 'Dental School, Vita-Salute San Raffaele University, Milan, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Bova', 'Affiliation': 'Dental School, Vita-Salute San Raffaele University, Milan, Italy.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Blasi', 'Affiliation': 'Department of Medical Sciences and Diagnostic Integrated, University of Genoa, Genova, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Gallo', 'Affiliation': 'Section of Biostatistics, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.'}, {'ForeName': 'Gianguido', 'Initials': 'G', 'LastName': 'Cossellu', 'Affiliation': ""Department of Biomedical, Surgical and Dental Sciences, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Gherlone', 'Affiliation': 'Dental School, Vita-Salute San Raffaele University, Milan, Italy.'}]",Lasers in medical science,['10.1007/s10103-019-02919-w'] 673,31782656,The feasibility of low-intensity psychological therapy for depression co-occurring with autism in adults: The Autism Depression Trial (ADEPT) - a pilot randomised controlled trial.,"Low-intensity cognitive behaviour therapy including behavioural activation is an evidence-based treatment for depression, a condition frequently co-occurring with autism. The feasibility of adapting low-intensity cognitive behaviour therapy for depression to meet the needs of autistic adults via a randomised controlled trial was investigated. The adapted intervention (guided self-help) comprised materials for nine individual sessions with a low-intensity psychological therapist. Autistic adults (n = 70) with depression (Patient Health Questionnaire-9 score ⩾10) recruited from National Health Service adult autism services and research cohorts were randomly allocated to guided self-help or treatment as usual. Outcomes at 10-, 16- and 24-weeks post-randomisation were blind to treatment group. Rates of retention in the study differed by treatment group with more participants attending follow-up in the guided self-help group than treatment as usual. The adapted intervention was well-received, 86% (n = 30/35) of participants attended the pre-defined 'dose' of five sessions of treatment and 71% (25/35) attended all treatment sessions. The findings of this pilot randomised controlled trial indicate that low-intensity cognitive behaviour therapy informed by behavioural activation can be successfully adapted to meet the needs of autistic people. Evaluation of the effectiveness of this intervention in a full scale randomised controlled trial is now warranted.",2020,Rates of retention in the study differed by treatment group with more participants attending follow-up in the guided self-help group than treatment as usual.,"['depression co-occurring with autism in adults', 'autistic adults', 'Autistic adults (n\u2009=\u200970) with depression (Patient Health Questionnaire-9 score ⩾10) recruited from National Health Service adult autism services and research cohorts']","['adapting low-intensity cognitive behaviour therapy', 'adapted intervention (guided self-help) comprised materials for nine individual sessions with a low-intensity psychological therapist', 'low-intensity psychological therapy', 'Low-intensity cognitive behaviour therapy', 'guided self-help or treatment as usual', 'low-intensity cognitive behaviour therapy']",['Rates of retention'],"[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0027462', 'cui_str': 'Health Services, National'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0035168'}]","[{'cui': 'C0596836', 'cui_str': 'Low intensity'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0841584', 'cui_str': 'Psychological therapies (procedure)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0035280', 'cui_str': 'Retention'}]",,0.170748,Rates of retention in the study differed by treatment group with more participants attending follow-up in the guided self-help group than treatment as usual.,"[{'ForeName': 'Ailsa', 'Initials': 'A', 'LastName': 'Russell', 'Affiliation': 'University of Bath, UK.'}, {'ForeName': 'Daisy M', 'Initials': 'DM', 'LastName': 'Gaunt', 'Affiliation': 'University of Bristol, UK.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Cooper', 'Affiliation': 'University of Bath, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Barton', 'Affiliation': 'Northumberland, Tyne and Wear NHS Foundation Trust, UK.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Horwood', 'Affiliation': 'University of Bristol, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kessler', 'Affiliation': 'University of Bristol, UK.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Metcalfe', 'Affiliation': 'University of Bristol, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Ensum', 'Affiliation': 'Avon and Wiltshire Mental Health Partnership NHS Trust, UK.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Ingham', 'Affiliation': 'Northumberland, Tyne and Wear NHS Foundation Trust, UK.'}, {'ForeName': 'Jeremy R', 'Initials': 'JR', 'LastName': 'Parr', 'Affiliation': 'Northumberland, Tyne and Wear NHS Foundation Trust, UK.'}, {'ForeName': 'Dheeraj', 'Initials': 'D', 'LastName': 'Rai', 'Affiliation': 'University of Bristol, UK.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Wiles', 'Affiliation': 'University of Bristol, UK.'}]",Autism : the international journal of research and practice,['10.1177/1362361319889272'] 674,31221932,Effect of Music Therapy on Sleep Quality.,"Context One of the important functions of nurses is to prepare a relaxing environment for patients, for whom they look after and fulfill sleep needs. Today, music therapy, one of nonpharmacological treatment approaches, can be used for enhancing the sleep quality of individuals. The increase of individuals' sleep quality by using music therapy will enable nurses to intervene in problems associated with sleep disorders and prevent insomnia and other relevant problems. Objective This study was conducted to determine the effect of music therapy on sleep quality of the students. Design The research was an experimental pretest-posttest control group design. Setting The research was conducted among the students studying in the nursing department at a university in the east of Turkey in the spring term of the academic year of 2015-2016. Participant Students who (1) got a total score of 5 and higher according to the Pittsburgh Sleep Quality Index (PSQI), (2) had no neurological/psychiatric disorder, (3) had no hearing problem, (4) received no medical treatment regarding sleep, and (5) volunteered to participate in the study were included in the study. The students who were included in the study were divided into experimental and control groups. Invention Students in the experimental group were instructed to keep the volume of the personal MP3 player to be used for listening to the music therapy below 70% and to use it for 1 h/d at most. No intervention was applied to students in the control group. They were asked to sustain their normal sleeping habits. Outcome Measure To collect the data, a questionnaire prepared by the researchers for determining sociodemographic characteristics of the students and PSQI were used. Results As a result of the study, it was found that the posttest PSQI mean scores of students in the experimental group, listening to music therapy, were lower than the mean scores of the students in the control group, and the difference between the groups was statistically significant. Conclusions As a result of this study, it was determined that music therapy increased the sleep quality of students. Being one of the nonpharmacological treatment approaches intended for solving sleep problems, music therapy is a pain-free, safe, and affordable treatment method without any side effect that could be used in every area of health.",2020,No intervention was applied to students in the control group.,"['students studying in the nursing department at a university in the east of Turkey in the spring term of the academic year of 2015-2016', '2) had no neurological/psychiatric disorder, (3) had no hearing problem, (4) received no medical treatment regarding sleep, and (5) volunteered to participate in the study were included in the study']","['music therapy', 'Music Therapy']","['Pittsburgh Sleep Quality Index (PSQI', ""individuals' sleep quality"", 'Sleep Quality', 'sleep quality', 'posttest PSQI mean scores']","[{'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0028678', 'cui_str': 'nursing care'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0041400', 'cui_str': 'Turkey'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder (disorder)'}, {'cui': 'C0011053', 'cui_str': 'Deafness'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0026868', 'cui_str': 'Music Therapy'}]","[{'cui': 'C3697468', 'cui_str': 'PSQI - Pittsburgh sleep quality index'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0168703,No intervention was applied to students in the control group.,"[{'ForeName': 'Mehtap', 'Initials': 'M', 'LastName': 'Kavurmaci', 'Affiliation': ''}, {'ForeName': 'Nuray', 'Initials': 'N', 'LastName': 'Dayapoğlu', 'Affiliation': ''}, {'ForeName': 'Mehtap', 'Initials': 'M', 'LastName': 'Tan', 'Affiliation': ''}]",Alternative therapies in health and medicine,[] 675,31791688,"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.","BACKGROUND Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a significant improvement in progression-free and overall survival with dose-dense weekly paclitaxel and 3-weekly carboplatin. In this study, we aimed to compare efficacy and safety of two dose-dense weekly regimens to standard 3-weekly chemotherapy in a predominantly European population with epithelial ovarian cancer. METHODS In this phase 3 trial, women with newly diagnosed International Federation of Gynecology and Obstetrics stage IC-IV epithelial ovarian cancer were randomly assigned to group 1 (carboplatin area under the curve [AUC]5 or AUC6 and 175 mg/m 2 paclitaxel every 3 weeks), group 2 (carboplatin AUC5 or AUC6 every 3 weeks and 80 mg/m 2 paclitaxel weekly), or group 3 (carboplatin AUC2 and 80 mg/m 2 paclitaxel weekly). Written informed consent was provided by all women who entered the trial. The protocol had the appropriate national research ethics committee approval for the countries where the study was conducted. Patients entered the trial after immediate primary surgery, or before neoadjuvant chemotherapy with subsequent planned delayed primary surgery. The trial coprimary outcomes were progression-free survival and overall survival. Data analyses were done on an intention-to-treat basis, and were powered to detect a hazard ratio of 0·75 in progression-free survival. The main comparisons were between the control group (group 1) and each of the weekly research groups (groups 2 and 3). FINDINGS Between June 6, 2011, and Nov 28, 2014, 1566 women were randomly assigned to treatment. 72% (365), completed six protocol-defined treatment cycles in group 1, 60% (305) in group 2, and 63% (322) in group 3, although 90% (454), 89% (454), and 85% (437) completed six platinum-based chemotherapy cycles, respectively. Paclitaxel dose intensification was achieved with weekly treatment (median total paclitaxel dose 1010 mg/m 2 in group 1; 1233 mg/m 2 in group 2; 1274 mg/m 2 in group 3). By February, 2017, 1018 (65%) patients had experienced disease progression. No significant progression-free survival increase was observed with either weekly regimen (restricted mean survival time 24·4 months [97·5% CI 23·0-26·0] in group 1, 24·9 months [24·0-25·9] in group 2, 25·3 months [23·9-26·9] in group 3; median progression-free survival 17·7 months [IQR 10·6-not reached] in group 1, 20·8 months [11·9-59·0] in group 2, 21·0 months [12·0-54·0] in group 3; log-rank p=0·35 for group 2 vs group 1; group 3 vs 1 p=0·51). Although grade 3 or 4 toxic effects increased with weekly treatment, these effects were predominantly uncomplicated. Febrile neutropenia and sensory neuropathy incidences were similar across groups. INTERPRETATION Weekly dose-dense chemotherapy can be delivered successfully as first-line treatment for epithelial ovarian cancer but does not significantly improve progression-free survival compared with standard 3-weekly chemotherapy in predominantly European populations. FUNDING Cancer Research UK, Medical Research Council, Health Research Board in Ireland, Irish Cancer Society, Cancer Australia.",2019,"No significant progression-free survival increase was observed with either weekly regimen (restricted mean survival time 24·4 months [97·5% CI 23·0-26·0] in group 1, 24·9 months [24·0-25·9] in group 2, 25·3 months [23·9-26·9] in group 3; median progression-free survival 17·7 months [IQR 10·6-not reached] in group 1, 20·8 months [11·9-59·0] in group 2, 21·0 months [12·0-54·0] in group 3; log-rank p=0·35 for group 2 vs group 1; group 3 vs 1 p=0·51).","['Between June 6, 2011, and Nov 28, 2014, 1566 women', 'epithelial ovarian cancer', 'predominantly European population with epithelial ovarian cancer', 'women with newly diagnosed International Federation of Gynecology and Obstetrics stage IC-IV epithelial ovarian cancer']","['neoadjuvant chemotherapy with subsequent planned delayed primary surgery', 'Carboplatin and paclitaxel', 'group 1 (carboplatin area under the curve [AUC]5 or AUC6 and 175 mg/m 2 paclitaxel every 3 weeks), group 2 (carboplatin AUC5 or AUC6 every 3 weeks and 80 mg/m 2 paclitaxel weekly), or group 3 (carboplatin AUC2 and 80 mg/m 2 paclitaxel', 'Paclitaxel', 'primary peritoneal carcinoma treatment (ICON8']","['toxic effects', 'Febrile neutropenia and sensory neuropathy incidences', 'disease progression', 'progression-free and overall survival', 'efficacy and safety', 'progression-free survival increase', 'progression-free survival', 'median progression-free survival', 'progression-free survival and overall survival']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0677886', 'cui_str': 'Carcinoma, Ovarian Epithelial'}, {'cui': 'C0239307', 'cui_str': 'European (ethnic group)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0450454', 'cui_str': 'FIGO Stage'}]","[{'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0441869', 'cui_str': 'Group 3 (qualifier value)'}, {'cui': 'C0948303', 'cui_str': 'Peritoneal carcinoma'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0746883', 'cui_str': 'Febrile Neutropenia'}, {'cui': 'C0151313', 'cui_str': 'Sensory neuropathy (disorder)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0242656', 'cui_str': 'Disease Progression'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",1566.0,0.186979,"No significant progression-free survival increase was observed with either weekly regimen (restricted mean survival time 24·4 months [97·5% CI 23·0-26·0] in group 1, 24·9 months [24·0-25·9] in group 2, 25·3 months [23·9-26·9] in group 3; median progression-free survival 17·7 months [IQR 10·6-not reached] in group 1, 20·8 months [11·9-59·0] in group 2, 21·0 months [12·0-54·0] in group 3; log-rank p=0·35 for group 2 vs group 1; group 3 vs 1 p=0·51).","[{'ForeName': 'Andrew R', 'Initials': 'AR', 'LastName': 'Clamp', 'Affiliation': 'Department of Medical Oncology, The Christie National Health Service Foundation Trust, and University of Manchester, Manchester, UK.'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'James', 'Affiliation': 'Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK. Electronic address: e.james@ucl.ac.uk.'}, {'ForeName': 'Iain A', 'Initials': 'IA', 'LastName': 'McNeish', 'Affiliation': 'Department of Surgery and Cancer, Imperial College London, London, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Dean', 'Affiliation': 'Oncology Department, St John of God Hospital, Subiaco, WA, Australia.'}, {'ForeName': 'Jae-Weon', 'Initials': 'JW', 'LastName': 'Kim', 'Affiliation': 'Department of Obstetrics and Gynaecology, Seoul National University, Seoul, Korea.'}, {'ForeName': 'Dearbhaile M', 'Initials': 'DM', 'LastName': ""O'Donnell"", 'Affiliation': 'Cancer Trials Ireland, Dublin, Ireland.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Hook', 'Affiliation': ""St James' University Hospital, Leeds, UK.""}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Coyle', 'Affiliation': 'Queen Alexandra Hospital, Portsmouth Hospitals National Health Service Trust, Portsmouth, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Blagden', 'Affiliation': 'Churchill Hospital, University of Oxford, Oxford, UK.'}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Brenton', 'Affiliation': 'Li Ka Shing Centre, Cancer Research UK Cambridge Institute, Cambridge, UK.'}, {'ForeName': 'Raj', 'Initials': 'R', 'LastName': 'Naik', 'Affiliation': 'Gynaecology Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Perren', 'Affiliation': ""St James' University Hospital, Leeds, UK.""}, {'ForeName': 'Sudha', 'Initials': 'S', 'LastName': 'Sundar', 'Affiliation': 'Institute of Cancer and Genomics, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Adrian D', 'Initials': 'AD', 'LastName': 'Cook', 'Affiliation': 'Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK.'}, {'ForeName': 'Gosala S', 'Initials': 'GS', 'LastName': 'Gopalakrishnan', 'Affiliation': 'Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK.'}, {'ForeName': 'Hani', 'Initials': 'H', 'LastName': 'Gabra', 'Affiliation': 'Department of Surgery and Cancer, Imperial College London, London, UK; Early Clinical Development, AstraZeneca, Cambridge, UK.'}, {'ForeName': 'Rosemary', 'Initials': 'R', 'LastName': 'Lord', 'Affiliation': 'Department of Oncology, Clatterbridge Cancer Centre, Wirral, UK.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Dark', 'Affiliation': 'Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK.'}, {'ForeName': 'Helena M', 'Initials': 'HM', 'LastName': 'Earl', 'Affiliation': ""Department of Medical Oncology, Addenbrooke's Hospital, Cambridge, UK.""}, {'ForeName': 'Marcia', 'Initials': 'M', 'LastName': 'Hall', 'Affiliation': 'Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK.'}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Banerjee', 'Affiliation': 'Gynaecological Unit, The Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, London, UK.'}, {'ForeName': 'Rosalind M', 'Initials': 'RM', 'LastName': 'Glasspool', 'Affiliation': 'Beatson West of Scotland Cancer Centre, Glasgow, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Jones', 'Affiliation': 'Velindre Cancer Centre, Wales, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Williams', 'Affiliation': 'Birmingham City Hospital, Birmingham, UK.'}, {'ForeName': 'Ann Marie', 'Initials': 'AM', 'LastName': 'Swart', 'Affiliation': 'Norwich Medical School, University of East Anglia, Norwich, UK.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Stenning', 'Affiliation': 'Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK.'}, {'ForeName': 'Mahesh', 'Initials': 'M', 'LastName': 'Parmar', 'Affiliation': 'Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Kaplan', 'Affiliation': 'Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK.'}, {'ForeName': 'Jonathan A', 'Initials': 'JA', 'LastName': 'Ledermann', 'Affiliation': 'University College London Cancer Institute, and University College London Hospitals, London, UK.'}]","Lancet (London, England)",['10.1016/S0140-6736(19)32259-7'] 676,31221505,Impact of coaching and self-hypnosis intervention on blood glucose levels of older adults in Indonesia.,"OBJECTIVE To explore the impact of an integrated method of coaching and self-hypnosis on the maintenance of blood glucose levels among older adults in Indonesia. METHOD The study's design was quasi-experimental with two sample groups: an intervention group and a controlled group. For the sampling method, 76 people were chosen using the multistage sampling method, then the member of the intervention group was chosen based on the study's purpose. This study used a paired t-test and an independent t-test. Non-fasting blood sugar tests (random blood sample) were taken twice, before and after the intervention for 4 weeks. RESULTS There was a significant difference between blood glucose levels before and after intervention in the intervention group (p=0.000). Coaching and self-hypnosis method was decreasing blood glucose levels significantly in the intervention group better than in the controlled group. CONCLUSIONS Coaching and self-hypnosis, when sustained for 4 weeks, can decrease blood glucose levels. This intervention can be part of lifestyle modification to decrease the blood glucose levels of older adults with diabetes mellitus. Furthermore, coaching and self-hypnosis intervention can also be integrated as part of the promotion and preventive acts in the prevention and management of non-communicable disease programs in communities.",2019,"Coaching and self-hypnosis method was decreasing blood glucose levels significantly in the intervention group better than in the controlled group. ","['older adults in Indonesia', 'older adults with diabetes mellitus']","['coaching and self-hypnosis', 'coaching and self-hypnosis intervention']",['blood glucose levels'],"[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0021247', 'cui_str': 'East Indies'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C3888013', 'cui_str': 'Hypnotism'}]","[{'cui': 'C0428554', 'cui_str': 'Blood glucose result - finding'}]",76.0,0.0127036,"Coaching and self-hypnosis method was decreasing blood glucose levels significantly in the intervention group better than in the controlled group. ","[{'ForeName': 'Desi', 'Initials': 'D', 'LastName': 'Deswita', 'Affiliation': 'Faculty of Nursing Universitas Indonesia, Depok, West Java, Indonesia; Health Polytechnic Padang, Padang, West Sumatra, Indonesia.'}, {'ForeName': 'Junaiti', 'Initials': 'J', 'LastName': 'Sahar', 'Affiliation': 'Faculty of Nursing Universitas Indonesia, Depok, West Java, Indonesia. Electronic address: junsr@ui.ac.id.'}, {'ForeName': 'Sigit', 'Initials': 'S', 'LastName': 'Mulyono', 'Affiliation': 'Faculty of Nursing Universitas Indonesia, Depok, West Java, Indonesia.'}]",Enfermeria clinica,['10.1016/j.enfcli.2019.04.022'] 677,31215837,Randomized Trial to Reduce Cardiovascular Risk in Women with Recent Preeclampsia.,"Background: To reduce cardiovascular disease (CVD) risk, we tested an online intervention to improve healthy lifestyle for women with recent preeclampsia. Materials and Methods: We conducted a randomized controlled 9-month clinical trial, Heart Health 4 Moms (HH4M), among 151 U.S. women with preeclampsia within 5 years. Sample size was planned to detect differences of 0.5 standard deviation units in primary outcomes between study arms. Preeclampsia history was validated by medical records; women with chronic hypertension were excluded. The intervention included online educational modules, a community forum, and communication with a lifestyle coach. The control group received internet links to CVD risk reduction information. Primary outcomes were self-efficacy to eat a healthy diet and increase physical activity; change in physical in/activity; adherence to the Dietary Approaches to Stop Hypertension (DASH) diet; and knowledge of and personal control over CVD risk. Secondary outcomes were weight and blood pressure. Results: In the intervention arm, 84% of participants accessed at least one online educational module; 89% completed at least three scheduled calls with the coach. At 9 months, intervention participants reported significantly greater knowledge of CVD risk factors (corrected p  = 0.01), increased self-efficacy for healthy eating ( p  = 0.03), and less physical inactivity than controls ( p  = 0.0006). The groups did not differ in sense of personal control of CVD risk factors, adherence to the DASH diet, self-efficacy for physical activity, or reported physical activity. There were no differences in secondary outcomes between groups. Conclusions: The HH4M program improved CVD risk knowledge, self-efficacy to achieve a healthy diet, and reduced physical inactivity among women with recent preeclampsia.",2019,"At 9 months, intervention participants reported significantly greater knowledge of CVD risk factors (corrected p  = 0.01), increased self-efficacy for healthy eating ( p  = 0.03), and less physical inactivity than controls ( p  = 0.0006).","['Heart Health 4 Moms (HH4M), among 151 U.S. women with preeclampsia within 5 years', 'women with recent preeclampsia', 'Preeclampsia history was validated by medical records; women with chronic hypertension were excluded', 'Women with Recent Preeclampsia']","['online educational modules, a community forum, and communication with a lifestyle coach', 'internet links to CVD risk reduction information']","['self-efficacy to eat a healthy diet and increase physical activity; change in physical in/activity; adherence to the Dietary Approaches to Stop Hypertension (DASH) diet; and knowledge of and personal control over CVD risk', 'personal control of CVD risk factors, adherence to the DASH diet, self-efficacy for physical activity, or reported physical activity', 'weight and blood pressure', 'CVD risk knowledge, self-efficacy', 'physical inactivity', 'self-efficacy for healthy eating', 'knowledge of CVD risk factors']","[{'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1442163', 'cui_str': 'Multiple of the median'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0032914', 'cui_str': 'EPH Toxemias'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}, {'cui': 'C0025102', 'cui_str': 'Medical Records'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}]","[{'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0557773', 'cui_str': 'Coach (physical object)'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0452415', 'cui_str': 'Healthy Diet'}, {'cui': 'C4039165', 'cui_str': 'Increased physical activity (finding)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C4053458', 'cui_str': 'Dietary Approaches To Stop Hypertension Diet'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}]",151.0,0.100584,"At 9 months, intervention participants reported significantly greater knowledge of CVD risk factors (corrected p  = 0.01), increased self-efficacy for healthy eating ( p  = 0.03), and less physical inactivity than controls ( p  = 0.0006).","[{'ForeName': 'Janet W', 'Initials': 'JW', 'LastName': 'Rich-Edwards', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Jennifer J', 'Initials': 'JJ', 'LastName': 'Stuart', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Geraldine', 'Initials': 'G', 'LastName': 'Skurnik', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Andrea T', 'Initials': 'AT', 'LastName': 'Roche', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Tsigas', 'Affiliation': 'Preeclampsia Foundation, Melbourne, Florida.'}, {'ForeName': 'Garrett M', 'Initials': 'GM', 'LastName': 'Fitzmaurice', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Louise E', 'Initials': 'LE', 'LastName': 'Wilkins-Haug', 'Affiliation': ""Department of Obstetrics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Sue E', 'Initials': 'SE', 'LastName': 'Levkoff', 'Affiliation': 'College of Social Work, University of South Carolina, Columbia, South Carolina.'}, {'ForeName': 'Ellen W', 'Initials': 'EW', 'LastName': 'Seely', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}]",Journal of women's health (2002),['10.1089/jwh.2018.7523'] 678,31771921,Impact on cardiometabolic risk of a weight loss intervention with higher protein from lean red meat: Combined results of 2 randomized controlled trials in obese middle-aged and older adults.,"BACKGROUND The recognized benefits of a higher protein diet on muscle mass and strength in older adults are tempered by concerns of the potentially negative cardiometabolic impact of dietary sources of animal protein. OBJECTIVE The aim of this study was to explore the cardiometabolic impact of 2 weight reduction diets: a higher protein diet, providing balanced portions of lean beef and pork throughout the day, vs. a diet following the Recommended Daily Allowance level of protein in obese middle-aged and older adults. METHODS Data from Measuring Eating, Activity and Strength: Understanding the Response-Using Protein and Protein Optimization in Women Enables Results-Using Protein were combined for the present analysis. Subjects were randomly assigned to a 6-month weight loss diet (500 kcal deficit) and prescribed a Recommended Daily Allowance level of protein (0.8 g protein/kg BW), control group, or a higher level of protein (1.2 g protein/kg BW), protein group. For the protein group, lean, high-quality protein was evenly distributed between meals or balanced throughout the day (30 g protein/meal). The following cardiometabolic markers were quantified by nuclear magnetic resonance spectroscopy: lipids, lipoproteins, GlycA, trimethylamine-N-oxide, betaine, branched-chain amino acids, and lipoprotein insulin resistance index scores. RESULTS In both groups (control [n = 27] and protein [n = 53]), there were significant (P ≤ .05) changes from baseline in weight loss (-6.2% and -7.2%), distance walked (+53.1 and +75.0 meters), and fasting plasma glucose (-7.5 and -6.2 mg/dL), respectively. At endpoint, protein group had significantly (P ≤ .05) lower triglycerides (-17.3 mg/dL), large very-low-density lipoprotein particle concentration (VLDL-P; -1.2 nmol/L), total low-density lipoprotein particle concentration (LDL-P; -67.8 nmol/L), small LDL-P (-59.4 nmol/L) and lipoprotein insulin resistance index (-5.9), whereas control group had significantly (P ≤ .05) lower GlycA (-13.1 μmol/L), total VLDL-P (-7.9 nmol/L), and small VLDL-P (-7.0 nmol/L). Differences between groups were observed for small VLDL-P (P = .02) and protein intake (P < .0001). CONCLUSIONS These findings suggest that a hypocaloric diet with either traditional (0.8 g/kg BW/d) or higher protein (1.2 g/kg BW/d; predominantly from lean red meat) content improves risk markers of cardiovascular disease and type II diabetes in obese middle-aged and older adults. Both diets were also associated with improved physical function, and neither had an adverse impact on cardiometabolic outcomes.",2019,"At endpoint, protein group had significantly (P ≤ .05) lower triglycerides (-17.3 mg/dL), large very-low-density lipoprotein particle concentration (VLDL-P; -1.2 nmol/L), total low-density lipoprotein particle concentration (LDL-P; -67.8 nmol/L), small LDL-P (-59.4 nmol/L) and lipoprotein insulin resistance index (-5.9), whereas control group had significantly (P ≤ .05) lower GlycA (-13.1 μmol/L), total VLDL-P (-7.9 nmol/L), and small VLDL-P","['obese middle-aged and older adults', 'obese middle-aged and older\xa0adults', 'older adults', 'Data from Measuring Eating, Activity and Strength', 'Women']","['weight reduction diets', '6-month weight loss diet (500\xa0kcal deficit) and prescribed a Recommended Daily Allowance level of protein', 'weight loss intervention with higher protein from lean red meat']","['small VLDL-P', 'total low-density lipoprotein particle concentration', 'fasting plasma glucose', 'total VLDL-P', 'physical function', 'lipoproteins, GlycA, trimethylamine-N-oxide, betaine, branched-chain amino acids, and lipoprotein insulin resistance index scores', 'risk markers of cardiovascular disease and type II diabetes', 'small LDL-P', 'protein intake', 'cardiometabolic outcomes', 'weight loss', 'large very-low-density lipoprotein particle concentration', 'lipoprotein insulin resistance index', 'distance walked', 'cardiometabolic risk', 'triglycerides']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205847', 'cui_str': 'Middle Aged'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0012167', 'cui_str': 'Weight Reduction Diet'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0439259', 'cui_str': 'kilocalorie'}, {'cui': 'C0524786', 'cui_str': 'Recommended Daily Allowances'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0452848', 'cui_str': 'Red Meat'}]","[{'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0523560', 'cui_str': 'VLDL cholesterol measurement'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0077194', 'cui_str': 'trimethylammonium oxide'}, {'cui': 'C0005304', 'cui_str': 'Betaine'}, {'cui': 'C0337112', 'cui_str': 'Chain, device (physical object)'}, {'cui': 'C3539946', 'cui_str': 'Amino acids'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}]",,0.0308859,"At endpoint, protein group had significantly (P ≤ .05) lower triglycerides (-17.3 mg/dL), large very-low-density lipoprotein particle concentration (VLDL-P; -1.2 nmol/L), total low-density lipoprotein particle concentration (LDL-P; -67.8 nmol/L), small LDL-P (-59.4 nmol/L) and lipoprotein insulin resistance index (-5.9), whereas control group had significantly (P ≤ .05) lower GlycA (-13.1 μmol/L), total VLDL-P (-7.9 nmol/L), and small VLDL-P","[{'ForeName': 'Kathryn N', 'Initials': 'KN', 'LastName': 'Porter Starr', 'Affiliation': 'Center for the Study of Aging, Duke University School of Medicine, Durham, NC, USA; Department of Medicine, Duke University School of Medicine, Durham, NC, USA; Geriatric Research, Education, and Clinical Center, Durham VA Medical Center, Durham, NC, USA. Electronic address: kathryn.starr@dm.duke.edu.'}, {'ForeName': 'Margery A', 'Initials': 'MA', 'LastName': 'Connelly', 'Affiliation': 'Laboratory Corporation of America Holdings (LabCorp), Morrisville, NC, USA.'}, {'ForeName': 'Melissa C', 'Initials': 'MC', 'LastName': 'Orenduff', 'Affiliation': 'Center for the Study of Aging, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Shelley R', 'Initials': 'SR', 'LastName': 'McDonald', 'Affiliation': 'Center for the Study of Aging, Duke University School of Medicine, Durham, NC, USA; Department of Medicine, Duke University School of Medicine, Durham, NC, USA; Geriatric Research, Education, and Clinical Center, Durham VA Medical Center, Durham, NC, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Sloane', 'Affiliation': 'Center for the Study of Aging, Duke University School of Medicine, Durham, NC, USA; Geriatric Research, Education, and Clinical Center, Durham VA Medical Center, Durham, NC, USA.'}, {'ForeName': 'Kim M', 'Initials': 'KM', 'LastName': 'Huffman', 'Affiliation': 'Department of Medicine and Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'William E', 'Initials': 'WE', 'LastName': 'Kraus', 'Affiliation': 'Department of Medicine and Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Connie W', 'Initials': 'CW', 'LastName': 'Bales', 'Affiliation': 'Center for the Study of Aging, Duke University School of Medicine, Durham, NC, USA; Department of Medicine, Duke University School of Medicine, Durham, NC, USA; Geriatric Research, Education, and Clinical Center, Durham VA Medical Center, Durham, NC, USA.'}]",Journal of clinical lipidology,['10.1016/j.jacl.2019.09.012'] 679,31785169,Daylight photodynamic therapy for prevention of new actinic keratosis and keratinocyte carcinomas in organ transplants. A cryotherapy-controlled randomized clinical trial.,"BACKGROUND Organ transplant recipients (OTR) have a higher risk of actinic keratosis (AK) and keratinocyte carcinomas (KC). There are no clinical trials assessing the effectiveness of daylight photodynamic therapy (DPDT) to prevent new AK and KC in OTR. OBJECTIVES To determine whether repeated treatments of field cancerization with DPDT are effective in preventing new AK and KC in OTR. METHODS A randomized, intra-subject controlled, evaluator-blind, split-face and/or scalp trial, from April 2016 to October 2018. Participants were OTR older than 18 years, 1-year posttransplant, with at least 5 AK on each hemi-face/hemi-scalp. One side received six field treatments with DPDT: two sessions 15 days apart at baseline, two at 3 months and two at 9 months after baseline. Control side received lesion-directed treatment with cryotherapy (double freeze-thaw) at baseline, 3 and 9 months. Total number of lesions (AK and KC) at 21 months, number of new AK and KC at 3, 9, 15 and 21 months and treatment preferences were analysed. RESULTS Of 24 men included, 23 were analysed at 3 months; and 21, at 9, 15 and 21 months. Mean (SD) age was 69.8 years (9.2). The total number of lesions at 21 months was 4.7 (4.3) for DPDT and 5.8 (5.0) for control side; P = 0.09. DPDT showed significantly lower means [SD] of new lesions compared to control side at 3 months (4.2 [3.4] vs. 6.8 [4.8]; P < 0.001), 9 months (3.0 [3.3] vs. 4.3 [3.4]; P = 0.04) and 15 months (3.0 [4.6] vs. 4.8 [5.0]; P = 0.02), and non-significant at 21 months (3.7 [3.5] vs. 5.0 [4.5]; P = 0.06). Most participants preferred DPDT. CONCLUSION DPDT showed potential effectiveness in preventing new AK and KC in OTR by consecutive treatments of field cancerization. The preference for DPDT could facilitate adherence to the long-term treatment necessary in these patients.",2020,"There are no clinical trials assessing the effectiveness of daylight photodynamic therapy (DPDT) to prevent new AK and KC in OTR. ","['new actinic keratosis and keratinocyte carcinomas in organ transplants', 'Organ transplant recipients (OTR', '24 men included', 'Participants were OTR older than 18 years, 1 year post-transplant, with at least 5 AK on each hemi-face/hemi-scalp']","['Control side received lesion-directed treatment with cryotherapy', 'daylight photodynamic therapy (DPDT', 'Daylight photodynamic therapy']","['means [SD] of new lesions', 'Total number of lesions', 'Total number of lesions (AK and KC', 'number of new AK and KC']","[{'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0022602', 'cui_str': 'Senile keratoma (disorder)'}, {'cui': 'C0022567', 'cui_str': 'Keratinocyte (cell)'}, {'cui': 'C0524930', 'cui_str': 'Organ Grafts'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0332835', 'cui_str': 'Grafts'}, {'cui': 'C1285521', 'cui_str': 'Hemi'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0036270', 'cui_str': 'Scalp'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4551716', 'cui_str': 'Cryotherapy'}, {'cui': 'C0031740', 'cui_str': 'Photodynamic Therapy'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0577303', 'cui_str': 'Total number of lesions (observable entity)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}]",,0.0874597,"There are no clinical trials assessing the effectiveness of daylight photodynamic therapy (DPDT) to prevent new AK and KC in OTR. ","[{'ForeName': 'I', 'Initials': 'I', 'LastName': 'Bernad', 'Affiliation': 'Department of Dermatology, Clínica Universidad de Navarra, Pamplona, Spain.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Aguado', 'Affiliation': 'Department of Dermatology, Clínica Universidad de Navarra, Pamplona, Spain.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Núñez-Córdoba', 'Affiliation': 'Research Support Service, Central Clinical Trials Unit, Clínica Universidad de Navarra, Pamplona, Spain.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Redondo', 'Affiliation': 'Department of Dermatology, Clínica Universidad de Navarra, Pamplona, Spain.'}]",Journal of the European Academy of Dermatology and Venereology : JEADV,['10.1111/jdv.16125'] 680,31782589,Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis.,"In a pivotal phase 3 study (Study 305), eribulin mesylate improved overall survival (OS) in patients with previously treated metastatic breast cancer (MBC) compared with treatment of physician's choice (TPC). This post hoc, pooled subgroup analysis of two phase 3 studies (Study 305 and Study 301) reports the influence of the number of prior chemotherapy regimens (0-6) on OS in patients with locally advanced/MBC randomized to eribulin versus TPC/capecitabine. Patients with ≤ 3 prior chemotherapies for locally advanced/MBC had longer median OS with eribulin (15.3 months) versus control (13.2 months; hazard ratio, 0.858; P = .01).",2020,"3 prior chemotherapies for locally advanced/MBC had longer median OS with eribulin (15.3 months) versus control (13.2 months; hazard ratio, 0.858; P = .01).","['Patients with\xa0≤', 'patients with previously treated metastatic breast cancer (MBC', 'patients with locally advanced/MBC randomized to', 'patients with metastatic breast cancer treated with eribulin']","['eribulin mesylate', 'eribulin versus TPC/capecitabine', 'chemotherapy regimens']","['overall survival (OS', 'median OS with eribulin']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer metastatic'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C2350866', 'cui_str': 'eribulin'}]","[{'cui': 'C2608038', 'cui_str': 'eribulin mesylate'}, {'cui': 'C2350866', 'cui_str': 'eribulin'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2350866', 'cui_str': 'eribulin'}]",305.0,0.0425496,"3 prior chemotherapies for locally advanced/MBC had longer median OS with eribulin (15.3 months) versus control (13.2 months; hazard ratio, 0.858; P = .01).","[{'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Cortes', 'Affiliation': 'IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona, Spain.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Twelves', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds and Leeds Teaching Hospitals Trust, Leeds, UK.""}]",The breast journal,['10.1111/tbj.13686'] 681,31197218,Vitamin D supplementation has no effects on progression of motor dysfunction in amyotrophic lateral sclerosis (ALS).,"OBJECTIVES To investigate the effects of cholecalciferol supplementation on the progression of motor disability in a cohort of amyotrophic lateral sclerosis (ALS) patients with low blood 25-hydroxyvitamin D3 [25(OH)D] levels, on the basis of the hypothesis of potential neuroprotective effects of vitamin D supplementation. METHODS Forty-eight ALS patients, 34 with deficient (<20 ng/mL) and 14 with insufficient (20-29 ng/mL) serum levels of 25(OH)D, were randomized and treated by 3 different doses of cholecalciferol [50.000, 75.000 and 100.000 international units (IU) /month] and evaluated after 6-months. Assessment of motor dysfunction at baseline and after 6 months included ALS Functional Rating Scale-Revised (ALFRS-R) and upper motor neuron (UMN) scores and blood samples for 25(OH)D levels. RESULTS Clinical data of 33 patients were available after 6 months. Analysis of Covariance (ANCOVA), with pre-treatment measurements included as covariate, did not show statistically significant differences in the ALSFRS-R (p > 0.05) and UMN (p > 0.05) among the patient groups who underwent 3 different doses of cholecalciferol. Conversely, the treatment with 75.000 IU/month or 100.000 IU/month induced a significant increase in serum levels of 25(OH)D in comparison with the supplementation with 50.000 IU/month; no significant differences were found between 75.000 IU/month and 100.000 IU/month. CONCLUSIONS Our findings highlighted that 6-month supplementation of vitamin D in ALS patients had no significant effects on motor dysfunction. However, it is recommended to prevent medical complications of vitamin D deficiency in ALS patients as well as in other populations of neurodegenerative patients, characterized by low mobility and decreased sun exposure.",2020,"Analysis of Covariance (ANCOVA), with pre-treatment measurements included as covariate, did not show statistically significant differences in the ALSFRS-R (p > 0.05) and UMN (p > 0.05) among the patient groups who underwent 3 different doses of cholecalciferol.","['ALS patients', 'Forty-eight ALS patients, 34 with deficient (<20\u2009ng/mL) and 14 with insufficient (20-29\u2009ng/mL) serum levels of 25(OH)D', 'amyotrophic lateral sclerosis (ALS', 'amyotrophic lateral sclerosis (ALS) patients with low blood 25-hydroxyvitamin D3 [25(OH)D']","['vitamin D', 'vitamin D supplementation', 'Vitamin D supplementation', 'cholecalciferol supplementation', 'cholecalciferol']","['ALS Functional Rating Scale-Revised (ALFRS-R) and upper motor neuron (UMN) scores and blood samples for 25(OH)D levels', 'ALSFRS-R', 'motor dysfunction', 'serum levels of 25(OH)D']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C0011155', 'cui_str': 'Deficient (qualifier value)'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0231180', 'cui_str': 'Insufficient'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0002736', 'cui_str': 'ALS (Amyotrophic Lateral Sclerosis)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0005768'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}]","[{'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0242215', 'cui_str': 'Cholecalciferols'}]","[{'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0524458', 'cui_str': 'Upper motor neuron (cell)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0521654', 'cui_str': 'Neurologic Deficits'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",48.0,0.0938312,"Analysis of Covariance (ANCOVA), with pre-treatment measurements included as covariate, did not show statistically significant differences in the ALSFRS-R (p > 0.05) and UMN (p > 0.05) among the patient groups who underwent 3 different doses of cholecalciferol.","[{'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Trojsi', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy. francesca.trojsi@unicampania.it.'}, {'ForeName': 'Mattia', 'Initials': 'M', 'LastName': 'Siciliano', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Passaniti', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Alvino', 'Initials': 'A', 'LastName': 'Bisecco', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Russo', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Lavorgna', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Esposito', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Ricciardi', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Maria Rosaria', 'Initials': 'MR', 'LastName': 'Monsurrò', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Gioacchino', 'Initials': 'G', 'LastName': 'Tedeschi', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'Santangelo', 'Affiliation': 'Department of Psychology, University of Campania ""Luigi Vanvitelli"", Caserta, Italy.'}]",European journal of clinical nutrition,['10.1038/s41430-019-0448-3'] 682,30978535,Nonceliac Gluten and Wheat Sensitivity.,"Non-celiac gluten and/or wheat sensitivity (NCGS) is thought to be an immune-mediated reaction to gluten or other components of wheat (eg, fructans or amylase trypsin inhibitors) with intestinal and extraintestinal symptoms which improve once gluten and/or wheat is eliminated from the diet and after a diagnosis of celiac disease and wheat allergy have been excluded with appropriate testing. However, there is a great deal of skepticism within the scientific community questioning the existence of NCGS as a distinct clinical disorder. There are no strict diagnostic criteria and a placebo-controlled rechallenge trial has been recommended for diagnosis. In research settings, a double-blind placebo-controlled rechallenge trial has been recommended for diagnosis. There are limited studies estimating the prevalence of NCGS using this study design. The existing studies have variable results likely due to the lack of a uniform diagnostic criterion, a great deal of dependence on the patient's perception of symptoms and a large nocebo effect in existing studies. In clinical practice, a single blind placebo-controlled rechallenge trial has been recommended for diagnosis. The pathogenesis of NCGS is unclear and there is no known biomarker or diagnostic histologic lesion for this condition. It is important to adopt a multidisciplinary team approach to patients with suspected NCGS with involvement of the primary care doctor, gastroenterologist, pathologist and nutritionist who may play an important role in diagnosis and treatment. There may especially be a role in elimination of food containing high quantity of both gluten and fructans. Furthermore, patients should be educated on the nutritional implications of consuming a long-term gluten-free diet.",2020,"However, there is a great deal of skepticism within the scientific community questioning the existence of NCGS as a distinct clinical disorder.",[],"['placebo', 'celiac gluten and/or wheat sensitivity (NCGS']",['Nonceliac Gluten and Wheat Sensitivity'],[],"[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2362561', 'cui_str': 'Gluten'}, {'cui': 'C0043137', 'cui_str': 'Wheat'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}]","[{'cui': 'C2362561', 'cui_str': 'Gluten'}, {'cui': 'C0043137', 'cui_str': 'Wheat'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}]",,0.124943,"However, there is a great deal of skepticism within the scientific community questioning the existence of NCGS as a distinct clinical disorder.","[{'ForeName': 'Anam', 'Initials': 'A', 'LastName': 'Khan', 'Affiliation': 'Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas. Electronic address: anam.khan@mdanderson.org.'}, {'ForeName': 'Milena Gould', 'Initials': 'MG', 'LastName': 'Suarez', 'Affiliation': 'Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas.'}, {'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'Murray', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.'}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2019.04.009'] 683,31786983,Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).,"Mineralocorticoid receptors (MRs) are implicated in the pathology of hypertension. MR blockers are recommended for the treatment of salt-sensitive or resistant hypertension. However, use of currently available MR blockers is limited by adverse events. This phase 3 multicenter, randomized, double-blind study compared the efficacy and safety of esaxerenone, a new selective nonsteroidal MR blocker, at 2.5 and 5 mg/day and eplerenone 50 mg/day in Japanese patients with essential hypertension. After a 4-week washout period, 1001 eligible adults with hypertension were randomized evenly to esaxerenone 2.5 or 5 mg/day or eplerenone 50 mg/day treatments, taken orally once daily for 12 weeks. Primary end points were changes in sitting systolic or diastolic blood pressure (BP) from baseline at the end of treatment. Esaxerenone 2.5 mg/day was noninferior to eplerenone for reductions in sitting and 24-hour BP. Reductions in BP with esaxerenone 5 mg/day were significantly greater than those with esaxerenone 2.5 mg/day. Changes in diurnal BP showed persistent 24-hour antihypertensive effects in all treatment groups. The proportions of patients achieving target sitting BP (<140/90 mm Hg) were 31.5%, 41.2%, and 27.5% with esaxerenone 2.5 and 5 mg/day and eplerenone 50 mg/day, respectively. Incidences of adverse events (all mild or moderate) were similar across treatment groups. These results indicate that esaxerenone is an effective and well-tolerated MR blocker in Japanese patients with essential hypertension, with BP-lowering activity at least equivalent to eplerenone. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT02890173.",2020,Reductions in BP with esaxerenone 5 mg/day were significantly greater than those with esaxerenone 2.5 mg/day.,"['Patients With Essential Hypertension (ESAX-HTN Study', '1001 eligible adults with hypertension', 'Japanese patients with essential hypertension']","['Esaxerenone', 'esaxerenone', 'Mineralocorticoid receptors (MRs', 'eplerenone', 'esaxerenone 2.5 or 5 mg/day or eplerenone', 'MR blockers', 'Esaxerenone (CS-3150) and Eplerenone']","['24-hour antihypertensive effects', 'sitting systolic or diastolic blood pressure (BP', 'sitting and 24-hour BP', 'efficacy and safety', 'proportions of patients achieving target sitting BP', 'Incidences of adverse events', 'Reductions in BP']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0085580', 'cui_str': 'Essential Hypertension'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C1556094', 'cui_str': 'Japanese'}]","[{'cui': 'C3541395', 'cui_str': 'Mineralocorticoids'}, {'cui': 'C0961485', 'cui_str': 'eplerenone'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}, {'cui': 'C4278755', 'cui_str': 'CS-3150'}]","[{'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0003364', 'cui_str': 'Anti-Hypertensive Drugs'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]",1001.0,0.0655234,Reductions in BP with esaxerenone 5 mg/day were significantly greater than those with esaxerenone 2.5 mg/day.,"[{'ForeName': 'Sadayoshi', 'Initials': 'S', 'LastName': 'Ito', 'Affiliation': 'From the Division of Nephrology, Endocrinology and Vascular Medicine, Department of Medicine, Tohoku University School of Medicine, Sendai, Japan (S.I.).'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Itoh', 'Affiliation': 'Department of Endocrinology, Metabolism and Nephrology, Keio University, School of Medicine, Tokyo, Japan (H.I.).'}, {'ForeName': 'Hiromi', 'Initials': 'H', 'LastName': 'Rakugi', 'Affiliation': 'Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan (H.R.).'}, {'ForeName': 'Yasuyuki', 'Initials': 'Y', 'LastName': 'Okuda', 'Affiliation': 'Daiichi Sankyo Co., Ltd., Tokyo, Japan (Y.O., M.Y., S.Y.).'}, {'ForeName': 'Motonobu', 'Initials': 'M', 'LastName': 'Yoshimura', 'Affiliation': 'Daiichi Sankyo Co., Ltd., Tokyo, Japan (Y.O., M.Y., S.Y.).'}, {'ForeName': 'Satoru', 'Initials': 'S', 'LastName': 'Yamakawa', 'Affiliation': 'Daiichi Sankyo Co., Ltd., Tokyo, Japan (Y.O., M.Y., S.Y.).'}]","Hypertension (Dallas, Tex. : 1979)",['10.1161/HYPERTENSIONAHA.119.13569'] 684,31773110,Effectiveness of Accelerated Recovery Performance for Post-ACL Reconstruction Rehabilitation.,"Atrophy and protracted recovery of normal function of the ipsilateral quadriceps femoris muscle following anterior cruciate ligament reconstruction surgery is well documented. The Accelerated Recovery Performance trainer is a type of electrical stimulation device that delivers a high-pulse frequency via a direct current, making it unique from many other devices on the market. The purpose of the present study was to investigate the effects of the direct current (via the Accelerated Recovery Performance trainer protocol) on gains in thigh circumference following anterior cruciate ligament reconstruction. Twenty-five patients were enrolled following isolated anterior cruciate ligament reconstruction and randomly assigned to either an isometric rehabilitation protocol augmented with the Accelerated Recovery Performance trainer protocol (experimental group) or the isometric rehabilitation protocol alone (control group). The two groups participated in sixteen sessions of directed rehabilitation over a two-month time period. Patients were followed with serial thigh circumference measurements at 5, 10, 15, and 20 centimeters above the superior patellar pole. Comparison of the overall mean circumferential gains in thigh circumference of the involved leg demonstrated approximately 3:1 gains in the ARP group over the control group, demonstrating it to be superior to isometric rehabilitation alone with regards to gains in thigh girth. The Accelerated Recovery Performance trainer protocol should be considered for post-anterior cruciate ligament reconstruction rehabilitation in order to reverse disuse atrophy of the ipsilateral quadriceps femoris.",2019,Twenty-five patients were enrolled following isolated anterior cruciate ligament reconstruction and randomly assigned to either an isometric rehabilitation protocol augmented with the Accelerated Recovery Performance trainer protocol (experimental group) or the isometric rehabilitation protocol alone (control group).,"['anterior cruciate ligament reconstruction surgery', 'anterior cruciate ligament reconstruction', 'Twenty-five patients were enrolled following isolated anterior cruciate ligament reconstruction']","['isometric rehabilitation protocol augmented with the Accelerated Recovery Performance trainer protocol (experimental group) or the isometric rehabilitation protocol alone (control group', 'direct current (via the Accelerated Recovery Performance trainer protocol']",['gains in thigh circumference'],"[{'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}]","[{'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0453962', 'cui_str': 'Trainers (physical object)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0442831', 'cui_str': 'Direct current (physical force)'}]","[{'cui': 'C0039866', 'cui_str': 'Thigh'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}]",25.0,0.0163297,Twenty-five patients were enrolled following isolated anterior cruciate ligament reconstruction and randomly assigned to either an isometric rehabilitation protocol augmented with the Accelerated Recovery Performance trainer protocol (experimental group) or the isometric rehabilitation protocol alone (control group).,"[{'ForeName': 'Anne R', 'Initials': 'AR', 'LastName': 'Wright', 'Affiliation': 'Division of Orthopaedic Surgery, John A. Burns School of Medicine, University of Hawai7#x2018;i, Honolulu, HI.'}, {'ForeName': 'Andrew B', 'Initials': 'AB', 'LastName': 'Richardson', 'Affiliation': 'Division of Orthopaedic Surgery, John A. Burns School of Medicine, University of Hawai7#x2018;i, Honolulu, HI.'}, {'ForeName': 'Christian K', 'Initials': 'CK', 'LastName': 'Kikuchi', 'Affiliation': 'Division of Orthopaedic Surgery, John A. Burns School of Medicine, University of Hawai7#x2018;i, Honolulu, HI.'}, {'ForeName': 'Daniel B', 'Initials': 'DB', 'LastName': 'Goldberg', 'Affiliation': 'Division of Orthopaedic Surgery, John A. Burns School of Medicine, University of Hawai7#x2018;i, Honolulu, HI.'}, {'ForeName': 'Jay M', 'Initials': 'JM', 'LastName': 'Marumoto', 'Affiliation': 'Division of Orthopaedic Surgery, John A. Burns School of Medicine, University of Hawai7#x2018;i, Honolulu, HI.'}, {'ForeName': 'Darryl M', 'Initials': 'DM', 'LastName': 'Kan', 'Affiliation': 'Division of Orthopaedic Surgery, John A. Burns School of Medicine, University of Hawai7#x2018;i, Honolulu, HI.'}]",Hawai'i journal of health & social welfare,[] 685,31910850,"Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).","BACKGROUND Few prospective studies have compared the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors. We aimed to clarify the efficacy of dapagliflozin versus sitagliptin for modulating cardiometabolic risk factors including high glycated hemoglobin (HbA1c) levels, hypoglycemia, and body weight. METHODS This prospective, randomized, open-label, blinded-endpoint, parallel-group trial enrolled 340 Japanese patients with early-stage type 2 diabetes receiving metformin alone or no glucose-lowering agents, who were randomized to receive dapagliflozin or sitagliptin for 24 weeks. The primary endpoint was the proportion of patients who achieved the composite endpoint of HbA1c level maintenance < 7.0% (53 mmol/mol), avoidance of hypoglycemia (maintenance of sensor glucose ≥ 3.0 mmol/L or ≥ 54 mg/dL), and ≥ 3.0% body weight loss from baseline. Secondary endpoints included components of the primary endpoint, other metabolic indices, and glucose variability indices measured using flash glucose monitoring. RESULTS Clinical characteristics of patients were age, 58.1 ± 12.2 years; known duration of diabetes, 5.8 ± 6.1 years; body weight, 74.7 ± 14.2 kg; body mass index, 27.9 ± 4.1 kg/m 2 ; and HbA1c level, 7.8 ± 0.8% at baseline. The achievement ratio of primary endpoint was significantly higher in the dapagliflozin group than in the sitagliptin group (24.4% vs. 13.8%, P < 0.05). While the rates of HbA1c level maintenance < 7.0% (53 mmol/mol) and avoidance of hypoglycemia were comparable between the groups (49.4 vs. 50.0% and 88.7 vs. 92.3% for dapagliflozin vs. sitagliptin, respectively), body weight loss of ≥ 3.0% was significantly achieved in the dapagliflozin group (54.4 vs. 19.6%, P < 0.001). Moreover, dapagliflozin was superior to sitagliptin regarding several secondary endpoints that modulate cardiometabolic risk, namely reducing fasting plasma glucose, insulin, uric acid, increasing high-density lipoprotein cholesterol, and suppressing the increase in serum creatinine and the decrease in estimated glomerular filtration rate. On the other hand, sitagliptin was superior to dapagliflozin in suppressing glucose variability. CONCLUSIONS Compared to sitagliptin, dapagliflozin was significantly more effective at improving cardiometabolic risk factors, suggesting that SGLT2 inhibitors might be more suitable than DPP-4 inhibitors for preventing cardiovascular events in patients with early-stage but inadequately controlled type 2 diabetes. Trial registration Trial number, UMIN000028014; registered on June 30, 2017.",2020,"Compared to sitagliptin, dapagliflozin was significantly more effective at improving cardiometabolic risk factors, suggesting that SGLT2 inhibitors might be more suitable than DPP-4 inhibitors for preventing cardiovascular events in patients with early-stage but inadequately controlled type 2 diabetes.","['patients with early-stage but inadequately controlled type 2 diabetes', 'Clinical characteristics of patients were age, 58.1\u2009±\u200912.2\xa0years; known duration of diabetes, 5.8\u2009±\u20096.1\xa0years; body weight, 74.7\u2009±\u200914.2\xa0kg; body mass index, 27.9\u2009±\u20094.1\xa0kg/m 2 ; and HbA1c level, 7.8\u2009±\u20090.8% at baseline', '340 Japanese patients with early-stage type 2 diabetes receiving metformin alone or no glucose-lowering agents, who were randomized to receive', 'Japanese patients with type 2 diabetes']","['dapagliflozin or sitagliptin', 'sitagliptin, dapagliflozin', 'sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors', 'dapagliflozin', 'dapagliflozin versus sitagliptin', 'DPP-4 inhibitors']","['achievement ratio of primary endpoint', 'avoidance of hypoglycemia (maintenance of sensor glucose ≥', 'rates of HbA1c level maintenance', 'estimated glomerular filtration rate', 'metabolic indices, and glucose variability indices measured using flash glucose monitoring', 'avoidance of hypoglycemia', 'serum creatinine', 'cardiometabolic risk factors', 'body weight loss', 'fasting plasma glucose, insulin, uric acid, increasing high-density lipoprotein cholesterol', 'glycated hemoglobin (HbA1c) levels, hypoglycemia, and body weight', 'proportion of patients who achieved the composite endpoint of HbA1c level maintenance', 'cardiovascular events']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2363430', 'cui_str': 'Early stage (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205309', 'cui_str': 'Known (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C4517796', 'cui_str': '5.8'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517756', 'cui_str': '4.1'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C4517730', 'cui_str': '340'}, {'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C1565750', 'cui_str': 'sitagliptin'}, {'cui': 'C0017739', 'cui_str': 'Sodium-Glucose Transport Proteins'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C3653297', 'cui_str': 'Dipeptidyl peptidase 4 (DPP-4) inhibitors'}, {'cui': 'C0058353', 'cui_str': 'DPPS'}]","[{'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C3811844'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0344323', 'cui_str': 'Flashing (disorder)'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0041980', 'cui_str': 'Uric Acid'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0023822', 'cui_str': 'High Density Lipoprotein Cholesterol'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",340.0,0.0471359,"Compared to sitagliptin, dapagliflozin was significantly more effective at improving cardiometabolic risk factors, suggesting that SGLT2 inhibitors might be more suitable than DPP-4 inhibitors for preventing cardiovascular events in patients with early-stage but inadequately controlled type 2 diabetes.","[{'ForeName': 'Ayako', 'Initials': 'A', 'LastName': 'Fuchigami', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan.'}, {'ForeName': 'Fumika', 'Initials': 'F', 'LastName': 'Shigiyama', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan.'}, {'ForeName': 'Toru', 'Initials': 'T', 'LastName': 'Kitazawa', 'Affiliation': 'Division of Diabetes, Endocrinology and Metabolism, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.'}, {'ForeName': 'Yosuke', 'Initials': 'Y', 'LastName': 'Okada', 'Affiliation': 'The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.'}, {'ForeName': 'Takamasa', 'Initials': 'T', 'LastName': 'Ichijo', 'Affiliation': 'Department of Diabetes and Endocrinology, Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Japan.'}, {'ForeName': 'Mariko', 'Initials': 'M', 'LastName': 'Higa', 'Affiliation': 'Department of Diabetes and Endocrinology, Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Japan.'}, {'ForeName': 'Toru', 'Initials': 'T', 'LastName': 'Hiyoshi', 'Affiliation': 'Division of Diabetes and Endocrinology, Japanese Red Cross Medical Center, Tokyo, Japan.'}, {'ForeName': 'Ikuo', 'Initials': 'I', 'LastName': 'Inoue', 'Affiliation': 'Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan.'}, {'ForeName': 'Kaoru', 'Initials': 'K', 'LastName': 'Iso', 'Affiliation': 'Department of Internal Medicine, Japan Community Health Care Organization Tokyo Kamata Medical Center, Tokyo, Japan.'}, {'ForeName': 'Hidenori', 'Initials': 'H', 'LastName': 'Yoshii', 'Affiliation': 'Department of Medicine, Diabetology and Endocrinology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan.'}, {'ForeName': 'Takahisa', 'Initials': 'T', 'LastName': 'Hirose', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Kumashiro', 'Affiliation': 'Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan. naoki.kumashiro@med.toho-u.ac.jp.'}]",Cardiovascular diabetology,['10.1186/s12933-019-0977-z'] 686,31194645,Improving Supply Chain for Essential Drugs in Low-Income Countries: Results from a Large Scale Randomized Experiment in Zambia.,"Despite increased investments in procurement of essential medicines, their availability at health facilities remains extremely low in many low- and middle-income countries. The lack of a well-functioning supply chain for essential medicines is often the cause of this poor availability. Using a randomized trial conducted in 439 health facilities and 24 districts in Zambia, this study helps understand the optimal supply chain structure for essential medicines distribution in the public sector in low-income countries. It shows that a more direct distribution system where clinics order and receive medicines supply directly from the central agency through a cross-docking arrangement significantly reduces the duration and frequency of stockouts compared to a traditional three-level drug distribution system. As an example, the frequency of stockouts for first line pediatric malaria medicines reduced from 47.9% to 13.3% and the number of days of stockout in a quarter reduced from 27 days to 5 days. The direct flow of demand and order information from health facilities to the central supply agency reduces the problem of diffuse accountability that exists in multi-tiered distribution systems. It also shifts the locus of decision making for complex supply chain functions such as scarce stock allocation and adjustment of health facility order quantities to levels in the system where staff competency is aligned with what the function needs. Even when supply chain system redesign such as the one evaluated in this paper are demonstrated to be technically robust using rigorous evidence, they often require navigating a complex political economy within the overall health system and its actors.",2019,It also shifts the locus of decision making for complex supply chain functions such as scarce stock allocation and adjustment of health facility order quantities to levels in the system where staff competency is aligned with what the function needs.,"['Low-Income Countries', '439 health facilities and 24 districts in Zambia']",[],['duration and frequency of stockouts'],"[{'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0018704', 'cui_str': 'Health Facilities'}, {'cui': 'C0043445', 'cui_str': 'Republic of Zambia'}]",[],"[{'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]",,0.0368209,It also shifts the locus of decision making for complex supply chain functions such as scarce stock allocation and adjustment of health facility order quantities to levels in the system where staff competency is aligned with what the function needs.,"[{'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Vledder', 'Affiliation': 'a GFF Secretariat , World Bank , Washington , DC , USA.'}, {'ForeName': 'Jed', 'Initials': 'J', 'LastName': 'Friedman', 'Affiliation': 'b Development Research Group , World Bank , Washington , DC , USA.'}, {'ForeName': 'Mirja', 'Initials': 'M', 'LastName': 'Sjöblom', 'Affiliation': 'a GFF Secretariat , World Bank , Washington , DC , USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Brown', 'Affiliation': 'd Supply Chain , Bill & Melinda Gates Foundation , Seattle , WA , USA.'}, {'ForeName': 'Prashant', 'Initials': 'P', 'LastName': 'Yadav', 'Affiliation': 'e Department of Global Health and Social Medicine , Harvard Medical School , Boston , MA , USA.'}]",Health systems and reform,['10.1080/23288604.2019.1596050'] 687,31186202,Battlefield acupuncture for post-partum pain: A randomized controlled trial.,"BACKGROUND AND PURPOSE Postpartum pain affects quality of life. Clinicians are increasingly using acupuncture for management of pain. Evidence based strategies that incorporate acupuncture for postpartum pain are lacking. METHODS We performed an exploratory, randomized clinical trial of Battlefield Auricular Acupuncture (BFA) plus standard analgesia versus standard analgesia alone for reduction of pain in the immediate postpartum period. RESULTS The mean time to 50% sustained reduction of initial pain in the standard analgesia group (n = 33) was 6 days compared to 5 days in the standard analgesia plus BFA (n = 37) group (p = 0.35). The mean total morphine equivalent units (MEUs) in the standard group compared to standard plus BFA group were 88 mg and 82 mg respectively (p = 0.45). CONCLUSIONS This exploratory comparison suggests that BFA may not provide additional benefit to standard analgesia for immediate postpartum pain; however, the trend toward faster reduction in pain indicates that a larger definitive study may be required.",2019,"The mean total morphine equivalent units (MEUs) in the standard group compared to standard plus BFA group were 88 mg and 82 mg respectively (p = 0.45). ",['Post-Partum Pain'],"['Battlefield Acupuncture', 'BFA', 'standard plus BFA', 'acupuncture', 'Battlefield Auricular Acupuncture (BFA) plus standard analgesia versus standard analgesia alone']","['reduction of pain', 'mean time to 50% sustained reduction of initial pain', 'mean total morphine equivalent units (MEUs']","[{'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0654146', 'cui_str': '4,4-difluoro-5-methyl-4-bora-3,4-diaza-3-indacenedodecanoic acid'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0752217', 'cui_str': 'Auricular Acupuncture'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}]","[{'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}]",,0.275105,"The mean total morphine equivalent units (MEUs) in the standard group compared to standard plus BFA group were 88 mg and 82 mg respectively (p = 0.45). ","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kim', 'Affiliation': '99th MDG, Nellis Air Force Base, Nevada 89191, United States; 375th MDG, Scott Air Force Base, Illinois 62225, United States.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Moss', 'Affiliation': '99th MDG, Nellis Air Force Base, Nevada 89191, United States.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Crawford', 'Affiliation': '99th MDG, Nellis Air Force Base, Nevada 89191, United States. Electronic address: paul.f.crawford.mil@mail.mil.'}]","Explore (New York, N.Y.)",['10.1016/j.explore.2019.05.001'] 688,31128875,"Effect on meningococcal serogroup W immunogenicity when Tdap was administered prior, concurrent or subsequent to the quadrivalent (ACWY) meningococcal CRM 197 -conjugate vaccine in adult Hajj pilgrims: A randomised controlled trial.","Immune responses to the capsular polysaccharide administered in the polysaccharide-protein conjugate vaccines can be either improved or suppressed by the pre-existence of immunity to the carrier protein. Receiving multiple vaccinations is essential for travellers such as Hajj pilgrims, and the use of conjugated vaccines is recommended. We studied the immune response to meningococcal serogroup W upon prior, concurrent and sequential administration of a quadrivalent meningococcal conjugate vaccine (MCV4) conjugated to CRM 197 (coadministered with 13 valent pneumococcal vaccine conjugate CRM 197 [PCV13]), and tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Australian adults before attending the Hajj pilgrimage in 2014. Participants were randomly assigned, by computer-generated numbers, to three study arms by 1:1:1 ratio. Group A received Tdap followed by MCV4-CRM 197 (+PCV13) 3-4 weeks later. Group B received all three vaccines in a single visit. Group C received MCV4-CRM 197 (+PCV13) followed by Tdap 3-4 weeks later. Blood samples obtained prior to and 3-4 weeks after immunisation with MCV4-CRM 197 were tested for meningococcal serogroup W-specific serum bactericidal antibody responses using baby rabbit complement (rSBA). One hundred and seven participants aged between 18 and 64 (median 40) years completed the study. No significant difference in meningococcal serogroup W rSBA geometric mean titre (GMT) was observed between the study arms post vaccination with MCV-CRM 197 but Group A tended to have a slightly lower GMT (A = 404, B = 984 and C = 1235, p = 0.15). No statistical difference was noticed between the groups in proportions of subjects achieving a ≥4-fold rise in rSBA titres or achieving rSBA titre ≥8 post vaccination. In conclusion, receipt of MCV4-CRM 197 vaccine prior, concurrent or subsequent to Tdap has similar immunologic response, and hence concurrent administration is both immunogenic and practical. However, further investigation into whether carrier induced suppression is a public health issue is suggested. Clinical trial registration: ANZCTR no. ACTRN12613000536763.",2019,No statistical difference was noticed between the groups in proportions of subjects achieving a ≥4-fold rise in rSBA titres or achieving rSBA titre ≥8,"['Australian adults before attending the Hajj pilgrimage in 2014', 'adult Hajj pilgrims', 'One hundred and seven participants aged between 18 and 64 (median 40) years completed the study']","['Tdap', 'MCV4-CRM 197 (+PCV13', 'quadrivalent meningococcal conjugate vaccine (MCV4) conjugated to CRM 197 (coadministered with 13 valent pneumococcal vaccine conjugate CRM 197 [PCV13]), and tetanus-diphtheria-acellular pertussis (Tdap) vaccine', 'Tdap followed by MCV4-CRM 197 (+PCV13']","['rSBA titres or achieving rSBA titre ≥8', 'meningococcal serogroup W rSBA geometric mean titre (GMT']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C4517529', 'cui_str': 'One hundred and seven'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0056499', 'cui_str': 'cross reacting material (CRM(197)) of diphtheria toxin'}, {'cui': 'C1660580', 'cui_str': 'Meningococcal conjugate vaccine'}, {'cui': 'C0301869', 'cui_str': 'Conjugate'}, {'cui': 'C2714181', 'cui_str': '13-valent pneumococcal vaccine'}, {'cui': 'C0012546', 'cui_str': 'Corynebacterium diphtheriae Infection'}, {'cui': 'C0982332', 'cui_str': 'acellular pertussis vaccine, inactivated'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}]","[{'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0449543', 'cui_str': 'Serogroup'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",107.0,0.0525044,No statistical difference was noticed between the groups in proportions of subjects achieving a ≥4-fold rise in rSBA titres or achieving rSBA titre ≥8,"[{'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Tashani', 'Affiliation': ""The Discipline of Child and Adolescent Health, Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, NSW, Australia; Faculty of Medicine, University of Tripoli, Ain Zara, Tripoli, Libya.""}, {'ForeName': 'Al-Mamoon', 'Initials': 'AM', 'LastName': 'Badahdah', 'Affiliation': ""The Discipline of Child and Adolescent Health, Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, NSW, Australia; National Centre for Immunisation Research and Surveillance (NCIRS), The Children's Hospital at Westmead, NSW, Australia; Department of Family and Community Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: almamoon.badahdah@health.nsw.gov.au.""}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Alfelali', 'Affiliation': ""The Discipline of Child and Adolescent Health, Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, NSW, Australia; National Centre for Immunisation Research and Surveillance (NCIRS), The Children's Hospital at Westmead, NSW, Australia; Department of Family and Community Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia.""}, {'ForeName': 'Osamah', 'Initials': 'O', 'LastName': 'Barasheed', 'Affiliation': 'The Executive Administration of Research and Innovation, King Abdullah Medical City in Holy Capital (KAMC-HC), Makkah 24246, Saudi Arabia.'}, {'ForeName': 'Amani S', 'Initials': 'AS', 'LastName': 'Alqahtani', 'Affiliation': 'Saudi Food and Drug Authority, Riyadh 13312, Saudi Arabia.'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Heron', 'Affiliation': ""National Centre for Immunisation Research and Surveillance (NCIRS), The Children's Hospital at Westmead, NSW, Australia.""}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Wong', 'Affiliation': ""Immunology Department, The Children's Hospital at Westmead, Westmead 2145, NSW, Australia.""}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Louth', 'Affiliation': 'Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, UK.'}, {'ForeName': 'Harunor', 'Initials': 'H', 'LastName': 'Rashid', 'Affiliation': ""The Discipline of Child and Adolescent Health, Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, NSW, Australia; National Centre for Immunisation Research and Surveillance (NCIRS), The Children's Hospital at Westmead, NSW, Australia; Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Biological Sciences and Sydney Medical School, University of Sydney, Sydney, NSW 2145, Australia.""}, {'ForeName': 'Ray', 'Initials': 'R', 'LastName': 'Borrow', 'Affiliation': 'Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Booy', 'Affiliation': ""The Discipline of Child and Adolescent Health, Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, NSW, Australia; National Centre for Immunisation Research and Surveillance (NCIRS), The Children's Hospital at Westmead, NSW, Australia; Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Biological Sciences and Sydney Medical School, University of Sydney, Sydney, NSW 2145, Australia; WHO Collaborating Centre for Mass Gatherings and High Consequence/High Visibility Events, Flinders University, Adelaide 5001, Australia.""}]",Vaccine,['10.1016/j.vaccine.2019.05.025'] 689,30945740,Sleep Apnea Multilevel Surgery (SAMS) trial protocol: a multicenter randomized clinical trial of upper airway surgery for patients with obstructive sleep apnea who have failed continuous positive airway pressure.,"STUDY OBJECTIVES Obstructive sleep apnea (OSA) is a serious and costly public health problem. The main medical treatment, continuous positive airway pressure, is efficacious when used, but poorly tolerated in up to 50% of patients. Upper airway reconstructive surgery is available when medical treatments fail but randomized trial evidence supporting its use is limited. This protocol details a randomized controlled trial designed to assess the clinical effectiveness, safety, and cost-effectiveness of a multilevel upper airway surgical procedure for OSA. METHODS A prospective, parallel-group, open label, randomized, controlled, multicenter clinical trial in adults with moderate or severe OSA who have failed or refused medical therapies. Six clinical sites in Australia randomly allocated participants in a 1:1 ratio to receive either an upper airway surgical procedure consisting of a modified uvulopalatopharyngoplasty and minimally invasive tongue volume reduction, or to continue with ongoing medical management, and followed them for 6 months. RESULTS Primary outcomes: difference between groups in baseline-adjusted 6 month OSA severity (apnea-hypopnea index) and subjective sleepiness (Epworth Sleepiness Scale). Secondary outcomes: other OSA symptoms (e.g. snoring and objective sleepiness), other polysomnography parameters (e.g. arousal index and 4% oxygen desaturation index), quality of life, 24 hr ambulatory blood pressure, adverse events, and adherence to ongoing medical therapies (medical group). CONCLUSIONS The Sleep Apnea Multilevel Surgery (SAMS) trial is of global public health importance for testing the effectiveness and safety of a multilevel surgical procedure for patients with OSA who have failed medical treatment. CLINICAL TRIAL REGISTRATION Multilevel airway surgery in patients with moderate-severe Obstructive Sleep Apnea (OSA) who have failed medical management to assess change in OSA events and daytime sleepiness. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366019&isReview=true Australian New Zealand Clinical Trials Registry ACTRN12614000338662, prospectively registered on 31 March 2014.",2019,"The main medical treatment, continuous positive airway pressure, is efficacious when used, but poorly tolerated in up to 50% of patients.","['patients with moderate-severe Obstructive Sleep Apnea (OSA', 'patients with obstructive sleep apnea who have failed continuous positive airway pressure', 'adults with moderate or severe OSA who have failed or refused medical therapies', 'Obstructive sleep apnea (OSA', 'patients with OSA who have failed medical treatment']","['Upper airway reconstructive surgery', 'upper airway surgery', 'Sleep Apnea Multilevel Surgery (SAMS', 'upper airway surgical procedure consisting of a modified uvulopalatopharyngoplasty and minimally invasive tongue volume reduction, or to continue with ongoing medical management, and followed them for 6 months', 'Multilevel airway surgery', 'multilevel upper airway surgical procedure']","['clinical effectiveness, safety, and cost-effectiveness', 'OSA symptoms (e.g. snoring and objective sleepiness), other polysomnography parameters (e.g. arousal index and 4% oxygen desaturation index), quality of life, 24 hr ambulatory blood pressure, adverse events, and adherence to ongoing medical therapies (medical group', 'baseline-adjusted 6 month OSA severity (apnea-hypopnea index) and subjective sleepiness (Epworth Sleepiness Scale', 'OSA events and daytime sleepiness']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0520679', 'cui_str': 'Syndrome, Sleep Apnea, Obstructive'}, {'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1705116', 'cui_str': 'Refused (qualifier value)'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy (procedure)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}, {'cui': 'C0524865', 'cui_str': 'Reconstructive Surgery'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0037315', 'cui_str': 'Sleep Hypopnea'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1535578', 'cui_str': 'Uvulopalatopharyngoplasty (procedure)'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C0040408', 'cui_str': 'Tongue'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C3850123', 'cui_str': 'Treatment Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0037384', 'cui_str': 'Snorings'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C2830004', 'cui_str': 'Somnolence'}, {'cui': 'C0162701', 'cui_str': 'Monitoring, Sleep'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0034380'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy (procedure)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C2111846', 'cui_str': 'Apnea-hypopnea index'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C3541276', 'cui_str': 'ESS - Epworth Sleepiness Scale'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0541854', 'cui_str': 'Daytime sleepiness'}]",,0.0881314,"The main medical treatment, continuous positive airway pressure, is efficacious when used, but poorly tolerated in up to 50% of patients.","[{'ForeName': 'A Simon', 'Initials': 'AS', 'LastName': 'Carney', 'Affiliation': 'Department of Surgery, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.'}, {'ForeName': 'Nick A', 'Initials': 'NA', 'LastName': 'Antic', 'Affiliation': 'Adelaide Institute for Sleep Health, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.'}, {'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Catcheside', 'Affiliation': 'Adelaide Institute for Sleep Health, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.'}, {'ForeName': 'Ching', 'Initials': 'C', 'LastName': 'Li Chai-Coetzer', 'Affiliation': 'Adelaide Institute for Sleep Health, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Cistulli', 'Affiliation': 'Department of Respiratory Medicine and Sleep, Royal North Shore Hospital, St Leonards, NSW, Australia.'}, {'ForeName': 'Billingsley', 'Initials': 'B', 'LastName': 'Kaambwa', 'Affiliation': 'Health Economics Unit, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.'}, {'ForeName': 'Stuart G', 'Initials': 'SG', 'LastName': 'MacKay', 'Affiliation': 'Illawarra ENT Head and Neck Clinic, Wollongong, NSW, Australia.'}, {'ForeName': 'Alison J', 'Initials': 'AJ', 'LastName': 'Pinczel', 'Affiliation': 'Adelaide Institute for Sleep Health, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.'}, {'ForeName': 'Edward M', 'Initials': 'EM', 'LastName': 'Weaver', 'Affiliation': 'Department of Otolaryngology/Head and Neck Surgery, University of Washington, Staff Surgeon, Seattle Veterans Affairs Medical Center, Seattle, WA.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Woodman', 'Affiliation': 'Flinders Centre for Epidemiology and Biostatistics, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.'}, {'ForeName': 'Charmaine M', 'Initials': 'CM', 'LastName': 'Woods', 'Affiliation': 'Department of Otolaryngology Head and Neck Surgery, Southern Adelaide Local Health Network, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.'}, {'ForeName': 'R Doug', 'Initials': 'RD', 'LastName': 'McEvoy', 'Affiliation': 'Adelaide Institute for Sleep Health, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.'}]",Sleep,['10.1093/sleep/zsz056'] 690,30030269,Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance).,"Prior to novel targeted agents for chronic lymphocytic leukemia (CLL), the best chemoimmunotherapy regimen in patients with non-del(11q) disease was unclear. The role of lenalidomide was also not defined. This phase 2 study randomized 342 untreated patients with non-del(11q) CLL requiring therapy to fludarabine plus rituximab (FR; n = 123), FR plus lenalidomide consolidation (FR+L; n = 109), or FR plus cyclophosphamide (FCR; n = 110) and compared 2-year progression-free survival (PFS) rates of each to the historical control rate with FC (60%). Patients with del(11q) in at least 20% of pretreatment cells continued with FCR (n = 27) or were reassigned to FCR+L (n = 31) and excluded from the primary analysis. Among non-del(11q) patients, 2-year PFS rates were 64% (90% confidence interval [CI], 57-71; FR), 72% (90% CI, 65-79; FR+L), and 74% (90% CI, 66-80; FCR); FR+L and FCR had rates significantly greater than historical control. Median PFS was significantly shorter with FR compared with FR+L ( P = .04) and FCR ( P < .001): 43 (95% CI, 33-50), 61 (95% CI, 45-71), and 97 (95% CI, 61 to not reached) months, respectively. Median follow-up was 73 months and median overall survival (OS) was only reached with FCR (101 months; 95% CI, 96 to not reached). With FR+L, the risk of death decreased over time and was lower than with FR at later time points ( P = .01), but not significantly different from FCR ( P = .21). Future studies incorporating short courses of lenalidomide into other novel treatment regimens are justified.",2018,Median PFS was significantly shorter with FR compared with FR+L ( P = .04) and FCR ( P < .001): 43,"['chronic lymphocytic leukemia (CLL', 'patients with non-del(11q) disease was unclear', 'benefits patients with CLL receiving', 'FR; n = 123), FR plus lenalidomide consolidation (FR+L; n = 109), or', '342 untreated patients with non-del(11q) CLL requiring therapy to', 'Patients with del(11q) in at least 20% of pretreatment cells continued with FCR (n = 27) or were reassigned to FCR+L (n = 31) and excluded from the primary analysis']","['FR plus cyclophosphamide (FCR', 'Lenalidomide consolidation', 'fludarabine plus rituximab', 'chemoimmunotherapy']","['2-year PFS rates', 'median overall survival (OS', 'FCR', '2-year progression-free survival (PFS) rates', 'risk of death', 'Median PFS']","[{'cui': 'C0023434', 'cui_str': 'Lymphoma, Small Lymphocytic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1144149', 'cui_str': 'lenalidomide'}, {'cui': 'C0702116', 'cui_str': 'Consolidation (morphologic abnormality)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}]","[{'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C1144149', 'cui_str': 'lenalidomide'}, {'cui': 'C0702116', 'cui_str': 'Consolidation (morphologic abnormality)'}, {'cui': 'C0059985', 'cui_str': 'fludarabine'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",342.0,0.113518,Median PFS was significantly shorter with FR compared with FR+L ( P = .04) and FCR ( P < .001): 43,"[{'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Byrd', 'Affiliation': 'Division of Hematology.'}, {'ForeName': 'Amy S', 'Initials': 'AS', 'LastName': 'Ruppert', 'Affiliation': 'Division of Hematology.'}, {'ForeName': 'Nyla A', 'Initials': 'NA', 'LastName': 'Heerema', 'Affiliation': 'Department of Pathology, The Ohio State University, Columbus, OH.'}, {'ForeName': 'Alese E', 'Initials': 'AE', 'LastName': 'Halvorson', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Hoke', 'Affiliation': 'Alliance Statistics and Data Center, Duke University, Durham, NC.'}, {'ForeName': 'Mitchell R', 'Initials': 'MR', 'LastName': 'Smith', 'Affiliation': 'Department of Medical Oncology and Hematology, George Washington University Cancer Center, Washington, DC.'}, {'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Godwin', 'Affiliation': 'Providence Cancer Center, Portland, OR.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Couban', 'Affiliation': 'QEII Health Sciences Centre, Halifax, NS, Canada.'}, {'ForeName': 'Todd A', 'Initials': 'TA', 'LastName': 'Fehniger', 'Affiliation': 'Division of Oncology, Washington University School of Medicine, St. Louis, MO.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Thirman', 'Affiliation': 'Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL.'}, {'ForeName': 'Martin S', 'Initials': 'MS', 'LastName': 'Tallman', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Frederick R', 'Initials': 'FR', 'LastName': 'Appelbaum', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Stone', 'Affiliation': 'Dana-Farber/Partners CancerCare, Harvard Cancer Center, Boston, MA; and.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Robinson', 'Affiliation': 'QEII Health Sciences Centre, Halifax, NS, Canada.'}, {'ForeName': 'Julie E', 'Initials': 'JE', 'LastName': 'Chang', 'Affiliation': 'Department of Medicine, University of Wisconsin, Madison, WI.'}, {'ForeName': 'Sumithra J', 'Initials': 'SJ', 'LastName': 'Mandrekar', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Larson', 'Affiliation': 'Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL.'}]",Blood advances,['10.1182/bloodadvances.2017015396'] 691,31170543,A mesh nebulizer is more effective than jet nebulizer to nebulize bronchodilators during non-invasive ventilation of subjects with COPD: A randomized controlled trial with radiolabeled aerosols.,"BACKGROUND Beneficial effects from non-invasive ventilation (NIV) in acute COPD are well-established, but the impact of nebulization during NIV has not been well described. AIM To compare pulmonary deposition and distribution across regions of interest with administration of radiolabeled aerosols generated by vibrating mesh nebulizers (VMN) and jet nebulizer (JN) during NIV. METHODS A crossover single dose study involving 9 stable subjects with moderate to severe COPD randomly allocated to receive aerosol administration by the VMN Aerogen and the MistyNeb jet nebulizer operating with oxygen at 8 lpm during NIV. Radiolabeled bronchodilators (fill volume of 3 mL: 0.5 mL salbutamol 2.5 mg + 0.125 mL ipratropium 0.25 mg and physiologic saline up to 3 mL) were delivered until sputtering during NIV (pressures of 12 cmH2O and 5 cmH2O - inspiratory and expiratory, respectively) using an oro-nasal facemask. Radioactivity counts were performed using a gamma camera and regions of interest (ROIs) were delimited. Aerosol mass balance based on counts from the lungs, upper airways, stomach, nebulizer, circuit, inspiratory and expiratory filters, and mask were determined and expressed as a percentage of the total. RESULTS Both inhaled and lung doses were greater with VMN (22.78 ± 3.38% and 12.05 ± 2.96%, respectively) than JN (12.51 ± 6.31% and 3.14 ± 1.71%; p = 0.008). Residual drug volume was lower in VMN than in JN (3.08 ± 1.3% versus 46.44 ± 5.83%, p = 0.001). Peripheral deposition of radioaerosol was significantly lower with JN than VMN. CONCLUSIONS VMN deposited > 3 fold more radioaerosol into the lungs of moderate to severe COPD patients than JN during NIV.",2019,"Both inhaled and lung doses were greater with VMN (22.78 ± 3.38% and 12.05 ± 2.96%, respectively) than JN (12.51 ± 6.31% and 3.14 ± 1.71%; p = 0.008).","['subjects with COPD', '9 stable subjects with moderate to severe COPD']","['mg\xa0+\xa00.125\xa0mL ipratropium 0.25\u202fmg and physiologic saline', 'radiolabeled aerosols generated by vibrating mesh nebulizers (VMN) and jet nebulizer (JN', 'aerosol administration by the VMN Aerogen and the MistyNeb jet nebulizer operating with oxygen', 'Radiolabeled bronchodilators (fill volume of 3\u202fmL: 0.5\u202fmL salbutamol 2.5', 'radiolabeled aerosols']","['Peripheral deposition of radioaerosol', 'Radioactivity counts', 'Residual drug volume', 'Aerosol mass balance based on counts from the lungs, upper airways, stomach, nebulizer, circuit, inspiratory and expiratory filters, and mask']","[{'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}]","[{'cui': 'C4517427', 'cui_str': '0.125 (qualifier value)'}, {'cui': 'C0027235', 'cui_str': 'Ipratropium'}, {'cui': 'C4517443', 'cui_str': '0.25 (qualifier value)'}, {'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0001712', 'cui_str': 'Aerosol (substance)'}, {'cui': 'C0181805', 'cui_str': 'Mesh (physical object)'}, {'cui': 'C0027524', 'cui_str': 'Nebulizers'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0006280', 'cui_str': 'Bronchodilators'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0001927', 'cui_str': 'Albuterol'}, {'cui': 'C3844011', 'cui_str': '2.5'}]","[{'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0333562', 'cui_str': 'Deposition (morphologic abnormality)'}, {'cui': 'C0034553', 'cui_str': 'Radioactive Disintegration'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0001712', 'cui_str': 'Aerosol (substance)'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C3714551', 'cui_str': 'Stomach structure (body structure)'}, {'cui': 'C0027524', 'cui_str': 'Nebulizers'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0180860', 'cui_str': 'Filter, device (physical object)'}, {'cui': 'C0024861', 'cui_str': 'Masks'}]",9.0,0.0594936,"Both inhaled and lung doses were greater with VMN (22.78 ± 3.38% and 12.05 ± 2.96%, respectively) than JN (12.51 ± 6.31% and 3.14 ± 1.71%; p = 0.008).","[{'ForeName': 'Valdecir Castor', 'Initials': 'VC', 'LastName': 'Galindo-Filho', 'Affiliation': 'Department of Physicaltherapy, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil. Electronic address: vcastorgalindo@yahoo.com.'}, {'ForeName': 'Luciana', 'Initials': 'L', 'LastName': 'Alcoforado', 'Affiliation': 'Department of Physicaltherapy, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil. Electronic address: lucalcoforado@yahoo.com.br.'}, {'ForeName': 'Catarina', 'Initials': 'C', 'LastName': 'Rattes', 'Affiliation': 'Department of Physicaltherapy, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil. Electronic address: catarina_rattes@hotmail.com.'}, {'ForeName': 'Dulciane Nunes', 'Initials': 'DN', 'LastName': 'Paiva', 'Affiliation': 'Department of Physicaltherapy, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil. Electronic address: dulciane@unisc.br.'}, {'ForeName': 'Simone Cristina Soares', 'Initials': 'SCS', 'LastName': 'Brandão', 'Affiliation': 'Department of Nuclear Medicine, Hospital Das Clínicas de Pernambuco, Recife, Pernambuco, Brazil. Electronic address: sbrandaonuclearufpe@gmail.com.'}, {'ForeName': 'James B', 'Initials': 'JB', 'LastName': 'Fink', 'Affiliation': 'Division of Respiratory Care, Rush Medical School, Chicago, IL, USA. Electronic address: fink.jim@gmail.com.'}, {'ForeName': 'Armèle', 'Initials': 'A', 'LastName': 'Dornelas de Andrade', 'Affiliation': 'Department of Physicaltherapy, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil. Electronic address: armeledornelas@yahoo.com.'}]",Respiratory medicine,['10.1016/j.rmed.2019.05.016'] 692,31189497,Basic life support training: Demonstration versus lecture - A randomised controlled trial.,"INTRODUCTION Basic life support (BLS) and the use of an automated external defibrillator (AED) improve survival from cardiac arrest. The gold standard for teaching BLS/AED is yet to be identified. The aim of this study was to compare the learning outcome of an instructor-led demonstration with a formal lecture for introducing BLS/AED skills. We hypothesized that a demonstration was superior to a lecture. METHODS First year-medical students were randomised to either a demonstration or a lecture using PowerPoint® Presentation for skill introduction during European Resuscitation Council BLS/AED courses. Participants were skill-tested after training and required to perform all skills correctly to pass the test. Finally, all participants were asked to state their preferred teaching method. RESULTS Overall, 247 participants were included in the analysis (demonstration group: 124, lecture group: 123). Pass rate was 63% in both groups, p = 1.00. Both groups performed median compression rates within guidelines recommendations, p = 0.09. Mean compression depth was 55 mm (10 mm) in the demonstration group compared with 52 mm (10 mm) in the lecture group, p = 0.05. Median tidal volume was 265 (192, 447) ml and 405 (262, 578) ml, p < 0.001, respectively. The lecture group was 3 s faster at initiating BLS, p < 0.001. In total, 226 (91%) participants preferred demonstration on a manikin for introducing BLS/AED. CONCLUSION There was no statistically significant difference in pass rate when comparing a demonstration with a lecture for introducing BLS/AED. The lecture group was slightly faster at initiating BLS. Most participants preferred a demonstration as introduction.",2020,There was no statistically significant difference in pass rate when comparing a demonstration with a lecture for introducing BLS/AED.,"['First year-medical students', '247 participants were included in the analysis (demonstration group: 124, lecture group: 123']","['automated external defibrillator (AED', 'demonstration or a lecture using PowerPoint® Presentation']","['Pass rate', 'Median tidal volume', 'Mean compression depth', 'pass rate', 'median compression rates']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0038495', 'cui_str': 'Students, Medical'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0376683', 'cui_str': 'Lecture'}]","[{'cui': 'C0180309', 'cui_str': 'Automated External Defibrillators'}, {'cui': 'C0376683', 'cui_str': 'Lecture'}, {'cui': 'C0449450', 'cui_str': 'Presentation (attribute)'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0040210', 'cui_str': 'Tidal Volume'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}]",247.0,0.0774313,There was no statistically significant difference in pass rate when comparing a demonstration with a lecture for introducing BLS/AED.,"[{'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Hansen', 'Affiliation': 'Research Center for Emergency Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, 8200 Aarhus, Denmark; Department of Internal Medicine, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark; Clinical Research Unit, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Bang', 'Affiliation': 'Research Center for Emergency Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, 8200 Aarhus, Denmark; Department of Internal Medicine, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark; Clinical Research Unit, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark.'}, {'ForeName': 'Stinne Eika', 'Initials': 'SE', 'LastName': 'Rasmussen', 'Affiliation': 'Research Center for Emergency Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, 8200 Aarhus, Denmark.'}, {'ForeName': 'Mette Amalie', 'Initials': 'MA', 'LastName': 'Nebsbjerg', 'Affiliation': 'Research Center for Emergency Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, 8200 Aarhus, Denmark.'}, {'ForeName': 'Kasper G', 'Initials': 'KG', 'LastName': 'Lauridsen', 'Affiliation': 'Research Center for Emergency Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, 8200 Aarhus, Denmark; Department of Internal Medicine, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark; Clinical Research Unit, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark.'}, {'ForeName': 'Katrine', 'Initials': 'K', 'LastName': 'Bjørnshave Bomholt', 'Affiliation': 'Research Center for Emergency Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, 8200 Aarhus, Denmark.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Krogh', 'Affiliation': 'Department of Anesthesia and Intensive Care, Aarhus University Hospital, Palle Juul-Jensens Blvd. 99, 8200 Aarhus, Denmark; Centre for Health Sciences Education, Aarhus University, Palle Juul-Jensens Blvd. 82, INCUBA Skejby building B, 8200 Aarhus, Denmark.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Løfgren', 'Affiliation': 'Research Center for Emergency Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, 8200 Aarhus, Denmark; Department of Internal Medicine, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark; Clinical Research Unit, Randers Regional Hospital, Skovlyvej 15, 8930 Randers, Denmark; Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Blvd. 82, INCUBA Skejby building 2, 8200 Aarhus, Denmark; Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Blvd. 69, 8200 Aarhus, Denmark. Electronic address: bo.loefgren@clin.au.dk.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.06.008'] 693,31761458,A pilot study of the effectiveness of a serious game CliniPup® on perioperative anxiety and pain in children.,"INTRODUCTION/AIM Children experience important anxiety before surgery. Anxiety and pain are positively correlated. Serious gaming is a non-pharmacological intervention to prepare children and parents for an operation. We aimed to evaluate the effectiveness of the serious game CliniPup® on anxiety and pain in children undergoing ambulatory surgery. METHOD A prospective randomized controlled pilot trial in 72 children aged 5 to 11 years old scheduled for day-care surgery (general surgery, dentistry, otorhinolaryngology, urology) was performed. Participants were randomly assigned into 3 groups: A (CliniPup®), B (""Empty game"" without educational information), or C (no game, oral information at the outpatient clinic, current standard of care). Anxiety, pain, and behaviour were evaluated by validated instruments at six time-points: T0: baseline, T1: 1 week preoperatively, T2: at hospital admission, T3: before discharge, T4: 1 week postoperatively, T5: 1 month postoperatively. RESULTS After playing the game (T1), the estimated mean anxiety score (VASa) was lower in Group A (1.9 units) versus Group B (2.7 units). The estimated mean VASa at T1 for Group A was 2.6 units lower compared to Group C (p = 0.003). For Group B, VASa levels were 1.8 units lower than in Group C (p = 0.045). After correction for ""surgery type"", Group A continued to show a significantly lower VASa compared to Group C (p = 0.044). On the other time points, no difference in anxiety and pain were observed, nor in post-hospitalization behaviour. CONCLUSION Children that played the CliniPup® game one week before surgery had a significant reduction in preoperative anxiety after playing the game, but not on the other time points. No differences on peri-operative pain were observed during the different time points. TYPE OF STUDY Randomized Trial. LEVEL OF EVIDENCE Level II.",2020,"For Group B, VASa levels were 1.8 units lower than in Group C (p = 0.045).","['children', 'children undergoing ambulatory surgery', '72 children aged 5 to 11\u202fyears old scheduled for day-care surgery (general surgery, dentistry, otorhinolaryngology, urology) was performed']","['A (CliniPup®), B (""Empty game"" without educational information), or C (no game, oral information at the outpatient clinic, current standard of care', 'serious game CliniPup®']","['mean anxiety score (VASa', 'Anxiety and pain', 'anxiety and pain', 'VASa', 'estimated mean VASa', 'VASa levels', 'Anxiety, pain, and behaviour', 'preoperative anxiety', 'perioperative anxiety and pain', 'peri-operative pain']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0002428', 'cui_str': 'Ambulatory Surgery'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0011017', 'cui_str': 'Day Care'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0011438', 'cui_str': 'Dentistry'}, {'cui': 'C0029892', 'cui_str': 'Otorhinolaryngology'}, {'cui': 'C0042077', 'cui_str': 'Urology'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}]",72.0,0.0403345,"For Group B, VASa levels were 1.8 units lower than in Group C (p = 0.045).","[{'ForeName': 'Lucas E', 'Initials': 'LE', 'LastName': 'Matthyssens', 'Affiliation': ""Department of Gastrointestinal and Paediatric Surgery, Princess Elisabeth Children's Hospital, Ghent University Hospital, Ghent University, C. Heymanslaan 10, B-9000 Ghent, Belgium. Electronic address: Lucas.Matthyssens@uzgent.be.""}, {'ForeName': 'Amber', 'Initials': 'A', 'LastName': 'Vanhulle', 'Affiliation': 'Faculty of Medicine and Health Sciences, Ghent University, Campus UZ Ghent, C. Heymanslaan 10, B-9000 Ghent, Belgium.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Seldenslach', 'Affiliation': 'Faculty of Medicine and Health Sciences, Ghent University, Campus UZ Ghent, C. Heymanslaan 10, B-9000 Ghent, Belgium.'}, {'ForeName': 'Geert', 'Initials': 'G', 'LastName': 'Vander Stichele', 'Affiliation': 'MindBytes BVBA, Schoondreef 7, Merksplas, Belgium.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Coppens', 'Affiliation': 'Department of Anaesthesiology and Perioperative Medicine, Ghent University Hospital, Ghent University, C. Heymanslaan 10, B-9000 Ghent, Belgium.'}, {'ForeName': 'Eline', 'Initials': 'E', 'LastName': 'Van Hoecke', 'Affiliation': ""Department of Paediatrics, Paediatric Psychology, Princess Elisabeth Children's Hospital, Ghent University Hospital, Ghent University, C. Heymanslaan 10, B-9000 Ghent, Belgium.""}]",Journal of pediatric surgery,['10.1016/j.jpedsurg.2019.10.031'] 694,31763984,Allogeneic cardiosphere-derived cells for the treatment of heart failure with reduced ejection fraction: the Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells (DYNAMIC) trial.,"AIMS The DYNAMIC trial assessed the safety and explored the efficacy of multivessel intracoronary infusion of allogeneic cardiosphere-derived cells (CDCs) in patients with heart failure and reduced ejection fraction (HFrEF). Here we report the results of the DYNAMIC trial. METHODS AND RESULTS We enrolled 14 patients with EF ≤35% and NYHA Class III-IV despite maximal medical and device-based therapy in this single-centre, open-label trial. Intracoronary catheterisation delivered four escalating doses (totalling 37.5-75 million cells) by sequential non-occlusive technique to all three major coronary arteries. The primary safety endpoint was a composite of post-infusion TIMI flow, ventricular tachycardia/fibrillation, sudden death, major adverse cardiac events or acute myocarditis within 72 hours. Twelve patients were male and EF averaged 23.0% (±4.5%). No primary safety endpoints were observed. Two patients died of HFrEF progression nine and 12 months following infusion. Compared to baseline, there was an improvement in EF (26.8% vs 22.9%, p=0.023) and left ventricular end-systolic volume (139.5 vs 177.8 cm3, p=0.03) at six months. Quality of life (QoL) scores and NYHA class (p=0.006) improved at six months. At 12 months, the improvement in EF and QoL remained significant. CONCLUSIONS Global intracoronary infusion of allogeneic CDCs is safe and feasible. The efficacy of allogeneic CDCs in HFrEF needs to be tested in larger randomised trials.",2020,Quality of life (QoL) scores and NYHA class (p=0.006) improved at 6 months.,"['Heart Failure with Reduced Ejection Fraction', '14 patients with EF≤35% and NYHA III-IV despite maximal medical- and device-based therapy in this single-center, open-label trial', 'patients with heart failure and reduced ejection fraction (HFrEF']","['Intracoronary catheterization', 'multivessel intracoronary infusion of allogeneic cardiosphere-derived cells (CDCs', 'allogeneic CDCs', 'Allogeneic Cardiosphere-derived Cells']","['left ventricular end-systolic volume', 'composite of post-infusion TIMI flow, ventricular tachycardia/fibrillation, sudden death, major adverse cardiac events or acute myocarditis within 72 hours', 'EF and QoL', 'EF', 'Quality of life (QoL) scores and NYHA class']","[{'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}]","[{'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0055295', 'cui_str': 'chenodeoxycholic acid sulfate conjugate'}]","[{'cui': 'C0080308', 'cui_str': 'Ventricular End-Systolic Volume'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0042514', 'cui_str': 'Tachycardia, Ventricular'}, {'cui': 'C0232197', 'cui_str': 'Fibrillation (disorder)'}, {'cui': 'C0011071', 'cui_str': 'Sudden death (event)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0155686', 'cui_str': 'Acute myocarditis (disorder)'}, {'cui': 'C1292423', 'cui_str': '72 hours (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}]",14.0,0.111307,Quality of life (QoL) scores and NYHA class (p=0.006) improved at 6 months.,"[{'ForeName': 'Tarun', 'Initials': 'T', 'LastName': 'Chakravarty', 'Affiliation': 'Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Timothy D', 'Initials': 'TD', 'LastName': 'Henry', 'Affiliation': ''}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Kittleson', 'Affiliation': ''}, {'ForeName': 'Joao', 'Initials': 'J', 'LastName': 'Lima', 'Affiliation': ''}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Siegel', 'Affiliation': ''}, {'ForeName': 'Leandro', 'Initials': 'L', 'LastName': 'Slipczuk', 'Affiliation': ''}, {'ForeName': 'Janice M', 'Initials': 'JM', 'LastName': 'Pogoda', 'Affiliation': ''}, {'ForeName': 'Rachel R', 'Initials': 'RR', 'LastName': 'Smith', 'Affiliation': ''}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Malliaras', 'Affiliation': ''}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Marbán', 'Affiliation': ''}, {'ForeName': 'Deborah D', 'Initials': 'DD', 'LastName': 'Ascheim', 'Affiliation': ''}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Marbán', 'Affiliation': ''}, {'ForeName': 'Raj R', 'Initials': 'RR', 'LastName': 'Makkar', 'Affiliation': ''}]",EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,['10.4244/EIJ-D-19-00035'] 695,31763936,The impact of flushing with pre-filled saline syringes on the incidence of peripheral venous catheter failure: A quasi-experimental study.,"BACKGROUND Short peripheral venous catheters are one of the most frequently used devices in hospitals. Peripheral venous catheter failure, defined as the unscheduled dysfunction of peripheral venous catheter, is common and frequently entails a new invasive procedure. Flushing the catheter maintains patency and could prolong peripheral venous catheter dwell time. The introduction of pre-filled saline flushing syringes as compared to manually filled saline flushing syringes could facilitate the frequency of catheter flushing, and subsequently it could reduce peripheral venous catheter failure rate. OBJECTIVE To demonstrate differences in overall peripheral venous catheter failure rates before and after the introduction of pre-filled saline flushing syringes and to assess the risk factors for peripheral venous catheter failure. METHODS Quasi-experimental design, before-and-after intervention study. Intervention: introduction of pre-filled saline syringes for flushing. Multicenter study conducted in medical and surgical wards of three European hospitals during a 9-month period (4 months pre-intervention, 5 months intervention). A multivariate Cox proportional model was used to identify factors associated with the occurrence of peripheral venous catheter failure. RESULTS Data from 3853 peripheral venous catheters in 1915 patients were analyzed. Compared to pre-intervention period, a significant decrease in peripheral venous catheter failure rate was observed in the intervention period (57% vs 43.4%, p < 0.001). Independent factors associated with peripheral venous catheter failure were as follows: Charlson score ⩾4 (hazard ratio: 1.648; 95% confidence interval: 1.069-2.527), days of hospital stay ⩾10 (hazard ratio: 1.468; 95% confidence interval: 1.172-1.837), and catheter ""D"" (hazard ratio: 1.758; 95% confidence interval: 1.058-2.919). CONCLUSION The use of pre-filled saline syringes significantly reduced peripheral venous catheter failure and increased catheter dwell time. Thus, it is important to reinforce the use of the pre-filled syringes for flushing to reduce the incidence of peripheral venous catheters' failure.",2020,"Compared to pre-intervention period, a significant decrease in peripheral venous catheter failure rate was observed in the intervention period (57% vs 43.4%, p < 0.001).","['Multicenter study conducted in medical and surgical wards of three European hospitals during a 9-month period (4\u2009months pre-intervention, 5\u2009months intervention', '3853 peripheral venous catheters in 1915 patients were analyzed']","['pre-filled saline syringes', 'flushing with pre-filled saline syringes']","['peripheral venous catheter failure', 'overall peripheral venous catheter failure rates', 'peripheral venous catheter failure rate', 'hospital stay ⩾10', 'peripheral venous catheter dwell time', 'peripheral venous catheter failure and increased catheter dwell time']","[{'cui': 'C1096776', 'cui_str': 'Multicenter Study'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C0239307', 'cui_str': 'European (ethnic group)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0745442', 'cui_str': 'Venous catheter (physical object)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0039142', 'cui_str': 'Syringes'}, {'cui': 'C0016382', 'cui_str': 'Flushing'}]","[{'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0745442', 'cui_str': 'Venous catheter (physical object)'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0429659', 'cui_str': 'Dwell time (observable entity)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}]",1915.0,0.0342401,"Compared to pre-intervention period, a significant decrease in peripheral venous catheter failure rate was observed in the intervention period (57% vs 43.4%, p < 0.001).","[{'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Saliba', 'Affiliation': 'Department of Infectious Diseases, Bellvitge University Hospital, Biomedical Research Institute of Bellvitge (IDIBELL), Barcelona, Spain.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Cuervo', 'Affiliation': 'Department of Infectious Diseases, Bellvitge University Hospital, Biomedical Research Institute of Bellvitge (IDIBELL), Barcelona, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Hornero', 'Affiliation': 'Department of Infectious Diseases, Bellvitge University Hospital, Biomedical Research Institute of Bellvitge (IDIBELL), Barcelona, Spain.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'De Carli', 'Affiliation': 'UOC Emerging Infections-CRAIDS, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Marani', 'Affiliation': 'UOC Emerging Infections-CRAIDS, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.'}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Puro', 'Affiliation': 'UOC Emerging Infections-CRAIDS, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Felisa López', 'Affiliation': 'Department of Infectious Diseases, Sant Joan de Reus University Hospital, Reus, Spain.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Iftimie', 'Affiliation': 'Department of Infectious Diseases, Sant Joan de Reus University Hospital, Reus, Spain.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Castro', 'Affiliation': 'Department of Infectious Diseases, Sant Joan de Reus University Hospital, Reus, Spain.'}, {'ForeName': 'Vicens', 'Initials': 'V', 'LastName': 'Diaz-Brito Fernandez', 'Affiliation': 'Department of Infectious Diseases, Sant Joan de Déu, Health Institute Sant Boi, Spain.'}, {'ForeName': 'Maria Carmen', 'Initials': 'MC', 'LastName': 'Alvarez Moya', 'Affiliation': 'Department of Infectious Diseases, Sant Joan de Déu, Health Institute Sant Boi, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Jimenez De La Rosa', 'Affiliation': 'Department of Infectious Diseases, Sant Joan de Déu, Health Institute Sant Boi, Spain.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Martínez-Sánchez', 'Affiliation': 'Department of Basic Sciences, International University of Catalonia, Barcelona, Spain.'}, {'ForeName': 'Emilio', 'Initials': 'E', 'LastName': 'Jimenez', 'Affiliation': 'Department of Infectious Diseases, Bellvitge University Hospital, Biomedical Research Institute of Bellvitge (IDIBELL), Barcelona, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Carratalà', 'Affiliation': 'Department of Infectious Diseases, Bellvitge University Hospital, Biomedical Research Institute of Bellvitge (IDIBELL), Barcelona, Spain.'}, {'ForeName': 'Miquel', 'Initials': 'M', 'LastName': 'Pujol', 'Affiliation': 'Department of Infectious Diseases, Bellvitge University Hospital, Biomedical Research Institute of Bellvitge (IDIBELL), Barcelona, Spain.'}]",The journal of vascular access,['10.1177/1129729819888423'] 696,31175566,Involving Patients in the Development and Evaluation of an Educational and Training Experiential Intervention (ETEI) to Improve Muscle Invasive Bladder Cancer Treatment Decision-making and Post-operative Self-care: a Mixed Methods Approach.,"This study aims to describe the acceptability and feasibility of an educational and training experiential intervention (ETEI) we developed to enhance muscle invasive bladder cancer (MIBC) patients with treatment decision-making and post-operative self-care. Twenty-five patients were randomized to a control group (N = 8) or ETEI group (N = 17). ETEI group participated in a nurse-led session on MIBC education. The control group received diet and nutrition education. Study questionnaires were completed at baseline and at 1-month post-intervention. Our results showed acceptable recruitment (58%) and retention rates (68%). The ETEI group reported increased knowledge (82% vs. 50%), improved decisional support (64% vs. 50%), improved communication (73% vs. 50%), and increased confidence in treatment decisions (73% vs. 50%) compared to the control group. Patients in the control group reported improved diet (50% v. 27%) as well as maintaining a healthy lifestyle (67% vs. 45%) compared to the ETEI group. Patients in the ETEI group reported a significant decrease in cancer worries and increases in self-efficacy beliefs over time compared to the control group. The ETEI was feasible, acceptable, and showed a potential for inducing desired changes in cancer worries and efficacy beliefs.",2020,Patients in the ETEI group reported a significant decrease in cancer worries and increases in self-efficacy beliefs over time compared to the control group.,"['Twenty-five patients', 'muscle invasive bladder cancer (MIBC) patients with treatment decision-making and post-operative self-care']","['control group (N\u2009=\u20098) or ETEI', 'educational and training experiential intervention (ETEI', 'diet and nutrition education', 'Educational and Training Experiential Intervention (ETEI) to Improve Muscle Invasive Bladder Cancer Treatment Decision-making and Post-operative Self-care', 'nurse-led session on MIBC education']","['cancer worries and efficacy beliefs', 'cancer worries', 'healthy lifestyle', 'retention rates', 'knowledge', 'confidence in treatment decisions', 'self-efficacy beliefs', 'improved decisional support', 'improved communication']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C1827293', 'cui_str': 'Invasive bladder cancer'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0036592', 'cui_str': 'Self Care'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0204934', 'cui_str': 'Nutritional education'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C1827293', 'cui_str': 'Invasive bladder cancer'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0036592', 'cui_str': 'Self Care'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0233481', 'cui_str': 'Worried (finding)'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C4277664', 'cui_str': 'Healthy Life Styles'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0009452', 'cui_str': 'Communication'}]",25.0,0.0314422,Patients in the ETEI group reported a significant decrease in cancer worries and increases in self-efficacy beliefs over time compared to the control group.,"[{'ForeName': 'Nihal', 'Initials': 'N', 'LastName': 'Mohamed', 'Affiliation': 'Department of Urology and Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY, 10028, USA. nihal.mohamed@mountsinai.org.'}, {'ForeName': 'Tung Ming', 'Initials': 'TM', 'LastName': 'Leung', 'Affiliation': 'Department of Urology and Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY, 10028, USA.'}, {'ForeName': 'Qainat N', 'Initials': 'QN', 'LastName': 'Shah', 'Affiliation': 'Albany Medical College, 43 New Scotland Ave., Albany, NY, 12208, USA.'}, {'ForeName': 'Sailaja', 'Initials': 'S', 'LastName': 'Pisipati', 'Affiliation': 'University of Nevada Reno School of Medicine, 1664 N Virginia St., Reno, NV, 89557, USA.'}, {'ForeName': 'Donna L', 'Initials': 'DL', 'LastName': 'Berry', 'Affiliation': 'Dana-Farber Cancer Institute, Harvard Cancer Center, 450 Brookline Ave., Boston, MA, 02215, USA.'}, {'ForeName': 'Emma K T', 'Initials': 'EKT', 'LastName': 'Benn', 'Affiliation': 'Department of Urology and Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY, 10028, USA.'}, {'ForeName': 'Cheryl T', 'Initials': 'CT', 'LastName': 'Lee', 'Affiliation': 'Department of Urology, Ohio State University, 915 Olentangy River Rd., Columbus, OH, 43212, USA.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Hall', 'Affiliation': 'Smith Institute for Urology, 450 Lakeville Road, Lake Success, NY, 11042, USA.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Mehrazin', 'Affiliation': 'Department of Urology and Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY, 10028, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Sfakianos', 'Affiliation': 'Department of Urology and Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY, 10028, USA.'}]",Journal of cancer education : the official journal of the American Association for Cancer Education,['10.1007/s13187-019-01534-1'] 697,30528222,Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.,"BACKGROUND Bone metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) are associated with debilitating pain and functional compromise. OBJECTIVE To compare pain palliation as the primary endpoint for cabozantinib versus mitoxantrone-prednisone in men with mCRPC and symptomatic bone metastases using patient-reported outcome measures. DESIGN, SETTING, AND PARTICIPANTS A randomized, double-blind phase 3 trial (COMET-2; NCT01522443) in men with mCRPC and narcotic-dependent pain from bone metastases who had progressed after treatment with docetaxel and either abiraterone or enzalutamide. INTERVENTION Cabozantinib 60mg once daily orally versus mitoxantrone 12mg/m 2 every 3wk plus prednisone 5mg twice daily orally. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS The primary endpoint was pain response at week 6 confirmed at week 12 (≥30% decrease from baseline in patient-reported average daily worst pain score via the Brief Pain Inventory without increased narcotic use). The planned sample size was 246 to achieve ≥90% power. RESULTS AND LIMITATIONS Enrollment was terminated early because cabozantinib did not demonstrate a survival benefit in the companion COMET-1 trial. At study closure, 119 participants were randomized (cabozantinib: N=61; mitoxantrone-prednisone: N=58). Complete pain and narcotic use data were available at baseline, week 6, and week 12 for 73/106 (69%) patients. There was no significant difference in the pain response with cabozantinib versus mitoxantrone-prednisone: the proportions of responders were 15% versus 17%, a -2% difference (95% confidence interval: -16% to 11%, p=0.8). Barriers to accrual included pretreatment requirements for a washout period of prior anticancer therapy and a narcotic optimization period to maximize analgesic dosing. CONCLUSIONS Cabozantinib treatment did not demonstrate better pain palliation than mitoxantrone-prednisone in heavily pretreated patients with mCRPC and symptomatic bone metastases. Future pain-palliation trials should incorporate briefer timelines from enrollment to treatment initiation. PATIENT SUMMARY Cabozantinib was not better than mitoxantrone-prednisone for pain relief in patients with castration-resistant prostate cancer and debilitating pain from bone metastases.",2019,"There was no significant difference in the pain response with cabozantinib versus mitoxantrone-prednisone: the proportions of responders were 15% versus 17%, a -2% difference (95% confidence interval: -16% to 11%, p=0.8).","['men with mCRPC and narcotic-dependent pain from bone metastases who had progressed after treatment with', 'patients with metastatic castration-resistant prostate cancer (mCRPC', 'Symptomatic Metastatic Castration-resistant Prostate Cancer', 'heavily pretreated patients with mCRPC and symptomatic bone metastases', '119 participants were randomized (cabozantinib: N=61', 'patients with castration-resistant prostate cancer and debilitating pain from bone metastases', 'men with mCRPC and symptomatic bone metastases using patient-reported outcome measures']","['docetaxel and either abiraterone or enzalutamide', 'mitoxantrone-prednisone', 'Cabozantinib Versus Mitoxantrone-prednisone', 'Cabozantinib 60mg once daily orally versus mitoxantrone 12mg/m 2 every 3wk plus prednisone 5mg twice daily orally']","['pain response', 'survival benefit', 'pain palliation', 'pain relief', 'Complete pain and narcotic use data']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0027415', 'cui_str': 'Narcotics'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0001758', 'cui_str': 'Follow-Up Care'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C3181682', 'cui_str': 'cabozantinib'}, {'cui': 'C1328504', 'cui_str': 'Castration-resistant prostate cancer'}, {'cui': 'C4277735', 'cui_str': 'Patient Reported Outcome Measures'}]","[{'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0754011', 'cui_str': 'abiraterone'}, {'cui': 'C3496793', 'cui_str': 'enzalutamide'}, {'cui': 'C0026259', 'cui_str': 'Mitoxantrone'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C3181682', 'cui_str': 'cabozantinib'}, {'cui': 'C4237943', 'cui_str': 'cabozantinib 60 MG'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1533720', 'cui_str': 'Prednisone 5 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0027415', 'cui_str': 'Narcotics'}, {'cui': 'C1947944', 'cui_str': 'Use'}]",119.0,0.320849,"There was no significant difference in the pain response with cabozantinib versus mitoxantrone-prednisone: the proportions of responders were 15% versus 17%, a -2% difference (95% confidence interval: -16% to 11%, p=0.8).","[{'ForeName': 'Ethan M', 'Initials': 'EM', 'LastName': 'Basch', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. Electronic address: ebasch@med.unc.edu.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Scholz', 'Affiliation': 'Prostate Oncology Specialists, Marina del Rey, CA, USA.'}, {'ForeName': 'Johann S', 'Initials': 'JS', 'LastName': 'de Bono', 'Affiliation': 'Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, England, UK.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Vogelzang', 'Affiliation': 'Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'de Souza', 'Affiliation': 'Western Sydney University School of Medicine, Sydney, Australia.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Marx', 'Affiliation': 'Sydney Medical School, University of Sydney and Sydney Adventist Hospital, Wahroonga, Australia.'}, {'ForeName': 'Ulka', 'Initials': 'U', 'LastName': 'Vaishampayan', 'Affiliation': 'Karmanos Cancer Institute, Detroit, MI, USA.'}, {'ForeName': 'Saby', 'Initials': 'S', 'LastName': 'George', 'Affiliation': 'Roswell Park Cancer Institute, Buffalo, NY, USA.'}, {'ForeName': 'James K', 'Initials': 'JK', 'LastName': 'Schwarz', 'Affiliation': 'University of Nebraska Medical Center, Omaha, NE, USA.'}, {'ForeName': 'Emmanuel S', 'Initials': 'ES', 'LastName': 'Antonarakis', 'Affiliation': 'The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.'}, {'ForeName': 'Joseph M', 'Initials': 'JM', 'LastName': ""O'Sullivan"", 'Affiliation': 'Belfast City Hospital, Belfast, Northern Ireland, UK.'}, {'ForeName': 'Arash Rezazadeh', 'Initials': 'AR', 'LastName': 'Kalebasty', 'Affiliation': 'Norton Cancer Institute, Louisville, KY, USA.'}, {'ForeName': 'Kim N', 'Initials': 'KN', 'LastName': 'Chi', 'Affiliation': 'British Columbia Cancer Agency, Vancouver, BC, Canada.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Dreicer', 'Affiliation': 'Emily Couric Clinical Cancer Center, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Hutson', 'Affiliation': 'Texas Oncology Sammons Cancer Center, Dallas, TX, USA.'}, {'ForeName': 'Amylou C', 'Initials': 'AC', 'LastName': 'Dueck', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA.'}, {'ForeName': 'Antonia V', 'Initials': 'AV', 'LastName': 'Bennett', 'Affiliation': 'Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Dayan', 'Affiliation': 'Department of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Milan', 'Initials': 'M', 'LastName': 'Mangeshkar', 'Affiliation': 'Exelixis, Inc., Alameda, CA, USA.'}, {'ForeName': 'Jaymes', 'Initials': 'J', 'LastName': 'Holland', 'Affiliation': 'Exelixis, Inc., Alameda, CA, USA.'}, {'ForeName': 'Aaron L', 'Initials': 'AL', 'LastName': 'Weitzman', 'Affiliation': 'Exelixis, Inc., Alameda, CA, USA.'}, {'ForeName': 'Howard I', 'Initials': 'HI', 'LastName': 'Scher', 'Affiliation': 'Department of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}]",European urology,['10.1016/j.eururo.2018.11.033'] 698,30680633,A pilot randomized controlled trial of 6-week combined exercise program on fasting insulin and fitness levels in individuals with spinal cord injury.,"PURPOSE The aim of this randomized controlled trial study was to investigate the effect of combined exercise program on the fasting insulin and fitness levels of people with spinal cord injury (SCI). METHODS A total of 19 individuals with SCI participated in a combined exercise program consisting of aerobic and resistance exercises for 60 min per day, 3 days per week for 6 weeks. Peak oxygen consumption, body mass index, percent body fat, waist circumference, shoulder abduction and adduction, shoulder flexion and extension, elbow flexion and extension, fasting insulin levels, and homeostasis model assessment of insulin resistance (HOMA-IR) levels were measured at baseline and after the intervention. RESULTS The 6-week exercise program significantly decreased the average fasting insulin (baseline: 7.5 ± 4.7 µU/ml vs. post-intervention: 4.5 ± 2.2 µU/ml, p < 0.05) and HOMA-IR (baseline: 1.5 ± 1.0 vs. post-intervention: 0.9 ± 0.4, p < 0.05) in the exercise group, whereas there was no change in control group (between group difference, mean fasting insulin: - 3.2 µU/ml, p = 0.003; mean HOMA-IR: - 0.66, p = 0.001). In addition, muscle strength of the shoulder flexors, extensors, abductors, adductors, and elbow flexors was significantly improved in the exercise group compared to the controls. CONCLUSION A combined exercise program is effective in decreasing fasting insulin and HOMA-IR levels while improving fitness in those with SCI. These slides can be retrieved under Electronic Supplementary Material.",2019,A combined exercise program is effective in decreasing fasting insulin and HOMA-IR levels while improving fitness in those with SCI.,"['people with spinal cord injury (SCI', '19 individuals with SCI participated in a', 'individuals with spinal cord injury']","['combined exercise program', 'combined exercise program consisting of aerobic and resistance exercises']","['Peak oxygen consumption, body mass index, percent body fat, waist circumference, shoulder abduction and adduction, shoulder flexion and extension, elbow flexion and extension, fasting insulin levels, and homeostasis model assessment of insulin resistance (HOMA-IR) levels', 'fasting insulin and HOMA-IR levels', 'average fasting insulin', 'fasting insulin and fitness levels', 'mean fasting insulin', 'muscle strength of the shoulder flexors, extensors, abductors, adductors, and elbow flexors', 'HOMA-IR']","[{'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C1305742', 'cui_str': 'Oxygen consumption'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0037004', 'cui_str': 'Shoulder'}, {'cui': 'C0231456', 'cui_str': 'Abduction, function (observable entity)'}, {'cui': 'C0231457', 'cui_str': 'Adduction, function (observable entity)'}, {'cui': 'C0231452', 'cui_str': 'Flexion, function (observable entity)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0013769', 'cui_str': 'Elbow'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C1829779', 'cui_str': 'Homeostasis model assessment'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}]",19.0,0.0718928,A combined exercise program is effective in decreasing fasting insulin and HOMA-IR levels while improving fitness in those with SCI.,"[{'ForeName': 'Dong-Il', 'Initials': 'DI', 'LastName': 'Kim', 'Affiliation': 'Department of Professional Therapy, Graduate School of Professional Therapy, Gachon University, Seongnam, Gyeonggi-do, Republic of Korea.'}, {'ForeName': 'J Andrew', 'Initials': 'JA', 'LastName': 'Taylor', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Can Ozan', 'Initials': 'CO', 'LastName': 'Tan', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Hyuna', 'Initials': 'H', 'LastName': 'Park', 'Affiliation': 'Department of Sport Industry Studies, Exercise Medicine and Rehabilitation Laboratory, Yonsei University, 50 Yonsei-Ro, Seodaemun-Gu, Seoul, 120-749, Korea.'}, {'ForeName': 'Ji Young', 'Initials': 'JY', 'LastName': 'Kim', 'Affiliation': ""Korea Disabled People's Development Institute, Seoul, Korea.""}, {'ForeName': 'Sang-Yong', 'Initials': 'SY', 'LastName': 'Park', 'Affiliation': 'Department of Physical Education, Gachon University, Seongnam, Gyeonggi-do, Republic of Korea.'}, {'ForeName': 'Kyong-Mee', 'Initials': 'KM', 'LastName': 'Chung', 'Affiliation': 'Department of Psychology, Yonsei University, Seoul, Korea.'}, {'ForeName': 'Young-Hee', 'Initials': 'YH', 'LastName': 'Lee', 'Affiliation': 'Department of Rehabilitation Medicine, Yonsei University Wonju College of Medicine, Wonju, Gangwon-do, Korea.'}, {'ForeName': 'Bum-Suk', 'Initials': 'BS', 'LastName': 'Lee', 'Affiliation': 'Department of Rehabilitation Medicine, National Rehabilitation Hospital, Seoul, Korea.'}, {'ForeName': 'Justin Y', 'Initials': 'JY', 'LastName': 'Jeon', 'Affiliation': 'Department of Sport Industry Studies, Exercise Medicine and Rehabilitation Laboratory, Yonsei University, 50 Yonsei-Ro, Seodaemun-Gu, Seoul, 120-749, Korea. jjeon@yonsei.ac.kr.'}]","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society",['10.1007/s00586-019-05885-7'] 699,30801859,Evening high-intensity interval exercise does not disrupt sleep or alter energy intake despite changes in acylated ghrelin in middle-aged men.,"NEW FINDINGS What is the central question of this study? What are the interactions between sleep and appetite following early evening high-intensity interval exercise (HIIE)? What is the main finding and its importance? HIIE can be performed in the early evening without subsequent sleep disruptions and may favourably alter appetite-related hormone concentrations. Nonetheless, perceived appetite and energy intake do not change with acute HIIE regardless of time of day. ABSTRACT Despite exercise benefits for sleep and appetite, due to increased time restraints, many adults remain inactive. Methods to improve exercise compliance include preferential time-of-day or engaging in short-duration, high-intensity interval exercise (HIIE). Hence, this study aimed to compare effects of HIIE time-of-day on sleep and appetite. Eleven inactive men undertook sleep monitoring to determine baseline (BASE) sleep stages and exclude sleep disorders. On separate days, participants completed 30 min HIIE (60 s work at 100% V ̇ O 2 peak , 240 s rest at 50% V ̇ O 2 peak ) in (1) the morning (MORN; 06.00-07.00 h), (2) the afternoon (AFT; 14.00-16.00 h) and (3) the early evening (EVEN: 19.00-20.00 h). Measures included appetite-related hormones (acylated ghrelin, leptin, peptide tyrosine tyrosine) and glucose pre-exercise, 30 min post-exercise and the next morning; overnight polysomnography (PSG; sleep stages); and actigraphy, self-reported sleep and food diaries for 48 h post-exercise. There were no between-trial differences for total sleep time (P = 0.46). Greater stage N3 sleep was recorded for MORN (23 ± 7%) compared to BASE (18 ± 7%; P = 0.02); however, no between-trial differences existed (P > 0.05). Rapid eye movement (REM) sleep was lower and non-REM sleep was higher for EVEN compared to BASE (P ≤ 0.05). At 30 min post-exercise, ghrelin was higher for AFT compared to MORN and EVEN (P = 0.01), while glucose was higher for MORN compared to AFT and EVEN (P ≤ 0.02). No between-trial differences were observed for perceived appetite (P ≥ 0.21) or energy intake (P = 0.57). Early evening HIIE can be performed without subsequent sleep disruptions and reduces acylated ghrelin. However, perceived appetite and energy intake appear to be unaffected by HIIE time of day.",2019,Rapid eye movement (REM) sleep was lower and non-REM sleep was higher for EVEN compared to BASE (P ≤ 0.05).,"['Eleven inactive men undertook sleep monitoring to determine baseline (BASE) sleep stages and exclude sleep disorders', 'middle-aged men']",['Evening high-intensity interval exercise'],"['perceived appetite', 'REM sleep', 'sleep and appetite', 'exercise compliance include preferential time-of-day or engaging in short-duration, high-intensity interval exercise (HIIE', 'Rapid eye movement (REM) sleep', 'Greater stage N3 sleep', 'appetite-related hormones (acylated ghrelin, leptin, peptide tyrosine tyrosine) and glucose pre-exercise, 30\xa0min post-exercise and the next morning; overnight polysomnography (PSG; sleep stages); and actigraphy, self-reported sleep and food diaries for 48\xa0h post-exercise', 'energy intake', 'total sleep time']","[{'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0041666', 'cui_str': 'Undertaking'}, {'cui': 'C0162701', 'cui_str': 'Monitoring, Sleep'}, {'cui': 'C0037319', 'cui_str': 'Sleep Stages'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0851578', 'cui_str': 'Sleep Disorders'}, {'cui': 'C0205847', 'cui_str': 'Middle Aged'}]","[{'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C0037322', 'cui_str': 'Sleep, Fast-Wave'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439548', 'cui_str': 'Temporal periods of day (qualifier value)'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C0439593', 'cui_str': 'Short duration (qualifier value)'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0234451', 'cui_str': 'Sleep, Slow-Wave'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0911014', 'cui_str': 'Ghrelin (substance)'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0077599', 'cui_str': 'tyrosyltyrosine'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C1979962', 'cui_str': 'After exercise (qualifier value)'}, {'cui': 'C0332170', 'cui_str': 'Morning (qualifier value)'}, {'cui': 'C0439583', 'cui_str': 'Overnight (qualifier value)'}, {'cui': 'C0162701', 'cui_str': 'Monitoring, Sleep'}, {'cui': 'C0037319', 'cui_str': 'Sleep Stages'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0012157', 'cui_str': 'Dietary Records'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",11.0,0.0753023,Rapid eye movement (REM) sleep was lower and non-REM sleep was higher for EVEN compared to BASE (P ≤ 0.05).,"[{'ForeName': 'Penelope', 'Initials': 'P', 'LastName': 'Larsen', 'Affiliation': 'School of Exercise Science, Sport and Health, Charles Sturt University, Bathurst, Australia.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Marino', 'Affiliation': 'School of Exercise Science, Sport and Health, Charles Sturt University, Bathurst, Australia.'}, {'ForeName': 'Kerri', 'Initials': 'K', 'LastName': 'Melehan', 'Affiliation': 'Royal Prince Alfred Hospital, Sydney.'}, {'ForeName': 'Kym J', 'Initials': 'KJ', 'LastName': 'Guelfi', 'Affiliation': 'School of Human Sciences (Exercise and Sports Science), University of Western Australia, Perth, Australia.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'Duffield', 'Affiliation': 'Sport and Exercise Discipline Group, University of Technology Sydney, Sydney, Australia.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Skein', 'Affiliation': 'School of Exercise Science, Sport and Health, Charles Sturt University, Bathurst, Australia.'}]",Experimental physiology,['10.1113/EP087455'] 700,2541168,Reactions to and antigenicity of two human-rhesus rotavirus reassortant vaccine candidates of serotypes 1 and 2 in Venezuelan infants.,"The reactions to and antigenicity of two human-rhesus rotavirus (RRV) reassortants (human rotavirus strain D x RRV and human rotavirus strain DS1 x RRV) with the VP7 neutralization specificity of a serotype 1 or serotype 2 rotavirus were evaluated in a placebo-controlled double-blind trial in 116 1- to 5-month-old infants in Caracas, Venezuela. The children were randomly divided into five groups to receive orally the following inocula: (i) 10(4) PFU of D x RRV reassortant; (ii) 10(4) PFU of DS1 x RRV reassortant; (iii) 10(4) PFU of RRV; (iv) 5 x 10(3) PFU of D x RRV and 5 x 10(3) PFU of RRV; and (v) placebo. The children were examined daily for 7 days following vaccine administration; 8 to 26% of the vaccinated infants developed a mild febrile reaction which in most cases lasted only 1 day. Seroresponses to rotavirus were observed in 39 to 65% of the vaccinees by plaque neutralization assay and in 57 to 88% by an immunoglobulin A enzyme-linked immunosorbent assay. Vaccine shedding was detected in 53 to 86% of the vaccinees. Analysis of neutralization antibody responses indicates that the VP4 protein represents an important component of the response induced by the vaccines.",1989,Seroresponses to rotavirus were observed in 39 to 65% of the vaccinees by plaque neutralization assay and in 57 to 88% by an immunoglobulin A enzyme-linked immunosorbent assay.,"['two human-rhesus rotavirus reassortant vaccine candidates of serotypes 1 and 2 in Venezuelan infants', '116 1- to 5-month-old infants in Caracas, Venezuela']","['PFU of D', 'RRV', 'placebo', 'human-rhesus rotavirus (RRV) reassortants (human rotavirus strain D x RRV and human rotavirus strain DS1 x RRV']","['Vaccine shedding', 'mild febrile reaction']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0035870', 'cui_str': 'Rotavirus'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0449550', 'cui_str': 'Serotype (UK)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C4517541', 'cui_str': '116 (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0042469', 'cui_str': 'Venezuela'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0035870', 'cui_str': 'Rotavirus'}, {'cui': 'C0318711', 'cui_str': 'Human rotavirus (organism)'}, {'cui': 'C0080194', 'cui_str': 'Strains'}]","[{'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0235723', 'cui_str': 'Reaction febrile'}]",116.0,0.077614,Seroresponses to rotavirus were observed in 39 to 65% of the vaccinees by plaque neutralization assay and in 57 to 88% by an immunoglobulin A enzyme-linked immunosorbent assay.,"[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Flores', 'Affiliation': 'Laboratory of Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Perez-Schael', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Blanco', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Vilar', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Garcia', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Perez', 'Affiliation': ''}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Daoud', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Midthun', 'Affiliation': ''}, {'ForeName': 'A Z', 'Initials': 'AZ', 'LastName': 'Kapikian', 'Affiliation': ''}]",Journal of clinical microbiology,[] 701,32410152,Letter to the Editor Re: Sera of Obese Type 2 Diabetic Patients Undergoing Metabolic Surgery Instead of Conventional Treatment Exert Beneficial Effects on Beta Cell Survival and Function: Results of a Randomized Clinical Study.,,2020,,['Sera of Obese Type 2 Diabetic Patients Undergoing'],"['Metabolic Surgery', 'Letter to the Editor Re']",['Beta Cell Survival and Function'],"[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1456587', 'cui_str': 'Metabolic surgery'}, {'cui': 'C0282413', 'cui_str': 'Letters as Topic'}]","[{'cui': 'C0030281', 'cui_str': 'Structure of beta Cell of islet'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",,0.0341806,,"[{'ForeName': 'Walter J', 'Initials': 'WJ', 'LastName': 'Pories', 'Affiliation': 'Department of Surgery, Brody School of Medicine, East Carolina University, 600 Moye Blvd, Greenville, NC, 27834, USA. poriesw@ecu.edu.'}, {'ForeName': 'G Lynis', 'Initials': 'GL', 'LastName': 'Dohm', 'Affiliation': 'Department of Surgery, Brody School of Medicine, East Carolina University, 600 Moye Blvd, Greenville, NC, 27834, USA.'}]",Obesity surgery,['10.1007/s11695-020-04665-3'] 702,31751758,Optimizing Value in the Evaluation of Chronic Spontaneous Urticaria: A Cost-Effectiveness Analysis.,"BACKGROUND Chronic spontaneous urticaria (CSU) affects approximately 1% of the general population. The cost-effectiveness of routine laboratory testing for secondary causes of CSU has not been formally evaluated. OBJECTIVE To characterize the cost-effectiveness of routine laboratory screening in adults with CSU. METHODS A Markov model using cohort analysis and microsimulations was created for adult patients aged 20 years, over a 10-year time horizon, randomized to receive screening laboratory testing or a no-testing approach. Laboratory results were derived from a previously published retrospective analysis of adult patients with CSU. Cost-effectiveness was evaluated at a willingness to pay threshold of $100,000/quality-adjusted life-year using the incremental cost-effectiveness ratio (ICER) in patients with untreated CSU, and patients treated with antihistamines, cyclosporine, or omalizumab. RESULTS Average laboratory costs per simulated patient with CSU were $573 (standard deviation [SD], $41), with only 0.16% (SD, 3.99%) of tests resulting in improved clinical outcomes. Testing costs per laboratory-associated positive outcome were $358,052 (no therapy), $357,576 (antihistamine therapy), $354,115 (cyclosporine), and $262,121 (omalizumab). Screening tests were not cost-effective, with ICERs of $856,905 (no therapy), $855,764 (antihistamine therapy), $847,483 (cyclosporine), and $627,318 (omalizumab). In the omalizumab-treated subgroup, testing could be cost-effective below $220 or if it resulted in a 0.73% rate of CSU resolution. From a simulated US population perspective, nation-wide screening costs could reach $941,750,741 to $1,833,501,483. CONCLUSIONS In CSU, the likelihood of clinical improvement from laboratory testing is very low, and testing is not cost-effective. These data support recommendations to not routinely perform laboratory testing in patients with CSU with otherwise normal histories and physical evaluations.",2020,"Screening tests were not cost-effective, with ICERs of $856,905 (no therapy), $855,764 (anti-histamine therapy), $847,483 (cyclosporine), and $627,318 (omalizumab).","['adult patients aged 20 years', 'Chronic Spontaneous Urticaria', 'adults with CSU', 'CSU patients with otherwise normal histories and physical evaluations']","['routine laboratory screening', 'screening laboratory testing or a no-testing approach', 'cyclosporine, or omalizumab']","['incremental cost-effectiveness ratio (ICER', 'Cost-effectiveness']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0578870', 'cui_str': 'Chronic idiopathic urticaria (disorder)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0010594', 'cui_str': 'Cyclosporins'}, {'cui': 'C0966225', 'cui_str': 'omalizumab'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",,0.0998448,"Screening tests were not cost-effective, with ICERs of $856,905 (no therapy), $855,764 (anti-histamine therapy), $847,483 (cyclosporine), and $627,318 (omalizumab).","[{'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Shaker', 'Affiliation': 'Section of Allergy and Immunology, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Department of Pediatrics, Geisel School of Medicine at Dartmouth, Hanover, NH; Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH. Electronic address: Marcus.S.Shaker@hitchcock.org.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Oppenheimer', 'Affiliation': 'Department of Internal Medicine, Rutgers New Jersey Medical School, Newark, NJ.'}, {'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'Wallace', 'Affiliation': 'Department of Medicine, Nova Southeastern Allopathic Medical School, Fort Lauderdale, Fla.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Lang', 'Affiliation': 'Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Todd', 'Initials': 'T', 'LastName': 'Rambasek', 'Affiliation': 'Division of Allergy and Immunology, Ohio University Heritage College of Osteopathic Medicine, Sandusky, Ohio.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Dykewicz', 'Affiliation': 'Department of Internal Medicine, Section of Allergy and Immunology, Saint Louis University School of Medicine, St. Louis, Mo.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Greenhawt', 'Affiliation': ""Section of Allergy and Immunology, Food Challenge and Research Unit, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo.""}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2019.11.004'] 703,30956267,"Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction　- The CIBIS-J Trial.","BACKGROUND The comparative tolerability, efficacy, and safety of bisoprolol and carvedilol have not been established in Japanese patients with heart failure and reduced ejection fraction (HFrEF). Methods and Results: The CIBIS-J trial is a multicenter, open-label, non-inferiority randomized controlled trial of bisoprolol vs. carvedilol in 217 patients with HFrEF (EF ≤40%). The primary endpoint was tolerability, defined as reaching and maintaining the maximum maintenance dose (bisoprolol 5 mg/day or carvedilol 20 mg/day) during 48 weeks of treatment. The primary endpoint was achieved in 41.4% of patients in bisoprolol (n=111) and 42.5% in carvedilol (n=106) groups. The non-inferiority of tolerability of bisoprolol compared with carvedilol was not supported, however, neither β-blocker was superior with regard to tolerability. Heart rate (HR) decreased in both groups and its decrease from baseline was significantly greater in the bisoprolol group (20.3 vs. 15.4 beats/min at 24 week, P<0.05). Plasma B-type natriuretic peptide (BNP) levels decreased in both groups and the decrease was significantly greater in the carvedilol group (12.4 vs. 39.0 % at 24 weeks, P<0.05). CONCLUSIONS There were no significant differences between bisoprolol and carvedilol in the tolerability of target doses in Japanese HFrEF patients. The clinical efficacy and safety were also similar despite the greater reduction in HR by bisoprolol and plasma BNP by carvedilol.",2019,There were no significant differences between bisoprolol and carvedilol in the tolerability of target doses in Japanese HFrEF patients.,"['Japanese HFrEF patients', 'Japanese patients with heart failure and reduced ejection fraction (HFrEF', 'Japanese Patients With Heart Failure and Reduced Ejection Fraction\u3000', '217 patients with HFrEF (EF ≤40']","['bisoprolol', 'Bisoprolol vs. Carvedilol', 'bisoprolol and carvedilol', 'carvedilol', 'bisoprolol 5 mg/day or carvedilol', 'bisoprolol vs. carvedilol']","['tolerability, defined as reaching and maintaining the maximum maintenance dose ', 'clinical efficacy and safety', 'Heart rate (HR', 'Plasma B-type natriuretic peptide (BNP) levels', 'Tolerability, Efficacy, and Safety', 'tolerability']","[{'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C4517646', 'cui_str': '217'}]","[{'cui': 'C0053799', 'cui_str': 'Bisoprolol'}, {'cui': 'C0054836', 'cui_str': 'carvedilol'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}]","[{'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C3714445', 'cui_str': 'Maintenance dose'}, {'cui': 'C0087113', 'cui_str': 'Treatment Efficacy'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0054015', 'cui_str': 'Nesiritide'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",217.0,0.0415076,There were no significant differences between bisoprolol and carvedilol in the tolerability of target doses in Japanese HFrEF patients.,"[{'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Tsutsui', 'Affiliation': 'Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University.'}, {'ForeName': 'Shin-Ichi', 'Initials': 'SI', 'LastName': 'Momomura', 'Affiliation': 'Jichi Medical University Saitama Medical Center.'}, {'ForeName': 'Tohru', 'Initials': 'T', 'LastName': 'Masuyama', 'Affiliation': 'Cardiovascular Division, Department of Internal Medicine, Hyogo College of Medicine.'}, {'ForeName': 'Yoshihiko', 'Initials': 'Y', 'LastName': 'Saito', 'Affiliation': 'First Department of Medicine, Nara Medical University.'}, {'ForeName': 'Issei', 'Initials': 'I', 'LastName': 'Komuro', 'Affiliation': 'Department of Cardiovascular Medicine, The University of Tokyo Hospital.'}, {'ForeName': 'Toyoaki', 'Initials': 'T', 'LastName': 'Murohara', 'Affiliation': 'Department of Cardiology, Nagoya University Graduate School of Medicine.'}, {'ForeName': 'Shintaro', 'Initials': 'S', 'LastName': 'Kinugawa', 'Affiliation': 'Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Circulation journal : official journal of the Japanese Circulation Society,['10.1253/circj.CJ-18-1199'] 704,31165350,"Ephedrine and phenylephrine induce opposite changes in cerebral and paraspinal tissue oxygen saturation, measured with near-infrared spectroscopy: a randomized controlled trial.","While the effects of phenylephrine (PE) and ephedrine (E) on cerebral oxygen saturation (rS c O 2 ) already has been studied, the effect on paraspinal oxygen saturation (rS ps O 2 ) is still unexplored. This study aims to assess the effect of PE and E on rS c O 2 and rS ps O 2 , measured with near-infrared spectroscopy. A randomized 4-treatment cross-over trial was designed in 28 patients under BIS-titrated anaesthesia with sevoflurane. If MAP decreased more than 20% from baseline, incremental doses of PE and/or E were given according to the randomization (group I: E-PE-E, group II: PE-E-PE, group III: E-E-E, group IV: PE-PE-PE). rS c O 2 and rS ps O 2 on T 3 -T 4 , T 9 -T 10 and L 1 -L 2 were recorded. Differences in rSO 2 (post-pretreatment) within each group were analyzed with paired Student's t test. Differences in effects of PE and E on rS c O 2 and rS ps O 2 were analyzed with linear mixed-modelling. Following PE administration, rS c O 2 decreased significantly (- 2.7% ± 3.5), while it remained stable following E (- 0.6% ± 3.6). Contrastingly, rS ps O 2 at T 3 -T 4 , T 9 -T 10 and L 1 -L 2 slightly increased following PE (0.4% ± 2.5, 0.7% ± 2.0 and - 0.1% ± 1.4, respectively), while it decreased after E administration (- 1.3% ± 3.4%, - 0.7% ± 2.6% and - 1.3% ± 2.7%, respectively). Compared to E, PE administration was associated with a significant decrease in rS c O 2 (- 2.1%, 95% CI [- 3.1%, - 1.2%], p < 0.001). In contrast, compared to PE, E was associated with a significant decrease in rS ps O 2 at T 3 -T 4 , T 9 -T 10 and L 1 -L 2 (- 2.0%, 95% CI [- 2.8, - 1.1], p < 0.001; - 1.4%, 95% CI [- 2.4%, - 0.4%], p = 0.006; and - 1.5%, 95% CI [- 2.3%, - 0.8%], p < 0.001, respectively). An opposite effect on rS c O 2 and rS ps O 2 was observed after bolus administration of PE and E.",2020,"Compared to E, PE administration was associated with a significant decrease in rS c O 2 (- 2.1%, 95% CI [- 3.1%, - 1.2%], p < 0.001).",['28 patients under BIS-titrated anaesthesia with'],"['rS', 'Ephedrine and phenylephrine', 'sevoflurane', 'phenylephrine (PE) and ephedrine (E']","['rS', 'cerebral and paraspinal tissue oxygen saturation', 'cerebral oxygen saturation', 'rS c O 2']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1872096', 'cui_str': 'bis(phenylacetylarginine)'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}]","[{'cui': 'C0014479', 'cui_str': 'Ephedrine'}, {'cui': 'C0031469', 'cui_str': 'Phenylephrine'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}]","[{'cui': 'C0442145', 'cui_str': 'Paraspinal (qualifier value)'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C4273907', 'cui_str': 'Cerebral oxygen saturation (observable entity)'}]",,0.401186,"Compared to E, PE administration was associated with a significant decrease in rS c O 2 (- 2.1%, 95% CI [- 3.1%, - 1.2%], p < 0.001).","[{'ForeName': 'Caroline M', 'Initials': 'CM', 'LastName': 'Vanpeteghem', 'Affiliation': 'Department of Anaesthesiology and Perioperative Medicine, University Hospital Ghent, Corneel Heymanslaan 10, 9000, Ghent, Belgium. caroline.vanpeteghem@ugent.be.'}, {'ForeName': 'Bas Y', 'Initials': 'BY', 'LastName': 'Bruneel', 'Affiliation': 'Department of Anaesthesiology and Perioperative Medicine, University Hospital Ghent, Corneel Heymanslaan 10, 9000, Ghent, Belgium.'}, {'ForeName': 'Isabeau M', 'Initials': 'IM', 'LastName': 'Lecoutere', 'Affiliation': 'Department of Anaesthesiology and Perioperative Medicine, University Hospital Ghent, Corneel Heymanslaan 10, 9000, Ghent, Belgium.'}, {'ForeName': 'Stefan G', 'Initials': 'SG', 'LastName': 'De Hert', 'Affiliation': 'Department of Anaesthesiology and Perioperative Medicine, University Hospital Ghent, Corneel Heymanslaan 10, 9000, Ghent, Belgium.'}, {'ForeName': 'Anneliese T', 'Initials': 'AT', 'LastName': 'Moerman', 'Affiliation': 'Department of Anaesthesiology and Perioperative Medicine, University Hospital Ghent, Corneel Heymanslaan 10, 9000, Ghent, Belgium.'}]",Journal of clinical monitoring and computing,['10.1007/s10877-019-00328-6'] 705,31742221,Comparison between Patellar Resurfacing and Retention in Total Knee Arthroplasty Regarding the Postoperative Satisfaction of Patients and Patellar Crepitus.,"Background Patellar crepitus after total knee arthroplasty (TKA) is not uncommon. The choice between patellar resurfacing or retention in TKA has remained controversial. Therefore, this randomized controlled trial aimed to evaluate the impact of patellar resurfacing on the incidence of patellar crepitus. In addition, we compared the clinical outcomes and satisfaction between the patients who underwent patellar retention or resurfacing. Methods A total of 63 patients randomly received patellar resurfacing or non-resurfacing TKA by one surgeon at Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Iran during May 2014-February 2017. Finally, 29 patients in the resurfaced group and 44 subjects with retained patella were evaluated pre-op and in an average follow-up period of 8.68 months using the clinical Knee Society Score (KSS), functional KSS, and Knee injury and Osteoarthritis Outcome Score (KOOS). Results Our findings demonstrated no significant difference between the two groups regarding the satisfaction of patients, KSS, and KOOS. It was shown that the latter scores improved in both groups in the follow-up period. Nonetheless, patellar crepitus was not statistically different between the two groups. Conclusion According to the results of the present study, patellar resurfacing did not lead to decreased patellar crepitus or enhanced clinical outcomes of TKA.",2019,"Our findings demonstrated no significant difference between the two groups regarding the satisfaction of patients, KSS, and KOOS.","['Total Knee Arthroplasty Regarding the Postoperative Satisfaction of Patients and Patellar Crepitus', '29 patients in the resurfaced group and 44 subjects with retained patella', 'by one surgeon at Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Iran during May 2014-February 2017', '63 patients randomly received']","['patellar retention or resurfacing', '\n\n\nPatellar crepitus after total knee arthroplasty (TKA', 'patellar resurfacing or retention in TKA', 'patellar resurfacing', 'patellar resurfacing or non-resurfacing TKA', 'Patellar Resurfacing and Retention']","['satisfaction of patients, KSS, and KOOS', 'latter scores', 'clinical Knee Society Score (KSS), functional KSS, and Knee injury and Osteoarthritis Outcome Score (KOOS', 'patellar crepitus']","[{'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030647', 'cui_str': 'Kneecap'}, {'cui': 'C0582175', 'cui_str': 'Surgeon (occupation)'}, {'cui': 'C0521321', 'cui_str': 'Imam'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}]","[{'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C1608424', 'cui_str': 'Patellar resurfacing'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0022744', 'cui_str': 'Knee Injuries'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}]",,0.0433543,"Our findings demonstrated no significant difference between the two groups regarding the satisfaction of patients, KSS, and KOOS.","[{'ForeName': 'Mohammad H', 'Initials': 'MH', 'LastName': 'Kaseb', 'Affiliation': 'Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Mortazavi', 'Affiliation': 'Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Ayati Firoozabadi', 'Affiliation': 'Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hesam', 'Initials': 'H', 'LastName': 'Toofan', 'Affiliation': 'Tehran University of Medical Sciences, Tehran, Iran.'}]",The archives of bone and joint surgery,[] 706,31124887,Dexamethasone Reduces Postoperative Nausea in Pediatric Upper Endoscopy With Deep Sedation: A Randomized Controlled Trial.,"OBJECTIVES We aimed to evaluate the effect of a single dose of preoperative dexamethasone on postoperative nausea and vomiting (PONV), a frequent complication and a major cause of delayed recovery in pediatric upper gastrointestinal endoscopy (UGIE) under sedation. METHODS In this double-blind randomized controlled study, 98 children aged 2 to 14, with American Society of Anesthesiologists status I to II, and undergoing elective UGIE with deep sedation were included and randomly assigned to 2 groups. Preoperatively, after anesthesia induction with sodium thiopental and maintenance with sevoflurane, patients in the intervention (n = 49) and control (n = 49) groups, respectively received 0.1 mg/kg i.v. dexamethasone and 2 cm i.v. 0.9% saline. Postoperatively, PONV incidence was measured as the primary outcome. RESULTS PONV incidence was significantly less in dexamethasone group (8.2%) compared to the control group (26.5%) (difference = 18.3%, 95% confidence interval: 3.4%-33%, P = 0.016). For secondary outcomes, between-group differences were not statistically significant: incidence of bronchospasm or laryngospasm (both 4.1%, P = 1); emergence delirium assessed with Pediatric Anesthesia Emergence Delirium scale (5.9 ± 3.4 vs 5.7 ± 3.2, P = 0.751); Modified Aldrete score at 0 minutes (9.4 ± 0.8 vs 9.3 ± 0.9, P = 0.909) and at 5 minutes (9.5 ± 0.7 vs 9.4 ± 0.9, P = 0.527); and recovery time (21.1 ± 6.6 vs 23.4 ± 8.6 minutes, P = 0.130). CONCLUSIONS A single preoperative dose of i.v. dexamethasone reduces PONV in children undergoing elective UGIE with deep sedation, but has no significant effect on the patient recovery time or the incidence of postoperative bronchospasm or laryngospasm and emergence delirium.",2019,"dexamethasone reduces PONV in children undergoing elective UGIE with deep sedation, but has no significant effect on the patient recovery time or the incidence of postoperative bronchospasm or laryngospasm and emergence delirium.","['pediatric upper gastrointestinal endoscopy (UGIE) under sedation', 'children undergoing elective UGIE with deep sedation', 'Pediatric Upper Endoscopy with Deep Sedation', '98 children aged 2-14, with ASA status I-II, and undergoing elective UGIE with deep sedation']","['pre-operative dexamethasone', 'Dexamethasone', 'sodium thiopental and maintenance with sevoflurane', 'dexamethasone']","['bronchospasm or laryngospasm', 'Emergence delirium assessed with PAED scale', 'Postoperative Nausea', 'postoperative nausea and vomiting (PONV', 'PONV incidence', 'recovery time', 'Modified Aldrete score']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0079304', 'cui_str': 'Esophagogastroduodenoscopy'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C1956064', 'cui_str': 'Deep Sedation'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]","[{'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C3541959', 'cui_str': 'Sodium supplement (substance)'}, {'cui': 'C0039925', 'cui_str': 'Thiopental'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}]","[{'cui': 'C0006266', 'cui_str': 'Bronchospasm'}, {'cui': 'C0023066', 'cui_str': 'Laryngospasm'}, {'cui': 'C0920253', 'cui_str': 'Postanesthetic Excitement'}, {'cui': 'C0222045'}, {'cui': 'C0520904', 'cui_str': 'Postoperative Nausea'}, {'cui': 'C0520909', 'cui_str': 'PONV'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C3164884', 'cui_str': 'Modified Aldrete score (assessment scale)'}]",98.0,0.649725,"dexamethasone reduces PONV in children undergoing elective UGIE with deep sedation, but has no significant effect on the patient recovery time or the incidence of postoperative bronchospasm or laryngospasm and emergence delirium.","[{'ForeName': 'Hamed', 'Initials': 'H', 'LastName': 'Moheimani', 'Affiliation': ""Students' Scientific Research Center, School of Medicine.""}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Yaseri', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.'}]",Journal of pediatric gastroenterology and nutrition,['10.1097/MPG.0000000000002398'] 707,30776447,Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer.,"INTRODUCTION A multicenter randomized clinical trial in France found an overall survival benefit of web-based patient-reported outcome (PRO)-based surveillance after initial treatment for lung cancer compared with conventional surveillance. The aim of this study was to assess the cost-effectiveness of this PRO-based surveillance in lung cancer patients. METHODS This medico-economic analysis used data from the clinical trial, augmented by abstracted chart data and costs of consultations, imaging, transportations, information technology, and treatments. Costs were calculated based on actual reimbursement rates in France, and health utilities were estimated based on scientific literature review. Willingness-to-pay thresholds of €30,000 per quality-adjusted life year (QALY) and €90,000 per QALY were used to define a very cost-effective and cost-effective strategy, respectively. Average annual costs of experimental and control surveillance approaches were calculated. The incremental cost-effectiveness ratio was expressed as cost per life-year gained and QALY gained, from the health insurance payer perspective. One-way and multivariate probabilistic sensitivity analyses were performed. RESULTS Average annual cost of surveillance follow-up was €362 lower per patient in the PRO arm (€941/year/patient) compared to control (€1,304/year/patient). The PRO approach presented an incremental cost-effectiveness ratio of €12,127 per life-year gained and €20,912 per QALY gained. The probabilities that the experimental strategy is very cost-effective and cost-effective were 97% and 100%, respectively. CONCLUSIONS Surveillance of lung cancer patients using web-based PRO reduced the follow-up costs. Compared to conventional monitoring, this surveillance modality represents a cost-effective strategy and should be considered in cancer care delivery.",2019,"The PRO approach presented an incremental cost-effectiveness ratio of €12,127 per life-year gained and €20,912 per QALY gained.","['Patients With Lung Cancer', 'lung cancer patients']","['Web-Based Patient', 'PRO-based surveillance']","['incremental cost-effectiveness ratio', 'actual reimbursement rates in France, and health utilities', 'overall survival benefit', 'cost-effectiveness', 'cost-effective and cost-effective']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1306460', 'cui_str': 'Primary malignant neoplasm of lung'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0733511', 'cui_str': 'Surveillance (regime/therapy)'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}]",,0.0855009,"The PRO approach presented an incremental cost-effectiveness ratio of €12,127 per life-year gained and €20,912 per QALY gained.","[{'ForeName': 'Thibaut', 'Initials': 'T', 'LastName': 'Lizée', 'Affiliation': 'Department of Radiation Oncology, Jean Bernard Center, Inter-Regional Institute of Oncology, Le Mans, France. Electronic address: lizee.thibaut@gmail.com.'}, {'ForeName': 'Ethan', 'Initials': 'E', 'LastName': 'Basch', 'Affiliation': 'Department of Radiation Oncology, Jean Bernard Center, Inter-Regional Institute of Oncology, Le Mans, France; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Trémolières', 'Affiliation': 'Department of Radiation Oncology, Jean Bernard Center, Inter-Regional Institute of Oncology, Le Mans, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Voog', 'Affiliation': 'Department of Medical Oncology, Jean Bernard Center, Inter-Regional Institute of Oncology, Le Mans, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Domont', 'Affiliation': 'Department of Medical Oncology, Jean Bernard Center, Inter-Regional Institute of Oncology, Le Mans, France.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Peyraga', 'Affiliation': 'Department of Radiation Oncology, Jean Bernard Center, Inter-Regional Institute of Oncology, Le Mans, France.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Urban', 'Affiliation': 'Department of Pneumology, University Hospital Center, Angers, France.'}, {'ForeName': 'Jaafar', 'Initials': 'J', 'LastName': 'Bennouna', 'Affiliation': 'Department of Medical Oncology, University Hospital Center, Nantes, France.'}, {'ForeName': 'Anne-Lise', 'Initials': 'AL', 'LastName': 'Septans', 'Affiliation': 'Department of Medical Biostatistics, WeProm, Le Mans, France.'}, {'ForeName': 'Magali', 'Initials': 'M', 'LastName': 'Balavoine', 'Affiliation': 'Department of Medical Biostatistics, WeProm, Le Mans, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Detournay', 'Affiliation': 'Cemka-Eval, Bourg-la-Reine, France.'}, {'ForeName': 'Fabrice', 'Initials': 'F', 'LastName': 'Denis', 'Affiliation': 'Department of Radiation Oncology, Jean Bernard Center, Inter-Regional Institute of Oncology, Le Mans, France.'}]",Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,['10.1016/j.jtho.2019.02.005'] 708,31145174,Exploring the Effects of Vitamin D Supplementation on Cognitive Functions and Mental Health Status in Subjects Under Methadone Maintenance Treatment.,"OBJECTIVES Vitamin D deficiency may be linked to several mental complications including cognitive deficits, depression, and anxiety in patients under methadone maintenance treatment (MMT). This study was designed to explore the effect of vitamin D supplementation on cognitive functions and mental health parameters in subjects under MMT. METHODS This randomized, double-blinded, placebo-controlled clinical trial was carried out among 64 patients under MMT. Participants were randomly allocated to receive either 50,000 IU vitamin D supplements (n = 32) or placebo (n = 32) every 2 weeks for 24 weeks. Cognitive functions and mental health parameters were taken at baseline and posttreatment to evaluate relevant variables. RESULTS After the 24-week intervention, compared with the placebo, serum 25(OH) vitamin D levels significantly increased in participants who received vitamin D supplements (β 14.50; 95% confidence interval [CI], 13.17-15.83; P < 0.001). In addition, compared with the placebo, subjects who received vitamin D had a significant reduction in Iowa Gambling Task (β -6.25; 95% CI, -8.60 to -3.90; P < 0.001), and significant increases in Verbal Fluency Test (β 2.82; 95% CI, 0.78-4.86; P = 0.007), Immediate Logic Memory (β 1. 32; 95% CI, 0.27-2.37; P = 0.01), Reverse Digit Span (β 2.06; 95% CI, 1.18-2.94; P < 0.001) and visual working memory (β 0.75; 95% CI, 0.33-1.16; P = 0.001). Also, vitamin D supplementation significantly improved BDI (β -2.76; 95% CI, -3.97 to -1.55; P < 0.001) compared with the placebo. When we applied Bonferroni correction, LM-Immediate (P = 0.07) became nonsignificant, and other mental health parameters did not alter. CONCLUSIONS Overall, taking 50,000 IU vitamin D supplements every 2 weeks for 24 weeks by patients under MMT had beneficial effects on cognitive functions and some mental health parameters. Further studies are needed to confirm our findings.",2020,"After the 24-week intervention, compared with the placebo, serum 25(OH) vitamin D levels significantly increased in participants who received vitamin D supplements (β 14.50; 95% confidence interval [CI], 13.17-15.83; P < 0.001).","['patients under methadone maintenance treatment (MMT', '64 patients under MMT', 'Subjects Under Methadone Maintenance Treatment', 'subjects under MMT']","['50,000 IU vitamin D supplements', 'vitamin D', 'vitamin D supplementation', 'placebo', 'Vitamin D Supplementation']","['Cognitive functions and mental health parameters', 'BDI', 'Immediate Logic Memory ', 'cognitive functions and some mental health parameters', 'Reverse Digit Span', 'visual working memory', 'serum 25(OH) vitamin D levels', 'Verbal Fluency Test', 'Iowa Gambling Task (β', 'Cognitive Functions and Mental Health Status', 'cognitive functions and mental health parameters']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0025605', 'cui_str': 'Methadone'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0046370', 'cui_str': 'MMT'}]","[{'cui': 'C3541352', 'cui_str': 'Vitamin D supplement (substance)'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0023963', 'cui_str': 'Logic'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0582802', 'cui_str': 'Digit'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0022037', 'cui_str': 'Iowa'}, {'cui': 'C0016995', 'cui_str': 'Gamblings'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]",64.0,0.738906,"After the 24-week intervention, compared with the placebo, serum 25(OH) vitamin D levels significantly increased in participants who received vitamin D supplements (β 14.50; 95% confidence interval [CI], 13.17-15.83; P < 0.001).","[{'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Ghaderi', 'Affiliation': 'Department of Addiction Studies, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran and Clinical Research Development Unit-Matini/Kargarnejad Hospital, Kashan University of Medical Sciences, Kashan, Iran (AG); University of Raparin, Kurdistan Region, Iraq (MR-A); Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran (M-HF); School of Public Health, University of Saskatchewan, Saskatoon, SK, Canada (NM); Department of Psychiatry, School of Medicine, Kashan University of Medical Science, Kashan, Iran (MM); Occupational Therapy Department, Rehabilitation School, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran (EP); Department of Clinical Psychology, School of Medicine, Kashan University of Medical Science, Kashan, Iran (AO); Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran (ZA).'}, {'ForeName': 'Morad', 'Initials': 'M', 'LastName': 'Rasouli-Azad', 'Affiliation': ''}, {'ForeName': 'Mohammad Hassan', 'Initials': 'MH', 'LastName': 'Farhadi', 'Affiliation': ''}, {'ForeName': 'Naghmeh', 'Initials': 'N', 'LastName': 'Mirhosseini', 'Affiliation': ''}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Motmaen', 'Affiliation': ''}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Pishyareh', 'Affiliation': ''}, {'ForeName': 'Abdollah', 'Initials': 'A', 'LastName': 'Omidi', 'Affiliation': ''}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': ''}]",Journal of addiction medicine,['10.1097/ADM.0000000000000550'] 709,31144609,A short bout of high-intensity exercise alters ipsilesional motor cortical excitability post-stroke.,"Background : Acute exercise can increase motor cortical excitability and enhance motor learning in healthy individuals, an effect known as exercise priming. Whether it has the same effects in people with stroke is unclear. Objectives : The objective of this study was to investigate whether a short, clinically-feasible high-intensity exercise protocol can increase motor cortical excitability in non-exercised muscles of chronic stroke survivors. Methods : Thirteen participants with chronic, unilateral stroke participated in two sessions, at least one week apart, in a crossover design. In each session, they underwent either high-intensity lower extremity exercise or quiet rest. Motor cortical excitability of the extensor carpi radialis muscles was measured bilaterally with transcranial magnetic stimulation before and immediately after either exercise or rest. Motor cortical excitability changes (post-exercise or rest measures normalized to pre-test measures) were compared between exercise vs. rest conditions. Results : All participants were able to reach the target high-intensity exercise level. Blood lactate levels increased significantly after exercise ( p < .001, d = 2.85). Resting motor evoked potentials from the lesioned hemisphere increased after exercise (mean 1.66; 95% CI: 1.19, 2.13) compared to the rest condition (mean 1.23; 95% CI: 0.64, 1.82), p = .046, d = 2.76, but this was not the case for the non-lesioned hemisphere ( p = .406, d = 0.25). Conclusions : High-intensity exercise can increase lesioned hemisphere motor cortical excitability in a non-exercised muscle post-stroke. Our short and clinically-advantageous exercise protocol shows promise as a potential priming method in stroke rehabilitation.",2019,"Resting motor evoked potentials from the lesioned hemisphere increased after exercise (mean 1.66; 95% CI: 1.19, 2.13) compared to the rest condition (mean 1.23; 95% CI: 0.64, 1.82), ","['Thirteen participants with chronic, unilateral stroke', 'people with stroke', 'non-exercised muscles of chronic stroke survivors', 'healthy individuals']","['intensity exercise', 'Acute exercise', 'high-intensity lower extremity exercise or quiet rest', ' ', 'clinically-feasible high-intensity exercise protocol', 'high-intensity exercise']","['motor cortical excitability and enhance motor learning', 'motor cortical excitability', 'Blood lactate levels', 'Motor cortical excitability changes', 'Motor cortical excitability of the extensor carpi radialis muscles']","[{'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C3536593', 'cui_str': 'Chronic stroke'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C4279937', 'cui_str': 'Acute Exercise'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0439654', 'cui_str': 'Quiet (qualifier value)'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}]","[{'cui': 'C4277734', 'cui_str': 'Cortical Excitability'}, {'cui': 'C0005768'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0224265', 'cui_str': 'Structure of extensor carpi radialis muscle'}]",13.0,0.212396,"Resting motor evoked potentials from the lesioned hemisphere increased after exercise (mean 1.66; 95% CI: 1.19, 2.13) compared to the rest condition (mean 1.23; 95% CI: 0.64, 1.82), ","[{'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'a Department of Physical Therapy, University of Delaware , Newark , DE , USA.'}, {'ForeName': 'Charalambos C', 'Initials': 'CC', 'LastName': 'Charalambous', 'Affiliation': 'a Department of Physical Therapy, University of Delaware , Newark , DE , USA.'}, {'ForeName': 'Darcy S', 'Initials': 'DS', 'LastName': 'Reisman', 'Affiliation': 'a Department of Physical Therapy, University of Delaware , Newark , DE , USA.'}, {'ForeName': 'Susanne M', 'Initials': 'SM', 'LastName': 'Morton', 'Affiliation': 'a Department of Physical Therapy, University of Delaware , Newark , DE , USA.'}]",Topics in stroke rehabilitation,['10.1080/10749357.2019.1623458'] 710,30980177,"Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial.","Increasing evidence suggests that the function of the GABAergic system is abnormally low in autism spectrum disorder (ASD). Baclofen, which functions as a selective agonist for GABA B receptors, does appear promising for the treatment of ASD. We conducted a 10-week randomized-controlled study aimed at evaluating the potential of baclofen as an adjuvant therapy to enhance the effect of risperidone in children with ASD. Sixty-four children (3-12 years) with moderate-to-severe irritability symptoms of ASD were included. We used the Aberrant Behavior Checklist-Community Edition (ABC-C) for the outcome measures on each of the follow-up visits (weeks 0, 5, and 10). Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004). Combined treatment with baclofen and risperidone exerted a greater effect on improvement of hyperactivity symptoms at both midpoint [Cohen's d, 95% confidence interval (CI) = - 3.14, - 5.56 to - 0.72] and endpoint (d, 95% CI = - 4.45, - 8.74 to - 0.16) when compared with treatment with placebo plus risperidone. The two treatments achieved comparable results for other outcome measures. Our data support safety and efficacy of baclofen as an adjuvant to risperidone for improvement of hyperactivity symptoms in children with ASD.",2019,"Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).","['Sixty-four children (3-12\xa0years) with moderate-to-severe irritability symptoms of ASD were included', 'autism', 'children with ASD']","['baclofen and risperidone', 'placebo', 'baclofen', 'risperidone', 'placebo plus risperidone', 'Baclofen']","['hyperactivity symptoms', 'ABC subscales', 'Aberrant Behavior Checklist-Community Edition (ABC-C', 'improvement of hyperactivity symptoms']","[{'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0022107', 'cui_str': 'Irritable Mood'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}]","[{'cui': 'C0004609', 'cui_str': 'Baclofen'}, {'cui': 'C0073393', 'cui_str': 'Risperidone'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0424295', 'cui_str': 'Increased purposeful goal-directed activity'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0443127', 'cui_str': 'Aberrant (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0441792', 'cui_str': 'Editions (qualifier value)'}]",64.0,0.377749,"Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).","[{'ForeName': 'Seyedeh-Mahsa', 'Initials': 'SM', 'LastName': 'Mahdavinasab', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran, 13337, Iran.'}, {'ForeName': 'Amene', 'Initials': 'A', 'LastName': 'Saghazadeh', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran, 13337, Iran.'}, {'ForeName': 'Nogol', 'Initials': 'N', 'LastName': 'Motamed-Gorji', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran, 13337, Iran.'}, {'ForeName': 'Salar', 'Initials': 'S', 'LastName': 'Vaseghi', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran, 13337, Iran.'}, {'ForeName': 'Mohammad-Reza', 'Initials': 'MR', 'LastName': 'Mohammadi', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran, 13337, Iran.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Alichani', 'Affiliation': 'Department of Psychiatry, Razi Hospital, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.'}, {'ForeName': 'Shahin', 'Initials': 'S', 'LastName': 'Akhondzadeh', 'Affiliation': 'Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran, 13337, Iran. s.akhond@neda.net.'}]",European child & adolescent psychiatry,['10.1007/s00787-019-01333-5'] 711,31864178,Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.,"BACKGROUND Previous analyses of BREAK-2 and BREAK-3 showed that durable outcomes lasting ≥3 years are achievable with dabrafenib in some patients with BRAF V600-mutant metastatic melanoma (MM); however, additional follow-up is needed to fully characterise the long-term impact of dabrafenib in these patients. METHODS BREAK-2 was a single-arm phase 2 study evaluating dabrafenib in treatment-naive or previously treated BRAF V600E/K-mutant MM. BREAK-3, a randomised (3:1) phase 3 study, assessed dabrafenib versus dacarbazine in previously untreated unresectable or metastatic BRAF V600E-mutant melanoma. Five-year analyses were performed. RESULTS All BREAK-2 patients (N = 92 [V600E, n = 76; V600K, n = 16]) discontinued treatment by the data cutoff. Median follow-up was 13.0 months. In BRAF V600E patients, 5-year progression-free survival (PFS) and overall survival (OS) were 11% and 20%, respectively. Subsequent immunotherapy was received by 22% of patients. In BREAK-3, median follow-up was 17.0 and 12.0 months in the dabrafenib (n = 187) and dacarbazine (n = 63) arms, respectively. Thirty-seven patients (59%) receiving dacarbazine crossed over to dabrafenib following disease progression as per protocol. Five-year PFS was 12% in the dabrafenib arm; all dacarbazine-arm patients progressed or were censored by 5 years. Dabrafenib improved PFS versus dacarbazine, regardless of baseline lactate dehydrogenase levels. Five-year OS rates were 24% and 22% in the dabrafenib and dacarbazine arms, respectively. Subsequent therapy in each arm included anti-CTLA-4 (dabrafenib [24%] and dacarbazine [24%]) and/or anti-PD-1 (8% and 2%) treatment. No new safety signals were observed. CONCLUSIONS AND RELEVANCE These data, representing extended follow-up for dabrafenib monotherapy, demonstrate that durable benefit lasting ≥5 years is achievable in a subset of patients. TRIAL REGISTRATION ClinicalTrials.gov (BREAK-2, NCT01153763; BREAK-3, NCT01227889).",2020,"Five-year OS rates were 24% and 22% in the dabrafenib and dacarbazine arms, respectively.","['previously untreated unresectable or metastatic BRAF V600E-mutant melanoma', 'patients with BRAF V600-mutant metastatic melanoma (MM', 'patients with BRAF V600-mutant metastatic melanoma receiving']","['dabrafenib versus dacarbazine', 'dabrafenib monotherapy', 'dacarbazine', 'dabrafenib in treatment-naive or previously treated BRAF V600E/K-mutant MM', 'dabrafenib']","['baseline lactate dehydrogenase levels', '5-year progression-free survival (PFS) and overall survival (OS']","[{'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0278883', 'cui_str': 'Metastatic melanoma'}]","[{'cui': 'C3467876', 'cui_str': 'dabrafenib'}, {'cui': 'C0010927', 'cui_str': 'Dacarbazine'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1292734', 'cui_str': 'Treats'}]","[{'cui': 'C0202113', 'cui_str': 'Lactate dehydrogenase measurement (procedure)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",37.0,0.387792,"Five-year OS rates were 24% and 22% in the dabrafenib and dacarbazine arms, respectively.","[{'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Hauschild', 'Affiliation': 'University Hospital Schleswig-Holstein, Kiel, Germany. Electronic address: ahauschild@dermatology.uni-kiel.de.'}, {'ForeName': 'Paolo A', 'Initials': 'PA', 'LastName': 'Ascierto', 'Affiliation': 'Istituto Nazionale Tumori IRCCS Fondazione ""G. Pascale,"" Naples, Italy.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Schadendorf', 'Affiliation': 'University Hospital of Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.'}, {'ForeName': 'Jean Jacques', 'Initials': 'JJ', 'LastName': 'Grob', 'Affiliation': 'Aix-Marseille University, Marseille, France.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Ribas', 'Affiliation': 'UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Kiecker', 'Affiliation': 'Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Dutriaux', 'Affiliation': 'Hôpital Saint-André, Bordeaux, France.'}, {'ForeName': 'Lev V', 'Initials': 'LV', 'LastName': 'Demidov', 'Affiliation': 'N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.'}, {'ForeName': 'Céleste', 'Initials': 'C', 'LastName': 'Lebbé', 'Affiliation': 'APHP Dermatology and CIC Department, Hôpital Saint-Louis, INSERM U976, University Paris Diderot, Paris, France.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Rutkowski', 'Affiliation': 'Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.'}, {'ForeName': 'Christian U', 'Initials': 'CU', 'LastName': 'Blank', 'Affiliation': 'The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Gutzmer', 'Affiliation': 'Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Millward', 'Affiliation': 'University of Western Australia, Sir Charles Gairdner Hospital, Perth, WA, Australia.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Kefford', 'Affiliation': 'Westmead Hospital and Macquarie University, Sydney, NSW, Australia.'}, {'ForeName': 'Tomas', 'Initials': 'T', 'LastName': 'Haas', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': ""D'Amelio"", 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Eduard', 'Initials': 'E', 'LastName': 'Gasal', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Bijoyesh', 'Initials': 'B', 'LastName': 'Mookerjee', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Paul B', 'Initials': 'PB', 'LastName': 'Chapman', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.10.033'] 712,31911641,Comparison of extubation success using noninvasive positive pressure ventilation (NIPPV) versus noninvasive neurally adjusted ventilatory assist (NI-NAVA).,"OBJECTIVE Compare rates of initial extubation success in preterm infants extubated to NIPPV or NI-NAVA. STUDY DESIGN In this pilot study, we randomized 30 mechanically ventilated preterm infants at the time of initial elective extubation to NI-NAVA or NIPPV in a 1:1 assignment. Primary study outcome was initial extubation success. RESULTS Rates of continuous extubation for 120 h were 92% in the NI-NAVA group and 69% in the NIPPV group (12/13 vs. 9/13, respectively, p = 0.14). Infants extubated to NI-NAVA remained extubated longer (median 18 vs. 4 days, p = 0.02) and experienced lower peak inspiratory pressures (PIP) than infants managed with NIPPV throughout the first 3 days after extubation. Survival analysis through 14 days post extubation showed a sustained difference in the primary study outcome until 12 days post extubation. CONCLUSIONS Our study is the first to suggest that a strategy of extubating preterm infants to NI-NAVA may be more successful.",2020,"Survival analysis through 14 days post extubation showed a sustained difference in the primary study outcome until 12 days post extubation. ","['30 mechanically ventilated preterm infants at the time of initial elective extubation to NI-NAVA or NIPPV in a 1:1 assignment', 'preterm infants extubated to NIPPV or NI-NAVA']",['noninvasive positive pressure ventilation (NIPPV) versus noninvasive neurally adjusted ventilatory assist (NI-NAVA'],"['peak inspiratory pressures (PIP', 'initial extubation success', 'Rates of continuous extubation', 'Infants extubated to NI-NAVA remained extubated longer']","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}]","[{'cui': 'C3164735', 'cui_str': 'Noninvasive positive pressure ventilation (procedure)'}, {'cui': 'C3178854', 'cui_str': 'Neurally Adjusted Ventilatory Assist'}]","[{'cui': 'C0232021', 'cui_str': 'Maximum inspiratory pressure (observable entity)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]",30.0,0.203056,"Survival analysis through 14 days post extubation showed a sustained difference in the primary study outcome until 12 days post extubation. ","[{'ForeName': 'Kartikeya', 'Initials': 'K', 'LastName': 'Makker', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA. kmakker@gmail.com.'}, {'ForeName': 'Josef', 'Initials': 'J', 'LastName': 'Cortez', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA.'}, {'ForeName': 'Kanishk', 'Initials': 'K', 'LastName': 'Jha', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA.'}, {'ForeName': 'Sanket', 'Initials': 'S', 'LastName': 'Shah', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA.'}, {'ForeName': 'Padma', 'Initials': 'P', 'LastName': 'Nandula', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Lowrie', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Smotherman', 'Affiliation': 'Center for Health Equity and Research (CHEQR), University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA.'}, {'ForeName': 'Shiva', 'Initials': 'S', 'LastName': 'Gautam', 'Affiliation': 'Center for Health Equity and Research (CHEQR), University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA.'}, {'ForeName': 'Mark L', 'Initials': 'ML', 'LastName': 'Hudak', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA.'}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-019-0578-4'] 713,31868074,Teaching Grapheme-Phoneme Correspondences Using a Direct Mapping Approach for At-Risk Second Language Learners: A Randomized Controlled Trial.,"Reading interventions developed to teach grapheme-phoneme correspondences (GPCs) were evaluated among L2 at-risk readers. In the direct mapping of grapheme (DMG) condition, children's attention was explicitly drawn to the application of a graphemes taught on that day to shared reading of words in authentic text. In the control condition there was no such systematic daily linkage of the GPCs and texts. The two reading interventions were otherwise identical. Two hundred fifty-three Chinese Grade 1 and Grade 2 students were screened, and those who scored in the bottom 30% of an English word-reading test were identified as L2 at-risk readers. Seventy-one L2 at-risk readers were thus randomly assigned to two conditions, both of which were small-group reading interventions: (a) DMG or (b) taught control. We hypothesized a significant main effect of Intervention condition and significant interaction of Intervention by Phonological Awareness (PA) effects on word reading, word attack, spelling, and sentence comprehension favoring the DMG intervention. Results showed that predicted interaction effects were significant for word reading, spelling, and sentence comprehension. No other effects were significant. Results suggest that the daily Direct Mapping of taught GPCs to shared book reading promotes reading development in at-risk English L2 readers with stronger phonological skills.",2020,Results suggest that the daily Direct Mapping of taught GPCs to shared book reading promotes reading development in at-risk English L2 readers with stronger phonological skills.,"['Two hundred fifty-three Chinese Grade 1 and Grade 2 students were screened, and those who scored in the bottom 30% of an English word-reading test were identified as L2 at-risk readers', 'Seventy-one L2 at-risk readers']","['small-group reading interventions: (a) DMG or (b) taught control', 'Teaching Grapheme-Phoneme Correspondences Using a Direct Mapping Approach']","['Phonological Awareness (PA) effects on word reading, word attack, spelling, and sentence comprehension', 'word reading, spelling, and sentence comprehension']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0450389', 'cui_str': '71 (qualifier value)'}]","[{'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}]","[{'cui': 'C0004448', 'cui_str': 'Situational Awareness'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C1304680', 'cui_str': 'Attack (finding)'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}]",253.0,0.0242646,Results suggest that the daily Direct Mapping of taught GPCs to shared book reading promotes reading development in at-risk English L2 readers with stronger phonological skills.,"[{'ForeName': 'Susanna Siu-Sze', 'Initials': 'SS', 'LastName': 'Yeung', 'Affiliation': 'The Education University of Hong Kong, New Territories, Hong Kong.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Savage', 'Affiliation': 'University College London, UK.'}]",Journal of learning disabilities,['10.1177/0022219419894563'] 714,31705869,Does Watching Videos Increase the Perioperative Anxiety in Patients Undergoing Third Molar Surgery? A Randomized Trial.,"PURPOSE The extraction of third molar teeth has usually been associated with a high level of anxiety, mainly from a lack of knowledge. We compared the effect of different informed consent formats on the perioperative anxiety level of patients scheduled for third molar surgery and explored the effects of watching a video about the surgical procedure from the Internet before the procedure on the patients' anxiety level. PATIENTS AND METHODS A total of 113 patients who had been admitted for the removal of impacted third molars were randomly divided into control (verbal information) and study (video plus verbal information) groups. The anxiety level was assessed using the Amsterdam Preoperative Anxiety and Information Scale, Modified Dental Anxiety Scale, and Spielberger's State-Trait Anxiety Inventory. Pain was evaluated using the visual analog scale (VAS). RESULTS The results showed that the study group had higher anxiety scores than the control group immediately after the consent process (P < .05). In all groups, the anxiety levels showed a decreasing trend after surgery. The VAS scores did not show significant differences when stratified by gender or educational level. No correlation was observed between age and the other variables. CONCLUSIONS According to our results, the patients who watched the procedural video in an uncontrolled situation from websites before the operation were prone to high anxiety. The verbal and written consent format resulted in satisfactory anxiety management. Further studies are needed to clarify whether the use of video consent with different formats, such as animation, would be more effective in managing anxiety when applied carefully and under the control of a clinician.",2020,"The anxiety level was assessed using the Amsterdam Preoperative Anxiety and Information Scale, modified Dental Anxiety Scale, and Spielberger's State-Trait Anxiety Inventory.","['Patients Undergoing Third Molar Surgery', 'patients scheduled for third molar surgery', '113 patients who had been admitted for the removal of impacted third molars']",[],"['satisfactory anxiety management', 'anxiety level', 'VAS scores', 'perioperative anxiety level', ""Amsterdam Preoperative Anxiety and Information Scale, modified Dental Anxiety Scale, and Spielberger's State-Trait Anxiety Inventory"", 'higher anxiety scores', 'visual analog scale (VAS', 'Pain', 'anxiety levels']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0026369', 'cui_str': 'Tooth, Wisdom'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}]",[],"[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety (observable entity)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0085380', 'cui_str': 'Fear, Dental'}, {'cui': 'C0451497', 'cui_str': 'Spielberger state-trait anxiety inventory'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",113.0,0.0223064,"The anxiety level was assessed using the Amsterdam Preoperative Anxiety and Information Scale, modified Dental Anxiety Scale, and Spielberger's State-Trait Anxiety Inventory.","[{'ForeName': 'Mehmet Melih', 'Initials': 'MM', 'LastName': 'Omezli', 'Affiliation': 'Associate Professor, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ordu University, Ordu, Turkey.'}, {'ForeName': 'Damla', 'Initials': 'D', 'LastName': 'Torul', 'Affiliation': 'Research Assistant, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ordu University, Ordu, Turkey. Electronic address: damlatorul@gmail.com.'}, {'ForeName': 'Kadircan', 'Initials': 'K', 'LastName': 'Kahveci', 'Affiliation': 'Research Assistant, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ordu University, Ordu, Turkey.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.09.027'] 715,31153107,Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.,"BACKGROUND Patients with idiopathic pulmonary fibrosis (IPF) demonstrate a range of lung function impairment. However, the efficacy of antifibrotics compared with placebo has not been assessed in patients with more advanced disease. This post-hoc analysis investigated the efficacy and safety of pirfenidone versus placebo in patients with IPF and more advanced lung function impairment, defined as percent predicted forced vital capacity (%FVC) < 50% and/or percent predicted carbon monoxide diffusing capacity <35%. METHODS Patients randomised to pirfenidone 2,403 mg/day or placebo in the ASCEND (NCT01366209) and CAPACITY (NCT00287716; NCT00287729) trials with more advanced baseline lung function impairment (pirfenidone, n = 90; placebo, n = 80) were included. Mortality, lung function, hospitalisation, exercise capacity and dyspnoea were investigated over 52 weeks. RESULTS At Week 52 versus placebo, pirfenidone was associated with significantly lower risks of all-cause mortality (hazard ratio [HR] 0.28; 95% confidence interval [CI] 0.09-0.86; p=0.0180), ≥10% absolute %FVC decline or all-cause mortality (HR 0.40; 95% CI 0.23-0.69; p=0.0006) and ≥10% absolute %FVC decline or respiratory-related hospitalisation or all-cause mortality (HR 0.46; 95% CI 0.28-0.76; p=0.0018). At Week 52, median treatment differences favouring pirfenidone were 36.7 m for 6-min walk distance and -8.0 points for the University of California-San Diego Shortness of Breath Questionnaire total score. Treatment-emergent adverse events (TEAEs) led to discontinuation in 14.4% and 21.3% of patients with pirfenidone and placebo, respectively. CONCLUSION Pirfenidone demonstrated clinically relevant benefits across multiple domains in patients with IPF and more advanced disease without an increased risk of discontinuation due to TEAEs. CLINICAL TRIALS REGISTRATION clinicaltrials. gov (ASCEND: NCT01366209; CAPACITY: NCT00287716; NCT00287729).",2019,"At Week 52, median treatment differences favouring pirfenidone were 36.7 m for 6-min walk distance and -8.0 points for the University of California-San Diego Shortness of Breath Questionnaire total score.","['patients with idiopathic pulmonary fibrosis and more advanced lung function impairment', 'Patients with idiopathic pulmonary fibrosis (IPF', 'patients with IPF and more advanced lung function impairment', 'advanced baseline lung function impairment (pirfenidone, n\u202f=\u202f90; placebo, n\u202f=\u202f80) were included', 'patients with more advanced disease']","['placebo', 'Pirfenidone', 'placebo, pirfenidone', 'pirfenidone versus placebo', 'pirfenidone 2,403\u202fmg/day or placebo']","['University of California-San Diego Shortness of Breath Questionnaire total score', 'Mortality, lung function, hospitalisation, exercise capacity and dyspnoea', 'FVC decline or respiratory-related hospitalisation or all-cause mortality', 'efficacy and safety']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0085786', 'cui_str': 'Alveolitis, Fibrosing'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0298067', 'cui_str': 'pirfenidone'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0298067', 'cui_str': 'pirfenidone'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}]","[{'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0013404', 'cui_str': 'Breathlessness'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",80.0,0.296389,"At Week 52, median treatment differences favouring pirfenidone were 36.7 m for 6-min walk distance and -8.0 points for the University of California-San Diego Shortness of Breath Questionnaire total score.","[{'ForeName': 'Steven D', 'Initials': 'SD', 'LastName': 'Nathan', 'Affiliation': 'Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, 8110 Gatehouse Road, Falls Church, VA, 22042, USA. Electronic address: Steven.Nathan@inova.org.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Costabel', 'Affiliation': 'Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Tüschener Weg 40, 45239, Essen, Germany. Electronic address: ulrich.costabel@rlk.uk-essen.de.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Albera', 'Affiliation': 'Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. Electronic address: carlo.albera@yahoo.it.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Behr', 'Affiliation': 'Department of Internal Medicine V, Comprehensive Pneumology Center, University of Munich (LMU) and Asklepios Fachkliniken München-Gauting, a member of the German Center for Lung Research (DZL), Robert-Koch-Allee 2, 82131, Gauting, Munich, Germany. Electronic address: juergen.behr@med.uni-muenchen.de.'}, {'ForeName': 'Wim A', 'Initials': 'WA', 'LastName': 'Wuyts', 'Affiliation': 'Department of Respiratory Medicine, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. Electronic address: wim.wuyts@uzleuven.be.'}, {'ForeName': 'Klaus-Uwe', 'Initials': 'KU', 'LastName': 'Kirchgaessler', 'Affiliation': 'F. Hoffmann-La Roche, Ltd., Konzern-Hauptsitz, Grenzacherstrasse 124, CH-4070, Basel, Switzerland. Electronic address: klaus-uwe.kirchgaessler@roche.com.'}, {'ForeName': 'John L', 'Initials': 'JL', 'LastName': 'Stauffer', 'Affiliation': 'Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA. Electronic address: stauffer.john@gene.com.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Morgenthien', 'Affiliation': 'Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA. Electronic address: morgente@gene.com.'}, {'ForeName': 'Willis', 'Initials': 'W', 'LastName': 'Chou', 'Affiliation': 'Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA. Electronic address: willis.chou@att.net.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Limb', 'Affiliation': 'Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA. Electronic address: limb.susan@gene.com.'}, {'ForeName': 'Paul W', 'Initials': 'PW', 'LastName': 'Noble', 'Affiliation': 'Department of Medicine, Cedars-Sinai Medical Center, 87000 Beverly Boulevard, Los Angeles, CA, 90048, USA. Electronic address: paul.noble@cshs.org.'}]",Respiratory medicine,['10.1016/j.rmed.2019.04.016'] 716,31530667,"Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.","OBJECTIVE To investigate the efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin. RESEARCH DESIGN AND METHODS Patients with type 2 diabetes uncontrolled on insulin with or without metformin were randomized to oral semaglutide 3 mg ( N = 184), 7 mg ( N = 182), or 14 mg ( N = 181) or to placebo ( N = 184) in a 52-week, double-blind trial. End points were change from baseline to week 26 in HbA 1c (primary) and body weight (confirmatory secondary). Two estimands were defined: treatment policy (effect regardless of trial product discontinuation or rescue medication) and trial product (effect assuming trial product continuation without rescue medication) in randomized patients. RESULTS Oral semaglutide was superior to placebo in reducing HbA 1c (estimated treatment difference [ETD] -0.5% [95% CI -0.7, -0.3], -0.9% [-1.1, -0.7], and -1.2% [-1.4, -1.0] for 3, 7, and 14 mg, respectively; P < 0.001) and body weight (ETD -0.9 kg [95% CI -1.8, -0.0], -2.0 kg [-3.0, -1.0], and -3.3 kg [-4.2, -2.3]; P = 0.0392 for 3 mg, P ≤ 0.0001 for 7 and 14 mg) at week 26 (treatment policy estimand). Significantly greater dose-dependent HbA 1c and body weight reductions versus placebo were achieved with oral semaglutide at weeks 26 and 52 (both estimands). The most frequent adverse event with oral semaglutide was nausea (11.4-23.2% of patients vs. 7.1% with placebo; mostly mild to moderate). CONCLUSIONS Oral semaglutide was superior to placebo in reducing HbA 1c and body weight when added to insulin with or without metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide 1 receptor agonists.",2019,"RESULTS Oral semaglutide was superior to placebo in reducing HbA 1c (estimated treatment differences [ETD] [95% CI]: -0.5% [-0.7, -0.3], -0.9% [-1.1, -0.7], -1.2% [-1.4, -1.0] for 3, 7, and 14 mg, respectively; P <0.001) and body weight (ETD [95% CI]: -0.9 kg [-1.8, -0.0], -2.0 kg [-3.0, -1.0], -3.3 kg [-4.2, -2.3]; P =0.0392 for 3 mg, P ≤0.0001 for 7 and 14 mg) at week 26 (treatment policy estimand).","['patients with type 2 diabetes', 'Patients with type 2 diabetes uncontrolled on insulin, ±', 'Patients with Type 2 Diabetes']","['insulin ± metformin', 'metformin', 'Insulin ± Metformin', 'oral semaglutide', 'Oral Semaglutide Versus Placebo', 'placebo', 'oral semaglutide added to insulin ± metformin']","['dose-dependent HbA 1c , and body weight reductions', 'HbA 1c and body weight', 'body weight', 'reducing HbA 1c', 'Efficacy, Safety and Tolerability', 'efficacy, safety and tolerability', 'nausea']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}]","[{'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C3885068', 'cui_str': 'semaglutide'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}]","[{'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",,0.109896,"RESULTS Oral semaglutide was superior to placebo in reducing HbA 1c (estimated treatment differences [ETD] [95% CI]: -0.5% [-0.7, -0.3], -0.9% [-1.1, -0.7], -1.2% [-1.4, -1.0] for 3, 7, and 14 mg, respectively; P <0.001) and body weight (ETD [95% CI]: -0.9 kg [-1.8, -0.0], -2.0 kg [-3.0, -1.0], -3.3 kg [-4.2, -2.3]; P =0.0392 for 3 mg, P ≤0.0001 for 7 and 14 mg) at week 26 (treatment policy estimand).","[{'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Zinman', 'Affiliation': 'Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada zinman@lunenfeld.ca.'}, {'ForeName': 'Vanita R', 'Initials': 'VR', 'LastName': 'Aroda', 'Affiliation': ""Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.""}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Buse', 'Affiliation': 'Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, NC.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Cariou', 'Affiliation': ""Department of Endocrinology, L'Institut du Thorax, CIC INSERM 1413, CHU Nantes, Université de Nantes, Nantes, France.""}, {'ForeName': 'Stewart B', 'Initials': 'SB', 'LastName': 'Harris', 'Affiliation': 'Department of Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.'}, {'ForeName': 'Søren Tetens', 'Initials': 'ST', 'LastName': 'Hoff', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Karen Boje', 'Initials': 'KB', 'LastName': 'Pedersen', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Mads Jeppe', 'Initials': 'MJ', 'LastName': 'Tarp-Johansen', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Eiichi', 'Initials': 'E', 'LastName': 'Araki', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes care,['10.2337/dc19-0898'] 717,31119849,The therapeutic relationship in Cognitive Behaviour Therapy with depressed adolescents: A qualitative study of good-outcome cases.,"OBJECTIVES This paper aimed to explore client experiences of the therapeutic relationship among adolescents with good outcomes after receiving Cognitive Behaviour Therapy (CBT) for moderate to severe depression. DESIGN This was a qualitative study employing Interpretative Phenomenological Analysis (IPA). METHODS As part of a randomized clinical trial, 77 adolescents with moderate to severe depression were interviewed using a semi-structured interview, which was audio-recorded. Five of these interviews, with adolescents aged 14-18 years who completed CBT and had good outcomes, were purposively sampled and analysed using IPA. RESULTS The findings indicated that a positive therapeutic relationship was fostered with therapists who respected the adolescents' autonomy and sense of individuality, while offering experiences of emotional closeness and connection. This was achieved by balancing the dual roles of being 'friendly' and affable, with being a 'professional expert' thereby embodying a collaborative and egalitarian approach. CONCLUSIONS The therapeutic relationship in CBT can help to motivate adolescents to engage with cognitively and emotionally challenging tasks. By providing an understanding of what helps and hinders the development of a positive therapeutic relationship, the current findings offer important insight into how therapists can foster positive relationships with depressed adolescents. This knowledge will make it more likely that adolescents will engage in the treatment process and in turn experience greater therapeutic gains. PRACTITIONER POINTS Offers a detailed phenomenological analysis of what fostered a positive therapeutic relationship in good outcome CBT, and what was experienced as harmful from the adolescents' perspective. Provides support that the therapeutic relationship is crucial in CBT; a respectful and understanding relationship provides a platform for the adolescent to carry out CBT activities and tasks.",2020,"The findings indicated that a positive therapeutic relationship was fostered with therapists who respected the adolescents' autonomy and sense of individuality, while offering experiences of emotional closeness and connection.","['adolescents aged 14-18\xa0years who completed CBT and had good outcomes', '77 adolescents with moderate to severe depression', 'depressed adolescents', 'adolescents with good outcomes after receiving']","['CBT', 'Cognitive Behaviour Therapy', 'Cognitive Behaviour Therapy (CBT']",[],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]",[],77.0,0.0309412,"The findings indicated that a positive therapeutic relationship was fostered with therapists who respected the adolescents' autonomy and sense of individuality, while offering experiences of emotional closeness and connection.","[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Wilmots', 'Affiliation': 'UCL and the Anna Freud National Centre for Children and Families, London, UK.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Midgley', 'Affiliation': 'Child Attachment and Psychological Therapies Research Unit (ChAPTRe), UCL and the Anna Freud National Centre for Children and Families, London, UK.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Thackeray', 'Affiliation': 'UCL and the Anna Freud National Centre for Children and Families, London, UK.'}, {'ForeName': 'Shirley', 'Initials': 'S', 'LastName': 'Reynolds', 'Affiliation': 'Charlie Waller Institute, School of Psychology and Clinical Language Sciences, University of Reading, UK.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Loades', 'Affiliation': 'Department of Psychology, University of Bath, UK.'}]",Psychology and psychotherapy,['10.1111/papt.12232'] 718,31526071,Efficacy of Proximal Resin Infiltration on Caries Inhibition: Results from a 3-Year Randomized Controlled Clinical Trial.,"This study reports 3-y outcomes of a split-mouth randomized clinical trial. Resin infiltration's capacity to arrest caries lesion progression in noncavitated proximal lesions is affirmed. Forty-two consented young adults, blinded to tooth surface allocation, were treated with resin infiltration on 1 randomly selected surface and concurrently experienced a mock infiltration procedure on another. Both treatments were provided as an adjunct to the currently accepted standard-of-care regimen (periodic prophylaxis and serial fluoride varnish applications) appropriate for the management of high caries risk. Challenging periods of low oral hygiene compliance were expected. The primary outcome measure was 3-y radiographic lesion progression. Blinded investigators evaluated each study surface for lesion progression with a series of images obtained at intervals over the 3-y course of study. Proportions of progressing lesions were compared with McNemar's test. Twenty-nine noncavitated lesion pairs in permanent posterior teeth demonstrating caries penetrating into inner enamel or outer dentin were included in the analyses. No adverse events were reported. Radiographic progression was recorded in 4 of 29 infiltrated lesions (14%) and 14 of 29 control lesions (48%, P < .003). Adjunct resin infiltration demonstrated a high 3-y efficacy of 71% (relative risk reduction). The prevented fraction was 86% for infiltration versus 52% for controls. Resin infiltration was 100% successful in arresting caries progression in inner enamel lesions (E2) and 64% in outer dentin lesions (D1). Supplementary microinvasive resin infiltration is significantly more efficacious in reducing proximal lesion progression than management by standard noninvasive therapy alone. Long-term results may shed light on whether this represents the arrest or delay of the caries disease process (ClinicalTrials.gov NCT01584024).",2019,Resin infiltration was 100% successful in arresting caries progression in inner enamel lesions (E2) and 64% in outer dentin lesions (D1).,"['Forty-two consented young adults', 'Twenty-nine noncavitated lesion pairs in permanent posterior teeth demonstrating caries penetrating into inner enamel or outer dentin']",['Proximal Resin Infiltration'],"['Radiographic progression', 'adverse events', 'proximal lesion progression', 'Caries Inhibition', '3-y radiographic lesion progression']","[{'cui': 'C4319566', 'cui_str': 'Forty-two'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0450351', 'cui_str': '29 (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0205355', 'cui_str': 'Permanent (qualifier value)'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C0205321', 'cui_str': 'Penetrating (qualifier value)'}, {'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}, {'cui': 'C0011350', 'cui_str': 'Enamel'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0011429', 'cui_str': 'Dentin'}]","[{'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C3669041', 'cui_str': 'Spread by direct extension (qualifier value)'}]","[{'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}]",,0.0841222,Resin infiltration was 100% successful in arresting caries progression in inner enamel lesions (E2) and 64% in outer dentin lesions (D1).,"[{'ForeName': 'M C', 'Initials': 'MC', 'LastName': 'Peters', 'Affiliation': 'School of Dentistry, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'A R', 'Initials': 'AR', 'LastName': 'Hopkins', 'Affiliation': 'Operative and Comprehensive Dentistry, USADC West Point, NY, USA.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Zhu', 'Affiliation': 'Biostatistics Program, Louisiana State University, New Orleans, LA, USA.'}, {'ForeName': 'Q', 'Initials': 'Q', 'LastName': 'Yu', 'Affiliation': 'Biostatistics Program, Louisiana State University, New Orleans, LA, USA.'}]",Journal of dental research,['10.1177/0022034519876853'] 719,31096099,High versus low mean arterial pressures in hepatorenal syndrome: A randomized controlled pilot trial.,"There is controversy regarding the mean arterial pressure (MAP) goals that should be targeted in the treatment of hepatorenal syndrome (HRS.) We conducted a study to assess different MAP targets in HRS in the intensive care unit (ICU). MATERIALS AND METHODS This is a prospective randomized controlled pilot trial. ICU patients had target mean arterial pressure (MAP) ≥ 85 mmHg (control arm) or 65-70 mmHg (study arm). Urine output and serum creatinine were trended and recorded. RESULTS A total of 18 patients were enrolled. The day four urine output in the high and low MAP group was 1194 (SD = 1249) mL/24 h and 920 (SD = 812) mL/24 h, respectively. The difference in day four - day one urine output was -689 (SD = 1684) mL/24 h and 272 (SD = 582) mL/24 h for the high and low MAP groups. The difference in serum creatinine at day four - day one was -0.54 (SD = 0.63) mg/dL and - 0.77 (SD = 1.14) mg/dL in the high and low MAP groups, respectively. CONCLUSION In this study, we failed to prove non-inferiority between a low and high target MAP in patients with HRS. TRIAL REGISTRATION This trial was registered with and approved by the University of Louisville Internal Review Board and hospital research review committees (IRB # 14.1190). The trial was registered with ClinicalTrials.gov (ID # NCT02789150). The IRB committee roster 7/21/2014-2/26/2015 is registered with IORG (IORG # IORG0000147; OMB # 0990-0279) and is available at http://louisville.edu/research/humansubjects/about-the-irb/rosters/RosterEffective20140721thru20150226.pdf.",2019,The difference in serum creatinine at day four - day one was -0.54,"['ICU patients had target mean arterial pressure (MAP)\u202f≥\u202f85\u202fmmHg (control arm) or 65-70\u202fmmHg (study arm', '18 patients were enrolled', 'hepatorenal syndrome', 'patients with HRS']",[],"['serum creatinine', 'Urine output and serum creatinine', 'mean arterial pressure (MAP) goals']","[{'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C0439475', 'cui_str': 'torr (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0019212', 'cui_str': 'Hepatorenal Syndrome'}]",[],"[{'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C1287298', 'cui_str': 'UO - Urine output'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C0018017', 'cui_str': 'Goals'}]",18.0,0.265903,The difference in serum creatinine at day four - day one was -0.54,"[{'ForeName': 'Benadin', 'Initials': 'B', 'LastName': 'Varajic', 'Affiliation': 'Department of Internal Medicine, University of Louisville, USA. Electronic address: b0vara01@louisville.edu.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Cavallazzi', 'Affiliation': 'Department of Pulmonary, Critical Care, and Sleep Disorders Medicine, University of Louisville, USA.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Mann', 'Affiliation': 'Department of Pulmonary, Critical Care, and Sleep Disorders Medicine, University of Louisville, USA.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Furmanek', 'Affiliation': 'Department of Infectious Disease, University of Louisville, USA.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Guardiola', 'Affiliation': 'Department of Pulmonary, Critical Care, and Sleep Disorders Medicine, University of Louisville, USA.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Saad', 'Affiliation': 'Department of Pulmonary, Critical Care, and Sleep Disorders Medicine, University of Louisville, USA.'}]",Journal of critical care,['10.1016/j.jcrc.2019.04.006'] 720,31112605,Personality Moderates Intervention Effects on Cognitive Function: A 6-Week Conversation-Based Intervention.,"BACKGROUND AND OBJECTIVES Social isolation is associated with a higher risk of dementia. We previously conducted and showed the efficacy of an intervention which uses conversation (the core component of social interactions) as a tool to enhance cognitive function. We now explore whether cognitive improvements through conversation-based intervention depend on an individual's personality. RESEARCH DESIGN AND METHODS We reexamined data from a 6-week randomized controlled trial (ClinicalTrials.gov Number: NCT01571427) to determine whether conversation-based intervention effects were moderated by personality traits in 83 older adults (mean age = 80.51 years, 49 cognitively intact, 34 individuals with mild cognitive impairment). The intervention group participated in daily 30-min face-to-face semi-structured conversations with trained interviewers through a web-enabled system for 6 weeks. At baseline, psychosocial questionnaires and a neuropsychological battery were completed. RESULTS Intervention group participants with high agreeableness, conscientiousness, and extraversion exhibited significant improvements in language-based executive function tasks beyond changes in the control group (ps < .05). An opposite pattern for delayed recall memory and working memory tasks emerged among highly extraverted participants (ps < .05). DISCUSSION AND IMPLICATIONS Our exploratory findings suggest the adaptive role of personality traits in conversation-based cognitive interventions may be limited to tasks incorporating a language component, and offer initial evidence for personalized approaches to cognitive health in late life.",2020,"An opposite pattern for delayed recall memory and working memory tasks emerged among highly extraverted participants (ps < .05). ","['83 older adults (mean age = 80.51 years, 49 cognitively intact, 34 individuals with mild cognitive impairment']",['daily 30-min face-to-face semi-structured conversations with trained interviewers through a web-enabled system for 6 weeks'],"['language-based executive function tasks', 'Cognitive Function', 'delayed recall memory and working memory tasks']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205266', 'cui_str': 'Intact (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0021821', 'cui_str': 'Interviewers'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0562342', 'cui_str': 'Empowered (finding)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0023008', 'cui_str': 'Languages'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}]",83.0,0.0918085,"An opposite pattern for delayed recall memory and working memory tasks emerged among highly extraverted participants (ps < .05). ","[{'ForeName': 'Eric S', 'Initials': 'ES', 'LastName': 'Cerino', 'Affiliation': 'School of Social and Behavioral Health Sciences, College of Public Health and Human Sciences, Oregon State University, Corvallis.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Hooker', 'Affiliation': 'School of Social and Behavioral Health Sciences, College of Public Health and Human Sciences, Oregon State University, Corvallis.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Goodrich', 'Affiliation': ""Department of Neurology, Layton Aging and Alzheimer's Disease Center, Oregon Health and Science University, Portland.""}, {'ForeName': 'Hiroko H', 'Initials': 'HH', 'LastName': 'Dodge', 'Affiliation': ""Department of Neurology, Layton Aging and Alzheimer's Disease Center, Oregon Health and Science University, Portland.""}]",The Gerontologist,['10.1093/geront/gnz063'] 721,31744796,Blood derived treatment from two allogeneic sources for severe dry eye associated to keratopathy: a multicentre randomised cross over clinical trial.,"AIM To compare the efficacy of cord blood and peripheral adult donor blood serum eyedrops, controlled for growth factor content, in the treatment of severe dry eye diseases (DED) resistant to conventional therapy. METHODS This was a multicentre randomised, double-masked, cross-over clinical trial. Sixty patients diagnosed as severe DED, associated to persistent corneal epithelial defects were randomised and equally assigned to group A (treated with cord blood serum (CBS)) or group B (treated with PBS), eyedrops administered eight times/day for 1 month. Primary outcome was the pretreatment and post-treatment change in corneal fluorescein staining. Secondary outcomes included the pretreatment and post-treatment change in Ocular Surface Disease Index (OSDI) questionnaire and Visual Analogue Score (VAS) of subjective symptoms, Schirmer I test, tear break-up time and conjunctival staining. Patients with relapse in signs or symptoms after further 2 months switched to the remaining group for one additional month. Data were statistically analysed (p<0.05). RESULTS Corneal staining was more significantly reduced after the CBS treatment, both VAS and OSDI score reduction was observed in both groups, but group A reported significantly less grittiness and pain. Nineteen patients shifted in the crossover period, the within individual comparison confirmed a better recovery in the CBS treatment period. Reduction in epithelial damage was positively associated with epidermal growth factor, transforming growth factorα and platelet-derived growth factor content. Levels of interleukins (IL-13) were positively associated with symptom decrease. CONCLUSIONS Overall, DED signs improved after both CBS and PBS treatments, with potential advantages of CBS for subjective symptoms and corneal damage reduction. CLINICAL TRIAL REGISTRATION NCT03064984.",2020,"Reduction in epithelial damage was positively associated with epidermal growth factor, transforming growth factorα and platelet-derived growth factor content.","['Sixty patients diagnosed as severe DED, associated to persistent corneal epithelial defects']","['cord blood serum (CBS)) or group B (treated with PBS), eyedrops', 'cord blood and peripheral adult donor blood serum eyedrops']","['corneal fluorescein staining', 'epidermal growth factor, transforming growth factorα and platelet-derived growth factor content', 'pretreatment and post-treatment change in Ocular Surface Disease Index (OSDI) questionnaire and Visual Analogue Score (VAS) of subjective symptoms, Schirmer', 'subjective symptoms and corneal damage reduction', 'VAS and OSDI score reduction', 'Corneal staining', 'grittiness and pain', 'Levels of interleukins (IL-13', 'Overall, DED signs', 'epithelial damage']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C3854510', 'cui_str': 'Persistent corneal epithelial defect (finding)'}]","[{'cui': 'C0162371', 'cui_str': 'Cord Blood'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441836', 'cui_str': 'Group B (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0015399', 'cui_str': 'Ophthalmic Drops'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0013018', 'cui_str': 'Donors'}]","[{'cui': 'C1318787', 'cui_str': 'Fluorescein stain'}, {'cui': 'C0242275', 'cui_str': 'Epidermal Growth Factor'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0032200', 'cui_str': 'Platelet-Derived Growth Factor'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C2919691', 'cui_str': 'Treatment changed'}, {'cui': 'C1557335', 'cui_str': 'Ocular surface disease'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0339289', 'cui_str': 'Corneal Damage'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0423232', 'cui_str': 'Corneal epithelial staining pattern (observable entity)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0021764', 'cui_str': 'Interleukins'}, {'cui': 'C0214743', 'cui_str': 'IL13'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C0010957', 'cui_str': 'Damage (morphologic abnormality)'}]",60.0,0.144284,"Reduction in epithelial damage was positively associated with epidermal growth factor, transforming growth factorα and platelet-derived growth factor content.","[{'ForeName': 'Emilio', 'Initials': 'E', 'LastName': 'Campos', 'Affiliation': 'Ophthalmology Unit, DIMES, Alma Mater Studiorum University of Bologna and S.Orsola-Malpighi Teaching Hospital, Bologna, Italy.'}, {'ForeName': 'Piera', 'Initials': 'P', 'LastName': 'Versura', 'Affiliation': 'Ophthalmology Unit, DIMES, Alma Mater Studiorum University of Bologna and S.Orsola-Malpighi Teaching Hospital, Bologna, Italy piera.versura@unibo.it.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Buzzi', 'Affiliation': ""Emilia Romagna Cord Blood Bank-Transfusion Service, AOU of Bologna Sant'Orsola-Malpighi Teaching Hospital, Bologna, Italy.""}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Fontana', 'Affiliation': 'Ophthalmology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Giannaccare', 'Affiliation': 'Ophthalmology Unit, DIMES, Alma Mater Studiorum University of Bologna and S.Orsola-Malpighi Teaching Hospital, Bologna, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Pellegrini', 'Affiliation': 'Ophthalmology Unit, DIMES, Alma Mater Studiorum University of Bologna and S.Orsola-Malpighi Teaching Hospital, Bologna, Italy.'}, {'ForeName': 'Nico', 'Initials': 'N', 'LastName': 'Lanconelli', 'Affiliation': 'Department of Physics and Astronomy, University of Bologna, Bologna, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Brancaleoni', 'Affiliation': 'Ospedale degli Infermi di Rimini, Rimini, Italy.'}, {'ForeName': 'Fabiana', 'Initials': 'F', 'LastName': 'Moscardelli', 'Affiliation': 'Ophthalmology Unit, DIMES, Alma Mater Studiorum University of Bologna and S.Orsola-Malpighi Teaching Hospital, Bologna, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Sebastiani', 'Affiliation': 'Ophthalmology Unit, DIMES, Alma Mater Studiorum University of Bologna and S.Orsola-Malpighi Teaching Hospital, Bologna, Italy.'}, {'ForeName': 'Cristiana', 'Initials': 'C', 'LastName': 'Vaselli', 'Affiliation': ""Emilia Romagna Cord Blood Bank-Transfusion Service, AOU of Bologna Sant'Orsola-Malpighi Teaching Hospital, Bologna, Italy.""}, {'ForeName': 'Vanda', 'Initials': 'V', 'LastName': 'Randi', 'Affiliation': ""Emilia Romagna Cord Blood Bank-Transfusion Service, AOU of Bologna Sant'Orsola-Malpighi Teaching Hospital, Bologna, Italy.""}]",The British journal of ophthalmology,['10.1136/bjophthalmol-2019-314859'] 722,31746743,"A multicentre, randomised controlled clinical study of drug-coated balloons for the treatment of coronary in-stent restenosis.","AIMS Treatment of in-stent restenosis of coronary stents is challenging. The use of drug-coated balloons (DCB) is a promising technique to treat in-stent restenosis without adding another metal layer. The aim of the AGENT ISR randomised trial is to evaluate angiographic and clinical outcomes in patients with ISR of a previously treated lesion who were treated with either a DCB with a new coating formulation (Agent) or a standard DCB (SeQuent Please). METHODS AND RESULTS AGENT ISR is a multicentre, randomised, open-label, non-inferiority study comparing the Agent and SeQuent Please DCB. A total of 125 patients (mean age ~68 years, 18% female) with in-stent restenosis of a previously treated lesion <28 mm in length were randomised at 11 sites in Europe to Agent (n=65) or SeQuent Please (n=60). The primary endpoint, six-month in-stent late lumen loss, in the Agent group (0.397±0.43 mm [n=51]) was non-inferior to that of the SeQuent Please group (0.393±0.536 mm [n=49]), as the two-sided upper 95% confidence boundary for the difference between groups was less than the pre-specified non-inferiority margin of 0.20 (difference 0.004, 95% CI [-0.189, 0.196]; pnon-inferiority=0.046). At one year, mortality was 3.1% in Agent and 1.7% in SeQuent Please patients (p>0.99), target lesion revascularisation 7.7% versus 10.0% (p=0.89), and stent thrombosis 0% versus 3.3% (p=0.44). Similar improvements in quality of life were seen in the two groups. CONCLUSIONS In this head-to-head comparison of two DCB, Agent proved to be non-inferior to SeQuent Please for in-stent late lumen loss at six months. CLINICAL TRIALS REGISTRATION NCT02151812 (http://clinicaltrials.gov/).",2020,"Please patients (P>0.99), target lesion revascularisation 7.7% vs. 10.0% (P=0.89), and stent thrombosis 0% vs. 3.3% (P=0.44).","['125 patients (mean age ~68 years, 18% female) with in-stent restenosis of a previously treated lesion <28 mm in length were randomised at 11 sites in Europe to Agent (n=65) or', 'Coronary In-stent Restenosis']","['drug-coated balloons (DCB', 'SeQuent']","['mortality', 'target lesion revascularisation', 'quality of life', '6-month in-stent late lumen loss', 'stent thrombosis']","[{'cui': 'C4319551', 'cui_str': 'One hundred and twenty-five'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C3272317', 'cui_str': 'Stent restenosis'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0453946', 'cui_str': 'Coat (physical object)'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft (physical object)'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0014742', 'cui_str': 'Erythema Multiforme'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}]",125.0,0.110984,"Please patients (P>0.99), target lesion revascularisation 7.7% vs. 10.0% (P=0.89), and stent thrombosis 0% vs. 3.3% (P=0.44).","[{'ForeName': 'Christian W', 'Initials': 'CW', 'LastName': 'Hamm', 'Affiliation': 'Universität Giessen, Giessen, Germany.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Dörr', 'Affiliation': ''}, {'ForeName': 'Jochen', 'Initials': 'J', 'LastName': 'Woehrle', 'Affiliation': ''}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Krackhardt', 'Affiliation': ''}, {'ForeName': 'Hüseyin', 'Initials': 'H', 'LastName': 'Ince', 'Affiliation': ''}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Zeus', 'Affiliation': ''}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Berland', 'Affiliation': ''}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Piot', 'Affiliation': ''}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Roubille', 'Affiliation': ''}, {'ForeName': 'Ingolf', 'Initials': 'I', 'LastName': 'Schult', 'Affiliation': ''}, {'ForeName': 'Dominic J', 'Initials': 'DJ', 'LastName': 'Allocco', 'Affiliation': ''}, {'ForeName': 'Holger', 'Initials': 'H', 'LastName': 'Nef', 'Affiliation': ''}]",EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,['10.4244/EIJ-D-19-00051'] 723,31035187,"Effect of physostigmine on recovery from septic shock following intra-abdominal infection - Results from a randomized, double-blind, placebo-controlled, monocentric pilot trial (Anticholium® per Se).","PURPOSE The cholinergic anti-inflammatory pathway has been shown to be accessible by physostigmine salicylate in animal models. However, the cholinesterase inhibitor is not approved for adjunctive therapy in sepsis, and tolerability and safety of high initial doses followed by continuous infusion have not been investigated. MATERIALS AND METHODS In this trial, 20 patients with perioperative septic shock due to intra-abdominal infection were eligible. The physostigmine group received an initial dose of 0.04 mg/kg physostigmine salicylate, followed by continuous infusion of 1 mg/h for 120 h; the placebo group was treated with 0.9% sodium chloride. Primary outcome was the mean Sequential Organ Failure Assessment (SOFA) score during treatment and up to 14 days. RESULTS Administration of physostigmine salicylate was well tolerated. Mean SOFA scores were 8.9 ± 2.5 and 11.3 ± 3.6 (mean ± SD) for physostigmine and placebo group, respectively. Adjusted for age, difference between means was not statistically significant (-2.37, 95% CI: -5.43 to 0.70, p = 0.121). Norepinephrine doses required only appeared lower in the physostigmine group (p = 0.064), along with a more rapid reduction from an elevated heart rate possibly indicating less hemodynamic instability. CONCLUSIONS Treatment with physostigmine salicylate was feasible and safe. Further studies are justified to assess the effect on recovery from septic shock. TRIAL REGISTRATION EudraCT Number 2012-001650-26, ClinicalTrials.gov identifier NCT03013322.",2019,"Norepinephrine doses required only appeared lower in the physostigmine group (p = 0.064), along with a more rapid reduction from an elevated heart rate possibly indicating less hemodynamic instability. ",['20 patients with perioperative septic shock due to intra-abdominal infection were eligible'],"['physostigmine salicylate', 'placebo', 'Norepinephrine', 'physostigmine', '0.9% sodium chloride', 'physostigmine and placebo']","['Mean SOFA scores', 'tolerated', 'mean Sequential Organ Failure Assessment (SOFA) score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036983', 'cui_str': 'Septic Shock'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C1112209', 'cui_str': 'Intra-Abdominal Infections'}]","[{'cui': 'C0071002', 'cui_str': 'physostigmine salicylate'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0202145', 'cui_str': 'Norepinephrine measurement (procedure)'}, {'cui': 'C0031849', 'cui_str': 'Physostigmine'}, {'cui': 'C4068881', 'cui_str': 'Zero point nine'}, {'cui': 'C0037494', 'cui_str': 'Sodium Chloride'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3494459', 'cui_str': 'SOFAS Scores'}]",20.0,0.709518,"Norepinephrine doses required only appeared lower in the physostigmine group (p = 0.064), along with a more rapid reduction from an elevated heart rate possibly indicating less hemodynamic instability. ","[{'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Pinder', 'Affiliation': 'Department of Anesthesiology, Heidelberg University Hospital, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany; Pharmacy Department, Heidelberg University Hospital, Im Neuenheimer Feld 670, 69120 Heidelberg, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Bruckner', 'Affiliation': 'Institute of Medical Biometry and Informatics (IMBI), Heidelberg University Hospital, Marsilius-Arkaden, Tower West, Im Neuenheimer Feld 130.3, 69120 Heidelberg, Germany.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Lehmann', 'Affiliation': 'Coordination Centre for Clinical Trials (KKS), Heidelberg University Hospital, Marsilius-Arkaden, Tower West, Im Neuenheimer Feld 130.3, 69120 Heidelberg, Germany.'}, {'ForeName': 'Johann', 'Initials': 'J', 'LastName': 'Motsch', 'Affiliation': 'Department of Anesthesiology, Heidelberg University Hospital, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany.'}, {'ForeName': 'Thorsten', 'Initials': 'T', 'LastName': 'Brenner', 'Affiliation': 'Department of Anesthesiology, Heidelberg University Hospital, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Larmann', 'Affiliation': 'Department of Anesthesiology, Heidelberg University Hospital, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Knebel', 'Affiliation': 'Department of General, Visceral, and Transplant Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany.'}, {'ForeName': 'Torsten', 'Initials': 'T', 'LastName': 'Hoppe-Tichy', 'Affiliation': 'Pharmacy Department, Heidelberg University Hospital, Im Neuenheimer Feld 670, 69120 Heidelberg, Germany.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Swoboda', 'Affiliation': 'Pharmacy Department, Heidelberg University Hospital, Im Neuenheimer Feld 670, 69120 Heidelberg, Germany.'}, {'ForeName': 'Markus A', 'Initials': 'MA', 'LastName': 'Weigand', 'Affiliation': 'Department of Anesthesiology, Heidelberg University Hospital, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Hofer', 'Affiliation': 'Department of Anesthesiology, Kaiserslautern Westpfalz Hospital, Hellmut-Hartert-Straße 1, 67655 Kaiserslautern, Germany.'}, {'ForeName': 'Johannes B', 'Initials': 'JB', 'LastName': 'Zimmermann', 'Affiliation': 'Department of Anesthesiology, Heidelberg University Hospital, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany. Electronic address: j.zimmermann@med.uni-heidelberg.de.'}]",Journal of critical care,['10.1016/j.jcrc.2019.04.012'] 724,31712735,Early symptoms and sensations as predictors of lung cancer: a machine learning multivariate model.,"The aim of this study was to identify a combination of early predictive symptoms/sensations attributable to primary lung cancer (LC). An interactive e-questionnaire comprised of pre-diagnostic descriptors of first symptoms/sensations was administered to patients referred for suspected LC. Respondents were included in the present analysis only if they later received a primary LC diagnosis or had no cancer; and inclusion of each descriptor required ≥4 observations. Fully-completed data from 506/670 individuals later diagnosed with primary LC (n = 311) or no cancer (n = 195) were modelled with orthogonal projections to latent structures (OPLS). After analysing 145/285 descriptors, meeting inclusion criteria, through randomised seven-fold cross-validation (six-fold training set: n = 433; test set: n = 73), 63 provided best LC prediction. The most-significant LC-positive descriptors included a cough that varied over the day, back pain/aches/discomfort, early satiety, appetite loss, and having less strength. Upon combining the descriptors with the background variables current smoking, a cold/flu or pneumonia within the past two years, female sex, older age, a history of COPD (positive LC-association); antibiotics within the past two years, and a history of pneumonia (negative LC-association); the resulting 70-variable model had accurate cross-validated test set performance: area under the ROC curve = 0.767 (descriptors only: 0.736/background predictors only: 0.652), sensitivity = 84.8% (73.9/76.1%, respectively), specificity = 55.6% (66.7/51.9%, respectively). In conclusion, accurate prediction of LC was found through 63 early symptoms/sensations and seven background factors. Further research and precision in this model may lead to a tool for referral and LC diagnostic decision-making.",2019,An interactive e-questionnaire comprised of pre-diagnostic descriptors of first symptoms/sensations was administered to patients referred for suspected LC.,"['Respondents were included in the present analysis only\xa0if they later received a primary LC diagnosis or had no cancer; and inclusion of each descriptor required ≥4 observations', 'primary lung cancer (LC', '506/670 individuals later diagnosed with primary LC (n\u2009=\u2009311) or no cancer (n\u2009=\u2009195']",[],"['cough that varied over the day, back pain/aches/discomfort, early satiety, appetite loss, and having less strength']","[{'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1306460', 'cui_str': 'Primary malignant neoplasm of lung'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C4517624', 'cui_str': '195'}]",[],"[{'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0234238', 'cui_str': 'Ache'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0239233', 'cui_str': 'Early satiety (fullness)'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}]",63.0,0.067058,An interactive e-questionnaire comprised of pre-diagnostic descriptors of first symptoms/sensations was administered to patients referred for suspected LC.,"[{'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Levitsky', 'Affiliation': 'Division of Innovative Care Research, Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet, SE-171 77, Solna, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Pernemalm', 'Affiliation': 'Cancer Proteomics Mass Spectrometry, Department of Oncology-Pathology, Karolinska Institutet, Science for Life Laboratory, SE-171 65, Solna, Sweden.'}, {'ForeName': 'Britt-Marie', 'Initials': 'BM', 'LastName': 'Bernhardson', 'Affiliation': 'Division of Innovative Care Research, Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet, SE-171 77, Solna, Sweden.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Forshed', 'Affiliation': 'Cancer Proteomics Mass Spectrometry, Department of Oncology-Pathology, Karolinska Institutet, Science for Life Laboratory, SE-171 65, Solna, Sweden.'}, {'ForeName': 'Karl', 'Initials': 'K', 'LastName': 'Kölbeck', 'Affiliation': 'Lung Oncology Center, Cancer Theme, Karolinska University Hospital, SE-171 76, Solna, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Olin', 'Affiliation': 'Lung Oncology Center, Cancer Theme, Karolinska University Hospital, SE-171 76, Solna, Sweden.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Henriksson', 'Affiliation': 'Department of Radiation Sciences and Oncology, University of Umeå, SE-901 87, Umeå, Sweden.'}, {'ForeName': 'Janne', 'Initials': 'J', 'LastName': 'Lehtiö', 'Affiliation': 'Cancer Proteomics Mass Spectrometry, Department of Oncology-Pathology, Karolinska Institutet, Science for Life Laboratory, SE-171 65, Solna, Sweden.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Tishelman', 'Affiliation': 'Division of Innovative Care Research, Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet, SE-171 77, Solna, Sweden.'}, {'ForeName': 'Lars E', 'Initials': 'LE', 'LastName': 'Eriksson', 'Affiliation': 'Division of Innovative Care Research, Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet, SE-171 77, Solna, Sweden. lars.eriksson@ki.se.'}]",Scientific reports,['10.1038/s41598-019-52915-x'] 725,31106550,A preoperative single dose of methadone for moderate-to-severely painful surgery reduces postoperative morphine consumption.,"BACKGROUND Data from patient questionnaires reveal that the intensity of postoperative pain is widely underestimated. Insufficient pain control may contribute to impaired short- and long-term outcome. Preoperative administration of methadone might potentially improve postoperative pain control due to its long pharmacological half-life. METHODS The aim of this study was to evaluate the effect of a single dose of methadone administered at anesthesia induction on postoperative analgesic requirements in ASA I-III patients after moderate-to-severely painful surgery scheduled for ≥90 minutes. Patients were randomized to receive either a single dose of methadone (0.2 mg/kg) or fentanyl (standard, 0.003 mg/kg) intravenously (IV) at anesthesia induction. For postoperative pain control, all study patients were accommodated with morphine on the basis of patient-controlled analgesia (PCA). RESULTS Per-protocol analysis revealed that the median cumulative morphine consumption was significantly lower in patients receiving a single dose of methadone, in the Postanesthesia Care Unit (0 mg vs. 7 mg of morphine, P<0.01) and during the first 72 hours after surgery (19 mg vs. 35 mg of morphine, P<0.05 for all days). Fentanyl consumption during surgery (0.25 mg [0.1-0.425 mg] in the study group vs. 0.3 mg [0.15-0.45 mg] in the control group, P=0.4499) was comparable among groups. Median pain scores at rest and in motion, and patient satisfaction were also similar in both groups (95.7% vs. 89.3% of patients were satisfied in the study and control group, respectively) during follow-up on postoperative days 1-3. CONCLUSIONS A single dose of methadone administered at anesthesia induction prior to moderate-to-severely painful surgery is a possible strategy to reduce postoperative morphine consumption.",2019,"Median pain scores at rest and in motion, and patient satisfaction were also similar in both groups (95.7% vs. 89.3% of patients were satisfied in the study and control group, respectively) during follow- up on postoperative days 1-3. ",['ASA I-III patients after moderate-to-severely painful surgery scheduled for ≥90 minutes'],"['methadone', 'fentanyl', 'morphine', 'Fentanyl consumption during surgery']","['median cumulative morphine consumption', 'postoperative pain control', 'postoperative analgesic requirements', 'Median pain scores at rest and in motion, and patient satisfaction']","[{'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}]","[{'cui': 'C0025605', 'cui_str': 'Methadone'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0443144', 'cui_str': 'At rest (qualifier value)'}, {'cui': 'C0687704', 'cui_str': 'Motions (qualifier value)'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}]",,0.0781543,"Median pain scores at rest and in motion, and patient satisfaction were also similar in both groups (95.7% vs. 89.3% of patients were satisfied in the study and control group, respectively) during follow- up on postoperative days 1-3. ","[{'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Bastian', 'Affiliation': 'Department for Anesthesia, Surgical Intensive Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Philipp K', 'Initials': 'PK', 'LastName': 'Buehler', 'Affiliation': 'Department of Intensive Care Medicine, University Hospital of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Dovile', 'Initials': 'D', 'LastName': 'Slizyte', 'Affiliation': 'Department for Anesthesia, Surgical Intensive Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Christoph A', 'Initials': 'CA', 'LastName': 'Rüst', 'Affiliation': 'Institute of Primary Care, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Toft', 'Affiliation': 'Department for Anaesthesia, Intensive Care and Emergency Medicine, See Hospital, Horgen, Switzerland.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Studer', 'Affiliation': 'Department for Anesthesia, Surgical Intensive Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Leopold', 'Initials': 'L', 'LastName': 'Lecheler', 'Affiliation': 'SOS Doctors, Zurich, Switzerland.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Aguirre', 'Affiliation': 'Department of Anesthesiology, Balgrist University Hospital, Zurich, Switzerland.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Siegemund', 'Affiliation': 'Department for Anesthesia, Surgical Intensive Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Alexa', 'Initials': 'A', 'LastName': 'Hollinger', 'Affiliation': 'Department for Anesthesia, Surgical Intensive Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital Basel, Basel, Switzerland - alexa.hollinger@usb.ch.'}]",Minerva anestesiologica,['10.23736/S0375-9393.19.13136-7'] 726,30819640,Improving care transitions through medication therapy management: A community partnership to reduce readmissions in multiple health-systems.,"OBJECTIVES The primary objective was to measure the impact of a pharmacist-provided medication therapy management program on 30-day postdischarge readmission rates. The secondary study objectives were to characterize the number and types of pharmacist interventions, to determine the impact of the intervention on primary and secondary medication nonadherence, and to measure patient satisfaction with the intervention. DESIGN Randomized, clinical trial. SETTING Six hospitals and a supermarket pharmacy chain with 60 pharmacies. PARTICIPANTS Four hundred patients discharged from a participating hospital with acute myocardial infarction, pneumonia, congestive heart failure, chronic obstructive pulmonary disease, or diabetes. MAIN OUTCOME MEASURES Primary outcome measure was 30-day readmission rate. Secondary outcomes were pharmacist interventions, primary and secondary medication nonadherence, and patient satisfaction. RESULTS Four hundred patients were enrolled. There was not a significant difference in 30-day readmission rates between intervention and control groups (11.3% vs. 10.7%; P = 0.49). A large portion of patients randomized to the intervention did not attend their appointment. In a per protocol (PP) analysis, which included the 62 intervention patients who attended their appointment and the 187 patients in the control group, there was a significant difference in 30-day readmission rates (1.6% vs. 10.7%; P = 0.02). In the PP analysis, controlling for baseline differences, patients in the intervention group were significantly less likely to experience a readmission (odds ratio, 0.126; 95% confidence interval, 0.016-0.968; P = 0.046). In the PP analysis, the percentage of prescriptions not picked up in the intervention group compared with the control group was reduced by 2.5%, (6.4% vs. 8.9%; P = 0.59). Pharmacists identified many interventions, averaging 6 per patient. CONCLUSION This study successfully implemented a large-scale transition of care program between multiple health systems and community pharmacies that reduced hospital readmissions. Pharmacists identified many interventions for patients. The transmission of patient information from the inpatient setting to the community pharmacy is key to transitioning patients successfully.",2019,There was not a significant difference in 30-day readmission rates between intervention and control groups (11.3% vs. 10.7%; P = 0.49).,"['Six hospitals and a supermarket pharmacy chain with 60 pharmacies', 'Four hundred patients discharged from a participating hospital with acute myocardial infarction, pneumonia, congestive heart failure, chronic obstructive pulmonary disease, or diabetes', 'Four hundred patients were enrolled']",['pharmacist-provided medication therapy management program'],"['experience a readmission', 'hospital readmissions', '30-day readmission rate', '30-day readmission rates', 'pharmacist interventions, primary and secondary medication nonadherence, and patient satisfaction', '30-day postdischarge readmission rates', 'percentage of prescriptions not picked']","[{'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0557778', 'cui_str': 'Supermarket (environment)'}, {'cui': 'C0031322', 'cui_str': 'Pharmacies'}, {'cui': 'C0337112', 'cui_str': 'Chain, device (physical object)'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0030685', 'cui_str': 'Patient Discharge'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction (disorder)'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure (disorder)'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C1611232', 'cui_str': 'Drug Therapy Management'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0600290', 'cui_str': 'Hospital Readmissions'}, {'cui': 'C0030700', 'cui_str': 'Thirty Day Readmission'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0746935', 'cui_str': 'Medication Non-Adherence'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0033080', 'cui_str': 'Prescriptions'}]",400.0,0.108063,There was not a significant difference in 30-day readmission rates between intervention and control groups (11.3% vs. 10.7%; P = 0.49).,"[{'ForeName': 'Pamela C', 'Initials': 'PC', 'LastName': 'Heaton', 'Affiliation': ''}, {'ForeName': 'Stacey', 'Initials': 'S', 'LastName': 'Frede', 'Affiliation': ''}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Kordahi', 'Affiliation': ''}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Lowery', 'Affiliation': ''}, {'ForeName': 'Brooke', 'Initials': 'B', 'LastName': 'Moorhead', 'Affiliation': ''}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Kirby', 'Affiliation': ''}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Kunze', 'Affiliation': ''}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Luder', 'Affiliation': ''}]",Journal of the American Pharmacists Association : JAPhA,['10.1016/j.japh.2019.01.005'] 727,30722059,"Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.","BACKGROUND Lefamulin, a pleuromutilin antibiotic, is active against pathogens commonly causing community-acquired bacterial pneumonia (CABP). The Lefamulin Evaluation Against Pneumonia (LEAP 1) study was a global noninferiority trial to evaluate the efficacy and safety of lefamulin for the treatment of CABP. METHODS In this double-blind study, adults with CABP of Pneumonia Outcomes Research Team risk class ≥III were randomized 1:1 to receive lefamulin at 150 mg intravenously (IV) every 12 hours or moxifloxacin at 400 mg IV every 24 hours. After 6 doses, patients could be switched to an oral study drug if prespecified improvement criteria were met. If methicillin-resistant Staphylococcus aureus was suspected, either linezolid or placebo was added to moxifloxacin or lefamulin, respectively. The US Food and Drug Administration primary endpoint was an early clinical response (ECR) 96 ± 24 hours after the first dose of the study drug in the intent-to-treat (ITT) population (noninferiority margin, 12.5%). The European Medicines Agency co-primary endpoints were an investigator assessment of clinical response (IACR) 5-10 days after the last dose of the study drug in the modified ITT (mITT) and clinically evaluable (CE) populations (noninferiority margin, 10%). RESULTS There were 551 patients randomized (n = 276 lefamulin; n = 275 moxifloxacin). Lefamulin was noninferior to moxifloxacin for ECR (87.3% vs 90.2%, respectively; difference -2.9%, 95% confidence interval [CI] g -8.5 to 2.8) and IACR (mITT, 81.7% vs 84.2%, respectively; difference -2.6%, 95% CI -8.9 to 3.9; CE, 86.9% vs 89.4%, respectively; difference -2.5%, 95% CI -8.4 to 3.4). Rates of study drug discontinuation due to treatment-emergent adverse events were 2.9% for lefamulin and 4.4% for moxifloxacin. CONCLUSIONS Lefamulin was noninferior to moxifloxacin for the primary efficacy endpoints and was generally safe and well tolerated. CLINICAL TRIALS REGISTRATION NCT02559310.",2019,Lefamulin was noninferior to moxifloxacin for ECR (87.3% vs 90.2%; difference:,"['Community-Acquired Bacterial Pneumonia', '551 patients were randomized (n=276 lefamulin; n=275', 'adults with CABP of Pneumonia Outcomes Research Team risk class ≥III']","['linezolid or placebo', 'moxifloxacin', 'lefamulin', 'IV-to-Oral Lefamulin, a Pleuromutilin Antibiotic', 'lefamulin 150 mg intravenously (IV) q12h or moxifloxacin 400 mg IV q24h']","['Efficacy and Safety', 'safe and well tolerated', 'early clinical response (ECR', 'investigator assessment of clinical response (IACR']","[{'cui': 'C0456394', 'cui_str': 'Community acquired (qualifier value)'}, {'cui': 'C0004626', 'cui_str': 'Pneumonia, Bacterial'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0035168'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}]","[{'cui': 'C0663241', 'cui_str': 'linezolid'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0071283', 'cui_str': 'pleuromutilin'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C1592286', 'cui_str': 'moxifloxacin 400 MG [Avelox]'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",551.0,0.472496,Lefamulin was noninferior to moxifloxacin for ECR (87.3% vs 90.2%; difference:,"[{'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'File', 'Affiliation': 'Summa Health, Akron, Ohio.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Goldberg', 'Affiliation': 'Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Das', 'Affiliation': 'Das Consulting, Guerneville, California.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Sweeney', 'Affiliation': 'Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Saviski', 'Affiliation': 'Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'Steven P', 'Initials': 'SP', 'LastName': 'Gelone', 'Affiliation': 'Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'Elyse', 'Initials': 'E', 'LastName': 'Seltzer', 'Affiliation': 'Urogen Pharma, New York.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Paukner', 'Affiliation': 'Nabriva Therapeutics GmbH, Vienna, Austria.'}, {'ForeName': 'Wolfgang W', 'Initials': 'WW', 'LastName': 'Wicha', 'Affiliation': 'Nabriva Therapeutics GmbH, Vienna, Austria.'}, {'ForeName': 'George H', 'Initials': 'GH', 'LastName': 'Talbot', 'Affiliation': 'Talbot Advisors LLC, Anna Maria, Florida.'}, {'ForeName': 'Leanne B', 'Initials': 'LB', 'LastName': 'Gasink', 'Affiliation': 'Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciz090'] 728,30980922,Effects of free weights and machine training on muscular strength in high-functioning older adults.,"BACKGROUND Resistance training is assumed to be a key player in counteracting the age-related decline of functional capacity as well as the incidence of falls in older adults. Functional training using free weights is presumed to mimic daily activities, but there is a lack of studies comparing free weight training with barbells and machine training in older adults. The purpose of this study was to evaluate the development of muscle strength for high resistance training in high functioning older people for machines as well as free-weights as well as testing the feasibility of free weight training for this target group. METHODS Thirty-two fitness trained women and men aged 60 to 86 years (mean: 66.9, SD: ±5.5) participated in this study. Machine exercisers (n = 16; chest press, leg press, upper row, biceps cable curls, triceps cable extension) vs. free weight exercisers (n = 16; squat, bench press, bent-over rowing, biceps curls, lying triceps press) participated twice à week for a total of 26 weeks. They trained the same five muscle groups for three sets with 10 to 12 repetitions at the 10-Repetition-Maximum, followed by 20 min of endurance training over six months. Three measurements (dynamic, isometric strength and endurance) were taken at the beginning, after 10 weeks and again after 26 weeks. RESULTS Repeated measures MANCOVA analysis revealed significant increases in the free weights training group (FWT) as well as in the machine training group (MT) over the period of 6 months. However, only for leg strength (113 vs. 44%) and triceps (89.0 vs. 28.3%) the free-weights group exhibited significant differences for the percentage increase over a period of 26 weeks compared to the machine group. A detraining period revealed the decline of the dynamic strength without training. The analysis of the follow-up questionnaire resulted in higher demands for safety, but also higher values for fun, motivation, future, and benefit for daily life for the FWT group compared to the MT group indicating an overall better evaluation of their training specific regime. CONCLUSION Our results demonstrate that especially free-weight training has benefits in improving leg and triceps strength as well as in the subjective perception in older adults. Nevertheless, our results do not overall indicate that free-weight training is superior to machine training for increasing strength.",2019,"The analysis of the follow-up questionnaire resulted in higher demands for safety, but also higher values for fun, motivation, future, and benefit for daily life for the FWT group compared to the MT group indicating an overall better evaluation of their training specific regime. ","['high functioning older people for machines', 'Thirty-two fitness trained women and men aged 60 to 86\u202fyears (mean', 'high-functioning older adults', 'older adults']","['Functional training', 'Machine exercisers (n\u202f=\u202f16; chest press, leg press, upper row, biceps cable curls, triceps cable extension) vs. free weight exercisers', 'free weights and machine training', 'high resistance training']","['muscular strength', 'leg strength']","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0336779', 'cui_str': 'Machine, device (physical object)'}, {'cui': 'C0450357', 'cui_str': '32 (qualifier value)'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0336779', 'cui_str': 'Machine, device (physical object)'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C4505111', 'cui_str': 'Rowing'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0180776', 'cui_str': 'Exerciser'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0442025', 'cui_str': 'Muscular (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}]",,0.02231,"The analysis of the follow-up questionnaire resulted in higher demands for safety, but also higher values for fun, motivation, future, and benefit for daily life for the FWT group compared to the MT group indicating an overall better evaluation of their training specific regime. ","[{'ForeName': 'Nadja', 'Initials': 'N', 'LastName': 'Schott', 'Affiliation': 'Dept. of Sport and Exercise Science, University of Stuttgart, Stuttgart, Germany. Electronic address: nadja.schott@inspo.uni-stuttgart.de.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Johnen', 'Affiliation': 'Dept. of Sport and Exercise Science, University of Stuttgart, Stuttgart, Germany.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Holfelder', 'Affiliation': 'Dept. of Sport and Exercise Science, University of Stuttgart, Stuttgart, Germany.'}]",Experimental gerontology,['10.1016/j.exger.2019.03.012'] 729,31429944,Influence of pain anticipation on brain activity and pain perception in Gulf War Veterans with chronic musculoskeletal pain.,"Anticipation of a painful experience can influence brain activity and increase sensitivity to experimental somatosensory stimuli in healthy adults, but this response is poorly understood among individuals with chronic musculoskeletal pain (CMP). Studies of brain and perceptual responses to somatosensory stimuli are used to make inferences about central nervous system dysfunction as a potential mechanism of symptoms. As such, we sought to (a) determine the influence of pain anticipation on pain-relevant brain regions and pain perception, and (b) characterize potential differences in these responses between Gulf War Veterans with CMP and matched healthy control (CO) Veterans. CMP (N = 30) and CO Veterans (N = 31) were randomized to conditions designed to generate expectations that either painful (pain) or nonpainful (no pain) stimuli would be administered. Brain responses to five nonpainful thermal stimuli were measured during fMRI, and each stimulus was rated for pain intensity and unpleasantness. In the pain condition, an incremental linear decrease in activity across stimuli was observed in the posterior cingulate cortex, cingulate cortex, and middle temporal gyrus. Further, in the pain condition, differential responses were observed between CMP and CO Veterans in the middle temporal gyrus. These findings indicate that brain responses to nonpainful thermal stimuli in Veterans with CMP are sensitive to pain anticipation, and we recommend accounting for the influence of pain anticipation in future investigations of central nervous system dysfunction in CMP.",2019,"In the pain condition, an incremental linear decrease in activity across stimuli was observed in the posterior cingulate cortex, cingulate cortex, and middle temporal gyrus.","['Veterans with CMP', 'Gulf War Veterans with CMP and matched healthy control (CO) Veterans', 'N\xa0=\xa030) and CO Veterans (N\xa0=\xa031', 'healthy adults', 'individuals with chronic musculoskeletal pain (CMP', 'Gulf War Veterans with chronic musculoskeletal pain']","['pain anticipation', 'CMP', 'painful (pain) or nonpainful (no pain) stimuli']","['pain intensity and unpleasantness', 'brain activity and pain perception']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0010729', 'cui_str': 'Cytidylic Acid'}, {'cui': 'C1449761', 'cui_str': 'Gulf War'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0746683', 'cui_str': 'Chronic musculoskeletal pain'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0010729', 'cui_str': 'Cytidylic Acid'}, {'cui': 'C0234225', 'cui_str': 'No pain'}, {'cui': 'C0234402', 'cui_str': 'Stimulus, function (observable entity)'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0443158', 'cui_str': 'Brain activity (observable entity)'}, {'cui': 'C3714605', 'cui_str': 'Pain Perception'}]",,0.0220629,"In the pain condition, an incremental linear decrease in activity across stimuli was observed in the posterior cingulate cortex, cingulate cortex, and middle temporal gyrus.","[{'ForeName': 'Jacob B', 'Initials': 'JB', 'LastName': 'Lindheimer', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin.'}, {'ForeName': 'Aaron J', 'Initials': 'AJ', 'LastName': 'Stegner', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin.'}, {'ForeName': 'Laura D', 'Initials': 'LD', 'LastName': 'Ellingson-Sayen', 'Affiliation': 'Department of Kinesiology, Iowa State University, Ames, Iowa.'}, {'ForeName': 'Stephanie M', 'Initials': 'SM', 'LastName': 'Van Riper', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin.'}, {'ForeName': 'Ryan J', 'Initials': 'RJ', 'LastName': 'Dougherty', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Falvo', 'Affiliation': 'Department of Veterans Affairs, NJ Health Care System, War Related Illness and Injury Study Center, East Orange, New Jersey.'}, {'ForeName': 'Dane B', 'Initials': 'DB', 'LastName': 'Cook', 'Affiliation': 'William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin.'}]",Psychophysiology,['10.1111/psyp.13452'] 730,31726935,Exposure to infant images enhances attention control in mothers.,"Viewing cute images has been reported to promote performance on tasks requiring carefulness, possibly related to an enhanced positive emotional state. However, it is unclear whether viewing infant images also enhances attention control in mothers. Therefore, this experimental study examined whether exposure to images of infants affected mothers' performance on a visual search task, studying associations with happy facial expressivity. Mothers ( N  = 101, M age  = 30.88) were randomly assigned to one of two conditions in which they either viewed images of infants or images of adults. Before and after viewing images, mothers performed a visual search task. Mothers' happy facial expressions at baseline and when viewing images were analysed. Viewing images of infants, in contrast to viewing images of adults, improved task performance indexed by accurateness, but not the number of correct responses. Images of infants elicited happy facial expressivity, which was associated with the number of correct responses on the visual search task. This study showed that viewing images of infants evokes happy facial expressions in mothers and can improve mothers' performance on a perceptual-cognitive task requiring attention control. Mothers' responses to infant images may be explained as an attentional preparedness for caregiving.",2020,"Images of infants elicited happy facial expressivity, which was associated with the number of correct responses on the visual search task.","['101, M age \u2009=\u200930.88', 'mothers', 'Mothers ( N\u2009 ']",[],"[""Mothers' happy facial expressions""]","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}]",[],"[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0018592', 'cui_str': 'Happinesses'}, {'cui': 'C0015457', 'cui_str': 'Facial Expression'}]",,0.0554223,"Images of infants elicited happy facial expressivity, which was associated with the number of correct responses on the visual search task.","[{'ForeName': 'Annemiek', 'Initials': 'A', 'LastName': 'Karreman', 'Affiliation': 'Department of Medical and Clinical Psychology, CoRPS - Center of Research on Psychological and Somatic disorders, Tilburg University, Tilburg, the Netherlands.'}, {'ForeName': 'Madelon M E', 'Initials': 'MME', 'LastName': 'Riem', 'Affiliation': 'Department of Medical and Clinical Psychology, CoRPS - Center of Research on Psychological and Somatic disorders, Tilburg University, Tilburg, the Netherlands.'}]",Cognition & emotion,['10.1080/02699931.2019.1689101'] 731,31740348,"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.","BACKGROUND Doravirine is a novel, non-nucleoside reverse transcriptase inhibitor that has shown non-inferior efficacy to ritonavir-boosted darunavir, with a superior lipid profile, in adults with HIV who were treatment naive at week 48 in the phase 3 DRIVE-FORWARD trial. Here we present the 96-week data for the study. METHODS This randomised, controlled, double-blind, multicentre, non-inferiority, phase 3 study was undertaken at 125 clinical centres in 15 countries. Eligible participants were adults (aged ≥18 years) infected with HIV-1 who were naive to antiretroviral therapy, with a plasma HIV-1 RNA concentration of 1000 copies per mL or higher at screening, and no known resistance to any of the study drugs. Participants were randomly assigned (1:1) using an interactive voice and web response system, stratified by baseline HIV-1 RNA concentration and background nucleoside reverse transcriptase inhibitor therapy, to doravirine (100 mg per day) or ritonavir-boosted darunavir (100 mg ritonavir and 800 mg darunavir per day), both with investigator-selected nucleoside reverse transcriptase inhibitors: emtricitabine and tenofovir disoproxil fumarate or abacavir and lamivudine. Participants and investigators were masked to treatment assignment until week 96. The primary efficacy endpoint was the proportion of participants who had a plasma HIV-1 RNA concentration of less than 50 copies per mL at week 48, which has been reported previously. Here we report the key secondary efficacy endpoint of the proportion of participants who achieved this concentration by week 96, assessed in all participants who received at least one dose of any study drug, regardless of whether it was their randomly assigned treatment. We used a US Food and Drug Administration snapshot approach and a margin of 10 percentage points to define the non-inferiority of doravirine to ritonavir-boosted darunavir at 96 weeks. Key safety endpoints were change in fasting serum lipid concentrations, the incidence of adverse events, and time to discontinuation due to an adverse event, assessed in all participants who received at least one dose of any study medication. This study is registered with ClinicalTrials.gov, NCT02275780, and is closed to accrual. FINDINGS Between Dec 1, 2014, and Oct 20, 2015, 1027 individuals were screened, of whom 769 participants were randomly assigned to doravirine (n=385) or ritonavir-boosted darunavir (n=384), and 383 in both groups were given at least one dose of their allocated treatment. Most participants were male (645 [84%] of 766) and white (560 [73%]), with a mean age of 35·2 years (SD 10·6). 292 participants in the doravirine group and 273 in the darunavir group completed 96 weeks of treatment. At week 96, a higher proportion of the doravirine group (277 [73%] of 383) achieved an HIV-1 RNA concentration of less than 50 copies per mL than did of the darunavir group (248 [66%] of 383; difference 7·1%, 95% CI 0·5-13·7). Responses were similar regardless of baseline characteristics. Treatment-emergent resistance to any study drug occurred in two (1%) of 383 participants in the doravirine group and one (<1%) of 383 in the ritonavir-boosted darunavir group. Significant differences were seen between treatment groups in mean changes from baseline in LDL cholesterol (-14·6 mg/dL, 95% CI -18·2 to -11·0) and non-HDL cholesterol (-18·4 mg/dL, -22·5 to -14·3). Frequencies of adverse events were similar between groups. No significant treatment difference (log-rank nominal p=0·063) through week 96 was observed in time to discontinuation due to an adverse event. The most common adverse events (week 0-96) were diarrhoea (65 [17%] in the doravirine group vs 91 [24%] in the ritonavir-boosted darunavir group), nausea (45 [12%] vs 52 [14%]), headache (57 [15%] vs 46 [12%]), and upper respiratory tract infection (51 [13%] vs 30 [8%]). Two participants, one in each group, died during treatment; neither death was considered to be related to study medication. INTERPRETATION These results through 96 weeks support the efficacy and safety results reported previously for doravirine at 48 weeks, supporting the use of doravirine for the long-term treatment of adults with previously untreated HIV-1 infection. FUNDING Merck.",2020,No significant treatment difference (log-rank nominal p=0·063) through week 96 was observed in time to discontinuation due to an adverse event.,"['participants who achieved this concentration by week 96, assessed in all participants who received at least one dose of any study drug, regardless of whether it was their randomly assigned treatment', 'Eligible participants were adults (aged ≥18 years) infected with HIV-1 who were naive to antiretroviral therapy, with a plasma HIV-1 RNA concentration of 1000 copies per mL or higher at screening, and no known resistance to any of the study drugs', 'antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD', 'adults with HIV who were treatment naive at week 48 in the phase 3 DRIVE-FORWARD trial', 'adults with previously untreated HIV-1 infection', '292 participants in the doravirine group and 273 in the darunavir group completed 96 weeks of treatment', 'Most participants were male (645 [84%] of 766) and white (560 [73%]), with a mean age of 35·2 years (SD 10·6', '383 participants in the doravirine group and one (<1%) of 383 in the ritonavir-boosted darunavir group', '125 clinical centres in 15 countries', '1027 individuals were screened, of whom 769 participants']","['doravirine to ritonavir-boosted darunavir', 'Doravirine versus ritonavir-boosted darunavir', 'interactive voice and web response system, stratified by baseline HIV-1 RNA concentration and background nucleoside reverse transcriptase inhibitor therapy, to doravirine (100 mg per day) or ritonavir-boosted darunavir (100 mg ritonavir and 800 mg darunavir per day), both with investigator-selected nucleoside reverse transcriptase inhibitors: emtricitabine and tenofovir disoproxil fumarate or abacavir and lamivudine', 'ritonavir-boosted darunavir', 'doravirine']","['death', 'diarrhoea', 'LDL cholesterol (-14·6', 'efficacy and safety', 'proportion of participants who had a plasma HIV-1 RNA concentration', 'headache', 'HIV-1 RNA concentration', 'upper respiratory tract infection', 'Frequencies of adverse events', 'non-HDL cholesterol (-18·4', 'fasting serum lipid concentrations, the incidence of adverse events, and time to discontinuation due to an adverse event', 'nausea']","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0205309', 'cui_str': 'Known (qualifier value)'}, {'cui': 'C0599685', 'cui_str': 'Anti-Retroviral Agents'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0439780', 'cui_str': 'Forward (qualifier value)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0439561', 'cui_str': 'Phase 3 (qualifier value)'}, {'cui': 'C2363741', 'cui_str': 'HIV-1 infection'}, {'cui': 'C4045491', 'cui_str': 'DORAVIRINE'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1435444', 'cui_str': 'darunavir'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C4319551', 'cui_str': 'One hundred and twenty-five'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}]","[{'cui': 'C4045491', 'cui_str': 'DORAVIRINE'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C1435444', 'cui_str': 'darunavir'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0028621', 'cui_str': 'Nucleosides'}, {'cui': 'C4521921', 'cui_str': 'Reverse transcriptase inhibitor'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C3844106', 'cui_str': 'Eight hundred'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0663655', 'cui_str': 'abacavir'}, {'cui': 'C0209738', 'cui_str': 'Lamivudine'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0041912', 'cui_str': 'Upper Respiratory Infections'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0729627', 'cui_str': 'Non-HDL cholesterol'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",769.0,0.490332,No significant treatment difference (log-rank nominal p=0·063) through week 96 was observed in time to discontinuation due to an adverse event.,"[{'ForeName': 'Jean-Michel', 'Initials': 'JM', 'LastName': 'Molina', 'Affiliation': 'University of Paris 7, Hôpital Saint Louis APHP, Paris, France.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Squires', 'Affiliation': 'Merck Sharpe & Dohme, Rahway, NJ, USA; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Paul E', 'Initials': 'PE', 'LastName': 'Sax', 'Affiliation': ""Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Cahn', 'Affiliation': 'Fundación Huesped, Buenos Aires, Argentina.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Lombaard', 'Affiliation': 'Josha Research, Bloemfontein, South Africa.'}, {'ForeName': 'Edwin', 'Initials': 'E', 'LastName': 'DeJesus', 'Affiliation': 'Orlando Immunology Center, Orlando, FL, USA.'}, {'ForeName': 'Ming-Tain', 'Initials': 'MT', 'LastName': 'Lai', 'Affiliation': 'Merck Sharpe & Dohme, Rahway, NJ, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Rodgers', 'Affiliation': 'Merck Sharpe & Dohme, Rahway, NJ, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Lupinacci', 'Affiliation': 'Merck Sharpe & Dohme, Rahway, NJ, USA.'}, {'ForeName': 'Sushma', 'Initials': 'S', 'LastName': 'Kumar', 'Affiliation': 'Merck Sharpe & Dohme, Rahway, NJ, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Sklar', 'Affiliation': 'Merck Sharpe & Dohme, Rahway, NJ, USA.'}, {'ForeName': 'George J', 'Initials': 'GJ', 'LastName': 'Hanna', 'Affiliation': 'Merck Sharpe & Dohme, Rahway, NJ, USA.'}, {'ForeName': 'Carey', 'Initials': 'C', 'LastName': 'Hwang', 'Affiliation': 'Merck Sharpe & Dohme, Rahway, NJ, USA.'}, {'ForeName': 'Elizabeth Anne', 'Initials': 'EA', 'LastName': 'Martin', 'Affiliation': 'Merck Sharpe & Dohme, Rahway, NJ, USA. Electronic address: elizabeth.martin1@merck.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The lancet. HIV,['10.1016/S2352-3018(19)30336-4'] 732,31668839,"Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).","PURPOSE Gemcitabine-oxaliplatin (GEMOX) demonstrated mild toxicity and promising effectiveness in patients with advanced urothelial cell cancer (UCC). We investigated the activity and safety of first-line GEMOX compared with gemcitabine-carboplatin (GCb) in cisplatin-ineligible patients with advanced UCC. METHODS Treatment-naive, cisplatin-ineligible patients with advanced UCC were randomly assigned to GEMOX (gemcitabine 1000 mg/m 2 , oxaliplatin 100 mg/m 2 on day 1 [D1] every 2 weeks) or GCb (1000 mg/m 2 of gemcitabine on D1 and D8 and carboplatin area under the curve of 4.5 mg/mL/min on D1 every 3 weeks). We evaluated the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). RESULTS Between January 2011 and March 2017, 80 patients were enrolled; 39 and 40 patients were allocated to GCb and GEMOX arms, respectively. The ORR was 48.7% in the GCb arm and 55.0% in the GEMOX arm. The median follow-up duration was 37.8 months; the median PFS and OS in the GCb and GEMOX arms were 5.5 months (95% confidence interval [CI], 4.8-6.2) vs. 4.4 months (95% CI, 2.7-6.1) and 9.1 months (95% CI, 5.2-13.0) vs. 11.0 months (95% CI, 6.9-15.0), respectively. ≥Leucopenia, neutropenia and fatigue of ≥ grade III were significantly more common in the GCb arm (26% vs. 3%, P = 0.003; 33% vs. 10%, P = 0.014; 15% vs. 3%, P = 0.012), whereas any-grade neuropathy was more common in the GEMOX arm (8% vs. 60%). CONCLUSIONS GEMOX showed similar efficacy with GCb and a favourable haematologic toxicity profile. GEMOX may be an additional chemotherapy option for patients with UCC ineligible for cisplatin-containing chemotherapy (NCT01487915).",2020,The median follow-up duration was 37.8 months; the median PFS and OS in the GCb and GEMOX arms were 5.5 months,"['patients with UCC ineligible for cisplatin-containing chemotherapy (NCT01487915', 'Treatment-naive, cisplatin-ineligible patients with advanced UCC', 'Between January 2011 and March 2017, 80 patients were enrolled; 39 and 40 patients', 'patients with advanced urothelial cell cancer (UCC', 'unfit patients with advanced urothelial carcinoma', 'ineligible patients with advanced UCC']","['Gemcitabine-oxaliplatin (GEMOX', 'GCb and GEMOX', 'GCb', 'gemcitabine plus oxaliplatin', 'gemcitabine-carboplatin (GCb', 'GEMOX', 'cisplatin', 'GEMOX (gemcitabine 1000\xa0mg/m 2 , oxaliplatin 100\xa0mg/m 2 on day 1 [D1] every 2 weeks) or GCb (1000\xa0mg/m 2 of gemcitabine on D1 and D8\xa0and carboplatin', 'Gemcitabine plus carboplatin']","['haematologic toxicity profile', 'mild toxicity', 'median PFS and OS', '≥Leucopenia, neutropenia\xa0and fatigue of ≥ grade III', 'ORR', 'activity and safety', 'objective response rate (ORR), progression-free survival (PFS)\xa0and overall survival (OS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0007138', 'cui_str': 'Carcinoma, Transitional Cell'}]","[{'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C4057589', 'cui_str': 'gemcitabine 1000 MG'}, {'cui': 'C4081033', 'cui_str': 'oxaliplatin 100 MG'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}]","[{'cui': 'C0205488', 'cui_str': 'Hematologic (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",80.0,0.138573,The median follow-up duration was 37.8 months; the median PFS and OS in the GCb and GEMOX arms were 5.5 months,"[{'ForeName': 'Inkeun', 'Initials': 'I', 'LastName': 'Park', 'Affiliation': 'Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea.'}, {'ForeName': 'Bong-Seog', 'Initials': 'BS', 'LastName': 'Kim', 'Affiliation': 'Division of Hemato-Oncology, Department of Internal Medicine, Veterans Health Service Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Ho Yeong', 'Initials': 'HY', 'LastName': 'Lim', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Hee-Jun', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Hyo Jin', 'Initials': 'HJ', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Republic of Korea.'}, {'ForeName': 'Yoon Ji', 'Initials': 'YJ', 'LastName': 'Choi', 'Affiliation': 'Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Kyong Hwa', 'Initials': 'KH', 'LastName': 'Park', 'Affiliation': 'Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Kyung Hee', 'Initials': 'KH', 'LastName': 'Lee', 'Affiliation': 'Division of Hemato-oncology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Republic of Korea.'}, {'ForeName': 'Shinkyo', 'Initials': 'S', 'LastName': 'Yoon', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Bumsik', 'Initials': 'B', 'LastName': 'Hong', 'Affiliation': 'Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jun Hyuk', 'Initials': 'JH', 'LastName': 'Hong', 'Affiliation': 'Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Hanjong', 'Initials': 'H', 'LastName': 'Ahn', 'Affiliation': 'Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jae Lyun', 'Initials': 'JL', 'LastName': 'Lee', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: jaelyun@amc.seoul.kr.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.08.034'] 733,31065889,Promoting physical activity through a psychological group intervention in cardiac rehabilitation: a randomized controlled trial.,"We examined the long-term effectiveness of a group-based psychological intervention (""MoVo-LISA"") to promote physical activity in patients with coronary heart disease. In this randomized controlled trial, N = 202 inactive patients with coronary heart disease were assigned to the control group (n = 102; treatment as usual) or the intervention group (n = 100; treatment as usual plus MoVo-LISA). Physical activity was assessed at baseline, 6 weeks (post-treatment), 6 months, and 12 months after discharge. ANCOVA for repeated measures revealed a significant interaction effect [p < .001; η p 2 = .214] indicating a large effect [d = 1.03] of the intervention on behavior change post-treatment. At 12-month follow-up, the level of physical activity in the intervention group was still 94 min per week higher than in the control group (p < .001; d = 0.57). Results of this RCT indicate that the MoVo-LISA intervention substantially improves the level of physical activity among initially inactive patients with coronary heart disease up to 1 year after the intervention.",2019,ANCOVA for repeated measures revealed a significant interaction effect [p < .001; η p 2 = .214] indicating a large effect [d = 1.03] of the intervention on behavior change post-treatment.,"['cardiac rehabilitation', 'patients with coronary heart disease', 'N\u2009=\u2009202 inactive patients with coronary heart disease']","['psychological group intervention', 'group-based psychological intervention (""MoVo-LISA', 'control group (n\u2009=\u2009102; treatment as usual) or the intervention group (n\u2009=\u2009100; treatment as usual plus MoVo-LISA', 'MoVo-LISA intervention']","['level of physical activity', 'Physical activity']","[{'cui': 'C0700431', 'cui_str': 'Cardiovascular Rehabilitation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0010068', 'cui_str': 'Coronary Disease'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}]","[{'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]",202.0,0.0563131,ANCOVA for repeated measures revealed a significant interaction effect [p < .001; η p 2 = .214] indicating a large effect [d = 1.03] of the intervention on behavior change post-treatment.,"[{'ForeName': 'Ramona', 'Initials': 'R', 'LastName': 'Wurst', 'Affiliation': 'Department of Sport Psychology, University of Freiburg, Schwarzwaldstrasse 175, 79117, Freiburg, Germany. Ramona.Wurst@sport.uni-freiburg.de.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Kinkel', 'Affiliation': 'Schwarzwaldklinik Bad Krozingen, Herbert-Hellmann-Allee 44, 79189, Freiburg, Germany.'}, {'ForeName': 'Jiaxi', 'Initials': 'J', 'LastName': 'Lin', 'Affiliation': 'Department of Sport Psychology, University of Freiburg, Schwarzwaldstrasse 175, 79117, Freiburg, Germany.'}, {'ForeName': 'Wiebke', 'Initials': 'W', 'LastName': 'Goehner', 'Affiliation': 'Catholic University of Applied Sciences, Karlstrasse 63, 79104, Freiburg, Germany.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Fuchs', 'Affiliation': 'Department of Sport Psychology, University of Freiburg, Schwarzwaldstrasse 175, 79117, Freiburg, Germany.'}]",Journal of behavioral medicine,['10.1007/s10865-019-00047-y'] 734,30104421,Lost Earnings and Nonmedical Expenses of Pediatric Hospitalizations.,"BACKGROUND AND OBJECTIVES Hospitalization-related nonmedical costs, including lost earnings and expenses such as transportation, meals, and child care, can lead to challenges in prioritizing postdischarge decisions. In this study, we quantify such costs and evaluate their relationship with sociodemographic factors, including family-reported financial and social hardships. METHODS This was a cross-sectional analysis of data collected during the Hospital-to-Home Outcomes Study, a randomized trial designed to determine the effects of a nurse home visit after standard pediatric discharge. Parents completed an in-person survey during the child's hospitalization. The survey included sociodemographic characteristics of the parent and child, measures of financial and social hardship, household income and also evaluated the family's total nonmedical cost burden, which was defined as all lost earnings plus expenses. A daily cost burden (DCB) standardized it for a 24-hour period. The daily cost burden as a percentage of daily household income (DCBi) was also calculated. RESULTS Median total cost burden for the 1372 households was $113, the median DCB was $51, and the median DCBi was 45%. DCB and DCBi varied across many sociodemographic characteristics. In particular, single-parent households (those with less work flexibility and more financial hardships experienced significantly higher DCB and DCBi. Those who reported ≥3 financial hardships lost or spent 6-times more of their daily income on nonmedical costs than those without hardships. Those with ≥1 social hardships lost or spent double their daily income compared with those without social hardships. CONCLUSIONS Nonmedical costs place burdens on families of children who are hospitalized, disproportionately affecting those with competing socioeconomic challenges.",2018,"Those with ≥1 social hardships lost or spent double their daily income compared with those without social hardships. ",[],[],"['nonmedical costs', 'Median total cost burden', 'median DCB']",[],[],"[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",1372.0,0.0472518,"Those with ≥1 social hardships lost or spent double their daily income compared with those without social hardships. ","[{'ForeName': 'Lenisa V', 'Initials': 'LV', 'LastName': 'Chang', 'Affiliation': 'Department of Economics, Carl H. Lindner College of Business, lenisa.chang@uc.edu.'}, {'ForeName': 'Anita N', 'Initials': 'AN', 'LastName': 'Shah', 'Affiliation': 'Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio; and.'}, {'ForeName': 'Erik R', 'Initials': 'ER', 'LastName': 'Hoefgen', 'Affiliation': 'Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio; and.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Auger', 'Affiliation': 'Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio; and.'}, {'ForeName': 'Huibin', 'Initials': 'H', 'LastName': 'Weng', 'Affiliation': 'Department of Economics, Carl H. Lindner College of Business.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Simmons', 'Affiliation': 'Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio; and.'}, {'ForeName': 'Samir S', 'Initials': 'SS', 'LastName': 'Shah', 'Affiliation': 'Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio; and.'}, {'ForeName': 'Andrew F', 'Initials': 'AF', 'LastName': 'Beck', 'Affiliation': 'Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio; and.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Pediatrics,['10.1542/peds.2018-0195'] 735,28694151,Liposomal bupivacaine decreases pain following retropubic sling placement: a randomized placebo-controlled trial.,"BACKGROUND Midurethral slings are commonly used to treat stress urinary incontinence. Pain control, however, may be a concern. Liposomal bupivacaine is a local anesthetic with slow release over 72 hours, demonstrated to lower pain scores and decrease narcotic use postoperatively. OBJECTIVE The purpose of this study was to examine the impact of liposomal bupivacaine on pain scores and narcotic consumption following retropubic midurethral sling placement. STUDY DESIGN This randomized, placebo-controlled trial enrolled women undergoing retropubic midurethral sling procedures with or without concomitant anterior or urethrocele repair. Subjects were allocated to receive liposomal bupivacaine (intervention) or normal saline placebo injected into the trocar paths and vaginal incision at the conclusion of the procedure. At the time of drug administration, surgeons became unblinded, but did not collect outcome data. Participants remained blinded to treatment. Surgical procedures and perioperative care were standardized. The primary outcome was the visual analog scale pain score 4 hours after discharge home. Secondary outcomes included narcotic consumption, time to first bowel movement, and pain scores collected in the mornings and evenings until postoperative day 6. The morning pain item assessed ""current level of pain""; the evening items queried ""current level of pain,"" ""most intense pain today,"" ""average pain today with activity,"" and ""average pain today with rest."" Likert scales were used to measure satisfaction with pain control at 1- and 2-week postoperative intervals. Sample size calculation deemed 52 subjects per arm necessary to detect a mean difference of 10 mm on a 100-mm visual analog scale. To account for 10% drop out, 114 participants were needed. RESULTS One hundred fourteen women were enrolled. After 5 exclusions, 109 cases were analyzed: 54 women received intervention, and 55 women received placebo. Mean participant age was 52 years, and mean body mass index was 30.4 kg/m 2 . Surgical and demographic characteristics were similar, except for a slightly higher body mass index in the placebo group (31.6 vs 29.2 kg/m 2 ; P=.050), and fewer placebo arm subjects received midazolam during anesthesia induction (44 vs 52; P=.015). For the primary outcome, pain score (millimeter) 4 hours after discharge home was lower in the intervention group (3.5 vs 13.0 millimeters; P=.014). Pain scores were also lower for subjects receiving liposomal bupivacaine at other time points collected during the first three postoperative days. Furthermore, fewer subjects in the intervention group consumed narcotic medication on postoperative day 2 (12 vs 27; P=.006). There was no difference in satisfaction with pain control between groups. Side-effects experienced, rate of postoperative urinary retention, and time to first bowel movement were similar between groups. Finally, no serious adverse events were noted. CONCLUSION Liposomal bupivacaine decreased postoperative pain scores following retropubic midurethral sling placement, though pain was low in both the intervention and placebo groups. Participants who received liposomal bupivacaine were less likely to use narcotics on postoperative day 2. For this common outpatient surgery, liposomal bupivacaine may be a beneficial addition. Given the cost of this intervention, however, future cost-effective analyses may be useful.",2017,"Liposomal bupivacaine is a local anesthetic with slow release over 72 hours, demonstrated to lower pain scores and decrease narcotic use postoperatively. ","['retropubic sling placement', '114 participants were needed', '109 cases were analyzed: 54 women received intervention, and 55 women received', 'One hundred fourteen women were enrolled', 'Mean participant age was 52 years, and mean body mass index was 30.4 kg/m 2 ']","['liposomal bupivacaine', 'placebo', 'midazolam', 'retropubic midurethral sling procedures with or without concomitant anterior or urethrocele repair', 'Liposomal bupivacaine', 'liposomal bupivacaine (intervention) or normal saline placebo']","['100-mm visual analog scale', 'narcotic consumption, time to first bowel movement, and pain scores', 'pain score (millimeter) 4 hours after discharge home', 'satisfaction with pain control', 'pain', 'postoperative pain scores', 'Likert scales', 'narcotic medication', 'rate of postoperative urinary retention, and time to first bowel movement', 'pain scores', 'pain scores and narcotic consumption', 'Pain scores', 'morning pain item assessed ""current level of pain""; the evening items queried ""current level of pain,"" ""most intense pain today,"" ""average pain today with activity,"" and ""average pain today with rest', 'visual analog scale pain score']","[{'cui': 'C0205499', 'cui_str': 'Retropubic approach (qualifier value)'}, {'cui': 'C1141000', 'cui_str': 'Sled, device (physical object)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C4708785', 'cui_str': 'One hundred and fourteen'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0205499', 'cui_str': 'Retropubic approach (qualifier value)'}, {'cui': 'C3179501', 'cui_str': 'Midurethral Slings'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0238502', 'cui_str': 'Prolapse of urethra (disorder)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}]","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0027415', 'cui_str': 'Narcotics'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C1292426', 'cui_str': '4 hours (qualifier value)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1304888', 'cui_str': 'Pain control (procedure)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451267', 'cui_str': 'Likert scale (assessment scale)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0080274', 'cui_str': 'Urinary Retention'}, {'cui': 'C0332170', 'cui_str': 'Morning (qualifier value)'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0587117', 'cui_str': 'Evening (qualifier value)'}, {'cui': 'C3543841', 'cui_str': 'Query'}, {'cui': 'C0310367', 'cui_str': 'Today'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C2732809', 'cui_str': 'Visual analog scale pain score (observable entity)'}]",114.0,0.683502,"Liposomal bupivacaine is a local anesthetic with slow release over 72 hours, demonstrated to lower pain scores and decrease narcotic use postoperatively. ","[{'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Mazloomdoost', 'Affiliation': 'Division of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics and Gynecology, TriHealth/Good Samaritan Hospital, Cincinnati, OH. Electronic address: donnamaz9@gmail.com.'}, {'ForeName': 'Rachel N', 'Initials': 'RN', 'LastName': 'Pauls', 'Affiliation': 'Division of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics and Gynecology, TriHealth/Good Samaritan Hospital, Cincinnati, OH.'}, {'ForeName': 'Erin N', 'Initials': 'EN', 'LastName': 'Hennen', 'Affiliation': 'Division of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics and Gynecology, TriHealth/Good Samaritan Hospital, Cincinnati, OH.'}, {'ForeName': 'Jennifer Y', 'Initials': 'JY', 'LastName': 'Yeung', 'Affiliation': 'Division of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics and Gynecology, TriHealth/Good Samaritan Hospital, Cincinnati, OH.'}, {'ForeName': 'Benjamin C', 'Initials': 'BC', 'LastName': 'Smith', 'Affiliation': 'Division of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics and Gynecology, TriHealth/Good Samaritan Hospital, Cincinnati, OH.'}, {'ForeName': 'Steven D', 'Initials': 'SD', 'LastName': 'Kleeman', 'Affiliation': 'Division of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics and Gynecology, TriHealth/Good Samaritan Hospital, Cincinnati, OH.'}, {'ForeName': 'Catrina C', 'Initials': 'CC', 'LastName': 'Crisp', 'Affiliation': 'Division of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics and Gynecology, TriHealth/Good Samaritan Hospital, Cincinnati, OH.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2017.07.001'] 736,31062373,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant.,"Tacrolimus or cyclosporine is prescribed with mycophenolic acid posttransplant and contributes to interpatient variability in mycophenolic acid pharmacokinetics and response. Cyclosporine inhibits enterohepatic circulation of the metabolite mycophenolic acid glucuronide, which is not described with tacrolimus. This study investigated mycophenolic acid pharmacokinetics and adverse effects in stable renal transplant recipients and the association with calcineurin inhibitors, sex, and race. Mycophenolic acid and mycophenolic acid glucuronide area under the concentration-time curve from 0 to 12 hours (AUC 0-12h ) and apparent clearance were determined at steady state in 80 patients receiving cyclosporine with mycophenolate mofetil and 67 patients receiving tacrolimus with mycophenolate sodium. Gastrointestinal adverse effects and hematologic parameters were evaluated. Statistical models evaluated mycophenolic acid pharmacokinetics and adverse effects. Mycophenolic acid AUC 0-12h was 1.70-fold greater with tacrolimus (68.9 ± 30.9 mg·h/L) relative to cyclosporine (40.8 ± 17.6 mg·h/L); P < .001. Target mycophenolic acid AUC 0-12h of 30-60 mg·h/L was achieved in 56.3% on cyclosporine compared with 34.3% receiving tacrolimus (P < .001). Mycophenolic acid clearance was 48% slower with tacrolimus (10.6 ± 4.7 L/h) relative to cyclosporine (20.5 ± 10.0 L/h); P < .001. Enterohepatic circulation occurred less frequently with cyclosporine (45%) compared with tacrolimus (78%); P < 0.001; with a 2.9-fold greater mycophenolic acid glucuronide AUC 0-12h to mycophenolic acid AUC 0-12h ratio (P < .001). Race did not affect mycophenolic acid pharmacokinetics. Gastrointestinal adverse effect scores were 2.2-fold higher with tacrolimus (P < .001) and more prominent in women (P = .017). Lymphopenia was more prevalent with tacrolimus (52.2%) than cyclosporine (22.5%); P < 0.001. Calcineurin inhibitors and sex contributed to interpatient variability in mycophenolic acid pharmacokinetics and adverse effects post-renal transplant, which could be attributed to differences in enterohepatic circulation.",2019,Enterohepatic circulation occurred less frequently with cyclosporine (45%) compared with tacrolimus (78%); P < 0.001; with a 2.9-fold greater mycophenolic acid glucuronide AUC 0-12h to mycophenolic acid AUC 0-12h ratio (P ,"['stable renal transplant recipients', '80 patients receiving', '17.6']","['tacrolimus with mycophenolate sodium', 'Calcineurin Inhibitor', 'cyclosporine', 'Calcineurin inhibitors', 'tacrolimus', 'cyclosporine with mycophenolate mofetil', 'Mycophenolic acid and mycophenolic acid glucuronide', 'mycophenolic acid pharmacokinetics', 'Tacrolimus or cyclosporine', 'Mycophenolic acid AUC', 'Cyclosporine']","['Lymphopenia', 'Gastrointestinal adverse effects and hematologic parameters', 'mycophenolic acid pharmacokinetics and adverse effects', 'Mycophenolic acid clearance', 'Enterohepatic circulation', 'mycophenolic acid pharmacokinetics', 'Target mycophenolic acid AUC', 'Gastrointestinal adverse effect scores', 'mycophenolic acid glucuronide AUC']","[{'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0022671', 'cui_str': 'Grafting, Kidney'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C1337395', 'cui_str': 'mycophenolate sodium'}, {'cui': 'C4521884', 'cui_str': 'Calcineurin inhibitor (disposition)'}, {'cui': 'C0010594', 'cui_str': 'Cyclosporins'}, {'cui': 'C0209368', 'cui_str': 'mycophenolate mofetil'}, {'cui': 'C0026933', 'cui_str': 'Mycophenolic Acid'}, {'cui': 'C0676811', 'cui_str': 'mycophenolic acid 7-O-glucuronide'}, {'cui': 'C0376690', 'cui_str': 'AUC'}]","[{'cui': 'C0024312', 'cui_str': 'Lymphocytopenia'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0205488', 'cui_str': 'Hematologic (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0026933', 'cui_str': 'Mycophenolic Acid'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0014362', 'cui_str': 'Entero-Hepatic Circulation'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0676811', 'cui_str': 'mycophenolic acid 7-O-glucuronide'}]",80.0,0.0689333,Enterohepatic circulation occurred less frequently with cyclosporine (45%) compared with tacrolimus (78%); P < 0.001; with a 2.9-fold greater mycophenolic acid glucuronide AUC 0-12h to mycophenolic acid AUC 0-12h ratio (P ,"[{'ForeName': 'Calvin J', 'Initials': 'CJ', 'LastName': 'Meaney', 'Affiliation': 'Immunosuppressive Pharmacology Research Program, Translational Pharmacology Research Core, Buffalo, NY, USA.'}, {'ForeName': 'Patcharaporn', 'Initials': 'P', 'LastName': 'Sudchada', 'Affiliation': 'Immunosuppressive Pharmacology Research Program, Translational Pharmacology Research Core, Buffalo, NY, USA.'}, {'ForeName': 'Joseph D', 'Initials': 'JD', 'LastName': 'Consiglio', 'Affiliation': 'Department of Biostatistics, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Gregory E', 'Initials': 'GE', 'LastName': 'Wilding', 'Affiliation': 'Department of Biostatistics, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Louise M', 'Initials': 'LM', 'LastName': 'Cooper', 'Affiliation': 'Immunosuppressive Pharmacology Research Program, Translational Pharmacology Research Core, Buffalo, NY, USA.'}, {'ForeName': 'Rocco C', 'Initials': 'RC', 'LastName': 'Venuto', 'Affiliation': 'Department of Medicine; Nephrology Division, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Tornatore', 'Affiliation': 'Immunosuppressive Pharmacology Research Program, Translational Pharmacology Research Core, Buffalo, NY, USA.'}]",Journal of clinical pharmacology,['10.1002/jcph.1428'] 737,30986760,The hospital-based evaluation of laxative prophylaxis in ICU (HELP-ICU): A pilot cluster-crossover randomized clinical trial.,"PURPOSE Prophylactic laxative regimens may prevent constipation but may increase diarrhea and subsequent rectal tube insertion. Our aim was to compare three prophylactic laxative regimens on the rate of rectal tube insertion (primary outcome) and major constipation- or diarrhea-associated complications. MATERIAL AND METHODS We conducted a cluster-crossover trial. Three pods in a single ICU were each randomized to one of three regimens for four months with rolling cross-over. All mechanically-ventilated and enterally-fed adult patients received either regimen: A) one coloxyl with senna BD from day one; B) two coloxyl with senna +20 ml lactulose BD commencing on day 3; or C) two coloxyl with senna tablets +20 ml lactulose BD commencing on day 6. RESULTS We enrolled 570 patients (A = 170, B = 205, C = 195) with similar baseline features. Overall, 53 (9.3%) patients received a rectal tube, and insertion rate was not statistically different between the three regimens (A = 12.9%, B = 7.8%, C = 7.7%; p = 0.15). The proportions of patients with other major constipation- or diarrhea-associated complications were similar, as were major patient-centred outcomes. CONCLUSION Earlier commencement of a prophylactic coloxyl-based laxative regimen (day 1 or 3) did not affect the rates of complications associated with constipation or diarrhea when compared to delayed introduction (day 6).",2019,"Overall, 53 (9.3%) patients received a rectal tube, and insertion rate was not statistically different between the three regimens (A = 12.9%, B = 7.8%, C = 7.7%; p = 0.15).","['We enrolled 570 patients (A\u202f=\u202f170, B\u202f=\u202f205, C\u202f=\u202f195) with similar baseline features']","['coloxyl with senna +20\u202fml lactulose BD', 'coloxyl with senna tablets +20\u202fml lactulose BD', 'prophylactic coloxyl-based laxative regimen']","['diarrhea-associated complications', 'rate of rectal tube insertion (primary outcome) and major constipation- or diarrhea-associated complications', 'rates of complications associated with constipation or diarrhea', 'rectal tube, and insertion rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517599', 'cui_str': 'One hundred and seventy'}, {'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C3489575', 'cui_str': 'sennosides, USP'}, {'cui': 'C0022957', 'cui_str': 'Lactulose'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0282090', 'cui_str': 'Laxatives'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0178099', 'cui_str': 'Insertion of tube into rectum (procedure)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0205052', 'cui_str': 'Rectal (qualifier value)'}, {'cui': 'C4318415', 'cui_str': 'Tube (unit of presentation)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}]",570.0,0.141363,"Overall, 53 (9.3%) patients received a rectal tube, and insertion rate was not statistically different between the three regimens (A = 12.9%, B = 7.8%, C = 7.7%; p = 0.15).","[{'ForeName': 'Tyler', 'Initials': 'T', 'LastName': 'Hay', 'Affiliation': 'The University of Melbourne, Melbourne Medical School, Parkville, Victoria, Australia.'}, {'ForeName': 'Adam M', 'Initials': 'AM', 'LastName': 'Deane', 'Affiliation': 'The University of Melbourne, Melbourne Medical School, Department of Medicine and Radiology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Intensive Care Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia. Electronic address: adam.deane@mh.org.au.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Rechnitzer', 'Affiliation': 'Intensive Care Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Fetterplace', 'Affiliation': 'The University of Melbourne, Melbourne Medical School, Department of Medicine and Radiology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Intensive Care Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Reilly', 'Affiliation': 'Intensive Care Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Ankravs', 'Affiliation': 'The University of Melbourne, Melbourne Medical School, Department of Medicine and Radiology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Intensive Care Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Bailey', 'Affiliation': 'Australian and New Zealand Intensive Care Research Centre, Monash University School of Public Health and Preventive Medicine, Melbourne, Australia; The University of Melbourne, Department of Medicine and Radiology, Parkville, Victoria, Australia.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Fazio', 'Affiliation': 'The University of Melbourne, Melbourne Medical School, Department of Medicine and Radiology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Business Intelligence Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Anstey', 'Affiliation': 'The University of Melbourne, Melbourne Medical School, Department of Medicine and Radiology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Intensive Care Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia.'}, {'ForeName': 'Rohit', 'Initials': 'R', 'LastName': ""D'Costa"", 'Affiliation': 'Australian and New Zealand Intensive Care Research Centre, Monash University School of Public Health and Preventive Medicine, Melbourne, Australia.'}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Presneill', 'Affiliation': 'The University of Melbourne, Melbourne Medical School, Department of Medicine and Radiology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Intensive Care Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia.'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'MacIsaac', 'Affiliation': 'The University of Melbourne, Melbourne Medical School, Department of Medicine and Radiology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Intensive Care Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia.'}, {'ForeName': 'Rinaldo', 'Initials': 'R', 'LastName': 'Bellomo', 'Affiliation': 'The University of Melbourne, Melbourne Medical School, Department of Medicine and Radiology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Intensive Care Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia; Australian and New Zealand Intensive Care Research Centre, Monash University School of Public Health and Preventive Medicine, Melbourne, Australia; Intensive Care Unit, The Austin Hospital, Heidelberg, Victoria, Australia.'}]",Journal of critical care,['10.1016/j.jcrc.2019.04.010'] 738,31095318,Engaging Caregivers in Health-Related Housing Decisions for Older Adults With Cognitive Impairment: A Cluster Randomized Trial.,"BACKGROUND AND OBJECTIVES Informal caregivers are rarely as involved as they want to be in the housing decisions of cognitively impaired older adults. Lack of awareness of available options and their benefits and risks may lead to decisions that do not reflect older adults' preferences, and to guilt and regret. We assessed the effect of training home care teams in interprofessional shared decision-making (SDM) on the proportion of caregivers who report being active in this decision. RESEARCH DESIGN AND METHODS In a two-arm pragmatic cluster randomized trial with home care teams working in health centers in the Province of Quebec, we randomized health centers to receive training in interprofessional SDM (intervention) or not (control). Eligible caregivers had made a housing decision for a cognitively impaired adult aged 65 years or older who was receiving services from a home care team. The primary outcome was the proportion of caregivers reporting an active role in decision making. We performed intention-to-treat multilevel analysis. RESULTS We consecutively enrolled a random group of 16 health centers and recruited 309 caregivers, among whom 296 were included in the analysis. In the intervention arm, the proportion of caregivers reporting an active role in decision making increased by 12% (95% CI -2% to 27%; p = .10). After removal of an influential cluster outlier, the proportion increased to 18% (95% CI: 7%-29%; p < .01). DISCUSSION AND IMPLICATIONS Training home care teams in interprofessional SDM increased caregiver involvement in health-related housing decisions for cognitively impaired older adults.",2020,"We assessed the effect of training home care teams in interprofessional shared decision-making (SDM) on the proportion of caregivers who report being active in this decision. ","['in health centers in the Province of Quebec', 'cognitively impaired older adults', 'consecutively enrolled a random group of 16 health centers and recruited 309 caregivers, among whom 296 were included in the analysis', 'Eligible caregivers had made a housing decision for a cognitively impaired adult aged 65 years or older who was receiving services from a home care team', 'Older Adults With Cognitive Impairment']","['home care teams working', 'training in interprofessional SDM (intervention) or not (control']",['proportion of caregivers reporting an active role in decision making'],"[{'cui': 'C0475309', 'cui_str': 'Health center (environment)'}, {'cui': 'C0034390', 'cui_str': 'Quebec'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0020056', 'cui_str': 'Housing'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0204977', 'cui_str': 'Home Care'}, {'cui': 'C0338656', 'cui_str': 'Cognitive Dysfunction'}]","[{'cui': 'C0204977', 'cui_str': 'Home Care'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0643808', 'cui_str': 'SDM'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0035820', 'cui_str': 'Role'}]",,0.262906,"We assessed the effect of training home care teams in interprofessional shared decision-making (SDM) on the proportion of caregivers who report being active in this decision. ","[{'ForeName': 'Rhéda', 'Initials': 'R', 'LastName': 'Adekpedjou', 'Affiliation': ""Centre de recherche sur les soins et les services de première ligne de l'Université Laval, Québec, Canada.""}, {'ForeName': 'Dawn', 'Initials': 'D', 'LastName': 'Stacey', 'Affiliation': 'Ottawa Hospital Research Institute and Faculty of Health Sciences, University of Ottawa, Ontario, Canada.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Brière', 'Affiliation': 'Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale, Québec, Canada.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Freitas', 'Affiliation': ""Centre de recherche sur les soins et les services de première ligne de l'Université Laval, Québec, Canada.""}, {'ForeName': 'Mirjam M', 'Initials': 'MM', 'LastName': 'Garvelink', 'Affiliation': ""Centre de recherche sur les soins et les services de première ligne de l'Université Laval, Québec, Canada.""}, {'ForeName': 'Maman Joyce', 'Initials': 'MJ', 'LastName': 'Dogba', 'Affiliation': 'Department of Family Medicine and Emergency Medicine.'}, {'ForeName': 'Pierre J', 'Initials': 'PJ', 'LastName': 'Durand', 'Affiliation': 'Department of Family Medicine and Emergency Medicine.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Desroches', 'Affiliation': 'School of Nutrition, Québec, Canada.'}, {'ForeName': 'Jordie', 'Initials': 'J', 'LastName': 'Croteau', 'Affiliation': ""Centre de recherche sur les soins et les services de première ligne de l'Université Laval, Québec, Canada.""}, {'ForeName': 'Louis-Paul', 'Initials': 'LP', 'LastName': 'Rivest', 'Affiliation': 'Department of Mathematics and Statistics, Université Laval, Québec, Canada.'}, {'ForeName': 'France', 'Initials': 'F', 'LastName': 'Légaré', 'Affiliation': ""Centre de recherche sur les soins et les services de première ligne de l'Université Laval, Québec, Canada.""}]",The Gerontologist,['10.1093/geront/gnz045'] 739,31734761,Split-face comparison of the picosecond 1064-nm Nd:YAG laser using a microlens array and the quasi-long-pulsed 1064-nm Nd:YAG laser for treatment of photoaging facial wrinkles and pores in Asians.,"Skin photoaging manifests deeper wrinkles and larger pore size. Various lasers have been tried for rejuvenation of photoaging skin, and the quasi-long-pulsed 1064-nm neodymium:yttrium-aluminum-garnet (Nd:YAG) laser is one promising treatment option. New types of laser device are emerging, including devices operating with picosecond pulse duration combined with a microlens array, which are regarded as a new breakthrough for skin rejuvenation. We aimed to evaluate the clinical effectiveness and safety of the picosecond 1064-nm Nd:YAG laser using a microlens array compared with the quasi-long-pulsed 1064-nm Nd:YAG laser in a split-face design. We designed a split-faced, prospective study and enrolled 25 subjects with photoaging facial wrinkles and enlarged pores. Each facial area was randomly assigned to undergo treatment with either the picosecond 1064-nm Nd:YAG laser (Pico-arm) or the quasi-long-pulsed 1064-nm Nd:YAG laser (Quasi-arm). We performed five laser sessions at 2-week intervals, and final results were assessed after 20 weeks after the initial laser session. We used a five-point global assessment scale, wrinkle and pore index derived from 3D camera analysis. We enrolled a total of 25 subjects (24 females and 1 male) with Fitzpatrick skin types III to IV and a mean age of 63.8 ± 5.7 years. After treatment, 54.2% of subjects in the Pico-arm reported at least moderate improvement in visible pores compared with 41.7% of the Quasi-arm (P = 0.001). A total of 12.5% of subjects in the Pico-arm showed moderate improvement in wrinkles versus 4.2% of the Quasi-arm (P = 0.125). There was a 41.3% reduction in the pore index in the Pico-arm compared to a 3.9% increase in the Quasi-arm (P = 0.048). There was a 16.4% reduction in the wrinkle index in the Pico-arm compared with a 0.5% reduction in the Quasi-arm (P = 0.01). Pain assessment score was higher in the Pico-arm than the Quasi-arm (3.65 ± 1.70 vs 1.28 ± 1.28, P = 0.001). No serious adverse events occurred during the study. Our findings suggest that the picosecond 1064-nm Nd:YAG laser with a microlens array is as effective as the quasi-long-pulsed 1064-nm Nd:YAG laser for treatment of photoaging wrinkles and pores.",2020,There was a 16.4% reduction in the wrinkle index in the Pico-arm compared with a 0.5% reduction in the Quasi-arm (P = 0.01).,"['enrolled 25 subjects with photoaging facial wrinkles and enlarged pores', 'photoaging facial wrinkles and pores in Asians', '25 subjects (24 females and 1 male) with Fitzpatrick skin types III to IV and a mean age of 63.8 ± 5.7 years']","['Nd:YAG laser (Pico-arm) or the quasi-long-pulsed 1064-nm', 'neodymium:yttrium-aluminum-garnet', 'YAG laser', 'picosecond 1064-nm Nd:YAG laser using a microlens array compared with the quasi-long-pulsed 1064-nm Nd:YAG laser', 'picosecond 1064-nm Nd:YAG laser using a microlens array and the quasi-long-pulsed 1064-nm', 'Nd:YAG laser', 'Nd:YAG']","['visible pores', 'Pain assessment score', 'moderate improvement in wrinkles', 'pore index', 'wrinkle index', 'serious adverse events']","[{'cui': 'C0263415', 'cui_str': 'Solar degeneration (disorder)'}, {'cui': 'C0262478', 'cui_str': 'Wrinkled face (finding)'}, {'cui': 'C0442800', 'cui_str': 'Enlarged (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0441731', 'cui_str': 'Type 3 (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517795', 'cui_str': 'Five point seven'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0587723', 'cui_str': 'Lasers, Yttrium Aluminum Garnet'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0027599', 'cui_str': 'Neodymium'}, {'cui': 'C1609285', 'cui_str': 'yttrium-aluminum-garnet'}]","[{'cui': 'C0205379', 'cui_str': 'Visible (qualifier value)'}, {'cui': 'C0030198', 'cui_str': 'Nociception Tests'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0037301', 'cui_str': 'Skin Wrinkling'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",25.0,0.0200192,There was a 16.4% reduction in the wrinkle index in the Pico-arm compared with a 0.5% reduction in the Quasi-arm (P = 0.01).,"[{'ForeName': 'Sunmin', 'Initials': 'S', 'LastName': 'Yim', 'Affiliation': 'Department of Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 03181, 29 Saemunan-ro, Jongno-gu, Seoul, Republic of Korea.'}, {'ForeName': 'Yun Ho', 'Initials': 'YH', 'LastName': 'Lee', 'Affiliation': 'Department of Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 03181, 29 Saemunan-ro, Jongno-gu, Seoul, Republic of Korea.'}, {'ForeName': 'Young-Jun', 'Initials': 'YJ', 'LastName': 'Choi', 'Affiliation': 'Department of Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 03181, 29 Saemunan-ro, Jongno-gu, Seoul, Republic of Korea.'}, {'ForeName': 'Won-Serk', 'Initials': 'WS', 'LastName': 'Kim', 'Affiliation': 'Department of Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 03181, 29 Saemunan-ro, Jongno-gu, Seoul, Republic of Korea. susini@naver.com.'}]",Lasers in medical science,['10.1007/s10103-019-02906-1'] 740,21257977,Presurgical stress management improves postoperative immune function in men with prostate cancer undergoing radical prostatectomy.,"OBJECTIVE To assess whether stress management (SM) improved immune outcomes in men undergoing surgery for prostate cancer. METHODS A total of 159 men were assigned randomly to a two-session presurgical SM intervention, a two-session supportive attention (SA) group, or a standard care (SC) group. Men in the SM group discussed their concerns about the upcoming surgery and were taught diaphragmatic breathing, guided imagery; they had an imaginal exposure to the day of surgery and learned adaptive coping skills. Men in the SA group discussed their concerns about the upcoming surgery and had a semistructured medical interview. Blood samples were collected at baseline (1 month before surgery) and 48 hours after surgery. Measures of mood (Profile of Mood States) were collected at baseline, 1 week pre surgery, and the morning of surgery. RESULTS Men in the SM group had significantly higher levels of natural killer cell cytotoxicity (p = .04) and higher levels of circulating proinflammatory cytokines (interleukin [IL]-12p70, p = .02; IL-1β, p = .02; tumor necrosis factor-α, p = .05) 48 hours post surgery than men in the SA group and higher levels of natural killer cell cytotoxicity (p = 0.02) and IL-1β (p = .05) than men in the SC group. Immune parameters increased for the SM group and decreased or stayed the same for the SA and SC groups. The SM group had significantly lower Profile of Mood States scores than the SC group (p = .006), with no other group differences between SA and SC groups. Changes in mood were not associated with immune outcomes. CONCLUSIONS The finding that SM leads to decreased presurgical mood-disturbance and increased immune parameters after surgery reveals the potential psychological and biological benefits of presurgical SM.",2011,"Men in the SM group had significantly higher levels of natural killer cell cytotoxicity (p = .04) and higher levels of circulating proinflammatory cytokines (interleukin [IL]-12p70,","['men with prostate cancer undergoing radical prostatectomy', 'men undergoing surgery for prostate cancer', 'A total of 159 men']","['Presurgical stress management', 'session presurgical SM intervention, a two-session supportive attention (SA) group, or a standard care (SC', 'stress management (SM']","['Measures of mood (Profile of Mood States', 'IL-1β', 'Blood samples', 'postoperative immune function', 'Mood States scores', 'circulating proinflammatory cytokines (interleukin [IL]-12p70', 'levels of natural killer cell cytotoxicity', 'Immune parameters', 'natural killer cell cytotoxicity']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy (procedure)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]","[{'cui': 'C0150788', 'cui_str': 'Manage stress control'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0451394', 'cui_str': 'Profile of mood states (assessment scale)'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0439662', 'cui_str': 'Immune (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0021764', 'cui_str': 'Interleukins'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0022688', 'cui_str': 'NK Cells'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",159.0,0.0361861,"Men in the SM group had significantly higher levels of natural killer cell cytotoxicity (p = .04) and higher levels of circulating proinflammatory cytokines (interleukin [IL]-12p70,","[{'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Cohen', 'Affiliation': 'Department of Behavioral Science-Unit 1330, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. lcohen@mdanderson.org'}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Parker', 'Affiliation': ''}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Vence', 'Affiliation': ''}, {'ForeName': 'Cheryln', 'Initials': 'C', 'LastName': 'Savary', 'Affiliation': ''}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Kentor', 'Affiliation': ''}, {'ForeName': 'Curtis', 'Initials': 'C', 'LastName': 'Pettaway', 'Affiliation': ''}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Babaian', 'Affiliation': ''}, {'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'Pisters', 'Affiliation': ''}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Miles', 'Affiliation': ''}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Wei', 'Affiliation': ''}, {'ForeName': 'Leslie', 'Initials': 'L', 'LastName': 'Wiltz', 'Affiliation': ''}, {'ForeName': 'Tejal', 'Initials': 'T', 'LastName': 'Patel', 'Affiliation': ''}, {'ForeName': 'Laszlo', 'Initials': 'L', 'LastName': 'Radvanyi', 'Affiliation': ''}]",Psychosomatic medicine,['10.1097/PSY.0b013e31820a1c26'] 741,30859184,The pharmacokinetics of nitrofurantoin in healthy female volunteers: a randomized crossover study.,"BACKGROUND Use of nitrofurantoin has increased significantly since its recent repositioning as a first-line agent for uncomplicated cystitis by multiple guidelines. However, current dosing regimens were developed in an era before robust pharmacokinetic testing and may not be optimal. Furthermore, formulations have been modified over the years. OBJECTIVES To reassess the plasma and urinary pharmacokinetic profile of macrocrystalline nitrofurantoin in two commonly used dosing regimens. METHODS In this open-label, randomized crossover pharmacokinetic trial, 12 healthy adult female volunteers were randomized to receive oral nitrofurantoin 100 mg q8h on days 1 and 2 and, after a washout period, 50 mg q6h on days 30 and 31, or the same dosing schemes in reversed order. Urine and blood were collected at steady state and analysed by UPLC. Pharmacokinetic analysis was performed by WinNonlin. RESULTS Plasma peak concentrations were low (mean 0.33 mg/L, SD 0.08, and 0.69 mg/L, SD 0.35, after 50 and 100 mg, respectively) and dose dependent. The AUC0-24 was higher (6.49 versus 4.43 mg·h/L, P = 0.021) for the 100 mg q8h dosing regimen, but the dose-normalized AUC was similar for the two regimens. In contrast, urinary concentrations were dose independent: increasing the nitrofurantoin dose delayed the time to peak urinary concentration, while steady-state AUC0-24 values remained unchanged (943.49 and 855.95 mg·h/L at 50 mg q6h and 100 mg q8h, respectively). CONCLUSIONS Plasma concentrations were relatively low and dose dependent. The dose-independent urinary concentrations suggest that excretion of nitrofurantoin into the urine is saturable. Pharmacodynamic studies are urgently required to determine the impact of these findings.",2019,"The AUC0-24 was higher (6.49 versus 4.43 mg·h/L, P = 0.021) for the 100 mg q8h dosing regimen, but the dose-normalized AUC was similar for the two regimens.","['healthy female volunteers', '12 healthy adult female volunteers']","['oral nitrofurantoin', 'nitrofurantoin']","['Plasma peak concentrations', 'urinary concentrations', 'Urine and blood']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0028156', 'cui_str': 'Nitrofurantoin'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0232827', 'cui_str': 'Urinary concentration, function (observable entity)'}, {'cui': 'C0042037'}, {'cui': 'C0005768'}]",12.0,0.0491764,"The AUC0-24 was higher (6.49 versus 4.43 mg·h/L, P = 0.021) for the 100 mg q8h dosing regimen, but the dose-normalized AUC was similar for the two regimens.","[{'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Huttner', 'Affiliation': 'Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.'}, {'ForeName': 'Rixt A', 'Initials': 'RA', 'LastName': 'Wijma', 'Affiliation': 'Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Stewardson', 'Affiliation': 'Department of Infectious Disease, Alfred Health and Central Clinical School, Monash University, Melbourne, Australia.'}, {'ForeName': 'Flaminia', 'Initials': 'F', 'LastName': 'Olearo', 'Affiliation': 'Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.'}, {'ForeName': 'Elodie', 'Initials': 'E', 'LastName': 'Von Dach', 'Affiliation': 'Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Harbarth', 'Affiliation': 'Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.'}, {'ForeName': 'Roger J M', 'Initials': 'RJM', 'LastName': 'Brüggemann', 'Affiliation': 'Department of Pharmacy and Center of Expertise in Mycology, Radboud University, Nijmegen, The Netherlands.'}, {'ForeName': 'Johan W', 'Initials': 'JW', 'LastName': 'Mouton', 'Affiliation': 'Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands.'}, {'ForeName': 'Anouk E', 'Initials': 'AE', 'LastName': 'Muller', 'Affiliation': 'Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands.'}]",The Journal of antimicrobial chemotherapy,['10.1093/jac/dkz095'] 742,30260488,Dietary Management of Blood Glucose in Medical Critically Ill Overweight and Obese Patients: An Open-Label Randomized Trial.,"BACKGROUND Enteral nutrition (EN) increases hyperglycemia due to high carbohydrate concentrations while providing insufficient protein. The study tested whether an EN formula with very high-protein- and low-carbohydrate-facilitated glucose control delivered higher protein concentrations within a hypocaloric protocol. METHODS This was a multicenter, randomized, open-label clinical trial with parallel design in overweight/obese mechanically ventilated critically ill patients prescribed 1.5 g protein/kg ideal body weight/day. Patients received either an experimental very high-protein (37%) and low-carbohydrate (29%) or control high-protein (25%) and conventional-carbohydrate (45%) EN formula. RESULTS A prespecified interim analysis was performed after enrollment of 105 patients (52 experimental, 53 control). Protein and energy delivery for controls and experimental groups on days 1-5 were 1.2 ± 0.4 and 1.1 ± 0.3 g/kg ideal body weight/day (P = .83), and 18.2 ± 6.0 and 12.5 ± 3.7 kcals/kg ideal body weight/day (P < .0001), respectively. The combined rate of glucose events outside the range of >110 and ≤150 mg/dL were not different (P = .54, primary endpoint); thereby the trial was terminated. The mean blood glucose for the control and the experimental groups were 138 (-SD 108, +SD 177) and 126 (-SD 99, +SD 160) mg/dL (P = .004), respectively. Mean rate of glucose events >150 mg/dL decreased (Δ = -13%, P = .015), whereas that of 80-110 mg/dL increased (Δ = 14%, P = .0007). Insulin administration decreased 10.9% (95% CI, -22% to 0.1%; P = .048) in the experimental group relative to the controls. Glycemic events ≤80 mg/dL and rescue dextrose use were not different (P = .23 and P = .53). CONCLUSIONS A very high-protein and low-carbohydrate EN formula in a hypocaloric protocol reduces hyperglycemic events and insulin requirements while increasing glycemic events between 80-110 mg/dL.",2019,"Mean rate of glucose events >150 mg/dL decreased (Δ = -13%, P = .015), whereas that of 80-110 mg/dL increased (Δ = 14%, P = .0007).","['Medical Critically Ill Overweight and Obese Patients', 'overweight/obese mechanically ventilated critically ill patients prescribed 1.5 g protein/kg ideal body weight/day']","['EN formula with very high-protein- and low-carbohydrate-facilitated glucose control', 'low-carbohydrate (29%) or control high-protein (25%) and conventional-carbohydrate (45%) EN formula', 'dL', 'Dietary Management of Blood Glucose', 'Enteral nutrition (EN']","['Protein and energy delivery', 'glycemic events', 'mean blood glucose', 'Mean rate of glucose events', 'hyperglycemic events and insulin requirements']","[{'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0010340', 'cui_str': 'Critically Ill'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0530867', 'cui_str': 'G13 Protein'}, {'cui': 'C0421272', 'cui_str': 'Normal Body Weight'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]","[{'cui': 'C0442804', 'cui_str': 'Very high (qualifier value)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0012160', 'cui_str': 'nutritional management'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0086225', 'cui_str': 'Enteral Feeding'}]","[{'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}]",,0.0304656,"Mean rate of glucose events >150 mg/dL decreased (Δ = -13%, P = .015), whereas that of 80-110 mg/dL increased (Δ = 14%, P = .0007).","[{'ForeName': 'Todd W', 'Initials': 'TW', 'LastName': 'Rice', 'Affiliation': 'Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'D Clark', 'Initials': 'DC', 'LastName': 'Files', 'Affiliation': 'Department of Internal Medicine-Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Peter E', 'Initials': 'PE', 'LastName': 'Morris', 'Affiliation': 'University of Kentucky Healthcare, Lexington, Kentucky, USA.'}, {'ForeName': 'Andrew C', 'Initials': 'AC', 'LastName': 'Bernard', 'Affiliation': 'University of Kentucky Healthcare, Lexington, Kentucky, USA.'}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Ziegler', 'Affiliation': 'Division of Endocrinology, Metabolism and Lipids, Emory University, Atlanta, Georgia, USA.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Drover', 'Affiliation': ""Department of Critical Care Medicine, Queen's University and Kingston Health Science Center, Kingston, Ontario, Canada.""}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Kress', 'Affiliation': 'The University of Chicago Medicine, Chicago, Illinois, USA.'}, {'ForeName': 'Kealy R', 'Initials': 'KR', 'LastName': 'Ham', 'Affiliation': 'Department of Critical Care Medicine, Regions Hospital, University of Minnesota, St. Paul, Minnesota, USA.'}, {'ForeName': 'Dominik J', 'Initials': 'DJ', 'LastName': 'Grathwohl', 'Affiliation': 'Nestlé Research Center, Vers-chez-les-Blanc, Lausanne, Switzerland.'}, {'ForeName': 'Maureen B', 'Initials': 'MB', 'LastName': 'Huhmann', 'Affiliation': 'Nestlé Health Science, Bridgewater, New Jersey, USA.'}, {'ForeName': 'Juan B Ochoa', 'Initials': 'JBO', 'LastName': 'Gautier', 'Affiliation': 'Nestlé Health Science, Bridgewater, New Jersey, USA.'}]",JPEN. Journal of parenteral and enteral nutrition,['10.1002/jpen.1447'] 743,31742796,Changes in Coping and Negative Cognitions as Mechanisms of Change in Online Treatment for Rape-Related Posttraumatic Stress Disorder.,"Cognitive behavioral therapy (CBT)-based interventions, including those administered via telepsychology, represent efficacious posttraumatic stress disorder (PTSD) treatments. Despite demonstrated efficacy, limited research has examined mechanisms of change for CBT. We examined trauma-related cognitions and coping as treatment mechanisms among 46 women who completed a randomized clinical trial of a CBT-based, telepsychology-delivered interactive program for rape survivors. The results indicated that both the interactive program, d = 1.5, and the active control condition, a psychoeducational website, d = 1.4, resulted in large reductions in posttest PTSD symptoms. Analysis of residual gain scores showed that reductions in the three types of assessed trauma-related cognitions were strongly related to reductions in PTSD symptoms among women assigned to the interactive program, rs = .60-.79, but only weakly related to symptom reduction among those assigned to active control, rs = .06-.31. The results also suggest that increases in trauma-related approach coping were weakly related to reductions in PTSD symptoms among participants in the interactive program, rs = -.16 and -.17, but, conversely, decreases in trauma-related approach coping were weakly related to reductions in PTSD symptoms among those in the active control group, rs = .07 and .28. Reductions in avoidance coping were modestly related to reductions in PTSD symptoms among women in the interactive program, rs = .38 and .38, but unrelated to changes in PTSD symptoms among those assigned to the active control, rs = .03 and .05. Implications for future work examining mechanisms of change for PTSD treatments are discussed.",2019,"Reductions in avoidance coping were modestly related to reductions in PTSD symptoms among women in the interactive program, rs = .38 and .38, but unrelated to changes in PTSD symptoms among those assigned to the active control, rs = .03 and .05.",['46 women who completed a randomized clinical trial of a'],"['CBT-based, telepsychology-delivered interactive program', 'Cognitive behavioral therapy (CBT)-based interventions']","['trauma-related approach coping', 'PTSD symptoms']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}]","[{'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]","[{'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",46.0,0.0150497,"Reductions in avoidance coping were modestly related to reductions in PTSD symptoms among women in the interactive program, rs = .38 and .38, but unrelated to changes in PTSD symptoms among those assigned to the active control, rs = .03 and .05.","[{'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Littleton', 'Affiliation': 'Department of Psychology, East Carolina University, Greenville, North Carolina, USA.'}, {'ForeName': 'Amie', 'Initials': 'A', 'LastName': 'Grills', 'Affiliation': 'School of Education, Boston University, Boston, Massachusetts, USA.'}]",Journal of traumatic stress,['10.1002/jts.22447'] 744,31004732,Effects of moderate mountain hiking and balneotherapy on community-dwelling older people: A randomized controlled trial.,"BACKGROUND Population aging is one of the greatest socio-economic challenges of the 21st century, as aging is a well-known risk factor for the development of chronic diseases and functional disabilities. A sedentary life-style promotes the progression of chronic diseases and impaired mobility in older people. Therefore, physical activity is essential for healthy aging. The optimal exercise program for older persons, which covers fall prevention as well as endurance and strength, still remains unclear. METHODS We performed a longitudinal, randomized, controlled intervention study to investigate the combined effects of moderate mountain hiking and balneotherapy on gait, balance, body composition and quality of life on high-functioning people aged 65-85 years. The intervention group (n = 106) participated in a seven-day holiday with mountain hiking tours. In addition, balneotherapy was applied. The control group (n = 33) spent a typical seven-day cultural holiday with sightseeing. Medical examinations were performed before (day 0) and after the intervention week (day 7), after two months (day 60) and after half a year (day 180). Statistical analysis was done by fully nonparametric analysis of variance-type testing. RESULTS An improvement of static balance was observed in the intervention group (treatment effect p = 0.02). No significant changes were found in dynamic balance, measured as center of pressure, gait parameters and self-assessed balance confidence. Only for gait speed, a short-term effect was observed (treatment p = 0.03). The gait speed increased in the intervention group. Although quality of life improved significantly in both groups, a sustainable effect until day 60 is only visible in the intervention group (interaction effect for treatment and day-60 p = 0.02). Significant interaction effects of treatment and time were found for total body water (p = 0.04), appendicular muscle mass (p = 0.04) and fat free mass index (p = 0.03), all indicating an increase of these variables in the intervention group. CONCLUSIONS A seven-day intervention with moderate mountain hiking in combination with balneotherapy is an effective training for highly functioning older persons, inducing short-term improvements in static balance and quality of life.",2019,"Although quality of life improved significantly in both groups, a sustainable effect until day 60 is only visible in the intervention group (interaction effect for treatment and day-60 p = 0.02).","['older people', 'highly functioning older persons', 'older persons', 'community-dwelling older people', 'high-functioning people aged 65-85\u202fyears']","['balneotherapy', 'seven-day holiday with mountain hiking tours', 'moderate mountain hiking and balneotherapy']","['static balance and quality of life', 'total body water', 'gait speed', 'dynamic balance, measured as center of pressure, gait parameters and self-assessed balance confidence', 'appendicular muscle mass', 'quality of life', 'static balance', 'gait, balance, body composition and quality of life']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0085867', 'cui_str': 'Balneotherapy'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0019843', 'cui_str': 'Holidays'}, {'cui': 'C0442533', 'cui_str': 'Mountain (environment)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}]","[{'cui': 'C0441463', 'cui_str': 'Static (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0034380'}, {'cui': 'C0429632', 'cui_str': 'Total body water (observable entity)'}, {'cui': 'C2009910', 'cui_str': 'Gait Speed'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle (finding)'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}]",,0.0413914,"Although quality of life improved significantly in both groups, a sustainable effect until day 60 is only visible in the intervention group (interaction effect for treatment and day-60 p = 0.02).","[{'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Prossegger', 'Affiliation': 'Institute of Ecomedicine, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Huber', 'Affiliation': 'Institute of Ecomedicine, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria; Department of Physiotherapy, Salzburg University of Applied Sciences, 5412 Puch/Urstein, Austria.'}, {'ForeName': 'Carina', 'Initials': 'C', 'LastName': 'Grafetstätter', 'Affiliation': 'Institute of Ecomedicine, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Pichler', 'Affiliation': 'Institute of Ecomedicine, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Renate', 'Initials': 'R', 'LastName': 'Weisböck-Erdheim', 'Affiliation': 'Institute of Ecomedicine, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Iglseder', 'Affiliation': 'Department of Geriatric Medicine, Salzburger Landeskliniken Betriebs-GesmbH, Christian-Doppler-Klinik, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Gerti', 'Initials': 'G', 'LastName': 'Wewerka', 'Affiliation': 'Department of Geriatric Medicine, Salzburger Landeskliniken Betriebs-GesmbH, Christian-Doppler-Klinik, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Arnulf', 'Initials': 'A', 'LastName': 'Hartl', 'Affiliation': 'Institute of Ecomedicine, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria. Electronic address: arnulf.hartl@pmu.ac.at.'}]",Experimental gerontology,['10.1016/j.exger.2019.04.006'] 745,31475696,Assessment of craniofacial hyperhidrosis and flushing by sphenopalatine blockade - a randomized trial.,"BACKGROUND Craniofacial hyperhidrosis (CFH) and flushing express nervous system autonomic dysfunction. Available reference treatments lack good compliance. The study objective was to investigate variations of CFH/flushing after two methods of sphenopalatine ganglion (SPG) blockade. METHODOLOGY CFH patients (n=25) were randomized in a ratio of 1:3 in two groups; 1) endoscopic application of topical lidocaine over SPG (TL; n=7); 2) endoscopic injection of lidocaine in the SPG (IL; n=18). CFH, flushing, rhinorrhoea, nasal obstruction, and smell detection were scored by Visual Analogue Scale (VAS). Nasal endoscopy, acoustic rhinometry, mucociliary transport test, smell/taste test, Schirmer test, Short Form-12, Chronic Skin Diseases Questionnaire, and Skin Satisfaction Questionnaire were also performed at visit 0, 1, 3 and 6 months. RESULTS At baseline, groups reported similar CFH VAS (TL: 89.3 plus or minus 17.5mm; IL: 85.7 plus or minus 22.1mm) or flushing VAS (TL: 52.7 plus or minus 30mm; IL: 59 plus or minus 33.8mm). After 6 months, the least squares mean of CFH VAS in IL was -38.1 (-47.3 to -28.9) compared to TL 1.9 (-12.2 to 15.9). However, flushing VAS did not improve. Any rhinological measure nor quality of life test showed significant changes. One patient presented controlled epistaxis intraoperatively during IL. CONCLUSIONS This preliminary study shows the sphenopalatine blockade injection as a safe procedure. Patients with CFH or flushing had significant improvement after lidocaine injection which lasted 6 months. Due to the small sample and the lack of objective measures more studies are needed.",2020,Any rhinological measure nor quality of life test showed significant changes.,['CFH patients (n=25'],"['sphenopalatine blockade injection', 'sphenopalatine ganglion (SPG) blockade', 'lidocaine', 'endoscopic application of topical lidocaine over SPG (TL; n=7); 2) endoscopic injection of lidocaine']","['quality of life test', 'CFH, flushing, rhinorrhoea, nasal obstruction, and smell detection', 'Nasal endoscopy, acoustic rhinometry, mucociliary transport test, smell/taste test, Schirmer test, Short Form-12, Chronic Skin Diseases Questionnaire, and Skin Satisfaction Questionnaire', 'Visual Analogue Scale (VAS', 'CFH VAS in IL']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C3540676', 'cui_str': 'Blockade'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0229062', 'cui_str': 'Pterygopalatine Ganglia'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}]","[{'cui': 'C0034380'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0016382', 'cui_str': 'Flushing'}, {'cui': 'C1260880', 'cui_str': 'Nasal catarrh'}, {'cui': 'C0027429', 'cui_str': 'Nasal Airway Obstruction'}, {'cui': 'C0998863', 'cui_str': 'Osmeridae'}, {'cui': 'C0189024', 'cui_str': 'Endoscopy of nose (procedure)'}, {'cui': 'C0430619', 'cui_str': 'Rhinometry, Acoustic'}, {'cui': 'C0026687', 'cui_str': 'Mucociliary Transport'}, {'cui': 'C0039336', 'cui_str': 'Gustation'}, {'cui': 'C0200152', 'cui_str': ""Schirmer's test (procedure)""}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C1290009', 'cui_str': 'Chronic disease of skin'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",,0.0595086,Any rhinological measure nor quality of life test showed significant changes.,"[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Lehrer', 'Affiliation': 'Rhinology and Skull Base Unit, Department of Otorhinolaryngology, Hospital Clinic, Universitat de Barcelona, Barcelona, Catalonia, Spain; Institut d Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Nogues', 'Affiliation': 'Rhinology and Skull Base Unit, Department of Otorhinolaryngology, Hospital Clinic, Universitat de Barcelona, Barcelona, Catalonia, Spain; Institut d Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Jaume', 'Affiliation': 'Department of Otorhinolaryngology, Hospital Comarcal d’Inca, Mallorca, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Mullol', 'Affiliation': 'Rhinology and Skull Base Unit, Department of Otorhinolaryngology, Hospital Clinic, Universitat de Barcelona, Barcelona, Catalonia, Spain; Institut d Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Barcelona, Catalonia, Spain.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Alobid', 'Affiliation': 'Rhinology and Skull Base Unit, Department of Otorhinolaryngology, Hospital Clinic, Universitat de Barcelona, Barcelona, Catalonia, Spain; Institut d Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Barcelona, Catalonia, Spain; Unidad Alergo Rino, Centro Medico Teknon, Barcelona, Catalonia, Spain.'}]",Rhinology,['10.4193/Rhin19.119'] 746,31024092,Effects of full-fat dairy products on subclinical vascular function in adults with elevated blood pressure: a randomized clinical trial.,"BACKGROUND High consumption of low- and non-fat dairy products improves vascular dysfunction associated with elevated arterial blood pressure (BP). Currently, it is unknown if conventional full-fat dairy products improve vascular functions. OBJECTIVES To determine if adding whole milk and full-fat dairy products to the normal routine diet improves vascular function in adults with elevated BP. DESIGN Sixty adults (age ± SEM; 58 ± 2 years) with elevated BP (systolic/diastolic; 120-159/ < 99 mmHg) were randomized into a controlled crossover intervention trial consisting of two 4-week dietary periods. The high dairy condition consisted of adding four daily servings of whole milk or full-fat dairy products to the normal diet and eliminated all dairy intake during the control (no dairy) condition. A 2-week washout period separated the dietary conditions. RESULTS Carotid-femoral pulse wave velocity (cfPWV) did not differ significantly between high dairy (11.3 ± 0.3 versus 10.9 ± 0.3 m/sec) and no dairy conditions (11.2 ± 0.3 versus 11.0 ± 0.3 m/sec). The results were consistent when ultrasound-derived vascular distension measures (arterial compliance, beta-stiffness index, and elastic modulus) were evaluated. Cardiovagal baroreceptor sensitivity (via Valsalva maneuver) demonstrated no significant difference for either dietary condition. Brachial arterial flow-mediated dilation (FMD) did not differ significantly during the high dairy (5.7 ± 0.5 versus 5.4 ± 0.6%) and no dairy conditions (6.5 ± 0.5 versus 5.6 ± 0.6%). CONCLUSIONS The solitary addition of whole milk and full-fat dairy products has no effect on subclinical vascular function in adults with elevated BP.",2020,"RESULTS Carotid-femoral pulse wave velocity (cfPWV) did not differ significantly between high dairy (11.3 ± 0.3 versus 10.9 ± 0.3 m/sec) and no dairy conditions (11.2 ± 0.3 versus 11.0 ± 0.3 m/sec).","['adults with elevated BP', 'adults with elevated BP.\nDESIGN\n\n\nSixty adults (age\u2009±\u2009SEM; 58\u2009±\u20092 years) with elevated BP (systolic/diastolic; 120-159/\u2009<\u200999\u2009mmHg', 'adults with elevated blood pressure']","['whole milk and full-fat dairy products to the normal routine diet', 'full-fat dairy products']","['Cardiovagal baroreceptor sensitivity', 'Carotid-femoral pulse wave velocity (cfPWV', 'arterial blood pressure (BP', 'Brachial arterial flow-mediated dilation (FMD', 'ultrasound-derived vascular distension measures (arterial compliance, beta-stiffness index, and elastic modulus', 'vascular function', 'subclinical vascular function']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497247', 'cui_str': 'Finding of increased blood pressure (finding)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0439475', 'cui_str': 'torr (qualifier value)'}]","[{'cui': 'C0452717', 'cui_str': 'Whole milk (substance)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0010947', 'cui_str': 'Dairy Products'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}]","[{'cui': 'C0033093', 'cui_str': 'Stretch Receptors, Arterial'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0232148', 'cui_str': 'Femoral pulse, function (observable entity)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C1272641', 'cui_str': 'Arterial Tension'}, {'cui': 'C0445456', 'cui_str': 'Brachial (qualifier value)'}, {'cui': 'C0429856', 'cui_str': 'Arterial flow (observable entity)'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C3714614', 'cui_str': 'Distention'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0427008', 'cui_str': 'Stiffness (finding)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C2350289', 'cui_str': 'Young Modulus'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0205211', 'cui_str': 'Subclinical (qualifier value)'}]",60.0,0.125608,"RESULTS Carotid-femoral pulse wave velocity (cfPWV) did not differ significantly between high dairy (11.3 ± 0.3 versus 10.9 ± 0.3 m/sec) and no dairy conditions (11.2 ± 0.3 versus 11.0 ± 0.3 m/sec).","[{'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Roy', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Brandon G', 'Initials': 'BG', 'LastName': 'Fico', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Brett D', 'Initials': 'BD', 'LastName': 'Baker', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Stephanie S', 'Initials': 'SS', 'LastName': 'Lapierre', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Jay A', 'Initials': 'JA', 'LastName': 'Shah', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Drew D', 'Initials': 'DD', 'LastName': 'Gourley', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Delfausse', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Hirofumi', 'Initials': 'H', 'LastName': 'Tanaka', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA. htanaka@austin.utexas.edu.'}]",European journal of clinical nutrition,['10.1038/s41430-019-0435-8'] 747,31030644,Efficacy of using non-linear pedagogy to support attacking players' individual learning objectives in elite-youth football: A randomised cross-over trial.,"The present study examined the efficacy of a coaching curriculum, based on non-linear pedagogy, on improving attacking players' individual learning objectives (ILOs) in elite-youth football. Participants included 22 attacking players (i.e., centre-forwards, wide-players and attacking midfield players) from a professional football academy in England. The players were randomly appointed to both control (CON) and intervention (INT) periods following baseline measures. The INT (non-linear) and CON (linear) periods were both designed to support the ILOs provided to each player as part of the elite player performance plan. The study adopted a randomised cross-over design and ILOs considered important for attacking players (i.e., strong foot finishing, weak foot finishing, 1-v-1 and decision-making) were evaluated using the Loughborough Shooting Skill Test. The results showed significant differences for INT in 1-v-1 ( P < 0.02) and decision-making ( P < 0.01). However, there were no significant differences for strong foot finishing, weak foot finishing or time taken. These results support non-linear pedagogy in developing 1-v-1 game play and decision-making but not for technical shooting proficiency.",2020,The results showed significant differences for INT in 1-v-1 (P< 0.02) and decision-making (P< 0.01).,"['elite-youth football', 'Participants included 22 attacking players (i.e., centre-forwards, wide-players and attacking midfield players) from a professional football academy in England']",['coaching curriculum'],[],"[{'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0336986', 'cui_str': 'Football'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1304680', 'cui_str': 'Attack (finding)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0000876', 'cui_str': 'Academies'}, {'cui': 'C0014282', 'cui_str': 'England'}]","[{'cui': 'C0557773', 'cui_str': 'Coach (physical object)'}, {'cui': 'C0220815', 'cui_str': 'curriculum'}]",[],22.0,0.0146472,The results showed significant differences for INT in 1-v-1 (P< 0.02) and decision-making (P< 0.01).,"[{'ForeName': 'Simon J', 'Initials': 'SJ', 'LastName': 'Roberts', 'Affiliation': 'School of Sport Studies, Leisure and Nutrition, Liverpool John Moores University , Liverpool, UK.'}, {'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Rudd', 'Affiliation': 'School of Sport Studies, Leisure and Nutrition, Liverpool John Moores University , Liverpool, UK.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Reeves', 'Affiliation': 'Institute of Coaching and Performance (ICaP), Faculty of Sport, Health and Wellbeing, University of Central Lancashire , Preston, UK.'}]",Journal of sports sciences,['10.1080/02640414.2019.1609894'] 748,30991255,The gut-brain relationship: Investigating the effect of multispecies probiotics on anxiety in a randomized placebo-controlled trial of healthy young adults.,"INTRO There has been an increased interest in understanding the therapeutic effect of gut-microbiota on health, particularly in mental health. However, limited research into the connection between gut-microbiota and mental health makes this study an important endeavor in exploring the effect of gut-microbiota, through probiotics intervention, on mental health like anxiety and factors related to anxiety (e.g., anxiety control, affect, negative mood regulation, and worry). METHOD Healthy college students (N = 86; 75.6% female), average age of 20.59, participated in a double-blind, placebo-control, and randomization-control study. Eligible participants completed a baseline survey before being assigned to a condition, which consisted of four probiotics conditions and one placebo condition. After 28 days of daily intake, the participants returned to complete their exit survey. RESULT Probiotics were observed to improve panic anxiety, neurophysiological anxiety, negative affect, worry, and increase negative mood regulation. Furthermore, post hoc analyses revealed that the CFU (colony-forming unit) level was more effective than species counts in accounting for the number of significant improvements. A ceiling effect was detected in the study, participants with high distress reported higher number of improvements than those with normative distress. CONCLUSION Overall, this study is the first to examine the effect of CFU and species count on probiotics' efficacy. The study's finding suggested that probiotics may have the therapeutic potential to treat anxiety, however, further research is necessary to make that determination.",2019,"Probiotics were observed to improve panic anxiety, neurophysiological anxiety, negative affect, worry, and increase negative mood regulation.","['Healthy college students', 'healthy young adults', 'N\xa0=\xa086; 75.6% female), average age of 20.59, participated in a double-blind, placebo-control, and randomization-control study']","['multispecies probiotics', 'placebo condition', 'placebo']","['panic anxiety, neurophysiological anxiety, negative affect, worry, and increase negative mood regulation']","[{'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotics'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0030318', 'cui_str': 'Panic'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C0233481', 'cui_str': 'Worried (finding)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0220905', 'cui_str': 'regulations'}]",,0.113799,"Probiotics were observed to improve panic anxiety, neurophysiological anxiety, negative affect, worry, and increase negative mood regulation.","[{'ForeName': 'Nhan', 'Initials': 'N', 'LastName': 'Tran', 'Affiliation': 'Department of Psychology, Houston Baptist University, 7502 Fondren Rd, Houston, TX 77074, United States. Electronic address: nhan.tran@utexas.edu.'}, {'ForeName': 'Masha', 'Initials': 'M', 'LastName': 'Zhebrak', 'Affiliation': 'Department of Psychology, Houston Baptist University, 7502 Fondren Rd, Houston, TX 77074, United States.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Yacoub', 'Affiliation': 'Department of Psychology, Houston Baptist University, 7502 Fondren Rd, Houston, TX 77074, United States.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Pelletier', 'Affiliation': 'Department of Psychology, Houston Baptist University, 7502 Fondren Rd, Houston, TX 77074, United States. Electronic address: jpelletier@hbu.edu.'}, {'ForeName': 'Darby', 'Initials': 'D', 'LastName': 'Hawley', 'Affiliation': 'Department of Psychology, Houston Baptist University, 7502 Fondren Rd, Houston, TX 77074, United States.'}]",Journal of affective disorders,['10.1016/j.jad.2019.04.043'] 749,32407327,How much is enough? Exploring the dose-response relationship between cash transfers and surgical utilization in a resource-poor setting.,"OBJECTIVE Cash transfers are a common intervention to incentivize salutary behavior in resource-constrained settings. Many cash transfer studies do not, however, account for the effect of the size of the cash transfer in design or analysis. A randomized, controlled trial of a cash-transfer intervention is planned to incentivize appropriate surgical utilization in Guinea. The aim of the current study is to determine the size of that cash transfer so as to maximize compliance while minimizing cost. METHODS Data were collected from nine coastal Guinean hospitals on their surgical capabilities and the cost of receiving surgery. These data were combined with publicly available data about the general Guinean population to create an agent-based model predicting surgical utilization. The model was validated to the available literature on surgical utilization. Cash transfer sizes from 0 to 1,000,000 Guinean francs were evaluated, with surgical compliance as the primary outcome. RESULTS Compliance with scheduled surgery increases as the size of a cash transfer increases. This increase is asymptotic, with a leveling in utilization occurring when the cash transfer pays for all the costs associated with surgical care. Below that cash transfer size, no other optima are found. Once a cash transfer completely covers the costs of surgery, other barriers to care such as distance and hospital quality dominate. CONCLUSION Cash transfers to incentivize health-promoting behavior appear to be dose-dependent. Maximal impact is likely only to occur when full patient costs are eliminated. These findings should be incorporated in the design of future cash transfer studies.",2020,"This increase is asymptotic, with a leveling in utilization occurring when the cash transfer pays for all the costs associated with surgical care.","['Data were collected from nine coastal Guinean hospitals on their surgical capabilities and the cost of receiving surgery', 'Guinea']",['cash-transfer intervention'],[],"[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0018381', 'cui_str': 'Guinea Republic'}]","[{'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.0274983,"This increase is asymptotic, with a leveling in utilization occurring when the cash transfer pays for all the costs associated with surgical care.","[{'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Strader', 'Affiliation': 'Program in Global Surgery and Social Change, Harvard Medical School, Boston, MA, United States of America.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Ashby', 'Affiliation': 'Program in Global Surgery and Social Change, Harvard Medical School, Boston, MA, United States of America.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Vervoort', 'Affiliation': 'Program in Global Surgery and Social Change, Harvard Medical School, Boston, MA, United States of America.'}, {'ForeName': 'Aref', 'Initials': 'A', 'LastName': 'Ebrahimi', 'Affiliation': 'Joslin Diabetes Center, Harvard Medical School, Boston, MA, United States of America.'}, {'ForeName': 'Shoghi', 'Initials': 'S', 'LastName': 'Agbortoko', 'Affiliation': 'Harvard College, Cambridge, MA, United States of America.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Lee', 'Affiliation': 'Harvard College, Cambridge, MA, United States of America.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Reiner', 'Affiliation': 'Harvard Graduate School of Education, Cambridge, MA, United States of America.'}, {'ForeName': 'Molly', 'Initials': 'M', 'LastName': 'Zeme', 'Affiliation': 'Harvard College, Cambridge, MA, United States of America.'}, {'ForeName': 'Mark G', 'Initials': 'MG', 'LastName': 'Shrime', 'Affiliation': 'Program in Global Surgery and Social Change, Harvard Medical School, Boston, MA, United States of America.'}]",PloS one,['10.1371/journal.pone.0232761'] 750,2473995,Clinical impact of rapid identification and susceptibility testing of bacterial blood culture isolates.,"Two hundred twenty-six patients with bacteremia were prospectively enrolled in a randomized trial that was performed to determine the clinical impact of the receipt of in vitro microbiological data by the physician soon after organism detection as opposed to having the physicians wait until similar data were available by routine methods. Identification and antibiotic susceptibility patterns of 110 isolates were determined by direct inoculation of the Vitek AutoMicrobic system (Vitek Systems, Inc., Hazelwood, Mo.) with a sample from a positive blood culture vial. One hundred sixteen isolates were processed by routine methods. Microbiological results were available within an average of 8.8 h by the direct method versus an average of 48 h by the routine method. In both groups an infectious disease fellow used the information to make therapeutic recommendations to the responsible physician. When compared with that provided by the routine method, the information provided by the direct method was significantly more likely to result in an initiation of antibiotic therapy, a change to more effective therapy, or a change to less expensive therapy. Recommendations were significantly more likely to be followed in patients whose isolates were processed by the direct method versus the routine method. A projected savings of $158 per patient was estimated for the patients who were changed to less expensive therapy or in whom antibiotics were discontinued because results were available sooner. These cost savings, coupled with changes in therapy made for reasons of efficacy, support the usefulness of the earlier reporting of the identity and antibiotic susceptibility patterns of bacterial blood culture isolates.",1989,Microbiological results were available within an average of 8.8 h by the direct method versus an average of 48 h by the routine method.,"['Two hundred twenty-six patients with bacteremia', 'One hundred sixteen isolates were processed by routine methods']",[],['cost savings'],"[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C4521054', 'cui_str': 'Process (qualifier value)'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}]",[],"[{'cui': 'C0085550', 'cui_str': 'Saving, Cost'}]",226.0,0.020065,Microbiological results were available within an average of 8.8 h by the direct method versus an average of 48 h by the routine method.,"[{'ForeName': 'G M', 'Initials': 'GM', 'LastName': 'Trenholme', 'Affiliation': ""Department of Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612.""}, {'ForeName': 'R L', 'Initials': 'RL', 'LastName': 'Kaplan', 'Affiliation': ''}, {'ForeName': 'P H', 'Initials': 'PH', 'LastName': 'Karakusis', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Stine', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Fuhrer', 'Affiliation': ''}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Landau', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Levin', 'Affiliation': ''}]",Journal of clinical microbiology,[] 751,30408848,Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.,"INTRODUCTION Concizumab enhances thrombin generation (TG) potential in haemophilia patients by inhibiting tissue factor pathway inhibitor (TFPI). In EXPLORER3 (phase 1b), a dose-dependent pharmacokinetic/pharmacodynamic (PK/PD) relationship was confirmed between concizumab dose, free TFPI and TG potential. AIM Determine the association between concizumab exposure, PD markers (free TFPI; peak TG) and bleeding episodes to establish the minimum concizumab concentration for achieving sufficient efficacy. METHODS Free TFPI predictions were generated using an estimated concizumab-free TFPI exposure-response (E max ) model based on concizumab phase 1/1b data for which simultaneously collected concizumab and free TFPI samples were available. Concizumab concentration at the time of a bleed was predicted using a PK model, based on available data for concizumab doses >50 μg/kg to ≤9 mg/kg. Peak TG vs concizumab concentration analyses and an E max model were constructed based on EXPLORER3 observations. RESULTS The E max model showed a tight PK/PD relationship between concizumab exposure and free TFPI; free TFPI decreased with increasing concizumab concentration. A strong correlation between concizumab concentration and peak TG was observed; concizumab >100 ng/mL re-established TG potential to within the normal reference range. Estimated EC 50 values for the identified concizumab-free TFPI and concizumab-TG potential models were very similar, supporting free TFPI as an important biomarker. A correlation between bleeding episode frequency and concizumab concentration was indicated; patients with a concizumab concentration >100 ng/mL experienced less frequent bleeding. The PK model predicted that once-daily dosing would minimize within-patient concizumab PK variability. CONCLUSION Concizumab phase 2 trials will target an exposure ≥100 ng/mL, with a once-daily regimen.",2019,Concizumab enhances thrombin generation (TG) potential in haemophilia patients by inhibiting tissue factor pathway inhibitor (TFPI).,"['haemophilia patients', 'patients with haemophilia']",['Concizumab'],"['frequent bleeding', 'Concizumab concentration', 'bleeding episode frequency and concizumab concentration', 'tight PK/PD relationship between concizumab exposure and free TFPI; free TFPI']","[{'cui': 'C1321589', 'cui_str': 'Hemophilia - specialty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C3494079', 'cui_str': 'monoclonal antibody 2021'}]","[{'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}, {'cui': 'C3494079', 'cui_str': 'monoclonal antibody 2021'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0453911', 'cui_str': 'Tights (physical object)'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0164707', 'cui_str': 'TFPI'}]",,0.0266492,Concizumab enhances thrombin generation (TG) potential in haemophilia patients by inhibiting tissue factor pathway inhibitor (TFPI).,"[{'ForeName': 'Hermann', 'Initials': 'H', 'LastName': 'Eichler', 'Affiliation': 'Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and University Hospital, Homburg/Saar, Germany.'}, {'ForeName': 'Pantep', 'Initials': 'P', 'LastName': 'Angchaisuksiri', 'Affiliation': 'Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Kaan', 'Initials': 'K', 'LastName': 'Kavakli', 'Affiliation': ""Department of Hematology, Ege University Children's Hospital, Izmir, Turkey.""}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Knoebl', 'Affiliation': 'Clinical Division of Hematology and Hemostasis, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Jerzy', 'Initials': 'J', 'LastName': 'Windyga', 'Affiliation': 'Department of Disorders of Hemostasis and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Jiménez-Yuste', 'Affiliation': 'Haematology Department, La Paz University Hospital, Madrid, Spain.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Harder Delff', 'Affiliation': 'Novo Nordisk A/S, Copenhagen, Denmark.'}, {'ForeName': 'Pratima', 'Initials': 'P', 'LastName': 'Chowdary', 'Affiliation': 'Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, UK.'}]",Haemophilia : the official journal of the World Federation of Hemophilia,['10.1111/hae.13627'] 752,27352792,Make a Move: A Comprehensive Effect Evaluation of a Sexual Harassment Prevention Program in Dutch Residential Youth Care.,"Sexual harassment-unwanted sexual comments, advances, or behaviors-and sexual violence are still prevalent worldwide, leading to a variety of physical, cognitive, and emotional problems among those being harassed. In particular, youth in care are at risk of becoming perpetrators (and victims) of sexual harassment. However, in general, there are very few interventions targeting this at-risk group, and no such programs exist in the Netherlands. To this end, a group intervention program-Make a Move-targeting determinants of sexual harassment was developed. This program was implemented and evaluated among boys ( N = 177) in Dutch residential youth care (20 institutions). A pre-test, post-test, and 6-month follow-up design including an intervention and a waiting list control group with randomized assignment of institutions (cluster randomized trial) was used to measure the effects of the intervention on determinants of sexual harassment. Multilevel (mixed) regression analysis with Bonferroni correction for multiple testing (α = .005) showed no significant effects of Make a Move on determinants of sexual harassment ( ps > .03, Cohen's ds < .44). Results are discussed in light of a three-way explanatory model focusing on intervention content, evaluation, and implementation as potential explanations for not finding any measurable intervention effects.",2019,"Multilevel (mixed) regression analysis with Bonferroni correction for multiple testing (α = .005) showed no significant effects of Make a Move on determinants of sexual harassment ( ps > .03, Cohen's ds < .44).","['boys ( N = 177) in Dutch residential youth care (20 institutions', 'Dutch Residential Youth Care']",['Sexual Harassment Prevention Program'],['sexual harassment'],"[{'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0013331', 'cui_str': 'Dutch (ethnic group)'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C1272753', 'cui_str': 'Institution'}]","[{'cui': 'C0162790', 'cui_str': 'Sexual Harrassment'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0162790', 'cui_str': 'Sexual Harrassment'}]",177.0,0.0189225,"Multilevel (mixed) regression analysis with Bonferroni correction for multiple testing (α = .005) showed no significant effects of Make a Move on determinants of sexual harassment ( ps > .03, Cohen's ds < .44).","[{'ForeName': 'Sanne', 'Initials': 'S', 'LastName': 'van Lieshout', 'Affiliation': '1 Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Fraukje E F', 'Initials': 'FEF', 'LastName': 'Mevissen', 'Affiliation': '1 Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'van Breukelen', 'Affiliation': '1 Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Jonker', 'Affiliation': '2 Rutgers, Utrecht, The Netherlands.'}, {'ForeName': 'Robert A C', 'Initials': 'RAC', 'LastName': 'Ruiter', 'Affiliation': '1 Maastricht University, Maastricht, The Netherlands.'}]",Journal of interpersonal violence,['10.1177/0886260516654932'] 753,30110194,CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.,"PURPOSE Metastatic esophagogastric cancer treatments after failure of second-line chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junction cancers. We assessed the safety and efficacy of nivolumab and nivolumab plus ipilimumab in Western patients with chemotherapy-refractory esophagogastric cancers. PATIENTS AND METHODS Patients with locally advanced or metastatic chemotherapy-refractory gastric, esophageal, or gastroesophageal junction cancer from centers in the United States and Europe received nivolumab or nivolumab plus ipilimumab. The primary end point was objective response rate. The association of tumor programmed death-ligand 1 status with response and survival was also evaluated. RESULTS Of 160 treated patients (59 with nivolumab 3 mg/kg, 49 with nivolumab 1 mg/kg plus ipilimumab 3 mg/kg, 52 with nivolumab 3 mg/kg plus ipilimumab 1 mg/kg), 79% had received two or more prior therapies. At the data cutoff, investigator-assessed objective response rates were 12% (95% CI, 5% to 23%), 24% (95% CI, 13% to 39%), and 8% (95% CI, 2% to 19%) in the three groups, respectively. Responses were observed regardless of tumor programmed death-ligand 1 status. With a median follow-up of 28, 24, and 22 months across the three groups, 12-month progression-free survival rates were 8%, 17%, and 10%, respectively; 12-month OS rates were 39%, 35%, and 24%, respectively. Treatment-related grade 3/4 adverse events were reported in 17%, 47%, and 27% of patients in the three groups, respectively. CONCLUSION Nivolumab and nivolumab plus ipilimumab demonstrated clinically meaningful antitumor activity, durable responses, encouraging long-term OS, and a manageable safety profile in patients with chemotherapy-refractory esophagogastric cancer. Phase III studies evaluating nivolumab or nivolumab plus ipilimumab in earlier lines of therapy for esophagogastric cancers are underway.",2018,Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junction cancers.,"['patients with chemotherapy-refractory esophagogastric cancer', 'Asian patients with advanced gastric or gastroesophageal junction cancers', 'Western patients with chemotherapy-refractory esophagogastric cancers', 'Patients With Metastatic Esophagogastric Cancer', 'Patients with locally advanced or metastatic chemotherapy-refractory gastric, esophageal, or gastroesophageal junction cancer from centers in the United States and Europe received']","['nivolumab or nivolumab plus ipilimumab', 'placebo', 'ipilimumab', 'Nivolumab and Nivolumab Plus Ipilimumab', 'Nivolumab and nivolumab plus ipilimumab', 'nivolumab and nivolumab plus ipilimumab']","['safety and efficacy', 'grade 3/4 adverse events', '12-month OS rates', 'objective response rate', '12-month progression-free survival rates', 'objective response rates', 'superior overall survival (OS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0475468', 'cui_str': 'Esophagogastric (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C0014871', 'cui_str': 'Gastroesophageal Junction'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0015176', 'cui_str': 'Europe'}]","[{'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0442757', 'cui_str': '3/4'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",160.0,0.144585,Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junction cancers.,"[{'ForeName': 'Yelena Y', 'Initials': 'YY', 'LastName': 'Janjigian', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Bendell', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}, {'ForeName': 'Emiliano', 'Initials': 'E', 'LastName': 'Calvo', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}, {'ForeName': 'Joseph W', 'Initials': 'JW', 'LastName': 'Kim', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}, {'ForeName': 'Paolo A', 'Initials': 'PA', 'LastName': 'Ascierto', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}, {'ForeName': 'Padmanee', 'Initials': 'P', 'LastName': 'Sharma', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}, {'ForeName': 'Patrick A', 'Initials': 'PA', 'LastName': 'Ott', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}, {'ForeName': 'Katriina', 'Initials': 'K', 'LastName': 'Peltola', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Jaeger', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}, {'ForeName': 'Jeffry', 'Initials': 'J', 'LastName': 'Evans', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'de Braud', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Chau', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}, {'ForeName': 'Christopher T', 'Initials': 'CT', 'LastName': 'Harbison', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}, {'ForeName': 'Cecile', 'Initials': 'C', 'LastName': 'Dorange', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Tschaika', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}, {'ForeName': 'Dung T', 'Initials': 'DT', 'LastName': 'Le', 'Affiliation': 'Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.2017.76.6212'] 754,30975923,Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.,"BACKGROUND Seribantumab (MM-121) is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 ( HER3/ErbB3 ) to block heregulin ( HRG/NRG )-mediated ErbB3 signaling and induce receptor downregulation. This open-label, randomized phase 1/2 study evaluated safety and efficacy of seribantumab plus erlotinib in advanced non-small cell lung cancer (NSCLC). Here, we report the activity of seribantumab plus erlotinib, versus erlotinib alone, in patients with EGFR wild-type tumors and describe the potential predictive power of HRG. MATERIALS AND METHODS Patients with EGFR wild-type NSCLC were assigned randomly to receive seribantumab + erlotinib or erlotinib alone. Patients underwent pretreatment core needle biopsy and archived tumor samples were collected to support prespecified biomarker analyses. RESULTS One hundred twenty-nine patients received seribantumab + erlotinib ( n = 85) or erlotinib alone ( n = 44). Median estimated progression-free survival (PFS) in the unselected intent-to-treat (ITT) population was 8.1 and 7.7 weeks in the experimental and control arm, respectively (hazard ratio [HR], 0.822; 95% confidence interval [CI], 0.37-1.828; p = 0.63), and median estimated overall survival was 27.3 and 40.3 weeks in the experimental and control arm, respectively (HR, 1.395; 95% CI, 0.846 to 2.301; p = .1898) In patients whose tumors had detectable HRG mRNA expression, treatment benefit was observed in the seribantumab + erlotinib combination (HR, 0.35; 95% CI, 0.16-0.76; p = .008). In contrast, in patients whose tumors were HRG negative, the HR was 2.15 (95% CI, 0.97-4.76; p = .059, HRG-by-treatment interaction, p value = .0016). CONCLUSION The addition of seribantumab to erlotinib did not result in improved PFS in unselected patients. However, predefined retrospective exploratory analyses suggest that detectable HRG mRNA levels identified patients who might benefit from seribantumab. An ongoing clinical trial of seribantumab, in combination with docetaxel, is underway in patients with advanced NSCLC and high HRG mRNA expression (NCT02387216). IMPLICATIONS FOR PRACTICE The poor prognosis of patients with non-small cell lung cancer (NSCLC) underscores the need for more effective treatment options, highlighting the unmet medical need in this patient population. The results of this study show that a novel biomarker, heregulin, may help to identify patients with advanced NSCLC who could benefit from treatment with seribantumab. On the basis of the observed safety profile and promising clinical efficacy, a prospective, randomized, open-label, international, multicenter phase II trial (SHERLOC, NCT02387216) is under way to investigate the efficacy and safety of seribantumab in combination with docetaxel in patients with heregulin-positive advanced adenocarcinoma.",2019,"In patients whose tumors had detectable HRG mRNA expression, treatment benefit was observed in the seribantumab + erlotinib combination (HR, 0.35; 95% CI, 0.16-0.76; p = .008).","['Patients with EGFR', 'unselected patients', 'patients with non-small cell lung cancer', 'wild-type NSCLC', 'patients with EGFR wild-type tumors and describe the potential predictive power of HRG', 'patients with heregulin-positive advanced adenocarcinoma', 'patients with advanced NSCLC and high HRG mRNA expression (NCT02387216', 'One hundred twenty-nine patients received', 'patients with advanced NSCLC who could benefit from treatment with seribantumab', 'Patients with EGFR Wild-Type Non-Small Cell Lung Cancer', 'advanced non-small cell lung cancer (NSCLC']","['seribantumab + erlotinib or erlotinib alone', 'seribantumab + erlotinib', 'Seribantumab in Combination with Erlotinib', 'docetaxel', 'erlotinib alone', 'seribantumab plus erlotinib', 'seribantumab', 'seribantumab plus erlotinib, versus erlotinib alone']","['safety and efficacy', 'detectable HRG mRNA expression, treatment benefit', 'Median estimated progression-free survival (PFS', 'PFS', 'median estimated overall survival', 'efficacy and safety']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}, {'cui': 'C0445392', 'cui_str': 'Wild (qualifier value)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0062751', 'cui_str': 'HRG'}, {'cui': 'C0597718', 'cui_str': 'Heregulin'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0001418', 'cui_str': 'Adenoma, Malignant'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0035696', 'cui_str': 'mRNA'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0450351', 'cui_str': '29 (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4042753', 'cui_str': 'seribantumab'}]","[{'cui': 'C4042753', 'cui_str': 'seribantumab'}, {'cui': 'C1135135', 'cui_str': 'erlotinib'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0062751', 'cui_str': 'HRG'}, {'cui': 'C0035696', 'cui_str': 'mRNA'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",129.0,0.0483113,"In patients whose tumors had detectable HRG mRNA expression, treatment benefit was observed in the seribantumab + erlotinib combination (HR, 0.35; 95% CI, 0.16-0.76; p = .008).","[{'ForeName': 'Lecia V', 'Initials': 'LV', 'LastName': 'Sequist', 'Affiliation': 'Massachusetts General Hospital, Boston, Massachusetts, USA LVSEQUIST@PARTNERS.ORG.'}, {'ForeName': 'Jhanelle Elaine', 'Initials': 'JE', 'LastName': 'Gray', 'Affiliation': 'H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.'}, {'ForeName': 'Wael A', 'Initials': 'WA', 'LastName': 'Harb', 'Affiliation': 'Horizon Oncology Center, Lafayette, Indiana, USA.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Lopez-Chavez', 'Affiliation': 'Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Doebele', 'Affiliation': 'University of Colorado Cancer Center, Aurora, Colorado, USA.'}, {'ForeName': 'Manuel R', 'Initials': 'MR', 'LastName': 'Modiano', 'Affiliation': 'Arizona Clinical Research Center, Tucson, Arizona, USA.'}, {'ForeName': 'David Michael', 'Initials': 'DM', 'LastName': 'Jackman', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, Massachusetts, USA.'}, {'ForeName': 'Maria Quintos', 'Initials': 'MQ', 'LastName': 'Baggstrom', 'Affiliation': 'Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.'}, {'ForeName': 'Akin', 'Initials': 'A', 'LastName': 'Atmaca', 'Affiliation': 'Department of Hematology and Oncology, Institute of Clinical Research at Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany.'}, {'ForeName': 'Enriqueta', 'Initials': 'E', 'LastName': 'Felip', 'Affiliation': ""Vall d'Hebron University Hospital, Barcelona, Spain.""}, {'ForeName': 'Mariano', 'Initials': 'M', 'LastName': 'Provencio', 'Affiliation': 'Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Cobo', 'Affiliation': 'Hospital Regional Universitario Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain.'}, {'ForeName': 'Bambang', 'Initials': 'B', 'LastName': 'Adiwijaya', 'Affiliation': 'Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.'}, {'ForeName': 'Geoffrey', 'Initials': 'G', 'LastName': 'Kuesters', 'Affiliation': 'Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.'}, {'ForeName': 'Walid S', 'Initials': 'WS', 'LastName': 'Kamoun', 'Affiliation': 'Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Andreas', 'Affiliation': 'Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.'}, {'ForeName': 'J Marc', 'Initials': 'JM', 'LastName': 'Pipas', 'Affiliation': 'Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Santillana', 'Affiliation': 'Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.'}, {'ForeName': 'Byoung Chul', 'Initials': 'BC', 'LastName': 'Cho', 'Affiliation': 'Yonsei University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Keunchil', 'Initials': 'K', 'LastName': 'Park', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Frances A', 'Initials': 'FA', 'LastName': 'Shepherd', 'Affiliation': 'Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.'}]",The oncologist,['10.1634/theoncologist.2018-0695'] 755,31363961,Does Lifestyle Intervention After Gastric Bypass Surgery Prevent Weight Regain? A Randomized Clinical Trial.,"BACKGROUND Weight regain after bariatric surgery often starts after 1-2 y, but studies evaluating strategies to prevent weight regain are lacking. The aim of this intervention was to evaluate the efficacy of a 2-y-group-based lifestyle intervention starting approximately 2 y after Roux-en-Y gastric bypass (RYGB) compared with usual care on weight regain and related metabolic risk factors. METHODS A total of 165 patients with a mean of 21 months (range 14-32) after RYGB were randomized to a lifestyle intervention group (LIG) or a usual care group (UCG). Of the 165 participants 86% completed the study. The LIG was offered 16 group meetings over 2 y with focus on healthy diet, physical activity, and behavioural strategies to prevent weight regain, in addition to usual care. RESULTS Mean (SD) total weight loss at study start was 30.1 ± 8.2%, while weight regain during the intervention was 4.9 ± 7.4 and 4.6 ± 9.2% in the LIG and UCG, respectively (P = 0.84). There were no differences in metabolic risk factors between the groups. The LIG participants attended 8 ± 4 group meetings, with no difference in weight regain between participants with high compared to lower participation. In all the participants, a positive association between weight increase from nadir to study start and weight regain during the intervention was found. Participants who reported physical activity ≥ 150 min/wk had smaller % weight regain compared with less active participants (β = - 5.2 [SE 2.0, 95% CI - 9.1 to - 1.4]). CONCLUSION We found no difference in weight regain between LIG and UCG.",2019,"150 min/wk had smaller % weight regain compared with less active participants (β = - 5.2 [SE 2.0, 95% CI - 9.1 to - 1.4]). ","['165 participants 86% completed the study', 'Participants who reported physical activity\u2009≥', '165 patients with a mean of 21\xa0months (range 14-32) after RYGB']","['2-y-group-based lifestyle intervention starting approximately 2\xa0y after Roux-en-Y gastric bypass (RYGB', 'lifestyle intervention group (LIG) or a usual care group (UCG', 'Lifestyle Intervention']","['Mean (SD) total weight loss', 'metabolic risk factors', 'weight regain']","[{'cui': 'C4319555', 'cui_str': '165 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0332232', 'cui_str': 'Approximate (qualifier value)'}, {'cui': 'C0585179', 'cui_str': 'Roux-en-Y Gastric Bypass'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}]",165.0,0.0321828,"150 min/wk had smaller % weight regain compared with less active participants (β = - 5.2 [SE 2.0, 95% CI - 9.1 to - 1.4]). ","[{'ForeName': 'Susanna E', 'Initials': 'SE', 'LastName': 'Hanvold', 'Affiliation': 'Section of Nutrition and Dietetics, Department of Clinical Service, Division of Medicine, Oslo University Hospital, Oslo, Norway. susanna@hanvold.no.'}, {'ForeName': 'Kathrine J', 'Initials': 'KJ', 'LastName': 'Vinknes', 'Affiliation': 'Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Elin B', 'Initials': 'EB', 'LastName': 'Løken', 'Affiliation': 'Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Anette', 'Initials': 'A', 'LastName': 'Hjartåker', 'Affiliation': 'Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Ole', 'Initials': 'O', 'LastName': 'Klungsøyr', 'Affiliation': 'Oslo Centre for Biostatistics and Epidemiology, Department for Research and Education, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Eline', 'Initials': 'E', 'LastName': 'Birkeland', 'Affiliation': 'Section of Nutrition and Dietetics, Department of Clinical Service, Division of Medicine, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Hilde', 'Initials': 'H', 'LastName': 'Risstad', 'Affiliation': 'Department of Endocrinology, Morbid Obesity and Preventive Medicine, Division of Medicine, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Hanne L', 'Initials': 'HL', 'LastName': 'Gulseth', 'Affiliation': 'Department of Endocrinology, Morbid Obesity and Preventive Medicine, Division of Medicine, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Helga', 'Initials': 'H', 'LastName': 'Refsum', 'Affiliation': 'Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Anne-Marie', 'Initials': 'AM', 'LastName': 'Aas', 'Affiliation': 'Section of Nutrition and Dietetics, Department of Clinical Service, Division of Medicine, Oslo University Hospital, Oslo, Norway.'}]",Obesity surgery,['10.1007/s11695-019-04109-7'] 756,30932951,Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.,"OBJECTIVE Compared with tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF) has been associated with improvement in markers of renal dysfunction in individual randomized trials; however, the comparative incidence of clinically significant renal events remains unclear. DESIGN We used a pooled data approach to increase the person-years of drug exposure analysed, maximizing our ability to detect differences in clinically significant outcomes. METHODS We pooled clinical renal safety data across 26 treatment-naive and antiretroviral switch studies to compare the incidence of proximal renal tubulopathy and discontinuation due to renal adverse events between participants taking TAF-containing regimens vs. those taking TDF-containing regimens. We performed secondary analyses from seven large randomized studies (two treatment-naive and five switch studies) to compare incidence of renal adverse events, treatment-emergent proteinuria, changes in serum creatinine, creatinine clearance, and urinary biomarkers (albumin, beta-2-microglobulin, and retinol binding protein-to-creatinine ratios). RESULTS Our integrated analysis included 9322 adults and children with HIV (n = 6360 TAF, n = 2962 TDF) with exposure of 12 519 person-years to TAF and 5947 to TDF. There were no cases of proximal renal tubulopathy in participants receiving TAF vs. 10 cases in those receiving TDF (P < 0.001), and fewer individuals on TAF (3/6360) vs. TDF (14/2962) (P < 0.001) discontinued due to a renal adverse event. Participants initiating TAF-based vs. TDF-based regimens had more favourable changes in renal biomarkers through 96 weeks of therapy. CONCLUSION These pooled data from 26 studies, with over 12 500 person-years of follow-up in children and adults, support the comparative renal safety of TAF over TDF.",2019,"Participants initiating TAF-based vs. TDF-based regimens had more favourable changes in renal biomarkers through 96 weeks of therapy. ","['participants taking TAF-containing regimens vs. those taking TDF-containing regimens', '9322 adults and children with HIV (n\u200a=\u200a6360 TAF, n\u200a=\u200a2962 TDF) with exposure of 12\u200a519 person-years to TAF and 5947 to TDF']","['tenofovir alafenamide vs. tenofovir disoproxil fumarate', 'tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF']","['Renal safety', 'proximal renal tubulopathy', 'renal adverse events, treatment-emergent proteinuria, changes in serum creatinine, creatinine clearance, and urinary biomarkers (albumin, beta-2-microglobulin, and retinol binding protein-to-creatinine ratios', 'renal biomarkers']","[{'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C3713958', 'cui_str': 'tenofovir alafenamide'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine (procedure)'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0201910', 'cui_str': 'Beta-2-microglobulin measurement (procedure)'}, {'cui': 'C1446172', 'cui_str': 'Retinol binding protein measurement (procedure)'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",9322.0,0.10091,"Participants initiating TAF-based vs. TDF-based regimens had more favourable changes in renal biomarkers through 96 weeks of therapy. ","[{'ForeName': 'Samir K', 'Initials': 'SK', 'LastName': 'Gupta', 'Affiliation': 'Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.'}, {'ForeName': 'Frank A', 'Initials': 'FA', 'LastName': 'Post', 'Affiliation': ""King's College Hospital NHS Foundation Trust, London, UK.""}, {'ForeName': 'José R', 'Initials': 'JR', 'LastName': 'Arribas', 'Affiliation': 'Instituto de Investigación Hospital Universitario La Paz, Hospital Universitario La Paz, Madrid, Spain.'}, {'ForeName': 'Joseph J', 'Initials': 'JJ', 'LastName': 'Eron', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, UNC School of Medicine.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Wohl', 'Affiliation': 'Division of Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.'}, {'ForeName': 'Amanda E', 'Initials': 'AE', 'LastName': 'Clarke', 'Affiliation': 'Sexual Health and Clinical Trials, Royal Sussex County Hospital, Brighton, UK.'}, {'ForeName': 'Paul E', 'Initials': 'PE', 'LastName': 'Sax', 'Affiliation': ""Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Hans-Jürgen', 'Initials': 'HJ', 'LastName': 'Stellbrink', 'Affiliation': 'Infectious Disease Medical Center, Hamburg.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Esser', 'Affiliation': 'Universitatsklinikum, Essen, Germany.'}, {'ForeName': 'Anton L', 'Initials': 'AL', 'LastName': 'Pozniak', 'Affiliation': 'Chelsea and Westminster Hospital and St Stephens AIDS Trust, London, UK.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Podzamczer', 'Affiliation': 'Infectious Diseases Service, Hospital Universitario de Bellvitge, Barcelona, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Waters', 'Affiliation': 'Mortimer Market Centre.'}, {'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Orkin', 'Affiliation': 'Barts Health NHS Trust, Ambrose King Centre, Royal London Hospital, London, UK.'}, {'ForeName': 'Jürgen K', 'Initials': 'JK', 'LastName': 'Rockstroh', 'Affiliation': 'University Hospital Bonn, Bonn, Germany.'}, {'ForeName': 'Tatiana', 'Initials': 'T', 'LastName': 'Mudrikova', 'Affiliation': 'Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Eugenia', 'Initials': 'E', 'LastName': 'Negredo', 'Affiliation': 'Universitat de Vic-Universitat Central de Catalunya, Barcelona, Spain.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Elion', 'Affiliation': 'Department of Clinical Investigations, Whitman-Walker Health, Washington, District of Columbia.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Guo', 'Affiliation': 'Departments of Biometrics and HIV & Emerging Viral Infections Clinical Research, Gilead Sciences, Inc., Foster City, California, USA.'}, {'ForeName': 'Lijie', 'Initials': 'L', 'LastName': 'Zhong', 'Affiliation': 'Departments of Biometrics and HIV & Emerging Viral Infections Clinical Research, Gilead Sciences, Inc., Foster City, California, USA.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Carter', 'Affiliation': 'Departments of Biometrics and HIV & Emerging Viral Infections Clinical Research, Gilead Sciences, Inc., Foster City, California, USA.'}, {'ForeName': 'Hal', 'Initials': 'H', 'LastName': 'Martin', 'Affiliation': 'Departments of Biometrics and HIV & Emerging Viral Infections Clinical Research, Gilead Sciences, Inc., Foster City, California, USA.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Brainard', 'Affiliation': 'Departments of Biometrics and HIV & Emerging Viral Infections Clinical Research, Gilead Sciences, Inc., Foster City, California, USA.'}, {'ForeName': 'Devi', 'Initials': 'D', 'LastName': 'SenGupta', 'Affiliation': 'Departments of Biometrics and HIV & Emerging Viral Infections Clinical Research, Gilead Sciences, Inc., Foster City, California, USA.'}, {'ForeName': 'Moupali', 'Initials': 'M', 'LastName': 'Das', 'Affiliation': 'Departments of Biometrics and HIV & Emerging Viral Infections Clinical Research, Gilead Sciences, Inc., Foster City, California, USA.'}]","AIDS (London, England)",['10.1097/QAD.0000000000002223'] 757,30927509,Therapeutic Alliance Between Physical Therapists and Patients With Knee Osteoarthritis Consulting Via Telephone: A Longitudinal Study.,"OBJECTIVE To explore therapeutic alliance between physical therapists and patients with knee osteoarthritis during telephone consultations. Specifically, to describe and compare physical therapist and patient ratings, to determine whether alliance changes over time, and to evaluate whether individual characteristics are associated with alliance. METHODS We performed a secondary analysis of 84 patients in the intervention arm of a randomized controlled trial who completed 5-10 consultations with 1 of 8 physical therapists via telephone over 26 weeks, involving education, advice, and prescription of a strengthening and physical activity program. Therapeutic alliance was measured after the second (week 4) and final consultations (week 26), using the Working Alliance Inventory-Short Form. RESULTS Patient and physical therapist ratings of the alliance were high. At week 4, patients rated the overall alliance, and all 3 subscales, higher than therapists. At 26 weeks, patients rated the Task subscale higher than therapists. Patient ratings for the Goal subscale decreased over time, while physical therapist ratings for total alliance and the Bond subscale increased. For patients, the variables of living with others, consulting with a therapist with no previous experience delivering care remotely, having more telephone consultations, and having a higher self-efficacy were associated with greater alliance ratings. Therapists were more likely to perceive a stronger alliance if they had less clinical experience and when treating patients who were younger and had higher self-efficacy. CONCLUSION Physical therapist perceptions of the therapeutic alliance tended to be lower than those of patients early in treatment, but differences were small and of unclear clinical significance. Some subgroups of patients rated the alliance more strongly than others.",2020,"Therapeutic alliance was measured after the second (week 4) and final consultations (week 26) using the Working Alliance Inventory (Short Form). ","['physiotherapists and patients with knee osteoarthritis consulting via', 'Secondary analysis of 84 patients in the intervention arm of a randomised controlled trial who completed 5-10 consultations with one of 8', 'physiotherapists and patients with knee osteoarthritis during telephone consultations']","['physiotherapists via telephone over 26 weeks, involving education, advice, and prescription of a strengthening and physical activity program', 'telephone']","['physiotherapist ratings for total alliance and ""bond"" sub-scale', 'Therapeutic alliance']","[{'cui': 'C2362565', 'cui_str': 'Physiotherapists'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis, Knee'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0175745', 'cui_str': 'Telephone consultation'}]","[{'cui': 'C2362565', 'cui_str': 'Physiotherapists'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0033080', 'cui_str': 'Prescriptions'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C2362565', 'cui_str': 'Physiotherapists'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0028758', 'cui_str': 'Object Relationship'}, {'cui': 'C1264637', 'cui_str': 'Substance amount'}, {'cui': 'C0222045'}, {'cui': 'C0814487', 'cui_str': 'Therapeutic Alliance'}]",84.0,0.0517591,"Therapeutic alliance was measured after the second (week 4) and final consultations (week 26) using the Working Alliance Inventory (Short Form). ","[{'ForeName': 'Belinda J', 'Initials': 'BJ', 'LastName': 'Lawford', 'Affiliation': 'University of Melbourne, Parkville, Victoria, Australia.'}, {'ForeName': 'Kim L', 'Initials': 'KL', 'LastName': 'Bennell', 'Affiliation': 'University of Melbourne, Parkville, Victoria, Australia.'}, {'ForeName': 'Penny K', 'Initials': 'PK', 'LastName': 'Campbell', 'Affiliation': 'University of Melbourne, Parkville, Victoria, Australia.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Kasza', 'Affiliation': 'Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'Rana S', 'Initials': 'RS', 'LastName': 'Hinman', 'Affiliation': 'University of Melbourne, Parkville, Victoria, Australia.'}]",Arthritis care & research,['10.1002/acr.23890'] 758,30260748,"White Sesame Seed Oil Mitigates Blood Glucose Level, Reduces Oxidative Stress, and Improves Biomarkers of Hepatic and Renal Function in Participants with Type 2 Diabetes Mellitus.","OBJECTIVES The study was designed to investigate the impact of white sesame seed oil (WSSO) consumption on fasting blood glucose (GLU), insulin (INS), glycosylated hemoglobin (HbA1c), and hepatic antioxidant enzymes. A secondary aim was to check the influence on serum biochemistry, hepatic, cardiac, and renal functions. METHODS Forty-six participants with type 2 diabetes were recruited and randomly divided into two equal groups: diabetic control (DCON) and diabetic sesame oil (DSO). At baseline and 30, 60, and 90 days, blood samples were drawn and analyzed. Two-way repeated-measures analysis of variance was used to evaluate the difference between groups and across time. RESULTS In both groups, GLU, INS, and HbA1c were not significantly different at baseline (mean 187.07 ± 5.63 mg/dl, mean 12.12 ± 1.03 μU/ml, and mean 7.55 ± 0.37%, respectively). At 90 days, GLU was significantly (p < 0.05) decreased in DSO (137.83 ± 3.16 mg/dl) when compared with DCON (218.13 ± 5.92 mg/dl), while INS was significantly increased in DSO (23.13 ± 1.15 μU/ml) as compared to DCON (7.93 ± 0.38 μU/ml). At 90 days, HbA1c was significantly lower (p < 0.05) in DSO as compared to DCON. Thiobarbituric acid reactive substances were significantly lower (p < 0.05) in DSO (1.08 ± 0.05 [MDA] nmol/ml) as compared to DCON (2.26 ± 0.07 [MDA] nmol/ml). In DSO, activities of hepatic antioxidant enzymes (superoxide dismutase, catalase, and glutathione peroxidase) increased while in DCON these activities decreased significantly (p < 0.05) across the time period. Biomarkers of liver, cardiac, and renal functions improved significantly in DSO as compared to DCON. CONCLUSION WSSO as a functional food may play an important role in GLU regulation and against deleterious effects of diabetes in humans with type 2 diabetes.",2019,Thiobarbituric acid reactive substances were significantly lower (p < 0.05) in DSO (1.08 ± 0.05 [MDA] nmol/ml) as compared to DCON (2.26 ± 0.07 [MDA] nmol/ml).,"['humans with type 2 diabetes', 'Forty-six participants with type 2 diabetes', 'Participants with Type 2 Diabetes Mellitus']","['diabetic control (DCON) and diabetic sesame oil (DSO', 'white sesame seed oil (WSSO) consumption']","['fasting blood glucose (GLU), insulin (INS), glycosylated hemoglobin (HbA1c), and hepatic antioxidant enzymes', 'GLU', 'Thiobarbituric acid reactive substances', 'Biomarkers of liver, cardiac, and renal functions', 'DSO, activities of hepatic antioxidant enzymes (superoxide dismutase, catalase, and glutathione peroxidase', 'GLU, INS, and HbA1c', 'serum biochemistry, hepatic, cardiac, and renal functions', 'DSO']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0036845', 'cui_str': 'Sesame Oil'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0440299', 'cui_str': 'Sesame seed (substance)'}, {'cui': 'C0028908', 'cui_str': 'Oils'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C3541394', 'cui_str': 'Enzymes'}, {'cui': 'C0061055', 'cui_str': 'Glu-(Abu)'}, {'cui': 'C0162781', 'cui_str': 'TBARs'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0069638', 'cui_str': 'orgotein'}, {'cui': 'C0007367', 'cui_str': 'CATALASE'}, {'cui': 'C0017822', 'cui_str': 'Glutathione:hydrogen-peroxide oxidoreductase'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005477', 'cui_str': 'Biochemistry'}]",46.0,0.0359798,Thiobarbituric acid reactive substances were significantly lower (p < 0.05) in DSO (1.08 ± 0.05 [MDA] nmol/ml) as compared to DCON (2.26 ± 0.07 [MDA] nmol/ml).,"[{'ForeName': 'Farhan', 'Initials': 'F', 'LastName': 'Aslam', 'Affiliation': 'a Department of Food Science and Human Nutrition, Faculty of Bio-Sciences , University of Veterinary and Animal Sciences , Lahore , Pakistan.'}, {'ForeName': 'Sanaullah', 'Initials': 'S', 'LastName': 'Iqbal', 'Affiliation': 'a Department of Food Science and Human Nutrition, Faculty of Bio-Sciences , University of Veterinary and Animal Sciences , Lahore , Pakistan.'}, {'ForeName': 'Muhammad', 'Initials': 'M', 'LastName': 'Nasir', 'Affiliation': 'a Department of Food Science and Human Nutrition, Faculty of Bio-Sciences , University of Veterinary and Animal Sciences , Lahore , Pakistan.'}, {'ForeName': 'Aftab Ahmad', 'Initials': 'AA', 'LastName': 'Anjum', 'Affiliation': 'b Department of Microbiology, Faculty of Veterinary Sciences , University of Veterinary and Animal Sciences , Lahore , Pakistan.'}]",Journal of the American College of Nutrition,['10.1080/07315724.2018.1500183'] 759,30831103,"Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial.","OBJECTIVE To compare efficacy, safety/side effects and acceptability of buccal versus sublingual administration of a misoprostol-only regimen commonly used for early medical abortion. STUDY DESIGN We conducted a randomized trial at six clinics in two Latin American countries. We randomized women seeking early abortion to buccal or sublingual administration of three doses of misoprostol 800 mcg repeated every 3 h. At initial follow-up (7-14 days after misoprostol), we offered women without a complete abortion aspiration or additional misoprostol plus waiting 7 more days. The primary outcome was continuing pregnancy at initial follow-up. Secondary outcomes included continuing pregnancy at final follow-up, incomplete abortion, successful abortion, side effects, acceptability and complications. We analyzed all outcomes as intention to treat. RESULTS We enrolled 401 women and randomized 202 into the buccal arm and 199 into the sublingual arm. Continuing pregnancy at initial follow-up occurred in 11/201 (5.5%) and 2/189 (1.1%) women, respectively (p=.02). Additional misoprostol at follow-up increased success, defined as complete abortion, from 170/201 (84.6%) to 184/199 (92.5%) in the buccal arm and 165/189 (87.3%) to 177/189 (93.7%) in the sublingual arm. We found no differences by gestational age. Women reported similar acceptability and side effects across groups except for chills and fever, which women using sublingual misoprostol reported more frequently (p<.05). CONCLUSIONS Sublingual administration was superior to buccal administration in reducing continuing pregnancy risk after a three-dose regimen of 800 mcg misoprostol. Complete abortion rates were comparable across groups, and in both cases, additional misoprostol at follow-up increased success. IMPLICATIONS If the primary goal is to avoid continuing pregnancy, sublingual administration of misoprostol 800 mcg every 3 h for three doses should be recommended. If chills or fever are a concern and the primary goal is to avoid surgery, buccal administration may be preferable. For either route, additional misoprostol can be given for incomplete abortion or continuing pregnancy.",2019,"Complete abortion rates were comparable across groups, and in both cases, additional misoprostol at follow-up increased success. ","['six clinics in two Latin American countries', '401 women and randomized 202 into the buccal arm and 199 into the sublingual arm']","['sublingual misoprostol alone', 'misoprostol', 'sublingual misoprostol', 'complete abortion aspiration or additional misoprostol plus waiting 7 more days']","['efficacy, safety/side effects and acceptability', 'continuing pregnancy at initial follow-up', 'Complete abortion rates', 'complete abortion', 'continuing pregnancy at final follow-up, incomplete abortion, successful abortion, side effects, acceptability and complications', 'continuing pregnancy risk', 'acceptability and side effects']","[{'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0442010', 'cui_str': 'Buccal (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C4521982', 'cui_str': 'Sublingual'}]","[{'cui': 'C4521982', 'cui_str': 'Sublingual'}, {'cui': 'C0085174', 'cui_str': 'Misoprostol'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0392535', 'cui_str': 'Abortion, Induced'}, {'cui': 'C0349707', 'cui_str': 'Aspiration - action (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0000794', 'cui_str': 'Abortion Rate'}, {'cui': 'C0392535', 'cui_str': 'Abortion, Induced'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0000810', 'cui_str': 'Abortion, Incomplete'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0404588', 'cui_str': 'Finding related to risk factor in pregnancy'}]",401.0,0.324467,"Complete abortion rates were comparable across groups, and in both cases, additional misoprostol at follow-up increased success. ","[{'ForeName': 'Wendy R', 'Initials': 'WR', 'LastName': 'Sheldon', 'Affiliation': 'Gynuity Health Projects, 220 East 42(nd) Street, Suite 710, New York, NY, 10017. Electronic address: wsheldon@gynuity.org.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Durocher', 'Affiliation': 'Gynuity Health Projects, 220 East 42(nd) Street, Suite 710, New York, NY, 10017.'}, {'ForeName': 'Ilana G', 'Initials': 'IG', 'LastName': 'Dzuba', 'Affiliation': 'Gynuity Health Projects, 220 East 42(nd) Street, Suite 710, New York, NY, 10017.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Sayette', 'Affiliation': 'Planned Parenthood Global, 123 William Street, New York, NY, 10038.'}, {'ForeName': 'Roxanne', 'Initials': 'R', 'LastName': 'Martin', 'Affiliation': 'Gynuity Health Projects, 220 East 42(nd) Street, Suite 710, New York, NY, 10017.'}, {'ForeName': 'Mónica Cárdenas', 'Initials': 'MC', 'LastName': 'Velasco', 'Affiliation': 'Planned Parenthood Global, 123 William Street, New York, NY, 10038.'}, {'ForeName': 'Beverly', 'Initials': 'B', 'LastName': 'Winikoff', 'Affiliation': 'Gynuity Health Projects, 220 East 42(nd) Street, Suite 710, New York, NY, 10017.'}]",Contraception,['10.1016/j.contraception.2019.02.002'] 760,31612482,A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.,"OBJECTIVE A phase 2, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab for the prevention of episodic migraine in Japanese patients was conducted. BACKGROUND Previous global clinical studies have demonstrated the efficacy of erenumab in the prevention of migraine. METHODS Patients were randomized to placebo or erenumab 28, 70, or 140 mg administered subcutaneously once per month for 6 months. The primary endpoint was change from baseline in mean monthly migraine days over months 4-6 of the double-blind treatment phase. Secondary endpoints included the proportion of patients achieving ≥50% reduction from baseline in mean monthly migraine days (≥50% response) and change from baseline in mean monthly acute migraine-specific medication treatment days (MSMD) and mean Headache Impact Test (HIT-6™) scores. Efficacy outcomes were also determined at months 1, 2, and 3. RESULTS Four hundred and seventy five patients were randomized 2:1:2:2 to placebo and erenumab 28, 70, and 140 mg, respectively. Greater reductions in monthly migraine days were observed for erenumab vs placebo with differences of -1.25 (95% CI: -2.10 to -0.41; P = .004), -2.31 (95% CI: -3.00 to -1.62; P < .001), and -1.89 (95% CI: -2.58 to -1.20; P < .001) days for erenumab 28, 70, and 140 mg. The odds of having a ≥50% response were 3.2, 5.6, and 4.7 times greater for erenumab 28 mg (95% CI: 1.30-7.88; P = .009), 70 mg (95% CI: 2.60-12.06; P < .001), and 140 mg (95% CI: 2.24-9.99; P < .001) than for placebo. Greater reductions from baseline in mean acute monthly MSMD were observed for erenumab vs placebo with differences of -1.07 (95% CI: -1.80 to -0.35; P = .004), -2.07 (95% CI: -2.66 to -1.49; P < .001), and -2.04 (95% CI: -2.63 to -1.45; P < .001) days for erenumab 28, 70, and 140 mg. Erenumab 70 and 140 mg also resulted in greater improvements in HIT-6™ scores. The safety profile was similar across treatment groups. The most common adverse event was nasopharyngitis, which occurred in 29.4% of patients in the placebo group and 28.9%-33.3% of patients in the erenumab groups. CONCLUSION Monthly subcutaneous injections of erenumab 70 mg demonstrated statistically significant and numerically maximal efficacy with a favorable safety profile, suggesting that erenumab is a potential new therapy for migraine prevention in Japan.",2019,"The most common adverse event was nasopharyngitis, which occurred in 29.4% of patients in the placebo group and 28.9%-33.3% of patients in the erenumab groups. ","['Patients', 'migraine prevention in Japan', 'Japanese Adults', 'Japanese patients', 'Four hundred and seventy five patients']","['placebo', 'erenumab', 'Erenumab']","['efficacy and safety', 'proportion of patients achieving ≥50% reduction from baseline in mean monthly migraine days (≥50% response) and change from baseline in mean monthly acute migraine-specific medication treatment days (MSMD) and mean Headache Impact Test (HIT-6™) scores', 'mean monthly migraine days', 'HIT-6™ scores', 'safety profile', 'mean acute monthly MSMD']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4517786', 'cui_str': '475 (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4542165', 'cui_str': 'erenumab'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1740836', 'cui_str': 'Acute migraine'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C3469597', 'cui_str': 'Medication treatment'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0596020', 'cui_str': 'Does hit (finding)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",475.0,0.576675,"The most common adverse event was nasopharyngitis, which occurred in 29.4% of patients in the placebo group and 28.9%-33.3% of patients in the erenumab groups. ","[{'ForeName': 'Fumihiko', 'Initials': 'F', 'LastName': 'Sakai', 'Affiliation': 'Saitama International Headache Center, Saitama, Japan.'}, {'ForeName': 'Takao', 'Initials': 'T', 'LastName': 'Takeshima', 'Affiliation': 'Headache Center, Department of Neurology, Tominaga Hospital, Osaka, Japan.'}, {'ForeName': 'Yoshihisa', 'Initials': 'Y', 'LastName': 'Tatsuoka', 'Affiliation': 'Department of Neurology, Tatsuoka Neurology Clinic, Kyoto, Japan.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Hirata', 'Affiliation': 'Department of Neurology, Dokkyo Medical University, Tochigi, Japan.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Lenz', 'Affiliation': 'Global Development, Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Sunfa', 'Initials': 'S', 'LastName': 'Cheng', 'Affiliation': 'Global Development, Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Toshiyasu', 'Initials': 'T', 'LastName': 'Hirama', 'Affiliation': 'Research & Development, Amgen Astellas BioPharma K.K., Tokyo, Japan.'}, {'ForeName': 'Daniel D', 'Initials': 'DD', 'LastName': 'Mikol', 'Affiliation': 'Global Development, Amgen Inc., Thousand Oaks, CA, USA.'}]",Headache,['10.1111/head.13652'] 761,31010387,Can local infiltration of lidocaine reduce the postoperative atrial fibrillation rate in patients undergoing lobectomy for lung cancer?,"Background: Postoperative atrial fibrillation (POAF) occurs frequently after lung cancer surgery. Unfortunately, owing to the multifactorial etiology of POAF, no single drug or intervention can prevent POAF in all cases. The effects of local interventions after lung cancer surgery are unknown. This study investigated the effects of local infiltration of an anesthetic (lidocaine) on the post-lobectomy POAF rate. Methods: This non-randomized study included 81 patients who underwent lobectomy for lung cancer. Patients were divided into a lidocaine-infiltration group comprising patients who received lidocaine infiltration around the pulmonary veins and a no-intervention group. Patients were monitored for the development of POAF during hospitalization. Pre- and postoperative demographic and clinical data were analyzed. Results: AF occurred in 3 (7.5%) of 40 patients in the lidocaine-infiltration group and in 10 (24.39%) of 41 patients in the standard surgical resection group. Overall, it was observed that intraoperative lidocaine infiltration resulted in a lower POAF rate ( p  < .05). Conclusion: Local infiltration of lidocaine around the pulmonary veins in patients undergoing lobectomy for lung cancer was associated with a lower incidence of POAF, which is attributable to the local anesthetic and autonomic effects of lidocaine.",2020,"Overall, it was observed that intraoperative lidocaine infiltration resulted in a lower POAF rate (p < .05). ","['patients undergoing lobectomy for lung cancer', 'lung cancer surgery', '81 patients who underwent lobectomy for lung cancer']","['lidocaine infiltration around the pulmonary veins and a no-intervention group', 'local interventions', 'lidocaine', 'lidocaine-infiltration', 'anesthetic (lidocaine']","['postoperative atrial fibrillation rate', 'POAF rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0405532', 'cui_str': 'Lobectomy of thyroid gland (procedure)'}, {'cui': 'C1306460', 'cui_str': 'Primary malignant neoplasm of lung'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C3669041', 'cui_str': 'Spread by direct extension (qualifier value)'}, {'cui': 'C0034090', 'cui_str': 'Vein of lung'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0002930', 'cui_str': 'Anesthesiology'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}]",81.0,0.0281965,"Overall, it was observed that intraoperative lidocaine infiltration resulted in a lower POAF rate (p < .05). ","[{'ForeName': 'Murat', 'Initials': 'M', 'LastName': 'Akkuş', 'Affiliation': 'Department of Thoracic Surgery, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ender', 'Initials': 'E', 'LastName': 'Öner', 'Affiliation': 'Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.'}]",Acta chirurgica Belgica,['10.1080/00015458.2019.1610259'] 762,30885760,"Comparison of a picosecond alexandrite laser versus a Q-switched alexandrite laser for the treatment of nevus of Ota: A randomized, split-lesion, controlled trial.","BACKGROUND Novel picosecond lasers have been available for various pigmentary disorders. However, there are limited data directly comparing picosecond lasers and Q-switched lasers for treatment of nevus of Ota. OBJECTIVE To compare the efficacy and safety of a picosecond alexandrite laser (PSAL) with a Q-switched alexandrite laser (QSAL) for the treatment of nevus of Ota. METHODS Each lesion of 56 enrolled participants was split into 2 parts and randomly assigned to either the PSAL or QSAL treatment arm. Each lesion was treated in up to 6 sessions in 12-week intervals. Efficacy and safety were determined using blinded visual evaluation and self-report at each follow-up visit. RESULTS The PSAL arm achieved a significantly better clearance (5-point scale, PSAL 4.53 vs QSAL 4.0) with fewer sessions (PSAL 5.26 vs QSAL 5.87) and less severe pain (Visual Analog Scale, PSAL 5.61 vs QSAL 6.40). Patients were more satisfied with PSAL than QSAL (Likert scale, 4.5 vs 4.0). Occurrences of postinflammatory hyperpigmentation (PSAL 26% vs QSAL 34%) and hypopigmentation (PSAL 21% vs QSAL 47%) were also lower in PSAL than QSAL arm. LIMITATIONS Lack of objective assessments and outcome measures. CONCLUSION PSAL demonstrated better clinical results and fewer adverse events than QSAL for the treatment of nevus of Ota.",2020,"RESULTS PSAL arm achieved a significantly better clearance (4.53 vs 4.0) with fewer sessions (5.26 vs 5.87) and less severe pain (5.61 vs 6.40).","['nevus of Ota', '56 participants enrolled was split into two parts']","['Q-switched alexandrite laser (QSAL', 'QSAL', 'picosecond alexandrite laser (PSAL', 'picosecond alexandrite laser versus a Q-switched alexandrite laser', 'PASL or QSAL']","['clearance', 'adverse events', 'Occurrences of post inflammatory hyperpigmentation', 'efficacy and safety', 'severe pain']","[{'cui': 'C0027961', 'cui_str': 'Nevus of Ota'}, {'cui': 'C0449719', 'cui_str': 'Part (attribute)'}]","[{'cui': 'C0392245', 'cui_str': 'Alexandrite Lasers'}]","[{'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0333616', 'cui_str': 'Postinflammatory hyperpigmentation (morphologic abnormality)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0278140', 'cui_str': 'Severe pain (finding)'}]",56.0,0.0503462,"RESULTS PSAL arm achieved a significantly better clearance (4.53 vs 4.0) with fewer sessions (5.26 vs 5.87) and less severe pain (5.61 vs 6.40).","[{'ForeName': 'Yiping', 'Initials': 'Y', 'LastName': 'Ge', 'Affiliation': 'Department of Cosmetic Laser Surgery, Hospital for Skin Disease and Institute of Dermatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Nanjing, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Cosmetic Laser Surgery, Hospital for Skin Disease and Institute of Dermatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Nanjing, China.'}, {'ForeName': 'Lifang', 'Initials': 'L', 'LastName': 'Guo', 'Affiliation': 'Department of Cosmetic Laser Surgery, Hospital for Skin Disease and Institute of Dermatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Nanjing, China.'}, {'ForeName': 'Mengli', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Department of Cosmetic Laser Surgery, Hospital for Skin Disease and Institute of Dermatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Nanjing, China.'}, {'ForeName': 'Qiuju', 'Initials': 'Q', 'LastName': 'Wu', 'Affiliation': 'Department of Cosmetic Laser Surgery, Hospital for Skin Disease and Institute of Dermatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Nanjing, China.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Zeng', 'Affiliation': 'Department of Cosmetic Laser Surgery, Hospital for Skin Disease and Institute of Dermatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Nanjing, China.'}, {'ForeName': 'Huizhen', 'Initials': 'H', 'LastName': 'Rong', 'Affiliation': 'Department of Cosmetic Laser Surgery, Hospital for Skin Disease and Institute of Dermatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Nanjing, China.'}, {'ForeName': 'Gaorong', 'Initials': 'G', 'LastName': 'Jia', 'Affiliation': 'Department of Cosmetic Laser Surgery, Hospital for Skin Disease and Institute of Dermatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Nanjing, China.'}, {'ForeName': 'Hualing', 'Initials': 'H', 'LastName': 'Shi', 'Affiliation': 'Department of Cosmetic Laser Surgery, Hospital for Skin Disease and Institute of Dermatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Nanjing, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Fang', 'Affiliation': 'Department of Cosmetic Laser Surgery, Hospital for Skin Disease and Institute of Dermatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Nanjing, China.'}, {'ForeName': 'Tong', 'Initials': 'T', 'LastName': 'Lin', 'Affiliation': 'Department of Cosmetic Laser Surgery, Hospital for Skin Disease and Institute of Dermatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Nanjing, China. Electronic address: ddlin@hotmail.com.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2019.03.016'] 763,31853609,Randomized Trial of Deep Vein Thrombosis Chemoprophylaxis with Bemiparin and Enoxaparin in Patients with Moderate to High Thrombogenic Risk Undergoing Plastic and Reconstructive Surgery Procedures.,"BACKGROUND Deep vein thrombosis (DVT) is a common complication during postoperative convalescence characterized by hypercoagulability, vascular endothelium damage and blood stasis. It increases noticeably in peri/postoperative phases of surgery procedures. Pulmonary embolism secondary to iliofemoral DVT is a frequent cause of death. METHODS Adult patients scheduled for plastic and reconstructive surgery (PRSx) with moderate to high thrombogenic risk were selected. We evaluated the efficacy and safety of bemiparin compared to enoxaparin as chemoprophylaxis for DVT. Following balanced general anesthesia techniques, patients were randomly assigned for subcutaneous enoxaparin 40 IU (Group-E) or bemiparin 3500 IU (Group-B) q24h starting 6 h after procedure conclusion for at least 10 days. All patients were evaluated for DVT through Doppler ultrasound mapping of the lower limbs. RESULTS Seventy-eight patients were evaluated, mostly women (83%), physical status ASA II (59%), ASA III (10%); Caprini's thrombogenic risk score 3-4 (moderate) 58%, 5-6 (high) 29%, > 6 (too high) 13%; demographics, clinical variables and scores were similar between groups. Median drainage time in breast surgery was 4 days in both groups (p = 0.238). In the case of abdominal surgery, median was 14 days in Group-E versus 13 days in Group-B (p = 0.059). No DVT was detected in either group. CONCLUSIONS DVT was prevented with bemiparin, without significant bleeding increase nor adverse events; moreover, the cost of bemiparin is lower than enoxaparin. Bemiparin can be considered as alternative drug for DVT chemoprophylaxis in PRSx procedures. LEVEL OF EVIDENCE III This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.",2020,Median drainage time in breast surgery was 4 days in both groups (p = 0.238).,"['Adult patients scheduled for plastic and reconstructive surgery (PRSx) with moderate to high thrombogenic risk were selected', 'Patients with Moderate to High Thrombogenic Risk Undergoing Plastic and Reconstructive Surgery Procedures']","['enoxaparin', 'bemiparin', 'Deep Vein Thrombosis Chemoprophylaxis with Bemiparin and Enoxaparin', 'subcutaneous enoxaparin 40\xa0IU (Group-E) or bemiparin 3500\xa0IU']","['Median drainage time', ""Caprini's thrombogenic risk score"", 'efficacy and safety', 'physical status ASA', 'DVT', 'adverse events']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C0032167', 'cui_str': 'Plastics'}, {'cui': 'C0524865', 'cui_str': 'Reconstructive Surgery'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}]","[{'cui': 'C0206460', 'cui_str': 'Enoxaparin'}, {'cui': 'C0916062', 'cui_str': 'bemiparin'}, {'cui': 'C0149871', 'cui_str': 'Deep Vein Thrombosis'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C0441839', 'cui_str': 'Group E (qualifier value)'}, {'cui': 'C4517736', 'cui_str': '3500'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0013103', 'cui_str': 'Drainage'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0149871', 'cui_str': 'Deep Vein Thrombosis'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",78.0,0.068905,Median drainage time in breast surgery was 4 days in both groups (p = 0.238).,"[{'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Revilla-Peñaloza', 'Affiliation': 'Anesthesiology Service, American British Cowdray Santa Fe Medical Center, No. 154 Carlos Graef Fernandez Av., Santa Fe, Del. Cuajimalpa, 053333, Mexico City, Mexico.'}, {'ForeName': 'Paul Jay', 'Initials': 'PJ', 'LastName': 'Olsoff-Pagovich', 'Affiliation': 'Plastic and Reconstructive Surgery, ABC Santa Fe Medical Center, No. 154 Carlos Graef Fernandez Av., Santa Fe, Cuajimalpa, 053333, Mexico City, Mexico.'}, {'ForeName': 'Jose Ramon', 'Initials': 'JR', 'LastName': 'Ochoa-Gomez', 'Affiliation': 'Plastic and Reconstructive Surgery, ABC Santa Fe Medical Center, No. 154 Carlos Graef Fernandez Av., Santa Fe, Cuajimalpa, 053333, Mexico City, Mexico.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Castaneda-Gaxiola', 'Affiliation': 'Angiology and Vascular Surgery, ABC Santa Fe Medical Center, No. 154 Carlos Graef Fernandez Av., Santa Fe, Cuajimalpa, 053333, Mexico City, Mexico.'}, {'ForeName': 'Ángel Iván', 'Initials': 'ÁI', 'LastName': 'Rubio-Gayosso', 'Affiliation': 'Sección de Estudios de posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, CP 11340, Mexico City, Mexico.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Ceballos', 'Affiliation': 'Sección de Estudios de posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, CP 11340, Mexico City, Mexico.'}, {'ForeName': 'Juan Arcadio', 'Initials': 'JA', 'LastName': 'Molina-Guarneros', 'Affiliation': 'Pharmacology Department, Faculty of Medicine, National Autonomous University of Mexico, Av. Universidad No. 3000, Colonia Ciudad Universitaria, CP 04510, Alcaldía Coyoacan, Mexico City, Mexico. jamg@unam.mx.'}]",Aesthetic plastic surgery,['10.1007/s00266-019-01573-5'] 764,30983678,Describing Research Design.,"This article explains how the research design of a study can simultaneously be described in many different ways as nonempirical or empirical, case-based or sample-based, observational or interventional, retrospective or prospective, cross-sectional or longitudinal, uncontrolled or controlled, single arm or multiple arm, nonrandomized or randomized, crossover or parallel group, nonblind, single-blind, or double-blind, superiority or noninferiority, exploratory (hypothesis generating) or confirmatory (hypothesis driven), and many others. Some of these categories can be associated with special types of research design as well, such as cohort studies, case-control studies, nested case-control studies, wedge design studies, and so on. Readers should understand which descriptors are mutually exclusive and which are not.",2019,"This article explains how the research design of a study can simultaneously be described in many different ways as nonempirical or empirical, case-based or sample-based, observational or interventional, retrospective or prospective, cross-sectional or longitudinal, uncontrolled or controlled, single arm or multiple arm, nonrandomized or randomized, crossover or parallel group, nonblind, single-blind, or double-blind, superiority or noninferiority, exploratory (hypothesis generating) or confirmatory (hypothesis driven), and many others.",[],[],[],[],[],[],,0.0501974,"This article explains how the research design of a study can simultaneously be described in many different ways as nonempirical or empirical, case-based or sample-based, observational or interventional, retrospective or prospective, cross-sectional or longitudinal, uncontrolled or controlled, single arm or multiple arm, nonrandomized or randomized, crossover or parallel group, nonblind, single-blind, or double-blind, superiority or noninferiority, exploratory (hypothesis generating) or confirmatory (hypothesis driven), and many others.","[{'ForeName': 'Chittaranjan', 'Initials': 'C', 'LastName': 'Andrade', 'Affiliation': 'Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.'}]",Indian journal of psychological medicine,['10.4103/IJPSYM.IJPSYM_66_19'] 765,31542243,Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study.,"BACKGROUND In selected metastatic renal cell carcinoma (mRCC) patients, radical metastasectomy followed by observation is a potential strategy. It is still to be defined whether systemic therapy should be administered following metastasectomy. OBJECTIVE To assess the potential benefit of postoperative treatment with sorafenib compared with observation alone after radical metastasectomy in mRCC patients. DESIGN, SETTING, AND PARTICIPANTS The RESORT trial was a multicenter, randomized, open-label, phase 2 study conducted between November 2012 and November 2017 in Italy. Patients with clear-cell mRCC pretreated with nephrectomy and undergoing radical metastasectomy (three or fewer lesions) were eligible for the study. Patients were randomized (1:1) within 12 wk from metastasectomy to sorafenib (standard dose 400 mg twice daily) or observation for a maximum of 52 wk. Stratification factors were interval from nephrectomy, site, and number of lesions. Overall, 76 patients were screened and 69 were randomized: 33 were assigned to sorafenib and 36 to observation. The primary endpoint was recurrence-free survival (RFS). Secondary endpoints were overall survival and the safety profile. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS RFS curves were estimated with the Kaplan-Meier method, and the log-rank test was used to statistically compare the curves. RESULTS AND LIMITATIONS At a median follow-up of 38 mo, median RFS was 37 mo (95% confidence interval [CI] 20-not available [NA]) in the observation arm versus 21 mo (95% CI 11-NA) in the sorafenib arm (log-rank test p = 0.404), with 12-, 24-, and 36-mo RFS probability of 74% versus 63%, 59% versus 49%, and 50% versus 41%, respectively, in the observation versus the sorafenib arm. Any-grade adverse event (AE) rates were 84% in the sorafenib arm and 31% in the observation arm; grade ≥3 AE rates were 22% and 3% in the sorafenib and the observation arm, respectively, with a rate of treatment discontinuation for AEs of 19% in the sorafenib arm. CONCLUSIONS This prospective study showed that systemic treatment with sorafenib did not increase RFS as compared with observation in mRCC patients following radical metastasectomy. PATIENT SUMMARY This article reports the clinical outcome of patients with metastatic renal cell carcinoma treated with sorafenib or managed with an observation-alone strategy after the radical surgery of metastases. We found that sorafenib did not improve the patient outcome in terms of relapse-free survival in this selected population.",2019,"This prospective study showed that systemic treatment with sorafenib did not increase RFS as compared with observation in mRCC patients following radical metastasectomy. ","['patients with metastatic renal cell carcinoma treated with sorafenib or managed with an observation-alone strategy after the radical surgery of metastases', 'Clear-cell Renal Cell Carcinoma', 'mRCC patients following radical metastasectomy', '76 patients were screened and 69 were randomized: 33 were assigned to', 'selected metastatic renal cell carcinoma (mRCC) patients', 'Patients with clear-cell mRCC pretreated with nephrectomy and undergoing radical metastasectomy (three or fewer lesions) were eligible for the study', 'November 2012 and November 2017 in Italy', 'mRCC patients']","['sorafenib', 'Sorafenib Versus Observation Following Radical Metastasectomy']","['RFS', 'relapse-free survival', 'median RFS', 'Any-grade adverse event (AE) rates', 'RFS probability', 'recurrence-free survival (RFS', 'overall survival and the safety profile', 'grade ≥3\u202fAE rates']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0278678', 'cui_str': 'Metastatic renal cell carcinoma'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439807', 'cui_str': 'Radical - extent'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0279702', 'cui_str': 'Clear Cell Renal Carcinoma'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C2363923', 'cui_str': 'Metastasectomy'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0229473', 'cui_str': 'Cell of Claudius (cell)'}, {'cui': 'C0027695', 'cui_str': 'Nephrectomy'}, {'cui': 'C0205388', 'cui_str': 'Few (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0022277', 'cui_str': 'Italy'}]","[{'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0439807', 'cui_str': 'Radical - extent'}, {'cui': 'C2363923', 'cui_str': 'Metastasectomy'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease (finding)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",76.0,0.256367,"This prospective study showed that systemic treatment with sorafenib did not increase RFS as compared with observation in mRCC patients following radical metastasectomy. ","[{'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Procopio', 'Affiliation': 'Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: giuseppe.procopio@istitutotumori.mi.it.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Apollonio', 'Affiliation': 'Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Cognetti', 'Affiliation': 'Medical Oncology Department, Istituto Nazionale Tumori Regina Elena, Rome, Italy.'}, {'ForeName': 'Rosalba', 'Initials': 'R', 'LastName': 'Miceli', 'Affiliation': 'Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Milella', 'Affiliation': 'Medical Oncology Department, Istituto Nazionale Tumori Regina Elena, Rome, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Mosca', 'Affiliation': 'Department of Oncology, Maggiore Della Carità University Hospital, Novara, Italy.'}, {'ForeName': 'Vincenzo Emanuele', 'Initials': 'VE', 'LastName': 'Chiuri', 'Affiliation': 'Medical Oncology Department, Ospedale Vito Fazzi, Lecce, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Bearz', 'Affiliation': 'Medical Oncology Department, National Cancer Institute, Aviano, Italy.'}, {'ForeName': 'Franco', 'Initials': 'F', 'LastName': 'Morelli', 'Affiliation': 'Medical Oncology Department, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.'}, {'ForeName': 'Cinzia', 'Initials': 'C', 'LastName': 'Ortega', 'Affiliation': 'Medical Oncology Department, Istituto per la Ricerca e la Cura del Cancro di Candiolo, Torino, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Atzori', 'Affiliation': 'Medical Oncology Department, University Hospital, University of Cagliari, Cagliari, Italy.'}, {'ForeName': 'Maddalena', 'Initials': 'M', 'LastName': 'Donini', 'Affiliation': 'Medical Oncology Department, Ospedale di Cremona, Cremona, Italy.'}, {'ForeName': 'Raffaele', 'Initials': 'R', 'LastName': 'Ratta', 'Affiliation': 'Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Raimondi', 'Affiliation': 'Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Claps', 'Affiliation': 'Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Antonia', 'Initials': 'A', 'LastName': 'Martinetti', 'Affiliation': 'Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Umberto', 'Initials': 'U', 'LastName': 'Capitanio', 'Affiliation': 'Division of Experimental Oncology, Urological Research Institute, San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Filippo G', 'Initials': 'FG', 'LastName': 'de Braud', 'Affiliation': 'Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.'}, {'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Cappelletti', 'Affiliation': 'Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Verzoni', 'Affiliation': 'Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}]",European urology oncology,['10.1016/j.euo.2019.08.011'] 766,27377563,"Relationships Between Mental Health, Skill Sets, and Violence Perpetration Among Adolescent Girls.","This study examines relationships between emotional health, stress management skills, fight-avoidance skills, and two forms of violence perpetration among adolescent girls at high risk for violence involvement. Participants ( n = 253) were 13- to 17-year-old girls enrolled in a randomized controlled trial. The current study was completed with baseline data collected prior to the start of the intervention. Analyses examined self-report outcome measures of physical violence perpetration in the past 6 months (five-item scale, α = .79) and relational aggression perpetration in the past 30 days (six-item scale, α = .77). Independent variables included baseline measures of self-esteem (four-item scale, α = .89), emotional distress (six-item scale, α = .89), stress management skills (eight-item scale, α = .86), and fight avoidance skills (five-item scale, α = .70). Multivariate regression models predicted each form of violence perpetration controlling for age, race/ethnicity, violence victimization, and clustering of participants within clinics. Initial bivariate results showed that stress management skills and fight avoidance skills were inversely and significantly related to perpetration of both relational and physical violence. Emotional distress was related to significantly higher levels of both violence outcomes. In contrast, self-esteem was not significantly related to either violence outcome. Multivariate analyses revealed that stress management skills and fight avoidance skills were significantly protective against perpetration of both relational aggression and physical violence. In conclusion, findings suggest that clinicians providing services to adolescent girls involved in high risk behaviors assess and foster girls' development of stress management and fight avoidance skills to help reduce their risk of involvement in relational violence and physical fighting.",2019,Multivariate analyses revealed that stress management skills and fight avoidance skills were significantly protective against perpetration of both relational aggression and physical violence.,"['Adolescent Girls', 'adolescent girls at high risk for violence involvement', 'Participants ( n = 253) were 13- to 17-year-old girls enrolled']",[],"['relational aggression perpetration', 'physical violence perpetration', 'stress management skills and fight avoidance skills', 'self-esteem', 'relational aggression and physical violence', 'Emotional distress', 'self-esteem (four-item scale, α = .89), emotional distress (six-item scale, α = .89), stress management skills (eight-item scale, α = .86), and fight avoidance skills', 'perpetration of both relational and physical violence', 'Relationships Between Mental Health, Skill Sets, and Violence Perpetration']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C0205428', 'cui_str': 'Involvements (qualifier value)'}, {'cui': 'C0444864', 'cui_str': 'AM 13 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]",[],"[{'cui': 'C0001807', 'cui_str': 'Aggression'}, {'cui': 'C0476480', 'cui_str': 'Physical violence'}, {'cui': 'C0150788', 'cui_str': 'Manage stress control'}, {'cui': 'C0036597', 'cui_str': 'Self Esteem'}, {'cui': 'C0700361', 'cui_str': 'Emotional distress'}, {'cui': 'C0222045'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0042693', 'cui_str': 'Violence'}]",253.0,0.0186214,Multivariate analyses revealed that stress management skills and fight avoidance skills were significantly protective against perpetration of both relational aggression and physical violence.,"[{'ForeName': 'Calae D', 'Initials': 'CD', 'LastName': 'Philippe', 'Affiliation': '1 University of Minnesota, Minneapolis, USA.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Gloppen', 'Affiliation': '1 University of Minnesota, Minneapolis, USA.'}, {'ForeName': 'Renee E', 'Initials': 'RE', 'LastName': 'Sieving', 'Affiliation': '1 University of Minnesota, Minneapolis, USA.'}, {'ForeName': 'Iris W', 'Initials': 'IW', 'LastName': 'Borowsky', 'Affiliation': '1 University of Minnesota, Minneapolis, USA.'}, {'ForeName': 'Sandra L', 'Initials': 'SL', 'LastName': 'Pettingell', 'Affiliation': '1 University of Minnesota, Minneapolis, USA.'}]",Journal of interpersonal violence,['10.1177/0886260516657909'] 767,27381981,Boozy Nights and Violent Fights: Perceptions of Environmental Cues to Violence and Crime in Licensed Venues.,"This article examines perceptions of environmental cues to crime, violence, and injuries in barroom settings, and how they differ between bar fight participants and non-participants. Bouncer friendliness, patron sex composition, and room temperature were chosen as experimental variables based on three criteria: (a) emerged as a theme in bar user focus groups, (b) unclear effects in the literature, and (c) policy relevant and easy to modify. These experimental variables were manipulated in written vignettes set in a bar. A three-part online questionnaire recorded 681 male university students' responses to questions on demographics, the experiment, drinking and clubbing habits, and the Snell Masculinity Scale. A 2 × 2 × 2 randomized independent groups factorial design with covariates was embedded in the questionnaire, measuring the effects of the experimental variables on bar users' perceived fear of victimization, likelihood and frequency of crime, venue preference, and perceived severity of injuries after accounting for prior bar fight participation and masculinity. Participants generally rated perceived fear of victimization, likelihood and frequency of crime, and severity of injuries to be highest when the bouncer was unfriendly, the temperature was hot, and patrons were majority male. Only main effects were significant ( p < .01). Masculinity scale responses were not related to participant perceptions. While fight participants (9.8% of the sample) and non-participants had similar perceptions of the risk associated with certain environmental cues, fight participants were significantly (a) less fearful of victimization in settings they perceived as dangerous and (b) more willing to drink in any hypothetical venue.",2019,"While fight participants (9.8% of the sample) and non-participants had similar perceptions of the risk associated with certain environmental cues, fight participants were significantly (a) less fearful of victimization in settings they perceived as dangerous and (b) more willing to drink in any hypothetical venue.",['681 male university students'],[],"['Masculinity scale responses', 'fear of victimization, likelihood and frequency of crime, and severity of injuries', 'fear of victimization, likelihood and frequency of crime, venue preference, and perceived severity of injuries', 'Bouncer friendliness, patron sex composition, and room temperature']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}]",[],"[{'cui': 'C0042757', 'cui_str': 'Masculinity'}, {'cui': 'C0222045'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0376695', 'cui_str': 'Victimization'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0010325', 'cui_str': 'Crime'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0558295', 'cui_str': 'Preferences (qualifier value)'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}]",681.0,0.016884,"While fight participants (9.8% of the sample) and non-participants had similar perceptions of the risk associated with certain environmental cues, fight participants were significantly (a) less fearful of victimization in settings they perceived as dangerous and (b) more willing to drink in any hypothetical venue.","[{'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'de Andrade', 'Affiliation': '1 Griffith University, Mt Gravatt, Queensland, Australia.'}, {'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Homel', 'Affiliation': '1 Griffith University, Mt Gravatt, Queensland, Australia.'}, {'ForeName': 'Lorraine', 'Initials': 'L', 'LastName': 'Mazerolle', 'Affiliation': '2 The University of Queensland, St Lucia, Australia.'}]",Journal of interpersonal violence,['10.1177/0886260516657910'] 768,30998125,"Effects of short-term sprint interval and moderate-intensity continuous training on liver fat content, lipoprotein profile, and substrate uptake: a randomized trial.","Type 2 diabetes (T2D) and increased liver fat content (LFC) alter lipoprotein profile and composition and impair liver substrate uptake. Exercise training mitigates T2D and reduces LFC, but the benefits of different training intensities in terms of lipoprotein classes and liver substrate uptake are unclear. The aim of this study was to evaluate the effects of moderate-intensity continuous training (MICT) or sprint interval training (SIT) on LFC, liver substrate uptake, and lipoprotein profile in subjects with normoglycemia or prediabetes/T2D. We randomized 54 subjects (normoglycemic group, n = 28; group with prediabetes/T2D, n = 26; age = 40-55 yr) to perform either MICT or SIT for 2 wk and measured LFC with magnetic resonance spectroscopy, lipoprotein composition with NMR, and liver glucose uptake (GU) and fatty acid uptake (FAU) using PET. At baseline, the group with prediabetes/T2D had higher LFC, impaired lipoprotein profile, and lower whole body insulin sensitivity and aerobic capacity compared with the normoglycemic group. Both training modes improved aerobic capacity ( P < 0.001) and lipoprotein profile (reduced LDL and increased large HDL subclasses; all P < 0.05) with no training regimen (SIT vs. MICT) or group effect (normoglycemia vs. prediabetes/T2D). LFC tended to be reduced in the group with prediabetes/T2D compared with the normoglycemic group posttraining ( P = 0.051). When subjects were divided according to LFC (high LFC, >5.6%; low LFC, <5.6%), training reduced LFC in subjects with high LFC ( P = 0.009), and only MICT increased insulin-stimulated liver GU ( P = 0.03). Short-term SIT and MICT are effective in reducing LFC in subjects with fatty liver and in improving lipoprotein profile regardless of baseline glucose tolerance. Short-term MICT is more efficient in improving liver insulin sensitivity compared with SIT. NEW & NOTEWORTHY In the short term, both sprint interval training and moderate-intensity continuous training (MICT) reduce liver fat content and improve lipoprotein profile; however, MICT seems to be preferable in improving liver insulin sensitivity.",2019,Both training modes improved aerobic capacity ( P < 0.001) and lipoprotein profile (reduced LDL and increased large HDL subclasses; all P < 0.05) with no training regimen (SIT vs. MICT) or group effect (normoglycemia vs. prediabetes/T2D).,"['54 subjects (normoglycemic group, n = 28; group with prediabetes/T2D, n = 26; age\u2009=\u200940-55 yr', 'subjects with normoglycemia or prediabetes']","['short-term sprint interval and moderate-intensity continuous training', 'sprint interval training and moderate-intensity continuous training (MICT', 'moderate-intensity continuous training (MICT) or sprint interval training (SIT', 'MICT or SIT']","['Type 2 diabetes (T2D) and increased liver fat content (LFC) alter lipoprotein profile and composition and impair liver substrate uptake', 'LFC, liver substrate uptake, and lipoprotein profile', 'lipoprotein composition with NMR, and liver glucose uptake (GU) and fatty acid uptake (FAU', 'LFC', 'aerobic capacity', 'liver insulin sensitivity', 'lipoprotein profile (reduced LDL and increased large HDL subclasses', 'MICT increased insulin-stimulated liver GU', 'liver fat content, lipoprotein profile, and substrate uptake', 'higher LFC, impaired lipoprotein profile, and lower whole body insulin sensitivity and aerobic capacity']","[{'cui': 'C0580545', 'cui_str': 'Blood glucose normal (finding)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0362046', 'cui_str': 'Prediabetes'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C4279979', 'cui_str': 'Sprint Interval Training'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}]","[{'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0015684', 'cui_str': 'Fatty Acids'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0445604', 'cui_str': 'Subclass (attribute)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}]",54.0,0.0301251,Both training modes improved aerobic capacity ( P < 0.001) and lipoprotein profile (reduced LDL and increased large HDL subclasses; all P < 0.05) with no training regimen (SIT vs. MICT) or group effect (normoglycemia vs. prediabetes/T2D).,"[{'ForeName': 'Kumail K', 'Initials': 'KK', 'LastName': 'Motiani', 'Affiliation': 'Turku PET Centre, University of Turku , Turku , Finland.'}, {'ForeName': 'Anna M', 'Initials': 'AM', 'LastName': 'Savolainen', 'Affiliation': 'Turku PET Centre, University of Turku , Turku , Finland.'}, {'ForeName': 'Jussi', 'Initials': 'J', 'LastName': 'Toivanen', 'Affiliation': 'Turku PET Centre, University of Turku , Turku , Finland.'}, {'ForeName': 'Jari-Joonas', 'Initials': 'JJ', 'LastName': 'Eskelinen', 'Affiliation': 'Turku PET Centre, University of Turku , Turku , Finland.'}, {'ForeName': 'Minna', 'Initials': 'M', 'LastName': 'Yli-Karjanmaa', 'Affiliation': 'Turku PET Centre, University of Turku , Turku , Finland.'}, {'ForeName': 'Kirsi A', 'Initials': 'KA', 'LastName': 'Virtanen', 'Affiliation': 'Turku PET Centre, Turku University Hospital , Turku , Finland.'}, {'ForeName': 'Virva', 'Initials': 'V', 'LastName': 'Saunavaara', 'Affiliation': 'Turku PET Centre, University of Turku , Turku , Finland.'}, {'ForeName': 'Marja A', 'Initials': 'MA', 'LastName': 'Heiskanen', 'Affiliation': 'Turku PET Centre, University of Turku , Turku , Finland.'}, {'ForeName': 'Riitta', 'Initials': 'R', 'LastName': 'Parkkola', 'Affiliation': 'Department of Radiology, Turku University Hospital , Turku , Finland.'}, {'ForeName': 'Merja', 'Initials': 'M', 'LastName': 'Haaparanta-Solin', 'Affiliation': 'Turku PET Centre, University of Turku , Turku , Finland.'}, {'ForeName': 'Olof', 'Initials': 'O', 'LastName': 'Solin', 'Affiliation': 'Turku PET Centre, University of Turku , Turku , Finland.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Savisto', 'Affiliation': 'Turku PET Centre, University of Turku , Turku , Finland.'}, {'ForeName': 'Eliisa', 'Initials': 'E', 'LastName': 'Löyttyniemi', 'Affiliation': 'Department of Biostatistics, University of Turku , Turku , Finland.'}, {'ForeName': 'Juhani', 'Initials': 'J', 'LastName': 'Knuuti', 'Affiliation': 'Turku PET Centre, University of Turku , Turku , Finland.'}, {'ForeName': 'Pirjo', 'Initials': 'P', 'LastName': 'Nuutila', 'Affiliation': 'Turku PET Centre, University of Turku , Turku , Finland.'}, {'ForeName': 'Kari K', 'Initials': 'KK', 'LastName': 'Kalliokoski', 'Affiliation': 'Turku PET Centre, University of Turku , Turku , Finland.'}, {'ForeName': 'Jarna C', 'Initials': 'JC', 'LastName': 'Hannukainen', 'Affiliation': 'Turku PET Centre, University of Turku , Turku , Finland.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00900.2018'] 769,30908139,Monitoring and Developing a Volunteer Patient Navigation Intervention to Improve Mammography Compliance in a Safety Net Hospital.,"PURPOSE Although mammography screening is crucial for cancer detection, screening rates have been declining, particularly in patients of low socioeconomic status and minorities. We sought to evaluate and improve the compliance rates at our safety net hospital through a prospective randomized controlled trial of a volunteer-run patient navigation intervention. METHODS Baseline 90-day institutional mammography compliance rates were evaluated for patients who received a physician order for screening mammograms over a 1-month period. This analysis aided in the creation of a prospective randomized controlled trial of a volunteer-run patient navigation intervention to improve compliance, with 49 total participants. The primary outcome was 14-day mammography compliance rates. Secondary analysis examined the efficacy of the intervention with respect to patient demographics, prior mammography compliance, family history of cancer, beliefs on mammography, and past medical history. RESULTS Analysis of baseline institutional compliance revealed a 47.87% compliance rate, with the majority of compliance occurring within 14 days of order placement. The patient navigation intervention significantly improved compliance by 34% (42% in the control group, 76% in the intervention group). Additional findings included significantly improved compliance in patients who believed they had a low susceptibility to cancer, those who understood the benefits of mammography and early diagnosis, those who had a prior mammogram, those who were employed, and those with a family history of cancer. CONCLUSION A system to monitor compliance and intervene using patient navigation significantly improved mammography compliance of patients in a safety net hospital. The relatively straightforward design of this volunteer-based intervention makes it affordable, easily replicable, and perhaps beneficial at other institutions.",2019,"The patient navigation intervention significantly improved compliance by 34% (42% in the control group, 76% in the intervention group).","['patients who received a physician order for screening mammograms over a 1-month period', '49 total participants']","['mammography screening', 'volunteer-run patient navigation intervention', 'Volunteer Patient Navigation Intervention']","['14-day mammography compliance rates', 'mammography compliance', 'compliance', 'compliance rates', 'patient demographics, prior mammography compliance, family history of cancer, beliefs on mammography, and past medical history']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]","[{'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C3494323', 'cui_str': 'Navigations, Patient'}]","[{'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0260515', 'cui_str': 'Family history of cancer'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0455458', 'cui_str': 'Past medical history'}]",,0.0482546,"The patient navigation intervention significantly improved compliance by 34% (42% in the control group, 76% in the intervention group).","[{'ForeName': 'Ilana G', 'Initials': 'IG', 'LastName': 'Margulies', 'Affiliation': '1 New York Medical College, Valhalla, NY.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Zwillenberg', 'Affiliation': '2 NYC Health + Hospitals/Metropolitan, New York, NY.'}, {'ForeName': 'Anisha', 'Initials': 'A', 'LastName': 'Chadda', 'Affiliation': '2 NYC Health + Hospitals/Metropolitan, New York, NY.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Gissel', 'Affiliation': '1 New York Medical College, Valhalla, NY.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lettera', 'Affiliation': '2 NYC Health + Hospitals/Metropolitan, New York, NY.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Bender', 'Affiliation': '2 NYC Health + Hospitals/Metropolitan, New York, NY.'}, {'ForeName': 'Marc K', 'Initials': 'MK', 'LastName': 'Wallack', 'Affiliation': '1 New York Medical College, Valhalla, NY.'}, {'ForeName': 'Anitha', 'Initials': 'A', 'LastName': 'Srinivasan', 'Affiliation': '1 New York Medical College, Valhalla, NY.'}]",Journal of oncology practice,['10.1200/JOP.18.00424'] 770,31655314,"Effectiveness of deep tissue massage therapy, and supervised strengthening and stretching exercises for subacute or persistent disabling neck pain. The Stockholm Neck (STONE) randomized controlled trial.","OBJECTIVE To compare the effectiveness of deep tissue massage, supervised strengthening and stretching exercises, and a combined therapy (exercise followed by massage) (index groups), with advice to stay active (control group). METHODS Randomized controlled trial of 619 adults with subacute or persistent neck pain allocated to massage (n = 145), exercise (n = 160), combined therapy (n = 169) or advice (n = 147). Primary outcomes were minimal clinically important improvements in neck pain intensity and pain-related disability based on adapted questions from the Chronic Pain Questionnaire. Secondary outcomes were perceived recovery and sickness absence. Outcomes were measured at seven, 12, 26 and 52 weeks. RESULTS We found improvement in pain intensity favouring massage and combined therapy compared to advice; at seven weeks (RR = 1.36; 95%CI:1.04-1.77) and 26 weeks (RR = 1.23; 95%CI:0.97-1.56); and seven (RR = 1.39; 95%CI:1.08-1.81) and 12 weeks (RR = 1.28; 95%CI:1.02-1.60) respectively, but not at later follow-ups. Exercise showed higher improvement of pain intensity at 26 weeks (RR = 1.31; 95%CI:1.04-1.65). Perceived recovery was higher in the index groups than in the advice group at all follow-ups. We found no consistent differences in pain related disability or sickness absence. CONCLUSIONS In this study, at 12-months follow-up, none of the index therapies were more effective than advice in terms of pain intensity in the long term or in terms of pain-related disability in the short or long term. However, the index therapies led to higher incidence of improvement in pain intensity in the short term, and higher incidence of favorable perceived recovery in the short and in the long term than advice. TRIAL REGISTRATION ISRCTN01453590. Registered 3 July 2014.",2020,Exercise showed higher improvement of pain intensity at 26 weeks (RR = 1.31; 95%CI:1.04-1.65).,"['subacute or persistent disabling neck pain', '619 adults with subacute or persistent neck pain allocated to massage (n\u202f=\u202f145']","['deep tissue massage, supervised strengthening and stretching exercises, and a combined therapy (exercise followed by massage) (index groups), with advice to stay active (control group', 'deep tissue massage therapy, and supervised strengthening and stretching exercises', 'exercise (n\u202f=\u202f160), combined therapy (n\u202f=\u202f169) or advice']","['neck pain intensity and pain-related disability based on adapted questions from the Chronic Pain Questionnaire', 'Perceived recovery', 'pain intensity', 'recovery and sickness absence', 'pain related disability or sickness absence']","[{'cui': 'C0205365', 'cui_str': 'Subacute course'}, {'cui': 'C0007859', 'cui_str': 'Neck Ache'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C4517577', 'cui_str': '145'}]","[{'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0600080', 'cui_str': 'Stretching procedure (procedure)'}, {'cui': 'C0033972', 'cui_str': 'Psychotherapy, Multiple'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to (procedure)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3536731', 'cui_str': 'Massage Therapy'}, {'cui': 'C4319554', 'cui_str': '160'}]","[{'cui': 'C0007859', 'cui_str': 'Neck Ache'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C1689985', 'cui_str': 'Absence'}]",619.0,0.205242,Exercise showed higher improvement of pain intensity at 26 weeks (RR = 1.31; 95%CI:1.04-1.65).,"[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Skillgate', 'Affiliation': 'Musculoskeletal and Sports Injury Epidemiology Center, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Naprapathögskolan - Scandinavian College of Naprapathic Manual Medicine, Stockholm, Sweden.'}, {'ForeName': 'Oscar Javier', 'Initials': 'OJ', 'LastName': 'Pico-Espinosa', 'Affiliation': 'Musculoskeletal and Sports Injury Epidemiology Center, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address: Oscar.pico.espinosa@ki.se.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Côté', 'Affiliation': 'Faculty of Health Sciences and UOIT-CMCC Centre for the Study of Disability Prevention and Rehabilitation, University of Ontario Institute of Technology, Toronto, Canada.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Jensen', 'Affiliation': 'Unit of Intervention and Implementation Research for Worker Health, Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Viklund', 'Affiliation': 'Musculoskeletal and Sports Injury Epidemiology Center, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Naprapathögskolan - Scandinavian College of Naprapathic Manual Medicine, Stockholm, Sweden.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Bottai', 'Affiliation': 'Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Lena W', 'Initials': 'LW', 'LastName': 'Holm', 'Affiliation': 'Musculoskeletal and Sports Injury Epidemiology Center, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.'}]",Musculoskeletal science & practice,['10.1016/j.msksp.2019.102070'] 771,31369841,Post-exercise hypotension and skeletal muscle oxygenation is regulated by nitrate-reducing activity of oral bacteria.,"Post-exercise hypotension (PEH) is a common physiological phenomenon leading to lower blood pressure after acute exercise, but it is not fully understood how this intriguing response occurs. This study investigated whether the nitrate-reducing activity of oral bacteria is a key mechanism to trigger PEH. Following a randomized, double blind and crossover design, twenty-three healthy individuals (15 males/8 females) completed two treadmill trials at moderate intensity. After exercise, participants rinsed their mouth with antibacterial mouthwash to inhibit the activity of oral bacteria or a placebo mouthwash. Blood pressure was measured before, 1h and 2 h after exercise. The microvascular response to a reactive hyperaemia test, as well as blood and salivary samples were taken before and 2 h after exercise to analyse nitrate and nitrite concentrations and the oral microbiome. As expected, systolic blood pressure (SBP) was lower (1 h: -5.2 ± 1.0 mmHg; P < 0.001); 2 h: -3.8 ± 1.1 mmHg, P = 0.005) after exercise compared to baseline in the placebo condition. This was accompanied by an increase of circulatory nitrite 2 h after exercise (2h: 100 ± 13 nM) compared to baseline (59 ± 9 nM; P = 0.013). Additionally, an increase in the peak of the tissue oxygenation index (TOI) during the reactive hyperaemia response was observed after exercise (86.1 ± 0.6%) compared to baseline levels (84.8 ± 0.5%; P = 0.010) in the placebo condition. On the other hand, the SBP-lowering effect of exercise was attenuated by 61% at 1 h in the recovery period, and it was fully attenuated 2 h after exercise with antibacterial mouthwash. This was associated with a lack of changes in circulatory nitrite (P > 0.05), and impaired microvascular response (peak TOI baseline: 85.1 ± 3.1%; peak TOI post-exercise: 84.6 ± 3.2%; P > 0.05). Diversity of oral bacteria did not change after exercise in any treatment. These findings show that nitrite synthesis by oral commensal bacteria is a key mechanism to induce the vascular response to exercise over the first period of recovery thereby promoting lower blood pressure and greater muscle oxygenation.",2019,"This was associated with a lack of changes in circulatory nitrite (P > 0.05), and impaired microvascular response (peak TOI baseline: 85.1 ± 3.1%; peak TOI post-exercise: 84.6 ± 3.2%; P > 0.05).",['twenty-three healthy individuals (15 males/8 females'],"['placebo mouthwash', 'Post-exercise hypotension (PEH']","['Blood pressure', 'circulatory nitrite', 'peak of the tissue oxygenation index (TOI) during the reactive hyperaemia response', 'microvascular response', 'systolic blood pressure (SBP']","[{'cui': 'C0450348', 'cui_str': '23 (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0026647', 'cui_str': 'Oral Rinse'}, {'cui': 'C2936233', 'cui_str': 'Postexercise Hypotension'}]","[{'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0028137', 'cui_str': 'Nitrites'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C1278185', 'cui_str': 'Oxygenation index'}, {'cui': 'C0205332', 'cui_str': 'Reactive (qualifier value)'}, {'cui': 'C0020452', 'cui_str': 'Hyperemia'}, {'cui': 'C0443258', 'cui_str': 'Microvascular (qualifier value)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}]",23.0,0.169928,"This was associated with a lack of changes in circulatory nitrite (P > 0.05), and impaired microvascular response (peak TOI baseline: 85.1 ± 3.1%; peak TOI post-exercise: 84.6 ± 3.2%; P > 0.05).","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Cutler', 'Affiliation': 'Institute of Health & Community, University of Plymouth, Plymouth, UK.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kiernan', 'Affiliation': 'Peninsula Medical School, University of Plymouth, Plymouth, UK.'}, {'ForeName': 'J R', 'Initials': 'JR', 'LastName': 'Willis', 'Affiliation': 'Centre for Genomic Regulation (CRG), The Barcelona Institute of Science & Technology, Barcelona, Spain.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Gallardo-Alfaro', 'Affiliation': 'Research Group on Community Nutrition and Oxidative Stress, University of Balearic Islands & CIBEROBN (CB12/03/30038), Palma de Mallorca, Spain.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Casas-Agustench', 'Affiliation': 'Institute of Health & Community, University of Plymouth, Plymouth, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'White', 'Affiliation': 'Institute of Health & Community, University of Plymouth, Plymouth, UK.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Hickson', 'Affiliation': 'Institute of Health & Community, University of Plymouth, Plymouth, UK.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Gabaldon', 'Affiliation': 'Centre for Genomic Regulation (CRG), The Barcelona Institute of Science & Technology, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; Institució Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Bescos', 'Affiliation': 'Institute of Health & Community, University of Plymouth, Plymouth, UK. Electronic address: Raul.Bescos@plymouth.ac.uk.'}]",Free radical biology & medicine,['10.1016/j.freeradbiomed.2019.07.035'] 772,31402072,A patient- and assessor-blinded randomized controlled trial of axillary reverse mapping (ARM) in patients with early breast cancer.,"BACKGROUND Axillary lymph node dissection (ALND) in breast cancer patients is infamous for its accompanying morbidity. Selective preservation of upper extremity lymphatic drainage and accompanying lymph nodes crossing the axillary basin - currently resected during a standard ALND - has been proposed as a valuable surgical refinement. METHODS Peroperative Axillary Reversed Mapping (ARM) was used for selective preservation of upper extremity lymphatic drainage. A multicentre patient- and assessor-blinded randomized study was performed in clinical node negative, sentinel node positive early breast cancer patients. Patients were randomized to undergo either standard-ALND or ARM-ALND. Primary outcome was the presence of surgery-related lymphedema at six, 12 and 24 months post-operatively. Secondary outcomes included patient reported and objective signs and symptoms of lymphedema, pain, paraesthesia, numbness, loss of shoulder mobility, quality of life and axillary recurrence risk. RESULTS No significant differences were found between both groups using the water displacement method with respect to measured lymphedema. ARM-ALND resulted in less reported complaints of lymphedema at six, 12 and 24 months postoperatively (p < 0.05). No axillary recurrence was found in both groups. CONCLUSIONS In contrast to results of volumetric measurement, patient reported outcomes support selective sparing of the upper extremity lymphatic drainage using ARM as valuable surgical refinement in case of ALND in clinically node negative, sentinel node positive early breast cancer. If completion ALND in clinically node negative, sentinel node positive early breast cancer is considered, selective sparing of upper extremity axillary lymphatics by implementing ARM should be carried out in order to reduce morbidity.",2020,"ARM-ALND resulted in less reported complaints of lymphedema at six, 12 and 24 months postoperatively (p < 0.05).","['sentinel node positive early breast cancer patients', 'breast cancer patients', 'patients with early breast cancer']","['standard-ALND or ARM-ALND', 'axillary reverse mapping (ARM', 'Peroperative Axillary Reversed Mapping (ARM']","['axillary recurrence', 'lymphedema', 'patient reported and objective signs and symptoms of lymphedema, pain, paraesthesia, numbness, loss of shoulder mobility, quality of life and axillary recurrence risk', 'presence of surgery-related lymphedema', 'complaints of lymphedema']","[{'cui': 'C0677944', 'cui_str': 'Signal node (disorder)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0004454', 'cui_str': 'Axilla'}]","[{'cui': 'C0004454', 'cui_str': 'Axilla'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0024236', 'cui_str': 'Lymphedema'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0037088', 'cui_str': 'Signs and Symptoms'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C0020580', 'cui_str': 'Reduced Sensation'}, {'cui': 'C0037004', 'cui_str': 'Shoulder'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0034380'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0277786', 'cui_str': 'Presenting complaint'}]",,0.0793643,"ARM-ALND resulted in less reported complaints of lymphedema at six, 12 and 24 months postoperatively (p < 0.05).","[{'ForeName': 'Martinus A', 'Initials': 'MA', 'LastName': 'Beek', 'Affiliation': 'Department of Surgery, Amphia Hospital, Breda, the Netherlands. Electronic address: MBeek@amphia.nl.'}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Gobardhan', 'Affiliation': 'Department of Surgery, Amphia Hospital, Breda, the Netherlands.'}, {'ForeName': 'Elisabeth G', 'Initials': 'EG', 'LastName': 'Klompenhouwer', 'Affiliation': 'Department of Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Marian B', 'Initials': 'MB', 'LastName': 'Menke-Pluijmers', 'Affiliation': 'Department of Surgery, Albert Schweitzer Hospital, Dordrecht, the Netherlands.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Steenvoorde', 'Affiliation': 'Department of Surgery, Medisch Spectrum Twente Hospital, Twente, the Netherlands.'}, {'ForeName': 'Jos Ws', 'Initials': 'JW', 'LastName': 'Merkus', 'Affiliation': 'Department of Surgery, Haga Hospital, The Hague, the Netherlands.'}, {'ForeName': 'Harm Jt', 'Initials': 'HJ', 'LastName': 'Rutten', 'Affiliation': 'Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands; Department of Surgery, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Adri C', 'Initials': 'AC', 'LastName': 'Voogd', 'Affiliation': 'Department of Epidemiology, Faculty of Health Medicine and Life Sciences, Research Institute Growth and Development (GROW), Maastricht University, Maastricht, the Netherlands; Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.'}, {'ForeName': 'Ernest Jt', 'Initials': 'EJ', 'LastName': 'Luiten', 'Affiliation': 'Department of Surgery, Amphia Hospital, Breda, the Netherlands.'}]",European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,['10.1016/j.ejso.2019.08.003'] 773,31493749,Examining motivational interviewing's effect on confidence and commitment using daily data.,"Mechanisms of behavior change (MOBC) within Motivational Interviewing (MI) are thought to operate via both relational and technical elements. These elements are hypothesized to increase client motivation and self-efficacy for change and subsequently decrease drinking. Only partial support for this causal chain exists, particularly when using within-session change talk as the primary intervening variable. This study explored whether commitment to moderate or abstain from drinking and confidence to moderate drinking in the next day measured via ecological momentary assessment (EMA) provided alternative support for the theory. Data were from a pilot randomized controlled trial testing active ingredients of MI. Problem drinkers (N = 89) seeking to moderate their drinking were randomly assigned to one of the three conditions: 1) MI; 2) Spirit only MI (SOMI), consisting of non-directive elements of MI, e.g., reflective listening; and 3) a non-therapy control. Participants completed daily EMA that measured confidence, both types of commitment, and drinks per day for a week prior to and during seven weeks of treatment. Hypotheses were not supported, and results were unexpected. Participants in SOMI were more likely to have higher daily confidence than those in MI; there were no condition differences for either type of commitment. All daily measures significantly predicted drinking; however, the MI group did not demonstrate a stronger relationship between the intervening variables and drinking, as hypothesized. Instead, participants in SOMI yielded the strongest relationship between daily commitment to abstain and drinking compared to the other two conditions. Multiple possible explanations for the unexpected findings are discussed.",2019,Participants in SOMI were more likely to have higher daily confidence than those in MI; there were no condition differences for either type of commitment.,['Problem drinkers (N\u202f=\u202f89) seeking to moderate their drinking'],"['Motivational Interviewing (MI', 'MI; 2) Spirit only MI (SOMI), consisting of non-directive elements of MI, e.g., reflective listening; and 3) a non-therapy control']",['client motivation and self-efficacy'],"[{'cui': 'C0687725', 'cui_str': 'Alcoholics'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}]","[{'cui': 'C0683474', 'cui_str': 'Motivational Interviewing'}, {'cui': 'C1705899', 'cui_str': 'Spirit (basic dose form)'}, {'cui': 'C0013879', 'cui_str': 'Elements'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",,0.0206516,Participants in SOMI were more likely to have higher daily confidence than those in MI; there were no condition differences for either type of commitment.,"[{'ForeName': 'Alexis', 'Initials': 'A', 'LastName': 'Kuerbis', 'Affiliation': 'Silberman School of Social Work, Hunter College at the City University of New York, New York, NY 10035, USA. Electronic address: ak1465@hunter.cuny.edu.'}, {'ForeName': 'Kevin G', 'Initials': 'KG', 'LastName': 'Lynch', 'Affiliation': 'Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA.'}, {'ForeName': 'Sijing', 'Initials': 'S', 'LastName': 'Shao', 'Affiliation': 'Center for Addiction Services and Personalized Interventions Research, Northwell Health, Great Neck, NY 11021, USA.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Morgenstern', 'Affiliation': 'Center for Addiction Services and Personalized Interventions Research, Northwell Health, Great Neck, NY 11021, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2019.04.038'] 774,31658111,Effectiveness of the virtual reality on cognitive function of children with hemiplegic cerebral palsy: a single-blind randomized controlled trial.,"Cerebral palsy is a term covering non-progressive motor and cognitive impairments caused by lesions of the brain. This study aims to evaluate the effectiveness of virtual reality-based rehabilitation program for children with hemiplegic cerebral palsy on cognitive functions. Ninety children (47 boys, 43 girls) with hemiplegic cerebral palsy were randomized to either study (n = 45; 11.18 ± 3.37 years) or control (n = 45; 11.06 ± 3.24 years) groups. The study group received virtual reality intervention in addition to Traditional Occupational Therapy intervention, and the control group received Traditional Occupational Therapy for 20 sessions. Both groups were evaluated by blinded assessors with Dynamic Occupational Therapy Cognitive Assessment for Children to collect information on cognitive functioning. Both groups' cognitive functions were improved after 10 weeks of interventions. The between-group comparison revealed significantly greater improvements in all subtest of cognitive functions in the virtual reality group than in the Traditional Occupational Therapy group (P < 0.001). Our results showed that 10 weeks of virtual reality-based rehabilitation enhanced cognitive functions in children with hemiplegic cerebral palsy. Using virtual reality applications in cognitive rehabilitation was recommended to improve spatial perception, praxis, visuomotor construction and thinking operations in children with cerebral palsy.",2020,Our results showed that 10 weeks of virtual reality-based rehabilitation enhanced cognitive functions in children with hemiplegic cerebral palsy.,"['children with hemiplegic cerebral palsy on cognitive functions', 'children with cerebral palsy', 'Ninety children (47 boys, 43 girls) with hemiplegic cerebral palsy', 'children with hemiplegic cerebral palsy']","['virtual reality intervention in addition to Traditional Occupational Therapy intervention, and the control group received Traditional Occupational Therapy', 'virtual reality-based rehabilitation', 'virtual reality-based rehabilitation program', 'virtual reality', 'Dynamic Occupational Therapy Cognitive Assessment']","['cognitive function', 'cognitive functions', 'spatial perception, praxis, visuomotor construction and thinking operations', 'subtest of cognitive functions']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0270805', 'cui_str': 'Hemiplegic cerebral palsy (disorder)'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0007789', 'cui_str': 'CP (Cerebral Palsy)'}, {'cui': 'C3816959', 'cui_str': 'Ninety'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C1318464', 'cui_str': 'Occupational Therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0441513', 'cui_str': 'Construction (attribute)'}, {'cui': 'C4319827', 'cui_str': 'Thought'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}]",90.0,0.0285749,Our results showed that 10 weeks of virtual reality-based rehabilitation enhanced cognitive functions in children with hemiplegic cerebral palsy.,"[{'ForeName': 'Orkun Tahir', 'Initials': 'OT', 'LastName': 'Aran', 'Affiliation': 'Hacettepe University Faculty of Health Sciences, Occupational Therapy, Ankara.'}, {'ForeName': 'Sedef', 'Initials': 'S', 'LastName': 'Şahin', 'Affiliation': 'Hacettepe University Faculty of Health Sciences, Occupational Therapy, Ankara.'}, {'ForeName': 'Barkin', 'Initials': 'B', 'LastName': 'Köse', 'Affiliation': 'Hacettepe University Faculty of Health Sciences, Occupational Therapy, Ankara.'}, {'ForeName': 'Zeynep Bahadir', 'Initials': 'ZB', 'LastName': 'Ağce', 'Affiliation': 'Üsküdar University Faculty of Health Sciences, Occupational Therapy, İstanbul, Turkey.'}, {'ForeName': 'Hülya', 'Initials': 'H', 'LastName': 'Kayihan', 'Affiliation': 'Hacettepe University Faculty of Health Sciences, Occupational Therapy, Ankara.'}]",International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation,['10.1097/MRR.0000000000000378'] 775,31719675,Longitudinal neovascular changes on optical coherence tomography angiography in proliferative diabetic retinopathy treated with panretinal photocoagulation alone versus with intravitreal conbercept plus panretinal photocoagulation: a pilot study.,"PURPOSE To investigate the longitudinal changes in neovascularization of the retinal elsewhere (NVE) size on optical coherence tomography angiography (OCTA) in proliferative diabetic retinopathy (PDR) treated by panretinal photocoagulation (PRP) alone or by single intravitreal conbercept injection plus PRP. METHODS A prospective pilot study. Forty-four PDR eyes with NVE confirmed by fundus fluorescein angiography (FFA) and OCTA were included. They were assigned to receive PRP alone (PRP group) or intravitreal conbercept injection plus PRP (combination group). Ophthalmic examinations, including BCVA and OCTA to measure the NVE size, were performed at baseline before each PRP session, and at 1, 3, and 6 months. RESULTS Twenty-nine eyes were included in the PRP group, and 15 eyes were included in the combination group. There was no significant difference between the two groups with respect to age, BCVA, and NVE area at baseline. In both groups, there was a significant (P < 0.05) NVE size reduction during the majority of study visits, with the reduction observed in the combination group significantly larger than that in the PRP group. No significant BCVA changes were observed in either groups, except that in the PRP group, the BCVA at 3 months was significantly improved (P < 0.05). No deaths or unexpected adverse events (AEs) were reported. CONCLUSIONS Intravitreal conbercept plus PRP was more effective than PRP monotherapy in NVE regression. Precise quantification of the NVE area by OCTA makes it a useful tool for monitoring the response of retinal neovascular lesions to the therapy.",2020,"There was no significant difference between the two groups with respect to age, BCVA, and NVE area at baseline.","['proliferative diabetic retinopathy treated with', 'Forty-four PDR eyes with NVE confirmed by fundus fluorescein angiography (FFA) and OCTA were included', 'proliferative diabetic retinopathy (PDR', 'Twenty-nine eyes were included in the PRP group, and 15 eyes were included in the combination group']","['optical coherence tomography angiography', 'intravitreal conbercept plus panretinal photocoagulation', 'PRP alone (PRP group) or intravitreal conbercept injection plus PRP', 'panretinal photocoagulation alone', 'panretinal photocoagulation (PRP) alone or by single intravitreal conbercept injection plus PRP', 'optical coherence tomography angiography (OCTA']","['No deaths or unexpected adverse events (AEs', 'NVE size reduction', 'BCVA changes', 'BCVA and OCTA to measure the NVE size', 'BCVA']","[{'cui': 'C0154830', 'cui_str': 'PDR - proliferative diabetic retinopathy'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by (contextual qualifier) (qualifier value)'}, {'cui': 'C0430878', 'cui_str': 'Retinal angiography'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0450351', 'cui_str': '29 (qualifier value)'}, {'cui': 'C0242848', 'cui_str': 'PrP (GSS)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0920367', 'cui_str': 'Tomography, Optical Coherence'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}, {'cui': 'C2352201', 'cui_str': 'KH902 fusion protein'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0730064', 'cui_str': 'Scatter retinal laser photocoagulation'}, {'cui': 'C0242848', 'cui_str': 'PrP (GSS)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",44.0,0.0175467,"There was no significant difference between the two groups with respect to age, BCVA, and NVE area at baseline.","[{'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'He', 'Affiliation': 'Department of Ophthalmology, Peking Union Medical College Hospital, Key Lab of Ocular Fundus Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Weihong', 'Initials': 'W', 'LastName': 'Yu', 'Affiliation': 'Department of Ophthalmology, Peking Union Medical College Hospital, Key Lab of Ocular Fundus Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. yuweihongeye@foxmail.com.'}]","Eye (London, England)",['10.1038/s41433-019-0628-3'] 776,30958973,Effects of high-velocity resistance training and creatine supplementation in untrained healthy aging males.,"The purpose was to investigate the effects of high-velocity resistance training (HVRT) and creatine supplementation in untrained healthy aging males. Participants were randomized to supplement with creatine (0.1 g·kg -1 ·day -1 of creatine + 0.1 g·kg -1 ·day -1 of maltodextrin) or placebo (0.2 g·kg -1 ·day -1 of maltodextrin) during 8 weeks of HVRT. Prior to and following HVRT and supplementation, assessments were made for muscle strength, muscle thickness, peak torque, and physical performance. There was a significant increase over time for all measures of muscle strength ( p < 0.001), muscle thickness ( p < 0.001), and some measures of peak torque (knee flexion; 1.05 and 3.14 rad/s; p < 0.001) and physical performance (balance board time-to-completion; p = 0.017). There was a group × time interaction for leg press strength ( p = 0.044) and total lower-body strength (leg press, knee flexion, knee extension combined; p = 0.039). The creatine group experienced greater gains in leg press and total lower-body strength compared with the placebo group, with no other differences. HVRT increases muscle strength, muscle thickness, and some measures of peak torque and physical performance in untrained healthy aging males. The addition of creatine supplementation to HVRT further augments the gains in leg press and total lower-body strength. Novelty High-velocity resistance training increases muscle mass and performance. Creatine supplementation increases lower-body muscle strength. High-velocity resistance training and creatine supplementation are safe interventions for aging adults.",2019,"There was a significant increase over time for all measures of muscle strength (p < 0.001), muscle thickness (p < 0.001) and some measures of peak torque (knee flexion; 1.05 and 3.14 rad/s; p < 0.001) and physical performance (balance board time-to-completion; p = 0.017).","['untrained healthy aging males', 'aging adults']","['High-velocity resistance training', 'high-velocity resistance training (HVRT) and creatine supplementation', 'creatine (0.1 g·kg-1·d-1 of creatine + 0.1 g·kg-1·d-1 of maltodextrin) or placebo (0.2 g·kg-1·d-1 of maltodextrin', 'high-velocity resistance training and creatine supplementation', 'HVRT']","['total lower-body strength (leg press, knee flexion', 'peak torque', 'gains in leg press and total lower-body strength', 'peak torque and physical performance', 'muscle strength, muscle thickness', 'muscle thickness', 'leg press strength', 'muscle strength', 'Novelty', 'muscle strength, muscle thickness, peak torque and physical performance', 'physical performance']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0010286', 'cui_str': 'Creatine'}, {'cui': 'C4517420', 'cui_str': 'Zero point one'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4517436', 'cui_str': '0.2'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1268088', 'cui_str': 'Lower body'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0231452', 'cui_str': 'Flexion, function (observable entity)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0376590', 'cui_str': 'Torque'}, {'cui': 'C2607857'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}]",,0.0330765,"There was a significant increase over time for all measures of muscle strength (p < 0.001), muscle thickness (p < 0.001) and some measures of peak torque (knee flexion; 1.05 and 3.14 rad/s; p < 0.001) and physical performance (balance board time-to-completion; p = 0.017).","[{'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Bernat', 'Affiliation': 'Faculty of Kinesiology and Health Studies, University of Regina, Regina, SK S4S 0A2, Canada.'}, {'ForeName': 'Darren G', 'Initials': 'DG', 'LastName': 'Candow', 'Affiliation': 'Faculty of Kinesiology and Health Studies, University of Regina, Regina, SK S4S 0A2, Canada.'}, {'ForeName': 'Karolina', 'Initials': 'K', 'LastName': 'Gryzb', 'Affiliation': 'Faculty of Kinesiology and Health Studies, University of Regina, Regina, SK S4S 0A2, Canada.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Butchart', 'Affiliation': 'Faculty of Kinesiology and Health Studies, University of Regina, Regina, SK S4S 0A2, Canada.'}, {'ForeName': 'Brad J', 'Initials': 'BJ', 'LastName': 'Schoenfeld', 'Affiliation': 'Department of Health Sciences, School of Health, Human Services and Nursing, CUNY Lehman College, Bronx, NY 10468, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Bruno', 'Affiliation': 'Faculty of Kinesiology and Health Studies, University of Regina, Regina, SK S4S 0A2, Canada.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2019-0066'] 777,30846465,Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.,"INTRODUCTION The Multicenter International Lymphangioleiomyomatosis (LAM) Efficacy of Sirolimus (MILES) trial revealed that sirolimus stabilised lung function in patients with moderately severe LAM. The purpose of this study was to further examine the MILES cohort for the effects of racial, demographic, clinical and physiological patient characteristics on disease progression and treatment response in LAM. METHODS MILES subjects were stratified on the basis of menopausal status (pre-menopausal/post-menopausal), race (Asian/Caucasian), bronchodilator responsiveness (present/absent), initial forced expiratory volume in 1 s (FEV 1 ; 51-70% versus ≤50% predicted) and tuberous sclerosis complex (TSC) association (yes/no). A linear mixed effects model was used to compare slope differences, and nonparametric tests were used to compare medians and proportions between treatment groups in each stratum. RESULTS In the MILES placebo group, pre-menopausal patients declined 5-fold faster than post-menopausal patients (mean±se FEV 1 slope -17±3 versus -3±3 mL·month -1 ; p=0.003). Upon treatment with sirolimus, both the pre-menopausal (-17±3 versus -1±2 mL·month -1 ; p<0.0001) and post-menopausal patients (-3±3 versus 6±3 mL·month -1 ; p=0.04) exhibited a beneficial response in mean±se FEV 1 slope compared with the placebo group. Race, LAM subtype, bronchodilator responsiveness or baseline FEV 1 did not impact the rate of disease progression in the placebo group or treatment response in the sirolimus group. Menopausal status and race had differential effects on the adverse event profile of sirolimus. Baseline serum vascular endothelial growth factor (VEGF)-D >600 pg·mL -1 identified subgroups of patients who were more likely to decline on placebo and respond to treatment with sirolimus. CONCLUSIONS In LAM patients, treatment with sirolimus is beneficial regardless of menopausal status, race, bronchodilator responsiveness, baseline FEV 1 or TSC association. Serum VEGF-D and menopausal status can help inform therapeutic decisions.",2019,FEV 1 did not impact the rate of disease progression in the placebo group or treatment response in the sirolimus group.,"['patients with moderately severe LAM', 'MILES subjects were stratified on the basis of menopausal status (pre-menopausal/post-menopausal), race (Asian/Caucasian']","['sirolimus', 'MILES placebo', 'placebo', 'Sirolimus (MILES', 'Lymphangioleiomyomatosis (LAM']","['rate of disease progression', 'Baseline serum vascular endothelial growth factor (VEGF)-D ', 'Serum VEGF-D and menopausal status']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0065041', 'cui_str': 'lipoarabinomannan'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C1626935', 'cui_str': 'Base'}, {'cui': 'C0025320', 'cui_str': 'Change of Life, Female'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}, {'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C0043157', 'cui_str': 'Whites'}]","[{'cui': 'C0072980', 'cui_str': 'Sirolimus'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0751674', 'cui_str': 'Lymphangioleiomyomatosis'}, {'cui': 'C0065041', 'cui_str': 'lipoarabinomannan'}]","[{'cui': 'C0242656', 'cui_str': 'Disease Progression'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0664390', 'cui_str': 'Vascular Endothelial Growth Factor D'}, {'cui': 'C0025320', 'cui_str': 'Change of Life, Female'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]",,0.156081,FEV 1 did not impact the rate of disease progression in the placebo group or treatment response in the sirolimus group.,"[{'ForeName': 'Nishant', 'Initials': 'N', 'LastName': 'Gupta', 'Affiliation': 'University of Cincinnati, Cincinnati, OH, USA.'}, {'ForeName': 'Hye-Seung', 'Initials': 'HS', 'LastName': 'Lee', 'Affiliation': 'University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Lisa R', 'Initials': 'LR', 'LastName': 'Young', 'Affiliation': 'Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Charlie', 'Initials': 'C', 'LastName': 'Strange', 'Affiliation': 'Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Moss', 'Affiliation': 'National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Lianne G', 'Initials': 'LG', 'LastName': 'Singer', 'Affiliation': 'University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Koh', 'Initials': 'K', 'LastName': 'Nakata', 'Affiliation': 'Niigata University Medical and Dental Hospital, Niigata, Japan.'}, {'ForeName': 'Alan F', 'Initials': 'AF', 'LastName': 'Barker', 'Affiliation': 'Oregon Health and Science University, Portland, OR, USA.'}, {'ForeName': 'Jeffrey T', 'Initials': 'JT', 'LastName': 'Chapman', 'Affiliation': 'Cleveland Clinic, Abu Dhabi, United Arab Emirates.'}, {'ForeName': 'Mark L', 'Initials': 'ML', 'LastName': 'Brantly', 'Affiliation': 'University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Stocks', 'Affiliation': 'University of Texas Health Sciences Center, Tyler, TX, USA.'}, {'ForeName': 'Kevin K', 'Initials': 'KK', 'LastName': 'Brown', 'Affiliation': 'National Jewish Health and the University of Colorado, Denver, CO, USA.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'Lynch', 'Affiliation': 'University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Hilary J', 'Initials': 'HJ', 'LastName': 'Goldberg', 'Affiliation': 'Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Gregory P', 'Initials': 'GP', 'LastName': 'Downey', 'Affiliation': 'National Jewish Health and the University of Colorado, Denver, CO, USA.'}, {'ForeName': 'Angelo M', 'Initials': 'AM', 'LastName': 'Taveira-DaSilva', 'Affiliation': 'National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Jeffrey P', 'Initials': 'JP', 'LastName': 'Krischer', 'Affiliation': 'University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Setchell', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Bruce C', 'Initials': 'BC', 'LastName': 'Trapnell', 'Affiliation': 'University of Cincinnati, Cincinnati, OH, USA.'}, {'ForeName': 'Yoshikazu', 'Initials': 'Y', 'LastName': 'Inoue', 'Affiliation': 'National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.'}, {'ForeName': 'Francis X', 'Initials': 'FX', 'LastName': 'McCormack', 'Affiliation': 'University of Cincinnati, Cincinnati, OH, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The European respiratory journal,['10.1183/13993003.02066-2018'] 778,30865281,"Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.","STUDY QUESTION Can asoprisnil, a selective progesterone receptor modulator, provide clinically meaningful improvements in heavy menstrual bleeding (HMB) associated with uterine fibroids with an acceptable safety profile? SUMMARY ANSWER Uninterrupted treatment with asoprisnil for 12 months effectively controlled HMB and reduced fibroid and uterine volume with few adverse events. WHAT IS KNOWN ALREADY In a 3-month study, asoprisnil (5, 10 and 25 mg) suppressed uterine bleeding, reduced fibroid and uterine volume, and improved hematological parameters in a dose-dependent manner. STUDY DESIGN, SIZE, DURATION In two Phase 3, double-blind, randomized, placebo-controlled, multicentre studies, women received oral asoprisnil 10 mg, asoprisnil 25 mg or placebo (2:2:1) once daily for up to 12 months. PARTICIPANTS/MATERIALS, SETTING, METHODS Premenopausal women ≥18 years of age in North America with HMB associated with uterine fibroids were included (N = 907). The primary efficacy endpoint was the percentage of women who met all three predefined criteria at 12 months or the final month for patients who prematurely discontinued: (1) ≥50% reduction in monthly blood loss (MBL) by menstrual pictogram, (2) hemoglobin concentration ≥11 g/dL or an increase of ≥1 g/dL, and (3) no interventional therapy for uterine fibroids. Secondary efficacy endpoints included changes in other menstrual bleeding parameters, volume of the largest fibroids, uterine volume and health-related quality of life (HRQL). MAIN RESULTS AND THE ROLE OF CHANCE In all, 90% and 93% of women in the asoprisnil 10-mg and 25-mg groups, respectively, and 35% of women in the placebo group met the primary endpoint (P < 0.001). Similar results were observed at month 6 (P < 0.001). The percentage of women who achieved amenorrhea in any specified month ranged from 66-78% in the asoprisnil 10-mg group and 83-93% in the asoprisnil 25-mg group, significantly higher than with placebo (3-12%, P < 0.001). Hemoglobin increased rapidly (by month 2) with asoprisnil treatment and was significantly higher versus placebo throughout treatment. The primary fibroid and uterine volumes were significantly reduced from baseline through month 12 with asoprisnil 10 mg (median changes up to -48% and -28%, respectively) and 25 mg (median changes up to -63% and -39%, respectively) versus placebo (median changes up to +16% and +13%, respectively; all P < 0.001). Dose-dependent, significant improvements in HRQL (Uterine Fibroid Symptom and Quality of Life instrument) were observed with asoprisnil treatment. Asoprisnil was generally well tolerated. Endometrial biopsies indicated dose- and time-dependent decreases in proliferative patterns and increases in quiescent or minimally stimulated endometrium at month 12 of treatment. Although not statistically significantly different at month 6, mean endometrial thickness at month 12 increased by ~2 mm in both asoprisnil groups compared with placebo (P < 0.01). This effect was associated with cystic changes in the endometrium on MRI and ultrasonography, which led to invasive diagnostic and therapeutic procedures in some asoprisnil-treated women. LIMITATIONS, REASONS FOR CAUTION Most study participants were black; few Asian and Hispanic women participated. The study duration may have been insufficient to fully characterize the endometrial effects. WIDER IMPLICATIONS OF THE FINDINGS Daily uninterrupted treatment with asoprisnil was highly effective in controlling menstrual bleeding, improving anemia, reducing fibroid and uterine volume, and increasing HRQL in women with HMB associated with uterine fibroids. However, this treatment led to an increase in endometrial thickness and invasive diagnostic and therapeutic procedures, with potential unknown consequences. STUDY FUNDING/COMPETING INTEREST(S) This trial was funded by AbbVie Inc. (prior sponsors: TAP Pharmaceutical Products Inc., Abbott Laboratories). E.A. Stewart was a site investigator in the Phase 2 study of asoprisnil and consulted for TAP during the design and conduct of these studies while at Harvard Medical School and Brigham and Women's Hospital. She received support from National Institutes of Health grants HD063312, HS023418 and HD074711 and research funding, paid to Mayo Clinic for patient care costs related to an NIH-funded trial from InSightec Ltd. She consulted for AbbVie, Allergan, Bayer HealthCare AG, Gynesonics, and Welltwigs. She received royalties from UpToDate and the Med Learning Group. M.P. Diamond received research funding for the conduct of the studies paid to the institution and consulted for AbbVie. He is a stockholder and board and director member of Advanced Reproductive Care. He has also received funding for study conduct paid to the institution from Bayer and ObsEva. A.R.W. Williams consulted for TAP and Repros Therapeutics Inc. He has current consultancies with PregLem SA, Gedeon Richter, HRA Pharma and Bayer. B.R. Carr consulted for and received research funding from AbbVie. E.R. Myers consulted for AbbVie, Allergan and Bayer. R.A. Feldman received compensation for serving as a principal investigator and participating in the conduct of the trial. W. Elger was co-inventor of several patents related to asoprisnil. C. Mattia-Goldberg is a former employee of AbbVie and may own AbbVie stock or stock options. B.M. Schwefel and K. Chwalisz are employees of AbbVie and may own AbbVie stock or stock options. TRIAL REGISTRATION NUMBER NCT00152269, NCT00160381 (clinicaltrials.gov). TRIAL REGISTRATION DATE 7 September 2005; 8 September 2005. DATE OF FIRST PATIENT’S ENROLMENT 12 September 2002; 6 September 2002.",2019,Hemoglobin increased rapidly (by month 2) with asoprisnil treatment and was significantly higher versus placebo throughout treatment.,"['women with HMB associated with uterine fibroids', '’S ENROLMENT\n\n\n12 September 2002; 6 September 2002', '7 September 2005; 8 September 2005', 'heavy menstrual bleeding with uterine fibroids', 'participants were black; few Asian and Hispanic women participated', 'Premenopausal women ≥18 years of age in North America with HMB associated with uterine fibroids were included (N = 907']","['selective progesterone receptor modulator asoprisnil', 'placebo', 'oral asoprisnil 10 mg, asoprisnil 25 mg or placebo']","['uterine bleeding, reduced fibroid and uterine volume, and improved hematological parameters', 'percentage of women who achieved amenorrhea', 'tolerated', 'HRQL (Uterine Fibroid Symptom and Quality of Life instrument', 'fibroid and uterine volume', 'primary fibroid and uterine volumes', 'monthly blood loss (MBL) by menstrual pictogram, (2) hemoglobin concentration ≥11', 'mean endometrial thickness', 'menstrual bleeding parameters, volume of the largest fibroids, uterine volume and health-related quality of life (HRQL', 'endometrial thickness and invasive diagnostic and therapeutic procedures', 'proliferative patterns', 'Hemoglobin', 'Safety and efficacy']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0042133', 'cui_str': 'Fibroid Uterus'}, {'cui': 'C0025323', 'cui_str': 'Heavy Menstrual Bleeding'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C3653463', 'cui_str': 'Progesterone receptor modulators'}, {'cui': 'C1455381', 'cui_str': 'benzaldehyde, 4-((11beta, 17beta)-17-methoxy-17-(methoxymethyl)-3-oxoestra-4, 9-dien-11beta-yl)-, 1-oxime'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0042134', 'cui_str': 'Uterine Bleeding'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0042133', 'cui_str': 'Fibroid Uterus'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0002453', 'cui_str': 'Amenorrhea'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034380'}, {'cui': 'C4551823', 'cui_str': 'instruments'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C1318517', 'cui_str': 'Hemoglobin concentration, dipstick - finding'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.275149,Hemoglobin increased rapidly (by month 2) with asoprisnil treatment and was significantly higher versus placebo throughout treatment.,"[{'ForeName': 'E A', 'Initials': 'EA', 'LastName': 'Stewart', 'Affiliation': 'Departments of Obstetrics & Gynecology and Surgery, Mayo Clinic and Mayo Medical School, Rochester, MN, USA.'}, {'ForeName': 'M P', 'Initials': 'MP', 'LastName': 'Diamond', 'Affiliation': 'Department of Obstetrics & Gynecology, Augusta University, Augusta, GA, USA.'}, {'ForeName': 'A R W', 'Initials': 'ARW', 'LastName': 'Williams', 'Affiliation': 'Department of Pathology, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'B R', 'Initials': 'BR', 'LastName': 'Carr', 'Affiliation': 'Department of Obstetrics & Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'E R', 'Initials': 'ER', 'LastName': 'Myers', 'Affiliation': 'Department of Obstetrics & Gynecology, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'R A', 'Initials': 'RA', 'LastName': 'Feldman', 'Affiliation': 'Miami Research Associates, Miami, FL, USA.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Elger', 'Affiliation': 'Evestra GmbH, Berlin-Dahlem, Germany.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Mattia-Goldberg', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}, {'ForeName': 'B M', 'Initials': 'BM', 'LastName': 'Schwefel', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Chwalisz', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}]","Human reproduction (Oxford, England)",['10.1093/humrep/dez007'] 779,30911991,"Bacillus coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study.","Functional constipation has a high prevalence in both adults and children affecting quality of life. Evidence suggests that probiotics can reduce the symptoms of constipation. As the effects of probiotics are strain specific, the efficacy of Bacillus coagulans Unique IS2 in the treatment of functional constipation in adults was evaluated. Subjects (n = 100) diagnosed with functional constipation were supplemented with either B. coagulans Unique IS2 (2 billion CFU) or placebo capsules once daily for 4 weeks. Subjects were evaluated for treatment success (defined as three or more spontaneous stools per week), stool consistency, difficulty of defecation, defecation and abdominal pain. By the end of the fourth week, there was a statistically significant (p < 0.001) increase in number of bowel movements in the probiotic treated group as compared to placebo. Ninety eight percent of subjects in the probiotic group achieved normal stool consistency as compared to placebo (74%). Moreover, there was relief from symptoms of incomplete evacuation, painful defecation and abdominal pain associated with constipation in probiotic treated group as compared to placebo. In conclusion, B. coagulans Unique IS2 significantly decreased the symptoms of constipation indicating effectiveness of the strain in the treatment of constipation.Trial registration: CTRI/2017/11/010539.",2020,"By the end of the fourth week, there was a statistically significant (p < 0.001) increase in number of bowel movements in the probiotic treated group as compared to placebo.","['Bacillus coagulans Unique IS2 in Constipation', 'Subjects (n\u2009=\u2009100) diagnosed with functional constipation']","['Placebo', 'placebo']","['number of bowel movements', 'stool consistency, difficulty of defecation, defecation and abdominal pain', 'normal stool consistency', 'symptoms of constipation', 'relief from symptoms of incomplete evacuation, painful defecation and abdominal pain associated with constipation']","[{'cui': 'C0004587', 'cui_str': 'Bacillus'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0401146', 'cui_str': 'Constipation - functional (disorder)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0332529', 'cui_str': 'Consistency finding'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C1301676', 'cui_str': 'Relieves (qualifier value)'}, {'cui': 'C0205257', 'cui_str': 'Incomplete (qualifier value)'}, {'cui': 'C1282573', 'cui_str': 'Evacuation procedure'}, {'cui': 'C0237326', 'cui_str': 'Dyschezia'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}]",,0.116527,"By the end of the fourth week, there was a statistically significant (p < 0.001) increase in number of bowel movements in the probiotic treated group as compared to placebo.","[{'ForeName': 'Ratna Sudha', 'Initials': 'RS', 'LastName': 'Madempudi', 'Affiliation': 'Centre for Research and Development, Unique Biotech Ltd., Plot No. 2, Phase II, Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India. sudha@uniquebiotech.com.'}, {'ForeName': 'Jayanthi', 'Initials': 'J', 'LastName': 'Neelamraju', 'Affiliation': 'Centre for Research and Development, Unique Biotech Ltd., Plot No. 2, Phase II, Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India.'}, {'ForeName': 'Jayesh J', 'Initials': 'JJ', 'LastName': 'Ahire', 'Affiliation': 'Centre for Research and Development, Unique Biotech Ltd., Plot No. 2, Phase II, Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India.'}, {'ForeName': 'Sandeep K', 'Initials': 'SK', 'LastName': 'Gupta', 'Affiliation': 'Department of Paediatrics, MV Hospital and Research Centre, First Floor, Room No. 01 314/30 Mirza Mandi Chowk, Lucknow, Uttar Pradesh, 226003, India.'}, {'ForeName': 'Vineet K', 'Initials': 'VK', 'LastName': 'Shukla', 'Affiliation': 'Department of Paediatrics, KRM Hospital and Research Centre, First Floor, Room No. 01 3/92-93 Vijayant Khand, Lucknow, Uttar Pradesh, 226010, India.'}]",Probiotics and antimicrobial proteins,['10.1007/s12602-019-09542-9'] 780,31709895,Effect of tunneled and nontunneled peripherally inserted central catheter placement: A randomized controlled trial.,"PURPOSE To compare the effect of tunneled and nontunneled peripherally inserted central catheter placement under B-mode ultrasound. METHODS A single center, randomized, controlled, nonblinded, prospective trial was conducted in Guangzhou, China, between July 2018 and May 2019. A total of 174 participants were randomized to the experimental group (tunneled peripherally inserted central catheter) or the control group (nontunneled peripherally inserted central catheter) and were followed until extubation. Basic characteristics, peripherally inserted central catheter characteristics, the incidence of complications, and the costs of peripherally inserted central catheter placement and maintenance were collected. Data were analyzed by intention-to-treat. RESULTS A total of 168 of the participants had successful peripherally inserted central catheter placements (85/87, 97.7% in the experimental group and 83/87, 95.4% in the control group, P  = 0.682). Compared to the control group, the experimental group had a lower incidence of complications during the placement (18.4% vs 32.2%, P  = 0.036), a lower incidence of wound oozing (27.6% vs 57.5%, P  < 0.001), a lower incidence of medical adhesive-related skin injury (9.2% vs 25.3%, P  = 0.005), a lower incidence of venous thrombosis (1.1% vs 9.2%, P  = 0.034), a lower incidence of catheter dislodgement (1.1% vs 9.2%, P  = 0.034), and lower costs of peripherally inserted central catheter maintenance at 1, 2, and 3 months ( P  < 0.05). CONCLUSION Tunneled peripherally inserted central catheter may be recommended for good effectiveness.",2020,"Compared to the control group, the experimental group had a lower incidence of complications during the placement (18.4% vs 32.2%, P  = 0.036), a lower incidence of wound oozing (27.6% vs 57.5%, P  < 0.001), a lower incidence of medical adhesive-related skin injury (9.2% vs 25.3%, P  = 0.005), a lower incidence of venous thrombosis (1.1% vs 9.2%, P  = 0.034), a lower incidence of catheter dislodgement (1.1% vs 9.2%, P  = 0.034), and lower costs of peripherally inserted central catheter maintenance at 1, 2, and 3 months ( P  < 0.05). ","['Guangzhou, China, between July 2018 and May 2019', '174 participants']","['tunneled and nontunneled peripherally inserted central catheter placement under B-mode ultrasound', 'tunneled and nontunneled peripherally inserted central catheter placement', 'experimental group (tunneled peripherally inserted central catheter) or the control group (nontunneled peripherally inserted central catheter']","['lower costs of peripherally inserted central catheter maintenance', 'successful peripherally inserted central catheter placements', 'catheter dislodgement', 'venous thrombosis', 'wound oozing', 'medical adhesive-related skin injury', 'incidence of complications']","[{'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C4517604', 'cui_str': 'One hundred and seventy-four'}]","[{'cui': 'C3854183', 'cui_str': 'Tunneler (physical object)'}, {'cui': 'C0179740', 'cui_str': 'Long line'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C1302166', 'cui_str': 'B mode ultrasound'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0179740', 'cui_str': 'Long line'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C0042487', 'cui_str': 'Phlebothrombosis'}, {'cui': 'C0406834', 'cui_str': 'Wound discharge finding'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0001516', 'cui_str': 'Adhesives'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0281980', 'cui_str': 'Injury of integument'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}]",174.0,0.137078,"Compared to the control group, the experimental group had a lower incidence of complications during the placement (18.4% vs 32.2%, P  = 0.036), a lower incidence of wound oozing (27.6% vs 57.5%, P  < 0.001), a lower incidence of medical adhesive-related skin injury (9.2% vs 25.3%, P  = 0.005), a lower incidence of venous thrombosis (1.1% vs 9.2%, P  = 0.034), a lower incidence of catheter dislodgement (1.1% vs 9.2%, P  = 0.034), and lower costs of peripherally inserted central catheter maintenance at 1, 2, and 3 months ( P  < 0.05). ","[{'ForeName': 'Can', 'Initials': 'C', 'LastName': 'Dai', 'Affiliation': 'School of Nursing, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Catheter Clinic, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Qiu-Mei', 'Initials': 'QM', 'LastName': 'Li', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Xiuquan', 'Initials': 'X', 'LastName': 'Guo', 'Affiliation': 'Department of Catheter Clinic, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Yu-Ying', 'Initials': 'YY', 'LastName': 'Fan', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Hui-Ying', 'Initials': 'HY', 'LastName': 'Qin', 'Affiliation': 'Department of Nursing, Sun Yat-sen University Cancer Center, Guangzhou, China.'}]",The journal of vascular access,['10.1177/1129729819888120'] 781,30848697,Myocardial protection and clinical outcomes in Tetralogy of Fallot patients undergoing intracardiac repair: a randomized study of two cardioplegic techniques.,"BACKGROUND Myocardial protection in Tetralogy of Fallot patients undergoing intracardiac repair is suboptimal due to hypertrophied right ventricle. Hypertrophied myocardium is more susceptible to poor myocardial preservation because of inadequate capillary density as compared to the myocytes. There is a capillary to myocyte ratio mismatch. But del Nido Cardioplegia owing to its less viscosity is able to get more evenly distributed under hypothermic cardiopulmonary bypass as opposed to blood Cardioplegia. We hypothesized that the del Nido Cardioplegia technique, would be beneficial in myocardial protection because of its composition and method of delivery, leading into better early and late clinical outcomes in patients undergoing Tetralogy of Fallot repair as compared to blood cardioplegia reconstituted using St Thomas Cardioplegia solution. The objective of the study was to identify a better technique of myocardial preservation in Tetralogy of Fallot patient. METHODS In total, 56 Tetralogy of Fallot patients undergoing intracardiac repair under mild hypothermic cardiopulmonary bypass were randomly allocated to receive antegrade Cardioplegia with either standard blood Cardioplegia (Group I) or del Nido Cardioplegia (Group II). Preoperative as well as postoperative data including echocardiographic parameters for right ventricle functions, creatine kinase MB level, inotropic requirement, mechanical ventilation duration, intensive care unit stay and hospital mortality were evaluated. RESULTS Inotropic score in the first 24 hours postoperatively was significantly lower in Group II compared to Group I (13.4 ± 7.2 vs. 21.2 ± 9.6, p = 0.003). Creatine kinase MB level (ng/mL) was comparable between the groups. Echocardiographic parameters for right ventricle functions were also comparable between the groups during early as well as after 3 to 6 months postoperatively. CONCLUSION Del Nido Cardioplegia is equally efficacious in providing myocardial protection during intracardiac repair under mild hypothermic cardiopulmonary bypass in Tetralogy of Fallot patients as compared to blood Cardioplegia solution with the added benefit of reducing inotropic requirement in first 24 hours postoperative period.",2019,"Echocardiographic parameters for right ventricle functions were also comparable between the groups during early as well as after 3 to 6 months postoperatively. ","['patients undergoing Tetralogy of Fallot repair', '56 Tetralogy of Fallot patients undergoing intracardiac repair under mild hypothermic cardiopulmonary bypass', 'Tetralogy of Fallot patient', 'Tetralogy of Fallot patients undergoing', 'intracardiac repair under mild hypothermic cardiopulmonary bypass in Tetralogy of Fallot patients', 'Tetralogy of Fallot patients undergoing intracardiac repair']","['intracardiac repair', 'antegrade Cardioplegia with either standard blood Cardioplegia (Group I) or del Nido Cardioplegia']","['Echocardiographic parameters for right ventricle functions', 'Inotropic score', 'postoperative data including echocardiographic parameters for right ventricle functions, creatine kinase MB level, inotropic requirement, mechanical ventilation duration, intensive care unit stay and hospital mortality', 'Creatine kinase MB level (ng/mL']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0397326', 'cui_str': 'Repair of tetralogy of Fallot (procedure)'}, {'cui': 'C0039685', 'cui_str': 'Tetralogy of Fallot'}, {'cui': 'C0729936', 'cui_str': 'Intracardiac (qualifier value)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0007202', 'cui_str': 'Heart-Lung Bypass'}]","[{'cui': 'C0729936', 'cui_str': 'Intracardiac (qualifier value)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C0677513', 'cui_str': 'Antegrade (qualifier value)'}, {'cui': 'C0018791', 'cui_str': 'Cardioplegia'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0005768'}, {'cui': 'C0441843', 'cui_str': 'Group I (qualifier value)'}]","[{'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0225883', 'cui_str': 'Right Ventricle'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0523584', 'cui_str': 'Creatine kinase MB measurement'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0085556', 'cui_str': 'Mortalities, In-house'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}]",56.0,0.0437195,"Echocardiographic parameters for right ventricle functions were also comparable between the groups during early as well as after 3 to 6 months postoperatively. ","[{'ForeName': 'Sunder Lal', 'Initials': 'SL', 'LastName': 'Negi', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Banashree', 'Initials': 'B', 'LastName': 'Mandal', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Rana Sandeep', 'Initials': 'RS', 'LastName': 'Singh', 'Affiliation': 'Department of Cardiothoracic and Vascular Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Goverdhan Dutt', 'Initials': 'GD', 'LastName': 'Puri', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}]",Perfusion,['10.1177/0267659119828890'] 782,30836169,Improving the cost-effectiveness of laypersons' paediatric basic life support skills training: A randomised non-inferiority study.,"AIM To compare dyad (training in pairs without an instructor) with resource-intensive instructor-led training for laypersons' paediatric resuscitation skills in a non-inferiority trial and examine cost-effectiveness of the training methods. METHODS In this randomised parallel group non-inferiority trial, 155 dyad and 175 instructor-led laypersons were trained in Basic Life Support and Foreign Body Airway Obstruction Management. Dyads were given instructional videos, hands-on exercises and provided feedback to their partner for 50 min. Instructor-led laypersons trained in groups of six for two hours. Learning were assessed in scenarios immediately after training and, subsequently, at 14 days, 1, and 3 months. Pass rates, cost-effectiveness of producing a competent layperson (passing both tests), and non-inferiority were analysed. RESULTS Sixty-eight (45.6%) dyad and 130 (74.3%) instructor-led laypersons passed the basic life support test (p < 0.001). For Foreign Body Airway Obstruction Management 77 (54.2%) dyad and 130 (79.3%) for instructor-led laypersons passed (p < 0.001). Skills decreased over three months for both groups. Forty-two (30.4%) dyad and ninety-eight (59.8%) for instructor-led laypersons were competent after training (p < 0.001). The lower effectiveness of dyad training had reduced costs (p < 0.001). For each 10,000 USD allocated to training, dyad training would result in 71 vs. 65 competent laypersons for instructor-led training. Non-inferiority of dyad training could not be established. CONCLUSION Instructor-led training was the most effective but also the most expensive training method, making it less cost-effective than dyad training. When the aim is to train for quantity rather than quality, dyad training would be the preferred choice of training method.",2019,The lower effectiveness of dyad training had reduced costs (p < 0.001).,['Sixty-eight (45.6'],"[""laypersons' paediatric basic life support skills training"", '155 dyad and 175 instructor-led laypersons were trained in Basic Life Support and Foreign Body Airway Obstruction Management', 'dyad (training in pairs without an instructor) with resource-intensive instructor-led training', 'dyad training', 'instructional videos, hands-on exercises and provided feedback to their partner for 50\u2009min']","['Skills', 'Pass rates, cost-effectiveness of producing a competent layperson', 'cost-effectiveness']","[{'cui': 'C0450387', 'cui_str': '68 (qualifier value)'}]","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0085873', 'cui_str': 'Basic life support (procedure)'}, {'cui': 'C0559197', 'cui_str': 'Skills training (procedure)'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C0556993', 'cui_str': 'Instructor (occupation)'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0016542', 'cui_str': 'Foreign Objects'}, {'cui': 'C0001883', 'cui_str': 'Airway Obstruction'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",,0.0768941,The lower effectiveness of dyad training had reduced costs (p < 0.001).,"[{'ForeName': 'Asbjørn', 'Initials': 'A', 'LastName': 'Hasselager', 'Affiliation': 'University of Copenhagen, Copenhagen Academy for Medical Education and Simulation (CAMES), RegionH, Denmark. Electronic address: ahasselager@dadlnet.dk.'}, {'ForeName': 'Cathrine', 'Initials': 'C', 'LastName': 'Bohnstedt', 'Affiliation': 'Department of Pediatrics, North Zealand Hospital, Denmark.'}, {'ForeName': 'Doris', 'Initials': 'D', 'LastName': 'Østergaard', 'Affiliation': 'University of Copenhagen, Copenhagen Academy for Medical Education and Simulation (CAMES), RegionH, Denmark.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Sønderskov', 'Affiliation': 'RedMitBarn - Firstaiders, Frederiksberg, Denmark.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Bihrmann', 'Affiliation': 'National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.'}, {'ForeName': 'Martin G', 'Initials': 'MG', 'LastName': 'Tolsgaard', 'Affiliation': 'University of Copenhagen, Copenhagen Academy for Medical Education and Simulation (CAMES), RegionH, Denmark.'}, {'ForeName': 'Torsten L B', 'Initials': 'TLB', 'LastName': 'Lauritsen', 'Affiliation': 'Department of Anaesthesia, The Juliane Marie Centre, Rigshospitalet University Hospital, Copenhagen, Denmark.'}]",Resuscitation,['10.1016/j.resuscitation.2019.02.032'] 783,19058914,Differential brain activation associated with laser-evoked burning and pricking pain: An event-related fMRI study.,"An important question remains as to how the brain differentially processes first (pricking) pain mediated by Adelta-nociceptors versus second (burning) pain mediated by C-nociceptors. In the present cross-over randomized, within-subjects controlled study, brain activity patterns were examined with event-related fMRI while pricking and burning pain were selectively evoked using a diode laser. Stimuli evoking equivalent pain intensities were delivered to the dorsum of the left foot. Different laser parameters were used to elicit pricking (60ms pulse duration) and burning (2.0s pulse duration) pain. Whole brain group analysis showed that several brain areas were commonly activated by pricking and burning pain, including bilateral thalamus, bilateral anterior insula, bilateral posterior parietal lobule, contralateral dorsolateral prefrontal cortex, ipsilateral cerebellum, and mid anterior cingulate cortex. These findings show that pricking and burning pain were associated with activity in many of the same nociceptive processing brain regions. This may be expected given that Adelta-and C-nociceptive signals converge to a great extent at the level of the dorsal horn. Other brain regions showed differential processing. Stronger activation in the pricking pain condition was found in the ipsilateral hippocampus, bilateral parahippocampal gyrus, bilateral fusiform gyrus, contralateral cerebellum and contralateral cuneus/parieto-occipital sulcus. Stronger activation in the burning pain condition was found in the ipsilateral dorsolateral prefrontal cortex. These differential activation patterns suggest preferential importance of Adelta-fiber signals versus C-fiber signals for these specific brain regions.",2009,"Stronger activation in the pricking pain condition was found in the ipsilateral hippocampus, bilateral parahippocampal gyrus, bilateral fusiform gyrus, contralateral cerebellum and contralateral cuneus/parieto-occipital sulcus.",[],['laser-evoked burning and pricking pain'],"['elicit pricking (60ms pulse duration) and burning (2.0s pulse duration) pain', 'burning pain, including bilateral thalamus, bilateral anterior insula, bilateral posterior parietal lobule, contralateral dorsolateral prefrontal cortex, ipsilateral cerebellum, and mid anterior cingulate cortex', 'ipsilateral hippocampus, bilateral parahippocampal gyrus, bilateral fusiform gyrus, contralateral cerebellum and contralateral cuneus/parieto-occipital sulcus']",[],"[{'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C1444748', 'cui_str': 'Provoked by (attribute)'}, {'cui': 'C0006434', 'cui_str': 'Burns'}, {'cui': 'C0423603', 'cui_str': 'Pricking pain (finding)'}]","[{'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0006434', 'cui_str': 'Burns'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0234230', 'cui_str': 'Pain, Burning'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0039729', 'cui_str': 'Thalamencephalon'}, {'cui': 'C0228259', 'cui_str': 'Anterior insula (body structure)'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C3853038', 'cui_str': 'Parietal Lobule'}, {'cui': 'C0441988', 'cui_str': 'Contralateral (qualifier value)'}, {'cui': 'C4019080', 'cui_str': 'Dorsolateral Prefrontal Cortex'}, {'cui': 'C0441989', 'cui_str': 'Ipsilateral (qualifier value)'}, {'cui': 'C0007765', 'cui_str': 'Parencephalon'}, {'cui': 'C0444598', 'cui_str': 'Mid (qualifier value)'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate'}, {'cui': 'C0949582', 'cui_str': 'Seahorses'}, {'cui': 'C0228249', 'cui_str': 'Gyrus Hippocampi'}, {'cui': 'C0228243', 'cui_str': 'Gyrus Fusiformis'}, {'cui': 'C0152307', 'cui_str': 'Cuneate Lobule'}, {'cui': 'C1744592', 'cui_str': 'Parietooccipital sulcus'}]",,0.0254801,"Stronger activation in the pricking pain condition was found in the ipsilateral hippocampus, bilateral parahippocampal gyrus, bilateral fusiform gyrus, contralateral cerebellum and contralateral cuneus/parieto-occipital sulcus.","[{'ForeName': 'Dieuwke S', 'Initials': 'DS', 'LastName': 'Veldhuijzen', 'Affiliation': 'Department of Biomedical Sciences, Dental School, University of Maryland, Baltimore, MD, USA. D.S.Veldhuijzen@umcutrecht.nl'}, {'ForeName': 'Michael I', 'Initials': 'MI', 'LastName': 'Nemenov', 'Affiliation': ''}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Keaser', 'Affiliation': ''}, {'ForeName': 'Jiachen', 'Initials': 'J', 'LastName': 'Zhuo', 'Affiliation': ''}, {'ForeName': 'Rao P', 'Initials': 'RP', 'LastName': 'Gullapalli', 'Affiliation': ''}, {'ForeName': 'Joel D', 'Initials': 'JD', 'LastName': 'Greenspan', 'Affiliation': ''}]",Pain,['10.1016/j.pain.2008.10.027'] 784,30923980,"Comment to: Laparoscopic versus hybrid approach for treatment of incisional ventral hernia: a prospective randomized multicenter study of 1-month follow-up results. Ahonen-Siirtola M, Nevala T, Vironen J et al.",,2020,,['incisional ventral hernia'],['Laparoscopic versus hybrid approach'],[],"[{'cui': 'C0019326', 'cui_str': 'Ventral Hernia'}]","[{'cui': 'C0020205', 'cui_str': 'Hybrids'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}]",[],,0.0307919,,"[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Snegovskikh', 'Affiliation': 'Department of Anesthesiology, Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI, 02903, USA. Denis_Snegovskikh@brown.edu.'}]",Hernia : the journal of hernias and abdominal wall surgery,['10.1007/s10029-019-01929-5'] 785,30896284,Maturity status effects on torque and muscle architecture of young soccer players.,"This study investigated the effects of maturity status on knee extensor torque and vastus lateralis architecture of young soccer players. Thirty-four males aged 13-18 years were divided into two groups: pubescent (PUB, n = 15) and postpubescent (POSP, n = 19). Torque by angle interaction was established for absolute [F(2.649, 84.771) = 9.066, p < 0.05] and relative to body mass [F(2.704, 86.533) = 4.050, p < 0.05] isometric torque with the POSP group showing greater values. Muscle volume torque-angle relationship was similar between groups. Absolute, relative to body mass, and relative to muscle volume concentric and eccentric torque-velocity relationship showed a non-significant interaction but a significant group effect in favour the POSP group for absolute and concentric torque relative to body mass. Torque-angle and torque-velocity relationship normalized by body mass allometric exponents showed a non-significant interactions and group effects. Muscle thickness (3.6 ± 0.6 vs. 3.8 ± 0.6 cm), fascicle length (8.3 ± 1.4 vs. 8.9 ± 1.6 cm) and pennation angle (15.0 ± 2.3 vs. 14.3 ± 3.2 degrees) was similar between PUB and POSP groups, respectively. Maturity status did not show a significant effect on muscle architecture and on isometric and dynamic torques when allometrically normalized.",2020,Maturity status did not show a significant effect on muscle architecture and on isometric and dynamic torques when allometrically normalized.,"['young soccer players', 'Thirty-four males aged 13-18\xa0years']",['POSP'],"['isometric torque', 'muscle architecture and on isometric and dynamic torques', 'fascicle length', 'Muscle thickness', 'Torque-angle and torque-velocity relationship', 'Muscle volume torque-angle relationship']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0037393', 'cui_str': 'Soccers'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",[],"[{'cui': 'C0376590', 'cui_str': 'Torque'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0003737', 'cui_str': 'Architecture'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0205143', 'cui_str': 'Angular (qualifier value)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}]",34.0,0.0139185,Maturity status did not show a significant effect on muscle architecture and on isometric and dynamic torques when allometrically normalized.,"[{'ForeName': 'Giovani Dos Santos', 'Initials': 'GDS', 'LastName': 'Cunha', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Exercise Research Laboratory, Universidade Federal do Rio Grande do Sul , Porto Alegre, Brazil.'}, {'ForeName': 'Marco Aurélio', 'Initials': 'MA', 'LastName': 'Vaz', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Exercise Research Laboratory, Universidade Federal do Rio Grande do Sul , Porto Alegre, Brazil.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Herzog', 'Affiliation': 'Faculty of Kinesiology and Department of Mechanical and Manufacturing Engineering, University of Calgary , Calgary, Canada.'}, {'ForeName': 'Jeam Marcel', 'Initials': 'JM', 'LastName': 'Geremia', 'Affiliation': 'Center for Physical Education and Sports, Universidade Federal de Santa Maria , Santa Maria, Brazil.'}, {'ForeName': 'Gabriela Tomedi', 'Initials': 'GT', 'LastName': 'Leites', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Exercise Research Laboratory, Universidade Federal do Rio Grande do Sul , Porto Alegre, Brazil.'}, {'ForeName': 'Álvaro', 'Initials': 'Á', 'LastName': 'Reischak-Oliveira', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Exercise Research Laboratory, Universidade Federal do Rio Grande do Sul , Porto Alegre, Brazil.'}]",Journal of sports sciences,['10.1080/02640414.2019.1589908'] 786,30887669,Effect of disease management education on the quality of life and self-efficacy levels of children with asthma.,"PURPOSE The aim of this study was to determine the effects of disease management education provided to children with asthma on their quality of life and self-efficacy levels. METHODS AND DESIGN The study design was a quasi-experimental design with The One Group Pretest-Posttest design. This study was conducted on 60 children with asthma between 10 and 18 years of age. Data were collected by ""Information Form"", ""Pediatric Asthma Quality of Life Questionnaire"", and ""Self-Efficacy Scale for Children and Adolescents with Asthma"". Children's quality of life and self-efficacy levels were assessed before receiving an individual asthma education intervention and then children were informed with an asthma management education book individually. Two months after the education intervention, the quality of life and self-efficacy levels of the children were re-evaluated. RESULTS The children's quality of life and self-efficacy levels increased significantly after education (p = 0.014). Maternal age, number of siblings, number of family members living in the same house, activity status, the frequency of experiencing symptoms, and the ability to use the inhalers on their own affected children quality of life. Child's age, knowledge about factors causing asthma, and ability to use medication on their own affected their self-efficacy ( p < 0.05). PRACTICE IMPLICATIONS According to these results, planned asthma education program and provided continuity of this education by nurses would be effective to improve the quality of life and levels of self-efficacy. Asthma management education for children with asthma by nurses after diagnosis is beneficial for improving the quality of life and levels of self-efficacy.",2019,Children's quality of life and self-efficacy levels were assessed before receiving an individual asthma education intervention and then children were informed with an asthma management education book individually.,"['Children and Adolescents with Asthma', '60 children with asthma between 10 and 18 years of age', 'children with asthma', 'children with asthma by nurses after diagnosis']",['disease management education'],"['quality of life and self-efficacy levels', 'quality of life and levels of self-efficacy', ""Children's quality of life and self-efficacy levels"", 'Information Form"", ""Pediatric Asthma Quality of Life Questionnaire"", and ""Self-Efficacy Scale', ""children's quality of life and self-efficacy levels""]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]","[{'cui': 'C0376636', 'cui_str': 'Disease Management'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0034380'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0222045'}]",60.0,0.0171477,Children's quality of life and self-efficacy levels were assessed before receiving an individual asthma education intervention and then children were informed with an asthma management education book individually.,"[{'ForeName': 'Esra Nur', 'Initials': 'EN', 'LastName': 'Kocaaslan', 'Affiliation': 'Department of Child Health Nursing, Trakya University Faculty of Health Sciences, Balkan Campus, Edirne, Turkey.'}, {'ForeName': 'Melahat', 'Initials': 'M', 'LastName': 'Akgün Kostak', 'Affiliation': 'Department of Child Health Nursing, Trakya University Faculty of Health Sciences, Balkan Campus, Edirne, Turkey.'}]",Journal for specialists in pediatric nursing : JSPN,['10.1111/jspn.12241'] 787,30898339,Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.,"In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the increase in total kidney volume and decline in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD). We investigated whether plasma copeptin levels, a marker of plasma vasopressin, are associated with disease progression, and whether pre-treatment copeptin and treatment-induced change in copeptin are associated with tolvaptan treatment efficacy. This post hoc analysis included 1,280 TEMPO 3:4 participants (aged 18-50 years, estimated creatinine clearance ≥60 ml/min and total kidney volume ≥750 mL) who had plasma samples available at baseline for measurement of copeptin using an automated immunofluorescence assay. In placebo-treated subjects, baseline copeptin predicted kidney growth and eGFR decline over 3 years. These associations were independent of sex, age, and baseline eGFR, but were no longer statistically significant after additional adjustment for baseline total kidney volume. In tolvaptan-treated subjects, copeptin increased from baseline to week 3 (6.3 pmol/L versus 21.9 pmol/L, respectively). In tolvaptan-treated subjects with higher baseline copeptin levels, a larger treatment effect was noted with respect to kidney growth rate and eGFR decline. Tolvaptan-treated subjects with a larger percentage increase in copeptin from baseline to week 3 had a better disease outcome, with less kidney growth and eGFR decline after three years. Copeptin holds promise as a biomarker to predict outcome and tolvaptan treatment efficacy in ADPKD.",2019,"Tolvaptan-treated subjects with a larger percentage increase in copeptin from baseline to week 3 had a better disease outcome, with less kidney growth and eGFR decline after three years.","['autosomal dominant polycystic kidney disease', '1,280 TEMPO 3:4 participants (aged 18-50 years, estimated creatinine clearance\xa0≥60 ml/min and total kidney volume\xa0≥750 mL) who had plasma samples available at baseline for measurement of copeptin using an automated immunofluorescence assay']","['tolvaptan', 'placebo']","['kidney growth rate and eGFR decline', 'kidney growth and eGFR decline', 'plasma copeptin levels', 'copeptin', 'total kidney volume and decline in estimated glomerular filtration rate (eGFR']","[{'cui': 'C0085413', 'cui_str': 'ADPKD'}, {'cui': 'C0076084', 'cui_str': '2,2,6,6-tetramethyl-4-piperidine-N-oxide'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine (procedure)'}, {'cui': 'C0439445', 'cui_str': 'mL/min'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0444263', 'cui_str': 'Plasma specimen'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0056279', 'cui_str': 'C-terminal provasopressin'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C0079603', 'cui_str': 'Immunofluorescence'}]","[{'cui': 'C1176308', 'cui_str': 'tolvaptan'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0449249', 'cui_str': 'Growth rate (attribute)'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0056279', 'cui_str': 'C-terminal provasopressin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C3811844'}]",,0.0346573,"Tolvaptan-treated subjects with a larger percentage increase in copeptin from baseline to week 3 had a better disease outcome, with less kidney growth and eGFR decline after three years.","[{'ForeName': 'Ron T', 'Initials': 'RT', 'LastName': 'Gansevoort', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. Electronic address: r.t.gansevoort@umcg.nl.'}, {'ForeName': 'Maatje D A', 'Initials': 'MDA', 'LastName': 'van Gastel', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.'}, {'ForeName': 'Arlene B', 'Initials': 'AB', 'LastName': 'Chapman', 'Affiliation': 'Section of Nephrology, University of Chicago, Chicago, Illinois, USA.'}, {'ForeName': 'Jaime D', 'Initials': 'JD', 'LastName': 'Blais', 'Affiliation': 'Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA.'}, {'ForeName': 'Frank S', 'Initials': 'FS', 'LastName': 'Czerwiec', 'Affiliation': 'Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA.'}, {'ForeName': 'Eiji', 'Initials': 'E', 'LastName': 'Higashihara', 'Affiliation': 'Department of ADPKD Research, Kyorin University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Ouyang', 'Affiliation': 'Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA.'}, {'ForeName': 'Ronald D', 'Initials': 'RD', 'LastName': 'Perrone', 'Affiliation': 'Department of Medicine, Division of Nephrology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Stade', 'Affiliation': 'BRAHMS GmbH, Hennigsdorf, Germany.'}, {'ForeName': 'Vicente E', 'Initials': 'VE', 'LastName': 'Torres', 'Affiliation': 'Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Devuyst', 'Affiliation': 'Institute of Physiology, University of Zurich, Zurich, Switzerland; and Division of Nephrology, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Kidney international,['10.1016/j.kint.2018.11.044'] 788,30877051,Predicting Patterns of Treatment Response and Outcome for Adolescents Who Are Suicidal and Depressed.,"OBJECTIVE Although several treatments have been shown to be effective in treatment of youth suicidal thoughts and behaviors (STBs), there is a pressing need to account for the substantial variation in adolescents' response to and outcomes from these treatments. METHOD Secondary analyses of data from a 16-week randomized trial of Attachment-Based Family Therapy (ABFT) and Family-Enhanced NonDirective Supportive Therapy (FE-NST) identified distinct classes of adolescents' treatment response. Established risk factors for STBs, along with treatment condition and sociodemographic variables, were then tested as predictors of class membership. RESULTS Three patterns of adolescents' treatment response and outcome were identified: a) nonresponders (15.8%), b) good responders (57.5%), and c) partial responders (26.7%). After controlling for initial symptom severity, nonresponders were more likely to have higher levels of nonsuicidal self-injury and pessimism and were more likely to meet diagnostic criteria for major depressive disorder (MDD) than good or partial responders. Partial responders were more likely than good responders to meet criteria for MDD and to have higher perceived burdensomeness. CONCLUSION Although most adolescents showed significant symptom reductions with both treatments, adolescents with higher pretreatment levels of pessimism, MDD, nonsuicidal self-injury, and perceived burdensomeness were less likely to show an optimal pattern of treatment benefit. The findings point to heterogeneity in treatment response that may require adapting treatments for adolescents with these pretreatment profiles. CLINICAL TRIAL REGISTRATION INFORMATION Attachment-Based Family Therapy for Suicidal Adolescents; http://clinicaltrials.gov; NCT01537419.",2019,"After controlling for initial symptom severity, nonresponders were more likely to have higher levels of nonsuicidal self-injury and pessimism and were more likely to meet diagnostic criteria for major depressive disorder (MDD) than good or partial responders.",['Adolescents'],['Attachment-Based Family Therapy (ABFT) and Family-Enhanced NonDirective Supportive Therapy (FE-NST'],"['nonsuicidal self-injury and pessimism', 'pessimism, MDD, nonsuicidal self-injury, and perceived burdensomeness']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0015618', 'cui_str': 'Family Therapy'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}]","[{'cui': 'C0085271', 'cui_str': 'Self-Injury'}, {'cui': 'C0424134', 'cui_str': 'Negative Thinking'}]",,0.0369664,"After controlling for initial symptom severity, nonresponders were more likely to have higher levels of nonsuicidal self-injury and pessimism and were more likely to meet diagnostic criteria for major depressive disorder (MDD) than good or partial responders.","[{'ForeName': 'Caroline H', 'Initials': 'CH', 'LastName': 'Abbott', 'Affiliation': 'University of Delaware, Newark. Electronic address: cabbott@psych.udel.edu.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Zisk', 'Affiliation': 'University of Delaware, Newark.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Bounoua', 'Affiliation': 'University of Delaware, Newark.'}, {'ForeName': 'Guy S', 'Initials': 'GS', 'LastName': 'Diamond', 'Affiliation': 'Drexel University, Philadelphia, PA.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Kobak', 'Affiliation': 'University of Delaware, Newark.'}]",Journal of the American Academy of Child and Adolescent Psychiatry,['10.1016/j.jaac.2018.12.013'] 789,30870245,Predictors of Exercise Training and Physical Activity Adherence in People Recently Hospitalized With Heart Failure: A BRIEF REPORT.,"PURPOSE For individuals with heart failure (HF), frequent attendance at exercise training programs and meeting physical activity (PA) guidelines are significantly associated with improvements in 6-min walk distance. Despite the evidence, adherence to exercise interventions remains poor. The aim of this study was to identify predictors of these 2 variables in patients recently hospitalized with HF. METHODS In this substudy of the Exercise Joins Education: Combined Therapy to Improve Outcomes in Newly-discharged Heart Failure (EJECTION-HF) trial, all participants were enrolled in a HF disease management program, including weekly review of a home exercise program for 12 wk. Intervention group participants additionally undertook twice weekly supervised exercise training. Primary outcomes were frequent exercise training program attendance (≥12 sessions) and attainment of PA guidelines (150 min/wk of moderate intensity exercise) at 12 wk. Participant and clinical characteristics were analyzed using a logistic regression model to identify significant predictors of each outcome. RESULTS A total of 278 participants provided PA data and 140 contributed attendance data. New diagnosis of HF was a significant predictor of frequent program attendance (OR = 2.3; 95% CI, 1.1-4.7; P = .03). Predictors of meeting PA guidelines at follow-up included new HF diagnosis (OR = 2.4; 95% CI, 1.2-4.8, P = .013), and being physically active at baseline (OR = 2.7; 95% CI, 1.3-5.6; P = .007). Gender, symptom severity, multimorbidity, and disability were not significantly associated with either outcome in multivariate analysis. CONCLUSION To improve adherence, specific strategies may be required for patients with decompensated HF and those physically inactive at time of referral.",2019,"New diagnosis of HF was a significant predictor of frequent program attendance (OR = 2.3; 95% CI, 1.1-4.7; P = .03).","['278 participants provided PA data and 140 contributed attendance data', 'Newly-discharged Heart Failure (EJECTION-HF) trial, all participants were enrolled in a HF disease management program, including weekly review of a home exercise program for 12 wk', 'individuals with heart failure (HF', 'patients with decompensated HF and those physically inactive at time of referral', 'People Recently Hospitalized With Heart Failure']","['Exercise Training and Physical Activity Adherence', 'supervised exercise training']","['Gender, symptom severity, multimorbidity, and disability', 'frequent exercise training program attendance (≥12 sessions) and attainment of PA guidelines', 'frequent program attendance']","[{'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0336969', 'cui_str': 'Ejection (qualifier value)'}, {'cui': 'C1303150', 'cui_str': 'Disease management program'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0699752', 'cui_str': 'Review of (contextual qualifier) (qualifier value)'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program (regime/therapy)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C1535889', 'cui_str': 'Multimorbidity'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C2728259', 'cui_str': 'Program'}]",278.0,0.0700865,"New diagnosis of HF was a significant predictor of frequent program attendance (OR = 2.3; 95% CI, 1.1-4.7; P = .03).","[{'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Adsett', 'Affiliation': ""Heart Support Service (Ms Adsett) and Departments of Physiotherapy (Ms Adsett) and Internal Medicine and Aged Care (Dr Mudge), Royal Brisbane and Women's Hospital, Brisbane, Australia; School of Allied Health Sciences, Griffith University, Gold Coast, Australia (Ms Adsett and Dr Morris); Menzies Health Institute, Queensland, Australia (Ms Adsett and Dr Morris); Metro North Hospital and Health Service, The Prince Charles Hospital, Allied Health Research Collaborative, Queensland, Australia (Dr Morris); and University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia (Dr Mudge).""}, {'ForeName': 'Norman R', 'Initials': 'NR', 'LastName': 'Morris', 'Affiliation': ''}, {'ForeName': 'Alison M', 'Initials': 'AM', 'LastName': 'Mudge', 'Affiliation': ''}]",Journal of cardiopulmonary rehabilitation and prevention,['10.1097/HCR.0000000000000407'] 790,30859185,Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years.,"BACKGROUND Yearly, millions of children are treated globally with ivermectin mainly for neglected tropical diseases. Anatomical, physiological and biochemical differences between children and adults may result in changes in pharmacokinetics. However, paediatric pharmacokinetic data of ivermectin are lacking. METHODS In the framework of a randomized controlled dose-finding trial in rural Côte d'Ivoire, Trichuris trichiura-infected pre-school-aged children (PSAC, 2-5 years) and school-aged children (SAC, 6-12 years) were assigned to 100 or 200 μg/kg and 200, 400 or 600 μg/kg ivermectin, respectively (ISRCTN registry no. ISRCTN15871729). Capillary blood was collected on dried blood spot cards until 72 h post-treatment. Ivermectin was quantified by LC-MS/MS, and pharmacokinetic parameters were evaluated by non-compartmental analysis. RESULTS C max and AUC increased in PSAC and SAC with ascending doses and were similar in both age groups when the current standard dose (200 μg/kg) was administered (∼23 ng/mL and ∼350 ng×h/mL, respectively). PSAC with lower BMI were associated with significantly higher AUCs. AUC and Cmax were ∼2-fold lower in children compared with parameters previously studied in adults, whereas body weight-adjusted CL/F (∼0.35 L/h/kg) was significantly higher in children. Tmax (∼6 h), t1/2 (∼18 h), mean residence time (MRTINF) (∼28 h) and V/F (∼8 L/kg) were similar in all paediatric treatment arms. CONCLUSIONS A positive association of AUC or Cmax with dose was observed in both age groups. Undernutrition might influence the AUC of ivermectin in PSAC. Ivermectin shows a lower exposure profile in children compared with adults, highlighting the need to establish dosing recommendations for different age groups.",2019,"RESULTS C max and AUC increased in PSAC and SAC with ascending doses and were similar in both age groups when the current standard dose (200 μg/kg) was administered (∼23 ng/mL and ∼350 ng×h/mL, respectively).","['Trichuris trichiura-infected children aged 2-12 years', ""rural Côte d'Ivoire, Trichuris trichiura-infected pre-school-aged children (PSAC, 2-5\u2009years) and school-aged children (SAC, 6-12\u2009years""]","['Ivermectin', 'ivermectin']","['AUC and Cmax', 'Capillary blood', 'Tmax (∼6 h), t1/2 (∼18\u2009h), mean residence time (MRTINF) (∼28\u2009h) and V/F', 'C max and AUC increased in PSAC and SAC']","[{'cui': 'C0040913', 'cui_str': 'Trichuris trichiura'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0424930', 'cui_str': 'Pre-school (environment)'}, {'cui': 'C0036375', 'cui_str': 'School'}]","[{'cui': 'C0022322', 'cui_str': 'Ivermectin'}]","[{'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0229666', 'cui_str': 'Capillary blood (substance)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}]",,0.325026,"RESULTS C max and AUC increased in PSAC and SAC with ascending doses and were similar in both age groups when the current standard dose (200 μg/kg) was administered (∼23 ng/mL and ∼350 ng×h/mL, respectively).","[{'ForeName': 'Jessica D', 'Initials': 'JD', 'LastName': 'Schulz', 'Affiliation': 'Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland.'}, {'ForeName': 'Jean T', 'Initials': 'JT', 'LastName': 'Coulibaly', 'Affiliation': 'Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Schindler', 'Affiliation': 'Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Wimmersberger', 'Affiliation': 'Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Keiser', 'Affiliation': 'Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland.'}]",The Journal of antimicrobial chemotherapy,['10.1093/jac/dkz083'] 791,29105594,Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.,"BACKGROUND In a previous trial involving patients with early autosomal dominant polycystic kidney disease (ADPKD; estimated creatinine clearance, ≥60 ml per minute), the vasopressin V 2 -receptor antagonist tolvaptan slowed the growth in total kidney volume and the decline in the estimated glomerular filtration rate (GFR) but also caused more elevations in aminotransferase and bilirubin levels. The efficacy and safety of tolvaptan in patients with later-stage ADPKD are unknown. METHODS We conducted a phase 3, randomized withdrawal, multicenter, placebo-controlled, double-blind trial. After an 8-week prerandomization period that included sequential placebo and tolvaptan run-in phases, during which each patient's ability to take tolvaptan without dose-limiting side effects was assessed, 1370 patients with ADPKD who were either 18 to 55 years of age with an estimated GFR of 25 to 65 ml per minute per 1.73 m 2 of body-surface area or 56 to 65 years of age with an estimated GFR of 25 to 44 ml per minute per 1.73 m 2 were randomly assigned in a 1:1 ratio to receive tolvaptan or placebo for 12 months. The primary end point was the change in the estimated GFR from baseline to follow-up, with adjustment for the exact duration that each patient participated (interpolated to 1 year). Safety assessments were conducted monthly. RESULTS The change from baseline in the estimated GFR was -2.34 ml per minute per 1.73 m 2 (95% confidence interval [CI], -2.81 to -1.87) in the tolvaptan group, as compared with -3.61 ml per minute per 1.73 m 2 (95% CI, -4.08 to -3.14) in the placebo group (difference, 1.27 ml per minute per 1.73 m 2 ; 95% CI, 0.86 to 1.68; P<0.001). Elevations in the alanine aminotransferase level (to >3 times the upper limit of the normal range) occurred in 38 of 681 patients (5.6%) in the tolvaptan group and in 8 of 685 (1.2%) in the placebo group. Elevations in the aminotransferase level were reversible after stopping tolvaptan. No elevations in the bilirubin level of more than twice the upper limit of the normal range were detected. CONCLUSIONS Tolvaptan resulted in a slower decline than placebo in the estimated GFR over a 1-year period in patients with later-stage ADPKD. (Funded by Otsuka Pharmaceuticals and Otsuka Pharmaceutical Development and Commercialization; REPRISE ClinicalTrials.gov number, NCT02160145 .).",2017,The change from baseline in the estimated GFR was -2.34,"['patients with early autosomal dominant polycystic kidney disease (ADPKD', 'Later-Stage Autosomal Dominant Polycystic Kidney Disease', '1370 patients with ADPKD who were either 18 to 55 years of age with an estimated GFR of 25 to 65 ml per minute per 1.73 m 2 of body-surface area or 56 to 65 years of age with an estimated GFR of 25 to 44 ml per minute per 1.73 m 2', 'patients with later-stage ADPKD']","['tolvaptan', 'Tolvaptan', 'placebo', 'tolvaptan or placebo']","['alanine aminotransferase level', 'aminotransferase and bilirubin levels', 'aminotransferase level', 'bilirubin level']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0085413', 'cui_str': 'ADPKD'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4524116', 'cui_str': 'Estimated GFR'}, {'cui': 'C0702093', 'cui_str': '/min'}, {'cui': 'C0005902', 'cui_str': 'Body Surface Area'}]","[{'cui': 'C1176308', 'cui_str': 'tolvaptan'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0201836', 'cui_str': 'Alanine aminotransferase measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0002594', 'cui_str': 'Aminotransferases'}, {'cui': 'C0344395', 'cui_str': 'Bilirubin measurement'}]",1370.0,0.687483,The change from baseline in the estimated GFR was -2.34,"[{'ForeName': 'Vicente E', 'Initials': 'VE', 'LastName': 'Torres', 'Affiliation': 'From the Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN (V.E.T.); the Section of Nephrology, University of Chicago, Chicago (A.B.C.); the Institute of Physiology, University of Zurich, Zurich, Switzerland (O.D.); the Division of Nephrology, Université Catholique de Louvain Medical School, Brussels (O.D.); the Division of Nephrology, University Medical Center Groningen, Groningen, the Netherlands (R.T.G.); the Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston (R.D.P.); the Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill (G.K.); and Otsuka Pharmaceutical Development and Commercialization, Rockville, MD (J.O., R.D.M., J.D.B., F.S.C., O.S.).'}, {'ForeName': 'Arlene B', 'Initials': 'AB', 'LastName': 'Chapman', 'Affiliation': 'From the Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN (V.E.T.); the Section of Nephrology, University of Chicago, Chicago (A.B.C.); the Institute of Physiology, University of Zurich, Zurich, Switzerland (O.D.); the Division of Nephrology, Université Catholique de Louvain Medical School, Brussels (O.D.); the Division of Nephrology, University Medical Center Groningen, Groningen, the Netherlands (R.T.G.); the Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston (R.D.P.); the Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill (G.K.); and Otsuka Pharmaceutical Development and Commercialization, Rockville, MD (J.O., R.D.M., J.D.B., F.S.C., O.S.).'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Devuyst', 'Affiliation': 'From the Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN (V.E.T.); the Section of Nephrology, University of Chicago, Chicago (A.B.C.); the Institute of Physiology, University of Zurich, Zurich, Switzerland (O.D.); the Division of Nephrology, Université Catholique de Louvain Medical School, Brussels (O.D.); the Division of Nephrology, University Medical Center Groningen, Groningen, the Netherlands (R.T.G.); the Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston (R.D.P.); the Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill (G.K.); and Otsuka Pharmaceutical Development and Commercialization, Rockville, MD (J.O., R.D.M., J.D.B., F.S.C., O.S.).'}, {'ForeName': 'Ron T', 'Initials': 'RT', 'LastName': 'Gansevoort', 'Affiliation': 'From the Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN (V.E.T.); the Section of Nephrology, University of Chicago, Chicago (A.B.C.); the Institute of Physiology, University of Zurich, Zurich, Switzerland (O.D.); the Division of Nephrology, Université Catholique de Louvain Medical School, Brussels (O.D.); the Division of Nephrology, University Medical Center Groningen, Groningen, the Netherlands (R.T.G.); the Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston (R.D.P.); the Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill (G.K.); and Otsuka Pharmaceutical Development and Commercialization, Rockville, MD (J.O., R.D.M., J.D.B., F.S.C., O.S.).'}, {'ForeName': 'Ronald D', 'Initials': 'RD', 'LastName': 'Perrone', 'Affiliation': 'From the Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN (V.E.T.); the Section of Nephrology, University of Chicago, Chicago (A.B.C.); the Institute of Physiology, University of Zurich, Zurich, Switzerland (O.D.); the Division of Nephrology, Université Catholique de Louvain Medical School, Brussels (O.D.); the Division of Nephrology, University Medical Center Groningen, Groningen, the Netherlands (R.T.G.); the Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston (R.D.P.); the Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill (G.K.); and Otsuka Pharmaceutical Development and Commercialization, Rockville, MD (J.O., R.D.M., J.D.B., F.S.C., O.S.).'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Koch', 'Affiliation': 'From the Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN (V.E.T.); the Section of Nephrology, University of Chicago, Chicago (A.B.C.); the Institute of Physiology, University of Zurich, Zurich, Switzerland (O.D.); the Division of Nephrology, Université Catholique de Louvain Medical School, Brussels (O.D.); the Division of Nephrology, University Medical Center Groningen, Groningen, the Netherlands (R.T.G.); the Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston (R.D.P.); the Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill (G.K.); and Otsuka Pharmaceutical Development and Commercialization, Rockville, MD (J.O., R.D.M., J.D.B., F.S.C., O.S.).'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Ouyang', 'Affiliation': 'From the Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN (V.E.T.); the Section of Nephrology, University of Chicago, Chicago (A.B.C.); the Institute of Physiology, University of Zurich, Zurich, Switzerland (O.D.); the Division of Nephrology, Université Catholique de Louvain Medical School, Brussels (O.D.); the Division of Nephrology, University Medical Center Groningen, Groningen, the Netherlands (R.T.G.); the Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston (R.D.P.); the Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill (G.K.); and Otsuka Pharmaceutical Development and Commercialization, Rockville, MD (J.O., R.D.M., J.D.B., F.S.C., O.S.).'}, {'ForeName': 'Robert D', 'Initials': 'RD', 'LastName': 'McQuade', 'Affiliation': 'From the Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN (V.E.T.); the Section of Nephrology, University of Chicago, Chicago (A.B.C.); the Institute of Physiology, University of Zurich, Zurich, Switzerland (O.D.); the Division of Nephrology, Université Catholique de Louvain Medical School, Brussels (O.D.); the Division of Nephrology, University Medical Center Groningen, Groningen, the Netherlands (R.T.G.); the Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston (R.D.P.); the Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill (G.K.); and Otsuka Pharmaceutical Development and Commercialization, Rockville, MD (J.O., R.D.M., J.D.B., F.S.C., O.S.).'}, {'ForeName': 'Jaime D', 'Initials': 'JD', 'LastName': 'Blais', 'Affiliation': 'From the Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN (V.E.T.); the Section of Nephrology, University of Chicago, Chicago (A.B.C.); the Institute of Physiology, University of Zurich, Zurich, Switzerland (O.D.); the Division of Nephrology, Université Catholique de Louvain Medical School, Brussels (O.D.); the Division of Nephrology, University Medical Center Groningen, Groningen, the Netherlands (R.T.G.); the Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston (R.D.P.); the Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill (G.K.); and Otsuka Pharmaceutical Development and Commercialization, Rockville, MD (J.O., R.D.M., J.D.B., F.S.C., O.S.).'}, {'ForeName': 'Frank S', 'Initials': 'FS', 'LastName': 'Czerwiec', 'Affiliation': 'From the Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN (V.E.T.); the Section of Nephrology, University of Chicago, Chicago (A.B.C.); the Institute of Physiology, University of Zurich, Zurich, Switzerland (O.D.); the Division of Nephrology, Université Catholique de Louvain Medical School, Brussels (O.D.); the Division of Nephrology, University Medical Center Groningen, Groningen, the Netherlands (R.T.G.); the Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston (R.D.P.); the Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill (G.K.); and Otsuka Pharmaceutical Development and Commercialization, Rockville, MD (J.O., R.D.M., J.D.B., F.S.C., O.S.).'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Sergeyeva', 'Affiliation': 'From the Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN (V.E.T.); the Section of Nephrology, University of Chicago, Chicago (A.B.C.); the Institute of Physiology, University of Zurich, Zurich, Switzerland (O.D.); the Division of Nephrology, Université Catholique de Louvain Medical School, Brussels (O.D.); the Division of Nephrology, University Medical Center Groningen, Groningen, the Netherlands (R.T.G.); the Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston (R.D.P.); the Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill (G.K.); and Otsuka Pharmaceutical Development and Commercialization, Rockville, MD (J.O., R.D.M., J.D.B., F.S.C., O.S.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1710030'] 792,29945562,"Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.","BACKGROUND Effective treatment options for advanced pancreatic cancer are finite. NAPOLI-1, a phase III randomized trial, demonstrated the efficacy of nanoliposomal irinotecan with fluorouracil/leucovorin (nal-IRI + 5-FU/LV) for the treatment of advanced pancreatic cancer following progression on gemcitabine-based chemotherapy. There are limited additional data on the safety and efficacy of nal-IRI + 5-FU/LV following FDA approval in October 2015. We examined the post-approval safety and effectiveness of nal-IRI + 5-FU/LV in advanced pancreatic cancer patients receiving treatment at Memorial Sloan Kettering Cancer Center. METHODS A retrospective chart review was conducted of all patients beginning treatment with nal-IRI + 5-FU/LV from October 2015 through June 2017. Using the electronic medical record and institutional database, information was extracted pertaining to demographics, performance status (ECOG), prior therapies, dose, duration of treatment, adverse events, progression free survival (PFS), overall survival (OS) and treatment response. RESULTS Fifty six patients were identified. Median progression free survival (PFS) was 2.9 months and median overall survival (OS) was 5.3 months. Patients with prior disease progression on irinotecan experienced PFS and OS of 2.2 and 3.9 mo, respectively. Patients without prior irinotecan exposure experienced significantly longer PFS (4.8 mo, p = 0.02) and OS (7.7 mo, p = 0.002), as did patients who received prior irinotecan without disease progression (PFS, 5.7 mo, p = 0.04; OS, 9.0 mo, p = .04). Progression on prior irinotecan was associated with greater lines of prior advanced disease chemotherapy (2 vs 1). Dose reductions (DR) were most frequently due to fatigue (42%) and diarrhea (37%), but were not associated with worse outcomes. In fact, patients with ≥1 DR experienced longer PFS (5.4 v 2.6 mo, p = 0.035). Sequential therapy with nab-paclitaxel + gemcitabine (nab-P + Gem) followed by nal-IRI + 5-FU/LV (n = 25) resulted in OS of 23.0 mo. Mutations in TP53 were associated with shorter PFS. CONCLUSIONS These data support the safety and efficacy of nal-IRI + 5-FU/LV, reinforcing results of NAPOLI-1. Patients without disease progression on prior irinotecan fared significantly better than patients with progression, when treated with nal-IRI + 5-FU/LV. Sequential therapy with nab-P + Gem followed by nal-IRI + 5-FU/LV demonstrates encouraging median OS. These findings provide guidance for patients most likely to benefit from nal-IRI + 5-FU/LV.",2018,"Patients without prior irinotecan exposure experienced significantly longer PFS (4.8 mo, p = 0.02) and OS (7.7 mo, p = 0.002), as did patients who received prior irinotecan without disease progression (PFS, 5.7 mo, p = 0.04; OS, 9.0 mo, p = .04).","['advanced pancreatic cancer following progression on', 'advanced pancreatic cancer, a single institution experience', 'advanced pancreatic cancer', 'patients beginning treatment with nal-IRI\u2009+\u20095-FU/LV from October 2015 through June 2017', 'advanced pancreatic cancer patients receiving treatment at Memorial Sloan Kettering Cancer Center', 'Patients with prior disease progression on irinotecan experienced PFS and OS of 2.2 and 3.9 mo, respectively', 'Fifty six patients were identified']","['nal-IRI\u2009+\u20095-FU/LV', '5-FU/LV', 'Nanoliposomal irinotecan with fluorouracil', 'Sequential therapy with nab-P\u2009+\u2009Gem followed by nal-IRI\u2009+\u20095-FU/LV', 'nanoliposomal irinotecan with fluorouracil/leucovorin (nal-IRI\u2009+\u20095-FU/LV', 'gemcitabine-based chemotherapy', 'irinotecan', 'Sequential therapy with nab-paclitaxel + gemcitabine (nab-P\u2009+\u2009Gem) followed by nal-IRI\u2009+\u20095-FU/LV']","['duration of treatment, adverse events, progression free survival (PFS), overall survival (OS) and treatment response', 'median overall survival (OS', 'longer PFS', 'Median progression free survival (PFS', 'diarrhea']","[{'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0346647', 'cui_str': 'Cancer of Pancreas'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0242656', 'cui_str': 'Disease Progression'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C4517698', 'cui_str': '3.9 (qualifier value)'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}]","[{'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0445501', 'cui_str': 'Gem (qualifier value)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C2721771', 'cui_str': 'levoleucovorin'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}]","[{'cui': 'C0444921', 'cui_str': 'Duration of treatment (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",56.0,0.0297941,"Patients without prior irinotecan exposure experienced significantly longer PFS (4.8 mo, p = 0.02) and OS (7.7 mo, p = 0.002), as did patients who received prior irinotecan without disease progression (PFS, 5.7 mo, p = 0.04; OS, 9.0 mo, p = .04).","[{'ForeName': 'Danielle C', 'Initials': 'DC', 'LastName': 'Glassman', 'Affiliation': 'David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, Weil Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Randze L', 'Initials': 'RL', 'LastName': 'Palmaira', 'Affiliation': 'David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, Weil Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Christina M', 'Initials': 'CM', 'LastName': 'Covington', 'Affiliation': 'David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, Weil Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Avni M', 'Initials': 'AM', 'LastName': 'Desai', 'Affiliation': 'David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, Weil Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Geoffrey Y', 'Initials': 'GY', 'LastName': 'Ku', 'Affiliation': 'David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, Weil Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, Weil Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'James J', 'Initials': 'JJ', 'LastName': 'Harding', 'Affiliation': 'David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, Weil Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Anna M', 'Initials': 'AM', 'LastName': 'Varghese', 'Affiliation': 'David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, Weil Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Eileen M', 'Initials': 'EM', 'LastName': ""O'Reilly"", 'Affiliation': 'David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, Weil Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Kenneth H', 'Initials': 'KH', 'LastName': 'Yu', 'Affiliation': 'David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, Weil Cornell Medical College, New York, NY, USA. yuk1@mskcc.org.'}]",BMC cancer,['10.1186/s12885-018-4605-1'] 793,30747030,Experimentally induced nostalgia reduces the amplitude of the event-related negativity.,"To initiate a neuroscientific approach to the science of nostalgia, we conducted an experiment testing distinct hypotheses involving the effects of nostalgia on the event-related negativity (ERN). Based on the view of the ERN as an index of action monitoring and research suggesting a negative impact of loneliness on cognitive control, we predicted that high loneliness would be associated with lower neural (ERN amplitude) and cognitive (post-error accuracy) indices of cognitive control. We further predicted that nostalgia would mitigate these effects based on past research indicating nostalgia counteracts loneliness. Alternatively, because other research describes ERN as a marker of defensive motivation and nostalgia has been shown to orient people away from avoidance and toward approach motivational states, we predicted that nostalgia would decrease ERN amplitude, irrespective of loneliness. We recruited 75 participants (N = 60 after rejection), measured loneliness, randomly assigned participants to a memory reflection task, and employed a flanker task. Neural and behavioral measures were recorded. We observed no significant effects involving loneliness and were thus unable to examine nostalgia as a loneliness intervention. However, consistent with the motivational model of nostalgia, participants in the nostalgia, compared to ordinary, condition had a significantly decreased ERN amplitude at electrode Cz.",2019,We observed no significant effects involving loneliness and were thus unable to examine nostalgia as a loneliness intervention.,"['75 participants (N\xa0=\xa060 after rejection), measured loneliness, randomly assigned participants to a']","['memory reflection task, and employed a flanker task']","['ERN amplitude', 'Neural and behavioral measures']","[{'cui': 'C0035015', 'cui_str': 'Rejection'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0023974', 'cui_str': 'Loneliness'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}]","[{'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0557351', 'cui_str': 'Employed (finding)'}]","[{'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",75.0,0.032284,We observed no significant effects involving loneliness and were thus unable to examine nostalgia as a loneliness intervention.,"[{'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Bocincova', 'Affiliation': 'Department of Psychology, North Dakota State University , Fargo , ND , USA.'}, {'ForeName': 'Taylor', 'Initials': 'T', 'LastName': 'Nelson', 'Affiliation': 'Department of Psychology, North Dakota State University , Fargo , ND , USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Johnson', 'Affiliation': 'Department of Psychology, North Dakota State University , Fargo , ND , USA.'}, {'ForeName': 'Clay', 'Initials': 'C', 'LastName': 'Routledge', 'Affiliation': 'Department of Psychology, North Dakota State University , Fargo , ND , USA.'}]",Social neuroscience,['10.1080/17470919.2019.1580612'] 794,25679506,A novel minimally-invasive method to sample human endothelial cells for molecular profiling.,"OBJECTIVE The endothelium is a key mediator of vascular homeostasis and cardiovascular health. Molecular research on the human endothelium may provide insight into the mechanisms underlying cardiovascular disease. Prior methodology used to isolate human endothelial cells has suffered from poor yields and contamination with other cell types. We thus sought to develop a minimally invasive technique to obtain endothelial cells derived from human subjects with higher yields and purity. METHODS Nine healthy volunteers underwent endothelial cell harvesting from antecubital veins using guidewires. Fluorescence-activated cell sorting (FACS) was subsequently used to purify endothelial cells from contaminating cells using endothelial surface markers (CD34/CD105/CD146) with the concomitant absence of leukocyte and platelet specific markers (CD11b/CD45). Endothelial lineage in the purified cell population was confirmed by expression of endothelial specific genes and microRNA using quantitative polymerase chain reaction (PCR). RESULTS A median of 4,212 (IQR: 2161-6583) endothelial cells were isolated from each subject. Quantitative PCR demonstrated higher expression of von Willebrand Factor (vWF, P<0.001), nitric oxide synthase 3 (NOS3, P<0.001) and vascular cell adhesion molecule 1 (VCAM-1, P<0.003) in the endothelial population compared to similarly isolated leukocytes. Similarly, the level of endothelial specific microRNA-126 was higher in the purified endothelial cells (P<0.001). CONCLUSION This state-of-the-art technique isolates human endothelial cells for molecular analysis in higher purity and greater numbers than previously possible. This approach will expedite research on the molecular mechanisms of human cardiovascular disease, elucidating its pathophysiology and potential therapeutic targets.",2015,"Quantitative PCR demonstrated higher expression of von Willebrand Factor (vWF, P<0.001), nitric oxide synthase 3 (NOS3, P<0.001) and vascular cell adhesion molecule 1 (VCAM-1, P<0.003) in the endothelial population compared to similarly isolated leukocytes.","['human subjects with higher yields and purity', 'Nine healthy volunteers underwent']","['Fluorescence-activated cell sorting (FACS', 'endothelial cell harvesting from antecubital veins using guidewires']","['expression of von Willebrand Factor (vWF, P<0.001), nitric oxide synthase 3 (NOS3, P<0.001) and vascular cell adhesion molecule', 'level of endothelial specific microRNA-126']","[{'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0016315', 'cui_str': 'Fluorescence'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0225336', 'cui_str': 'Endothelial Cells'}, {'cui': 'C1276271', 'cui_str': 'Structure of antecubital vein'}]","[{'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0042971', 'cui_str': 'von Willebrand factor'}, {'cui': 'C0132555', 'cui_str': 'Nitric Oxide Synthase'}, {'cui': 'C0078056', 'cui_str': 'CD106 Antigens'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C1101610', 'cui_str': 'miRNA'}]",9.0,0.0699266,"Quantitative PCR demonstrated higher expression of von Willebrand Factor (vWF, P<0.001), nitric oxide synthase 3 (NOS3, P<0.001) and vascular cell adhesion molecule 1 (VCAM-1, P<0.003) in the endothelial population compared to similarly isolated leukocytes.","[{'ForeName': 'Stephen W', 'Initials': 'SW', 'LastName': 'Waldo', 'Affiliation': 'Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, MA, United States of America.'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Brenner', 'Affiliation': 'Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, CA, United States of America.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'McCabe', 'Affiliation': 'Currently, Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Dela Cruz', 'Affiliation': 'Division of Cardiology and the Center of Excellence in Vascular Research, San Francisco General Hospital, University of California, San Francisco, CA, United States of America.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Long', 'Affiliation': 'Division of Experimental Medicine, University of California, San Francisco, CA, United States of America.'}, {'ForeName': 'Venkata A', 'Initials': 'VA', 'LastName': 'Narla', 'Affiliation': 'Division of Cardiology and the Center of Excellence in Vascular Research, San Francisco General Hospital, University of California, San Francisco, CA, United States of America.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': 'Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA, United States of America.'}, {'ForeName': 'Ameya', 'Initials': 'A', 'LastName': 'Kulkarni', 'Affiliation': 'Division of Cardiology, Mid-Atlantic Permanente Medical Group.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Sinclair', 'Affiliation': 'Division of Experimental Medicine, University of California, San Francisco, CA, United States of America.'}, {'ForeName': 'Stephen Y', 'Initials': 'SY', 'LastName': 'Chan', 'Affiliation': 'Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA, United States of America.'}, {'ForeName': 'Suzaynn F', 'Initials': 'SF', 'LastName': 'Schick', 'Affiliation': 'Division of Occupational and Environmental Medicine, University of California, San Francisco, CA, United States of America.'}, {'ForeName': 'Namita', 'Initials': 'N', 'LastName': 'Malik', 'Affiliation': 'Division of Occupational and Environmental Medicine, University of California, San Francisco, CA, United States of America.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Ganz', 'Affiliation': 'Division of Cardiology and the Center of Excellence in Vascular Research, San Francisco General Hospital, University of California, San Francisco, CA, United States of America.'}, {'ForeName': 'Priscilla Y', 'Initials': 'PY', 'LastName': 'Hsue', 'Affiliation': 'Division of Cardiology and the Center of Excellence in Vascular Research, San Francisco General Hospital, University of California, San Francisco, CA, United States of America.'}]",PloS one,['10.1371/journal.pone.0118081'] 795,31696741,A randomized controlled trial on ambulatory blood pressure lowering effect of CPAP in patients with obstructive sleep apnea and nocturnal hypertension.,"Objective: In a randomised controlled trial, we investigated the blood pressure (BP) lowering effect of continuous positive airway pressure (CPAP) in patients with moderate-severe obstructive sleep apnoea syndrome (OSAS, an apnoea-hypopnoea index, AHI of 15 or higher) and nocturnal hypertension (night-time systolic/diastolic BP ≥120/70 mmHg). Methods: Sixty patients were randomly assigned to CPAP or sham CPAP, while maintaining their antihypertensive treatment. Ambulatory BP monitoring was performed at baseline (first run-in visit) and the end of follow-up. Clinic and home BP were measured at baseline and each of the monthly follow-up visits. Results: Of the 60 patients, 47 completed the 3-month study. CPAP ( n  = 26), compared with sham CPAP ( n  = 21), slightly and non-significantly reduced 24-h systolic/diastolic BP by -2.8/-2.5 mmHg ( p  ≥ 0.27), with a slightly greater between-group difference in the daytime (-4.0/-2.8 mmHg, p  ≥ 0.29) than night-time (-0.2/-1.5 mmHg, p  ≥ 0.50). The CPAP treatment did not significantly influence clinic or home BP during follow-up ( p  ≥ 0.27). Nonetheless, simple and partial correlation analyses showed that the ambulatory BP lowering effect was dependent on the daytime pulse rate at baseline ( r  ≥ 0.47, p  ≤ 0.01). In patients with a daytime pulse rate greater than 85 beats/min, the mean changes in daytime systolic BP were significantly greater in the CPAP ( n  = 10) than sham CPAP group ( n  = 11), with a between-group mean difference of -10.1 mmHg ( p  = 0.048). Conclusions: The CPAP treatment did not show significant ambulatory BP lowering effect in patients with moderate-severe OSAS and nocturnal hypertension. However, it may be effective in lowering daytime BP in patients with a faster pulse rate.",2020,The CPAP treatment did not significantly influence clinic or home BP during follow-up ( p  ≥ 0.27).,"['patients with moderate-severe OSAS and nocturnal hypertension', 'Sixty patients', 'patients with obstructive sleep apnea and nocturnal hypertension', 'patients with moderate-severe obstructive sleep apnoea syndrome (OSAS, an apnoea-hypopnoea index, AHI of 15 or higher) and nocturnal hypertension (night-time systolic/diastolic BP ≥120/70\u2009mmHg', '60 patients, 47 completed the 3-month study']","['continuous positive airway pressure (CPAP', 'sham CPAP', 'CPAP', 'CPAP or sham CPAP', 'ambulatory blood pressure']","['clinic or home BP', 'daytime systolic BP', 'daytime pulse rate', 'daytime', 'blood pressure (BP', '24-h systolic/diastolic BP', 'Clinic and home BP', 'Ambulatory BP monitoring', 'ambulatory BP lowering effect']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0240526', 'cui_str': 'Night time (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0520679', 'cui_str': 'Syndrome, Sleep Apnea, Obstructive'}, {'cui': 'C2111846', 'cui_str': 'Apnea-hypopnea index'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0439475', 'cui_str': 'torr (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}]","[{'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0332169', 'cui_str': 'Daytime (qualifier value)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0232117', 'cui_str': 'Pulse Rate'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0020649', 'cui_str': 'Blood Pressure, Low'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}]",60.0,0.0583359,The CPAP treatment did not significantly influence clinic or home BP during follow-up ( p  ≥ 0.27).,"[{'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, the Shanghai Institute of Hypertension, Department of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Yi-Bang', 'Initials': 'YB', 'LastName': 'Cheng', 'Affiliation': 'Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, the Shanghai Institute of Hypertension, Department of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Shen', 'Affiliation': 'Health Systems, Philips Research China, Shanghai, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Yin', 'Affiliation': 'Health Systems, Philips Research China, Shanghai, China.'}, {'ForeName': 'Hua-Hua', 'Initials': 'HH', 'LastName': 'Yi', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Feng', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Qing-Yun', 'Initials': 'QY', 'LastName': 'Li', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, the Shanghai Institute of Hypertension, Department of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Ji-Guang', 'Initials': 'JG', 'LastName': 'Wang', 'Affiliation': 'Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, the Shanghai Institute of Hypertension, Department of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}]",Blood pressure,['10.1080/08037051.2019.1686343'] 796,30668274,A double-blind HD-tDCS/EEG study examining right temporoparietal junction involvement in facial emotion processing.,"Prior studies have demonstrated that aspects of social cognition can be modulated via temporoparietal junction (TPJ) transcranial direct current stimulation (tDCS). However, this technique lacks focality and electrophysiological effects or correlates are rarely examined. The present study investigated whether anodal and/or cathodal high-definition tDCS (HD-tDCS) would influence facial emotion processing performance relative to sham stimulation, and whether task performance changes were related to neurophysiological changes. Participants completed a facial emotion attribution tasks before and after rTPJ HD-tDCS, with event-related potentials (ERP) recorded during task performance. Anodal rTPJ HD-tDCS improved facial emotion processing performance for static depictions of fear (but not surprise). Stimulation condition influenced P300 latency, and also influenced the relationship between behavioural and electrophysiological (ERP) outcomes in several circumstances, findings which both support and challenge anodal-excitation/cathodal-inhibition accounts of tDCS effects. Results suggest that rTPJ anodal HD-tDCS can influence facial emotion recognition (i.e., affective mentalizing), and elucidate the nature and distribution of underlying neurophysiological processes. Stimulation effects, however, might depend on the intensity and salience/valence (negativity/threat) of the emotion, and these behavioural effects may not relate directly or simply to the ERPs assessed here.",2019,Anodal rTPJ HD-tDCS improved facial emotion processing performance for static depictions of fear (but not surprise).,[],"['Anodal rTPJ HD-tDCS', 'anodal and/or cathodal high-definition tDCS (HD-tDCS', 'rTPJ anodal HD-tDCS']","['facial emotion recognition', 'facial emotion attribution tasks', 'facial emotion processing performance', 'intensity and salience/valence (negativity/threat) of the emotion']",[],"[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C3539107', 'cui_str': 'Definition (core metadata concept)'}]","[{'cui': 'C0013987', 'cui_str': 'Emotions'}, {'cui': 'C0524637', 'cui_str': 'Recognition (Psychology)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}]",,0.0372602,Anodal rTPJ HD-tDCS improved facial emotion processing performance for static depictions of fear (but not surprise).,"[{'ForeName': 'Peter H', 'Initials': 'PH', 'LastName': 'Donaldson', 'Affiliation': 'Deakin Child Study Centre, School of Psychology, Deakin University , Geelong , Australia.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Kirkovski', 'Affiliation': 'Deakin Child Study Centre, School of Psychology, Deakin University , Geelong , Australia.'}, {'ForeName': 'Nicole J', 'Initials': 'NJ', 'LastName': 'Rinehart', 'Affiliation': 'Deakin Child Study Centre, School of Psychology, Deakin University , Geelong , Australia.'}, {'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Enticott', 'Affiliation': 'Deakin Child Study Centre, School of Psychology, Deakin University , Geelong , Australia.'}]",Social neuroscience,['10.1080/17470919.2019.1572648'] 797,32407810,Mifepristone-misoprostol versus misoprostol-alone regimen for medication abortion at ≥24 weeks' gestation.,"OBJECTIVE To compare time from misoprostol initiation to fetal expulsion for mifepristone-misoprostol versus misoprostol-alone regimens of medication abortion performed at ≥24 weeks' gestation. STUDY DESIGN We conducted a retrospective study of medication abortion performed at ≥24 weeks' gestation between May 2016 and January 2018 at one site, comparing outcomes of patients receiving mifepristone-misoprostol versus misoprostol alone during two periods. All patients received feticidal injection and laminaria; the mifepristone-misoprostol group also received mifepristone 200 mg orally around the time of initial laminaria. Beginning 24-72 h later (depending on cervical assessment), both groups received misoprostol buccally every two hours. RESULTS Analyses included 257 patients in the mifepristone-misoprostol group and 152 patients in the misoprostol-alone group. Median time from misoprostol initiation to fetal expulsion was similar between groups (4.8 h vs. 4.9 h; p = 0.43). Patients in the mifepristone-misoprostol group received less misoprostol overall (median [IQR]: 800 mcg [800-1200 mcg] vs. 1200 mcg [800-1600 mcg]; p < 0.01) and fewer patients received a second round of laminaria (n = 56, 22% vs. n = 58, 33%; p < 0.01) than the misoprostol-alone group. Seven patients (2%) were transferred to a hospital for complications; this proportion did not vary by regimen. CONCLUSIONS Addition of mifepristone was not associated with a reduction in induction interval at ≥24 weeks. However, patients in the mifepristone-misoprostol group received a lower total dose of misoprostol and were less likely to require two days of laminaria. The clinical significance of these differences is unclear, but may have implications for patient experience. Both regimens had low rates of complications. IMPLICATIONS A randomized controlled trial comparing the mifepristone-misoprostol and misoprostol-alone regimens at ≥24 weeks is needed, as is evidence on patient perspectives on these regimens. Given the existing evidence, either regimen is reasonable.",2020,"Both regimens had low rates of complications. ","['257 patients in the', ""medication abortion at ≥24 weeks' gestation"", 'group and 152 patients in the misoprostol-alone group']","['Mifepristone-misoprostol', 'misoprostol-alone', 'mifepristone-misoprostol versus misoprostol', 'mifepristone', 'misoprostol-alone group', 'misoprostol', 'mifepristone-misoprostol', 'misoprostol-alone regimen', 'mifepristone-misoprostol and misoprostol-alone regimens']","['Median time from misoprostol initiation to fetal expulsion', 'low rates of complications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0085174', 'cui_str': 'Misoprostol'}]","[{'cui': 'C0026088', 'cui_str': 'Mifepristone'}, {'cui': 'C0085174', 'cui_str': 'Misoprostol'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0085174', 'cui_str': 'Misoprostol'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0015965', 'cui_str': 'Fetuses'}, {'cui': 'C1293107', 'cui_str': 'Expulsion'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",,0.139039,"Both regimens had low rates of complications. ","[{'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Wingo', 'Affiliation': 'Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, 1330 Broadway Suite 1100, Oakland, CA 94612, USA. Electronic address: erin.wingo@ucsf.edu.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Raifman', 'Affiliation': 'Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, 1330 Broadway Suite 1100, Oakland, CA 94612, USA.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Landau', 'Affiliation': ""Southwestern Women's Options, 522 Lomas Blvd NE, Albuquerque, NM 87102, USA.""}, {'ForeName': 'Shelley', 'Initials': 'S', 'LastName': 'Sella', 'Affiliation': ""Southwestern Women's Options, 522 Lomas Blvd NE, Albuquerque, NM 87102, USA.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Grossman', 'Affiliation': 'Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, 1330 Broadway Suite 1100, Oakland, CA 94612, USA.'}]",Contraception,['10.1016/j.contraception.2020.05.001'] 798,30817090,Transcutaneous bilirubin levels of newborn infants performed abdominal massage: A randomized controlled trial.,"PURPOSE This study was designed as a randomized controlled trial to determine the effect of abdominal massage on bilirubin levels of newborn infants. DESIGN AND METHODS The sample group consisted of 90 newborn infants (experimental group: 44; control group: 46) who were followed in a university hospital after birth between March and August 2017. The data were collected using an Information Form, Observation Form, and Transcutaneous Bilirubin Level Meter. Bilirubin levels were measured 1 hr after the first breastfeeding in both groups. The abdominal massage was performed for 5 min in each session, was continued in three sessions per day; was completed in totally six sessions for 2 days in infants in the experimental group. The second bilirubin measurements were repeated at the 48th hour after the birth and bilirubin levels were compared in two groups. The Student t test was used to evaluate the normally distributed data and the Mann-Whitney U test was used to carry out statistics in nonnormal distribution of quantitative data. RESULTS The bilirubin levels of the groups (experimental group: 1.06 ± 0.92; control group: 1.01 ± 0.98) were statistically similar before abdominal massage, t(88) = 0.25, p = 0.803. The difference of the bilirubin levels was compared in the groups before and after abdominal massage. The increase of bilirubin levels in the experimental group (1.96 ± 1.69 mg/dl) was statistically significantly lower compared with the control group (2.80 ± 2.30 mg/dl), t(88) = -1.974, p = 0.048. PRACTICE IMPLICATIONS Abdominal massage is effective to reduce bilirubin levels of newborn infants.",2019,"The increase of bilirubin levels in the experimental group (1.96 ± 1.69 mg/dl) was statistically significantly lower compared with the control group (2.80 ± 2.30 mg/dl), t(88) = -1.974, p = 0.048. ","['newborn infants', '90 newborn infants (experimental group: 44; control group: 46) who were followed in a university hospital after birth between March and August 2017', 'newborn infants performed abdominal massage']","['abdominal massage', 'Abdominal massage']","['Transcutaneous bilirubin levels', 'Bilirubin levels', 'bilirubin levels', 'second bilirubin measurements']","[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C2316341', 'cui_str': 'Massage of abdomen (regime/therapy)'}]","[{'cui': 'C2316341', 'cui_str': 'Massage of abdomen (regime/therapy)'}]","[{'cui': 'C0344395', 'cui_str': 'Bilirubin measurement'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}]",90.0,0.0374847,"The increase of bilirubin levels in the experimental group (1.96 ± 1.69 mg/dl) was statistically significantly lower compared with the control group (2.80 ± 2.30 mg/dl), t(88) = -1.974, p = 0.048. ","[{'ForeName': 'Duygu', 'Initials': 'D', 'LastName': 'Gözen', 'Affiliation': 'Department of Pediatric Nursing, Florence Nightingale, Faculty of Nursing, University of Istanbul-Cerrahpaşa, Istanbul, Turkey.'}, {'ForeName': 'Özge Eda', 'Initials': 'ÖE', 'LastName': 'Yılmaz', 'Affiliation': 'Department of Pediatric Nursing, Florence Nightingale, Faculty of Nursing, University of Istanbul-Cerrahpaşa, Istanbul, Turkey.'}, {'ForeName': 'Şadiye', 'Initials': 'Ş', 'LastName': 'Dur', 'Affiliation': 'Department of Pediatric Nursing, Florence Nightingale, Faculty of Nursing, University of Istanbul-Cerrahpaşa, Istanbul, Turkey.'}, {'ForeName': 'Sabiha', 'Initials': 'S', 'LastName': 'Çağlayan', 'Affiliation': 'Department of Neonatology, Medipol University Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ayhan', 'Initials': 'A', 'LastName': 'Taştekin', 'Affiliation': 'Department of Neonatology, Medipol University Hospital, Istanbul, Turkey.'}]",Journal for specialists in pediatric nursing : JSPN,['10.1111/jspn.12237'] 799,27833233,Effectiveness of Metacognitive Therapy in Patients with Social Anxiety Disorder: A Pilot Investigation.,"Metacognitive therapy (MCT) is a recent psychological intervention for emotional disorders. Its efficacy in social anxiety disorder (SAD) is yet to be established. AIMS We examined the effectiveness of an MCT in patients with SAD. A two group case-control design with baseline, post, and 3 months follow-up was adopted. The control group received training in applied relaxation (AR). Four patients with Diagnostic and Statistical Manual-IV diagnosis of social anxiety were sequentially allotted to receive either MCT or AR. Patients were assessed on postevent processing (PEP), social anxiety, depression, and fear on negative evaluation. Clinical significance was calculated. MCT was more effective than AR in reducing social avoidance, PEP, and self-consciousness. While overall both interventions were effective in reducing social anxiety, MCT was marginally more effective. MCT may be a promising therapeutic approach in the management of SAD.",2016,"MCT was more effective than AR in reducing social avoidance, PEP, and self-consciousness.","['social anxiety disorder (SAD', 'Four patients with Diagnostic and Statistical Manual-IV diagnosis of social anxiety', 'patients with SAD', 'Patients with Social Anxiety Disorder']","['Metacognitive therapy (MCT', 'Metacognitive Therapy', 'training in applied relaxation (AR', 'MCT', 'MCT or AR']","['postevent processing (PEP), social anxiety, depression, and fear on negative evaluation', 'social anxiety, MCT', 'social avoidance, PEP, and self-consciousness']","[{'cui': 'C0031572', 'cui_str': 'Social Anxiety Disorder'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0424166', 'cui_str': 'Social Anxiety'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1173173', 'cui_str': 'N-methanocarbathymidine'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}]","[{'cui': 'C0424166', 'cui_str': 'Social Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1173173', 'cui_str': 'N-methanocarbathymidine'}, {'cui': 'C0359587', 'cui_str': 'Peptamen'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0234421', 'cui_str': 'Consciousness'}]",4.0,0.0108759,"MCT was more effective than AR in reducing social avoidance, PEP, and self-consciousness.","[{'ForeName': 'Jayasree', 'Initials': 'J', 'LastName': 'Lakshmi', 'Affiliation': 'Department of Clinical Psychology, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Paulomi Matam', 'Initials': 'PM', 'LastName': 'Sudhir', 'Affiliation': 'Department of Clinical Psychology, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Mahendra Prakash', 'Initials': 'MP', 'LastName': 'Sharma', 'Affiliation': 'Department of Clinical Psychology, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Suresh Bada', 'Initials': 'SB', 'LastName': 'Math', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.'}]",Indian journal of psychological medicine,[] 800,30768161,A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.,"BACKGROUND The first-line eradication rate of standard triple therapy for Helicobacter pylori infection has declined to <80%, and alternative therapies with >90% success rates are needed. Inconsistent eradication rates were reported for proton pump inhibitor- and amoxicillin-containing high-dose dual therapy. OBJECTIVES We performed a prospective, randomized controlled study to assess the efficacy of esomeprazole- and amoxicillin-containing high-dose dual therapy and investigated the influencing clinical factors. PATIENTS AND METHODS We recruited 240/278 eligible H. pylori-infected patients after exclusion. They were randomly assigned to 14 day high-dose dual therapy (esomeprazole 40 mg three times daily and amoxicillin 750 mg four times daily for 14 days; EA group) or 7 day non-bismuth quadruple therapy (esomeprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days; EACM group). Urea breath tests were followed up 8 weeks later. RESULTS The eradication rates for the EA and EACM groups were 91.7% (95% CI = 85.3%-96.0%) and 86.7% (95% CI = 79.3%-92.2%) (P = 0.21) in ITT analysis; and 95.7% (95% CI = 90.2%-98.6%) and 92.0% (95% CI = 85.4%-96.3%) (P = 0.26) in PP analysis. The adverse event rates were 9.6% versus 23.0% in the two groups (P = 0.01). The H. pylori culture positivity rate was 91.8%. The antibiotic resistance rates were amoxicillin, 0%; clarithromycin, 14.6%; and metronidazole, 33.7%. CONCLUSIONS A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy achieves a high eradication rate as first-line anti-H. pylori therapy, comparable to that with 7 day non-bismuth quadruple therapy but with fewer adverse events.",2019,The eradication rates for the EA and EACM groups were 91.7% (95% CI = 85.3%-96.0%) and 86.7% (95% CI = 79.3%-92.2%) (P = 0.21) in ITT analysis; and 95.7% (95% CI = 90.2%-98.6%) and 92.0% (95% CI = 85.4%-96.3%) (P = 0.26) in PP analysis.,"['Taiwan', 'We recruited 240/278 eligible H. pylori-infected patients after exclusion']","['clarithromycin', 'amoxicillin', 'dual therapy (esomeprazole 40\u2009mg three times daily and amoxicillin 750\u2009mg four times daily for 14\u2009days; EA group) or 7\u2009day non-bismuth quadruple therapy (esomeprazole 40\u2009mg twice daily, clarithromycin 500\u2009mg twice daily, amoxicillin 1\u2009g twice daily and metronidazole', 'metronidazole', 'esomeprazole- and amoxicillin-containing high-dose dual therapy', 'esomeprazole- and amoxicillin-containing high-dose dual therapy regimen']","['Helicobacter pylori infection', 'H. pylori culture positivity rate', 'antibiotic resistance rates', 'adverse events', 'Urea breath tests', 'adverse event rates', 'eradication rates', 'eradication rate']","[{'cui': 'C0039260', 'cui_str': 'Formosa'}, {'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0231290', 'cui_str': 'Status post (contextual qualifier) (qualifier value)'}]","[{'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1127610', 'cui_str': 'Esomeprazole 40 MG'}, {'cui': 'C0556984', 'cui_str': 'Three times daily (qualifier value)'}, {'cui': 'C4517868', 'cui_str': '750 (qualifier value)'}, {'cui': 'C0585291', 'cui_str': 'Four times daily (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0005642', 'cui_str': 'Bismuth'}, {'cui': 'C0205175', 'cui_str': 'Quadruple (qualifier value)'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C0984982', 'cui_str': 'Clarithromycin 500 MG'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0937846', 'cui_str': 'Esomeprazole'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}]","[{'cui': 'C0850666', 'cui_str': 'Infection caused by Helicobacter pylori'}, {'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C0220814', 'cui_str': 'culture'}, {'cui': 'C0949285', 'cui_str': 'Antibiotic Resistance, Microbial'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0070525', 'cui_str': 'phenacemide'}, {'cui': 'C0006153', 'cui_str': 'Breath Tests'}]",,0.0367119,The eradication rates for the EA and EACM groups were 91.7% (95% CI = 85.3%-96.0%) and 86.7% (95% CI = 79.3%-92.2%) (P = 0.21) in ITT analysis; and 95.7% (95% CI = 90.2%-98.6%) and 92.0% (95% CI = 85.4%-96.3%) (P = 0.26) in PP analysis.,"[{'ForeName': 'Wei-Chen', 'Initials': 'WC', 'LastName': 'Tai', 'Affiliation': 'Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Chih-Ming', 'Initials': 'CM', 'LastName': 'Liang', 'Affiliation': 'Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Chung-Mou', 'Initials': 'CM', 'LastName': 'Kuo', 'Affiliation': 'Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Pao-Yuan', 'Initials': 'PY', 'LastName': 'Huang', 'Affiliation': 'Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Cheng-Kun', 'Initials': 'CK', 'LastName': 'Wu', 'Affiliation': 'Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Shih-Cheng', 'Initials': 'SC', 'LastName': 'Yang', 'Affiliation': 'Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Yuan-Hung', 'Initials': 'YH', 'LastName': 'Kuo', 'Affiliation': 'Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Ming-Tsung', 'Initials': 'MT', 'LastName': 'Lin', 'Affiliation': 'Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Chen-Hsiang', 'Initials': 'CH', 'LastName': 'Lee', 'Affiliation': 'Chang Gung University College of Medicine, Kaohsiung, Taiwan.'}, {'ForeName': 'Chien-Ning', 'Initials': 'CN', 'LastName': 'Hsu', 'Affiliation': 'Department of Pharmacy, Kaohsiung Gang Gung Memorial Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Keng-Liang', 'Initials': 'KL', 'LastName': 'Wu', 'Affiliation': 'Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Tsung-Hui', 'Initials': 'TH', 'LastName': 'Hu', 'Affiliation': 'Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Seng-Kee', 'Initials': 'SK', 'LastName': 'Chuah', 'Affiliation': 'Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.'}]",The Journal of antimicrobial chemotherapy,['10.1093/jac/dkz046'] 801,31693643,Low-Volume High-Intensity Aerobic Interval Training Is an Efficient Method to Improve Cardiorespiratory Fitness After Myocardial Infarction: PILOT STUDY FROM THE INTERFARCT PROJECT.,"PURPOSE To analyze the changes in cardiorespiratory fitness (CRF) and body composition following 2 different (low-volume vs high-volume) high-intensity aerobic interval training (HIIT) programs with Mediterranean diet (Mediet) recommendations in individuals after myocardial infarction (MI) and compared with an attention control group (AC). METHODS Body composition and CRF were assessed before and after a 16-wk intervention in 70 participants (58.4 ± 8.5 yr) diagnosed with MI. All participants received Mediet recommendations and were randomly assigned to the AC group (physical activity recommendations, n = 14) or one of the 2 supervised aerobic exercise groups (2 d/wk training): high-volume (40 min) HIIT (n = 28) and low-volume (20 min) HIIT (n = 28). RESULTS Following the intervention, no significant changes were seen in the AC group and no differences between HIIT groups were found in any of the studied variables. Only HIIT groups showed reductions in waist circumference (low-volume HIIT, Δ = -4%, P < .05; high-volume HIIT, Δ = -2%, P < .001) and improvements in CRF (low-volume HIIT, Δ = 15%, P < .01; high-volume HIIT, Δ = 22%; P < .001) with significant between-group differences (attention control vs HIIT groups). CONCLUSIONS Results suggest that a 16-wk intervention (2 d/wk) of different HIIT volumes with Mediet recommendations could equally improve CRF and waist circumference after MI. Low-volume HIIT may be a potent and time-efficient exercise training strategy to improve functional capacity.",2020,"Following the intervention, no significant changes were seen in the AC group and no differences between HIIT groups were found in any of the studied variables.","['70 participants (58.4 ± 8.5 yr) diagnosed with MI', 'After Myocardial Infarction', 'individuals after myocardial infarction (MI']","['2 different (low-volume vs high-volume) high-intensity aerobic interval training (HIIT) programs with Mediterranean diet (Mediet) recommendations', 'Low-Volume High-Intensity Aerobic Interval Training', 'AC group (physical activity recommendations, n = 14) or one of the 2 supervised aerobic exercise groups (2 d/wk training): high-volume (40 min) HIIT', 'attention control group (AC']","['CRF and waist circumference', 'CRF', 'cardiorespiratory fitness (CRF) and body composition', 'Cardiorespiratory Fitness', 'waist circumference']","[{'cui': 'C4517877', 'cui_str': '8.5'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1138412', 'cui_str': 'Diet, Mediterranean'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0010132', 'cui_str': 'corticorelin'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}]",70.0,0.0315702,"Following the intervention, no significant changes were seen in the AC group and no differences between HIIT groups were found in any of the studied variables.","[{'ForeName': 'Jon Ander', 'Initials': 'JA', 'LastName': 'Jayo-Montoya', 'Affiliation': 'Department of Physical Education and Sport, Physical Activity and Sport Sciences Section, Faculty of Education and Sport, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Araba/Álava, Basque Country, Spain (Ms Jayo-Montoya and Drs Gorostegi-Anduaga and Maldonado-Martín); Primary Care Administration of Burgos, Health Service of the Castilla & León Community (Sacyl), Spain (Dr Aispuru and Ms Villar-Zabala); Department of Physiology, Faculty of Medicine, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Basque Country, Spain (Dr Aispuru); and Cardiology Department (Drs Gallardo-Lobo and Matajira-Chia) and Internal Medicine Department (Dr Blanco-Guzmán), Santiago Apóstol Hospital, Miranda de Ebro, Burgos, Spain.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Maldonado-Martín', 'Affiliation': ''}, {'ForeName': 'G Rodrigo', 'Initials': 'GR', 'LastName': 'Aispuru', 'Affiliation': ''}, {'ForeName': 'Ilargi', 'Initials': 'I', 'LastName': 'Gorostegi-Anduaga', 'Affiliation': ''}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Gallardo-Lobo', 'Affiliation': ''}, {'ForeName': 'Tatiana', 'Initials': 'T', 'LastName': 'Matajira-Chia', 'Affiliation': ''}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Villar-Zabala', 'Affiliation': ''}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Blanco-Guzmán', 'Affiliation': ''}]",Journal of cardiopulmonary rehabilitation and prevention,['10.1097/HCR.0000000000000453'] 802,29528689,A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements.,"OBJECTIVES Identify if cost-effectiveness of Maintenance Cognitive Simulation Therapy (MCST) differs by type of living arrangement and cognitive ability of the person with dementia. Next, a value of information analysis is performed to inform decisions about future research. METHODS Incremental cost-effectiveness analysis applying seemingly unrelated regressions using data from a multicentre RCT of MCST versus treatment as usual in a population which had already received 7 weeks of CST for dementia (ISRCTN: 26286067). The findings from the cost-effectiveness analysis are used to inform a value of information analysis. RESULTS The results are dependent upon how quality adjusted life years (QALYs) are measured. MCST might be cost-effective compared to standard treatment for those who live alone and those with higher levels of cognitive functioning. If a further RCT was to be conducted for this sub-group of the population, value of information analysis suggests a total sample of 48 complete cases for both sub-groups would be required for a two-arm trial. The expected net gain of conducting this future research is £920 million. CONCLUSION Preliminary results suggest that MCST may be most cost-efficient for people with dementia who live alone and/or who have higher cognition. Future research in this area is needed.",2019,MCST might be cost-effective compared to standard treatment for those who live alone and those with higher levels of cognitive functioning.,"['people with dementia', 'person with dementia', 'people with dementia who live alone and/or who have higher cognition', 'population which had already received 7 weeks of CST for dementia (ISRCTN: 26286067']","['MCST', 'maintenance cognitive stimulation therapy (MCST', 'Maintenance Cognitive Simulation Therapy (MCST']",[],"[{'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0439044', 'cui_str': 'Lives alone (finding)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0560172', 'cui_str': 'cSt'}]","[{'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0150174', 'cui_str': 'Cognitive stimulation (regime/therapy)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",[],,0.14575,MCST might be cost-effective compared to standard treatment for those who live alone and those with higher levels of cognitive functioning.,"[{'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Brown', 'Affiliation': 'a Health Economics Group, IHS , Newcastle University , UK.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': ""D'Amico"", 'Affiliation': 'b Personal Social Service Research Unit , London School of Economics and Political Science , UK.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Knapp', 'Affiliation': 'b Personal Social Service Research Unit , London School of Economics and Political Science , UK.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Orrell', 'Affiliation': 'c Institute of Mental Health , University of Nottingham , UK.'}, {'ForeName': 'Amritpal', 'Initials': 'A', 'LastName': 'Rehill', 'Affiliation': 'b Personal Social Service Research Unit , London School of Economics and Political Science , UK.'}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Vale', 'Affiliation': 'a Health Economics Group, IHS , Newcastle University , UK.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Robinson', 'Affiliation': 'd IHS , Newcastle University , UK.'}]",Aging & mental health,['10.1080/13607863.2018.1442410'] 803,27098821,Primary care randomised controlled trial of a tailored interactive website for the self-management of respiratory infections (Internet Doctor).,"OBJECTIVE To assess an internet-delivered intervention providing advice to manage respiratory tract infections (RTIs). DESIGN Open pragmatic parallel group randomised controlled trial. SETTING Primary care in UK. PARTICIPANTS Adults (aged ≥18) registered with general practitioners, recruited by postal invitation. INTERVENTION Patients were randomised with computer-generated random numbers to access the intervention website (intervention) or not (control). The intervention tailored advice about the diagnosis, natural history, symptom management (particularly paracetamol/ibuprofen use) and when to seek further help. OUTCOMES Primary: National Health Service (NHS) contacts for those reporting RTIs from monthly online questionnaires for 20 weeks. Secondary: hospitalisations; symptom duration/severity. RESULTS Results 3044 participants were recruited. 852 in the intervention group and 920 in the control group reported one or more RTIs, among whom there a modest increase in NHS Direct contacts in the intervention group (intervention 44/1734 (2.5%) versus control 24/1842 (1.3%); multivariate Risk Ratio (RR) 2.53 (95% CI 1.10 to 5.82, p=0.029)). Conversely reduced contact with doctors occurred (283/1734 (16.3%) vs 368/1845 (20.0%); risk ratio 0.71, 0.53 to 0.95, p=0.019). Reduction in contacts occurred despite slightly longer illness duration (11.3 days versus 10.9 days respectively; multivariateestimate 0.48 days longer (-0.16 to 1.12, p=0.141) and more days of illness rated moderately bad or worse illness (0.53 days; 0.12 to 0.94, p=0.012). The estimate of slower symptom resolution in the intervention group was attenuated when controlling for whether individuals had used webpages which advocated ibuprofen use (length of illness 0.22 days, −0.51 to 0.95, p=0.551; moderately bad or worse symptoms 0.36 days, −0.08 to 0.80, p=0.105). There was no evidence of increased hospitalisations (risk ratio 0.13; 0.02 to 1.01; p=0.051). CONCLUSIONS An internet-delivered intervention for the self-management of RTIs modifies help-seeking behaviour, and does not result in more hospital admissions due to delayed help seeking. Advising the use of ibuprofen may not be helpful. TRIAL REGISTRATION NUMBER ISRCTN91518452.",2016,"CONCLUSIONS An internet-delivered intervention for the self-management of RTIs modifies help-seeking behaviour, and does not result in more hospital admissions due to delayed help seeking.","['Adults (aged ≥18) registered with general practitioners, recruited by postal invitation', 'Primary care in UK', '3044 participants were recruited']","['intervention tailored advice about the diagnosis, natural history, symptom management (particularly paracetamol/ibuprofen', 'tailored interactive website', 'ibuprofen', 'computer-generated random numbers to access the intervention website (intervention) or not (control']","['hospitalisations; symptom duration/severity', 'multivariate Risk Ratio', 'NHS Direct contacts', 'illness duration', 'contact with doctors', 'slower symptom resolution']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0017319', 'cui_str': 'Physicians, General Practice'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}]","[{'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0175860', 'cui_str': 'Natural History'}, {'cui': 'C1536570', 'cui_str': 'Symptom management (procedure)'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0332158', 'cui_str': 'Contact with (contextual qualifier) (qualifier value)'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0439834', 'cui_str': 'Slowly'}]",3044.0,0.183596,"CONCLUSIONS An internet-delivered intervention for the self-management of RTIs modifies help-seeking behaviour, and does not result in more hospital admissions due to delayed help seeking.","[{'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Little', 'Affiliation': 'Primary Care Group, Primary Care and Population Sciences Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Stuart', 'Affiliation': 'Primary Care Group, Primary Care and Population Sciences Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Panayiota', 'Initials': 'P', 'LastName': 'Andreou', 'Affiliation': 'Primary Care Group, Primary Care and Population Sciences Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'McDermott', 'Affiliation': 'Primary Care Group, Primary Care and Population Sciences Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Joseph', 'Affiliation': 'Centre for the Applications of Health Psychology, University of Southampton, Southampton, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Mullee', 'Affiliation': 'Research Design Service South Central, Primary Care and Population Sciences Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Moore', 'Affiliation': 'Primary Care Group, Primary Care and Population Sciences Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Broomfield', 'Affiliation': 'Primary Care Group, Primary Care and Population Sciences Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Tammy', 'Initials': 'T', 'LastName': 'Thomas', 'Affiliation': 'Primary Care Group, Primary Care and Population Sciences Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Yardley', 'Affiliation': 'Centre for the Applications of Health Psychology, University of Southampton, Southampton, UK.'}]",BMJ open,['10.1136/bmjopen-2015-009769'] 804,30710315,Three-dimensional versus two-dimensional high-definition laparoscopy in cholecystectomy: a prospective randomized controlled study.,"BACKGROUND While 3D laparoscopy increases surgical performance under laboratory conditions, it is unclear whether it improves outcomes in real clinical scenarios. The aim of this trial was to determine whether the 3D laparoscopy can enhance surgical efficacy in laparoscopic cholecystectomy (LCC). METHOD This prospective randomized controlled study was conducted between February 2015 and April 2017 in a day case unit of an academic teaching hospital. Patients scheduled for elective LCC were assessed for eligibility. The exclusion criteria were: (1) planned secondary operation in addition to LCC, (2) predicted to be high-risk for conversion, and (3) surgeons with less than five previous 3D laparoscopic procedures. Patients were operated on by 12 residents and 3 attendings. The primary endpoint was operation time. All surgeons were tested for stereoaquity (Randot® stereotest). The study was registered in ClinicalTrials.gov (NCT02357589). RESULTS A total of 210 patients were randomized; 105 to 3D laparoscopy and 104 to 2D laparoscopy. Median operation time as similar in the 3D and 2D laparoscopy groups (49 min vs. 48 min, p = 0.703). Operation times were similar in subgroup analyses for surgeon's sex (male vs. female), surgeon's status (resident vs. attending), surgeon's stereovision (stereopsis 10 vs. less than 10), surgeon's experience (performed 200 LCCs or below versus over 200 LCCs), or patient's BMI (≤ 25 vs. 25-30 vs. > 30). No differences in intra- or postoperative complications were noted between the 3D and 2D groups. CONCLUSION 3D laparoscopy did not show any advantages over 2D laparoscopy in LCC.",2019,"No differences in intra- or postoperative complications were noted between the 3D and 2D groups. ","['210 patients were randomized; 105 to', 'February 2015 and April 2017 in a day case unit of an academic teaching hospital', ' (2) predicted to be high-risk for conversion, and (3) surgeons with less than five previous 3D laparoscopic procedures', 'Patients were operated on by 12 residents and 3 attendings']","['3D laparoscopy and 104 to 2D laparoscopy', 'laparoscopic cholecystectomy (LCC', 'planned secondary operation in addition to LCC', 'Three-dimensional versus two-dimensional high-definition laparoscopy in cholecystectomy', '3D laparoscopy']","['Median operation time', 'operation time', 'surgical efficacy', 'intra- or postoperative complications']","[{'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0020027', 'cui_str': 'Teaching Hospitals'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0439836', 'cui_str': 'Conversions (qualifier value)'}, {'cui': 'C0582175', 'cui_str': 'Surgeon (occupation)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0521291', 'cui_str': 'Laparoscopic-assisted procedure'}]","[{'cui': 'C0031150', 'cui_str': 'Celioscopy'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0162522', 'cui_str': 'Cholecystectomy, Celioscopic'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C3539107', 'cui_str': 'Definition (core metadata concept)'}, {'cui': 'C0008320', 'cui_str': 'Cholecystectomy'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C0032787', 'cui_str': 'Postoperative Complications'}]",210.0,0.101487,"No differences in intra- or postoperative complications were noted between the 3D and 2D groups. ","[{'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Koppatz', 'Affiliation': 'Department of Abdominal Surgery, University of Helsinki and HUS Helsinki University Hospital, Haartmaninkatu 4, 00029 HUS, Helsinki, Finland.'}, {'ForeName': 'Jukka', 'Initials': 'J', 'LastName': 'Harju', 'Affiliation': 'Department of Abdominal Surgery, University of Helsinki and HUS Helsinki University Hospital, Haartmaninkatu 4, 00029 HUS, Helsinki, Finland.'}, {'ForeName': 'Jukka', 'Initials': 'J', 'LastName': 'Sirén', 'Affiliation': 'Department of Abdominal Surgery, University of Helsinki and HUS Helsinki University Hospital, Haartmaninkatu 4, 00029 HUS, Helsinki, Finland.'}, {'ForeName': 'Panu', 'Initials': 'P', 'LastName': 'Mentula', 'Affiliation': 'Department of Abdominal Surgery, University of Helsinki and HUS Helsinki University Hospital, Haartmaninkatu 4, 00029 HUS, Helsinki, Finland.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Scheinin', 'Affiliation': 'Department of Abdominal Surgery, University of Helsinki and HUS Helsinki University Hospital, Haartmaninkatu 4, 00029 HUS, Helsinki, Finland.'}, {'ForeName': 'Ville', 'Initials': 'V', 'LastName': 'Sallinen', 'Affiliation': 'Department of Abdominal Surgery, University of Helsinki and HUS Helsinki University Hospital, Haartmaninkatu 4, 00029 HUS, Helsinki, Finland. ville.sallinen@helsinki.fi.'}]",Surgical endoscopy,['10.1007/s00464-019-06666-5'] 805,31688930,Five-Day Changes in Biomarkers of Exposure Among Adult Smokers After Completely Switching From Combustible Cigarettes to a Nicotine-Salt Pod System.,"INTRODUCTION This study examined changes in biomarkers of exposure (BoE) after 5 days of nicotine-salt pod system (NSPS) use, compared with continuation of usual-cigarette smoking and cigarette abstinence, among adult combustible cigarette smokers. AIMS AND METHODS A randomized, open-label, parallel-cohort, confinement study of healthy adult smokers, naive to NSPS use, was conducted. Participants (N = 90) were randomized to six cohorts (n = 15 each): exclusive ad libitum use of NSPS (four flavors: Virginia Tobacco, Mint, Mango, Creme), continuation of usual-brand cigarette smoking, or cigarette abstinence. Total nicotine equivalents and BoE (NNN, NNAL, 3-HPMA, MHBMA, S-PMA, HMPMA, CEMA, 1-OHP, and COHb) were measured. RESULTS Eight non-nicotine BoEs, measured in urine, were reduced by an aggregate of 85.0% in the pooled NSPS cohort; increased by 14.4% in the cigarette cohort (p < .001 for pooled NSPS vs. cigarette); and reduced by 85.3% in the abstinence cohort (p > .05; 99.6% relative reduction between pooled NSPS vs. abstinence). Similar changes in individual BoEs were also observed (p < .001 for each BoE between pooled NSPS vs. cigarettes; and abstinence vs. pooled NSPS; p > .05 for each BoE between pooled NSPS vs. abstinence). Blood COHb decreased by 71.8% in the pooled NSPS cohort and 69.1% in the abstinence cohort (p > .05) and increased by 13.3% in the cigarette cohort (p < .001). Mean total urine nicotine equivalents increased in the pooled NSPS and cigarette cohorts by 9% and 26%, respectively, and did not significantly differ (p > .05). CONCLUSION Complete switching from cigarettes to NSPS produced significant reductions in key non-nicotine BoEs associated with cigarette smoking. IMPLICATIONS The results of this study concorded with evidence that complete switching from combustible cigarettes to tobacco and nontobacco-flavored vapor products may reduce exposure to key carcinogens and other toxicants known to be associated with tobacco-related diseases. Future research is needed to assess the long-term health effects of NSPS use. These results should not be interpreted to mean that the use of NSPS is without any risk, particularly for nonusers of tobacco products.",2020,"Mean total urine nicotine equivalents increased in the pooled NSPS and cigarette cohorts by 9% and 26%, respectively, and did not significantly differ (P>0.05). ","['healthy adult smokers, naive to NSPS use was conducted', 'Adult Smokers after Completely Switching from Combustible Cigarettes to a Nicotine-Salt Pod System', 'Participants (N=90) were randomized to 6 cohorts (n=15 each', 'adult combustible cigarette smokers']","['nicotine-salt pod system (NSPS', 'exclusive ad libitum use of NSPS (4 flavors: Virginia Tobacco, Mint, Mango, Creme), continuation of usual brand cigarette smoking, or cigarette abstinence']","['Blood COHb', 'Mean total urine nicotine equivalents', 'individual BoEs', 'Total nicotine equivalents and biomarkers of exposure (NNN, NNAL, 3-HPMA, MHBMA, S-PMA, HMPMA, CEMA, 1-OHP, and COHb']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4554154', 'cui_str': 'Completely - dosing instruction fragment (qualifier value)'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0036140', 'cui_str': 'Salts'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0337667', 'cui_str': 'Cigarette smoker (finding)'}]","[{'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0036140', 'cui_str': 'Salts'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0042753', 'cui_str': 'Virginia'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0452249', 'cui_str': 'Mint - sweet'}, {'cui': 'C0330955', 'cui_str': 'Mangifera indica'}, {'cui': 'C0700219', 'cui_str': 'Cigarette Smoking'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}]","[{'cui': 'C0005768'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0042037'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0063186', 'cui_str': 'hydroxypropyl methacrylate'}, {'cui': 'C0048451', 'cui_str': 'p-methoxy-alpha-methylphenethylamine'}]",,0.0160007,"Mean total urine nicotine equivalents increased in the pooled NSPS and cigarette cohorts by 9% and 26%, respectively, and did not significantly differ (P>0.05). ","[{'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Jay', 'Affiliation': 'JUUL Labs, Inc., San Francisco, CA.'}, {'ForeName': 'Erika L', 'Initials': 'EL', 'LastName': 'Pfaunmiller', 'Affiliation': 'Celerion, Inc., Lincoln, NE.'}, {'ForeName': 'Norman J', 'Initials': 'NJ', 'LastName': 'Huang', 'Affiliation': 'JUUL Labs, Inc., San Francisco, CA.'}, {'ForeName': 'Gal', 'Initials': 'G', 'LastName': 'Cohen', 'Affiliation': 'JUUL Labs, Inc., San Francisco, CA.'}, {'ForeName': 'Donald W', 'Initials': 'DW', 'LastName': 'Graff', 'Affiliation': 'JUUL Labs, Inc., San Francisco, CA.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntz206'] 806,31686255,High-power therapeutic ultrasound for treatment of abdominal localized adiposity-double-blind randomized clinical trial.,"This study aimed to evaluate the effects of high-power therapeutic ultrasound in the treatment of abdominal localized adiposity in an isolated manner, with the use of neutral gel comparing ultrasonic application with 5% lipolytic active caffeine gel (phonophoresis). A total of 90 healthy women aged between 18 and 40 years were randomized and divided into two groups. The volunteers underwent anamnesis evaluation, perimetry, bioimpedance, ultrasound examination, and blood tests (complete lipidogram, creatinine, and vitamin D) before and after the end of the 10-session ultrasound protocol (3 MHz, 2 W/cm 2 , and 30w). Comparisons between groups and pre-post evaluation were performed by a two-way repeated-measures analysis of variance. Values of p < 0.05 indicated statistical significance. The results demonstrated a significant reduction in both groups, for the perimetry (p < 0.001) and measurements of adipose tissue thickness (p < 0.001). The examinations exhibited a significant alteration only of the complete lipidogram, but without significance (p > 0.05). When comparing the groups, no statistically significant difference was identified in any of the analyzed parameters. The high-power ultrasonic therapy is efficient in reducing localized adiposity, regardless of whether it is applied with neutral gel or 5% caffeine gel.",2020,"The results demonstrated a significant reduction in both groups, for the perimetry (p < 0.001) and measurements of adipose tissue thickness (p < 0.001).",['90 healthy women aged between 18 and 40 years'],"['neutral gel comparing ultrasonic application with 5% lipolytic active caffeine gel (phonophoresis', 'high-power therapeutic ultrasound', 'High-power therapeutic ultrasound']","['perimetry, bioimpedance, ultrasound examination, and blood tests (complete lipidogram, creatinine, and vitamin D', 'adipose tissue thickness']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C1456803', 'cui_str': 'Ultrasonics'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0031582', 'cui_str': 'Phonophoresis'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0041620', 'cui_str': 'Ultrasonic Therapy'}]","[{'cui': 'C0031061', 'cui_str': 'Perimetry'}, {'cui': 'C0948501', 'cui_str': 'Ultrasound examination'}, {'cui': 'C0018941', 'cui_str': 'Blood Tests'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0001527', 'cui_str': 'Fatty Tissue'}]",90.0,0.0472504,"The results demonstrated a significant reduction in both groups, for the perimetry (p < 0.001) and measurements of adipose tissue thickness (p < 0.001).","[{'ForeName': 'Karina', 'Initials': 'K', 'LastName': 'da Silva Siqueira', 'Affiliation': 'Graduate Program in Electrical and Computer Engineering (CPGEI), Federal University of Technology Paraná (UTFPR), Curitiba, PR, Brazil. karinasiqueirafisio@gmail.com.'}, {'ForeName': 'Joaquim Miguel', 'Initials': 'JM', 'LastName': 'Maia', 'Affiliation': 'Electronics Engineering Department (DAELN) and Graduate Program in Electrical and Computer Engineering (CPGEI), Federal University of Technology Paraná (UTFPR), Curitiba, PR, Brazil.'}]",Lasers in medical science,['10.1007/s10103-019-02895-1'] 807,30281866,Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: A randomized trial in a pediatric population.,"BACKGROUND The efficacy and safety of 300 index of reactivity (IR) tablets of house dust mite (HDM) allergen extracts in Japanese pediatric (5-16 years old) patients with allergic rhinitis (AR) were assessed in a double-blind, randomized, placebo-controlled study (JAPIC CTI-152981). METHODS Patients were randomized 1:1 to HDM sublingual tablets or placebo once daily for 52 weeks. The primary end-point was average adjusted symptom score (AASS; average of daily Rhinitis Total Symptom Scores, comprising sneezing, rhinorrhea, nasal congestion, and nasal pruritus, adjusted for rescue medication use), analyzed during Weeks 48-52 (mixed-effects model for repeated measures). RESULTS Of 438 patients randomized, 403 (92%; 193 active, 210 placebo) completed the study. AASS (least-squares [LS] mean [SE]) during Weeks 48-52 was significantly (P = 0.0005) lower in the active group compared with placebo (6.32 [0.20] vs 7.27 [0.19]; relative LS mean difference, -13%). Immunological responses (IgE and IgG4 antibodies specific to antigens of two HDM species) were significantly greater in the active group compared with placebo (P < 0.0001). Almost all patients experienced mild or moderate adverse events (AEs). The most common treatment-related AEs were oral pruritus, mouth edema, throat irritation, and ear pruritus. One patient experienced serious pseudocroup (subglottic laryngitis) that recovered. There were no deaths or anaphylaxis requiring the use of injectable adrenaline. CONCLUSIONS The HDM tablet significantly improved symptoms of HDM-induced perennial AR and was associated with a significant immunological response. The safety profile in pediatric patients was consistent with that in adults, with no new safety concerns.",2019,"during Weeks 48-52 was significantly (P = 0.0005) lower in the active group compared with placebo (6.32 [0.20] vs 7.27 [0.19]; relative LS mean difference, -13%).","['Japanese pediatric (5-16\xa0years old', 'Patients', 'allergic rhinoconjunctivitis', 'pediatric patients', '438 patients randomized, 403 (92%; 193 active, 210 placebo) completed the study', 'pediatric population', 'patients with allergic rhinitis (AR']","['300 index of reactivity (IR) tablets of house dust mite (HDM) allergen extracts', 'placebo', 'AASS (least-squares [LS] mean [SE', 'house dust mite sublingual tablet', 'HDM sublingual tablets or placebo']","['Immunological responses (IgE and IgG4 antibodies specific to antigens of two HDM species', 'oral pruritus, mouth edema, throat irritation, and ear pruritus', 'average adjusted symptom score (AASS; average of daily Rhinitis Total Symptom Scores, comprising sneezing, rhinorrhea, nasal congestion, and nasal pruritus, adjusted for rescue medication use', 'serious pseudocroup (subglottic laryngitis', 'mild or moderate adverse events (AEs', 'symptoms of HDM-induced perennial AR']","[{'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0861154', 'cui_str': 'Allergic rhinoconjunctivitis'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C2607914', 'cui_str': 'Rhinitis, Allergic'}]","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0057489', 'cui_str': 'Allergens, House Dust Mites'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0023189', 'cui_str': 'Least Squares'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3539110', 'cui_str': 'house dust mites'}, {'cui': 'C0991582', 'cui_str': 'Sublingual Tablet'}]","[{'cui': 'C0205470', 'cui_str': 'Immunologic (qualifier value)'}, {'cui': 'C0202086', 'cui_str': 'Immunoglobulin E measurement (procedure)'}, {'cui': 'C0020860', 'cui_str': 'IgG4'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0003320', 'cui_str': 'Antigens'}, {'cui': 'C0948521', 'cui_str': 'Itching mouth'}, {'cui': 'C0230028', 'cui_str': 'Structure of oral region of face'}, {'cui': 'C0013604', 'cui_str': 'Hydrops'}, {'cui': 'C0700184', 'cui_str': 'Throat irritation (finding)'}, {'cui': 'C0849907', 'cui_str': 'Itching of ear'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0009443', 'cui_str': 'Common Cold'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0037383', 'cui_str': 'Sneezings'}, {'cui': 'C1260880', 'cui_str': 'Nasal catarrh'}, {'cui': 'C0027424', 'cui_str': 'Nasal congestion (finding)'}, {'cui': 'C0850060', 'cui_str': 'Nasal pruritus'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0339875', 'cui_str': 'Acute subglottic laryngitis (disorder)'}, {'cui': 'C4049282', 'cui_str': 'Subglottic laryngitis'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}]",438.0,0.588916,"during Weeks 48-52 was significantly (P = 0.0005) lower in the active group compared with placebo (6.32 [0.20] vs 7.27 [0.19]; relative LS mean difference, -13%).","[{'ForeName': 'Yoshitaka', 'Initials': 'Y', 'LastName': 'Okamoto', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.'}, {'ForeName': 'Shigeharu', 'Initials': 'S', 'LastName': 'Fujieda', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, University of Fukui, Fukui, Japan.'}, {'ForeName': 'Mitsuhiro', 'Initials': 'M', 'LastName': 'Okano', 'Affiliation': 'Department of Otorhinolaryngology, School of Medicine, International University of Health and Welfare, Narita, Japan.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Hida', 'Affiliation': 'Biostatistics Center, Shionogi & Co., Ltd., Osaka, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Kakudo', 'Affiliation': 'Project Management Department, Shionogi & Co., Ltd., Osaka, Japan.'}, {'ForeName': 'Keisuke', 'Initials': 'K', 'LastName': 'Masuyama', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medical Science, University of Yamanashi, Yamanashi, Japan.'}]",Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,['10.1111/pai.12984'] 808,31654643,Difference in the Effects of Lidocaine With Epinephrine and Prilocaine With Felypressin on the Autonomic Nervous System During Extraction of the Impacted Mandibular Third Molar: A Randomized Controlled Trial.,"PURPOSE Complications during local anesthesia include increased blood pressure and vasovagal reflex, which are caused by changes in the autonomic nervous system. The commonly used local anesthetic preparations are lidocaine to which the vasoconstrictor epinephrine is added (lidocaine-epinephrine) and prilocaine to which the vasoconstrictor felypressin is added (prilocaine-felypressin); however, their effects during dental treatment are unclear. We examined the effects of these 2 different local anesthetic preparations on the autonomic nervous system and circulation during extraction of the impacted mandibular third molar. MATERIALS AND METHODS In this randomized controlled trial, 40 female patients scheduled for extraction of an impacted mandibular third molar were randomized to the lidocaine-epinephrine group or prilocaine-felypressin group. Heart rate variability, heart rate, and systolic blood pressure were recorded during the experiment. Descriptive and bivariate statistics were computed, and the P value was set at .05. RESULTS The low frequency-high frequency ratio was significantly increased in the prilocaine-felypressin group during extraction compared with that in the lidocaine-epinephrine group (P < .05). In the lidocaine-epinephrine group, a significant decrease in the high-frequency component was observed during bone removal and extraction compared with that at rest (P < .05). In both groups, a significant increase in systolic blood pressure was observed during local anesthesia, incision and reflection of the flap, bone removal, separation of the tooth crown, extraction, and suturing compared with that at rest (P < .01). CONCLUSIONS This study is the first to investigate the differences in the influence of 2 different local anesthetic preparations on the autonomic nervous system during extraction of the mandibular third molar. Changes in circulatory dynamics during tooth extraction with the 2 different local anesthetic preparations were the result of a decrease in parasympathetic nervous activity with lidocaine-epinephrine and an increase in sympathetic nervous activity with prilocaine-felypressin.",2020,"In both groups, a significant increase in systolic blood pressure was observed during local anesthesia, incision and reflection of the flap, bone removal, separation of the tooth crown, extraction, and suturing compared with that at rest (P < .01). ",['40 female patients scheduled for extraction of an impacted mandibular third molar'],"['Epinephrine', 'lidocaine-epinephrine', 'lidocaine', 'prilocaine', 'Prilocaine', 'prilocaine-felypressin', 'Felypressin', 'Lidocaine']","['sympathetic nervous activity', 'blood pressure and vasovagal reflex', 'local anesthesia, incision and reflection of the flap, bone removal, separation of the tooth crown, extraction, and suturing', 'Heart rate variability, heart rate, and systolic blood pressure', 'high-frequency component', 'parasympathetic nervous activity', 'Autonomic Nervous System', 'systolic blood pressure', 'low frequency-high frequency ratio']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0026369', 'cui_str': 'Tooth, Wisdom'}]","[{'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0033124', 'cui_str': 'Prilocaine'}, {'cui': 'C0015777', 'cui_str': 'Felypressin'}]","[{'cui': 'C0027769', 'cui_str': 'Nervousness'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0034929', 'cui_str': 'Reflex'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia (procedure)'}, {'cui': 'C0184898', 'cui_str': 'Incision - attribute'}, {'cui': 'C0038925', 'cui_str': 'Surgical Flaps'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0237868', 'cui_str': 'Separation'}, {'cui': 'C0226993', 'cui_str': 'Tooth Crowns'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0205212', 'cui_str': 'High frequency (qualifier value)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0004388', 'cui_str': 'Visceral Nervous System'}, {'cui': 'C0205213', 'cui_str': 'Low frequency (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",40.0,0.0681789,"In both groups, a significant increase in systolic blood pressure was observed during local anesthesia, incision and reflection of the flap, bone removal, separation of the tooth crown, extraction, and suturing compared with that at rest (P < .01). ","[{'ForeName': 'Kaoru', 'Initials': 'K', 'LastName': 'Yamashita', 'Affiliation': 'Assistant Professor, Department of Dental Anesthesiology, Field of Oral Maxillofacial Rehabilitation, Developmental Therapeutics Course, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.'}, {'ForeName': 'Toshiro', 'Initials': 'T', 'LastName': 'Kibe', 'Affiliation': 'Assistant Professor, Department of Oral and Maxillofacial Surgery, Field of Oral and Maxillofacial Surgery, Developmental Therapeutics Course, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. Electronic address: s2000@dent.kagoshima-u.ac.jp.'}, {'ForeName': 'Rumi', 'Initials': 'R', 'LastName': 'Shidou', 'Affiliation': 'PhD Student, Department of Dental Anesthesiology, Field of Oral Maxillofacial Rehabilitation, Developmental Therapeutics Course, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Kohjitani', 'Affiliation': 'Associate Professor, Department of Dental Anesthesiology, Field of Oral Maxillofacial Rehabilitation, Developmental Therapeutics Course, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.'}, {'ForeName': 'Norifumi', 'Initials': 'N', 'LastName': 'Nakamura', 'Affiliation': 'Professor, Department of Oral and Maxillofacial Surgery, Field of Oral and Maxillofacial Surgery, Developmental Therapeutics Course, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.'}, {'ForeName': 'Mitsutaka', 'Initials': 'M', 'LastName': 'Sugimura', 'Affiliation': 'Professor, Department of Dental Anesthesiology, Field of Oral Maxillofacial Rehabilitation, Developmental Therapeutics Course, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.09.019'] 809,31685037,Whole-grain consumption and its effects on hepatic steatosis and liver enzymes in patients with non-alcoholic fatty liver disease: a randomised controlled clinical trial.,"Non-alcoholic fatty liver disease (NAFLD) is a considerable challenge to public health across the globe. Whole grain is highly recommended as an inseparable part of a healthy diet and has been proposed as an effective way to manage NAFLD. The objective in the present study was to evaluate the effects of whole-grain consumption on hepatic steatosis and liver enzymes as primary outcomes in patients with NAFLD. Over the 12 weeks of this open-label, randomised controlled clinical trial, 112 patients (mean age 43 (sd 8·7) years; BMI 32·2 (sd 4·3) kg/m2) were randomly assigned to two groups to receive dietary advice, either to obtain at least half of their cereal servings each day from whole-grain foods or from usual cereals. By the end of the study, the grades of NAFLD showed a significant decrease in the intervention group (P < 0·001). In addition, a significant reduction in serum concentration of alanine aminotransferase (P < 0·001), aspartate aminotransferase (P < 0·001), γ-glutamyltransferase (P = 0·009), systolic blood pressure (P = 0·004) and diastolic blood pressure (P = 0·008) was observed in the intervention group compared with the control group. After adjusting, however, no significant differences were found between the two groups in terms of lipid profile, glycaemic status and anthropometric measurements. Overall, our study demonstrated that consumption of whole grains for 12 weeks had beneficial effects on hepatic steatosis and liver enzymes concentrations in patients with NAFLD.",2020,"In addition, a significant reduction in serum concentration of alanine aminotransferase (P < 0.001), aspartate aminotransferase (P < 0.001), γ-glutamyltransferase (P = 0.009), systolic blood pressure (P = 0.004) and diastolic blood pressure (P = 0.008) were observed in the intervention group compared to the control group.","['Nonalcoholic fatty liver disease (NAFLD', 'Patients with Nonalcoholic Fatty Liver Disease', 'patients with NAFLD', '112 patients [mean age: 43± 8.7 y; body mass index (BMI) (kg/m2): 32.2 ± 4.3']","['whole grain consumption', 'dietary advice; either to obtain at least half of their cereal servings each day from whole-grain foods or from usual cereals']","['hepatic steatosis and liver enzymes concentrations', 'systolic blood pressure', 'γ-glutamyltransferase', 'diastolic blood pressure', 'lipid profile, glycemic status, and anthropometric measurements', 'hepatic steatosis and liver enzymes', 'Hepatic Steatosis and Liver Enzymes', 'serum concentration of alanine aminotransferase', 'aspartate aminotransferase']","[{'cui': 'C0400966', 'cui_str': 'NAFLD'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517880', 'cui_str': '8.7 (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C4517759', 'cui_str': 'Four point three'}]","[{'cui': 'C4042940', 'cui_str': 'Whole Grains'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0204932', 'cui_str': 'Diet education (procedure)'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0007757', 'cui_str': 'Cereal Grain'}]","[{'cui': 'C2711227', 'cui_str': 'Liver Steatosis'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme (substance)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0201836', 'cui_str': 'Alanine aminotransferase measurement (procedure)'}, {'cui': 'C0004002', 'cui_str': 'L-Aspartate-2-Oxoglutarate Aminotransferase'}]",112.0,0.0795983,"In addition, a significant reduction in serum concentration of alanine aminotransferase (P < 0.001), aspartate aminotransferase (P < 0.001), γ-glutamyltransferase (P = 0.009), systolic blood pressure (P = 0.004) and diastolic blood pressure (P = 0.008) were observed in the intervention group compared to the control group.","[{'ForeName': 'Masoumeh', 'Initials': 'M', 'LastName': 'Dorosti', 'Affiliation': 'Student Research Committee, Department of Nutrition, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Jafary Heidarloo', 'Affiliation': 'Gastroenterology and Hepatology subdivision of Internal Medicine, Imam Khomeini Hospital, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Farnush', 'Initials': 'F', 'LastName': 'Bakhshimoghaddam', 'Affiliation': 'Student Research Committee, Department of Nutrition, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Alizadeh', 'Affiliation': 'Food and Beverages Safety Research Center, Urmia University of Medical Sciences, Urmia, Iran.'}]",The British journal of nutrition,['10.1017/S0007114519002769'] 810,32408253,Effect of amino acids on IGF1 gene expression in human myotubes and skeletal muscle.,"OBJECTIVE Insulin-like growth factor I (IGF1) is an important regulator of collagen and extracellular matrix protein expression. We aimed to evaluate the effect of amino acids (AAs) on expression of IGF1 and IGF1-dependent genes in human myotubes and skeletal muscle and supposed that AAs administration increases IGF1 levels in blood and expression of IGF1 and IGF1-dependent genes in trained skeletal muscle, thereby reducing training-induced muscle damage. DESIGN Human myotubes were incubated with Arg and Leu for 24 h. Then, the effects of long-term branched chain AAs administration (10 weeks, 0.1 g/kg body mass/day) to volunteers (six subjects per AAs and placebo groups) performing large training volumes regularly (cross country skiers, training twice a day) were examined. RESULTS Incubating the myotubes with AAs increases expression of IGF1 mRNA isoforms and IGF1 secretion by 2-3 times. In athletes, long-term AAs administration increased basal blood levels of IGF1 (~50%) and expression of IGF1Ea mRNA slightly in skeletal muscle. There is no marked increase in expression of COL1A1, COL3A1, COL5A1, and LOX genes in skeletal muscle after AAs administration. However, expression of these genes in the combined group (placebo + AAs; n = 12) significantly correlated with the expression of IGF1Ea mRNA in muscle and did not correlate with IGF1 levels in the blood. CONCLUSIONS AAs administration increases IGF1 expression in vitro and in vivo. To obtain more pronounced changes in expression of IGF1 and IGF1-dependent genes in skeletal muscle, it may be necessary to increase the dose and/or duration of AAs administration.",2020,"There is no marked increase in expression of COL1A1, COL3A1, COL5A1, and LOX genes in skeletal muscle after AAs administration.","['human myotubes and skeletal muscle', 'Human myotubes were incubated with Arg and Leu for 24\xa0h']","['Insulin-like growth factor', 'amino acids', 'amino acids (AAs']","['IGF1 gene expression', 'IGF1 expression', 'basal blood levels of IGF1', 'expression of IGF1 mRNA isoforms and IGF1 secretion', 'expression of IGF1Ea mRNA', 'expression of COL1A1, COL3A1, COL5A1, and LOX genes in skeletal muscle', 'IGF1 levels']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C1704336', 'cui_str': 'Skeletal muscle fiber'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0003761', 'cui_str': 'Argentina'}, {'cui': 'C0023401', 'cui_str': 'Leucine'}]","[{'cui': 'C0037657', 'cui_str': 'Somatomedin'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}]","[{'cui': 'C0202220', 'cui_str': 'Somatomedin-C measurement'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0597298', 'cui_str': 'Isoforms'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0972255', 'cui_str': 'type I collagen alpha 1'}, {'cui': 'C0024375', 'cui_str': 'Protein-lysine 6-oxidase'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}]",,0.0302591,"There is no marked increase in expression of COL1A1, COL3A1, COL5A1, and LOX genes in skeletal muscle after AAs administration.","[{'ForeName': 'Egor M', 'Initials': 'EM', 'LastName': 'Lednev', 'Affiliation': 'Institute of Biomedical Problems of the RAS, 76A Khoroshevskoye Shosse, Moscow 123007, Russian Federation. Electronic address: ledhauz@gmail.com.'}, {'ForeName': 'Irina V', 'Initials': 'IV', 'LastName': 'Kravchenko', 'Affiliation': 'Federal Research Centre «Fundamentals of Biotechnology» of the Russian Academy of Sciences, 33 build 2, Leninsky prospect, Moscow 119071, Russian Federation.'}, {'ForeName': 'Vladimir A', 'Initials': 'VA', 'LastName': 'Furalyov', 'Affiliation': 'Federal Research Centre «Fundamentals of Biotechnology» of the Russian Academy of Sciences, 33 build 2, Leninsky prospect, Moscow 119071, Russian Federation.'}, {'ForeName': 'Evgeny A', 'Initials': 'EA', 'LastName': 'Lysenko', 'Affiliation': 'Institute of Biomedical Problems of the RAS, 76A Khoroshevskoye Shosse, Moscow 123007, Russian Federation.'}, {'ForeName': 'Iulia S', 'Initials': 'IS', 'LastName': 'Lemesheva', 'Affiliation': 'Institute of Biomedical Problems of the RAS, 76A Khoroshevskoye Shosse, Moscow 123007, Russian Federation.'}, {'ForeName': 'Alexandr A', 'Initials': 'AA', 'LastName': 'Grushin', 'Affiliation': 'Russian Olympic Committee, Luzhnetskaya Embankment 8, Russia, Moscow 119991, Russian Federation.'}, {'ForeName': 'Vadim E', 'Initials': 'VE', 'LastName': 'Dubrov', 'Affiliation': 'Lomonosov Moscow State University, Faculty of Fundamental Medicine, 27 build. 1, Lomonosovsky Prospekt, Moscow 119991, Russian Federation.'}, {'ForeName': 'Olga L', 'Initials': 'OL', 'LastName': 'Vinogradova', 'Affiliation': 'Institute of Biomedical Problems of the RAS, 76A Khoroshevskoye Shosse, Moscow 123007, Russian Federation.'}, {'ForeName': 'Daniil V', 'Initials': 'DV', 'LastName': 'Popov', 'Affiliation': 'Institute of Biomedical Problems of the RAS, 76A Khoroshevskoye Shosse, Moscow 123007, Russian Federation.'}]",Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society,['10.1016/j.ghir.2020.101323'] 811,30738780,"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.","BACKGROUND Abiraterone acetate plus prednisone or prednisolone improves progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer. Radium-223 improves overall survival and delays the onset of symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases. We assessed concurrent treatment with abiraterone acetate plus prednisone or prednisolone and radium-223 in such patients. METHODS We did a randomised, double-blind, placebo-controlled, phase 3 trial at 165 oncology and urology centres in 19 countries. Eligible patients were aged 18 years or older, and had histologically confirmed, progressive, chemotherapy-naive, asymptomatic or mildly symptomatic castration-resistant prostate cancer and bone metastases, Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of at least 6 months, and adequate haematological, renal, and liver function. Participants were randomly assigned (1:1) according to a permuted block design (block size 4) via interactive response technology to receive up to six intravenous injections of radium-223 (55 kBq/kg) or matching placebo once every 4 weeks. All patients were also scheduled to receive oral abiraterone acetate 1000 mg once daily plus oral prednisone or prednisolone 5 mg twice daily during and after radium-223 or placebo treatment. The primary endpoint was symptomatic skeletal event-free survival, which was assessed in the intention-to-treat population. Safety analyses were done in all patients who received at least one dose of any study drug. This trial is registered with ClinicalTrials.gov, number NCT02043678. Enrolment has been completed, and follow-up is ongoing. FINDINGS Between March 30, 2014, and Aug 12, 2016, 806 patients were randomly assigned to receive radium-223 (n=401) or placebo (n=405) in addition to abiraterone acetate plus prednisone or prednisolone. The study was unblinded prematurely, on Nov 17, 2017, after more fractures and deaths were noted in the radium-223 group than in the placebo group (in an unplanned ad-hoc analysis), but all patients had completed radium-223 or placebo before this date. At the primary analysis (data cutoff Feb 15, 2018), 196 (49%) of 401 patients in radium-223 group had had at least one symptomatic skeletal event or died, compared with 190 (47%) of 405 patients in the placebo group (median follow-up 21·2 months [IQR 17·0-25·8]). Median symptomatic skeletal event-free survival was 22·3 months (95% CI 20·4-24·8) in the radium-223 group and 26·0 months (21·8-28·3) in the placebo group (hazard ratio 1·122 [95% CI 0·917-1·374]; p=0·2636). Fractures (any grade) occurred in 112 (29%) of 392 patients in the radium-223 group and 45 (11%) of 394 patients in the placebo group. The most common grade 3-4 treatment-emergent adverse events were hypertension (43 [11%] patients in the radium-223 group vs 52 [13%] patients in the placebo group), fractures (36 [9%] vs 12 [3%]) and increased alanine aminotransferase concentrations (34 [9%] vs 28 [7%]). Serious treatment-emergent adverse events occurred in 160 (41%) patients in the radium-223 group and 155 (39%) in the placebo group. Treatment-related deaths occurred in two (1%) patients in the radium-223 group (acute myocardial infarction and interstitial lung disease) and one (<1%) in the placebo group (arrhythmia). INTERPRETATION The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic skeletal event-free survival in patients with castration-resistant prostate cancer and bone metastases, and was associated with an increased frequency of bone fractures compared with placebo. Thus, we do not recommend use of this combination. FUNDING Bayer.",2019,Median symptomatic skeletal event-free survival was 22·3 months (95% CI 20·4-24·8) in the radium-223 group and 26·0 months (21·8-28·3) in the placebo group (hazard ratio,"['Eligible patients were aged 18 years or older, and had histologically confirmed, progressive, chemotherapy-naive, asymptomatic or mildly symptomatic castration-resistant prostate cancer and bone metastases', 'Between March 30, 2014, and Aug 12, 2016, 806 patients', 'patients with castration-resistant prostate cancer and bone metastases (ERA 223', '165 oncology and urology centres in 19 countries', 'patients with castration-resistant prostate cancer and bone metastases', 'patients with metastatic castration-resistant prostate cancer']","['permuted block design (block size 4) via interactive response technology to receive up to six intravenous injections of radium-223 (55 kBq/kg) or matching placebo', 'abiraterone acetate plus prednisone or prednisolone and radium-223', 'radium-223 or placebo', 'placebo', 'oral abiraterone acetate 1000 mg once daily plus oral prednisone or prednisolone', 'Abiraterone acetate plus prednisone or prednisolone', 'Radium-223', 'abiraterone acetate plus prednisone or prednisolone', 'radium-223', 'radium-223 to abiraterone acetate and prednisone or prednisolone']","['symptomatic skeletal event-free survival', 'frequency of bone fractures', 'symptomatic skeletal event or died', 'adequate haematological, renal, and liver function', 'progression-free survival and overall survival', 'fractures and deaths', 'Serious treatment-emergent adverse events', 'alanine aminotransferase concentrations', 'deaths', 'overall survival', 'Median symptomatic skeletal event-free survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic (finding)'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C1328504', 'cui_str': 'Castration-resistant prostate cancer'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C4319555', 'cui_str': '165 (qualifier value)'}, {'cui': 'C0042077', 'cui_str': 'Urology'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}]","[{'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0021494', 'cui_str': 'Intravenous Injections'}, {'cui': 'C0303282', 'cui_str': 'Ra-223 radioisotope'}, {'cui': 'C0560040', 'cui_str': 'kBq'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2607886', 'cui_str': 'abiraterone acetate'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}]","[{'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0205411', 'cui_str': 'Adequate (qualifier value)'}, {'cui': 'C0232741', 'cui_str': 'Liver function (observable entity)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0201836', 'cui_str': 'Alanine aminotransferase measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",806.0,0.756152,Median symptomatic skeletal event-free survival was 22·3 months (95% CI 20·4-24·8) in the radium-223 group and 26·0 months (21·8-28·3) in the placebo group (hazard ratio,"[{'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Smith', 'Affiliation': 'Massachusetts General Hospital Cancer Center, Boston, MA, USA. Electronic address: smith.matthew@mgh.harvard.edu.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Parker', 'Affiliation': 'Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK.'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Saad', 'Affiliation': 'University of Montreal Hospital Center, Montreal, QC, Canada.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Miller', 'Affiliation': 'Charité Berlin, Berlin, Germany.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Tombal', 'Affiliation': 'Cliniques Universitaires Saint-Luc, Brussels, Belgium.'}, {'ForeName': 'Quan Sing', 'Initials': 'QS', 'LastName': 'Ng', 'Affiliation': 'National Cancer Centre Singapore, Singapore.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Boegemann', 'Affiliation': 'University of Muenster Medical Center, Muenster, Germany.'}, {'ForeName': 'Vsevolod', 'Initials': 'V', 'LastName': 'Matveev', 'Affiliation': 'N N Blokhin Cancer Research Center, Moscow, Russia.'}, {'ForeName': 'Josep Maria', 'Initials': 'JM', 'LastName': 'Piulats', 'Affiliation': 'Catalan Cancer Institute, IDIBELL, CIBERONC, Barcelona, Spain.'}, {'ForeName': 'Luis Eduardo', 'Initials': 'LE', 'LastName': 'Zucca', 'Affiliation': 'Barretos Cancer Hospital, Barretos, Brazil.'}, {'ForeName': 'Oleg', 'Initials': 'O', 'LastName': 'Karyakin', 'Affiliation': 'Medical Radiological Research Center, Kaluga, Russia.'}, {'ForeName': 'Go', 'Initials': 'G', 'LastName': 'Kimura', 'Affiliation': 'Nippon Medical School Hospital, Tokyo, Japan.'}, {'ForeName': 'Nobuaki', 'Initials': 'N', 'LastName': 'Matsubara', 'Affiliation': 'National Cancer Center Hospital East, Chiba, Japan.'}, {'ForeName': 'William Carlos', 'Initials': 'WC', 'LastName': 'Nahas', 'Affiliation': 'Instituto Do Cancer Do Estado De Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Franco', 'Initials': 'F', 'LastName': 'Nolè', 'Affiliation': 'IEO, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.'}, {'ForeName': 'Eli', 'Initials': 'E', 'LastName': 'Rosenbaum', 'Affiliation': 'Rabin Medical Center Davidoff Center, Petach-Tikva, Israel.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Heidenreich', 'Affiliation': 'University Hospital Cologne, Cologne, Germany.'}, {'ForeName': 'Yoshiyuki', 'Initials': 'Y', 'LastName': 'Kakehi', 'Affiliation': 'Kagawa University, Kagawa, Japan.'}, {'ForeName': 'Amily', 'Initials': 'A', 'LastName': 'Zhang', 'Affiliation': 'Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.'}, {'ForeName': 'Heiko', 'Initials': 'H', 'LastName': 'Krissel', 'Affiliation': 'Bayer, Berlin, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Teufel', 'Affiliation': 'Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.'}, {'ForeName': 'Junwu', 'Initials': 'J', 'LastName': 'Shen', 'Affiliation': 'Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Wagner', 'Affiliation': 'Bayer Consumer Care, Basel, Switzerland.'}, {'ForeName': 'Celestia', 'Initials': 'C', 'LastName': 'Higano', 'Affiliation': 'University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}]",The Lancet. Oncology,['10.1016/S1470-2045(18)30860-X'] 812,30830724,Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.,"AIM Phase III, randomized, double-blind study evaluating the efficacy and safety of ertugliflozin in Asian patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin, including evaluation in the China subpopulation. MATERIALS AND METHODS A 26-week, double-blind study of 506 Asian patients (80.2% from mainland China), randomized 1:1:1 to placebo, ertugliflozin 5- or 15 mg, was performed. Primary endpoint was change from baseline in HbA1c at week 26. Secondary endpoints were change from baseline at week 26 in fasting plasma glucose (FPG), body weight (BW), systolic/diastolic blood pressure (SBP/DBP), and proportion of patients with HbA1c <7.0%. Hypotheses for the primary endpoint and FPG and BW secondary endpoints were tested in the China subpopulation. RESULTS At week 26, least squares mean (95% CI) change from baseline HbA1c was significantly greater with ertugliflozin 5- and 15 mg versus placebo: -1.0% (-1.1, -0.9), -0.9% (-1.0, -0.8), -0.2% (-0.3, -0.1), respectively. Ertugliflozin significantly reduced FPG, BW and SBP. Reductions in DBP with ertugliflozin were not significant. At week 26, 16.2%, 38.2% and 40.8% of patients had HbA1c <7.0% with placebo, ertugliflozin 5- and 15 mg, respectively. 59.3%, 56.5% and 53.3% of patients experienced adverse events with placebo, ertugliflozin 5- and 15 mg, respectively. Incidence of symptomatic hypoglycaemia was higher for ertugliflozin 15 mg vs placebo. Results in the China subpopulation were consistent. CONCLUSIONS Ertugliflozin significantly improved glycaemic control and reduced BW and SBP in Asian patients with T2DM. Ertugliflozin was generally well-tolerated. Results in the China subpopulation were consistent with the overall population. ClinicalTrials.gov: NCT02630706.",2019,"At week 26, least squares mean (95% CI) change from baseline HbA1c was significantly greater with ertugliflozin 5- and 15 mg versus placebo: -1.0% (-1.1, -0.9),","['Asian patients with T2DM', 'Asian patients with type 2 diabetes mellitus inadequately controlled with', 'Asian patients with type 2 diabetes mellitus (T2DM', '506 Asian patients (80.2% from mainland China']","['placebo', 'Ertugliflozin', 'metformin', 'placebo, ertugliflozin', 'placebo, ertugliflozin 5- or 15\u2009mg', 'ertugliflozin', 'metformin monotherapy']","['glycaemic control and reduced BW and SBP', 'tolerated', 'adverse events', 'FPG, BW and SBP', 'Incidence of symptomatic hypoglycaemia', 'fasting plasma glucose (FPG), body weight (BW), systolic/diastolic blood pressure (SBP/DBP), and proportion of patients with HbA1c <7.0', 'efficacy and safety', 'Safety and efficacy']","[{'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4079805', 'cui_str': 'ertugliflozin'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",506.0,0.307856,"At week 26, least squares mean (95% CI) change from baseline HbA1c was significantly greater with ertugliflozin 5- and 15 mg versus placebo: -1.0% (-1.1, -0.9),","[{'ForeName': 'Linong', 'Initials': 'L', 'LastName': 'Ji', 'Affiliation': ""Peking University People's Hospital, Beijing, China.""}, {'ForeName': 'Yanmei', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': ""Yancheng First People's Hospital, Yancheng, China.""}, {'ForeName': 'Heng', 'Initials': 'H', 'LastName': 'Miao', 'Affiliation': 'The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Yongli', 'Initials': 'Y', 'LastName': 'Xie', 'Affiliation': ""Pingxiang People's Hospital, Pingxiang, China.""}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Yang', 'Affiliation': 'Pfizer (China) R&D Co., Shanghai, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Pfizer (China) R&D Co., Shanghai, China.'}, {'ForeName': 'Yuting', 'Initials': 'Y', 'LastName': 'Mu', 'Affiliation': 'Pfizer (China) R&D Co., Shanghai, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Yan', 'Affiliation': 'Pfizer (China) R&D Co., Shanghai, China.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Pan', 'Affiliation': 'Pfizer Inc., New York, New York.'}, {'ForeName': 'Brett', 'Initials': 'B', 'LastName': 'Lauring', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Shu', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'MSD China, Beijing, China.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Huyck', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Qiu', 'Affiliation': 'MSD China, Beijing, China.'}, {'ForeName': 'Steven G', 'Initials': 'SG', 'LastName': 'Terra', 'Affiliation': 'Pfizer Inc., Andover, Massachusetts.'}]","Diabetes, obesity & metabolism",['10.1111/dom.13681'] 813,31704161,Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes.,"Cardiovascular disease (CVD) is the primary cause of morbidity and mortality in patients with type 2 diabetes (T2D). This review examines the impact of cardiovascular outcome trials (CVOTs) on clinical practice. To date, all CVOTs have shown non-inferiority versus placebo (both added to standard of care) against a primary endpoint of 3- or 4-point major adverse cardiovascular event (MACE), confirming CV safety of these treatments. Additionally, some CVOTs have shown superiority to placebo against the same MACE endpoint, suggesting a cardioprotective action for these treatments. This is reflected in guideline updates, which primary care physicians should consider when personalizing treatments.",2020,"To date, all CVOTs have shown non-inferiority versus placebo (both added to standard of care) against a primary endpoint of 3- or 4-point major adverse cardiovascular event (MACE), confirming CV safety of these treatments.","['patients with type 2 diabetes (T2D', 'type 2 diabetes']",['placebo'],[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]",[],,0.166855,"To date, all CVOTs have shown non-inferiority versus placebo (both added to standard of care) against a primary endpoint of 3- or 4-point major adverse cardiovascular event (MACE), confirming CV safety of these treatments.","[{'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Chilton', 'Affiliation': 'Division of Cardiology, University of Texas Health Science Center, San Antonio, TX, USA. Electronic address: chilton@uthscsa.edu.'}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Dungan', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism, Ohio State University, Columbus, OH, USA.'}, {'ForeName': 'Jay H', 'Initials': 'JH', 'LastName': 'Shubrook', 'Affiliation': 'Touro University California College of Osteopathic Medicine, Primary Care Department, Vallejo, CA, USA.'}, {'ForeName': 'Guillermo E', 'Initials': 'GE', 'LastName': 'Umpierrez', 'Affiliation': 'Center of Diabetes and Metabolism, Emory University, Atlanta, GA, USA.'}]",Primary care diabetes,['10.1016/j.pcd.2019.09.008'] 814,29200573,Neural Effects of Transcranial Direct Current Stimulation in Schizophrenia: A Case Study using Functional Near-infrared Spectroscopy.,"Schizophrenia is a severe neuropsychiatric disorder characterized by delusions, hallucinations, behavioral symptoms, and cognitive deficits. Roughly, 70%-80% of schizophrenia patients experience auditory verbal hallucinations (AVHs), with 25%-30% demonstrating resistance to conventional antipsychotic medications. Studies suggest a promising role for add-on transcranial direct current stimulation (tDCS) in the treatment of medication-refractory AVHs. The mechanisms through which tDCS could be therapeutic in such cases are unclear, but possibly involve neuroplastic effects. In recent years, functional near-infrared spectroscopy (fNIRS) has been used successfully to study tDCS-induced neuroplastic changes. In a double-blind, sham-controlled design, we applied fNIRS to measure task-dependent cerebral blood flow (CBF) changes as a surrogate outcome of single session tDCS-induced effects on neuroplasticity in a schizophrenia patient with persistent auditory hallucinations. The observations are discussed in this case report.",2017,"In a double-blind, sham-controlled design, we applied fNIRS to measure task-dependent cerebral blood flow (CBF) changes as a surrogate outcome of single session tDCS-induced effects on neuroplasticity in a schizophrenia patient with persistent auditory hallucinations.","['Schizophrenia', 'schizophrenia patient with persistent auditory hallucinations']","['transcranial direct current stimulation (tDCS', 'Transcranial Direct Current Stimulation']",['schizophrenia patients experience auditory verbal hallucinations (AVHs'],"[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0233762', 'cui_str': 'Hallucinations, Auditory'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C2721589', 'cui_str': 'Verbal hallucinations'}]",,0.0608365,"In a double-blind, sham-controlled design, we applied fNIRS to measure task-dependent cerebral blood flow (CBF) changes as a surrogate outcome of single session tDCS-induced effects on neuroplasticity in a schizophrenia patient with persistent auditory hallucinations.","[{'ForeName': 'S Trevor', 'Initials': 'ST', 'LastName': 'Taylor', 'Affiliation': 'Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee, USA.'}, {'ForeName': 'Harleen', 'Initials': 'H', 'LastName': 'Chhabra', 'Affiliation': 'Department of Psychiatry and Translational Psychiatry Laboratory, Neurobiology Research Centre, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Vanteemar S', 'Initials': 'VS', 'LastName': 'Sreeraj', 'Affiliation': 'Department of Psychiatry and Translational Psychiatry Laboratory, Neurobiology Research Centre, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Venkataram', 'Initials': 'V', 'LastName': 'Shivakumar', 'Affiliation': 'Department of Psychiatry and Translational Psychiatry Laboratory, Neurobiology Research Centre, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Sunil V', 'Initials': 'SV', 'LastName': 'Kalmady', 'Affiliation': 'Department of Psychiatry and Translational Psychiatry Laboratory, Neurobiology Research Centre, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Ganesan', 'Initials': 'G', 'LastName': 'Venkatasubramanian', 'Affiliation': 'Department of Psychiatry and Translational Psychiatry Laboratory, Neurobiology Research Centre, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.'}]",Indian journal of psychological medicine,['10.4103/IJPSYM.IJPSYM_238_17'] 815,31900620,The impact of the caregiver-oncologist relationship on caregiver experiences of end-of-life care and bereavement outcomes.,"PURPOSE The quality of the relationship between oncologists and cancer patients has been associated with caregiver bereavement outcomes, but no studies have examined whether the perceived quality of the relationship between cancer caregivers and oncologists is associated with caregiver experiences of end-of-life care or psychological adjustment after the patient's death. METHODS We conducted secondary analyses of data collected in the Values and Options in Cancer Care (VOICE) study, a randomized controlled trial of an intervention that improved communication between oncologists and patients/caregivers (n = 204 dyads). At study entry, we assessed caregivers' experiences with the oncologist using four items from the Human Connection Scale. Following patients' deaths, we assessed bereaved caregivers' experiences with end-of-life cancer care (Quality of Death; Peace, Equanimity, and Acceptance in the Cancer Experience [PEACE]; Caregiver Evaluation of the Quality of End-of-Life Care [CEQUEL]; and modified Decision Regret scales) and psychological adjustment (Prolonged Grief Disorder-13 and Purpose in Life scales). We conducted multivariable regressions examining prospective associations between caregiver experiences with the oncologist at study entry and outcome variables. RESULTS Data were collected from 105 caregivers of patients who died during the course of the study. Positive experience with the oncologist was prospectively associated with better experiences of end-of-life care, as reflected in better quality of death (estimate = 0.33, SE = 0.14, p = 0.02), PEACE (estimate = 0.11, SE = 0.05, p = 0.04), and decisional regret (estimate = - 0.16, SE = 0.06, p = 0.01). Caregivers' experience with the oncologist was not significantly associated with indicators of psychological adjustment. CONCLUSION Caregivers' early experiences with oncologists may affect their experiences of the patient's end-of-life care.",2020,"Caregivers' experience with the oncologist was not significantly associated with indicators of psychological adjustment. ","['oncologists and patients/caregivers (n = 204 dyads', '105 caregivers of patients who died during the course of the study']",[],"['decisional regret', 'quality of death', ""bereaved caregivers' experiences with end-of-life cancer care (Quality of Death; Peace, Equanimity, and Acceptance in the Cancer Experience [PEACE]; Caregiver Evaluation of the Quality of End-of-Life Care [CEQUEL]; and modified Decision Regret scales) and psychological adjustment (Prolonged Grief Disorder-13 and Purpose in Life scales""]","[{'cui': 'C0259990', 'cui_str': 'Oncologists'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]",[],"[{'cui': 'C0080101', 'cui_str': 'Regret'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0039548', 'cui_str': 'End of Life Care'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0557904', 'cui_str': 'Psychological Adjustment'}, {'cui': 'C4511668', 'cui_str': 'Prolonged grief disorder (finding)'}, {'cui': 'C1285529', 'cui_str': 'Purpose (attribute)'}]",204.0,0.11253,"Caregivers' experience with the oncologist was not significantly associated with indicators of psychological adjustment. ","[{'ForeName': 'Amy W', 'Initials': 'AW', 'LastName': 'An', 'Affiliation': 'Department of Medicine, Division of Palliative Care, University of Rochester Medical Center, 601 Elmwood Ave, Box 687, Rochester, NY, 14642, USA. amy_an@urmc.rochester.edu.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Ladwig', 'Affiliation': 'Department of Medicine, Division of Palliative Care, University of Rochester Medical Center, 601 Elmwood Ave, Box 687, Rochester, NY, 14642, USA.'}, {'ForeName': 'Ronald M', 'Initials': 'RM', 'LastName': 'Epstein', 'Affiliation': 'Department of Medicine, Division of Palliative Care, University of Rochester Medical Center, 601 Elmwood Ave, Box 687, Rochester, NY, 14642, USA.'}, {'ForeName': 'Holly G', 'Initials': 'HG', 'LastName': 'Prigerson', 'Affiliation': 'Department of Medicine, Division of Geriatrics and Palliative Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Paul R', 'Initials': 'PR', 'LastName': 'Duberstein', 'Affiliation': 'Department of Health Behavior, Society, and Policy, Rutgers School of Public Health, Piscataway, New Jersey, USA.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-019-05185-2'] 816,29381375,Heart rate variability biofeedback: implications for cognitive and psychiatric effects in older adults.,"OBJECTIVES Two decades of heart rate variability (HRV) biofeedback research have focused on adolescent and adult populations with a variety of symptoms and conditions at the exclusion of older adults. This study explores HRV biofeedback as a novel treatment to decrease psychiatric symptoms and improve cognitive functioning in older adults. METHODS Participants enrolled in a three-week intervention that included six 30-min biofeedback sessions. Neuropsychological and psychiatric measures were administered before and after the intervention. RESULTS Decreases in depression (Cohen's d = 1.02, p < .001), state anxiety (Cohen's d = 0.82, p = .003), and trait anxiety (Cohen's d = 0.84, p = .002) were observed. An increase in attentional skills as measured by the Trail Making Test - Part A was seen (Cohen's d = 1.00, p = .001). Differences in executive skills as measured by the Trial Making Test - Part B and the Stroop Task did not reach statistical significance. CONCLUSION This study suggests that older adults may benefit from HRV biofeedback interventions much like the younger populations that have been studied for decades. Depression, anxiety, and attentional skills were positively affected. Several participants reported improved sleep quality and stress management. Future studies should corroborate these findings.",2019,"Differences in executive skills as measured by the Trial Making Test - Part B and the Stroop Task did not reach statistical significance. ","['adolescent and adult populations with a variety of symptoms and conditions at the exclusion of older adults', 'Participants enrolled in a three-week intervention that included six 30-min biofeedback sessions', 'older adults']","['HRV biofeedback interventions', 'HRV biofeedback']","['trait anxiety', 'Depression, anxiety, and attentional skills', 'depression', 'Neuropsychological and psychiatric measures', 'executive skills', 'psychiatric symptoms', 'state anxiety', 'attentional skills', 'sleep quality and stress management', 'cognitive functioning']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C4082109', 'cui_str': 'Three weeks'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0678663', 'cui_str': 'Biofeedback, function (observable entity)'}]","[{'cui': 'C0678663', 'cui_str': 'Biofeedback, function (observable entity)'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0233401', 'cui_str': 'Psychiatric symptom (finding)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0150788', 'cui_str': 'Manage stress control'}]",6.0,0.0932941,"Differences in executive skills as measured by the Trial Making Test - Part B and the Stroop Task did not reach statistical significance. ","[{'ForeName': 'Dylan J', 'Initials': 'DJ', 'LastName': 'Jester', 'Affiliation': 'a Department of Psychology , University of Wisconsin\xa0-\xa0La Crosse , La Crosse , WI , USA.'}, {'ForeName': 'Ellen K', 'Initials': 'EK', 'LastName': 'Rozek', 'Affiliation': 'a Department of Psychology , University of Wisconsin\xa0-\xa0La Crosse , La Crosse , WI , USA.'}, {'ForeName': 'Ryan A', 'Initials': 'RA', 'LastName': 'McKelley', 'Affiliation': 'a Department of Psychology , University of Wisconsin\xa0-\xa0La Crosse , La Crosse , WI , USA.'}]",Aging & mental health,['10.1080/13607863.2018.1432031'] 817,31736187,Stress-related suppression of peripheral cytokines predicts future relapse in alcohol-dependent individuals with and without subclinical depression.,"Chronic alcohol abuse and depressive symptoms are both associated with peripheral cytokine changes. Despite this, cytokine adaptations have not been assessed in co-morbid populations or prospectively as predictors of relapse. We examine cytokine responses to stress in alcohol-dependent individuals and social drinkers, both with and without subclinical depression. We also examine the potential link between cytokine adaptations in response to stress and prospective alcohol relapse risk. Thirty-three, alcohol-dependent individuals (21 with and 12 without high depressive symptoms) and 37 controls (16 with and 21 without high depressive symptoms) were exposed to two 5-minute personalized guided imagery conditions (stress and neutral) across consecutive days in a randomized and counterbalanced order. Alcohol craving and serum measures of tumor necrosis factor alpha (TNFα), tumor necrosis factor receptor 1 (TNFR1), interleukin-6 (IL-6), and interleukin-1 receptor antagonist (IL-1ra) were collected prior to and following imagery exposure. Following treatment discharge, follow-up interviews were conducted over 90 days to assess relapse. Dampened IL-1ra and IL-6 in response to stress was observed as a function of alcohol dependence and not moderated by depressive symptoms. Lower levels of IL-6 following stress also predicted greater drinking days following treatment. Conversely, high depressive symptomatology was associated solely with pro-inflammatory adaptations. Stress-related suppression of TNFα predicted drinking severity only in alcohol-dependent individuals with subclinical depression, and suppressed TNFR1 following stress was only seen in individuals with subclinical depression. Stress-induced suppression of pro-inflammatory TNF markers may indicate a risk factor for alcohol-dependent individuals with co-occurring depressive symptoms.",2019,"Alcohol craving and serum measures of tumor necrosis factor alpha (TNFα), tumor necrosis factor receptor 1 (TNFR1), interleukin-6 (IL-6), and interleukin-1 receptor antagonist (IL-1ra) were collected prior to and following imagery exposure.","['alcohol-dependent individuals with and without subclinical depression', 'Thirty-three, alcohol-dependent individuals (21 with and 12 without high depressive symptoms) and 37 controls (16 with and 21 without high depressive symptoms', 'alcohol-dependent individuals and social drinkers, both with and without subclinical depression']",['5-minute personalized guided imagery conditions (stress and neutral'],"['Chronic alcohol abuse and depressive symptoms', 'Alcohol craving and serum measures of tumor necrosis factor alpha (TNFα), tumor necrosis factor receptor 1 (TNFR1), interleukin-6 (IL-6), and interleukin-1 receptor antagonist (IL-1ra']","[{'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205211', 'cui_str': 'Subclinical (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0450358', 'cui_str': '33 (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0337676', 'cui_str': 'Social drinker (finding)'}]","[{'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0150627', 'cui_str': 'Imagery'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}]","[{'cui': 'C0001973', 'cui_str': 'Alcohol Dependence'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0556385', 'cui_str': 'Craving for alcohol (finding)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0077503', 'cui_str': 'TNF Receptors'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C2317059', 'cui_str': 'Interleukin 1 receptor antagonist product'}, {'cui': 'C1704264', 'cui_str': 'IL-1 Inhibitor, Urine'}]",,0.0329056,"Alcohol craving and serum measures of tumor necrosis factor alpha (TNFα), tumor necrosis factor receptor 1 (TNFR1), interleukin-6 (IL-6), and interleukin-1 receptor antagonist (IL-1ra) were collected prior to and following imagery exposure.","[{'ForeName': 'Helen C', 'Initials': 'HC', 'LastName': 'Fox', 'Affiliation': 'Department of Psychiatry, School of Medicine, Stony Brook University, Stony Brook, NY, USA.'}, {'ForeName': 'Verica', 'Initials': 'V', 'LastName': 'Milivojevic', 'Affiliation': 'The Yale Stress Center, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'MacDougall', 'Affiliation': 'The Yale Stress Center, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'LaVallee', 'Affiliation': 'The Yale Stress Center, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Simpson', 'Affiliation': 'Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Gustavo A', 'Initials': 'GA', 'LastName': 'Angarita', 'Affiliation': 'Clinical Neuroscience Research Unit, The Connecticut Mental Health Center, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Rajita', 'Initials': 'R', 'LastName': 'Sinha', 'Affiliation': 'The Yale Stress Center, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.'}]",Addiction biology,['10.1111/adb.12832'] 818,29433668,"Effect of a mass radio campaign on family behaviours and child survival in Burkina Faso: a repeated cross-sectional, cluster-randomised trial.","BACKGROUND Media campaigns can potentially reach a large audience at relatively low cost but, to our knowledge, no randomised controlled trials have assessed their effect on a health outcome in a low-income country. We aimed to assess the effect of a radio campaign addressing family behaviours on all-cause post-neonatal under-5 child mortality in rural Burkina Faso. METHODS In this repeated cross-sectional, cluster randomised trial, clusters (distinct geographical areas in rural Burkina Faso with at least 40 000 inhabitants) were selected by Development Media International based on their high radio listenership (>60% of women listening to the radio in the past week) and minimum distances between radio stations to exclude population-level contamination. Clusters were randomly allocated to receive the intervention (a comprehensive radio campaign) or control group (no radio media campaign). Household surveys were performed at baseline (from December, 2011, to February, 2012), midline (in November, 2013, and after 20 months of campaigning), and endline (from November, 2014, to March, 2015, after 32 months of campaigning). Primary analyses were done on an intention-to-treat basis, based on cluster-level summaries and adjusted for imbalances between groups at baseline. The primary outcome was all-cause post-neonatal under-5 child mortality. The trial was designed to detect a 20% reduction in the primary outcome with a power of 80%. Routine data from health facilities were also analysed for evidence of changes in use and these data had high statistical power. The indicators measured were new antenatal care attendances, facility deliveries, and under-5 consultations. This trial is registered with ClinicalTrial.gov, number NCT01517230. FINDINGS The intervention ran from March, 2012, to January, 2015. 14 clusters were selected and randomly assigned to the intervention group (n=7) or the control group (n=7). The average number of villages included per cluster was 34 in the control group and 29 in the intervention group. 2269 (82%) of 2784 women in the intervention group reported recognising the campaign's radio spots at endline. Post-neonatal under-5 child mortality decreased from 93·3 to 58·5 per 1000 livebirths in the control group and from 125·1 to 85·1 per 1000 livebirths in the intervention group. There was no evidence of an intervention effect (risk ratio 1·00, 95% CI 0·82-1·22; p>0·999). In the first year of the intervention, under-5 consultations increased from 68 681 to 83 022 in the control group and from 79 852 to 111 758 in the intervention group. The intervention effect using interrupted time-series analysis was 35% (95% CI 20-51; p<0·0001). New antenatal care attendances decreased from 13 129 to 12 997 in the control group and increased from 19 658 to 20 202 in the intervention group in the first year (intervention effect 6%, 95% CI 2-10; p=0·004). Deliveries in health facilities decreased from 10 598 to 10 533 in the control group and increased from 12 155 to 12 902 in the intervention group in the first year (intervention effect 7%, 95% CI 2-11; p=0·004). INTERPRETATION A comprehensive radio campaign had no detectable effect on child mortality. Substantial decreases in child mortality were observed in both groups over the intervention period, reducing our ability to detect an effect. This, nevertheless, represents the first randomised controlled trial to show that mass media alone can change health-seeking behaviours. FUNDING Wellcome Trust and Planet Wheeler Foundation.",2018,"There was no evidence of an intervention effect (risk ratio 1·00, 95% CI 0·82-1·22; p>0·999).","['2269 (82%) of 2784 women in the intervention group reported', 'rural Burkina Faso', 'clusters (distinct geographical areas in rural Burkina Faso with at least 40\u2008000 inhabitants', '14 clusters']","['mass radio campaign', 'radio campaign addressing family behaviours', 'intervention (a comprehensive radio campaign) or control group (no radio media campaign']","['New antenatal care attendances', 'family behaviours and child survival', ""recognising the campaign's radio spots"", 'new antenatal care attendances, facility deliveries, and under-5 consultations', 'under-5 consultations', 'cause post-neonatal under-5 child mortality', 'child mortality', 'Post-neonatal under-5 child mortality', 'Deliveries in health facilities']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0006409', 'cui_str': 'Upper Volta'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}]","[{'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0034546', 'cui_str': 'Radio'}, {'cui': 'C0376649', 'cui_str': 'Address'}, {'cui': 'C1321224', 'cui_str': 'Family behavior'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}]","[{'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0033052', 'cui_str': 'Antenatal Care'}, {'cui': 'C1321224', 'cui_str': 'Family behavior'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0034546', 'cui_str': 'Radio'}, {'cui': 'C0848332', 'cui_str': 'Spots on skin (disorder)'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0008083', 'cui_str': 'Child Mortality'}, {'cui': 'C0018704', 'cui_str': 'Health Facilities'}]",,0.135438,"There was no evidence of an intervention effect (risk ratio 1·00, 95% CI 0·82-1·22; p>0·999).","[{'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Sarrassat', 'Affiliation': 'Centre for Maternal, Adolescent, Reproductive and Child Health (MARCH), London School of Hygiene & Tropical Medicine, London, UK. Electronic address: sophie.sarrassat@lshtm.ac.uk.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Meda', 'Affiliation': 'Centre Muraz, Bobo Dioulasso, Burkina Faso.'}, {'ForeName': 'Hermann', 'Initials': 'H', 'LastName': 'Badolo', 'Affiliation': 'Centre Muraz, Bobo Dioulasso, Burkina Faso.'}, {'ForeName': 'Moctar', 'Initials': 'M', 'LastName': 'Ouedraogo', 'Affiliation': 'Africsanté, Bobo Dioulasso, Burkina Faso.'}, {'ForeName': 'Henri', 'Initials': 'H', 'LastName': 'Some', 'Affiliation': 'Africsanté, Bobo Dioulasso, Burkina Faso.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Bambara', 'Affiliation': 'Direction Générale des Études et des Statistiques Sectorielles (DGESS), Ministère de la Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Murray', 'Affiliation': 'Development Media International, London, UK.'}, {'ForeName': 'Pieter', 'Initials': 'P', 'LastName': 'Remes', 'Affiliation': 'Development Media International, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Matthiew', 'Initials': 'M', 'LastName': 'Lavoie', 'Affiliation': 'Development Media International, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Cousens', 'Affiliation': 'Centre for Maternal, Adolescent, Reproductive and Child Health (MARCH), London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Roy', 'Initials': 'R', 'LastName': 'Head', 'Affiliation': 'Development Media International, London, UK.'}]",The Lancet. Global health,['10.1016/S2214-109X(18)30004-4'] 819,31685304,Gentle facemask ventilation during induction of anesthesia.,"BACKGROUND To determine the level of inspiratory pressure minimizing the risk of gastric insufflation while providing adequate pulmonary ventilation. METHODS In this prospective, randomized, double-blind study, patients were allocated to one of the two groups (P10, P15) defined by the inspiratory pressure applied during controlled-pressure ventilation: 10 and 15 cm H 2 O. Anesthesia was induced using propofol and sufentanil; no neuromuscular-blocking agent was administered. Once loss of eyelash reflex occurred, facemask ventilation was started for a 2-min period. The cross-sectional antral area was measured using ultrasonography before and after facemask ventilation. Respiratory parameters were recorded. RESULTS Forty patients were analyzed. Mean tidal volume was about 7 ml/kg in group P10, and was >11 ml/kg in group P15 in the same period. As indicated by ultrasonography test, the antral area in P15 group was markedly incresed compared with P10 group. CONCLUSION Inspiratory pressure of 10 cm H 2 O allowed for reduced occurrence of gastric insufflation with proper lung ventilation during induction of anesthesia with sufentanil and propofol in nonparalyzed and nonobese patients.",2020,"As indicated by ultrasonography test, the antral area in P15 group was markedly incresed compared with P10 group. ","['Forty patients were analyzed', 'nonparalyzed and nonobese patients']","['Gentle facemask ventilation', 'propofol and sufentanil; no neuromuscular-blocking agent', 'sufentanil and propofol']","['eyelash reflex', 'Inspiratory pressure', 'Mean tidal volume']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0027866', 'cui_str': 'Neuromuscular Blockers'}]","[{'cui': 'C0422906', 'cui_str': 'Eyelash reflex (observable entity)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0040210', 'cui_str': 'Tidal Volume'}]",40.0,0.0642312,"As indicated by ultrasonography test, the antral area in P15 group was markedly incresed compared with P10 group. ","[{'ForeName': 'Qingfu', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.""}, {'ForeName': 'Quanhong', 'Initials': 'Q', 'LastName': 'Zhou', 'Affiliation': ""Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.""}, {'ForeName': 'Junfeng', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China. Electronic address: zhangjunfeng16@126.com.""}, {'ForeName': 'Daqiang', 'Initials': 'D', 'LastName': 'Zhao', 'Affiliation': ""Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China. Electronic address: daqiangzhao23@yeah.net.""}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.158399'] 820,32407901,A novel extended prophylactic antibiotic regimen in preterm pre-labor rupture of membranes: A randomized trial.,"OBJECTIVES Prophylactic antibiotic use in preterm pre-labor rupture of membranes (PPROM) is associated with a significant reduction in intra-amniotic infection and improved neonatal outcome. However, data is insufficient to determine the optimal antibiotic regimen. Considering the rise in Escherichia coli and Klebsiella pneumonia early-onset sepsis rate and the emergence of ampicillin resistance, our aim is to compare the efficiency of two antibiotic regimens in prolonging pregnancy and reducing infectious morbidity. DESIGN This multicenter randomized unblinded controlled prospective trial compared two antibiotic prophylactic protocols in PPROM: ampicillin + roxithromycin vs. cefuroxime + roxithromycin in 84 women with PPROM, from 12/2015-12/2019. RESULTS The median latency period was significantly longer (p = 0.039) in the cefuroxime + roxithromycin group (4.63 [0.59-50.18] days) than in the ampicillin + roxithromycin group (2.3 [0.15-58.3] days). Neonatal admission to neonatal intensive care unit rate, hospitalization length, neonatal respiratory distress syndrome, neonatal fever, and need for respiratory support or mechanical ventilation, were similar between the groups. K. pneumonia cultures were significantly more frequent in the ampicillin + roxithromycin group. None of the cultures were group B Streptococcus positive. CONCLUSIONS To prolong latency period and reduce gram-negative early-onset sepsis, cefuroxime + roxithromycin is recommended as the first-line protocol in PPROM. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02819570.",2020,The median latency period was significantly longer (p = 0.039) in the cefuroxime + roxithromycin group (4.63 [0.59-50.18] days) than in the ampicillin + roxithromycin group (2.3 [0.15-58.3] days).,"['preterm pre-labor rupture of membranes', 'PPROM', '84 women with PPROM, from 12/2015-12/2019', 'preterm pre-labor rupture of membranes (PPROM']","['ampicillin\u2009+\u2009roxithromycin vs cefuroxime\u2009+\u2009roxithromycin', 'ampicillin\u2009+\u2009roxithromycin', 'cefuroxime\u2009+\u2009roxithromycin', 'prophylactic antibiotic regimen']","['K. pneumonia cultures', 'median latency period', 'Neonatal admission to neonatal intensive care unit rate, hospitalization length, neonatal respiratory distress syndrome, neonatal fever, and need for respiratory support or mechanical ventilation']","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C0233308', 'cui_str': 'Spontaneous rupture of fetal membranes'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0002680', 'cui_str': 'Ampicillin'}, {'cui': 'C0035891', 'cui_str': 'Roxithromycin'}, {'cui': 'C0007562', 'cui_str': 'Cefuroxime'}, {'cui': 'C0362063', 'cui_str': 'Other prophylactic chemotherapy'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]","[{'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0023103', 'cui_str': 'Latency Period (Psychology)'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0035220', 'cui_str': 'Respiratory distress syndrome in the newborn'}, {'cui': 'C0235839', 'cui_str': 'Fever of the newborn'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}]",84.0,0.100097,The median latency period was significantly longer (p = 0.039) in the cefuroxime + roxithromycin group (4.63 [0.59-50.18] days) than in the ampicillin + roxithromycin group (2.3 [0.15-58.3] days).,"[{'ForeName': 'Maya Frank', 'Initials': 'MF', 'LastName': 'Wolf', 'Affiliation': 'Department of Obstetrics and Gynecology, Galilee Medical Center, Nahariya, Israel; Azrieli Faculty of Medicine, Bar Ilan University, Israel. Electronic address: homesickid@yahoo.com.'}, {'ForeName': 'Inshirah', 'Initials': 'I', 'LastName': 'Sgayer', 'Affiliation': 'Department of Obstetrics and Gynecology, Galilee Medical Center, Nahariya, Israel; Azrieli Faculty of Medicine, Bar Ilan University, Israel.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Miron', 'Affiliation': 'Department of Pediatrics A, Emek Medical Center, Afula, Israel; Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Krencel', 'Affiliation': 'Department of Obstetrics and Gynecology, Galilee Medical Center, Nahariya, Israel; Azrieli Faculty of Medicine, Bar Ilan University, Israel.'}, {'ForeName': 'Vered Fleisher', 'Initials': 'VF', 'LastName': 'Sheffer', 'Affiliation': 'Azrieli Faculty of Medicine, Bar Ilan University, Israel; Neonatal Intensive Care Unit, Galilee Medical Center, Nahariya, Israel.'}, {'ForeName': 'Suraya Saied', 'Initials': 'SS', 'LastName': 'Idriss', 'Affiliation': 'Department of Obstetrics and Gynecology, Bnai-Zion Medical Center, Israel; Technion - Israel Institute of Technology, Israel.'}, {'ForeName': 'Rami N', 'Initials': 'RN', 'LastName': 'Sammour', 'Affiliation': 'Department of Obstetrics and Gynecology, Bnai-Zion Medical Center, Israel; Technion - Israel Institute of Technology, Israel.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Peleg', 'Affiliation': 'Azrieli Faculty of Medicine, Bar Ilan University, Israel; Department of Obstetrics and Gynecology, Ziv Medical Center, Safed, Israel.'}, {'ForeName': 'Inbar Ben', 'Initials': 'IB', 'LastName': 'Shachar', 'Affiliation': 'Azrieli Faculty of Medicine, Bar Ilan University, Israel; Department of Obstetrics and Gynecology, Ziv Medical Center, Safed, Israel.'}, {'ForeName': 'Hagai', 'Initials': 'H', 'LastName': 'Rechnitzer', 'Affiliation': 'Azrieli Faculty of Medicine, Bar Ilan University, Israel; Clinical Microbiology Laboratory, Galilee Medical Center, Nahariya, Israel.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Bornstein', 'Affiliation': 'Department of Obstetrics and Gynecology, Galilee Medical Center, Nahariya, Israel; Azrieli Faculty of Medicine, Bar Ilan University, Israel.'}]",International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,['10.1016/j.ijid.2020.05.005'] 821,30684076,Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.,"BACKGROUND AND AIMS Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a novel class of drugs that lower glucose by inducing renal glycosuria. We aimed to explore whether SGLT2 inhibitor added to the usual care for patients with type 2 diabetes mellitus (T2DM) and biopsy-proven nonalcoholic steatohepatitis (NASH) will benefit NASH histology. METHODS In this investigator-initiated, single-arm, open-label, pilot study, nine biopsy-proven NASH patients with T2DM were given empagliflozin 25 mg daily for 24 weeks. Liver biopsy was repeated at the end of treatment. The histological outcomes were compared with the placebo group of a previous 48-week clinical trial. RESULTS There was a significant reduction in body mass index (median change, Δ = -0.7 kg per m 2 , p = 0.011), waist circumference (Δ = -3 cm, p = 0.033), systolic blood pressure (Δ = -9 mmHg, p = 0.024), diastolic blood pressure (Δ = -6 mmHg, p = 0.033), fasting blood glucose (Δ = -1.7 mmol/L, p = 0.008), total cholesterol (Δ = -0.5 mmol/L, p = 0.011), gamma glutamyl transpeptidase (Δ = -19 U/L, p = 0.013), volumetric liver fat fraction (Δ = -7.8%, p = 0.017), steatosis (Δ = -1, p = 0.014), ballooning (Δ = -1, p = 0.034), and fibrosis (Δ = 0, p = 0.046). All histological components either remained unchanged or improved, except in one patient who had worsening ballooning. Empagliflozin resulted in significantly greater improvements in steatosis (67% vs. 26%, p = 0.025), ballooning (78% vs. 34%, p = 0.024), and fibrosis (44% vs. 6%, p = 0.008) compared with historical placebo. CONCLUSION This pilot study provides primary histological evidence that empagliflozin may be useful for the treatment of NASH. This preliminary finding should prompt larger clinical trials to assess the effectiveness of empagliflozin and other SGLT2 inhibitors for the treatment of NASH in T2DM patients. Trial registry number ClincialTrials.gov number, NCT02964715.",2020,"Empagliflozin resulted in significantly greater improvements in steatosis (67% vs. 26%, p = 0.025), ballooning (78% vs. 34%, p = 0.024), and fibrosis (44% vs. 6%, p = 0.008) compared with historical placebo. ","['Patients with Type 2 Diabetes Mellitus', 'patients with type 2 diabetes mellitus (T2DM) and biopsy-proven nonalcoholic steatohepatitis (NASH) will benefit NASH histology', 'T2DM patients']","['Empagliflozin', 'empagliflozin', 'placebo', 'SGLT2 inhibitor']","['Liver biopsy', 'waist circumference', 'fasting blood glucose', 'total cholesterol', 'steatosis', 'fibrosis', 'volumetric liver fat fraction', 'systolic blood pressure', 'gamma glutamyl transpeptidase', 'body mass index', 'diastolic blood pressure']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0456369', 'cui_str': 'Proven (qualifier value)'}, {'cui': 'C3241937', 'cui_str': 'Nonalcoholic Steatohepatitis'}, {'cui': 'C0344441', 'cui_str': 'Histologic test (procedure)'}]","[{'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3273807', 'cui_str': 'Gliflozins'}]","[{'cui': 'C0193388', 'cui_str': 'Biopsy of liver (procedure)'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0152254', 'cui_str': 'Fatty degeneration (morphologic abnormality)'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0445383', 'cui_str': 'Volumetric (qualifier value)'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0202035', 'cui_str': 'Gamma glutamyl transferase measurement (procedure)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}]",,0.122103,"Empagliflozin resulted in significantly greater improvements in steatosis (67% vs. 26%, p = 0.025), ballooning (78% vs. 34%, p = 0.024), and fibrosis (44% vs. 6%, p = 0.008) compared with historical placebo. ","[{'ForeName': 'Lee-Lee', 'Initials': 'LL', 'LastName': 'Lai', 'Affiliation': 'Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Shireene Ratna', 'Initials': 'SR', 'LastName': 'Vethakkan', 'Affiliation': 'Endocrine Unit, Department of Medicine, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia. shireene.vethakkan@gmail.com.'}, {'ForeName': 'Nik Raihan', 'Initials': 'NR', 'LastName': 'Nik Mustapha', 'Affiliation': 'Department of Pathology, Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia.'}, {'ForeName': 'Sanjiv', 'Initials': 'S', 'LastName': 'Mahadeva', 'Affiliation': 'Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Wah-Kheong', 'Initials': 'WK', 'LastName': 'Chan', 'Affiliation': 'Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia. wahkheong2003@hotmail.com.'}]",Digestive diseases and sciences,['10.1007/s10620-019-5477-1'] 822,30674696,"Effects of programmed intermittent thoracic paravertebral bolus of levobupivacaine on the spread of sensory block: a randomized, controlled, double-blind study.","BACKGROUND AND OBJECTIVES This randomized, controlled, double-blind trial compared the effectiveness of levobupivacaine delivery of a programmed intermittent paravertebral bolus with a continuous paravertebral infusion. METHODS Thirty-two consecutively enrolled patients who underwent unilateral video-assisted thoracic surgery were randomized to receive either a programmed intermittent paravertebral bolus of 10 mL of 0.2% levobupivacaine every 2 hours (Bolus group, n=16) or a continuous paravertebral infusion of 0.2% levobupivacaine at 5 mL/hour (Infusion group, n=16) after the operation. Postoperatively, after injection of 20 mL of 0.25% levobupivacaine through the paravertebral catheter, a mechanical infusion pump was set depending on the assigned group. The primary efficacy outcome was the number of anesthetized dermatomes 24 hours after the initial bolus of levobupivacaine. The secondary efficacy outcomes included the number of anesthetized dermatomes at other time points, pain at rest and coughing, additional analgesic use and patient acceptance of the analgesic technique. Arterial levobupivacaine concentration was measured to ensure safety. P<0.05 was considered statistically significant. RESULTS The mean (95% CI) number of anesthetized dermatomes 24 hours after the initial bolus of levobupivacaine was significantly larger among subjects receiving programmed intermittent bolus (n=16) compared with those receiving continuous infusion (n=16; 6.8 (5.7-7.9) vs 3.1 (2.0-4.2); p<0.001). The arterial levobupivacaine concentration did not reach a toxic level. CONCLUSIONS The programmed intermittent paravertebral bolus of levobupivacaine provided a wider dermatomal spread of sensory block than continuous paravertebral infusion with an identical hourly dose of levobupivacaine. TRIAL REGISTRATION NUMBER UMIN000022532.",2019,"The programmed intermittent paravertebral bolus of levobupivacaine provided a wider dermatomal spread of sensory block than continuous paravertebral infusion with an identical hourly dose of levobupivacaine. ",['Thirty-two consecutively enrolled patients who underwent unilateral video-assisted thoracic surgery'],"['levobupivacaine', 'programmed intermittent paravertebral bolus of 10\u2009mL of 0.2% levobupivacaine', 'continuous paravertebral infusion of 0.2% levobupivacaine']","['Arterial levobupivacaine concentration', 'spread of sensory block', 'number of anesthetized dermatomes at other time points, pain at rest and coughing, additional analgesic use and patient acceptance of the analgesic technique', 'arterial levobupivacaine concentration', 'number of anesthetized dermatomes 24\u2009hours']","[{'cui': 'C0450357', 'cui_str': '32 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0752151', 'cui_str': 'VATS'}]","[{'cui': 'C0873118', 'cui_str': 'Levobupivacaine'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0442150', 'cui_str': 'Paravertebral (qualifier value)'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}]","[{'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0873118', 'cui_str': 'Levobupivacaine'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0332261', 'cui_str': 'Spread (attribute)'}, {'cui': 'C0445254', 'cui_str': 'Sensory (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1720436', 'cui_str': 'Anesthetized'}, {'cui': 'C0392338', 'cui_str': 'Dermatome (body structure)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0234253', 'cui_str': 'Rest pain (finding)'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0412784', 'cui_str': 'Analgesic technique (procedure)'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}]",32.0,0.404802,"The programmed intermittent paravertebral bolus of levobupivacaine provided a wider dermatomal spread of sensory block than continuous paravertebral infusion with an identical hourly dose of levobupivacaine. ","[{'ForeName': 'Kumiko', 'Initials': 'K', 'LastName': 'Hida', 'Affiliation': 'Department of Anesthesiology, Nagasaki University School of Medicine, Nagasaki, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Murata', 'Affiliation': 'Department of Anesthesiology, Nagasaki University School of Medicine, Nagasaki, Japan hiroakimurata122@gmail.com.'}, {'ForeName': 'Taiga', 'Initials': 'T', 'LastName': 'Ichinomiya', 'Affiliation': 'Department of Anesthesiology, Nagasaki University School of Medicine, Nagasaki, Japan.'}, {'ForeName': 'Haruka', 'Initials': 'H', 'LastName': 'Inoue', 'Affiliation': 'Department of Anesthesiology, Nagasaki University School of Medicine, Nagasaki, Japan.'}, {'ForeName': 'Shuntaro', 'Initials': 'S', 'LastName': 'Sato', 'Affiliation': 'Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Hara', 'Affiliation': 'Department of Anesthesiology, Nagasaki University School of Medicine, Nagasaki, Japan.'}]",Regional anesthesia and pain medicine,['10.1136/rapm-2018-100021'] 823,30884155,Massage intervention for preterm infants by their mothers: A randomized controlled trial.,"OBJECTIVE Studies of the impact of infant massage intervention on the growth of preterm infants have been conducted in neonatal intensive care units (NICUs) and have demonstrated positive effects; however, few data exist regarding the effects of massage interventions by mothers on the growth of infants in the NICU. The purpose of this randomized controlled trial was to examine the effects of a 2-week massage intervention conducted by mothers on their preterm infants. METHODS Of 112 stable preterm infants born at a gestational age (GA) between 32 and 34 weeks and enrolled from an affiliated hospital, 54 were randomly allocated to an intervention group, and 58 were allocated to a control group. Mothers were trained to conduct a massage intervention in the intervention group, while the control group received standard care. For the infants in both groups, height (Ht), weight (Wt), and head circumference (HC) were measured at the onset of massage intervention, after one week, and after two weeks. Fifteen mothers were interviewed about their preparation for and completion of the massage intervention. RESULTS Repeated-measures analysis of variance showed that weight, height and head circumference significantly increased in the intervention group. Preterm infants who underwent the two-week massage intervention had higher mean weight, height, and head circumference (F = 41.151, 6.621, 24.158, respectively; p < .001). This study developed modified massage intervention guidance to provide recommendations for optimal massage intervention by mothers in the NICU: (a) Adapt to the NICU atmosphere; (b) control the mother's strength; (c) slowly perform each period of the massage, that is (i) place in a prone position (5 + 5 min); (ii) place in supine position (5 min); (d) stay relaxed and watch the preterm infant's response. PRACTICE IMPLICATIONS Trained mothers conducted massage interventions, which can improve the growth of preterm infants. We developed massage intervention guidance to provide recommendations for optimal massage intervention by mothers in the NICU. We recommend that mothers apply massage intervention for preterm infants in the NICU.",2019,"RESULTS Repeated-measures analysis of variance showed that weight, height and head circumference significantly increased in the intervention group.","['112 stable preterm infants born at a gestational age\xa0(GA) between 32 and 34 weeks and enrolled from an affiliated hospital, 54', 'preterm infants by their mothers', 'mothers in the NICU', 'Trained mothers conducted', 'Fifteen mothers', 'mothers on their preterm infants', 'preterm infants', 'preterm infants in the NICU']","['massage intervention guidance', 'infant massage intervention', 'Massage intervention', 'control group received standard care', 'massage intervention', 'modified massage intervention guidance', 'massage interventions']","['height (Ht), weight (Wt), and head circumference (HC', 'mean weight, height, and head circumference', 'weight, height and head circumference']","[{'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0021709', 'cui_str': 'Newborn ICU'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]","[{'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0695595', 'cui_str': 'Infant massage (regime/therapy)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]","[{'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0262499', 'cui_str': 'Head circumference (observable entity)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",112.0,0.068904,"RESULTS Repeated-measures analysis of variance showed that weight, height and head circumference significantly increased in the intervention group.","[{'ForeName': 'Xiaoning', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'School of Nursing, Xuzhou Medical University, Xuzhou, Jiangsu, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Pediatric Department, the Affiliated Hospital of Xuzhou Medical College, Jiangsu, China.'}]",Journal for specialists in pediatric nursing : JSPN,['10.1111/jspn.12238'] 824,31673708,A Phase II Study of Neoadjuvant Stereotactic Radiosurgery for Large Brain Metastases: Clinical Trial Protocol.,"BACKGROUND Brain metastases which require resection are treated with surgery followed by whole brain radiation therapy or postoperative cavity boost stereotactic radiosurgery (POCBS). Recently a novel strategy using neoadjuvant stereotactic radiosurgery (NaSRS) followed by resection was reported, demonstrating lower rates of postoperative leptomeningeal dissemination (LMD) and symptomatic radiation toxicity compared to a comparative cohort of patients treated with postoperative SRS. OBJECTIVE To determine if the rate of symptomatic radiation toxicity at 1 yr in patients who receive NaSRS differs significantly from historical rates for patients treated with POCBS. METHODS This is a multi-center, non-randomized, open phase II clinical trial. A total of 30 patients with up to 10 brain metastases, at least 1 of which is appropriate for surgical resection, will be enrolled for over 4 yr. All enrolled patients will be assigned to receive NaSRS followed by surgery. EXPECTED OUTCOME This study will clarify whether symptomatic radiation toxicity caused by NaSRS is significantly decreased compared to historical rates associated with POCBS. Secondary endpoints will include 1-yr local control (LC) of the treated lesion, 1-yr rates of LMD, median survival and 2-yr rates of progression-free and overall survival. Tertiary analyses will include correlation between LC and radiation toxicity with pretreatment clinical factors, serum markers, radiomic features, and molecular assessments of the resected tumors. DISCUSSION This prospective study will determine the toxicity associated with NaSRS and provide additional quantitative metrics of efficacy for future comparative trials.",2020,"Secondary endpoints will include 1-yr local control (LC) of the treated lesion, 1-yr rates of LMD, median survival and 2-yr rates of progression-free and overall survival.","['30 patients with up to 10 brain metastases, at least 1 of which is appropriate for surgical resection, will be enrolled for over 4 yr', 'Large Brain Metastases', 'patients who receive NaSRS differs significantly from historical rates for patients treated with POCBS']","['neoadjuvant stereotactic radiosurgery (NaSRS', 'surgery followed by whole brain radiation therapy or postoperative cavity boost stereotactic radiosurgery (POCBS', 'NaSRS followed by surgery', 'Neoadjuvant Stereotactic Radiosurgery']","['postoperative leptomeningeal dissemination (LMD) and symptomatic radiation toxicity', '1-yr local control (LC) of the treated lesion, 1-yr rates of LMD, median survival and 2-yr rates of progression-free and overall survival', 'rate of symptomatic radiation toxicity', 'LC and radiation toxicity with pretreatment clinical factors, serum markers, radiomic features, and molecular assessments of the resected tumors', 'symptomatic radiation toxicity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0220650', 'cui_str': 'Secondary malignant neoplasm of brain (disorder)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C3846112', 'cui_str': 'Radiosurgery, Stereotactic'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C1520143', 'cui_str': 'Whole brain radiation therapy (regime/therapy)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C1510420', 'cui_str': 'Cavity (morphologic abnormality)'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0011793', 'cui_str': 'Dextran 40'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0162491', 'cui_str': 'Serum Markers'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}]",,0.0605815,"Secondary endpoints will include 1-yr local control (LC) of the treated lesion, 1-yr rates of LMD, median survival and 2-yr rates of progression-free and overall survival.","[{'ForeName': 'Hirokazu', 'Initials': 'H', 'LastName': 'Takami', 'Affiliation': 'Division of Neurosurgery, Toronto Western Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'Farshad', 'Initials': 'F', 'LastName': 'Nassiri', 'Affiliation': 'Division of Neurosurgery, Toronto Western Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'Fabio Y', 'Initials': 'FY', 'LastName': 'Moraes', 'Affiliation': 'Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Gelareh', 'Initials': 'G', 'LastName': 'Zadeh', 'Affiliation': 'Division of Neurosurgery, Toronto Western Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Bernstein', 'Affiliation': 'Division of Neurosurgery, Toronto Western Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'Tatiana', 'Initials': 'T', 'LastName': 'Conrad', 'Affiliation': 'Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Berlin', 'Affiliation': 'Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Normand', 'Initials': 'N', 'LastName': 'Laperriere', 'Affiliation': 'Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Barbara-Ann', 'Initials': 'BA', 'LastName': 'Millar', 'Affiliation': 'Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'David Benjamin', 'Initials': 'DB', 'LastName': 'Shultz', 'Affiliation': 'Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Kongkham', 'Affiliation': 'Division of Neurosurgery, Toronto Western Hospital, Toronto, Ontario, Canada.'}]",Neurosurgery,['10.1093/neuros/nyz442'] 825,31622058,[Allokin-alpha - new approaches in the treatment of chronic virus Epstein-Barr infections.],"INTRODUCTION Epstein-Barr virus causes recurrent infectious mononucleosis-like symptoms. Today it is shown that the poisons of insects and animals are rich sources of antimicrobial substances (peptides) and contain a wide range of active biological compounds. Antimicrobial peptides play an important role in the immune response of the innate immunity of the host in the presence of pathogenic microorganisms. Russia has developed an antiviral drug Allokin-alpha on the basis of antimicrobial peptides. The active ingredient of this drug is cytokin-like peptide alloferon. The aim of the study is to evaluate the effect of allokin-alpha therapy on the amount of EBV DNA in saliva samples and clinical complaints in patients with chronic Epstein-Barr infection (ChEBVI). MATERIAL AND METHODS 59 patients with ChEBVI were examined (45 women and 14 men; mean age 32.52 ± 1.75 years). Patients were examined quantification of DNA Epstein-Barr virus in saliva samples by the method of polymerase chain reaction (PCR) with hybridization-fluorescence detection in ""real time"" mode. The analytical sensitivity of the test system is 400 copies / ml. Patients were randomized into two groups: group 1 (25 patients) received Allokin-alpha therapy (9 injections of s / c, 1.0 mg every other day); group 2 (33 patients) received Valtrex (500 mg x 2 times / day, by mouth) for two months. RESULTS 59.67% of patients had negative PCR results after treatment with Allocin-alpha. Only 27.27% of patients had negative PCR results after two months of treatment with Valtrex. In a correlation analysis, a significant effect of the initial number of copies of DNA EBV on the severity of clinical complaints in patients was revealed in the general group ChEBVI. DISCUSSION Allokin-alpha improves the recognition of virus-infected cells and helps suppress viral replication. CONCLUSIONS Allocin-alpha therapy can be recommended for the treatment of chronic EBVI at a dose of 1 mg subcutaneously every other day with a course dose of at least 9 injections.",2019,"In a correlation analysis, a significant effect of the initial number of copies of DNA EBV on the severity of clinical complaints in patients was revealed in the general group ChEBVI. ","['59 patients with ChEBVI were examined (45 women and 14 men; mean age 32.52 ± 1.75 years', 'patients with chronic Epstein-Barr infection (ChEBVI', 'chronic virus Epstein-Barr infections']","['Allocin-alpha therapy', 'Valtrex', 'Allokin-alpha therapy', 'Allokin-alpha - new approaches', 'allokin-alpha therapy']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517514', 'cui_str': '1.75'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0042776', 'cui_str': 'Virus'}]","[{'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0592245', 'cui_str': 'Valtrex'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}]",[],45.0,0.0344685,"In a correlation analysis, a significant effect of the initial number of copies of DNA EBV on the severity of clinical complaints in patients was revealed in the general group ChEBVI. ","[{'ForeName': 'I A', 'Initials': 'IA', 'LastName': 'Rakitianskaya', 'Affiliation': 'Outpatient Department of Allergology-Immunology and Clinical Transfusiology City Ambulant Department №112, St. Petersburg, 195427, Russian Federation.'}, {'ForeName': 'T S', 'Initials': 'TS', 'LastName': 'Riabova', 'Affiliation': 'Outpatient Department of Allergology-Immunology and Clinical Transfusiology City Ambulant Department №112, St. Petersburg, 195427, Russian Federation.'}, {'ForeName': 'U A', 'Initials': 'UA', 'LastName': 'Todzhibaev', 'Affiliation': 'Outpatient Department of Allergology-Immunology and Clinical Transfusiology City Ambulant Department №112, St. Petersburg, 195427, Russian Federation.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Kalashnikova', 'Affiliation': 'The Nikiforov Russian Center of Emergency and Radiation Medicine, St. Petersburg, 194044, Russian Federation.'}]",Voprosy virusologii,['10.18821/0507-4088-2019-64-3-118-124'] 826,31680010,Randomized clinical trial of BioFoam® Surgical Matrix to achieve hemostasis after liver resection.,"BACKGROUND Topical agents were designed to facilitate hemostasis during hepatic resection. The aim of this prospective randomized controlled clinical trial was to evaluate the effectiveness and safety of BioFoam® Surgical Matrix for achieving hemostasis after open hepatic resection. METHODS This was a prospective, randomized controlled monocentric trial of patients undergoing elective open liver resection between December 2015 and September 2017. The primary endpoint was time-to-complete hemostasis. RESULTS A total of 101 patients were enrolled in this trial, giving 51 patients in the BioFoam® group and 50 patients in the control group (without use of BioFoam®). Time-to-complete hemostasis was significantly reduced in the BioFoam® group (156 ± 129 versus 307 ± 264 s; P = 0.001). There were no significant differences in postoperative bile leaks (n = 6 (12%) vs. n = 5 (10%); P = 0.776), postoperative morbidity (n = 37 (73%) vs. n = 40 (80%); P = 0.482) or mortality (n = 3 (6%) vs. n = 1 (2%); P = 0.618) between groups. CONCLUSION BioFoam® is a safe topical agent for achieving faster hemostasis during hepatic resection, however, the true clinical relevance of this finding needs to be further evaluated. ClinicalTrials.gov ID NCT02612220.",2020,Time-to-complete hemostasis was significantly reduced in the BioFoam® group (156 ± 129 versus 307 ± 264 s; P = 0.001).,"['101 patients were enrolled in this trial, giving 51 patients in the BioFoam® group and 50 patients in the control group (without use of BioFoam®', 'patients undergoing elective open liver resection between December 2015 and September 2017']","['BioFoam®', 'BioFoam® Surgical Matrix']","['postoperative bile leaks', 'mortality', 'postoperative morbidity', 'time-to-complete hemostasis', 'Time-to-complete hemostasis']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0019144', 'cui_str': 'Hepatectomy'}]","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C4319583', 'cui_str': 'Matrix'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0005388', 'cui_str': 'Bile'}, {'cui': 'C0332234', 'cui_str': 'Leaking (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0740166', 'cui_str': 'Haemostasis'}]",51.0,0.143819,Time-to-complete hemostasis was significantly reduced in the BioFoam® group (156 ± 129 versus 307 ± 264 s; P = 0.001).,"[{'ForeName': 'Nuh N', 'Initials': 'NN', 'LastName': 'Rahbari', 'Affiliation': 'Department of Gastrointestinal, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany. Electronic address: nuh.rahbari@umm.de.'}, {'ForeName': 'Emrullah', 'Initials': 'E', 'LastName': 'Birgin', 'Affiliation': 'Department of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.'}, {'ForeName': 'Dorothée', 'Initials': 'D', 'LastName': 'Sturm', 'Affiliation': 'Department of Gastrointestinal, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Uta', 'Initials': 'U', 'LastName': 'Schwanebeck', 'Affiliation': 'Coordination Center for Clinical Trials Dresden, Biostatistics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Weitz', 'Affiliation': 'Department of Gastrointestinal, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Reissfelder', 'Affiliation': 'Department of Gastrointestinal, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany.'}]",HPB : the official journal of the International Hepato Pancreato Biliary Association,['10.1016/j.hpb.2019.10.1529'] 827,31676953,Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.,"BACKGROUND Studies of patients treated with bevacizumab and other vascular epithelial growth factor (VEGF) inhibitors have reported that hypertension adverse events (AEs) are associated with improved overall survival (OS) or progression-free survival (PFS). OBJECTIVE Our objective was to evaluate the association between early AEs and survival outcomes for patients treated with ramucirumab, an antibody targeting the VEGF receptor-2 (VEGFR-2), plus FOLFIRI for metastatic colorectal cancer (mCRC). METHODS Data from 529 patients treated with ramucirumab plus FOLFIRI for mCRC in the RAISE clinical trial (NCT01183780) were evaluated to see whether early (first 6 weeks of therapy) AEs predicted subsequent OS and PFS. A Cox proportional hazard approach was used to evaluate associations between early AEs and survival outcomes. A secondary analysis between FOLFIRI and placebo was conducted as a sensitivity analysis. RESULTS Of 529 patients treated with ramucirumab plus FOLFIRI, 479 were alive and progression free at 6 weeks after commencing therapy. No significant association was identified between hypertension occurring within the first 42 days of ramucirumab plus FOLFIRI therapy and OS (grade 1-2, hazard ratio [HR] 0.90 [95% confidence interval (CI) 0.66-1.24]; grade 3+, HR 1.02 [95% CI 0.67-1.55]; P = 0.803) or PFS (grade 1-2, HR 0.98 [95% CI 0.74-1.28]; grade 3+, HR 0.93 [95% CI 0.64-1.37]; P = 0.93). However, there was a significant association between diarrhea occurring within the first 42 days of ramucirumab plus FOLFIRI therapy and worse OS (grade 1-2, HR 0.96 [95% CI 0.76-1.20]; grade 3+, HR 2.72 [95% CI 1.67-4.44]; P = 0.001) and PFS (grade 1-2, HR 1.01 [95% CI 0.83-1.23]; grade 3+, HR 2.22 [95% CI 1.43-3.45]; P = 0.005). No other AEs were significantly associated with OS or PFS. CONCLUSIONS Ramucirumab-induced hypertension was not associated with improved OS and PFS in patients with mCRC treated with ramucirumab and FOLFIRI, but severe diarrhea was associated with poorer OS and PFS. CLINICAL TRIAL REGISTRATION No. NCT01183780.",2019,"No significant association was identified between hypertension occurring within the first 42 days of ramucirumab plus FOLFIRI therapy and OS (grade 1-2, hazard ratio [HR] 0.90 [95% confidence interval (CI) 0.66-1.24]; grade 3+, HR 1.02","['patients treated with ramucirumab, an antibody targeting the VEGF receptor-2 (VEGFR-2), plus FOLFIRI for metastatic colorectal cancer (mCRC', 'Patients with Metastatic Colorectal Cancer Treated with', '529 patients treated with']","['FOLFIRI and placebo', 'Ramucirumab', 'ramucirumab plus FOLFIRI', 'bevacizumab and other vascular epithelial growth factor (VEGF) inhibitors', 'ramucirumab plus FOLFIRI for mCRC']","['severe diarrhea', 'overall survival (OS) or progression-free survival (PFS', 'OS and PFS', 'hypertension', 'Survival Outcomes', 'PFS', 'diarrhea', 'subsequent OS and PFS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C2742502', 'cui_str': 'ramucirumab'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0148199', 'cui_str': 'VEGF Receptors'}, {'cui': 'C0378796', 'cui_str': 'Flk-1 Protein'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0346973', 'cui_str': 'Secondary malignant neoplasm of large intestine'}, {'cui': 'C4517806', 'cui_str': '529 (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2742502', 'cui_str': 'ramucirumab'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0018284', 'cui_str': 'Growth factor (substance)'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C1443924', 'cui_str': 'Severe diarrhea'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",479.0,0.295579,"No significant association was identified between hypertension occurring within the first 42 days of ramucirumab plus FOLFIRI therapy and OS (grade 1-2, hazard ratio [HR] 0.90 [95% confidence interval (CI) 0.66-1.24]; grade 3+, HR 1.02","[{'ForeName': 'Huezin H', 'Initials': 'HH', 'LastName': 'Lim', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia. lim0654@flinders.edu.au.'}, {'ForeName': 'Ashley M', 'Initials': 'AM', 'LastName': 'Hopkins', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Rowland', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia.'}, {'ForeName': 'Hoi Y', 'Initials': 'HY', 'LastName': 'Yuen', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia.'}, {'ForeName': 'Christos S', 'Initials': 'CS', 'LastName': 'Karapetis', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Sorich', 'Affiliation': 'College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia.'}]",Targeted oncology,['10.1007/s11523-019-00683-z'] 828,31674219,Are self-efficacy measures confounded with motivation? An experimental test.,"Standard measures of self-efficacy (SE) may confound perceived capability and motivation because respondents interpret the word ""can"" as ""will"". Objective: To test whether priming for the meaning of the word ""can"" changes self-efficacy ratings. Design: In an experimental test, 134 university students responded to an on-line standardized measure of exercise SE and provided definitions of the words ""can"" and ""will"". One month later participants were randomized to complete (a) the same questionnaire (control), (b) the same questionnaire but with presentation of each participant's definition of ""can"" prior to the SE measure (definition priming), or (c) the same questionnaire but with SE items (""I can exercise…"") placed side-by-side with behavioral intention items (""I will exercise…"") (side-by-side priming). Results: SE increased relative to controls for side-by-side (b = 12.08, SE  = 2.70, p <.01) but not definition priming (ns), with the former even stronger among participants ( n  = 91) who provided strict (i.e., literal) rather than liberal definitions of ""can"" (b = 15.38, SE  = 3.21, p <.001). Conclusion: Priming of the meaning of the word ""can"" led to increases in self-efficacy ratings among those who hold a literal meaning of the word ""can"". This suggests that for many respondents standard assessments of SE may be confounded by motivation.",2020,"increased relative to controls for side-by-side (b = 12.08, SE  = 2.70, p <.01) but not definition priming (ns), with the former even stronger among participants ( n  = 91) who provided strict (i.e., literal) rather than liberal definitions of ""can"" (b = 15.38, SE  = 3.21, p <.001). ",['134 university students'],"['can"" prior to the SE measure (definition priming), or (c) the same questionnaire but with SE items (""I can exercise…"") placed side-by-side with behavioral intention items (""I will exercise…', 'SE']",['self-efficacy ratings'],"[{'cui': 'C4517565', 'cui_str': 'One hundred and thirty-four'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}]","[{'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C3539107', 'cui_str': 'Definition (core metadata concept)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",134.0,0.0141905,"increased relative to controls for side-by-side (b = 12.08, SE  = 2.70, p <.01) but not definition priming (ns), with the former even stronger among participants ( n  = 91) who provided strict (i.e., literal) rather than liberal definitions of ""can"" (b = 15.38, SE  = 3.21, p <.001). ","[{'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Williams', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, USA.'}, {'ForeName': 'Shira', 'Initials': 'S', 'LastName': 'Dunsiger', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, USA.'}, {'ForeName': 'Jessica A', 'Initials': 'JA', 'LastName': 'Emerson', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Dionne', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, USA.'}, {'ForeName': 'Ryan E', 'Initials': 'RE', 'LastName': 'Rhodes', 'Affiliation': 'Behavioural Medicine Laboratory, School of Exercise Science, Physical and Health Education, University of Victoria, Victoria, Canada.'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Beauchamp', 'Affiliation': 'School of Kinesiology, University of British Columbia, Vancouver, Canada.'}]",Psychology & health,['10.1080/08870446.2019.1683179'] 829,30507604,Comparative analysis of radiation dose and image quality between organ dose modulation and 3D smart mA modulation during head-neck CT angiography.,"OBJECTIVE To assess the difference in absorbed organ dose and image quality for head-neck CT angiography using organ dose modulation compared with 3D smart mA modulation in different body mass indices (BMIs) using an adaptive statistical iterative reconstruction (ASiR-V) algorithm. METHODS Three hundred patients underwent head-neck CTA were equally divided into three groups: A (18.5 kg/m2≦BMI < 24.9 kg/m2), B (24.9 kg/m2≦BMI < 29.9 kg/m2) and C (29.9 kg/m2≦BMI≦34.9 kg/m2). The groups were randomly subdivided into two subgroups (n = 50): A1-A2, B1-B2 and C1-C2. The patients in subgroups A1, B1 and C1 underwent organ dose modulation with the ASiR-V algorithm, while other patients underwent 3D smart mA modulation. The signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) of all head-neck CT angiography images were calculated. Images were then subjectively evaluated. Mean values of several indices including dose-length product (DLP) were computed. The DLP was converted to the effective dose (ED). SNR, CNR and ED in groups A, B, and C were compared in statistical data analysis. RESULTS SNR, CNR, and subjective image scores show no statistical differences in three groups (P  >  0.05). However, there is significant difference of ED values (P  <  0.05) . For example, in subgroup A1 mean ED values are 15.30% and 23.66% lower than those in subgroup A2 at thyroid gland and eye lens, respectively. Similar patterns also exist in groups B (B1 vs. B2) and C (C1 vs. C2). CONCLUSIONS Using organ dose modulation and applying the ASiR-V algorithm can more effectively reduce the radiation dose in head-neck CT angiography than using 3D smart mA modulation, while maintaining image quality. Thus, using organ-based dose modulation has the additional benefit of reducing dose to the thyroid gland and eye lens.",2019,"RESULTS SNR, CNR, and subjective image scores show no statistical differences in three groups (P  >  0.05).","['head-neck CT angiography', 'Three hundred patients underwent head-neck CTA']",[],"['signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR', 'SNR, CNR, and subjective image scores', 'Mean values of several indices including dose-length product (DLP', 'ED values']","[{'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0027536', 'cui_str': 'Necking (finding)'}, {'cui': 'C1536105', 'cui_str': 'Angiography, CT'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]",[],"[{'cui': 'C2986823', 'cui_str': 'Signal-To-Noise Ratio'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1444754', 'cui_str': 'Length property'}]",300.0,0.0196109,"RESULTS SNR, CNR, and subjective image scores show no statistical differences in three groups (P  >  0.05).","[{'ForeName': 'Yongxia', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Department of Radiology, The Affiliated Hospital of Hebei University, China.'}, {'ForeName': 'Yize', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Medical school, Hebei University, China.'}, {'ForeName': 'Yunfeng', 'Initials': 'Y', 'LastName': 'Bao', 'Affiliation': 'Department of Radiology, Hebei General Hospital, China.'}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Geng', 'Affiliation': 'Medical school, Hebei University, China.'}, {'ForeName': 'Tianle', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Medical school, Hebei University, China.'}, {'ForeName': 'Dongxue', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Medical school, Hebei University, China.'}]",Journal of X-ray science and technology,['10.3233/XST-180443'] 830,30653375,The effects of relaxation training on depression and anxiety in people living with long-term neurological conditions.,"Purpose: The present study investigated the effects of a relaxation training program on self-reported depression and anxiety in participants living with long-term neurological conditions, including acquired brain injury, stroke, Parkinson's disease, and multiple sclerosis. Materials and methods : A five-session relaxation training program, plus a follow-up session was offered to people living with a long-term neurological condition as part of routine clinical practice, and was delivered in their own homes. A self-report measure (Hospital Anxiety and Depression Scale) was administered at the pre- and post-intervention time points and at follow-up, around 5 weeks after the final session. Participants also completed an individual assessment of change questionnaire at follow-up, reporting on subjective views of observed changes. Results: Statistically significant improvements were found on measures of both anxiety and depression following completion of the relaxation program. Scores at follow-up (mean = 5 weeks) revealed the improvement was maintained for anxiety, and there was further significant improvement for depression. Reliable change analyses from pre- to post-intervention demonstrated a clinically significant decrease in anxiety scores for 47% of participants and in depression scores for 30% of participants. No clinically significant increase in depression and anxiety was identified from pre- to post-intervention, and this was generally maintained at follow-up. Conclusion: Relaxation training is proposed as a clinically effective treatment for anxiety and depression in people living with long-term neurological conditions, which could in turn lead to better functional outcomes of neurorehabilitation. The program investigated here has additional benefits of being delivered in people's own homes, which overcomes barriers to attending hospital, and is consistent with trends towards home as opposed to hospital care. This program may also be less costly to administer as it can be delivered as part of a stepped-care program by therapy assistants under supervision from qualified staff, and encourages self-management over the longer term. Design limitations may reduce the generalisability of these findings, but are clinically encouraging and should stimulate further research.Implications for RehabilitationRelaxation training…• could be offered as an effective first-line intervention, as an alternative to medication to treat anxiety and depression to people living with Long-Term Neurological Conditionsis a self-management strategy which can be taught in people's own homes, if getting out of the house is difficultcan be delivered as a stepped-care intervention via therapy assistants, helping to reduce costs and demands on rehabilitation servicesmay help to improve the functional outcomes of wider rehabilitation interventions by addressing psychological issues which can be a barrier.",2020,Reliable change analyses from pre- to post-intervention demonstrated a clinically significant decrease in anxiety scores for 47% of participants and in depression scores for 30% of participants.,"['people living with long-term neurological conditions', ""participants living with long-term neurological conditions, including acquired brain injury, stroke, Parkinson's disease, and multiple sclerosis""]","['Relaxation training', 'relaxation training program', 'Rehabilitation Relaxation training…', 'relaxation training']","['depression', 'anxiety and depression', 'anxiety scores', 'depression and anxiety', 'A self-report measure (Hospital Anxiety and Depression Scale']","[{'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0270611', 'cui_str': 'Brain Injuries'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}]","[{'cui': 'C0282333', 'cui_str': 'Relaxation Therapy'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}]","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}]",,0.0173286,Reliable change analyses from pre- to post-intervention demonstrated a clinically significant decrease in anxiety scores for 47% of participants and in depression scores for 30% of participants.,"[{'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Hampson', 'Affiliation': ""Department of Paediatric Clinical Psychology, Sheffield Children's Hospital, Sheffield, UK.""}, {'ForeName': 'Lorraine', 'Initials': 'L', 'LastName': 'King', 'Affiliation': 'Department of Clinical Neuropsychology, Salford Royal NHS Foundation Trust, Salford, UK.'}, {'ForeName': 'Linda-Mary', 'Initials': 'LM', 'LastName': 'Eriksson', 'Affiliation': 'Alternative Futures Group, Manchester, UK.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Smee', 'Affiliation': 'Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK.'}]",Disability and rehabilitation,['10.1080/09638288.2018.1554009'] 831,29489429,Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).,"Purpose Observational studies have reported increased colon cancer recurrence and mortality in patients with states of hyperinsulinemia, including type 2 diabetes, obesity, sedentary lifestyle, and high glycemic load diet. Nut intake has been associated with a lower risk of type 2 diabetes, metabolic syndrome, and insulin resistance. However, the effect of nut intake on colon cancer recurrence and survival is not known. Patients and Methods We conducted a prospective, observational study of 826 eligible patients with stage III colon cancer who reported dietary intake on food frequency questionnaires while enrolled onto a randomized adjuvant chemotherapy trial. Using Cox proportional hazards regression, we assessed associations of nut intake with cancer recurrence and mortality. Results After a median follow-up of 6.5 years, compared with patients who abstained from nuts, individuals who consumed two or more servings of nuts per week experienced an adjusted hazard ratio (HR) for disease-free survival of 0.58 (95% CI, 0.37 to 0.92; P trend = .03) and an HR for overall survival of 0.43 (95% CI, 0.25 to 0.74; P trend = .01). In subgroup analysis, the apparent benefit was confined to tree nut intake (HR for disease-free survival, 0.54; 95% CI, 0.34 to 0.85; P trend = .04; and HR for overall survival, 0.47; 95% CI, 0.27 to 0.82; P trend = .04). The association of total nut intake with improved outcomes was maintained across other known or suspected risk factors for cancer recurrence and mortality. Conclusion Diets with a higher consumption of nuts may be associated with a significantly reduced incidence of cancer recurrence and death in patients with stage III colon cancer.",2018,The association of total nut intake with improved outcomes was maintained across other known or suspected risk factors for cancer recurrence and mortality.,"['patients with stage III colon cancer', 'patients with states of hyperinsulinemia, including type 2 diabetes, obesity, sedentary lifestyle, and high glycemic load diet', 'Patients With Stage III Colon Cancer', '826 eligible patients with stage III colon cancer who reported dietary intake on food frequency questionnaires while enrolled onto a randomized adjuvant chemotherapy trial']",[],"['colon cancer recurrence and survival', 'cancer recurrence and death', 'Nut Consumption and Survival', 'adjusted hazard ratio (HR) for disease-free survival', 'nut intake with cancer recurrence and mortality', 'colon cancer recurrence and mortality', 'overall survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3 (qualifier value)'}, {'cui': 'C0007102', 'cui_str': 'Cancer of Colon'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0020459', 'cui_str': 'Hyperinsulinemia'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1532253', 'cui_str': 'Sedentary Behavior'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C4042927', 'cui_str': 'Glycemic Load'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}]",[],"[{'cui': 'C0007102', 'cui_str': 'Cancer of Colon'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0028723', 'cui_str': 'Nuts'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0242793', 'cui_str': 'Disease-Free Survival'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",826.0,0.363781,The association of total nut intake with improved outcomes was maintained across other known or suspected risk factors for cancer recurrence and mortality.,"[{'ForeName': 'Temidayo', 'Initials': 'T', 'LastName': 'Fadelu', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Sui', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Niedzwiecki', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Xing', 'Initials': 'X', 'LastName': 'Ye', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Leonard B', 'Initials': 'LB', 'LastName': 'Saltz', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Mayer', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Rex B', 'Initials': 'RB', 'LastName': 'Mowat', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Renaud', 'Initials': 'R', 'LastName': 'Whittom', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Hantel', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Al B', 'Initials': 'AB', 'LastName': 'Benson', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Atienza', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Messino', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Hedy L', 'Initials': 'HL', 'LastName': 'Kindler', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Venook', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Shuji', 'Initials': 'S', 'LastName': 'Ogino', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Kimmie', 'Initials': 'K', 'LastName': 'Ng', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Kana', 'Initials': 'K', 'LastName': 'Wu', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Willett', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Giovannucci', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Meyerhardt', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Bao', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}, {'ForeName': 'Charles S', 'Initials': 'CS', 'LastName': 'Fuchs', 'Affiliation': ""Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.""}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.2017.75.5413'] 832,24379492,Assessment of Cognitive Behavioral Therapy on Quality of Life of Patients with Chronic War-related Post-traumatic Stress Disorder.,"BACKGROUND Post-traumatic stress disorder (PTSD) is the one of the most commonly observed psychiatric disorder in veterans. The condition can lead to considerable social, occupational, and interpersonal dysfunction. PTSD occurring after combat injury appears to be strongly correlated with the extent of injury, and develops over several months. Present study was designed for assessing the cognitive behavioral therapy in the quality of life (QOL) of war-related PTSD in veterans compared to control group and compare applied treatments with each other. MATERIALS AND METHODS In the present study, we assessment effects of cognitive behavioral therapy such as problem solving, exposure therapy and their combination on QOL in 120 Iranian PTSD patients veterans after Iran-Iraq war. They were randomly allocated to one of four equal interventional groups: (a) Problem solving therapy (b) exposure therapy (c) combined therapy (exposure therapy plus problem solving) (d) control group. Before and after study intervention, patients were evaluated by short form-36 (SF-36) questionnaire. RESULTS Post-test and follow-up SF-36 scores were 55.6±4 and 55.1±3.6 in exposure therapy, 50±4.4 and 56.1±3.8 in problem solving, and 48.73±3.8 and 50.9±4.2 in combined therapy. In comparing to control group, all intervention showed significant improvement in QOL in PTSD patients. CONCLUSION According to the results of the present study, behavioral therapy can improve QOL in PTSD patients.",2013,They were randomly allocated to one of four equal interventional groups: (a) Problem solving therapy (b) exposure therapy (c) combined therapy (exposure therapy plus problem solving) (d) control group.,"['PTSD patients', '120 Iranian PTSD patients veterans after Iran-Iraq war', 'Patients with Chronic War-related Post-traumatic Stress Disorder']","['cognitive behavioral therapy such as problem solving, exposure therapy and their combination on QOL', 'Cognitive Behavioral Therapy', 'cognitive behavioral therapy', 'Problem solving therapy (b) exposure therapy (c) combined therapy (exposure therapy plus problem solving) (d) control group']","['QOL', 'Quality of Life', 'quality of life (QOL', 'short form-36 (SF-36) questionnaire', 'SF-36 scores']","[{'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0554962', 'cui_str': 'Iranian (NMO) (ethnic group)'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}, {'cui': 'C0022066', 'cui_str': 'Republic of Iraq'}, {'cui': 'C0043027', 'cui_str': 'War'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C3669643', 'cui_str': 'Problem solving (qualifier value)'}, {'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C1303140', 'cui_str': 'Problem solving therapy'}, {'cui': 'C0033972', 'cui_str': 'Psychotherapy, Multiple'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0034380'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",120.0,0.0111172,They were randomly allocated to one of four equal interventional groups: (a) Problem solving therapy (b) exposure therapy (c) combined therapy (exposure therapy plus problem solving) (d) control group.,"[{'ForeName': 'Mohammadjavad', 'Initials': 'M', 'LastName': 'Ahmadizadeh', 'Affiliation': 'Behavioral Sciences Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Khodabakhsh', 'Initials': 'K', 'LastName': 'Ahmadi', 'Affiliation': 'Behavioral Sciences Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Jafar', 'Initials': 'J', 'LastName': 'Anisi', 'Affiliation': 'Behavioral Sciences Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Amir Bahrami', 'Initials': 'AB', 'LastName': 'Ahmadi', 'Affiliation': 'Occupational Medicine Research Center, Iran University of Medical Sicences, Tehran, Iran.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.122222'] 833,31671432,Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.,"BACKGROUND Chronic rhinosinusitis with nasal polyposis (CRSwNP) is associated with substantial sinus opacification. In a phase 2a study (NCT01920893), dupilumab, a fully human anti-IL-4Rα monoclonal antibody, improved outcomes in CRSwNP refractory to intranasal corticosteroids. We evaluated dupilumab’s effect on sinus opacification in relation to effects on nasal polyp burden, symptoms, and health-related quality of life (HRQoL) in patients with CRSwNP. METHODOLOGY 16-week randomized, double-blind, placebo-controlled, parallel-group study in 60 adults with CRSwNP. Patients received weekly subcutaneous dupilumab 300-mg or placebo and daily mometasone furoate nasal spray. Sinus opacification was assessed using standard and Zinreich-modified Lundâ€""Mackay (zLMK) scoring. Correlation was assessed between zLMK score and CRSwNP endpoints, including nasal polyp score (NPS), SNOT-22, daily symptom scores, and UPSIT smell-test score. RESULTS Baseline characteristics were similar across treatment groups. Mean plus/minus SD baseline LMK scores of 18.7 plus/minus 5.5 (placebo) and 18.6 plus/minus 5.0 (dupilumab) indicated severe disease with extensive opacification involving all sinuses. Baseline LMK and LMK scores correlated with NPS severity and loss of sense of smell (daily symptoms; SNOT-22 smell/taste; loss of sense of smell [UPSIT]). At Week 16, dupilumab-treated patients had significantly improved sinus opacification measured by LMK in all individual sinuses vs placebo. Dupilumab also showed similar efficacy with zLMK, with only small differences from LMK, and correlated with SNOT22 smell/taste. The most common adverse events were nasopharyngitis, injection-site reactions, and headache. CONCLUSIONS In patients with CRSwNP, baseline LMK showed extensive sinus opacification and correlated with symptoms, HRQoL, and hyposmia. Dupilumab treatment reduces opacification across all sinuses and related symptoms in patients with CRSwNP.",2020,"At Week 16, dupilumab-treated patients had significantly improved sinus opacification measured by LMK in all individual sinuses vs placebo.","['Chronic rhinosinusitis with nasal polyposis (CRSwNP', 'patients with CRSwNP', '60 adults with CRSwNP']","['placebo', 'zLMK', 'subcutaneous dupilumab 300-mg or placebo and daily mometasone furoate nasal spray', 'Dupilumab']","['Mean plus/minus SD baseline LMK scores', 'Baseline LMK and LMK scores correlated with NPS severity and loss of sense of smell (daily symptoms; SNOT-22 smell/taste; loss of sense of smell [UPSIT', 'nasal polyp burden, symptoms, and health-related quality of life (HRQoL', 'sinus opacification', 'nasopharyngitis, injection-site reactions, and headache', 'extensive sinus opacification', 'severe disease with extensive opacification', 'Sinus opacification', 'zLMK score and CRSwNP endpoints, including nasal polyp score (NPS), SNOT-22, daily symptom scores, and UPSIT smell-test score']","[{'cui': 'C0149516', 'cui_str': 'Chronic sinusitis (disorder)'}, {'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C0334108', 'cui_str': 'Multiple polyps (morphologic abnormality)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C3660996', 'cui_str': 'dupilumab'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0066700', 'cui_str': 'mometasone furoate'}, {'cui': 'C0461725', 'cui_str': 'Nasal Spray'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0332288', 'cui_str': 'Without (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0003126', 'cui_str': 'Anosmia'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0998863', 'cui_str': 'Osmeridae'}, {'cui': 'C0039336', 'cui_str': 'Gustation'}, {'cui': 'C0027430', 'cui_str': 'Nasal Polyps'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0016169', 'cui_str': 'Fistula'}, {'cui': 'C0449584', 'cui_str': 'Opacification (attribute)'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0151735', 'cui_str': 'Injection Site Adverse Event'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0205231', 'cui_str': 'Extensive (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",60.0,0.426378,"At Week 16, dupilumab-treated patients had significantly improved sinus opacification measured by LMK in all individual sinuses vs placebo.","[{'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Bachert', 'Affiliation': 'Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium, and Clintec, Karolinska Institute, Stockholm, Sweden.'}, {'ForeName': 'S James', 'Initials': 'SJ', 'LastName': 'Zinreich', 'Affiliation': 'Division of Neuroradiology, Department of Radiology, Johns Hopkins Hospital, Baltimore, MD, USA.'}, {'ForeName': 'Peter W', 'Initials': 'PW', 'LastName': 'Hellings', 'Affiliation': 'Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Joaquim', 'Initials': 'J', 'LastName': 'Mullol', 'Affiliation': 'Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, and Rhinology Unit and Smell Clinic, Department of Otorhinolaryngo logy, Hospital Clinic, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.'}, {'ForeName': 'Daniel L', 'Initials': 'DL', 'LastName': 'Hamilos', 'Affiliation': 'Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Gevaert', 'Affiliation': 'Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium, and Clintec, Karolinska Institute, Stockholm, Sweden.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Naclerio', 'Affiliation': 'Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Nikhil', 'Initials': 'N', 'LastName': 'Amin', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Vijay N', 'Initials': 'VN', 'LastName': 'Joish', 'Affiliation': 'Formerly employed at Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Chunpeng', 'Initials': 'C', 'LastName': 'Fan', 'Affiliation': 'Sanofi, Bridgewater, NJ, USA.'}, {'ForeName': 'Donghui', 'Initials': 'D', 'LastName': 'Zhang', 'Affiliation': 'Sanofi, Bridgewater, NJ, USA.'}, {'ForeName': 'Heribert', 'Initials': 'H', 'LastName': 'Staudinger', 'Affiliation': 'Sanofi, Bridgewater, NJ, USA.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Pirozzi', 'Affiliation': 'Sanofi, Bridgewater, NJ, USA.'}, {'ForeName': 'Neil M H', 'Initials': 'NMH', 'LastName': 'Graham', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Asif', 'Initials': 'A', 'LastName': 'Khan', 'Affiliation': 'Sanofi, Chilly-Mazarin, France.'}, {'ForeName': 'Leda P', 'Initials': 'LP', 'LastName': 'Mannent', 'Affiliation': 'Sanofi, Chilly-Mazarin, France.'}]",Rhinology,['10.4193/Rhin18.282'] 834,30656993,A randomized controlled feasibility trial of paracetamol during febrile neutropenia in hemato-oncology patients.,"The efficacy of paracetamol (acetaminophen) as an antipyretic during febrile neutropenia (FN) has not previously been established. We conducted a randomized double-blind placebo-controlled feasibility trial: hemato-oncology patients at high FN risk were randomly assigned to six hourly oral paracetamol (1 g) or placebo during the first 42 hours of FN. Fifty-three participants were screened, thirty-seven enrolled; 22 developed FN and commenced treatment (13 paracetamol; 9 placebo); recruitment rates were below, and retention rates met, pre-defined feasibility criteria. During the first 24 hours of FN, paracetamol recipients had significantly lower peak temperature than placebo: mean 38.2 (standard deviation 0.8) °C versus 38.9 (0.4) °C; difference -0.78 °C (95% CI -1.38 to -0.18); p  = .013. Bacterial load measurement was not informative. Paracetamol lowers body temperature during FN, and definitive trials to determine its impact on FN outcomes are needed. Australian New Zealand Clinical Trials Registry reference ACTRN12613000601730; funded by Health Research Council of New Zealand.",2019,"During the first 24 hours of FN, paracetamol recipients had significantly lower peak temperature than placebo: mean 38.2 (standard deviation 0.8)","['patients at high FN risk', 'hemato-oncology patients', 'Fifty-three participants were screened, thirty-seven enrolled; 22 developed FN and commenced treatment (13']","['placebo', 'paracetamol; 9 placebo', 'Paracetamol', 'paracetamol', 'hemato-oncology', 'paracetamol (acetaminophen']","['febrile neutropenia', 'peak temperature']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C4319569', 'cui_str': '37 (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}]","[{'cui': 'C0746883', 'cui_str': 'Febrile Neutropenia'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}]",53.0,0.628978,"During the first 24 hours of FN, paracetamol recipients had significantly lower peak temperature than placebo: mean 38.2 (standard deviation 0.8)","[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Weinkove', 'Affiliation': 'a Wellington Blood and Cancer Centre, Capital and Coast DHB , Wellington , New Zealand.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Bowden', 'Affiliation': 'c Department of Pathology and Molecular Medicine , University of Otago Wellington , Wellington , New Zealand.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Wood', 'Affiliation': 'a Wellington Blood and Cancer Centre, Capital and Coast DHB , Wellington , New Zealand.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Campion', 'Affiliation': 'a Wellington Blood and Cancer Centre, Capital and Coast DHB , Wellington , New Zealand.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Carter', 'Affiliation': 'a Wellington Blood and Cancer Centre, Capital and Coast DHB , Wellington , New Zealand.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Hall', 'Affiliation': 'd Institute of Environmental Science and Research , Upper Hutt , New Zealand.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Weatherall', 'Affiliation': 'e Department of Medicine , University of Otago Wellington , Wellington , New Zealand.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Beasley', 'Affiliation': 'f Medical Research Institute of New Zealand , Wellington , New Zealand.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Young', 'Affiliation': 'f Medical Research Institute of New Zealand , Wellington , New Zealand.'}]",Leukemia & lymphoma,['10.1080/10428194.2018.1538512'] 835,30136445,"A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers: A prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics.","A randomised, controlled multicentre clinical trial was conducted at 14 wound care centres in the United States to confirm the efficacy of dehydrated human amnion/chorion membrane allograft (dHACM) for the treatment of chronic lower extremity ulcers in persons with diabetes. Patients with a lower extremity ulcer of at least 4 weeks duration were entered into a 2-week study run-in phase and treated with alginate wound dressings and appropriate offloading. Those with less than or equal to 25% wound closure after run-in were randomly assigned to receive weekly dHACM application in addition to offloading or standard of care with alginate wound dressings, for 12 weeks. A total of 110 patients were included in the intent-to-treat (ITT) analysis, with n = 54 in the dHACM group and n = 56 in the no-dHACM group. Of the participants, 98 completed the study per protocol, with 47 receiving dHACM and 51 not receiving dHACM. The primary study outcome was percentage of study ulcers completely healed in 12 weeks, with both ITT and per-protocol participants receiving weekly dHACM significantly more likely to completely heal than those not receiving dHACM (ITT-70% versus 50%, P = 0.0338, per-protocol-81% versus 55%, P = 0.0093). A Kaplan-Meier analysis was performed to compare the time-to-healing performance with/without dHACM, showing a significantly improved time to healing with the use of allograft, log-rank P < 0.0187. Cox regression analysis showed that dHACM-treated subjects were more than twice as likely to heal completely within 12 weeks than no-dHACM subjects (HR: 2.15, 95% confidence interval 1.30-3.57, P = 0.003). At the final follow up at 16 weeks, 95% of dHACM-healed ulcers and 86% of healed ulcers in the no-dHACM group remained closed. These results confirm that dHACM is an efficacious treatment for lower extremity ulcers in a heterogeneous patient population.",2019,"At the final follow up at 16 weeks, 95% of dHACM-healed ulcers and 86% of healed ulcers in the no-dHACM group remained closed.","['110 patients from 14 wound clinics', 'diabetic foot ulcers', 'Those with less than or equal to 25% wound closure after run', '14 wound care centres in the United States', 'persons with diabetes', 'A total of 110 patients were included in the intent-to-treat (ITT) analysis, with n =\u200954 in the dHACM group and n =\u200956 in the no-dHACM group', 'Patients with a lower extremity ulcer of at least 4 weeks duration']","['dehydrated human amnion/chorion membrane dHACM allograft', 'dehydrated human amnion/chorion membrane allograft (dHACM', 'dHACM', 'alginate wound dressings and appropriate offloading', 'dHACM application in addition to offloading or standard of care with alginate wound dressings']","['healed ulcers', 'dHACM significantly more likely to completely heal', 'time-to-healing performance', 'percentage of study ulcers completely healed', 'time to healing']","[{'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C1456868', 'cui_str': 'Diabetic foot ulcer (disorder)'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0450015', 'cui_str': 'Method of wound closure (attribute)'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C0886052', 'cui_str': 'Administers care to wound sites'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0023223', 'cui_str': 'Leg Ulcer'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}]","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0002630', 'cui_str': 'Amniotic Membrane'}, {'cui': 'C0008503', 'cui_str': 'Chorion'}, {'cui': 'C0025255', 'cui_str': 'Membranes'}, {'cui': 'C0450127', 'cui_str': 'Allogeneic Grafts'}, {'cui': 'C0102137', 'cui_str': 'alginate'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0013119', 'cui_str': 'Dressings'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}]","[{'cui': 'C0333293', 'cui_str': 'Healing ulcer (morphologic abnormality)'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C4554154', 'cui_str': 'Completely - dosing instruction fragment (qualifier value)'}, {'cui': 'C0205249', 'cui_str': 'Healed (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}]",110.0,0.060453,"At the final follow up at 16 weeks, 95% of dHACM-healed ulcers and 86% of healed ulcers in the no-dHACM group remained closed.","[{'ForeName': 'William', 'Initials': 'W', 'LastName': 'Tettelbach', 'Affiliation': 'Wound Care & Hyperbaric Medicine Clinical Services, Intermountain Healthcare, Salt Lake City, Utah.'}, {'ForeName': 'Shawn', 'Initials': 'S', 'LastName': 'Cazzell', 'Affiliation': 'Limb Preservation Platform, Inc., Fresno, California.'}, {'ForeName': 'Alexander M', 'Initials': 'AM', 'LastName': 'Reyzelman', 'Affiliation': 'Center for Clinical Research, Inc., San Francisco, California.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Sigal', 'Affiliation': 'Foot and Ankle Clinic, Los Angeles, California.'}, {'ForeName': 'Joseph M', 'Initials': 'JM', 'LastName': 'Caporusso', 'Affiliation': 'Futuro Clinical Trials, Texas.'}, {'ForeName': 'Patrick S', 'Initials': 'PS', 'LastName': 'Agnew', 'Affiliation': 'Coastal Podiatry, Inc., Virginia Beach, Virginia.'}]",International wound journal,['10.1111/iwj.12976'] 836,30659676,Double transcranial direct current stimulation of the brain increases cerebral energy levels and systemic glucose tolerance in men.,"Transcranial direct current stimulation (tDCS) is a neuromodulatory method that has been tested experimentally and has already been used as an adjuvant therapeutic option to treat a number of neurological disorders and neuropsychiatric diseases. Beyond its well known local effects within the brain, tDCS also transiently promotes systemic glucose uptake and reduces the activity of the neurohormonal stress axes. We aimed to test whether the effects of a single tDCS application could be replicated upon double stimulation to persistently improve systemic glucose tolerance and stress axes activity in humans. In a single-blinded cross-over study, we examined 15 healthy male volunteers. Anodal tDCS vs sham was applied twice in series. Systemic glucose tolerance was investigated by the standard hyperinsulinaemic-euglycaemic glucose clamp procedure, and parameters of neurohormonal stress axes activity were measured. Because tDCS-induced brain energy consumption has been shown to be part of the mechanism underlying the assumed effects, we monitored the cerebral high-energy phosphates ATP and phosphocreatine by 31 phosphorus magnetic resonance spectroscopy. As hypothesised, analyses revealed that double anodal tDCS persistently increases glucose tolerance compared to sham. Moreover, we observed a significant rise in cerebral high-energy phosphate content upon double tDCS. Accordingly, the activity of the neurohormonal stress axes was reduced upon tDCS compared to sham. Our data demonstrate that double tDCS promotes systemic glucose uptake and reduces stress axes activity in healthy humans. These effects suggest that repetitive tDCS may be a future non-pharmacological option for combating glucose intolerance in type 2 diabetes patients.",2019,"Accordingly, the activity of the neurohormonal stress axes was reduced upon tDCS compared to sham.","['healthy humans', 'humans', '15 healthy male volunteers', 'type 2 diabetes patients', 'men']","['Anodal tDCS', 'Transcranial direct current stimulation (tDCS', 'repetitive tDCS']","['glucose tolerance', 'cerebral high-energy phosphate content', 'Systemic glucose tolerance', 'systemic glucose tolerance and stress axes activity', 'standard hyperinsulinaemic-euglycaemic glucose clamp procedure, and parameters of neurohormonal stress axes activity']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1601799', 'cui_str': 'phosphate ion'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0004457', 'cui_str': 'C2 Vertebra'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0015159', 'cui_str': 'Glucose Clamping'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",31.0,0.11243,"Accordingly, the activity of the neurohormonal stress axes was reduced upon tDCS compared to sham.","[{'ForeName': 'Ewelina K', 'Initials': 'EK', 'LastName': 'Wardzinski', 'Affiliation': 'Section of Psychoneurobiology, Center of Brain, Behavior and Metabolism, University of Luebeck, Luebeck, Germany.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Friedrichsen', 'Affiliation': 'Section of Psychoneurobiology, Center of Brain, Behavior and Metabolism, University of Luebeck, Luebeck, Germany.'}, {'ForeName': 'Sina', 'Initials': 'S', 'LastName': 'Dannenberger', 'Affiliation': 'Section of Psychoneurobiology, Center of Brain, Behavior and Metabolism, University of Luebeck, Luebeck, Germany.'}, {'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Kistenmacher', 'Affiliation': 'Section of Psychoneurobiology, Center of Brain, Behavior and Metabolism, University of Luebeck, Luebeck, Germany.'}, {'ForeName': 'Uwe H', 'Initials': 'UH', 'LastName': 'Melchert', 'Affiliation': 'Section of Psychoneurobiology, Center of Brain, Behavior and Metabolism, University of Luebeck, Luebeck, Germany.'}, {'ForeName': 'Kamila', 'Initials': 'K', 'LastName': 'Jauch-Chara', 'Affiliation': 'Section of Psychoneurobiology, Center of Brain, Behavior and Metabolism, University of Luebeck, Luebeck, Germany.'}, {'ForeName': 'Kerstin M', 'Initials': 'KM', 'LastName': 'Oltmanns', 'Affiliation': 'Section of Psychoneurobiology, Center of Brain, Behavior and Metabolism, University of Luebeck, Luebeck, Germany.'}]",Journal of neuroendocrinology,['10.1111/jne.12688'] 837,30511130,"A New Feasible Technique for Polytetrafluoroethylene Suture Buttress-Reinforced Pancreaticojejunostomy (PBRP): Mechanical Analysis and a Prospective, Randomized Controlled Trial.","OBJECTIVES Postoperative pancreatic fistula (POPF) is a major concern after pancreatoduodenectomy (PD). We recently designed a new anastomotic method to reduce the rate of pancreatic fistula: polytetrafluoroethylene suture buttress-reinforced pancreaticojejunostomy (PBRP). METHODS An animal model and a computer simulation were used to measure the maximum stress and tensile strength of the pancreas with and without the suture buttresses. Then, a randomized controlled trial (RCT) was performed to compare the outcome of PD between patients who underwent PBRP vs traditional pancreaticojejunostomy (TP). RESULTS The maximum load in the animal model was significantly higher with the suture buttresses than without (5.47 ± 1.67 N vs 3.72 ± 1.36 N, p < 0.01), and in the computer simulation, the peak stress was lower with the suture buttresses than without (54.86 vs 486.8 MPa). There were no significant differences between the two groups in the overall frequency of POPF, but the rate of clinically relevant POPF was significantly lower in the PBRP group (2.8 vs 22.8%, p = 0.028). The pancreaticojejunostomy time was significantly longer in the PBRP group (19.57 ± 3.31 vs 17.17 ± 4.83 min, p = 0.018), and the PBRP group showed a shorter drainage tube retention duration (10 vs 12 days, p = 0.006) and postoperative hospital stay (13 d vs 15 d, p = 0.031). CONCLUSIONS PBRP is a feasible and reliable procedure for preventing clinically relevant POPF. Additional multi-institution randomized trials should be conducted to confirm these results.",2019,"There were no significant differences between the two groups in the overall frequency of POPF, but the rate of clinically relevant POPF was significantly lower in the PBRP group (2.8 vs 22.8%, p = 0.028).",[],"['PBRP vs traditional pancreaticojejunostomy (TP', 'Polytetrafluoroethylene Suture', 'polytetrafluoroethylene suture buttress-reinforced pancreaticojejunostomy (PBRP', 'Buttress-Reinforced Pancreaticojejunostomy (PBRP', 'PBRP']","['postoperative hospital stay', 'overall frequency of POPF', 'pancreaticojejunostomy time', 'maximum stress and tensile strength', 'rate of clinically relevant POPF', 'peak stress', 'shorter drainage tube retention duration']",[],"[{'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0030303', 'cui_str': 'Pancreatojejunostomy'}, {'cui': 'C0183744', 'cui_str': 'Polytetrafluoroethylene suture (physical object)'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0030303', 'cui_str': 'Pancreatojejunostomy'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C1540845', 'cui_str': 'Muscle tensile strength, function (observable entity)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0013103', 'cui_str': 'Drainage'}, {'cui': 'C4318415', 'cui_str': 'Tube (unit of presentation)'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C2926735', 'cui_str': 'Duration'}]",,0.0882071,"There were no significant differences between the two groups in the overall frequency of POPF, but the rate of clinically relevant POPF was significantly lower in the PBRP group (2.8 vs 22.8%, p = 0.028).","[{'ForeName': 'Xinxin', 'Initials': 'X', 'LastName': 'Shao', 'Affiliation': 'Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Pan Jia Yuan Nan Li, Chaoyang District, Beijing, 100021, China.'}, {'ForeName': 'Yibin', 'Initials': 'Y', 'LastName': 'Xie', 'Affiliation': 'Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Pan Jia Yuan Nan Li, Chaoyang District, Beijing, 100021, China.'}, {'ForeName': 'Quan', 'Initials': 'Q', 'LastName': 'Xu', 'Affiliation': 'Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Pan Jia Yuan Nan Li, Chaoyang District, Beijing, 100021, China.'}, {'ForeName': 'Anqiang', 'Initials': 'A', 'LastName': 'Sun', 'Affiliation': 'Key Laboratory for Biomechanics and Mechanobiology of Ministry of Education, School of Biological Science and Medical Engineering, Beihang University, Beijing, 100083, China.'}, {'ForeName': 'Zhenze', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'National Research Center for Rehabilitation Technical Aids, Beijing, 100176, China.'}, {'ForeName': 'Yantao', 'Initials': 'Y', 'LastName': 'Tian', 'Affiliation': 'Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Pan Jia Yuan Nan Li, Chaoyang District, Beijing, 100021, China. zlyytyt@163.com.'}]",Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,['10.1007/s11605-018-4059-4'] 838,30591354,Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.,"BACKGROUND Abiraterone and enzalutamide are associated with side effects that may impair health-related quality of life (HRQoL). OBJECTIVE To assess patient-reported HRQoL, depression symptoms, and cognitive function for abiraterone versus enzalutamide. DESIGN, SETTING, AND PARTICIPANTS We randomized 202 patients in a phase II study of abiraterone versus enzalutamide for first-line treatment of metastatic castration-resistant prostate cancer (ClinicalTrials.gov: NCT02125357). INTERVENTION Patients completed Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Patient Health Questionnaire-9 (PHQ-9) questionnaires, and Montreal Cognitive Assessment (MoCA) cognitive assessments at baseline and on treatment. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS To compare the change in FACT-P scores over time between treatment arms, we used a mixed model for repeated measures (MMRM). For FACT-P domains where there was an interaction between the treatment arm and age, we constructed separate models for patients aged <75 and ≥75yr. We compared the proportion of patients with clinically meaningful change from baseline for FACT-P, and the proportion of patients with an abnormal score and median change from baseline for PHQ-9 and MoCA using Fisher's exact test and Mann-Whitney U test. RESULTS AND LIMITATIONS In the MMRM analysis, there was a positive test for interaction in the treatment arm by age for total FACT-P (p=0.048). FACT-P change from baseline over time was better for abiraterone than for enzalutamide in the ≥75-yr model (p=0.003), with no difference in the <75-yr model (p>0.9). A higher proportion of patients experienced clinically meaningful worsening with enzalutamide for the physical and functional well-being domains (37% vs 21%, p=0.013; 39% vs 23%, p=0.015). The distribution of change in PHQ-9 scores from baseline favored abiraterone at weeks 4, 8, and 12. These analyses were not prespecified, and results should be considered to be hypothesis generating. CONCLUSIONS Patient-reported outcomes favored abiraterone compared with enzalutamide with differences in FACT-P HRQoL and PHQ-9 depression scores. Differences in the total FACT-P scores were seen only in the elderly patient subgroup. PATIENT SUMMARY In this report, we examined the change in patient-reported quality-of-life scores from the start of treatment over time for patients treated with abiraterone versus enzalutamide for metastatic castration-resistant prostate cancer. We found that elderly patients treated with abiraterone had better quality of life over time, with no difference between treatments for the younger subgroup of patients.",2019,"A higher proportion of patients experienced clinically meaningful worsening with enzalutamide for the physical and functional well-being domains (37% vs 21%, p=0.013; 39% vs 23%, p=0.015).","['metastatic castration-resistant prostate cancer', 'Patients with Metastatic Castration-resistant Prostate Cancer', 'We randomized 202 patients in a phase II study of', 'patients aged <75 and ≥75yr', 'elderly patients treated with']","['abiraterone versus enzalutamide', 'Abiraterone Plus Prednisone Versus Enzalutamide', 'abiraterone', 'Patients completed Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Patient Health Questionnaire-9']","['total FACT-P scores', 'quality-of-life scores', 'PHQ-9 scores', 'FACT-P HRQoL and PHQ-9 depression scores', 'quality of life', 'PHQ-9) questionnaires, and Montreal Cognitive Assessment (MoCA) cognitive assessments']","[{'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0754011', 'cui_str': 'abiraterone'}, {'cui': 'C3496793', 'cui_str': 'enzalutamide'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3496286'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",202.0,0.104514,"A higher proportion of patients experienced clinically meaningful worsening with enzalutamide for the physical and functional well-being domains (37% vs 21%, p=0.013; 39% vs 23%, p=0.015).","[{'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Khalaf', 'Affiliation': 'Department of Medical Oncology, BC Cancer Vancouver Centre, Vancouver, BC, Canada.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Sunderland', 'Affiliation': 'Department of Biostatistics, BC Cancer Vancouver Centre, Vancouver, BC, Canada.'}, {'ForeName': 'Bernhard J', 'Initials': 'BJ', 'LastName': 'Eigl', 'Affiliation': 'Department of Medical Oncology, BC Cancer Vancouver Centre, Vancouver, BC, Canada.'}, {'ForeName': 'Christian K', 'Initials': 'CK', 'LastName': 'Kollmannsberger', 'Affiliation': 'Department of Medical Oncology, BC Cancer Vancouver Centre, Vancouver, BC, Canada.'}, {'ForeName': 'Nikita', 'Initials': 'N', 'LastName': 'Ivanov', 'Affiliation': 'Department of Medical Oncology, BC Cancer Vancouver Centre, Vancouver, BC, Canada.'}, {'ForeName': 'Daygen L', 'Initials': 'DL', 'LastName': 'Finch', 'Affiliation': 'Department of Medical Oncology, BC Cancer Southern Interior, Kelowna, BC, Canada.'}, {'ForeName': 'Conrad', 'Initials': 'C', 'LastName': 'Oja', 'Affiliation': 'Department of Medical Oncology, BC Cancer Fraser Valley, Surrey, BC, Canada.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Vergidis', 'Affiliation': 'Department of Medical Oncology, BC Cancer Island Centre, Victoria, BC, Canada.'}, {'ForeName': 'Muhammad', 'Initials': 'M', 'LastName': 'Zulfiqar', 'Affiliation': 'Department of Medical Oncology, BC Cancer Abbotsford Centre, Abbotsford, BC, Canada.'}, {'ForeName': 'Martin E', 'Initials': 'ME', 'LastName': 'Gleave', 'Affiliation': 'Department of Urological Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Kim N', 'Initials': 'KN', 'LastName': 'Chi', 'Affiliation': 'Department of Medical Oncology, BC Cancer Vancouver Centre, Vancouver, BC, Canada; Department of Urological Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada. Electronic address: kchi@bccancer.bc.ca.'}]",European urology,['10.1016/j.eururo.2018.12.015'] 839,30621460,A qualitative analysis of pressure injury development among medically underserved adults with spinal cord injury.,"Purpose: Medically underserved adults with spinal cord injury (SCI) remain at high risk of incurring medically serious pressure injuries even after receiving education in prevention techniques. The purpose of this research is to identify circumstances leading to medically serious pressure injury development in medically underserved adults with SCI during a lifestyle-based pressure injury prevention program, and provide recommendations for future rehabilitation approaches and intervention design. Methods: This study entailed a qualitative secondary case analysis of treatment notes from a randomized controlled trial. Participants were 25 community-dwelling, medically underserved adults with SCI who developed medically serious pressure injuries during the course of the intervention of the RCT. Results and conclusions: Among the 25 participants, 40 unique medically serious pressure injuries were detected. The six themes related to medically serious pressure injury development were: (1) lack of rudimentary knowledge pertaining to wound care ; (2) equipment and supply issues ; (3) comorbidities ; (4) non-adherence to prescribed bed rest ; (5) inactivity ; and (6) circumstances beyond the intervention's reach. Together, these factors may have undermined the effectiveness of the intervention program. Modifications, such as assessing health literacy levels of patients prior to providing care, providing tailored wound care education, and focusing on equipment needs, have potential for altering future rehabilitation programs and improving health outcomes.Implications for rehabilitationTo provide patients with spinal cord injury with the necessary information to prevent medically serious pressure injury development, health care providers need to understand their patient's unique personal contexts, including socio-economic status, language skills, and mental/cognitive functioning.When providing wound care information to patients with spinal cord injury who have developed a medically serious pressure injury, practitioners should take into account the level of health literacy of their patient in order to provide education that is appropriate and understandable.Practitioners should be aware of how to help their patient advocate for outside services and care that address their equipment needs, such as finding funding or grants to pay for expensive medical equipment.",2020,The six themes related to medically serious pressure injury development were: (1) lack of rudimentary knowledge pertaining to wound care; (2) equipment and supply issues; (3) comorbidities; (4) non-adherence to prescribed bed rest; (5) inactivity; and (6) circumstances beyond the intervention's reach.,"['patients with spinal cord injury', 'medically underserved adults with spinal cord injury', 'Participants were 25 community-dwelling, medically underserved adults with SCI who developed medically serious pressure injuries during the course of the intervention of the RCT', '25 participants, 40 unique medically serious pressure injuries', 'patients with spinal cord injury who have developed a medically serious pressure injury, practitioners', 'medically underserved adults with SCI during a lifestyle-based pressure injury prevention program', 'Medically underserved adults with spinal cord injury (SCI']",[],"[""medically serious pressure injury development were: (1) lack of rudimentary knowledge pertaining to wound care; (2) equipment and supply issues; (3) comorbidities; (4) non-adherence to prescribed bed rest; (5) inactivity; and (6) circumstances beyond the intervention's reach""]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4045975', 'cui_str': 'Community Dwelling'}, {'cui': 'C0332679', 'cui_str': 'Pressure injury'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]",[],"[{'cui': 'C0332679', 'cui_str': 'Pressure injury'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0332268', 'cui_str': 'Lacking (qualifier value)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0886052', 'cui_str': 'Administers care to wound sites'}, {'cui': 'C0014674', 'cui_str': 'Apparatus and Instruments'}, {'cui': 'C0457432', 'cui_str': 'Non-compliant (qualifier value)'}, {'cui': 'C0004910', 'cui_str': 'Bedrest'}, {'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}]",40.0,0.0512108,The six themes related to medically serious pressure injury development were: (1) lack of rudimentary knowledge pertaining to wound care; (2) equipment and supply issues; (3) comorbidities; (4) non-adherence to prescribed bed rest; (5) inactivity; and (6) circumstances beyond the intervention's reach.,"[{'ForeName': 'Lucía I', 'Initials': 'LI', 'LastName': 'Floríndez', 'Affiliation': 'USC Mrs. T.H. Chan Division of Occupational Science and Occupational Therapy in the Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Mike E', 'Initials': 'ME', 'LastName': 'Carlson', 'Affiliation': 'USC Mrs. T.H. Chan Division of Occupational Science and Occupational Therapy in the Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Pyatak', 'Affiliation': 'USC Mrs. T.H. Chan Division of Occupational Science and Occupational Therapy in the Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Jeanine', 'Initials': 'J', 'LastName': 'Blanchard', 'Affiliation': 'USC Mrs. T.H. Chan Division of Occupational Science and Occupational Therapy in the Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Alison M', 'Initials': 'AM', 'LastName': 'Cogan', 'Affiliation': 'USC Mrs. T.H. Chan Division of Occupational Science and Occupational Therapy in the Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Alix G', 'Initials': 'AG', 'LastName': 'Sleight', 'Affiliation': 'USC Mrs. T.H. Chan Division of Occupational Science and Occupational Therapy in the Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Hill', 'Affiliation': 'USC Mrs. T.H. Chan Division of Occupational Science and Occupational Therapy in the Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Jesus', 'Initials': 'J', 'LastName': 'Diaz', 'Affiliation': 'USC Mrs. T.H. Chan Division of Occupational Science and Occupational Therapy in the Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Erna', 'Initials': 'E', 'LastName': 'Blanche', 'Affiliation': 'USC Mrs. T.H. Chan Division of Occupational Science and Occupational Therapy in the Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Garber', 'Affiliation': 'Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Florence A', 'Initials': 'FA', 'LastName': 'Clark', 'Affiliation': 'USC Mrs. T.H. Chan Division of Occupational Science and Occupational Therapy in the Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.'}]",Disability and rehabilitation,['10.1080/09638288.2018.1552328'] 840,29338322,Associations of mindfulness with depressive symptoms and well-being in older adults: the moderating role of neuroticism.,"OBJECTIVE To investigate whether observed interactions of mindfulness with the personality trait neuroticism extend to older adults and to aspects of psychological functioning other than depressive symptoms, and whether effects of mindfulness training in this population depend on levels of neuroticism. METHOD We performed a secondary analysis of data from a randomized controlled trial of Mindfulness-Based Stress Reduction (MBSR) for community-dwelling older adults. We investigated whether neuroticism moderates associations of dispositional mindfulness with various aspects of psychological and physical functioning at baseline, as well as effects of MBSR on these outcomes. RESULTS Significant two-way interactions showed that greater mindfulness was associated with fewer depressive symptoms and less negative affect at baseline in individuals with average or higher levels of neuroticism. In contrast, mindfulness was associated with greater positive affect and vitality and fewer physical symptoms regardless of the level of neuroticism. There were no effects of MBSR on these outcomes at any level of neuroticism. CONCLUSION Mindfulness may be more protective against psychological ill-being in older adults with higher levels of neuroticism, but conducive to positive psychological and physical well-being regardless of this personality trait. The potential moderating role of neuroticism should be further evaluated in studies of mindfulness-based interventions in older adults.",2019,"RESULTS Significant two-way interactions showed that greater mindfulness was associated with fewer depressive symptoms and less negative affect at baseline in individuals with average or higher levels of neuroticism.","['community-dwelling older adults', 'older adults']","['mindfulness training', 'Mindfulness-Based Stress Reduction (MBSR', 'MBSR']",['depressive symptoms'],"[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]","[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}]",,0.0290384,"RESULTS Significant two-way interactions showed that greater mindfulness was associated with fewer depressive symptoms and less negative affect at baseline in individuals with average or higher levels of neuroticism.","[{'ForeName': 'Ari J', 'Initials': 'AJ', 'LastName': 'Elliot', 'Affiliation': 'a Department of Psychiatry , University of Rochester , Rochester , NY , USA.'}, {'ForeName': 'Autumn M', 'Initials': 'AM', 'LastName': 'Gallegos', 'Affiliation': 'a Department of Psychiatry , University of Rochester , Rochester , NY , USA.'}, {'ForeName': 'Jan A', 'Initials': 'JA', 'LastName': 'Moynihan', 'Affiliation': 'a Department of Psychiatry , University of Rochester , Rochester , NY , USA.'}, {'ForeName': 'Benjamin P', 'Initials': 'BP', 'LastName': 'Chapman', 'Affiliation': 'a Department of Psychiatry , University of Rochester , Rochester , NY , USA.'}]",Aging & mental health,['10.1080/13607863.2017.1423027'] 841,31420724,Impact of Intermittent Pringle Maneuver on Long-Term Survival After Hepatectomy for Hepatocellular Carcinoma: Result from Two Combined Randomized Controlled Trials.,"BACKGROUND Hepatectomy remains an important curative treatment for hepatocellular carcinoma (HCC). Intermittent Pringle maneuver (IPM) is commonly applied during hepatectomy for control of bleeding. Whether the ischemia/reperfusion injury brought by IPM adversely affects the operative outcomes is controversial. This study aims to examine whether the application of IPM during hepatectomy affects the long-term outcomes. METHODS Two randomized controlled trials (RCT) have been carried out previously to evaluate the short-term outcomes of IPM. The present study represented a post hoc analysis on the HCC patients from the first RCT and all patients from the second RCT, and the long-term outcomes were evaluated. RESULTS There were 88 patients each in the IPM group and the no-Pringle-maneuver (NPM) group. The patient demographics, type and extent of liver resection and histopathological findings were comparable between the two groups. The 1-, 3-, 5-year overall survival in the IPM and NPM groups was 92.0%, 82.0%, 72.1% and 93.2%, 68.8%, 58.1%, respectively (P = 0.030). The 1-, 3-, 5-year disease-free survival in the IPM and NPM groups was 73.6%, 56.2%, 49.7% and 71.6%, 49.4%, 40.3%, respectively (P = 0.366). On multivariable analysis, IPM was a favorable factor for overall survival (P = 0.035). Subgroup analysis showed that a clamp time of 16-30 min (P = 0.024) and cirrhotic patients with IPM (P = 0.009) had better overall survival. CONCLUSION IPM provided a better overall survival after hepatectomy for patients with HCC. Such survival benefit was noted in cirrhotic patients, and the beneficial duration of clamp was 16-30 min. TRIAL REGISTRATION NCT00730743 and NCT01759901 ( http://www.clinicaltrials.gov ).",2019,"The 1-, 3-, 5-year disease-free survival in the IPM and NPM groups was 73.6%, 56.2%, 49.7% and 71.6%, 49.4%, 40.3%, respectively (P = 0.366).","['88 patients each in the IPM group and the no-Pringle-maneuver (NPM) group', 'patients with HCC', 'Hepatocellular Carcinoma', 'hepatocellular carcinoma (HCC', 'cirrhotic patients']","['Intermittent Pringle maneuver (IPM', 'IPM']","['5-year disease-free survival', 'overall survival', '5-year overall survival', 'Such survival benefit', 'Long-Term Survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2239176', 'cui_str': 'Liver Cell Carcinoma, Adult'}, {'cui': 'C0439686', 'cui_str': 'Cirrhotic (qualifier value)'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0242793', 'cui_str': 'Disease-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}]",88.0,0.266899,"The 1-, 3-, 5-year disease-free survival in the IPM and NPM groups was 73.6%, 56.2%, 49.7% and 71.6%, 49.4%, 40.3%, respectively (P = 0.366).","[{'ForeName': 'Kit Fai', 'Initials': 'KF', 'LastName': 'Lee', 'Affiliation': 'Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32, Ngan Shing Street, Shatin, N.T., Hong Kong SAR, China.'}, {'ForeName': 'Charing C N', 'Initials': 'CCN', 'LastName': 'Chong', 'Affiliation': 'Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32, Ngan Shing Street, Shatin, N.T., Hong Kong SAR, China.'}, {'ForeName': 'Sunny Y S', 'Initials': 'SYS', 'LastName': 'Cheung', 'Affiliation': 'Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32, Ngan Shing Street, Shatin, N.T., Hong Kong SAR, China.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Wong', 'Affiliation': 'Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32, Ngan Shing Street, Shatin, N.T., Hong Kong SAR, China.'}, {'ForeName': 'Andrew K Y', 'Initials': 'AKY', 'LastName': 'Fung', 'Affiliation': 'Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32, Ngan Shing Street, Shatin, N.T., Hong Kong SAR, China.'}, {'ForeName': 'Hon Ting', 'Initials': 'HT', 'LastName': 'Lok', 'Affiliation': 'Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32, Ngan Shing Street, Shatin, N.T., Hong Kong SAR, China.'}, {'ForeName': 'Paul B S', 'Initials': 'PBS', 'LastName': 'Lai', 'Affiliation': 'Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32, Ngan Shing Street, Shatin, N.T., Hong Kong SAR, China. paullai@surgery.cuhk.edu.hk.'}]",World journal of surgery,['10.1007/s00268-019-05130-8'] 842,30588836,"The Antioxidant Effects of Hydroxytyrosol and Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease, in a Clinical Trial: A New Treatment?","Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in children. Several studies suggest that the improvement of oxidative stress is suggested as a possible therapeutic strategy for pediatric nonalcoholic steatohepatitis. We performed a randomized, double-blind placebo-controlled trial to test the potential efficacy, assessed by improvement of oxidative stress parameters and liver ultrasound, and tolerability of a mixture of vitamin E and hydroxytyrosol (HXT) in adolescents with biopsy-proven NAFLD. Four hundred forty consecutive patients were screened, 80 of these with biopsy-proven NAFLD were enrolled. Forty patients received an oral dose of HXT and vitamin E and 40 children received the capsules of placebo for 4 months. Seventy patients completed the study. Patients in the treatment arm showed a decrease of insulin resistance (IR), triglyceride levels, oxidative stress parameters, and steatosis grade. Noteworthy, the steatosis improvement correlates with the levels of advanced glycation end products and carbonylated proteins. The HXT and vitamin E treatment improved the main oxidative stress parameters, IR, and steatosis in children with NAFLD. The use of two natural molecules that may have antioxidant effects seems a promising strategy that could be easily diet integrated to improve NAFLD-related liver damage in children.",2019,"Patients in the treatment arm showed a decrease of insulin resistance (IR), triglyceride levels, oxidative stress parameters, and steatosis grade.","['children with NAFLD', 'Forty patients', 'Four hundred forty consecutive patients were screened, 80 of these with biopsy-proven NAFLD were enrolled', 'chronic liver disease in children', 'Seventy patients completed the study', 'adolescents with biopsy-proven NAFLD']","['Hydroxytyrosol and Vitamin E', 'vitamin E and hydroxytyrosol (HXT', 'placebo', 'HXT and vitamin E']","['insulin resistance (IR), triglyceride levels, oxidative stress parameters, and steatosis grade', 'main oxidative stress parameters, IR, and steatosis', 'oxidative stress parameters and liver ultrasound, and tolerability']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0400966', 'cui_str': 'NAFLD'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0456369', 'cui_str': 'Proven (qualifier value)'}, {'cui': 'C0341439', 'cui_str': 'Chronic liver disease (disorder)'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0243264', 'cui_str': 'hydroxytyrosol'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0428475', 'cui_str': 'Triglyceride level - finding'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0152254', 'cui_str': 'Fatty degeneration (morphologic abnormality)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0205225', 'cui_str': 'Principal (qualifier value)'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}]",440.0,0.32018,"Patients in the treatment arm showed a decrease of insulin resistance (IR), triglyceride levels, oxidative stress parameters, and steatosis grade.","[{'ForeName': 'Valerio', 'Initials': 'V', 'LastName': 'Nobili', 'Affiliation': ""1 Department of Pediatric Subspecialties, Hepatology Gastroenterology, and Nutrition, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Alisi', 'Affiliation': ""3 Research Unit of Multifactorial Genetics and Epigenetics, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.""}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Mosca', 'Affiliation': '2 Department of Pediatrics, Sapienza University, Rome, Italy.'}, {'ForeName': 'Annalisa', 'Initials': 'A', 'LastName': 'Crudele', 'Affiliation': ""3 Research Unit of Multifactorial Genetics and Epigenetics, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.""}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Zaffina', 'Affiliation': '4 Clinical-Technological Innovations Research Area, Occupational Medicine/Health Technology Assessment and Safety Research Unit, Bambino Gesù Children Hospital-IRCCS, Rome, Italy.'}, {'ForeName': 'Marcella', 'Initials': 'M', 'LastName': 'Denaro', 'Affiliation': '5 Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.'}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Smeriglio', 'Affiliation': '5 Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.'}, {'ForeName': 'Domenico', 'Initials': 'D', 'LastName': 'Trombetta', 'Affiliation': '5 Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.'}]",Antioxidants & redox signaling,['10.1089/ars.2018.7704'] 843,31842828,"Promoting activity, Independence and stability in early dementia (PrAISED): a, multisite, randomised controlled, feasibility trial.","BACKGROUND We tested the feasibility of delivering and evaluating a complex therapy intervention which aimed to promote activity and independence for people with early dementia (PrAISED). Feasibility questions were on: recruitment, randomisation, intervention delivery, adherence and withdrawals, level of supervision required, adverse events, data collection and sample size assumptions. METHODS We conducted a three-arm, multi-site, single-blind, randomised controlled feasibility trial. Eligibility criteria were aged 65 years or older, diagnosed mild dementia or mild cognitive impairment, able to walk without human help, and communicate in English, no co-morbidities that prevented participation in cognitive assessment and capacity to give consent. Participants were recruited from Memory Assessment Service clinics and the 'Join Dementia Research' register. Patient participants were randomised 1:1:1 to a high intensity supervision PrAISED intervention, moderate intensity supervision PrAISED intervention or brief falls prevention assessment and advice (control). The PrAISED intervention aimed for participants to complete three hours of PrAISED exercises a week for 12 months. It included individualised activity and exercise plans and supervised exercises with regular re-assessment and progression, and was delivered by occupational therapists, physiotherapists and rehabilitation support workers. Primary efficacy outcome was the Disability Assessment for Dementia (DAD), measured after 12 months. Secondary outcomes included physical activity, quality of life, mood, cognition, strength, balance, rate of falls, frailty and carer strain. Falls and activity were ascertained by monthly diary. RESULTS Between September 2016 and March 2017 we recruited 60 patient participants and 54 carer participants from two sites. Forty-nine patient participants completed a follow-up interview. Feasibility outcomes were mostly satisfactory, including recruitment and retention, intervention delivery and data completeness for most scales used. We could not maintain blinding of researchers at follow-up and experienced difficulties collecting data using some questionnaires and devices. Participants only completed a mean 77 (moderate supervision) and 71 (high supervision) minutes per week of PrAISED exercises over 12 months. We recorded 19 adverse events, none serious and related to the intervention. CONCLUSION We conclude that with some adjustments to the trial protocol, it is feasible to deliver the PrAISED intervention and conduct a trial. TRIAL REGISTRATION ClinicalTrials.gov: NCT02874300 (first posted 22nd August 2016), ISRCTN: 10550694 (date assigned 31st August 2016).",2019,"Secondary outcomes included physical activity, quality of life, mood, cognition, strength, balance, rate of falls, frailty and carer strain.","['Between September 2016 and March 2017', 'people with early dementia (PrAISED', 'Eligibility criteria were aged 65\u2009years or older, diagnosed mild dementia or mild cognitive impairment, able to walk without human help, and communicate in English, no co-morbidities that prevented participation in cognitive assessment and capacity to give consent', '60 patient participants and 54 carer participants from two sites', 'early dementia (PrAISED', ""Participants were recruited from Memory Assessment Service clinics and the 'Join Dementia Research' register"", 'Participants only completed a mean 77 (moderate supervision) and 71 (high supervision) minutes per week of PrAISED exercises over 12\u2009months']","['individualised activity and exercise plans and supervised exercises with regular re-assessment and progression, and was delivered by occupational therapists, physiotherapists and rehabilitation support workers', 'complex therapy intervention', 'high intensity supervision PrAISED intervention, moderate intensity supervision PrAISED intervention or brief falls prevention assessment and advice (control']","['recruitment, randomisation, intervention delivery, adherence and withdrawals, level of supervision required, adverse events, data collection and sample size assumptions', 'Falls and activity', 'Disability Assessment for Dementia (DAD', 'physical activity, quality of life, mood, cognition, strength, balance, rate of falls, frailty and carer strain', 'recruitment and retention, intervention delivery and data completeness']","[{'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0557963', 'cui_str': 'Praising (procedure)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C3494623', 'cui_str': 'Mild dementia'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C2712089', 'cui_str': 'Able to walk (finding)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0566001', 'cui_str': 'Does communicate (finding)'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1305660', 'cui_str': 'Carer (occupation)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0439045', 'cui_str': 'Memory assessment finding'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0035168'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0028807', 'cui_str': 'Occupational therapist (occupation)'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapists'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C0557963', 'cui_str': 'Praising (procedure)'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0150223', 'cui_str': 'Fall prevention (procedure)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0010995', 'cui_str': 'Data Collection'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0051767', 'cui_str': 'DASD'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0034380'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C1305660', 'cui_str': 'Carer (occupation)'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0439812', 'cui_str': 'Completeness (qualifier value)'}]",,0.171255,"Secondary outcomes included physical activity, quality of life, mood, cognition, strength, balance, rate of falls, frailty and carer strain.","[{'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Goldberg', 'Affiliation': 'School of Health Sciences, University of Nottingham, Queens Medical Centre, Nottingham, NG7 2UH, UK. sarah.goldberg@nottingham.ac.uk.'}, {'ForeName': 'Veronika', 'Initials': 'V', 'LastName': 'van der Wardt', 'Affiliation': 'Division of Rehabilitation, Ageing and Wellbeing, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Brand', 'Affiliation': 'NWORTH, School of Health Sciences, Bangor University, Bangor, UK.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Burgon', 'Affiliation': 'Division of Rehabilitation, Ageing and Wellbeing, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Rupinder', 'Initials': 'R', 'LastName': 'Bajwa', 'Affiliation': 'Division of Rehabilitation, Ageing and Wellbeing, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Hoare', 'Affiliation': 'NWORTH, School of Health Sciences, Bangor University, Bangor, UK.'}, {'ForeName': 'Pip L', 'Initials': 'PL', 'LastName': 'Logan', 'Affiliation': 'Division of Rehabilitation, Ageing and Wellbeing, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Rowan H', 'Initials': 'RH', 'LastName': 'Harwood', 'Affiliation': 'School of Health Sciences, University of Nottingham, Queens Medical Centre, Nottingham, NG7 2UH, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMC geriatrics,['10.1186/s12877-019-1379-5'] 844,31665879,Effect of simplified Tai Chi exercise on relieving symptoms of patients with mild to moderate Parkinson's disease.,"BACKGROUND Tai Chi, a kind of physical exercise, may act as a non-pharmacologic approach to reducing the symptoms of Parkinson's disease. This study was conducted to investigate the effect of simplified Tai Chi training plus routine exercise on motor and non-motor symptoms in patients with mild to moderate Parkinson's disease in comparison with routine exercise regimen alone. METHODS Forty-one outpatients and inpatients with Parkinson's disease (PD) were randomized into Tai Chi group (N.=19) and routine exercise group as control group (N.=22) for 12 weeks. The Tai Chi group included both Tai Chi traning and routine exercise. Motor and non-motor functions were assessed. Motor function was evaluated by Unified Parkinson's Disease Rating Scale part III (UPDRS-III) and Berg Balance Scale (BBS). The non-motor symptoms like quality of life, sleep quality, depression and anxiety state, cognitive function were assessed by Parkinson's Disease Questionnaire-39 (PDQ-39), Parkinson's Disease Sleep Scale (PDSS), Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), Montreal Cognitive Assessment (MOCA) respectively. RESULTS After 12 weeks of intervention, participants in both Tai Chi and routine exercise groups gained effects in UPDRS-III, BBS, PDQ-39, PDSS and HAMD compared to the baseline. However, significant improvements between Tai Chi group and routine exercise group were only found in PDSS (P=0.029) and MoCA (P=0.024). CONCLUSIONS Tai Chi training plus routine exercise might therefore be an ideal alternative non-pharmacological approach for the motor and non-motor symptoms of PD patients, and especially be more useful for the improvement of sleep quality and cognitive function in Parkinson's disease compared with routine exercise regimen alone.",2020,"After 12 weeks of intervention, participants in both Tai Chi and routine exercise groups gained effects in UPDRS-III, BBS, PDQ-39, PDSS and HAMD compared to the baseline.","[""patients with mild to moderate Parkinson's disease"", ""patients with mild to moderate Parkinson's disease in comparison with routine exercise regimen alone"", ""41 outpatients and inpatients with Parkinson's disease (PD""]","['routine exercise group as control group', 'Tai Chi traning and routine exercise', 'simplified Tai Chi training plus routine exercise', 'simplified Tai Chi exercise', 'Tai Chi and routine exercise', 'Tai Chi']","['motor and non-motor symptoms', 'UPDRS-III, BBS, PDQ-39, PDSS and HAMD', 'Motor function', 'PDSS', ""Parkinson's Disease Questionnaire-39 (PDQ-39), Parkinson's Disease Sleep Scale (PDSS), Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), Montreal Cognitive Assessment (MOCA) respectively"", 'non-motor symptoms like quality of life, sleep quality, depression and anxiety state, cognitive function', 'Motor and non-motor functions', ""Unified Parkinson's Disease Rating Scale part III (UPDRS-III) and Berg Balance Scale (BBS""]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}]","[{'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0376403', 'cui_str': 'Taiji'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0426980', 'cui_str': 'Motor symptoms (finding)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0234130', 'cui_str': 'Motor function (observable entity)'}, {'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0222045'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C3496286'}, {'cui': 'C0034380'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0700613', 'cui_str': 'Anxiety state (finding)'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}]",41.0,0.0117291,"After 12 weeks of intervention, participants in both Tai Chi and routine exercise groups gained effects in UPDRS-III, BBS, PDQ-39, PDSS and HAMD compared to the baseline.","[{'ForeName': 'Mingjin', 'Initials': 'M', 'LastName': 'Zhu', 'Affiliation': 'Department of Rehabilitation Medicine, Tongde Hospital of Zhejiang Province, Zhejiang Chinese Medical University, Hanghzou, China.'}, {'ForeName': 'Yonghua', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'The Fourth School of Medicine, Zhejiang Chinese Medical University, Hanghzou, China.'}, {'ForeName': 'Jiafei', 'Initials': 'J', 'LastName': 'Pan', 'Affiliation': 'Department of Rehabilitation Medicine, Tongde Hospital of Zhejiang Province, Zhejiang Chinese Medical University, Hanghzou, China.'}, {'ForeName': 'Changyong', 'Initials': 'C', 'LastName': 'Fu', 'Affiliation': 'Department of Neurology, Tongde Hospital of Zhejiang Province, Zhejiang Chinese Medical University, Hanghzou, China.'}, {'ForeName': 'Yaqun', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Rehabilitation Medicine, Tongde Hospital of Zhejiang Province, Zhejiang Chinese Medical University, Hanghzou, China - dr_yqwang@zcmu.edu.cn.'}]",The Journal of sports medicine and physical fitness,['10.23736/S0022-4707.19.10104-1'] 845,30225981,'Ripple' effect on infant zBMI trajectory of an internet-based weight loss program for low-income postpartum women.,"BACKGROUND Weight loss interventions can have positive 'ripple' effects on untreated partners in the home, but ripple effects on infants are unknown. OBJECTIVE To examine whether a 12-month internet-based weight loss intervention for postpartum mothers had a positive ripple effect on participants' infants. METHODS A 12-month cluster randomized, assessor-blind, clinical trial enrolling 371 postpartum women at 12 Women, Infants, Children clinics in CA. Clinics were randomized to standard Women, Infants, Children or an internet-based weight loss intervention for mothers. RESULTS A total of 333 of the 371 (89.8%) mothers assented for infant participation. Infants were 5.3 ± 3.2 months; 75.9% were Hispanic and 64% were breastfeeding. Infant retention was 272/333 (82.7%) at 6 months post enrollment and 251/333 (75.3%) at 12 months post enrollment. In intent-to-treat analysis, a significant interaction between group and time was observed (p = 0.008) with the offspring of intervention mothers exhibiting lower zBMI change from study entry through 6 months (0.23 [CI, 0.03, 0.44] vs. 0.65 [0.50, 0.79] zBMI change, respectively; p = 0.001) but was not significant through 12 months (p = 0.16). Regardless of group, maternal reports at the final assessment indicated that infants (aged =17.2 ± 3.4 months) consumed sweetened beverages (0.93 ± 1.5/week), juice (2.0 ± 1.4/day), 'junk food' (7.8 ± 5.4/week) and fast food (2/month), and 46.7% of the infants had a TV in their bedroom. CONCLUSIONS An internet-based weight loss program for low-income, postpartum mothers had a positive 'ripple' effect on the zBMI of infants in the home during the first 6 months of treatment.",2019,"In intent-to-treat analysis, a significant interaction between group and time was observed (p = 0.008) with the offspring of intervention mothers exhibiting lower zBMI change from study entry through 6 months (0.23 [CI, 0.03, 0.44] vs. 0.65 [0.50, 0.79] zBMI change, respectively; p = 0.001) but was not significant through 12 months (p = 0.16).","['low-income postpartum women', '371 postpartum women at 12 Women, Infants, Children clinics in CA', 'A total of 333 of the 371 (89.8%) mothers assented for infant participation', ""postpartum mothers had a positive ripple effect on participants' infants""]","['internet-based weight loss intervention for mothers', 'internet-based weight loss intervention', 'internet-based weight loss program']","['zBMI change', 'Infant retention']","[{'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0032804', 'cui_str': 'Postpartum Women'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4517724', 'cui_str': 'Three hundred and thirty-three'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0086839', 'cui_str': 'Postpartum Period'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C3179079', 'cui_str': 'Weight Loss Programs'}]","[{'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0035280', 'cui_str': 'Retention'}]",371.0,0.182126,"In intent-to-treat analysis, a significant interaction between group and time was observed (p = 0.008) with the offspring of intervention mothers exhibiting lower zBMI change from study entry through 6 months (0.23 [CI, 0.03, 0.44] vs. 0.65 [0.50, 0.79] zBMI change, respectively; p = 0.001) but was not significant through 12 months (p = 0.16).","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Phelan', 'Affiliation': 'Department of Kinesiology and Public Health, California Polytechnic State University, San Luis Obispo, CA, USA.'}, {'ForeName': 'T A', 'Initials': 'TA', 'LastName': 'Hagobian', 'Affiliation': 'Department of Kinesiology and Public Health, California Polytechnic State University, San Luis Obispo, CA, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ventura', 'Affiliation': 'Department of Kinesiology and Public Health, California Polytechnic State University, San Luis Obispo, CA, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Brannen', 'Affiliation': 'Department of Kinesiology and Public Health, California Polytechnic State University, San Luis Obispo, CA, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Erickson-Hatley', 'Affiliation': 'Departments of Health Behavior and Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Schaffner', 'Affiliation': 'Statistics Department, California Polytechnic State University, San Luis Obispo, CA, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Muñoz-Christian', 'Affiliation': 'Modern Languages Department, California Polytechnic State University, San Luis Obispo, CA, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Mercado', 'Affiliation': 'Department of Kinesiology and Public Health, California Polytechnic State University, San Luis Obispo, CA, USA.'}, {'ForeName': 'D F', 'Initials': 'DF', 'LastName': 'Tate', 'Affiliation': 'Departments of Health Behavior and Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}]",Pediatric obesity,['10.1111/ijpo.12456'] 846,29710284,Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial.,"Importance The American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors (ACS guidelines) include maintaining (1) a healthy body weight; (2) physical activity; and (3) a diet that includes vegetables, fruits, and whole grains. It is not known whether patients with colon cancer who follow these guidelines have improved survival. Objective To examine whether a lifestyle consistent with the ACS guidelines is associated with improved survival rates after colon cancer. Design, Setting, and Participants This prospective cohort study included 992 patients with stage III colon cancer who were enrolled in the CALGB 89803 randomized adjuvant chemotherapy trial from 1999 through 2001. Data for the present study were analyzed between November 2016 and December 2017. Exposures We assigned an ACS guidelines score for each included patient based on body mass index; physical activity; and intake of vegetables, fruits, whole grains, and red/processed meats (score range, 0-6, with higher score indicating healthier behaviors). Secondarily, we examined a score that also included alcohol intake in addition to the other factors (range, 0-8). Lifestyle was assessed during and 6 months after chemotherapy. Main Outcomes and Measures Hazard ratios (HRs) and 95% confidence intervals (CIs) for disease-free, recurrence-free, and overall survival. Results Of the 992 patients enrolled in the study, 430 (43%) were women, and the mean (SD) age was 59.6 (11.2) years (range, 21-85 years). Over a 7-year median follow-up, we observed 335 recurrences and 299 deaths (43 deaths without recurrence). Compared with patients with a 0 to 1 ACS guidelines score (n = 262; 26%), patients with a 5 to 6 score (n = 91; 9%) had a 42% lower risk of death during the study period (HR, 0.58; 95% CI, 0.34-0.99; P = .01 for trend) and improved disease-free survival (HR, 0.69; 95% CI, 0.45-1.06; P = .03 for trend). When alcohol consumption was included in the score, the adjusted HRs comparing patients with scores of 6 to 8 (n = 162; 16%) vs those with scores of 0 to 2 (187; 91%) were 0.49 for overall survival (95% CI, 0.32-0.76; P = .002 for trend), 0.58 for disease-free survival (95% CI, 0.40, 0.84; P = .01 for trend), and 0.64 for recurrence-free survival (95% CI, 0.44-0.94; P = .05 for trend). Conclusions and Relevance Having a healthy body weight, being physically active, and eating a diet rich in vegetables, fruits, and whole grains after diagnosis of stage III colon cancer was associated with a longer survival. Trial Registration clinicaltrials.gov Identifier: NCT00003835.",2018,"Over a 7-year median follow-up, we observed 335 recurrences and 299 deaths (43 deaths without recurrence).","['November 2016 and December 2017', '992 patients with stage III colon cancer who were enrolled in the CALGB 89803 randomized adjuvant chemotherapy trial from 1999 through 2001', 'Cancer Survivors', 'After Colon Cancer Diagnosis', '992 patients enrolled in the study, 430 (43%) were women, and the mean (SD) age was 59.6 (11.2) years (range, 21-85 years', 'patients with colon cancer']",['American Cancer Society Nutrition and Physical Activity Guidelines'],"['Measures\n\n\nHazard ratios (HRs) and 95% confidence intervals (CIs) for disease-free, recurrence-free, and overall survival', 'survival', 'Survival', 'survival rates', 'disease-free survival', 'recurrence-free survival', 'risk of death', 'overall survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3 (qualifier value)'}, {'cui': 'C0007102', 'cui_str': 'Cancer of Colon'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517531', 'cui_str': '11.2 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}]","[{'cui': 'C0002455', 'cui_str': 'American Cancer Society'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0220845', 'cui_str': 'guidelines'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0009667', 'cui_str': 'Confidence Intervals'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0242793', 'cui_str': 'Disease-Free Survival'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease (finding)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",992.0,0.314587,"Over a 7-year median follow-up, we observed 335 recurrences and 299 deaths (43 deaths without recurrence).","[{'ForeName': 'Erin L', 'Initials': 'EL', 'LastName': 'Van Blarigan', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of California, San Francisco.'}, {'ForeName': 'Charles S', 'Initials': 'CS', 'LastName': 'Fuchs', 'Affiliation': 'Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Niedzwiecki', 'Affiliation': 'Alliance Statistics and Data Center, Duke University, Durham, North Carolina.'}, {'ForeName': 'Sui', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.'}, {'ForeName': 'Leonard B', 'Initials': 'LB', 'LastName': 'Saltz', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Mayer', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.'}, {'ForeName': 'Rex B', 'Initials': 'RB', 'LastName': 'Mowat', 'Affiliation': 'Toledo Community Hospital Oncology Program, Toledo, Ohio.'}, {'ForeName': 'Renaud', 'Initials': 'R', 'LastName': 'Whittom', 'Affiliation': 'Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Hantel', 'Affiliation': 'Loyola University, Stritch School of Medicine, Naperville, Illinois.'}, {'ForeName': 'Al', 'Initials': 'A', 'LastName': 'Benson', 'Affiliation': 'Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Atienza', 'Affiliation': 'Virginia Oncology Associates, Norfolk, Virginia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Messino', 'Affiliation': 'Southeast Clinical Oncology Research Consortium, Mission Hospitals Inc, Asheville, North Carolina.'}, {'ForeName': 'Hedy', 'Initials': 'H', 'LastName': 'Kindler', 'Affiliation': 'University of Chicago Comprehensive Cancer Center, Chicago, Illinois.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Venook', 'Affiliation': 'Helen Diller Family Comprehensive Cancer Center, San Francisco, California.'}, {'ForeName': 'Shuji', 'Initials': 'S', 'LastName': 'Ogino', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.'}, {'ForeName': 'Edward L', 'Initials': 'EL', 'LastName': 'Giovannucci', 'Affiliation': 'Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Kimmie', 'Initials': 'K', 'LastName': 'Ng', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.'}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Meyerhardt', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.'}]",JAMA oncology,['10.1001/jamaoncol.2018.0126'] 847,30548692,"Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).","OBJECTIVES To evaluate the long-term safety (primary objective) and efficacy (secondary objective) of antimuscarinic add-on therapy in patients receiving mirabegron. METHODS During a 2-week screening period, patients (aged ≥20 years, mirabegron treatment for ≥6 weeks, residual overactive bladder symptoms) received mirabegron 50 mg once daily. These patients were subsequently randomized to 52 weeks' treatment with mirabegron 50 mg/day plus an antimuscarinic (solifenacin 5 mg, propiverine 20 mg, imidafenacin 0.2 mg, or tolterodine 4 mg) with the potential to double the antimuscarinic dose (except for tolterodine) at week 8. Safety assessments included treatment-emergent adverse events, vital signs, 12-lead electrocardiograms, post-void residual volume, and laboratory evaluations. Efficacy was assessed using changes from baseline in overactive bladder symptom score total score; overactive bladder questionnaire short form score; micturitions, urgency episodes, urinary incontinence episodes, and urgency urinary incontinence episodes/24 h; mean volume voided per micturition; and number of night-time micturitions. RESULTS Overall, 80.2% of patients (88.1% women, mean age 65 years) experienced at least one treatment-emergent adverse event, with similar rates for all treatments. The adverse events most commonly reported were dry mouth, nasopharyngitis, and constipation. No marked change was observed in systolic or diastolic blood pressure for any treatment, although pulse rate increased slightly in the mirabegron and propiverine, and mirabegron and tolterodine groups. For all treatments, significant improvements were observed in all efficacy parameters, including overactive bladder symptom score total and questionnaire short form scores. CONCLUSIONS Antimuscarinic add-on therapy is well tolerated and effective after initial treatment with mirabegron in patients with overactive bladder symptoms.",2019,"For all treatments, significant improvements were observed in all efficacy parameters, including overactive bladder symptom score total and questionnaire short form scores. ","['patients with overactive bladder symptoms', 'patients with overactive bladder who had a suboptimal response to mirabegron monotherapy', 'patients receiving mirabegron', 'patients (aged ≥20\xa0years, mirabegron treatment for ≥6\xa0weeks, residual overactive bladder symptoms) received']","['mirabegron 50\xa0mg once daily', 'mirabegron 50\xa0mg/day plus an antimuscarinic (solifenacin 5\xa0mg, propiverine 20\xa0mg, imidafenacin 0.2\xa0mg, or tolterodine 4\xa0mg) with the potential to double the antimuscarinic dose (except for tolterodine']","['Efficacy', 'episodes/24\xa0h; mean volume voided per micturition; and number of night-time micturitions', 'systolic or diastolic blood pressure', 'overactive bladder symptom score total score; overactive bladder questionnaire short form score; micturitions, urgency episodes, urinary incontinence episodes, and urgency urinary incontinence', 'dry mouth, nasopharyngitis, and constipation', 'tolerated and effective', 'Safety assessments included treatment-emergent adverse events, vital signs, 12-lead electrocardiograms, post-void residual volume, and laboratory evaluations', 'overactive bladder symptom score total and questionnaire short form scores', 'pulse rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0878773', 'cui_str': 'Overactive Bladder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C2983812', 'cui_str': 'mirabegron'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}]","[{'cui': 'C3474335', 'cui_str': 'mirabegron 50 MG'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C4521482', 'cui_str': 'Antimuscarinic'}, {'cui': 'C1099677', 'cui_str': 'Solifenacin'}, {'cui': 'C0138666', 'cui_str': 'propiverine'}, {'cui': 'C1876226', 'cui_str': 'imidafenacin'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0388753', 'cui_str': 'tolterodine'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0332300', 'cui_str': 'Except for (attribute)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0042034', 'cui_str': 'Micturition'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0240526', 'cui_str': 'Night time (qualifier value)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0878773', 'cui_str': 'Overactive Bladder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0439609', 'cui_str': 'Urgency (qualifier value)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0042024', 'cui_str': 'Urinary Incontinence'}, {'cui': 'C0043352', 'cui_str': 'Mouth Dryness'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0518766'}, {'cui': 'C0430456', 'cui_str': '12 lead ECG'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0035190', 'cui_str': 'Residual respiratory volume (observable entity)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0232117', 'cui_str': 'Pulse Rate'}]",,0.078883,"For all treatments, significant improvements were observed in all efficacy parameters, including overactive bladder symptom score total and questionnaire short form scores. ","[{'ForeName': 'Osamu', 'Initials': 'O', 'LastName': 'Yamaguchi', 'Affiliation': 'Department of Chemical Biology and Applied Chemistry, Nihon University School of Engineering, Koriyama, Japan.'}, {'ForeName': 'Hidehiro', 'Initials': 'H', 'LastName': 'Kakizaki', 'Affiliation': 'Department of Urology, Asahikawa Medical University, Asahikawa, Japan.'}, {'ForeName': 'Yukio', 'Initials': 'Y', 'LastName': 'Homma', 'Affiliation': 'Department of Urology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Yasuhiko', 'Initials': 'Y', 'LastName': 'Igawa', 'Affiliation': 'Department of Continence Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Takeda', 'Affiliation': 'Department of Urology, Graduate Faculty of Interdisciplinary Research, University of Yamanashi, Chuo, Japan.'}, {'ForeName': 'Osamu', 'Initials': 'O', 'LastName': 'Nishizawa', 'Affiliation': 'Department of Urology, North Alps Medical Center, Azumi Hospital, Nagano, Japan.'}, {'ForeName': 'Momokazu', 'Initials': 'M', 'LastName': 'Gotoh', 'Affiliation': 'Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.'}, {'ForeName': 'Masaki', 'Initials': 'M', 'LastName': 'Yoshida', 'Affiliation': 'Department of Urology, National Center for Geriatrics and Gerontology, Obu, Japan.'}, {'ForeName': 'Osamu', 'Initials': 'O', 'LastName': 'Yokoyama', 'Affiliation': 'Department of Urology, University of Fukui Faculty of Medical Sciences, Fukui, Japan.'}, {'ForeName': 'Narihito', 'Initials': 'N', 'LastName': 'Seki', 'Affiliation': 'Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Okitsu', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Hamada', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Akiko', 'Initials': 'A', 'LastName': 'Kobayashi', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Kuroishi', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}]",International journal of urology : official journal of the Japanese Urological Association,['10.1111/iju.13868'] 848,30240024,Pain relief following a single-dose intra-articular injection of methylprednisolone in the temporomandibular joint arthralgia-A multicentre randomised controlled trial.,"BACKGROUND Temporomandibular joint (TMJ) arthralgia is a painful condition assumed to be associated with local inflammation. OBJECTIVE The objective of the present study was to determine the efficacy for reducing pain of a single-dose intra-articular (IA) injection of methylprednisolone to the TMJ. The hypothesis was that methylprednisolone would effectively reduce TMJ pain. METHODS This randomised, double-blind, parallel-group, multicentre, controlled study included visits for enrolment, treatment and 4-week follow-up. The study included patients 18 years and older who had been diagnosed with unilateral TMJ arthralgia. All participants were randomly assigned to receive 1 mL IA injections of methylprednisolone or saline. The primary outcome was change in recorded pain intensity on a visual analogue scale (VAS) at maximum jaw opening, analysed in the per protocol population. RESULTS In total, 54 patients were randomly assigned to single-dose IA injections with methylprednisolone (n = 27) or saline (n = 27). Between baseline and the 4-week follow-up, VAS-rated pain intensity at maximum jaw opening decreased from a mean of 61.0 (95% confidence interval [CI]: 50.1; 70.7) to 33.9 (95% CI: 21.6; 46.2) in the methylprednisolone group and from 59.6 (95% CI: 50.7; 65.9) to 33.9 (95% CI: 23.8; 43.9) in the saline group. The between-group difference was not significant (P = 0.812). Treatment-related adverse events were doubled in the methylprednisolone group. CONCLUSION Methylprednisolone provided no additional benefit for reducing pain, but caused more harm compared with saline following a single-dose IA injection in patients with TMJ arthralgia.",2019,"Between baseline and the 4-week follow-up, VAS-rated pain intensity at maximum jaw opening decreased from a mean of 61.0 (95% confidence interval [CI]: 50.1; 70.7) to 33.9 (95% CI: 21.6; 46.2) in the methylprednisolone group and from 59.6 (95% CI: 50.7; 65.9) to 33.9 (95% CI: 23.8; 43.9) in the saline group.","['54 patients', 'patients with TMJ arthralgia', 'patients 18\xa0years and older who had been diagnosed with unilateral TMJ arthralgia']","['Methylprednisolone', 'methylprednisolone or saline', 'saline', 'methylprednisolone']","['Pain relief', 'pain', 'recorded pain intensity on a visual analogue scale (VAS) at maximum jaw opening, analysed in the per protocol population', 'adverse events', 'TMJ pain', 'VAS-rated pain intensity at maximum jaw opening']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0039493', 'cui_str': 'TMJ'}, {'cui': 'C0003862', 'cui_str': 'Joint Pain'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}]","[{'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0022359', 'cui_str': 'Jaw'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0039493', 'cui_str': 'TMJ'}]",54.0,0.674104,"Between baseline and the 4-week follow-up, VAS-rated pain intensity at maximum jaw opening decreased from a mean of 61.0 (95% confidence interval [CI]: 50.1; 70.7) to 33.9 (95% CI: 21.6; 46.2) in the methylprednisolone group and from 59.6 (95% CI: 50.7; 65.9) to 33.9 (95% CI: 23.8; 43.9) in the saline group.","[{'ForeName': 'Göran', 'Initials': 'G', 'LastName': 'Isacsson', 'Affiliation': 'Department of Orofacial Pain and Jaw Function, Västmanland County Hospital, Västerås, Sweden.'}, {'ForeName': 'Mohamad', 'Initials': 'M', 'LastName': 'Schumann', 'Affiliation': 'Department of Orofacial Pain and Jaw Function, Västmanland County Hospital, Västerås, Sweden.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Nohlert', 'Affiliation': 'Centre for Clinical Research, Uppsala University, Västerås, Sweden.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Mejersjö', 'Affiliation': 'Clinic of Orofacial Pain, Sahlgrenska Academy and Public Dental Health, Gothenburg, Sweden.'}, {'ForeName': 'Åke', 'Initials': 'Å', 'LastName': 'Tegelberg', 'Affiliation': 'Department of Orofacial Pain and Jaw Function, Postgraduate Dental Education Center, Örebro, Sweden.'}]",Journal of oral rehabilitation,['10.1111/joor.12718'] 849,30554932,"Is regional ankle block needed in conjunction with general anaesthesia for first ray surgery? A randomised controlled trial of ultrasound guided ankle block versus ""blind"" local infiltration.","BACKGROUND Regional anaesthesia is commonly utilised for foot and ankle surgery. Debate remains at to the level of regional anaesthesia that is required. The objective of this study was to evaluate whether surgeon-delivered ""blind"" local anaesthetic infiltration around the first ray (metatarsal block without ultrasound guidance) was as effective as an ultrasound guided ankle block in providing post-operative analgesia after osseous first ray surgery performed under general anaesthetic. METHODS 50 patients were recruited to a single surgeon and anaesthetist double-blinded randomised controlled trial at a single-centre. 20mls of 0.5% levobupivacaine was used to perform either an ankle or metatarsal nerve block. RESULTS Forty-eight patients completed the study: 25 in the ankle block treatment arm and 23 in the metatarsal block arm. The demographics were comparable between groups. There was no statistical difference in visual analogue pain scores at two (21.3 vs 15.2), six (23.6 vs 20.8) and 24 (42.2 vs 50.4) hours following the procedure between the two groups (metatarsal block vs ankle block). Metatarsal block groups had a faster return of normal sensation (2.3 vs 2.8h) but there was no difference in time to safe mobilisation (2.6 vs 2.8h). CONCLUSION This study demonstrates the efficacy and safety of surgeon delivered ""blind"" metatarsal block is comparable to an ultrasound guided ankle block for first ray surgery performed under general anaesthetic. LEVEL OF EVIDENCE 1.",2020,"There was no statistical difference in visual analogue pain scores at two (21.3 vs 15.2), six (23.6 vs 20.8) and 24 (42.2 vs 50.4) hours following the procedure between the two groups (metatarsal block vs ankle block).","['50 patients were recruited to a single surgeon and anaesthetist double-blinded randomised controlled trial at a single-centre', 'Forty-eight patients completed the study: 25 in the ankle block treatment arm and 23 in the metatarsal block arm']","['ultrasound guided ankle block versus ""blind"" local infiltration', 'levobupivacaine', 'surgeon-delivered ""blind"" local anaesthetic infiltration around the first ray (metatarsal block without ultrasound guidance', 'surgeon delivered ""blind"" metatarsal block']","['faster return of normal sensation', 'efficacy and safety', 'time to safe mobilisation', 'visual analogue pain scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0582175', 'cui_str': 'Surgeon (occupation)'}, {'cui': 'C0473161', 'cui_str': 'Anesthetist'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0394745', 'cui_str': 'Local anesthetic ankle block (procedure)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0025584', 'cui_str': 'Metatarsals'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}]","[{'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0394745', 'cui_str': 'Local anesthetic ankle block (procedure)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C3669041', 'cui_str': 'Spread by direct extension (qualifier value)'}, {'cui': 'C0873118', 'cui_str': 'Levobupivacaine'}, {'cui': 'C0582175', 'cui_str': 'Surgeon (occupation)'}, {'cui': 'C0198813', 'cui_str': 'Local anesthesia, by infiltration (procedure)'}, {'cui': 'C0450284', 'cui_str': 'First ray (body structure)'}, {'cui': 'C0025584', 'cui_str': 'Metatarsals'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure (procedure)'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0576709', 'cui_str': 'Normal sensation (finding)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0185112', 'cui_str': 'Mobilizing (regime/therapy)'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}]",50.0,0.391939,"There was no statistical difference in visual analogue pain scores at two (21.3 vs 15.2), six (23.6 vs 20.8) and 24 (42.2 vs 50.4) hours following the procedure between the two groups (metatarsal block vs ankle block).","[{'ForeName': 'Veronica I', 'Initials': 'VI', 'LastName': 'Roberts', 'Affiliation': 'Orthopaedic Surgery, Leicester General Hospital, University Hospitals of Leicester, Leicester, England, UK.'}, {'ForeName': 'Randeep S', 'Initials': 'RS', 'LastName': 'Aujla', 'Affiliation': 'Orthopaedic Surgery, Leicester General Hospital, University Hospitals of Leicester, Leicester, England, UK. Electronic address: Randeep.aujla@hotmail.co.uk.'}, {'ForeName': 'Sheela', 'Initials': 'S', 'LastName': 'Vinay', 'Affiliation': ''}, {'ForeName': 'Felix N', 'Initials': 'FN', 'LastName': 'Fombon', 'Affiliation': 'Orthopaedic Surgery, Leicester General Hospital, University Hospitals of Leicester, Leicester, England, UK.'}, {'ForeName': 'Harvinder', 'Initials': 'H', 'LastName': 'Singh', 'Affiliation': 'Orthopaedic Surgery, Leicester General Hospital, University Hospitals of Leicester, Leicester, England, UK.'}, {'ForeName': 'Maneesh', 'Initials': 'M', 'LastName': 'Bhatia', 'Affiliation': 'Orthopaedic Surgery, Leicester General Hospital, University Hospitals of Leicester, Leicester, England, UK.'}]",Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons,['10.1016/j.fas.2018.11.012'] 850,29789969,Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.,"BACKGROUND In hormone receptor-positive advanced breast cancer, a progression-free survival benefit was reported with addition of bevacizumab to first-line letrozole. However, increased toxicity was observed. We hypothesized that functional age measures could be used to identify patients at risk for toxicity while receiving letrozole plus bevacizumab for hormone receptor-positive advanced breast cancer. METHODS CALGB 40503 was a phase III trial that enrolled patients with hormone receptor-positive advanced breast cancer randomized to letrozole with or without bevacizumab. Patients randomized to bevacizumab were approached to complete a validated assessment tool evaluating physical function, comorbidity, cognition, psychological state, social support, and nutritional status. The relationship between pretreatment assessment measures and the incidence of grade ≥ 3 (National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0) adverse events was determined. RESULTS One hundred thirteen (58%) of 195 patients treated with letrozole plus bevacizumab completed the pretreatment assessment questionnaire. One patient was excluded due to missing adverse event data. The median age of patients was 56. Frequently reported grade ≥ 3 adverse events were hypertension (26%), pain (20%), and proteinuria (7%). Two hemorrhagic events (one grade 5) and 1 thrombosis event occurred. Age ≥ 65 years (p < 0.01), decreased vision (p = 0.04), and poorer pretreatment physical function measures (p < 0.05) were found on univariate analysis to be significantly associated with increased incidence of grade ≥ 3 adverse events. Upon multivariate analysis, age ≥ 65 years (p = 0.01) and decreased vision (p = 0.04) remained significant. Univariable and multivariable logistic regression models demonstrated associations between age, vision, the ability to walk up flights of stairs, and grade ≥ 3 adverse events. CONCLUSIONS Age (≥ 65 years), decreased vision, and impairments in physical function correlated with increased incidence of toxicity in patients receiving first-line letrozole plus bevacizumab. When evaluating therapy likely to increase toxicity, functional assessment measures can identify patients at increased risk for side effects who may benefit from closer monitoring.",2018,"65 years (p < 0.01), decreased vision (p = 0.04), and poorer pretreatment physical function measures (p < 0.05) were found on univariate analysis to be significantly associated with increased incidence of grade ≥ 3 adverse events.","['One hundred thirteen (58%) of 195 patients treated with', 'Age\u2009≥', 'Age (≥', 'patients with hormone receptor-positive advanced breast cancer treated with', 'enrolled patients with hormone receptor-positive advanced breast cancer randomized to']","['bevacizumab plus letrozole', 'bevacizumab', 'letrozole plus bevacizumab', 'letrozole with or without bevacizumab']","['toxicity, functional assessment measures', 'decreased vision, and impairments in physical function', 'pain', 'physical function, comorbidity, cognition, psychological state, social support, and nutritional status', 'poorer pretreatment physical function measures', 'toxicity', 'incidence of grade\u2009≥\u20093 (National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0) adverse events', 'decreased vision']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0246421', 'cui_str': 'letrozole'}]","[{'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0451169', 'cui_str': 'Functional assessment measure (assessment scale)'}, {'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0037438'}, {'cui': 'C0392209', 'cui_str': 'Nutrition Status'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C1516728', 'cui_str': 'CTCAE (Common Terminology Criteria for Adverse Events)'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.0247561,"65 years (p < 0.01), decreased vision (p = 0.04), and poorer pretreatment physical function measures (p < 0.05) were found on univariate analysis to be significantly associated with increased incidence of grade ≥ 3 adverse events.","[{'ForeName': 'Daneng', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA, 91010, USA. danli@coh.org.'}, {'ForeName': 'Linda M', 'Initials': 'LM', 'LastName': 'McCall', 'Affiliation': 'Alliance Statistics and Data Center, Duke University, Durham, NC, USA.'}, {'ForeName': 'Olwen M', 'Initials': 'OM', 'LastName': 'Hahn', 'Affiliation': 'University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.'}, {'ForeName': 'Clifford A', 'Initials': 'CA', 'LastName': 'Hudis', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Harvey J', 'Initials': 'HJ', 'LastName': 'Cohen', 'Affiliation': 'Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Hyman B', 'Initials': 'HB', 'LastName': 'Muss', 'Affiliation': 'UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.'}, {'ForeName': 'Aminah', 'Initials': 'A', 'LastName': 'Jatoi', 'Affiliation': 'Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Jacqueline M', 'Initials': 'JM', 'LastName': 'Lafky', 'Affiliation': 'Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Karla V', 'Initials': 'KV', 'LastName': 'Ballman', 'Affiliation': 'Weill Medical College of Cornell University, New York, NY, USA.'}, {'ForeName': 'Eric P', 'Initials': 'EP', 'LastName': 'Winer', 'Affiliation': 'Dana-Farber/Partners CancerCare, Boston, MA, USA.'}, {'ForeName': 'Debu', 'Initials': 'D', 'LastName': 'Tripathy', 'Affiliation': 'MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Schneider', 'Affiliation': 'Indiana University Cancer Center, Indianapolis, IN, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Barry', 'Affiliation': 'Dana-Farber/Partners CancerCare, Boston, MA, USA.'}, {'ForeName': 'Maura N', 'Initials': 'MN', 'LastName': 'Dickler', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Arti', 'Initials': 'A', 'LastName': 'Hurria', 'Affiliation': 'Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA, 91010, USA.'}]",Breast cancer research and treatment,['10.1007/s10549-018-4828-5'] 851,30334934,Regional Versus General Anesthesia: Effect of Anesthetic Techniques on Clinical Outcome in Lumbar Spine Surgery: A Prospective Randomized Controlled Trial.,"BACKGROUND There are only a few prospective clinical trials investigating the effects of different anesthetic techniques on clinical outcomes after lumbar spine surgery. The purpose of this study was to evaluate clinical outcomes in patients receiving general (GA) and regional anesthesia (RA) for lumbar spine surgery. METHODS This was a single-center, 2-arm, trial in which 100 patients undergoing lumbar spine surgery were randomized to receive either RA or GA (50 per group). The primary endpoint was morphine consumption during the first postoperative 48 hours. In addition, anesthesia time, transition time (defined as time from end of surgery to admission to the postoperative anesthesia care unit), visual analogue scale (VAS) for pain, and patient satisfaction at hospital discharge were recorded. RESULTS There was no difference in the primary endpoint (cumulative morphine consumption at 48 h) between the 2 anesthesia types. Anesthesia and transition times were significantly shorter in the RA compared with the GA group-anesthesia time 125.4±23.6 minutes for GA versus 99.4±13.5 minutes for RA, transition time 22.5 minutes for GA versus 10.0 minutes for RA (both P<0.001). The VAS for pain on arrival to the postoperative anesthetic care unit was lower for patients who received RA compared with GA (crude and adjusted, both <0.001). 84% of patients in the RA group were completely satisfied compared with 74% in the GA group (P<0.001). There was a significant difference in the sex analysis for VAS for pain over time; females reported higher VAS for pain from the preoperative assessment to 6 weeks after the operation (P<0.001). CONCLUSIONS There was no difference in postoperative morphine consumption in patients receiving GA and RA for lumbar spine surgery. RA was associated with shorter anesthesia and transition times, lower VAS for pain at arrival at the postoperative anesthesia care unit, and higher patient satisfaction at hospital discharge.",2020,"Anesthesia and transition times were significantly shorter in the RA compared with the GA group-anesthesia time 125.4±23.6 minutes for GA versus 99.4±13.5 minutes for RA, transition time 22.5 minutes for GA versus 10.0 minutes for RA (both P<0.001).","['lumbar spine surgery', 'patients receiving GA and RA for lumbar spine surgery', '100 patients undergoing lumbar spine surgery', 'patients receiving general (GA) and regional anesthesia (RA) for lumbar spine surgery', 'Lumbar Spine Surgery']","['Anesthetic Techniques', 'Regional Versus General Anesthesia', 'RA or GA']","['morphine consumption', 'Anesthesia and transition times', 'shorter anesthesia and transition times, lower VAS for pain', 'postoperative morphine consumption', 'anesthesia time, transition time (defined as time from end of surgery to admission to the postoperative anesthesia care unit), visual analogue scale (VAS) for pain, and patient satisfaction at hospital discharge', 'primary endpoint (cumulative morphine consumption']","[{'cui': 'C3887615', 'cui_str': 'Lumbar spine structure (body structure)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0002911', 'cui_str': 'Anesthesia, Regional'}]","[{'cui': 'C0002930', 'cui_str': 'Anesthesiology'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0002915', 'cui_str': 'General Anesthesia'}]","[{'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0034871', 'cui_str': 'Hospital Recovery Rooms'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}]",100.0,0.165003,"Anesthesia and transition times were significantly shorter in the RA compared with the GA group-anesthesia time 125.4±23.6 minutes for GA versus 99.4±13.5 minutes for RA, transition time 22.5 minutes for GA versus 10.0 minutes for RA (both P<0.001).","[{'ForeName': 'Bertram', 'Initials': 'B', 'LastName': 'Baenziger', 'Affiliation': 'Clinic of Anesthesiology, Intensive Care Medicine and Pain Therapy.'}, {'ForeName': 'Najia', 'Initials': 'N', 'LastName': 'Nadi', 'Affiliation': 'Center of Neuro- and Spine Surgery, Hirslanden Klinik St. Anna Lucerne.'}, {'ForeName': 'Ramon', 'Initials': 'R', 'LastName': 'Doerig', 'Affiliation': 'Clinic of Anesthesiology, Intensive Care Medicine and Pain Therapy.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Proemmel', 'Affiliation': 'Center of Neuro- and Spine Surgery, Hirslanden Klinik St. Anna Lucerne.'}, {'ForeName': 'Brigitta', 'Initials': 'B', 'LastName': 'Gahl', 'Affiliation': 'Clinical Trial Unit Berne, University Berne, Switzerland.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Hodel', 'Affiliation': 'Clinic of Anesthesiology, Intensive Care Medicine and Pain Therapy.'}, {'ForeName': 'Oliver N', 'Initials': 'ON', 'LastName': 'Hausmann', 'Affiliation': 'Center of Neuro- and Spine Surgery, Hirslanden Klinik St. Anna Lucerne.'}]",Journal of neurosurgical anesthesiology,['10.1097/ANA.0000000000000555'] 852,32061417,Effects of Kinesio Taping on Post-Needling Induced Pain After Dry Needling of Active Trigger Point in Individuals With Mechanical Neck Pain.,"OBJECTIVE The purpose of this study was to assess the effectiveness of the application of kinesio taping in reducing induced pain after dry needling of active trigger points (TrPs) to the upper trapezius muscle. METHODS Consecutive patients had mechanical neck pain (n = 34, 44% female) with active TrPs in the upper trapezius muscle. All participants received dry needling into upper trapezius active TrPs. Then, they were randomly divided into a kinesio taping group, which received an adhesive tape (Kinesio Tex), and a control group, which did not receive the taping. The numeric pain rating scale was assessed (0-10) at post-needling; immediately after; and 24 hours, 48 hours, and 72 hours after needling. Neck- and shoulder-related disability was assessed before and 72 hours after needling with the Neck Disability Index (NDI) and the Shoulder Pain and Disability Index, respectively. The pressure pain threshold (PPT) over the TrP was also assessed post-needling, immediately post-intervention, and 72 hours after needling. RESULTS The analysis of covariance did not find a significant group × time interaction (P = .26) for post-needling soreness: both groups exhibited similar changes in post-needling induced pain (P < .001). No significant group × time interactions were observed for changes in NDI (P = .62), SPADI (P = .41), or PPTs (P = .52): similar improvements were found after the needling procedure for the NDI (P < .001), Shoulder Pain and Disability Index (P < .001), and PPT (P < .001). The number of local twitch responses and sex (all, P > .30) did not influence the effect for any outcome. CONCLUSION The application of kinesio taping after dry needling of active TrPs in the upper trapezius muscle was not effective for reducing post-needling induced pain in people with mechanical neck pain. Further, the application of kinesio taping as a post-needling intervention did not influence short-term changes in disability.",2020,The analysis of covariance did not find a significant group × time interaction (P = .26) for post-needling soreness: both groups exhibited similar changes in post-needling induced pain (P < .001).,"['Individuals With Mechanical Neck Pain', 'Consecutive patients had mechanical neck pain (n\xa0= 34, 44% female) with active TrPs in the upper trapezius muscle', 'people with mechanical neck pain']","['kinesio taping group, which received an adhesive tape (Kinesio Tex), and a control group, which did not receive the taping', 'dry needling into upper trapezius active TrPs', 'kinesio taping', 'Kinesio Taping']","['pressure pain threshold (PPT', 'numeric pain rating scale', 'Neck Disability Index (NDI) and the Shoulder Pain and Disability Index', 'SPADI', 'disability', 'changes in NDI', 'number of local twitch responses and sex', 'Pain', 'pain', 'Neck- and shoulder-related disability', 'Shoulder Pain and Disability Index']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}, {'cui': 'C0007859', 'cui_str': 'Neck Ache'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0224361', 'cui_str': 'Trapezius'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0001514', 'cui_str': 'Adhesive tape, device (physical object)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0394648', 'cui_str': 'Dry needle acupuncture (procedure)'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0224361', 'cui_str': 'Trapezius'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}]","[{'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0162703', 'cui_str': 'Pain Threshold'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0222045'}, {'cui': 'C0027536', 'cui_str': 'Necking (finding)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0037011', 'cui_str': 'Shoulder Pain'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0231530', 'cui_str': 'Muscle twitch (finding)'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0037004', 'cui_str': 'Shoulder'}]",,0.0912431,The analysis of covariance did not find a significant group × time interaction (P = .26) for post-needling soreness: both groups exhibited similar changes in post-needling induced pain (P < .001).,"[{'ForeName': 'Jose Luis', 'Initials': 'JL', 'LastName': 'Arias-Buría', 'Affiliation': 'Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, Alcorcón, Spain.'}, {'ForeName': 'María M', 'Initials': 'MM', 'LastName': 'Franco-Hidalgo-Chacón', 'Affiliation': 'Department of Physical Therapy, Universidad Francisco de Vitoria, Madrid, Spain.'}, {'ForeName': 'Joshua A', 'Initials': 'JA', 'LastName': 'Cleland', 'Affiliation': 'Department of Physical Therapy, Franklin Pierce University, Manchester, New Hampshire.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Palacios-Ceña', 'Affiliation': 'Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, Alcorcón, Spain.'}, {'ForeName': 'Stella', 'Initials': 'S', 'LastName': 'Fuensalida-Novo', 'Affiliation': 'Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, Alcorcón, Spain.'}, {'ForeName': 'César', 'Initials': 'C', 'LastName': 'Fernández-de-Las-Peñas', 'Affiliation': 'Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, Alcorcón, Spain. Electronic address: cesarfdlp@yahoo.es.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2019.02.011'] 853,30479060,"Comparison of the efficacy and safety of povidone-iodine foam dressing (Betafoam), hydrocellular foam dressing (Allevyn), and petrolatum gauze for split-thickness skin graft donor site dressing.","We evaluated the efficacy and safety of a povidone-iodine (PVP-I) foam dressing (Betafoam) for donor site dressing versus a hydrocellular foam dressing (Allevyn) and petrolatum gauze. This prospective Phase 4 study was conducted between March 2016 and April 2017 at eight sites in Korea. A total of 106 consenting patients (aged ≥ 19 years, scheduled for split-thickness skin graft) were randomised 1:1:1 to PVP-I foam, hydrocellular, or petrolatum gauze dressings for up to 28 days after donor site collection. We assessed time to complete epithelialisation, proportion with complete epithelialisation at Day 14, and wound infection. Epithelialisation time was the shortest with PVP-I foam dressing (12.74 ± 3.51 days) versus hydrocellular foam dressing (16.61 ± 4.45 days; P = 0.0003) and petrolatum gauze (15.06 ± 4.26 days, P = 0.0205). At Day 14, 83.87% of PVP-I foam dressing donor sites had complete epithelialisation, versus 36.36% of hydrocellular foam dressing donor sites (P = 0.0001) and 55.88% of petrolatum gauze donor sites (P = 0.0146). There were no wound infections. Incidence rates of adverse events were comparable across groups (P = 0.1940). PVP-I foam dressing required less time to complete epithelialisation and had a good safety profile.",2019,Epithelialisation time was the shortest with PVP-,"['106 consenting patients (aged ≥ 19 years, scheduled for split-thickness skin graft', 'March 2016 and April 2017 at eight sites in Korea']","['povidone-iodine foam dressing (Betafoam), hydrocellular foam dressing (Allevyn), and petrolatum gauze for split-thickness skin graft donor site dressing', 'povidone-iodine (PVP-I) foam dressing (Betafoam', 'I foam, hydrocellular, or petrolatum gauze dressings', 'hydrocellular foam dressing (Allevyn) and petrolatum gauze', 'PVP']","['time to complete epithelialisation', 'wound infections', 'time to complete epithelialisation, proportion with complete epithelialisation at Day 14, and wound infection', 'Epithelialisation time', 'efficacy and safety', 'Incidence rates of adverse events', 'complete epithelialisation']","[{'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0439061', 'cui_str': 'Split thickness skin transplantation'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0022771', 'cui_str': 'Korea'}]","[{'cui': 'C0032857', 'cui_str': 'Povidone-Iodine'}, {'cui': 'C3164124', 'cui_str': 'Foam dressing'}, {'cui': 'C0031262', 'cui_str': 'Petrolatum'}, {'cui': 'C0590323', 'cui_str': 'Gauzes (physical object)'}, {'cui': 'C0439061', 'cui_str': 'Split thickness skin transplantation'}, {'cui': 'C1444716', 'cui_str': 'Donor site (attribute)'}, {'cui': 'C0013119', 'cui_str': 'Dressings'}, {'cui': 'C0991510', 'cui_str': 'Foam (basic dose form)'}, {'cui': 'C3266204', 'cui_str': 'Petrolatum gauze dressing'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0334029', 'cui_str': 'Epithelialization (morphologic abnormality)'}, {'cui': 'C0043241', 'cui_str': 'Wound Infection'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",106.0,0.0278509,Epithelialisation time was the shortest with PVP-,"[{'ForeName': 'Chang Sik', 'Initials': 'CS', 'LastName': 'Pak', 'Affiliation': 'Seoul National University Bundang Hospital, Seoul, South Korea.'}, {'ForeName': 'Dae Hwan', 'Initials': 'DH', 'LastName': 'Park', 'Affiliation': 'Daegu Catholic University Medical Center, Seoul, South Korea.'}, {'ForeName': 'Tae Suk', 'Initials': 'TS', 'LastName': 'Oh', 'Affiliation': 'Asan Medical Center, Seoul, South Korea.'}, {'ForeName': 'Won Jai', 'Initials': 'WJ', 'LastName': 'Lee', 'Affiliation': 'Severance Hospital, Yonsei University Health System, Seoul, South Korea.'}, {'ForeName': 'Young Joon', 'Initials': 'YJ', 'LastName': 'Jun', 'Affiliation': ""Seoul St. Mary's Hospital, The Catholic University of South Korea, Seoul, South Korea.""}, {'ForeName': 'Kyung Ah', 'Initials': 'KA', 'LastName': 'Lee', 'Affiliation': 'Inje University Haeundae Paik Hospital, Seoul, South Korea.'}, {'ForeName': 'Kap Sung', 'Initials': 'KS', 'LastName': 'Oh', 'Affiliation': 'Samsung Medical Center, Seoul, South Korea.'}, {'ForeName': 'Kyung Hee', 'Initials': 'KH', 'LastName': 'Kwak', 'Affiliation': 'Mundipharma Korea Ltd, Seoul, South Korea.'}, {'ForeName': 'Jong Won', 'Initials': 'JW', 'LastName': 'Rhie', 'Affiliation': ""Seoul St. Mary's Hospital, The Catholic University of South Korea, Seoul, South Korea.""}]",International wound journal,['10.1111/iwj.13043'] 854,30466891,"Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.","BACKGROUND Glutathione S-transferase 1 (GSTP1) expression is inactivated in >90% of all prostate cancers in association with aberrant DNA methylation. Detection of serum free methylated GSTP1 (mGSTP1) DNA is associated with overall survival (OS) and response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC) in test and internal validation cohorts. OBJECTIVE To assess the relationship between serum free mGSTP1 and treatment outcomes in SYNERGY, a phase 3 multicentre randomised trial testing the addition of custirsen to first-line chemotherapy with docetaxel in mCRPC. DESIGN, SETTING, AND PARTICIPANTS Serum free mGSTP1 DNA was measured by a sensitive methylation-specific polymerase chain reaction assay in paired samples (baseline and after two cycles of docetaxel) from 600 patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Associations between serum free mGSTP1 at baseline, change in mGSTP1 after docetaxel, OS, and time to prostate-specific antigen (PSA) progression were examined using Cox proportional hazards models and Kaplan-Meier methods. RESULTS AND LIMITATIONS Serum free mGSTP1 was detectable at baseline in 458 (81%) patients. Of those with detectable mGSTP1 at baseline, mGSTP1 became undetectable after two cycles in 243 (53%). Undetectable mGSTP1 at baseline was associated with longer OS (hazard ratio [HR] 0.4, 95% confidence interval [CI] 0.29-0.55; p<0.00001). The event of mGSTP1 becoming undetectable after two cycles of chemotherapy was associated with longer OS (HR 0.36, 95% CI 0.29-0.46; p<0.00001) and longer time to PSA progression (HR 0.44, 95% CI 0.35-0.56; p<0.00001). Associations between mGSTP1 and clinical outcomes were independent of other established prognostic variables. Analysis was limited by the lack of radiographic progression-free survival data. CONCLUSIONS This is the first study to externally validate the prognostic role of a circulating epigenetic biomarker in mCRPC. Further studies are needed to validate serum free mGSTP1 as a surrogate endpoint for clinical trials and as a potential clinical decision tool. PATIENT SUMMARY In this study, we confirmed that a blood marker predicted outcomes after chemotherapy for metastatic prostate cancer. This marker may accelerate future clinical trials of new therapies and be useful in the clinic to guide treatment decisions.",2019,"Detection of serum free methylated GSTP1 (mGSTP1) DNA is associated with overall survival (OS) and response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC) in test and internal validation cohorts. ","['600 patients', 'metastatic prostate cancer']","['custirsen to first-line chemotherapy with docetaxel', 'docetaxel']","['longer time to PSA progression', 'Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer', 'Serum free mGSTP1', 'radiographic progression-free survival data', 'mGSTP1 after docetaxel, OS, and time to prostate-specific antigen (PSA) progression']","[{'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1282496', 'cui_str': 'Metastasis from malignant tumor of prostate'}]","[{'cui': 'C4079860'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}]","[{'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0201544', 'cui_str': 'Prostate specific antigen measurement (procedure)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0017837', 'cui_str': 'Glutathione Organic Nitrate Ester Reductase'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1328504', 'cui_str': 'Castration-resistant prostate cancer'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0138741', 'cui_str': 'gamma-Seminoprotein'}]",600.0,0.274201,"Detection of serum free methylated GSTP1 (mGSTP1) DNA is associated with overall survival (OS) and response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC) in test and internal validation cohorts. ","[{'ForeName': 'Kate L', 'Initials': 'KL', 'LastName': 'Mahon', 'Affiliation': ""Chris O'Brien Lifehouse, Sydney, Australia; Garvan Institute of Medical Research, Sydney, Australia; University of NSW, Sydney, Australia; University of Sydney, Sydney, Australia.""}, {'ForeName': 'Wenjia', 'Initials': 'W', 'LastName': 'Qu', 'Affiliation': 'Garvan Institute of Medical Research, Sydney, Australia.'}, {'ForeName': 'Hui-Ming', 'Initials': 'HM', 'LastName': 'Lin', 'Affiliation': 'Garvan Institute of Medical Research, Sydney, Australia; University of NSW, Sydney, Australia.'}, {'ForeName': 'Calan', 'Initials': 'C', 'LastName': 'Spielman', 'Affiliation': 'Garvan Institute of Medical Research, Sydney, Australia.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Cain', 'Affiliation': 'Oncogenex Pharmaceuticals Inc., Bothell, WA, USA.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Jacobs', 'Affiliation': 'Oncogenex Pharmaceuticals Inc., Bothell, WA, USA.'}, {'ForeName': 'Martin R', 'Initials': 'MR', 'LastName': 'Stockler', 'Affiliation': ""Chris O'Brien Lifehouse, Sydney, Australia; University of Sydney, Sydney, Australia; National Health and Medical Research Council Clinical Trials Centre, Sydney, Australia.""}, {'ForeName': 'Celestia S', 'Initials': 'CS', 'LastName': 'Higano', 'Affiliation': 'University of Washington, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA.'}, {'ForeName': 'Johann S', 'Initials': 'JS', 'LastName': 'de Bono', 'Affiliation': 'Royal Marsden Hospital and Institute of Cancer Research, London, UK.'}, {'ForeName': 'Kim N', 'Initials': 'KN', 'LastName': 'Chi', 'Affiliation': 'University of British Columbia, BC Cancer Agency, Vancouver Prostate Centre, Vancouver, BC, Canada.'}, {'ForeName': 'Susan J', 'Initials': 'SJ', 'LastName': 'Clark', 'Affiliation': 'Garvan Institute of Medical Research, Sydney, Australia; University of NSW, Sydney, Australia.'}, {'ForeName': 'Lisa Glen', 'Initials': 'LG', 'LastName': 'Horvath', 'Affiliation': ""Chris O'Brien Lifehouse, Sydney, Australia; Garvan Institute of Medical Research, Sydney, Australia; University of NSW, Sydney, Australia; University of Sydney, Sydney, Australia. Electronic address: lisa.horvath@lh.org.au.""}]",European urology,['10.1016/j.eururo.2018.11.001'] 855,30339035,"The Effect of Diet-Exercise Trainings Provided to Overweight and Obese Teenagers through Creative Drama on Their Knowledge, Attitude, and Behaviors.","BACKGROUND This study was conducted in Turkey as an empirical study in randomized, controlled, and time series design for the purpose of evaluating the effects of the Diet-Exercise trainings with creative drama method provided to overweight/obese teenagers. METHODS This study was designed to highlight the effect of interactive education provided to slightly overweight/obese teenagers through creative drama on modifiable factors that caused obesity. Seventy-six overweight/obese teenagers studying at sixth and seventh grades of upper primary education were included in the study (38 participants in the Study Group and 38 participants in the Control Group). Training courses that were designed based on creative drama method were implemented in five sessions with teenager groups (n = 12-13); and the mothers were also trained in a session in this study (for the Study Group). RESULTS At the end of the study, it was determined that the knowledge, attitude, the order of the meals, and healthy diet-exercise behavior points of the teenagers in the Study Group increased; and the difference between the Study Group and the Control Group was significant (p < 0.05). The BMI, body weight, and waist/height rate of the teenagers in the Study Group decreased at a significant level after the study was completed (p < 0.05); and significant increases were determined in the waist circumference and body weight measurements of the Control Group (p < 0.05). CONCLUSIONS As a conclusion, overweight/obese teenagers may be reached with school-based educational programs, and they may be made to acquire positive attitudes and behaviors through diet and exercises designed with interactive methods like creative drama.",2019,This study was designed to highlight the effect of interactive education provided to slightly overweight/obese teenagers through creative drama on modifiable factors that caused obesity.,"['Seventy-six overweight/obese teenagers studying at sixth and seventh grades of upper primary education were included in the study (38 participants in the Study Group and 38 participants in the Control Group', 'overweight/obese teenagers', 'Overweight and Obese Teenagers']","['Diet-Exercise Trainings', 'Diet-Exercise trainings', 'interactive education']","['BMI, body weight, and waist/height rate of the teenagers', 'waist circumference and body weight measurements']","[{'cui': 'C4319622', 'cui_str': 'Seventy-six'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1521910', 'cui_str': 'Teens'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205440', 'cui_str': 'Sixth (qualifier value)'}, {'cui': 'C0205441', 'cui_str': 'Seventh (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0230097', 'cui_str': 'Waist (surface region)'}, {'cui': 'C1521910', 'cui_str': 'Teens'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}]",76.0,0.0238316,This study was designed to highlight the effect of interactive education provided to slightly overweight/obese teenagers through creative drama on modifiable factors that caused obesity.,"[{'ForeName': 'Mukaddes', 'Initials': 'M', 'LastName': 'Demir Acar', 'Affiliation': '1 Nursing Department, Faculty of Health Sciences, Tokat Gaziosmanpasa University, Tokat, Turkey.'}, {'ForeName': 'Meral', 'Initials': 'M', 'LastName': 'Bayat', 'Affiliation': '3 Nursing Department, Faculty of Health Sciences, Erciyes University, Kayseri, Turkey.'}]",Childhood obesity (Print),['10.1089/chi.2018.0046'] 856,30114712,Bilateral Paravertebral Block versus Thoracic Epidural Analgesia for Pain Control Post-Cardiac Surgery: A Randomized Controlled Trial.,"BACKGROUND Adequate pain control after cardiac surgery is essential. Paravertebral block is a simple technique and avoids the potential complications of epidural catheters. The objective of this study is to compare the effect of ultrasound-guided bilateral thoracic paravertebral block with thoracic epidural block on pain control after cardiac surgery. MATERIALS AND METHODS Between March 2016 and 2017, 145 patients who had cardiac surgery through median sternotomy were randomized by stratified blocked randomization into two groups. Group I ( n  = 70 patients) had bilateral ultrasound-guided thoracic paravertebral block and Group II ( n  = 75 patients) had thoracic epidural analgesia. The primary end point was the postoperative visual analogue scale (VAS). The duration of mechanical ventilation, intensive care unit (ICU), and hospital stay were the secondary end points. The study design is a randomized parallel superiority clinical trial. RESULTS Both groups had similar preoperative and operative characteristics. No significant difference in VAS measured immediately after endotracheal extubation then after 12, 24, and 48 hours between groups ( p  = 0.45). Pain score significantly declined with the repeated measures ( p  < 0.001) and the decline was not related to the treatment group. Postoperative pain was significantly related to diabetes mellitus ( p  = 0.039). Six patients in group I (8.5%) required an additional dose of morphine versus three patients (4%) in group II ( p  = 0.30). Patients in group I had significantly shorter ICU stay ( p  = 0.005) and lower incidence of urinary retention ( p  = 0.04) and vomiting ( p  = 0.018). No difference was found in operative complications between groups. CONCLUSION This randomized parallel controlled trial demonstrates that ultrasound-guided paravertebral block is safe and effective method for relieving post-cardiac surgery sternotomy pain compared with thoracic epidural analgesia but not superior to it.",2020,Patients in group I had significantly shorter ICU stay ( p  = 0.005) and lower incidence of urinary retention ( p  = 0.04) and vomiting ( p  = 0.018).,"['Six patients in group', '145 patients who had cardiac surgery through median sternotomy', 'Between March 2016 and 2017', 'Pain Control Post-Cardiac Surgery']","['ultrasound-guided paravertebral block', 'bilateral ultrasound-guided thoracic paravertebral block and Group II', 'ultrasound-guided bilateral thoracic paravertebral block with thoracic epidural block', 'morphine', 'Bilateral Paravertebral Block versus Thoracic Epidural Analgesia', 'thoracic epidural analgesia']","['vomiting', 'operative complications', 'diabetes mellitus', 'postoperative visual analogue scale (VAS', 'shorter ICU stay', 'Postoperative pain', 'urinary retention', 'VAS', 'pain control', 'thoracic epidural analgesia', 'Pain score', 'duration of mechanical ventilation, intensive care unit (ICU), and hospital stay']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C1282959', 'cui_str': 'Median Sternotomy'}, {'cui': 'C1304888', 'cui_str': 'Pain control (procedure)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]","[{'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0442150', 'cui_str': 'Paravertebral (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0394835', 'cui_str': 'Local anesthetic thoracic epidural block (procedure)'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0002769', 'cui_str': 'Analgesia, Epidural'}]","[{'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0080274', 'cui_str': 'Urinary Retention'}, {'cui': 'C1304888', 'cui_str': 'Pain control (procedure)'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0002769', 'cui_str': 'Analgesia, Epidural'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",,0.112836,Patients in group I had significantly shorter ICU stay ( p  = 0.005) and lower incidence of urinary retention ( p  = 0.04) and vomiting ( p  = 0.018).,"[{'ForeName': 'Hatem A', 'Initials': 'HA', 'LastName': 'El Shora', 'Affiliation': 'Anesthesia and Surgical ICU Department, Faculty of Medicine-Tanta University, Tanta, Gharbeya, Egypt.'}, {'ForeName': 'Ahmed A', 'Initials': 'AA', 'LastName': 'El Beleehy', 'Affiliation': 'Anesthesia and Surgical ICU Department, Faculty of Medicine-Tanta University, Tanta, Gharbeya, Egypt.'}, {'ForeName': 'Amr A', 'Initials': 'AA', 'LastName': 'Abdelwahab', 'Affiliation': 'Department of Cardiothoracic Surgery, Faculty of Medicine-Tanta University, Tanta, Gharbeya, Egypt.'}, {'ForeName': 'Gaser A', 'Initials': 'GA', 'LastName': 'Ali', 'Affiliation': 'Department of Cardiothoracic Surgery, Faculty of Medicine- Zagazig University, Zagazig, Sharkia, Egypt.'}, {'ForeName': 'Tarek E', 'Initials': 'TE', 'LastName': 'Omran', 'Affiliation': 'Department of Cardiothoracic Surgery, Faculty of Medicine-Tanta University, Tanta, Gharbeya, Egypt.'}, {'ForeName': 'Essam A', 'Initials': 'EA', 'LastName': 'Hassan', 'Affiliation': 'Department of Cardiothoracic Surgery, Faculty of Medicine-Tanta University, Tanta, Gharbeya, Egypt.'}, {'ForeName': 'Amr A', 'Initials': 'AA', 'LastName': 'Arafat', 'Affiliation': 'Department of Cardiothoracic Surgery, Faculty of Medicine-Tanta University, Tanta, Gharbeya, Egypt.'}]",The Thoracic and cardiovascular surgeon,['10.1055/s-0038-1668496'] 857,29882170,Laparoscopic versus hybrid approach for treatment of incisional ventral hernia: a prospective randomized multicenter study of 1-month follow-up results.,"PURPOSE The seroma rate following laparoscopic incisional ventral hernia repair (LIVHR) is up to 78%. LIVHR is connected to a relatively rare but dangerous complication, enterotomy, especially in cases with complex adhesiolysis. Closure of the fascial defect and extirpation of the hernia sack may reduce the risk of seromas and other hernia-site events. Our aim was to evaluate whether hybrid operation has a lower rate of the early complications compared to the standard LIVHR. METHODS This is a multicenter randomized-controlled clinical trial. From November 2012 to May 2015, 193 patients undergoing LIVHR for primary incisional hernia with fascial defect size from 2 to 7 cm were recruited in 11 Finnish hospitals. Patients were randomized to either a laparoscopic (LG) or to a hybrid (HG) repair group. The outcome measures were the incidence of clinically and radiologically detected seromas and their extent 1 month after surgery, peri/postoperative complications, and pain. RESULTS Bulging was observed by clinical evaluation in 46 (49%) LG patients and in 27 (31%) HG patients (p = 0.022). Ultrasound examination detected more seromas (67 vs. 45%, p = 0.004) and larger seromas (471 vs. 112 cm 3 , p = 0.025) after LG than after HG. In LG, there were 5 (5.3%) enterotomies compared to 1 (1.1%) in HG (p = 0.108). Adhesiolysis was more complex in LG than in HG (26.6 vs. 13.3%, p = 0.028). Patients in HG had higher pain scores on the first postoperative day (VAS 5.2 vs. 4.3, p = 0.019). CONCLUSION Closure of the fascial defect and extirpation of the hernia sack reduce seroma formation. In hybrid operations, the risk of enterotomy seems to be lower than in laparoscopic repair, which should be considered in cases with complex adhesions. CLINICAL TRIAL NUMBER NCT02542085.",2018,"Ultrasound examination detected more seromas (67 vs. 45%, p = 0.004) and larger seromas (471 vs. 112 cm 3 , p = 0.025) after LG than after HG.","['From November 2012 to May 2015, 193 patients undergoing LIVHR for primary incisional hernia with fascial defect size from 2 to 7\xa0cm were recruited in 11 Finnish hospitals', 'incisional ventral hernia']","['hybrid operation', 'laparoscopic incisional ventral hernia repair (LIVHR', 'laparoscopic (LG) or to a hybrid (HG) repair group', 'Laparoscopic versus hybrid approach']","['incidence of clinically and radiologically detected seromas and their extent 1\xa0month after surgery, peri/postoperative complications, and pain', 'seroma rate', 'pain scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0267716', 'cui_str': 'Postoperative Hernia'}, {'cui': 'C0015641', 'cui_str': 'Fascia'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0019326', 'cui_str': 'Ventral Hernia'}]","[{'cui': 'C0020205', 'cui_str': 'Hybrids'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C0019334', 'cui_str': 'Repair of ventral hernia (procedure)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0442726', 'cui_str': 'Detected (qualifier value)'}, {'cui': 'C0262627', 'cui_str': 'Seroma'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C0032787', 'cui_str': 'Postoperative Complications'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}]",193.0,0.153366,"Ultrasound examination detected more seromas (67 vs. 45%, p = 0.004) and larger seromas (471 vs. 112 cm 3 , p = 0.025) after LG than after HG.","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ahonen-Siirtola', 'Affiliation': 'Division of Gastroenterology, Department of Surgery, Oulu University Hospital, PL 21, 90029, Oulu, Finland. mirella.ahonen@oulu.fi.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Nevala', 'Affiliation': 'Department of Radiology, Oulu University Hospital, Oulu, Finland.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Vironen', 'Affiliation': 'Department of Surgery, Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Kössi', 'Affiliation': 'Department of Surgery, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Pinta', 'Affiliation': 'Department of Surgery, Seinäjoki Central Hospital, Seinäjoki, Finland.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Niemeläinen', 'Affiliation': 'Department of Surgery, Valkeakoski Regional Hospital, Valkeakoski, Finland.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Keränen', 'Affiliation': 'Department of Surgery, Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ward', 'Affiliation': 'Department of Surgery, Päijät-Häme Central Hospital, Lahti, Finland.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Vento', 'Affiliation': 'Department of Surgery, Kymenlaakso Central Hospital, Kotka, Finland.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Karvonen', 'Affiliation': 'Department of Surgery, Turku University Hospital, Turku, Finland.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Ohtonen', 'Affiliation': 'Division of Gastroenterology, Department of Surgery, Oulu University Hospital, PL 21, 90029, Oulu, Finland.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Mäkelä', 'Affiliation': 'Division of Gastroenterology, Department of Surgery, Oulu University Hospital, PL 21, 90029, Oulu, Finland.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Rautio', 'Affiliation': 'Division of Gastroenterology, Department of Surgery, Oulu University Hospital, PL 21, 90029, Oulu, Finland.'}]",Hernia : the journal of hernias and abdominal wall surgery,['10.1007/s10029-018-1784-2'] 858,29861177,A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands.,"BACKGROUND We conducted a post-hoc analysis of a double blind, randomized, placebo-controlled trial of 13-valent pneumococcal conjugate vaccine (PCV13) among adults aged 65 years or older to assess public health impact. METHODS For all outcomes, we included all randomized subjects, using a modified intention-to-treat (mITT) approach to determine vaccine efficacy (VE), vaccine preventable disease incidence (VPDI) defined as control minus vaccinated group incidence, and numbers needed to vaccinate (NNV) (based on a five-year duration of protection). RESULTS Results are reported for, in order, clinical, adjudicated (clinical plus radiologic infiltrate determined by committee), pneumococcal, and vaccine-type pneumococcal (VT-Sp) community-acquired pneumonia; invasive pneumococcal disease (IPD) and VT-IPD. VEs (95% CI) for all hospital episodes were 8.1% (-0.6%, 16.1%), 6.7% (-4.1%, 16.3%), 22.2% (2.0%, 38.3%), 37.5% (14.3%, 54.5%), 49.3% (23.2%, 66.5%), and 75.8% (47.6%, 88.8%). VPDIs per 100,000 person-years of observation (PYOs) were 72, 37, 25, 25, 20, and 15 with NNVs of 277, 535, 816, 798, 1016, and 1342. For clinical CAP, PCV13 was associated with a reduction of 909 (-115, 2013) hospital days per 100,000 PYOs translating to a reduction over 5 years of one hospital day for every 22 people vaccinated. When comparing at-risk persons (defined by self-report of diabetes, chronic lung disease, or other underlying conditions) to not at-risk persons, VEs were similar or lower, but because baseline incidences were higher the VPDIs were approximately 2-10 times higher and NNVs 50-90% lower. CONCLUSION A public health analysis of pneumonia and IPD outcomes in a randomized controlled trial found substantial burden reduction following adult PCV13 immunization implemented in a setting with an ongoing infant PCV7-PCV10 program. VPDIs were higher among at-risk adults. FUNDING The original study and the current analysis were funded by Pfizer.",2019,"For clinical CAP, PCV13 was associated with a reduction of 909 (-115, 2013) hospital days per 100,000 PYOs translating to a reduction over 5 years of one hospital day for every 22 people vaccinated.",['adults aged 65\u202fyears or older to assess public health impact'],"['placebo', '13-valent pneumococcal conjugate vaccine (PCV13', 'modified intention-to-treat (mITT) approach']","['vaccine efficacy (VE), vaccine preventable disease incidence (VPDI', 'VPDIs', 'hospital episodes']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1579319', 'cui_str': 'Streptococcus pneumoniae conjugate vaccine'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}]","[{'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C1547273', 'cui_str': 'Preventable'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}]",,0.533032,"For clinical CAP, PCV13 was associated with a reduction of 909 (-115, 2013) hospital days per 100,000 PYOs translating to a reduction over 5 years of one hospital day for every 22 people vaccinated.","[{'ForeName': 'Bradford D', 'Initials': 'BD', 'LastName': 'Gessner', 'Affiliation': 'Pfizer Vaccines, Collegeville, PA, USA. Electronic address: Bradford.gessner@Pfizer.com.'}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Jiang', 'Affiliation': 'Pfizer Vaccines, Collegeville, PA, USA.'}, {'ForeName': 'Cornelis H', 'Initials': 'CH', 'LastName': 'Van Werkhoven', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands.'}, {'ForeName': 'Heather L', 'Initials': 'HL', 'LastName': 'Sings', 'Affiliation': 'Pfizer Vaccines, Collegeville, PA, USA.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Webber', 'Affiliation': 'Pfizer Vaccines, Collegeville, PA, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Scott', 'Affiliation': 'Pfizer Vaccines, Collegeville, PA, USA.'}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Neuzil', 'Affiliation': 'Centers for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': ""O'Brien"", 'Affiliation': 'Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Richard G', 'Initials': 'RG', 'LastName': 'Wunderink', 'Affiliation': 'Department of Medicine, Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Diederick E', 'Initials': 'DE', 'LastName': 'Grobbee', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands; Julius Clinical, Academic Contract Research Organization, Zeist, The Netherlands.'}, {'ForeName': 'Marc J M', 'Initials': 'MJM', 'LastName': 'Bonten', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Jodar', 'Affiliation': 'Pfizer Vaccines, Collegeville, PA, USA.'}]",Vaccine,['10.1016/j.vaccine.2018.05.097'] 859,31658113,"A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of a Nicotine Mint Lozenge (2 and 4 mg) in Smoking Cessation.","OBJECTIVE To evaluate the efficacy in smoking cessation and safety of 2 and 4 mg nicotine mint lozenges in Chinese adult smokers. METHODS This was a multicenter, randomized, stratified, double-blind, placebo-controlled, parallel-group study. The low-dependence stratum included 483 smokers (241 randomized to active 2 mg nicotine lozenge and 242 to placebo lozenge). The high-dependence stratum included 240 smokers (120 randomized to active 4 mg nicotine lozenge and 120 to placebo lozenge). The primary endpoint was successful smoking cessation at 6 weeks postquit, defined as continuous abstinence from smoking for the 28-day period up to and including the 6-week visit (verified by CO measurement). Cochran-Mantel-Haenszel tests were performed to compare quit rates between active nicotine and placebo separately for the high-dependence and low-dependence strata. RESULTS The primary analysis showed that in the low-dependence (2 mg) stratum, 59 subjects (24.5%) of 241 in the active nicotine group and 52 subjects (21.5%) of 242 in the placebo group were successful quitters (P = .3851). In the high-dependence (4 mg) stratum, 37 subjects (30.8%) of 120 in the active nicotine group and 24 subjects (20.2%) of 119 in the placebo group were successful quitters (P = .0565). CONCLUSIONS The 4 mg nicotine lozenge provided a directionally significant improvement in smoking cessation rates compared with placebo in Chinese adult smokers with high nicotine dependence for the primary endpoint. The 2 mg nicotine lozenge provided higher, but nonsignificant, smoking cessation rates than placebo. Both nicotine lozenges were generally well tolerated in Chinese adult smokers.",2020,The 4 mg nicotine lozenge provided a directionally significant improvement in smoking cessation rates compared with placebo in Chinese adult smokers with high nicotine dependence for the primary endpoint.,"['240 smokers (120 randomized to active 4\u200amg', 'Chinese adult smokers', '483 smokers (241 randomized to active 2\u200amg']","['Placebo', 'nicotine mint lozenges', 'placebo', 'nicotine lozenges', 'nicotine and placebo', 'Nicotine Mint Lozenge ', 'nicotine lozenge']","['tolerated', 'smoking cessation rates', 'successful quitters', 'low-dependence', 'Efficacy and Safety', 'successful smoking cessation at 6 weeks postquit, defined as continuous abstinence from smoking for the 28-day period up to and including the 6-week visit (verified by CO measurement', 'quit rates']","[{'cui': 'C4319600', 'cui_str': '240 (qualifier value)'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0452249', 'cui_str': 'Mint - sweet'}, {'cui': 'C4319836', 'cui_str': 'Lozenge'}, {'cui': 'C1253423', 'cui_str': 'Nicotine Oral Lozenge'}]","[{'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0439857', 'cui_str': 'Patient dependence on (contextual qualifier) (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}]",241.0,0.194046,The 4 mg nicotine lozenge provided a directionally significant improvement in smoking cessation rates compared with placebo in Chinese adult smokers with high nicotine dependence for the primary endpoint.,"[{'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Xiao', 'Affiliation': 'Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China (DX, CW), Tobacco Medicine and Tobacco Cessation Center, China-Japan Friendship Hospital, Beijing, China (DX), National Clinical Research Center for Respiratory Diseases, Beijing, China (DX, CW), GlaxoSmithKline Consumer Healthcare, Parsippany, NJ (MK), Department of Respiratory Medicine, The First Hospital of China Medical University, Shenyang, China (JK), Institute of Respiratory Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China (CW).'}, {'ForeName': 'Mitchell', 'Initials': 'M', 'LastName': 'Kotler', 'Affiliation': ''}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Kang', 'Affiliation': ''}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': ''}]",Journal of addiction medicine,['10.1097/ADM.0000000000000547'] 860,30336852,"Intraoperative ketamine for prevention of depressive symptoms after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial.","BACKGROUND Ketamine is a general anaesthetic with anti-depressant effects at subanaesthetic doses. We hypothesised that intraoperative administration of ketamine would prevent or mitigate postoperative depressive symptoms in surgical patients. METHODS We conducted an international, randomised clinical trial testing the effects of intraoperative administration of ketamine [0.5 mg kg -1 (Lo-K) or 1.0 mg kg -1 (Hi-K)] vs control [saline placebo (P)] in patients ≥60 yr old undergoing major surgery with general anaesthesia. We administered the Patient Health Questionnaire-8 before the operation, on postoperative day (POD) 3 (primary outcome), and on POD30 to assess depressive symptoms, a secondary outcome of the original trial. RESULTS There was no significant difference on POD3 in the proportion of patients with symptoms suggestive of depression between the placebo [23/156 (14.7%)] and combined ketamine (Lo-K plus Hi-K) [61/349 (17.5%)] groups [difference = -2.7%; 95% confidence interval (CI), 5.0% to -9.4%; P=0.446]. Of the total cohort, 9.6% (64/670; 95% CI, 7.6-12.0%) had symptoms suggestive of depression before operation, which increased to 16.6% (84/505; 95% CI, 13.6-20.1%) on POD3, and decreased to 11.9% (47/395; 95% CI, 9.1-15.5%) on POD30. Of the patients with depressive symptoms on POD3 and POD30, 51% and 49%, respectively, had no prior history of depression or depressive symptoms. CONCLUSIONS Major surgery is associated with new-onset symptoms suggestive of depression in patients ≥60 yr old. Intraoperative administration of subanaesthetic ketamine does not appear to prevent or improve depressive symptoms. CLINICAL TRIALS REGISTRATION NCT01690988.",2018,"There was no significant difference on POD3 in the proportion of patients with symptoms suggestive of depression between the placebo [23/156 (14.7%)] and combined ketamine (Lo-K plus Hi-K) [61/349 (17.5%)] groups [difference = -2.7%; 95% confidence interval (CI), 5.0% to -9.4%; P=0.446].","['surgical patients', 'patients ≥60\xa0yr old undergoing major surgery with general anaesthesia', 'patients ≥60\xa0yr old', 'after major surgery in older adults']","['ketamine', 'Intraoperative ketamine', 'subanaesthetic ketamine', 'control [saline placebo (P', 'Ketamine']","['symptoms suggestive of depression', 'POD3', 'depressive symptoms']","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0002915', 'cui_str': 'General Anesthesia'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332299', 'cui_str': 'Suggestive of (attribute)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}]",,0.79005,"There was no significant difference on POD3 in the proportion of patients with symptoms suggestive of depression between the placebo [23/156 (14.7%)] and combined ketamine (Lo-K plus Hi-K) [61/349 (17.5%)] groups [difference = -2.7%; 95% confidence interval (CI), 5.0% to -9.4%; P=0.446].","[{'ForeName': 'G A', 'Initials': 'GA', 'LastName': 'Mashour', 'Affiliation': 'Center for Consciousness Science, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, USA. Electronic address: gmashour@umich.edu.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ben Abdallah', 'Affiliation': 'Department of Anesthesiology, Washington University School of Medicine, Saint Louis, MO, USA.'}, {'ForeName': 'K O', 'Initials': 'KO', 'LastName': 'Pryor', 'Affiliation': 'Department of Anesthesiology, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'El-Gabalawy', 'Affiliation': 'Department of Clinical Health Psychology, University of Manitoba, Winnipeg, MB, Canada; Department of Anesthesia and Perioperative Medicine, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'P E', 'Initials': 'PE', 'LastName': 'Vlisides', 'Affiliation': 'Center for Consciousness Science, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, USA.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Jacobsohn', 'Affiliation': 'Department of Anesthesia, University of Manitoba, Winnipeg, MB, Canada; Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Lenze', 'Affiliation': 'Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA.'}, {'ForeName': 'H R', 'Initials': 'HR', 'LastName': 'Maybrier', 'Affiliation': 'Department of Anesthesiology, Washington University School of Medicine, Saint Louis, MO, USA.'}, {'ForeName': 'R A', 'Initials': 'RA', 'LastName': 'Veselis', 'Affiliation': 'Department of Anesthesiology, Weill Cornell Medicine, New York, NY, USA; Department of Neuroanesthesiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Avidan', 'Affiliation': 'Department of Anesthesiology, Washington University School of Medicine, Saint Louis, MO, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",British journal of anaesthesia,['10.1016/j.bja.2018.03.030'] 861,30122646,"Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up.","BACKGROUND A quadrivalent human papillomavirus vaccine (qHPV; HPV6/11/16/18) has demonstrated efficacy and effectiveness worldwide. We report qHPV vaccine efficacy for up to 6.5 years after first administration among Chinese women 20-45 years of age. METHODS In this randomized, double-blind, placebo-controlled, multicenter, Phase 3 study (NCT00834106), women were randomized 1:1 to receive 3 doses of qHPV vaccine or placebo (Day 1, Month 2, Month 6). Endo-ecto-cervical and external genital swabs were collected for HPV testing and gynecologic examinations, and cervical cytology testing were performed at Day 1 and Months 7, 12, 18, 24, 30, 42, 54, 66, and 78. Any abnormality in cytology testing would trigger colposcopy examination and cervical biopsy, if necessary. Efficacy against genital disease, persistent infection, and the composite endpoint was assessed. Primary efficacy analyses were conducted in the per-protocol efficacy (PPE) population. RESULTS Of 3006 participants randomized, 2759 (91.8%) and 2374 (79%) completed the Month 30 and Month 78 visits, respectively. At Month 78, efficacy among women aged 20-45 years was 100% (95% CI: 32.3, 100; 0 vs 7 cases) and 100% (95% CI: 70.9, 100; 0 vs 14 cases) against HPV16/18-related cervical intraepithelial neoplasia Grade 2 or 3, adenocarcinoma in situ, and cervical cancer (CIN 2+) and HPV6/11/16/18-related CIN 1+, respectively, in the PPE population. The efficacy against cervical 6-month and 12-month persistent infection was 91.6% (95% CI: 66.0, 99.0) and 97.5% (95% CI: 85.1, 99.9) at Month 30 and Month 78, respectively, in the PPE population. The vaccine also reduced the rate of cervical cytology abnormalities associated with HPV6/11/16/18, with an efficacy of 94.0% (95% CI: 81.5, 98.8). The vaccine was generally well tolerated (reported separately). CONCLUSION The qHPV vaccine is efficacious against endpoints of persistent infection and genital precancerous lesions in Chinese women aged 20-45 years.",2019,The qHPV vaccine is efficacious against endpoints of persistent infection and genital precancerous lesions in Chinese women aged 20-45 years.,"['Chinese women aged 20-45\u202fyears', 'Chinese women 20-45\u202fyears of age', '3006 participants randomized, 2759 (91.8%) and 2374 (79%) completed the Month 30 and Month 78 visits, respectively', 'Chinese women']","['qHPV vaccine', 'qHPV vaccine or placebo', 'quadrivalent human papillomavirus vaccine', 'placebo']","['rate of cervical cytology abnormalities', 'Grade 2 or 3, adenocarcinoma in situ, and cervical cancer', 'qHPV vaccine efficacy', 'efficacy against cervical 6-month and 12-month persistent infection', 'HPV16/18-related cervical intraepithelial neoplasia', 'per-protocol efficacy (PPE) population', 'Efficacy against genital disease, persistent infection']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1512511', 'cui_str': 'HPV Vaccines'}]","[{'cui': 'C0856201', 'cui_str': 'Cervical cytology'}, {'cui': 'C0000769', 'cui_str': 'anomalies'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0334276', 'cui_str': 'Adenocarcinoma, Intraepithelial'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix (disorder)'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0205064', 'cui_str': 'Cervical (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1264606', 'cui_str': 'Persistent infection'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0206708', 'cui_str': 'Cervical Intraepithelial Neoplasms'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0017420', 'cui_str': 'Reproductive System'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",3006.0,0.376611,The qHPV vaccine is efficacious against endpoints of persistent infection and genital precancerous lesions in Chinese women aged 20-45 years.,"[{'ForeName': 'Lihui', 'Initials': 'L', 'LastName': 'Wei', 'Affiliation': ""Department of Obstetrics and Gynecology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China.""}, {'ForeName': 'Xing', 'Initials': 'X', 'LastName': 'Xie', 'Affiliation': ""Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, 1 Xueshi Road, Hangzhou 310006, China.""}, {'ForeName': 'Jihong', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Department of Gynecologic Oncology, Cancer Center, Sun Yat-sen University, 651 Dongfeng Road East, Guangzhou 510060, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': ""Department of Obstetrics and Gynecology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China.""}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': 'Department of Cancer Epidemiology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, Beijing 100021, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Zhao', 'Affiliation': ""Department of Obstetrics and Gynecology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China.""}, {'ForeName': 'Shaoming', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Department of Cancer Epidemiology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, Beijing 100021, China.'}, {'ForeName': 'Xueyan', 'Initials': 'X', 'LastName': 'Liao', 'Affiliation': 'MSD R&D (China), 21 Rongda Road, Wangjing R&D Base, Zhongguancun Electronic Zone West Zone, Chaoyang District, Beijing 100012, China.'}, {'ForeName': 'Qiong', 'Initials': 'Q', 'LastName': 'Shou', 'Affiliation': 'MSD R&D (China), 21 Rongda Road, Wangjing R&D Base, Zhongguancun Electronic Zone West Zone, Chaoyang District, Beijing 100012, China.'}, {'ForeName': 'Yuanzheng', 'Initials': 'Y', 'LastName': 'Qiu', 'Affiliation': 'MSD R&D (China), 21 Rongda Road, Wangjing R&D Base, Zhongguancun Electronic Zone West Zone, Chaoyang District, Beijing 100012, China.'}, {'ForeName': 'Youlin', 'Initials': 'Y', 'LastName': 'Qiao', 'Affiliation': 'Department of Cancer Epidemiology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, Beijing 100021, China. Electronic address: qiaoy@cicams.ac.cn.'}, {'ForeName': 'Alfred J', 'Initials': 'AJ', 'LastName': 'Saah', 'Affiliation': 'Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA. Electronic address: Alfred_saah@merck.com.'}]",Vaccine,['10.1016/j.vaccine.2018.08.009'] 862,31648851,Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).,"BACKGROUND The present study (VINGEM) is the first randomised trial comparing vinflunine/gemcitabine (VG) to standard carboplatin/gemcitabine (CG) in patients with advanced urothelial carcinoma (aUC) ineligible for treatment with cisplatin. PATIENTS AND METHODS Patients with aUC, creatinine clearance 30-60 ml/min, performance status ≤1 and no prior chemotherapy for metastatic disease were randomised to the experimental arm (vinflunine 280 or 250 mg/m 2 day 1, gemcitabine 1000 mg/m 2 days 1 and 8, q21 days) or the control arm (carboplatin AUC 4.5 day 1, gemcitabine 1000 mg/m 2 days 1 and 8, q21 days). Primary end-point was progression-free survival (PFS). RESULTS Sixty-two patients were randomised; a total of 59 patients were treated (29 VG, 30 CG). There was no significant difference in PFS between the treatment arms: median 6.2 months for VG versus 6.3 months for CG (hazard ratio [HR]: 0.75, 95% confidence interval [CI]: 0.44-1.28; P = 0.293). Median overall survival was 12.5 months for VG versus 10.6 months for CG. The overall response rate (ORR) was higher in the VG arm than in the CG arm (63% versus 40%) but was not statistically significant in the intention-to-treat analysis. Furthermore, VG showed a high complete response (CR) rate, 22% versus 3% in CG. In the per-protocol group, both ORR and CR were significantly higher for VG than for CG. The most common adverse events (AEs) were fatigue, haematological toxicities, gastrointestinal disorders and nausea/vomiting. Common grade III/IV AEs were neutropenia (VG 62%, CG 43%), thrombocytopenia (VG 7%, CG 37%) and febrile neutropenia (VG 31%, CG 7%). CONCLUSIONS The combination of VG did not improve PFS compared with standard treatment with CG in patients unfit for cisplatin due to renal impairment. The response rate of VG indicates, however, an active regimen and warrants further studies. CLINICALTRIALS. GOV NUMBER NCT02665039.",2020,The combination of VG did not improve PFS compared with standard treatment with CG in patients unfit for cisplatin due to renal impairment.,"['patients unfit for cisplatin due to renal impairment', 'Patients with aUC, creatinine clearance 30-60\xa0ml/min, performance status ≤1 and no prior chemotherapy for metastatic disease', 'Sixty-two patients were randomised; a total of 59 patients were treated (29 VG, 30 CG', 'cisplatin-ineligible patients with advanced urothelial carcinoma', 'patients with advanced urothelial carcinoma (aUC) ineligible for treatment with cisplatin']","['experimental arm (vinflunine 280 or 250\xa0mg/m 2 day 1, gemcitabine 1000\xa0mg/m 2 days 1 and 8, q21 days) or the control arm (carboplatin AUC 4.5 day 1', 'vinflunine/gemcitabine (VG) to standard carboplatin/gemcitabine (CG', 'gemcitabine 1000', 'Vinflunine/gemcitabine versus carboplatin/gemcitabine']","['complete response (CR) rate', 'fatigue, haematological toxicities, gastrointestinal disorders and nausea/vomiting', 'progression-free survival (PFS', 'neutropenia', 'febrile neutropenia', 'ORR and CR', 'Median overall survival', 'PFS', 'overall response rate (ORR', 'thrombocytopenia']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C1565489', 'cui_str': 'Renal Insufficiency'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine (procedure)'}, {'cui': 'C0439445', 'cui_str': 'mL/min'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C2939420', 'cui_str': 'Metastatic disease'}, {'cui': 'C4517835', 'cui_str': '62 (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0007138', 'cui_str': 'Carcinoma, Transitional Cell'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0672663', 'cui_str': 'vinflunine'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C4057589', 'cui_str': 'gemcitabine 1000 MG'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C3844009', 'cui_str': 'Four point five'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}]","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0017178', 'cui_str': 'Gastrointestinal Diseases'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0746883', 'cui_str': 'Febrile Neutropenia'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0040034', 'cui_str': 'Thrombopenia'}]",30.0,0.161964,The combination of VG did not improve PFS compared with standard treatment with CG in patients unfit for cisplatin due to renal impairment.,"[{'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Holmsten', 'Affiliation': 'PO Bäckencancer, Tema Cancer, Karolinska Universitetssjukhuset and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Electronic address: karin.holmsten@ki.se.'}, {'ForeName': 'Niels Viggo', 'Initials': 'NV', 'LastName': 'Jensen', 'Affiliation': 'Department of Oncology, Odense Universitetshospital, Odense, Denmark.'}, {'ForeName': 'Lene Sonne', 'Initials': 'LS', 'LastName': 'Mouritsen', 'Affiliation': 'Department of Oncology, Herlev Gentofte Hospital, Herlev, Denmark.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Jonsson', 'Affiliation': 'Department of Oncology, Norrlands Universitetssjukhus, Umeå, Sweden.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Mellnert', 'Affiliation': 'Department of Oncology, Skånes Universitetssjukhus, Lund, Sweden.'}, {'ForeName': 'Mads', 'Initials': 'M', 'LastName': 'Agerbæk', 'Affiliation': 'Department of Oncology, Aarhus Universitetshospital, Aarhus, Denmark.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Nilsson', 'Affiliation': 'Department of Oncology, Västmanlands Sjukhus, Västerås, Sweden.'}, {'ForeName': 'Mette', 'Initials': 'M', 'LastName': 'Moe', 'Affiliation': 'Department of Oncology, Aalborg Universitetshospital, Aalborg, Denmark.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Carus', 'Affiliation': 'Department of Oncology, Aalborg Universitetshospital, Aalborg, Denmark.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Öfverholm', 'Affiliation': 'Department of Oncology, Sahlgrenska Universitetssjukhuset, Göteborg, Sweden.'}, {'ForeName': 'Outi', 'Initials': 'O', 'LastName': 'Lahdenperä', 'Affiliation': 'Department of Oncology, Åbo Universitetscentralsjukhus, Åbo, Finland.'}, {'ForeName': 'Yvonne', 'Initials': 'Y', 'LastName': 'Brandberg', 'Affiliation': 'PO Bäckencancer, Tema Cancer, Karolinska Universitetssjukhuset and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Hemming', 'Initials': 'H', 'LastName': 'Johansson', 'Affiliation': 'PO Bäckencancer, Tema Cancer, Karolinska Universitetssjukhuset and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Mats', 'Initials': 'M', 'LastName': 'Hellström', 'Affiliation': 'PO Bäckencancer, Tema Cancer, Karolinska Universitetssjukhuset and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Hans von der', 'Initials': 'HV', 'LastName': 'Maase', 'Affiliation': 'Department of Oncology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Helle', 'Initials': 'H', 'LastName': 'Pappot', 'Affiliation': 'Department of Oncology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Ullén', 'Affiliation': 'PO Bäckencancer, Tema Cancer, Karolinska Universitetssjukhuset and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.08.033'] 863,29962570,Role of Novel Dietary Supplement N-acetyl Cysteine in Treating Negative Symptoms in Schizophrenia: A 6-Month Follow-up Study.,"Background Abnormal metabolism of dopamine and glutamate in schizophrenia induces oxidative stress that is exacerbated by brain glutathione (GSH) deficiency. N-acetyl cysteine (NAC) increases brain GSH levels and is being used as an adjunctive agent in patients with schizophrenia. This open-label exploratory study in a naturalistic setting was conceived to examine the efficacy of NAC augmentation in treating negative syndrome in schizophrenia. Aims To examine the efficacy of add-on NAC (1200 mg) in treating negative symptoms measured using Scale for the Assessment of Negative Symptoms (SANS) and clinical global impression (CGI) at baseline and 24 weeks. Subjects and Methods In a 24-week feasibility study with open-label design, thirty patients with the International Classification of Diseases-Tenth Edition diagnosis of schizophrenia were recruited. Eligible patients were required to have been treated with stable dose of clozapine or amisulpride for negative symptoms for a minimum period of 8 weeks were selected for the study. The subjects were assigned to receive NAC (1.2 g/day) as an add-on treatment. Severity of negative symptoms was measured using SANS and CGI-severity at baseline and improvement with NAC measured using CGI-improvement at 24 weeks. Serum interleukin-6 was assessed before NAC initiation at baseline. Results NAC augmentation showed a significantly greater improvement in negative symptoms on total SANS and CGI scores at 24 weeks. Conclusions NAC may be effective as an adjunct for the treatment of negative symptoms in schizophrenia.",2018,Severity of negative symptoms was measured using SANS and CGI-severity at baseline and improvement with NAC measured using CGI-improvement at 24 weeks.,"['Schizophrenia', 'thirty patients with the International Classification of Diseases-Tenth Edition diagnosis of schizophrenia were recruited', 'Eligible patients were required to have been treated with stable dose of', 'Subjects and Methods', 'for negative symptoms for a minimum period of 8 weeks were selected for the study', 'patients with schizophrenia']","['Novel Dietary Supplement N-acetyl Cysteine', 'clozapine or amisulpride', 'NAC', 'NAC augmentation', 'N-acetyl cysteine (NAC']","['negative symptoms on total SANS and CGI scores', 'Severity of negative symptoms', 'brain GSH levels', 'Negative Symptoms (SANS) and clinical global impression (CGI', 'Serum interleukin-6']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0870733', 'cui_str': 'International Statistical Classification of Diseases and Related Health Problems'}, {'cui': 'C0205444', 'cui_str': 'Tenth (qualifier value)'}, {'cui': 'C0441792', 'cui_str': 'Editions (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0242295', 'cui_str': 'Dietary Supplementations'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C0009079', 'cui_str': 'Clozapine'}, {'cui': 'C0103045', 'cui_str': 'Amisulpride'}, {'cui': 'C1293122', 'cui_str': 'Augmentation procedure'}]","[{'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}]",30.0,0.0547334,Severity of negative symptoms was measured using SANS and CGI-severity at baseline and improvement with NAC measured using CGI-improvement at 24 weeks.,"[{'ForeName': 'Hema', 'Initials': 'H', 'LastName': 'Tharoor', 'Affiliation': 'Schizophrenia Research Foundation (India), Chennai, Tamil Nadu, India.'}, {'ForeName': 'Sindhu', 'Initials': 'S', 'LastName': 'Mara', 'Affiliation': 'Schizophrenia Research Foundation (India), Chennai, Tamil Nadu, India.'}, {'ForeName': 'Subhashini', 'Initials': 'S', 'LastName': 'Gopal', 'Affiliation': 'Schizophrenia Research Foundation (India), Chennai, Tamil Nadu, India.'}]",Indian journal of psychological medicine,['10.4103/IJPSYM.IJPSYM_322_17'] 864,29932590,"Results of the Optimizing Outcomes in Women with Gestational Diabetes Mellitus and Their Infants, a Cluster Randomized, Controlled Pilot Study: Lessons Learned.","The purpose of this pilot study was as follows: Aim I was to determine the feasibility of the intervention, including its acceptability, and tofurther refine intervention materials and study procedures including recruitment, enrollment, intervention, retention, and data collection. Aim 2 was to test the initial effects of the intervention on the primary outcome of fasting blood glucose and secondary outcomes including metabolic, clinical, adiposity, health behavior, and self-efficacy outcomes in women. Aim 3 examined infant feeding. Infant weight and adiposity growth are discussed in this manuscript. The intervention group received the Phase I intervention, which included 14 classes, each lasting 60 minutes, with the first class delivered during pregnancy on the benefits of breastfeeding for maternal metabolic control andfor infant health. The classes resumed 6 weeks postpartum and were delivered weekly. The Phase II intervention included 3 monthly classes, each lasting 60 minutes, during which the interventionist facilitated a group discussion and assisted the women with problems related to breastfeeding, nutrition, or exercise. Results demonstrated that 100 women were enrolled in the study; however, secondary to the majority of women returning to work part-time or full-time, the retention for the intervention and data collection was poor. In addition, statistical significancefor the primary outcomes was not achieved. However, women made some changes in adiposity and health behaviors, and infants made changes in adiposity growth. Both lessons learned and future research are discussed.",2016,"The Phase II intervention included 3 monthly classes, each lasting 60 minutes, during which the interventionist facilitated a group discussion and assisted the women with problems related to breastfeeding, nutrition, or exercise.","['Women with Gestational Diabetes Mellitus', '100 women were enrolled in the study', 'women']","['interventionist facilitated a group discussion and assisted the women with problems related to breastfeeding, nutrition, or exercise']","['adiposity growth', 'adiposity and health behaviors', 'metabolic, clinical, adiposity, health behavior, and self-efficacy outcomes']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0085207', 'cui_str': 'Diabetes, Pregnancy-Induced'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0557061', 'cui_str': 'Discussion (procedure)'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C1563743', 'cui_str': 'Adiposis'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0018687'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",100.0,0.0291865,"The Phase II intervention included 3 monthly classes, each lasting 60 minutes, during which the interventionist facilitated a group discussion and assisted the women with problems related to breastfeeding, nutrition, or exercise.","[{'ForeName': 'Diane C', 'Initials': 'DC', 'LastName': 'Berry', 'Affiliation': ''}, {'ForeName': 'Emily G', 'Initials': 'EG', 'LastName': 'Hall', 'Affiliation': ''}, {'ForeName': 'Madeline N', 'Initials': 'MN', 'LastName': 'Neal', 'Affiliation': ''}, {'ForeName': 'Reuben', 'Initials': 'R', 'LastName': 'Adatorwovor', 'Affiliation': ''}, {'ForeName': 'Todd A', 'Initials': 'TA', 'LastName': 'Schwartz', 'Affiliation': ''}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Stuebe', 'Affiliation': ''}]",Journal of National Black Nurses' Association : JNBNA,[] 865,29875528,Two-Year Follow-up of Isolated Epileptiform Discharges in Autism: An Endophenotypic Biomarker?,"Context A significant subset of autistic children exhibit abnormal isolated epileptiform discharges (IEDs) in the absence of clinical epilepsy. The etiological significance of such IEDs is under much debate. Aims The aim is to study the relationship between IEDs with risk factors, clinical severity, behavioral problems, and social-quotient and follow-up for the occurrence of new seizures. Settings and Design This study was a prospective double-blind comparative study of autistic children with and without IEDs. Subjects and Methods All autistic children attending Child Psychiatry Department of tertiary care postgraduate teaching hospital in April 2013 were included in the study. Electroencephalography, risk factors, and clinical severity were assessed. The same cohort of 72 children was followed for 2 years and reassessed. Statistical Analysis Used Independent sample t -test, Chi-square test, Pearson correlation, and linear by linear association were the statistical methods used. Results Twenty-four (42%) of the followed up sample exhibited IEDs. 10.52% had converted to clinical seizures within the follow-up period. While there was no difference between risk factors and age at diagnosis between the IED and non-IED groups, there was a significant difference between disease severity, behavioral problems and social quotient between the groups. Conclusions IED in a subgroup of autistic children point to more severe illness, severe behavioral problems, and severe social impairment over a 2-year follow-up period. Can IED be considered a neurobehavioral endophenotype in autism?",2018,"While there was no difference between risk factors and age at diagnosis between the IED and non-IED groups, there was a significant difference between disease severity, behavioral problems and social quotient between the groups. ","['autistic children with and without IEDs', 'Subjects and Methods\n\n\nAll autistic children attending Child Psychiatry Department of tertiary care postgraduate teaching hospital in April 2013 were included in the study', 'Autism', '72 children was followed for 2 years and reassessed']",[],"['severe illness, severe behavioral problems, and severe social impairment', 'disease severity, behavioral problems and social quotient', 'Electroencephalography, risk factors, and clinical severity', 'clinical seizures']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0008088', 'cui_str': 'Child Psychiatry'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0020027', 'cui_str': 'Teaching Hospitals'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",[],"[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0233514', 'cui_str': 'Behavioral Problem'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0013819', 'cui_str': 'EEG'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}]",72.0,0.0468566,"While there was no difference between risk factors and age at diagnosis between the IED and non-IED groups, there was a significant difference between disease severity, behavioral problems and social quotient between the groups. ","[{'ForeName': 'Vimal Doshi', 'Initials': 'VD', 'LastName': 'Veerappan', 'Affiliation': 'Department of Child Psychiatry and Child Guidance Clinic, Institute of Child Health and Hospital for Children, Madras Medical College and Research Institute, Chennai, Tamil Nadu, India.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Sweetha', 'Affiliation': 'Department of Medicine, Government Hospital, Salem, Tamil Nadu, India.'}, {'ForeName': 'H R', 'Initials': 'HR', 'LastName': 'Kavitha', 'Affiliation': 'Department of Pediatrics, Fortis La Femme, Bengaluru, Karnataka, India.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Sivalingam', 'Affiliation': 'Department of Child Psychiatry and Child Guidance Clinic, Institute of Child Health and Hospital for Children, Madras Medical College and Research Institute, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Shanthi', 'Initials': 'S', 'LastName': 'Nambi', 'Affiliation': 'Director and Head, Institute of Mental Health, Madras Medical College, Institute of Mental Health, Madras Medical College and Research Institute, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Leema', 'Initials': 'L', 'LastName': 'Pauline', 'Affiliation': 'Department of Pediatric Neurology, Institute of Child Health and Hospital for Children, Madras Medical College and Research Institute, Chennai, Tamil Nadu, India.'}]",Indian journal of psychological medicine,['10.4103/IJPSYM.IJPSYM_555_17'] 866,29932542,Promoting Mammography with African-American Women in the Emergency Department Using Lay Health Workers.,The objective of this study was to test the efficacy of a pilot intervention to increase mammography utilization among African-American women recruited from those waiting in the emergency department (ED)for non-urgent complaints. In a 3-armed pilot of a randomized controlled trial we compared the effects of a brief motivational interview delivered by a lay health worker with those of a culturally targeted brochure and a usual care control group. The results showed that one quarter (23%) of the sample reported having never had a mammogram prior to the study. There was no group difference by mammography status at the 3-month interview. More than one quarter of those retained in the study indicated they had received a mammogram during the study (27.4%). The conclusions from the study were that lay health workers are a valuable asset and may be used in innovative settings such as the ED to increase screening among vulnerable populations.,2016,There was no group difference by mammography status at the 3-month interview.,"['African-American women recruited from those waiting in the emergency department (ED)for non-urgent complaints', 'African-American Women in the Emergency Department Using Lay Health Workers']","['brief motivational interview delivered by a lay health worker with those of a culturally targeted brochure and a usual care control group', 'pilot intervention']","['mammography utilization', 'mammography status']","[{'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0439609', 'cui_str': 'Urgency (qualifier value)'}, {'cui': 'C0277786', 'cui_str': 'Presenting complaint'}, {'cui': 'C0600261', 'cui_str': 'Lying'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1306056', 'cui_str': 'Worker'}]","[{'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0473169', 'cui_str': 'Aviators'}]","[{'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0042153', 'cui_str': 'use'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]",,0.0238229,There was no group difference by mammography status at the 3-month interview.,"[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hatcher', 'Affiliation': ''}, {'ForeName': 'Nancy E', 'Initials': 'NE', 'LastName': 'Schoenberg', 'Affiliation': ''}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Dignan', 'Affiliation': ''}, {'ForeName': 'Mary Kay', 'Initials': 'MK', 'LastName': 'Rayens', 'Affiliation': ''}]",Journal of National Black Nurses' Association : JNBNA,[] 867,29932560,A Multiple Behavior Self-Monitoring Intervention for African- American Veterans with Type 2 Diabetes: A Feasibility Implementation Study.,"The purpose of this study was to determine the feasibility of implementing a multiple-behavior self-monitoring intervention within a diabetes education program. This study was a 3-month pre- post-design, conducted with African-Americans (N = 20), who attended diabetes education classes at a large Veteran's Affairs (VA) hospital in Southwest Texas. Participants selfmonitored their blood glucose, diet, exercise, and weight on either a smart phone application or paper diaries. Paired t tests showed strong evidence that patient self-monitoring of healthy lifestyle behaviors improved blood glucose (t = -3.858, p = .001) and HbAlc (t = -4.428, p <.001), respectively. Moreover Spearman's correlation coefficient showed significant correlations between blood glucose and exercise (rs = -.68, p = .008) and HbAlc and exercise (rs = -.56, p = .036). This feasibility study showed that multiple-behavior self-monitoring was effective in lowering blood glucose and HbA1c levels among African-American Veterans; however, a randomized controlled trial with a larger sample is needed to validate these preliminary findings.",2017,"Paired t tests showed strong evidence that patient self-monitoring of healthy lifestyle behaviors improved blood glucose (t = -3.858, p = .001) and HbAlc (t = -4.428, p <.001), respectively.","['American Veterans with Type 2 Diabetes', 'African-American Veterans', ""African-Americans (N = 20), who attended diabetes education classes at a large Veteran's Affairs (VA) hospital in Southwest Texas""]",['African'],"['blood glucose, diet, exercise, and weight', 'blood glucose', 'blood glucose and exercise', 'blood glucose and HbA1c levels', 'HbAlc and exercise']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0039711', 'cui_str': 'Texas'}]",[],"[{'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",20.0,0.0169061,"Paired t tests showed strong evidence that patient self-monitoring of healthy lifestyle behaviors improved blood glucose (t = -3.858, p = .001) and HbAlc (t = -4.428, p <.001), respectively.","[{'ForeName': 'Ngozi D', 'Initials': 'ND', 'LastName': 'Mbue', 'Affiliation': ''}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Stanley G', 'Initials': 'SG', 'LastName': 'Cron', 'Affiliation': ''}, {'ForeName': 'Jane A', 'Initials': 'JA', 'LastName': 'Anderson', 'Affiliation': ''}]",Journal of National Black Nurses' Association : JNBNA,[] 868,30273200,The Effect of Ultra-low-dose Intrathecal Naloxone on Pain Intensity After Lumbar Laminectomy With Spinal Fusion: A Randomized Controlled Trial.,"BACKGROUND Despite advances in pain management, several patients continue to experience severe acute pain after lumbar spine surgery. The aim of this study was to assess the safety and effectiveness of single ultra-low-dose intrathecal (IT) naloxone in combination with IT morphine for reducing pain intensity, pruritus, nausea, and vomiting in patients undergoing lumbar laminectomy with spinal fusion. MATERIALS AND METHODS In this double-blind trial, patients scheduled for lumbar laminectomy with spinal fusion were randomly assigned to receive single ultra-low-dose IT naloxone (20 μg) and IT morphine (0.2 mg) (group M+N) or IT morphine (0.2 mg) alone (group M). The severity of postoperative pain, pruritus and nausea, and frequency of vomiting were assessed at recovery from anesthesia and, subsequently, at 1, 3, 6, 12, and 24 hours postoperatively using an 11-point (0-10) visual analogue scale. RESULTS A total of 77 patients completed the study, and there were significant differences in postoperative pain, pruritus, and nausea visual analogue scale between the groups (P<0.05). After adjusting for body mass index and surgery duration, IT naloxone administration reduced the pain score (coefficient=1.84; 95% confidence interval [CI], 1.05-2.63; P<0.001), and the scores of pruritus and nausea (coefficient=0.9; 95% CI, 0.44-1.37; P<0.001 and coefficient=0.71; 95% CI, 0.12-1.31; P=0.02, respectively) compared with IT morphine alone. No serious adverse effects were observed. CONCLUSIONS The addition of ultra-low-dose IT naloxone to IT morphine provides excellent postoperative pain management and effectively controls pruritus and nausea in patients undergoing laminectomy with spinal fusion.",2020,"A total of 77 patients completed the study, and there were significant differences in postoperative pain, pruritus, and nausea visual analogue scale between the groups (P<0.05).","['After Lumbar Laminectomy With Spinal Fusion', 'patients undergoing laminectomy with spinal fusion', 'pain management, several patients continue to experience severe acute pain after lumbar spine surgery', 'patients scheduled for lumbar laminectomy with spinal fusion', 'patients undergoing lumbar laminectomy with spinal fusion']","['Ultra-low-dose Intrathecal Naloxone', 'single ultra-low-dose', 'ultra-low-dose IT naloxone to IT morphine', 'IT morphine', 'single ultra-low-dose intrathecal (IT) naloxone', 'IT naloxone (20\u2009μg) and IT morphine']","['serious adverse effects', 'Pain Intensity', 'scores of pruritus and nausea', 'severity of postoperative pain, pruritus and nausea, and frequency of vomiting', 'pain score', 'pain intensity, pruritus, nausea, and vomiting', 'safety and effectiveness', 'postoperative pain, pruritus, and nausea visual analogue scale']","[{'cui': 'C1112614', 'cui_str': 'Lumbar laminectomy'}, {'cui': 'C0037935', 'cui_str': 'Spinal Fusion'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0185975', 'cui_str': 'Laminectomy with spinal fusion (procedure)'}, {'cui': 'C0002766', 'cui_str': 'Pain management (procedure)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0184567', 'cui_str': 'Acute Pain'}, {'cui': 'C3887615', 'cui_str': 'Lumbar spine structure (body structure)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}]","[{'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0027358', 'cui_str': 'Naloxone'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}]","[{'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0042965', 'cui_str': 'Vomitus (substance)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",77.0,0.517423,"A total of 77 patients completed the study, and there were significant differences in postoperative pain, pruritus, and nausea visual analogue scale between the groups (P<0.05).","[{'ForeName': 'Abolfazl', 'Initials': 'A', 'LastName': 'Firouzian', 'Affiliation': 'Departments of Anesthesiology.'}, {'ForeName': 'Afshin', 'Initials': 'A', 'LastName': 'Gholipour Baradari', 'Affiliation': 'Departments of Anesthesiology.'}, {'ForeName': 'Saeid', 'Initials': 'S', 'LastName': 'Ehteshami', 'Affiliation': 'Neurosurgery.'}, {'ForeName': 'Alieh', 'Initials': 'A', 'LastName': 'Zamani Kiasari', 'Affiliation': 'Departments of Anesthesiology.'}, {'ForeName': 'Misagh', 'Initials': 'M', 'LastName': 'Shafizad', 'Affiliation': 'Neurosurgery.'}, {'ForeName': 'Sajad', 'Initials': 'S', 'LastName': 'Shafiei', 'Affiliation': 'Neurosurgery.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Younesi Rostami', 'Affiliation': 'Faculty of Medicine.'}, {'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Alipour', 'Affiliation': 'Epidemiology.'}, {'ForeName': 'Shahram', 'Initials': 'S', 'LastName': 'Ala', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmacy.'}, {'ForeName': 'Hadi', 'Initials': 'H', 'LastName': 'Darvishi-Khezri', 'Affiliation': 'Student Research Committee, Thalassemia Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran.'}, {'ForeName': 'Kaveh', 'Initials': 'K', 'LastName': 'Haddadi', 'Affiliation': 'Neurosurgery.'}]",Journal of neurosurgical anesthesiology,['10.1097/ANA.0000000000000537'] 869,30190185,Adolescent Stress Management in a Primary Care Clinic.,"INTRODUCTION The American Academy of Pediatrics recommends that adolescents be screened for mental health concerns and receive anticipatory guidance on stress management strategies. METHODS Eighty-six participants (50 participants in the intervention group; 36 participants in the control group) participated in the study. Intervention group participants received training in diaphragmatic breathing, progressive muscle relaxation, and use of no-cost/low-cost exercise options. Biofeedback was used to guide relaxation. Subjective distress and heart rate variability was measured before and after the intervention. RESULTS After the intervention, decreased levels of perceived stress and increased heart rate variability were reported compared with the control group. DISCUSSION This study show that an integrated care model in a primary care setting is feasible and effective at improving stress management.",2019,"After the intervention, decreased levels of perceived stress and increased heart rate variability were reported compared with the control group. ","['Adolescent Stress Management in a Primary Care Clinic', 'Eighty-six participants (50 participants in the intervention group; 36 participants in the control group) participated in the study']","['training in diaphragmatic breathing, progressive muscle relaxation, and use of no-cost/low-cost exercise options']","['Subjective distress and heart rate variability', 'levels of perceived stress and increased heart rate variability']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0150788', 'cui_str': 'Manage stress control'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic (environment)'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0231898', 'cui_str': 'Diaphragmatic breathing (finding)'}, {'cui': 'C0004361', 'cui_str': 'Progressive Relaxation'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}]",86.0,0.0203309,"After the intervention, decreased levels of perceived stress and increased heart rate variability were reported compared with the control group. ","[{'ForeName': 'Elizabeth B', 'Initials': 'EB', 'LastName': 'Mason', 'Affiliation': ''}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Burkhart', 'Affiliation': ''}, {'ForeName': 'Rina', 'Initials': 'R', 'LastName': 'Lazebnik', 'Affiliation': ''}]",Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners,['10.1016/j.pedhc.2018.08.001'] 870,30146405,"A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX®.","OBJECTIVE VARIVAX® (varicella virus vaccine, live Oka/Merck, Merck & Co., Inc., Kenilworth, NJ, USA) was originally licensed as a frozen formulation. A refrigerator-stable formulation of VARIVAX was subsequently developed to allow for increased availability of the product around the world. The objective of this study (V210-051) was to demonstrate that the safety, tolerability and immunogenicity profile of the refrigerator-stable formulation of VARIVAX was similar to the frozen formulation. METHODS In this double-blind, randomized, multicenter study, healthy 12- to 23-month-old children with negative vaccination and clinical histories for measles, mumps, rubella, varicella, and zoster were vaccinated with either a refrigerator-stable formulation of VARIVAX (at two dosage levels; 8000 PFU [N = 320] or 25,000 PFU [N = 315]) or the frozen formulation of VARIVAX (10,000 PFU, N = 323) given concomitantly with M-M-RII® (measles, mumps, and rubella virus vaccine live, Merck & Co., Inc., Kenilworth, NJ, USA). Children were followed for 42 days after vaccination for adverse experiences. Immunogenicity was evaluated 6 weeks after vaccination. RESULTS The refrigerator-stable formulation of VARIVAX was generally well tolerated. The incidence of adverse experiences was similar between all three groups. No vaccine-related serious adverse experiences were reported with any of the vaccine formulations. The immune response (percentage of subjects with varicella antibody titers ≥5 gpELISA units) for both refrigerator-stable formulations of VARIVAX at 6 weeks postvaccination was similar to that of the frozen formulation. Administration of either refrigerator-stable formulation of VARIVAX with M-M-RII yielded seroconversion rates and GMTs for measles, mumps and rubella that were comparable to those achieved after administration of the frozen formulation of VARIVAX with M-M-RII. CONCLUSION The safety, tolerability, and immunogenicity profile of the refrigerator-stable varicella vaccine was similar to that of the frozen formulation.",2019,The immune response (percentage of subjects with varicella antibody titers ≥5 gpELISA units) for both refrigerator-stable formulations of VARIVAX at 6 weeks postvaccination was similar to that of the frozen formulation.,"['healthy 12- to 23-month-old children with negative vaccination and clinical histories for measles, mumps, rubella, varicella, and zoster were vaccinated with either a refrigerator-stable formulation of VARIVAX (at two dosage levels; 8000 PFU [N\u202f=\u202f320] or 25,000 PFU [N\u202f=\u202f315]) or the']","['refrigerator-stable formulation of VARIVAX®', 'VARIVAX', 'frozen formulation of VARIVAX (10,000 PFU, N\u202f=\u202f323) given concomitantly with M-M-RII® (measles, mumps, and rubella virus vaccine live, Merck & Co., Inc., Kenilworth, NJ, USA', 'VARIVAX with M-M-RII']","['tolerated', 'incidence of adverse experiences', 'safety, tolerability and immunogenicity profile', 'safety, tolerability, and immunogenicity profile', 'Immunogenicity']","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}, {'cui': 'C0025007', 'cui_str': 'Rubeola'}, {'cui': 'C0026780', 'cui_str': 'Parotitis, Epidemic'}, {'cui': 'C0035920', 'cui_str': 'Measles, German'}, {'cui': 'C0008049', 'cui_str': 'Varicella'}, {'cui': 'C0019360', 'cui_str': 'Shingles'}, {'cui': 'C0034958', 'cui_str': 'Icebox'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0947706', 'cui_str': 'Varivax'}, {'cui': 'C0178602', 'cui_str': 'Dosages (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C3840857', 'cui_str': '8000 (qualifier value)'}, {'cui': 'C4517711', 'cui_str': '320 (qualifier value)'}]","[{'cui': 'C0034958', 'cui_str': 'Icebox'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0947706', 'cui_str': 'Varivax'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0025007', 'cui_str': 'Rubeola'}, {'cui': 'C0035923', 'cui_str': 'rubella, live attenuated'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.074554,The immune response (percentage of subjects with varicella antibody titers ≥5 gpELISA units) for both refrigerator-stable formulations of VARIVAX at 6 weeks postvaccination was similar to that of the frozen formulation.,"[{'ForeName': 'Keith S', 'Initials': 'KS', 'LastName': 'Reisinger', 'Affiliation': 'Primary Physicians Research, Pittsburgh, PA, United States.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Richardson', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, United States.'}, {'ForeName': 'Edgardo A', 'Initials': 'EA', 'LastName': 'Malacaman', 'Affiliation': 'MD Research, North Canton, OH, United States.'}, {'ForeName': 'Myron J', 'Initials': 'MJ', 'LastName': 'Levin', 'Affiliation': 'University of Colorado Anschutz Medical Campus, Aurora, CO, United States.'}, {'ForeName': 'Julie L', 'Initials': 'JL', 'LastName': 'Gardner', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, United States.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, United States.'}, {'ForeName': 'Jon E', 'Initials': 'JE', 'LastName': 'Stek', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, United States.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Kuter', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, United States. Electronic address: barbara_kuter@merck.com.'}]",Vaccine,['10.1016/j.vaccine.2018.01.089'] 871,30531556,Choice of ANesthesia for EndoVAScular Treatment of Acute Ischemic Stroke (CANVAS): Results of the CANVAS Pilot Randomized Controlled Trial.,"BACKGROUND The effect of choice of anesthesia on clinical outcome for endovascular treatment (EVT) in patients with acute ischemic stroke (AIS) remains unclear. METHODS We conducted a pilot trial of 43 patients with acute anterior circulation ischemic stroke having EVT. Patients were randomly allocated to receive general anesthesia or conscious sedation. We documented the rate of recruitment and rate of conversion from conscious sedation to general anesthesia. In addition, we recorded the change in National Institute of Health stroke scale (NIHSS) on day 7, the rate of successful reperfusion and measured neurological function by certified researchers using modified Rankin Score (mRS 0 to 2) at 90 days. RESULTS The recruitment rate was 31.4% and majority of patients were excluded because of delay in hospital presentation and posterior circulation stroke. The rate of conversion from conscious sedation to general anesthesia was 18.2%. This was primarily related to excessive sedation and uncontrolled movement. Change in NIHSS score, rate of successful reperfusion and functional recovery were similar between groups. CONCLUSIONS It was feasible to randomize AIS patients receiving either general anesthesia or conscious sedation for EVT.",2020,"Change in NIHSS score, rate of successful reperfusion and functional recovery were similar between groups. ","['patients with acute ischemic stroke (AIS', 'Acute Ischemic Stroke (CANVAS', '43 patients with acute anterior circulation ischemic stroke having EVT']","['anesthesia', 'ANesthesia', 'general anesthesia or conscious sedation for EVT', 'endovascular treatment (EVT', 'general anesthesia or conscious sedation']","['recruitment rate', 'rate of conversion', 'NIHSS score, rate of successful reperfusion and functional recovery', 'rate of recruitment and rate of conversion', 'National Institute of Health stroke scale (NIHSS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}]","[{'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C0002915', 'cui_str': 'General Anesthesia'}, {'cui': 'C0079159', 'cui_str': 'Sedation, Moderate'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0439836', 'cui_str': 'Conversions (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0035124', 'cui_str': 'Reperfusion'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C3472496', 'cui_str': 'National Institutes of Health stroke scale'}]",43.0,0.131693,"Change in NIHSS score, rate of successful reperfusion and functional recovery were similar between groups. ","[{'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': 'Departments of Anesthesiology.'}, {'ForeName': 'Fa', 'Initials': 'F', 'LastName': 'Liang', 'Affiliation': 'Departments of Anesthesiology.'}, {'ForeName': 'Youxuan', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Departments of Anesthesiology.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Departments of Anesthesiology.'}, {'ForeName': 'Zhongrong', 'Initials': 'Z', 'LastName': 'Miao', 'Affiliation': 'Interventional Neurology, Beijing Tiantan Hospital.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Division of Hematology and Medical Oncology, Department of Medicine, Department of Epidemiology and Biostatistics.'}, {'ForeName': 'Adrian W', 'Initials': 'AW', 'LastName': 'Gelb', 'Affiliation': 'Department of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, CA.'}, {'ForeName': 'Matthew T V', 'Initials': 'MTV', 'LastName': 'Chan', 'Affiliation': 'Department of Anaesthesia and Intensive Care, the Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, PR China.'}, {'ForeName': 'Yuming', 'Initials': 'Y', 'LastName': 'Peng', 'Affiliation': 'Departments of Anesthesiology.'}, {'ForeName': 'Ruquan', 'Initials': 'R', 'LastName': 'Han', 'Affiliation': 'Departments of Anesthesiology.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of neurosurgical anesthesiology,['10.1097/ANA.0000000000000567'] 872,30325871,Single Low Dose of Human Recombinant Antithrombin (ATryn) has no Impact on Endotoxin-Induced Disseminated Intravascular Coagulation: An Experimental Randomized Open Label Controlled Study.,"BACKGROUND Antithrombin (AT) III physiological levels are decreased during septic shock and supplementation therapy could therefore be beneficial. OBJECTIVE We hypothesized that the use of recombinant human AT could reduce disseminated intravascular coagulation (DIC) occurrence. METHODS We conducted a randomized open label controlled experimental study. Ten female ""Large White"" pigs were challenged with i.v. infusion of Escherichia coli endotoxin. Two groups of 5 pigs were randomly assigned to receive either recombinant human AT 100 U/kg over 30 min (ATryn group) or 0.9% saline (control group). AT III levels, coagulation, hemostasis, inflammation parameters, hemodynamics, and microcirculatory parameters were measured over a 5-h period. Immediately after euthanasia, kidneys were withdrawn for histology evaluation. Statistical analysis was performed with nonparametric tests and Dunn's test for multiple comparisons. RESULTS AT III activity was significantly higher in the ATryn group than in the control group from 60% (213% [203-223] vs. 104% [98-115], P = 0.008, respectively) to 300 min (115% [95-124] vs. 79% [67-93], P = 0.03). Recombinant human AT supplementation had no impact on hemodynamics, microcirculatory parameters, and sequential changes of coagulation parameters (platelet count, fibrinogen level, thrombin-AT complexes, and von Willebrand factor). Interleukin 6 and tumor necrosis factor α values were statistically the same for both groups throughout the study. Percentage of thrombosed glomeruli and percentage of thrombosed capillary in glomerulus were not significantly different between both groups. CONCLUSIONS In our model of endotoxic shock, a single low dose of recombinant human AT did not prevent DIC occurrence, severity, inflammatory profile, or hemodynamic alterations.",2019,"Recombinant human antithrombin supplementation had no impact on hemodynamics, microcirculatory parameters and sequential changes of coagulation parameters (platelet count, fibrinogen level, thrombin-antithrombin complexes and von Willebrand factor).","['Ten female ""Large White"" pigs', 'Two groups of five pigs', 'induced Disseminated Intravascular Coagulation']","['Atryn®', 'recombinant human antithrombin 100\u200aU/kg over 30 minutes [ATryn group] or 0.9% saline [control group', 'recombinant human antithrombin', 'Recombinant human antithrombin supplementation', 'Endotoxin', 'intravenous infusion of E.coli endotoxin', 'recombinant human Antithrombin', 'Human Recombinant Antithrombin']","['Disseminated Intravascular Coagulation occurrence, severity, inflammatory profile or hemodynamic alterations', 'Antithrombin III levels, coagulation, hemostasis, inflammation parameters, hemodynamics and microcirculatory parameters', 'hemodynamics, microcirculatory parameters and sequential changes of coagulation parameters (platelet count, fibrinogen level, thrombin-antithrombin complexes and von Willebrand factor', 'Disseminated Intravascular Coagulation (DIC) occurrence', 'Interleukin 6 and Tumor Necrosis Factor', 'Percentage of thrombosed glomeruli and percentage of thrombosed capillary', 'AT III activity', 'alpha values']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0039005', 'cui_str': 'Pigs'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0012739', 'cui_str': 'Consumption Coagulopathy'}]","[{'cui': 'C2609610', 'cui_str': 'ATryn'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0003440', 'cui_str': 'Direct Thrombin Inhibitors'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C1300561', 'cui_str': 'unit/kg'}, {'cui': 'C1442458', 'cui_str': 'Thirty minutes (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0014264', 'cui_str': 'Endotoxins'}, {'cui': 'C0021440', 'cui_str': 'Infusions, Intravenous'}]","[{'cui': 'C0012739', 'cui_str': 'Consumption Coagulopathy'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0003438', 'cui_str': 'Antithrombin III'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0441509', 'cui_str': 'Coagulation - action (qualifier value)'}, {'cui': 'C0740166', 'cui_str': 'Haemostasis'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1287267', 'cui_str': 'Finding of platelet count (finding)'}, {'cui': 'C0337428', 'cui_str': 'Fibrinogen measurement'}, {'cui': 'C0863178', 'cui_str': 'Thrombin'}, {'cui': 'C0003440', 'cui_str': 'Direct Thrombin Inhibitors'}, {'cui': 'C0042971', 'cui_str': 'von Willebrand factor'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'Tumor Necrosis Factors'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0006901', 'cui_str': 'Capillaries'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",10.0,0.0610579,"Recombinant human antithrombin supplementation had no impact on hemodynamics, microcirculatory parameters and sequential changes of coagulation parameters (platelet count, fibrinogen level, thrombin-antithrombin complexes and von Willebrand factor).","[{'ForeName': 'Thibault', 'Initials': 'T', 'LastName': 'Duburcq', 'Affiliation': 'INSERM UMR 1190, Translational Research for Diabetes, European Genomic Institute for Diabetes, University of Lille, Lille, France.'}, {'ForeName': 'Arthur', 'Initials': 'A', 'LastName': 'Durand', 'Affiliation': 'CHU Lille, Centre de Réanimation, Lille, France.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Tournoys', 'Affiliation': 'CHU Lille, Centre de Biologie Pathologie, Lille, France.'}, {'ForeName': 'Viviane', 'Initials': 'V', 'LastName': 'Gnemmi', 'Affiliation': 'CHU Lille, Centre de Biologie Pathologie, Lille, France.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Bonner', 'Affiliation': 'INSERM UMR 1190, Translational Research for Diabetes, European Genomic Institute for Diabetes, University of Lille, Lille, France.'}, {'ForeName': 'Valery', 'Initials': 'V', 'LastName': 'Gmyr', 'Affiliation': 'INSERM UMR 1190, Translational Research for Diabetes, European Genomic Institute for Diabetes, University of Lille, Lille, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Hubert', 'Affiliation': 'INSERM UMR 1190, Translational Research for Diabetes, European Genomic Institute for Diabetes, University of Lille, Lille, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Pattou', 'Affiliation': 'INSERM UMR 1190, Translational Research for Diabetes, European Genomic Institute for Diabetes, University of Lille, Lille, France.'}, {'ForeName': 'Mercedes', 'Initials': 'M', 'LastName': 'Jourdain', 'Affiliation': 'INSERM UMR 1190, Translational Research for Diabetes, European Genomic Institute for Diabetes, University of Lille, Lille, France.'}]","Shock (Augusta, Ga.)",['10.1097/SHK.0000000000001274'] 873,31870562,"Effect of a 6-week ""Mediterranean"" dietary intervention on in vitro human embryo development: the Preconception Dietary Supplements in Assisted Reproduction double-blinded randomized controlled trial.","OBJECTIVE To study the impact of increased dietary intake of omega-3 fatty acids, vitamin D, and olive oil for 6 weeks before in vitro fertilization (IVF) or IVF-intracytoplasmic sperm injection (ICSI) on morphokinetic markers of early embryo development. DESIGN A double-blinded randomized controlled trial. SETTING Academic IVF unit. PATIENT(S) A total of 111 couples undergoing IVF or IVF-ICSI were recruited. INTERVENTIONS(S) Fifty-five couples received the 6-week study intervention of a daily supplement drink enriched with omega-3 fatty acids and vitamin D plus additional olive oil and olive oil-based spread, and 56 couples received the control intervention. MAIN OUTCOME MEASURE(S) The primary end point for the study was the time taken for completion of the second cell cycle after fertilization (CC2). Secondary end points included time to complete the third and fourth cell cycles (CC3 and CC4), the synchrony of the second and third cell cycles (S2 and S3), and the day 3 and day 5 Known Implantation Data Scores (KIDScores). RESULT(S) There was no difference in CC2 between the two groups. However, CC4 was accelerated in the study group compared with the control group, and a significantly shortened S3 as well as an increase in KIDScore on day 3 were observed, indicating improved embryo quality in the study group. CONCLUSION(S) This study demonstrates that a short period of dietary supplementation alters the rate of embryo cleavage. Further research is required to investigate the mechanisms that regulate this effect, and whether the impact on embryo development translates into improved clinical outcomes. CLINICAL TRIAL REGISTRATION NUMBER ISRCTN50956936.",2020,There was no difference in CC2 between the two groups.,"['111 couples undergoing IVF or IVF-ICSI were recruited', 'Academic IVF unit in the United Kingdom', '\n\n\nFifty-five couples']","['Preconception Dietary Supplements', 'omega-3 fatty acids, vitamin D, and olive oil', 'daily supplement drink enriched with omega-3 fatty acids and vitamin D plus additional olive oil and olive oil-based spread, and 56 couples received the control intervention', 'IVF-intracytoplasmic sperm injection (ICSI', 'dietary supplementation', 'Mediterranean"" dietary intervention']","['time to complete the third and fourth cell cycles (CC3 and CC4), the synchrony of the second and third cell cycles (S2 and S3), and the day 3 and day 5 Known Implantation Data Scores (KIDScores', 'CC2', 'embryo quality', 'vitro human\xa0embryo development', 'CC4', 'rate of embryo cleavage', 'time taken for completion of the second cell cycle after fertilization (CC2']","[{'cui': 'C4517538', 'cui_str': '111 (qualifier value)'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0015915', 'cui_str': 'Test-Tube Fertilization'}, {'cui': 'C0455164', 'cui_str': 'ICSI'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom'}, {'cui': 'C0450382', 'cui_str': '55 (qualifier value)'}]","[{'cui': 'C0242295', 'cui_str': 'Dietary Supplementations'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0332261', 'cui_str': 'Spread (attribute)'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0015915', 'cui_str': 'Test-Tube Fertilization'}, {'cui': 'C0455164', 'cui_str': 'ICSI'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205438', 'cui_str': 'Fourth (qualifier value)'}, {'cui': 'C0007586', 'cui_str': 'Cell Division Cycle'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205309', 'cui_str': 'Known (qualifier value)'}, {'cui': 'C0021107', 'cui_str': 'Insertion procedure'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0013935', 'cui_str': 'Embryo'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0013936', 'cui_str': 'Embryonic Development'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0015914', 'cui_str': 'Fertilization'}]",55.0,0.509738,There was no difference in CC2 between the two groups.,"[{'ForeName': 'Alexandra J', 'Initials': 'AJ', 'LastName': 'Kermack', 'Affiliation': 'NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, United Kingdom; Centre for Human Development, Stem Cells and Regeneration, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; Complete Fertility Centre, Department of Obstetrics and Gynaecology, Princess Anne Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom. Electronic address: alexandra.kermack@uhs.nhs.uk.'}, {'ForeName': 'Philippa', 'Initials': 'P', 'LastName': 'Lowen', 'Affiliation': 'Complete Fertility Centre, Department of Obstetrics and Gynaecology, Princess Anne Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.'}, {'ForeName': 'Susan J', 'Initials': 'SJ', 'LastName': 'Wellstead', 'Affiliation': 'Complete Fertility Centre, Department of Obstetrics and Gynaecology, Princess Anne Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.'}, {'ForeName': 'Helena L', 'Initials': 'HL', 'LastName': 'Fisk', 'Affiliation': 'Centre for Human Development, Stem Cells and Regeneration, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Montag', 'Affiliation': 'Ilabcomm, St. Augustin, Germany.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Cheong', 'Affiliation': 'NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, United Kingdom; Centre for Human Development, Stem Cells and Regeneration, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; Complete Fertility Centre, Department of Obstetrics and Gynaecology, Princess Anne Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.'}, {'ForeName': 'Clive', 'Initials': 'C', 'LastName': 'Osmond', 'Affiliation': 'Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom.'}, {'ForeName': 'Franchesca D', 'Initials': 'FD', 'LastName': 'Houghton', 'Affiliation': 'Centre for Human Development, Stem Cells and Regeneration, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.'}, {'ForeName': 'Philip C', 'Initials': 'PC', 'LastName': 'Calder', 'Affiliation': 'NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, United Kingdom; Centre for Human Development, Stem Cells and Regeneration, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.'}, {'ForeName': 'Nick S', 'Initials': 'NS', 'LastName': 'Macklon', 'Affiliation': ""NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, United Kingdom; Centre for Human Development, Stem Cells and Regeneration, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; Complete Fertility Centre, Department of Obstetrics and Gynaecology, Princess Anne Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom; Reprohealth, Zealand University Hospital, Roskilde, Denmark; London Women's Clinic, London, United Kingdom.""}]",Fertility and sterility,['10.1016/j.fertnstert.2019.09.041'] 874,30052475,Effects of daily inspiratory muscle training on respiratory muscle strength and chest wall regional volumes in haemodialysis patients: a randomised clinical trial.,"Purpose: Evaluating the effects of interdialytic daily inspiratory muscle training (IMT) on respiratory muscle strength, chest wall regional volumes, diaphragmatic mobility and thickness, pulmonary function, functional capacity, and quality of life (QoL) in haemodialysis (HD) patients. Method: A randomised, and double-blind clinical trial composed of 24 chronic kidney disease patients undergoing HD. Patients were allocated into the IMT group ( n  = 12) or sham group ( n  = 12) and performed daily IMT twice per day with a load of 50% inspiratory muscle strength for the IMT group and 5 cmH 2 O for the sham group during 8 weeks. Respiratory muscle strength, diaphragm thickness and mobility, chest wall regional volumes, functional capacity, and QoL were measured. Results: At the end of the study, an increase in inspiratory and expiratory muscle strength was observed for both groups, but no significant difference was found between them. Changed volume distribution was also observed in the IMT group, with significantly increased inspiratory capacity in the pulmonary compartment compared to the sham group. Conclusions: Daily interdialytic IMT promoted a change in chest wall regional volumes, with an increase in the inspiratory capacity of the pulmonary rib cage. Both groups had increased inspiratory and expiratory muscle strength with daily respiratory exercise. Trial registration: www.ClinicalTrials.gov; study number: NCT02599987; name of trial registry: IMT in Patients with End-stage Renal Disease.Implications for rehabilitationMuscular impairment in chronic kidney disease patients results from a series of common alterations, affecting respiratory muscles.Patients with chronic kidney disease have low values of diaphragmatic thickness.The daily inspiratory muscle training (IMT) or breathing exercise over a period of 8 weeks provided increased respiratory muscle strength.The daily inspiratory muscle training presented a change in tri-compartment distribution of lung volume compared to the sham group, with increased inspiratory capacity of the pulmonary rib cage.",2019,"The daily inspiratory muscle training presented a change in tri-compartment distribution of lung volume compared to the sham group, with increased inspiratory capacity of the pulmonary rib cage.","['Patients with End-stage Renal Disease', '24 chronic kidney disease patients undergoing HD', 'Patients with chronic kidney disease', 'chronic kidney disease patients', 'haemodialysis (HD) patients', 'haemodialysis patients']","['IMT', 'daily inspiratory muscle training', 'daily inspiratory muscle training (IMT) or breathing exercise', 'interdialytic daily inspiratory muscle training (IMT']","['respiratory muscle strength, chest wall regional volumes, diaphragmatic mobility and thickness, pulmonary function, functional capacity, and quality of life (QoL', 'inspiratory and expiratory muscle strength', 'chest wall regional volumes', 'Respiratory muscle strength, diaphragm thickness and mobility, chest wall regional volumes, functional capacity, and QoL', 'respiratory muscle strength and chest wall regional volumes', 'inspiratory capacity', 'respiratory muscle strength', 'Changed volume distribution', 'diaphragmatic thickness']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0022661', 'cui_str': 'End-Stage Kidney Disease'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0454511', 'cui_str': 'Inspiratory muscle training (regime/therapy)'}, {'cui': 'C0006155', 'cui_str': 'Respiratory Muscle Training'}]","[{'cui': 'C0035231', 'cui_str': 'Ventilatory Muscles'}, {'cui': 'C0205076', 'cui_str': 'Chest Wall'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0011980', 'cui_str': 'Respiratory Diaphragm'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0034380'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0021610', 'cui_str': 'Inspiratory Capacity'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}]",,0.040879,"The daily inspiratory muscle training presented a change in tri-compartment distribution of lung volume compared to the sham group, with increased inspiratory capacity of the pulmonary rib cage.","[{'ForeName': 'Ana Irene Carlos de', 'Initials': 'AIC', 'LastName': 'Medeiros', 'Affiliation': 'Department of Physical Therapy, Universidade Federal de Pernambuco, Recife, Brazil.'}, {'ForeName': 'Daniella Cunha', 'Initials': 'DC', 'LastName': 'Brandão', 'Affiliation': 'Department of Physical Therapy, Universidade Federal de Pernambuco, Recife, Brazil.'}, {'ForeName': 'Renata Janaína Pereira de', 'Initials': 'RJP', 'LastName': 'Souza', 'Affiliation': 'Department of Physical Therapy, Universidade Federal de Pernambuco, Recife, Brazil.'}, {'ForeName': 'Helen Kerlen Bastos', 'Initials': 'HKB', 'LastName': 'Fuzari', 'Affiliation': 'Department of Physical Therapy, Universidade Federal de Pernambuco, Recife, Brazil.'}, {'ForeName': 'Carlos Eduardo Santos Rêgo', 'Initials': 'CESR', 'LastName': 'Barros', 'Affiliation': 'Department of Physical Therapy, Universidade Federal de Pernambuco, Recife, Brazil.'}, {'ForeName': 'Jefferson Belarmino Nunes', 'Initials': 'JBN', 'LastName': 'Barbosa', 'Affiliation': 'Department of Physical Therapy, Universidade Federal de Pernambuco, Recife, Brazil.'}, {'ForeName': 'Jéssica Costa', 'Initials': 'JC', 'LastName': 'Leite', 'Affiliation': 'Department of Physical Therapy, Universidade Federal de Pernambuco, Recife, Brazil.'}, {'ForeName': 'Frederico Castelo Branco', 'Initials': 'FCB', 'LastName': 'Cavalcanti', 'Affiliation': 'Unit of Nephrology, Real Hospital Português de Beneficência em Pernambuco, Recife, Brazil.'}, {'ForeName': 'Arméle', 'Initials': 'A', 'LastName': 'Dornelas de Andrade', 'Affiliation': 'Department of Physical Therapy, Universidade Federal de Pernambuco, Recife, Brazil.'}, {'ForeName': 'Patrícia Érika', 'Initials': 'PÉ', 'LastName': 'de Melo Marinho', 'Affiliation': 'Department of Physical Therapy, Universidade Federal de Pernambuco, Recife, Brazil.'}]",Disability and rehabilitation,['10.1080/09638288.2018.1485181'] 875,29869897,"Risky, Dramatic, and Unrealistic: Reality Television Portrayals of Pregnancy and Childbirth and their Effects on Women's Fear and Self-Efficacy.","Because portrayals of pregnancy and childbirth on reality television (TV) often highlight risk, drama, and the use of medical interventions, it is possible that exposure to this content could influence women's fear of childbirth and childbirth self-efficacy. To test this question, we conducted an experiment among 213 undergraduate women who were assigned to view a video clip of either medicalized births from reality TV, midwife-attended births from reality TV, or a neutral childbirth education clip. Findings indicated that childbirth attitudes did vary across conditions, with participants in the medicalized condition reporting the highest fear of childbirth and lowest childbirth self-efficacy. Participants' feelings about potential pregnancy also varied depending on the clip viewed. Because the likelihood of witnessing a birth in person before becoming pregnant is lower than in previous years, these findings have significant implications for how women form their understandings of pregnancy and childbirth.",2019,"Findings indicated that childbirth attitudes did vary across conditions, with participants in the medicalized condition reporting the highest fear of childbirth and lowest childbirth self-efficacy.",['213 undergraduate women who were assigned to view a'],"['video clip of either medicalized births from reality TV, midwife-attended births from reality TV, or a neutral childbirth education clip']","['childbirth attitudes', 'highest fear of childbirth and lowest childbirth self-efficacy']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0449911', 'cui_str': 'View (attribute)'}]","[{'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0175722', 'cui_str': 'Clip'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0425187', 'cui_str': 'Midwife attends (finding)'}, {'cui': 'C3658257', 'cui_str': 'Childbirth Classes'}]","[{'cui': 'C1148523', 'cui_str': 'Childbirth'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0522187', 'cui_str': 'Tocophobia (finding)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",213.0,0.046954,"Findings indicated that childbirth attitudes did vary across conditions, with participants in the medicalized condition reporting the highest fear of childbirth and lowest childbirth self-efficacy.","[{'ForeName': 'Kali', 'Initials': 'K', 'LastName': 'Vitek', 'Affiliation': 'Department of Psychology, University of Michigan.'}, {'ForeName': 'L Monique', 'Initials': 'LM', 'LastName': 'Ward', 'Affiliation': 'Department of Psychology, University of Michigan.'}]",Health communication,['10.1080/10410236.2018.1481708'] 876,31642350,Editor's Choice: Consistency tendency and the theory of planned behavior: a randomized controlled crossover trial in a physical activity context.,"Objective: This study examined the effects of consistency tendency on the predictive power of the theory of planned behavior (TPB) in relation to physical activity behavior. Methods: In this randomized controlled cross-over trial, we recruited 770 undergraduate students from Indonesia who were randomly assigned into two groups. Participants completed physical activity versions of TPB measures at T1 (baseline) and T2 (post 1 week), and the International Physical Activity Questionnaire at T3 (post 1 month). At T1 and T2, the TPB questions were either presented in ensemble-order (i.e., consistency tendency supressed) or alternate-order (i.e., consistency tendency facilitated). Results: The parameter estimates of the model (CFI > .92, TLI > .90, SRMR < .08, RMSEA < .08) aligned with the tenets of TPB. As compared to ensemble-order, a TPB measured in alternate-order yielded stronger cross-sectional relationships, but this pattern did not appear in the prospective relationships in TPB (i.e., intention/perceived behavioral control and behavior). Conclusions: Consistency tendency inflated the factor correlations of cross-sectionally measured TPB variables, but the inflation was not observed in the prospective prediction of behavior. Health psychology questionnaires with items presented in ensemble order may represent a viable means of reducing the confounding effect of consistency tendency.",2020,"As compared to ensemble-order, a TPB measured in alternate-order yielded stronger cross-sectional relationships, but this pattern did not appear in the prospective relationships in TPB (i.e., intention/perceived behavioral control and behavior). ",['770 undergraduate students from Indonesia who were randomly assigned into two groups'],['planned behavior (TPB'],"['physical activity versions of TPB measures', 'International Physical Activity Questionnaire']","[{'cui': 'C4517873', 'cui_str': '770'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0021247', 'cui_str': 'East Indies'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",770.0,0.0292494,"As compared to ensemble-order, a TPB measured in alternate-order yielded stronger cross-sectional relationships, but this pattern did not appear in the prospective relationships in TPB (i.e., intention/perceived behavioral control and behavior). ","[{'ForeName': 'Derwin K C', 'Initials': 'DKC', 'LastName': 'Chan', 'Affiliation': 'Faculty of Education and Human Development, The Education University of Hong Kong, New Territories, Hong Kong.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Stenling', 'Affiliation': 'University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'Cleoputri', 'Initials': 'C', 'LastName': 'Yusainy', 'Affiliation': 'Department of Psychology, Brawijaya University, Malang, Indonesia.'}, {'ForeName': 'Ziadatul', 'Initials': 'Z', 'LastName': 'Hikmiah', 'Affiliation': 'Department of Psychology, Brawijaya University, Malang, Indonesia.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Ivarsson', 'Affiliation': 'School of Health and Welfare, Halmstad University, Halmstad, Sweden.'}, {'ForeName': 'Martin S', 'Initials': 'MS', 'LastName': 'Hagger', 'Affiliation': 'University of California, Merced, CA, USA.'}, {'ForeName': 'Ryan E', 'Initials': 'RE', 'LastName': 'Rhodes', 'Affiliation': 'Health and Physical Education, University of Victoria, Victoria, BC, Canada.'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Beauchamp', 'Affiliation': 'University of British Columbia, Vancouver, BC, Canada.'}]",Psychology & health,['10.1080/08870446.2019.1677904'] 877,31604060,Is Low-Level Laser Therapy Effective for Pain Control After the Surgical Removal of Unerupted Third Molars? A Randomized Trial.,"PURPOSE One of the main challenges after extraction of unerupted third molars is pain control, and one of the treatments for pain control is low-level laser therapy (LLLT). Thus, this study aimed to assess the effectiveness of LLLT for pain control after extraction of lower third molars. MATERIALS AND METHODS This randomized, double-blind, split-mouth study included patients who required bilateral extraction of unerupted lower third molars. Patients received LLLT on 1 side (laser group) but not on the opposite side (control group). On the experimental side, each patient received a laser application at 5 intraoral points for 30 seconds per point. This procedure was simulated on the control side. The pain control response was assessed with a modified pain visual analog scale at the following times: immediately after surgery (T0), after laser application (T1), 24 hours after surgery (T2), 48 hours after surgery (T3), and 72 hours after surgery (T4). RESULTS Thirty-two patients, 56.25% of whom were women, underwent extraction; the average age was 22.2 years. At the times analyzed, the laser group presented better results than the control group. As for the times, there were differences in pain scores between T0 (8.03 ± 14.87) and T3 (2.66 ± 4.23), as well as T4 (3.36 ± 7.83), in the laser group and differences between T0 (19.76 ± 26.66) and T3 (7.11 ± 10.76), as well as T4 (6.26 ± 13.14), in the control group. CONCLUSION LLLT was effective in reducing pain after surgical removal of unerupted third molars. At T3 and T4, pain reduction in relation to T0 was noted in both groups.",2020,"At T3 and T4, pain reduction in relation to T0 was noted in both groups.","['Thirty-two patients, 56.25% of whom were women, underwent extraction; the average age was 22.2\xa0years', 'patients who required bilateral extraction of unerupted lower third molars']",['LLLT'],"['pain scores', 'Pain Control', 'pain', 'modified pain visual analog scale', 'pain control response']","[{'cui': 'C0450357', 'cui_str': '32 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0442051', 'cui_str': 'Lower third (qualifier value)'}, {'cui': 'C0026367', 'cui_str': 'Molar'}]","[{'cui': 'C4019433', 'cui_str': 'LLLT'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C1304888', 'cui_str': 'Pain control (procedure)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",32.0,0.181256,"At T3 and T4, pain reduction in relation to T0 was noted in both groups.","[{'ForeName': 'Pâmela Letícia', 'Initials': 'PL', 'LastName': 'Santos', 'Affiliation': 'Assistant Professor, Department of Health Sciences, Implantology Post Graduation Course, Dental School, University of Araraquara, Araraquara, Brazil. Electronic address: pamelalsantos@hotmail.com.'}, {'ForeName': 'Ana Paula', 'Initials': 'AP', 'LastName': 'Marotto', 'Affiliation': 'Surgeon-Dentist, Department of Health Sciences, University of Araraquara (UNIARA), Araraquara, São Paulo, Brazil.'}, {'ForeName': 'Thaiz', 'Initials': 'T', 'LastName': 'Zatta da Silva', 'Affiliation': 'Department of Health Sciences, University of Araraquara (UNIARA), Araraquara, São Paulo, Brazil.'}, {'ForeName': 'Mariele Pecorali', 'Initials': 'MP', 'LastName': 'Bottura', 'Affiliation': 'Surgeon-Dentist, Department of Health Sciences, University of Araraquara (UNIARA), Araraquara, São Paulo, Brazil.'}, {'ForeName': 'Mayra', 'Initials': 'M', 'LastName': 'Valencise', 'Affiliation': 'Surgeon-Dentist, Department of Health Sciences, University of Araraquara (UNIARA), Araraquara, São Paulo, Brazil.'}, {'ForeName': 'Daniela Oliveira', 'Initials': 'DO', 'LastName': 'Marques', 'Affiliation': 'Department of Health Sciences, University of Araraquara (UNIARA), Araraquara, São Paulo, Brazil.'}, {'ForeName': 'Thallita Pereira', 'Initials': 'TP', 'LastName': 'Queiroz', 'Affiliation': 'Assistant Professor, Department of Health Sciences, Implantology Post Graduation Course, Dental School, University of Araraquara, Araraquara, Brazil.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.08.029'] 878,29396217,"Effects of water quality, sanitation, handwashing, and nutritional interventions on diarrhoea and child growth in rural Bangladesh: a cluster randomised controlled trial.","BACKGROUND Diarrhoea and growth faltering in early childhood are associated with subsequent adverse outcomes. We aimed to assess whether water quality, sanitation, and handwashing interventions alone or combined with nutrition interventions reduced diarrhoea or growth faltering. METHODS The WASH Benefits Bangladesh cluster-randomised trial enrolled pregnant women from villages in rural Bangladesh and evaluated outcomes at 1-year and 2-years' follow-up. Pregnant women in geographically adjacent clusters were block-randomised to one of seven clusters: chlorinated drinking water (water); upgraded sanitation (sanitation); promotion of handwashing with soap (handwashing); combined water, sanitation, and handwashing; counselling on appropriate child nutrition plus lipid-based nutrient supplements (nutrition); combined water, sanitation, handwashing, and nutrition; and control (data collection only). Primary outcomes were caregiver-reported diarrhoea in the past 7 days among children who were in utero or younger than 3 years at enrolment and length-for-age Z score among children born to enrolled pregnant women. Masking was not possible for data collection, but analyses were masked. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov, number NCC01590095. FINDINGS Between May 31, 2012, and July 7, 2013, 5551 pregnant women in 720 clusters were randomly allocated to one of seven groups. 1382 women were assigned to the control group; 698 to water; 696 to sanitation; 688 to handwashing; 702 to water, sanitation, and handwashing; 699 to nutrition; and 686 to water, sanitation, handwashing, and nutrition. 331 (6%) women were lost to follow-up. Data on diarrhoea at year 1 or year 2 (combined) were available for 14 425 children (7331 in year 1, 7094 in year 2) and data on length-for-age Z score in year 2 were available for 4584 children (92% of living children were measured at year 2). All interventions had high adherence. Compared with a prevalence of 5·7% (200 of 3517 child weeks) in the control group, 7-day diarrhoea prevalence was lower among index children and children under 3 years at enrolment who received sanitation (61 [3·5%] of 1760; prevalence ratio 0·61, 95% CI 0·46-0·81), handwashing (62 [3·5%] of 1795; 0·60, 0·45-0·80), combined water, sanitation, and handwashing (74 [3·9%] of 1902; 0·69, 0·53-0·90), nutrition (62 [3·5%] of 1766; 0·64, 0·49-0·85), and combined water, sanitation, handwashing, and nutrition (66 [3·5%] of 1861; 0·62, 0·47-0·81); diarrhoea prevalence was not significantly lower in children receiving water treatment (90 [4·9%] of 1824; 0·89, 0·70-1·13). Compared with control (mean length-for-age Z score -1·79), children were taller by year 2 in the nutrition group (mean difference 0·25 [95% CI 0·15-0·36]) and in the combined water, sanitation, handwashing, and nutrition group (0·13 [0·02-0·24]). The individual water, sanitation, and handwashing groups, and combined water, sanitation, and handwashing group had no effect on linear growth. INTERPRETATION Nutrient supplementation and counselling modestly improved linear growth, but there was no benefit to the integration of water, sanitation, and handwashing with nutrition. Adherence was high in all groups and diarrhoea prevalence was reduced in all intervention groups except water treatment. Combined water, sanitation, and handwashing interventions provided no additive benefit over single interventions. FUNDING Bill & Melinda Gates Foundation.",2018,Adherence was high in all groups and diarrhoea prevalence was reduced in all intervention groups except water treatment.,"['rural Bangladesh', 'children born to enrolled pregnant women', 'Pregnant women in geographically adjacent clusters', '5551 pregnant women in 720 clusters', '1382 women were assigned to the control group; 698 to water; 696 to sanitation; 688 to handwashing; 702 to water, sanitation, and handwashing; 699 to nutrition; and 686 to water, sanitation, handwashing, and nutrition', 'Between May 31, 2012, and July 7, 2013', ""pregnant women from villages in rural Bangladesh and evaluated outcomes at 1-year and 2-years' follow-up"", 'children who were in utero or younger than 3 years at enrolment and length-for-age']","['water quality, sanitation, and handwashing interventions alone or combined with nutrition interventions', 'Combined water, sanitation, and handwashing interventions', 'water quality, sanitation, handwashing, and nutritional interventions', 'chlorinated drinking water (water); upgraded sanitation (sanitation); promotion of handwashing with soap (handwashing); combined water, sanitation, and handwashing; counselling on appropriate child nutrition plus lipid-based nutrient supplements (nutrition); combined water, sanitation, handwashing, and nutrition; and control (data collection only']","['7-day diarrhoea prevalence', 'Z score', 'diarrhoea or growth faltering', 'Adherence', 'diarrhoea', 'caregiver-reported diarrhoea', 'diarrhoea prevalence', 'diarrhoea and child growth']","[{'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0205117', 'cui_str': 'Juxta-posed (qualifier value)'}, {'cui': 'C4517865', 'cui_str': 'Seven hundred and twenty'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0036172', 'cui_str': 'Sanitation'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0562518', 'cui_str': 'Village environment (environment)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0597680', 'cui_str': 'Water Quality'}, {'cui': 'C0036172', 'cui_str': 'Sanitation'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0599638', 'cui_str': 'Drinking Water'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0037392', 'cui_str': 'Soap'}, {'cui': 'C0341618', 'cui_str': 'Counsel (occupation)'}, {'cui': 'C1720755', 'cui_str': 'Child Nutritional Physiology Phenomena'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0600644', 'cui_str': 'Collection'}]","[{'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",5551.0,0.14078,Adherence was high in all groups and diarrhoea prevalence was reduced in all intervention groups except water treatment.,"[{'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Luby', 'Affiliation': 'Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA. Electronic address: sluby@stanford.edu.'}, {'ForeName': 'Mahbubur', 'Initials': 'M', 'LastName': 'Rahman', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'Benjamin F', 'Initials': 'BF', 'LastName': 'Arnold', 'Affiliation': 'School of Public Health University of California Berkeley, Berkeley, CA, USA.'}, {'ForeName': 'Leanne', 'Initials': 'L', 'LastName': 'Unicomb', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'Sania', 'Initials': 'S', 'LastName': 'Ashraf', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Winch', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Christine P', 'Initials': 'CP', 'LastName': 'Stewart', 'Affiliation': 'Department of Nutrition, University of California Davis, Davis, CA, USA.'}, {'ForeName': 'Farzana', 'Initials': 'F', 'LastName': 'Begum', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'Faruqe', 'Initials': 'F', 'LastName': 'Hussain', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'Jade', 'Initials': 'J', 'LastName': 'Benjamin-Chung', 'Affiliation': 'School of Public Health University of California Berkeley, Berkeley, CA, USA.'}, {'ForeName': 'Elli', 'Initials': 'E', 'LastName': 'Leontsini', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Abu M', 'Initials': 'AM', 'LastName': 'Naser', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'Sarker M', 'Initials': 'SM', 'LastName': 'Parvez', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'Alan E', 'Initials': 'AE', 'LastName': 'Hubbard', 'Affiliation': 'School of Public Health University of California Berkeley, Berkeley, CA, USA.'}, {'ForeName': 'Audrie', 'Initials': 'A', 'LastName': 'Lin', 'Affiliation': 'School of Public Health University of California Berkeley, Berkeley, CA, USA.'}, {'ForeName': 'Fosiul A', 'Initials': 'FA', 'LastName': 'Nizame', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'Kaniz', 'Initials': 'K', 'LastName': 'Jannat', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'Ayse', 'Initials': 'A', 'LastName': 'Ercumen', 'Affiliation': 'School of Public Health University of California Berkeley, Berkeley, CA, USA.'}, {'ForeName': 'Pavani K', 'Initials': 'PK', 'LastName': 'Ram', 'Affiliation': 'School of Public Health and Health Professions, University of Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Kishor K', 'Initials': 'KK', 'LastName': 'Das', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'Jaynal', 'Initials': 'J', 'LastName': 'Abedin', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'Thomas F', 'Initials': 'TF', 'LastName': 'Clasen', 'Affiliation': 'Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Kathryn G', 'Initials': 'KG', 'LastName': 'Dewey', 'Affiliation': 'Department of Nutrition, University of California Davis, Davis, CA, USA.'}, {'ForeName': 'Lia C', 'Initials': 'LC', 'LastName': 'Fernald', 'Affiliation': 'School of Public Health University of California Berkeley, Berkeley, CA, USA.'}, {'ForeName': 'Clair', 'Initials': 'C', 'LastName': 'Null', 'Affiliation': 'Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Tahmeed', 'Initials': 'T', 'LastName': 'Ahmed', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Colford', 'Affiliation': 'School of Public Health University of California Berkeley, Berkeley, CA, USA.'}]",The Lancet. Global health,['10.1016/S2214-109X(17)30490-4'] 879,29396219,"Effects of water quality, sanitation, handwashing, and nutritional interventions on diarrhoea and child growth in rural Kenya: a cluster-randomised controlled trial.","BACKGROUND Poor nutrition and exposure to faecal contamination are associated with diarrhoea and growth faltering, both of which have long-term consequences for child health. We aimed to assess whether water, sanitation, handwashing, and nutrition interventions reduced diarrhoea or growth faltering. METHODS The WASH Benefits cluster-randomised trial enrolled pregnant women from villages in rural Kenya and evaluated outcomes at 1 year and 2 years of follow-up. Geographically-adjacent clusters were block-randomised to active control (household visits to measure mid-upper-arm circumference), passive control (data collection only), or compound-level interventions including household visits to promote target behaviours: drinking chlorinated water (water); safe sanitation consisting of disposing faeces in an improved latrine (sanitation); handwashing with soap (handwashing); combined water, sanitation, and handwashing; counselling on appropriate maternal, infant, and young child feeding plus small-quantity lipid-based nutrient supplements from 6-24 months (nutrition); and combined water, sanitation, handwashing, and nutrition. Primary outcomes were caregiver-reported diarrhoea in the past 7 days and length-for-age Z score at year 2 in index children born to the enrolled pregnant women. Masking was not possible for data collection, but analyses were masked. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01704105. FINDINGS Between Nov 27, 2012, and May 21, 2014, 8246 women in 702 clusters were enrolled and randomly assigned an intervention or control group. 1919 women were assigned to the active control group; 938 to passive control; 904 to water; 892 to sanitation; 917 to handwashing; 912 to combined water, sanitation, and handwashing; 843 to nutrition; and 921 to combined water, sanitation, handwashing, and nutrition. Data on diarrhoea at year 1 or year 2 were available for 6494 children and data on length-for-age Z score in year 2 were available for 6583 children (86% of living children were measured at year 2). Adherence indicators for sanitation, handwashing, and nutrition were more than 70% at year 1, handwashing fell to less than 25% at year 2, and for water was less than 45% at year 1 and less than 25% at year 2; combined groups were comparable to single groups. None of the interventions reduced diarrhoea prevalence compared with the active control. Compared with active control (length-for-age Z score -1·54) children in nutrition and combined water, sanitation, handwashing, and nutrition were taller by year 2 (mean difference 0·13 [95% CI 0·01-0·25] in the nutrition group; 0·16 [0·05-0·27] in the combined water, sanitation, handwashing, and nutrition group). The individual water, sanitation, and handwashing groups, and combined water, sanitation, and handwashing group had no effect on linear growth. INTERPRETATION Behaviour change messaging combined with technologically simple interventions such as water treatment, household sanitation upgrades from unimproved to improved latrines, and handwashing stations did not reduce childhood diarrhoea or improve growth, even when adherence was at least as high as has been achieved by other programmes. Counselling and supplementation in the nutrition group and combined water, sanitation, handwashing, and nutrition interventions led to small growth benefits, but there was no advantage to integrating water, sanitation, and handwashing with nutrition. The interventions might have been more efficacious with higher adherence or in an environment with lower baseline sanitation coverage, especially in this context of high diarrhoea prevalence. FUNDING Bill & Melinda Gates Foundation, United States Agency for International Development.",2018,None of the interventions reduced diarrhoea prevalence compared with the active control.,"['enrolled pregnant women from villages in rural Kenya and evaluated outcomes at 1 year and 2 years of follow-up', 'Between Nov 27, 2012, and May 21, 2014, 8246 women in 702 clusters', 'rural Kenya', '1919 women were assigned to the active control group; 938 to passive control; 904 to water; 892 to sanitation; 917 to handwashing; 912 to']","['water, sanitation, handwashing, and nutrition interventions', 'passive control (data collection only), or compound-level interventions including household visits to promote target behaviours: drinking chlorinated water (water); safe sanitation consisting of disposing faeces in an improved latrine (sanitation); handwashing with soap (handwashing); combined water, sanitation, and handwashing; counselling on appropriate maternal, infant, and young child feeding plus small-quantity lipid-based nutrient supplements from 6-24 months (nutrition); and combined water, sanitation, handwashing, and nutrition', 'water quality, sanitation, handwashing, and nutritional interventions', 'combined water, sanitation, and handwashing; 843 to nutrition; and 921 to combined water, sanitation, handwashing, and nutrition']","['Adherence indicators for sanitation, handwashing, and nutrition', 'Z score', 'diarrhoea or growth faltering', 'diarrhoea', 'caregiver-reported diarrhoea in the past 7 days and length-for-age', 'diarrhoea prevalence', 'diarrhoea and child growth']","[{'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0562518', 'cui_str': 'Village environment (environment)'}, {'cui': 'C0022558', 'cui_str': 'Republic of Kenya'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0036172', 'cui_str': 'Sanitation'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}]","[{'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0036172', 'cui_str': 'Sanitation'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0010995', 'cui_str': 'Data Collection'}, {'cui': 'C0205198', 'cui_str': 'Compound (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0023124', 'cui_str': 'Latrines'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0037392', 'cui_str': 'Soap'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0341618', 'cui_str': 'Counsel (occupation)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C1265611', 'cui_str': 'Quantity finding'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0597680', 'cui_str': 'Water Quality'}]","[{'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0036172', 'cui_str': 'Sanitation'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",1919.0,0.149973,None of the interventions reduced diarrhoea prevalence compared with the active control.,"[{'ForeName': 'Clair', 'Initials': 'C', 'LastName': 'Null', 'Affiliation': 'Innovations for Poverty Action, Kakamega, Kenya; Center for International Policy Research and Evaluation, Mathematica Policy Research, Washington, DC, USA; Rollins School of Public Health, Emory University, Atlanta, GA, USA. Electronic address: cnull@mathematica-mpr.com.'}, {'ForeName': 'Christine P', 'Initials': 'CP', 'LastName': 'Stewart', 'Affiliation': 'Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'Amy J', 'Initials': 'AJ', 'LastName': 'Pickering', 'Affiliation': 'Department of Civil and Environmental Engineering, Stanford University, Stanford, CA, USA; Department of Civil and Environmental Engineering, Tufts University, Medford, MA, USA.'}, {'ForeName': 'Holly N', 'Initials': 'HN', 'LastName': 'Dentz', 'Affiliation': 'Innovations for Poverty Action, Kakamega, Kenya; Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'Benjamin F', 'Initials': 'BF', 'LastName': 'Arnold', 'Affiliation': 'Division of Epidemiology, School of Public Health, University of California, Berkeley, CA, USA.'}, {'ForeName': 'Charles D', 'Initials': 'CD', 'LastName': 'Arnold', 'Affiliation': 'Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'Jade', 'Initials': 'J', 'LastName': 'Benjamin-Chung', 'Affiliation': 'Division of Epidemiology, School of Public Health, University of California, Berkeley, CA, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Clasen', 'Affiliation': 'Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Kathryn G', 'Initials': 'KG', 'LastName': 'Dewey', 'Affiliation': 'Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'Lia C H', 'Initials': 'LCH', 'LastName': 'Fernald', 'Affiliation': 'Division of Community Health Sciences, School of Public Health, University of California, Berkeley, CA, USA.'}, {'ForeName': 'Alan E', 'Initials': 'AE', 'LastName': 'Hubbard', 'Affiliation': 'Division of Biostatistics, School of Public Health, University of California, Berkeley, CA, USA.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Kariger', 'Affiliation': 'Division of Community Health Sciences, School of Public Health, University of California, Berkeley, CA, USA.'}, {'ForeName': 'Audrie', 'Initials': 'A', 'LastName': 'Lin', 'Affiliation': 'Division of Epidemiology, School of Public Health, University of California, Berkeley, CA, USA.'}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Luby', 'Affiliation': 'Department of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Mertens', 'Affiliation': 'Division of Epidemiology, School of Public Health, University of California, Berkeley, CA, USA.'}, {'ForeName': 'Sammy M', 'Initials': 'SM', 'LastName': 'Njenga', 'Affiliation': 'Eastern and Southern Africa Centre of International Parasite Control, Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Geoffrey', 'Initials': 'G', 'LastName': 'Nyambane', 'Affiliation': 'Innovations for Poverty Action, Kakamega, Kenya.'}, {'ForeName': 'Pavani K', 'Initials': 'PK', 'LastName': 'Ram', 'Affiliation': 'Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Colford', 'Affiliation': 'Division of Epidemiology, School of Public Health, University of California, Berkeley, CA, USA.'}]",The Lancet. Global health,['10.1016/S2214-109X(18)30005-6'] 880,29302609,Effectiveness of the Healthy Lifestyles Programme (HeLP) to prevent obesity in UK primary-school children: a cluster randomised controlled trial.,"Background Although childhood overweight and obesity prevalence has increased substantially worldwide in the past three decades, scarce evidence exists for effective preventive strategies. We aimed to establish whether a school-based intervention for children aged 9-10 years would prevent excessive weight gain after 24 months. Methods This pragmatic cluster randomised controlled trial of the Healthy Lifestyles Programme (HeLP), a school-based obesity prevention intervention, was done in 32 schools in southwest England. All state-run primary and junior schools in Devon and Plymouth (UK) with enough pupils for at least one year-5 class were eligible. Schools were assigned (1:1) using a computer-generated sequence to either intervention or control, stratified by the number of year-5 classes (one vs more than one) and the proportion of children eligible for free school meals (<19% [the national average] vs ≥19%). HeLP was delivered to year-5 children (ages 9-10 years) over 1 year, and included dynamic and interactive activities such as physical activity workshops, education sessions delivered by teachers with short homework tasks, drama sessions, and setting goals to modify behaviour (with parental support and one-to-one discussions with HeLP coordinators). The primary outcome was change in body-mass index (BMI) standard deviation score (SDS) between baseline and 24 months, analysed in children with BMI data available for both timepoints. This study is registered with the International Standard Randomised Controlled Trial register, number ISRCTN15811706, and the trial status is complete. Findings Between March 21, 2012, and Sept 30, 2013, 32 eligible schools with 1324 children were recruited, of which 16 schools (676 children) were randomly assigned to the HeLP intervention and 16 schools (648 children) to control. All schools that began the trial completed the intervention, and 1244 children (628 in intervention group and 616 in control group) had BMI data at both baseline and 24 months for the primary outcome analysis. Mean BMI SDS was 0·32 (SD 1·16) at baseline and 0·35 (1·25) at 24 months in the intervention group, and 0·18 (1·14) at baseline and 0·22 (1·22) at 24 months in the control group. With adjustment for school-level clustering, baseline BMI scores, sex, cohort, and number of year-5 classes and socioeconomic status of each school, the mean difference in BMI SDS score (intervention-control) at 24 months was -0·02 (95% CI -0·09 to 0·05), p=0·57. One parent reported an adverse event related to their child's eating and activity behaviours, but agreed for the child to continue trial participation after discussion with the chief investigator. Interpretation Despite a theoretically informed and extensively piloted intervention that achieved high levels of engagement, follow-up, and fidelity of delivery, we found no effect of the intervention on preventing overweight or obesity. Although schools are an ideal setting in which to deliver population-based interventions, school-based interventions might not be sufficiently intense to affect both the school and the family environment, and hence the weight status of children. Future research should focus on more upstream determinants of obesity and use whole-systems approaches. Funding UK National Institute for Health Research, Public Health Research Programme.",2018,"This pragmatic cluster randomised controlled trial of the Healthy Lifestyles Programme (HeLP), a school-based obesity prevention intervention, was done in 32 schools in southwest England.","['UK primary-school children', 'children aged 9-10 years', '32 schools in southwest England', 'All state-run primary and junior schools in Devon and Plymouth (UK) with enough pupils for at least one year-5 class were eligible', 'Findings\n\n\nBetween March 21, 2012, and Sept 30, 2013, 32 eligible schools with 1324 children were recruited, of which 16 schools (676 children']","['HeLP intervention', 'dynamic and interactive activities such as physical activity workshops, education sessions delivered by teachers with short homework tasks, drama sessions, and setting goals to modify behaviour (with parental support and one-to-one discussions with HeLP coordinators', 'school-based intervention', 'Healthy Lifestyles Programme (HeLP), a school-based obesity prevention intervention', 'Healthy Lifestyles Programme (HeLP']","['BMI SDS score', 'overweight or obesity', 'Mean BMI SDS', 'change in body-mass index (BMI) standard deviation score (SDS', 'BMI data', 'excessive weight gain']","[{'cui': 'C0033145', 'cui_str': 'Primary Schools'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0557793', 'cui_str': 'Junior school (environment)'}, {'cui': 'C0454849', 'cui_str': 'Devonshire (geographic location)'}, {'cui': 'C0034121', 'cui_str': 'Pupil'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C2607943', 'cui_str': 'findings'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0221457', 'cui_str': 'Teacher (occupation)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0589414', 'cui_str': 'Homework, function (observable entity)'}, {'cui': 'C0013109', 'cui_str': 'Drama'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0018017', 'cui_str': 'Goals'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0418946', 'cui_str': 'Parental support (regime/therapy)'}, {'cui': 'C0557061', 'cui_str': 'Discussion (procedure)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0000765', 'cui_str': 'Excessive weight gain (finding)'}]",1324.0,0.0875582,"This pragmatic cluster randomised controlled trial of the Healthy Lifestyles Programme (HeLP), a school-based obesity prevention intervention, was done in 32 schools in southwest England.","[{'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Lloyd', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, University of Exeter, Exeter, UK. Electronic address: j.j.lloyd@exeter.ac.uk.'}, {'ForeName': 'Siobhan', 'Initials': 'S', 'LastName': 'Creanor', 'Affiliation': 'Peninsula Clinical Trials Unit and Medical Statistics, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Logan', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, University of Exeter, Exeter, UK.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Green', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, University of Exeter, Exeter, UK.'}, {'ForeName': 'Sarah G', 'Initials': 'SG', 'LastName': 'Dean', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, University of Exeter, Exeter, UK.'}, {'ForeName': 'Melvyn', 'Initials': 'M', 'LastName': 'Hillsdon', 'Affiliation': 'Sport and Health Sciences, University of Exeter, Exeter, UK.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Abraham', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, University of Exeter, Exeter, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Tomlinson', 'Affiliation': 'Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Pearson', 'Affiliation': 'Public Health Devon, Devon County Council Commissioning Headquarters, Exeter, UK.'}, {'ForeName': 'Rod S', 'Initials': 'RS', 'LastName': 'Taylor', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, University of Exeter, Exeter, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Ryan', 'Affiliation': 'ISCA Academy, Earl Richards Road South, Exeter, UK.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Price', 'Affiliation': 'Sport and Health Sciences, University of Exeter, Exeter, UK.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Streeter', 'Affiliation': 'Peninsula Clinical Trials Unit and Medical Statistics, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK.'}, {'ForeName': 'Katrina', 'Initials': 'K', 'LastName': 'Wyatt', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, University of Exeter, Exeter, UK.'}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(17)30151-7'] 881,31622740,"Efficacy of Auricular Neurostimulation in Adolescents With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial.","BACKGROUND & AIMS Auricular neurostimulation therapy, in which a noninvasive device delivers percutaneous electrical nerve field stimulation (PENFS) to the external ear, is effective in pediatric patients with functional abdominal pain disorders. Preclinical studies showed that PENFS modulates central pain pathways and attenuates visceral hyperalgesia. We evaluated the efficacy of PENFS in adolescents with irritable bowel syndrome (IBS). METHODS We analyzed data from pediatric patients with IBS who participated in a double-blind trial at a tertiary care gastroenterology clinic from June 2015 through November 2016. Patients were randomly assigned to groups that received PENFS (n = 27; median age, 15.3 y; 24 female) or a sham stimulation (n = 23; median age, 15.6 y; 21 female), 5 days/week for 4 weeks. The primary endpoint was number of patients with a reduction of 30% or more in worst abdominal pain severity after 3 weeks. Secondary endpoints were reduction in composite abdominal pain severity score, reduction in usual abdominal pain severity, and improvement in global symptom based on a symptom response scale (-7 to +7; 0 = no change) after 3 weeks. RESULTS Reductions of 30% or more in worst abdominal pain were observed in 59% of patients who received PENFS vs 26% of patients who received the sham stimulation (P = .024). The patients who received PENFS had a composite pain median score of 7.5 (interquartile range [IQR], 3.6-14.4) vs 14.4 for the sham group (IQR, 4.5-39.2) (P = .026) and a usual pain median score of 3.0 (IQR, 3.0-5.0) vs 5.0 in the sham group (IQR, 3.0-7.0) (P = .029). A symptom response scale score of 2 or more was observed in 82% of patients who received PENFS vs 26% of patients in the sham group (P ≤ .001). No significant side effects were reported. CONCLUSIONS Auricular neurostimulation reduces abdominal pain scores and improves overall wellbeing in adolescents with IBS. PENFS is a noninvasive treatment option for pediatric patients with functional bowel disorders. ClinicalTrials.gov no: NCT02367729.",2020,"RESULTS Reductions of 30% or more in worst abdominal pain were observed in 59% of patients who received PENFS vs 26% of patients who received the sham stimulation (P=.024).","['n=27; median age, 15.3 y; 24 female) or a', 'pediatric patients with functional bowel disorders', 'adolescents with irritable bowel syndrome (IBS', 'adolescents with IBS', 'Adolescents With Irritable Bowel Syndrome', 'pediatric patients with IBS who participated in a double-blind trial at a tertiary care gastroenterology clinic from June 2015 through November 2016', 'pediatric patients with functional abdominal pain disorders']","['sham stimulation', 'percutaneous electrical nerve field stimulation (PENFS', 'Auricular Neurostimulation', 'PENFS']","['side effects', 'abdominal pain scores', 'usual pain median score', 'reduction in composite abdominal pain severity score, reduction in usual abdominal pain severity, and improvement in global symptom based on a symptom response scale', 'symptom response scale score', 'number of patients with a reduction of 30% or more in worst abdominal pain severity', 'overall wellbeing', 'worst abdominal pain', 'composite pain median score', 'visceral hyperalgesia']","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517578', 'cui_str': '15.3'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0022104', 'cui_str': 'Irritable Bowel Syndrome'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C3834491', 'cui_str': 'Gastroenterology clinic (environment)'}, {'cui': 'C1609533', 'cui_str': 'Functional abdominal pain'}]","[{'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach - access (qualifier value)'}, {'cui': 'C0442828', 'cui_str': 'Electrical (qualifier value)'}, {'cui': 'C0027740', 'cui_str': 'Nerve structure'}, {'cui': 'C0440042', 'cui_str': ""Field's""}, {'cui': 'C0521307', 'cui_str': 'Neurostimulation'}]","[{'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0457451', 'cui_str': 'Severity score (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0222045'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0442045', 'cui_str': 'Visceral (qualifier value)'}, {'cui': 'C0020429', 'cui_str': 'Hyperalgesic Sensations'}]",,0.520423,"RESULTS Reductions of 30% or more in worst abdominal pain were observed in 59% of patients who received PENFS vs 26% of patients who received the sham stimulation (P=.024).","[{'ForeName': 'Amornluck', 'Initials': 'A', 'LastName': 'Krasaelap', 'Affiliation': 'Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin.'}, {'ForeName': 'Manu R', 'Initials': 'MR', 'LastName': 'Sood', 'Affiliation': 'Division of Quantitative Health Sciences, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin.'}, {'ForeName': 'B U K', 'Initials': 'BUK', 'LastName': 'Li', 'Affiliation': 'Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Unteutsch', 'Affiliation': 'Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin.'}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Yan', 'Affiliation': 'Division of Quantitative Health Sciences, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin.'}, {'ForeName': 'Melodee', 'Initials': 'M', 'LastName': 'Nugent', 'Affiliation': 'Division of Quantitative Health Sciences, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin.'}, {'ForeName': 'Pippa', 'Initials': 'P', 'LastName': 'Simpson', 'Affiliation': 'Division of Quantitative Health Sciences, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Kovacic', 'Affiliation': 'Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: kkovacic@mcw.edu.'}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2019.10.012'] 882,31634870,Investigations of Silymarine Effects on Prognosis of Patients With Severe and Moderate Traumatic Brain Injury.,"Objective The purpose of this study was to evaluate Silymarine effects on prognosis of patients with severe and moderate traumatic brain injury. Study Design This double blind, placebo-controlled clinical trial. Setting Valiasr hospital hospital in Arak, Iran. Subjects and Methods Research was performed among patients between 15 and 65 years of age with severe moderate (Glasgow Coma Scale score 9 to 12) and moderate (GCS 3 to 8) traumatic brain injury (TBI). Patients were divided into two groups (Each group: 40 patients). Patients assigned to the control groupwere receiving all standard treatments. Patients in case groups were administered 140 mg of silymarin every 8 hours for 7 days. We Checked the Glasgow Outcome Scale (GOS), GCS, age, gender, location, mechanism of trauma, site of accident and the incidence time of accident to arrival at emergency unite. Statistical analysis was conducted using SPSS (SPSS version 18; Chicago, IL). Results Our findings suggested that there was no a significant difference between intervention group and control in terms of parameters as GOS, GCS, age, gender, location, mechanism of trauma, and site of accident and the incidence time of accident to arrival at emergency unite (P > .05). Brain CT in two groups showed a significant difference (P = .002), where in the silymarin group there were more normal cases when comparing with control group. Conclusions Silymarin did not reveal a significant effect for improving prognosis of patients with moderate and severe TBI.",2020,"Brain CT in two groups showed a significant difference (P = .002), where in the silymarin group there were more normal cases when comparing with control group. ","['patients between 15 and 65 years of age with severe moderate (Glasgow Coma Scale score 9 to 12) and moderate (GCS 3 to 8) traumatic brain injury (TBI', 'Setting\n\n\nValiasr hospital hospital in Arak, Iran', 'Patients With Severe and Moderate Traumatic Brain Injury', 'patients with severe and moderate traumatic brain injury']","['placebo', 'Silymarine', 'silymarin']","['Glasgow Outcome Scale (GOS), GCS, age, gender, location, mechanism of trauma, site of accident and the incidence time of accident to arrival at emergency unite', 'GOS, GCS, age, gender, location, mechanism of trauma, and site of accident and the incidence time of accident to arrival at emergency unite']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0017594', 'cui_str': 'Glasgow coma scale (assessment scale)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0876926', 'cui_str': 'TBI (Traumatic Brain Injury)'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0037135', 'cui_str': 'Silymarin'}]","[{'cui': 'C0701887', 'cui_str': 'Glasgow Outcome Scale'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0450429', 'cui_str': 'Location (attribute)'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms (qualifier value)'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C2945843', 'cui_str': 'Site of (attribute)'}, {'cui': 'C1961149', 'cui_str': 'Accidental physical contact (event)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0175673', 'cui_str': 'Emergency (qualifier value)'}]",,0.096076,"Brain CT in two groups showed a significant difference (P = .002), where in the silymarin group there were more normal cases when comparing with control group. ","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Nazemi Rafi', 'Affiliation': ''}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Jafari', 'Affiliation': ''}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Solhi', 'Affiliation': ''}, {'ForeName': 'Jila', 'Initials': 'J', 'LastName': 'Mohseni', 'Affiliation': ''}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Kamali', 'Affiliation': ''}]",Alternative therapies in health and medicine,[] 883,29403135,A 12-week Comparative Prospective Open-label Randomized Controlled Study in Depression Patients Treated with Vilazodone and Escitalopram in a Tertiary Care Hospital in North India.,"Background Depression is a leading cause of morbidity in modern world and introduction of selective serotonin reuptake inhibitors (SSRIs) was a revolution for treating depression. However, sexual dysfunction and weight gain always remained an issue for patients leading to discontinuation of treatment. Vilazodone is a novel SSRI and literature show better efficacy and decrease weight gain and sexual dysfunction. Aim of study This study aims to compare the efficacy, sexual dysfunction, and weight gain caused due to vilazodone and escitalopram. Methodology This is an open-label randomized, controlled study; 60 patients diagnosed as depression were divided into two groups of 30 each. One group was started on vilazodone and one on escitalopram randomly. The groups were compared on the basis of efficacy, weight gain, and sexual dysfunction by applying Hamilton Depression Rating Scale (HDRS) and Arizona Sexual Experience Scale (ASEX) at baseline, 4, and 12 weeks interval. Statistical analysis was done by applying Chi-square, t -test, and fisher exact test and descriptive analysis. Results Vilazodone group shows fall in HDRS with 18.77 ± 4.3, 14.83 ± 3.68, and 9.63 ± 3.06 while it was 18.8 ± 4.09, 14.3 ± 2.96, and 8.43 ± 2.1 at baseline, 4, and 12 weeks, respectively. ASEX score in vilazodone was found to have 16.87 ± 2.97, 15.37 ± 3.1, and 11.73 ± 3.55 while on escitalopram, 16.4 ± 3.35, 17.13 ± 3.48, and 18.37 ± 4.09 at first visit, 4, and 12 weeks, respectively. Patients on vilazodone had mean weight of 69.63 ± 7.7, 69.83 ± 7.83, and 69.9 ± 7.69 while on escitalopram, 72.47 ± 7.95, 72.87 ± 7.9, and 75.6 ± 8.46 at baseline, 4, and 12 weeks, respectively. Conclusions Our study shows that vilazodone has better efficacy, lesser weight gain, and lesser sexual dysfunction.",2018,"ASEX score in vilazodone was found to have 16.87 ± 2.97, 15.37 ± 3.1, and 11.73 ± 3.55 while on escitalopram, 16.4 ± 3.35, 17.13 ± 3.48, and 18.37 ± 4.09 at first visit, 4, and 12 weeks, respectively.","['Patients on vilazodone had mean weight of 69.63 ± 7.7, 69.83 ± 7.83, and 69.9 ± 7.69 while on escitalopram, 72.47 ± 7.95, 72.87 ± 7.9, and 75.6 ± 8.46 at baseline, 4, and 12 weeks, respectively', '60 patients diagnosed as depression', 'in a Tertiary Care Hospital in North India', 'Depression Patients Treated with']","['Vilazodone and Escitalopram', 'Vilazodone', 'vilazodone']","['ASEX score', 'efficacy, lesser weight gain', 'efficacy, sexual dysfunction, and weight gain', 'efficacy, weight gain, and sexual dysfunction by applying Hamilton Depression Rating Scale (HDRS) and Arizona Sexual Experience Scale (ASEX', 'sexual dysfunction and weight gain always', 'weight gain and sexual dysfunction']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1530072', 'cui_str': 'vilazodone'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C4517860', 'cui_str': '7.7 (qualifier value)'}, {'cui': 'C1099456', 'cui_str': 'Escitalopram'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0337954', 'cui_str': 'Tertiary care hospital (environment)'}, {'cui': 'C0021201', 'cui_str': 'Republic of India'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C1530072', 'cui_str': 'vilazodone'}, {'cui': 'C1099456', 'cui_str': 'Escitalopram'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0549622', 'cui_str': 'Sexual disorder (disorder)'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C0003787', 'cui_str': 'Arizona'}]",60.0,0.0405999,"ASEX score in vilazodone was found to have 16.87 ± 2.97, 15.37 ± 3.1, and 11.73 ± 3.55 while on escitalopram, 16.4 ± 3.35, 17.13 ± 3.48, and 18.37 ± 4.09 at first visit, 4, and 12 weeks, respectively.","[{'ForeName': 'Manish', 'Initials': 'M', 'LastName': 'Bathla', 'Affiliation': 'Department of Psychiatry, MM Institute of Medical Sciences and Research, Ambala, Haryana, India.'}, {'ForeName': 'Shazia', 'Initials': 'S', 'LastName': 'Anjum', 'Affiliation': 'Department of Psychiatry, MM Institute of Medical Sciences and Research, Ambala, Haryana, India.'}, {'ForeName': 'Manpreet', 'Initials': 'M', 'LastName': 'Singh', 'Affiliation': 'Department of Psychiatry, MM Institute of Medical Sciences and Research, Ambala, Haryana, India.'}, {'ForeName': 'Saminder', 'Initials': 'S', 'LastName': 'Panchal', 'Affiliation': 'Department of Psychiatry, MM Institute of Medical Sciences and Research, Ambala, Haryana, India.'}, {'ForeName': 'Gurvinder Pal', 'Initials': 'GP', 'LastName': 'Singh', 'Affiliation': 'Department of Psychiatry, MM Institute of Medical Sciences and Research, Ambala, Haryana, India.'}]",Indian journal of psychological medicine,['10.4103/IJPSYM.IJPSYM_368_17'] 884,31628043,Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses.,"INTRODUCTION We used European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) data from the LUME-Colon 1 study to illustrate different methods of statistical analysis for health-related quality of life (HRQoL), and compared the results. PATIENTS AND METHODS Patients were randomized 1:1 to receive nintedanib 200 mg twice daily plus best supportive care (n = 386) or matched placebo plus best supportive care (n = 382). Five methods (mean treatment difference averaged over time, using a mixed-effects growth curve model; mixed-effects models for repeated measurements (MMRM); time-to-deterioration (TTD); status change; and responder analysis) were used to analyze EORTC QLQ-C30 global health status (GHS)/QoL and scores from functional scales. RESULTS Overall, GHS/QoL and physical functioning deteriorated over time. Mean treatment difference slightly favored nintedanib over placebo for physical functioning (adjusted mean, 2.66; 95% confidence interval [CI], 0.97-4.34) and social functioning (adjusted mean, 2.62; 95% CI, 0.66-4.47). GHS/QoL was numerically better with nintedanib versus placebo (adjusted mean, 1.61; 95% CI, -0.004 to 3.27). MMRM analysis had similar results, with better physical functioning in the nintedanib group at all timepoints. There was no significant delay in GHS/QoL deterioration (10%) and physical functioning (16%) with nintedanib versus placebo (TTD analysis). Status change analysis showed a higher proportion of patients with markedly improved GHS/QoL and physical functioning in the nintedanib versus placebo groups. Responder analysis showed a similar, less pronounced pattern. CONCLUSION Analyses of EORTC QLQ-C30 data showed that HRQoL was not impaired by treatment with nintedanib versus placebo. Analysis and interpretation of HRQoL endpoints should consider symptom type and severity and course of disease.",2019,Analyses of EORTC QLQ-C30 data showed that HRQoL was not impaired by treatment with nintedanib versus placebo.,['Patients'],"['placebo', 'nintedanib 200 mg twice daily plus best supportive care (n\xa0= 386) or matched placebo plus best supportive care']","['Overall, GHS/QoL and physical functioning', 'GHS/QoL', 'physical functioning', 'social functioning', 'Health-related Quality of Life', 'EORTC QLQ-C30 global health status (GHS)/QoL and scores from functional scales', 'GHS/QoL and physical functioning', 'GHS/QoL deterioration']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2930789', 'cui_str': 'nintedanib'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0222045'}]",386.0,0.226032,Analyses of EORTC QLQ-C30 data showed that HRQoL was not impaired by treatment with nintedanib versus placebo.,"[{'ForeName': 'Heinz-Josef', 'Initials': 'HJ', 'LastName': 'Lenz', 'Affiliation': 'Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, CA. Electronic address: lenz@usc.edu.'}, {'ForeName': 'Guillem', 'Initials': 'G', 'LastName': 'Argiles', 'Affiliation': ""Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.""}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Yoshino', 'Affiliation': 'Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Lonardi', 'Affiliation': 'Phase 1 Trial Unit and Medical Oncology Unit 1, Istituto Oncologico Veneto IRCCS, Padova, Italy.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Falcone', 'Affiliation': 'Department of Oncology, University of Pisa, Pisa, Italy.'}, {'ForeName': 'María Luisa', 'Initials': 'ML', 'LastName': 'Limón', 'Affiliation': 'Medical Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Sobrero', 'Affiliation': 'Medical Oncology 1, Ospedale Policlinico San Martino IRCCS, Genova, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Hastedt', 'Affiliation': 'TA CNS Retinopathies Emerging Areas, Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Peil', 'Affiliation': 'Biostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Voss', 'Affiliation': 'Biostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.'}, {'ForeName': 'Ingolf', 'Initials': 'I', 'LastName': 'Griebsch', 'Affiliation': 'TA Oncology, Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Van Cutsem', 'Affiliation': 'Digestive Oncology, University Hospitals Leuven and KULeuven, Leuven, Belgium.'}]",Clinical colorectal cancer,['10.1016/j.clcc.2019.08.005'] 885,31617896,Quality of life predicting long-term outcomes in cardiac resynchronization therapy patients.,"AIMS While improvement in quality of life (QoL) has been widely reported in cardiac resynchronization therapy (CRT) patients, its predictive value is not well-understood. We aimed to assess the predictive role of baseline QoL on long-term heart failure (HF) or death events in mild HF patients enrolled in Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). METHODS AND RESULTS A total of 1791 of 1820 patients had their QoL evaluated at baseline, using the EuroQol-5 dimensions (EQ-5D) and the Kansas City Cardiomyopathy Questionnaires (KCCQ). Kaplan-Meier survival analyses and multivariate Cox models were utilized. Issues within any of the domains of the baseline EQ-5D questionnaire (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) were associated with long-term mortality (median follow-up 5.6 years) (all P < 0.05). Heart failure or death events were predicted by issues in baseline mobility [hazard ratio (HR) = 1.41, P < 0.001], usual activities (HR = 1.41, P < 0.001), and anxiety/depression (HR = 1.21, P = 0.035). The risk of HF events alone was significantly higher in patients with baseline mobility issues (HR = 1.42, P < 0.001) or usual activity (HR = 1.35, P = 0.003). Every 10% increase in the visual analogue scale (0-100) was associated with an 8% lower risk of all-cause mortality (P = 0.006), and a 6% lower risk of HF/death (P = 0.002). Mobility issues also predicted echocardiographic reverse remodelling (-33.08 mL vs. -31.17 mL, P = 0.043). Using the KCCQ, patients in the lower tertile of the clinical summary or physical limitations score had a significantly higher risk of long-term HF or death (P < 0.05). CONCLUSION In mild HF patients enrolled in MADIT-CRT, multiple baseline QoL questionnaire domains were predictors of echocardiographic remodelling, long-term all-cause mortality, and HF events.",2019,"The risk of HF events alone was significantly higher in patients with baseline mobility issues (HR = 1.42, P < 0.001) or usual activity (HR = 1.35, P = 0.003).","['cardiac resynchronization therapy patients', 'A total of 1791 of 1820 patients had their QoL evaluated at baseline, using the EuroQol-5 dimensions (EQ-5D) and the Kansas City Cardiomyopathy Questionnaires (KCCQ', 'mild HF patients enrolled in Multicenter Automatic Defibrillator Implantation Trial with']",['Cardiac Resynchronization Therapy (MADIT-CRT'],"['usual activity', 'usual activities', 'risk of HF/death', 'risk of long-term HF or death', 'Quality of life predicting long-term outcomes', 'risk of HF events alone', 'quality of life (QoL', 'long-term mortality', 'baseline EQ-5D questionnaire (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression', 'anxiety/depression', 'Heart failure or death events', 'visual analogue scale']","[{'cui': 'C1167956', 'cui_str': 'Cardiac Resynchronization'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0439534', 'cui_str': 'Dimensions (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0878544', 'cui_str': 'Cardiomyopathies'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C0180307', 'cui_str': 'Defibrillators'}, {'cui': 'C0021107', 'cui_str': 'Insertion procedure'}]","[{'cui': 'C1167956', 'cui_str': 'Cardiac Resynchronization'}]","[{'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0036592', 'cui_str': 'Self Care'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",1820.0,0.125056,"The risk of HF events alone was significantly higher in patients with baseline mobility issues (HR = 1.42, P < 0.001) or usual activity (HR = 1.35, P = 0.003).","[{'ForeName': 'Klaudia Vivien', 'Initials': 'KV', 'LastName': 'Nagy', 'Affiliation': 'Semmelweis University Heart and Vascular Center, Budapest, Hungary.'}, {'ForeName': 'Bela', 'Initials': 'B', 'LastName': 'Merkely', 'Affiliation': 'Semmelweis University Heart and Vascular Center, Budapest, Hungary.'}, {'ForeName': 'Spencer', 'Initials': 'S', 'LastName': 'Rosero', 'Affiliation': 'Heart Research Follow-up Program, Cardiology Division, University of Rochester Medical Center, 265 Crittenden Blvd., Box 653, Rochester, NY 14642, USA.'}, {'ForeName': 'Laszlo', 'Initials': 'L', 'LastName': 'Geller', 'Affiliation': 'Semmelweis University Heart and Vascular Center, Budapest, Hungary.'}, {'ForeName': 'Annamaria', 'Initials': 'A', 'LastName': 'Kosztin', 'Affiliation': 'Semmelweis University Heart and Vascular Center, Budapest, Hungary.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'McNitt', 'Affiliation': 'Heart Research Follow-up Program, Cardiology Division, University of Rochester Medical Center, 265 Crittenden Blvd., Box 653, Rochester, NY 14642, USA.'}, {'ForeName': 'Bronislava', 'Initials': 'B', 'LastName': 'Polonsky', 'Affiliation': 'Heart Research Follow-up Program, Cardiology Division, University of Rochester Medical Center, 265 Crittenden Blvd., Box 653, Rochester, NY 14642, USA.'}, {'ForeName': 'Ilan', 'Initials': 'I', 'LastName': 'Goldenberg', 'Affiliation': 'Heart Research Follow-up Program, Cardiology Division, University of Rochester Medical Center, 265 Crittenden Blvd., Box 653, Rochester, NY 14642, USA.'}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Zareba', 'Affiliation': 'Heart Research Follow-up Program, Cardiology Division, University of Rochester Medical Center, 265 Crittenden Blvd., Box 653, Rochester, NY 14642, USA.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Kutyifa', 'Affiliation': 'Heart Research Follow-up Program, Cardiology Division, University of Rochester Medical Center, 265 Crittenden Blvd., Box 653, Rochester, NY 14642, USA.'}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euz262'] 886,31625399,Psychosocial impact of inclusion of HPV test on the management of women with atypical squamous cells of undetermined significance: a study within a randomised pragmatic trial in a middle-income country.,"Objective: To assess the psychosocial impact of human papillomavirus (HPV) testing, colposcopy, and Pap-smear, as triage strategies after a Pap-smear with atypical squamous cells of undetermined significance (ASCUS). We also sought to evaluate the psychosocial impact based on the results of the strategies. Methods: Nested within a randomised pragmatic trial, which compared an immediate colposcopy, repeat Pap-smear, and high risk HPV test, we enrolled 675 women between 2012 and 2014. Participants completed surveys at enrollment, two weeks after triage test results, and 1 year thereafter to assess cervical cancer and HPV knowledge, self-esteem, anxiety and HPV impact (HIP). Results: Knowledge, self-esteem, anxiety and HIP improved with no differences among arms. At the baseline, 31.4% and 32.7% of the participants had state anxiety and trait anxiety, respectively, which decreased to 10.7% and 13.3% in the last survey. Compared to HPV-negative women, HPV-positive women in the second survey had worse HIP scores (HPV-: M 22.9 [SD: 15.20]; HPV+: M 35.9 [SD: 19.91]; p <  0.001), trait anxiety (HPV-: M 15.4 [SD 12.73]; HPV+: M 22.9 [SD 13.29]; p  = 0.001), and state anxiety (HPV-: M 10.7 [SD 11.25]; HPV+: M 21.4 [SD 14.81]; p <  0.001). Conclusions : HPV testing as a triage strategy for women with ASCUS does not differ from colposcopies or Pap-smears in terms of psychosocial outcomes.",2020,"Results: Knowledge, self-esteem, anxiety and HIP improved with no differences among arms.","['women with atypical squamous cells of undetermined significance', 'women with ASCUS', 'enrolled 675 women between 2012 and 2014']","['HPV test', 'human papillomavirus (HPV) testing, colposcopy, and Pap-smear', 'HPV', 'immediate colposcopy, repeat Pap-smear, and high risk HPV test']","['Results: Knowledge, self-esteem, anxiety and HIP', 'state anxiety and trait anxiety', 'state anxiety', 'trait anxiety', 'HIP scores', 'cervical cancer and HPV knowledge, self-esteem, anxiety and HPV impact (HIP']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0521184', 'cui_str': 'ASCUS'}, {'cui': 'C4517854', 'cui_str': '675 (qualifier value)'}]","[{'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0009417', 'cui_str': 'Colposcopy'}, {'cui': 'C0079104', 'cui_str': 'Cervical Smears'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}]","[{'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0036597', 'cui_str': 'Self Esteem'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix (disorder)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}]",675.0,0.123197,"Results: Knowledge, self-esteem, anxiety and HIP improved with no differences among arms.","[{'ForeName': 'Isabel C', 'Initials': 'IC', 'LastName': 'Garcés-Palacio', 'Affiliation': 'Grupo de Epidemiología, Facultad Nacional de Salud Pública, Universidad de Antioquia (UdeA), Medellín, Colombia.'}, {'ForeName': 'Gloria I', 'Initials': 'GI', 'LastName': 'Sanchez', 'Affiliation': 'Grupo Infección y Cáncer, Facultad de Medicina, Universidad de Antioquia (UdeA), Medellín, Colombia.'}, {'ForeName': 'Armando', 'Initials': 'A', 'LastName': 'Baena Zapata', 'Affiliation': 'Grupo Infección y Cáncer, Facultad de Medicina, Universidad de Antioquia (UdeA), Medellín, Colombia.'}, {'ForeName': 'Verónica', 'Initials': 'V', 'LastName': 'Córdoba Sánchez', 'Affiliation': 'Grupo Atropos, Universidad de Antioquia (UdeA), Medellín, Colombia.'}, {'ForeName': 'Yenny', 'Initials': 'Y', 'LastName': 'Urrea Cosme', 'Affiliation': 'Grupo Atropos, Universidad de Antioquia (UdeA), Medellín, Colombia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Rodríguez Zabala', 'Affiliation': 'Grupo Atropos, Universidad de Antioquia (UdeA), Medellín, Colombia.'}, {'ForeName': 'Mario Alberto', 'Initials': 'MA', 'LastName': 'Ruiz Osorio', 'Affiliation': 'Grupo Atropos, Universidad de Antioquia (UdeA), Medellín, Colombia.'}]",Psychology & health,['10.1080/08870446.2019.1678749'] 887,31610750,Self-Controlled Practice to Achieve Neuro-Cognitive Engagement: Underlying Brain Processes to Enhance Cognitive-Motor Learning and Performance.,"While self-controlled practice has been shown to be an effective practice methodology, the neuro-cognitive correlates of its effectiveness are unclear. We investigated whether learners participating in self-controlled practice exhibit increased neuro-cognitive engagement compared to externally controlled practice. Two groups (self-controlled and yoked) of 16 participants practiced and performed a golf putting task over 3 days. Working memory engagement, central executive activity, and cortical activation were assessed via electroencephalography as indicators of neuro-cognitive engagement. The self-controlled group exhibited more consistent working memory engagement, and greater central executive activity, compared to the yoked group during practice. Relationships were also observed between neuro-cognitive engagement during self-controlled practice and performance improvement, indicating that self-controlled practice uniquely benefitted from increased neuro-cognitive engagement.",2020,"The self-controlled group exhibited more consistent working memory engagement, and greater central executive activity, compared to the yoked group during practice.","['Neuro-Cognitive Engagement', 'learners participating in self-controlled practice exhibit increased neuro-cognitive engagement']",[],"['Working memory engagement, central executive activity, and cortical activation', 'central executive activity', 'neuro-cognitive engagement']","[{'cui': 'C0684274', 'cui_str': 'Self Regulation'}, {'cui': 'C0015272', 'cui_str': 'Exhibits'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}]",[],"[{'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",16.0,0.0214753,"The self-controlled group exhibited more consistent working memory engagement, and greater central executive activity, compared to the yoked group during practice.","[{'ForeName': 'Kyle J', 'Initials': 'KJ', 'LastName': 'Jaquess', 'Affiliation': 'Department of Kinesiology, School of Public Health, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Yingzhi', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'Department of Kinesiology, School of Public Health, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Seppo E', 'Initials': 'SE', 'LastName': 'Iso-Ahola', 'Affiliation': 'Department of Kinesiology, School of Public Health, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Rodolphe J', 'Initials': 'RJ', 'LastName': 'Gentili', 'Affiliation': 'Department of Kinesiology, School of Public Health, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Bradley D', 'Initials': 'BD', 'LastName': 'Hatfield', 'Affiliation': 'Department of Kinesiology, School of Public Health, University of Maryland, College Park, MD, USA.'}]",Journal of motor behavior,['10.1080/00222895.2019.1651245'] 888,29284810,Efficacy and Tolerability of Clozapine versus Quetiapine in Treatment-resistant Schizophrenia.,"Objectives To compare the efficacy and tolerability of clozapine and quetiapine in patients with treatment-resistant schizophrenia (TRS). Patients and Methods In this prospective, randomized, open label study of 14 weeks, 53 patients with schizophrenia diagnosed as per ICD-10 and fulfilling the modified version of Conley and Kelly's criteria of TRS were randomly assigned to receive clozapine or quetiapine as per a computer-generated random table. After 2-weeks of dose-titration phase, doses were fixed at minimum therapeutic dose and subsequently adjusted according to the clinical improvement. All patients received dosage of respective drug in therapeutic range. 13 patients were lost to follow up. Treatment efficacy and side effects were evaluated with standardized rating scales. Results Clozapine group (reduction in total score: mean=14.45, SD=10.39) had significantly greater reductions (P=0.004; CI=3.541-17.059) in the Positive and Negative Syndrome Scale (PANSS) total score, PANSS positive subscale and PANSS general psychopathology subscale at 14 weeks in comparison to the quetiapine group (reduction in total score: mean=4.15, SD=10.71). Significant reduction in PANSS negative subscale was seen with both drugs but no significant difference was present between the two drugs. At 14 weeks, 30% patients in clozapine group and 15% patients in quetiapine group showed response. Clozapine led to significantly greater side effects (P< 0.001, CI=2.241-6.059) on Glassgow Antipsychotic Side-effect Scale (GASS) than quetiapine. Conclusions Clozapine was found to be more efficacious than quetiapine in patients with TRS but was associated with greater side effects. Both the drugs were found to be equally effective in reducing the negative symptoms.",2017,"Clozapine led to significantly greater side effects (P< 0.001, CI=2.241-6.059) on Glassgow Antipsychotic Side-effect Scale (GASS) than quetiapine. ","['patients with TRS', 'patients with treatment-resistant schizophrenia (TRS', ""53 patients with schizophrenia diagnosed as per ICD-10 and fulfilling the modified version of Conley and Kelly's criteria of TRS"", '13 patients were lost to follow up']","['Clozapine', 'clozapine or quetiapine', 'clozapine and quetiapine', 'clozapine', 'quetiapine', 'Quetiapine']","['Efficacy and Tolerability', 'side effects', 'efficacy and tolerability', 'PANSS negative subscale', 'Treatment efficacy and side effects', 'Glassgow Antipsychotic Side-effect Scale (GASS', 'Positive and Negative Syndrome Scale (PANSS) total score, PANSS positive subscale and PANSS general psychopathology subscale']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3544321', 'cui_str': 'Treatment-resistant schizophrenia'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C1137110', 'cui_str': 'ICD-10'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1302313', 'cui_str': 'Lost to Follow-Up'}]","[{'cui': 'C0009079', 'cui_str': 'Clozapine'}, {'cui': 'C0123091', 'cui_str': 'quetiapine'}]","[{'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0087113', 'cui_str': 'Treatment Efficacy'}, {'cui': 'C0040615', 'cui_str': 'Antipsychotic Drugs'}, {'cui': 'C0222045'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale (assessment scale)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}]",53.0,0.0156774,"Clozapine led to significantly greater side effects (P< 0.001, CI=2.241-6.059) on Glassgow Antipsychotic Side-effect Scale (GASS) than quetiapine. ","[{'ForeName': 'Mitesh', 'Initials': 'M', 'LastName': 'Kumar', 'Affiliation': 'Department of Psychiatry, Government Medical College and Hospital, Chandigarh, India.'}, {'ForeName': 'B S', 'Initials': 'BS', 'LastName': 'Chavan', 'Affiliation': 'Department of Psychiatry, Government Medical College and Hospital, Chandigarh, India.'}, {'ForeName': 'Ajeet', 'Initials': 'A', 'LastName': 'Sidana', 'Affiliation': 'Department of Psychiatry, Government Medical College and Hospital, Chandigarh, India.'}, {'ForeName': 'Subhash', 'Initials': 'S', 'LastName': 'Das', 'Affiliation': 'Department of Psychiatry, Government Medical College and Hospital, Chandigarh, India.'}]",Indian journal of psychological medicine,['10.4103/IJPSYM.IJPSYM_111_17'] 889,29262795,Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: study protocol for a randomized controlled trial (UPGRADE trial).,"BACKGROUND The number of bariatric interventions for morbid obesity is increasing worldwide. Rapid weight loss is a major risk factor for gallstone development. Approximately 11 % of patients who underwent Roux-en-Y gastric bypass develop symptomatic gallstone disease. Gallstone disease can lead to severe complications and often requires hospitalization and surgery. Ursodeoxycholic acid (UDCA) prevents the formation of gallstones after bariatric surgery. However, randomized controlled trials with symptomatic gallstone disease as primary endpoint have not been conducted. Currently, major guidelines make no definite statement about postoperative UDCA prophylaxis and most bariatric centers do not prescribe UDCA. METHODS A randomized, placebo-controlled, double-blind multicenter trial will be performed for which 980 patients will be included. The study population consists of consecutive patients scheduled to undergo Roux-en-Y gastric bypass or sleeve gastrectomy in three bariatric centers in the Netherlands. Patients will undergo a preoperative ultrasound and randomization will be stratified for pre-existing gallstones and for type of surgery. The intervention group will receive UDCA 900 mg once daily for six months. The placebo group will receive similar-looking placebo tablets. The primary endpoint is symptomatic gallstone disease after 24 months, defined as admission or hospital visit for symptomatic gallstone disease. Secondary endpoints consist of the development of gallstones on ultrasound at 24 months, number of cholecystectomies, side-effects of UDCA and quality of life. Furthermore, cost-effectiveness, cost-utility and budget impact analyses will be performed. DISCUSSION The UPGRADE trial will answer the question whether UDCA reduces the incidence of symptomatic gallstone disease after Roux-en-Y gastric bypass or sleeve gastrectomy. Furthermore it will determine if treatment with UDCA is cost-effective. TRIAL REGISTRATION Netherlands Trial Register (trialregister.nl) 6135 . Date registered: 21-Nov-2016.",2017,"The primary endpoint is symptomatic gallstone disease after 24 months, defined as admission or hospital visit for symptomatic gallstone disease.","['symptomatic gallstone disease after bariatric surgery', '980 patients will be included', 'consecutive patients scheduled to undergo Roux-en-Y gastric bypass or sleeve gastrectomy in three bariatric centers in the Netherlands']","['UDCA 900\xa0mg once daily for six months', 'similar-looking placebo tablets', 'placebo', 'Ursodeoxycholic acid (UDCA', 'Ursodeoxycholic acid', 'Roux-en-Y gastric bypass', 'UDCA', 'Roux-en-Y gastric bypass or sleeve gastrectomy']","['symptomatic gallstone disease', 'cost-effectiveness, cost-utility and budget impact analyses', 'admission or hospital visit for symptomatic gallstone disease', 'development of gallstones on ultrasound at 24\xa0months, number of cholecystectomies, side-effects of UDCA and quality of life']","[{'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0947622', 'cui_str': 'Cholecystolithiasis'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1456587', 'cui_str': 'Bariatric Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C0585179', 'cui_str': 'Roux-en-Y Gastric Bypass'}, {'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}, {'cui': 'C1450026', 'cui_str': 'Bariatrics'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C4517900', 'cui_str': '900 (qualifier value)'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0042105', 'cui_str': 'ursodesoxycholic acid'}, {'cui': 'C0585179', 'cui_str': 'Roux-en-Y Gastric Bypass'}, {'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}]","[{'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0947622', 'cui_str': 'Cholecystolithiasis'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C2955667', 'cui_str': 'Does budget (finding)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C1704447', 'cui_str': 'Patient visit for (contextual qualifier) (qualifier value)'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0008320', 'cui_str': 'Cholecystectomy'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0034380'}]",980.0,0.284392,"The primary endpoint is symptomatic gallstone disease after 24 months, defined as admission or hospital visit for symptomatic gallstone disease.","[{'ForeName': 'Thomas C C', 'Initials': 'TCC', 'LastName': 'Boerlage', 'Affiliation': 'Department of internal medicine, MC Slotervaart, Amsterdam, the Netherlands.'}, {'ForeName': 'Sylke', 'Initials': 'S', 'LastName': 'Haal', 'Affiliation': 'Department of internal medicine, MC Slotervaart, Amsterdam, the Netherlands.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Maurits de Brauw', 'Affiliation': 'Department of surgery, MC Slotervaart, Amsterdam, the Netherlands.'}, {'ForeName': 'Yair I Z', 'Initials': 'YIZ', 'LastName': 'Acherman', 'Affiliation': 'Department of surgery, MC Slotervaart, Amsterdam, the Netherlands.'}, {'ForeName': 'Sjoerd', 'Initials': 'S', 'LastName': 'Bruin', 'Affiliation': 'Department of surgery, MC Slotervaart, Amsterdam, the Netherlands.'}, {'ForeName': 'Arnold W J M', 'Initials': 'AWJM', 'LastName': 'van de Laar', 'Affiliation': 'Department of surgery, MC Slotervaart, Amsterdam, the Netherlands.'}, {'ForeName': 'Daan E', 'Initials': 'DE', 'LastName': 'Moes', 'Affiliation': 'Department of surgery, MC Slotervaart, Amsterdam, the Netherlands.'}, {'ForeName': 'Bart A', 'Initials': 'BA', 'LastName': 'van Wagensveld', 'Affiliation': 'Department of surgery, OLVG, Amsterdam, the Netherlands.'}, {'ForeName': 'Claire E E', 'Initials': 'CEE', 'LastName': 'de Vries', 'Affiliation': 'Department of surgery, OLVG, Amsterdam, the Netherlands.'}, {'ForeName': 'Ruben', 'Initials': 'R', 'LastName': 'van Veen', 'Affiliation': 'Department of surgery, OLVG, Amsterdam, the Netherlands.'}, {'ForeName': 'Ruben', 'Initials': 'R', 'LastName': 'Schouten', 'Affiliation': 'Department of surgery, MC Zuiderzee, Lelystad, the Netherlands.'}, {'ForeName': 'Marcel G', 'Initials': 'MG', 'LastName': 'Dijkgraaf', 'Affiliation': 'Clinical Research Unit, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Fockens', 'Affiliation': 'Department of gastroenterology & hepatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands.'}, {'ForeName': 'Victor E A', 'Initials': 'VEA', 'LastName': 'Gerdes', 'Affiliation': 'Department of internal medicine, MC Slotervaart, Amsterdam, the Netherlands.'}, {'ForeName': 'Rogier P', 'Initials': 'RP', 'LastName': 'Voermans', 'Affiliation': 'Department of gastroenterology & hepatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands. R.p.voermans@amc.uva.nl.'}]",BMC gastroenterology,['10.1186/s12876-017-0674-x'] 890,31611626,T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol.,"The NOPHO ALL2008 is a population-based study using an unmodified pediatric protocol in patients 1-45 years of age with acute lymphoblastic leukemia. Patients with T-ALL were given a traditional pediatric scheme if fast responding (minimal residual disease (MRD) < 0.1% day 29), or intensive block-based chemotherapy if slow responding (MRD > 0.1% day 29). Both treatment arms included pediatric doses of high-dose methotrexate and asparaginase. If MRD ≥ 5% on day 29 or ≥0.1% after consolidation, patients were assigned to allogeneic hematopoietic stem cell transplantation. The 5-year overall survival of the 278 T-ALL patients was 0.75 (95% CI 0.69-0.81), being 0.82 (0.74-0.88) for patients 1.0-9.9 years, 0.76 (0.66-0.86) for those 10.0-17.9 years, and 0.65 (0.55-0.75) for the older patients. The risk of death in first remission was significantly higher in adults (12%) compared with the 1-9 years group (4%). The MRD responses in the three age groups were similar, and only a nonsignificant increase in relapse risk was found in adults. In conclusion, an unmodified pediatric protocol in patients 1-45 years is effective in all age groups. The traditional pediatric treatment schedule was safe for all patients, but the intensive block therapy led to a high toxic death rate in adults.",2020,The risk of death in first remission was significantly higher in adults (12%) compared with the 1-9 years group (4%).,['patients 1-45 years of age with acute lymphoblastic leukemia'],"['intensive block-based chemotherapy', 'methotrexate and asparaginase', 'allogeneic hematopoietic stem cell transplantation']","['T-cell acute lymphoblastic leukemia', 'MRD responses', 'toxic death rate', 'relapse risk', '5-year overall survival', 'risk of death in first remission']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1961102', 'cui_str': 'Lymphocytic Leukemia, Acute'}]","[{'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0003993', 'cui_str': 'ASPARAGINASE'}, {'cui': 'C0472699', 'cui_str': 'Hematopoietic Stem Cell Transplantation'}]","[{'cui': 'C1961099', 'cui_str': 'Leukemia, Lymphocytic, Acute, T-Cell'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}]",278.0,0.042444,The risk of death in first remission was significantly higher in adults (12%) compared with the 1-9 years group (4%).,"[{'ForeName': 'P', 'Initials': 'P', 'LastName': 'Quist-Paulsen', 'Affiliation': ""Department of Hematology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway. Petter.Quist-Paulsen@ntnu.no.""}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Toft', 'Affiliation': 'Department of Hematology, Herlev University Hospital, University of Copenhagen, Herlev, Denmark.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Heyman', 'Affiliation': ""Childhood Cancer Research Unit, Karolinska Institute, Astrid Lindgren's Childrens' Hospital, Karolinska University Hospital, Stockholm, Sweden.""}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Abrahamsson', 'Affiliation': 'Department of Pediatrics, Institution for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Griškevičius', 'Affiliation': 'Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Hallböök', 'Affiliation': 'Department of Medical Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Ó G', 'Initials': 'ÓG', 'LastName': 'Jónsson', 'Affiliation': ""Children's Hospital, Landspitali University Hospital, Reykjavík, Iceland.""}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Palk', 'Affiliation': 'Department of Hematology, North Estonia Medical Centre, Tallinn, Estonia.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Vaitkeviciene', 'Affiliation': ""Centre for Pediatric Oncology and Hematology, Children's Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos, Vilnius University, Vilnius, Lithuania.""}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Vettenranta', 'Affiliation': 'Division of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Åsberg', 'Affiliation': ""Department of Pediatrics, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.""}, {'ForeName': 'T L', 'Initials': 'TL', 'LastName': 'Frandsen', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Opdahl', 'Affiliation': 'Department of Public Health and Nursing, Faculty of Medicine and Health Science, NTNU, Trondheim, Norway.'}, {'ForeName': 'H V', 'Initials': 'HV', 'LastName': 'Marquart', 'Affiliation': 'Department of Clinical Immunology, Section 7631, University Hospital Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Siitonen', 'Affiliation': 'Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland.'}, {'ForeName': 'L T', 'Initials': 'LT', 'LastName': 'Osnes', 'Affiliation': 'Department of Immunology, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Hultdin', 'Affiliation': 'Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.'}, {'ForeName': 'U M', 'Initials': 'UM', 'LastName': 'Overgaard', 'Affiliation': 'Department of Hematology, The University Hospital Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Wartiovaara-Kautto', 'Affiliation': 'Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Schmiegelow', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.'}]",Leukemia,['10.1038/s41375-019-0598-2'] 891,29200561,Efficacy of Adjunctive Single Session Counseling for Medically Unexplained Symptoms: A Randomized Controlled Trial.,"Context Medically unexplained symptoms (MUS) are often poorly responsive to standard treatments. Aim The aim of the study is to assess short-term efficacy of adjunctive single session cognitive behavior therapy (CBT)-based counseling for patients with MUS. Setting and Design Randomized controlled trial at a psychosomatic clinic of a tertiary care hospital. Materials and Methods Patients with MUS were randomized to receive either the single session counseling (intervention group) ( n = 41) or control group which received treatment as usual ( n = 35). The counseling intervention focused on three areas - cognitive reattribution, shifting focus, and guided muscular relaxation and lasted around 30 min. The two groups were assessed at baseline and after 1 month for change in outcome measures. Statistical Analysis Used Repeated measures analysis of variance. P value was adjusted for multiple comparisons using Bonferroni correction and set at <0.01 for significance. Results Both groups did not differ on change in the primary outcome measure: Patient Health Questionnaire - 15 scores ( P = 0.055). However, at follow-up, the intervention group showed statistically greater reduction in the number of workdays lost ( P = 0.005). Trend level changes were noted for depressive symptom reduction only in the intervention group ( P = 0.022). Conclusions One session CBT-based therapy demonstrates potentially important benefits over standard care among Indian patients with MUS. Further testing in larger samples with longer follow-up periods is therefore recommended.",2017,Both groups did not differ on change in the primary outcome measure: Patient Health Questionnaire - 15 scores ( P = 0.055).,"['patients with MUS', 'Patients with MUS', 'Indian patients with MUS', 'psychosomatic clinic of a tertiary care hospital', 'Medically Unexplained Symptoms']","['adjunctive single session cognitive behavior therapy (CBT)-based counseling', 'single session counseling (intervention group) ( n = 41) or control group which received treatment as usual', 'Adjunctive Single Session Counseling']","['depressive symptom reduction', 'number of workdays lost', 'Patient Health Questionnaire - 15 scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0026809', 'cui_str': 'Mice'}, {'cui': 'C1524069', 'cui_str': 'Indian (racial group)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0337954', 'cui_str': 'Tertiary care hospital (environment)'}, {'cui': 'C3839861', 'cui_str': 'Medically Unexplained Symptoms'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1879301', 'cui_str': 'Patient Health Questionnaire'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0911394,Both groups did not differ on change in the primary outcome measure: Patient Health Questionnaire - 15 scores ( P = 0.055).,"[{'ForeName': 'Vikas', 'Initials': 'V', 'LastName': 'Menon', 'Affiliation': 'Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.'}, {'ForeName': 'Balasubramanian', 'Initials': 'B', 'LastName': 'Shanmuganathan', 'Affiliation': 'Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.'}, {'ForeName': 'Jaiganesh Selvapandian', 'Initials': 'JS', 'LastName': 'Thamizh', 'Affiliation': 'Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.'}, {'ForeName': 'Anand Babu', 'Initials': 'AB', 'LastName': 'Arun', 'Affiliation': 'Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.'}, {'ForeName': 'Siddharth', 'Initials': 'S', 'LastName': 'Sarkar', 'Affiliation': 'Department of Psychiatry and National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India.'}]",Indian journal of psychological medicine,['10.4103/IJPSYM.IJPSYM_73_17'] 892,31610998,Differential treatment effects of an integrated motivational interviewing and exercise intervention on depressive symptom profiles and associated factors: A randomised controlled cross-over trial among youth with major depression.,"BACKGROUND Exercise is increasingly recognised as an efficacious intervention for major depressive disorder (MDD) but to our knowledge differential treatment effects on depressive symptom profiles (cognitive, somatic and affective) and associated changes in psychological, physiological and behavioural factors have not been examined among youth with MDD. METHODS Sixty-eight participants (mean age 20.8) meeting DSM-IV diagnostic criteria for MDD were randomised to an Immediate intervention or Control/delayed condition (n = 34 per group). The integrated intervention comprised an initial session of motivational interviewing (MI) followed by a 12-week, multi-modal exercise program. Changes in depressive symptom profiles were assessed with the Beck Depression Inventory-II (BDI-II) total score and factorial symptom subscales. RESULTS There were significant differential improvements in BDI-II total scores post-treatment among intervention participants, which were also observed across the cognitive and affective subscales. Individual BDI-II items from the cognitive subscale showing significant differential improvement related to negative self-concept, while those from the affective subscale related to interest/activation; the energy item within the somatic subscale also revealed significant differential improvement. Significant differential improvements were also observed in exercise participation, negative automatic thoughts, behavioural activation and bench press repetitions among intervention participants, which correlated significantly with depression improvements. LIMITATIONS The exercise intervention was delivered in a supervised, group format and potential social meditators of change cannot be excluded. CONCLUSIONS Exercise differentially effects depressive symptom profiles with similar antidepressant effects as would be expected from psychological therapies improving negative cognition and emotional health.",2019,"Significant differential improvements were also observed in exercise participation, negative automatic thoughts, behavioural activation and bench press repetitions among intervention participants, which correlated significantly with depression improvements. ","['Sixty-eight participants (mean age 20.8) meeting DSM-IV diagnostic criteria for MDD', 'major depressive disorder (MDD', 'youth with major depression']","['Immediate intervention or Control/delayed condition', 'integrated intervention comprised an initial session of motivational interviewing (MI) followed by a 12-week, multi-modal exercise program', 'integrated motivational interviewing and exercise intervention', 'exercise intervention']","['negative cognition and emotional health', 'exercise participation, negative automatic thoughts, behavioural activation and bench press repetitions', 'depressive symptom profiles and associated factors', 'cognitive and affective subscales', 'Beck Depression Inventory-II (BDI-II) total score and factorial symptom subscales', 'BDI-II total scores', 'depressive symptom profiles']","[{'cui': 'C0450387', 'cui_str': '68 (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0556656', 'cui_str': 'Meetings (procedure)'}, {'cui': 'C0220952', 'cui_str': 'DSM-IV'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0087178', 'cui_str': 'Youth'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0683474', 'cui_str': 'Motivational Interviewing'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0424004', 'cui_str': 'Negative automatic thoughts (finding)'}, {'cui': 'C0454326', 'cui_str': 'Bench press (regime/therapy)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory (assessment scale)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",68.0,0.012155,"Significant differential improvements were also observed in exercise participation, negative automatic thoughts, behavioural activation and bench press repetitions among intervention participants, which correlated significantly with depression improvements. ","[{'ForeName': 'Yasmina', 'Initials': 'Y', 'LastName': 'Nasstasia', 'Affiliation': 'School of Psychology, University of Newcastle, Callaghan, NSW 2308, Australia. Electronic address: yasmina.nasstasia@newcastle.edu.au.'}, {'ForeName': 'Amanda L', 'Initials': 'AL', 'LastName': 'Baker', 'Affiliation': 'School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW 2308, Australia.'}, {'ForeName': 'Terry J', 'Initials': 'TJ', 'LastName': 'Lewin', 'Affiliation': 'School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW 2308, Australia.'}, {'ForeName': 'Sean A', 'Initials': 'SA', 'LastName': 'Halpin', 'Affiliation': 'School of Psychology, University of Newcastle, Callaghan, NSW 2308, Australia.'}, {'ForeName': 'Leanne', 'Initials': 'L', 'LastName': 'Hides', 'Affiliation': 'School of Psychology, University of Queensland, St Lucia, QLD 4072, Australia.'}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Kelly', 'Affiliation': 'School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW 2308, Australia.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Callister', 'Affiliation': 'Priority Research Centre for Physical Activity and Nutrition, University of Newcastle, Callaghan, NSW 2308, Australia.'}]",Journal of affective disorders,['10.1016/j.jad.2019.08.035'] 893,31337525,Design and rationale of the STroke secondary prevention with catheter ABLation and EDoxaban clinical trial in patients with non-valvular atrial fibrillation: The STABLED study.,"BACKGROUND Catheter ablation (CA) has been reported to reduce risk of stroke in patients with nonvalvular atrial fibrillation (NVAF) in retrospective studies. However, the risks and benefits of CA have not been well elucidated in patients with NVAF and who have suffered a recent ischemic stroke in prospective randomized trials. Thus, the aim of the STABLED clinical trial is to investigate the efficacy and safety of CA with anticoagulant therapy using edoxaban in patients with NVAF and a history of recent ischemic stroke. METHODS AND DESIGN The STABLED trial is a multicenter, prospective, randomized, open-label, standard medication-controlled study in Japan. The target patient number is 250, comprising 125 patients receiving standard medication and 125 receiving CA. For patients allocated to the CA group, ablation is to be performed between 1 to 6 months from the onset of index stroke. The observation period will be 3 years from the day of random allocation of the final patient to any of the groups. The primary outcome measure is the composite of recurrence of ischemic stroke, systemic embolism, all-cause death, and hospitalization for heart failure. CONCLUSION This study will investigate the effectiveness and safety of CA and basic anticoagulation treatment with edoxaban for patients with NVAF who have suffered a recent ischemic stroke. The aim is to determine the best evidence for an optimal treatment strategy for patients with NVAF and recent stroke. TRIAL REGISTRATION UMIN000031424/NCT03777631.",2019,"The primary outcome measure is the composite of recurrence of ischemic stroke, systemic embolism, all-cause death, and hospitalization for heart failure. ","['patients with NVAF and who have suffered a recent ischemic stroke', 'Japan', 'patients with NVAF who have suffered a recent ischemic stroke', 'patients with NVAF and a history of recent ischemic stroke', 'patients with NVAF and recent stroke', '125 patients receiving standard medication and 125 receiving CA', 'patients with nonvalvular atrial fibrillation (NVAF', 'patients with non-valvular atrial fibrillation']","['catheter ABLation and EDoxaban', 'CA', 'Catheter ablation (CA', 'edoxaban']","['composite of recurrence of ischemic stroke, systemic embolism, all-cause death, and hospitalization for heart failure']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C4319551', 'cui_str': 'One hundred and twenty-five'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}]","[{'cui': 'C0162563', 'cui_str': 'Catheter Ablation'}, {'cui': 'C2975435', 'cui_str': 'edoxaban'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0013922', 'cui_str': 'Embolism'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}]",125.0,0.0923911,"The primary outcome measure is the composite of recurrence of ischemic stroke, systemic embolism, all-cause death, and hospitalization for heart failure. ","[{'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Sakamoto', 'Affiliation': 'Department of Neurological Science, Nippon Medical School, Tokyo, Japan. Electronic address: yuki-sakamoto@nms.ac.jp.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Nishiyama', 'Affiliation': 'Department of Neurological Science, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Yu-Ki', 'Initials': 'YK', 'LastName': 'Iwasaki', 'Affiliation': 'Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Daida', 'Affiliation': 'Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kazunori', 'Initials': 'K', 'LastName': 'Toyoda', 'Affiliation': 'Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Kitagawa', 'Affiliation': ""Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan.""}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Okumura', 'Affiliation': 'Department of Cardiovascular Center, Saiseikai Kumamoto Hospital, Kumamoto, Japan.'}, {'ForeName': 'Kengo', 'Initials': 'K', 'LastName': 'Kusano', 'Affiliation': 'Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.'}, {'ForeName': 'Nobuhisa', 'Initials': 'N', 'LastName': 'Hagiwara', 'Affiliation': ""Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.""}, {'ForeName': 'Shigeru', 'Initials': 'S', 'LastName': 'Fujimoto', 'Affiliation': 'Division of Neurology, Department of Medicine, Jichi Medical University, Tochigi, Japan.'}, {'ForeName': 'Susumu', 'Initials': 'S', 'LastName': 'Miyamoto', 'Affiliation': 'Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.'}, {'ForeName': 'Toshiaki', 'Initials': 'T', 'LastName': 'Otsuka', 'Affiliation': 'Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan; Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan.'}, {'ForeName': 'Yasuyuki', 'Initials': 'Y', 'LastName': 'Iguchi', 'Affiliation': 'Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Kanamaru', 'Affiliation': 'Department of Neurological Science, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Teppei', 'Initials': 'T', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Jumpei', 'Initials': 'J', 'LastName': 'Kaburagi', 'Affiliation': 'Department of Medical Science, Daiichi Sankyo Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Kimura', 'Affiliation': 'Department of Medical Science, Daiichi Sankyo Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Takuyuki', 'Initials': 'T', 'LastName': 'Matsumoto', 'Affiliation': 'Safety and Risk Management Department, Daiichi Sankyo Co., Tokyo, Japan.'}, {'ForeName': 'Kazumi', 'Initials': 'K', 'LastName': 'Kimura', 'Affiliation': 'Department of Neurological Science, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Wataru', 'Initials': 'W', 'LastName': 'Shimizu', 'Affiliation': 'Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of cardiology,['10.1016/j.jjcc.2019.06.002'] 894,31605608,"Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial.",,2020,,"['1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial']",[],[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019196', 'cui_str': 'Parenterally-Transmitted Non-A, Non-B Hepatitis'}, {'cui': 'C1285573', 'cui_str': 'Genotype determination'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C2976303', 'cui_str': 'sofosbuvir'}, {'cui': 'C3252090', 'cui_str': 'daclatasvir'}, {'cui': 'C1096780', 'cui_str': 'Clinical Trial, Phase 3'}]",[],[],,0.0355185,,"[{'ForeName': 'Shahin', 'Initials': 'S', 'LastName': 'Merat', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciz931'] 895,31603201,"Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults.","BACKGROUND Ebola virus (EBOV) epidemics pose a major public health risk. There currently is no licensed human vaccine against EBOV. The safety and immunogenicity of a recombinant EBOV glycoprotein (GP) nanoparticle vaccine formulated with or without Matrix-M adjuvant were evaluated to support vaccine development. METHODS A phase 1, placebo-controlled, dose-escalation trial was conducted in 230 healthy adults to evaluate 4 EBOV GP antigen doses as single- or 2-dose regimens with or without adjuvant. Safety and immunogenicity were assessed through 1-year postdosing. RESULTS All EBOV GP vaccine formulations were well tolerated. Receipt of 2 doses of EBOV GP with adjuvant showed a rapid increase in anti-EBOV GP immunoglobulin G titers with peak titers observed on Day 35 representing 498- to 754-fold increases from baseline; no evidence of an antigen dose response was observed. Serum EBOV-neutralizing and binding antibodies using wild-type Zaire EBOV (ZEBOV) or pseudovirion assays were 3- to 9-fold higher among recipients of 2-dose EBOV GP with adjuvant, compared with placebo on Day 35, which persisted through 1 year. CONCLUSIONS Ebola virus GP vaccine with Matrix-M adjuvant is well tolerated and elicits a robust and persistent immune response. These data suggest that further development of this candidate vaccine for prevention of EBOV disease is warranted.",2020,Receipt of 2 doses of EBOV GP with adjuvant showed a rapid increase in anti-EBOV GP IgG titers with peak titers observed on Day 35 representing 498- to 754-fold increases from baseline; no evidence of an antigen dose-response was observed.,"['Healthy Adults', '230 healthy adults to evaluate 4 EBOV GP antigen doses as single- or 2-dose regimens with or without adjuvant']","['placebo', 'recombinant EBOV glycoprotein (GP) nanoparticle vaccine', 'EBOV GP vaccine with Matrix-M adjuvant', 'Ebola Virus Glycoprotein (EBOV GP) Nanoparticle Vaccine with Matrix-M™ Adjuvant']","['tolerated', 'anti-EBOV GP IgG titers', 'Safety and immunogenicity', 'Serum EBOV-neutralizing and binding antibodies using wild-type ZEBOV or pseudovirion assays']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0003320', 'cui_str': 'Antigens'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0017968', 'cui_str': 'Glycoproteins'}, {'cui': 'C1450054', 'cui_str': 'Nanoparticles'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C4549501', 'cui_str': 'Matrix-M'}, {'cui': 'C0949892', 'cui_str': 'Ebola Virus'}]","[{'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1145667', 'cui_str': 'Binding - action (qualifier value)'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0445392', 'cui_str': 'Wild (qualifier value)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C1510438', 'cui_str': 'Assay technique (qualifier value)'}]",230.0,0.254616,Receipt of 2 doses of EBOV GP with adjuvant showed a rapid increase in anti-EBOV GP IgG titers with peak titers observed on Day 35 representing 498- to 754-fold increases from baseline; no evidence of an antigen dose-response was observed.,"[{'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'Fries', 'Affiliation': 'Novavax, Inc., Gaithersburg, Maryland, USA.'}, {'ForeName': 'Iksung', 'Initials': 'I', 'LastName': 'Cho', 'Affiliation': 'Novavax, Inc., Gaithersburg, Maryland, USA.'}, {'ForeName': 'Verena', 'Initials': 'V', 'LastName': 'Krähling', 'Affiliation': 'Institute of Virology, Philipps University of Marburg, Marburg, Germany.'}, {'ForeName': 'Sarah K', 'Initials': 'SK', 'LastName': 'Fehling', 'Affiliation': 'Institute of Virology, Philipps University of Marburg, Marburg, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Strecker', 'Affiliation': 'Institute of Virology, Philipps University of Marburg, Marburg, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Becker', 'Affiliation': 'Institute of Virology, Philipps University of Marburg, Marburg, Germany.'}, {'ForeName': 'Jay W', 'Initials': 'JW', 'LastName': 'Hooper', 'Affiliation': 'US Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Maryland, USA.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Kwilas', 'Affiliation': 'US Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Maryland, USA.'}, {'ForeName': 'Sapeckshita', 'Initials': 'S', 'LastName': 'Agrawal', 'Affiliation': 'Novavax, Inc., Gaithersburg, Maryland, USA.'}, {'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Wen', 'Affiliation': 'Novavax, Inc., Gaithersburg, Maryland, USA.'}, {'ForeName': 'Maggie', 'Initials': 'M', 'LastName': 'Lewis', 'Affiliation': 'Novavax, Inc., Gaithersburg, Maryland, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Fix', 'Affiliation': 'Novavax, Inc., Gaithersburg, Maryland, USA.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Thomas', 'Affiliation': 'Novavax, Inc., Gaithersburg, Maryland, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Flyer', 'Affiliation': 'Novavax, Inc., Gaithersburg, Maryland, USA.'}, {'ForeName': 'Gale', 'Initials': 'G', 'LastName': 'Smith', 'Affiliation': 'Novavax, Inc., Gaithersburg, Maryland, USA.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Glenn', 'Affiliation': 'Novavax, Inc., Gaithersburg, Maryland, USA.'}]",The Journal of infectious diseases,['10.1093/infdis/jiz518'] 896,31866076,"Negative symptoms predict high relapse rates and both predict less favorable functional outcome in first episode psychosis, independent of treatment strategy.","BACKGROUND In first episode psychosis (FEP) baseline negative symptoms (BNS) and relapse both predict less favorable functional outcome. Relapse-prevention is one of the most important goals of treatment. Apart from discontinuation of antipsychotics, natural causes of relapse are unexplained. We hypothesized that BNS, apart from predicting worse functional outcome, might also increase relapse risk. METHODS We performed a post-hoc analysis of 7-year follow-up data of a FEP cohort (n = 103) involved in a dose-reduction/discontinuation (DR) vs. maintenance treatment (MT) trial. We examined: 1) what predicted relapse, 2) what predicted functional outcome, and 3) if BNS predicted relapse, whether MT reduced relapse rates compared to DR. After remission patients were randomly assigned to DR or MT for 18 months. Thereafter, treatment was uncontrolled. OUTCOMES BNS and duration of untreated psychosis (DUP) predicted relapse. Number of relapses, BNS, and treatment strategy predicted functional outcome. BNS was the strongest predictor of relapse, while number of relapses was the strongest predictor of functional outcome above BNS and treatment strategy. Overall and within MT, but not within DR, more severe BNS predicted significantly higher relapse rates. Treatment strategies did not make a difference in relapse rates, regardless of BNS severity. INTERPRETATION BNS not only predicted worse functional outcome, but also relapses during follow-up. Since current low dose maintenance treatment strategies did not prevent relapse proneness in patients with more severe BNS, resources should be deployed to find optimal treatment strategies for this particular group of patients.",2020,"Treatment strategies did not make a difference in relapse rates, regardless of BNS severity. ",['After remission patients'],[],"['BNS and duration of untreated psychosis (DUP) predicted relapse', 'relapse rates', 'relapse rates, regardless of BNS severity']","[{'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]",[],"[{'cui': 'C0099085', 'cui_str': '2-Naphthalenol, 6-bromo-, hydrogen sulfate'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",,0.0518748,"Treatment strategies did not make a difference in relapse rates, regardless of BNS severity. ","[{'ForeName': 'Lex', 'Initials': 'L', 'LastName': 'Wunderink', 'Affiliation': 'Department of Research and Education, Friesland Mental Health Care Services, Sixmastraat 2, 8932 PA Leeuwarden, the Netherlands; Department of Psychiatry, University Medical Center Groningen, Groningen University, PO Box 30.001, 9700 RB Groningen, the Netherlands. Electronic address: lexwunderink@gmail.com.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'van Bebber', 'Affiliation': 'Department of Psychiatry, University Medical Center Groningen, Groningen University, PO Box 30.001, 9700 RB Groningen, the Netherlands.'}, {'ForeName': 'Sjoerd', 'Initials': 'S', 'LastName': 'Sytema', 'Affiliation': 'Department of Psychiatry, University Medical Center Groningen, Groningen University, PO Box 30.001, 9700 RB Groningen, the Netherlands.'}, {'ForeName': 'Nynke', 'Initials': 'N', 'LastName': 'Boonstra', 'Affiliation': 'Department of Research and Education, Friesland Mental Health Care Services, Sixmastraat 2, 8932 PA Leeuwarden, the Netherlands; NHL Stenden University of Applied Science, Leeuwarden, the Netherlands.'}, {'ForeName': 'Rob R', 'Initials': 'RR', 'LastName': 'Meijer', 'Affiliation': 'Department of Psychometrics and Statistics, University of Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Johanna T W', 'Initials': 'JTW', 'LastName': 'Wigman', 'Affiliation': 'Department of Psychiatry, University Medical Center Groningen, Groningen University, PO Box 30.001, 9700 RB Groningen, the Netherlands.'}]",Schizophrenia research,['10.1016/j.schres.2019.12.001'] 897,29061910,Health Coaching in Severe COPD After a Hospitalization: A Qualitative Analysis of a Large Randomized Study.,"BACKGROUND We recently demonstrated in a randomized study the feasibility and effectiveness of telephone-based health coaching using motivational interviewing on decreasing hospital readmissions and improving quality of life at 6 and 12 months after hospital discharge. In this qualitative study, we sought to explore the health-coaching intervention as seen from the perspective of the participants who received the intervention and the coaches who delivered it. METHODS Semistructured participant interviews ( n = 24) and a focus group of all health coaches ( n = 3) who participated in this study were conducted. Interviews and focus group were recorded and transcribed verbatim. Transcripts were analyzed using coding and categorizing techniques and thematic analysis. Mixed-method triangulation was used to merge quantitative and qualitative data. RESULTS Content analysis revealed 4 predominant themes of the coaching intervention: health-coaching relationship, higher participant confidence and reassurance (most related to improvement in physical quality of life), improved health-care system access (most related to decreased hospital readmissions), and increased awareness of COPD symptoms (most related to improvement in emotional quality of life). The strongest theme was the relationship with the health coach, including coach style and motivational interviewing approach. Health coaches' focus group also noted the importance of the coaching relationship as the most significant theme. CONCLUSIONS This study provided themes to further inform the delivery and implementation of health-coaching interventions in patients with COPD after hospital discharge. Health coaching forged partnerships and created a platform for patient engagement, which was confirmed by both participants and health coaches.",2017,"Health coaching forged partnerships and created a platform for patient engagement, which was confirmed by both participants and health coaches.","['participants who received the intervention and the coaches who delivered it', 'Semistructured participant interviews ( n = 24) and a focus group of all health coaches ( n = 3) who participated in this study were conducted', 'at 6 and 12 months after hospital discharge', 'Severe COPD', 'patients with COPD after hospital discharge']","['health-coaching intervention', 'Health Coaching', 'telephone-based health coaching using motivational interviewing']","['hospital readmissions and improving quality of life', 'physical quality of life), improved health-care system access', 'awareness of COPD symptoms', 'emotional quality of life']","[{'cui': 'C0557773', 'cui_str': 'Coach (physical object)'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0016400', 'cui_str': 'Focus Groups'}, {'cui': 'C2317129', 'cui_str': 'Health coach'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C2317129', 'cui_str': 'Health coach'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0683474', 'cui_str': 'Motivational Interviewing'}]","[{'cui': 'C0600290', 'cui_str': 'Hospital Readmissions'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0018696', 'cui_str': 'Health Care Systems'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0004448', 'cui_str': 'Situational Awareness'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}]",,0.0376267,"Health coaching forged partnerships and created a platform for patient engagement, which was confirmed by both participants and health coaches.","[{'ForeName': 'Roberto P', 'Initials': 'RP', 'LastName': 'Benzo', 'Affiliation': 'Mindful Breathing Laboratory, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota. benzo.roberto@mayo.edu.'}, {'ForeName': 'Janae L', 'Initials': 'JL', 'LastName': 'Kirsch', 'Affiliation': 'Mindful Breathing Laboratory, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Julie C', 'Initials': 'JC', 'LastName': 'Hathaway', 'Affiliation': 'Section of Patient Education, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Charlene E', 'Initials': 'CE', 'LastName': 'McEvoy', 'Affiliation': 'HealthPartners Institute for Education and Research, Bloomington, Minnesota.'}, {'ForeName': 'Kristin S', 'Initials': 'KS', 'LastName': 'Vickers', 'Affiliation': 'Division of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.'}]",Respiratory care,['10.4187/respcare.05574'] 898,29188171,Managing persistent wound leakage after total knee and hip arthroplasty. Results of a nationwide survey among Dutch orthopaedic surgeons.,"Background: Persistent wound leakage after joint arthroplasty is a scantily investigated topic, despite the claimed relation with a higher risk of periprosthetic joint infection. This results in a lack of evidence-based clinical guidelines for the diagnosis and treatment of persistent wound leakage after joint arthroplasty. Without such guideline, clinical practice in orthopaedic hospitals varies widely. In preparation of a nationwide multicenter randomized controlled trial on the optimal treatment of persistent wound leakage, we evaluated current Dutch orthopaedic care for persistent wound leakage after joint arthroplasty. Methods: We conducted a questionnaire-based online survey among all 700 members of the Netherlands Orthopaedic Association, consisting of 23 questions on the definition, classification, diagnosis and treatment of persistent wound leakage after joint arthroplasty. Results: The questionnaire was completed by 127 respondents, representing 68% of the Dutch hospitals that perform orthopaedic surgery. The results showed wide variation in the classification, definition, diagnosis and treatment of persistent wound leakage among Dutch orthopaedic surgeons. 56.7% of the respondents used a protocol for diagnosis and treatment of persistent wound leakage, but only 26.8% utilized the protocol in every patient. Most respondents (59.1%) reported a maximum period of persistent wound leakage before starting non-surgical treatment of 3 to 7 days after index surgery and 44.1% of respondents reported a maximum period of wound leakage of 10 days before converting to surgical treatment. Conclusions: The wide variety in clinical practice underscores the importance of developing an evidence-based clinical guideline for the diagnosis and treatment of persistent wound leakage after joint arthroplasty. To this end, a nationwide multicenter randomized controlled trial will be conducted in the Netherlands, which may provide evidence on this important and poorly understood topic.",2017,This results in a lack of evidence-based clinical guidelines for the diagnosis and treatment of persistent wound leakage after joint arthroplasty.,"['Dutch orthopaedic surgeons', '127 respondents, representing 68% of the Dutch hospitals that perform orthopaedic surgery', 'total knee and hip arthroplasty', 'among all 700 members of the Netherlands Orthopaedic Association, consisting of 23 questions on the definition, classification, diagnosis and treatment of persistent wound leakage after joint arthroplasty', 'after joint arthroplasty']",['questionnaire-based online survey'],"['wound leakage', 'persistent wound leakage', 'maximum period of persistent wound leakage']","[{'cui': 'C0013331', 'cui_str': 'Dutch (ethnic group)'}, {'cui': 'C0334891', 'cui_str': 'Orthopedists'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0186193', 'cui_str': 'Arthroplasty of coxofemoral joint'}, {'cui': 'C4517862', 'cui_str': '700 (qualifier value)'}, {'cui': 'C0680022', 'cui_str': 'Member of (attribute)'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C3539107', 'cui_str': 'Definition (core metadata concept)'}, {'cui': 'C0008903', 'cui_str': 'taxonomy'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0015376', 'cui_str': 'Extravasation (morphologic abnormality)'}, {'cui': 'C0003893', 'cui_str': 'Arthroplasty'}]","[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]","[{'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0015376', 'cui_str': 'Extravasation (morphologic abnormality)'}]",,0.10084,This results in a lack of evidence-based clinical guidelines for the diagnosis and treatment of persistent wound leakage after joint arthroplasty.,"[{'ForeName': 'Frank-Christiaan', 'Initials': 'FC', 'LastName': 'Wagenaar', 'Affiliation': 'Department of Orthopaedics, OCON, Center for Orthopaedic Surgery, Hengelo, The Netherlands.'}, {'ForeName': 'Claudia A M', 'Initials': 'CAM', 'LastName': 'Löwik', 'Affiliation': 'Department of Orthopaedics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Stevens', 'Affiliation': 'Department of Orthopaedics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Sjoerd K', 'Initials': 'SK', 'LastName': 'Bulstra', 'Affiliation': 'Department of Orthopaedics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Yvette', 'Initials': 'Y', 'LastName': 'Pronk', 'Affiliation': 'Research Department, Kliniek Viasana, Mill, The Netherlands.'}, {'ForeName': 'Inge', 'Initials': 'I', 'LastName': 'van den Akker-Scheek', 'Affiliation': 'Department of Orthopaedics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Marjan', 'Initials': 'M', 'LastName': 'Wouthuyzen-Bakker', 'Affiliation': 'Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Rob G H H', 'Initials': 'RGHH', 'LastName': 'Nelissen', 'Affiliation': 'Department of Orthopaedics, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Rudolf W', 'Initials': 'RW', 'LastName': 'Poolman', 'Affiliation': 'Department of Orthopaedics, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'van der Weegen', 'Affiliation': 'Department of Orthopaedics, Sint Anna Ziekenhuis, Geldrop, The Netherlands.'}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'Jutte', 'Affiliation': 'Department of Orthopaedics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}]",Journal of bone and joint infection,['10.7150/jbji.22327'] 899,29197067,Cervical cancer screening through human papillomavirus testing in community health campaigns versus health facilities in rural western Kenya.,"OBJECTIVE To determine the effectiveness of community health campaigns (CHCs) as a strategy for human papillomavirus (HPV)-based cervical cancer screening in rural western Kenya. METHODS Between January and November 2016, a cluster-randomized trial was carried out in 12 communities in western Kenya to investigate high-risk HPV testing offered via self-collection to women aged 25-65 years in CHCs versus government health facilities. Outcome measures were the total number of women accessing cervical cancer screening and the proportion of HPV-positive women accessing treatment. RESULTS In total, 4944 women underwent HPV-based cervical cancer screening in CHCs (n=2898) or health facilities (n=2046). Screening uptake as a proportion of total eligible women in the population was greater in communities assigned to CHCs (60.0% vs 37.0%, P<0.001). Rates of treatment acquisition were low in both arms (CHCs 39.2%; health facilities 31.5%; P=0.408). DISCUSSION Cervical cancer screening using HPV testing of self-collected samples reached a larger proportion of women when offered through periodic CHCs compared with health facilities. The community-based model is a promising strategy for cervical cancer prevention. Lessons learned from this trial can be used to identify ways of maximizing the impact of such strategies through greater community participation and improved linkage to treatment. ClinicalTrials.gov registration: NCT02124252.",2018,"Rates of treatment acquisition were low in both arms (CHCs 39.2%; health facilities 31.5%; P=0.408). ","['human papillomavirus (HPV)-based cervical cancer screening in rural western Kenya', '4944 women underwent HPV-based cervical cancer screening in CHCs (n=2898) or health facilities (n=2046', 'Cervical cancer screening through human papillomavirus testing in community health campaigns versus health facilities in rural western Kenya', 'Between January and November 2016, a cluster-randomized trial was carried out in 12 communities in western Kenya to investigate high-risk HPV testing offered via self-collection to women aged 25-65\xa0years in CHCs versus government health facilities']",['community health campaigns (CHCs'],"['Rates of treatment acquisition', 'total number of women accessing cervical cancer screening and the proportion of HPV-positive women accessing treatment']","[{'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix (disorder)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0022558', 'cui_str': 'Republic of Kenya'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0018704', 'cui_str': 'Health Facilities'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0018104', 'cui_str': 'Government'}]","[{'cui': 'C0034019', 'cui_str': 'Community Health'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix (disorder)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}]",4944.0,0.103403,"Rates of treatment acquisition were low in both arms (CHCs 39.2%; health facilities 31.5%; P=0.408). ","[{'ForeName': 'Megan J', 'Initials': 'MJ', 'LastName': 'Huchko', 'Affiliation': 'Duke Global Health Institute, Duke University, Durham, NC, USA.'}, {'ForeName': 'Saduma', 'Initials': 'S', 'LastName': 'Ibrahim', 'Affiliation': 'Center for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Cinthia', 'Initials': 'C', 'LastName': 'Blat', 'Affiliation': 'Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Craig R', 'Initials': 'CR', 'LastName': 'Cohen', 'Affiliation': 'Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Smith', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Hiatt', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Bukusi', 'Affiliation': 'Center for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.'}]",International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,['10.1002/ijgo.12415'] 900,31851011,Effects of Home Exercises on Shoulder Pain and Pathology in Chronic Spinal Cord Injury: A Randomized Controlled Trial.,"OBJECTIVE The aims of this study were to replicate findings that a home exercise program intervention improved shoulder pain and function and to assess changes in supraspinatus tendon pathology associated with the home exercise program in persons with chronic spinal cord injury. DESIGN The study is a single-blind randomized controlled trial. Individuals with spinal cord injury of at least 1 yr and chronic shoulder pain of moderate or greater average intensity were enrolled. Participants were randomized to a 12-wk home exercise program consisting of strengthening and stretching exercises or to an education-only control group, with immediate postintervention and 4-wk postintervention (16 wks) follow-ups. The main outcome measures were self-report measures of shoulder pain and impairment, the Physical Examination of the Shoulder Scale, quantitative ultrasound metrics of the supraspinatus tendon, and the Ultrasound Shoulder Pathology Rating Scale. RESULTS Thirty-two participants were randomized to home exercise program or education-only control condition. The mean ± SD age was 44.8 ± 12.5; 81.3% were male; 65.6% had motor complete paraplegia. Using a per-protocol, within-group analysis method, significant differences were observed between baseline and postintervention for the home exercise program group for the least pain intensity (P = 0.02), number of days with shoulder pain (P = 0.042), Physical Examination of the Shoulder Scale scores (dominant side, P = 0.036; nondominant side, P = 0.008), the Disabilities of the Arm, Shoulder, and Hand (P = 0.028), and the Patient Global Impression of Change (P = 0.015). The education-only control condition group demonstrated significant changes in average unpleasantness of shoulder pain after the intervention period (P = 0.049). Comparisons in changes from baseline between groups showed that the home exercise program group had greater improvements in nondominant-side Physical Examination of the Shoulder Scale scores and global impression of change, whereas the education-only control condition group had greater improvements in depressive symptoms.For quantitative ultrasound measures, no significant changes were found with within-group analyses for the home exercise program group, although the education-only control condition group demonstrated a decrease in tendon width in the nondominant-side supraspinatus tendon (P = 0.036). Comparison of changes between groups suggests that the education-only control condition group had a greater increase in dominant shoulder supraspinatus tendon ultrasound contrast at the end of the study. CONCLUSIONS Changes in several measures of shoulder pain and function occurred after the home exercise program intervention, although the magnitude of changes was only significantly greater than those of the education-only control condition group for two measures. Significant changes in supraspinatus pathology were not detected with quantitative ultrasound metrics.",2020,"Participants were randomized to a 12-week HEP consisting of strengthening and stretching exercises or to an education-only control group (CON), with immediate post-intervention and 4-week post-intervention (16 weeks) follow-ups.","['Individuals with SCI of at least 1 year and chronic shoulder pain of moderate or greater average intensity were enrolled', 'Chronic Spinal Cord Injury', '32 participants', 'Average age was 44.8 ', 'persons with chronic spinal cord injury (SCI']","['home exercise program (HEP) intervention', 'HEP consisting of strengthening and stretching exercises or to an education-only control group (CON), with immediate post-intervention and 4-week post-intervention', 'CON', 'Home Exercises', 'HEP or CON', 'HEP']","['tendon width', 'Patient Global Impression of Change', 'least pain intensity', 'self-report measures of shoulder pain and impairment, and the Physical Examination of the Shoulder Scale (PESS), quantitative ultrasound (QUS) metrics of the supraspinatus tendon, and the Ultrasound Shoulder Pathology Rating Scale (USPRS', 'depressive symptoms', 'supraspinatus pathology', 'motor complete paraplegia', 'PESS scores', 'shoulder pain and function', 'average unpleasantness of shoulder pain', 'Shoulder Pain and Pathology', 'number of days with shoulder pain', 'non-dominant side PESS scores and global impression of change']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0037011', 'cui_str': 'Shoulder Pain'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0027361', 'cui_str': 'Persons'}]","[{'cui': 'C0475647', 'cui_str': 'Home exercise program (regime/therapy)'}, {'cui': 'C0449198', 'cui_str': 'HEP (body structure)'}, {'cui': 'C0600080', 'cui_str': 'Stretching procedure (procedure)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0039508', 'cui_str': 'Tendons'}, {'cui': 'C0487742', 'cui_str': 'Width (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0037011', 'cui_str': 'Shoulder Pain'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0031809', 'cui_str': 'Physical Examination'}, {'cui': 'C0037004', 'cui_str': 'Shoulder'}, {'cui': 'C0222045'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0699680', 'cui_str': 'Metric'}, {'cui': 'C0584869', 'cui_str': 'Supraspinatus'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C1659098', 'cui_str': 'Complete paraplegia'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0445549', 'cui_str': 'Non-dominant side (qualifier value)'}]",32.0,0.0837195,"Participants were randomized to a 12-week HEP consisting of strengthening and stretching exercises or to an education-only control group (CON), with immediate post-intervention and 4-week post-intervention (16 weeks) follow-ups.","[{'ForeName': 'Diana D', 'Initials': 'DD', 'LastName': 'Cardenas', 'Affiliation': 'From the South Florida SCI Model System, Department of Physical Medicine & Rehabilitation, University of Miami Miller School of Medicine, Miami, Florida (DDC, ERF, RI); Miami Veterans Administration Medical Center, Miami, Florida (ERF); Department of Physical Medicine & Rehabilitation, University of Alabama at Birmingham, Birmingham, Alabama (RC); and Jackson Memorial Hospital, Miami, Florida (MFO).'}, {'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Felix', 'Affiliation': ''}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Cowan', 'Affiliation': ''}, {'ForeName': 'Melanie F', 'Initials': 'MF', 'LastName': 'Orell', 'Affiliation': ''}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Irwin', 'Affiliation': ''}]",American journal of physical medicine & rehabilitation,['10.1097/PHM.0000000000001362'] 901,28852238,"Anxiety Treatment of Opioid Dependent Patients with Buprenorphine: A Randomized, Double-blind, Clinical Trial.","OBJECTIVE The objective of this study is to examine the impact of vary doses of buprenorphine on anxiety symptoms in opioid-dependent inpatients over a 7 days period, using a randomized controlled trial design. DESIGN Patients were randomized to three groups. PATIENTS AND METHODS Fourteen men who met the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for both opioid use disorder and generalized anxiety disorder and were seeking for treatment. INTERVENTION Patients obtain dosages of 32 mg or 64 mg or 96 mg of buprenorphine as a single dose only and were treated in a psychiatric inpatient unit. Of 14 subjects; 5 (35.7%) obtained 32 mg, 4 (28.6%) obtained 64 mg, and 5 (35.7%) obtained 96 mg of buprenorphine. MEASUREMENTS Administering daily Hamilton Anxiety Rating Scale and interview. RESULTS All the patients ended the 7-day treatment time. The results showed a significant reduction in anxiety symptoms within each of the three groups ( P = 0.00), but no difference in outcome between the groups ( P = 0.605). CONCLUSIONS The outcome suggests a single high dose of buprenorphine can supply a speedy, safe, simple, and suitable means of anxiety treatment. The single high dose of buprenorphine could be a novel mechanism medication that provides a rapid and sustained improvement for generalized anxiety disorder in opioid dependent patients. Placebo-controlled trials of longer duration are needed to evaluate ability, safety, and psychological and physiological influence of extended exposure to this medication.",2017,"The results showed a significant reduction in anxiety symptoms within each of the three groups ( P = 0.00), but no difference in outcome between the groups ( P = 0.605). ","['opioid-dependent inpatients over a 7 days period', 'Fourteen men who met the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for both opioid use disorder and generalized anxiety disorder and were seeking for treatment']","['Patients obtain dosages of 32 mg or 64 mg or 96 mg of buprenorphine', 'Placebo', 'buprenorphine', 'Buprenorphine']","['Administering daily Hamilton Anxiety Rating Scale and interview', 'anxiety symptoms']","[{'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0163299', 'cui_str': 'A 7'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C1136324', 'cui_str': 'Diagnostic and Statistical Manual of Mental Disorders'}, {'cui': 'C0205439', 'cui_str': 'Fifth (qualifier value)'}, {'cui': 'C0441792', 'cui_str': 'Editions (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0270549', 'cui_str': 'Generalized anxiety disorder (disorder)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C0178602', 'cui_str': 'Dosages (qualifier value)'}, {'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0222045'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}]",14.0,0.0812831,"The results showed a significant reduction in anxiety symptoms within each of the three groups ( P = 0.00), but no difference in outcome between the groups ( P = 0.605). ","[{'ForeName': 'Jamshid', 'Initials': 'J', 'LastName': 'Ahmadi', 'Affiliation': 'Substance Abuse Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Mina Sefidfard', 'Initials': 'MS', 'LastName': 'Jahromi', 'Affiliation': 'Substance Abuse Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.211765'] 902,30810465,Targeted Workup after Initial Febrile Urinary Tract Infection: Using a Novel Machine Learning Model to Identify Children Most Likely to Benefit from Voiding Cystourethrogram.,"PURPOSE Significant debate persists regarding the appropriate workup in children with an initial urinary tract infection. Greatly preferable to all or none approaches in the current guideline would be a model to identify children at highest risk for a recurrent urinary tract infection plus vesicoureteral reflux to allow for targeted voiding cystourethrogram while children at low risk could be observed. We sought to develop a model to predict the probability of recurrent urinary tract infection associated vesicoureteral reflux in children after an initial urinary tract infection. MATERIALS AND METHODS We included subjects from the RIVUR (Randomized Intervention for Children with Vesico-Ureteral Reflux) and CUTIE (Careful Urinary Tract Infection Evaluation) trials in our study, excluding the prophylaxis treatment arm of the RIVUR. The main outcome was defined as recurrent urinary tract infection associated vesicoureteral reflux. Missing data were imputed using optimal tree imputation. Data were split into training, validation and testing sets. Machine learning algorithm hyperparameters were tuned by the validation set with fivefold cross-validation. RESULTS A total of 500 subjects, including 305 from the RIVUR and 195 from the CUTIE trials, were included in study. Of the subjects 90% were female and mean ± SD age was 21 ± 19 months. A recurrent urinary tract infection developed in 72 patients, of whom 53 also had vesicoureteral reflux (10.6% of the total). The final model included age, sex, race, weight, the systolic blood pressure percentile, dysuria, the urine albumin-to-creatinine ratio, prior antibiotic exposure and current medication. The model predicted recurrent urinary tract infection associated vesicoureteral reflux with an AUC of 0.761 (95% CI 0.714-0.808) in the testing set. CONCLUSIONS Our predictive model using a novel machine learning algorithm provided promising performance to facilitate individualized treatment of children with an initial urinary tract infection and identify those most likely to benefit from voiding cystourethrogram after the initial urinary tract infection. This would allow for more selective application of this test, increasing the yield while also minimizing overuse.",2019,"The model predicted recurrent urinary tract infection associated vesicoureteral reflux with an AUC of 0.761 (95% CI 0.714-0.808) in the testing set. ","['children with an initial urinary tract infection', 'children after an initial urinary tract infection', 'Of the subjects 90% were female and mean ± SD age was 21 ± 19 months', 'We included subjects from the RIVUR (Randomized Intervention for Children with Vesico-Ureteral Reflux) and CUTIE (Careful Urinary Tract Infection Evaluation) trials in our study, excluding the prophylaxis treatment arm of the RIVUR', 'Children', 'A total of 500 subjects, including 305 from the RIVUR and 195 from the CUTIE trials, were included in study']","['novel machine learning algorithm', 'Novel Machine Learning Model']","['vesicoureteral reflux', 'systolic blood pressure percentile, dysuria, the urine albumin-to-creatinine ratio, prior antibiotic exposure and current medication', 'recurrent urinary tract infection', 'recurrent urinary tract infection associated vesicoureteral reflux']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0042580', 'cui_str': 'Vesicoureteral Reflux'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C4517703', 'cui_str': 'Three hundred and five'}, {'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0336779', 'cui_str': 'Machine, device (physical object)'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0002045'}, {'cui': 'C0376284', 'cui_str': 'Machine Learning'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}]","[{'cui': 'C0042580', 'cui_str': 'Vesicoureteral Reflux'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0013428', 'cui_str': 'Dysuria'}, {'cui': 'C0042037'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0262655', 'cui_str': 'Recurrent urinary tract infection (disorder)'}]",90.0,0.0232945,"The model predicted recurrent urinary tract infection associated vesicoureteral reflux with an AUC of 0.761 (95% CI 0.714-0.808) in the testing set. ","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ""Department of Urology, Boston Children's Hospital , Boston , Massachusetts.""}]",The Journal of urology,['10.1097/JU.0000000000000186'] 903,31810744,Sex Differences in Vasovagal Syncope: A Post Hoc Analysis of the Prevention of Syncope Trials (POST) I and II.,"BACKGROUND Vasovagal syncope (VVS) occurs in > 40% of individuals at least once in their lifetime. Sex-dependent differences in presentation and outcomes are not understood. We sought to determine differences in clinical presentation, treatment modalities, and outcomes of VVS between men and women. METHODS Data were collected as part of the Prevention of Syncope Trials (POST) I and II, 2 multicenter, placebo-controlled, randomized trials testing the effectiveness of metoprolol and fludrocortisone, respectively. Data regarding clinical presentation, outcomes, and time to first syncope event after randomization were compared. RESULTS Of the 418 patients (280 women and 138 men), women were younger at the time of first syncope event (21 vs 26 years P = 0.002) and had a lower baseline systolic blood pressure (117 vs 124 mm Hg, P < 0.001). Response to heat as a trigger for syncope was more common in women (68% vs 48%, P = 0.011). Clinical presentation in women consisted more commonly of feeling warm, having seizures, and experiencing more postsyncope fatigue (68% vs 54%, P = 0.048; 10% vs 2.7%, P = 0.045; 75% vs 59%, P = 0.017, respectively). Women were more likely to experience recurrent syncope after adjustment for prerandomization syncope burden and randomization assignment (hazard ratio, 1.56; 95% confidence interval, 1.10-2.22; P = 0.012). CONCLUSION Clinical presentation and provocative factors of VVS differ between men and women, as do recurrent events. Recognition of these differences may help target therapy specifically in men and women.",2020,"Response to heat as a trigger for syncope was more common in women (68% vs 48%, P = 0.011).","['418 patients (280 women and 138 men', 'men and women', 'Data were collected as part of the Prevention of Syncope Trials (POST']","['placebo', 'metoprolol and fludrocortisone']","['time of first syncope event', 'experience recurrent syncope', 'postsyncope fatigue', 'Vasovagal Syncope', 'Syncope Trials (POST', 'baseline systolic blood pressure', 'time to first syncope event']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C1292711', 'cui_str': 'Part of (attribute)'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0039070', 'cui_str': 'Fainting'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0025859', 'cui_str': 'Metoprolol'}, {'cui': 'C0016280', 'cui_str': 'Fludrocortisone'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0039070', 'cui_str': 'Fainting'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0042420', 'cui_str': 'Syncope, Vasodepressor'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C4274438', 'cui_str': 'Baseline systolic blood pressure'}]",280.0,0.348786,"Response to heat as a trigger for syncope was more common in women (68% vs 48%, P = 0.011).","[{'ForeName': 'Adam P', 'Initials': 'AP', 'LastName': 'Deveau', 'Affiliation': 'Dalhousie University Medical School, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Sheldon', 'Affiliation': 'University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Connor', 'Initials': 'C', 'LastName': 'Maxey', 'Affiliation': 'University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Ritchie', 'Affiliation': 'University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Doucette', 'Affiliation': 'Research Methods Unit, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Ratika', 'Initials': 'R', 'LastName': 'Parkash', 'Affiliation': 'Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada. Electronic address: Ratika.Parkash@nshealth.ca.'}]",The Canadian journal of cardiology,['10.1016/j.cjca.2019.10.008'] 904,32023606,Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.,"Chronic kidney disease (CKD) is associated with excess cardiovascular morbidity and mortality compared to the general population. Hyperphosphataemia, associated with vascular calcification and arterial stiffness, may play a key role in the pathogenesis of cardiovascular disease (CVD) associated with CKD, although phosphate reduction strategies have not consistently proven to beneficially affect clinically relevant outcomes. The IMpact of Phosphate Reduction On Vascular End-points in CKD (IMPROVE-CKD) study is an international, multi-centre, randomized, placebo-controlled trial investigating the effect of the phosphate binder lanthanum carbonate on intermediate cardiovascular markers in patients with stage 3b-4 CKD. The primary end-point is change in carotid-femoral pulse wave velocity (PWV, SphygmoCor) after 96 weeks. Secondary outcomes include change in abdominal aortic calcification (AAC, computed tomography), serum phosphate and fibroblast growth factor 23 (FGF-23). In total, 278 participants were recruited and randomized, mean age 63 ± 13 years, 69% male, 45% diabetes, 32% CVD, 33% stage 3b CKD and 67% stage 4 CKD. Mean estimated glomerular filtration rate and serum phosphate were 26.6 ± 8.3 mL/min/1.72 m2 and 1.25 ± 0.20 mmol/L, respectively. Median (interquartile range) intact and c-terminal FGF-23 levels were 133.0 (89.1-202) pg/mL and 221.1 (154.3-334.1) RU/mL, respectively. Mean PWV was 10.8 ± 3.6 m/s and 81% had AAC (median Agatston score 1,535 [63-5,744] Hounsfield units). PWV ≥10 m/s was associated with older age, diabetes, CVD, presence of AAC, higher systolic blood pressure (BP), larger waist circumference and higher alkaline phosphatase. AAC was associated with older age, male sex, diabetes, CVD, higher diastolic BP, dyslipidaemia (and use of statins), smoking, larger waist circumference and increased PWV. In conclusion, IMPROVE-CKD participants had high baseline risk for cardiovascular events, as suggested by high baseline PWV and AAC values.",2020,Mean estimated glomerular filtration rate and serum phosphate were 26.6 ± 8.3 mL,"['278 participants were recruited and randomized, mean age 63 ± 13 years, 69% male, 45% diabetes, 32% CVD, 33% stage 3b CKD and 67% stage 4 CKD', 'Chronic Kidney Disease Cohort with High Cardiovascular Risk', 'patients with stage 3b-4 CKD', 'Chronic kidney disease (CKD']","['placebo', 'phosphate binder lanthanum carbonate', 'AAC', 'Phosphate Reduction']","['older age, diabetes, CVD, presence of AAC, higher systolic blood pressure (BP), larger waist circumference and higher alkaline phosphatase', 'Mean PWV', 'Mean estimated glomerular filtration rate and serum phosphate', 'carotid-femoral pulse wave velocity (PWV, SphygmoCor', 'change in abdominal aortic calcification (AAC, computed tomography), serum phosphate and fibroblast growth factor 23 (FGF-23', 'diastolic BP, dyslipidaemia (and use of statins), smoking, larger waist circumference and increased PWV', 'Median (interquartile range) intact and c-terminal FGF-23 levels']","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0457164', 'cui_str': 'Stage 3b'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4 (qualifier value)'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1601799', 'cui_str': 'phosphate ion'}, {'cui': 'C0179302', 'cui_str': 'Binder'}, {'cui': 'C0768119', 'cui_str': 'lanthanum carbonate'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]","[{'cui': 'C1999167', 'cui_str': 'Old-age (finding)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0002059', 'cui_str': 'Orthophosphoric-monoester phosphohydrolase (alkaline optimum)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3811844'}, {'cui': 'C0036820', 'cui_str': 'Serum phosphate'}, {'cui': 'C0232148', 'cui_str': 'Femoral pulse, function (observable entity)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C1096249', 'cui_str': 'Aortic calcification'}, {'cui': 'C0040395', 'cui_str': 'Tomographic imaging'}, {'cui': 'C3272931', 'cui_str': 'FGF-23'}, {'cui': 'C1869029', 'cui_str': 'Dyslipidaemia (SMQ)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0205266', 'cui_str': 'Intact (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",278.0,0.229105,Mean estimated glomerular filtration rate and serum phosphate were 26.6 ± 8.3 mL,"[{'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'Lioufas', 'Affiliation': 'Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia, Nicole.Lioufas2@wh.org.au.'}, {'ForeName': 'Eugenia', 'Initials': 'E', 'LastName': 'Pedagogos', 'Affiliation': 'Department of Medicine (RMH), University of Melbourne, Parkville, Victoria, Australia.'}, {'ForeName': 'Carmel M', 'Initials': 'CM', 'LastName': 'Hawley', 'Affiliation': 'Australasian Kidney Trials Network, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Elaine M', 'Initials': 'EM', 'LastName': 'Pascoe', 'Affiliation': 'Australasian Kidney Trials Network, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Grahame J', 'Initials': 'GJ', 'LastName': 'Elder', 'Affiliation': 'Department of Renal Medicine, Westmead Hospital, Westmead, New South Wales, Australia.'}, {'ForeName': 'Sunil V', 'Initials': 'SV', 'LastName': 'Badve', 'Affiliation': 'Department of Nephrology, St. George Hospital, Sydney, New South Wales, Australia.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Valks', 'Affiliation': 'Australasian Kidney Trials Network, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Nigel D', 'Initials': 'ND', 'LastName': 'Toussaint', 'Affiliation': 'Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of nephrology,['10.1159/000505717'] 905,28852235,Group Work Intervention for the Parents of Children with Mental Health Issues Admitted in the Tertiary Care Center.,"OBJECTIVES The objective of this study was to develop a structured curriculum for a group-based parenting program for parents/caregivers of children or adolescents treated in the inpatient child and adolescent mental health unit of a national health institute. METHODS Data from group session reports of 3 years of conducting group-based parenting programs in the same setting were analyzed and prominent themes of discussions were shortlisted before finally arriving at a six-session group parenting program module. RESULTS A six-session intervention module was designed by psychiatric social workers experienced in group work. The content followed combination of various theoretical approaches and methodologies ultimately aiming in improving the overall knowledge and understanding of parents or caregivers on various child and adolescent mental health issues, and enhancing their skills and competence in dealing with various emotional and behavioral problems in children. CONCLUSION Group-based parenting programs are found to be effective in improving the over psychosocial health of parents and the emotional and behavioral problems of children and adolescents as a result of better parenting. Development and standardization of culture appropriate group intervention curriculums would help in the development of this cost effective method as a medium of change.",2017,"The content followed combination of various theoretical approaches and methodologies ultimately aiming in improving the overall knowledge and understanding of parents or caregivers on various child and adolescent mental health issues, and enhancing their skills and competence in dealing with various emotional and behavioral problems in children. ","['children', 'parents/caregivers of children or adolescents treated in the inpatient child and adolescent mental health unit of a national health institute', 'Data from group session reports of 3 years of conducting group-based parenting programs in the same setting were analyzed and prominent themes of discussions were shortlisted before finally arriving at a six-session group parenting program module', 'Parents of Children with Mental Health Issues Admitted in the Tertiary Care Center']",['structured curriculum for a group-based parenting program'],[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0205402', 'cui_str': 'Prominent (qualifier value)'}, {'cui': 'C0557061', 'cui_str': 'Discussion (procedure)'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C0030551', 'cui_str': 'Parent of (observable entity)'}, {'cui': 'C0587437', 'cui_str': 'Tertiary Hospital'}]","[{'cui': 'C0220815', 'cui_str': 'curriculum'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2728259', 'cui_str': 'Program'}]",[],,0.0246162,"The content followed combination of various theoretical approaches and methodologies ultimately aiming in improving the overall knowledge and understanding of parents or caregivers on various child and adolescent mental health issues, and enhancing their skills and competence in dealing with various emotional and behavioral problems in children. ","[{'ForeName': 'N Janardhana', 'Initials': 'NJ', 'LastName': 'Navaneetham', 'Affiliation': 'Department of Psychiatric Social Work, NIMHANS, Bengaluru, Karnataka, India.'}, {'ForeName': 'Divya', 'Initials': 'D', 'LastName': 'Ravindran', 'Affiliation': 'Social Worker, Child Protection Unit, UK.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.211762'] 906,28685626,Lurasidone for the treatment of irritability and anger in autism spectrum disorders.,"INTRODUCTION Autism Spectrum Disorder (ASD) is a heterogeneous neurodevelopmental disorder characterized by deficits in social interaction and communication as well as restricted patterns of behaviors and interests. Irritability marked by tantrums, self-injury and aggression occurs frequently in youth with ASD, causing significant parent and caregiver distress. Atypical antipsychotics have been the most studied drug class targeting irritability in ASD. Risperidone and aripiprazole are Food and Drug Administration (FDA)-approved atypical antipsychotics for treatment of irritability in youth with ASD. However, other atypical antipsychotics, such as lurasidone, are often considered for off-label use in the treatment of irritability, whether because of tolerability issues with risperidone and aripiprazole or because of the drug-refractory nature of this symptom cluster. Areas covered: Following a comprehensive review of the literature this article summarizes information on the efficacy and tolerability of lurasidone as a potential off label treatment of irritability in children and adolescents with ASD. Available data included a 6 week randomized, blind, fixed dose, placebo-controlled study and a case study. Expert opinion: To date the safety and tolerability of lurasidone in treating irritability in youth with ASD has yet to be established with, lurasidone being the only antipsychotic with published negative placebo-controlled results.",2017,"Expert opinion: To date the safety and tolerability of lurasidone in treating irritability in youth with ASD has yet to be established with, lurasidone being the only antipsychotic with published negative placebo-controlled results.","['autism spectrum disorders', 'children and adolescents with ASD', 'youth with ASD']","['Risperidone and aripiprazole are Food and Drug Administration (FDA)-approved atypical antipsychotics', 'Lurasidone', 'placebo', 'risperidone and aripiprazole', 'lurasidone']","['Irritability marked by tantrums, self-injury and aggression', 'irritability and anger', 'efficacy and tolerability']","[{'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0087178', 'cui_str': 'Youth'}]","[{'cui': 'C0073393', 'cui_str': 'Risperidone'}, {'cui': 'C0299792', 'cui_str': 'aripiprazole'}, {'cui': 'C0041714', 'cui_str': 'Food and Drug Administration'}, {'cui': 'C0205540', 'cui_str': 'Approved (qualifier value)'}, {'cui': 'C1276996', 'cui_str': 'Atypical antipsychotic'}, {'cui': 'C2003424', 'cui_str': 'lurasidone'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0022107', 'cui_str': 'Irritable Mood'}, {'cui': 'C0522501', 'cui_str': 'Massive (qualifier value)'}, {'cui': 'C0085271', 'cui_str': 'Self-Injury'}, {'cui': 'C0001807', 'cui_str': 'Aggression'}, {'cui': 'C0476479', 'cui_str': 'Irritability and anger (finding)'}]",,0.0430143,"Expert opinion: To date the safety and tolerability of lurasidone in treating irritability in youth with ASD has yet to be established with, lurasidone being the only antipsychotic with published negative placebo-controlled results.","[{'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'McClellan', 'Affiliation': ""a Division of Child and Adolescent Psychiatry , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA.""}, {'ForeName': 'Kelli C', 'Initials': 'KC', 'LastName': 'Dominick', 'Affiliation': ""a Division of Child and Adolescent Psychiatry , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA.""}, {'ForeName': 'Ernest V', 'Initials': 'EV', 'LastName': 'Pedapati', 'Affiliation': ""a Division of Child and Adolescent Psychiatry , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA.""}, {'ForeName': 'Logan K', 'Initials': 'LK', 'LastName': 'Wink', 'Affiliation': ""a Division of Child and Adolescent Psychiatry , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA.""}, {'ForeName': 'Craig A', 'Initials': 'CA', 'LastName': 'Erickson', 'Affiliation': ""a Division of Child and Adolescent Psychiatry , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA.""}]",Expert opinion on investigational drugs,['10.1080/13543784.2017.1353600'] 907,31688431,PrevenTion of contrast-inducEd nephropAThy with urinE alkalinization: the TEATE study design.,": Intravascular administration of iodinated contrast media is an essential tool for the imaging of blood vessels and cardiac chambers, as well as for percutaneous coronary and structural interventions. Along with the spreading of diagnostic and interventional procedures, the increasing incidence of contrast-induced nephropathy (CIN) has become an important and prognostically relevant problem. CIN is thought to be largely dependent on oxidative damage, and is a considerable cause of renal failure, being associated with prolonged hospitalization and significant morbidity/mortality. The most effective treatment strategy of this serious complication remains prevention, and several preventive measures have been extensively investigated in the last few years.Preprocedural hydration is the best-known and mostly accepted strategy. The administration of sodium bicarbonate has controversial effects, and is likely to be ineffective when the infused dose is unable to achieve adequate urine alkalinization. Since alkaline pH suppresses the production of free radicals, increasing urine pH would be an attractive goal for CIN prevention.In a prospective randomized controlled, open-label clinical trial we will test the hypothesis that urine alkalinization with either oral or intravenous bicarbonate on top of hydration alone is the main determinant of CIN prevention (primary endpoint) in a population of patients with moderate or severe chronic kidney disease scheduled for coronary angiography and/or angioplasty. If we then demonstrate nonsignificant differences in urine alkalinization and incidence of CIN between the two bicarbonate groups (secondary endpoint), a practical implication will be that oral administration is preferable for practical reasons over the administration of intravenous bicarbonate.",2020,"If we then demonstrate nonsignificant differences in urine alkalinization and incidence of CIN between the two bicarbonate groups (secondary endpoint), a practical implication will be that oral administration is preferable for practical reasons over the administration of intravenous bicarbonate.",['patients with moderate or severe chronic kidney disease scheduled for coronary angiography and/or angioplasty'],"['oral or intravenous bicarbonate', 'sodium bicarbonate', 'iodinated contrast media', 'bicarbonate']",['urine alkalinization and incidence of CIN'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0085532', 'cui_str': 'Angiography of coronary arteries'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0005367', 'cui_str': 'Hydrogen Carbonates'}, {'cui': 'C0074722', 'cui_str': 'Sodium Bicarbonate'}, {'cui': 'C1960405', 'cui_str': 'Iodinated contrast media'}]","[{'cui': 'C0042037'}, {'cui': 'C0220856', 'cui_str': 'incidence'}]",,0.0423409,"If we then demonstrate nonsignificant differences in urine alkalinization and incidence of CIN between the two bicarbonate groups (secondary endpoint), a practical implication will be that oral administration is preferable for practical reasons over the administration of intravenous bicarbonate.","[{'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Lombardi', 'Affiliation': 'Cardiology Department, Institute of Cardiology.'}, {'ForeName': 'Michela', 'Initials': 'M', 'LastName': 'Molisana', 'Affiliation': 'Cardiology Department, Institute of Cardiology.'}, {'ForeName': 'Eugenio', 'Initials': 'E', 'LastName': 'Genovesi', 'Affiliation': 'Cardiology Department, Institute of Cardiology.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'De Innocentiis', 'Affiliation': 'Cardiology Department, Institute of Cardiology.'}, {'ForeName': 'Ugo', 'Initials': 'U', 'LastName': 'Limbruno', 'Affiliation': 'Cardiology Department, Azienda USL Toscana Sud-Est, Grosseto.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Misuraca', 'Affiliation': 'Cardiology Department, Azienda USL Toscana Sud-Est, Grosseto.'}, {'ForeName': 'Luciano', 'Initials': 'L', 'LastName': 'Moretti', 'Affiliation': ""Ospedale 'C.e G. Mazzoni', Ascoli Piceno.""}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Di Vito', 'Affiliation': ""Ospedale 'C.e G. Mazzoni', Ascoli Piceno.""}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Di Nicola', 'Affiliation': ""Department of Biostatistics, G. d'Annunzio University, Chieti.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Zimarino', 'Affiliation': 'Cardiology Department, Institute of Cardiology.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Renda', 'Affiliation': 'Cardiology Department, Institute of Cardiology.'}, {'ForeName': 'Raffaele', 'Initials': 'R', 'LastName': 'De Caterina', 'Affiliation': 'Department of Cardiology, University of Pisa, Pisa.'}]","Journal of cardiovascular medicine (Hagerstown, Md.)",['10.2459/JCM.0000000000000892'] 908,31714330,Effects of sacubutril/valsartan on nutritional status in heart failure with reduced ejection fraction.,"BACKGROUND Malnutrition commonly occurs in patients with heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan, which is an AT1 neprilysin inhibitor, has been shown to reduce mortality and hospitalization in patients with HFrEF. However, its effects on nutritional status remain unclear. METHODS Sacubitril/valsartan was initiated in 164 symptomatic patients with HFrEF receiving an optimal medical treatment with angiotensin inhibition (mean age: 63 ± 20 years; 120 males, 60% ischemic cause). The New York Heart Association (NYHA) functional class and nutritional statuses of the patients were evaluated at the switching to AT1 neprilysin inhibitor and at the 6th-month follow-up of the maximum sacubitril/valsartan dose using the geriatric nutritional risk index (GNRI), controlling nutritional status (CONUT) score, prognostic nutritional index (PNI), and prealbumin. RESULTS After the sacubutril/valsartan treatment, a significant reduction in the number (%) of malnourished patients was observed according to CONUT (before 47% vs. after 7%, P < 0.001), GNRI (before 39% vs. after 19%, P < 0.001), PNI scores (before 36% vs. after 12%, P = 0.002), and prealbumin (before 41% vs. after 12%, P < 0.001). Also significant changes were observed at the baseline and follow-up in the mean scores of the three different nutritional indexes and prealbumin levels [CONUT: 2.68 ± 2.5, 1.02 ± 1.0 (P < 0.001); GNRI: 97.1 ± 9.7, 101.2 ± 5.9 (P < 0.001); PNI: 38.8 ± 4.8, 41.6 ± 3.7 (P < 0.001); prealbumin: 14.6 ± 6.9 mg/dl, 17.1 ± 5.2 mg/dl (P < 0.001)]. Overall, the patients exhibited a significant functional improvement following the initiation of sacubitril/valsartan: 23% of the patients improved by two NYHA classes, 48% improved by one NYHA class, and 39% remained stable. CONCLUSION In patients with HFrEF, the switch from angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy to sacubitril/valsartan resulted in a significant improvement in both nutritional and functional statuses.",2020,"Also significant changes were observed at the baseline and follow-up in the mean scores of the three different nutritional indexes and prealbumin levels [CONUT: 2.68 ± 2.5, 1.02 ± 1.0 (P < 0.001); GNRI: 97.1 ± 9.7, 101.2 ± 5.9 (P < 0.001); PNI: 38.8 ± 4.8, 41.6 ± 3.7 (P < 0.001); prealbumin: 14.6 ± 6.9 mg/dl, 17.1 ± 5.2 mg/dl (P < 0.001)].","['patients with heart failure with reduced ejection fraction (HFrEF', 'patients with HFrEF', '164 symptomatic patients with HFrEF receiving an optimal medical treatment with angiotensin inhibition (mean age: 63\u200a±\u200a20 years; 120 males, 60% ischemic cause', 'heart failure with reduced ejection fraction']","['valsartan', 'Sacubitril/valsartan', 'sacubutril/valsartan', 'angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy to sacubitril/valsartan']","['PNI scores', 'geriatric nutritional risk index (GNRI), controlling nutritional status (CONUT) score, prognostic nutritional index (PNI), and prealbumin', 'mortality and hospitalization', 'GNRI']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0003018', 'cui_str': 'Angiotensins'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}]","[{'cui': 'C0216784', 'cui_str': 'valsartan'}, {'cui': 'C4033631', 'cui_str': 'sacubitril / valsartan'}, {'cui': 'C0003015', 'cui_str': 'ACE Inhibitors'}, {'cui': 'C0521942', 'cui_str': 'Angiotensin II Receptor Blockers'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0017469', 'cui_str': 'Geriatrics'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0392209', 'cui_str': 'Nutrition Status'}, {'cui': 'C0033326', 'cui_str': 'Prognostic Nutritional Index (PNI)'}, {'cui': 'C0032923', 'cui_str': 'Transthyretin'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}]",164.0,0.0151827,"Also significant changes were observed at the baseline and follow-up in the mean scores of the three different nutritional indexes and prealbumin levels [CONUT: 2.68 ± 2.5, 1.02 ± 1.0 (P < 0.001); GNRI: 97.1 ± 9.7, 101.2 ± 5.9 (P < 0.001); PNI: 38.8 ± 4.8, 41.6 ± 3.7 (P < 0.001); prealbumin: 14.6 ± 6.9 mg/dl, 17.1 ± 5.2 mg/dl (P < 0.001)].","[{'ForeName': 'Seçkin', 'Initials': 'S', 'LastName': 'Dereli', 'Affiliation': 'Department of Cardiology, Ordu State Hospital.'}, {'ForeName': 'Adil', 'Initials': 'A', 'LastName': 'Bayramoğlu', 'Affiliation': 'Deparment of Cardiology, Ordu University Faculty of Medicine, Ordu, Turkey.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Kaya', 'Affiliation': 'Deparment of Cardiology, Ordu University Faculty of Medicine, Ordu, Turkey.'}]","Journal of cardiovascular medicine (Hagerstown, Md.)",['10.2459/JCM.0000000000000895'] 909,28566028,A Randomized Controlled Trial of the Rochester Forensic Assertive Community Treatment Model.,"OBJECTIVE Forensic assertive community treatment (FACT) is an adaptation of the assertive community treatment model and is designed to serve justice-involved adults with serious mental illness. This study compared the effectiveness of a standardized FACT model and enhanced treatment as usual in reducing jail and hospital use and in promoting engagement in outpatient mental health services. METHODS Seventy adults with psychotic disorders who were arrested for misdemeanor crimes and who were eligible for conditional discharge were recruited from the Monroe County, New York, court system. Participants were randomly assigned to receive either FACT (N=35) or enhanced treatment as usual (N=35) for one year. Criminal justice and mental health service utilization outcomes were measured by using state and county databases. RESULTS Forty-nine participants (70%) completed the full one-year intervention period. Nineteen (27%) were removed early by judicial order, one was removed by county health authorities, and one died of a medical illness. Intent-to-treat analysis for all 70 participants showed that those receiving the FACT intervention had fewer mean±SD convictions (.4±.7 versus .9±1.3, p=.023), fewer mean days in jail (21.5±25.9 versus 43.5±59.2, p=.025), fewer mean days in the hospital (4.4±15.1 versus 23.8±64.2, p=.025), and more mean days in outpatient mental health treatment (305.5±92.1 versus 169.4±139.6, p<.001) compared with participants who received treatment as usual. CONCLUSIONS The Rochester FACT model was associated with fewer convictions for new crimes, less time in jail and hospitals, and more time in outpatient treatment among justice-involved adults with psychotic disorders compared with treatment as usual.",2017,"The Rochester FACT model was associated with fewer convictions for new crimes, less time in jail and hospitals, and more time in outpatient treatment among justice-involved adults with psychotic disorders compared with treatment as usual.","['adults with serious mental illness', 'Seventy adults with psychotic disorders who were arrested for misdemeanor crimes and who were eligible for conditional discharge were recruited from the Monroe County, New York, court system', 'outpatient mental health services', 'Nineteen (27%) were removed early by judicial order, one was removed by county health authorities, and one died of a medical illness']","['Forensic assertive community treatment (FACT', 'FACT', 'FACT intervention', 'standardized FACT model']",['mean±SD convictions'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder (disorder)'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}, {'cui': 'C0237477', 'cui_str': 'Arrested (qualifier value)'}, {'cui': 'C0010325', 'cui_str': 'Crime'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0025355', 'cui_str': 'Mental Hygiene Services'}, {'cui': 'C0450337', 'cui_str': '19 (qualifier value)'}, {'cui': 'C1883720', 'cui_str': 'Removes'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}]","[{'cui': 'C2713614', 'cui_str': 'Assertive Community Treatment'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}]",[],70.0,0.12954,"The Rochester FACT model was associated with fewer convictions for new crimes, less time in jail and hospitals, and more time in outpatient treatment among justice-involved adults with psychotic disorders compared with treatment as usual.","[{'ForeName': 'J Steven', 'Initials': 'JS', 'LastName': 'Lamberti', 'Affiliation': 'Dr. Lamberti, Dr. Weisman, Dr. Cerulli, Mr. Jacobowitz, and Dr. Caine are with the Department of Psychiatry, Dr. Williams is with the Department of Medicine and the Department of Clinical and Social Sciences in Psychology, Dr. Strawderman and Mr. Harrington are with the Department of Biostatistics and Computational Biology, and Ms. Lamberti is with the School of Nursing, all at the University of Rochester Medical Center, Rochester, New York. Dr. Mueser is with the Center for Psychiatric Rehabilitation, Boston University, Boston. Judge Marks (ret.) is with the Monroe County Courts, Rochester, New York.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Weisman', 'Affiliation': 'Dr. Lamberti, Dr. Weisman, Dr. Cerulli, Mr. Jacobowitz, and Dr. Caine are with the Department of Psychiatry, Dr. Williams is with the Department of Medicine and the Department of Clinical and Social Sciences in Psychology, Dr. Strawderman and Mr. Harrington are with the Department of Biostatistics and Computational Biology, and Ms. Lamberti is with the School of Nursing, all at the University of Rochester Medical Center, Rochester, New York. Dr. Mueser is with the Center for Psychiatric Rehabilitation, Boston University, Boston. Judge Marks (ret.) is with the Monroe County Courts, Rochester, New York.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Cerulli', 'Affiliation': 'Dr. Lamberti, Dr. Weisman, Dr. Cerulli, Mr. Jacobowitz, and Dr. Caine are with the Department of Psychiatry, Dr. Williams is with the Department of Medicine and the Department of Clinical and Social Sciences in Psychology, Dr. Strawderman and Mr. Harrington are with the Department of Biostatistics and Computational Biology, and Ms. Lamberti is with the School of Nursing, all at the University of Rochester Medical Center, Rochester, New York. Dr. Mueser is with the Center for Psychiatric Rehabilitation, Boston University, Boston. Judge Marks (ret.) is with the Monroe County Courts, Rochester, New York.'}, {'ForeName': 'Geoffrey C', 'Initials': 'GC', 'LastName': 'Williams', 'Affiliation': 'Dr. Lamberti, Dr. Weisman, Dr. Cerulli, Mr. Jacobowitz, and Dr. Caine are with the Department of Psychiatry, Dr. Williams is with the Department of Medicine and the Department of Clinical and Social Sciences in Psychology, Dr. Strawderman and Mr. Harrington are with the Department of Biostatistics and Computational Biology, and Ms. Lamberti is with the School of Nursing, all at the University of Rochester Medical Center, Rochester, New York. Dr. Mueser is with the Center for Psychiatric Rehabilitation, Boston University, Boston. Judge Marks (ret.) is with the Monroe County Courts, Rochester, New York.'}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Jacobowitz', 'Affiliation': 'Dr. Lamberti, Dr. Weisman, Dr. Cerulli, Mr. Jacobowitz, and Dr. Caine are with the Department of Psychiatry, Dr. Williams is with the Department of Medicine and the Department of Clinical and Social Sciences in Psychology, Dr. Strawderman and Mr. Harrington are with the Department of Biostatistics and Computational Biology, and Ms. Lamberti is with the School of Nursing, all at the University of Rochester Medical Center, Rochester, New York. Dr. Mueser is with the Center for Psychiatric Rehabilitation, Boston University, Boston. Judge Marks (ret.) is with the Monroe County Courts, Rochester, New York.'}, {'ForeName': 'Kim T', 'Initials': 'KT', 'LastName': 'Mueser', 'Affiliation': 'Dr. Lamberti, Dr. Weisman, Dr. Cerulli, Mr. Jacobowitz, and Dr. Caine are with the Department of Psychiatry, Dr. Williams is with the Department of Medicine and the Department of Clinical and Social Sciences in Psychology, Dr. Strawderman and Mr. Harrington are with the Department of Biostatistics and Computational Biology, and Ms. Lamberti is with the School of Nursing, all at the University of Rochester Medical Center, Rochester, New York. Dr. Mueser is with the Center for Psychiatric Rehabilitation, Boston University, Boston. Judge Marks (ret.) is with the Monroe County Courts, Rochester, New York.'}, {'ForeName': 'Patricia D', 'Initials': 'PD', 'LastName': 'Marks', 'Affiliation': 'Dr. Lamberti, Dr. Weisman, Dr. Cerulli, Mr. Jacobowitz, and Dr. Caine are with the Department of Psychiatry, Dr. Williams is with the Department of Medicine and the Department of Clinical and Social Sciences in Psychology, Dr. Strawderman and Mr. Harrington are with the Department of Biostatistics and Computational Biology, and Ms. Lamberti is with the School of Nursing, all at the University of Rochester Medical Center, Rochester, New York. Dr. Mueser is with the Center for Psychiatric Rehabilitation, Boston University, Boston. Judge Marks (ret.) is with the Monroe County Courts, Rochester, New York.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Strawderman', 'Affiliation': 'Dr. Lamberti, Dr. Weisman, Dr. Cerulli, Mr. Jacobowitz, and Dr. Caine are with the Department of Psychiatry, Dr. Williams is with the Department of Medicine and the Department of Clinical and Social Sciences in Psychology, Dr. Strawderman and Mr. Harrington are with the Department of Biostatistics and Computational Biology, and Ms. Lamberti is with the School of Nursing, all at the University of Rochester Medical Center, Rochester, New York. Dr. Mueser is with the Center for Psychiatric Rehabilitation, Boston University, Boston. Judge Marks (ret.) is with the Monroe County Courts, Rochester, New York.'}, {'ForeName': 'Donald', 'Initials': 'D', 'LastName': 'Harrington', 'Affiliation': 'Dr. Lamberti, Dr. Weisman, Dr. Cerulli, Mr. Jacobowitz, and Dr. Caine are with the Department of Psychiatry, Dr. Williams is with the Department of Medicine and the Department of Clinical and Social Sciences in Psychology, Dr. Strawderman and Mr. Harrington are with the Department of Biostatistics and Computational Biology, and Ms. Lamberti is with the School of Nursing, all at the University of Rochester Medical Center, Rochester, New York. Dr. Mueser is with the Center for Psychiatric Rehabilitation, Boston University, Boston. Judge Marks (ret.) is with the Monroe County Courts, Rochester, New York.'}, {'ForeName': 'Tara A', 'Initials': 'TA', 'LastName': 'Lamberti', 'Affiliation': 'Dr. Lamberti, Dr. Weisman, Dr. Cerulli, Mr. Jacobowitz, and Dr. Caine are with the Department of Psychiatry, Dr. Williams is with the Department of Medicine and the Department of Clinical and Social Sciences in Psychology, Dr. Strawderman and Mr. Harrington are with the Department of Biostatistics and Computational Biology, and Ms. Lamberti is with the School of Nursing, all at the University of Rochester Medical Center, Rochester, New York. Dr. Mueser is with the Center for Psychiatric Rehabilitation, Boston University, Boston. Judge Marks (ret.) is with the Monroe County Courts, Rochester, New York.'}, {'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Caine', 'Affiliation': 'Dr. Lamberti, Dr. Weisman, Dr. Cerulli, Mr. Jacobowitz, and Dr. Caine are with the Department of Psychiatry, Dr. Williams is with the Department of Medicine and the Department of Clinical and Social Sciences in Psychology, Dr. Strawderman and Mr. Harrington are with the Department of Biostatistics and Computational Biology, and Ms. Lamberti is with the School of Nursing, all at the University of Rochester Medical Center, Rochester, New York. Dr. Mueser is with the Center for Psychiatric Rehabilitation, Boston University, Boston. Judge Marks (ret.) is with the Monroe County Courts, Rochester, New York.'}]","Psychiatric services (Washington, D.C.)",['10.1176/appi.ps.201600329'] 910,28611230,Effect of a Motivational Interviewing-Based Health Coaching on Quality of Life in Subjects With COPD.,"BACKGROUND Improving quality of life (QOL) is a key goal in the care of patients with COPD. Pulmonary rehabilitation (PR) has clearly been shown to improve QOL, but is not accessible to many eligible patients. There is a need for alternative programs designed to improve patient well-being that are accessible to all patients with COPD. Our goal was to pilot test a simple, telephone-based health-coaching intervention that was recently shown to decrease readmission among hospitalized COPD patients and stable COPD patients eligible for PR. METHODS Subjects received a 3-month intervention consisting of 10 health-coaching telephone calls based on motivational interviewing principles. Outcome measures included dyspnea level, measured by the modified Medical Research Council scale, and QOL, measured by the Chronic Respiratory Questionnaire and a single-item general self-rated health status. RESULTS Fifty subjects with moderate to severe COPD were enrolled in the study. Forty-four subjects (86%) completed the study intervention. Dyspnea measured by the modified Medical Research Council score improved significantly after the intervention ( P = .002). The domains of fatigue, emotional function, and mastery on the Chronic Respiratory Disease Questionnaire and the single-item QOL question also improved significantly after the 3 months of health coaching ( P = .001, P = .001, P = .007, and P = .03, respectively). Thirty-six (71%) subjects had a clinically meaningful improvement in at least 1 study end point (either in the severity of dyspnea or a domain of QOL). Thirty subjects (58%) had an improvement of ≥0.5 points, the minimum clinically important difference in at least 1 component of the Chronic Respiratory Disease Questionnaire. CONCLUSIONS A telephone-delivered motivational interviewing-based coaching program for COPD patients is a feasible, well-accepted (by both participants and providers), simple, and novel intervention to improve the well-being of patients with COPD. This pilot study provides insight into a possible alternative to a conventional PR program for patients with limited access to that program.",2017,"Thirty subjects (58%) had an improvement of ≥0.5 points, the minimum clinically important difference in at least 1 component of the Chronic Respiratory Disease Questionnaire. ","['patients with limited access to that program', 'Forty-four subjects (86%) completed the study intervention', 'hospitalized COPD patients and stable COPD patients eligible for PR', 'patients with COPD', 'Subjects With COPD', 'Fifty subjects with moderate to severe COPD', 'Subjects received a 3-month']","['intervention consisting of 10 health-coaching telephone calls based on motivational interviewing principles', 'telephone-based health-coaching intervention', 'Pulmonary rehabilitation (PR', 'telephone-delivered motivational interviewing-based coaching program', 'conventional PR program', 'Motivational Interviewing-Based Health Coaching']","['modified Medical Research Council score', 'Dyspnea', 'severity of dyspnea or a domain of QOL', 'Quality of Life', 'Chronic Respiratory Disease Questionnaire', 'fatigue, emotional function, and mastery on the Chronic Respiratory Disease Questionnaire and the single-item QOL question', 'dyspnea level, measured by the modified Medical Research Council scale, and QOL, measured by the Chronic Respiratory Questionnaire and a single-item general self-rated health status']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C2317129', 'cui_str': 'Health coach'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0683474', 'cui_str': 'Motivational Interviewing'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation (regime/therapy)'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]","[{'cui': 'C0079816', 'cui_str': 'Medical Research'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0013404', 'cui_str': 'Breathlessness'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0034380'}, {'cui': 'C3164900', 'cui_str': 'Chronic respiratory disease questionnaire (assessment scale)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0018759', 'cui_str': 'Level of Health'}]",44.0,0.024575,"Thirty subjects (58%) had an improvement of ≥0.5 points, the minimum clinically important difference in at least 1 component of the Chronic Respiratory Disease Questionnaire. ","[{'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Rehman', 'Affiliation': 'Pulmonary Medicine, Mayo Clinic Health System, Austin, Minnesota.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Karpman', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Vickers Douglas', 'Affiliation': 'Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Roberto P', 'Initials': 'RP', 'LastName': 'Benzo', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine benzo.roberto@mayo.edu.'}]",Respiratory care,['10.4187/respcare.04984'] 911,28615760,Use of Mobile Phone Technology to Improve follow-up at a Community Mental Health Clinic: A Randomized Control Trial.,"BACKGROUND Mobile phone technology is being used worldwide to improve follow-ups in health care. AIM Aim of the study is to evaluate whether the use of mobile technology will improve or not the follow-up of Indian patients from a community mental health center. MATERIALS AND METHODS Patients or caregivers having mobile phones and consenting for study were enrolled, and sociodemographic and clinical details of patients were taken. Participants were randomized into two groups (short message service [SMS] vs. non-SMS group). At first intervention level, a SMS was sent to SMS group (not in non-SMS group) 1 day before their appointment. At second-level intervention (voice call level), patients from both groups who missed their first appointment were given a voice call requesting them to come for follow-up, and the reasons for first missed appointments (MA) were also elicited. The effect of these two intervention levels (first SMS for SMS group and next voice calls for both groups) on follow-up was evaluated. RESULTS A total of 214 patients were enrolled in the study. At first SMS intervention level of SMS group ( n = 106), 62.26% of participants reached appointment-on-time (RA), while in the non-SMS/as usual group ( n = 108), 45.37% of patients RA. The difference of these groups is statistically significant. At second-level intervention (voice call), 66 of 88 (another 15 were unable to contact) were came for follow-up consultation within 2 days of MA. Distance and diagnosis of alcohol dependence were significantly associated with MA. Social reasons were most common reasons for first MA. CONCLUSION The use of mobile phone technology in an outpatient community psychiatric clinic improved follow-up significantly.",2017,Distance and diagnosis of alcohol dependence were significantly associated with MA.,"['Patients or caregivers having mobile phones and consenting for study were enrolled, and sociodemographic and clinical details of patients were taken', '214 patients were enrolled in the study', 'Indian patients from a community mental health center']","['mobile phone technology', 'message service [SMS] vs. non-SMS', 'Mobile Phone Technology']",['Distance and diagnosis of alcohol dependence'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C1136360', 'cui_str': 'Mobile Phone'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C1524069', 'cui_str': 'Indian (racial group)'}, {'cui': 'C0009474', 'cui_str': 'CMHC'}]","[{'cui': 'C1136360', 'cui_str': 'Mobile Phone'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}]","[{'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0001973', 'cui_str': 'Alcohol Dependence'}]",214.0,0.0449008,Distance and diagnosis of alcohol dependence were significantly associated with MA.,"[{'ForeName': 'Gaurav', 'Initials': 'G', 'LastName': 'Singh', 'Affiliation': 'Department of Psychiatry, K.D. Medical College Hospital and Research Center, Mathura, Uttar Pradesh, India.'}, {'ForeName': 'Narayana', 'Initials': 'N', 'LastName': 'Manjunatha', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Sabina', 'Initials': 'S', 'LastName': 'Rao', 'Affiliation': 'Sakra Hospital, Bengaluru, Karnataka, India.'}, {'ForeName': 'H N', 'Initials': 'HN', 'LastName': 'Shashidhara', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Sydney', 'Initials': 'S', 'LastName': 'Moirangthem', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Rajendra K', 'Initials': 'RK', 'LastName': 'Madegowda', 'Affiliation': 'Department of Child and Adolescent Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Binukumar', 'Affiliation': 'Biostatistics, National Institute of Mental Health and Neurosciences, Karnataka, India.'}, {'ForeName': 'Mathew', 'Initials': 'M', 'LastName': 'Varghese', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.207325'] 912,31543318,Treatment of the displaced intracapsular fracture for the 'fitter' elderly patients: A randomised trial of total hip arthroplasty versus hemiarthroplasty for 105 patients.,Controversy exists for the optimum method of surgical treatment for the 'fitter' elderly patient with a displaced intracapsular fracture. 105 patients were randomised to treatment with either a cemented polished tapered stem hemiarthroplasty or a cemented total hip arthroplasty (THR) with a cemented acetabular cup. All patients were followed up for a minimum of one year using a blinded assessment of functional outcome. Those patients treated with a THR had a tendency to a longer hospital stay and increased medical (12 versus 62) and surgical complications (4 versus 2) in comparison to those treated by hemiarthroplasty. Mean operative times (842 versus 52 min) and operative blood loss (335mls versus 244mls) were increased for THR. Final outcome measures of residual pain and regain of function were similar for both methods of treatment. We recommend that caution should be exercised regarding the increased promotion of THR for intracapsular hip fractures until further studies are completed.,2019,Mean operative times (842 versus 52 min) and operative blood loss (335mls versus 244mls) were increased for THR.,"['105 patients', ""fitter' elderly patient with a displaced intracapsular fracture"", '1054 patients', ""displaced intracapsular fracture for the 'fitter' elderly patients""]","['total hip arthroplasty versus hemiarthroplasty', 'THR', 'cemented polished tapered stem hemiarthroplasty or a cemented total hip arthroplasty (THR) with a cemented acetabular cup']","['residual pain and regain of function', 'longer hospital stay and increased medical', 'Mean operative times', 'operative blood loss', 'surgical complications']","[{'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0012727', 'cui_str': 'Displacement (morphologic abnormality)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0186193', 'cui_str': 'Arthroplasty of coxofemoral joint'}, {'cui': 'C0744743', 'cui_str': 'Hemi-Arthroplasty'}, {'cui': 'C0032377', 'cui_str': 'Polishes'}, {'cui': 'C0162731', 'cui_str': 'STEM'}, {'cui': 'C1704479', 'cui_str': 'Cement'}, {'cui': 'C2949743', 'cui_str': 'Cup - unit of product usage'}]","[{'cui': 'C3805255', 'cui_str': 'Residual pain'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}]",1054.0,0.0309414,Mean operative times (842 versus 52 min) and operative blood loss (335mls versus 244mls) were increased for THR.,"[{'ForeName': 'Martyn J', 'Initials': 'MJ', 'LastName': 'Parker', 'Affiliation': 'Department of Orthopaedics, Peterborough City Hospital, Peterborough and Stamford Hospital NHS Foundation Trust, Bretton Gate, Peterborough PE3 9GZ, England, United Kingdom. Electronic address: Martyn.parker1@nhs.net.'}, {'ForeName': 'Shirley', 'Initials': 'S', 'LastName': 'Cawley', 'Affiliation': 'Department of Orthopaedics, Peterborough City Hospital, Peterborough and Stamford Hospital NHS Foundation Trust, Bretton Gate, Peterborough PE3 9GZ, England, United Kingdom. Electronic address: Shirley.cawley@nhs.net.'}]",Injury,['10.1016/j.injury.2019.09.018'] 913,31586424,"A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3 months of age.","OBJECTIVES Investigate the efficacy of caspofungin in participants <3 months of age with invasive Candida infection (ICI). METHODS This multicentre, randomized, double-blind, comparator-controlled, Phase 2 study (protocol MK0991-064; NCT01945281) enrolled participants <3 months of age with culture-confirmed ICI within 96 h of study entry. Participants were randomly assigned 2:1 to once-daily intravenous 2 mg/kg caspofungin or intravenous 1 mg/kg amphotericin B deoxycholate (dAMB). The primary endpoint was fungal-free survival (FFS) 2 weeks after treatment in the full-analysis-set (FAS) population, defined as participants with culture-confirmed ICI who received ≥1 dose of therapy. Planned enrolment was 90 participants. RESULTS Fifty-one participants were enrolled; 49 received treatment (caspofungin, n=33; dAMB, n=16); 2 additional participants did not have confirmed infections at study entry. The study was terminated after ∼ 3.5 years because of low enrolment. Forty-seven participants were included in the FAS population (caspofungin, n=31; dAMB, n=16). FFS rate at 2 weeks after treatment was 71.0% (22/31) in the caspofungin arm and 68.8% (11/16) in the dAMB arm [difference, stratified by weight, - 0.9% (95% CI, - 24.3%-27.7%)]. Adverse events developed in 84.8% (28/33) of participants in the caspofungin arm and 100% (16/16) in the dAMB arm. CONCLUSIONS Among neonates and infants with confirmed ICI, FFS at 2 weeks was similar in the caspofungin and dAMB treatment arms. A smaller proportion of participants who received caspofungin experienced adverse events.",2020,"Adverse events developed in 84.8% (28/33) of participants in the caspofungin arm and 100% (16/16) in the dAMB arm. ","['Fifty-one participants were enrolled; 49 received treatment (caspofungin, n=33; dAMB, n=16); 2 additional participants did not have confirmed infections at study entry', 'invasive candidiasis in neonates and infants younger than 3\u2009months of age', 'Phase 2 study (protocol MK0991-064; NCT01945281) enrolled participants <3\u2009months of age with culture-confirmed ICI within 96\u2009h of study entry', 'participants <3\u2009months of age with invasive Candida infection (ICI', 'Forty-seven participants were included in the FAS population (caspofungin, n=31; dAMB, n=16']","['daily intravenous 2\u2009mg/kg caspofungin or intravenous 1\u2009mg/kg amphotericin B deoxycholate (dAMB', 'caspofungin versus amphotericin B deoxycholate', 'caspofungin']","['Adverse events', 'FFS rate', 'adverse events', 'fungal-free survival (FFS']","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0537894', 'cui_str': 'Caspofungin'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439560', 'cui_str': 'Phase 2 (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0537895', 'cui_str': 'MK0991'}, {'cui': 'C0220814', 'cui_str': 'culture'}, {'cui': 'C0006840', 'cui_str': 'Moniliasis'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0537894', 'cui_str': 'Caspofungin'}, {'cui': 'C0051761', 'cui_str': 'D-AmB cpd'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",51.0,0.624103,"Adverse events developed in 84.8% (28/33) of participants in the caspofungin arm and 100% (16/16) in the dAMB arm. ","[{'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Merck & Co., Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Firdose Lambey', 'Initials': 'FL', 'LastName': 'Nakwa', 'Affiliation': 'Chris Hani Baragwanath Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Fábio', 'Initials': 'F', 'LastName': 'Araujo Motta', 'Affiliation': 'Hospital Pequeno Príncipe, Curitiba, Paraná, Brazil.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Merck & Co., Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Mary Beth', 'Initials': 'MB', 'LastName': 'Dorr', 'Affiliation': 'Merck & Co., Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Leah J', 'Initials': 'LJ', 'LastName': 'Anderson', 'Affiliation': 'Merck & Co., Inc, Kenilworth, NJ, USA.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Kartsonis', 'Affiliation': 'Merck & Co., Inc, Kenilworth, NJ, USA.'}]",The Journal of antimicrobial chemotherapy,['10.1093/jac/dkz398'] 914,28450082,Randomized Trial of a Children's Book Versus Brochures for Safe Sleep Knowledge and Adherence in a High-Risk Population.,"OBJECTIVE Sleep-related infant deaths have plateaued in the past decade, disproportionately affecting low socioeconomic status (SES) families. Printed materials are widely used for anticipatory guidance, yet none for safe sleep has been studied. We tested the efficacy of a specially designed children's book compared to brochures for safe sleep knowledge and adherence, which we hypothesized would be greater due to superior readability and engagement. METHODS This randomized controlled trial involved low-SES mothers (n = 282) enrolled in a home visiting program. Home visitors (n = 56) were randomly assigned to perform safe sleep teaching and assessments during 3 visits: third trimester, 1 week old, and 2 months old, exclusively utilizing a specially designed children's book or brochures, and surveys incorporating the American Academy of Pediatrics' safe sleep recommendations. Outcomes were safe sleep knowledge, adherence, and usefulness of materials, controlling for maternal health literacy. RESULTS Safe sleep knowledge increased across all time points with no overall group difference, though gains for sleep-evocative and general health items varied. Odds of bed sharing were higher and exclusive crib use lower for the brochure group (P < .05). Mothers and home visitors reported similar usefulness, though home visitors reported greater dialogue via the book and mothers in the book group reported more book sharing with their baby. CONCLUSIONS While a specially designed children's book and brochures were equally effective conveying aggregate safe sleep knowledge in low-SES mothers, adherence to exclusive crib use and avoiding bed sharing were greater in the book group, attributable to enhanced dialogue, readability and emotional engagement. Children's books are a promising mode of anticipatory guidance, warranting further investigation.",2017,Odds of bed sharing were higher and exclusive crib use lower for the brochure group (P < .05).,"['Home visitors (n\xa0=\xa056', 'low-SES mothers (n\xa0=\xa0282) enrolled in a home visiting program']","[""Children's Book Versus Brochures"", ""safe sleep teaching and assessments during 3 visits: third trimester, 1 week old, and 2 months old, exclusively utilizing a specially designed children's book or brochures, and surveys incorporating the American Academy of Pediatrics' safe sleep recommendations""]","['safe sleep knowledge, adherence, and usefulness of materials, controlling for maternal health literacy']","[{'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C4517681', 'cui_str': '282'}, {'cui': 'C0020043', 'cui_str': 'Home Visits'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0006002', 'cui_str': 'Books'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0032981', 'cui_str': 'Last Trimester'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0000876', 'cui_str': 'Academies'}]","[{'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0024921', 'cui_str': 'Maternal Health'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}]",282.0,0.0585412,Odds of bed sharing were higher and exclusive crib use lower for the brochure group (P < .05).,"[{'ForeName': 'John S', 'Initials': 'JS', 'LastName': 'Hutton', 'Affiliation': ""Division of General and Community Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Reading and Literacy Discovery Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Electronic address: John1.Hutton@cchmc.org.""}, {'ForeName': 'Resmi', 'Initials': 'R', 'LastName': 'Gupta', 'Affiliation': ""Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Gruber', 'Affiliation': ""Division of General and Community Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Berndsen', 'Affiliation': ""Every Child Succeeds, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'DeWitt', 'Affiliation': ""Division of General and Community Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Reading and Literacy Discovery Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Ollberding', 'Affiliation': ""Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Judith B', 'Initials': 'JB', 'LastName': 'Van Ginkel', 'Affiliation': ""Every Child Succeeds, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Robert T', 'Initials': 'RT', 'LastName': 'Ammerman', 'Affiliation': ""Every Child Succeeds, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}]",Academic pediatrics,['10.1016/j.acap.2017.04.018'] 915,26686932,The permuted locus trial--Well suited for emerging pathogens?,"The recent Ebola virus epidemic was waning by the time stakeholders were ready to field vaccines for testing but an evidence-based response to a novel pathogen will surely be required again. Here, we present a design for such a randomized controlled trial. The permuted locus trial was originally intended for studying the influence of water wells on trachoma. While outcomes can be measured in individuals, neither individuals nor groups are themselves randomized to arms, just potential well-sites, or in the case of an epidemic, index cases. The permuted locus trial may be used when classic individual and cluster-randomized trial design and analyses may not be optimal.",2016,The recent Ebola virus epidemic was waning by the time stakeholders were ready to field vaccines for testing but an evidence-based response to a novel pathogen will surely be required again.,[],[],[],[],[],[],,0.0973394,The recent Ebola virus epidemic was waning by the time stakeholders were ready to field vaccines for testing but an evidence-based response to a novel pathogen will surely be required again.,"[{'ForeName': 'Travis C', 'Initials': 'TC', 'LastName': 'Porco', 'Affiliation': 'F.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA; Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA; Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Jeremy D', 'Initials': 'JD', 'LastName': 'Keenan', 'Affiliation': 'F.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA; Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Wayne T A', 'Initials': 'WT', 'LastName': 'Enanoria', 'Affiliation': 'Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Lietman', 'Affiliation': 'F.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA; Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA; Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA. Electronic address: tom.lietman@ucsf.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2015.12.008'] 916,28480522,A randomized controlled trial of Velcro versus standard twill ties following pediatric tracheotomy.,"OBJECTIVES/HYPOTHESIS Tracheotomy is a common procedure. A reliable method of securing the tracheotomy tube is essential to minimize accidental decannulation. However, skin breakdown has been reported in ∼30% of patients. We sought to evaluate rates of skin-related complications and accidental decannulation with the use of Velcro ties compared to twill ties. STUDY DESIGN A nonblinded, randomized controlled trial comparing Velcro versus twill ties in patients undergoing tracheotomy between July 1, 2014 and January 31, 2016. METHODS Patients ≤21 years of age were recruited and randomized to receive either Velcro or twill ties. The primary outcome measure was skin-related complications. The secondary outcome measure was accidental decannulation. Outcome measures were followed through postoperative day 5. RESULTS Ninety-three patients were eligible, and 63 were enrolled. No patients were withdrawn. Fifty-seven patients were included in the analysis. Twenty-seven (47.4%) received Velcro, and 30 (52.6%) received twill. Five enrolled patients did not undergo tracheotomy (one Velcro, four twill). One was diagnosed with a genetic skin condition after enrollment but prior to undergoing tracheotomy. Patient characteristics were similar between groups. No significant differences were found with respect to skin-related complications (P = .59). Six patients (20%) with twill ties required early tie change compared to two (7.4%) with Velcro ties (P = .5). Two accidental decannulations occurred in the twill group compared to one in the Velcro group (P = 1.0). CONCLUSIONS Our study demonstrated no differences in skin-related complications or accidental decannulation between Velcro and twill tracheotomy ties in the immediate postoperative period following tracheotomy. Our study suggests that Velcro ties are a viable alternative to twill ties. LEVEL OF EVIDENCE 1b Laryngoscope, 127:1996-2001, 2017.",2017,Our study demonstrated no differences in skin-related complications or accidental decannulation between Velcro and twill tracheotomy ties in the immediate postoperative period following tracheotomy.,"['Ninety-three patients were eligible, and 63 were enrolled', 'Five enrolled patients did not undergo tracheotomy (one Velcro, four twill', 'patients undergoing tracheotomy between July 1, 2014 and January 31, 2016', 'pediatric tracheotomy', 'Patients ≤21 years of age', 'Fifty-seven patients were included in the analysis']","['Velcro', 'Velcro or twill ties']","['skin-related complications', 'early tie change', 'accidental decannulations', 'accidental decannulation']","[{'cui': 'C3816959', 'cui_str': 'Ninety'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0040591', 'cui_str': 'Tracheotomy'}, {'cui': 'C0453982', 'cui_str': 'Velcro (physical object)'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517815', 'cui_str': '57'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}]","[{'cui': 'C0453982', 'cui_str': 'Velcro (physical object)'}, {'cui': 'C0453920', 'cui_str': 'Tie (physical object)'}]","[{'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0453920', 'cui_str': 'Tie (physical object)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0521129', 'cui_str': 'Accidental (qualifier value)'}, {'cui': 'C0398305', 'cui_str': 'Vascular cannula removal (procedure)'}]",5.0,0.156381,Our study demonstrated no differences in skin-related complications or accidental decannulation between Velcro and twill tracheotomy ties in the immediate postoperative period following tracheotomy.,"[{'ForeName': 'Catherine K', 'Initials': 'CK', 'LastName': 'Hart', 'Affiliation': ""Division of Pediatric Otolaryngology-Head and Neck Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Kareem O', 'Initials': 'KO', 'LastName': 'Tawfik', 'Affiliation': ""Division of Pediatric Otolaryngology-Head and Neck Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Jareen', 'Initials': 'J', 'LastName': 'Meinzen-Derr', 'Affiliation': ""Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'John Drew', 'Initials': 'JD', 'LastName': 'Prosser', 'Affiliation': 'Division of Pediatric Otolaryngology-Head and Neck Surgery, Augusta University, Augusta, Georgia, U.S.A.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Brumbaugh', 'Affiliation': ""Division of Pediatric Otolaryngology-Head and Neck Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Myer', 'Affiliation': ""Division of Pediatric Otolaryngology-Head and Neck Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Jonette A', 'Initials': 'JA', 'LastName': 'Ward', 'Affiliation': ""Division of Pediatric Otolaryngology-Head and Neck Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'de Alarcon', 'Affiliation': ""Division of Pediatric Otolaryngology-Head and Neck Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}]",The Laryngoscope,['10.1002/lary.26608'] 917,28515547,A Randomized Pilot Study of Brief Intervention versus Simple Advice for Women Tobacco Users in an Urban Community in India.,"AIM The study aimed to assess the efficacy of providing brief intervention (BI) for women tobacco users in a community-based setting. METHODS In this open-labeled randomized study, a representative sample of women ( n = 100) from a community in East Delhi were screened using Alcohol, Smoking and Substance Involvement Screening Test. Eligible women were randomized to BI or simple advice (SA) arms. At baseline, they were assessed for tobacco use characteristics and severity of nicotine dependence using Fagerstrom's test for nicotine dependence. Intervention in the form of a single session of BI or SA to quit tobacco was provided at baseline. All participants were assessed at 1 week and 3 months following intervention. The principal outcome was self-reported abstinence from tobacco use at 3 months follow-up. RESULTS The mean age of the sample was 43 years (standard deviation = 13). Most women were married (80%), housewives (69%), illiterate (61%), socioeconomically disadvantaged and were smokeless tobacco users (94%). The subjects in the BI group were twice more likely to stop tobacco use as compared to individuals in the SA group (odds ratio = 2.2, 95% confidence interval: 0.962-5.197, P = 0.06). CONCLUSION The study results are suggestive of beneficial effect of BI. A larger study might provide more significant results.",2017,"The subjects in the BI group were twice more likely to stop tobacco use as compared to individuals in the SA group (odds ratio = 2.2, 95% confidence interval: 0.962-5.197, P = 0.06). ","['Most women were married (80%), housewives (69%), illiterate (61%), socioeconomically disadvantaged and were smokeless tobacco users (94', 'Eligible women', 'representative sample of women ( n = 100) from a community in East Delhi were screened using Alcohol, Smoking and Substance Involvement Screening Test', 'Women Tobacco Users in an Urban Community in India', 'women tobacco users in a community-based setting']","['brief intervention (BI', 'BI or simple advice (SA', 'Brief Intervention versus Simple Advice']",['self-reported abstinence from tobacco use'],"[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0555047', 'cui_str': 'Married (finding)'}, {'cui': 'C0040338', 'cui_str': 'Smokeless Tobacco'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0439861', 'cui_str': 'Substance (substance)'}, {'cui': 'C0205428', 'cui_str': 'Involvements (qualifier value)'}, {'cui': 'C0871311', 'cui_str': 'Screening test'}, {'cui': 'C3853727', 'cui_str': 'Tobacco user (finding)'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0021201', 'cui_str': 'Republic of India'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0205352', 'cui_str': 'Simple (qualifier value)'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0040335', 'cui_str': 'Tobacco use'}]",,0.0786649,"The subjects in the BI group were twice more likely to stop tobacco use as compared to individuals in the SA group (odds ratio = 2.2, 95% confidence interval: 0.962-5.197, P = 0.06). ","[{'ForeName': 'Sonali', 'Initials': 'S', 'LastName': 'Jhanjee', 'Affiliation': 'National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Rakesh', 'Initials': 'R', 'LastName': 'Lal', 'Affiliation': 'National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Ashwami', 'Initials': 'A', 'LastName': 'Mishra', 'Affiliation': 'National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Deepak', 'Initials': 'D', 'LastName': 'Yadav', 'Affiliation': 'National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.203121'] 918,28529851,Does an Antibiotic-Loaded Hydrogel Coating Reduce Early Post-Surgical Infection After Joint Arthroplasty?,"Background : Infection remains among the main reasons for joint prosthesis failure. Preclinical reports have suggested that antibacterial coatings of implants may prevent bacterial adhesion and biofilm formation. This study presents the results of the first clinical trial on an antibiotic-loaded fast-resorbable hydrogel coating (Defensive Antibacterial Coating, DAC ® ) in patients undergoing hip or knee prosthesis. Methods: In this multicenter, randomized prospective study, a total of 380 patients, scheduled to undergo primary (n=270) or revision (n=110) total hip (N=298) or knee (N=82) joint replacement with a cementless or a hybrid implant, were randomly assigned, in six European orthopedic centers, to receive an implant either with the antibiotic-loaded DAC coating (treatment group) or without coating (control group). Pre- and postoperative assessment of clinical scores, wound healing, laboratory tests, and x-ray exams were performed at fixed time intervals. Results: Overall, 373 patients were available at a mean follow-up of 14.5 ± 5.5 months (range 6 to 24). On average, wound healing, laboratory and radiographic findings showed no significant difference between the two groups. Eleven early surgical site infections were observed in the control group and only one in the treatment group (6% vs. 0.6%; p=0.003). No local or systemic side effects related to the DAC hydrogel coating were observed, and no detectable interference with implant osteointegration was noted. Conclusions: The use of a fast-resorbable, antibiotic-loaded hydrogel implant coating can reduce the rate of early surgical site infections, without any detectable adverse events or side effects after hip or knee joint replacement with a cementless or hybrid implant.",2016,"No local or systemic side effects related to the DAC hydrogel coating were observed, and no detectable interference with implant osteointegration was noted. ","['373 patients were available at a mean follow-up of 14.5 ± 5.5 months (range 6 to 24', 'patients undergoing hip or knee prosthesis', '380 patients, scheduled to undergo primary (n=270) or revision (n=110) total hip (N=298) or knee (N=82) joint replacement with a cementless or a hybrid implant']","['antibiotic-loaded DAC coating (treatment group) or without coating (control group', ' ', 'antibiotic-loaded fast-resorbable hydrogel coating (Defensive Antibacterial Coating, DAC ® ']","['Eleven early surgical site infections', 'DAC hydrogel coating', 'Pre- and postoperative assessment of clinical scores, wound healing, laboratory tests, and x-ray exams', 'rate of early surgical site infections', 'average, wound healing, laboratory and radiographic findings']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C3844008', 'cui_str': '5.5'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0022748', 'cui_str': 'Knee Prosthesis'}, {'cui': 'C4319693', 'cui_str': 'Three hundred and eighty'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0439617', 'cui_str': 'Revision - value'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0185317', 'cui_str': 'Joint Replacement'}, {'cui': 'C0020205', 'cui_str': 'Hybrids'}, {'cui': 'C2828363', 'cui_str': 'Implant'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0453946', 'cui_str': 'Coat (physical object)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0063083', 'cui_str': 'Hydrogel, Polyethylene Glycol Dimethacrylate'}, {'cui': 'C0279516', 'cui_str': 'Anti-Bacterial Agents'}]","[{'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0038941', 'cui_str': 'Postoperative Wound Infection'}, {'cui': 'C0063083', 'cui_str': 'Hydrogel, Polyethylene Glycol Dimethacrylate'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0022885', 'cui_str': 'Laboratory test (procedure)'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C2607943', 'cui_str': 'findings'}]",380.0,0.070605,"No local or systemic side effects related to the DAC hydrogel coating were observed, and no detectable interference with implant osteointegration was noted. ","[{'ForeName': 'Carlo Luca', 'Initials': 'CL', 'LastName': 'Romanò', 'Affiliation': 'Department of Reconstructive Surgery of Osteo-articular Infections C.R.I.O. Unit, I.R.C.C.S. Galeazzi Orthopaedic Institute, Milano, Italy.'}, {'ForeName': 'Kostantinos', 'Initials': 'K', 'LastName': 'Malizos', 'Affiliation': 'Orthopaedic Surgery & Trauma, Medical School, University of Thessaly, Larissa, Greece.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Capuano', 'Affiliation': 'Department of Orthopaedics, San Luca Hospital - Vallo della Lucania, Italy.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Mezzoprete', 'Affiliation': 'Department of Orthopaedics, San Camillo de Lellis Hospital - Rieti, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': ""D'Arienzo"", 'Affiliation': 'Orthopaedic Surgery & Trauma, University Clinic, Palermo, Italy.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Van Der Straeten', 'Affiliation': 'Department of Orthopaedics, Medical University Ghent, Belgium.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Scarponi', 'Affiliation': 'Department of Reconstructive Surgery of Osteo-articular Infections C.R.I.O. Unit, I.R.C.C.S. Galeazzi Orthopaedic Institute, Milano, Italy.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Drago', 'Affiliation': 'Clinical Chemistry and Microbiology Laboratory, I.R.C.C.S. Galeazzi Orthopaedic Institute, Milano, Italy.'}]",Journal of bone and joint infection,['10.7150/jbji.15986'] 919,31521682,CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial.,"OBJECTIVES The authors investigated the impact of coronary artery bypass grafting (CABG) on first and recurrent hospitalization in this population. BACKGROUND In the STICH (Surgical Treatment for Ischemic Heart Failure) trial, CABG reduced all-cause death and hospitalization in patients with and ischemic cardiomyopathy and left ventricular ejection fraction <35%. METHODS A total of 1,212 patients were randomized (610 to CABG + optimal medical therapy [CABG] and 602 to optimal medical therapy alone [MED] alone) and followed for a median of 9.8 years. All-cause and cause-specific hospitalizations were analyzed as time-to-first-event and as recurrent event analysis. RESULTS Of the 1,212 patients, 757 died (62.4%) and 732 (60.4%) were hospitalized at least once, for a total of 2,549 total all-cause hospitalizations. Most hospitalizations (66.2%) were for cardiovascular causes, of which approximately one-half (907 or 52.9%) were for heart failure. More than 70% of all hospitalizations (1,817 or 71.3%) were recurrent events. The CABG group experienced fewer all-cause hospitalizations in the time-to-first-event (349 CABG vs. 383 MED, adjusted hazard ratio [HR]: 0.85; 95% confidence interval [CI]: 0.74 to 0.98; p = 0.03) and in recurrent event analyses (1,199 CABG vs. 1,350 MED, HR: 0.78, 95% CI: 0.65 to 0.94; p < 0.001). This was driven by fewer total cardiovascular (CV) hospitalizations (744 vs. 968; p < 0.001, adjusted HR: 0.66, 95% CI: 0.55 to 0.81; p = 0.001), the majority of which were due to HF (395 vs. 512; p < 0.001, adjusted HR: 0.68, 95% CI: 0.52-0.89; p = 0.005). We did not observe a difference in non-CV events. CONCLUSIONS CABG reduces all-cause, CV, and HF hospitalizations in time-to-first-event and recurrent event analyses. (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease [STICH]; NCT00023595).",2019,"This was driven by fewer total cardiovascular (CV) hospitalizations (744 vs. 968; p < 0.001, adjusted HR: 0.66, 95% CI: 0.55 to 0.81; p = 0.001), the majority of which were due to HF (395 vs. 512; p < 0.001, adjusted HR: 0.68, 95% CI: 0.52-0.89; p = 0.005).","['Patients With Ischemic Cardiomyopathy', '1,212 patients were randomized (610 to', 'patients with and ischemic cardiomyopathy and left ventricular ejection fraction\xa0<35', '1,212 patients']","['CABG\xa0+ optimal medical therapy [CABG', 'coronary artery bypass grafting (CABG', 'CABG', 'optimal medical therapy alone [MED] alone']","['total cardiovascular (CV) hospitalizations', 'recurrent events', 'heart failure']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0349782', 'cui_str': 'Generalized ischemic myocardial dysfunction (disorder)'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction (observable entity)'}]","[{'cui': 'C0010055', 'cui_str': 'Coronary Artery Bypass Grafting'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy (procedure)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}]",1212.0,0.0583005,"This was driven by fewer total cardiovascular (CV) hospitalizations (744 vs. 968; p < 0.001, adjusted HR: 0.66, 95% CI: 0.55 to 0.81; p = 0.001), the majority of which were due to HF (395 vs. 512; p < 0.001, adjusted HR: 0.68, 95% CI: 0.52-0.89; p = 0.005).","[{'ForeName': 'Jonathan G', 'Initials': 'JG', 'LastName': 'Howlett', 'Affiliation': 'Libin Cardiovascular Institute and University of Calgary Medical Centre, Calgary, Canada. Electronic address: howlettjonathan@gmail.com.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Stebbins', 'Affiliation': 'Duke Clinical Research Institute and Department of Biostatistics and Bioinformatics, Durham, North Carolina.'}, {'ForeName': 'Mark C', 'Initials': 'MC', 'LastName': 'Petrie', 'Affiliation': 'British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Pardeep S', 'Initials': 'PS', 'LastName': 'Jhund', 'Affiliation': 'British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Serenella', 'Initials': 'S', 'LastName': 'Castelvecchio', 'Affiliation': 'Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Donato, San Donato Milanese, Milan, Italy.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Cherniavsky', 'Affiliation': 'E. Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation, Novosibirsk, Russia.'}, {'ForeName': 'Carla A', 'Initials': 'CA', 'LastName': 'Sueta', 'Affiliation': 'University of North Carolina School of Medicine, Chapel Hill, North Carolina.'}, {'ForeName': 'Ambuj', 'Initials': 'A', 'LastName': 'Roy', 'Affiliation': 'All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Ileana L', 'Initials': 'IL', 'LastName': 'Piña', 'Affiliation': 'Albert Einstein College of Medicine, Montefiore Medical Center, New York City, New York.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Wurm', 'Affiliation': 'Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Mark H', 'Initials': 'MH', 'LastName': 'Drazner', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'Bert', 'Initials': 'B', 'LastName': 'Andersson', 'Affiliation': 'Department of Cardiology, Sahlgrenska University Hospital, Goteborg, Sweden.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Batlle', 'Affiliation': 'Centro de Investigación Cardiovascular Uruguayo Casa De Galicia, Montevideo, Uruguay.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Senni', 'Affiliation': 'Papa Giovanni XXIII Hospital, Bergamo, Italy.'}, {'ForeName': 'Lukasz', 'Initials': 'L', 'LastName': 'Chrzanowski', 'Affiliation': 'Medical University of Lodz, Lodz, Poland.'}, {'ForeName': 'Bela', 'Initials': 'B', 'LastName': 'Merkely', 'Affiliation': 'Semmelweis University, Budapest, Budapest, Hungary.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Carson', 'Affiliation': 'Washington VA Medical Center, Washington, DC.'}, {'ForeName': 'Patrice M', 'Initials': 'PM', 'LastName': 'Desvigne-Nickens', 'Affiliation': 'Division of Cardiovascular Sciences, National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, Maryland.'}, {'ForeName': 'Kerry L', 'Initials': 'KL', 'LastName': 'Lee', 'Affiliation': 'Duke Clinical Research Institute and Department of Biostatistics and Bioinformatics, Durham, North Carolina.'}, {'ForeName': 'Eric J', 'Initials': 'EJ', 'LastName': 'Velazquez', 'Affiliation': 'Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Hussein R', 'Initials': 'HR', 'LastName': 'Al-Khalidi', 'Affiliation': 'Duke Clinical Research Institute and Department of Biostatistics and Bioinformatics, Durham, North Carolina.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JACC. Heart failure,['10.1016/j.jchf.2019.04.018'] 920,32492153,VITamin D and OmegA-3 TriaL (VITAL): Effects of Vitamin D Supplements on Risk of Falls in the US Population.,"CONTEXT It is unclear whether vitamin D supplementation reduces risk of falls, and results from randomized controlled trials (RCTs) are conflicting. OBJECTIVE The objective of this work is to determine whether 2000 IU/day of supplemental vitamin D3 decreases fall risk. DESIGN VITamin D and OmegA-3 TriaL (VITAL) is a double-blind, placebo-controlled RCT including 25 871 adults, randomly assigned November 2011 to March 2014 and treated for 5.3 years (median). SETTING This is a nationwide study. PARTICIPANTS Men 50 years or older and women 55 years or older (mean age, 67.1 years) without cancer or cardiovascular disease at baseline participated in this study. INTERVENTIONS Interventions included vitamin D3 (cholecalciferol; 2000 IU/day) and/or omega-3 fatty acids (1 g/day) or respective placebos in a 2 × 2 factorial design. MAIN OUTCOME MEASURES Main outcome measures include 2 or more falls and falls resulting in a doctor or hospital visit. RESULTS Baseline serum total 25-hydroxyvitamin D (25[OH]D) level was 77 nmol/L; characteristics were well-balanced between groups. Numbers of participants with 2 or more falls were similar between active and placebo groups (9.8% vs 9.4%). Over 5 years, there were no differences in the proportion having 2 or more falls (odds ratio [OR] = 0.97; 95% CI, 0.90-1.05, P = .50), falls resulting in a doctor visit (OR = 1.03; 95% CI, 0.94-1.13, P = .46), or resulting in a hospital visit (OR = 1.04; 95% CI, 0.90-1.19, P = .61) between groups. Results did not differ between those with baseline 25(OH)D less than 50 vs 50 nmol/L or greater or other cut points. CONCLUSION Daily supplemental vitamin D3 vs placebo did not decrease fall risk in generally healthy adults not selected for vitamin D insufficiency. This large RCT does not indicate that supplemental vitamin D should be used for primary prevention of falls in the US population.",2020,Results did not differ between those with baseline 25(OH)D,"['Men ≥50 and women ≥55 years (mean age 67.1 years) without cancer or cardiovascular disease at baseline', 'Nationwide study', '25,871 adults, randomized November 2011-March 2014 and treated for 5.3 years (median', 'generally healthy adults']","['vitamin D3 vs. placebo', 'supplemental vitamin D3', 'VITamin D and OmegA-3 TriaL (VITAL', 'placebo-controlled RCT', 'VITamin D and OmegA-3 TriaL', 'Vitamin D3 (cholecalciferol; 2,000 IU/day', 'Vitamin D Supplements', 'and/or omega-3 fatty acids (1 g/day) or respective placebos', 'vitamin D supplementation', 'placebo']","['proportion having ≥2 falls', 'falls resulting in a doctor visit', 'Risk of Falls', 'Baseline serum total 25-hydroxyvitamin D [25(OH)D] level', 'fall risk', 'falls, falls resulting in a doctor or hospital visit']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for'}, {'cui': 'C4708663', 'cui_str': '5.3'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439465', 'cui_str': 'IU/day'}, {'cui': 'C0420176', 'cui_str': 'Vitamin D supplement therapy'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}]","[{'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1268740', 'cui_str': 'At risk for falls'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]",25871.0,0.702356,Results did not differ between those with baseline 25(OH)D,"[{'ForeName': 'Meryl S', 'Initials': 'MS', 'LastName': 'LeBoff', 'Affiliation': ""Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital Boston, Massachusetts.""}, {'ForeName': 'Elle M', 'Initials': 'EM', 'LastName': 'Murata', 'Affiliation': ""Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital Boston, Massachusetts.""}, {'ForeName': 'Nancy R', 'Initials': 'NR', 'LastName': 'Cook', 'Affiliation': 'Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Peggy', 'Initials': 'P', 'LastName': 'Cawthon', 'Affiliation': 'California Pacific Medical Center, Research Institute, University of California, San Francisco, California.'}, {'ForeName': 'Sharon H', 'Initials': 'SH', 'LastName': 'Chou', 'Affiliation': ""Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital Boston, Massachusetts.""}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Kotler', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Vadim', 'Initials': 'V', 'LastName': 'Bubes', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Julie E', 'Initials': 'JE', 'LastName': 'Buring', 'Affiliation': 'Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': 'Harvard Medical School, Boston, Massachusetts.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgaa311'] 921,28241247,Peritoneal Dialysis vs Furosemide for Prevention of Fluid Overload in Infants After Cardiac Surgery: A Randomized Clinical Trial.,"Importance Fluid overload after congenital heart surgery is frequent and a major cause of morbidity and mortality among infants. Many programs have adopted the use of peritoneal dialysis (PD) for fluid management; however, its benefits compared with those of traditional diuretic administration are unknown. Objective To determine whether infants randomized to PD vs furosemide for the treatment of oliguria have a higher incidence of negative fluid balance on postoperative day 1, as well as avoidance of 10% fluid overload; shorter duration of mechanical ventilation, intensive care unit stay, and inotrope use; and fewer electrolyte abnormalities. Design, Setting, and Participants This single-center, unblinded, randomized clinical trial compared methods of fluid removal after cardiac surgery from October 1, 2011, through March 13, 2015, in a large tertiary pediatric hospital in Ohio. The parents or guardians of all eligible infants (aged <6 months) undergoing cardiac surgery with catheter placement for PD were approached for inclusion. No patients were withdrawn for adverse effects. Recruitment was powered for the primary outcome, and analysis was based on intention to treat. Patients randomized to PD were hypothesized to have superior outcomes. Interventions Infants received intravenous furosemide (1 mg/kg every 6 hours) or a standardized PD regimen. Main Outcomes and Measures The primary end point was incidence of negative fluid balance on postoperative day 1. Secondary end points included incidence of fluid overload, duration of mechanical ventilation and intensive care unit stay, electrolyte abnormalities and repletion doses, duration of inotropic administration, and mortality. Results Seventy-three patients (47 boys [64%] and 26 girls [35%]; median age, 8 [interquartile range (IQR), 6-14] days) received treatment and completed the trial. No difference was found between the PD and furosemide groups in the incidence of negative fluid balance on the first postoperative day. The furosemide group was 3 times more likely to have 10% fluid overload (odds ratio [OR], 3.0; 95% CI, 1.3-6.9), was more likely to have prolonged ventilator use (OR, 3.1; 95% CI, 1.2-8.2), and had a longer duration of inotrope use (median, 5.5 [IQR, 4-8] vs 4.0 [IQR, 3-6] days) and higher electrolyte abnormality scores (median, 6 [IQR, 4-7] vs 3 [IQR, 2-5]) compared with the PD group. No statistically significant differences in mortality (3 patients [9.4%] in the furosemide group vs 1 patient [3.1%] in the PD group) or length of cardiac intensive care unit (median, 7 [IQR, 6-12] vs 9 [IQR, 5-15] days) or hospital (15 [IQR, 10-28] vs 14 [IQR, 9-22] days) stay were observed. No serious complications were observed. Dialysis was discontinued early in 9 of 41 patients in the PD group for pleural-peritoneal communication. Conclusions and Relevance Use of PD is safe and allows for superior fluid management with improved clinical outcomes compared with diuretic administration. Use of PD should be strongly considered among infants at high risk for postoperative acute kidney injury and fluid overload. Trial Registration clinicaltrials.gov Identifer: NCT01709227.",2017,No difference was found between the PD and furosemide groups in the incidence of negative fluid balance on the first postoperative day.,"['infants', 'parents or guardians of all eligible infants (aged <6 months) undergoing', 'Seventy-three patients (47 boys [64%] and 26 girls [35%]; median age, 8 [interquartile range (IQR), 6-14] days) received treatment and completed the trial', 'after cardiac surgery from October 1, 2011, through March 13, 2015, in a large tertiary pediatric hospital in Ohio', 'Infants']","['cardiac surgery with catheter placement for PD', 'fluid removal', 'intravenous furosemide', 'Peritoneal Dialysis vs Furosemide', 'PD vs furosemide', 'furosemide']","['longer duration of inotrope use', 'serious complications', 'adverse effects', 'length of cardiac intensive care unit', 'incidence of negative fluid balance', 'negative fluid balance', 'prolonged ventilator use', 'electrolyte abnormality scores', 'mortality', 'incidence of fluid overload, duration of mechanical ventilation and intensive care unit stay, electrolyte abnormalities and repletion doses, duration of inotropic administration, and mortality']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C1274041', 'cui_str': 'Guardian'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0020017', 'cui_str': 'Hospitals, Pediatric'}, {'cui': 'C0028905', 'cui_str': 'Ohio'}]","[{'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C0883301', 'cui_str': 'Catheter placement'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0016860', 'cui_str': 'Furosemide'}, {'cui': 'C0031139', 'cui_str': 'Peritoneal Dialysis'}]","[{'cui': 'C0439591', 'cui_str': 'Long duration (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0587446', 'cui_str': 'Cardiac intensive care unit (environment)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0429652', 'cui_str': 'Negative fluid balance (finding)'}, {'cui': 'C0087153', 'cui_str': 'Ventilators'}, {'cui': 'C0151613', 'cui_str': 'Electrolytes abnormal (finding)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0546817', 'cui_str': 'Hypervolemia (disorder)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1533734', 'cui_str': 'Administration'}]",,0.378266,No difference was found between the PD and furosemide groups in the incidence of negative fluid balance on the first postoperative day.,"[{'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Kwiatkowski', 'Affiliation': ""Heart Institute, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 2Division of Cardiology, Department of Pediatrics, Stanford University, Palo Alto, California.""}, {'ForeName': 'Stuart L', 'Initials': 'SL', 'LastName': 'Goldstein', 'Affiliation': ""Heart Institute, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 3Center for Acute Care Nephrology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Cooper', 'Affiliation': ""Heart Institute, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 3Center for Acute Care Nephrology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Nelson', 'Affiliation': ""Heart Institute, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 3Center for Acute Care Nephrology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'David L S', 'Initials': 'DL', 'LastName': 'Morales', 'Affiliation': ""Heart Institute, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Catherine D', 'Initials': 'CD', 'LastName': 'Krawczeski', 'Affiliation': 'Division of Cardiology, Department of Pediatrics, Stanford University, Palo Alto, California.'}]",JAMA pediatrics,['10.1001/jamapediatrics.2016.4538'] 922,28368738,Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.,"We previously reported 10-valent pneumococcal non-typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine (PHiD-CV) efficacy in a double-blind randomized trial (ClinicalTrials.gov: NCT00466947) against various diseases, including acute otitis media (AOM). Here, we provide further analyses. In the Panamanian subset, 7,359 children were randomized (1:1) to receive PHiD-CV or control vaccine at age 2/4/6 and 15-18 months. Of these, 2,000 had nasopharyngeal swabs collected. AOM cases were captured when parents sought medical attention for children with AOM symptoms; surveillance was enhanced approximately 2 y into the study through regular telephone calls or home visits by study personnel, who advised parents to visit the clinic if their child had AOM symptoms. Mean follow-up was 31.4 months. Clinical AOM (C-AOM) cases were assessed by physicians and confirmed by otorhinolaryngologists. Middle ear fluid samples, taken from children with C-AOM after specific informed consent, and nasopharyngeal samples were cultured for pathogen identification. For 7,359 children, 2,574 suspected AOM cases were assessed by a primary healthcare physician; 649 cases were C-AOM cases as per protocol definition. From the 503 MEF samples collected, 158 resulted in a positive culture. In the intent-to-treat cohort (7,214 children), PHiD-CV showed VE against first C-AOM (24.0% [95% CI: 8.7, 36.7]) and bacterial (B-AOM) episodes (48.0% [20.3, 66.1]) in children <24 months, which declined thereafter with age. Pre-booster VE against C-AOM was 30.7% [12.9, 44.9]; post-booster, -6.7% [-36.4, 16.6]. PHiD-CV VE was 17.7% [-6.1, 36.2] against moderate and 32.7% [-20.5, 62.4] against severe C-AOM. VE against vaccine-serotype pneumococcal NPC was 31.2% [5.3, 50.3] 3 months post-booster, and 25.6% [12.7, 36.7] across all visits. NTHi colonization rates were low and no significant reduction was observed. PHiD-CV showed efficacy against C-AOM and B-AOM in children younger than 24 months, and reduced vaccine-serotype NPC.",2017,"PHiD-CV showed efficacy against C-AOM and B-AOM in children younger than 24 months, and reduced vaccine-serotype NPC.","['Panamanian children', 'children younger than 24\xa0months, and reduced vaccine-serotype NPC', '2,000 had nasopharyngeal swabs collected', 'acute otitis media (AOM', '7,359 children, 2,574 suspected AOM cases', '7,359 children']","['VE against vaccine-serotype pneumococcal NPC', 'PHiD-CV or control vaccine', '10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine']","['PHiD-CV VE', 'efficacy against C-AOM and B-AOM', 'NTHi colonization rates', 'PHiD-CV showed VE against first C-AOM']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0449550', 'cui_str': 'Serotype (UK)'}, {'cui': 'C0444192', 'cui_str': 'Nasopharyngeal swab (specimen)'}, {'cui': 'C0271429', 'cui_str': 'Acute otitis media (disorder)'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}]","[{'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0449550', 'cui_str': 'Serotype (UK)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0138826', 'cui_str': 'surface-exposed lipoprotein D, Haemophilus influenzae'}, {'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}]",[],7359.0,0.257043,"PHiD-CV showed efficacy against C-AOM and B-AOM in children younger than 24 months, and reduced vaccine-serotype NPC.","[{'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Sáez-Llorens', 'Affiliation': 'a Department of Infectious Diseases , Hospital del Niño, Panama City, Panama; Distinguished Member of the SNI , Senacyt , Panama.'}, {'ForeName': 'Stella', 'Initials': 'S', 'LastName': 'Rowley', 'Affiliation': 'b Department of Otorhinolaryngology Hospital del Niño , Panama City , Panama.'}, {'ForeName': 'Digna', 'Initials': 'D', 'LastName': 'Wong', 'Affiliation': 'c Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT) , Panama City , Panama.'}, {'ForeName': 'Mirna', 'Initials': 'M', 'LastName': 'Rodríguez', 'Affiliation': 'c Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT) , Panama City , Panama.'}, {'ForeName': 'Arlene', 'Initials': 'A', 'LastName': 'Calvo', 'Affiliation': 'd Health Research International , Panama City , Panama.'}, {'ForeName': 'Marisol', 'Initials': 'M', 'LastName': 'Troitiño', 'Affiliation': 'd Health Research International , Panama City , Panama.'}, {'ForeName': 'Albino', 'Initials': 'A', 'LastName': 'Salas', 'Affiliation': 'd Health Research International , Panama City , Panama.'}, {'ForeName': 'Vielka', 'Initials': 'V', 'LastName': 'Vega', 'Affiliation': 'd Health Research International , Panama City , Panama.'}, {'ForeName': 'Maria Mercedes', 'Initials': 'MM', 'LastName': 'Castrejón', 'Affiliation': 'e GSK Vaccines , Panama City , Panama.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Lommel', 'Affiliation': 'f GSK Vaccines , Wavre , Belgium.'}, {'ForeName': 'Thierry G', 'Initials': 'TG', 'LastName': 'Pascal', 'Affiliation': 'f GSK Vaccines , Wavre , Belgium.'}, {'ForeName': 'William P', 'Initials': 'WP', 'LastName': 'Hausdorff', 'Affiliation': 'f GSK Vaccines , Wavre , Belgium.'}, {'ForeName': 'Dorota', 'Initials': 'D', 'LastName': 'Borys', 'Affiliation': 'f GSK Vaccines , Wavre , Belgium.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Ruiz-Guiñazú', 'Affiliation': 'f GSK Vaccines , Wavre , Belgium.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Ortega-Barría', 'Affiliation': 'e GSK Vaccines , Panama City , Panama.'}, {'ForeName': 'Juan Pablo', 'Initials': 'JP', 'LastName': 'Yarzabal', 'Affiliation': 'f GSK Vaccines , Wavre , Belgium.'}, {'ForeName': 'Lode', 'Initials': 'L', 'LastName': 'Schuerman', 'Affiliation': 'f GSK Vaccines , Wavre , Belgium.'}]",Human vaccines & immunotherapeutics,['10.1080/21645515.2017.1287640'] 923,28342282,Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve gastrectomy.,"BACKGROUND Severe obesity has been shown to limit access to renal transplantation in patients with end-stage renal disease (ESRD). Laparoscopic sleeve gastrectomy (LSG) has been performed in the ESRD population to assist in achieving waitlist and transplant eligibility. Little is known about how LSG impacts the bioequivalence of tacrolimus products and immunosuppression pharmacokinetics. METHODS This was a prospective, open-label, single-dose, crossover, two-period pharmacokinetic (PK) study. The purpose of this study was to assess single-dose PK of immediate-release tacrolimus (IR-TAC), extended-release tacrolimus (ER-TAC), and mycophenolic acid (MPA) in adult ESRD patients post-LSG. RESULTS Twenty-three subjects were included in the 24-hour PK assessments. The ratio of geometric means between ER-TAC and IR-TAC was 103.5% (90% CI; 89.6%-119.6%) for AUC 0-24 and 92.5% (90% CI; 80.4%-106.4%) for C max . PK parameters were similar between ER-TAC and IR-TAC, except for C min (P=.004) and C max (P=.04). MPA AUC 0-24 was similar when given with either ER-TAC or IR-TAC (P=.32). Patients expressing CYP3A5*1 genotypes had lower tacrolimus AUC 0-24 values vs those with CYP3A5*3/*3 (IR-TACP<.001; ER-TACP=.008). Genotype did not impact MPA PK. CONCLUSION Dose modification of immunosuppressants post-LSG may not be necessary aside from standard therapeutic drug monitoring.",2017,MPA AUC 0-24 was similar when given with either ER-TAC or IR-TAC (P=.32).,"['patients with end-stage renal disease (ESRD', 'Twenty-three subjects were included in the 24-hour PK assessments', 'adult ESRD patients post-LSG']","['laparoscopic sleeve gastrectomy', 'immunosuppressants post-LSG', 'immediate-release tacrolimus (IR-TAC), extended-release tacrolimus (ER-TAC), and mycophenolic acid (MPA', 'Laparoscopic sleeve gastrectomy (LSG']","['ratio of geometric means between ER-TAC and IR-TAC', 'PK parameters', 'tacrolimus AUC']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0022661', 'cui_str': 'End-Stage Kidney Disease'}, {'cui': 'C0450348', 'cui_str': '23 (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]","[{'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}, {'cui': 'C0021081', 'cui_str': 'Immunosuppressants'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C3489891', 'cui_str': 'TAC(a)'}, {'cui': 'C0026933', 'cui_str': 'Mycophenolic Acid'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3489891', 'cui_str': 'TAC(a)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0376690', 'cui_str': 'AUC'}]",23.0,0.0413904,MPA AUC 0-24 was similar when given with either ER-TAC or IR-TAC (P=.32).,"[{'ForeName': 'Tayyab S', 'Initials': 'TS', 'LastName': 'Diwan', 'Affiliation': 'Division of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.'}, {'ForeName': 'Alicia B', 'Initials': 'AB', 'LastName': 'Lichvar', 'Affiliation': 'Division of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.'}, {'ForeName': 'Abbie D', 'Initials': 'AD', 'LastName': 'Leino', 'Affiliation': 'Division of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.'}, {'ForeName': 'Alexander A', 'Initials': 'AA', 'LastName': 'Vinks', 'Affiliation': ""Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Christians', 'Affiliation': 'Department of Anesthesiology, iC42 Clinical Research and Development, University of Colorado Denver, Aurora, CO, USA.'}, {'ForeName': 'Adele R', 'Initials': 'AR', 'LastName': 'Shields', 'Affiliation': 'Division of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Cardi', 'Affiliation': 'The Christ Hospital, Cincinnati, OH, USA.'}, {'ForeName': 'Tsuyoshi', 'Initials': 'T', 'LastName': 'Fukuda', 'Affiliation': ""Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Tomoyuki', 'Initials': 'T', 'LastName': 'Mizuno', 'Affiliation': ""Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Tiffany', 'Initials': 'T', 'LastName': 'Kaiser', 'Affiliation': 'Division of Digestive Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.'}, {'ForeName': 'E Steve', 'Initials': 'ES', 'LastName': 'Woodle', 'Affiliation': 'Division of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.'}, {'ForeName': 'Rita R', 'Initials': 'RR', 'LastName': 'Alloway', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.'}]",Clinical transplantation,['10.1111/ctr.12975'] 924,28086853,"Taking ACTION to reduce pain: ACTION study rationale, design and protocol of a randomized trial of a proactive telephone-based coaching intervention for chronic musculoskeletal pain among African Americans.","BACKGROUND Rates of chronic pain are rising sharply in the United States and worldwide. Presently, there is evidence of racial disparities in pain treatment and treatment outcomes in the United States but few interventions designed to address these disparities. There is growing consensus that chronic musculoskeletal pain is best addressed by a biopsychosocial approach that acknowledges the role of psychological and environmental factors, some of which differ by race. METHODS/DESIGN The primary aim of this randomized controlled trial is to test the effectiveness of a non-pharmacological, self-regulatory intervention, administered proactively by telephone, at improving pain outcomes and increasing walking among African American patients with hip, back and knee pain. Participants assigned to the intervention will receive a telephone counselor delivered pedometer-mediated walking intervention that incorporates action planning and motivational interviewing. The intervention will consist of 6 telephone counseling sessions over an 8-10 week period. Participants randomly assigned to Usual Care will receive an informational brochure and a pedometer. The primary outcome is chronic pain-related physical functioning, assessed at 6 months, by the revised Roland and Morris Disability Questionnaire, a measure recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT). We will also examine whether the intervention improves other IMMPACT-recommended domains (pain intensity, emotional functioning, and ratings of overall improvement). Secondary objectives include examining whether the intervention reduces health care service utilization and use of opioid analgesics and whether key contributors to racial/ethnic disparities targeted by the intervention mediate improvement in chronic pain outcomes Measures will be assessed by mail and phone surveys at baseline, three months, and six months. Data analysis of primary aims will follow intent-to-treat methodology. DISCUSSION We will tailor our intervention to address key contributors to racial pain disparities and examine the effects of the intervention on important pain treatment outcomes for African Americans with chronic musculoskeletal pain. TRIAL REGISTRATION ClinicalTrials.gov: NCT01983228 . Registered 6 November 2013.",2017,Participants assigned to the intervention will receive a telephone counselor delivered pedometer-mediated walking intervention that incorporates action planning and motivational interviewing.,"['African Americans with chronic musculoskeletal pain', 'African American patients with hip, back and knee pain', 'chronic musculoskeletal pain among African Americans']","['telephone counselor delivered pedometer-mediated walking intervention that incorporates action planning and motivational interviewing', 'proactive telephone-based coaching intervention', 'Usual Care will receive an informational brochure and a pedometer', 'non-pharmacological, self-regulatory intervention']","['chronic pain-related physical functioning, assessed at 6\xa0months, by the revised Roland and Morris Disability Questionnaire, a measure recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT', 'pain', 'IMMPACT-recommended domains (pain intensity, emotional functioning, and ratings of overall improvement', 'health care service utilization and use of opioid analgesics and whether key contributors to racial/ethnic disparities targeted by the intervention mediate improvement in chronic pain outcomes Measures']","[{'cui': 'C0746683', 'cui_str': 'Chronic musculoskeletal pain'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0231749', 'cui_str': 'Knee pain (finding)'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1571885', 'cui_str': 'Counselors'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0441472', 'cui_str': 'Action (qualifier value)'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning (observable entity)'}, {'cui': 'C0683474', 'cui_str': 'Motivational Interviewing'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0557773', 'cui_str': 'Coach (physical object)'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0205464', 'cui_str': 'Pharmacologic (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}]","[{'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0424093', 'cui_str': 'Initiative (observable entity)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0030198', 'cui_str': 'Nociception Tests'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C4704820', 'cui_str': 'Services Utilization'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0002772', 'cui_str': 'Analgesics, Opioid'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}]",,0.139063,Participants assigned to the intervention will receive a telephone counselor delivered pedometer-mediated walking intervention that incorporates action planning and motivational interviewing.,"[{'ForeName': 'Rozina H', 'Initials': 'RH', 'LastName': 'Bhimani', 'Affiliation': 'School of Nursing, AGH Cooperative, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Lee J S', 'Initials': 'LJ', 'LastName': 'Cross', 'Affiliation': 'Center for Chronic Disease Outcomes Research (a VA HSR&D Center of Excellence), Veterans Affairs Medical Center, Minneapolis, MN, USA.'}, {'ForeName': 'Brent C', 'Initials': 'BC', 'LastName': 'Taylor', 'Affiliation': 'Center for Chronic Disease Outcomes Research (a VA HSR&D Center of Excellence), Veterans Affairs Medical Center, Minneapolis, MN, USA.'}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Meis', 'Affiliation': 'Center for Chronic Disease Outcomes Research (a VA HSR&D Center of Excellence), Veterans Affairs Medical Center, Minneapolis, MN, USA.'}, {'ForeName': 'Steven S', 'Initials': 'SS', 'LastName': 'Fu', 'Affiliation': 'Center for Chronic Disease Outcomes Research (a VA HSR&D Center of Excellence), Veterans Affairs Medical Center, Minneapolis, MN, USA.'}, {'ForeName': 'Kelli D', 'Initials': 'KD', 'LastName': 'Allen', 'Affiliation': 'Center for Health Services Research in Primary Care, Veterans Affairs (a VA HSR&D Center of Excellence), Veterans Affairs Medical Center, Durham, NC, USA.'}, {'ForeName': 'Sarah L', 'Initials': 'SL', 'LastName': 'Krein', 'Affiliation': 'Center for Clinical Management Research, Veterans Affairs Healthcare System, Ann Arbor, MI, USA.'}, {'ForeName': 'Tam', 'Initials': 'T', 'LastName': 'Do', 'Affiliation': 'Center for Chronic Disease Outcomes Research (a VA HSR&D Center of Excellence), Veterans Affairs Medical Center, Minneapolis, MN, USA.'}, {'ForeName': 'Robert D', 'Initials': 'RD', 'LastName': 'Kerns', 'Affiliation': 'Departments of Psychiatry, Neurology and Psychology, Yale University, New Haven, CT, USA.'}, {'ForeName': 'Diana J', 'Initials': 'DJ', 'LastName': 'Burgess', 'Affiliation': 'Center for Chronic Disease Outcomes Research (a VA HSR&D Center of Excellence), Veterans Affairs Medical Center, Minneapolis, MN, USA. diana.burgess@va.gov.'}]",BMC musculoskeletal disorders,['10.1186/s12891-016-1363-6'] 925,28132795,Developing a standardized measurement of alcohol intoxication.,"INTRODUCTION We assessed multiple examinations and assessment tools to develop a standardized measurement of alcohol intoxication to aid medical decision making in the Emergency Department. METHODS Volunteers underwent an alcohol challenge. Pre- and post-alcohol challenge, subjects were videotaped performing three standardized clinical examinations: (1) Standardized Field Sobriety Test (SFST) examination, (2) Hack's Impairment Index (HII) examination, and (3) Cincinnati Intoxication Examination (CIE). Emergency clinicians evaluated the level of intoxication using five standardized assessment tools in a blinded and randomized fashion: (1) SFST assessment tool (range 0-18), (2) HII assessment tool (range 0-1), (3) St. Elizabeth Alcohol Intoxication Scale (STE, range 0-17), (4) a Visual Analog Scale (VAS, range 0-100), and (5) a Binary Intoxication Question (BIQ). Construct validity was assessed along with inter- and intra-rater reliability. RESULTS Median scores pre- and post-alcohol challenge were: SFST 6 (interquartile range 5) and 11 (3), respectively; HII 0 (0.05), 0.1 (0.1); STE 0 (1), 1 (2); VAS 10 (22), 33 (31). For BIQ, 59% and 91% indicated intoxication, respectively. Inter-rater reliability scores were: SFST 0.71 (95% confidence interval 0.48-0.86) to 0.93 (0.88-0.97) depending on examination component; HII 0.90 (0.82-0.95); STE 0.86 (0.75-0.93); VAS 0.92 (0.88-0.94); BIQ 0.3. Intra-rater reliability scores were: SFST 0.74 (0.64-0.82) to 0.87 (0.81-0.91); HII 0.85 (0.79-0.90); STE 0.78 (0.68-0.85); VAS 0.82 (0.74-0.87); BIQ 0.71. VAS reliability was best when paired with the HII and SFST examinations. CONCLUSIONS HII examination, paired with either a VAS or HII assessment tool, yielded valid and reliable measurements of alcohol intoxication.",2017,Inter-rater reliability scores were: SFST 0.71 (95% confidence interval 0.48-0.86) to 0.93 (0.88-0.97) depending on examination component; HII 0.90 (0.82-0.95); STE 0.86 (0.75-0.93); VAS 0.92 (0.88-0.94); BIQ 0.3.,['Volunteers underwent an alcohol challenge'],"[""Pre- and post-alcohol challenge, subjects were videotaped performing three standardized clinical examinations: (1) Standardized Field Sobriety Test (SFST) examination, (2) Hack's Impairment Index (HII) examination, and (3) Cincinnati Intoxication Examination (CIE""]","['Intra-rater reliability scores', 'VAS reliability', 'level of intoxication']","[{'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}]","[{'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0031809', 'cui_str': 'Physical Examination'}, {'cui': 'C0440042', 'cui_str': ""Field's""}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0728899', 'cui_str': 'Intoxication'}]","[{'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0728899', 'cui_str': 'Intoxication'}]",,0.0527259,Inter-rater reliability scores were: SFST 0.71 (95% confidence interval 0.48-0.86) to 0.93 (0.88-0.97) depending on examination component; HII 0.90 (0.82-0.95); STE 0.86 (0.75-0.93); VAS 0.92 (0.88-0.94); BIQ 0.3.,"[{'ForeName': 'Justin L', 'Initials': 'JL', 'LastName': 'Benoit', 'Affiliation': 'University of Cincinnati College of Medicine, Department of Emergency Medicine, 231 Albert Sabin Way, PO Box 670769, Cincinnati, OH 45267-0769, USA. Electronic address: justin.benoit@uc.edu.'}, {'ForeName': 'Kimberly W', 'Initials': 'KW', 'LastName': 'Hart', 'Affiliation': 'University of Cincinnati College of Medicine, Department of Emergency Medicine, 231 Albert Sabin Way, PO Box 670769, Cincinnati, OH 45267-0769, USA.'}, {'ForeName': 'Adam A', 'Initials': 'AA', 'LastName': 'Soliman', 'Affiliation': 'University of Cincinnati College of Medicine, Department of Emergency Medicine, 231 Albert Sabin Way, PO Box 670769, Cincinnati, OH 45267-0769, USA.'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Barczak', 'Affiliation': 'University of Cincinnati College of Medicine, Department of Emergency Medicine, 231 Albert Sabin Way, PO Box 670769, Cincinnati, OH 45267-0769, USA.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Sibilia', 'Affiliation': 'University of Cincinnati College of Medicine, Department of Emergency Medicine, 231 Albert Sabin Way, PO Box 670769, Cincinnati, OH 45267-0769, USA.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Lindsell', 'Affiliation': 'University of Cincinnati College of Medicine, Department of Emergency Medicine, 231 Albert Sabin Way, PO Box 670769, Cincinnati, OH 45267-0769, USA.'}, {'ForeName': 'Gregory J', 'Initials': 'GJ', 'LastName': 'Fermann', 'Affiliation': 'University of Cincinnati College of Medicine, Department of Emergency Medicine, 231 Albert Sabin Way, PO Box 670769, Cincinnati, OH 45267-0769, USA.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2017.01.009'] 926,32415575,"Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).","INTRODUCTION Patients with plaque psoriasis often have nail psoriasis, which is difficult to treat. Ixekizumab (IXE) and ustekinumab (UST) are biologics with established efficacy in nail psoriasis. We present post hoc data from a head-to-head trial of IXE and UST (IXORA-S) to examine the efficacy in nail psoriasis in patients with moderate-to-severe plaque psoriasis over 52 weeks. METHODS In IXORA-S,  randomised patients received IXE (N = 136) or UST (N = 166) per label for 52 weeks. Eighty-four (61.8%) and 105 (63.3%) of the patients treated with IXE or UST, respectively, had baseline fingernail psoriasis (Nail Psoriasis Severity Index [NAPSI] > 0); of these, 54 (64.3%) and 63 (60.0%) patients, respectively, had significant baseline fingernail psoriasis (defined as NAPSI ≥ 16 with ≥ 4 fingernails involved). The proportion of patients achieving NAPSI = 0, a NAPSI score change from baseline and correlations in Psoriasis Area of Severity Index (PASI) and NAPSI improvement over 52 weeks were examined. RESULTS Progressive improvement occurred in both treatment groups over 52 weeks. Statistically significantly more patients achieved NAPSI = 0 with IXE versus UST by week 16-20, and the proportions continued to increase through week 52 among patients with baseline nail psoriasis (61.9 vs. 28.6%, respectively; P < 0.001), including those with significant nail psoriasis (57.4 vs. 17.5%, respectively; P < 0.001). Similar results were observed for NAPSI score improvement from baseline to week 52. Interestingly, the presence of nail psoriasis was associated with lower skin response with UST but not with IXE. CONCLUSIONS Ixekizumab was superior to UST in the clearance of nail psoriasis, with earlier improvement continued through 52 weeks regardless of baseline nail severity. TRIAL REGISTRATION ClinicalTrials.gov identifier; NCT02561806.",2020,Ixekizumab (IXE) and ustekinumab (UST) are biologics with established efficacy in nail psoriasis.,"['patients with moderate-to-severe plaque psoriasis over 52\xa0weeks', 'Patients with plaque psoriasis often have nail psoriasis', 'nail psoriasis', 'Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis']","['IXE and UST (IXORA-S', 'IXE or UST', 'IXE', 'Ixekizumab', 'Ixekizumab (IXE) and ustekinumab (UST', 'UST']","['Psoriasis Area of Severity Index (PASI) and NAPSI improvement', 'nail psoriasis', 'NAPSI score improvement', 'baseline fingernail psoriasis (Nail Psoriasis Severity Index [NAPSI', 'Progressive improvement', 'skin response']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0406317', 'cui_str': 'Chronic small plaque psoriasis'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0406322', 'cui_str': 'Psoriasis of nail'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}]","[{'cui': 'C3489764', 'cui_str': 'ixekizumab'}, {'cui': 'C1608841', 'cui_str': 'ustekinumab'}]","[{'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0406322', 'cui_str': 'Psoriasis of nail'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0222001', 'cui_str': 'Fingernails'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0312646', 'cui_str': 'Finding related to response to skin test'}]",,0.0802576,Ixekizumab (IXE) and ustekinumab (UST) are biologics with established efficacy in nail psoriasis.,"[{'ForeName': 'Norman', 'Initials': 'N', 'LastName': 'Wasel', 'Affiliation': 'Stratica Medical and Probity Medical Research, Edmonton, AB, Canada. nwasel@straticamedical.com.'}, {'ForeName': 'Diamant', 'Initials': 'D', 'LastName': 'Thaçi', 'Affiliation': 'Research Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'Lars E', 'Initials': 'LE', 'LastName': 'French', 'Affiliation': 'Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University of Munich (LMU Munich), Munich, Germany.'}, {'ForeName': 'Curdin', 'Initials': 'C', 'LastName': 'Conrad', 'Affiliation': 'Department of Dermatology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Dutronc', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Gaia', 'Initials': 'G', 'LastName': 'Gallo', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Lovisa', 'Initials': 'L', 'LastName': 'Berggren', 'Affiliation': 'HaaPACS GmbH, Schriesheim, Germany.'}, {'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Lacour', 'Affiliation': ""Department of Dermatology, University Hospital of Nice-Côte d'Azur, Nice, France.""}]",Dermatology and therapy,['10.1007/s13555-020-00383-x'] 927,31848443,Quality of life and psychological outcomes of body-weight supported locomotor training in spinal cord injured persons with long-standing incomplete lesions.,"STUDY DESIGN Health-related quality of life (HRQOL) data from two parallel independent single-blinded controlled randomized studies of manual (Study 1) and robotic (Study 2) locomotor training were combined (ClinicalTrials.gov #NCT00854555). OBJECTIVE To assess effects of body-weight supported locomotor training (BWSLT) programs on HRQOL in persons with long-standing motor incomplete spinal cord injury and poor walking function. SETTINGS Two inpatient rehabilitation facilities and one outpatient clinic in Norway. METHODS Data were merged into intervention (locomotor training 60 days) or control group (""usual care""). Participants completed questionnaires before randomization and 2-4 weeks after the study period, including demographic characteristics, HRQOL (36-Item Short-Form Health Status Survey, SF-36), physical activity (The International Physical Activity Questionnaire Short Form, IPAQ-SF), exercise barrier self-efficacy (EBSE), and motivation for training (Behavioral Regulation in Exercise Questionnaire, BREQ). Physical outcomes i.e., Lower extremity motor score (LEMS) was assessed. The main outcome was change in HRQOL. Secondary outcomes included changes in IPAQ-SF, EBSE, BREQ, and physical outcomes. RESULTS We recruited 37 of 60 predetermined participants. They were autonomously motivated with high baseline physical activity. BWSLT with manual or robot assistance did not improve HRQOL, though LEMS increased in the BWSLT group compared with control group. CONCLUSIONS The study was underpowered due to recruitment problems. The training programs seem to benefit LEMS, but not other physical outcomes, and had minimal effects on HRQOL, EBSE, and motivation. Autonomous motivation and high physical activity prior to the study possibly limited the attainable outcome benefits, in addition to limitations due to poor baseline physical function.",2020,"BWSLT with manual or robot assistance did not improve HRQOL, though LEMS increased in the BWSLT group compared with control group. ","['spinal cord injured persons with long-standing incomplete lesions', 'Two inpatient rehabilitation facilities and one outpatient clinic in Norway', 'persons with long-standing motor incomplete spinal cord injury and poor walking function', 'We recruited 37 of 60 predetermined participants']","['intervention (locomotor training 60 days) or control group (""usual care', 'manual (Study 1) and robotic (Study 2) locomotor training', 'body-weight supported locomotor training', 'body-weight supported locomotor training (BWSLT) programs']","['Physical outcomes i.e., Lower extremity motor score (LEMS', 'Quality of life and psychological outcomes', 'demographic characteristics, HRQOL (36-Item Short-Form Health Status Survey, SF-36), physical activity (The International Physical Activity Questionnaire Short Form, IPAQ-SF), exercise barrier self-efficacy (EBSE), and motivation for training (Behavioral Regulation in Exercise Questionnaire, BREQ', 'changes in IPAQ-SF, EBSE, BREQ, and physical outcomes', 'HRQOL, EBSE, and motivation', 'HRQOL', 'change in HRQOL', 'LEMS']","[{'cui': 'C0037925', 'cui_str': 'Myelon'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C3888057', 'cui_str': 'Stand'}, {'cui': 'C0205257', 'cui_str': 'Incomplete (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C3845566', 'cui_str': 'Rehabilitation facility'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}, {'cui': 'C0028423', 'cui_str': 'Kingdom of Norway'}, {'cui': 'C4545488', 'cui_str': 'Incomplete spinal cord injury (disorder)'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C0031843', 'cui_str': 'function'}]","[{'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0419113', 'cui_str': 'Locomotor training (regime/therapy)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0115922', 'cui_str': 'leukocyte pyrogen'}, {'cui': 'C0034380'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0018759', 'cui_str': 'Level of Health'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0443172', 'cui_str': 'State changes'}]",60.0,0.0940601,"BWSLT with manual or robot assistance did not improve HRQOL, though LEMS increased in the BWSLT group compared with control group. ","[{'ForeName': 'Anu', 'Initials': 'A', 'LastName': 'Piira', 'Affiliation': 'Department of Health and Care Sciences, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. anu.piira@kurbadet.no.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Lannem', 'Affiliation': 'Sunnaas Rehabilitation Hospital, Nesodden, Norway.'}, {'ForeName': 'Knut', 'Initials': 'K', 'LastName': 'Gjesdal', 'Affiliation': 'Department of Cardiology, Oslo university hospital Ullevål and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Knutsen', 'Affiliation': 'North Norway Rehabilitation Center, Tromsø, Norway.'}, {'ForeName': 'Lone', 'Initials': 'L', 'LastName': 'Jørgensen', 'Affiliation': 'Department of Health and Care Sciences, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Glott', 'Affiliation': 'Sunnaas Rehabilitation Hospital, Nesodden, Norway.'}, {'ForeName': 'Nils', 'Initials': 'N', 'LastName': 'Hjeltnes', 'Affiliation': 'Sunnaas Rehabilitation Hospital, Nesodden, Norway.'}, {'ForeName': 'Synnøve F', 'Initials': 'SF', 'LastName': 'Knutsen', 'Affiliation': 'North Norway Rehabilitation Center, Tromsø, Norway.'}, {'ForeName': 'Marit', 'Initials': 'M', 'LastName': 'Sørensen', 'Affiliation': 'Department of Coaching and Psychology, Norwegian School of Sport Sciences, Oslo, Norway.'}]",Spinal cord,['10.1038/s41393-019-0401-2'] 928,32090660,Benefits of EEG-Neurofeedback on the Modulation of Impulsivity in a Sample of Cocaine and Heroin Long-Term Abstinent Inmates: A Pilot Study.,"The aim of this pilot study was to assess whether neurofeedback (NFB) can be useful in the treatment of impulsive behavior in long-term abstinent cocaine and heroin addicts. A single-blind sham-controlled NFB protocol was carried out to assess the effects of NFB on impulsivity in 20 (10 + 10) cocaine and heroin long-term abstinent addicts ( Diagnostic and Statistical Manual of Mental Disorders [4th ed., text rev.; DSM-IV-TR ]). Psychotic and neurologic diseases were excluded. Participants underwent 40 NFB sessions based on the very slow cortical potential range. Inhibitory deficits were specifically addressed through right and left prefrontal training. Clinical improvement was measured with Likert-type scales, the Hamilton Depression Rating Scale, and the State-Trait Anxiety Inventory, and impulsivity was assessed using the Barratt Impulsiveness Scale and the Continuous Performance Test. Although the results are preliminary due to the small sample size, the NFB-treated group showed a significant clinical improvement, including symptoms of anxiety and depression, with two differentiated time periods. No significant clinical improvement was found in the control group. A significant decrease in the post- versus pre-treatment measures of global impulsivity, nonplanning impulsivity, and error commission measures was found in the NFB-treated group; effect size ( d Korr ) in the pre-post control design was moderate. No significant change was found in the control group. Despite the limitations of this study, the results suggest that NFB is better than placebo in improving impulsivity and clinical symptoms of anxiety and depression in long-term abstinent cocaine- and heroin-dependent individuals.",2020,"A significant decrease in the post- versus pre-treatment measures of global impulsivity, nonplanning impulsivity, and error commission measures was found in the NFB-treated group; effect size ( d Korr ) in the pre-post control design was moderate.","['Impulsivity in a Sample of Cocaine and Heroin Long-Term Abstinent Inmates', 'impulsive behavior in long-term abstinent cocaine and heroin addicts']","['placebo', 'neurofeedback (NFB', 'EEG-Neurofeedback', 'NFB', 'cocaine and heroin long-term abstinent addicts']","['Inhibitory deficits', 'Barratt Impulsiveness Scale and the Continuous Performance Test', 'Likert-type scales, the Hamilton Depression Rating Scale, and the State-Trait Anxiety Inventory, and impulsivity', 'global impulsivity, nonplanning impulsivity, and error commission measures', 'Psychotic and neurologic diseases', 'impulsivity and clinical symptoms of anxiety and depression', 'symptoms of anxiety and depression']","[{'cui': 'C0021125', 'cui_str': 'Impulsivity'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C0011892', 'cui_str': 'diamorphine'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0457801', 'cui_str': 'Current non-drinker of alcohol (finding)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2713543', 'cui_str': 'Neurofeedback'}, {'cui': 'C0013819', 'cui_str': 'EEG'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C0011892', 'cui_str': 'diamorphine'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0457801', 'cui_str': 'Current non-drinker of alcohol (finding)'}]","[{'cui': 'C0564567', 'cui_str': 'Impulsive character (finding)'}, {'cui': 'C0222045'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0021125', 'cui_str': 'Impulsivity'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.0175654,"A significant decrease in the post- versus pre-treatment measures of global impulsivity, nonplanning impulsivity, and error commission measures was found in the NFB-treated group; effect size ( d Korr ) in the pre-post control design was moderate.","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Corominas-Roso', 'Affiliation': ""Psychiatry Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.""}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Ibern', 'Affiliation': 'Generalitat de Catalunya, Barcelona, Spain.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Capdevila', 'Affiliation': 'Generalitat de Catalunya, Barcelona, Spain.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Ramon', 'Affiliation': 'Generalitat de Catalunya, Barcelona, Spain.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Roncero', 'Affiliation': 'Biomedical Network Research Center on Mental Health, Madrid, Spain.'}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Ramos-Quiroga', 'Affiliation': ""Psychiatry Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.""}]",International journal of offender therapy and comparative criminology,['10.1177/0306624X20904704'] 929,31907323,Cautionary study on the effects of pay for performance on quality of care: a pilot randomised controlled trial using standardised patients.,"BACKGROUND Due to the difficulty of studying incentives in practice, there is limited empirical evidence of the full-impact pay-for-performance (P4P) incentive systems. OBJECTIVE To evaluate the impact of P4P in a controlled, simulated environment. DESIGN We employed a simulation-based randomised controlled trial with three standardised patients to assess advanced practice providers' performance. Each patient reflected one of the following: (A) indicated for P4P screenings, (B) too young for P4P screenings, or (C) indicated for P4P screenings, but screenings are unrelated to the reason for the visit. Indication was determined by the 2016 Centers for Medicare and Medicaid Services quality measures. INTERVENTION The P4P group was paid $150 and received a bonus of $10 for meeting each of five outcome measures (breast cancer, colorectal cancer, pneumococcal, tobacco use and depression screenings) for each of the three cases (max $300). The control group received $200. SETTING Learning resource centre. PARTICIPANTS 35 advanced practice primary care providers (physician assistants and nurse practitioners) and 105 standardised patient encounters. MEASUREMENTS Adherence to incentivised outcome measures, interpersonal communication skills, standards of care, and misuse. RESULTS The Type a patient was more likely to receive indicated P4P screenings in the P4P group (3.82 out of 5 P4P vs 2.94 control, p=0.02), however, received lower overall standards of care under P4P (31.88 P4P vs 37.06 control, p=0.027). The Type b patient was more likely to be prescribed screenings not indicated, but highlighted by P4P: breast cancer screening (47% P4P vs 0% control, p<0.01) and colorectal cancer screening (24% P4P vs 0% control, p=0.03). The P4P group over-reported completion of incentivised measures resulting in overpayment (average of $9.02 per patient). LIMITATIONS A small sample size and limited variability in patient panel limit the generalisability of findings. CONCLUSIONS Our findings caution the adoption of P4P by highlighting the unintended consequences of the incentive system.",2020,"The Type a patient was more likely to receive indicated P4P screenings in the P4P group (3.82 out of 5 P4P vs 2.94 control, p=0.02), however, received lower overall standards of care under P4P (31.88 P4P vs 37.06 control, p=0.027).","[""three standardised patients to assess advanced practice providers' performance"", '35 advanced practice primary care providers (physician assistants and nurse practitioners) and 105 standardised patient encounters.\nMEASUREMENTS', 'Learning resource centre']",[],"['quality of care', 'P4P screenings', 'interpersonal communication skills, standards of care, and misuse', 'colorectal cancer screening']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C2735026', 'cui_str': 'Primary care provider (occupation)'}, {'cui': 'C0031833', 'cui_str': ""Physicians' Extenders""}, {'cui': 'C0028657', 'cui_str': 'Nurse practitioner (occupation)'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]",[],"[{'cui': 'C0034379', 'cui_str': 'Quality of Care'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0870313', 'cui_str': 'Communication skills'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}]",35.0,0.114741,"The Type a patient was more likely to receive indicated P4P screenings in the P4P group (3.82 out of 5 P4P vs 2.94 control, p=0.02), however, received lower overall standards of care under P4P (31.88 P4P vs 37.06 control, p=0.027).","[{'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Green', 'Affiliation': 'College of Health Solutions, Arizona State University, Tempe, Arizona, USA ellen.green@asu.edu.'}, {'ForeName': 'Katherine S', 'Initials': 'KS', 'LastName': 'Peterson', 'Affiliation': 'Mayo Clinic Scottsdale, Scottsdale, Arizona, USA.'}, {'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Markiewicz', 'Affiliation': 'Mayo Clinic Scottsdale, Scottsdale, Arizona, USA.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': ""O'Brien"", 'Affiliation': 'College of Health Solutions, Arizona State University, Tempe, Arizona, USA.'}, {'ForeName': 'Noel M', 'Initials': 'NM', 'LastName': 'Arring', 'Affiliation': 'Department of Systems, Population and Leadership, University of Michigan, Ann Arbor, Michigan, USA.'}]",BMJ quality & safety,['10.1136/bmjqs-2019-010260'] 930,32414338,Ultrasound in managing extrapulmonary tuberculosis: a randomized controlled two-center study.,"BACKGROUND Patients with clinically suspected tuberculosis are often treated empirically, as diagnosis - especially of extrapulmonary tuberculosis - remains challenging. This leads to an overtreatment of tuberculosis and to underdiagnosis of possible differential diagnoses. METHODS This open-label, parallel-group, superiority randomized controlled trial is done in a rural and an urban center in Tanzania. HIV-positive and -negative adults (≥18 years) with clinically suspected extrapulmonary tuberculosis are randomized in a 1:1 ratio to an intervention- or control group, stratified by center and HIV status. The intervention consists of a management algorithm including extended focused assessment of sonography for HIV and tuberculosis (eFASH) in combination with chest X-ray and microbiological tests. Treatment with anti-tuberculosis drugs is started, if eFASH is positive, chest X-ray suggests tuberculosis, or a microbiological result is positive for tuberculosis. Patients in the control group are managed according national guidelines. Treatment is started if microbiology is positive or empirically according to the treating physician. The primary outcome is the proportion of correctly managed patients at 6 months (i.e patients who were treated with anti-tuberculosis treatment and had definite or probable tuberculosis, and patients who were not treated with anti-tuberculosis treatment and did not have tuberculosis). Secondary outcomes are the proportion of symptom-free patients at two and 6 months, and time to death. The sample size is 650 patients. DISCUSSION This study will determine, whether ultrasound in combination with other tests can increase the proportion of correctly managed patients with clinically suspected extrapulmonary tuberculosis, thus reducing overtreatment with anti-tuberculosis drugs. TRIAL REGISTRATION PACTR, Registration number: PACTR201712002829221, registered December 1st 2017.",2020,"This study will determine, whether ultrasound in combination with other tests can increase the proportion of correctly managed patients with clinically suspected extrapulmonary tuberculosis, thus reducing overtreatment with anti-tuberculosis drugs. ","['correctly managed patients with clinically suspected extrapulmonary tuberculosis', 'rural and an urban center in Tanzania', 'managing extrapulmonary tuberculosis', 'patients who were treated with anti-tuberculosis treatment and had definite or probable tuberculosis, and patients who were not treated with anti-tuberculosis treatment and did not have tuberculosis', 'Patients with clinically suspected tuberculosis', '650 patients', 'HIV-positive and -negative adults (≥18\u2009years) with clinically suspected extrapulmonary tuberculosis']","['management algorithm including extended focused assessment of sonography for HIV and tuberculosis (eFASH) in combination with chest X-ray and microbiological tests', 'intervention- or control']","['proportion of symptom-free patients at two and 6\xa0months, and time to death']","[{'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0679362', 'cui_str': 'Tuberculosis, extrapulmonary'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0039298', 'cui_str': 'Tanzania'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0041296', 'cui_str': 'Tuberculosis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439544', 'cui_str': 'Definite'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C3844101', 'cui_str': '650'}, {'cui': 'C0019699', 'cui_str': 'HIV positive'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0041296', 'cui_str': 'Tuberculosis'}, {'cui': 'C0039985', 'cui_str': 'Plain chest X-ray'}, {'cui': 'C0025953', 'cui_str': 'microbiology'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0436342', 'cui_str': 'Free of symptoms'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",,0.184641,"This study will determine, whether ultrasound in combination with other tests can increase the proportion of correctly managed patients with clinically suspected extrapulmonary tuberculosis, thus reducing overtreatment with anti-tuberculosis drugs. ","[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Ndege', 'Affiliation': 'Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania. rndege@ihi.or.tz.'}, {'ForeName': 'Omary', 'Initials': 'O', 'LastName': 'Ngome', 'Affiliation': 'Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania.'}, {'ForeName': 'Farida', 'Initials': 'F', 'LastName': 'Bani', 'Affiliation': 'Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania.'}, {'ForeName': 'Yvan', 'Initials': 'Y', 'LastName': 'Temba', 'Affiliation': 'Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania.'}, {'ForeName': 'Herieth', 'Initials': 'H', 'LastName': 'Wilson', 'Affiliation': 'Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Vanobberghen', 'Affiliation': 'Department of Medicine, Swiss Tropical and Public Health Institute, Basel, Switzerland.'}, {'ForeName': 'Jerry', 'Initials': 'J', 'LastName': 'Hella', 'Affiliation': 'Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania.'}, {'ForeName': 'Winfrid', 'Initials': 'W', 'LastName': 'Gingo', 'Affiliation': 'St Francis Referral Hospital, Ifakara, United Republic of Tanzania.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Sasamalo', 'Affiliation': 'Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania.'}, {'ForeName': 'Dorcas', 'Initials': 'D', 'LastName': 'Mnzava', 'Affiliation': 'Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania.'}, {'ForeName': 'Namvua', 'Initials': 'N', 'LastName': 'Kimera', 'Affiliation': 'Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Hiza', 'Affiliation': 'Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Wigayi', 'Affiliation': 'Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania.'}, {'ForeName': 'Herry', 'Initials': 'H', 'LastName': 'Mapesi', 'Affiliation': 'Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania.'}, {'ForeName': 'Irene B', 'Initials': 'IB', 'LastName': 'Kato', 'Affiliation': 'Mwananyamala Regional Referral Hospital, Dar es salaam, United Republic of Tanzania.'}, {'ForeName': 'Francis', 'Initials': 'F', 'LastName': 'Mhimbira', 'Affiliation': 'Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Reither', 'Affiliation': 'Department of Medicine, Swiss Tropical and Public Health Institute, Basel, Switzerland.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Battegay', 'Affiliation': 'Faculty of Medicine, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Daniel H', 'Initials': 'DH', 'LastName': 'Paris', 'Affiliation': 'Department of Medicine, Swiss Tropical and Public Health Institute, Basel, Switzerland.'}, {'ForeName': 'Maja', 'Initials': 'M', 'LastName': 'Weisser', 'Affiliation': 'Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Rohacek', 'Affiliation': 'Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania. mrohacek@ihi.or.tz.'}]",BMC infectious diseases,['10.1186/s12879-020-05073-9'] 931,32413530,Cranberry capsules are not superior to placebo capsules in managing acute non-haemorrhagic radiation cystitis in prostate cancer patients: A phase III double blinded randomised placebo controlled clinical trial.,"PURPOSE Acute radiation cystitis affects the quality of life of many prostate cancer patients. A previous pilot study suggested that cranberry capsules may decrease some of the symptoms of acute radiation cystitis. Here we further test their effectiveness in a multicentre double blinded placebo-controlled clinical trial. MATERIAL AND METHODS A total of 108 prostate cancer patients were recruited at three New Zealand hospitals between September 2016 and January 2019. Out of this cohort, 101 patients provided datasets for analysis (51 men on cranberry capsules and 50 men on beetroot-containing placebo capsules). Patients took two capsules each morning during RT and for 2 weeks after completion of RT. Three measures were used to assess cystitis severity: modified RTOG, O'Leary interstitial cystitis scale and a sensitive novel radiation induced cystitis assessment scale (RICAS). Cystitis severity was scored at baseline and weekly thereafter during RT and for two weeks after completion of RT. Radiation protocols were stratified to conventional fractionation or hypo-fractionated radiation therapy (CHHiP) to the prostate or radiation to the prostate bed. RESULTS Cranberry capsules performed significantly worse than placebo capsules with respect to day time frequency and bladder control, using the more sensitive RICAS scale. No significant difference in cystitis severity was seen between patients receiving hypofractionation and those receiving conventional fractionation to the prostate gland. CONCLUSION Cranberry capsules were not superior to beetroot-containing placebo capsules in managing radiation cystitis in our prostate patient cohort. RICAS may be a useful tool for measuring radiation cystitis in future studies.",2020,"No significant difference in cystitis severity was seen between patients receiving hypofractionation and those receiving conventional fractionation to the prostate gland. ","['101 patients provided datasets for analysis (51 men on cranberry capsules and 50 men on beetroot-containing placebo capsules', 'many prostate cancer patients', 'prostate cancer patients', '108 prostate cancer patients were recruited at three New Zealand hospitals between September 2016 and January 2019']","['conventional fractionation or hypo-fractionated radiation therapy (CHHiP', 'Cranberry capsules', 'placebo capsules', 'RICAS', 'cranberry capsules', 'placebo']","['Cystitis severity', 'sensitive RICAS scale', 'symptoms of acute radiation cystitis', 'cystitis severity', ""cystitis severity: modified RTOG, O'Leary interstitial cystitis scale and a sensitive novel radiation induced cystitis assessment scale (RICAS""]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150098', 'cui_str': 'Data Set'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0453273', 'cui_str': 'Cranberry preparation'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0453112', 'cui_str': 'Beetroot'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0524811', 'cui_str': 'Dose Fractionation, Radiotherapy'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0453273', 'cui_str': 'Cranberry preparation'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0010692', 'cui_str': 'Cystitis'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}]","[{'cui': 'C0010692', 'cui_str': 'Cystitis'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0403637', 'cui_str': 'Acute radiation cystitis'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0282488', 'cui_str': 'Ulcerative cystitis'}, {'cui': 'C0205314', 'cui_str': 'New'}]",108.0,0.254135,"No significant difference in cystitis severity was seen between patients receiving hypofractionation and those receiving conventional fractionation to the prostate gland. ","[{'ForeName': 'Patries M', 'Initials': 'PM', 'LastName': 'Herst', 'Affiliation': 'Department of Radiation Therapy, University of Otago, Wellington, New Zealand. Electronic address: patries.herst@otago.ac.nz.'}, {'ForeName': 'Andre', 'Initials': 'A', 'LastName': 'Aumata', 'Affiliation': 'Radiation Oncology Department, Southern Blood and Cancer Centre, Dunedin Hospital, New Zealand.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Sword', 'Affiliation': 'Kathleen Kilgour Centre, Tauranga, New Zealand.'}, {'ForeName': 'Rowan', 'Initials': 'R', 'LastName': 'Jones', 'Affiliation': 'Auckland Radiation Oncology, Epsom, New Zealand.'}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Purdie', 'Affiliation': ""Dean's Department, University of Otago, Wellington, New Zealand.""}, {'ForeName': 'Shaun', 'Initials': 'S', 'LastName': 'Costello', 'Affiliation': 'Radiation Oncology Department, Southern Blood and Cancer Centre, Dunedin Hospital, New Zealand.'}]",Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,['10.1016/j.radonc.2020.05.006'] 932,27636157,Associations between PTSD and intimate partner and non-partner aggression among substance using veterans in specialty mental health.,"BACKGROUND Risk factors of violence perpetration in veterans include substance use and posttraumatic stress disorder (PTSD); however, it is unknown whether these factors are associated with greater risk for partner or non-partner violence. This study investigated the associations between probable PTSD, heavy drinking, marijuana use, cocaine use, and partner and non-partner violence perpetration. METHODS Self-report questionnaires assessing past-year partner and non-partner aggression (CTS2) as well as past-month substance use (SAOM), probable PTSD (PCL-C), and probable depression (PHQ-9) were administered to 810 substance using veterans entering VA mental health treatment. RESULTS In bivariate analyses, probable PTSD in substance using veterans was associated with violence perpetration (partner physical, χ 2 =11.46, p=0.001, φ=0.12; non-partner physical, χ 2 =50.64, p<0.001, φ=0.25; partner injury, χ 2 =6.41, p=0.011, φ=0.09; non-partner injury, χ 2 =42.71, p<0.001, φ=0.23). In multiple logistic regression analyses that adjusted for sociodemographic characteristics, probable PTSD was independently associated with non-partner physical (odds ratio [OR], 2.82; 95% confidence interval [CI], 1.97-4.05) and injury aggression (OR, 3.96; CI, 2.56-6.13). Cocaine and heavy drinking were independently associated with non-partner physical and injury aggression and non-partner injury aggression respectively. CONCLUSIONS The results provide evidence that probable PTSD, heavy drinking, and cocaine use are associated with increased risk of non-partner violence perpetration in substance using veterans. These results underscore the importance of screening for PTSD symptoms and violence perpetration towards non-partners in substance using veterans presenting for treatment.",2017,"Cocaine and heavy drinking were independently associated with non-partner physical and injury aggression and non-partner injury aggression respectively. ","['veterans include substance use and posttraumatic stress disorder (PTSD', 'Self-report questionnaires assessing past-year partner and non-partner aggression (CTS2) as well as past-month substance use (SAOM']",[],"['non-partner physical and injury aggression and non-partner injury aggression respectively', 'Cocaine and heavy drinking', 'injury aggression']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0001807', 'cui_str': 'Aggression'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]",[],"[{'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0001807', 'cui_str': 'Aggression'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}]",,0.0131093,"Cocaine and heavy drinking were independently associated with non-partner physical and injury aggression and non-partner injury aggression respectively. ","[{'ForeName': 'Katherine R', 'Initials': 'KR', 'LastName': 'Buchholz', 'Affiliation': 'VA Serious Mental Illness Treatment Resource and Evaluation Center (SMITREC), 2800 Plymouth Road, Bldg 16, Ann Arbor, MI 48109, United States; VA Ann Arbor Healthcare System, Psychiatry, (116C) 2215 Fuller Road, Ann Arbor, MI 48105, United States; Department of Psychiatry, University of Michigan Medical School, United States. Electronic address: kbuchhol@med.umich.edu.'}, {'ForeName': 'Kipling M', 'Initials': 'KM', 'LastName': 'Bohnert', 'Affiliation': 'VA Serious Mental Illness Treatment Resource and Evaluation Center (SMITREC), 2800 Plymouth Road, Bldg 16, Ann Arbor, MI 48109, United States; VA Ann Arbor Healthcare System, Psychiatry, (116C) 2215 Fuller Road, Ann Arbor, MI 48105, United States; Department of Psychiatry, University of Michigan Medical School, United States.'}, {'ForeName': 'Rebecca K', 'Initials': 'RK', 'LastName': 'Sripada', 'Affiliation': 'VA Serious Mental Illness Treatment Resource and Evaluation Center (SMITREC), 2800 Plymouth Road, Bldg 16, Ann Arbor, MI 48109, United States; VA Ann Arbor Healthcare System, Psychiatry, (116C) 2215 Fuller Road, Ann Arbor, MI 48105, United States; Department of Psychiatry, University of Michigan Medical School, United States.'}, {'ForeName': 'Sheila A M', 'Initials': 'SA', 'LastName': 'Rauch', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 12 Executive Park Dr, NE, 2nd Floor, Atlanta, GA 30329, United States; Mental Health Service Line, Atlanta VA Medical Center, (116C) 1670 Clairmont Rd, Decatur, GA 30033, United States.'}, {'ForeName': 'Quyen M', 'Initials': 'QM', 'LastName': 'Epstein-Ngo', 'Affiliation': 'Department of Emergency Medicine, Injury Center, University of Michigan, 2800 Plymouth Road, Suite B10-GG080, Ann Arbor, MI 48109, United States; Institute for Research on Women and Gender, University of Michigan, 1136 Lane Hall, Ann Arbor, MI 48109, United States.'}, {'ForeName': 'Stephen T', 'Initials': 'ST', 'LastName': 'Chermack', 'Affiliation': 'VA Ann Arbor Healthcare System, Psychiatry, (116C) 2215 Fuller Road, Ann Arbor, MI 48105, United States; Department of Psychiatry, Addiction Research Center, University of Michigan, United States.'}]",Addictive behaviors,['10.1016/j.addbeh.2016.08.039'] 933,32415610,Randomized clinical trial of a novel donor-derived cfDNA test to detect rejection in CPV-simulated renal transplant patients.,"PURPOSE Five-year kidney graft loss currently stands at about 30%. We evaluate the clinical utility of a blood test measuring donor-derived cell-free DNA that detects rejection earlier and, potentially, improves diagnostic and therapeutic accuracy. METHODS In a randomized controlled experiment, we measured the clinical practice of 175 practicing nephrologists, both with and without the use of dd-cfDNA testing. Providers cared for six simulated post-renal transplant patient cases whose ages ranged from 30 to 75 years and were 3-24 months post-transplant with typical presentations. RESULTS 154 nephrologists completed two rounds of simulated cases. At baseline, the study arms performed similarly, demonstrating no significant differences either in primary diagnosis (p = 0.853), decisions to biopsy or refer to transplant center (p = 1.000), or therapeutic management (p = 0.488). After introduction of the dd-cfDNA test, intervention nephrologists were more likely to arrive at the diagnosis of rejection (OR 4.00, 95% CI 1.93-8.30), make a correct decision on biopsy/transplant center referral (OR 11.07, 95% CI 4.87-25.16), and properly adjust therapeutic management (OR 2.37, 95% CI 1.07-5.24). CONCLUSION A sample of nationally representative, practicing nephrologists given dd-cfDNA to evaluate post-transplant patients were more likely to correctly diagnose early and subclinical allograft rejection, to send for biopsy or refer to transplant center, and to appropriately change treatment than those nephrologists without dd-cfDNA access.",2020,"At baseline, the study arms performed similarly, demonstrating no significant differences either in primary diagnosis (p = 0.853), decisions to biopsy or refer to transplant center (p = 1.000), or therapeutic management (p = 0.488).","['CPV-simulated renal transplant patients', '154 nephrologists completed two rounds of simulated cases', '175 practicing nephrologists, both with and without the use of dd-cfDNA testing', 'Providers cared for six simulated post-renal transplant patient cases whose ages ranged from 30 to 75\xa0years and were 3-24\xa0months post-transplant with typical presentations']","['novel donor-derived cfDNA test', 'blood test measuring donor-derived cell-free DNA']","['correct decision on biopsy/transplant center referral', 'decisions to biopsy or refer to transplant center']","[{'cui': 'C0006893', 'cui_str': 'Cape Verde islands'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C5191279', 'cui_str': '154'}, {'cui': 'C0260039', 'cui_str': 'Nephrologist'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332490', 'cui_str': 'Round shape'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C4289789', 'cui_str': 'Cell free DNA'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C4289789', 'cui_str': 'Cell free DNA'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]","[{'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}]",,0.0283824,"At baseline, the study arms performed similarly, demonstrating no significant differences either in primary diagnosis (p = 0.853), decisions to biopsy or refer to transplant center (p = 1.000), or therapeutic management (p = 0.488).","[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Peabody', 'Affiliation': 'School of Medicine, University of California, 450 Pacific Ave, Suite 200, San Francisco, CA, 94133, USA. jpeabody@qurehealthcare.com.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Billings', 'Affiliation': 'Natera, Inc, San Carlos, CA, USA.'}, {'ForeName': 'Czarlota', 'Initials': 'C', 'LastName': 'Valdenor', 'Affiliation': 'QURE Healthcare, San Francisco, CA, USA.'}, {'ForeName': 'Zach', 'Initials': 'Z', 'LastName': 'Demko', 'Affiliation': 'Natera, Inc, San Carlos, CA, USA.'}, {'ForeName': 'Solomon', 'Initials': 'S', 'LastName': 'Moshkevich', 'Affiliation': 'Natera, Inc, San Carlos, CA, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Tran', 'Affiliation': 'QURE Healthcare, San Francisco, CA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Paculdo', 'Affiliation': 'QURE Healthcare, San Francisco, CA, USA.'}]",International urology and nephrology,['10.1007/s11255-020-02491-1'] 934,32492293,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.,"BACKGROUND Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine. Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown. METHODS We conducted a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis. We enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure). Within 4 days after exposure, we randomly assigned participants to receive either placebo or hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days). The primary outcome was the incidence of either laboratory-confirmed Covid-19 or illness compatible with Covid-19 within 14 days. RESULTS We enrolled 821 asymptomatic participants. Overall, 87.6% of the participants (719 of 821) reported a high-risk exposure to a confirmed Covid-19 contact. The incidence of new illness compatible with Covid-19 did not differ significantly between participants receiving hydroxychloroquine (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); the absolute difference was -2.4 percentage points (95% confidence interval, -7.0 to 2.2; P = 0.35). Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported. CONCLUSIONS After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. (Funded by David Baszucki and Jan Ellison Baszucki and others; ClinicalTrials.gov number, NCT04308668.).",2020,"Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported. ","['United States and parts of Canada testing', '821 asymptomatic participants', 'enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure']","['placebo', 'Hydroxychloroquine', 'placebo or hydroxychloroquine', 'hydroxychloroquine']","['Side effects', 'incidence of new illness compatible with Covid-19', 'incidence of either laboratory-confirmed Covid-19 or illness compatible with Covid-19 within 14 days', 'serious adverse reactions']","[{'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0454979', 'cui_str': 'Part of Canada'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0028798', 'cui_str': 'Exposure, Occupational'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0183251', 'cui_str': 'Shield'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}]",821.0,0.751633,"Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported. ","[{'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Boulware', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Matthew F', 'Initials': 'MF', 'LastName': 'Pullen', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Ananta S', 'Initials': 'AS', 'LastName': 'Bangdiwala', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Katelyn A', 'Initials': 'KA', 'LastName': 'Pastick', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Sarah M', 'Initials': 'SM', 'LastName': 'Lofgren', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Okafor', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Caleb P', 'Initials': 'CP', 'LastName': 'Skipper', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Alanna A', 'Initials': 'AA', 'LastName': 'Nascene', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Melanie R', 'Initials': 'MR', 'LastName': 'Nicol', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Abassi', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Nicole W', 'Initials': 'NW', 'LastName': 'Engen', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Cheng', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'LaBar', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Sylvain A', 'Initials': 'SA', 'LastName': 'Lother', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Lauren J', 'Initials': 'LJ', 'LastName': 'MacKenzie', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Glen', 'Initials': 'G', 'LastName': 'Drobot', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Marten', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Zarychanski', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Kelly', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Ilan S', 'Initials': 'IS', 'LastName': 'Schwartz', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Emily G', 'Initials': 'EG', 'LastName': 'McDonald', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Radha', 'Initials': 'R', 'LastName': 'Rajasingham', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Todd C', 'Initials': 'TC', 'LastName': 'Lee', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Kathy H', 'Initials': 'KH', 'LastName': 'Hullsiek', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}]",The New England journal of medicine,['10.1056/NEJMoa2016638'] 935,31564448,Effect of traditional opera on older adults with dementia.,"This study evaluates the effectiveness of traditional Chinese opera on older adults with dementia; those who met the inclusion criteria were categorized into intervention (n = 21) and control (n = 22) groups. Traditional Chinese opera was organized for the intervention group for 12 weeks. The Mini-Mental State Examination (MMSE), the Chinese version of the neuropsychiatric inventory (CNPI), and Quality of Life in Alzheimer's disease (QOL-AD) assessed the effectiveness at the pre-test stage and after 6 and 12 weeks of the intervention, and generalized estimated equation was used for statistical analysis. Statistically significant (P < 0.05) differences were observed between the intervention and control groups in terms of MMSE, CNPI, and QOL-AD. Traditional Chinese opera can potentially be an effective therapy for improving the cognitive function of older adults with dementia, reducing their behavioral and psychiatric symptoms and enhancing their quality of life.",2020,"Statistically significant (P < 0.05) differences were observed between the intervention and control groups in terms of MMSE, CNPI, and QOL-AD.",['older adults with dementia'],"['traditional opera', 'traditional Chinese opera']","[""Mini-Mental State Examination (MMSE), the Chinese version of the neuropsychiatric inventory (CNPI), and Quality of Life in Alzheimer's disease (QOL-AD"", 'MMSE, CNPI, and QOL-AD']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}]","[{'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0034380'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}]",,0.035962,"Statistically significant (P < 0.05) differences were observed between the intervention and control groups in terms of MMSE, CNPI, and QOL-AD.","[{'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Hangzhou Normal University, No. 2318 Yuhangtang Rd, Cangqian, Yuhang District, Hangzhou, Zhejiang Province, China. Electronic address: 250359609@qq.com.'}, {'ForeName': 'Dongmei', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Hangzhou Normal University, No. 2318 Yuhangtang Rd, Cangqian, Yuhang District, Hangzhou, Zhejiang Province, China. Electronic address: 1241993514@qq.com.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Xu', 'Affiliation': 'Hangzhou Normal University, No. 2318 Yuhangtang Rd, Cangqian, Yuhang District, Hangzhou, Zhejiang Province, China. Electronic address: xh3674@sina.com.'}, {'ForeName': 'Ziyan', 'Initials': 'Z', 'LastName': 'Hu', 'Affiliation': 'Hangzhou Normal University, No. 2318 Yuhangtang Rd, Cangqian, Yuhang District, Hangzhou, Zhejiang Province, China. Electronic address: 627936837@qq.com.'}]","Geriatric nursing (New York, N.Y.)",['10.1016/j.gerinurse.2019.08.002'] 936,31907649,Is Xbox 360 Kinect-based virtual reality training as effective as standard physiotherapy in patients undergoing breast cancer surgery?,"PURPOSE Breast cancer surgery may be associated with pain and physical symptoms in the upper limbs. Functional impairment and pain-related avoidance of movement may further increase disability level. This study aimed to investigate the potential effects of early postoperative virtual reality (VR) therapy on pain, range of motion (ROM), muscle strength, functionality, and fear of movement. METHODS Forty women with breast cancer who had undergone unilateral mastectomy with axillary lymph node dissection and who were receiving adjuvant therapy were included in the study and randomly assigned to two groups: the Kinect-based rehabilitation group (KBRG) and the standardized physical therapy group (SPTG). The KBRG (n = 20) received VR therapy using Xbox Kinect-based games and the SPTG (n = 20) received standard physiotherapy. Study subjects were assessed at baseline and after the 6-week treatment. Outcome measures were pain (visual analogue scale), grip strength (dynamometer), functionality (disabilities of the arm shoulder and hand questionnaire), muscle strength (handheld dynamometer), ROM (digital goniometer), and fear of movement (Tampa kinesiophobia scale (TKS)). RESULTS Both groups detected significant changes in pain, ROM, muscle strength, grip strength, functionality, and TKS scores after the treatment (p < 0.01). Fear of movement was significantly improved in the KBRG and the SPTG displayed more improvement in functionality (p < 0.05). There were no differences in ROM, muscle strength, grip strength, and pain between the groups after the treatment (p > 0.05). CONCLUSION Kinect-based VR therapy resulted in significant outcomes that were comparable to those obtained under standard physiotherapy in the early postoperative phase in patients who had undergone breast cancer surgery. TRIAL REGISTRATION This study is registered at ClinicalTrials.gov ( ClinicalTrials.gov identifier: NCT03618433).",2020,"Both groups detected significant changes in pain, ROM, muscle strength, grip strength, functionality, and TKS scores after the treatment (p < 0.01).","['Forty women with breast cancer who had undergone unilateral mastectomy with axillary lymph node dissection and who were receiving', 'patients undergoing breast cancer surgery', 'patients who had undergone breast cancer surgery']","['adjuvant therapy', 'Kinect-based VR therapy', 'standard physiotherapy', 'VR therapy using Xbox Kinect-based games and the SPTG', 'KBRG', 'Kinect-based rehabilitation group (KBRG) and the standardized physical therapy group (SPTG', 'Xbox 360 Kinect-based virtual reality training', 'early postoperative virtual reality (VR) therapy']","['pain, ROM, muscle strength, grip strength, functionality, and TKS scores', 'Fear of movement', 'ROM, muscle strength, grip strength, and pain', 'pain and physical symptoms', 'pain, range of motion (ROM), muscle strength, functionality, and fear of movement', 'pain (visual analogue scale), grip strength (dynamometer), functionality (disabilities of the arm shoulder and hand questionnaire), muscle strength (handheld dynamometer), ROM (digital goniometer), and fear of movement (Tampa kinesiophobia scale (TKS']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0024886', 'cui_str': 'Total Mastectomy'}, {'cui': 'C0193867', 'cui_str': 'Excision of axillary lymph nodes'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4319607', 'cui_str': '360 (qualifier value)'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C3494470', 'cui_str': 'Virtual Reality Immersion Therapy'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0429271', 'cui_str': 'Grip strength (observable entity)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0080078', 'cui_str': 'Range of Motion'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C2919270', 'cui_str': 'Disabilities of the arm, shoulder and hand outcome measurement'}, {'cui': 'C0180572', 'cui_str': 'Dynamometer (physical object)'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray (qualifier value)'}, {'cui': 'C4285782', 'cui_str': 'Kinesiophobia'}, {'cui': 'C0222045'}]",40.0,0.0550651,"Both groups detected significant changes in pain, ROM, muscle strength, grip strength, functionality, and TKS scores after the treatment (p < 0.01).","[{'ForeName': 'Özlem', 'Initials': 'Ö', 'LastName': 'Feyzioğlu', 'Affiliation': 'Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey. ozlem.feyzioglu@acibadem.edu.tr.'}, {'ForeName': 'Selvi', 'Initials': 'S', 'LastName': 'Dinçer', 'Affiliation': 'Department of Radiation Oncology, Ministry of Health Okmeydanı Research and Training Hospital, Istanbul, Turkey.'}, {'ForeName': 'Arzu', 'Initials': 'A', 'LastName': 'Akan', 'Affiliation': 'Department of Breast and Endocrine Surgery, Ministry of Health Okmeydanı Research and Training Hospital, Istanbul, Turkey.'}, {'ForeName': 'Zeliha Candan', 'Initials': 'ZC', 'LastName': 'Algun', 'Affiliation': 'Faculty of Health Science, Department of Physiotherapy and Rehabilitation, Istanbul Medipol University, Istanbul, Turkey.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-019-05287-x'] 937,31566573,Outcomes of rotational atherectomy versus modified balloon angioplasty in severely calcified coronary lesions based on target lesion location: a post hoc analysis of the PREPARE-CALC randomised trial.,,2020,,['severely calcified coronary lesions'],['rotational atherectomy versus modified balloon angioplasty prior to drug-eluting stent implantation'],[],"[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}]","[{'cui': 'C0162655', 'cui_str': 'Rotational Atherectomy'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0002996', 'cui_str': 'Dilation, Transluminal Arterial'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C0021107', 'cui_str': 'Insertion procedure'}]",[],,0.0860408,,"[{'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Rheude', 'Affiliation': 'Deutsches Herzzentrum, Munich, Germany.'}, {'ForeName': 'Ralph', 'Initials': 'R', 'LastName': 'Toelg', 'Affiliation': ''}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Byrne', 'Affiliation': ''}, {'ForeName': 'Abdelhakim', 'Initials': 'A', 'LastName': 'Allali', 'Affiliation': ''}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Wiebe', 'Affiliation': ''}, {'ForeName': 'Dmitriy S', 'Initials': 'DS', 'LastName': 'Sulimov', 'Affiliation': ''}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Voll', 'Affiliation': ''}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Cassese', 'Affiliation': ''}, {'ForeName': 'Gert', 'Initials': 'G', 'LastName': 'Richardt', 'Affiliation': ''}, {'ForeName': 'Adnan', 'Initials': 'A', 'LastName': 'Kastrati', 'Affiliation': ''}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Abdel-Wahab', 'Affiliation': ''}]",EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,['10.4244/EIJ-D-19-00488'] 938,32492600,Cross-fading motives for simultaneous alcohol and marijuana use: Associations with young adults' use and consequences across days.,"BACKGROUND Many young adults engage in simultaneous alcohol and marijuana (SAM) use so that their effects overlap. Little is known about motivations for dual substance use and associations with use and consequences. This study examined daily-level associations between cross-fading motives and levels of alcohol and marijuana use and consequences. METHODS Young adults who reported SAM use in the month prior were surveyed in two 14-day bursts. Data included 1049 SAM use days from 281 young adults (age 18-25; M age = 21.80, SD = 2.16; 50 % women). Multilevel models assessed between- and within-person effects of cross-fading motives (i.e., to enhance the effects of marijuana and/or alcohol use by using them simultaneously) on alcohol and marijuana use and consequences, after adjusting for general enhancement, social, coping, and conformity motives and the amount of alcohol and marijuana used that day. RESULTS On 76 % of SAM use days, participants endorsed cross-fading motives (i.e., to enhance the effect of alcohol or marijuana or to get drunk and high at the same time). Having stronger cross-fading motives was associated with greater alcohol use, perceived intoxication, and positive alcohol consequences at the between- and within-person levels. In addition, between-person, individuals who reported stronger cross-fading motives on average reported more negative alcohol consequences and positive marijuana consequences on average. Cross-fading motives on a given day were not associated with marijuana use or marijuana consequences that day. CONCLUSIONS Cross-fading motives were common and varied from day to day. Understanding the motivational context for dual substance use may support future interventions for cross-fading.",2020,"Cross-fading motives on a given day were not associated with marijuana use or marijuana consequences that day. ","['Data included 1049 SAM use days from 281 young adults (age 18-25; M age = 21.80, SD = 2.16; 50 % women', 'Young adults who reported SAM use in the month prior were surveyed in two 14-day bursts']",[],['negative alcohol consequences and positive marijuana consequences'],"[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0024810', 'cui_str': 'Marihuana Smoking'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0450335', 'cui_str': '18/25'}, {'cui': 'C4517627', 'cui_str': '2.16'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}]",[],"[{'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0686907', 'cui_str': 'Consequence of'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}]",1049.0,0.0152649,"Cross-fading motives on a given day were not associated with marijuana use or marijuana consequences that day. ","[{'ForeName': 'Megan E', 'Initials': 'ME', 'LastName': 'Patrick', 'Affiliation': ""Institute for Translational Research in Children's Mental Health and Institute of Child Development, University of Minnesota, 1100 Washington Ave S., Suite 101, Minneapolis, MN 55415, USA. Electronic address: mpatrick@umn.edu.""}, {'ForeName': 'Charles B', 'Initials': 'CB', 'LastName': 'Fleming', 'Affiliation': 'University of Washington, Department of Psychiatry and Behavioral Sciences, 1100 NE 45th St., Suite 300, Seattle, WA, 98105, USA.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Fairlie', 'Affiliation': 'University of Washington, Department of Psychiatry and Behavioral Sciences, 1100 NE 45th St., Suite 300, Seattle, WA, 98105, USA.'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Lee', 'Affiliation': 'University of Washington, Department of Psychiatry and Behavioral Sciences, 1100 NE 45th St., Suite 300, Seattle, WA, 98105, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108077'] 939,31554519,Effects of a multidisciplinary quality of life intervention on sleep quality in patients with advanced cancer receiving radiation therapy.,"OBJECTIVES Sleep disturbances are prevalent in cancer patients, especially those with advanced disease. There are few published intervention studies that address sleep issues in advanced cancer patients during the course of treatment. This study assesses the impact of a multidisciplinary quality of life (QOL) intervention on subjective sleep difficulties in patients with advanced cancer. METHOD This randomized trial investigated the comparative effects of a multidisciplinary QOL intervention (n = 54) vs. standard care (n = 63) on sleep quality in patients with advanced cancer receiving radiation therapy as a secondary endpoint. The intervention group attended six intervention sessions, while the standard care group received informational material only. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS), administered at baseline and weeks 4 (post-intervention), 27, and 52. RESULTS The intervention group had a statistically significant improvement in the PSQI total score and two components of sleep quality and daytime dysfunction than the control group at week 4. At week 27, although both groups showed improvements in sleep measures from baseline, there were no statistically significant differences between groups in any of the PSQI total and component scores, or ESS. At week 52, the intervention group used less sleep medication than control patients compared to baseline (p = 0.04) and had a lower ESS score (7.6 vs. 9.3, p = 0.03). SIGNIFICANCE OF RESULTS A multidisciplinary intervention to improve QOL can also improve sleep quality of advanced cancer patients undergoing radiation therapy. Those patients who completed the intervention also reported the use of less sleep medication.",2020,The intervention group had a statistically significant improvement in the PSQI total score and two components of sleep quality and daytime dysfunction than the control group at week 4.,"['advanced cancer patients undergoing radiation therapy', 'patients with advanced cancer', 'patients with advanced cancer receiving radiation therapy', 'patients with advanced cancer receiving radiation therapy as a secondary endpoint', 'cancer patients, especially those with advanced disease', 'advanced cancer patients']","['intervention group attended six intervention sessions, while the standard care group received informational material only', 'multidisciplinary quality of life intervention', 'multidisciplinary quality of life (QOL) intervention', 'multidisciplinary QOL intervention (n = 54) vs. standard care']","['sleep measures', 'Sleep quality', 'PSQI total and component scores, or ESS', 'lower ESS score', 'sleep quality', 'sleep medication', 'Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS', 'PSQI total score', 'sleep quality and daytime dysfunction', 'subjective sleep difficulties']","[{'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0034619', 'cui_str': 'radiation therapy'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0034380'}]","[{'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C3697468', 'cui_str': 'PSQI - Pittsburgh sleep quality index'}, {'cui': 'C3541276', 'cui_str': 'ESS - Epworth Sleepiness Scale'}, {'cui': 'C0332169', 'cui_str': 'Daytime (qualifier value)'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}]",,0.0294239,The intervention group had a statistically significant improvement in the PSQI total score and two components of sleep quality and daytime dysfunction than the control group at week 4.,"[{'ForeName': 'Melanie T', 'Initials': 'MT', 'LastName': 'Gentry', 'Affiliation': 'Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Pamela J', 'Initials': 'PJ', 'LastName': 'Atherton', 'Affiliation': 'Cancer Center Statistics Section, Division of Biomedical Statistics and Informatics, Department of Health Sciences, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Lapid', 'Affiliation': 'Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Preetha Sharone', 'Initials': 'PS', 'LastName': 'Rosen', 'Affiliation': 'Peace Health St John Medical Center, Longview, Washington, WA.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Kung', 'Affiliation': 'Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Jarrett', 'Initials': 'J', 'LastName': 'Richardson', 'Affiliation': 'Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Shehzad K', 'Initials': 'SK', 'LastName': 'Niazi', 'Affiliation': 'Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL.'}, {'ForeName': 'William V', 'Initials': 'WV', 'LastName': 'Bobo', 'Affiliation': 'Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL.'}, {'ForeName': 'Matthew M', 'Initials': 'MM', 'LastName': 'Clark', 'Affiliation': 'Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Teresa A', 'Initials': 'TA', 'LastName': 'Rummans', 'Affiliation': 'Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.'}]",Palliative & supportive care,['10.1017/S1478951519000750'] 940,27335517,Third-person Diagnostic Interview on the Cognitive Insight Level of Psychotic Patients with an Insight at the Denial Level.,"OBJECTIVES According to the previous findings, the third-person technique improved the clinical insight of psychotic patients, therefore the present study aims to examine the effect of a third-person interview compared to a first-person interview on the level of cognitive insight of psychotic patients with an insight at the denial level. MATERIALS AND METHODS In this study, using interviews and questionnaires, a total number of 44 patients of Razi Psychiatric Educational and Treatment Center with an insight at the denial level being assessed using diagnostic interviews were divided randomly into two groups. Then, the two groups of patients' cognitive insights were evaluated using Beck Cognitive Insight Scale. RESULTS The findings indicated that in psychotic patients with an insight at the denial level, the third-person technique of interview compared to the first-person had little effect on the improvement of overall cognitive insight and its components, including self-reflection and self-assurance; however, this effect was not strong enough to make a significant difference between the two groups of patients. CONCLUSION According to the study findings, we can conclude that the third-person interview compared to the first-person interview has no effect on the improvement of the cognitive insight of psychotic patients with an insight at the denial level. This finding is consistent with the previous studies indicating that although the theory of mind has some correlations with the clinical insight of patients, it has no effect on their cognitive insight.",2016,"The findings indicated that in psychotic patients with an insight at the denial level, the third-person technique of interview compared to the first-person had little effect on the improvement of overall cognitive insight and its components, including self-reflection and self-assurance; however, this effect was not strong enough to make a significant difference between the two groups of patients. CONCLUSION ","['Psychotic Patients with an Insight at the Denial Level', 'psychotic patients with an insight at the denial level', '44 patients of Razi Psychiatric Educational and Treatment Center with an insight at the denial level being assessed using diagnostic interviews']",[],"['overall cognitive insight and its components, including self-reflection and self-assurance', 'Beck Cognitive Insight Scale']","[{'cui': 'C0033975', 'cui_str': 'Psychoses'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0233820', 'cui_str': 'Self-understanding'}, {'cui': 'C0011317', 'cui_str': 'Denial'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0935630', 'cui_str': 'Interview'}]",[],"[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0233820', 'cui_str': 'Self-understanding'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0222045'}]",,0.0205867,"The findings indicated that in psychotic patients with an insight at the denial level, the third-person technique of interview compared to the first-person had little effect on the improvement of overall cognitive insight and its components, including self-reflection and self-assurance; however, this effect was not strong enough to make a significant difference between the two groups of patients. CONCLUSION ","[{'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Mehdizadeh', 'Affiliation': 'Department of Clinical Psychology, Science and Research Branch, Islamic Azad University, Tehran, Iran.'}, {'ForeName': 'Omid', 'Initials': 'O', 'LastName': 'Rezaei', 'Affiliation': 'Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.183088'] 941,29284812,Quality of the Reviews Submitted by Attendees of a Workshop on Peer Review.,"Objective The objective of the study was to study the methodological quality and error detection of the review by the participants of a peer review workshop. Methods All participants of the workshop were invited to peer review a randomized controlled trial. The manuscript was E-mailed to them after introducing eight deliberate errors to it. Specific instructions and a deadline were provided. All the reviews were analyzed using review quality instrument (RQI). Furthermore, the rate and the type of errors identified were recorded. Results Of 25 participants, 16 (64%) returned the reviews. The mean total score on RQI was 4.12 (standard deviation 0.70, 95% confidence interval 3.74-4.50); the items which most reviewers did not discuss where the importance of research question and originality of the paper. The number of errors correctly identified varied from 0 to 6 (median 3), the most common being a wrong conclusion (87.5%), randomization procedure (50%), written informed consent (50%), ethics committee approval (42.8%), and masking (31.2%). Only 5 (31.2%) gave an overall recommendation on whether the manuscript should be accepted or not. Conclusions Major errors were readily identified by the reviewers; however, the need for training was felt in some areas in which the review quality was modest.",2017,"The mean total score on RQI was 4.12 (standard deviation 0.70, 95% confidence interval 3.74-4.50); the items which most reviewers did not discuss where the importance of research question and originality of the paper.",[],[],['mean total score on RQI'],[],[],"[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0482056,"The mean total score on RQI was 4.12 (standard deviation 0.70, 95% confidence interval 3.74-4.50); the items which most reviewers did not discuss where the importance of research question and originality of the paper.","[{'ForeName': 'Samir Kumar', 'Initials': 'SK', 'LastName': 'Praharaj', 'Affiliation': 'Department of Psychiatry, Kasturba Medical College, Manipal, Karnataka, India.'}, {'ForeName': 'Shahul', 'Initials': 'S', 'LastName': 'Ameen', 'Affiliation': 'Department of Psychiatry, St. Thomas Hospital, Changanassery, Kerala, India.'}]",Indian journal of psychological medicine,['10.4103/IJPSYM.IJPSYM_372_17'] 942,32416201,Effect of exercise-based cardiac rehabilitation on clinical outcomes in patients with myocardial infarction in the absence of obstructive coronary artery disease (MINOCA).,"BACKGROUND Myocardial infarction in the absence of obstructive coronary artery disease (MINOCA) is characterized by clinical evidence of myocardial infarction with nonobstructive coronary stenosis on angiography (stenosis < 50%). Studies on the effect that exercise-based cardiac rehabilitation (CR) has on outcomes in MINOCA patients are lacking. Therefore, the purpose of this study was to determine the effect of exercise-based CR on clinical outcomes in patients with MINOCA. METHODS A total of 524 participants with MINOCA were recruited in this prospective cohort study from August 2014 to October 2016 and followed for three years. We randomly divided 524 patients into an exercise-based cardiac rehabilitation group (CR+) and a control group (CR-). The CR+ group followed a home-based exercise-training program three times a week during the three years of moderate continuous training (MCT; 65%-75% of peak heart rate) on a bicycle or treadmill. RESULTS After one year of follow-up, the Short Form 36 (SF-36) survey showed apparent improvement in the mean physical health score in the CR+ group compared with the CR- group (P < 0.01). During the three-year follow-up, all-cause mortality occurred in 60 individuals, and major adverse cardiovascular events (MACE) happened in 136 individuals. Kaplan-Meier curves indicated a significant reduction in all-cause mortality (log-rank P < 0.05) and MACE (log-rank P < 0.01) in the CR+ group. A multivariate Cox regression analysis indicated that exercise-based CR was associated with a significant reduction in all-cause mortality (hazard ratio [HR] = 0.483; 95% confidence interval [CI], 0.279-0.818; P < 0.01) and MACE (HR = 0.574; 95% CI, 0.403-0.827; P < 0.001). CONCLUSIONS A long-term exercise-based CR program was associated with superior physical health and a significant reduction in all-cause mortality and MACE in patients with MINOCA.",2020,Kaplan-Meier curves indicated a significant reduction in all-cause mortality (log-rank P < 0.05) and MACE (log-rank P < 0.01) in the CR+ group.,"['524 patients into an', 'patients with myocardial infarction in the absence of obstructive coronary artery disease (MINOCA', '524 participants with MINOCA were recruited in this prospective cohort study from August 2014 to October 2016 and followed for three years', 'patients with MINOCA']","['exercise-based cardiac rehabilitation group (CR+) and a control group (CR', 'bicycle or treadmill', 'exercise-based cardiac rehabilitation (CR', 'exercise-based CR', 'exercise-based cardiac rehabilitation', 'CR']","['cause mortality', 'mean physical health score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0005375', 'cui_str': 'Bicycle'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",524.0,0.0357636,Kaplan-Meier curves indicated a significant reduction in all-cause mortality (log-rank P < 0.05) and MACE (log-rank P < 0.01) in the CR+ group.,"[{'ForeName': 'Chao-Jie', 'Initials': 'CJ', 'LastName': 'He', 'Affiliation': 'Department of Cardiology, The First Hospital of Jiaxing, The Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314001, China.'}, {'ForeName': 'Chun-Yan', 'Initials': 'CY', 'LastName': 'Zhu', 'Affiliation': 'Department of Anesthesiology, The First Hospital of Jiaxing, The Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314001, China.'}, {'ForeName': 'Yu-Juan', 'Initials': 'YJ', 'LastName': 'Zhu', 'Affiliation': 'Department of Cardiology, The First Hospital of Jiaxing, The Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314001, China.'}, {'ForeName': 'Zhuo-Xuan', 'Initials': 'ZX', 'LastName': 'Zou', 'Affiliation': 'Department of Cardiology, The First Hospital of Jiaxing, The Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314001, China.'}, {'ForeName': 'Shi-Jun', 'Initials': 'SJ', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiology, The First Hospital of Jiaxing, The Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314001, China.'}, {'ForeName': 'Chang-Lin', 'Initials': 'CL', 'LastName': 'Zhai', 'Affiliation': 'Department of Cardiology, The First Hospital of Jiaxing, The Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314001, China.'}, {'ForeName': 'Hui-Lin', 'Initials': 'HL', 'LastName': 'Hu', 'Affiliation': 'Department of Cardiology, The First Hospital of Jiaxing, The Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314001, China. Electronic address: huhuilin1979@sohu.com.'}]",International journal of cardiology,['10.1016/j.ijcard.2020.05.019'] 943,32416072,"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.","BACKGROUND Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a poor clinical outcome. The aim of this international phase 3 study was to assess the efficacy and safety of ivosidenib (AG-120)-a small-molecule targeted inhibitor of mutated IDH1-in patients with previously treated IDH1-mutant cholangiocarcinoma. METHODS This multicentre, randomised, double-blind, placebo-controlled, phase 3 study included patients from 49 hospitals in six countries aged at least 18 years with histologically confirmed, advanced, IDH1-mutant cholangiocarcinoma who had progressed on previous therapy, and had up to two previous treatment regimens for advanced disease, an Eastern Cooperative Oncology Group performance status score of 0 or 1, and a measurable lesion as defined by Response Evaluation Criteria in Solid Tumors version 1.1. Patients were randomly assigned (2:1) with a block size of 6 and stratified by number of previous systemic treatment regimens for advanced disease to oral ivosidenib 500 mg or matched placebo once daily in continuous 28-day cycles, by means of an interactive web-based response system. Placebo to ivosidenib crossover was permitted on radiological progression per investigator assessment. The primary endpoint was progression-free survival by independent central review. The intention-to-treat population was used for the primary efficacy analyses. Safety was assessed in all patients who had received at least one dose of ivosidenib or placebo. Enrolment is complete; this study is registered with ClinicalTrials.gov, NCT02989857. FINDINGS Between Feb 20, 2017, and Jan 31, 2019, 230 patients were assessed for eligibility, and as of the Jan 31, 2019 data cutoff date, 185 patients were randomly assigned to ivosidenib (n=124) or placebo (n=61). Median follow-up for progression-free survival was 6·9 months (IQR 2·8-10·9). Progression-free survival was significantly improved with ivosidenib compared with placebo (median 2·7 months [95% CI 1·6-4·2] vs 1·4 months [1·4-1·6]; hazard ratio 0·37; 95% CI 0·25-0·54; one-sided p<0·0001). The most common grade 3 or worse adverse event in both treatment groups was ascites (four [7%] of 59 patients receiving placebo and nine [7%] of 121 patients receiving ivosidenib). Serious adverse events were reported in 36 (30%) of 121 patients receiving ivosidenib and 13 (22%) of 59 patients receiving placebo. There were no treatment-related deaths. INTERPRETATION Progression-free survival was significantly improved with ivosidenib compared with placebo, and ivosidenib was well tolerated. This study shows the clinical benefit of targeting IDH1 mutations in advanced, IDH1-mutant cholangiocarcinoma. FUNDING Agios Pharmaceuticals.",2020,Progression-free survival was significantly improved with ivosidenib compared with placebo (median 2·7 months [95% CI 1·6-4·2] vs 1·4 months [1·4-1·6]; hazard ratio 0·37; 95% CI 0·25-0·54; one-sided p<0·0001).,"['mutated IDH1-in patients with previously treated IDH1-mutant cholangiocarcinoma', 'patients from 49 hospitals in six countries aged at least 18 years with histologically confirmed, advanced, IDH1-mutant cholangiocarcinoma who had progressed on previous therapy, and had up to two previous treatment regimens for advanced disease, an Eastern Cooperative Oncology Group performance status score of 0 or 1, and a measurable lesion as defined by Response Evaluation Criteria in Solid Tumors version 1.1', 'Between Feb 20, 2017, and Jan 31, 2019, 230 patients were assessed for eligibility, and as of the Jan 31, 2019 data cutoff date, 185 patients']","['Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy', 'ivosidenib or placebo', 'Placebo', 'oral ivosidenib 500 mg or matched placebo', 'ivosidenib', 'ivosidenib (AG-120)-a small-molecule targeted inhibitor', 'placebo']","['Safety', 'tolerated', 'progression-free survival', 'Median follow-up for progression-free survival', 'adverse event', 'efficacy and safety', 'Progression-free survival', 'Serious adverse events']","[{'cui': 'C0022157', 'cui_str': 'Isocitrate dehydrogenase'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0206698', 'cui_str': 'Cholangiocarcinoma'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C1709926', 'cui_str': 'RECIST'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C4517491', 'cui_str': '1.1'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0011008', 'cui_str': 'Date'}, {'cui': 'C4517617', 'cui_str': '185'}]","[{'cui': 'C4682397', 'cui_str': 'ivosidenib'}, {'cui': 'C0022157', 'cui_str': 'Isocitrate dehydrogenase'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0206698', 'cui_str': 'Cholangiocarcinoma'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C3827169', 'cui_str': 'AG-120'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0567416', 'cui_str': 'Molecule'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",230.0,0.76452,Progression-free survival was significantly improved with ivosidenib compared with placebo (median 2·7 months [95% CI 1·6-4·2] vs 1·4 months [1·4-1·6]; hazard ratio 0·37; 95% CI 0·25-0·54; one-sided p<0·0001).,"[{'ForeName': 'Ghassan K', 'Initials': 'GK', 'LastName': 'Abou-Alfa', 'Affiliation': 'Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Macarulla', 'Affiliation': ""Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.""}, {'ForeName': 'Milind M', 'Initials': 'MM', 'LastName': 'Javle', 'Affiliation': 'Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Robin K', 'Initials': 'RK', 'LastName': 'Kelley', 'Affiliation': 'Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Sam J', 'Initials': 'SJ', 'LastName': 'Lubner', 'Affiliation': 'Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI, USA.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Adeva', 'Affiliation': 'Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Cleary', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.'}, {'ForeName': 'Daniel V', 'Initials': 'DV', 'LastName': 'Catenacci', 'Affiliation': 'Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.'}, {'ForeName': 'Mitesh J', 'Initials': 'MJ', 'LastName': 'Borad', 'Affiliation': 'Department of Hematology-Oncology, Mayo Clinic Cancer Center, Phoenix, AZ, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Bridgewater', 'Affiliation': 'Department of Medical Oncology, UCL Cancer Institute, London, UK.'}, {'ForeName': 'William P', 'Initials': 'WP', 'LastName': 'Harris', 'Affiliation': 'Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Adrian G', 'Initials': 'AG', 'LastName': 'Murphy', 'Affiliation': 'Department of Oncology-Gastrointestinal Cancer, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Do-Youn', 'Initials': 'DY', 'LastName': 'Oh', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Whisenant', 'Affiliation': 'Medical Oncology and Hematology, Utah Cancer Specialists, Salt Lake City, UT, USA.'}, {'ForeName': 'Maeve A', 'Initials': 'MA', 'LastName': 'Lowery', 'Affiliation': 'Trinity St James Cancer Institute, Trinity College Dublin, Dublin, Ireland.'}, {'ForeName': 'Lipika', 'Initials': 'L', 'LastName': 'Goyal', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Rachna T', 'Initials': 'RT', 'LastName': 'Shroff', 'Affiliation': 'Department of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA.'}, {'ForeName': 'Anthony B', 'Initials': 'AB', 'LastName': 'El-Khoueiry', 'Affiliation': 'Department of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Fan', 'Affiliation': 'Agios Pharmaceuticals, Cambridge, MA, USA.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Wu', 'Affiliation': 'Agios Pharmaceuticals, Cambridge, MA, USA.'}, {'ForeName': 'Christina X', 'Initials': 'CX', 'LastName': 'Chamberlain', 'Affiliation': 'Agios Pharmaceuticals, Cambridge, MA, USA.'}, {'ForeName': 'Liewen', 'Initials': 'L', 'LastName': 'Jiang', 'Affiliation': 'Agios Pharmaceuticals, Cambridge, MA, USA.'}, {'ForeName': 'Camelia', 'Initials': 'C', 'LastName': 'Gliser', 'Affiliation': 'Agios Pharmaceuticals, Cambridge, MA, USA.'}, {'ForeName': 'Shuchi S', 'Initials': 'SS', 'LastName': 'Pandya', 'Affiliation': 'Agios Pharmaceuticals, Cambridge, MA, USA.'}, {'ForeName': 'Juan W', 'Initials': 'JW', 'LastName': 'Valle', 'Affiliation': 'Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Andrew X', 'Initials': 'AX', 'LastName': 'Zhu', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA; Jiahui International Cancer Center, Jiahui Health, Shanghai, China. Electronic address: azhu@mgh.harvard.edu.'}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30157-1'] 944,31296923,Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.,"BACKGROUND Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2.35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment. METHODS Prognostic and predictive values of post-operative CEA in patients with stage II CC were evaluated with Kaplan-Meier survival curves and Cox model with interaction terms. Disease-free survival (DFS) and overall survival (OS) were estimated. RESULTS Among 899 stage II CC patients, post-operative CEA was available in 867 (96.4%); and 434 (48.65%) had a high-risk stage II disease. The 3-year DFS rate was 88.5% and 78.7% in the ≤ 2.35 ng/mL and > 2.35 ng/mL group, respectively (P = 0.006). Use of oxaliplatin showed survival benefit only in patients with high-risk stage II CC and post-operative CEA > 2.35 ng/ml (interaction term P = 0.09 and 0.03 for DFS and OS). CONCLUSION CEA is a strong prognostic factor for DFS and OS in stage II CC. In the MOSAIC trial, only high-risk stage II CC patients with post-operative CEA > 2.35 ng/mL benefited from the addition of oxaliplatin to LV5FU2. TRIAL REGISTRATION NCT00275210 (January 11, 2006).",2019,"Use of oxaliplatin showed survival benefit only in patients with high-risk stage II CC and post-operative CEA > 2.35 ng/ml (interaction term P = 0.09 and 0.03 for DFS and OS). ","['patients with high-risk disease', 'patients with stage II CC', 'patients with stage II colon cancer', 'stage II colon cancer (CC']","['oxaliplatin', 'CEA']","['3-year DFS rate', 'Disease-free survival (DFS) and overall survival (OS', 'post-operative CEA', 'survival benefit']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2 (qualifier value)'}, {'cui': 'C0007102', 'cui_str': 'Cancer of Colon'}]","[{'cui': 'C0069717', 'cui_str': 'oxaliplatin'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0242793', 'cui_str': 'Disease-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]",,0.250109,"Use of oxaliplatin showed survival benefit only in patients with high-risk stage II CC and post-operative CEA > 2.35 ng/ml (interaction term P = 0.09 and 0.03 for DFS and OS). ","[{'ForeName': 'Edouard', 'Initials': 'E', 'LastName': 'Auclin', 'Affiliation': 'Department of Hepato-Gastroenterology and Gastrointestinal Oncology, Sorbonne Paris-Cité, Paris Descartes University, Hôpital Européen Georges Pompidou, Paris, France.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'André', 'Affiliation': 'Department of Medical Oncology, Sorbonne University, Hôpital Saint Antoine, Paris, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Taieb', 'Affiliation': 'Department of Hepato-Gastroenterology and Gastrointestinal Oncology, Sorbonne Paris-Cité, Paris Descartes University, Hôpital Européen Georges Pompidou, Paris, France.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Banzi', 'Affiliation': 'Unit of Medical Oncology, Clinical Cancer Center, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy.'}, {'ForeName': 'Jean-Luc', 'Initials': 'JL', 'LastName': 'Van Laethem', 'Affiliation': 'Department of Gastroenterology and Digestive diseases, Hopital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium.'}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Tabernero', 'Affiliation': ""Vall d'Hebron University Hospital and Institute of Oncology (VHIO), CIBERONC, Universitat Autònoma de Barcelona, Barcelona, Spain.""}, {'ForeName': 'Tamas', 'Initials': 'T', 'LastName': 'Hickish', 'Affiliation': 'Department of Oncology, Royal Bournemouth Hospital and Bournemouth University, Bournemouth, UK.'}, {'ForeName': 'Aimery', 'Initials': 'A', 'LastName': 'de Gramont', 'Affiliation': 'Oncology Multidisciplinary Research Group (GERCOR), Paris, France.'}, {'ForeName': 'Dewi', 'Initials': 'D', 'LastName': 'Vernerey', 'Affiliation': 'Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, Besançon, France. dvernerey@chu-besancon.fr.'}]",British journal of cancer,['10.1038/s41416-019-0521-7'] 945,26862079,Alcohol Screening and Intervention Among United States Adults who Attend Ambulatory Healthcare.,"BACKGROUND There is limited data on the extent to which indicated alcohol interventions are delivered in U.S. ambulatory care settings. OBJECTIVE To assess the receipt of alcohol-related services, including assessment of use, advice to reduce drinking, and information about alcohol treatment, during ambulatory care visits. DESIGN Secondary data analysis of the 2013 National Survey on Drug Use and Health, a cross-sectional, nationally representative survey of civilians in the non-institutionalized U.S. general population (response rate 71.7 %). PARTICIPANTS Adult ambulatory care users in the public use data file who did not obtain emergency or inpatient services (n = 17,266). MAIN MEASURES Measurements included respondents' alcohol consumption, heavy episodic drinking, alcohol use disorder, healthcare use, and receipt of alcohol-related interventions. KEY RESULTS Approximately 71.1 % of ambulatory care users received an alcohol assessment. Among past-month heavy episodic drinkers without an alcohol use disorder who reported receiving an alcohol assessment, 4.4 % were advised to cut back. Among individuals with alcohol abuse and alcohol dependence who reported receiving an alcohol assessment, 2.9 % and 7.0 %, respectively, were offered information about treatment. CONCLUSIONS Rates of alcohol screening and assessment were relatively high among adults who attended healthcare visits, but rates of intervention were low, even when individuals were assessed for use. Efforts are needed to expand delivery of interventions when patients are identified as positive for risky drinking, hazardous alcohol use, and alcohol use disorders during ambulatory care visits.",2016,"CONCLUSIONS Rates of alcohol screening and assessment were relatively high among adults who attended healthcare visits, but rates of intervention were low, even when individuals were assessed for use.","['individuals with alcohol abuse and alcohol dependence who reported receiving an alcohol assessment, 2.9 % and 7.0 %, respectively, were offered information about treatment', '2013 National Survey on Drug Use and Health, a cross-sectional, nationally representative survey of civilians in the non-institutionalized U.S. general population (response rate 71.7 ', 'United States Adults who Attend Ambulatory Healthcare', 'Adult ambulatory care users in the public use data file who did not obtain emergency or inpatient services (n\u2009=\u200917,266', 'Among past-month heavy episodic drinkers without an alcohol use disorder who reported receiving an alcohol assessment, 4.4 % were advised to cut back']","['Alcohol Screening and Intervention', 'alcohol assessment']","[""respondents' alcohol consumption, heavy episodic drinking, alcohol use disorder, healthcare use, and receipt of alcohol-related interventions""]","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0085762', 'cui_str': 'Alcohol abuse (disorder)'}, {'cui': 'C0001973', 'cui_str': 'Alcohol Dependence'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C4517641', 'cui_str': '2.9 (qualifier value)'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0449889', 'cui_str': 'Drug used (attribute)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0205155', 'cui_str': 'Sectional (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C0002423', 'cui_str': 'Outpatient Care'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0180853', 'cui_str': 'File, device (physical object)'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C0175673', 'cui_str': 'Emergency (qualifier value)'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C0556335', 'cui_str': 'Binge drinker (finding)'}, {'cui': 'C0001956', 'cui_str': 'Alcohol Use Disorder'}, {'cui': 'C4517761', 'cui_str': '4.4'}, {'cui': 'C0000925', 'cui_str': 'Incised wound - morphology (morphologic abnormality)'}]","[{'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C1455761', 'cui_str': 'Episodic (qualifier value)'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C0001956', 'cui_str': 'Alcohol Use Disorder'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}]",,0.0194969,"CONCLUSIONS Rates of alcohol screening and assessment were relatively high among adults who attended healthcare visits, but rates of intervention were low, even when individuals were assessed for use.","[{'ForeName': 'Joseph E', 'Initials': 'JE', 'LastName': 'Glass', 'Affiliation': 'School of Social Work, University of Wisconsin-Madison, 1350 University Ave., Madison, WI, 53706, USA. jglass2@wisc.edu.'}, {'ForeName': 'Kipling M', 'Initials': 'KM', 'LastName': 'Bohnert', 'Affiliation': 'Veterans Affairs Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.'}, {'ForeName': 'Richard L', 'Initials': 'RL', 'LastName': 'Brown', 'Affiliation': 'Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.'}]",Journal of general internal medicine,['10.1007/s11606-016-3614-5'] 946,32492882,Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.,"BACKGROUND In metastatic breast cancer (MBC) patients, no biomarker predicting benefit to a bevacizumab-containing therapy has been established yet. MicroRNAs (miRNAs) are involved in angiogenesis and treatment resistance and therefore could be of predictive value. METHODS Profiling of 754 miRNAs was performed in tumor samples of 58 MBC patients treated with a bevacizumab-containing first-line regimen (learning set). Based on progression-free survival (PFS), patients were divided into responders (R) and non-responders (NR). Differentially expressed miRNAs between R and NR were analyzed in a cohort of 57 patients treated with first-line chemotherapy without bevacizumab (control set), to exclude miRNAs providing prognostic information. MiRNA candidates significantly associated with PFS in multivariate analysis were further validated in tumor samples of 203 patients treated within the phase III trial TANIA randomizing between chemotherapy either alone or with bevacizumab after progression on first-line bevacizumab. RESULTS Low expression of miR-20a-5p (multivariate p = 0.035) and miR-21-5p (multivariate p = 0.004) were significantly associated with longer PFS in the learning set, but not in the control set. In samples from the TANIA trial, low expression of miR-20a-5p was also significantly associated with longer PFS (hazard ration (HR) 0.60; 95%-CI 0.37-0.89; p = 0.012) and longer overall survival (OS; HR 0.54; 95%-CI 0.32-0.83; p = 0.007) in the bevacizumab arm but not in the chemotherapy-only arm (PFS: HR 0.73, p = 0.119; OS: HR 1.01; p = 0.964). For miR-21-5p no significant association with PFS or OS in both treatment arms was observed. CONCLUSION MiR-20a-5p expression in breast cancer tissue was predictive for a greater benefit from bevacizumab-containing therapy in two independent cohorts.",2020,"RESULTS Low expression of miR-20a-5p (multivariate p = 0.035) and miR-21-5p (multivariate p = 0.004) were significantly associated with longer PFS in the learning set, but not in the control set.","['Metastatic Breast Cancer Patients', 'metastatic breast cancer (MBC) patients', 'Profiling of 754 miRNAs was performed in tumor samples of 58 MBC patients treated with a']","['bevacizumab-containing first-line regimen (learning set', 'bevacizumab-containing therapy', 'bevacizumab', 'Bevacizumab']","['progression-free survival (PFS', 'PFS or OS', 'overall survival']","[{'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1101610', 'cui_str': 'MicroRNA'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0475358', 'cui_str': 'Tumor tissue sample'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.032456,"RESULTS Low expression of miR-20a-5p (multivariate p = 0.035) and miR-21-5p (multivariate p = 0.004) were significantly associated with longer PFS in the learning set, but not in the control set.","[{'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Rinnerthaler', 'Affiliation': 'Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute, Oncologic Center Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Simon Peter', 'Initials': 'SP', 'LastName': 'Gampenrieder', 'Affiliation': 'Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute, Oncologic Center Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'Hackl', 'Affiliation': 'Institute of Bioinformatics, Biocenter, Medical University of Innsbruck, 6020 Innsbruck, Austria.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Steiner', 'Affiliation': 'Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute, Oncologic Center Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Monzo-Fuentes', 'Affiliation': 'Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute, Oncologic Center Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Melchardt', 'Affiliation': 'Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute, Oncologic Center Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Magnes', 'Affiliation': 'Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute, Oncologic Center Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Huemer', 'Affiliation': 'Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute, Oncologic Center Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Westphal', 'Affiliation': 'Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute, Oncologic Center Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Clemens', 'Initials': 'C', 'LastName': 'Hufnagl', 'Affiliation': 'Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute, Oncologic Center Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Cornelia', 'Initials': 'C', 'LastName': 'Hauser-Kronberger', 'Affiliation': 'Department of Pathology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Egle', 'Affiliation': 'Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute, Oncologic Center Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Greil', 'Affiliation': 'Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute, Oncologic Center Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.'}]",Journal of clinical medicine,['10.3390/jcm9061663'] 947,32416073,"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.","BACKGROUND Patients with advanced or metastatic oesophageal squamous cell carcinoma have poor prognosis and few treatment options after first-line therapy. We aimed to assess efficacy and safety of the anti-PD-1 antibody camrelizumab versus investigator's choice of chemotherapy in previously treated patients. METHODS ESCORT is a randomised, open-label, phase 3 study of patients aged 18 to 75 years with a histological or cytological diagnosis of advanced or metastatic oesophageal squamous cell carcinoma done at 43 hospitals in China. Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and had progressed on, or were intolerant to, first-line standard therapy. Patients were randomly assigned (1:1) to camrelizumab (200 mg every 2 weeks) or chemotherapy with docetaxel (75 mg/m 2 every 3 weeks) or irinotecan (180 mg/m 2 every 2 weeks), all given intravenously. Central randomisation was done using the Randomization and Trial Supply Management system with block size randomly generated as four or six and stratified by disease and ECOG performance status. The primary endpoint was overall survival, assessed in randomised patients who had received at least one dose of treatment. Safety was assessed in all treated patients. The trial is registered with ClinicalTrials.gov, NCT03099382, and is closed to new participants. FINDINGS From May 10, 2017, to July 24, 2018, 457 (75%) of 607 screened patients were randomly assigned to treatment, of whom 228 received camrelizumab treatment and 220 received chemotherapy. As of data cutoff on May 6, 2019, with a median follow-up time of 8·3 months (IQR 4·1-12·8) in the camrelizumab group and 6·2 months (3·6-10·1) in the chemotherapy group, median overall survival was 8·3 months (95% CI 6·8-9·7) in the camrelizumab group and 6·2 months (5·7-6·9) in the chemotherapy group (hazard ratio 0·71 [95% CI 0·57-0·87]; two-sided p=0·0010). The most common treatment-related adverse events of grade 3 or worse were anaemia (camrelizumab vs chemotherapy: six [3%] vs 11 [5%]), abnormal hepatic function (four [2%] vs one [<1%]), and diarrhoea (three [1%] vs nine [4%]). Serious treatment-related adverse events occurred in 37 (16%) of 228 patients in the camrelizumab group, and in 32 (15%) of 220 patients in the chemotherapy group. Ten treatment-related deaths occurred, seven (3%) in the camrelizumab group (three deaths from unknown causes, one enterocolitis, one hepatic function abnormal, one pneumonitis, and one myocarditis) and three (1%) in the chemotherapy group (two deaths from unknown causes, and one gastrointestinal haemorrhage). INTERPRETATION Second-line camrelizumab significantly improved overall survival in patients with advanced or metastatic oesophageal squamous cell carcinoma compared with chemotherapy, with a manageable safety profile. It might represent a potential option of standard second-line treatment for patients with oesophageal squamous cell carcinoma in China. FUNDING Jiangsu Hengrui Medicine.",2020,"Serious treatment-related adverse events occurred in 37 (16%) of 228 patients in the camrelizumab group, and in 32 (15%) of 220 patients in the chemotherapy group.","['Patients with advanced or metastatic oesophageal squamous cell carcinoma', 'Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and had progressed on, or were intolerant to, first-line standard therapy', 'From May 10, 2017, to July 24, 2018, 457 (75%) of 607 screened patients', 'advanced or metastatic oesophageal squamous cell carcinoma (ESCORT', 'patients with oesophageal squamous cell carcinoma in China', 'patients with advanced or metastatic oesophageal squamous cell carcinoma', 'patients aged 18 to 75 years with a histological or cytological diagnosis of advanced or metastatic oesophageal squamous cell carcinoma done at 43 hospitals in China', 'previously treated patients']","['anti-PD-1 antibody camrelizumab', 'camrelizumab', 'chemotherapy with docetaxel', 'Camrelizumab', 'camrelizumab treatment and 220 received chemotherapy', 'chemotherapy', 'irinotecan']","['Safety', 'overall survival', 'diarrhoea', 'efficacy and safety', 'median overall survival', 'adverse events', 'deaths', 'abnormal hepatic function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0279626', 'cui_str': 'Squamous cell carcinoma of esophagus'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0205471', 'cui_str': 'Cytologic'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C4682408', 'cui_str': 'camrelizumab'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0086565', 'cui_str': 'Abnormal liver function'}]",,0.242005,"Serious treatment-related adverse events occurred in 37 (16%) of 228 patients in the camrelizumab group, and in 32 (15%) of 220 patients in the chemotherapy group.","[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jianming', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Department of Gastrointestinal Oncology, Cancer Center, Fifth Medical Center General Hospital of PLA, Beijing, China. Electronic address: jmxu2003@yahoo.com.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Radiation Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China.'}, {'ForeName': 'Wu', 'Initials': 'W', 'LastName': 'Zhuang', 'Affiliation': 'Department of Thoracic Medical Oncology, Fujian Province Cancer Hospital, Fuzhou, China.'}, {'ForeName': 'Yiping', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Zhendong', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Oncology Department, The Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China.'}, {'ForeName': 'Helong', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': ""Oncology Department, Tangdu Hospital of the Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Zuoxing', 'Initials': 'Z', 'LastName': 'Niu', 'Affiliation': 'Internal Medicine Ward 4, Shandong Cancer Hospital, Jinan, China.'}, {'ForeName': 'Qingxia', 'Initials': 'Q', 'LastName': 'Fan', 'Affiliation': 'Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Lizhu', 'Initials': 'L', 'LastName': 'Lin', 'Affiliation': 'Oncology Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Kangsheng', 'Initials': 'K', 'LastName': 'Gu', 'Affiliation': 'Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Medical Oncology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Ba', 'Affiliation': 'Medical Oncology, Tianjin Cancer Hospital, Tianjin, China.'}, {'ForeName': 'Zhanhui', 'Initials': 'Z', 'LastName': 'Miao', 'Affiliation': 'Oncology Department, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.'}, {'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Jiang', 'Affiliation': ""Oncology Department, The First People's Hospital of Lianyungang, Lianyungang, China.""}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Zeng', 'Affiliation': ""Oncology Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China.""}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Medical Oncology, Cancer Hospital of Central South University, Changsha, China.'}, {'ForeName': 'Zhichao', 'Initials': 'Z', 'LastName': 'Fu', 'Affiliation': 'Department of Radiotherapy, 900 Hospital of the Joint Logistics Team, Fuzhou, China.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Gan', 'Affiliation': 'The Oncology Department, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.'}, {'ForeName': 'Xianbao', 'Initials': 'X', 'LastName': 'Zhan', 'Affiliation': 'Department of Medical Oncology, Changhai Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Tianshu', 'Initials': 'T', 'LastName': 'Liu', 'Affiliation': 'Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Zhiping', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Integrated Chinese and Western Medical Oncology, Jiangxi Cancer Hospital, Nanchang, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Shen', 'Affiliation': 'Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China.'}, {'ForeName': 'Yongqian', 'Initials': 'Y', 'LastName': 'Shu', 'Affiliation': 'Medical Oncology, Jiangsu Province Hospital, Nanjing, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Jiangsu Hengrui Medicine, Shanghai, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Yang', 'Affiliation': 'Jiangsu Hengrui Medicine, Shanghai, China.'}, {'ForeName': 'Jianjun', 'Initials': 'J', 'LastName': 'Zou', 'Affiliation': 'Jiangsu Hengrui Medicine, Shanghai, China.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30110-8'] 948,31221014,Improving Teachers' Comprehension of Curriculum-Based Measurement Progress-Monitoring Graphs.,"The authors examined three instructional approaches for improving teachers' curriculum-based measurement (CBM) graph comprehension, each differing in the extent to which reading the data, interpreting the data, and linking the data to instruction were emphasized. Participants were 164 elementary school teachers who were randomly assigned to one of three CBM instructional approaches or a control condition. Instruction was delivered via videos. Prior to and after receiving instruction, teachers completed a CBM graph-comprehension task. They also evaluated the instructional videos. Teachers in the three instructional groups improved more in CBM graph comprehension than control teachers. Improvements were seen primarily in interpreting and linking the data to instruction, two important but difficult aspects of CBM graph comprehension. Differences between the instructional groups were found for interpreting the data. Teachers evaluated the videos positively. Results indicate that teachers' CBM graph comprehension can be improved via video instruction. Implications for teaching teachers to implement CBM are discussed.",2019,Teachers in the three instructional groups improved more in CBM graph comprehension than control teachers.,['Participants were 164 elementary school teachers'],['CBM instructional approaches or a control condition'],['CBM graph comprehension'],"[{'cui': 'C0870482', 'cui_str': 'Elementary School Teachers'}]","[{'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0162340', 'cui_str': 'Understanding'}]",164.0,0.012912,Teachers in the three instructional groups improved more in CBM graph comprehension than control teachers.,"[{'ForeName': 'Roxette M', 'Initials': 'RM', 'LastName': 'van den Bosch', 'Affiliation': '1 Department of Education and Child Studies, Leiden University, Leiden, The Netherlands.'}, {'ForeName': 'Christine A', 'Initials': 'CA', 'LastName': 'Espin', 'Affiliation': '1 Department of Education and Child Studies, Leiden University, Leiden, The Netherlands.'}, {'ForeName': 'Ron J', 'Initials': 'RJ', 'LastName': 'Pat-El', 'Affiliation': '2 Department of Methods and Statistics, Open University of the Netherlands, Rotterdam, The Netherlands.'}, {'ForeName': 'Nadira', 'Initials': 'N', 'LastName': 'Saab', 'Affiliation': '3 Graduate School of Teaching (ICLON), Leiden University, Leiden, The Netherlands.'}]",Journal of learning disabilities,['10.1177/0022219419856013'] 949,30548375,A qualitative evaluation of the effects of Metacognitive Reflection and Insight Therapy: 'Living more consciously'.,"OBJECTIVES Extensive research showed that one of the major difficulties that people with schizophrenia spectrum disorders are struggling with involves their ability to reflect on their own and others' mental activities, also defined as metacognition. Several new psychotherapies have been developed to assist patients (re)gain metacognitive capacity, including Metacognitive Reflection and Insight Therapy (MERIT). The current study investigated the client's subjective experience of psychotherapy, to determine whether service users found MERIT effective and whether these gains align with quantitative findings, which processes they considered responsible for these benefits, in which ways participants found MERIT similar or different from other interventions, and whether they experienced non-desirable factors and outcomes. DESIGN All participants who had participated in a randomized controlled trial investigating the efficacy of MERIT were offered a structured post-therapy interview by an independent assessor. Fourteen out of 18 (77%) participants, all of whom had completed therapy, responded. RESULTS Most participants (10/14) indicated that they had experienced the therapy as beneficial to their recovery, and in general contributed to their understanding of their own thinking, which maps closely onto the quantitative findings reported elsewhere. They mainly attributed these changes to their own active role in therapy, the intervention letting them vent and self-express, and forming an alliance with the therapist. CONCLUSIONS Participants reports of change map closely onto the quantitative findings from the randomized controlled trial. Findings are discussed in the frameworks of the metacognitive model of psychosis and the integrative intersubjective model of psychotherapy for psychosis emphasizing the role of the clients as active agent of change. PRACTITIONER POINTS The use of a systematic, qualitative interview at the conclusion of therapy may yield important information regarding process and outcome. Analysis of the interview revealed that clients' perceptions regarding change within themselves closely maps onto quantitative findings. MERIT may not be the appropriate intervention for all clients; some may prefer a more solution-oriented approach such as CBTp or Metacognition-Oriented Social Skills training. Self-expressing with a trained clinician may be therapeutic in itself.",2020,"Several new psychotherapies have been developed to assist patients (re)gain metacognitive capacity, including Metacognitive Reflection and Insight Therapy (MERIT).","['Fourteen out of 18 (77%) participants, all of whom had completed therapy, responded', 'All participants who had participated', 'people with schizophrenia spectrum disorders']",['Metacognitive Reflection'],[],"[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",[],[],,0.0559332,"Several new psychotherapies have been developed to assist patients (re)gain metacognitive capacity, including Metacognitive Reflection and Insight Therapy (MERIT).","[{'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'de Jong', 'Affiliation': 'Department of Clinical Psychology, University of Amsterdam, The Netherlands.'}, {'ForeName': 'Ilanit', 'Initials': 'I', 'LastName': 'Hasson-Ohayon', 'Affiliation': 'Department of Psychology, Bar-Ilan University, Ramat-Gan, Israel.'}, {'ForeName': 'Rozanne', 'Initials': 'R', 'LastName': 'van Donkersgoed', 'Affiliation': 'Parnassia Dijk en Duin, Zaandam, The Netherlands.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Aleman', 'Affiliation': 'Department of Clinical Psychology and Experimental Psychopathology, Faculty of Behavioral Sciences, University of Groningen, The Netherlands.'}, {'ForeName': 'Gerdina Hendrika Maria', 'Initials': 'GHM', 'LastName': 'Pijnenborg', 'Affiliation': 'Department of Clinical Psychology and Experimental Psychopathology, Faculty of Behavioral Sciences, University of Groningen, The Netherlands.'}]",Psychology and psychotherapy,['10.1111/papt.12212'] 950,31742447,Engagement and Weight Loss in a Web and Mobile Program for Low-Income Postpartum Women: Fit Moms/ Mamás Activas .,"Internet-based weight loss programs can be effective in promoting weight loss and are less-intensive than traditional face-to-face approaches, which may provide more flexibility for postpartum, low-income women to engage in such programs. Few studies have examined patterns of engagement in internet-based programs for this population. This article used data from the internet-based Fit Moms/ Mamás Activas intervention, a 12-month cluster randomized controlled trial that was effective in promoting postpartum weight loss among low-income, predominantly Hispanic women. The overall objectives of this study were to (1) characterize patterns of engagement with the Fit Moms/ Mamás Activas website among intervention participants and (2) explore associations between engagement and 12-month weight loss outcomes among study completers (87.4%). A number of engagement variables were calculated for each participant, including website logins; time spent on the website; number of posts to the ""Discussion Forum;"" number of days tracking weight, diet, and physical activity; number of page visits to various website components; and number of in-person visits attended. The average number of logins was 70.74 (approximately once weekly), and average total time spent on the website was 185.35 minutes (approximately 3 hours) over 1 year. Self-monitoring (""Web Diary"") and social support (""Discussion Forum"") were the most frequently visited components of the website, and more frequent engagement with these components, as well as greater attendance at in-person group sessions, predicted greater percent weight loss at 12 months. Interventions highlighting these features may be particularly effective for weight loss in this population.",2019,"Internet-based weight loss programs can be effective in promoting weight loss and are less-intensive than traditional face-to-face approaches, which may provide more flexibility for postpartum, low-income women to engage in such programs.","['low-income, predominantly Hispanic women', 'Low-Income Postpartum Women']",['Internet-based weight loss programs'],"['average number of logins', 'average total time spent', 'Engagement and Weight Loss', 'weight loss', 'postpartum weight loss']","[{'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0032804', 'cui_str': 'Postpartum Women'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C3179079', 'cui_str': 'Weight Loss Programs'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0086839', 'cui_str': 'Postpartum Period'}]",,0.0483306,"Internet-based weight loss programs can be effective in promoting weight loss and are less-intensive than traditional face-to-face approaches, which may provide more flexibility for postpartum, low-income women to engage in such programs.","[{'ForeName': 'Julianne M', 'Initials': 'JM', 'LastName': 'Power', 'Affiliation': 'University of North Carolina at Chapel Hill, NC, USA.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Phelan', 'Affiliation': 'California Polytechnic State University, San Luis Obispo, CA, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Hatley', 'Affiliation': 'University of North Carolina at Chapel Hill, NC, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Brannen', 'Affiliation': 'California Polytechnic State University, San Luis Obispo, CA, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Muñoz-Christian', 'Affiliation': 'California Polytechnic State University, San Luis Obispo, CA, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Legato', 'Affiliation': 'California Polytechnic State University, San Luis Obispo, CA, USA.'}, {'ForeName': 'Deborah F', 'Initials': 'DF', 'LastName': 'Tate', 'Affiliation': 'University of North Carolina at Chapel Hill, NC, USA.'}]",Health education & behavior : the official publication of the Society for Public Health Education,['10.1177/1090198119873915'] 951,26702168,Impact of Modafinil Add-on with Atypical Anti-psychotics on Excessive Daytime Drowsiness.,"BACKGROUND Atypical antipsychotic drugs are known to cause many side effects which include daytime drowsiness. So many add on drugs are tried to reduce the same. MATERIALS AND METHODS 72 patients who were on atypical antipsychotic drugs were randomly assigned to either Modafinil or placebo and were followed for a period of 12 weeks. Daytime drowsiness, was taken at baseline, week 3, and at week 12 by using VAS, EDD scales. RESULTS The results were analyzed and showed that the Modafinil add on therapy significantly reduced the daytime Drowsiness. CONCLUSIONS Modafinil could be a potential candidate in selected group of patients to decrease some of the unwanted adverse events like daytime drowsiness produced by atypical antipsychotics.",2015,"The results were analyzed and showed that the Modafinil add on therapy significantly reduced the daytime Drowsiness. ",['72 patients who were on atypical antipsychotic drugs'],"['Modafinil or placebo', 'Modafinil']","['Excessive Daytime Drowsiness', 'daytime Drowsiness', 'Daytime drowsiness']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1276996', 'cui_str': 'Atypical antipsychotic'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}]","[{'cui': 'C0066677', 'cui_str': 'modafinil'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0442802', 'cui_str': 'Excessive (qualifier value)'}, {'cui': 'C0332169', 'cui_str': 'Daytime (qualifier value)'}, {'cui': 'C0013144', 'cui_str': 'Drowsy (finding)'}]",72.0,0.0340113,"The results were analyzed and showed that the Modafinil add on therapy significantly reduced the daytime Drowsiness. ","[{'ForeName': 'P Lakshmi', 'Initials': 'PL', 'LastName': 'Prasuna', 'Affiliation': 'Department of Psychiatry, Sri Venkateswara Medical College, Tirupati, Andhra Pradesh, India.'}, {'ForeName': 'T P', 'Initials': 'TP', 'LastName': 'Sudhakar', 'Affiliation': 'Department of Psychiatry, Sri Venkateswara Medical College, Tirupati, Andhra Pradesh, India.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.168561'] 952,26664080,Correlation Between Personality Traits and Testosterone Concentrations in Healthy Population.,"OBJECTIVE High plasma testosterone levels have been associated with aggression, sexual behaviour and social status. The aim of this paper was to study the correlation between basal plasma testosterone levels and personality variables in healthy participants. MATERIALS AND METHODS Fifty-four participants were randomly enrolled into this study. Basal plasma testosterone levels were measured between 8:30 am and 10 am. After 24 hours of blood drawing, each subject completed personality questionnaires. RESULTS Positive correlation between basal plasma testosterone levels and anti-social personality traits in both genders was observed (r = 0.336 and P < 0.018). Also, a positive correlation was observed between basal plasmatestosterone levels and criminal thinking traits (r = 0. 376, P < 0.05) and Millon compulsive (r = 0.386, P < 0.010) in both genders. In female participants, a positive correlation between basal plasmatestosterone levels and psychoticism (r = 0. 25, P < 0.019) and Cloninger AUTO TCI (r = 0.507, P < 0.004) was observed. In males participants positive correlation between baseline plasmatic Testosterone levels and Millon Antisocial trait (r = 0. 544, P < 0.19) and Millon Hypomania trait (r = 0. 485, P < 0.41) and Millon Drug Abuse trait (r = 0.632, P < 0.05) was reported. CONCLUSION Our results suggest gender differences in clinical and personality variables related with basal plasma testosterone level. In men, high plasma testosterone levels were associated with clinical traits, substance abuse and hypomania. Women with higher basal testosterone levels showed higher scores on personality self-direction traits.",2015,Women with higher basal testosterone levels showed higher scores on personality self-direction traits.,"['Healthy Population', 'Fifty-four participants were randomly enrolled into this study', 'healthy participants']",[],"['Basal plasma testosterone levels', 'Millon Hypomania trait', 'basal plasmatestosterone levels and criminal thinking traits', 'personality self-direction traits', 'Millon compulsive', 'basal plasma testosterone levels and personality variables', 'basal plasma testosterone levels and anti-social personality traits', 'Cloninger AUTO TCI', 'basal plasma testosterone level', 'plasma testosterone levels', 'baseline plasmatic Testosterone levels and Millon Antisocial trait', 'Millon Drug Abuse trait']","[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C4517807', 'cui_str': 'Fifty-four'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]",[],"[{'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C1276039', 'cui_str': 'Plasma testosterone measurement'}, {'cui': 'C0241934', 'cui_str': 'Hypomanic mood (finding)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C2607966', 'cui_str': 'Criminals'}, {'cui': 'C0031208', 'cui_str': 'Personality'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439755', 'cui_str': 'Directions (qualifier value)'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0233849', 'cui_str': 'Personality finding'}, {'cui': 'C0523912', 'cui_str': 'Testosterone measurement (procedure)'}, {'cui': 'C0013146', 'cui_str': 'Drug abuse (disorder)'}]",54.0,0.0600769,Women with higher basal testosterone levels showed higher scores on personality self-direction traits.,"[{'ForeName': 'Kazuhiro', 'Initials': 'K', 'LastName': 'Tajima-Pozo', 'Affiliation': 'Department of Psychiatry, Foundation Alcorcon University Hospital, Madrid, Spain.'}, {'ForeName': 'Camila', 'Initials': 'C', 'LastName': 'Bayón', 'Affiliation': 'Institute of Psychiatry and Mental Health, San Carlos University Hospital, Madrid, Spain.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Díaz-Marsá', 'Affiliation': 'Institute of Psychiatry and Mental Health, San Carlos University Hospital, Madrid, Spain.'}, {'ForeName': 'Jose Luis', 'Initials': 'JL', 'LastName': 'Carrasco', 'Affiliation': 'Institute of Psychiatry and Mental Health, San Carlos University Hospital, Madrid, Spain.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.162956'] 953,31126960,"Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).","PURPOSE Limited options exist for patients with advanced pancreatic cancer progressing after 1 or more lines of therapy. A phase II study in patients with previously treated metastatic pancreatic cancer showed that combining GVAX pancreas (granulocyte-macrophage colony-stimulating factor-secreting allogeneic pancreatic tumor cells) with cyclophosphamide (Cy) and CRS-207 (live, attenuated Listeria monocytogenes expressing mesothelin) resulted in median overall survival (OS) of 6.1 months, which compares favorably with historical OS achieved with chemotherapy. In the current study, we compared Cy/GVAX + CRS-207, CRS-207 alone, and standard chemotherapy in a three-arm, randomized, controlled phase IIb trial. PATIENTS AND METHODS Patients with previously treated metastatic pancreatic adenocarcinoma were randomized 1:1:1 to receive Cy/GVAX + CRS-207 (arm A), CRS-207 (arm B), or physician's choice of single-agent chemotherapy (arm C). The primary cohort included patients who had failed ≥2 prior lines of therapy, including gemcitabine. The primary objective compared OS between arms A and C in the primary cohort. The second-line cohort included patients who had received 1 prior line of therapy. Additional objectives included OS between all treatment arms, safety, and tumor responses. RESULTS The study did not meet its primary efficacy endpoint. At the final study analysis, median OS [95% confidence interval (CI)] in the primary cohort ( N = 213) was 3.7 (2.9-5.3), 5.4 (4.2-6.4), and 4.6 (4.2-5.7) months in arms A, B, and C, respectively, showing no significant difference between arm A and arm C [ P = not significant (NS), HR = 1.17; 95% CI, 0.84-1.64]. The most frequently reported adverse events in all treatment groups were chills, pyrexia, fatigue, and nausea. No treatment-related deaths occurred. CONCLUSIONS The combination of Cy/GVAX + CRS-207 did not improve survival over chemotherapy. (ClinicalTrials.gov ID: NCT02004262) See related commentary by Salas-Benito et al., p. 5435 .",2019,"The most frequently reported adverse events in all treatment groups were chills, pyrexia, fatigue, and nausea.","['patients with advanced pancreatic cancer progressing after 1 or more lines of therapy', 'patients who had failed ≥2 prior lines of therapy, including', 'patients who had received 1 prior line of therapy', 'Patients and Methods: Patients with previously treated metastatic pancreatic adenocarcinoma', 'patients with previously treated metastatic pancreatic cancer', 'Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study']","['gemcitabine', 'cyclophosphamide (Cy) and CRS-207', 'Chemotherapy', 'GVAX Pancreas and CRS-207', 'Cy/GVAX + CRS-207', 'Cy/GVAX + CRS-207, CRS-207 alone, and standard chemotherapy', ""Cy/GVAX + CRS-207 (arm A), CRS-207 (arm B), or physician's choice of single-agent chemotherapy""]","['survival', 'median overall survival (OS', 'adverse events', 'median OS', 'chills, pyrexia, fatigue, and nausea', 'safety, and tumor responses']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0346647', 'cui_str': 'Cancer of Pancreas'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0281361', 'cui_str': 'Adenocarcinoma of pancreas'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}]","[{'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}]",,0.202644,"The most frequently reported adverse events in all treatment groups were chills, pyrexia, fatigue, and nausea.","[{'ForeName': 'Dung T', 'Initials': 'DT', 'LastName': 'Le', 'Affiliation': 'The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. dle@jhmi.edu.'}, {'ForeName': 'Vincent J', 'Initials': 'VJ', 'LastName': 'Picozzi', 'Affiliation': 'Virginia Mason Medical Center, Seattle, Washington.'}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Ko', 'Affiliation': 'University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Zev A', 'Initials': 'ZA', 'LastName': 'Wainberg', 'Affiliation': 'University of California Los Angeles, Los Angeles, California.'}, {'ForeName': 'Hedy', 'Initials': 'H', 'LastName': 'Kindler', 'Affiliation': 'University of Chicago Medical Center, Chicago, Illinois.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Wang-Gillam', 'Affiliation': 'Washington University School of Medicine in St. Louis, St. Louis, Missouri.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Oberstein', 'Affiliation': 'Columbia University Medical Center, New York, New York.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Morse', 'Affiliation': 'Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Herbert J', 'Initials': 'HJ', 'LastName': 'Zeh', 'Affiliation': 'University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Weekes', 'Affiliation': 'University of Colorado Cancer Center, Aurora, Colorado.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Reid', 'Affiliation': 'University of San Diego Moores Cancer Center, La Jolla, California.'}, {'ForeName': 'Erkut', 'Initials': 'E', 'LastName': 'Borazanci', 'Affiliation': 'HonorHealth, Tgen, Scottsdale, Arizona.'}, {'ForeName': 'Todd', 'Initials': 'T', 'LastName': 'Crocenzi', 'Affiliation': 'Providence Cancer Center, Portland, Oregon.'}, {'ForeName': 'Noelle K', 'Initials': 'NK', 'LastName': 'LoConte', 'Affiliation': 'University of Wisconsin Carbone Cancer Center, Madison, Wisconsin.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Musher', 'Affiliation': 'Baylor College of Medicine, Houston, Texas.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Laheru', 'Affiliation': 'The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.'}, {'ForeName': 'Aimee', 'Initials': 'A', 'LastName': 'Murphy', 'Affiliation': 'Aduro Biotech, Berkeley, California.'}, {'ForeName': 'Chan', 'Initials': 'C', 'LastName': 'Whiting', 'Affiliation': 'Aduro Biotech, Berkeley, California.'}, {'ForeName': 'Nitya', 'Initials': 'N', 'LastName': 'Nair', 'Affiliation': 'Aduro Biotech, Berkeley, California.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Enstrom', 'Affiliation': 'Aduro Biotech, Berkeley, California.'}, {'ForeName': 'Sandy', 'Initials': 'S', 'LastName': 'Ferber', 'Affiliation': 'Array Biostatistics, LLC, Chicago, Illinois.'}, {'ForeName': 'Dirk G', 'Initials': 'DG', 'LastName': 'Brockstedt', 'Affiliation': 'Aduro Biotech, Berkeley, California.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Jaffee', 'Affiliation': 'The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-18-2992'] 954,26371358,A Postpartum Community-Based Weight Management Intervention Designed for Low-Income Women: Feasibility and Initial Efficacy Testing.,"Postpartum weight retention increases a woman's risk of entering subsequent pregnancies overweight or obese, and women who are overweight or obese in pregnancy face higher rates of complications for themselves and their infants. This study assessed the feasibility, acceptability, and initial efficacy of an intervention to prevent postpartum weight retention in predominantly low-income African-American women. A randomized control pilot study was conducted to test the effects of the intervention on weight, adiposity, health behaviors, and eating and exercise self-efficacy from baseline (Time 1) to study completion (Time 2). The women in the experimental group had significantly greater decreases in triceps skinfolds (p = 0.01) and subscapular skinfolds (p = 0.04) and had significantly greater nutrition knowledge (p =0.04) than the control group. The results indicate that women randomized to a postpartum weight management program significantly decreased adiposity, increased nutrition knowledge and action, and, in addition, the women found the intervention acceptable.",2015,The women in the experimental group had significantly greater decreases in triceps skinfolds (p = 0.01) and subscapular skinfolds (p = 0.04) and had significantly greater nutrition knowledge (p =0.04) than the control group.,"['Low-Income Women', 'predominantly low-income African-American women']",[],"['postpartum weight retention', 'Postpartum weight retention', 'triceps skinfolds', 'nutrition knowledge', 'weight, adiposity, health behaviors, and eating and exercise self-efficacy', 'feasibility, acceptability, and initial efficacy', 'subscapular skinfolds', 'adiposity, increased nutrition knowledge and action']","[{'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}]",[],"[{'cui': 'C4704811', 'cui_str': 'Postpartum Weight Retention'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C1563743', 'cui_str': 'Adiposis'}, {'cui': 'C0018687'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0441472', 'cui_str': 'Action (qualifier value)'}]",,0.0294224,The women in the experimental group had significantly greater decreases in triceps skinfolds (p = 0.01) and subscapular skinfolds (p = 0.04) and had significantly greater nutrition knowledge (p =0.04) than the control group.,"[{'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Berry', 'Affiliation': ''}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Verbiest', 'Affiliation': ''}, {'ForeName': 'Emily Gail', 'Initials': 'EG', 'LastName': 'Hall', 'Affiliation': ''}, {'ForeName': 'Ida', 'Initials': 'I', 'LastName': 'Dawson', 'Affiliation': ''}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Norton', 'Affiliation': ''}, {'ForeName': 'Shaderika', 'Initials': 'S', 'LastName': 'Willis', 'Affiliation': ''}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'McDonald', 'Affiliation': ''}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Stuebe', 'Affiliation': ''}]",Journal of National Black Nurses' Association : JNBNA,[] 955,26405104,Agreement between novice and experienced trachoma graders improves after a single day of didactic training.,"BACKGROUND/AIMS Prevalence estimates and treatment decisions for trachoma are based entirely on ocular clinical examination. The aim of the current study is to demonstrate that ophthalmic assistants can be trained and certified to provide trachoma grading within a single day. METHODS Conjunctival photographs from an area with endemic trachoma were randomised into two sets of 60 cases. Photographs were graded for trachomatous inflammation-follicular (TF) and trachomatous inflammation-intense (TI) by three experienced graders. Inter-rater reliability of eight ophthalmic assistants and three experienced graders were compared before and after training. RESULTS The mean κ agreement between the ophthalmic assistants and the consensus grades of the experienced graders for TF was 0.38 (95% CI 0.18 to 0.58) before training, and increased to 0.60 (95% CI 0.42 to 0.78) after training (p=0.07). The mean κ agreement for TI was 0.16 (95% CI 0.02 to 0.30) before training, and increased to 0.39 (95% CI 0.20 to 0.58) after training (p=0.02). CONCLUSION A single day of training improves agreement between prospective and experienced trachoma graders, and provides the basis for certification of workers who are able to accurately grade trachoma and generate reliable prevalence estimates.",2016,Photographs were graded for trachomatous inflammation-follicular (TF) and trachomatous inflammation-intense (TI) by three experienced graders.,['Conjunctival photographs from an area with endemic trachoma'],[],"['mean κ agreement', 'trachomatous inflammation-follicular (TF) and trachomatous inflammation-intense (TI', 'mean κ agreement for TI']","[{'cui': 'C0441468', 'cui_str': 'Photograph (physical object)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0243130', 'cui_str': 'endemics'}, {'cui': 'C0040592', 'cui_str': 'Egyptian Ophthalmia'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0439682', 'cui_str': 'Follicular (qualifier value)'}]",,0.0426889,Photographs were graded for trachomatous inflammation-follicular (TF) and trachomatous inflammation-intense (TI) by three experienced graders.,"[{'ForeName': 'Bidya P', 'Initials': 'BP', 'LastName': 'Prasad', 'Affiliation': 'Geta Eye Hospital, Geta, Dhangadhi, Nepal.'}, {'ForeName': 'Ramesh C', 'Initials': 'RC', 'LastName': 'Bhatta', 'Affiliation': 'Geta Eye Hospital, Geta, Dhangadhi, Nepal.'}, {'ForeName': 'Jsp', 'Initials': 'J', 'LastName': 'Chaudhary', 'Affiliation': 'Geta Eye Hospital, Geta, Dhangadhi, Nepal.'}, {'ForeName': 'Shekhar', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'National Trachoma Program, Nepal Netra Jyoti Sangh, Tripureswor, Kathmandu, Nepal.'}, {'ForeName': 'Sailesh', 'Initials': 'S', 'LastName': 'Mishra', 'Affiliation': 'National Trachoma Program, Nepal Netra Jyoti Sangh, Tripureswor, Kathmandu, Nepal.'}, {'ForeName': 'Puja A', 'Initials': 'PA', 'LastName': 'Cuddapah', 'Affiliation': 'F.I. Proctor Foundation, University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Nicole E', 'Initials': 'NE', 'LastName': 'Stoller', 'Affiliation': 'F.I. Proctor Foundation, University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Sun N', 'Initials': 'SN', 'LastName': 'Yu', 'Affiliation': 'F.I. Proctor Foundation, University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Salman A', 'Initials': 'SA', 'LastName': 'Rahman', 'Affiliation': 'F.I. Proctor Foundation, University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Deiner', 'Affiliation': 'Department of Ophthalmology, University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Jeremy D', 'Initials': 'JD', 'LastName': 'Keenan', 'Affiliation': 'F.I. Proctor Foundation, University of California San Francisco, San Francisco, California, USA Department of Ophthalmology, University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Bruce D', 'Initials': 'BD', 'LastName': 'Gaynor', 'Affiliation': 'F.I. Proctor Foundation, University of California San Francisco, San Francisco, California, USA Department of Ophthalmology, University of California San Francisco, San Francisco, California, USA.'}]",The British journal of ophthalmology,['10.1136/bjophthalmol-2015-307224'] 956,32419143,"Comment on ""Clinical pathway for enhanced recovery after surgery for gastric cancer: A prospective single-center phase II clinical trial for safety and efficacy"".",,2020,,['gastric cancer'],[],[],"[{'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}]",[],[],,0.0111715,,"[{'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Hu', 'Affiliation': 'Department of General Surgery, Tongde Hospital of Zhejiang Province, Hangzhou, China.'}, {'ForeName': 'Xiyin', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of Traditional Chinese Medicine, Community Health Service Center of Guali Town of Xiaoshan, Hangzhou, China.'}]",Journal of surgical oncology,['10.1002/jso.25954'] 957,26580240,"Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial.","CONTEXT Sildenafil increases insulin sensitivity in mice. In humans, phosphodiesterase 5 inhibition improves disposition index, but the mechanism of this effect has not been elucidated and may depend on duration. In addition, increasing cyclic GMP without increasing nitric oxide could have beneficial effects on fibrinolytic balance. OBJECTIVE The objective was to test the hypothesis that chronic phosphodiesterase 5 inhibition with sildenafil improves insulin sensitivity and secretion without diminishing fibrinolytic function. DESIGN This was a randomized, double-blind, placebo-controlled study. SETTING This trial was conducted at Vanderbilt Clinical Research Center. PARTICIPANTS Participants included overweight individuals with prediabetes. INTERVENTIONS Subjects were randomized to treatment with sildenafil 25 mg three times a day or matching placebo for 3 months. Subjects underwent a hyperglycemic clamp prior to and at the end of treatment. MAIN OUTCOME MEASURES The primary outcomes of the study were insulin sensitivity and glucose-stimulated insulin secretion. RESULT Twenty-one subjects completed each treatment arm. After 3 months, the insulin sensitivity index was significantly greater in the sildenafil group compared to the placebo group by 1.84 mg/kg/min per μU/mL*100 (95% confidence interval, 0.01 to 3.67 mg/kg/min per μU/mL*100; P = .049), after adjusting for baseline insulin sensitivity index and body mass index. In contrast, there was no effect of 3-month treatment with sildenafil on acute- or late-phase glucose-stimulated insulin secretion (P > .30). Sildenafil decreased plasminogen activator inhibitor-1 (P = .01), without altering tissue-plasminogen activator. In contrast to placebo, sildenafil also decreased the urine albumin-to-creatinine ratio from 12.67 ± 14.67 to 6.84 ± 4.86 μg/mg Cr. This effect persisted 3 months after sildenafil discontinuation. CONCLUSIONS Three-month phosphodiesterase 5 inhibition enhances insulin sensitivity and improves markers of endothelial function.",2015,Sildenafil decreased plasminogen activator inhibitor-1,"['mice', 'Participants included overweight individuals with prediabetes', 'Prediabetes']","['placebo', 'hyperglycemic clamp', 'sildenafil', 'placebo, sildenafil', 'sildenafil 25 mg three times a day or matching placebo', 'Sildenafil']","['plasminogen activator inhibitor-1', 'Insulin Sensitivity', 'acute- or late-phase glucose-stimulated insulin secretion', 'insulin sensitivity and glucose-stimulated insulin secretion', 'disposition index', 'insulin sensitivity and improves markers of endothelial function', 'urine albumin-to-creatinine ratio', 'insulin sensitivity index', 'insulin sensitivity']","[{'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0362046', 'cui_str': 'Prediabetes'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C0529793', 'cui_str': 'sildenafil'}, {'cui': 'C0812795', 'cui_str': 'sildenafil 25 MG'}, {'cui': 'C0556984', 'cui_str': 'Three times daily (qualifier value)'}]","[{'cui': 'C0030190', 'cui_str': 'SERPINE1 Protein'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C1256369', 'cui_str': 'Insulin Secretion'}, {'cui': 'C0743223', 'cui_str': 'Disposition (disposition)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0042037'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",21.0,0.700158,Sildenafil decreased plasminogen activator inhibitor-1,"[{'ForeName': 'Claudia E', 'Initials': 'CE', 'LastName': 'Ramirez', 'Affiliation': 'Departments of Medicine (C.E.R., J.L.G., J.M.L., N.J.B., C.A.S.) and Biostatistics (H.N., C.Y.), Vanderbilt University School of Medicine, Nashville, Tennessee 37232.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Nian', 'Affiliation': 'Departments of Medicine (C.E.R., J.L.G., J.M.L., N.J.B., C.A.S.) and Biostatistics (H.N., C.Y.), Vanderbilt University School of Medicine, Nashville, Tennessee 37232.'}, {'ForeName': 'Chang', 'Initials': 'C', 'LastName': 'Yu', 'Affiliation': 'Departments of Medicine (C.E.R., J.L.G., J.M.L., N.J.B., C.A.S.) and Biostatistics (H.N., C.Y.), Vanderbilt University School of Medicine, Nashville, Tennessee 37232.'}, {'ForeName': 'Jorge L', 'Initials': 'JL', 'LastName': 'Gamboa', 'Affiliation': 'Departments of Medicine (C.E.R., J.L.G., J.M.L., N.J.B., C.A.S.) and Biostatistics (H.N., C.Y.), Vanderbilt University School of Medicine, Nashville, Tennessee 37232.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Luther', 'Affiliation': 'Departments of Medicine (C.E.R., J.L.G., J.M.L., N.J.B., C.A.S.) and Biostatistics (H.N., C.Y.), Vanderbilt University School of Medicine, Nashville, Tennessee 37232.'}, {'ForeName': 'Nancy J', 'Initials': 'NJ', 'LastName': 'Brown', 'Affiliation': 'Departments of Medicine (C.E.R., J.L.G., J.M.L., N.J.B., C.A.S.) and Biostatistics (H.N., C.Y.), Vanderbilt University School of Medicine, Nashville, Tennessee 37232.'}, {'ForeName': 'Cyndya A', 'Initials': 'CA', 'LastName': 'Shibao', 'Affiliation': 'Departments of Medicine (C.E.R., J.L.G., J.M.L., N.J.B., C.A.S.) and Biostatistics (H.N., C.Y.), Vanderbilt University School of Medicine, Nashville, Tennessee 37232.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/jc.2015-3415'] 958,32041913,"A Double-blind, Randomized Controlled Trial of Ciplukan (Physalis angulata Linn) Extract on Skin Fibrosis, Inflammatory, Immunology, and Fibrosis Biomarkers in Scleroderma Patients.","BACKGROUND scleroderma is an autoimmune disease characterized by organ fibrosis, resistant to standard treatment. It is suspected the addition of Physalis angulata Linn. (Ciplukan) extract as adjuvant therapy can improve the scleroderma skin fibrosis. The aim at this study is to evaluate the effect of ciplukan extract as adjuvant on scleroderma skin fibrosis in standard therapy, based on modified Rodnan skin scale (MRSS), inflammatory biomarkers, immunology and serum fibrosis. METHODS double-blind, randomized clinical trial was performed in scleroderma patients with stable disease at Cipto Mangunkusumo hospital and Hasan Sadikin hospital during November 2015-March 2017 who met the selection criteria and continued to receive standard therapy. The subjects were randomly allocated into two groups: the study group received the ciplukan  extract 3 x 250 mg / day for 12 weeks and the placebo group. Examination of MRSS, ESR, P1NP, BAFF and sCD40L was performed every 4 weeks until the end of the study. RESULTS fifty-nine subjects completed the study. They consisted of 29 subjects of the treatment group and 30 of the placebo group, with an average age of 41 (SD 9) years, the proportion of women: male = 9 : 1. There was a significant improvement of skin fibrosis in the study group with a highly significant decrease in MRSS (35.9% VS 6.3%, p <0.001) and a relative decrease in P1NP levels (17.8% VS 0.7%, p = 0.002). No decrease in ESR, BAFF and sCD40L levels in both groups. There was a weak but significant positive correlation between MRSS with P1NP levels (r = 0.236, p = 0.036). CONCLUSION Ciplukan extract with dose 3 x 250 mg for 12 weeks as adjuvant on scleroderma standard therapy alleviates skin fibrosis significantly based on MRSS and P1NP levels.",2019,"No decrease in ESR, BAFF and sCD40L levels in both groups.","['scleroderma patients with stable disease at Cipto Mangunkusumo hospital and Hasan Sadikin hospital during November 2015-March 2017 who met the selection criteria and continued to receive standard therapy', 'Scleroderma Patients', 'fifty-nine subjects completed the study', 'group, with an average age of 41 (SD 9) years, the proportion of women: male = 9 : 1']","['Ciplukan (Physalis angulata Linn) Extract', 'ciplukan extract', 'placebo', 'Ciplukan extract', 'ciplukan\xa0 extract']","['scleroderma skin fibrosis', 'modified Rodnan skin scale (MRSS), inflammatory biomarkers, immunology and serum fibrosis', 'Skin Fibrosis, Inflammatory, Immunology, and Fibrosis Biomarkers', 'MRSS with P1NP levels', 'P1NP levels', 'skin fibrosis', 'Examination of MRSS, ESR, P1NP, BAFF and sCD40L', 'ESR, BAFF and sCD40L levels', 'MRSS']","[{'cui': 'C0011644', 'cui_str': 'Dermatosclerosis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0242801', 'cui_str': 'Selection Criteria'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C3830128', 'cui_str': '59 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0331244', 'cui_str': 'Physalis'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0011644', 'cui_str': 'Dermatosclerosis'}, {'cui': 'C0263008', 'cui_str': 'Fibrosis of the skin (disorder)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0222045'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0152036', 'cui_str': 'Immunology'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}]",,0.113681,"No decrease in ESR, BAFF and sCD40L levels in both groups.","[{'ForeName': 'Sumartini', 'Initials': 'S', 'LastName': 'Dewi', 'Affiliation': 'Department of Internal Medicine, Faculty of Medicine, Padjadjaran University - Hasan Sadikin Hospital, Bandung, Indonesia. sppd_dewi@yahoo.co.id.'}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'Isbagio', 'Affiliation': ''}, {'ForeName': 'Erni Hernawati', 'Initials': 'EH', 'LastName': 'Purwaningsih', 'Affiliation': ''}, {'ForeName': 'Nyoman', 'Initials': 'N', 'LastName': 'Kertia', 'Affiliation': ''}, {'ForeName': 'Rianto', 'Initials': 'R', 'LastName': 'Setiabudy', 'Affiliation': ''}, {'ForeName': 'Siti', 'Initials': 'S', 'LastName': 'Setiati', 'Affiliation': ''}]",Acta medica Indonesiana,[] 959,30883291,Catecholamine Modulation of Evidence Accumulation during Perceptual Decision Formation: A Randomized Trial.,"Recent behavioral modeling and pupillometry studies suggest that neuromodulatory arousal systems play a role in regulating decision formation but neurophysiological support for these observations is lacking. We employed a randomized, double-blinded, placebo-controlled, crossover design to probe the impact of pharmacological enhancement of catecholamine levels on perceptual decision-making. Catecholamine levels were manipulated using the clinically relevant drugs methylphenidate and atomoxetine, and their effects were compared with those of citalopram and placebo. Participants performed a classic EEG oddball paradigm that elicits the P3b, a centro-parietal potential that has been shown to trace evidence accumulation, under each of the four drug conditions. We found that methylphenidate and atomoxetine administration shortened RTs to the oddball targets. The neural basis of this behavioral effect was an earlier P3b peak latency, driven specifically by an increase in its buildup rate without any change in its time of onset or peak amplitude. This study provides neurophysiological evidence for the catecholaminergic enhancement of a discrete aspect of human decision-making, that is, evidence accumulation. Our results also support theoretical accounts suggesting that catecholamines may enhance cognition via increases in neural gain.",2019,We found that methylphenidate and atomoxetine administration shortened RTs to the oddball targets.,[],"['atomoxetine', 'citalopram and placebo', 'placebo', 'methylphenidate and atomoxetine']",['Catecholamine levels'],[],"[{'cui': 'C0076823', 'cui_str': 'atomoxetine'}, {'cui': 'C0008845', 'cui_str': 'Citalopram'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0025810', 'cui_str': 'Methylphenidate'}]","[{'cui': 'C0546632', 'cui_str': 'Catecholamine measurement (procedure)'}]",,0.510939,We found that methylphenidate and atomoxetine administration shortened RTs to the oddball targets.,"[{'ForeName': 'Gerard M', 'Initials': 'GM', 'LastName': 'Loughnane', 'Affiliation': 'Trinity College, University of Dublin.'}, {'ForeName': 'Méadhbh B', 'Initials': 'MB', 'LastName': 'Brosnan', 'Affiliation': 'Monash University.'}, {'ForeName': 'Jessica J M', 'Initials': 'JJM', 'LastName': 'Barnes', 'Affiliation': 'University of Queensland.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Dean', 'Affiliation': 'University of Queensland.'}, {'ForeName': 'Sanjay L', 'Initials': 'SL', 'LastName': 'Nandam', 'Affiliation': 'Monash University.'}, {'ForeName': 'Redmond G', 'Initials': 'RG', 'LastName': ""O'Connell"", 'Affiliation': 'Trinity College, University of Dublin.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Bellgrove', 'Affiliation': 'Trinity College, University of Dublin.'}]",Journal of cognitive neuroscience,['10.1162/jocn_a_01393'] 960,31559634,FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.,"OBJECTIVE To compare effectiveness of onabotulinumtoxinA and topiramate for chronic migraine (CM) prevention. BACKGROUND The efficacy* of onabotulinumtoxinA and topiramate has been established in placebo-controlled randomized clinical trials (*defined as the benefit of treatment under ideal conditions). The effectiveness* of the 2 preventive treatments, however, has not been established (*the benefit of treatment under real-world conditions, representing a blend of efficacy and tolerability). METHODS In this multicenter, randomized, parallel-group, post-authorization, open-label prospective study (FORWARD; ClinicalTrials.gov, NCT02191579), we randomized adults with CM (1:1) to onabotulinumtoxinA 155 U every 12 weeks for 3 cycles or topiramate ""immediate release"" 50-100 mg/day to week 36. Primary outcome measure was proportion of patients achieving ≥50% reduction in headache days (weeks 29-32). Missing values were imputed using baseline observation carried forward (BOCF) methodology. After 12 weeks, patients initially randomized to topiramate could cross over to onabotulinumtoxinA treatment. We monitored and recorded all adverse events (AEs). RESULTS We enrolled 282 patients (onabotulinumtoxinA, n = 140; topiramate, n = 142) and 148 patients completed randomized treatment (onabotulinumtoxinA, n = 120 [86%]; topiramate, n = 28 [20%]). Primary reasons for withdrawal were ineffective treatment (onabotulinumtoxinA, n = 7 [5%]; topiramate, n = 27 [19%]) and AEs (onabotulinumtoxinA, n = 5 [4%]; topiramate, n = 72 [51%]). Eighty topiramate patients crossed over to onabotulinumtoxinA. In the BOCF analysis, a significantly higher proportion of patients randomized to onabotulinumtoxinA experienced ≥50% reduction in headache frequency compared with those randomized to topiramate (40% [56/140] vs 12% [17/142], respectively; adjusted OR, 4.9 [95% CI, 2.7-9.1]; P < .001). OnabotulinumtoxinA was superior to topiramate in meeting secondary endpoints. In a post hoc analysis using observed data, the 50% responder rates at week 12 were 45.6% for onabotulinumtoxinA (n = 125) and 29.4% for topiramate (n = 109) (P = .015). AEs were reported by 48% (105/220) of onabotulinumtoxinA and 79% (112/142) of topiramate patients. Results were similar in those who crossed over to onabotulinumtoxinA. CONCLUSIONS While using imputation methods of accounting for differences in discontinuation rates, we found onabotulinumtoxinA to have greater clinical utility than topiramate, largely because of tolerability issues associated with the latter and a relatively higher number of onabotulinumtoxinA patients remaining on treatment.",2019,AEs were reported by 48% (105/220) of onabotulinumtoxinA and 79% (112/142) of topiramate patients.,"['282 patients (onabotulinumtoxinA, n\xa0=\xa0140; topiramate, n\xa0=\xa0142) and 148 patients completed', 'Eighty topiramate patients crossed over to onabotulinumtoxinA', 'Adults With Chronic Migraine']","['OnabotulinumtoxinA and Topiramate', 'topiramate', 'OnabotulinumtoxinA', 'placebo', 'onabotulinumtoxinA', 'topiramate ""immediate release"" 50-100\xa0mg/day to week 36', 'onabotulinumtoxinA and topiramate', 'randomized treatment (onabotulinumtoxinA']","['adverse events (AEs', 'proportion of patients achieving ≥50% reduction in headache days', 'headache frequency']","[{'cui': 'C4517681', 'cui_str': '282'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2719767', 'cui_str': 'onabotulinumtoxinA'}, {'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C0076829', 'cui_str': 'topiramate'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0010366', 'cui_str': 'Crossing Over, Genetic'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1960870', 'cui_str': 'Chronic migraine'}]","[{'cui': 'C2719767', 'cui_str': 'onabotulinumtoxinA'}, {'cui': 'C0076829', 'cui_str': 'topiramate'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]",282.0,0.146814,AEs were reported by 48% (105/220) of onabotulinumtoxinA and 79% (112/142) of topiramate patients.,"[{'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'Rothrock', 'Affiliation': 'Department of Neurology, George Washington University School of Medicine, Washington, DC, USA.'}, {'ForeName': 'Aubrey Manack', 'Initials': 'AM', 'LastName': 'Adams', 'Affiliation': 'Global Medical Affairs, Allergan plc, Irvine, CA, USA.'}, {'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Lipton', 'Affiliation': 'Department of Neurology, Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Stephen D', 'Initials': 'SD', 'LastName': 'Silberstein', 'Affiliation': 'Department of Neurology, Jefferson Headache Center, Philadelphia, PA, USA.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Jo', 'Affiliation': 'Global Medical Affairs, Allergan plc, Irvine, CA, USA.'}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'Department of Statistics, Pharmaceutical Product Development, Austin, TX, USA.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Blumenfeld', 'Affiliation': 'Department of Neurology, Headache Center of Southern California, The Neurology Center, Carlsbad, CA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Headache,['10.1111/head.13653'] 961,30597541,"The ""me too"" decision: An analog study of therapist self-disclosure of psychological problems.","OBJECTIVES To test the exploratory hypothesis that client perceptions of therapists are most favorable when therapists self-disclose their own personal experience with the same psychological problem to a moderate (vs. none, mild, or extreme) extent. METHOD Undergraduate participants (N = 104; 63.5% female) were randomly assigned to read one of the four vignettes, which differed only in the extent to which the therapist disclosed their own personal experience with the same presenting problem (none, mild, moderate, or extreme). Participants then responded to questions assessing their perceptions of the therapist. RESULTS The data generally supported the hypothesis. The moderate disclosure condition yielded the most favorable client perceptions, which differed significantly from those yielded by the no disclosure condition. CONCLUSIONS Despite limitations and need for replication, this study provides perhaps the first empirical data regarding the effect of the extent, rather than the mere presence or absence, of therapist self-disclosure regarding personal psychological experiences.",2019,"The moderate disclosure condition yielded the most favorable client perceptions, which differed significantly from those yielded by the no disclosure condition. ",['Undergraduate participants (N\u2009=\u2009104; 63.5% female'],[],[],"[{'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0086287', 'cui_str': 'Females'}]",[],[],,0.019302,"The moderate disclosure condition yielded the most favorable client perceptions, which differed significantly from those yielded by the no disclosure condition. ","[{'ForeName': 'Rebecca W', 'Initials': 'RW', 'LastName': 'McCormic', 'Affiliation': 'Department of Psychology, Southern Illinois University Edwardsville, Edwardsville, Illinois.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Pomerantz', 'Affiliation': 'Department of Psychology, Southern Illinois University Edwardsville, Edwardsville, Illinois.'}, {'ForeName': 'Eunyoe', 'Initials': 'E', 'LastName': 'Ro', 'Affiliation': 'Department of Psychology, Southern Illinois University Edwardsville, Edwardsville, Illinois.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Segrist', 'Affiliation': 'Department of Psychology, Southern Illinois University Edwardsville, Edwardsville, Illinois.'}]",Journal of clinical psychology,['10.1002/jclp.22736'] 962,31454851,Pharmacological prophylaxis versus pancreatic duct stenting plus pharmacological prophylaxis for prevention of post-ERCP pancreatitis in high risk patients: a randomized trial.,"BACKGROUND Acute pancreatitis is a serious complication of endoscopic retrograde cholangiopancreatography (ERCP). The aim of this noninferiority study was to evaluate the effectiveness of pancreatic duct (PD) stenting plus pharmacological prophylaxis vs. pharmacological prophylaxis alone in the prevention of post-ERCP pancreatitis (PEP) in high risk patients. METHODS In this randomized, controlled, double-blind, noninferiority trial, patients at high risk of developing PEP were randomly allocated to pharmacological prophylaxis (rectal indomethacin, sublingual isosorbide dinitrate, and intravenous hydration with Ringer's lactate) plus PD stenting (group A) or pharmacological prophylaxis alone (group B). The rate and severity of PEP, serum amylase levels, and length of hospital stay after ERCP were assessed. RESULTS During 21 months, a total of 414 patients (mean age 55.5 ± 17.0 years; 60.2 % female) were enrolled (207 in each group). PEP occurred in 59 patients (14.3 %, 95 % confidence interval [CI] 11.1 % - 17.9 %: 26 patients [12.6 %, 95 %CI 8.6 % - 17.6 %] in group A and 33 [15.9 %, 95 %CI 11.4 % - 21.4 %] in group B). There was no significant difference between the two groups in PEP severity ( P  = 0.59), amylase levels after 2 hours ( P  = 0.31) or 24 hours ( P  = 0.08), and length of hospital stay ( P  = 0.07). CONCLUSIONS The study failed to demonstrate noninferiority or inferiority of pharmacological prophylaxis alone compared with PD stenting plus pharmacological prophylaxis in the prevention of PEP in high risk patients.",2019,"There was no significant difference between the two groups in PEP severity ( P  = 0.59), amylase levels after 2 hours ( P  = 0.31) or 24 hours ( P  = 0.08), and length of hospital stay ( P  = 0.07). ","['high risk patients', 'patients at high risk of developing PEP', '414 patients (mean age 55.5\u200a±\u200a17.0 years; 60.2\u200a% female) were enrolled (207 in each group']","['Pharmacological prophylaxis versus pancreatic duct stenting plus pharmacological prophylaxis', 'endoscopic retrograde cholangiopancreatography (ERCP', 'pancreatic duct (PD) stenting plus pharmacological prophylaxis vs. pharmacological prophylaxis alone', ""pharmacological prophylaxis (rectal indomethacin, sublingual isosorbide dinitrate, and intravenous hydration with Ringer's lactate) plus PD stenting (group A) or pharmacological prophylaxis alone"", 'PD stenting plus pharmacological prophylaxis']","['length of hospital stay', 'rate and severity of PEP, serum amylase levels, and length of hospital stay after ERCP', 'amylase levels', 'PEP severity', 'PEP']","[{'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0359587', 'cui_str': 'Peptamen'}, {'cui': 'C4517771', 'cui_str': 'Four hundred and fourteen'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0205464', 'cui_str': 'Pharmacologic (qualifier value)'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}, {'cui': 'C0030288', 'cui_str': 'Pancreatic duct structure (body structure)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0008310', 'cui_str': 'ERCP'}, {'cui': 'C0205052', 'cui_str': 'Rectal (qualifier value)'}, {'cui': 'C0021246', 'cui_str': 'Indomethacin'}, {'cui': 'C4521982', 'cui_str': 'Sublingual'}, {'cui': 'C0022252', 'cui_str': 'Isosorbide Dinitrate'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C1321013', 'cui_str': 'Hydration'}, {'cui': 'C0073385', 'cui_str': ""Hartmann's Solution""}, {'cui': 'C0441835', 'cui_str': 'Group A (qualifier value)'}]","[{'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0359587', 'cui_str': 'Peptamen'}, {'cui': 'C0428349', 'cui_str': 'Serum amylase (pancreatic) measurement'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0008310', 'cui_str': 'ERCP'}, {'cui': 'C0201883', 'cui_str': 'Amylase measurement (procedure)'}]",414.0,0.140876,"There was no significant difference between the two groups in PEP severity ( P  = 0.59), amylase levels after 2 hours ( P  = 0.31) or 24 hours ( P  = 0.08), and length of hospital stay ( P  = 0.07). ","[{'ForeName': 'Rasoul', 'Initials': 'R', 'LastName': 'Sotoudehmanesh', 'Affiliation': 'Liver and Pancreaticobiliary Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ali-Asgari', 'Affiliation': 'Liver and Pancreaticobiliary Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Morteza', 'Initials': 'M', 'LastName': 'Khatibian', 'Affiliation': 'Liver and Pancreaticobiliary Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Mohamadnejad', 'Affiliation': 'Liver and Pancreaticobiliary Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Shahin', 'Initials': 'S', 'LastName': 'Merat', 'Affiliation': 'Liver and Pancreaticobiliary Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Anahita', 'Initials': 'A', 'LastName': 'Sadeghi', 'Affiliation': 'Liver and Pancreaticobiliary Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Keshtkar', 'Affiliation': 'Department of Health Science Educational Development, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Bagheri', 'Affiliation': 'Liver and Pancreaticobiliary Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Delavari', 'Affiliation': 'Liver and Pancreaticobiliary Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Amani', 'Affiliation': 'Liver and Pancreaticobiliary Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Homayoon', 'Initials': 'H', 'LastName': 'Vahedi', 'Affiliation': 'Liver and Pancreaticobiliary Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Siavosh', 'Initials': 'S', 'LastName': 'Nasseri-Moghaddam', 'Affiliation': 'Liver and Pancreaticobiliary Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Sima', 'Affiliation': 'Liver and Pancreaticobiliary Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohamad A', 'Initials': 'MA', 'LastName': 'Eloubeidi', 'Affiliation': 'Anniston Digestive Health, Anniston, Alabama, United States.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Malekzadeh', 'Affiliation': 'Liver and Pancreaticobiliary Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}]",Endoscopy,['10.1055/a-0977-3119'] 963,1730487,Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers.,"Three attenuated Salmonella typhi strains have been constructed by introducing deletions in aroC and aroD or deletions in cya and crp into one of two wild-type parent strains, Ty2 or ISP1820. These mutant strains were designated CVD 906 (ISP1820 delta aroC delta aroD), CVD 908 (Ty2 delta aroC delta aroD), and chi 3927 (Ty2 delta cya delta crp). Two studies were conducted with 36 healthy adult inpatient volunteers to determine in a double-blind fashion the safety and immunogenicity of approximately 5 x 10(4) and 5 x 10(5) CFU of each of these three vaccine candidates given as a single dose. No statistically significant difference in the incidence of reactions among vaccinees was observed. Fever (oral temperature greater than or equal to 38.2 degrees C) occurred in 2 of 12 volunteers who received CVD 906, in 0 of 12 who received CVD 908, and in 1 of 12 who received chi 3927. Vaccine bacteremia without symptoms occurred in 1 of 12 vaccinees who received CVD 906, in 0 of 12 who received CVD 908, and in 2 of 12 who received chi 3927. Overall, 19 (53%) of 36 vaccinees developed immunoglobulin G antibody to S. typhi lipopolysaccharide after vaccination, with no statistically significant differences in the rate of seroconversion among volunteers in the three groups. We conclude that defined mutations in the aromatic biosynthetic pathway and in the cyclic AMP global regulatory system attenuate S. typhi. Mutant strains CVD 906, CVD 908, and chi 3927 are highly (and approximately equally) immunogenic but possibly differ in their propensity to induce fever. Further studies are needed to document the apparent relative safety of CVD 908 as a typhoid vaccine and as a vaccine carrier of foreign antigens.",1992,"Overall, 19 (53%) of 36 vaccinees developed immunoglobulin G antibody to S. typhi lipopolysaccharide after vaccination, with no statistically significant differences in the rate of seroconversion among volunteers in the three groups.","['of approximately 5 x 10(4) and 5 x 10(5', '36 healthy adult inpatient volunteers', 'adult volunteers']",['delta aroC delta aroD and delta cya delta crp'],"['immunoglobulin G antibody', 'Fever (oral temperature', 'Vaccine bacteremia without symptoms', 'safety and immunogenicity', 'rate of seroconversion', 'incidence of reactions']","[{'cui': 'C0332232', 'cui_str': 'Approximate (qualifier value)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0439097', 'cui_str': 'Delta'}]","[{'cui': 'C1292065', 'cui_str': 'Antibody, immunoglobulin G class'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C1532216', 'cui_str': 'Oral temperature'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}]",36.0,0.102989,"Overall, 19 (53%) of 36 vaccinees developed immunoglobulin G antibody to S. typhi lipopolysaccharide after vaccination, with no statistically significant differences in the rate of seroconversion among volunteers in the three groups.","[{'ForeName': 'C O', 'Initials': 'CO', 'LastName': 'Tacket', 'Affiliation': 'Department of Medicine, University of Maryland School of Medicine, Baltimore 21201.'}, {'ForeName': 'D M', 'Initials': 'DM', 'LastName': 'Hone', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Curtiss', 'Affiliation': ''}, {'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Kelly', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Losonsky', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Guers', 'Affiliation': ''}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Harris', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Edelman', 'Affiliation': ''}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Levine', 'Affiliation': ''}]",Infection and immunity,[] 964,32418922,A breathing movement sensor for chest radiography during inspiration in children aged less than 3 years: a prospective randomized controlled study.,"Chest radiographs should be obtained at the peak of inspiration so that radiological findings can be precisely interpreted. However, this is not easily achieved, particularly in young children who do not follow the instruction to hold their breath. We developed a sensor that detects the breathing movements and conducted a randomized controlled study to determine whether the sensor would increase the proportion of chest radiographs obtained in the inspiration phase. We recruited 124 infants and children aged less than 3 years, who visited the pediatric department of a general hospital in Tokyo, Japan, and allocated them into one of two groups: with-sensor and without-sensor groups. Overall, 81% of all images were obtained during inspiration. The proportion of chest radiographs taken during inspiration was not statistically different between the two groups (81% vs. 82%). In the with-sensor group, radiologic technologists were able to obtain chest radiographs of the same quality while not observing the chest movement, but the sensor. The use of the sensor did not increase the proportion of chest radiographs taken in the inspiration phase in this study. However, this null result may indicate the possibility of utilizing the sensor for automatizing chest radiography in the future.",2020,The proportion of chest radiographs taken during inspiration was not statistically different between the two groups (81% vs. 82%).,"['young children', '124 infants and children aged less than 3 years, who visited the pediatric department of a general hospital in Tokyo, Japan, and allocated them into one of two groups: with-sensor and without-sensor groups', 'children aged less than 3 years']",[],"['proportion of chest radiographs taken during inspiration', 'proportion of chest radiographs']","[{'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0587482', 'cui_str': 'Pediatric department'}, {'cui': 'C0020008', 'cui_str': 'Hospitals, General'}, {'cui': 'C0040371', 'cui_str': 'Tokyo'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",[],"[{'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C1306645', 'cui_str': 'Plain radiography'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}]",124.0,0.0201476,The proportion of chest radiographs taken during inspiration was not statistically different between the two groups (81% vs. 82%).,"[{'ForeName': 'Mari', 'Initials': 'M', 'LastName': 'Honda', 'Affiliation': 'Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'ForeName': 'Rei', 'Initials': 'R', 'LastName': 'Haruyama', 'Affiliation': 'Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Sugiura', 'Affiliation': 'Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'ForeName': 'Kaori', 'Initials': 'K', 'LastName': 'Ohara', 'Affiliation': 'Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'ForeName': 'Kazuya', 'Initials': 'K', 'LastName': 'Mochigi', 'Affiliation': 'Department of Radiological Physics and Technology, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'ForeName': 'Yuzuru', 'Initials': 'Y', 'LastName': 'Kono', 'Affiliation': 'Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Shichino', 'Affiliation': 'Department of Pediatrics, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'ForeName': 'Hideko', 'Initials': 'H', 'LastName': 'Uryu', 'Affiliation': 'Department of Pediatrics, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Mizoue', 'Affiliation': 'Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'ForeName': 'Terumi', 'Initials': 'T', 'LastName': 'Marutani', 'Affiliation': 'Department of Clinical Trial Management, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Ebihara', 'Affiliation': 'Department of Clinical Trial Management, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'ForeName': 'Fumiya', 'Initials': 'F', 'LastName': 'Uchiyama', 'Affiliation': 'Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Makise', 'Affiliation': 'Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'ForeName': 'Hidechika', 'Initials': 'H', 'LastName': 'Akashi', 'Affiliation': 'Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.'}]",Bioscience trends,['10.5582/bst.2020.03024'] 965,26371354,The Impact of STORY on Depression and Fatigue in African-American Women with Breast Cancer.,"The intervention Sisters Tell Others and Revive Yourself (STORY) is a teleconference intervention for African-American women with breast cancer that was studied with a randomized, non-blinded, intention-to-treat trial between 2006 and 2010 in the southeastern United States. This secondary data analysis research measured the impact of STORY on depression and fatigue in African-American women (N = 168) with breast cancer. The were no significant differences in depression or fatigue found between the intervention and control groups based on the Wilcoxon signed-rank test. Further research is needed to develop effective interventions aimed at decreasing depression and fatigue in African-American women with breast cancer.",2015,The were no significant differences in depression or fatigue found between the intervention and control groups based on the Wilcoxon signed-rank test.,"['African-American women (N = 168) with breast cancer', 'African-American women with breast cancer', 'African-American Women with Breast Cancer', 'African-American women with breast cancer that was studied with a randomized, non-blinded, intention-to-treat trial between 2006 and 2010 in the southeastern United States']","['STORY', 'intervention Sisters Tell Others and Revive Yourself (STORY', 'teleconference intervention']","['Depression and Fatigue', 'depression or fatigue']","[{'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4319556', 'cui_str': 'One hundred and sixty-eight'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C1292734', 'cui_str': 'Treats'}]","[{'cui': 'C0337514', 'cui_str': 'Sister'}, {'cui': 'C0039450', 'cui_str': 'Teleconference'}]","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}]",168.0,0.0389128,The were no significant differences in depression or fatigue found between the intervention and control groups based on the Wilcoxon signed-rank test.,"[{'ForeName': 'Sue P', 'Initials': 'SP', 'LastName': 'Heiney', 'Affiliation': ''}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Reavis', 'Affiliation': ''}, {'ForeName': 'Abbas S', 'Initials': 'AS', 'LastName': 'Tavakoli', 'Affiliation': ''}, {'ForeName': 'Swann Arp', 'Initials': 'SA', 'LastName': 'Adams', 'Affiliation': ''}, {'ForeName': 'Pearman D', 'Initials': 'PD', 'LastName': 'Hayne', 'Affiliation': ''}, {'ForeName': 'Sally P', 'Initials': 'SP', 'LastName': 'Weinrich', 'Affiliation': ''}]",Journal of National Black Nurses' Association : JNBNA,[] 966,29557705,Global sensitivity analysis of clinical trials with missing patient-reported outcomes.,"Randomized trials with patient-reported outcomes are commonly plagued by missing data. The analysis of such trials relies on untestable assumptions about the missing data mechanism. To address this issue, it has been recommended that the sensitivity of the trial results to assumptions should be a mandatory reporting requirement. In this paper, we discuss a recently developed methodology (Scharfstein et al., Biometrics, 2018) for conducting sensitivity analysis of randomized trials in which outcomes are scheduled to be measured at fixed points in time after randomization and some subjects prematurely withdraw from study participation. The methodology is explicated in the context of a placebo-controlled randomized trial designed to evaluate a treatment for bipolar disorder. We present a comprehensive data analysis and a simulation study to evaluate the performance of the method. A software package entitled SAMON (R and SAS versions) that implements our methods is available at www.missingdatamatters.org .",2019,The methodology is explicated in the context of a placebo-controlled randomized trial designed to evaluate a treatment for bipolar disorder.,['bipolar disorder'],['placebo'],[],"[{'cui': 'C0005586', 'cui_str': 'Psychosis, Manic-Depressive'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]",[],,0.247271,The methodology is explicated in the context of a placebo-controlled randomized trial designed to evaluate a treatment for bipolar disorder.,"[{'ForeName': 'Daniel O', 'Initials': 'DO', 'LastName': 'Scharfstein', 'Affiliation': 'Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Aidan', 'Initials': 'A', 'LastName': 'McDermott', 'Affiliation': 'Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}]",Statistical methods in medical research,['10.1177/0962280218759565'] 967,26371360,Patient-Centered Community Diabetes Education Program Improves Glycemic Control in African-American Patients with Poorly Controlled Type 2 Diabetes: Importance of Point of Care Metabolic Measurements.,"African-Americans with type 2 diabetes (T2DM) have higher morbidity and mortality partly attributed to poor glucose control and lack of formal diabetes self-management education and support (DSMES) programs compared to Whites. Therefore, the objective of this study was to compare the clinical and metabolic parameters during DSMES vs. standard care in African-Americans with T2DM attending primary care inner city clinics. We recruited 124 African-American patients with T2DM, randomized into Group 1-DSMES (n = 58) and Group 2-standard care group (n = 38) for 6 months. Body weight, blood pressure, random blood sugars and point-of-care (POC) hemoglobin A1C (A1C) and lipids/lipoproteins were measured at 0, 3, and 6 months. At 6 months, Group 1 had significant reduction in A1C (8.2 ± 1.4% vs. 7.5 ± 1.5%, p = 0.02) and random glucose (190.4 ± 77.6 vs. 160.6 ± 59.8 mg/dl, p = 0.03). However, there were no changes in body weight, blood pressure, or lipids/lipoprotein levels. We found no significant changes in the clinical/metabolic parameters in Group 2. We concluded that DSMES, supplemented with POC testing, was associated with significant improvements in glycemic control without changes in body weight, blood pressure, or lipids/lipoproteins. We recommend the inclusion of DSMES with POC testing in managing African-American patients with T2DM attending inner city primary care clinics.",2015,"At 6 months, Group 1 had significant reduction in A1C (8.2 ± 1.4% vs. 7.5 ± 1.5%, p = 0.02) and random glucose (190.4 ± 77.6 vs. 160.6 ± 59.8 mg/dl, p = 0.03).","['124 African-American patients with T2DM', 'African-Americans with T2DM attending primary care inner city clinics', 'African-American patients with T2DM attending inner city primary care clinics', 'Patient-Centered Community Diabetes Education Program', 'African-American Patients with Poorly Controlled Type 2 Diabetes', 'African-Americans with type 2 diabetes (T2DM']","['Group 1-DSMES', 'DSMES with POC testing', 'DSMES', 'DSMES vs. standard care']","['Body weight, blood pressure, random blood sugars and point-of-care (POC) hemoglobin A1C (A1C) and lipids/lipoproteins', 'clinical/metabolic parameters', 'A1C', 'glycemic control without changes in body weight, blood pressure, or lipids/lipoproteins', 'body weight, blood pressure, or lipids/lipoprotein levels', 'Glycemic Control']","[{'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0557849', 'cui_str': 'Inner city environment (environment)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic (environment)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0729314', 'cui_str': 'Education provision (procedure)'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0282664', 'cui_str': 'Point-of-Care'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4521595', 'cui_str': 'Lcpl'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",124.0,0.0169461,"At 6 months, Group 1 had significant reduction in A1C (8.2 ± 1.4% vs. 7.5 ± 1.5%, p = 0.02) and random glucose (190.4 ± 77.6 vs. 160.6 ± 59.8 mg/dl, p = 0.03).","[{'ForeName': 'Trudy', 'Initials': 'T', 'LastName': 'Gaillard', 'Affiliation': ''}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Amponsah', 'Affiliation': ''}, {'ForeName': 'Kwame', 'Initials': 'K', 'LastName': 'Osei', 'Affiliation': ''}]",Journal of National Black Nurses' Association : JNBNA,[] 968,31786163,Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa.,"BACKGROUND Recessive dystrophic epidermolysis bullosa (RDEB) is a hereditary blistering disorder due to a lack of type VII collagen. At present, treatment is mainly supportive. OBJECTIVES To determine whether intravenous allogeneic bone marrow-derived mesenchymal stromal/stem cells (BM-MSCs) are safe in RDEB adults and if the cells improve wound healing and quality of life. METHODS We conducted a prospective, phase I/II, open-label study recruiting 10 RDEB adults to receive 2 intravenous infusions of BM-MSCs (on day 0 and day 14; each dose 2-4 × 10 6  cells/kg). RESULTS BM-MSCs were well tolerated with no serious adverse events to 12 months. Regarding efficacy, there was a transient reduction in disease activity scores (8/10 subjects) and a significant reduction in itch. One individual showed a transient increase in type VII collagen. LIMITATIONS Open-label trial with no placebo. CONCLUSIONS MSC infusion is safe in RDEB adults and can have clinical benefits for at least 2 months.",2020,"Regarding efficacy, there was transient reduction in disease activity scores (8 of 10 subjects) and significant reduction in itch.","['10 RDEB adults', 'adults with recessive dystrophic epidermolysis bullosa']","['intravenous allogeneic mesenchymal stromal cell therapy', 'intravenous infusions of BM-MSCs', 'placebo', 'intravenous allogeneic bone marrow-derived mesenchymal stromal/stem cells (BM-MSC', 'MSC infusion']","['disease activity scores', 'transient increase in C7', 'wound healing and quality of life']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0079474', 'cui_str': 'Hallopeau-Siemens Disease'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C3178844', 'cui_str': 'Mesenchymal Stromal Cells'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0021440', 'cui_str': 'Infusions, Intravenous'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0005953', 'cui_str': 'Bone Marrow'}, {'cui': 'C0038250', 'cui_str': 'Mother Cells'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}]","[{'cui': 'C4706353', 'cui_str': 'Disease Activity Score'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0034380'}]",,0.0278886,"Regarding efficacy, there was transient reduction in disease activity scores (8 of 10 subjects) and significant reduction in itch.","[{'ForeName': 'Ellie', 'Initials': 'E', 'LastName': 'Rashidghamat', 'Affiliation': ""St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK.""}, {'ForeName': 'Tendai', 'Initials': 'T', 'LastName': 'Kadiyirire', 'Affiliation': ""St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK.""}, {'ForeName': 'Salma', 'Initials': 'S', 'LastName': 'Ayis', 'Affiliation': ""School of Population Health and Environmental Sciences, King's College London, London, UK.""}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Petrof', 'Affiliation': 'Department of Dermatology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': ""The Robin Eady National Diagnostic Epidermolysis Bullosa Laboratory, Viapath, Guy's Hospital, London, UK.""}, {'ForeName': 'Venu', 'Initials': 'V', 'LastName': 'Pullabhatla', 'Affiliation': ""UK NIHR GSTFT/KCL Comprehensive Biomedical Research Centre, Guy's & St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Chrysanthi', 'Initials': 'C', 'LastName': 'Ainali', 'Affiliation': ""St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK; Dignosis Ltd, London, UK.""}, {'ForeName': 'Alyson', 'Initials': 'A', 'LastName': 'Guy', 'Affiliation': ""The Robin Eady National Diagnostic Epidermolysis Bullosa Laboratory, Viapath, Guy's Hospital, London, UK.""}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Aristodemou', 'Affiliation': ""The Robin Eady National Diagnostic Epidermolysis Bullosa Laboratory, Viapath, Guy's Hospital, London, UK.""}, {'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'McMillan', 'Affiliation': ""The Robin Eady National Diagnostic Epidermolysis Bullosa Laboratory, Viapath, Guy's Hospital, London, UK.""}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Ozoemena', 'Affiliation': ""The Robin Eady National Diagnostic Epidermolysis Bullosa Laboratory, Viapath, Guy's Hospital, London, UK.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Mee', 'Affiliation': ""Immunodermatology Laboratory, Viapath, St Thomas' Hospital, London, UK.""}, {'ForeName': 'Rashida', 'Initials': 'R', 'LastName': 'Pramanik', 'Affiliation': ""St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK.""}, {'ForeName': 'Alka', 'Initials': 'A', 'LastName': 'Saxena', 'Affiliation': ""UK NIHR GSTFT/KCL Comprehensive Biomedical Research Centre, Guy's & St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Rosamund', 'Initials': 'R', 'LastName': 'Nuamah', 'Affiliation': ""UK NIHR GSTFT/KCL Comprehensive Biomedical Research Centre, Guy's & St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Emanuele', 'Initials': 'E', 'LastName': 'de Rinaldis', 'Affiliation': 'I&I Precision Immunology, Sanofi, Cambridge, Massachusetts.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Serrano', 'Affiliation': ""Clinical Trial Management Research Platform, NIHR Biomedical Research Centre, Guy's & St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Clarisse', 'Initials': 'C', 'LastName': 'Maurin', 'Affiliation': ""Clinical Trial Management Research Platform, NIHR Biomedical Research Centre, Guy's & St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Martinez-Queipo', 'Affiliation': ""St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK.""}, {'ForeName': 'Su M', 'Initials': 'SM', 'LastName': 'Lwin', 'Affiliation': ""St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK.""}, {'ForeName': 'Dusko', 'Initials': 'D', 'LastName': 'Ilic', 'Affiliation': ""Stem Cell Laboratories, Guy's Assisted Conception Unit, Department of Women & Children's Health, Faculty of Life Sciences & Medicine, King's College London, London, UK.""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Martinez', 'Affiliation': 'Department of Dermatology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Dazzi', 'Affiliation': ""Department of Haematological Medicine, The Rayne Institute, King's College London, London, UK.""}, {'ForeName': 'Ineke', 'Initials': 'I', 'LastName': 'Slaper-Cortenbach', 'Affiliation': 'Cell Therapy Facility, Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Kasper', 'Initials': 'K', 'LastName': 'Westinga', 'Affiliation': 'Cell Therapy Facility, Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Zeddies', 'Affiliation': 'Cell Therapy Facility, Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'van den Broek', 'Affiliation': 'Cell Therapy Facility, Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Alexandros', 'Initials': 'A', 'LastName': 'Onoufriadis', 'Affiliation': ""St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK.""}, {'ForeName': 'Jemima E', 'Initials': 'JE', 'LastName': 'Mellerio', 'Affiliation': ""St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK.""}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'McGrath', 'Affiliation': ""St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK. Electronic address: john.mcgrath@kcl.ac.uk.""}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2019.11.038'] 969,32417976,"Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial.","PURPOSE This trial was conducted to confirm the non-inferiority of remimazolam versus propofol in the induction and maintenance of general anesthesia in surgical patients. METHODS Surgical patients (n = 375) were randomized to remimazolam started at 6 or 12 mg/kg/h by continuous intravenous (IV) infusion until the loss of consciousness (LoC), followed by 1 mg/kg/h to be adjusted as appropriate until the end of surgery or IV propofol administered as a slow bolus of 2.0-2.5 mg/kg until LoC followed by 4-10 mg/kg/h until the end of surgery. Efficacy was measured via the combined primary endpoint of no intraoperative awakening/recall, no need for rescue sedatives, and no body movements. Adverse events and adverse drug reactions (ADRs) were monitored for safety. RESULTS Efficacy rates were 100% in all treatment groups, and the non-inferiority of remimazolam was demonstrated [95% confidence interval (- 0.0487; 0.0250)]. The time to LoC was longer in the remimazolam 6 (p < 0.0001) and 12 mg/kg/h (p = 0.0149) groups versus propofol. The time to extubation was longer in both remimazolam groups versus the propofol group (p ≤ 0.0001). The incidence of ADRs was similar in the remimazolam groups (39.3% and 42.7%, respectively) compared with the propofol group (61.3%). Decreased blood pressure occurred in 20.0% and 24.0% of patients treated with 6 and 12 mg/kg/h remimazolam, respectively, compared with 49.3% of patients receiving propofol. Injection site pain was reported in 18.7% of propofol patients but not in those receiving remimazolam. CONCLUSIONS This trial demonstrated that remimazolam was well tolerated and non-inferior to propofol with regard to efficacy as a sedative hypnotics for general anesthesia. CLINICAL TRIAL REGISTRATION This trial is registered with the Japan Pharmaceutical Information Center - Clinical Trials Information (JapicCTI). JapicCTI number: 121973.",2020,The time to LoC was longer in the remimazolam 6 (p < 0.0001) and 12 mg/kg/h (p = 0.0149) groups versus propofol.,"['Surgical patients (n\u2009=\u2009375', 'general anesthesia', 'surgical patients']","['propofol', 'remimazolam', 'remimazolam versus propofol']","['blood pressure', 'time to LoC', 'Injection site pain', 'time to extubation', 'Efficacy and safety', 'intraoperative awakening/recall, no need for rescue sedatives, and no body movements', 'incidence of ADRs', 'Efficacy', 'Adverse events and adverse drug reactions (ADRs', 'Efficacy rates']","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517745', 'cui_str': '375'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}]","[{'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C3179470', 'cui_str': 'remimazolam'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0041657', 'cui_str': 'Loss of consciousness'}, {'cui': 'C0151828', 'cui_str': 'Injection site pain'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C1720052', 'cui_str': 'Awakening'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0020592', 'cui_str': 'HYPNOTICS AND SEDATIVES'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0041755', 'cui_str': 'Adverse reaction to drug'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.184452,The time to LoC was longer in the remimazolam 6 (p < 0.0001) and 12 mg/kg/h (p = 0.0149) groups versus propofol.,"[{'ForeName': 'Matsuyuki', 'Initials': 'M', 'LastName': 'Doi', 'Affiliation': 'Department of Anesthesiology and Intensive Care, Hamamatsu University Hospital, 1-20-1 Handayama, Higashi-Ku, Hamamatsu-Shi, 431-3192, Japan. matsuyuki_doi@nifty.com.'}, {'ForeName': 'Kiyoshi', 'Initials': 'K', 'LastName': 'Morita', 'Affiliation': 'Okayama University, Okayama, Japan.'}, {'ForeName': 'Junzo', 'Initials': 'J', 'LastName': 'Takeda', 'Affiliation': 'Keio University, Tokyo, Japan.'}, {'ForeName': 'Atsuhiro', 'Initials': 'A', 'LastName': 'Sakamoto', 'Affiliation': 'Department of Anesthesiology, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Michiaki', 'Initials': 'M', 'LastName': 'Yamakage', 'Affiliation': 'Department of Anesthesiology, Sapporo Medical University School of Medicine, Sapporo, Japan.'}, {'ForeName': 'Toshiyasu', 'Initials': 'T', 'LastName': 'Suzuki', 'Affiliation': 'Department of Anesthesiology, Tokai University of Medicine, Isehara, Kanagawa, Japan.'}]",Journal of anesthesia,['10.1007/s00540-020-02788-6'] 970,32417345,Randomized controlled trial to identify the optimal radiotherapy scheme for palliative treatment of incurable head and neck squamous cell carcinoma.,"BACKGROUND No randomized controlled trials (RCT) have yet identified the optimal palliative radiotherapy scheme in patients with incurable head and neck squamous cell carcinoma (HNSCC). We conducted RCT to compare two radiation schemes in terms of efficacy, toxicity and quality-of-life (QoL). MATERIALS AND METHODS Patients with locally-advanced HNSCC who were ineligible for radical treatment and those with limited metastatic disease were randomly assigned in 1:1 ratio to arm 1 (36 Gy in 6 fractions, twice a week) or arm 2 (50 Gy in 16 fractions, four times a week). RESULTS The trial was discontinued early because of slow accrual (34 patients enrolled). Objective response rates were 38.9% and 57.1% for arm 1 and 2 respectively (p = 0.476). The median time to loco-regional progression was not reached. The loco-regional control rates at 1 year was 57.4% and 69.3% in arm 1 and 2 (p = 0.450, HR = 0.56, 95%CI 0.12-2.58). One-year overall survival was 33.3% and 57.1%, with medians of 35.4 and 59.5 weeks, respectively (p = 0.215, HR = 0.55, 95%CI 0.21-1.43). Acute grade ≥3 toxicity was lower in arm 1 (16.7% versus 57.1%, p = 0.027), with the largest difference in grade 3 mucositis (5.6% versus 42.9%, p = 0.027). However, no significant deterioration in any of the patient-reported QoL-scales was found. CONCLUSION No solid conclusion could be made on this incomplete study which is closed early. Long-course radiotherapy did not show significantly better oncologic outcomes, but was associated with more acute grade 3 mucositis. No meaningful differences in QoL-scores were found. Therefore, the shorter schedule might be carefully advocated. However, this recommendation should be interpreted with great caution because of the inadequate statistical power.",2020,Objective response rates were 38.9% and 57.1% for arm 1 and 2 respectively (p=0.476).,"['patients with incurable head and neck squamous cell carcinoma (HNSCC', 'incurable head and neck squamous cell carcinoma', 'Patients with locally-advanced HNSCC who were ineligible for radical treatment and those with limited metastatic disease']",[],"['grade 3 mucositis', 'QoL-scores', 'efficacy, toxicity and quality-of-life (QoL', 'Acute grade ≥3 toxicity', 'median time to loco-regional progression', 'QoL-scales', 'overall survival', 'loco-regional control rates', 'acute grade 3 mucositis', 'oncologic outcomes', 'Objective response rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1168401', 'cui_str': 'Squamous cell carcinoma of head and neck'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0302912', 'cui_str': 'Radical'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}]",[],"[{'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0333355', 'cui_str': 'Inflammatory disease of mucous membrane'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205478', 'cui_str': 'Oncologic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0018017', 'cui_str': 'Goal'}]",34.0,0.193028,Objective response rates were 38.9% and 57.1% for arm 1 and 2 respectively (p=0.476).,"[{'ForeName': 'Abrahim', 'Initials': 'A', 'LastName': 'Al-Mamgani', 'Affiliation': 'Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: a.almamgani@nki.nl.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'Kessels', 'Affiliation': 'Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Cornelia G', 'Initials': 'CG', 'LastName': 'Verhoef', 'Affiliation': 'Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Arash', 'Initials': 'A', 'LastName': 'Navran', 'Affiliation': 'Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Hamming-Vrieze', 'Affiliation': 'Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Johannes H A M', 'Initials': 'JHAM', 'LastName': 'Kaanders', 'Affiliation': 'Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Roel J H M', 'Initials': 'RJHM', 'LastName': 'Steenbakkers', 'Affiliation': 'Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, the Netherlands.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Tans', 'Affiliation': 'Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Hoebers', 'Affiliation': 'Department of Radiation Oncology (MAASTRO Clinic), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, The Netherlands.'}, {'ForeName': 'Francisca', 'Initials': 'F', 'LastName': 'Ong', 'Affiliation': 'Department of Radiation Oncology, Medisch Spectrum Twente, The Netherlands.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'van Werkhoven', 'Affiliation': 'Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Johannes A', 'Initials': 'JA', 'LastName': 'Langendijk', 'Affiliation': 'Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, the Netherlands.'}]",Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,['10.1016/j.radonc.2020.05.020'] 971,31549861,"The effects of an expressive writing intervention on pregnancy rates, alexithymia and psychophysical health during an assisted reproductive treatment.","Objective: World Health Organization reported that in developed countries one in four couples experience infertility with serious implications for the psychophysical well-being. Aim of this study was to evaluate the effects of Pennebaker's writing technique on pregnancy rates, alexithymia and psychophysical health during an assisted reproductive treatment (ART). Method: 91 women admitted for an ART were randomly divided into two groups: an experimental one ( n  = 46), where women wrote about their thoughts and emotions concerning the infertility experience, and a control group ( n  = 45) where women did not write. All subjects completed a socio-demographic questionnaire, the 20-item Toronto Alexithymia Scale and the Symptoms Checklist-90-R before and after the writing sessions. Results: A significant difference in pregnancy rates between the experimental group ( n  = 13) and the control group ( n  = 5) was found (χ 2 = 4.216; p < .04). A significant difference was also found between women who participated in the study (experimental + control= 91) and women who declined to participate, in the direction of more ART successes ( n  = 18 vs. n  = 0) in the group of women who participated (χ 2 = 10.17; p < .01). Conclusions: The findings support the usefulness of the writing technique during ART in promoting treatment success.",2020,A significant difference in pregnancy rates between the experimental group ( n  = 13) and the control group ( n  = 5) was found (χ 2 = 4.216; p < .04).,['91 women admitted for an ART'],"[""Pennebaker's writing technique"", 'women wrote about their thoughts and emotions concerning the infertility experience, and a control group', 'expressive writing intervention']","['pregnancy rates', 'ART successes', 'pregnancy rates, alexithymia and psychophysical health', 'socio-demographic questionnaire, the 20-item Toronto Alexithymia Scale and the Symptoms Checklist-90-R']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0003826', 'cui_str': 'Arts'}]","[{'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0032975', 'cui_str': 'Pregnancy Rate'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0002020', 'cui_str': 'Alexithymia'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0222045'}, {'cui': 'C0451524', 'cui_str': 'Symptom checklist (assessment scale)'}]",91.0,0.0358192,A significant difference in pregnancy rates between the experimental group ( n  = 13) and the control group ( n  = 5) was found (χ 2 = 4.216; p < .04).,"[{'ForeName': 'Alessia', 'Initials': 'A', 'LastName': 'Renzi', 'Affiliation': 'Department of Dynamic and Clinical Psychology, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Solano', 'Affiliation': 'Department of Dynamic and Clinical Psychology, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Michela', 'Initials': 'M', 'LastName': 'Di Trani', 'Affiliation': 'Department of Dynamic and Clinical Psychology, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Ginobbi', 'Affiliation': 'Casamadre Association, Rome, Italy.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Minutolo', 'Affiliation': 'Department of Reproductive Medicine, Altamedica-Artemisia SpA, Rome, Italy.'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Tambelli', 'Affiliation': 'Department of Dynamic and Clinical Psychology, Sapienza University of Rome, Rome, Italy.'}]",Psychology & health,['10.1080/08870446.2019.1667500'] 972,32417629,"Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial.","OBJECTIVE This study was performed to evaluate the impact of melatonin supplementation on clinical and metabolic profiles in people with Parkinson's disease (PD). METHODS This randomized, double-blind, placebo-controlled clinical trial was conducted among 60 patients with PD. Participants were randomly divided into two groups to intake either 10 mg melatonin (two melatonin capsules, 5 mg each) (n = 30) or placebo (n = 30) once a day, 1 h before bedtime for 12 weeks. RESULTS Melatonin supplementation significantly reduced the Unified Parkinson's Disease Rating Scale (UPDRS) part I score (β -2.33; 95% CI, -3.57, -1.09; P < 0.001), Pittsburgh Sleep Quality Index (PSQI) (β -1.82; 95% CI, -3.36, -0.27; P = 0.02), Beck Depression Inventory (BDI) (β -3.32; 95% CI, -5.23, -1.41; P = 0.001) and Beck Anxiety Inventory (BAI) (β -2.22; 95% CI, -3.84, -0.60; P = 0.008) compared with the placebo treatment. Compared with the placebo, melatonin supplementation resulted in a significant reduction in serum high sensitivity C-reactive protein (hs-CRP) (β -0.94 mg/L; 95% CI, -1.55, -0.32; P = 0.003) and a significant elevation in plasma total antioxidant capacity (TAC) (β 108.09 mmol/L; 95% CI, 78.21, 137.97; P < 0.001) and total glutathione (GSH) levels (β 77.08 μmol/L; 95% CI, 44.29, 109.86; P < 0.001). Additionally, consuming melatonin significantly decreased serum insulin levels (β -1.79 μIU/mL; 95% CI, -3.12, -0.46; P = 0.009), homeostasis model of assessment-insulin resistance (HOMA-IR) (β -0.47; 95% CI, -0.80, -0.13; P = 0.007), total- (β -13.16 mg/dL; 95% CI, -25.14, -1.17; P = 0.03) and LDL- (β -10.44 mg/dL; 95% CI, -20.55, -0.34; P = 0.04) compared with the placebo. CONCLUSIONS Overall, melatonin supplementation for 12 weeks to patients with PD had favorable effects on the UPDRS part I score, PSQI, BDI, BAI, hs-CRP, TAC, GSH, insulin levels, HOMA-IR, total-, LDL-cholesterol, and gene expression of TNF-α, PPAR-γ and LDLR, but did not affect other metabolic profiles.",2020,"Additionally, consuming melatonin significantly decreased serum insulin levels (β -1.79 μIU/mL; 95% CI, -3.12, -0.46; P = 0.009), homeostasis model of assessment-insulin resistance (HOMA-IR) (β -0.47; 95% CI, -0.80, -0.13; P = 0.007), total- (β","[""Parkinson's disease"", ""people with Parkinson's disease (PD"", '60 patients with PD']","['melatonin supplementation', 'Melatonin supplementation', 'placebo, melatonin supplementation', 'melatonin (two melatonin capsules', 'placebo']","['Pittsburgh Sleep Quality Index (PSQI', 'homeostasis model of assessment-insulin resistance (HOMA-IR', 'UPDRS part I score, PSQI, BDI, BAI, hs-CRP, TAC, GSH, insulin levels, HOMA-IR, total-, LDL-cholesterol, and gene expression of TNF-α, PPAR-γ and LDLR', 'serum high sensitivity C-reactive protein (hs-CRP', 'plasma total antioxidant capacity (TAC', 'total glutathione (GSH) levels', 'LDL', 'Beck Anxiety Inventory (BAI) ', 'Beck Depression Inventory (BDI', 'serum insulin levels', ""Unified Parkinson's Disease Rating Scale (UPDRS) part I score (β""]","[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}]","[{'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006448', 'cui_str': 'Burundi'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C3489891', 'cui_str': 'TAC Alternate'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0166418', 'cui_str': 'PPAR'}, {'cui': 'C0034821', 'cui_str': 'LDL receptor'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0202053', 'cui_str': 'Glutathione measurement'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}]",60.0,0.782673,"Additionally, consuming melatonin significantly decreased serum insulin levels (β -1.79 μIU/mL; 95% CI, -3.12, -0.46; P = 0.009), homeostasis model of assessment-insulin resistance (HOMA-IR) (β -0.47; 95% CI, -0.80, -0.13; P = 0.007), total- (β","[{'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Daneshvar Kakhaki', 'Affiliation': 'Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Vahidreza', 'Initials': 'V', 'LastName': 'Ostadmohammadi', 'Affiliation': 'Infectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran; Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Kouchaki', 'Affiliation': 'Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran; Department of Neurology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Esmat', 'Initials': 'E', 'LastName': 'Aghadavod', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Bahmani', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Omid Reza', 'Initials': 'OR', 'LastName': 'Tamtaji', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Russel', 'Initials': 'R', 'LastName': 'J Reiter', 'Affiliation': 'Department of Cellular and Structural Biology, University of Texas Health Science, Center, San Antonio, TX, USA.'}, {'ForeName': 'Mohammad Ali', 'Initials': 'MA', 'LastName': 'Mansournia', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: asemi_z@Kaums.ac.ir.'}]",Clinical neurology and neurosurgery,['10.1016/j.clineuro.2020.105878'] 973,32417812,Reducing lumbar spine flexion using real-time biofeedback during patient handling tasks.,"BACKGROUND Patient handling activities require caregivers to adopt postures that increase the risk of back injury. Training programs relying primarily on didactic methods have been shown to be ineffective at reducing this risk. The use of real-time biofeedback has potential as an alternative training method. OBJECTIVE To investigate the effect of real-time biofeedback on time spent by caregivers in end-range lumbar spine flexion. METHODS Novice participants were divided into intervention (n = 10) and control (n = 10) groups and were asked to perform a set of simulated care activities eight times on two consecutive days. Individuals in the intervention group watched a training video on safer movement strategies and received real-time auditory feedback from a wearable device (PostureCoach) in four training trials whenever their lumbar spine flexion exceeded a threshold (70% of maximum flexion). Changes in end-range lumbar spine flexion were compared between groups and across trials. RESULTS Participants in the intervention group saw reductions in end-range lumbar spine flexion during the simulated patient handling tasks at the end of the training compared to their baseline trials while there was no change for the control group. CONCLUSIONS The training program including PostureCoach has the potential to help caregivers learn to use safer postures that reduce the risk of back injury.",2020,"RESULTS Participants in the intervention group saw reductions in end-range lumbar spine flexion during the simulated patient handling tasks at the end of the training compared to their baseline trials while there was no change for the control group. ",['Novice participants'],"['training video on safer movement strategies and received real-time auditory feedback from a wearable device (PostureCoach', 'real-time biofeedback']","['end-range lumbar spine flexion', 'lumbar spine flexion']",[],"[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C4505348', 'cui_str': 'Wearable Technology'}, {'cui': 'C0005491', 'cui_str': 'Biofeedback procedure'}]","[{'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0024091', 'cui_str': 'Bone structure of lumbar vertebra'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}]",,0.0415063,"RESULTS Participants in the intervention group saw reductions in end-range lumbar spine flexion during the simulated patient handling tasks at the end of the training compared to their baseline trials while there was no change for the control group. ","[{'ForeName': 'Mohammadhasan', 'Initials': 'M', 'LastName': 'Owlia', 'Affiliation': 'Toronto Rehabilitation Institute, University Health Network, ON, Canada.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Kamachi', 'Affiliation': 'Toronto Rehabilitation Institute, University Health Network, ON, Canada.'}, {'ForeName': 'Tilak', 'Initials': 'T', 'LastName': 'Dutta', 'Affiliation': 'Toronto Rehabilitation Institute, University Health Network, ON, Canada.'}]","Work (Reading, Mass.)",['10.3233/WOR-203149'] 974,31006728,Long-Term Comparison of Ethyl Icosapentate vs. Omega-3-Acid Ethyl in Patients With Cardiovascular Disease and Hypertriglyceridemia (DEFAT Trial).,"BACKGROUND Numerous studies have demonstrated a reduction in cardiovascular events when the low-density lipoprotein cholesterol (LDL) level is decreased by statin therapy. However, despite good control of LDL, cardiovascular events may increase if the triglyceride (TG) level is high. We conducted a long-term comparison of treatment of hypertriglyceridemia with ethyl icosapentate (EPA) vs. omega-3-acid ethyl (EPA+docosahexaenoic acid [DHA]).Methods and Results:Cardiac surgery patients with hypertriglyceridemia were randomized to an EPA group (1.8 g t.i.d.) or an EPA+DHA group (2 g s.i.d.) and observed for 3 years. The primary endpoints were the serum TG level and its percent change. Secondary endpoints included lipid markers, fatty acid parameters, serum creatinine, cystatin-C, oxidized LDL, high-sensitivity C-reactive protein, and MACCE. An interview to assess study drug adherence was conducted 6 months after completing the study. TG levels were significantly lower in the EPA+DHA group than in the EPA group. Levels of remnant-like particles-cholesterol, oxidized LDL, and cystatin-C were also significantly lower in the EPA+DHA group than in the EPA group. Compliance with treatment was significantly worse in the EPA group. CONCLUSIONS Better results were obtained in the EPA+DHA group, but more patients showed poor compliance with treatment in the EPA group, making detailed comparison of the 2 groups difficult. Even so, TG were reduced while EPA and DHA levels were increased in the EPA+DHA group, together with a reduction in oxidative stress and remnant-like particles-cholesterol. Decreased compliance with medication in the EPA group significantly affected the results of this study, clearly indicating the importance of good compliance.",2019,"Levels of remnant-like particles-cholesterol, oxidized LDL, and cystatin-C were also significantly lower in the EPA+DHA group than in the EPA group.","['Patients With Cardiovascular Disease and Hypertriglyceridemia (DEFAT Trial', 'Cardiac surgery patients with hypertriglyceridemia']","['Ethyl Icosapentate vs. Omega-3-Acid Ethyl', 'hypertriglyceridemia with ethyl icosapentate (EPA) vs. omega-3-acid ethyl (EPA+docosahexaenoic acid [DHA]).Methods\u2004and\u2004Results', 'EPA+DHA', 'EPA']","['TG levels', 'triglyceride (TG) level', 'lipid markers, fatty acid parameters, serum creatinine, cystatin-C, oxidized LDL, high-sensitivity C-reactive protein, and MACCE', 'serum TG level', 'EPA and DHA levels', 'oxidative stress and remnant-like particles-cholesterol', 'density lipoprotein cholesterol (LDL) level', 'Levels of remnant-like particles-cholesterol, oxidized LDL, and cystatin-C']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0020557', 'cui_str': 'Hypertriglyceridemia'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}]","[{'cui': 'C1719844', 'cui_str': 'Greek letter omega'}, {'cui': 'C0001128', 'cui_str': 'Acids'}, {'cui': 'C0020557', 'cui_str': 'Hypertriglyceridemia'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0059057', 'cui_str': 'EPA (prealbumin)'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0428475', 'cui_str': 'Triglyceride level - finding'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0015684', 'cui_str': 'Fatty Acids'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0071744', 'cui_str': 'Cystatin 3'}, {'cui': 'C0348035', 'cui_str': 'oxidized low density lipoprotein'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0059057', 'cui_str': 'EPA (prealbumin)'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0674390', 'cui_str': 'remnant-like particle cholesterol'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0065055', 'cui_str': 'lipoprotein cholesterol'}]",,0.0329428,"Levels of remnant-like particles-cholesterol, oxidized LDL, and cystatin-C were also significantly lower in the EPA+DHA group than in the EPA group.","[{'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Sezai', 'Affiliation': 'Department of Cardiovascular Surgery, Nihon University School of Medicine.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Unosawa', 'Affiliation': 'Department of Cardiovascular Surgery, Nihon University School of Medicine.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Taoka', 'Affiliation': 'Department of Cardiovascular Surgery, Nihon University School of Medicine.'}, {'ForeName': 'Shunji', 'Initials': 'S', 'LastName': 'Osaka', 'Affiliation': 'Department of Cardiovascular Surgery, Nihon University School of Medicine.'}, {'ForeName': 'Kazuaki', 'Initials': 'K', 'LastName': 'Obata', 'Affiliation': 'Sekino Hospital.'}, {'ForeName': 'Sakie', 'Initials': 'S', 'LastName': 'Kanno', 'Affiliation': 'Sekino Hospital.'}, {'ForeName': 'Hisakuni', 'Initials': 'H', 'LastName': 'Sekino', 'Affiliation': 'Sekino Hospital.'}, {'ForeName': 'Masashi', 'Initials': 'M', 'LastName': 'Tanaka', 'Affiliation': 'Department of Cardiovascular Surgery, Nihon University School of Medicine.'}]",Circulation journal : official journal of the Japanese Circulation Society,['10.1253/circj.CJ-18-0764'] 975,26130725,Impact of Tailored Interventions to Reduce Drug Use and Sexual Risk Behaviors Among Homeless Gay and Bisexual Men.,"A randomized controlled trial was conducted with homeless gay and bisexual men to assess the impact of two culturally sensitive intervention programs on reduction of drug use and risky sexual behavior. In this study, gay and bisexual men between 18 and 46 years of age were randomly assigned to one of two culturally sensitive behavioral intervention programs: a Nurse Case Management Plus Contingency Management (NCM + CM; n = 204) or a Standard Education Plus Contingency Management (SE + CM; n = 210) program. Regardless of group assignment, significant and clinically relevant reductions were observed in stimulant use over time. Multivariable predictors of stimulant use at 4- and 8-month follow-up evaluations were recent injection drug use, tested positive for HIV, or for use of amphetamine. Data revealed a significant linear decline over time for those who had sex with multiple partners. Furthermore, being HIV positive was associated with reporting multiple partners, while higher homophobia scores and having children were inversely related to reports of having sex with multiple partners at follow-up. Culturally sensitive approaches are needed to successfully reduce drug use and risky sexual activities among gay and bisexual populations.",2017,"Regardless of group assignment, significant and clinically relevant reductions were observed in stimulant use over time.","['homeless gay and bisexual men', 'Homeless Gay and Bisexual Men', 'gay and bisexual men between 18 and 46 years of age']","['culturally sensitive behavioral intervention programs: a Nurse Case Management Plus Contingency Management (NCM + CM; n = 204) or a Standard Education Plus Contingency Management (SE + CM; n = 210) program', 'culturally sensitive intervention programs', 'amphetamine']","['homophobia scores', 'Drug Use and Sexual Risk Behaviors', 'reduction of drug use and risky sexual behavior']","[{'cui': 'C0237154', 'cui_str': 'Homelessness'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C2129310', 'cui_str': 'Bisexual (finding)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0332324', 'cui_str': 'Sensitive (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0085971', 'cui_str': 'Case Management'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0002658', 'cui_str': 'Amphetamine'}]","[{'cui': 'C0680423', 'cui_str': 'Anti-Homosexual Bias'}, {'cui': 'C0449889', 'cui_str': 'Drug used (attribute)'}, {'cui': 'C0086931', 'cui_str': 'Risk Behavior'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0036864', 'cui_str': 'Sexual Behavior'}]",210.0,0.0296926,"Regardless of group assignment, significant and clinically relevant reductions were observed in stimulant use over time.","[{'ForeName': 'Adeline', 'Initials': 'A', 'LastName': 'Nyamathi', 'Affiliation': '1 University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Cathy J', 'Initials': 'CJ', 'LastName': 'Reback', 'Affiliation': '2 Friends Community Center, Los Angeles, CA, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Shoptaw', 'Affiliation': '1 University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Benissa E', 'Initials': 'BE', 'LastName': 'Salem', 'Affiliation': '1 University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Sheldon', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': '3 San Diego State University, San Diego, CA, USA.'}, {'ForeName': 'Kartik', 'Initials': 'K', 'LastName': 'Yadav', 'Affiliation': '1 University of California, Los Angeles, CA, USA.'}]",American journal of men's health,['10.1177/1557988315590837'] 976,26140898,The Relationship of Endoscopic Proficiency to Educational Expense for Virtual Reality Simulator Training Amongst Surgical Trainees.,"With the introduction of Fundamentals of Endoscopic Surgery, training methods in flexible endoscopy are being augmented with simulation-based curricula. The investment for virtual reality simulators warrants further research into its training advantage. Trainees were randomized into bedside or simulator training groups (BED vs SIM). SIM participated in a proficiency-based virtual reality curriculum. Trainees' endoscopic skills were rated using the Global Assessment of Gastrointestinal Endoscopic Skills (GAGES) in the patient care setting. The number of cases to reach 90 per cent of the maximum GAGES score and calculated costs of training were compared. Nineteen residents participated in the study. There was no difference in the average number of cases required to achieve 90 per cent of the maximum GAGES score for esophagogastroduodenoscopy, 13 (SIM) versus11 (BED) (P = 0.63), or colonoscopy 21 (SIM) versus 4 (BED) (P = 0.34). The average per case cost of training for esophagogastroduodenoscopy was $35.98 (SIM) versus $39.71 (BED) (P = 0.50), not including the depreciation costs associated with the simulator ($715.00 per resident over six years). Use of a simulator appeared to increase the cost of training without accelerating the learning curve or decreasing faculty time spent in instruction. The importance of simulation in endoscopy training will be predicated on more cost-effective simulators.",2015,Use of a simulator appeared to increase the cost of training without accelerating the learning curve or decreasing faculty time spent in instruction.,['Nineteen residents participated in the study'],['Virtual Reality Simulator Training'],"['maximum GAGES score for esophagogastroduodenoscopy, 13 (SIM) versus11 (BED', 'Global Assessment of Gastrointestinal Endoscopic Skills (GAGES', 'average per case cost of training for esophagogastroduodenoscopy']","[{'cui': 'C0450337', 'cui_str': '19 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0183309', 'cui_str': 'Simulator (physical object)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0079304', 'cui_str': 'Esophagogastroduodenoscopy'}, {'cui': 'C0004916', 'cui_str': 'Beds'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]",19.0,0.0247339,Use of a simulator appeared to increase the cost of training without accelerating the learning curve or decreasing faculty time spent in instruction.,"[{'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Raque', 'Affiliation': 'Hiram C. Polk, Jr. MD Department of Surgery, University of Louisville School of Medicine, Louisville, Kentucky, USA.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Goble', 'Affiliation': ''}, {'ForeName': 'Veronica M', 'Initials': 'VM', 'LastName': 'Jones', 'Affiliation': ''}, {'ForeName': 'Lindsey E', 'Initials': 'LE', 'LastName': 'Waldman', 'Affiliation': ''}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Sutton', 'Affiliation': ''}]",The American surgeon,[] 977,3290233,Test-of-cure stool cultures for traveler's diarrhea.,"Whether enteropathogens were eradicated or persisted in test-of-cure stool cultures from 251 patients with traveler's diarrhea, the durations of diarrhea were similar within the antimicrobial agent-treated (32 versus 33 h) and placebo-treated (82 versus 96 h) groups. Routine test-of-cure stool cultures can be useful for evaluating treatment failures and for assessing asymptomatic carriage of enteropathogens after treatment, but they are not mandated in the design of placebo-controlled antimicrobial treatment trials in traveler's diarrhea when the focus of the trial is clinical efficacy.",1988,"Whether enteropathogens were eradicated or persisted in test-of-cure stool cultures from 251 patients with traveler's diarrhea, the durations of diarrhea were similar within the antimicrobial agent-treated (32 versus 33 h) and placebo-treated (82 versus 96 h) groups.","[""251 patients with traveler's diarrhea"", ""traveler's diarrhea""]",['placebo'],['durations of diarrhea'],"[{'cui': 'C0761050', 'cui_str': '(GVGVP)251'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0277528', 'cui_str': ""Traveler's diarrhea (disorder)""}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",251.0,0.112927,"Whether enteropathogens were eradicated or persisted in test-of-cure stool cultures from 251 patients with traveler's diarrhea, the durations of diarrhea were similar within the antimicrobial agent-treated (32 versus 33 h) and placebo-treated (82 versus 96 h) groups.","[{'ForeName': 'C D', 'Initials': 'CD', 'LastName': 'Ericsson', 'Affiliation': 'Program in Infectious Diseases and Clinical Microbiology, University of Texas Medical School, Houston 77030.'}, {'ForeName': 'H L', 'Initials': 'HL', 'LastName': 'DuPont', 'Affiliation': ''}, {'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Mathewson', 'Affiliation': ''}, {'ForeName': 'P C', 'Initials': 'PC', 'LastName': 'Johnson', 'Affiliation': ''}, {'ForeName': 'F J', 'Initials': 'FJ', 'LastName': 'de la Cabada', 'Affiliation': ''}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Bitsura', 'Affiliation': ''}]",Journal of clinical microbiology,[] 978,25157725,Association between early administration of high-dose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age.,"IMPORTANCE Premature infants are at risk of developing encephalopathy of prematurity, which is associated with long-term neurodevelopmental delay. Erythropoietin was shown to be neuroprotective in experimental and retrospective clinical studies. OBJECTIVE To determine if there is an association between early high-dose recombinant human erythropoietin treatment in preterm infants and biomarkers of encephalopathy of prematurity on magnetic resonance imaging (MRI) at term-equivalent age. DESIGN, SETTING, AND PARTICIPANTS A total of 495 infants were included in a randomized, double-blind, placebo-controlled study conducted in Switzerland between 2005 and 2012. In a nonrandomized subset of 165 infants (n=77 erythropoietin; n=88 placebo), brain abnormalities were evaluated on MRI acquired at term-equivalent age. INTERVENTIONS Participants were randomly assigned to receive recombinant human erythropoietin (3000 IU/kg; n=256) or placebo (n=239) intravenously before 3 hours, at 12 to 18 hours, and at 36 to 42 hours after birth. MAIN OUTCOMES AND MEASURES The primary outcome of the trial, neurodevelopment at 24 months, has not yet been assessed. The secondary outcome, white matter disease of the preterm infant, was semiquantitatively assessed from MRI at term-equivalent age based on an established scoring method. The resulting white matter injury and gray matter injury scores were categorized as normal or abnormal according to thresholds established in the literature by correlation with neurodevelopmental outcome. RESULTS At term-equivalent age, compared with untreated controls, fewer infants treated with recombinant human erythropoietin had abnormal scores for white matter injury (22% [17/77] vs 36% [32/88]; adjusted risk ratio [RR], 0.58; 95% CI, 0.35-0.96), white matter signal intensity (3% [2/77] vs 11% [10/88]; adjusted RR, 0.20; 95% CI, 0.05-0.90), periventricular white matter loss (18% [14/77] vs 33% [29/88]; adjusted RR, 0.53; 95% CI, 0.30-0.92), and gray matter injury (7% [5/77] vs 19% [17/88]; adjusted RR, 0.34; 95% CI, 0.13-0.89). CONCLUSIONS AND RELEVANCE In an analysis of secondary outcomes of a randomized clinical trial of preterm infants, high-dose erythropoietin treatment within 42 hours after birth was associated with a reduced risk of brain injury on MRI. These findings require assessment in a randomized trial designed primarily to assess this outcome as well as investigation of the association with neurodevelopmental outcomes. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00413946.",2014,"At term-equivalent age, compared with untreated controls, fewer infants treated with recombinant human erythropoietin had abnormal scores for white matter injury (22%","['preterm infants and biomarkers of encephalopathy of prematurity on magnetic resonance imaging (MRI) at term-equivalent age', 'preterm infants and brain MRI abnormality at term-equivalent age', 'A total of 495 infants', 'Premature infants', '165 infants (n=77 erythropoietin; n=88 placebo), brain abnormalities were evaluated on MRI acquired at term-equivalent age', 'controlled study conducted in Switzerland between 2005 and 2012']","['Erythropoietin', 'high-dose erythropoietin', 'recombinant human erythropoietin', 'placebo']","['gray matter injury', 'white matter signal intensity', 'white matter injury and gray matter injury scores', 'abnormal scores', 'periventricular white matter loss', 'white matter disease of the preterm infant']","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0085584', 'cui_str': 'Encephalopathies'}, {'cui': 'C0728731', 'cui_str': 'Prematurity of fetus (disorder)'}, {'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0000769', 'cui_str': 'anomalies'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C4319555', 'cui_str': '165 (qualifier value)'}, {'cui': 'C0014822', 'cui_str': 'Erythropoietin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0439661', 'cui_str': 'Acquired (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}]","[{'cui': 'C0014822', 'cui_str': 'Erythropoietin'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0018220', 'cui_str': 'Gray Matter'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0682708'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205161', 'cui_str': 'Abnormal (qualifier value)'}, {'cui': 'C0228157', 'cui_str': 'Periventricular white matter (body structure)'}, {'cui': 'C0270612', 'cui_str': 'White Matter Diseases'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}]",495.0,0.622277,"At term-equivalent age, compared with untreated controls, fewer infants treated with recombinant human erythropoietin had abnormal scores for white matter injury (22%","[{'ForeName': 'Russia Ha-Vinh', 'Initials': 'RH', 'LastName': 'Leuchter', 'Affiliation': 'Division of Development and Growth, Department of Pediatrics, University Hospital of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Gui', 'Affiliation': 'Division of Development and Growth, Department of Pediatrics, University Hospital of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Poncet', 'Affiliation': 'Clinical Research Center and Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva and University Hospital of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Cornelia', 'Initials': 'C', 'LastName': 'Hagmann', 'Affiliation': 'Division of Neonatology, University Hospital, Zurich, Switzerland.'}, {'ForeName': 'Gregory Anton', 'Initials': 'GA', 'LastName': 'Lodygensky', 'Affiliation': 'Division of Development and Growth, Department of Pediatrics, University Hospital of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Ernst', 'Initials': 'E', 'LastName': 'Martin', 'Affiliation': ""MR-Center, University Children's Hospital Zurich, Zurich, Switzerland.""}, {'ForeName': 'Brigitte', 'Initials': 'B', 'LastName': 'Koller', 'Affiliation': 'Division of Neonatology, University Hospital, Zurich, Switzerland.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Darqué', 'Affiliation': 'Division of Development and Growth, Department of Pediatrics, University Hospital of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Hans Ulrich', 'Initials': 'HU', 'LastName': 'Bucher', 'Affiliation': 'Division of Neonatology, University Hospital, Zurich, Switzerland.'}, {'ForeName': 'Petra Susan', 'Initials': 'PS', 'LastName': 'Hüppi', 'Affiliation': 'Division of Development and Growth, Department of Pediatrics, University Hospital of Geneva, Geneva, Switzerland.'}]",JAMA,['10.1001/jama.2014.9645'] 979,32420695,"A randomized, double-blind, vehicle-controlled clinical study of hair regeneration using adipose-derived stem cell constituent extract in androgenetic alopecia.","Accumulating evidence suggests that adipose-derived stem cell constituent extract (ADSC-CE) helps hair regrowth in patients with androgenetic alopecia (AGA). However, the effects of ADSC-CE have not been demonstrated in a randomized, double-blind, vehicle-controlled clinical trial. In this randomized, double-blind, vehicle-controlled clinical trial, 38 patients (29 men) with AGA were assigned to an intervention group (IG), with twice-daily self-application of the ADSC-CE topical solution over the scalp with fingers, or to a control group (CG). Changes in hair count and thickness at 16 weeks from the baseline were evaluated using a phototrichogram. Overall, 34 (89%) patients (mean age, 45.3 years) completed the study. The phototrichogram at week 8 showed more increase in hair count in the IG than in the CG, and intergroup differences in the change of hair count remained significant until week 16 with overall changes of 28.1% vs 7.1%, respectively. Similarly, a significant improvement in hair diameter was observed in the IG (14.2%) after 16 weeks when compared with hair diameter in the CG (6.3%). Our findings suggest that the application of the ADSC-CE topical solution has enormous potential as an alternative therapeutic strategy for hair regrowth in patients with AGA, by increasing both hair density and thickness while maintaining adequate treatment safety.",2020,"The phototrichogram at week 8 showed more increase in hair count in the IG than in the CG, and intergroup differences in the change of hair count remained significant until week 16 with overall changes of 28.1% vs 7.1%, respectively.","['patients with androgenetic alopecia (AGA', 'androgenetic alopecia', '38 patients (29 men) with AGA']","['hair regeneration using adipose-derived stem cell constituent extract', 'adipose-derived stem cell constituent extract (ADSC-CE', 'ADSC-CE', 'intervention group (IG), with twice-daily self-application of the ADSC-CE topical solution over the scalp with fingers, or to a control group (CG']","['hair count and thickness', 'hair count', 'change of hair count', 'hair diameter']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162311', 'cui_str': 'Alopecia hereditaria'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0034963', 'cui_str': 'Regeneration'}, {'cui': 'C0038250', 'cui_str': 'Stem cell'}, {'cui': 'C0729650', 'cui_str': 'Constituents'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0991555', 'cui_str': 'Cutaneous solution'}, {'cui': 'C0036270', 'cui_str': 'Scalp structure'}, {'cui': 'C0016129', 'cui_str': 'Digit of hand structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}]",38.0,0.46629,"The phototrichogram at week 8 showed more increase in hair count in the IG than in the CG, and intergroup differences in the change of hair count remained significant until week 16 with overall changes of 28.1% vs 7.1%, respectively.","[{'ForeName': 'Young Jin', 'Initials': 'YJ', 'LastName': 'Tak', 'Affiliation': 'Department of Family Medicine, Pusan National University School of Medicine, Yangsan, South Korea.'}, {'ForeName': 'Sang Yeoup', 'Initials': 'SY', 'LastName': 'Lee', 'Affiliation': 'Family Medicine Clinic and Research Institute of Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea.'}, {'ForeName': 'A Ra', 'Initials': 'AR', 'LastName': 'Cho', 'Affiliation': 'Department of Family Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea.'}, {'ForeName': 'Young Sil', 'Initials': 'YS', 'LastName': 'Kim', 'Affiliation': 'T-Stem, Co., Ltd, Changwon-si, South Korea.'}]",Stem cells translational medicine,['10.1002/sctm.19-0410'] 980,25649275,The placebo effect in inflammatory skin reactions: the influence of verbal suggestion on itch and weal size.,"PURPOSE To investigate suggestion-induced placebo effects in inflammatory skin reactions. METHODS A healthy sample of volunteers (N = 48) attended two laboratory sessions. In each, a local short term inflammatory skin reaction was induced with histamine. Participants were told that one session was a control session and the other was a treatment session in which an antihistamine cream would be applied to the arm to reduce the size of the weal and the experience of itch. Inert aqueous cream was applied in both sessions. Participants were randomly allocated to undergo either the control or the treatment session first. RESULTS The placebo manipulation successfully reduced self-reported itch from the control to the placebo treatment session, but no placebo effect was demonstrated in weal size. Order effects were observed such that only those who underwent control procedures first had a smaller weal in the placebo treatment session as compared to the control session. The same order effect was seen for reported itch at one minute post histamine administration, but this disappeared at the three and five minute measures. CONCLUSION Findings suggest that explicit verbal suggestion can reduce the experience of itch. In addition to conscious awareness, a concrete representation of the suggested changes gained from prior experience to the stimulus may be an important component of placebo effects on inflammatory skin reactions.",2015,Order effects were observed such that only those who underwent control procedures first had a smaller weal in the placebo treatment session as compared to the control session.,['A healthy sample of volunteers (N = 48) attended two laboratory sessions'],"['antihistamine cream', 'placebo', 'Inert aqueous cream', 'histamine']","['weal size', 'inflammatory skin reactions']","[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}]","[{'cui': 'C0019590', 'cui_str': 'Antihistamines'}, {'cui': 'C1378128', 'cui_str': 'Cream'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0019588', 'cui_str': 'Histamine'}]","[{'cui': 'C0221232', 'cui_str': 'Wheal'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0221743', 'cui_str': 'Skin reaction (observable entity)'}]",48.0,0.0506608,Order effects were observed such that only those who underwent control procedures first had a smaller weal in the placebo treatment session as compared to the control session.,"[{'ForeName': 'Margot', 'Initials': 'M', 'LastName': 'Darragh', 'Affiliation': 'The University of Auckland, New Zealand. Electronic address: m.darragh@auckland.ac.nz.'}, {'ForeName': 'Joshua W-H', 'Initials': 'JW', 'LastName': 'Chang', 'Affiliation': 'The University of Auckland, New Zealand. Electronic address: wcha657@aucklanduni.ac.nz.'}, {'ForeName': 'Roger J', 'Initials': 'RJ', 'LastName': 'Booth', 'Affiliation': 'The University of Auckland, New Zealand. Electronic address: rj.booth@auckland.ac.nz.'}, {'ForeName': 'Nathan S', 'Initials': 'NS', 'LastName': 'Consedine', 'Affiliation': 'The University of Auckland, New Zealand. Electronic address: n.consedine@auckland.ac.nz.'}]",Journal of psychosomatic research,['10.1016/j.jpsychores.2015.01.011'] 981,31548150,"Outcomes of open ""crown"" type v. percutaneous Bunnell type repair of acute Achilles tendon ruptures. Randomized control study.","BACKGROUND The optimal treatment of acute Achilles tendon ruptures (AATR) is still under debate. The purpose of this study was to evaluate outcomes of open repair comparing with percutaneous procedure for AATR. METHODS 100 patients with AATR were randomized in two groups: open ""crown"" type (group A) and percutaneous Bunnell type repair (group B). 87 patients were available for the mean follow up of 27months RESULTS: No statistically significant difference was observed between groups in ATRS score, leg circumference, single heel rise, Achilles resting angle, time back to work and sports and overall patient satisfaction. Percutaneous technique was much faster. Overall 13 complications occurred in both groups (5 and 8 respectively). No deep infection occurred, no revisions were needed. CONCLUSIONS Both techniques showed to be effective and safe when using absorbable suture material with a high patient satisfaction and a low complication rate, but percutaneous repair was significantly faster.",2020,"Both techniques showed to be effective and safe when using absorbable suture material with a high patient satisfaction and a low complication rate, but percutaneous repair was significantly faster.","['acute Achilles tendon ruptures (AATR', '100 patients with AATR', '87 patients were available for the mean follow up of 27months RESULTS', 'acute Achilles tendon ruptures']","['percutaneous procedure for AATR', 'open ""crown"" type v. percutaneous Bunnell type repair', 'open ""crown"" type (group A) and percutaneous Bunnell type repair']","['ATRS score, leg circumference, single heel rise, Achilles resting angle, time back to work and sports and overall patient satisfaction', 'effective and safe', 'deep infection', 'Overall 13 complications']","[{'cui': 'C0263970', 'cui_str': 'Rupture of Achilles tendon'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C1274040', 'cui_str': 'Result'}]","[{'cui': 'C0522523', 'cui_str': 'Percutaneous approach - access (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C3853546', 'cui_str': 'Dental Crowns'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C0441835', 'cui_str': 'Group A (qualifier value)'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0018870', 'cui_str': 'Heel'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0205143', 'cui_str': 'Angular (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0425105', 'cui_str': 'Back to Work'}, {'cui': 'C0038039', 'cui_str': 'Sports'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}]",100.0,0.091142,"Both techniques showed to be effective and safe when using absorbable suture material with a high patient satisfaction and a low complication rate, but percutaneous repair was significantly faster.","[{'ForeName': 'Aleksas', 'Initials': 'A', 'LastName': 'Makulavičius', 'Affiliation': 'Vilnius University, Faculty of Medicine, Clinic of Rheumatology, Traumatology Orthopaedic and Reconstructive Surgery, Centre of Orthopedics and Traumatology, Republican Vilnius University Hospital, Šiltnamių g. 29, LT-04130 Vilnius, Lithuania. Electronic address: makulaviciusa@gmail.com.'}, {'ForeName': 'Giedrius', 'Initials': 'G', 'LastName': 'Mazarevičius', 'Affiliation': 'Vilnius University, Faculty of Medicine, Clinic of Rheumatology, Traumatology Orthopaedic and Reconstructive Surgery, Centre of Orthopedics and Traumatology, Republican Vilnius University Hospital, Šiltnamių g. 29, LT-04130 Vilnius, Lithuania.'}, {'ForeName': 'Mindaugas', 'Initials': 'M', 'LastName': 'Klinga', 'Affiliation': 'Vilnius University, Faculty of Medicine, Clinic of Rheumatology, Traumatology Orthopaedic and Reconstructive Surgery, Centre of Orthopedics and Traumatology, Republican Vilnius University Hospital, Šiltnamių g. 29, LT-04130 Vilnius, Lithuania.'}, {'ForeName': 'Matas', 'Initials': 'M', 'LastName': 'Urmanavičius', 'Affiliation': 'Vilnius University, Faculty of Medicine, Clinic of Rheumatology, Traumatology Orthopaedic and Reconstructive Surgery, Centre of Orthopedics and Traumatology, Republican Vilnius University Hospital, Šiltnamių g. 29, LT-04130 Vilnius, Lithuania.'}, {'ForeName': 'Povilas', 'Initials': 'P', 'LastName': 'Masionis', 'Affiliation': 'Vilnius University, Faculty of Medicine, Clinic of Rheumatology, Traumatology Orthopaedic and Reconstructive Surgery, Centre of Orthopedics and Traumatology, Republican Vilnius University Hospital, Šiltnamių g. 29, LT-04130 Vilnius, Lithuania.'}, {'ForeName': 'Xavier Martin', 'Initials': 'XM', 'LastName': 'Oliva', 'Affiliation': 'Barcelona University, Faculty of Medicine, Department of Embriology and Human Anatomy, Barcelona, Spain.'}, {'ForeName': 'Valentinas', 'Initials': 'V', 'LastName': 'Uvarovas', 'Affiliation': 'Vilnius University, Faculty of Medicine, Clinic of Rheumatology, Traumatology Orthopaedic and Reconstructive Surgery, Centre of Orthopedics and Traumatology, Republican Vilnius University Hospital, Šiltnamių g. 29, LT-04130 Vilnius, Lithuania.'}, {'ForeName': 'Narūnas', 'Initials': 'N', 'LastName': 'Porvaneckas', 'Affiliation': 'Vilnius University, Faculty of Medicine, Clinic of Rheumatology, Traumatology Orthopaedic and Reconstructive Surgery, Centre of Orthopedics and Traumatology, Republican Vilnius University Hospital, Šiltnamių g. 29, LT-04130 Vilnius, Lithuania.'}]",Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons,['10.1016/j.fas.2019.07.011'] 982,25336768,Enhancing Mother Infant Interactions through Video Feedback Enabled Interventions in Women with Schizophrenia: A Single Subject Research Design Study.,"BACKGROUND It has been shown that mother infant interactions are often impaired in mothers with schizophrenia. Contributory factors include psychotic symptoms, negative symptoms and surrogate parenting by others. AIM This study describes the effectiveness of video feedback in enhancing mother-infant interaction in mothers with schizophrenia who have impaired interaction with their infant. MATERIALS AND METHODS Two women with schizophrenia who were admitted for persistent psychotic symptoms and poor mothering skills, participated in the intervention. Pre intervention parenting assessment was done using video recording of mother infant interaction. Six sessions of mothering intervention were provided using video feedback and a repeat recording was done. Pre-and post-intervention videos were subsequently rated in a blind fashion by an independent expert in perinatal psychiatry using the pediatric infant parent exam (PIPE) scale. RESULTS Pre and post intervention comparison of PIPE scores indicating significant improvement in several areas of mothering. CONCLUSIONS Video feedback is a simple and inexpensive tool which can be used for improving mothering skills among mothers with postpartum psychosis or schizophrenia even in low resource settings.",2014,"CONCLUSIONS Video feedback is a simple and inexpensive tool which can be used for improving mothering skills among mothers with postpartum psychosis or schizophrenia even in low resource settings.","['mothers with schizophrenia who have impaired interaction with their infant', 'Women with Schizophrenia', 'mothers with schizophrenia', 'Two women with schizophrenia who were admitted for persistent psychotic symptoms and poor mothering skills, participated in the intervention', 'mothers with postpartum psychosis or schizophrenia']","['Video Feedback Enabled Interventions', 'video feedback']",['PIPE scores'],"[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0871189', 'cui_str': 'Psychotic symptom'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C0520678', 'cui_str': 'Postpartum psychosis (disorder)'}]","[{'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0562342', 'cui_str': 'Empowered (finding)'}]","[{'cui': 'C0071109', 'cui_str': ""piperazine-N,N'-bis(2-ethanesulfonic acid), sodium salt""}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",2.0,0.0366468,"CONCLUSIONS Video feedback is a simple and inexpensive tool which can be used for improving mothering skills among mothers with postpartum psychosis or schizophrenia even in low resource settings.","[{'ForeName': 'Pashapu Dharma', 'Initials': 'PD', 'LastName': 'Reddy', 'Affiliation': 'Department of Psychiatric Social Work, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Geehta', 'Initials': 'G', 'LastName': 'Desai', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Ameer', 'Initials': 'A', 'LastName': 'Hamza', 'Affiliation': 'Department of Psychiatric Social Work, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Sheshachala', 'Initials': 'S', 'LastName': 'Karthik', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Supraja Thirumalai', 'Initials': 'ST', 'LastName': 'Ananthanpillai', 'Affiliation': 'Department of Psychiatric Social Work, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Prabha S', 'Initials': 'PS', 'LastName': 'Chandra', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.140702'] 983,32418361,"Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.","INTRODUCTION The API AutosomalDominant AD (ADAD) Colombia Trial is a placebo-controlled clinical trial of crenezumab in 252 cognitively unimpaired 30 to 60-year-old Presenilin 1 (PSEN1) E280A kindred members, including mutation carriers randomized to active treatment or placebo and non-carriers who receive placebo. METHODS Of the 252 enrolled, we present data on a total of 242 mutation carriers and non-carriers matched by age range, excluding data on 10 participants to protect participant confidentiality, genetic status, and trial integrity. RESULTS We summarize demographic, clinical, cognitive, and behavioral data from 167 mutation carriers and 75 non-carriers, 30 to 53 years of age. Carriers were significantly younger than non-carriers ((mean age ± SD) 37 ± 5 vs 42 ± 6), had significantly lower Mini Mental Status Exam (MMSE) scores (28.8 ± 1.4 vs 29.2 ± 1.0), and had consistently lower memory scores. DISCUSSION Although PSEN1 E280A mutation carriers in the Trial are cognitively unimpaired, they have slightly lower MMSE and memory scores than non-carriers. Their demographic characteristics are representative of the local population.",2020,"Carriers were significantly younger than non-carriers ((mean age ± SD) 37 ± 5 vs 42 ± 6), had significantly lower Mini Mental Status Exam (MMSE) scores (28.8 ± 1.4 vs 29.2 ± 1.0), and had consistently lower memory scores. ","['167 mutation carriers and 75 non-carriers, 30 to 53 years of age', '252 cognitively unimpaired 30 to 60-year-old Presenilin 1 (PSEN1', 'Of the 252 enrolled, we present data on a total of 242 mutation carriers and non-carriers matched by age range, excluding data on 10 participants to protect participant confidentiality, genetic status, and trial integrity', 'E280A kindred members, including mutation carriers randomized to active treatment or']","['API AutosomalDominant AD (ADAD', 'placebo and non-carriers who receive placebo', 'crenezumab', 'placebo']",['Mini Mental Status Exam (MMSE) scores'],"[{'cui': 'C4517595', 'cui_str': '167'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0299212', 'cui_str': 'Presenilin 1'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0017296', 'cui_str': 'Gene therapy'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0002191', 'cui_str': 'alpha 1-Antitrypsin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}, {'cui': 'C3493199', 'cui_str': 'crenezumab'}]","[{'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",252.0,0.37236,"Carriers were significantly younger than non-carriers ((mean age ± SD) 37 ± 5 vs 42 ± 6), had significantly lower Mini Mental Status Exam (MMSE) scores (28.8 ± 1.4 vs 29.2 ± 1.0), and had consistently lower memory scores. ","[{'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Rios-Romenets', 'Affiliation': 'Neurosciences Group of Antioquia/University of Antioquia, Medellin, Colombia.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Lopera', 'Affiliation': 'Neurosciences Group of Antioquia/University of Antioquia, Medellin, Colombia.'}, {'ForeName': 'Kaycee M', 'Initials': 'KM', 'LastName': 'Sink', 'Affiliation': 'Genentech Inc., South San Francisco, California, USA.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Hu', 'Affiliation': 'Genentech Inc., South San Francisco, California, USA.'}, {'ForeName': 'Qinshu', 'Initials': 'Q', 'LastName': 'Lian', 'Affiliation': 'Genentech Inc., South San Francisco, California, USA.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Guthrie', 'Affiliation': 'Genentech Inc., South San Francisco, California, USA.'}, {'ForeName': 'Jillian', 'Initials': 'J', 'LastName': 'Smith', 'Affiliation': 'Roche Products Ltd, Welwyn Garden City, UK.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Cho', 'Affiliation': 'Genentech Inc., South San Francisco, California, USA.'}, {'ForeName': 'Howard', 'Initials': 'H', 'LastName': 'Mackey', 'Affiliation': 'Genentech Inc., South San Francisco, California, USA.'}, {'ForeName': 'Jessica B', 'Initials': 'JB', 'LastName': 'Langbaum', 'Affiliation': ""Banner Alzheimer's Institute, Phoenix, Arizona, USA.""}, {'ForeName': 'Ronald G', 'Initials': 'RG', 'LastName': 'Thomas', 'Affiliation': 'University of California, San Diego, California, USA.'}, {'ForeName': 'Margarita', 'Initials': 'M', 'LastName': 'Giraldo-Chica', 'Affiliation': 'Neurosciences Group of Antioquia/University of Antioquia, Medellin, Colombia.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Tobon', 'Affiliation': 'Neurosciences Group of Antioquia/University of Antioquia, Medellin, Colombia.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Acosta-Baena', 'Affiliation': 'Neurosciences Group of Antioquia/University of Antioquia, Medellin, Colombia.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Muñoz', 'Affiliation': 'Neurosciences Group of Antioquia/University of Antioquia, Medellin, Colombia.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Ospina', 'Affiliation': 'Neurosciences Group of Antioquia/University of Antioquia, Medellin, Colombia.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Tirado', 'Affiliation': 'Neurosciences Group of Antioquia/University of Antioquia, Medellin, Colombia.'}, {'ForeName': 'Eliana', 'Initials': 'E', 'LastName': 'Henao', 'Affiliation': 'Neurosciences Group of Antioquia/University of Antioquia, Medellin, Colombia.'}, {'ForeName': 'Yamile', 'Initials': 'Y', 'LastName': 'Bocanegra', 'Affiliation': 'Neurosciences Group of Antioquia/University of Antioquia, Medellin, Colombia.'}, {'ForeName': 'Kewei', 'Initials': 'K', 'LastName': 'Chen', 'Affiliation': ""Banner Alzheimer's Institute, Phoenix, Arizona, USA.""}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Su', 'Affiliation': ""Banner Alzheimer's Institute, Phoenix, Arizona, USA.""}, {'ForeName': 'Dhruman', 'Initials': 'D', 'LastName': 'Goradia', 'Affiliation': ""Banner Alzheimer's Institute, Phoenix, Arizona, USA.""}, {'ForeName': 'Pradeep', 'Initials': 'P', 'LastName': 'Thiyyagura', 'Affiliation': ""Banner Alzheimer's Institute, Phoenix, Arizona, USA.""}, {'ForeName': 'Paul S', 'Initials': 'PS', 'LastName': 'VanGilder', 'Affiliation': ""Banner Alzheimer's Institute, Phoenix, Arizona, USA.""}, {'ForeName': 'Ji', 'Initials': 'J', 'LastName': 'Luo', 'Affiliation': ""Banner Alzheimer's Institute, Phoenix, Arizona, USA.""}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Ghisays', 'Affiliation': ""Banner Alzheimer's Institute, Phoenix, Arizona, USA.""}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Lee', 'Affiliation': ""Banner Alzheimer's Institute, Phoenix, Arizona, USA.""}, {'ForeName': 'Michael H', 'Initials': 'MH', 'LastName': 'Malek-Ahmadi', 'Affiliation': ""Banner Alzheimer's Institute, Phoenix, Arizona, USA.""}, {'ForeName': 'Hillary D', 'Initials': 'HD', 'LastName': 'Protas', 'Affiliation': ""Banner Alzheimer's Institute, Phoenix, Arizona, USA.""}, {'ForeName': 'Yinghua', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': ""Banner Alzheimer's Institute, Phoenix, Arizona, USA.""}, {'ForeName': 'Yakeel T', 'Initials': 'YT', 'LastName': 'Quiroz', 'Affiliation': 'Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Eric M', 'Initials': 'EM', 'LastName': 'Reiman', 'Affiliation': ""Banner Alzheimer's Institute, Phoenix, Arizona, USA.""}, {'ForeName': 'Pierre N', 'Initials': 'PN', 'LastName': 'Tariot', 'Affiliation': ""Banner Alzheimer's Institute, Phoenix, Arizona, USA.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': 'Neurosciences Group of Antioquia/University of Antioquia, Medellin, Colombia.'}]",Alzheimer's & dementia : the journal of the Alzheimer's Association,['10.1002/alz.12109'] 984,25534356,Tract-based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants.,"Despite improved survival, many preterm infants undergo subsequent neurodevelopmental impairment. To date, no neuroprotective therapies have been implemented into clinical practice. Erythropoietin, a haematopoietic cytokine used for treatment of anaemia of prematurity, has been shown to have neuroprotective and neuroregenerative effects on the brain in many experimental studies. The aim of the study was to assess the effect of recombinant human erythropoietin on the microstructural development of the cerebral white matter using tract-based spatial statistics performed at term equivalent age. A randomized, double-blind placebo-controlled, prospective multicentre study applying recombinant human erythropoietin in the first 42 h after preterm birth entitled 'Does erythropoietin improve outcome in preterm infant' was conducted in Switzerland (NCT00413946). Preterm infants were given recombinant human erythropoietin (3000 IU) or an equivalent volume of placebo (NaCl 0.9%) intravenously before 3 h of age after birth, at 12-18 h and at 36-42 h after birth. High resolution diffusion tensor imaging was obtained at 3 T in 58 preterm infants with mean (standard deviation) gestational age at birth 29.75 (1.44) weeks, and at scanning at 41.1 (2.09) weeks. Imaging was performed at a single centre. Voxel-wise statistical analysis of the fractional anisotropy data was carried out using tract-based spatial statistics to test for differences in fractional anisotropy between infants treated with recombinant human erythropoietin and placebo using a general linear model, covarying for the gestational age at birth and the corrected gestational age at the time of the scan. Preterm infants treated with recombinant human erythropoietin demonstrated increased fractional anisotropy in the genu and splenium of the corpus callosum, the anterior and posterior limbs of the internal capsule, and the corticospinal tract bilaterally. Mean fractional anisotropy was significantly higher in preterm infants treated with recombinant human erythropoietin than in those treated with placebo (P < 0.001). We conclude that early recombinant human erythropoietin administration improves white matter development in preterm infants assessed by diffusion tensor imaging and tract-based spatial statistics.",2015,"Preterm infants treated with recombinant human erythropoietin demonstrated increased fractional anisotropy in the genu and splenium of the corpus callosum, the anterior and posterior limbs of the internal capsule, and the corticospinal tract bilaterally.","['58 preterm infants with mean (standard deviation) gestational age at birth 29.75 (1.44) weeks, and at scanning at 41.1 (2.09) weeks', 'preterm infants', 'Preterm infants treated with', 'Preterm infants']","['recombinant human erythropoietin (3000 IU) or an equivalent volume of placebo', 'Erythropoietin', 'placebo', 'recombinant human erythropoietin', 'recombinant human erythropoietin and placebo']","['Mean fractional anisotropy', 'fractional anisotropy']","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0456129', 'cui_str': 'Length of gestation at birth'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0014822', 'cui_str': 'Erythropoietin'}, {'cui': 'C0470279', 'cui_str': 'Three thousand'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0085406', 'cui_str': 'Anisotropy'}]",58.0,0.216695,"Preterm infants treated with recombinant human erythropoietin demonstrated increased fractional anisotropy in the genu and splenium of the corpus callosum, the anterior and posterior limbs of the internal capsule, and the corticospinal tract bilaterally.","[{'ForeName': 'Ruth L', 'Initials': 'RL', 'LastName': ""O'Gorman"", 'Affiliation': ""1 MR Research Centre, Children's University Hospital of Zurich, Switzerland.""}, {'ForeName': 'Hans U', 'Initials': 'HU', 'LastName': 'Bucher', 'Affiliation': '2 Department of Neonatology, University Hospital of Zurich, Switzerland.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Held', 'Affiliation': '3 Horten Centre, University Hospital of Zurich, Switzerland.'}, {'ForeName': 'Brigitte M', 'Initials': 'BM', 'LastName': 'Koller', 'Affiliation': '2 Department of Neonatology, University Hospital of Zurich, Switzerland.'}, {'ForeName': 'Petra S', 'Initials': 'PS', 'LastName': 'Hüppi', 'Affiliation': '3 Horten Centre, University Hospital of Zurich, Switzerland 4 Division of Development and Growth, Department of Paediatrics, University of Geneva, Switzerland.'}, {'ForeName': 'Cornelia F', 'Initials': 'CF', 'LastName': 'Hagmann', 'Affiliation': '2 Department of Neonatology, University Hospital of Zurich, Switzerland Cornelia.hagmann@usz.ch.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Brain : a journal of neurology,['10.1093/brain/awu363'] 985,25703043,Family caregivers' mental health is associated with postoperative recovery of elderly patients with hip fracture: a sample in Taiwan.,"OBJECTIVE This study investigated the relationship between family caregivers' mental health and postoperative recovery for elderly patients with hip fracture in Taiwan. METHODS This study is a secondary analysis of data from a randomized controlled trial with 12-month follow-up on 276 family caregiver-patient dyads. Categories of caregiver mental-health trajectory groups were identified by latent-class finite-mixture modeling. Differences in these groups were explored using the generalized estimating equation approach for effects on patients' postoperative recovery, including pain intensity, range of motion, maximum muscle strength, recovery of self-care ability, mobility, re-hospitalization, and health-related quality of life. RESULTS The patterns of family caregivers' mental health best fit a three-group trajectory model (poor, moderate, and good). Compared to patients with caregivers in the ""poor"" mental health group, patients with caregivers in the ""good"" group had better trajectories in physical functional recovery, including mobility, muscle strength, hip flexion and extension, and ankle extension. These patients were also less likely to be hospitalized, experienced less pain, and had better physical and mental health. Patients with caregivers in the ""moderate"" group likewise performed better than those in the ""poor"" group. CONCLUSION During the first year following discharge, postoperative recovery of patients after hip fracture was associated with their family caregivers' mental health. When a family caregiver's mental health was ""poor,"" the patient recovering after hip-fracture surgery was more likely to recover poorly. These results suggest that health care providers could consider family caregivers' mental well-being while estimating recovery times and health outcomes of patients following hip fracture.",2015,"During the first year following discharge, postoperative recovery of patients after hip fracture was associated with their family caregivers' mental health.","['276 family caregiver-patient dyads', 'elderly patients with hip fracture', 'elderly patients with hip fracture in Taiwan']",[],"['pain intensity, range of motion, maximum muscle strength, recovery of self-care ability, mobility, re-hospitalization, and health-related quality of life', 'physical functional recovery, including mobility, muscle strength, hip flexion and extension, and ankle extension']","[{'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0019557', 'cui_str': 'Hip Fractures'}, {'cui': 'C0039260', 'cui_str': 'Formosa'}]",[],"[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0080078', 'cui_str': 'Range of Motion'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0562734', 'cui_str': 'Ability to perform self-care activities'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0231452', 'cui_str': 'Flexion, function (observable entity)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0003086', 'cui_str': 'Regio tarsalis'}]",276.0,0.048408,"During the first year following discharge, postoperative recovery of patients after hip fracture was associated with their family caregivers' mental health.","[{'ForeName': 'Hsin-Yun', 'Initials': 'HY', 'LastName': 'Liu', 'Affiliation': 'Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan.'}, {'ForeName': 'Ching-Tzu', 'Initials': 'CT', 'LastName': 'Yang', 'Affiliation': 'School of Nursing, College of Medicine, Chang Gung University, Taoyuan, Taiwan.'}, {'ForeName': 'Huey-Shinn', 'Initials': 'HS', 'LastName': 'Cheng', 'Affiliation': 'Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.'}, {'ForeName': 'Chi-Chuan', 'Initials': 'CC', 'LastName': 'Wu', 'Affiliation': 'Traumatological Division, Department of Orthopedics, Chang Gung Memorial Hospital, Taoyuan, Taiwan.'}, {'ForeName': 'Ching-Yen', 'Initials': 'CY', 'LastName': 'Chen', 'Affiliation': 'Section of General Psychiatry, Department of Psychiatry, Chang Gung Memorial Hospital, Taoyuan, Taiwan.'}, {'ForeName': 'Yea-Ing L', 'Initials': 'YL', 'LastName': 'Shyu', 'Affiliation': 'Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan; School of Nursing, College of Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address: yeaing@mail.cgu.edu.tw.'}]",Journal of psychosomatic research,['10.1016/j.jpsychores.2015.02.002'] 986,25687878,Galvanic Vestibular Stimulation: a new model of placebo-induced nausea.,"OBJECTIVE Traditional rotation-based models of placebo nausea are limited because they do not have vehicle settings and are tied to their context. The present study introduces a new model for examining placebo-induced nausea in the laboratory that overcomes these limitations, namely, Galvanic Vestibular Stimulation (GVS). GVS stimulates the vestibular system to cause nausea through sensory mismatch with visual cues and importantly has a non-nauseating placebo setting. Using this, we tested whether conditioning could elicit placebo nausea when participants were later exposed to placebo stimulation as well as whether this placebo nausea was generalised across contexts--something that is extremely difficult to test with rotation-based models of placebo nausea. METHODS Thirty healthy undergraduate students were randomised to receive either placebo GVS (controls) or active GVS during training (Context-Consistent and Context-Change). On test, all groups received placebo GVS. The controls and Context-Consistent groups were tested in the same context as training, whereas the Context-Change group was tested in a new context. RESULTS Participants conditioned with nausea during training had significantly higher nausea symptom ratings after placebo stimulation on test than those given no conditioning. This placebo-induced nausea also generalised to a novel test context with no differences observed between the Context-Change and Context-Consistent groups. CONCLUSION GVS provides a new model of placebo-induced nausea that overcomes limitations to traditional rotation-based paradigms. Future studies should use this device to explore the effect of instructions and conditioning on the development of placebo nausea and to assess the efficacy of conditioning-based interventions for clinical use.",2015,"RESULTS Participants conditioned with nausea during training had significantly higher nausea symptom ratings after placebo stimulation on test than those given no conditioning.",['Thirty healthy undergraduate students'],"['placebo', 'Galvanic Vestibular Stimulation', 'placebo GVS (controls) or active GVS during training (Context-Consistent and Context-Change', 'GVS', 'placebo GVS']","['nausea', 'nausea symptom ratings']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0449255', 'cui_str': 'Context (attribute)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]","[{'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0429688', 'cui_str': 'Symptom ratings (staging scale)'}]",30.0,0.261478,"RESULTS Participants conditioned with nausea during training had significantly higher nausea symptom ratings after placebo stimulation on test than those given no conditioning.","[{'ForeName': 'V F', 'Initials': 'VF', 'LastName': 'Quinn', 'Affiliation': 'School of Psychology, The University of Sydney, Australia. Electronic address: benicky.quinn@sydney.edu.au.'}, {'ForeName': 'H G', 'Initials': 'HG', 'LastName': 'MacDougall', 'Affiliation': 'School of Psychology, The University of Sydney, Australia.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Colagiuri', 'Affiliation': 'School of Psychology, The University of Sydney, Australia.'}]",Journal of psychosomatic research,['10.1016/j.jpsychores.2014.12.011'] 987,24249927,Tramadol use in premature ejaculation: daily versus sporadic treatment.,"AIM Premature ejaculation (PME) is defined as ejaculation with the minimal sexual stimulation before, on or shortly after penetration and or before a person wishes it. It is a function of the time between intra-vaginal penetration and intra-vaginal ejaculation. Tramadol has shown efficacy in PME when used as sporadic basis. In this study, we compared the use of 100 mg of tramadol as sporadic treatment (administered 6-8 h before coitus) versus continued treatment with the objective of evaluating the therapeutic results of both modalities. We assumed our alternative hypothesis that they have similar effects. MATERIALS AND METHODS A prospective study was carried out on 60 patients divided into two groups of 30 patients each. Intra-vaginal ejaculation latency time (IELT) and coital frequency were measured both prior to and after the treatment. Group A received tramadol 100 mg daily for 4 weeks and on request (sporadically) for 4 weeks more. Group B was given placebo in the same manner. Results were statistically analyzed using the Student t-test. RESULTS Mean IELT prior to treatment was 59.2 s in Group A and 58.7 s in Group B. Mean pre-treatment coital frequency was 2.44 times/week for Group A and 2.13 times/week for Group B. Mean IELT was 202.5 s after continued tramadol treatment and 238.2 s after sporadic treatment in Group A. Mean IELT with daily placebo was 94.8 s and with sporadic placebo was 96.6 s. Coital frequency increased to 4.32 times/week with daily tramadol treatment and 4.86 times with sporadic treatment. Coital frequency increased to 2.88 times/week with daily placebo treatment and 3.23 times with sporadic treatment. CONCLUSIONS The results of PME treatment with tramadol are similar with both continued and sporadic administration. The sex life of patients improved and they reported greater satisfaction with the sporadic treatment.",2013,"Coital frequency increased to 2.88 times/week with daily placebo treatment and 3.23 times with sporadic treatment. ","['premature ejaculation', '60 patients divided into two groups of 30 patients each']","['placebo', 'sporadic placebo', 'IELT with daily placebo', 'tramadol', 'Premature ejaculation (PME', 'Tramadol']","['Coital frequency', 'Intra-vaginal ejaculation latency time (IELT) and coital frequency', 'Mean pre-treatment coital frequency', 'Mean IELT']","[{'cui': 'C0033038', 'cui_str': 'Ejaculatio Praecox'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205422', 'cui_str': 'Sporadic (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C0033038', 'cui_str': 'Ejaculatio Praecox'}]","[{'cui': 'C0009252', 'cui_str': 'Coital Frequency'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0013746', 'cui_str': 'Ejaculation'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",60.0,0.0193518,"Coital frequency increased to 2.88 times/week with daily placebo treatment and 3.23 times with sporadic treatment. ","[{'ForeName': 'Amil H', 'Initials': 'AH', 'LastName': 'Khan', 'Affiliation': 'Department of Psychiatry, BRD Medical College, Gorakhpur, Uttar Pradesh,, India.'}, {'ForeName': 'Deepa', 'Initials': 'D', 'LastName': 'Rasaily', 'Affiliation': ''}]",Indian journal of psychological medicine,['10.4103/0253-7176.119477'] 988,24860217,A Placebo Controlled Trial on Add-on Modafinil on the Anti-psychotic Treatment Emergent Hyperglycemia and Hyperlipidemia.,"UNLABELLED Modafinil is non stimulant drug which is marketed for mainly Narcolepsy and daytime drowsiness. The clinical experience and Summary of Product Characteristics (SPC) of the drug also mentions Anorexia as one of the side effects. Anorexia can have a direct impact on the carbohydrate and fat intake, which may, in turn, regulate antipsychotic induced dyslipidemia and Hyperglycaemia. AIM To compare the effects of Modafinil- ADDON with Placebo add on with olanzapine, Clozapine and Risperidone in drug naive subjects and people who were started on the drugs within 15days of assessment. MATERIALS AND METHODS Randomized, Double blind, Placebo controlled study, which was conducted at two centres, one at department of Psychiatry, S.V Medical College, Tirupati and the other at Asha hospitals, Hyderabad. Seventy two patient were randomised, sixty three patients have completed the total study period of three months. The dose of Modafinil was 200 mgs constantly as Flexible doses of Olanzapine, Clozapine and Risperidone as per clinical need was given. A baseline, three week and twelve week assessments of Fasting blood Glucose and fasting Serum cholesterol were made and the groups were compared on these parameters. RESULTS From baseline to week 3 there was a significant raise in Fasting serum cholesterol followed by a fall from week 3 to week 12 in the Modafinil addon group, though it could not be considered a drug for hypercholesteremia like Statins in controlling hyperlipidaemia. The implications of these findings were discussed.",2014,"there was a significant raise in Fasting serum cholesterol followed by a fall from week 3 to week 12 in the Modafinil addon group, though it could not be considered a drug for hypercholesteremia like Statins in controlling hyperlipidaemia.","['Anti-psychotic Treatment Emergent Hyperglycemia and Hyperlipidemia', 'drug naive subjects and people who were started on the drugs within 15days of assessment', 'Seventy two patient were randomised, sixty three patients have completed the total study period of three months', 'two centres, one at department of Psychiatry, S.V Medical College, Tirupati and the other at Asha hospitals, Hyderabad']","['Olanzapine, Clozapine and Risperidone', 'Placebo', 'Modafinil', 'olanzapine, Clozapine and Risperidone']","['Fasting serum cholesterol', 'Fasting blood Glucose and fasting Serum cholesterol']","[{'cui': 'C0033975', 'cui_str': 'Psychoses'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0020473', 'cui_str': 'Hyperlipemia'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C4319632', 'cui_str': 'Seventy-two'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319614', 'cui_str': '63 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4082119', 'cui_str': 'Three months (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}]","[{'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C0009079', 'cui_str': 'Clozapine'}, {'cui': 'C0073393', 'cui_str': 'Risperidone'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0066677', 'cui_str': 'modafinil'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0587184', 'cui_str': 'Serum cholesterol'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}]",,0.0716564,"there was a significant raise in Fasting serum cholesterol followed by a fall from week 3 to week 12 in the Modafinil addon group, though it could not be considered a drug for hypercholesteremia like Statins in controlling hyperlipidaemia.","[{'ForeName': 'Pathapati Lakshmi', 'Initials': 'PL', 'LastName': 'Prasuna', 'Affiliation': 'Department of Child and Adolescent Psychiatry, NIMHANS, Bangalore, Karnataka, India.'}, {'ForeName': 'Kommu John', 'Initials': 'KJ', 'LastName': 'Vijay Sagar', 'Affiliation': 'Department of Child and Adolescent Psychiatry, NIMHANS, Bangalore, Karnataka, India.'}, {'ForeName': 'Thatikonda Padma', 'Initials': 'TP', 'LastName': 'Sudhakar', 'Affiliation': 'Department of Child and Adolescent Psychiatry, NIMHANS, Bangalore, Karnataka, India.'}, {'ForeName': 'Gundugurthi Prasada', 'Initials': 'GP', 'LastName': 'Rao', 'Affiliation': 'Department of Child and Adolescent Psychiatry, NIMHANS, Bangalore, Karnataka, India.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.130982'] 989,24701008,Silent Epidemic: The Effects of Neurofeedback on Quality-of-Life.,"BACKGROUND The complex interaction of human, vehicle and environmental factors along with a lack of sustainable preventive programs has contributed to the ""silent epidemic"" of traumatic brain injuries (TBI). TBI poses a grave threat to the quality-of-life (QOL). AIM The aim of the present study was to examine the effects of neurofeedback in QOL in patients with TBI. MATERIALS AND METHODS Pre- and post-interventional study design was adopted. Sixty patients, 30 in the intervention group (IG) and 30 in waitlist group with the diagnosis of TBI in the age range of 18-49 years were assessed on QOL scale, after obtaining the informed consent. Patients in the IG were given 20 sessions of alpha-theta neurofeedback training (NFT), 5 sessions / week. STATISTICS ANALYSIS Descriptive statistics, Spearman's correlation, Mann-Whitney and Chi-squared test was used. RESULTS AND CONCLUSION Patients in the IG showed statistical improvements in QOL post post-neurofeedback. Results are encouraging for the incorporation of NFT into treatment programs for patients with TBI in improving QOL.",2014,"RESULTS AND CONCLUSION Patients in the IG showed statistical improvements in QOL post post-neurofeedback.","['Sixty patients, 30 in the intervention group (IG) and 30 in waitlist group with the diagnosis of TBI in the age range of 18-49 years', 'patients with TBI in improving QOL', 'patients with TBI']",['alpha-theta neurofeedback training (NFT'],"['QOL scale', 'Quality-of-Life']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}]","[{'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C2713543', 'cui_str': 'Neurofeedback'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0222045'}, {'cui': 'C0034380'}]",60.0,0.0340417,"RESULTS AND CONCLUSION Patients in the IG showed statistical improvements in QOL post post-neurofeedback.","[{'ForeName': 'Rajakumari Pampa', 'Initials': 'RP', 'LastName': 'Reddy', 'Affiliation': 'Department of Clinical Psychology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.'}, {'ForeName': 'Jamuna', 'Initials': 'J', 'LastName': 'Rajeswaran', 'Affiliation': 'Department of Clinical Psychology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.'}, {'ForeName': 'Indira Devi', 'Initials': 'ID', 'LastName': 'Bhagavatula', 'Affiliation': 'Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.'}, {'ForeName': 'Thennarasu', 'Initials': 'T', 'LastName': 'Kandavel', 'Affiliation': 'Department of Biostatistics, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.127246'] 990,24701009,Seizure duration decreases over a course of bifrontal and not bitemporal electroconvulsive therapy.,"CONTEXT Mechanism of action of electroconvulsive therapy (ECT) is unclear. Anticonvulsant action of ECT has also been one among the hypothesized mechanisms. Anticonvulsant effect may manifest during ECT in at least two ways (a) increased seizure threshold (b) decrease in seizure duration. In depression, increased seizure threshold has been shown to be associated with better antidepressant response. However, relationship between seizure duration and antidepressant activity has been inconsistent. These issues are not investigated in conditions other than depression. AIMS We examined seizure duration over the course of ECT in schizophrenia patients. SETTINGS AND DESIGN Material for this analysis was obtained from a clinical trial examining the differential efficacy of bifrontal ECT (BFECT) versus bitemporal ECT (BTECT) in schizophrenia patients. As a part of study 122 schizophrenia patients who were prescribed ECT were randomized to receive either BFECT or BTECT. SUBJECTS AND METHODS Final analysis was conducted on data from 70 patients, as the rest of the data either had artifact or there was a significant change in medication status. Electroencephalogram seizure duration was noted in each session for these patients. RESULTS Seizure duration declined significantly from second ECT to 6(th) ECT (repeated measures analysis of variance F = 4.255; P = 0.006). When separate analysis was conducted for BTECT and BFECT patients the decline in seizure duration from 2(nd) to 6(th) ECT was significant only with BFECT (F = 3.94; P = 0.014) and not with BTECT (F = 0.966; P = 0.424). CONCLUSIONS Better anticonvulsant effects with BFECT may explain the better therapeutic observed with BFECT in schizophrenia as well as mania in our earlier studies.",2014,"RESULTS Seizure duration declined significantly from second ECT to 6(th) ECT (repeated measures analysis of variance F = 4.255; P = 0.006).","['Final analysis was conducted on data from 70 patients, as the rest of the data either had artifact or there was a significant change in medication status', '122 schizophrenia patients who were prescribed ECT', 'schizophrenia patients']","['bifrontal ECT (BFECT) versus bitemporal ECT (BTECT', 'BFECT or BTECT', 'BFECT', 'ECT', 'electroconvulsive therapy (ECT']","['seizure threshold (b) decrease in seizure duration', 'Seizure duration', 'Electroencephalogram seizure duration']","[{'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0085089', 'cui_str': 'Artifacts'}, {'cui': 'C1292718', 'cui_str': 'Is a'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0013806', 'cui_str': 'Electroshock Therapy'}]","[{'cui': 'C0445448', 'cui_str': 'Bifrontal (qualifier value)'}, {'cui': 'C0013806', 'cui_str': 'Electroshock Therapy'}, {'cui': 'C0445452', 'cui_str': 'Bitemporal (qualifier value)'}]","[{'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0449864', 'cui_str': 'Threshold (property) (qualifier value)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1527380', 'cui_str': 'Electroencephalogram'}]",122.0,0.158427,"RESULTS Seizure duration declined significantly from second ECT to 6(th) ECT (repeated measures analysis of variance F = 4.255; P = 0.006).","[{'ForeName': 'Hulegar A', 'Initials': 'HA', 'LastName': 'Abhishekh', 'Affiliation': 'Medical Student, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India.'}, {'ForeName': 'Jagadisha', 'Initials': 'J', 'LastName': 'Thirthalli', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.'}, {'ForeName': 'Anusha', 'Initials': 'A', 'LastName': 'Hegde', 'Affiliation': 'Medical Student, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India.'}, {'ForeName': 'Vivek H', 'Initials': 'VH', 'LastName': 'Phutane', 'Affiliation': 'Department of Psychiatry, Royal Melbourne Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Channaveerachari N', 'Initials': 'CN', 'LastName': 'Kumar', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.'}, {'ForeName': 'Kesavan', 'Initials': 'K', 'LastName': 'Muralidharan', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.'}, {'ForeName': 'Bangalore N', 'Initials': 'BN', 'LastName': 'Gangadhar', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.127248'] 991,24701015,Acute antidepressant effects of intramuscular versus intravenous ketamine.,"OBJECTIVE Conventional antidepressants take two weeks before their therapeutic action begins. Recent studies have reported on the rapid antidepressant effect of ketamine when given as an intravenous (I.V.) infusion. Little is known about its intramuscular (I.M.) use in depression. Hence this study was conducted to compare the safety, tolerability and efficacy of I.M. versus. I.V. ketamine in Major Depression (ICD-10). MATERIALS AND METHODS It was a randomized open label parallel group study in a tertiary care teaching hospital. Study sample consisted of 27 subjects having major depression divided randomly into three groups of nine subjects each. Ketamine administered to each group in the dose of 0.5 mg/kg as an I.V. infusion, as 0.5 mg/kg I.M. or 0.25 mg/kg I.M. respectively. Depression rated on the Hamilton Depression Rating Scale (HAM-D) before the injection, two hours later, the next day, and after three days. Data analyzed using the Statistical Package for Social Sciences (SPSS). RESULTS Mean age of the sample was 36.81 years (SD 11.815). Two hours after the injection, HAM-D fell by 58.86%, 60.29% & 57.36% in each group respectively. The improvement was sustained for next three days. Adverse effects noticed were rare, of mild nature and transient, lasting less than an hour. CONCLUSIONS Intramuscular ketamine in the dose of 0.25 mg/kg is as effective and safe as 0.5 mg/kg given either I.M. or I.V., substantially alleviating depressive symptoms within a few hours and sustained for 3 days.",2014,"Two hours after the injection, HAM-D fell by 58.86%, 60.29% & 57.36% in each group respectively.","['It was a randomized open label parallel group study in a tertiary care teaching hospital', 'Mean age of the sample was 36.81 years (SD 11.815', '27 subjects having major depression divided randomly into three groups of nine subjects each']","['Ketamine', 'ketamine', 'intramuscular versus intravenous ketamine']","['effective and safe', 'Hamilton Depression Rating Scale (HAM-D', 'safety, tolerability and efficacy', 'depressive symptoms', 'HAM-D fell']","[{'cui': 'C1292718', 'cui_str': 'Is a'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0020027', 'cui_str': 'Teaching Hospitals'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0332849', 'cui_str': 'Divide'}]","[{'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular (qualifier value)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}]","[{'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C3853311', 'cui_str': 'Ham'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0000921', 'cui_str': 'Falls'}]",,0.0520595,"Two hours after the injection, HAM-D fell by 58.86%, 60.29% & 57.36% in each group respectively.","[{'ForeName': 'Harihar', 'Initials': 'H', 'LastName': 'Chilukuri', 'Affiliation': 'Department of Psychiatry, Malla Reddy Institute of Medical Sciences, Hyderabad, Andhra Pradesh, India.'}, {'ForeName': 'Narasimha Pothula', 'Initials': 'NP', 'LastName': 'Reddy', 'Affiliation': 'Department of Anaesthesia, Narayana Medical College, Nellore, Andhra Pradesh, India.'}, {'ForeName': 'Ram Mohan', 'Initials': 'RM', 'LastName': 'Pathapati', 'Affiliation': 'Department of Pharmacology, Narayana Medical College, Nellore, Andhra Pradesh, India.'}, {'ForeName': 'Arkalgud Nagesha', 'Initials': 'AN', 'LastName': 'Manu', 'Affiliation': 'Department of Psychiatry, Narayana Medical College, Nellore, Andhra Pradesh, India.'}, {'ForeName': 'Sharada', 'Initials': 'S', 'LastName': 'Jollu', 'Affiliation': 'Department of Psychiatry, Narayana Medical College, Nellore, Andhra Pradesh, India.'}, {'ForeName': 'Ahammed Basha', 'Initials': 'AB', 'LastName': 'Shaik', 'Affiliation': 'Department of Statistics, Narayana Medical College, Nellore, Andhra Pradesh, India.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.127258'] 992,24867959,A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.,"BACKGROUND Peripheral neuropathy is the dose limiting toxicity of bortezomib in patients with multiple myeloma (MM). OBJECTIVES To examine the safety, feasibility and efficacy of acupuncture in reducing bortezomib-induced peripheral neuropathy (BIPN) symptoms. METHODS Patients with MM experiencing persistent BIPN ≥grade 2 despite adequate medical intervention and discontinuation of bortezomib received 10 acupuncture treatments for 10 weeks (2×/week for 2 weeks, 1×/week for 4 weeks, and then biweekly for 4 weeks). Responses were assessed by the Clinical Total Neuropathy Score (TNSc), Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire, and the Neuropathy Pain Scale (NPS). Repeated-measures analysis of variance was used to test for monotonic decline in scores on each of the measures. Serial serum levels of proinflammatory and neurotrophic cytokines were obtained at baseline and weeks 1, 2, 4, 8, and 14. RESULTS Twenty-seven patients with MM were enrolled in the trial. There were no adverse events associated with the acupuncture treatments. TNSc data were deemed invalid and therefore were not reported. At weeks 10 and 14, FACT/GOG-Ntx and NPS showed significant reduction suggesting decreased pain, and improved function (P values were <.0001 for both FACT/GOG-Ntx and NPS at weeks 10 and 14). However, nerve conduction studies did not significantly change between baseline assessment and end of study. There was no correlation in serum cytokines for responders versus none responders. CONCLUSIONS Acupuncture is safe, feasible and produces subjective improvements in patients' symptoms. A follow-up randomized controlled trial is warranted.",2014,"At weeks 10 and 14, FACT/GOG-Ntx and NPS showed significant reduction suggesting decreased pain, and improved function (P values were <.0001 for both FACT/GOG-Ntx and NPS at weeks 10 and 14).","['Twenty-seven patients with MM were enrolled in the trial', 'patients with multiple myeloma', 'patients with multiple myeloma (MM', 'Patients with MM experiencing persistent BIPN ≥grade 2 despite adequate medical intervention and discontinuation of']","['bortezomib received 10 acupuncture treatments', 'acupuncture', 'bortezomib', 'Acupuncture']","['Clinical Total Neuropathy Score (TNSc), Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire, and the Neuropathy Pain Scale (NPS', 'Serial serum levels of proinflammatory and neurotrophic cytokines', 'serum cytokines', 'safety, feasibility and efficacy', 'pain, and improved function']","[{'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0026764', 'cui_str': 'Myelomatosis'}, {'cui': 'C0205411', 'cui_str': 'Adequate (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}]","[{'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C0394664', 'cui_str': 'Acupuncture Treatment'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy (disorder)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205480', 'cui_str': 'Gynecologic (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0235032', 'cui_str': 'Neurotoxin Diseases'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C4704801', 'cui_str': 'Neurotrophic'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}]",27.0,0.0565512,"At weeks 10 and 14, FACT/GOG-Ntx and NPS showed significant reduction suggesting decreased pain, and improved function (P values were <.0001 for both FACT/GOG-Ntx and NPS at weeks 10 and 14).","[{'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Bao', 'Affiliation': 'The University of Maryland School of Medicine, Baltimore, MD, USA baot@mskcc.org.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Goloubeva', 'Affiliation': 'The University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Colleen', 'Initials': 'C', 'LastName': 'Pelser', 'Affiliation': 'The University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Porter', 'Affiliation': 'The University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Primrose', 'Affiliation': 'The University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Hester', 'Affiliation': 'The University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Mariola', 'Initials': 'M', 'LastName': 'Sadowska', 'Affiliation': 'The University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Rena', 'Initials': 'R', 'LastName': 'Lapidus', 'Affiliation': 'The University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Medeiros', 'Affiliation': 'The University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Lixing', 'Initials': 'L', 'LastName': 'Lao', 'Affiliation': 'The University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Susan G', 'Initials': 'SG', 'LastName': 'Dorsey', 'Affiliation': 'The University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Ashraf Z', 'Initials': 'AZ', 'LastName': 'Badros', 'Affiliation': 'The University of Maryland School of Medicine, Baltimore, MD, USA.'}]",Integrative cancer therapies,['10.1177/1534735414534729'] 993,31321887,Index participant characteristics and HIV assisted partner services efficacy in Kenya: results of a cluster randomized trial.,"INTRODUCTION We have previously demonstrated that assisted partner services (aPS) increases HIV testing and case finding among partners of persons living with HIV (PLHIV) in a cluster randomized trial in Kenya. However, the efficacy of aPS may vary across populations. In this analysis, we explore differences in aPS efficacy by characteristics of index participants. METHODS Eighteen HIV testing sites were randomized to immediate versus 6-week delayed aPS. Participants were PLHIV (or index participants) and their sexual partners. Partners of index participants were contacted for HIV testing and linked to care if HIV positive. Primary outcomes were the number of partners per index participant who: 1) tested for HIV, 2) tested HIV positive and 3) enrolled in HIV care. We used generalized estimating equations to assess differences in aPS efficacy by region, testing location, gender, age and knowledge of HIV status. RESULTS From 2013 to 2015, the study enrolled 1119 index participants, 625 of whom were in the immediate group. These index participants named 1286 sexual partners. Immediate aPS was more efficacious than delayed aPS in promoting HIV testing among partners in high compared to low HIV prevalence regions (Nyanza incidence rate ratio (IRR) 7.2; 95% confidence interval (CI) 5.4, 9.6 vs. Nairobi/Central IRR 3.4 95% CI 2.3, 4.8). Higher rates of partner HIV testing were also observed for index participants in rural/peri-urban compared to urban sites (IRR 6.6; 95% CI 4.5, 9.6 vs. IRR 3.5 95% CI 2.5, 5.0 respectively), for female versus male index participants (IRR 5.8 95% CI 4.2, 7.9 vs. IRR 3.7; 95% CI 2.4, 5.8 respectively) and for newly diagnosed versus known HIV-positive index participants (IRR 6.0 95% CI 4.2, 8.7 vs. IRR 3.3; 95% CI 2.0, 7.7 respectively). Providing aPS to female versus male index participants also had a significantly higher HIV case finding rate (IRR 9.1; 95% CI 4.0, 20.9 vs. IRR 3.2 95% CI 1.7, 6.0 respectively.) CONCLUSIONS: While it is known that aPS promotes increases in HIV testing and case finding, this is the first study to demonstrate significant differences in aPS efficacy across characteristics of the index participant. Understanding these differences and their drivers will be critical as aPS is brought to scale in order to ensure all PLHIV have access to these services.",2019,"Immediate aPS was more efficacious than delayed aPS in promoting HIV testing among partners in high compared to low HIV prevalence regions (Nyanza incidence rate ratio (IRR) 7.2; 95% confidence interval (CI) 5.4, 9.6 vs. Nairobi/Central IRR 3.4 95% CI 2.3, 4.8).","['persons living with HIV (PLHIV) in a cluster randomized trial in Kenya', 'Eighteen HIV testing sites', 'Kenya', 'Participants were PLHIV (or index participants) and their sexual partners', 'These index participants named 1286 sexual partners', 'From 2013 to 2015, the study enrolled 1119 index participants, 625 of whom were in the immediate group']","['immediate versus 6-week delayed aPS', 'assisted partner services (aPS']","['number of partners per index participant who: 1) tested for HIV, 2) tested HIV positive and 3) enrolled in HIV care', 'Higher rates of partner HIV testing', 'aPS efficacy']","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0022558', 'cui_str': 'Republic of Kenya'}, {'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C1321876', 'cui_str': 'Human immunodeficiency virus test (procedure)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0036911', 'cui_str': 'Sexual Partners'}, {'cui': 'C4522128', 'cui_str': 'Name (property)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4517838', 'cui_str': 'Six hundred and twenty-five'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0085409', 'cui_str': 'Polyendocrinopathies, Autoimmune'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0085409', 'cui_str': 'Polyendocrinopathies, Autoimmune'}]",1119.0,0.212368,"Immediate aPS was more efficacious than delayed aPS in promoting HIV testing among partners in high compared to low HIV prevalence regions (Nyanza incidence rate ratio (IRR) 7.2; 95% confidence interval (CI) 5.4, 9.6 vs. Nairobi/Central IRR 3.4 95% CI 2.3, 4.8).","[{'ForeName': 'Sarah J', 'Initials': 'SJ', 'LastName': 'Masyuko', 'Affiliation': 'National AIDS and STI Control Program, Ministry of Health, Nairobi, Kenya.'}, {'ForeName': 'Peter K', 'Initials': 'PK', 'LastName': 'Cherutich', 'Affiliation': 'Department of Preventive and Promotive Health Services, Ministry of Health, Nairobi, Kenya.'}, {'ForeName': 'Marielle G', 'Initials': 'MG', 'LastName': 'Contesse', 'Affiliation': 'Department of Epidemiology, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Peter M', 'Initials': 'PM', 'LastName': 'Maingi', 'Affiliation': 'VCT and HIV Prevention Unit, Kenyatta National Hospital, Nairobi, Kenya.'}, {'ForeName': 'Beatrice M', 'Initials': 'BM', 'LastName': 'Wamuti', 'Affiliation': 'Department of Research and Programs, Kenyatta National Hospital, Nairobi, Kenya.'}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Macharia', 'Affiliation': 'National AIDS and STI Control Program, Ministry of Health, Nairobi, Kenya.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Bukusi', 'Affiliation': 'VCT and HIV Prevention Unit, Kenyatta National Hospital, Nairobi, Kenya.'}, {'ForeName': 'Felix A', 'Initials': 'FA', 'LastName': 'Otieno', 'Affiliation': 'Department of Research and Programs, Kenyatta National Hospital, Nairobi, Kenya.'}, {'ForeName': 'Hans Ml', 'Initials': 'HM', 'LastName': 'Spiegel', 'Affiliation': 'Department of Health and Human Services, Kelly Government Solutions, Contractor to National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.'}, {'ForeName': 'Matthew D', 'Initials': 'MD', 'LastName': 'Dunbar', 'Affiliation': 'Department of Computer Science and Demography, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Golden', 'Affiliation': 'Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Barbra A', 'Initials': 'BA', 'LastName': 'Richardson', 'Affiliation': 'Department of Global Health, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Carey', 'Initials': 'C', 'LastName': 'Farquhar', 'Affiliation': 'Department of Global Health, University of Washington, Seattle, WA, USA.'}]",Journal of the International AIDS Society,['10.1002/jia2.25305'] 994,24682975,Randomized study of placebo and framing information in direct-to-consumer print advertisements for prescription drugs.,"BACKGROUND Research suggests that quantitative information in direct-to-consumer (DTC) prescription drug ads may be helpful for consumers. PURPOSE The objective was to examine the effect of adding placebo rates and framing to DTC ads. METHODS In study 1, 2,000 Internet panel members with chronic pain participated in a randomized controlled experiment of DTC ads varying in placebo rate and framing. In study 2, 596 physicians ranked DTC ads varying in placebo rate and framing by how well they conveyed scientific information and their usefulness for patients. RESULTS In study 1, participants who viewed placebo rates were able to recall them and use them to form certain perceptions. A mixed frame led to lower placebo rate recall and perceived efficacy. In study 2, overall, physicians preferred a placebo/single frame ad. CONCLUSIONS Adding placebo rates to DTC ads may be useful for consumers. The evidence does not support using a mixed frame.",2014,A mixed frame led to lower placebo rate recall and perceived efficacy.,"['596 physicians ranked DTC ads varying in placebo rate and framing by how well they conveyed scientific information and their usefulness for patients', '2,000 Internet panel members with chronic pain participated']","['DTC ads varying in placebo', 'placebo', 'placebo/single frame ad', 'DTC']",['placebo rate recall and perceived efficacy'],"[{'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0699794', 'cui_str': 'Rank (attribute)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0180979', 'cui_str': 'Frame (physical object)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]",,0.65941,A mixed frame led to lower placebo rate recall and perceived efficacy.,"[{'ForeName': 'Amie C', 'Initials': 'AC', 'LastName': ""O'Donoghue"", 'Affiliation': 'U.S. Food and Drug Administration, Silver Spring, MD, USA, amie.odonoghue@fda.hhs.gov.'}, {'ForeName': 'Helen W', 'Initials': 'HW', 'LastName': 'Sullivan', 'Affiliation': ''}, {'ForeName': 'Kathryn J', 'Initials': 'KJ', 'LastName': 'Aikin', 'Affiliation': ''}]",Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,['10.1007/s12160-014-9603-1'] 995,31957648,A pilot randomized controlled trial of cognitive behavioral treatment for trauma-related nightmares in active duty military personnel.,"STUDY OBJECTIVES The aim of this study was to obtain preliminary data on the efficacy, credibility, and acceptability of Exposure, relaxation, and rescripting therapy for military service members and veterans (ERRT-M) in active duty military personnel with trauma-related nightmares. METHODS Forty participants were randomized to either 5 sessions of ERRT-M or 5 weeks of minimal contact control (MCC) followed by ERRT-M. Assessments were completed at baseline, posttreatment/postcontrol, and 1-month follow-up. RESULTS Differences between ERRT-M and control were generally medium in size for nightmare frequency (Cohen d = -0.53), nights with nightmares (d = -0.38), nightmare severity (d = -0.60), fear of sleep (d = -0.44), and symptoms of insomnia (d = -0.52), and depression (d = -0.51). In the 38 participants who received ERRT-M, there were statistically significant, medium-sized decreases in nightmare frequency (d = -0.52), nights with nightmares (d = -0.50), nightmare severity (d = -0.55), fear of sleep (d = -0.48), and symptoms of insomnia (d = -0.59), posttraumatic stress disorder (PTSD) (d = -0.58) and depression (d = -0.59) from baseline to 1-month follow-up. Participants generally endorsed medium to high ratings of treatment credibility and expectancy. The treatment dropout rate (17.5%) was comparable to rates observed for similar treatments in civilians. CONCLUSIONS ERRT-M produced medium effect-size reductions in nightmares and several secondary outcomes including PTSD, depression, and insomnia. Participants considered ERRT-M to be credible. An adequately powered randomized clinical trial is needed to confirm findings and to compare ERRT-M to an active treatment control. CLINICAL TRIAL REGISTRATION Registry: ClinicalTrials.gov; Title: A Pilot Randomized Controlled Trial of Treatment for Trauma-Related Nightmares In Active Duty Military Personnel; Identifier: NCT02506595; URL: https://clinicaltrials.gov/ct2/show/NCT02506595.",2020,"CONCLUSIONS ERRT-M produced medium effect-size reductions in nightmares and several secondary outcomes including PTSD, depression, and insomnia.","['military service members and veterans (ERRT-M) in active duty military personnel with trauma-related nightmares', 'Forty participants', 'trauma-related nightmares in active duty military personnel', 'Trauma-Related Nightmares']","['ERRT-M or 5 weeks of minimal contact control (MCC) followed by ERRT-M. Assessments were completed at baseline, posttreatment/postcontrol, and 1-month follow-up', 'cognitive behavioral treatment']","['efficacy, credibility, and acceptability of Exposure, relaxation', 'treatment dropout rate', 'nightmare frequency', 'symptoms of insomnia', 'PTSD, depression, and insomnia', 'fear of sleep', 'posttraumatic stress disorder (PTSD', 'nights with nightmares', 'nightmare severity']","[{'cui': 'C0336524', 'cui_str': 'Military services member'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C3831794', 'cui_str': 'Active duty military'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0028084', 'cui_str': 'Nightmares'}]","[{'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0547040', 'cui_str': 'Minimal (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0028084', 'cui_str': 'Nightmares'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",40.0,0.135922,"CONCLUSIONS ERRT-M produced medium effect-size reductions in nightmares and several secondary outcomes including PTSD, depression, and insomnia.","[{'ForeName': 'Kristi E', 'Initials': 'KE', 'LastName': 'Pruiksma', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Taylor', 'Affiliation': 'Department of Psychology, University of North Texas, Denton, Texas.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Mintz', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas.'}, {'ForeName': 'Karin L', 'Initials': 'KL', 'LastName': 'Nicholson', 'Affiliation': 'Department of Medicine, Carl R. Darnall Army Medical Center, Fort Hood, Texas.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Rodgers', 'Affiliation': 'Department of Medicine, Carl R. Darnall Army Medical Center, Fort Hood, Texas.'}, {'ForeName': 'Stacey', 'Initials': 'S', 'LastName': 'Young-McCaughan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas.'}, {'ForeName': 'Brittany N', 'Initials': 'BN', 'LastName': 'Hall-Clark', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas.'}, {'ForeName': 'Brooke A', 'Initials': 'BA', 'LastName': 'Fina', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Dondanville', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas.'}, {'ForeName': 'Briana', 'Initials': 'B', 'LastName': 'Cobos', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Wardle-Pinkston', 'Affiliation': 'Department of Psychology, University of North Texas, Denton, Texas.'}, {'ForeName': 'Brett T', 'Initials': 'BT', 'LastName': 'Litz', 'Affiliation': 'Massachusetts Veterans Epidemiological Research and Information Center VA Boston Healthcare System, Boston, Massachusetts.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Roache', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas.'}, {'ForeName': 'Alan L', 'Initials': 'AL', 'LastName': 'Peterson', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine,['10.5664/jcsm.8116'] 996,24049230,A computerized stroop test for the evaluation of psychotropic drugs in healthy participants.,"BACKGROUND The Stroop paradigm evaluates susceptibility to interference and is sensitive to dysfunction in frontal lobes and drug effects. The aim of the present study was to establish a simple and reliable computerized version of Stroop color-word test, which can be used for screening of various psychotropic drugs. MATERIALS AND METHODS The standardized method was followed in all cases, by recording the reaction time (RT) in msec in 24 healthy participants using computerized version of Stroop color-word test. Reproducibility of the test procedure was evaluated by recording the RTs by a single experimenter on two sessions (interday reproducibility). Validity of the model was further tested by evaluating the psychotropic effect of Zolpidem 5 mg, Caffeine 500 mg, or Placebo on 24 healthy subjects in a randomized, double blind three-way crossover design. RESULTS The method was found to produce low variability with coefficient of variation less than 10%. Interday reproducibility was very good as shown by Bland-Altman plot with most of the values within ±2SD. There was a significant increase in RTs in Stroop performance with Zolpidem at 1 hr and 2 hrs; in contrast, caffeine significantly decreased RTs in Stroop performance at 1 hr only compared to placebo. CONCLUSION The Stroop color-word recording and analysis system is simple, sensitive to centrally acting drug effects, and has potential for future experimental psychomotor assessment studies.",2013,"There was a significant increase in RTs in Stroop performance with Zolpidem at 1 hr and 2 hrs; in contrast, caffeine significantly decreased RTs in Stroop performance at 1 hr only compared to placebo. ","['24 healthy participants using computerized version of Stroop color-word test', '24 healthy subjects', 'healthy participants']","['Caffeine 500 mg, or Placebo', 'Zolpidem']","['RTs in Stroop performance', 'Interday reproducibility']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0582675', 'cui_str': 'Stroop neuropsychological screening test (assessment scale)'}]","[{'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0078839', 'cui_str': 'zolpidem'}]",[],24.0,0.0582741,"There was a significant increase in RTs in Stroop performance with Zolpidem at 1 hr and 2 hrs; in contrast, caffeine significantly decreased RTs in Stroop performance at 1 hr only compared to placebo. ","[{'ForeName': 'Raveendranadh', 'Initials': 'R', 'LastName': 'Pilli', 'Affiliation': ""Department of Clinical Pharmacology and Therapeutics, ICMR Advanced Centre for Clinical Pharmacodynamics, Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad, Andhra Pradesh, India.""}, {'ForeName': 'Mur', 'Initials': 'M', 'LastName': 'Naidu', 'Affiliation': ''}, {'ForeName': 'Usha Rani', 'Initials': 'UR', 'LastName': 'Pingali', 'Affiliation': ''}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Shobha', 'Affiliation': ''}, {'ForeName': 'A Praveen', 'Initials': 'AP', 'LastName': 'Reddy', 'Affiliation': ''}]",Indian journal of psychological medicine,['10.4103/0253-7176.116251'] 997,24165255,Vancomycin intermittent dosing versus continuous infusion for treatment of ventilator-associated pneumonia in trauma patients.,"Current guidelines for the empiric treatment of ventilator-associated pneumonia (VAP) recommend that vancomycin is dosed 15 mg/kg and administered twice daily for a target trough level of 15 to 20 μg/mL. This study compared conventional intermittent vancomycin infusion (IVI) with continuous vancomycin infusion (CVI). Our prospective, randomized study compared CVI with IVI in trauma patients with suspected VAP. The primary outcome measure was a serum vancomycin level within the target level 48 hours after initiation of therapy. Treatment groups were compared using standard statistical methods. The study included 73 patients, 36 IVI and 37 CVI. Eighteen patients were withdrawn from the study as a result of discontinuation of the drug before 48 hours or failure to draw levels at the appropriate time, resulting in 27 IVI and 28 CVI study patients. There were no differences between treatment groups in gender (P = 0.97), Injury Severity Score (P = 0.70), total body weight (P = 0.36), or age (P = 0.81). The mean serum vancomycin level for the IVI group was 8.9 ± 3.9 μg/mL, and the CVI level was 19.8 ± 6.13 μg/mL (P < 0.0001). Two patients in the IVI group (7.4%) were in the therapeutic range compared with 16 (57.1%) in the CVI group (P < 0.0001). Six patients in the CVI group (21.4%) and none of the IVI patients had supratherapeutic levels. Four patients developed renal insufficiency, three IVI (11.1%) and one CVI (3.6%) (P = 0.36). The current American Trauma Society dosing recommendations for vancomycin for presumptive VAP treatment are inadequate. Continuous vancomycin infusion should be adopted as the standard dosing strategy.",2013,"There were no differences between treatment groups in gender (P = 0.97), Injury Severity Score (P = 0.70), total body weight (P = 0.36), or age (P = 0.81).","['trauma patients with suspected VAP', 'Eighteen patients were withdrawn from the study as a result of discontinuation of the drug before 48 hours or failure to draw levels at the appropriate time, resulting in 27 IVI and 28 CVI study patients', '73 patients, 36 IVI and 37 CVI', 'trauma patients']","['Continuous vancomycin', 'Vancomycin intermittent dosing versus continuous infusion', 'CVI', 'vancomycin', 'conventional intermittent vancomycin infusion (IVI) with continuous vancomycin infusion (CVI']","['Injury Severity Score', 'therapeutic range', 'total body weight', 'supratherapeutic levels', 'serum vancomycin level', 'CVI level', 'mean serum vancomycin level', 'renal insufficiency']","[{'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn (finding)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0439586', 'cui_str': '48 hours (qualifier value)'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0013113', 'cui_str': 'Drawing'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0332294', 'cui_str': 'Resulting in (attribute)'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0042313', 'cui_str': 'Vancomycin'}, {'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0444889', 'cui_str': 'Continuous infusion (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}]","[{'cui': 'C0021504', 'cui_str': 'ISS Score'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1278120', 'cui_str': 'Serum vancomycin measurement'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0035078', 'cui_str': 'Kidney Failure'}]",73.0,0.0989045,"There were no differences between treatment groups in gender (P = 0.97), Injury Severity Score (P = 0.70), total body weight (P = 0.36), or age (P = 0.81).","[{'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Schmelzer', 'Affiliation': 'F.H. Sammy Ross, Jr. Trauma Center, Carolinas Medical Center, Charlotte, North Carolina, USA.'}, {'ForeName': 'A Britton', 'Initials': 'AB', 'LastName': 'Christmas', 'Affiliation': ''}, {'ForeName': 'H James', 'Initials': 'HJ', 'LastName': 'Norton', 'Affiliation': ''}, {'ForeName': 'B Todd', 'Initials': 'BT', 'LastName': 'Heniford', 'Affiliation': ''}, {'ForeName': 'Ronald F', 'Initials': 'RF', 'LastName': 'Sing', 'Affiliation': ''}]",The American surgeon,[] 998,32492942,"Adjunctive Cilostazol to Dual Antiplatelet Therapy to Enhance Mobilization of Endothelial Progenitor Cell in Patients with Acute Myocardial Infarction: A Randomized, Placebo-Controlled EPISODE Trial.","BACKGROUND Endothelial progenitor cells (EPCs) have the potential to protect against atherothrombotic event occurrences. There are no data to evaluate the impact of cilostazol on EPC levels in high-risk patients. METHODS We conducted a randomized, double-blind, placebo-controlled trial to assess the effect of adjunctive cilostazol on EPC mobilization and platelet reactivity in patients with acute myocardial infarction (AMI). Before discharge, patients undergoing percutaneous coronary intervention (PCI) were randomly assigned to receive cilostazol SR capsule (200-mg) a day ( n = 30) or placebo ( n = 30) on top of dual antiplatelet therapy (DAPT) with clopidogrel and aspirin. Before randomization (baseline) and at 30-day follow-up, circulating EPC levels were analyzed using flow cytometry and hemostatic measurements were evaluated by VerifyNow and thromboelastography assays. The primary endpoint was the relative change in EPC levels between baseline and 30-day. RESULTS At baseline, there were similar levels of EPC counts between treatments, whereas patients with cilostazol showed higher levels of EPC counts compared with placebo after 30 days. Cilostazol versus placebo treatment displayed significantly higher changes in EPC levels between baseline and follow-up (ΔCD133 + /KDR + : difference 216%, 95% confidence interval (CI) 44~388%, p = 0.015; ΔCD34 + /KDR + : difference 183%, 95% CI 25~342%, p = 0.024). At 30-day follow-up, platelet reactivity was lower in the cilostazol group compared with the placebo group (130 ± 45 versus 169 ± 62 P2Y12 Reaction Unit, p = 0.009). However, there were no significant correlations between the changes of EPC levels and platelet reactivity. CONCLUSION Adjunctive cilostazol on top of clopidogrel and aspirin versus DAPT alone is associated with increased EPC mobilization and decreased platelet reactivity in AMI patients, suggesting its pleiotropic effects against atherothrombotic events (NCT04407312).",2020,"At 30-day follow-up, platelet reactivity was lower in the cilostazol group compared with the placebo group (130 ± 45 versus 169 ± 62 P2Y12 Reaction Unit, p = 0.009).","['patients undergoing percutaneous coronary intervention (PCI', 'Patients with Acute Myocardial Infarction', 'patients with acute myocardial infarction (AMI']","['Adjunctive Cilostazol', 'adjunctive cilostazol', 'dual antiplatelet therapy (DAPT) with clopidogrel and aspirin', 'Placebo', 'clopidogrel and aspirin versus DAPT', 'cilostazol', 'Endothelial progenitor cells (EPCs', 'cilostazol SR capsule', 'Cilostazol versus placebo', 'placebo']","['EPC levels and platelet reactivity', 'platelet reactivity', 'relative change in EPC levels', 'EPC mobilization and platelet reactivity', 'EPC mobilization', 'circulating EPC levels', 'EPC levels', 'EPC counts']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}]","[{'cui': 'C0055729', 'cui_str': 'cilostazol'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0634829', 'cui_str': '1,2-dilinolenoyl-3-(4-aminobutyryl)propane-1,2,3-triol'}, {'cui': 'C3850017', 'cui_str': 'Circulating Endothelial Progenitor Cells'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}]","[{'cui': 'C0169014', 'cui_str': 'erucylphosphocholine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0439157', 'cui_str': 'counts'}]",,0.682286,"At 30-day follow-up, platelet reactivity was lower in the cilostazol group compared with the placebo group (130 ± 45 versus 169 ± 62 P2Y12 Reaction Unit, p = 0.009).","[{'ForeName': 'Yongwhi', 'Initials': 'Y', 'LastName': 'Park', 'Affiliation': 'Department of Internal Medicine, School of Medicine, Gyeongsang National University, Jinju 52828, Korea.'}, {'ForeName': 'Jin Hyun', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Institute of the Health Sciences, Gyeongsang National University, Jinju 52727, Korea.'}, {'ForeName': 'Tae Ho', 'Initials': 'TH', 'LastName': 'Kim', 'Affiliation': 'Biomedical Research Institute, Gyeongsang National University Hospital, Jinju52727, Korea.'}, {'ForeName': 'Jin-Sin', 'Initials': 'JS', 'LastName': 'Koh', 'Affiliation': 'Department of Internal Medicine, School of Medicine, Gyeongsang National University, Jinju 52828, Korea.'}, {'ForeName': 'Seok-Jae', 'Initials': 'SJ', 'LastName': 'Hwang', 'Affiliation': 'Department of Internal Medicine, School of Medicine, Gyeongsang National University, Jinju 52828, Korea.'}, {'ForeName': 'Jin-Yong', 'Initials': 'JY', 'LastName': 'Hwang', 'Affiliation': 'Department of Internal Medicine, School of Medicine, Gyeongsang National University, Jinju 52828, Korea.'}, {'ForeName': 'Young-Hoon', 'Initials': 'YH', 'LastName': 'Jeong', 'Affiliation': 'Department of Internal Medicine, School of Medicine, Gyeongsang National University, Jinju 52828, Korea.'}]",Journal of clinical medicine,['10.3390/jcm9061678'] 999,32492884,Short-Term Effects of PENS versus Dry Needling in Subjects with Unilateral Mechanical Neck Pain and Active Myofascial Trigger Points in Levator Scapulae Muscle: A Randomized Controlled Trial.,"Procedures such as dry needling (DN) or percutaneous electrical nerve stimulation (PENS) are commonly proposed for the treatment of myofascial trigger points (MTrP). The aim of the present study is to investigate if PENS is more effective than DN in the short term in subjects with mechanical neck pain. This was an evaluator-blinded randomized controlled trial. Subjects were recruited through announcements and randomly allocated into DN or PENS groups. Pain intensity, disability, pressure pain threshold (PPT), range of motion (ROM), and side-bending strength were measured. The analyses included mixed-model analyses of variance and pairwise comparisons with Bonferroni correction. The final sample was composed of 44 subjects (22 per group). Both groups showed improvements in pain intensity (η p 2 = 0.62; p < 0.01), disability (η p 2 = 0.74; p < 0.01), PPT (η p 2 = 0.79; p < 0.01), and strength (η p 2 = 0.37; p < 0.01). The PENS group showed greater improvements in disability (mean difference, 3.27; 95% CI, 0.27-6.27) and PPT (mean difference, 0.88-1.35; p < 0.01). Mixed results were obtained for ROM. PENS seems to produce greater improvements in PPT and disability in the short term.",2020,"Both groups showed improvements in pain intensity (η p 2 = 0.62; p < 0.01), disability (η p 2 = 0.74; p < 0.01), PPT (η p 2 = 0.79; p < 0.01), and strength (η p 2 = 0.37; p < 0.01).","['Subjects with Unilateral Mechanical Neck Pain and Active Myofascial Trigger Points in Levator Scapulae Muscle', 'subjects with mechanical neck pain']","['dry needling (DN) or percutaneous electrical nerve stimulation (PENS', 'PENS', 'PENS versus Dry Needling']","['strength', 'disability', 'pain intensity', 'PPT and disability', 'Pain intensity, disability, pressure pain threshold (PPT), range of motion (ROM), and side-bending strength']","[{'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0458343', 'cui_str': 'Trigger point'}, {'cui': 'C0224368', 'cui_str': 'Structure of levator scapulae muscle'}]","[{'cui': 'C0394648', 'cui_str': 'Dry needle acupuncture'}, {'cui': 'C0040654', 'cui_str': 'Percutaneous electrical nerve stimulation'}]","[{'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C4704755', 'cui_str': 'Fracture Strength'}]",,0.141071,"Both groups showed improvements in pain intensity (η p 2 = 0.62; p < 0.01), disability (η p 2 = 0.74; p < 0.01), PPT (η p 2 = 0.79; p < 0.01), and strength (η p 2 = 0.37; p < 0.01).","[{'ForeName': 'Santiago', 'Initials': 'S', 'LastName': 'Garcia-de-Miguel', 'Affiliation': 'Physiotherapy and Pain Group, University of Alcalá, 28871 Madrid, Spain.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Pecos-Martin', 'Affiliation': 'Physiotherapy and Pain Group, University of Alcalá, 28871 Madrid, Spain.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Larroca-Sanz', 'Affiliation': 'Department of Plastic and Restorative Surgery, University Hospital QuironSalud Madrid, 28223 Madrid, Spain.'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Sanz-de-Vicente', 'Affiliation': 'Center of Sports Medicine of the Agencia Española de Protección de la Salud en el Deporte, 28040 Madrid, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Garcia-Montes', 'Affiliation': 'Department of Physical Therapy, General University Hospital Gregorio Marañón, 28007 Madrid, Spain.'}, {'ForeName': 'Ruben', 'Initials': 'R', 'LastName': 'Fernandez-Matias', 'Affiliation': 'Research Institute of Physiotherapy and Pain, University of Alcala, 28805 Madrid, Spain.'}, {'ForeName': 'Tomas', 'Initials': 'T', 'LastName': 'Gallego-Izquierdo', 'Affiliation': 'Physiotherapy and Pain Group, University of Alcalá, 28871 Madrid, Spain.'}]",Journal of clinical medicine,['10.3390/jcm9061665'] 1000,32492883,EUS-Guided Versus Percutaneous Celiac Neurolysis for the Management of Intractable Pain Due to Unresectable Pancreatic Cancer: A Randomized Clinical Trial.,"Although endoscopic ultrasound-guided celiac neurolysis (EUS-CN) and percutaneous celiac neurolysis (PCN) are utilized to manage intractable pain in pancreatic cancer patients, no direct comparison has been made between the two methods. We compared the efficacy and safety of EUS-CN and PCN in managing intractable pain in such patients. Sixty pancreatic cancer patients with intractable pain were randomly assigned to EUS-CN ( n = 30) or PCN ( n = 30). The primary outcomes were pain reduction in numerical rating scale (NRS) and opioid requirement reduction. Secondary outcomes were: successful pain response (NRS decrease ≥50% or ≥3-point reduction from baseline); quality of life; patient satisfaction; adverse events; and survival rate at 3 months postintervention. Both groups reported sustained decreases in pain scores up to 3 months postintervention (mean reductions in abdominal pain: 0.9 (95% confidence interval (CI): -0.8 to 4.2) and 1.7 (95% CI: -0.3 to 2.1); back pain: 1.3 (95% CI: -0.9 to 3.4) and 2.5 (95% CI: -0.2 to 5.2) in EUS-CN, and PCN groups, respectively). The differences in mean pain scores between the two groups at baseline and 3 months were -0.5 ( p = 0.46) and -1.4 ( p = 0.11) for abdominal pain and 0.1 ( p = 0.85) and -0.9 ( p = 0.31) for back pain in favor of PCN. No significant differences were noted in opioid requirement reduction and other outcomes. EUS-CN and PCN were similarly effective and safe in managing intractable pain in pancreatic cancer patients. Either methods may be used depending on the resources and expertise of each institution.",2020,The differences in mean pain scores between the two groups at baseline and 3 months were -0.5 ( p = 0.46) and -1.4 ( p = 0.11) for abdominal pain and 0.1 ( p = 0.85) and -0.9 ( p = 0.31) for back pain in favor of PCN.,"['Intractable Pain Due to Unresectable Pancreatic Cancer', 'pancreatic cancer patients', 'Sixty pancreatic cancer patients with intractable pain']","['EUS-CN', 'PCN', 'EUS-CN and PCN', 'endoscopic ultrasound-guided celiac neurolysis (EUS-CN', 'percutaneous celiac neurolysis (PCN', 'EUS-Guided Versus Percutaneous Celiac Neurolysis']","['successful pain response (NRS decrease ≥50% or ≥3-point reduction from baseline); quality of life; patient satisfaction; adverse events; and survival rate', 'pain scores', 'pain reduction in numerical rating scale (NRS) and opioid requirement reduction', 'back pain', 'mean pain scores', 'opioid requirement reduction', 'abdominal pain']","[{'cui': 'C0030200', 'cui_str': 'Refractory Pain'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0854776', 'cui_str': 'Pancreatic carcinoma non-resectable'}, {'cui': 'C0235974', 'cui_str': 'Carcinoma of pancreas'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0376443', 'cui_str': 'Endoscopic ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0007570', 'cui_str': 'Celiac disease'}, {'cui': 'C0196878', 'cui_str': 'Neurolysis'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}]","[{'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0424543', 'cui_str': 'Response to pain'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}]",60.0,0.213644,The differences in mean pain scores between the two groups at baseline and 3 months were -0.5 ( p = 0.46) and -1.4 ( p = 0.11) for abdominal pain and 0.1 ( p = 0.85) and -0.9 ( p = 0.31) for back pain in favor of PCN.,"[{'ForeName': 'Won Jae', 'Initials': 'WJ', 'LastName': 'Yoon', 'Affiliation': 'Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul 07804, Korea.'}, {'ForeName': 'Yul', 'Initials': 'Y', 'LastName': 'Oh', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.'}, {'ForeName': 'Changhoon', 'Initials': 'C', 'LastName': 'Yoo', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.'}, {'ForeName': 'Sunguk', 'Initials': 'S', 'LastName': 'Jang', 'Affiliation': 'Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH 44195, USA.'}, {'ForeName': 'Seong-Sik', 'Initials': 'SS', 'LastName': 'Cho', 'Affiliation': 'Department of Occupational and Environmental Medicine, College of Medicine, Dong-A University, Busan 49201, Korea.'}, {'ForeName': 'Jeong-Hun', 'Initials': 'JH', 'LastName': 'Suh', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.'}, {'ForeName': 'Seong-Soo', 'Initials': 'SS', 'LastName': 'Choi', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.'}, {'ForeName': 'Do Hyun', 'Initials': 'DH', 'LastName': 'Park', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.'}]",Journal of clinical medicine,['10.3390/jcm9061666'] 1001,23439798,"A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults.","CONTEXT Stress is a state of mental or emotional strain or tension, which can lead to underperformance and adverse clinical conditions. Adaptogens are herbs that help in combating stress. Ayurvedic classical texts, animal studies and clinical studies describe Ashwagandha as a safe and effective adaptogen. AIMS The aim of the study was to evaluate the safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha roots in reducing stress and anxiety and in improving the general well-being of adults who were under stress. SETTINGS AND DESIGN Single center, prospective, double-blind, randomized, placebo-controlled trial. MATERIALS AND METHODS A total of 64 subjects with a history of chronic stress were enrolled into the study after performing relevant clinical examinations and laboratory tests. These included a measurement of serum cortisol, and assessing their scores on standard stress-assessment questionnaires. They were randomized to either the placebo control group or the study drug treatment group, and were asked to take one capsule twice a day for a period of 60 days. In the study drug treatment group, each capsule contained 300 mg of high-concentration full-spectrum extract from the root of the Ashwagandha plant. During the treatment period (on Day 15, Day 30 and Day 45), a follow-up telephone call was made to all subjects to check for treatment compliance and to note any adverse reactions. Final safety and efficacy assessments were done on Day 60. STATISTICAL ANALYSIS t-test, Mann-Whitney test. RESULTS The treatment group that was given the high-concentration full-spectrum Ashwagandha root extract exhibited a significant reduction (P<0.0001) in scores on all the stress-assessment scales on Day 60, relative to the placebo group. The serum cortisol levels were substantially reduced (P=0.0006) in the Ashwagandha group, relative to the placebo group. The adverse effects were mild in nature and were comparable in both the groups. No serious adverse events were reported. CONCLUSION The findings of this study suggest that a high-concentration full-spectrum Ashwagandha root extract safely and effectively improves an individual's resistance towards stress and thereby improves self-assessed quality of life.",2012,"The serum cortisol levels were substantially reduced (P=0.0006) in the Ashwagandha group, relative to the placebo group.","['64 subjects with a history of chronic stress', 'adults who were under stress', 'adults']","['high-concentration full-spectrum extract of Ashwagandha roots', 'high-concentration full-spectrum extract of ashwagandha root', 'placebo']","['stress and anxiety', 'serious adverse events', 'self-assessed quality of life', 'safety and efficacy', 'adverse effects', 'serum cortisol levels', 'Final safety and efficacy assessments']","[{'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1532530', 'cui_str': 'Full spectrum'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C0613707', 'cui_str': 'Ashwagandha'}, {'cui': 'C0563017', 'cui_str': 'Anal penetration using finger (finding)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0034380'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0236396', 'cui_str': 'Serum cortisol measurement'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",64.0,0.254325,"The serum cortisol levels were substantially reduced (P=0.0006) in the Ashwagandha group, relative to the placebo group.","[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Chandrasekhar', 'Affiliation': 'Department of Neuropsychiatry and Geriatric Psychiatry, Asha Hospital, Hyderabad, Andhra Pradesh, India.'}, {'ForeName': 'Jyoti', 'Initials': 'J', 'LastName': 'Kapoor', 'Affiliation': ''}, {'ForeName': 'Sridhar', 'Initials': 'S', 'LastName': 'Anishetty', 'Affiliation': ''}]",Indian journal of psychological medicine,['10.4103/0253-7176.106022'] 1002,23723543,The effect of life skills training on emotional intelligence of the medical sciences students in iran.,"BACKGROUND Emotional intelligence has a major role in mental health and life skills training, and could be viewed as a bridge relating to emotional intelligence and mental health. AIM The present study is aimed at determining the effect of life skills training on the emotional intelligence among the first year students of Mazandaran University of Medical Sciences. MATERIALS AND METHODS: IN THIS EXPERIMENTAL STUDY, THE SUBJECTS WERE SELECTED BY RANDOM SAMPLING AND ALLOCATED INTO TWO GROUPS: Case group (n=20) and control group (n=19); they matched for gender, experience of stressful life events in the past six months, level of interest in the field of study, and level of emotional intelligence. The two groups responded to Bar-on Emotional Quotient Inventory before starting the experiment. Subsequently, the case group underwent life skills training. After the training, Bar-on Emotional Quotient Inventory was responded by the case and control groups again. The data was analyzed using descriptive statistics including Chi-square test, paired and independent t-tests, using SPSS software version 15. RESULTS AND CONCLUSION In the case group, the scores of emotional intelligence after life skills training were significantly improved (t=11.703 df=19 P=0.001), while no significant difference was observed in the control group (t=0.683 df =18 P=0.503). By performing programs such as life skills training, the levels of emotional intelligence of the students could be increased, which itself could lead to academic success, reduced substance abuse, and increased stress tolerance in the students.",2012,"In the case group, the scores of emotional intelligence after life skills training were significantly improved (t=11.703 df=19 P=0.001), while no significant difference was observed in the control group (t=0.683 df =18 P=0.503).","['emotional intelligence among the first year students of Mazandaran University of Medical Sciences', 'emotional intelligence of the medical sciences students in iran']",['life skills training'],"['stress tolerance', 'scores of emotional intelligence after life skills training']","[{'cui': 'C1510539', 'cui_str': 'Emotional Intelligences'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}]","[{'cui': 'C0556562', 'cui_str': 'Life skills training (procedure)'}]","[{'cui': 'C0520943', 'cui_str': 'Stress tolerance'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1510539', 'cui_str': 'Emotional Intelligences'}, {'cui': 'C0556562', 'cui_str': 'Life skills training (procedure)'}]",,0.025345,"In the case group, the scores of emotional intelligence after life skills training were significantly improved (t=11.703 df=19 P=0.001), while no significant difference was observed in the control group (t=0.683 df =18 P=0.503).","[{'ForeName': 'Hamideh A', 'Initials': 'HA', 'LastName': 'Lolaty', 'Affiliation': 'Department of Psychiatric Nursing, Psychiatry and Behavioral Sciences Research Center, Mazandaran University of Medical, Sciences, Sari, Iran.'}, {'ForeName': 'Sharbanoo', 'Initials': 'S', 'LastName': 'Ghahari', 'Affiliation': ''}, {'ForeName': 'Abdolhakim', 'Initials': 'A', 'LastName': 'Tirgari', 'Affiliation': ''}, {'ForeName': 'Jabbar Heydari', 'Initials': 'JH', 'LastName': 'Fard', 'Affiliation': ''}]",Indian journal of psychological medicine,['10.4103/0253-7176.108217'] 1003,32034255,Plasma lipid profile associates with the improvement of psychological well-being in individuals with perceived stress symptoms.,"Psychological stress is a suggested risk factor of metabolic disorders, but molecular mediators are not well understood. We investigated the association between the metabolic profiles of fasting plasma and the improvement of psychological well-being using non-targeted liquid chromatography-mass spectrometry (LC-MS) platform. The metabolic profiles of volunteers participating in the face-to-face intervention group (n = 60) in a randomised lifestyle intervention were compared to ones of controls (n = 64) between baseline and 36-week follow-up. Despite modest differences in metabolic profile between groups, we found associations between phosphatidylcholines (PCs) and several parameters indicating stress, adiposity, relaxation, and recovery. The relief of heart-rate-variability-based stress had positive, while improved indices of recovery and relaxation in the intervention group had an inverse association with the reduction of e.g. lysophosphatidylcholines (LPC). Interleukin-1 receptor antagonist and adiposity correlated positively with the suppressed PCs and negatively with the elevated plasmalogens PC(P-18:0/22:6) and PC(P-18:0/20:4). Also, we found changes in an unknown class of lipids over time regardless of the intervention groups, which also correlated with physiological and psychological markers of stress. The associations between lipid changes with some markers of psychological wellbeing and body composition may suggest the involvement of these lipids in the shared mechanisms between psychological and metabolic health.",2020,Interleukin-1 receptor antagonist and adiposity correlated positively with the suppressed PCs and negatively with the elevated plasmalogens PC(P-18:0/22:6) and PC(P-18:0/20:4).,['volunteers participating in the face-to-face intervention group (n\u2009=\u200960) in a'],['randomised lifestyle intervention'],"['metabolic profile', 'stress, adiposity, relaxation, and recovery', 'relief of heart-rate-variability-based stress', 'Interleukin-1 receptor antagonist and adiposity']","[{'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0023676', 'cui_str': 'Lifestyle'}]","[{'cui': 'C3853758', 'cui_str': 'Metabolic Profile'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C1563743', 'cui_str': 'Adiposis'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C1301676', 'cui_str': 'Relieves (qualifier value)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2317059', 'cui_str': 'Interleukin 1 receptor antagonist product'}]",64.0,0.0212621,Interleukin-1 receptor antagonist and adiposity correlated positively with the suppressed PCs and negatively with the elevated plasmalogens PC(P-18:0/22:6) and PC(P-18:0/20:4).,"[{'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Noerman', 'Affiliation': 'Institute of Public Health and Clinical Nutrition, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland.'}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Klåvus', 'Affiliation': 'Institute of Public Health and Clinical Nutrition, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland.'}, {'ForeName': 'Elina', 'Initials': 'E', 'LastName': 'Järvelä-Reijonen', 'Affiliation': 'Institute of Public Health and Clinical Nutrition, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Karhunen', 'Affiliation': 'Institute of Public Health and Clinical Nutrition, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland.'}, {'ForeName': 'Seppo', 'Initials': 'S', 'LastName': 'Auriola', 'Affiliation': 'School of Pharmacy, University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Riitta', 'Initials': 'R', 'LastName': 'Korpela', 'Affiliation': 'Medical Faculty, Pharmacology and Human Microbe Research program, University of Helsinki, P.O. Box 63, FI-00014, Helsinki, Finland.'}, {'ForeName': 'Raimo', 'Initials': 'R', 'LastName': 'Lappalainen', 'Affiliation': 'Department of Psychology, Faculty of Education and Psychology, University of Jyväskylä, PO Box 35, FI-40014, Jyväskylä, Finland.'}, {'ForeName': 'Urho M', 'Initials': 'UM', 'LastName': 'Kujala', 'Affiliation': 'Faculty of Sport and Health Sciences, University of Jyväskylä, P.O. Box 35, FI-40014, Jyväskylä, Finland.'}, {'ForeName': 'Sampsa', 'Initials': 'S', 'LastName': 'Puttonen', 'Affiliation': 'Finnish Institute of Occupational Health, P.O. Box 40, FI-00251, Helsinki, Finland.'}, {'ForeName': 'Marjukka', 'Initials': 'M', 'LastName': 'Kolehmainen', 'Affiliation': 'Institute of Public Health and Clinical Nutrition, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland. marjukka.kolehmainen@uef.fi.'}, {'ForeName': 'Kati', 'Initials': 'K', 'LastName': 'Hanhineva', 'Affiliation': 'Institute of Public Health and Clinical Nutrition, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland.'}]",Scientific reports,['10.1038/s41598-020-59051-x'] 1004,32034241,"Efficacy of platelet-rich plasma as an adjuvant to surgical carpal ligament release: a prospective, randomized controlled clinical trial.","The purpose of this study is to evaluate the efficiency of local platelet-rich plasma (PRP) injection as an adjuvant treatment after carpal ligament release. We conducted a prospective randomized, triple-blinded, controlled trial. Fifty participants with mild to extreme carpal tunnel syndrome (CTS) were randomly assigned either to the PRP (n = 25) or the platelet-poor plasma (PPP, n = 25) group. After performing open surgical release of the carpal ligament, the inside of the carpal tunnel was irrigated with 3 mL of PRP or PPP according to each participant's group allocation. The primary outcome was hand grip strength (HGS). Secondary outcomes were the time taken off work after surgery (in days) and scores on the Wong-Baker Faces Scale, Boston Carpal Tunnel Questionnaire, and Southampton Wound Assessment Scale. We evaluated patients before treatment and at 6-weeks. As expected, the pain levels, symptom severity, and functional status improved in all the patients after surgery. However, intragroup analysis revealed that only the participants in the PRP group had regained their pre-operative HGS levels at 6-weeks follow-up. These findings indicate that PRP is an effective adjuvant treatment in patients with mild to severe CTS who require surgery.",2020,"However, intragroup analysis revealed that only the participants in the PRP group had regained their pre-operative HGS levels at 6-weeks follow-up.","['carpal ligament release', 'patients with mild to severe CTS who require surgery', 'Fifty participants with mild to extreme carpal tunnel syndrome (CTS', 'surgical carpal ligament release']","['platelet-rich plasma', 'local platelet-rich plasma (PRP) injection', 'PRP', 'platelet-poor plasma (PPP, n\u2009=\u200925) group']","['hand grip strength (HGS', 'time taken off work after surgery (in days) and scores on the Wong-Baker Faces Scale, Boston Carpal Tunnel Questionnaire, and Southampton Wound Assessment Scale', 'pain levels, symptom severity, and functional status', 'pre-operative HGS levels']","[{'cui': 'C0023685', 'cui_str': 'Ligaments'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0205403', 'cui_str': 'Extreme (qualifier value)'}, {'cui': 'C0007286', 'cui_str': 'Amyotrophy, Thenar, Of Carpal Origin'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma (substance)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0242848', 'cui_str': 'PrP (GSS)'}, {'cui': 'C0370219', 'cui_str': 'Platelet poor plasma'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1293900', 'cui_str': 'Hand grip'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0238749', 'cui_str': 'Baker, general (occupation)'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0222045'}, {'cui': 'C0006037', 'cui_str': 'Boston'}, {'cui': 'C0007286', 'cui_str': 'Amyotrophy, Thenar, Of Carpal Origin'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0558033', 'cui_str': 'Wound assessment'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",50.0,0.0338514,"However, intragroup analysis revealed that only the participants in the PRP group had regained their pre-operative HGS levels at 6-weeks follow-up.","[{'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Trull-Ahuir', 'Affiliation': 'Department of Nursing, Faculty of Health Sciences, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Sala', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology, Umivale MATEPSSN.15, Valencia, Spain.'}, {'ForeName': 'Joaquín', 'Initials': 'J', 'LastName': 'Chismol-Abad', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology, Umivale MATEPSSN.15, Valencia, Spain.'}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Vila-Caballer', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health Sciences, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain. maria_amparo.vila@uchceu.es.'}, {'ForeName': 'Juan Francisco', 'Initials': 'JF', 'LastName': 'Lisón', 'Affiliation': 'Department of Medicine, Faculty of Health Sciences, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain. juanfran@uchceu.es.'}]",Scientific reports,['10.1038/s41598-020-59113-0'] 1005,23162189,Effect of a single dose of dextromethorphan on psychomotor performance and working memory capacity.,"BACKGROUND Previous studies show that the prolonged use of dextromethorphan produces cognitive deterioration in humans. AIM The aim of this study was to investigate the effect of a single dose of dextroemthrophan on psychomotor performance and working memory capacity. MATERIALS AND METHODS This is a randomized, double-blind, controlled, and prospective study. Thirty-six (17 women, 19 men) medical students enrolled in the study; half of them (7 women, 11 men) were given placebo, while the other half (10 women, 8 men) received dextromethorphan. The choice reaction time, critical flicker fusion threshold, and N-back working memory task were measured before and after 2 h of taking the drugs. RESULTS Dextromethorphan showed a significant deterioration in the 3-back working memory task (P<0.05). No significant changes were seen as regards the choice reaction time components (total, recognition, motor) and critical flicker fusion threshold (P>0.05). On the other hand, placebo showed no significant changes as regards the choice reaction time, critical flicker fusion threshold, and N-back working memory task (P>0.05). CONCLUSION A single dose of dextromethorphan has no effect on attention and arousal but may significantly impair the working memory capacity.",2012,Dextromethorphan showed a significant deterioration in the 3-back working memory task (P<0.05).,"['Thirty-six (17 women, 19 men) medical students enrolled in the study; half of them (7 women, 11 men', 'humans']","['Dextromethorphan', 'dextromethorphan', 'placebo', 'dextroemthrophan']","['choice reaction time components (total, recognition, motor) and critical flicker fusion threshold (P>0.05', 'choice reaction time, critical flicker fusion threshold, and N-back working memory task', 'choice reaction time, critical flicker fusion threshold, and N-back working memory task (P>0.05', '3-back working memory task', 'psychomotor performance and working memory capacity', 'attention and arousal']","[{'cui': 'C4319606', 'cui_str': 'Thirty-six'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0038495', 'cui_str': 'Students, Medical'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0011816', 'cui_str': 'Dextromethorphan'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0524637', 'cui_str': 'Recognition (Psychology)'}, {'cui': 'C0016236', 'cui_str': 'Flicker Fusion'}, {'cui': 'C0449864', 'cui_str': 'Threshold (property) (qualifier value)'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0033923', 'cui_str': 'Psychomotor Performance'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}]",,0.170984,Dextromethorphan showed a significant deterioration in the 3-back working memory task (P<0.05).,"[{'ForeName': 'Hayder M', 'Initials': 'HM', 'LastName': 'Al-Kuraishy', 'Affiliation': 'Department of Pharmacology, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq.'}, {'ForeName': 'Ali I', 'Initials': 'AI', 'LastName': 'Al-Gareeb', 'Affiliation': ''}, {'ForeName': 'Ammar Waham', 'Initials': 'AW', 'LastName': 'Ashor', 'Affiliation': ''}]",Indian journal of psychological medicine,['10.4103/0253-7176.101779'] 1006,31812327,"Pilot randomised controlled trial of a brief coping-focused intervention for hearing voices blended with smartphone-based ecological momentary assessment and intervention (SAVVy): Feasibility, acceptability and preliminary clinical outcomes.","BACKGROUND Voice-hearing experiences can be distressing and impairing, and existing psychological treatments show modest effectiveness. Ecological momentary assessment and intervention (EMA/I) are two promising approaches which may be used as digital tools to support and enhance existing psychological therapies. The aim of this study was to investigate the potential clinical utility of smartphone-based EMA/I in a blended, coping focused therapy for voice-hearing experiences. METHOD This pilot RCT focused on feasibility, acceptability and preliminary estimations of efficacy. Thirty-four participants with persisting and distressing voices were randomised to receive the four-session intervention along-side treatment-as-usual (TAU) or TAU-only. RESULTS Findings supported the feasibility and acceptability of the approach, with good engagement and satisfaction rates, and clinical outcomes showed the intervention holds promise for improving coping, overall severity of voices and to some degree their negative impact. CONCLUSION This is the first examination of the use of EMA/I in a blended therapy for psychotic experiences, with findings suggesting these technologies show promise as clinical tools.",2020,"Thirty-four participants with persisting and distressing voices were randomised to receive the four-session intervention along-side treatment-as-usual (TAU) or TAU-only. ","['Thirty-four participants with persisting and distressing voices', 'voice-hearing experiences']","['brief coping-focused intervention for hearing voices blended with smartphone-based ecological momentary assessment and intervention (SAVVy', 'Ecological momentary assessment and intervention', 'EMA', 'smartphone-based EMA', 'four-session intervention along-side treatment-as-usual (TAU) or TAU-only']",[],"[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0423539', 'cui_str': 'Finding of ability to hear voice'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4277684', 'cui_str': 'Ecological Momentary Assessment'}, {'cui': 'C0268596', 'cui_str': 'Glutaric aciduria, type 2'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",[],34.0,0.0528688,"Thirty-four participants with persisting and distressing voices were randomised to receive the four-session intervention along-side treatment-as-usual (TAU) or TAU-only. ","[{'ForeName': 'Imogen H', 'Initials': 'IH', 'LastName': 'Bell', 'Affiliation': 'Centre for Mental Health, Swinburne University of Technology, Australia. Electronic address: imogen.bell@orygen.org.au.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Rossell', 'Affiliation': ""Centre for Mental Health, Swinburne University of Technology, Australia; Department of Psychiatry, St. Vincent's Hospital, Australia.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Farhall', 'Affiliation': 'Department of Psychology and Counselling, La Trobe University, Australia; NorthWestern Mental Health, Melbourne Health, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Hayward', 'Affiliation': 'Sussex Partnership NHS Foundation Trust, UK; School of Psychology, University of Sussex, UK.'}, {'ForeName': 'Michelle H', 'Initials': 'MH', 'LastName': 'Lim', 'Affiliation': 'Centre for Mental Health, Swinburne University of Technology, Australia.'}, {'ForeName': 'Sarah F', 'Initials': 'SF', 'LastName': 'Fielding-Smith', 'Affiliation': 'Sussex Partnership NHS Foundation Trust, UK; School of Psychology, University of Sussex, UK.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Thomas', 'Affiliation': 'Centre for Mental Health, Swinburne University of Technology, Australia. Electronic address: neilthomas@swin.edu.au.'}]",Schizophrenia research,['10.1016/j.schres.2019.10.026'] 1007,22717102,Ethnicity interacts with the OPRM1 gene in experimental pain sensitivity.,"Robust interindividual variation in pain sensitivity has been observed, and recent evidence suggests that some of the variability may be genetically mediated. Our previous data revealed significantly higher pressure pain thresholds among individuals possessing the minor G allele of the A118G SNP of the mu-opioid receptor gene (OPRM1) compared with those with 2 consensus alleles. Moreover, ethnic differences in pain sensitivity have been widely reported. Yet, little is known about the potential interactive associations of ethnicity and genotype with pain perception. This study aimed to identify ethnic differences in OPRM1 allelic associations with experimental pain responses. A total of 247 healthy young adults from three ethnic groups (81 African Americans; 79 non-white Hispanics; and 87 non-Hispanic whites) underwent multiple experimental pain modalities (thermal, pressure, ischemic, cold pressor). Few African Americans (7.4%) expressed the rare allele of OPRM1 compared to non-Hispanic whites and Hispanics (28.7% vs. 27.8%, respectively). Across the entire sample, OPRM1 genotype did not significantly affect pain sensitivity. However, analysis in each ethnic group separately revealed significant genotype effects for most pain modalities among non-Hispanic-whites (P<.05) but not Hispanics or African Americans. The G allele was associated with decreased pain sensitivity among whites only; a trend in the opposite direction emerged in Hispanics. The reasons for this dichotomy are unclear; they may involve ethnic differences in haplotypic structure, or A118G may be a tag-SNP linked to other functional polymorphisms. These findings demonstrate an ethnicity-dependent association of OPRM1 genotype with pain sensitivity. Additional research is warranted to uncover the mechanisms influencing these relationships.",2012,The G allele was associated with decreased pain sensitivity among whites only; a trend in the opposite direction emerged in Hispanics.,['247 healthy young adults from three ethnic groups (81 African Americans; 79 non-white Hispanics; and 87 non-Hispanic whites'],"['multiple experimental pain modalities (thermal, pressure, ischemic, cold pressor']","['pain sensitivity', 'rare allele of OPRM1', 'pressure pain thresholds']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0015031', 'cui_str': 'Ethnicity'}, {'cui': 'C1533020', 'cui_str': 'Hispanic, white'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0043157', 'cui_str': 'Whites'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0444689', 'cui_str': 'Cold pressor test (procedure)'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0522498', 'cui_str': 'Uncommon (qualifier value)'}, {'cui': 'C0002085', 'cui_str': 'Allelomorphs'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0162703', 'cui_str': 'Pain Threshold'}]",247.0,0.0870398,The G allele was associated with decreased pain sensitivity among whites only; a trend in the opposite direction emerged in Hispanics.,"[{'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Hastie', 'Affiliation': 'Department of Community Dentistry and Behavioral Science, University of Florida College of Dentistry, Gainesville, FL 32610-3628, USA. bhastie@dental.ufl.edu'}, {'ForeName': 'Joseph L', 'Initials': 'JL', 'LastName': 'Riley', 'Affiliation': ''}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Kaplan', 'Affiliation': ''}, {'ForeName': 'Dyanne G', 'Initials': 'DG', 'LastName': 'Herrera', 'Affiliation': ''}, {'ForeName': 'Claudia M', 'Initials': 'CM', 'LastName': 'Campbell', 'Affiliation': ''}, {'ForeName': 'Kathrina', 'Initials': 'K', 'LastName': 'Virtusio', 'Affiliation': ''}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Mogil', 'Affiliation': ''}, {'ForeName': 'Margaret R', 'Initials': 'MR', 'LastName': 'Wallace', 'Affiliation': ''}, {'ForeName': 'Roger B', 'Initials': 'RB', 'LastName': 'Fillingim', 'Affiliation': ''}]",Pain,['10.1016/j.pain.2012.03.022'] 1008,23061175,The effect of acceptance training on psychological and physical health outcomes in elders with chronic conditions.,"This pilot trial investigated the short and long-term effects of Acceptance Training (ACT) intervention on acceptance, perceived health, functional status, anxiety, and depression in elders with chronic conditions living in retirement communities (RCs). The ACT intervention combined Rational Emotive Behavior Therapy with music, relaxation, and guided imagery during six weekly 2-hour sessions. Face-to-face interviews were conducted with 16 African-American and 46 White elders across four data collection points in six randomly selected RCs using well-established measures of perceived health, functional status, anxiety, and depression, and a measure of acceptance of chronic conditions adapted from a previous measure of acceptance of diabetes. While changes were found in perceived health, functional status, anxiety, and depression, the most significant changes occurred in the elders' acceptance of chronic conditions immediately after the intervention (t = -2.62, p < .02), and these changes persisted for 6 and 12 weeks (t's = -2.74, -3.32, p's < .01), respectively. Although a 40% attrition rate reduced the sample size from 62 (N = 62) to 37 (N = 37), the significant increases in acceptance over time provide initial evidence for the fidelity of the ACT intervention.",2011,"Although a 40% attrition rate reduced the sample size from 62 (N = 62) to 37 (N = 37), the significant increases in acceptance over time provide initial evidence for the fidelity of the ACT intervention.","['16 African-American and 46 White elders', 'elders with chronic conditions living in retirement communities (RCs', 'elders with chronic conditions']","['acceptance training', 'ACT intervention combined Rational Emotive Behavior Therapy with music, relaxation, and guided imagery', 'Acceptance Training (ACT) intervention']","[""elders' acceptance of chronic conditions"", 'perceived health, functional status, anxiety, and depression', 'acceptance, perceived health, functional status, anxiety, and depression', 'attrition rate', 'psychological and physical health outcomes']","[{'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0337650', 'cui_str': 'Living in retirement community (finding)'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0004933', 'cui_str': 'Behavior Modification'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0150627', 'cui_str': 'Imagery'}]","[{'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}]",6.0,0.0189436,"Although a 40% attrition rate reduced the sample size from 62 (N = 62) to 37 (N = 37), the significant increases in acceptance over time provide initial evidence for the fidelity of the ACT intervention.","[{'ForeName': 'Patricia E', 'Initials': 'PE', 'LastName': 'McDonald', 'Affiliation': 'Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, OH 44106-4904, USA. pxm9@case.edu'}, {'ForeName': 'Jaclene A', 'Initials': 'JA', 'LastName': 'Zauszniewski', 'Affiliation': ''}, {'ForeName': 'Abir K', 'Initials': 'AK', 'LastName': 'Bekhet', 'Affiliation': ''}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'DeHelian', 'Affiliation': ''}, {'ForeName': 'Diana L', 'Initials': 'DL', 'LastName': 'Morris', 'Affiliation': ''}]",Journal of National Black Nurses' Association : JNBNA,[] 1009,32027015,The role of testosterone in menopausal hormone treatment. What is the evidence?,"About 40% of postmenopausal women have decreased sexual desire, causing distress. Estrogen therapy attenuates vaginal complaints but has no effect on sexual desire. Although sexual function has been linked to testosterone, there is no clear relation between sexual desire and circulating levels of testosterone. Nevertheless, treatment with transdermal (patch) testosterone improved sexual function in several randomized controlled trials. Women with hypoactive sexual desire disorder who were treated with testosterone reported more satisfying sexual episodes and sexual desire compared with the placebo group. Adverse effects were mild. However, there is no testosterone drug designed for women available on the European market. Consequently, women who opt for testosterone treatment have to use preparations made for men with a high drug concentration. Adequate dosage for women is therefore challenging. A trial of 5 mg transdermal testosterone (gel or cream) daily or less has been suggested, followed by close monitoring of side effects and hormone level.",2020,Women with hypoactive sexual desire disorder who were treated with testosterone reported more satisfying sexual episodes and sexual desire compared with the placebo group.,"['Women with hypoactive sexual desire disorder', 'men with high drug concentration']","['testosterone', 'placebo', 'Estrogen therapy', 'transdermal (patch) testosterone', 'transdermal testosterone (gel or cream']","['sexual function', 'Adverse effects', 'sexual desire causing distress', 'satisfying sexual episodes and sexual desire']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0020594', 'cui_str': 'Hypoactive Sexual Desire Disorder'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]","[{'cui': 'C0523912', 'cui_str': 'Testosterone measurement (procedure)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0279494'}, {'cui': 'C4521342', 'cui_str': 'Transdermal (intended site)'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C1378128', 'cui_str': 'Cream'}]","[{'cui': 'C0278092', 'cui_str': 'Sexual function (observable entity)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0424400', 'cui_str': 'Erotic interest (observable entity)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}]",,0.244414,Women with hypoactive sexual desire disorder who were treated with testosterone reported more satisfying sexual episodes and sexual desire compared with the placebo group.,"[{'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Johansen', 'Affiliation': ""Division of Women's Health, Oslo University Hospital, Oslo, Norway.""}, {'ForeName': 'Angelica', 'Initials': 'A', 'LastName': 'Lindén Hirschberg', 'Affiliation': ""Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.""}, {'ForeName': 'Mette H', 'Initials': 'MH', 'LastName': 'Moen', 'Affiliation': 'Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.'}]",Acta obstetricia et gynecologica Scandinavica,['10.1111/aogs.13819'] 1010,32083653,Intraoperative localization of cardiac conduction tissue regions using real-time fibre-optic confocal microscopy: first in human trial.,"OBJECTIVES The aim of this study was to evaluate the feasibility and safety of fibre-optic confocal microscopy (FCM) using fluorescein sodium dye for the intraoperative location of conduction tissue regions during paediatric heart surgery. METHODS The pilot study included 6 patients undergoing elective surgery for the closure of isolated secundum atrial septal defect aged 30 days to 21 years. FCM imaging was integrated within the normal intraoperative protocol for atrial septal defect repair. Fluorescein sodium dye was applied on the arrested heart. FCM images were acquired at the atrioventricular node region, sinus node region and right ventricle (RV). Total imaging time was limited to 3 min. Any adverse events related to the study were recorded and analysed. Subjects received standard postoperative care. Trained reviewers (n = 9) classified, de-identified and randomized FCM images (n = 60) recorded from the patients as presenting striated, reticulated or indistinguishable microstructures. The reliability of reviewer agreement was assessed using Fleiss' kappa. RESULTS The FCM imaging instruments were integrated effectively into the cardiac surgery operating room. All adverse events found in the study were deemed expected and not related to FCM imaging. Reticulated myocardial microstructures were found during FCM imaging at atrioventricular node and sinus node regions, while striated microstructures were observed in RV. Reliability of agreement of reviewers classifying the FCM images was high (Fleiss' kappa: 0.822). CONCLUSIONS FCM using fluorescein sodium dye was found to be safe for use during paediatric heart surgery. The study demonstrates the potential for FCM to be effective in identifying conduction tissue regions during congenital heart surgery. CLINICAL TRIAL REGISTRATION NUMBER NCT03189134.",2020,"Reliability of agreement of reviewers classifying the FCM images was high (Fleiss' kappa: 0.822). ","['6 patients undergoing elective surgery for the closure of isolated secundum atrial septal defect aged 30\u2009days to 21\u2009years', 'paediatric heart surgery']","['real-time fibre-optic confocal microscopy', 'fibre-optic confocal microscopy (FCM) using fluorescein sodium dye', 'FCM', 'FCM using fluorescein sodium dye', 'standard postoperative care', 'Fluorescein sodium dye']","['Reticulated myocardial microstructures', 'Total imaging time']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0206058', 'cui_str': 'Elective Surgical Procedures'}, {'cui': 'C0185003', 'cui_str': 'Reparative closure (procedure)'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C0344724', 'cui_str': 'Atrial septal defect within oval fossa (disorder)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C0242842', 'cui_str': 'Microscopy, Confocal'}, {'cui': 'C0147866', 'cui_str': 'fluorescein sodium'}, {'cui': 'C0013343', 'cui_str': 'Dyes'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0032786', 'cui_str': 'Postoperative Care'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",6.0,0.039689,"Reliability of agreement of reviewers classifying the FCM images was high (Fleiss' kappa: 0.822). ","[{'ForeName': 'Aditya K', 'Initials': 'AK', 'LastName': 'Kaza', 'Affiliation': ""Department of Cardiac Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Abhijit', 'Initials': 'A', 'LastName': 'Mondal', 'Affiliation': ""Department of Cardiac Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Breanna', 'Initials': 'B', 'LastName': 'Piekarski', 'Affiliation': ""Department of Cardiac Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Frank B', 'Initials': 'FB', 'LastName': 'Sachse', 'Affiliation': 'Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Hitchcock', 'Affiliation': 'Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA.'}]",European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,['10.1093/ejcts/ezaa040'] 1011,32493052,Continuous intravenous versus intermittent bolus midazolam with remifentanil during arteriovenous fistula placement with monitored anesthesia care in chronic renal failure patients: a randomized controlled trial.,"BACKGROUND There is limited data on the use of intravenous continuous infusion (CI) versus intravenous intermittent bolus (IB) doses of midazolam for conscious sedation in patients with chronic renal failure. Unexpected adverse events can occur in chronic renal failure patients undergoing short procedures. OBJECTIVE Investigate and compare the sedoanalgesic and adverse effects of intravenous continuous infusion (CI) use of midazolam with intravenous intermittent bolus (IB) doses of midazolam while using intravenous remifentanil as a rescue medication, and assess patient and surgeon satisfaction. DESIGN Prospective, randomized, single-blind controlled study. SETTINGS Two tertiary care hospitals. PATIENTS AND METHODS Study included patients aged 43-81 years with a diagnosis of chronic renal failure who were referred for an arteriovenous fistula procedure with modified anesthesia care between August 2012 and April 2016. The patients were randomized to intravenous CI or IB doses of midazolam. IB doses of remifentanil were used as a rescue medication. MAIN OUTCOME MEASURES Primary outcomes were amounts of midazolam and remifentanil medications during the operation, the amount of remifentanil as a rescue medication, and the satisfaction of patient and surgeon. SAMPLE SIZE 116 assessed for eligibility; 99 randomized to CI (n=50) or IB doses (n=49 of midazolam). RESULTS The total dose of midazolam by CI was greater than with midazolam by IB ( P =.002). The total dose of remifentanil was higher with IB doses of midazolam in comparison to CI of midazolam ( P =.001). The groups were similar in sedation and pain control, duration of procedure, recovery time, patient satisfaction and adverse events; surgeon satisfaction was greater with CI versus IB ( P =.035). CONCLUSION Intravenous CI midazolam during MAC provides better surgeon satisfaction then IB midazolam and can be used safely for arteriovenous fistula procedures. LIMITATIONS Two different surgeon groups. CONFLICT OF INTEREST None.",2020,"The groups were similar in sedation and pain control, duration of procedure, recovery time, patient satisfaction and adverse events; surgeon satisfaction was greater with CI versus IB ( P =.035). ","['Study included patients aged 43-81 years with a diagnosis of chronic renal failure who were referred for an arteriovenous fistula procedure with modified anesthesia care between August 2012 and April 2016', 'patients with chronic renal failure', 'chronic renal failure patients undergoing short procedures', 'Two tertiary care hospitals', 'chronic renal failure patients']","['Intravenous CI midazolam', 'remifentanil', 'midazolam with remifentanil', 'midazolam', 'intravenous continuous infusion (CI', 'intravenous continuous infusion (CI) versus intravenous intermittent bolus (IB) doses of midazolam']","['amounts of midazolam and remifentanil medications during the operation, the amount of remifentanil as a rescue medication, and the satisfaction of patient and surgeon', 'sedation and pain control, duration of procedure, recovery time, patient satisfaction and adverse events; surgeon satisfaction']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0003855', 'cui_str': 'Arteriovenous fistula'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0337954', 'cui_str': 'Tertiary care hospital'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0444889', 'cui_str': 'Continuous infusion'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C1301695', 'cui_str': 'Intermittent bolus'}]","[{'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.247795,"The groups were similar in sedation and pain control, duration of procedure, recovery time, patient satisfaction and adverse events; surgeon satisfaction was greater with CI versus IB ( P =.035). ","[{'ForeName': 'Gonul', 'Initials': 'G', 'LastName': 'Sagiroglu', 'Affiliation': 'From the Department of Anesthesiology, Faculty of Medicine, Trakya University, Edirne, Turkey.'}, {'ForeName': 'Ayse', 'Initials': 'A', 'LastName': 'Baysal', 'Affiliation': 'From the Department of Anesthesiology and Reanimation, Pendik Bolge Hospital, Istanbul, Turkey.'}]",Annals of Saudi medicine,['10.5144/0256-4947.2020.175'] 1012,22546131,"A double-blind, randomized, active-controlled study for post-hemorrhoidectomy pain management with liposome bupivacaine, a novel local analgesic formulation.","This randomized, active-controlled study evaluated the extent and duration of analgesia after administration of liposome bupivacaine (LB), a novel formulation of bupivacaine, compared with bupivacaine HCl given via local infiltration in excisional hemorrhoidectomy. One hundred patients were randomly assigned to receive a single dose of bupivacaine HCl 75 mg (0.25% with 1:200,000 epinephrine) or LB 66, 199, or 266 mg upon completion of hemorrhoidectomy. Postoperative pain intensity was assessed using a numeric rating scale at rest to calculate a cumulative pain score (area under the curve). Cumulative pain scores were significantly lower with LB at each study dose (P < 0.05) compared with bupivacaine HCl 72 hours after surgery. Post hoc analysis showed that mean total postoperative opioid consumption was statistically significantly lower for the LB 266-mg group compared with the bupivacaine HCl group during the 12- to 72-hour postoperative period (P = 0.019). Median time to first opioid use was 19 hours for LB 266 mg versus 8 hours for bupivacaine HCl (P = 0.005). Incidence of opioid-related adverse events was 4 per cent for LB 266 mg compared with 35 per cent for bupivacaine HCl (P = 0.007). Local infiltration with LB resulted in significantly reduced postsurgical pain compared with bupivacaine HCl in patients after hemorrhoidectomy surgery.",2012,Local infiltration with LB resulted in significantly reduced postsurgical pain compared with bupivacaine HCl in patients after hemorrhoidectomy surgery.,"['One hundred patients', 'excisional hemorrhoidectomy', 'patients after hemorrhoidectomy surgery']","['hemorrhoidectomy', 'bupivacaine', 'liposome bupivacaine (LB', 'liposome bupivacaine', 'bupivacaine HCl', 'bupivacaine HCl 75 mg (0.25% with 1:200,000 epinephrine) or LB']","['postsurgical pain', 'mean total postoperative opioid consumption', 'Postoperative pain intensity', 'Median time to first opioid use', 'Cumulative pain scores', 'cumulative pain score (area under the curve', 'numeric rating scale']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019108', 'cui_str': 'Hemorrhoidectomy'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0019108', 'cui_str': 'Hemorrhoidectomy'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0023828', 'cui_str': 'Liposomes'}, {'cui': 'C0443985', 'cui_str': 'Flinders medical center-7 marker (substance)'}, {'cui': 'C4517443', 'cui_str': '0.25 (qualifier value)'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0222045'}]",,0.191732,Local infiltration with LB resulted in significantly reduced postsurgical pain compared with bupivacaine HCl in patients after hemorrhoidectomy surgery.,"[{'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Haas', 'Affiliation': 'Colorectal Surgical Associates, Ltd, LLP, Houston, Texas, USA.'}, {'ForeName': 'Erol', 'Initials': 'E', 'LastName': 'Onel', 'Affiliation': ''}, {'ForeName': 'Howard', 'Initials': 'H', 'LastName': 'Miller', 'Affiliation': ''}, {'ForeName': 'Madhu', 'Initials': 'M', 'LastName': 'Ragupathi', 'Affiliation': ''}, {'ForeName': 'Paul F', 'Initials': 'PF', 'LastName': 'White', 'Affiliation': ''}]",The American surgeon,[] 1013,31356702,Efficacy of Behavioral Couples Therapy Versus Individual Recovery Counseling for Addressing Posttraumatic Stress Disorder Among Women With Drug Use Disorders.,"Behavioral couples therapy (BCT) for substance use disorder shares similar intervention strategies with empirically supported couples therapies for posttraumatic stress disorder (PTSD). Like couples-based PTSD therapies, BCT includes interventions that may help to improve PTSD, such as increasing positive behavioral exchanges and improving communication. Studies have yet to examine whether BCT, which has demonstrated efficacy for improving substance-related outcomes, is efficacious for reducing PTSD. We conducted a secondary analysis of a randomized clinical trial comparing individually based treatment (IBT) to BCT plus IBT (BCT+IBT) for women with drug use disorders. Women in both conditions received 26 therapy sessions over 13 weeks. Women completed the PTSD Diagnostic Scale at baseline, posttreatment, and quarterly during the 1-year follow-up. Of the 61 women who were randomized to treatment, 51 (83.6%) reported a lifetime traumatic event. Of the 50 women who endorsed a ""worst traumatic event,"" 25 (50.0%) had a baseline PTSD diagnosis. The treatments did not differ on baseline PTSD severity or diagnosis. Women who received BCT+IBT had significant reductions in PTSD severity from baseline to each of four posttreatment follow-ups, ds = 0.34-0.80; there were no changes in the IBT group. Generalized estimating equation results showed that women who received BCT+IBT had significantly lower PTSD severity during follow-up versus those who received IBT, d = 0.35. There were no differences in the proportion of participants diagnosed with PTSD following treatment. This was the first study to show that BCT+IBT is efficacious for reducing PTSD among women with drug use disorders.",2019,"Women who received BCT+IBT had significant reductions in PTSD severity from baseline to each of four posttreatment follow-ups, ds = 0.34-0.80; there were no changes in the IBT group.","['61 women', '50 women who endorsed a ""worst traumatic event,"" 25 (50.0%) had a baseline PTSD diagnosis', 'Women With Drug Use Disorders', 'women with drug use disorders']","['Behavioral couples therapy (BCT', 'Behavioral Couples Therapy Versus Individual Recovery Counseling', 'individually based treatment (IBT) to BCT plus IBT (BCT+IBT', 'BCT+IBT']","['lifetime traumatic event', 'PTSD Diagnostic Scale', 'baseline PTSD severity or diagnosis', 'PTSD severity']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0332663', 'cui_str': 'Traumatic (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0013222', 'cui_str': 'Drug Use Disorders'}]","[{'cui': 'C0302822', 'cui_str': 'Couples Therapy'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0332663', 'cui_str': 'Traumatic (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0222045'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]",61.0,0.0395731,"Women who received BCT+IBT had significant reductions in PTSD severity from baseline to each of four posttreatment follow-ups, ds = 0.34-0.80; there were no changes in the IBT group.","[{'ForeName': 'Jeremiah A', 'Initials': 'JA', 'LastName': 'Schumm', 'Affiliation': 'School of Professional Psychology, Wright State University, Dayton, Ohio, USA.'}, {'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': ""O'Farrell"", 'Affiliation': 'VA Boston Healthcare System, Brockton, Massachusetts, USA.'}, {'ForeName': 'Marie M', 'Initials': 'MM', 'LastName': 'Murphy', 'Affiliation': 'VA Boston Healthcare System, Brockton, Massachusetts, USA.'}, {'ForeName': 'Patrice', 'Initials': 'P', 'LastName': 'Muchowski', 'Affiliation': 'AdCare Hospital of Worcester, Inc., Worcester, Massachusetts, USA.'}]",Journal of traumatic stress,['10.1002/jts.22415'] 1014,22192488,Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial.,"BACKGROUND In trachoma control programmes, azithromycin is distributed to treat the strains of chlamydia that cause ocular disease. We aimed to compare the effect of annual versus twice-yearly distribution of azithromycin on infection with these strains. METHODS We did a cluster-randomised trial in 24 subdistricts in northern Ethiopia, which we randomly assigned to receive annual or twice-yearly treatment for all residents of all ages. Random assignment was done with the RANDOM and SORT functions of Microsoft Excel. All individuals were offered their assigned treatment of a single, directly observed, oral dose of azithromycin. A 6 week course of topical 1% tetracycline ointment, applied twice daily to both eyes but not directly observed, was offered as an alternative to azithromycin in patients younger than 12 months, and in patients with self-reported pregnancy, with allergy, or who refused azithromycin. Our primary, prespecified outcome was the prevalence of ocular chlamydial infection in a random sample of children aged 0-9 years at baseline and every 6 months for a total of 42 months within sentinel villages. Our analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00322972. FINDINGS Antibiotic coverage of children aged 1-9 years was greater than 80% (range 80·9 to 93·0) at all study visits. In the groups treated annually, the prevalence of infection in children aged 0-9 years was reduced from a mean 41·9% (95% CI 31·5 to 52·2) at baseline to 1·9% (0·3 to 3·5) at 42 months. In the groups treated twice yearly, the prevalence of infection was reduced from a mean 38·3% (29·0 to 47·6) at baseline to 3·2 % (0·0 to 6·5) at 42 months. The prevalence of ocular chlamydial infection in children aged 0-9 years in groups treated annually was not different from that of the groups treated twice yearly at 18, 30, and 42 months (pooled regression p>0·99, 95 % CI -0·06 to 0·06). The mean elimination time in the twice-yearly treatment group was 7·5 months earlier (2·3 to 17·3) than that of the annual group (p=0·10, Cox proportional hazards model). INTERPRETATION After 42 months of treatment, the prevalence of ocular infection with chlamydia was similar in the groups treated annually and twice yearly. However, elimination of infection might have been more rapid in the groups of villages that received treatment twice yearly. FUNDING National Institutes of Health (NEI U10 EY016214).",2012,"After 42 months of treatment, the prevalence of ocular infection with chlamydia was similar in the groups treated annually and twice yearly.","['hyperendemic trachoma in Ethiopia', 'children aged 1-9 years was greater than 80% (range 80·9 to 93·0) at all study visits', 'patients younger than 12 months, and in patients with self-reported pregnancy, with allergy, or who refused', '24 subdistricts in northern Ethiopia', 'children aged 0-9 years']","['azithromycin', 'tetracycline ointment']","['mean elimination time', 'ocular chlamydial infection', 'prevalence of ocular chlamydial infection', 'prevalence of infection', 'prevalence of ocular infection with chlamydia']","[{'cui': 'C0040592', 'cui_str': 'Egyptian Ophthalmia'}, {'cui': 'C0015024', 'cui_str': 'Federal Democratic Republic of Ethiopia'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0002111', 'cui_str': 'Allergy Specialty'}, {'cui': 'C1705116', 'cui_str': 'Refused (qualifier value)'}]","[{'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0039651', 'cui_str': 'Tetracyclines'}, {'cui': 'C0028912', 'cui_str': 'Salves'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C4521296', 'cui_str': 'Ocular (intended site)'}, {'cui': 'C0008149', 'cui_str': 'Chlamydia Infections'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0015403', 'cui_str': 'Ocular Infections'}, {'cui': 'C0008148', 'cui_str': 'Chlamydia'}]",,0.0975701,"After 42 months of treatment, the prevalence of ocular infection with chlamydia was similar in the groups treated annually and twice yearly.","[{'ForeName': 'Teshome', 'Initials': 'T', 'LastName': 'Gebre', 'Affiliation': 'The Carter Center, Addis Ababa, Ethiopia.'}, {'ForeName': 'Berhan', 'Initials': 'B', 'LastName': 'Ayele', 'Affiliation': ''}, {'ForeName': 'Mulat', 'Initials': 'M', 'LastName': 'Zerihun', 'Affiliation': ''}, {'ForeName': 'Asrat', 'Initials': 'A', 'LastName': 'Genet', 'Affiliation': ''}, {'ForeName': 'Nicole E', 'Initials': 'NE', 'LastName': 'Stoller', 'Affiliation': ''}, {'ForeName': 'Zhaoxia', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': ''}, {'ForeName': 'Jenafir I', 'Initials': 'JI', 'LastName': 'House', 'Affiliation': ''}, {'ForeName': 'Sun N', 'Initials': 'SN', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Kathryn J', 'Initials': 'KJ', 'LastName': 'Ray', 'Affiliation': ''}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Emerson', 'Affiliation': ''}, {'ForeName': 'Jeremy D', 'Initials': 'JD', 'LastName': 'Keenan', 'Affiliation': ''}, {'ForeName': 'Travis C', 'Initials': 'TC', 'LastName': 'Porco', 'Affiliation': ''}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Lietman', 'Affiliation': ''}, {'ForeName': 'Bruce D', 'Initials': 'BD', 'LastName': 'Gaynor', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(11)61515-8'] 1015,32421737,Predictors of change of health workers' knowledge and skills after the Helping Mothers Survive Bleeding after Birth (HMS BAB) in-facility training in Tanzania.,"BACKGROUND Our study aimed to assess the effect of Helping Mothers Survive Bleeding after Birth on knowledge and skills of health workers and whether such effect varies by health workers characteristics. METHODS Nested in a cluster-randomised trial to assess the effect of the training on health outcomes, we assessed changes in knowledge and simulated skills in 61 facilities. The assessments were done i) before, ii) immediately-after training session and iii) at 10-month follow-up for subset of health-workers of implementation facilities as defined by the trial. We used a self-administered questionnaire and Objective Structures Clinical Examinations to assess three skill sets: Active Management of Third Stage of Labour, removal of retained placenta and management of severe postpartum haemorrhage. We computed summary statistics and used the paired t-test to assess change of knowledge and skills immediately post-training and at 10-month follow-up. Linear regression was done to assess association of scores and health worker characteristics. RESULTS Of the 636 health workers included, 606 (96.7%) and 591 (91.4%) completed the knowledge and skills assessments, respectively. Majority of the participants (68%) were nurse-midwives. Knowledge scores increased by 15 percentage-points from 77.5% to 93% (95% CI 14.3, 16.3, p-value <0.000), and skills scores by 47 percentage-points (95% CI 46.5, 49.2, p-value <0.000) from 37.5% to 83%. There was a 4.0% decline of skills at 10-month follow-up. The decline was higher in auxiliary staff (-11.8%) and least in nurse-midwives (-2.1%) p-value <0.001. Health workers who assisted less than 5 deliveries in the last month, those who never attended postpartum haemorrhage in-service training and profession experience >8 years were associated with lower mean skill change immediately post-training. CONCLUSION Our study supports the potential of the Helping Mothers Survive Bleeding after Birth training to increase knowledge and skills of postpartum haemorrhage among all professional groups. Auxiliary staff benefited most from the training but also showed higher skill decline at 10-month. Our study highlights the importance to disaggregate knowledge and skills by health workers characteristics.",2020,"Knowledge scores increased by 15 percentage-points from 77.5% to 93% (95% CI 14.3, 16.3, p-value <0.000), and skills scores by 47 percentage-points (95% CI 46.5, 49.2, p-value <0.000) from 37.5% to 83%.","['61 facilities', 'Health workers who assisted less than 5 deliveries in the last month, those who never attended postpartum haemorrhage in-service training and profession experience >8 years', 'Of the 636 health workers', 'Mothers Survive Bleeding after Birth (HMS BAB) in-facility training in Tanzania']",[],"['knowledge and skills of postpartum haemorrhage', 'Knowledge scores', 'auxiliary staff', 'skills scores', 'skill decline']","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0557286', 'cui_str': 'No formal education'}, {'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0028811', 'cui_str': 'Occupation'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0262500', 'cui_str': 'Routine health maintenance'}, {'cui': 'C0039298', 'cui_str': 'Tanzania'}]",[],"[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}]",,0.0861455,"Knowledge scores increased by 15 percentage-points from 77.5% to 93% (95% CI 14.3, 16.3, p-value <0.000), and skills scores by 47 percentage-points (95% CI 46.5, 49.2, p-value <0.000) from 37.5% to 83%.","[{'ForeName': 'Fadhlun', 'Initials': 'F', 'LastName': 'Alwy Al-Beity', 'Affiliation': 'Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Andrea Barnabas', 'Initials': 'AB', 'LastName': 'Pembe', 'Affiliation': 'Department of Obstetrics and Gynaecology, Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania.'}, {'ForeName': 'Gaetano', 'Initials': 'G', 'LastName': 'Marrone', 'Affiliation': 'Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Ulrika', 'Initials': 'U', 'LastName': 'Baker', 'Affiliation': 'Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Hanson', 'Affiliation': 'Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.'}]",PloS one,['10.1371/journal.pone.0232983'] 1016,32422373,Add-On Omalizumab for Inadequately Controlled Severe Pollinosis Despite Standard-of-Care: A Randomized Study.,"BACKGROUND Cedar pollinosis (CP), a common form of seasonal allergic rhinitis (AR), is a substantial medical problem in Japan due to its high prevalence and severe symptoms. Omalizumab (anti-IgE therapy) has previously proven to be effective in CP/AR, but no studies for inadequately controlled severe CP/AR despite standard-of-care (SoC) have been conducted. OBJECTIVE To determine the efficacy of omalizumab added to SoC in patients with inadequately controlled severe CP in a randomized, double-blinded, placebo-controlled, phase III study. METHODS Adult/adolescent patients with severe CP whose symptoms were inadequately controlled despite nasal corticosteroids plus 1 or more oral medications in the previous 2 seasons were randomized to receive omalizumab (n = 162) or placebo (n = 175). All patients received concomitant antihistamines and nasal corticosteroids as SoC. The primary endpoint was the mean nasal symptom score during the severe symptom period. Secondary endpoints included mean ocular symptom score, quality of life (QoL), and safety. RESULTS The SoC + omalizumab treatment had statistically significantly and clinically important lower nasal (least squares mean difference, -1.03, P < .001) and ocular (-0.87, P < .001) symptom scores compared with SoC + placebo, respectively. Differences in scores for individual components of nasal and ocular symptoms were also statistically and clinically significant. SoC + omalizumab also improved QoL scores as overall and in all domains. No unexpected safety signals were observed. CONCLUSIONS In patients with severe CP, omalizumab added to SoC demonstrated consistent efficacy in improving symptoms and QoL, and was well tolerated. These results indicate that omalizumab could be a promising therapeutic option for severe CP/AR.",2020,"The SoC + omalizumab treatment had statistically significantly and clinically important lower nasal (LS mean difference, -1.03, p<0.001) and ocular (-0.87, p<0.001) symptom scores compared with SoC + placebo respectively.","['Severe adult/adolescent CP patients whose symptoms were inadequately controlled despite nasal corticosteroids plus one or more oral medications in the previous two seasons', 'Cedar pollinosis (CP', 'patients with inadequately controlled severe CP']","['Omalizumab (anti-IgE therapy', 'concomitant antihistamines and nasal corticosteroids as SoC', 'SoC + Omalizumab', 'omalizumab', 'SoC + placebo', 'placebo']","['individual components of nasal and ocular symptoms', 'QoL scores', 'mean ocular symptom score, quality-of-life, and safety', 'mean nasal symptom score']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0018621', 'cui_str': 'Seasonal allergic rhinitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}]","[{'cui': 'C0966225', 'cui_str': 'omalizumab'}, {'cui': 'C0051978', 'cui_str': 'Anti-Immunoglobulin E antibody'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0019590', 'cui_str': 'Histamine receptor antagonist'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0231918', 'cui_str': 'Nose symptoms'}]",175.0,0.216499,"The SoC + omalizumab treatment had statistically significantly and clinically important lower nasal (LS mean difference, -1.03, p<0.001) and ocular (-0.87, p<0.001) symptom scores compared with SoC + placebo respectively.","[{'ForeName': 'Kimihiro', 'Initials': 'K', 'LastName': 'Okubo', 'Affiliation': 'Department of Otolaryngology, Nippon Medical School, Tokyo, Japan. Electronic address: ent-kimi@nms.ac.jp.'}, {'ForeName': 'Mitsuhiro', 'Initials': 'M', 'LastName': 'Okano', 'Affiliation': 'Department of Otorhinolaryngology, International University of Health and Welfare School of Medicine, Narita, Japan.'}, {'ForeName': 'Norio', 'Initials': 'N', 'LastName': 'Sato', 'Affiliation': 'Novartis Pharma K.K., Tokyo, Japan.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Tamaki', 'Affiliation': 'Novartis Pharma K.K., Tokyo, Japan.'}, {'ForeName': 'Hiromi', 'Initials': 'H', 'LastName': 'Suzuki', 'Affiliation': 'Novartis Pharma K.K., Tokyo, Japan.'}, {'ForeName': 'Alkaz', 'Initials': 'A', 'LastName': 'Uddin', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Fogel', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ.'}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2020.04.068'] 1017,22345836,A single blind comparative clinical study of the effects of chlorpromazine and risperidone on positive and negative symptoms in patients of schizophrenia.,"OBJECTIVES The present study was undertaken to test the comparative efficacy of chlorpromazine and risperidone in patients of schizophrenia in a tertiary care hospital of Maharashtra. MATERIALS AND METHODS About 100 subjects of either sex between 15 and 75 years of age were randomly assigned either chlorpromazine or risperidone. Only those patients were included who met International Classification of Diseases 10 revision criteria by World Health Organization. To avoid bias, the test drugs were coded as A and B. The study coordinator was unaware of the prescribed drugs; however, the prescribing psychiatrist knew about the drug treatment. RESULTS Both chlorpromazine and risperidone significantly decreased the mean score of positive and general symptoms in patients of schizophrenia. Although chlorpromazine decreased the mean score of negative symptoms, it was not statistically significant. Risperidone reduced the mean score of negative symptoms to a significant extent. The cost (Rs. 3000-4000) of risperidone was more than the cost (Rs. 700-1000) of chlorpromazine per patient per annum. The dropouts were less (25%) in the risperidone group than in the chlorpromazine group (75%). The more purchase of risperidone than of chlorpromazine was observed in our study. CONCLUSION The response rates for positive and general symptoms were found to be equal for both chlorpromazine and risperidone. However, risperidone was found to be more effective than chlorpromazine in treating negative symptoms. The dropout rate was less in the risperidone group than in the chlorpromazine group. The compliance was also better in the risperidone group, even though the cost of risperidone was more than that of chlorpromazine.",2011,The dropouts were less (25%) in the risperidone group than in the chlorpromazine group (75%).,"['100 subjects of either sex between 15 and 75 years of age', 'patients of schizophrenia', 'Only those patients were included who met International Classification of Diseases 10 revision criteria by World Health Organization', 'patients of schizophrenia in a tertiary care hospital of Maharashtra']","['Risperidone', 'chlorpromazine and risperidone', 'risperidone', 'chlorpromazine', 'chlorpromazine or risperidone']","['mean score of negative symptoms', 'mean score of positive and general symptoms', 'positive and negative symptoms', 'dropout rate', 'response rates for positive and general symptoms']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0870733', 'cui_str': 'International Statistical Classification of Diseases and Related Health Problems'}, {'cui': 'C0439617', 'cui_str': 'Revision - value'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0043237', 'cui_str': 'WHO'}, {'cui': 'C0337954', 'cui_str': 'Tertiary care hospital (environment)'}]","[{'cui': 'C0073393', 'cui_str': 'Risperidone'}, {'cui': 'C0008286', 'cui_str': 'Chlorpromazine'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0159028', 'cui_str': 'General symptom (finding)'}]",,0.0146699,The dropouts were less (25%) in the risperidone group than in the chlorpromazine group (75%).,"[{'ForeName': 'Amrita Prakash', 'Initials': 'AP', 'LastName': 'Singam', 'Affiliation': 'Department of Pharmacology, Indira Gandhi Medical College, Nagpur, Maharashtra, India.'}, {'ForeName': 'Abhishek', 'Initials': 'A', 'LastName': 'Mamarde', 'Affiliation': ''}, {'ForeName': 'Prakash B', 'Initials': 'PB', 'LastName': 'Behere', 'Affiliation': ''}]",Indian journal of psychological medicine,['10.4103/0253-7176.92061'] 1018,22345845,Translation and validation of the insomnia severity index in hindi language.,"AIMS AND OBJECTIVES Translation of the Insomnia Severity Index from English to Hindi and Validation of the Hindi version. MATERIALS AND METHODS The translation process of the Insomnia Severity Index was initiated after obtaining due permission from the author of the original version of the same. Translation was carried out by using standard translation procedures, such as combined translation, decentering, and pretest method. The final version of the Insomnia Severity Index in Hindi was finally validated. A randomly selected sample size of 65 subjects was enrolled for the purpose of validation and testing the reliability of Hindi version of the Insomnia Severity Index. Insomnia was present in 45 subjects and they constituted the insomnia group. The rest 20 subjects did not have insomnia and were included in the control group. The Hindi version of the Insomnia Severity Index was applied to both the groups. RESULTS The total sample constituted of 50.8% males and 49.2% females. The mean age in the control group was 30.8±8.3 years and that in the insomnia group was 40.3±4 years (t=3.04; P=0.001). The translated version of the Insomnia Severity Index showed a reliability of 0.91 (Cronbach's α=0.91). This was not just simple translation, but many of the words were changed to adapt it for the local population. CONCLUSION The Hindi version of the Insomnia Severity Index is a valid and reliable tool that can be administered for the assessment of severity of insomnia.",2011,The Hindi version of the Insomnia Severity Index is a valid and reliable tool that can be administered for the assessment of severity of insomnia.,"['hindi language', '65 subjects', '45 subjects and they constituted the insomnia group']",[],"['Insomnia Severity Index', 'reliability of Hindi version of the Insomnia Severity Index', 'Insomnia']","[{'cui': 'C0019547', 'cui_str': 'Hindi language (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]",[],"[{'cui': 'C4520529', 'cui_str': 'Insomnia severity index (assessment scale)'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}]",65.0,0.0183886,The Hindi version of the Insomnia Severity Index is a valid and reliable tool that can be administered for the assessment of severity of insomnia.,"[{'ForeName': 'Vivekananda', 'Initials': 'V', 'LastName': 'Lahan', 'Affiliation': 'Department of Psychiatry, Himalayan Institute of Medical Sciences, Swami Ram Nagar, Doiwala, Dehradun, India.'}, {'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Gupta', 'Affiliation': ''}]",Indian journal of psychological medicine,['10.4103/0253-7176.92060'] 1019,21105622,A prospective clinical evaluation of the effects of intraoperative systemic anticoagulation in patients undergoing arteriovenous fistula surgery.,"No standard presently exists for the use of systemic heparin during angioaccess surgery to decrease the incidence of postoperative thrombotic complications. Our objective was to study the effects of intraoperatively administered heparin on 30-day patency and postoperative bleeding complications in patients undergoing autogenous arteriovenous (AV) fistula surgery. A prospective, double-blinded, randomized controlled study was performed on 48 patients undergoing AV fistula creation from April 2007 through November 2009. Of the 48 patients, 22 were randomized to the control group and received no heparin. Twenty-six were randomized to receive heparin (75 units/kg intravenously) before clamping of the artery. There was no significant difference in 30-day patency between the heparin and control groups (92% vs. 86%, P = 0.65), respectively. Three patients (12%) developed hematomas in the heparin group compared with one (5%) in the control group; however the difference was not statistically significant (P = 0.61). The results suggest that intraoperative administration of heparin has no statistically significant effect on 30-day patency rates or postoperative bleeding complications. Larger trials with longer term follow-up and assessment of maturation rates are needed to determine the effect of intraoperative anticoagulation on these outcomes of arteriovenous fistula surgery.",2010,The results suggest that intraoperative administration of heparin has no statistically significant effect on 30-day patency rates or postoperative bleeding complications.,"['48 patients undergoing AV fistula creation from April 2007 through November 2009', 'patients undergoing autogenous arteriovenous (AV) fistula surgery', 'patients undergoing arteriovenous fistula surgery', '48 patients', 'Twenty-six']","['no heparin', 'systemic heparin', 'intraoperative systemic anticoagulation', 'heparin']","['30-day patency rates or postoperative bleeding complications', 'postoperative thrombotic complications', 'hematomas', '30-day patency and postoperative bleeding complications', '30-day patency']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0398221', 'cui_str': 'Arteriovenous fistulization (procedure)'}, {'cui': 'C0443145', 'cui_str': 'Autogenous (qualifier value)'}, {'cui': 'C0003855', 'cui_str': 'Arteriovenous fistula (morphologic abnormality)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}]","[{'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}]","[{'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0032788', 'cui_str': 'Blood Loss, Postoperative'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}]",48.0,0.263354,The results suggest that intraoperative administration of heparin has no statistically significant effect on 30-day patency rates or postoperative bleeding complications.,"[{'ForeName': 'Bonnie R', 'Initials': 'BR', 'LastName': 'Wang', 'Affiliation': 'University of Southern California, Department of Surgery, Los Angeles, California 90033, USA.'}, {'ForeName': 'Vincent L', 'Initials': 'VL', 'LastName': 'Rowe', 'Affiliation': ''}, {'ForeName': 'Sung Wan', 'Initials': 'SW', 'LastName': 'Ham', 'Affiliation': ''}, {'ForeName': 'Sukgu', 'Initials': 'S', 'LastName': 'Han', 'Affiliation': ''}, {'ForeName': 'Kaushal', 'Initials': 'K', 'LastName': 'Patel', 'Affiliation': ''}, {'ForeName': 'Fred A', 'Initials': 'FA', 'LastName': 'Weaver', 'Affiliation': ''}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Woo', 'Affiliation': ''}]",The American surgeon,[] 1020,21799554,An Open-label Trial of Risperidone and Fluoxetine in Children with Autistic Disorder.,"OBJECTIVE Various studies have shown the effectiveness of risperidone and fluoxetine in the management of behavioral problems in autism. AIM The purpose of this study was to compare these two drugs in the management of behavioral problems in autism. MATERIALS AND METHODS Forty children with autism were divided into 2 groups in a 16-week open trial that compared these two drugs. Parents rated the children using the Aberrant Behavior Checklist (ABC) and the Conners' Parent Rating Scale - Revised (CPRS-R). The author rated the children using the Children's Psychiatric Rating Scale and Clinical Global Impression (CGI) Scale. RESULTS The risperidone group showed significant improvement in areas like irritability and hyperactivity, while the fluoxetine group showed significant improvement in speech deviance, social withdrawal and stereotypy. When the two drugs were compared, fluoxetine showed greater improvement in stereotypy, while both drugs showed improvement on the general autism scale; and on anger, hyperactivity and irritability scales. CONCLUSIONS In this open trial, both drugs were well tolerated and appeared to be beneficial in the treatment of common behavioral problems in children with autism. Further controlled and double-blind studies in larger samples are warranted.",2010,"The risperidone group showed significant improvement in areas like irritability and hyperactivity, while the fluoxetine group showed significant improvement in speech deviance, social withdrawal and stereotypy.","['Children with Autistic Disorder', 'children with autism', 'Forty children with autism', 'autism']","['risperidone and fluoxetine', 'risperidone', 'fluoxetine', 'Risperidone and Fluoxetine']","[""Aberrant Behavior Checklist (ABC) and the Conners' Parent Rating Scale - Revised (CPRS-R"", 'stereotypy', 'anger, hyperactivity and irritability scales', 'areas like irritability and hyperactivity', 'general autism scale', ""Children's Psychiatric Rating Scale and Clinical Global Impression (CGI) Scale"", 'speech deviance, social withdrawal and stereotypy']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}]","[{'cui': 'C0073393', 'cui_str': 'Risperidone'}, {'cui': 'C0016365', 'cui_str': 'Fluoxetine'}]","[{'cui': 'C0443127', 'cui_str': 'Aberrant (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0222045'}, {'cui': 'C0038273', 'cui_str': 'Stereotypic Movement Disorder'}, {'cui': 'C0002957', 'cui_str': 'Anger'}, {'cui': 'C0424295', 'cui_str': 'Increased purposeful goal-directed activity'}, {'cui': 'C0022107', 'cui_str': 'Irritable Mood'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C3639708', 'cui_str': 'Clinical global impression scale'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0424095', 'cui_str': 'Social withdrawal (finding)'}]",40.0,0.0152326,"The risperidone group showed significant improvement in areas like irritability and hyperactivity, while the fluoxetine group showed significant improvement in speech deviance, social withdrawal and stereotypy.","[{'ForeName': 'Avinash', 'Initials': 'A', 'LastName': 'Desousa', 'Affiliation': 'Consultant Child and Adolescent Psychiatrist, Mumbai, India.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.70522'] 1021,21679588,Randomized objective comparison of live tissue training versus simulators for emergency procedures.,"There is a lack of objective analysis comparing live tissue and simulator training. This article aims to objectively determine the difference in outcomes. Twenty-four Air Force volunteers without prior experience performing emergency procedures were randomly assigned to receive training in tube thoracostomy (chest tube) and cricothyroidotomy training on either a pig model (Sus scrofa domestica) or on the TraumaMan simulator. One week posttraining, students were tested on human cadavers with objective and subjective results recorded. Average completion time for tube thoracostomy in the animal model group was 2 minutes 4 seconds and 1 minute 51 seconds in the simulator group with a mean difference of 12 seconds (P = 0.74). Average completion time for cricothyroidotomy in the animal model group was 2 minutes 35 seconds and 3 minutes 29 seconds in the simulator group with a mean difference of 53 seconds (P = 0.32). Overall confidence was 9 per cent higher in the animal trained group (P = 0.42). Success rate of cricothyroidotomy was 75 per cent in the animal model group and 58 per cent in the simulator-trained group (P = 0.67). Success rate of chest tube placement was 92 per cent in the animal group and 83 per cent in the simulator group (P = 1.00). There was no statistically significant difference in chest tube and cricothyroidotomy outcomes or confidence in the groups trained with live animal models or simulators at the 95 per cent confidence interval. Trends suggest a possible difference, but the number of cadavers required to reach greater than 95 per cent statistical confidence prohibited continuation of the study.",2011,There was no statistically significant difference in chest tube and cricothyroidotomy outcomes or confidence in the groups trained with live animal models or simulators at the 95 per cent confidence interval.,['Twenty-four Air Force volunteers without prior experience performing emergency procedures'],"['live tissue training', 'training in tube thoracostomy (chest tube) and cricothyroidotomy training on either a pig model (Sus scrofa domestica) or on the TraumaMan simulator']","['chest tube and cricothyroidotomy outcomes or confidence', 'Success rate of cricothyroidotomy', 'Average completion time for cricothyroidotomy', 'Overall confidence', 'Average completion time for tube thoracostomy', 'Success rate of chest tube placement']","[{'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C1298802', 'cui_str': 'Emergency procedure'}]","[{'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0189476', 'cui_str': 'Tube thoracostomy'}, {'cui': 'C0008034', 'cui_str': 'Chest Tubes'}, {'cui': 'C0396429', 'cui_str': 'Cricothyroidotomy (procedure)'}, {'cui': 'C0039005', 'cui_str': 'Pigs'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C1136016', 'cui_str': 'Sus scrofa domestica'}, {'cui': 'C0183309', 'cui_str': 'Simulator (physical object)'}]","[{'cui': 'C0008034', 'cui_str': 'Chest Tubes'}, {'cui': 'C0396429', 'cui_str': 'Cricothyroidotomy (procedure)'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0189476', 'cui_str': 'Tube thoracostomy'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}]",,0.0790417,There was no statistically significant difference in chest tube and cricothyroidotomy outcomes or confidence in the groups trained with live animal models or simulators at the 95 per cent confidence interval.,"[{'ForeName': 'Andrew B', 'Initials': 'AB', 'LastName': 'Hall', 'Affiliation': 'Keesler Medical Center, 301 Fisher Street, Keesler AFB, Mississippi 39534, USA. andrew.hall.2@us.af.mil'}]",The American surgeon,[] 1022,21516922,A comparison of lidocaine versus normal saline for local anesthesia before intravenous cannula insertion.,"A number of studies have found that one of the leading causes of patient dissatisfaction with nursing care is directly related to the pain associated with the method of IV (intravenous) cannulation. The purpose of this study was to identify which solution, lidocaine hydrochloride 1% (LIDO), normal saline with preservatives (NSP), or normal saline without preservatives (NS), would have the best local anesthetic effect, as reported by patients, for venous cannulation. The research design was a randomized, double-blind study that compared three solutions for their anesthetic effect during initiation of peripheral IV catheters. The sample consisted of 60 (N=60) patients. The setting was in the radiology outpatient department. The Wong-Baker FACES Pain Rating Scale was used to measure the amount of pain. Data analysis was completed using the Analysis of Variance (ANOVA) and post hoc Scheffé test (Post-Hoc ANOVA). Findings from this study indicated that LIDO and NSP provided equal anesthetic effects.",2010,Findings from this study indicated that LIDO and NSP provided equal anesthetic effects.,['sample consisted of 60 (N=60) patients'],"['lidocaine hydrochloride 1% (LIDO), normal saline with preservatives (NSP), or normal saline without preservatives (NS', 'lidocaine', 'normal saline', 'LIDO and NSP']",['Baker FACES Pain Rating Scale'],"[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0546869', 'cui_str': 'Lidocaine Hydrochloride'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}]","[{'cui': 'C0238749', 'cui_str': 'Baker, general (occupation)'}, {'cui': 'C0015468', 'cui_str': 'Face Pain'}, {'cui': 'C0222045'}]",60.0,0.346916,Findings from this study indicated that LIDO and NSP provided equal anesthetic effects.,"[{'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Campbell-Jones', 'Affiliation': 'Department of Home Health Services, Southeast Missouri Hospital, Cape Girardeau, MO 63701, USA. vcampbell-jones@sehosp.org'}]",Journal of National Black Nurses' Association : JNBNA,[] 1023,22021950,Stress and social support.,"BACKGROUND This is an experimental study and it discusses the effectiveness of social support in managing academic stress among students. AIM The purpose of this study is to understand the importance of social support in managing stress. MATERIALS AND METHODS Simple random sampling was assigned to a number of 120 students, equally divided into an experimental and a control group. Classes on social support as coping mechanisms were given to the experimental group only. The accumulated data were then analyzed, descriptive statistics were used to interpret and evaluate the prevalence of academic stress, and social support. Correlation analysis was employed in the examination of the relationship between stress and social support. RESULTS The findings of this study indicate that there are significant differences between the experimental group and the control group in relation to stress and social support. Eventually, the experimental group proved to cope with academic stress better than the control group, and they were satisfied with their academic performance during the experimentation. CONCLUSION Hence, it is highly advisable to encourage the students to use social support as coping mechanisms.",2011,"Eventually, the experimental group proved to cope with academic stress better than the control group, and they were satisfied with their academic performance during the experimentation. ","['Simple random sampling was assigned to a number of 120 students, equally divided into an experimental and a control group', 'students']",[],[],"[{'cui': 'C0205352', 'cui_str': 'Simple (qualifier value)'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],[],,0.0134885,"Eventually, the experimental group proved to cope with academic stress better than the control group, and they were satisfied with their academic performance during the experimentation. ","[{'ForeName': 'Shadiya', 'Initials': 'S', 'LastName': 'Baqutayan', 'Affiliation': 'Perdana School of Science Technology and Innovation Policy University Technology, Malaysia.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.85392'] 1024,22021951,"Repetitive Transcranial Magnetic Stimulation in the Treatment of depression: A Randomized, Double-blind, Placebo-controlled Trial.","BACKGROUND The efficacy of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression has never been reported as yet in the Indian literature. AIMS To study the efficacy of rTMS in the treatment of depression and to evaluate its safety and tolerability. SETTINGS AND DESIGN A randomized, double-blind, sham-controlled trial was conducted at the Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore. MATERIALS AND METHODS 23 patients with depression were randomized to receive either active (n=9) or sham (n=14) treatment with rTMS. Treatment consisted of six sessions of rTMS for 2 weeks (10 trains of pulses, intensity equal to motor threshold, 10 Hz frequency, train duration of 5 seconds, 1 minute inter-train duration). Response was assessed using Hamilton Depression Rating Scale (HDRS), Montgomery Åsberg Depression Rating Scale (MADRS) and Clinical Global Index (CGI). The safety and tolerability was assessed with side-effect checklist for electroconvulsive therapy. 50% reduction in HDRS scores from baseline was defined as treatment response. Outcome measures were analyzed by repeated measures analysis of variance. Chi-square test was used to analyze the categorical variables. RESULTS No statistical significance was seen on the baseline socio-demographic and illness characteristics (Pearson's Chi-square=0.5). Although HDRS (sham 22.0-12.4; active 22.8-12.7) and MADRS (sham 30.7-17.3; active 31.8-16.7) scores reduced by the end of 2 weeks treatment, it was not statistically significant. One patient developed manic symptoms early in the treatment. CONCLUSIONS Treatment with rTMS did not show improvement at the end of 2 weeks. More studies with larger sample size and with higher rTMS dosages need to be done.",2011,"active 31.8-16.7) scores reduced by the end of 2 weeks treatment, it was not statistically significant.","['23 patients with depression', 'depression']","['repetitive transcranial magnetic stimulation (rTMS', 'Placebo', 'rTMS', 'MADRS', 'HDRS', 'active (n=9) or sham (n=14) treatment with rTMS', 'Repetitive Transcranial Magnetic Stimulation']","['HDRS scores', 'manic symptoms', 'Hamilton Depression Rating Scale (HDRS), Montgomery Åsberg Depression Rating Scale (MADRS) and Clinical Global Index (CGI', 'baseline socio-demographic and illness characteristics', 'safety and tolerability']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0338831', 'cui_str': 'Manic State'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",23.0,0.365535,"active 31.8-16.7) scores reduced by the end of 2 weeks treatment, it was not statistically significant.","[{'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Lingeswaran', 'Affiliation': 'Department of Psychiatry, Indira Gandhi Medical College and Research Institute, Kathirkamam, Pondicherry, India.'}]",Indian journal of psychological medicine,['10.4103/0253-7176.85393'] 1025,21716778,Study of the effect of nortriptyline and fluvoxamine on psychomotor functions in healthy volunteers.,"BACKGROUND Today, many antidepressants are available, but they often cause adverse effects, particularly psychomotor and cognitive. It leads to patient maladjustment and may impair psychomotor performance. Fluvoxamine is a newer antidepressant and hence the present study was planned to investigate its effect on psychomotor functions and compare with nortriptyline and record their adverse reactions. MATERIALS AND METHODS A total of 26 healthy volunteers were included in this double-blind, placebocontrolled, crossover study. Single oral doses of fluvoxamine 50 mg, nortriptyline 50 mg and placebo were administered following a Latin square design. The objective parameters-six digit cancellation test, digit symbol substitution test, critical flicker fusion test, arithmetic ability test, hand steadiness test and subjective parameters such as visual analogue scale 1, 2, 3 were tested at 0, 2 and 4 h. The side-effects were also investigated. RESULTS Nortriptyline impaired all subjective and objective psychomotor functions while fluvoxamine did not show any significant effect on objective tests. However, on subjective parameters, there was a significant effect. The side-effects observed were dryness of mouthwith the nortriptyline and nausea and headache with fluvoxamine. CONCLUSION Fluvoxamine is a better antidepressant drug in comparison with nortriptyline as it causes a less impairment of psychomotor functions.",2010,"RESULTS Nortriptyline impaired all subjective and objective psychomotor functions while fluvoxamine did not show any significant effect on objective tests.","['healthy volunteers', '26 healthy volunteers']","['Fluvoxamine', 'fluvoxamine', 'nortriptyline 50 mg and placebo', 'nortriptyline and fluvoxamine', 'placebocontrolled']","['objective parameters-six digit cancellation test, digit symbol substitution test, critical flicker fusion test, arithmetic ability test, hand steadiness test and subjective parameters such as visual analogue scale', 'psychomotor functions', 'subjective and objective psychomotor functions', 'nausea and headache']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0085228', 'cui_str': 'Fluvoxamine'}, {'cui': 'C1123877', 'cui_str': 'Nortriptyline 50 MG'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0028420', 'cui_str': 'Nortriptyline'}]","[{'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0582802', 'cui_str': 'Digit'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0016236', 'cui_str': 'Flicker Fusion'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}]",26.0,0.04165,"RESULTS Nortriptyline impaired all subjective and objective psychomotor functions while fluvoxamine did not show any significant effect on objective tests.","[{'ForeName': 'Ajay', 'Initials': 'A', 'LastName': 'Khade', 'Affiliation': 'Department of Pharmacology, Rajiv Gandhi Institute of Medical Sciences (RIMS), Adilabad, AP, India.'}, {'ForeName': 'Mohammed Shakeel Mohamemed', 'Initials': 'MS', 'LastName': 'Bashir', 'Affiliation': ''}, {'ForeName': 'A S', 'Initials': 'AS', 'LastName': 'Kale', 'Affiliation': ''}, {'ForeName': 'Avinash', 'Initials': 'A', 'LastName': 'Turankar', 'Affiliation': ''}]",Indian journal of psychological medicine,['10.4103/0253-7176.78506'] 1026,31399438,Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial.,"OBJECTIVE To explore gallbladder- and biliary tract-related events reported for the liraglutide and placebo groups in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial. RESEARCH DESIGN AND METHODS LEADER was an international, randomized, double-blind, controlled cardiovascular (CV) outcomes trial. Participants with type 2 diabetes at high risk for CV events ( n = 9,340) were randomized 1:1 to receive either liraglutide (≤1.8 mg daily; n = 4,668) or placebo ( n = 4,672), with both groups also receiving standard care (treatment period: 3.5-5 years). Acute gallstone disease was a medical event of special interest. This post hoc analysis categorized captured events of acute gallbladder or biliary disease into four groups: uncomplicated gallbladder stones, complicated gallbladder stones, cholecystitis, and biliary obstruction. Time to first event by treatment group was analyzed using Cox regression. RESULTS There was an increased risk of acute gallbladder or biliary disease with liraglutide versus placebo ( n = 141 of 4,668 vs. n = 88 of 4,672 patients, respectively; hazard ratio [HR] 1.60; 95% CI 1.23, 2.09; P < 0.001). Similar trends were observed for each of the four categories of gallbladder- or biliary tract-related events. Cholecystectomy was performed more frequently in liraglutide-treated patients (HR 1.56; 95% CI 1.10, 2.20; P = 0.013) but for similar proportions of the patients who experienced gallbladder- or biliary tract-related events (57% with liraglutide vs. 59% with placebo). CONCLUSIONS Although LEADER was not specifically designed to assess acute gallbladder or biliary disease, the trial showed an increased risk of gallbladder- or biliary tract-related events with liraglutide versus placebo, which appeared to be consistent across four categories of these events. Further studies should investigate the relevant mechanisms.",2019,"There was an increased risk of acute gallbladder or biliary disease with liraglutide versus placebo ( n = 141 of 4,668 vs. n = 88 of 4,672 patients, respectively; hazard ratio [HR] 1.60; 95% CI 1.23, 2.09; P < 0.001).","['Participants with type 2 diabetes at high risk for CV events ( n = 9,340', 'Patients With Type 2 Diabetes at High Risk for Cardiovascular Events', 'Diabetes']","['Liraglutide', 'liraglutide', 'liraglutide and placebo', 'placebo', 'Placebo', 'liraglutide versus placebo']","['gallbladder- or biliary tract-related events', 'risk of acute gallbladder or biliary disease', 'gallbladder stones, complicated gallbladder stones, cholecystitis, and biliary obstruction', 'Acute Gallbladder or Biliary Disease']","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]","[{'cui': 'C1456408', 'cui_str': 'liraglutide'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0016976', 'cui_str': 'Gallbladder'}, {'cui': 'C0005423', 'cui_str': 'Biliary System'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0947622', 'cui_str': 'Cholecystolithiasis'}, {'cui': 'C0008325', 'cui_str': 'Gallbladder Inflammation'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}]",4672.0,0.459866,"There was an increased risk of acute gallbladder or biliary disease with liraglutide versus placebo ( n = 141 of 4,668 vs. n = 88 of 4,672 patients, respectively; hazard ratio [HR] 1.60; 95% CI 1.23, 2.09; P < 0.001).","[{'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Nauck', 'Affiliation': 'Diabetes Center Bochum-Hattingen, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany michael.nauck@rub.de.'}, {'ForeName': 'Marie Louise', 'Initials': 'ML', 'LastName': 'Muus Ghorbani', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Eskil', 'Initials': 'E', 'LastName': 'Kreiner', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Hans A', 'Initials': 'HA', 'LastName': 'Saevereid', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Buse', 'Affiliation': 'University of North Carolina School of Medicine, Chapel Hill, NC.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes care,['10.2337/dc19-0415'] 1027,21146469,Drug response profiles to experimental pain are opioid and pain modality specific.,"UNLABELLED Given our limited ability to predict analgesic efficacy, further research is needed to understand factors influencing analgesic response patterns. The aim of this study was to better understand the relationship between morphine and butorphanol analgesic efficacy tested against multiple pain modalities within the same individuals. Participants included healthy men (n = 72) and women (n = 67) who underwent thermal, pressure, and ischemic experimental pain testing before and after the double-blind administration of morphine and butorphanol during separate testing sessions. Factor analysis revealed 6 factors with analgesic effects grouped primarily by pain modality and specific to either morphine or butorphanol. Hierarchical cluster analysis of individual factor scores led to 4 distinct drug response profiles. Three groups displayed exceptional analgesic efficacy produced by 1 type of opioid on 1 pain stimulus modality, whereas the fourth drug response profile was characterized by average analgesic efficacy across all pain modalities for both opioids. These findings suggest that opioids with varying efficacy at the μ and κ receptors produce independent effects on unique pain mechanisms and that individual responsiveness for some is dependent on pain mechanism and opioid type, although a subset of the population is moderately responsive to opioids regardless of efficacy of receptor binding or predominant pain mechanism being activated. PERSPECTIVE This investigation provides a foundation for understanding patterns of opioid efficacy in varying types of pain. Our findings suggest that opioid response patterns are more complex than originally thought with about half of individuals exhibiting opioid and pain modality specific analgesic response profiles.",2011,Factor analysis revealed 6 factors with analgesic effects grouped primarily by pain modality and specific to either morphine or butorphanol.,"['Participants included healthy men (n = 72) and women (n = 67) who underwent thermal, pressure, and ischemic experimental pain testing before and after the double-blind administration of']","['morphine', 'morphine and butorphanol', 'morphine or butorphanol']",['exceptional analgesic efficacy'],"[{'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C1533734', 'cui_str': 'Administration'}]","[{'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0006491', 'cui_str': 'Butorphanol'}]","[{'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}]",72.0,0.160016,Factor analysis revealed 6 factors with analgesic effects grouped primarily by pain modality and specific to either morphine or butorphanol.,"[{'ForeName': 'Lindsay L', 'Initials': 'LL', 'LastName': 'Kindler', 'Affiliation': 'Comprehensive Center for Pain Research, University of Florida College of Dentistry, Gainesville, Florida, USA.'}, {'ForeName': 'Kimberly T', 'Initials': 'KT', 'LastName': 'Sibille', 'Affiliation': ''}, {'ForeName': 'Toni L', 'Initials': 'TL', 'LastName': 'Glover', 'Affiliation': ''}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Staud', 'Affiliation': ''}, {'ForeName': 'Joseph L', 'Initials': 'JL', 'LastName': 'Riley', 'Affiliation': ''}, {'ForeName': 'Roger B', 'Initials': 'RB', 'LastName': 'Fillingim', 'Affiliation': ''}]",The journal of pain : official journal of the American Pain Society,['10.1016/j.jpain.2010.07.011'] 1028,31836261,In the eye of the beholder? Oxytocin effects on eye movements in schizophrenia.,"BACKGROUND Individuals with schizophrenia have difficulty in extracting salient information from faces. Eye-tracking studies have reported that these individuals demonstrate reduced exploratory viewing behaviour (i.e. reduced number of fixations and shorter scan paths) compared to healthy controls. Oxytocin has previously been demonstrated to exert pro-social effects and modulate eye gaze during face exploration. In this study, we tested whether oxytocin has an effect on visual attention in patients with schizophrenia. METHODS Nineteen male participants with schizophrenia received intranasal oxytocin 40UI or placebo in a double-blind, placebo-controlled, crossover fashion during two visits separated by seven days. They engaged in a free-viewing eye-tracking task, exploring images of Caucasian men displaying angry, happy, and neutral emotional expressions; and control images of animate and inanimate stimuli. Eye-tracking parameters included: total number of fixations, mean duration of fixations, dispersion, and saccade amplitudes. RESULTS We found a main effect of treatment, whereby oxytocin increased the total number of fixations, dispersion, and saccade amplitudes, while decreasing the duration of fixations compared to placebo. This effect, however, was non-specific to facial stimuli. When restricting the analysis to facial images only, we found the same effect. In addition, oxytocin modulated fixation rates in the eye and nasion regions. DISCUSSION This is the first study to explore the effects of oxytocin on eye gaze in schizophrenia. Oxytocin had enhanced exploratory viewing behaviour in response to both facial and inanimate control stimuli. We suggest that the acute administration of intranasal oxytocin may have the potential to enhance visual attention in schizophrenia.",2020,"We found a main effect of treatment, whereby oxytocin increased the total number of fixations, dispersion, and saccade amplitudes, while decreasing the duration of fixations compared to placebo.","['patients with schizophrenia', 'Nineteen male participants with schizophrenia received', 'schizophrenia']","['oxytocin', 'intranasal oxytocin', 'intranasal oxytocin 40UI or placebo', 'Oxytocin', 'placebo']","['fixation rates', 'total number of fixations, dispersion, and saccade amplitudes', 'total number of fixations, mean duration of fixations, dispersion, and saccade amplitudes', 'visual attention']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332624', 'cui_str': 'Dispersion'}, {'cui': 'C0036019', 'cui_str': 'Saccadic eye movement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0589102', 'cui_str': 'Visual attention'}]",19.0,0.185774,"We found a main effect of treatment, whereby oxytocin increased the total number of fixations, dispersion, and saccade amplitudes, while decreasing the duration of fixations compared to placebo.","[{'ForeName': 'Lilla A', 'Initials': 'LA', 'LastName': 'Porffy', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. Electronic address: lilla.a.porffy@kcl.ac.uk.""}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Bell', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Coutrot', 'Affiliation': 'Laboratoire des Sciences du Numérique de Nantes, CNRS, Université de Nantes, Nantes, France.'}, {'ForeName': 'Rebekah', 'Initials': 'R', 'LastName': 'Wigton', 'Affiliation': 'Department of Neurology, Harvard Medical School, Boston, MA, USA; Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': ""D'Oliveira"", 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Mareschal', 'Affiliation': 'Biological and Experimental Psychology, School of Biological and Chemical Sciences, Queen Mary University, London, UK.'}, {'ForeName': 'Sukhwinder S', 'Initials': 'SS', 'LastName': 'Shergill', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}]",Schizophrenia research,['10.1016/j.schres.2019.11.044'] 1029,32424022,Whole-Grain Processing and Glycemic Control in Type 2 Diabetes: A Randomized Crossover Trial.,"OBJECTIVE To consider the effects of whole-grain processing, specifically milling, on glycemic control in free-living adults with type 2 diabetes. RESEARCH DESIGN AND METHODS Participants of this crossover trial were randomized to two interventions of 2 weeks, separated by washout. They were advised to replace the grain foods they normally consumed with intervention foods. Intervention foods were nutrient-matched whole-grain products of wheat, oats, and brown rice that differed in their degree of processing. No other lifestyle advice was given. Continuous glucose monitoring systems were worn. Other cardiometabolic risk factors and alkylresorcinols (a biomarker of whole-grain intake) were measured pre- and postintervention. RESULTS Thirty-one adults with type 2 diabetes (63 ± 13 years old, BMI 32.4 ± 7 kg/m 2 , HbA 1c 7.5 ± 3.4% [59 ± 14 mmol/mol]) commenced the trial; 28 (90%) completed both interventions. The increase in alkylresorcinols did not differ between interventions, and there was no difference in reported energy intake. Postprandial responses were 9% (95% CI 3-15) lower following breakfast and 6% (1-10) lower following all meals of less-processed whole grains when compared with finely milled grains. Day-long glycemic variability also was reduced when measured by 24-h SD (-0.16 mmol/L [95% CI -0.25 to -0.06]) and mean amplitude of glycemic excursion (-0.36 [95% CI -0.65 to -0.08]). Mean change in body weight differed by 0.81 kg (95% CI 0.62-1.05) between interventions, increasing during the finely milled intervention and decreasing during the less-processed whole-grain intervention. This was not a mediating factor for the glycemic variables considered. CONCLUSIONS Consuming less-processed whole-grain foods over 2 weeks improved measures of glycemia in free-living adults with type 2 diabetes compared with an equivalent amount of whole-grain foods that were finely milled. Dietary advice should promote the consumption of minimally processed whole grains.",2020,"The increase in alkylresorcinols did not differ between interventions, and there was no difference in reported energy intake.","['Type 2 Diabetes', 'free-living adults with type 2 diabetes', 'Thirty-one adults with type 2 diabetes (63 ± 13 years old, BMI 32.4 ± 7 kg/m 2 , HbA 1c 7.5 ± 3.4% [59 ± 14 mmol/mol]) commenced the trial; 28 (90%) completed both interventions']","['whole-grain processing, specifically milling']","['glycemia', 'reported energy intake', 'mean amplitude of glycemic excursion', 'Mean change in body weight', 'Postprandial responses', 'alkylresorcinols']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517709', 'cui_str': '32.4'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C4517692', 'cui_str': '3.4'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C4042940', 'cui_str': 'Whole Grains'}, {'cui': 'C0599997', 'cui_str': 'Mill'}]","[{'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}]",31.0,0.0556802,"The increase in alkylresorcinols did not differ between interventions, and there was no difference in reported energy intake.","[{'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Åberg', 'Affiliation': 'Department of Medicine, University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Mann', 'Affiliation': 'Department of Medicine, University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'Silke', 'Initials': 'S', 'LastName': 'Neumann', 'Affiliation': 'Department of Pathology, University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'Alastair B', 'Initials': 'AB', 'LastName': 'Ross', 'Affiliation': 'AgResearch, Lincoln University, Lincoln, New Zealand.'}, {'ForeName': 'Andrew N', 'Initials': 'AN', 'LastName': 'Reynolds', 'Affiliation': 'Department of Medicine, University of Otago, Dunedin, New Zealand andrew.reynolds@otago.ac.nz.'}]",Diabetes care,['10.2337/dc20-0263'] 1030,31372864,The role of neuropsychological mechanisms in implementation intentions to reduce alcohol consumption among heavy drinkers: a randomized trial.,"Implementation intention formation, which involves identifying triggers and linking them with coping strategies, has proven effective at reducing alcohol consumption in general populations. For the first time, the present study tested the ability of implementation intentions to reduce alcohol consumption among heavy drinkers and to explore potential neuropsychological mechanisms. At baseline, participants were randomized to form implementation intentions or to an active control group. There was a 5.7 unit (1 unit = 10 ml or 8 g ethanol) per week reduction ([95%CI 0.15, 11.19], p = 0.048) in alcohol consumption at 1 month follow-up among participants who formed implementation intentions, which was significantly more than controls F(1, 91) = 3.95, p = 0.048, a medium effect size (d = 0.47, Cohen, 1992). No significant differences in performance on the neuropsychological tasks were found between groups. The present study demonstrates for the first time that implementation intentions reduce alcohol consumption among heavy drinkers.",2020,No significant differences in performance on the neuropsychological tasks were found between groups.,['heavy drinkers'],['10\xa0ml or 8\xa0g ethanol'],"['performance on the neuropsychological tasks', 'alcohol consumption']","[{'cui': 'C0337678', 'cui_str': 'Heavy drinker (finding)'}]","[{'cui': 'C1318217', 'cui_str': '8G'}, {'cui': 'C0202304', 'cui_str': 'Alcohol measurement (procedure)'}]","[{'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}]",,0.0398301,No significant differences in performance on the neuropsychological tasks were found between groups.,"[{'ForeName': 'Elly', 'Initials': 'E', 'LastName': 'McGrath', 'Affiliation': 'Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. elly.mcgrath@manchester.ac.uk.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Elliott', 'Affiliation': 'Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Millar', 'Affiliation': 'Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Armitage', 'Affiliation': 'Division of Psychology and Mental Health, Manchester Centre for Health Psychology, Manchester Academic Health Science Centre, United Kingdom and NIHR Manchester Biomedical Research Centre and NIHR Greater Manchester Patient Safety Translational Research Centre, University of Manchester, Manchester, UK.'}]",Journal of behavioral medicine,['10.1007/s10865-019-00078-5'] 1031,20857772,"Exploring effects of therapeutic massage and patient teaching in the practice of diaphragmatic breathing on blood pressure, stress, and anxiety in hypertensive African-American women: an intervention study.","The problem of hypertension among African-Americans is one of the major areas of health disparities. The American Heart Association (2009) noted that the prevalence of hypertension among African-Americans is perhaps among the highest in the world and this is particularly so among African-American women (44.0%). The purpose of this study was to determine how therapeutic chair massage and patient teaching in diaphragmatic breathing affected African-American women's blood pressure, stress, and anxiety levels over one week or six weeks time periods. A Modified Stress, Coping, and Adaptation Model (Roy, 1976; Lazarus, 1966), Descriptives, T-tests, Pearson Product Moment Correlations, Multivariate analysis of variance (MANOVA), and Multivariate analysis of variance with covariate (MANCOVA) were used. Descriptive statistics indicated a significance for decreased systolic blood pressure levels for the one week post massage intervention measurement with p = .01, diastolic blood pressure level significance for the same group p = .02, significance for this group's State Trait Anxiety Inventory (STAI) Y2 Scale score p = .01, and Roy's Largest Root p = .03.",2010,"Descriptive statistics indicated a significance for decreased systolic blood pressure levels for the one week post massage intervention measurement with p = .01, diastolic blood pressure level significance for the same group p = .02, significance for this group's State Trait Anxiety Inventory (STAI) Y2 Scale score p = .01, and Roy's Largest Root p = .03.","['African-Americans', ""affected African-American women's"", 'hypertensive African-American women', 'African-American women (44.0']","['diaphragmatic breathing', 'therapeutic chair massage and patient teaching in diaphragmatic breathing', 'therapeutic massage and patient teaching']","['diastolic blood pressure level significance', 'blood pressure, stress, and anxiety levels', 'State Trait Anxiety Inventory (STAI) Y2 Scale score', 'systolic blood pressure levels', 'blood pressure, stress, and anxiety']","[{'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}]","[{'cui': 'C0231898', 'cui_str': 'Diaphragmatic breathing (finding)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0179847', 'cui_str': 'Chair (physical object)'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}]","[{'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety (observable entity)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}]",,0.0172482,"Descriptive statistics indicated a significance for decreased systolic blood pressure levels for the one week post massage intervention measurement with p = .01, diastolic blood pressure level significance for the same group p = .02, significance for this group's State Trait Anxiety Inventory (STAI) Y2 Scale score p = .01, and Roy's Largest Root p = .03.","[{'ForeName': 'Lenetra L', 'Initials': 'LL', 'LastName': 'Jefferson', 'Affiliation': 'Dillard University, 2601 Gentilly Blvd., New Orleans, LA 70122, USA. ljefferson@dillard.edu'}]",Journal of National Black Nurses' Association : JNBNA,[] 1032,20216107,"Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.","INTRODUCTION Three common haplotypes in the gene encoding catechol-O-methyltransferase (COMT) have been associated with pain modulation and the risk of developing chronic musculoskeletal pain, namely temporomandibular disorder (TMD). Haplotypes coding for higher enzymatic activity were correlated with lower pain perception. Rodent studies showed that COMT inhibition increases pain sensitivity through beta2/3-adrenergic receptors. We hypothesized that the nonselective beta-adrenergic antagonist propranolol will reduce clinical and experimental pain in TMD patients in a manner dependent on the individuals' COMT diplotype. METHODS Forty Caucasian female participants meeting the Research Diagnostic Criteria for TMD were genotyped for COMT polymorphisms and completed a randomized, double-blind, placebo-controlled, two-period crossover pilot study. Each period consisted of a baseline assessment week followed by an intervention week (propranolol or placebo). Changes in clinical pain ratings, psychological status, and responses to heat and pressure stimuli between baseline and intervention weeks were compared across periods. RESULTS The number of patients reporting a reduction in pain intensity rating was greater during propranolol treatment (P=0.014) compared with placebo. Propranolol significantly reduced a composite pain index (P=0.02) but did not decrease other clinical and experimental pain ratings. When stratified by the COMT high activity haplotype, a beneficial effect of propranolol on pain perception was noted in patients not carrying this haplotype, a diminished benefit was observed in the heterozygotes, and no benefit was noted in the homozygotes. CONCLUSION COMT haplotypes may serve as genetic predictors of propranolol treatment outcome, identifying a subgroup of TMD patients who will benefit from propranolol therapy.",2010,Propranolol significantly reduced a composite pain index (P=0.02) but did not decrease other clinical and experimental pain ratings.,"['Forty Caucasian female participants meeting the Research Diagnostic Criteria for TMD were genotyped for COMT polymorphisms', 'chronic musculoskeletal pain']","['intervention week (propranolol or placebo', 'nonselective beta-adrenergic antagonist propranolol', 'propranolol', 'placebo', 'catechol-O-methyltransferase polymorphism', 'COMT inhibition', 'propranolol therapy', 'Propranolol']","['composite pain index', 'pain perception', 'pain intensity rating', 'clinical pain ratings, psychological status, and responses to heat and pressure stimuli', 'clinical and experimental pain ratings', 'pain sensitivity']","[{'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0035168'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1285573', 'cui_str': 'Genotype determination'}, {'cui': 'C0032529', 'cui_str': 'Polymorphism (Genetics)'}, {'cui': 'C0746683', 'cui_str': 'Chronic musculoskeletal pain'}]","[{'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0033497', 'cui_str': 'Propranolol'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0001645', 'cui_str': 'beta-Adrenoceptor Antagonists'}, {'cui': 'C0007407', 'cui_str': 'Catechol Methyltransferase'}, {'cui': 'C0032529', 'cui_str': 'Polymorphism (Genetics)'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C3714605', 'cui_str': 'Pain Perception'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0234402', 'cui_str': 'Stimulus, function (observable entity)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}]",40.0,0.680128,Propranolol significantly reduced a composite pain index (P=0.02) but did not decrease other clinical and experimental pain ratings.,"[{'ForeName': 'Inna E', 'Initials': 'IE', 'LastName': 'Tchivileva', 'Affiliation': 'Center for Neurosensory Disorders, School of Dentistry, University of North Carolina, Chapel Hill, NC 27599-7450, USA. tchivilei@dentistry.unc.edu'}, {'ForeName': 'Pei Feng', 'Initials': 'PF', 'LastName': 'Lim', 'Affiliation': ''}, {'ForeName': 'Shad B', 'Initials': 'SB', 'LastName': 'Smith', 'Affiliation': ''}, {'ForeName': 'Gary D', 'Initials': 'GD', 'LastName': 'Slade', 'Affiliation': ''}, {'ForeName': 'Luda', 'Initials': 'L', 'LastName': 'Diatchenko', 'Affiliation': ''}, {'ForeName': 'Samuel A', 'Initials': 'SA', 'LastName': 'McLean', 'Affiliation': ''}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Maixner', 'Affiliation': ''}]",Pharmacogenetics and genomics,['10.1097/FPC.0b013e328337f9ab'] 1033,20583512,"Design, development, and validation of a take-home simulator for fundamental laparoscopic skills: using Nintendo Wii for surgical training.","Assuring quality surgical trainees within the confines of reduced work hours mandates reassessment of educational paradigms. Surgical simulators have been shown to be effective in teaching surgical residents, but their use is limited by cost and time constraints. The Nintendo Wii gaming console is inexpensive and allows natural hand movements similar to those performed in laparoscopy to guide game play. We hypothesize that surgical skills can be improved through take-home simulators adapted from affordable off-the-shelf gaming consoles. A total of 21 surgical residents participated in a prospective, controlled study. An experimental group of 14 surgical residents was assigned to play Marble Mania on the Nintendo Wii using a unique physical controller that interfaces with the WiiMote controller followed by a simulated electrocautery task. Seven residents assigned to the control group performed the electrocautery task without playing the game first. When compared with the control group, the experimental group performed the task with fewer errors and superior movement proficiency (P < 0.05). The experimental group demonstrated increased ambidexterity with improvement in proficiency of the nondominant hand over time. In conclusion, the Nintendo Wii gaming device along with Marble Mania serves as an effective take-home surgical simulator.",2010,"When compared with the control group, the experimental group performed the task with fewer errors and superior movement proficiency (P < 0.05).","['14 surgical residents', '21 surgical residents']","['Nintendo Wii for surgical training', 'electrocautery task without playing the game first', 'play Marble Mania on the Nintendo Wii using a unique physical controller that interfaces with the WiiMote controller followed by a simulated electrocautery task']",[],"[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}]","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0013804', 'cui_str': 'Surgical Diathermy'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0205689', 'cui_str': 'Marble'}, {'cui': 'C0338831', 'cui_str': 'Manic State'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}]",[],21.0,0.015994,"When compared with the control group, the experimental group performed the task with fewer errors and superior movement proficiency (P < 0.05).","[{'ForeName': 'Ravia', 'Initials': 'R', 'LastName': 'Bokhari', 'Affiliation': 'Phoenix Integrated Surgical Residency, Phoenix, Arizona 85006, USA. raviabokhari@hotmail.com'}, {'ForeName': 'Jyoti', 'Initials': 'J', 'LastName': 'Bollman-McGregor', 'Affiliation': ''}, {'ForeName': 'Kanav', 'Initials': 'K', 'LastName': 'Kahoi', 'Affiliation': ''}, {'ForeName': 'Marshall', 'Initials': 'M', 'LastName': 'Smith', 'Affiliation': ''}, {'ForeName': 'Ara', 'Initials': 'A', 'LastName': 'Feinstein', 'Affiliation': ''}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Ferrara', 'Affiliation': ''}]",The American surgeon,[] 1034,31339515,"Topical Itraconazole for the Treatment of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome or High-Frequency Basal Cell Carcinomas: A Phase 2, Open-Label, Placebo-Controlled Trial.",,2019,,['Patients'],['Topical Itraconazole'],['Basal Cell Carcinoma'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0064113', 'cui_str': 'Itraconazole'}]","[{'cui': 'C0007117', 'cui_str': 'Epithelioma, Basal Cell'}]",,0.0271058,,"[{'ForeName': 'Grace K', 'Initials': 'GK', 'LastName': 'Sohn', 'Affiliation': 'Department of Dermatology, Stanford University, Stanford, California.'}, {'ForeName': 'Gina P', 'Initials': 'GP', 'LastName': 'Kwon', 'Affiliation': 'Department of Dermatology, Stanford University, Stanford, California.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Bailey-Healy', 'Affiliation': 'Department of Dermatology, Stanford University, Stanford, California.'}, {'ForeName': 'Amar', 'Initials': 'A', 'LastName': 'Mirza', 'Affiliation': 'Department of Dermatology, Stanford University, Stanford, California.'}, {'ForeName': 'Kavita', 'Initials': 'K', 'LastName': 'Sarin', 'Affiliation': 'Department of Dermatology, Stanford University, Stanford, California.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Oro', 'Affiliation': 'Department of Dermatology, Stanford University, Stanford, California.'}, {'ForeName': 'Jean Y', 'Initials': 'JY', 'LastName': 'Tang', 'Affiliation': 'Department of Dermatology, Stanford University, Stanford, California.'}]",JAMA dermatology,['10.1001/jamadermatol.2019.1541'] 1035,31350894,The Experimental Tobacco Marketplace: Demand and Substitutability as a Function of Cigarette Taxes and e-Liquid Subsidies.,"INTRODUCTION The experimental tobacco marketplace (ETM) approximates real-world situations by estimating the effects of several, concurrently available products and policies on budgeted purchasing. Although the effects of increasing cigarette price on potentially less harmful substitutability are well documented, the effects of other, nuanced pricing policies remain speculative. This study used the ETM as a tool to assess the effects of two pricing policies, conventional cigarette taxation and e-liquid subsidization, on demand and substitutability. METHODS During sampling periods, participants were provided 2-day samples of 24 mg/mL e-liquid, after which ETM purchase sessions occurred. Across two ETM sessions, conventional cigarettes were taxed or e-liquid was subsidized in combination with increasing cigarette price. The other four available products were always price constant and not taxed or subsidized. RESULTS E-liquid functioned as a substitute for conventional cigarettes across all conditions. Increasing cigarette taxation and e-liquid subsidization increased the number of participants for which e-liquid functioned as a substitute. Cigarette taxation decreased cigarette demand, by decreasing demand intensity, and marginally increased the initial intensity of e-liquid substitution, but did not affect the functions' slopes (substitutability). E-liquid subsidization resulted in large increases in the initial intensity of e-liquid substitution, but did not affect e-liquid substitutability nor cigarette demand. IMPLICATIONS 24 mg/mL e-cigarette e-liquid was the only product to significantly substitute for cigarettes in at least one condition throughout the experiment; it functioned as a significant substitute throughout all four tax and all four subsidy conditions. Increasing cigarette taxes decreased cigarette demand through decreases in demand intensity but did not affect e-cigarette substitution. Increasing e-liquid subsidies increased e-liquid initial intensity of substitution but did not affect cigarette demand. CONCLUSIONS This study extended research on the behavioral economics of conventional cigarette demand and e-liquid substitutability in a complex marketplace. The results suggest that the most efficacious method to decrease conventional cigarette purchasing and increase e-liquid purchasing may involve greatly increasing cigarette taxes while also increasing the value of e-liquid through potentially less harmful product subsidization or differential taxation.",2020,"Cigarette taxation decreased cigarette demand, by decreasing demand intensity, and marginally increased the initial intensity of e-liquid substitution, but did not affect the functions' slopes (substitutability).",[],[],"['Increasing cigarette taxation and e-liquid subsidization', 'initial intensity of e-liquid substitution']",[],[],"[{'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0039370', 'cui_str': 'Taxation'}, {'cui': 'C4543628', 'cui_str': 'Electronic cigarette liquid (physical object)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}]",,0.0121748,"Cigarette taxation decreased cigarette demand, by decreasing demand intensity, and marginally increased the initial intensity of e-liquid substitution, but did not affect the functions' slopes (substitutability).","[{'ForeName': 'Derek A', 'Initials': 'DA', 'LastName': 'Pope', 'Affiliation': 'Addiction Recovery Research Center, Fralin Biomedical Research Institute at VTC, Roanoke, VA.'}, {'ForeName': 'Lindsey', 'Initials': 'L', 'LastName': 'Poe', 'Affiliation': 'Addiction Recovery Research Center, Fralin Biomedical Research Institute at VTC, Roanoke, VA.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Stein', 'Affiliation': 'Addiction Recovery Research Center, Fralin Biomedical Research Institute at VTC, Roanoke, VA.'}, {'ForeName': 'Brent A', 'Initials': 'BA', 'LastName': 'Kaplan', 'Affiliation': 'Addiction Recovery Research Center, Fralin Biomedical Research Institute at VTC, Roanoke, VA.'}, {'ForeName': 'William B', 'Initials': 'WB', 'LastName': 'DeHart', 'Affiliation': 'Addiction Recovery Research Center, Fralin Biomedical Research Institute at VTC, Roanoke, VA.'}, {'ForeName': 'Alexandra M', 'Initials': 'AM', 'LastName': 'Mellis', 'Affiliation': 'Addiction Recovery Research Center, Fralin Biomedical Research Institute at VTC, Roanoke, VA.'}, {'ForeName': 'Bryan W', 'Initials': 'BW', 'LastName': 'Heckman', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Leonard H', 'Initials': 'LH', 'LastName': 'Epstein', 'Affiliation': 'Department of Pediatrics, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY.'}, {'ForeName': 'Frank J', 'Initials': 'FJ', 'LastName': 'Chaloupka', 'Affiliation': 'Department of Economics, University of Illinois at Chicago, Chicago, IL.'}, {'ForeName': 'Warren K', 'Initials': 'WK', 'LastName': 'Bickel', 'Affiliation': 'Addiction Recovery Research Center, Fralin Biomedical Research Institute at VTC, Roanoke, VA.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntz116'] 1036,31364501,Pump controlled retrograde trial off using the Cardiohelp console: safety considerations.,,2019,,[],[],[],[],[],[],,0.0665031,,"[{'ForeName': 'Adrian C', 'Initials': 'AC', 'LastName': 'Mattke', 'Affiliation': ""Paediatric Intensive Care Unit, Queensland Children's Hospital, South Brisbane, QLD, Australia.""}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Haisz', 'Affiliation': ""Paediatric Intensive Care Unit, Queensland Children's Hospital, South Brisbane, QLD, Australia.""}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Black', 'Affiliation': ""Paediatric Critical Care Research Group, Queensland Children's Hospital, South Brisbane, QLD, Australia.""}, {'ForeName': 'Prem', 'Initials': 'P', 'LastName': 'Venugopal', 'Affiliation': 'School of Medicine, The University of Queensland, Brisbane, QLD, Australia.'}]",Perfusion,['10.1177/0267659119865827'] 1037,31869494,The effect of ventilation tube insertion on quality of life in children with persistent otitis media with effusion.,"OBJECTIVES To determine the effect of ventilation tube (VT) surgery on quality of life (QoL) in children with persistent otitis media with effusion (OME). DESIGN Secondary analysis of trial data (oral steroids versus placebo for persistent OME), comparing QoL by history of VT surgery performed between 5 weeks and 12 months post-randomisation. Multilevel regression models were used to identify the association between VT surgery and QoL scores at 12 months, controlling for pre-exposure risk factors associated with surgery, including pre-surgery hearing level. SETTING Ear, nose and throat (ENT), paediatric audiology and audiovestibular medicine (AVM) departments in Wales and England. PARTICIPANTS A total of 327 children aged 2-8 years with OME symptoms for at least three months and audiometry-proven bilateral hearing loss with VT surgery status. MAIN OUTCOME MEASURES Otitis Media questionnaire (OM8-30) and Paediatric Quality of Life Inventory (PedsQL) total and subscale scores, and the Health Utilities Index Mark 3 (HUI3) at 12 months post-randomisation. RESULTS Participants who had VT surgery had no significant difference in OM8-30, PedsQL or HUI total scores. OM8-30 hearing difficulty (HD) subscale scores at 12 months were better in those who had VT surgery (adjusted mean difference (aMD) = -0.46 (95% confidence interval: -0.69 to -0.23), P < .001), and this varied by when the surgery occurred (aMD for surgery between 5 weeks and 6 months = -0.4 [-0.67 to -0.13], P = .004 and between 6 and 12 months = -0.54, [-0.87 to -0.22], P = .001). CONCLUSION Ventilation tube surgery was associated with an improvement in HD-related functional health status but no change in overall QoL.",2020,"RESULTS Participants who had VT surgery had no significant difference in OM8-30, PedsQL or HUI total scores.","['Ear, nose and throat (ENT), paediatric audiology and audiovestibular medicine (AVM) departments in Wales and England', '327 children aged 2 to 8 years old with OME symptoms for at least three months and audiometry proven bilateral hearing loss with VT surgery status', 'children with persistent otitis media with effusion', 'children with persistent otitis media with effusion (OME']","['ventilation tube insertion', 'steroids versus placebo', 'ventilation tube (VT) surgery']","['VT surgery and QoL scores', 'OM8-30, PedsQL or HUI total scores', 'quality of life (QoL', 'HD related functional health status', 'quality of life', 'overall QoL', 'OM8-30 hearing difficulty (HD) subscale scores', 'Otitis Media questionnaire (OM8-30) and Paediatric Quality of Life Inventory (PedsQL) total and subscale scores, and the Health Utilities Index Mark 3 (HUI3']","[{'cui': 'C0150934', 'cui_str': 'Ear, nose and throat structure'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0004285', 'cui_str': 'Audiology'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4082119', 'cui_str': 'Three months (qualifier value)'}, {'cui': 'C0004286', 'cui_str': 'Audiometry'}, {'cui': 'C0456369', 'cui_str': 'Proven (qualifier value)'}, {'cui': 'C0018775', 'cui_str': 'Hearing Loss, Bilateral'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0029883', 'cui_str': 'Otitis Media, Secretory'}]","[{'cui': 'C0850121', 'cui_str': 'Ventilation tube'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0018759', 'cui_str': 'Level of Health'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0459443', 'cui_str': 'Subscale score (qualifier value)'}, {'cui': 'C0029882', 'cui_str': 'Middle Ear Inflammation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0522501', 'cui_str': 'Massive (qualifier value)'}]",327.0,0.0881923,"RESULTS Participants who had VT surgery had no significant difference in OM8-30, PedsQL or HUI total scores.","[{'ForeName': 'Leigh N', 'Initials': 'LN', 'LastName': 'Sanyaolu', 'Affiliation': 'The Division of Population Medicine, Heath Park, Cardiff, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Cannings-John', 'Affiliation': 'The Centre for Trials Research, Heath Park, Cardiff, UK.'}, {'ForeName': 'Christopher C', 'Initials': 'CC', 'LastName': 'Butler', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, Oxford, UK.'}, {'ForeName': 'Nick A', 'Initials': 'NA', 'LastName': 'Francis', 'Affiliation': 'The Division of Population Medicine, Heath Park, Cardiff, UK.'}]",Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery,['10.1111/coa.13502'] 1038,31529622,Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.,"OBJECTIVE To expand on available information on the efficacy of oral lasmiditan for the acute treatment of migraine with particular focus on the timing of the effect and on its impact on migraine-associated symptoms. BACKGROUND Lasmiditan is a novel selective 5-hydroxytryptamine 1F receptor agonist that lacks vasoconstrictive activity. In 2 phase 3 studies, SAMURAI and SPARTAN, lasmiditan met primary and key secondary efficacy endpoints at 2 hours following initial dose. METHODS Integrated analyses were completed from 2 phase 3 clinical trials, SPARTAN and SAMURAI. Baseline data and data collected every 30 minutes up to 2 hours after taking lasmiditan (50, 100, or 200 mg) or placebo were analyzed to determine the onset of efficacy. A total of 5236 patients were randomized to be treated with placebo (N = 1493), lasmiditan 50 mg (N = 750), lasmiditan 100 mg (N = 1498), or lasmiditan 200 mg (N = 1495). Data were analyzed to determine the onset of improvement for the following efficacy measures: pain freedom, most bothersome symptom freedom, pain relief, freedom from associated individual symptoms (photophobia, phonophobia, or nausea), total migraine freedom (defined as pain freedom and freedom from associated symptoms), and freedom from migraine-related functional disability. Time to meaningful headache relief and time to first become pain free were also analyzed. RESULTS Significantly higher rates of pain freedom (100 mg, 10.0%, P = .012; 200 mg, 15.5%, P < .001; Placebo, 7.0%) and total migraine freedom (100 mg, 8.9%, P = .017; 200 mg, 12.4%, P < .001; Placebo, 6.1%) were achieved starting at 60 minutes in 100- and 200-mg lasmiditan-treated groups compared with placebo group. Rates of freedom from most bothersome symptom (100 mg, 11.1%, P = .015; 200 mg, 13.0%, P < .001; Placebo, 7.9%), and pain relief (100 mg, 17.5%, P = .007; 200 mg, 19.1%, P < .001; Placebo, 13.4%) were significantly higher starting as early as 30 minutes in lasmiditan 100- and 200-mg lasmiditan-treated groups. A significantly higher percentage of patients in the 200-mg lasmiditan-treated group achieved freedom from photophobia (13.7%, P = .005; Placebo, 9.2%) and phonophobia (17.4%, P = .042; Placebo, 13.4%) starting at 30 minutes. A significantly greater proportion of patients in the 200-mg lasmiditan-treated group achieved freedom from migraine-related functional disability starting at 60 minutes (16.4%, P < .001; Placebo, 11.1%). All efficacy measures, except for freedom from nausea, were statistically significant after lasmiditan treatment (50, 100, or 200 mg) compared with placebo at 90 and 120 minutes. Finally, patients taking lasmiditan had a higher likelihood of achieving meaningful headache relief and becoming headache pain free within 24 hours compared with those taking placebo (P < .001). CONCLUSIONS Patients treated with lasmiditan for a migraine attack reported an earlier onset of efficacy compared with those treated with placebo. Some of the efficacy measures such as pain relief demonstrated improvement as early as the first assessment at 30 minutes after 100- or 200-mg lasmiditan treatment.",2019,"Significantly higher rates of pain freedom (100 mg, 10.0%, P = .012; 200 mg, 15.5%, P ","['Migraine', 'A total of 5236 patients']","['placebo', 'Placebo', 'lasmiditan 50\xa0mg (N\xa0=\xa0750), lasmiditan 100\xa0mg (N\xa0=\xa01498), or lasmiditan 200\xa0mg', 'Oral Treatment With Lasmiditan']","['Rates of freedom from most bothersome symptom', 'freedom from photophobia', 'phonophobia', 'pain relief', 'total migraine freedom', 'freedom from migraine-related functional disability starting', 'nausea', 'meaningful headache relief and becoming headache pain free', 'efficacy measures: pain freedom, most bothersome symptom freedom, pain relief, freedom from associated individual symptoms (photophobia, phonophobia, or nausea), total migraine freedom (defined as pain freedom and freedom from associated symptoms), and freedom from migraine-related functional disability', 'Time to meaningful headache relief and time to first become pain free', 'pain freedom']","[{'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4517868', 'cui_str': '750 (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0085636', 'cui_str': 'Light Sensitivity'}, {'cui': 'C0751466', 'cui_str': 'Phonophobia'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C1301676', 'cui_str': 'Relieves (qualifier value)'}, {'cui': 'C0908489', 'cui_str': 'Pain-Free'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0521989', 'cui_str': 'Associated symptom (finding)'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",5236.0,0.279658,"Significantly higher rates of pain freedom (100 mg, 10.0%, P = .012; 200 mg, 15.5%, P ","[{'ForeName': 'Messoud', 'Initials': 'M', 'LastName': 'Ashina', 'Affiliation': 'Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Raghavendra', 'Initials': 'R', 'LastName': 'Vasudeva', 'Affiliation': 'Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Jin', 'Affiliation': 'Covance Chiltern, Princeton, NJ, USA.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Lombard', 'Affiliation': 'Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Gray', 'Affiliation': 'Eli Lilly Canada Inc, Toronto, ON, Canada.'}, {'ForeName': 'Erin G', 'Initials': 'EG', 'LastName': 'Doty', 'Affiliation': 'Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Yunes-Medina', 'Affiliation': 'Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Kraig S', 'Initials': 'KS', 'LastName': 'Kinchen', 'Affiliation': 'Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Tassorelli', 'Affiliation': 'Headache Science Centre, IRCCS C. Mondino Foundation, Pavia, Italy.'}]",Headache,['10.1111/head.13636'] 1039,31804186,A Web-Based Self-Titration Program to Control Blood Pressure in Patients With Primary Hypertension: Randomized Controlled Trial.,"BACKGROUND Hypertension is a major cause of mortality in cardiac, vascular, and renal disease. Effective control of elevated blood pressure has been shown to reduce target organ damage. A Web-based self-titration program may empower patients to control their own disease, share decisions about antihypertensive dose titration, and improve self-management, ultimately improving health-related quality of life. OBJECTIVE Our primary aim was to evaluate the effects of a Web-based self-titration program for improving blood pressure control in patients with primary hypertension. Our secondary aim was to evaluate the effects of that program on improving health-related quality of life. METHODS This was a parallel-group, double-blind, randomized controlled trial with assessments at baseline, 3 months, and 6 months. We included patients with primary hypertension (blood pressure>130/80 mm Hg) from a cardiology outpatient department in northern Taiwan and divided them randomly into intervention and control groups. The intervention group received the Web-based self-titration program, while the control group received usual care. The random allocation was concealed from participants and outcome evaluators. Health-related quality of life was measured by the EuroQol five-dimension self-report questionnaire. We used generalized estimating equations to evaluate the effects of the intervention. RESULTS We included 222 patients and divided them equally into intervention (n=111) and control (n=111) groups. Patients receiving the Web-based self-titration program showed significantly greater improvement in the systolic and diastolic blood pressure control than those who did not receive this program, at 3 months (-21.4 mm Hg and -5.4 mm Hg, respectively; P<.001) and 6 months (-27.8 mm Hg and -9.7 mm Hg, respectively; P<.001). Compared with the control group, the intervention group showed a significant decrease in the overall defined daily dose at both 3 (-0.202, P=.003) and 6 (-0.236, P=.001) months. Finally, health-related quality of life improved significantly in the intervention group compared with the control group at both 3 and 6 months (both, P<.001). CONCLUSIONS A Web-based self-titration program can provide immediate feedback to patients about how to control their blood pressure and manage their disease at home. This program not only decreases mean blood pressure but also increases health-related quality of life in patients with primary hypertension. TRIAL REGISTRATION ClinicalTrials.gov NCT03470974; https://clinicaltrials.gov/ct2/show/NCT03470974.",2019,"Patients receiving the Web-based self-titration program showed significantly greater improvement in the systolic and diastolic blood pressure control than those who did not receive this program, at 3 months (-21.4 mm Hg and -5.4 mm Hg, respectively; P<.001) and 6 months (-27.8 mm Hg and -9.7 mm Hg, respectively; P<.001).","['Patients With Primary Hypertension', 'patients with primary hypertension', 'patients with primary hypertension (blood pressure>130/80 mm Hg) from a cardiology outpatient department in northern Taiwan', '222 patients and divided them equally into intervention (n=111) and control (n=111) groups']","['Web-based self-titration program, while the control group received usual care', 'Web-based self-titration program']","['overall defined daily dose', 'mean blood pressure', 'blood pressure control', 'systolic and diastolic blood pressure control', 'health-related quality of life', 'Health-related quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0085580', 'cui_str': 'Essential Hypertension'}, {'cui': 'C0005768'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0039260', 'cui_str': 'Formosa'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0332286', 'cui_str': 'Into (attribute)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}]",222.0,0.0743844,"Patients receiving the Web-based self-titration program showed significantly greater improvement in the systolic and diastolic blood pressure control than those who did not receive this program, at 3 months (-21.4 mm Hg and -5.4 mm Hg, respectively; P<.001) and 6 months (-27.8 mm Hg and -9.7 mm Hg, respectively; P<.001).","[{'ForeName': 'Chi-Wen', 'Initials': 'CW', 'LastName': 'Kao', 'Affiliation': 'Department of Nursing, Tri-Service General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Ting-Yu', 'Initials': 'TY', 'LastName': 'Chen', 'Affiliation': 'School of Nursing, Chung-Jen Junior College of Nursing, Health Sciences and Management, Chiayi, Taiwan.'}, {'ForeName': 'Shu-Meng', 'Initials': 'SM', 'LastName': 'Cheng', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Wei-Shiang', 'Initials': 'WS', 'LastName': 'Lin', 'Affiliation': 'Division of Cardiology, Tri-Service General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Yue-Cune', 'Initials': 'YC', 'LastName': 'Chang', 'Affiliation': 'Department of Mathematics, Tamkang University, Taipei, Taiwan.'}]",Journal of medical Internet research,['10.2196/15836'] 1040,31213044,Utility of ultrasonography in identification of midline and epidural placement in severely obese parturients.,"BACKGROUND Due to body habitus, lumbar epidural placement can be challenging in severely obese parturients. Several studies have been published assessing the usefulness of ultrasonography in the placement of neuraxial blocks. One patient population that is under-represented in these studies is the severely obese parturient. We sought to determine if performing an abbreviated ultrasound exam of the lumbar spine to determine midline by locating spinous process could facilitate lumbar epidural placement in severely obese parturients. METHODS One hundred fifty patients with a Body Mass Index (BMI) of ≥35 kg/m2 were randomized into two groups. The palpation (P) group had midline identified by the traditional palpation technique. The ultrasonography (U) group had midline identified by ultrasound visualization of the spinous process in the transverse plane. Midline identification and epidural placement were done by both junior and senior anesthesiology residents at our teaching institution. RESULTS Data were analyzed on all 150 patients. BMI was similar in the U and P groups (43.3 vs. 44.4 kg/m2, P=0.359). Time for epidural placement (6.2 vs. 9.0 minutes, P<0.01) and total procedure time (6.9 vs. 9.5 minutes, P<0.01) were significantly less in the U group. The number of needle passes (2.1 vs. 2.8, P=0.02) was also less in the U group. There was no significant difference in the failure rates of the U and P groups (4.0% vs. 9.3%, P=0.19). CONCLUSIONS The use of an abbreviated ultrasound exam to identify midline in severely obese parturients can reduce the time required for lumbar epidural placement.",2019,"The number of needle passes (2.1 vs 2.8, p=0.02) was also less in the U group.","['One hundred fifty patients with a body mass index (BMI) of ≥ 35 kg/m2', 'junior and senior anesthesiology residents at our teaching institution', 'Data were analyzed on all 150 patients', 'severely obese parturients']","['abbreviated ultrasound exam', 'ultrasonography']","['failure rates', 'BMI', 'number of needle passes', 'Time for epidural placement', 'total procedure time']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0002930', 'cui_str': 'Anesthesiology'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0041618', 'cui_str': 'Echotomography'}]","[{'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}]",150.0,0.0607957,"The number of needle passes (2.1 vs 2.8, p=0.02) was also less in the U group.","[{'ForeName': 'Michelle D', 'Initials': 'MD', 'LastName': 'Tubinis', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Sara A', 'Initials': 'SA', 'LastName': 'Lester', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Caylen N', 'Initials': 'CN', 'LastName': 'Schlitz', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Charity J', 'Initials': 'CJ', 'LastName': 'Morgan', 'Affiliation': 'Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Yasser', 'Initials': 'Y', 'LastName': 'Sakawi', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Mark F', 'Initials': 'MF', 'LastName': 'Powell', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, AL, USA - mfpowell@uabmc.edu.'}]",Minerva anestesiologica,['10.23736/S0375-9393.19.13617-6'] 1041,32429983,Development of an intervention to facilitate implementation and uptake of diabetic retinopathy screening.,"BACKGROUND 'Implementation interventions' refer to methods used to enhance the adoption and implementation of clinical interventions such as diabetic retinopathy screening (DRS). DRS is effective, yet uptake is often suboptimal. Despite most routine management taking place in primary care and the central role of health care professionals (HCP) in referring to DRS, few interventions have been developed for primary care. We aimed to develop a multifaceted intervention targeting both professionals and patients to improve DRS uptake as an example of a systematic development process combining theory, stakeholder involvement, and evidence. METHODS First, we identified target behaviours through an audit in primary care of screening attendance. Second, we interviewed patients (n = 47) and HCP (n = 30), to identify determinants of uptake using the Theoretical Domains Framework, mapping these to behaviour change techniques (BCTs) to develop intervention content. Thirdly, we conducted semi-structured consensus groups with stakeholders, specifically users of the intervention, i.e. patients (n = 15) and HCPs (n = 16), regarding the feasibility, acceptability, and local relevance of selected BCTs and potential delivery modes. We consulted representatives from the national DRS programme to check intervention 'fit' with existing processes. We applied the APEASE criteria (affordability, practicability, effectiveness, acceptability, side effects, and equity) to select the final intervention components, drawing on findings from the previous steps, and a rapid evidence review of operationalised BCT effectiveness. RESULTS We identified potentially modifiable target behaviours at the patient (consent, attendance) and professional (registration) level. Patient barriers to consent/attendance included confusion between screening and routine eye checks, and fear of a negative result. Enablers included a recommendation from friends/family or professionals and recognising screening importance. Professional barriers to registration included the time to register patients and a lack of readily available information on uptake in their local area/practice. Most operationalised BCTs were acceptable to patients and HCPs while the response to feasibility varied. After considering APEASE, the core intervention, incorporating a range of BCTs, involved audit/feedback, electronic prompts targeting professionals, HCP-endorsed reminders (face-to-face, by phone and letter), and an information leaflet for patients. CONCLUSIONS Using the example of an intervention to improve DRS uptake, this study illustrates an approach to integrate theory with user involvement. This process highlighted tensions between theory-informed and stakeholder suggestions, and the need to apply the Theoretical Domains Framework (TDF)/BCT structure flexibly. The final intervention draws on the trusted professional-patient relationship, leveraging existing services to enhance implementation of the DRS programme. Intervention feasibility in primary care will be evaluated in a randomised cluster pilot trial.",2020,"After considering APEASE, the core intervention, incorporating a range of BCTs, involved audit/feedback, electronic prompts targeting professionals, HCP-endorsed reminders (face-to-face, by phone and letter), and an information leaflet for patients. ",[],['HCPs'],[],[],[],[],47.0,0.0559924,"After considering APEASE, the core intervention, incorporating a range of BCTs, involved audit/feedback, electronic prompts targeting professionals, HCP-endorsed reminders (face-to-face, by phone and letter), and an information leaflet for patients. ","[{'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Riordan', 'Affiliation': 'School of Public Health, University College Cork, Western Gateway Building, Western Rd, Cork, Ireland. fiona.riordan@ucc.ie.'}, {'ForeName': 'Emmy', 'Initials': 'E', 'LastName': 'Racine', 'Affiliation': 'School of Public Health, University College Cork, Western Gateway Building, Western Rd, Cork, Ireland.'}, {'ForeName': 'Eunice T', 'Initials': 'ET', 'LastName': 'Phillip', 'Affiliation': 'School of Public Health, University College Cork, Western Gateway Building, Western Rd, Cork, Ireland.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Bradley', 'Affiliation': 'Department of General Practice, University College Cork, Cork, Ireland.'}, {'ForeName': 'Fabiana', 'Initials': 'F', 'LastName': 'Lorencatto', 'Affiliation': 'Centre for Behaviour Change, University College London, London, England.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Murphy', 'Affiliation': 'Department of General Practice, Royal College of Surgeons of Ireland, Dublin, Ireland.'}, {'ForeName': 'Aileen', 'Initials': 'A', 'LastName': 'Murphy', 'Affiliation': 'Department of Economics, Cork University Business School, University College Cork, Cork, Ireland.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Browne', 'Affiliation': 'School of Public Health, University College Cork, Western Gateway Building, Western Rd, Cork, Ireland.'}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Smith', 'Affiliation': 'Department of General Practice, Royal College of Surgeons of Ireland, Dublin, Ireland.'}, {'ForeName': 'Patricia M', 'Initials': 'PM', 'LastName': 'Kearney', 'Affiliation': 'School of Public Health, University College Cork, Western Gateway Building, Western Rd, Cork, Ireland.'}, {'ForeName': 'Sheena M', 'Initials': 'SM', 'LastName': 'McHugh', 'Affiliation': 'School of Public Health, University College Cork, Western Gateway Building, Western Rd, Cork, Ireland.'}]",Implementation science : IS,['10.1186/s13012-020-00982-4'] 1042,32431275,Efficacy of a Spatial Repellent for Control of Malaria in Indonesia: A Cluster-Randomized Controlled Trial.,"A cluster-randomized, double-blinded, placebo-controlled trial was conducted to estimate the protective efficacy (PE) of a spatial repellent (SR) against malaria infection in Sumba, Indonesia. Following radical cure in 1,341 children aged ≥ 6 months to ≤ 5 years in 24 clusters, households were given transfluthrin or placebo passive emanators (devices designed to release vaporized chemical). Monthly blood screening and biweekly human-landing mosquito catches were performed during a 10-month baseline (June 2015-March 2016) and a 24-month intervention period (April 2016-April 2018). Screening detected 164 first-time infections and an accumulative total of 459 infections in 667 subjects in placebo-control households, and 134 first-time and 253 accumulative total infections among 665 subjects in active intervention households. The 24-cluster protective effect of 27.7% and 31.3%, for time to first-event and overall (total new) infections, respectively, was not statistically significant. Purportedly, this was due in part to zero to low incidence in some clusters, undermining the ability to detect a protective effect. Subgroup analysis of 19 clusters where at least one infection occurred during baseline showed 33.3% ( P -value = 0.083) and 40.9% ( P -value = 0.0236, statistically significant at the one-sided 5% significance level) protective effect to first infection and overall infections, respectively. Among 12 moderate- to high-risk clusters, a statistically significant decrease in infection by intervention was detected (60% PE). Primary entomological analysis of impact was inconclusive. Although this study suggests SRs prevent malaria, additional evidence is required to demonstrate the product class provides an operationally feasible and effective means of reducing malaria transmission.",2020,"Screening detected 164 first-time infections and an accumulative total of 459 infections in 667 subjects in placebo-control households, and 134 first-time and 253 accumulative total infections among 665 subjects in active intervention households.","['Control of Malaria in Indonesia', '1,341 children aged ≥ 6 months to ≤ 5 years in 24 clusters, households were given', '667 subjects in placebo-control households, and 134 first-time and 253 accumulative total infections among 665 subjects in active intervention households']","['transfluthrin or placebo passive emanators (devices designed to release vaporized chemical', 'Monthly blood screening and biweekly human-landing mosquito catches', 'placebo']","['infection by intervention', 'protective efficacy (PE', '24-cluster protective effect', 'time to first-event and overall (total new) infections']","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0021247', 'cui_str': 'Indonesia'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C4517851', 'cui_str': '667'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C4517848', 'cui_str': '665'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C3178479', 'cui_str': 'transfluthrin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0086137', 'cui_str': 'Device Design'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0220806', 'cui_str': 'Chemical'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0585332', 'cui_str': 'Biweekly'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0557668', 'cui_str': 'Landing'}, {'cui': 'C0026584', 'cui_str': 'Family Culicidae'}, {'cui': 'C0231617', 'cui_str': 'Catch'}]","[{'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205314', 'cui_str': 'New'}]",1341.0,0.277179,"Screening detected 164 first-time infections and an accumulative total of 459 infections in 667 subjects in placebo-control households, and 134 first-time and 253 accumulative total infections among 665 subjects in active intervention households.","[{'ForeName': 'Din', 'Initials': 'D', 'LastName': 'Syafruddin', 'Affiliation': 'Department of Parasitology, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia.'}, {'ForeName': 'Puji B S', 'Initials': 'PBS', 'LastName': 'Asih', 'Affiliation': 'Eijkman Institute for Molecular Biology, Jakarta, Indonesia.'}, {'ForeName': 'Ismail Ekoprayitno', 'Initials': 'IE', 'LastName': 'Rozi', 'Affiliation': 'Eijkman Institute for Molecular Biology, Jakarta, Indonesia.'}, {'ForeName': 'Dendi Hadi', 'Initials': 'DH', 'LastName': 'Permana', 'Affiliation': 'Eijkman Institute for Molecular Biology, Jakarta, Indonesia.'}, {'ForeName': 'Anggi Puspa', 'Initials': 'AP', 'LastName': 'Nur Hidayati', 'Affiliation': 'Eijkman Institute for Molecular Biology, Jakarta, Indonesia.'}, {'ForeName': 'Lepa', 'Initials': 'L', 'LastName': 'Syahrani', 'Affiliation': 'Eijkman Institute for Molecular Biology, Jakarta, Indonesia.'}, {'ForeName': 'Siti', 'Initials': 'S', 'LastName': 'Zubaidah', 'Affiliation': 'Eijkman Institute for Molecular Biology, Jakarta, Indonesia.'}, {'ForeName': 'Dian', 'Initials': 'D', 'LastName': 'Sidik', 'Affiliation': 'Department of Epidemiology, Faculty of Public Health, Universitas Hasanuddin, Makassar, Indonesia.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Bangs', 'Affiliation': 'Public Health and Malaria Control, PT Freeport Indonesia, International SOS, Kuala Kencana, Papua, Indonesia.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Bøgh', 'Affiliation': 'The Sumba Foundation, Public Health and Malaria Control, Bali, Indonesia.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Liu', 'Affiliation': 'Department of Applied and Computational Mathematics and Statistics, University of Notre Dame, Notre Dame, Indiana.'}, {'ForeName': 'Evercita C', 'Initials': 'EC', 'LastName': 'Eugenio', 'Affiliation': 'Department of Applied and Computational Mathematics and Statistics, University of Notre Dame, Notre Dame, Indiana.'}, {'ForeName': 'Jared', 'Initials': 'J', 'LastName': 'Hendrickson', 'Affiliation': 'Center for Computer Research, University of Notre Dame, Notre Dame, Indiana.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Burton', 'Affiliation': 'Department of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana.'}, {'ForeName': 'J Kevin', 'Initials': 'JK', 'LastName': 'Baird', 'Affiliation': 'Nuffield Department of Medicine, Centre for Tropical Medicine, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Collins', 'Affiliation': 'Center for Computer Research, University of Notre Dame, Notre Dame, Indiana.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Grieco', 'Affiliation': 'Department of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana.'}, {'ForeName': 'Neil F', 'Initials': 'NF', 'LastName': 'Lobo', 'Affiliation': 'Department of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana.'}, {'ForeName': 'Nicole L', 'Initials': 'NL', 'LastName': 'Achee', 'Affiliation': 'Department of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.19-0554'] 1043,31475938,Which method for frozen shoulder mobilization: manual posterior capsule stretching or scapular mobilization?,"OBJECTIVES This study aimed to compare the superiority of scapular mobilization, manual capsule stretching, and the combination of these two techniques in the treatment of frozen shoulder patients to evaluate the acute effects of these techniques on shoulder movements. METHODS This study designed to a single-blinded, randomized, and pre-post assessment study. This study was included 54 patients diagnosed with stage 3 frozen shoulder. Group 1 (n=27) received scapular mobilization, and Group 2 (n=27) received manual posterior capsule stretching. After the patients were assessed, the interventions were re-applied with a crossover design to obtain results for the combined application (n=54). The range of motion, active total elevation, active internal rotation, and posterior capsule tensions of the shoulder joint were recorded before and immediately after mobilization. RESULTS Statistical analysis showed an increase in all range of motion values (p<0.05), except for shoulder internal rotation (p>0.05), without significant difference among the groups (p>0.05). The posterior capsule flexibility did not change in any group (p>0.05). CONCLUSIONS Scapular mobilization and manual posterior capsule interventions were effective in improving the acute joint range of motion in frozen shoulder patients.",2019,"RESULTS Statistical analysis showed an increase in all range of motion values (p<0.05), except for shoulder internal rotation (p>0.05), without significant difference among the groups (p>0.05).","['frozen shoulder patients', '54 patients diagnosed with stage 3 frozen shoulder']","['scapular mobilization', 'scapular mobilization, manual capsule stretching', 'manual posterior capsule stretching', 'Scapular mobilization and manual posterior capsule interventions']","['posterior capsule flexibility', 'acute joint range of motion', 'range of motion values', 'range of motion, active total elevation, active internal rotation, and posterior capsule tensions of the shoulder joint', 'shoulder internal rotation']","[{'cui': 'C0311223', 'cui_str': 'Shoulder Adhesive Capsulitis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3 (qualifier value)'}]","[{'cui': 'C0300926', 'cui_str': 'mobilization'}, {'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}]","[{'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0080078', 'cui_str': 'Range of Motion'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0231459', 'cui_str': 'Medial rotation - action (qualifier value)'}, {'cui': 'C0233494', 'cui_str': 'Tension (finding)'}, {'cui': 'C0037009', 'cui_str': 'Glenohumeral Joint'}, {'cui': 'C0037004', 'cui_str': 'Shoulder'}]",54.0,0.110987,"RESULTS Statistical analysis showed an increase in all range of motion values (p<0.05), except for shoulder internal rotation (p>0.05), without significant difference among the groups (p>0.05).","[{'ForeName': 'Irem', 'Initials': 'I', 'LastName': 'Duzgun', 'Affiliation': 'Hacettepe University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey.'}, {'ForeName': 'Elif', 'Initials': 'E', 'LastName': 'Turgut', 'Affiliation': 'Hacettepe University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey.'}, {'ForeName': 'Leyla', 'Initials': 'L', 'LastName': 'Eraslan', 'Affiliation': 'Hacettepe University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey.'}, {'ForeName': 'Bulent', 'Initials': 'B', 'LastName': 'Elbasan', 'Affiliation': 'Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey.'}, {'ForeName': 'Deran', 'Initials': 'D', 'LastName': 'Oskay', 'Affiliation': 'Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey.'}, {'ForeName': 'Ozgur Ahmet', 'Initials': 'OA', 'LastName': 'Atay', 'Affiliation': 'Hacettepe University, Faculty of Medicine, Department of Orthopedic and Traumatology, Ankara, Turkey.'}]",Journal of musculoskeletal & neuronal interactions,[] 1044,30745190,A novel naloxone training compared with current recommended training in an overdose simulation.,"OBJECTIVES The aim of this study was to determine if a novel naloxone training program with a focus on situational stress management yields better results than the currently recommended state training in a simulated overdose response. METHODS Students were randomized to receive either the state training or a novel training developed by the Wilkes University Nesbitt School of Pharmacy. After their respective training, each student individually completed a live simulated overdose response with an added stressor of a panicked bystander. A checklist was used to evaluate students during the simulation, and the results were compared. RESULTS The average grade for the novel training students was 89% compared with 64% for the state training students (P < 0.001). There was no statistically significant difference in time to complete the simulation. CONCLUSION Students who underwent the novel training received the state training. The novel training appears to be effective in preparing students to manage a live opioid overdose.",2019,"There was no statistically significant difference in time to complete the simulation. ","['Students', 'Students who underwent the']","['naloxone training', 'novel training received the state training', 'state training or a novel training developed by the Wilkes University Nesbitt School of Pharmacy', 'naloxone training program']",[],"[{'cui': 'C0038492', 'cui_str': 'Student (occupation)'}]","[{'cui': 'C0027358', 'cui_str': 'Naloxone'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0031322', 'cui_str': 'Pharmacies'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",[],,0.0146137,"There was no statistically significant difference in time to complete the simulation. ","[{'ForeName': 'Thomas S', 'Initials': 'TS', 'LastName': 'Franko', 'Affiliation': ''}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Distefano', 'Affiliation': ''}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Lewis', 'Affiliation': ''}]",Journal of the American Pharmacists Association : JAPhA,['10.1016/j.japh.2018.12.022'] 1045,19724043,Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.,"CONTEXT Mass oral azithromycin distribution to affected communities is a cornerstone of the World Health Organization's trachoma elimination program. Antibiotics are provided to target the ocular strains of chlamydia that cause trachoma, but may also be efficacious against respiratory disease, diarrhea, and malaria--frequent causes of childhood mortality in trachoma-endemic areas. OBJECTIVE To compare mortality rates of participants aged 1 to 9 years in treated communities with those in untreated communities. DESIGN, SETTING, AND PARTICIPANTS We conducted a cluster-randomized clinical trial of mass azithromycin administration for trachoma control. Forty-eight communities (known as subkebeles) were randomized into 1 of 3 treatment schedules (annual treatment of all residents [15,902 participants], biannual treatment of all residents [17,288 participants], or quarterly treatment of children only [14,716 participants]) or into 1 group for which treatment was delayed by 1 year (control, 18,498 participants). Twelve subkebeles were randomized to each of the 4 schedules with all children in each of the 3 communities being eligible for treatment. The trial was conducted in a field setting in rural Ethiopia, May 2006 to May 2007. INTERVENTIONS A single dose of oral azithromycin (adults, 1 g; children, 20 mg/kg) was administered for treatment of ocular Chlamydia trachomatis infection. Antibiotic coverage levels for children aged 1 to 9 years exceeded 80% at all visits. MAIN OUTCOME MEASURE The main outcome measure was the community-specific mortality risk for children aged 1 to 9 years over the course of 1 year. Mortality was measured by enumerative census at baseline and again after 1 year. Comparison of the risk of mortality was a prespecified outcome for the clinical trial. RESULTS The odds ratio for childhood mortality in the intervention communities was 0.51 (95% confidence interval, 0.29-0.90; P = .02; clustered logistic regression) compared with the control group. In the treated communities, the estimated overall mortality rate during this period for children aged 1 to 9 years in the untreated group was 8.3 per 1000 person-years (95% confidence interval, 5.3-13.1), while among the treated communities, the estimated overall mortality rate was 4.1 per 1000 person-years (95% confidence interval, 3.0-5.7) for children aged 1 to 9 years. CONCLUSION In a trachoma-endemic area, mass distribution of oral azithromycin was associated with reduced mortality in children. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00322972.",2009,"In a trachoma-endemic area, mass distribution of oral azithromycin was associated with reduced mortality in children. ","['children aged 1 to 9 years exceeded 80% at all visits', 'trachoma control', 'participants aged 1 to 9 years in treated communities with those in untreated communities', 'children', 'Forty-eight communities (known as subkebeles', 'field setting in rural Ethiopia, May 2006 to May 2007', 'Ethiopian children']","['oral azithromycin', 'azithromycin']","['Mortality', 'mortality rates', 'odds ratio for childhood mortality', 'community-specific mortality risk', 'Antibiotic coverage levels', 'overall mortality', 'overall mortality rate']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0040592', 'cui_str': 'Egyptian Ophthalmia'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C0205309', 'cui_str': 'Known (qualifier value)'}, {'cui': 'C0440042', 'cui_str': ""Field's""}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0015024', 'cui_str': 'Federal Democratic Republic of Ethiopia'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0282638', 'cui_str': 'Premedication, Antibiotic'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",18498.0,0.22032,"In a trachoma-endemic area, mass distribution of oral azithromycin was associated with reduced mortality in children. ","[{'ForeName': 'Travis C', 'Initials': 'TC', 'LastName': 'Porco', 'Affiliation': 'F.I. Proctor Foundation, and Department of Ophthalmology, University of California San Francisco, San Francisco, CA 94143, USA.'}, {'ForeName': 'Teshome', 'Initials': 'T', 'LastName': 'Gebre', 'Affiliation': ''}, {'ForeName': 'Berhan', 'Initials': 'B', 'LastName': 'Ayele', 'Affiliation': ''}, {'ForeName': 'Jenafir', 'Initials': 'J', 'LastName': 'House', 'Affiliation': ''}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Keenan', 'Affiliation': ''}, {'ForeName': 'Zhaoxia', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': ''}, {'ForeName': 'Kevin Cyrus', 'Initials': 'KC', 'LastName': 'Hong', 'Affiliation': ''}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Stoller', 'Affiliation': ''}, {'ForeName': 'Kathryn J', 'Initials': 'KJ', 'LastName': 'Ray', 'Affiliation': ''}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Emerson', 'Affiliation': ''}, {'ForeName': 'Bruce D', 'Initials': 'BD', 'LastName': 'Gaynor', 'Affiliation': ''}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Lietman', 'Affiliation': ''}]",JAMA,['10.1001/jama.2009.1266'] 1046,32330613,Comparison of Radiation Exposure Among 3 Different Endoscopic Diskectomy Techniques for Lumbar Disk Herniation.,"BACKGROUND Lumbar disk herniation can be successfully treated by lumbar endoscopic spinal procedures. However, one of the most important disadvantages of the endoscopic methods used is radiation exposure. There are multiple endoscopic spinal procedures and this study aims to compare unilateral biportal endoscopic diskectomy (UBED), percutaneous endoscopic lumbar diskectomy (PELD), and microendoscopic diskectomy (MED) methods in terms of radiation exposure. METHODS A total of 75 people were included in this prospective and multicenter study. The demographic characteristics, operating times (minutes), levels of surgery, lumbar disk herniation types, radiation exposures (dose area product [DAP]), and fluoroscopy times (seconds) of the groups were compared. RESULTS Mean DAP values were 1.39 Gy·cm 2 in the UBED group, 2.46 Gy·cm 2 in the PELD group, and 1.01 Gy·cm 2 in the MED group. The UBED group had no statistically significant difference with the MED and PELD groups in terms of DAP (P = 0.281 and P = 0.058, respectively), whereas the PELD group had statistically significantly higher DAP values than the MED group (P = 0.016). The maximum mean duration of fluoroscopy usage time was 34.9 seconds in the PELD group, 19.3 seconds in the UBED group, and 4.6 seconds in the MED group. The differences between the groups were significant (P ≤ 0.001). CONCLUSIONS The more the level of invasiveness is reduced in spinal surgery, the greater the exposure to radiation. In this study, the groups are listed as PELD > UBED > MED according to the duration and level of radiation exposure.",2020,"Mean DAP values were 1.39 Gy·cm 2 in the UBED group, 2.46 Gy·cm 2 in the PELD group, and 1.01 Gy·cm 2 in the MED group.","['Lumbar Disk Herniation', 'A total of 75 people']","['unilateral biportal endoscopic diskectomy (UBED), percutaneous endoscopic lumbar diskectomy (PELD), and microendoscopic diskectomy (MED']","['maximum mean duration of fluoroscopy usage time', 'level of invasiveness', 'Mean DAP values', 'demographic characteristics, operating times (minutes), levels of surgery, lumbar disk herniation types, radiation exposures (dose area product [DAP]), and fluoroscopy times (seconds', 'DAP values']","[{'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C1705370', 'cui_str': 'Disc - unit of product usage'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0206078', 'cui_str': 'Discectomy of spine'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1301757', 'cui_str': 'Invasiveness'}, {'cui': 'C0045587', 'cui_str': '2,6-diaminopurine'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C1096776', 'cui_str': 'Multicenter Studies'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C1705370', 'cui_str': 'Disc - unit of product usage'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0015333', 'cui_str': 'Exposure to radiation'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205436', 'cui_str': 'Second'}]",75.0,0.0289979,"Mean DAP values were 1.39 Gy·cm 2 in the UBED group, 2.46 Gy·cm 2 in the PELD group, and 1.01 Gy·cm 2 in the MED group.","[{'ForeName': 'Abdullah', 'Initials': 'A', 'LastName': 'Merter', 'Affiliation': 'Department of Orthopedics, Spine Section, School of Medicine, Ibn-i Sina Hospital, Ankara University, Ankara, Turkey. Electronic address: dr.merter@gmail.com.'}, {'ForeName': 'Oguz', 'Initials': 'O', 'LastName': 'Karaeminogullari', 'Affiliation': 'Department of Orthopedics, Spine Section, Bayindir Sogutozu Hospital, Ankara, Turkey.'}, {'ForeName': 'Motohide', 'Initials': 'M', 'LastName': 'Shibayama', 'Affiliation': 'Department of Orthopedics, Spine Section, Aichi Spine Hospital, Aichi Prefecture, Japan.'}]",World neurosurgery,['10.1016/j.wneu.2020.04.079'] 1047,31697336,Continuous versus intermittent infusion of cefotaxime in critically ill patients: a randomized controlled trial comparing plasma concentrations.,"BACKGROUND In critical care patients, reaching optimal β-lactam concentrations poses challenges, as infections are caused more often by microorganisms associated with higher MICs, and critically ill patients typically have an unpredictable pharmacokinetic/pharmacodynamic profile. Conventional intermittent dosing frequently yields inadequate drug concentrations, while continuous dosing might result in better target attainment. Few studies address cefotaxime concentrations in this population. OBJECTIVES To assess total and unbound serum levels of cefotaxime and an active metabolite, desacetylcefotaxime, in critically ill patients treated with either continuously or intermittently dosed cefotaxime. METHODS Adult critical care patients with indication for treatment with cefotaxime were randomized to treatment with either intermittent dosing (1 g every 6 h) or continuous dosing (4 g/24 h, after a loading dose of 1 g). We defined a preset target of reaching and maintaining a total cefotaxime concentration of 4 mg/L from 1 h after start of treatment. CCMO trial registration number NL50809.042.14, Clinicaltrials.gov NCT02560207. RESULTS Twenty-nine and 30 patients, respectively, were included in the continuous dosing group and the intermittent dosing group. A total of 642 samples were available for analysis. In the continuous dosing arm, 89.3% met our preset target, compared with 50% in the intermittent dosing arm. Patients not reaching this target had a significantly higher creatinine clearance on the day of admission. CONCLUSIONS These results support the application of a continuous dosing strategy of β-lactams in critical care patients and the practice of therapeutic drug monitoring in a subset of patients with higher renal clearance and need for prolonged treatment for further optimization, where using total cefotaxime concentrations should suffice.",2020,"In the continuous dosing arm, 89.3% met our preset target, compared with 50% in the intermittent dosing arm.","['critically ill patients', 'Twenty-nine and 30 patients', 'critically ill patients treated with either continuously or intermittently dosed cefotaxime', 'Adult critical care patients with indication for treatment with']",['cefotaxime'],['creatinine clearance'],"[{'cui': 'C0010340', 'cui_str': 'Critically Ill'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0450351', 'cui_str': '29 (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0007554', 'cui_str': 'Cefotaxime'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0010337', 'cui_str': 'Critical Care'}, {'cui': 'C0392360', 'cui_str': 'Reason for (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0007554', 'cui_str': 'Cefotaxime'}]","[{'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine (procedure)'}]",,0.0851593,"In the continuous dosing arm, 89.3% met our preset target, compared with 50% in the intermittent dosing arm.","[{'ForeName': 'Heleen', 'Initials': 'H', 'LastName': 'Aardema', 'Affiliation': 'University of Groningen, University Medical Center Groningen, Department of Critical Care, Groningen, The Netherlands.'}, {'ForeName': 'Wouter', 'Initials': 'W', 'LastName': 'Bult', 'Affiliation': 'University of Groningen, University Medical Center Groningen, Department of Critical Care, Groningen, The Netherlands.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'van Hateren', 'Affiliation': 'University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.'}, {'ForeName': 'Willem', 'Initials': 'W', 'LastName': 'Dieperink', 'Affiliation': 'University of Groningen, University Medical Center Groningen, Department of Critical Care, Groningen, The Netherlands.'}, {'ForeName': 'Daan J', 'Initials': 'DJ', 'LastName': 'Touw', 'Affiliation': 'University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.'}, {'ForeName': 'Jan-Willem C', 'Initials': 'JC', 'LastName': 'Alffenaar', 'Affiliation': 'University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.'}, {'ForeName': 'Jan G', 'Initials': 'JG', 'LastName': 'Zijlstra', 'Affiliation': 'University of Groningen, University Medical Center Groningen, Department of Critical Care, Groningen, The Netherlands.'}]",The Journal of antimicrobial chemotherapy,['10.1093/jac/dkz463'] 1048,31571560,What makes one respond to acupuncture for insomnia? Perspectives of cancer survivors.,"OBJECTIVE Like any therapy, acupuncture is effective for some patients, while not helpful for others. Understanding from a patients' perspective what makes one respond or not to acupuncture can help guide further intervention development. This study aimed to identify factors that influence the perception of acupuncture's therapeutic effect among cancer survivors with insomnia. METHOD We conducted post-treatment semi-structured interviews with cancer survivors who were randomized to the acupuncture group in a clinical trial for the treatment of insomnia. Survivors were categorized into Responders and Non-Responders to acupuncture treatment based on the change in the Insomnia Severity Index with a reduction of eight points or greater as the cut-off for the response. An integrated approach to data analysis was utilized by merging an a priori set of codes derived from the key ideas and a set of codes that emerged from the data through a grounded theory approach. Codes were examined for themes and patterns. RESULTS Among 28 cancer survivors interviewed, 18 (64%) were classified as Responders. Participants perceived the ability to respond to acupuncture as dependent on treatment that effectively: (1) alleviated co-morbidities contributing to insomnia, (2) supported sleep hygiene practices, and (3) provided a durable therapeutic effect. Acupuncture treatment that did not address one of these themes often detracted from positive treatment outcomes and diminished perceived benefit from acupuncture. SIGNIFICANCE OF RESULTS We identified patient-perceived contributors to response to acupuncture, such as co-morbid medical conditions, adequate support for sleep hygiene practices, and temporary therapeutic relief. Addressing these factors may improve the overall effectiveness of acupuncture for insomnia.",2020,"Acupuncture treatment that did not address one of these themes often detracted from positive treatment outcomes and diminished perceived benefit from acupuncture. ","['28 cancer survivors', 'cancer survivors with insomnia', 'cancer survivors']","['acupuncture', 'Acupuncture']",['Insomnia Severity Index'],"[{'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}]","[{'cui': 'C4520529', 'cui_str': 'Insomnia severity index (assessment scale)'}]",,0.0602409,"Acupuncture treatment that did not address one of these themes often detracted from positive treatment outcomes and diminished perceived benefit from acupuncture. ","[{'ForeName': 'Sally A D', 'Initials': 'SAD', 'LastName': 'Romero', 'Affiliation': 'Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Jiang', 'Affiliation': 'School of Medicine, New York University, New York, NY.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Bussell', 'Affiliation': 'A Center for Oriental Medicine, Chicago, IL.'}, {'ForeName': 'Whitney', 'Initials': 'W', 'LastName': 'Eriksen', 'Affiliation': 'Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Katherine N', 'Initials': 'KN', 'LastName': 'Duhamel', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Frances K', 'Initials': 'FK', 'LastName': 'Barg', 'Affiliation': 'Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Jun J', 'Initials': 'JJ', 'LastName': 'Mao', 'Affiliation': 'Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.'}]",Palliative & supportive care,['10.1017/S1478951519000762'] 1049,19671086,Cognitive-affective and somatic side effects of morphine and pentazocine: side-effect profiles in healthy adults.,"OBJECTIVE The side effects of opioids have been widely investigated, but it is unknown whether the subjective effects of mu agonists and mixed action opioids produce similar symptom profiles. This study examined the structure and predictive validity of somatic and cognitive/affective side-effect profiles of morphine and pentazocine using the Somatic Side Effects Questionnaire and the Cognitive and Affective Side Effects Questionnaire. DESIGN The subjects were 122 female and 90 male healthy volunteers that received an intravenous bolus administration of either 0.08 mg/kg of morphine or 0.5 mg/kg pentazocine. Pre- and post-drug experimental pain testing was also performed. Exploratory and confirmatory factor analysis resulted in similar factor structures for both drugs. RESULTS The most frequently reported side effects across both drugs involved feeling relaxed, sedation, and feeling in control. At equianalgesic doses, pentazocine had greater aversive side effects than morphine, whereas morphine was more associated with feelings of control and euphoria. For both drugs, females reported greater frequency of negative side effects than males. Using cluster analysis, we identified similar symptom profiles for each drug. These drug-related side-effect profiles were linked with analgesic responses. Specifically, groups that had a more positive side-effect profile experienced the greatest analgesic effect based on changes in ischemic pain sensitivity. CONCLUSIONS These findings have implications for decisions regarding opioid management of acute, chronic, and malignant pain conditions.",2010,"Specifically, groups that had a more positive side-effect profile experienced the greatest analgesic effect based on changes in ischemic pain sensitivity. ","['subjects were 122 female and 90 male healthy volunteers', 'healthy adults']","['morphine and pentazocine', 'intravenous bolus administration of either 0.08 mg/kg of morphine or 0.5 mg/kg pentazocine', 'morphine', 'pentazocine']","['feelings of control and euphoria', 'feeling relaxed, sedation, and feeling', 'Cognitive-affective and somatic side effects', 'ischemic pain sensitivity', 'aversive side effects']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0030873', 'cui_str': 'Pentazocine'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C4517417', 'cui_str': 'Zero point zero eight'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}]","[{'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0235146', 'cui_str': 'Euphoria'}, {'cui': 'C0522165', 'cui_str': 'Feeling calm (finding)'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}]",122.0,0.0249591,"Specifically, groups that had a more positive side-effect profile experienced the greatest analgesic effect based on changes in ischemic pain sensitivity. ","[{'ForeName': 'Joseph L', 'Initials': 'JL', 'LastName': 'Riley', 'Affiliation': 'Department of Community Dentistry and Behavioral Science, University of Florida, Gainesville, FL 32610-3628, USA. jriley@dental.ufl.edu'}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Hastie', 'Affiliation': ''}, {'ForeName': 'Toni L', 'Initials': 'TL', 'LastName': 'Glover', 'Affiliation': ''}, {'ForeName': 'Roger B', 'Initials': 'RB', 'LastName': 'Fillingim', 'Affiliation': ''}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Staud', 'Affiliation': ''}, {'ForeName': 'Claudia M', 'Initials': 'CM', 'LastName': 'Campbell', 'Affiliation': ''}]","Pain medicine (Malden, Mass.)",['10.1111/j.1526-4637.2009.00680.x'] 1050,19329003,Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial.,"BACKGROUND Trachoma-control programmes distribute oral azithromycin to treat the ocular strains of chlamydia that cause the disease and to control infection. Theoretically, elimination of infection is feasible if untreated individuals receive an indirect protective effect from living in repeatedly treated communities, which is similar to herd protection in vaccine programmes. We assessed indirect protection against trachoma with mass azithromycin distributions. METHODS In a cluster randomised trial, 24 subkebeles (government-defined units) in Amhara, Ethiopia, were randomised, with use of a simple random sample, to distribution four times per year of single-dose oral azithromycin to children aged 1-10 years (12 subkebeles, 4764 children), or to delayed treatment until after the study (control; 12 subkebeles, 6014 children). We compared the prevalence of ocular chlamydial infection in untreated individuals 11 years and older between baseline and 12 months in the treated subkebeles, and at 12 months between the treated and control subkebeles. Health-care and laboratory personnel were blinded to study group. Analysis was intention to treat. The study is registered with clinicaltrials.gov, number NCT00322972. FINDINGS At 12 months, 637 children aged 1-10 years and 561 adults and children aged 11 years and older were analysed in the children-treated group, and 618 and 550, respectively, in the control group. The mean prevalence of infection in children decreased from 48.4% (95% CI 42.9-53.9) to 3.6% (0.8-6.4) after four mass treatments. At 12 months, the mean prevalence of infection in the untreated age group (>/=11 years) was 47% (95% CI 33-57) less than baseline (p=0.002), and 35% (95% CI 1-57) less than that in untreated communities (p=0.04). INTERPRETATION Frequent treatment of children, who are a core group for transmission of trachoma, could eventually eliminate infection from the entire community. Herd protection is offered by repeated mass antibiotic treatments, providing a strategy for elimination of a bacterial disease when an effective vaccine is unavailable. FUNDING National Institutes of Health.",2009,The mean prevalence of infection in children decreased from 48.4% (95% CI 42.9-53.9) to 3.6% (0.8-6.4) after four mass treatments.,"['untreated individuals 11 years and older between baseline and 12 months in the treated subkebeles, and at 12 months between the treated and control subkebeles', 'to children aged 1-10 years (12 subkebeles, 4764 children), or to delayed treatment until after the study (control; 12 subkebeles, 6014 children', '24 subkebeles (government-defined units) in Amhara, Ethiopia', '637 children aged 1-10 years and 561 adults and children aged 11 years and older were analysed in the children-treated group, and 618 and 550, respectively, in the control group']",['azithromycin'],"['ocular chlamydial infection', 'mean prevalence of infection']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3693346', 'cui_str': 'Delayed Treatment'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0018104', 'cui_str': 'Government'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0015024', 'cui_str': 'Federal Democratic Republic of Ethiopia'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C3844103', 'cui_str': '550 (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0052796', 'cui_str': 'Azithromycin'}]","[{'cui': 'C4521296', 'cui_str': 'Ocular (intended site)'}, {'cui': 'C0008149', 'cui_str': 'Chlamydia Infections'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C3714514', 'cui_str': 'Infection'}]",6014.0,0.256114,The mean prevalence of infection in children decreased from 48.4% (95% CI 42.9-53.9) to 3.6% (0.8-6.4) after four mass treatments.,"[{'ForeName': 'Jenafir I', 'Initials': 'JI', 'LastName': 'House', 'Affiliation': 'FI Proctor Foundation, University of California, San Francisco, USA.'}, {'ForeName': 'Berhan', 'Initials': 'B', 'LastName': 'Ayele', 'Affiliation': ''}, {'ForeName': 'Travis C', 'Initials': 'TC', 'LastName': 'Porco', 'Affiliation': ''}, {'ForeName': 'Zhaoxia', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': ''}, {'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Hong', 'Affiliation': ''}, {'ForeName': 'Teshome', 'Initials': 'T', 'LastName': 'Gebre', 'Affiliation': ''}, {'ForeName': 'Kathryn J', 'Initials': 'KJ', 'LastName': 'Ray', 'Affiliation': ''}, {'ForeName': 'Jeremy D', 'Initials': 'JD', 'LastName': 'Keenan', 'Affiliation': ''}, {'ForeName': 'Nicole E', 'Initials': 'NE', 'LastName': 'Stoller', 'Affiliation': ''}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Whitcher', 'Affiliation': ''}, {'ForeName': 'Bruce D', 'Initials': 'BD', 'LastName': 'Gaynor', 'Affiliation': ''}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Emerson', 'Affiliation': ''}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Lietman', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(09)60323-8'] 1051,32125970,A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex.,"INRODUCTION The mechanistic target of rapamycin inhibitors (mTORi) sirolimus and everolimus stabilize lung function in patients with pulmonary lymphangioleiomyomatosis (LAM) but do not induce remission. Pre-clinical studies suggest that simvastatin in combination with sirolimus induces LAM cell death. The objective of this study was to assess the safety of simvastatin with either sirolimus or everolimus in LAM patients. METHODS This was a phase II single arm trial evaluating the safety of escalating daily simvastatin (20-40 mg) in LAM patients already treated with sirolimus or everolimus. Adverse events and changes in lipid panel profile, pulmonary function tests, and VEGF-D were assessed. RESULTS Ten LAM patients on a stable dose of mTORi for >3 months were treated with 20 mg simvastatin for two months followed by 40 mg for two months. The most common adverse events were peripheral edema (30%), cough (30%), and diarrhea (30%). No patients withdrew or had a reduction in simvastatin dose because of adverse events. Two patients required sirolumus dose reduction for supratherapeutic trough levels following simvastatin initiation. Total cholesterol and low density lipoproteins declined over the study period (-46.0 mg/dL±20.8, p = 0.008; -41.9 mg/dL±22.0, p = 0.01, respectively). There was also a decline in FEV1 (-82.0 mL±86.4, p = 0.02) but no significant change in FVC, DLCO, or VEGF-D. CONCLUSIONS The combination of simvastatin with mTORi in LAM patients is safe and well-tolerated from an adverse events perspective. The addition of simvastatin, however, was associated with decline in FEV1 and the efficacy of this combination should be explored in larger trials.",2020,"Total cholesterol and low density lipoproteins declined over the study period (-46.0 mg/dL±20.8, p = 0.008; -41.9 ","['LAM patients', 'patients with pulmonary lymphangioleiomyomatosis (LAM', 'LAM patients already treated with', 'patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex']","['Simvastatin (SOS', 'sirolimus or everolimus', 'simvastatin', 'rapamycin inhibitors (mTORi) sirolimus and everolimus', 'sirolimus']","['diarrhea', 'peripheral edema', 'LAM cell death', 'FEV1', 'FVC, DLCO, or VEGF-D.\nCONCLUSIONS', 'supratherapeutic trough levels', 'Total cholesterol and low density lipoproteins', 'Adverse events and changes in lipid panel profile, pulmonary function tests, and VEGF-D']","[{'cui': 'C0065041', 'cui_str': 'lipoarabinomannan'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0349649', 'cui_str': 'Pulmonary lymphangioleiomyomatosis (disorder)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0041341', 'cui_str': 'Sclerosis Tuberosa'}]","[{'cui': 'C0074554', 'cui_str': 'Simvastatin'}, {'cui': 'C0072980', 'cui_str': 'Sirolimus'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0085649', 'cui_str': 'Peripheral edema (morphologic abnormality)'}, {'cui': 'C0065041', 'cui_str': 'lipoarabinomannan'}, {'cui': 'C0007587', 'cui_str': 'Cell Death'}, {'cui': 'C0078058', 'cui_str': 'Vascular Endothelial Growth Factor A'}, {'cui': 'C0444506', 'cui_str': 'Trough (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0200382', 'cui_str': 'Lipid panel (procedure)'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}, {'cui': 'C0664390', 'cui_str': 'Vascular Endothelial Growth Factor D'}]",10.0,0.0691696,"Total cholesterol and low density lipoproteins declined over the study period (-46.0 mg/dL±20.8, p = 0.008; -41.9 ","[{'ForeName': 'Vera P', 'Initials': 'VP', 'LastName': 'Krymskaya', 'Affiliation': 'Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Courtwright', 'Affiliation': 'Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Fleck', 'Affiliation': 'Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Dorgan', 'Affiliation': 'Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Kotloff', 'Affiliation': 'Department of Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Francis X', 'Initials': 'FX', 'LastName': 'McCormack', 'Affiliation': 'Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.'}, {'ForeName': 'Maryl', 'Initials': 'M', 'LastName': 'Kreider', 'Affiliation': 'Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, Philadelphia, PA, USA. Electronic address: maryelizabeth.kreider@uphs.upenn.edu.'}]",Respiratory medicine,['10.1016/j.rmed.2020.105898'] 1052,32428027,Effects of the Community Score Card approach on reproductive health service-related outcomes in Malawi.,"BACKGROUND Social accountability approaches are increasingly being employed in low-resource settings to improve government services. In line with the continuous quality improvement (CQI) philosophy that quality is the product of a linked chain, collaborative social accountability approaches like the Community Score Card (CSC) aim to empower clients and frontline service providers to transform their own lives and hold public officials to account for state obligations. Despite being a critical focus of collaborative social accountability approaches, to our knowledge, a quantitative survey of health workers to understand the impact of these approaches on their self-reported responsibilities and service provision has not been conducted. To fill this gap, we carried out a quantitative survey with health workers to assess the CSC's impact on health worker-reported service responsibilities and provision and complement women's self-reports. METHODS We evaluated the effect of the CSC on reproductive health-related outcomes using a cluster-randomized design in Ntcheu district, Malawi. We matched 10 pairs of health facilities and surrounding catchment communities; one from each pair was randomly assigned to the intervention and control arms. The intervention communities and health workers each completed 3-4 cycles of the CSC process by endline. We then surveyed all health workers in the 20 intervention and comparison sites at endline (n = 412) to estimate the intervention's impact. RESULTS Significantly (p < .05) more health workers in the CSC intervention areas compared to control areas reported responsibility for antenatal care, comprehensive antenatal care counseling, recording of the number of pregnant and postpartum women seen each month, and the average age of their last family planning client was younger. In addition, marginally significantly (p < .10) more health workers in treatment versus control areas report visiting women at their home at least once during their pregnancy. However, health worker-reported responsibility for HIV testing was significantly lower in intervention areas than in control. CONCLUSIONS The CSC aims to empower health workers to collaborate with the community and rest of the health system to identify and overcome the diverse and context-specific range of performance barriers they face. In doing so, it aims to support them to demand and ensure quality care for themselves from the health system so they can, in turn, deliver quality services to clients. Our results contribute to the evidence that the CSC may hold promise at improving service provision. While there is increasing evidence that collaborative social accountability approaches like the CSC are effective means to improving reproductive health-related service provision and outcomes in low-resource settings, additional research is needed.",2020,"Significantly (p < .05) more health workers in the CSC intervention areas compared to control areas reported responsibility for antenatal care, comprehensive antenatal care counseling, recording of the number of pregnant and postpartum women seen each month, and the average age of their last family planning client was younger.","['surveyed all health workers in the 20 intervention and comparison sites at endline (n = 412', 'reproductive health service-related outcomes in Malawi', 'We matched 10 pairs of health facilities and surrounding catchment communities']","['Community Score Card approach', 'CSC']",['health workers'],"[{'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C1136000', 'cui_str': 'Reproductive Health Services'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0024548', 'cui_str': 'Malawi'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1306056', 'cui_str': 'Worker'}]",,0.064098,"Significantly (p < .05) more health workers in the CSC intervention areas compared to control areas reported responsibility for antenatal care, comprehensive antenatal care counseling, recording of the number of pregnant and postpartum women seen each month, and the average age of their last family planning client was younger.","[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Gullo', 'Affiliation': 'CARE USA, Atlanta, Georgia, United States of America.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Galavotti', 'Affiliation': 'CARE USA, Atlanta, Georgia, United States of America.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Sebert Kuhlmann', 'Affiliation': 'College for Public Health & Social Justice, Saint Louis University, St. Louis, Missouri, United States of America.'}, {'ForeName': 'Thumbiko', 'Initials': 'T', 'LastName': 'Msiska', 'Affiliation': 'CARE Malawi, Lilongwe, Malawi.'}, {'ForeName': 'Phil', 'Initials': 'P', 'LastName': 'Hastings', 'Affiliation': 'Far Harbor, LLC, Austin, TX, United States of America.'}, {'ForeName': 'C Nathan', 'Initials': 'CN', 'LastName': 'Marti', 'Affiliation': 'Far Harbor, LLC, Austin, TX, United States of America.'}]",PloS one,['10.1371/journal.pone.0232868'] 1053,31950865,"Re: ""Toward Respiratory-Gated Retrograde Intrarenal Surgery: A Prospective Controlled Randomized Study"" by Kourmpetis et al.",,2020,,[],['Respiratory-Gated Retrograde Intrarenal Surgery'],"['Kourmpetis V, Dekalo S, Levy N, Nir T, Bar-Yosef Y, Beri A, Yossepowitch O']",[],"[{'cui': 'C0439784', 'cui_str': 'Retrograde direction (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0993613', 'cui_str': 'Bar (basic dose form)'}]",,0.015348,,"[{'ForeName': 'Linjie', 'Initials': 'L', 'LastName': 'Peng', 'Affiliation': 'Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Zhong', 'Affiliation': 'Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.'}]",Journal of endourology,['10.1089/end.2019.0881'] 1054,31522271,18 F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab.,"PURPOSE We evaluated the prognostic value of 18 F-sodium fluoride (NaF) PET/CT in patients with urological malignancies treated with cabozantinib and nivolumab with or without ipilimumab. METHODS We prospectively recruited patients with advanced urological malignancies into a phase I trial of cabozantinib plus nivolumab with or without ipilimumab. NaF PET/CT scans were performed pre- and 8 weeks post-treatment. We measured the total volume of fluoride avid bone (FTV) using a standardized uptake value (SUV) threshold of 10. We used Kaplan-Meier analysis to predict the overall survival (OS) of patients in terms of SUVmax, FTV, total lesion fluoride (TLF) uptake at baseline and 8 weeks post-treatment, and percent change in FTV and TLF. RESULT Of 111 patients who underwent NaF PET/CT, 30 had bone metastases at baseline. Four of the 30 patients survived for the duration of the study period. OS ranged from 0.23 to 34 months (m) (median 6.0 m). The baseline FTV of all 30 patients ranged from 9.6 to 1570 ml (median 439 ml). The FTV 8 weeks post-treatment was 56-6296 ml (median 448 ml) from 19 available patients. Patients with higher TLF at baseline had shorter OS than patients with lower TLF (3.4 vs 14 m; p = 0.022). Patients with higher SUVmax at follow-up had shorter OS than patients with lower SUVmax (5.6 vs 24 m; p = 0.010). However, FTV and TLF 8 weeks post-treatment did not show a significant difference between groups (5.6 vs 17 m; p = 0.49), and the percent changes in FTV (12 vs 14 m; p = 0.49) and TLF (5.6 vs 17 m; p = 0.54) also were not significant. CONCLUSION Higher TLF at baseline and higher SUVmax at follow-up NaF PET/CT corresponded with shorter survival in patients with bone metastases from urological malignancies who underwent treatment. NaF PET/CT may be a useful predictor of OS in this population.",2020,Higher TLF at baseline and higher SUVmax at follow-up NaF PET/CT corresponded with shorter survival in patients with bone metastases from urological malignancies who underwent treatment.,"['111 patients who underwent', 'patients with advanced genitourinary malignancies treated with', 'patients with bone metastases from urological malignancies who underwent treatment', 'patients with urological malignancies treated with cabozantinib and nivolumab with or without ipilimumab', 'patients with advanced urological malignancies into a phase I trial of']","['cabozantinib plus nivolumab with or without ipilimumab', 'sodium fluoride (NaF) PET/CT', '18 F-Sodium fluoride PET/CT', 'NaF PET/CT', 'cabozantinib and nivolumab with or without ipilimumab']","['SUVmax, FTV, total lesion fluoride (TLF) uptake', 'overall survival', 'FTV', 'TLF', 'overall survival (OS', 'total volume of fluoride avid bone (FTV']","[{'cui': 'C4517538', 'cui_str': '111 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C3653764', 'cui_str': 'UROLOGICALS'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C3181682', 'cui_str': 'cabozantinib'}, {'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}]","[{'cui': 'C3181682', 'cui_str': 'cabozantinib'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C3652487', 'cui_str': 'sodium fluoride (18F)'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}, {'cui': 'C0302995', 'cui_str': '18F radioisotope'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0016327', 'cui_str': 'Fluorides'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0262950', 'cui_str': 'Bones'}]",111.0,0.0526902,Higher TLF at baseline and higher SUVmax at follow-up NaF PET/CT corresponded with shorter survival in patients with bone metastases from urological malignancies who underwent treatment.,"[{'ForeName': 'Ilhan', 'Initials': 'I', 'LastName': 'Lim', 'Affiliation': 'Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, B3B403, Bethesda, MD, 20892, USA.'}, {'ForeName': 'Maria Liza', 'Initials': 'ML', 'LastName': 'Lindenberg', 'Affiliation': 'Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, B3B403, Bethesda, MD, 20892, USA.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Mena', 'Affiliation': 'Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, B3B403, Bethesda, MD, 20892, USA.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Verdini', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Joanna H', 'Initials': 'JH', 'LastName': 'Shih', 'Affiliation': 'Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Mayfield', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Thompson', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Lin', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Vega', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Marissa', 'Initials': 'M', 'LastName': 'Mallek', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Cadena', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Diaz', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Mortazavi', 'Affiliation': 'Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Knopp', 'Affiliation': 'Wright Center of Innovation in Biomedical Imaging, Division of Imaging Science, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Chadwick', 'Initials': 'C', 'LastName': 'Wright', 'Affiliation': 'Wright Center of Innovation in Biomedical Imaging, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Stein', 'Affiliation': 'Division of Genitourinary Medical Oncology, Department of Medicine, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'Sumanta', 'Initials': 'S', 'LastName': 'Pal', 'Affiliation': 'City of Hope Comprehensive Cancer Center, Duarte, CA, USA.'}, {'ForeName': 'Peter L', 'Initials': 'PL', 'LastName': 'Choyke', 'Affiliation': 'Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, B3B403, Bethesda, MD, 20892, USA.'}, {'ForeName': 'Andrea B', 'Initials': 'AB', 'LastName': 'Apolo', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. andrea.apolo@nih.gov.'}]",European journal of nuclear medicine and molecular imaging,['10.1007/s00259-019-04483-5'] 1055,31932097,Corrigendum to 'A nonrandomized controlled clinical pilot trial on 8 wk of intermittent fasting (24 h/wk)' Nutrition. 2018;46:143-152.e2.,,2020,,[],"[""Intermittent Fasting (24 H/Wk)' Nutrition""]",[],[],"[{'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}]",[],,0.0312217,,"[{'ForeName': 'Christian S', 'Initials': 'CS', 'LastName': 'Kessler', 'Affiliation': 'Charité- Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Social Medicine, Epidemiology and Health Economics, Berlin, Germany; Immanuel Hospital Berlin, Department of Internal and Complementary Medicine, Berlin, Germany. Electronic address: c.kessler@immanuel.de.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Stange', 'Affiliation': 'Immanuel Hospital Berlin, Department of Internal and Complementary Medicine, Berlin, Germany.'}, {'ForeName': 'Maike', 'Initials': 'M', 'LastName': 'Schlenkermann', 'Affiliation': 'Charité- Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Social Medicine, Epidemiology and Health Economics, Berlin, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Jeitler', 'Affiliation': 'Charité- Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Social Medicine, Epidemiology and Health Economics, Berlin, Germany; Immanuel Hospital Berlin, Department of Internal and Complementary Medicine, Berlin, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Michalsen', 'Affiliation': 'Charité- Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Social Medicine, Epidemiology and Health Economics, Berlin, Germany; Immanuel Hospital Berlin, Department of Internal and Complementary Medicine, Berlin, Germany.'}, {'ForeName': 'Antonia', 'Initials': 'A', 'LastName': 'Selle', 'Affiliation': 'Karl von Ossietzky University Oldenburg, Faculty V for Mathematics and Natural Sciences, Institute for Biology and Environmental Sciences, Oldenburg, Germany.'}, {'ForeName': 'Franca', 'Initials': 'F', 'LastName': 'Raucci', 'Affiliation': 'IFOM FIRC Institute of Molecular Oncology, Milan, Italy.'}, {'ForeName': 'Nico', 'Initials': 'N', 'LastName': 'Steckhan', 'Affiliation': 'Charité- Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Social Medicine, Epidemiology and Health Economics, Berlin, Germany.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2019.110701'] 1056,18482870,Ethnic differences in diffuse noxious inhibitory controls.,"UNLABELLED Substantial evidence indicates that the experience of both clinical and experimental pain differs among ethnic groups. Specifically, African Americans generally report higher levels of clinical pain and greater sensitivity to experimentally induced pain; however, little research has examined the origins of these differences. Differences in central pain-inhibitory mechanisms may contribute to this disparity. Diffuse noxious inhibitory controls (DNIC), or counterirritation, is a phenomenon thought to reflect descending inhibition of pain signals. The current study assessed DNIC in 57 healthy young adults from 2 different ethnic groups: African Americans and non-Hispanic whites. Repeated assessments of the nociceptive flexion reflex (NFR) as well as ratings of electrical pain were obtained before, during, and after an ischemic arm pain procedure (as well as a sham procedure). The DNIC condition (ie, ischemic arm pain) produced substantial reductions in pain ratings as well as electrophysiologic measures of the NFR for all participants when compared with the sham condition (P < .001). The DNIC condition produced significantly greater reductions in verbal pain ratings among non-Hispanic whites when compared with African Americans (P = .02), whereas ethnic groups showed comparable reductions in NFR. The findings of this study suggest differences in endogenous pain inhibition between African Americans and non-Hispanic whites and that additional research to determine the mechanisms underlying these effects is warranted. PERSPECTIVE This study adds to the growing literature examining ethnic differences in experimental pain perception. Our data suggest that these variations may be influenced by differences in descending inhibition.",2008,"The DNIC condition produced significantly greater reductions in verbal pain ratings among non-Hispanic whites when compared with African Americans (P = .02), whereas ethnic groups showed comparable reductions in NFR.","['African Americans and non-Hispanic whites', '57 healthy young adults from 2 different ethnic groups: African Americans and non-Hispanic whites', 'African Americans']",[],"['endogenous pain inhibition', 'nociceptive flexion reflex (NFR', 'verbal pain ratings', 'NFR', 'clinical pain', 'pain ratings']","[{'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0015031', 'cui_str': 'Ethnicity'}]",[],"[{'cui': 'C0205227', 'cui_str': 'Endogenous (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}, {'cui': 'C0231452', 'cui_str': 'Flexion, function (observable entity)'}, {'cui': 'C0034929', 'cui_str': 'Reflex'}, {'cui': 'C1264664', 'cui_str': 'Number fraction'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}]",57.0,0.0411007,"The DNIC condition produced significantly greater reductions in verbal pain ratings among non-Hispanic whites when compared with African Americans (P = .02), whereas ethnic groups showed comparable reductions in NFR.","[{'ForeName': 'Claudia M', 'Initials': 'CM', 'LastName': 'Campbell', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-7101, USA. ccampb41@son.jhmi.edu'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'France', 'Affiliation': ''}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Robinson', 'Affiliation': ''}, {'ForeName': 'Henrietta L', 'Initials': 'HL', 'LastName': 'Logan', 'Affiliation': ''}, {'ForeName': 'Gary R', 'Initials': 'GR', 'LastName': 'Geffken', 'Affiliation': ''}, {'ForeName': 'Roger B', 'Initials': 'RB', 'LastName': 'Fillingim', 'Affiliation': ''}]",The journal of pain : official journal of the American Pain Society,['10.1016/j.jpain.2008.03.010'] 1057,31405532,Pilot testing a stretching regimen for prevention of night time nocturnal leg cramps.,"Nocturnal leg cramps (NLC) are painful, involuntary muscle contractions that affect the quality of sleep. The aim of this study was to examine the feasibility and effectiveness of a stretching regimen in frail older adults aged over 75 years with NLC. The experimental group (n = 15) received an intervention, which they were instructed to perform three daily exercises to stretch the calves and hamstrings. After six weeks, frequency and pain intensity of NLC were both significantly decreased in the experimental group compared to the control group. A paired samples t-test reveals a statistically significant decrease in cramp frequency (t = 2.2, df 28, P = 0.04) and cramp intensity (t = 2.7, df 28, P = 0.01). Therefore, a six-week stretching regimen is likely to reduce the frequency and pain intensity of NLC in frail older adults aged over 75 years.",2020,"After six weeks, frequency and pain intensity of NLC were both significantly decreased in the experimental group compared to the control group.","['frail older adults aged over 75 years', 'frail older adults aged over 75 years with NLC']",['stretching regimen'],"['cramp intensity', 'frequency and pain intensity of NLC', 'night time nocturnal leg cramps', 'Nocturnal leg cramps (NLC', 'feasibility and effectiveness', 'cramp frequency']","[{'cui': 'C0079379', 'cui_str': 'Frail Older Adults'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0600080', 'cui_str': 'Stretching procedure (procedure)'}]","[{'cui': 'C1446787', 'cui_str': 'Cramping'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0240526', 'cui_str': 'Night time (qualifier value)'}, {'cui': 'C0028250', 'cui_str': 'Nocturnal Leg Cramps'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}]",,0.0223517,"After six weeks, frequency and pain intensity of NLC were both significantly decreased in the experimental group compared to the control group.","[{'ForeName': 'Joannes', 'Initials': 'J', 'LastName': 'Hallegraeff', 'Affiliation': 'Hanze University of Applied Sciences, Groningen, the Netherlands; SOMT University of Physiotherapy, Amersfoort, the Netherlands. Electronic address: h.hallegraeff@somtuniversity.nl.'}, {'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'de Greef', 'Affiliation': 'Hanze University of Applied Sciences, Groningen, the Netherlands; University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.'}]","Geriatric nursing (New York, N.Y.)",['10.1016/j.gerinurse.2019.07.010'] 1058,32101137,The learning curve of one anastomosis gastric bypass and its impact as a preceding procedure to Roux-en Y gastric bypass: initial experience of one hundred and five consecutive cases.,"BACKGROUND The aim of this study was to assess the learning curve of one anastomosis gastric bypass (OAGB-MGB) at the start of a low volume bariatric unit and analyze its impact as a preceding procedure to Roux-en Y gastric bypass (RYGB). METHODS From January 2014 to December 2017, all patients who underwent bariatric surgeries in our teaching hospital that were performed by the same surgeon were enrolled. The first 47 patients who underwent OAGB-MGB were assigned to group A. RYGB has been offered as a treatment option since July 2016; thereafter, 26 patients who underwent OAGB-MGB and 32 patients who underwent RYGB at the same time interval were assigned to group B and group C, respectively. Baseline characteristics, perioperative outcomes and percentage of total weight loss (%TWL) up to 12 months postoperatively were collected and analyzed between groups. RESULTS Compared to the patients in group C, those in groups A and B were older (39.4 yrs. and 42.2 yrs., respectively, vs. 34.2 yrs.; p = 0.021) and predominantly male (48.9 and 73.1%, respectively vs. 40.6%; p = 0.04), and they had a higher body mass index (41.8 kg/m 2 and 43.3 kg/m 2 , respectively vs. 37.7 kg/m 2 ; p = 0.002) and a higher incidence of hypertension (44.7 and 61.5%, respectively vs. 21.9%; p = 0.008). In addition, the operation time was significantly reduced (118.2 min and 115.8 min, respectively vs. 153.1 min; p <  0.001), and the length of stay was shortened (3.0 days and 2.9 days, respectively vs. 3.4 days; p = 0.002) in groups B and C compared to group A. No mortality, conversion or leakage was reported throughout the study period. The 30-day complication rate was decreased in group C compared to groups A and B (0% vs. 6.4 and 7.7%, respectively; p = 0.307). The %TWL at the 12-month follow-up was 36.3, 30.9 and 28.3% for groups A, B and C, respectively (p <  0.001). CONCLUSION Our study verified the early emergence of a learning curve effect for OAGB-MGB, and the proficiency acquired can be transferred to subsequent practice for RYGB in terms of acceptable operation time and length of stay without an increase in complications.",2020,"The 30-day complication rate was decreased in group C compared to groups A and B (0% vs. 6.4 and 7.7%, respectively; p = 0.307).","['From January 2014 to December 2017, all patients who underwent bariatric surgeries in our teaching hospital that were performed by the same surgeon were enrolled', '47 patients who underwent OAGB-MGB']","['anastomosis gastric bypass (OAGB-MGB', 'OAGB-MGB']","['higher body mass index', 'hypertension', 'mortality, conversion or leakage', 'Baseline characteristics, perioperative outcomes and percentage of total weight loss (%TWL', 'length of stay', 'operation time', '30-day complication rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1456587', 'cui_str': 'Bariatric Surgery'}, {'cui': 'C0020027', 'cui_str': 'Teaching Hospitals'}]","[{'cui': 'C0332853', 'cui_str': 'Anastomosis (morphologic abnormality)'}, {'cui': 'C0017125', 'cui_str': 'Gastric Bypass'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0439836', 'cui_str': 'Conversions (qualifier value)'}, {'cui': 'C0015376', 'cui_str': 'Extravasation (morphologic abnormality)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}]",,0.0172331,"The 30-day complication rate was decreased in group C compared to groups A and B (0% vs. 6.4 and 7.7%, respectively; p = 0.307).","[{'ForeName': 'Hung-Chieh', 'Initials': 'HC', 'LastName': 'Lo', 'Affiliation': 'Division of Trauma and Emergency Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, No. 111, Sec. 3, Xinglong Rd., Wenshan Dist., Taipei City, 116, Taiwan, Republic of China. carfishcat@yahoo.com.tw.'}]",BMC surgery,['10.1186/s12893-020-00697-9'] 1059,31926810,Intermittent theta burst stimulation (iTBS) adjustment effects of schizophrenia: Results from an exploratory outcome of a randomized double-blind controlled study.,,2020,,[],"['schizophrenia', 'Intermittent theta burst stimulation (iTBS']",[],[],"[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}]",[],,0.447642,,"[{'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China; Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders, Hefei, China; Collaborative Innovation Center for Neuropsychiatric Disorders and Mental Health, Anhui, China.'}, {'ForeName': 'Xingui', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China; Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders, Hefei, China; Collaborative Innovation Center for Neuropsychiatric Disorders and Mental Health, Anhui, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders, Hefei, China; Collaborative Innovation Center for Neuropsychiatric Disorders and Mental Health, Anhui, China; Anhui Mental Health Center, Hefei, Anhui, China.'}, {'ForeName': 'Kongliang', 'Initials': 'K', 'LastName': 'He', 'Affiliation': 'Department of Medical Psychology, Chaohu Clinical Medical College, Anhui Medical University, Hefei, China.'}, {'ForeName': 'Feifei', 'Initials': 'F', 'LastName': 'Xu', 'Affiliation': 'Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders, Hefei, China; Collaborative Innovation Center for Neuropsychiatric Disorders and Mental Health, Anhui, China; Anhui Mental Health Center, Hefei, Anhui, China.'}, {'ForeName': 'Guixian', 'Initials': 'G', 'LastName': 'Xiao', 'Affiliation': 'Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China; Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders, Hefei, China; Collaborative Innovation Center for Neuropsychiatric Disorders and Mental Health, Anhui, China.'}, {'ForeName': 'Panpan', 'Initials': 'P', 'LastName': 'Hu', 'Affiliation': 'Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China; Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders, Hefei, China; Collaborative Innovation Center for Neuropsychiatric Disorders and Mental Health, Anhui, China.'}, {'ForeName': 'Bensheng', 'Initials': 'B', 'LastName': 'Qiu', 'Affiliation': 'Centers for Biomedical Engineering, University of Science and Technology of China, Hefei, China.'}, {'ForeName': 'Gong-Jun', 'Initials': 'GJ', 'LastName': 'Ji', 'Affiliation': 'Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders, Hefei, China; Collaborative Innovation Center for Neuropsychiatric Disorders and Mental Health, Anhui, China; Anhui Mental Health Center, Hefei, Anhui, China. Electronic address: jigongjun@163.com.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China; Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders, Hefei, China; Collaborative Innovation Center for Neuropsychiatric Disorders and Mental Health, Anhui, China. Electronic address: wangkai1964@126.com.'}]",Schizophrenia research,['10.1016/j.schres.2019.12.008'] 1060,32046429,Alleviation of Symptoms and Improvement of Endometrial Receptivity Following Laparoscopic Adenomyoma Excision and Secondary Therapy with the Levonorgestrel-releasing Intrauterine System.,"To assess the treatment efficacy of adenomyoma and improvement in implantation receptivity associated with the levonorgestrel-releasing intrauterine system (LNG-IUS) combined with adenomyoma resection. Fifty subjects (control group) underwent laparoscopic adenomyoma excision and received gonadotropin-releasing hormone (GnRH) agonists, and 201 subjects (experimental group) underwent laparoscopic adenomyoma resection and received GnRH agonists combined with the LNG-IUS. Pipelle endometrial biopsies were obtained in the mid-luteal phase, before the operation, and 19 months after the operation. Menstrual blood loss was measured using a pictorial blood loss assessment chart. Pain intensity during menstruation was evaluated on a 10-point visual analog scale (VAS). The volume of uterus was measured through ultrasound. Quantification of HOXA10 promoter methylation was performed through bisulfite sequencing polymerase chain reaction (BSP). Real-time polymerase chain reaction analyzed the expression levels of endometrial HOXA10-mRNA and leukemia inhibitory factor (LIF)-mRNA. After surgery, the scores for dysmenorrhea and menorrhagia were significantly improved, and the volume of the uterus was obviously reduced (all p < 0.01). The mean number of methylated CpG sites, level of endometrial HOXA10-mRNA, and level of endometrial LIF-mRNA were 5.6 ± 1.7 versus 3.9 ± 1.3, 0.8 ± 0.2 versus 0.9 ± 0.3, and 0.8 ± 0.2 versus 1.0 ± 0.2, respectively, in the control group versus the experimental group at 19 months after surgery, and significant improvements were observed in the experimental group (p < 0.001, p = 0.034, p < 0.001). Laparoscopic adenomyoma excision and GnRH agonists can alleviate the symptoms, reduce the number of methylated CpG sites in HOXA10, and improve endometrial HOXA10-mRNA and endometrial LIF-mRNA levels. When combined with subsequent use of the LNG-IUS, better efficacy can be achieved.",2020,"Laparoscopic adenomyoma excision and GnRH agonists can alleviate the symptoms, reduce the number of methylated CpG sites in HOXA10, and improve endometrial HOXA10-mRNA and endometrial LIF-mRNA levels.",['Fifty subjects (control group) underwent'],"['laparoscopic adenomyoma excision and received gonadotropin-releasing hormone (GnRH) agonists, and 201 subjects (experimental group) underwent laparoscopic adenomyoma resection and received GnRH agonists combined with the LNG-IUS', 'levonorgestrel-releasing intrauterine system (LNG-IUS) combined with adenomyoma resection', 'Laparoscopic Adenomyoma Excision and Secondary Therapy with the Levonorgestrel-releasing Intrauterine System', 'adenomyoma', 'Laparoscopic adenomyoma excision and GnRH agonists']","['Pipelle endometrial biopsies', '10-point visual analog scale (VAS', 'implantation receptivity', 'Alleviation of Symptoms and Improvement of Endometrial Receptivity', 'mean number of methylated CpG sites, level of endometrial HOXA10-mRNA, and level of endometrial LIF-mRNA', 'scores for dysmenorrhea and menorrhagia', 'Menstrual blood loss', 'Pain intensity', 'volume of uterus', 'volume of the uterus']","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0206622', 'cui_str': 'Adenomyoma'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C4543260', 'cui_str': 'Gonadotropin'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0023610', 'cui_str': 'Gonadorelin'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C1708694', 'cui_str': 'Levonorgestrel-releasing intrauterine system'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0441192', 'cui_str': 'Pipelle (physical object)'}, {'cui': 'C1510477', 'cui_str': 'Endometrial biopsy (procedure)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0021107', 'cui_str': 'Insertion procedure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0035696', 'cui_str': 'mRNA'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0013390', 'cui_str': 'Pain, Menstrual'}, {'cui': 'C0025323', 'cui_str': 'Heavy Menstrual Bleeding'}, {'cui': 'C0694689', 'cui_str': 'Menstrual blood (substance)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0042149', 'cui_str': 'Womb'}]",,0.0552896,"Laparoscopic adenomyoma excision and GnRH agonists can alleviate the symptoms, reduce the number of methylated CpG sites in HOXA10, and improve endometrial HOXA10-mRNA and endometrial LIF-mRNA levels.","[{'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Wu', 'Affiliation': ""Department of Gynecology, Zhejiang Provincial Peoples' Hospital, Peoples' Hospital of Hangzhou Medical College, Hangzhou, 310014, Zhejiang, People's Republic of China.""}, {'ForeName': 'Yawan', 'Initials': 'Y', 'LastName': 'Lian', 'Affiliation': ""Department of Obstetrics and Gynecology, Fujian Huian Hospital, Quanzhou, 362100, Fujian, People's Republic of China.""}, {'ForeName': 'Lifeng', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': ""Department of Gynecology, Zhejiang Provincial Peoples' Hospital, Peoples' Hospital of Hangzhou Medical College, Hangzhou, 310014, Zhejiang, People's Republic of China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': ""Department of Gynecology, Zhejiang Provincial Peoples' Hospital, Peoples' Hospital of Hangzhou Medical College, Hangzhou, 310014, Zhejiang, People's Republic of China.""}, {'ForeName': 'Tan', 'Initials': 'T', 'LastName': 'Lin', 'Affiliation': ""Department of Obstetrics and Gynecology, Fujian Provincial Hospital, Clinical Medical School of Fujian Medical University, 134 East Road, Fuzhou, 350001, Fujian, People's Republic of China. okwq31@sina.com.""}]","Reproductive sciences (Thousand Oaks, Calif.)",['10.1007/s43032-019-00130-4'] 1061,17942227,Across- and within-session variability of ratings of painful contact heat stimuli.,"This study examined within- and across-session consistency of visual analog scale (VAS) pain intensity and unpleasantness ratings of contact heat stimuli in 64 subjects (32 male). Subjects participated in four sessions over 14 days, with three stimulus series per session. Two levels of painful heat (pain-lo: rated 40, and pain-hi: rated 70 on a 0-100 VAS) were delivered in randomized order during each series, with temperatures selected on an individual subject basis to equalize pain perception across subjects. Across-session ratings declined by the fourth session for both pain levels (p=0.01). Within-session ratings declined by the third series for both pain levels (p<0.001). While significant, changes in across- and within-session ratings were of small magnitude. Comparison of coefficients of variation (CVs) for across- and within-session ratings revealed that pain-lo ratings were more variable than pain-hi ratings (p<0.001). Across- and within-session CVs were highly correlated for each pain level (pain-lo p<0.001; pain-hi p=0.001), suggesting that variability of VAS ratings is a characteristic of individual subjects over both short and long time scales. Across- and within-session CVs were significantly negatively correlated with individual ratings of the stimuli, but were not correlated with demographic or psychosocial factors. Furthermore, sex did not impact consistency of ratings, demonstrating that neither sex is more variable in ratings than the other over time. Taken together, these findings suggest that VAS ratings of painful contact heat are relatively stable over time but the variability of these ratings is significantly impacted by the perceived intensity of the stimulus.",2008,"Across- and within-session CVs were significantly negatively correlated with individual ratings of the stimuli, but were not correlated with demographic or psychosocial factors.","['64 subjects (32 male', 'rated 70 on a 0-100 VAS']",[],"['pain level', 'VAS ratings', 'pain-lo ratings', 'painful heat (pain-lo: rated 40, and pain-hi', 'pain levels', 'visual analog scale (VAS) pain intensity and unpleasantness ratings']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]",[],"[{'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",,0.0278738,"Across- and within-session CVs were significantly negatively correlated with individual ratings of the stimuli, but were not correlated with demographic or psychosocial factors.","[{'ForeName': 'Raimi L', 'Initials': 'RL', 'LastName': 'Quiton', 'Affiliation': 'Department of Biomedical Sciences, Dental School, and Program in Neuroscience, University of Maryland, Baltimore, MD 21201, USA. rquit001@umaryland.edu'}, {'ForeName': 'Joel D', 'Initials': 'JD', 'LastName': 'Greenspan', 'Affiliation': ''}]",Pain,[] 1062,17688420,Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?,"The aim of the present study was to evaluate the effects of a normal-sodium (120 mmol sodium) diet compared with a low-sodium diet (80 mmol sodium) on readmissions for CHF (congestive heart failure) during 180 days of follow-up in compensated patients with CHF. A total of 232 compensated CHF patients (88 female and 144 male; New York Heart Association class II-IV; 55-83 years of age, ejection fraction <35% and serum creatinine <2 mg/dl) were randomized into two groups: group 1 contained 118 patients (45 females and 73 males) receiving a normal-sodium diet plus oral furosemide [250-500 mg, b.i.d. (twice a day)]; and group 2 contained 114 patients (43 females and 71 males) receiving a low-sodium diet plus oral furosemide (250-500 mg, b.i.d.). The treatment was given at 30 days after discharge and for 180 days, in association with a fluid intake of 1000 ml per day. Signs of CHF, body weight, blood pressure, heart rate, laboratory parameters, ECG, echocardiogram, levels of BNP (brain natriuretic peptide) and aldosterone levels, and PRA (plasma renin activity) were examined at baseline (30 days after discharge) and after 180 days. The normal-sodium group had a significant reduction (P<0.05) in readmissions. BNP values were lower in the normal-sodium group compared with the low sodium group (685+/-255 compared with 425+/-125 pg/ml respectively; P<0.0001). Significant (P<0.0001) increases in aldosterone and PRA were observed in the low-sodium group during follow-up, whereas the normal-sodium group had a small significant reduction (P=0.039) in aldosterone levels and no significant difference in PRA. After 180 days of follow-up, aldosterone levels and PRA were significantly (P<0.0001) higher in the low-sodium group. The normal-sodium group had a lower incidence of rehospitalization during follow-up and a significant decrease in plasma BNP and aldosterone levels, and PRA. The results of the present study show that a normal-sodium diet improves outcome, and sodium depletion has detrimental renal and neurohormonal effects with worse clinical outcome in compensated CHF patients. Further studies are required to determine if this is due to a high dose of diuretic or the low-sodium diet.",2008,"After 180 days of follow-up, aldosterone levels and PRA were significantly (P<0.0001) higher in the low-sodium group.","['114 patients (43 females and 71 males) receiving a', 'compensated patients with CHF', '232 compensated CHF patients (88 female and 144 male; New York Heart Association class II-IV; 55-83 years of age, ejection fraction <35% and serum creatinine <2 mg/dl', 'compensated CHF patients', 'compensated congestive heart failure', '118 patients (45 females and 73 males) receiving a']","['low-sodium diet plus oral furosemide', 'normal-sodium (120 mmol sodium) diet compared with a low-sodium diet (80 mmol sodium', 'Normal-sodium diet compared with low-sodium diet', 'normal-sodium diet plus oral furosemide']","['plasma BNP and aldosterone levels, and PRA', 'PRA', 'aldosterone and PRA', 'readmissions for CHF (congestive heart failure', 'Signs of CHF, body weight, blood pressure, heart rate, laboratory parameters, ECG, echocardiogram, levels of BNP (brain natriuretic peptide) and aldosterone levels, and PRA (plasma renin activity', 'BNP values', 'incidence of rehospitalization', 'aldosterone levels and PRA', 'aldosterone levels']","[{'cui': 'C4708785', 'cui_str': 'One hundred and fourteen'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0205432', 'cui_str': 'Compensated (qualifier value)'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0441886', 'cui_str': 'Class 2 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure (disorder)'}, {'cui': 'C4517542', 'cui_str': '118'}]","[{'cui': 'C0012169', 'cui_str': 'Diet, Low-Salt'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0016860', 'cui_str': 'Furosemide'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C3541959', 'cui_str': 'Sodium supplement (substance)'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0301592', 'cui_str': 'Sodium diet (finding)'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C1095989', 'cui_str': 'Brain natriuretic peptide measurement (procedure)'}, {'cui': 'C0373535', 'cui_str': 'Aldosterone measurement (procedure)'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure (disorder)'}, {'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1623258', 'cui_str': 'ECG'}, {'cui': 'C0013516', 'cui_str': 'Transthoracic Echocardiography'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0054015', 'cui_str': 'Nesiritide'}, {'cui': 'C0035094', 'cui_str': 'Angiotensinogenase'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}]",232.0,0.026723,"After 180 days of follow-up, aldosterone levels and PRA were significantly (P<0.0001) higher in the low-sodium group.","[{'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Paterna', 'Affiliation': 'Department of Emergency Medicine, University of Palermo, Piazzale delle Cliniche 2, 90100 Palermo, Italy.'}, {'ForeName': 'Parrinello', 'Initials': 'P', 'LastName': 'Gaspare', 'Affiliation': ''}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Fasullo', 'Affiliation': ''}, {'ForeName': 'Filippo M', 'Initials': 'FM', 'LastName': 'Sarullo', 'Affiliation': ''}, {'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Di Pasquale', 'Affiliation': ''}]","Clinical science (London, England : 1979)",[] 1063,32119937,Prospective randomized trial comparing the pocket-creation method and conventional method of colorectal endoscopic submucosal dissection.,"BACKGROUND AND AIMS Colorectal endoscopic submucosal dissection (ESD) is recognized as a challenging procedure. Previously, we reported that a new ESD strategy using the pocket-creation method (PCM) is useful for colorectal ESD, but no prospective randomized study has evaluated the efficacy of the PCM. The aim of this study was to evaluate the efficacy and safety of PCM for colorectal ESD compared with the conventional method (CM). METHODS This was a prospective randomized controlled trial at 3 institutions in Japan. Patients with superficial colorectal neoplastic lesions >20 mm predicted to be intramucosal were randomly assigned to undergo ESD using the PCM or CM. Primary outcome was the ESD completion rate defined as completion of colorectal ESD with an en bloc resection using the assigned ESD method without changing to other methods or assisted by other devices. RESULTS We analyzed 59 patients with 59 colorectal tumors in the PCM group and 55 in the CM group. The ESD completion rate was significantly higher in the PCM group compared with the CM group (93% [55/59] vs 73% [40/55]; P  = .01). En bloc resection rates, R0 resection rates, procedure time, and dissection speed were not significantly different between the 2 groups. The incidence of adverse events was similar in the 2 groups. CONCLUSIONS Use of the PCM allows the endoscopist to complete the procedure with the intended method more often than the CM with similar clinical outcomes. (Clinical trial registration number: UMIN 000024394.).",2020,"En bloc resection rates, R0 resection rates, procedure time and dissection speed were not significantly different comparing the 2 groups.","['Patients with superficial colorectal neoplastic lesions >20 mm predicted to be intramucosal', '59 patients with 59 colorectal tumors in the PCM group and 55 in the CM group', '3 institutions in Japan']","['pocket-creation method and conventional method of colorectal endoscopic submucosal dissection', 'conventional method (CM', 'PCM or CM', 'Colorectal endoscopic submucosal dissection (ESD', 'PCM']","['En bloc resection rates, R0 resection rates, procedure time and dissection speed', 'efficacy and safety', 'ESD completion rate defined as completion of colorectal ESD with an en bloc resection using the assigned ESD method without changing to other methods or assisted by other devices', 'adverse events', 'ESD completion rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205124', 'cui_str': 'Superficial (qualifier value)'}, {'cui': 'C0555952', 'cui_str': 'Colorectal (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0009404', 'cui_str': 'Colorectal Tumors'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C0441513', 'cui_str': 'Construction (attribute)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0555952', 'cui_str': 'Colorectal (qualifier value)'}, {'cui': 'C1700929', 'cui_str': 'Endoscopic Submucosal Dissection'}]","[{'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0012737', 'cui_str': 'Dissection'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0555952', 'cui_str': 'Colorectal (qualifier value)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",59.0,0.0662173,"En bloc resection rates, R0 resection rates, procedure time and dissection speed were not significantly different comparing the 2 groups.","[{'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Yamashina', 'Affiliation': 'Department of Medicine, Division of Gastroenterology, Jichi Medical University, Shimotsuke, Japan; Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan.'}, {'ForeName': 'Daiki', 'Initials': 'D', 'LastName': 'Nemoto', 'Affiliation': 'Department of Coloproctology, Fukushima Medical University, Aizu Medical Center, Aizuwakamatsu, Japan.'}, {'ForeName': 'Yoshikazu', 'Initials': 'Y', 'LastName': 'Hayashi', 'Affiliation': 'Department of Medicine, Division of Gastroenterology, Jichi Medical University, Shimotsuke, Japan.'}, {'ForeName': 'Hisashi', 'Initials': 'H', 'LastName': 'Fukuda', 'Affiliation': 'Department of Medicine, Division of Gastroenterology, Jichi Medical University, Shimotsuke, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Okada', 'Affiliation': 'Department of Medicine, Division of Gastroenterology, Jichi Medical University, Shimotsuke, Japan.'}, {'ForeName': 'Takahito', 'Initials': 'T', 'LastName': 'Takezawa', 'Affiliation': 'Department of Medicine, Division of Gastroenterology, Jichi Medical University, Shimotsuke, Japan.'}, {'ForeName': 'Masato', 'Initials': 'M', 'LastName': 'Aizawa', 'Affiliation': 'Department of Coloproctology, Fukushima Medical University, Aizu Medical Center, Aizuwakamatsu, Japan.'}, {'ForeName': 'Hirotsugu', 'Initials': 'H', 'LastName': 'Sakamoto', 'Affiliation': 'Department of Medicine, Division of Gastroenterology, Jichi Medical University, Shimotsuke, Japan.'}, {'ForeName': 'Yoshimasa', 'Initials': 'Y', 'LastName': 'Miura', 'Affiliation': 'Department of Medicine, Division of Gastroenterology, Jichi Medical University, Shimotsuke, Japan.'}, {'ForeName': 'Keijiro', 'Initials': 'K', 'LastName': 'Sunada', 'Affiliation': 'Department of Medicine, Division of Gastroenterology, Jichi Medical University, Shimotsuke, Japan.'}, {'ForeName': 'Alan Kawarai', 'Initials': 'AK', 'LastName': 'Lefor', 'Affiliation': 'Department of Surgery, Jichi Medical University, Shimotsuke, Japan.'}, {'ForeName': 'Kazutomo', 'Initials': 'K', 'LastName': 'Togashi', 'Affiliation': 'Department of Coloproctology, Fukushima Medical University, Aizu Medical Center, Aizuwakamatsu, Japan.'}, {'ForeName': 'Hironori', 'Initials': 'H', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Medicine, Division of Gastroenterology, Jichi Medical University, Shimotsuke, Japan.'}]",Gastrointestinal endoscopy,['10.1016/j.gie.2020.02.034'] 1064,31177924,Indomethacin down-regulating HMGB1 and TNF-α to prevent pancreatitis after endoscopic retrograde cholangiopancreatography.,"Background and aims: Several articles demonstrated that non-steroidal anti-inflammation drugs (NSAIDs) were effective in reducing the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography (PEP). However, studies revealed inconsistent results. The mechanism of NSAIDs in preventing PEP is still little known. Therefore, the aim of our study was to evaluate the efficacy of NSAIDs for PEP prophylaxis and further to explore the mechanism of NSAIDs for prevention of PEP. Methods: Patients who underwent endoscopic retrograde cholangiopancreatography (ERCP) were randomly assigned to receive 100 mg rectal indomethacin or glycerin suppository 15-20 min before ERCP. The primary outcome was the rate of PEP. And the levels of serum HMGB1 and TNF-α were also measured before ERCP and 3 and 24 h after ERCP. Univariate analysis and multivariate analysis were carried out to estimate the independent risk factors for PEP. Results: Totally, 100 patients were enrolled, 50 received indomethacin and 50 with placebo (glycerin suppository). PEP developed in six patients in indomethacin group and 16 in the control group, the difference was significant ( p  = .016). The levels of HMGB1 and TNF-α were significantly decreased in indomethacin group at 3 ( p  < .0001) and 24 h ( p  < .0001) after ERCP, compared to the control group. Multivariate analysis revealed that duration of ERCP (OR, 0.221; 95% CI, 0.072-0.680; p  = .008) and usage of NSAIDs (OR, 0.278; 95% CI, 0.090-0.861; p  = .026) were independent predictors of PEP. Conclusions: Rectal indomethacin could significantly reduce the risk of PEP by down-regulating the levels of HMGB1 and TNF-α.",2019,"The levels of HMGB1 and TNF-α were significantly decreased in indomethacin group at 3 ( p  < .0001) and 24 h ( p  < .0001) after ERCP, compared to the control group.","['100 patients were enrolled, 50 received']","['100\u2009mg rectal indomethacin or glycerin suppository 15-20\u2009min before ERCP', 'Rectal indomethacin', 'placebo (glycerin suppository', 'HMGB1', 'endoscopic retrograde cholangiopancreatography (ERCP', 'Indomethacin', 'indomethacin']","['levels of HMGB1 and TNF-α', 'rate of PEP', 'duration of ERCP', 'PEP', 'levels of serum', 'risk of PEP by down-regulating the levels of HMGB1 and TNF-α']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0205052', 'cui_str': 'Rectal (qualifier value)'}, {'cui': 'C0021246', 'cui_str': 'Indomethacin'}, {'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C0038854', 'cui_str': 'Suppository'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0008310', 'cui_str': 'ERCP'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0019796', 'cui_str': 'Heparin-Binding Protein p30'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0019796', 'cui_str': 'Heparin-Binding Protein p30'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0359587', 'cui_str': 'Peptamen'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0008310', 'cui_str': 'ERCP'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",100.0,0.091839,"The levels of HMGB1 and TNF-α were significantly decreased in indomethacin group at 3 ( p  < .0001) and 24 h ( p  < .0001) after ERCP, compared to the control group.","[{'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Departments of Gastroenterology, Yijishan Hospital of Wannan Medical College , Wuhu , PR China.'}, {'ForeName': 'Miaomiao', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': 'Departments of Gastroenterology, Yijishan Hospital of Wannan Medical College , Wuhu , PR China.'}, {'ForeName': 'Tingting', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Departments of Gastroenterology, Yijishan Hospital of Wannan Medical College , Wuhu , PR China.'}, {'ForeName': 'Yuliang', 'Initials': 'Y', 'LastName': 'Jia', 'Affiliation': 'Departments of Gastroenterology, Yijishan Hospital of Wannan Medical College , Wuhu , PR China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Departments of Gastroenterology, Yijishan Hospital of Wannan Medical College , Wuhu , PR China.'}, {'ForeName': 'Heming', 'Initials': 'H', 'LastName': 'Yuan', 'Affiliation': 'Departments of Gastroenterology, Yijishan Hospital of Wannan Medical College , Wuhu , PR China.'}, {'ForeName': 'Guozheng', 'Initials': 'G', 'LastName': 'Zhang', 'Affiliation': 'Departments of Gastroenterology, Yijishan Hospital of Wannan Medical College , Wuhu , PR China.'}, {'ForeName': 'Chiyi', 'Initials': 'C', 'LastName': 'He', 'Affiliation': 'Departments of Gastroenterology, Yijishan Hospital of Wannan Medical College , Wuhu , PR China.'}]",Scandinavian journal of gastroenterology,['10.1080/00365521.2019.1623306'] 1065,31513088,Effectiveness of Chinese herbal medicine granules and traditional Chinese medicine-based psychotherapy for perimenopausal depression in Chinese women: a randomized controlled trial.,"OBJECTIVE The aim of the study was to assess the effectiveness of Chinese herbal medicine combined with traditional Chinese medicine (TCM)-based psychotherapy (TBP) on perimenopausal depression (PMD). METHODS This multicenter, randomized, placebo-controlled clinical trial was conducted in nine hospitals in China between August 2015 and June 2017. The study included 307 women with PMD who were divided randomly into two treatment groups: the Bushen Tiaogan formula (BSTG) plus TBP (n = 156) and placebo plus TBP (n = 151). All participants underwent treatment for 8 weeks and were followed up for 4 weeks. The primary outcome measures included scores of the Greene Climacteric Scale (GCS), Self-Rating Depression Scale (SDS), and Self-Rating Anxiety Scale (SAS). Secondary outcomes included serum levels of sex hormones and lipids, as well as adverse events. RESULTS The average GCS, SDS, and SAS scores after treatment were significantly lower in the BSTG-plus-TBP group than those in the placebo-plus-TBP group, and the differences were greatest at the end of the 12th week: the average GCS scores were 10.8 in the BSTG-plus-TBP group versus 18.5 in the placebo-plus-TBP group (P < 0.001); the average SDS scores were 30.7 in the BSTG-plus-TBP group versus 45.4 in the placebo-plus-TBP group (P < 0.001); the SAS scores were 28.6 in the BSTG-plus-TBP group versus 42.6 in the placebo-plus-TBP group (P < 0.001). In addition, treatments with BSTG plus TBP significantly reduced the levels of basal follicle-stimulating hormone (P = 0.045) and triglycerides (P = 0.039) and increased the level of high-density lipoprotein cholesterol (P < 0.001) compared to placebo treatments with TBP. No serious adverse events occurred, and the safety indices of complete blood counts, renal function, and liver function were within normal ranges, before and after treatments. CONCLUSIONS Treatment with BSTG formula plus TBP was more effective than TBP alone for improving PMD symptoms, sexual hormone levels, and blood lipid conditions in women with mild PMD.",2019,"The average GCS, SDS, and SAS scores after treatment were significantly lower in the BSTG-plus-TBP group than those in the placebo-plus-TBP group, and the differences were greatest at the end of the 12th week: the average GCS scores were 10.8 in the BSTG-plus-TBP group versus 18.5 in the placebo-plus-TBP group (P < 0.001); the average SDS scores were 30.7 in the BSTG-plus-TBP group versus 45.4 in the placebo-plus-TBP group (P < 0.001); the SAS scores were 28.6 in the BSTG-plus-TBP group versus 42.6 in the placebo-plus-TBP group (P < 0.001).","['nine hospitals in China between August 2015 and June 2017', '307 women with PMD', 'women with mild PMD', 'perimenopausal depression in Chinese women']","['placebo plus TBP', 'Chinese herbal medicine granules and traditional Chinese medicine-based psychotherapy', 'Chinese herbal medicine combined with traditional Chinese medicine (TCM)-based psychotherapy (TBP', 'placebo', 'TBP', 'BSTG plus TBP', 'placebo-plus-TBP', 'Bushen Tiaogan formula (BSTG) plus TBP', 'BSTG-plus-TBP']","['safety indices of complete blood counts, renal function, and liver function', 'serious adverse events', 'average GCS scores', 'serum levels of sex hormones and lipids, as well as adverse events', 'level of high-density lipoprotein cholesterol', 'average GCS, SDS, and SAS scores', 'levels of basal follicle-stimulating hormone', 'perimenopausal depression (PMD', 'SAS scores', 'PMD symptoms, sexual hormone levels, and blood lipid conditions', 'average SDS scores', 'scores of the Greene Climacteric Scale (GCS), Self-Rating Depression Scale (SDS), and Self-Rating Anxiety Scale (SAS', 'triglycerides']","[{'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C3839366', 'cui_str': 'Perimenopausal state (finding)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0077021', 'cui_str': 'tributyl phosphate'}, {'cui': 'C1273412', 'cui_str': 'Chinese herbal medicine'}, {'cui': 'C3853573', 'cui_str': 'Granules'}, {'cui': 'C0025124', 'cui_str': 'Zhong Yi Xue'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1273567', 'cui_str': 'Psychotherapy (specialty)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0009555', 'cui_str': 'Complete Blood Count'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0232741', 'cui_str': 'Liver function (observable entity)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0036884', 'cui_str': 'Gonadal Steroid Hormones'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0023822', 'cui_str': 'High Density Lipoprotein Cholesterol'}, {'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C0733758', 'cui_str': 'Follicle Stimulating Hormone'}, {'cui': 'C3839366', 'cui_str': 'Perimenopausal state (finding)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C1287355', 'cui_str': 'Finding of hormone level (finding)'}, {'cui': 'C0005768'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0008943', 'cui_str': 'Change of Life'}, {'cui': 'C0222045'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}]",307.0,0.281065,"The average GCS, SDS, and SAS scores after treatment were significantly lower in the BSTG-plus-TBP group than those in the placebo-plus-TBP group, and the differences were greatest at the end of the 12th week: the average GCS scores were 10.8 in the BSTG-plus-TBP group versus 18.5 in the placebo-plus-TBP group (P < 0.001); the average SDS scores were 30.7 in the BSTG-plus-TBP group versus 45.4 in the placebo-plus-TBP group (P < 0.001); the SAS scores were 28.6 in the BSTG-plus-TBP group versus 42.6 in the placebo-plus-TBP group (P < 0.001).","[{'ForeName': 'Xiao-Jing', 'Initials': 'XJ', 'LastName': 'Cao', 'Affiliation': 'Department of Gynecology, Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Xu-Chun', 'Initials': 'XC', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Xiaoyun', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ''}]","Menopause (New York, N.Y.)",['10.1097/GME.0000000000001380'] 1066,16789198,Physical Maps of Autographa californica and Rachiplusia ou Nuclear Polyhedrosis Virus Recombinants.,"TN-368 cells were infected simultaneously with the closely related Autographa california (AcMNPV) and Rachiplusia ou (RoMNPV) nuclear polyhedrosis viruses. Progeny viral isolates were plaque purified, and their DNAs were analyzed with restriction endonucleases. Of 100 randomly cloned plaques, 7 were AcMNPV and RoMNPV recombinants, 5 were RoMNPV, and 88 were AcMNPV. The recombinants contained DNA sequences derived from both parental genomes. By comparing the restriction cleavage patterns of parental and recombinant DNAs, the crossover sites were mapped. A single double crossover was detected in each of the seven recombinant genomes. In addition, six of the seven recombinants revealed a crossover site mapping between 78 and 89% of the genome. The structural polypeptides of the seven recombinants and two parental viruses were analyzed by polyacrylamide gel electrophoresis, and their polyhedrins were identified by tryptic peptide mapping. An analysis of the segregation of three enveloped nucleocapsid proteins and of the polyhedrins among the recombinants located the DNA sequences coding for AcMNPV structural polypeptides with molecular weights of 37,000 (a capsid polypeptide), 56,000, and 90,000 and the RoMNPV structural polypeptides with molecular weights of 36,000 (a capsid polypeptide), 56,000, and 91,000. The AcMNPV and RoMNPV polypeptides of molecular weights 37,000 and 36,000, respectively, mapped within 78 to 89% or 1 to 29%, the polypeptides of molecular weights 55,000 and 56,000 mapped within 78 to 29%, and the polypeptides of molecular weights 90,000 and 91,000 mapped within 19 to 56% of the genome. The region of the parental DNAs that codes for polyhedrin was located within 70 to 89% of the genome.",1980,TN-368 cells were infected simultaneously with the closely related Autographa california (AcMNPV) and Rachiplusia ou (RoMNPV) nuclear polyhedrosis viruses.,"['Of 100 randomly cloned plaques, 7 were AcMNPV and RoMNPV recombinants, 5 were RoMNPV, and 88 were AcMNPV']",[],['polypeptides of molecular weights'],"[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0009013', 'cui_str': 'Clones'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0303134', 'cui_str': '7Be radioisotope'}]",[],"[{'cui': 'C1305923', 'cui_str': 'Polypeptides'}, {'cui': 'C0026385', 'cui_str': 'Molecular Weight'}]",,0.0376357,TN-368 cells were infected simultaneously with the closely related Autographa california (AcMNPV) and Rachiplusia ou (RoMNPV) nuclear polyhedrosis viruses.,"[{'ForeName': 'M D', 'Initials': 'MD', 'LastName': 'Summers', 'Affiliation': 'Department of Entomology, Texas A&M University, College Station, Texas 77843.'}, {'ForeName': 'G E', 'Initials': 'GE', 'LastName': 'Smith', 'Affiliation': ''}, {'ForeName': 'J D', 'Initials': 'JD', 'LastName': 'Knell', 'Affiliation': ''}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Burand', 'Affiliation': ''}]",Journal of virology,[] 1067,31366999,The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial.,"BACKGROUND Breast cancer diagnosis may be a teachable moment for lifestyle behaviour change and to prevent adjuvant therapy associated weight gain. We assessed the acceptability and effectiveness of two weight control programmes initiated soon after breast cancer diagnosis to reduce weight amongst overweight or obese women and prevent gains in normal-weight women. METHODS Overweight or obese (n = 243) and normal weight (n = 166) women were randomised to a three-month unsupervised home (home), a supervised community weight control programme (community) or to standard written advice (control). Primary end points were change in weight and body fat at 12 months. Secondary end points included change in insulin, cardiovascular risk markers, quality of life and cost-effectiveness of the programmes. RESULTS Forty-three percent of eligible women were recruited. Both programmes reduced weight and body fat: home vs. control mean (95% CI); weight -2.3 (-3.5, -1.0) kg, body fat -1.6 (-2.6, -0.7) kg, community vs. control; weight -2.4 (-3.6, -1.1) kg, body fat -1.4 (-2.4, -0.5) kg (all p < 0.001). The community group increased physical activity, reduced insulin, cardiovascular disease risk markers, increased QOL and was cost-effective. CONCLUSIONS The programmes were equally effective for weight control, but the community programme had additional benefits. CLINICAL TRIAL REGISTRATION ISRCTN68576140.",2019,Both programmes reduced weight and body fat: home vs. control,"['overweight or obese women and prevent gains in normal-weight women', 'Forty-three percent of eligible women were recruited', 'Overweight or obese (n\u2009=\u2009243) and normal weight (n\u2009', '166) women', 'breast cancer diagnosis']","['home versus community-based weight control programmes', 'supervised community weight control programme (community) or to standard written advice (control']","['change in weight and body fat', 'acceptability and effectiveness', 'change in insulin, cardiovascular risk markers, quality of life and cost-effectiveness of the programmes', 'physical activity, reduced insulin, cardiovascular disease risk markers, increased QOL and was cost-effective', 'weight and body fat']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C2712185', 'cui_str': 'Normal weight (finding)'}, {'cui': 'C0450368', 'cui_str': '43 (qualifier value)'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen (regime/therapy)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0034380'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}]",,0.108066,Both programmes reduced weight and body fat: home vs. control,"[{'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Harvie', 'Affiliation': 'Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK. michelle.harvie@manchester.ac.uk.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Pegington', 'Affiliation': 'Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Debbie', 'Initials': 'D', 'LastName': 'McMullan', 'Affiliation': 'Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Bundred', 'Affiliation': 'Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Livingstone', 'Affiliation': 'The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Campbell', 'Affiliation': 'School of Applied Sciences, Edinburgh Napier University, Edinburgh, UK.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Wolstenholme', 'Affiliation': 'Nuffield Department of Population Health, Health Economics Research Centre, University of Oxford, Oxford, UK.'}, {'ForeName': 'Eleanora', 'Initials': 'E', 'LastName': 'Lovato', 'Affiliation': 'Nuffield Department of Population Health, Health Economics Research Centre, University of Oxford, Oxford, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Campbell', 'Affiliation': 'National Perinatal Epidemiology Unit, University of Oxford, Oxford, UK.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Adams', 'Affiliation': 'Clinical Radiology, Faculty of Medicine Biology and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Speed', 'Affiliation': 'The School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, UK.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Morris', 'Affiliation': 'Department of Medical Statistics, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Sacha', 'Initials': 'S', 'LastName': 'Howell', 'Affiliation': 'Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Howell', 'Affiliation': 'Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.'}]",British journal of cancer,['10.1038/s41416-019-0522-6'] 1068,31383985,Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.,"Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC) significantly increased non-progression rate in advanced ovarian cancer (OC) patients. We report final overall survival (OS) results to further strengthen the efficacy of DD-EPIC in the front-line therapy. In this phase 2 trial, 218 patients with FIGO IIIC-IV OC were randomly allocated to receive DD-EPIC followed by intravenous (IV) chemotherapy (DD-EPIC group), or IV chemotherapy alone (IV group). The study was prespecified to detect differences in progression-free survival (PFS) and OS. At a median follow-up period of 69.1 months, the median OS was 67.5 and 46.3 months in the DD-EPIC and IV group, respectively. The probability rate of OS at 5 years was 61.0% with DD-EPIC, and 38.2% with IV (hazard ratio [HR] for death from OC, 0.70; 95% confidence interval [CI], 0.49-1.00). DD-EPIC was associated with a prolonged PFS compared with the IV group (the estimated rate of PFS at 5 years, 26.0% vs. 8.5%; HR for disease progression, 0.64; 95% CI, 0.47-0.86). DD-EPIC was associated with a longer OS than IV chemotherapy alone. It may be considered as a valuable option of the front-line therapy for advanced ovarian cancer.Trial registration: ClinicalTrials.gov, NCT01669226 (date of registration: August 20, 2012).",2019,"DD-EPIC was associated with a prolonged PFS compared with the IV group (the estimated rate of PFS at 5 years, 26.0% vs. 8.5%; HR for disease progression, 0.64; 95% CI, 0.47-0.86).","['advanced ovarian cancer (OC) patients', 'advanced ovarian cancer', '218 patients with FIGO IIIC-IV OC']","['dose-dense early postoperative intraperitoneal chemotherapy', 'Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC', 'DD-EPIC followed by intravenous (IV) chemotherapy (DD-EPIC group), or IV chemotherapy alone']","['median OS', 'probability rate of OS', 'Survival benefits', 'progression-free survival (PFS) and OS']","[{'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1140680', 'cui_str': 'Ovary Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517647', 'cui_str': 'Two hundred and eighteen'}]","[{'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439794', 'cui_str': 'Dense (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0442120', 'cui_str': 'Intraperitoneal (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0413365', 'cui_str': 'Intravenous chemotherapy (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",218.0,0.207204,"DD-EPIC was associated with a prolonged PFS compared with the IV group (the estimated rate of PFS at 5 years, 26.0% vs. 8.5%; HR for disease progression, 0.64; 95% CI, 0.47-0.86).","[{'ForeName': 'Tingyan', 'Initials': 'T', 'LastName': 'Shi', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Jiang', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Pu', 'Affiliation': 'Department of Obstetrics and Gynecology, Wuxi Caner Hospital, Jiangsu, China.'}, {'ForeName': 'Huijuan', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Dongsheng', 'Initials': 'D', 'LastName': 'Tu', 'Affiliation': ""Department of Mathematics and Statistics, Queen's University, Kingston, Canada.""}, {'ForeName': 'Zhiyuan', 'Initials': 'Z', 'LastName': 'Dai', 'Affiliation': 'Department of Obstetrics and Gynecology, Suzhou Municipal Hospital, Jiangsu, China.'}, {'ForeName': 'Yunlang', 'Initials': 'Y', 'LastName': 'Cai', 'Affiliation': 'Department of Obstetrics and Gynecology, Zhongda Hospital Southeast University, Jiangsu, China.'}, {'ForeName': 'Yuqin', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Cheng', 'Affiliation': 'Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Huixun', 'Initials': 'H', 'LastName': 'Jia', 'Affiliation': 'Clinical Statistics Center, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Ruiqin', 'Initials': 'R', 'LastName': 'Tu', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Huaying', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': 'Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Yuting', 'Initials': 'Y', 'LastName': 'Luan', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Shumo', 'Initials': 'S', 'LastName': 'Cai', 'Affiliation': 'Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Rongyu', 'Initials': 'R', 'LastName': 'Zang', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China. ryzang@yahoo.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",British journal of cancer,['10.1038/s41416-019-0543-1'] 1069,32428586,"Integrating an online weight management program with population health management in primary care: Design, methods, and baseline data from the PROPS randomized controlled trial (Partnerships for Reducing Overweight and Obesity with Patient-centered Strategies).","BACKGROUND Scalable, low-cost weight management strategies are needed in primary care. We conducted a pragmatic, cluster-randomized controlled trial to examine the effectiveness of an online weight management program integrated with population health management support. METHODS We adapted an online weight management program and integrated it with population health management support in 15 primary care practices (24 clinics). We randomized the 24 clinics to usual care (UC), online program alone (OP), or combined intervention (CI). Eligible participants had to be ages 20 to 70 and have a recent primary care visit, body mass index (BMI) ≥ 27 and < 40 kg/m 2 , and a diagnosis of hypertension or type 2 diabetes. Participants attended routine visits and completed surveys over 18 months. The primary outcome is absolute weight change at 12 months (± 90 days) after enrollment, calculated from weights measured at primary care visits and recorded in the electronic health record. RESULTS We enrolled 840 participants between July 2016 and August 2017 (326 UC, 216 OP, and 298 CI.) At enrollment, participants' mean age was 59.3 years, their mean weight was 203.1 pounds, and their mean BMI was 32.5 kg/m 2 ; 60% of participants were female, 76.8% were white, 96.4% had hypertension, and 24.4% had type 2 diabetes. CONCLUSION It is feasible to adapt an online weight management program and integrate it with population health management support in primary care. The results of this trial will provide valuable information about the effectiveness of these strategies in primary care settings. ClinicalTrials.govregistration number:NCT02656693.",2020,"We randomized the 24 clinics to usual care (UC), online program alone (OP), or combined intervention (CI).","['Eligible participants had to be ages 20 to 70 and have a recent primary care visit, body mass index (BMI)\u202f≥\u202f27 and\u202f<\u202f40\u202fkg/m 2 , and a diagnosis of hypertension or type 2 diabetes', '15 primary care practices (24 clinics', ""At enrollment, participants' mean age was 59.3\u202fyears, their mean weight was 203.1 pounds, and their mean BMI was 32.5\u202fkg/m 2 ; 60% of participants were female, 76% were white, 96.4% had hypertension, and 24.4% had type 2 diabetes"", 'We enrolled 840 participants between July 2016 and August 2017 (326 UC, 216 OP, and 298 CI']","['online weight management program with population health management', 'online weight management program and integrated it with population health management support', 'usual care (UC), online program alone (OP), or combined intervention (CI', 'online weight management program integrated with population health management support']","['absolute weight change at 12\u202fmonths (± 90\u202fdays) after enrollment, calculated from weights measured at primary care visits and recorded in the electronic health record']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0439219', 'cui_str': 'lb'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C4517710', 'cui_str': '32.5'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C4708913', 'cui_str': '840'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C5191353', 'cui_str': '326'}, {'cui': 'C4708905', 'cui_str': '216'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205171', 'cui_str': 'Singular'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C4273558', 'cui_str': 'Weight management program'}, {'cui': 'C4704688', 'cui_str': 'Population Health Management'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0043101', 'cui_str': 'Weights and Measures'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}]",840.0,0.0950447,"We randomized the 24 clinics to usual care (UC), online program alone (OP), or combined intervention (CI).","[{'ForeName': 'Heather J', 'Initials': 'HJ', 'LastName': 'Baer', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, United States of America; Harvard Medical School, Boston, MA, United States of America; Harvard T.H. Chan School of Public Health, Boston, MA, United States of America. Electronic address: hbaer@bwh.harvard.edu.""}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'De La Cruz', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, United States of America.""}, {'ForeName': 'Ronen', 'Initials': 'R', 'LastName': 'Rozenblum', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, United States of America; Harvard Medical School, Boston, MA, United States of America.""}, {'ForeName': 'Nyryan V', 'Initials': 'NV', 'LastName': 'Nolido', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, United States of America.""}, {'ForeName': 'E John', 'Initials': 'EJ', 'LastName': 'Orav', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, United States of America; Harvard Medical School, Boston, MA, United States of America; Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.""}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Metzler', 'Affiliation': ""Department of Nutrition, Brigham and Women's Hospital, Boston, MA, United States of America.""}, {'ForeName': 'Jason P', 'Initials': 'JP', 'LastName': 'Block', 'Affiliation': ""Harvard Medical School, Boston, MA, United States of America; Department of Population Medicine, Harvard Pilgrim Healthcare Institute, Brigham and Women's Hospital, Boston, MA, United States of America.""}, {'ForeName': 'Florencia', 'Initials': 'F', 'LastName': 'Halperin', 'Affiliation': ""Harvard Medical School, Boston, MA, United States of America; Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Boston, MA, United States of America.""}, {'ForeName': 'Katherine D', 'Initials': 'KD', 'LastName': 'McManus', 'Affiliation': ""Department of Nutrition, Brigham and Women's Hospital, Boston, MA, United States of America.""}, {'ForeName': 'Louis J', 'Initials': 'LJ', 'LastName': 'Aronne', 'Affiliation': 'BMIQ Professionals Program, Intellihealth/BMIQ, United States of America; Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York, NY, United States of America.'}, {'ForeName': 'Guadalupe', 'Initials': 'G', 'LastName': 'Minero', 'Affiliation': 'BMIQ Professionals Program, Intellihealth/BMIQ, United States of America.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Bates', 'Affiliation': ""Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, United States of America; Harvard Medical School, Boston, MA, United States of America; Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.""}]",Contemporary clinical trials,['10.1016/j.cct.2020.106026'] 1070,32429720,Immunotherapy in patients with local HPV infection and high-grade squamous intraepithelial lesion following uterine cervical conization.,"OBJECTIVE To establish the clearance of cervical human papillomavirus (HPV) infection following postoperative immunotherapy with inosine pranobex in women receiving surgical treatment of established high-grade squamous intraepithelial lesion (HSIL) of the uterine cervix. MATERIALS AND METHODS Over the six-year study period, 32 women with cervical HPV infection following electroconization (loop electrosurgical excision procedure) of the uterine cervix for established HSIL were randomly divided into two groups: I ( n  = 10) without and II ( n  = 22) with postoperative inosine pranobex immunotherapy. Follow-up after 24 and 48 months included cervical testing for HPV persistence and after 12, 24, and 48 months with cytology and colposcopy for dysplasia relapse (confirmed histologically). RESULTS Relapse monitoring in 32 women after 12 months revealed 1 and 0 HSIL positive in groups I and II, respectively; after 24 months an additional 3 patients in each group were positive; and after 48 months an additional 3 and 1 patients were positive in groups I and II, respectively ( p  < .05). The groups significantly differed ( p  < .05) with regard to clearing the most common high-risk HPV genotypes (HPV 16 and HPV 56). CONCLUSIONS Inosine pranobex immunotherapy in HPV-positive patients following cervical conization significantly increased the clearance of viral infection with high-risk genotypes and reduced relapse of HSIL.",2020,The groups significantly differed ( p  < .05) with regard to clearing the most common high-risk HPV genotypes (HPV 16 and HPV 56).,"['32 women with cervical HPV infection following electroconization (loop electrosurgical excision procedure) of the uterine cervix for established HSIL', 'patients with local HPV infection and high-grade squamous intraepithelial lesion following uterine cervical conization', 'women receiving surgical treatment of established high-grade squamous intraepithelial lesion (HSIL) of the uterine cervix']","['Immunotherapy', 'postoperative inosine pranobex immunotherapy', 'postoperative immunotherapy with inosine pranobex']","['clearance of viral infection', 'relapse of HSIL', '0 HSIL positive']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0343641', 'cui_str': 'Human papilloma virus infection'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0184930', 'cui_str': 'Loop electrosurgical excision procedure'}, {'cui': 'C0007874', 'cui_str': 'Cervix uteri structure'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0333875', 'cui_str': 'High-grade squamous intraepithelial lesion'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0195324', 'cui_str': 'Cone biopsy of cervix'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]","[{'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0022230', 'cui_str': 'Inosine Pranobex'}]","[{'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0333875', 'cui_str': 'High-grade squamous intraepithelial lesion'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",32.0,0.0411971,The groups significantly differed ( p  < .05) with regard to clearing the most common high-risk HPV genotypes (HPV 16 and HPV 56).,"[{'ForeName': 'Stefan Miladinov', 'Initials': 'SM', 'LastName': 'Kovachev', 'Affiliation': 'Department of Gynecology, Military Medical Academy, Sofia, Bulgaria.'}]",Immunopharmacology and immunotoxicology,['10.1080/08923973.2020.1765374'] 1071,32045025,Assessing the impact of a family nurse-led intervention on young mothers' references to internal states.,"A mother's propensity to refer to internal states during mother-child interactions is important for her child's developing social understanding. However, adolescent mothers are less likely to reference internal states when interacting with their children. We investigated whether young mothers' references to internal states are promoted by the Family Nurse Partnership (FNP) intervention, an intensive home-visiting programme designed to support adolescent mothers in England. We also investigated family, maternal, and child factors associated with young mothers' references to inner states during interactions with their children. Adolescent mothers (n = 483, aged ≤ 19 years when recruited in pregnancy) and their children participated in an observational substudy of a randomized controlled trial investigating the impact of FNP compared to usual care. Mother-child dyads were video-recorded during free play, and mothers' speech was coded for use of internal state language (references to cognitions, desires, emotions, intentions, preferences, physiology, and perception). We found no differences in mothers' use of internal state language between the FNP and usual care groups. A sample-wide investigation identified that other features of mothers' language and relationship status with the child's father were associated with internal state language use. Findings are discussed with reference to targeted interventions and implications for future research.",2020,We found no differences in mothers' use of internal state language between the FNP and usual care groups.,"['adolescent mothers in England', 'Adolescent mothers (n\xa0=\xa0483, aged ≤ 19 years when recruited in pregnancy) and their children participated', 'adolescent mothers']","['Family Nurse Partnership (FNP) intervention', 'family nurse-led intervention', 'FNP']",[],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0023175', 'cui_str': 'Lead'}]",[],483.0,0.0187136,We found no differences in mothers' use of internal state language between the FNP and usual care groups.,"[{'ForeName': 'Amy L', 'Initials': 'AL', 'LastName': 'Paine', 'Affiliation': 'Cardiff University Centre for Human Developmental Science, School of Psychology, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Cannings-John', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Channon', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Lugg-Widger', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Cerith S', 'Initials': 'CS', 'LastName': 'Waters', 'Affiliation': 'Cardiff University Centre for Human Developmental Science, School of Psychology, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Robling', 'Affiliation': 'Centre for Trials Research, Cardiff University, Cardiff, UK.'}]",Infant mental health journal,['10.1002/imhj.21849'] 1072,32435057,"Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design.","BACKGROUND Exercise may improve fatigue in multiple myeloma survivors, but trial evidence is limited, and exercise may be perceived as risky in this older patient group with osteolytic bone destruction. METHODS In this Phase 2 Zelen trial, multiple myeloma survivors who had completed treatment at least 6 weeks ago, or were on maintenance only, were enrolled in a cohort study and randomly assigned to usual care or a 6-month exercise programme of tailored aerobic and resistance training. Outcome assessors and usual care participants were masked. The primary outcome was the FACIT-F fatigue score with higher scores denoting less fatigue. RESULTS During 2014-2016, 131 participants were randomised 3:1 to intervention (n = 89) or usual care (n = 42) to allow for patients declining allocation to the exercise arm. There was no difference between groups in fatigue at 3 months (between-group mean difference: 1.6 [95% CI: -1.1-4.3]) or 6 months (0.3 [95% CI: -2.6-3.1]). Muscle strength improved at 3 months (8.4 kg [95% CI: 0.5-16.3]) and 6 months (10.8 kg [95% CI: 1.2-20.5]). Using per-protocol analysis, cardiovascular fitness improved at 3 months (+1.2 ml/kg/min [95% CI: 0.3-3.7]). In participants with clinical fatigue (n = 17), there was a trend towards less fatigue with exercise over 6 months (6.3 [95% CI: -0.6-13.3]). There were no serious adverse events. CONCLUSIONS Exercise appeared safe and improved muscle strength and cardiovascular fitness, but benefits in fatigue appeared limited to participants with clinical fatigue at baseline. Future studies should focus on patients with clinical fatigue. CLINICAL TRIAL REGISTRATION The study was registered with ISRCTN (38480455) and is completed.",2020,Muscle strength improved at 3 months (8.4 kg [95% CI: 0.5-16.3]) and 6 months (10.8 kg [95% CI: 1.2-20.5]).,"['older patient group with osteolytic bone destruction', 'During 2014-2016, 131 participants', 'patients with clinical fatigue', 'multiple myeloma survivors (MASCOT', 'multiple myeloma survivors who had completed treatment at least 6 weeks ago, or were on maintenance only', 'multiple myeloma survivors']","['usual care or a 6-month exercise programme of tailored aerobic and resistance training', 'exercise intervention', 'usual care']","['Muscle strength', 'fatigue', 'cardiovascular fitness', 'FACIT-F fatigue score', 'Fatigue, quality of life and physical fitness', 'fatigue with exercise', 'safe and improved muscle strength and cardiovascular fitness']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0238790', 'cui_str': 'Bone destruction'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0003023', 'cui_str': 'Angola'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",131.0,0.234799,Muscle strength improved at 3 months (8.4 kg [95% CI: 0.5-16.3]) and 6 months (10.8 kg [95% CI: 1.2-20.5]).,"[{'ForeName': 'Dimitrios A', 'Initials': 'DA', 'LastName': 'Koutoukidis', 'Affiliation': 'Department of Behavioural Science and Health, University College London, London, UK.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Land', 'Affiliation': 'Department of Behavioural Science and Health, University College London, London, UK.'}, {'ForeName': 'Allan', 'Initials': 'A', 'LastName': 'Hackshaw', 'Affiliation': 'Cancer Research UK & UCL Cancer Trials Centre, University College London, London, UK.'}, {'ForeName': 'Malgorzata', 'Initials': 'M', 'LastName': 'Heinrich', 'Affiliation': 'Department of Behavioural Science and Health, University College London, London, UK.'}, {'ForeName': 'Orla', 'Initials': 'O', 'LastName': 'McCourt', 'Affiliation': 'Department of Behavioural Science and Health, University College London, London, UK.'}, {'ForeName': 'Rebecca J', 'Initials': 'RJ', 'LastName': 'Beeken', 'Affiliation': 'Department of Behavioural Science and Health, University College London, London, UK.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Philpott', 'Affiliation': 'Department of Behavioural Science and Health, University College London, London, UK.'}, {'ForeName': 'Dunnya', 'Initials': 'D', 'LastName': 'DeSilva', 'Affiliation': 'Cancer Institute, University College London, London, UK.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Rismani', 'Affiliation': 'Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Rabin', 'Affiliation': 'Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.'}, {'ForeName': 'Rakesh', 'Initials': 'R', 'LastName': 'Popat', 'Affiliation': 'Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.'}, {'ForeName': 'Charalampia', 'Initials': 'C', 'LastName': 'Kyriakou', 'Affiliation': 'Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.'}, {'ForeName': 'Xenofon', 'Initials': 'X', 'LastName': 'Papanikolaou', 'Affiliation': 'Department of Haematology, Lister Hospital, Stevenage, UK.'}, {'ForeName': 'Atul', 'Initials': 'A', 'LastName': 'Mehta', 'Affiliation': 'Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Paton', 'Affiliation': 'Institute of Sport, Exercise and Health, London, UK.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Fisher', 'Affiliation': 'Department of Behavioural Science and Health, University College London, London, UK.'}, {'ForeName': 'Kwee L', 'Initials': 'KL', 'LastName': 'Yong', 'Affiliation': 'Cancer Institute, University College London, London, UK. kwee.yong@ucl.ac.uk.'}]",British journal of cancer,['10.1038/s41416-020-0866-y'] 1073,30169192,"Intraoperative clonidine for prevention of postoperative agitation in children anaesthetised with sevoflurane (PREVENT AGITATION): a randomised, placebo-controlled, double-blind trial.","BACKGROUND Postoperative agitation is a frequent and stressful condition for a child, their family, and their health-care providers, and prevention would be of benefit. We aimed to assess the effects of intravenous clonidine administered intraoperatively on the incidence of postoperative agitation, pain, and adverse events. METHODS We did this randomised, placebo-controlled, double-blind trial (PREVENT AGITATION) at one tertiary-level hospital and two urban-district hospitals in Denmark. Children aged 1-5 years, with an American Society of Anesthesiologists physical classification score of 1-2, who were scheduled for anaesthesia with sevoflurane and fentanyl were randomly assigned (1:1) in blocks of ten by computer-generated centralised randomisation, stratified by age (<2 years or ≥2 years) and site, to receive either intravenous clonidine 3 μg/kg or an equal quantity of isotonic saline in identical vials, administered around 20 min before the completion of surgery. Data were collected from the postoperative care unit (24 h) and at follow-up (30 days). Our primary outcome was the proportion of patients with one or more episodes of postoperative agitation, measured every 15 min in the postoperative care unit (POCU) with the four-point Watcha scale (ie, Watcha >2). We analysed by intention to treat. The trial is registered with ClinicalTrials.gov (number NCT02361476). FINDINGS Between January and December, 2015, of the 379 eligible children, we randomly assigned 191 to receive clonidine treatment and 188 to receive placebo; 75 were girls (20%). Nine were excluded from the primary outcome analysis because of missing data points. 46 (25%) of 187 clonidine participants compared with 86 (47%) of 183 placebo participants had one or more episodes of postoperative agitation (Watcha score >2; relative risk 0·56, 95% CI 0·43-0·73; p<0·0001). 30 (20%) of 150 boys in the clonidine group were agitated compared with 69 (47%) of 147 boys in the placebo group (0·43, 0·30-0·61; p<0·0001). The observed effect was not significant in girls. Incidence of adverse events was similar in the clonidine and placebo groups. INTERPRETATION On the basis of our results, clonidine might be used to safely prevent postoperative agitation in boys anaesthetised with sevoflurane. FUNDING Danish Society of Anaesthesia and Intensive Care.",2018,"Incidence of adverse events was similar in the clonidine and placebo groups. ","['children anaesthetised with', 'Children aged 1-5 years, with an American Society of Anesthesiologists physical classification score of 1-2, who were scheduled for anaesthesia with', ' at one tertiary-level hospital and two urban-district hospitals in Denmark', 'boys anaesthetised with sevoflurane', 'Between January and December, 2015, of the 379 eligible children']","['placebo', 'sevoflurane', 'clonidine 3 μg/kg or an equal quantity of isotonic saline', 'clonidine', 'sevoflurane and fentanyl', 'Intraoperative clonidine']","['proportion of patients with one or more episodes of postoperative agitation', 'Incidence of adverse events', 'postoperative agitation, pain, and adverse events', 'episodes of postoperative agitation']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0008903', 'cui_str': 'taxonomy'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0020006', 'cui_str': 'Hospitals, District'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0009014', 'cui_str': 'Clonidine'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C1265611', 'cui_str': 'Quantity finding'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated (finding)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",379.0,0.769819,"Incidence of adverse events was similar in the clonidine and placebo groups. ","[{'ForeName': 'Mogens', 'Initials': 'M', 'LastName': 'Ydemann', 'Affiliation': 'Department of Anaesthesiology, Juliane Marie Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Department of Neuroanaesthesiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Electronic address: mogens@ydemann.dk.'}, {'ForeName': 'Bettina Nygaard', 'Initials': 'BN', 'LastName': 'Nielsen', 'Affiliation': 'Department of Anaesthesiology, Juliane Marie Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Steen', 'Initials': 'S', 'LastName': 'Henneberg', 'Affiliation': 'Department of Anaesthesiology, Juliane Marie Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Janus Christian', 'Initials': 'JC', 'LastName': 'Jakobsen', 'Affiliation': 'Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Jørn', 'Initials': 'J', 'LastName': 'Wetterslev', 'Affiliation': 'Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Torsten', 'Initials': 'T', 'LastName': 'Lauritsen', 'Affiliation': 'Department of Anaesthesiology, Juliane Marie Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Steen', 'Affiliation': 'Department of Anaesthesiology, Vejle Hospital, Vejle, Denmark.'}, {'ForeName': 'Birgitte', 'Initials': 'B', 'LastName': 'Edstrøm', 'Affiliation': 'Department of Anaesthesiology, Zealand University Hospital, Køge, Denmark.'}, {'ForeName': 'Arash', 'Initials': 'A', 'LastName': 'Afshari', 'Affiliation': 'Department of Anaesthesiology, Juliane Marie Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(17)30127-X'] 1074,32101857,"Assessment of the Effect of Short-Term Combined High-Intensity Interval Training on TLR4, NF-κB and IRF3 Expression in Young Overweight and Obese Girls.","Obesity is commonly associated with immunometabolic dysfunctions. Activation of inflammatory macrophages through TLR4 (toll-like receptor 4) and the anti-inflammatory impact of exercise have been and are the new concerns among researchers. A new short-term combined high-intensity interval training was proposed in young sedentary overweight/obese females. All participants were allocated to one of two groups: the exercise group (EG) and the control group (CG), where the EG participated in a 2-week combined training and the CG continued its routine lifestyle. Gene expression levels of TLR4, NF-κB(nuclear factor κB), and IRF3 (interferon regulatory factor 3) were assessed by real-time PCR. Physiological, anthropometric, and biomedical metabolic factors were assessed. The between-group comparisons indicated a tendency to a decrease in NF-κB gene expression in the EG. The IRF3 levels were not significantly changed compared to CG and the levels before training. Fasting glucose levels and β-cell function revealed a significant improvement in EG. These findings indicated that this protocol decreased meta-inflammation levels and improved insulin resistance independent of body composition changes. Consequently, combined training may be recommended as a therapeutic approach in metabolic diseases.",2020,"Gene expression levels of TLR4, NF-κB(nuclear factor κB), and IRF3 (interferon regulatory factor 3) were assessed by real-time PCR.","['Young Overweight and Obese Girls', 'young sedentary overweight/obese females']","['exercise group (EG) and the control group (CG', 'combined training and the CG continued its routine lifestyle', 'new short-term combined high-intensity interval training', 'Short-Term Combined High-Intensity Interval Training']","['Fasting glucose levels and β-cell function', 'NF-κB gene expression', 'TLR4, NF-κB and IRF3 Expression', 'Gene expression levels of TLR4, NF-κB(nuclear factor κB), and IRF3 (interferon regulatory factor 3', 'meta-inflammation levels', 'IRF3 levels']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C4277545', 'cui_str': 'High-Intensity Intermittent Exercise'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0428548', 'cui_str': 'Glucose level - finding'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1510506', 'cui_str': 'Interferon Regulatory Factor 3'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",,0.0128358,"Gene expression levels of TLR4, NF-κB(nuclear factor κB), and IRF3 (interferon regulatory factor 3) were assessed by real-time PCR.","[{'ForeName': 'Nakisa', 'Initials': 'N', 'LastName': 'Soltani', 'Affiliation': 'Department of Exercise Physiology, Faculty of Sport Sciences, University of Isfahan, Isfahan, Iran.'}, {'ForeName': 'Nafiseh', 'Initials': 'N', 'LastName': 'Esmaeil', 'Affiliation': 'Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, n_esmaeil@med.mui.ac.ir.'}, {'ForeName': 'Sayed Mohammad', 'Initials': 'SM', 'LastName': 'Marandi', 'Affiliation': 'Department of Exercise Physiology, Faculty of Sport Sciences, University of Isfahan, Isfahan, Iran.'}, {'ForeName': 'Volga', 'Initials': 'V', 'LastName': 'Hovsepian', 'Affiliation': 'Department of Exercise Physiology, Faculty of Sport Sciences, University of Isfahan, Isfahan, Iran.'}, {'ForeName': 'Tooba', 'Initials': 'T', 'LastName': 'Momen', 'Affiliation': 'Department of Allergy and Clinical Immunology, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Noncommunicable Diseases, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Armindokht', 'Initials': 'A', 'LastName': 'Shahsanai', 'Affiliation': 'Department of Community and Family Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Roya', 'Initials': 'R', 'LastName': 'Kelishadi', 'Affiliation': 'Department of Pediatrics/Child Growth and Development Research Center, Research Institute for Primordial Prevention of Noncommunicable Diseases, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",Public health genomics,['10.1159/000506057'] 1075,32007346,Increased global cognition correlates with increased thalamo-temporal connectivity in response to targeted cognitive training for recent onset schizophrenia.,"Patients with schizophrenia exhibit disrupted thalamocortical connections that relate to aspects of symptoms and deficits in cognition. Targeted cognitive training (TCT) of the auditory system in schizophrenia has been shown to improve cognition, but its impact on thalamocortical connectivity is not known. Here we examined thalamocortical connections that may be neuroplastic in response to TCT using a region of interest (ROI) approach. Participants were randomly assigned to either 40 h of TCT (N = 24) or an active control condition (CG; N = 20). Participants underwent resting state fMRI and cognitive testing both before and after training. Changes in thalamocortical connectivity were measured in 15 ROIs derived from a previous study comparing a large sample of schizophrenia subjects with healthy controls. A significant group by time interaction was observed in a left superior temporal ROI which was previously found to exhibit thalamocortical hyper-connectivity in patients with schizophrenia. Changes in this ROI reflected thalamic connectivity increases in the TCT group, while the CG group showed decreases. Additionally, the relationship between connectivity change and change in global cognition showed a slope difference between groups, with increases in thalamo-temporal connectivity correlating with improvements in global cognition in TCT. No significant relationships were observed with changes in clinical symptoms or functioning. These findings demonstrate that TCT may influence intrinsic functional connections in young individuals with schizophrenia, such that improvements in cognition correspond to compensatory increases in connectivity in a temporal region previously shown to exhibit thalamic hyper-connectivity.",2020,A significant group by time interaction was observed in a left superior temporal ROI which was previously found to exhibit thalamocortical hyper-connectivity in patients with schizophrenia.,"['patients with schizophrenia', 'Patients with schizophrenia', 'schizophrenia subjects with healthy controls', 'young individuals with schizophrenia']","['Targeted cognitive training (TCT', 'TCT']","['clinical symptoms or functioning', 'connectivity change and change in global cognition', 'thalamic connectivity', 'thalamocortical connectivity', 'time interaction']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0677634', 'cui_str': 'Reptilase Time'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}]",,0.0173449,A significant group by time interaction was observed in a left superior temporal ROI which was previously found to exhibit thalamocortical hyper-connectivity in patients with schizophrenia.,"[{'ForeName': 'Ian S', 'Initials': 'IS', 'LastName': 'Ramsay', 'Affiliation': 'University of Minnesota, Department of Psychiatry, USA. Electronic address: ramsa045@umn.edu.'}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Roach', 'Affiliation': 'Veterans Affairs Medical Center San Francisco, USA.'}, {'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Fryer', 'Affiliation': 'University of California, San Francisco Department of Psychiatry, USA; Veterans Affairs Medical Center San Francisco, USA.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Fisher', 'Affiliation': 'University of Minnesota, Department of Psychiatry, USA.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Loewy', 'Affiliation': 'University of California, San Francisco Department of Psychiatry, USA.'}, {'ForeName': 'Judith M', 'Initials': 'JM', 'LastName': 'Ford', 'Affiliation': 'University of California, San Francisco Department of Psychiatry, USA; Veterans Affairs Medical Center San Francisco, USA.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Vinogradov', 'Affiliation': 'University of Minnesota, Department of Psychiatry, USA.'}, {'ForeName': 'Daniel H', 'Initials': 'DH', 'LastName': 'Mathalon', 'Affiliation': 'University of California, San Francisco Department of Psychiatry, USA; Veterans Affairs Medical Center San Francisco, USA.'}]",Schizophrenia research,['10.1016/j.schres.2020.01.020'] 1076,32428937,"Phenolic-rich Pomegranate Peel Extract: In Vitro, Cellular, and In Vivo Activities for Skin Hyperpigmentation Treatment.","The pomegranate phenolics are reported to have cutaneous benefits and to be effective in treating skin disorders, including hyperpigmentation. In this context, a preparation method was developed by which to obtain phenolic-rich pomegranate peel extract. Sinapic acid was presented as the major pomegranate peel phenolics, followed by gallic and ellagic acids, and 4 additional phenolics. The extract exhibited strong antioxidant activity with an in vitro tyrosinase inhibitory effect. The skin hyperpigmentation treating potency was confirmed by the suppression of cellular melanogenesis through tyrosinase and TRP-2 inhibitions as examined in the B16F10 melanoma cells. Cellular antioxidant and proliferative activities of the extract toward human dermal fibroblasts were evidenced, as well as an inhibitory effect against MMP-2. The extract was developed into the stable serum and mask. The products were proved to be non-irritated in 30 Thai volunteers participating in a single application closed patch test. A split-face, randomized, double-blind, placebo-controlled test of the skin lightening effect was evaluated in the 30 volunteers over 28 consecutive daily treatments and monitored by the Mexameter MX 18. The active serum and mask were better in facial skin lightening efficacy than the placebo (p < 0.005). That was in accordance with the sensory evaluation scored by the volunteers. Phenolic-rich pomegranate peel extract is evidenced as a safe herbal derived material promising for skin hyperpigmentation treatment. Supportive information regarding chemical and biological profiles is presented with the confirmed safety and cutaneous benefits in volunteers.",2020,The active serum and mask were better in facial skin lightening efficacy than the placebo (p < 0.005).,"['volunteers', '30 volunteers over 28 consecutive daily treatments and monitored by the Mexameter MX 18', '30 Thai volunteers participating in a single application closed patch test']","['Phenolic-rich Pomegranate Peel Extract', 'Phenolic-rich pomegranate peel extract', 'placebo']","['facial skin lightening efficacy', 'Cellular antioxidant and proliferative activities']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0039724', 'cui_str': 'Thai language'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0030646', 'cui_str': 'Patch test'}]","[{'cui': 'C0359916', 'cui_str': 'Substance with phenol structure'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C1509685', 'cui_str': 'POMEGRANATE FRUIT EXTRACT'}, {'cui': 'C0237849', 'cui_str': 'Peeling of skin'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0222084', 'cui_str': 'Skin structure of face'}, {'cui': 'C1306868', 'cui_str': 'Lightening of fetus'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0334094', 'cui_str': 'Proliferation'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",30.0,0.0547414,The active serum and mask were better in facial skin lightening efficacy than the placebo (p < 0.005).,"[{'ForeName': 'Mayuree', 'Initials': 'M', 'LastName': 'Kanlayavattanakul', 'Affiliation': 'School of Cosmetic Science, Mae Fah Luang University, Chiang Rai, Thailand.'}, {'ForeName': 'Wichayada', 'Initials': 'W', 'LastName': 'Chongnativisit', 'Affiliation': 'School of Cosmetic Science, Mae Fah Luang University, Chiang Rai, Thailand.'}, {'ForeName': 'Puxvadee', 'Initials': 'P', 'LastName': 'Chaikul', 'Affiliation': 'School of Cosmetic Science, Mae Fah Luang University, Chiang Rai, Thailand.'}, {'ForeName': 'Nattaya', 'Initials': 'N', 'LastName': 'Lourith', 'Affiliation': 'School of Cosmetic Science, Mae Fah Luang University, Chiang Rai, Thailand.'}]",Planta medica,['10.1055/a-1170-7785'] 1077,31509319,"Fish skin grafts compared to human amnion/chorion membrane allografts: A double-blind, prospective, randomized clinical trial of acute wound healing.","Chronic, nonhealing wounds consume a great deal of healthcare resources and are a major public health problem, associated with high morbidity and significant economic costs. Skin grafts are commonly used to facilitate wound closure. The grafts can come from the patient's own skin (autograft), a human donor (allograft), or from a different species (xenograft). A fish skin xenograft from cold-water fish (Atlantic cod, Gadus morhua) is a relatively recent option that shows promising preclinical and clinical results in wound healing. Chronic wounds vary greatly in etiology and nature, requiring large cohorts for effective comparison between therapeutic alternatives. In this study, we attempted to imitate the status of a freshly debrided chronic wound by creating acute full-thickness wounds, 4 mm in diameter, on healthy volunteers to compare two materials frequently used to treat chronic wounds: fish skin and dHACM. The purpose is to give an indication of the efficacy of the two therapeutic alternatives in the treatment of chronic wounds in a simple, standardized, randomized, controlled, double-blind study. All volunteers were given two identical punch biopsy wounds, one of which was treated with a fish skin graft and the other with dehydrated human amnion/chorion membrane allograft (dHACM). In the study, 170 wounds were treated (85 wounds per group). The primary endpoint was defined as time to heal (full epithelialization) by blinded assessment at days 14, 18, 21, 25, and 28. The superiority hypothesis was that the fish skin grafts would heal the wounds faster than the dHACM. To evaluate the superiority hypothesis, a mixed Cox proportional hazard model was used. Wounds treated with fish skin healed significantly faster (hazard ratio 2.37; 95% confidence interval: (1.75-3.22; p = 0.0014) compared with wounds treated with dHACM. The results show that acute biopsy wounds treated with fish skin grafts heal faster than wounds treated with dHACM.",2020,Wounds treated with fish skin healed significantly faster (hazard ratio 2.37; 95% confidence interval: (1.75-3.22; p = 0.0014) compared with wounds treated with dHACM.,['healthy volunteers'],"['fish-skin graft and the other with dehydrated human amnion/chorion membrane allograft (dHACM', 'Fish-Skin Grafts', 'Human Amnion/Chorion Membrane Allografts', 'skin and dHACM', 'dHACM']",['time to heal (full epithelialization'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0020758', 'cui_str': 'Ichthyosis Congenita'}, {'cui': 'C1527362', 'cui_str': 'grafts'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0002630', 'cui_str': 'Amniotic Membrane'}, {'cui': 'C0008503', 'cui_str': 'Chorion'}, {'cui': 'C0025255', 'cui_str': 'Membranes'}, {'cui': 'C0450127', 'cui_str': 'Allogeneic Grafts'}, {'cui': 'C1123023', 'cui_str': 'Skin'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205249', 'cui_str': 'Healed (qualifier value)'}, {'cui': 'C0334029', 'cui_str': 'Epithelialization (morphologic abnormality)'}]",170.0,0.0686379,Wounds treated with fish skin healed significantly faster (hazard ratio 2.37; 95% confidence interval: (1.75-3.22; p = 0.0014) compared with wounds treated with dHACM.,"[{'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Kirsner', 'Affiliation': 'Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Margolis', 'Affiliation': 'Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.'}, {'ForeName': 'Baldur T', 'Initials': 'BT', 'LastName': 'Baldursson', 'Affiliation': 'Department of Dermatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Petursdottir', 'Affiliation': 'Department of Dermatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland.'}, {'ForeName': 'Olafur B', 'Initials': 'OB', 'LastName': 'Davidsson', 'Affiliation': 'Mathematics Division of the Science Institute, University of Iceland, Reykjavik, Iceland.'}, {'ForeName': 'Dot', 'Initials': 'D', 'LastName': 'Weir', 'Affiliation': 'Catholic Health Advanced Wound Healing Centers, Buffalo, New York.'}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Lantis', 'Affiliation': ""Division of Vascular/Endovascular Surgery, Mount Sinai St. Luke's-West Hospitals, Icahn School of Medicine, New York, New York.""}]",Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society,['10.1111/wrr.12761'] 1078,15712819,Culturally appropriate breast health educational intervention program for African-American women.,"The purpose of this study was to provide a culturally specific intervention program for African-American women to alter selected behavioral risk factors, psychosocial responses, and breast self-care variables. Two primary directional hypotheses were tested with an alpha set at 0.05. These hypotheses were: (1) a Culturally Appropriate Breast Educational Intervention Program (CABHEIP) will lower selected behavioral risk factors (high fat intake, inadequate amount of physical activity, inadequate fiber intake) and selected psychosocial responses (perceived stress, negative coping, low self-efficacy, perceived barriers to Breast Self Examination [BSE] and Clinical Breast Examination [CBE]) in African-American women, 20 to 40 years of age, who participate in the program as compared to whose who do not participate; and (2) a CABHEIP will raise compliance with BSE, proficiency of BSE, and perceived benefits of BSE and CBE in African-American women, 20 to 40 years of age, who participate in the program as compared to those who do not participate. A sample of 120 (N = 120) African-American women was randomly assigned to the control and treatment groups (60 women per group; (n = 60 intervention group; n = 60 attention control group). The sample was obtained from a population of African-American women from four southern and three central Mississippi counties. The intervention group, in clusters of 3 to 9 women, received education on breast cancer, breast self-exams, healthy eating, exercise, and stress management; and heard stories from breast cancer survivors. The attention control group, in clusters of 3 to 8 women, received education on poison control in the home environment. Data was collected and analyzed using descriptive statistics, correlation coefficients, and repeated measures of analysis of covariance (ANCOVA) controlling for covariates. Significant differences between groups for BSE proficiency I (p < 0.0001), BSE proficiency II (p = 0.013), and benefit BSE (p = 0.053) were found. Compliance for BSE approached significance between groups (p = 0.053). Significance to nursing is that education can change outcomes in health promotion for breast cancer in African-American women. Further studies with similar interventions and larger sample sizes are needed to determine other avenues to decrease modifiable risk factors for breast cancer in African-American women.",2004,"Significant differences between groups for BSE proficiency I (p < 0.0001), BSE proficiency II (p = 0.013), and benefit BSE (p = 0.053) were found.","['African-American women from four southern and three central Mississippi counties', 'A sample of 120 (N = 120) African-American women', 'African-American women', 'African-American women, 20 to 40 years of age, who participate in the program as compared to whose who do not participate; and (2) a CABHEIP will raise compliance with BSE, proficiency of BSE, and perceived benefits of BSE and CBE in African-American women, 20 to 40 years of age, who participate in the program as compared to those who do not participate']","['Clinical Breast Examination [CBE', 'education on poison control in the home environment', 'Culturally Appropriate Breast Educational Intervention Program (CABHEIP', 'culturally specific intervention program', 'education on breast cancer, breast self-exams, healthy eating, exercise, and stress management; and heard stories from breast cancer survivors', 'Culturally appropriate breast health educational intervention program', '60 intervention group; n = 60 attention control group']",['benefit BSE'],"[{'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0026221', 'cui_str': 'Mississippi'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0442818', 'cui_str': 'Raised (qualifier value)'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0199850', 'cui_str': 'Examination of breast (procedure)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0032344', 'cui_str': 'poisoning'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0452415', 'cui_str': 'Healthy Diet'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0150788', 'cui_str': 'Manage stress control'}, {'cui': 'C0018767', 'cui_str': 'Audition'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],120.0,0.0189149,"Significant differences between groups for BSE proficiency I (p < 0.0001), BSE proficiency II (p = 0.013), and benefit BSE (p = 0.053) were found.","[{'ForeName': 'Mary Ann', 'Initials': 'MA', 'LastName': 'Kelley', 'Affiliation': 'Capstone College of Nursing, University of Alabama, Tuscaloosa, AL 35487-0358, USA. mkelley@bama.ua.edu'}]",Journal of National Black Nurses' Association : JNBNA,[] 1079,32436085,A Trinity regimen with aflibercept for treatment-naïve neovascular age-related macular degeneration: 2-year outcomes.,"PURPOSE To evaluate the advantages of the Trinity regimen for treatment-naïve neovascular age-related macular degeneration (nAMD). METHODS Thirty-one treatment-naïve nAMD eyes were treated using the Trinity regimen with an intravitreal aflibercept injection (IVA) and evaluated after 24 months. Three treatment methods, pro re nata (PRN), treat and extend (TAE), and fixed regimen were changed depending on recurrence frequency. After the initial treatment, PRN or TAE (started for 4 or 8 weeks) was selected as per the recurrence interval. Subsequently, the recurrence interval became constant, transitioning from a TAE to fixed regimen. When the recurrence frequency became irregular, the treatment regimen was changed to TAE. RESULTS After the initial treatment, 15 eyes (48.4%) were allocated to the PRN group, 12 (38.7%) to the TAE 8-week group, and 4 (12.9%) to the TAE 4-week group. Mean logMAR significantly improved in all cases, 0.53 ± 0.40 at baseline to 0.36 ± 0.34 at 24 months (p < 0.01), in the PRN group (0.63 ± 0.46 to 0.42 ± 0.43, p < 0.01), and the TAE 8-week group (0.44 ± 0.29 to 0.27 ± 0.19, p < 0.05). LogMAR in the TAE 4-week group was maintained. The mean number of injections for all and in the PRN, TAE 8-week, and TAE 4-week groups were 9.7, 5.3, 13.1, and 15.8, respectively, with the PRN group being significantly less (p < 0.01). CONCLUSION The Trinity regimen delivered the benefits of the PRN, TAE, and FIXED regimens while minimizing injections during the early treatment phase without visual loss. TRIAL REGISTRATION This trial was registered with the University Hospital Medical Information Network (UMIN ID: 000038335).",2020,"Mean logMAR significantly improved in all cases, 0.53 ± 0.40 at baseline to 0.36 ± 0.34 at 24 months (p < 0.01), in the PRN group (0.63 ± 0.46 to 0.42 ± 0.43, p < 0.01), and the TAE 8-week group (0.44 ± 0.29 to 0.27 ± 0.19, p < 0.05).","['treatment-naïve neovascular age-related macular degeneration', 'treatment-naïve neovascular age-related macular degeneration (nAMD', 'Thirty-one', 'treatment-naïve nAMD eyes']","['intravitreal aflibercept injection (IVA', 'aflibercept', 'PRN or TAE']","['Mean logMAR', 'mean number of injections']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0271084', 'cui_str': 'Exudative age-related macular degeneration'}, {'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}]","[{'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C4050106', 'cui_str': 'aflibercept Injection'}, {'cui': 'C0268575', 'cui_str': 'Isovaleryl-CoA dehydrogenase deficiency'}, {'cui': 'C1134659', 'cui_str': 'aflibercept'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0067792', 'cui_str': 'N-acetyltryptophanamide'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]",,0.0281063,"Mean logMAR significantly improved in all cases, 0.53 ± 0.40 at baseline to 0.36 ± 0.34 at 24 months (p < 0.01), in the PRN group (0.63 ± 0.46 to 0.42 ± 0.43, p < 0.01), and the TAE 8-week group (0.44 ± 0.29 to 0.27 ± 0.19, p < 0.05).","[{'ForeName': 'Makiko', 'Initials': 'M', 'LastName': 'Wakuta', 'Affiliation': 'Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube City, Yamaguchi, 755-0046, Japan.'}, {'ForeName': 'Nanami', 'Initials': 'N', 'LastName': 'Nomi', 'Affiliation': 'JCHO Shimonoseki Medical Center, Shimonoseki, Japan.'}, {'ForeName': 'Tadahiko', 'Initials': 'T', 'LastName': 'Ogata', 'Affiliation': 'Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube City, Yamaguchi, 755-0046, Japan.'}, {'ForeName': 'Manami', 'Initials': 'M', 'LastName': 'Ota', 'Affiliation': 'Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube City, Yamaguchi, 755-0046, Japan.'}, {'ForeName': 'Chiemi', 'Initials': 'C', 'LastName': 'Yamashiro', 'Affiliation': 'Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube City, Yamaguchi, 755-0046, Japan.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Hatano', 'Affiliation': 'Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube City, Yamaguchi, 755-0046, Japan.'}, {'ForeName': 'Ryoji', 'Initials': 'R', 'LastName': 'Yanai', 'Affiliation': 'Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube City, Yamaguchi, 755-0046, Japan.'}, {'ForeName': 'Kazuhiro', 'Initials': 'K', 'LastName': 'Tokuda', 'Affiliation': 'Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube City, Yamaguchi, 755-0046, Japan.'}, {'ForeName': 'Kazuhiro', 'Initials': 'K', 'LastName': 'Kimura', 'Affiliation': 'Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube City, Yamaguchi, 755-0046, Japan. k.kimura@yamaguchi-u.ac.jp.'}]",Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,['10.1007/s00417-020-04745-1'] 1080,30883357,Rationale and Design of a Clinical Trial of Adapted Tango to Improve Negative Health Impacts in Middle Aged African-American Female Caregivers of Persons with Alzheimer's Disease (ACT Trial).,"Alzheimer's disease (AD) is a devastating progressive neurodegenerative disease resulting in memory loss and a severe reduction in ability to perform activities of daily living. The role of caring for someone with AD frequently falls to female family members, often daughters. The burden of caregiving can increase stress and anxiety and cause health decline in the caregiver. The combination of ethnicity-related genetic factors promoting the development of dementias among African-Americans (AA) and the increased risk among women for developing AD means that AA women who are caregivers of a parent with AD are at great risk for developing dementias including AD. The proposed study would compare the cognitive, motor, and psychosocial benefits of a well-established 12 week, 20-lesson adapted Argentine Tango intervention (N = 30) to a no-contact control group (N = 10) in middle-aged (45-65 years) AA women who are caregivers of a parent with AD in the metro Atlanta area.",2019,The combination of ethnicity-related genetic factors promoting the development of dementias among African-Americans (AA) and the increased risk among women for developing AD means that AA women who are caregivers of a parent with AD are at great risk for developing dementias including AD.,"[""Alzheimer's disease (AD"", ""Middle Aged African-American Female Caregivers of Persons with Alzheimer's Disease (ACT Trial"", 'AA women who are caregivers of a parent with AD in the metro Atlanta area', 'group (N\u200a=\u200a10) in middle-aged (45-65 years']","['20-lesson adapted Argentine Tango intervention', 'no-contact control']",['Negative Health Impacts'],"[{'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C0205847', 'cui_str': 'Middle Aged'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}]",,0.0430654,The combination of ethnicity-related genetic factors promoting the development of dementias among African-Americans (AA) and the increased risk among women for developing AD means that AA women who are caregivers of a parent with AD are at great risk for developing dementias including AD.,"[{'ForeName': 'Madeleine E', 'Initials': 'ME', 'LastName': 'Hackney', 'Affiliation': 'Department of Medicine, Division of General Medicine and Geriatrics, Emory School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'McCullough', 'Affiliation': 'Emory University Rollins School of Public Health, Atlanta, GA, USA.'}, {'ForeName': 'Allison A', 'Initials': 'AA', 'LastName': 'Bay', 'Affiliation': 'Department of Medicine, Division of General Medicine and Geriatrics, Emory School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Hayley A', 'Initials': 'HA', 'LastName': 'Silverstein', 'Affiliation': 'Department of Medicine, Division of General Medicine and Geriatrics, Emory School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Ariel R', 'Initials': 'AR', 'LastName': 'Hart', 'Affiliation': 'Department of Medicine, Division of General Medicine and Geriatrics, Emory School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Ryan J', 'Initials': 'RJ', 'LastName': 'Shin', 'Affiliation': 'Emory University College of Arts and Sciences, Atlanta, GA, USA.'}, {'ForeName': 'Whitney', 'Initials': 'W', 'LastName': 'Wharton', 'Affiliation': 'Department of Neurology, Atlanta, Emory University School of Medicine, GA, USA.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-181130'] 1081,32077140,The effects of meclizine on motion sickness revisited.,"AIMS Antihistamines make up the first line of treatments against motion-sickness. Still, their efficacy and specific mechanism have come into question. The aim of this study was to investigate the effect of meclizine on motion-sensitivity. METHODS This study was carried out as a triple-blinded randomized trial involving 12 healthy subjects who were exposed to (i) vestibular (VES), (ii) visual (VIS) and (iii) visual-vestibular (VIS+VES) stimulations in the roll plane. Subjects were divided into 2 groups by stratified randomization, receiving either meclizine or a placebo. Stimulations were carried out before, and after, drug administration, presented at 2 intensity levels of 14 and 28°/s 2 . Eye movements were tracked, and torsional slow-phase velocities, amplitudes and nystagmus beats were retrieved. Subjects initially graded for their motion-sickness susceptibility. RESULTS Susceptibility had no effect on intervention outcome. Despite large variations, repeated ANOVAS showed that meclizine led to a relative increase in torsional velocity compared to placebo during vestibular stimulation for both intensities: 2.36 (7.65) from -0.01 (4.17) during low intensities, and 2.61 (6.67) from -3.49 (4.76) during high. The visual-vestibular stimuli yielded a decrease during low acceleration, -0.40 (3.87) from 3.75 (5.62), but increased during high, 3.88 (6.51) from -3.88 (8.55). CONCLUSIONS Meclizine had an inhibitory effect on eye movement reflexes for low accelerations during VIS+VES trials. This indicates that meclizine may not primarily work through sensory-specific mechanisms, but rather on a more central level. Practically, meclizine shows promise in targeting motion-sickness evoked by everyday activities, but its use may be counterproductive in high-acceleration environments.",2020,"CONCLUSIONS Meclizine had an inhibitory effect on eye movement reflexes for low accelerations during VIS+VES trials.","['12 healthy subjects who were exposed to i) vestibular (VES), ii) visual (VIS), and iii) visual-vestibular (VIS+VES) stimulations in the roll plane', 'Subjects initially graded their motion-sickness susceptibility']","['placebo', 'Meclizine or a placebo', 'Meclizine']","['eye movement reflexes', 'torsional slow-phase velocities, amplitudes and nystagmus beats', 'torsional velocity', 'motion-sensitivity']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0026603', 'cui_str': 'Motion Sickness'}, {'cui': 'C1264642', 'cui_str': 'Susceptibility (property) (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0025039', 'cui_str': 'meclozine'}]","[{'cui': 'C0015413', 'cui_str': 'Eye Movements'}, {'cui': 'C0034929', 'cui_str': 'Reflex'}, {'cui': 'C0450425', 'cui_str': 'Torsional (qualifier value)'}, {'cui': 'C0439834', 'cui_str': 'Slowly'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0028738', 'cui_str': 'Nystagmus, Pathologic'}, {'cui': 'C0687704', 'cui_str': 'Motions (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}]",12.0,0.132329,"CONCLUSIONS Meclizine had an inhibitory effect on eye movement reflexes for low accelerations during VIS+VES trials.","[{'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Wibble', 'Affiliation': 'Department of Clinical Neuroscience, Division of Ophthalmology and Vision, Marianne Bernadotte Centre, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Engström', 'Affiliation': 'Department of Clinical Neuroscience, Division of Ophthalmology and Vision, Marianne Bernadotte Centre, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Verrecchia', 'Affiliation': 'Department of Clinical Neuroscience, Division of Ophthalmology and Vision, Marianne Bernadotte Centre, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Pansell', 'Affiliation': 'Department of Clinical Neuroscience, Division of Ophthalmology and Vision, Marianne Bernadotte Centre, Karolinska Institutet, Stockholm, Sweden.'}]",British journal of clinical pharmacology,['10.1111/bcp.14257'] 1082,32429737,Effects of Montmorency Tart Cherry Juice Consumption on Cardiometabolic Biomarkers in Adults with Metabolic Syndrome: A Randomized Controlled Pilot Trial.,"Greater than one-third of adults in the United States have metabolic syndrome (MetS), a cluster of risk factors highly associated with the development of cardiovascular diseases. Premature vascular dysfunction in MetS may lead to accelerated age-related atherogenesis and arterial stiffening, thereby increasing cardiovascular risk. Montmorency tart cherries ( Prunus cerasus L.) are rich in bioactive compounds, such as anthocyanins, known to exert cardiovascular protective effects. Previous research suggests that tart cherry juice consumption may improve cardiovascular health. The objective of this study was to evaluate the effects of daily consumption of tart cherry juice on hemodynamics, arterial stiffness, and blood biomarkers of cardiovascular and metabolic health in men and women with MetS. In a randomized, single-blind, placebo-controlled, parallel-arm pilot clinical trial, 19 men and women 20 to 60 years of age with MetS consumed 240 mL of tart cherry juice (Tart Cherry; n  = 5 males, 4 females) or an isocaloric placebo-control drink (Control; n  = 5 males, 5 females) twice daily for 12 weeks. Arterial stiffness (pulse wave velocity), brachial and aortic blood pressures, wave reflection (augmentation index), and blood biomarkers of cardiovascular and metabolic health were assessed at baseline and 6 and 12 weeks. Oxidized low-density lipoprotein and soluble vascular cell adhesion molecule-1 were significantly lower ( P  = .047 and P  = .036, respectively) in Tart Cherry than Control at 12 weeks, but were not significantly lower than baseline values. There was a trend for total cholesterol to be lower ( P  = .08) in Tart Cherry than Control at 12 weeks. No significant changes were observed in hemodynamics, arterial stiffness, or other blood biomarkers assessed. These results suggest that daily tart cherry consumption may attenuate processes involved in accelerated atherogenesis without affecting hemodynamics or arterial stiffness parameters in this population. The pilot nature of this study warrants interpreting these findings with caution, and future clinical trials with a larger sample size are needed to confirm these findings.",2020,"Oxidized low-density lipoprotein and soluble vascular cell adhesion molecule-1 were significantly lower ( P  = .047 and P  = .036, respectively) in Tart Cherry than Control at 12 weeks, but were not significantly lower than baseline values.","['men and women with MetS', 'Adults with Metabolic Syndrome', '19 men and women 20 to 60 years of age with MetS consumed 240\u2009mL of tart cherry juice (Tart Cherry; n \u2009=\u20095 males, 4 females) or an']","['isocaloric placebo-control drink (Control; n \u2009=\u20095 males, 5 females) twice daily for 12 weeks', 'Montmorency Tart Cherry Juice Consumption', 'daily consumption of tart cherry juice', 'placebo']","['Oxidized low-density lipoprotein and soluble vascular cell adhesion molecule-1', 'hemodynamics, arterial stiffness, or other blood biomarkers assessed', 'cardiovascular health', 'total cholesterol', 'hemodynamics, arterial stiffness, and blood biomarkers of cardiovascular and metabolic health', 'Arterial stiffness (pulse wave velocity), brachial and aortic blood pressures, wave reflection (augmentation index), and blood biomarkers of cardiovascular and metabolic health', 'Cardiometabolic Biomarkers']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0982074', 'cui_str': 'CHERRY JUICE'}, {'cui': 'C0330657', 'cui_str': 'Prunus cerasus'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0982074', 'cui_str': 'CHERRY JUICE'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0348035', 'cui_str': 'Oxidized low density lipoprotein'}, {'cui': 'C0078056', 'cui_str': 'Lymphocyte antigen CD106'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0456180', 'cui_str': 'Aortic pressure'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",19.0,0.103495,"Oxidized low-density lipoprotein and soluble vascular cell adhesion molecule-1 were significantly lower ( P  = .047 and P  = .036, respectively) in Tart Cherry than Control at 12 weeks, but were not significantly lower than baseline values.","[{'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'Johnson', 'Affiliation': 'Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, Colorado, USA.'}, {'ForeName': 'Negin', 'Initials': 'N', 'LastName': 'Navaei', 'Affiliation': 'Department of Nutrition, Food, and Exercise Sciences, Florida State University, Tallahassee, Florida, USA.'}, {'ForeName': 'Shirin', 'Initials': 'S', 'LastName': 'Pourafshar', 'Affiliation': 'Department of Nutrition, Food, and Exercise Sciences, Florida State University, Tallahassee, Florida, USA.'}, {'ForeName': 'Salvador J', 'Initials': 'SJ', 'LastName': 'Jaime', 'Affiliation': 'Department of Nutrition, Food, and Exercise Sciences, Florida State University, Tallahassee, Florida, USA.'}, {'ForeName': 'Neda S', 'Initials': 'NS', 'LastName': 'Akhavan', 'Affiliation': 'Department of Nutrition, Food, and Exercise Sciences, Florida State University, Tallahassee, Florida, USA.'}, {'ForeName': 'Stacey', 'Initials': 'S', 'LastName': 'Alvarez-Alvarado', 'Affiliation': 'Department of Nutrition, Food, and Exercise Sciences, Florida State University, Tallahassee, Florida, USA.'}, {'ForeName': 'Gabriela V', 'Initials': 'GV', 'LastName': 'Proaño', 'Affiliation': 'Department of Nutrition, Food, and Exercise Sciences, Florida State University, Tallahassee, Florida, USA.'}, {'ForeName': 'Nicole S', 'Initials': 'NS', 'LastName': 'Litwin', 'Affiliation': 'Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, Colorado, USA.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Clark', 'Affiliation': 'Department of Nutrition, Food, and Exercise Sciences, Florida State University, Tallahassee, Florida, USA.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Foley', 'Affiliation': 'Department of Nutrition, Food, and Exercise Sciences, Florida State University, Tallahassee, Florida, USA.'}, {'ForeName': 'Kelli S', 'Initials': 'KS', 'LastName': 'George', 'Affiliation': 'Department of Nutrition, Food, and Exercise Sciences, Florida State University, Tallahassee, Florida, USA.'}, {'ForeName': 'Marcus L', 'Initials': 'ML', 'LastName': 'Elam', 'Affiliation': 'Department of Human Nutrition and Food Science, California State Polytechnic University, Pomona, California, USA.'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Payton', 'Affiliation': 'Department of Statistics, Oklahoma State University, Stillwater, Oklahoma, USA.'}, {'ForeName': 'Bahram H', 'Initials': 'BH', 'LastName': 'Arjmandi', 'Affiliation': 'Department of Nutrition, Food, and Exercise Sciences, Florida State University, Tallahassee, Florida, USA.'}, {'ForeName': 'Arturo', 'Initials': 'A', 'LastName': 'Figueroa', 'Affiliation': 'Department of Nutrition, Food, and Exercise Sciences, Florida State University, Tallahassee, Florida, USA.'}]",Journal of medicinal food,['10.1089/jmf.2019.0240'] 1083,15853281,Senior nursing students respond to an HIV experiential-teaching method with an African-American female.,"This experimental study compared an HIV experiential-teaching method to the traditional lecture and discussion method to determine if one method was more likely to produce significant indications of senior nursing students' willingness and perceived preparedness to provide HIV-patient care to affected clients. The sample included 70 (N = 70) baccalaureate senior nursing students from one university. In this study, 35 (n = 35) students were randomized into either the experimental group or into the control lecture and discussion group (n = 351 Unlike the traditional lecture and discussion method, the experiential-teaching method entitled ""To be Touched by AIDS"" included an affective component with an African-American female who was an HIV-Positive intravenous drug user. Findings from this study indicated that the experiential-teaching method was efficacious in increasing willingness to provide HIV patient care to affected clients using a Wilcoxon (Z = -251 p< 0.05) test as compared to the traditional lecture and discussion method of teaching Further findings from this study also suggested that there was a weak inverse correlation found using a Spearman Rho. Nonetheless, there was a statistically significant relationship between perceived preparedness and willingness to provide care to affected HIV clients (r(s) = -0.26, p = 0.05) in the experiential-teaching group as compared to the traditional lecture and discussion group. It is plausible to assume that in light of these statistical findings, nurse educators need to incorporate components of HIV experiential-teaching methods in an effort to assist future nurses. These experiential-teaching methods, such as situational role-playing and patients recollections of lived experiences as HIV-Positive individuals would aid future nurses in providing optimal healthcare to all patients, but particularly to those who are HIV-Positive.",2004,"-0.26, p = 0.05) in the experiential-teaching group as compared to the traditional lecture and discussion group.","['The sample included 70 (N = 70) baccalaureate senior nursing students from one university', '35 (n = 35) students', 'Senior nursing students respond to an HIV experiential-teaching method with an African-American female', ""senior nursing students' willingness and perceived preparedness to provide HIV-patient care to affected clients""]","['control lecture and discussion group (n = 351 Unlike the traditional lecture and discussion method, the experiential-teaching method entitled ""To be Touched by AIDS"" included an affective component with an African-American female who was an HIV-Positive intravenous drug user']",[],"[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0038496', 'cui_str': 'Pupil Nurses'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0039403', 'cui_str': 'Teaching Methods'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0017313'}, {'cui': 'C0008942', 'cui_str': 'Clients'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0376683', 'cui_str': 'Lecture'}, {'cui': 'C0557061', 'cui_str': 'Discussion (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0039403', 'cui_str': 'Teaching Methods'}, {'cui': 'C0152054', 'cui_str': 'Therapeutic Touch'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}, {'cui': 'C0242566', 'cui_str': 'Intravenous drug user (finding)'}]",[],351.0,0.0148727,"-0.26, p = 0.05) in the experiential-teaching group as compared to the traditional lecture and discussion group.","[{'ForeName': 'Judith Bacchus', 'Initials': 'JB', 'LastName': 'Cornelius', 'Affiliation': 'University of Pennsylvania, Philadelphia, PA, USA. cornajas@aol.com'}]",Journal of National Black Nurses' Association : JNBNA,[] 1084,32436048,Is intracytoplasmic sperm (ICSI) better than traditional in vitro fertilization (IVF): confirmation of higher blastocyst rates per oocyte using a split insemination design.,"PURPOSE To explore the effects of traditional vs. intracytoplasmic sperm injection (ICSI) insemination method on the outcome of high-quality blastocyst development in a split sibling oocyte cohort. METHODS In this retrospective cohort study, we analyzed 62 ICSI/IVF split cycles. Sibling oocytes were randomly assigned to ICSI or IVF insemination. Two hundred thirty-four ICSI-only cycles and 152 IVF-only cycles were also analyzed for comparison. Blastocysts were graded by Gardner's embryo grading and were considered a high-quality blastocyst if 3BB or better (Gardner 1999). RESULTS In the ICSI/IVF split group, (1) ICSI oocytes had a higher fertilization rate per oocyte allocated (73% vs 62%, p < 0.001), (2) more high-quality day 2 embryos (69% vs 55%, p < 0.005), (3) ICSI oocytes had a lower blastulation rate per 2PN (46% vs 54%, p < 0.05), but a higher blastulation rate when calculated per oocyte allocated (40% vs 32%, p < 0.05). The ICSI-only group had a lower fertilization rate (65% vs 70%, p < 0.001) but more high-quality day 2 embryos in comparison to the IVF-only group (68% vs 64%, p < .05). The total high-quality blastulation rate was higher for the IVF-only group per 2PN (49% vs 43%, p < 0.05) and per oocyte retrieved (34% vs 28%, p < 0.05). CONCLUSIONS This distinctive IVF/ICSI sibling oocyte split design demonstrated a higher-quality blastulation rate in the IVF group compared to the ICSI group when calculated per 2PN, but not per oocyte allocated to each insemination procedure.",2020,"The ICSI-only group had a lower fertilization rate (65% vs 70%, p < 0.001) but more high-quality day 2 embryos in comparison to the IVF-only group (68% vs 64%, p < .05).","['Sibling oocytes', 'a split sibling oocyte cohort']","['ICSI', 'ICSI or IVF insemination', '2PN', 'traditional vs. intracytoplasmic sperm injection (ICSI) insemination method']","['fertilization rate', 'high-quality day 2 embryos', 'blastulation rate', 'quality blastulation rate', 'blastulation rate per 2PN', 'total high-quality blastulation rate']","[{'cui': 'C0029045', 'cui_str': 'Oocyte'}, {'cui': 'C0037047', 'cui_str': 'Sibling'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}]","[{'cui': 'C0455164', 'cui_str': 'IVF - In vitro fertilization with intracytoplasmic sperm injection (ICSI)'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C0021586', 'cui_str': 'Insemination'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0015914', 'cui_str': 'Fertilization'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0013935', 'cui_str': 'Embryos'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",,0.207194,"The ICSI-only group had a lower fertilization rate (65% vs 70%, p < 0.001) but more high-quality day 2 embryos in comparison to the IVF-only group (68% vs 64%, p < .05).","[{'ForeName': 'May-Tal', 'Initials': 'MT', 'LastName': 'Sauerbrun-Cutler', 'Affiliation': 'Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women & Infants Hospital, 90 plain street, Providence, RI, 02905, USA. msauerbruncutle@wihri.org.'}, {'ForeName': 'Warren J', 'Initials': 'WJ', 'LastName': 'Huber', 'Affiliation': 'The Fertility Institute of New Orleans, 4770 S I-10 Service Rd W Ste 201, Metairie, LA, 94087, USA.'}, {'ForeName': 'Phinnara', 'Initials': 'P', 'LastName': 'Has', 'Affiliation': 'Division of Research, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women & Infants Hospital, 90 Plain Street, Providence, RI, 02905, USA.'}, {'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Shen', 'Affiliation': 'Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women & Infants Hospital, 90 plain street, Providence, RI, 02905, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Hackett', 'Affiliation': 'Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women & Infants Hospital, 90 plain street, Providence, RI, 02905, USA.'}, {'ForeName': 'Ruben', 'Initials': 'R', 'LastName': 'Alvero', 'Affiliation': 'Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Stanford Medical School, 1195 W Fremont Ave, Sunnyvale, CA, 94087, USA.'}, {'ForeName': 'Shunping', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women & Infants Hospital, 90 plain street, Providence, RI, 02905, USA.'}]",Journal of assisted reproduction and genetics,['10.1007/s10815-020-01819-1'] 1085,32433510,A trial comparing continuous positive airway pressure (CPAP) devices in preterm infants.,"OBJECTIVE To test the hypothesis that infants born <30 weeks' gestation supported by Seattle-PAP will have lower rates of continuous positive airway pressure (CPAP) failure than infants supported with conventional, Fisher&Paykel-CPAP (FP-CPAP). STUDY DESIGN Randomized trial (3/2017-01/2019) at 5 NICUs. The primary outcome was CPAP failure; subgroup analyses (gestational age, receipt antenatal corticosteroids) were performed. RESULTS A total of 232 infants were randomized. Infants in the Seattle-PAP and FP-CPAP groups had mean gestational ages of 27.0 and 27.2 weeks, respectively. We observed no differences in rates of treatment failure between Seattle-PAP (40/112, 35.7%) and FP-CPAP (38/120, 31.7%; risk difference, 4.1%; 95% CI, -8.1-16.2; P = 0.51). Subgroup analysis indicated no differences in rates of CPAP failure. We observed no differences between the two groups in frequencies of adverse events or duration of respiratory support. CONCLUSIONS Among infants born <30 weeks' gestation, rates of CPAP failure did not differ between Seattle-PAP and FP-CPAP.",2020,"Among infants born <30 weeks' gestation, rates of CPAP failure did not differ between Seattle-PAP and FP-CPAP.","['232 infants were randomized', ""infants born <30 weeks' gestation"", 'preterm infants']",['continuous positive airway pressure (CPAP) devices'],"['rates of treatment failure', 'rates of CPAP failure', 'CPAP failure; subgroup analyses (gestational age, receipt antenatal corticosteroids', 'FP-CPAP', 'continuous positive airway pressure (CPAP) failure']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C2828394', 'cui_str': 'Antenatal'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}]",232.0,0.309661,"Among infants born <30 weeks' gestation, rates of CPAP failure did not differ between Seattle-PAP and FP-CPAP.","[{'ForeName': 'Carl H', 'Initials': 'CH', 'LastName': 'Backes', 'Affiliation': ""Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. Carl.backesjr@nationwidechildrens.org.""}, {'ForeName': 'Jennifer N', 'Initials': 'JN', 'LastName': 'Cooper', 'Affiliation': 'Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Notestine', 'Affiliation': ""Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Crystal M', 'Initials': 'CM', 'LastName': 'Alfred', 'Affiliation': 'Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Molly K', 'Initials': 'MK', 'LastName': 'Ball', 'Affiliation': 'Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Brian K', 'Initials': 'BK', 'LastName': 'Rivera', 'Affiliation': ""Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Jane M', 'Initials': 'JM', 'LastName': 'Lamp', 'Affiliation': ""Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Marzec', 'Affiliation': ""Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Stenger', 'Affiliation': 'Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Mohannad', 'Initials': 'M', 'LastName': 'Moallem', 'Affiliation': 'Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Randy R', 'Initials': 'RR', 'LastName': 'Miller', 'Affiliation': 'Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Apurwa', 'Initials': 'A', 'LastName': 'Naik', 'Affiliation': 'OhioHealth Grant Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Lindsey J', 'Initials': 'LJ', 'LastName': 'Beer', 'Affiliation': 'Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Howard', 'Affiliation': ""Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, WA, USA.""}, {'ForeName': 'Stephen E', 'Initials': 'SE', 'LastName': 'Welty', 'Affiliation': ""Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, WA, USA.""}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Peter Richardson', 'Affiliation': ""Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, WA, USA.""}, {'ForeName': 'Noah H', 'Initials': 'NH', 'LastName': 'Hillman', 'Affiliation': ""SSM Health, Cardinal Glennon Children's Hospital, St. Louis University, St. Louis, MO, USA.""}, {'ForeName': 'John A F', 'Initials': 'JAF', 'LastName': 'Zupancic', 'Affiliation': 'Division of Newborn Medicine, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Larissa I', 'Initials': 'LI', 'LastName': 'Stanberry', 'Affiliation': 'Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.'}, {'ForeName': 'Thomas N', 'Initials': 'TN', 'LastName': 'Hansen', 'Affiliation': ""Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, WA, USA.""}, {'ForeName': 'Charles V', 'Initials': 'CV', 'LastName': 'Smith', 'Affiliation': ""Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, WA, USA.""}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-020-0690-5'] 1086,31519516,"Complications and Adverse Events of Three Magnetic Resonance Imaging-based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial.","BACKGROUND Three techniques of magnetic resonance imaging (MRI)-based targeted biopsy (TB) of the prostate exist. There is no superiority regarding diagnostic efficacy of prostate cancer (PCa) detection. OBJECTIVE To compare adverse events (AEs) among three TB techniques and to evaluate the effect on urinary and erectile function. DESIGN, SETTING, AND PARTICIPANTS Post hoc analysis of a multicentre randomised controlled trial among men with negative systematic biopsy (SB) and suspicion of PCa. INTERVENTION In 234 patients, 3-T multiparametric MRI demonstrated PIRADS≥ 3 lesions, and patients were randomised 1:1:1 for TB: transrectal in-bore MRI TB (MRI-TB), transperineal MRI-transrectal ultrasound (TRUS) fusion TB (FUS-TB), and transrectal cognitive TRUS TB (COG-TB). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS AEs (Clavien-Dindo) were compared using Pearson chi-square test. Univariate logistic regression tests were performed for the number of cores, biopsy approach, and usage of anticoagulants. The participants filled in baseline and 30-d postbiopsy International Prostate Symptom Score (IPSS) and International Index of Erectile Function (IIEF-5) questionnaires. The delta between measurements was compared using one-way analysis of variance. RESULTS AND LIMITATIONS There were significant differences in minor AEs: 53% in MRI-TB, 71% in FUS-TB, and 85% in COG-TB (p < 0.001). The number of cores was associated with AEs (odds ratio [OR] 1.11 per extra biopsy [95% confidence interval {CI} 1.06-1.17, p < 0.001]). Anticoagulants were not associated with bleeding complications (OR 1.24 [95% CI 0.66-2.35, p = 0.5]). Transrectal approach (MRI-TB + COG-TB) increased the risk of any AE (OR 2.54 [95% CI 1.16-5.77, p < 0.05]) and nonsignificantly increased the risk of urinary tract infections (OR 3.69 [95% CI 0.46-168.4, p = 0.3]). Biopsy did not impact urinary (ΔIPSS 0.3, p = 0.1) and erectile function (ΔIIEF-5 -0.4, p = 0.5). The main limitation was that additional SB was performed in FUS-TB and COG-TB, and was omitted in MRI-TB, making comparison difficult. CONCLUSIONS There was a significant difference in minor AEs among groups. An increase in the number of cores increased the overall risk of AEs. A low AE occurrence in MRI-TB was likely caused by the omission of SB. Prostate biopsy did not impact self-reported urinary and erectile functions. PATIENT SUMMARY In this study, we compared the complication rates of three techniques of magnetic resonance imaging (MRI)-based targeted biopsy of the prostate. We found a significant difference in the occurrence of minor complication rates among three groups in favour of transrectal in-bore MRI targeted biopsy, likely caused by the omission of additional systematic biopsy in this group.",2019,"Biopsy did not impact urinary (ΔIPSS 0.3, p = 0.1) and erectile function (ΔIIEF-5 -0.4, p = 0.5).","['men with negative systematic biopsy (SB) and suspicion of PCa', 'Men with Prior Negative Biopsies', '234 patients, 3-T multiparametric MRI demonstrated PIRADS≥ 3 lesions, and patients']","['Transrectal approach (MRI-TB\u202f+\u202fCOG-TB', 'Magnetic Resonance Imaging-based Target Biopsy Techniques', 'magnetic resonance imaging (MRI)-based targeted biopsy of the prostate', 'magnetic resonance imaging (MRI)-based targeted biopsy (TB']","['erectile function', 'risk of any AE (OR', 'bleeding complications (OR', 'complication rates', 'occurrence of minor complication rates', 'overall risk of AEs', 'MRI TB (MRI-TB), transperineal MRI-transrectal ultrasound (TRUS) fusion TB (FUS-TB), and transrectal cognitive TRUS TB (COG-TB', 'postbiopsy International Prostate Symptom Score (IPSS) and International Index of Erectile Function (IIEF-5) questionnaires', 'risk of urinary tract infections']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0220922', 'cui_str': 'systematics'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0242114', 'cui_str': 'Suspicion'}, {'cui': 'C0030625', 'cui_str': 'PCA'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1097281', 'cui_str': '3-(DMP)-T'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}]","[{'cui': 'C0205518', 'cui_str': 'Transrectal approach (qualifier value)'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}]","[{'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0026193', 'cui_str': 'Minors'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0205500', 'cui_str': 'Perineal approach (qualifier value)'}, {'cui': 'C0373345', 'cui_str': 'Transrectal ultrasound'}, {'cui': 'C1293131', 'cui_str': 'Fusion procedure (procedure)'}, {'cui': 'C0205518', 'cui_str': 'Transrectal approach (qualifier value)'}, {'cui': 'C1998280', 'cui_str': 'International prostate symptom score (assessment scale)'}, {'cui': 'C2960541', 'cui_str': 'International index of erectile function'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}]",234.0,0.447051,"Biopsy did not impact urinary (ΔIPSS 0.3, p = 0.1) and erectile function (ΔIIEF-5 -0.4, p = 0.5).","[{'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Wegelin', 'Affiliation': 'Department of Urology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands. Electronic address: o.wegelin@antoniusziekenhuis.nl.'}, {'ForeName': 'Leonie', 'Initials': 'L', 'LastName': 'Exterkate', 'Affiliation': 'Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.'}, {'ForeName': 'Marloes', 'Initials': 'M', 'LastName': 'van der Leest', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.'}, {'ForeName': 'Johannes C', 'Initials': 'JC', 'LastName': 'Kelder', 'Affiliation': 'Department of Epidemiology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.'}, {'ForeName': 'J L H Ruud', 'Initials': 'JLHR', 'LastName': 'Bosch', 'Affiliation': 'Department of Urology, UMC, Utrecht, The Netherlands.'}, {'ForeName': 'Jelle O', 'Initials': 'JO', 'LastName': 'Barentsz', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.'}, {'ForeName': 'Diederik M', 'Initials': 'DM', 'LastName': 'Somford', 'Affiliation': 'Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.'}, {'ForeName': 'Harm H E', 'Initials': 'HHE', 'LastName': 'van Melick', 'Affiliation': 'Department of Urology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.'}]",European urology oncology,['10.1016/j.euo.2019.08.007'] 1087,32027841,A trial for post-exposure prophylaxis against henipaviruses.,,2020,,[],[],[],[],[],[],,0.0267004,,"[{'ForeName': 'Hossain M S', 'Initials': 'HMS', 'LastName': 'Sazzad', 'Affiliation': 'The Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia; icddr,b, Dhaka, Bangladesh. Electronic address: hsazzad@kirby.unsw.edu.au.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(19)30687-5'] 1088,31918579,"Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial.","Although Staphylococcus aureus is a common cause of bacteremia, treatment options are limited. The need for new therapies is particularly urgent for methicillin-resistant S. aureus bacteremia (SAB). Ceftobiprole is an advanced-generation, broad-spectrum cephalosporin with activity against both methicillin-susceptible and -resistant S. aureus . This is a Phase III, randomized, double-blind, active-controlled, parallel-group, multicenter, two-part study to establish the efficacy and safety of ceftobiprole compared with daptomycin in the treatment of SAB, including infective endocarditis. Anticipated enrollment is 390 hospitalized adult patients, aged ≥18 years, with confirmed or suspected complicated SAB. The primary end point is overall success rate. Target completion of the study is in the second half of 2021. Clinicaltrials.gov identifier: NCT03138733.",2020,The primary end point is overall success rate.,"['390 hospitalized adult patients, aged ≥18\xa0years, with confirmed or suspected complicated SAB', 'Staphylococcus aureus bacteremia']","['Ceftobiprole versus daptomycin', 'daptomycin', 'ceftobiprole']","['overall success rate', 'efficacy and safety']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C1142423', 'cui_str': 'Bacteremia caused by Staphylococcus aureus'}]","[{'cui': 'C1100584', 'cui_str': 'ceftobiprole'}, {'cui': 'C0057144', 'cui_str': 'Daptomycin'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",390.0,0.557965,The primary end point is overall success rate.,"[{'ForeName': 'Kamal', 'Initials': 'K', 'LastName': 'Hamed', 'Affiliation': 'Basilea Pharmaceutica International Ltd, Basel, Switzerland.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Engelhardt', 'Affiliation': 'Basilea Pharmaceutica International Ltd, Basel, Switzerland.'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Jones', 'Affiliation': 'Basilea Pharmaceutica International Ltd, Basel, Switzerland.'}, {'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Saulay', 'Affiliation': 'Basilea Pharmaceutica International Ltd, Basel, Switzerland.'}, {'ForeName': 'Thomas L', 'Initials': 'TL', 'LastName': 'Holland', 'Affiliation': 'Department of Medicine, Duke University Medical Center & Duke Clinical Research Institute, Durham, NC, USA.'}, {'ForeName': 'Harald', 'Initials': 'H', 'LastName': 'Seifert', 'Affiliation': 'Institute for Medical Microbiology, Immunology & Hygiene, University Hospital of Cologne, Cologne, Germany.'}, {'ForeName': 'Vance G', 'Initials': 'VG', 'LastName': 'Fowler', 'Affiliation': 'Department of Medicine, Duke University Medical Center & Duke Clinical Research Institute, Durham, NC, USA.'}]",Future microbiology,['10.2217/fmb-2019-0332'] 1089,31335198,Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS).,"Background: Titration of basal insulin led by either the physician or the patient is not well understood in India. This analysis of Indian subset of Asian Treat to Target Lantus Study (ATLAS) compared effectiveness of patient-led with physician-led titration of once-daily insulin glargine 100 U/mL (Glargine-U-100) in patients with type 2 diabetes mellitus (T2DM) uncontrolled on oral antidiabetes drug (OAD). Methods: In this open-label parallel group study, randomized patients (either physician-led or patient-led [self-titration] group) followed the same dose titration algorithm (fasting blood glucose [FBG] target 110 mg/dL [6.1 mmol/L]). The primary endpoint was change in mean glycated hemoglobin (HbA1c) at week 24 in the patient-led group versus the physician-led group. Results: Patients (40-75 years) were randomized to either the physician-led group ( n  = 39) or the patient-led group ( n  = 36). At week 24, self-titration led to a greater decline in HbA1c than physician-led titration (-1.3% vs. -1.1%). Mean decrease in FBG was more in the patient-led group than in the physician-led group (-53.7 mg/dL vs. -35.5 mg/dL). Mean daily dose of Glargine-U-100 at week 24 was higher in the patient-led group than in the physician-led group (30.0 U vs. 23.8 U). At any time during the study, 30.6% and 7.7% of patients in the patient-led and physician-led groups, respectively, showed target HbA1c level of <7.0% without severe hypoglycemia. Treatment satisfaction and quality of life improved in both groups. Overall, treatment was safe and well tolerated, and none of the events led to treatment discontinuation. Conclusion: Patient-led adjustment of Glargine-U-100 in outpatient setting can be a safe and effective method for glycemic control in Indian patients with T2DM uncontrolled on OADs.",2019,"At week 24, self-titration led to a greater decline in HbA1c than physician-led titration (-1.3% vs. -1.1%).","['Indian patients with T2DM uncontrolled on OADs', 'patients with type 2 diabetes mellitus (T2DM) uncontrolled on oral antidiabetes drug (OAD', 'Patients (40-75 years', 'Conclusion: Patient-led adjustment of Glargine-U-100 in outpatient setting', 'Indian Patients with Type 2 Diabetes Mellitus']","['U/mL', 'Glargine-U-100', 'physician-led or patient-led [self-titration] group) followed the same dose titration algorithm (fasting blood glucose [FBG] target 110\u2009mg/dL', 'Physician-Led Versus Patient-Led Titration of Insulin Glargine', 'insulin glargine 100']","['Treatment satisfaction and quality of life', 'mean glycated hemoglobin (HbA1c', 'safe and well tolerated', 'Mean decrease in FBG', 'Mean daily dose of Glargine-U-100']","[{'cui': 'C1524069', 'cui_str': 'Indian (racial group)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled (qualifier value)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0421258', 'cui_str': 'Diabetic - poor control (finding)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0456081', 'cui_str': 'Adjustment (procedure)'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]","[{'cui': 'C2945590', 'cui_str': 'unit/mL'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0002045'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0034380'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]",,0.0823775,"At week 24, self-titration led to a greater decline in HbA1c than physician-led titration (-1.3% vs. -1.1%).","[{'ForeName': 'Anoop', 'Initials': 'A', 'LastName': 'Misra', 'Affiliation': 'Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, New Delhi, India.'}, {'ForeName': 'Mayur', 'Initials': 'M', 'LastName': 'Patel', 'Affiliation': 'All India Institute of Diabetes and Research, Swasthya Diabetes Care, Jay Mangal Society, Ahmedabad, India.'}, {'ForeName': 'Pankaj', 'Initials': 'P', 'LastName': 'Agarwal', 'Affiliation': 'Hormone Care and Research Centre SB-5, Ghaziabad, India.'}, {'ForeName': 'Sailesh', 'Initials': 'S', 'LastName': 'Lodha', 'Affiliation': 'Dear Foundation, Jaipur, India.'}, {'ForeName': 'Nikhil', 'Initials': 'N', 'LastName': 'Tandon', 'Affiliation': 'Department of Endocrinology, 3rd Floor Biotechnology Block, AIIMS, New Delhi, India.'}, {'ForeName': 'Mohan', 'Initials': 'M', 'LastName': 'Magdum', 'Affiliation': 'Jehangir Clinical Development Pvt. Ltd., Jehangir Hospital, Pune, India.'}, {'ForeName': 'Chittaranjan', 'Initials': 'C', 'LastName': 'Yajnik', 'Affiliation': 'Diabetes Unit, KEM hospital Research Centre, Pune, India.'}, {'ForeName': 'Romik', 'Initials': 'R', 'LastName': 'Ghosh', 'Affiliation': 'Medical Affairs Department, Sanofi, Mumbai, India.'}, {'ForeName': 'Ajit', 'Initials': 'A', 'LastName': 'Walekar', 'Affiliation': 'Clinical Study Unit, Sanofi, Mumbai, India.'}]",Diabetes technology & therapeutics,['10.1089/dia.2019.0037'] 1090,32104959,Palatal augmentation prostheses in individuals treated for head and neck cancer: Effects on speech and oral transport.,"BACKGROUND Negative side effects affecting articulation and oral transport are common after treatment for head and neck cancer (HNC). The aim of this study was to assess the effects on speech and patient-reported experience of palatal augmentation prostheses (PAP) in this patient group. METHODS Twenty consecutive patients who had received a PAP were included. We performed a blinded randomized listener assessment of recordings of the patients' speech with and without the PAP. Patient-reported experiences were collected from medical records. RESULTS The listener assessment showed that production of velar sounds improved significantly for 12 of 19 patients; 12 of 19 patients also reported easier or better speech with the PAP. All six patients treated for tongue cancer reported speech improvement. Seven of 20 patients reported better transport of food or saliva. CONCLUSION A PAP can help patients treated for HNC to more precisely articulated velar consonants and can benefit oral transport.",2020,The listener assessment showed that production of velar sounds improved significantly for 12 of 19 patients; 12 of 19 patients also reported easier or better speech with the PAP.,"['Twenty consecutive patients who had received a PAP were included', ""patients' speech with and without the PAP"", 'individuals treated for head and neck cancer', 'head and neck cancer (HNC']","['palatal augmentation prostheses (PAP', 'Palatal augmentation prostheses']","['speech improvement', 'better transport of food or saliva', 'production of velar sounds']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for (contextual qualifier) (qualifier value)'}, {'cui': 'C0278996', 'cui_str': 'Cancer of Head and Neck'}]","[{'cui': 'C0700374', 'cui_str': 'Palate'}, {'cui': 'C1293122', 'cui_str': 'Augmentation procedure'}, {'cui': 'C0175649', 'cui_str': 'Prosthesis'}]","[{'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C1317949', 'cui_str': 'Transport (physical object)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0036087', 'cui_str': 'Saliva (substance)'}, {'cui': 'C0033268'}, {'cui': 'C1293120', 'cui_str': 'Sounding'}]",20.0,0.0418413,The listener assessment showed that production of velar sounds improved significantly for 12 of 19 patients; 12 of 19 patients also reported easier or better speech with the PAP.,"[{'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Löfhede', 'Affiliation': 'Department of Otorhinolaryngology, Sahlgrenska University Hospital, Gothenburg, Sweden.'}, {'ForeName': 'Madeleine', 'Initials': 'M', 'LastName': 'Wertsén', 'Affiliation': 'Clinic of Pedodontics and Special Dental Care, Sahlgrenska University Hospital, Mölndal, Sweden.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Havstam', 'Affiliation': 'Department of Otorhinolaryngology, Sahlgrenska University Hospital, Gothenburg, Sweden.'}]",Head & neck,['10.1002/hed.26124'] 1091,32046452,Does Adding Fluoxetine to Combined Oral Contraceptives Containing Drospirenone Improve the Management of Severe Premenstrual Syndrome? A 6-Month Randomized Double-Blind Placebo-Controlled Three-Arm Trial.,"To compare efficacy of combined use of fluoxetine and combined oral contraceptives (COC) versus COC alone in treating severe premenstrual syndrome (PMS), a randomized double-blind placebo-controlled three-arm trial was conducted at Cairo and Beni-Suef University Hospitals. PMS was diagnosed prospectively using the Daily Record of Severity of Problems (DRSP). Three hundred women with severe PMS were randomly divided into three equal groups. Group 1 received oral fluoxetine 20 mg daily in addition to COC containing drospirenone daily for 21 days. Group 2 received COC containing drospirenone daily for 21 days in addition to daily oral placebo. Group 3 received placebo similar to COC and oral placebo similar to fluoxetine. Drug duration was 6 months, and women kept daily records of their symptoms using the Daily Record of Severity of Problems (DSRP) form. The main outcome was the number of women with improved PMS in the final cycle of treatment. Women with improved PMS decreased progressively between groups during last treatment month (65% vs. 50% and 2% respectively; p < 0.0001). Combined use of fluoxetine and COC containing drospirenone is superior to COC in severe PMS.",2020,Women with improved PMS decreased progressively between groups during last treatment month (65% vs. 50% and 2% respectively; p < 0.0001).,"['Three hundred women with severe PMS', 'treating severe premenstrual syndrome (PMS']","['Placebo', 'COC containing drospirenone', 'fluoxetine and COC containing drospirenone', 'Drospirenone', 'fluoxetine and combined oral contraceptives (COC', 'fluoxetine', 'oral fluoxetine', 'placebo', 'Fluoxetine', 'COC alone']","['number of women with improved PMS', 'PMS']","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0033046', 'cui_str': 'PMS - Premenstrual syndrome'}, {'cui': 'C1292734', 'cui_str': 'Treats'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0043822', 'cui_str': 'drospirenone'}, {'cui': 'C0016365', 'cui_str': 'Fluoxetine'}, {'cui': 'C0009906', 'cui_str': 'Contraceptive Agents, Female, Combined'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0033046', 'cui_str': 'PMS - Premenstrual syndrome'}]",300.0,0.532028,Women with improved PMS decreased progressively between groups during last treatment month (65% vs. 50% and 2% respectively; p < 0.0001).,"[{'ForeName': 'Nesreen AbdelFattah AbdAllah', 'Initials': 'NAA', 'LastName': 'Shehata', 'Affiliation': 'Department of Obstetrics and Gynecology, Beni-Suef University, Beni Suef, Egypt. nesoomar@yahoo.com.'}, {'ForeName': 'Ghada Abdel Fattah Abdel', 'Initials': 'GAFA', 'LastName': 'Moety', 'Affiliation': 'Department of Obstetrics and Gynecology, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Hamada Ashry Abd', 'Initials': 'HAA', 'LastName': 'El Wahed', 'Affiliation': 'Department of Obstetrics and Gynecology, Beni-Suef University, Beni Suef, Egypt.'}, {'ForeName': 'Ashraf Samir', 'Initials': 'AS', 'LastName': 'Fahim', 'Affiliation': 'Department of Obstetrics and Gynecology, Beni-Suef University, Beni Suef, Egypt.'}, {'ForeName': 'Maha Ali', 'Initials': 'MA', 'LastName': 'Katta', 'Affiliation': 'Department of Obstetrics and Gynecology, Beni-Suef University, Beni Suef, Egypt.'}, {'ForeName': 'Gaber Khalaf', 'Initials': 'GK', 'LastName': 'Hussein', 'Affiliation': 'Department of Obstetrics and Gynecology, Beni-Suef University, Beni Suef, Egypt.'}]","Reproductive sciences (Thousand Oaks, Calif.)",['10.1007/s43032-019-00080-x'] 1092,32433648,Pre-injury activity predicts outcomes following distal radius fractures in patients age 60 and older.,"INTRODUCTION One out of every 5 elderly patients will suffer a distal radius fracture and these injuries are often related to poor bone health. Several surgical subspecialties have demonstrated that pre-injury activity level can impact patient outcomes. To determine the importance of physical activity, we examined the relationship between pre-injury activity and patient-reported and functional outcomes among fracture patients. METHODS This is a retrospective analysis of prospectively collected data from participants enrolled in the Wrist and Radius Injury Surgical Trial (WRIST) from April 10, 2012 to December 31, 2016. This study included 304 adults, 60 years or older with isolated unstable distal radius fractures; 187 were randomized to one of three surgical treatments and 117 opted for casting. Participants opting for surgery were randomized to receive volar locking plate, percutaneous pinning, or external fixation. Participants who chose not to have surgery were treated with casting. All participants were stratified prior to analysis into highly and less-active groups based on pre-injury Rapid Assessment of Physical Activity Scores. RESULTS 280 patients had 12-month assessments of outcomes. Highly active participants scored 8 and 5 points greater on the Michigan Hand Questionnaire at 6 weeks and 3 months respectively, p<0.05. Highly active participants demonstrated greater grip strength at the 3-month (p = 0.017) and 6-month (p = 0.007) time-points. Highly active participants treated with volar locking plate scored 10+ points greater on the Michigan Hand Questionnaire compared to the less-active group at the 6-week (p = 0.032), 3-month (p = 0.009) and 12-month (0.004) time points, with an effect size larger than 0.50, suggesting pre-injury level of activity had a significant clinical impact. CONCLUSIONS Higher levels of pre-injury activity are predictive of patient-reported and functional outcomes following distal radius fracture. Because of the greater PROs, the early mobility and lower risk of hardware infection reported in the literature, volar plating is preferable to other treatments for highly active patients who request and meet indications for surgery. TRIAL REGISTRATION clinicaltrials.gov identifier: NCT01589692.",2020,"Highly active participants scored 8 and 5 points greater on the Michigan Hand Questionnaire at 6 weeks and 3 months respectively, p<0.05.","['Participants opting for surgery', '280 patients had 12-month assessments of outcomes', 'fracture patients', 'patients age 60 and older', 'Participants who chose not to have surgery were treated with casting', '304 adults, 60 years or older with isolated unstable distal radius fractures; 187', 'participants enrolled in the Wrist and Radius Injury Surgical Trial (WRIST) from April 10, 2012 to December 31, 2016']","['volar locking plate', 'volar locking plate, percutaneous pinning, or external fixation', 'distal radius fractures']","['Physical Activity Scores', 'grip strength', 'Michigan Hand Questionnaire']","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0179686', 'cui_str': 'Cast'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0443343', 'cui_str': 'Unstable status'}, {'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius'}, {'cui': 'C4517618', 'cui_str': '187'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0034627', 'cui_str': 'Bone structure of radius'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0443349', 'cui_str': 'Volar'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0407333', 'cui_str': 'External skeletal fixation procedure'}, {'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0025939', 'cui_str': 'Michigan'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",304.0,0.0768138,"Highly active participants scored 8 and 5 points greater on the Michigan Hand Questionnaire at 6 weeks and 3 months respectively, p<0.05.","[{'ForeName': 'Rachel C', 'Initials': 'RC', 'LastName': 'Hooper', 'Affiliation': 'Hand Surgery Fellow, Section of Plastic Surgery, Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, United States of America.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Zhou', 'Affiliation': 'PhD Candidate, Department of Biostatistics, University of Michigan, Ann Arbor, MI, United States of America.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Associate Professor, Department of Biostatistics, University of Michigan, Ann Arbor, MI, United States of America.'}, {'ForeName': 'Melissa J', 'Initials': 'MJ', 'LastName': 'Shauver', 'Affiliation': 'Clinical Research Coordinator, Section of Plastic Surgery, Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, United States of America.'}, {'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Chung', 'Affiliation': 'Charles B. G. de Nancrede Professor of Surgery, Section of Plastic Surgery, Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, United States of America.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",PloS one,['10.1371/journal.pone.0232684'] 1093,31501078,Reducing Pain and Fear in Children During Venipuncture: A Randomized Controlled Study.,"BACKGROUND Venous blood sampling is a common procedure in the hospital setting and cause significant pain and stress for children. AIM This study was conducted to determine and compare the effects of balloon inflation, ball squeezing, and coughing methods on levels of pain and fear during venipuncture in children aged 7-12 years. DESIGN Experimental, randomized controlled study. SETTING The study was conducted at a state hospital in Turkey between March and July 2017. PARTICIPANTS/SUBJECTS The study population comprised children 7-12 years of age who were subjected to venous blood sampling in the phlebotomy unit of a state hospital. The study sample included 120 children for a confidence interval of 95% and statistical power of 80%. METHODS The children were assigned to one of four groups (balloon inflation, ball squeezing, coughing, and control groups), each including 30 participants. The children's pain and fear were rated before and after the procedure by the children themselves, their parents, and a researcher using the Wong-Baker FACES Pain Rating Scale and Children's Fear Scale, respectively. RESULTS Mean scores for pain and fear after the procedure were lower in all intervention groups compared with the control group (p = .001). There was no statistical difference in pain or fear scores between the intervention groups; however, the children in the coughing group had the lowest scores for both pain and fear. CONCLUSION Balloon inflation, ball squeezing, and coughing were all effective in reducing pain and fear associated with venipuncture in children aged 7-12 years. These are simple, rapid, and cost-effective methods that nurses can implement during venipuncture with minimal equipment and preparation.",2020,"There was no statistical difference in pain or fear scores between the intervention groups; however, the children in the coughing group had the lowest scores for both pain and fear. ","['120 children for a confidence interval of 95% and statistical power of 80', 'Children', 'children aged 7-12\xa0years', 'The study was conducted at a state hospital in Turkey between March and July\xa02017', 'The study population comprised children 7-12\xa0years of age who were subjected to venous blood sampling in the phlebotomy unit of a state hospital']","['Venipuncture', 'balloon inflation, ball squeezing, and coughing methods']","['pain or fear scores', 'Mean scores for pain and fear', 'pain and fear associated with venipuncture', ""Baker FACES Pain Rating Scale and Children's Fear Scale"", 'Pain and Fear', 'pain and fear']","[{'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0009667', 'cui_str': 'Confidence Intervals'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0020026', 'cui_str': 'Hospitals, State'}, {'cui': 'C0041400', 'cui_str': 'Turkey'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0190979', 'cui_str': 'Venesection'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}]","[{'cui': 'C0600406', 'cui_str': 'Venipuncture (procedure)'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft (physical object)'}, {'cui': 'C1318493', 'cui_str': 'Inflation'}, {'cui': 'C0413258', 'cui_str': 'Barotrauma of descent (disorder)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0600406', 'cui_str': 'Venipuncture (procedure)'}, {'cui': 'C0238749', 'cui_str': 'Baker, general (occupation)'}, {'cui': 'C0015468', 'cui_str': 'Face Pain'}, {'cui': 'C0222045'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",120.0,0.0558702,"There was no statistical difference in pain or fear scores between the intervention groups; however, the children in the coughing group had the lowest scores for both pain and fear. ","[{'ForeName': 'Burcu', 'Initials': 'B', 'LastName': 'Aykanat Girgin', 'Affiliation': 'Sağlık Bilimleri University, Hamidiye Nursing Faculty, İstanbul, Turkey.'}, {'ForeName': 'İlknur', 'Initials': 'İ', 'LastName': 'Göl', 'Affiliation': 'Çankırı Karatekin University, Faculty of Health Sciences, Çankırı, Turkey. Electronic address: ilknurnayirgol@gmail.com.'}]",Pain management nursing : official journal of the American Society of Pain Management Nurses,['10.1016/j.pmn.2019.07.006'] 1094,31502659,Long-term follow-up of two randomized trials comparing laparoscopic Nissen 360° with anterior 90° partial fundoplication.,"BACKGROUND The side-effects of Nissen fundoplication have led to modifications, including partial fundoplications such as an anterior 90° wrap. Five-year follow-up of two randomized trials suggested fewer side-effects following anterior 90° partial fundoplication, but better reflux control after Nissen fundoplication. However, longer-term outcomes have not been reported. This study combined data from previous trials to determine 10-year outcomes. METHODS From 1999 to 2003, 191 patients were enrolled in two randomized trials comparing anterior 90° partial versus Nissen fundoplication. Trial protocols were similar, and data were combined to determine long-term clinical outcomes. Patients completed annual questionnaires assessing dysphagia, heartburn, medications, satisfaction and other symptoms. Visual analogue scales (0-10), a composite dysphagia score (0-45) and yes/no responses were used. RESULTS Of the 191 patients, 152 (79·6 per cent) were available for 10-year follow-up. After anterior 90° fundoplication, patients reported less dysphagia to solids (score 2·03 versus 3·18 for the Nissen procedure; P = 0·037). Heartburn scores were lower after Nissen fundoplication (1·90 versus 2·83 for anterior 90° fundoplication; P = 0·035) and fewer patients required proton pump inhibitors (PPIs) (22 versus 39 per cent respectively; P = 0·035). Satisfaction scores were similar for both anterior 90° and Nissen groups (7·45 versus 7·36 respectively; P = 0·566), and the majority considered their original decision for surgery to be correct (86 versus 84 per cent; P = 0·818). CONCLUSION After 10 years, both procedures achieved similar success as measured by global satisfaction measures. Patients who had a Nissen fundoplication reported more dysphagia, whereas more heartburn and PPI consumption were reported after anterior 90° fundoplication. Registration numbers: ACTRN12607000298415 and ACTRN12607000304437 (http://www.anzctr.org.au/).",2020,Heartburn scores were lower after Nissen fundoplication (1·90 versus 2·83 for anterior 90° fundoplication; P = 0·035) and fewer patients required proton pump inhibitors (PPIs) (22 versus 39 per cent respectively; P = 0·035).,"['Of the 191 patients, 152 (79·6 per cent) were available for 10-year follow-up', 'From 1999 to 2003, 191 patients']","['laparoscopic Nissen 360° with anterior 90° partial fundoplication', 'anterior 90° partial versus Nissen fundoplication', 'Nissen fundoplication']","['side-effects', 'heartburn and PPI consumption', 'annual questionnaires assessing dysphagia, heartburn, medications, satisfaction and other symptoms', 'dysphagia', 'Visual analogue scales', 'composite dysphagia score', 'Heartburn scores', 'dysphagia to solids', 'Satisfaction scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0562018', 'cui_str': 'cent (qualifier value)'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]","[{'cui': 'C4319607', 'cui_str': '360 (qualifier value)'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0701808', 'cui_str': 'Partial fundoplication (procedure)'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C3887679', 'cui_str': 'Nissen Operation'}]","[{'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0018834', 'cui_str': 'Pyrosis'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0302909', 'cui_str': 'Solid substance (substance)'}]",191.0,0.159811,Heartburn scores were lower after Nissen fundoplication (1·90 versus 2·83 for anterior 90° fundoplication; P = 0·035) and fewer patients required proton pump inhibitors (PPIs) (22 versus 39 per cent respectively; P = 0·035).,"[{'ForeName': 'R J', 'Initials': 'RJ', 'LastName': 'Hopkins', 'Affiliation': 'Flinders University Department of Surgery, Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Irvine', 'Affiliation': 'Flinders University Department of Surgery, Flinders Medical Centre, Bedford Park, South Australia, Australia.'}, {'ForeName': 'G G', 'Initials': 'GG', 'LastName': 'Jamieson', 'Affiliation': 'University of Adelaide Discipline of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'P G', 'Initials': 'PG', 'LastName': 'Devitt', 'Affiliation': 'University of Adelaide Discipline of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'D I', 'Initials': 'DI', 'LastName': 'Watson', 'Affiliation': 'Flinders University Department of Surgery, Flinders Medical Centre, Bedford Park, South Australia, Australia.'}]",The British journal of surgery,['10.1002/bjs.11327'] 1095,32436761,Glyceryl trinitrate in first-episode psychosis unmedicated with antipsychotics: A randomised controlled pilot study.,"BACKGROUND There is a pressing need for new classes of treatment for psychosis. A key therapeutic target for novel compounds is the NMDA receptor, which may be modulated by nitric oxide donors such as sodium nitroprusside (SNP). Recent studies of SNP in patients with psychosis have mixed results, and the drug has to be administered intravenously. Glyceryl trinitrate (GTN) is a well-established cardiovascular medicine that is also a nitric oxide donor, and can be given orally. AIMS We explored the safety and potential effects of GTN in unmedicated patients with a first episode of psychosis. METHODS This was a single-centre, randomised, double-blind, placebo-controlled trial from December 2016 to April 2019 (ClinicalTrials.gov identifier: NCT02906553). Patients received 3 × sprays of GTN or placebo for three consecutive days, and were re-assessed on Days 1, 2, 3 and 7. The primary outcome was cognition (Jumping to Conclusions task), secondary outcomes were symptoms (Positive and Negative Syndrome Scale (PANSS)), verbal memory (Hopkins Verbal Learning task), and mood (Bond-Lader Visual Analogue Scales). RESULTS Nineteen patients were randomised, and 13 participants were included in the analyses. Compared with placebo, GTN was well tolerated, but was not associated with significant effects on cognition, symptoms, or mood. Bayesian statistics indicate that our results were 2× more likely under the null hypothesis than the alternative hypothesis, providing anecdotal evidence that GTN does not improve psychotic symptoms. CONCLUSIONS We found no indication of an effect of GTN on symptoms of psychosis or cognition.",2020,"Compared with placebo, GTN was well tolerated, but was not associated with significant effects on cognition, symptoms, or mood.","['Nineteen patients were randomised, and 13 participants were included in the analyses', 'patients with psychosis', 'unmedicated patients with a first episode of psychosis', 'controlled trial from December 2016 to April 2019 (ClinicalTrials.gov identifier', 'first-episode psychosis unmedicated with antipsychotics']","['GTN', 'Glyceryl trinitrate (GTN', 'SNP', 'placebo, GTN', '3 × sprays of GTN or placebo', 'Glyceryl trinitrate', 'placebo']","['tolerated', 'cognition (Jumping to Conclusions task), secondary outcomes were symptoms (Positive and Negative Syndrome Scale (PANSS)), verbal memory (Hopkins Verbal Learning task), and mood (Bond-Lader Visual Analogue Scales', 'symptoms of psychosis or cognition', 'psychotic symptoms', 'cognition, symptoms, or mood']","[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0439615', 'cui_str': 'First episode'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0600091', 'cui_str': 'Identifier'}, {'cui': 'C0040615', 'cui_str': 'Antipsychotic agent'}]","[{'cui': 'C0017887', 'cui_str': 'Nitroglycerin'}, {'cui': 'C0037533', 'cui_str': 'Sodium nitroprusside'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0871189', 'cui_str': 'Psychotic symptom'}]",19.0,0.469584,"Compared with placebo, GTN was well tolerated, but was not associated with significant effects on cognition, symptoms, or mood.","[{'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Merritt', 'Affiliation': 'Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Catalan', 'Affiliation': 'Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Cowley', 'Affiliation': 'Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK.'}, {'ForeName': 'Arsime', 'Initials': 'A', 'LastName': 'Demjaha', 'Affiliation': 'Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Taylor', 'Affiliation': 'Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'McGuire', 'Affiliation': 'Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Cooper', 'Affiliation': 'Newham Centre for Mental Health, Unit for Social and Community Psychiatry, Queen Mary University of London, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Morrison', 'Affiliation': 'Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881120922967'] 1096,31767043,Variation in care for children undergoing the Fontan operation for hypoplastic left heart syndrome.,"BACKGROUND The Single Ventricle Reconstruction Trial randomised neonates with hypoplastic left heart syndrome to a shunt strategy but otherwise retained standard of care. We aimed to describe centre-level practice variation at Fontan completion. METHODS Centre-level data are reported as median or median frequency across all centres and range of medians or frequencies across centres. Classification and regression tree analysis assessed the association of centre-level factors with length of stay and percentage of patients with prolonged pleural effusion (>7 days). RESULTS The median Fontan age (14 centres, 320 patients) was 3.1 years (range from 1.7 to 3.9), and the weight-for-age z-score was -0.56 (-1.35 + 0.44). Extra-cardiac Fontans were performed in 79% (4-100%) of patients at the 13 centres performing this procedure; lateral tunnels were performed in 32% (3-100%) at the 11 centres performing it. Deep hypothermic circulatory arrest (nine centres) ranged from 6 to 100%. Major complications occurred in 17% (7-33%). The length of stay was 9.5 days (9-12); 15% (6-33%) had prolonged pleural effusion. Centres with fewer patients (<6%) with prolonged pleural effusion and fewer (<41%) complications had a shorter length of stay (<10 days; sensitivity 1.0; specificity 0.71; area under the curve 0.96). Avoiding deep hypothermic circulatory arrest and higher weight-for-age z-score were associated with a lower percentage of patients with prolonged effusions (<9.5%; sensitivity 1.0; specificity = 0.86; area under the curve 0.98). CONCLUSIONS Fontan perioperative practices varied widely among study centres. Strategies to decrease the duration of pleural effusion and minimise complications may decrease the length of stay. Further research regarding deep hypothermic circulatory arrest is needed to understand its association with prolonged pleural effusion.",2019,The length of stay was 9.5 days (9-12); 15% (6-33%) had prolonged pleural effusion.,"['The median Fontan age (14 centres, 320 patients) was 3.1\xa0years (range from 1.7 to 3.9), and the weight-for-age z-score was -0.56 ', 'neonates with hypoplastic left heart syndrome', 'children undergoing the Fontan operation for hypoplastic left heart syndrome', 'patients with prolonged pleural effusion (>7\xa0days']",[],"['shorter length of stay', 'prolonged pleural effusion', 'length of stay', 'duration of pleural effusion', 'Major complications']","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C4517711', 'cui_str': '320 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517683', 'cui_str': '3.1 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C4517512', 'cui_str': '1.7 (qualifier value)'}, {'cui': 'C4517698', 'cui_str': '3.9 (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0152101', 'cui_str': 'Left Heart Hypoplasia Syndrome'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0190010', 'cui_str': 'Norwood Procedure, Stage III'}, {'cui': 'C0032227', 'cui_str': 'Pleural Effusion'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]",[],"[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C0032227', 'cui_str': 'Pleural Effusion'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}]",320.0,0.0949982,The length of stay was 9.5 days (9-12); 15% (6-33%) had prolonged pleural effusion.,"[{'ForeName': 'Aaron W', 'Initials': 'AW', 'LastName': 'Eckhauser', 'Affiliation': ""Divisions of Cardiothoracic Surgery and Pediatric Cardiology, University of Utah, Primary Children's Hospital, Salt Lake City, UT, USA.""}, {'ForeName': 'Maria I', 'Initials': 'MI', 'LastName': 'Van Rompay', 'Affiliation': 'New England Research Institutes, Watertown, MA, USA.'}, {'ForeName': 'Chitra', 'Initials': 'C', 'LastName': 'Ravishankar', 'Affiliation': ""Division of Pediatric Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.""}, {'ForeName': 'Jane W', 'Initials': 'JW', 'LastName': 'Newburger', 'Affiliation': ""Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Ram Kumar', 'Affiliation': ""Heart Institute, Children's Hospital of Los Angeles, Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.""}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Pizarro', 'Affiliation': 'Nemours Cardiac Center, Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, USA.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Ghanayem', 'Affiliation': ""Division of Pediatric Critical Care, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.""}, {'ForeName': 'Felicia L', 'Initials': 'FL', 'LastName': 'Trachtenberg', 'Affiliation': 'New England Research Institutes, Watertown, MA, USA.'}, {'ForeName': 'Kristin M', 'Initials': 'KM', 'LastName': 'Burns', 'Affiliation': 'Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD, USA.'}, {'ForeName': 'Garick D', 'Initials': 'GD', 'LastName': 'Hill', 'Affiliation': ""Division of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Atz', 'Affiliation': 'Division of Cardiology, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Michelle S', 'Initials': 'MS', 'LastName': 'Hamstra', 'Affiliation': ""Division of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Mjaye', 'Initials': 'M', 'LastName': 'Mazwi', 'Affiliation': 'Department of Critical Care Medicine, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Patsy', 'Initials': 'P', 'LastName': 'Park', 'Affiliation': 'Division of Pediatric Cardiology, Duke University, Durham, NC, USA.'}, {'ForeName': 'Marc E', 'Initials': 'ME', 'LastName': 'Richmond', 'Affiliation': 'Division of Pediatric Cardiology, Columbia University College of Physicians & Surgeons, New York, NY, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Wolf', 'Affiliation': 'Division of Pediatric Cardiology, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Jeffrey D', 'Initials': 'JD', 'LastName': 'Zampi', 'Affiliation': ""Division of Pediatric Cardiology, University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, MI, USA.""}, {'ForeName': 'Jeffrey P', 'Initials': 'JP', 'LastName': 'Jacobs', 'Affiliation': ""Division of Cardiovascular Surgery, Johns Hopkins University and All Children's Hospital, St. Petersburg, FL, USA.""}, {'ForeName': 'L LuAnn', 'Initials': 'LL', 'LastName': 'Minich', 'Affiliation': ""Divisions of Cardiothoracic Surgery and Pediatric Cardiology, University of Utah, Primary Children's Hospital, Salt Lake City, UT, USA.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Cardiology in the young,['10.1017/S1047951119002658'] 1097,31845903,An Electronic Screening and Brief Intervention for Hazardous and Harmful Drinking Among Swedish University Students: Reanalysis of Findings From a Randomized Controlled Trial Using a Bayesian Framework.,"BACKGROUND Due to a resurgent debate on the misuse of P values, the Journal of Medical Internet Research is hosting a standing theme issue inviting the reanalysis of (primarily digital health) trial data using a Bayesian framework. This first paper in this series focuses on an electronic screening and brief intervention (eSBI), targeting harmful and hazardous alcohol consumption, which student health care centers across Sweden have routinely administerd to all students during the past decade. The second Alcohol Email Assessment and Feedback Study Dismantling Effectiveness for University Students (AMADEUS-2) trial aimed to assess the effect of the eSBI on alcohol consumption among students who were harmful and hazardous drinkers. A two-arm randomized controlled trial design was employed, randomizing eligible participants to either a waiting list or direct access to an eSBI. Follow-up assessments were conducted 2 months after randomization. Subsequent analysis of the trial followed the conventional null hypothesis approach, and no statistical significance was found between groups at follow-up with respect to the number of standard drinks consumed weekly. However, in an unspecified sensitivity analysis, it was discovered that removing three potential outliers made the difference between the groups significant. OBJECTIVE The objective of this study is to reperform the primary and sensitivity analysis of the AMADEUS-2 trial using a Bayesian framework and to compare the results with those of the original analysis. METHODS The same regression models used in the original analysis were employed in this reanalysis (negative binomial regression). Model parameters were given uniform priors. Markov chain Monte Carlo was used for Bayesian inference, and posterior probabilities were calculated for prespecified thresholds of interest. RESULTS Null hypothesis tests did not identify a statistically significant difference between the intervention and control groups, potentially due to a few extreme data points. The Bayesian analysis indicated a 93.6% probability that there was a difference in grams of alcohol consumed at follow-up between the intervention and control groups and a 71.5% probability that the incidence rate ratio was <0.96. Posterior probabilities increased when excluding three potential outliers, yet such post hoc analyses were not necessary to show the preference toward offering an eSBI to harmful and hazardous drinkers among university students. CONCLUSIONS The null hypothesis framework relies on point estimates of parameters. P values can therefore swing heavily, depending on a single or few data points alone, casting doubt on the value of the analysis. Bayesian analysis results in a distribution over parameter values and is therefore less sensitive to outliers and extreme values. Results from analyses of trials of interventions where small-to-modest effect sizes are expected can be more robust in a Bayesian framework, making this a potentially better approach for analyzing digital health research data. TRIAL REGISTRATION International Standard Randomized Controlled Trial Number (ISRCTN) 02335307; http://www.isrctn.com/ISRCTN02335307.",2019,"Posterior probabilities increased when excluding three potential outliers, yet such post hoc analyses were not necessary to show the preference toward offering an eSBI to harmful and hazardous drinkers among university students. ","['randomizing eligible participants to either a waiting list or direct access to an eSBI', 'student health care centers across Sweden have routinely administerd to all students during the past decade', 'students who were harmful and hazardous drinkers', 'Hazardous and Harmful Drinking Among Swedish University Students', 'University Students']","['eSBI', 'Electronic Screening and Brief Intervention', 'electronic screening and brief intervention (eSBI']","['alcohol consumption', 'grams of alcohol', 'Posterior probabilities', 'incidence rate ratio']","[{'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C0041740', 'cui_str': 'Universities'}]","[{'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}]","[{'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0439208', 'cui_str': 'gram (qualifier value)'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",,0.0931566,"Posterior probabilities increased when excluding three potential outliers, yet such post hoc analyses were not necessary to show the preference toward offering an eSBI to harmful and hazardous drinkers among university students. ","[{'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Bendtsen', 'Affiliation': 'Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.'}]",Journal of medical Internet research,['10.2196/14420'] 1098,31495577,Pain Management with ROP Position in Turkish Preterm Infants During Eye Examinations: A Randomized Controlled Trial.,"PURPOSE The purpose of this study was to evaluate the effects of infant positioning on pain, heart rate, oxygen saturation and crying time during examination. DESIGN & METHODS The randomized controlled experimental study was carried out on 70 preterm infants. ROP position + pacifier was used in the experimental group (n = 35) while only the pacifier was used in the control group. Heart rates, oxygen saturation, crying duration and pain score (Premature Infant Pain Profile-PIPP) were evaluated before, during and after the screening. RESULTS The preterm infants in the experimental group recorded lower pain scores at the beginning of the screening (p = 0.01), at the end of the screening (p = 0.01) and after screening (p = 0.01) than those in the control group. The heart rate was higher in the control group during screening (p = 0.010) and after screening (p = 0.008) than in the preterm infants in the experimental group. Oxygen saturation was not significantly different between the groups before, during or after screening. Crying duration was lower in the experimental group than in the control group (p = 0.010). CONCLUSIONS Positioning of the infant to support behavioral organization was found to be effective in reducing pain and shortening crying time during eye examination, and had favorable effects on physiological variables with ROP position during eye examinations. PRACTICE IMPLICATIONS ROP position is a practical and effective non-pharmacological method during eye examinations by neonatal nurses.",2019,"The preterm infants in the experimental group recorded lower pain scores at the beginning of the screening (p = 0.01), at the end of the screening (p = 0.01) and after screening (p = 0.01) than those in the control group.","['Turkish preterm infants during eye examinations', '70 preterm infants']","['ROP position\u202f+\u202fpacifier', 'Pain management with ROP position']","['Crying duration', 'pain, heart rate, oxygen saturation and crying time', 'Oxygen saturation', 'Heart rates, oxygen saturation, crying duration and pain score (Premature Infant Pain Profile-PIPP', 'lower pain scores', 'heart rate', 'pain and shortening crying time']","[{'cui': 'C0554967', 'cui_str': 'Turkish (NMO) (ethnic group)'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0200149', 'cui_str': 'Ophthalmic examination and evaluation (procedure)'}]","[{'cui': 'C1561964', 'cui_str': 'Patient Positioning'}, {'cui': 'C0030172', 'cui_str': 'Pacifiers'}, {'cui': 'C0002766', 'cui_str': 'Pain management (procedure)'}]","[{'cui': 'C0010399', 'cui_str': 'Cryings'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C1282927', 'cui_str': 'Shortened (qualifier value)'}]",,0.0296314,"The preterm infants in the experimental group recorded lower pain scores at the beginning of the screening (p = 0.01), at the end of the screening (p = 0.01) and after screening (p = 0.01) than those in the control group.","[{'ForeName': 'Özlem', 'Initials': 'Ö', 'LastName': 'Metreş', 'Affiliation': 'The Turkısh Republıc of Demiroglu Bilim University, Faculty of Health Scıences, İstanbul, Turkey. Electronic address: ozlem.metres@demiroglu.bilim.edu.tr.'}, {'ForeName': 'Suzan', 'Initials': 'S', 'LastName': 'Yıldız', 'Affiliation': 'Istanbul University-Cerrahpasa, Florence Nightingale Faculty of Nursing, Department of Child Health and Diseases Nursing, İstanbul, Turkey. Electronic address: suzyil@istanbul.edu.tr.'}]",Journal of pediatric nursing,['10.1016/j.pedn.2019.08.013'] 1099,31479717,"Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial.","INTRODUCTION The simple phenol hydroxytyrosol (OHTyr) has been associated with the beneficial health effects of extra virgin olive oil. Pre-clinical studies have identified Tyr hydroxylation, mediated by cytochrome P450 isoforms CYP2A6 and CYP2D6, as an additional source of OHTyr. AIM We aimed to (i) confirm Tyr to OHTyr bioconversion in vivo in humans, (ii) assess the cardiovascular benefits of this bioconversion, and (iii) determine their interaction with a polygenic activity score (PAS) from CYP2A6 and CYP2D6 genotypes. METHODS Randomized, crossover, controlled study. Individuals at cardiovascular risk (n = 33) received: white wine (WW) (females 1, males 2 standard drinks/day), WW plus Tyr capsules (WW + Tyr) (25  mg Tyr capsule, one per WW drink), and water (control) ad libitum. Participants were classified by a PAS as low versus normal activity metabolizers. RESULTS OHTyr recovery following WW + Tyr was higher than after other interventions (P < 0.05). Low PAS individuals had lower OHTyr/Tyr ratios compared to individuals with normal PAS. WW + Tyr improved endothelial function, increased plasma HDL-cholesterol and antithrombin IIII, and decreased plasma homocysteine, endothelin 1, and CD40L, P65/RELA, and CFH gene expression in peripheral blood mononuclear cells (p < 0.05). Combining Tyr capsule(s) with WW abolished the increase in iNOS, eNOS, VEGFA, and CHF expressions promoted by WW (p < 0.05). CONCLUSIONS Tyr, and its partial biotransformation into OHTyr, promoted cardiovascular health-related benefits in humans after dietary doses of Tyr. The study design allowed the health effects of individual phenols to be singled out from the dietary matrix in which they are naturally found.",2019,Low PAS individuals had lower OHTyr/,"['humans', 'Individuals at cardiovascular risk (n\xa0=\xa033) received']","[' white wine (WW) (females 1, males 2 standard drinks/day), WW plus Tyr capsules (WW\xa0+\xa0Tyr) (25\xa0\xa0mg', 'WW\xa0', 'phenol hydroxytyrosol (OHTyr']","['iNOS, eNOS, VEGFA, and CHF expressions', 'polygenic activity score (PAS', 'endothelial function, increased plasma HDL-cholesterol and antithrombin IIII, and decreased plasma homocysteine, endothelin 1, and CD40L, P65/RELA, and CFH gene expression in peripheral blood mononuclear cells']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}]","[{'cui': 'C0349372', 'cui_str': 'White wine (substance)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0147288', 'cui_str': 'Tyr(TMA)'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C0031428', 'cui_str': 'Phenols'}, {'cui': 'C0243264', 'cui_str': 'hydroxytyrosol'}]","[{'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol, HDL2'}, {'cui': 'C0003440', 'cui_str': 'Direct Thrombin Inhibitors'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0019878', 'cui_str': '2-amino-4-mercaptobutyric acid'}, {'cui': 'C0079281', 'cui_str': 'Endothelin Type 1'}, {'cui': 'C0167627', 'cui_str': 'T-B Cell Activating Molecule'}, {'cui': 'C0299809', 'cui_str': 'p65(PAK)'}, {'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}]",,0.053272,Low PAS individuals had lower OHTyr/,"[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Boronat', 'Affiliation': ""Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Dr. Aiguader 88, 08003, Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra (CEXS-UPF), Dr. Aiguader 80, 08003, Barcelona, Spain.""}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Mateus', 'Affiliation': ""Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Dr. Aiguader 88, 08003, Barcelona, Spain.""}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Soldevila-Domenech', 'Affiliation': ""Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Dr. Aiguader 88, 08003, Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra (CEXS-UPF), Dr. Aiguader 80, 08003, Barcelona, Spain.""}, {'ForeName': 'Mercè', 'Initials': 'M', 'LastName': 'Guerra', 'Affiliation': 'Department of Experimental and Health Sciences, Universitat Pompeu Fabra (CEXS-UPF), Dr. Aiguader 80, 08003, Barcelona, Spain.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Rodríguez-Morató', 'Affiliation': 'Department of Experimental and Health Sciences, Universitat Pompeu Fabra (CEXS-UPF), Dr. Aiguader 80, 08003, Barcelona, Spain; CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN, CB06/03/028), Monforte de Lemos 3-5, 28029, Madrid, Spain.'}, {'ForeName': 'Carlota', 'Initials': 'C', 'LastName': 'Varon', 'Affiliation': ""Department of Pharmacy, Vall d'Hebron Barcelona Hospital Campus, Passeig de Vall d'Hebron 119-129, 08035, Barcelona, Spain.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Muñoz', 'Affiliation': 'Cardiovascular Risk and Nutrition Research Group, IMIM (Hospital del Mar Research Institute), Dr. Aiguader 88, 08003, Barcelona, Spain; CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN, CB06/03/028), Monforte de Lemos 3-5, 28029, Madrid, Spain.'}, {'ForeName': 'Francina', 'Initials': 'F', 'LastName': 'Barbosa', 'Affiliation': 'CAP Barceloneta, Parc Sanitari Rovira Virgili, Passeig Marítim, 25 08003, Barcelona, Spain.'}, {'ForeName': 'Juan Carlos', 'Initials': 'JC', 'LastName': 'Morales', 'Affiliation': 'Department of Biochemistry and Molecular Pharmacology, Instituto de Parasitología y Biomedicina López Neyra, CSIC, PTS Granada, Avda. del Conocimiento 17, 18016, Armilla, Granada, Spain.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Gaedigk', 'Affiliation': ""Children's Mercy Kansas City, Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, and University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.""}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Langohr', 'Affiliation': ""Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Dr. Aiguader 88, 08003, Barcelona, Spain; Department of Statistics and Operations Research, Polytechnic University of Catalonia, Barcelona, Spain.""}, {'ForeName': 'Maria-Isabel', 'Initials': 'MI', 'LastName': 'Covas', 'Affiliation': 'Cardiovascular Risk and Nutrition Research Group, IMIM (Hospital del Mar Research Institute), Dr. Aiguader 88, 08003, Barcelona, Spain; NUPROAS Handesbolag (NUPROAS HB), Nacka, Sweden.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Pérez-Mañá', 'Affiliation': 'School of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain; Hospital Universitari Germans Trias i Pujol (IGTP), Badalona, Spain.'}, {'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Fitó', 'Affiliation': 'Cardiovascular Risk and Nutrition Research Group, IMIM (Hospital del Mar Research Institute), Dr. Aiguader 88, 08003, Barcelona, Spain; CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN, CB06/03/028), Monforte de Lemos 3-5, 28029, Madrid, Spain.'}, {'ForeName': 'Rachel F', 'Initials': 'RF', 'LastName': 'Tyndale', 'Affiliation': ""Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Departments of Pharmacology & Toxicology, and Psychiatry, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada.""}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'de la Torre', 'Affiliation': ""Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Dr. Aiguader 88, 08003, Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra (CEXS-UPF), Dr. Aiguader 80, 08003, Barcelona, Spain; CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN, CB06/03/028), Monforte de Lemos 3-5, 28029, Madrid, Spain. Electronic address: rtorre@imim.es.""}]",Free radical biology & medicine,['10.1016/j.freeradbiomed.2019.08.032'] 1100,31454561,Mobile health and supervised rehabilitation versus mobile health alone in breast cancer survivors: Randomized controlled trial.,"BACKGROUND Survival rates in cancer are increasing exponentially, with a corresponding increase/influence in disability-adjusted life-years. Efforts should be made to explore the optimal balance between unsupervised/distance-based and supervised/onsite approaches to cancer care. OBJECTIVE This study aimed to compare the clinical efficacy of the BENECA mobile Health (mHealth) lifestyle application combined with a supervised rehabilitation program (BENECA and supervised rehabilitation) versus the BENECA mHealth lifestyle application alone on quality of life (QoL) and functional outcomes of breast cancer survivors. METHODS This randomized controlled trial included 80 survivors of breast cancer diagnosed at stage I-IIIA, who completed adjuvant therapy and were overweight or obese at diagnosis. Participants were randomly allocated (ratio 1:1, 3 waves) to BENECA mHealth and rehabilitation for 2months (n=40) or BENECA mHealth and usual care (BENECA mHealth alone; n=40). Participants completed a questionnaire at baseline (T1), 8-weeks post-intervention (T2) and 6-month follow-up (T3). The primary outcome was QoL assessed with the EORT QLQ-C30. Secondary outcomes included upper-limb functionality and body composition. Statistical (between-group analyses of covariance) and clinical effects were analyzed by intention to treat. RESULTS Both groups showed improved outcomes, but global QoL was significantly better with BENECA mHealth and rehabilitation than BENECA mHealth alone (mean difference, 12.76; 95% confidence interval 4.85; 20.67; P=0.004), with a moderate-to-large effect size (d=72). The proportion of participants reporting reliable clinical improvement on global QoL at T2 was higher with BENECA mHealth and rehabilitation than BENECA mHealth alone (57.5% vs 26.3%, P=0.008). Improvement in subjective and objective upper-limb functionality was also higher with BENECA mHealth and rehabilitation. CONCLUSIONS The BENECA mHealth lifestyle application with a supervised rehabilitation program had a statistically and clinically significant effect on QoL and upper-limb functionality in breast cancer survivors and is a unique and important promising new approach.",2020,The BENECA mHealth lifestyle application with a supervised rehabilitation program had a statistically and clinically significant effect on QoL and upper-limb functionality in breast cancer survivors and is a unique and important promising new approach.,"['breast cancer survivors', '80 survivors of breast cancer diagnosed at stage I-IIIA, who completed adjuvant therapy and were overweight or obese at diagnosis']","['supervised rehabilitation program', 'BENECA mobile Health (mHealth) lifestyle application combined with a supervised rehabilitation program (BENECA and supervised rehabilitation', 'BENECA mHealth and rehabilitation for 2 months (n=40) or BENECA mHealth and usual care (BENECA mHealth alone', 'Mobile health and supervised rehabilitation versus mobile health alone']","['QoL assessed with the EORT QLQ-C30', 'quality of life (QoL) and functional outcomes', 'global QoL', 'QoL and upper-limb functionality', 'upper-limb functionality and body composition', 'subjective and objective upper-limb functionality']","[{'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1 (qualifier value)'}, {'cui': 'C0016712', 'cui_str': ""Freund's Adjuvant""}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]","[{'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0034380'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}]",80.0,0.132467,The BENECA mHealth lifestyle application with a supervised rehabilitation program had a statistically and clinically significant effect on QoL and upper-limb functionality in breast cancer survivors and is a unique and important promising new approach.,"[{'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Lozano-Lozano', 'Affiliation': 'Department of Physical Therapy, Faculty of Health Sciences, University of Granada, Avda. de la Ilustración, 60, 18016 Granada, Spain; Sport and Health Joint University Institute (iMUDS), Granada, Spain; Biohealth Research Institute in Granada (ibs.GRANADA), Granada, Spain; ""Cuídate"" Support Unit for Oncology Patients (UAPO-Cuídate), Granada, Spain.'}, {'ForeName': 'Lydia', 'Initials': 'L', 'LastName': 'Martín-Martín', 'Affiliation': 'Department of Physical Therapy, Faculty of Health Sciences, University of Granada, Avda. de la Ilustración, 60, 18016 Granada, Spain; Sport and Health Joint University Institute (iMUDS), Granada, Spain; Biohealth Research Institute in Granada (ibs.GRANADA), Granada, Spain; ""Cuídate"" Support Unit for Oncology Patients (UAPO-Cuídate), Granada, Spain.'}, {'ForeName': 'Noelia', 'Initials': 'N', 'LastName': 'Galiano-Castillo', 'Affiliation': 'Department of Physical Therapy, Faculty of Health Sciences, University of Granada, Avda. de la Ilustración, 60, 18016 Granada, Spain; Sport and Health Joint University Institute (iMUDS), Granada, Spain; Biohealth Research Institute in Granada (ibs.GRANADA), Granada, Spain; ""Cuídate"" Support Unit for Oncology Patients (UAPO-Cuídate), Granada, Spain. Electronic address: noeliagaliano@ugr.es.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Fernández-Lao', 'Affiliation': 'Department of Physical Therapy, Faculty of Health Sciences, University of Granada, Avda. de la Ilustración, 60, 18016 Granada, Spain; Sport and Health Joint University Institute (iMUDS), Granada, Spain; Biohealth Research Institute in Granada (ibs.GRANADA), Granada, Spain; ""Cuídate"" Support Unit for Oncology Patients (UAPO-Cuídate), Granada, Spain.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Cantarero-Villanueva', 'Affiliation': 'Department of Physical Therapy, Faculty of Health Sciences, University of Granada, Avda. de la Ilustración, 60, 18016 Granada, Spain; Sport and Health Joint University Institute (iMUDS), Granada, Spain; Biohealth Research Institute in Granada (ibs.GRANADA), Granada, Spain; ""Cuídate"" Support Unit for Oncology Patients (UAPO-Cuídate), Granada, Spain.'}, {'ForeName': 'Isabel B', 'Initials': 'IB', 'LastName': 'López-Barajas', 'Affiliation': '""San Cecilio"" University Hospital, Oncology Unit, Granada, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Arroyo-Morales', 'Affiliation': 'Department of Physical Therapy, Faculty of Health Sciences, University of Granada, Avda. de la Ilustración, 60, 18016 Granada, Spain; Sport and Health Joint University Institute (iMUDS), Granada, Spain; Biohealth Research Institute in Granada (ibs.GRANADA), Granada, Spain; ""Cuídate"" Support Unit for Oncology Patients (UAPO-Cuídate), Granada, Spain.'}]",Annals of physical and rehabilitation medicine,['10.1016/j.rehab.2019.07.007'] 1101,30473185,"Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.","The safety and immunogenicity of the second generation oral enterotoxigenic Escherichia coli (ETEC) vaccine ETVAX, consisting of inactivated recombinant E. coli strains over-expressing the colonization factors (CFs) CFA/I, CS3, CS5 and CS6 and the heat labile toxoid LCTBA, were evaluated in Bangladeshi volunteers. To enable analysis of antibody responses against multiple vaccine antigens for subsequent use in small sample volumes from children, a sensitive electrochemiluminescence (ECL) assay for analysis of intestine-derived antibody-secreting cell responses using the antibodies in lymphocyte secretions (ALS) assay was established using Meso Scale Discovery technology. Three groups of Bangladeshi adults (n = 15 per group) received two oral doses of ETVAX with or without double mutant LT (dmLT) adjuvant or placebo in the initial part of a randomized, double-blind, placebo-controlled, age-descending, dose-escalation trial. CF- and LTB-specific ALS and plasma IgA responses were analyzed by ECL and/or ELISA. ETVAX was safe and well tolerated in the adults. Magnitudes of IgA ALS responses determined by ECL and ELISA correlated well (r = 0.85 to 0.98 for the five primary antigens, P < 0.001) and ECL was selected as the ALS readout method. ALS IgA responses against each of the primary antigens were detected in 87-100% of vaccinees after the first and in 100% after the second vaccine dose. Plasma IgA responses against different CFs and LTB were observed in 62-93% and 100% of vaccinees, respectively. No statistically significant adjuvant effect of dmLT on antibody responses to any antigen was detected, but the overall antigenic breadth of the plasma IgA response tended to favor the adjuvanted vaccine when responses to 4 or more or 5 vaccine antigens were considered. Responses in placebo recipients were infrequent and mainly detected against single antigens. The promising results in adults supported testing ETVAX in descending age groups of children. ClinicalTrials.gov Identifier: NCT02531802.",2019,"Plasma IgA responses against different CFs and LTB were observed in 62-93% and 100% of vaccinees, respectively.","['Three groups of Bangladeshi adults (n\u202f=\u202f15 per group', 'Bangladeshi volunteers', 'adults supported testing ETVAX in descending age groups of children', 'Bangladeshi adults']","['oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX', 'placebo', 'dmLT', 'enterotoxigenic Escherichia coli (ETEC) vaccine ETVAX', 'ETVAX with or without double mutant LT (dmLT) adjuvant or placebo', 'ETVAX']","['safe and well tolerated', 'Plasma IgA responses against different CFs and LTB', 'antibody responses', 'CF- and LTB-specific ALS and plasma IgA responses', 'Magnitudes of IgA ALS responses', 'safety and immunogenicity', 'ALS IgA responses', 'overall antigenic breadth of the plasma IgA response']","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0422784', 'cui_str': 'Bangladeshi'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0205386', 'cui_str': 'Descending (qualifier value)'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0580797', 'cui_str': 'E coli, Enterotoxigenic'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0003261', 'cui_str': 'Antibody Response'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C1704240', 'cui_str': 'Magnitudes (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.214677,"Plasma IgA responses against different CFs and LTB were observed in 62-93% and 100% of vaccinees, respectively.","[{'ForeName': 'Marjahan', 'Initials': 'M', 'LastName': 'Akhtar', 'Affiliation': 'icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh.'}, {'ForeName': 'Mohiul I', 'Initials': 'MI', 'LastName': 'Chowdhury', 'Affiliation': 'icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh.'}, {'ForeName': 'Taufiqur R', 'Initials': 'TR', 'LastName': 'Bhuiyan', 'Affiliation': 'icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Kaim', 'Affiliation': 'GUVAX (Gothenburg University Vaccine Research Institute), Dept. of Microbiology and Immunology, Inst. of Biomedicine, University of Gothenburg, Sweden.'}, {'ForeName': 'Tasnuva', 'Initials': 'T', 'LastName': 'Ahmed', 'Affiliation': 'icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh.'}, {'ForeName': 'Tanzeem A', 'Initials': 'TA', 'LastName': 'Rafique', 'Affiliation': 'icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh.'}, {'ForeName': 'Arifuzzaman', 'Initials': 'A', 'LastName': 'Khan', 'Affiliation': 'icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh.'}, {'ForeName': 'Sadia I A', 'Initials': 'SIA', 'LastName': 'Rahman', 'Affiliation': 'icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh.'}, {'ForeName': 'Farhana', 'Initials': 'F', 'LastName': 'Khanam', 'Affiliation': 'icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh.'}, {'ForeName': 'Yasmin A', 'Initials': 'YA', 'LastName': 'Begum', 'Affiliation': 'icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh.'}, {'ForeName': 'Mir Z', 'Initials': 'MZ', 'LastName': 'Sharif', 'Affiliation': 'icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh.'}, {'ForeName': 'Laila N', 'Initials': 'LN', 'LastName': 'Islam', 'Affiliation': 'Dept. of Biochemistry and Molecular Biology, University of Dhaka, Bangladesh.'}, {'ForeName': 'Nils', 'Initials': 'N', 'LastName': 'Carlin', 'Affiliation': 'Scandinavian Biopharma, Solna, Sweden.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Maier', 'Affiliation': 'PATH, Washington, DC, USA.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Fix', 'Affiliation': 'PATH, Washington, DC, USA.'}, {'ForeName': 'Thomas F', 'Initials': 'TF', 'LastName': 'Wierzba', 'Affiliation': 'PATH, Washington, DC, USA.'}, {'ForeName': 'Richard I', 'Initials': 'RI', 'LastName': 'Walker', 'Affiliation': 'PATH, Washington, DC, USA.'}, {'ForeName': 'A Louis', 'Initials': 'AL', 'LastName': 'Bourgeois', 'Affiliation': 'PATH, Washington, DC, USA.'}, {'ForeName': 'Ann-Mari', 'Initials': 'AM', 'LastName': 'Svennerholm', 'Affiliation': 'GUVAX (Gothenburg University Vaccine Research Institute), Dept. of Microbiology and Immunology, Inst. of Biomedicine, University of Gothenburg, Sweden.'}, {'ForeName': 'Firdausi', 'Initials': 'F', 'LastName': 'Qadri', 'Affiliation': 'icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Lundgren', 'Affiliation': 'GUVAX (Gothenburg University Vaccine Research Institute), Dept. of Microbiology and Immunology, Inst. of Biomedicine, University of Gothenburg, Sweden. Electronic address: anna.lundgren@microbio.gu.se.'}]",Vaccine,['10.1016/j.vaccine.2018.11.040'] 1102,31858835,Training Inhibitory Control Induced Robust Neural Changes When Behavior Is Affected: A Follow-up Study Using Cognitive Event-Related Potentials.,"Cognitive training results in significant, albeit modest, improvements in specific cognitive functions across a range of mental illnesses. Inhibitory control, defined as the ability to stop the execution of an automatic reaction or a planned motor behavior, is known to be particularly important for the regulation of health behaviors, including addictive behaviors. For example, several studies have indicated that inhibitory training can lead to reduced alcohol consumption or a loss of weight/reduced energy intake. However, the exact neurocognitive mechanisms that underlie such behavioral changes induced by training are still matter of debate. In the present study, we investigated the long-term impact (ie, at 1 week posttraining) of an inhibitory training program (composed of 4 consecutive daily training sessions of 20 minutes each) on the performance of a Go/No-go task. Healthy participants were randomly assigned to 1 of 3 designated groups: (1) an Inhibition Training (IT) group that received training based on a hybrid flanker Go/No-go task; (2) a group that received a noninhibition-based (ie, episodic memory; EM) training; and (3) a No-Training (NT) group to control for test-retest effects. Each group underwent 3 sessions of a Go/No-go task concomitant with the recording of event-related potentials. Our results revealed a specific impact of the Inhibitory Training on the Go/No-go task, indexed by a faster process compared with the other 2 groups. This effect was neurophysiologically indexed by a faster N2 component on the difference NoGo-Go waveform. Importantly, effects at both the behavioral and at the neural level were still readily discernible 1 week posttraining. Thus, our data clearly corroborate the notion that cognitive training is effective, while also indicating that it may persist over time.",2020,"Our results revealed a specific impact of the Inhibitory Training on the Go/No-go task, indexed by a faster process compared with the other 2 groups.",['Healthy participants'],"['Inhibition Training (IT) group that received training based on a hybrid flanker', 'noninhibition-based (ie, episodic memory; EM) training; and (3) a No-Training (NT', 'Go/No-go task concomitant with the recording of event-related potentials', 'inhibitory training program', 'Cognitive training']","['Neural Changes', 'specific cognitive functions']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0020205', 'cui_str': 'Hybrids'}, {'cui': 'C0561843', 'cui_str': 'Autobiographical Memory'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0282171', 'cui_str': 'Potentials, Event-Related'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}]",,0.0162187,"Our results revealed a specific impact of the Inhibitory Training on the Go/No-go task, indexed by a faster process compared with the other 2 groups.","[{'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Schroder', 'Affiliation': ""Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.""}, {'ForeName': 'Macha', 'Initials': 'M', 'LastName': 'Dubuson', 'Affiliation': ""Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.""}, {'ForeName': 'Clémence', 'Initials': 'C', 'LastName': 'Dousset', 'Affiliation': ""Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.""}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Mortier', 'Affiliation': ""Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.""}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Kornreich', 'Affiliation': ""Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.""}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Campanella', 'Affiliation': ""Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.""}]",Clinical EEG and neuroscience,['10.1177/1550059419895146'] 1103,31950156,Effect of Omega-3 Supplementation in Patients With Smell Dysfunction Following Endoscopic Sellar and Parasellar Tumor Resection: A Multicenter Prospective Randomized Controlled Trial.,"BACKGROUND Endoscopic endonasal approaches pose the potential risk of olfactory loss. Loss of olfaction and potentially taste can be permanent and greatly affect patients' quality of life. Treatments for olfactory loss have had limited success. Omega-3 supplementation may be a therapeutic option with its effect on wound healing and nerve regeneration. OBJECTIVE To evaluate the impact on olfaction in patients treated with omega-3 supplementation following endoscopic skull base tumor resection. METHODS In this multi-institutional, prospective, randomized controlled trial, 110 patients with sellar or parasellar tumors undergoing endoscopic resection were randomized to nasal saline irrigations or nasal saline irrigations plus omega-3 supplementation. The University of Pennsylvania Smell Identification Test (UPSIT) was administered preoperatively and at 6 wk, 3 mo, and 6 mo postoperatively. RESULTS Eighty-seven patients completed all 6 mo of follow-up (41 control arm, 46 omega-3 arm). At 6 wk postoperatively, 25% of patients in both groups experienced a clinically significant loss in olfaction. At 3 and 6 mo, patients receiving omega-3 demonstrated significantly less persistent olfactory loss compared to patients without supplementation (P = .02 and P = .01, respectively). After controlling for multiple confounding variables, omega-3 supplementation was found to be protective against olfactory loss (odds ratio [OR] 0.05, 95% CI 0.003-0.81, P = .03). Tumor functionality was a significant independent predictor for olfactory loss (OR 32.7, 95% CI 1.15-929.5, P = .04). CONCLUSION Omega-3 supplementation appears to be protective for the olfactory system during the healing period in patients who undergo endoscopic resection of sellar and parasellar masses.",2020,"Tumor functionality was a significant independent predictor for olfactory loss (OR 32.7, 95% CI 1.15-929.5, P = .04). ","['patients treated with omega-3 supplementation following endoscopic skull base tumor resection', '110 patients with sellar or parasellar tumors undergoing endoscopic resection', 'patients who undergo endoscopic resection of sellar and parasellar masses', 'Patients With Smell Dysfunction Following Endoscopic Sellar and Parasellar Tumor Resection']","['Omega-3 supplementation', 'nasal saline irrigations or nasal saline irrigations plus omega-3 supplementation', 'Omega-3 Supplementation']","['olfaction', 'protective against olfactory loss', 'persistent olfactory loss', 'olfactory loss']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C1719844', 'cui_str': 'Greek letter omega'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0149543', 'cui_str': 'Cranial Base'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0998863', 'cui_str': 'Osmeridae'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}]","[{'cui': 'C1719844', 'cui_str': 'Greek letter omega'}, {'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0022100', 'cui_str': 'Lavage'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0037361', 'cui_str': 'Sense of Smell'}, {'cui': 'C0439826', 'cui_str': 'Olfactory (qualifier value)'}]",110.0,0.0704208,"Tumor functionality was a significant independent predictor for olfactory loss (OR 32.7, 95% CI 1.15-929.5, P = .04). ","[{'ForeName': 'Carol H', 'Initials': 'CH', 'LastName': 'Yan', 'Affiliation': 'Department of Otolaryngology/Head and Neck Surgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Aakanksha', 'Initials': 'A', 'LastName': 'Rathor', 'Affiliation': 'Department of Otolaryngology/Head and Neck Surgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Kaelyn', 'Initials': 'K', 'LastName': 'Krook', 'Affiliation': 'Department of Otolaryngology/Head and Neck Surgery, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Yifei', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': 'Department of Otolaryngology/Head and Neck Surgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Melissa R', 'Initials': 'MR', 'LastName': 'Rotella', 'Affiliation': 'Department of Otolaryngology/Head and Neck Surgery, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Dodd', 'Affiliation': 'Department of Neurosurgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Peter H', 'Initials': 'PH', 'LastName': 'Hwang', 'Affiliation': 'Department of Otolaryngology/Head and Neck Surgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Jayakar V', 'Initials': 'JV', 'LastName': 'Nayak', 'Affiliation': 'Department of Otolaryngology/Head and Neck Surgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Nelson M', 'Initials': 'NM', 'LastName': 'Oyesiku', 'Affiliation': 'Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'DelGaudio', 'Affiliation': 'Department of Otolaryngology/Head and Neck Surgery, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Joshua M', 'Initials': 'JM', 'LastName': 'Levy', 'Affiliation': 'Department of Otolaryngology/Head and Neck Surgery, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Wise', 'Affiliation': 'Department of Psychology, Oglethorpe University, Atlanta, Georgia.'}, {'ForeName': 'Sarah K', 'Initials': 'SK', 'LastName': 'Wise', 'Affiliation': 'Department of Otolaryngology/Head and Neck Surgery, Emory University School of Medicine, Atlanta, Georgia.'}, {'ForeName': 'Zara M', 'Initials': 'ZM', 'LastName': 'Patel', 'Affiliation': 'Department of Otolaryngology/Head and Neck Surgery, Stanford University School of Medicine, Stanford, California.'}]",Neurosurgery,['10.1093/neuros/nyz559'] 1104,31871115,Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.,"BACKGROUND There is a lack of data exploring the use and optimal timing of immunotherapy and chemoradiation therapy (CRT) in node-positive cervical cancer. Further translational research into mechanisms of response and resistance to immunotherapy in advanced cervical cancer is warranted. PRIMARY OBJECTIVES To determine if sequencing of atezolizumab and CRT result in differential immune activation, as determined by clonal expansion of T cell receptor beta (TCRB) repertoires in peripheral blood on day 21. STUDY HYPOTHESIS There is a difference for clonal expansion of T cell receptor beta repertoires in the peripheral blood at day 21 between the priming and concurrent atezolizumab and CRT in Arm A vs the concurrent atezolizumab and CRT in Arm B. TRIAL DESIGN Locally advanced cervical cancer patients with lymph node-positive disease will be randomized on this open-label, randomized trial with two experimental arms. Arm A will get one dose of atezolizumab prior to cisplatin CRT, and then two subsequent doses of atezolizumab during the CRT, and Arm B will get three doses during CRT. Patients will be followed for 2 years to assess outcomes. MAJOR INCLUSION/EXCLUSION CRITERIA Patients must have histologically confirmed, newly diagnosed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): FIGO 2009 clinical stages IB2/IIA with positive para-aortic nodes, or FIGO 2009 clinical stages IIB/IIIB/IVA with positive pelvic or para-aortic lymph nodes. Exclusion criteria include those who had a prior hysterectomy or lymph node dissection. PRIMARY ENDPOINTS Clonal expansion of TCRB) repertoires in peripheral blood on day 21. SAMPLE SIZE The sample size will be 40 patients. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS We estimate accrual to finish by the summer of 2020 with presentation of results to follow in 2021. TRIAL REGISTRATION NCT03738228.",2020,"There is a difference for clonal expansion of T cell receptor beta repertoires in the peripheral blood at day 21 between the priming and concurrent atezolizumab and CRT in Arm A vs the concurrent atezolizumab and CRT in Arm B. ","['Patients must have histologically confirmed, newly diagnosed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): FIGO 2009 clinical stages IB2/IIA with positive para-aortic nodes, or FIGO 2009 clinical stages IIB/IIIB/IVA with positive pelvic or para-aortic lymph nodes', '40 patients', 'node-positive locally advanced cervical cancer', 'Exclusion criteria include those who had a prior hysterectomy or lymph node dissection', 'advanced cervical cancer', 'node-positive cervical cancer', 'Locally advanced cervical cancer patients with lymph node-positive disease']","['Anti-PD-L1 (atezolizumab', 'immunotherapy and chemoradiation therapy (CRT', 'atezolizumab and CRT', 'atezolizumab', 'atezolizumab prior to cisplatin CRT']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix (disorder)'}, {'cui': 'C0007137', 'cui_str': 'Carcinoma, Planocellular'}, {'cui': 'C0001418', 'cui_str': 'Adenoma, Malignant'}, {'cui': 'C0206623', 'cui_str': 'Adenosquamous cell carcinoma'}, {'cui': 'C0205563', 'cui_str': 'Clinical staging (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0740255', 'cui_str': 'Para-aortic lymph node group (body structure)'}, {'cui': 'C0030797', 'cui_str': 'Pelvic Region'}, {'cui': 'C0229789', 'cui_str': 'Para-aortic node (body structure)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0242382', 'cui_str': 'Lymph Node Dissection'}, {'cui': 'C0024204', 'cui_str': 'Lymphatic gland'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C4055433', 'cui_str': 'atezolizumab'}, {'cui': 'C0021083', 'cui_str': 'Immunotherapy'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}]",[],,0.173007,"There is a difference for clonal expansion of T cell receptor beta repertoires in the peripheral blood at day 21 between the priming and concurrent atezolizumab and CRT in Arm A vs the concurrent atezolizumab and CRT in Arm B. ","[{'ForeName': 'Jyoti', 'Initials': 'J', 'LastName': 'Mayadev', 'Affiliation': 'Department of Radiation Medicine and Applied Sciences, University of California San Diego Medical Center, La Jolla, California, USA jmayadev@ucsd.edu.'}, {'ForeName': 'Dmitriy', 'Initials': 'D', 'LastName': 'Zamarin', 'Affiliation': 'Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Deng', 'Affiliation': 'Department of Biostatistics and Bioinformatics, NRG Oncology, Clinical Trial Development Division, Buffalo, New York, USA.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Lankes', 'Affiliation': ""Biopathology Center, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.""}, {'ForeName': 'Roisin', 'Initials': 'R', 'LastName': ""O'Cearbhaill"", 'Affiliation': 'Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.'}, {'ForeName': 'Carol A', 'Initials': 'CA', 'LastName': 'Aghajanian', 'Affiliation': 'Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.'}, {'ForeName': 'Russell', 'Initials': 'R', 'LastName': 'Schilder', 'Affiliation': 'Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.'}]",International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,['10.1136/ijgc-2019-001012'] 1105,30944040,Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).,"BACKGROUND Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells. The primary objective of the study is to evaluate the change in cerebral glucose metabolic rate after 12 months of treatment with liraglutide in participants with Alzheimer's disease compared to those who are receiving placebo. METHODS/DESIGN ELAD is a 12-month, multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild Alzheimer's dementia. A total of 206 participants will be randomised to receive either liraglutide or placebo as a daily injection for a year. The primary outcome will be the change in cerebral glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cingulate) from baseline to follow-up in the treatment group compared with the placebo group. The key secondary outcomes are the change from baseline to 12 months in z scores for clinical and cognitive measures (Alzheimer's Disease Assessment Scale-Cognitive Subscale and Executive domain scores of the Neuropsychological Test Battery, Clinical Dementia Rating Sum of Boxes, and Alzheimer's Disease Cooperative Study-Activities of Daily Living) and the incidence and severity of treatment-emergent adverse events or clinically important changes in safety assessments. Other secondary outcomes are 12-month change in magnetic resonance imaging volume, diffusion tensor imaging parameters, reduction in microglial activation in a subgroup of participants, reduction in tau formation and change in amyloid levels in a subgroup of participants measured by tau and amyloid imaging, and changes in composite scores using support machine vector analysis in the treatment group compared with the placebo group. DISCUSSION Alzheimer's disease is a leading cause of morbidity worldwide. As available treatments are only symptomatic, the search for disease-modifying therapies is a priority. If the ELAD trial is successful, liraglutide and GLP-1 analogues will represent an important class of compounds to be further evaluated in clinical trials for Alzheimer's treatment. TRIAL REGISTRATION ClinicalTrials.gov, NCT01843075 . Registration 30 April 2013.",2019,"Other secondary outcomes are 12-month change in magnetic resonance imaging volume, diffusion tensor imaging parameters, reduction in microglial activation in a subgroup of participants, reduction in tau formation and change in amyloid levels in a subgroup of participants measured by tau and amyloid imaging, and changes in composite scores using support machine vector analysis in the treatment group compared with the placebo group. ","[""participants with mild Alzheimer's dementia"", '206 participants', ""Alzheimer's disease"", ""participants with Alzheimer's disease""]","['liraglutide or placebo', 'novel GLP-1 analogue liraglutide', 'placebo', 'liraglutide']","['tau formation and change in amyloid levels', ""z scores for clinical and cognitive measures (Alzheimer's Disease Assessment Scale-Cognitive Subscale and Executive domain scores of the Neuropsychological Test Battery, Clinical Dementia Rating Sum of Boxes, and Alzheimer's Disease Cooperative Study-Activities of Daily Living) and the incidence and severity of treatment-emergent adverse events or clinically important changes in safety assessments"", 'change in cerebral glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cingulate', 'cerebral glucose metabolic rate', 'magnetic resonance imaging volume, diffusion tensor imaging parameters, reduction in microglial activation']","[{'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}]","[{'cui': 'C1456408', 'cui_str': 'liraglutide'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-Like Peptide 1'}]","[{'cui': 'C1720655', 'cui_str': 'Tau'}, {'cui': 'C0439634', 'cui_str': 'Formations (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0450989', 'cui_str': ""Alzheimer's disease assessment scale (assessment scale)""}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychologic Tests'}, {'cui': 'C0542351', 'cui_str': 'Battery (event)'}, {'cui': 'C0451074', 'cui_str': 'Dementia Rating Scale'}, {'cui': 'C1638312', 'cui_str': 'Boxes'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001288', 'cui_str': 'ADL'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0949582', 'cui_str': 'Seahorses'}, {'cui': 'C0205098', 'cui_str': 'Medial (qualifier value)'}, {'cui': 'C0039485', 'cui_str': 'Temporal Region'}, {'cui': 'C0175191', 'cui_str': 'Posterior Cingulate'}, {'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C1537007', 'cui_str': 'Diffusion Tensor MRI'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]",206.0,0.670611,"Other secondary outcomes are 12-month change in magnetic resonance imaging volume, diffusion tensor imaging parameters, reduction in microglial activation in a subgroup of participants, reduction in tau formation and change in amyloid levels in a subgroup of participants measured by tau and amyloid imaging, and changes in composite scores using support machine vector analysis in the treatment group compared with the placebo group. ","[{'ForeName': 'Grazia Daniela', 'Initials': 'GD', 'LastName': 'Femminella', 'Affiliation': 'Department of Medicine, Imperial College London, London, UK.'}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Frangou', 'Affiliation': 'Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Sharon B', 'Initials': 'SB', 'LastName': 'Love', 'Affiliation': 'Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Busza', 'Affiliation': 'Department of Medicine, Imperial College London, London, UK.'}, {'ForeName': 'Clive', 'Initials': 'C', 'LastName': 'Holmes', 'Affiliation': 'Southern Health NHS Foundation Trust, Havant, UK.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Ritchie', 'Affiliation': 'Department of Medicine, Imperial College London, London, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Lawrence', 'Affiliation': ""SW London and St George's Mental Health Trust, London , UK.""}, {'ForeName': 'Brady', 'Initials': 'B', 'LastName': 'McFarlane', 'Affiliation': 'Southern Health NHS Foundation Trust, Havant, UK.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Tadros', 'Affiliation': 'Aston Medical school, Aston University, Birmingham, UK.'}, {'ForeName': 'Basil H', 'Initials': 'BH', 'LastName': 'Ridha', 'Affiliation': 'Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Bannister', 'Affiliation': 'South London and Maudsley NHS Foundation Trust, London, UK.'}, {'ForeName': 'Zuzana', 'Initials': 'Z', 'LastName': 'Walker', 'Affiliation': 'University College London and Essex Partnership University NHS Foundation Trust, Runwell, UK.'}, {'ForeName': 'Hilary', 'Initials': 'H', 'LastName': 'Archer', 'Affiliation': 'North Bristol NHS Trust, Bristol, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Coulthard', 'Affiliation': 'North Bristol NHS Trust, Bristol, UK.'}, {'ForeName': 'Ben R', 'Initials': 'BR', 'LastName': 'Underwood', 'Affiliation': 'Cambridgeshire and Peterborough NHS Foundation Trust, Peterborough, UK.'}, {'ForeName': 'Aparna', 'Initials': 'A', 'LastName': 'Prasanna', 'Affiliation': 'Black Country Partnership NHS Foundation Trust, West Bromwich, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Koranteng', 'Affiliation': 'Northamptonshire Healthcare NHS Foundation Trust, Kettering, UK.'}, {'ForeName': 'Salman', 'Initials': 'S', 'LastName': 'Karim', 'Affiliation': 'Lancashire Care NHS Foundation Trust, Preston, UK.'}, {'ForeName': 'Kehinde', 'Initials': 'K', 'LastName': 'Junaid', 'Affiliation': 'Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, UK.'}, {'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'McGuinness', 'Affiliation': ""Centre for Public Health, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Ramin', 'Initials': 'R', 'LastName': 'Nilforooshan', 'Affiliation': 'Surrey and Borders Partnership NHS Foundation Trust, Leatherhead, UK.'}, {'ForeName': 'Ajay', 'Initials': 'A', 'LastName': 'Macharouthu', 'Affiliation': 'NHS Ayrshire and Arran, Crosshouse, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Donaldson', 'Affiliation': 'NHS Lanarkshire, Glasgow, UK.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Thacker', 'Affiliation': 'Derbyshire Healthcare NHS Foundation Trust, Derby, UK.'}, {'ForeName': 'Gregor', 'Initials': 'G', 'LastName': 'Russell', 'Affiliation': 'Bradford District Care NHS Foundation Trust, Bradford, UK.'}, {'ForeName': 'Naghma', 'Initials': 'N', 'LastName': 'Malik', 'Affiliation': '5 Boroughs Partnership NHS Foundation Trust, Warrington, UK.'}, {'ForeName': 'Vandana', 'Initials': 'V', 'LastName': 'Mate', 'Affiliation': 'Cornwall Partnership NHS Foundation Trust, Redruth, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Knight', 'Affiliation': 'Somerset Partnership NHS Foundation Trust, Bridgwater, UK.'}, {'ForeName': 'Sajeev', 'Initials': 'S', 'LastName': 'Kshemendran', 'Affiliation': 'South Staffordshire and Shropshire Healthcare NHS Foundation Trust, Stafford, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Harrison', 'Affiliation': 'Alzheimer Center VUmc Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Brooks', 'Affiliation': 'Department of Medicine, Imperial College London, London, UK.'}, {'ForeName': 'Anthony Peter', 'Initials': 'AP', 'LastName': 'Passmore', 'Affiliation': ""Centre for Public Health, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Clive', 'Initials': 'C', 'LastName': 'Ballard', 'Affiliation': 'South London and Maudsley NHS Foundation Trust, London, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Edison', 'Affiliation': 'Department of Medicine, Imperial College London, London, UK. paul.edison@imperial.ac.uk.'}]",Trials,['10.1186/s13063-019-3259-x'] 1106,31796304,[The effects of remifentanil used during cesarean section on oxidative stress markers in correlation with maternal hemodynamics and neonatal outcome: a randomized controlled trial].,"BACKGROUND AND OBJECTIVE Remifentanil is used to attenuate maternal hemodynamic response to intubation and surgical stress during Induction-Delivery period of cesarean section. The goal was to compare the effects of two remifentanil dosing regimens on oxidative stress level, in correlation with its hemodynamic and neonatal effects. METHODS Fifty-one patients, 17 per group, enrolled for elective cesarean section were randomly divided by computer-generated codes into three parallel groups: (A) patients received a 1μg.kg -1 remifentanil bolus immediately before induction, followed by 0.15μg.kg -1 .min -1 infusion, that was stopped after skin incision; (B) patients received a 1μg.kg -1 remifentanil bolus immediately before induction; (C) (control), patients did not receive remifentanil until delivery. Maternal venous blood samples were taken at basal time, at extraction and 30minutes after the end of operation for spectrophotometrical determination of malondialdehyde and advanced oxidation protein products concentration. The same was conducted for umbilical venous sample. RESULTS Systolic blood pressure and heart rate remained significantly lower in group A compared to B and C during entire Induction-Delivery period (p<0.001, p=0.02 after intubation; p=0.006, p=0.03 after skin incision; p=0.029, p=0.04 after extraction; respectively). Malondialdehyde concentration was lower at time of extraction in maternal blood in group A compared to B and C (p=0.026). All neonatal Apgar scores were ≥ 8 and umbilical acid-base values within normal range. CONCLUSIONS The remifentanil dosing regimen applied in group A significantly attenuated lipid peroxidation and maternal hemodynamic response during entire I-D period, without compromising neonatal outcome.",2019,"RESULTS Systolic blood pressure and heart rate remained significantly lower in group A compared to B and C during entire Induction-Delivery period (p<0.001, p=0.02 after intubation; p=0.006, p=0.03 after skin incision; p=0.029, p=0.04 after extraction; respectively).","['Fifty-one patients, 17 per group, enrolled for elective cesarean section']","['1μg.kg -1 remifentanil bolus immediately before induction', 'remifentanil', 'Remifentanil', '1μg.kg -1 remifentanil', 'caesarean section']","['maternal hemodynamic response', 'lipid peroxidation and maternal hemodynamic response', 'oxidative stress markers', 'oxidative stress level', 'Malondialdehyde concentration', 'Systolic blood pressure and heart rate', 'Maternal venous blood samples', 'All neonatal Apgar scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}]","[{'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0007876', 'cui_str': 'C-Section (OB)'}]","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0023775', 'cui_str': 'Lipid Peroxidation'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0444255', 'cui_str': 'Venous blood specimen'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0003533', 'cui_str': 'Apgar Score'}]",51.0,0.0576957,"RESULTS Systolic blood pressure and heart rate remained significantly lower in group A compared to B and C during entire Induction-Delivery period (p<0.001, p=0.02 after intubation; p=0.006, p=0.03 after skin incision; p=0.029, p=0.04 after extraction; respectively).","[{'ForeName': 'Marija S', 'Initials': 'MS', 'LastName': 'Kutlesic', 'Affiliation': 'University Clinical Centre Nis, Clinic of Anaesthesiology, Niš, Sérvia. Electronic address: mkutlesic5@gmail.com.'}, {'ForeName': 'Gordana', 'Initials': 'G', 'LastName': 'Kocic', 'Affiliation': 'University of Niš, Faculty of Medicine, Niš, Sérvia.'}, {'ForeName': 'Ranko M', 'Initials': 'RM', 'LastName': 'Kutlesic', 'Affiliation': 'University of Niš, Faculty of Medicine, Niš, Sérvia; University Clinical Centre Niš, Clinic of Obstetrics and Gynaecology, Niš, Sérvia.'}]",Revista brasileira de anestesiologia,['10.1016/j.bjan.2019.05.005'] 1107,31484181,Endoscopic Tympanoplasty without Mastoidectomy for Active Mucosal Chronic Otitis Media with Mastoid and Tympanic Antrum Lesions: A Prospective Clinical Study.,"OBJECTIVE This study aims to assess the effectiveness of endoscopic tympanoplasty without mastoidectomy in the management of active mucosal chronic otitis media (COM) patients with mastoid and tympanic antrum lesions. METHODS It is a prospective controlled study where 42 patients with active mucosal COM with mastoid and tympanic antrum lesions or normal aeration were recruited from the outpatient clinic of the otology department, Eye Ear Nose and Throat Hospital of Fudan University. All patients underwent endoscopic tympanoplasty without mastoidectomy by using the underlay technique with tragal cartilage graft with one side-perichondrium. The follow-up period was at least 3 months and results were evaluated in terms of graft uptake, ear dryness and hearing improvement. RESULTS Statistics showed no significant difference in graft uptake between the mastoid and tympanic antrum lesions group (90.5%) and the normal aeration group (95.2%). There was no significant difference in ear dryness between the mastoid and tympanic antrum lesions group (95.2%) and the normal aeration group (100%). Hearing improvement was comparable in the 2 groups. CONCLUSION Regardless of the occurrence of soft density shadows in temporal bone showed by high-resolution computerized tomography in the mastoid and tympanic antrum, mastoidectomy is an unnecessary procedure for dealing with active mucosal COM without cholesteatoma. Therefore, this study shows that endoscopic tympanoplasty without mastoidectomy may be applied to active mucosal COM without cholesteatoma.",2019,"The follow-up period was at least 3 months and results were evaluated in terms of graft uptake, ear dryness and hearing improvement. ","['42 patients with active mucosal COM with mastoid and tympanic antrum lesions or normal aeration were recruited from the outpatient clinic of the otology department, Eye Ear Nose and Throat Hospital of Fudan University', 'Active Mucosal Chronic Otitis Media with Mastoid and Tympanic Antrum Lesions', 'active mucosal chronic otitis media (COM) patients with mastoid and tympanic antrum lesions']","['Endoscopic Tympanoplasty without Mastoidectomy', 'endoscopic tympanoplasty without mastoidectomy', 'endoscopic tympanoplasty without mastoidectomy by using the underlay technique with tragal cartilage graft with one side-perichondrium']","['Hearing improvement', 'graft uptake, ear dryness and hearing improvement', 'graft uptake', 'ear dryness']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0026724', 'cui_str': 'Mucosal Tissue'}, {'cui': 'C0446908', 'cui_str': 'Mastoid Bone'}, {'cui': 'C0229428', 'cui_str': 'Mastoid antrum structure'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}, {'cui': 'C0086746', 'cui_str': 'Otology'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0013443', 'cui_str': 'Vestibulocochlear Apparatus'}, {'cui': 'C0028429', 'cui_str': 'Nose'}, {'cui': 'C0230069', 'cui_str': 'Structure of anterior portion of neck'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0271441', 'cui_str': 'Chronic otitis media (disorder)'}]","[{'cui': 'C0041447', 'cui_str': 'Tympanoplasty'}, {'cui': 'C0198154', 'cui_str': 'Mastoidectomy'}, {'cui': 'C0444455', 'cui_str': 'Underlay (qualifier value)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C1271247', 'cui_str': 'Grafting of cartilage'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0225361', 'cui_str': 'Perichondrium (body structure)'}]","[{'cui': 'C0018767', 'cui_str': 'Audition'}, {'cui': 'C1527362', 'cui_str': 'grafts'}, {'cui': 'C0013443', 'cui_str': 'Vestibulocochlear Apparatus'}]",,0.0377483,"The follow-up period was at least 3 months and results were evaluated in terms of graft uptake, ear dryness and hearing improvement. ","[{'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'He', 'Affiliation': 'Department of Otorhinolaryngology Head and Neck Surgery, Chongqing General Hospital, Chongqing, China.'}, {'ForeName': 'Zhu', 'Initials': 'Z', 'LastName': 'Shou', 'Affiliation': ""Department of Otorhinolaryngology, The People's Hospital of Yubei, Chongqing, China.""}, {'ForeName': 'Yuelin', 'Initials': 'Y', 'LastName': 'Hsieh', 'Affiliation': 'Department of Otology and Skull Base Surgery, Eye Ear Nose and Throat Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Chengjin', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Otology and Skull Base Surgery, Eye Ear Nose and Throat Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jinyu', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Otology and Skull Base Surgery, Eye Ear Nose and Throat Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Zhao', 'Initials': 'Z', 'LastName': 'Han', 'Affiliation': 'Department of Otology and Skull Base Surgery, Eye Ear Nose and Throat Hospital, Fudan University, Shanghai, China, sfhanzao@163.com.'}, {'ForeName': 'Fang-Lu', 'Initials': 'FL', 'LastName': 'Chi', 'Affiliation': 'Department of Otology and Skull Base Surgery, Eye Ear Nose and Throat Hospital, Fudan University, Shanghai, China.'}]",ORL; journal for oto-rhino-laryngology and its related specialties,['10.1159/000501912'] 1108,31445345,"A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder.","BACKGROUND Escalating doses of selective serotonin reuptake inhibitors are often used to treat patients with a suboptimal response to the standard dose. This study assessed the efficacy and safety of dose escalation of escitalopram, up to 30 mg, in non-remitters with major depressive disorder (MDD) after treatment with the standard dose. METHOD We recruited 98 patients with MDD (aged 18-65 years). After 4 weeks of open-label treatment with 10-20 mg of escitalopram per day, non-remitters [Montgomery-Åsberg Depression Rating Scale (MADRS) score > 10] were randomized 1:1 for double-blind treatment with either escitalopram (30 mg per day) or escitalopram (20 mg per day) plus placebo for 6 weeks. The primary efficacy outcome was a change in the total MADRS score. RESULTS After 4 weeks of open-label treatment, 12 patients achieved remission, and 36 dropped out, leaving 50 non-remitters, of whom 44 (88%) completed the double-blind study. The primary outcome measure, the least-squares mean (standard error) change in the total MADRS score at week 6 was significantly different (p = 0.046) between the groups [-8.0 (1.2) in the placebo dose-escalation and -11.8 (1.2) in the escitalopram dose-escalation]. The dose escalation of escitalopram was well tolerated. However, the response and remission rates and quality of life showed no significant differences. LIMITATIONS Small sample size and short follow-up period CONCLUSION: This study suggests that dose escalation of escitalopram up to 30 mg per day may be beneficial for the treatment of depressive symptoms in non-remitters after standard (10-20 mg/day) treatment.",2019,"However, the response and remission rates and quality of life showed no significant differences. ","['for major depressive disorder', 'non-remitters with major depressive disorder (MDD) after treatment with the standard dose', '98 patients with MDD (aged 18-65 years']","['placebo', 'open-label treatment with 10-20\u202fmg of escitalopram per day, non-remitters [Montgomery-Åsberg Depression Rating Scale (MADRS) score\xa0>\xa010', 'escitalopram', 'escitalopram (30\u202fmg per day) or escitalopram']","['depressive symptoms', 'total MADRS score', 'least-squares mean (standard error) change in the total MADRS score', 'response and remission rates and quality of life', 'efficacy and safety', 'tolerated']","[{'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0001758', 'cui_str': 'Follow-Up Care'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1099456', 'cui_str': 'Escitalopram'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]","[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0023189', 'cui_str': 'Least Squares'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",98.0,0.297506,"However, the response and remission rates and quality of life showed no significant differences. ","[{'ForeName': 'Eun Young', 'Initials': 'EY', 'LastName': 'Kim', 'Affiliation': 'Mental Health Center, Seoul National University Health Care Center, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea; Department of Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea.'}, {'ForeName': 'Se Hyun', 'Initials': 'SH', 'LastName': 'Kim', 'Affiliation': 'Department of Psychiatry, Seoul National University Hospital, 103 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea; Department of Psychiatry and Behavioral Science, Institute of Human Behavioral Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea.'}, {'ForeName': 'Hyun Jeong', 'Initials': 'HJ', 'LastName': 'Lee', 'Affiliation': 'Mental Health Clinic, National Cancer Center, Ilsandong-gu, Goyang-si, Gyeonggi-do 10326, Republic of Korea; Cancer Survivorship Branch, National Cancer Control Institute, National Cancer Center, Ilsandong-gu, Goyang-si, Gyeonggi-do 10326, Republic of Korea.'}, {'ForeName': 'Nam Young', 'Initials': 'NY', 'LastName': 'Lee', 'Affiliation': 'Department of Psychiatry, Dongguk University International Hospital, Dongguk University Medical School, 27 Dongguk-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 10326, Republic of Korea.'}, {'ForeName': 'Hye Young', 'Initials': 'HY', 'LastName': 'Kim', 'Affiliation': 'Department of Psychiatry, Inha University Hospital, 27 Inhang-ro, Jung-gu, Incheon 22332, Republic of Korea.'}, {'ForeName': 'C Hyung Keun', 'Initials': 'CHK', 'LastName': 'Park', 'Affiliation': 'Department of Psychiatry and Behavioral Science, Institute of Human Behavioral Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea; Department of Psychiatry, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.'}, {'ForeName': 'Yong Min', 'Initials': 'YM', 'LastName': 'Ahn', 'Affiliation': 'Department of Psychiatry, Seoul National University Hospital, 103 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea; Department of Psychiatry and Behavioral Science, Institute of Human Behavioral Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea. Electronic address: aym@snu.ac.kr.'}]",Journal of affective disorders,['10.1016/j.jad.2019.08.057'] 1109,31279221,A randomized controlled trial of unguided internet cognitive behaviour therapy for perfectionism in adolescents: Impact on risk for eating disorders.,"OBJECTIVE Perfectionism is a risk factor for the development and maintenance of eating disorders. The objective of this study was to examine the efficacy of unguided Internet cognitive behaviour therapy for perfectionism (ICBT-P) as a treatment and prevention for perfectionism and symptoms of eating disorders, anxiety, depression and self-esteem in female adolescents. METHOD Young women (N = 94, 14-19 years) who self-identified as having difficulties with perfectionism but did not have a clinical eating disorder diagnosis were recruited. Participants were randomly allocated into one of three groups: unguided ICBT-P, unguided ICBT for nonspecific stress management (ICBT-S), or waitlist control. RESULTS All analyses were intent-to-treat. ICBT-P resulted in the most favorable outcomes at post-treatment and 3- and 6-months follow-up. ICBT-P was superior to control on all outcome measures at 3- and 6-months and superior to ICBT-S on all outcomes over most time points (ds = 0.13-0.94). Clinical significance analysis demonstrated that the treatment prevented symptom increases over 6-month follow-up, with ICBT-P superior to ICBT-S in prevention of clinical perfectionism and depressive symptoms, and ICBT-P superior to waitlist control in prevention of eating disorder symptoms. There was relatively high attrition, although there were no differences in attrition between the groups at 3- and 6-month follow-up and rates were commensurate with other Internet interventions. DISCUSSION The findings support unguided ICBT-P as a useful target for preventing eating disorder and associated symptoms in female youth who self-identify as perfectionistic. ANZCTR TRIAL NUMBER ACTRN12615001098527.",2019,ICBT-P was superior to control on all outcome measures at 3- and 6-months and superior to ICBT-S on all outcomes over most time points (ds = 0.13-0.94).,"['Young women (N\u202f=\u202f94, 14-19 years) who self-identified as having difficulties with perfectionism but did not have a clinical eating disorder diagnosis were recruited', 'female adolescents', 'adolescents']","['unguided internet cognitive behaviour therapy', 'unguided Internet cognitive behaviour therapy for perfectionism (ICBT-P', 'unguided ICBT-P, unguided ICBT for nonspecific stress management (ICBT-S), or waitlist control']",['attrition'],"[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0815110', 'cui_str': 'Perfectionism'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0013473', 'cui_str': 'Eating Disorders'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0815110', 'cui_str': 'Perfectionism'}, {'cui': 'C0150788', 'cui_str': 'Manage stress control'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",[],,0.0298183,ICBT-P was superior to control on all outcome measures at 3- and 6-months and superior to ICBT-S on all outcomes over most time points (ds = 0.13-0.94).,"[{'ForeName': 'Chloe Y', 'Initials': 'CY', 'LastName': 'Shu', 'Affiliation': 'School of Psychology, Curtin University, Perth, Australia; Eating Disorders Program, Child and Adolescent Mental Health Service, Perth, Australia.'}, {'ForeName': 'Hunna J', 'Initials': 'HJ', 'LastName': 'Watson', 'Affiliation': 'School of Psychology, Curtin University, Perth, Australia; Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, United States; School of Pediatrics and Child Health, University of Western Australia, Perth, Australia.'}, {'ForeName': 'Rebecca A', 'Initials': 'RA', 'LastName': 'Anderson', 'Affiliation': 'School of Psychology, Curtin University, Perth, Australia.'}, {'ForeName': 'Tracey D', 'Initials': 'TD', 'LastName': 'Wade', 'Affiliation': 'School of Psychology, Flinders University, South Australia, Australia. Electronic address: tracey.wade@flinders.edu.au.'}, {'ForeName': 'Robert T', 'Initials': 'RT', 'LastName': 'Kane', 'Affiliation': 'School of Psychology, Curtin University, Perth, Australia.'}, {'ForeName': 'Sarah J', 'Initials': 'SJ', 'LastName': 'Egan', 'Affiliation': 'School of Psychology, Curtin University, Perth, Australia. Electronic address: S.Egan@exchange.curtin.edu.au.'}]",Behaviour research and therapy,['10.1016/j.brat.2019.103429'] 1110,32069516,Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers.,"AIMS Hetrombopag olamine is a novel small-molecule, nonpeptide thrombopoietin receptor agonist developed for immune thrombocytopenia treatment. This study aims to determine the safety and the effect of fasting duration after administration of hetrombopag on pharmacokinetics and pharmacodynamics in Chinese healthy subjects. METHODS A randomized, open-label, single-dose, 3-period crossover, self-control trial was conducted. 15 eligible subjects were enrolled and received hetrombopag 7.5 mg at day 1 of each period followed by a standard meal 4 hours postdose (treatment A/fasting condition), or a high-calorie, high-fat meal 1 hour postdose (treatment B), or a high-calorie, high-fat meal 2 hours postdose (treatment C). The plasma concentrations of hetrombopag were determined by validated liquid chromatography-tandem mass spectrometry, platelet counts were quantified by blood test. Analysis was performed using a mixed model, including treatment, period as fixed effects and participant as a random effect. RESULTS Compared with treatment A, peak concentration and area under concentration-time curve extrapolated to infinity decreased by 56 and 74.6%, and 44 and 61% in treatments B and C, respectively. The mean platelet number on day 6 increased by 15.8, 6.96 and 10.26%, respectively, in treatments A, B and C in comparison with baseline platelet level. No severe adverse events happened in any of the 3 treatments. CONCLUSION Hetrombopag was well tolerated in healthy male subjects under fasted/fed conditions. The shorter fasting duration resulted in lower hetrombopag exposure, corresponding to a lower level of platelet elevation. Therefore, we recommended oral administration of hetrombopag on an empty stomach (fasting condition) or at least 2 hours before a meal to achieve maximum bioavailability.",2020,"The mean platelet number on day 6 increase by 15.8%, 6.96% and 10.26% respectively in treatment A, B and C in comparison with baseline platelet level.","['Chinese healthy subjects', 'healthy male subjects', '15 eligible subjects', 'Healthy Volunteers']","['hetrombopag', 'hetrombopag 7.5 mg at day 1 of each period followed by a standard meal 4 h post-dose (treatment A/fasting condition), or a high-calorie, high-fat meals 1 h post-dose (treatment B), or a high-calorie, high-fat meals 2 h post-dose (treatment C', 'Post-dose Fasting Duration']","['plasma concentrations of hetrombopag', 'severe adverse events', 'shorter fasting duration', 'mean platelet number', 'C max and AUC 0-∞']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C4505753', 'cui_str': '5-(3-(2-(1-(bicyclo(4.2.0)octa-1,3,5-trien-3-yl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2-hydroxyphenyl)furan-2-carboxylic acid'}, {'cui': 'C4517859', 'cui_str': 'Seven point five'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0444664', 'cui_str': 'Standard meal (finding)'}, {'cui': 'C0439568', 'cui_str': 'Post-dose (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0700308', 'cui_str': 'Protium (substance)'}, {'cui': 'C0011744', 'cui_str': 'Hydrogen-2'}, {'cui': 'C2926735', 'cui_str': 'Duration'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C4505753', 'cui_str': '5-(3-(2-(1-(bicyclo(4.2.0)octa-1,3,5-trien-3-yl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2-hydroxyphenyl)furan-2-carboxylic acid'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0032181', 'cui_str': 'Blood Platelet Number'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0376690', 'cui_str': 'AUC'}]",15.0,0.0406373,"The mean platelet number on day 6 increase by 15.8%, 6.96% and 10.26% respectively in treatment A, B and C in comparison with baseline platelet level.","[{'ForeName': 'Guoping', 'Initials': 'G', 'LastName': 'Yang', 'Affiliation': 'Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan China.'}, {'ForeName': 'Ranglang', 'Initials': 'R', 'LastName': 'Huang', 'Affiliation': 'Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan China.'}, {'ForeName': 'Shuang', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': 'Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan China.'}, {'ForeName': 'Xingfei', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan China.'}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan China.'}, {'ForeName': 'Honghui', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan China.'}, {'ForeName': 'Zhijun', 'Initials': 'Z', 'LastName': 'Huang', 'Affiliation': 'Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan China.'}, {'ForeName': 'Chengxian', 'Initials': 'C', 'LastName': 'Guo', 'Affiliation': 'Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Pei', 'Affiliation': 'Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan China.'}, {'ForeName': 'Yanfei', 'Initials': 'Y', 'LastName': 'Tai', 'Affiliation': 'Department of Clinical Research, Jiangsu Hengrui Medicine Co., LTD., Shanghai, China.'}, {'ForeName': 'Yancong', 'Initials': 'Y', 'LastName': 'Shen', 'Affiliation': 'Department of Clinical Research, Jiangsu Hengrui Medicine Co., LTD., Shanghai, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan China.'}, {'ForeName': 'Chan', 'Initials': 'C', 'LastName': 'Zou', 'Affiliation': 'Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan China.'}]",British journal of clinical pharmacology,['10.1111/bcp.14259'] 1111,31472393,A 6-day combined wake and light therapy trial for unipolar depression.,"BACKGROUND There are a dozen studies on double or triple chronotherapy in depression (sleep deprivation [wake therapy] + light therapy + sleep advance/stabilization). We investigated efficacy and feasibility of a modified triple chronotherapy protocol. METHODS Thirty-five hospitalized patients with moderately severe non-seasonal depressive disorder, mostly free from antidepressants, underwent a 6-day protocol consisting of partial sleep deprivation late in the second half of the night (from 4:00 to 8:00) in a light therapy room (blue-enhanced white light increased hourly from 600→1300→2200→2800 lx) alternating with recovery nights with morning light treatment from 7:00 to 8:00. Patients were randomized to wear glasses with no filter (clear, N = 19) or filtering blue wavelength (orange-appearance, light intensity diminution by ∼70%, N = 16) during the treatments. Sleep was targeted to be shifted at least 1 h earlier. Depression was scored using HDRS-17 (Hamilton Depression Rating Scale) and BDI-II (Beck Depression Inventory-II) - before and after the 6-days treatment, HDRS-6-SR - daily, and visual analogue scales (VAS) for mood and energy - several times every day. RESULTS Depression levels significantly declined following the first night and after 6-days treatment, with no difference between white and orange lights. Nevertheless, some superiority of white light emerged with respect to response rate (mood VAS), immediate effect during the 4-h treatment sessions (energy VAS), and expected treatment outcomes. All patients successfully advanced bedtime/wake-up (by 30-40 minutes) and resisted naps during daytime. LIMITATIONS Relatively small sample size. CONCLUSIONS The modified triple chronotherapy was well tolerated and improved depression. Light spectrum/intensity plays some role in the response.",2019,"RESULTS Depression levels significantly declined following the first night and after 6-days treatment, with no difference between white and orange lights.","['unipolar depression', 'Thirty-five hospitalized patients with moderately severe non-seasonal depressive disorder, mostly free from antidepressants, underwent a 6-day protocol consisting of partial sleep deprivation late in the second half of the night (from 4:00 to 8:00) in a']","['wear glasses with no filter (clear, N\u202f=\u202f19) or filtering blue wavelength (orange-appearance, light intensity diminution', 'light therapy room (blue-enhanced white light increased hourly from 600→1300→2200→2800']","['Depression levels', 'HDRS-6-SR - daily, and visual analogue scales (VAS) for mood and energy - several times every day', 'Sleep', 'response rate (mood VAS', 'tolerated and improved depression', 'HDRS-17 (Hamilton Depression Rating Scale) and BDI-II (Beck Depression Inventory-II) ']","[{'cui': 'C0041696', 'cui_str': 'Unipolar Depression'}, {'cui': 'C4319605', 'cui_str': 'Thirty-five'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0521113', 'cui_str': 'Non-seasonal (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant Drugs'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0037316', 'cui_str': 'Sleep Deprivation'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}]","[{'cui': 'C0558172', 'cui_str': 'Wears glasses (finding)'}, {'cui': 'C0180860', 'cui_str': 'Filter, device (physical object)'}, {'cui': 'C2963144', 'cui_str': 'Clear (qualifier value)'}, {'cui': 'C1260957', 'cui_str': 'Blue color (qualifier value)'}, {'cui': 'C0449819', 'cui_str': 'Wavelength (qualifier value)'}, {'cui': 'C0440277', 'cui_str': 'Oranges'}, {'cui': 'C0700364', 'cui_str': 'Appearances (qualifier value)'}, {'cui': 'C0596836', 'cui_str': 'Low intensity'}, {'cui': 'C0031765', 'cui_str': 'Photoradiation Therapy'}, {'cui': 'C0563228', 'cui_str': 'White light (physical force)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0558292', 'cui_str': 'Hourly (qualifier value)'}]","[{'cui': 'C1319226', 'cui_str': 'Level of depression'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory (assessment scale)'}]",35.0,0.0244468,"RESULTS Depression levels significantly declined following the first night and after 6-days treatment, with no difference between white and orange lights.","[{'ForeName': 'Konstantin V', 'Initials': 'KV', 'LastName': 'Danilenko', 'Affiliation': 'Institute of Physiology and Basic Medicine, Timakova, 4, Novosibirsk 630117, Russia. Electronic address: kvdani@mail.ru.'}, {'ForeName': 'Maria Y', 'Initials': 'MY', 'LastName': 'Lebedinskaia', 'Affiliation': 'Institute of Physiology and Basic Medicine, Timakova, 4, Novosibirsk 630117, Russia.'}, {'ForeName': 'Evgenia V', 'Initials': 'EV', 'LastName': 'Gadetskaia', 'Affiliation': 'Institute of Physiology and Basic Medicine, Timakova, 4, Novosibirsk 630117, Russia.'}, {'ForeName': 'Alexei A', 'Initials': 'AA', 'LastName': 'Markov', 'Affiliation': 'Institute of Physiology and Basic Medicine, Timakova, 4, Novosibirsk 630117, Russia.'}, {'ForeName': 'Yana A', 'Initials': 'YA', 'LastName': 'Ivanova', 'Affiliation': 'Institute of Physiology and Basic Medicine, Timakova, 4, Novosibirsk 630117, Russia.'}, {'ForeName': 'Lyubomir I', 'Initials': 'LI', 'LastName': 'Aftanas', 'Affiliation': 'Institute of Physiology and Basic Medicine, Timakova, 4, Novosibirsk 630117, Russia; Novosibirsk State University, Novosibirsk, Russia.'}]",Journal of affective disorders,['10.1016/j.jad.2019.08.051'] 1112,10878069,Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase.,"The performances of two methods of nucleotide sequencing were compared for the detection of drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase (RT) in viruses isolated from highly RT inhibitor-experienced individuals. Of 11,677 amino acids deduced from population PCR products by both cycle sequencing and sequencing by hybridization to high-density arrays of oligonucleotide probes, 97.4% were concordant by both methods, 0.8% were discordant, and 1.7% had an ambiguous determination by at least one method. A higher rate of discordance (3.9%) was observed among RT inhibitor resistance-associated codons. In 45% of the isolates, RT codon 67 was deduced as the wild-type Asp by hybridization sequencing but as the zidovudine resistance-associated Asn by cycle sequencing. In other resistance-associated codon discordances, cycle sequencing also more commonly called a known resistance-associated amino acid than hybridization sequencing did. The nucleotide sequence in the vicinity of several codons with discordant calls influenced population-based hybridization sequencing. For isolates evaluated by additional sequencing of molecular clones of PCR products by both methods, the discordance between methods was less frequent (0.4% of all 5,994 amino acids and 0 of 494 drug resistance-associated codons). At positions which were discordant or ambiguous in the population sequences, the results of sequencing of clones by both methods were usually in agreement with the population cycle sequencing result. In summary, most RT codons were highly concordant by both methods of population-based sequencing, with discordances due in large part to genetic mixtures within or adjacent to discordant codons.",2000,The performances of two methods of nucleotide sequencing were compared for the detection of drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase (RT) in viruses isolated from highly RT inhibitor-experienced individuals.,['human immunodeficiency virus type 1 reverse transcriptase (RT) in viruses isolated from highly RT inhibitor-experienced individuals'],[],[],"[{'cui': 'C0121925', 'cui_str': 'HIV-1 reverse transcriptase'}, {'cui': 'C0042776', 'cui_str': 'Virus'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]",[],[],,0.0589665,The performances of two methods of nucleotide sequencing were compared for the detection of drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase (RT) in viruses isolated from highly RT inhibitor-experienced individuals.,"[{'ForeName': 'G J', 'Initials': 'GJ', 'LastName': 'Hanna', 'Affiliation': 'Massachusetts General Hospital, Boston, Massachusetts 02129, USA.'}, {'ForeName': 'V A', 'Initials': 'VA', 'LastName': 'Johnson', 'Affiliation': ''}, {'ForeName': 'D R', 'Initials': 'DR', 'LastName': 'Kuritzkes', 'Affiliation': ''}, {'ForeName': 'D D', 'Initials': 'DD', 'LastName': 'Richman', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Martinez-Picado', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Sutton', 'Affiliation': ''}, {'ForeName': 'J D', 'Initials': 'JD', 'LastName': 'Hazelwood', 'Affiliation': ''}, {'ForeName': 'R T', 'Initials': 'RT', 'LastName': ""D'Aquila"", 'Affiliation': ''}]",Journal of clinical microbiology,[] 1113,31470735,The Use of Online Physician Training Can Improve Patient Experience and Physician Burnout.,"The authors tested the efficacy of an integrated approach to improving patient experience and physician burnout using a 24-week online training program coupled with a physician engagement strategy. Physicians from different disciplines were randomized to intervention (n = 30) and control (n = 33) groups. Patient experience, physician burnout, and satisfaction data were assessed using patient and provider surveys. Comparisons were made pre and post intervention, and between the groups. Intervention group mean scores increased (+1.40 points) while control group scores dropped (-0.11 points; P = .039). Scores on physician burnout surveys for the intervention group improved in all areas and changes in 2 domains were statistically significant. In all, 73.5% of physicians felt the program was effective. This integrated intervention enhanced patient experience scores and positively affected physicians' level of burnout, and physicians believed this exercise was useful.",2020,Intervention group mean scores increased (+1.40 points) while control group scores dropped (-0.11 points; P = .039).,[],['Online Physician Training'],"['Patient experience, physician burnout, and satisfaction data']",[],"[{'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state (disorder)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",,0.0129183,Intervention group mean scores increased (+1.40 points) while control group scores dropped (-0.11 points; P = .039).,"[{'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Congiusta', 'Affiliation': 'Northwell Health, New Hyde Park, NY.'}, {'ForeName': 'Eric M', 'Initials': 'EM', 'LastName': 'Ascher', 'Affiliation': 'Northwell Health, New Hyde Park, NY.'}, {'ForeName': 'Seungjun', 'Initials': 'S', 'LastName': 'Ahn', 'Affiliation': 'Feinstein Institute for Medical Research, Northwell Health, Great Neck, NY.'}, {'ForeName': 'Ira S', 'Initials': 'IS', 'LastName': 'Nash', 'Affiliation': 'Northwell Health, New Hyde Park, NY.'}]",American journal of medical quality : the official journal of the American College of Medical Quality,['10.1177/1062860619869833'] 1114,31466807,Pilot testing the caregiver self-management intervention for caregivers of relatives with dementia.,"This study was designed to examine the feasibility of a caregiving self-management support program developed for caregivers of relatives with dementia in Shanghai. A total of 41 caregivers were recruited for a quasi-experimental study. The experimental group of 26 participants attended six bi-weekly social support group sessions. The control group of 15 participants received three monthly telephone instructions. All of participants received an illustrated caregiver educational booklet and three educational presentations during a six-month follow-up period. The results demonstrated a stronger sense of self-efficacy regarding the gathering of information about dementia care in both study groups compared to the baseline data. Caregivers participating in the group sessions reported better health-related quality of life, improved responses to behavioral disturbances, and efficacy in the management of stress than those who received telephone instructions. This study provided some preliminary information regarding ways to improve self-management for the target population in mainland China.",2020,"Caregivers participating in the group sessions reported better health-related quality of life, improved responses to behavioral disturbances, and efficacy in the management of stress than those who received telephone instructions.","['A total of 41 caregivers were recruited for a quasi-experimental study', 'caregivers of relatives with dementia in Shanghai', 'caregivers of relatives with dementia', 'target population in mainland China', '26 participants attended']","['telephone instructions', 'caregiver self-management intervention', 'caregiving self-management support program', 'six bi-weekly social support group sessions', 'illustrated caregiver educational booklet']","['better health-related quality of life, improved responses to behavioral disturbances, and efficacy']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C2985410', 'cui_str': 'Clinical Trials, Nonrandomized'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0039309', 'cui_str': 'Target Population'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C1456498', 'cui_str': 'Attended'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0037438'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}]","[{'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}]",41.0,0.0287799,"Caregivers participating in the group sessions reported better health-related quality of life, improved responses to behavioral disturbances, and efficacy in the management of stress than those who received telephone instructions.","[{'ForeName': 'Shu Ying', 'Initials': 'SY', 'LastName': 'Zhang', 'Affiliation': 'Tongji University School of Medicine, Tongji University, 1239 Si Ping Road, Shanghai 200092, China. Electronic address: zhangsy@tongji.edu.cn.'}, {'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Wu', 'Affiliation': 'Tongji University School of Medicine, Tongji University, 1239 Si Ping Road, Shanghai 200092, China.'}, {'ForeName': 'Dan Li', 'Initials': 'DL', 'LastName': 'Tang', 'Affiliation': 'Tongji University School of Medicine, Tongji University, 1239 Si Ping Road, Shanghai 200092, China.'}, {'ForeName': 'Xiao Shan', 'Initials': 'XS', 'LastName': 'Rong', 'Affiliation': 'Tongji University School of Medicine, Tongji University, 1239 Si Ping Road, Shanghai 200092, China.'}, {'ForeName': 'Qi Hao', 'Initials': 'QH', 'LastName': 'Guo', 'Affiliation': ""Department of gerontology, Shanghai Jiaotong University affiliated sixth people's hospital, Shanghai 200233, China. Electronic address: qhguo@sjtu.edu.cn.""}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Fang', 'Affiliation': ""Department of Neurology, Shanghai Tenth People's Hospital, Tongji University, 301 Yan Chang Zhong Road, Shanghai 200072, China.""}, {'ForeName': 'Qian Hua', 'Initials': 'QH', 'LastName': 'Zhao', 'Affiliation': 'Department of Neurology, Huashan Hospital, Fudan University, 12 Wu Lu Mu Qi Zhong Road, Shanghai 200041, China.'}, {'ForeName': 'Yan Xin', 'Initials': 'YX', 'LastName': 'Zhao', 'Affiliation': ""Department of Neurology, Shanghai Tenth People's Hospital, Tongji University, 301 Yan Chang Zhong Road, Shanghai 200072, China. Electronic address: zhao_yanxin@126.com.""}]","Geriatric nursing (New York, N.Y.)",['10.1016/j.gerinurse.2019.08.006'] 1115,31464343,Vitamin D levels were significantly higher during and after lifestyle intervention in pregnancy: A randomized controlled trial.,"INTRODUCTION Vitamin D deficiency is common in pregnancy, especially in obese women. Lifestyle intervention could potentially result in higher levels of vitamin D. We therefore aimed to study the effect of lifestyle intervention during pregnancy on serum levels of 25-hydroxyvitamin D (25(OH)D). MATERIAL AND METHODS A total of 360 obese women were randomized before gestational age 14 weeks to lifestyle intervention (diet and exercise) or routine clinical follow up (controls). Clinical outcomes and levels of 25(OH)D were determined three times: At gestational age 12-15 weeks (baseline), gestational age 28-30 weeks and 6 months postpartum. RESULTS A total of 304 (84%) women completed the intervention study and 238 (66%) attended postpartum follow up. Vitamin D levels were similar in the two groups at baseline. At gestational age 28-30 weeks and 6 months postpartum, 25(OH)D levels were significantly higher in the intervention group than in controls (75.6 vs 66.8 nmol/L, P = 0.009) and (54.8 vs 43.1 nmol/L, P = 0.013), respectively. Concurrently, vitamin D deficiency (25-hydroxyvitamin D <50 nmol/L) was less frequent in the intervention group than in controls: 15 vs 25% (P = 0.038) at gestational age 28-30 and 45 vs 63% (P = 0.011) 6 months postpartum, respectively. CONCLUSIONS Lifestyle intervention during pregnancy was associated with significantly increased vitamin D levels in late pregnancy and postpartum compared with controls.",2020,"Concurrently, vitamin D deficiency (25(OH)D <50 nmol/L) was less frequent in the intervention group compared to controls: 15% vs. 25% (P = 0.038) at gestational age 28-30 and 45% vs. 63% (P = 0.011) six months postpartum, respectively. ","['A total of 304 (84', '360 obese women were randomised before gestational age 14 weeks to', 'women completed the intervention study, and 238 (66%) attended postpartum follow-up', 'obese women', 'At gestational age 12-15 weeks (baseline), gestational age 28-30 weeks and six months postpartum']","['lifestyle intervention', 'lifestyle intervention (diet and exercise) or routine clinical follow-up (controls', 'Lifestyle intervention']","['Vitamin D levels', 'vitamin D levels', 'serum levels of 25-hydroxyvitamin D (25(OH)D', '25(OH)D levels', 'higher levels of Vitamin D']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4319607', 'cui_str': '360 (qualifier value)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1096775', 'cui_str': 'Intervention Study'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0086839', 'cui_str': 'Postpartum Period'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C4082120', 'cui_str': 'Six months'}]","[{'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0535968', 'cui_str': '25-hydroxyvitamin D'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]",360.0,0.0883229,"Concurrently, vitamin D deficiency (25(OH)D <50 nmol/L) was less frequent in the intervention group compared to controls: 15% vs. 25% (P = 0.038) at gestational age 28-30 and 45% vs. 63% (P = 0.011) six months postpartum, respectively. ","[{'ForeName': 'Mette H', 'Initials': 'MH', 'LastName': 'Tanvig', 'Affiliation': 'Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Dorte M', 'Initials': 'DM', 'LastName': 'Jensen', 'Affiliation': 'Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Marianne S', 'Initials': 'MS', 'LastName': 'Andersen', 'Affiliation': 'Department of Clinical Research, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Per G', 'Initials': 'PG', 'LastName': 'Ovesen', 'Affiliation': 'Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Jan S', 'Initials': 'JS', 'LastName': 'Jørgensen', 'Affiliation': 'Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Christina A', 'Initials': 'CA', 'LastName': 'Vinter', 'Affiliation': 'Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark.'}]",Acta obstetricia et gynecologica Scandinavica,['10.1111/aogs.13722'] 1116,11902023,An intervention to increase coping and reduce health care utilization for school-age children and adolescents with sickle cell disease.,"The purpose of this study was to examine whether coping with pain changed immediately and one year after a self-care intervention for school-age children and adolescents with sickle cell disease (SCD). Sixty-five children and 32 adolescents attended an educational program for living with SCD. They were then randomly assigned to relaxation, art therapy or attention-control groups. Coping was measured before, after the intervention, and 12 months later. Thirty-three children and 14 adolescents completed the one year follow-up. Although there was no significant increase in the overall number of coping strategies school-age children and adolescents used from baseline to 12 months, there was a significant increase in those strategies specifically targeted by the intervention. For adolescents, there was a significant increase in the total number of coping scores used before the intervention and one year later. When compared to well African-American adolescents, overall coping scores in this sample were significantly lower. Health care utilization related to clinic visits, emergency department visits and hospitalizations decreased significantly for all participants in the study.",2001,"For adolescents, there was a significant increase in the total number of coping scores used before the intervention and one year later.","['Sixty-five children and 32 adolescents attended an educational program for living with SCD', 'Thirty-three children and 14 adolescents completed the one year follow-up', 'school-age children and adolescents with sickle cell disease', 'school-age children and adolescents with sickle cell disease (SCD']","['self-care intervention', 'relaxation, art therapy or attention-control groups']","['overall number of coping strategies school', 'total number of coping scores', 'health care utilization', 'overall coping scores']","[{'cui': 'C0450385', 'cui_str': '65 (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0964695', 'cui_str': 's(7)(beta)CD'}, {'cui': 'C0450358', 'cui_str': '33 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0002895', 'cui_str': 'Sickle Cell Disease'}]","[{'cui': 'C0036592', 'cui_str': 'Self Care'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0003827', 'cui_str': 'Art Therapy'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030672', 'cui_str': 'Patient Acceptance of Healthcare'}]",65.0,0.0173012,"For adolescents, there was a significant increase in the total number of coping scores used before the intervention and one year later.","[{'ForeName': 'M E', 'Initials': 'ME', 'LastName': 'Broome', 'Affiliation': 'Center for Nursing Research, NB G012, School of Nursing, University of Alabama at Birmingham, 1530 3rd Ave. South, Birmingham, AL 35294-1210, USA. broomem@son.uab.edu'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Maikler', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Kelber', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Bailey', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Lea', 'Affiliation': ''}]",Journal of National Black Nurses' Association : JNBNA,[] 1117,31422858,A multicenter randomized controlled trial of a modified Valsalva maneuver for cardioversion of supraventricular tachycardias.,"CLINICAL QUESTION Valsalva maneuver is a recognized treatment for supraventricular tachycardia, but in clinical setting it has a low chance to achieve successful cardioversion. Studies suggested that the postural modification of valsalva maneuver may improve the rate of cardioversion. We further modified the maneuver and conduct a multicenter randomized controlled trial to test its efficacy. RESEARCH IN CONTEXT Appelboam A, Reuben A, Mann C, et al. Postural modification of the standard Valsalva maneuver for emergency treatment for supraventricular tachycardias (REVERT): a randomized controlled trial. Lancet 2015; 386 (10005):1747-53 [1]. Allison Michaud, PhD, Eddy Lang. Leg lift Valsalva maneuver for treatment of supraventricular tachycardias. CJEM 2017; 19(3):235-237 [2]. OBJECTIVE To verify the efficacy of the modified Valsalva maneuver in SVT in Chinese population and simplify the operation process further.",2020,Postural modification of the standard Valsalva maneuver for emergency treatment for supraventricular tachycardias (REVERT): a randomized controlled trial.,['supraventricular tachycardias (REVERT'],"['modified Valsalva maneuver', 'standard Valsalva maneuver', 'Leg lift Valsalva maneuver', 'modified Valsalva maneuver in SVT']",['rate of cardioversion'],"[{'cui': 'C0039240', 'cui_str': 'Supraventricular tachycardia (disorder)'}]","[{'cui': 'C0042293', 'cui_str': 'Valsalva Maneuver'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0181620', 'cui_str': 'Lift'}, {'cui': 'C0039240', 'cui_str': 'Supraventricular tachycardia (disorder)'}]","[{'cui': 'C0013778', 'cui_str': 'Electrical Cardioversion'}]",,0.0422851,Postural modification of the standard Valsalva maneuver for emergency treatment for supraventricular tachycardias (REVERT): a randomized controlled trial.,"[{'ForeName': 'Chaofeng', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': ""Cardiac Center, Beijing Chaoyang Hospital affiliated to Capital Medical University, China; Jiangsu People's Hospital of Xuzhou branch (Xuzhou Third People's Hospital), China. Electronic address: doctorchenchaofeng@163.com.""}, {'ForeName': 'Tsz Kin', 'Initials': 'TK', 'LastName': 'Tam', 'Affiliation': 'Prince of Wales Hospital, Hong Kong.'}, {'ForeName': 'Shuai', 'Initials': 'S', 'LastName': 'Sun', 'Affiliation': ""Shanxi provincial people's hospital, China.""}, {'ForeName': 'Yanyan', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': ""Jiangsu People's Hospital of Xuzhou branch (Xuzhou Third People's Hospital), China.""}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Teng', 'Affiliation': 'Xuzhou mine hospital, China.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Jin', 'Affiliation': 'Xuzhou mine hospital, China.'}, {'ForeName': 'Liujian', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'Shanghai prison general hospital, China.'}, {'ForeName': 'Xingpeng', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Cardiac Center, Beijing Chaoyang Hospital affiliated to Capital Medical University, China. Electronic address: xpliu71@vip.sina.com.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.158371'] 1118,31462735,MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.,"We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance, or Benda induction alone. Patients with a clonal marker (t[14;18] translocation and/or immunoglobulin heavy or light chain rearrangement) detected at study screening were assessed for MRD at mid-induction (MI), end of induction (EOI), and every 6-24 months post-EOI/discontinuation by real-time quantitative PCR. At MI, 41/52 (79%) patients receiving G-Benda were MRD-negative vs. 17/36 (47%) patients receiving Benda alone (p = 0.0029). At EOI, 54/63 (86%) patients receiving G-Benda were MRD-negative vs. 30/55 (55%) receiving Benda alone (p = 0.0002). MRD-negative patients at EOI had improved progression-free survival (HR, 0.33, 95% CI, 0.19-0.56, p < 0.0001) and overall survival (HR, 0.39, 95% CI, 0.19-0.78, p = 0.008) vs. MRD-positive patients, and maintained their MRD-negative status for longer if they received G maintenance than if they did not. These results suggest that the addition of G to Benda-based treatment during induction can significantly contribute to the speed and depth of response, and G maintenance in MRD-negative patients potentially delays lymphoma regrowth.",2020,patients receiving Benda alone (p = 0.0029).,"['rituximab-refractory follicular lymphoma (FL', 'Patients with a clonal marker (t[14;18] translocation and/or immunoglobulin heavy or light chain rearrangement']","['obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance, or Benda induction alone', 'bendamustine']","['MRD response', 'progression-free survival', 'overall survival']","[{'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0024301', 'cui_str': 'Brill-Symmers Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0021027', 'cui_str': 'Immune Globulins'}, {'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C0337112', 'cui_str': 'Chain, device (physical object)'}]","[{'cui': 'C2742503', 'cui_str': 'obinutuzumab'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0525079', 'cui_str': 'bendamustine'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",,0.0473059,patients receiving Benda alone (p = 0.0029).,"[{'ForeName': 'Christiane', 'Initials': 'C', 'LastName': 'Pott', 'Affiliation': 'University Hospital Schleswig-Holstein, Kiel, Germany. c.pott@med2.uni-kiel.de.'}, {'ForeName': 'Laurie H', 'Initials': 'LH', 'LastName': 'Sehn', 'Affiliation': 'British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Belada', 'Affiliation': 'Department of Internal Medicine-Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Gribben', 'Affiliation': 'Queen Mary University of London, London, UK.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Hoster', 'Affiliation': 'Hospital of the Ludwig-Maximilians University, Munich, Germany.'}, {'ForeName': 'Brad', 'Initials': 'B', 'LastName': 'Kahl', 'Affiliation': 'Washington University School of Medicine, St Louis, MO, USA.'}, {'ForeName': 'Britta', 'Initials': 'B', 'LastName': 'Kehden', 'Affiliation': 'University Hospital Schleswig-Holstein, Kiel, Germany.'}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Nicolas-Virelizier', 'Affiliation': 'University of Lyon, Lyon, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Spielewoy', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Guenter', 'Initials': 'G', 'LastName': 'Fingerle-Rowson', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Harbron', 'Affiliation': 'Roche, Welwyn Garden City, UK.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Mundt', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Wassner-Fritsch', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Bruce D', 'Initials': 'BD', 'LastName': 'Cheson', 'Affiliation': 'Georgetown University Hospital, Washington, DC, USA.'}]",Leukemia,['10.1038/s41375-019-0559-9'] 1119,11854983,A progressive relaxation intervention at the worksite for African-American women.,"This study examined the efficacy of a worksite-based intervention in reducing blood pressure and personal strain in African-American women. The experimental group (n = 22) was taught a 7-muscle group progressive relaxation intervention. The women, for home practice, used audiocassette tapes and diaries. The control group (n = 21) was asked to set aside 30 minutes for relaxation. All women who participated in the study were visited at the worksite weekly for eight weeks. At the conclusion of the study, the experimental group had a significantly lower mean physical strain score (23.23 [SD = 6.85] v. 27.41 [SD = 8.49]) and interpersonal strain (25.81 [SD = 6.25] v. 23.57 [SD = 6.06]); both groups had significant reductions in psychological strain scores. Although there were no significant differences in the blood pressure of the two groups at the end of the 8-week intervention (121.95 [SD = 13.28] v. 129.33 [SD = 14.30]), the mean systolic blood pressure of the treatment group did decrease from 130 mmHg to 121 mmHg. Findings from this study support the use of the work-place as a means of improving the cardiovascular health of working African-American women.",2000,Although there were no significant differences in the blood pressure of the two groups at the end of the 8-week intervention (121.95 [SD = 13.28] v. 129.33,"['African-American women', 'All women who participated in the study were visited at the worksite weekly for eight weeks', 'working African-American women']","['7-muscle group progressive relaxation intervention', 'worksite-based intervention', 'progressive relaxation intervention']","['mean systolic blood pressure', 'blood pressure and personal strain', 'psychological strain scores', 'interpersonal strain', 'blood pressure', 'mean physical strain score']","[{'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0162579', 'cui_str': 'Job Site'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0043227', 'cui_str': 'Work'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0004361', 'cui_str': 'Progressive Relaxation'}, {'cui': 'C0162579', 'cui_str': 'Job Site'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}]",,0.0212785,Although there were no significant differences in the blood pressure of the two groups at the end of the 8-week intervention (121.95 [SD = 13.28] v. 129.33,"[{'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Webb', 'Affiliation': 'College of Nursing, University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'K A', 'Initials': 'KA', 'LastName': 'Smyth', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Yarandi', 'Affiliation': ''}]",Journal of National Black Nurses' Association : JNBNA,[] 1120,31470444,Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.,"In patients requiring dual antiplatelet therapy (DAPT) who also have an indication to be treated with oral anticoagulant (OAC) drugs, aspirin withdrawal reduces the risk of bleeding. There is limited data on the pharmacodynamic effects associated with adding a nonvitamin K antagonist OAC on a background of aspirin and a P2Y 12 inhibitor as well as dropping aspirin. Seventy-five patients on DAPT (aspirin plus clopidogrel) were randomized to DAPT plus high-dose edoxaban (60 mg once daily, Group A), DAPT plus low-dose edoxaban (30 mg once daily, Group B), or DAPT only (Group C) for 10 ± 2 days (Phase I). Afterwards, Groups A and B interrupted aspirin and maintained clopidogrel plus edoxaban for 10 ± 2 days, while patients in Group C maintained DAPT (Phase II). Platelet aggregation and clot kinetics were assessed at baseline, end of Phase I, and end of Phase II using thrombelastography (TEG), light transmittance aggregometry (LTA), VerifyNow P2Y 12 , and serum thromboxane-B 2 . The primary endpoint was the comparison of maximum amplitude (MA) measured by TEG, a measure of clot strength, between patients on DAPT plus high-dose edoxaban and patients on DAPT only. Edoxaban prolonged in a dose-dependent manner speed of thrombin generation (TEG R; Group A: 7.7 [6.8-8.7] vs. Group B: 7.4 [6.4-8.5] vs. Group C: 6.3 [5.7-7.0]; p  = 0.05) but did not affect other markers of clot kinetics, including TEG MA (Group A: 63 [61-64] vs. Group B: 65 [63-67] vs. Group C: 64 [63-65]; p  = 0.10). After aspirin discontinuation, platelet reactivity assessed by LTA using thrombin receptor activating peptide as agonist increased to a greater extent with low-dose edoxaban. Stopping aspirin did not affect markers of P2Y 12 reactivity and had no or marginal effects on clot kinetics, but increased markers sensitive to cyclooxygenase-1 blockade.",2020,Edoxaban prolonged in a dose-dependent manner speed of thrombin generation (TEG R;,"['patients requiring dual antiplatelet therapy (DAPT) who also have an indication to be treated with oral anticoagulant (OAC) drugs', 'Seventy-five patients on', 'Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with']","['TEG MA', 'DAPT (aspirin plus clopidogrel', 'aspirin', 'edoxaban', 'aspirin withdrawal', 'Edoxaban', 'Aspirin and Clopidogrel', 'DAPT plus high-dose edoxaban', 'DAPT plus low-dose edoxaban', 'aspirin and maintained clopidogrel plus edoxaban']","['clot kinetics', 'manner speed of thrombin generation (TEG R', 'platelet reactivity', 'Platelet aggregation and clot kinetics', 'risk of bleeding', 'comparison of maximum amplitude (MA) measured by TEG, a measure of clot strength']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulation Agents'}, {'cui': 'C4319621', 'cui_str': 'Seventy-five'}, {'cui': 'C1956346', 'cui_str': 'Coronary Artery Disease'}]","[{'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C2975435', 'cui_str': 'edoxaban'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}]","[{'cui': 'C0302148', 'cui_str': 'Blood coagulum'}, {'cui': 'C0863178', 'cui_str': 'Thrombin'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0677599', 'cui_str': 'Platelet aggregation'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",75.0,0.0318158,Edoxaban prolonged in a dose-dependent manner speed of thrombin generation (TEG R;,"[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Franchi', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Fabiana', 'Initials': 'F', 'LastName': 'Rollini', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Emilio', 'Initials': 'E', 'LastName': 'Garcia', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Rivas Rios', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Rivas', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Malhar', 'Initials': 'M', 'LastName': 'Agarwal', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Megha', 'Initials': 'M', 'LastName': 'Kureti', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Deepa', 'Initials': 'D', 'LastName': 'Nagaraju', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Wali', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Maryuri', 'Initials': 'M', 'LastName': 'Briceno', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Jae Youn', 'Initials': 'JY', 'LastName': 'Moon', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Kairouz', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Dmitry', 'Initials': 'D', 'LastName': 'Yaranov', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Latonya', 'Initials': 'L', 'LastName': 'Been', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Siva', 'Initials': 'S', 'LastName': 'Suryadevara', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Soffer', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Martin M', 'Initials': 'MM', 'LastName': 'Zenni', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Theodore A', 'Initials': 'TA', 'LastName': 'Bass', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}, {'ForeName': 'Dominick J', 'Initials': 'DJ', 'LastName': 'Angiolillo', 'Affiliation': 'University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States.'}]",Thrombosis and haemostasis,['10.1055/s-0039-1695772'] 1121,31468596,"The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial.","Infertility is a major, worldwide problem that is affected, and mediated, by several factors, in particular, oxidative stress. Thus, the aim of this study was to evaluate the effect of lycopene supplementation on spermatogram and seminal oxidative stress. In this randomized, double-blind, placebo-controlled trial study, 44 infertile men with oligozoospermia were randomly divided into two groups: The experimental group was supplemented with 25 mg of lycopene, and the control group received placebo for 12 weeks. Anthropometric, physical activity and dietary assessment, semen analysis, total antioxidant capacity (TAC), malondialdehyde, and glutathione peroxidase were measured pre- and post-intervention. At the end of the study, there was a significant increase in total sperm count and concentration in the lycopene group, and the latter total count remained significant after adjustment (p < .05). Intragroup analysis showed a significant increase in ejaculate volume, total sperm count, concentration total motility, nonprogressive, and nonmotility in lycopene group (p < .05). The TAC changes, in both groups, remained significant after adjustment (p < .05). Also, within-group analysis showed a significant increase in TAC levels (p < .05). Lycopene supplement can improve sperm parameters and oxidative stress biomarkers in oligozoospermia infertile men; however, further studies with larger sample size and duration are required.",2019,"Intragroup analysis showed a significant increase in ejaculate volume, total sperm count, concentration total motility, nonprogressive, and nonmotility in lycopene group (p < .05).","['infertile men', '44 infertile men with oligozoospermia', 'oligozoospermia infertile men']","['placebo', 'Lycopene supplement', 'lycopene supplement', 'lycopene', 'lycopene supplementation']","['total sperm count and concentration', 'spermatogram and seminal oxidative stress', 'sperm parameters and oxidative stress biomarkers', 'latter total count', 'TAC levels', 'ejaculate volume, total sperm count, concentration total motility, nonprogressive, and nonmotility', 'Anthropometric, physical activity and dietary assessment, semen analysis, total antioxidant capacity (TAC), malondialdehyde, and glutathione peroxidase']","[{'cui': 'C0021359', 'cui_str': 'Infertility'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0868910', 'cui_str': 'Oligozoospermia (finding)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0065331', 'cui_str': 'lycopene'}]","[{'cui': 'C0429846', 'cui_str': 'Sperm total count procedure'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0037868', 'cui_str': 'Sperm'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C3489891', 'cui_str': 'TAC(a)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0427992', 'cui_str': 'Semen volume measurement'}, {'cui': 'C1510470', 'cui_str': 'Motility (observable entity)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0017822', 'cui_str': 'Glutathione:hydrogen-peroxide oxidoreductase'}]",,0.232569,"Intragroup analysis showed a significant increase in ejaculate volume, total sperm count, concentration total motility, nonprogressive, and nonmotility in lycopene group (p < .05).","[{'ForeName': 'Mehran', 'Initials': 'M', 'LastName': 'Nouri', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Amani', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Mohammadhossein', 'Initials': 'M', 'LastName': 'Nasr-Esfahani', 'Affiliation': 'Department of Reproductive Biotechnology, Reproductive Biomedicine Research Centre, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.'}, {'ForeName': 'Mohammad Javad', 'Initials': 'MJ', 'LastName': 'Tarrahi', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.6493'] 1122,12242746,"The effects of instructor gender on the knowledge, feelings, behavior and self-efficacy related to AIDS prevention education of African-American women.","A quasi-experimental design was used to test the effects of instructor gender on knowledge, feelings, behavior and self-efficacy related to AIDS prevention education of 44 African-American women (N = 44) when such instruction was provided by male instructors as compared to their female counterparts. The groups consisting of 11 members each (n = 11) were randomly assigned to one of four instructors of which two were males and two were females (n = 2 males and n = 2 females). A pre- and post-test questionnaire designed specifically for use with African-American women was administered to determine if there was a significant difference in measured learning outcomes when AIDS education was provided by instructors based on gender to these African-American women enrolled in the study. The women who had male instructors scored significantly higher on the behavior post-test as compared to those who had female instructors. No significant differences were found for the effect of male and female instructors on the women's feelings and knowledge scores. In addition, instructor gender did not effect change in self-efficacy. AIDS prevention education significantly increased self-efficacy scores regardless of instructor gender.",2002,The women who had male instructors scored significantly higher on the behavior post-test as compared to those who had female instructors.,"['African-American women', 'African-American women enrolled in the study', '44 African-American women (N = 44', '11 members each (n = 11) were randomly assigned to one of four instructors of which two were males and two were females (n = 2 males and n = 2 females']",[],"['self-efficacy scores', 'self-efficacy', 'learning outcomes', ""women's feelings and knowledge scores"", 'knowledge, feelings, behavior and self-efficacy']","[{'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0556993', 'cui_str': 'Instructor (occupation)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}]",[],"[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]",11.0,0.0178252,The women who had male instructors scored significantly higher on the behavior post-test as compared to those who had female instructors.,"[{'ForeName': 'Cheryl S', 'Initials': 'CS', 'LastName': 'Sadler', 'Affiliation': 'University of Akron, College of Nursing, 206 Carroll Street, Akron, Ohio 44325-3701, USA. Cheryl6@uakron.edu'}]",Journal of National Black Nurses' Association : JNBNA,[] 1123,31362966,Efficacy of different surgical approaches in the clinical and survival outcomes of patients with early-stage cervical cancer: protocol of a phase III multicentre randomised controlled trial in China.,"INTRODUCTION In the last three decades, minimally invasive surgery (MIS) for radical hysterectomy (RH) has become a popular treatment option for early-stage cervical cancer. However, a recently published randomised controlled trial (LACC trial) and an epidemiological study in the USA revealed strong evidence against the survival advantage of MIS for RH. However, the influencing factors of research centres and the learning curves of surgeons in these studies lacked sufficient evaluation. The efficacy of different surgical approaches for early-stage cervical cancer in the clinical and survival outcomes remains to be validated. METHODS AND ANALYSIS Patients diagnosed with FIGO (2009) stage IA1 (with lymphovascular space invasion), IA2 or IB1 cervical cancer with histological subtype of squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma will be recruited in this multicentre randomised controlled study. Patients will be randomly assigned to undergo MIS (robot-assisted or laparoscopic RH) or abdominal RH. Within 2 years, 1448 patients in 28 centres in China will be recruited to meet the criteria of a non-inferiority threshold of HR of 1.6 with bilateral nominal α <0.05 and power of 0.8. All surgeries will be performed by the indicated experienced surgeons. At least 100 RH cases in the individual past one decade of practice will be analysed as proof of learning curves. The primary objective of this study is 5-year disease-free survival. The secondary objectives include the overall survival rate, progression-free survival rate, disease-free survival rate, cost-effectiveness and quality of life. ETHICS AND DISSEMINATION This study has been approved by the Institutional Review Board of Peking Union Medical College Hospital and is filed on record by all other centres. Written informed consent will be obtained from all eligible participants before enrolment. The results will be disseminated through community events, academic conferences, student theses and peer-reviewed journals. TRIAL REGISTRATION NUMBER NCT03739944.",2019,"The secondary objectives include the overall survival rate, progression-free survival rate, disease-free survival rate, cost-effectiveness and quality of life. ","['Patients diagnosed with FIGO (2009) stage IA1 (with lymphovascular space invasion), IA2 or IB1 cervical cancer with histological subtype of squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma', 'patients with early-stage cervical cancer', 'early-stage cervical cancer', '1448 patients in 28 centres in China will be recruited to meet the criteria of a non-inferiority threshold of HR of 1.6 with bilateral nominal α <0.05\u2009and power of 0.8']","['radical hysterectomy (RH', 'MIS (robot-assisted or laparoscopic RH) or abdominal RH', 'minimally invasive surgery (MIS']","['5-year disease-free survival', 'overall survival rate, progression-free survival rate, disease-free survival rate, cost-effectiveness and quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0450454', 'cui_str': 'FIGO Stage'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix (disorder)'}, {'cui': 'C0205462', 'cui_str': 'Histologic (qualifier value)'}, {'cui': 'C0449560', 'cui_str': 'Subtype (attribute)'}, {'cui': 'C0007137', 'cui_str': 'Carcinoma, Planocellular'}, {'cui': 'C0001418', 'cui_str': 'Adenoma, Malignant'}, {'cui': 'C0206623', 'cui_str': 'Adenosquamous cell carcinoma'}, {'cui': 'C2363430', 'cui_str': 'Early stage (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0449864', 'cui_str': 'Threshold (property) (qualifier value)'}, {'cui': 'C4517508', 'cui_str': '1.6 (qualifier value)'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C4517411', 'cui_str': '0.05'}, {'cui': 'C4517481', 'cui_str': '0.8'}]","[{'cui': 'C2987682', 'cui_str': 'Radical hysterectomy (procedure)'}, {'cui': 'C0336537', 'cui_str': 'Robot, device (physical object)'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C0282624', 'cui_str': 'Minimal Surgical Procedures'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0242793', 'cui_str': 'Disease-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0034380'}]",1448.0,0.271334,"The secondary objectives include the overall survival rate, progression-free survival rate, disease-free survival rate, cost-effectiveness and quality of life. ","[{'ForeName': 'Xiaopei', 'Initials': 'X', 'LastName': 'Chao', 'Affiliation': 'Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China lileigh@163.com.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.'}, {'ForeName': 'Shuiqing', 'Initials': 'S', 'LastName': 'Ma', 'Affiliation': 'Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.'}, {'ForeName': 'Xianjie', 'Initials': 'X', 'LastName': 'Tan', 'Affiliation': 'Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.'}, {'ForeName': 'Sen', 'Initials': 'S', 'LastName': 'Zhong', 'Affiliation': 'Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.'}, {'ForeName': 'Jinghe', 'Initials': 'J', 'LastName': 'Lang', 'Affiliation': 'Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.'}, {'ForeName': 'Aoshuang', 'Initials': 'A', 'LastName': 'Cheng', 'Affiliation': 'Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.'}, {'ForeName': 'Wenhui', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.'}]",BMJ open,['10.1136/bmjopen-2019-029055'] 1124,32439823,Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials.,"We assessed whether oral insulin slowed metabolic decline after 1 year of treatment in individuals at high risk for type 1 diabetes. Two oral insulin trials that did not show efficacy overall and had type 1 diabetes as the primary end point were analyzed: the Diabetes Prevention Trial-Type 1 (DPT-1) and the TrialNet oral insulin trials. Oral glucose tolerance tests at baseline and after 1 year of treatment were analyzed. Among those at high risk (with a Diabetes Prevention Trial-Type 1 Risk Score [DPTRS] ≥6.75), the area under the curve (AUC) C-peptide increased significantly from baseline to 1 year in each oral insulin group, whereas the AUC glucose increased significantly in each placebo group. At 1 year, the AUC C-peptide/AUC glucose (AUC Ratio) was significantly higher in the oral insulin group than in the placebo group in each trial ( P < 0.05; P = 0.057 when adjusted for age in the TrialNet trial) and in both trials combined ( P < 0.01 with or without adjustment for age). For a DPTRS <6.75, oral insulin groups did not differ from placebo groups in the AUC Ratio. The findings suggest that 1 year of treatment with oral insulin slows metabolic deterioration in individuals at high risk for type 1 diabetes. Moreover, the findings further suggest that metabolic end points can be useful adjuncts to the diagnostic end point in assessments of preventive treatments for the disorder.",2020,AUC glucose was significantly higher (p<0.05) in the oral insulin group than in the placebo group in each trial,['individuals at high risk for type 1 diabetes'],"['oral insulin', 'placebo']","['AUC glucose', 'Slowed Metabolic Decline', 'AUC C-peptide', 'Oral glucose tolerance tests']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}]",,0.112215,AUC glucose was significantly higher (p<0.05) in the oral insulin group than in the placebo group in each trial,"[{'ForeName': 'Jay M', 'Initials': 'JM', 'LastName': 'Sosenko', 'Affiliation': 'University of Miami Miller School of Medicine, Miami, FL jsosenko@med.miami.edu.'}, {'ForeName': 'Jay S', 'Initials': 'JS', 'LastName': 'Skyler', 'Affiliation': 'University of Miami Miller School of Medicine, Miami, FL.'}, {'ForeName': 'Kevan C', 'Initials': 'KC', 'LastName': 'Herold', 'Affiliation': 'Yale University School of Medicine, New Haven, CT.'}, {'ForeName': 'Desmond A', 'Initials': 'DA', 'LastName': 'Schatz', 'Affiliation': 'University of Florida Diabetes Institute, Gainesville, FL.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Haller', 'Affiliation': 'University of Florida Diabetes Institute, Gainesville, FL.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Pugliese', 'Affiliation': 'University of Miami Miller School of Medicine, Miami, FL.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Cleves', 'Affiliation': 'University of South Florida, Tampa, FL.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Geyer', 'Affiliation': 'University of South Florida, Tampa, FL.'}, {'ForeName': 'Lisa E', 'Initials': 'LE', 'LastName': 'Rafkin', 'Affiliation': 'University of Miami Miller School of Medicine, Miami, FL.'}, {'ForeName': 'Della', 'Initials': 'D', 'LastName': 'Matheson', 'Affiliation': 'University of Miami Miller School of Medicine, Miami, FL.'}, {'ForeName': 'Jerry P', 'Initials': 'JP', 'LastName': 'Palmer', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes,['10.2337/db20-0166'] 1125,32004567,Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study.,"BACKGROUND Scientific rationale and encouraging first clinical results suggest the interest of using apremilast for treating vitiligo. OBJECTIVE This study aimed to compare the efficacy of apremilast in combination therapy with narrowband (NB)-UVB versus placebo and NB-UVB treatment for repigmentation in patients with nonsegmental vitiligo. DESIGN This was a 52-week prospective randomized placebo-controlled study. PARTICIPANTS Adult patients with vitiligo participated. INTERVENTIONS Group A received, in addition to phototherapy, apremilast at the label dosage, and group B received placebo. After 24 weeks, patients who responded (decreased Vitiligo Area Scoring Index >30%) were rerandomized to receive apremilast or placebo, combined with twice-weekly NB-UVB for 24 additional weeks. Main outcome and measure: The primary outcome measure was the comparison between the two groups of the Vitiligo Area Scoring Index score at 24 weeks. RESULTS Eighty patients were randomized (40 in each group). After 24 weeks, the mean Vitiligo Area Scoring Index score decreased from 23.63 to 19.49 (P = 0.011) in the apremilast + UVB group and from 21.57 to 15.25 (P < 0.0001) in the placebo + UVB group. The difference between the two groups was not statistically significant (P = 0.18). No statistically significant differences were observed between the two groups after an additional 24 weeks of treatment. CONCLUSIONS AND RELEVANCE Apremilast does not bring any benefit to NB-UVB for treating vitiligo.",2020,"After 24 weeks, the mean VASI score decreased from 23.63 to 19.49 (p=0.011) in apremilast+UVB group and from 21.57 to 15.25 (p<0.0001) in the placebo+UVB group.","['80 patients', 'After 24 weeks, patients who responded (decreased VASI>30', 'Adult patients with vitiligo', 'patients with non-segmental vitiligo']","['narrowband UVB', 'apremilast or placebo', 'narrowband (NB)-UVB versus placebo and NB-UVB treatment', 'placebo', 'placebo+UVB']","['VASI score', 'mean VASI score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0042900', 'cui_str': 'Vitiligo'}, {'cui': 'C1274648', 'cui_str': 'Segmental vitiligo'}]","[{'cui': 'C1678805', 'cui_str': 'apremilast'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",80.0,0.280086,"After 24 weeks, the mean VASI score decreased from 23.63 to 19.49 (p=0.011) in apremilast+UVB group and from 21.57 to 15.25 (p<0.0001) in the placebo+UVB group.","[{'ForeName': 'Abdallah', 'Initials': 'A', 'LastName': 'Khemis', 'Affiliation': ""Department of Dermatology, University Hospital Center of Nice, University of Côte d'Azur, Nice, France.""}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Fontas', 'Affiliation': ""Department of Research and Innovation, University Hospital Center of Nice, University of Côte d'Azur, Nice, France.""}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Moulin', 'Affiliation': ""Department of Dermatology, University Hospital Center of Nice, University of Côte d'Azur, Nice, France.""}, {'ForeName': 'Henri', 'Initials': 'H', 'LastName': 'Montaudié', 'Affiliation': ""Department of Dermatology, University Hospital Center of Nice, University of Côte d'Azur, Nice, France; Université Côte d'Azur, INSERM U1065, Team 12, C3M, Nice, France.""}, {'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Lacour', 'Affiliation': ""Department of Dermatology, University Hospital Center of Nice, University of Côte d'Azur, Nice, France.""}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Passeron', 'Affiliation': ""Department of Dermatology, University Hospital Center of Nice, University of Côte d'Azur, Nice, France; Université Côte d'Azur, INSERM U1065, Team 12, C3M, Nice, France. Electronic address: passeron@unice.fr.""}]",The Journal of investigative dermatology,['10.1016/j.jid.2019.11.031'] 1126,10390212,Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.,"Zanamivir is a potent inhibitor of influenza A and B virus neuraminidases and is active topically in experimental and natural human influenza. We conducted this double-blinded, placebo-controlled study to evaluate the safety and efficacy of intravenously administered zanamivir. Susceptible volunteers were randomized to receive either saline or zanamivir (600 mg) intravenously twice daily for 5 days beginning 4 h prior to intranasal inoculation with approximately 10(5) 50% tissue culture infectious doses (TCID50) of influenza A/Texas/36/91 (H1N1) virus. Reductions in the frequency of viral shedding (0% versus 100% in placebo, P < 0.005) and seroconversion (14% versus 100% in placebo, P < 0.005) and decreases in viral titer areas under the curve (0 versus 11.6 [median] log10 TCID50. day/ml in placebo, P < 0.005) were observed in the zanamivir group, as were reductions in fever (14% versus 88% in placebo, P < 0.05), upper respiratory tract illness (0% versus 100% in placebo, P < 0.005), total symptom scores (1 versus 44 [median] in placebo, P < 0.005), and nasal-discharge weight (3.9 g versus 17.5 g [median] in placebo, P < 0.005). Zanamivir was detectable in nasal lavage samples collected on days 2 and 4 (unadjusted median concentrations, 10.5 and 12.0 ng/ml of nasal wash, respectively). This study demonstrates that intravenously administered zanamivir is distributed to the respiratory mucosa and is protective against infection and illness following experimental human influenza A virus inoculation.",1999,"Reductions in the frequency of viral shedding (0% versus 100% in placebo, P < 0.005) and seroconversion (14% versus 100% in placebo, P < 0.005) and decreases in viral titer areas under the curve (0 versus 11.6 [median] log10 TCID50.",['Susceptible volunteers'],"['saline or zanamivir', 'placebo', 'Zanamivir', 'zanamivir']","['total symptom scores', 'viral titer areas', 'seroconversion', 'nasal lavage samples', 'fever', 'safety and efficacy', 'upper respiratory tract illness', 'Safety and efficacy', 'nasal-discharge weight', 'frequency of viral shedding']","[{'cui': 'C0231204', 'cui_str': 'Susceptible (qualifier value)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0216660', 'cui_str': 'Zanamivir'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C2748213', 'cui_str': 'Viral titre'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C2350442', 'cui_str': 'Nasal Irrigation'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0458578', 'cui_str': 'Upper respiratory tract structure'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C1260880', 'cui_str': 'Nasal catarrh'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0162633', 'cui_str': 'Viral Shedding'}]",,0.31449,"Reductions in the frequency of viral shedding (0% versus 100% in placebo, P < 0.005) and seroconversion (14% versus 100% in placebo, P < 0.005) and decreases in viral titer areas under the curve (0 versus 11.6 [median] log10 TCID50.","[{'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Calfee', 'Affiliation': 'Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA.'}, {'ForeName': 'A W', 'Initials': 'AW', 'LastName': 'Peng', 'Affiliation': ''}, {'ForeName': 'L M', 'Initials': 'LM', 'LastName': 'Cass', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Lobo', 'Affiliation': ''}, {'ForeName': 'F G', 'Initials': 'FG', 'LastName': 'Hayden', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1127,31456474,Comparative efficacy of active recovery and cold water immersion as post-match recovery interventions in elite youth soccer.,"The current study compared cold-water immersion (CWI) and active recovery (AR) to static stretching (SS) on muscle recovery post-competitive soccer matches in elite youth players (n = 15). In a controlled crossover design, participants played a total of nine competitive soccer games, comprising three 80 minute games for each intervention (SS, CWI and AR). Muscle oedema, creatine kinase (CK), countermovement jump performance (CMJA) and perceived muscle soreness (PMS) were assessed pre-, immediately post-, and 48 hours post-match and compared across time-intervals and between interventions. Following SS, all markers of muscle damage remained significantly elevated (P < 0.05) compared to baseline at 48 hours post-match. Following AR and CWI, CMJA returned to baseline at 48 hours post-match, whilst CK returned to baseline following CWI at 48 hours post-match only. Analysis between recovery interventions revealed a significant improvement in PMS (P < 0.05) at 48 hours post-match when comparing AR and CWI to SS, with no significant differences between AR and CWI observed (P > 0.05). Analysis of %change for CK and CMJA revealed significant improvements for AR and CWI compared to SS. The present study indicated both AR and CWI are beneficial recovery interventions for elite young soccer players following competitive soccer matches, of which were superior to SS.",2020,"Muscle oedema, creatine kinase (CK), countermovement jump performance (CMJA) and perceived muscle soreness (PMS) were assessed pre-, immediately post-, and 48 hours post-match and compared across time-intervals and between interventions.","['elite young soccer players', 'participants played a total of nine competitive soccer games', 'elite youth soccer', 'elite youth players (n\xa0=\xa015']","['cold-water immersion (CWI) and active recovery (AR) to static stretching (SS', 'AR and CWI', 'active recovery and cold water immersion']","['AR and CWI', 'Muscle oedema, creatine kinase (CK), countermovement jump performance (CMJA) and perceived muscle soreness (PMS', 'PMS', 'muscle damage']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0037393', 'cui_str': 'Soccers'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0087178', 'cui_str': 'Youth'}]","[{'cui': 'C4708833', 'cui_str': 'Cold water'}, {'cui': 'C0020940', 'cui_str': 'Immersion'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C1720875', 'cui_str': 'Static Stretching'}]","[{'cui': 'C3266963', 'cui_str': 'Muscle oedema'}, {'cui': 'C0201973', 'cui_str': 'Creatine kinase measurement (procedure)'}, {'cui': 'C0560453', 'cui_str': 'Does jump (finding)'}, {'cui': 'C0231528', 'cui_str': 'Muscle Pain'}, {'cui': 'C0033046', 'cui_str': 'PMS - Premenstrual syndrome'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage'}]",,0.032547,"Muscle oedema, creatine kinase (CK), countermovement jump performance (CMJA) and perceived muscle soreness (PMS) were assessed pre-, immediately post-, and 48 hours post-match and compared across time-intervals and between interventions.","[{'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Pooley', 'Affiliation': 'Medical & Sports Science Department, Tottenham Hotspur Football Club , London, UK.'}, {'ForeName': 'Owen', 'Initials': 'O', 'LastName': 'Spendiff', 'Affiliation': 'Applied & Human Sciences, School of Life Sciences, Pharmacy and Chemistry, Kingston University , London, UK.'}, {'ForeName': 'Matt', 'Initials': 'M', 'LastName': 'Allen', 'Affiliation': 'Medical & Sports Science Department, Tottenham Hotspur Football Club , London, UK.'}, {'ForeName': 'Hannah Jayne', 'Initials': 'HJ', 'LastName': 'Moir', 'Affiliation': 'Applied & Human Sciences, School of Life Sciences, Pharmacy and Chemistry, Kingston University , London, UK.'}]",Journal of sports sciences,['10.1080/02640414.2019.1660448'] 1128,10582898,Oral bioavailability and pharmacokinetics of trovafloxacin in patients with AIDS.,"Trovafloxacin pharmacokinetics were evaluated in 12 subjects with AIDS. By using a randomized design, single 200-mg doses of oral trovafloxacin and intravenous alatrofloxacin were administered. The mean absolute bioavailability was 91%. The pharmacokinetics of trovafloxacin when administered orally as the active form or intravenously as the prodrug (alatrofloxacin) are not altered in subjects with AIDS compared to those in healthy adults.",1999,Trovafloxacin pharmacokinetics were evaluated in 12 subjects with AIDS.,"['patients with AIDS', '12 subjects with AIDS', 'subjects with AIDS compared to those in healthy adults']","['trovafloxacin', 'oral trovafloxacin and intravenous alatrofloxacin']","['Oral bioavailability and pharmacokinetics', 'Trovafloxacin pharmacokinetics', 'mean absolute bioavailability']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0379881', 'cui_str': 'trovafloxacin'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0540776', 'cui_str': 'alatrofloxacin'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0379881', 'cui_str': 'trovafloxacin'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}]",12.0,0.0189596,Trovafloxacin pharmacokinetics were evaluated in 12 subjects with AIDS.,"[{'ForeName': 'M K', 'Initials': 'MK', 'LastName': 'Lacy', 'Affiliation': 'Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, Kansas 66160, USA.'}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Nicolau', 'Affiliation': ''}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Nightingale', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Geffken', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Teng', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Vincent', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Quintiliani', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1129,10543758,Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study.,"Culture and susceptibility testing of Helicobacter pylori strains was performed in a large multinational, multicenter randomized clinical trial. Culture was carried out on gastric biopsy samples obtained from 516 patients at entry and had a sensitivity of 99% when the [(13)C]urea breath test was used as a reference. Susceptibility testing was performed for clarithromycin and metronidazole on 485 strains by an agar dilution method and the epsilometer test (Etest) and for amoxicillin by an agar dilution method only. Resistance to clarithromycin (>1 microgram/ml) was found in 3% of the H. pylori strains, with a perfect correlation between Etest and agar dilution methods. Resistance to metronidazole (>8 microliter/ml) was found in 27% of the strains by agar dilution, but there were important discrepancies between it and the Etest method. No resistance to amoxicillin was found. The logarithms of the MICs of the three antibiotics against susceptible strains had a distribution close to normal. The impact of resistance was tested in the four arms of the trial. There were not enough clarithromycin-resistant strains to evaluate the impact of resistance on the cure rate of clarithromycin-based regimens. For metronidazole-resistant strains, the impact noted in the clarithromycin-metronidazole arm was partially overcome when omeprazole was added (76% eradication for resistant strains versus 95% for susceptible strains). Secondary resistance to clarithromycin occurred in strains from 12 of 105 patients (11.4%) after the failure of a clarithromycin-based regimen to effect eradication. The detection of point mutations in clarithromycin-resistant strains was performed by a combination of PCR and restriction fragment length polymorphism. Mutations (A2142G and 2143G) were found in all strains tested except one. This study stresses the importance of performing susceptibility tests in clinical trials in order to explain the results of different treatments.",1999,"Resistance to clarithromycin (>1 microgram/ml) was found in 3% of the H. pylori strains, with a perfect correlation between Etest and agar dilution methods.",['Mutations '],"['omeprazole', 'amoxicillin', 'clarithromycin', 'clarithromycin and metronidazole', 'clarithromycin-metronidazole', 'metronidazole']",[],"[{'cui': 'C0026882', 'cui_str': 'Mutation'}]","[{'cui': 'C0028978', 'cui_str': 'Omeprazole'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}]",[],,0.0492576,"Resistance to clarithromycin (>1 microgram/ml) was found in 3% of the H. pylori strains, with a perfect correlation between Etest and agar dilution methods.","[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Mégraud', 'Affiliation': 'Laboratoire de Bactériologie, Hôpital Pellegrin, Bordeaux, France. francis.mégraud@chu-aquitaine.fr'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Lehn', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Lind', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Bayerdörffer', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': ""O'Morain"", 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Spiller', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Unge', 'Affiliation': ''}, {'ForeName': 'S V', 'Initials': 'SV', 'LastName': 'van Zanten', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Wrangstadh', 'Affiliation': ''}, {'ForeName': 'C F', 'Initials': 'CF', 'LastName': 'Burman', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1130,10543767,"Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.","The pharmacokinetics, safety, and tolerability of oral moxifloxacin, a new 8-methoxy quinolone, were assessed in a randomized, double-blind, placebo-controlled study in which healthy male and female volunteers received either 400 mg of moxifloxacin once daily (n = 10) or a placebo once daily (n = 5) for 10 days. Plasma moxifloxacin concentrations on days 1 and 10 were measured by high-performance liquid chromatography and fluorometric detection. Standard pharmacokinetic parameters were estimated by noncompartmental methods. Natural logarithmic estimates for each pharmacokinetic variable of each subject were analyzed by a two-way analysis of variance. Hematology, blood chemistry, vital signs, and adverse events were monitored, and electrocardiograms (ECG) were performed. Plasma moxifloxacin concentrations of predicted therapeutic relevance were achieved in this study. For day 1, the mean maximum concentration of drug in serum (C(max)) and the area under the concentration-time curve from 0 to 24 h (AUC(0-24)) were 3. 4 mg/liter and 30.2 mg. h/liter, respectively. Corresponding means on day 10 were 4.5 mg/liter and 48 mg. h/liter, respectively. On day 10, the mean elimination half-life was approximately 12 h. Plasma moxifloxacin concentrations exceeded the MIC for Streptococcus pneumoniae throughout the 24-h dosing period. The day 1 and day 10 mean AUC/MIC ratios were 121 and 192, respectively, and the mean C(max)/MIC ratios were 13 and 18, respectively. Moxifloxacin was well tolerated; no clinically relevant changes in the standard laboratory tests, vital signs, or ECG were observed. Pharmacokinetic parameters demonstrated linearity, and estimates of pharmacokinetic/pharmacodynamic ratios (AUC/MIC and C(max)/MIC) indicate that the regimen of 400-mg once daily should be effective for treating a variety of infections. Moxifloxacin was found to be safe and well tolerated in healthy volunteers when it was given as a single daily 400-mg dose for 10 days.",1999,"Moxifloxacin was well tolerated; no clinically relevant changes in the standard laboratory tests, vital signs, or ECG were observed.","['healthy volunteers', 'healthy male and female volunteers']","['Moxifloxacin', 'placebo', 'moxifloxacin']","['pharmacokinetics, safety, and tolerability', 'Hematology, blood chemistry, vital signs, and adverse events', 'tolerated', 'pharmacokinetic/pharmacodynamic ratios (AUC/MIC and C(max)/MIC', 'mean C(max)/MIC ratios', 'mean AUC/MIC ratios', 'standard laboratory tests, vital signs, or ECG', 'Plasma moxifloxacin concentrations', 'safe and well tolerated', 'mean maximum concentration of drug in serum (C(max)) and the area under the concentration-time curve', 'mean elimination half-life']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018943', 'cui_str': 'Hematology'}, {'cui': 'C0005774', 'cui_str': 'Blood Chemical Analysis'}, {'cui': 'C0518766'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0427978', 'cui_str': 'Minimum Inhibitory Concentration'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0022885', 'cui_str': 'Laboratory test (procedure)'}, {'cui': 'C1623258', 'cui_str': 'ECG'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}]",,0.108479,"Moxifloxacin was well tolerated; no clinically relevant changes in the standard laboratory tests, vital signs, or ECG were observed.","[{'ForeName': 'J T', 'Initials': 'JT', 'LastName': 'Sullivan', 'Affiliation': 'Pharmaceutical Division, Bayer Corporation, West Haven, Connecticut, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Woodruff', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Lettieri', 'Affiliation': ''}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Agarwal', 'Affiliation': ''}, {'ForeName': 'G J', 'Initials': 'GJ', 'LastName': 'Krol', 'Affiliation': ''}, {'ForeName': 'P T', 'Initials': 'PT', 'LastName': 'Leese', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Watson', 'Affiliation': ''}, {'ForeName': 'A H', 'Initials': 'AH', 'LastName': 'Heller', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1131,10471591,Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients.,"The pharmacokinetics of levofloxacin, administered in high doses and with extended dosing intervals, was studied in human immunodeficiency virus (HIV)-infected patients. Thirty patients received either 750 mg of the drug or a placebo once daily for 14 days, followed by 750 mg or 1,000 mg of the drug or a placebo three times weekly for an additional 14 days. Levofloxacin disposition was characterized by rapid oral absorption, with peak concentrations occurring approximately 1.5 h after dosing and elimination half-lives from 7.2 to 9.4 h. The overall incidence of any adverse effect was 70% (1,000 mg) to 95% (750 mg) for levofloxacin-treated patients and 71% for those taking the placebo. Levofloxacin pharmacokinetic parameters for HIV-infected patients were consistent with those observed in studies of healthy volunteers.",1999,"The overall incidence of any adverse effect was 70% (1,000 mg) to 95% (750 mg) for levofloxacin-treated patients and 71% for those taking the placebo.","['human immunodeficiency virus (HIV)-infected patients', 'healthy volunteers', 'human immunodeficiency virus-infected patients']","['levofloxacin', 'placebo', 'Levofloxacin']",['overall incidence of any adverse effect'],"[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0282386', 'cui_str': 'Levofloxacin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0001688', 'cui_str': 'side effects'}]",,0.150401,"The overall incidence of any adverse effect was 70% (1,000 mg) to 95% (750 mg) for levofloxacin-treated patients and 71% for those taking the placebo.","[{'ForeName': 'S C', 'Initials': 'SC', 'LastName': 'Piscitelli', 'Affiliation': 'Departments of Pharmacy, National Institutes of Health, Bethesda, Maryland 20892-1880, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Spooner', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Baird', 'Affiliation': ''}, {'ForeName': 'A T', 'Initials': 'AT', 'LastName': 'Chow', 'Affiliation': ''}, {'ForeName': 'C L', 'Initials': 'CL', 'LastName': 'Fowler', 'Affiliation': ''}, {'ForeName': 'R R', 'Initials': 'RR', 'LastName': 'Williams', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Natarajan', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Masur', 'Affiliation': ''}, {'ForeName': 'R E', 'Initials': 'RE', 'LastName': 'Walker', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1132,10508004,Penetration of moxifloxacin into peripheral compartments in humans.,"To characterize the penetration of moxifloxacin (BAY 12-8039) into peripheral target sites, the present study aimed at measuring unbound moxifloxacin concentrations in the interstitial space fluid by means of microdialysis, an innovative clinical sampling technique. In addition, moxifloxacin concentrations were measured in cantharides-induced skin blisters, saliva, and capillary plasma and compared to total- and free-drug concentrations in venous plasma. For this purpose, 12 healthy volunteers received moxifloxacin in an open randomized crossover fashion either as a single oral dose of 400 mg or as a single intravenous infusion of 400 mg over 60 min. An almost-complete equilibration of the free unbound plasma fraction of moxifloxacin with the interstitial space fluid was observed, with mean area under the concentration-time curve (AUC)(interstitial fluid)/AUC(total-plasma) ratios ranging from 0.38 to 0.55 and mean AUC(interstitial fluid)/AUC(free-plasma) ratios ranging from 0.81 to 0.86. The skin blister concentration/plasma concentration ratio reached values above 1.5 after 24 h, indicating a preferential penetration of moxifloxacin into inflamed lesions. The moxifloxacin concentrations in saliva and capillary blood were similar to the corresponding levels in plasma. Our data show that moxifloxacin concentrations attained in the interstitial space fluid in humans and in skin blister fluid following single doses of 400 mg exceed the values for the MIC at which 90% of isolates are inhibited for most clinically relevant bacterial strains, notably including penicillin-resistant Streptococcus pneumoniae. These findings support the use of moxifloxacin for the treatment of soft tissue and respiratory tract infections in humans.",1999,These findings support the use of moxifloxacin for the treatment of soft tissue and respiratory tract infections in humans.,"['12 healthy volunteers', 'humans']",['moxifloxacin'],"['mean area under the concentration-time curve (AUC)(interstitial fluid)/AUC(total-plasma) ratios', 'skin blister concentration/plasma concentration ratio', 'cantharides-induced skin blisters, saliva, and capillary plasma']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0536495', 'cui_str': 'moxifloxacin'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C1319688', 'cui_str': 'Blister - unit of product usage'}, {'cui': 'C0006884', 'cui_str': 'Cantharides'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0036087', 'cui_str': 'Saliva (substance)'}, {'cui': 'C0006901', 'cui_str': 'Capillaries'}]",12.0,0.0307704,These findings support the use of moxifloxacin for the treatment of soft tissue and respiratory tract infections in humans.,"[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Müller', 'Affiliation': 'Department of Clinical Pharmacology, Section of Clinical Pharmacokinetics, Vienna University School of Medicine, Vienna, Austria. markus.mueller@univie.ac.at'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Stass', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Brunner', 'Affiliation': ''}, {'ForeName': 'J G', 'Initials': 'JG', 'LastName': 'Möller', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Lackner', 'Affiliation': ''}, {'ForeName': 'H G', 'Initials': 'HG', 'LastName': 'Eichler', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1133,32441031,Electrocautery Needling and the 308-nm Excimer Lamp: A Synergistic Combination for the Treatment of Stable Non-segmental Vitiligo.,"INTRODUCTION Vitiligo is an acquired chronic depigmentation disorder caused by the destruction of melanocytes. Although various treatments have been proposed for the management of vitiligo, achieving repigmentation and preventing relapse remains challenging. The aim of the study was to evaluate the effectiveness of electrocautery needling (EC needling) as a treatment for stable non-segmental vitiligo and to determine if the effectiveness of this treatment could be enhanced by combining it with the 308-nm excimer lamp (excimer lamp). METHODS Thirty patients with stable non-segmental vitiligo were enrolled in this self-controlled, non-blinded study. Three vitiligo lesions of similar size, location and disease duration were selected from each patient and randomly assigned to one of three groups treated weekly with EC needling, an excimer lamp or a combination of both (combination group), respectively. The effectiveness of treatment on the repigmentation percentage and the number of treatments required for initial pigmentation were assessed. RESULTS There was no significant difference in the repigmentation percentage between the EC needling group and the excimer lamp group (P = 0.789). The mean number of treatments required for initial repigmentation was lower in the EC needling group than in the excimer lamp group (P = 0.049). The repigmentation percentage was significantly higher in the combination group than in the EC needling group (P = 0.027) and excimer lamp group (P = 0.005). Evidence of initial pigmentation was obtained earlier in lesions treated with the combination therapy than in lesions treated with excimer lamp therapy alone (P = 0.019). Vitiligo lesions on the face and neck regions showed the highest repigmentation percentage among all anatomical regions, whereas lesions on the hands and feet showed the worst treatment response. CONCLUSION Electrocautery needling monotherapy was effective in treating vitiligo, and its efficacy was enhanced when combined with the 308-nm excimer lamp. This combined approach to treat vitiligo is safe and helps increase patient compliance.",2020,There was no significant difference in the repigmentation percentage between the EC needling group and the excimer lamp group (P = 0.789).,"['Thirty patients with stable non-segmental vitiligo', 'Stable Non-segmental Vitiligo', 'stable non-segmental vitiligo']","['excimer lamp therapy', 'Electrocautery needling monotherapy', 'Electrocautery Needling and the 308-nm Excimer Lamp', 'excimer lamp', '308-nm excimer lamp (excimer lamp', 'electrocautery needling (EC needling', 'EC needling, an excimer lamp or a combination of both (combination group']","['repigmentation percentage', 'Vitiligo lesions', 'mean number of treatments required for initial repigmentation', 'initial pigmentation']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C1274648', 'cui_str': 'Segmental vitiligo'}]","[{'cui': 'C0392223', 'cui_str': 'Lamp'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0013804', 'cui_str': 'Electrocoagulation'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0042900', 'cui_str': 'Vitiligo'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332121', 'cui_str': 'Treatment required for'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0031911', 'cui_str': 'Pigmentation'}]",30.0,0.0265379,There was no significant difference in the repigmentation percentage between the EC needling group and the excimer lamp group (P = 0.789).,"[{'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Department of Dermatology, Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Pui Mun', 'Initials': 'PM', 'LastName': 'Wong', 'Affiliation': 'Department of Dermatology, Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Lingli', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Department of Pigmentation Research and Therapeutics, Graduate School of Medicine, Osaka City University, Osaka, Japan.'}, {'ForeName': 'Ichiro', 'Initials': 'I', 'LastName': 'Katayama', 'Affiliation': 'Department of Pigmentation Research and Therapeutics, Graduate School of Medicine, Osaka City University, Osaka, Japan.'}, {'ForeName': 'Huali', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': 'Department of TCM Chemistry, School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Huimin', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Dermatology, Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine, Shanghai, China. zhanghm@shutcm.edu.cn.'}]",Dermatology and therapy,['10.1007/s13555-020-00395-7'] 1134,31423686,Cost-Effectiveness Analysis of Peripheral Nerve Field Stimulation as Add-On Therapy to Spinal Cord Stimulation in the Treatment of Chronic Low Back Pain in Failed Back Surgery Syndrome Patients.,"OBJECTIVE Presently, there is only limited evidence about the cost-effectiveness of peripheral nerve field stimulation (PNFS) and no evidence to date on the cost-effectiveness of PNFS as an add-on therapy to spinal cord stimulation (SCS). In a multicenter randomized controlled trial, PNFS as add-on therapy to SCS demonstrated clinical effectiveness in treating chronic low back pain in failed back surgery syndrome (FBSS) patients. We report here the cost-effectiveness of PNFS as additional therapy. MATERIALS AND METHODS Cost-effectiveness analysis was performed from a health-care perspective using the general principles of cost-utility analysis, using empirical data from our multicenter randomized controlled trial on the effectiveness of hybrid SCS + PNFS on low back pain in FBSS patients, who were back pain non-responders to initial SCS-therapy, over a time-horizon of three months. Outcome measures were costs and quality-adjusted life-years (QALYs). Cost and QALYs were integrated using the net monetary benefit (NMB). Differences in costs, effects, and NMB were analyzed using multilevel regression. Uncertainty surrounding the NMB was presented by cost-effectiveness acceptability curves. RESULTS A total of 52 patients implanted with both SCS and PNFS, randomly assigned to a group with PNFS either activated or inactive, completed the controlled part of the study. With mean total costs for the SCS + active PNFS group of €1813.86 (SD €109.78) versus €1103.64 (SD €123.43) for the SCS + inactive PNFS group at three months, we found an incremental cost-utility ratio of €25.311 per QALY gained and a probability being cost-effective of more than 80% given a willingness to pay for a QALY of about €40.000. CONCLUSIONS From a Dutch national health-care context, when the willingness to pay threshold is up to 60.000 Euros per QALY, PNFS as an add-on therapy to SCS for the treatment of low back pain in FBSS patients has a high probability of being cost-effective.",2020,"A total of 52 patients implanted with both SCS and PNFS, randomly assigned to a group with PNFS either activated or inactive, completed the controlled part of the study.","['FBSS patients, who were back pain non-responders to initial SCS-therapy, over a time-horizon of three months', 'failed back surgery syndrome (FBSS) patients', '52 patients implanted with both SCS and PNFS', 'Failed Back Surgery Syndrome Patients']","['peripheral nerve field stimulation (PNFS', 'hybrid SCS\u2009+\u2009PNFS', 'PNFS either activated or inactive', 'PNFS', 'Peripheral Nerve Field Stimulation as Add-On Therapy to Spinal Cord Stimulation']","['costs, effects, and NMB', 'incremental cost-utility ratio', 'mean total costs', 'costs and quality-adjusted life-years (QALYs', 'Cost and QALYs', 'low back pain']","[{'cui': 'C1963763', 'cui_str': 'Failed Back Surgery Syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C4082119', 'cui_str': 'Three months (qualifier value)'}, {'cui': 'C2828363', 'cui_str': 'Implant'}]","[{'cui': 'C0031119', 'cui_str': 'Peripheral Nerves'}, {'cui': 'C0440042', 'cui_str': ""Field's""}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0020205', 'cui_str': 'Hybrids'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0394477', 'cui_str': 'Spinal Cord Stimulation'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0080071', 'cui_str': 'QALY'}, {'cui': 'C0024031', 'cui_str': 'Low Back Ache'}]",,0.122038,"A total of 52 patients implanted with both SCS and PNFS, randomly assigned to a group with PNFS either activated or inactive, completed the controlled part of the study.","[{'ForeName': 'Eric-Jan J A A', 'Initials': 'EJAA', 'LastName': 'van Gorp', 'Affiliation': 'Albert Schweitzer Hospital, Department of Anesthesiology, Unit of Pain Medicine, Sliedrecht, The Netherlands.'}, {'ForeName': 'Eddy M M', 'Initials': 'EMM', 'LastName': 'Adang', 'Affiliation': 'Department for Health Evidence, Radboud University Medical Centre, Nijmegen, The Netherlands.'}, {'ForeName': 'Ismail', 'Initials': 'I', 'LastName': 'Gültuna', 'Affiliation': 'Albert Schweitzer Hospital, Department of Anesthesiology, Unit of Pain Medicine, Sliedrecht, The Netherlands.'}, {'ForeName': 'Tanja E', 'Initials': 'TE', 'LastName': 'Hamm-Faber', 'Affiliation': 'Albert Schweitzer Hospital, Department of Anesthesiology, Unit of Pain Medicine, Sliedrecht, The Netherlands.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Bürger', 'Affiliation': 'Rijnland Hospital, Department of Anesthesiology, Leiderdorp, The Netherlands.'}, {'ForeName': 'Jan Willem', 'Initials': 'JW', 'LastName': 'Kallewaard', 'Affiliation': 'Rijnstate Hospital, Department of Anesthesiology, Velp, The Netherlands.'}, {'ForeName': 'Johannes W C L', 'Initials': 'JWCL', 'LastName': 'Schapendonk', 'Affiliation': 'Diakonessenhuis, Department of Anesthesiology, Zeist, The Netherlands.'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Vonhögen', 'Affiliation': 'Sint Maartenskliniek, Department of Anesthesiology, Nijmegen, The Netherlands.'}, {'ForeName': 'Ewald', 'Initials': 'E', 'LastName': 'Bronkhorst', 'Affiliation': 'Radboud University Medical Centre, Department of Cariology and Preventive Dentistry, Nijmegen, The Netherlands.'}, {'ForeName': 'Onno P', 'Initials': 'OP', 'LastName': 'Teernstra', 'Affiliation': 'Atrium Medical Centre, Department of Neurosurgery, Heerlen, The Netherlands.'}, {'ForeName': 'Kris C P', 'Initials': 'KCP', 'LastName': 'Vissers', 'Affiliation': 'Department of Anesthesiology, Pain Medicine and Palliative Care, Radboud University Medical Centre, The Netherlands.'}]",Neuromodulation : journal of the International Neuromodulation Society,['10.1111/ner.13032'] 1135,32440935,"Correction to: A prospective randomized trial comparing corifollitropin-α late-start (day 4) versus standard administration (day 2) in expected poor, normal, and high responders undergoing controlled ovarian stimulation for IVF.",The original article unfortunately has a missing acknowledgement.,2020,The original article unfortunately has a missing acknowledgement.,[],['corifollitropin-α late-start (day 4) versus standard administration'],[],[],"[{'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]",[],,0.0221903,The original article unfortunately has a missing acknowledgement.,"[{'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Revelli', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy. alberto.revelli@unito.it.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Gennarelli', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Sestero', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Canosa', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Carosso', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Salvagno', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Pittatore', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Filippini', 'Affiliation': 'Clinical Statistics, Department of Surgical Sciences, University of Torino, Corso Bramante 88, Turin, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Benedetto', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}]",Journal of assisted reproduction and genetics,['10.1007/s10815-020-01823-5'] 1136,10388668,Changes of fermentation pathways of fecal microbial communities associated with a drug treatment that increases dietary starch in the human colon.,"Acarbose inhibits starch digestion in the human small intestine. This increases the amount of starch available for microbial fermentation to acetate, propionate, and butyrate in the colon. Relatively large amounts of butyrate are produced from starch by colonic microbes. Colonic epithelial cells use butyrate as an energy source, and butyrate causes the differentiation of colon cancer cells. In this study we investigated whether colonic fermentation pathways changed during treatment with acarbose. We examined fermentations by fecal suspensions obtained from subjects who participated in an acarbose-placebo crossover trial. After incubation with [1-13C]glucose and 12CO2 or with unlabeled glucose and 13CO2, the distribution of 13C in product C atoms was determined by nuclear magnetic resonance spectrometry and gas chromatography-mass spectrometry. Regardless of the treatment, acetate, propionate, and butyrate were produced from pyruvate formed by the Embden-Meyerhof-Parnas pathway. Considerable amounts of acetate were also formed by the reduction of CO2. Butyrate formation from glucose increased and propionate formation decreased with acarbose treatment. Concomitantly, the amounts of CO2 reduced to acetate were 30% of the total acetate in untreated subjects and 17% of the total acetate in the treated subjects. The acetate, propionate, and butyrate concentrations were 57, 20, and 23% of the total final concentrations, respectively, for the untreated subjects and 57, 13, and 30% of the total final concentrations, respectively, for the treated subjects.",1999,"Regardless of the treatment, acetate, propionate, and butyrate were produced from pyruvate formed by the Embden-Meyerhof-Parnas pathway.","['human colon', 'subjects who participated in an']","['acarbose-placebo', 'Acarbose', 'acarbose']","['Butyrate formation from glucose increased and propionate formation', 'CO2 reduced to acetate', 'acetate, propionate, and butyrate concentrations']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0009368', 'cui_str': 'Colon'}]","[{'cui': 'C0050393', 'cui_str': 'Acarbose'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0006521', 'cui_str': 'Butyrates'}, {'cui': 'C0439634', 'cui_str': 'Formations (qualifier value)'}, {'cui': 'C0860803', 'cui_str': 'Glucose high'}, {'cui': 'C0392214', 'cui_str': 'Propionate'}, {'cui': 'C1143776', 'cui_str': 'cobalt(II) bis(2,2,6,6-tetramethylheptane-3,5-dionate)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0000975', 'cui_str': 'Acetate'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",,0.0367337,"Regardless of the treatment, acetate, propionate, and butyrate were produced from pyruvate formed by the Embden-Meyerhof-Parnas pathway.","[{'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Wolin', 'Affiliation': 'Wadsworth Center for Laboratories and Research, New York State Department of Health, Albany, New York 12201-0509, USA. meyer.wolin@wadsworth.org'}, {'ForeName': 'T L', 'Initials': 'TL', 'LastName': 'Miller', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Yerry', 'Affiliation': ''}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Bank', 'Affiliation': ''}, {'ForeName': 'G A', 'Initials': 'GA', 'LastName': 'Weaver', 'Affiliation': ''}]",Applied and environmental microbiology,[] 1137,31420920,Aspirin for the prevention and treatment of pre-eclampsia: A matter of COX-1 and/or COX-2 inhibition?,"Since the 1970s, we have known that aspirin can reduce the risk of pre-eclampsia. However, the underlying mechanisms explaining this risk reduction are poorly understood. Both cyclooxygenase (COX)-1- and COX-2-dependent effects might be involved. As a consequence of this knowledge hiatus, the optimal dose and timing of initiation of aspirin therapy are not clear. Here, we review how (COX-1 versus COX-2 inhibition) and when (prevention versus treatment) aspirin therapy may interfere with the mechanisms implicated in the pathogenesis of pre-eclampsia. The available evidence suggests that both COX-1- and COX-2-dependent effects play important roles in the early stage of aberrant placental development and in the next phase leading to the clinical syndrome of pre-eclampsia. Collectively, these data suggest that high-dose (dual COX inhibition) aspirin may be superior to standard low-dose (selective COX-1 inhibition) aspirin for the prevention and also treatment of pre-eclampsia. Therefore, we conclude that more functional and biochemical tests are needed to unravel the contribution of prostanoids in the mechanisms implicated in the pathogenesis of pre-eclampsia and the potential of dual COX and/or selective COX-2 inhibition for the prevention and treatment of pre-eclampsia. This information is vital if we are to deduce the suitability, optimal timing and dose of aspirin and/or a specific COX-2 inhibitor (most likely using modified forms that do not cross the placenta) that can then be tested in a randomized, controlled trial instead of the current practice of empirical dosing regimens.",2020,COX-1 versus,['preeclampsia'],"['aspirin', 'Aspirin', 'COX-1', 'aspirin therapy']",[],"[{'cui': 'C0032914', 'cui_str': 'EPH Toxemias'}]","[{'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C0442996', 'cui_str': 'Cox (qualifier value)'}, {'cui': 'C4303556', 'cui_str': 'Aspirin therapy'}]",[],,0.0687423,COX-1 versus,"[{'ForeName': 'Katrina M', 'Initials': 'KM', 'LastName': 'Mirabito Colafella', 'Affiliation': 'Cardiovascular Disease Program, Monash Biomedicine Discovery Institute, Monash University, Melbourne, Vic, Australia.'}, {'ForeName': 'Rugina I', 'Initials': 'RI', 'LastName': 'Neuman', 'Affiliation': 'Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Willy', 'Initials': 'W', 'LastName': 'Visser', 'Affiliation': 'Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'A H Jan', 'Initials': 'AHJ', 'LastName': 'Danser', 'Affiliation': 'Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Jorie', 'Initials': 'J', 'LastName': 'Versmissen', 'Affiliation': 'Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.'}]",Basic & clinical pharmacology & toxicology,['10.1111/bcpt.13308'] 1138,10582873,Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients.,"This multicenter, randomized, dose-ranging study was performed to determine the safety and efficacy of two different doses of azithromycin for treating disseminated Mycobacterium avium complex (MAC) in patients with AIDS. Eighty-eight AIDS patients with symptoms and blood cultures consistent with disseminated MAC were treated with 600 or 1,200 mg of azithromycin daily for 6 weeks; 62 patients completed the entire 6 weeks of study. Of note, this study was done prior to the time when combination antiretroviral or anti-MAC regimens were the standard of care. Over the 6-week study period, symptomatic improvement was noted in both dose groups. Microbiological responses were comparable, with mean decreases of 1. 5 and 2.0 log CFU/ml in the high- and low-dose groups, respectively. Sterilization of blood cultures occurred in 54% of samples; patients with lower baseline colony counts were more likely to achieve culture negativity. Resistance developed in one patient. Gastrointestinal symptoms were the most common side effects and were more frequent in patients receiving 1,200 mg. Azithromycin is a useful alternative treatment for disseminated MAC infection in AIDS patients. Symptomatic improvement correlates with measurable decreases in mycobacterial load.",1999,Sterilization of blood cultures occurred in 54% of samples; patients with lower baseline colony counts were more likely to achieve culture negativity.,"['patients with AIDS', 'Eighty-eight AIDS patients with symptoms and blood cultures consistent with disseminated MAC', 'AIDS patients']","['Azithromycin', 'azithromycin']","['Gastrointestinal symptoms', 'Microbiological responses', 'symptomatic improvement', 'Sterilization of blood cultures', 'mycobacterial load', 'safety and efficacy']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517898', 'cui_str': '88 (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0200949', 'cui_str': 'Blood Culture Test'}, {'cui': 'C0332290', 'cui_str': 'Consistent with (qualifier value)'}, {'cui': 'C0205221', 'cui_str': 'Disseminated (qualifier value)'}, {'cui': 'C0009545', 'cui_str': 'C5b-9'}]","[{'cui': 'C0052796', 'cui_str': 'Azithromycin'}]","[{'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0362065', 'cui_str': 'Sterilization'}, {'cui': 'C0200949', 'cui_str': 'Blood Culture Test'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0238502,Sterilization of blood cultures occurred in 54% of samples; patients with lower baseline colony counts were more likely to achieve culture negativity.,"[{'ForeName': 'S L', 'Initials': 'SL', 'LastName': 'Koletar', 'Affiliation': 'The Ohio State University Medical Center, Columbus, Ohio 43210, USA. koletar.1@osu.edu'}, {'ForeName': 'A J', 'Initials': 'AJ', 'LastName': 'Berry', 'Affiliation': ''}, {'ForeName': 'M H', 'Initials': 'MH', 'LastName': 'Cynamon', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Jacobson', 'Affiliation': ''}, {'ForeName': 'J S', 'Initials': 'JS', 'LastName': 'Currier', 'Affiliation': ''}, {'ForeName': 'R R', 'Initials': 'RR', 'LastName': 'MacGregor', 'Affiliation': ''}, {'ForeName': 'M W', 'Initials': 'MW', 'LastName': 'Dunne', 'Affiliation': ''}, {'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Williams', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1139,10471564,"Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer.","The aim of the present study was to determine the efficacy of an antibiotic-lock technique in preventing endoluminal catheter-related infection with gram-positive bacteria in neutropenic patients with hematologic malignancies. Patients with nontunneled, multilumen central venous catheters were assigned in a randomized, double-blinded manner to receive either 10 U of heparin per ml (57 patients) or 10 U of heparin per ml and 25 microg of vancomycin per ml (60 patients), which were instilled in the catheter lumen and which were allowed to dwell in the catheter lumen for 1 h every 2 days. Insertion-site and hub swabs were taken twice weekly. The primary and secondary end points of the trial were significant colonization of the catheter hub and catheter-related bacteremia, respectively. Significant colonization of the catheter hub occurred in nine (15.8%) patients receiving heparin (seven patients were colonized with Staphylococcus epidermidis, one patient was colonized with Staphylococcus capitis, and one patient was colonized with Corynebacterium sp.), whereas the catheter hubs of none of the patients receiving heparin and vancomycin were colonized (P = 0.001). Catheter-related bacteremia developed in four (7%) patients receiving heparin (three patients had S. epidermidis bacteremia and one patient had S. capitis bacteremia), whereas none of the patients in the heparin and vancomycin group had catheter-related bacteremia (P = 0.05). The times to catheter hub colonization and to catheter-related bacteremia by the Kaplan-Meier method were longer in patients receiving heparin and vancomycin than in patients receiving heparin alone (P = 0.004 and P = 0.06, respectively). Our study shows that a solution containing heparin and vancomycin administered by using an antibiotic-lock technique effectively prevents catheter hub colonization with gram-positive bacteria and subsequent bacteremia during chemotherapy-induced neutropenia in patients with hematologic malignancy.",1999,"Catheter-related bacteremia developed in four (7%) patients receiving heparin (three patients had S. epidermidis bacteremia and one patient had S. capitis bacteremia), whereas none of the patients in the heparin and vancomycin group had catheter-related bacteremia (P = 0.05).","['Patients with nontunneled, multilumen central venous catheters', 'patients with hematologic malignancy', 'neutropenic patients with cancer', 'neutropenic patients with hematologic malignancies']","['antibiotic-lock technique', 'heparin and vancomycin', 'heparin per ml (57 patients) or 10 U of heparin per ml and 25 microg of vancomycin', 'heparin']","['Catheter-related bacteremia', 'S. capitis bacteremia', 'Significant colonization of the catheter hub', 'colonization of the catheter hub and catheter-related bacteremia', 'catheter-related bacteremia']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1145640', 'cui_str': 'Central Venous Catheters'}, {'cui': 'C0376545', 'cui_str': 'Hematological Neoplasms'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0042313', 'cui_str': 'Vancomycin'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C2919319', 'cui_str': 'Catheter hub (physical object)'}]",7.0,0.0867152,"Catheter-related bacteremia developed in four (7%) patients receiving heparin (three patients had S. epidermidis bacteremia and one patient had S. capitis bacteremia), whereas none of the patients in the heparin and vancomycin group had catheter-related bacteremia (P = 0.05).","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Carratalà', 'Affiliation': ""Infectious Disease Service, Ciutat Sanitària i Universitària de Bellvitge, Institut Català d'Oncologia, University of Barcelona, Barcelona, Spain. jcarratala@csub.scs.es""}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Niubó', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Fernández-Sevilla', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Juvé', 'Affiliation': ''}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Castellsagué', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Berlanga', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Liñares', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Gudiol', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1140,10471565,Low-dose treatment with sulfadoxine-pyrimethamine combinations selects for drug-resistant Plasmodium falciparum strains.,"A total of 252 children were enrolled in a drug trial to assess the effect of minimal doses of sulfadoxine (Sdx) and pyrimethamine (Pyr). Parasite samples isolated from these patients were analyzed before and after treatment to investigate the level of drug-resistant strains. The parasite genes encoding dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) were assayed for point mutations that are associated with resistance against drugs. Before treatment, Pyr(r) genotypes of the DHFR gene were found in 42% of all samples, 8% of the patients harbored a mixed parasite population and 50% had a sensitive DHFR genotype. In terms of the DHPS gene, we found mutations in 45% of the parasites. Twenty-four percent had a Ser(436) mutation, and 26% had a Gly(437) mutation. Recrudescent parasites were highly enriched for both Pyr(r) and Sdx(r) strains after treatment (P < 0.001 and P = 0.029, respectively).",1999,"Recrudescent parasites were highly enriched for both Pyr(r) and Sdx(r) strains after treatment (P < 0.001 and P = 0.029, respectively).","['252 children', 'Twenty-four percent had a Ser(436) mutation, and 26% had a Gly(437) mutation', 'drug-resistant Plasmodium falciparum strains']","['sulfadoxine-pyrimethamine', 'sulfadoxine (Sdx) and pyrimethamine (Pyr']",['parasite genes encoding dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS'],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0032150', 'cui_str': 'Plasmodium falciparum'}, {'cui': 'C0080194', 'cui_str': 'Strains'}]","[{'cui': 'C0700599', 'cui_str': 'Pyrimethamine / Sulfadoxine'}, {'cui': 'C0038679', 'cui_str': 'Sulfadoxine'}, {'cui': 'C0034283', 'cui_str': 'Pyrimethamine'}]","[{'cui': 'C0521066', 'cui_str': 'parasites'}, {'cui': 'C0017337', 'cui_str': 'Genes'}, {'cui': 'C0039667', 'cui_str': 'Dihydrofolate Reductase'}, {'cui': 'C0012314', 'cui_str': 'Dihydropteroate Pyrophosphorylase'}]",252.0,0.078932,"Recrudescent parasites were highly enriched for both Pyr(r) and Sdx(r) strains after treatment (P < 0.001 and P = 0.029, respectively).","[{'ForeName': 'J F', 'Initials': 'JF', 'LastName': 'Kun', 'Affiliation': 'Department of Parasitology, Institute for Tropical Medicine, University of Tübingen, D-72074 Tübingen, Germany. juergen.kun@uni-tuebingen.de'}, {'ForeName': 'L G', 'Initials': 'LG', 'LastName': 'Lehman', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Lell', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Schmidt-Ott', 'Affiliation': ''}, {'ForeName': 'P G', 'Initials': 'PG', 'LastName': 'Kremsner', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1141,10438868,Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers.,"Virosomal vaccines were prepared by extracting hemagglutinin (HA) and neuraminidase from influenza virus and incorporating it in the membranes of liposomes composed of phosphatidylcholine. Two intranasal spray vaccine series were prepared: one series comprised 7.5 micrograms of HA of each of three strains recommended by the World Health Organization and 1 microgram of Escherichia coli heat-labile toxin (HLT), and the other contained the HA without HLT. In addition, a third vaccine preparation contained 15 micrograms of HA and 2 micrograms of HLT. The parenteral virosomal vaccine contained 15 micrograms of HA without additional adjuvant. The immunogenicity of a single spray vaccination (15 micrograms of HA and 2 micrograms of HLT) was compared with that of two vaccinations (7.5 micrograms of HA with or without 1 microgram of HLT) with an interval of 1 week in 60 healthy working adults. Twenty volunteers received one parenteral virosomal vaccine. Two nasal spray vaccinations with HLT-adjuvanted virosomal influenza vaccine induced a humoral immune response which was comparable to that with a single parenteral vaccination. A significantly higher induction of influenza virus-specific immunoglobulin A was noted in the saliva after two nasal applications. The immune response after a single spray vaccination was significantly lower. It could be shown that the use of HLT as a mucosal adjuvant is necessary to obtain a humoral immune response comparable to that with parenteral vaccination. All vaccines were well tolerated.",1999,Two nasal spray vaccinations with HLT-adjuvanted virosomal influenza vaccine induced a humoral immune response which was comparable to that with a single parenteral vaccination.,"['Twenty volunteers received one', '60 healthy working adults', 'adult volunteers']","['single spray vaccination (15 micrograms of HA and 2 micrograms of HLT', 'parenteral virosomal vaccine contained 15 micrograms of HA without additional adjuvant', 'HLT-adjuvanted virosomal influenza vaccine', 'parenteral virosomal vaccine', 'HA and 2 micrograms of HLT', 'HLT', 'Escherichia coli heat-labile toxin (HLT), and the other contained the HA without HLT', 'phosphatidylcholine', 'two vaccinations (7.5 micrograms of HA with or without 1 microgram of HLT', 'intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin']","['tolerated', 'humoral immune response']","[{'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C4521772', 'cui_str': 'Spray'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0439211', 'cui_str': 'microgram'}, {'cui': 'C4522267', 'cui_str': 'Parenteral (intended site)'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0021403', 'cui_str': 'Influenza Vaccines'}, {'cui': 'C0116555', 'cui_str': 'heat-labile enterotoxin, E coli'}, {'cui': 'C1959616', 'cui_str': 'Phosphatidyl Cholines'}, {'cui': 'C4517859', 'cui_str': 'Seven point five'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}]",[{'cui': 'C1155229'}],60.0,0.0219757,Two nasal spray vaccinations with HLT-adjuvanted virosomal influenza vaccine induced a humoral immune response which was comparable to that with a single parenteral vaccination.,"[{'ForeName': 'U', 'Initials': 'U', 'LastName': 'Glück', 'Affiliation': 'Division of Occupational Medicine, SUVA Swiss National Accident Insurance Institute, CH-6002 Lucerne, Switzerland.'}, {'ForeName': 'J O', 'Initials': 'JO', 'LastName': 'Gebbers', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Glück', 'Affiliation': ''}]",Journal of virology,[] 1142,10390201,Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.,"The nephrotoxicity and ototoxicity associated with once-daily versus twice-daily administration of aminoglycosides was assessed in patients with suspected or proven gram-negative bacterial infections in a randomized, double-blind clinical trial. Patients who received therapy for >/=72 h were evaluated for toxicity. Patients also received concomitant antibiotics as deemed necessary for treatment of their infection. Plasma aminoglycoside concentrations, prospective aminoglycoside dosage adjustment, and serial audiologic and renal status evaluations were performed. The probability of occurrence of a nephrotoxic event and its relationship to doses and daily aminoglycoside exposure served as the main outcome measurement. One hundred twenty-three patients were enrolled in the study, with 83 patients receiving therapy for at least 72 h. For 74 patients plasma aminoglycoside concentrations were available for analysis, and the patients formed the group evaluable for toxicity. The primary infectious diagnosis for the patients who were enrolled in the study were bacteremia or sepsis, respiratory infections, skin and soft tissue infections, or urosepsis or pyelonephritis. Of the 74 patients evaluable for toxicity, 39 received doses twice daily and 35 received doses once daily and a placebo 12 h later. Nephrotoxicity occurred in 6 of 39 (15.4%) patients who received aminoglycosides twice daily and 0 of 35 patients who received aminoglycosides once daily. The schedule of aminoglycoside administration, concomitant use of vancomycin, and daily area under the plasma concentration-time curve (AUC) for the aminoglycosides were found to be significant predictors of nephrotoxicity by multivariate logistic regression analysis (P /=200/microliter received 70 mg of d4T in a fasting state or 1 h before or 5 min after a standardized high-fat breakfast. A 7- to 15-day washout period was included between treatments. Blood and urine were collected before and for 10 h after dosing, and plasma and urine d4T concentrations were determined with a validated radioimmunoassay. Plasma drug concentration-time data were analyzed with a noncompartmental model. The mean maximum plasma drug concentration (Cmax) and the time to Cmax (Tmax) for administration of d4T after a meal were significantly lower and longer (P = 0.0001 for both measures) than those observed in the fasting state, although the area under the concentration-time curve from time zero to infinity (AUC0-infinity) was not significantly different. Neither of these parameters was significantly altered when d4T was taken 1 h before a meal. The bioavailability of d4T taken after a meal was 95% of that observed in the fasting state, and it was 97% when d4T was administered before a meal (P > 0.05 for both comparisons with the fasting state). The results of this study indicate that (i) ingestion of food does not affect the bioavailability of d4T and that patients with HIV infection can take it without regard to meals, and (ii) absorption is essentially complete within 1 h when d4T is administered in the fasted state.",1998,"The mean maximum plasma drug concentration (Cmax) and the time to Cmax (Tmax) for administration of d4T after a meal were significantly lower and longer (P = 0.0001 for both measures) than those observed in the fasting state, although the area under the concentration-time curve from time zero to infinity (AUC0-infinity) was not significantly different.","['subjects with human immunodeficiency virus infection', 'Fifteen subjects with human immunodeficiency virus (HIV) infection and CD4']","['stavudine', 'stavudine (d4T']","['mean maximum plasma drug concentration (Cmax) and the time to Cmax (Tmax', 'Blood and urine', 'bioavailability of d4T taken', 'plasma and urine d4T concentrations']","[{'cui': 'C0019693', 'cui_str': 'T-Lymphotropic Virus Type III Infections, Human'}]","[{'cui': 'C0164662', 'cui_str': 'Stavudine'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0005768'}, {'cui': 'C0042037'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0164662', 'cui_str': 'Stavudine'}]",15.0,0.0295784,"The mean maximum plasma drug concentration (Cmax) and the time to Cmax (Tmax) for administration of d4T after a meal were significantly lower and longer (P = 0.0001 for both measures) than those observed in the fasting state, although the area under the concentration-time curve from time zero to infinity (AUC0-infinity) was not significantly different.","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Kaul', 'Affiliation': 'Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey, USA. kauls@bms.com'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Christofalo', 'Affiliation': ''}, {'ForeName': 'R H', 'Initials': 'RH', 'LastName': 'Raymond', 'Affiliation': ''}, {'ForeName': 'M B', 'Initials': 'MB', 'LastName': 'Stewart', 'Affiliation': ''}, {'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Macleod', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1170,9736563,Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state.,"Several quinolone antibacterial agents are known to inhibit the metabolism of theophylline, with the potential to cause adverse events due to raised theophylline concentrations during coadministration. A randomized crossover study was therefore conducted with 12 healthy male volunteers (ages, 23 to 34 years; body weight, 64 to 101 kg) to evaluate a possible interaction between rufloxacin and theophylline. Both drugs were administered at steady state. Following the administration of an oral loading dose of 400 mg on day 1, rufloxacin was given orally at 200 mg once daily on days 2 to 7 during one period only. During both periods, 146 mg of theophylline was administered orally twice daily for 3 days (which were days 4 to 6 of the rufloxacin coadministration period) and intravenously once the next morning to test for an interaction. Theophylline and rufloxacin concentrations were measured by reversed-phase high-pressure liquid chromatography, the pharmacokinetics of theophylline at steady state following administration of the last dose were calculated by compartment-model-independent methods. To compare the treatments, analysis of variance-based point estimates and 90% confidence intervals (given in parentheses) were calculated for the mean ratios of the pharmacokinetic parameters from the test (rufloxacin coadministration) over those from the reference (theophylline without rufloxacin) period. These were as follows: maximum concentration at steady state, 1.01 (0.96 to 1.07); area under the concentration-time curve from 0 to 12 h, 0.98 (0.94 to 1.02); half-life, 0.99 (0.95 to 1.03); total clearance at steady state, 1. 02 (0.99 to 1.06); and volume of distribution in the elimination phase, 1.01 (0.97 to 1.05). In conclusion, rufloxacin did not affect theophylline pharmacokinetics at steady state. Therefore, therapeutic coadministration of rufloxacin and theophylline is not expected to cause an increased incidence of theophylline-related adverse events.",1998,"Therefore, therapeutic coadministration of rufloxacin and theophylline is not expected to cause an increased incidence of theophylline-related adverse events.","['12 healthy male volunteers (ages, 23 to 34 years; body weight, 64 to 101 kg', 'steady state']","['theophylline', 'rufloxacin and theophylline', 'rufloxacin']","['concentration-time curve', 'total clearance', 'maximum concentration', 'Theophylline and rufloxacin concentrations', 'theophylline pharmacokinetics']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}]","[{'cui': 'C0039771', 'cui_str': 'Theophylline'}, {'cui': 'C0073704', 'cui_str': 'rufloxacin'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0039771', 'cui_str': 'Theophylline'}, {'cui': 'C0073704', 'cui_str': 'rufloxacin'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}]",12.0,0.0314978,"Therefore, therapeutic coadministration of rufloxacin and theophylline is not expected to cause an increased incidence of theophylline-related adverse events.","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kinzig-Schippers', 'Affiliation': 'IBMP-Institute for Biomedical and Pharmaceutical Research, 90562 Nürnberg-Heroldsberg, Germany.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Fuhr', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Cesana', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Müller', 'Affiliation': ''}, {'ForeName': 'A H', 'Initials': 'AH', 'LastName': 'Staib', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Rietbrock', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Sörgel', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1171,9869576,"Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.","The population pharmacokinetics of nevirapine (NVP), zidovudine (ZDV), and didanosine (ddI) were evaluated in a total of 175 patients infected with human immunodeficiency virus randomized to receive either a double combination of ZDV plus ddI or a triple combination of NVP plus ZDV plus ddI as a substudy of the AIDS Clinical Trials Group Protocol 241. Levels (approximating 3.5 determinations/patient) of the three drugs in plasma were measured during 44 of a total 48 weeks of study treatment, and a set of potential covariates was available for nonlinear mixed-effect modeling analysis. A one-compartment model with zero-order input and first-order elimination was fitted to the NVP data. Individual oral clearance (CL) and volume of distribution (V) averaged 0.0533 liters/h/kg of body weight and 1.17 liters/kg, respectively. Gender was the only covariate which significantly correlated with the CL of NVP. ZDV and ddI data were described by a two-compartment model with zero-order input and first-order elimination. Individual mean oral CL, VSS (volume of distribution at steady state), and V of ZDV were 1.84 liters/h/kg and 6.68 and 2.67 liters/kg, respectively, with body weight and age as correlates of CL and body weight as a correlate of VSS. The average individual oral CL, VSS, and V of ddI were 1.64 liters/h/kg and 3.56 and 2.74 liters/kg, respectively, with body weight as a significant correlate of both CL and VSS. The relative bioavailability (F) of ZDV and ddI in the triple combination compared to that in the double combination was also evaluated. No significant effects of the combination regimens on the F of ddI were detected (FTRIPLE = 1.05 and FDOUBLE = 1 by definition), but the F of ZDV was markedly reduced by the triple combination, being only 67.7% of that of the double combination. Large (>50%) intraindividual variability was associated with both ZDV and ddI pharmacokinetics. Individual cumulative area under the plasma drug level-time curve of the three drugs was calculated for the entire study period as a measure of drug exposure based on the individual data and the final-model estimates of structural and statistical parameters.",1999,"No significant effects of the combination regimens on the F of ddI were detected (FTRIPLE = 1.05 and FDOUBLE = 1 by definition), but the F of ZDV was markedly reduced by the triple combination, being only 67.7% of that of the double combination.","['175 patients infected with human immunodeficiency virus', 'human immunodeficiency virus-infected patients']","['nevirapine (NVP), zidovudine (ZDV), and didanosine (ddI', 'nevirapine, zidovudine, and didanosine', 'ZDV plus ddI or a triple combination of NVP plus ZDV plus ddI']","['Individual mean oral CL, VSS (volume of distribution at steady state), and V of ZDV', 'Individual cumulative area under the plasma drug level-time curve', 'average individual oral CL, VSS, and V of ddI', 'Individual oral clearance (CL) and volume of distribution (V', 'F of ddI', 'relative bioavailability (F) of ZDV and ddI', 'F of ZDV']","[{'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}]","[{'cui': 'C0132326', 'cui_str': 'Nevirapine'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}, {'cui': 'C0012133', 'cui_str': 'Didanosine'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}]","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0428212', 'cui_str': 'Finding of drug level (finding)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0012133', 'cui_str': 'Didanosine'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}]",,0.0453395,"No significant effects of the combination regimens on the F of ddI were detected (FTRIPLE = 1.05 and FDOUBLE = 1 by definition), but the F of ZDV was markedly reduced by the triple combination, being only 67.7% of that of the double combination.","[{'ForeName': 'X J', 'Initials': 'XJ', 'LastName': 'Zhou', 'Affiliation': 'Departments of Pharmacology and Medicine, Divisions of Clinical Pharmacology and Infectious Diseases, Birmingham Veterans Affairs Medical Center, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama 35294-0019, USA.'}, {'ForeName': 'L B', 'Initials': 'LB', 'LastName': 'Sheiner', 'Affiliation': ''}, {'ForeName': 'R T', 'Initials': 'RT', 'LastName': ""D'Aquila"", 'Affiliation': ''}, {'ForeName': 'M D', 'Initials': 'MD', 'LastName': 'Hughes', 'Affiliation': ''}, {'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Hirsch', 'Affiliation': ''}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Fischl', 'Affiliation': ''}, {'ForeName': 'V A', 'Initials': 'VA', 'LastName': 'Johnson', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Myers', 'Affiliation': ''}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Sommadossi', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1172,9869578,Limited-sampling strategy models for itraconazole and hydroxy-itraconazole based on data from a bioequivalence study.,"The extensive interindividual variability in oral bioavailability of itraconazole prompted an assessment of the bioequivalence of two formulations marketed in Brazil, namely, Sporanox (reference) and Traconal (test). Eighteen healthy volunteers received single 200-mg oral doses of each formulation at 2-week intervals in a randomized, crossover protocol. The concentrations of itraconazole and hydroxy-itraconazole in plasma were measured by high-performance liquid chromatography, and the datum points (n = 396) were subsequently used to develop limited-sampling strategy models for estimation of the areas under the curve (AUCs) for both compounds. The 90% confidence intervals for individual percent ratios (test/reference formulations) of the maximum concentration of drug in serum, the AUC from 0 to 48 h and the AUC from time zero to infinity (AUC0-infinity) for itraconazole and hydoxy-itraconazole were below the range of 80 to 125%, suggesting that these formulations are not bioequivalent. Linear regression analysis of the AUC0-infinity against time and a ""jackknife"" validation procedure revealed that models based on three sampling times accurately predict (R2, >0.98; bias, <3%; precision, 3 to 7%) the AUC0-infinity for each of the four formulation-compound pairs tested. Increasing the number of sampling points to more than three adds little to the accuracy of the estimates of AUC0-infinity. The three-point models developed for the reference formulation were validated retrospectively and were found to predict within 2% the AUC0-infinity reported in previous studies performed under similar protocols. In conclusion, the data in this study indicate (i) that the tested formulations are not bioequivalent when single doses are compared and (ii) that limited-sampling strategy models based on three points predict accurately the AUC0-infinitys for itraconazole and hydroxy-itraconazole and could be a valuable tool in pharmacokinetic and bioequivalence studies of single oral doses of itraconazole.",1999,"The extensive interindividual variability in oral bioavailability of itraconazole prompted an assessment of the bioequivalence of two formulations marketed in Brazil, namely, Sporanox (reference) and Traconal (test).",['Eighteen healthy volunteers'],"['itraconazole and hydroxy-itraconazole', 'itraconazole and hydoxy-itraconazole', 'itraconazole']","['maximum concentration of drug in serum, the AUC']","[{'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0064113', 'cui_str': 'Itraconazole'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0376690', 'cui_str': 'AUC'}]",396.0,0.0325098,"The extensive interindividual variability in oral bioavailability of itraconazole prompted an assessment of the bioequivalence of two formulations marketed in Brazil, namely, Sporanox (reference) and Traconal (test).","[{'ForeName': 'G', 'Initials': 'G', 'LastName': 'Suarez-Kurtz', 'Affiliation': 'Instituto Nacional de Câncer, Coordenação de Pesquisa, Programa de Farmacologia, Rio de Janeiro, Brazil. kurtz@inca.org.br'}, {'ForeName': 'F A', 'Initials': 'FA', 'LastName': 'Bozza', 'Affiliation': ''}, {'ForeName': 'F L', 'Initials': 'FL', 'LastName': 'Vicente', 'Affiliation': ''}, {'ForeName': 'C G', 'Initials': 'CG', 'LastName': 'Ponte', 'Affiliation': ''}, {'ForeName': 'C J', 'Initials': 'CJ', 'LastName': 'Struchiner', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1173,9869584,"Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects.","The pharmacokinetics in serum and leukocyte (WBC) exposures of 1,500 mg of oral azithromycin administered as 3-day (500 mg/day, days 1 to 3) and 5-day (500 mg on day 1 and 250 mg/day on days 2 to 5) regimens were compared in 12 healthy volunteers. Serum, polymorphonuclear leukocytes, and mononuclear leukocytes were collected over a 12-day period from the start of each regimen. Results of the study indicate that the exposures of serum and both types of WBCs were similar with both regimens. Drug concentrations in day 12 WBCs were well above the MICs for all relevant community-acquired respiratory tract pathogens. Terminal half-lives in serum obtained by both regimens were essentially equal at 66 h and consistent with past reports. These results indicate that the standard 1,500-mg dose of oral azithromycin can be administered over either 5 or 3 days.",1999,Drug concentrations in day 12 WBCs were well above the MICs for all relevant community-acquired respiratory tract pathogens.,"['healthy subjects', '12 healthy volunteers']","['oral azithromycin', 'azithromycin']","['Serum, polymorphonuclear leukocytes, and mononuclear leukocytes']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear Leukocytes'}, {'cui': 'C0023517', 'cui_str': 'Leukocytes, Mononuclear'}]",12.0,0.0148111,Drug concentrations in day 12 WBCs were well above the MICs for all relevant community-acquired respiratory tract pathogens.,"[{'ForeName': 'G W', 'Initials': 'GW', 'LastName': 'Amsden', 'Affiliation': 'Clinical Pharmacology Research Center, Departments of Pharmacy and Medicine, and Research Institute, Bassett Healthcare, Cooperstown, New York 13326, USA. guy.amsden@bassett.org'}, {'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Nafziger', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Foulds', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1174,9835498,Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients.,"This study evaluated the efficacy of low-dose dopamine for prevention of amphotericin B-induced nephrotoxicity in autologous bone marrow transplant and leukemia patients. Seventy-one patients undergoing cytoreductive therapy who required amphotericin B were randomly assigned in an unblinded fashion to a group receiving continuous-infusion low-dose dopamine (3 microgram/kg/min) or a group receiving no dopamine. Amphotericin B was dosed at 0.5 or 1.0 mg/kg/day based on computerized tomography scan results or presence of positive blood cultures. No patient received saline boluses. The rate of nephrotoxicity, severity as graded by Southwest Oncology Group toxicity criteria, and time to each grade of nephrotoxicity were compared between the two groups. Eighty percent of the no-dopamine group and 66.7% of the dopamine group developed nephrotoxicity, defined as a 1.5-fold or greater increase in baseline serum creatinine level (P = 0.20). No statistical difference was noted at any grade of nephrotoxicity between the two groups. Thirty-four percent of patients in the no-dopamine group versus 17.6% in the dopamine group had a 2.5-fold or greater increase in serum creatinine level, which was not statistically significant (P = 0.0888). Ten patients developed grade IV nephrotoxicity and were withdrawn from the study, 7 in the no-dopamine group and 3 in the dopamine group (P = 0.19). The time to each grade of nephrotoxicity was also not significantly different for the two groups. Eleven adverse drug reactions were reported in the dopamine group in comparison to one in the no-dopamine group. Thus, dopamine offers little in the way of prevention of nephrotoxicity associated with amphotericin B therapy. Although the significance of drug reactions in the dopamine group is not clearly established due to lack of cardiac monitoring in the no-dopamine group, dopamine therapy is not without complications.",1998,"Eighty percent of the no-dopamine group and 66.7% of the dopamine group developed nephrotoxicity, defined as a 1.5-fold or greater increase in baseline serum creatinine level (P = 0.20).","['autologous bone marrow transplant and leukemia patients', 'Seventy-one patients undergoing cytoreductive therapy who required amphotericin B', 'bone marrow transplant patients and leukemia patients']","['dopamine', 'low-dose dopamine', 'Amphotericin B', 'amphotericin B-induced nephrotoxicity', 'continuous-infusion low-dose dopamine (3 microgram/kg/min) or a group receiving no dopamine', 'amphotericin B therapy']","['rate of nephrotoxicity, severity as graded by Southwest Oncology Group toxicity criteria, and time to each grade of nephrotoxicity', 'grade of nephrotoxicity', 'Eleven adverse drug reactions', 'baseline serum creatinine level', 'serum creatinine level', 'time to each grade of nephrotoxicity', 'amphotericin B nephrotoxicity', 'nephrotoxicity', 'grade IV nephrotoxicity']","[{'cui': 'C0194037', 'cui_str': 'Autologous bone marrow transplant (procedure)'}, {'cui': 'C0023418', 'cui_str': 'Leucocythaemia'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0450389', 'cui_str': '71 (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0002679', 'cui_str': 'Amphotericin B'}, {'cui': 'C0005961', 'cui_str': 'Grafting, Bone Marrow'}]","[{'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0002679', 'cui_str': 'Amphotericin B'}, {'cui': 'C0599918', 'cui_str': 'Nephrotoxicity'}, {'cui': 'C0444889', 'cui_str': 'Continuous infusion (qualifier value)'}, {'cui': 'C0439211', 'cui_str': 'microgram'}, {'cui': 'C1532757', 'cui_str': 'kg/min'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0599918', 'cui_str': 'Nephrotoxicity'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0041755', 'cui_str': 'Drug Side Effects'}, {'cui': 'C0600061', 'cui_str': 'Serum creatinine level - finding'}, {'cui': 'C0002679', 'cui_str': 'Amphotericin B'}]",71.0,0.033103,"Eighty percent of the no-dopamine group and 66.7% of the dopamine group developed nephrotoxicity, defined as a 1.5-fold or greater increase in baseline serum creatinine level (P = 0.20).","[{'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Camp', 'Affiliation': 'Department of Pharmaceutical Services, Emory University Hospital, Emory University, Atlanta, Georgia 30322, USA. MJCampOBI@earthlink.net'}, {'ForeName': 'J R', 'Initials': 'JR', 'LastName': 'Wingard', 'Affiliation': ''}, {'ForeName': 'C E', 'Initials': 'CE', 'LastName': 'Gilmore', 'Affiliation': ''}, {'ForeName': 'L S', 'Initials': 'LS', 'LastName': 'Lin', 'Affiliation': ''}, {'ForeName': 'S P', 'Initials': 'SP', 'LastName': 'Dix', 'Affiliation': ''}, {'ForeName': 'T G', 'Initials': 'TG', 'LastName': 'Davidson', 'Affiliation': ''}, {'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Geller', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1175,9835524,No interaction between ciprofloxacin and an oral contraceptive.,"Several antibiotics have been reported to lessen the ovarian suppression produced by oral contraceptive agents, as a result of drug interactions. The present investigation was designed to study the likelihood of the occurrence of any such interaction between the fluoroquinolone antibiotic ciprofloxacin (Ciproxin) at a dosage of 500 mg twice a day and the ""low-dose"" oral contraceptive Marvelon (30 microgram of ethinyl estradiol [EE] plus 150 microgram of desogestrel). Twenty-four healthy female volunteers were studied in a double-blind, placebo-controlled, randomized crossover trial. There were no significant differences between measurements of the area under the concentration-time curve of EE up to 24 h after oral contraceptive intake during placebo and ciprofloxacin administration on days 11 and 16 of the cycles, indicating the absence of pharmacokinetic interaction. Similarly, no clinically significant differences in the levels of sex hormone binding globulin were found between the placebo and ciprofloxacin cycles, indicating no major variation in EE levels during ciprofloxacin and placebo treatment. Ten subjects in each of the placebo and ciprofloxacin groups had early-follicular-phase levels of 17-beta estradiol (<184 ng/liter) at one or more points during their cycles, but none had values above the early-follicular-phase range, indicating no significant ovarian activity. In addition, all subjects had progesterone levels of <2 ng/ml, indicating the absence of ovulation. Only two subjects, who received the placebo, had evidence of sustained follicular growth to a potentially ovulatory follicle ( approximately 18 mm). We conclude that ciprofloxacin does not interfere with the ovarian suppression produced by the low-dose oral contraceptive Marvelon.",1998,"Similarly, no clinically significant differences in the levels of sex hormone binding globulin were found between the placebo and ciprofloxacin cycles, indicating no major variation in EE levels during ciprofloxacin and placebo treatment.",['Twenty-four healthy female volunteers'],"['placebo', 'placebo and ciprofloxacin', 'ciprofloxacin', 'ethinyl estradiol [EE] plus 150 microgram of desogestrel', 'fluoroquinolone antibiotic ciprofloxacin (Ciproxin']","['ovarian suppression', 'concentration-time curve of EE', 'early-follicular-phase levels of 17-beta estradiol', 'sustained follicular growth to a potentially ovulatory follicle', 'EE levels', 'levels of sex hormone binding globulin', 'progesterone levels']","[{'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0015011', 'cui_str': 'Ethinyl Estradiol'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0439211', 'cui_str': 'microgram'}, {'cui': 'C0057558', 'cui_str': 'Desogestrel'}, {'cui': 'C0949665', 'cui_str': 'Fluoroquinolones'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}]","[{'cui': 'C0221103', 'cui_str': 'Binocular vision suppression (disorder)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0016434', 'cui_str': 'Menstrual Cycle, Follicular Phase'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0439682', 'cui_str': 'Follicular (qualifier value)'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0429470', 'cui_str': 'Ovulatory (finding)'}, {'cui': 'C0202218', 'cui_str': 'Sex hormone binding globulin measurement (procedure)'}, {'cui': 'C0428409', 'cui_str': 'Progesterone level'}]",24.0,0.22034,"Similarly, no clinically significant differences in the levels of sex hormone binding globulin were found between the placebo and ciprofloxacin cycles, indicating no major variation in EE levels during ciprofloxacin and placebo treatment.","[{'ForeName': 'P C', 'Initials': 'PC', 'LastName': 'Scholten', 'Affiliation': 'Department of Gynaecology and Obstetrics, University Hospital of Utrecht, 3584 CX Utrecht, The Netherlands.'}, {'ForeName': 'R M', 'Initials': 'RM', 'LastName': 'Droppert', 'Affiliation': ''}, {'ForeName': 'M G', 'Initials': 'MG', 'LastName': 'Zwinkels', 'Affiliation': ''}, {'ForeName': 'H L', 'Initials': 'HL', 'LastName': 'Moesker', 'Affiliation': ''}, {'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Nauta', 'Affiliation': ''}, {'ForeName': 'I M', 'Initials': 'IM', 'LastName': 'Hoepelman', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1176,9736567,"Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.","9-[2-(R)-(Phosphonomethoxy)propyl]adenine (PMPA) is a nucleotide analogue with potent antiretroviral activity in vitro and in simian models. A randomized, double-blind, placebo-controlled, dose-escalation clinical trial of intravenous PMPA monotherapy was conducted in 20 human immunodeficiency virus (HIV)-infected adults with CD4 cell counts of >/=200 cells/mm3 and plasma HIV RNA levels of >/=10,000 copies/ml. Two dose levels were evaluated (1 and 3 mg/kg of body weight/day). Ten subjects were enrolled at each dose level (eight randomized to receive PMPA and two randomized to receive placebo). On day 1, a single dose of PMPA or placebo was administered by intravenous infusion. Beginning on study day 8, PMPA or placebo was administered once daily for an additional 7 consecutive days. All subjects tolerated dosing without significant adverse events. Mean peak serum PMPA concentrations were 2.7 +/- 0.9 and 9.1 +/- 2.1 microgram/ml in the 1- and 3-mg/kg cohorts, respectively. Serum concentrations declined in a biexponential fashion, with a terminal half-life of 4 to 8 h. At 3 mg/kg/day, a single infusion of PMPA resulted in a 0.4 log10 median decline in plasma HIV RNA by study day 8. Following 7 consecutive days of study drug administration thereafter, the median changes in plasma HIV RNA from baseline were -1.1, -0.6, and 0.1 log10 in the 3-mg/kg/day, 1-mg/kg/day, and placebo dose groups, respectively. Following the final dose in the 3-mg/kg/day cohort, the reduction in HIV RNA was sustained for 7 days before returning toward baseline. Further studies evaluating an oral prodrug of PMPA are under way.",1998,All subjects tolerated dosing without significant adverse events.,"['Ten subjects were enrolled at each dose level (eight randomized to receive', 'HIV-infected adults', '20 human immunodeficiency virus (HIV)-infected adults with CD4 cell counts of >/=200 cells/mm3 and plasma HIV RNA levels of >/=10,000 copies/ml']","['PMPA', 'PMPA or placebo', 'placebo', '9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy', 'intravenous PMPA monotherapy', '9-[2-(R)-(Phosphonomethoxy)propyl]adenine (PMPA']","['median changes in plasma HIV RNA', 'plasma HIV RNA', 'Mean peak serum PMPA concentrations', 'Safety, pharmacokinetics, and antiretroviral activity', 'Serum concentrations', 'HIV RNA']","[{'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0439243', 'cui_str': 'mm3'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0035668', 'cui_str': 'RNA'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0599685', 'cui_str': 'Anti-Retroviral Agents'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",20.0,0.399905,All subjects tolerated dosing without significant adverse events.,"[{'ForeName': 'S G', 'Initials': 'SG', 'LastName': 'Deeks', 'Affiliation': 'University of California, San Francisco, and San Francisco General Hospital, San Francisco, California, USA. sdeeks@sfaids.ucsf'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Barditch-Crovo', 'Affiliation': ''}, {'ForeName': 'P S', 'Initials': 'PS', 'LastName': 'Lietman', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Hwang', 'Affiliation': ''}, {'ForeName': 'K C', 'Initials': 'KC', 'LastName': 'Cundy', 'Affiliation': ''}, {'ForeName': 'J F', 'Initials': 'JF', 'LastName': 'Rooney', 'Affiliation': ''}, {'ForeName': 'N S', 'Initials': 'NS', 'LastName': 'Hellmann', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Safrin', 'Affiliation': ''}, {'ForeName': 'J O', 'Initials': 'JO', 'LastName': 'Kahn', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1177,9756781,Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution and effect of food.,"Pleconaril is an orally active broad-spectrum antipicornaviral agent which demonstrates excellent penetration into the central nervous system, liver, and nasal epithelium. We report the results of a randomized two-way crossover study designed to characterize the disposition of a single dose (200 mg) of pleconaril oral solution in fed and fasting humans. Twelve healthy adult subjects (18.7 to 39 years of age) participated in this study. Each subject received a single 200-mg dose of pleconaril oral solution, both coadministered with a standard English breakfast and following a 10-h predose fast. There was a minimum 7-day washout period between pleconaril doses. Repeated blood samples (n = 10) were obtained over 24 h postdose, and the pleconaril level in plasma was quantified by gas chromatography. Plasma concentration-versus-time data were curve fitted for each subject by using a nonlinear weighted least-squares algorithm, and pharmacokinetic parameters were determined from the polyexponential estimates. Pleconaril disposition was best characterized by a one-compartment open model with first-order absorption. The apparent bioavailability of pleconaril oral solution was significantly increased with the administration of food. The area under the concentration-time curve and maximum concentration of pleconaril in plasma achieved following the standard English breakfast (i.e., 9.08 +/- 3.23 mg/liter . h and 1.14 +/- 0.58 mg/liter, respectively) were 2.2- and 2.5-fold higher, respectively than those achieved in the fasting state (i.e., 4.08 +/- 2.74 mg/liter . h and 0.46 +/- 0.30 mg/liter, respectively). Mean plasma pleconaril concentrations 12 h after a single 200-mg oral dose (fed, 0.25 +/- 0.2 mg/liter; fasting, 0.11 +/- 0.10 mg/liter) in healthy adults remained greater than that required to inhibit more than 90% of the enteroviruses in cell culture (i.e., 0.07 mg/liter). To enhance the oral bioavailability of pleconaril, coadministration with a fat-containing meal is recommended.",1998,"Mean plasma pleconaril concentrations 12 h after a single 200-mg oral dose (fed, 0.25 +/-","['Twelve healthy adult subjects (18.7 to 39 years of age) participated in this study', 'fed and fasting humans', 'healthy adults']","['Pleconaril', 'pleconaril oral solution', 'pleconaril oral solution, both coadministered with a standard English breakfast', 'pleconaril, coadministration with a fat-containing meal', 'pleconaril (VP63843) oral solution']","['pleconaril level in plasma', 'Plasma concentration-versus-time data', 'area under the concentration-time curve and maximum concentration of pleconaril in plasma', 'Mean plasma pleconaril concentrations', 'fasting state', 'apparent bioavailability of pleconaril oral solution']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C2987508', 'cui_str': 'Feeding (observable entity)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0759032', 'cui_str': 'pleconaril'}, {'cui': 'C0991536', 'cui_str': 'Oral Solution'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C4553621', 'cui_str': 'With breakfast'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}]","[{'cui': 'C0759032', 'cui_str': 'pleconaril'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0991536', 'cui_str': 'Oral Solution'}]",12.0,0.0317399,"Mean plasma pleconaril concentrations 12 h after a single 200-mg oral dose (fed, 0.25 +/-","[{'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Abdel-Rahman', 'Affiliation': ""Section of Pediatric Clinical Pharmacology and Experimental Therapeutics, The Children's Mercy Hospital, University of Missouri-Kansas City, Kansas City, Missouri 64108, USA.""}, {'ForeName': 'G L', 'Initials': 'GL', 'LastName': 'Kearns', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1178,9784543,Complement activation in relation to capillary leakage in children with septic shock and purpura.,"To assess the relationship between capillary leakage and inflammatory mediators during sepsis, blood samples were taken on hospital admission, as well as 24 and 72 h later, from 52 children (median age, 3.3 years) with severe meningococcal sepsis, of whom 38 survived and 14 died. Parameters related to cytokines (interleukin 6 [IL-6] IL-8, plasma phospholipase A2, and C-reactive protein [CRP]), to neutrophil degranulation (elastase and lactoferrin), to complement activation (C3a, C3b/c, C4b/c, and C3- and C4-CRP complexes), and to complement regulation (functional and inactivated C1 inhibitor and C4BP) were determined. The degree of capillary leakage was derived from the amount of plasma infused and the severity of disease by assessing the pediatric risk of mortality (PRISM) score. Levels of IL-6, IL-8, C3b/c, C3-CRP complexes, and C4BP on admission, adjusted for the duration of skin lesions, were significantly different in survivors and nonsurvivors (C3b/c levels were on average 2.2 times higher in nonsurvivors, and C3-CRP levels were 1.9 times higher in survivors). Mortality was independently related to the levels of C3b/c and C3-CRP complexes. In agreement with this, levels of complement activation products correlated well with the PRISM score or capillary leakage. Thus, these data show that complement activation in patients with severe meningococcal sepsis is associated with a poor outcome and a more severe disease course. Further studies should reveal whether complement activation may be a target for therapeutical intervention in this disease.",1998,"Levels of IL-6, IL-8, C3b/c, C3-CRP complexes, and C4BP on admission, adjusted for the duration of skin lesions, were significantly different in survivors and nonsurvivors (C3b/c levels were on average 2.2 times higher in nonsurvivors, and C3-CRP levels were 1.9 times higher in survivors).","['52 children (median age, 3.3 years) with severe meningococcal sepsis, of whom 38 survived and 14 died', 'children with septic shock and purpura', 'patients with severe meningococcal sepsis']",[],"['C3-CRP levels', 'cytokines (interleukin 6 [IL-6] IL-8, plasma phospholipase A2, and C-reactive protein [CRP]), to neutrophil degranulation (elastase and lactoferrin), to complement activation (C3a, C3b/c, C4b/c, and C3- and C4-CRP complexes), and to complement regulation (functional and inactivated C1 inhibitor and C4BP', 'Mortality', 'PRISM score or capillary leakage', 'degree of capillary leakage', 'Levels of IL-6, IL-8, C3b/c, C3-CRP complexes, and C4BP on admission, adjusted for the duration of skin lesions', 'pediatric risk of mortality (PRISM) score', 'levels of C3b/c and C3-CRP complexes']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517688', 'cui_str': '3.3 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0025306', 'cui_str': 'Meningococcemia (disorder)'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0036983', 'cui_str': 'Septic Shock'}, {'cui': 'C0034150', 'cui_str': 'Purpura'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]",[],"[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0031667', 'cui_str': 'Lecithinase A2'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear Leukocytes'}, {'cui': 'C0030306', 'cui_str': 'Elastase'}, {'cui': 'C0022942', 'cui_str': 'Lactoferrin'}, {'cui': 'C0009528', 'cui_str': 'Complement Activation'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0009498', 'cui_str': 'Complement System Proteins'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C1446194', 'cui_str': 'Serum C1 inhibitor antigen measurement'}, {'cui': 'C0056193', 'cui_str': 'Complement C4b-Binding Protein'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0006901', 'cui_str': 'Capillaries'}, {'cui': 'C0015376', 'cui_str': 'Extravasation (morphologic abnormality)'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0457453', 'cui_str': 'On admission (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0037284', 'cui_str': 'Skin lesion (disorder)'}, {'cui': 'C0475502', 'cui_str': 'Pediatric risk of mortality (assessment scale)'}]",,0.0252741,"Levels of IL-6, IL-8, C3b/c, C3-CRP complexes, and C4BP on admission, adjusted for the duration of skin lesions, were significantly different in survivors and nonsurvivors (C3b/c levels were on average 2.2 times higher in nonsurvivors, and C3-CRP levels were 1.9 times higher in survivors).","[{'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Hazelzet', 'Affiliation': ""Divisions of Pediatric Intensive Care, Department of Pediatrics, Sophia Children's Hospital/University Hospital Rotterdam, The Netherlands. hazelzet@alg.azr.nl""}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'de Groot', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'van Mierlo', 'Affiliation': ''}, {'ForeName': 'K F', 'Initials': 'KF', 'LastName': 'Joosten', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'van der Voort', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Eerenberg', 'Affiliation': ''}, {'ForeName': 'M H', 'Initials': 'MH', 'LastName': 'Suur', 'Affiliation': ''}, {'ForeName': 'W C', 'Initials': 'WC', 'LastName': 'Hop', 'Affiliation': ''}, {'ForeName': 'C E', 'Initials': 'CE', 'LastName': 'Hack', 'Affiliation': ''}]",Infection and immunity,[] 1179,9797204,Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.,"The pharmacokinetic interaction between indinavir and ritonavir was evaluated in five groups of healthy adult volunteers to explore the potential for twice-daily (b.i.d.) dosing of this combination. All subjects received 800 mg of indinavir every 8 h (q8h) on day 2. In addition, subjects in group I received one dose of 800 mg of indinavir on day 1 and 800 mg of indinavir q8h on day 17. Subjects in Groups II and IV each received one dose of 600 mg of indinavir on days 1 and 17, and subjects in groups III and V each received one dose of 400 mg of indinavir on days 1 and 17. During days 3 to 17, ritonavir placebo or ritonavir at 200, 300, 300, or 400 mg q12h was given to groups I, II, III, IV, and V, respectively. Ritonavir at steady state probably inhibited the cytochrome P-450 3A metabolism of indinavir and substantially increased plasma indinavir concentrations, with the area under the plasma concentration-time curve (AUC) increasing up to 475% and the peak concentration in serum (Cmax) increasing up to 110%. The Cmax/trough concentration ratio decreased from 50 in standard q8h regimens to less than 14 when indinavir was administered with ritonavir. For a constant indinavir dose, an increase in the ritonavir dose yielded similar indinavir AUCs, Cmaxs, and concentrations at 12 h (C12s). For a constant ritonavir dose, an increase in the indinavir dose resulted in approximately proportional increases in the indinavir AUC, less than proportional increases in Cmax, and slightly more than proportional increases in C12. Ritonavir reduced between-subject variability in the indinavir AUC and trough concentrations and did not affect indinavir renal clearance. With the altered pharmacokinetic profile, indinavir likely could be given as a b.i.d. combination regimen with ritonavir. This could potentially improve patient compliance and thereby reduce treatment failures.",1998,Ritonavir reduced between-subject variability in the indinavir AUC and trough concentrations and did not affect indinavir renal clearance.,"['five groups of healthy adult volunteers', 'healthy volunteers']","['indinavir and ritonavir', 'ritonavir placebo or ritonavir', 'ritonavir and indinavir', 'Ritonavir', 'indinavir', 'ritonavir']","['plasma concentration-time curve (AUC', 'Pharmacokinetic interaction', 'pharmacokinetic interaction', 'plasma indinavir concentrations', 'peak concentration in serum (Cmax', 'Cmax/trough concentration ratio', 'indinavir renal clearance']","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0376637', 'cui_str': 'Indinavir'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C1868980', 'cui_str': 'Pharmacokinetic interaction'}, {'cui': 'C0376637', 'cui_str': 'Indinavir'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0444506', 'cui_str': 'Trough (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0232813', 'cui_str': 'Renal clearance, function (observable entity)'}]",,0.0426414,Ritonavir reduced between-subject variability in the indinavir AUC and trough concentrations and did not affect indinavir renal clearance.,"[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Hsu', 'Affiliation': 'Abbott Laboratories, Abbott Park, Illinois 60064-3500, USA. Ann.Hsu@Abbott.com'}, {'ForeName': 'G R', 'Initials': 'GR', 'LastName': 'Granneman', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Cao', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Carothers', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Japour', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'El-Shourbagy', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Dennis', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Berg', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Erdman', 'Affiliation': ''}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Leonard', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Sun', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1180,9797234,Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.,"Nosocomial pneumonia and acute peritonitis may be caused by a wide array of pathogens, and combination therapy is often recommended. We have previously shown that imipenem-cilastatin monotherapy was as efficacious as the combination of imipenem-cilastatin plus netilmicin in these two settings. The efficacy of imipenem-cilastatin is now compared to that of piperacillin-tazobactam as monotherapy in patients with nosocomial pneumonia or acute peritonitis. Three hundred seventy one patients with nosocomial pneumonia or peritonitis were randomly assigned to receive either imipenem-cilastatin (0.5 g four times a day) or piperacillin-tazobactam (4.5 g three times a day). Three hundred thirteen were assessable (154 with nosocomial pneumonia and 159 with peritonitis). For nosocomial pneumonia, clinical-failure rates in the piperacillin-tazobactam group (13 of 75 [17%]) and in the imipenem-cilastatin group (23 of 79 [29%]) were similar (P = 0.09), as were the numbers of deaths due to infection (6 in the imipenem-cilastatin group [8%], 7 in the piperacillin-tazobactam group [9%]) (P = 0.78). For acute peritonitis, clinical success rates were comparable (piperacillin-tazobactam, 72 of 76 [95%]; imipenem-cilastatin, 77 of 83 [93%]). For infections due to Pseudomonas aeruginosa, 45 patients had nosocomial pneumonia (21 in the piperacillin-tazobactam group and 24 in the imipenem-cilastatin group) and 10 had peritonitis (5 in each group). In the patients with nosocomial pneumonia, clinical failure was less frequent in the piperacillin-tazobactam group (2 of 21 [10%]) than in the imipenem-cilastatin [corrected] group (12 of 24 [50%]) (P = 0.004). Bacterial resistance to allocated regimen was the main cause of clinical failure (1 in the piperacillin-tazobactam group and 12 in the imipenem-cilastatin group). For the patients with peritonitis, no difference in clinical outcome was observed (five of five cured in each group). The overall frequencies of adverse events related to treatment in the two groups were similar (24 in the piperacillin-tazobactam group, 22 in the imipenem-cilastatin group). Diarrhea was significantly more frequent in the piperacillin-tazobactam group (10 of 24) than in the imipenem-cilastatin group (2 of 22). This study suggests that piperacillin-tazobactam monotherapy is at least as effective and safe as imipenem-cilastatin monotherapy in the treatment of nosocomial pneumonia or peritonitis. In P. aeruginosa pneumonia, piperacillin-tazobactam achieved a better clinical efficacy than imipenem-cilastatin, due to reduced development of microbiological resistance. Tolerance was comparable, with the exception of diarrhea, which was more frequent with piperacillin-tazobactam.",1998,"For the patients with peritonitis, no difference in clinical outcome was observed (five of five cured in each group).","['Three hundred seventy one patients with nosocomial pneumonia or peritonitis', 'nosocomial pneumonia or peritonitis', 'patients with nosocomial pneumonia or acute peritonitis', 'group) and 10 had peritonitis (5 in each group', 'Three hundred thirteen were assessable (154 with nosocomial pneumonia and 159 with peritonitis']","['imipenem-cilastatin', 'imipenem-cilastatin monotherapy', 'imipenem-cilastatin and piperacillin-tazobactam', 'piperacillin-tazobactam monotherapy', 'piperacillin-tazobactam', 'imipenem-cilastatin plus netilmicin']","['clinical success rates', 'clinical efficacy', 'clinical failure', 'diarrhea', 'numbers of deaths due to infection', 'Diarrhea', 'nosocomial pneumonia, clinical-failure rates', 'microbiological resistance', 'Tolerance', 'overall frequencies of adverse events', 'nosocomial pneumonia']","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0450389', 'cui_str': '71 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1443237', 'cui_str': 'Nosocomial Pneumonia'}, {'cui': 'C0031154', 'cui_str': 'Peritonitis'}, {'cui': 'C0267750', 'cui_str': 'Acute peritonitis (disorder)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C3715149', 'cui_str': '13'}]","[{'cui': 'C0071972', 'cui_str': 'Cilastatin / Imipenem'}, {'cui': 'C0250480', 'cui_str': 'Piperacillin / tazobactam'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0027780', 'cui_str': 'Netilmicin'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0087113', 'cui_str': 'Treatment Efficacy'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C1443237', 'cui_str': 'Nosocomial Pneumonia'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",371.0,0.0926489,"For the patients with peritonitis, no difference in clinical outcome was observed (five of five cured in each group).","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Jaccard', 'Affiliation': 'Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Troillet', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Harbarth', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Zanetti', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Aymon', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Schneider', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Chiolero', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Ricou', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Romand', 'Affiliation': ''}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Huber', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Ambrosetti', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Praz', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Lew', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Bille', 'Affiliation': ''}, {'ForeName': 'M P', 'Initials': 'MP', 'LastName': 'Glauser', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Cometta', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1181,9797239,A multicenter phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes.,"A randomized, double-blind, clinic-initiated, sequential dose-escalation pilot study was performed to compare the safety and efficacy of single applications of 1, 3, and 5% cidofovir gel with placebo in the treatment of early, lesional, recurrent genital herpes at five Canadian outpatient sites. Ninety-six patients began treatment within 12 h of lesion appearance and were evaluated twice daily until healing of the lesion occurred. Cidofovir gel at all strengths significantly decreased the median time to negative virus culture in a dose-dependent fashion (3.0 days in the placebo group versus 2.2, 1.3, and 1.1 days in the 1, 3, and 5% cidofovir gel treatment groups, respectively; P = 0.02, 0.0001, and 0.0003, respectively). A trend toward a reduction in the median time to complete healing in association with treatment was present, but the differences were not statistically significant (5.0 days in the placebo group versus 4.3, 4.1, and 4.6 days in the 1, 3, and 5% cidofovir gel treatment groups, respectively). Application site reactions occurred in 3, 5, 19, and 22% of the patients in these four groups, respectively. Treatment-associated lesion recrudescence with delayed healing, which is suggestive of local toxicity, was observed in three patients treated with 5% cidofovir gel and one patient treated with 3% cidofovir gel. In summary, single-dose application of cidofovir gel confers a significant antiviral effect on lesions of recurrent genital herpes. Additional studies are warranted to further identify the optimal efficacious dose of cidofovir in association with the maximum gel strength that can be tolerated.",1998,"Cidofovir gel at all strengths significantly decreased the median time to negative virus culture in a dose-dependent fashion (3.0 days in the placebo group versus 2.2, 1.3, and 1.1 days in the 1, 3, and 5% cidofovir gel treatment groups, respectively; P = 0.02, 0.0001, and 0.0003, respectively).","['early, lesional, recurrent genital herpes at five Canadian outpatient sites', 'recurrent genital herpes']","['cidofovir gel with placebo', 'single-dose cidofovir gel', 'cidofovir gel', 'placebo']","['median time to complete healing', 'local toxicity', 'antiviral effect on lesions of recurrent genital herpes', 'Application site reactions', 'safety and efficacy', 'median time to negative virus culture']","[{'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0019342', 'cui_str': 'Herpes Simplex Virus Genital Infection'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}]","[{'cui': 'C0286079', 'cui_str': 'Cidofovir'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C1874329', 'cui_str': 'Antivirals, topical'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0019342', 'cui_str': 'Herpes Simplex Virus Genital Infection'}, {'cui': 'C0151505', 'cui_str': 'Application site reaction (disorder)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0200955', 'cui_str': 'Culture for viruses'}]",96.0,0.0448977,"Cidofovir gel at all strengths significantly decreased the median time to negative virus culture in a dose-dependent fashion (3.0 days in the placebo group versus 2.2, 1.3, and 1.1 days in the 1, 3, and 5% cidofovir gel treatment groups, respectively; P = 0.02, 0.0001, and 0.0003, respectively).","[{'ForeName': 'S L', 'Initials': 'SL', 'LastName': 'Sacks', 'Affiliation': 'Viridae Clinical Sciences, Inc., and Department of Pharmacology and Therapeutics, Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada. sacks@viridae.com'}, {'ForeName': 'S D', 'Initials': 'SD', 'LastName': 'Shafran', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Diaz-Mitoma', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Trottier', 'Affiliation': ''}, {'ForeName': 'R G', 'Initials': 'RG', 'LastName': 'Sibbald', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Hughes', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Safrin', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Rudy', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'McGuire', 'Affiliation': ''}, {'ForeName': 'H S', 'Initials': 'HS', 'LastName': 'Jaffe', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1182,9673264,"Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults.","Pertussis infection is increasingly recognized in older children and adults, indicating the need of booster immunizations in these age groups. We investigated the induction of pertussis-specific immunity in schoolchildren and adults after booster immunization and natural infection. The expression of mRNA of gamma interferon (IFN-gamma), interleukin-2 (IL-2), IL-4, and IL-5 in the peripheral blood mononuclear cells (PBMCs) was assayed by reverse transcription-PCR. The PBMCs of 17 children immunized with one dose of an acellular vaccine containing pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN) significantly proliferated in vitro after stimulation with the vaccine antigens. The PBMCs of seven infected individuals markedly proliferated in the presence of PT and FHA, but the cells of only two of these subjects responded to PRN. At least one of the antigens induced mRNA for IL-4 and/or IL-5 in the cells of 93% of tested vaccinees and patients, and FHA induced IFN-gamma mRNA in the cells of two-thirds of them. Expression of mRNA for IFN-gamma correlated with the production of the cytokine protein. Anti-FHA immunoglobulin G antibodies significantly correlated with FHA-induced proliferative responses both before and after immunization. These results show that booster immunization with acellular pertussis vaccine induces both antibody- and cell-mediated immune responses in schoolchildren. Further, booster immunization and natural infection seem to induce the expression of mRNA of T-helper 1 (Th1) and Th2 type cytokines in similar manners. This observation supports the use of acellular pertussis vaccines for booster immunizations of older children, adolescents, and adults.",1998,"The expression of mRNA of gamma interferon (IFN-gamma), interleukin-2 (IL-2), IL-4, and IL-5 in the peripheral blood mononuclear cells (PBMCs) was assayed by reverse transcription-PCR.","['17 children immunized with one dose of an', 'older children, adolescents, and adults', 'schoolchildren', 'older children and adults', 'schoolchildren and adults after booster immunization and natural infection']","['acellular pertussis vaccines', 'acellular vaccine containing pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN']","['IL-4 and/or IL-5', 'expression of mRNA of gamma interferon (IFN-gamma), interleukin-2 (IL-2), IL-4, and IL-5 in the peripheral blood mononuclear cells (PBMCs']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0020975', 'cui_str': 'Immunization, Booster'}, {'cui': 'C0205296', 'cui_str': 'Natural (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}]","[{'cui': 'C0982332', 'cui_str': 'acellular pertussis vaccine, inactivated'}, {'cui': 'C0887895', 'cui_str': 'Vaccines, Acellular'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0020731', 'cui_str': 'Histamine-Sensitizing Factor'}, {'cui': 'C0018909', 'cui_str': 'Hemagglutinin'}, {'cui': 'C0136166', 'cui_str': 'pertactin'}, {'cui': 'C0558288', 'cui_str': 'prn'}]","[{'cui': 'C0021758', 'cui_str': 'Interleukin-4'}, {'cui': 'C0021759', 'cui_str': 'Interleukin-5'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0035696', 'cui_str': 'mRNA'}, {'cui': 'C3539881', 'cui_str': 'gamma-interferon'}, {'cui': 'C1552644', 'cui_str': 'Greek letter gamma'}, {'cui': 'C0021756', 'cui_str': 'TCGF'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}]",17.0,0.0217869,"The expression of mRNA of gamma interferon (IFN-gamma), interleukin-2 (IL-2), IL-4, and IL-5 in the peripheral blood mononuclear cells (PBMCs) was assayed by reverse transcription-PCR.","[{'ForeName': 'Q', 'Initials': 'Q', 'LastName': 'He', 'Affiliation': 'National Public Health Institute, Department in Turku, Turku University Hospital, Turku, Finland. qiuhe@utu.fi'}, {'ForeName': 'N N', 'Initials': 'NN', 'LastName': 'Tran Minh', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Edelman', 'Affiliation': ''}, {'ForeName': 'M K', 'Initials': 'MK', 'LastName': 'Viljanen', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Arvilommi', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Mertsola', 'Affiliation': ''}]",Infection and immunity,[] 1183,30324827,"The effect of low-level laser therapy and physical exercise on pain, stiffness, function, and spatiotemporal gait variables in subjects with bilateral knee osteoarthritis: a blind randomized clinical trial.","Objective: To evaluate the effects of individual and combination therapies (low-level laser therapy and physical exercises) on pain, stiffness, function, and spatiotemporal gait variables in subjects with bilateral knee osteoarthritis (OA). Methods: Subjects with knee OA (Grades 1-3) were evaluated and randomized into four groups: Control Group (CG), untreated; Laser Group (LG), treated with laser at 808 nm, 5.6 J; Exercise Group (EG), treated with exercise; and Laser + Exercise Group (LEG), treated with laser and exercises. The treatment was carried out twice a week for 2 months. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire was applied for evaluation and reevaluation; evaluation of spatiotemporal gait variables was performed using GAITRite equipment. Results: The EG showed significant improvement in pain ( p  = 0.006) and function ( p  = 0.01) according to WOMAC. Regarding gait variables, in intergroup analysis after 8 weeks all groups receiving intervention showed a significant increase in gait speed: LG versus CG ( p  = 0.03); EG versus CG ( p  = 0.04) and LEG versus CG ( p  = 0.005). Only the group treated with laser + exercise showed a significant increase ( p  = 0.009) in the cadence and duration of single right limb support ( p  = 0.04), and only the groups treated with exercise and laser + exercise showed significant decreases in the duration of right limb support ( p  = 0.035 and p  = 0.003, respectively), compared to the CG. Conclusions: The group treated only with exercise showed improvement in WOMAC questionnaire scores. Regarding the gait variables, all groups undergoing the interventions showed increases in the gait speed compared to the CG. The laser and exercise combination therapy provided the best results for the other gait variables (cadence and duration of right limb support and duration of single right limb support).Implications for rehabilitationThere are differences in gait patterns in patients with knee OA, including decreased gait speed, cadence, and step length.The results shown in the present study provide additional information about the physical therapy approaches that should be chosen during clinical practical to improve gait performance in individuals with knee osteoarthritis.The improvement in gait performance is a relevant issue due to the fact that is associated to physical independence and better quality of life.",2019,The EG showed significant improvement in pain (p = 0.006) and function (p = 0.01) according to WOMAC.,"['subjects with bilateral knee osteoarthritis', 'subjects with bilateral knee osteoarthritis (OA', 'individuals with knee osteoarthritis', 'patients with knee OA', 'Subjects with knee OA (Grades 1-3']","['laser and exercise combination therapy', 'Control Group (CG), untreated; Laser Group (LG), treated with laser at 808\u2009nm, 5.6 J; Exercise Group (EG), treated with exercise; and Laser\u2009+\u2009Exercise Group (LEG), treated with laser and exercises', 'laser\u2009+\u2009exercise', 'individual and combination therapies (low-level laser therapy and physical exercises', 'low-level laser therapy and physical exercise']","['pain', 'Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire', 'cadence and duration of single right limb support', 'gait speed', 'gait speed, cadence, and step length', 'gait speed: LG', 'WOMAC questionnaire scores', 'gait performance', 'pain, stiffness, function, and spatiotemporal gait variables', 'duration of right limb support']","[{'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis, Knee'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}]","[{'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0556895', 'cui_str': 'Combination therapy (regime/therapy)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C4517794', 'cui_str': '5.6 (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0279027', 'cui_str': 'Low-Power Laser Therapy'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3472647', 'cui_str': 'WOMAC index'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0015385', 'cui_str': 'Limbs'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C2009910', 'cui_str': 'Gait Speed'}, {'cui': 'C0427126', 'cui_str': 'Step length (observable entity)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0427008', 'cui_str': 'Stiffness (finding)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}]",,0.0209443,The EG showed significant improvement in pain (p = 0.006) and function (p = 0.01) according to WOMAC.,"[{'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'de Matos Brunelli Braghin', 'Affiliation': 'Physiotherapy Course, Department of Health Science, Ribeirao Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Elisa Cavalheiro', 'Initials': 'EC', 'LastName': 'Libardi', 'Affiliation': 'Physiotherapy Course, Department of Health Science, Ribeirao Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Carina', 'Initials': 'C', 'LastName': 'Junqueira', 'Affiliation': 'Physiotherapy Course, Department of Health Science, Ribeirao Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Natalia Camargo', 'Initials': 'NC', 'LastName': 'Rodrigues', 'Affiliation': 'Physiotherapy Course, Department of Health Science, Ribeirao Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.'}, {'ForeName': 'Marcello Henrique', 'Initials': 'MH', 'LastName': 'Nogueira-Barbosa', 'Affiliation': 'Division of Radiology of the Internal Medicine Department, Ribeirao Preto Medical School University of Sao Paulo, Ribeirao Preto, SP, Brazil.'}, {'ForeName': 'Ana Claudia Muniz', 'Initials': 'ACM', 'LastName': 'Renno', 'Affiliation': 'Department of Biosciences, Federal University of São Paulo (UNIFESP), Santos, SP, Brazil.'}, {'ForeName': 'Daniela Cristina', 'Initials': 'DC', 'LastName': 'Carvalho de Abreu', 'Affiliation': 'Physiotherapy Course, Department of Health Science, Ribeirao Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.'}]",Disability and rehabilitation,['10.1080/09638288.2018.1493160'] 1184,9559773,Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. The Cefepime Study Group.,"Effective empiric treatment of pneumonia requires antibiotic coverage against gram-negative and gram-positive pathogens, including drug-resistant isolates. We compared the safety and efficacy of intravenous (i.v.) cefepime (2 g administered every 12 h) to those of i.v. ceftriaxone (1 g administered every 12 h) for the empiric treatment of hospitalized patients with community-acquired pneumonia. Of the 115 patients randomized to the study, 86 (cefepime recipients, n = 40; ceftriaxone recipients, n = 46) were evaluated for clinical efficacy (clinically evaluated patients). Favorable clinical outcomes (cure or improvement) were comparable among clinically evaluated patients in the cefepime and ceftriaxone treatment arms (95.0 versus 97.8%, respectively; 95% confidence interval for treatment difference [data for ceftriaxone group minus data for cefepime group], -5.1 to +10.8%). The most common bacteria isolated from patients in both treatment groups were Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus. In clinically evaluated patients with a microbiologic response, all (100%) of the 32 pathogens from cefepime-treated patients and 97.4% (38 of 39) of the pathogens from ceftriaxone-treated patients were eradicated (documented or presumed eradication). The one persistent infection in the ceftriaxone group was caused by Pseudomonas fluorescens. Both treatments were well tolerated. Our data thus suggest that cefepime and ceftriaxone have comparable safety and efficacy for the treatment of pneumonia in hospitalized patients.",1998,"The most common bacteria isolated from patients in both treatment groups were Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus.","['hospitalized patients with community-acquired pneumonia', '115 patients randomized to the study, 86 (cefepime recipients, n = 40; ceftriaxone recipients, n = 46', 'hospitalized patients']","['Cefepime versus ceftriaxone', 'ceftriaxone']","['safety and efficacy', 'tolerated']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0694549', 'cui_str': 'Community acquired pneumonia (disorder)'}, {'cui': 'C4517540', 'cui_str': '115 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0055003', 'cui_str': 'cefepime'}, {'cui': 'C0007561', 'cui_str': 'Ceftriaxone'}]","[{'cui': 'C0055003', 'cui_str': 'cefepime'}, {'cui': 'C0007561', 'cui_str': 'Ceftriaxone'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}]",115.0,0.0325474,"The most common bacteria isolated from patients in both treatment groups were Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus.","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Zervos', 'Affiliation': 'Infectious Diseases Division, Wayne State University, William Beaumont Hospital, Royal Oak, Michigan 48073, USA. mzervos@beaumont.edu'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Nelson', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1185,9559784,"Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts.","Genital human papillomavirus infection is one of the most common sexually transmitted diseases. Imiquimod is a new agent, an immune-response modifier, that has been demonstrated to have potent in vivo antiviral and antitumor effects in animal models. The present prospective, multicenter, double-blind, randomized, vehicle-controlled trial evaluated the efficacy and safety of daily patient-applied imiquimod for up to 16 weeks for the treatment of external genital warts. Wart recurrence was investigated during a 12-week treatment-free follow-up period. In the intent-to-treat analysis, baseline warts cleared from 49 of 94 (52%) patients treated with 5% imiquimod cream, 13 of 90 (14%) patients treated with 1% imiquimod cream, and 3 of 95 (4%) vehicle-treated patients; the differences between the groups treated with vehicle and imiquimod were significant (P < 0.0001). For subjects who completed the follow-up period, recurrence rates after a complete response were 19% (9 of 48 patients) in the 5% imiquimod cream group, 17% (2 of 12) in the 1% imiquimod cream group, and 0% (0 of 3) in the vehicle-treated group. There were no systemic reactions, although local skin reactions (generally of mild or moderate severity) were common, particularly in the 5% imiquimod cream group. Local reactions caused two patients to discontinue treatment. The most frequently reported local skin reactions were erythema, excoriation or flaking, and erosion. Patient-applied 5% imiquimod cream is effective for the treatment of external genital warts and has a favorable safety profile.",1998,Patient-applied 5% imiquimod cream is effective for the treatment of external genital warts and has a favorable safety profile.,['external genital warts'],"['vehicle and imiquimod', 'Imiquimod', 'imiquimod cream', 'daily patient-applied imiquimod']","['efficacy and safety', 'systemic reactions', 'Local reactions', 'local skin reactions were erythema, excoriation or flaking, and erosion', 'recurrence rates', 'local skin reactions', 'Wart recurrence']","[{'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0009663', 'cui_str': 'Warts, Venereal'}]","[{'cui': 'C0042444', 'cui_str': 'Drug vehicle (substance)'}, {'cui': 'C0165032', 'cui_str': 'imiquimod'}, {'cui': 'C1378128', 'cui_str': 'Cream'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1632850', 'cui_str': 'Apply'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}, {'cui': 'C0853813', 'cui_str': 'Local reaction'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0221743', 'cui_str': 'Skin reaction (observable entity)'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0015256', 'cui_str': 'Excoriation of skin (disorder)'}, {'cui': 'C0333307', 'cui_str': 'Superficial ulcer (morphologic abnormality)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C3665596', 'cui_str': 'Verruca'}]",,0.0203033,Patient-applied 5% imiquimod cream is effective for the treatment of external genital warts and has a favorable safety profile.,"[{'ForeName': 'K R', 'Initials': 'KR', 'LastName': 'Beutner', 'Affiliation': 'Department of Dermatology, University of California, San Francisco 94143, USA. kbeutner@solderm.com'}, {'ForeName': 'S K', 'Initials': 'SK', 'LastName': 'Tyring', 'Affiliation': ''}, {'ForeName': 'K F', 'Initials': 'KF', 'LastName': 'Trofatter', 'Affiliation': ''}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Douglas', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Spruance', 'Affiliation': ''}, {'ForeName': 'M L', 'Initials': 'ML', 'LastName': 'Owens', 'Affiliation': ''}, {'ForeName': 'T L', 'Initials': 'TL', 'LastName': 'Fox', 'Affiliation': ''}, {'ForeName': 'A J', 'Initials': 'AJ', 'LastName': 'Hougham', 'Affiliation': ''}, {'ForeName': 'K A', 'Initials': 'KA', 'LastName': 'Schmitt', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1186,9559790,Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients.,"We used information available from routine clinic visits to characterize the pharmacokinetics of didanosine in 82 human immunodeficiency virus-infected patients. A total of 271 blood samples were collected for the measurement of didanosine concentrations in plasma (mean +/- standard deviation [SD], 3.30 +/- 2.21 samples/patient). Bayesian estimates of didanosine oral clearance (CL[oral]) were obtained for these patients by the POSTHOC option within the NONMEM software package. Population priors from a previous NONMEM analysis of didanosine pharmacokinetics were used. The mean +/- SD CL(oral) was 132 +/- 27.7 liters/h, which agrees reasonably well with estimates obtained from previous pharmacokinetic studies of didanosine. Estimates of individual didanosine exposure were then used to consider potential relationships between drug exposure and surrogate marker response over a 6-month period. No correlations were found between the didanosine area under the concentration-time curve from 0 to 6 months and the absolute CD4 cell count (r = 0.305; 0.1 < P < 0.2), weight response (r = 0.0857; P > 0.4), or percentage of CD4 lymphocytes (r = 0.0559; P > 0.4). Future efforts to characterize didanosine exposure in outpatients by random sampling methods should involve more directed efforts to limit residual variability in the data.",1998,"No correlations were found between the didanosine area under the concentration-time curve from 0 to 6 months and the absolute CD4 cell count (r = 0.305; 0.1 < P < 0.2), weight response (r = 0.0857; P > 0.4), or percentage of CD4 lymphocytes (r = 0.0559; P > 0.4).","['human immunodeficiency virus-infected outpatients', '82 human immunodeficiency virus-infected patients']","['didanosine oral clearance (CL[oral', 'didanosine', 'individual didanosine']","['percentage of CD4 lymphocytes', 'concentration-time curve', 'absolute CD4 cell count', 'weight response']","[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0012133', 'cui_str': 'Didanosine'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0039215', 'cui_str': 'CD4-Positive Lymphocytes'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}]",,0.0179033,"No correlations were found between the didanosine area under the concentration-time curve from 0 to 6 months and the absolute CD4 cell count (r = 0.305; 0.1 < P < 0.2), weight response (r = 0.0857; P > 0.4), or percentage of CD4 lymphocytes (r = 0.0559; P > 0.4).","[{'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Adams', 'Affiliation': 'Department of Pharmacy Practice, School of Pharmacy, State University of New York at Buffalo, 14260, USA.'}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Shelton', 'Affiliation': ''}, {'ForeName': 'R G', 'Initials': 'RG', 'LastName': 'Hewitt', 'Affiliation': ''}, {'ForeName': 'T H', 'Initials': 'TH', 'LastName': 'Grasela', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'DeRemer', 'Affiliation': ''}, {'ForeName': 'G D', 'Initials': 'GD', 'LastName': 'Morse', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1187,9449273,Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria.,"An open, randomized comparison of artemether-benflumetol (CGP 56 697; Novartis) with artesunate-mefloquine was conducted in 617 patients with acute uncomplicated multidrug-resistant falciparum malaria on the western border of Thailand. Both treatments rapidly and reliably cleared fever and parasitemia, and there was no significant difference in the initial therapeutic response parameters. Parasite genotyping was used to distinguish recrudescences from new infections. The 63-day cure rate for artesunate-mefloquine (94%) was significantly higher than the cure rate for artemether-benflumetol (81%) (P < 0.001). Both regimens were well tolerated. Nausea, vomiting, dizziness, sleep disorders, and other neurological side effects were between two and four times more common in the artesunate-mefloquine group than in the artemether-benflumetol group (P < 0.001). Artemether-benflumetol is effective and very well tolerated in the treatment of multidrug-resistant falciparum malaria. A higher dose than that used in the present study may improve efficacy.",1998,Artemether-benflumetol is effective and very well tolerated in the treatment of multidrug-resistant falciparum malaria.,"['617 patients with acute uncomplicated multidrug-resistant falciparum malaria on the western border of Thailand', 'multidrug-resistant falciparum malaria']","['artesunate-mefloquine', 'artemether-benflumetol and artesunate-mefloquine', 'artemether-benflumetol (CGP 56 697; Novartis) with artesunate-mefloquine']","['efficacy', 'tolerated', 'initial therapeutic response parameters', '63-day cure rate', 'Nausea, vomiting, dizziness, sleep disorders, and other neurological side effects', 'cure rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0024535', 'cui_str': 'Plasmodium falciparum Malaria'}, {'cui': 'C0205284', 'cui_str': 'Marginal (qualifier value)'}, {'cui': 'C0039725', 'cui_str': 'Kingdom of Thailand'}]","[{'cui': 'C0052432', 'cui_str': 'artesunate'}, {'cui': 'C0025153', 'cui_str': 'Mefloquine'}, {'cui': 'C0936150', 'cui_str': 'artemether / lumefantrine'}]","[{'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0521982', 'cui_str': 'Therapeutic response, function (observable entity)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0851578', 'cui_str': 'Sleep Disorders'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}]",617.0,0.0285611,Artemether-benflumetol is effective and very well tolerated in the treatment of multidrug-resistant falciparum malaria.,"[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'van Vugt', 'Affiliation': 'Shoklo Malaria Research Unit, Mae Sod, Tak Province, Thailand.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Brockman', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Gemperli', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Luxemburger', 'Affiliation': ''}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Gathmann', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Royce', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Slight', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Looareesuwan', 'Affiliation': ''}, {'ForeName': 'N J', 'Initials': 'NJ', 'LastName': 'White', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Nosten', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1188,9420037,"Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.","Isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) are the most important drugs for the treatment of tuberculosis (TB). The pharmacokinetics of all three drugs in the plasma of 24 healthy males were studied as part of a randomized cross-over phase I study of two dosage forms. Subjects ingested single doses of INH at 250 mg, RIF at 600 mg, and PZA at 1,500 mg. Plasma was collected for 36 h and was assayed by high-performance liquid chromatography. The data were analyzed by noncompartmental, iterative two-stage maximum a posteriori probability Bayesian (IT2B) and nonparametric expectation maximization (NPEM) population modeling methods. Fast and slow acetylators of INH had median peak concentrations in plasma (C[max]) of 2.44 and 3.64 microg/ml, respectively, both of which occurred at 1.0 h postdose (time of maximum concentrations of drugs in plasma [T(max)]), with median elimination half-lives (t1/2) of 1.2 and 3.3 h, respectively (by the NPEM method). RIF produced a median C(max) of 11.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 3.4 h. PZA produced a median C(max) of 28.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 10.0 h. The pharmacokinetic behaviors of INH, RIF, and PZA were well described by the three methods used. These models can serve as benchmarks for comparison with models for other populations, such as patients with TB or TB with AIDS.",1997,"RIF produced a median C(max) of 11.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 3.4 h. PZA produced a median C(max) of 28.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 10.0 h.","['patients with TB or TB with AIDS', '24 healthy males']","['RIF at 600 mg, and PZA', 'Isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA', 'INH', 'isoniazid, rifampin, and pyrazinamide']","['posteriori probability Bayesian (IT2B) and nonparametric expectation maximization ', 'median peak concentrations in plasma (C[max', 'pharmacokinetic behaviors of INH, RIF, and PZA', 'Plasma']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0022209', 'cui_str': 'isoniazid'}, {'cui': 'C0035608', 'cui_str': 'rifampicin'}, {'cui': 'C0034239', 'cui_str': 'Pyrazinamide'}, {'cui': 'C0208681', 'cui_str': 'factor XIIa inhibitor'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0208681', 'cui_str': 'factor XIIa inhibitor'}]",24.0,0.0812697,"RIF produced a median C(max) of 11.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 3.4 h. PZA produced a median C(max) of 28.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 10.0 h.","[{'ForeName': 'C A', 'Initials': 'CA', 'LastName': 'Peloquin', 'Affiliation': 'Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado 80206, USA.'}, {'ForeName': 'G S', 'Initials': 'GS', 'LastName': 'Jaresko', 'Affiliation': ''}, {'ForeName': 'C L', 'Initials': 'CL', 'LastName': 'Yong', 'Affiliation': ''}, {'ForeName': 'A C', 'Initials': 'AC', 'LastName': 'Keung', 'Affiliation': ''}, {'ForeName': 'A E', 'Initials': 'AE', 'LastName': 'Bulpitt', 'Affiliation': ''}, {'ForeName': 'R W', 'Initials': 'RW', 'LastName': 'Jelliffe', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1189,9916056,"Preliminary assessment of the safety and immunogenicity of a new CTXPhi-negative, hemagglutinin/protease-defective El Tor strain as a cholera vaccine candidate.","Vibrio cholerae 638 (El Tor, Ogawa), a new CTXPhi-negative hemagglutinin/protease-defective strain that is a cholera vaccine candidate, was examined for safety and immunogenicity in healthy adult volunteers. In a double-blind placebo-controlled study, no significant adverse reactions were observed in volunteers ingesting strain 638. Four volunteers of 42 who ingested strain 638 and 1 of 14 who received placebo experienced loose stools. The strain strongly colonized the human small bowel, as evidenced by its isolation from the stools of 37 of 42 volunteers. V. cholerae 638, at doses ranging from 4 x 10(7) to 2 x 10(9) vibrios, elicited significant serum vibriocidal antibody and anti-Ogawa immunoglobulin A antibody secreting cell responses.",1999,"In a double-blind placebo-controlled study, no significant adverse reactions were observed in volunteers ingesting strain 638.","['Four volunteers of 42 who ingested strain 638 and 1 of 14 who received', 'volunteers ingesting strain 638', 'healthy adult volunteers']","['placebo', 'new CTXPhi-negative, hemagglutinin/protease-defective El Tor strain']","['loose stools', 'adverse reactions', 'serum vibriocidal antibody and anti-Ogawa immunoglobulin']","[{'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0018909', 'cui_str': 'Hemagglutinin'}, {'cui': 'C0030940', 'cui_str': 'Peptide Hydrolases'}, {'cui': 'C0080194', 'cui_str': 'Strains'}]","[{'cui': 'C2129214', 'cui_str': 'Loose stool (finding)'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0443037', 'cui_str': 'Ogawa'}, {'cui': 'C0021027', 'cui_str': 'Immune Globulins'}]",4.0,0.106091,"In a double-blind placebo-controlled study, no significant adverse reactions were observed in volunteers ingesting strain 638.","[{'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Benítez', 'Affiliation': 'Grupo de Genética, Centro Nacional de Investigaciones Científicas, "" Havana, Cuba. jbenitez@mail.coin.missouri.edu'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'García', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Silva', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'García', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Fando', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Cedré', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Pérez', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Campos', 'Affiliation': ''}, {'ForeName': 'B L', 'Initials': 'BL', 'LastName': 'Rodríguez', 'Affiliation': ''}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Pérez', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Valmaseda', 'Affiliation': ''}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Pérez', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Pérez', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ramírez', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Ledón', 'Affiliation': ''}, {'ForeName': 'M D', 'Initials': 'MD', 'LastName': 'Jidy', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Lastre', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Bravo', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Sierra', 'Affiliation': ''}]",Infection and immunity,[] 1190,9916067,A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses.,"Recent attention to mucosal immunization strategies has been focused on the nasal route for vaccine delivery. This study was designed to determine the effectiveness of a liposome-protein vaccine compared to that of a protein-only vaccine in inducing immune responses in humans. Healthy subjects were randomly assigned to two groups and immunized intranasally with a crude antigen preparation rich in glucosyltransferase (C-GTF) from Streptococcus mutans, alone or in liposomes. Parotid saliva, nasal wash, and serum were collected prior to and at weekly intervals following immunization and were analyzed for anti-C-GTF activity by enzyme-linked immunosorbent assay. The levels of immunoglobulin A (IgA) anti-C-GTF activity in the nasal wash from both groups after immunization increased to a mean peak of fivefold over the baseline level on day 28. Salivary IgA anti-C-GTF responses were induced to a lesser extent. IgG and IgA anti-C-GTF responses in serum were detected on day 14. The IgA responses were predominantly of the IgA1 subclass. These results show that C-GTF vaccines were more effective in inducing a local secretory IgA antibody response than a salivary or serum response when they were given intranasally. The IgA1 anti-C-GTF response in nasal wash samples for liposomal antigen versus antigen only was the only response which was significantly different (P < 0.04). This suggests that the form of the antigen affects the magnitude of the local mucosal response but not that of a disseminated response. These results provide evidence for the effective use of a nasal protein vaccine in humans for the induction of mucosal and systemic responses.",1999,The IgA1 anti-C-GTF response in nasal wash samples for liposomal antigen versus antigen only was the only response which was significantly different (P < 0.04).,"['Healthy subjects', 'humans']","['immunized intranasally with a crude antigen preparation rich in glucosyltransferase (C-GTF) from Streptococcus mutans, alone or in liposomes', 'liposome-protein vaccine', 'nasal immunization with a Streptococcus mutans antigen alone', 'protein-only vaccine']","['local secretory IgA antibody response', 'Parotid saliva, nasal wash, and serum', 'IgG and IgA anti-C-GTF responses', 'Salivary IgA anti-C-GTF responses', 'IgA1 anti-C-GTF response', 'levels of immunoglobulin A (IgA) anti-C-GTF activity', 'local mucosal response']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0003320', 'cui_str': 'Antigens'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C0017772', 'cui_str': 'Glucosyltransferases'}, {'cui': 'C0038409', 'cui_str': 'Streptococcus mutans'}, {'cui': 'C0023828', 'cui_str': 'Liposomes'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C0020971', 'cui_str': 'Sensitization, Immunologic'}]","[{'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0020838', 'cui_str': 'Secretory IgA'}, {'cui': 'C0003261', 'cui_str': 'Antibody Response'}, {'cui': 'C0030580', 'cui_str': 'Parotid Gland'}, {'cui': 'C0036087', 'cui_str': 'Saliva (substance)'}, {'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C1547959', 'cui_str': 'Wash - dosing instruction imperative'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0432626', 'cui_str': 'Blood group antibody c (substance)'}, {'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}, {'cui': 'C0020840', 'cui_str': 'IgA1'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0026724', 'cui_str': 'Mucosal Tissue'}]",,0.0181393,The IgA1 anti-C-GTF response in nasal wash samples for liposomal antigen versus antigen only was the only response which was significantly different (P < 0.04).,"[{'ForeName': 'N K', 'Initials': 'NK', 'LastName': 'Childers', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, University of Alabama at Birmingham, Birmingham, Alabama, USA. nkc@uab.edu'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Tong', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Mitchell', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Kirk', 'Affiliation': ''}, {'ForeName': 'M W', 'Initials': 'MW', 'LastName': 'Russell', 'Affiliation': ''}, {'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Michalek', 'Affiliation': ''}]",Infection and immunity,[] 1191,9660986,Oral cimetidine prolongs clarithromycin absorption.,"The present study was conducted to identify any potential interaction between oral cimetidine and clarithromycin. Twelve healthy subjects were administered single doses of clarithromycin alone and with oral cimetidine dosed to steady state. Cimetidine prolonged the absorption of clarithromycin, as evidenced by decreased peak concentrations of both clarithromycin and 14-OH-clarithromycin (14OHC) in serum (46 and 43%, respectively), a delay in the formation of 14OHC (increase of 68%), and increases in both of their half-lives (75 and 82%, respectively), despite no changes in total oral clearance or area under the concentration-time curve for either compound. No mechanism for this interaction has been identified.",1998,"Cimetidine prolonged the absorption of clarithromycin, as evidenced by decreased peak concentrations of both clarithromycin and 14-OH-clarithromycin (14OHC) in serum (46 and 43%, respectively), a delay in the formation of 14OHC (increase of 68%), and increases in both of their half-lives (75 and 82%, respectively), despite no changes in total oral clearance or area under the concentration-time curve for either compound.",['Twelve healthy subjects'],"['cimetidine and clarithromycin', 'Cimetidine', 'clarithromycin alone and with oral cimetidine', 'Oral cimetidine']","['total oral clearance or area under the concentration-time curve', 'absorption of clarithromycin', 'peak concentrations of both clarithromycin and 14-OH-clarithromycin (14OHC', 'formation of 14OHC']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0008783', 'cui_str': 'Cimetidine'}, {'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0090409', 'cui_str': 'Erythromycin, 14-hydroxy-6-O-methyl-'}, {'cui': 'C0439634', 'cui_str': 'Formations (qualifier value)'}]",12.0,0.0168276,"Cimetidine prolonged the absorption of clarithromycin, as evidenced by decreased peak concentrations of both clarithromycin and 14-OH-clarithromycin (14OHC) in serum (46 and 43%, respectively), a delay in the formation of 14OHC (increase of 68%), and increases in both of their half-lives (75 and 82%, respectively), despite no changes in total oral clearance or area under the concentration-time curve for either compound.","[{'ForeName': 'G W', 'Initials': 'GW', 'LastName': 'Amsden', 'Affiliation': 'Clinical Pharmacology Research Center, Bassett Healthcare, Cooperstown, New York 13326, USA. amsden@telenet.net'}, {'ForeName': 'K L', 'Initials': 'KL', 'LastName': 'Cheng', 'Affiliation': ''}, {'ForeName': 'C A', 'Initials': 'CA', 'LastName': 'Peloquin', 'Affiliation': ''}, {'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Nafziger', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1192,31416897,Heterogeneity of Treatment Effects From an Intensive Lifestyle Weight Loss Intervention on Cardiovascular Events in Patients With Type 2 Diabetes: Data From the Look AHEAD Trial.,"OBJECTIVE To explore the presence of heterogeneity of treatment effect (HTE) of an intensive lifestyle intervention on the occurrence of major cardiovascular events (MACE) in overweight or obese patients with type 2 diabetes, and to identify patient characteristics associated with individual treatment effect. RESEARCH DESIGN AND METHODS In 4,901 participants from the Action for Health in Diabetes (Look AHEAD) trial, a penalized Cox regression model to predict treatment effect of intensive lifestyle intervention for the risk of MACE was derived, including all possible treatment-by-covariate interaction terms. The ability of the model to predict HTE was confirmed by calculating hazard ratios (HRs) and absolute risk change in quartiles of predicted treatment effect, and baseline patient characteristics were compared between quartiles. RESULTS In quartile 1 of predicted treatment effect, with the highest predicted risk reduction, there was a significant treatment benefit of intensive lifestyle intervention (HR 0.64 [95% CI 0.49-0.83]), whereas there was no effect from treatment in quartiles 2 and 3 (HR 0.81 [95% CI 0.58-1.14] and 1.13 [95% CI 0.80-1.60], respectively) and a detrimental effect in quartile 4 (HR 1.37 [95% CI 1.09-1.73]). Several patient characteristics in demographics, medical history, physical examination, and laboratory values were associated with the level of treatment effect. CONCLUSIONS This post hoc analysis of the Look AHEAD trial showed that an intensive lifestyle intervention aimed at weight loss may reduce cardiovascular events in selected patients but may have a detrimental treatment effect in others.",2019,,['Patients With Type 2 Diabetes'],['Intensive Lifestyle Weight Loss Intervention'],['Cardiovascular Events'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}]","[{'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",,0.172102,,"[{'ForeName': 'Tamar I', 'Initials': 'TI', 'LastName': 'de Vries', 'Affiliation': 'Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'Jannick A N', 'Initials': 'JAN', 'LastName': 'Dorresteijn', 'Affiliation': 'Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'Yolanda', 'Initials': 'Y', 'LastName': 'van der Graaf', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Frank L J', 'Initials': 'FLJ', 'LastName': 'Visseren', 'Affiliation': 'Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Westerink', 'Affiliation': 'Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands j.westerink-3@umcutrecht.nl.'}]",Diabetes care,['10.2337/dc19-0776'] 1193,9624473,Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group.,"The aim of the present pilot study was to compare the efficacy and safety of trimethoprim (TMP) and sulfamethoxazole (SMX) with those of the standard therapy pyrimethamine (P)-sulfadiazine (S) for the treatment of toxoplasmic encephalitis in patients with AIDS. This was a pilot, multicenter, randomized, and prospective study. Patients were randomly assigned to receive TMP (10 mg/kg of body weight/day) and SMX (50 mg/kg/day) or P (50 mg daily) and S (60 mg/kg/day) as acute therapy (for 4 weeks) and then as maintenance therapy for 3 months at half of the original dosage. Seventy-seven patients were enrolled and randomized to the study: 40 patients were treated with TMP-SMX and 37 were treated with P-S. There was no statistically significant difference in clinical efficacy during acute therapy. In contrast, patients randomized to TMP-SMX appeared more likely to achieve a complete radiologic response after acute therapy. Adverse reactions were significantly more frequent in patients treated with P-S, and skin rash was the most common adverse event noted in these patients. In conclusion, the results of the study suggest that TMP-SMX appears to be a valuable alternative to P-S, in particular in patients with opportunistic bacterial infections.",1998,"Adverse reactions were significantly more frequent in patients treated with P-S, and skin rash was the most common adverse event noted in these patients.","['patients with AIDS', 'patients with opportunistic bacterial infections', 'Seventy-seven patients were enrolled and randomized to the study: 40 patients were treated with']","['standard therapy pyrimethamine (P)-sulfadiazine (S', 'trimethoprim (TMP) and sulfamethoxazole (SMX', 'trimethoprim-sulfamethoxazole', 'TMP-SMX', 'TMP', 'pyrimethamine-sulfadiazine', 'SMX']","['efficacy and safety', 'clinical efficacy', 'skin rash', 'complete radiologic response', 'Adverse reactions']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004623', 'cui_str': 'Bacterial Infections'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0034283', 'cui_str': 'Pyrimethamine'}, {'cui': 'C0038675', 'cui_str': 'Sulfadiazine'}, {'cui': 'C0041041', 'cui_str': 'Trimethoprim'}, {'cui': 'C0038689', 'cui_str': 'Sulfamethoxazole'}, {'cui': 'C0041044', 'cui_str': 'Sulfamethoxazole / Trimethoprim'}, {'cui': 'C0625823', 'cui_str': 'TMPS'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0087113', 'cui_str': 'Treatment Efficacy'}, {'cui': 'C0015230', 'cui_str': 'Skin Rash'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205483', 'cui_str': 'Radiologic (qualifier value)'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}]",40.0,0.0964198,"Adverse reactions were significantly more frequent in patients treated with P-S, and skin rash was the most common adverse event noted in these patients.","[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Torre', 'Affiliation': 'Department of Infectious Diseases, Regional Hospital, Varese, Italy.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Casari', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Speranza', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Donisi', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Gregis', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Poggio', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Ranieri', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Orani', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Angarano', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Chiodo', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Fiori', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Carosi', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1194,9624484,Oral antimicrobial prophylaxis in bone marrow transplant recipients: randomized trial of ciprofloxacin versus ciprofloxacin-vancomycin.,"The optimal oral antimicrobial prophylactic regimen for bone marrow transplant recipients remains to be elucidated. We randomized 84 patients to receive either oral ciprofloxacin or ciprofloxacin plus vancomycin at hospital admission. Patients were monitored for bacteremias and clinical parameters, and stool and throat swab surveillance cultures were performed. The addition of vancomycin resulted in a significant decrease in the frequency of patients with surveillance cultures positive for coagulase-negative staphylococci (stool cultures, 44 versus 23%; throat swab cultures, 37 versus 19%) and alpha-hemolytic streptococci (throat swab cultures, 90 versus 60%). The frequencies of positivity for Candida spp. and gram-negative organisms on surveillance cultures were comparable. Despite these results, no differences in the incidences of bacteremias (12 of 41 versus 12 of 43 patients) or clinical parameters such as number of days to first fever, total number of febrile days, length of stay, and number of transfusions could be demonstrated. Because of a lack of efficacy of vancomycin and emerging problems with vancomycin-resistant isolates, vancomycin should not be used in oral antimicrobial prophylaxis regimens.",1998,"The addition of vancomycin resulted in a significant decrease in the frequency of patients with surveillance cultures positive for coagulase-negative staphylococci (stool cultures, 44 versus 23%; throat swab cultures, 37 versus 19%) and alpha-hemolytic streptococci (throat swab cultures, 90 versus 60%).",['bone marrow transplant recipients'],"['Oral antimicrobial prophylaxis', 'ciprofloxacin-vancomycin', 'ciprofloxacin', 'oral ciprofloxacin or ciprofloxacin plus vancomycin', 'vancomycin-resistant isolates, vancomycin', 'vancomycin']","['number of days to first fever, total number of febrile days, length of stay, and number of transfusions', 'incidences of bacteremias', 'frequency of patients with surveillance cultures positive for coagulase-negative staphylococci']","[{'cui': 'C4545296', 'cui_str': 'Bone marrow transplant recipient'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1136254', 'cui_str': 'Microbicides'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0042313', 'cui_str': 'Vancomycin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0199960', 'cui_str': 'Transfusion - action (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0201227', 'cui_str': 'Surveillance culture'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0009118', 'cui_str': 'Coagulase'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}]",84.0,0.13372,"The addition of vancomycin resulted in a significant decrease in the frequency of patients with surveillance cultures positive for coagulase-negative staphylococci (stool cultures, 44 versus 23%; throat swab cultures, 37 versus 19%) and alpha-hemolytic streptococci (throat swab cultures, 90 versus 60%).","[{'ForeName': 'C D', 'Initials': 'CD', 'LastName': 'Ford', 'Affiliation': 'Department of Medicine, LDS Hospital, Salt Lake City, Utah 84143, USA. idcford@ihc.com'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Reilly', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Wood', 'Affiliation': ''}, {'ForeName': 'D C', 'Initials': 'DC', 'LastName': 'Classen', 'Affiliation': ''}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Burke', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1195,9499103,Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy.,"Potent antiretroviral therapy can reduce human immunodeficiency virus (HIV) in plasma to levels below the limit of detection for up to 2 years, but the extent to which viral replication is suppressed is unknown. To search for ongoing viral replication in 10 patients on combination antiretroviral therapy for up to 1 year, the emergence of genotypic drug resistance across different compartments was studied and correlated with plasma viral RNA levels. In addition, lymph node (LN) mononuclear cells were assayed for the presence of multiply spliced RNA. Population sequencing of HIV-1 pol was done on plasma RNA, peripheral blood mononuclear cell (PBMC) RNA, PBMC DNA, LN RNA, LN DNA, and RNA from virus isolated from PBMCs or LNs. A special effort was made to obtain sequences from patients with undetectable plasma RNA, emphasizing the rapidly emerging lamivudine-associated M184V mutation. Furthermore, concordance of drug resistance mutations across compartments was investigated. No evidence for viral replication was found in patients with plasma HIV RNA levels of <20 copies/ml. In contrast, evolving genotypic drug resistance or the presence of multiply spliced RNA provided evidence for low-level replication in subjects with plasma HIV RNA levels between 20 and 400 copies/ml. All patients failing therapy showed multiple drug resistance mutations in different compartments, and multiply spliced RNA was present upon examination. Concordance of nucleotide sequences from different tissue compartments obtained concurrently from individual patients was high: 98% in the protease and 94% in the reverse transcriptase regions. These findings argue that HIV replication differs significantly between patients on potent antiretroviral therapy with low but detectable viral loads and those with undetectable viral loads.",1998,"Potent antiretroviral therapy can reduce human immunodeficiency virus (HIV) in plasma to levels below the limit of detection for up to 2 years, but the extent to which viral replication is suppressed is unknown.",['10 patients on combination antiretroviral therapy for up to 1 year'],[],"['multiple drug resistance mutations', 'viral replication', 'plasma viral RNA levels', 'plasma RNA, peripheral blood mononuclear cell (PBMC) RNA, PBMC DNA, LN RNA, LN DNA, and RNA', 'lymph node (LN) mononuclear cells']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",[],"[{'cui': 'C0242640', 'cui_str': 'Multi-Drug Resistance'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0035736', 'cui_str': 'RNA, Viral'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C0024204', 'cui_str': 'Lymphatic gland'}, {'cui': 'C0007634', 'cui_str': 'Cells'}]",,0.0489478,"Potent antiretroviral therapy can reduce human immunodeficiency virus (HIV) in plasma to levels below the limit of detection for up to 2 years, but the extent to which viral replication is suppressed is unknown.","[{'ForeName': 'H F', 'Initials': 'HF', 'LastName': 'Günthard', 'Affiliation': 'Department of Pathology, School of Medicine, University of California San Diego, La Jolla 92093-0679, USA. hgunthar@ucsd.edu'}, {'ForeName': 'J K', 'Initials': 'JK', 'LastName': 'Wong', 'Affiliation': ''}, {'ForeName': 'C C', 'Initials': 'CC', 'LastName': 'Ignacio', 'Affiliation': ''}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Guatelli', 'Affiliation': ''}, {'ForeName': 'N L', 'Initials': 'NL', 'LastName': 'Riggs', 'Affiliation': ''}, {'ForeName': 'D V', 'Initials': 'DV', 'LastName': 'Havlir', 'Affiliation': ''}, {'ForeName': 'D D', 'Initials': 'DD', 'LastName': 'Richman', 'Affiliation': ''}]",Journal of virology,[] 1196,9257763,Pharmacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular injections.,"The pharmacokinetics of isepamicin following administration of a 1-g dose were evaluated for 18 healthy male volunteers between the ages of 26 and 38. In a randomized crossover fashion, each volunteer received doses of isepamicin by a 30-min intravenous infusion and as an intramuscular injection. Blood samples were collected at specified times after dosing and assayed for isepamicin by a validated radioimmunoassay method. The individual plasma concentration-time curves were analyzed by noncompartmental methods. In general, the pharmacokinetics after intravenous infusion and intramuscular injection were similar. As expected, the maximum concentration of isepamicin in serum following intramuscular injection (37.2 microg/ml) was lower than the observed concentration at the end of infusion (66.7 microg/ml). The areas under the concentration-time curves from 0 h to infinity following intramuscular and intravenous administration were 164.8 and 154.5 microg x hr/ml, respectively, indicating complete absorption following intramuscular administration. The respective mean terminal-phase half-life (t1/2) values were 2.6 and 3.6 h. Although t1/2 was slightly longer following intravenous infusion, the small difference in the observed t1/2 values was not considered to be clinically significant. Total body clearances following intramuscular injection and intravenous infusion were 1.3 and 1.4 ml/min/kg, respectively, which were similar to renal serum creatinine clearances in healthy volunteers (> 1.14 ml/min/kg). The drug was safe and well tolerated. The results of the present study clearly show complete absorption of isepamicin following intramuscular administration. The similarity in the pharmacokinetics after intravenous infusion and intramuscular dosing would permit interchangeable administration of isepamicin by either route without compromising clinical efficacy.",1997,"As expected, the maximum concentration of isepamicin in serum following intramuscular injection (37.2 microg/ml) was lower than the observed concentration at the end of infusion (66.7 microg/ml).",['18 healthy male volunteers between the ages of 26 and 38'],['isepamicin'],"['Blood samples', 'individual plasma concentration-time curves', 'renal serum creatinine clearances', 'Total body clearances', 'safe and well tolerated', 'maximum concentration of isepamicin in serum']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0124008', 'cui_str': 'D-Streptamine, O-6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-N1-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (S)-'}]","[{'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0124008', 'cui_str': 'D-Streptamine, O-6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-N1-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (S)-'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",18.0,0.0779602,"As expected, the maximum concentration of isepamicin in serum following intramuscular injection (37.2 microg/ml) was lower than the observed concentration at the end of infusion (66.7 microg/ml).","[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Radwanski', 'Affiliation': 'Department of Drug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, Kenilworth, New Jersey 07033-0539, USA.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Batra', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Cayen', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Korduba', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Cutler', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Affrime', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Nomeir', 'Affiliation': ''}, {'ForeName': 'C C', 'Initials': 'CC', 'LastName': 'Lin', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1197,9257765,Circadian variation in urinary excretion of ciprofloxacin after a single-dose oral administration at 1000 and 2200 hours in human subjects.,"Ciprofloxacin is routinely prescribed to treat a variety of infections, including those of the urinary tract. To achieve optimum therapeutic benefits of the drug, all of the factors which influence its pharmacokinetics and effectiveness need to be determined. This study investigated the urinary excretion kinetics of ciprofloxacin upon oral administration of a single dose of 250 mg at 1000 or 2200 h in 12 healthy human subjects in a crossover design. The urine samples were analyzed for unchanged ciprofloxacin by a sensitive high-performance liquid chromatography method. A significant decrease in the rate and extent of ciprofloxacin excretion following 2200 h (109.59 versus 53.8 mg [P < 0.05]) administration was observed. This result may be due to circadian changes in the factors affecting renal excretion and also probably metabolism of ciprofloxacin.",1997,A significant decrease in the rate and extent of ciprofloxacin excretion following 2200 h (109.59 versus 53.8 mg [P < 0.05]) administration was observed.,"['12 healthy human subjects in a crossover design', 'human subjects']","['Ciprofloxacin', 'ciprofloxacin']","['urinary excretion kinetics', 'rate and extent of ciprofloxacin excretion']","[{'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C0242817', 'cui_str': 'Cross-Over Design'}]","[{'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}]","[{'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0439792', 'cui_str': 'Extents (qualifier value)'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}]",,0.0336775,A significant decrease in the rate and extent of ciprofloxacin excretion following 2200 h (109.59 versus 53.8 mg [P < 0.05]) administration was observed.,"[{'ForeName': 'V V', 'Initials': 'VV', 'LastName': 'Rao', 'Affiliation': 'University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Rambhau', 'Affiliation': ''}, {'ForeName': 'B R', 'Initials': 'BR', 'LastName': 'Rao', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Srinivasu', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1198,9257777,Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. The STD Study Group.,"In a randomized open study, 351 male patients with uncomplicated gonorrhea were given single oral doses of grepafloxacin (400 mg) or cefixime (400 mg). In the 299 microbiologically evaluable patients, urethral infections were cured in 99% (147 of 149) of those receiving grepafloxacin and 97% (145 of 150) of those given cefixime. Eradication rates for both regimens were 100% in the 16% (47 of 299) of participants who were infected with penicillin-resistant Neisseria gonorrhoeae and 97% in the 21% (62 of 299) of participants infected with tetracycline-resistant strains. Grepafloxacin is a well-tolerated alternative to cefixime for treatment of uncomplicated gonorrhea in males.",1997,Grepafloxacin is a well-tolerated alternative to cefixime for treatment of uncomplicated gonorrhea in males.,"['351 male patients with uncomplicated gonorrhea', 'uncomplicated gonorrhea in males', '299 microbiologically evaluable patients', 'uncomplicated gonorrhea in men']","['grepafloxacin', 'Grepafloxacin', 'grepafloxacin with cefixime', 'cefixime']","['Eradication rates', 'urethral infections']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018081', 'cui_str': 'Neisseria gonorrhoeae Infection'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0287721', 'cui_str': 'grepafloxacin'}, {'cui': 'C0060400', 'cui_str': 'Cefixime'}]",[{'cui': 'C0948357'}],351.0,0.0675693,Grepafloxacin is a well-tolerated alternative to cefixime for treatment of uncomplicated gonorrhea in males.,"[{'ForeName': 'E W', 'Initials': 'EW', 'LastName': 'Hook', 'Affiliation': 'University of Alabama at Birmingham and Jefferson County Health Department, 35294, USA.'}, {'ForeName': 'W M', 'Initials': 'WM', 'LastName': 'McCormack', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Martin', 'Affiliation': ''}, {'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Jones', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Bean', 'Affiliation': ''}, {'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Maroli', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1199,9687407,"Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects.","The pharmacokinetics of moxifloxacin were investigated in six studies after oral administration of 50, 100, 200, 400, 600, and 800 mg. Eight healthy male volunteers were included in each study. With doses of up to 200 mg the study was performed as a double-blind, randomized group comparison (n = 6 verum and n = 2 matched placebo); with the higher doses the study was conducted with a double-blind, randomized, crossover design. Safety and tolerability were assessed by evaluation of vital signs, electrocardiograms, electroencephalograms, clinical chemistry parameters, results of urinalysis, and adverse events. The drug was well tolerated. The concentrations of moxifloxacin in plasma, urine, and saliva were determined by a validated high-pressure liquid chromatography assay with fluorescence detection. In addition, plasma and urine samples were analyzed by a bioassay. A good correlation between both methods was seen, indicating an absence of major active metabolites. The mean maximum concentrations of moxifloxacin in plasma (Cmax) ranged from 0.29 mg/liter (50-mg dose) to 4.73 mg/liter (800-mg dose) and were reached 0.5 to 4 h following drug administration. After reaching the Cmax, plasma moxifloxacin concentrations declined in a biphasic manner. Within 4 to 5 h they fell to about 30 to 55% of the Cmax, and thereafter a terminal half-life of 11 to 14 h accounted for the major part of the area under the concentration-time curve (AUC). During the absorption phase concentrations in saliva were even higher than those in plasma, whereas in the terminal phase a constant ratio of the concentration in saliva/concentration in plasma of between 0.5 and 1 was observed, indicating a correlation between unbound concentrations in plasma and levels in saliva (protein binding level, approximately 48%). AUC and Cmax increased proportionally to the dose over the whole range of doses investigated. Urinary excretion amounted to approximately 20% of the dose. Data on renal clearance (40 to 51 ml/min/1.73 m2) indicated partial tubular reabsorption of the drug. The pharmacokinetic parameters derived from compartmental and noncompartmental analyses were in good agreement. The kinetics could be described best by fitting the data to a two-compartment body model.",1998,The mean maximum concentrations of moxifloxacin in plasma (Cmax) ranged from 0.29 mg/liter (50-mg dose) to 4.73 mg/liter (800-mg dose) and were reached 0.5 to 4 h following drug administration.,"['healthy subjects', 'Eight healthy male volunteers']","['verum and n = 2 matched placebo', 'moxifloxacin']","['concentration-time curve (AUC', 'partial tubular reabsorption', 'concentrations of moxifloxacin in plasma, urine, and saliva', 'tolerated', 'Safety and tolerability', 'Pharmacokinetics, safety, and tolerability', 'AUC and Cmax', 'vital signs, electrocardiograms, electroencephalograms, clinical chemistry parameters, results of urinalysis, and adverse events', 'Urinary excretion', 'renal clearance', 'plasma and urine samples', 'Cmax, plasma moxifloxacin concentrations', 'mean maximum concentrations of moxifloxacin in plasma (Cmax']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0232816', 'cui_str': 'Tubular reabsorption, function (observable entity)'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0042037'}, {'cui': 'C0036087', 'cui_str': 'Saliva (substance)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0518766'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C1527380', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0008000', 'cui_str': 'Chemistry, Clinical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0042014', 'cui_str': 'Urinalysis'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0232813', 'cui_str': 'Renal clearance, function (observable entity)'}, {'cui': 'C1610733', 'cui_str': 'Urine specimen'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",8.0,0.105594,The mean maximum concentrations of moxifloxacin in plasma (Cmax) ranged from 0.29 mg/liter (50-mg dose) to 4.73 mg/liter (800-mg dose) and were reached 0.5 to 4 h following drug administration.,"[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Stass', 'Affiliation': 'Pharma Research Center, Institute of Clinical Pharmacology, Bayer AG, 42096 Wuppertal, Germany. heino.stass.hs@bayer-ag.de'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Dalhoff', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Kubitza', 'Affiliation': ''}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Schühly', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1200,9620430,Positive result by serology indicates active Helicobacter pylori infection in patients with atrophic gastritis.,"Patients with atrophic corpus gastritis and elevated Helicobacter pylori antibody titers but 13C-urea breath test (13C-UBT) and histology results negative for H. pylori were randomized into eradication therapy or follow-up only. Antibody levels decreased significantly in six out of seven patients in the eradication group, while in the follow-up group, the titers declined in only one out of eight patients. In patients with atrophic corpus gastritis, positive serology results may indicate an ongoing infection in spite of negative 13C-UBT and histology results.",1998,"Antibody levels decreased significantly in six out of seven patients in the eradication group, while in the follow-up group, the titers declined in only one out of eight patients.","['patients with atrophic gastritis', 'Patients with atrophic corpus gastritis and elevated Helicobacter pylori antibody titers but 13C-urea breath test (13C-UBT) and histology results negative for H. pylori', 'patients with atrophic corpus gastritis']",[],['Antibody levels'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0017154', 'cui_str': 'Gastritis, Atrophic'}, {'cui': 'C0333641', 'cui_str': 'Atrophy'}, {'cui': 'C0017152', 'cui_str': 'Gastritis'}, {'cui': 'C0369303', 'cui_str': 'Helicobacter pylori antibody (substance)'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C1318610', 'cui_str': '13C urea breath test'}, {'cui': 'C0344441', 'cui_str': 'Histologic test (procedure)'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}]",[],"[{'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",8.0,0.0121791,"Antibody levels decreased significantly in six out of seven patients in the eradication group, while in the follow-up group, the titers declined in only one out of eight patients.","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Kokkola', 'Affiliation': 'Second Department of Surgery, Helsinki University Central Hospital, Finland.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Rautelin', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Puolakkainen', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Sipponen', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Färkkilä', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Haapiainen', 'Affiliation': ''}, {'ForeName': 'T U', 'Initials': 'TU', 'LastName': 'Kosunen', 'Affiliation': ''}]",Journal of clinical microbiology,[] 1201,9559801,Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.,"The safety and pharmacokinetics of once-daily oral levofloxacin in 16 healthy male volunteers were investigated in a randomized, double-blind, placebo-controlled study. Subjects were randomly assigned to the treatment (n = 10) or placebo group (n = 6). In study period 1, 750 mg of levofloxacin or a placebo was administered orally as a single dose on day 1, followed by a washout period on days 2 and 3; dosing resumed for days 4 to 10. Following a 3-day washout period, 1 g of levofloxacin or a placebo was administered in a similar fashion in period 2. Plasma and urine levofloxacin concentrations were measured by high-pressure liquid chromatography. Pharmacokinetic parameters were estimated by model-independent methods. Levofloxacin was rapidly absorbed after single and multiple once-daily 750-mg and 1-g doses with an apparently large volume of distribution. Peak plasma levofloxacin concentration (Cmax) values were generally attained within 2 h postdose. The mean values of Cmax and area under the concentration-time curve from 0 to 24 h (AUC0-24) following a single 750-mg dose were 7.1 microg/ml and 71.3 microg x h/ml, respectively, compared to 8.6 microg/ml and 90.7 microg x h/ml, respectively, at steady state. Following the single 1-g dose, mean Cmax and AUC0-24 values were 8.9 microg/ml and 95.4 microg x h/ml, respectively; corresponding values at steady state were 11.8 microg/ml and 118 microg x h/ml. These Cmax and AUC0-24 values indicate modest and similar degrees of accumulation upon multiple dosing at the two dose levels. Values of apparent total body clearance (CL/F), apparent volume of distribution (Vss/F), half-life (t1/2), and renal clearance (CL[R]) were similar for the two dose levels and did not vary from single to multiple dosing. Mean steady-state values for CL/F, Vss/F, t1/2, and CL(R) following 750 mg of levofloxacin were 143 ml/min, 100 liters, 8.8 h, and 116 ml/min, respectively; corresponding values for the 1-g dose were 146 ml/min, 105 liters, 8.9 h, and 105 ml/min. In general, the pharmacokinetics of levofloxacin in healthy subjects following 750-mg and 1-g single and multiple once-daily oral doses appear to be consistent with those found in previous studies of healthy volunteers given 500-mg doses. Levofloxacin was well tolerated at either high dose level. The most frequently reported drug-related adverse events were nausea and headache.",1998,"Following the single 1-g dose, mean Cmax and AUC0-24 values were 8.9 microg/ml and 95.4 microg x h/ml, respectively; corresponding values at steady state were 11.8 microg/ml and 118 microg x h/ml.","['healthy subjects', 'healthy volunteers', '16 healthy male volunteers']","['levofloxacin', 'placebo', 'Levofloxacin']","['Mean steady-state values', 'nausea and headache', 'Plasma and urine levofloxacin concentrations', 'Pharmacokinetic parameters', 'tolerated', 'Values of apparent total body clearance (CL/F), apparent volume of distribution (Vss/F), half-life (t1/2), and renal clearance (CL[R', 'mean values of Cmax and area under the concentration-time curve', 'mean Cmax and AUC0-24 values', 'safety and pharmacokinetics', 'Peak plasma levofloxacin concentration (Cmax) values']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0282386', 'cui_str': 'Levofloxacin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0042037'}, {'cui': 'C0282386', 'cui_str': 'Levofloxacin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}, {'cui': 'C0232813', 'cui_str': 'Renal clearance, function (observable entity)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}]",16.0,0.263931,"Following the single 1-g dose, mean Cmax and AUC0-24 values were 8.9 microg/ml and 95.4 microg x h/ml, respectively; corresponding values at steady state were 11.8 microg/ml and 118 microg x h/ml.","[{'ForeName': 'S C', 'Initials': 'SC', 'LastName': 'Chien', 'Affiliation': 'The R. W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869, USA.'}, {'ForeName': 'F A', 'Initials': 'FA', 'LastName': 'Wong', 'Affiliation': ''}, {'ForeName': 'C L', 'Initials': 'CL', 'LastName': 'Fowler', 'Affiliation': ''}, {'ForeName': 'S V', 'Initials': 'SV', 'LastName': ""Callery-D'Amico"", 'Affiliation': ''}, {'ForeName': 'R R', 'Initials': 'RR', 'LastName': 'Williams', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Nayak', 'Affiliation': ''}, {'ForeName': 'A T', 'Initials': 'AT', 'LastName': 'Chow', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1202,9559810,Effect of grapefruit juice on clarithromycin pharmacokinetics.,"To investigate whether grapefruit juice inhibits the metabolism of clarithromycin, 12 healthy subjects were given water or grapefruit juice before and after a clarithromycin dose of 500 mg in a randomized crossover study. Administration of grapefruit juice increased the time to peak concentration of both clarithromycin (82 +/- 35 versus 148 +/- 83 min; P = 0.02) and 14-hydroxyclarithromycin (84 +/- 38 min versus 173 +/- 85; P = 0.01) but did not affect other pharmacokinetic parameters.",1998,Administration of grapefruit juice increased the time to peak concentration of both clarithromycin (82 +/-,['12 healthy subjects'],"['clarithromycin', '14-hydroxyclarithromycin', 'grapefruit juice']","['clarithromycin pharmacokinetics', 'time to peak concentration']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0090409', 'cui_str': 'Erythromycin, 14-hydroxy-6-O-methyl-'}, {'cui': 'C0452456', 'cui_str': 'GRAPEFRUIT JUICE'}]","[{'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",12.0,0.0534583,Administration of grapefruit juice increased the time to peak concentration of both clarithromycin (82 +/-,"[{'ForeName': 'K L', 'Initials': 'KL', 'LastName': 'Cheng', 'Affiliation': 'Department of Pharmacy Services, Bassett Healthcare, Cooperstown, New York 13326-1394, USA.'}, {'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Nafziger', 'Affiliation': ''}, {'ForeName': 'C A', 'Initials': 'CA', 'LastName': 'Peloquin', 'Affiliation': ''}, {'ForeName': 'G W', 'Initials': 'GW', 'LastName': 'Amsden', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1203,9559811,Fluconazole pharmacokinetics in burn patients.,"The pharmacokinetics of fluconazole in nine adult patients with severe (30 to 95% total body surface area) burns were studied. There was no significant difference in half-life (t1/2), clearance (CL), or volume of distribution (V) over time in five patients on days 3 and 8 of the study (P > 0.05). Combined parameter estimates (means +/- standard deviations) for all nine patients for the two study periods were as follows: t1/2, 24.4 +/- 5.8 h; CL, 0.36 +/- 0.09 ml/min/kg; and V, 0.72 +/- 0.12 liters/kg. These estimates of t1/2 and CL in burn patients were approximately 13% shorter and 30% more rapid, respectively, than the most extreme estimates reported for other populations.",1998,"There was no significant difference in half-life (t1/2), clearance (CL), or volume of distribution (V) over time in five patients on days 3 and 8 of the study (P > 0.05).","['all nine patients for the two study periods were as follows: t1/2, 24.4 ', 'nine adult patients with severe (30 to 95% total body surface area) burns were studied', 'burn patients']","['fluconazole', 'Fluconazole']","['half-life (t1/2), clearance (CL), or volume of distribution (V) over time']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0439175', 'cui_str': '% of total (qualifier value)'}, {'cui': 'C0005902', 'cui_str': 'Body Surface Area'}, {'cui': 'C0006434', 'cui_str': 'Burns'}]","[{'cui': 'C0016277', 'cui_str': 'Fluconazole'}]","[{'cui': 'C0018517', 'cui_str': 'Halflife'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",9.0,0.061754,"There was no significant difference in half-life (t1/2), clearance (CL), or volume of distribution (V) over time in five patients on days 3 and 8 of the study (P > 0.05).","[{'ForeName': 'B A', 'Initials': 'BA', 'LastName': 'Boucher', 'Affiliation': 'Department of Clinical Pharmacy, University of Tennessee, Memphis 38163, USA. bboucher@utmem1.utmem.edu'}, {'ForeName': 'S R', 'Initials': 'SR', 'LastName': 'King', 'Affiliation': ''}, {'ForeName': 'H L', 'Initials': 'HL', 'LastName': 'Wandschneider', 'Affiliation': ''}, {'ForeName': 'W L', 'Initials': 'WL', 'LastName': 'Hickerson', 'Affiliation': ''}, {'ForeName': 'S D', 'Initials': 'SD', 'LastName': 'Hanes', 'Affiliation': ''}, {'ForeName': 'V L', 'Initials': 'VL', 'LastName': 'Herring', 'Affiliation': ''}, {'ForeName': 'T W', 'Initials': 'TW', 'LastName': 'Canada', 'Affiliation': ''}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Hess', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1204,9449256,Comparison of strategies using cefpirome and ceftazidime for empiric treatment of pneumonia in intensive care patients. The Cefpirome Pneumonia Study Group.,"In an international, multicenter, open-label, randomized comparative study, adult patients in intensive care units were enrolled to receive cefpirome intravenously at 2 g twice daily or ceftazidime intravenously at 2 g three times daily for the empiric treatment of pneumonia. Randomization was performed after a double stratification according to the investigator's initial choice of monotherapy or combination therapy and then on the basis of the severity of disease. The primary endpoint was the clinical response at the end of treatment in the intent-to-treat population. Data for all patients were reviewed by a blinded observer. Of the 400 enrolled patients, 201 received cefpirome (monotherapy, 56%) and 199 received ceftazidime (monotherapy, 51%). Pneumonia was hospital acquired for 75% of the patients. Clinical failures rates were 34 versus 36% (odds ratio = 0.922; upper bound of 90% confidence interval = 1.301) in the intent-to-treat analysis for cefpirome and ceftazidime, respectively. For the cefpirome and ceftazidime groups, there were 35 versus 30% clinical failures among monotherapy-stratified patients, respectively, and 34 versus 42% clinical failures among combination therapy-stratified patients, respectively. The rates of clinical failures in the per-protocol analysis were 38 and 42%, respectively. In the population of patients evaluable for bacteriologic efficacy, eradication or presumed eradication was obtained for 71% (172 of 241) and 70% (162 of 230) of the pathogens isolated from the patients receiving cefpirome and ceftazidime, respectively. The mortality rates within 2 weeks after the end of treatment were similar (cefpirome group, 31%; ceftazidime group, 26%), as were the percentages of patients with at least one treatment-related adverse event (17 and 19%, respectively). An empiric treatment strategy with cefpirome at 2 g twice daily is equivalent in terms of efficacy and tolerance to ceftazidime at 2 g three times daily for the treatment of pneumonia in patients in intensive care units.",1998,"Clinical failures rates were 34 versus 36% (odds ratio = 0.922; upper bound of 90% confidence interval = 1.301) in the intent-to-treat analysis for cefpirome and ceftazidime, respectively.","['400 enrolled patients, 201 received cefpirome (monotherapy, 56%) and 199 received', 'intensive care patients', 'pneumonia in patients in intensive care units', 'adult patients in intensive care units']","['ceftazidime (monotherapy', 'cefpirome intravenously at 2 g twice daily or ceftazidime', 'ceftazidime', 'cefpirome and ceftazidime']","['adverse event', 'Clinical failures rates', 'mortality rates', 'rates of clinical failures', 'clinical response', 'efficacy and tolerance', 'bacteriologic efficacy, eradication or presumed eradication']","[{'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0062986', 'cui_str': 'cefpirome'}, {'cui': 'C0085559'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0007559', 'cui_str': 'Ceftazidime'}, {'cui': 'C0062986', 'cui_str': 'cefpirome'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0205465', 'cui_str': 'Bacteriologic (qualifier value)'}]",400.0,0.0874051,"Clinical failures rates were 34 versus 36% (odds ratio = 0.922; upper bound of 90% confidence interval = 1.301) in the intent-to-treat analysis for cefpirome and ceftazidime, respectively.","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Wolff', 'Affiliation': 'Hôpital Bichat-Claude Bernard, Paris, France. Wolff.m@bch.ap-hp.paris.fr'}]",Antimicrobial agents and chemotherapy,[] 1205,9449270,Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.,"A randomized, prospective, double-blind, double-dummy, multicenter study investigated the efficacy and safety of 10 days of oral therapy with grepafloxacin at 400 mg once daily, grepafloxacin at 600 mg once daily, or ciprofloxacin at 500 mg twice daily in 624 patients with acute bacterial exacerbations of chronic bronchitis. At the end of treatment, clinical success (cure or improvement) was achieved for 93% (140 of 151), 88% (137 of 156), and 91% (145 of 160) of patients in the groups receiving grepafloxacin at 400 mg, grepafloxacin at 600 mg, and ciprofloxacin, respectively (clinically evaluable population). At follow-up (14 to 28 days posttreatment), the clinical success rates were 87% (124 of 143), 81% (122 of 151), and 80% (123 of 154) in the groups receiving grepafloxacin at 400 mg and 600 mg and ciprofloxacin, respectively. A total of 379 pathogens were isolated from 290 patients, with the most common isolates being Moraxella catarrhalis (21%), Staphylococcus aureus (20%), Haemophilus influenzae (18%), and Streptococcus pneumoniae (7%). For the evaluable population, successful bacteriologic response was obtained at the end of treatment for 96% (92 of 96), 98% (87 of 89), and 92% (82 of 90) of patients receiving grepafloxacin at 400 mg, grepafloxacin at 600 mg, and ciprofloxacin, respectively, and was maintained in 86% (82 of 95), 88% (78 of 89), and 82% (69 of 84) of patients, respectively, at follow-up. All pretreatment S. pneumoniae isolates were susceptible to grepafloxacin, but two strains were resistant to ciprofloxacin. All treatments were well tolerated, with the most frequently reported drug-related adverse events being nausea, taste perversion, and headache. All drug-related adverse events in the grepafloxacin groups were mild or moderate in severity. This study demonstrates that 10-day courses of grepafloxacin given at 400 or 600 mg once daily were as effective, clinically and bacteriologically, as ciprofloxacin given at 500 mg twice daily for the treatment of acute bacterial exacerbations of chronic bronchitis.",1998,"All treatments were well tolerated, with the most frequently reported drug-related adverse events being nausea, taste perversion, and headache.","['acute bacterial exacerbations of chronic bronchitis', '624 patients with acute bacterial exacerbations of chronic bronchitis', 'A total of 379 pathogens were isolated from 290 patients, with the most common isolates being Moraxella catarrhalis (21%), Staphylococcus aureus (20%), Haemophilus influenzae (18%), and Streptococcus pneumoniae (7']","['grepafloxacin', 'ciprofloxacin']","['Efficacy and safety', 'efficacy and safety', 'clinical success rates', 'clinical success (cure or improvement', 'successful bacteriologic response', 'nausea, taste perversion, and headache']","[{'cui': 'C1735365', 'cui_str': 'Acute bacterial exacerbation of chronic bronchitis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0450254', 'cui_str': 'Pathogen'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C0205214', 'cui_str': 'Common (qualifier value)'}, {'cui': 'C0026536', 'cui_str': 'Moraxella'}, {'cui': 'C0038172', 'cui_str': 'Staphylococcus aureus'}, {'cui': 'C0018483', 'cui_str': 'Haemophilus influenzae'}, {'cui': 'C0038410', 'cui_str': 'Streptococcus pneumoniae'}]","[{'cui': 'C0287721', 'cui_str': 'grepafloxacin'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0205465', 'cui_str': 'Bacteriologic (qualifier value)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0013378', 'cui_str': 'Taste, Distorted'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}]",624.0,0.171055,"All treatments were well tolerated, with the most frequently reported drug-related adverse events being nausea, taste perversion, and headache.","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Chodosh', 'Affiliation': 'Veterans Affairs Outpatient Clinic, Boston, Massachusetts 02114, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Lakshminarayan', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Swarz', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Breisch', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1206,9371345,"Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.","We investigated the pharmacokinetics of zidovudine, zalcitabine, and saquinavir in AIDS Clinical Trial Group protocol 229. Patients received either saquinavir, zalcitabine, or a combination of both, together with zidovudine three times a day. Approximately 100 patients were enrolled in each treatment arm, and intensive pharmacokinetic studies were performed on about 25 patients per arm at weeks 1 and 12. We estimated the pharmacokinetic parameters of all three drugs by using parametric and nonparametric methods. The mean values of the pharmacokinetic parameters of zidovudine (clearance [CL]/bioavailability [F], 168 liters/h; volume of distribution [V]/F, 185 liters; half-life, 0.76 h) and zalcitabine (CL/F, 25 liters/h; V/F, 92.2 liters; half-life, 2.7 h) were similar to those reported previously. For saquinavir, the mean pharmacokinetic parameter estimates using parametric methods were as follows: maximum concentration of drug in serum [Cmax], 70.8 ng/ml; time to Cmax, 3.11 h; area under the curve, 809 ng x h/ml; CL/F, 989 liters/h; V/F, 1,503 liters; half-life, 1.38 h. For all three drugs, clearance decreased with age. Weight did not influence the clearance of zidovudine, but the clearance of zalcitabine and saquinavir increased with weight. There were no differences in pharmacokinetic parameters between study weeks and arms, suggesting that there is no change in kinetics with chronic administration and that there are no significant pharmacokinetic interactions among these three drugs.",1997,"Weight did not influence the clearance of zidovudine, but the clearance of zalcitabine and saquinavir increased with weight.",['Approximately 100 patients'],"['saquinavir, zalcitabine', 'zalcitabine and saquinavir', 'zidovudine, zalcitabine, and saquinavir', 'saquinavir, zidovudine, and zalcitabine', 'zalcitabine', 'zidovudine']","['mean values of the pharmacokinetic parameters of zidovudine (clearance [CL]/bioavailability [F], 168 liters/h; volume of distribution', 'pharmacokinetic parameters', 'Weight']","[{'cui': 'C0332232', 'cui_str': 'Approximate (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0286738', 'cui_str': 'Saquinavir'}, {'cui': 'C0012132', 'cui_str': 'Zalcitabine'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C4319556', 'cui_str': 'One hundred and sixty-eight'}, {'cui': 'C0475211', 'cui_str': 'L'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}]",,0.129396,"Weight did not influence the clearance of zidovudine, but the clearance of zalcitabine and saquinavir increased with weight.","[{'ForeName': 'G F', 'Initials': 'GF', 'LastName': 'Vanhove', 'Affiliation': 'Division of Clinical Pharmacology, Stanford University, California, USA.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Kastrissios', 'Affiliation': ''}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Gries', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Verotta', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Park', 'Affiliation': ''}, {'ForeName': 'A C', 'Initials': 'AC', 'LastName': 'Collier', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Squires', 'Affiliation': ''}, {'ForeName': 'L B', 'Initials': 'LB', 'LastName': 'Sheiner', 'Affiliation': ''}, {'ForeName': 'T F', 'Initials': 'TF', 'LastName': 'Blaschke', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1207,9660994,Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.,"Adefovir dipivoxil [bis(pivaloyloxymethyl)-ester prodrug], an orally bioavailable prodrug of adefovir [9-(2-phosphonylmethoxyethyl)adenine], is currently in phase III clinical trials for the treatment of human immunodeficiency virus (HIV). In vitro experiments demonstrated that either a K65R or a K70E mutation in HIV reverse transcriptase (RT) was selected in the presence of adefovir, conferring a 16- or 9-fold decrease in susceptibility to adefovir, respectively. Previous data demonstrated that patients receiving adefovir dipivoxil monotherapy (125 mg daily) for 12 weeks experienced a median decrease in HIV RNA levels of 0.5 log10 copies/ml and that resistance to adefovir dipivoxil did not arise during that period. In the present investigation, a further study was undertaken to investigate whether RT mutations developed among viruses from patients who completed the 12-week study and who opted to enroll in a maintenance phase of prolonged (6- to 12-month) adefovir dipivoxil therapy (120 mg daily). Concomitant treatment with antiretroviral agents was permitted during the maintenance phase. The median decreases in HIV RNA levels for patients who completed 6 or 12 months of maintenance-phase dosing were 0.6 and 1.14 log10 copies/ml, respectively. The reductions in the HIV RNA levels were similar among patients who received adefovir dipivoxil with or without concomitant treatment with antiretroviral agents. Viruses from 8 of 29 patients dosed for up to 12 months developed RT mutations that were not present at baseline; these mutations may have been related to adefovir dipivoxil therapy. Viruses from two of the eight patients developed the K70E mutation while the patients were on therapy, but none of the viruses from patients developed the K65R RT substitution. Despite the development of RT mutations, sustained reductions (6 to 12 months) in viral load (> or = 0.7 log10 copies/ml decrease from baseline) were observed in all eight patients.",1998,The reductions in the HIV RNA levels were similar among patients who received adefovir dipivoxil with or without concomitant treatment with antiretroviral agents.,"['human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy', 'human immunodeficiency virus (HIV', 'patients who completed the 12-week study and who opted to enroll in a maintenance phase of prolonged (6- to 12-month']","['adefovir [9-(2-phosphonylmethoxyethyl)adenine', 'adefovir dipivoxil therapy', 'adefovir dipivoxil', 'Adefovir dipivoxil [bis(pivaloyloxymethyl)-ester prodrug', 'adefovir dipivoxil monotherapy']","['HIV RNA levels', 'viral load', 'RT mutations', 'K65R RT substitution']","[{'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C0540694', 'cui_str': 'adefovir dipivoxil'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0050175', 'cui_str': 'adefovir'}, {'cui': 'C0540694', 'cui_str': 'adefovir dipivoxil'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1872096', 'cui_str': 'bis(phenylacetylarginine)'}, {'cui': 'C0014898', 'cui_str': 'Esters'}, {'cui': 'C0033262', 'cui_str': 'Drug Precursors'}]","[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}]",,0.059347,The reductions in the HIV RNA levels were similar among patients who received adefovir dipivoxil with or without concomitant treatment with antiretroviral agents.,"[{'ForeName': 'A S', 'Initials': 'AS', 'LastName': 'Mulato', 'Affiliation': 'Gilead Sciences, Inc., Foster City, California 94404, USA.'}, {'ForeName': 'P D', 'Initials': 'PD', 'LastName': 'Lamy', 'Affiliation': ''}, {'ForeName': 'M D', 'Initials': 'MD', 'LastName': 'Miller', 'Affiliation': ''}, {'ForeName': 'W X', 'Initials': 'WX', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'K E', 'Initials': 'KE', 'LastName': 'Anton', 'Affiliation': ''}, {'ForeName': 'N S', 'Initials': 'NS', 'LastName': 'Hellmann', 'Affiliation': ''}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Cherrington', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1208,9593129,Five-day cefdinir treatment for streptococcal pharyngitis. Cefdinir Pharyngitis Study Group.,"A multicenter, randomized, controlled, investigator-blind study was performed to evaluate the safety and efficacy of oral cefdinir versus oral penicillin V for the treatment of pharyngitis due to group A beta-hemolytic streptococci (GABHS). Patients 13 years of age and older were randomized to receive either oral cefdinir (300 mg twice a day) for 5 days followed by placebo for 5 days or oral penicillin V (250 mg four times a day) for 10 days. Throat cultures were obtained, and signs and symptoms of pharyngitis were recorded at study admission and follow-up visits on study days 11 to 15, 16 to 20, and 25 to 31. Patients kept a diary to record medication intake and their assessment of throat pain at admission and at each day of study treatment. Five hundred fifty-eight patients were enrolled, of whom 432 (77.4%) were clinically and microbiologically evaluable. The GABHS eradication rates 5 to 10 days after completion of therapy were 193 of 218 (88.5%) in the cefdinir group and 176 of 214 (82.2%) in the penicillin group (P = 0.053). Clinical cure rates were 89.0 and 84.6%, respectively (P = 0.80). By the time of the long-term follow-up visit, 2 to 3 weeks after completion of treatment, 156 of 191 (81.7%) of the assessable cefdinir patients and 152 of 195 (77.9%) of the penicillin patients remained free of GABHS. Both treatments were well tolerated, with adverse reaction rates of 18.3% in the cefdinir study arm and 15.0% in the penicillin study arm (P = 0.278). Five-day treatment with cefdinir is safe and effective therapy for GABHS pharyngitis. Based on its twice-a-day dosage and shorter course of therapy, leading to potentially greater patient compliance, cefdinir may be considered for use in the treatment of pharyngitis caused by GABHS.",1998,"Both treatments were well tolerated, with adverse reaction rates of 18.3% in the cefdinir study arm and 15.0% in the penicillin study arm (P = 0.278).","['Patients 13 years of age and older', 'Five hundred fifty-eight patients were enrolled, of whom 432 (77.4%) were clinically and microbiologically evaluable', 'pharyngitis due to group A beta-hemolytic streptococci (GABHS']","['placebo', 'cefdinir', 'oral penicillin V', 'oral cefdinir', 'oral cefdinir versus oral penicillin V']","['GABHS eradication rates', 'safety and efficacy', 'tolerated, with adverse reaction rates', 'free of GABHS', 'Clinical cure rates', 'signs and symptoms of pharyngitis']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0031350', 'cui_str': 'Pharyngitis'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C1541907', 'cui_str': 'Beta-hemolytic Streptococcus, group A'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0060405', 'cui_str': 'cefdinir'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0030840', 'cui_str': 'phenoxymethylpenicillin'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}, {'cui': 'C0332296', 'cui_str': 'Free of (attribute)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0037088', 'cui_str': 'Signs and Symptoms'}, {'cui': 'C0031350', 'cui_str': 'Pharyngitis'}]",558.0,0.0354944,"Both treatments were well tolerated, with adverse reaction rates of 18.3% in the cefdinir study arm and 15.0% in the penicillin study arm (P = 0.278).","[{'ForeName': 'K J', 'Initials': 'KJ', 'LastName': 'Tack', 'Affiliation': 'Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105, USA. tackk@aa.wl.com'}, {'ForeName': 'D C', 'Initials': 'DC', 'LastName': 'Henry', 'Affiliation': ''}, {'ForeName': 'W M', 'Initials': 'WM', 'LastName': 'Gooch', 'Affiliation': ''}, {'ForeName': 'D N', 'Initials': 'DN', 'LastName': 'Brink', 'Affiliation': ''}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Keyserling', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1209,9593133,Comparison of concentrations of sulbactam-ampicillin administered by bolus injections or bolus plus continuous infusion in tissues of patients undergoing colorectal surgery.,"The concentrations of sulbactam and ampicillin were determined in sera and different abdominal tissues of 16 patients who underwent elective colorectal surgery. Patients were randomly allocated to two groups. At the time of induction of anesthesia, patients in group 1 (eight patients) were given 1,000 mg of sulbactam with 2,000 mg of ampicillin by intravenous bolus injection (3 min). This dose was administered again after 2 h by bolus injection by the same route. Patients in group 2 (eight patients) were given the same initial dose of sulbactam-ampicillin by bolus injection (3 min). Then, a continuous infusion of 1,000 mg of sulbactam with 2,000 mg of ampicillin in normal saline was immediately started and was administered over a 4-h period. Blood samples were collected to determine peak (10 min) and trough (end of surgery) antibiotic levels. Serial blood samples were also collected at predetermined periods (at the time of opening and closing of the abdominal cavity and at the time of surgical anastomosis). Abdominal wall fat, epiploic fat, and colonic wall tissue samples were collected simultaneously. Antibiotic concentrations were determined by high-performance liquid chromatography. Similar levels of the drugs in serum were observed for the two regimens of administration, with trough sulbactam levels of 33 +/- 16 and 37 +/- 22 microg/ml in groups 1 and 2, respectively, and trough ampicillin levels of 72 +/- 55 and 79 +/- 47 microg/ml in groups 1 and 2, respectively. Similar sulbactam concentrations were observed in abdominal tissues whichever regimen of administration was used; in fatty tissues the sulbactam concentrations ranged from 2.7 to 3.8 microg/g for group 1 and from 1.7 to 4.0 microg/g for group 2, and sulbactam concentrations in the colonic wall were 5.6 +/- 7.7 and 6.8 +/- 3.2 microg/g in groups 1 and 2, respectively (not significant). Again, no influence of the regimen of administration was observed on tissue ampicillin concentrations; in fatty tissues ampicillin concentrations ranged from 4.1 to 5.4 microg/g for group 1 and from 3.2 to 5.8 microg/g for group 2, and sulbactam concentrations in the colonic wall were 7.0 +/- 2.8 and 11.0 +/- 4.7 microg/g for groups 1 and 2, respectively (not significant). In most patients, the concentrations of ampicillin-sulbactam were greater than the MIC at which 50% of isolates are inhibited (MIC50) for Bacteroides fragilis in the fatty tissues. In the colonic wall, for most patients the concentrations of ampicillin-sulbactam were greater than the MIC90 for B. fragilis. No influence of the regimen of administration was observed on the ratio of the two components in the tissues investigated and in sera. In conclusion, a second intraoperative bolus injection or a continuous infusion were equally effective in maintaining sulbactam-ampicillin concentrations in abdominal tissues. The first method of administration can be recommended since it is easier to handle.",1998,No influence of the regimen of administration was observed on the ratio of the two components in the tissues investigated and in sera.,"['patients undergoing colorectal surgery', '16 patients who underwent elective colorectal surgery']","['sulbactam with 2,000 mg of ampicillin', 'sulbactam-ampicillin']","['concentrations of ampicillin-sulbactam', 'Serial blood samples', 'trough ampicillin levels', 'Similar sulbactam concentrations', 'tissue ampicillin concentrations', 'Abdominal wall fat, epiploic fat, and colonic wall tissue samples', 'Antibiotic concentrations', 'concentrations of sulbactam and ampicillin']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009369', 'cui_str': 'Colon and Rectal Surgery Specialty'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}]","[{'cui': 'C0038665', 'cui_str': 'Sulbactam'}, {'cui': 'C0002680', 'cui_str': 'Ampicillin'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C2930041', 'cui_str': 'Ampicillin / Sulbactam'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0444506', 'cui_str': 'Trough (qualifier value)'}, {'cui': 'C0524017', 'cui_str': 'Ampicillin measurement (procedure)'}, {'cui': 'C0038665', 'cui_str': 'Sulbactam'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0002680', 'cui_str': 'Ampicillin'}, {'cui': 'C0836916', 'cui_str': 'Abdominal Wall'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0009368', 'cui_str': 'Colon'}, {'cui': 'C0205380', 'cui_str': 'Walled (qualifier value)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}]",,0.0408032,No influence of the regimen of administration was observed on the ratio of the two components in the tissues investigated and in sera.,"[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Martin', 'Affiliation': 'Department of Anesthesia and Intensive Care, Nord Hospital, Marseilles University Hospital System and Marseilles Medical School, France. cmartin@ap-hm.fr'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Cotin', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Giraud', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Beccani-Argème', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Alliot', 'Affiliation': ''}, {'ForeName': 'M N', 'Initials': 'MN', 'LastName': 'Mallet', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Argème', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1210,9593141,"Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group.","The present randomized, double-blind, placebo-controlled, multicenter clinical trial was designed to compare the efficacy and tolerability of sorivudine [1-beta-D-arabinofuranosyl-E-(2-bromovinyl)uracil] and acyclovir for the treatment of dermatomal herpes zoster in human immunodeficiency virus (HIV)-seropositive patients. A total of 170 HIV-seropositive adults presenting with herpes zoster (confirmed by direct fluorescent-antigen testing and/or viral culture) were enrolled and randomized to receive a 10-day course of orally administered sorivudine (40 mg once daily plus acyclovir placebos) or acyclovir (800 mg five times daily plus sorivudine placebo). Patients were monitored daily to document the events of cutaneous healing, pain, zoster-related complications, and drug-related adverse events. Patients were reassessed on days 21 and 28 and then once monthly for 1 year. The primary efficacy endpoint was time to the cessation of new vesicle formation. Secondary efficacy endpoints included times to other events of cutaneous healing, resolution of pain, and frequency of dissemination and zoster recurrence. In a multivariate analysis, sorivudine was superior to acyclovir for reducing the times to the cessation of new vesicle formation (relative risk [RR] = 1.54, 95% confidence interval [CI] = 1.00 to 2.36; P = 0.049) and total lesion crusting (RR = 1.48, 95% CI = 1.07 to 2.04; P = 0.017). In a univariate analysis, there was a trend favoring sorivudine for the cessation of new vesicle formation (median of 3 versus 4 days; P = 0.07) and a significant advantage for time to total lesion crusting (median of 7 versus 8 days; P = 0.02). The time to the resolution of zoster-associated pain, the frequency of dissemination, and the frequency of zoster recurrence were not different between the two treatment groups. Both drugs were well tolerated. Sorivudine is an effective drug for the treatment of herpes zoster in HIV-infected patients and results in accelerated cutaneous healing when compared with acyclovir therapy.",1998,"In a multivariate analysis, sorivudine was superior to acyclovir for reducing the times to the cessation of new vesicle formation (relative risk [RR] =","['dermatomal herpes zoster in human immunodeficiency virus (HIV)-seropositive patients', '170 HIV-seropositive adults presenting with herpes zoster (confirmed by direct fluorescent-antigen testing and/or viral culture', 'human immunodeficiency virus-infected patients']","['placebo', 'acyclovir', 'Sorivudine', 'Sorivudine versus acyclovir', 'sorivudine [1-beta-D-arabinofuranosyl-E-(2-bromovinyl)uracil', 'sorivudine (40 mg once daily plus acyclovir placebos) or acyclovir (800 mg five times daily plus sorivudine placebo']","['time to the cessation of new vesicle formation', 'cutaneous healing, pain, zoster-related complications, and drug-related adverse events', 'time to the resolution of zoster-associated pain, the frequency of dissemination, and the frequency of zoster recurrence', 'tolerated', 'total lesion crusting', 'efficacy and tolerability', 'times to other events of cutaneous healing, resolution of pain, and frequency of dissemination and zoster recurrence', 'time to total lesion crusting']","[{'cui': 'C0019360', 'cui_str': 'Shingles'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0521143', 'cui_str': 'Seropositive (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517599', 'cui_str': 'One hundred and seventy'}, {'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by (contextual qualifier) (qualifier value)'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0303920', 'cui_str': 'Fluorescent'}, {'cui': 'C0003320', 'cui_str': 'Antigens'}, {'cui': 'C0200955', 'cui_str': 'Culture for viruses'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0001367', 'cui_str': 'Acyclovir'}, {'cui': 'C0207628', 'cui_str': 'sorivudine'}, {'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3844106', 'cui_str': 'Eight hundred'}, {'cui': 'C0585292', 'cui_str': 'Five times daily (qualifier value)'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0333262', 'cui_str': 'Vesicle (morphologic abnormality)'}, {'cui': 'C0439634', 'cui_str': 'Formations (qualifier value)'}, {'cui': 'C4521174', 'cui_str': 'Cutaneous'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0019360', 'cui_str': 'Shingles'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}]",170.0,0.28629,"In a multivariate analysis, sorivudine was superior to acyclovir for reducing the times to the cessation of new vesicle formation (relative risk [RR] =","[{'ForeName': 'J W', 'Initials': 'JW', 'LastName': 'Gnann', 'Affiliation': 'Division of Infectious Diseases, University of Alabama at Birmingham, 35294-2170, USA. jgnann@uabid.dom.uab.edu'}, {'ForeName': 'C S', 'Initials': 'CS', 'LastName': 'Crumpacker', 'Affiliation': ''}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Lalezari', 'Affiliation': ''}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Smith', 'Affiliation': ''}, {'ForeName': 'S K', 'Initials': 'SK', 'LastName': 'Tyring', 'Affiliation': ''}, {'ForeName': 'K F', 'Initials': 'KF', 'LastName': 'Baum', 'Affiliation': ''}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Borucki', 'Affiliation': ''}, {'ForeName': 'W P', 'Initials': 'WP', 'LastName': 'Joseph', 'Affiliation': ''}, {'ForeName': 'G J', 'Initials': 'GJ', 'LastName': 'Mertz', 'Affiliation': ''}, {'ForeName': 'R T', 'Initials': 'RT', 'LastName': 'Steigbigel', 'Affiliation': ''}, {'ForeName': 'G A', 'Initials': 'GA', 'LastName': 'Cloud', 'Affiliation': ''}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Soong', 'Affiliation': ''}, {'ForeName': 'L C', 'Initials': 'LC', 'LastName': 'Sherrill', 'Affiliation': ''}, {'ForeName': 'D A', 'Initials': 'DA', 'LastName': 'DeHertogh', 'Affiliation': ''}, {'ForeName': 'R J', 'Initials': 'RJ', 'LastName': 'Whitley', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1211,9303380,Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients.,"Fluconazole, an inhibitor of certain human cytochrome P-450 isozymes, is used for the prevention and treatment of a broad range of fungal infections that predominantly affect immunocompromised individuals. This study evaluated the influence of fluconazole on the steady-state pharmacokinetics of delavirdine, a nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase, in 13 HIV-1-infected patients with CD4 counts ranging from 186 to 480/mm3. Both the control group (n = 5) and the fluconazole group (n = 8) received 300 mg of delavirdine mesylate every 8 h for 30 days; subjects in the fluconazole group took a 400-mg, once-daily dose of fluconazole on study days 16 to 30. Harvested plasma from serial blood samples collected on days 15, 16, and 30 were assayed for concentrations of delavirdine and its N-desalkyl metabolite by a reversed-phase high-pressure liquid chromatography (HPLC) method. Blood samples obtained on days 16 and 30 were also assayed for fluconazole by HPLC. Delavirdine mesylate alone and in combination with fluconazole was well tolerated. There were no significant differences (P > 0.16) in delavirdine pharmacokinetic parameters between treatment groups on day 15 or day 30. After coadministration of fluconazole and delavirdine mesylate for 2 weeks (day 30), no significant differences (P > 0.058) were observed in any delavirdine pharmacokinetic parameters relative to those after receiving delavirdine mesylate alone (day 15) after in the fluconazole group. Fluconazole pharmacokinetic parameters were similar to those previously reported for healthy volunteers and HIV-positive patients. On the basis of these findings, fluconazole and delavirdine mesylate may be taken concurrently without adjustment of the dose of either drug.",1997,There were no significant differences (P > 0.16) in delavirdine pharmacokinetic parameters between treatment groups on day 15 or day 30.,"['human immunodeficiency virus-positive patients', 'healthy volunteers and HIV-positive patients', '13 HIV-1-infected patients with CD4 counts ranging from 186 to 480/mm3']","['fluconazole', 'Delavirdine mesylate', 'fluconazole and delavirdine mesylate', 'delavirdine mesylate', 'delavirdine', 'Fluconazole']","['delavirdine pharmacokinetic parameters', 'tolerated', 'steady-state pharmacokinetics']","[{'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C4319609', 'cui_str': '480'}, {'cui': 'C0439243', 'cui_str': 'mm3'}]","[{'cui': 'C0016277', 'cui_str': 'Fluconazole'}, {'cui': 'C0543492', 'cui_str': 'Delavirdine Mesylate'}, {'cui': 'C0288165', 'cui_str': 'Delavirdine'}]","[{'cui': 'C0288165', 'cui_str': 'Delavirdine'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}]",,0.0206183,There were no significant differences (P > 0.16) in delavirdine pharmacokinetic parameters between treatment groups on day 15 or day 30.,"[{'ForeName': 'M T', 'Initials': 'MT', 'LastName': 'Borin', 'Affiliation': 'Clinical Pharmacokinetics, Pharmacia and Upjohn, Inc., Kalamazoo, Michigan 49001, USA. marie.t.borin@am.pnu.com'}, {'ForeName': 'S R', 'Initials': 'SR', 'LastName': 'Cox', 'Affiliation': ''}, {'ForeName': 'B D', 'Initials': 'BD', 'LastName': 'Herman', 'Affiliation': ''}, {'ForeName': 'B J', 'Initials': 'BJ', 'LastName': 'Carel', 'Affiliation': ''}, {'ForeName': 'R D', 'Initials': 'RD', 'LastName': 'Anderson', 'Affiliation': ''}, {'ForeName': 'W W', 'Initials': 'WW', 'LastName': 'Freimuth', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1212,9303394,Effect of foscarnet cream on experimental UV radiation-induced herpes labialis.,"A topical 3% foscarnet cream formulation was evaluated for its ability to treat experimental UV radiation (UVR)-induced herpes labialis in a double-blind study. Healthy adult volunteers with a history of sunlight-induced herpes labialis were randomly assigned at four centers to receive either foscarnet cream (n = 152) or a vehicle control (n = 150). Following measurement of the minimal erythematous dose (MED), the subjects' lips were exposed to 4 MEDs of UV light. Subjects applied the cream on the UVR-exposed area approximately eight times daily beginning immediately after UVR exposure and continuing for 7 days, or until all lesions had a minimum of 4 days of treatment. There were no significant differences between groups in the percentages of subjects that developed any lesion, aborted lesions (did not progress beyond a papule), immediate lesions (developed within 48 h of UVR), or delayed classic lesions (developed 48 h to 7 days after UVR). Treatment with foscarnet significantly reduced the mean lesion area (49 versus 81 mm2; P = 0.01), the maximum lesion area (80 versus 141 mm2; P = 0.01), and the time to healing (P = 0.03) of the delayed classic lesions (n = 78). There was also a trend for a decrease in the mean duration of these lesions (156 versus 191 h; P = 0.08) and the duration of pain (3.9 versus 4.3 days; P = 0.06) in foscarnet-treated subjects. There were no clinically significant adverse reactions. These data suggest that topical foscarnet can be efficacious and deserves further evaluation for the treatment of herpes labialis.",1997,"Treatment with foscarnet significantly reduced the mean lesion area (49 versus 81 mm2; P = 0.01), the maximum lesion area (80 versus 141 mm2; P = 0.01), and the time to healing (P = 0.03) of the delayed classic lesions (n = 78).","['Healthy adult volunteers with a history of sunlight-induced herpes labialis', 'experimental UV radiation-induced herpes labialis']","['vehicle control', 'foscarnet', 'topical foscarnet', 'foscarnet cream']","['time to healing', 'mean lesion area', 'delayed classic lesions', 'adverse reactions', 'maximum lesion area', 'mean duration of these lesions', 'duration of pain']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0038817', 'cui_str': 'Sunshine'}, {'cui': 'C0019340', 'cui_str': 'Herpes NOS'}, {'cui': 'C4319812', 'cui_str': 'Ultraviolet Radiation'}]","[{'cui': 'C0042444', 'cui_str': 'Drug vehicle (substance)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0070895', 'cui_str': 'Foscarnet'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C1378128', 'cui_str': 'Cream'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439658', 'cui_str': 'Classic (qualifier value)'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.0422254,"Treatment with foscarnet significantly reduced the mean lesion area (49 versus 81 mm2; P = 0.01), the maximum lesion area (80 versus 141 mm2; P = 0.01), and the time to healing (P = 0.03) of the delayed classic lesions (n = 78).","[{'ForeName': 'D I', 'Initials': 'DI', 'LastName': 'Bernstein', 'Affiliation': ""Division of Infectious Diseases, Children's Hospital Medical Center, Cincinnati, Ohio 45229-3039, USA. dib@chmcc.org""}, {'ForeName': 'C J', 'Initials': 'CJ', 'LastName': 'Schleupner', 'Affiliation': ''}, {'ForeName': 'T G', 'Initials': 'TG', 'LastName': 'Evans', 'Affiliation': ''}, {'ForeName': 'D A', 'Initials': 'DA', 'LastName': 'Blumberg', 'Affiliation': ''}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Bryson', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Grafford', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Broberg', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Martin-Munley', 'Affiliation': ''}, {'ForeName': 'S L', 'Initials': 'SL', 'LastName': 'Spruance', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1213,9303395,"A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.","Five hundred ninety patients were enrolled in a prospective, multicenter, randomized trial comparing the efficacy and safety of 7 to 14 days of levofloxacin treatment with that of ceftriaxone and/or cefuroxime axetil in the management of community-acquired pneumonia in adults. Patients received either intravenous and/or oral levofloxacin (500 mg once daily) or the comparative agents, parenteral ceftriaxone (1 to 2 g once to twice daily) and/or oral cefuroxime axetil (500 mg twice daily). Erythromycin or doxycycline could be added to the comparator arm at the investigator's discretion. The decision to use an intravenous or oral antimicrobial agent for initial therapy was made by the investigator. Clinical and microbiological evaluations were completed at the baseline, during treatment, 5 to 7 days posttherapy, and 3 to 4 weeks posttherapy. Four hundred fifty-six patients (226 given levofloxacin and 230 administered ceftriaxone and/or cefuroxime axetil) were evaluable for clinical efficacy. Streptococcus pneumoniae and Haemophilus influenzae were isolated in 15 and 12%, respectively, of clinically evaluable patients. One hundred fifty atypical pathogens were identified: 101 were Chlamydia pneumoniae, 41 were Mycoplasma pneumoniae, and 8 were Legionella pneumophila. Clinical success at 5 to 7 days posttherapy was superior for the levofloxacin group (96%) compared with the ceftriaxone and/or cefuroxime axetil group (90%) (95% confidence interval [CI] of -10.7 to -1.3). Among patients with typical respiratory pathogens who were evaluable for microbiological efficacy, the overall bacteriologic eradication rates were superior for levofloxacin (98%) compared with the ceftriaxone and/or cefuroxime axetil group (85%) (95% CI of -21.6 to -4.8). Levofloxacin eradicated 100% of the most frequently reported respiratory pathogens (i.e., H. influenzae and S. pneumoniae) and provided a >98% clinical success rate in patients with atypical pathogens. Both levofloxacin and ceftriaxone-cefuroxime axetil eradicated 100% of the S. pneumoniae cells detected in blood culture. Drug-related adverse events were reported in 5.8% of patients receiving levofloxacin and in 8.5% of patients administered ceftriaxone and/or cefuroxime axetil. Gastrointestinal and central and peripheral nervous system adverse events were the most common events reported in each treatment group. In conclusion, these results demonstrate that treatment with levofloxacin is superior to ceftriaxone and/or cefuroxime axetil therapy in the management of community-acquired pneumonia in adults.",1997,Clinical success at 5 to 7 days posttherapy was superior for the levofloxacin group (96%) compared with the ceftriaxone and/or cefuroxime axetil group (90%) (95% confidence interval [CI] of -10.7 to -1.3).,"['One hundred fifty atypical pathogens were identified: 101 were Chlamydia pneumoniae, 41 were Mycoplasma pneumoniae, and 8 were Legionella pneumophila', 'Four hundred fifty-six patients (226 given', 'adults with community-acquired pneumonia', 'community-acquired pneumonia in adults', 'Five hundred ninety patients']","['oral cefuroxime axetil', 'ceftriaxone and/or cefuroxime axetil', 'Erythromycin or doxycycline', 'levofloxacin', 'levofloxacin and ceftriaxone-cefuroxime axetil', 'ceftriaxone', 'ceftriaxone and/or cefuroxime axetil therapy', 'intravenous and/or oral levofloxacin', 'Levofloxacin']","['microbiological efficacy', 'Clinical success', 'efficacy and safety', 'blood culture', 'overall bacteriologic eradication rates', 'respiratory pathogens', 'adverse events', 'Gastrointestinal and central and peripheral nervous system adverse events', 'Streptococcus pneumoniae and Haemophilus influenzae']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0205182', 'cui_str': 'Atypical (qualifier value)'}, {'cui': 'C0450254', 'cui_str': 'Pathogen'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0085504', 'cui_str': 'Chlamydia pneumoniae'}, {'cui': 'C0026941', 'cui_str': 'Mycoplasma pneumoniae'}, {'cui': 'C0023238', 'cui_str': 'Legionella pneumophila'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0694549', 'cui_str': 'Community acquired pneumonia (disorder)'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C3816959', 'cui_str': 'Ninety'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0055015', 'cui_str': 'cefuroxime axetil'}, {'cui': 'C0007561', 'cui_str': 'Ceftriaxone'}, {'cui': 'C0014806', 'cui_str': 'Erythromycin'}, {'cui': 'C0013090', 'cui_str': 'Doxycycline'}, {'cui': 'C0282386', 'cui_str': 'Levofloxacin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0200949', 'cui_str': 'Blood Culture Test'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205465', 'cui_str': 'Bacteriologic (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0206417', 'cui_str': 'Peripheral Nervous System'}, {'cui': 'C0038410', 'cui_str': 'Streptococcus pneumoniae'}, {'cui': 'C0018483', 'cui_str': 'Haemophilus influenzae'}]",590.0,0.0373159,Clinical success at 5 to 7 days posttherapy was superior for the levofloxacin group (96%) compared with the ceftriaxone and/or cefuroxime axetil group (90%) (95% confidence interval [CI] of -10.7 to -1.3).,"[{'ForeName': 'T M', 'Initials': 'TM', 'LastName': 'File', 'Affiliation': 'Northeastern Ohio Universities College of Medicine, Rootstown 44272, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Segreti', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Dunbar', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Player', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Kohler', 'Affiliation': ''}, {'ForeName': 'R R', 'Initials': 'RR', 'LastName': 'Williams', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Kojak', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Rubin', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1214,9333047,Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects.,"The effects of food and sucralfate on the pharmacokinetics of levofloxacin following the administration of a single 500-mg oral dose were investigated in a randomized, three-way crossover study with young healthy subjects (12 males and 12 females). Levofloxacin was administered under three conditions: fasting, fed (immediately after a standardized high-fat breakfast), and fasting with sucralfate given 2 h following the administration of levofloxacin. The concentrations of levofloxacin in plasma and urine were determined by high-pressure liquid chromatography. By noncompartmental methods, the maximum concentration of drug in serum (Cmax), the time to Cmax (Tmax), the area under the concentration-time curve (AUC), half-life (t1/2), clearance (CL/F), renal clearance (CLR), and cumulative amount of levofloxacin in urine (Ae) were estimated. The individual profiles of the drug concentration in plasma showed little difference among the three treatments. The only consistent effect of the coadministration of levofloxacin with a high-fat meal for most subjects was that levofloxacin absorption was delayed and Cmax was slightly reduced (Tmax, 1.0 and 2.0 h for fasting and fed conditions, respectively [P = 0.002]; Cmax, 5.9 +/- 1.3 and 5.1 +/- 0.9 microg/ml [90% confidence interval = 0.79 to 0.94] for fasting and fed conditions, respectively). Sucralfate, which was administered 2 h after the administration of levofloxacin, appeared to have no effect on levofloxacin's disposition compared with that under the fasting condition. Mean values of Cmax and AUC from time zero to infinity were 6.7 +/- 3.2 microg/ml and 47.9 +/- 8.4 microg x h/ml, respectively, following the administration of sucralfate compared to values of 5.9 +/- 1.3 microg/ml and 50.5 +/- 8.1 microg x h/ml, respectively, under fasting conditions. The mean t1/2, CL/F, CLR, and Ae values were similar among all three treatment groups. In conclusion, the absorption of levofloxacin was slightly delayed by food, although the overall bioavailability of levofloxacin following a high-fat meal was not altered. Finally, sucralfate did not alter the disposition of levofloxacin when sucralfate was given 2 h after the administration of the antibacterial agent, thus preventing a potential drug-drug interaction.",1997,"The mean t1/2, CL/F, CLR, and Ae values were similar among all three treatment groups.","['young healthy subjects (12 males and 12 females', 'healthy subjects']","['Sucralfate', 'levofloxacin', 'food and sucralfate', 'sucralfate', 'Levofloxacin']","['maximum concentration of drug in serum (Cmax), the time to Cmax (Tmax), the area under the concentration-time curve (AUC), half-life (t1/2), clearance (CL/F), renal clearance (CLR), and cumulative amount of levofloxacin in urine (Ae', 'overall bioavailability', 'concentrations of levofloxacin in plasma and urine', 'disposition of levofloxacin', 'Mean values of Cmax and AUC', 'mean t1/2, CL/F, CLR, and Ae values']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0038633', 'cui_str': 'Sucralfate'}, {'cui': 'C0282386', 'cui_str': 'Levofloxacin'}, {'cui': 'C0016452', 'cui_str': 'Food'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0232813', 'cui_str': 'Renal clearance, function (observable entity)'}, {'cui': 'C0282386', 'cui_str': 'Levofloxacin'}, {'cui': 'C0042037'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0743223', 'cui_str': 'Disposition (disposition)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0109978', 'cui_str': 'Cl(3)R'}]",,0.0423739,"The mean t1/2, CL/F, CLR, and Ae values were similar among all three treatment groups.","[{'ForeName': 'L J', 'Initials': 'LJ', 'LastName': 'Lee', 'Affiliation': 'Hoechst Marion Roussel, Inc., Bridgewater, New Jersey 08807-0800, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Hafkin', 'Affiliation': ''}, {'ForeName': 'I D', 'Initials': 'ID', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Hoh', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Dix', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1215,9257738,Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.,"In an open, randomized, triple crossover study, the effects of cisapride and sucralfate on the pharmacokinetics of sparfloxacin were assessed. Fifteen healthy volunteers received 400 mg of sparfloxacin as a single oral dose on day 0. In a random order, concomitant doses of 10 mg of cisapride three times daily from day -2 to day 2 and 1 g of sucralfate four times daily from day -2 to day 0 were administered. Sparfloxacin concentrations were measured by bioassay and high-performance liquid chromatography. Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6. For the cisapride group there was a significant decrease in the sparfloxacin T(max) (1.9 +/- 2.1 h) and a significant increase in C(max) (1.74 +/- 0.73 microg/ml). The QTc interval for patients receiving sparfloxacin and cisapride was prolonged by 7.7% compared to the QTc interval during medication-free periods. Significant differences in the values for the group receiving sucralfate compared to the values for the group receiving sparfloxacin alone were found: C(max), 0.77 +/- 0.31 microg/ml; AUC, 18.6 +/- 5.8 microg x h/ml; t1/2, 26 +/- 10 h; and UR x f, 5.8 +/- 1.8%. Concomitant adminstration of cisapride accelerates the absorption and increases the peak concentration of sparfloxacin without having a significant effect on the extent of bioavailability. Coadministration of sucralfate leads to a 44% decrease in the bioavailability of sparfloxacin.",1997,For the cisapride group there was a significant decrease in the sparfloxacin T(max),['Fifteen healthy volunteers'],"['cisapride', 'sparfloxacin and cisapride', 'cisapride and sucralfate', 'sucralfate', 'sparfloxacin']","['pharmacokinetics of sparfloxacin', 'standard deviation): maximum concentration of drug in serum (C(max', 'Sparfloxacin concentrations', 'concentration-time curve (AUC', 'mean residence time', 'Pharmacokinetic parameters', 'metabolite-sparfloxacin ratio', 'bioavailability', 'sparfloxacin T(max', 'C(max', 'QTc interval', 'bioavailability of sparfloxacin']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0072916', 'cui_str': 'Cisapride'}, {'cui': 'C0052585', 'cui_str': 'sparfloxacin'}, {'cui': 'C0038633', 'cui_str': 'Sucralfate'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0052585', 'cui_str': 'sparfloxacin'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0860814', 'cui_str': 'QTc'}, {'cui': 'C1272706', 'cui_str': 'Interval'}]",15.0,0.0376548,For the cisapride group there was a significant decrease in the sparfloxacin T(max),"[{'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Zix', 'Affiliation': 'Department of Pulmonary and Infectious Diseases, City Hospital Zehlendorf-Heckeshorn, Freie Universitat Berlin, Germany.'}, {'ForeName': 'H F', 'Initials': 'HF', 'LastName': 'Geerdes-Fenge', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Rau', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Vöckler', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Borner', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Koeppe', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Lode', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1216,9257745,Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients.,"An open-label randomized trial comparing the efficacy and safety of cefepime versus piperacillin plus gentamicin (P+G) given intravenously for the treatment of febrile episodes in neutropenic patients with underlying malignancy was conducted at two oncology centers. Over a 30-month period 111 patients were enrolled and 99 patients were found to be suitable for evaluation. At the 72-h time of evaluation, cefepime monotherapy and P+G combination therapy produced comparable clinical response rates (78% for both). P+G and cefepime produced comparable response rates in microbiologically documented (78 versus 71%), clinically documented (100 versus 100%), and possible (75 versus 79%) infections. The P+G and cefepime treatments achieved comparable microbiological eradication of gram-negative (100 versus 71%) (P = 0.09) and gram-positive (44 versus 70%) (P = 0.37) organisms. There were no statistically significant differences in the rates of superinfection between the groups; however, more superinfections of fungal origin were noted in the P+G group. Cefepime was demonstrated to be an effective and safe treatment for febrile episodes in neutropenic patients with malignancies, and its lack of nephrotoxicity compared to P+G was noteworthy. Cefepime appears to be a candidate for monotherapy in febrile neutropenic cancer patients.",1997,"Cefepime was demonstrated to be an effective and safe treatment for febrile episodes in neutropenic patients with malignancies, and its lack of nephrotoxicity compared to P+G was noteworthy.","['febrile neutropenic cancer patients', 'neutropenic patients with underlying malignancy was conducted at two oncology centers', '111 patients were enrolled and 99 patients', 'neutropenic patients with malignancies']","['cefepime versus piperacillin-gentamicin', 'cefepime versus piperacillin plus gentamicin (P+G']","['clinical response rates', 'gram-positive', 'microbiological eradication of gram-negative', 'febrile episodes', 'rates of superinfection', 'superinfections of fungal origin']","[{'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C4517538', 'cui_str': '111 (qualifier value)'}]","[{'cui': 'C0055003', 'cui_str': 'cefepime'}, {'cui': 'C0031955', 'cui_str': 'Piperacillin'}, {'cui': 'C0017436', 'cui_str': 'Gentamicins'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0439208', 'cui_str': 'gram (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0038826', 'cui_str': 'Superinvasion, Microbial'}, {'cui': 'C0439659', 'cui_str': 'Origins (qualifier value)'}]",111.0,0.0434972,"Cefepime was demonstrated to be an effective and safe treatment for febrile episodes in neutropenic patients with malignancies, and its lack of nephrotoxicity compared to P+G was noteworthy.","[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Yamamura', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Gucalp', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Carlisle', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Cimino', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Roberts', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Rotstein', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1217,9257749,Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate.,"Ciprofloxacin, when given intravenously (i.v.), is secreted in significant amounts via the mucosa into the intestinal lumen. Sucralfate inhibits the antimicrobial activity of ciprofloxacin. The effect of combined therapy on the intestinal flora was investigated in 16 healthy volunteers. They were randomly assigned to two groups. Group A received 2 g of sucralfate orally three times a day for 7 days and 400 mg of ciprofloxacin i.v. twice a day (b.i.d.) starting 3 days after the sucralfate administration began. Group B was given only 400 mg of ciprofloxacin i.v. b.i.d. for 4 days. A total of 9 stool samples were collected from each subject beginning the week before ciprofloxacin was administered and on days -1, 1, 2, 3, 4, 7, 9, and 10 or 11 after commencement of the infusion period. The aerobic fecal flora was determined by standard microbiological methods. Measurements of fecal ciprofloxacin levels were based on high-performance liquid chromatography. Counts of bacteria of the family Enterobacteriaceae decreased in all subjects and were below 10(2) CFU/g in eight of eight subjects (group A) and six of eight subjects (group B) on day 4, but they returned to normal in all but one subject (group A) 10 days after the last infusion. The decreases in levels of bacteria of the family Enterobacteriaceae were not significantly different in groups A and B (Kaplan-Meier test). Staphylococci and nonfermenters responded variably, enterococci and lactobacilli remained unchanged, and candida levels increased transiently in four subjects (two in each group). Maximum fecal drug levels ranged from 251 to 811 microg/g. No significant difference could be found between the two groups. The i.v. application of ciprofloxacin eliminates intestinal bacteria of the family Enterobacteriaceae in a rapid and selective manner. This effect is not affected by simultaneous oral application of sucralfate.",1997,Counts of bacteria of the family Enterobacteriaceae decreased in all subjects and were below 10(2),['16 healthy volunteers'],"['Sucralfate', 'Ciprofloxacin', 'combined therapy', 'ciprofloxacin i.v', 'ciprofloxacin', 'sucralfate']","['Counts of bacteria of the family Enterobacteriaceae', 'levels of bacteria of the family Enterobacteriaceae', 'enterococci and lactobacilli', 'aerobic intestinal microflora and fecal drug levels', 'Maximum fecal drug levels', 'fecal ciprofloxacin levels', 'candida levels']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0038633', 'cui_str': 'Sucralfate'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0033972', 'cui_str': 'Psychotherapy, Multiple'}]","[{'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C1510439', 'cui_str': 'bacteria'}, {'cui': 'C0014346', 'cui_str': 'Coliform Bacilli'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiome'}, {'cui': 'C0428212', 'cui_str': 'Finding of drug level (finding)'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0006836', 'cui_str': 'Monilia'}]",16.0,0.0493349,Counts of bacteria of the family Enterobacteriaceae decreased in all subjects and were below 10(2),"[{'ForeName': 'W A', 'Initials': 'WA', 'LastName': 'Krueger', 'Affiliation': 'Department of Anaesthesiology, Tübingen University Hospital, Germany.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Ruckdeschel', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Unertl', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1218,9257757,Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.,"This phase I, double-blind, randomized, placebo-controlled, parallel-design study was conducted to evaluate the safety and pharmacokinetics of levofloxacin in human immunodeficiency virus (HIV)-infected subjects concomitantly receiving a stable regimen of zidovudine (AZT). Sixteen HIV-infected males with CD4-cell counts ranging from 100 to 550 and not experiencing significant AZT intolerance were enrolled. Subjects received levofloxacin (350 mg of levofloxacin hemihydrate) or a placebo (eight subjects per treatment group) as a single oral dose on day 1, multiple doses every 8 h from days 3 to 9, and a single dose on day 10. On days 1 and 10, an AZT dose (100 mg) was administered concurrently with the study drug. In between these doses, AZT was administered according to the regimen used by the subject prior to entering the study up to a maximum of 500 mg/day. Plasma levofloxacin concentrations were monitored for 36 h after levofloxacin dosing on day 1, immediately prior to the morning doses on days 3 to 9, and for 72 h after dosing on day 10. Plasma AZT concentrations were monitored on day 0 for baseline (for 6 h after the AZT dose) and for 4 h after the AZT doses on days 1 and 10. Levofloxacin was rapidly absorbed (time to maximum plasma concentration, approximately 1.0 h) and extensively distributed in the body with an apparent volume of distribution of approximately 104 liters (approximately 1.34 liters/kg). Steady-state conditions on day 10 were confirmed. Pharmacokinetic profiles of levofloxacin from single doses and multiple (three-times-daily) doses were similar, with a moderate accumulation (observed day 10-to-day 1 ratio of the maximum plasma concentration, approximately 185% versus expected 169%; for the corresponding ratio of the area under the concentration-time curve from 0 to 8 h [AUC(0-8)], the values were observed 217% versus expected 169%) at steady state. Mean average steady-state peak plasma concentration, plasma levofloxacin concentration at the end of the dosing interval, AUC(0-8), terminal half-life, and total body clearance were 7.06 microg/ml, 3.62 microg/ml, 37.4 microg x h/ml, 7.2 h, and 9.4 liters/h (0.12 liters/h/kg), respectively. Pharmacokinetic profiles of levofloxacin in HIV-infected patients did not appear to be affected by the concomitant administration of AZT; nor were AZT pharmacokinetics altered by levofloxacin. Oral administration of 350 mg of levofloxacin hemihydrate every 8 h appeared to be well tolerated by the subjects. There were no apparent differences in adverse events between the two treatment groups. There were no clinically significant changes from baseline in any laboratory parameter or vital sign following treatments observed in this study. The study results suggest that there is no need for levofloxacin dosage adjustment in HIV-seropositive subjects who concomitantly receive AZT.",1997,"Levofloxacin was rapidly absorbed (time to maximum plasma concentration, approximately 1.0 h) and extensively distributed in the body with an apparent volume of distribution of approximately 104 liters (approximately 1.34 liters/kg).","['HIV-seropositive subjects who concomitantly receive AZT', 'human immunodeficiency virus-infected individuals receiving concomitant', 'human immunodeficiency virus (HIV)-infected subjects concomitantly receiving a stable regimen of', 'Sixteen HIV-infected males with CD4-cell counts ranging from 100 to 550 and not experiencing significant AZT intolerance were enrolled']","['oral levofloxacin', 'zidovudine', 'placebo', 'levofloxacin hemihydrate', 'AZT', 'levofloxacin', 'Levofloxacin', 'zidovudine (AZT']","['Pharmacokinetic profiles', 'Plasma levofloxacin concentrations', 'terminal half-life, and total body clearance', 'Plasma AZT concentrations', 'laboratory parameter or vital sign', 'adverse events', 'Mean average steady-state peak plasma concentration, plasma levofloxacin concentration', 'safety and pharmacokinetics']","[{'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3844103', 'cui_str': '550 (qualifier value)'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0231199', 'cui_str': 'Intolerance, function (observable entity)'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0282386', 'cui_str': 'Levofloxacin'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4511692', 'cui_str': 'Levofloxacin hemihydrate (substance)'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0282386', 'cui_str': 'Levofloxacin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0518766'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.083699,"Levofloxacin was rapidly absorbed (time to maximum plasma concentration, approximately 1.0 h) and extensively distributed in the body with an apparent volume of distribution of approximately 104 liters (approximately 1.34 liters/kg).","[{'ForeName': 'S C', 'Initials': 'SC', 'LastName': 'Chien', 'Affiliation': 'The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869, USA.'}, {'ForeName': 'A T', 'Initials': 'AT', 'LastName': 'Chow', 'Affiliation': ''}, {'ForeName': 'M C', 'Initials': 'MC', 'LastName': 'Rogge', 'Affiliation': ''}, {'ForeName': 'R R', 'Initials': 'RR', 'LastName': 'Williams', 'Affiliation': ''}, {'ForeName': 'C W', 'Initials': 'CW', 'LastName': 'Hendrix', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1219,9666011,Random amplification of polymorphic DNA and microsatellite genotyping of pre- and posttreatment isolates of Candida spp. from human immunodeficiency virus-infected patients on different fluconazole regimens.,"Twelve patients infected with the human immunodeficiency virus (HIV) and with CD4 cell counts below 100 cells/microliter received fluconazole daily (200 mg; five patients) or weekly (400 mg; seven patients) for fungal prophylaxis during a 6-month period. Oropharyngeal swabs were taken at regular intervals in order to detect colonization with Candida spp. All yeast isolates were examined with respect to the development over time of fluconazole resistance. Genetic diversity among the strains was assessed in order to discriminate between selection of a resistant subclone and patient recolonization. Genotyping was performed through random amplification of polymorphic DNA (RAPD) analysis. Specific site polymorphisms were assayed by tracking length variability in several microsatellite loci. Finally, to maximize resolution, one of these loci (ERK1) was analyzed by nucleotide sequencing. Although the number of strains analyzed was too small to allow statistical verification, it appeared that when fluconazole was given weekly, a smaller fraction of the strains showed diminished sensitivity than when it was given daily. Genetic analyses allowed three different scenarios to be discerned. Resistance development in an otherwise apparently unchanged strain was seen for 1 of the 12 patients. Clear strain replacement was observed for 3 of the remaining 11 patients. For all other patients minor differences were seen in either the RAPD genotype or the microsatellite allele composition during the course of treatment. In general, microsatellite sequence data is in agreement with data obtained by other methods, but occasionally within-patient heterogeneity is indicated. The present results show that during fluconazole treatment colonizing strains can remain identical, be replaced by clearly different strains, or undergo small changes. Within a patient there may be different levels of intrastrain variation.",1998,For all other patients minor differences were seen in either the RAPD genotype or the microsatellite allele composition during the course of treatment.,['Twelve patients infected with the human immunodeficiency virus (HIV) and with CD4 cell counts below 100 cells/microliter received'],['fluconazole'],"['Clear strain replacement', 'Resistance development', 'sensitivity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0439378', 'cui_str': 'cells/microliter'}]","[{'cui': 'C0016277', 'cui_str': 'Fluconazole'}]","[{'cui': 'C2963144', 'cui_str': 'Clear (qualifier value)'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}]",,0.0366497,For all other patients minor differences were seen in either the RAPD genotype or the microsatellite allele composition during the course of treatment.,"[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Metzgar', 'Affiliation': 'Department of Biology, University of California at San Diego, La Jolla 92093-0116, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'van Belkum', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Field', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Haubrich', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Wills', 'Affiliation': ''}]",Journal of clinical microbiology,[] 1220,9661000,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers.,"Twelve healthy volunteers participated in this randomized crossover study to compare the concentrations and recovery levels of fleroxacin and pefloxacin in urine and to assess their bactericidal activities against 12 strains of urinary pathogens with different susceptibilities over a wide range of MICs. The volunteers received a single oral dose of 400 mg of fleroxacin or 800 mg of pefloxacin. The mean cumulative renal excretion of unchanged fleroxacin, N-demethyl-fleroxacin, and N-oxide-fleroxacin accounted for 67, 7, and 6% of the total dose, respectively. The total urinary recovery of pefloxacin and the active metabolite norfloxacin was 34%. In the time-kill and the urinary bactericidal titer (UBT) studies, only the subjects' urine not supplemented with broth was used. With most tested organisms and both quinolones it took more than 8 h to achieve a reduction in CFU of 99.9% (3 log units). Overall, there was a good correlation between UBTs and MICs for the strains. Against Escherichia coli ATCC 25922 the median UBTs were similar for both antibiotics and at least 1:8 for 96 h; against the E. coli strain for which the MIC was 0.5 microgram/ml the UBT was at least 1:4 for 48 h. The UBTs of both drugs against Klebsiella pneumoniae were at least 1:16 for 72 h. The UBTs for Staphylococcus aureus (the MIC for which was 16 micrograms/ml) of both antibiotics were low, and in some of the samples, no bactericidal titers were observed. UBTs for Proteus mirabilis of pefloxacin are significantly higher than those of fleroxacin. For Pseudomonas aeruginosa the median UBTs were present for the 24-to-48-h interval. The same is true for Enterococcus faecalis. Against Staphylococcus saprophyticus, UBTs were present for at least 48 h with both quinolones. Overall, a single oral dose of 400 mg of fleroxacin exhibits UBTs comparable to those of 800 mg of pefloxacin. Therefore, it may be expected that half of the dose of fleroxacin gives comparable results in the treatment of urinary tract infections; this should be substantiated in comparative clinical trials.",1998,Against Escherichia coli ATCC 25922 the median UBTs were similar for both antibiotics and at least 1:8 for 96 h; against the E. coli strain for which the MIC was 0.5 microgram/,"['Twelve healthy volunteers', 'healthy volunteers']","['fleroxacin exhibits UBTs', 'pefloxacin', 'fleroxacin', 'fleroxacin and pefloxacin']","['mean cumulative renal excretion of unchanged fleroxacin, N-demethyl-fleroxacin, and N-oxide-fleroxacin', 'Urinary excretion and bactericidal activities', 'bactericidal titers', 'total urinary recovery']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0085161', 'cui_str': 'Fleroxacin'}, {'cui': 'C0015272', 'cui_str': 'Exhibits'}, {'cui': 'C0030771', 'cui_str': 'Pefloxacin'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1373187', 'cui_str': 'Renal Excretion'}, {'cui': 'C0442739', 'cui_str': 'Id status quo'}, {'cui': 'C0085161', 'cui_str': 'Fleroxacin'}, {'cui': 'C0030015', 'cui_str': 'Oxides'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0544570', 'cui_str': 'Bactericidal activity (observable entity)'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",12.0,0.0552145,Against Escherichia coli ATCC 25922 the median UBTs were similar for both antibiotics and at least 1:8 for 96 h; against the E. coli strain for which the MIC was 0.5 microgram/,"[{'ForeName': 'K G', 'Initials': 'KG', 'LastName': 'Naber', 'Affiliation': 'Department of Urology, St. Elisabeth Hospital, Straubing, Germany.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Theuretzbacher', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kinzig', 'Affiliation': ''}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Savov', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Sörgel', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1221,9661022,Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients.,"The effect of coadministration of ritonavir and zidovudine (ZDV) on the pharmacokinetics of these drugs was investigated in a three-period, multidose, crossover study. Eighteen asymptomatic, human immunodeficiency virus-positive men were assigned randomly to six different sequences of the following three regimens: ZDV (200 mg every 8 h [q8h] alone for 4 days, ritonavir (300 mg q6h) alone for 4 days, and ZDV with ritonavir for 4 days. Ritonavir pharmacokinetics were unaffected by coadministration with ZDV. However, ZDV exposure was reduced by about 26% (P < 0.05) in the presence of ritonavir. The maximum concentration in (Cmax) of ZDV plasma decreased from 748 +/- 375 (mean +/- standard deviation) to 546 +/- 296, and area under the concentration-time curve from 0 to 24 h (AUC0-24) decreased from 3,052 +/- 1,007 to 2,261 +/- 715 when coadministered with ritonavir. In contrast, the ZDV elimination rate constant was unaffected by ritonavir, suggesting that there was no change in ZDV systemic metabolism. Correspondingly, differences in ZDV-glucuronide Cmax and AUC were not statistically significantly different between regimens (P > 0.31). Also, there were no apparent differences in the formation of 3'-amino-3'-deoxythymidine or in the adverse event profiles between the regimens. The lack of change in ritonavir pharmacokinetics suggests that dosage adjustment of ritonavir is unnecessary when it is administered concurrently with ZDV. The clinical relevance of a 26% reduction in ZDV exposure when ZDV is administered with ritonavir is unknown. In addition to other multidrug regimens, the long-term safety and efficacy of coadministration of ritonavir and ZDV is being investigated.",1998,"However, ZDV exposure was reduced by about 26% (P < 0.05) in the presence of ritonavir.","['Eighteen asymptomatic, human immunodeficiency virus-positive men', 'human immunodeficiency virus-infected patients']","['ritonavir and zidovudine (ZDV', 'ZDV', 'ZDV (200 mg every 8 h [q8h] alone for 4 days, ritonavir (300 mg q6h) alone for 4 days, and ZDV with ritonavir', ""3'-amino-3'-deoxythymidine"", 'ritonavir and zidovudine', 'ritonavir and ZDV', 'ritonavir']","['concentration-time curve', 'ZDV-glucuronide Cmax and AUC', 'Ritonavir pharmacokinetics', 'ZDV elimination rate constant', 'ZDV exposure', 'maximum concentration in (Cmax) of ZDV plasma', 'ZDV systemic metabolism']","[{'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic (finding)'}, {'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0094213', 'cui_str': ""3'-amino-3'-deoxythymidine""}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0752086', 'cui_str': 'Glucuronides'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}]",18.0,0.0631932,"However, ZDV exposure was reduced by about 26% (P < 0.05) in the presence of ritonavir.","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Cato', 'Affiliation': 'Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064, USA. acato@ligand.com'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Qian', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Hsu', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Levy', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Leonard', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Granneman', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1222,9661037,Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.,"The bioavailabilities and bioequivalences of single 200-mg doses of itraconazole solution and two capsule formulations were evaluated in a crossover study of 30 male volunteers. The two capsule formulations were bioequivalent. The bioavailabilities of the solutions itraconazole and hydroxyitraconazole were 30 to 33% and 35 to 37% greater, respectively, than those of either capsule. However, the maximum concentrations of the drug in plasma (Cmax), the times to Cmax, and the terminal half-lives were comparable for all three formulations. These data indicate that the bioavailabilities of itraconazole and hydroxyitraconazole are enhanced when administered as an oral solution instead of capsules.",1998,The two capsule formulations were bioequivalent.,"['30 male volunteers', 'healthy volunteers']","['hydroxypropyl-beta-cyclodextrin solution', 'itraconazole and hydroxyitraconazole', 'itraconazole solution', 'itraconazole']","['Enhanced bioavailability', 'maximum concentrations of the drug in plasma (Cmax), the times to Cmax, and the terminal half-lives']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0046237', 'cui_str': 'hydroxypropyl betadex'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0064113', 'cui_str': 'Itraconazole'}, {'cui': 'C0249851', 'cui_str': '3H-1,2,4-triazol-3-one, 4-(4-(4-(4-(((2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-2,4-dihydro-2-(2-hydroxy-1-methylpropyl)-, rel-'}]","[{'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}]",30.0,0.0430277,The two capsule formulations were bioequivalent.,"[{'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Barone', 'Affiliation': 'College of Pharmacy, Rutgers-State University of New Jersey, Piscataway 08855-0789, USA. jbarone@rci.rutgers.edu'}, {'ForeName': 'B L', 'Initials': 'BL', 'LastName': 'Moskovitz', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Guarnieri', 'Affiliation': ''}, {'ForeName': 'A E', 'Initials': 'AE', 'LastName': 'Hassell', 'Affiliation': ''}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Colaizzi', 'Affiliation': ''}, {'ForeName': 'R H', 'Initials': 'RH', 'LastName': 'Bierman', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Jessen', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1223,9593146,Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration.,"To evaluate the potential for an interaction between clarithromycin and loratadine, healthy male volunteers (n = 24) received each of the following regimens according to a randomized crossover design: 500 mg of clarithromycin orally every 12 h (q12h) for 10 days, 10 mg of loratadine orally q24h for 10 days, and the combination of clarithromycin and loratadine. A washout interval of 14 days separated regimens. The addition of loratadine did not statistically significantly affect the steady-state pharmacokinetics of clarithromycin or its active metabolite, 14(R)-hydroxy-clarithromycin. However, the addition of clarithromycin statistically significantly altered the steady-state maximum observed plasma concentration and the area under the plasma concentration-time curve over a dosing interval for loratadine (+36 and +76%, respectively) and for descarboethoxyloratadine (DCL), the active metabolite of loratadine (+69 and +49%, respectively). Clarithromycin probably inhibits the oxidative metabolism of loratadine and DCL by the cytochrome P-450 3A subfamily. Electrocardiograms (n = 12) were obtained over 24-h periods at baseline and steady state (day 10). The mean maximum QTc interval and area under the QTc interval-time curve on day 10 were modestly increased (<3%) from baseline for all three regimens, but no QTc interval exceeded 439 ms for any subject. Elevated steady-state concentrations of loratadine and DCL do not appear to be associated with adverse cardiovascular effects related to prolongation of the QTc interval. Loratadine and clarithromycin were well tolerated, alone and in combination.",1998,Clarithromycin probably inhibits the oxidative metabolism of loratadine and DCL by the cytochrome P-450 3A subfamily.,['healthy male volunteers (n = 24'],"['clarithromycin and loratadine', 'clarithromycin', 'Clarithromycin', 'Loratadine and clarithromycin', 'loratadine', 'descarboethoxyloratadine (DCL']","['Steady-state pharmacokinetics and electrocardiographic pharmacodynamics', 'steady-state maximum observed plasma concentration and the area under the plasma concentration-time curve', 'steady-state pharmacokinetics', 'mean maximum QTc interval and area under the QTc interval-time curve', 'oxidative metabolism']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0065180', 'cui_str': 'Loratadine'}, {'cui': 'C0908935', 'cui_str': 'desloratadine'}]","[{'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C3875135', 'cui_str': 'Observes (attribute)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0860814', 'cui_str': 'QTc'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}]",12.0,0.0324947,Clarithromycin probably inhibits the oxidative metabolism of loratadine and DCL by the cytochrome P-450 3A subfamily.,"[{'ForeName': 'R A', 'Initials': 'RA', 'LastName': 'Carr', 'Affiliation': 'Abbott Laboratories, Abbott Park, Illinois 60064-3500, USA. robert.a.carr@abbott.com'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Edmonds', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Shi', 'Affiliation': ''}, {'ForeName': 'C S', 'Initials': 'CS', 'LastName': 'Locke', 'Affiliation': ''}, {'ForeName': 'L E', 'Initials': 'LE', 'LastName': 'Gustavson', 'Affiliation': ''}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Craft', 'Affiliation': ''}, {'ForeName': 'S I', 'Initials': 'SI', 'LastName': 'Harris', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Palmer', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1224,9593156,Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients.,"In this multicenter study, the efficacy of and tolerability for meropenem were compared with those for the combination of cefuroxime-gentamicin (+/- metronidazole) for the treatment of serious bacterial infections in patients > or = 65 years of age. A total of 79 patients were randomized; thirty-nine received meropenem (1 g/8 h), and 40 received cefuroxime (1.5 g/8 h) plus gentamicin (4 mg/kg of body weight daily) for 5 to 10 days. Metronidazole (500 mg/6 h) could be added to the cefuroxime-gentamicin regimen for the treatment of intra-abdominal infections (n = 10). Seventy patients were evaluable for clinical efficacy; the primary diagnoses were as follows: pneumonia in 41 patients (20 treated with meropenem, 21 treated with cefuroxime-gentamicin), intra-abdominal infection in 10 patients (7 meropenem, 3 cefuroxime-gentamicin-metronidazole), urinary tract infection (UTI) in 11 patients (6 meropenem, 5 cefuroxime-gentamicin), sepsis syndrome in 7 patients (4 meropenem, 3 cefuroxime-gentamicin), and ""other"" in 1 patient (cefuroxime-gentamicin). The pathogens isolated from 18 patients with bacteremia were as follows: Staphylococcus spp. (n = 2), Streptococcus spp. (n = 2), members of the family Enterobacteriaceae (n = 11), and Bacteroides spp. (n = 3). A satisfactory clinical response at the end of therapy was achieved in 26 of 37 (70%) and 24 of 33 (73%) evaluable patients treated with meropenem and combination therapy, respectively. Clinical success was achieved in 23 of 31 (74%) and 21 of 28 (75%) evaluable patients with infections other than UTIs, respectively. A satisfactory microbiological response occurred in 15 of 22 (68%) patients in the meropenem group compared with 12 of 19 (63%) treated with combination therapy. Renal failure occurred during therapy in 2 of 39 (5%) meropenem recipients compared with 5 of 40 (13%) of those treated with combination therapy. The findings in this small study indicate that meropenem is as efficacious for and as well tolerated by elderly patients as the combination of cefuroxime-gentamicin (+/- metronidazole).",1998,"Clinical success was achieved in 23 of 31 (74%) and 21 of 28 (75%) evaluable patients with infections other than UTIs, respectively.","['10 patients (7', '79 patients were randomized; thirty-nine received', '11 patients (6', 'Seventy patients were evaluable for clinical efficacy; the primary diagnoses were as follows', '18 patients with bacteremia were as follows', 'patients > or = 65 years of age', 'elderly patients', '41 patients (20 treated with']","['meropenem, 3 cefuroxime-gentamicin), and ""other"" in 1 patient (cefuroxime-gentamicin', 'cefuroxime plus gentamicin', 'meropenem, 5 cefuroxime-gentamicin', 'gentamicin', 'meropenem', 'cefuroxime', 'cefuroxime-gentamicin (+/- metronidazole', 'Meropenem', 'Metronidazole', 'cefuroxime-gentamicin', 'meropenem, 3 cefuroxime-gentamicin-metronidazole), urinary tract infection (UTI']","['Clinical success', 'Renal failure', 'satisfactory microbiological response', 'efficacy of and tolerability']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3816447', 'cui_str': '39 (qualifier value)'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0087113', 'cui_str': 'Treatment Efficacy'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0066005', 'cui_str': 'meropenem'}, {'cui': 'C0007562', 'cui_str': 'Cefuroxime'}, {'cui': 'C0017436', 'cui_str': 'Gentamicins'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0035078', 'cui_str': 'Kidney Failure'}]",79.0,0.0532288,"Clinical success was achieved in 23 of 31 (74%) and 21 of 28 (75%) evaluable patients with infections other than UTIs, respectively.","[{'ForeName': 'C A', 'Initials': 'CA', 'LastName': 'Jaspers', 'Affiliation': 'Department of Medicine, University Hospital Utrecht, The Netherlands.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Kieft', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Speelberg', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Buiting', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'van Marwijk Kooij', 'Affiliation': ''}, {'ForeName': 'G J', 'Initials': 'GJ', 'LastName': 'Ruys', 'Affiliation': ''}, {'ForeName': 'H H', 'Initials': 'HH', 'LastName': 'Vincent', 'Affiliation': ''}, {'ForeName': 'M C', 'Initials': 'MC', 'LastName': 'Vermeulen', 'Affiliation': ''}, {'ForeName': 'A G', 'Initials': 'AG', 'LastName': 'Olink', 'Affiliation': ''}, {'ForeName': 'I M', 'Initials': 'IM', 'LastName': 'Hoepelman', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1225,9517944,Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.,"This study evaluated the tolerance and potential pharmacokinetic interactions between clarithromycin (500 mg every 12 h) and rifabutin (300 mg daily) in clinically stable human immunodeficiency virus-infected volunteers with CD4 counts of <200 cells/mm3. Thirty-four subjects were randomized equally to either regimen A or regimen B. On days 1 to 14, subjects assigned to regimen A received clarithromycin and subjects assigned to regimen B received rifabutin, and then both groups received both drugs on days 15 to 42. Of the 14 regimen A and the 15 regimen B subjects who started combination therapy, 1 subject in each group prematurely discontinued therapy due to toxicity, but 19 of 29 subjects reported nausea, vomiting, and/or diarrhea. Pharmacokinetic analysis included data for 11 regimen A and 14 regimen B subjects. Steady-state pharmacokinetic parameters for single-agent therapy (day 14) and combination therapy (day 42) were compared. Regimen A resulted in a mean decrease of 44% (P = 0.003) in the clarithromycin area under the plasma concentration-time curve (AUC), while there was a mean increase of 57% (P = 0.004) in the AUC of the clarithromycin metabolite 14-OH-clarithromycin. Regimen B resulted in a mean increase of 99% (P = 0.001) in the rifabutin AUC and a mean increase of 375% (P < 0.001) in the AUC of the rifabutin metabolite 25-O-desacetyl-rifabutin. The usefulness of this combination for prophylaxis of Mycobacterium avium infections is limited by frequent gastrointestinal adverse events. Coadministration of clarithromycin and rifabutin results in significant bidirectional pharmacokinetic interactions. The resulting increase in rifabutin levels may explain the increased frequency of uveitis observed with concomitant use of these drugs.",1998,"Regimen A resulted in a mean decrease of 44% (P = 0.003) in the clarithromycin area under the plasma concentration-time curve (AUC), while there was a mean increase of 57% (P = 0.004) in the AUC of the clarithromycin metabolite 14-OH-clarithromycin.","['Thirty-four subjects', 'clinically stable human immunodeficiency virus-infected volunteers with CD4 counts of <200 cells/mm3', 'human immunodeficiency virus-infected volunteers']","['clarithromycin', 'rifabutin and clarithromycin', 'rifabutin', 'clarithromycin and rifabutin']","['Tolerance and pharmacokinetic interactions', 'plasma concentration-time curve (AUC', 'rifabutin levels', 'tolerance and potential pharmacokinetic interactions', 'nausea, vomiting, and/or diarrhea']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0439243', 'cui_str': 'mm3'}]","[{'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0140575', 'cui_str': 'Rifabutin'}]","[{'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C1868980', 'cui_str': 'Pharmacokinetic interaction'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0140575', 'cui_str': 'Rifabutin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",34.0,0.0187393,"Regimen A resulted in a mean decrease of 44% (P = 0.003) in the clarithromycin area under the plasma concentration-time curve (AUC), while there was a mean increase of 57% (P = 0.004) in the AUC of the clarithromycin metabolite 14-OH-clarithromycin.","[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Hafner', 'Affiliation': 'Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852-7620, USA. rh23v@nih.gov'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Bethel', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Power', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Landry', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Banach', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Mole', 'Affiliation': ''}, {'ForeName': 'H C', 'Initials': 'HC', 'LastName': 'Standiford', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Follansbee', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Kumar', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Raasch', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Cohn', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Mushatt', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Drusano', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1226,9517954,Effect of terbinafine on theophylline pharmacokinetics in healthy volunteers.,"Twelve healthy volunteers were enrolled in an open-label, randomized, crossover study. Subjects received single doses of theophylline (5 mg/kg) with and without multiple-dose terbinafine, and 11 blood samples were collected over 24 h. The study phases were separated by a 4-week washout period. Theophylline serum data were modeled via noncompartmental analysis. When the control phase (i.e., no terbinafine) was compared to the treatment phase (terbinafine), theophylline exposure (the area under the serum concentration-time curve from time zero to infinity) increased by 16% (P = 0.03), oral clearance decreased by 14% (P = 0.04), and half-life increased by 24% (P = 0.002). No significant changes in other theophylline pharmacokinetic parameters were evident.",1998,No significant changes in other theophylline pharmacokinetic parameters were evident.,"['Twelve healthy volunteers', 'healthy volunteers']","['terbinafine), theophylline', 'theophylline', 'terbinafine']","['Theophylline serum data', 'theophylline pharmacokinetics', 'oral clearance', 'theophylline pharmacokinetic parameters', 'life']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0956383', 'cui_str': 'Terbinafine, (Z)-isomer'}, {'cui': 'C0039771', 'cui_str': 'Theophylline'}]","[{'cui': 'C0039771', 'cui_str': 'Theophylline'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0376558', 'cui_str': 'Life'}]",12.0,0.00879005,No significant changes in other theophylline pharmacokinetic parameters were evident.,"[{'ForeName': 'E F', 'Initials': 'EF', 'LastName': 'Trépanier', 'Affiliation': 'Department of Pharmacy Services, Bassett Healthcare, Cooperstown, New York 13326-1394, USA.'}, {'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Nafziger', 'Affiliation': ''}, {'ForeName': 'G W', 'Initials': 'GW', 'LastName': 'Amsden', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1227,9371346,"Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy.","The relationship of CD4+ cell response, level of RNA in plasma, and quantitative peripheral blood mononuclear cell (PBMC) titer to apparent drug exposure was investigated by using data from AIDS Clinical Trial Group protocol 229, a multicenter randomized study. Patients received either saquinavir, zalcitabine, or a combination of both, along with open-label zidovudine. Approximately 100 patients were enrolled in each arm, and the primary study duration was 24 weeks. Individual drug exposure, the area under the concentration-time curve, was estimated by using population-based pharmacokinetic methods. Response was defined as the maximum increase in CD4+ cell count or the maximum decrease in RNA in plasma or PBMC titer adjusted for baseline CD4+ cell count, RNA in plasma, and PBMC titer, respectively. Regression of responses on exposure demonstrated an exposure effect for saquinavir which was significant for the maximum increase in CD4+ cell count and the decrease in RNA in plasma. For the PBMC titer, no significant relationship could be demonstrated but the results suggested a trend similar to that of the other response variables. For all three response variables, the slope of the saquinavir exposure response was greater with the triple combination (saquinavir, zidovudine, and zalcitabine) than with the combination of saquinavir and zidovudine, suggesting possible synergism between saquinavir and zalcitabine.",1997,Regression of responses on exposure demonstrated an exposure effect for saquinavir which was significant for the maximum increase in CD4+ cell count and the decrease in RNA in plasma.,"['Approximately 100 patients were enrolled in each arm, and the primary study duration was 24 weeks']","['saquinavir, zidovudine, and zalcitabine', 'saquinavir and zalcitabine', 'saquinavir and zidovudine', 'saquinavir, zalcitabine, or a combination of both, along with open-label zidovudine', 'triple combination (saquinavir, zidovudine, and zalcitabine', 'saquinavir']","['slope of the saquinavir exposure response', 'CD4+ cell count', 'CD4+ cell response, level of RNA in plasma, and quantitative peripheral blood mononuclear cell (PBMC) titer', 'RNA in plasma or PBMC titer adjusted for baseline CD4+ cell count, RNA in plasma, and PBMC titer']","[{'cui': 'C0332232', 'cui_str': 'Approximate (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0286738', 'cui_str': 'Saquinavir'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}, {'cui': 'C0012132', 'cui_str': 'Zalcitabine'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}]","[{'cui': 'C0286738', 'cui_str': 'Saquinavir'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C3251824', 'cui_str': 'Cell positive for CD4 antigen'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0475208', 'cui_str': 'TITR'}]",,0.102086,Regression of responses on exposure demonstrated an exposure effect for saquinavir which was significant for the maximum increase in CD4+ cell count and the decrease in RNA in plasma.,"[{'ForeName': 'G F', 'Initials': 'GF', 'LastName': 'Vanhove', 'Affiliation': 'Division of Clinical Pharmacology, Stanford University, California, USA.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Gries', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Verotta', 'Affiliation': ''}, {'ForeName': 'L B', 'Initials': 'LB', 'LastName': 'Sheiner', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Coombs', 'Affiliation': ''}, {'ForeName': 'A C', 'Initials': 'AC', 'LastName': 'Collier', 'Affiliation': ''}, {'ForeName': 'T F', 'Initials': 'TF', 'LastName': 'Blaschke', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1228,9371351,Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions.,"The effects of a 10-day course of moderate-dose (10 mg/kg/day) or high-dose (20 mg/kg/day) trimethoprim therapy on serum creatinine, measured creatinine clearance, urinary creatinine excretion, and serum folate were studied in 20 healthy volunteers. Serum creatinine concentrations increased significantly during trimethoprim therapy, began to decrease near day 10, and returned to baseline during the washout phase at both dosage levels. At the same time, measured creatinine clearance and urine creatinine changed in the opposite direction. No clinical or statistical differences were noted between changes in the moderate- versus the high-dose phases. Serum folate concentration decreases during high-dose trimethoprim therapy were statistically significant. Adverse drug reactions in the two groups were statistically different during the first study period, with the high-dose group having a 75% incidence rate and the moderate-dose group having an 11% incidence rate (P < 0.02). Serum creatinine, measured creatinine clearance, and urinary creatinine excretion demonstrated statistically, but not clinically, significant changes during trimethoprim therapy. In addition, high-dose trimethoprim caused significantly more adverse drug reactions than moderate-dose trimethoprim in normal volunteers.",1997,"Serum creatinine concentrations increased significantly during trimethoprim therapy, began to decrease near day 10, and returned to baseline during the washout phase at both dosage levels.","['20 healthy volunteers', 'normal volunteers']","['trimethoprim therapy', 'trimethoprim']","['Adverse drug reactions', 'creatinine clearance and urine creatinine', 'Serum creatinine concentrations', 'serum creatinine and creatinine clearance and adverse reactions', 'Serum folate concentration', 'Serum creatinine, measured creatinine clearance, and urinary creatinine excretion', 'serum creatinine, measured creatinine clearance, urinary creatinine excretion, and serum folate', 'adverse drug reactions']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C3661466', 'cui_str': 'Normal Volunteers'}]","[{'cui': 'C0041041', 'cui_str': 'Trimethoprim'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0041755', 'cui_str': 'Drug Side Effects'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine (procedure)'}, {'cui': 'C0042037'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0178638', 'cui_str': 'Folate'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}]",20.0,0.0450118,"Serum creatinine concentrations increased significantly during trimethoprim therapy, began to decrease near day 10, and returned to baseline during the washout phase at both dosage levels.","[{'ForeName': 'O', 'Initials': 'O', 'LastName': 'Naderer', 'Affiliation': 'Department of Pharmacy Services, Bassett Healthcare, Cooperstown, New York 13326-1394, USA.'}, {'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Nafziger', 'Affiliation': ''}, {'ForeName': 'J S', 'Initials': 'JS', 'LastName': 'Bertino', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1229,9284163,Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.,"To provide optimum protection against classical and El Tor biotypes of Vibrio cholerae O1, a single-dose, oral cholera vaccine was developed by combining two live, attenuated vaccine strains, CVD 103-HgR (classical, Inaba) and CVD 111 (El Tor, Ogawa). The vaccines were formulated in a double-chamber sachet; one chamber contained lyophilized bacteria, and the other contained buffer. In the first study, 23 U.S. adult volunteers received CVD 103-HgR at 10(8) CFU plus CVD 111 at 10(8), 10(7), or 10(6) CFU, CVD 111 alone at 10(7) CFU, or placebo. In the second study, 275 Peruvian adults were randomized to receive CVD 103-HgR at 10(9) CFU plus CVD 111 at 10(9) or 10(8) CFU, CVD 111 alone at 10(9) CFU, CVD 103-HgR alone at 10(9) CFU, or placebo. Three of 15 U.S. volunteers who received CVD 111 at 10(7) or 10(8) CFU developed mild diarrhea, compared to none of 4 who received CVD 111 at 10(6) CFU and 1 of 4 who received placebo. Twelve (63%) of 19 vaccine recipients shed the El Tor vaccine strain. All but one volunteer developed significant Ogawa and Inaba vibriocidal antibody titers. Volunteers who received CVD 111 at 10(7) CFU had geometric mean Ogawa titers four to five times higher than those of volunteers who received the lower dose. In the second study, all dosage regimens were well tolerated in Peruvians. About 20% of volunteers who received CVD 111 at the high dose excreted the El Tor organism, compared to 7% in the low-dose group. CVD 111 was detected in the stools of two placebo recipients, neither of whom had symptoms or seroconverted. In all vaccine groups, 69 to 76% developed fourfold rises in Inaba vibriocidal antibodies. Among those who received the bivalent vaccine, 53 to 75% also developed significant rises in Ogawa vibriocidal antibodies. We conclude that it is feasible to produce a single-dose, oral bivalent vaccine that is safe and immunogenic against both biotypes (El Tor and classical) and both serotypes (Inaba and Ogawa) of cholera for populations in both developed and developing parts of the world.",1997,"CVD 111 was detected in the stools of two placebo recipients, neither of whom had symptoms or seroconverted.","['Three of 15 U.S. volunteers who received CVD 111 at 10(7) or 10(8', '23 U.S. adult volunteers received CVD 103-HgR at 10(8', 'Volunteers who received CVD 111 at 10(7', 'adult volunteers from the United States and Peru', '275 Peruvian adults']","['placebo', 'CFU, CVD 103-HgR alone at 10(9) CFU, or placebo', 'CVD 103-HgR at 10(9', 'bivalent vaccine', 'bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine']","['Inaba vibriocidal antibodies', 'significant Ogawa and Inaba vibriocidal antibody titers', 'geometric mean Ogawa titers', 'mild diarrhea', 'Ogawa vibriocidal antibodies']","[{'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C4517538', 'cui_str': '111 (qualifier value)'}, {'cui': 'C0591126', 'cui_str': 'AT 10'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0961644', 'cui_str': 'cholera vaccine CVD 103-HgR'}, {'cui': 'C0031238', 'cui_str': 'Peru'}, {'cui': 'C4517676', 'cui_str': '275'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0961644', 'cui_str': 'cholera vaccine CVD 103-HgR'}, {'cui': 'C0591126', 'cui_str': 'AT 10'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C4517538', 'cui_str': '111 (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0008359', 'cui_str': 'Cholera Vaccine'}]","[{'cui': 'C0443008', 'cui_str': 'Inaba'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0443037', 'cui_str': 'Ogawa'}, {'cui': 'C1287242', 'cui_str': 'Finding of antibody titer (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",275.0,0.199317,"CVD 111 was detected in the stools of two placebo recipients, neither of whom had symptoms or seroconverted.","[{'ForeName': 'D N', 'Initials': 'DN', 'LastName': 'Taylor', 'Affiliation': 'U.S. Naval Medical Research Institute Detachment, Lima, Peru. taylor@namrid.sld.pe'}, {'ForeName': 'C O', 'Initials': 'CO', 'LastName': 'Tacket', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Losonsky', 'Affiliation': ''}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Castro', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Gutierrez', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Meza', 'Affiliation': ''}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Nataro', 'Affiliation': ''}, {'ForeName': 'J B', 'Initials': 'JB', 'LastName': 'Kaper', 'Affiliation': ''}, {'ForeName': 'S S', 'Initials': 'SS', 'LastName': 'Wasserman', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Edelman', 'Affiliation': ''}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Levine', 'Affiliation': ''}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Cryz', 'Affiliation': ''}]",Infection and immunity,[] 1230,9333058,Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria.,"Pyrimethamine-sulfadoxine, the first choice for uncomplicated falciparum malaria in Africa, exerts strong selection pressure for resistance because of its slow elimination. It is likely that resistance will emerge rapidly, and there is no widely affordable replacement. Chlorproguanil-dapsone is cheap, rapidly eliminated, more potent than pyrimethamine-sulfadoxine, and could be introduced in the near future to delay the onset of antifolate resistance and as ""salvage therapy"" for pyrimethamine-sulfadoxine failure. A total of 448 children were randomly allocated (double blind) to either a single dose of pyrimethamine-sulfadoxine or to one of two chlorproguanil-dapsone regimens: a single dose or three doses at 24-h intervals. Reinfections are clinically indistinguishable from recrudescence and are more likely after treatment with rapidly eliminated drugs; we measured the incidence of parasitemia in 205 initially aparasitemic children to allow comparison with the three treatment groups. The patients and a community surveillance group were followed up for 28 days. At the study end point, 31.2% (95% confidence interval, 24.9-38.0) of the community surveillance group subjects were parasitemic, compared with subjects in the treatment groups, whose rates of parasitemia were 40.8% (32.9-49.0; relative risk [RR], 1.31 [0.99-1.73]) after triple-dose chlorproguanil-dapsone, 19.7% (13.5-27.2; RR, 0.63 [0.43-0.93]) after pyrimethamine-sulfadoxine, and 65.6% (57.5-73.0; RR, 2.10 [1.66-2.65]) after single-dose chlorproguanil-dapsone. Pyrimethamine-sulfadoxine and triple-dose chlorproguanil-dapsone were effective treatments. Pyrimethamine-sulfadoxine provided chemoprophylaxis during follow-up because of its slow elimination. Triple-dose chlorproguanil-dapsone should now be developed in an attempt to reduce the rate of emergence of antifolate resistance in Africa and for affordable salvage therapy in cases of pyrimethamine-sulfadoxine failure.",1997,"At the study end point, 31.2% (95% confidence interval, 24.9-38.0) of the community surveillance group subjects were parasitemic, compared with subjects in the treatment groups, whose rates of parasitemia were 40.8% (32.9-49.0; relative risk [RR], 1.31 [0.99-1.73]) after triple-dose chlorproguanil-dapsone, 19.7% (13.5-27.2; RR, 0.63 [0.43-0.93]) after pyrimethamine-sulfadoxine, and 65.6% (57.5-73.0; RR, 2.10 [1.66-2.65]) after single-dose chlorproguanil-dapsone.","['uncomplicated falciparum malaria', '205 initially aparasitemic children', '448 children']","['Chlorproguanil-dapsone', 'pyrimethamine-sulfadoxine', 'Pyrimethamine-sulfadoxine and triple-dose chlorproguanil-dapsone', 'Pyrimethamine-sulfadoxine']","['rates of parasitemia', 'incidence of parasitemia']","[{'cui': 'C0024535', 'cui_str': 'Plasmodium falciparum Malaria'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C1957158', 'cui_str': 'chloroguanil, dapsone drug combination'}, {'cui': 'C0034283', 'cui_str': 'Pyrimethamine'}, {'cui': 'C0038679', 'cui_str': 'Sulfadoxine'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C0242723', 'cui_str': 'Parasitemia'}, {'cui': 'C0220856', 'cui_str': 'incidence'}]",448.0,0.111884,"At the study end point, 31.2% (95% confidence interval, 24.9-38.0) of the community surveillance group subjects were parasitemic, compared with subjects in the treatment groups, whose rates of parasitemia were 40.8% (32.9-49.0; relative risk [RR], 1.31 [0.99-1.73]) after triple-dose chlorproguanil-dapsone, 19.7% (13.5-27.2; RR, 0.63 [0.43-0.93]) after pyrimethamine-sulfadoxine, and 65.6% (57.5-73.0; RR, 2.10 [1.66-2.65]) after single-dose chlorproguanil-dapsone.","[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Amukoye', 'Affiliation': 'Kilifi Research Unit, Kenya Medical Research Institute.'}, {'ForeName': 'P A', 'Initials': 'PA', 'LastName': 'Winstanley', 'Affiliation': ''}, {'ForeName': 'W M', 'Initials': 'WM', 'LastName': 'Watkins', 'Affiliation': ''}, {'ForeName': 'R W', 'Initials': 'RW', 'LastName': 'Snow', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Hatcher', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Mosobo', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Ngumbao', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Lowe', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ton', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Minyiri', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Marsh', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1231,9333057,Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.,"The pharmacokinetics of once-daily oral levofloxacin (study A) or intravenous levofloxacin (study B) in 40 healthy male volunteers were investigated in two separate randomized, double-blind, parallel-design, placebo-controlled studies. Levofloxacin at 500 mg or placebo was administered orally or intravenously as a single dose on day 1; daily oral or intravenous dosing resumed on days 4 to 10. In a third study (study C), the comparability of the bioavailabilities of two oral and one intravenous levofloxacin formulations were investigated with 24 healthy male subjects in an open-label, randomized, three-way crossover study. Levofloxacin at 500 mg as a single tablet or an intravenous infusion was administered on day 1; following a 1-week washout period, subjects received the second regimen (i.e., the other oral formulation or the intravenous infusion); the third and final regimen was administered following a 1-week washout period. The concentrations of drug in plasma and urine were measured by validated high-pressure liquid chromatography methods. Pharmacokinetic parameters were estimated by noncompartmental methods. In both study A (oral levofloxacin) and study B (intravenous levofloxacin), steady state was attained within 48 h after the start of the multiple dosing on day 4. Levofloxacin pharmacokinetics were linear and predictable for the single and multiple 500-mg, once-daily oral and intravenous dosing regimens, and the values of the pharmacokinetic parameters for the oral and intravenous administrations were similar. Study C indicated that levofloxacin was rapidly and completely absorbed from the oral tablets, with mean times to the maximum concentration of drug in serum of approximately 1.5 h and mean absolute bioavailability of > or =99%. These results support the interchangeability of the oral and intravenous routes of levofloxacin administration.",1997,"Levofloxacin pharmacokinetics were linear and predictable for the single and multiple 500-mg, once-daily oral and intravenous dosing regimens, and the values of the pharmacokinetic parameters for the oral and intravenous administrations were similar.","['40 healthy male volunteers', '24 healthy male subjects in an open-label']","['placebo', 'levofloxacin) and study B (intravenous levofloxacin', 'intravenous levofloxacin', 'levofloxacin', 'levofloxacin formulations', 'Levofloxacin']","['concentrations of drug in plasma and urine', 'Pharmacokinetic parameters']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0282386', 'cui_str': 'Levofloxacin'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0042037'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",40.0,0.0437726,"Levofloxacin pharmacokinetics were linear and predictable for the single and multiple 500-mg, once-daily oral and intravenous dosing regimens, and the values of the pharmacokinetic parameters for the oral and intravenous administrations were similar.","[{'ForeName': 'S C', 'Initials': 'SC', 'LastName': 'Chien', 'Affiliation': 'The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869, USA.'}, {'ForeName': 'M C', 'Initials': 'MC', 'LastName': 'Rogge', 'Affiliation': ''}, {'ForeName': 'L G', 'Initials': 'LG', 'LastName': 'Gisclon', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Curtin', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Wong', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Natarajan', 'Affiliation': ''}, {'ForeName': 'R R', 'Initials': 'RR', 'LastName': 'Williams', 'Affiliation': ''}, {'ForeName': 'C L', 'Initials': 'CL', 'LastName': 'Fowler', 'Affiliation': ''}, {'ForeName': 'W K', 'Initials': 'WK', 'LastName': 'Cheung', 'Affiliation': ''}, {'ForeName': 'A T', 'Initials': 'AT', 'LastName': 'Chow', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1232,32051454,Prospective Cohort study of Predictors of Follow-Up Diagnostic Colonoscopy from a Pragmatic Trial of FIT Screening.,"The goal of this study was to explore diagnostic colonoscopy completion in adults with abnormal screening fecal immunochemical test (FIT) results. This was a secondary analysis of the Strategies and Opportunities to Stop Colon Cancer in Priority Populations (Stop CRC) study, a cluster-randomized pragmatic trial to increase uptake of CRC screening in federally qualified community health clinics. Diagnostic colonoscopy completion and reasons for non-completion were ascertained through a manual review of electronic health records, and completion was compared across a wide range of individual patient health and sociodemographic characteristics. Among 2,018 adults with an abnormal FIT result, 1066 (52.8%) completed a follow-up colonoscopy within 12 months. Completion was generally similar across a wide range of participant subpopulations; however, completion was higher for participants who were younger, Hispanic, Spanish-speaking, and had zero or one of the Charlson medical comorbidities, compared to their counterparts. Neighborhood-level predictors were not associated with diagnostic colonoscopy completion. Thus, completion of a diagnostic colonoscopy was relatively low in a large sample of community health clinic adults who had an abnormal screening FIT result. While completion was generally similar across a wide range of characteristics, younger, healthier, Hispanic participants tended to have a higher likelihood of completion.",2020,"Completion was generally similar across a wide range of participant subpopulations; however, completion was higher for participants who were younger, Hispanic, Spanish-speaking, and had zero or one of the Charlson medical comorbidities, compared to their counterparts.","['community health clinic adults who had an abnormal screening FIT result', '2,018 adults with an abnormal FIT result, 1066 (52.8%) completed a follow-up colonoscopy within 12 months', 'federally qualified community health clinics', 'adults with abnormal screening fecal immunochemical test (FIT) results']",[],[],"[{'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205161', 'cui_str': 'Abnormal (qualifier value)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",[],[],2018.0,0.17443,"Completion was generally similar across a wide range of participant subpopulations; however, completion was higher for participants who were younger, Hispanic, Spanish-speaking, and had zero or one of the Charlson medical comorbidities, compared to their counterparts.","[{'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': ""O'Connor"", 'Affiliation': ""Kaiser Permanente Center for Health Research, 3800 N. Interstate Avenue, Portland, OR, 97227, USA. Elizabeth.O'Connor@kpchr.org.""}, {'ForeName': 'Carrie M', 'Initials': 'CM', 'LastName': 'Nielson', 'Affiliation': 'Kaiser Permanente Center for Health Research, 3800 N. Interstate Avenue, Portland, OR, 97227, USA.'}, {'ForeName': 'Amanda F', 'Initials': 'AF', 'LastName': 'Petrik', 'Affiliation': 'Kaiser Permanente Center for Health Research, 3800 N. Interstate Avenue, Portland, OR, 97227, USA.'}, {'ForeName': 'Beverly B', 'Initials': 'BB', 'LastName': 'Green', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute, 1730 Minor Avenue, Suite 1600, Seattle, WA, 98101, USA.'}, {'ForeName': 'Gloria D', 'Initials': 'GD', 'LastName': 'Coronado', 'Affiliation': 'Kaiser Permanente Center for Health Research, 3800 N. Interstate Avenue, Portland, OR, 97227, USA.'}]",Scientific reports,['10.1038/s41598-020-59032-0'] 1233,32051513,Prevalence of Non-Celiac Gluten Sensitivity in Patients with Refractory Functional Dyspepsia: a Randomized Double-blind Placebo Controlled Trial.,"Refractory functional dyspepsia (RFD) is characterized by symptoms persistence in spite of medical treatment or H. pylori eradication. No study has yet investigated the presence of gluten-dependent RFD as a clinical presentation of Non-Celiac Gluten Sensitivity (NCGS). Patients with RFD, in whom celiac disease, wheat allergy and H. pylori infection had been ruled out, followed a six weeks long gluten-free diet (GFD). Symptoms were evaluated by means of visual analogue scales; patients with ≥30% improvement in at least one of the reported symptoms after GFD underwent a double-blind placebo controlled gluten challenge. Subjects were randomly divided in two groups and symptoms were evaluated after the gluten/placebo challenge. GFD responders were further followed on for 3 months to evaluate the relationship between symptoms and gluten consumption. Out of 77 patients with RFD, 50 (65%) did not respond to GFD; 27 (35%) cases showed gastrointestinal symptoms improvement while on GFD; after blind gluten ingestion, symptoms recurred in 5 cases (6.4% of patients with RFD, 18% of GFD responders) suggesting the presence of NCGS. Furthermore, such extra-intestinal symptoms as fatigue and weakness (P = 0.000), musculo-skeletal pain (P = 0.000) and headache (P = 0.002) improved in NCGS patients on GFD. Because of the high prevalence of NCGS among patients with RFD, a diagnostic/therapeutic roadmap evaluating the effect of GFD in patients with RFD seems a reasonable (and simple) approach.",2020,"Furthermore, such extra-intestinal symptoms as fatigue and weakness (P = 0.000), musculo-skeletal pain (P = 0.000) and headache (P = 0.002) improved in NCGS patients on GFD.","['Patients with RFD, in whom celiac disease, wheat allergy and H. pylori infection', 'Patients with Refractory Functional Dyspepsia', 'Refractory functional dyspepsia (RFD']","['Placebo', 'placebo']","['extra-intestinal symptoms as fatigue and weakness', 'gastrointestinal symptoms improvement', 'musculo-skeletal pain', 'headache']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2927794', 'cui_str': 'RFD'}, {'cui': 'C0007570', 'cui_str': 'Sprue, Nontropical'}, {'cui': 'C0949570', 'cui_str': 'Allergy, Wheat'}, {'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0267167', 'cui_str': 'Nonulcer dyspepsia (disorder)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C3714552', 'cui_str': 'Weakness - general'}, {'cui': 'C0151825', 'cui_str': 'Bone pain (finding)'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}]",77.0,0.255539,"Furthermore, such extra-intestinal symptoms as fatigue and weakness (P = 0.000), musculo-skeletal pain (P = 0.000) and headache (P = 0.002) improved in NCGS patients on GFD.","[{'ForeName': 'Bijan', 'Initials': 'B', 'LastName': 'Shahbazkhani', 'Affiliation': 'Division of Gastroenterology and Liver Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad M', 'Initials': 'MM', 'LastName': 'Fanaeian', 'Affiliation': 'Division of Gastroenterology and Liver Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Mohammadfanaeian@gmail.com.'}, {'ForeName': 'Mohammad J', 'Initials': 'MJ', 'LastName': 'Farahvash', 'Affiliation': 'Division of Gastroenterology and Liver Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Najmeh', 'Initials': 'N', 'LastName': 'Aletaha', 'Affiliation': 'Division of Gastroenterology and Liver Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Foroogh', 'Initials': 'F', 'LastName': 'Alborzi', 'Affiliation': 'Division of Gastroenterology and Liver Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Elli', 'Affiliation': ""Center for Prevention and Diagnosis of Celiac Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Amirhossein', 'Initials': 'A', 'LastName': 'Shahbazkhani', 'Affiliation': 'Division of Gastroenterology and Liver Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Jayran', 'Initials': 'J', 'LastName': 'Zebardast', 'Affiliation': 'Cognitive Science Special Linguistics, Institute of Cognitive Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Rostami-Nejad', 'Affiliation': 'Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}]",Scientific reports,['10.1038/s41598-020-59532-z'] 1234,9174182,Modeling the response of pneumonia to antimicrobial therapy.,"The response to antimicrobial therapy in patients with pneumonia was assessed by using a previously developed pneumonia scoring system. Patients from two different clinical trials were evaluated. The first group (n = 22) was treated with cefmenoxime. For these patients, doses were adjusted to achieve an area under the plasma concentration-versus-time curve (AUC) above the MIC of 140 microg x h/ml and pneumonia response scores were evaluated retrospectively. The second group (n = 21) were treated with either ciprofloxacin (CIP) or ceftazidime (TAZ) in a randomized clinical trial. Here, doses were adjusted to achieve AUC from 0 to 24 h/MIC values that were > 250 SIT(-1) x h (estimate of the area under the curve of inverse serum inhibitory titer versus time) and pneumonia response scoring was concurrent. In both studies eradication of the pathogen was determined by serial endotracheal cultures and clinical parameters were scored daily. A decrease in total score was indicative of an improving clinical condition. The percent change in clinical daily score was determined for each day of treatment. The rate of clinical response was determined by linear regression of the percent change in daily clinical score versus time during the course of antimicrobial therapy. Factors predictive of time to eradication were explored by interval analysis. Logistic regression was used to determine the earliest time point in therapy at which treatment scores predicted outcome. Kruskal-Wallis analysis of variance was used for statistical analysis, and significance was accepted at P < 0.05. There were no differences in baseline scores at day one for the patients treated with different antibiotics (P = 0.58). For patients with pathogen eradication, a significant difference between the two studies in time to eradication was found: 4.8 days for cefmenoxime-treated patients and 1.4 days for CIP- or TAZ-treated patients (P < 0.001). For patients experiencing bacterial eradication, the rates of clinical change for cefmenoxime and CIP or TAZ treatment were similar (P = 0.77). For patients with organisms that were not eradicated, the rates of change were similar (P = 0.14). There was a significant difference in the rate of change for patients experiencing eradication compared with that for patients in which the organism persisted (P << 0.01). Both treatment group and rate were found to be predictive of days to eradication. There was a significant difference in the percent change in clinical score on day 3 of therapy for patients with bacteria that were eradicated versus those with persistent organisms (P < 0.01). The percent change was more predictive of outcome with each subsequent day. Patients who demonstrated a > or = 10% reduction in clinical score after 72 h of treatment had an 88% probability of bacterial eradication. The clinical scoring system is a useful tool for modeling the response of pneumonia to antimicrobial therapy. The ability to predict outcome relatively early in therapy, by using a scoring system of clinical parameters which can be routinely monitored, will aid in assessing the response to antimicrobial therapy in clinical as well as in research settings.",1997,There were no differences in baseline scores at day one for the patients treated with different antibiotics (P = 0.58).,['patients with pneumonia'],"['ciprofloxacin (CIP) or ceftazidime (TAZ', 'cefmenoxime']","['baseline scores', 'clinical daily score', 'clinical score', 'rate of clinical response', 'total score', 'pneumonia response scores', 'rate of change for patients experiencing eradication', 'time to eradication']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}]","[{'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0007559', 'cui_str': 'Ceftazidime'}, {'cui': 'C0007549', 'cui_str': '5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6alpha,7beta(Z)))-'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",21.0,0.0381085,There were no differences in baseline scores at day one for the patients treated with different antibiotics (P = 0.58).,"[{'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Hyatt', 'Affiliation': 'The Clinical Pharmacokinetics Laboratory, Millard Fillmore Health System, Buffalo, New York, USA.'}, {'ForeName': 'A B', 'Initials': 'AB', 'LastName': 'Luzier', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Forrest', 'Affiliation': ''}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Ballow', 'Affiliation': ''}, {'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Schentag', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1235,9174206,Pharmacodynamic effects of amoxicillin versus cefotaxime against penicillin-susceptible and penicillin-resistant pneumococcal strains: a phase I study.,"Serum bactericidal activity against a penicillin-susceptible strain and a penicillin-resistant strain of Streptococcus pneumoniae (amoxicillin and cefotaxime MICs, 0.001 and 1 microg/ml, respectively, and MBCs, 0.01 and 2 microg/ml, respectively) was measured in 12 healthy volunteers who each received an oral 875-mg dose of amoxicillin and an intramuscular 1-g dose of cefotaxime in a crossover fashion. The areas under the bactericidal activity-time curves for the two strains were found to be similar for both antibiotics despite the significantly higher (P < 0.002) AUC/MIC and peak level/MIC values for cefotaxime.",1997,The areas under the bactericidal activity-time curves for the two strains were found to be similar for both antibiotics despite the significantly higher (P < 0.002),['12 healthy volunteers who each received an oral 875-mg dose of'],"['cefotaxime', 'cefotaxime against penicillin-susceptible and penicillin-resistant pneumococcal strains', 'amoxicillin']","['Pharmacodynamic effects', 'AUC/MIC and peak level/MIC values', 'bactericidal activity-time curves', 'Serum bactericidal activity']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C4517897', 'cui_str': '875'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C0007554', 'cui_str': 'Cefotaxime'}, {'cui': 'C0030842', 'cui_str': 'Antibiotics, Penicillin'}, {'cui': 'C0231204', 'cui_str': 'Susceptible (qualifier value)'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}]","[{'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0427978', 'cui_str': 'Minimum Inhibitory Concentration'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0544570', 'cui_str': 'Bactericidal activity (observable entity)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",12.0,0.065298,The areas under the bactericidal activity-time curves for the two strains were found to be similar for both antibiotics despite the significantly higher (P < 0.002),"[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Aguilar', 'Affiliation': 'Medical Department, SmithKline Beecham Pharmaceuticals, Madrid, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Rosendo', 'Affiliation': ''}, {'ForeName': 'I P', 'Initials': 'IP', 'LastName': 'Balcabao', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Martín', 'Affiliation': ''}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Giménez', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Frías', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Prieto', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1236,9174209,Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers.,"The steady-state concentrations of clarithromycin and azithromycin in plasma were compared with concomitant concentrations in epithelial lining fluid (ELF) and alveolar macrophages (AM) obtained in intrapulmonary samples during bronchoscopy and bronchoalveolar lavage from 40 healthy, nonsmoking adult volunteers. Mean plasma clarithromycin, 14-(R)-hydroxyclarithromycin, and azithromycin concentrations were similar to those previously reported. Clarithromycin was extensively concentrated in ELF (range of mean +/- standard deviation concentrations, 34.4 +/- 29.3 microg/ml at 4 h to 4.6 +/- 3.7 microg/ml at 24 h) and AM (480 +/- 533 microg/ml at 4 h to 99 +/- 50 microg/ml at 24 h). The concentrations of azithromycin in ELF were 1.01 +/- 0.45 microg/ml at 4 h to 1.22 +/- 0.59 microg/ml at 24 h, and those in AM were 42.7 +/- 28.7 microg/ml at 4 h to 41.7 +/- 12.1 microg/ml at 24 h. The concentrations of 14-(R)-hydroxyclarithromycin in the AM ranged from 89.3 +/- 52.8 microg/ml at 4 h to 31.3 +/- 17.7 microg/ml at 24 h. During the period of 24 h after drug administration, azithromycin and clarithromycin achieved mean concentrations in ELF and AM higher than the concomitant concentrations in plasma.",1997,"During the period of 24 h after drug administration, azithromycin and clarithromycin achieved mean concentrations in ELF and AM higher than the concomitant concentrations in plasma.","['40 healthy, nonsmoking adult volunteers', 'healthy adult volunteers']","['Clarithromycin', 'clarithromycin and azithromycin', 'azithromycin and clarithromycin']","['Mean plasma clarithromycin, 14-(R)-hydroxyclarithromycin, and azithromycin concentrations', 'mean concentrations in ELF and AM', 'concentrations of 14-(R)-hydroxyclarithromycin', 'concentrations of azithromycin in ELF']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0090409', 'cui_str': 'Erythromycin, 14-hydroxy-6-O-methyl-'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",,0.0387493,"During the period of 24 h after drug administration, azithromycin and clarithromycin achieved mean concentrations in ELF and AM higher than the concomitant concentrations in plasma.","[{'ForeName': 'K A', 'Initials': 'KA', 'LastName': 'Rodvold', 'Affiliation': 'College of Pharmacy, University of Illinois, Chicago 60612, USA. kar@uic.edu'}, {'ForeName': 'M H', 'Initials': 'MH', 'LastName': 'Gotfried', 'Affiliation': ''}, {'ForeName': 'L H', 'Initials': 'LH', 'LastName': 'Danziger', 'Affiliation': ''}, {'ForeName': 'R J', 'Initials': 'RJ', 'LastName': 'Servi', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1237,9174180,Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen.,"A brief therapeutic regimen of praziquantel, reduced to a single day, has been effective for treatment of neurocysticercosis. To study its pharmacokinetic characteristics, levels of praziquantel in plasma were determined for eight healthy volunteers after the administration of three oral doses of 25 mg/kg of body weight given at 2-h intervals, alone and with the simultaneous administration of cimetidine. Each volunteer received both regimens in a randomized crossover design. Blood samples were taken during a period of 12 h, and praziquantel concentration was measured by high-performance liquid chromatography. Levels of praziquantel in plasma remained above 300 ng/ml during a period of 12 h; they increased 100% when cimetidine was jointly administered. Compared with other regimens, the high levels obtained and the longer duration of action seem to be advantageous in prolonging the exposure of the parasites to the drug and support previous clinical experience showing that the treatment of neurocysticercosis with praziquantel can be reduced from 2 weeks to 1 day with the drug still retaining its cysticidal properties. Moreover, simultaneous administration of praziquantel and cimetidine could improve further the efficacy of the single-day therapy for cysticercosis and other parasitic diseases, such as schistosomiasis.",1997,Levels of praziquantel in plasma remained above 300 ng/ml during a period of 12 h; they increased 100% when cimetidine was jointly administered.,['eight healthy volunteers'],"['praziquantel', 'cimetidine', 'praziquantel and cimetidine']",['Levels of praziquantel in plasma'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0032911', 'cui_str': 'Praziquantel'}, {'cui': 'C0008783', 'cui_str': 'Cimetidine'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0032911', 'cui_str': 'Praziquantel'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}]",8.0,0.033741,Levels of praziquantel in plasma remained above 300 ng/ml during a period of 12 h; they increased 100% when cimetidine was jointly administered.,"[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Jung', 'Affiliation': 'Instituto Nacional de Neurologia y Neurocirugia and Universidad Nacional Autonoma de Mexico, Mexico City.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Medina', 'Affiliation': ''}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Castro', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Corona', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Sotelo', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1238,9169739,"Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers.","During development of Peru-15, a new live oral vaccine for cholera, the role of buffer needed to be evaluated. Generally, oral bacterial vaccines are acid labile and need to be administered by using a formulation which protects them from gastric acid. We compared three different buffers for use with Peru-15, including a standard bicarbonate-ascorbic acid buffer, Alka-Seltzer, and a new electrolyte-rice buffer, CeraVacx. Saline served as the control. Thirty-nine healthy adult volunteers received Peru-15 (10(8) CFU) with one of the three buffers or saline in a double-masked study. The volunteers were monitored for symptoms for 7 days after the dose, serum was tested for antibody responses by vibriocidal antibody and immunoglobulin G antitoxin enzyme-linked immunosorbent assays, and stool samples were tested for excretion of the vaccine strain. Side effects were minimal in all groups. All 30 volunteers who took Peru-15 with a buffer showed significant rises in vibriocidal antibody titer. The magnitude of the rises was higher in the CeraVacx group than in the other two buffer groups. Four of nine volunteers who took the vaccine with saline also showed increased titers, but they were lower than those in any of the three buffer groups. Excretion of the vaccine strain was similar in the buffer groups, but excretion was not associated with the magnitude of the vibriocidal responses. Excretion of Peru-15 was not detected in the saline group. We conclude that buffer does amplify the serological response to Peru-15 and that CeraVacx may provide benefits not provided by other buffers.",1997,"Excretion of the vaccine strain was similar in the buffer groups, but excretion was not associated with the magnitude of the vibriocidal responses.","['outpatient volunteers', 'Thirty-nine healthy adult volunteers received']","['standard bicarbonate-ascorbic acid buffer, Alka-Seltzer, and a new electrolyte-rice buffer, CeraVacx', 'Saline', 'Peru-15 (10(8) CFU', 'vaccine with saline']","['vibriocidal antibody titer', 'Side effects', 'Excretion of the vaccine strain', 'Excretion of Peru-15']","[{'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C3816447', 'cui_str': '39 (qualifier value)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0005367', 'cui_str': 'Hydrogen Carbonates'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0006353', 'cui_str': 'Buffers'}, {'cui': 'C0051166', 'cui_str': 'Alka-Seltzer'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0013832', 'cui_str': 'Electrolytes'}, {'cui': 'C0035567', 'cui_str': 'Rice'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C1566272', 'cui_str': 'Peru 15'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}]","[{'cui': 'C1287242', 'cui_str': 'Finding of antibody titer (finding)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C1566272', 'cui_str': 'Peru 15'}]",39.0,0.0544255,"Excretion of the vaccine strain was similar in the buffer groups, but excretion was not associated with the magnitude of the vibriocidal responses.","[{'ForeName': 'D A', 'Initials': 'DA', 'LastName': 'Sack', 'Affiliation': 'Department of International Health, The Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland 21205, USA. dsack@phnet.sph.jhu.edu'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Shimko', 'Affiliation': ''}, {'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Sack', 'Affiliation': ''}, {'ForeName': 'J G', 'Initials': 'JG', 'LastName': 'Gomes', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'MacLeod', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': ""O'Sullivan"", 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Spriggs', 'Affiliation': ''}]",Infection and immunity,[] 1239,9169747,Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines.,"Cytokine profiles were examined 1 month after primary vaccination of infants with a whole-cell pertussis vaccine (wP) (Connaught) or either of two acellular pertussis vaccines, aP-Chiron Biocine (aP-CB) or aP-SmithKline Beecham (aP-SB), each combined with diphtheria-tetanus toxoids (DT), in Bordetella pertussis antigen-stimulated or unstimulated peripheral blood mononuclear cells (PBMC). Pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN) were used as antigens, and the children were defined as responsive when their PBMC proliferated in response to these antigens. The controls were either children who received only DT or children who received pertussis vaccine but whose PBMC did not proliferate upon stimulation with B. pertussis antigens (unresponsive children). Antigen-stimulated PBMC of responsive wP recipients were characterized by an elevated production of T-helper-cell type 1 cytokines gamma interferon (IFN-gamma) and interleukin 2 (IL-2), low to minimal production of IL-5, and no production of IL-4. The PBMC of aP vaccine-responsive recipients showed, in addition to the elevated IFN-gamma production, a consistent, antigen-dependent production of type 2 cytokines (IL-4 and IL-5), with PRN being the most and PT being the least effective antigen. Type 2 cytokine induction was more pronounced in aP-SB than in aP-CB recipients, as shown by the presence of IL-4 mRNA transcripts and higher IL-5 production in the former (161.6 +/- 36 and 47.9 +/- 44 pg/ml [mean +/- standard error for five subjects each], respectively, after PRN stimulation). Appreciable, antigen-unstimulated (constitutive) IFN-gamma production was also detected in PBMC cultures of all vaccinees. However, this spontaneous IFN-gamma production was, in most vaccinees, significantly lower than the antigen-driven cytokine production. In contrast, no constitutive type 2 cytokine production was ever observed in any vaccine group. PBMC from the two control groups (either DT or pertussis vaccine recipients) did not show any type 2 cytokine production, while IFN-gamma production was comparable in both antigen-stimulated and unstimulated conditions. Absence of type 2 cytokines and low levels of constitutive IFN-gamma production were also seen in prevaccination children. Thus, pertussis vaccines induce in infants a basically type 1 cytokine profile, which is, however, accompanied by some production of type 2 cytokines. The latter are more expressed by aP-SB than by aP-CB recipients, and with PRN than with other antigens, and they are minimally expressed in wP recipients and with PT as antigen. Our data also highlight a constitutive IFN-gamma production in infancy, which might reflect natural immunization and/or the burden of concomitant vaccinations and which may have an impact on T-helper-cell cytokine pattern polarization consequent to pertussis vaccination.",1997,"Antigen-stimulated PBMC of responsive wP recipients were characterized by an elevated production of T-helper-cell type 1 cytokines gamma interferon (IFN-gamma) and interleukin 2 (IL-2), low to minimal production of IL-5, and no production of IL-4.",['infants with whole-cell or acellular pertussis vaccines'],"['whole-cell pertussis vaccine (wP) (Connaught) or either of two acellular pertussis vaccines, aP-Chiron Biocine (aP-CB) or aP-SmithKline Beecham (aP-SB), each combined with diphtheria-tetanus toxoids (DT), in Bordetella pertussis antigen-stimulated or unstimulated peripheral blood mononuclear cells (PBMC', 'Vaccine- and antigen-dependent type 1 and type 2 cytokine induction', 'Pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN', 'pertussis vaccine']","['constitutive IFN-gamma production', 'constitutive type 2 cytokine production', 'antigen-unstimulated (constitutive) IFN-gamma production', 'IL-4 mRNA transcripts and higher IL-5 production', 'type 2 cytokine production, while IFN-gamma production', 'Cytokine profiles']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0982332', 'cui_str': 'acellular pertussis vaccine, inactivated'}]","[{'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0031237', 'cui_str': 'Pertussis Vaccine'}, {'cui': 'C0982332', 'cui_str': 'acellular pertussis vaccine, inactivated'}, {'cui': 'C0914797', 'cui_str': 'chiron'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0012546', 'cui_str': 'Corynebacterium diphtheriae Infection'}, {'cui': 'C0305062', 'cui_str': 'Clostridium tetani toxoid antigen, inactivated'}, {'cui': 'C0368784', 'cui_str': 'Bordetella pertussis antigen'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0003320', 'cui_str': 'Antigens'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0020731', 'cui_str': 'Histamine-Sensitizing Factor'}, {'cui': 'C0018909', 'cui_str': 'Hemagglutinin'}, {'cui': 'C0136166', 'cui_str': 'pertactin'}, {'cui': 'C0558288', 'cui_str': 'prn'}]","[{'cui': 'C1552644', 'cui_str': 'Greek letter gamma'}, {'cui': 'C0033268'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0003320', 'cui_str': 'Antigens'}, {'cui': 'C0439819', 'cui_str': 'Unstimulated (qualifier value)'}, {'cui': 'C0021758', 'cui_str': 'Interleukin-4'}, {'cui': 'C0035696', 'cui_str': 'mRNA'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0021759', 'cui_str': 'Interleukin-5'}]",,0.021713,"Antigen-stimulated PBMC of responsive wP recipients were characterized by an elevated production of T-helper-cell type 1 cytokines gamma interferon (IFN-gamma) and interleukin 2 (IL-2), low to minimal production of IL-5, and no production of IL-4.","[{'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Ausiello', 'Affiliation': 'Department of Bacteriology and Medical Mycology, Istituto Superiore di Sanità, Rome, Italy.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Urbani', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'la Sala', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Lande', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Cassone', 'Affiliation': ''}]",Infection and immunity,[] 1240,9210675,Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS.,"Few reports on the effects of AIDS on the absorption of orally (p.o.) administered agents exist. To help fill this informational gap, we administered ciprofloxacin to 12 patients with AIDS by two dosing regimens (400 mg given intravenously [i.v.] and 500 mg given p.o. every 12 h) in a randomized, crossover fashion. Pharmacokinetic parameters were determined by noncompartmental methods. Mean values (+/- standard deviations [SD]) for p.o. ciprofloxacin were as follows: peak concentration of drug in serum (Cmax), 2.94 +/- 0.51 microg/ml; time to Cmax, 1.38 +/- 0.43 h; area under the concentration-time curve from 0 to 12 h (AUC(0-12)), 12.13 +/- 3.21 microg x h/ml; and half-life (t(1/2)), 3.86 +/- 0.48 h. Mean values (+/- SD) for i.v. ciprofloxacin were as follows: Cmax, 3.61 +/- 0.82 microg/ml; time to Cmax, 1.0 h; AUC(0-12), 11.92 +/- 2.92 microg x h/ml; and t(1/2), 3.98 +/- 0.94 h. The mean percent absolute bioavailability for ciprofloxacin was calculated to be 82% +/- 13%, similar to the value for healthy volunteers. We conclude that ciprofloxacin when administered p.o. to patients with AIDS is well absorbed, as evidenced by excellent bioavailability and is not affected by gastrointestinal changes in the absence of infectious gastroenteritis and severe diarrhea.",1997,"0.43 h; area under the concentration-time curve from 0 to 12 h (AUC(0-12)), 12.13 +/-","['patients with AIDS', '12 patients with AIDS', 'healthy volunteers']",['ciprofloxacin'],"['peak concentration of drug in serum (Cmax', '0.43 h; area under the concentration-time curve', 'Pharmacokinetic parameters', 'Oral bioavailability and pharmacokinetics', 'mean percent absolute bioavailability for ciprofloxacin', 'Mean values ']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",12.0,0.0645764,"0.43 h; area under the concentration-time curve from 0 to 12 h (AUC(0-12)), 12.13 +/-","[{'ForeName': 'R C', 'Initials': 'RC', 'LastName': 'Owens', 'Affiliation': 'Department of Clinical Pharmacy Services, Medical Center of Delaware, Newark 19718, USA.'}, {'ForeName': 'K B', 'Initials': 'KB', 'LastName': 'Patel', 'Affiliation': ''}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Banevicius', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Quintiliani', 'Affiliation': ''}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Nightingale', 'Affiliation': ''}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Nicolau', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1241,9210689,Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia.,"Six hundred ninety patients were enrolled in a multicenter, randomized, double-blind trial comparing the efficacy and safety of cefdinir with those of cefaclor in the treatment of community-acquired pneumonia. Patients received either 10 days of treatment with cefdinir (n = 347) at 300 mg twice daily or 10 days of treatment with cefaclor (n = 343) at 500 mg three times daily. Microbiological assessments were performed on sputum specimens obtained at admission and at the two posttherapy visits, if available. Respiratory tract pathogens were isolated from 538 (78%) of 690 patient admission sputum specimens, with the predominant pathogens being Haemophilus parainfluenzae, Haemophilus influenzae, Streptococcus pneumoniae, and Staphylococcus aureus. The microbiological eradication rates at the test-of-cure visit were 92% (238 of 260 pathogens) and 93% (245 of 264 pathogens) for the evaluable patients treated with cefdinir and cefaclor, respectively. A satisfactory clinical response (cure plus improvement) was achieved in 89% (166 of 187) and 86% (160 of 186) of the evaluable patients treated with cefdinir and cefaclor, respectively. Except for the incidence of diarrhea, adverse event rates while on treatment were equivalent between the two treatment groups. Diarrhea incidence during therapy was higher for patients treated with cefdinir (13.7%) than for patients treated with cefaclor (5.3%). These results indicate that cefdinir is effective and safe in the treatment of patients with pneumonia.",1997,Diarrhea incidence during therapy was higher for patients treated with cefdinir (13.7%) than for patients treated with cefaclor (5.3%).,"['patients with pneumonia', 'Six hundred ninety patients', 'community-acquired pneumonia']","['cefaclor', 'cefdinir', 'cefdinir and cefaclor']","['effective and safe', 'efficacy and safety', 'Respiratory tract pathogens', 'Diarrhea incidence', 'diarrhea, adverse event rates', 'microbiological eradication rates']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C3816959', 'cui_str': 'Ninety'}, {'cui': 'C0694549', 'cui_str': 'Community acquired pneumonia (disorder)'}]","[{'cui': 'C0007537', 'cui_str': 'Cefaclor'}, {'cui': 'C0060405', 'cui_str': 'cefdinir'}]","[{'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282335', 'cui_str': 'Respiratory Tract'}, {'cui': 'C0450254', 'cui_str': 'Pathogen'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",690.0,0.0683384,Diarrhea incidence during therapy was higher for patients treated with cefdinir (13.7%) than for patients treated with cefaclor (5.3%).,"[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Drehobl', 'Affiliation': 'Centre for Health Care, San Diego, California, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Bianchi', 'Affiliation': ''}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Keyserling', 'Affiliation': ''}, {'ForeName': 'K J', 'Initials': 'KJ', 'LastName': 'Tack', 'Affiliation': ''}, {'ForeName': 'T J', 'Initials': 'TJ', 'LastName': 'Griffin', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1242,9210690,Prospective randomized comparison of cefodizime versus cefuroxime for perioperative prophylaxis in patients undergoing coronary artery bypass grafting.,"The effects of cefodizime and cefuroxime on neutrophil phagocytosis and reactive oxygen production in 54 patients undergoing elective coronary artery bypass grafting were studied. Both drugs were administered twice at a dosage of 40 mg/kg of body weight (pre- and intraoperative). Phagocytic capacity was assessed by measuring the uptake of fluorescein isothiocyanate-labeled Escherichia coli and Staphylococcus aureus by flow cytometry. Reactive oxygen generation after phagocytosis was estimated by determining the amount of dihydrorhodamine 123 converted to rhodamine 123 intracellularly. In both groups the mean phagocytic ability for E. coli and S. aureus decreased during surgery (-21 and -8%, respectively, for the cefodizime group and -39 and -38%, respectively, for the cefuroxime group; P < 0.05 for all). In the cefodizime group a normalization of mean E. coli and S. aureus neutrophil phagocytosis was seen on day 5 (+9 and -4% compared to preoperative values; P > 0.35 for both), whereas in cefuroxime-treated patients phagocytic ability remained depressed (-37 and -31%; P < 0.04 for both). In both groups mean neutrophil reactive oxygen intermediate (ROI) production after E. coli and S. aureus phagocytosis increased during cardiopulmonary bypass (+44 and +83%, respectively, in the cefodizime group and +58 and +73%, respectively, in the cefuroxime group; P < 0.05 for all). One day after surgery E. coli- and S. aureus-driven neutrophil ROI production was not different from the preoperative values (-2 and +12%, respectively, for the cefodizime group and +7 and +15%, respectively, for the cefuroxime group; P > 0.15 for all). Postoperative serum levels of the C-reactive protein on days 2 and 7 were lower in cefodizime-treated patients (19 +/- 6 and 4 +/- 2 mg/liter versus 23 +/- 6 and 11 +/- 5 mg/liter; P < 0.05 for both). In addition to cefodizime's antimicrobial activity during perioperative prophylaxis, its use in coronary artery bypass grafting can prevent procedure-related prolonged postoperative neutrophil phagocytosis impairment.",1997,Postoperative serum levels of the C-reactive protein on days 2 and 7 were lower in cefodizime-treated patients (19 +/-,"['54 patients undergoing elective coronary artery bypass grafting were studied', 'patients undergoing coronary artery bypass grafting']","['cefuroxime', 'cefodizime and cefuroxime', 'cefodizime versus cefuroxime']","['mean phagocytic ability for E. coli and S. aureus', 'Postoperative serum levels', 'normalization of mean E. coli and S. aureus neutrophil phagocytosis', 'mean neutrophil reactive oxygen intermediate (ROI) production after E. coli and S. aureus phagocytosis', 'neutrophil ROI production', 'Reactive oxygen generation after phagocytosis', 'Phagocytic capacity', 'neutrophil phagocytosis and reactive oxygen production']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0010055', 'cui_str': 'Coronary Artery Bypass Grafting'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0007562', 'cui_str': 'Cefuroxime'}, {'cui': 'C0055007', 'cui_str': 'cefodizime'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0014834', 'cui_str': 'Escherichia coli'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear Leukocytes'}, {'cui': 'C0031308', 'cui_str': 'Phagocytosis'}, {'cui': 'C0205332', 'cui_str': 'Reactive (qualifier value)'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0033268'}, {'cui': 'C0079411', 'cui_str': 'Generations'}]",54.0,0.0482425,Postoperative serum levels of the C-reactive protein on days 2 and 7 were lower in cefodizime-treated patients (19 +/-,"[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Wenisch', 'Affiliation': 'Department of Internal Medicine I, University Hospital of Vienna, Austria.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Bartunek', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Zedtwitz-Liebenstein', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Hiesmayr', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Parschalk', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Pernerstorfer', 'Affiliation': ''}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Graninger', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1243,32047245,Effects of exogenous testosterone application on network connectivity within emotion regulation systems.,"Studies with steroid hormones underlined the vital role of testosterone on social-emotional processing. However, there is still a lack of studies investigating whether testosterone modulates network connectivity during resting-state. Here, we tested how the exogenous application of testosterone would affect functional connectivity between regions implicated in emotion regulation. In total, 96 male participants underwent resting-state fMRI scanning. Before the measurement, half of the subjects received 5 g Testim TM gel (containing 50 mg testosterone) and the other half a corresponding amount of placebo gel. Seeds for the connectivity analysis were meta-analytically defined. First, all regions associated with emotion regulation were chosen via Neurosynth (data driven). Among those, specific seeds were selected and categorized based on the neural model of emotion regulation by Etkin and colleagues (Etkin et al., 2015) (theory-guided). Resting-state connectivity analysis revealed decreased connectivity between the right DLPFC and the right amygdala as well as between the VMPFC and the left IPL for the testosterone group compared to the placebo group. A complementary dynamic causal modeling (DCM) analysis on findings from the resting-state connectivity analysis underlined a bidirectional coupling which was decreased close to zero by testosterone administration. Our results demonstrate that testosterone administration disrupts resting-state connectivity within fronto-subcortical and fronto-parietal circuits. The findings suggest that even without a specific task (e.g. challenge, reward processing) testosterone modulates brain networks important for social-emotional processing.",2020,Our results demonstrate that testosterone administration disrupts resting-state connectivity within fronto-subcortical and fronto-parietal circuits.,['96 male participants underwent'],"['resting-state fMRI scanning', 'testosterone', 'placebo gel', '5\u2009g Testim TM gel (containing 50\u2009mg testosterone', 'placebo', 'exogenous testosterone application']","['network connectivity within emotion regulation systems', 'social-emotional processing']","[{'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0523912', 'cui_str': 'Testosterone measurement (procedure)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C1170653', 'cui_str': 'Testim'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0205228', 'cui_str': 'Exogenous (qualifier value)'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}]","[{'cui': 'C0013987', 'cui_str': 'Emotions'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}]",96.0,0.101316,Our results demonstrate that testosterone administration disrupts resting-state connectivity within fronto-subcortical and fronto-parietal circuits.,"[{'ForeName': 'Mikhail', 'Initials': 'M', 'LastName': 'Votinov', 'Affiliation': 'Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, 52074, Aachen, Germany. mvotinov@ukaachen.de.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Wagels', 'Affiliation': 'Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, 52074, Aachen, Germany.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Hoffstaedter', 'Affiliation': 'Institute of Neuroscience and Medicine (INM-7), Research Centre Jülich, Jülich, Germany.'}, {'ForeName': 'Thilo', 'Initials': 'T', 'LastName': 'Kellermann', 'Affiliation': 'Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, 52074, Aachen, Germany.'}, {'ForeName': 'Katharina S', 'Initials': 'KS', 'LastName': 'Goerlich', 'Affiliation': 'Department of Biomedical Sciences of Cells & Systems, Section Cognitive Neuroscience, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Simon B', 'Initials': 'SB', 'LastName': 'Eickhoff', 'Affiliation': 'Institute of Neuroscience and Medicine (INM-7), Research Centre Jülich, Jülich, Germany.'}, {'ForeName': 'Ute', 'Initials': 'U', 'LastName': 'Habel', 'Affiliation': 'Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, 52074, Aachen, Germany.'}]",Scientific reports,['10.1038/s41598-020-59329-0'] 1244,9210677,Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis. Cefdinir Sinusitis Study Group.,"Cefdinir is an extended-spectrum oral cephalosporin that is active against pathogens commonly seen in acute community-acquired bacterial sinusitis (ACABS), including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Two randomized, investigator-blind, multicenter trials (one in the United States and one in Europe) compared two dosage regimens of cefdinir (600 mg once a day for 10 days and 300 mg twice a day for 10 days) to amoxicillin-clavulanate (A-C) (500 mg three times a day for 10 days) for adult and adolescent patients with ACABS. Twelve hundred twenty-nine patients entered the U.S. study, 698 with antral puncture; 569 patients entered the European study, all with antral puncture. Clinical response (cure or improvement) was determined 7 to 14 days and 3 to 5 weeks posttherapy. Microbiologic eradication rates were determined 10 to 30 days posttherapy in a subset of patients who underwent pre- and posttherapy sinus aspirate culture. Rates of adverse events and treatment discontinuations due to adverse events were examined. Cefdinir, given once or twice daily, was as effective clinically (approximately 90% cure rate) as amoxicillin-clavulanate given three times daily in the treatment of ACABS. Microbiologic eradication rates were also similar in the three groups. The major side effect was mild diarrhea, occurring in approximately 20% of each group. Cefdinir caused fewer adverse events requiring treatment discontinuation.",1997,Microbiologic eradication rates were also similar in the three groups.,"['acute community-acquired bacterial sinusitis', 'Twelve hundred twenty-nine patients entered the U.S. study, 698 with antral puncture; 569 patients entered the European study, all with antral puncture', 'adult and adolescent patients with ACABS']","['Cefdinir', 'cefdinir', 'cefdinir and amoxicillin-clavulanate', 'amoxicillin-clavulanate', 'amoxicillin-clavulanate (A-C']","['Clinical response (cure or improvement', 'adverse events', 'Microbiologic eradication rates', 'mild diarrhea', 'Rates of adverse events']","[{'cui': 'C0456394', 'cui_str': 'Community acquired (qualifier value)'}, {'cui': 'C1262006', 'cui_str': 'Bacterial sinusitis (disorder)'}, {'cui': 'C0450351', 'cui_str': '29 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0293352', 'cui_str': 'Antral'}, {'cui': 'C0033119', 'cui_str': 'Puncture wound - injury (disorder)'}, {'cui': 'C0239307', 'cui_str': 'European (ethnic group)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0060405', 'cui_str': 'cefdinir'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0110038', 'cui_str': 'Clavulanate'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",1229.0,0.0230829,Microbiologic eradication rates were also similar in the three groups.,"[{'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Gwaltney', 'Affiliation': 'Department of Internal Medicine, University of Virginia Health Science Center, Charlottesville 22908, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Savolainen', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Rivas', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Schenk', 'Affiliation': ''}, {'ForeName': 'W M', 'Initials': 'WM', 'LastName': 'Scheld', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Sydnor', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Keyserling', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Leigh', 'Affiliation': ''}, {'ForeName': 'K J', 'Initials': 'KJ', 'LastName': 'Tack', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1245,32437937,Causes of fever in primary care in Southeast Asia and the performance of C-reactive protein in discriminating bacterial from viral pathogens.,"OBJECTIVES This study investigated causes of fever in the primary levels of care in Southeast Asia, and evaluated whether C-reactive protein (CRP) could distinguish bacterial from viral pathogens. METHODS Blood and nasopharyngeal swab specimens were taken from children and adults with fever (>37.5 °C) or history of fever (<14 days) in Thailand and Myanmar. RESULTS Of 773 patients with at least one blood or nasopharyngeal swab specimen collected, 227 (29.4%) had a target organism detected. Influenza virus type A was detected in 85/227 cases (37.5%), followed by dengue virus (30 cases, 13.2%), respiratory syncytial virus (24 cases, 10.6%) and Leptospira spp. (nine cases, 4.0%). Clinical outcomes were similar between patients with a bacterial or a viral organism, regardless of antibiotic prescription. CRP was higher among patients with a bacterial organism compared with those with a viral organism (median 18 mg/L, interquartile range [10-49] versus 10 mg/L [≤8-22], p = 0.003), with an area under the curve of 0.65 (95% CI 0.55-0.75). CONCLUSIONS Serious bacterial infections requiring antibiotics are an exception rather than the rule in the first line of care. CRP testing could assist in ruling out such cases in settings where diagnostic uncertainty is high and routine antibiotic prescription is common. The original CRP randomised controlled trial was registered with ClinicalTrials.gov, number NCT02758821.",2020,"CRP was higher among patients with a bacterial organism compared to those with a viral organism (median 18mg/L, interquartile range [10-49] versus 10mg/L [≤8-22], p-value 0.003), with an area under the curve of 0.65, 95% confidence interval (0.55-0.75). ","['fever in the primary levels of care in Southeast Asia', '773 patients with at least one blood or nasopharyngeal swab specimen collected, 227 (29.4%) had a target organism detected', 'Blood and nasopharyngeal swab specimens were taken from children and adults with fever (>37.5˚C) or history of fever (<14 days) in Thailand and Myanmar']",[],"['respiratory syncytial virus', 'CRP']","[{'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003983', 'cui_str': 'South east Asian country'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0444192', 'cui_str': 'Nasopharyngeal swab'}, {'cui': 'C0029235', 'cui_str': 'Organism'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0039725', 'cui_str': 'Thailand'}, {'cui': 'C0006416', 'cui_str': 'Burma'}]",[],"[{'cui': 'C0035236', 'cui_str': 'Syncytial Virus, Respiratory'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}]",773.0,0.237316,"CRP was higher among patients with a bacterial organism compared to those with a viral organism (median 18mg/L, interquartile range [10-49] versus 10mg/L [≤8-22], p-value 0.003), with an area under the curve of 0.65, 95% confidence interval (0.55-0.75). ","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Althaus', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom. Electronic address: thomas.a@tropmedres.ac.'}, {'ForeName': 'Janjira', 'Initials': 'J', 'LastName': 'Thaipadungpanit', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Rachel C', 'Initials': 'RC', 'LastName': 'Greer', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Myo Maung Maung', 'Initials': 'MMM', 'LastName': 'Swe', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Myanmar-Oxford Clinical Research Unit (MOCRU), Medical Action Myanmar (MAM), Yangon, Myanmar.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Dittrich', 'Affiliation': 'Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.'}, {'ForeName': 'Pimnara', 'Initials': 'P', 'LastName': 'Peerawaranun', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Pieter W', 'Initials': 'PW', 'LastName': 'Smit', 'Affiliation': 'Maasstad Ziekenhuis Hospital, Department of Medical Microbiology, Rotterdam, The Netherlands; Public Health Laboratory (GGD), Amsterdam, The Netherlands.'}, {'ForeName': 'Tri', 'Initials': 'T', 'LastName': 'Wangrangsimakul', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Blacksell', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Jonas M', 'Initials': 'JM', 'LastName': 'Winchell', 'Affiliation': 'Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.'}, {'ForeName': 'Maureen H', 'Initials': 'MH', 'LastName': 'Diaz', 'Affiliation': 'Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.'}, {'ForeName': 'Nicholas P J', 'Initials': 'NPJ', 'LastName': 'Day', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Smithuis', 'Affiliation': 'Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom; Myanmar-Oxford Clinical Research Unit (MOCRU), Medical Action Myanmar (MAM), Yangon, Myanmar.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Turner', 'Affiliation': 'Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom; Cambodia-Oxford Medical Research Unit (COMRU), Angkor Hospital for Children, Siem Reap, Cambodia.'}, {'ForeName': 'Yoel', 'Initials': 'Y', 'LastName': 'Lubell', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.'}]",International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,['10.1016/j.ijid.2020.05.016'] 1246,9124858,Effects of nifedipine and diltiazem on pharmacokinetics of cefpodoxime following its oral administration.,"We compared the effects of nifedipine and diltiazem on the uptake of cefpodoxime proxetil (CP). The study was aimed at establishing the impact of increased mesenteric blood flow due to calcium channel blockers on passive transport. Twelve volunteers were given CP (200 mg) orally in a crossover design. The absorption, disposition, and elimination parameters of cefpodoxime were compared among the following three treatment groups: CP alone, CP following oral administration of diltiazem (60 mg), or CP following oral administration of nifedipine (20 mg). No statistically significant difference in pharmacokinetic parameters was observed between the three treatment groups.",1996,No statistically significant difference in pharmacokinetic parameters was observed between the three treatment groups.,['Twelve volunteers were given'],"['nifedipine and diltiazem', 'nifedipine', 'CP', 'diltiazem', 'calcium channel blockers']","['pharmacokinetics of cefpodoxime', 'mesenteric blood flow', 'absorption, disposition, and elimination parameters of cefpodoxime', 'pharmacokinetic parameters', 'uptake of cefpodoxime proxetil (CP']","[{'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C1947971', 'cui_str': 'Give'}]","[{'cui': 'C0028066', 'cui_str': 'Nifedipine'}, {'cui': 'C0012373', 'cui_str': 'Diltiazem'}, {'cui': 'C1153433', 'cui_str': 'Calcium channel'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0055011', 'cui_str': 'cefpodoxime'}, {'cui': 'C0025474', 'cui_str': 'Mesentery'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C0743223', 'cui_str': 'Disposition (disposition)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0108938', 'cui_str': 'cefpodoxime proxetil'}]",12.0,0.0222406,No statistically significant difference in pharmacokinetic parameters was observed between the three treatment groups.,"[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Deslandes', 'Affiliation': 'Service de Pharmacie Clinique et des Biomatériaw, Institut National de la Santé et de la Recherche Médicale, Paris, France.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Camus', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Lacroix', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Carbon', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Farinotti', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1247,9124864,Treatment of enteric fever with pefloxacin for 7 days versus 5 days: a randomized clinical trial.,"In this prospective study of enteric fever, 22 patients received 400 mg of pefloxacin twice daily for 5 days (group A) and 24 received 400 mg of pefloxacin twice daily for 7 days (group B). Causative microorganisms were Salmonella typhi (8 in group A, 11 in group B) and Salmonella paratyphi B (14 in group A, 13 in group B). The clinical cure and bacterial eradication rates were 96% (21 of 22) in group A and 100% in group B. In conclusion, 5-day oral administration of pefloxacin was as effective as 7-day treatment of enteric fever caused by Salmonella spp.",1996,"Causative microorganisms were Salmonella typhi (8 in group A, 11 in group B) and Salmonella paratyphi B (14 in group A, 13 in group B).",[],['pefloxacin'],['clinical cure and bacterial eradication rates'],[],"[{'cui': 'C0030771', 'cui_str': 'Pefloxacin'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}]",,0.0321247,"Causative microorganisms were Salmonella typhi (8 in group A, 11 in group B) and Salmonella paratyphi B (14 in group A, 13 in group B).","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Unal', 'Affiliation': 'Department of Internal Medicine, School of Medicine, Hacettepe University, Ankara, Turkey. su04-k@servis2.net.tr'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Hayran', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Tuncer', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Gür', 'Affiliation': ''}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Uzun', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Akova', 'Affiliation': ''}, {'ForeName': 'H E', 'Initials': 'HE', 'LastName': 'Akalin', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1248,9124839,Comparison of single-dose cefuroxime axetil with ciprofloxacin in treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing Neisseria gonorrhoeae strains.,"A randomized, multicenter, investigator-blind trial was conducted to compare the efficacies of cefuroxime axetil and ciprofloxacin for treatment of patients with uncomplicated gonorrhea caused by penicillinase-producing Neisseria gonorrhoeae (PPNG). A total of 832 patients (434 females and 398 males) received a single oral dose of cefuroxime axetil (1,000 mg [417 patients]) or ciprofloxacin (500 mg [415 patients]). N. gonorrhoeae was eradicated from the cervix in 114 of 118 (97%) and 118 of 119 (99%) bacteriologically evaluable females treated with cefuroxime axetil and ciprofloxacin, respectively (P = 0.213; difference, -2%; 95% confidence interval, -6 to 1%), and from the urethra in 154 of 166 (93%) and 171 of 171 (100%) bacteriologically evaluable male patients treated with cefuroxime axetil and ciprofloxacin, respectively (P < 0.001; difference, -7%; 95% confidence interval, -11 to -3%). Both treatments were effective in eradicating N. gonorrhoeae in females with rectal infections (cefuroxime axetil, 29 of 30 [97%]; ciprofloxacin, 25 of 25 [100%]; P = 1.00). In small numbers of patients, cefuroxime axetil was less effective than ciprofloxacin in treating males with pharyngeal infections (eradication in 4 of 10 and in 8 of 8 patients, respectively; P = 0.013). PPNG was eradicated from the cervix in 22 of 23 (96%) and 32 of 32 (100%) bacteriologically evaluable female patients treated with cefuroxime axetil and ciprofloxacin, respectively (P = 0.418; difference, -4%; 95% confidence interval, -13 to 4%), and from the urethra in 35 of 36 (97%) and 34 of 34 (100%) bacteriologically evaluable male patients treated with cefuroxime axetil and ciprofloxacin, respectively (P = 1.00; difference, -3%; 95% confidence interval, -8 to 3%). The incidences of drug-related adverse events were similar for the two study drugs. In summary, treatment with a single oral dose of cefuroxime axetil is as effective as treatment with a single oral dose of ciprofloxacin in eradicating PPNG from males and females with uncomplicated gonorrhea (urethral and endocervical), and both regimens are well-tolerated. However, in the present study, cefuroxime axetil was less effective than ciprofloxacin in treating urethral gonococcal infections in male patients, although both study drugs were highly effective in treating cervical gonococcal infections in female patients.",1996,"Both treatments were effective in eradicating N. gonorrhoeae in females with rectal infections (cefuroxime axetil, 29 of 30 [97%]; ciprofloxacin, 25 of 25 [100%]; P = 1.00).","['male patients', 'females with rectal infections ', 'uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing Neisseria gonorrhoeae strains', '832 patients (434 females and 398 males', 'males and females with uncomplicated gonorrhea (urethral and endocervical', 'female patients', 'patients with uncomplicated gonorrhea caused by penicillinase-producing Neisseria gonorrhoeae (PPNG']","['cefuroxime axetil with ciprofloxacin', 'cefuroxime axetil and ciprofloxacin', 'cefuroxime axetil', 'ciprofloxacin']","['urethral gonococcal infections', 'incidences of drug-related adverse events']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0205052', 'cui_str': 'Rectal (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0018081', 'cui_str': 'Neisseria gonorrhoeae Infection'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0030841', 'cui_str': 'Penicillinase'}, {'cui': 'C0475776', 'cui_str': 'Penicillinase-producing Neisseria gonorrhoeae (organism)'}, {'cui': 'C0041967', 'cui_str': 'Urethra'}, {'cui': 'C4521006', 'cui_str': 'Endocervical'}]","[{'cui': 'C0055015', 'cui_str': 'cefuroxime axetil'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}]","[{'cui': 'C0041967', 'cui_str': 'Urethra'}, {'cui': 'C0018081', 'cui_str': 'Neisseria gonorrhoeae Infection'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",832.0,0.147902,"Both treatments were effective in eradicating N. gonorrhoeae in females with rectal infections (cefuroxime axetil, 29 of 30 [97%]; ciprofloxacin, 25 of 25 [100%]; P = 1.00).","[{'ForeName': 'E M', 'Initials': 'EM', 'LastName': 'Thorpe', 'Affiliation': 'Shelby County Health Department STD Clinic, Memphis, Tennessee, USA.'}, {'ForeName': 'J R', 'Initials': 'JR', 'LastName': 'Schwebke', 'Affiliation': ''}, {'ForeName': 'E W', 'Initials': 'EW', 'LastName': 'Hook', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Rompalo', 'Affiliation': ''}, {'ForeName': 'W M', 'Initials': 'WM', 'LastName': 'McCormack', 'Affiliation': ''}, {'ForeName': 'K L', 'Initials': 'KL', 'LastName': 'Mussari', 'Affiliation': ''}, {'ForeName': 'G C', 'Initials': 'GC', 'LastName': 'Giguere', 'Affiliation': ''}, {'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Collins', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1249,9124837,Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections.,"The efficacies and safeties of a 3-day, 3-dose course of azithromycin (10 mg/kg of body weight per day) and a 10-day, 30-dose course of erythromycin (40 mg/kg/day) for the treatment of acute lower respiratory tract infections in children were compared in an open randomized multicenter study. Sixty-eight of 85 evaluable patients (80%) had radiologically proven pneumonia, and 20% had bronchitis. Treatment success defined as cure or major improvement was achieved in 42 of 45 (93%) azithromycin recipients versus 36 of 40 (90%) erythromycin recipients. Adverse events were reported in 12 of 45 and 6 of 40 of the patients treated with azithromycin and erythromycin, respectively, a difference which was not statistically significant. In conclusion, a 3-day course of azithromycin is as effective as a 10-day course of erythromycin in the treatment of community-acquired lower respiratory tract infections in children, with comparable safety and acceptability profiles. This shorter treatment course might have a beneficial effect on compliance, especially in the pediatric age group.",1996,"Adverse events were reported in 12 of 45 and 6 of 40 of the patients treated with azithromycin and erythromycin, respectively, a difference which was not statistically significant.","['children with community-acquired acute lower respiratory tract infections', 'Sixty-eight of 85 evaluable patients (80%) had radiologically proven pneumonia, and 20% had bronchitis', 'acute lower respiratory tract infections in children']","['erythromycin', 'azithromycin', 'azithromycin and erythromycin']","['Adverse events', 'cure or major improvement']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0456394', 'cui_str': 'Community acquired (qualifier value)'}, {'cui': 'C0238990', 'cui_str': 'Acute lower respiratory tract infection (disorder)'}, {'cui': 'C0450387', 'cui_str': '68 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0456369', 'cui_str': 'Proven (qualifier value)'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0006277', 'cui_str': 'Bronchitis'}]","[{'cui': 'C0014806', 'cui_str': 'Erythromycin'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}]",,0.0234741,"Adverse events were reported in 12 of 45 and 6 of 40 of the patients treated with azithromycin and erythromycin, respectively, a difference which was not statistically significant.","[{'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Roord', 'Affiliation': ""Het Wilhelmina Kinderziekenhuis, University Children's Hospital, Utrecht, The Netherlands.""}, {'ForeName': 'B H', 'Initials': 'BH', 'LastName': 'Wolf', 'Affiliation': ''}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Gossens', 'Affiliation': ''}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Kimpen', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1250,9145841,Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects.,"The multiple-dose pharmacokinetics of ritonavir were investigated in four groups of human immunodeficiency virus-positive male subjects (with 16 subjects per group) under nonfasting conditions; a 3:1 ritonavir:placebo ratio was used. Ritonavir was given at 200 (group I), 300 (group II), 400 (group III), or 500 (group IV) mg every 12 h for 2 weeks. The multiple-dose pharmacokinetics of ritonavir were moderately dose dependent, with the clearance for group IV (6.8 +/- 2.7 liters/h) being an average of 32% lower than that for group I (10.0 +/- 3.2 liters/h). First-pass metabolism should be minimal for ritonavir. The functional half-life, estimated from peak and trough concentrations, were similar among the dosage groups, averaging 3.1 and 5.7 h after the morning and evening doses, respectively. The area under the concentration-time curve at 24 h (AUC24) and apparent terminal-phase elimination rate constant remained relatively time invariant, but predose concentrations decreased 30 to 70% over time. Concentration-dependent autoinduction is the most likely mechanism for the time-dependent pharmacokinetics. The Km and initial maximum rate of metabolism (Vmax) values estimated from population pharmacokinetic modeling (nonlinear mixed-effects models) were 3.43 microg/ml and 46.9 mg/h, respectively. The group IV Vmax increased to 68 mg/h after 2 weeks. The maximum concentration of ritonavir in serum (Cmax) and AUC after the evening doses were an average of 30 to 40% lower than the values after the morning doses, while the concentration at 12 h was an average of 32% lower than the predose concentration, probably due to protracted absorption. Less than 2% of the dose was eliminated unchanged in the urine. Triglyceride levels increased from the levels at the baseline, and the levels were correlated with baseline triglyceride levels and AUC, Cmax, or predose concentrations.",1997,"The functional half-life, estimated from peak and trough concentrations, were similar among the dosage groups, averaging 3.1 and 5.7 h after the morning and evening doses, respectively.","['human immunodeficiency virus-infected subjects', 'four groups of human immunodeficiency virus-positive male subjects (with 16 subjects per group) under nonfasting conditions; a 3:1']","['ritonavir:placebo', 'Ritonavir', 'ritonavir']","['area under the concentration-time curve', 'predose concentrations', 'maximum concentration of ritonavir in serum (Cmax) and AUC', 'Triglyceride levels', 'baseline triglyceride levels and AUC, Cmax, or predose concentrations', 'Km and initial maximum rate of metabolism (Vmax) values']","[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0428475', 'cui_str': 'Triglyceride level - finding'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.0487662,"The functional half-life, estimated from peak and trough concentrations, were similar among the dosage groups, averaging 3.1 and 5.7 h after the morning and evening doses, respectively.","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Hsu', 'Affiliation': 'Abbott Laboratories, Abbott Park, Illinois 60064-3500, USA.'}, {'ForeName': 'G R', 'Initials': 'GR', 'LastName': 'Granneman', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Witt', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Locke', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Denissen', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Molla', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Valdes', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Smith', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Erdman', 'Affiliation': ''}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Lyons', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Niu', 'Affiliation': ''}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Decourt', 'Affiliation': ''}, {'ForeName': 'J B', 'Initials': 'JB', 'LastName': 'Fourtillan', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Girault', 'Affiliation': ''}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Leonard', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1251,9145856,Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects.,"Aminosidine is an older, broad-spectrum aminoglycoside antibiotic that has been shown to be effective in in vitro and animal models against multiple-drug-resistant tuberculosis and the Mycobacterium avium complex. The objective of this randomized, parallel trial was to characterize the single-dose pharmacokinetics of aminosidine sulfate in healthy subjects (eight males, eight females). Sixteen adults (mean [+/- standard deviation] age, 27.6 +/- 5.6 years) were randomly allocated to receive a single, intramuscular aminosidine sulfate injection at a dose of 12 or 15 mg/kg of body weight. Serial plasma and urine samples were collected over a 24-h period and used to determine aminosidine concentrations by high-performance liquid chromatographic assay. A one-compartment model with first-order input, first-order output, and a lag time (Tlag) and with a weighting factor of 1/y2 best described the data. Compartmental and noncompartmental pharmacokinetic parameters were estimated with the microcomputer program WinNonlin. One subject was not included (15-mg/kg group) because of the lack of sampling time data. On average, subjects attained peak concentrations of 22.4 +/- 3.2 microg/ml at 1.34 +/- 0.45 h. All subjects had plasma aminosidine concentrations below 2 microg/ml at 12 h, and all but two subjects (one in each dosing group) had undetectable plasma aminosidine concentrations at 24 h. The dose-adjusted area under the concentration-time curve from 0 h to infinity of aminosidine was identical for the 12- and 15-mg/kg groups (9.29 +/- 1.5 versus 9.29 +/- 2.2 microg x h/ml per mg/kg; P = 0.998). Similarly, no significant differences (P > 0.05) were observed between dosing groups for peak aminosidine concentration in plasma, time to peak aminosidine concentration in plasma, Tlag, apparent clearance, renal clearance, elimination rate constant, and elimination half-life. A significant difference was observed for the volume of distribution (0.35 versus 0.41 liters/kg; P = 0.037) between the 12 and 15 mg/kg dosing groups. Now that comparable pharmacokinetic profiles between dosing groups have been demonstrated, therapeutic equivalency testing via in vitro pharmacokinetic and pharmacodynamic modelling and randomized clinical trials in humans should be conducted.",1997,"Similarly, no significant differences (P > 0.05) were observed between dosing groups for peak aminosidine concentration in plasma, time to peak aminosidine concentration in plasma, Tlag, apparent clearance, renal clearance, elimination rate constant, and elimination half-life.","['Sixteen adults (mean [+/- standard deviation] age, 27.6 ', '5.6 years', 'healthy subjects', 'healthy subjects (eight males, eight females']","['Aminosidine', 'aminosidine sulfate injection', 'aminosidine sulfate', 'aminosidine']","['volume of distribution', 'undetectable plasma aminosidine concentrations', 'Serial plasma and urine samples', 'peak aminosidine concentration in plasma, time to peak aminosidine concentration in plasma, Tlag, apparent clearance, renal clearance, elimination rate constant, and elimination half-life', 'plasma aminosidine concentrations']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517794', 'cui_str': '5.6 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0030576', 'cui_str': 'Paromomycin'}, {'cui': 'C0038720', 'cui_str': 'Sulfates, Inorganic'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]","[{'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0030576', 'cui_str': 'Paromomycin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1610733', 'cui_str': 'Urine specimen'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0232813', 'cui_str': 'Renal clearance, function (observable entity)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}]",16.0,0.0445953,"Similarly, no significant differences (P > 0.05) were observed between dosing groups for peak aminosidine concentration in plasma, time to peak aminosidine concentration in plasma, Tlag, apparent clearance, renal clearance, elimination rate constant, and elimination half-life.","[{'ForeName': 'T P', 'Initials': 'TP', 'LastName': 'Kanyok', 'Affiliation': 'College of Pharmacy, University of Illinois at Chicago, 60612, USA.'}, {'ForeName': 'A D', 'Initials': 'AD', 'LastName': 'Killian', 'Affiliation': ''}, {'ForeName': 'K A', 'Initials': 'KA', 'LastName': 'Rodvold', 'Affiliation': ''}, {'ForeName': 'L H', 'Initials': 'LH', 'LastName': 'Danziger', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1252,9145871,Effect of food intake on pharmacokinetics of oral artemisinin in healthy Vietnamese subjects.,"The influence of food intake on the pharmacokinetics of artemisinin was studied with six healthy Vietnamese male subjects. In a crossover study, artemisinin capsules (500 mg) were administered with and without food after an overnight fast. Plasma samples were obtained up to 24 h after intake of each drug. Measurement of artemisinin concentrations was performed by high-performance liquid chromatography with electrochemical detection. Tolerance was evaluated according to subjective and objective findings, including repeated physical examinations, routine blood investigations, and electrocardiograms. Pharmacokinetics were analyzed with a noncompartmental method and with a one-compartment model. This model had either zero-order or first-order input. No statistically significant differences were found between the results of the two experimental conditions. Specifically, there were no consistent differences in parameters most likely to be affected by food intake, including absorption profile, absorption rate, bioavailability (f) (as reflected in area under the concentration time curve [AUC]), and drug clearance. Some mean +/- standard deviation parameters after food were as follows: maximum concentration of drug in serum (Cmax), 443 +/- 224 microg x liter(-1); time to Cmax, 1.78 +/- 1.2 h; AUC, 2,092 +/- 1,441 ng x ml(-1) x h, apparent clearance/f, 321 +/- 167 liter x h(-1); mean residence time, 4.42 +/- 1.31 h; and time at which half of the terminal value was reached, 0.97 +/- 0.68 h. The total amount of artemisinin excreted in urine was less than 1% of the dose. We conclude that food intake has no major effect on artemisinin pharmacokinetics. In addition, we conclude tentatively that artemisinin is cleared by the liver, that this clearance does not depend on liver blood flow (i.e., that artemisinin is a so-called low-clearance drug), and that absorption of the drug is not affected by food intake.",1997,No statistically significant differences were found between the results of the two experimental conditions.,"['healthy Vietnamese subjects', 'six healthy Vietnamese male subjects']","['artemisinin capsules', 'food intake']","['artemisinin pharmacokinetics', 'absorption profile, absorption rate, bioavailability (f) (as reflected in area under the concentration time curve [AUC]), and drug clearance', 'liver blood flow', 'maximum concentration of drug in serum (Cmax', 'total amount of artemisinin excreted in urine']","[{'cui': 'C1561452', 'cui_str': 'Vietnamese'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C1136174', 'cui_str': 'Artemisinins'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}]","[{'cui': 'C1136174', 'cui_str': 'Artemisinins'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0558058', 'cui_str': 'Reflecting (finding)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C4085663', 'cui_str': 'Drug clearance'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0042037'}]",6.0,0.0372854,No statistically significant differences were found between the results of the two experimental conditions.,"[{'ForeName': 'T K', 'Initials': 'TK', 'LastName': 'Dien', 'Affiliation': 'Institute for Clinical Research in Tropical Medicine, Bach Mai Hospital, Hanoi, Vietnam.'}, {'ForeName': 'P J', 'Initials': 'PJ', 'LastName': 'de Vries', 'Affiliation': ''}, {'ForeName': 'N X', 'Initials': 'NX', 'LastName': 'Khanh', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Koopmans', 'Affiliation': ''}, {'ForeName': 'L N', 'Initials': 'LN', 'LastName': 'Binh', 'Affiliation': ''}, {'ForeName': 'D D', 'Initials': 'DD', 'LastName': 'Duc', 'Affiliation': ''}, {'ForeName': 'P A', 'Initials': 'PA', 'LastName': 'Kager', 'Affiliation': ''}, {'ForeName': 'C J', 'Initials': 'CJ', 'LastName': 'van Boxtel', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1253,9145878,Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing.,"Two doses of gentamicin (2 and 7 mg/kg of body weight) were administered to 11 healthy volunteers in a randomized, crossover single-dose study to compare their pharmacokinetics. Doses were infused over 1 h with a syringe infusion pump, and 14 concentrations in sera were obtained over an 8-h period. Concentration in serum versus time data were fitted to a two-compartment pharmacokinetic model. In addition, to mimic the clinical setting, subjects' data were fitted by the Sawchuk-Zaske method. Distributional and postdistributional peak concentrations, along with the last obtained concentration in serum, were utilized to compare the following pharmacokinetic variables: volume of distribution at steady state (Vss), half-life, clearance (CL), and maximum concentration in serum (Cmax). With two-compartment pharmacokinetic fitting, significant differences in distribution half-life (average, 21.8 and 41.6 min [P < or = 0.05]) and gentamicin CL (76.6 +/- 6.6 and 67.2 +/- 4.2 ml/min/1.73 m2 [P < or = 0.001]) were found between traditional-dose and high-dose groups, respectively. When the data for concentrations in sera were fitted to a one-compartment pharmacokinetic model by using either the distributional or the postdistributional Cmax, statistically significant differences (P < or = 0.001) were found between Vss, half-life, CL, and Cmax values for both dosage groups. The results show that the pharmacokinetics of gentamicin at a large dose differ significantly from those at the traditional dose. This information has direct implications for once-daily aminoglycoside (ODA) literature when the Cmax values reported are distributional and therefore show falsely high Cmax/MIC ratio estimates. In addition, ODA nomogram dosing tools developed with distributional Cmax values are probably inaccurate.",1997,"With two-compartment pharmacokinetic fitting, significant differences in distribution half-life (average, 21.8 and 41.6 min [P < or = 0.05]) and gentamicin CL (76.6 +/-",['11 healthy volunteers'],"['gentamicin CL', 'gentamicin']","['Distributional and postdistributional peak concentrations', 'life, CL, and Cmax values', 'distribution half-life', 'pharmacokinetic variables: volume of distribution at steady state (Vss), half-life, clearance (CL), and maximum concentration in serum (Cmax']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0017436', 'cui_str': 'Gentamicins'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",11.0,0.0404591,"With two-compartment pharmacokinetic fitting, significant differences in distribution half-life (average, 21.8 and 41.6 min [P < or = 0.05]) and gentamicin CL (76.6 +/-","[{'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Demczar', 'Affiliation': 'Department of Pharmacy Services, Bassett Healthcare, Cooperstown, New York 13326, USA.'}, {'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Nafziger', 'Affiliation': ''}, {'ForeName': 'J S', 'Initials': 'JS', 'LastName': 'Bertino', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1254,9145877,Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers.,"The pharmacokinetics (PK) and pharmacodynamics (PD) of cefotaxime and ofloxacin and of their combination were examined in a three-period randomized crossover study involving 12 healthy adults. The PK of cefotaxime and ofloxacin were modeled. PD was assessed from the predicted concentrations in serum and serum untrafiltrate inhibitory titers for 10 test organisms. An inhibitory sigmoid Emax model based on the probability of bacterial growth was used, where Emax = 1 and EC50 is the concentration resulting in a 50% probability of growth. The total body clearance (CL(T)) and volume of distribution at steady state (V(SS)) for cefotaxime were 0.236 liters/kg/h and 0.207 liters/kg, respectively, for the monotherapy and 0.231 liters/kg/h and 0.208 liters/kg for the combination therapy. Ofloxacin exhibited PK parameters of 0.143 liters/kg/h for CL(T) and 1.20 liters/kg for V(SS) following the monotherapy and of 0.141 liters/kg/h for CL(T) and 1.16 liters/kg for V(SS) following combination therapy. For the combination therapy, an interaction term, theta, defined the type and relative extent of interaction. The range of observed theta values (-0.033 to 0.067) is consistent with an additive PD interaction according to standards similar to those used for the in vitro fractional inhibitory concentration index.",1997,Ofloxacin exhibited PK parameters of 0.143 liters/kg/h for CL(T) and 1.20 liters/kg for V(SS) following the monotherapy and of 0.141 liters/kg/h for CL(T) and 1.16 liters/kg for V(SS) following combination therapy.,['12 healthy adults'],"['Ofloxacin', 'cefotaxime and ofloxacin']","['pharmacokinetics (PK) and pharmacodynamics (PD', 'total body clearance (CL(T)) and volume of distribution at steady state (V(SS']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0028902', 'cui_str': 'Ofloxacin'}, {'cui': 'C0007554', 'cui_str': 'Cefotaxime'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}]",12.0,0.0430179,Ofloxacin exhibited PK parameters of 0.143 liters/kg/h for CL(T) and 1.20 liters/kg for V(SS) following the monotherapy and of 0.141 liters/kg/h for CL(T) and 1.16 liters/kg for V(SS) following combination therapy.,"[{'ForeName': 'D E', 'Initials': 'DE', 'LastName': 'Nix', 'Affiliation': 'Millard Fillmore Health System, School of Pharmacy, State University of New York at Buffalo, USA. nix@pharmacy.arizona.edu'}, {'ForeName': 'J H', 'Initials': 'JH', 'LastName': 'Wilton', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Hyatt', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Thomas', 'Affiliation': ''}, {'ForeName': 'L C', 'Initials': 'LC', 'LastName': 'Strenkoski-Nix', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Forrest', 'Affiliation': ''}, {'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Schentag', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1255,9145887,Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues.,"The concentrations of teicoplanin in the sera and mediastinal and heart tissues of 23 patients undergoing cardiac surgery were measured after two regimens of teicoplanin administration. Intraoperative pharmacokinetic parameters were also obtained. Patients were randomized into two groups. Those in group 1 were given teicoplanin at 6 mg x kg(-1) intravenously at the time of induction of anesthesia. Patients in group 2 were given teicoplanin at 12 mg x kg(-1) during the same period. The maximum concentration in serum (71 +/- 20 and 131 +/- 44 mg x l(-1)), the minimum concentration in serum (3.6 +/- 1.3 and 6.8 +/- 2.1 mg x l(-1)), the area under the concentration-time curve (AUC) from 0 to 12 h (108 +/- 20 and 217 +/- 38 microg x h x ml(-1)), and the AUC from 0 h to infinity (154 +/- 36 and 292 +/- 77 microg x h x ml(-1)) were twice as high after 12-mg x kg(-1) injections as after 6-mg x kg(-1) injections. No differences in mean residence time (9.7 +/- 4.9 and 8.4 +/- 2.7 h) or terminal half-life (8.5 +/- 3.8 and 7.5 +/- 2.3 h) were observed. Teicoplanin penetrated mediastinal and heart tissues but not sternal bone, where the antibiotic was detectable in only 1 of 13 patients in group 1 and 2 of 10 patients in group 2. In group 1, 7 of 13 patients had teicoplanin concentrations in tissue that were lower than the MIC for 90% of the strains of potential pathogens tested (MIC90) that cause infection after cardiac surgery. All of the patients in group 2 but one had teicoplanin concentrations in tissue (other than in sternal bone) far in excess of the MIC90 for the potential pathogens. In conclusion, the 12-mg x kg(-1) regimen of teicoplanin is followed by a significant increase in teicoplanin concentrations in heart and mediastinal tissues and should be preferred to the 6-mg x kg(-1) regimen if teicoplanin is selected for antimicrobial prophylaxis in open heart surgery.",1997,"Teicoplanin penetrated mediastinal and heart tissues but not sternal bone, where the antibiotic was detectable in only 1 of 13 patients in group 1 and 2 of 10 patients in group 2.",['23 patients undergoing cardiac surgery'],"['Teicoplanin', 'teicoplanin']","['teicoplanin concentrations in tissue', 'mean residence time', 'Intraoperative pharmacokinetic parameters', 'teicoplanin concentrations', 'maximum concentration in serum', 'area under the concentration-time curve (AUC', 'minimum concentration in serum']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}]","[{'cui': 'C0145106', 'cui_str': 'Teicoplanin'}]","[{'cui': 'C0145106', 'cui_str': 'Teicoplanin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}]",23.0,0.0399868,"Teicoplanin penetrated mediastinal and heart tissues but not sternal bone, where the antibiotic was detectable in only 1 of 13 patients in group 1 and 2 of 10 patients in group 2.","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Martin', 'Affiliation': 'Department of Anesthesia and Intensive Care, Hôpital Nord, Marseille, France.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Bourget', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Alaya', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Sertin', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Atlani', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Ennabli', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Said', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1256,9145895,Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants.,"We compared ciprofloxacin alone with ciprofloxacin plus rifampin (C + R) as a prophylactic antibacterial regimen for 40 patients with solid tumors treated with high-dose chemotherapy and autologous stem cell transplantation support. No differences were found between groups in the time elapsed to the onset of fever, incidence of febrile episodes, amphotericin B use, and length of hospital stay. However, C + R combination prophylaxis significantly reduced the incidence of gram-positive bacteremia (five versus zero episodes) but was associated with a higher incidence of drug-related side effects.",1997,"However, C + R combination prophylaxis significantly reduced the incidence of gram-positive bacteremia (five versus zero episodes) but was associated with a higher incidence of drug-related side effects.","['neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants', '40 patients with solid tumors treated with high-dose chemotherapy and autologous stem cell transplantation support']","['ciprofloxacin plus rifampin (C + R', 'ciprofloxacin-rifampin prophylaxis', 'ciprofloxacin']","['time elapsed to the onset of fever, incidence of febrile episodes, amphotericin B use, and length of hospital stay', 'incidence of gram-positive bacteremia']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C4521706', 'cui_str': 'Cytotoxic'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1518999', 'cui_str': 'Peripheral Stem Cells'}, {'cui': 'C0332835', 'cui_str': 'Grafts'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C1504389', 'cui_str': 'Stem Cell Transplantation'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}]","[{'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0035608', 'cui_str': 'rifampicin'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0332162', 'cui_str': 'Onset of (contextual qualifier) (qualifier value)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0002679', 'cui_str': 'Amphotericin B'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0744474', 'cui_str': 'Gram-positive bacteremia'}]",40.0,0.0909264,"However, C + R combination prophylaxis significantly reduced the incidence of gram-positive bacteremia (five versus zero episodes) but was associated with a higher incidence of drug-related side effects.","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Hidalgo', 'Affiliation': 'Division of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Hornedo', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Lumbreras', 'Affiliation': ''}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Trigo', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Gómez', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Perea', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ruiz', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Hitt', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Cortés-Funes', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1257,9124829,Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS.,"Four intravenous dosages of foscarnet given for 10 days were compared with no therapy in persons with AIDS who had asymptomatic cytomegalovirus (CMV) viremia. CMV viremia was quantitated by endpoint cell dilution microcultures, pp65 antigenemia assay, and measurement of CMV DNA in peripheral blood leukocytes by a quantitative-competitive PCR. Human immunodeficiency virus type 1 (HIV-1) viremia was quantitated by endpoint cell dilution microculture, serum p24 antigen assay, and PCR for HIV-1 RNA in plasma. Twenty-seven subjects who had received a median of 22 months of nucleoside antiretroviral therapy were enrolled. Twenty-two subjects received foscarnet, which was well tolerated and decreased the CMV burden, as reflected by all three indicator assays. During the 10 days of dosing, the level of CMV viremia, as measured by 50 percent tissue culture infective doses, decreased from 117.5 to 12.7 (P = 0.001), the amount of CMV DNA decreased from 20,328 copies to 622 copies per 150,000 leukocytes (P = 0.02), and the level of CMV pp65 antigenemia decreased from 14.9 to 1.6 positive peripheral blood mononuclear cells per 50,000 leukocytes (P = 0.008). A significant pharmacodynamic relationship was found between the peak foscarnet concentration and a decrease in the level of CMV antigenemia (P < 0.05). Foscarnet had no effect on quantitative HIV-1 microcultures during the 10 days of treatment, but the HIV-1 p24 antigen level in serum decreased significantly, from 454 to 305 pg/ml (P = 0.01). Also, a significant pharmacodynamic relationship was seen between plasma HIV-1 RNA concentrations and both peak foscarnet concentration (P < 0.01) and the area under the foscarnet time-concentration curve (P < 0.05). Reductions in the levels of CMV and HIV-1 viremia correlated quantitatively with systemic exposure to foscarnet, whereas control subjects actually experienced an increase in CMV and HIV-1 burdens. The dual antiviral activity of foscarnet shown in this trial encourages investigation of its use in combination with other antiretroviral therapies for persons with AIDS.",1996,"Reductions in the levels of CMV and HIV-1 viremia correlated quantitatively with systemic exposure to foscarnet, whereas control subjects actually experienced an increase in CMV and HIV-1 burdens.","['persons with AIDS who had asymptomatic cytomegalovirus (CMV) viremia', 'persons with AIDS', 'blood of persons with AIDS', 'Twenty-seven subjects who had received a median of 22 months of nucleoside antiretroviral therapy were enrolled']","['Foscarnet', 'foscarnet']","['endpoint cell dilution microculture, serum p24 antigen assay, and PCR for HIV-1 RNA in plasma', 'peak foscarnet concentration', 'CMV and HIV-1 burdens', 'CMV viremia', 'level of CMV pp65 antigenemia', 'quantities of cytomegalovirus', 'area under the foscarnet time-concentration curve', 'levels of CMV and HIV-1 viremia', 'amount of CMV DNA', 'plasma HIV-1 RNA concentrations and both peak foscarnet concentration', 'CMV burden', 'quantitative HIV-1 microcultures', 'level of CMV antigenemia', 'HIV-1 p24 antigen level in serum', 'level of CMV viremia']","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic (finding)'}, {'cui': 'C0877635', 'cui_str': 'Cytomegalovirus viremia'}, {'cui': 'C0005768'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0028621', 'cui_str': 'Nucleosides'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}]","[{'cui': 'C0070895', 'cui_str': 'Foscarnet'}]","[{'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0079240', 'cui_str': 'Dilution Technics'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0085219', 'cui_str': 'HIV Major Core Protein p24'}, {'cui': 'C0430420', 'cui_str': 'Antigen level'}, {'cui': 'C3853643', 'cui_str': 'Probe with target amplification technique (qualifier value)'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0070895', 'cui_str': 'Foscarnet'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0877635', 'cui_str': 'Cytomegalovirus viremia'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1265611', 'cui_str': 'Quantity finding'}, {'cui': 'C0010825', 'cui_str': 'Salivary Gland Viruses'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0042749', 'cui_str': 'Viremia'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C0486954', 'cui_str': 'Human immunodeficiency virus, type I protein 24 antigen'}]",27.0,0.0213519,"Reductions in the levels of CMV and HIV-1 viremia correlated quantitatively with systemic exposure to foscarnet, whereas control subjects actually experienced an increase in CMV and HIV-1 burdens.","[{'ForeName': 'H H', 'Initials': 'HH', 'LastName': 'Balfour', 'Affiliation': 'Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA. balfo001@.tc.umn.edu'}, {'ForeName': 'C V', 'Initials': 'CV', 'LastName': 'Fletcher', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Erice', 'Affiliation': ''}, {'ForeName': 'W K', 'Initials': 'WK', 'LastName': 'Henry', 'Affiliation': ''}, {'ForeName': 'E P', 'Initials': 'EP', 'LastName': 'Acosta', 'Affiliation': ''}, {'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Smith', 'Affiliation': ''}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Holm', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Boivin', 'Affiliation': ''}, {'ForeName': 'D H', 'Initials': 'DH', 'LastName': 'Shepp', 'Affiliation': ''}, {'ForeName': 'C S', 'Initials': 'CS', 'LastName': 'Crumpacker', 'Affiliation': ''}, {'ForeName': 'C A', 'Initials': 'CA', 'LastName': 'Eaton', 'Affiliation': ''}, {'ForeName': 'S S', 'Initials': 'SS', 'LastName': 'Martin-Munley', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1258,9124831,Comparative study of once-weekly azithromycin and once-daily amoxicillin treatments in prevention of recurrent acute otitis media in children.,"Continuous chemoprophylaxis is effective in the prevention of new episodes of acute otitis media (AOM) in otitis-prone children, but compliance can be a problem and thus efficacy can be decreased. Intermittent chemoprophylaxis has so far shown conflicting results. Azithromycin, which has a peculiar pharmacokinetics, resulting, even after a single dose, in persistently elevated concentrations in respiratory tissues, could permit a periodic administration with higher compliance. We compared a 6-month course of once-weekly azithromycin (5 or 10 mg/kg of body weight) with that of once-daily amoxicillin (20 mg/kg) in a single-blind, randomized study of prophylaxis for recurrent AOM in 159 children aged 6 months to 5 years with at least three episodes of AOM in the preceding 6 months. In the amoxicillin group, 23 (31.1%) of 74 children developed 29 episodes of AOM, while in the 10-mg/kg azithromycin group, 11 (14.9%) of 74 children experienced 15 episodes. The 5-mg/kg/week azithromycin trial was prematurely interrupted after nine cases, due to the high occurrence rate of AOM (55.5%). During the 6-month prophylaxis period, the proportion of children with middle ear effusion declined similarly in both groups. No substantial modification of the nasopharyngeal flora was noted at the end of prophylaxis in both antimicrobial groups. In the 6-month-postprophylaxis follow-up period, about 40% of children in both groups again developed AOM. Azithromycin at 10 mg/kg once weekly can be regarded as a valid alternative to once-daily low-dose amoxicillin for the prophylaxis of AOM. Although in the present study no microbiological drawback was noted, accurate selection of children eligible for prophylaxis is mandatory to avoid the risk of emergence of resistant strains.",1996,"Continuous chemoprophylaxis is effective in the prevention of new episodes of acute otitis media (AOM) in otitis-prone children, but compliance can be a problem and thus efficacy can be decreased.","['159 children aged 6 months to 5 years with at least three episodes of AOM in the preceding 6 months', 'recurrent acute otitis media in children', 'otitis-prone children']","['amoxicillin', 'Azithromycin', 'azithromycin', 'azithromycin and once-daily amoxicillin']","['nasopharyngeal flora', '29 episodes of AOM', 'AOM', 'proportion of children with middle ear effusion']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0395866', 'cui_str': 'Recurrent acute otitis media (disorder)'}, {'cui': 'C0029877', 'cui_str': 'Ear Inflammation'}]","[{'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}]","[{'cui': 'C0027442', 'cui_str': 'Rhinopharynx'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0029883', 'cui_str': 'Otitis Media, Secretory'}]",159.0,0.0295219,"Continuous chemoprophylaxis is effective in the prevention of new episodes of acute otitis media (AOM) in otitis-prone children, but compliance can be a problem and thus efficacy can be decreased.","[{'ForeName': 'P', 'Initials': 'P', 'LastName': 'Marchisio', 'Affiliation': 'Department of Pediatrics (4), University of Milan Medical School, Italy.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Principi', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Sala', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Lanzoni', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Sorella', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Massimini', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1259,9124832,Lymphocyte proliferative response and subset profiles during extended periods of chloroquine or primaquine prophylaxis.,"Immune suppression and disturbances of normal leukocyte populations are side effects attributed to many antimalarial drugs and were concerns during a recent year-long placebo-controlled trial that compared daily primaquine (0.5 mg of base per kg of body weight per day) with weekly chloroquine (300 mg of base one time per week) for malaria prophylaxis. The study took place in Irian Jaya, Indonesia, from July 1994 to August 1995 and enrolled 129 Javanese men with normal glucose-6-phosphate dehydrogenase function. Tests for lymphocyte function and subset composition were conducted blindly on a cross-section of subjects during weeks 10 (n = 42) and 48 (n = 72) of supervised prophylaxis. Lymphocyte function, measured as the proliferative response of peripheral blood mononuclear cells to a panel of mitogens (pokeweed mitogen, phytohemagglutinin, and concanavalin A) and antigens (purified protein derivative of Mycobacterium tuberculosis and Clostridium tetani toxoid) and expressed as a stimulation index, allowed for statistical comparison between groups and sampling times. The lymphocyte subset composition for each group and time point was based on flow cytometry profiling, and the results were expressed as the mean percentages of CD3 (total T cells), CD19 (total B cells), CD4+ (T-helper and inducer cells), and CD8+ (T suppressor and cytotoxic cells), CD3/CD16+ CD56 (natural killer cells), CD3/anti-HLA-DR (activated T cells) cells and the CD4+/CD8+ ratios. Lymphocyte stimulation indices were statistically comparable among the placebo, primaquine, and chloroquine groups at both time points, although the primaquine group was distinguished by having repeatedly greater proportions of subjects with high ( > 3.0) stimulation indices. The lymphocyte subset profiles of these groups at both time points were also similar and undistorted relative to those of healthy reference populations matched for age, sex, and ethnicity. The results provide quantitative support for the safety of daily primaquine prophylaxis.",1996,"Lymphocyte stimulation indices were statistically comparable among the placebo, primaquine, and chloroquine groups at both time points, although the primaquine group was distinguished by having repeatedly greater proportions of subjects with high ( > 3.0) stimulation indices.","['Irian Jaya, Indonesia, from July 1994 to August 1995 and enrolled 129 Javanese men with normal glucose-6-phosphate dehydrogenase function']","['primaquine', 'placebo, primaquine', 'chloroquine', 'chloroquine or primaquine prophylaxis']","['Lymphocyte function', 'lymphocyte subset composition', 'Lymphocyte proliferative response', 'Lymphocyte stimulation indices', 'mean percentages of CD3 (total T cells), CD19 (total B cells), CD4+ (T-helper and inducer cells), and CD8+ (T suppressor and cytotoxic cells), CD3/CD16+ CD56 (natural killer cells), CD3/anti-HLA-DR (activated T cells) cells and the CD4+/CD8+ ratios', 'proliferative response of peripheral blood mononuclear cells']","[{'cui': 'C0021249', 'cui_str': 'West Irian'}, {'cui': 'C0021247', 'cui_str': 'East Indies'}, {'cui': 'C0337901', 'cui_str': 'Javanese (ethnic group)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0017757', 'cui_str': 'Glucose-6-Phosphate Dehydrogenase'}, {'cui': 'C0031843', 'cui_str': 'function'}]","[{'cui': 'C0033126', 'cui_str': 'Primaquine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0008269', 'cui_str': 'Chloroquine'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}]","[{'cui': 'C4018897', 'cui_str': 'Lymphocyte component of blood'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0079720', 'cui_str': 'Lymphocyte Subpopulations'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0024262', 'cui_str': 'Lymphoblast Transformation'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0004561', 'cui_str': 'B-Cells'}, {'cui': 'C0018894', 'cui_str': 'T-Lymphocytes, Helper'}, {'cui': 'C4521706', 'cui_str': 'Cytotoxic'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0022688', 'cui_str': 'NK Cells'}, {'cui': 'C0019764', 'cui_str': 'HLA-DR'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}]",129.0,0.036251,"Lymphocyte stimulation indices were statistically comparable among the placebo, primaquine, and chloroquine groups at both time points, although the primaquine group was distinguished by having repeatedly greater proportions of subjects with high ( > 3.0) stimulation indices.","[{'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Fryauff', 'Affiliation': 'U.S. Naval Medical Research Unit No. 2, Jakarta, Irian Jaya, Indonesia. fryauff@smtp.namru2.go.id'}, {'ForeName': 'A L', 'Initials': 'AL', 'LastName': 'Richards', 'Affiliation': ''}, {'ForeName': 'J K', 'Initials': 'JK', 'LastName': 'Baird', 'Affiliation': ''}, {'ForeName': 'T L', 'Initials': 'TL', 'LastName': 'Richie', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Mouzin', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Tjitra', 'Affiliation': ''}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Sutamihardja', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Ratiwayanto', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Hadiputranto', 'Affiliation': ''}, {'ForeName': 'R P', 'Initials': 'RP', 'LastName': 'Larasati', 'Affiliation': ''}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Pudjoprawoto', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Subianto', 'Affiliation': ''}, {'ForeName': 'S L', 'Initials': 'SL', 'LastName': 'Hoffman', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1260,9124845,Comparative serum bactericidal activities of ceftizoxime and cefotaxime against intermediately penicillin-resistant Streptococcus pneumoniae.,"In a randomized crossover study involving 12 healthy volunteers, 1 g of ceftizoxime or cefotaxime was administered intravenously every 12 h for a total of three doses on two separate weekends. The duration of serum bactericidal titers (SBTs) greater than 1:2 and the time serum drug concentrations remained above the MIC (T > MIC) were determined against three clinical isolates of Streptococcus pneumoniae with intermediate resistance to penicillin. The duration of SBTs and T > MIC for both antimicrobial agents exceeded 50% of the dosing interval for all isolates. Ceftizoxime's T > MIC was statistically greater than that of cefotaxime, indicating that its longer half-life in serum (1.7 h) compared with that of cefotaxime (approximately 1 h) compensates for its slightly lower microbiologic activity against the penicillin-resistant pneumococci tested in this study.",1996,The duration of SBTs and T > MIC for both antimicrobial agents exceeded 50% of the dosing interval for all isolates.,['12 healthy volunteers'],"['ceftizoxime or cefotaxime', 'ceftizoxime and cefotaxime', 'cefotaxime', ""Ceftizoxime's T ""]","['duration of SBTs and T > MIC', 'microbiologic activity', 'MIC', 'duration of serum bactericidal titers (SBTs']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0007560', 'cui_str': 'Ceftizoxime'}, {'cui': 'C0007554', 'cui_str': 'Cefotaxime'}]","[{'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0427978', 'cui_str': 'Minimum Inhibitory Concentration'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0036782', 'cui_str': 'Schlichter Test'}]",12.0,0.0201554,The duration of SBTs and T > MIC for both antimicrobial agents exceeded 50% of the dosing interval for all isolates.,"[{'ForeName': 'K B', 'Initials': 'KB', 'LastName': 'Patel', 'Affiliation': 'Department of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, New York 11201, USA.'}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Nicolau', 'Affiliation': ''}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Nightingale', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Quintiliani', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1261,32441870,"Ripple Effects of a Community-Based Randomized Trial for Rural Women: Strong Hearts, Healthy Communities.","OBJECTIVE This study aimed to examine (1) whether the Strong Hearts, Healthy Communities intervention (SHHC) improved social network members' (SNMs') weight, exercise, and diet and (2) whether SNMs' weight and behavioral changes were modified by their relationship closeness and/or spatial closeness with trial participants. METHODS Eight towns received the SHHC intervention, which focused on building individual healthy behaviors and creating supportive social and built environments for exercise and healthy eating. Eight towns received an education-only control intervention. SNMs (n = 487) were recruited to complete a questionnaire at baseline and at 6 months that asked about demographics, weight, height, exercise, and eating habits. RESULTS SHHC's effect on SNMs differed depending on their relationship closeness with trial participants. Among SNMs who had a very close relationship with trial participants, those associated with the intervention group lost more weight and decreased BMI more than those associated with the control group (weight [kilograms] between-group difference: Δ = -1.68; 95% CI: -3.10 to -0.25; P = 0.021; BMI between-group difference: Δ = -0.60; 95% CI: -1.16 to -0.04; P = 0.034). Spatial closeness did not modify any of SHHC's ripple effects. CONCLUSIONS Relationship closeness, rather than spatial closeness, played an important role in influencing a rural community-based intervention's ripple effects.",2020,"Spatial closeness did not modify any of SHHC's ripple effects. ","['Rural Women: Strong Hearts, Healthy Communities', 'SNMs (n\xa0=\xa0487', 'Eight towns received the']","['SHHC intervention, which focused on building individual healthy behaviors and creating supportive social and built environments for exercise and healthy eating', ""Strong Hearts, Healthy Communities intervention (SHHC) improved social network members' (SNMs') weight, exercise, and diet and (2) whether SNMs' weight"", 'education-only control intervention']",['weight and decreased BMI'],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0557750', 'cui_str': 'Town environment'}]","[{'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C4505382', 'cui_str': 'Built Environment'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0231255', 'cui_str': 'Decreased body mass index'}]",487.0,0.0803002,"Spatial closeness did not modify any of SHHC's ripple effects. ","[{'ForeName': 'Brian K', 'Initials': 'BK', 'LastName': 'Lo', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, New York, USA.'}, {'ForeName': 'Meredith L', 'Initials': 'ML', 'LastName': 'Graham', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, New York, USA.'}, {'ForeName': 'Galen', 'Initials': 'G', 'LastName': 'Eldridge', 'Affiliation': 'Texas A&M AgriLife Research, Texas A&M University, College Station, Texas, USA.'}, {'ForeName': 'Maria R', 'Initials': 'MR', 'LastName': 'Donoso', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, New York, USA.'}, {'ForeName': 'Sara C', 'Initials': 'SC', 'LastName': 'Folta', 'Affiliation': 'Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Strogatz', 'Affiliation': 'Bassett Research Institute, Bassett Healthcare Network, Cooperstown, New York, USA.'}, {'ForeName': 'Miriam E', 'Initials': 'ME', 'LastName': 'Nelson', 'Affiliation': 'Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts, USA.'}, {'ForeName': 'Lynn C', 'Initials': 'LC', 'LastName': 'Paul', 'Affiliation': 'College of Education, Health and Human Development, Montana State University, Bozeman, Montana, USA.'}, {'ForeName': 'Stephen A', 'Initials': 'SA', 'LastName': 'Parry', 'Affiliation': 'Cornell Statistical Consulting Unit, Cornell University, Ithaca, New York, USA.'}, {'ForeName': 'Rebecca A', 'Initials': 'RA', 'LastName': 'Seguin-Fowler', 'Affiliation': 'Texas A&M AgriLife Research, Texas A&M University, College Station, Texas, USA.'}]","Obesity (Silver Spring, Md.)",['10.1002/oby.22817'] 1262,9087480,Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group.,"Three hundred ninety-four patients, aged 6 months to 12 years, entered a multicenter, randomized, controlled, investigator-blind study comparing cefdinir, 7 mg/kg of body weight twice a day, with cephalexin, 10 mg/kg four times a day, each given for 10 days. The most common infections treated were impetigo and secondary infection of preexisting dermatitis. The most common pathogens isolated were Staphylococcus aureus and Streptococcus pyogenes. Two hundred thirty-one patients were microbiologically evaluable. Microbiologic eradication rates were 164 of 165 pathogens (99.4%) in the cefdinir group and 152 of 156 pathogens (97.4%) in the cephalexin group (P = 0.14). Clinical cure rates were 116 of 118 patients (98.3%) in the cefdinir group and 106 of 113 patients (93.8%) in the cephalexin group (P = 0.056). Sixteen percent of cefdinir patients and 11% of cephalexin patients experienced adverse events (P = 0.11), the most common being diarrhea, which affected 8% of the cefdinir group and 4% of the cephalexin group. Cefdinir appears to be an effective and well-tolerated agent for the treatment of uncomplicated skin and skin structure infections in pediatric patients.",1997,Microbiologic eradication rates were 164 of 165 pathogens (99.4%) in the cefdinir group and 152 of 156 pathogens (97.4%) in the cephalexin group (P = 0.14).,"['pediatric patients', 'Two hundred thirty-one patients were microbiologically evaluable', 'Three hundred ninety-four patients, aged 6 months to 12 years']","['Cefdinir', 'cefdinir', 'cephalexin', 'cefdinir versus cephalexin']","['adverse events', 'Microbiologic eradication rates', 'Clinical cure rates', 'skin infections']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0450355', 'cui_str': '31 (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C3816959', 'cui_str': 'Ninety'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0060405', 'cui_str': 'cefdinir'}, {'cui': 'C0007716', 'cui_str': 'Cephalexin'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0037278', 'cui_str': 'Skin Diseases, Infectious'}]",231.0,0.0476898,Microbiologic eradication rates were 164 of 165 pathogens (99.4%) in the cefdinir group and 152 of 156 pathogens (97.4%) in the cephalexin group (P = 0.14).,"[{'ForeName': 'K J', 'Initials': 'KJ', 'LastName': 'Tack', 'Affiliation': 'Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105, USA. tackk@aa.wl.com'}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Keyserling', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'McCarty', 'Affiliation': ''}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Hedrick', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1263,9087484,Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.,"The genetic mechanisms of human immunodeficiency virus type 1 (HIV-1) resistance to dideoxyinosine (ddI) in vivo have been described based on data from primary HIV-1 isolates. To better define the spectrum of HIV-1 reverse transcriptase (RT) changes occurring during ddI therapy, we determined the genotype and ddI susceptibility of the RT gene of HIV RNA isolated from the plasma of 23 patients who had received 1 to 2 years (mean, 87 +/- 16 weeks) of ddI monotherapy. Population-based sequencing of plasma virus showed that 12 of 23 (52%) patients developed known ddI resistance mutations: L74V (7 patients), K65R (2 patients), L74V with M184V (3 patients), and L74V with K65R (1 patient). Five patients developed one or more known zidovudine resistance mutations (at codons 41, 67, 70, 215, and/or 219) during the study. Other amino acid substitutions were found, but only S68G and L210W occurred in more than one patient. Studies of sensitivity to ddI were performed on population-based recombinant-virus stocks generated by homologous recombination between a plasmid containing an HXB2 clone with the RT gene deleted and RT-PCR products of the RT genes from patients' plasma RNA. The sequences of the virus stocks produced by this procedure were typically identical to the sequence of the input PCR product from plasma RNA. Both an MT-2 cell-based culture assay and a cell-free virion-associated RT inhibition assay showed that viruses possessing an L74V and/or M184V mutation or a K65R mutation had reduced sensitivity to ddI. Viruses without these specific mutations had no change in sensitivity to ddI. The results presented here show that the spectrum of RT mutations in a population of patients on ddI monotherapy is more complex than previously described. The development of multiple mutational patterns, including those that confer resistance to other nucleoside analogs, highlights the complexity of using the currently available nucleoside analogs for antiretroviral therapy.",1997,"Population-based sequencing of plasma virus showed that 12 of 23 (52%) patients developed known ddI resistance mutations: L74V (7 patients), K65R (2 patients), L74V with M184V (3 patients), and L74V with K65R (1 patient).","['infected individuals receiving', '23 patients who had received 1 to 2 years (mean, 87 ', 'Five patients developed one or more known zidovudine resistance mutations (at codons 41, 67, 70, 215, and/or 219) during the study']","['dideoxyinosine (ddI', 'dideoxyinosine monotherapy']",['S68G and L210W'],"[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205309', 'cui_str': 'Known (qualifier value)'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C0009221', 'cui_str': 'Codon'}, {'cui': 'C4709308', 'cui_str': '215 (qualifier value)'}, {'cui': 'C4517648', 'cui_str': '219 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0012133', 'cui_str': 'Didanosine'}]",[],,0.0430044,"Population-based sequencing of plasma virus showed that 12 of 23 (52%) patients developed known ddI resistance mutations: L74V (7 patients), K65R (2 patients), L74V with M184V (3 patients), and L74V with K65R (1 patient).","[{'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Winters', 'Affiliation': 'Center for AIDS Research, Stanford University, California, USA.'}, {'ForeName': 'R W', 'Initials': 'RW', 'LastName': 'Shafer', 'Affiliation': ''}, {'ForeName': 'R A', 'Initials': 'RA', 'LastName': 'Jellinger', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Mamtora', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Gingeras', 'Affiliation': ''}, {'ForeName': 'T C', 'Initials': 'TC', 'LastName': 'Merigan', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1264,9021203,"Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.","Owing to the broad spectrum of activity afforded by beta-lactam-beta-lactamase inhibitor preparations, these agents are frequently selected as empiric therapy for the treatment of mixed infections such as intra-abdominal and diabetic foot infections, either alone or in combination with an aminoglycoside. Twelve healthy volunteers were enrolled in a randomized, open-label, four-way crossover trial comparing the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against microorganisms commonly isolated from mixed infections. Subjects received the following regimes: (i) 3.375 g of piperacillin-tazobactam intravenously (i.v.) every 6 h (q6h) (ii) 4.5 g of piperacillin-tazobactam i.v. q8h, (iii) 3.1 g of ticarcillin-clavulanate i.v. q6h, and (iv) 3.0 g of ampicillin-sulbactam i.v. q6h. Serum bactericidal titers were determined and used to calculate the duration of measurable bactericidal activity over the dosing interval of each of the regimens against two clinical isolates of Bacillus fragilis, Escherichia coli, Enterococcus faecalis, and Pseudomonas aeruginosa. The percentage of the dosing interval over which drug concentrations in serum remained above the MIC for each organism was determined and compared with the observed duration of bactericidal activity was noted (r = 0.78; P < 0.001). All of the regimens demonstrated good activity against B. fragilis and E. coli. Against E. faecalis and P. aeruginosa, however, all of the regimens provided bactericidal activity for less than 50% of the respective dosing intervals. These data suggest that use of shorter dosing intervals or continuous-infusion regimens should be considered in combination with an aminoglycoside to improve the bactericidal profiles of these agents for E. faecalis and P. aeruginosa.",1997,"Against E. faecalis and P. aeruginosa, however, all of the regimens provided bactericidal activity for less than 50% of the respective dosing intervals.",['Twelve healthy volunteers'],"['aminoglycoside', 'piperacillin-tazobactam', 'piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam', 'ampicillin-sulbactam i.v', 'piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against microorganisms commonly isolated from mixed infections']","['good activity against B. fragilis and E. coli', 'bactericidal activity', 'percentage of the dosing interval over which drug concentrations in serum', 'Serum bactericidal titers']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0002556', 'cui_str': 'Aminoglycosides'}, {'cui': 'C0250480', 'cui_str': 'Piperacillin / tazobactam'}, {'cui': 'C0040193', 'cui_str': 'Ticarcillin'}, {'cui': 'C0110038', 'cui_str': 'Clavulanate'}, {'cui': 'C2930041', 'cui_str': 'Ampicillin / Sulbactam'}, {'cui': 'C0445623', 'cui_str': 'Microorganism (organism)'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C0275524', 'cui_str': 'Co-infection'}]","[{'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0014834', 'cui_str': 'Escherichia coli'}, {'cui': 'C0544570', 'cui_str': 'Bactericidal activity (observable entity)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0036782', 'cui_str': 'Schlichter Test'}]",12.0,0.0234889,"Against E. faecalis and P. aeruginosa, however, all of the regimens provided bactericidal activity for less than 50% of the respective dosing intervals.","[{'ForeName': 'M E', 'Initials': 'ME', 'LastName': 'Klepser', 'Affiliation': 'Department of Pharmacy, Hartford Hospital, Connecticut 06102, USA. michael-klepser@uiowa.edu'}, {'ForeName': 'M N', 'Initials': 'MN', 'LastName': 'Marangos', 'Affiliation': ''}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Zhu', 'Affiliation': ''}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Nicolau', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Quintiliani', 'Affiliation': ''}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Nightingale', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1265,8968883,Detection of adeno-associated virus type 2 sequences in the human genital tract.,"Adeno-associated virus (AAV) is a defective parvovirus with unknown pathogenicity. It requires helper functions for its normal replication in human tissue and therefore is not readily isolated from clinical specimens. We have used the PCR method to examine the following clinical samples for the presence of AAV sequences: (i) 15 nasopharyngeal aspirates from symptomatic patients, (ii) 7 swab or fluid specimens from vesicles of patients suspected of having varicella-zoster virus infections, (iii) 21 human papilloma virus-positive genital biopsy specimens, (iv) 61 genital swab specimens from women suspected of having herpes simplex virus (HSV) infection examined either directly or following propagation in tissue culture, (v) 62 samples of first-trimester aborted material, including 38 samples from spontaneous abortions and 24 samples from induced abortions, (vi) 11 samples of chorionic villi taken from women undergoing genetic prenatal diagnosis, and (vii) three lots of cultured human embryonic cells. AAV sequences were detected only in samples taken from the genital tracts of women suspected of having HSV infection and not in any of the other types of samples. Samples from 11 patients were positive for AAV: for 4 patients the original swab sample was positive, for 4 patients the cultured swab sample was positive, and for 3 patients both the original swab samples and the cultures were positive. Five of the 11 patients were infected with HSV. Our study demonstrates the presence of AAV in the female genital tract. However, in contrast to a previous report (E. Tobiasch, M. Rabreau, K. Geletneky, S. Larue-Charlus, F. Severin, N. Becker, and J. R. Schlehofer, J. Med. Virol. 44:215-222, 1994), we did not find solid evidence of its replication in maternal or embryonal tissues from the first trimester of pregnancy. The questions of a potential pathogenic etiology of AAV and the interaction with HSV remain open.",1997,"Samples from 11 patients were positive for AAV: for 4 patients the original swab sample was positive, for 4 patients the cultured swab sample was positive, and for 3 patients both the original swab samples and the cultures were positive.","['15 nasopharyngeal aspirates from symptomatic patients, (ii) 7 swab or fluid specimens from vesicles of patients suspected of having varicella-zoster virus infections, (iii) 21 human papilloma virus-positive genital biopsy specimens, (iv) 61 genital swab specimens from women suspected of having herpes simplex virus (HSV) infection examined either directly or following propagation in tissue culture, (v) 62 samples of first-trimester aborted material, including 38 samples from spontaneous abortions and 24 samples from induced abortions, (vi) 11 samples of chorionic villi taken from women undergoing genetic prenatal diagnosis, and (vii) three lots of cultured human embryonic cells', 'human genital tract', 'Five of the 11 patients were infected with HSV']",[],['AAV sequences'],"[{'cui': 'C0444067', 'cui_str': 'Nasopharyngeal aspirate (specimen)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1261188', 'cui_str': 'Swab (physical object)'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C0333262', 'cui_str': 'Vesicle (morphologic abnormality)'}, {'cui': 'C0522483', 'cui_str': 'Patient suspected of (contextual qualifier) (qualifier value)'}, {'cui': 'C0586989', 'cui_str': 'Varicella Zoster Virus Infection'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0017420', 'cui_str': 'Reproductive System'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0444195', 'cui_str': 'Genital swab (specimen)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C0042769', 'cui_str': 'Viral Infections'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0040284', 'cui_str': 'Tissue culture (procedure)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0032979', 'cui_str': 'Early Placental Phase'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0000786', 'cui_str': 'Vaginal expulsion of product of conception'}, {'cui': 'C0392535', 'cui_str': 'Abortion, Induced'}, {'cui': 'C0008508', 'cui_str': 'Placental Villi'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0017399', 'cui_str': 'genetics'}, {'cui': 'C0033053', 'cui_str': 'Intrauterine Diagnosis'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0007634', 'cui_str': 'Cells'}]",[],[],11.0,0.0581544,"Samples from 11 patients were positive for AAV: for 4 patients the original swab sample was positive, for 4 patients the cultured swab sample was positive, and for 3 patients both the original swab samples and the cultures were positive.","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Friedman-Einat', 'Affiliation': 'Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Grossman', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Mileguir', 'Affiliation': ''}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Smetana', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ashkenazi', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Barkai', 'Affiliation': ''}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Varsano', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Glick', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Mendelson', 'Affiliation': ''}]",Journal of clinical microbiology,[] 1266,9056005,"Bactericidal activity of low-dose clindamycin administered at 8- and 12-hour intervals against Staphylococcus aureus, Streptococcus pneumoniae, and Bacteroides fragilis.","Twelve volunteers received 300 mg of clindamycin intravenously (i.v.) or orally (p.o.) administered every 8 h (q8h) or q12h by random assignment over four study periods. Serum bactericidal titers were determined for each regimen against two isolates each of Staphylococcus aureus, Streptococcus pneumoniae (one penicillin-sensitive isolate and one penicillin-resistant isolate), and Bacteroides fragilis. The duration of measurable bactericidal activity over the dosing interval (expressed as a percentage of the dosing interval) was determined for each isolate. No significant differences in the duration of activity were observed between i.v. and p.o. regimens dosed according to the same interval (P > 0.05). All regimens provided bactericidal activity against S. pneumoniae for 100% of their respective dosing intervals. Against B. fragilis, bactericidal activity was observed for greater than 80% of the dosing interval for each of the regimens. Although a statistically significant difference favoring the q8h i.v. regimen (P < 0.05) was detected, this difference is not believed to be clinically significant. The q8h and q12h regimens provided measurable bactericidal activity against S. aureus for greater than 85 and 50% of the dosing intervals, respectively (P < 0.001). Clindamycin dosed at 300 mg i.v. or p.o., q8h or q12h, provides adequate coverage against S. aureus, S. pneumoniae, and B. fragilis.",1997,"The q8h and q12h regimens provided measurable bactericidal activity against S. aureus for greater than 85 and 50% of the dosing intervals, respectively (P < 0.001).",[],"['clindamycin', 'Clindamycin']","['duration of activity', 'bactericidal activity', 'Bactericidal activity', 'bactericidal activity against S. pneumoniae', 'bactericidal activity against S. aureus', 'duration of measurable bactericidal activity', 'Serum bactericidal titers']",[],"[{'cui': 'C0008947', 'cui_str': 'Clindamycin'}]","[{'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0544570', 'cui_str': 'Bactericidal activity (observable entity)'}, {'cui': 'C0036782', 'cui_str': 'Schlichter Test'}]",,0.0377808,"The q8h and q12h regimens provided measurable bactericidal activity against S. aureus for greater than 85 and 50% of the dosing intervals, respectively (P < 0.001).","[{'ForeName': 'M E', 'Initials': 'ME', 'LastName': 'Klepser', 'Affiliation': 'Department of Pharmacy, Hartford Hospital, Connecticut 06102, USA. michael-klepser@uiowa.edu'}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Nicolau', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Quintiliani', 'Affiliation': ''}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Nightingale', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1267,32438041,"Corrigendum to ""Efficacy of strategies to increase participation in cervical cancer screening: GPs offering self-sampling kits for HPV testing versus recommendations to have a pap smear taken - A randomised controlled trial"" [Papillomavirus Res. 9 (2020) 100194].",,2020,"This difference remained significant after adjusting for covariates (age category, education level, time interval since last Pap smear, past Pap smear-taker). ","['cervical cancer screening', 'women who are currently not screened', 'Eighty-eight consenting women', 'Women aged 25-64 who did not have a Pap smear since three years and consulted a GP practice in a Flemish municipality between November, 2014 and April, 2015']",['vaginal self-sampling kit or control arm where women were encouraged to make an appointment for having a Pap smear taken by a clinician'],"['education level, time interval since last Pap smear, past Pap smear-taker']","[{'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C4517898', 'cui_str': '88'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0079104', 'cui_str': 'Smear cervix'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0376242', 'cui_str': 'Flemish language'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0079104', 'cui_str': 'Smear cervix'}, {'cui': 'C1515187', 'cui_str': 'Take'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0079104', 'cui_str': 'Smear cervix'}, {'cui': 'C1444637', 'cui_str': 'Past'}]",88.0,0.039767,"This difference remained significant after adjusting for covariates (age category, education level, time interval since last Pap smear, past Pap smear-taker). ","[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Peeters', 'Affiliation': 'Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Cornet', 'Affiliation': 'De Groet, General Practice, Oetingen, Gooik, Belgium.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Cammu', 'Affiliation': 'Department Uro-gynaecology, UZ Brussels, Brussels, Belgium.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Verhoeven', 'Affiliation': 'Department of Primary and Interdisciplinary Care (ELIZA), University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Devroey', 'Affiliation': 'Department of Family Medicine and Chronic Care, Vrije Universiteit Brussel, Brussels, Belgium.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Arbyn', 'Affiliation': 'Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium. Electronic address: marc.arbyn@sciensano.be.'}]","Papillomavirus research (Amsterdam, Netherlands)",['10.1016/j.pvr.2020.100201'] 1268,9009296,Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans.,"A single-dose, oral Salmonella typhi vaccine strain has been sought as a carrier or vector of cloned genes encoding protective antigens of other pathogens. Such a hybrid vaccine, administered orally, would stimulate immune responses both at the mucosal surface and in the systemic compartment and would potentially provide protection against multiple pathogens. S. typhi CVD 908 and CVD 906, which harbor deletions in aroC and aroD, were further engineered by deletion in htrA to produce strains CVD 908-htrA and CVD 906-htrA, which are unable to sustain growth and are severely impaired in their ability to survive in host tissues. These strains were fed to humans at doses of 5 x 10(7) to 5 x 10(9) CFU with buffer, and safety and immune responses were assessed. CVD 908-htrA and CVD 906-htrA were well tolerated in volunteers; mild diarrhea in 3 of 36 volunteers and mild fever in 1 volunteer were the only notable adverse responses. The vaccine strains were not detected in blood cultures and only transiently detected in stool. Serum immune responses to S. typhi lipopolysaccharide and H antigens were observed in 75 to 100% of volunteers who received 5 x 10(8) to 5 x 10(9) CFU, and cells secreting S. typhi-specific antibodies were found in all volunteers after ingestion of either strain. Sixty-three percent to 83% of volunteers developed lymphoproliferative responses to S. typhi flagellar and particulate antigens after the higher doses. These studies demonstrate the potential of CVD 908-htrA as a live vector for the delivery of heterologous genes, and a clinical trial of such a construct is planned.",1997,"Serum immune responses to S. typhi lipopolysaccharide and H antigens were observed in 75 to 100% of volunteers who received 5 x 10(8) to 5 x 10(9) CFU, and cells secreting S. typhi-specific antibodies were found in all volunteers after ingestion of either strain.",['humans'],"['oral Salmonella typhi vaccine strain', 'live oral Salmonella typhi vaccine strains']","['stool', 'diarrhea', 'mild fever', 'blood cultures', 'lymphoproliferative responses', 'Serum immune responses']","[{'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0036125', 'cui_str': 'Salmonella typhosa'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0080194', 'cui_str': 'Strains'}]","[{'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0200949', 'cui_str': 'Blood Culture Test'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0301872', 'cui_str': 'Immune response, function (observable entity)'}]",36.0,0.049764,"Serum immune responses to S. typhi lipopolysaccharide and H antigens were observed in 75 to 100% of volunteers who received 5 x 10(8) to 5 x 10(9) CFU, and cells secreting S. typhi-specific antibodies were found in all volunteers after ingestion of either strain.","[{'ForeName': 'C O', 'Initials': 'CO', 'LastName': 'Tacket', 'Affiliation': 'Department of Medicine, University of Maryland School of Medicine, Baltimore 21201, USA. ctacket@umppa1.ab.umd.edu'}, {'ForeName': 'M B', 'Initials': 'MB', 'LastName': 'Sztein', 'Affiliation': ''}, {'ForeName': 'G A', 'Initials': 'GA', 'LastName': 'Losonsky', 'Affiliation': ''}, {'ForeName': 'S S', 'Initials': 'SS', 'LastName': 'Wasserman', 'Affiliation': ''}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Nataro', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Edelman', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Pickard', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Dougan', 'Affiliation': ''}, {'ForeName': 'S N', 'Initials': 'SN', 'LastName': 'Chatfield', 'Affiliation': ''}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Levine', 'Affiliation': ''}]",Infection and immunity,[] 1269,8843283,Effects of two oral erythromycin ethylsuccinate formulations on the motility of the small intestine in human beings.,"Fourteen-membered macrolides are known to produce alterations in digestive tract motor activity; these include the induction of strong gastric contractions and a decrease in the motility of the small intestine. The aim of the study was to compare the effects of two different formulations of erythromycin ethylsuccinate (EE) on duodenojejunal motility. Compared with the more commonly used crystalline formulation of EE (CEE), the amorphous formulation (AEE) has previously been described to have greater bioavailability and to induce significantly fewer gastrointestinal side effects when given at therapeutic and what have been considered to be equivalent oral doses (i.e., CEE, 1,000 mg every 12 h; AEE, 500 mg every 12 h). In a crossover double-blind study, duodenojejunal manometric recordings were performed for 10 volunteers treated with placebo, CEE at 1,000 mg, or AEE at 500 mg. Recordings for each volunteer were obtained for a fed period after a standard dinner and then for a nocturnal fasting period. When compared with the placebo, CEE significantly decreased the motility index of the duodenum during the 30 min after the peak serum erythromycin concentrations, shortened the duration of the fed state, and had no effect during the fasting state. In contrast, AEE did not significantly modify any motility parameter. Because AEE produced significantly lower concentrations in serum than CEE, these results do not necessarily imply that the two formulations of EE act differently on the motility of the small intestine.",1996,"When compared with the placebo, CEE significantly decreased the motility index of the duodenum during the 30 min after the peak serum erythromycin concentrations, shortened the duration of the fed state, and had no effect during the fasting state.","['10 volunteers treated with', 'human beings']","['erythromycin ethylsuccinate formulations', 'placebo, CEE at 1,000 mg, or AEE', 'erythromycin ethylsuccinate (EE', 'duodenojejunal manometric recordings', 'placebo, CEE']","['duodenojejunal motility', 'motility index of the duodenum']","[{'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0014810', 'cui_str': 'Erythromycin Ethylsuccinate'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0046018', 'cui_str': 'CEES'}, {'cui': 'C0450198', 'cui_str': 'Duodenojejunal (qualifier value)'}]","[{'cui': 'C0450198', 'cui_str': 'Duodenojejunal (qualifier value)'}, {'cui': 'C1510470', 'cui_str': 'Motility (observable entity)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0013303', 'cui_str': 'Duodenum'}]",10.0,0.0452121,"When compared with the placebo, CEE significantly decreased the motility index of the duodenum during the 30 min after the peak serum erythromycin concentrations, shortened the duration of the fed state, and had no effect during the fasting state.","[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Caron', 'Affiliation': 'Groupe de Recherche sur les Anti-Microbiens, Hôpital Charles Nicolle, Rouen, France.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bouaniche', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Delatour', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Ducrotte', 'Affiliation': ''}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Torlotin', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Denis', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Humbert', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Rouveix', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1270,8980757,Comparison of dirithromycin and penicillin for treatment of streptococcal pharyngitis.,"In the treatment of group A beta-hemolytic streptococcal pharyngitis, penicillin is the drug of choice and erythromycin is the alternative. In a double-blind, randomized study, dirithromycin, a new macrolide, was compared with penicillin for the treatment of streptococcal pharyngitis. Of 121 patients who were treated with dirithromycin, 96.7% manifested a favorable clinical response, and of 136 patients treated with penicillin, 94.2% manifested a favorable clinical response. Streptococci were eradicated from the pharynges of 85.3% of 116 dirithromycin-treated patients and 82.5% of 126 penicillin-treated patients who returned for follow-up. There were no statistically significant differences in efficacy between the two groups. The incidence of abdominal symptoms was higher in dirithromycin-treated patients. Being as efficacious as penicillin and having the advantages over erythromycin of once-daily dosing and the lack of drug interactions, dirithromycin is an alternative to penicillin in the treatment of streptococcal pharyngitis for patients 12 years of age and older.",1997,Streptococci were eradicated from the pharynges of 85.3% of 116 dirithromycin-treated patients and 82.5% of 126 penicillin-treated patients who returned for follow-up.,"['streptococcal pharyngitis', '121 patients who were treated with', 'patients 12 years of age and older']","['penicillin', 'dirithromycin', 'erythromycin', 'dirithromycin and penicillin']","['efficacy', 'favorable clinical response', 'incidence of abdominal symptoms']","[{'cui': 'C0036689', 'cui_str': 'Streptococcal sore throat (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C0030842', 'cui_str': 'Antibiotics, Penicillin'}, {'cui': 'C0058445', 'cui_str': 'dirithromycin'}, {'cui': 'C0014806', 'cui_str': 'Erythromycin'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0740651', 'cui_str': 'Abdominal symptom'}]",,0.110224,Streptococci were eradicated from the pharynges of 85.3% of 116 dirithromycin-treated patients and 82.5% of 126 penicillin-treated patients who returned for follow-up.,"[{'ForeName': 'V S', 'Initials': 'VS', 'LastName': 'Watkins', 'Affiliation': 'Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Smietana', 'Affiliation': ''}, {'ForeName': 'P M', 'Initials': 'PM', 'LastName': 'Conforti', 'Affiliation': ''}, {'ForeName': 'G D', 'Initials': 'GD', 'LastName': 'Sides', 'Affiliation': ''}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Huck', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1271,8980774,Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.,"Delavirdine is a nonnucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type 1 (HIV-1) that is currently being evaluated in combination regimens with various nucleoside analogs, including didanosine. Due to the pH-dependent solubility of delavirdine, the buffering agents in didanosine formulations may reduce delavirdine absorption. To evaluate the potential interaction between these agents, 12 HIV-infected patients (mean [+/- standard deviation] CD4+ cell count, 304 +/- 213/mm3) were enrolled in a three-way crossover single-dose study. Didanosine (125 to 200 mg given as buffered tablets) and delavirdine mesylate (400 mg) pharmacokinetics were evaluated when each drug was given alone (treatments A and B, respectively), when the two drugs were given concurrently (treatment C), and when didanosine was given 1 h after delavirdine (treatment D). Delavirdine exposure was reduced by concurrent administration of didanosine. The maximum drug concentration in serum (Cmax) was reduced from 7.22 +/- 4.0 to 3.51 +/- 1.9 microM, and the area under the concentration-time curve from 0 h to infinity (AUC0-->infinity) was reduced from 22.5 +/- 14 to 14 +/- 5.7 microM.h. The extent of N-dealkylation, as indicated by the ratio of the N-dealkylated delavirdine AUC0-->infinity to the delavirdine AUC0-->infinity, was unchanged across study treatments (P = 0.708). Reductions in didanosine exposure were observed during concurrent administration with delavirdine with a Cmax reduction from 4.65 +/- 2.0 to 3.22 +/- 0.59 microM and an AUC0-->infinity reduction from 7.93 +/- 3.9 to 6.54 +/- 2.3 microM.h. Thus, concurrent administration of delavirdine and didanosine may reduce the AUC0-->infinity of both drugs, although the clinical significance of this reduction is unknown. Administration of delavirdine 1 h before didanosine avoided the interaction. Due to the single-dose nature of this study, these findings require further evaluation at steady state.",1997,"The extent of N-dealkylation, as indicated by the ratio of the N-dealkylated delavirdine AUC0-->infinity to the delavirdine AUC0-->infinity, was unchanged across study treatments (P = 0.708).","['patients with human immunodeficiency virus infection', '12 HIV-infected patients (mean ']","['delavirdine and didanosine', 'didanosine', 'Delavirdine', 'Didanosine', 'delavirdine mesylate and didanosine', 'delavirdine mesylate ', 'delavirdine']","['delavirdine absorption', 'area under the concentration-time curve', 'maximum drug concentration in serum (Cmax']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019693', 'cui_str': 'T-Lymphotropic Virus Type III Infections, Human'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]","[{'cui': 'C0288165', 'cui_str': 'Delavirdine'}, {'cui': 'C0012133', 'cui_str': 'Didanosine'}, {'cui': 'C0543492', 'cui_str': 'Delavirdine Mesylate'}]","[{'cui': 'C0288165', 'cui_str': 'Delavirdine'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",,0.0335424,"The extent of N-dealkylation, as indicated by the ratio of the N-dealkylated delavirdine AUC0-->infinity to the delavirdine AUC0-->infinity, was unchanged across study treatments (P = 0.708).","[{'ForeName': 'G D', 'Initials': 'GD', 'LastName': 'Morse', 'Affiliation': 'Department of Pharmacy Practice, State University of New York at Buffalo, USA.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Fischl', 'Affiliation': ''}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Shelton', 'Affiliation': ''}, {'ForeName': 'S R', 'Initials': 'SR', 'LastName': 'Cox', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Driver', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'DeRemer', 'Affiliation': ''}, {'ForeName': 'W W', 'Initials': 'WW', 'LastName': 'Freimuth', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1272,8975918,Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults.,"Conjugation of carbohydrate antigens to protein carriers significantly improves the immune response to many carbohydrates. In order to evaluate the potential for this approach to improve the performance of pneumococcal vaccine in the elderly, we evaluated pneumococcal polysaccharide-derived oligosaccharides conjugated to cross-reacting material 197 (CRM197) (CRM-OS) in 49 older adults over 60 years of age (median age, 66 years) and compared the results to those from 50 younger adults under age 45 (median age, 27 years). Subjects were randomly assigned to receive licensed 23-valent polysaccharide vaccine (PS) which contain 25 micrograms of polysaccharide per serotype, or 5-valent CRM-OS, which contains 10 micrograms of oligosaccharide per serotype, in double-blind fashion. Both vaccines were associated with moderate local pain on administration. Antibody responses to type 14 were seen in the majority of both younger and older subjects following administration of both CRM-OS and PS, and there was no significant improvement of responses with CRM-OS in either age group. Antibody responses in young adults to the less immunogenic type 6B were seen in only 36% of subjects receiving PS and in 56% of subjects receiving CRM-OS (P = 0.15), and the geometric mean 6B titer 1 month after vaccination was higher in CRM-OS recipients (10.9 versus 3.7 micrograms/ml; P = 0.04). However, 6B responses were poor following the administration of either vaccine to elderly adults and there was no difference between results with CRM-OS and those with PS in this age group. Relatively few subjects developed measurable mucosal immunoglobulin A responses in nasal secretions following administration of either vaccine. Revaccination of CRM-OS recipients with PS at 2 months did not result in significant additional responses to 6B or 14. Though CRM-OS is possibly more immunogenic in young adults, the formulation of the pneumococcal glycoconjugate vaccine used in this study does not appear to offer an advantage to the elderly for types 6B or 14.",1997,Relatively few subjects developed measurable mucosal immunoglobulin,"['young adults', 'young and elderly adults', '49 older adults over 60 years of age (median age, 66 years) and compared the results to those from 50 younger adults under age 45 (median age, 27 years']","['licensed 23-valent polysaccharide vaccine (PS) which contain 25 micrograms of polysaccharide per serotype, or 5-valent CRM-OS, which contains 10 micrograms of oligosaccharide', 'vaccine', 'pneumococcal polysaccharide-derived oligosaccharides conjugated to cross-reacting material 197 (CRM197) (CRM-OS', 'pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines']","['Antibody responses', 'immunogenic type 6B', 'measurable mucosal immunoglobulin', 'responses with CRM-OS', 'moderate local pain', 'geometric mean 6B titer 1 month after vaccination']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1274040', 'cui_str': 'Result'}]","[{'cui': 'C0023636', 'cui_str': 'Permits'}, {'cui': 'C0032594', 'cui_str': 'Glycans'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0439211', 'cui_str': 'microgram'}, {'cui': 'C0449550', 'cui_str': 'Serotype (UK)'}, {'cui': 'C0028959', 'cui_str': 'Oligosaccharides'}, {'cui': 'C0301869', 'cui_str': 'Conjugate'}, {'cui': 'C0056499', 'cui_str': 'cross reacting material (CRM(197)) of diphtheria toxin'}]","[{'cui': 'C0003261', 'cui_str': 'Antibody Response'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0026724', 'cui_str': 'Mucosal Tissue'}, {'cui': 'C0021027', 'cui_str': 'Immune Globulins'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]",197.0,0.0467055,Relatively few subjects developed measurable mucosal immunoglobulin,"[{'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Shelly', 'Affiliation': 'Department of Medicine, University of Rochester, New York, USA.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Jacoby', 'Affiliation': ''}, {'ForeName': 'G J', 'Initials': 'GJ', 'LastName': 'Riley', 'Affiliation': ''}, {'ForeName': 'B T', 'Initials': 'BT', 'LastName': 'Graves', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Pichichero', 'Affiliation': ''}, {'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Treanor', 'Affiliation': ''}]",Infection and immunity,[] 1273,8878569,"Gamma radiation-sterilized, triple-lumen catheters coated with a low concentration of chlorhexidine were not efficacious at preventing catheter infections in intensive care unit patients.","In a randomized, double-blind trial, gamma radiation-sterilized, chlorhexidine-coated triple-lumen catheters were compared with uncoated control catheters for their ability to prevent catheter infection in 254 intensive care unit patients. The chlorhexidine coating was not efficacious, and a rabbit model demonstrated that reduction of chlorhexidine activity by gamma radiation sterilization was the likely explanation for the failure.",1996,"The chlorhexidine coating was not efficacious, and a rabbit model demonstrated that reduction of chlorhexidine activity by gamma radiation sterilization was the likely explanation for the failure.","['intensive care unit patients', '254 intensive care unit patients']","['gamma radiation-sterilized, chlorhexidine-coated triple-lumen catheters', 'uncoated control catheters', 'Gamma radiation-sterilized, triple-lumen catheters', 'chlorhexidine']",[],"[{'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0017011', 'cui_str': 'Radiation, Gamma'}, {'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C0453946', 'cui_str': 'Coat (physical object)'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",[],,0.139979,"The chlorhexidine coating was not efficacious, and a rabbit model demonstrated that reduction of chlorhexidine activity by gamma radiation sterilization was the likely explanation for the failure.","[{'ForeName': 'R J', 'Initials': 'RJ', 'LastName': 'Sherertz', 'Affiliation': 'Section on Infectious Diseases, Bowman Gray School of Medicine, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'S O', 'Initials': 'SO', 'LastName': 'Heard', 'Affiliation': ''}, {'ForeName': 'I I', 'Initials': 'II', 'LastName': 'Raad', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Gentry', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Bowton', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Scuderi', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': ''}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Carruth', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Satishchandra', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Pepe', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Mosenthal', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Burke', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Dupuis', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1274,9003618,Molecular typing of Helicobacter pylori isolates from a multicenter U.S. clinical trial by ureC restriction fragment length polymorphism.,The molecular typing of 81 pretreatment Helicobacter pylori isolates and the comparison of 18 pretreatment-posttreatment pairs is described by restriction fragment length polymorphism (RFLP) of the ureC gene. The results of our study show the extreme genomic diversity of H. pylori and indicate that infection by H. pylori in the United States does not appear to be limited to a small number of RFLP types.,1997,The results of our study show the extreme genomic diversity of H. pylori and indicate that infection by H. pylori in the United States does not appear to be limited to a small number of RFLP types.,[],[],[],[],[],[],,0.0382125,The results of our study show the extreme genomic diversity of H. pylori and indicate that infection by H. pylori in the United States does not appear to be limited to a small number of RFLP types.,"[{'ForeName': 'V D', 'Initials': 'VD', 'LastName': 'Shortridge', 'Affiliation': 'Abbott Laboratories, Abbott Park, Illinois 60064-3500, USA. dee.shortridge@abbott.com'}, {'ForeName': 'G G', 'Initials': 'GG', 'LastName': 'Stone', 'Affiliation': ''}, {'ForeName': 'R K', 'Initials': 'RK', 'LastName': 'Flamm', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Beyer', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Versalovic', 'Affiliation': ''}, {'ForeName': 'D W', 'Initials': 'DW', 'LastName': 'Graham', 'Affiliation': ''}, {'ForeName': 'S K', 'Initials': 'SK', 'LastName': 'Tanaka', 'Affiliation': ''}]",Journal of clinical microbiology,[] 1275,8878586,Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin.,"Single-dose and steady-state pharmacokinetics of antivirally acting hypericin (H) and pseudohypericin (PH) were studied in 13 healthy volunteers by administration of St. John's Wort extract LI 160, a plantal antidepressant. Oral administration of 250, 750, and 1,500 micrograms of H and 526, 1,578, and 3,156 micrograms of PH resulted in median peak levels in plasma (Cmax) of 1.3, 7.2, and 16.6 micrograms/liter for H and 3.4, 12.1, and 29.7 micrograms/liter for PH, respectively. The Cmax and the area under the curve values for the lowest dose were disproportionally lower than those for the higher doses. A lag time of 1.9 h for H was remarkably longer than the 0.4-h lag time for PH. Median half-lives for absorption, distribution, and elimination were 0.6, 6.0, and 43.1 h after 750 micrograms of H and 1.3, 1.4, and 24.8 h after 1,578 micrograms of PH, respectively. Fourteen-day treatment with 250 micrograms of H and 526 micrograms of PH three times a day resulted in median steady-state trough levels of 7.9 micrograms/liter for H and 4.8 micrograms/liter for PH after 7 and 4 days, respectively; the corresponding Cssmax levels were 8.8 and 8.5 micrograms/liter, respectively. Kinetic parameters after intravenous administration of Hypericum extract (115 and 38 micrograms for H and PH, respectively) in two subjects corresponded to those estimated after an oral dosage. Both H and PH were initially distributed into a central volume of 4.2 and 5.0 liter, respectively. The mean distribution volumes at steady state were 19.7 liters for H and 39.3 liters for PH, and the mean total clearance rates were 9.2 ml/min for H and 43.3 ml/min for PH. The systemic availability of H and PH from LI 160 was roughly estimated to be 14 and 21%, respectively. Treatment with Hypericum extract, even in high doses, was well tolerated.",1996,The Cmax and the area under the curve values for the lowest dose were disproportionally lower than those for the higher doses.,"[""13 healthy volunteers by administration of St. John's Wort extract LI 160, a plantal antidepressant""]","['Single-dose and steady-state pharmacokinetics of antivirally acting hypericin (H) and pseudohypericin (PH', 'Hypericum extract', 'hypericin and pseudohypericin']","['median peak levels in plasma (Cmax', 'median steady-state trough levels', 'Cmax and the area under the curve values', 'Median half-lives for absorption, distribution, and elimination', 'systemic availability of H and PH', 'corresponding Cssmax levels', 'tolerated', 'mean distribution volumes at steady state', 'Kinetic parameters', 'mean total clearance rates']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0813171', 'cui_str': ""St. John's wort""}, {'cui': 'C0966327', 'cui_str': 'LI 160'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant Drugs'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0063220', 'cui_str': 'hypericin'}, {'cui': 'C0072538', 'cui_str': 'pseudohypericin'}, {'cui': 'C1706292', 'cui_str': 'Hypericum extract'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0444506', 'cui_str': 'Trough (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}]",13.0,0.0317628,The Cmax and the area under the curve values for the lowest dose were disproportionally lower than those for the higher doses.,"[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Kerb', 'Affiliation': 'Institute of Clinical Pharmacology, University Clinic Charité, Humboldt University of Berlin, Germany.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Brockmöller', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Staffeldt', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ploch', 'Affiliation': ''}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Roots', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1276,8878595,"Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients.","Fifty patients with newly diagnosed lepromatous leprosy were allocated randomly to one of five groups and treated with either a month-long standard regimen of multidrug therapy (MDT) for multibacillary leprosy, a single dose of 600 mg of rifampin, a month-long regimen with the dapsone (DDS) and clofazimine (CLO) components of the standard MDT, or a single dose of 2,000 mg of clarithromycin (CLARI) plus 200 mg of minocycline (MINO), with or without the addition of 800 mg of ofloxacin (OFLO). At the end of 1 month, clinical improvement accompanied by significant decreases of morphological indexes in skin smears was observed in about half of the patients of each group. A significant bactericidal effect was demonstrated in the great majority of patients in all five groups by inoculating the footpads of mice with organisms recovered from biopsy samples obtained before and after treatment. Rifampin proved to be a bactericidal drug against Mycobacterium leprae more potent than any combination of the other drugs. A single dose of CLARI-MINO, with or without OFLO, displayed a degree of bactericidal activity similar to that of a regimen daily of doses of DDS-CLO for 1 month, suggesting that it may be possible to replace the DDS and CLO components of the MDT with a monthly dose of CLARI-MINO, with or without OFLO. However, gastrointestinal adverse events were quite frequent among patients treated with CLARI-MINO, with or without OFLO, and may be attributed to the higher dosage of CLARI or MINO or to the combination of CLARI-MINO plus OFLO. In future trials, therefore, we propose to reduce the dosages of the drugs to 1,000 mg of CLARI, 100 mg of MINO, and 400 mg of OFLO.",1996,Rifampin proved to be a bactericidal drug against Mycobacterium leprae more potent than any combination of the other drugs.,"['Fifty patients with newly diagnosed lepromatous leprosy', 'patients']","['clarithromycin plus minocycline, with or without ofloxacin', 'multidrug therapy (MDT) for multibacillary leprosy, a single dose of 600 mg of rifampin, a month-long regimen with the dapsone (DDS) and clofazimine (CLO) components of the standard MDT, or a single dose of 2,000 mg of clarithromycin (CLARI) plus 200 mg of minocycline (MINO), with or without the addition of 800 mg of ofloxacin (OFLO', 'CLARI, 100 mg of MINO, and 400 mg of OFLO', 'Rifampin']","['bactericidal effect', 'morphological indexes in skin smears', 'Bactericidal activity', 'gastrointestinal adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0023348', 'cui_str': 'Leprosy, Lepromatous'}]","[{'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0026187', 'cui_str': 'Minocycline'}, {'cui': 'C0028902', 'cui_str': 'Ofloxacin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1562585', 'cui_str': 'Borderline Lepromatous'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0035608', 'cui_str': 'rifampicin'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0010980', 'cui_str': 'Dapsone'}, {'cui': 'C0008996', 'cui_str': 'Clofazimine'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3844106', 'cui_str': 'Eight hundred'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}]","[{'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0444186', 'cui_str': 'Smear test'}, {'cui': 'C0544570', 'cui_str': 'Bactericidal activity (observable entity)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.0421747,Rifampin proved to be a bactericidal drug against Mycobacterium leprae more potent than any combination of the other drugs.,"[{'ForeName': 'B', 'Initials': 'B', 'LastName': 'Ji', 'Affiliation': 'Faculté de Médecine Pitié-Salpêtrière, Paris, France.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Jamet', 'Affiliation': ''}, {'ForeName': 'E G', 'Initials': 'EG', 'LastName': 'Perani', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Sow', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Lienhardt', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Petinon', 'Affiliation': ''}, {'ForeName': 'J H', 'Initials': 'JH', 'LastName': 'Grosset', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1277,8878600,Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever.,"The pharmacokinetics of oral and intravenous ofloxacin (7.5 mg.kg of body weight-1 given over 30 min) were studied in an open crossover study of 17 Vietnamese children, aged between 5 and 14 years, with acute uncomplicated typhoid fever. Following oral administration, the median (95% confidence interval [CI]) time to peak concentration of ofloxacin in serum (Cmax) was 1.7 h (1.4 to 1.9 h) and the mean (95% CI) Cmax was 5.5 mg.liter-1 (4.7 to 6.3 mg.liter-1) compared with a Cmax of 8.7 mg.liter-1 (7.6 to 9.7 mg.liter-1) following the intravenous infusion. The median (95% CI) total apparent volume of distribution following the first intravenous dose, 1.35 liter.kg-1 (1.17 to 1.73 liter.kg-1), was significantly larger than that following the second dose, 0.99 liter.kg-1 (0.86 to 1.17 liter.kg-1; P < 0.0005), although the estimates for systemic clearance were similar: 0.255 liter.kg-1 h-1 (0.147 to 0.325 liter.kg-1 h-1) compared with 0.172 liter.kg-1 h-1 (0.127 to 0.292 liter.kg-1 h-1; P = 0.14). The mean residence times (95% CI) following intravenous and oral administration were similar: 5.24 h (4.84 to 6.58 h) and 6.24 h (5.32 to 7.85 h), respectively. The mean (95% CI) oral bioavailability was 91% (74 to 109%). The peak concentrations in serum were 10 to 100 times higher than the maximum MICs for ofloxacin against multidrug-resistant Salmonella typhi isolated in this area. Although the systemic clearance values were higher than those reported previously for adults, these data overall suggest that weight-or area-adjusted dose regimens for the treatment of typhoid in older children should be the same as those for adults.",1996,"The mean residence times (95% CI) following intravenous and oral administration were similar: 5.24 h (4.84 to 6.58 h) and 6.24 h (5.32 to 7.85 h), respectively.","['older children', '17 Vietnamese children, aged between 5 and 14 years, with acute uncomplicated typhoid fever', 'children with multidrug-resistant typhoid fever']","['ofloxacin', 'oral and intravenous ofloxacin']","['peak concentrations in serum', 'mean residence times', 'systemic clearance', 'systemic clearance values', 'peak concentration of ofloxacin in serum (Cmax', 'oral bioavailability']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1561452', 'cui_str': 'Vietnamese'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0041466', 'cui_str': 'Salmonella typhi Infection'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}]","[{'cui': 'C0028902', 'cui_str': 'Ofloxacin'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0028902', 'cui_str': 'Ofloxacin'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}]",17.0,0.117208,"The mean residence times (95% CI) following intravenous and oral administration were similar: 5.24 h (4.84 to 6.58 h) and 6.24 h (5.32 to 7.85 h), respectively.","[{'ForeName': 'D B', 'Initials': 'DB', 'LastName': 'Bethell', 'Affiliation': 'Centre for Tropical Diseases, Ho Chi Minh City, Vietnam.'}, {'ForeName': 'N P', 'Initials': 'NP', 'LastName': 'Day', 'Affiliation': ''}, {'ForeName': 'N M', 'Initials': 'NM', 'LastName': 'Dung', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'McMullin', 'Affiliation': ''}, {'ForeName': 'H T', 'Initials': 'HT', 'LastName': 'Loan', 'Affiliation': ''}, {'ForeName': 'D T', 'Initials': 'DT', 'LastName': 'Tam', 'Affiliation': ''}, {'ForeName': 'L T', 'Initials': 'LT', 'LastName': 'Minh', 'Affiliation': ''}, {'ForeName': 'N T', 'Initials': 'NT', 'LastName': 'Linh', 'Affiliation': ''}, {'ForeName': 'N Q', 'Initials': 'NQ', 'LastName': 'Dung', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Vinh', 'Affiliation': ''}, {'ForeName': 'A P', 'Initials': 'AP', 'LastName': 'MacGowan', 'Affiliation': ''}, {'ForeName': 'L O', 'Initials': 'LO', 'LastName': 'White', 'Affiliation': ''}, {'ForeName': 'N J', 'Initials': 'NJ', 'LastName': 'White', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1278,8913468,"Safety, toleration, and pharmacokinetics of intravenous azithromycin.","To date, the clinical pharmacology of large intravenous doses of azithromycin has not been described. In the present study, single 2-h intravenous infusions of 1, 2, and 4 g of azithromycin were administered to three parallel groups (in each group, six received active drug and two received placebo) of healthy male subjects. Toleration (assessed by scores of subject-administered visual analog scale tests spanning 0 [good] to 10 [poor]), safety, pharmacokinetics, and serum motilin levels were monitored for up to 240 h after the start of each intravenous infusion. Mean nausea scores of 0.0, 0.0, 1.0, and 0.5 and abdominal cramping scores of 0.0, 0.0, 0.4, and 0.4 for 12-h periods after doses of 0, 1, 2, and 4 g of azithromycin, respectively, suggested that azithromycin was well tolerated. Because of the standardized 1-mg/ml infusates, all subjects in the 4-g dosing group complained of an urgent need to urinate. There were no consistent trends in endogenous motilin levels throughout the study. The maximum concentration of azithromycin in serum (10 micrograms/ml after a 4-g dose) and the area under the concentration-time curve (82 micrograms.h/ml after a 4-g dose) were dose related. The mean pharmacokinetic parameters were an elimination half-life of 69 h, total systemic clearance of 10 ml/min/kg, and a volume of distribution at steady state of 33.3 liters/kg. The pharmacokinetic results suggest that the long half-life of azithromycin is due to extensive uptake and slow release of the drug from tissues rather than an inability to clear the drug. Single intravenous doses of up to 4 g of azithromycin in healthy subjects are generally well tolerated, and quantifiable concentrations may persist in serum for 10 days or more.",1996,There were no consistent trends in endogenous motilin levels throughout the study.,"['healthy subjects', 'healthy male subjects']","['placebo', 'azithromycin']","['Safety, toleration, and pharmacokinetics', 'maximum concentration of azithromycin', 'safety, pharmacokinetics, and serum motilin levels', 'Toleration', 'tolerated', 'mean pharmacokinetic parameters', 'endogenous motilin levels', 'total systemic clearance', 'Mean nausea scores']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0026594', 'cui_str': 'Motilin (substance)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205227', 'cui_str': 'Endogenous (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0549404,There were no consistent trends in endogenous motilin levels throughout the study.,"[{'ForeName': 'D R', 'Initials': 'DR', 'LastName': 'Luke', 'Affiliation': 'Pfizer Central Research, Pfizer Inc., Groton, Connecticut, USA.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Foulds', 'Affiliation': ''}, {'ForeName': 'S F', 'Initials': 'SF', 'LastName': 'Cohen', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Levy', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1279,8913472,Effects of topical erythromycin on ecology of aerobic cutaneous bacterial flora.,"We have demonstrated previously that application of topical erythromycin, an antibiotic commonly used for the treatment of acne, results in an increased density of cutaneous erythromycin-resistant (Emr) coagulase-negative staphylococci; however, it is unknown if this increase results in an overall higher density of total cutaneous staphylococci or if upon cessation of erythromycin use, Emr coagulase-negative staphylococci remain at an increased density compared with the pretreatment density. To investigate this, 2% erythromycin or vehicle was applied to each subject's forehead (n = 225) twice a day by laboratory personnel for a period of 6 weeks. Samples were obtained for culture from the forehead, anterior nares, and back of the subjects at baseline and at weeks 6, 9, and 12 of the study. Cultures were performed on differential media. Plates into which erythromycin was incorporated (8 micrograms/ml) were used to identify Emr coagulase-negative staphylococci. The species of all Emr coagulase-negative staphylococci were determined, and an antibiogram for 16 antibiotics was obtained. The baseline prevalence of Emr coagulase-negative staphylococci on the forehead and nose was about 80% at the two study sites, whereas that on the back was 50%. The baseline density of Emr coagulase-negative staphylococci on the forehead, nose, and back was approximately 20% of the total flora. Following 6 weeks of erythromycin treatment, the prevalence of Emr coagulase-negative staphylococci on the forehead and nose was nearly 100% and the densities were 73 and 62%, respectively; the prevalence and density for the back were 78 and 42%, respectively. The most prevalent erythromycin resistance gene expressed by the Emr coagulase-negative staphylococci was ermC. There was no increase in the numbers of Staphylococcus aureus, gram-negative rods, or yeasts, nor was there increased resistance to any other antibiotic except clindamycin. The density of total aerobic organisms also remained static. There were no changes in the prevalence or density of Emr coagulase-negative staphylococci in the vehicle group. A statistically significant decrease in the prevalence and density of Emr coagulase-negative staphylococci in the erythromycin group was observed within 3 weeks posttreatment and by 6 weeks posttreatment, the prevalence and density returned to baseline values. These data demonstrate that the increased prevalence and density of Emr coagulase-negative staphylococci as a result of topical 2% erythromycin use are transient on both population and individual levels.",1996,"There was no increase in the numbers of Staphylococcus aureus, gram-negative rods, or yeasts, nor was there increased resistance to any other antibiotic except clindamycin.",[],"['topical erythromycin', 'erythromycin']","['numbers of Staphylococcus aureus, gram-negative rods, or yeasts', 'prevalence and density of Emr coagulase-negative staphylococci', 'density of total aerobic organisms', 'baseline density of Emr coagulase-negative staphylococci on the forehead, nose, and back', 'ecology of aerobic cutaneous bacterial flora', 'prevalence of Emr coagulase-negative staphylococci on the forehead and nose', 'prevalence or density of Emr coagulase-negative staphylococci']",[],"[{'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0014806', 'cui_str': 'Erythromycin'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0038172', 'cui_str': 'Staphylococcus aureus'}, {'cui': 'C0314752', 'cui_str': 'Gram-negative bacillus (organism)'}, {'cui': 'C0043393', 'cui_str': 'Yeasts'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0009118', 'cui_str': 'Coagulase'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0029235', 'cui_str': 'Organism - attribute'}, {'cui': 'C0016540', 'cui_str': 'Forehead'}, {'cui': 'C0028429', 'cui_str': 'Nose'}, {'cui': 'C0013546', 'cui_str': 'Environmental Science'}, {'cui': 'C4521174', 'cui_str': 'Cutaneous'}]",225.0,0.0250362,"There was no increase in the numbers of Staphylococcus aureus, gram-negative rods, or yeasts, nor was there increased resistance to any other antibiotic except clindamycin.","[{'ForeName': 'B R', 'Initials': 'BR', 'LastName': 'Vowels', 'Affiliation': 'Department of Dermatology, School of Medicine, University of Pennsylvania, Philadelphia 19104-6142, USA.'}, {'ForeName': 'D S', 'Initials': 'DS', 'LastName': 'Feingold', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Sloughfy', 'Affiliation': ''}, {'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Foglia', 'Affiliation': ''}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Konnikov', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Ordoukhanian', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Starkey', 'Affiliation': ''}, {'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Leyden', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1280,8913487,"Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals.",Atevirdine is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV-infected patients with CD4+ cell counts of between 200 and 750 cells per mm3. Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4+ cell counts. The data do not support the use of atevirdine as a monotherapy in the treatment of HIV-infected patients.,1996,There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4+ cell counts.,"['asymptomatic antiretroviral naive HIV-infected patients with CD4+ cell counts of between 200 and 750 cells per mm3', 'asymptomatic human immunodeficiency virus-infected individuals', 'HIV-infected patients']","['atevirdine', 'Atevirdine', 'placebo']","['Safety, tolerance, and efficacy', 'viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4+ cell counts']","[{'cui': 'C0231221', 'cui_str': 'Asymptomatic (finding)'}, {'cui': 'C0599685', 'cui_str': 'Anti-Retroviral Agents'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4517868', 'cui_str': '750 (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0439243', 'cui_str': 'mm3'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0210243', 'cui_str': 'atevirdine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0085219', 'cui_str': 'HIV Major Core Protein p24'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C3853643', 'cui_str': 'Probe with target amplification technique (qualifier value)'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}]",,0.181687,There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4+ cell counts.,"[{'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Been-Tiktak', 'Affiliation': 'Department of Internal Medicine, University Hospital Utrecht, The Netherlands.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Williams', 'Affiliation': ''}, {'ForeName': 'H M', 'Initials': 'HM', 'LastName': 'Vrehen', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Richens', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Aldam', 'Affiliation': ''}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'van Loon', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Loveday', 'Affiliation': ''}, {'ForeName': 'C A', 'Initials': 'CA', 'LastName': 'Boucher', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Ward', 'Affiliation': ''}, {'ForeName': 'I V', 'Initials': 'IV', 'LastName': 'Weller', 'Affiliation': ''}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Borleffs', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1281,8926071,Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.,"The safety and immunogenicity of investigational conjugates, composed of the O-specific polysaccharides of Shigella sonnei and Shigella flexneri type 2a covalently bound to Pseudomonas aeruginosa recombinant exoprotein A (rEPA), were evaluated in 192 Israeli soldiers. None had significant local reactions or fever. Fourteen days after injection, 90% of S. sonnei-rEPA recipients and 73 to 77% of S. flexneri-rEPA recipients had a fourfold or greater increase in serum immunoglobulin G (IgG) and IgA anti-lipopolysaccharide (anti-LPS) levels; at 2 years, these remained higher than at prevaccination (P < 0.01). There was a fourfold or greater increase in IgM anti-LPS in 20% of vaccinees at 2 weeks, but levels returned to prevaccination values at 6 to 12 months. IgG was the highest and most sustained class of LPS antibodies. Reinjection at day 42 did not boost antibody levels. Eighteen of 23 (78%) who received S. sonnei-rEPA and 13 of 19 (68%) who received S. flexneri-rEPA. had significant IgA-secreting cell responses. Significant IgG antibody-secreting cell responses were detected in 19 of 23 (83%) and 11 of 19 (58%) volunteers following vaccination with S. sonnei-rEPA and S. flexneri 2a-rEPA, respectively. On the basis of these data, further evaluation of the Shigella conjugates for protective efficacy in field trials in Israel was started.",1996,"There was a fourfold or greater increase in IgM anti-LPS in 20% of vaccinees at 2 weeks, but levels returned to prevaccination values at 6 to 12 months.","['Israeli volunteers', '192 Israeli soldiers']","['recombinant exoprotein A (rEPA', 'S. sonnei-rEPA', 'investigational Shigella conjugate vaccines']","['IgM anti-LPS', 'local reactions or fever', 'Safety and immunogenicity', 'Significant IgG antibody-secreting cell responses', 'serum immunoglobulin G (IgG) and IgA anti-lipopolysaccharide (anti-LPS) levels', 'significant IgA-secreting cell responses']","[{'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C0524647', 'cui_str': 'Soldiers'}]","[{'cui': 'C0036953', 'cui_str': 'Shigella'}, {'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}]","[{'cui': 'C0020861', 'cui_str': 'IgM'}, {'cui': 'C0052060', 'cui_str': 'Limulus anti-LPS factor'}, {'cui': 'C0853813', 'cui_str': 'Local reaction'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0085820', 'cui_str': 'Antibody-Secreting Cells'}, {'cui': 'C0858459', 'cui_str': 'Serum immunoglobulin G'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0023810', 'cui_str': 'Lipoglycans'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}]",192.0,0.0373701,"There was a fourfold or greater increase in IgM anti-LPS in 20% of vaccinees at 2 weeks, but levels returned to prevaccination values at 6 to 12 months.","[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Cohen', 'Affiliation': 'Medical Corps, Israel Defence Force and Sackler School of Medicine, Tel Aviv University.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Ashkenazi', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Green', 'Affiliation': ''}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Lerman', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Slepon', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Robin', 'Affiliation': ''}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Orr', 'Affiliation': ''}, {'ForeName': 'D N', 'Initials': 'DN', 'LastName': 'Taylor', 'Affiliation': ''}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Sadoff', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Chu', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Shiloach', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Schneerson', 'Affiliation': ''}, {'ForeName': 'J B', 'Initials': 'JB', 'LastName': 'Robbins', 'Affiliation': ''}]",Infection and immunity,[] 1282,8945569,Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain.,"An attenuated strain of Salmonella typhi delta(cya) delta(crp-cdt) delta(asd) expressing a gene encoding a hepatitis B virus core-pre-S protein was tested in female adult volunteers for its ability to elicit a systemic and a mucosal immune response. Specifically, our purpose was to evaluate the potential of such a vaccine strain to induce specific secretory immunoglobulin A (sIgA) at genital and rectal surfaces. Oral and rectal routes of immunization were compared: oral immunization induced seroconversion against the bacterial lipopolysaccharide (LPS) in six out of seven volunteers, while after rectal immunization only one out of six volunteers seroconverted against LPS. To our disappointment, the latter volunteer was also the only one who seroconverted against the carried antigen (pre-S1), demonstrating the poor ability of this live vaccine to induce an immune response against the carried antigen. Anti-LPS sIgA was found in both the vaginal and cervical secretions of a volunteer who presented a strong seroconversion after oral immunization (16-fold increase in anti-LPS IgG). Smaller amounts of anti-LPS sIgA were found in the rectal secretions of one orally and one rectally immunized volunteer and in the saliva of three orally and one rectally immunized woman. Our data show for the first time that it is possible to induce specific sIgA in the genital and rectal tracts of women by using an S. typhi vaccine strain.",1996,Smaller amounts of anti-LPS sIgA were found in the rectal secretions of one orally and one rectally immunized volunteer and in the saliva of three orally and one rectally immunized woman.,"['adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain', 'female adult volunteers']",[],[],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0332161', 'cui_str': 'Attenuated by (contextual qualifier) (qualifier value)'}, {'cui': 'C0036125', 'cui_str': 'Salmonella typhosa'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0080194', 'cui_str': 'Strains'}]",[],[],7.0,0.0218573,Smaller amounts of anti-LPS sIgA were found in the rectal secretions of one orally and one rectally immunized volunteer and in the saliva of three orally and one rectally immunized woman.,"[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Nardelli-Haefliger', 'Affiliation': 'Department of Gynecology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. DNARDELL@ulrec1.unil.ch'}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Kraehenbuhl', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Curtiss', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Schodel', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Potts', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Kelly', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'De Grandi', 'Affiliation': ''}]",Infection and immunity,[] 1283,8843294,"Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.","Data were gathered during an activity-controlled trial in which seriously ill, elderly patients were randomized to receive intravenous ceftazidime or ciprofloxacin and for which adaptive feedback control of drug concentrations in plasma and activity profiles was prospectively performed. The adaptive feedback control algorithm for ceftazidime used an initial population model, a maximum a posteriori (MAP)-Bayesian pharmacokinetic parameter value estimator, and an optimal, sparse sampling strategy for ceftazidime that had been derived from data in the literature obtained from volunteers. Iterative two-stage population pharmacokinetic analysis was performed to develop an unbiased MAP-Bayesian estimator and updated optimal, sparse sampling strategies. The final median values of the population parameters were follows: the volume of distribution of the central compartment was equal to 0.249 liter/kg, the volume of distribution of the peripheral compartment was equal to 0.173 liter/kg, the distributional clearance between the central and peripheral compartments was equal to 0.2251 liter/h/kg, the slope of the total clearance (CL) versus the creatinine clearance (CLCR) was equal to 0.000736 liter/h/kg of CL/1 ml/min/1.73 m2 of CLCR, and nonrenal clearance was equal to + 0.00527 liter/h/kg. Optimal sampling times were dependent on CLCR; for CLCR of > or = 30 ml/min/1.73 m2, the optimal sampling times were 0.583, 3.0, 7.0, and 16.0 h and, for CLCR of < 30 ml/min/1.73 m2, optimal sampling times were 0.583, 4.15, 11.5, and 24.0 h. The study demonstrates that because pharmacokinetic information from volunteers may often not be reflective of specialty populations such as critically ill elderly individuals, iterative two-stage population pharmacokinetic analysis, MAP-Bayesian parameter estimation, and optimal, sparse sampling strategy can be important tools in characterizing their pharmacokinetics.",1996,"Optimal sampling times were dependent on CLCR; for CLCR of > or = 30 ml/min/1.73 m2, the optimal sampling times were 0.583, 3.0, 7.0, and 16.0 h and, for CLCR of < 30 ml/min/1.73 m2, optimal sampling times were 0.583, 4.15, 11.5, and 24.0 h.",['elderly patients'],"['ceftazidime or ciprofloxacin', 'ceftazidime']","['total clearance (CL) versus the creatinine clearance (CLCR', 'volume of distribution of the central compartment', 'nonrenal clearance']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0007559', 'cui_str': 'Ceftazidime'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine (procedure)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]",,0.0416021,"Optimal sampling times were dependent on CLCR; for CLCR of > or = 30 ml/min/1.73 m2, the optimal sampling times were 0.583, 3.0, 7.0, and 16.0 h and, for CLCR of < 30 ml/min/1.73 m2, optimal sampling times were 0.583, 4.15, 11.5, and 24.0 h.","[{'ForeName': 'A D', 'Initials': 'AD', 'LastName': 'Kashuba', 'Affiliation': 'Center for Clinical Pharmacy Research, School of Pharmacy, State University of New York at Buffalo 14260, USA.'}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Ballow', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Forrest', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1284,8834888,Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations.,"The efficacy and safety of rufloxacin (400 mg, single dose) were compared to those of norfloxacin (400 mg twice a day for 3 days) for the treatment of women with uncomplicated cystitis. In addition, urine levels, drug level/MIC ratio, and urine antibacterial activity 72 to 84 h after treatment initiation were determined in a subgroup of patients for pharmacodynamic assessment. A total of 203 women were included and treated in this open, randomized clinical trial; 100 patients received norfloxacin, whereas 103 received rufloxacin. Of these, 156 (74 and 82 patients in the norfloxacin and rufloxacin groups, respectively) were considered bacteriologically evaluable. At the first follow-up visits (3 to 12 days after starting the treatment), bacteriological cure rates were 99 and 94% for norfloxacin and rufloxacin, respectively. Seventy-nine percent (119 of 150) of bacteriologically cured patients attended a long-term follow-up visit (4 to 6 weeks after starting the treatment), where a relapse rate of 4% (2 of 54) and 5% (3 of 64) were found in the norfloxacin and rufloxacin groups, respectively. The pharmacodynamic evaluation performed in 35 patients showed similar median urine levels (approximately equal to 25 micrograms/ml) and urine antibacterial activity for both treatment groups against initial isolates, despite a higher norfloxacin level/MIC ratio due to the lower MIC of norfloxacin. Twenty-one patients (20%) in the rufloxacin group and 12 patients (12%) in the norfloxacin group reported 39 and 16 adverse events, respectively, almost all of them being mild and lasting < 24 h. Overall, gastrointestinal reactions were the most frequent adverse events reported. However, 12 patients treated with rufloxacin reported 15 central nervous system adverse events. This study shows that single doses of rufloxacin are as effective as a norfloxacin 3-day standard treatment in uncomplicated cystitis. The results obtained with rufloxacin are consistent with its pharmacodynamic properties.",1996,"The pharmacodynamic evaluation performed in 35 patients showed similar median urine levels (approximately equal to 25 micrograms/ml) and urine antibacterial activity for both treatment groups against initial isolates, despite a higher norfloxacin level/MIC ratio due to the lower MIC of norfloxacin.","['women with uncomplicated cystitis', 'uncomplicated cystitis', 'A total of 203 women', '35 patients', '12 patients treated with']","['norfloxacin and rufloxacin', 'norfloxacin', 'rufloxacin']","['relapse rate', 'Overall, gastrointestinal reactions', '15 central nervous system adverse events', 'efficacy and safety', 'urine levels, drug level/MIC ratio, and urine antibacterial activity', 'bacteriological cure rates', 'norfloxacin level/MIC ratio', 'median urine levels', 'urine antibacterial activity']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0010692', 'cui_str': 'Cystitis'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0028365', 'cui_str': 'Norfloxacin'}, {'cui': 'C0073704', 'cui_str': 'rufloxacin'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0042037'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0428212', 'cui_str': 'Finding of drug level (finding)'}, {'cui': 'C0427978', 'cui_str': 'Minimum Inhibitory Concentration'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0279516', 'cui_str': 'Anti-Bacterial Agents'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0205465', 'cui_str': 'Bacteriologic (qualifier value)'}, {'cui': 'C0028365', 'cui_str': 'Norfloxacin'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",203.0,0.0540856,"The pharmacodynamic evaluation performed in 35 patients showed similar median urine levels (approximately equal to 25 micrograms/ml) and urine antibacterial activity for both treatment groups against initial isolates, despite a higher norfloxacin level/MIC ratio due to the lower MIC of norfloxacin.","[{'ForeName': 'G', 'Initials': 'G', 'LastName': 'Del Río', 'Affiliation': 'Nephrology Department, Fundación Puigvert, Barcelona, Spain.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Dalet', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Aguilar', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Caffaratti', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Dal-Ré', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1285,8834905,"Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents.","The pharmacokinetics and tolerability of 1-g doses of ceftriaxone diluted in sterile water, 1% lidocaine, or buffered lidocaine were investigated. No difference in bioequivalence was noted between the three treatments. No difference in peak creatine kinase values was seen. By use of a quantitative pain scale, injection of ceftriaxone with the water diluent was significantly more painful than that with either of the other two diluents. No difference in injection pain was noted for lidocaine or buffered lidocaine.",1996,No difference in injection pain was noted for lidocaine or buffered lidocaine.,[],"['ceftriaxone injections', 'lidocaine, or buffered lidocaine', 'lidocaine', 'lidocaine, buffered lidocaine, and sterile water diluents', 'ceftriaxone']","['peak creatine kinase values', 'bioequivalence', 'injection pain', 'pharmacokinetics and tolerability']",[],"[{'cui': 'C4050974', 'cui_str': 'Ceftriaxone Injection'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0006353', 'cui_str': 'Buffers'}, {'cui': 'C0359299', 'cui_str': 'sterile water'}, {'cui': 'C0007561', 'cui_str': 'Ceftriaxone'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0201973', 'cui_str': 'Creatine kinase measurement (procedure)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0039789', 'cui_str': 'Generic Equivalency'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}]",,0.0268355,No difference in injection pain was noted for lidocaine or buffered lidocaine.,"[{'ForeName': 'C J', 'Initials': 'CJ', 'LastName': 'Hayward', 'Affiliation': 'Department of Pharmacy Services, Bassett Healthcare, Cooperstown, New York 13326, USA.'}, {'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Nafziger', 'Affiliation': ''}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Kohlhepp', 'Affiliation': ''}, {'ForeName': 'J S', 'Initials': 'JS', 'LastName': 'Bertino', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1286,8843295,Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers.,"Rifampin and rifabutin induce the metabolism of many drugs, which may result in subtherapeutic concentrations and failure of therapy. However, differences between rifabutin and rifampin in potency of induction, and the specific enzymes which are altered, are not clear. This study, involving 12 adult male volunteers, compared the effects of 14-day courses of rifampin and rifabutin on clearance of theophylline, a substrate for the hepatic microsomal enzyme CYP1A2. Subjects were given oral theophylline solution (5 mg/kg of body weight) on day 1 and then randomized to receive daily rifampin (300 mg) or rifabutin (300 mg) on days 3 to 16. Theophylline was readministered as described above on day 15. The first treatment sequence was followed by a 2-week washout period; subjects then received the alternative treatment. Theophylline concentrations were determined for 46 h after each dose, and pharmacokinetic parameters were determined. One subject developed flu-like symptoms while taking rifabutin and withdrew voluntarily. Results from the remaining 11 subjects are reported. Compared with the baseline, the mean area under the concentration-time curve (AUC) (+/- standard deviation) for theophylline declined significantly following rifampin treatment (from 140 +/- 37 to 100 +/- 24 micrograms . h/ml, P <0.001); there was no significant change following rifabutin treatment (136 +/- 48 to 128 +/- 45 micrograms.h/ml). Baseline theophylline AUCs before each treatment phase were not different. A comparison of equal doses of rifampin and rifabutin administered to healthy volunteers for 2 weeks indicates that induction of CYP1A2, as measured by theophylline clearance, is significantly less following rifabutin treatment than it is following rifampin treatment. However, the relative induction potency for other metabolic enzymes remains to be investigated.",1996,Baseline theophylline AUCs before each treatment phase were not different.,"['12 adult male volunteers', 'healthy volunteers', 'healthy male volunteers', '48 to 128 ']","['daily rifampin', 'rifabutin and rifampin', 'oral theophylline solution', 'theophylline', 'Theophylline', 'rifampin', 'rifabutin', 'rifampin and rifabutin', 'theophylline clearance by rifampin and rifabutin', 'Rifampin and rifabutin']","['mean area under the concentration-time curve (AUC', 'Theophylline concentrations']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0035608', 'cui_str': 'rifampicin'}, {'cui': 'C0140575', 'cui_str': 'Rifabutin'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0039771', 'cui_str': 'Theophylline'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0039771', 'cui_str': 'Theophylline'}]",12.0,0.0507316,Baseline theophylline AUCs before each treatment phase were not different.,"[{'ForeName': 'J G', 'Initials': 'JG', 'LastName': 'Gillum', 'Affiliation': 'Department of Pharmacy and Pharmaceutics, School of Pharmacy, Virginia Commonwealth University/Medical College of Virginia, Richmond 23298-0533, USA.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Sesler', 'Affiliation': ''}, {'ForeName': 'V L', 'Initials': 'VL', 'LastName': 'Bruzzese', 'Affiliation': ''}, {'ForeName': 'D S', 'Initials': 'DS', 'LastName': 'Israel', 'Affiliation': ''}, {'ForeName': 'R E', 'Initials': 'RE', 'LastName': 'Polk', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1287,8851579,Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.,"The pharmacokinetics of amphotericin B administered in a conventional 5% dextrose (glucose) (5% D) solution and in a 20% fat emulsion formulation (Intralipid; 20% IL) were compared in 16 patients (mean age, 42 years [range, 18 to 70 years]) who had been hospitalized for hematological malignancies and with proven or suspected fungal infections. All of the patients received 50 mg (approximately 1 mg/kg of body weight per day) of amphotericin B daily in random order, either as a 50-ml lipid emulsion (20% IL) (group I) or in 500 ml of 5% D (group II). Five serum samples were taken during the 24 h after drug administration, and the levels of amphotericin B were measured by high-pressure liquid chromatography. Serum amphotericin B concentrations declined rapidly during the first 6 h, and subsequent measurements revealed a slow terminal elimination phase in both groups. The maximum serum amphotericin B concentration was significantly lower when the drug was administered in 20% IL (1.46 +/- 0.61 versus 2.83 +/- 1.17 micrograms/ml; P = 0.02). The area under the concentration-time curve from 0 to 24 h was also much lower in group I (17.22 +/- 11.15 versus 28.98 +/- 15.46 micrograms.h/ml). The half-life of the distribution phase was approximately three times longer in group I (2.92 +/- 2.34 h versus 0.64 +/- 0.24 h; P = 0.011). Conversely, the half-lives of the elimination phase were approximately equal in the two groups (11.44 +/- 5.18 versus 15.23 +/- 5.25 h). The mean residence times were also similar in both groups (19.41 +/- 11.13 versus 19.65 +/- 7.86 h). The clearance and the steady-state volume of distribution of amphotericin B in group I were about twice as great as those in group II (62.97 +/- 35.51 versus 33.01 +/- 14.33 ml/kg/h and 1,043.92 +/- 512.10 versus 562.32 +/- 152.05 ml/kg [P = 0.034], respectively). Finally, the volume of distribution in the central compartment was greater in group I than in group II (618.17 +/- 231.80 versus 328.19 +/- 151.71 ml/kg; P = 0.013), but there were no differences in the volume of distribution in the peripheral compartment (425.75 +/- 352.87 versus 234.14 +/- 75.92 ml/kg). These results suggest that amphotericin B has a different pharmacokinetic profile when it is administered in 20% IL than when it is administered in the standard 5% D form and that the main difference is due to a clear-cut difference in the steady-state volume of distribution, especially that in the central compartment.",1996,The clearance and the steady-state volume of distribution of amphotericin B in group I were about twice as great as those in group II (62.97 +/-,"['patients with neutropenia', '16 patients (mean age, 42 years [range, 18 to 70 years]) who had been hospitalized for hematological malignancies and with proven or suspected fungal infections']","['amphotericin B daily in random order, either as a 50-ml lipid emulsion', 'amphotericin B', 'amphotericin B administered in a conventional 5% dextrose (glucose) (5% D) solution and in a 20% fat emulsion formulation (Intralipid', 'conventional formulation versus fat emulsion formulation of amphotericin B']","['concentration-time curve', 'levels of amphotericin B', 'mean residence times', 'Serum amphotericin B concentrations', 'maximum serum amphotericin B concentration', 'volume of distribution in the central compartment']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0376545', 'cui_str': 'Hematological Neoplasms'}, {'cui': 'C0456369', 'cui_str': 'Proven (qualifier value)'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C0026946', 'cui_str': 'Fungal Infections'}]","[{'cui': 'C0002679', 'cui_str': 'Amphotericin B'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0014020', 'cui_str': 'Emulsions'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0017725', 'cui_str': 'dextrose'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0304483', 'cui_str': 'Fat emulsion (substance)'}, {'cui': 'C0733854', 'cui_str': 'Intralipid'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0002679', 'cui_str': 'Amphotericin B'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]",,0.0391528,The clearance and the steady-state volume of distribution of amphotericin B in group I were about twice as great as those in group II (62.97 +/-,"[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ayestarán', 'Affiliation': ""Servicio de Farmacia, Hospital Vall d'Hebron, Barcelona, Spain.""}, {'ForeName': 'R M', 'Initials': 'RM', 'LastName': 'López', 'Affiliation': ''}, {'ForeName': 'J B', 'Initials': 'JB', 'LastName': 'Montoro', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Estíbalez', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Pou', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Julià', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'López', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Pascual', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1288,8851613,Penetration of ciprofloxacin and fleroxacin into biliary tract.,"Forty patients with chronic cholecystitis or cholelithiasis were prospectively randomized for therapy with either ciprofloxacin or fleroxacin to study the penetration of these two agents into gallbladder tissue, plasma, and bile. Patients received a 3-day course of ciprofloxacin (500 mg twice a day) or fleroxacin (400 mg once daily) and were subdivided into four groups reflecting intraoperative sample collection at 4, 7, 14, and 25 to 26 h following the last quinolone dose. Mean concentrations in plasma for ciprofloxacin and fleroxacin at 4 and 25 to 26 h postdose were 2.5 and 10 micrograms/ml and 0.3 and 1.8 micrograms/ml, respectively. The concentrations of ciprofloxacin and fleroxacin in bile and gallbladder wall tissue at 25 to 26 h postdose were 4.5 and 8.6 micrograms/ml and 1.2 and 4.4 micrograms/ml, respectively. Both agents demonstrate rapid tissue penetration with persistence at levels appropriate for treatment of biliary pathogens.",1996,"Forty patients with chronic cholecystitis or cholelithiasis were prospectively randomized for therapy with either ciprofloxacin or fleroxacin to study the penetration of these two agents into gallbladder tissue, plasma, and bile.",['Forty patients with chronic cholecystitis or cholelithiasis'],"['ciprofloxacin or fleroxacin', 'ciprofloxacin and fleroxacin', 'fleroxacin', 'ciprofloxacin']","['concentrations of ciprofloxacin and fleroxacin in bile and gallbladder wall tissue', 'Mean concentrations in plasma for ciprofloxacin and fleroxacin']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0085694', 'cui_str': 'Chronic cholecystitis (disorder)'}, {'cui': 'C0008350', 'cui_str': 'Cholelithiasis'}]","[{'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0085161', 'cui_str': 'Fleroxacin'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0085161', 'cui_str': 'Fleroxacin'}, {'cui': 'C0005388', 'cui_str': 'Bile'}, {'cui': 'C0016976', 'cui_str': 'Gallbladder'}, {'cui': 'C0205380', 'cui_str': 'Walled (qualifier value)'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}]",,0.031371,"Forty patients with chronic cholecystitis or cholelithiasis were prospectively randomized for therapy with either ciprofloxacin or fleroxacin to study the penetration of these two agents into gallbladder tissue, plasma, and bile.","[{'ForeName': 'C E', 'Initials': 'CE', 'LastName': 'Edmiston', 'Affiliation': 'Department of Surgery, Medical College of Wisconsin, Milwaukee 53226, USA. edmiston@post.its.mcw.edu'}, {'ForeName': 'E C', 'Initials': 'EC', 'LastName': 'Suarez', 'Affiliation': ''}, {'ForeName': 'A P', 'Initials': 'AP', 'LastName': 'Walker', 'Affiliation': ''}, {'ForeName': 'M P', 'Initials': 'MP', 'LastName': 'Demeure', 'Affiliation': ''}, {'ForeName': 'C T', 'Initials': 'CT', 'LastName': 'Frantzides', 'Affiliation': ''}, {'ForeName': 'W J', 'Initials': 'WJ', 'LastName': 'Schulte', 'Affiliation': ''}, {'ForeName': 'S D', 'Initials': 'SD', 'LastName': 'Wilson', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1289,8891147,Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin.,"The bronchopulmonary and plasma pharmacokinetics of clarithromycin (CLA; 500 mg given twice daily for nine doses) or azithromycin (AZ; 500 mg for the first dose and then 250 mg once daily for four doses) were assessed in 41 healthy nonsmokers. Bronchoalveolar lavage was performed at 4, 8, 12, or 24 h after administration of the last dose. The concentrations (mean +/- standard deviation) of CLA, 14-hydroxyclarithromycin, and AZ were measured in plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) cells by high-performance liquid chromatography assay. The concentrations of CLA achieved in ELF were 34.02 +/- 5.16 micrograms/ml at 4 h, 20.63 +/- 4.49 micrograms/ml at 8 h, 23.01 +/- 11.9 micrograms/ml at 12 h, and 4.17 +/- 0.29 microgram/ml at 24 h, whereas at the same time points AZ concentrations remained below the limit of assay sensitivity (0.01 microgram/ml) for all but two subjects. The concentrations of CLA in the AM cells were significantly higher than those of AZ at 8 h (703 +/- 235 and 388 +/- 53 micrograms/ml, respectively). However, the ratio of the concentration in AM cells/concentration in plasma was significantly higher for AZ than for CLA for all time points because of the lower concentration of AZ in plasma. These results indicate that while AZ has higher tissue concentration to plasma ratios, as shown by other investigators, the absolute concentrations of CLA in AM cells and ELF are higher for up to 8 and 12 h, respectively, after administration of the last dose.",1996,whereas at the same time points AZ concentrations remained below the limit of assay sensitivity (0.01 microgram/ml) for all but two subjects.,"['41 healthy nonsmokers', '235 and 388 ']","['AZ', 'clarithromycin (CLA', 'CLA', 'clarithromycin and azithromycin', 'azithromycin (AZ']","['Bronchoalveolar lavage', 'CLA, 14-hydroxyclarithromycin, and AZ were measured in plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) cells', 'concentrations of CLA in the AM cells', 'concentrations of CLA achieved in ELF', 'ratio of the concentration in AM cells/concentration in plasma']","[{'cui': 'C4554605', 'cui_str': 'Nonsmokers'}]","[{'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}]","[{'cui': 'C1535502', 'cui_str': 'Lung Lavage'}, {'cui': 'C0090409', 'cui_str': 'Erythromycin, 14-hydroxy-6-O-methyl-'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C0085236', 'cui_str': 'Pulmonary Macrophages'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",41.0,0.0326898,whereas at the same time points AZ concentrations remained below the limit of assay sensitivity (0.01 microgram/ml) for all but two subjects.,"[{'ForeName': 'K B', 'Initials': 'KB', 'LastName': 'Patel', 'Affiliation': 'Department of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, New York 11201, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Xuan', 'Affiliation': ''}, {'ForeName': 'P R', 'Initials': 'PR', 'LastName': 'Tessier', 'Affiliation': ''}, {'ForeName': 'J H', 'Initials': 'JH', 'LastName': 'Russomanno', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Quintiliani', 'Affiliation': ''}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Nightingale', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1290,8851594,Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.,"The pharmacodynamics and pharmacokinetics of ceftazidime administered by continuous infusion and intermittent bolus over a 4-day period were compared. We conducted a prospective, randomized, crossover study of 12 critically ill patients with suspected gram-negative infections. The patients were randomized to receive ceftazidime either as a 2-g intravenous (i.v.) loading dose followed by a 3-g continuous infusion (CI) over 24 h or as 2 g i.v. every 8 h (q8h), each for 2 days. After 2 days, the patients were crossed over and received the opposite regimen. Each regimen also included tobramycin (4 to 7 mg/kg of body weight, given i.v. q24h). Eighteen blood samples were drawn on study days 2 and 4 to evaluate the pharmacokinetics of ceftazidime and its pharmacodynamics against a clinical isolate of Pseudomonas aeruginosa (R288). The patient demographics (means +/- standard deviations) were as follows: age, 57 +/- 12 years; sex, nine males and three females; APACHE II score, 15 +/- 3; diagnosis, 9 of 12 patients with pneumonia. The mean pharmacokinetic parameters for ceftazidime given as an intermittent bolus (IB) (means +/- standard deviations) were as follows: maximum concentration of drug in serum, 124.4 +/- 52.6 micrograms/ml; minimum concentration in serum, 25.0 +/- 17.5 micrograms/ml; elimination constant, 0.268 +/- 0.205 h-1; half-life, 3.48 +/- 1.61 h; and volume of distribution, 18.9 +/- 9.0 liters. The steady-state ceftazidime concentration for CI was 29.7 +/- 17.4 micrograms/ml, which was not significantly different from the targeted concentrations. The range of mean steady-state ceftazidime concentrations for the 12 patients was 10.6 to 62.4 micrograms/ml. Tobramycin peak concentrations ranged between 7 and 20 micrograms/ml. As expected, the area under the curve for the 2-g q8h regimen was larger than that for CI (P = 0.003). For IB and CI, the times that the serum drug concentration was greater than the MIC were 92 and 100%, respectively, for each regimen against the P. aeruginosa clinical isolate. The 24-h bactericidal titers in serum, at which the tobramycin concentrations were < 1.0 microgram/ml in all patients, were the same for CI and IB (1:4). In the presence of tobramycin, the area under the bactericidal titer-time curve (AUBC) was significantly greater for IB than CI (P = 0.001). After tobramycin was removed from the serum, no significant difference existed between the AUBCs for CI and IB. We conclude that CI of ceftazidime utilizing one-half the IB daily dose was equivalent to the IB treatment as judged by pharmacodynamic analysis of critically ill patients with suspected gram-negative infections. No evaluation comparing the clinical efficacies of these two dosage regimens was performed.",1996,"After tobramycin was removed from the serum, no significant difference existed between the AUBCs for CI and IB.","['12 patients with pneumonia', 'critically ill patients with suspected gram-negative infections', '12 critically ill patients with suspected gram-negative infections', '12 years; sex, nine males and three females; APACHE II score, 15 ']","['ceftazidime', 'tobramycin']","['maximum concentration of drug in serum, 124.4 ', 'mean pharmacokinetic parameters', '24-h bactericidal titers', 'Tobramycin peak concentrations', 'bactericidal titer-time curve (AUBC', 'serum drug concentration', 'range of mean steady-state ceftazidime concentrations', 'steady-state ceftazidime concentration']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0010340', 'cui_str': 'Critically Ill'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C0439208', 'cui_str': 'gram (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0489438', 'cui_str': 'APACHE II score'}]","[{'cui': 'C0007559', 'cui_str': 'Ceftazidime'}, {'cui': 'C0040341', 'cui_str': 'Tobramycin'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0040341', 'cui_str': 'Tobramycin'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0007559', 'cui_str': 'Ceftazidime'}]",12.0,0.0415763,"After tobramycin was removed from the serum, no significant difference existed between the AUBCs for CI and IB.","[{'ForeName': 'A S', 'Initials': 'AS', 'LastName': 'Benko', 'Affiliation': 'Department of Pharmacy Services, Detroit Receiving Hospital, Michigan 48201,'}, {'ForeName': 'D M', 'Initials': 'DM', 'LastName': 'Cappelletty', 'Affiliation': ''}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Kruse', 'Affiliation': ''}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Rybak', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1291,8851595,Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.,"Ten patients were treated with conventional dosing (CD) and continuous-infusion (CI) vancomycin therapy in this prospective, randomized, crossover study. Patients were randomized to receive either CD or CI therapy for 2 consecutive days and then crossed over to receive the opposite regimen for 2 days. CD therapy consisted of 1 g of vancomycin every 12 h. CI therapy consisted of a 500-mg loading dose followed by 2 g infused over 24 h. Ten serum samples were obtained on the second day of each therapy for pharmacokinetic and pharmacodynamic analyses. Two clinical isolates of Staphylococcus aureus, one methicillin sensitive (MSSA 1199) and one methicillin resistant (MRSA 494), were chosen for pharmacodynamic evaluation of both regimens. The patient demographics (means +/- standard deviations [SD]) were as follows: sex, six males, four females; age, 36 +/- 11 years; and serum creatinine, 0.72 +/- 0.18 mg/dl. Mean pharmacokinetic parameters +/- SD for CD therapy were as follows: elimination rate constant, 0.16 +/- 0.07 h-1; half-life, 5.6 +/- 3.5 h; volume of distribution, 33.7 +/- 25 liters, 0.5 +/- 0.2 liters/kg; maximum concentration in serum, 53.4 +/- 19.3 micrograms/ml; and minimum concentration, 8.4 +/- 5.9 micrograms/ml. The steady-state concentration for CI was 20.2 +/- 11.1 micrograms/ml. Overall, both regimens resulted in the MIC being exceeded 100% of the time. The mean CD trough serum bactericidal titer (SBT) was 1:8, and the average CI SBTs were 1:16 for both isolates. Even though there was no statistically significant difference between CD trough and CI SBTs, the CI SBTs remained > 1:8 for 100% of the time versus 60% of the time for CD therapy. During CI therapy, 20 and 40% of the patients maintained SBTs of > 1:32 throughout the dosing interval for MSSA 1199 and MRSA 494, respectively. During CD therapy, however, only 10% of patients maintained SBTs of > 1:32 during the entire dosing interval for both isolates. The mean areas under the bactericidal titer-time curve (AUBC24s) +/- SD for MSSA 1199 were 528 +/- 263 for CD therapy and 547 +/- 390 for CI therapy. The mean AUBC24s +/- SD against MRSA 494 were 531 +/- 247 for CD and 548 +/- 293 for CI therapy. Similar to the AUBC24, the mean area under the concentration-time curve for a 24-h dosing interval divided by the MIC (AUC/MIC24) ratios +/- SD were 550.0 +/- 265.7 for CD and 552.6 +/- 373.4 for CI therapy, respectively. No statistically significant differences were found between any of the pharmacodynamic parameters for CD and CI therapy. In addition, no adverse effects with either CD or CI therapy were observed during the study. We conclude that CI and CD vancomycin therapy demonstrated equivalent pharmacodynamic activities. Although CI therapy was more likely to result in SBTs that remained above 1:8 for the entire regimen, the clinical impact of this result is unknown. Serum drug concentration variability was observed with both treatment regimens but to a lesser extent with CI administration. CI administration of vancomycin should be further evaluated to determine the clinical utility of this method of administration.",1996,"Even though there was no statistically significant difference between CD trough and CI SBTs, the CI SBTs remained > 1:8 for 100% of the time versus 60% of the time for CD therapy.","['patients with suspected or documented gram-positive infections', 'standard deviations [SD]) were as follows: sex, six males, four females; age, 36 ']","['conventional dosing (CD) and continuous-infusion (CI) vancomycin therapy', 'CD or CI therapy', 'CI and CD vancomycin therapy', 'conventional dosing versus continuous-infusion vancomycin therapy', 'vancomycin']","['average CI SBTs', 'Mean pharmacokinetic parameters ', 'Serum drug concentration variability', 'pharmacodynamic parameters for CD and CI therapy', 'mean area under the concentration-time curve', 'mean areas under the bactericidal titer-time curve (AUBC24s) ', 'mean AUBC24s ', 'equivalent pharmacodynamic activities', 'mean CD trough serum bactericidal titer (SBT', 'steady-state concentration', 'CD trough and CI SBTs, the CI SBTs']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0439208', 'cui_str': 'gram (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0444889', 'cui_str': 'Continuous infusion (qualifier value)'}, {'cui': 'C0042313', 'cui_str': 'Vancomycin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0444506', 'cui_str': 'Trough (qualifier value)'}, {'cui': 'C0036782', 'cui_str': 'Schlichter Test'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}]",,0.0215795,"Even though there was no statistically significant difference between CD trough and CI SBTs, the CI SBTs remained > 1:8 for 100% of the time versus 60% of the time for CD therapy.","[{'ForeName': 'J K', 'Initials': 'JK', 'LastName': 'James', 'Affiliation': 'Department of Pharmacy Services, Detroit Receiving Hospital, Michigan 48201,'}, {'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Palmer', 'Affiliation': ''}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Levine', 'Affiliation': ''}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Rybak', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1292,8851608,Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.,"Atevirdine is a nonnucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type 1 and is currently in phase II clinical trials. Atevirdine is most soluble at a pH of < 2, and therefore, normal gastric acidity is most likely necessary for optimal bioavailability. Because of the rapid development of resistance in vitro, atevirdine is being evaluated in combination with didanosine and/or zidovudine in both two- and three-drug combination regimens. To examine the influence of concurrent didanosine (buffered tablet formulation) on the disposition of atevirdine, 12 human immunodeficiency virus type 1-infected subjects (mean CD4+ cell count, 199 cells per mm3; range, 13 to 447 cells/mm3) participated in a three-way, partially randomized, crossover, single-dose study to evaluate the pharmacokinetics of didanosine and atevirdine when each drug was given alone (treatments A and B, respectively) versus concurrently (treatment C). Concurrent administration of didanosine and atevirdine significantly reduced the maximum concentration of atevirdine in serum from 3.45 +/- 2.8 to 0.854 +/- 0.33 microM (P = 0.004). Likewise, the mean atevirdine area under the concentration-time curve from 0 to 24 h after administration of the combination was reduced to 6.47 +/- 2.2 microM.h (P = 0.004) relative to a value of 11.3 +/- 4.8 microM.h for atevirdine alone. Atevirdine had no statistically significant effect on the pharmacokinetic parameters of didanosine. Concurrent administration of single doses of atevirdine and didanosine resulted in a markedly lower maximum concentration of atevirdine in serum and area under the concentration-time curve, with a minimal effect on the disposition of didanosine. It is unknown whether an interaction of similar magnitude would occur under steady-state conditions; thus, combination regimens which include both atevirdine and didanosine should be designed so that their administration times are separated. Since the duration of the buffering effect of didanosine formulations is unknown, atevirdine should be given prior to didanosine.",1996,Atevirdine is a nonnucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type 1 and is currently in phase II clinical trials.,"['subjects with human immunodeficiency virus infections', '12 human immunodeficiency virus type 1-infected subjects (mean CD4+ cell count, 199 cells per mm3; range, 13 to 447 cells/mm3']","['Atevirdine', 'didanosine', 'Didanosine', 'didanosine and/or zidovudine', 'didanosine (buffered tablet formulation', 'atevirdine and didanosine', 'didanosine and atevirdine']","['pharmacokinetic parameters of didanosine', 'mean atevirdine area under the concentration-time curve', 'maximum concentration of atevirdine in serum and area under the concentration-time curve', 'maximum concentration of atevirdine']","[{'cui': 'C0019693', 'cui_str': 'T-Lymphotropic Virus Type III Infections, Human'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0439243', 'cui_str': 'mm3'}, {'cui': 'C3542016', 'cui_str': 'Range'}]","[{'cui': 'C0210243', 'cui_str': 'atevirdine'}, {'cui': 'C0012133', 'cui_str': 'Didanosine'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}, {'cui': 'C0006353', 'cui_str': 'Buffers'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0012133', 'cui_str': 'Didanosine'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0210243', 'cui_str': 'atevirdine'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",,0.0458624,Atevirdine is a nonnucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type 1 and is currently in phase II clinical trials.,"[{'ForeName': 'G D', 'Initials': 'GD', 'LastName': 'Morse', 'Affiliation': 'Department of Pharmacy Practice, State University of New York at Buffalo, Amherst, NY 14260, USA.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Fischl', 'Affiliation': ''}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Shelton', 'Affiliation': ''}, {'ForeName': 'M T', 'Initials': 'MT', 'LastName': 'Borin', 'Affiliation': ''}, {'ForeName': 'M R', 'Initials': 'MR', 'LastName': 'Driver', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'DeRemer', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'C P', 'Initials': 'CP', 'LastName': 'Wajszczuk', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1293,8851614,Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers.,"The pharmacokinetics of oral fleroxacin were compared in men and premenopausal women. The total volume of distribution of the drug was significantly smaller in women in the single-dose trial. No difference in other pharmacokinetic parameters was noted. Since adverse events appear to occur in women more commonly than in men, dose-response studies of fleroxacin in women may be appropriate.",1996,No difference in other pharmacokinetic parameters was noted.,"['male and premenopausal female volunteers', 'men and premenopausal women']","['oral fleroxacin', 'fleroxacin']","['pharmacokinetic parameters', 'total volume of distribution of the drug']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0085161', 'cui_str': 'Fleroxacin'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}]",,0.0309034,No difference in other pharmacokinetic parameters was noted.,"[{'ForeName': 'J S', 'Initials': 'JS', 'LastName': 'Bertino', 'Affiliation': 'Department of Pharmacy Services, Bassett Healthcare, Cooperstown, New York 13326-1394, USA. jbertino@cscns.com'}, {'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Nafziger', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1294,8851621,Penetration of ceftriaxone (1 or 2 grams intravenously) into mediastinal and cardiac tissues in humans.,"Penetration of ceftriaxone into heart tissues (valves, myocardium, auricles, and pericardium) and mediastinal tissues (fat and sternal bone) was evaluated after two regimens of ceftriaxone administration. Ten patients (group 1) were given 1,000 mg of ceftriaxone intravenously 30 min before anesthesia. Ten other patients (group 2) received the same dose and then a second 1,000-mg dose at the time of initiation of cardiopulmonary bypass. Similar and very satisfactory penetrations of ceftriaxone into tissue were observed for both groups. During opening and closure of the thorax, mean ceftriaxone concentration was in excess of the MIC at which 90% of the potential pathogens were inhibited (> or = 4 micrograms/g) in the thoracic fat, the sternal bone, and the pericardium. No significant differences between the two administration regimens in penetration of ceftriaxone into tissue were observed. During cardiopulmonary bypass, the ceftriaxone concentration was > or = 4 micrograms/g in the myocardium, the endocardium, and the auricle. The regimen of ceftriaxone administration did not significantly influence penetration of the drug into heart tissues. However, for some patients in the two groups and mainly in the sternal bone at the time of thorax closure (6 patients in group 1 and 5 patients in group 2), ceftriaxone levels in tissues were less than the MICs (4 micrograms/g) for some potential pathogens (methicillin-susceptible Staphylococcus aureus and methicillin-susceptible Staphylococcus epidermidis). During the different steps of the surgical procedures, all (10 of 10) patients in each group had tissue ceftriaxone levels greater than the MICs for gram-negative aerobic bacilli (0.1 microgram/g), except for Pseudomonas spp.",1996,No significant differences between the two administration regimens in penetration of ceftriaxone into tissue were observed.,['humans'],['ceftriaxone'],"['heart tissues (valves, myocardium, auricles, and pericardium) and mediastinal tissues (fat and sternal bone', 'influence penetration of the drug into heart tissues', 'penetration of ceftriaxone into tissue', 'sternal bone at the time of thorax closure', 'tissue ceftriaxone levels']","[{'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0007561', 'cui_str': 'Ceftriaxone'}]","[{'cui': 'C1272575', 'cui_str': 'Heart tissue'}, {'cui': 'C3888056', 'cui_str': 'Valve (physical object)'}, {'cui': 'C0027061', 'cui_str': 'Muscle, Cardiac'}, {'cui': 'C0928075', 'cui_str': 'Pinna, Ear'}, {'cui': 'C0031050', 'cui_str': 'Pericardium'}, {'cui': 'C0025066', 'cui_str': 'Mediastinum'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0007561', 'cui_str': 'Ceftriaxone'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1293774', 'cui_str': 'Thorax closure'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",10.0,0.0195615,No significant differences between the two administration regimens in penetration of ceftriaxone into tissue were observed.,"[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Martin', 'Affiliation': 'Department of Anesthesia and Intensive Care, Hôpital Nord, Marseille, France.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Viviand', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Alaya', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Lokiec', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Ennabli', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Said', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Pecking', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1295,8890204,"Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.","We evaluated the safety and immunogenicity of attenuated Shigella flexneri 2a vaccine candidate CVD 1203, which harbors precise deletions in the plasmid gene virG and in the chromosomal gene aroA. CVD 1203 invades epithelial cells but undergoes minimal intracellular proliferation and cell-to-cell spread. Fasting healthy volunteers, aged 18 to 40 years, were randomly allocated (double-blind design) to receive either CVD 1203 vaccine or placebo, along with sodium bicarbonate buffer, on days 0 and 14, as follows. At the time of the first inoculation, 10 subjects received placebo (group 1) and 22 subjects received either 1.5 x 10(8) (group 2; 11 subjects) or 1.5 x 10(9) (group 3; 11 subjects) CFU of CVD 1203. Fourteen days later, subjects from group 1 received 1.2 x 10(6) CFU of CVD 1203 and subjects from groups 2 and 3 received 1.2 x 10(8) vaccine organisms. Clinical tolerance was dose dependent. After a single dose of CVD 1203 at 10(6), 10(8), or 10(9) CFU, self-limited (<48-h duration) objective reactogenicity (fever, diarrhea, or dysentery) developed in 0, 18, and 72% of subjects, respectively, and in no placebo recipients. CVD 1203 induced immunoglobulin G seroconversion to S. flexneri 2a lipopolysaccharide (LPS) in 30, 45, and 36% of subjects from groups 1, 2, and 3, respectively, and stimulated immunoglobulin A-producing anti-LPS antibody-secreting cells in 60, 91, and 100% of subjects, respectively. After vaccination, significant rises in tumor necrosis factor alpha concentration in serum (groups 1, 2, and 3) and stool (group 2) samples were observed. We conclude that engineered deletions in virG and aroA markedly attenuate wild-type S. flexneri but preserve immunogenicity; however, less reactogenic vaccines are needed.",1996,"After vaccination, significant rises in tumor necrosis factor alpha concentration in serum (groups 1, 2, and 3) and stool (group 2) samples were observed.","['Fasting healthy volunteers, aged 18 to 40 years']","['CVD 1203 vaccine or placebo, along with sodium bicarbonate', 'placebo']","['safety and immunogenicity', 'Safety, immunogenicity, and transmissibility', 'tumor necrosis factor alpha concentration', 'CVD 1203 induced immunoglobulin G seroconversion', 'objective reactogenicity (fever, diarrhea, or dysentery', 'deletions in aroA and virG']","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0074722', 'cui_str': 'Sodium Bicarbonate'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0202087', 'cui_str': 'Immunoglobulin G measurement (procedure)'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0013369', 'cui_str': 'Infectious Diarrheal Disease'}, {'cui': 'C1442161', 'cui_str': 'Deletion (morphologic abnormality)'}]",1203.0,0.116637,"After vaccination, significant rises in tumor necrosis factor alpha concentration in serum (groups 1, 2, and 3) and stool (group 2) samples were observed.","[{'ForeName': 'K L', 'Initials': 'KL', 'LastName': 'Kotloff', 'Affiliation': 'Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, USA. kkotloff@umppa1.ab.umd.edu.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Noriega', 'Affiliation': ''}, {'ForeName': 'G A', 'Initials': 'GA', 'LastName': 'Losonsky', 'Affiliation': ''}, {'ForeName': 'M B', 'Initials': 'MB', 'LastName': 'Sztein', 'Affiliation': ''}, {'ForeName': 'S S', 'Initials': 'SS', 'LastName': 'Wasserman', 'Affiliation': ''}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Nataro', 'Affiliation': ''}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Levine', 'Affiliation': ''}]",Infection and immunity,[] 1296,8849259,Two or three days of ofloxacin treatment for uncomplicated multidrug-resistant typhoid fever in children.,"An open randomized comparison of 2 days (Ofx2) versus 3 days (Ofx3) of oral ofloxacin treatment (15 mg/kg/day) was conducted with Vietnamese children between 1 and 15 years of age with suspected typhoid fever. Of 108 children enrolled, 100 were blood culture positive for Salmonella typhi, and 86% of the isolates were multidrug resistant. There were no significant adverse effects. The therapeutic responses were similar in both groups, with mean (+/- standard deviation) fever clearances of 107 +/- 60 h in the Ofx3 group and 100 +/- 64 h in the Ofx2 group (P > 0.2). There were six ""clinical"" failures in the Ofx2 group and two clinical failures in the Ofx3 group (P > 0.2), in which fever and symptoms persisted for more than 1 week after the start of treatment, but only one of these was culture positive (Ofx3). There was one suspected relapse, and one carrier was identified. Short courses of ofloxacin are simple, inexpensive, safe, and effective for the treatment of uncomplicated multidrug-resistant typhoid fever.",1996,"Short courses of ofloxacin are simple, inexpensive, safe, and effective for the treatment of uncomplicated multidrug-resistant typhoid fever.","['uncomplicated multidrug-resistant typhoid fever in children', '108 children enrolled, 100 were blood culture positive for Salmonella typhi, and 86% of the isolates were multidrug resistant', '107 ', 'Vietnamese children between 1 and 15 years of age with suspected typhoid fever']","['oral ofloxacin treatment', 'ofloxacin']","['six ""clinical"" failures', 'therapeutic responses', 'adverse effects', 'fever and symptoms']","[{'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0041466', 'cui_str': 'Salmonella typhi Infection'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0877418', 'cui_str': 'Blood culture positive for salmonella'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C4517529', 'cui_str': 'One hundred and seven'}, {'cui': 'C1561452', 'cui_str': 'Vietnamese'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0028902', 'cui_str': 'Ofloxacin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0521982', 'cui_str': 'Therapeutic response, function (observable entity)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",108.0,0.310776,"Short courses of ofloxacin are simple, inexpensive, safe, and effective for the treatment of uncomplicated multidrug-resistant typhoid fever.","[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Vinh', 'Affiliation': 'Centre for Tropical Diseases, Ho Chi Minh City, Vietnam.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Wain', 'Affiliation': ''}, {'ForeName': 'T N', 'Initials': 'TN', 'LastName': 'Vo', 'Affiliation': ''}, {'ForeName': 'N N', 'Initials': 'NN', 'LastName': 'Cao', 'Affiliation': ''}, {'ForeName': 'T C', 'Initials': 'TC', 'LastName': 'Mai', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Bethell', 'Affiliation': ''}, {'ForeName': 'T T', 'Initials': 'TT', 'LastName': 'Nguyen', 'Affiliation': ''}, {'ForeName': 'S D', 'Initials': 'SD', 'LastName': 'Tu', 'Affiliation': ''}, {'ForeName': 'M D', 'Initials': 'MD', 'LastName': 'Nguyen', 'Affiliation': ''}, {'ForeName': 'N J', 'Initials': 'NJ', 'LastName': 'White', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1297,8723448,Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis.,"Concentrations of doxycycline and penicillin G in serum and cerebrospinal fluid (CSF) were analyzed in 46 patients during treatment for neuroborreliosis. Twenty patients were treated intravenously with penicillin G at 3 g every 6 h (q6h), and 26 patients were treated orally with doxycycline at 200 mg q24h. All samples were collected on day 13 of treatment. The median concentrations of penicillin G in serum were 0.5, 37, and 5.6 micrograms/ml before and 1 and 3 h after drug administration, and that in CSF was 0.5 (range, 0.3 to 1.6) microgram/ml after 2 to 3 h. The median concentrations of doxycycline in serum were 2.1, 6.1, and 4.7 micrograms/ml before and 2 and 6 h after drug administration, and that in CSF was 0.6 (range, 0.4 to 2.5) microgram/ml after 4 h. All patients had concentrations of penicillin G or doxycycline in CSF above the lowest reported MICs of penicillin G (0.003 microgram/ml) and doxycycline (0.12 microgram/ml) for Borrelia burgdorferi. However, no patients had a drug concentration in CSF above the highest reported MIC of penicillin G (8 micrograms/ml), and only one had a drug concentration in CSF above the highest reported MIC of doxycycline (2 micrograms/ml), despite good clinical response to treatment. No treatment failure or relapse was observed during a 1-year follow-up, although one patient treated with penicillin G and one treated with doxycycline were retreated because of residual pain. The chosen dosages of penicillin G and doxycycline seem to give sufficient concentrations in serum and CSF for the treatment of neuroborreliosis.",1996,"No treatment failure or relapse was observed during a 1-year follow-up, although one patient treated with penicillin G and one treated with doxycycline were retreated because of residual pain.","['46 patients during treatment for neuroborreliosis', 'Twenty patients', 'sera and cerebrospinal fluid of patients treated for neuroborreliosis']","['doxycycline', 'penicillin G or doxycycline', 'doxycycline and penicillin G', 'penicillin G and doxycycline', 'penicillin G']","['median concentrations of doxycycline in serum', 'failure or relapse', 'drug concentration in CSF', 'serum and cerebrospinal fluid (CSF', 'median concentrations of penicillin G in serum', 'residual pain']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0948264', 'cui_str': 'Neuroborreliosis'}, {'cui': 'C0007807'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for (contextual qualifier) (qualifier value)'}]","[{'cui': 'C0013090', 'cui_str': 'Doxycycline'}, {'cui': 'C0030827', 'cui_str': 'benzylpenicillin'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0013090', 'cui_str': 'Doxycycline'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0007807'}, {'cui': 'C0030827', 'cui_str': 'benzylpenicillin'}, {'cui': 'C3805255', 'cui_str': 'Residual pain'}]",20.0,0.0198333,"No treatment failure or relapse was observed during a 1-year follow-up, although one patient treated with penicillin G and one treated with doxycycline were retreated because of residual pain.","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Karlsson', 'Affiliation': 'Department of Infectious Diseases, Danderyd Hospital, Stockholm, Sweden.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Hammers', 'Affiliation': ''}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Nilsson-Ehle', 'Affiliation': ''}, {'ForeName': 'A S', 'Initials': 'AS', 'LastName': 'Malmborg', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Wretlind', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1298,8787889,Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.,"The pharmacokinetics and serum bactericidal activities (SBAs) of imipenem and meropenem were investigated in a randomized crossover study. Twelve healthy male volunteers received a constant 30-min infusion of either 1 g of imipenem plus 1 g of cilastatin or 1 g of meropenem. The concentrations of the drugs in serum and urine were determined by bioassay and high-pressure liquid chromatography. Pharmacokinetic parameters were based on an open two-compartment model and a noncompartmental technique. At the end of infusion, the mean concentrations of imipenem and meropenem measured in serum were 61.2 +/- 9.8 and 51.6 +/- 6.5 mg/liter, respectively; urinary recoveries were 48.6% +/- 8.2% and 60.0% +/- 6.5% of the dose in 12 h, respectively; and the areas under the concentration-time curve from time zero to infinity were 96.1 +/- 14.4 and 70.5 +/- 10.3 mg.h/liter, respectively (P < or = 0.02). Imipenem had a mean half-life of 66.7 +/- 10.4 min; that of meropenem was 64.4 +/- 6.9 min. The volumes of distribution at steady state of imipenem and meropenem were 15.3 +/- 3.3 and 18.6 +/- 3.0 liters/70 kg, respectively, and the mean renal clearances per 1.73 m2 were 85.6 +/- 17.6 and 144.6 +/- 26.0 ml/min, respectively. Both antibiotics were well tolerated in this single-dose administration study. The SBAs were measured by the microdilution method of Reller and Stratton (L. B. Reller and C. W. Stratton, J. Infect. Dis. 136:196-204, 1977) against 40 clinically isolated strains. Mean reciprocal bactericidal titers were measured 1 and 6 h after administration. After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis. Both drugs had rather short biological elimination half-lives and a predominantly renal route of elimination. Both carbapenems revealed high SBAs against clinically important pathogens at 1 h; meropenem had a higher SBA against E. cloacae and P. mirabilis, and the SBA of imipenem against S. aureus was greater than the SBA of meropenem.",1996,"Both carbapenems revealed high SBAs against clinically important pathogens at 1 h; meropenem had a higher SBA against E. cloacae and P. mirabilis, and the SBA of imipenem against S. aureus was greater than the SBA of meropenem.","['136:196-204, 1977) against 40 clinically isolated strains', 'Twelve healthy male volunteers']","['imipenem and meropenem', 'meropenem', 'Imipenem', 'meropenem and imipenem-cilastatin', 'imipenem plus 1 g of cilastatin or 1 g of meropenem']","['median SBAs', 'volumes of distribution at steady state of imipenem and meropenem', 'pharmacokinetics and serum bactericidal activities (SBAs', 'urinary recoveries', 'concentrations of the drugs in serum and urine', 'mean concentrations of imipenem and meropenem measured in serum', 'mean renal clearances', 'tolerated', 'Mean reciprocal bactericidal titers', 'Serum bactericidal activities and comparative pharmacokinetics']","[{'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0020933', 'cui_str': 'Imipenem'}, {'cui': 'C0066005', 'cui_str': 'meropenem'}, {'cui': 'C0071972', 'cui_str': 'Cilastatin / Imipenem'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0008777', 'cui_str': 'Cilastatin'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0020933', 'cui_str': 'Imipenem'}, {'cui': 'C0066005', 'cui_str': 'meropenem'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0544570', 'cui_str': 'Bactericidal activity (observable entity)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0042037'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0232813', 'cui_str': 'Renal clearance, function (observable entity)'}, {'cui': 'C0475208', 'cui_str': 'TITR'}]",12.0,0.0608751,"Both carbapenems revealed high SBAs against clinically important pathogens at 1 h; meropenem had a higher SBA against E. cloacae and P. mirabilis, and the SBA of imipenem against S. aureus was greater than the SBA of meropenem.","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Dreetz', 'Affiliation': 'Department for Chest and Infectious Diseases, City-Hospital Zehlendorf, Berlin, Germany.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Hamacher', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Eller', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Borner', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Koeppe', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Schaberg', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Lode', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1299,8723472,"Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection.","Zidovudine is widely prescribed for the treatment of human immunodeficiency virus (HIV) infection. Trimethoprim and dapsone are commonly used in the management of Pneumocystis carinii pneumonia in HIV-infected patients. To examine the pharmacokinetic interactions among these drugs, eight HIV-infected patients (26 to 43 years old) with a mean CD4 count of 524.4 +/- 405.7 cells per mm3 received zidovudine (200 mg), trimethoprim (200 mg), and dapsone (100 mg) as single agents and in two- and three-drug combinations. Blood and urine samples were collected at a specified time and analyzed for zidovudine, zidovudine-glucuronide, trimethoprim, dapsone, and monoacetyl-dapsone concentrations under single-dose and steady-state conditions. Zidovudine did not influence the pharmacokinetic disposition of dapsone or trimethoprim. Dapsone had no effect on the pharmacokinetic disposition of zidovudine. Trimethoprim significantly decreased the renal clearance of zidovudine by 58% (5.0 +/- 1.8 versus 2.1 +/- 0.5 ml/min/kg of body weight [P < 0.05]). There was a concurrent 54% decrease in the mean urinary recovery of zidovudine (11.7 +/- 3.5 versus 5.4 +/- 3.0 [P < 0.05]), and the metabolic ratio was decreased by 78% (0.32 +/- 0.4 versus 0.07 +/- 0.05 [P < 0.05]). The mean area under the concentration-time curve from 0 to 6 h of the zidovudine-glucuronide/ zidovudine ratio was unchanged. We conclude that zidovudine, trimethoprim, and dapsone can be coadministered to patients with AIDS without significant pharmacokinetic interaction. However, in AIDS patients with liver impairment and impaired glucuronidation, doses of zidovudine may need to be decreased.",1996,Trimethoprim significantly decreased the renal clearance of zidovudine by 58% (5.0 +/-,"['Pneumocystis carinii pneumonia in HIV-infected patients', 'patients with human immunodeficiency virus infection', 'patients with AIDS without significant pharmacokinetic interaction', 'eight HIV-infected patients (26 to 43 years old) with a mean CD4 count of 524.4 ', 'human immunodeficiency virus (HIV) infection']","['Dapsone', 'Zidovudine', 'Trimethoprim and dapsone', 'zidovudine-glucuronide/ zidovudine', 'Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions', 'zidovudine, zidovudine-glucuronide, trimethoprim, dapsone', 'zidovudine, trimethoprim, and dapsone', 'trimethoprim', 'Trimethoprim', 'dapsone', 'zidovudine']","['pharmacokinetic disposition of zidovudine', 'Blood and urine samples', 'pharmacokinetic disposition of dapsone or trimethoprim', 'mean urinary recovery', 'metabolic ratio', 'mean area under the concentration-time curve', 'renal clearance of zidovudine']","[{'cui': 'C1535939', 'cui_str': 'Pneumocystis jirovecii Pneumonia'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019693', 'cui_str': 'T-Lymphotropic Virus Type III Infections, Human'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C1868980', 'cui_str': 'Pharmacokinetic interaction'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}]","[{'cui': 'C0010980', 'cui_str': 'Dapsone'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}, {'cui': 'C0041041', 'cui_str': 'Trimethoprim'}, {'cui': 'C1868980', 'cui_str': 'Pharmacokinetic interaction'}, {'cui': 'C0046790', 'cui_str': ""AZT-5'-glucuronide""}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0743223', 'cui_str': 'Disposition (disposition)'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}, {'cui': 'C0005768'}, {'cui': 'C1610733', 'cui_str': 'Urine specimen'}, {'cui': 'C0010980', 'cui_str': 'Dapsone'}, {'cui': 'C0041041', 'cui_str': 'Trimethoprim'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0232813', 'cui_str': 'Renal clearance, function (observable entity)'}]",,0.0237534,Trimethoprim significantly decreased the renal clearance of zidovudine by 58% (5.0 +/-,"[{'ForeName': 'B L', 'Initials': 'BL', 'LastName': 'Lee', 'Affiliation': 'Department of Medicine, University of California, San Francisco 94110, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Safrin', 'Affiliation': ''}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Makrides', 'Affiliation': ''}, {'ForeName': 'J G', 'Initials': 'JG', 'LastName': 'Gambertoglio', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1300,8723473,Effect of polyaspartic acid on pharmacokinetics of gentamicin after single intravenous dose in the dog.,"The effects of poly-L-aspartic acid on the pharmacokinetics of gentamicin were examined by using a randomized crossover trial design with the dog. When analyzed according to a three-compartment open model, poly-L-aspartic acid reduced some first-order rate equation constants (A3, lambda 1, and lambda 3), the deep peripheral compartment exit microconstant (k31), the elimination rate constant (k(el)), and the area under the concentration-time curve from 0 to 480 h (AUC0-480) (0.21-, 0.60-, 0.26-, 0.27-, 0.72-, and 0.76-fold, respectively; P < 0.05) but increased the volume of distribution at steady state (Vss), the volume of distribution calculated by the area method (V(area)), the apparent volume of the peripheral compartment (Vp), and all mean time parameters. These results suggested that poly-L-aspartic acid increased the distribution of gentamicin to or binding within the deep peripheral compartment and that poly-L-aspartic acid may have delayed gentamicin transit through the peripheral tissues. In contrast, poly-L-aspartic acid did not alter pharmacokinetic parameters relevant to the central or shallow peripheral compartments to a clinically significant extent. Although gentamicin's pharmacokinetic parameters of relevance to therapeutic drug monitoring were not directly altered, this study has provided pharmacokinetic evidence that poly-L-aspartic acid alters the peripheral distribution of gentamicin. This pharmacokinetic interaction occurred after a single intravenous dose of each drug. Therefore, this interaction should be investigated further, before polyaspartic acid can be considered for use as a clinical nephroprotectant.",1996,"In contrast, poly-L-aspartic acid did not alter pharmacokinetic parameters relevant to the central or shallow peripheral compartments to a clinically significant extent.",[],"['polyaspartic acid', 'poly-L-aspartic acid', 'gentamicin']","['volume of distribution at steady state (Vss), the volume of distribution calculated by the area method (V(area)), the apparent volume of the peripheral compartment (Vp), and all mean time parameters', 'elimination rate constant (k(el)), and the area under the concentration-time curve']",[],"[{'cui': 'C0137723', 'cui_str': 'polyaspartic acid'}, {'cui': 'C0004015', 'cui_str': 'L-aspartic acid'}, {'cui': 'C0017436', 'cui_str': 'Gentamicins'}]","[{'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0444686', 'cui_str': 'Calculated (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}]",,0.0205862,"In contrast, poly-L-aspartic acid did not alter pharmacokinetic parameters relevant to the central or shallow peripheral compartments to a clinically significant extent.","[{'ForeName': 'T', 'Initials': 'T', 'LastName': 'Whittem', 'Affiliation': 'Department of Veterinary Clinical Sciences, Massey University, Palmerston North, New Zealand. whittem@uiuc.edu'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Parton', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Turner', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1301,8787872,Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.,"Twelve adult males participated in a randomized crossover phase I clinical trial comparing serum bactericidal titers (SBTs), urine bactericidal titers (UBTs), and urine killing rates (UKRs) against Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 29213, after the administration of single 400-mg doses of rufloxacin and norfloxacin at different times up to 72 h postdose. SBTs were significantly higher (P < 0.05) against E. coli from 8 to 48 h and against S. aureus from 4 to 24 h with rufloxacin. UBTs for E. coli were higher (P < 0.05) for norfloxacin at early sample times (0 to 8 h) but higher for rufloxacin (P < 0.05) at sample times from 16 h on for both E. coli and S. aureus. Similar UKRs were obtained for both quinolones for 0 to 2 h and 8 to 12 h, but the UKR was maintained for 72 h with rufloxacin. The high and sustained mean levels of rufloxacin in urine (> 35 micrograms/ml), median UBTs (> 32 for E. coli and 16 for S. aureus) and UKRs for E. coli suggest prolonged urine antibacterial activity (for at least 72 h) and its use as a single 400-mg dose in the treatment of uncomplicated cystitis.",1996,UBTs for E. coli were higher (P < 0.05) for norfloxacin at early sample times (0 to 8 h) but higher for rufloxacin (P < 0.05) at sample times from 16 h on for both E. coli and S. aureus.,"['Twelve adult males', 'healthy volunteers']","['norfloxacin', 'rufloxacin and norfloxacin', 'rufloxacin']","['SBTs', 'median UBTs', 'serum bactericidal titers (SBTs), urine bactericidal titers (UBTs), and urine killing rates (UKRs', 'urine antibacterial activity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0028365', 'cui_str': 'Norfloxacin'}, {'cui': 'C0073704', 'cui_str': 'rufloxacin'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0036782', 'cui_str': 'Schlichter Test'}, {'cui': 'C0042037'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0162388', 'cui_str': 'Killing'}, {'cui': 'C0279516', 'cui_str': 'Anti-Bacterial Agents'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",,0.112002,UBTs for E. coli were higher (P < 0.05) for norfloxacin at early sample times (0 to 8 h) but higher for rufloxacin (P < 0.05) at sample times from 16 h on for both E. coli and S. aureus.,"[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Aguilar', 'Affiliation': 'Medical Department, SmithKline Beecham Pharmaceuticals, Universidad Complutense, Madrid, Spain.'}, {'ForeName': 'I P', 'Initials': 'IP', 'LastName': 'Balcabao', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Salvá', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Martín', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Costa', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Prieto', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Dal-ré', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1302,8787880,Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.,"Since beta-lactam antibiotics have concentration-independent killing, bacterial eradication is a function of the time the serum drug concentration remains above the drug's MIC (T > MIC). We compared the serum bactericidal titers (SBTs) of ceftazidime given by continuous infusion (CI) or by intermittent bolus dosing (BD) against two clinical isolates each of Pseudomonas aeruginosa and Escherichia coli to determine if CI would allow lower daily dosing while still providing equal bactericidal activity compared with BD. This was an open-labeled, randomized, steady-state, four-way crossover study with 12 healthy volunteers. The ceftazidime regimens were 1 g every 8 h (q8h) BD, 1 g q12h BD, 3 g over 24 h CI, and 2 g over 24 h CI. The areas under the bactericidal curves were calculated by the trapezoidal rule using the reciprocal of the SBT. For all organisms the areas under the bactericidal curves for intermittent versus the CI regimens were the same for equal doses (P > 0.05). For both strains of E. coli all four regimens provided SBTs of > or = 1:2 over the dosing interval and 100% T > MIC. The 1-g q8h BD and q12h BD regimens provided T > MIC of 82 and 52%, respectively, for both P. aeruginosa isolates (MICs, 4 micrograms/ml). In comparison, the 2- and 3-g CI regimens always maintained SBTs of > or = 1:2 and T > MIC over the 24-h period as serum drug concentrations were 12.8 +/- 3.0 and 18.2 +/- 4.5 micrograms/ml, respectively. CI optimizes the pharmacodynamic and pharmacoeconomic profile of ceftazidime by providing adequate antibacterial activity over the 24-h dosing period with a reduction in the total daily dose of the antimicrobial agent.",1996,For all organisms the areas under the bactericidal curves for intermittent versus the CI regimens were the same for equal doses (P > 0.05).,['12 healthy volunteers'],['ceftazidime'],"['serum drug concentrations', 'Serum bactericidal activity', 'serum bactericidal titers (SBTs']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0007559', 'cui_str': 'Ceftazidime'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0544570', 'cui_str': 'Bactericidal activity (observable entity)'}, {'cui': 'C0036782', 'cui_str': 'Schlichter Test'}]",12.0,0.0253263,For all organisms the areas under the bactericidal curves for intermittent versus the CI regimens were the same for equal doses (P > 0.05).,"[{'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Nicolau', 'Affiliation': 'Department of Pharmacy, Hartford Hospital, Connecticut 06102, USA.'}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Nightingale', 'Affiliation': ''}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Banevicius', 'Affiliation': ''}, {'ForeName': 'Q', 'Initials': 'Q', 'LastName': 'Fu', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Quintiliani', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1303,8787882,Double-blind comparison of cefazolin and ceftizoxime for prophylaxis against infections following elective biliary tract surgery.,"Antibiotics have been shown to reduce the incidence of wound infections after elective biliary tract procedures. Cefazolin and cefoxitin are among the agents most commonly promoted for this purpose. Cefoxitin has been substituted with ceftizoxime in many institutions; however, the role of ceftizoxime as a prophylactic agent in this setting has not been determined. To assess the comparative prophylactic efficacies of cefazolin and ceftizoxime in biliary tract surgery, we conducted a double-blind, randomized prospective clinical trial in a tertiary-care teaching hospital. Adult patients were randomized to one of two treatment groups and received a 30-min preoperative dose of study drug and as many as two postoperative doses at 12 and 24 h, depending on hospitalization status. Cefazolin and ceftizoxime were given as 1,000-mg doses. Patients with infections, those receiving prior antibiotics, or those with beta-lactam allergies were excluded. Over the 19-month study tenure, 167 patients were enrolled. Seventeen patients were excluded from analysis because of protocol violations. Of the 150 evaluable patients (72 and 78 receiving cefazolin and ceftizoxime doses, respectively), there was no significant difference among groups regarding sex, age, weight, preoperative Apache II score, baseline chemistry, and hematological parameters. Groups were also equivalent regarding the surgeon, type of procedure, characteristics (blood loss, drains, organ injury, and complications), and duration of hospital stay (mean, 5.6 versus 4.3 days [P = 0.31]). No clinical evidence of infection (7-day hospital stay and 30-day follow-up) was identified in 93% of cefazolin and 92% of ceftizoxime patients (P = 1.0). Microbiological confirmation was found in only 18% of primary-site infections. In conclusion, cefazolin and ceftizoxime appear to be equivalent for the prevention of infection in biliary tract surgery with the dosage regimens studied.",1996,No clinical evidence of infection (7-day hospital stay and 30-day follow-up) was identified in 93% of cefazolin and 92% of ceftizoxime patients (P = 1.0).,"['biliary tract surgery', 'elective biliary tract surgery', 'Patients with infections, those receiving prior antibiotics, or those with beta-lactam allergies were excluded', '167 patients were enrolled', '150 evaluable patients (72 and 78 receiving', 'Adult patients', 'Seventeen patients were excluded from analysis because of protocol violations']","['Cefazolin and ceftizoxime', 'cefazolin and ceftizoxime', 'Cefazolin and cefoxitin', 'ceftizoxime', 'Cefoxitin', 'cefazolin']","['surgeon, type of procedure, characteristics (blood loss, drains, organ injury, and complications), and duration of hospital stay', 'infection (7-day hospital stay and 30-day follow-up', 'Microbiological confirmation']","[{'cui': 'C0005423', 'cui_str': 'Biliary System'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0282215', 'cui_str': 'beta-Lactams'}, {'cui': 'C0002111', 'cui_str': 'Allergy Specialty'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C4517595', 'cui_str': '167 (qualifier value)'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0450331', 'cui_str': '17 (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}]","[{'cui': 'C0007546', 'cui_str': 'Cefazolin'}, {'cui': 'C0007560', 'cui_str': 'Ceftizoxime'}, {'cui': 'C0007557', 'cui_str': 'Cefoxitin'}]","[{'cui': 'C0582175', 'cui_str': 'Surgeon (occupation)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0180499', 'cui_str': 'Drain, device (physical object)'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0587438', 'cui_str': 'Day hospital (environment)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]",167.0,0.233168,No clinical evidence of infection (7-day hospital stay and 30-day follow-up) was identified in 93% of cefazolin and 92% of ceftizoxime patients (P = 1.0).,"[{'ForeName': 'P J', 'Initials': 'PJ', 'LastName': 'Jewesson', 'Affiliation': 'Department of Pharmacy, Vancouver Hospital and Health Sciences Centre, British Columbia, Canada. jewesson@unixg.ubc.ca'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Stiver', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Wai', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Frighetto', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Nickoloff', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Smith', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Schwartz', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Sleigh', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Danforth', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Scudamore', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Chow', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1304,8787884,Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.,"A randomized, double-blind study was conducted to evaluate the safety and pharmacokinetics of acyclovir following multiple-dose oral administration of valaciclovir (three times a day for 8 days) in geriatric volunteers (65 to 83 years of age). Pharmacokinetic evaluation was performed for three groups: normotensive subjects given 500-mg doses of valaciclovir (n = 11), normotensive subjects given, 1,000-mg doses of valaciclovir (n = 9), and thiazide diuretic-treated hypertensive subjects given 500-mg doses of valaciclovir (n = 9). Valaciclovir, the l-valyl ester of acylclovir, was rapidly absorbed and converted to acyclovir, with plasma valaciclovir concentrations generally undetectable or < or = 0.4 microgram/ml. The peak concentration of drug in plasma (Cmax) for acyclovir occurred at 1 to 2 h, and the half-life of acyclovir was 3 to 4 h in all three elderly groups. The Cmax and area under the concentration-time curve from 0 h to infinity (AUC0-infinity) values of acyclovir obtained on days 1 and 8 indicated no unexpected accumulation at steady state. The steady-state acyclovir Cmax (4.30 and 5.98 micrograms/ml) and daily AUC0-infinity (44 and 74 h.micrograms/ml) following dosing of valaciclovir (500 and 1,000 mg) three times a day were two to three times greater than those expected after high-dose oral acyclovir treatment (800 mg, five times daily). There were no valaciclovir-related changes or abnormalities in safety parameters and no reports of serious adverse experiences in these elderly volunteers. The plasma acyclovir concentration-time curves for the hypertensive and normotensive (500-mg valaciclovir treatment) elderly groups were almost superimposable, and acyclovir pharmacokinetic parameters for the two groups were not significantly different, indicating that concomitant thiazide diuretics do not alter acyclovir pharmacokinetics following valaciclovir dosing in the elderly. Compared with historical data for younger volunteers (creatinine clearance [CLCR] > 75 ml/min/1.73 m2), the elderly subjects (CLCR = 40 to 65 ml/min/1.73 m2) showed higher (approximately 15 to 20%) mean Cmaxs and higher (approximately 30 to 50%) mean AUC(0-infinity)s of acyclovir (P < 0.01), which were consistent with age-related decreases in CLCR. The increased acyclovir exposure from valaciclovir dosing will permit reduced dosing frequency and may result in improved efficacy in the management of herpesvirus diseases.",1996,There were no valaciclovir-related changes or abnormalities in safety parameters and no reports of serious adverse experiences in these elderly volunteers.,"['three groups: normotensive subjects given 500-mg doses of', 'geriatric volunteers (65 to 83 years of age', 'geriatric volunteers with and without concomitant diuretic therapy', 'elderly volunteers']","['valaciclovir', 'acyclovir', 'normotensive subjects given, 1,000-mg doses of valaciclovir', 'multiple-dose valaciclovir', 'Valaciclovir', 'thiazide diuretic-treated hypertensive subjects given 500-mg doses of valaciclovir']","['Pharmacokinetics and safety', 'acyclovir pharmacokinetics', 'peak concentration of drug in plasma (Cmax) for acyclovir', 'mean AUC(0-infinity)s of acyclovir', 'acyclovir pharmacokinetic parameters', 'steady-state acyclovir Cmax', 'plasma acyclovir concentration-time curves', 'CLCR', 'Cmax and area under the concentration-time curve', 'safety and pharmacokinetics']","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2712122', 'cui_str': 'Normal blood pressure (finding)'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0017469', 'cui_str': 'Geriatrics'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0948575', 'cui_str': 'Diuretic therapy'}]","[{'cui': 'C0249458', 'cui_str': 'valacyclovir'}, {'cui': 'C0001367', 'cui_str': 'Acyclovir'}, {'cui': 'C2712122', 'cui_str': 'Normal blood pressure (finding)'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0012802', 'cui_str': 'Benzothiadiazine Diuretics'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0001367', 'cui_str': 'Acyclovir'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}]",,0.0374987,There were no valaciclovir-related changes or abnormalities in safety parameters and no reports of serious adverse experiences in these elderly volunteers.,"[{'ForeName': 'L H', 'Initials': 'LH', 'LastName': 'Wang', 'Affiliation': 'Glaxo Wellcome Inc., Research Triangle Park, North Carolina 27709, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Schultz', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Weller', 'Affiliation': ''}, {'ForeName': 'M L', 'Initials': 'ML', 'LastName': 'Smiley', 'Affiliation': ''}, {'ForeName': 'M R', 'Initials': 'MR', 'LastName': 'Blum', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1305,8787886,"Pharmacokinetics and metabolism of genaconazole, a potent antifungal drug, in men.","The pharmacokinetics of genaconazole, a racemic triazole antifungal agent comprising 50% RR and 50% SS enantiomers, were studied in 12 healthy male volunteers after a single oral dose of 200 mg. The serum samples were analyzed for the two enantiomers by using a chiral high-pressure liquid chromatography assay. The concentrations of the RR and SS enantiomers in serum were virtually identical. The mean values for the maximum concentrations in serum (Cmax) (1.7 micrograms/ml), times to Cmax (4.0 to 4.2 h), half-lives (83 h), and areas under the concentration-time curve from 0 h to infinity (195 to 199 micrograms.h/ml) were similar for the two enantiomers. The results showed that the pharmacokinetic profiles of the two enantiomers were similar after a single oral dosing of the racemate. The pharmacokinetics of the RR enantiomer were also evaluated in 12 healthy male volunteers after a single oral dose of 100 or 200 mg. The ratios of the Cmaxs and of the areas under the concentration-time curves from 0 h to infinity for the two doses were about 2, indicating a dose proportionality. In a separate study, six healthy male volunteers received a single oral dose of 50 mg of 14C-labeled genaconazole. The Cmax values for total radioactivity (14C) and intact genaconazole were virtually identical (0.6 micrograms/ml). The mean half-lives in serum were about 73 h for both total radioactivity and genaconazole. The amounts of total radioactivity excreted in the 0 to 240-h interval (representing approximately three half-lives) in urine and feces were 66.6 and 9.3% of the dose, respectively; 64.4% of the dose was excreted in urine as parent drug. There were no detectable metabolites in either serum or urine. The data demonstrate that genaconazole (racemate) is well absorbed, undergoes negligible biotransformation, and is slowly excreted, primarily in the urine.",1996,"The mean values for the maximum concentrations in serum (Cmax) (1.7 micrograms/ml), times to Cmax (4.0 to 4.2 h), half-lives (83 h), and areas under the concentration-time curve from 0 h to infinity (195 to 199 micrograms.h/ml) were similar for the two enantiomers.","['men', '12 healthy male volunteers after a single oral dose of 200 mg', 'six healthy male volunteers', '12 healthy male volunteers after a single oral dose of 100 or 200 mg']","['genaconazole', 'single oral dose of 50 mg of 14C-labeled genaconazole']","['mean half-lives in serum', 'Cmax values for total radioactivity (14C) and intact genaconazole', 'total radioactivity excreted', 'mean values for the maximum concentrations in serum (Cmax', 'concentrations of the RR and SS enantiomers in serum']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]","[{'cui': 'C0208867', 'cui_str': 'genaconazole'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0034553', 'cui_str': 'Radioactive Disintegration'}, {'cui': 'C0205266', 'cui_str': 'Intact (qualifier value)'}, {'cui': 'C0208867', 'cui_str': 'genaconazole'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",6.0,0.0302081,"The mean values for the maximum concentrations in serum (Cmax) (1.7 micrograms/ml), times to Cmax (4.0 to 4.2 h), half-lives (83 h), and areas under the concentration-time curve from 0 h to infinity (195 to 199 micrograms.h/ml) were similar for the two enantiomers.","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Lin', 'Affiliation': 'Department of Drug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Radwanski', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Affrime', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Brannan', 'Affiliation': ''}, {'ForeName': 'M N', 'Initials': 'MN', 'LastName': 'Cayen', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1306,8725997,Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women.,"Several prophylactic medications for opportunistic or recurrent infections are used in human immunodeficiency virus-infected individuals. Essential to the efficacy evaluation of these agents is the accurate reporting of medication compliance. We hypothesized that poor patient compliance with thrice-weekly fluconazole prophylaxis would correlate with the occurrence of clinical events. Fluconazole compliance was monitored electronically by using the Medication Event Monitoring Systems with 19 women receiving fluconazole at 50 mg thrice weekly for prophylaxis of recurrent mucocutaneous candidiasis. During 202 patient-months of follow-up, eight breakthrough episodes of mucocutaneous candidiasis developed in four women; compliance data were available for seven of these episodes. At 6 months of therapy, more women with greater than or equal to 80% compliance were disease free compared with women with less than 80% compliance (P < 0.05; the Fisher exact test). These data suggest that documentation of medication compliance is essential in studies of chronic prophylaxis in human immunodeficiency virus-infected patients to properly evaluate drug efficacy and to avoid erroneous conclusions concerning drug failure.",1996,"At 6 months of therapy, more women with greater than or equal to 80% compliance were disease free compared with women with less than 80% compliance (P < 0.05; the Fisher exact test).","['human immunodeficiency virus-infected individuals', 'human immunodeficiency virus-infected women']","['fluconazole', 'fluconazole prophylaxis', 'Fluconazole']",[],"[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0016277', 'cui_str': 'Fluconazole'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}]",[],,0.0155611,"At 6 months of therapy, more women with greater than or equal to 80% compliance were disease free compared with women with less than 80% compliance (P < 0.05; the Fisher exact test).","[{'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Geletko', 'Affiliation': 'Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, Kingston 02881-0809, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Segarra', 'Affiliation': ''}, {'ForeName': 'K H', 'Initials': 'KH', 'LastName': 'Mayer', 'Affiliation': ''}, {'ForeName': 'T C', 'Initials': 'TC', 'LastName': 'Fiore', 'Affiliation': ''}, {'ForeName': 'F A', 'Initials': 'FA', 'LastName': 'Bettencourt', 'Affiliation': ''}, {'ForeName': 'T P', 'Initials': 'TP', 'LastName': 'Flanigan', 'Affiliation': ''}, {'ForeName': 'M N', 'Initials': 'MN', 'LastName': 'Dudley', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1307,8807058,"Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.","Delavirdine mesylate (DLV) is a potent nonnucleoside reverse transcriptase inhibitor with activity specific for human immunodeficiency virus type 1. In the present phase I/II study we evaluated the safety, toxicity, pharmacokinetics, and antiretroviral activities of two-drug and three-drug combinations of DLV and conventional doses of nucleoside analogs compared with those of both DLV monotherapy and two-drug nucleoside analog therapy. A total of 85 human immunodeficiency virus type 1 infected patients with CD4 counts of 100 to 300 cells per mm3 were enrolled in two periods: in the first period patients were randomized to receive either zidovudine (ZDV) plus didanosine (group 1) or ZDV plus didanosine plus escalating doses (400 to 1,200 mg/day) of DLV (group 2). In the second period, patients were randomized to receive either 1,200 mg of DLV alone per day (group 3) or ZDV plus 1,200 mg of DLV per day (group 4). DLV demonstrated good oral bioavailability at all five doses tested. The major toxicity was a transient mild rash which appeared in 44% of all DLV recipients. Overall, group 2 patients demonstrated more sustained improvements in CD4 counts, percent CD4 cells, branched DNA levels, p24 antigen levels, and virus titers in plasma than group 1, 3, or 4 patients. The magnitude of the response correlated with the intensity of prior nucleoside analog treatment, the non-syncytium-inducing or syncytium-inducing viral phenotype at baseline, and the presence of a wild-type codon at amino acid position 215 in the baseline reverse transcriptase genotype. Despite a transient rash, DLV therapy was well tolerated. Combination therapy with DLV and nucleoside analogs appears promising, with the three-drug combination appearing to be more potent that either two-drug combinations or monotherapy.",1996,"Overall, group 2 patients demonstrated more sustained improvements in CD4 counts, percent CD4 cells, branched DNA levels, p24 antigen levels, and virus titers in plasma than group 1, 3, or 4 patients.","['human immunodeficiency virus type 1-infected patients', '85 human immunodeficiency virus type 1 infected patients with CD4 counts of 100 to 300 cells per mm3 were enrolled in two periods: in the first period patients']","['ZDV plus didanosine', 'DLV monotherapy and two-drug nucleoside analog therapy', 'delavirdine (U-90152S) and conventional nucleosides', 'ZDV plus 1,200 mg of DLV', 'DLV and nucleoside analogs', 'DLV', 'Delavirdine mesylate (DLV', 'nucleoside analogs', 'zidovudine (ZDV) plus didanosine']","['good oral bioavailability', 'tolerated', 'safety, toxicity, pharmacokinetics, and antiretroviral activities', 'major toxicity', 'CD4 counts, percent CD4 cells, branched DNA levels, p24 antigen levels, and virus titers in plasma']","[{'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0439243', 'cui_str': 'mm3'}]","[{'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0012133', 'cui_str': 'Didanosine'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C1579410', 'cui_str': 'Nucleoside Analogs'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0288165', 'cui_str': 'Delavirdine'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0028621', 'cui_str': 'Nucleosides'}, {'cui': 'C0543492', 'cui_str': 'Delavirdine Mesylate'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}]","[{'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0599685', 'cui_str': 'Anti-Retroviral Agents'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0205384', 'cui_str': 'Branching (qualifier value)'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0085219', 'cui_str': 'HIV Major Core Protein p24'}, {'cui': 'C0430420', 'cui_str': 'Antigen level'}, {'cui': 'C2713348', 'cui_str': 'Virus Titer'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}]",85.0,0.0497093,"Overall, group 2 patients demonstrated more sustained improvements in CD4 counts, percent CD4 cells, branched DNA levels, p24 antigen levels, and virus titers in plasma than group 1, 3, or 4 patients.","[{'ForeName': 'R T', 'Initials': 'RT', 'LastName': 'Davey', 'Affiliation': 'National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892, USA. rdavey@pop.niaid.nih.gov'}, {'ForeName': 'D G', 'Initials': 'DG', 'LastName': 'Chaitt', 'Affiliation': ''}, {'ForeName': 'G F', 'Initials': 'GF', 'LastName': 'Reed', 'Affiliation': ''}, {'ForeName': 'W W', 'Initials': 'WW', 'LastName': 'Freimuth', 'Affiliation': ''}, {'ForeName': 'B R', 'Initials': 'BR', 'LastName': 'Herpin', 'Affiliation': ''}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Metcalf', 'Affiliation': ''}, {'ForeName': 'P S', 'Initials': 'PS', 'LastName': 'Eastman', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Falloon', 'Affiliation': ''}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Kovacs', 'Affiliation': ''}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Polis', 'Affiliation': ''}, {'ForeName': 'R E', 'Initials': 'RE', 'LastName': 'Walker', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Masur', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Boyle', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Coleman', 'Affiliation': ''}, {'ForeName': 'S R', 'Initials': 'SR', 'LastName': 'Cox', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Wathen', 'Affiliation': ''}, {'ForeName': 'C L', 'Initials': 'CL', 'LastName': 'Daenzer', 'Affiliation': ''}, {'ForeName': 'H C', 'Initials': 'HC', 'LastName': 'Lane', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1308,8807071,Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients.,"Rifabutin, 600 mg/day, was compared with a placebo in the early treatment of culture-proven Mycobacterium avium bacteremia in patients with AIDS. Following 14 days' treatment, bacteriological success, defined as a negative culture or a reduction in the number of CFU of M. avium organisms per milliliter of blood by a factor of > or = 0.5 log from the baseline, was observed in 7 of 10 (70%) evaluable rifabutin patients and in 1 of 13 (8%) evaluable placebo patients (P = 0.002). Rifabutin is active against M. avium as a single agent and can make a significant contribution to combination regimens for the treatment of disseminated M. avium infection in AIDS patients.",1996,"Following 14 days' treatment, bacteriological success, defined as a negative culture or a reduction in the number of CFU of M. avium organisms per milliliter of blood by a factor of > or = 0.5 log from the baseline, was observed in 7 of 10 (70%) evaluable rifabutin patients and in 1 of 13 (8%) evaluable placebo patients (P = 0.002).","['patients with AIDS', 'AIDS patients']","['placebo', 'Rifabutin', 'rifabutin']","['bacteriological success', 'number of CFU of M. avium organisms per milliliter of blood']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0140575', 'cui_str': 'Rifabutin'}]","[{'cui': 'C0205465', 'cui_str': 'Bacteriologic (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0029235', 'cui_str': 'Organism - attribute'}, {'cui': 'C0439526', 'cui_str': 'per milliliter'}, {'cui': 'C0005768'}]",,0.0228354,"Following 14 days' treatment, bacteriological success, defined as a negative culture or a reduction in the number of CFU of M. avium organisms per milliliter of blood by a factor of > or = 0.5 log from the baseline, was observed in 7 of 10 (70%) evaluable rifabutin patients and in 1 of 13 (8%) evaluable placebo patients (P = 0.002).","[{'ForeName': 'B', 'Initials': 'B', 'LastName': 'Dautzenberg', 'Affiliation': 'Groupe Hospitalier Pitié Salpêtrière, Paris, France.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Castellani', 'Affiliation': ''}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Pellegrin', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Vittecoq', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Truffot-Pernot', 'Affiliation': ''}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Pirotta', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Sassella', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1309,8807068,Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers.,"Five adults completed this four-way randomized crossover study to compare the effects of oral treatment with ciprofloxacin, clarithromycin, and a combination of the two drugs on theophylline pharmacokinetics. The area under the concentration-time curve for theophylline during combination therapy was not different from that for ciprofloxacin alone. Beta error may explain this finding, but any real effect from combination treatment appears to be clinically unimportant.",1996,The area under the concentration-time curve for theophylline during combination therapy was not different from that for ciprofloxacin alone.,['healthy volunteers'],"['ciprofloxacin, clarithromycin', 'ciprofloxacin', 'ciprofloxacin and clarithromycin']",['theophylline pharmacokinetics'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0055856', 'cui_str': 'Clarithromycin'}]","[{'cui': 'C0039771', 'cui_str': 'Theophylline'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}]",5.0,0.0398234,The area under the concentration-time curve for theophylline during combination therapy was not different from that for ciprofloxacin alone.,"[{'ForeName': 'J G', 'Initials': 'JG', 'LastName': 'Gillum', 'Affiliation': 'School of Pharmacy, Virginia Commonwealth University, Medical College of Virginia, Richmond 23298-0533, USA.'}, {'ForeName': 'D S', 'Initials': 'DS', 'LastName': 'Israel', 'Affiliation': ''}, {'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Scott', 'Affiliation': ''}, {'ForeName': 'M W', 'Initials': 'MW', 'LastName': 'Climo', 'Affiliation': ''}, {'ForeName': 'R E', 'Initials': 'RE', 'LastName': 'Polk', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1310,8807070,"Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea.","Thirty-nine patients with uncomplicated gonorrhea were randomized to receive single, oral 50-, 100-, or 200-mg doses of trovafloxacin (CP-99,219), a new quinolone antibiotic. All 31 evaluable patients were cured of infection. Trovafloxacin was well tolerated. The trovafloxacin MICs at which 50 and 90% of 36 Neisseria gonorrhoeae isolates are inhibited were 0.002 and 0.004 mg/liter, respectively (MIC range, < 0.0005 to 0.008 mg/liter). These preliminary studies suggest that trovafloxacin is effective for the treatment of uncomplicated gonorrhea at single oral doses as low as 50 mg.",1996,These preliminary studies suggest that trovafloxacin is effective for the treatment of uncomplicated gonorrhea at single oral doses as low as 50 mg.,"['uncomplicated gonorrhea', 'Thirty-nine patients with uncomplicated gonorrhea']","['trovafloxacin', 'CP-99,219 (trovafloxacin', 'Trovafloxacin', 'trovafloxacin (CP-99,219', 'quinolone antibiotic']","['tolerated', 'trovafloxacin MICs', 'cured of infection']","[{'cui': 'C0018081', 'cui_str': 'Neisseria gonorrhoeae Infection'}, {'cui': 'C3816447', 'cui_str': '39 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0379881', 'cui_str': 'trovafloxacin'}, {'cui': 'C0214255', 'cui_str': 'CP 99219'}, {'cui': 'C0034428', 'cui_str': 'Oxoquinolines'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}]","[{'cui': 'C0379881', 'cui_str': 'trovafloxacin'}, {'cui': 'C0427978', 'cui_str': 'Minimum Inhibitory Concentration'}, {'cui': 'C3714514', 'cui_str': 'Infection'}]",,0.0413836,These preliminary studies suggest that trovafloxacin is effective for the treatment of uncomplicated gonorrhea at single oral doses as low as 50 mg.,"[{'ForeName': 'E W', 'Initials': 'EW', 'LastName': 'Hook', 'Affiliation': 'Department of Medicine, University of Alabama at Birmingham, USA. ehook@uabid.dom.uab.edu'}, {'ForeName': 'G B', 'Initials': 'GB', 'LastName': 'Pinson', 'Affiliation': ''}, {'ForeName': 'C J', 'Initials': 'CJ', 'LastName': 'Blalock', 'Affiliation': ''}, {'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Johnson', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1311,8787869,Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes.,"Twenty-six hospitalized patients participated in a randomized crossover study to evaluate the effect of enteral feedings on ciprofloxacin absorption when given orally or via gastrostomy or jejunostomy tubes. Patients in the oral group received an intact 500-mg ciprofloxacin tablet alone or ciprofloxacin plus three oral doses of Sustacal (240 ml given 8 h before, with, and 4 h after ciprofloxacin administration). Patients with gastrostomy or jejunostomy tubes received 500 mg of crushed ciprofloxacin in 60 ml water via the feeding tube. After a washout period, the patients received ciprofloxacin with a continuous enteral formula (Jevity) given at 60 to 90 ml/h beginning 6 h before drug administration and continuing for 10 h. Serial blood samples were analyzed for ciprofloxacin concentration by high-performance liquid chromatography. The maximum ciprofloxacin concentrations in serum for ciprofloxacin given and for ciprofloxacin plus enteral feeding for the oral, gastrostomy, and jejunostomy groups were (mean +/- standard deviation) 2.59 +/- 1.24 versus 1.43 +/- 0.61 micrograms/ml (P < 0.05), 3.68 +/- 1.36 versus 2.27 +/- 0.67 micrograms/ml (P < 0.05), and 3.78 +/- 1.87 versus 1.45 +/- 0.48 micrograms/ml (P < 0.05), respectively. Corresponding values for area under the concentration-time curve were 13.4 +/- 8.32 versus 9.44 +/- 4.74 micrograms/h/ml (P < 0.05) 15.9 +/- 6.62 versus 7.44 +/- 3.16 (micrograms/h/ml (P < 0.05), and 18.1 +/- 9.37 versus 5.82 +/- 2.63 micrograms.h/ml (P < 0.05). We conclude that enteral feedings given orally or via gastrostomy or jejunostomy tubes resulted in a 27 to 67% reduction in the mean bioavailability of ciprofloxacin in hospitalized patients. The decreased absorption may be clinically important, especially when the enteral feeding is coadministered with ciprofloxacin by the oral and jejunostomy tube routes. Reductions in maximum levels of ciprofloxacin in serum as a result of feedings given via a gastrostomy tube are similar to those following oral administration on an empty stomach, making a clinically important interaction by this route less likely.",1996,"Reductions in maximum levels of ciprofloxacin in serum as a result of feedings given via a gastrostomy tube are similar to those following oral administration on an empty stomach, making a clinically important interaction by this route less likely.","['Twenty-six hospitalized patients', 'Patients with', 'hospitalized patients']","['intact 500-mg ciprofloxacin tablet alone or ciprofloxacin', 'gastrostomy or jejunostomy tubes received 500 mg of crushed ciprofloxacin', 'ciprofloxacin absorption when given orally or via gastrostomy or jejunostomy tubes', 'ciprofloxacin']","['maximum ciprofloxacin concentrations', 'mean bioavailability', 'Ciprofloxacin absorption']","[{'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0205266', 'cui_str': 'Intact (qualifier value)'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0017196', 'cui_str': 'Gastrostomy'}, {'cui': 'C0879216', 'cui_str': 'Jejunostomy tube'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0393365', 'cui_str': 'Approach via gastrostomy (qualifier value)'}]","[{'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}]",,0.0497533,"Reductions in maximum levels of ciprofloxacin in serum as a result of feedings given via a gastrostomy tube are similar to those following oral administration on an empty stomach, making a clinically important interaction by this route less likely.","[{'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Healy', 'Affiliation': 'College of Pharmacy, University of Cincinnati, Ohio 45267, USA. Dan.Healy@UC.EDU'}, {'ForeName': 'M C', 'Initials': 'MC', 'LastName': 'Brodbeck', 'Affiliation': ''}, {'ForeName': 'C E', 'Initials': 'CE', 'LastName': 'Clendening', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1312,8709213,"Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.","Human immunodeficiency virus type 1 (HIV-1) isolates obtained prior to and during a combination therapy trial comparing zidovudine (AZT; 3'-azidothymidine) monotherapy with AZT plus 2',3'-dideoxyinosine (ddI) or AZT plus 2',3'-dideoxycytidine (ddC) were assessed for the development of drug resistance. Drug susceptibility was measured by using two different phenotypic assays, one that requires infection of peripheral blood mononuclear cells with HIV-1 isolated from cocultures and a second based on infection of HeLa CD4+ cells with recombinant virus containing the reverse transcriptase (RT) of the clinical isolate. In addition, genotypic assessment of resistance was obtained by DNA sequencing of the RT coding region. No difference in the development of AZT resistance was noted in isolates from individuals receiving AZT monotherapy or combination therapy. However, a low frequency of ddI or ddC resistance was seen in isolates from the combination arms, which may at least partially explain the enhanced efficacy observed with these drug combinations compared with monotherapy. It was noted from DNA sequencing that a relatively high frequency of the nonnucleoside RT inhibitor resistance mutation, codon 181 changed from encoding Tyr to encoding Cys, was present in some isolates both before and during nucleoside analog combination therapy. Since these patients were unlikely to have access to nonnucleoside RT inhibitors, it is probable that this mutation preexisted at a reasonable level in the wild-type virus population. Comparisons of the AZT susceptibility assays indicated a good correlation between the phenotypic and genotypic determinations. However, direct numerical comparisons between the phenotypic assays were not reliable, suggesting that valid comparisons of different resistance data sets will require the use of the same assay procedure.",1996,No difference in the development of AZT resistance was noted in isolates from individuals receiving AZT monotherapy or combination therapy.,[],"['zidovudine (AZT) monotherapy', ""AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy"", 'nonnucleoside RT inhibitors', ""zidovudine (AZT; 3'-azidothymidine) monotherapy with AZT plus 2',3'-dideoxyinosine (ddI) or AZT plus 2',3'-dideoxycytidine""]","['Drug susceptibility', 'low frequency of ddI or ddC resistance', 'AZT resistance']",[],"[{'cui': 'C0043474', 'cui_str': 'Zidovudine'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0012133', 'cui_str': 'Didanosine'}, {'cui': 'C0012132', 'cui_str': 'Zalcitabine'}, {'cui': 'C0556895', 'cui_str': 'Combination therapy (regime/therapy)'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C1264642', 'cui_str': 'Susceptibility (property) (qualifier value)'}, {'cui': 'C0205213', 'cui_str': 'Low frequency (qualifier value)'}, {'cui': 'C0012133', 'cui_str': 'Didanosine'}, {'cui': 'C0012132', 'cui_str': 'Zalcitabine'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}]",,0.0480189,No difference in the development of AZT resistance was noted in isolates from individuals receiving AZT monotherapy or combination therapy.,"[{'ForeName': 'B A', 'Initials': 'BA', 'LastName': 'Larder', 'Affiliation': 'Glaxo Wellcome Research and Development, Stevenage, Hertfordshire, United Kingdom.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Kohli', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Bloor', 'Affiliation': ''}, {'ForeName': 'S D', 'Initials': 'SD', 'LastName': 'Kemp', 'Affiliation': ''}, {'ForeName': 'P R', 'Initials': 'PR', 'LastName': 'Harrigan', 'Affiliation': ''}, {'ForeName': 'R T', 'Initials': 'RT', 'LastName': 'Schooley', 'Affiliation': ''}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Lange', 'Affiliation': ''}, {'ForeName': 'K N', 'Initials': 'KN', 'LastName': 'Pennington', 'Affiliation': ''}, {'ForeName': 'M H', 'Initials': 'MH', 'LastName': 'St Clair', 'Affiliation': ''}]",Journal of virology,[] 1313,8723449,Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.,"Combinations of beta-lactams plus aminoglycosides have been standard therapy for suspected infections in granulocytopenic cancer patients, especially those with profound long-lasting granulocytopenia. With the advent of new broad-spectrum bactericidal antibiotics such as extended-spectrum cephalosporins or carbapenems, the need to combine beta-lactams with aminoglycosides became more controversial. The objective of this prospective randomized multicenter study was to compare the efficacy, safety, and tolerance of meropenem monotherapy with those of the combination of ceftazidime plus amikacin for the empirical treatment of fever in granulocytopenic cancer patients. Of 1,034 randomized patients, 958 were assessable in the intent-to-treat analysis for response to antibacterial therapy, including 483 in the meropenem group and 475 in the ceftazidime-plus-amikacin group. The median durations of neutropenia were 16 and 17 days, respectively. A successful outcome was reported in 270 of 483 (56%) patients treated with monotherapy compared with 245 of 475 (52%) patients treated with the combination group (P = 0.20). The success rates in the monotherapy group and the combination group were similar by type of infection (single gram-negative bacteremia, single gram-positive bacteremia, clinically documented infection, and possible infection). The occurrence of further infections assessed in patients for whom the allocated regimen was not modified did not differ between the two groups (12% in both groups). Mortality due to the presenting infection or further infection was relatively low (8 patients treated with the monotherapy compared with 13 patients treated with the combination). A total of 1,027 patients were evaluable for adverse events; the proportion of those who developed adverse effects was similar between the two groups (29% in both groups), and only 19 (4%) patients in the monotherapy group and 31 (6%) in the combination group experienced an adverse event related or probably related to the study drug. Allergic reactions were the only reason for stopping the protocol antibiotic(s) (3 and 5 patients, respectively). This study confirms that monotherapy with meropenem is as effective as the combination of ceftazidime plus amikacin for the empiric treatment of fever in persistently granulocytopenic cancer patients, and both regimens were well tolerated.",1996,The occurrence of further infections assessed in patients for whom the allocated regimen was not modified did not differ between the two groups (12% in both groups).,"['granulocytopenic cancer patients', 'group', 'persistently granulocytopenic cancer patients', 'granulocytopenic patients with cancer', '1,034 randomized patients, 958 were assessable in the intent-to-treat analysis for response to antibacterial therapy, including 483 in the meropenem group and 475 in the']","['beta-lactams plus aminoglycosides', 'meropenem', 'ceftazidime-plus-amikacin', 'monotherapy', 'meropenem monotherapy', 'ceftazidime plus amikacin']","['adverse event', 'efficacy, safety, and tolerance', 'Allergic reactions', 'Mortality', 'median durations of neutropenia', 'adverse effects', 'success rates', 'occurrence of further infections']","[{'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0279516', 'cui_str': 'Anti-Bacterial Agents'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0066005', 'cui_str': 'meropenem'}, {'cui': 'C4517786', 'cui_str': '475 (qualifier value)'}]","[{'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0002556', 'cui_str': 'Aminoglycosides'}, {'cui': 'C0066005', 'cui_str': 'meropenem'}, {'cui': 'C0007559', 'cui_str': 'Ceftazidime'}, {'cui': 'C0002499', 'cui_str': 'Amikacin'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C1527304', 'cui_str': 'Allergic Reaction'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}]",1034.0,0.0703571,The occurrence of further infections assessed in patients for whom the allocated regimen was not modified did not differ between the two groups (12% in both groups).,"[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Cometta', 'Affiliation': 'Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Calandra', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Gaya', 'Affiliation': ''}, {'ForeName': 'S H', 'Initials': 'SH', 'LastName': 'Zinner', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'de Bock', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Del Favero', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Bucaneve', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Crokaert', 'Affiliation': ''}, {'ForeName': 'W V', 'Initials': 'WV', 'LastName': 'Kern', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Klastersky', 'Affiliation': ''}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Langenaeken', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Micozzi', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Padmos', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Paesmans', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Viscoli', 'Affiliation': ''}, {'ForeName': 'M P', 'Initials': 'MP', 'LastName': 'Glauser', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1314,8723457,Ciprofloxacin pharmacokinetics in burn patients.,"Many drugs exhibit altered pharmacokinetic parameters in burn patients. We prospectively evaluated the pharmacokinetics of ciprofloxacin in eight burn patients with active infections. Each patient received a 400-mg dose of ciprofloxacin intravenously (i.v.) every 8 h, with each dose infused over 1 h by using a rate control device. Blood samples for analysis of plasma ciprofloxacin concentrations, determined by high-performance liquid chromatography, were obtained immediately predose, at the end of the infusion, and 1, 2, 3, 4, 5, 6, and 7 h after the end of the infusion. Urine was collected from 0 to 2, 2 to 4, and 4 to 8 h following the same dose, and an aliquot was saved for determination of the ciprofloxacin concentration. Urine was also collected for 24 h prior to this dose for measurement of creatinine clearance (CLCR). Pharmacokinetic parameters were estimated by noncompartmental analysis. Mean maximum and minimum plasma ciprofloxacin concentrations were 4.2 +/- 1.1 and 0.70 +/- 0.55 microgram/ml, respectively. Mean values for clearance (CL), renal clearance (CLR), volume of distribution, terminal elimination rate constant, half-life (t1/2), and area under the concentration-time curve (AUC) were 29.1 +/- 17.5 liters/h, 13.5 +/- 10.1 liters/h, 1.75 +/- 0.41 liters/kg, 0.222 +/- 0.098 h-1, 4.5 +/- 3.9 h, and 20.7 +/- 16.6 micrograms.h/ml, respectively. CL was higher and t1/2 was shorter than noted in previous studies of acutely ill, hospitalized patients. A good correlation was noted between creatinine clearance CL(CR) and both total ciprofloxacin CL (r = 0.85) and CLR (r = 0.84). A moderate inverse correlation was noted between percent body surface area burned and total ciprofloxacin CL (r = -0.55). An AUC/MIC ratio above 125 SIT-1 (where SIT is serum inhibitory titer), which has been strongly correlated with clinical response and time to bacterial eradication, was achieved in five of eight patients (63%) with a MIC of 0.25 microgram/ml. At a ciprofloxacin dosage of 400 mg i.v. every 12 h, an AUC/MIC ratio above 125 SIT-1 would have been achieved in only two of eight patients (25%). We conclude that ciprofloxacin CL is highly variable, but generally increased, in burn patients compared with that in acutely ill, general medical and surgical patients. Because of an increase in CL, a ciprofloxacin dosage of 400 mg i.v. every 8 h is more likely to produce the desired response in burn patients than the same dose given every 12 h.",1996,A good correlation was noted between creatinine clearance CL(CR) and both total ciprofloxacin CL (r = 0.85) and CLR (r = 0.84).,"['eight burn patients with active infections', 'burn patients']","['ciprofloxacin CL', 'Ciprofloxacin', 'ciprofloxacin']","['total ciprofloxacin CL', 'Pharmacokinetic parameters', 'Mean maximum and minimum plasma ciprofloxacin concentrations', 'CL', 'creatinine clearance CL(CR', 'Mean values for clearance (CL), renal clearance (CLR), volume of distribution, terminal elimination rate constant, half-life (t1/2), and area under the concentration-time curve (AUC', 'creatinine clearance (CLCR']","[{'cui': 'C0006434', 'cui_str': 'Burns'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}]","[{'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine (procedure)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0232813', 'cui_str': 'Renal clearance, function (observable entity)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}]",,0.0704848,A good correlation was noted between creatinine clearance CL(CR) and both total ciprofloxacin CL (r = 0.85) and CLR (r = 0.84).,"[{'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Garrelts', 'Affiliation': 'Via Christi Regional Medical Center, University of Kansas, School of Medicine-Wichita, USA.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Jost', 'Affiliation': ''}, {'ForeName': 'S F', 'Initials': 'SF', 'LastName': 'Kowalsky', 'Affiliation': ''}, {'ForeName': 'G J', 'Initials': 'GJ', 'LastName': 'Krol', 'Affiliation': ''}, {'ForeName': 'J T', 'Initials': 'JT', 'LastName': 'Lettieri', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1315,8723461,Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group.,"Community-acquired pneumonia occurs 3 to 4 million times per year in the United States, accounting for about 500,000 hospitalizations annually. Empiric treatment is usually instituted because of a lack of early organism-specific diagnostic tests. This study compared empiric therapy with ofloxacin to standard antibiotic regimens (usually a beta-lactam with or without a macrolide) for patients hospitalized for community-acquired pneumonia. Therapy was administered to 298 patients (146 receiving ofloxacin and 152 receiving standard therapy); 227 patients (ofloxacin, 109; standard treatment, 118) were evaluable for treatment efficacy. The most common pyogenic respiratory pathogens were Haemophilus influenzae (30 isolates) and Streptococcus pneumoniae (24 isolates). There was evidence of infection with either Mycoplasma pneumoniae (38 patients), Chlamydia pneumoniae (40 patients), or a Legionella sp. (8 patients) in a total of 79 patients (35%). The clinical success rates were similar in both groups among evaluable patients (92%, ofloxacin; 87%, standard therapy) and among patients with atypical respiratory pathogens (88%, ofloxacin; 81%, standard therapy). The mean numbers (+/- the standard deviations) of intravenous doses of antibiotics were 7.5 +/- 8.0 in the ofloxacin group and 18.4 +/- 18.5 in the standard therapy group (P < 0.001); the mean number of oral doses of ofloxacin per patient was 19.7 +/- 11.2, compared with 30.2 +/- 16.0 oral antibiotic doses in the standard therapy group (P < 0.001). All treatments were well tolerated and associated with no significant clinical or laboratory abnormalities. The findings of this study indicate that ofloxacin is active against traditional bacterial pathogens as well as the major atypical respiratory pathogens. When given as monotherapy for the empiric treatment of community-acquired pneumonia, ofloxacin is as effective as standard antimicrobial therapy.",1996,The most common pyogenic respiratory pathogens were Haemophilus influenzae (30 isolates) and Streptococcus pneumoniae (24 isolates).,"['community-acquired pneumonia requiring hospitalization', 'and 152 receiving standard therapy); 227 patients', '298 patients (146 receiving', 'patients hospitalized for community-acquired pneumonia']","['Ofloxacin', 'ofloxacin', 'ofloxacin to standard antibiotic regimens (usually a beta-lactam with or without a macrolide']","['tolerated and associated with no significant clinical or laboratory abnormalities', 'clinical success rates', 'mean numbers ', 'mean number of oral doses']","[{'cui': 'C0694549', 'cui_str': 'Community acquired pneumonia (disorder)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0028902', 'cui_str': 'Ofloxacin'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0282215', 'cui_str': 'beta-Lactams'}, {'cui': 'C0003240', 'cui_str': 'Substance with macrolide structure and antibacterial mechanism of action (substance)'}]","[{'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0000769', 'cui_str': 'anomalies'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]",118.0,0.0519427,The most common pyogenic respiratory pathogens were Haemophilus influenzae (30 isolates) and Streptococcus pneumoniae (24 isolates).,"[{'ForeName': 'J F', 'Initials': 'JF', 'LastName': 'Plouffe', 'Affiliation': 'Ohio State University, Columbus, USA.'}, {'ForeName': 'M T', 'Initials': 'MT', 'LastName': 'Herbert', 'Affiliation': ''}, {'ForeName': 'T M', 'Initials': 'TM', 'LastName': 'File', 'Affiliation': ''}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Baird', 'Affiliation': ''}, {'ForeName': 'J N', 'Initials': 'JN', 'LastName': 'Parsons', 'Affiliation': ''}, {'ForeName': 'J B', 'Initials': 'JB', 'LastName': 'Kahn', 'Affiliation': ''}, {'ForeName': 'K T', 'Initials': 'KT', 'LastName': 'Rielly-Gauvin', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1316,32437664,"First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.","BACKGROUND Addition of trastuzumab to first-line chemotherapy improves overall survival in patients with HER2-positive metastatic gastric cancer. We assessed the safety and activity of pembrolizumab in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic oesophagogastric (gastric, oesophageal, or gastroesophageal junction) cancer. METHODS This study was an investigator-initiated, open-label, non-randomised, single-arm, single centre, phase 2 trial in patients aged 18 years or older with HER2-positive metastatic oesophagogastric cancer. Eligible patients had measurable or evaluable non-measurable disease, Eastern Cooperative Oncology Group performance status of 0, 1, or 2, and left ventricular ejection fraction of at least 53%. Patients were eligible to receive an initial induction cycle of 200 mg flat dose of intravenous pembrolizumab and 8 mg/kg loading dose of intravenous trastuzumab. For subsequent cycles, patients received 130 mg/m 2 of intravenous oxaliplatin or 80 mg/m 2 of cisplatin on day 1, 850 mg/m 2 of oral capecitabine twice a day for 2 weeks followed by 1 week off (or intravenous 5-fluorouracil, 800 mg/m 2 per day on days 1-5), and a 200 mg flat dose of intravenous pembrolizumab, and 6 mg/kg of trastuzumab, administered on day 1 of each 3-week cycle. The primary endpoint was 6-month progression-free survival, defined as the proportion of patients alive and free of progression at 6 months, assessed in patients who received at least one dose of trastuzumab and pembrolizumab. The regimen would be considered worthy of further investigation if 26 or more of 37 patients were progression-free at 6 months. This trial is registered with ClinicalTrials.gov, NCT02954536, and is ongoing, but closed to enrolment. FINDINGS Between Nov 11, 2016, and Jan 23, 2019, 37 patients were enrolled. At the time of data cutoff on Aug 6, 2019, median follow-up among survivors was 13·0 months (IQR 11·7-23·5). The primary endpoint was achieved; 26 (70%; 95% CI 54-83) of 37 patients were progression-free at 6 months. The most common treatment-related adverse event of any grade was neuropathy, which was reported in 36 (97%) of 37 patients. The most common grade 3 or 4 adverse events were lymphocytopenia (seven [19%] patients with grade 3 and two [5%] with grade 4), grade 3 decreased electrolytes (six [16%] patients), and grade 3 anaemia (four [11%] patients). Serious adverse events occurred in two patients patients (both grade 3 nephritis leading to treatment discontinuation). Four patients discontinued pembrolizumab because of immune-related adverse events. There were no treatment-related deaths. INTERPRETATION Pembrolizumab can be safely combined with trastuzumab and chemotherapy and has promising activity in HER2-positive metastatic oesophagogastric cancer. A randomised phase 3 clinical trial assessing the efficacy and safety of pembrolizumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic oesophagogastric cancer is underway. FUNDING Merck & Co.",2020,The primary endpoint was achieved; 26 (70%; 95% CI 54-83) of 37 patients were progression-free at 6 months.,"['HER2-positive metastatic oesophagogastric cancer', 'Eligible patients had measurable or evaluable non-measurable disease, Eastern Cooperative Oncology Group performance status of 0, 1, or 2, and left ventricular ejection fraction of at least 53', 'patients aged 18 years or older with HER2-positive metastatic oesophagogastric cancer', 'first-line HER2-positive metastatic oesophagogastric cancer', 'HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer', 'Between Nov 11, 2016, and Jan 23, 2019, 37 patients were enrolled', 'first-line HER2-positive metastatic oesophagogastric (gastric, oesophageal, or gastroesophageal junction) cancer', 'patients with HER2-positive metastatic gastric cancer']","['oxaliplatin', 'intravenous pembrolizumab and 8 mg/kg loading dose of intravenous trastuzumab', 'trastuzumab and pembrolizumab', 'trastuzumab to first-line chemotherapy', 'trastuzumab and chemotherapy', 'capecitabine', 'cisplatin', 'pembrolizumab, and 6 mg/kg of trastuzumab', 'pembrolizumab versus placebo', 'First-line pembrolizumab and trastuzumab', '5-fluorouracil', 'pembrolizumab']","['safety and activity', '6-month progression-free survival, defined as the proportion of patients alive and free of progression', 'overall survival', 'grade 3 decreased electrolytes', 'grade 3 anaemia', 'efficacy and safety', 'Serious adverse events']","[{'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0475468', 'cui_str': 'Esophagogastric'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0014871', 'cui_str': 'Cardioesophageal junction structure'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C0278498', 'cui_str': 'Gastric cancer stage IV'}]","[{'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2584946', 'cui_str': 'Alive'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0740464', 'cui_str': 'Electrolytes NOS decreased'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",37.0,0.193351,The primary endpoint was achieved; 26 (70%; 95% CI 54-83) of 37 patients were progression-free at 6 months.,"[{'ForeName': 'Yelena Y', 'Initials': 'YY', 'LastName': 'Janjigian', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: janjigiy@mskcc.org.'}, {'ForeName': 'Steven B', 'Initials': 'SB', 'LastName': 'Maron', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Walid K', 'Initials': 'WK', 'LastName': 'Chatila', 'Affiliation': 'Marie-Josée & Henry R Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Tri-Institutional Program in Computational Biology and Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Brittanie', 'Initials': 'B', 'LastName': 'Millang', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Shweta S', 'Initials': 'SS', 'LastName': 'Chavan', 'Affiliation': 'Marie-Josée & Henry R Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Carly', 'Initials': 'C', 'LastName': 'Alterman', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Joanne F', 'Initials': 'JF', 'LastName': 'Chou', 'Affiliation': 'Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Michal F', 'Initials': 'MF', 'LastName': 'Segal', 'Affiliation': 'Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Marc Z', 'Initials': 'MZ', 'LastName': 'Simmons', 'Affiliation': 'Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Parisa', 'Initials': 'P', 'LastName': 'Momtaz', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Shcherba', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Geoffrey Y', 'Initials': 'GY', 'LastName': 'Ku', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Zervoudakis', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Elizabeth S', 'Initials': 'ES', 'LastName': 'Won', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Kelsen', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Ilson', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Rebecca J', 'Initials': 'RJ', 'LastName': 'Nagy', 'Affiliation': 'Guardant Health, Redwood City, CA, USA.'}, {'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Lanman', 'Affiliation': 'Guardant Health, Redwood City, CA, USA.'}, {'ForeName': 'Ryan N', 'Initials': 'RN', 'LastName': 'Ptashkin', 'Affiliation': 'Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Mark T A', 'Initials': 'MTA', 'LastName': 'Donoghue', 'Affiliation': 'Marie-Josée & Henry R Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Marinela', 'Initials': 'M', 'LastName': 'Capanu', 'Affiliation': 'Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Barry S', 'Initials': 'BS', 'LastName': 'Taylor', 'Affiliation': 'Marie-Josée & Henry R Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Solit', 'Affiliation': 'Marie-Josée & Henry R Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Nikolaus', 'Initials': 'N', 'LastName': 'Schultz', 'Affiliation': 'Marie-Josée & Henry R Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Jaclyn F', 'Initials': 'JF', 'LastName': 'Hechtman', 'Affiliation': 'Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30169-8'] 1317,8606118,"Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines.","Healthy adults (n=330) were randomized to receive either a bivalent vaccine composed of Vibrio cholerae CVD 103-HgR and Salmonella typhi Ty21a or a placebo. The combined vaccine was well tolerated. Approximately 80% of vaccines manifested a significant rise in anti-S. typhi immunoglobulin G or immunoglobulin A lipopolysaccharide antibody levels. Significant (fourfold or greater) rises in anti-Inaba or anti-Ogawa vibriocidal antibody titer were achieved by 94 and 80% of vaccine recipients, respectively. Elevated baseline vibriocidal antibody titers showed a modest suppressive effect on the rate of seroconversion.",1996,Approximately 80% of vaccines manifested a significant rise in anti-S. typhi immunoglobulin G or immunoglobulin A lipopolysaccharide antibody levels.,['Healthy adults (n=330'],"['combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines', 'placebo', 'bivalent vaccine composed of Vibrio cholerae CVD 103-HgR and Salmonella typhi Ty21a or a placebo']","['anti-Inaba or anti-Ogawa vibriocidal antibody titer', 'tolerated', 'rate of seroconversion', 'safety and immunogenicity']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0036125', 'cui_str': 'Salmonella typhosa'}, {'cui': 'C0042629', 'cui_str': 'Vibrio cholerae'}, {'cui': 'C0961644', 'cui_str': 'cholera vaccine CVD 103-HgR'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0443008', 'cui_str': 'Inaba'}, {'cui': 'C0443037', 'cui_str': 'Ogawa'}, {'cui': 'C1287242', 'cui_str': 'Finding of antibody titer (finding)'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",330.0,0.640836,Approximately 80% of vaccines manifested a significant rise in anti-S. typhi immunoglobulin G or immunoglobulin A lipopolysaccharide antibody levels.,"[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Kollaritsch', 'Affiliation': 'Institute for Specific Prophylaxis and Tropical Medicine, University of Vienna, Austria.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Furer', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Herzog', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Wiedermann', 'Affiliation': ''}, {'ForeName': 'J U', 'Initials': 'JU', 'LastName': 'Que', 'Affiliation': ''}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Cryz', 'Affiliation': ''}]",Infection and immunity,[] 1318,8606066,Influence of endotoxin on daytime sleep in humans.,"Administration of endotoxin in the evening has been shown to transiently suppress rapid eye movement (REM) and to promote non-REM sleep in humans. In a single-blind placebo-controlled crossover design, we assessed the effects of Salmonella abortus equi endotoxin administered intravenously in the morning on the primary host response and on daytime sleep by use of a multiple napping protocol in healthy volunteers. The extent of the host response achieved by 0.8 ng of endotoxin per kg of body weight given at 0900 h was comparable to that previously reported to result from the administration of 0.4 ng/kg at 1900 h. However, sleep was only slightly influenced. Endotoxin reduced the amount of REM sleep and increased REM latency. Non-REM sleep amount in the first nap, although not significantly changed, correlated negatively with the individual peak levels of interleukin-6 (r = -0.73, P < 0.05). Subjective tiredness, sleep onset latency, total sleep time, and the amounts of slow-wave and non-REM sleep were not affected by endotoxin throughout the entire experiment. Spectral analysis of the electroencephalogram obtained during non-REM sleep yielded no condition differences. We conclude that endotoxin administration in the morning to healthy volunteers, while activating the host defense to the same extent as a lower dose that has been reported to promote non-REM sleep when given in the evening, does not affect non-REM sleep. REM sleep suppression is, to date, the most consistently reported effect of endotoxin on human sleep.",1996,"Endotoxin reduced the amount of REM sleep and increased REM latency. Non-REM sleep amount in the first nap, although not significantly changed, correlated negatively with the individual peak levels of interleukin-6 (r = -0.73, P < 0.05).","['healthy volunteers', 'humans']","['endotoxin', 'Endotoxin', 'Salmonella abortus equi endotoxin', 'placebo']","['individual peak levels of interleukin-6', 'amount of REM sleep and increased REM latency. Non-REM sleep amount', 'daytime sleep', 'Subjective tiredness, sleep onset latency, total sleep time, and the amounts of slow-wave and non-REM sleep']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0014264', 'cui_str': 'Endotoxins'}, {'cui': 'C0036111', 'cui_str': 'Salmonella'}, {'cui': 'C0000781', 'cui_str': 'Aborted Embryo'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0037322', 'cui_str': 'Sleep, Fast-Wave'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0560134', 'cui_str': 'rem'}, {'cui': 'C4075948', 'cui_str': 'Sleeps during day (finding)'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C4505222', 'cui_str': 'REM Sleep Latency'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1265611', 'cui_str': 'Quantity finding'}, {'cui': 'C0439834', 'cui_str': 'Slowly'}]",,0.0235748,"Endotoxin reduced the amount of REM sleep and increased REM latency. Non-REM sleep amount in the first nap, although not significantly changed, correlated negatively with the individual peak levels of interleukin-6 (r = -0.73, P < 0.05).","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Korth', 'Affiliation': 'Clinical Institute, Max Planck Institute of Psychiatry, Munich, Germany.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Mullington', 'Affiliation': ''}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Schreiber', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Pollmächer', 'Affiliation': ''}]",Infection and immunity,[] 1319,8550186,Passive immunization with monoclonal antibodies against Porphyromonas gingivalis in patients with periodontitis.,"Selective inhibition of recolonization of Porphyromonas gingivalis was investigated by topical application of monoclonal antibody (MAb). To select a MAb to P. gingivalis with the potential for recognizing most strains of P. gingivalis, we examined seven MAbs, one of which (MAb 61BG 1.3) recognized all 22 laboratory strains and serotypes of P. gingivalis tested as well as 105 human clinical isolates. A comparative study of the number of P. gingivalis bacteria identified by conventional culture and immunofluorescence with MAb 61BG 1.3 showed a very significant correlation between the two methods (Spearman r = 0.85, P < 0.001). Fourteen patients with periodontitis, who harbored P. gingivalis in their subgingival plaque, were treated by root planing and with metronidazole to suppress any detectable P. gingivalis. In this double-blind study, the patients were then divided randomly into two groups; one was treated with MAb to P. gingivalis, and the other was treated with saline. Each patient had four subgingival applications of 3 micrograms of MAb (or saline) per tooth at 1, 3, 7, and 10 days after P. gingivalis was suppressed. The number of P. gingivalis bacteria was then monitored, and significantly less recolonization of the sites with the most severe periodontitis was found in the MAb-treated patients than in the control patients (P < 0.01). This was evident at 6 and 9 months after the application of MAb, but by 12 months, P. gingivalis, was also found to recolonize these sites in two of the MAb-treated patients. The effect of MAb was specific to P. gingivalis, since the numbers of spirochetes were not significantly different between the two groups. However, no significant difference in any clinical periodontal indices between the immunized and control patients at 6 and 12 months was observed. This is the first demonstration that a putative periodontal pathogen can be selectively prevented from recolonization for up to 9 months in sites with the most severe periodontitis. This strategy could be used to establish directly in humans whether a microorganism is involved in the pathogenesis of periodontitis, by repeated application of the corresponding MAb at about 6-month intervals and by comparing the clinical indices between the MAb-treated and control patients.",1996,"However, no significant difference in any clinical periodontal indices between the immunized and control patients at 6 and 12 months was observed.","['patients with periodontitis', 'Fourteen patients with periodontitis, who harbored P. gingivalis in their subgingival plaque']","['Passive immunization with monoclonal antibodies', 'saline', 'MAb', 'MAb (or saline', 'metronidazole']","['number of P. gingivalis bacteria', 'clinical periodontal indices', 'recolonization of the sites with the most severe periodontitis']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0475311', 'cui_str': 'Harbor (environment)'}, {'cui': 'C0399451', 'cui_str': 'Subgingival plaque (disorder)'}]","[{'cui': 'C0020974', 'cui_str': 'Immunization, Passive'}, {'cui': 'C3542957', 'cui_str': 'Antineoplastic MAbs'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1510439', 'cui_str': 'bacteria'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0031092', 'cui_str': 'Periodontal Index'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0031099', 'cui_str': 'Periodontitis'}]",14.0,0.0185321,"However, no significant difference in any clinical periodontal indices between the immunized and control patients at 6 and 12 months was observed.","[{'ForeName': 'V', 'Initials': 'V', 'LastName': 'Booth', 'Affiliation': ""Department of Periodontology and Preventive Dentistry, United Medical School of Guy's Hospital, London, United Kingdom.""}, {'ForeName': 'F P', 'Initials': 'FP', 'LastName': 'Ashley', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Lehner', 'Affiliation': ''}]",Infection and immunity,[] 1320,8698504,"Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.","A set of isogenic strains was constructed from the meningococcal reference strain H44/76 (B:15:P1.7,16) which differed only in their outer membrane protein (OMP) compositions. First, three isogenic strains lacking the expression of either class 3 (PorB) or class 4 (RmpM) OMP or both were obtained. Second, three isogenic class 1 OMP loop-deficient strains of H44/76 lacking the predicted loop 1 or 4 or both of class 1 OMP (PorA) were obtained. Third, three isogenic class 1 OMP strains which differed by point mutations in the predicted loop 4 of subtype P1.16 were constructed. Strains were constructed through transformation with gene constructs made in Escherichia coli and their homologous recombination into the meningococcal chromosome. This study describes the contribution of one of the six class 1 OMPs, PorA P1.7,16, in the development of bactericidal antibodies after a single immunization of adult volunteers with 50 or 100 micrograms of protein within a hexavalent PorA outer membrane vesicle vaccine. PorA-, PorB-, and RpmM-deficient isogenic strains were used to define the human immune response against PorA. The loop-deficient isogenic strains were used to define the contribution of loops 1 and 4 of PorA in the development of bactericidal anti-PorA antibodies. The isogenic strains carrying a point mutation in loop 4 were used to study the cross-reactivity of the induced bactericidal antibodies against target strains showing microheterogeneity. The results indicate that a single immunization with the hexavalent PorA vaccine induced a dose-dependent bactericidal immune response, which is directed mainly against PorA. The epitope specificity of antibodies is directed mostly against loop 1, although loop 4 and as-yet-unidentified epitopes of PorA P1.7,16 are also involved.",1996,"The results indicate that a single immunization with the hexavalent PorA vaccine induced a dose-dependent bactericidal immune response, which is directed mainly against PorA.",['adult volunteers with 50 or 100 micrograms of protein within a hexavalent PorA outer membrane vesicle vaccine'],[],['expression of either class 3 (PorB) or class 4 (RmpM'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0439211', 'cui_str': 'microgram'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0025255', 'cui_str': 'Membranes'}, {'cui': 'C0333262', 'cui_str': 'Vesicle (morphologic abnormality)'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}]",[],"[{'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0441887', 'cui_str': 'Class 3 (qualifier value)'}, {'cui': 'C0441888', 'cui_str': 'Class 4 (qualifier value)'}]",,0.0302265,"The results indicate that a single immunization with the hexavalent PorA vaccine induced a dose-dependent bactericidal immune response, which is directed mainly against PorA.","[{'ForeName': 'E R', 'Initials': 'ER', 'LastName': 'van der Voort', 'Affiliation': 'Laboratory of Vaccine Development and Immune Mechanisms, National Institute of Public Health and the Environment, Bilthoven, The Netherlands. lvmervdv@rivm.nl'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'van der Ley', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'van der Biezen', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'George', 'Affiliation': ''}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Tunnela', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'van Dijken', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Kuipers', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Poolman', 'Affiliation': ''}]",Infection and immunity,[] 1321,8849265,Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts.,"Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is effective in countering chemotherapy-induced neutropenia. However, serum rhG-CSF levels cannot be maintained throughout the course of rhG-CSF therapy. The drop in serum rhG-CSF levels may vary with the duration of rhG-CSF administration or with the circulating neutrophil counts. We investigated the relationship between serum G-CSF levels and circulating neutrophil counts and the pharmacokinetics of rhG-CSF for patients with lung cancer who had been treated with myelosuppressive chemotherapy and then with subcutaneous rhG-CSF (lenograstim, 2 micrograms per kg of body weight per day). Twelve patients were randomly assigned to four groups with different rhG-CSF therapy schedules. Serum G-CSF levels were measured by an enzyme immunoassay method. Serum G-CSF levels during the rhG-CSF therapy greatly exceeded endogenous G-CSF levels and were mainly due to the presence of exogenous rhG-CSF rather than increased levels of endogenous G-CSF. Despite the duration of rhG-CSF administration, serum G-CSF levels during rhG-CSF therapy were inversely correlated with circulating neutrophil counts (r2 = 0.73, P < 0.0001). The value for the area under the concentration-time curve of rhG-CSF on the day of neutrophilia was lower than that on the day of neutropenia (P < 0.05). Our results suggest that the fall in serum G-CSF levels during rhG-CSF therapy may result from increased clearance and/or decreased absorption of rhG-CSF, two processes related to circulating neutrophil counts.",1996,Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is effective in countering chemotherapy-induced neutropenia.,"['patients with lung cancer who had been treated with myelosuppressive chemotherapy and then with subcutaneous rhG-CSF (lenograstim, 2 micrograms per kg of body weight per day', 'Twelve patients']",['Recombinant human granulocyte colony-stimulating factor (rhG-CSF'],"['serum rhG-CSF levels', 'endogenous G-CSF levels', 'duration of rhG-CSF administration, serum G-CSF levels', 'circulating neutrophil counts', 'serum G-CSF levels and circulating neutrophil counts', 'serum G-CSF levels', 'Serum G-CSF levels']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1306460', 'cui_str': 'Primary malignant neoplasm of lung'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C0218640', 'cui_str': 'lenograstim'}, {'cui': 'C0439211', 'cui_str': 'microgram'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0439505', 'cui_str': 'per day'}]","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0018183', 'cui_str': 'Granulocytic cell'}, {'cui': 'C0439158', 'cui_str': 'colonies (qualifier value)'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205227', 'cui_str': 'Endogenous (qualifier value)'}, {'cui': 'C0079459', 'cui_str': 'G-CSF'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0200633', 'cui_str': 'Neutrophil count (procedure)'}]",12.0,0.0117686,Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is effective in countering chemotherapy-induced neutropenia.,"[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Takatani', 'Affiliation': 'Second Department of Internal Medicine, School of Medicine, Nagasaki University, Japan.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Soda', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Fukuda', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Watanabe', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Kinoshita', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Nakamura', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Oka', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 1322,32437393,"Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial.","OBJECTIVES Systemic sclerosis (SSc) is an auto-immune, multi organ disease marked by severe gastrointestinal (GI) involvement and gut dysbiosis. Here, we aimed to determine the safety and efficacy of fecal microbiota transplantation (FMT) using commercially-available anaerobic cultivated human intestinal microbiota (ACHIM) in SSc. METHODS Ten patients with SSc were randomized to ACHIM (n = 5) or placebo (n = 5) in a double-blind, placebo-controlled 16-week pilot. All patients had mild to severe upper and lower GI symptoms including diarrhea, distention/bloating and/or fecal incontinence at baseline. Gastroduodenoscopy transfer of ACHIM or placebo was performed at weeks 0 and 2. Primary endpoints were safety and clinical efficacy on GI symptoms assessed at weeks 4 and 16. Secondary endpoints included changes in relative abundance of total, immunoglobulin (Ig) A- and IgM-coated fecal bacteria measured by 16s rRNA sequencing. RESULTS ACHIM side effects were mild and transient. Two placebo controls experienced procedure-related serious adverse events; one developed laryngospasms at week 0 gastroduodenoscopy necessitating study exclusion whilst one encountered duodenal perforation during gastroduodenoscopy at the last study visit (week 16). Decreased bloating, diarrhea and/or fecal incontinence was observed in four of five patients in the FMT group (week 4 or/and 16) and in two of four in the placebo group (week 4 or 16). Relative abundance, richness and diversity of total and IgA-coated and IgM-coated bacteria fluctuated more after FMT, than after placebo. CONCLUSIONS FMT of commercially-available ACHIM is associated with gastroduodenoscopy complications but reduces lower GI symptoms by possibly altering the gut microbiota in patients with SSc.",2020,"Relative abundance, richness and diversity of total and IgA-coated and IgM-coated bacteria fluctuated more after FMT, than after placebo. ","['Ten patients with SSc', 'systemic sclerosis', 'patients with SSc']","['fecal microbiota transplantation (FMT', 'FMT', 'ACHIM or placebo', 'ACHIM', 'Fecal microbiota transplantation', 'placebo']","['safety and clinical efficacy on GI symptoms', 'changes in relative abundance of total, immunoglobulin (Ig) A- and IgM-coated fecal bacteria measured by 16s rRNA sequencing', 'procedure-related serious adverse events', 'mild to severe upper and lower GI symptoms including diarrhea, distention/bloating and/or fecal incontinence', 'Decreased bloating, diarrhea and/or fecal incontinence', 'Relative abundance, richness and diversity of total and IgA-coated and IgM-coated bacteria fluctuated']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036421', 'cui_str': 'Systemic sclerosis'}]","[{'cui': 'C2242628', 'cui_str': 'Fecal microbiota transplantation'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0020861', 'cui_str': 'Immunoglobulin M'}, {'cui': 'C0453946', 'cui_str': 'Coat'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0035701', 'cui_str': 'Ribosomal RNA'}, {'cui': 'C0162801', 'cui_str': 'Analysis, Sequence'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0231241', 'cui_str': 'Fluctuating'}]",10.0,0.365308,"Relative abundance, richness and diversity of total and IgA-coated and IgM-coated bacteria fluctuated more after FMT, than after placebo. ","[{'ForeName': 'Håvard', 'Initials': 'H', 'LastName': 'Fretheim', 'Affiliation': 'Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Brian K', 'Initials': 'BK', 'LastName': 'Chung', 'Affiliation': 'Institute of Clinical Medicine, University of Oslo, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Henriette', 'Initials': 'H', 'LastName': 'Didriksen', 'Affiliation': 'Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Espen S', 'Initials': 'ES', 'LastName': 'Bækkevold', 'Affiliation': 'Department of Pathology and Centre for Immune Regulation, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Øyvind', 'Initials': 'Ø', 'LastName': 'Midtvedt', 'Affiliation': 'Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Cathrine', 'Initials': 'C', 'LastName': 'Brunborg', 'Affiliation': 'Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Holm', 'Affiliation': 'Institute of Clinical Medicine, University of Oslo, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Jørgen', 'Initials': 'J', 'LastName': 'Valeur', 'Affiliation': 'Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway.'}, {'ForeName': 'Anders Heiervang', 'Initials': 'AH', 'LastName': 'Tennøe', 'Affiliation': 'Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Torhild', 'Initials': 'T', 'LastName': 'Garen', 'Affiliation': 'Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Tore', 'Initials': 'T', 'LastName': 'Midtvedt', 'Affiliation': 'Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Trøseid', 'Affiliation': 'Institute of Clinical Medicine, University of Oslo, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Hasse', 'Initials': 'H', 'LastName': 'Zarè', 'Affiliation': 'Clinical Trial Unit, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'May Brit', 'Initials': 'MB', 'LastName': 'Lund', 'Affiliation': 'Institute of Clinical Medicine, University of Oslo, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Johannes R', 'Initials': 'JR', 'LastName': 'Hov', 'Affiliation': 'Institute of Clinical Medicine, University of Oslo, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Knut E A', 'Initials': 'KEA', 'LastName': 'Lundin', 'Affiliation': 'Department of Gastroenterology, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Øyvind', 'Initials': 'Ø', 'LastName': 'Molberg', 'Affiliation': 'Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Anna-Maria', 'Initials': 'AM', 'LastName': 'Hoffmann-Vold', 'Affiliation': 'Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}]",PloS one,['10.1371/journal.pone.0232739'] 1323,31432287,Safety and efficacy of prophylactic resorbable biosynthetic mesh following midline laparotomy in clean/contemned field: preliminary results of a randomized double blind prospective trial.,"BACKGROUND Incisional hernia (IH) is one of the most common sequelae of laparotomy. MATERIALS AND METHODS We present a double-blind randomized study examining feasibility, safety and incisional hernia rate using a prophylactic Bio-A biosynthetic stripe (Gore) in a sub-lay position after midline laparotomy in patients undergoing operations in clean-contaminated and contaminated field. One hundred patients who underwent a midline laparotomy of at least 10 cm in a clean-contaminated and contaminated field were considered. Patients were divided into two groups: [Group A closed in double layer using PDS 0 with WL/SL of 1:4; Group B closure in double layer using PDS 0 and sub-lay positioning a 3 cm-wide BIO A (Gore) strip extended for the entire length of the incision]. The primary objective of the study was to identify IH rate in the two groups at 1- and 2-year follow-up. Secondary objective was to identify any differences in the two groups in terms of post-operative pain, morbidity and mortality. RESULTS Out of a total of 100 patients included in the study, a 2-year follow-up was possible for 47 patients in group A and 45 in group B. The incidence of IH was 11/47 in group A (22%) and 3/45 in group B (6%) [p < 0.01]. Furthermore, no statistically significant difference was noted about post-operative morbidity and pain related to the wall closure method. CONCLUSIONS The prophylactic use of a BIO-A biosynthetic stripe (Gore) showed a statistically significant reduction in the incisional hernia rate in patients who underwent clean-contaminated and contaminated surgery.",2020,The prophylactic use of a BIO-A biosynthetic stripe (Gore) showed a statistically significant reduction in the incisional hernia rate in patients who underwent clean-contaminated and contaminated surgery.,"['patients undergoing operations in clean-contaminated and contaminated field', '100 patients included in the study, a 2-year follow-up was possible for 47 patients in group A and 45 in group', 'One hundred patients who underwent a midline laparotomy of at least 10\xa0cm in a clean-contaminated and contaminated field were considered', 'midline laparotomy in clean/contemned field', 'patients who underwent clean-contaminated and contaminated surgery']","['prophylactic Bio-A biosynthetic stripe (Gore', 'prophylactic resorbable biosynthetic mesh']","['incidence of IH', 'Safety and efficacy', 'post-operative pain, morbidity and mortality', 'incisional hernia rate', 'feasibility, safety and incisional hernia rate', 'IH rate', 'post-operative morbidity and pain']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0440042', 'cui_str': ""Field's""}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0332149', 'cui_str': 'Possible (qualifier value)'}, {'cui': 'C0441835', 'cui_str': 'Group A (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0023038', 'cui_str': 'Laparotomy'}, {'cui': 'C0205279', 'cui_str': 'Contaminated (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}, {'cui': 'C1532935', 'cui_str': 'Striped'}, {'cui': 'C0181805', 'cui_str': 'Mesh (physical object)'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0267716', 'cui_str': 'Postoperative Hernia'}]",100.0,0.230939,The prophylactic use of a BIO-A biosynthetic stripe (Gore) showed a statistically significant reduction in the incisional hernia rate in patients who underwent clean-contaminated and contaminated surgery.,"[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Pizza', 'Affiliation': 'ASL Napoli 2 Nord, Via Lupoli, 27, 80027, Frattamaggiore, Naples, Italy. francesco_pizza@libero.it.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': ""D'Antonio"", 'Affiliation': 'ASL Napoli 2 Nord, Via Lupoli, 27, 80027, Frattamaggiore, Naples, Italy.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Arcopinto', 'Affiliation': 'AORN ""A. Cardarelli"", Naples, Italy.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': ""Dell'Isola"", 'Affiliation': 'AORN Azienda Dei Colli ""A. Cotugno"", Naples, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Marvaso', 'Affiliation': 'ASL Napoli 2 Nord, Via Lupoli, 27, 80027, Frattamaggiore, Naples, Italy.'}]",Hernia : the journal of hernias and abdominal wall surgery,['10.1007/s10029-019-02025-4'] 1324,32438531,Intermittent Fasting Does Not Uniformly Impact Genes Involved in Circadian Regulation in Women with Obesity.,"OBJECTIVE This study aimed to examine the effects of intermittent fasting (IF) on mRNA levels of peripheral clock genes in skeletal muscle and subcutaneous adipose tissue (SAT) in women with obesity. METHODS Women were randomized to one of two IF protocols and provided with all foods at 100% or 70% of calculated weekly energy requirements for 8 weeks. Breakfast was consumed before a 24-hour fast, which was initiated on three nonconsecutive days per week. Muscle and SAT biopsies were performed at 8 am after an overnight fast at baseline and at week 8 on a refed day and again following a 24-hour fast at week 8 for analysis of the mRNA levels of key genes involved in circadian regulation. RESULTS A group-by-time interaction was observed in Per2 in muscle (F = 3.497, P = 0.044) and SAT (F = 6.686, P = 0.008), but significance was lost upon post hoc adjustment. A time effect was observed in Rorα in muscle, which was decreased by refeeding in both groups (F = 7.225, P = 0.003). CONCLUSIONS There was no universal effect of IF to alter peripheral clocks, which may be partly because of the alignment of the fasting/feeding cycle with the biological clock. Optimizing intermittent fasting protocols could be important to prevent circadian misalignment in humans.",2020,"RESULTS A group-by-time interaction was observed in Per2 in muscle (F = 3.497, P = 0.044) and SAT (F = 6.686, P = 0.008), but significance was lost upon post hoc adjustment.","['women with obesity', 'Women with Obesity', 'Women']",['intermittent fasting (IF'],[],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C4704881', 'cui_str': 'Intermittent Fasting'}]",[],,0.0900366,"RESULTS A group-by-time interaction was observed in Per2 in muscle (F = 3.497, P = 0.044) and SAT (F = 6.686, P = 0.008), but significance was lost upon post hoc adjustment.","[{'ForeName': 'Lijun', 'Initials': 'L', 'LastName': 'Zhao', 'Affiliation': 'Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Amy T', 'Initials': 'AT', 'LastName': 'Hutchison', 'Affiliation': 'Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Gary A', 'Initials': 'GA', 'LastName': 'Wittert', 'Affiliation': 'Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Campbell H', 'Initials': 'CH', 'LastName': 'Thompson', 'Affiliation': 'Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Kylie', 'Initials': 'K', 'LastName': 'Lange', 'Affiliation': 'Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Liu', 'Affiliation': 'Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Leonie K', 'Initials': 'LK', 'LastName': 'Heilbronn', 'Affiliation': 'Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.'}]","Obesity (Silver Spring, Md.)",['10.1002/oby.22775'] 1325,31376708,Feasibility and dissemination of a computerized home-based treatment for Generalized Anxiety Disorder: A randomized clinical trial.,"Generalized Anxiety Disorder (GAD) is a prevalent, impairing, and undertreated psychiatric disorder. We examined if a home-based computerized treatment program can feasibly be delivered and successfully treat GAD symptoms. Using a randomized control trial, we compared three active groups receiving computerized sequenced Attention Bias Modification (ABM) followed by Applied Relaxation psychoeducation (AR-pe), the reversed sequence of AR-pe and ABM, and a simultaneous ABM and AR-pe group to an assessment only control group. The participants comprised 169 adults with a diagnosis of GAD. We asked participants to complete as many as twenty-four 30-min sessions of an at-home computerized treatment program over 12 weeks. The control group received 24 brief assessment questionnaires as well as assessments of attention bias. Results from intent-to-treat analyses show faster rate of improvement for symptoms of anxiety as measured by the Hamilton Anxiety Rating Scale (HAM-A) over time in groups that received active training in contrast to the clinical monitoring (CM) control group. Follow-up analyses revealed that both sequenced groups improved in anxiety when compared to the control group, while the simultaneous group did not outperform the control group. Results suggest that sequenced delivery of ABM and AR, may be a viable home-based treatment option for individuals with GAD who have limited access to resources or are otherwise unable to seek available treatments that require engagement outside of the home. TRIAL REGISTRATION: clinicaltrial. gov Identifier: NCT00602563.",2019,Results from intent-to-treat analyses show faster rate of improvement for symptoms of anxiety as measured by the Hamilton Anxiety Rating Scale (HAM-A) over time in groups that received active training in contrast to the clinical monitoring (CM) control group.,"['169 adults with a diagnosis of GAD', 'individuals with GAD', 'Generalized Anxiety Disorder']","['computerized home-based treatment', 'computerized sequenced Attention Bias Modification (ABM) followed by Applied Relaxation psychoeducation (AR-pe']","['Hamilton Anxiety Rating Scale (HAM-A', 'Generalized Anxiety Disorder (GAD', 'anxiety']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0270549', 'cui_str': 'Generalized anxiety disorder (disorder)'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005346', 'cui_str': 'Bias'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0871175', 'cui_str': 'Psycho-education'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0222045'}, {'cui': 'C3853311', 'cui_str': 'Ham'}, {'cui': 'C0270549', 'cui_str': 'Generalized anxiety disorder (disorder)'}]",169.0,0.0251471,Results from intent-to-treat analyses show faster rate of improvement for symptoms of anxiety as measured by the Hamilton Anxiety Rating Scale (HAM-A) over time in groups that received active training in contrast to the clinical monitoring (CM) control group.,"[{'ForeName': 'Nader', 'Initials': 'N', 'LastName': 'Amir', 'Affiliation': 'Joint Doctoral Program in Clinical Psychology, San Diego State University and University of California, San Diego, San Diego, CA, USA; Center for Understanding and Treating Anxiety (CUTA), San Diego State University, San Diego, CA, USA. Electronic address: namir@mail.sdsu.edu.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Taboas', 'Affiliation': 'Center for Understanding and Treating Anxiety (CUTA), San Diego State University, San Diego, CA, USA.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Montero', 'Affiliation': 'Center for Understanding and Treating Anxiety (CUTA), San Diego State University, San Diego, CA, USA.'}]",Behaviour research and therapy,['10.1016/j.brat.2019.103446'] 1326,31299461,A randomized controlled trial of a bidirectional cultural adaptation of cognitive behavior therapy for children and adolescents with anxiety disorders.,"BACKGROUND Cognitive behavior therapy (CBT) programs with ethnic and cultural sensitivity are scarce. This study was the first randomized controlled trial of cognitive behavior therapy for children and adolescents with anxiety disorders using bidirectional cultural adaptation. METHODS The Japanese Anxiety Children/Adolescents Cognitive Behavior Therapy program (JACA-CBT) was developed based on existing evidence-based CBT for anxious youth and optimized through feedback from clinicians in the indigenous cultural group. Fifty-one children and adolescents aged 8-15 with anxiety disorders were randomly allocated to either a cognitive behavioral treatment (CBT: 122.08 days, SD = 48.15) or a wait-list control condition (WLC: 70.00 days, SD = 11.01). Participants were assessed at pre-treatment and post-treatment as well as 3 and 6 months after completion of treatment (92.88 days, SD = 17.72 and 189.42 days, SD = 25.06) using a diagnostic interview, self-report measures of anxiety, depression, cognitive errors, and a parent-report measure of anxiety. RESULTS A significant difference was found between the CBT and WLC at post-treatment, specifically 50% of participants in the treatment condition were free from their principal diagnoses compared to 12% in the wait-list condition, χ 2 (1, N = 51) = 8.55, η 2  = 0.17, p < .01. In addition, participants in the treatment condition showed significant improvement in clinical severity and child-self reported depression, F (1, 49) = 12.38, p < .001, F (1, 47.60) = 5.95, p < .05. At post-treatment, Hedge's g between the conditions was large for clinical severity, 1.00 (95% CI = 0.42-1.58), and moderate for the self-report anxiety scale, 0.43 (0.19-1.04), two depression scales, 0.39 (0.22-1.00), 0.48 (0.14-1.09), and the cognitive errors scale, 0.38 (0.24-0.99). Finally, significant improvements in diagnostic status were evident at the 3 and 6-month follow-up assessments when combining the CBT and WLC, ps < .001. CONCLUSION The current results support the transportability of CBT and the efficacy of a bidirectional, culturally adapted cognitive behavior therapy in an underrepresented population.",2019,"At post-treatment, Hedge's g between the conditions was large for clinical severity, 1.00 (95% CI = 0.42-1.58), and moderate for the self-report anxiety scale, 0.43 (0.19-1.04), two depression scales, 0.39 (0.22-1.00), 0.48 (0.14-1.09), and the cognitive errors scale, 0.38 (0.24-0.99).","['Fifty-one children and adolescents aged 8-15 with anxiety disorders', 'children and adolescents with anxiety disorders', 'children and adolescents with anxiety disorders using bidirectional cultural adaptation', 'Japanese Anxiety Children/Adolescents']","['Cognitive Behavior Therapy program (JACA-CBT', 'bidirectional cultural adaptation of cognitive behavior therapy', 'cognitive behavior therapy', 'cognitive behavioral treatment (CBT: 122.08 days, SD\u202f=\u202f48.15) or a wait-list control condition (WLC', 'Cognitive behavior therapy (CBT']","['clinical severity and child-self reported depression', 'cognitive errors scale', 'CBT and WLC', 'diagnostic interview, self-report measures of anxiety, depression, cognitive errors, and a parent-report measure of anxiety', 'diagnostic status', 'self-report anxiety scale']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0003469', 'cui_str': 'Anxiety Disorders'}, {'cui': 'C0392673', 'cui_str': 'Adaptation, function (observable entity)'}, {'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0392673', 'cui_str': 'Adaptation, function (observable entity)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]",51.0,0.0573246,"At post-treatment, Hedge's g between the conditions was large for clinical severity, 1.00 (95% CI = 0.42-1.58), and moderate for the self-report anxiety scale, 0.43 (0.19-1.04), two depression scales, 0.39 (0.22-1.00), 0.48 (0.14-1.09), and the cognitive errors scale, 0.38 (0.24-0.99).","[{'ForeName': 'Shin-Ichi', 'Initials': 'SI', 'LastName': 'Ishikawa', 'Affiliation': 'Faculty of Psychology, Doshisha University, 1-3 Tatara Miyakodani, Kyotanabe City, Kyoto, 610-0394, Japan. Electronic address: ishinn@mail.doshisha.ac.jp.'}, {'ForeName': 'Kazuyo', 'Initials': 'K', 'LastName': 'Kikuta', 'Affiliation': 'Faculty of Psychology, Doshisha University, 1-3 Tatara Miyakodani, Kyotanabe City, Kyoto, 610-0394, Japan. Electronic address: honma.arigato@gmail.com.'}, {'ForeName': 'Mie', 'Initials': 'M', 'LastName': 'Sakai', 'Affiliation': 'Psychiatry and Cognitive-Behavioral Medicine, Graduate School of Medical Sciences, Naogya City University, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. Electronic address: mie.sakai.38@gmail.com.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Mitamura', 'Affiliation': 'College of Comprehensive Psychology, Ritsumeikan University, 2-150 Iwakura-cho, Ibaraki, Osaka, 567-8570, Japan. Electronic address: t.mitamura1992@red.zero.jp.'}, {'ForeName': 'Naoyasu', 'Initials': 'N', 'LastName': 'Motomura', 'Affiliation': 'Faculty of Nursing, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Osaka, 569-8686, Japan. Electronic address: motomura@osaka-med.ac.jp.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Hudson', 'Affiliation': 'Centre for Emotional Health, Department of Psychology, Macquarie University, NSW, 2109, Australia. Electronic address: jennie.hudson@mq.edu.au.'}]",Behaviour research and therapy,['10.1016/j.brat.2019.103432'] 1327,8432597,Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children.,Salmonella typhi Ty21a vaccine in a liquid formulation was evaluated in 634 Thai children 2 to 6 years of age. The seroconversion rate was 69% for those who received vaccine versus 14% for those who received placebo (P < 0.005). The immune responses among vaccine recipients ranged from 60% in 3-year-olds to 81% for 6-year-olds.,1993,The seroconversion rate was 69% for those who received vaccine versus 14% for those who received placebo (P < 0.005).,"['634 Thai children 2 to 6 years of age', 'young Thai children']","['Salmonella typhi Ty21a vaccine', 'placebo', 'vaccine']","['seroconversion rate', 'immune responses', 'Safety and immunogenicity']","[{'cui': 'C0337910', 'cui_str': 'Thai'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}]","[{'cui': 'C0036125', 'cui_str': 'Salmonella typhosa'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0301872', 'cui_str': 'Immune response, function (observable entity)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",634.0,0.072128,The seroconversion rate was 69% for those who received vaccine versus 14% for those who received placebo (P < 0.005).,"[{'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Cryz', 'Affiliation': 'Swiss Serum and Vaccine Institute, Berne.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Vanprapar', 'Affiliation': ''}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Thisyakorn', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Olanratmanee', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Losonsky', 'Affiliation': ''}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Levine', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Chearskul', 'Affiliation': ''}]",Infection and immunity,[] 1328,8454328,Safety and immunogenicity in human volunteers of a chloroform-methanol residue vaccine for Q fever.,"Current Q fever vaccines, consisting of Formalin-inactivated phase I whole Coxiella burnetii, are highly efficacious in preventing disease in high-risk settings but are associated with a risk of unacceptable local reactions in previously immune individuals and require cumbersome preliminary immunologic evaluation of potential vaccinees. A vaccine prepared from the residue of chloroform-methanol extraction of phase I Henzerling strain C. burnetii (CMR) has been shown to be less reactogenic but still immunogenic and protective in small animals and sheep. In a placebo-controlled trial, we immunized 35 healthy adults unscreened for markers of prior C. burnetii immunity with a single subcutaneous CMR dose of 30, 60, 120, or 240 micrograms. None of those receiving the 30- or 60-micrograms CMR dose and none of the placebo recipients experienced any adverse effects. Five of 15 120-micrograms dose CMR recipients complained of transient discomfort in the inoculated arm; erythema or induration of > or = 100 mm2 was noted in three and four, respectively, and two had malaise and low-grade fever (< 101 degrees F, orally). No 240-micrograms dose vaccinee reported limb discomfort, but 7 of 10 had erythema and/or induration of > or = 100 mm2 (P < 0.001 versus placebo). Two reported malaise, and one had low-grade fever. All adverse effects were self-limited. Serum immunoglobulin M responses were optimally detected with CMR antigen and occurred in 50, 60, 73, and 90% of recipients of the 30-, 60-, 120-, and 240-micrograms doses, respectively; results with phase I whole-cell antigen were similar. Serum immunoglobulin G responses were best detected with phase II antigen and were seen in 20, 20, and 40% of those receiving the 60-, 120-, and 240-micrograms doses, respectively. Peripheral blood T-cell proliferative responses to C. burnetii recall antigens were transient and of low magnitude but were seen with CMR antigen in 33% of 120-micrograms dose recipients and 40% of 240-micrograms dose recipients. Data from this study and those from comparative-efficacy trials in primates should provide the basis for field trials of the CMR vaccine.",1993,None of those receiving the 30- or 60-micrograms CMR dose and none of the placebo recipients experienced any adverse effects.,"['35 healthy adults unscreened for markers of prior C. burnetii immunity with a single subcutaneous CMR dose of 30, 60, 120, or 240 micrograms', 'human volunteers of a chloroform-methanol residue vaccine for Q fever']",['placebo'],"['malaise and low-grade fever', 'erythema', 'Peripheral blood T-cell proliferative responses', 'Serum immunoglobulin M responses', 'Serum immunoglobulin G responses', 'limb discomfort', 'Safety and immunogenicity', 'adverse effects', 'transient discomfort']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0020964', 'cui_str': 'Immunity'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C4319600', 'cui_str': '240 (qualifier value)'}, {'cui': 'C0439211', 'cui_str': 'microgram'}, {'cui': 'C0020155', 'cui_str': 'Human Volunteers'}, {'cui': 'C0008238', 'cui_str': 'Chloroform'}, {'cui': 'C2933877', 'cui_str': 'phenylmethoxymethanol'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0034362', 'cui_str': 'Query Fever'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0231218', 'cui_str': 'Undifferentiated illness: Vague ill health'}, {'cui': 'C0239574', 'cui_str': 'Low grade fever'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood (substance)'}, {'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0858458', 'cui_str': 'Serum immunoglobulin M'}, {'cui': 'C0858459', 'cui_str': 'Serum immunoglobulin G'}, {'cui': 'C0854303', 'cui_str': 'Limb discomfort'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}]",35.0,0.094055,None of those receiving the 30- or 60-micrograms CMR dose and none of the placebo recipients experienced any adverse effects.,"[{'ForeName': 'L F', 'Initials': 'LF', 'LastName': 'Fries', 'Affiliation': 'Department of International Health, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland 21205.'}, {'ForeName': 'D M', 'Initials': 'DM', 'LastName': 'Waag', 'Affiliation': ''}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Williams', 'Affiliation': ''}]",Infection and immunity,[] 1329,8262653,Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine.,"Vaccination of infants with Haemophilus influenzae type b (Hib) capsular polysaccharide (HibCP) coupled to carrier proteins has proven protective against invasive Hib diseases in several trials. However, insufficient immunogenicity has been noted in certain populations. Therefore, studies analyzing factors influencing the antibody response to conjugate vaccines are needed. In this study, the response to HibCP coupled to tetanus toxoid (TT) was examined in relation to (i) priming with or coadministration of the carrier protein and (ii) the levels of passively acquired maternal TT antibodies. One hundred forty-four infants were vaccinated with HibCP-TT at 5 and 6 months. They were randomized into three groups that received TT as part of a diphtheria-tetanus-polio vaccine at either 6 and 7 months (group A), 5 and 6 months (group B), or 4 and 5 months (group C). Maternally acquired TT antibodies inhibited the anti-HibCP response to the first HibCP-TT dose in groups A and B (r = -0.5 and -0.4, respectively; P < 0.005). In these groups, infants with prevaccination anti-TT levels above the median failed to reach the defined long-term protective level of HibCP antibodies (1 microgram/ml) more often than infants with low prevaccination levels after the first (P = 0.0001) and the second (P = 0.01) doses of HibCP-TT. In contrast, active priming with TT at 4 months resulted in a threefold-higher median level of anti-HibCP (group C; 1.34 micrograms/ml) than in the unprimed group (group A; 0.40 microgram/ml) after the first dose of HibCP-TT (P = 0.01). Coadministration of TT had no enhancing effect (group B; 0.58 microgram/ml). No significant differences between the median anti-HibCP levels were seen after the second HibCP-TT dose (6.72, 9.63, and 11.44 micrograms/ml in groups A, B, and C, respectively; P = 0.25).",1994,"Maternally acquired TT antibodies inhibited the anti-HibCP response to the first HibCP-TT dose in groups A and B (r = -0.5 and -0.4, respectively; P < 0.005).","['One hundred forty-four infants were vaccinated with', 'infants with', 'human infants to a Haemophilus influenzae type b conjugate vaccine']","['diphtheria-tetanus-polio vaccine', 'HibCP-TT', 'Haemophilus influenzae type b (Hib) capsular polysaccharide (HibCP', 'TT', 'HibCP coupled to tetanus toxoid (TT']","['anti-HibCP response', 'median level of anti-HibCP', 'median anti-HibCP levels']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0121772', 'cui_str': 'Haemophilus influenzae type b'}, {'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}]","[{'cui': 'C0012546', 'cui_str': 'Corynebacterium diphtheriae Infection'}, {'cui': 'C0032371', 'cui_str': 'Poliomyelitis Infection'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0121772', 'cui_str': 'Haemophilus influenzae type b'}, {'cui': 'C0205151', 'cui_str': 'Capsular (qualifier value)'}, {'cui': 'C0032594', 'cui_str': 'Glycans'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0305062', 'cui_str': 'Clostridium tetani toxoid antigen, inactivated'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",144.0,0.0291701,"Maternally acquired TT antibodies inhibited the anti-HibCP response to the first HibCP-TT dose in groups A and B (r = -0.5 and -0.4, respectively; P < 0.005).","[{'ForeName': 'T', 'Initials': 'T', 'LastName': 'Barington', 'Affiliation': 'Department of Medicine TTA, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Gyhrs', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Kristensen', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Heilmann', 'Affiliation': ''}]",Infection and immunity,[] 1330,8359923,"Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels.","Groups of 122 Peruvian adults of low socioeconomic level (SEL) and 125 of high SEL received a randomly allocated 5 x 10(9)- or 5 x 10(8)-CFU dose of CVD 103-HgR live oral cholera vaccine or a placebo. The vaccine was well tolerated. Vibriocidal seroconversions occurred in 78% of high-SEL and 72% of low-SEL subjects who ingested the high dose and in 78 and 49%, respectively, of those who received the low dose.",1993,"Vibriocidal seroconversions occurred in 78% of high-SEL and 72% of low-SEL subjects who ingested the high dose and in 78 and 49%, respectively, of those who received the low dose.","['Peruvian adults of high and low socioeconomic levels', 'Groups of 122 Peruvian adults of low socioeconomic level (SEL) and 125 of high SEL']","['single-dose live oral cholera vaccine CVD 103-HgR', '10(8)-CFU dose of CVD 103-HgR live oral cholera vaccine or a placebo']","['tolerated', 'Vibriocidal seroconversions', 'Safety, immunogenicity, and excretion pattern']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4319551', 'cui_str': 'One hundred and twenty-five'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0961644', 'cui_str': 'cholera vaccine CVD 103-HgR'}, {'cui': 'C0008359', 'cui_str': 'Cholera Vaccine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}]",,0.414818,"Vibriocidal seroconversions occurred in 78% of high-SEL and 72% of low-SEL subjects who ingested the high dose and in 78 and 49%, respectively, of those who received the low dose.","[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Gotuzzo', 'Affiliation': 'Instituto de Medicina Tropical, Universidad Peruana Cayetano Heredia, Lima.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Butron', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Seas', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Penny', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Ruiz', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Losonsky', 'Affiliation': ''}, {'ForeName': 'C F', 'Initials': 'CF', 'LastName': 'Lanata', 'Affiliation': ''}, {'ForeName': 'S S', 'Initials': 'SS', 'LastName': 'Wasserman', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Salazar', 'Affiliation': ''}, {'ForeName': 'J B', 'Initials': 'JB', 'LastName': 'Kaper', 'Affiliation': ''}]",Infection and immunity,[] 1331,31108015,"Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.","Ruzasvir (MK-8408, an NS5A inhibitor) and uprifosbuvir (MK-3682, a nonstructural protein 5B nucleotide inhibitor) are highly potent direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) infection. A phase III clinical trial evaluating the two-drug combination of ruzasvir 60 mg plus  uprifosbuvir 450 mg suggested suboptimal efficacy in certain HCV genotypes (C-BREEZE 1; NCT02759315). The aim of the present study was to evaluate the efficacy and safety of ruzasvir in combination with uprifosbuvir administered at a higher dose than that assessed in the earlier study (C-BREEZE 2: NCT02956629/Merck protocol PN041). Treatment-naïve or interferon (with or without ribavirin)-experienced participants with or without compensated cirrhosis were enrolled. All participants received ruzasvir 180 mg plus uprifosbuvir 450 mg once daily for 12 weeks. The primary objectives were the proportion of participants with HCV RNA <15 lU/mL at 12 weeks after the end of study therapy (SVR12), and safety and tolerability of the study drug. Overall, 282 participants were enrolled. SVR12 (n/N) was 91.3% (42/46) in participants infected with HCV genotype (GT) 1a; GT1b, 96.7% (29/30); GT2, 91.5% (43/47); GT3, 73.8% (45/61); GT4, 98.2% (55/56); GT5, 100.0% (18/18); and GT6, 90.9% (20/22). Adverse events (AEs) were reported by 61.3% of participants; drug-related AEs were reported by 33.3%. The most frequent (≥5% of participants) drug-related AEs in all participants were fatigue (7.8%) and headache (7.4%). In conclusion, the two-drug combination of ruzasvir 180 mg plus uprifosbuvir 450 mg for 12 weeks was highly effective and well tolerated in participants infected with HCV GT1, GT2, GT4, GT5 and GT6, with a lower efficacy in GT3-infected persons.",2019,Adverse events (AEs) were reported by 61.3% of participants; drug-related AEs were reported by 33.3%.,"['participants with or without compensated cirrhosis were enrolled', 'Adults with Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6', '282 participants were enrolled']","['Ruzasvir 180 mg and Uprifosbuvir', 'Two-Drug Direct-Acting Antiviral Agent Regimen', 'ruzasvir 180\u2009mg\u2009plus\u2009uprifosbuvir 450\u2009mg once daily for 12 weeks', 'Ruzasvir (MK-8408, an NS5A inhibitor) and uprifosbuvir (MK-3682', 'Treatment-naive or interferon\u2009(with or without\u2009ribavirin)-experienced', 'ruzasvir']","['safety and tolerability', 'headache', 'effective and well-tolerated', 'Efficacy and Safety', 'Adverse events (AEs', 'efficacy and safety of rusasvir']","[{'cui': 'C0205432', 'cui_str': 'Compensated (qualifier value)'}, {'cui': 'C1623038', 'cui_str': 'Cirrhosis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3805156', 'cui_str': 'Chronic hepatitis C virus genotype 1'}, {'cui': 'C4517681', 'cui_str': '282'}]","[{'cui': 'C4508570', 'cui_str': ""Carbamic acid, N,N'-(((6S)-6-(2-cyclopropyl-5-thiazolyl)-1-fluoro-6H-indolo(1,2-c)(1,3)benzoxazine-3,10-diyl)bis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanedi yl)))bis-, dimethyl ester""}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C4706174', 'cui_str': ""Uridine, 2'-chloro-2'-deoxy-2'-methyl-5'-O-((R)-(((1R)-1-methyl-2-(1-methylethoxy)-2-oxoethyl)amino)phenoxyphosphinyl)-""}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0003451', 'cui_str': 'Antiviral Drugs'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C3844104', 'cui_str': 'Four hundred and fifty'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C4550236', 'cui_str': 'MK-8408'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C4706175', 'cui_str': 'MK-3682'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0021747', 'cui_str': 'Interferons'}, {'cui': 'C0035525', 'cui_str': 'Ribavirin'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",282.0,0.0403518,Adverse events (AEs) were reported by 61.3% of participants; drug-related AEs were reported by 33.3%.,"[{'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Lawitz', 'Affiliation': 'Texas Liver Institute, University of Texas Health San Antonio, San Antonio, Texas.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Gane', 'Affiliation': 'Auckland Clinical Studies, Auckland, New Zealand.'}, {'ForeName': 'Jordan J', 'Initials': 'JJ', 'LastName': 'Feld', 'Affiliation': 'Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Buti', 'Affiliation': ""Liver Unit Hospital Universitari Vall d'Hebron and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) del Instituto de Salud Carlos III, Barcelona, Spain.""}, {'ForeName': 'Graham R', 'Initials': 'GR', 'LastName': 'Foster', 'Affiliation': 'Queen Mary University, London, UK.'}, {'ForeName': 'Mordechai', 'Initials': 'M', 'LastName': 'Rabinovitz', 'Affiliation': 'University of Pittsburgh Medical Center, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Eduard', 'Initials': 'E', 'LastName': 'Burnevich', 'Affiliation': 'I.M. Sechenov First Moscow State Medical University, Moscow, Russia.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Katchman', 'Affiliation': 'Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Krzysztof', 'Initials': 'K', 'LastName': 'Tomasiewicz', 'Affiliation': 'Medical University of Lublin, Lublin, Poland.'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Lahser', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Jackson', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Shaughnessy', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Klopfer', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Wendy W', 'Initials': 'WW', 'LastName': 'Yeh', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Michael N', 'Initials': 'MN', 'LastName': 'Robertson', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'George J', 'Initials': 'GJ', 'LastName': 'Hanna', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Eliav', 'Initials': 'E', 'LastName': 'Barr', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': 'Heather L', 'Initials': 'HL', 'LastName': 'Platt', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of viral hepatitis,['10.1111/jvh.13132'] 1332,31422365,Evaluation of the efficacy of a virtual reality-based safety training and human factors training method: study protocol for a randomised-controlled trial.,"BACKGROUND The construction industry has a high risk of occupational accidents and injuries. More randomised controlled trials are needed to identify effective techniques for improving the occupational safety of construction sector workers. New technologies such as virtual reality (VR) offer the potential to develop engaging learning tools for safety training. Although the number of VR applications in occupational safety training is increasing, only a few studies have evaluated the learning outcomes of VR safety training. Furthermore, previous studies indicate that learning to recognise human factors at work has positive outcomes for safety skills. However, there is lack of knowledge regarding the efficacy of human factors-related training in the construction industry. OBJECTIVE To evaluate the efficacy and the implementation process of a VR-based safety training and a human factors-related safety training. METHODS In Finland, 8 study organisations and approximately 130 construction sector workers will participate in a randomised controlled trial. The study participants will be randomly assigned to one of four intervention arms: (1) immersive VR safety training alone, (2) lecture-based safety training alone, (3) combined immersive VR safety training and HF Tool training or (4) combined lecture-based safety training and HF Tool training. We will test the efficacy of the safety training processes in these four arms. Randomisation of study participants is stratified by work experience. Baseline assessment will take place before randomisation. The short-term follow-up measurements of all study participants will be conducted immediately after the VR safety training and lecture-based safety training. The study participants will complete second measurements immediately after the HF Tool training approximately 1 month after previous safety training. The second measurement of the intervention arms 1 and 2 study participants will be conducted during the same week as that of the intervention arms 3 and 4 participants, who will not take part in the HF Tool training. Finally, semistructured individual interviews will be conducted to evaluate the learning process. OUTCOME MEASURES Outcome measures include safety knowledge, safety locus of control, safety self-efficacy, perceived control over safety issues, safety-related outcome expectancies, safety motivation and safety performance. DISCUSSION Study results will provide knowledge on the efficacy of VR safety training and human factors-related safety training. Furthermore, study provides knowledge on pedagogical techniques that can be used to guide future intervention plans and development. TRIAL REGISTRATION NUMBER ISRCTN55183871.",2020,"The study participants will be randomly assigned to one of four intervention arms: (1) immersive VR safety training alone, (2) lecture-based safety training alone, (3) combined immersive VR safety training and HF Tool training or (4) combined lecture-based safety training and HF Tool training.",['130 construction sector workers'],"['VR-based safety training', 'immersive VR safety training alone, (2) lecture-based safety training alone, (3) combined immersive VR safety training and HF Tool training or (4) combined lecture-based safety training and HF Tool training', 'virtual reality-based safety training']","['safety knowledge, safety locus of control, safety self-efficacy, perceived control over safety issues, safety-related outcome expectancies, safety motivation and safety performance']","[{'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C0441513', 'cui_str': 'Construction (attribute)'}, {'cui': 'C1306056', 'cui_str': 'Worker'}]","[{'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0376683', 'cui_str': 'Lecture'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0023953', 'cui_str': 'Locus of Control'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}]",,0.0257857,"The study participants will be randomly assigned to one of four intervention arms: (1) immersive VR safety training alone, (2) lecture-based safety training alone, (3) combined immersive VR safety training and HF Tool training or (4) combined lecture-based safety training and HF Tool training.","[{'ForeName': 'Mikko', 'Initials': 'M', 'LastName': 'Nykänen', 'Affiliation': 'Finnish Institute of Occupational Health, Helsinki, Finland mikko.nykanen@ttl.fi.'}, {'ForeName': 'Vuokko', 'Initials': 'V', 'LastName': 'Puro', 'Affiliation': 'Finnish Institute of Occupational Health, Helsinki, Finland.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Tiikkaja', 'Affiliation': 'Finnish Institute of Occupational Health, Helsinki, Finland.'}, {'ForeName': 'Henriikka', 'Initials': 'H', 'LastName': 'Kannisto', 'Affiliation': 'Finnish Institute of Occupational Health, Helsinki, Finland.'}, {'ForeName': 'Eero', 'Initials': 'E', 'LastName': 'Lantto', 'Affiliation': 'Finnish Institute of Occupational Health, Helsinki, Finland.'}, {'ForeName': 'Frans', 'Initials': 'F', 'LastName': 'Simpura', 'Affiliation': 'Finnish Institute of Occupational Health, Helsinki, Finland.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Uusitalo', 'Affiliation': 'Finnish Institute of Occupational Health, Helsinki, Finland.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Lukander', 'Affiliation': 'Finnish Institute of Occupational Health, Helsinki, Finland.'}, {'ForeName': 'Tuula', 'Initials': 'T', 'LastName': 'Räsänen', 'Affiliation': 'Finnish Institute of Occupational Health, Helsinki, Finland.'}, {'ForeName': 'Anna-Maria', 'Initials': 'AM', 'LastName': 'Teperi', 'Affiliation': 'Finnish Institute of Occupational Health, Helsinki, Finland.'}]",Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention,['10.1136/injuryprev-2019-043304'] 1333,8195389,Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans.,"On the basis of the ability of the attenuated cold-adapted strain of influenza A virus to suppress disease production in ferrets simultaneously infected with epidemic influenza virus (P. Whitaker-Dowling, H.F. Maassab, and J.S. Youngner, J. Infect. Dis. 164:1200-1202, 1991), an evaluation of the ability of the cold-adapted virus to modify clinical disease in humans was made. Adult volunteers with prechallenge serum hemagglutination-inhibition titers to the influenza A/Kawasaki/86 (H1N1) virus of < or = 1:8 received either 10(7) 50% tissue culture infective doses of the wild-type A/Kawasaki virus or a mixture of 10(7) 50% tissue culture infective doses of each of the wild-type virus and a cold-adapted A/Kawasaki reassortant virus by intranasal drops in a randomized, double-blind fashion. Symptoms and wild-type virus shedding were assessed daily for 6 days following challenge. Results were compared with those derived from another group of volunteers who received only cold-adapted virus. Volunteers who received the mixed inoculum of cold-adapted and wild-type viruses had lower symptom scores than those who received wild-type virus alone, suggesting that coinfection with the cold-adapted virus may modify wild-type virus infection, but the differences were not statistically significant in this small study. The data demonstrate that administration of cold-adapted influenza A virus to humans at the time of wild-type virus infection is a safe procedure.",1994,"Adult volunteers with prechallenge serum hemagglutination-inhibition titers to the influenza A/Kawasaki/86 (H1N1) virus of < or = 1:8 received either 10(7) 50% tissue culture infective doses of the wild-type A/Kawasaki virus or a mixture of 10(7) 50% tissue culture infective doses of each of the wild-type virus and a cold-adapted A/Kawasaki reassortant virus by intranasal drops in a randomized, double-blind fashion.","['Adult volunteers with prechallenge serum hemagglutination-inhibition titers to the influenza A/Kawasaki/86 (H1N1) virus of < or = 1:8 received either', 'humans']","['simultaneous administration of cold-adapted and wild-type influenza', '10(7) 50% tissue culture infective doses of the wild-type A/Kawasaki virus or a mixture of 10(7) 50% tissue culture infective doses of each of the wild-type virus and a cold-adapted A/Kawasaki reassortant virus by intranasal drops']","['symptom scores', 'Symptoms and wild-type virus shedding']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0018904', 'cui_str': 'Hemagglutination Inhibition Tests'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C2076600', 'cui_str': 'Influenza caused by Influenza A virus subtype H1N1'}, {'cui': 'C0042776', 'cui_str': 'Virus'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0009443', 'cui_str': 'Common Cold'}, {'cui': 'C0445392', 'cui_str': 'Wild (qualifier value)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0021400', 'cui_str': 'Influenza, Human'}, {'cui': 'C0040284', 'cui_str': 'Tissue culture (procedure)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0042776', 'cui_str': 'Virus'}, {'cui': 'C0439962', 'cui_str': 'Mixture (qualifier value)'}, {'cui': 'C0085391', 'cui_str': 'Reassortant Viruses'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C4318619', 'cui_str': 'Drop (unit of presentation)'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0445392', 'cui_str': 'Wild (qualifier value)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0162633', 'cui_str': 'Viral Shedding'}]",,0.0395593,"Adult volunteers with prechallenge serum hemagglutination-inhibition titers to the influenza A/Kawasaki/86 (H1N1) virus of < or = 1:8 received either 10(7) 50% tissue culture infective doses of the wild-type A/Kawasaki virus or a mixture of 10(7) 50% tissue culture infective doses of each of the wild-type virus and a cold-adapted A/Kawasaki reassortant virus by intranasal drops in a randomized, double-blind fashion.","[{'ForeName': 'J S', 'Initials': 'JS', 'LastName': 'Youngner', 'Affiliation': 'Department of Molecular Genetics and Biochemistry, School of Medicine, University of Pittsburgh, Pennsylvania 15261.'}, {'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Treanor', 'Affiliation': ''}, {'ForeName': 'R F', 'Initials': 'RF', 'LastName': 'Betts', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Whitaker-Dowling', 'Affiliation': ''}]",Journal of clinical microbiology,[] 1334,31424410,A Pilot Double-Blind Randomized Controlled Trial of Cognitive Training Combined with Transcranial Direct Current Stimulation for Amnestic Mild Cognitive Impairment.,"BACKGROUND There is currently no effective intervention for improving memory in people at increased risk for dementia. Cognitive training (CT) has been promising, though effects are modest, particularly at follow-up. OBJECTIVE To investigate whether adjunctive non-invasive brain stimulation (transcranial direct current stimulation, tDCS) could enhance the memory benefits of CT in amnestic mild cognitive impairment (aMCI). METHODS Participants with aMCI were randomized to receive CT with either Active tDCS (2 mA for 30 min and 0.016 mA for 30 min) or Sham tDCS (0.016 mA for 60 min) for 15 sessions over a period of 5 weeks in a double-blind, sham-controlled, parallel group clinical trial. The primary outcome measure was the California Verbal Learning Task 2nd Edition. RESULTS 68 participants commenced the intervention. Intention-to-treat (ITT) analysis showed that the CT+Active tDCS group significantly improved at post treatment (p = 0.033), and the CT+Sham tDCS group did not (p = 0.050), but there was no difference between groups. At the 3-month follow-up, both groups showed large-sized memory improvements compared to pre-treatment (CT+Active tDCS: p < 0.01, d = 0.99; CT+Sham tDCS: p < 0.01, d = 0.74), although there was no significant difference between groups. CONCLUSION This study found that CT+Active tDCS did not produce greater memory improvement compared to CT+Sham tDCS. Large-sized memory improvements occurred in both conditions at follow-up. One possible interpretation, based on recent novel findings, is that low intensity tDCS (used as 'sham') may have contributed biological effects. Further work should use a completely inert tDCS sham condition.",2019,"At the 3-month follow-up, both groups showed large-sized memory improvements compared to pre-treatment (CT+Active tDCS: p < 0.01, d = 0.99; CT+Sham tDCS: p < 0.01, d = 0.74), although there was no significant difference between groups. ","['amnestic mild cognitive impairment (aMCI', '68 participants commenced the intervention', 'Participants with aMCI', 'Amnestic Mild Cognitive Impairment']","['adjunctive non-invasive brain stimulation (transcranial direct current stimulation, tDCS', 'Cognitive Training Combined with Transcranial Direct Current Stimulation', 'CT with either Active tDCS (2\u200amA for 30\u200amin and 0.016\u200amA for 30\u200amin) or Sham tDCS', 'CT+Sham tDCS', 'CT+Active tDCS', 'Cognitive training (CT']","['large-sized memory improvements', 'California Verbal Learning Task 2nd Edition', 'Intention-to-treat (ITT) analysis']","[{'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}]","[{'cui': 'C0205303', 'cui_str': 'Non-invasive (qualifier value)'}, {'cui': 'C0870227', 'cui_str': 'Brain stimulation'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0042531', 'cui_str': 'Verbal Learning'}, {'cui': 'C0205436', 'cui_str': 'Second - ordinal'}, {'cui': 'C0441792', 'cui_str': 'Editions (qualifier value)'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}]",68.0,0.327367,"At the 3-month follow-up, both groups showed large-sized memory improvements compared to pre-treatment (CT+Active tDCS: p < 0.01, d = 0.99; CT+Sham tDCS: p < 0.01, d = 0.74), although there was no significant difference between groups. ","[{'ForeName': 'Donel M', 'Initials': 'DM', 'LastName': 'Martin', 'Affiliation': 'Black Dog Institute, Sydney, Australia.'}, {'ForeName': 'Adith', 'Initials': 'A', 'LastName': 'Mohan', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Alonzo', 'Affiliation': 'Black Dog Institute, Sydney, Australia.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Gates', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Oyetunde', 'Initials': 'O', 'LastName': 'Gbadeyan', 'Affiliation': 'University of Queensland Centre for Clinical Research, Brisbane, Australia.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Meinzer', 'Affiliation': 'University of Queensland Centre for Clinical Research, Brisbane, Australia.'}, {'ForeName': 'Perminder', 'Initials': 'P', 'LastName': 'Sachdev', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Brodaty', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Colleen', 'Initials': 'C', 'LastName': 'Loo', 'Affiliation': 'Black Dog Institute, Sydney, Australia.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-190306'] 1335,7890391,Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults.,"The safety and immunogenicity of the live oral attenuated vaccine strains vibrio cholerae CVD 103-HgR and Salmonella typhi Ty21a were evaluated alone or in a combined bivalent formulation in four groups composed of 185 healthy European adults. All presentations were well tolerated. The serum anti-S. typhi lipopolysaccharide immunoglobulin G and immunoglobulin A antibody responses were comparable for all groups (66 to 72% seroconversion). The serum vibriocidal antibody seroconversion rate ranged from 78 to 92.5% (P > 0.05) among the groups. However, the peak and geometric mean vibriocidal antibody titers were significantly higher (P < 0.005) in the groups which received the bivalent formulation along with two doses of Ty21a than in the group which received CVD 103-HgR followed by two doses of killed Escherichia coli K-12 placebo. The ingestion of a placebo shortly after CVD 103-HgR may have suppressed the magnitude of the immune response. These findings demonstrate the feasibility of producing multivalent live oral attenuated vaccines.",1995,"However, the peak and geometric mean vibriocidal antibody titers were significantly higher (P < 0.005) in the groups which received the bivalent formulation along with two doses of Ty21a than in the group which received CVD 103-HgR followed by two doses of killed Escherichia coli K-12 placebo.","['185 healthy European adults', 'healthy adults']","['live oral bivalent typhoid fever', 'killed Escherichia coli K-12 placebo', 'live oral attenuated vaccine strains vibrio cholerae CVD 103-HgR and Salmonella typhi Ty21a', 'placebo']","['serum anti-S. typhi lipopolysaccharide immunoglobulin G and immunoglobulin A antibody responses', 'tolerated', 'serum vibriocidal antibody seroconversion rate', 'safety and immunogenicity', 'Safety and immunogenicity', 'peak and geometric mean vibriocidal antibody titers']","[{'cui': 'C4517617', 'cui_str': '185 (qualifier value)'}, {'cui': 'C0239307', 'cui_str': 'European (ethnic group)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0041466', 'cui_str': 'Salmonella typhi Infection'}, {'cui': 'C4521763', 'cui_str': 'Killed'}, {'cui': 'C0014834', 'cui_str': 'Escherichia coli'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0042629', 'cui_str': 'Vibrio cholerae'}, {'cui': 'C0961644', 'cui_str': 'cholera vaccine CVD 103-HgR'}, {'cui': 'C0036125', 'cui_str': 'Salmonella typhosa'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0023810', 'cui_str': 'Lipoglycans'}, {'cui': 'C0202087', 'cui_str': 'Immunoglobulin G measurement (procedure)'}, {'cui': 'C1292068', 'cui_str': 'Antibody, immunoglobulin A class (substance)'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1287242', 'cui_str': 'Finding of antibody titer (finding)'}]",185.0,0.180058,"However, the peak and geometric mean vibriocidal antibody titers were significantly higher (P < 0.005) in the groups which received the bivalent formulation along with two doses of Ty21a than in the group which received CVD 103-HgR followed by two doses of killed Escherichia coli K-12 placebo.","[{'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Cryz', 'Affiliation': 'Swiss Serum and Vaccine Institute, Berne.'}, {'ForeName': 'J U', 'Initials': 'JU', 'LastName': 'Que', 'Affiliation': ''}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Levine', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Wiedermann', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Kollaritsch', 'Affiliation': ''}]",Infection and immunity,[] 1336,8027328,Effect of delayed processing of blood samples on performance of cytomegalovirus antigenemia assay.,"This prospective, parallel, and blind study of 120 blood samples from immunocompromised patients examined the influence of delayed sample processing on cytomegalovirus antigenemia assay. Cytomegalovirus was detected in 49 samples (40.8%): 41 were processed within 2 to 4 h, and 40 were reprocessed the following day. Results were discrepant in 17 of the samples with the lowest positive cell counts. Differences between the two days did not reach statistical significance.",1994,"Cytomegalovirus was detected in 49 samples (40.8%): 41 were processed within 2 to 4 h, and 40 were reprocessed the following day.",['120 blood samples from immunocompromised patients examined the influence of delayed sample processing on cytomegalovirus antigenemia assay'],[],"['cytomegalovirus antigenemia assay', 'Cytomegalovirus']","[{'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0085393', 'cui_str': 'Immunosuppressed Host'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0010825', 'cui_str': 'Salivary Gland Viruses'}, {'cui': 'C1510438', 'cui_str': 'Assay technique (qualifier value)'}]",[],"[{'cui': 'C0010825', 'cui_str': 'Salivary Gland Viruses'}, {'cui': 'C1510438', 'cui_str': 'Assay technique (qualifier value)'}]",,0.0246942,"Cytomegalovirus was detected in 49 samples (40.8%): 41 were processed within 2 to 4 h, and 40 were reprocessed the following day.","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Niubò', 'Affiliation': ""Servicio de Microbiología, Hospital Prínceps d'Espanya, Ciutat Sanitària i Universitària de Bellvitge, Barcelona.""}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Pérez', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Carvajal', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Ardanuy', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Martín', 'Affiliation': ''}]",Journal of clinical microbiology,[] 1337,8039909,Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.,"A meningococcal vaccine containing group A and C polysaccharides conjugated to CRM197 was evaluated in 50 adults. Vaccinees were entered into one of five groups: 30 adults received a single dose of either 22, 11, or 5.5 micrograms of the conjugated A-C vaccine; 10 received an approved meningococcal vaccine; and 10 received saline injections. Local and systemic reactions to vaccines were recorded, and immune responses were determined. The experimental meningococcal vaccine was well tolerated, with the most frequent reaction being pain at the injection site. Both A and C polysaccharide components of the experimental vaccine were highly immunogenic, and total antibody concentrations 1 month postvaccination were not significantly different from the mean antibody concentrations among adults given the approved meningococcal vaccine. In addition, significant rises in immunoglobulin G, A, and M antibodies to both A and C polysaccharides occurred. Antibody concentrations measured at 6 and 12 months postvaccination had declined but remained significantly higher than prevaccination concentrations. Postvaccination meningococcal group C functional antibody activity increased more than 600-fold for both the polysaccharide and the conjugate vaccines. Further studies of this conjugated meningococcal vaccine are indicated for young children and infants.",1994,Antibody concentrations measured at 6 and 12 months postvaccination had declined but remained significantly higher than prevaccination concentrations.,"['50 adults', 'adults', 'young children and infants']","['conjugated A-C vaccine; 10 received an approved meningococcal vaccine', 'meningococcal A and C polysaccharide conjugate vaccine', 'saline injections']","['functional antibody activity', 'immunoglobulin G, A, and M antibodies', 'Antibody concentrations', 'highly immunogenic, and total antibody concentrations', 'mean antibody concentrations']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0301869', 'cui_str': 'Conjugate'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0205540', 'cui_str': 'Approved (qualifier value)'}, {'cui': 'C0700144', 'cui_str': 'Meningococcus vaccine (product)'}, {'cui': 'C0032594', 'cui_str': 'Glycans'}, {'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]","[{'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0202087', 'cui_str': 'Immunoglobulin G measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",50.0,0.0622538,Antibody concentrations measured at 6 and 12 months postvaccination had declined but remained significantly higher than prevaccination concentrations.,"[{'ForeName': 'E L', 'Initials': 'EL', 'LastName': 'Anderson', 'Affiliation': 'Department of Medicine, Saint Louis University School of Medicine, Missouri.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Bowers', 'Affiliation': ''}, {'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Mink', 'Affiliation': ''}, {'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Kennedy', 'Affiliation': ''}, {'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Belshe', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Harakeh', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Pais', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Holder', 'Affiliation': ''}, {'ForeName': 'G M', 'Initials': 'GM', 'LastName': 'Carlone', 'Affiliation': ''}]",Infection and immunity,[] 1338,8039873,Heavy-chain isotype patterns of human antibody-secreting cells induced by Haemophilus influenzae type b conjugate vaccines in relation to age and preimmunity.,"The influence of preexisting immunity on the heavy-chain isotypes of circulating antibody-secreting cells (AbSC) induced by vaccination with Haemophilus influenzae type b (Hib) capsular polysaccharide (HibCP) coupled to tetanus toxoid (TT) or diphtheria toxoid (DT) and by vaccination with TT or DT alone in 51 healthy adults and 9 infants was studied. In adults, the isotypes of TT and DT AbSC were dominated by immunoglobulin G1 (IgG1) followed by IgG4 and IgA1. HibCP AbSC were dominated by the isotype IgA1 followed by (in decreasing order) IgG2, IgA2, IgM, and IgG1. The isotype distributions of TT and DT AbSC were independent of whether the toxoids were coupled to HibCP, and the isotypes of HibCP AbSC were not influenced by the nature of the carrier (TT or DT). Furthermore, the isotype distributions were unaffected by recent immunization with components of the conjugates, although this reduced the numbers of AbSC. The heavy-chain gene usage of HibCP AbSC in adults differed clearly from that in infants, which was restricted largely to the genes mu, gamma 1, and alpha 1, all lying upstream in the heavy-chain constant-region gene locus, while the usage in adults also, to different extents, involved the downstream genes gamma 2 and alpha 2. The ratio between the numbers of HibCP AbSC using heavy-chain genes from the downstream duplication unit (gamma 2, gamma 4, and alpha 2) and those using genes from the upstream duplication unit (gamma 3, gamma 1, and alpha 1) correlated with the preimmunization level of natural HibCP antibodies (r = 0.59; P = 0.00002). A possible role of natural exposure for Hib or cross-reactive bacteria on the mucosal surfaces in the shaping of the isotype response to HibCP conjugate vaccines is discussed.",1994,"The isotype distributions of TT and DT AbSC were independent of whether the toxoids were coupled to HibCP, and the isotypes of HibCP AbSC were not influenced by the nature of the carrier (TT or DT).",['51 healthy adults and 9 infants was studied'],['Haemophilus influenzae type b (Hib) capsular polysaccharide (HibCP) coupled to tetanus toxoid (TT) or diphtheria toxoid (DT) and by vaccination with TT or DT alone'],"['numbers of AbSC', 'preimmunization level of natural HibCP antibodies', 'IgG2, IgA2, IgM, and IgG1']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0121772', 'cui_str': 'Haemophilus influenzae type b'}, {'cui': 'C0205151', 'cui_str': 'Capsular (qualifier value)'}, {'cui': 'C0032594', 'cui_str': 'Glycans'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0305062', 'cui_str': 'Clostridium tetani toxoid antigen, inactivated'}, {'cui': 'C0012551', 'cui_str': 'diphtheria toxoid vaccine, inactivated'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205296', 'cui_str': 'Natural (qualifier value)'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0020856', 'cui_str': 'IgG2'}, {'cui': 'C0020841', 'cui_str': 'IgA2'}, {'cui': 'C0020861', 'cui_str': 'IgM'}, {'cui': 'C0020855', 'cui_str': 'IgG1'}]",51.0,0.024002,"The isotype distributions of TT and DT AbSC were independent of whether the toxoids were coupled to HibCP, and the isotypes of HibCP AbSC were not influenced by the nature of the carrier (TT or DT).","[{'ForeName': 'T', 'Initials': 'T', 'LastName': 'Barington', 'Affiliation': 'Department of Medicine TTA, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Juul', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Gyhrs', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Heilmann', 'Affiliation': ''}]",Infection and immunity,[] 1339,7929770,Clinical impact of rapid in vitro susceptibility testing and bacterial identification.,"During the past decade, a variety of instrument-assisted bacterial identification and antimicrobial susceptibility test systems have been developed which permit provision of test results in a matter of hours rather than days, as has been the case with traditional overnight procedures. These newer rapid techniques are much more expensive than older methods. It has been presumed but not proven that the clinical benefits of rapid testing to patients with infection offset the added cost. The intent of this study was to objectively define the clinical impact of rapid bacterial identification and antimicrobial susceptibility testing. A 1-year study was performed in which infected, hospitalized patients in a tertiary-care, teaching, medical center were randomly assigned to one of two groups: patients for whom identification and susceptibility testing was performed by using a semi-automated, rapid, same-day procedure and those for whom testing was accomplished by using traditional overnight techniques. The two groups were compared with respect to numerous demographic descriptors, and then patients were monitored prospectively through the end of their hospitalization with the aim of determining whether there existed objectively defineable differences in management and outcome between the two groups. The mean lengths of time to provision of susceptibility and identification test results in the rapid test group were 11.3 and 9.6 h, respectively. In the overnight test group, these values were 19.6 and 25.9 h, respectively (P < 0.0005). There were 273 evaluable patients in the first group and 300 in the second group. Other than the length of time required to provide susceptibility and identification test results, no significant differences were noted between the two groups with respect to > 100 demographic descriptors. With regard to measures of outcome, the mean lengths of hospitalization were also the same in both groups. Mortality rates were however, lower in the rapid test group (i.e., 8.8% versus 15.3%). Similarly, statistically significantly fewer laboratory studies, imaging procedures, days of intubation, and days in an intensive or intermediate-care area were observed with patients in the rapid test group. Rapid testing was also associated with significantly shortened lengths of elapsed time prior to alterations in antimicrobial therapy. Lastly, patient costs for hospitalization were significantly lower in the rapid test group. The results of this study indicate the rapid same-day bacterial identification and susceptibility testing in the microbiology laboratory can have a major impact on the care and outcome of hospitalized patients with infection.",1994,"In the overnight test group, these values were 19.6 and 25.9 h, respectively (P < 0.0005).","['273 evaluable patients in the first group and 300 in the second group', 'infected, hospitalized patients in a tertiary-care, teaching, medical center', 'hospitalized patients with infection']",[],"['laboratory studies, imaging procedures, days of intubation, and days in an intensive or intermediate-care area', 'mean lengths of hospitalization', 'Lastly, patient costs for hospitalization', 'Mortality rates', 'mean lengths of time to provision of susceptibility and identification test results']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0565990', 'cui_str': 'Medical center (environment)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}]",[],"[{'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0079595', 'cui_str': 'Imaging technique (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1264642', 'cui_str': 'Susceptibility (property) (qualifier value)'}, {'cui': 'C0020792', 'cui_str': 'Identification'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0208794,"In the overnight test group, these values were 19.6 and 25.9 h, respectively (P < 0.0005).","[{'ForeName': 'G V', 'Initials': 'GV', 'LastName': 'Doern', 'Affiliation': 'Department of Hospital Laboratories, University of Massachusetts Medical Center, Worcester 01655.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Vautour', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gaudet', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Levy', 'Affiliation': ''}]",Journal of clinical microbiology,[] 1340,32685613,Visual feedback therapy for restoration of upper limb function of stroke patients.,"Objective To investigate the effects of mirror neuron theory-based visual feedback therapy (VFT) on restoration of upper limb function of stroke patients and motor-related cortical function using functional magnetic resonance imaging (fMRI). Methods Hemiplegic stroke patients were randomly divided into two groups: a VFT group and a control (CTL) group. Sixteen patients in the VFT group received conventional rehabilitation (CR) and VFT for 8 weeks, while 15 patients in the CTL group received only CR. The Barthel Index (BI) was used to assess the activities of daily living at baseline and the 8 th week of the recovery training period. The Fugl-Meyer assessment (FMA) scale, somatosensory evoked potential (SEP), and fMRI were used to evaluate the recovery effect of the training therapies. The latencies and amplitudes of N9 and N20 were measured. Before recovery training, fMRI was performed for all patients in the VFT and CTL groups. In addition, 17 patients (9 in the VFT group and 8 in the CTL group) underwent fMRI for follow-up 2 months after treatment. Qualitative data were analyzed using the χ 2 test. The independent sample t -test was used to compare normally distributed data among different groups, the paired sample t -test was used to compare data between groups, and the non-parametric test was used to comparing data without normal distribution among groups. Results There were no significant differences between the VFT and CTL group in all indexes. However, after 8 weeks of recovery training, these indexes were all significantly improved ( P  < 0.05). As compared with the CTL group, the FMA scores, BI, and N9/N20 latencies and amplitudes of SEP in the VFT group were significantly improved ( P  < 0.05). Two months after recovery training, fMRI showed that the degree of activation of the bilateral central anterior gyrus, parietal lobe, and auxiliary motor areas was significantly higher in the VFT group than the CTL group ( P  < 0.05). Conclusions VFT based on mirror neuron theory is an effective approach to improve upper extremity motor function and daily activity performance of stroke patients. The therapeutic mechanism promotes motor relearning by activating the mirror neuron system and motor cortex. SEP amplitudes increased only for patients who participated in visual feedback. VFT promotes sensory-motor plasticity and behavioral changes in both the motor and sensory domains.",2020,"As compared with the CTL group, the FMA scores, BI, and N9/N20 latencies and amplitudes of SEP in the VFT group were significantly improved ( P  < 0.05).","['Methods\n\n\nHemiplegic stroke patients', 'stroke patients', 'Sixteen patients in the']","['VFT and CTL', 'VFT', 'Visual feedback therapy', 'conventional rehabilitation (CR) and VFT', 'CTL', 'functional magnetic resonance imaging (fMRI', 'mirror neuron theory-based visual feedback therapy (VFT', 'VFT group and a control (CTL', 'CTL group received only CR']","['FMA scores, BI, and N9/N20 latencies and amplitudes of SEP', 'SEP amplitudes', 'upper extremity motor function and daily activity performance', 'latencies and amplitudes of N9 and N20', 'degree of activation of the bilateral central anterior gyrus, parietal lobe, and auxiliary motor areas', 'Fugl-Meyer assessment (FMA) scale, somatosensory evoked potential (SEP), and fMRI', 'Barthel Index (BI', 'activities of daily living']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3715157', 'cui_str': '16'}]","[{'cui': 'C2936181', 'cui_str': 'Visual Feedback'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C3178760', 'cui_str': 'Mirror Neurons'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1527374', 'cui_str': 'Group Therapy'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C0242465', 'cui_str': 'Response Latency'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0030560', 'cui_str': 'Parietal lobe structure'}, {'cui': 'C0026607', 'cui_str': 'Motor cortex'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0015216', 'cui_str': 'Somatosensory evoked potential'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]",,0.021355,"As compared with the CTL group, the FMA scores, BI, and N9/N20 latencies and amplitudes of SEP in the VFT group were significantly improved ( P  < 0.05).","[{'ForeName': 'Mei-Hong', 'Initials': 'MH', 'LastName': 'Zhu', 'Affiliation': 'Rehabilitation Medicine Center of the Second Affiliated Hospital of Jiaxing, University, Jiaxing, Zhejiang, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Zeng', 'Affiliation': 'Rehabilitation Medicine Center of the Second Affiliated Hospital of Jiaxing, University, Jiaxing, Zhejiang, China.'}, {'ForeName': 'Mei-Fang', 'Initials': 'MF', 'LastName': 'Shi', 'Affiliation': 'Rehabilitation Medicine Center of the Second Affiliated Hospital of Jiaxing, University, Jiaxing, Zhejiang, China.'}, {'ForeName': 'Xu-Dong', 'Initials': 'XD', 'LastName': 'Gu', 'Affiliation': 'Rehabilitation Medicine Center of the Second Affiliated Hospital of Jiaxing, University, Jiaxing, Zhejiang, China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Shen', 'Affiliation': 'Rehabilitation Medicine Center of the Second Affiliated Hospital of Jiaxing, University, Jiaxing, Zhejiang, China.'}, {'ForeName': 'Ye-Ping', 'Initials': 'YP', 'LastName': 'Zheng', 'Affiliation': 'Rehabilitation Medicine Center of the Second Affiliated Hospital of Jiaxing, University, Jiaxing, Zhejiang, China.'}, {'ForeName': 'Ya-Ping', 'Initials': 'YP', 'LastName': 'Jia', 'Affiliation': 'Rehabilitation Medicine Center of the Second Affiliated Hospital of Jiaxing, University, Jiaxing, Zhejiang, China.'}]",International journal of nursing sciences,['10.1016/j.ijnss.2020.04.004'] 1341,7852551,Diagnosis of cytomegalovirus infections by shell vial assay and conventional cell culture during antiviral prophylaxis.,"A total of 3,552 specimens for conventional cytomegalovirus (CMV) culture and shell vial assay for CMV immediate-early antigen were obtained during a prospective randomized trial for prophylaxis of CMV disease after liver transplantation. Prophylaxis with ganciclovir for 2 weeks and then high-dose acyclovir for 2.5 months was compared with high-dose acyclovir alone for 3 months. During the first 12 weeks after transplantation, when the patients were on prophylaxis, there were significantly more clinical samples positive by the shell vial assay and negative by standard culture in comparison with the number of samples obtained from weeks 13 to 24, after prophylaxis was discontinued, that were positive by the shell vial assay and negative by standard culture. In contrast, significantly fewer samples were positive by both the shell vial assay and standard culture during the first 12 weeks compared with the number obtained 13 to 24 weeks after transplantation that were positive by both methods. Samples positive by the shell vial assay only were obtained significantly more frequently from patients with asymptomatic than symptomatic CMV infections, while samples positive by both methods were obtained significantly more often from patients with symptomatic CMV infection. It was concluded that antiviral prophylaxis with high-dose acyclovir or ganciclovir and then high-dose acyclovir and asymptomatic CMV infection are associated with a decrease in the level of CMV isolation by standard cell culture in comparison with that by the shell vial assay.",1994,"Samples positive by the shell vial assay only were obtained significantly more frequently from patients with asymptomatic than symptomatic CMV infections, while samples positive by both methods were obtained significantly more often from patients with symptomatic CMV infection.","['3,552 specimens for conventional cytomegalovirus (CMV) culture and shell vial assay for CMV immediate-early antigen', 'CMV disease after liver transplantation']","['ganciclovir', 'acyclovir or ganciclovir', 'acyclovir']",['level of CMV isolation'],"[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C1294247', 'cui_str': 'Cytomegalovirus culture'}, {'cui': 'C1706398', 'cui_str': 'Vil'}, {'cui': 'C1510438', 'cui_str': 'Assay technique (qualifier value)'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0003320', 'cui_str': 'Antigens'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0023911', 'cui_str': 'Transplantation, Hepatic'}]","[{'cui': 'C0017066', 'cui_str': 'Ganciclovir'}, {'cui': 'C0001367', 'cui_str': 'Acyclovir'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0220862', 'cui_str': 'isolation'}]",3552.0,0.0230558,"Samples positive by the shell vial assay only were obtained significantly more frequently from patients with asymptomatic than symptomatic CMV infections, while samples positive by both methods were obtained significantly more often from patients with symptomatic CMV infection.","[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Mañez', 'Affiliation': 'Department of Surgery, University of Pittsburgh Medical Center, Pennsylvania 15213.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'St George', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Linden', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Martin', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Kusne', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Grossi', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ho', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Rinaldo', 'Affiliation': ''}]",Journal of clinical microbiology,[] 1342,7591118,Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.,"The antibody kinetics in sera from 27 adults after three doses of the Norwegian group B meningococcal outer membrane vesicle (OMV) vaccine was studied. The vaccinees received the third dose 4 to 5 years after the first two. Antibody responses against outer membrane proteins (OMPs) and lipopolysaccharides were studied by enzyme-linked immunosorbent assay and immunoblotting and with serum bactericidal assays (SBA) with three variants of the vaccine strain, 44/76. Six weeks after the second injection, the geometric mean (GM) of the levels of immunoglobulin G (IgG) against OMVs was about sevenfold higher than that of prevaccination levels, and 74% of the vaccinees developed a greater-than-twofold rise in SBA titer. After 6 months, the GM of IgG levels declined to about threefold higher, and after 4 to 5 years it declined to about twofold higher, than that before vaccination. The third dose induced a rapid increase in SBA titers in 96% of the vaccinees, and the GM of levels of IgG against OMVs rose to about 14-fold the prevaccination level. One year later, the IgG antibody levels had dropped to 4.6-fold the prevaccination level, but 88% of the vaccinees still showed bactericidal activity. The response after the two first doses was higher in individuals with prevaccination antibodies, but no such effect was found after three doses. The use of defined mutants in SBA and linear multiple regression analyses indicated that among the major OMPs, antibodies to the Opc and class 1 proteins made the most important single contributions to the bactericidal activity against the vaccine strain, but it also demonstrated the importance of antibodies against other antigens. After three doses, 68% of the vaccinees showed a significant SBA response against a strain lacking both the Opc and the class 1 proteins. Three doses converted almost all subjects to SBA responders and gave higher antibody levels and relatively less serosubtype-specific bactericidal activity than did two doses, probably indicating a broader cross-protection against heterologous strains.",1995,"The response after the two first doses was higher in individuals with prevaccination antibodies, but no such effect was found after three doses.",[],[],"['antibody levels', 'GM of IgG levels', 'antibody kinetics', 'GM of levels of IgG against OMVs', 'IgG antibody levels', 'bactericidal activity', 'SBA response', 'serosubtype-specific bactericidal activity', 'SBA titer', 'SBA titers', 'geometric mean (GM) of the levels of immunoglobulin G (IgG) against OMVs']",[],[],"[{'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0544570', 'cui_str': 'Bactericidal activity (observable entity)'}, {'cui': 'C0449544', 'cui_str': 'Serosubtype (attribute)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0202087', 'cui_str': 'Immunoglobulin G measurement (procedure)'}]",,0.0294701,"The response after the two first doses was higher in individuals with prevaccination antibodies, but no such effect was found after three doses.","[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Rosenqvist', 'Affiliation': 'Department of Vaccinology, National Institute of Public Health, Oslo, Norway.'}, {'ForeName': 'E A', 'Initials': 'EA', 'LastName': 'Høiby', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Wedege', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Bryn', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Kolberg', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Klem', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Rønnild', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Bjune', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Nøkleby', 'Affiliation': ''}]",Infection and immunity,[] 1343,32495329,[Effects of the Otago Exercise Program on Lower Extremity Strength in Residents of a Long-Term Care Institution].,"BACKGROUND Falls are a very common problem in older adults. Improving lower extremity muscle strength is the primary objective of fall-prevention programs. PURPOSE The aim of the study was to evaluate the effects of the Otago Exercise Program (OEP) on the lower extremity muscle strength of residents living in a long-term care institution. METHODS In this repeated measurement study, participants were allocated into either the experimental group (EG) or the control group (CG). All of the participants maintained normal activities, and EG participants were additionally enrolled in a 6-month group OEP led by a physiotherapist. The OEP, comprising warm-up exercises, strength training, balance training, and walking training, requires about 45 minutes per session, 3 times a week. A total of 78 OEP sessions were performed during the 6-month intervention. A 30-Second Sit-to-Stand Test and lower extremity muscle strength measurements were performed at baseline, after 3 months, and after 6 months. RESULTS The twenty participants in this study had a mean age over 80 years and were recruited from a long-term care institution in southern Taiwan. There were ten participants in each group, and the mean total OEP session attendance for EG participants was 92.8%. Although the EG had lower extremity muscle strength than the CG at baseline, the EG had achieved significant improvements in the muscle strength values for the knee extensor, knee flexor, ankle plantar flexors, and dorsiflexors after 6 months (group x time interaction, p < .05). In addition, the results of the 30-second sit-to-stand test for the EG were poor at baseline and significantly better after 6 months, while the results for the CG worsened between baseline and 6 months. CONCLUSIONS / IMPLICATIONS FOR PRACTICE The results of this study support that participating in a group-based OEP three times per week over 6 months effectively improves lower extremity muscle strength in older adults. Therefore, OEP should be incorporated into fall-prevention programs organized in long-term care institutions.",2020,"Although the EG had lower extremity muscle strength than the CG at baseline, the EG had achieved significant improvements in the muscle strength values for the knee extensor, knee flexor, ankle plantar flexors, and dorsiflexors after 6 months (group x time interaction, p < .05).","['Residents of a Long-Term Care Institution', 'older adults', 'participants maintained normal activities, and EG participants were additionally enrolled in a 6-month group OEP led by a physiotherapist', 'twenty participants in this study had a mean age over 80 years and were recruited from a long-term care institution in southern Taiwan', 'residents living in a long-term care institution']","['Otago Exercise Program (OEP', 'strength training, balance training, and walking training', 'Otago Exercise Program']","['extremity muscle strength', 'knee flexor, ankle plantar flexors, and dorsiflexors', 'mean total OEP session attendance', 'muscle strength values', 'Lower Extremity Strength']","[{'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001795', 'cui_str': 'Oldest Old'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]","[{'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}]",,0.0147171,"Although the EG had lower extremity muscle strength than the CG at baseline, the EG had achieved significant improvements in the muscle strength values for the knee extensor, knee flexor, ankle plantar flexors, and dorsiflexors after 6 months (group x time interaction, p < .05).","[{'ForeName': 'Yung-Chi', 'Initials': 'YC', 'LastName': 'Cheng', 'Affiliation': 'EMBA, PT, Leader, Department of Rehabilitation, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Taiwan, ROC.'}, {'ForeName': 'Yen-Chi', 'Initials': 'YC', 'LastName': 'Liao', 'Affiliation': 'MSN, RN, Director, Department of Nursing, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Taiwan, ROC.'}, {'ForeName': 'Ling-Yu', 'Initials': 'LY', 'LastName': 'Hsieh', 'Affiliation': 'MSN, RN, Researcher, Department of Nursing, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Taiwan, ROC.'}]",Hu li za zhi The journal of nursing,['10.6224/JN.202006_67(3).07'] 1344,32685607,Stop to Ask and Respond: Effects of a Small-Group Self-Questioning Intervention on Reading Comprehension Performance.,"Self-questioning, a strategic approach for monitoring one's own comprehension, has shown promising outcomes for a diverse range of learners. The current study sought to replicate and extend this area of research by examining the effects of a small-group self-questioning intervention with systematic prompt fading on students' reading comprehension performance. Two small groups of fifth grade students performing among the lowest on reading comprehension in their general education classroom were selected to participate in this study. Three participants in each group were taught to stop to ask and respond to questions (STAR strategy) while chorally reading expository text passages. A multiple probe design across the small groups was used to examine the effects of this self-questioning strategy on the reading comprehension performance when prompts were systematically faded. Results indicated the groups, on average, demonstrated an increase in the number of comprehension questions answered correctly. Implications for practice are discussed.",2019,"Results indicated the groups, on average, demonstrated an increase in the number of comprehension questions answered correctly.","['Two small groups of fifth grade students performing among the lowest on reading comprehension in their general education classroom', ""students' reading comprehension performance""]","['Small-Group Self-Questioning Intervention', 'small-group self-questioning intervention']","['Reading Comprehension Performance', 'number of comprehension questions']","[{'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205439', 'cui_str': 'Fifth'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",3.0,0.0123247,"Results indicated the groups, on average, demonstrated an increase in the number of comprehension questions answered correctly.","[{'ForeName': 'Laurice M', 'Initials': 'LM', 'LastName': 'Joseph', 'Affiliation': 'The Ohio State University.'}, {'ForeName': 'Sheila', 'Initials': 'S', 'LastName': 'Alber-Morgan', 'Affiliation': 'The Ohio State University.'}, {'ForeName': 'Leigh Ann', 'Initials': 'LA', 'LastName': 'Amspaugh', 'Affiliation': 'The Ohio State University.'}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Ross', 'Affiliation': 'The Ohio State University.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Helton', 'Affiliation': 'The Ohio State University.'}, {'ForeName': 'Moira', 'Initials': 'M', 'LastName': 'Konrad', 'Affiliation': 'The Ohio State University.'}, {'ForeName': 'Carrie', 'Initials': 'C', 'LastName': 'Davenport', 'Affiliation': 'The Ohio State University.'}]",Research and Practice in the Schools : The Official Journal of the Texas Association of School Psychologists,[] 1345,7678586,Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components.,"Recently, conjugate vaccines containing Haemophilus influenzae type b capsular polysaccharide (HibCP) coupled to protein carriers were introduced for use in infants and certain adult risk groups. Similar conjugate vaccines against other capsulated bacteria are currently under development for both children and adults. Despite its potential importance, the possible influence of preexisting immunity to the components of such conjugates on the vaccination response in humans has been addressed by few studies. To study this issue, we randomized 82 healthy adult volunteers into six groups and vaccinated them twice, with a 4-week interval between immunizations. Four groups received tetanus toxoid (TT) or diphtheria toxoid (DT) and then HibCP coupled to TT (HibCP-TT) or DT (HibCP-DT). Two groups received HibCP-TT followed by HibCP-DT or vice versa. The total antibody levels to HibCP, TT, and DT and the anti-HibCP immunoglobulin G1 (IgG1) and IgG2 levels were measured before and 4 weeks after the immunizations. For some of the vaccinees, the number of circulating antibody-secreting cells was evaluated 7 days after immunization. Surprisingly, preimmunization with the relevant carrier protein reduced the subsequent increase in the total HibCP antibody levels (P < 0.05), affecting the IgG1 and the IgG2 subclasses equally. Also, the responses to the carrier portions of the conjugates were suppressed, as demonstrated by the lack of significant increases in the antibody levels (P > or = 0.29) and, for HibCP-TT, by reduced numbers of anticarrier antibody-secreting cells (P = 0.009). Similar non-epitope-specific suppression was seen in the groups receiving both conjugates. Thus, preimmunization with one conjugate reduced the subsequent response to the carrier portion of the other conjugate (HibCP-DT and then HibCP-TT, P = 0.00002; HibCP-TT and then HibCP-DT, P = 0.06) as well as to HibCP itself. Possible mechanisms behind this non-epitope-specific suppression and its relevance for vaccine development are discussed.",1993,"The total antibody levels to HibCP, TT, and DT and the anti-HibCP immunoglobulin G1 (IgG1) and IgG2 levels were measured before and 4 weeks after the immunizations.","['children and adults', '82 healthy adult volunteers into six groups and vaccinated them twice, with a 4-week interval between immunizations']","['HibCP-TT followed by HibCP-DT or vice versa', 'conjugate vaccines containing Haemophilus influenzae type b capsular polysaccharide (HibCP', 'tetanus toxoid (TT) or diphtheria toxoid (DT) and then HibCP coupled to TT (HibCP-TT) or DT (HibCP-DT']","['antibody levels', 'numbers of anticarrier antibody-secreting cells', 'total antibody levels to HibCP, TT, and DT and the anti-HibCP immunoglobulin G1 (IgG1) and IgG2 levels', 'total HibCP antibody levels']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0020971', 'cui_str': 'Sensitization, Immunologic'}]","[{'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0121772', 'cui_str': 'Haemophilus influenzae type b'}, {'cui': 'C0205151', 'cui_str': 'Capsular (qualifier value)'}, {'cui': 'C0032594', 'cui_str': 'Glycans'}, {'cui': 'C0305062', 'cui_str': 'Clostridium tetani toxoid antigen, inactivated'}, {'cui': 'C0012551', 'cui_str': 'diphtheria toxoid vaccine, inactivated'}, {'cui': 'C0010222', 'cui_str': 'Couples'}]","[{'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0085820', 'cui_str': 'Antibody-Secreting Cells'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0020855', 'cui_str': 'IgG1'}, {'cui': 'C0020856', 'cui_str': 'IgG2'}]",82.0,0.0170234,"The total antibody levels to HibCP, TT, and DT and the anti-HibCP immunoglobulin G1 (IgG1) and IgG2 levels were measured before and 4 weeks after the immunizations.","[{'ForeName': 'T', 'Initials': 'T', 'LastName': 'Barington', 'Affiliation': 'Laboratory of Medical Immunology, Rigshospitalet, University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Skettrup', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Juul', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Heilmann', 'Affiliation': ''}]",Infection and immunity,[] 1346,7790461,Long-term colonization with single and multiple strains of Helicobacter pylori assessed by DNA fingerprinting.,"The gastric pathogen Helicobacter pylori establishes long-term chronic infections that can lead to gastritis, peptic ulcers, and cancer. The species is so diverse that distinctly different strains are generally recovered from each patient. To better understand the dynamics of long-term carriage, we characterized H. pylori isolates from initial and follow-up biopsy specimens from a patient population at high risk of H. pylori infection and gastric cancer. Eighty-five isolates were obtained from 23 patients and were analyzed by genomic restriction enzyme analysis, arbitrarily primed PCR fingerprinting, (random amplified polymorphic DNA analysis), and/or restriction of specific PCR-amplified genes (restriction fragment length polymorphism analysis). A single strain was found in sequential biopsy specimens from 12 of 15 patients (80%) receiving sucralfate. In the remaining three patients treated with sucralfate, two strains were identified in two patients and three strains were identified in the third patient. In contrast, a single strain was found in sequential biopsy specimens from only three of eight patients (37%) receiving bismuth, metronidazole, and nitrofurantoin. Two strains were identified in five other patients receiving bismuth-antibiotic (63%). Immunoglobulin G antibodies to H. pylori were present in the sera of all patients. Thus, H. pylori colonization can persist for long periods (up to at least 4 years), despite high titers of immunoglobulin G antibodies in serum. Resistance to metronidazole was noted in some strains before and/or after treatment, but all strains remained susceptible to amoxicillin, tetracycline, and nitrofurantoin. We conclude that H. pylori genotypes, as measured by several sensitive DNA fingerprinting methods, can remain stable for years in vivo, despite the acquisition or loss of drug resistance, circulating antibody, or exposure to antibiotics or sucralfate.",1995,A single strain was found in sequential biopsy specimens from 12 of 15 patients (80%) receiving sucralfate.,['patient population at high risk of H. pylori infection and gastric cancer'],"['amoxicillin, tetracycline, and nitrofurantoin', 'bismuth-antibiotic', 'bismuth, metronidazole, and nitrofurantoin', 'sucralfate', 'metronidazole']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0024623', 'cui_str': 'Cancer of Stomach'}]","[{'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0039651', 'cui_str': 'Tetracyclines'}, {'cui': 'C0028156', 'cui_str': 'Nitrofurantoin'}, {'cui': 'C0005642', 'cui_str': 'Bismuth'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0038633', 'cui_str': 'Sucralfate'}]",[],85.0,0.0162611,A single strain was found in sequential biopsy specimens from 12 of 15 patients (80%) receiving sucralfate.,"[{'ForeName': 'N S', 'Initials': 'NS', 'LastName': 'Taylor', 'Affiliation': 'Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge 02139, USA.'}, {'ForeName': 'J G', 'Initials': 'JG', 'LastName': 'Fox', 'Affiliation': ''}, {'ForeName': 'N S', 'Initials': 'NS', 'LastName': 'Akopyants', 'Affiliation': ''}, {'ForeName': 'D E', 'Initials': 'DE', 'LastName': 'Berg', 'Affiliation': ''}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Thompson', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Shames', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Yan', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Fontham', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Janney', 'Affiliation': ''}, {'ForeName': 'F M', 'Initials': 'FM', 'LastName': 'Hunter', 'Affiliation': ''}]",Journal of clinical microbiology,[] 1347,7085070,Effect of cimetidine and antacid on gastric microbial flora.,"The effect of a standard regimen of cimetidine on the gastric flora of 20 male volunteers was studied in a double-blind manner and compared with the effects of a standard antacid regimen. Postprandial microbial titers in gastric aspirates were significantly higher at 4, 8, and 16 weeks of therapy in subjects taking antacids and at 4 weeks in subjects taking cimetidine when compared with their pretreatment titers. Although not significant, there was a tendency for fasting microbial titers to be higher in subjects receiving cimetidine as compared with pretreatment titers. The higher titers were primarily related to increases in survival of mouth flora (viridans streptococci and Neisseria spp.); Enterobacteriaceae and other nitrate-reducing organisms were unusual isolates. There was no significant difference in the total titers or types of organisms isolated when subjects taking cimetidine were compared with those taking antacid.",1982,"Postprandial microbial titers in gastric aspirates were significantly higher at 4, 8, and 16 weeks of therapy in subjects taking antacids and at 4 weeks in subjects taking cimetidine when compared with their pretreatment titers.",['20 male volunteers'],"['cimetidine', 'cimetidine and antacid']","['Postprandial microbial titers', 'survival of mouth flora (viridans streptococci and Neisseria spp', 'gastric microbial flora', 'fasting microbial titers', 'total titers']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0008783', 'cui_str': 'Cimetidine'}, {'cui': 'C0003138', 'cui_str': 'Alkalinizing Agents'}]","[{'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0230028', 'cui_str': 'Structure of oral region of face'}, {'cui': 'C0318157', 'cui_str': 'Streptococcus Viridans Group'}, {'cui': 'C0027571', 'cui_str': 'Neisseria'}, {'cui': 'C0075148', 'cui_str': 'stable plasma protein solution'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",20.0,0.035645,"Postprandial microbial titers in gastric aspirates were significantly higher at 4, 8, and 16 weeks of therapy in subjects taking antacids and at 4 weeks in subjects taking cimetidine when compared with their pretreatment titers.","[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Snepar', 'Affiliation': ''}, {'ForeName': 'G A', 'Initials': 'GA', 'LastName': 'Poporad', 'Affiliation': ''}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Romano', 'Affiliation': ''}, {'ForeName': 'W D', 'Initials': 'WD', 'LastName': 'Kobasa', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Kaye', 'Affiliation': ''}]",Infection and immunity,[] 1348,32685659,"Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study.","We designed a placebo controlled, double-blind, randomized, dose-finding phase II study on OMT-28 in the maintenance of sinus rhythm after electrical cardioversion (DCC) in patients with persistent atrial fibrillation (PROMISE-AF). OMT-28 is a first-in-class, synthetic analog of 17,18-epoxyeicosatetetraenoic acid, a bioactive lipid mediator generated by cytochrome P450 enzymes from the omega-3 fatty acid eicosapentaenoic acid. OMT-28 improves Ca 2+ -handling and mitochondrial function in cardiomyocytes and reduces pro-inflammatory signaling. This unique mode of action may provide a novel approach to target key mechanism contributing to AF pathophysiology. In a recent phase I study, OMT-28 was safe and well tolerated and showed favorable pharmacokinetics. The PROMISE-AF study (NCT03906799) is designed to assess the efficacy (primary objective), safety, and population pharmacokinetics (secondary objectives) of three different doses of OMT-28, administered once daily, versus placebo until the end of the follow-up period. Recruitment started in March 2019 and the study will include a total of 120 patients. The primary efficacy endpoint is the AF burden (% time with any AF), evaluated over a 13-week treatment period after DCC. AF burden is calculated based on continuous ECG monitoring using an insertable cardiac monitor (ICM). The primary efficacy analysis will be conducted on the modified intention-to-treat (mITT) population, whereas the safety analysis will be done on the safety population. Although ICMs have been used in other interventional studies to assess arrhythmia, PROMISE-AF will be the first study to assess antiarrhythmic efficacy and safety of a novel rhythm-stabilizing drug after DCC by using ICMs.",2020,OMT-28 improves Ca 2+ -handling and mitochondrial function in cardiomyocytes and reduces pro-inflammatory signaling.,"['patients with persistent atrial fibrillation (PROMISE-AF', 'patients with persistent atrial fibrillation', '120 patients']","['electrical cardioversion (DCC', 'OMT-28', 'placebo']","['AF burden (% time with any AF', 'antiarrhythmic efficacy and safety', 'safe and well tolerated']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}, {'cui': 'C4319550', 'cui_str': '120'}]","[{'cui': 'C0013778', 'cui_str': 'Cardioversion'}, {'cui': 'C1259909', 'cui_str': 'DCC protein, human'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0003195', 'cui_str': 'Antiarrhythmic agent'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",120.0,0.0652627,OMT-28 improves Ca 2+ -handling and mitochondrial function in cardiomyocytes and reduces pro-inflammatory signaling.,"[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Berlin', 'Affiliation': 'OMEICOS Therapeutics GmbH, Berlin, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Goette', 'Affiliation': 'Cardiology and Intensive Care Medicine, St. Vincenz-Hospital, Paderborn, Germany.'}, {'ForeName': 'Luciana', 'Initials': 'L', 'LastName': 'Summo', 'Affiliation': 'OMEICOS Therapeutics GmbH, Berlin, Germany.'}, {'ForeName': 'Janine', 'Initials': 'J', 'LastName': 'Lossie', 'Affiliation': 'OMEICOS Therapeutics GmbH, Berlin, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Gebauer', 'Affiliation': 'OMEICOS Therapeutics GmbH, Berlin, Germany.'}, {'ForeName': 'Naab', 'Initials': 'N', 'LastName': 'Al-Saady', 'Affiliation': 'Covance Inc., Maidenhead, United Kingdom.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Calo', 'Affiliation': 'Division of Cardiology, Policlinico Casilino, 00169 Rome, Italy.'}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'Naccarelli', 'Affiliation': 'Heart and Vascular Institute, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.'}, {'ForeName': 'Wolf-Hagen', 'Initials': 'WH', 'LastName': 'Schunck', 'Affiliation': 'Max Delbrueck Center for Molecular Medicine, Berlin, Germany.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Fischer', 'Affiliation': 'OMEICOS Therapeutics GmbH, Berlin, Germany.'}, {'ForeName': 'A John', 'Initials': 'AJ', 'LastName': 'Camm', 'Affiliation': ""St. George's University of London, London, United Kingdom.""}, {'ForeName': 'Dobromir', 'Initials': 'D', 'LastName': 'Dobrev', 'Affiliation': 'Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany.'}]",International journal of cardiology. Heart & vasculature,['10.1016/j.ijcha.2020.100573'] 1349,7822046,Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.,"Persons of blood group O are at increased risk of developing cholera gravis. In a randomized, placebo-controlled, double-blind safety-immunogenicity trial of live oral cholera vaccine CVD 103-HgR in 5- to 9-year-old Chilean children, vibriocidal antibody seroconversion (74% overall) did not differ by blood group. However, the reciprocal geometric mean titer (GMT) in blood group O vaccines (GMT = 486) was higher than that in non-O vaccines (GMT = 179) (P < 0.02).",1995,Persons of blood group O are at increased risk of developing cholera gravis.,['persons of blood group O'],"['live cholera vaccine strain CVD', 'live oral cholera vaccine CVD 103-HgR', 'placebo']","['vibriocidal antibody seroconversion', 'risk of developing cholera gravis', '103-HgR elicits', 'serum vibriocidal antibody titers', 'reciprocal geometric mean titer (GMT']","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0427625', 'cui_str': 'Blood group O (finding)'}]","[{'cui': 'C0008359', 'cui_str': 'Cholera Vaccine'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0961644', 'cui_str': 'cholera vaccine CVD 103-HgR'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0008354', 'cui_str': 'Vibrio cholerae Infection'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C4517526', 'cui_str': 'One hundred and three'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1287242', 'cui_str': 'Finding of antibody titer (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0475208', 'cui_str': 'TITR'}]",,0.401462,Persons of blood group O are at increased risk of developing cholera gravis.,"[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Lagos', 'Affiliation': 'Centro para Vacunas en Desarrollo-Chile.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Avendaño', 'Affiliation': ''}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Prado', 'Affiliation': ''}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Horwitz', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Wasserman', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Losonsky', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Cryz', 'Affiliation': ''}, {'ForeName': 'J B', 'Initials': 'JB', 'LastName': 'Kaper', 'Affiliation': ''}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Levine', 'Affiliation': ''}]",Infection and immunity,[] 1350,7814484,High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults.,"The reactogenicity and immunogenicity of purified influenza virus hemagglutinin (HA) vaccines administered intramuscularly were evaluated in two placebo-controlled clinical trials. A total of 139 healthy young adults were randomized to receive increasing doses of monovalent influenza A/Taiwan/1/86 (H1N1) virus HA (range, 0 to 405 micrograms per dose [study 1]). An additional 139 subjects were given increasing doses of a trivalent HA vaccine containing equal amounts of A/H1N1 virus, A/Shanghai/16/89 (H3N2) virus, and influenza B/Yamagata/16/88 virus HA (range, 0 to 135 micrograms of HA per strain, 0 to 405 micrograms per dose) or a standard dose of commercial influenza vaccine (study 2). Increasing doses of HA were associated with increasing frequencies of symptoms at the vaccination site early after vaccination, but all doses were well tolerated. Occurrence of systemic symptoms was unrelated to dose. Increasing the dose of HA resulted in increasingly higher postimmunization levels of serum hemagglutination inhibiting and neutralizing antibody levels versus influenza A/H1N1 virus in study 1 (P < 0.05); these enhanced responses persisted for up to 6 months. Nasal secretory immunoglobulin A and G antibody responses were assessed 2 weeks after immunization with monovalent H1N1 virus HA; the frequencies of significant responses also increased in a dose-related fashion. Similar increases in serum antibody levels were noted for both A/H1N1 and A/H3N2 viruses in study 2. These data provide a basis for proceeding with the evaluation of high doses of purified HA in the elderly.",1994,Similar increases in serum antibody levels were noted for both A/H1N1 and A/H3N2 viruses in study 2.,"['139 subjects', 'healthy young adults', '139 healthy young adults']","['monovalent influenza A/Taiwan/1/86 (H1N1) virus HA', 'purified influenza A virus hemagglutinin', 'trivalent HA vaccine containing equal amounts of A/H1N1 virus, A/Shanghai/16/89 (H3N2) virus, and influenza B/Yamagata/16/88 virus HA (range, 0 to 135 micrograms of HA per strain, 0 to 405 micrograms per dose) or a standard dose of commercial influenza vaccine', 'purified influenza virus hemagglutinin (HA) vaccines']","['serum antibody levels', 'tolerated', 'serum hemagglutination inhibiting and neutralizing antibody levels', 'Occurrence of systemic symptoms', 'Nasal secretory immunoglobulin A and G antibody responses', 'reactogenicity and immunogenicity', 'serum and nasal secretion antibody responses']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C2076600', 'cui_str': 'Influenza caused by Influenza A virus subtype H1N1'}, {'cui': 'C0042776', 'cui_str': 'Virus'}, {'cui': 'C0029347', 'cui_str': 'Influenza A virus'}, {'cui': 'C0018909', 'cui_str': 'Hemagglutinin'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C1265611', 'cui_str': 'Quantity finding'}, {'cui': 'C1615607', 'cui_str': 'Influenza A Virus, H1N1 Subtype'}, {'cui': 'C0021400', 'cui_str': 'Influenza, Human'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0439211', 'cui_str': 'microgram'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C4517768', 'cui_str': 'Four hundred and five'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0021403', 'cui_str': 'Influenza Vaccines'}, {'cui': 'C4316910', 'cui_str': 'Influenzavirus'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0018905', 'cui_str': 'Hemagglutination assay (procedure)'}, {'cui': 'C1142254', 'cui_str': 'Neutralising antibodies'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C0020838', 'cui_str': 'Secretory IgA'}, {'cui': 'C0003261', 'cui_str': 'Antibody Response'}, {'cui': 'C0036537', 'cui_str': 'Secretions'}]",139.0,0.0286285,Similar increases in serum antibody levels were noted for both A/H1N1 and A/H3N2 viruses in study 2.,"[{'ForeName': 'W A', 'Initials': 'WA', 'LastName': 'Keitel', 'Affiliation': 'Acute Viral Respiratory Disease Unit, Baylor College of Medicine, Houston, TX 77030-3498.'}, {'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Couch', 'Affiliation': ''}, {'ForeName': 'T R', 'Initials': 'TR', 'LastName': 'Cate', 'Affiliation': ''}, {'ForeName': 'K R', 'Initials': 'KR', 'LastName': 'Hess', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Baxter', 'Affiliation': ''}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Quarles', 'Affiliation': ''}, {'ForeName': 'R L', 'Initials': 'RL', 'LastName': 'Atmar', 'Affiliation': ''}, {'ForeName': 'H R', 'Initials': 'HR', 'LastName': 'Six', 'Affiliation': ''}]",Journal of clinical microbiology,[] 1351,32688225,Gender and racial/ethnic differences in physiologic responses in the Stimulant Reduction Intervention using Dosed Exercise Study.,"Exercise may be beneficial for individuals in substance use disorder (SUD) treatment given the higher rates of both medical and psychiatric comorbidity, namely mood and anxiety disorders, compared to the general population. Gender and/or racial/ethnic differences in health benefits and response to prescribed exercise have been reported and may have implications for designing exercise interventions in SUD programs. METHOD Data are from the National Drug Abuse Treatment Clinical Trials Network (NIDA/CTN) Stimulant Reduction Intervention using Dosed Exercise (STRIDE) trial. Gender differences across racial/ethnic groups in physiological responses and stimulant withdrawal severity across time were analyzed using linear mixed effects models. RESULTS Males completed significantly more exercise sessions than females and were more adherent to the prescribed exercise dose of 12 Kcal/Kg/Week. Controlling for age, race/ethnicity, treatment group and stimulant withdrawal severity, there was a significant gender by time interaction for body mass index (BMI) (p < 0.001), waist circumference (p < 0.001) and heart rate measured prior to exercise sessions (p < 0.01). For females, body mass index (BMI) and waist circumference increased over time while for males BMI and waist circumference stayed unchanged or slightly decreased with time. Heart rate over time significantly increased for females at a higher rate than in males. Stimulant withdrawal severity was similar in males and females at baseline but males exhibited a significant decrease over time while females did not. Although baseline differences were observed, there were no time by race/ethnicity differences in physiologic responses. DISCUSSION Gender differences in response to exercise may have implications for developing gender specific exercise interventions in SUD programs.",2020,Stimulant withdrawal severity was similar in males and females at baseline but males exhibited a significant decrease over time while females did not.,['Data are from the National Drug Abuse Treatment Clinical Trials Network (NIDA/CTN'],['Stimulant Reduction Intervention'],"['waist circumference', 'heart rate', 'time interaction for body mass index (BMI', 'Heart rate over time', 'Stimulant withdrawal severity', 'body mass index (BMI) and waist circumference', 'exercise sessions']","[{'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0013146', 'cui_str': 'Drug abuse'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}]","[{'cui': 'C0002763', 'cui_str': 'Central stimulant'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1997739', 'cui_str': 'Psychostimulant withdrawal'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0431347,Stimulant withdrawal severity was similar in males and females at baseline but males exhibited a significant decrease over time while females did not.,"[{'ForeName': 'T K', 'Initials': 'TK', 'LastName': 'Killeen', 'Affiliation': 'Medical University of South Carolina, Charleston, SC, USA. Electronic address: killeent@musc.edu.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Wolf', 'Affiliation': 'Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'T L', 'Initials': 'TL', 'LastName': 'Greer', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Carmody', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'C D', 'Initials': 'CD', 'LastName': 'Rethorst', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'M H', 'Initials': 'MH', 'LastName': 'Trivedi', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106546'] 1352,32685661,Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty - A randomized controlled study.,"Background Although balloon pulmonary angioplasty (BPA) improves symptoms and pulmonary hemodynamics in patients with chronic thromboembolic pulmonary hypertension (CTEPH), the effects of riociguat on hemodynamics and exercise capacity in patients after BPA remain to be elucidated. Methods and Results This study was a single-center, prospective, randomized, open-label trial. From November 2015 to November 2018, we prospectively examined 21 patients with CTEPH (65 ± 9 years old, M/F 2/19) who showed hemodynamic improvement with mean pulmonary arterial pressure (mPAP) < 30 mmHg after BPA without any vasodilators. We performed hemodynamic evaluation and expired gas analysis both at rest and during exercise in supine position using cycle ergometer. After right heart catheterization during exercise, they were randomly assigned to 2 groups with minimized method, using age, sex, and resting mPAP; riociguat (N = 10) and control (N = 11) groups. After 6 months, exercise capacity evaluated by 6-min walk distance and cardiopulmonary exercise testing, and resting hemodynamic parameters were comparable in both groups. However, cardiac output (CO) (6.0 ± 1.7-7.4 ± 1.6, P < 0.01) and pulmonary vascular resistance (4.8 ± 1.8-3.2 ± 0.7 Wood units, P = 0.02) at peak workload were significantly improved in the riociguat group as compared with the control group. The slope of linearized mPAP-CO relationship was significantly decreased in the riociguat group [14.5 (7.8, 14.7) to 6.41 (5.1, 11.4), P < 0.01] but not in the control group. Conclusions These results indicate that riociguat exerts beneficial effects on hemodynamic response to exercise in CTEPH patients even after hemodynamic improvement by BPA.",2020,"< 0.01) and pulmonary vascular resistance (4.8 ± 1.8-3.2 ± 0.7 Wood units, P = 0.02) at peak workload were significantly improved in the riociguat group as compared with the control group.","['CTEPH patients after balloon pulmonary angioplasty ', 'From November 2015 to November 2018, we prospectively examined 21 patients with CTEPH (65\xa0±', 'patients after BPA remain to be elucidated', 'patients with chronic thromboembolic pulmonary hypertension (CTEPH']","['riociguat', 'balloon pulmonary angioplasty (BPA']","['hemodynamics and exercise capacity', 'hemodynamic improvement with mean pulmonary arterial pressure (mPAP', 'symptoms and pulmonary hemodynamics', 'cardiac output (CO', 'pulmonary vascular resistance', 'slope of linearized mPAP-CO relationship', 'exercise capacity evaluated by 6-min walk distance and cardiopulmonary exercise testing, and resting hemodynamic parameters', 'hemodynamic response', 'hemodynamic responses', 'peak workload']","[{'cui': 'C2363973', 'cui_str': 'Chronic thromboembolic pulmonary hypertension'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty of blood vessel'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C2717561', 'cui_str': 'riociguat'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty of blood vessel'}]","[{'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C3854605', 'cui_str': 'Mean pulmonary arterial pressure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0007165', 'cui_str': 'Cardiac output'}, {'cui': 'C0456261', 'cui_str': 'Pulmonary vascular resistance'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary exercise test'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}]",,0.0206065,"< 0.01) and pulmonary vascular resistance (4.8 ± 1.8-3.2 ± 0.7 Wood units, P = 0.02) at peak workload were significantly improved in the riociguat group as compared with the control group.","[{'ForeName': 'Tatsuo', 'Initials': 'T', 'LastName': 'Aoki', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Koichiro', 'Initials': 'K', 'LastName': 'Sugimura', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Yosuke', 'Initials': 'Y', 'LastName': 'Terui', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Shunsuke', 'Initials': 'S', 'LastName': 'Tatebe', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Shigefumi', 'Initials': 'S', 'LastName': 'Fukui', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Masanobu', 'Initials': 'M', 'LastName': 'Miura', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Saori', 'Initials': 'S', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Nobuhiro', 'Initials': 'N', 'LastName': 'Yaoita', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Suzuki', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Haruka', 'Initials': 'H', 'LastName': 'Sato', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Katsuya', 'Initials': 'K', 'LastName': 'Kozu', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Konno', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Miyata', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Kotaro', 'Initials': 'K', 'LastName': 'Nochioka', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Kimio', 'Initials': 'K', 'LastName': 'Satoh', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Shimokawa', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}]",International journal of cardiology. Heart & vasculature,['10.1016/j.ijcha.2020.100579'] 1353,32688368,Thymus size in children with moderate malnutrition: a cohort study from Burkina Faso.,"BACKGROUND Moderate acute malnutrition (MAM) affects millions of children, increasing their risk of dying from infections. Thymus atrophy may be a marker of malnutrition-associated immunodeficiency, but factors associated with thymus size in children with MAM are unknown, as is the effect of nutritional interventions on thymus size. METHODS Thymus size was measured by ultrasound in 279 children in Burkina Faso with MAM, diagnosed by low mid-upper arm circumference (MUAC) and/or low weight-for-length z-score (WLZ), who received 12 weeks treatment with different food supplements as part of a randomized trial. Correlates of thymus size and of changes in thymus size after treatment, and after another 12 weeks of follow-up were identified. RESULTS Thymus size correlated positively with age, anthropometry and blood haemoglobin, and was smaller in children with malaria. Children with malnutrition diagnosed using MUAC had a smaller thymus than children diagnosed based on WLZ. Thymus size increased during and after treatment, similarly across the different food supplement groups. CONCLUSIONS In children with MAM, the thymus is smaller in children with anaemia or malaria, and grows with recovery. Assuming that thymus size reflects vulnerability, low MUAC seems to identify more vulnerable children than low WLZ in children with MAM. IMPACT Thymus atrophy is known to be a marker of the immunodeficiency associated with malnutrition in children.In children with moderate malnutrition, we found the thymus to be smaller in children with anaemia or malaria.Assuming that thymus size reflects vulnerability, low MUAC seems to identify more vulnerable children than low weight for length.Thymus atrophy appears reversible with recovery from malnutrition, with similar growth seen in children randomized to treatment with different nutritional supplements.",2020,"Thymus size increased during and after treatment, similarly across the different food supplement groups. ","['279 children in Burkina Faso with MAM, diagnosed by low mid-upper arm circumference (MUAC) and/or low weight-for-length z-score (WLZ), who received 12 weeks treatment with different food supplements as part of a randomized trial', 'Children with malnutrition diagnosed using', 'children with moderate malnutrition']","['MUAC', 'WLZ']",['Thymus size'],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0006409', 'cui_str': 'Burkina Faso'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0562351', 'cui_str': 'Mid upper arm circumference'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0562351', 'cui_str': 'Mid upper arm circumference'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}]","[{'cui': 'C0040112', 'cui_str': 'Thymus Extracts'}, {'cui': 'C0456389', 'cui_str': 'Size'}]",279.0,0.033117,"Thymus size increased during and after treatment, similarly across the different food supplement groups. ","[{'ForeName': 'Maren J H', 'Initials': 'MJH', 'LastName': 'Rytter', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 30, 1958, Frederiksberg C, Denmark. marenrytter@hotmail.com.'}, {'ForeName': 'Bernardette', 'Initials': 'B', 'LastName': 'Cichon', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 30, 1958, Frederiksberg C, Denmark.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Fabiansen', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 30, 1958, Frederiksberg C, Denmark.'}, {'ForeName': 'Charles W', 'Initials': 'CW', 'LastName': 'Yameogo', 'Affiliation': 'Institut de Recherche en Sciences de la Santé, Ouagadougou, 03 BP:7048, Ouagadougou 03, Burkina Faso.'}, {'ForeName': 'Sylvain Z', 'Initials': 'SZ', 'LastName': 'Windinmi', 'Affiliation': 'Centre Médical Chirurgicale Pédiatrique, Ouahigouya, Burkina Faso.'}, {'ForeName': 'Kim F', 'Initials': 'KF', 'LastName': 'Michaelsen', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 30, 1958, Frederiksberg C, Denmark.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Filteau', 'Affiliation': 'London School of Hygiene and Tropical Medicine, Faculty of Epidemiology and Population Health, Keppel Street, London, WC1E 7HT, UK.'}, {'ForeName': 'Dorthe L', 'Initials': 'DL', 'LastName': 'Jeppesen', 'Affiliation': 'Department of Paediatrics, Copenhagen University Hospital Hvidovre, Kettergårds allé 30, 2650, Hvidovre, Denmark.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Friis', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 30, 1958, Frederiksberg C, Denmark.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Briend', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 30, 1958, Frederiksberg C, Denmark.'}, {'ForeName': 'Vibeke B', 'Initials': 'VB', 'LastName': 'Christensen', 'Affiliation': 'Médecins Sans Frontières-Denmark, Strandlodsvej 44, 2. 2300, København S, Denmark.'}]",Pediatric research,['10.1038/s41390-020-1057-5'] 1354,31389769,Effects of Developmental Task Constraints on Kinematic Synergies during Catching in Children with Developmental Delays.,"The aim of this study was to examine effects of a task intervention on kinematic synergies in catching. Participants were young children (5.58 ± 0.52 years) with the lowest scores on two-hand catching, according to assessments with the Test of Gross Motor Development-2 (TGMD-2) and were allocated into two groups. The constraints group took part in an 8-week intervention, whereas the control group experienced a typical physical education. Both groups were assessed with motor development and kinematic coordination measures with a catching task with a ball thrown from 2 m distance. Kinematic variables were recorded using a wireless motion capture system. A principal component analysis (PCA) was used to measure the kinematic synergies formed among active body parts. Two synergies that emerged in catching were mainly utilised for ""reaching"" and ""catching"" the ball. The control group tended to re-organise the majority of active body parts into two functional units in all phases, whereas the constraints group adapted their active parts into functional units according to the requirement of the novel movement in the transfer task. The findings of this study suggested that task constraints could facilitate object control by re-organisation of active body parts into functional synergies to achieve successful performance.",2020,"The control group tended to re-organise the majority of active body parts into two functional units in all phases, whereas the constraints group adapted their active parts into functional units according to the requirement of the novel movement in the transfer task.","['Participants were young children (5.58\u2009±\u20090.52\u2009years) with the lowest scores on two-hand catching, according to assessments with the Test of Gross Motor Development-2 (TGMD-2', 'Children with Developmental Delays']","['Developmental Task Constraints', 'task intervention', 'control group experienced a typical physical education']","['motor development and kinematic coordination measures', 'Kinematic Synergies']","[{'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0439806', 'cui_str': 'Gross (qualifier value)'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0424605', 'cui_str': 'Developmental delay (disorder)'}]","[{'cui': 'C0458003', 'cui_str': 'Developmental (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0031805', 'cui_str': 'Physical Education'}]","[{'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0600169', 'cui_str': 'Kinematics'}, {'cui': 'C0242414', 'cui_str': 'Coordination (observable entity)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",,0.0130458,"The control group tended to re-organise the majority of active body parts into two functional units in all phases, whereas the constraints group adapted their active parts into functional units according to the requirement of the novel movement in the transfer task.","[{'ForeName': 'Shahab', 'Initials': 'S', 'LastName': 'Parvinpour', 'Affiliation': 'Faculty of Physical Education and Sport Sciences, Kharazmi University, Tehran, Iran.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Shafizadeh', 'Affiliation': 'Faculty of Health and Well-Being, Sheffield Hallam University, Sheffield, UK.'}, {'ForeName': 'Marzie', 'Initials': 'M', 'LastName': 'Balali', 'Affiliation': 'Faculty of Physical Education and Sport Sciences, Central Tehran Branch, Islamic Azad University, Tehran, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Abbasi', 'Affiliation': 'Faculty of Physical Education and Sport Sciences, Kharazmi University, Tehran, Iran.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Wheat', 'Affiliation': 'Faculty of Health and Well-Being, Sheffield Hallam University, Sheffield, UK.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Davids', 'Affiliation': 'Faculty of Health and Well-Being, Sheffield Hallam University, Sheffield, UK.'}]",Journal of motor behavior,['10.1080/00222895.2019.1649998'] 1355,32496074,"Effects of the COVID-19 pandemic and nationwide lockdown on trust, attitudes toward government, and well-being.","The contagiousness and deadliness of COVID-19 have necessitated drastic social management to halt transmission. The immediate effects of a nationwide lockdown were investigated by comparing matched samples of New Zealanders assessed before (N prelockdown = 1,003) and during the first 18 days of lockdown (N lockdown = 1,003). Two categories of outcomes were examined: (a) institutional trust and attitudes toward the nation and government and (b) health and well-being. Applying propensity score matching to approximate the conditions of a randomized controlled experiment, the study found that people in the pandemic/lockdown group reported higher trust in science, politicians, and police, higher levels of patriotism, and higher rates of mental distress compared to people in the prelockdown prepandemic group. Results were confirmed in within-subjects analyses. The study highlights social connectedness, resilience, and vulnerability in the face of adversity and has applied implications for how countries face this global challenge. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,Two categories of outcomes were examined: (a) institutional trust and attitudes toward the nation and government and (b) health and well-being.,[],"['COVID-19 pandemic and nationwide lockdown', 'nationwide lockdown']","['institutional trust and attitudes toward the nation and government and (b) health and well-being', 'mental distress']",[],"[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}]","[{'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0018104', 'cui_str': 'Government'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0235109', 'cui_str': 'Mental distress'}]",,0.0275454,Two categories of outcomes were examined: (a) institutional trust and attitudes toward the nation and government and (b) health and well-being.,"[{'ForeName': 'Chris G', 'Initials': 'CG', 'LastName': 'Sibley', 'Affiliation': 'School of Psychology, University of Auckland.'}, {'ForeName': 'Lara M', 'Initials': 'LM', 'LastName': 'Greaves', 'Affiliation': 'School of Social Sciences, University of Auckland.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Satherley', 'Affiliation': 'School of Psychology, University of Auckland.'}, {'ForeName': 'Marc S', 'Initials': 'MS', 'LastName': 'Wilson', 'Affiliation': 'School of Psychology, Victoria University of Wellington.'}, {'ForeName': 'Nickola C', 'Initials': 'NC', 'LastName': 'Overall', 'Affiliation': 'School of Psychology, University of Auckland.'}, {'ForeName': 'Carol H J', 'Initials': 'CHJ', 'LastName': 'Lee', 'Affiliation': 'School of Psychology, University of Auckland.'}, {'ForeName': 'Petar', 'Initials': 'P', 'LastName': 'Milojev', 'Affiliation': 'School of Humanities, University of Auckland.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Bulbulia', 'Affiliation': 'School of Humanities, University of Auckland.'}, {'ForeName': 'Danny', 'Initials': 'D', 'LastName': 'Osborne', 'Affiliation': 'School of Psychology, University of Auckland.'}, {'ForeName': 'Taciano L', 'Initials': 'TL', 'LastName': 'Milfont', 'Affiliation': 'School of Psychology, Victoria University of Wellington.'}, {'ForeName': 'Carla A', 'Initials': 'CA', 'LastName': 'Houkamau', 'Affiliation': 'Department of Management and International Business, University of Auckland.'}, {'ForeName': 'Isabelle M', 'Initials': 'IM', 'LastName': 'Duck', 'Affiliation': 'Silverdale Medical.'}, {'ForeName': 'Raine', 'Initials': 'R', 'LastName': 'Vickers-Jones', 'Affiliation': 'School of Psychology, University of Queensland.'}, {'ForeName': 'Fiona Kate', 'Initials': 'FK', 'LastName': 'Barlow', 'Affiliation': 'School of Psychology, University of Queensland.'}]",The American psychologist,['10.1037/amp0000662'] 1356,6862626,Selenium and immune functions in humans.,"Earlier animal experiments have shown that selenium depletion may decrease immune functions. In this human study, 40 volunteers from a population with low serum selenium concentrations were supplemented with selenium or placebo for 11 weeks. Blood samples were drawn at intervals for analysis of selenium status and immune function. At the end of the supplementation period, plasma selenium levels were 74 ng/ml in the placebo group and 169 ng/ml in the supplemented group. The improvement in selenium status was associated with a 57% increase in the activity of platelet glutathione peroxidase in the group supplemented with selenium, but there was no increase in the activity of this enzyme in the placebo-treated subjects. Immune function was measured in vitro by tests of lymphocyte and granulocyte activity. Intracellular killing of Staphylococcus aureus by granulocytes was slightly lower in the placebo group than in the selenium group at the end of the supplementation period (77.2 compared to 85.2%; P less than 0.05). No significant changes were observed in phagocytosis, chemotactic factor generation, antibody or leukocyte migration inhibitory factor production by lymphocytes, or proliferative responses to phytohemagglutinin or concanavalin A. These results suggest that the selenium deficiency of the order found in Finland and some other areas of the world has little, if any, influence on the immune functions measured in this study.",1983,"No significant changes were observed in phagocytosis, chemotactic factor generation, antibody or leukocyte migration inhibitory factor production by lymphocytes, or proliferative responses to phytohemagglutinin or concanavalin A.","['40 volunteers from a population with low serum selenium concentrations', 'humans']","['selenium or placebo', 'placebo']","['Immune function', 'plasma selenium levels', 'activity of this enzyme', 'activity of platelet glutathione peroxidase', 'selenium status', 'phagocytosis, chemotactic factor generation, antibody or leukocyte migration inhibitory factor production by lymphocytes, or proliferative responses to phytohemagglutinin or concanavalin A', 'Intracellular killing of Staphylococcus aureus by granulocytes']","[{'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0858170', 'cui_str': 'Serum selenium'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0439662', 'cui_str': 'Immune (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0858169', 'cui_str': 'Plasma selenium'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C3541394', 'cui_str': 'Enzymes'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0017822', 'cui_str': 'Glutathione:hydrogen-peroxide oxidoreductase'}, {'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0031308', 'cui_str': 'Phagocytosis'}, {'cui': 'C0008013', 'cui_str': 'Chemotaxins'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0023513', 'cui_str': 'Migration-Inhibition Factors, Leukocyte'}, {'cui': 'C0033268'}, {'cui': 'C4018897', 'cui_str': 'Lymphocyte component of blood'}, {'cui': 'C0031858', 'cui_str': 'Phaseolus vulgaris Lectins'}, {'cui': 'C0009630', 'cui_str': 'Concanavalin A'}, {'cui': 'C0178719', 'cui_str': 'Intracellular (qualifier value)'}, {'cui': 'C0162388', 'cui_str': 'Killing'}, {'cui': 'C0038172', 'cui_str': 'Staphylococcus aureus'}, {'cui': 'C0018183', 'cui_str': 'Granulocytic cell'}]",40.0,0.0710494,"No significant changes were observed in phagocytosis, chemotactic factor generation, antibody or leukocyte migration inhibitory factor production by lymphocytes, or proliferative responses to phytohemagglutinin or concanavalin A.","[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Arvilommi', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Poikonen', 'Affiliation': ''}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Jokinen', 'Affiliation': ''}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Muukkonen', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Räsänen', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Foreman', 'Affiliation': ''}, {'ForeName': 'J K', 'Initials': 'JK', 'LastName': 'Huttunen', 'Affiliation': ''}]",Infection and immunity,[] 1357,32141723,"Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.","OBJECTIVE To assess the antipsychotic efficacy and safety of a combination of olanzapine and samidorphan (OLZ/SAM). METHODS This 4-week, phase 3, randomized, double-blind, placebo- and olanzapine-controlled study was conducted from December 2015 to June 2017 in adults with schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria who were experiencing an acute exacerbation. Patients were randomized 1:1:1 to OLZ/SAM, olanzapine monotherapy, or placebo. The primary and key secondary efficacy endpoint assessed was the change in Positive and Negative Syndrome Scale (PANSS) total score and Clinical Global Impressions-Severity of Illness Scale (CGI-S) score between baseline and week 4, respectively, for OLZ/SAM versus placebo. Safety monitoring occurred throughout. RESULTS 401 patients received ≥ 1 dose of study drug; 352 completed treatment. Treatment with OLZ/SAM resulted in significant improvements versus placebo in PANSS total and CGI-S scores from baseline to week 4 (least squares [LS] mean ± SE: -6.4 ± 1.8 [P < .001] and -0.38 ± 0.12 [P = .002], respectively). Olanzapine treatment resulted in similar improvements (PANSS and CGI-S LS mean ± SE of -5.3 ± 1.84 [P = .004] and -0.44 ± 0.12 [P < .001], respectively). Adverse events (AEs) occurred in 54.5%, 54.9%, and 44.8% of patients on OLZ/SAM, olanzapine, and placebo, respectively. Weight gain, somnolence, dry mouth, anxiety, and headache were the most common AEs (ie, ≥ 5%) with active treatment. CONCLUSIONS OLZ/SAM treatment resulted in statistically and clinically significant efficacy improvements over 4 weeks versus placebo in adults with acutely exacerbated schizophrenia. Improvements were similar to those observed with olanzapine. OLZ/SAM was well tolerated, with a safety profile similar to that of olanzapine. TRIAL REGISTRATIONS ClinicalTrials.gov identifier: NCT02634346; EudraCT number: 2015-003373-15​​.",2020,"Treatment with OLZ/SAM resulted in significant improvements versus placebo in PANSS total and CGI-S scores from baseline to week 4 (least squares [LS] mean ± SE: -6.4 ± 1.8 [P < .001] and -0.38 ± 0.12 [P = .002], respectively).","['401 patients received ≥ 1 dose of study drug; 352 completed treatment', 'Adult Patients With an Acute Exacerbation of Schizophrenia', 'December 2015 to June 2017 in adults with schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria who were experiencing an acute exacerbation', 'adults with acutely exacerbated schizophrenia']","['OLZ/SAM, olanzapine monotherapy, or placebo', 'placebo', 'Olanzapine', 'olanzapine', 'OLZ/SAM', 'olanzapine and samidorphan (OLZ/SAM', 'Olanzapine and Samidorphan']","['PANSS total and CGI-S scores', 'antipsychotic efficacy and safety', 'Weight gain, somnolence, dry mouth, anxiety, and headache', 'Adverse events (AEs', 'Safety monitoring', 'change in Positive and Negative Syndrome Scale (PANSS) total score and Clinical Global Impressions-Severity of Illness Scale (CGI-S) score', 'Efficacy and Safety']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C1136324', 'cui_str': 'Diagnostic and Statistical Manual of Mental Disorders'}, {'cui': 'C0205439', 'cui_str': 'Fifth (qualifier value)'}, {'cui': 'C0441792', 'cui_str': 'Editions (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1444749', 'cui_str': 'Exacerbated (qualifier value)'}]","[{'cui': 'C1563296', 'cui_str': 'Systolic anterior movement of mitral valve'}, {'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4277369', 'cui_str': '3-carboxamido-4-hydroxynaltrexone'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0040615', 'cui_str': 'Antipsychotic Drugs'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C2830004', 'cui_str': 'Somnolence'}, {'cui': 'C0043352', 'cui_str': 'Mouth Dryness'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale (assessment scale)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0222045'}]",,0.293013,"Treatment with OLZ/SAM resulted in significant improvements versus placebo in PANSS total and CGI-S scores from baseline to week 4 (least squares [LS] mean ± SE: -6.4 ± 1.8 [P < .001] and -0.38 ± 0.12 [P = .002], respectively).","[{'ForeName': 'Steven G', 'Initials': 'SG', 'LastName': 'Potkin', 'Affiliation': 'School of Medicine, University of California, Irvine, California, USA.'}, {'ForeName': 'Jelena', 'Initials': 'J', 'LastName': 'Kunovac', 'Affiliation': 'Altea Research, Las Vegas, Nevada, USA.'}, {'ForeName': 'Bernard L', 'Initials': 'BL', 'LastName': 'Silverman', 'Affiliation': 'Alkermes, Inc, Waltham, Massachusetts, USA.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Simmons', 'Affiliation': 'Alkermes, Inc, Waltham, Massachusetts, USA.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': 'Alkermes, Inc, Waltham, Massachusetts, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'DiPetrillo', 'Affiliation': 'Alkermes, Inc, Waltham, Massachusetts, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'McDonnell', 'Affiliation': 'Alkermes Pharma Ireland Limited, Connaught House, 1 Burlington Rd, Dublin D04 C5Y6, Ireland. david.mcdonnell@alkermes.com.'}]",The Journal of clinical psychiatry,['10.4088/JCP.19m12769'] 1358,32141724,Early- Versus Adult-Onset Schizophrenia as a Predictor of Response to Neuroscience-Informed Cognitive Training.,"BACKGROUND Developmental stages characterized by greater neural plasticity might be critical periods during which the effects of cognitive training (CT) could theoretically be maximized. However, experiencing a first episode of schizophrenia during childhood or adolescence (ie, early-onset schizophrenia [EOS]) may reduce the brain's ability to benefit from CT. This study examined the effects of EOS versus onset at > 18 years of age (ie, adult-onset schizophrenia [AOS]) as a predictor of response to CT and the relationship between duration of illness and cognitive improvements. METHODS This study is a secondary analysis of data from 2 randomized trials that examined the cognitive effects of neuroscience-informed auditory training (AT) exercises in 84 outpatients with schizophrenia (26 EOS, 58 AOS, recruited between 2004 and 2014). RESULTS There was a significant effect of time in all cognitive domains (F > 10.22, P < .002). The effect of EOS was significant only for verbal learning and memory (F = 5.79, P = .018). AOS increased the mean change score by 5.70 points in this domain, whereas EOS showed no change (t = -2.280, P = .025). However, the difference between AOS and EOS was no longer statistically significant after control for multiple comparisons. Shorter duration of illness was associated with greater improvement in problem solving in the AOS group (r = -0.27, P = .040). CONCLUSIONS Auditory training is effective in improving cognition in both EOS and AOS. Treatment effects in all cognitive domains were similar, with the exception of verbal learning and memory. This result requires replication. Cognitive training provided earlier in the course of the illness results in greater improvements in executive functions. TRIAL REGISTRATION ClinicalTrials.gov identifiers: NCT00312962, NCT00694889​​.",2020,"There was a significant effect of time in all cognitive domains (F > 10.22, P < .002).","['84 outpatients with schizophrenia (26 EOS, 58 AOS, recruited between 2004 and 2014', 'versus onset at > 18 years of age (ie, adult-onset schizophrenia [AOS']","['Cognitive training', 'Auditory training', 'neuroscience-informed auditory training (AT) exercises', 'EOS', 'cognitive training (CT', 'Early']","['time in all cognitive domains', 'verbal learning and memory', 'Shorter duration of illness', 'problem solving', 'mean change score', 'AOS and EOS']","[{'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0027910', 'cui_str': 'Neurosciences'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0042531', 'cui_str': 'Verbal Learning'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0439593', 'cui_str': 'Short duration (qualifier value)'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C3669643', 'cui_str': 'Problem solving (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",84.0,0.0583286,"There was a significant effect of time in all cognitive domains (F > 10.22, P < .002).","[{'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Puig', 'Affiliation': 'Department of Child and Adolescent Psychiatry and Psychology, Hospital Clínic Barcelona, Villarroel 170, 08036-Spain. opuig@clinic.ub.es.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Fisher', 'Affiliation': 'Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Loewy', 'Affiliation': 'Department of Psychiatry, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Miley', 'Affiliation': 'Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Ian S', 'Initials': 'IS', 'LastName': 'Ramsay', 'Affiliation': 'Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Cameron S', 'Initials': 'CS', 'LastName': 'Carter', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of California, Davis, California, USA.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Ragland', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of California, Davis, California, USA.'}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Niendam', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of California, Davis, California, USA.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Vinogradov', 'Affiliation': 'Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota, USA.'}]",The Journal of clinical psychiatry,['10.4088/JCP.18m12369'] 1359,6432839,Cost-effective method of triple-site culturing for Neisseria gonorrhoeae.,"The efficacy of the use of a single modified Thayer-Martin triplate versus that of three separate modified Thayer-Martin plates for the recovery of Neisseria gonorrhoeae from pharyngeal, anal, and genital sites were studied. A total of 98 males and 74 females who showed intracellular gram-negative diplococci on genital Gram stain were studied. Of 172 patients, 164 had gonorrhea at one or more sites. In the first group of 45 males and 21 females, a single swab from each site was used to inoculate randomly both a standard plate (100 mm in diameter) and one-third of a triplate. In the second group of 53 males and 53 females, two swabs were used for collection from each site. One of each pair of swabs was randomly inoculated onto a standard plate and a triplate. There was no significant difference between the results obtained by inoculation with single swabs and those obtained by inoculation with two swabs. There were no significant differences between the positivity rates obtained with the triplate and those obtained with three standard plates used at each site. Cost (39% that of three separate plates) and acceptance by clinic and laboratory personnel make the triplate method an economical, accurate, and effective triple-site screening system.",1984,There were no significant differences between the positivity rates obtained with the triplate and those obtained with three standard plates used at each site.,"['Neisseria gonorrhoeae', '53 males and 53 females, two swabs were used for collection from each site', '98 males and 74 females who showed intracellular gram-negative diplococci on genital Gram stain were studied', '45 males and 21 females, a single swab from each site was used to inoculate randomly both a standard plate (100 mm in diameter) and one-third of a triplate', '172 patients, 164 had gonorrhea at one or more sites']",['single modified Thayer-Martin triplate versus that of three separate modified Thayer-Martin plates'],['positivity rates'],"[{'cui': 'C0027573', 'cui_str': 'Gonococcus'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C1261188', 'cui_str': 'Swab (physical object)'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0178719', 'cui_str': 'Intracellular (qualifier value)'}, {'cui': 'C0439208', 'cui_str': 'gram (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C1295730', 'cui_str': 'Diplococci'}, {'cui': 'C0017420', 'cui_str': 'Reproductive System'}, {'cui': 'C0061856', 'cui_str': ""Gram's stain""}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0441255', 'cui_str': 'Standard plate (physical object)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C1301886', 'cui_str': 'Diameter (qualifier value)'}, {'cui': 'C4517601', 'cui_str': '172 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018081', 'cui_str': 'Neisseria gonorrhoeae Infection'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0443299', 'cui_str': 'Separate (qualifier value)'}, {'cui': 'C0407295', 'cui_str': 'Fixation of fracture using plate (procedure)'}]",[],98.0,0.0202456,There were no significant differences between the positivity rates obtained with the triplate and those obtained with three standard plates used at each site.,"[{'ForeName': 'T', 'Initials': 'T', 'LastName': 'Gartner', 'Affiliation': ''}, {'ForeName': 'L D', 'Initials': 'LD', 'LastName': 'Edwards', 'Affiliation': ''}]",Journal of clinical microbiology,[] 1360,32054315,Effects of pivotal response treatment on reciprocal vocal contingency in a randomized controlled trial of children with autism spectrum disorder.,"LAY ABSTRACT A recent randomized controlled trial found that children with autism spectrum disorder who received a pivotal response treatment package showed improved language and social communication skills following the intervention. The pivotal response treatment package includes clinician-delivered and parent-implemented strategies. Reciprocal vocal contingency is an automated measure of vocal reciprocity derived from daylong audio samples from the child's natural environment. It may provide stronger and complementary evidence of the effects of the pivotal response treatment package because it is at lower risk for detection bias than parent report and brief parent-child interaction measures. The current study compared reciprocal vocal contingency for 24 children with autism spectrum disorder in the pivotal response treatment package group and 24 children with autism spectrum disorder in the control group. The pivotal response treatment package group received 24 weeks of the pivotal response treatment package intervention. The control group received their usual intervention services during that time. The groups did not differ in reciprocal vocal contingency when the intervention started or after 12 weeks of intervention. However, after 24 weeks the pivotal response treatment package group had higher ranked reciprocal vocal contingency scores than the control group. These findings are consistent with results from parent report and parent-child interaction measures obtained during the trial. The participants in the pivotal response treatment package exhibited greater vocal responsiveness to adult vocal responses to their vocalizations than the control group. Findings support the effectiveness of the pivotal response treatment package on vocal reciprocity of children with autism spectrum disorder, which may be a pivotal skill for language development.",2020,The participants in the pivotal response treatment package exhibited greater vocal responsiveness to adult vocal responses to their vocalizations than the control group.,"['24 children with autism spectrum disorder in the pivotal response treatment package group and 24 children with autism spectrum disorder in the control group', 'children with autism spectrum disorder']","['usual intervention services', 'pivotal response treatment package intervention', 'Reciprocal vocal contingency', 'pivotal response treatment package', 'reciprocal vocal contingency', 'pivotal response treatment']","['reciprocal vocal contingency', 'language and social communication skills', 'ranked reciprocal vocal contingency scores', 'vocal responsiveness to adult vocal responses']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1704710', 'cui_str': 'Package'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1704710', 'cui_str': 'Package'}]","[{'cui': 'C0023008', 'cui_str': 'Languages'}, {'cui': 'C0870313', 'cui_str': 'Communication skills'}, {'cui': 'C0699794', 'cui_str': 'Rank (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]",24.0,0.0319462,The participants in the pivotal response treatment package exhibited greater vocal responsiveness to adult vocal responses to their vocalizations than the control group.,"[{'ForeName': 'Jena', 'Initials': 'J', 'LastName': 'McDaniel', 'Affiliation': 'The University of Kansas, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Yoder', 'Affiliation': 'Vanderbilt University, USA.'}, {'ForeName': 'Madison', 'Initials': 'M', 'LastName': 'Crandall', 'Affiliation': 'Vanderbilt University, USA.'}, {'ForeName': 'Maria Estefania', 'Initials': 'ME', 'LastName': 'Millan', 'Affiliation': 'Stanford University, USA.'}, {'ForeName': 'Christina Mich', 'Initials': 'CM', 'LastName': 'Ardel', 'Affiliation': 'Stanford University, USA.'}, {'ForeName': 'Grace W', 'Initials': 'GW', 'LastName': 'Gengoux', 'Affiliation': 'Stanford University, USA.'}, {'ForeName': 'Antonio Y', 'Initials': 'AY', 'LastName': 'Hardan', 'Affiliation': 'Stanford University, USA.'}]",Autism : the international journal of research and practice,['10.1177/1362361320903138'] 1361,31413313,A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor.,"Acute graft-versus-host disease (aGVHD) remains one of the leading causes of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. No consensus exists on the best second-line treatment of steroid-refractory acute GVHD (SR-aGVHD). Previously published smaller studies on the use of sirolimus in SR-aGVHD treatment report a response rate of 57 to 86%, with 40% overall survival. The association of tacrolimus and mTOR inhibitor is supported by pre-clinical data and has been used as GVHD prophylaxis. We report 42 patients who received tacrolimus and mTOR inhibitor as a second- or third-line treatment of SR-aGVHD. Thirty-one patients were treated in second-line, with an overall response rate of 48.5% (complete response: 42%). Eleven patients were treated in third-line, with an overall response rate of 27%. Thirty-eight patients had at least one episode of infection, due to bacteria, viruses, fungi and parasites in 61, 42, 12 and two episodes, respectively. For patients treated in second-line, six-month and one-year survival were 61% and 42%, respectively. None of the patients treated in third-line survived. These results were not promising enough to initiate a phase three randomized clinical trial, but tacrolimus and mTOR inhibitor can be discussed among other options for patients with SR-aGVHD.",2020,"For patients treated in second-line, six-month and one-year survival were 61% and 42%, respectively.","['42 patients who received', 'patients with SR-aGVHD', 'allogeneic hematopoietic stem cell transplantation']","['tacrolimus and mTOR inhibitor as a second- or third-line treatment of SR-aGVHD', 'tacrolimus and mTOR inhibitor']","['response rate', 'year survival', 'overall response rate', 'overall survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0856825', 'cui_str': 'Acute graft-versus-host disease (disorder)'}, {'cui': 'C0472699', 'cui_str': 'Hematopoietic Stem Cell Transplantation'}]","[{'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C2986605', 'cui_str': 'Third line treatment'}, {'cui': 'C0856825', 'cui_str': 'Acute graft-versus-host disease (disorder)'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",42.0,0.0304372,"For patients treated in second-line, six-month and one-year survival were 61% and 42%, respectively.","[{'ForeName': 'Alienor', 'Initials': 'A', 'LastName': 'Xhaard', 'Affiliation': ""Service d'hématologie-greffe, Hôpital Saint-Louis, Université Paris Diderot, Paris, France. alienor.xhaard@aphp.fr.""}, {'ForeName': 'Manon', 'Initials': 'M', 'LastName': 'Launay', 'Affiliation': 'Service de pharmacologie, Hôpital Européen Georges-Pompidou, Paris, France.'}, {'ForeName': 'Flore', 'Initials': 'F', 'LastName': 'Sicre de Fontbrune', 'Affiliation': ""Service d'hématologie-greffe, Hôpital Saint-Louis, Université Paris Diderot, Paris, France.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Michonneau', 'Affiliation': ""Service d'hématologie-greffe, Hôpital Saint-Louis, Université Paris Diderot, Paris, France.""}, {'ForeName': 'Aurelien', 'Initials': 'A', 'LastName': 'Sutra Del Galy', 'Affiliation': ""Service d'hématologie-greffe, Hôpital Saint-Louis, Université Paris Diderot, Paris, France.""}, {'ForeName': 'Tereza', 'Initials': 'T', 'LastName': 'Coman', 'Affiliation': ""Service d'hématologie-greffe, Hôpital Saint-Louis, Université Paris Diderot, Paris, France.""}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Pagliuca', 'Affiliation': ""Service d'hématologie-greffe, Hôpital Saint-Louis, Université Paris Diderot, Paris, France.""}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Dhedin', 'Affiliation': ""Service d'hématologie adolescents-jeunes adultes, Hôpital Saint-Louis, Université Paris Diderot, Paris, France.""}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Robin', 'Affiliation': ""Service d'hématologie-greffe, Hôpital Saint-Louis, Université Paris Diderot, Paris, France.""}, {'ForeName': 'Regis', 'Initials': 'R', 'LastName': 'Peffault de Latour', 'Affiliation': ""Service d'hématologie-greffe, Hôpital Saint-Louis, Université Paris Diderot, Paris, France.""}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Socie', 'Affiliation': ""Service d'hématologie-greffe, Hôpital Saint-Louis, Université Paris Diderot, Paris, France.""}]",Bone marrow transplantation,['10.1038/s41409-019-0633-y'] 1362,32141678,Patient-reported swallowing function after treatment for early-stage oropharyngeal carcinoma: Population-based study.,"BACKGROUND Single-modality treatment (surgery or radiotherapy [RT]) is a curative treatment option for early-stage oropharyngeal carcinoma (OPC) with comparable (excellent) oncological outcomes. This study aimed to compare self-reported swallowing function. METHODS Participants with a T1-2N0-2bM0 OPC who were offered single-modality treatment and were recruited to the Head and Neck 5000 study were included. Prospectively collected self-reported swallowing function was compared between surgery and RT. RESULTS Those offered RT (n = 150) had less favorable baseline characteristics than those offered surgery (n = 150). At 12-month follow up, RT participants reported more swallowing problems (35% vs 23%, RR 1.3; 95% CI 0.8-2.3, P = .277) in models adjusted for baseline characteristics. In those allocated to surgery who received adjuvant therapy (n = 78, 52%), the proportion with swallowing problems was similar to those allocated to RT alone. CONCLUSIONS Participants offered surgery alone had similar mortality but improved swallowing, although this was not statistically significant. However, over half of participants offered surgery alone received surgery and adjuvant therapy.",2020,"At 12-month follow up, RT participants reported more swallowing problems (35% vs 23%, RR 1.3; 95% CI 0.8-2.3, P = .277) in models adjusted for baseline characteristics.","['Participants with a T1-2N0-2bM0 OPC who were offered single-modality treatment and were recruited to the Head and Neck 5000 study were included', 'early-stage oropharyngeal carcinoma (OPC']","['adjuvant therapy', 'Single-modality treatment (surgery or radiotherapy [RT']","['swallowing function', 'swallowing problems', 'proportion with swallowing problems']","[{'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0027536', 'cui_str': 'Necking (finding)'}, {'cui': 'C4319610', 'cui_str': '5000 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C2363430', 'cui_str': 'Early stage (qualifier value)'}, {'cui': 'C1522409', 'cui_str': 'Oropharyngeal route (qualifier value)'}, {'cui': 'C0007097', 'cui_str': 'Epithelioma'}]","[{'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}]","[{'cui': 'C0326374', 'cui_str': 'Swallows'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0392678', 'cui_str': 'Swallowing problem (finding)'}]",5000.0,0.121253,"At 12-month follow up, RT participants reported more swallowing problems (35% vs 23%, RR 1.3; 95% CI 0.8-2.3, P = .277) in models adjusted for baseline characteristics.","[{'ForeName': 'Rebecca T', 'Initials': 'RT', 'LastName': 'Karsten', 'Affiliation': 'Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Michiel W M', 'Initials': 'MWM', 'LastName': 'van den Brekel', 'Affiliation': 'Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Ludi E', 'Initials': 'LE', 'LastName': 'Smeele', 'Affiliation': 'Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Arash', 'Initials': 'A', 'LastName': 'Navran', 'Affiliation': 'Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Leary', 'Affiliation': 'Bristol Biomedical Research Centre, National Institute of Health (NIHR), University of Bristol, Bristol, UK.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Ingarfield', 'Affiliation': 'Bristol Biomedical Research Centre, National Institute of Health (NIHR), University of Bristol, Bristol, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Pawlita', 'Affiliation': 'Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Waterboer', 'Affiliation': 'Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Steve J', 'Initials': 'SJ', 'LastName': 'Thomas', 'Affiliation': 'Bristol Biomedical Research Centre, National Institute of Health (NIHR), University of Bristol, Bristol, UK.'}, {'ForeName': 'Andy R', 'Initials': 'AR', 'LastName': 'Ness', 'Affiliation': 'Bristol Biomedical Research Centre, National Institute of Health (NIHR), University of Bristol, Bristol, UK.'}]",Head & neck,['10.1002/hed.26131'] 1363,32141721,The Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues: An Update From the US Food and Drug Administration.,"OBJECTIVE Concerns of increasing placebo response and declining treatment effect in acute schizophrenia trials have been reported for new drug applications (NDAs) submitted to the US Food and Drug Administration (FDA) during an 18-year period from 1991 through January 2009 (ie, the pre-2009 period). Current exploratory analyses provide an update in the trends observed in placebo response, treatment effect, and dropout rates for NDAs submitted from February 2009 to 2015 (ie, the post-2009 period). DATA SOURCES Clinical trial data from all acute schizophrenia trials that were submitted as part of NDAs to the US FDA during a 24-year period from 1991 to 2015. STUDY SELECTION Aggregate trial-level efficacy data from multicenter, multiregional, randomized, placebo-controlled, 4- to 8-week, fixed- and flexible-dose trials in adult schizophrenia patients were compiled. There were 12 NDAs pre-2009 (32 trials, N = 11,567) and 3 NDAs post-2009 (14 trials, N = 6,434). DATA EXTRACTION Baseline demographic and disease variables and scores on the Positive and Negative Syndrome Scale (PANSS) were summarized and compared for the two time periods (pre-2009 and post-2009). The primary efficacy measure was mean change from baseline to endpoint in total PANSS score obtained by last-observation-carried-forward analysis. Regional differences in placebo response and treatment effect were explored for the two time periods based on baseline patient characteristics, sample size, and dropout rates. RESULTS Trials were predominantly multiregional (10/14; 71%) during the post-2009 period compared to the pre-2009 period (11/32; 34%). The overall trial success rates were 57% (8/14) and 78% (25/32) during the post-2009 and pre-2009 periods, respectively. Comparing the pre-2009 and post-2009 periods, the mean placebo response (change from baseline in PANSS score) increased from -6.4 to -10.5 and the mean treatment effect (drug response - placebo response) declined from -8.6 to -5.8 , with substantial differences observed especially in North American trials. In North American trials, placebo response increased from -4.3 (pre-2009) to -8.5 (post-2009), and treatment effect decreased from -9.0 (pre-2009) to -3.4 (post-2009). The difference in placebo response (pre- and post-2009: -10.0 and -11.3 ) and treatment effect (pre and post-2009: -8.1 and -6.4 ) in multiregional trials for the two time periods remained minimal. Baseline disease severity remained similar in the pre- and post-2009 time periods, with PANSS scores ranging between 85 and 100. Trials with higher mean baseline PANSS scores tended to show higher treatment effect irrespective of the time period and region. Post-2009, dropout rates were higher (55%) in North American trials compared with 33% in multiregional trials, similar to the pre-2009 trend. CONCLUSIONS The continuing trend of increasing placebo responses and decreasing treatment effects in schizophrenia trials over the 24-year period does remain of great concern, especially with respect to North American trials. However, given the current global nature of drug development, close attention to trial conduct and reexamination of design elements for future trials may be warranted.",2020,"Regional differences in placebo response and treatment effect were explored for the two time periods based on baseline patient characteristics, sample size, and dropout rates. ","['Schizophrenia Trials Continues', 'adult schizophrenia patients']",['placebo'],"['Baseline demographic and disease variables and scores on the Positive and Negative Syndrome Scale (PANSS', 'dropout rates', 'Baseline disease severity', 'total PANSS score', 'placebo response', 'mean placebo response', 'overall trial success rates']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale (assessment scale)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",11567.0,0.465673,"Regional differences in placebo response and treatment effect were explored for the two time periods based on baseline patient characteristics, sample size, and dropout rates. ","[{'ForeName': 'Mathangi', 'Initials': 'M', 'LastName': 'Gopalakrishnan', 'Affiliation': 'Center for Translational Medicine, School of Pharmacy, University of Maryland, Baltimore, MD. mgopalakrishnan@rx.umaryland.edu.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Zhu', 'Affiliation': 'Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.'}, {'ForeName': 'Tiffany R', 'Initials': 'TR', 'LastName': 'Farchione', 'Affiliation': 'Division of Psychiatry Products, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.'}, {'ForeName': 'Mitchell', 'Initials': 'M', 'LastName': 'Mathis', 'Affiliation': 'Division of Psychiatry Products, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.'}, {'ForeName': 'Mehul', 'Initials': 'M', 'LastName': 'Mehta', 'Affiliation': 'Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.'}, {'ForeName': 'Ramana', 'Initials': 'R', 'LastName': 'Uppoor', 'Affiliation': 'Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.'}, {'ForeName': 'Islam', 'Initials': 'I', 'LastName': 'Younis', 'Affiliation': 'Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.'}]",The Journal of clinical psychiatry,['10.4088/JCP.19r12960'] 1364,32685782,Evaluation of safety and efficacy of different protocols of collagen cross linking for keratoconus.,"Introduction: Collagen cross-linking is a well-established modality that could stop the keratoconus from progressing. Off late, newer protocols have been suggested for progressive keratoconus, which include the use of hypoosmolar riboflavin for thinner corneas and the use of accelerated CXL protocol to reduce the effective treatment time. Objective: To assess the safety and efficacy of different protocols of conventional CXL, hypoosmolar CXL and accelerated CXL in patients with keratoconus. Materials & methods: It was a prospective, interventional study with minimum of 12 months follow-up. Patients were divided into 3 groups; conventional CXL, CXL using hypotonic riboflavin and accelerated CXL group. Primary outcome measures - For efficacy, Sim Kmax and Sim Kmin (Progression (Kmax > +1 D), stabilization (Kmax +1 D to -1 D) and regression (Kmax > -1 D). For safety - endothelial count evaluation (decrease >10% amounted to compromise the safety of the procedure). Secondary outcome measures - BCVA and adverse events. Results: 32 eyes underwent isotonic CXL treatment. Pre-treatment and post-treatment BCVA were 0.16 +/- 0.15 and 0.10 +/- 0.11 log MAR; specular counts 2782.81 +/- 307.25 (cells/ mm2) and 2708.5 +/- 263.27 (cells/ mm2) (p=0.05); KMax values 55.31 +/- 4.12 D and 53.9 +/- 3.77 D (p=0.0001). 16 eyes underwent hypotonic CXL treatment. Pre-treatment and post-treatment BCVA were 0.15 +/- 0.13 log MAR and 0.14 +/- 0.14; specular count 2701.19 +/- 243.25 (cells/ mm2) and 2713.5 +/- 369 (cells/ mm2) (p= 1) and KMax values 54.74 +/- 7.44 D and 52.74 +/- 6.76 D (p = 0.002). 15 eyes underwent accelerated CXL treatment. Pre-treatment and post-treatment BCVA were 0.16 +/- 0.15 and 0.10 +/- 0.12 log MAR; specular counts 2967.53 +/- 356.48 and 2893.07 +/- 336.55 (cells/ mm2) (p = 0.78) and KMax values 55.19 +/- 5.46 D and 54.24 +/- 5.33 D (p = 0.337). Conclusion: All three protocols appeared safe and efficacious as therapeutic regimen for progressive keratoconus.",2020,"Patients were divided into 3 groups; conventional CXL, CXL using hypotonic riboflavin and accelerated CXL group.","['16 eyes underwent', 'patients with keratoconus', '15 eyes underwent']","['isotonic CXL treatment', 'Sim Kmax and Sim Kmin', 'conventional CXL, CXL using hypotonic riboflavin and accelerated CXL group', 'conventional CXL, hypoosmolar CXL and accelerated CXL', 'accelerated CXL treatment', 'hypotonic CXL treatment']","['safety and efficacy', 'safety - endothelial count evaluation', 'safe and efficacious', ' BCVA and adverse events']","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022578', 'cui_str': 'Keratoconus'}]","[{'cui': 'C0454287', 'cui_str': 'Isotonic exercise'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C3553774', 'cui_str': 'Karyomegalic interstitial nephritis'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0035527', 'cui_str': 'Riboflavin'}, {'cui': 'C0521110', 'cui_str': 'Accelerated'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.0249556,"Patients were divided into 3 groups; conventional CXL, CXL using hypotonic riboflavin and accelerated CXL group.","[{'ForeName': 'Tanu', 'Initials': 'T', 'LastName': 'Singh', 'Affiliation': 'Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India.'}, {'ForeName': 'Mukesh', 'Initials': 'M', 'LastName': 'Taneja', 'Affiliation': 'L.V. Prasad Eye Institute, Telangana, India.'}, {'ForeName': 'Somasheila', 'Initials': 'S', 'LastName': 'Murthy', 'Affiliation': 'L.V. Prasad Eye Institute, Telangana, India.'}, {'ForeName': 'Pravin Krishna', 'Initials': 'PK', 'LastName': 'Vaddavalli', 'Affiliation': 'L.V. Prasad Eye Institute, Telangana, India.'}]",Romanian journal of ophthalmology,[] 1365,6339379,Specific immune response in the respiratory tract after administration of an oral polyvalent bacterial vaccine.,"An oral killed polyvalent bacterial vaccine was assessed in a double-blind trial involving healthy volunteers. Three courses of oral vaccine were given over a 2-month period; each course contained 10(10) Haemophilus influenzae and 7 X 10(9) Staphylococcus aureus organisms. Immunity was assessed by monitoring antibody in saliva and serum over a 3-month period. No evidence of a nonspecific effect on immune parameters (immunoglobulin levels and Escherichia coli antibody) was detected in saliva or serum. An increase in H. influenzae antibody in saliva was detected in 55% of subjects receiving the vaccine compared with 6.7% of the placebo group. Antibody was associated with immunoglobulin A (IgA), IgG, and IgM, but the greatest increases over preimmunization levels were detected in the IgA class. No increase in serum antibody levels was detected. Subjects with higher preimmunization levels of salivary antibody to H. influenzae were less likely to respond to the oral bacterial vaccine. No increase in S. aureus antibody was detected in saliva or serum.",1983,No evidence of a nonspecific effect on immune parameters (immunoglobulin levels and Escherichia coli antibody) was detected in saliva or serum.,['healthy volunteers'],"['oral killed polyvalent bacterial vaccine', 'placebo', 'vaccine', 'oral vaccine', 'oral polyvalent bacterial vaccine']","['preimmunization levels', 'immune parameters (immunoglobulin levels and Escherichia coli antibody', 'serum antibody levels', 'immunoglobulin A (IgA), IgG, and IgM', 'H. influenzae antibody in saliva', 'S. aureus antibody']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C4521763', 'cui_str': 'Killed'}, {'cui': 'C0004632', 'cui_str': 'Bacterin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439662', 'cui_str': 'Immune (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0428536', 'cui_str': 'Immunoglobulin level - finding'}, {'cui': 'C0310969', 'cui_str': 'Escherichia coli antibody (substance)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0020861', 'cui_str': 'IgM'}, {'cui': 'C0036087', 'cui_str': 'Saliva (substance)'}]",,0.121575,No evidence of a nonspecific effect on immune parameters (immunoglobulin levels and Escherichia coli antibody) was detected in saliva or serum.,"[{'ForeName': 'R L', 'Initials': 'RL', 'LastName': 'Clancy', 'Affiliation': ''}, {'ForeName': 'A W', 'Initials': 'AW', 'LastName': 'Cripps', 'Affiliation': ''}, {'ForeName': 'A J', 'Initials': 'AJ', 'LastName': 'Husband', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Buckley', 'Affiliation': ''}]",Infection and immunity,[] 1366,32179181,Efficacy of strategies to increase participation in cervical cancer screening: GPs offering self-sampling kits for HPV testing versus recommendations to have a pap smear taken - A randomised controlled trial.,"Background Cervical cancer is preventable by early detection and treatment of pre-cancerous lesions. The current screening policy in Belgium (3-yearly cytology on Pap smears) covers 60% of the target population. Offering self-samples by GPs can overcome barriers for women who are currently not screened. Methods Women aged 25–64 who did not have a Pap smear since three years and consulted a GP practice in a Flemish municipality between November 2014 and April 2015 were allocated in a 1:1 ratio to either the intervention arm where women were given a vaginal self-sampling kit or control arm where women were encouraged to make an appointment for having a Pap smear taken by a clinician. Results Eighty-eight consenting women were randomised. 35 (78%) out of 45 women in the self-sampling arm participated in screening compared to 22 (51%) out of 43 women in the control arm (p = 0.009). This difference remained significant after adjusting for covariates (age category, education level, time interval since last Pap smear, past Pap smear-taker). Conclusion GPs offering self-sampling kits resulted in a high participation. Larger trials should confirm this effect and evaluate feasibility of this approach.4. The authors would also like to include the following sentence in the acknowledgement “The laboratory AML (Antwerp, Belgium) is acknowledged for the free HPV testing on the self-samples.""",2020,,['cervical cancer screening'],[],[],"[{'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix (disorder)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}]",[],[],,0.0359161,,"[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Peeters', 'Affiliation': 'Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Cornet', 'Affiliation': 'De Groet, General Practice Oetingen, Gooik, Belgium.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Cammu', 'Affiliation': ''}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Verhoeven', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Devroey', 'Affiliation': 'General Medicine, Vrije Universiteit Brussel, Brussels, Belgium.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Arbyn', 'Affiliation': 'Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium. Electronic address: marc.arbyn@sciensano.be.'}]","Papillomavirus research (Amsterdam, Netherlands)",['10.1016/j.pvr.2020.100194'] 1367,30773772,Effect of a novel supplementary porridge on the nutritional status of infants and young children diagnosed with moderate acute malnutrition in Uganda: a cluster randomised control trial.,"BACKGROUND Moderate acute malnutrition (MAM) and anaemia are prevalent among infants and young children (IYC) in Uganda. A lack of consensus regarding the most effective strategy for managing MAM among IYC resulted in the present study comparing the effect of malted sorghum-based porridge (MSBP) (an active malt, extruded maize and soy sorghum supplementary porridge developed for the purpose of the present study) as an intervention versus an extruded maize and soy micronutrient fortified blend (CSB+) as a control and current standard care. Outcome measures were anthropometric status and haemoglobin levels. METHODS The study comprised a double-blind cluster randomised control trial with eight to 10 conveniently sampled consenting mother-IYC pairs per cluster who were randomly assigned to the intervention (n = 110) or control (n = 110) for 3 months. Weekly anthropometric measurements were taken. Haemoglobin levels were measured at baseline and end line. Mean length-for-age, weight-for-age, length-for-weight and mean haemoglobin levels of the treatment and control groups were compared using an independent t-test. The Z-test was used to compare proportions of the outcome indicators between the treatment and control groups. RESULTS Difference in mean weight-for-age Z-scores in the treatment group improved compared to control (P = 0.010). The change in mean haemoglobin levels was lower in the treatment versus the control group (P = 0.010). The proportion of IYC recovering from MAM between treatment and control did not differ significantly (P = 0.055). CONCLUSIONS Recovery rates after supplementation with MSBP versus CSB+ resulted in similar weight-for-length and haemoglobin levels. Therefore, MSBP has the potential for being scaled up in the management of IYC with MAM in Uganda.",2019,The change in mean haemoglobin levels was lower in the treatment versus the control group (P = 0.010).,"['infants and young children (IYC) in Uganda', '10 conveniently sampled consenting mother-IYC pairs per cluster', 'infants and young children diagnosed with moderate acute malnutrition in Uganda']","['extruded maize and soy micronutrient fortified blend (CSB', 'MSBP versus CSB', 'novel supplementary porridge']","['mean haemoglobin levels', 'similar weight-for-length and haemoglobin levels', 'proportion of IYC recovering from MAM', 'mean weight-for-age Z-scores', 'anthropometric status and haemoglobin levels', 'Haemoglobin levels', 'Mean length-for-age, weight-for-age, length-for-weight and mean haemoglobin levels']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0041573', 'cui_str': 'Republic of Uganda'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0162429', 'cui_str': 'Malnutrition'}]","[{'cui': 'C0010028', 'cui_str': 'Zea mays'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C0452575', 'cui_str': 'Porridge (substance)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0521108', 'cui_str': 'Recovering from (contextual qualifier) (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]",110.0,0.0874852,The change in mean haemoglobin levels was lower in the treatment versus the control group (P = 0.010).,"[{'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Kajjura', 'Affiliation': 'School of Health Science, College of Health Sciences, Makerere University, Kampala, Uganda.'}, {'ForeName': 'F J', 'Initials': 'FJ', 'LastName': 'Veldman', 'Affiliation': 'School of Health Care Sciences, Sefako Makgatho Health Sciences University, Pretoria, South Africa.'}, {'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Kassier', 'Affiliation': 'College of Agriculture, Engineering and Science, University of KwaZulu-Natal, Pietermaritzburg, South Africa.'}]",Journal of human nutrition and dietetics : the official journal of the British Dietetic Association,['10.1111/jhn.12635'] 1368,32170751,Routine glucose assessment in the emergency department for detecting unrecognised diabetes: a cluster randomised trial.,,2020,,[],[],[],[],[],[],,0.0954482,,"[{'ForeName': 'Spiros', 'Initials': 'S', 'LastName': 'Fourlanos', 'Affiliation': 'Royal Melbourne Hospital, Melbourne, VIC.'}, {'ForeName': 'Rahul', 'Initials': 'R', 'LastName': 'Barmanray', 'Affiliation': 'Royal Melbourne Hospital, Melbourne, VIC.'}, {'ForeName': 'Mervyn', 'Initials': 'M', 'LastName': 'Kyi', 'Affiliation': 'Royal Melbourne Hospital, Melbourne, VIC.'}]",The Medical journal of Australia,['10.5694/mja2.50550'] 1369,32170756,Routine glucose assessment in the emergency department for detecting unrecognised diabetes: a cluster randomised trial.,,2020,,[],[],[],[],[],[],,0.0954482,,"[{'ForeName': 'N Wah', 'Initials': 'NW', 'LastName': 'Cheung', 'Affiliation': 'Westmead Hospital, Sydney, NSW.'}, {'ForeName': 'Lesley V', 'Initials': 'LV', 'LastName': 'Campbell', 'Affiliation': ""St Vincent's Hospital, Sydney, NSW.""}, {'ForeName': 'Sandy', 'Initials': 'S', 'LastName': 'Middleton', 'Affiliation': 'Australian Catholic University Nursing Research Institute, Sydney, NSW.'}]",The Medical journal of Australia,['10.5694/mja2.50549'] 1370,32171738,Cathodal transcranial direct current stimulation over the right dorsolateral prefrontal cortex cancels out the cost of selective retrieval on subsequent analogical reasoning.,"Analogical reasoning involves mapping the relation between two concepts within a specific field into a new domain to selectively retrieve a possible solution. Neuroimaging studies have shown that both selective retrieval and reasoning by analogy are related to activity in prefrontal regions such as the dorsolateral prefrontal cortex (DLPFC). In the present study, we investigate the role of the right DLPFC in modulating memory accessibility and its impact on analogical reasoning by using transcranial direct current stimulation (tDCS). Participants performed a four-term reasoning task after performing repeated selective retrieval of previously presented items, some of which could be used as solutions in the analogical test. During selective retrieval, half of the participants received cathodal tDCS over the right DLPFC and the other half received sham stimulation. The results reveal that whereas the sham group showed the expected cost in performance that is associated with selective retrieval, the cathodal group did not exhibit such an impairment in reasoning. No general effects of tDCS on analogical performance were observed. Altogether, our results support the involvement of the right DLPFC as a core component of a control network that selectively contributes to the retrieval component of analogical reasoning, but with little role in mapping relations between different domains.",2020,No general effects of tDCS on analogical performance were observed.,[],"['Cathodal transcranial direct current stimulation', 'tDCS', 'transcranial direct current stimulation (tDCS', 'cathodal tDCS']",['analogical performance'],[],"[{'cui': 'C3850024', 'cui_str': 'tDCS'}]",[],,0.018029,No general effects of tDCS on analogical performance were observed.,"[{'ForeName': 'Tania M', 'Initials': 'TM', 'LastName': 'Valle', 'Affiliation': 'Department of Experimental Psychology and Research Center for Mind, Brain and Behavior, University of Granada, Spain. Electronic address: mtaniavalle@ugr.es.'}, {'ForeName': 'M Teresa', 'Initials': 'MT', 'LastName': 'Bajo', 'Affiliation': 'Department of Experimental Psychology and Research Center for Mind, Brain and Behavior, University of Granada, Spain. Electronic address: mbajo@ugr.es.'}, {'ForeName': 'Carlos J', 'Initials': 'CJ', 'LastName': 'Gómez-Ariza', 'Affiliation': 'Department of Psychology, University of Jaen, Spain. Electronic address: cjgomez@ujaen.es.'}]",Neuropsychologia,['10.1016/j.neuropsychologia.2020.107431'] 1371,32138746,Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study.,"BACKGROUND The Action to Control Cardiovascular Risk in Diabetes (ACCORD)-Lipid study found no evidence of a beneficial effect of statin-fibrate combined treatment, compared to statins alone, on cardiovascular outcomes and mortality in type 2 diabetes mellitus after 5 years of active treatment. However, a beneficial reduction in major CVD events was shown in a pre-specified sub-group of participants with dyslipidemia. The extended follow-up of this trial provides the opportunity to further investigate possible beneficial effects of fibrates in this group of patients. We aimed to evaluate possible ""legacy effects"" of fibrate add-on therapy on mortality and major cardiovascular outcomes in patients with dyslipidemia. METHODS The ACCORD-lipid study was a randomized controlled trial of 5518 participants assigned to receive simvastatin plus fenofibrate vs simvastatin plus placebo. After randomized treatment allocation had finished at the end of the trial, all surviving participants were invited to attend an extended follow-up study (ACCORDION) to continue prospective collection of clinical outcomes. We undertook a secondary analysis of trial and post-trial data in patients who had dyslipidemia. The primary outcome was all-cause and cardiovascular mortality, and secondary outcomes were nonfatal myocardial infarction, stroke, congestive heart failure and major coronary heart disease. We used an intention-to-treat approach to analysis to make comparisons between the original randomized treatment groups. RESULTS 853 participants with dyslipidemia had survived at the end of the trial. Most participants continued to use statins, but few used fibrates in either group during the post-trial period. The incidence rates in the fenofibrate group were lower with respect to all-cause mortality, CVD mortality, nonfatal myocardial infarction, congestive heart failure and major coronary heart disease than those in the placebo group over a post-trial follow-up. Allocation to the combined fibrate-statin treatment arm during the trial period had a beneficial legacy effect on all-cause mortality (adjusted HR = 0.65, 95% CI 0.45-0.94; P = 0.02). CONCLUSIONS Fibrate treatment during the initial trial period was associated with a legacy benefit of improved survival over a post-trial follow-up. These findings support re-evaluation of fibrates as an add-on strategy to statins in order to reduce cardiovascular risk in diabetic patients with dyslipidemia. Trial registration clinicaltrials.gov, Identifier: NCT00000620.",2020,"The incidence rates in the fenofibrate group were lower with respect to all-cause mortality, CVD mortality, nonfatal myocardial infarction, congestive heart failure and major coronary heart disease than those in the placebo group over a post-trial follow-up.","['5518 participants assigned to receive', 'patients who had dyslipidemia', 'patients with dyslipidemia', 'diabetic patients with dyslipidemia', '853 participants with dyslipidemia had survived at the end of the trial', 'type 2 diabetes mellitus after 5\xa0years of active treatment']","['placebo', 'simvastatin plus fenofibrate vs simvastatin plus placebo', 'fenofibrate']","['nonfatal myocardial infarction, stroke, congestive heart failure and major coronary heart disease', 'mortality and major cardiovascular outcomes', 'cause and cardiovascular mortality', 'mortality, CVD mortality, nonfatal myocardial infarction, congestive heart failure and major coronary heart disease', 'legacy benefit of improved survival', 'incidence rates', 'cardiovascular risk']","[{'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemias'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0011860', 'cui_str': 'Diabetes Mellitus, Type 2'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0074554', 'cui_str': 'Simvastatin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0033228', 'cui_str': 'Fenofibrate'}]","[{'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure (disorder)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0010068', 'cui_str': 'Coronary Disease'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C2979241', 'cui_str': 'Legacy'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}]",5518.0,0.224535,"The incidence rates in the fenofibrate group were lower with respect to all-cause mortality, CVD mortality, nonfatal myocardial infarction, congestive heart failure and major coronary heart disease than those in the placebo group over a post-trial follow-up.","[{'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Zhu', 'Affiliation': 'Australian Centre for Public and Population Health Research, Faculty of Health, University of Technology Sydney, Sydney, NSW, Australia. Lin.Zhu@uts.edu.au.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Hayen', 'Affiliation': 'Australian Centre for Public and Population Health Research, Faculty of Health, University of Technology Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Katy J L', 'Initials': 'KJL', 'LastName': 'Bell', 'Affiliation': 'School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.'}]",Cardiovascular diabetology,['10.1186/s12933-020-01002-x'] 1372,32685721,"Diabetic neuropathy is associated with increased pain perception, low serum beta-endorphin and increase insulin resistance among Nigerian cohorts in Ekiti State.","Introduction There has been an increase in the global prevalence of diabetic polyneuropathy and research evidence suggests that insulin resistance plays an important role in its development and prognosis. However, there seem to be a dearth of information in understanding the likely interplay between beta endorphin, insulin resistance and pain perception especially in the setting of painful diabetic neuropathy. Method This study recruited 120 volunteers divided into four groups (30 per group): group 1 healthy volunteer (control); group 2 DM type 2 without neuropathy (DM group); group 3 DM type 2 with painful neuropathy (DPN group); group 4 DM type 2 without painful neuropathy (DN). All subjects were evaluated for pain threshold and neuropathy using an ischemia-induced pain model and biothesiometer respectively. Their beta-endorphin, glycated hemoglobin, fasting plasma insulin, and HOMA values were determined and means compared using ANOVA. Result Serum beta-endorphin is significantly reduced in DN and DPN (∗p < 0.001) compared with the control and DM group. Also, DPN and DN patients have significantly increased insulin resistance compared to those without neuropathy (∗p < 0.001; ∗p < 0.0001 respectively). There is a significant positive correlation between the pain threshold and beta-endorphin in all the groups except DN group. The correlation between beta-endorphin and insulin resistance was negative and significant in control and DM groups only. Suggestive that the fact that insulin resistance plays an important role in diabetes polyneuropathy, does not alone explain the chronic pain perception noticed in the DPN patients. Conclusion The present study demonstrates that diabetic neuropathy patients have a poor endogenous opioid peptide system which is associated with increased pain perception and high insulin resistance. However, insulin resistance alone does not explain the chronic pain perception noticed in the DPN patients. Thus, further study is required.",2020,Serum beta-endorphin is significantly reduced in DN and DPN (∗p < 0.001) compared with the control and DM group.,"['120 volunteers divided into four groups (30 per group): group 1', 'Nigerian cohorts in Ekiti State', 'diabetic neuropathy patients']",['healthy volunteer (control); group 2 DM type 2 without neuropathy (DM group); group 3 DM type 2 with painful neuropathy (DPN group); group 4 DM type 2 without painful neuropathy (DN'],"['Serum beta-endorphin', 'insulin resistance', 'pain perception and high insulin resistance', 'beta-endorphin, glycated hemoglobin, fasting plasma insulin, and HOMA values', 'chronic pain perception', 'beta-endorphin and insulin resistance', 'pain perception, low serum beta-endorphin and increase insulin resistance', 'pain threshold and beta-endorphin']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C1556089', 'cui_str': 'Nigerians'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0011882', 'cui_str': 'Diabetic neuropathy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C1850383', 'cui_str': 'Neuropathy, Painful'}, {'cui': 'C0027270', 'cui_str': 'Nicotinamide adenine dinucleotide (NAD)'}, {'cui': 'C0441876', 'cui_str': 'Group 4'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005210', 'cui_str': 'Beta endorphin'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0020459', 'cui_str': 'Hyperinsulinism'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}]",120.0,0.0383041,Serum beta-endorphin is significantly reduced in DN and DPN (∗p < 0.001) compared with the control and DM group.,"[{'ForeName': 'Olabode O', 'Initials': 'OO', 'LastName': 'Akintoye', 'Affiliation': 'Physiology Department, College of Medicine, Ekiti State University, Ado Ekiti, Nigeria.'}, {'ForeName': 'Bamidele V', 'Initials': 'BV', 'LastName': 'Owoyele', 'Affiliation': 'Physiology Department, College of Health Sciences, University of Ilorin, Ilorin, Nigeria.'}, {'ForeName': 'Oyesanmi A', 'Initials': 'OA', 'LastName': 'Fabunmi', 'Affiliation': 'Physiology Department, College of Medicine, Ekiti State University, Ado Ekiti, Nigeria.'}, {'ForeName': 'Taiwo H', 'Initials': 'TH', 'LastName': 'Raimi', 'Affiliation': 'Department of Medicine, College of Medicine, Ekiti State University, Ado Ekiti, Nigeria.'}, {'ForeName': 'Adesola A', 'Initials': 'AA', 'LastName': 'Oniyide', 'Affiliation': 'Physiology Department, College of Health Sciences, Afe Babalola University, Ado Ekiti, Nigeria.'}, {'ForeName': 'Abimbola O', 'Initials': 'AO', 'LastName': 'Akintoye', 'Affiliation': 'Department of Medicine, College of Medicine, Ekiti State University, Ado Ekiti, Nigeria.'}, {'ForeName': 'Ayodeji J', 'Initials': 'AJ', 'LastName': 'Ajibare', 'Affiliation': 'Physiology Department, College of Medicine, Ekiti State University, Ado Ekiti, Nigeria.'}, {'ForeName': 'David D', 'Initials': 'DD', 'LastName': 'Ajayi', 'Affiliation': 'Department of Chemical Pathology, Ekiti State University Teaching Hospital, Ado Ekiti, Nigeria.'}, {'ForeName': 'Gbenga S', 'Initials': 'GS', 'LastName': 'Adeleye', 'Affiliation': 'Physiology Department, College of Medicine, Ekiti State University, Ado Ekiti, Nigeria.'}]",Heliyon,['10.1016/j.heliyon.2020.e04377'] 1373,31578418,The impact of patient sex on intensive care unit admission: a blinded randomized survey.,"The gender distribution in intensive care units is consistently found to be around 60% men and 40% women. This might be medically sound. Our main purpose with this study was to investigate if physicians admit men and women to the intensive care unit equally. We sought to answer this question using a blinded randomized survey study. We used an online survey tool, with a hyperlink on European society of intensive care medicine webpage. Responders were randomized to either a critical care case Jane or a critical care case John, otherwise identical. The responders were asked if they would admit Jane/John to an intensive care unit, yes or no. Possible differences in admittance rate on the basis of the gender of the patient were analysed. In addition, we analysed if the gender of the responder affected admittance rate, regardless of the gender of the patient. 70.1% of the responders randomized to the John case opted to admit, vs. 68.3% of the responders randomized to the Jane case, p = 0.341. Regardless the gender of the patient, 70.1% of male responders opted to admit the patient, vs. 69.7% of female responders, p = 0.886. In this blinded randomized multicentre survey study, we could not demonstrate any difference in willingness to admit a patient to ICU, solely based on the gender of the patient. Patient gender as a factor for ICU admittance. A blinded randomized survey.",2019,"In this blinded randomized multicentre survey study, we could not demonstrate any difference in willingness to admit a patient to ICU, solely based on the gender of the patient.","['patient sex on intensive care unit admission', 'physicians admit men and women to the intensive care unit equally']","['critical care case Jane or a critical care case John, otherwise identical']",[],"[{'cui': 'C0150831', 'cui_str': 'Patient sex (observable entity)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0010337', 'cui_str': 'Critical Care'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0205280', 'cui_str': 'Identical (qualifier value)'}]",[],,0.156929,"In this blinded randomized multicentre survey study, we could not demonstrate any difference in willingness to admit a patient to ICU, solely based on the gender of the patient.","[{'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Zettersten', 'Affiliation': 'Perioperative Medicine and Intensive Care, Karolinska University Hospital, Solna, Stockholm, Sweden. erik.zettersten@sll.se.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'Jäderling', 'Affiliation': 'Perioperative Medicine and Intensive Care, Karolinska University Hospital, Solna, Stockholm, Sweden.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Larsson', 'Affiliation': 'Perioperative Medicine and Intensive Care, Karolinska University Hospital, Solna, Stockholm, Sweden.'}, {'ForeName': 'Max', 'Initials': 'M', 'LastName': 'Bell', 'Affiliation': 'Perioperative Medicine and Intensive Care, Karolinska University Hospital, Solna, Stockholm, Sweden.'}]",Scientific reports,['10.1038/s41598-019-50836-3'] 1374,32134683,Effects of exercise training and sex on dynamic responses of O 2 uptake in type 2 diabetes.,"Effects of training and sex on oxygen uptake dynamics during exercise in type 2 diabetes mellitus (T2DM) are not well established. We tested the hypotheses that exercise training improves the time constant of the primary phase of oxygen uptake (τ p oxygen uptake) and with greater effect in males than females. Forty-one subjects with T2DM were assigned to 2 training groups (T male , T female ) and 2 control groups (C male , C female ), and were assessed before and after a 12-week intervention period. Twelve weeks of aerobic/resistance training was performed 3 times per week, 60-90 min per session. Assessments included ventilatory threshold (VT), peak oxygen uptake, τ p oxygen uptake (80%VT), and dynamic responses of cardiac output, mean arterial pressure and systemic vascular conductance (80%VT). Training significantly decreased τ p oxygen uptake in males by a mean of 20% (T male = 42.7 ± 6.2 to 34.3 ± 7.2 s) and females by a mean of 16% (T female = 42.2 ± 9.3 to 35.4 ± 8.6 s); whereas τ p oxygen uptake was not affected in controls (C male = 41.6 ± 9.8 to 42.9 ± 7.6 s; C female = 40.4 ± 12.2 to 40.6 ± 13.4 s). Training increased peak oxygen uptake in both sexes (12%-13%) but did not alter systemic cardiovascular dynamics in either sex. Training improved oxygen uptake dynamics to a similar extent in males and females in the absence of changes in systemic cardiovascular dynamics. Novelty Similar training improvements in oxygen uptake dynamics were observed in males and females with T2DM. In both sexes these improvements occurred without changes in systemic cardiovascular dynamics.",2020,Training increased V̇O2peak in both sexes (12-13 %) but did not alter systemic cardiovascular dynamics in either sex.,"['males than females', 'Forty-one subjects with T2DM', 'type 2 diabetes', 'males and females with type 2 diabetes', 'type 2 diabetes mellitus (T2DM']","['training and sex', 'aerobic/resistance training', 'exercise training']","['taupV̇O2', 'systemic cardiovascular dynamics', 'ventilatory threshold (VT), V̇O2peak, taupV̇O2 (80 %VT) and dynamic responses of cardiac output, mean arterial pressure and systemic vascular conductance', 'time constant of the primary phase of V̇O2 (taupV̇O2', 'V̇O2 dynamics']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011860', 'cui_str': 'Diabetes Mellitus, Type 2'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0449864', 'cui_str': 'Threshold (property) (qualifier value)'}, {'cui': 'C0007165', 'cui_str': 'Cardiac Output'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}]",41.0,0.016161,Training increased V̇O2peak in both sexes (12-13 %) but did not alter systemic cardiovascular dynamics in either sex.,"[{'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Green', 'Affiliation': 'School of Science and Health, Western Sydney University, Sydney 2567, Australia.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Kiely', 'Affiliation': 'Department of Physiology, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.'}, {'ForeName': 'Eamonn', 'Initials': 'E', 'LastName': ""O'Connor"", 'Affiliation': 'Department of Physiology, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.'}, {'ForeName': 'Norita', 'Initials': 'N', 'LastName': 'Gildea', 'Affiliation': 'Department of Physiology, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.'}, {'ForeName': 'Donal', 'Initials': 'D', 'LastName': ""O'Shea"", 'Affiliation': ""Endocrinology, St Columcille's and St Vincent's Hospitals, Dublin, Dublin 18, Ireland.""}, {'ForeName': 'Mikel', 'Initials': 'M', 'LastName': 'Egaña', 'Affiliation': 'Department of Physiology, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2019-0636'] 1375,32144789,Potential strategy for assessing QT/QTc interval for drugs that produce rapid changes in heart rate: Electrocardiographic assessment of the effects of intravenous remimazolam on cardiac repolarization.,"AIMS Remimazolam is a new, ultra-short-acting benzodiazepine developed for intravenous (IV) use during procedural sedation and in general anaesthesia. Two trials were conducted to characterize its effects on cardiac repolarization. METHODS A thorough QT/QTc (TQT) study assessed electrocardiography effects of therapeutic and supratherapeutic doses of remimazolam and midazolam. To investigate whether RR-QT hysteresis effects due to rapid heart rate changes might have confounded the QTc assessments in the TQT trial, a second trial used continuous IV remimazolam infusion to achieve stable heart rates during periods of stable remimazolam plasma concentration. RESULTS During the TQT, both compounds produced a 10-20-beats/min increase in heart rate within 30 seconds, persisting for 5-10 minutes. Within 30 seconds, the upper bound of the 2-sided 90% confidence interval for the placebo-corrected change from baseline for QTcI (ΔΔQTcI) exceeded 10 ms for both doses of remimazolam (ΔΔQTcI 7.2 [3.2, 11.2] ms for the 10 mg dose and 10.4 [6.5, 14.3] ms for the 20 mg dose) as well as for the 7.5-mg dose of midazolam (8.2 [4.4, 12.1] ms). At 2 minutes after IV bolus, the upper bound of the 2-sided 90% confidence interval for ΔΔQTcI exceeded 10 ms only for the remimazolam 20-mg dose (6.3 [2.3, 10.2] ms). During the second study, during periods of stable heart rate, remimazolam had no clinically significant effect on QTc (peak ΔΔQTcI 3.4 [-1.1, 7.6] ms). CONCLUSION Remimazolam does not prolong cardiac repolarization (QTc). The methods reported here may allow assessment of the QTc effects of other drugs given by IV bolus.",2020,Remimazolam does not prolong cardiac repolarization (QTc).,[],"['midazolam', 'remimazolam and midazolam', 'QT/QTc', 'remimazolam', 'benzodiazepine', 'Remimazolam']","['cardiac repolarization', 'QTc', 'cardiac repolarization (QTc', 'heart rate']",[],"[{'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C3179470', 'cui_str': 'remimazolam'}, {'cui': 'C0860814', 'cui_str': 'QTc'}, {'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}]","[{'cui': 'C0860814', 'cui_str': 'QTc'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}]",,0.0724755,Remimazolam does not prolong cardiac repolarization (QTc).,"[{'ForeName': 'Robert B', 'Initials': 'RB', 'LastName': 'Kleiman', 'Affiliation': 'eResearch Technology, Philadelphia, PA, USA.'}, {'ForeName': 'Borje', 'Initials': 'B', 'LastName': 'Darpo', 'Affiliation': 'eResearch Technology, Philadelphia, PA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Thorn', 'Affiliation': 'Statistical Resources, Chapel Hill, NC, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Stoehr', 'Affiliation': 'Paion Germany GmbH, Aachen, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Schippers', 'Affiliation': 'Paion Germany GmbH, Aachen, Germany.'}]",British journal of clinical pharmacology,['10.1111/bcp.14270'] 1376,32227108,Music Therapist Experiences of a Randomized Controlled Trial as Clinician Researchers.,"Music therapy clinicians bring an important perspective to the design and conduct of clinically meaningful studies. Unfortunately, there continue to be roadblocks that hinder clinician involvement in research and the development of successful partnerships between academic researchers and practicing clinicians. To help grow clinician involvement, it is important that research teams share their experiences. As such, the purpose of this qualitative study was to share music therapists' perspectives about their experience of working as a research clinician on a large multisite randomized controlled trial. 10 board-certified music therapists provided written responses to 6 data-generating questions about: (a) reasons for participating, (b) perceived challenges and benefits, (c) experiences of quality assurance monitoring, (d) professional growth, (e) value of research, and (f) advice for clinicians considering research involvement. Using thematic content analysis, we identified primary themes and subthemes for each question (20 themes; 30 subthemes). Qualitative analysis revealed not only common challenges, such as reconciling clinical and research responsibilities, but also benefits, including continued professional growth, greater understanding of research processes, and research participation as a way to advocate and advance the profession. Finally, for clinicians interested in becoming involved in research, therapists noted the importance of having workplace support from a mentor, supervisor, and/or administrator; seeking out available resources; and knowing roles and responsibilities before initiating research involvement. Findings offer important insight and recommendations to support the involvement of clinicians in research and support further exploration of clinician involvement in dissemination efforts to improve translation and uptake of research into practice.",2020,"Unfortunately, there continue to be roadblocks that hinder clinician involvement in research and the development of successful partnerships between academic researchers and practicing clinicians.",[],[],[],[],[],[],10.0,0.0426504,"Unfortunately, there continue to be roadblocks that hinder clinician involvement in research and the development of successful partnerships between academic researchers and practicing clinicians.","[{'ForeName': 'Amanda K', 'Initials': 'AK', 'LastName': 'Henley', 'Affiliation': 'Indiana University School of Nursing, Indianapolis, IN.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Collier', 'Affiliation': ""Children's Healthcare of Atlanta, Atlanta, GA.""}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Robertson', 'Affiliation': ""Children's Mercy Hospital, Kansas City, MO.""}, {'ForeName': 'Marial A', 'Initials': 'MA', 'LastName': 'Biard', 'Affiliation': ""Texas Children's Hospital, Houston, TX.""}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Bruno', 'Affiliation': 'Eating Recovery Center of Ohio, Cincinnati, OH.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Bush', 'Affiliation': 'West Virginia University, Morgantown, WV.'}, {'ForeName': 'Erinn', 'Initials': 'E', 'LastName': 'Frees', 'Affiliation': ""Children's Minnesota, Minneapolis, MN.""}, {'ForeName': 'Caitlin', 'Initials': 'C', 'LastName': 'Krater', 'Affiliation': 'Riley Hospital for Children at Indiana University Health, Indianapolis, IN.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Woolever', 'Affiliation': ""Children's Minnesota, Minneapolis, MN.""}, {'ForeName': 'Debra S', 'Initials': 'DS', 'LastName': 'Burns', 'Affiliation': 'School of Engineering and Technology at IUPUI Department of Music and Arts Technology, Indianapolis, IN.'}, {'ForeName': 'Sheri L', 'Initials': 'SL', 'LastName': 'Robb', 'Affiliation': 'Indiana University School of Nursing, Indianapolis, IN.'}]",Journal of music therapy,['10.1093/jmt/thaa005'] 1377,32497605,The duration of intrapartum supplemental oxygen administration and umbilical cord oxygen content.,"BACKGROUND Maternal oxygen (O 2 ) administration is a commonly performed intrauterine resuscitation technique though to improve fetal oxygenation. However, hyperoxygenation is known to be harmful in both neonates and adults. Currently, there are no formal recommendations on whether a certain dose or duration of O 2 may be most helpful in improving umbilical cord gases or neonatal outcomes. OBJECTIVE We tested the hypothesis that prolonged supplemental O 2 exposure during labor is associated with increased umbilical cord O 2 concentrations. STUDY DESIGN This was a planned secondary analysis of a randomized noninferiority trial comparing O 2 with room air in laboring patients. Patients were randomized to receive either 10 L/min O 2 or room air at any point during active labor when they developed a category II fetal heart tracing that would otherwise require resuscitation. The primary outcome variable for this analysis was partial pressure of O 2 in the umbilical vein. The secondary outcome variable was partial pressure of O 2 in the umbilical artery. These outcome variables were compared between patients with short durations of O 2 exposure and those with long durations of O 2 exposure, defined as <75th percentile and ≥75th percentile of duration, respectively. The outcomes were also compared among the groups that received room air, O 2 for short durations, and O 2 for long durations. RESULTS Among the 99 patients with paired and validated cord gases who were included in this analysis, the partial pressure of O 2 in the umbilical vein was significantly lower in patients who received O 2 supplementation for longer durations than in those who received O 2 for shorter durations (median interquartile range 25.5 [21.5-33] vs 32.5 [26.5-37.5] mm Hg; P<.03). There was no difference in the partial pressure of O 2 in the umbilical artery or other cord gases between the short and long duration O 2 supplementation groups. Other methods of intrauterine resuscitation were similar between the short and long duration O 2 supplementation groups. There was no difference in the partial pressure of O 2 in the umbilical artery or in the umbilical vein when the room air, short duration O 2 supplementation, and long duration O 2 supplementation groups were compared. CONCLUSION Longer durations of O 2 exposure are not associated with a higher partial pressure of O 2 in the umbilical cord. In fact, patients with longer durations of O 2 exposure had lower partial pressure of O 2 in the umbilical vein, suggesting impaired placental O 2 transfer with prolonged O 2 exposure.",2020,"There was no difference in UA or UV pO 2 when compared between RA, short duration O 2 , and long duration O 2 groups. ",['laboring patients'],[],"['umbilical vein (UV) pO 2 ', 'duration of intrapartum supplemental oxygen administration and umbilical cord oxygen content', 'UA pO 2 or other cord gases', 'umbilical artery (UA) pO 2 ']","[{'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",[],"[{'cui': 'C0041637', 'cui_str': 'Structure of umbilical vein'}, {'cui': 'C0297199', 'cui_str': 'PO-2'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0456337', 'cui_str': 'Intrapartum'}, {'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}, {'cui': 'C0041633', 'cui_str': 'Umbilical cord structure'}, {'cui': 'C0523806', 'cui_str': 'Oxygen measurement'}, {'cui': 'C3489532', 'cui_str': 'Cone-Rod Dystrophy 2'}, {'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0041632', 'cui_str': 'Structure of umbilical artery'}]",99.0,0.283401,"There was no difference in UA or UV pO 2 when compared between RA, short duration O 2 , and long duration O 2 groups. ","[{'ForeName': 'Virginia Y', 'Initials': 'VY', 'LastName': 'Watkins', 'Affiliation': 'Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO. Electronic address: Watkinsv@wustl.edu.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Martin', 'Affiliation': 'Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO.'}, {'ForeName': 'George A', 'Initials': 'GA', 'LastName': 'Macones', 'Affiliation': 'Department of Obstetrics and Gynecology, Dell Medical School, The University of Texas at Austin, Austin, TX.'}, {'ForeName': 'Methodius G', 'Initials': 'MG', 'LastName': 'Tuuli', 'Affiliation': 'Department of Obstetrics and Gynecology, Indiana University, Bloomington, IN.'}, {'ForeName': 'Alison G', 'Initials': 'AG', 'LastName': 'Cahill', 'Affiliation': 'Department of Obstetrics and Gynecology, Dell Medical School, The University of Texas at Austin, Austin, TX.'}, {'ForeName': 'Nandini', 'Initials': 'N', 'LastName': 'Raghuraman', 'Affiliation': 'Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.05.056'] 1378,32493693,"Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.","BACKGROUND Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in China for dialysis-dependent CKD anemia. METHODS This phase 3, 24-week, double-blind, double-dummy study evaluated roxadustat's noninferiority to darbepoetin alfa for hemodialysis-dependent CKD anemia. We randomly assigned Japanese patients to oral roxadustat three times weekly or to darbepoetin alfa injections once weekly, titrating doses to maintain hemoglobin between 10-12 g/dl. The primary end point was change of average hemoglobin from baseline to weeks 18-24 ( ∆ Hb 18-24 ). Secondary end points were average hemoglobin and proportion of patients with hemoglobin between 10-12 g/dl (maintenance rate) at weeks 18-24, and iron parameters. Safety assessments included treatment-emergent adverse events and adjudicated ophthalmologic findings. RESULTS We randomly assigned 303 patients to roxadustat ( n =151) or darbepoetin alfa ( n =152). The difference between roxadustat and darbepoetin alfa in ∆ Hb 18-24 was -0.02 g/dl (95% confidence interval, -0.18 to 0.15), confirming roxadustat's noninferiority to darbepoetin alfa. Average hemoglobin at weeks 18-24 with roxadustat was 10.99 g/dl (95% confidence interval: 10.88 to 11.10), confirming its efficacy. Among patients with one or more hemoglobin value during weeks 18-24, the maintenance rate was 95.2% with roxadustat and 91.3% with darbepoetin alfa. Serum iron, ferritin, and transferrin saturation remained clinically stable with roxadustat; transferrin and total iron binding capacity increased through week 4 before stabilizing. Common treatment-emergent adverse events were nasopharyngitis, shunt stenosis, diarrhea, contusion, and vomiting. The proportion of patients with new or worsening retinal hemorrhage was 32.4% with roxadustat and 36.6% with darbepoetin alfa. We observed no clinically meaningful changes in retinal thickness groups. CONCLUSIONS Roxadustat maintained hemoglobin within 10-12 g/dl in patients on hemodialysis and was noninferior to darbepoetin alfa. Treatment-emergent adverse events were consistent with previous reports. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients with Anemia, NCT02952092 (ClinicalTrials.gov).",2020,"Serum iron, ferritin, and transferrin saturation remained clinically stable with roxadustat; transferrin and total iron binding capacity increased through week 4 before stabilizing.","['hemodialysis-dependent CKD anemia', 'Hemodialysis Chronic Kidney Disease Patients with Anemia, NCT02952092 (ClinicalTrials.gov', 'CKD Patients with Anemia on Hemodialysis in Japan', '∆', '303 patients to roxadustat ( n =151) or']","['ASP1517', 'darbepoetin alfa', 'darbepoetin alfa injections']","['proportion of patients with new or worsening retinal hemorrhage', 'Serum iron, ferritin, and transferrin saturation', 'Safety assessments included treatment-emergent adverse events and adjudicated ophthalmologic findings', 'Average hemoglobin', 'hemoglobin value', 'change of average hemoglobin', 'total iron binding capacity', 'nasopharyngitis, shunt stenosis, diarrhea, contusion, and vomiting', 'maintenance rate', 'average hemoglobin and proportion of patients with hemoglobin']","[{'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C0937950', 'cui_str': 'darbepoetin alfa'}, {'cui': 'C4027177', 'cui_str': 'darbepoetin alfa Injection'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0035317', 'cui_str': 'Retinal hemorrhage'}, {'cui': 'C1318312', 'cui_str': 'Serum iron measurement'}, {'cui': 'C0015879', 'cui_str': 'Ferritin'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0029087', 'cui_str': 'Ophthalmology'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0700379', 'cui_str': 'Total iron binding capacity'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C1142174', 'cui_str': 'Shunt stenosis'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0009938', 'cui_str': 'Contusion'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}]",303.0,0.137155,"Serum iron, ferritin, and transferrin saturation remained clinically stable with roxadustat; transferrin and total iron binding capacity increased through week 4 before stabilizing.","[{'ForeName': 'Tadao', 'Initials': 'T', 'LastName': 'Akizawa', 'Affiliation': 'Department of Nephrology, Showa University School of Medicine, Tokyo, Japan akizawa@med.showa-u.ac.jp.'}, {'ForeName': 'Manabu', 'Initials': 'M', 'LastName': 'Iwasaki', 'Affiliation': 'Department of Data Science, Yokohama City University, Yokohama, Japan.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Yamaguchi', 'Affiliation': 'Japan-Asia Data Science, Development, Astellas Pharma, Inc., Tokyo, Japan.'}, {'ForeName': 'Yoshikatsu', 'Initials': 'Y', 'LastName': 'Majikawa', 'Affiliation': 'Japan-Asia Clinical Development 2, Development, Astellas Pharma, Inc., Tokyo, Japan.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Reusch', 'Affiliation': 'Development Medical Science Urology and Nephrology, Astellas Pharma Europe B.V., Leiden, The Netherlands.'}]",Journal of the American Society of Nephrology : JASN,['10.1681/ASN.2019060623'] 1379,32493720,Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials.,"A maternal vaccine capable of boosting neutralizing antibody (NAb) responses directed against circulating viruses in HIV-infected pregnant women could effectively decrease mother-to-child transmission of HIV. However, it is not known if an HIV envelope (Env) vaccine administered to infected pregnant women could enhance autologous virus neutralization and thereby reduce this risk of vertical HIV transmission. Here, we assessed autologous virus NAb responses in maternal plasma samples obtained from AIDS Vaccine Evaluation Group (AVEG) protocols 104 and 102, representing historical phase I safety and immunogenicity trials of recombinant HIV Env subunit vaccines administered to HIV-infected pregnant women (ClinicalTrials registration no. NCT00001041). Maternal HIV Env-specific plasma binding and neutralizing antibody responses were characterized before and after vaccination in 15 AVEG 104 ( n  = 10 vaccine recipients, n  = 5 placebo recipients) and 2 AVEG 102 ( n  = 1 vaccine recipient, n  = 1 placebo recipient) participants. Single-genome amplification (SGA) was used to obtain HIV env gene sequences of autologous maternal viruses for pseudovirus production and neutralization sensitivity testing in pre- and postvaccination plasma of HIV-infected pregnant vaccine recipients ( n  = 6 gp120, n  = 1 gp160) and placebo recipients ( n  = 3). We detected an increase in Env subunit MN gp120-specific IgG binding in the group of vaccine recipients between the first immunization visit and the last visit at delivery ( P  = 0.027, 2-sided Wilcoxon test). While no difference was observed in the levels of autologous virus neutralization potency between groups, in both groups maternal plasma collected at delivery more effectively neutralized autologous viruses from early pregnancy than late pregnancy. Immunization strategies capable of further enhancing these autologous virus NAb responses in pregnant women will be important to block vertical transmission of HIV. IMPORTANCE Maternal antiretroviral therapy (ART) has effectively reduced but not eliminated the burden of mother-to-child transmission of HIV across the globe, as an estimated 160,000 children were newly infected with HIV in 2018. Thus, additional preventive strategies beyond ART will be required to close the remaining gap and end the pediatric HIV epidemic. A maternal active immunization strategy that synergizes with maternal ART could further reduce infant HIV infections. In this study, we found that two historic HIV Env vaccines did not enhance the ability of HIV-infected pregnant women to neutralize autologous viruses. Therefore, next-generation maternal HIV vaccine candidates must employ alternate approaches to achieve potent neutralizing antibody and perhaps nonneutralizing antibody responses to effectively impede vertical virus transmission. Moreover, these approaches must reflect the broad diversity of HIV strains and widespread availability of ART worldwide.",2020,"While no difference was observed in the levels of autologous virus neutralization potency between groups, in both groups maternal plasma collected at delivery more effectively neutralized autologous viruses from early pregnancy than late pregnancy.","['160,000 children were newly infected with HIV in 2018', 'HIV-infected pregnant women', 'HIV-infected pregnant women (ClinicalTrials registration no', 'pregnant women']","['Maternal antiretroviral therapy (ART', 'Single-genome amplification (SGA', 'recombinant HIV Env subunit vaccines', 'AVEG 102 ( n \u2009=\u20091 vaccine recipient, n \u2009=\u20091 placebo', 'placebo']","['Env subunit MN gp120-specific IgG binding', 'levels of autologous virus neutralization potency', 'Maternal HIV Env-specific plasma binding and neutralizing antibody responses']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0887892', 'cui_str': 'Vaccines, Subunit'}, {'cui': 'C0085432', 'cui_str': 'AIDS Vaccines'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0599220', 'cui_str': 'Protein Subunit'}, {'cui': 'C0019691', 'cui_str': 'env Protein gp120, HIV'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0332297', 'cui_str': 'Bounded by'}, {'cui': 'C0282682', 'cui_str': 'Blocking antibody'}]",160000.0,0.230413,"While no difference was observed in the levels of autologous virus neutralization potency between groups, in both groups maternal plasma collected at delivery more effectively neutralized autologous viruses from early pregnancy than late pregnancy.","[{'ForeName': 'Eliza D', 'Initials': 'ED', 'LastName': 'Hompe', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Jesse F', 'Initials': 'JF', 'LastName': 'Mangold', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Kumar', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Joshua A', 'Initials': 'JA', 'LastName': 'Eudailey', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'McGuire', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Barton F', 'Initials': 'BF', 'LastName': 'Haynes', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'M Anthony', 'Initials': 'MA', 'LastName': 'Moody', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Peter F', 'Initials': 'PF', 'LastName': 'Wright', 'Affiliation': 'Department of Pediatrics, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.'}, {'ForeName': 'Genevieve G', 'Initials': 'GG', 'LastName': 'Fouda', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Elena E', 'Initials': 'EE', 'LastName': 'Giorgi', 'Affiliation': 'Los Alamos National Laboratory, Los Alamos, New Mexico, USA.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Gao', 'Affiliation': 'Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Sallie R', 'Initials': 'SR', 'LastName': 'Permar', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA sallie.permar@duke.edu.'}]",mSphere,['10.1128/mSphere.00254-20'] 1380,32686217,"Comparison of mechanical, chemical and physical human models of in vivo skin damage: Randomized controlled trial.","INTRODUCTION Human in vivo models of skin damage were often used in research of cutaneous disorders. The most commonly used models were tape-stripping as mechanical, sodium lauryl sulphate-induced irritation as chemical and ultraviolet radiation as physical damage model. In regard to differences between models, they were expected to have different responses to damage and recovery, with unique skin parameters' changes over time. OBJECTIVE The aim was to compare skin parameters in three different skin damage models on the same anatomical location, with and without topical treatment. METHODS Four test sites on each forearm were randomly assigned to three skin damage models with the fourth sites on each forearm chosen as a control, undamaged site. Skin parameters were assessed using non-invasive methods. RESULTS Sodium lauryl sulphate irritation caused the strongest damage with delayed reaction to the irritant. Tape stripping leads to highest initial skin barrier disruption but afterwards it showed the fastest skin recovery. Ultraviolet radiation did not affect skin barrier function, but it elevated skin erythema and melanin level. Tested preparation did not lead to changes in measured parameters. CONCLUSION The skin of the participants had different response to three skin damage models with distinct changes of skin parameters and recovery. The trial was registered at ClinicalTrials.gov under the identifier NCT03783819.",2020,"Ultraviolet radiation did not affect skin barrier function, but it elevated skin erythema and melanin level.","['Four test sites on each forearm', 'vivo skin damage']",['Ultraviolet radiation'],"['Skin parameters', 'elevated skin erythema and melanin level', 'skin barrier function']","[{'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0016536', 'cui_str': 'Forearm structure'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0010957', 'cui_str': 'Damage'}]","[{'cui': 'C0041625', 'cui_str': 'Ultraviolet radiation'}]","[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0025196', 'cui_str': 'Melanin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",,0.0249029,"Ultraviolet radiation did not affect skin barrier function, but it elevated skin erythema and melanin level.","[{'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Leskur', 'Affiliation': 'Department of Pharmacy, University of Split School of Medicine, Split, Croatia.'}, {'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Perišić', 'Affiliation': 'Department of Pharmacy, University of Split School of Medicine, Split, Croatia.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Romac', 'Affiliation': 'Department of Pharmacy, University of Split School of Medicine, Split, Croatia.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Šušak', 'Affiliation': 'Department of Pharmacy, University of Split School of Medicine, Split, Croatia.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Šešelja Perišin', 'Affiliation': 'Department of Pharmacy, University of Split School of Medicine, Split, Croatia.'}, {'ForeName': 'Josipa', 'Initials': 'J', 'LastName': 'Bukić', 'Affiliation': 'Department of Pharmacy, University of Split School of Medicine, Split, Croatia.'}, {'ForeName': 'Doris', 'Initials': 'D', 'LastName': 'Rušić', 'Affiliation': 'Department of Pharmacy, University of Split School of Medicine, Split, Croatia.'}, {'ForeName': 'Nebojša', 'Initials': 'N', 'LastName': 'Kladar', 'Affiliation': 'Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.'}, {'ForeName': 'Biljana', 'Initials': 'B', 'LastName': 'Božin', 'Affiliation': 'Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.'}, {'ForeName': 'Darko', 'Initials': 'D', 'LastName': 'Modun', 'Affiliation': 'Department of Pharmacy, University of Split School of Medicine, Split, Croatia.'}]",Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI),['10.1111/srt.12932'] 1381,32503395,Effects of Collaborative Care for Comorbid Attention Deficit Hyperactivity Disorder Among Children With Behavior Problems in Pediatric Primary Care.,"This study evaluates the impact of a 6-month care management intervention for 206 children diagnosed with comorbid attention deficit hyperactivity disorder (ADHD) from a sample of 321 five- to 12-year-old children recruited for treatment of behavior problems in 8 pediatric primary care offices. Practices were cluster-randomized to Doctor Office Collaboration Care (DOCC) or Enhanced Usual Care (EUC). Chart reviews documented higher rates of service delivery, prescription of medication for ADHD, and titration in DOCC (vs EUC). Based on complex conditional models, DOCC showed greater acute improvement in individualized ADHD treatment goals and follow-up improvements in quality of life and ADHD and oppositional defiant disorder goals. Medication use had a significant effect on acute and follow-up ADHD symptom reduction and quality of life. Medication continuity was associated with some long-term gains. A collaborative care intervention for behavior problems that incorporated treatment guidelines for ADHD in primary care was more effective than psychoeducation and facilitated referral to community treatment.",2020,A collaborative care intervention for behavior problems that incorporated treatment guidelines for ADHD in primary care was more effective than psychoeducation and facilitated referral to community treatment.,"['Children', 'Comorbid Attention Deficit Hyperactivity Disorder', '206 children diagnosed with comorbid attention deficit hyperactivity disorder (ADHD) from a sample of 321 five- to 12-year-old children recruited for treatment of behavior problems in 8 pediatric primary care offices']","['Collaborative Care', 'care management intervention', 'Doctor Office Collaboration Care (DOCC) or Enhanced Usual Care (EUC']","['quality of life and ADHD and oppositional defiant disorder goals', 'acute and follow-up ADHD symptom reduction and quality of life', 'Medication continuity']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0442603', 'cui_str': 'Office'}]","[{'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0031834', 'cui_str': ""Physician's Office""}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0029121', 'cui_str': 'Oppositional defiant disorder'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0456391', 'cui_str': 'Continuities'}]",206.0,0.0862828,A collaborative care intervention for behavior problems that incorporated treatment guidelines for ADHD in primary care was more effective than psychoeducation and facilitated referral to community treatment.,"[{'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Kolko', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}, {'ForeName': 'Jonathan A', 'Initials': 'JA', 'LastName': 'Hart', 'Affiliation': 'UPMC Western Psychiatric Hospital, Pittsburgh, PA, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Campo', 'Affiliation': 'Ohio State University, Morgantown, WV, USA.'}, {'ForeName': 'Dara', 'Initials': 'D', 'LastName': 'Sakolsky', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Rounds', 'Affiliation': 'UPMC Western Psychiatric Hospital, Pittsburgh, PA, USA.'}, {'ForeName': 'Mark L', 'Initials': 'ML', 'LastName': 'Wolraich', 'Affiliation': 'University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'ForeName': 'Stephen R', 'Initials': 'SR', 'LastName': 'Wisniewski', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}]",Clinical pediatrics,['10.1177/0009922820920013'] 1382,32506275,"Preoperative meloxicam versus postoperative meloxicam for pain control, patients' satisfaction and function recovery in hip osteoarthritis patients who receive total hip arthroplasty: a randomized, controlled study.","This study aimed to compare the analgesic effect, patients' satisfaction, tolerance and hip-joint function recovery by preoperative meloxicam versus postoperative meloxicam in treating hip osteoarthritis (OA) patients receiving total hip arthroplasty (THA). 132 hip OA patients who underwent THA surgery were allocated into postoperative analgesia (POST) and preoperative analgesia (PRE) groups at a 1:1 ratio. In the PRE group, patients took meloxicam 15 mg at 24 h pre-operation, 7.5 mg at 4 h, 24 h, 48 h and 72 h post-operation; in the POST group, patients received meloxicam 15 mg at 4 h post-operation, then 7.5 mg at 24 h, 48 h and 72 h post-operation. Furthermore, postoperative pain, consumption of patient-controlled analgesia (PCA), overall satisfaction and adverse events were evaluated within 96 h post-operation; meanwhile, Harris hip score was assessed within 6 months post-operation. Pain VAS at rest at 6 h, 12 h, 24 h, and pain VAS at passive movement at 6 h, 12 h were decreased in PRE group compared to POST group. In addition, additional consumption of PCA and the total consumption of PCA were both reduced in PRE group compared to POST group. Additionally, overall satisfaction in PRE group was higher at 24 h, 48 h and 72 h compared to POST group. While Harris hip score was of no difference between POST group and PRE group at M3 or M6. Besides, no difference in adverse events incidence was found between the two groups. In conclusion, preoperative meloxicam achieves better efficacy and similar tolerance compared to postoperative meloxicam in hip OA patients post THA.",2020,"In addition, additional consumption of PCA and the total consumption of PCA were both reduced in PRE group compared to POST group.","['hip osteoarthritis patients who receive total hip arthroplasty', '132 hip OA patients who underwent THA surgery', 'treating hip osteoarthritis (OA) patients receiving total hip arthroplasty (THA']","['postoperative analgesia (POST) and preoperative analgesia (PRE', 'meloxicam 15\xa0mg at 4\xa0h post-operation', 'meloxicam', 'Preoperative meloxicam versus postoperative meloxicam', 'meloxicam versus postoperative meloxicam']","['overall satisfaction', 'total consumption of PCA', 'Pain VAS', 'efficacy and similar tolerance', 'adverse events incidence', 'pain VAS at passive movement', ""analgesic effect, patients' satisfaction, tolerance and hip-joint function recovery"", 'Furthermore, postoperative pain, consumption of patient-controlled analgesia (PCA), overall satisfaction and adverse events']","[{'cui': 'C0029410', 'cui_str': 'Osteoarthritis of hip'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C1128682', 'cui_str': 'meloxicam 15 MG'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0083381', 'cui_str': 'meloxicam'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0078944', 'cui_str': 'Patient controlled analgesia'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0079991', 'cui_str': 'Passive movement'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019558', 'cui_str': 'Hip joint structure'}, {'cui': 'C0599766', 'cui_str': 'Recovery of Function'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}]",132.0,0.0274409,"In addition, additional consumption of PCA and the total consumption of PCA were both reduced in PRE group compared to POST group.","[{'ForeName': 'Lingyun', 'Initials': 'L', 'LastName': 'Ren', 'Affiliation': ""Department of Anesthesiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26, Shengli Street, Wuhan, 430014, People's Republic of China.""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Meng', 'Affiliation': ""Department of Anesthesiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26, Shengli Street, Wuhan, 430014, People's Republic of China.""}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Yan', 'Affiliation': ""Department of Anesthesiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26, Shengli Street, Wuhan, 430014, People's Republic of China. haodunye9398649@163.com.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Sun', 'Affiliation': ""Department of Anesthesiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26, Shengli Street, Wuhan, 430014, People's Republic of China.""}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Yao', 'Affiliation': ""Department of Anesthesiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26, Shengli Street, Wuhan, 430014, People's Republic of China.""}]",Inflammopharmacology,['10.1007/s10787-020-00718-2'] 1383,32506975,Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.,"INTRODUCTION Interstitial lung disease (ILD) is a leading cause of death in patients with systemic sclerosis (SSc). Nonspecific immunosuppressants have been the first-line treatment for SSc-associated ILD (SSc-ILD). Nintedanib, an oral triple kinase inhibitor targeting profibrotic pathways, has been employed for the treatment of idiopathic pulmonary fibrosis and has recently received marketing approval in the United States and Japan, based on the results of a placebo-controlled randomized controlled trial. In this clinical trial, nintedanib delayed the progression of SSc-ILD compared with placebo. AREAS COVERED This review covers current pharmacotherapies for SSc-ILD, drug profiles of nintedanib, and efficacy and safety profiles of nintedanib in patients with idiopathic pulmonary fibrosis and SSc-ILD observed in randomized controlled trails. EXPERT OPINION Currently, we have two treatment options for SSc-ILD, i.e., immunosuppressants and antifibrotic agents. However, appropriate utilization of antifibrotic agents in clinical practice remains challenging, i.e., in which cases they are to be used, timing of use, how to use them properly, and whether in combination with immunosuppressants.",2020,"In this clinical trial, Nintedanib delayed the progression of SSc-ILD compared with placebo. ","['systemic sclerosis-associated interstitial lung disease', 'patients with systemic sclerosis (SSc', 'patients with idiopathic pulmonary fibrosis and SSc-ILD']","['Nintedanib', 'placebo']",[],"[{'cui': 'C0036421', 'cui_str': 'Systemic sclerosis'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0206062', 'cui_str': 'Interstitial lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1800706', 'cui_str': 'Idiopathic pulmonary fibrosis'}]","[{'cui': 'C2930789', 'cui_str': 'nintedanib'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.0547629,"In this clinical trial, Nintedanib delayed the progression of SSc-ILD compared with placebo. ","[{'ForeName': 'Yoshioki', 'Initials': 'Y', 'LastName': 'Yamasaki', 'Affiliation': 'Department of Allergy and Rheumatology, Nippon Medical School , Tokyo, Japan.'}, {'ForeName': 'Masataka', 'Initials': 'M', 'LastName': 'Kuwana', 'Affiliation': 'Department of Allergy and Rheumatology, Nippon Medical School , Tokyo, Japan.'}]",Expert review of clinical immunology,['10.1080/1744666X.2020.1777857'] 1384,32685787,Direct and crossover effects of Phenylephrine and Cyclopentolate on foveal avascular zone and vessel density of macular capillary plexuses: an optical coherence tomography angiography study.,"Purpose: To determine the influence of phenylephrine and cyclopentolate on foveal avascular zone (FAZ) and vessel density of macular capillary plexus measurements via optical coherence tomography angiography (OCTA). Materials and Methods: The participants were separated into 2 groups according to the administration of drops. One drop of phenylephrine 2.5% was administered on one eye of each subject in the phenylephrine group (n=30) and one drop of cyclopentolate 1% in the cyclopentolate group (n=30). FAZ parameters and vessel density values of both superficial (SCP) and deep capillary plexuses (DCP) were calculated via OCTA priorly and at 45 min following the drop administration in both eyes. Vessel density, acircularity index of FAZ, FAZ area, perimeter of FAZ and foveal density-300 were evaluated via OCTA. Results: The vessel density values of fovea in SCP and DCP was 18.51±7.14% and 36.05±8.76% and significantly decreased to 16.16±6.26% and 33.29±9.47% respectively after drop instillation in dilated eyes in phenylephrine group (p=0.041 and p=0.032). Likewise, the vessel density values in SCP and DCP were 21.56±7.74% and 39.27±8.76% and significantly decreased to 18.89±7.32% and 35.36±5.75% respectively, after drop instillation in dilated eyes in cyclopentolate group (p=0.035 and p=0.028). However, there was no significant difference between before and after instillation of drops in terms of foveal density-300 value via FAZ assessment tool in both dilated and nondilated contralateral eyes in both groups (p>0.05 for all). Conclusions: Mydriasis with phenylephrine and/ or cyclopentolate did not affect the foveal density-300 values while analyzing the perfusion of macula. Vessel density in foveal region should be evaluated via FAZ evaluation software of the OCTA.",2020,and/ or cyclopentolate did not affect the foveal density-300 values while analyzing the perfusion of macula.,[],"['cyclopentolate', 'phenylephrine', 'optical coherence tomography angiography (OCTA', 'Phenylephrine and Cyclopentolate', 'phenylephrine and cyclopentolate']","['vessel density values in SCP and DCP', 'FAZ parameters and vessel density values of both superficial (SCP) and deep capillary plexuses (DCP', 'foveal density-300 values', 'foveal avascular zone (FAZ) and vessel density of macular capillary plexus measurements', 'Vessel density, acircularity index of FAZ, FAZ area, perimeter of FAZ and foveal density-300', 'vessel density values of fovea in SCP and DCP', 'foveal avascular zone and vessel density of macular capillary plexuses']",[],"[{'cui': 'C0010582', 'cui_str': 'Cyclopentolate'}, {'cui': 'C0031469', 'cui_str': 'Phenylephrine'}, {'cui': 'C0920367', 'cui_str': 'Optical coherence tomography'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}]","[{'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C1145610', 'cui_str': 'sodium cellulose phosphate'}, {'cui': 'C0950248', 'cui_str': 'Des-gamma-carboxy prothrombin'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0006901', 'cui_str': 'Structure of capillary blood vessel (organ)'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C1275950', 'cui_str': 'Foveal avascular zone'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0182215', 'cui_str': 'Perimeter'}, {'cui': 'C0016622', 'cui_str': 'Structure of fovea centralis'}]",,0.0577051,and/ or cyclopentolate did not affect the foveal density-300 values while analyzing the perfusion of macula.,"[{'ForeName': 'Yasin Şakir', 'Initials': 'YŞ', 'LastName': 'Göker', 'Affiliation': 'Ulucanlar Eye Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Hasan', 'Initials': 'H', 'LastName': 'Kızıltoprak', 'Affiliation': 'Ulucanlar Eye Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Kemal', 'Initials': 'K', 'LastName': 'Tekin', 'Affiliation': 'Ercis State Hospital, Ophthalmology Department, Van, Turkey.'}, {'ForeName': 'Esat', 'Initials': 'E', 'LastName': 'Yetkin', 'Affiliation': 'Ulucanlar Eye Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Mustafa Salih', 'Initials': 'MS', 'LastName': 'Karatepe', 'Affiliation': 'Ulucanlar Eye Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Kübra', 'Initials': 'K', 'LastName': 'Özdemir', 'Affiliation': 'Ulucanlar Eye Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Gokhan', 'Initials': 'G', 'LastName': 'Demir', 'Affiliation': 'Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey.'}]",Romanian journal of ophthalmology,[] 1385,32497261,"NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma.","BACKGROUND A current recommendation for the treatment of patients with locoregionally advanced nasopharyngeal carcinoma (NPC) is conventional fractionated radiotherapy (RT) with concurrent cisplatin followed by adjuvant cisplatin and 5-fluorouracil (PF). This randomized NPC-0501 trial evaluated the therapeutic effect of changing to an induction-concurrent sequence or accelerated-fractionation sequence, and/or replacing 5-fluorouracil with capecitabine (X). METHODS Patients with American Joint Committee on Cancer/International Union Against Cancer stage III to stage IVB NPC initially were randomly allocated to 1 of 6 treatment arms (6-arm full-randomization cohort). The protocol was amended in 2009 to permit centers to opt out of randomization regarding fractionation (3-arm chemotherapy cohort). RESULTS A total of 803 patients were accrued (1 of whom was nonevaluable) from 2006 to 2012. Based on the overall comparisons, neither changing the chemotherapy sequence nor accelerated fractionation improved treatment outcome. However, secondary analyses demonstrated that when adjusted for RT parameters and other significant factors, the induction-concurrent sequence, especially the induction-PX regimen, achieved significant improvements in progression-free survival (PFS) and overall survival. Efficacy varied among different RT groups: although no impact was observed in the accelerated-fractionation group and the 3-arm chemotherapy cohort, a comparison of the induction-concurrent versus concurrent-adjuvant sequence in the conventional-fractionation group demonstrated a significant benefit in PFS (78% vs 62% at 5 years; P = .015) and a marginal benefit in overall survival (84% vs 72%; P = .042) after adjusting for multiple comparisons. Comparison of the induction-PX versus the adjuvant-PF regimen demonstrated better PFS (78% vs 62%; P = .027) without an increase in overall late toxicity. CONCLUSIONS For patients irradiated using conventional fractionation, changing the chemotherapy sequence from a concurrent-adjuvant to an induction-concurrent sequence, particularly using induction cisplatin and capecitabine, potentially could improve efficacy without an adverse impact on late toxicity. However, further validation is needed for confirmation of these findings.",2020,"Efficacy varied among different RT groups: although no impact was observed in the accelerated-fractionation group and the 3-arm chemotherapy cohort, a comparison of the induction-concurrent versus concurrent-adjuvant sequence in the conventional-fractionation group demonstrated a significant benefit in PFS (78% vs 62% at 5 years; P = .015) and a marginal benefit in overall survival (84% vs 72%; P = .042) after adjusting for multiple comparisons.","['patients with advanced nasopharyngeal carcinoma', 'Patients with American Joint Committee on Cancer/International Union Against Cancer stage III to stage IVB NPC initially', 'A total of 803 patients were accrued (1 of whom was nonevaluable) from 2006 to 2012', 'patients with locoregionally advanced nasopharyngeal carcinoma (NPC']","['conventional fractionated radiotherapy (RT) with concurrent cisplatin followed by adjuvant cisplatin and 5-fluorouracil (PF', '5-fluorouracil with capecitabine, and altering fractionation', '5-fluorouracil with capecitabine (X', 'cisplatin and capecitabine']","['progression-free survival (PFS) and overall survival', 'PFS', 'overall survival', 'Efficacy', 'overall late toxicity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C2931822', 'cui_str': 'Nasopharyngeal carcinoma'}, {'cui': 'C0441915', 'cui_str': 'AJCC'}, {'cui': 'C0441914', 'cui_str': 'UICC'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0441775', 'cui_str': 'Stage IVb'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0524811', 'cui_str': 'Dose Fractionation, Radiotherapy'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0040539', 'cui_str': 'TO'}]",803.0,0.103638,"Efficacy varied among different RT groups: although no impact was observed in the accelerated-fractionation group and the 3-arm chemotherapy cohort, a comparison of the induction-concurrent versus concurrent-adjuvant sequence in the conventional-fractionation group demonstrated a significant benefit in PFS (78% vs 62% at 5 years; P = .015) and a marginal benefit in overall survival (84% vs 72%; P = .042) after adjusting for multiple comparisons.","[{'ForeName': 'Anne W M', 'Initials': 'AWM', 'LastName': 'Lee', 'Affiliation': 'Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Guangdong, China.'}, {'ForeName': 'Roger K C', 'Initials': 'RKC', 'LastName': 'Ngan', 'Affiliation': 'Department of Clinical Oncology, The University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Wai-Tong', 'Initials': 'WT', 'LastName': 'Ng', 'Affiliation': 'Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong.'}, {'ForeName': 'Stewart Y', 'Initials': 'SY', 'LastName': 'Tung', 'Affiliation': 'Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, Hong Kong.'}, {'ForeName': 'Ashley A C', 'Initials': 'AAC', 'LastName': 'Cheng', 'Affiliation': 'Department of Clinical Oncology, Princess Margaret Hospital, Hong Kong, Hong Kong.'}, {'ForeName': 'Dora L W', 'Initials': 'DLW', 'LastName': 'Kwong', 'Affiliation': 'Department of Clinical Oncology, The University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Tai-Xiang', 'Initials': 'TX', 'LastName': 'Lu', 'Affiliation': 'Department of Clinical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Anthony T C', 'Initials': 'ATC', 'LastName': 'Chan', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong.'}, {'ForeName': 'Henry C K', 'Initials': 'HCK', 'LastName': 'Sze', 'Affiliation': 'Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong.'}, {'ForeName': 'Harry H Y', 'Initials': 'HHY', 'LastName': 'Yiu', 'Affiliation': 'Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong.'}, {'ForeName': 'Frank C S', 'Initials': 'FCS', 'LastName': 'Wong', 'Affiliation': 'Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, Hong Kong.'}, {'ForeName': 'Kam-Tong', 'Initials': 'KT', 'LastName': 'Yuen', 'Affiliation': 'Department of Clinical Oncology, Princess Margaret Hospital, Hong Kong, Hong Kong.'}, {'ForeName': 'Rick', 'Initials': 'R', 'LastName': 'Chappell', 'Affiliation': 'Department of Biostatistics, University of Wisconsin Medical School, Madison, Wisconsin, USA.'}, {'ForeName': 'Horace C W', 'Initials': 'HCW', 'LastName': 'Choi', 'Affiliation': 'Department of Clinical Oncology, The University of Hong Kong, Hong Kong, Hong Kong.'}]",Cancer,['10.1002/cncr.32972'] 1386,32502445,"Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial.","BACKGROUND In the phase 3 LACC trial and a subsequent population-level review, minimally invasive radical hysterectomy was shown to be associated with worse disease-free survival and higher recurrence rates than was open radical hysterectomy in patients with early stage cervical cancer. Here, we report the results of a secondary endpoint, quality of life, of the LACC trial. METHODS The LACC trial was a randomised, open-label, phase 3, non-inferiority trial done in 33 centres worldwide. Eligible participants were women aged 18 years or older with International Federation of Gynaecology and Obstetrics (FIGO) stage IA1 with lymphovascular space invasion, IA2, or IB1 adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma of the cervix, with an Eastern Cooperative Oncology Group performance status of 0 or 1, who were scheduled to have a type 2 or 3 radical hysterectomy. Participants were randomly assigned (1:1) to receive open or minimally invasive radical hysterectomy. Randomisation was done centrally using a computerised minimisation program, stratified by centre, disease stage according to FIGO guidelines, and age. Neither participants nor investigators were masked to treatment allocation. The primary endpoint of the LACC trial was disease-free survival at 4·5 years, and quality of life was a secondary endpoint. Eligible patients completed validated quality-of-life and symptom assessments (12-item Short Form Health Survey [SF-12], Functional Assessment of Cancer Therapy-Cervical [FACT-Cx], EuroQoL-5D [EQ-5D], and MD Anderson Symptom Inventory [MDASI]) before surgery and at 1 and 6 weeks and 3 and 6 months after surgery (FACT-Cx was also completed at additional timepoints up to 54 months after surgery). Differences in quality of life over time between treatment groups were assessed in the modified intention-to-treat population, which included all patients who had surgery and completed at least one baseline (pretreatment) and one follow-up (at any timepoint after surgery) questionnaire, using generalised estimating equations. The LACC trial is registered with ClinicalTrials.gov, NCT00614211. FINDINGS Between Jan 31, 2008, and June 22, 2017, 631 patients were enrolled; 312 assigned to the open surgery group and 319 assigned to the minimally invasive surgery group. 496 (79%) of 631 patients had surgery completed at least one baseline and one follow-up quality-of-life survey and were included in the modified intention-to-treat analysis (244 [78%] of 312 patients in the open surgery group and 252 [79%] of 319 participants in the minimally invasive surgery group). Median follow-up was 3·0 years (IQR 1·7-4·5). At baseline, no differences in the mean FACT-Cx total score were identified between the open surgery (129·3 [SD 18·8]) and minimally invasive surgery groups (129·8 [19·8]). No differences in mean FACT-Cx total scores were identified between the groups 6 weeks after surgery (128·7 [SD 19·9] in the open surgery group vs 130·0 [19·8] in the minimally invasive surgery group) or 3 months after surgery (132·0 [21·7] vs 133·0 [22·1]). INTERPRETATION Since recurrence rates are higher and disease-free survival is lower for minimally invasive radical hysterectomy than for open surgery, and postoperative quality of life is similar between the treatment groups, gynaecological oncologists should recommend open radical hysterectomy for patients with early stage cervical cancer. FUNDING MD Anderson Cancer Center and Medtronic.",2020,"No differences in mean FACT-Cx total scores were identified between the groups 6 weeks after surgery (128·7 [SD 19·9] in the open surgery group vs 130·0 [19·8] in the minimally invasive surgery group) or 3 months after surgery (132·0 [21·7] vs 133·0 [22·1]). ","['patients with early stage cervical cancer', '496 (79%) of 631 patients had surgery completed at least one baseline and one follow-up quality-of-life survey and were included in the modified intention-to-treat analysis (244 [78%] of 312 patients in the open surgery group and 252 [79%] of 319 participants in the minimally invasive surgery group', 'patients with cervical cancer after', '631 patients were enrolled; 312 assigned to the open surgery group and 319 assigned to the minimally invasive surgery group', '33 centres worldwide', 'Eligible participants were women aged 18 years or older with International Federation of Gynaecology and Obstetrics (FIGO) stage IA1 with lymphovascular space invasion, IA2, or IB1 adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma of the cervix, with an Eastern Cooperative Oncology Group performance status of 0 or 1, who were scheduled to have a type 2 or 3 radical hysterectomy', 'Between Jan 31, 2008, and June 22, 2017']","['open versus minimally invasive radical hysterectomy (LACC', 'radical hysterectomy', 'open or minimally invasive radical hysterectomy']","['quality of life', 'validated quality-of-life and symptom assessments (12-item Short Form Health Survey [SF-12], Functional Assessment of Cancer Therapy-Cervical', 'mean FACT-Cx total scores', 'postoperative quality of life', 'Quality of life', 'disease-free survival at 4·5 years, and quality of life', 'mean FACT-Cx total score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C4517660', 'cui_str': '244'}, {'cui': 'C4517706', 'cui_str': '312'}, {'cui': 'C0348025', 'cui_str': 'Open approach'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0282624', 'cui_str': 'Procedures, Minimally Invasive Surgical'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0018417', 'cui_str': 'Gynecology'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0458828', 'cui_str': 'Stage 1A1'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C1269955', 'cui_str': 'Tumour invasion'}, {'cui': 'C0001418', 'cui_str': 'Adenocarcinoma'}, {'cui': 'C0007137', 'cui_str': 'Squamous cell carcinoma'}, {'cui': 'C0346202', 'cui_str': 'Adenosquamous carcinoma of cervix'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C2987682', 'cui_str': 'Radical hysterectomy'}]","[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C2987682', 'cui_str': 'Radical hysterectomy'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C3494437', 'cui_str': 'Symptom Assessment'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0439234', 'cui_str': 'year'}]",631.0,0.221146,"No differences in mean FACT-Cx total scores were identified between the groups 6 weeks after surgery (128·7 [SD 19·9] in the open surgery group vs 130·0 [19·8] in the minimally invasive surgery group) or 3 months after surgery (132·0 [21·7] vs 133·0 [22·1]). ","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Frumovitz', 'Affiliation': 'Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mfrumovitz@mdanderson.org.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Obermair', 'Affiliation': 'Queensland Centre for Gynaecological Cancer Research, The University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Coleman', 'Affiliation': 'Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Rene', 'Initials': 'R', 'LastName': 'Pareja', 'Affiliation': 'Instituto Nacional de Cancerología, Bogotá, Colombia; Clínica de Oncología Astorga, Medellín, Colombia.'}, {'ForeName': 'Aldo', 'Initials': 'A', 'LastName': 'Lopez', 'Affiliation': 'Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.'}, {'ForeName': 'Reitan', 'Initials': 'R', 'LastName': 'Ribero', 'Affiliation': 'Erasto Gaertner Hospital, Curitiba, Brazil.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Isla', 'Affiliation': 'Instituto Nacional de Cancerología, Mexico City, Mexico.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Rendon', 'Affiliation': 'Instituto de Cancerologia-Las Americas, Medellín, Colombia.'}, {'ForeName': 'Marcus Q', 'Initials': 'MQ', 'LastName': 'Bernardini', 'Affiliation': 'Princess Margaret Cancer Center, Toronto, ON, Canada.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Buda', 'Affiliation': 'San Gerardo Hospital, Monza, Italy.'}, {'ForeName': 'Renato', 'Initials': 'R', 'LastName': 'Moretti-Marquez', 'Affiliation': 'Hospital Israelita Albert Einstein, Centro de Oncologia e Hematologia, São Paulo, Brazil.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Zevallos', 'Affiliation': 'Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.'}, {'ForeName': 'Marcelo A', 'Initials': 'MA', 'LastName': 'Vieira', 'Affiliation': 'Barretos Cancer Hospital, São Paulo, Brazil.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Zhu', 'Affiliation': 'Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Hangzhou, China.'}, {'ForeName': 'Russell P', 'Initials': 'RP', 'LastName': 'Land', 'Affiliation': 'School of Medicine, The University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Nicklin', 'Affiliation': 'School of Medicine, The University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Asher', 'Affiliation': 'National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Kristy P', 'Initials': 'KP', 'LastName': 'Robledo', 'Affiliation': 'National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Val', 'Initials': 'V', 'LastName': 'Gebski', 'Affiliation': 'National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Pedro T', 'Initials': 'PT', 'LastName': 'Ramirez', 'Affiliation': 'Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30081-4'] 1387,32502564,What Is the Impact of Engaging With Natural Environments Delivered Via Virtual Reality on the Psycho-emotional Health of People With Spinal Cord Injury Receiving Rehabilitation in Hospital? Findings From a Pilot Randomized Controlled Trial.,"OBJECTIVES This study investigated (1) the effect of engaging with 20-minute simulated natural environments delivered via virtual reality (VR) on current mood state and (2) the effect of engaging with multiple VR sessions over a period of a week on the depressive symptoms of people with a spinal cord injury (SCI). DESIGN Randomized controlled trial design. SETTING Spinal Cord Injury Rehabilitation Unit in Australia. PARTICIPANTS Participants (N=24) were assigned to a group engaging in VR sessions during week 1 (group 1, n=10) or week 2 (group 2, n=14). INTERVENTIONS The intervention week involved participation in up to three 20-minute VR sessions over 3 consecutive days. The control condition involved regular rehabilitation practice over a week. MAIN OUTCOME MEASURES The Patient Health Questionnaire-8 (PHQ-8) was completed prior to the first week (T1), after the first week and prior to the second week (T2), and after the second week (T3). Current feeling states, including depressed/happy, anxious/relaxed, and not feeling good/feeling good, were rated immediately prior and after each VR session. RESULTS Levels of happiness, relaxation, and feeling good were significantly higher subsequent to engaging with each VR session. Between-group differences in PHQ-8 scores were significantly greater for participants who experienced the intervention during the first week compared to participants within the control group: intervention participants had significant improvements in psycho-emotional health. Within-group PHQ-8 scores were reduced for each group subsequent to experiencing the intervention; however, differences were not significant. CONCLUSIONS Engaging with simulated natural environments delivered via VR can favorably affect the psycho-emotional health of people with SCI receiving rehabilitation in hospital. Future research including larger samples and investigating the effect over a longer time period is required to confirm the findings presented.",2020,"Within-group PHQ-8 scores reduced for each group subsequent to experiencing the intervention, however differences were not significant. ","['people with SCI receiving rehabilitation in hospital', 'Spinal Cord Injury Rehabilitation Unit in Australia', 'Participants (n=24', 'people with spinal cord injury receiving rehabilitation in hospital']","['engaging with 20 minute simulated natural environments delivered via virtual reality (VR', 'group engaging in VR sessions', 'natural environments delivered via virtual reality', 'engaging with multiple VR sessions']","['Levels of happiness, relaxation, and feeling good', 'psycho-emotional health', 'Patient Health Questionnaire-8 (PHQ-8', 'PHQ-8 scores']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0204101', 'cui_str': 'Spinal cord injury rehabilitation'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}]","[{'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0557745', 'cui_str': 'Natural environment'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",24.0,0.0262716,"Within-group PHQ-8 scores reduced for each group subsequent to experiencing the intervention, however differences were not significant. ","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Lakhani', 'Affiliation': 'School of Psychology and Public Health, La Trobe University, Melbourne, Victoria; Hopkins Centre, Menzies Health Institute Queensland, Griffith University, Meadowbrook, Queensland. Electronic address: a.lakhani@latrobe.edu.au.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Martin', 'Affiliation': 'Hopkins Centre, Menzies Health Institute Queensland, Griffith University, Meadowbrook, Queensland; Occupational Therapy Department, PA Hospital, Metro South Health Division of Rehabilitation, Woolloongabba, Queensland.'}, {'ForeName': 'Lyndal', 'Initials': 'L', 'LastName': 'Gray', 'Affiliation': 'Occupational Therapy Department, PA Hospital, Metro South Health Division of Rehabilitation, Woolloongabba, Queensland.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Mallison', 'Affiliation': 'Western Sydney University, Penrith, New South Wales.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Grimbeek', 'Affiliation': 'Upper Brookfield, Brisbane, Queensland.'}, {'ForeName': 'Izak', 'Initials': 'I', 'LastName': 'Hollins', 'Affiliation': 'Hopkins Centre, Menzies Health Institute Queensland, Griffith University, Meadowbrook, Queensland.'}, {'ForeName': 'Col', 'Initials': 'C', 'LastName': 'Mackareth', 'Affiliation': 'Spinal Life Australia, Woolloongabba, Queensland, Australia.'}]",Archives of physical medicine and rehabilitation,['10.1016/j.apmr.2020.05.013'] 1388,31353364,Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma.,"Talimogene laherparepvec (T-VEC) has demonstrated efficacy for unresectable melanoma. We explored response patterns from a phase 2 study evaluating patients with unresectable stage IIIB-IVM1c malignant melanoma who received T-VEC plus ipilimumab or ipilimumab alone. Patients with objective response per modified irRC were evaluated for pseudo-progression (single ≥25% increase in tumour burden before response). Patients without pseudo-progression were classified by whether they responded within or after 6 months of treatment start; those with pseudo-progression were classified by whether pseudo-progression was due to increase in existing lesions or development of new lesions. Overall, 39% (n = 38/98) in the combination arm and 18% (n = 18/100) in the ipilimumab arm had an objective response. Eight responders (combination, n = 7 [18.4%]; ipilimumab, n = 1 [5.6%]) had pseudo-progression; most occurred by week 12 and were caused by an increase in existing lesions. These data reinforce use of T-VEC through initial progression when combined with checkpoint inhibitors.Trial Registration NCT01740297 (ClinicalTrials.gov; date of registration, December 4, 2012); 2012-000307-32 (ClinicalTrialsRegister.eu; date of registration, May 13, 2014).",2019,Patients with objective response per modified irRC were evaluated for pseudo-progression (single ≥25% increase in tumour burden before response).,"['metastatic unresectable melanoma', 'patients with unresectable stage IIIB-IVM1c malignant melanoma who received']","['ipilimumab or ipilimumab alone', 'Talimogene laherparepvec (T-VEC', 'T-VEC plus ipilimumab or ipilimumab alone']","['objective response', 'pseudo-progression']","[{'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0456599', 'cui_str': 'Stage 3B'}]","[{'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C1831828', 'cui_str': 'talimogene laherparepvec'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0205237', 'cui_str': 'False'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}]",,0.159882,Patients with objective response per modified irRC were evaluated for pseudo-progression (single ≥25% increase in tumour burden before response).,"[{'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Chesney', 'Affiliation': 'James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA. jason.chesney@louisville.edu.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Puzanov', 'Affiliation': 'Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Collichio', 'Affiliation': 'The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Mohammed M', 'Initials': 'MM', 'LastName': 'Milhem', 'Affiliation': 'University of Iowa Hospitals and Clinics, Iowa City, IA, USA.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Hauschild', 'Affiliation': 'University of Kiel, Kiel, Germany.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Anjali', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Garbe', 'Affiliation': 'University Hospital Tübingen, Tübingen, Germany.'}, {'ForeName': 'Parminder', 'Initials': 'P', 'LastName': 'Singh', 'Affiliation': 'Mayo Clinic, Phoenix, AZ, USA.'}, {'ForeName': 'Janice M', 'Initials': 'JM', 'LastName': 'Mehnert', 'Affiliation': 'Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.'}]",British journal of cancer,['10.1038/s41416-019-0530-6'] 1389,32506744,Altered activation in sensorimotor network after applying rTMS over the primary motor cortex at different frequencies.,"INTRODUCTION Repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex (M1) can modulate brain activity both in the stimulated site and remote brain areas of the sensorimotor network. However, the modulatory effects of rTMS at different frequencies remain unclear. Here, we employed finger-tapping task-based fMRI to investigate alterations in activation of the sensorimotor network after the application of rTMS over the left M1 at different frequencies. MATERIALS AND METHODS Forty-five right-handed healthy participants were randomly divided into three groups by rTMS frequency (HF, high-frequency, 3 Hz; LF, low-frequency, 1 Hz; and SHAM) and underwent two task-fMRI sessions (RH, finger-tapping with right index finger; LH, finger-tapping with left index finger) before and after applying rTMS over the left M1. We defined regions of interest (ROIs) in the sensorimotor network based on group-level activation maps (pre-rTMS) from RH and LH tasks and calculated the percentage signal change (PSC) for each ROI. We then assessed the differences of PSC within HF or LF groups and between groups. RESULTS Application of rTMS at different frequencies resulted in a change in activation of several areas of the sensorimotor network. We observed the increased PSC in M1 after high-frequency stimulation, while we detected the reduced PSC in the primary sensory cortex (S1), ventral premotor cortex (PMv), supplementary motor cortex (SMA), and putamen after low-frequency stimulation. Moreover, the PSC in the SMA, dorsal premotor cortex (PMd), and putamen in the HF group was higher than in the LF group after stimulation. CONCLUSION Our findings suggested that activation alterations within sensorimotor network are dependent on the frequency of rTMS. Therefore, our findings contribute to understanding the effects of rTMS on brain activation in healthy individuals and ultimately may further help to suggest mechanisms of how rTMS could be employed as a therapeutic tool.",2020,"Moreover, the PSC in the SMA, dorsal premotor cortex (PMd), and putamen in the HF group was higher than in the LF group after stimulation. ","['Forty-five right-handed healthy participants', 'healthy individuals']","['rTMS', 'Repetitive transcranial magnetic stimulation (rTMS', 'rTMS frequency (HF, high-frequency, 3\xa0Hz; LF, low-frequency, 1\xa0Hz; and SHAM) and underwent two task-fMRI sessions (RH, finger-tapping with right index finger; LH, finger-tapping with left index finger']","['SMA, dorsal premotor cortex (PMd), and putamen', 'primary sensory cortex (S1), ventral premotor cortex (PMv), supplementary motor cortex (SMA), and putamen after low-frequency stimulation']","[{'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0230370', 'cui_str': 'Structure of right hand'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0205213', 'cui_str': 'Low frequency'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0016129', 'cui_str': 'Digit of hand structure'}, {'cui': 'C0034115', 'cui_str': 'Centesis'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0230388', 'cui_str': 'Index finger structure'}]","[{'cui': 'C3496174', 'cui_str': 'Supplementary Motor Area'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0228202', 'cui_str': 'Premotor cortex'}, {'cui': 'C0037658', 'cui_str': 'Somatosensory Cortex'}, {'cui': 'C1704448', 'cui_str': 'Ventral'}, {'cui': 'C0205213', 'cui_str': 'Low frequency'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]",45.0,0.0177725,"Moreover, the PSC in the SMA, dorsal premotor cortex (PMd), and putamen in the HF group was higher than in the LF group after stimulation. ","[{'ForeName': 'Xiaoyu', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Institute of Psychological Sciences, Hangzhou Normal University, Hangzhou, China.'}, {'ForeName': 'Lingyu', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Institute of Psychological Sciences, Hangzhou Normal University, Hangzhou, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wei', 'Affiliation': 'Institute of Psychological Sciences, Hangzhou Normal University, Hangzhou, China.'}, {'ForeName': 'Tingting', 'Initials': 'T', 'LastName': 'Zhu', 'Affiliation': 'Institute of Psychological Sciences, Hangzhou Normal University, Hangzhou, China.'}, {'ForeName': 'Guo-Feng', 'Initials': 'GF', 'LastName': 'Huang', 'Affiliation': 'School of Information and Electronics Technology, Jiamusi University, Jiamusi, China.'}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'School of Information and Electronics Technology, Jiamusi University, Jiamusi, China.'}, {'ForeName': 'Hui-Bin', 'Initials': 'HB', 'LastName': 'Ma', 'Affiliation': 'School of Information and Electronics Technology, Jiamusi University, Jiamusi, China.'}, {'ForeName': 'Yating', 'Initials': 'Y', 'LastName': 'Lv', 'Affiliation': 'Institute of Psychological Sciences, Hangzhou Normal University, Hangzhou, China.'}]",Brain and behavior,['10.1002/brb3.1670'] 1390,32507157,Influence of the order of aerobic and resistance exercise on hemodynamic responses and arterial stiffness in young normotensive individuals.,"AIMS To investigate the effects of a combination of aerobic and resistance exercises and the inverse sequence on the hemodynamic parameters and indicators of arterial stiffness in healthy young adult subjects. METHODS Fifteen subjects were randomized in a crossover procedure according to two experimental conditions: combined aerobic exercise (30 min of treadmill running, 75-80% - peak VO 2 ) followed by resistance exercise (5 exercises, 3 sets - 10 RM) (AR) or vice versa (RA). Data of the hemodynamic parameters and arterial stiffness were obtained at baseline and after exercise (post-10, post-20, and post-30 min). Two-way ANOVA for repeated measurements was performed with the Newman-Keuls post-hoc. The significance level adopted was p < 0.05. RESULTS The results of the two-way ANOVA for repeated measures were not statistically significant for brachial and central systolic and diastolic blood pressure, respectively, or arterial stiffness indicators: reflected wave indicators and pulse wave velocity (P > 0.05). Statistically significant interactions were observed before and after the exercise sessions for heart rate and rate pressure product (P = < 0.001). CONCLUSION The performance order of aerobic exercise followed by resistance exercise (AR) and the reverse order (RA) present similar changes in blood pressure (BP) and arterial stiffness. However, resistance exercise before aerobic exercise promotes increases in heart rate and rate product pressure.",2020,"Statistically significant interactions were observed before and after the exercise sessions for heart rate and rate pressure product (P = < 0.001). ","['healthy young adult subjects', 'young normotensive individuals', 'Fifteen subjects']","['combined aerobic exercise (30\u202fmin of treadmill running, 75-80% - peak VO 2 ) followed by resistance exercise (5 exercises, 3 sets - 10 RM) (AR) or vice versa (RA', 'aerobic and resistance exercises', 'aerobic exercise followed by resistance exercise (AR) and the reverse order (RA', 'aerobic and resistance exercise']","['blood pressure (BP) and arterial stiffness', 'heart rate and rate product pressure', 'hemodynamic responses and arterial stiffness', 'brachial and central systolic and diastolic blood pressure', 'heart rate and rate pressure product']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C2712122', 'cui_str': 'Normal blood pressure'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C4284072', 'cui_str': 'Order document'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}]",15.0,0.0449737,"Statistically significant interactions were observed before and after the exercise sessions for heart rate and rate pressure product (P = < 0.001). ","[{'ForeName': 'Wagner Jorge Ribeiro', 'Initials': 'WJR', 'LastName': 'Domingues', 'Affiliation': 'Federal University of Amazonas, Institute of Social Sciences, Education and Animal Science, Parintins Macurany Road, 1805, Parintins, Amazonas, 69152-240, Brazil. Electronic address: wjrdomingues@ufam.edu.br.'}, {'ForeName': 'Antonio Henrique', 'Initials': 'AH', 'LastName': 'Germano-Soares', 'Affiliation': 'Associated Graduate Program in Physical Education UPE/UFPB, University of Pernambuco, Brazil. Electronic address: henrique_soares1991@hotmail.com.'}, {'ForeName': 'Bruno Remígio', 'Initials': 'BR', 'LastName': 'Cavalcante', 'Affiliation': 'Associated Graduate Program in Physical Education UPE/UFPB, University of Pernambuco, Brazil. Electronic address: br_13remigio@outlook.com.'}, {'ForeName': 'Rinaldo Ramos', 'Initials': 'RR', 'LastName': 'Matias da Silva', 'Affiliation': 'Nove de Julho University - UNINOVE, Sao Paulo, Brazil. Electronic address: rinaldo.ramos@outlook.com.'}, {'ForeName': 'Pollyana Mayara', 'Initials': 'PM', 'LastName': 'Nunhes', 'Affiliation': 'State University of Maringa - UEM, Maringa, Brazil. Electronic address: polly_nunhes@hotmail.com.'}, {'ForeName': 'Gustavo Marçal', 'Initials': 'GM', 'LastName': 'Gonçalves da Silva', 'Affiliation': 'University Institute of Maia - ISMAI, Porto, Portugal. Electronic address: gugonsilva@gmail.com.'}, {'ForeName': 'Ewertton', 'Initials': 'E', 'LastName': 'Bezerra', 'Affiliation': 'Faculty of Physical Education and Physiotherapy, Federal University of Amazonas, Manaus, Amazonas, Brazil. Electronic address: ewsbezerra@yahoo.com.br.'}, {'ForeName': 'Nórton Luís', 'Initials': 'NL', 'LastName': 'Oliveira', 'Affiliation': 'Faculty of Sport, University of Porto, Portugal. Electronic address: nloedfisica@gmail.com.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Oliveira', 'Affiliation': 'Faculty of Sport, University of Porto, Porto, Portugal. Electronic address: joliveira@fade.up.pt.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2019.09.005'] 1391,32507159,Impact of hippotherapy for balance improvement and flexibility in elderly people.,"INTRODUCTION The decrease in functional ability, strength, balance, flexibility, agility, and coordination owing to neurological and muscular changes is one of the characteristic features of the human aging process. Hippotherapy has been highlighted as a therapeutic approach with physical and psychological benefits for this section of the population. However, the effects of hippotherapy in elderly people need to be further studied by assessing their balance and flexibility. METHODS Thirty elderly people were recruited and divided into two groups; 15 in the Hippotherapy Group (HG), and 15 in the control group (CG) (aged 66.07 ± 5.80 and 68.47 ± 5.85 years, respectively). The HG received ten 30-min sessions of hippotherapy once a week. Assessment included the Berg Balance Scale (BBS), the Timed Up and Go test (TUG), the Functional Reach Test (FRT)and the Sit-and-Reach Test with the Well's box before the first and after the tenth session of hippotherapy; and the Sit-and-Reach Test before and after each session. RESULTS The HG demonstrated a significant difference in the TUG test execution time and the FRT scores before and after the hippotherapy sessions (p = 0.036, p = 0.030, respectively), indicating an improvement in functional range. The examination of flexibility with the Wells's box also revealed a significant difference in the rates (cm) before and after 10 sessions of the hippotherapy for the HG (p = 0.033). CONCLUSIONS The present findings showthat hippotherapy improved elderly people's functional mobility, dynamic balance, and flexibility. These results will guide professionals who treat this population.",2020,"The HG demonstrated a significant difference in the TUG test execution time and the FRT scores before and after the hippotherapy sessions (p = 0.036, p = 0.030, respectively), indicating an improvement in functional range.","['Thirty elderly people were recruited and divided into two groups; 15 in the Hippotherapy Group (HG), and 15 in the control group (CG) (aged 66.07\u202f±\u202f5.80 and 68.47\u202f±\u202f5.85 years, respectively', 'elderly people']","['Hippotherapy', 'hippotherapy']","['functional range', 'TUG test execution time and the FRT scores', 'functional ability, strength, balance, flexibility, agility, and coordination owing to neurological and muscular changes', ""Berg Balance Scale (BBS), the Timed Up and Go test (TUG), the Functional Reach Test (FRT)and the Sit-and-Reach Test with the Well's box"", ""elderly people's functional mobility, dynamic balance, and flexibility""]","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0454416', 'cui_str': 'Hippotherapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0454416', 'cui_str': 'Hippotherapy'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1278561', 'cui_str': 'Judicial execution'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1998271', 'cui_str': 'Functional reach test'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C1321055', 'cui_str': 'Functional reach'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0006080', 'cui_str': 'Boxing'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}]",30.0,0.0177894,"The HG demonstrated a significant difference in the TUG test execution time and the FRT scores before and after the hippotherapy sessions (p = 0.036, p = 0.030, respectively), indicating an improvement in functional range.","[{'ForeName': 'Luanna Honorato', 'Initials': 'LH', 'LastName': 'Diniz', 'Affiliation': 'Concentration Area Human Pathology - Universidade Federal do TriânguloMineiro - UFTM, Uberaba, Minas Gerais, Brazil. Electronic address: luannahd@hotmail.com.'}, {'ForeName': 'Edneia Corrêa', 'Initials': 'EC', 'LastName': 'de Mello', 'Affiliation': 'Concentration Area Human Pathology - Universidade Federal do TriânguloMineiro - UFTM, Uberaba, Minas Gerais, Brazil. Electronic address: edneia.mello38@gmail.com.'}, {'ForeName': 'Mariane Fernandes', 'Initials': 'MF', 'LastName': 'Ribeiro', 'Affiliation': 'Concentration Area Human Pathology - Universidade Federal do TriânguloMineiro - UFTM, PhysicalTherapistat Associação de Pais e Amigos dos Excepcionais de Uberaba - APAE, Uberaba, Minas Gerais, Brazil. Electronic address: maryanefernandes@yahoo.com.br.'}, {'ForeName': 'Janaine Brandão', 'Initials': 'JB', 'LastName': 'Lage', 'Affiliation': 'Concentration Area Human Pathology - Universidade Federal do TriânguloMineiro - UFTM, PhysicalTherapistat Associação de Pais e Amigos dos Excepcionais de Uberaba - APAE, Uberaba, Minas Gerais, Brazil. Electronic address: ja.bl@terra.com.br.'}, {'ForeName': 'Domingos Emanuel', 'Initials': 'DE', 'LastName': 'Bevilacqua Júnior', 'Affiliation': 'Concentration Area Human Pathology - Universidade Federal do TriânguloMineiro - UFTM, PhysicalTherapistat Associação de Pais e Amigos dos Excepcionais de Uberaba - APAE, Uberaba, Minas Gerais, Brazil. Electronic address: domingos_fisio@hotmail.com.'}, {'ForeName': 'Alex Abadio', 'Initials': 'AA', 'LastName': 'Ferreira', 'Affiliation': 'Associação de Pais e Amigos dos Excepcionais de Uberaba - APAE, Uberaba, Minas Gerais, Brazil. Electronic address: alexabferreira@hotmail.com.'}, {'ForeName': 'Mara Lúcia da Fonseca', 'Initials': 'MLDF', 'LastName': 'Ferraz', 'Affiliation': 'Concentration Area General Pathology, Biologist and Lecturer at Universidade Federal do TriânguloMineiro - UFTM, Uberaba, Minas Gerais, Brazil. Electronic address: mara@patge.uftm.edu.br.'}, {'ForeName': 'Rodrigo César', 'Initials': 'RC', 'LastName': 'Rosa', 'Affiliation': 'Senior Lecturer of the Discipline of Human Anatomy -Universidade Federal do TriânguloMineiro - UFTM, Uberaba, Minas Gerais, Brazil. Electronic address: rodrigo.rosa@uftm.edu.br.'}, {'ForeName': 'Vicente de Paula Antunes', 'Initials': 'VPA', 'LastName': 'Teixeira', 'Affiliation': 'Concentration Area General Pathology, Senior Lecturer of the Discipline of General Pathology - Universidade Federal do TriânguloMineiro - UFTM, Uberaba, Minas Gerais, Brazil. Electronic address: vicenteantunes54@gmail.com.'}, {'ForeName': 'Ana Paula', 'Initials': 'AP', 'LastName': 'Espindula', 'Affiliation': 'Concentration Area Human Pathology e Post Doctorate Student and Lecturer at Universidade Federal do TriânguloMineiro - UFTM, Uberaba, Minas Gerais, Brazil. Electronic address: anapaulaespindula@yahoo.com.br.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2019.10.002'] 1392,32507160,"The effect of aerobic and resistance exercise training on the health related quality of life, physical function, and muscle strength among hemodialysis patients with Type 2 diabetes.","INTRODUCTION Diabetic patients who undergo hemodialysis commonly suffer from reduction of both exercise capacity and muscle strength. These factors may have a negative effect on health related quality of life (HRQoL) and physical function. We investigated the effect of aerobic and resistance exercise training on the HRQoL, physical function, and muscle strength among hemodialysis patients with Type 2 diabetes. METHODS Twenty-eight diabetic patients who were on hemodialysis in the Milad Hospital (Tehran, Iran) were recruited for the study. Subjects were randomized into control (n = 13) and exercise training groups (n = 15). The exercise training group performed combined aerobic and resistance exercise training at moderate intensity (11-15/20 on the Borg scale) during hemodialysis treatment, 3 times a week for 8 weeks. The primary outcomes consisted of physical function measured by a 6-min walk test (6MWT), HR-QoL measured by the Short Form Health Survey (SF-36), and lower limb muscle strength measured using a hand-held Digital Dynamometer. RESULTS The 6MWT distance increased significantly in the exercise training group (36%). Bilateral hip flexor strength (right, 24.5%; left, 30.4%) and abductor strength (right, 27.6%; left, 25.2%) decreased significantly in the non-exercising control group but no significant change was found in the exercise group (P > 0.05). There were no significant changes in any of the 8 generic subscales of HR-QoL neither in the exercise training group nor controls following an 8- week study. CONCLUSIONS 8 weeks of combined aerobic-resistance exercise training among diabetic hemodialysis patients seem to be effective in improvement of physical function and lower limb muscle strength.",2020,"There were no significant changes in any of the 8 generic subscales of HR-QoL neither in the exercise training group nor controls following an 8- week study. ","['Diabetic patients who undergo hemodialysis commonly suffer from reduction of both exercise capacity and muscle strength', 'hemodialysis patients with Type 2 diabetes', 'diabetic hemodialysis patients', 'Twenty-eight diabetic patients who were on hemodialysis in the Milad Hospital (Tehran, Iran) were recruited for the study']","['exercise training', 'combined aerobic-resistance exercise training', 'aerobic and resistance exercise training', 'exercise training group performed combined aerobic and resistance exercise training']","['6MWT distance', 'physical function measured by a 6-min walk test (6MWT), HR-QoL measured by the Short Form Health Survey (SF-36), and lower limb muscle strength measured using a hand-held Digital Dynamometer', 'abductor strength', 'Bilateral hip flexor strength', 'generic subscales of HR-QoL', 'physical function and lower limb muscle strength', 'HRQoL, physical function, and muscle strength', 'health related quality of life, physical function, and muscle strength']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0675390', 'cui_str': 'ARID1A protein, human'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0180572', 'cui_str': 'Dynamometer'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}]",28.0,0.011937,"There were no significant changes in any of the 8 generic subscales of HR-QoL neither in the exercise training group nor controls following an 8- week study. ","[{'ForeName': 'Boshra', 'Initials': 'B', 'LastName': 'Jamshidpour', 'Affiliation': 'Department of Physiotherapy, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.'}, {'ForeName': 'Farid', 'Initials': 'F', 'LastName': 'Bahrpeyma', 'Affiliation': 'Department of Physiotherapy, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Electronic address: bahrpeyf@modares.ac.ir.'}, {'ForeName': 'Mohammad-Reza', 'Initials': 'MR', 'LastName': 'Khatami', 'Affiliation': 'Nephrology Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2019.10.003'] 1393,32508183,"App-based supplemental exercise in rehabilitation, adherence, and effect on outcomes: a randomized controlled trial.","QUESTION To determine the uptake of an app-based supplemental exercise programme in a rehabilitation setting and the effect of such a programme on length of stay and function compared to usual care physiotherapy. DESIGN Randomized controlled trial with random allocation and assessor blinding. PARTICIPANTS A total of 144 individuals with mixed diagnoses (orthopaedic, neurological, reconditioning) admitted for inpatient sub-acute rehabilitation. INTERVENTIONS Participants were randomly allocated to usual care physiotherapy (control group) or usual care physiotherapy with the addition of an app-based supplemental exercise programme (intervention group). OUTCOME MEASURES The primary measure of interest was total supplementary exercise dosage completed by the intervention group. The primary between-group outcome measure was length of stay with secondary measures including walking endurance (Six-Minute Walk Test), walking speed (10-Metre Walk Test), functional mobility (Timed Up and Go Test) and level of disability (Functional Independence Measure). RESULTS Participants in the intervention group performed 7 minutes (SD: 9) or 49 repetitions (SD: 48) of supplementary exercise using the app each day. There were no differences between the groups for length of stay (mean difference (MD): -0.5 days, 95% confidence interval (CI): -3.2 to 2.2) or change in any secondary functional outcome measures, including walking speed (MD: -0.1 m/s, 95% CI: -0.2 to 0.0) and disability (MD: -0.9, 95% CI: -3.6 to 1.8). CONCLUSION A small supplementary exercise dose was achieved by participants in the intervention group. However, such a programme did not affect length of stay or functional outcomes when compared to usual care.",2020,"There were no differences between the groups for length of stay (mean difference (MD): -0.5 days, 95% confidence interval (CI): -3.2 to 2.2) or change in any secondary functional outcome measures, including walking speed (MD: -0.1 m/s, 95% CI: -0.2 to 0.0) and disability (MD: -0.9, 95% CI: -3.6 to 1.8). ","['A total of 144 individuals with mixed diagnoses (orthopaedic, neurological, reconditioning) admitted for inpatient sub-acute rehabilitation']","['usual care physiotherapy (control group) or usual care physiotherapy with the addition of an app-based supplemental exercise programme (intervention group', 'app-based supplemental exercise programme', 'App-based supplemental exercise']","['length of stay or functional outcomes', 'disability', 'length of stay', 'length of stay and function', 'walking speed', 'length of stay with secondary measures including walking endurance (Six-Minute Walk Test), walking speed (10-Metre Walk Test), functional mobility (Timed Up and Go Test) and level of disability (Functional Independence Measure']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}]","[{'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0475209', 'cui_str': 'meter'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0451172', 'cui_str': 'Functional independence measure'}]",144.0,0.122362,"There were no differences between the groups for length of stay (mean difference (MD): -0.5 days, 95% confidence interval (CI): -3.2 to 2.2) or change in any secondary functional outcome measures, including walking speed (MD: -0.1 m/s, 95% CI: -0.2 to 0.0) and disability (MD: -0.9, 95% CI: -3.6 to 1.8). ","[{'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Li', 'Affiliation': 'Department of Health Professions, Macquarie University, Sydney, NSW, Australia.'}, {'ForeName': 'Tram', 'Initials': 'T', 'LastName': 'Bui', 'Affiliation': 'Royal Rehab, Sydney, NSW, Australia.'}, {'ForeName': 'Hoang T', 'Initials': 'HT', 'LastName': 'Phan', 'Affiliation': 'Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Llado', 'Affiliation': 'Royal Rehab, Sydney, NSW, Australia.'}, {'ForeName': 'Clayton', 'Initials': 'C', 'LastName': 'King', 'Affiliation': 'Royal Rehab, Sydney, NSW, Australia.'}, {'ForeName': 'Katharine', 'Initials': 'K', 'LastName': 'Scrivener', 'Affiliation': 'Department of Health Professions, Macquarie University, Sydney, NSW, Australia.'}]",Clinical rehabilitation,['10.1177/0269215520928119'] 1394,32505866,"Compared to Facebook, Instagram use causes more appearance comparison and lower body satisfaction in college women.","The current experiment tested the effect of social media use on college women's appearance comparisons, mood, and body satisfaction. We randomly assigned 308 undergraduate women (aged 18-26) to use Facebook, use Instagram, or play a matching game (the control condition) on an iPad for seven minutes. Compared to the Facebook condition, Instagram users retrospectively reported spending more time viewing images or videos containing people. Participants in both the Facebook and Instagram conditions also retrospectively reported engaging in more appearance comparisons relative to those in the control condition, but Instagram users reported significantly more appearance comparisons than those in the Facebook condition. Those who used Instagram, but not Facebook, showed decreased body satisfaction, decreased positive affect, and increased negative affect. Results are consistent with previous research suggesting social media use influences body satisfaction and social comparison, and that Instagram may be a particularly harmful platform when it comes to body image because of its focus on photos over text.",2020,"Those who used Instagram, but not Facebook, showed decreased body satisfaction, decreased positive affect, and increased negative affect.","[""college women's"", '308 undergraduate women (aged 18-26) to use', 'college women']","['Facebook, use Instagram, or play a matching game (the control condition']","['body satisfaction', 'appearance comparisons, mood, and body satisfaction']","[{'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0026516', 'cui_str': 'Mood'}]",308.0,0.0383295,"Those who used Instagram, but not Facebook, showed decreased body satisfaction, decreased positive affect, and increased negative affect.","[{'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Engeln', 'Affiliation': 'Department of Psychology, Northwestern University, United States. Electronic address: rengeln@northwestern.edu.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Loach', 'Affiliation': 'Department of Psychology, Northwestern University, United States.'}, {'ForeName': 'Megan N', 'Initials': 'MN', 'LastName': 'Imundo', 'Affiliation': 'Department of Psychology, University of California, Los Angeles, United States.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Zola', 'Affiliation': 'Oxford Internet Institute, University of Oxford, United Kingdom.'}]",Body image,['10.1016/j.bodyim.2020.04.007'] 1395,32511900,Effects of Vitamin D on Apoptosis and Quality of Sperm in Asthenozoospermia.,"OBJECTIVE Vitamin D receptor (VDR) is expressed in human spermatozoa. However, the role of vitamin D (VD) in human male reproduction has not yet been clarified. In this study, effects of VD on sperm parameters and its apoptosis in asthenozoospermic and healthy men were evaluated. METHODS The study was carried out on discharged semen samples of 80 asthenozoospermic and healthy men. The samples were divided into control and experimental groups (received 20 µMol of VD). This study assessed sperm motility using the Makler chamber, their morphology by Diff quick, apoptosis and necrosis by Annexin-V and TUNEL assays, and their chromatin integrity was assessed by Aniline blue and Toluidine blue staining, according to WHO guidelines. RESULTS The results revealed that: 1) the total number of motile sperms was increased by VD in both groups, but it was only significant in the asthenozoospermia group. 2) The progressive motility was increased with significant difference in both groups.3) Morphology of sperm did not show any changes due to VD in any of the groups. 4) Early apoptosis and necrosis of sperms were reduced in both groups, but the results of late apoptosis showed no statistical difference in these groups. 5) The percentage of positive toluidine blue was significantly decreased after using VD in the asthenozoospermia group. CONCLUSION VD could improve motility, early apoptosis, and sperm necrosis, especially in asthenozoospermic men and it could be used for therapeutic opportunities.",2020,"Early apoptosis and necrosis of sperms were reduced in both groups, but the results of late apoptosis showed no statistical difference in these groups.","['asthenozoospermic and healthy men', 'discharged semen samples of 80 asthenozoospermic and healthy men']","['Vitamin D receptor (VDR', 'Vitamin D', 'vitamin D (VD']","['percentage of positive toluidine blue', 'progressive motility', 'motility, early apoptosis, and sperm necrosis', 'Early apoptosis and necrosis of sperms', 'total number of motile sperms', 'Apoptosis and Quality of Sperm in Asthenozoospermia']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0444176', 'cui_str': 'Seminal fluid specimen'}]","[{'cui': 'C0108082', 'cui_str': 'Vitamin D3 Receptor'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0040380', 'cui_str': 'Tolonium chloride'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0007608', 'cui_str': 'Motility, Cell'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0162638', 'cui_str': 'Apoptosis'}, {'cui': 'C0037868', 'cui_str': 'Spermatozoa'}, {'cui': 'C0027540', 'cui_str': 'Necrosis'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0577264', 'cui_str': 'Sperm motile'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0403823', 'cui_str': 'Asthenospermia'}]",,0.0152186,"Early apoptosis and necrosis of sperms were reduced in both groups, but the results of late apoptosis showed no statistical difference in these groups.","[{'ForeName': 'Mahin Taheri', 'Initials': 'MT', 'LastName': 'Moghadam', 'Affiliation': 'Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Ghazal', 'Initials': 'G', 'LastName': 'Hosseini', 'Affiliation': 'Department of Anatomical Sciences, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences,Ahvaz, Iran.'}, {'ForeName': 'Forouzan', 'Initials': 'F', 'LastName': 'Absalan', 'Affiliation': 'Department of anatomical sciences, Abadan School of Medical Sciences, Abadan, Iran.'}, {'ForeName': 'Mahmoud Hashemi', 'Initials': 'MH', 'LastName': 'Tabar', 'Affiliation': 'Department of Anatomical Sciences, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences,Ahvaz, Iran.'}, {'ForeName': 'Roshan', 'Initials': 'R', 'LastName': 'Nikbakht', 'Affiliation': 'Fertility, Infertility and Perinatology Center, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}]",JBRA assisted reproduction,['10.5935/1518-0557.20200009'] 1396,32512272,Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.,"INTRODUCTION Recently updated three-year survival data from the PACIFIC trial showed that durvalumab consolidation therapy improved OS rates versus placebo for patients with unresectable stage III non-small cell lung cancer (NSCLC) after chemoradiotherapy. Considering the impact of the high cost of durvalumab, its cost-effectiveness should be updated to see if its cost-effectiveness has changed from the US payers' perspective. METHODS A comprehensive Markov model was used to evaluate mean lifetime costs and effectiveness of first-line durvalumab consolidation therapy versus placebo for patients with unresectable stage III NSCLC imputing updated survival and quality-of-life data from the PACIFIC trial. The main endpoints include total costs, life years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). One-way, two-way, and probabilistic sensitivity analyses were conducted to access the uncertainty in the variables. We also considered durvalumab cost-effectiveness in the subgroups. RESULTS Durvalumab consolidation therapy resulted in additional 1.34 LYs and 1.01 QALYs, resulting in an ICER of $138,920 per QALY versus the placebo treatment. One-way sensitivity analysis revealed that the utility values of two treatments, body weight, and unit cost of durvalumab have the greatest influence on the result. Subgroup analyses demonstrated that durvalumab was more cost effective for patients with non-squamous-cell lung cancer, followed by 25% or greater PD-L1 expression. Probabilistic sensitivity analysis showed that the probability of durvalumab being cost-effective versus the placebo is 62.6% at a willingness-to-pay (WTP) of $150,000 per QALY CONCLUSION: Our analyses demonstrated that receiving durvalumab consolidation therapy was more cost-effective than placebo at a WTP threshold of $150,000. These results can be of use to US practitioners in the application of durvalumab and for durvalumab prescription and reimbursement policies.",2020,"Subgroup analyses demonstrated that durvalumab was more cost effective for patients with non-squamous-cell lung cancer, followed by 25% or greater PD-L1 expression.","['patients with unresectable stage III non-small cell lung cancer (NSCLC) after chemoradiotherapy', 'patients with unresectable stage III NSCLC imputing updated survival and quality-of-life data from the PACIFIC trial', 'stage III non-small-cell lung cancer']","['durvalumab consolidation therapy', 'durvalumab', 'Durvalumab vs placebo consolidation therapy after chemoradiotherapy', 'placebo']","['total costs, life years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs', 'mean lifetime costs and effectiveness', 'OS rates', 'cost effective']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278506', 'cui_str': 'Non-small cell lung cancer stage III'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C4055109', 'cui_str': 'durvalumab'}, {'cui': 'C0521530', 'cui_str': 'Lung consolidation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.0947434,"Subgroup analyses demonstrated that durvalumab was more cost effective for patients with non-squamous-cell lung cancer, followed by 25% or greater PD-L1 expression.","[{'ForeName': 'Jiaqi', 'Initials': 'J', 'LastName': 'Han', 'Affiliation': 'Department of Head and Neck Oncology and Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, PR China.'}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Tian', 'Affiliation': 'Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, PR China.'}, {'ForeName': 'Jiangping', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Department of Head and Neck Oncology and Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, PR China.'}, {'ForeName': 'Youling', 'Initials': 'Y', 'LastName': 'Gong', 'Affiliation': 'Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China. Electronic address: gongyouling@hotmail.com.'}]","Lung cancer (Amsterdam, Netherlands)",['10.1016/j.lungcan.2020.05.011'] 1397,32513581,Effects of soy isoflavones on serum lipids and lipoprotein (a) in peritoneal dialysis patients.,"BACKGROUND AND AIM Lipid abnormalities are common in peritoneal dialysis (PD) patients and no effective treatment to decrease serum lipoprotein (a) [Lp(a)] in dialysis patients is known so far. Therefore, this research was designed to investigate the effects of soy isoflavone supplement on serum lipids and Lp(a) in PD patients. METHODS & RESULTS In this randomized, double-blind, placebo-controlled trial, 40 PD patients were randomly assigned to either the isoflavone or the placebo group. The patients in the isoflavone group received 100 mg soy isoflavone daily for 8 weeks, whereas the placebo group received corresponding placebos. At baseline and the end of the 8th week, 7 mL of blood was obtained from each patient and serum triglycerides, total cholesterol, low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and Lp(a) were measured. Serum Lp(a) reduced significantly up to 10% in the isoflavone group at the end of week 8 compared to baseline (P < 0.05), and the reduction was significant in comparison with the placebo group (P < 0.05). Serum HDL-C increased significantly up to 11.5% in the isoflavone group at the end of week 8 compared to baseline (P = 0.05), and the increment was significant in comparison with the placebo group (P < 0.05). There were no significant differences between the two groups in mean changes of serum triglycerides, total cholesterol, and LDL-C. CONCLUSIONS This study indicates that daily administration of 100 mg soy isoflavones reduces serum Lp(a) and increases HDL-C concentration which are two determinants of cardiovascular disease in PD patients. CLINICALTRIALS.GOV: NCT03773029. REGISTRATION NUMBER AND DATE NCT03773029 - 2018.",2020,"There were no significant differences between the two groups in mean changes of serum triglycerides, total cholesterol, and LDL-C. ","['peritoneal dialysis (PD) patients', 'PD patients', 'peritoneal dialysis patients', '40 PD patients']","['soy isoflavone supplement', 'placebos', 'isoflavone', '100\xa0mg soy isoflavones', 'soy isoflavones', '100\xa0mg soy isoflavone', 'placebo']","['serum lipoprotein (a) [Lp(a', 'HDL-C concentration', 'mean changes of serum triglycerides, total cholesterol, and LDL-C', 'Serum Lp(a', 'serum lipids and lipoprotein (a', 'Serum HDL-C', 'serum triglycerides, total cholesterol, low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and Lp(a', 'serum Lp(a', 'serum lipids and Lp(a']","[{'cui': 'C0031139', 'cui_str': 'Peritoneal dialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4076257', 'cui_str': 'Soy isoflavone'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0022179', 'cui_str': 'Isoflavone Derivatives'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0023820', 'cui_str': 'Lipoprotein'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0542495', 'cui_str': 'Measurement of serum triglyceride level'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0428462', 'cui_str': 'Measurement of serum lipid level'}]",40.0,0.329101,"There were no significant differences between the two groups in mean changes of serum triglycerides, total cholesterol, and LDL-C. ","[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Yari', 'Affiliation': 'National Nutrition and Food Technology Research Institute, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran. Electronic address: zahrayari_nut@yahoo.com.'}, {'ForeName': 'Hadi', 'Initials': 'H', 'LastName': 'Tabibi', 'Affiliation': 'Department of Clinical Nutrition & Dietetics, National Nutrition and Food Technology Research Institute, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran. Electronic address: hadtabibi@yahoo.com.'}, {'ForeName': 'Iraj', 'Initials': 'I', 'LastName': 'Najafi', 'Affiliation': 'Department of Nephrology, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. Electronic address: NAJAFI63800@yahoo.com.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Hedayati', 'Affiliation': 'Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran. Electronic address: Hedayati@endocrine.ac.ir.'}, {'ForeName': 'Mina', 'Initials': 'M', 'LastName': 'Movahedian', 'Affiliation': 'National Nutrition and Food Technology Research Institute, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran. Electronic address: nutritionist1993@gmail.com.'}]","Nutrition, metabolism, and cardiovascular diseases : NMCD",['10.1016/j.numecd.2020.04.023'] 1398,32514060,"Commentary on ""A pragmatic randomized controlled trial testing the effects of the international scientific SCI exercise guidelines on SCI chronic pain: protocol for the EPIC-SCI trial"".",,2020,,[],['international scientific SCI exercise guidelines'],['SCI chronic pain'],[],"[{'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}]","[{'cui': 'C0150055', 'cui_str': 'Chronic pain'}]",,0.242921,,"[{'ForeName': 'Sara J', 'Initials': 'SJ', 'LastName': 'Mulroy', 'Affiliation': 'Rancho Los Amigos National Rehabilitation Center, Downey, CA, USA. smulroy@dhs.lacounty.gov.'}]",Spinal cord,['10.1038/s41393-020-0494-7'] 1399,32514590,Time to intra-arrest therapeutic hypothermia in out-of-hospital cardiac arrest patients and its association with neurologic outcome: a propensity matched sub-analysis of the PRINCESS trial.,"PURPOSE To study the association between early initiation of intra-arrest therapeutic hypothermia and neurologic outcome in out-of-hospital cardiac arrest. METHODS A prespecified sub-analysis of the PRINCESS trial (NCT01400373) that randomized 677 bystander-witnessed cardiac arrests to transnasal evaporative intra-arrest cooling initiated by emergency medical services or cooling started after hospital arrival. Early cooling (intervention) was defined as intra-arrest cooling initiated < 20 min from collapse (i.e., ≤ median time to cooling in PRINCESS). Propensity score matching established comparable control patients. Primary outcome was favorable neurologic outcome, Cerebral Performance Category (CPC) 1-2 at 90 days. Complete recovery (CPC 1) was among secondary outcomes. RESULTS In total, 300 patients were analyzed and the proportion with CPC 1-2 at 90 days was 35/150 (23.3%) in the intervention group versus 24/150 (16%) in the control group, odds ratio (OR) 1.92, 95% confidence interval (CI) 0.95-3.85, p = .07. In patients with shockable rhythm, CPC 1-2 was 29/57 (50.9%) versus 17/57 (29.8%), OR 3.25, 95%, CI 1.06-9.97, p = .04. The proportion with CPC 1 at 90 days was 31/150 (20.7%) in the intervention group and 17/150 (11.3%) in controls, OR 2.27, 95% CI 1.12-4.62, p = .02. In patients with shockable rhythms, the proportion with CPC 1 was 27/57 (47.4%) versus 12/57 (21.1%), OR 5.33, 95% CI 1.55-18.3, p = .008. CONCLUSIONS In the whole study population, intra-arrest cooling initiated < 20 min from collapse compared to cooling initiated at hospital was not associated with improved favorable neurologic outcome. In the subgroup with shockable rhythms, early cooling was associated with improved favorable outcome and complete recovery.",2020,"The proportion with CPC 1 at 90 days was 31/150 (20.7%) in the intervention group and 17/150 (11.3%) in controls, OR 2.27, 95% CI 1.12-4.62, p = .02.",[],"['677 bystander-witnessed cardiac arrests to transnasal evaporative intra-arrest cooling initiated by emergency medical services or cooling started after hospital arrival', 'Time to intra-arrest therapeutic hypothermia']","['favorable outcome and complete recovery', 'favorable neurologic outcome, Cerebral Performance Category (CPC', 'favorable neurologic outcome']",[],"[{'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0521131', 'cui_str': 'Transnasal approach'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0013961', 'cui_str': 'Emergency medical services'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0020674', 'cui_str': 'Induction of hypothermia'}]","[{'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}]",677.0,0.16917,"The proportion with CPC 1 at 90 days was 31/150 (20.7%) in the intervention group and 17/150 (11.3%) in controls, OR 2.27, 95% CI 1.12-4.62, p = .02.","[{'ForeName': 'Akil', 'Initials': 'A', 'LastName': 'Awad', 'Affiliation': 'Department of Medicine, Center for Resuscitation Science, Karolinska Institute, Solna, Sweden.'}, {'ForeName': 'Fabio Silvio', 'Initials': 'FS', 'LastName': 'Taccone', 'Affiliation': 'Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Jonsson', 'Affiliation': 'Department of Medicine, Center for Resuscitation Science, Karolinska Institute, Solna, Sweden.'}, {'ForeName': 'Sune', 'Initials': 'S', 'LastName': 'Forsberg', 'Affiliation': 'Department of Medicine, Center for Resuscitation Science, Karolinska Institute, Solna, Sweden.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Hollenberg', 'Affiliation': 'Department of Medicine, Center for Resuscitation Science, Karolinska Institute, Solna, Sweden.'}, {'ForeName': 'Anatolij', 'Initials': 'A', 'LastName': 'Truhlar', 'Affiliation': 'Emergency Medical Services of the Hradec Kralove Region, Hradec Králové, Czech Republic.'}, {'ForeName': 'Mattias', 'Initials': 'M', 'LastName': 'Ringh', 'Affiliation': 'Department of Medicine, Center for Resuscitation Science, Karolinska Institute, Solna, Sweden.'}, {'ForeName': 'Benjamin S', 'Initials': 'BS', 'LastName': 'Abella', 'Affiliation': 'The Center for Resuscitation Science and Department of Emergency Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Lance B', 'Initials': 'LB', 'LastName': 'Becker', 'Affiliation': 'Department of Emergency Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, 11030, USA.'}, {'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'Vincent', 'Affiliation': 'Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.'}, {'ForeName': 'Leif', 'Initials': 'L', 'LastName': 'Svensson', 'Affiliation': 'Department of Medicine, Center for Resuscitation Science, Karolinska Institute, Solna, Sweden.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Nordberg', 'Affiliation': 'Department of Medicine, Center for Resuscitation Science, Karolinska Institute, Solna, Sweden. per.nordberg@sll.se.'}]",Intensive care medicine,['10.1007/s00134-020-06024-3'] 1400,32235883,Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption.,"We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection as an exploratory study to determine the safety and duration of viremic control after treatment interruption. The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306).",2020,"The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306).",['26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection'],"['Ad26 and MVA vaccines', 'Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo', 'placebo']",['delayed time to viral rebound'],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0343752', 'cui_str': 'Acute HIV infection'}]","[{'cui': 'C3178367', 'cui_str': 'MVA vaccine'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0042214', 'cui_str': 'Vaccinia'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0439750', 'cui_str': 'Mosaic'}, {'cui': 'C0369498', 'cui_str': 'HIV-1 antigen'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0522486', 'cui_str': 'Delay time'}, {'cui': 'C0521026', 'cui_str': 'viruses'}]",26.0,0.159031,"The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306).","[{'ForeName': 'Donn J', 'Initials': 'DJ', 'LastName': 'Colby', 'Affiliation': 'SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.'}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Sarnecki', 'Affiliation': 'Janssen Vaccines, Bern, Switzerland.'}, {'ForeName': 'Dan H', 'Initials': 'DH', 'LastName': 'Barouch', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.'}, {'ForeName': 'Somporn', 'Initials': 'S', 'LastName': 'Tipsuk', 'Affiliation': 'SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Stieh', 'Affiliation': 'Janssen Vaccines & Prevention BV, Leiden, the Netherlands.'}, {'ForeName': 'Eugène', 'Initials': 'E', 'LastName': 'Kroon', 'Affiliation': 'SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Schuetz', 'Affiliation': 'Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.'}, {'ForeName': 'Jintana', 'Initials': 'J', 'LastName': 'Intasan', 'Affiliation': 'SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Sacdalan', 'Affiliation': 'SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.'}, {'ForeName': 'Suteeraporn', 'Initials': 'S', 'LastName': 'Pinyakorn', 'Affiliation': 'Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.'}, {'ForeName': 'Pornsuk', 'Initials': 'P', 'LastName': 'Grandin', 'Affiliation': 'Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.'}, {'ForeName': 'Hongshuo', 'Initials': 'H', 'LastName': 'Song', 'Affiliation': 'Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.'}, {'ForeName': 'Sodsai', 'Initials': 'S', 'LastName': 'Tovanabutra', 'Affiliation': 'Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.'}, {'ForeName': 'Zhanna', 'Initials': 'Z', 'LastName': 'Shubin', 'Affiliation': 'Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.'}, {'ForeName': 'Dohoon', 'Initials': 'D', 'LastName': 'Kim', 'Affiliation': 'Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.'}, {'ForeName': 'Dominic', 'Initials': 'D', 'LastName': 'Paquin-Proulx', 'Affiliation': 'Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Eller', 'Affiliation': 'Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.'}, {'ForeName': 'Rasmi', 'Initials': 'R', 'LastName': 'Thomas', 'Affiliation': 'Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'de Souza', 'Affiliation': 'SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Wieczorek', 'Affiliation': 'US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.'}, {'ForeName': 'Victoria R', 'Initials': 'VR', 'LastName': 'Polonis', 'Affiliation': 'US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.'}, {'ForeName': 'Amélie', 'Initials': 'A', 'LastName': 'Pagliuzza', 'Affiliation': 'Centre de Recherche du CHUM and Department of Microbiology, Infectiology and Immunology, Montréal, Canada.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Chomont', 'Affiliation': 'Centre de Recherche du CHUM and Department of Microbiology, Infectiology and Immunology, Montréal, Canada.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Peter', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'Nkolola', 'Affiliation': 'Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Vingerhoets', 'Affiliation': 'Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Truyers', 'Affiliation': 'Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'ForeName': 'Maria G', 'Initials': 'MG', 'LastName': 'Pau', 'Affiliation': 'Janssen Vaccines & Prevention BV, Leiden, the Netherlands.'}, {'ForeName': 'Hanneke', 'Initials': 'H', 'LastName': 'Schuitemaker', 'Affiliation': 'Janssen Vaccines & Prevention BV, Leiden, the Netherlands.'}, {'ForeName': 'Nittaya', 'Initials': 'N', 'LastName': 'Phanuphak', 'Affiliation': 'SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.'}, {'ForeName': 'Nelson', 'Initials': 'N', 'LastName': 'Michael', 'Affiliation': 'Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.'}, {'ForeName': 'Merlin L', 'Initials': 'ML', 'LastName': 'Robb', 'Affiliation': 'Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA. mrobb@hivresearch.org.'}, {'ForeName': 'Frank L', 'Initials': 'FL', 'LastName': 'Tomaka', 'Affiliation': 'Janssen Research & Development, Titusville, NJ, USA.'}, {'ForeName': 'Jintanat', 'Initials': 'J', 'LastName': 'Ananworanich', 'Affiliation': 'SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.'}]",Nature medicine,['10.1038/s41591-020-0774-y'] 1401,31026216,Why Does Prevention of Recurrent Urinary Tract Infection not Result in Less Renal Scarring? A Deeper Dive into the RIVUR Trial.,"PURPOSE The RIVUR (Randomized Intervention for Children with Vesicoureteral Reflux) trial reported that antibiotic prophylaxis reduced recurrent urinary tract infection but antibiotic prophylaxis was not associated with decreased new renal scarring. However, the original reports did not assess the relationship among recurrent urinary tract infection, new renal scarring and antibiotic prophylaxis in detail. Therefore, we investigated the relationship among these issues. MATERIALS AND METHODS We included subjects with dimercaptosuccinic acid scan within 6 months of enrollment and at least 1 followup dimercaptosuccinic acid scan from the RIVUR trial. The primary outcome was recurrent urinary tract infection associated new renal scarring, defined as recurrent urinary tract infection and new changes on dimercaptosuccinic acid scan. Due to a low number of events, propensity score was used to adjust for confounders. Multivariate logistic regression was fitted to investigate the associations between the covariates and the outcome. RESULTS A total of 489 patients (91% female, mean age 20.3 months) were included in the study. Any new renal scarring was more common among those with recurrent urinary tract infection (OR 4.1, 95% CI 2.0-8.5, p <0.01) after adjusting for age, sex, index urinary tract infection, duplication, bowel bladder dysfunction and antibiotic prophylaxis. Recurrent urinary tract infection associated new renal scarring occurred in 5 of 244 (2%) patients on antibiotic prophylaxis and 13 of 245 (5%) on placebo. Compared to antibiotic prophylaxis, placebo was associated with a higher risk of recurrent urinary tract infection associated new renal scarring (OR 3.1, 95% CI 1.0-8.8, p=0.04) after adjusting for age, sex, race, index urinary tract infection, bowel bladder dysfunction, duplication, hydronephrosis, vesicoureteral reflux grade and baseline renal scarring. There were no differences in scar severity at final dimercaptosuccinic acid scan (p=0.88) or change from baseline (p=0.53) between antibiotic prophylaxis and placebo. CONCLUSIONS Recurrent urinary tract infection was associated with new renal scarring in the RIVUR trial. When limited to recurrent urinary tract infection associated new renal scarring, antibiotic prophylaxis was associated with a decreased risk of this outcome. It remains unclear why new renal scarring developed in a proportion of subjects without recurrent urinary tract infection. The results should be carefully interpreted due to the inherent limitations.",2019,"There were no differences in scar severity at final dimercaptosuccinic acid scan (p=0.88) or change from baseline (p=0.53) between antibiotic prophylaxis and placebo. ","['Children with Vesicoureteral Reflux', 'We included subjects with dimercaptosuccinic acid scan within 6 months of enrollment and at least 1 followup dimercaptosuccinic acid scan from the RIVUR trial', '489 patients (91% female, mean age 20.3 months) were included in the study']","['antibiotic prophylaxis', 'antibiotic prophylaxis, placebo', 'placebo']","['higher risk of recurrent urinary tract infection associated new renal scarring', 'index urinary tract infection, bowel bladder dysfunction, duplication, hydronephrosis, vesicoureteral reflux grade and baseline renal scarring', 'recurrent urinary tract infection associated new renal scarring, defined as recurrent urinary tract infection and new changes on dimercaptosuccinic acid scan', 'scar severity at final dimercaptosuccinic acid scan', 'Recurrent urinary tract infection associated new renal scarring']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0042580', 'cui_str': 'Vesicoureteral Reflux'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1875873', 'cui_str': '2,3-Dimercaptosuccinic Acid'}, {'cui': 'C0441633'}, {'cui': 'C0332285', 'cui_str': 'In (attribute)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0282638', 'cui_str': 'Premedication, Antibiotic'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0262655', 'cui_str': 'Recurrent urinary tract infection (disorder)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C1700247', 'cui_str': 'Renal scarring'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C0232841', 'cui_str': 'Bladder dysfunction (finding)'}, {'cui': 'C0332597', 'cui_str': 'Duplication (finding)'}, {'cui': 'C0020295', 'cui_str': 'Hydronephrosis'}, {'cui': 'C0042580', 'cui_str': 'Vesicoureteral Reflux'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1875873', 'cui_str': '2,3-Dimercaptosuccinic Acid'}, {'cui': 'C0441633'}, {'cui': 'C0008767', 'cui_str': 'Cicatrization'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}]",489.0,0.0321717,"There were no differences in scar severity at final dimercaptosuccinic acid scan (p=0.88) or change from baseline (p=0.53) between antibiotic prophylaxis and placebo. ","[{'ForeName': 'Hsin-Hsiao', 'Initials': 'HH', 'LastName': 'Wang', 'Affiliation': ""Department of Urology, Boston Children's Hospital , Boston , Massachusetts.""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kurtz', 'Affiliation': ""Department of Urology, Boston Children's Hospital , Boston , Massachusetts.""}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Logvinenko', 'Affiliation': ""Department of Urology, Boston Children's Hospital , Boston , Massachusetts.""}, {'ForeName': 'Caleb', 'Initials': 'C', 'LastName': 'Nelson', 'Affiliation': ""Department of Urology, Boston Children's Hospital , Boston , Massachusetts.""}]",The Journal of urology,['10.1097/JU.0000000000000292'] 1402,32498113,"Pharmacokinetics, Safety, and Bioequivalence of Two Empagliflozin Formulations after Single Oral Administration under Fasting and Fed Conditions in Healthy Chinese Subjects: An Open-label Randomized Single-dose Two-sequence, Two-treatment, Two-period Crossover Study.","OBJECTIVES To evaluate the pharmacokinetic properties and safety of empagliflozin, and the bioequivalence of test formulation empagliflozin tablet compared with the brand-name drug Jardiance (reference formulation) after single oral administration under fasting and fed conditions in healthy Chinese subjects. METHODS An open-label randomized single-dose two-sequence, two-treatment, two-period crossover study was conducted in healthy Chinese subjects, with 30 subjects under fasting condition and another 30 subjects under fed condition. Under each condition, subjects received a single oral administration of either the test or reference empagliflozin formulation, and then they received a single oral dose of the other formulation after a 7-day washout period. RESULTS A total of 29 subjects under each condition completed the study. The maximum plasma drug concentration, the area under the plasma concentration-time curve (AUC) from 0 to t (AUC 0-t ), and the AUC from 0 to infinity (AUC 0-∞ ) of test formulation and reference formulation was 186.90 ± 47.21 and 190.60 ± 40.94 ng/ml, 1303.04 ± 234.28 and 1267.78 ± 217.07 ng·hour/ml, and 1328.08 ± 243.84 and 1293.22 ± 224.82 ng·hour/ml under fasting condition, and 151.55 ± 23.86 and 154.08 ± 30.40 ng/ml, 1215.65 ± 197.62 and 1199.26 ± 186.23 ng·hour/ml, and 1241.76 ± 202.47 and 1225.54 ± 192.10 ng·hour/ml under fed condition, respectively. CONCLUSIONS The two formulations of empagliflozin were bioequivalent, and both were generally well tolerated under fasting and fed conditions.",2020,"The maximum plasma concentration (C max ), the area under the plasma concentration-time curve (AUC) from 0 to t (AUC 0-t ), and the AUC from 0 to infinity (AUC 0-∞ ) of test formulation and reference formulation was 186.90 ± 47.21 and 190.60 ± 40.94 ng/mL, 1303.04 ± 234.28 and 1267.78 ± 217.07 ng·h/mL, and 1328.08 ± 243.84 and 1293.22 ± 224.82 ng·h/mL under fasting condition, and 151.55 ± 23.86 and 154.08 ± 30.40 ng/mL, 1215.65 ± 197.62 and 1199.26 ± 186.23 ng·h/mL, and 1241.76 ± 202.47 and 1225.54 ± 192.10 ng·h/mL under fed condition, respectively. ","['29 subjects under each condition completed the study', 'healthy Chinese subjects', 'healthy Chinese subjects, with 30 subjects under fasting condition and another 30 subjects under fed condition']","['empagliflozin formulations', 'empagliflozin formulation', 'empagliflozin']","['maximum plasma concentration (C max ), the area under the plasma concentration-time curve (AUC', 'Pharmacokinetics, safety, and bioequivalence']","[{'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}]","[{'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0039789', 'cui_str': 'Equivalencies, Therapeutic'}]",30.0,0.0489666,"The maximum plasma concentration (C max ), the area under the plasma concentration-time curve (AUC) from 0 to t (AUC 0-t ), and the AUC from 0 to infinity (AUC 0-∞ ) of test formulation and reference formulation was 186.90 ± 47.21 and 190.60 ± 40.94 ng/mL, 1303.04 ± 234.28 and 1267.78 ± 217.07 ng·h/mL, and 1328.08 ± 243.84 and 1293.22 ± 224.82 ng·h/mL under fasting condition, and 151.55 ± 23.86 and 154.08 ± 30.40 ng/mL, 1215.65 ± 197.62 and 1199.26 ± 186.23 ng·h/mL, and 1241.76 ± 202.47 and 1225.54 ± 192.10 ng·h/mL under fed condition, respectively. ","[{'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, China.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Zhang', 'Affiliation': 'Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, China.'}, {'ForeName': 'Aihua', 'Initials': 'A', 'LastName': 'Du', 'Affiliation': 'Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, China.'}, {'ForeName': 'Yanan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, China.'}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, China.'}, {'ForeName': 'Siqi', 'Initials': 'S', 'LastName': 'Zang', 'Affiliation': 'Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, China.'}, {'ForeName': 'Xiaona', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, China.'}, {'ForeName': 'Zejuan', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, China.'}, {'ForeName': 'Haiqing', 'Initials': 'H', 'LastName': 'Zhen', 'Affiliation': 'GCP Office, Aerospace Center Hospital, Beijing, China.'}, {'ForeName': 'Yujing', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Beijing Sun-Novo Pharmaceutical Research Co., Ltd., Beijing, China.'}, {'ForeName': 'Shuya', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': ""President's Office, Aerospace 731 Hospital, Beijing, China.""}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, China.'}]",Pharmacotherapy,['10.1002/phar.2432'] 1403,32498240,An Integrative Neuro-Psychotherapy Treatment to Foster the Adjustment in Acquired Brain Injury Patients-A Randomized Controlled Study.,"Adjustment disorders (AjD) with depressive symptoms following an acquired brain injury (ABI) is a common phenomenon. Although brain injuries are increasing more and more, research on psychological therapies is comparably scarce. The present study compared, by means of a randomized controlled trial (RCT), a newly developed integrative treatment (Standard PLUS) to a standard neuropsychological treatment (Standard). Primary outcomes were depressive symptoms assessed with the Beck Depression Inventory (BDI-II) at post-treatment and 6-month follow-up assessment. In total, 25 patients (80% after a stroke) were randomized to one of the two conditions. Intention-to-treat analyses showed that the two groups did not significantly differ either at post-treatment nor at follow-up assessment regarding depressive symptoms. Both treatments showed large within-group effect sizes on depressive symptoms. Regarding secondary outcomes, patients in the Standard PLUS condition reported more emotion regulation skills at post-assessment than in the control condition. However, this difference was not present anymore at follow-up assessment. Both treatments showed medium to large within-group effects sizes on most measures for patients suffering from an AjD after ABI. More research with larger samples is needed to investigate who profits from which intervention.",2020,Both treatments showed medium to large within-group effects sizes on most measures for patients suffering from an AjD after ABI.,"['Adjustment disorders (AjD) with depressive symptoms following an acquired brain injury (ABI', '25 patients (80% after a stroke', 'patients suffering from an AjD after ABI']",['Integrative Neuro-Psychotherapy Treatment'],"['emotion regulation skills', 'depressive symptoms', 'depressive symptoms assessed with the Beck Depression Inventory (BDI-II']","[{'cui': 'C0001546', 'cui_str': 'Adjustment disorder'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0027855', 'cui_str': 'Neurology'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0006448', 'cui_str': 'Burundi'}]",25.0,0.128683,Both treatments showed medium to large within-group effects sizes on most measures for patients suffering from an AjD after ABI.,"[{'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Urech', 'Affiliation': 'Department of Neurology, Inselspital Bern, Bern University Hospital, 3010 Bern, Switzerland.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Krieger', 'Affiliation': 'Department of Psychology, University of Bern, 3012 Bern, Switzerland.'}, {'ForeName': 'Eveline', 'Initials': 'E', 'LastName': 'Frischknecht', 'Affiliation': 'Department of Psychology, University of Bern, 3012 Bern, Switzerland.'}, {'ForeName': 'Franziska', 'Initials': 'F', 'LastName': 'Stalder-Lüthy', 'Affiliation': 'Department of Neurology, Spitalzentrum Biel, 2501 Biel, Switzerland.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Grosse Holtforth', 'Affiliation': 'Department of Psychology, University of Bern, 3012 Bern, Switzerland.'}, {'ForeName': 'René Martin', 'Initials': 'RM', 'LastName': 'Müri', 'Affiliation': 'Department of Neurology, Inselspital Bern, Bern University Hospital, 3010 Bern, Switzerland.'}, {'ForeName': 'Hansjörg', 'Initials': 'H', 'LastName': 'Znoj', 'Affiliation': 'Department of Psychology, University of Bern, 3012 Bern, Switzerland.'}, {'ForeName': 'Helene', 'Initials': 'H', 'LastName': 'Hofer', 'Affiliation': 'Department of Neurology, Inselspital Bern, Bern University Hospital, 3010 Bern, Switzerland.'}]",Journal of clinical medicine,['10.3390/jcm9061684'] 1404,32498248,Ubiquinol-10 Intake Is Effective in Relieving Mild Fatigue in Healthy Individuals.,"Our double-blind, placebo-controlled study evaluated effects of ubiquinol, the reduced form of coenzyme Q 10 , on mild fatigue in healthy individuals experiencing fatigue in daily life that had continued for more than 1 and less than 6 months. The participants received 100-mg/day (Ubq100; age 44.0 ± 9.8 years; 14 females and 6 males) or 150-mg/day ubiquinol (Ubq150; age 40.4 ± 11.8 years; 14 females and 8 males) or placebo (Plc; age 41.3 ± 13.4 years; 13 females and 7 males) daily for 12 weeks. Measurements of subjective and objective fatigue were conducted by using questionnaires-based fatigue scales/visual analogue scales and autonomic nerve function/biological oxidation index, respectively, prior to the first dosing and every 4 weeks thereafter. Serum ubiquinol level increased three- to four-fold after 4 weeks and remained significantly higher than that after Plc administration throughout the intake period. Although a higher blood level of ubiquinol was observed with Ubq150 than with Ubq100, the difference was not statistically significant. In both Ubq100 and Ubq150 groups, subjective levels of fatigue sensation and sleepiness after cognitive tasks, which consisted of the modified Advanced Trail Making Test, the modified Stroop Color-Word Test, and the Digit Symbol Substitution Test, improved significantly compared with those in the placebo group, suggesting an anti-fatigue effect. The Ubq150 group demonstrated significant improvement compared with the Plc group regarding subjective level of relaxation after task, sleepiness before and after task, motivation for task, and serum level of oxidative stress. Correlation analysis between blood level of ubiquinol and each evaluated effect suggested a positive relationship with relaxation after task, motivation for cognitive task, and parasympathetic activity. The results of the study suggest that ubiquinol intake relieves mild fatigue in healthy individuals.",2020,"The Ubq150 group demonstrated significant improvement compared with the Plc group regarding subjective level of relaxation after task, sleepiness before and after task, motivation for task, and serum level of oxidative stress.","['healthy individuals experiencing fatigue in daily life that had continued for more than 1 and less than 6 months', 'healthy individuals', 'Healthy Individuals', 'Plc; age 41.3 ± 13.4 years; 13 females and 7 males) daily for 12 weeks', 'participants received 100-mg/day (Ubq100; age 44.0 ± 9.8 years; 14 females and 6 males) or 150-mg/day ubiquinol (Ubq150; age 40.4 ± 11.8 years; 14 females and 8 males) or']","['ubiquinol intake', 'Ubiquinol-10 Intake', 'placebo']","['subjective level of relaxation after task, sleepiness before and after task, motivation for task, and serum level of oxidative stress', 'subjective levels of fatigue sensation and sleepiness', 'blood level of ubiquinol', 'Serum ubiquinol level', 'relaxation after task, motivation for cognitive task, and parasympathetic activity', 'mild fatigue', 'Measurements of subjective and objective fatigue', 'questionnaires-based fatigue scales/visual analogue scales and autonomic nerve function/biological oxidation index', 'modified Stroop Color-Word Test, and the Digit Symbol Substitution Test']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517770', 'cui_str': '41.3'}, {'cui': 'C4517558', 'cui_str': '13.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0077656', 'cui_str': 'ubiquinol'}]","[{'cui': 'C0077656', 'cui_str': 'ubiquinol'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0077659', 'cui_str': 'ubiquinol-10'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C2586108', 'cui_str': 'Level of fatigue'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0077656', 'cui_str': 'ubiquinol'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0206250', 'cui_str': 'Autonomic nerve structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0582675', 'cui_str': 'Stroop neuropsychological screening test'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",,0.0818902,"The Ubq150 group demonstrated significant improvement compared with the Plc group regarding subjective level of relaxation after task, sleepiness before and after task, motivation for task, and serum level of oxidative stress.","[{'ForeName': 'Kei', 'Initials': 'K', 'LastName': 'Mizuno', 'Affiliation': 'Osaka City University Center for Health Science Innovation, Osaka 530-0011, Japan.'}, {'ForeName': 'Akihiro T', 'Initials': 'AT', 'LastName': 'Sasaki', 'Affiliation': 'Osaka City University Center for Health Science Innovation, Osaka 530-0011, Japan.'}, {'ForeName': 'Kyosuke', 'Initials': 'K', 'LastName': 'Watanabe', 'Affiliation': 'Osaka City University Center for Health Science Innovation, Osaka 530-0011, Japan.'}, {'ForeName': 'Yasuyoshi', 'Initials': 'Y', 'LastName': 'Watanabe', 'Affiliation': 'Osaka City University Center for Health Science Innovation, Osaka 530-0011, Japan.'}]",Nutrients,['10.3390/nu12061640'] 1405,32497783,Study protocol: Using peer support to aid in prevention and treatment in prediabetes (UPSTART).,"BACKGROUND There is an urgent need to develop and evaluate effective and scalable interventions to prevent or delay the onset of type 2 diabetes mellitus (T2DM). METHODS In this randomized controlled pragmatic trial, 296 adults with prediabetes will be randomized to either a peer support arm or enhanced usual care. Participants in the peer support arm meet face-to-face initially with a trained peer coach who also is a patient at the same health center to receive information on locally available wellness and diabetes prevention programs, discuss behavioral goals related to diabetes prevention, and develop an action plan for the next week to meet their goals. Over six months, peer coaches call their assigned participants weekly to provide support for weekly action steps. In the final 6 months, coaches call participants at least once monthly. Participants in the enhanced usual care arm receive information on local resources and periodic updates on available diabetes prevention programs and resources. Changes in A1c, weight, waist circumference and other patient-centered outcomes and mediators and moderators of intervention effects will be assessed. RESULTS At least 296 participants and approximately 75 peer supporters will be enrolled. DISCUSSION Despite evidence that healthy lifestyle interventions can improve health behaviors and reduce risk for T2DM, engagement in recommended behavior change is low. This is especially true among racial and ethnic minority and low-income adults. Regular outreach and ongoing support from a peer coach may help participants to initiate and sustain healthy behavior changes to reduce their risk of diabetes. TRIAL REGISTRATION The ClinicalTrials.gov registration number is NCT03689530.",2020,"Changes in A1c, weight, waist circumference and other patient-centered outcomes and mediators and moderators of intervention effects will be assessed. ","['296 adults with prediabetes', 'At least 296 participants and approximately 75 peer supporters will be enrolled']","['peer support arm or enhanced usual care', 'peer support arm meet face-to-face initially with a trained peer coach who also is a patient at the same health center to receive information on locally available wellness and diabetes prevention programs, discuss behavioral goals related to diabetes prevention, and develop an action plan']","['Changes in A1c, weight, waist circumference', 'health behaviors']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}]","[{'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C1273866', 'cui_str': 'Action plan (community)'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",296.0,0.0609549,"Changes in A1c, weight, waist circumference and other patient-centered outcomes and mediators and moderators of intervention effects will be assessed. ","[{'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Heisler', 'Affiliation': 'Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States of America; VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, United States of America. Electronic address: mheisler@umich.edu.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Kullgren', 'Affiliation': 'Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States of America; VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, United States of America; Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, MI, United States of America; University of Michigan Institute for Healthcare Policy and Innovation, Ann Arbor, MI, United States of America. Electronic address: jkullgre@med.umich.edu.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Richardson', 'Affiliation': 'Department of Family Medicine, University of Michigan Medical School, Ann Arbor, MI, United States of America. Electronic address: caroli@umich.edu.'}, {'ForeName': 'Shelley', 'Initials': 'S', 'LastName': 'Stoll', 'Affiliation': 'Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States of America. Electronic address: scstoll@umich.edu.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Alvarado Nieves', 'Affiliation': 'University of Michigan, Department of Internal Medicine- Metabolism, Endocrinology and Diabetes, United States of America. Electronic address: alvaradc@med.umich.edu.'}, {'ForeName': 'Deanne', 'Initials': 'D', 'LastName': 'Wiley', 'Affiliation': 'Kaiser Permanente Northern California, United States of America. Electronic address: deanne.wiley@kp.org.'}, {'ForeName': 'Tali', 'Initials': 'T', 'LastName': 'Sedgwick', 'Affiliation': 'Kaiser Permanente Northern California Division of Research, United States of America. Electronic address: Tali.S.Sedgwick@kp.org.'}, {'ForeName': 'Alyce', 'Initials': 'A', 'LastName': 'Adams', 'Affiliation': 'Kaiser Permanente Northern California, United States of America. Electronic address: Alyce.S.Adams@kp.org.'}, {'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Hedderson', 'Affiliation': 'Kaiser Permanente Northern California, United States of America. Electronic address: Monique.m.hedderson@kp.org.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Kim', 'Affiliation': 'The Permanente Medical Group (Kaiser Permanente, Northern California), United States of America. Electronic address: Eileen.Kim@kp.org.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Rao', 'Affiliation': 'The Permanente Medical Group (Kaiser Permanente, Northern California), United States of America. Electronic address: megan.rao@kp.org.'}, {'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Schmittdiel', 'Affiliation': 'Kaiser Permanente Northern California Division of Research, United States of America. Electronic address: Julie.A.Schmittdiel@kp.org.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106048'] 1406,32502795,Comparison of underwater gait training and overground gait training for improving the walking and balancing ability of patients with severe hemiplegic stroke: A randomized controlled pilot trial.,"BACKGROUND Walking training is an essential intervention to improve the function in stroke patients. However, only a limited number of gait training strategies are available for stroke patients with relatively severe disabilities. RESEARCH QUESTION Is underwater gait training or overground gait training more effective in severe stroke patients? METHODS A total of 21 patients with severe hemiplegic stroke were randomly assigned to the experimental and control groups. All participants (n = 21) received 60-minute sessions of general physical therapy, 5 times a week for a period of 12 weeks. Additionally, the experimental and control groups underwent underwater and overground walking training, respectively, for 30 min twice times a week for 12 weeks. Postural assessment for stroke score, center of pressure path length and velocity, step time and step length difference, and walking velocity were measured before and after the 12-week training. RESULTS Both groups showed a significant decrease in the center of pressure path length and velocity after the intervention compared to the values before the intervention (p < .05). However, there was no significant difference in the center of pressure path length and velocity changes after training between the two groups (p > .05). In the walking variables, the step length difference changes after training between the two groups showed a significant difference (p < .05). In the experimental group, the step length difference increased after the intervention compared to that before the intervention (+4.55 cm), whereas that of the control group decreased (-1.25 cm). SIGNIFICANCE In severe stroke patients, underwater gait training can be effective for improving balancing ability, but it may be less effective on the improvement of gait function than overground walking. CLINICAL TRIAL REGISTRATION NUMBER KCT0002587 (https://cris.nih.go.kr).",2020,"However, there was no significant difference in the center of pressure path length and velocity changes after training between the two groups (p > .05).","['21 patients with severe hemiplegic stroke', 'stroke patients', 'severe stroke patients', 'stroke patients with relatively severe disabilities', 'patients with severe hemiplegic stroke']","['Walking training', 'underwater gait training', '60-minute sessions of general physical therapy', 'underwater and overground walking training', 'underwater gait training and overground gait training', 'underwater gait training or overground gait training']","['center of pressure path length and velocity', 'Postural assessment for stroke score, center of pressure path length and velocity, step time and step length difference, and walking velocity', 'gait function', 'center of pressure path length and velocity changes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0231170', 'cui_str': 'Disability'}]","[{'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}, {'cui': 'C3853333', 'cui_str': 'Sixty minutes'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}]","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0427126', 'cui_str': 'Step length'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",21.0,0.0299419,"However, there was no significant difference in the center of pressure path length and velocity changes after training between the two groups (p > .05).","[{'ForeName': 'Nan-Hyang', 'Initials': 'NH', 'LastName': 'Kim', 'Affiliation': 'Department of Physical Therapy, Graduate School of Daejeon University, Republic of Korea. Electronic address: kimnan1004@hanmail.net.'}, {'ForeName': 'Hoon-Young', 'Initials': 'HY', 'LastName': 'Park', 'Affiliation': 'Department of Physical Therapy, Graduate School of Daejeon University, Republic of Korea. Electronic address: phy9234@naver.com.'}, {'ForeName': 'Jin-Kyu', 'Initials': 'JK', 'LastName': 'Son', 'Affiliation': 'Department of Physical Therapy, College of Health and Medical Science, Daejeon University, Republic of Korea. Electronic address: thswlsrb1004@naver.com.'}, {'ForeName': 'Young', 'Initials': 'Y', 'LastName': 'Moon', 'Affiliation': 'Department of Physical Therapy, Graduate School of Daejeon University, Republic of Korea. Electronic address: moyo2ng@naver.com.'}, {'ForeName': 'Jun-Ho', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Department of Emergency Medical Technology, College of Health and Medical Science, Daejeon University, Republic of Korea. Electronic address: jhlee@dju.kr.'}, {'ForeName': 'Yong-Jun', 'Initials': 'YJ', 'LastName': 'Cha', 'Affiliation': 'Department of Physical Therapy, College of Health and Medical Science, Daejeon University, Republic of Korea. Electronic address: cha0874@dju.kr.'}]",Gait & posture,['10.1016/j.gaitpost.2020.05.022'] 1407,32505019,"Indentation marks, skin temperature and comfort of two cervical collars: A single-blinded randomized controlled trial in healthy volunteers.","BACKGROUND Collar-related pressure ulcers (CRPU) are a problem in trauma patients with a suspicion of cervical cord injury patients. Indentation marks (IM), skin temperature (T sk ) and comfort could play a role in the development of CRPU. Two comparable cervical collars are the Stifneck® and Philadelphia®. However, the differences between them remain unclear. AIM To determine and compare occurrence and severity of IM, T sk and comfort of the Stifneck® and Philadelphia® in immobilized healthy adults. METHODS This single-blinded randomized controlled trial compared two groups of immobilized participants in supine position for 20 min. RESULTS All participants (n = 60) generated IM in at least one location in the observed area. Total occurrence was higher in the Stifneck®-group (n = 95 versus n = 69; p = .002). T sk increased significantly with 1.0  °C in the Stifneck®-group and 1.3 °C in the Philadelphia®-group (p = .024). Comfort was rated 3 on a scale of 5 (p = .506). CONCLUSION The occurrence of IM in both groups was high. In comparison to the Stifneck®, fewer and less severe IM were observed from the Philadelphia®. The T sk increased significantly with both collars; however, no clinical difference in increase of T sk between them was found. The results emphasize the need for a better design of cervical collars regarding CRPU.",2020,Total occurrence was higher in the Stifneck®-group,"['immobilized healthy adults', 'trauma patients with a suspicion of cervical cord injury patients', 'healthy volunteers', 'participants in supine position for 20\xa0min']","['immobilized', 'Collar-related pressure ulcers (CRPU']","['Indentation marks (IM), skin temperature (T sk ) and comfort', 'T sk', 'severe IM', 'Total occurrence', 'Indentation marks, skin temperature and comfort of two cervical collars']","[{'cui': 'C0020944', 'cui_str': 'Immobilization - action'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0242114', 'cui_str': 'Suspicion'}, {'cui': 'C0457846', 'cui_str': 'Segment of cervical spinal cord'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0038846', 'cui_str': 'Supine body position'}, {'cui': 'C0439232', 'cui_str': 'min'}]","[{'cui': 'C0020944', 'cui_str': 'Immobilization - action'}, {'cui': 'C0175751', 'cui_str': 'Cervical collar'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0011127', 'cui_str': 'Pressure ulcer'}]","[{'cui': 'C0332467', 'cui_str': 'Indentation'}, {'cui': 'C0522501', 'cui_str': 'Massive'}, {'cui': 'C0037294', 'cui_str': 'Temperature of skin'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0175751', 'cui_str': 'Cervical collar'}]",,0.152707,Total occurrence was higher in the Stifneck®-group,"[{'ForeName': 'J P L', 'Initials': 'JPL', 'LastName': 'Leenen', 'Affiliation': 'Department of Surgery, Isala, Dr. van Heesweg 2, 8025 AB Zwolle, The Netherlands. Electronic address: j.p.l.leenen@isala.nl.'}, {'ForeName': 'H W', 'Initials': 'HW', 'LastName': 'Ham', 'Affiliation': 'Emergency Department, University Medical Center Utrecht, University of Applied Science, Institute of Nursing Studies, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Electronic address: w.h.ham@umcutrecht.nl.'}, {'ForeName': 'L P H', 'Initials': 'LPH', 'LastName': 'Leenen', 'Affiliation': 'Department of Traumatology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Electronic address: l.p.h.leenen@umcutrecht.nl.'}]",International emergency nursing,['10.1016/j.ienj.2020.100878'] 1408,32686234,A randomized controlled study comparing guided bone regeneration with connective tissue graft to reestablish buccal convexity at implant sites: A 1-year volumetric analysis.,"OBJECTIVES To volumetrically compare guided bone regeneration (GBR) with connective tissue graft (CTG) to reestablish convexity at the buccal aspect of single implants. MATERIALS AND METHODS Patients with a single tooth gap in the anterior maxilla and horizontal alveolar defect were enrolled in a single-blind randomized clinical trial (RCT). All sites had a buccopalatal bone dimension of at least 6 mm, received a single implant, and were randomly allocated to the control (GBR) or test group (CTG) to reestablish buccal soft tissue convexity. Patients received a provisional crown at 3 months and a permanent crown at 6 months. Primary outcomes were volumetric increase (mm 3 ) and linear increase (mm) in buccal soft tissue profile (BSP) within a well-defined area of interest at fixed time points. Alveolar process deficiency was a secondary outcome. RESULTS Twenty-one patients were included per group (control: 11 females, mean age 51; test: 9 females, mean age 48). After 1 year, GBR resulted in a significant volumetric increase of 20.74 mm 3 (P < .001) corresponding to linear increase in BSP of 1.30 mm (P < .001). For CTG, this was 15.86 (P < .001) and 1.19 mm (P < .001), respectively. The changes over time in volume (P = .173) and BSP (P = .241) were not significantly different between the groups. Twenty-nine percentage and 26% of the final volumetric increase was the result of installing and altering prosthetic components in the control and test groups, respectively. Alveolar process deficiency significantly reduced from pre-op to 1 year following GBR (P < .001) and CTG (P < .001). The difference between the groups was not significant (P = .342). However, 58% of the patients treated with GBR and 38% treated with CTG failed to show perfect soft tissue convexity at the buccal aspect. CONCLUSION GBR as well as CTG are effective in reducing horizontal alveolar defects for aesthetic purposes. However, in about half of the cases, either strategy failed to optimally reestablish buccal convexity.",2020,"After 1 year, GBR resulted in a significant volumetric increase of 20.74 mm 3 (P < .001) corresponding to linear increase in BSP of 1.30 mm (P < .001).","['mean age 51; test: 9 females, mean age 48', 'Patients with a single tooth gap in the anterior maxilla and horizontal alveolar defect', 'Twenty-one patients were included per group (control: 11 females']","['guided bone regeneration with connective tissue graft to reestablish buccal convexity at implant sites', 'provisional crown', 'CTG', 'guided bone regeneration (GBR) with connective tissue graft (CTG', 'control (GBR) or test group (CTG) to reestablish buccal soft tissue convexity']","['volumetric increase (mm 3 ) and linear increase (mm) in buccal soft tissue profile (BSP', 'Alveolar process deficiency', 'soft tissue convexity', 'result of installing and altering prosthetic components', 'BSP', 'changes over time in volume']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0061928', 'cui_str': 'GTPase-Activating Protein'}, {'cui': 'C0459697', 'cui_str': 'Anterior segment of maxilla'}, {'cui': 'C0205126', 'cui_str': 'Horizontal'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0005972', 'cui_str': 'Bone Regeneration'}, {'cui': 'C0009780', 'cui_str': 'Connective tissue'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0010384', 'cui_str': 'Crown'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0225317', 'cui_str': 'Soft tissue'}]","[{'cui': 'C0445383', 'cui_str': 'Volumetric'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0225317', 'cui_str': 'Soft tissue'}, {'cui': 'C0053935', 'cui_str': 'Bone Sialoprotein'}, {'cui': 'C0002386', 'cui_str': 'Alveolar process'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",21.0,0.107511,"After 1 year, GBR resulted in a significant volumetric increase of 20.74 mm 3 (P < .001) corresponding to linear increase in BSP of 1.30 mm (P < .001).","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'De Bruyckere', 'Affiliation': 'Faculty of Medicine and Pharmacy, Oral Health Research Group (ORHE), Vrije Universiteit Brussel (VUB), Brussels, Belgium.'}, {'ForeName': 'Ricardo Garcia', 'Initials': 'RG', 'LastName': 'Cabeza', 'Affiliation': 'Department of Periodontology and Oral Implantology, Faculty of Medicine and Health Sciences, Dental School, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Aryan', 'Initials': 'A', 'LastName': 'Eghbali', 'Affiliation': 'Faculty of Medicine and Pharmacy, Oral Health Research Group (ORHE), Vrije Universiteit Brussel (VUB), Brussels, Belgium.'}, {'ForeName': 'Faris', 'Initials': 'F', 'LastName': 'Younes', 'Affiliation': 'Department of Periodontology and Oral Implantology, Faculty of Medicine and Health Sciences, Dental School, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Cleymaet', 'Affiliation': 'Faculty of Medicine and Pharmacy, Oral Health Research Group (ORHE), Vrije Universiteit Brussel (VUB), Brussels, Belgium.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Cosyn', 'Affiliation': 'Faculty of Medicine and Pharmacy, Oral Health Research Group (ORHE), Vrije Universiteit Brussel (VUB), Brussels, Belgium.'}]",Clinical implant dentistry and related research,['10.1111/cid.12934'] 1409,32686337,Raloxifene Prevents Early Periprosthetic Bone Loss for Postmenopausal Women after Uncemented Total Hip Arthroplasty: A Randomized Placebo-Controlled Clinical Trial.,"OBJECTIVE To examine the results of raloxifene for prevention of periprosthetic bone loss around the femoral stem in patients undergoing total hip arthroplasty (THA). METHODS Between January 2015 and May 2017, 240 female patients between 55 and 80 years underwent primary THA and were randomly allocated to receive 60 mg raloxifene hydrochloride per day (treatment group, TG, n = 120) or placebo (control group, CG, n = 120) orally at bedtime using computer-generated randomization sequence generation. Baseline data, the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC), women's quality of life (QoL) score, bone mineral density (BMD) around the prosthesis, and adverse events were compared between the two groups. The measuring range of BMD around the prosthesis was divided into seven regions of interest (ROI). The sample size was calculated to detect a mean difference in BMD of 0.15 g/cm 2 with a standard deviation (SD) of 0.3. The error was set at 0.05 and the power level at 90% with additional compensation for a possible dropout rate of 20%. RESULTS A total of 240 participants in the study up to 24 months after THA. There were no significant differences in the mean BMD of all the zones between groups before surgery (all P > 0.05). However, there were significant differences in the BMD of Gruen zones 4 and 7 between groups at 6 months postoperatively (both P < 0.05); there were significant differences in Gruen zones 1, 4, 6, and 7 at 12 months postoperatively (all P < 0.01); there were significant differences in Gruen zones 1, 2, 4, 6, and 7 at 24 months postoperatively (all P < 0.001). Patients taking raloxifene reported higher QoL scores, with better improvement in BMD in all areas except in zones 3 and 5 compared with the control group. There were no significant differences in WOMAC pain (P = 0.4045), WOMAC function (P = 0.4456) and women's QoL scores (P = 0.5983) between groups before surgery. However, WOMAC pain, WOMAC function and women's QoL score in the treatment group were significantly better at all time points (all P < 0.05). Patients in the treatment group showed no increased adverse events, including cardiac events, stroke, venous thromboembolism, and gynecological cancer (all P > 0.05), but did show decreased odds of breast cancer in comparison with those using a placebo (P = 0.0437). CONCLUSION Raloxifene can help inhibit bone loss around the prosthesis and improve the QoL of postmenopausal women after THA with no increased adverse events, and can even decrease the odds of breast cancer.",2020,"There were no significant differences in WOMAC pain (P = 0.4045), WOMAC function (P = 0.4456) and women's QoL scores (P = 0.5983) between groups before surgery.","['240 female patients between 55 and 80\u2009years underwent primary THA', 'Between January 2015 and May 2017', '240 participants in the study up to 24\u2009months after THA', 'Postmenopausal Women after Uncemented Total Hip Arthroplasty', 'patients undergoing total hip arthroplasty (THA']","['Placebo', 'placebo (control group, CG, n = 120) orally at bedtime using computer-generated randomization sequence generation', 'Raloxifene', 'raloxifene hydrochloride', 'raloxifene', 'placebo']","[""WOMAC pain, WOMAC function and women's QoL score"", 'bone loss', 'periprosthetic bone loss', 'Early Periprosthetic Bone Loss', ""Western Ontario McMaster Universities Osteoarthritis Index (WOMAC), women's quality of life (QoL) score, bone mineral density (BMD) around the prosthesis, and adverse events"", 'BMD', 'odds of breast cancer', 'range of BMD', ""women's QoL scores"", 'QoL scores', 'WOMAC pain', 'adverse events, including cardiac events, stroke, venous thromboembolism, and gynecological cancer', 'adverse events', 'WOMAC function', 'BMD of Gruen zones', 'mean BMD']","[{'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0521112', 'cui_str': 'Bedtime'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0004793', 'cui_str': 'Base sequence'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0244404', 'cui_str': 'Raloxifene'}, {'cui': 'C0618111', 'cui_str': 'Raloxifene hydrochloride'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0175649', 'cui_str': 'Prosthesis'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0018417', 'cui_str': 'Gynecology'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",240.0,0.0719752,"There were no significant differences in WOMAC pain (P = 0.4045), WOMAC function (P = 0.4456) and women's QoL scores (P = 0.5983) between groups before surgery.","[{'ForeName': 'Long', 'Initials': 'L', 'LastName': 'Gong', 'Affiliation': 'Department of Orthopaedic Surgery, China-Japan Friendship Hospital, Peking Union Medical College, Chinese Academy of Medical College, Beijing, China.'}, {'ForeName': 'Yao-Yao', 'Initials': 'YY', 'LastName': 'Zhang', 'Affiliation': 'Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, China.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Yang', 'Affiliation': 'Bao Ding Maternal and Children Hospital, Baoding, China.'}, {'ForeName': 'Huan-Juan', 'Initials': 'HJ', 'LastName': 'Qian', 'Affiliation': 'Department of Orthopedics Surgery, 81 Group Military Hospital of Chinese PLA, Baoding, China.'}, {'ForeName': 'Ling-Kun', 'Initials': 'LK', 'LastName': 'Zhang', 'Affiliation': 'Department of Orthopedics Surgery, 81 Group Military Hospital of Chinese PLA, Baoding, China.'}, {'ForeName': 'Ming-Sheng', 'Initials': 'MS', 'LastName': 'Tan', 'Affiliation': 'Department of Orthopaedic Surgery, China-Japan Friendship Hospital, Peking Union Medical College, Chinese Academy of Medical College, Beijing, China.'}]",Orthopaedic surgery,['10.1111/os.12696'] 1410,32511981,"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.","BACKGROUND Resistance to approved inhibitors of KIT proto-oncogene, receptor tyrosine kinase (KIT), and platelet-derived growth factor receptor α (PDGFRA) is a clinical challenge for patients with advanced gastrointestinal stromal tumours. We compared the efficacy and safety of ripretinib, a switch-control tyrosine kinase inhibitor active against a broad spectrum of KIT and PDGFRA mutations, with placebo in patients with previously treated, advanced gastrointestinal stromal tumours. METHODS In this double-blind, randomised, placebo-controlled, phase 3 study, we enrolled adult patients in 29 specialised hospitals in 12 countries. We included patients aged 18 years or older who had advanced gastrointestinal stromal tumours with progression on at least imatinib, sunitinib, and regorafenib or documented intolerance to any of these treatments despite dose modifications, and who had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Eligible patients were randomly assigned (2:1) to receive either oral ripretinib 150 mg once daily (ripretenib group) or placebo once daily (placebo group). Randomisation was done via an interactive response system using randomly permuted block sizes of six and stratified according to number of previous therapies and ECOG performance status. Patients, investigators, research staff, and the sponsor study team were masked to a patient's treatment allocation until the blinded independent central review (BICR) showed progressive disease for the patient. The primary endpoint was progression-free survival, assessed by BICR. The primary analysis was done in the intention-to-treat population and safety was assessed in patients who received at least one dose of study drug. Patients randomly assigned to placebo were permitted to cross over to ripretinib 150 mg at the time of disease progression. The INVICTUS study is registered with ClinicalTrials.gov, number NCT03353753, and with WHO International Clinical Trials Registry Platform, number EUCTR2017-002446-76-ES; follow-up is ongoing. FINDINGS Between Feb 27, 2018, and Nov 16, 2018, 129 of 154 assessed patients were randomly assigned to receive either ripretinib (n=85) or placebo (n=44). At data cutoff (May 31, 2019), at a median follow-up of 6·3 months (IQR 3·2-8·2) in the ripretinib group and 1·6 months (1·1-2·7) in the placebo group, 51 patients in the ripretinib group and 37 in the placebo group had had progression-free survival events. In the double-blind period, median progression-free survival was 6·3 months (95% CI 4·6-6·9) with ripretinib compared with 1·0 months (0·9-1·7) with placebo (hazard ratio 0·15, 95% CI 0·09-0·25; p<0·0001). The most common (>2%) grade 3 or 4 treatment-related treatment-emergent adverse events in the ripretinib group (n=85) included lipase increase (four [5%]), hypertension (three [4%]), fatigue (two [2%]), and hypophosphataemia (two (2%]); in the placebo group (n=43), the most common (>2%) grade 3 or 4 treatment-related treatment-emergent adverse events were anaemia (three [7%]), fatigue (one [2%]), diarrhoea (one [2%]), decreased appetite (one [2%]), dehydration (one [2%]), hyperkalaemia (one [2%]), acute kidney injury (one [2%]), and pulmonary oedema (one [2%]). Treatment-related serious adverse events were reported in eight (9%) of 85 patients who received ripretinib and three (7%) of 43 patients who received placebo. Treatment-related deaths occurred in one patient in the placebo group (septic shock and pulmonary oedema) and one patient in the ripretinib group (cause of death unknown; the patient died during sleep). INTERPRETATION Ripretinib significantly improved median progression-free survival compared with placebo and had an acceptable safety profile in patients with advanced gastrointestinal stromal tumours who were resistant to approved treatments. FUNDING Deciphera Pharmaceuticals.",2020,"Ripretinib significantly improved median progression-free survival compared with placebo and had an acceptable safety profile in patients with advanced gastrointestinal stromal tumours who were resistant to approved treatments. ","['enrolled adult patients in 29 specialised hospitals in 12 countries', 'patients aged 18 years or older who had advanced gastrointestinal stromal tumours with progression on at least imatinib, sunitinib, and regorafenib or documented intolerance to any of these treatments despite dose modifications, and who had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2', 'patients with advanced gastrointestinal stromal tumours who were resistant to approved treatments', 'Between Feb 27, 2018, and Nov 16, 2018, 129 of 154 assessed patients', 'patients with previously treated, advanced gastrointestinal stromal tumours', 'patients with advanced gastrointestinal stromal tumours (INVICTUS', 'patients with advanced gastrointestinal stromal tumours', 'Eligible patients']","['ripretinib', 'oral ripretinib 150 mg once daily (ripretenib group) or placebo once daily (placebo', 'placebo']","['lipase increase', 'median progression-free survival', 'progression-free survival events', 'intention-to-treat population and safety', 'fatigue', 'hyperkalaemia', 'acute kidney injury', 'septic shock and pulmonary oedema', 'diarrhoea', 'dehydration', 'serious adverse events', 'pulmonary oedema', 'hypertension', 'deaths', 'decreased appetite', 'progression-free survival, assessed by BICR']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0238198', 'cui_str': 'Gastrointestinal stromal tumor'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0935989', 'cui_str': 'imatinib'}, {'cui': 'C1176020', 'cui_str': 'sunitinib'}, {'cui': 'C2980094', 'cui_str': 'regorafenib'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0231199', 'cui_str': 'Intolerance'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}, {'cui': 'C5191279', 'cui_str': '154'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0549475', 'cui_str': 'Lipase increased'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0020461', 'cui_str': 'Hyperkalemia'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0036983', 'cui_str': 'Septic shock'}, {'cui': 'C0034063', 'cui_str': 'Pulmonary edema'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0011175', 'cui_str': 'Dehydration'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0232462', 'cui_str': 'Decrease in appetite'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0282443', 'cui_str': 'Review'}]",,0.788248,"Ripretinib significantly improved median progression-free survival compared with placebo and had an acceptable safety profile in patients with advanced gastrointestinal stromal tumours who were resistant to approved treatments. ","[{'ForeName': 'Jean-Yves', 'Initials': 'JY', 'LastName': 'Blay', 'Affiliation': 'Department of Medicine, Centre Léon Bérard, Lyon, France; Headquarters, Unicancer, Paris, France; LYRICAN, Lyon, France; Faculte Lyon Est, Université Claude Bernard, Lyon, France. Electronic address: jean-yves.blay@lyon.unicancer.fr.'}, {'ForeName': 'César', 'Initials': 'C', 'LastName': 'Serrano', 'Affiliation': ""Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain.""}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Heinrich', 'Affiliation': 'Department of Medicine, Portland VA Health Care System, Portland, OR, USA; OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Zalcberg', 'Affiliation': 'Department of Epidemiology and Preventative Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Bauer', 'Affiliation': 'Department of Medical Oncology, West German Cancer Center, University of Duisburg-Essen, Essen, Germany; German Consortium for Translational Cancer Research (DKTK), Partner Site Essen, Germany.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Gelderblom', 'Affiliation': 'Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Schöffski', 'Affiliation': 'Leuven Cancer Institute and Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Robin L', 'Initials': 'RL', 'LastName': 'Jones', 'Affiliation': 'Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, UK; Division of Clinical Studies, The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Attia', 'Affiliation': 'Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.'}, {'ForeName': 'Gina', 'Initials': 'G', 'LastName': ""D'Amato"", 'Affiliation': 'Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Chi', 'Affiliation': 'Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Reichardt', 'Affiliation': 'Department of Oncology, Helios Klinikum Berlin-Buch, Berlin, Germany.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Meade', 'Affiliation': 'Deciphera Pharmaceuticals, Waltham, MA, USA.'}, {'ForeName': 'Kelvin', 'Initials': 'K', 'LastName': 'Shi', 'Affiliation': 'Deciphera Pharmaceuticals, Waltham, MA, USA.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Ruiz-Soto', 'Affiliation': 'Deciphera Pharmaceuticals, Waltham, MA, USA.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'George', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'von Mehren', 'Affiliation': 'Department of Hematology and Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.'}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30168-6'] 1411,32512691,Daily School Physical Activity Improves Academic Performance.,"Physical activity (PA) may improve brain development, cognition, concentration and academic performance. In this prospective controlled intervention study, we increased the level of PA in 338 children aged 6-8 years at study start, from the Swedish standard of 60 min per week to 200 min per week (40 min daily). The intervention continued in all nine compulsory school years until the students graduated between 2007-2012. All other 689,881 Swedish children who graduated the same years were included as a control group. We registered at graduation eligibility rate for upper secondary school and the final grade score (from 0 to 320 grade points). We also registered the same end points in the 295 students in the index school and in all other 471,926 Swedish students who graduated in 2003-2006, that is, those who graduated before the intervention study started. Before the intervention, academic performance was similar among children in the index school as for all other Swedish boys and girls. With the intervention, the eligibility rate increased for boys in the index school by 7.3 percentage points and the mean grade scores by 13.3 points. This should be compared with a decrease of 0.8 percentage points in eligibility rate and an increase by 2.7 points in grade score in other Swedish boys. No changes were seen for intervention girls, neither in eligibility rates or grade scores. By introducing daily school-based PA in compulsory school, more boys would probably reach the eligibility rate for higher education.",2020,"No changes were seen for intervention girls, neither in eligibility rates or grade scores.","['689,881 Swedish children who graduated the same years were included as a control group', '338 children aged 6-8 years at study start, from the Swedish standard of 60 min per week to 200 min per week (40 min daily', '295 students in the index school and in all other 471,926 Swedish students who graduated in 2003-2006, that is, those who graduated before the intervention study started']",['Physical activity (PA'],"['eligibility rate', 'Daily School Physical Activity Improves Academic Performance', 'eligibility rates or grade scores', 'academic performance', 'brain development, cognition, concentration and academic performance']","[{'cui': 'C0038996', 'cui_str': 'Swedish language'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0588053', 'cui_str': 'Graduate'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C1096775', 'cui_str': 'Intervention Study'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0036373', 'cui_str': 'Academic Test Performance'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",689881.0,0.0199294,"No changes were seen for intervention girls, neither in eligibility rates or grade scores.","[{'ForeName': 'Jesper', 'Initials': 'J', 'LastName': 'Fritz', 'Affiliation': 'Clinical and Molecular Osteoporosis Research Unit, Department of Orthopedics and Clinical Sciences, Lund University, 20502 Malmö, Sweden.'}, {'ForeName': 'Marcus E', 'Initials': 'ME', 'LastName': 'Cöster', 'Affiliation': 'Clinical and Molecular Osteoporosis Research Unit, Department of Orthopedics and Clinical Sciences, Lund University, 20502 Malmö, Sweden.'}, {'ForeName': 'Björn E', 'Initials': 'BE', 'LastName': 'Rosengren', 'Affiliation': 'Clinical and Molecular Osteoporosis Research Unit, Department of Orthopedics and Clinical Sciences, Lund University, 20502 Malmö, Sweden.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Karlsson', 'Affiliation': 'Clinical and Molecular Osteoporosis Research Unit, Department of Orthopedics and Clinical Sciences, Lund University, 20502 Malmö, Sweden.'}, {'ForeName': 'Magnus K', 'Initials': 'MK', 'LastName': 'Karlsson', 'Affiliation': 'Clinical and Molecular Osteoporosis Research Unit, Department of Orthopedics and Clinical Sciences, Lund University, 20502 Malmö, Sweden.'}]","Sports (Basel, Switzerland)",['10.3390/sports8060083'] 1412,32513049,Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder.,"BACKGROUND Overactive bladder (OAB) is common in patients with multiple sclerosis (MS) with a limited number of treatment options. OBJECTIVE To investigate the effect of transcutaneous tibial nerve stimulation (TTNS) and pelvic floor muscle training (PFMT) with biofeedback on OAB symptoms in female MS patients. METHODS This study was conducted at the outpatient MS clinic in Istanbul. At baseline bladder diary, post-voiding residue (PVR), OAB, and Qualiveen Scales (QoL: Quality of Life; Siup: Specific Impact of Urinary Problems on QoL) were assessed. Patients were allocated to receive TTNS or PFMT daily for 6 weeks and reevaluated using the same tests. RESULTS Fifty-five patients (TTNS = 28, PFMT = 27) were included. Compared with baseline, both TTNS and PFMT groups improved in terms of OAB ( p  = 0.0001, p  = 0.0001), Qualiveen-siup ( p  = 0.0001, p  = 0.0001), Qualiveen-QoL ( p  = 0.002, p  = 0.006), PVR ( p  = 0.0001, p  = 0.21), frequency ( p  = 0.0001, p  = 0.69), nocturia ( p  = 0.0001, p  = 0.19), urgency ( p  = 0.0001, p  = 0.0001), and urge incontinence ( p  = 0.0001, p  = 0.0001). Between-group comparisons showed significant differences in 24-hour frequency ( p  = 0.002) in favor of TTNS. CONCLUSION Our study demonstrates the efficacy of both TTNS and PFMT for managing OAB symptoms in MS, associated with a significant impact on QoL, but did not show superiority of the methods. Further studies are needed to explore differences between these two non-invasive treatments.",2020,"Compared with baseline, both TTNS and PFMT groups improved in terms of OAB ( p  = 0.0001, p  = 0.0001), Qualiveen-siup ( p  = 0.0001, p  = 0.0001), Qualiveen-QoL ( p  = 0.002, p  = 0.006), PVR ( p  = 0.0001, p  = 0.21), frequency ( p  = 0.0001, p  = 0.69), nocturia ( p  = 0.0001, p  = 0.19), urgency ( p  = 0.0001, p  = 0.0001), and urge incontinence ( p  = 0.0001, p  = 0.0001).","['outpatient MS clinic in Istanbul', 'women with multiple sclerosis for the management of overactive bladder', 'Fifty-five patients (TTNS\u2009=\u200928, PFMT\u2009=\u200927) were included', 'patients with multiple sclerosis (MS', 'female MS patients']","['TTNS and PFMT', 'transcutaneous tibial nerve stimulation (TTNS) and pelvic floor muscle training (PFMT', 'TTNS or PFMT', 'transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback']","['OAB', 'baseline bladder diary, post-voiding residue (PVR), OAB, and Qualiveen Scales (QoL: Quality of Life; Siup: Specific Impact of Urinary Problems on QoL', 'nocturia', 'urge incontinence', '24-hour frequency', 'OAB symptoms', 'urgency', 'PVR', 'Qualiveen-QoL']","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C3839267', 'cui_str': 'Multiple sclerosis clinic'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0878773', 'cui_str': 'Overactive bladder'}, {'cui': 'C0450382', 'cui_str': '55'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040186', 'cui_str': 'Structure of tibial nerve'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C4087139', 'cui_str': 'Pelvic floor muscle training'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0040186', 'cui_str': 'Structure of tibial nerve'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C4087139', 'cui_str': 'Pelvic floor muscle training'}, {'cui': 'C0005491', 'cui_str': 'Biofeedback procedure'}]","[{'cui': 'C0878773', 'cui_str': 'Overactive bladder'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0430970', 'cui_str': 'Urinary frequency volume chart'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0042034', 'cui_str': 'Micturition'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0028734', 'cui_str': 'Nocturia'}, {'cui': 'C0150045', 'cui_str': 'Urge incontinence of urine'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}]",55.0,0.139033,"Compared with baseline, both TTNS and PFMT groups improved in terms of OAB ( p  = 0.0001, p  = 0.0001), Qualiveen-siup ( p  = 0.0001, p  = 0.0001), Qualiveen-QoL ( p  = 0.002, p  = 0.006), PVR ( p  = 0.0001, p  = 0.21), frequency ( p  = 0.0001, p  = 0.69), nocturia ( p  = 0.0001, p  = 0.19), urgency ( p  = 0.0001, p  = 0.0001), and urge incontinence ( p  = 0.0001, p  = 0.0001).","[{'ForeName': 'Cansu', 'Initials': 'C', 'LastName': 'Polat Dunya', 'Affiliation': 'Florence Nightingale Faculty of Nursing, Istanbul University-Cerrahpasa, Istanbul, Turkey.'}, {'ForeName': 'Zeliha', 'Initials': 'Z', 'LastName': 'Tulek', 'Affiliation': 'Florence Nightingale Faculty of Nursing, Istanbul University-Cerrahpasa, Istanbul, Turkey.'}, {'ForeName': 'Murat', 'Initials': 'M', 'LastName': 'Kürtüncü', 'Affiliation': 'Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Jalesh N', 'Initials': 'JN', 'LastName': 'Panicker', 'Affiliation': 'Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery and UCL Queen Square Institute of Neurology, London, UK.'}, {'ForeName': 'Mefkure', 'Initials': 'M', 'LastName': 'Eraksoy', 'Affiliation': 'Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}]","Multiple sclerosis (Houndmills, Basingstoke, England)",['10.1177/1352458520926666'] 1413,32513334,The effect of 12 weeks of euenergetic high-protein diet in regulating appetite and body composition of women with normal-weight obesity: a randomised controlled trial.,"Normal-weight obesity (NWO) syndrome is associated with metabolic diseases. The present study aimed to investigate the effects of 12 weeks of a high-protein (HP) v. a standard protein (SP) diet on appetite, anthropometry and body composition in NWO women. In this clinical trial, fifty NWO women were randomly allocated to HP (n 25) or SP (n 25) diet groups. Women in the HP and SP groups consumed 25 and 15 % of their total energy intake from protein for 12 weeks. Weight, fat mass (FM), lean body mass (LBM), waist circumference (WC) and appetite were evaluated at baseline and following their 3-month intervention. After 12 weeks, the LBM was higher in HP compared with no significant changes in the SP group (mean between-group difference = 1·5 kg; 95 % CI 3·1, 0·01; effect size (d) = 0·4). Furthermore, the HP group had lower FM (mean between-group difference -1·1 kg; 95 % CI 1, -3·3; d = -0·2), body fat percentage (BFP) (mean between-group difference -2 %; 95 % CI 0·7, -5·2; d = -0·3) and WC (mean between-group difference -1·4 cm; 95 % CI 0·6, -3·6; d = -0·2) at the end of the study in comparison with the SP group. In both groups, weight and appetite were unchanged over time without significant differences between groups. Twelve weeks of euenergetic diets with different dietary protein contents resulted in no significant weight loss in women with NWO. However, an HP diet significantly improved body composition (LBM, FM, BFP and WC) in this population.",2020,12 weeks of eucaloric diets with different dietary protein content resulted in no significant weight loss in women with NWO.,"['50 NWO women', 'women with NWO', 'women with Normal Weight Obesity', 'NWO women']","['HP diet', 'HP', 'SP', 'equicaloric high protein diet', 'high-protein (HP) versus a standard protein (SP) diet']","['body composition (LBM, FM, BFP, and WC', 'Normal weight obesity (NWO) syndrome', 'weight and appetite', 'weight loss', 'LBM', 'body fat percentage (BFP', 'appetite and body composition', 'FM', 'Weight, fat mass (FM), lean body mass (LBM), waist circumference (WC), and appetite']","[{'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0425403', 'cui_str': 'Increased protein diet'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0045933', 'cui_str': '2-benzyl-3-formylpropanoic acid'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439165', 'cui_str': 'Percent'}]",50.0,0.102932,12 weeks of eucaloric diets with different dietary protein content resulted in no significant weight loss in women with NWO.,"[{'ForeName': 'Neda', 'Initials': 'N', 'LastName': 'Haghighat', 'Affiliation': 'Laparascopy Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, 71348-14336, Iran.'}, {'ForeName': 'Damoon', 'Initials': 'D', 'LastName': 'Ashtary-Larky', 'Affiliation': 'Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, 61357-15794, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Bagheri', 'Affiliation': 'Department of Exercise Physiology, University of Isfahan, Isfahan, 8174673441, Iran.'}, {'ForeName': 'Marzieh', 'Initials': 'M', 'LastName': 'Mahmoodi', 'Affiliation': 'Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, 71348-14336, Iran.'}, {'ForeName': 'Majdadin', 'Initials': 'M', 'LastName': 'Rajaei', 'Affiliation': 'Department of Radiotherapy and Oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, 71348-14336, Iran.'}, {'ForeName': 'Meysam', 'Initials': 'M', 'LastName': 'Alipour', 'Affiliation': 'Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, 61357-15794, Iran.'}, {'ForeName': 'Wesam', 'Initials': 'W', 'LastName': 'Kooti', 'Affiliation': 'Lung Diseases & Allergy Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, 13446-666147, Iran.'}, {'ForeName': 'Vahideh', 'Initials': 'V', 'LastName': 'Aghamohammdi', 'Affiliation': 'Department of Nutrition, Khalkhal University of Medical Sciences, Khalkhal, 5681761351, Iran.'}, {'ForeName': 'Alexei', 'Initials': 'A', 'LastName': 'Wong', 'Affiliation': 'Department of Health and Human Performance, Marymount University, Arlington, VA22207, USA.'}]",The British journal of nutrition,['10.1017/S0007114520002019'] 1414,32520718,Dose-Response Relationship of a Web-Based Tailored Intervention Promoting Human Papillomavirus Vaccination: Process Evaluation of a Randomized Controlled Trial.,"BACKGROUND In the Netherlands, human papillomavirus (HPV) vaccination uptake remains low. To improve informed decision making (IDM) and HPV vaccination acceptability, we systematically developed an interactive, web-based tailored intervention to which mothers of Dutch girls were invited to participate. OBJECTIVE The aim of this study was to provide insight into the intervention's working mechanisms by evaluating (1) program use, (2) program acceptability, and (3) the relationship of program use with program acceptability and intervention effects (ie, dose-response relationship). METHODS Only mothers from the intervention arm of a randomized controlled trial that assessed the effectiveness of the web-based, tailored intervention were included in this study. They were invited to visit the website of the web-based intervention between baseline (January 2015, just before access to the intervention) and follow up (March 2015, prior to the first HPV vaccination). Indicators for program use were time of website use (ie, duration of intervention exposure) and completeness (ie, proportion of all available web pages visited). HPV vaccination uptake registered by Praeventis was used as the primary outcome. Secondary outcomes were IDM, decisional conflict, and social-psychological determinants of HPV vaccination uptake. RESULTS Among the 3995 invited mothers, 2509 (62.80%) logged on to the website, 2239 of whom (89.24%) visited at least one page of the intervention components. On average, mothers spent 21.39 minutes (SD 12.41) on the website and completed 50.04% (SD 26.18%) of the website components. Participants rated the website 7.64 (SD 1.39) on a 10-point scale. Program acceptability was significantly associated with completeness (β=4.36, P<.001), but not with time of website use (β=-.07, P=.77). Intention-to-treat analysis (N=3995) showed a significant positive effect of completeness on all outcome measures (all P<.003; Bonferroni-corrected α=.05/15 factors), including on HPV vaccination uptake. Time of website use had a significant positive effect on all outcomes (all P<.003), except for uptake (P=.20), risk perception when not vaccinated (P=.14), subjective norms (P=.03), and habit (P=.01). CONCLUSIONS Program use and acceptability of the intervention were adequate. Completeness was positively associated with acceptability. Furthermore, positive effects (ie, dose-response effects) were found for completeness and time of website use on the mothers' IDM, decisional conflict, and almost all of the social-psychological determinants of HPV vaccination acceptability. In addition, the extent to which mothers completed the intervention had a positive impact on their daughters' vaccination uptake. This indicates that the web-based, tailored intervention fits well with the mothers' needs, and that completeness of use is essential for improving HPV vaccination uptake, acceptability, and IDM. Program use should therefore be promoted. TRIAL REGISTRATION Netherlands Trial Register NTR4795; https://www.trialregister.nl/trial/4795.",2020,"Time of website use had a significant positive effect on all outcomes (P's <.003), except for uptake (P = .195), risk perception when not vaccinated (P = .144), subjective norms (P = .032), and habit (P = .013). ","['mothers of Dutch girls to-be-invited', '3995 invited mothers, 2509 mothers (62.80%) logged in', '2239 mothers (89.24%) visited at least one page of the intervention components']",[],"['decision-making (IDM), decisional conflict, and social psychological determinants of HPV vaccination uptake', 'Program acceptability', 'risk perception', 'HPV vaccination uptake', 'HPV vaccination uptake, acceptability, and IDM', 'completeness and time of website use on the mothers IDM, decisional conflict, and almost all of the social-psychological determinants of HPV vaccination acceptability', 'subjective norms']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0013862', 'cui_str': 'Polyacrylamide gel electrophoresis'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0449432', 'cui_str': 'Component'}]",[],"[{'cui': 'C0011109', 'cui_str': 'Decision making'}, {'cui': 'C0700287', 'cui_str': 'Informing'}, {'cui': 'C0231394', 'cui_str': 'Decisional conflict'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0439812', 'cui_str': 'Completeness'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}]",3995.0,0.0847614,"Time of website use had a significant positive effect on all outcomes (P's <.003), except for uptake (P = .195), risk perception when not vaccinated (P = .144), subjective norms (P = .032), and habit (P = .013). ","[{'ForeName': 'Mirjam', 'Initials': 'M', 'LastName': 'Pot', 'Affiliation': 'Child Health, Netherlands Organization for Applied Scientific Research (TNO), Leiden, Netherlands.'}, {'ForeName': 'Theo Gwm', 'Initials': 'TG', 'LastName': 'Paulussen', 'Affiliation': 'Child Health, Netherlands Organization for Applied Scientific Research (TNO), Leiden, Netherlands.'}, {'ForeName': 'Robert Ac', 'Initials': 'RA', 'LastName': 'Ruiter', 'Affiliation': 'Department of Work and Social Psychology, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Liesbeth', 'Initials': 'L', 'LastName': 'Mollema', 'Affiliation': 'National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control, Bilthoven, Netherlands.'}, {'ForeName': 'Miranda', 'Initials': 'M', 'LastName': 'Hofstra', 'Affiliation': 'Child Health, Netherlands Organization for Applied Scientific Research (TNO), Leiden, Netherlands.'}, {'ForeName': 'Hilde M', 'Initials': 'HM', 'LastName': 'Van Keulen', 'Affiliation': 'Child Health, Netherlands Organization for Applied Scientific Research (TNO), Leiden, Netherlands.'}]",Journal of medical Internet research,['10.2196/14822'] 1415,32521810,The Bluegreen Algae (AFA) Consumption over 48 Hours Increases the Total Number of Peripheral CD34+ Cells in Healthy Patients: Effect of Short-Term and Long-Term Nutritional Supplementation (Curcumin/AFA) on CD34+ Levels (Blood).,"Several active principles from plants could trigger the release of stem cells from the bone marrow. Stem cell mobilizers have shown side effects in patients. Thus, the purpose of this paper is to find the natural products from plants (curcuminoids, glycosinolate of sulforaphane, AFA bluegreen algae), which could be potential stem mobilizes without adverse side effects. The antioxidant curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-2,5-dione], glycosinolate of sulforaphane (broccoli) or AFA ( Aphanizomenon flos ) extract promote beneficial effects in patients. The number of circulating stem cells were monitored by HSC marker-CD34 by flow cytometry in peripheral blood from healthy subjects. CD34 is a hematological stem cells (HSC) marker. A double-blind study was conducted in 22 healthy subjects. We have evaluated whether short-term AFA- Aphanizomenon flos aquae -algae or curcuminoids consumption (powder or liquid formulation) over 48 consecutive hours could increase the total number of peripheral CD34+ blood cells ( n = 22, n = 5 subjects/group). The total number of circulating CD34 + cells were quantified after short-term and long-term nutritional supplementation; their levels were compared with their own basal levels ( n = 5/group, controls: before taking any supplement) or placebo-treated patients ( n = 7); their average age was 54 years old. We also evaluated whether long-term nutritional supplementation with several nutraceuticals could enhance HSC mobilization by increasing the total number of peripheral CD-34+ cell after seven or 38 consecutive days of administration ( n = 5, with seven placebo-treated patients). The long-term administration take place with these doses/day [curcuminoids: 2000 mg/day, equivalent to 120 mg of curcuminoids/day), glycosinolate of sulforaphane (66 mg/day), plus AFA Algae bluegreen extract (400 mg/day)]. On the last day (10 A.M.) of treatment, blood samples were collected six hours after taking these supplements; the average age was 54 years old. Notably, the blue green AFA algae extract consumption over 48 h enhances HSC mobilization by increasing the total number of peripheral CD34+ cells. The long-term administration with curcuminoids, glycosinolate of sulforaphane, and AFA bluegreen algae extract also increased the total number of CD34-HSC cells after seven or 38 days of consecutive of administration in healthy subjects.",2020,The number of circulating stem cells were monitored by HSC marker-CD34 by flow cytometry in peripheral blood from healthy subjects.,"['Healthy Patients', 'treated patients ( n = 7); their average age was 54 years old', 'healthy subjects', '22 healthy subjects', 'patients']","['AFA Algae bluegreen extract', 'glycosinolate of sulforaphane', 'placebo', 'curcuminoids, glycosinolate of sulforaphane, and AFA bluegreen algae extract', 'antioxidant curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-2,5-dione], glycosinolate of sulforaphane (broccoli) or AFA ( Aphanizomenon flos ) extract', 'blue green AFA algae extract consumption']","['total number of circulating CD34 + cells', 'total number of CD34-HSC cells', 'CD34+ Levels (Blood', 'Bluegreen Algae (AFA) Consumption', 'HSC mobilization', 'number of circulating stem cells', 'Total Number of Peripheral CD34+ Cells', 'total number of peripheral CD34+ cells', 'total number of peripheral CD34+ blood cells']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C1565999', 'cui_str': '(11C)2-(2-(dimethylaminomethylphenylthio))-5-fluoromethylphenylamine'}, {'cui': 'C0002028', 'cui_str': 'Algae'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0163159', 'cui_str': 'sulforafan'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0010467', 'cui_str': 'Curcumin'}, {'cui': 'C0331720', 'cui_str': 'Aphanizomenon'}, {'cui': 'C1319009', 'cui_str': 'Blue green color'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0882849', 'cui_str': 'Cell positive for CD34 antigen'}, {'cui': 'C0054953', 'cui_str': 'Lymphocyte antigen CD34'}, {'cui': 'C0018956', 'cui_str': 'Hematopoietic stem cell'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0002028', 'cui_str': 'Algae'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0038250', 'cui_str': 'Stem cell'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0005773', 'cui_str': 'Blood cell'}]",22.0,0.0700897,The number of circulating stem cells were monitored by HSC marker-CD34 by flow cytometry in peripheral blood from healthy subjects.,"[{'ForeName': 'José Joaquín', 'Initials': 'JJ', 'LastName': 'Merino', 'Affiliation': 'Department Farmacologia, Farmacognosia y Botánica, Facultad de Farmacia, Universidad Complutense de Madrid, 28040 \u200eMadrid\u200e, Spain.'}, {'ForeName': 'María Eugenia', 'Initials': 'ME', 'LastName': 'Cabaña-Muñoz', 'Affiliation': 'Private Dentist Practice, Private Clinic, 30001 Murcia, Spain.'}, {'ForeName': 'María Jesús', 'Initials': 'MJ', 'LastName': 'Pelaz', 'Affiliation': 'Stem Cell S.A Laboratory, 47151 Valladolid, Spain.'}]",Journal of personalized medicine,['10.3390/jpm10020049'] 1416,32522244,Phase II trial evaluating the clinical efficacy of cefixime for treatment of active syphilis in non-pregnant women in Brazil (CeBra).,"BACKGROUND Syphilis is a sexually and vertically transmitted infection caused by the bacteria Treponema pallidum for which there are few proven alternatives to penicillin for treatment. For pregnant women infected with syphilis, penicillin is the only WHO-recommended treatment that will treat the mother and cross the placenta to treat the unborn infant and prevent congenital syphilis. Recent shortages, national level stockouts as well as other barriers to penicillin use call for the urgent identification of alternative therapies to treat pregnant women infected with syphilis. METHODS This prospective, randomized, non-comparative trial will enroll non-pregnant women aged 18 years and older with active syphilis, defined as a positive rapid treponemal and a positive non-treponemal RPR test with titer ≥1:16. Women will be a, domized in a 2:1 ratio to receive the oral third generation cephalosporin cefixime at a dose of 400 mg two times per day for 10 days (n = 140) or benzathine penicillin G 2.4 million units intramuscularly based on the stage of syphilis infection (n = 70). RPR titers will be collected at enrolment, and at three, six, and nine months following treatment. Participants experiencing a 4-fold (2 titer) decline by 6 months will be considered as having an adequate or curative treatment response. DISCUSSION Demonstration of efficacy of cefixime in the treatment of active syphilis in this Phase 2 trial among non-pregnant women will inform a proposed randomized controlled trial to evaluate cefixime as an alternative treatment for pregnant women with active syphilis to evaluate prevention of congenital syphilis. TRIAL REGISTRATION Trial identifier: www.Clinicaltrials.gov, NCT03752112. Registration Date: November 22, 2018.",2020,"DISCUSSION Demonstration of efficacy of cefixime in the treatment of active syphilis in this Phase 2 trial among non-pregnant women will inform a proposed randomized controlled trial to evaluate cefixime as an alternative treatment for pregnant women with active syphilis to evaluate prevention of congenital syphilis. ","['pregnant women infected with', 'pregnant women infected with syphilis', 'non-pregnant women', 'pregnant women with active syphilis', 'pregnant women aged 18\u2009years and older with active syphilis, defined as a positive rapid treponemal and a positive non-treponemal RPR test with titer ≥1:16', 'Participants experiencing a 4-fold (2 titer) decline by 6\u2009months will be considered as having an adequate or curative treatment response', 'non-pregnant women in Brazil (CeBra']","['benzathine penicillin', 'cefixime', 'cephalosporin cefixime', 'syphilis, penicillin']",['RPR titers'],"[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0039128', 'cui_str': 'Syphilis'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0201405', 'cui_str': 'Rapid plasma reagin test'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0185026', 'cui_str': 'Plication'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}]","[{'cui': 'C0030829', 'cui_str': 'benzathine benzylpenicillin'}, {'cui': 'C0060400', 'cui_str': 'Cefixime'}, {'cui': 'C3536856', 'cui_str': 'Cephalosporin antibiotic product'}, {'cui': 'C0039128', 'cui_str': 'Syphilis'}, {'cui': 'C0030842', 'cui_str': 'Penicillin'}]","[{'cui': 'C0201405', 'cui_str': 'Rapid plasma reagin test'}, {'cui': 'C0475208', 'cui_str': 'Titer'}]",,0.230271,"DISCUSSION Demonstration of efficacy of cefixime in the treatment of active syphilis in this Phase 2 trial among non-pregnant women will inform a proposed randomized controlled trial to evaluate cefixime as an alternative treatment for pregnant women with active syphilis to evaluate prevention of congenital syphilis. ","[{'ForeName': 'Melanie M', 'Initials': 'MM', 'LastName': 'Taylor', 'Affiliation': 'Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland. mtaylor@who.int.'}, {'ForeName': 'Edna Oliveira', 'Initials': 'EO', 'LastName': 'Kara', 'Affiliation': 'Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'Maria Alix Leite', 'Initials': 'MAL', 'LastName': 'Araujo', 'Affiliation': 'University of Fortaleza (UNIFOR), Fortaleza, Brazil.'}, {'ForeName': 'Mariangela Freitas', 'Initials': 'MF', 'LastName': 'Silveira', 'Affiliation': 'Post-Graduate Program in Epidemiology, Federal University of Pelotas, Pelotas, Brazil.'}, {'ForeName': 'Angelica Espinosa', 'Initials': 'AE', 'LastName': 'Miranda', 'Affiliation': 'Federal University of Espírito Santo, Vitória, Brazil.'}, {'ForeName': 'Ivo Castelo', 'Initials': 'IC', 'LastName': 'Branco Coelho', 'Affiliation': 'Federal University of Ceará, Ambulatório de IST do Hospital Universitário da Universidade Federal do Ceará, Fortaleza, Brazil.'}, {'ForeName': 'Maria Luiza', 'Initials': 'ML', 'LastName': 'Bazzo', 'Affiliation': 'Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'ForeName': 'Gerson Fernando', 'Initials': 'GF', 'LastName': 'Mendes Pereira', 'Affiliation': 'Brazil Ministry of Health, Secretariat for Health Surveillance, Department of Chronic Conditions and Sexually Transmitted Infections, Brasília, Brazil.'}, {'ForeName': 'Silvana', 'Initials': 'S', 'LastName': 'Pereira Giozza', 'Affiliation': 'Brazil Ministry of Health, Secretariat for Health Surveillance, Department of Chronic Conditions and Sexually Transmitted Infections, Brasília, Brazil.'}, {'ForeName': 'Ximena Pamela Díaz', 'Initials': 'XPD', 'LastName': 'Bermudez', 'Affiliation': 'University of Brasília, Brasília, Brazil.'}, {'ForeName': 'Maeve B', 'Initials': 'MB', 'LastName': 'Mello', 'Affiliation': 'University of Brasília, Brasília, Brazil.'}, {'ForeName': 'Ndema', 'Initials': 'N', 'LastName': 'Habib', 'Affiliation': 'Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'My Huong', 'Initials': 'MH', 'LastName': 'Nguyen', 'Affiliation': 'Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'Soe Soe', 'Initials': 'SS', 'LastName': 'Thwin', 'Affiliation': 'Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Broutet', 'Affiliation': 'Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.'}]",BMC infectious diseases,['10.1186/s12879-020-04980-1'] 1417,32524803,"[Obstacles, difficulties, and facilitators in setting up a research project funded by the Hospital Program for Nursing and Paramedical Research : Lessons learned from a mental health research project]","Nursing research continues to grow and become self-sustaining. It was in this context that we received funding from the Hospital Program for Nursing and Paramedical Research for our research project on schizophrenia. Schizophrenia is a mental disorder that affects 1% of the general population, and is a crippling disease both cognitively and socially. Cognitive remediation and therapeutic education are nursing practices deemed suitable for the psychosocial rehabilitation of schizophrenia patients. We hypothesized that a therapeutic education program placed upstream of cognitive remediation would have beneficial effects. We planned to include eighty patients aged eighteen to sixty, randomized into two groups, one combining cognitive remediation and therapeutic education, the second using just cognitive remediation. Each patient was assessed using a range of neuropsychological scales. Due to difficulties encountered in including and following up with participants, our statistical results could not be used. We therefore turned our focus to the factors that facilitate and hinder the setting up of a nursing research project. We organized these factors into three areas : those related to the nurse ; those related to the care facility and the organization ; and those related to the research. The results were consistent with the literature and show how important it is to encourage nurses to be more involved in a scientific approach.",2020,The results were consistent with the literature and show how important it is to encourage nurses to be more involved in a scientific approach.,"['schizophrenia patients', 'eighty patients aged eighteen to sixty']",[],[],"[{'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3715206', 'cui_str': '18'}]",[],[],80.0,0.0143253,The results were consistent with the literature and show how important it is to encourage nurses to be more involved in a scientific approach.,"[{'ForeName': 'Mickaël', 'Initials': 'M', 'LastName': 'Mastracci', 'Affiliation': ''}, {'ForeName': 'Bilitys', 'Initials': 'B', 'LastName': 'Simon', 'Affiliation': ''}, {'ForeName': 'Ludovic', 'Initials': 'L', 'LastName': 'Serna', 'Affiliation': ''}, {'ForeName': 'Pierrette', 'Initials': 'P', 'LastName': 'Estingoy', 'Affiliation': ''}, {'ForeName': 'Annick', 'Initials': 'A', 'LastName': 'Perrin-Niquet', 'Affiliation': ''}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Bagur', 'Affiliation': ''}, {'ForeName': 'Annick', 'Initials': 'A', 'LastName': 'Bechet', 'Affiliation': ''}]",Recherche en soins infirmiers,['10.3917/rsi.140.0069'] 1418,32530426,Pay-it-forward gonorrhoea and chlamydia testing among men who have sex with men in China: a randomised controlled trial.,"BACKGROUND WHO recommends that men who have sex with men (MSM) receive gonorrhoea and chlamydia testing, but many evidence-based preventive services are unaffordable. The pay-it-forward strategy offers an individual a gift (eg, a test for sexually transmitted diseases) and then asks whether they would like to give a gift (eg, a future test) to another person. This study examined the effectiveness of a pay-it-forward programme to increase gonorrhoea and chlamydia testing among MSM in China. METHODS We did a randomised controlled superiority trial at three HIV testing sites run by MSM community-based organisations in Guangzhou and Beijing, China. We included MSM aged 16 years or older who were seeking HIV testing and met indications for gonorrhoea and chlamydia testing. Restricted randomisation was done using computer-generated permuted blocks. 30 groups were randomised into three arms (1:1:1): a pay-it-forward arm in which men were offered free gonorrhoea and chlamydia testing and then asked whether they would like to donate for testing of prospective participants, a pay-what-you-want arm in which men were offered free testing and given the option to pay any desired amount for the test, and a standard-of-care arm in which testing was offered at ¥150 (US$22). There was no masking to arm assignment. The primary outcome was gonorrhoea and chlamydia test uptake ascertained by administrative records. We used generalised estimating equations to estimate intervention effects with one-sided 95% CIs and a prespecified superiority margin of 20%. The trial is registered with ClinicalTrials.gov, NCT03741725. FINDINGS Between Dec 8, 2018, and Jan 19, 2019, 301 men were recruited and included in the analysis. 101 were randomly assigned to the pay-it-forward group, 100 to the pay-what-you-want group, and 100 to the standard-of-care group. Test uptake for gonorrhoea and chlamydia was 56% (57 of 101 participants) in the pay-it-forward arm, 46% (46 of 100 participants) in the pay-what-you-want arm, and 18% (18 of 100 participants) in the standard-of-care arm. The estimated difference in test uptake between the pay-it-forward and standard-of-care group was 38·4% (95% CI lower bound 28·4%). Among men in the pay-it-forward arm, 54 of 57 (95%) chose to donate to support testing for others. INTERPRETATION The pay-it-forward strategy can increase gonorrhoea and chlamydia testing uptake among Chinese MSM and could be a useful tool for scaling up preventive services that carry a mandatory fee. FUNDING US National Institute of Health; Special Programme for Research and Training in Tropical Diseases, sponsored by UNICEF, UNDP, World Bank, and WHO; the National Key Research and Development Program of China; Doris Duke Charitable Foundation; and Social Entrepreneurship to Spur Health.",2020,"Test uptake for gonorrhoea and chlamydia was 56% (57 of 101 participants) in the pay-it-forward arm, 46% (46 of 100 participants) in the pay-what-you-want arm, and 18% (18 of 100 participants) in the standard-of-care arm.","['MSM aged 16 years or older who were seeking HIV testing and met indications for gonorrhoea and chlamydia testing', 'men who have sex with men in China', 'MSM in China', 'three HIV testing sites run by MSM community-based organisations in Guangzhou and Beijing, China', 'Between Dec 8, 2018, and Jan 19, 2019, 301 men were recruited and included in the analysis', 'men who have sex with men (MSM']","['pay-it-forward arm in which men were offered free gonorrhoea and chlamydia testing', 'pay-it-forward group, 100 to the pay-what-you-want group, and 100 to the standard-of-care group', 'Pay-it-forward gonorrhoea and chlamydia testing', 'pay-it-forward programme', 'pay-what-you-want arm in which men were offered free testing and given the option to pay any desired amount for the test, and a standard-of-care arm in which testing']",['gonorrhoea and chlamydia test uptake'],"[{'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0018081', 'cui_str': 'Gonorrhea'}, {'cui': 'C0008148', 'cui_str': 'Chlamydia'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0018081', 'cui_str': 'Gonorrhea'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}]","[{'cui': 'C0018081', 'cui_str': 'Gonorrhea'}, {'cui': 'C0008148', 'cui_str': 'Chlamydia'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",301.0,0.098425,"Test uptake for gonorrhoea and chlamydia was 56% (57 of 101 participants) in the pay-it-forward arm, 46% (46 of 100 participants) in the pay-what-you-want arm, and 18% (18 of 100 participants) in the standard-of-care arm.","[{'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Yang', 'Affiliation': 'Dermatology Hospital of Southern Medical University, Guangzhou, China; University of North Carolina at Chapel Hill, Project-China, Guangzhou, China.'}, {'ForeName': 'Tiange P', 'Initials': 'TP', 'LastName': 'Zhang', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China; Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.'}, {'ForeName': 'Weiming', 'Initials': 'W', 'LastName': 'Tang', 'Affiliation': 'Dermatology Hospital of Southern Medical University, Guangzhou, China; University of North Carolina at Chapel Hill, Project-China, Guangzhou, China.'}, {'ForeName': 'Jason J', 'Initials': 'JJ', 'LastName': 'Ong', 'Affiliation': 'Central Clinical School, Monash University, Melbourne, VIC, Australia; London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Alexander', 'Affiliation': 'Yale Institute for Network Science, Yale University, New Haven, CT, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Forastiere', 'Affiliation': 'Yale Institute for Network Science, Yale University, New Haven, CT, USA; Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.'}, {'ForeName': 'Navin', 'Initials': 'N', 'LastName': 'Kumar', 'Affiliation': 'Yale Institute for Network Science, Yale University, New Haven, CT, USA.'}, {'ForeName': 'Katherine T', 'Initials': 'KT', 'LastName': 'Li', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China; Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Zou', 'Affiliation': 'Department of Biostatistics, University of North Carolina at Chapel Hill, NC, USA.'}, {'ForeName': 'Ligang', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Dermatology Hospital of Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Guodong', 'Initials': 'G', 'LastName': 'Mi', 'Affiliation': 'Blued, Beijing, China.'}, {'ForeName': 'Yehua', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China.'}, {'ForeName': 'Wenting', 'Initials': 'W', 'LastName': 'Huang', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Lee', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China.'}, {'ForeName': 'Weizan', 'Initials': 'W', 'LastName': 'Zhu', 'Affiliation': 'Zhitong Guangzhou LGBT Center, Guangzhou, China.'}, {'ForeName': 'Danyang', 'Initials': 'D', 'LastName': 'Luo', 'Affiliation': 'Zhitong Guangzhou LGBT Center, Guangzhou, China.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Vickerman', 'Affiliation': 'School of Social and Community Medicine, University of Bristol, Bristol, UK.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China; London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Yang', 'Affiliation': 'Dermatology Hospital of Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Nicholas A', 'Initials': 'NA', 'LastName': 'Christakis', 'Affiliation': 'Yale Institute for Network Science, Yale University, New Haven, CT, USA.'}, {'ForeName': 'Joseph D', 'Initials': 'JD', 'LastName': 'Tucker', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China; London School of Hygiene and Tropical Medicine, London, UK. Electronic address: jdtucker@med.unc.edu.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(20)30172-9'] 1419,32502443,"Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.","BACKGROUND Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through multiple mechanisms and augmented antitumour activity in multiple malignancies. We aimed to assess the efficacy and safety of atezolizumab (anti-PD-L1) alone and combined with bevacizumab (anti-VEGF) in patients with unresectable hepatocellular carcinoma. METHODS GO30140 is an open-label, multicentre, multiarm, phase 1b study that enrolled patients at 26 academic centres and community oncology practices in seven countries worldwide. The study included five cohorts, and the two hepatocellular carcinoma cohorts, groups A and F, are described here. Inclusion criteria for these two groups included age 18 years and older; histologically, cytologically, or clinically (per American Association for the Study of Liver Diseases criteria) confirmed unresectable hepatocellular carcinoma that was not amenable to curative treatment; no previous systemic treatment; and Eastern Cooperative Oncology Group performance status of 0 or 1. In group A, all patients received atezolizumab (1200 mg) and bevacizumab (15 mg/kg) intravenously every 3 weeks. In group F, patients were randomly assigned (1:1) to receive intravenous atezolizumab (1200 mg) plus intravenous bevacizumab (15 mg/kg) every 3 weeks or atezolizumab alone by interactive voice-web response system using permuted block randomisation (block size of two) and stratification factors of geographical region; macrovascular invasion, extrahepatic spread, or both; and baseline α-fetoprotein concentration. Primary endpoints were confirmed objective response rate in all patients who received the combination treatment for group A and progression-free survival in the intention-to-treat population in group F, both assessed by an independent review facility according to Response Evaluation Criteria in Solid Tumors version 1.1. In both groups, safety was assessed in all patients who received at least one dose of any study treatment. This study is registered with ClinicalTrials.gov, NCT02715531, and is closed to enrolment. FINDINGS In group A, 104 patients were enrolled between July 20, 2016, and July 31, 2018, and received atezolizumab plus bevacizumab. With a median follow-up of 12·4 months (IQR 8·0-16·2), 37 (36%; 95% CI 26-46) of 104 patients had a confirmed objective response. The most common grade 3-4 treatment-related adverse events were hypertension (13 [13%]) and proteinuria (seven [7%]). Treatment-related serious adverse events occurred in 25 (24%) patients and treatment-related deaths in three (3%) patients (abnormal hepatic function, hepatic cirrhosis, and pneumonitis). In group F, 119 patients were enrolled and randomly assigned (60 to atezolizumab plus bevacizumab; 59 to atezolizumab monotherapy) between May 18, 2018, and March 7, 2019. With a median follow-up of 6·6 months (IQR 5·5-8·5) for the atezolizumab plus bevacizumab group and 6·7 months (4·2-8·2) for the atezolizumab monotherapy group, median progression-free survival was 5·6 months (95% CI 3·6-7·4) versus 3·4 months (1·9-5·2; hazard ratio 0·55; 80% CI 0·40-0·74; p=0·011). The most common grade 3-4 treatment-related adverse events in group F were hypertension (in three [5%] patients in the atezolizumab plus bevacizumab group; none in the atezolizumab monotherapy group) and proteinuria (in two [3%] patients in the atezolizumab plus bevacizumab group; none in the atezolizumab monotherapy group). Treatment-related serious adverse events occurred in seven (12%) patients in the atezolizumab plus bevacizumab group and two (3%) patients in the atezolizumab monotherapy group. There were no treatment-related deaths. INTERPRETATION Our study shows longer progression-free survival with a combination of atezolizumab plus bevacizumab than with atezolizumab alone in patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy. Therefore, atezolizumab plus bevacizumab might become a promising treatment option for these patients. This combination is being compared with standard-of-care sorafenib in a phase 3 trial. FUNDING F Hoffmann-La Roche/Genentech.",2020,The most common grade 3-4 treatment-related adverse events in group F were hypertension,"['119 patients', 'patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy', 'unresectable hepatocellular carcinoma (GO30140', 'Inclusion criteria for these two groups included age 18 years and older; histologically, cytologically, or clinically (per American Association for the Study of Liver Diseases criteria) confirmed unresectable hepatocellular carcinoma that was not amenable to curative treatment; no previous systemic treatment; and Eastern Cooperative Oncology Group performance status of 0 or 1', 'enrolled patients at 26 academic centres and community oncology practices in seven countries worldwide', '104 patients were enrolled between July 20, 2016, and July 31, 2018, and received', 'patients with unresectable hepatocellular carcinoma']","['atezolizumab alone', 'intravenous atezolizumab (1200 mg) plus intravenous bevacizumab', 'atezolizumab (anti-PD-L1) alone and combined with bevacizumab (anti-VEGF', 'atezolizumab', 'atezolizumab alone by interactive voice-web response system', 'Atezolizumab with or without bevacizumab', 'standard-of-care sorafenib', 'atezolizumab monotherapy', 'bevacizumab', 'atezolizumab plus bevacizumab']","['median progression-free survival', 'progression-free survival', 'efficacy and safety', 'serious adverse events', 'proteinuria', 'objective response rate', 'hypertension']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1112459', 'cui_str': 'Liver cell carcinoma non-resectable'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0023895', 'cui_str': 'Disease of liver'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C4517527', 'cui_str': '104'}]","[{'cui': 'C4055433', 'cui_str': 'atezolizumab'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C4517548', 'cui_str': '1200'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",104.0,0.146586,The most common grade 3-4 treatment-related adverse events in group F were hypertension,"[{'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Lee', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Baek-Yeol', 'Initials': 'BY', 'LastName': 'Ryoo', 'Affiliation': 'Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Chih-Hung', 'Initials': 'CH', 'LastName': 'Hsu', 'Affiliation': 'National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Kazushi', 'Initials': 'K', 'LastName': 'Numata', 'Affiliation': 'Yokohama City University Medical Center, Yokohama, Japan.'}, {'ForeName': 'Stacey', 'Initials': 'S', 'LastName': 'Stein', 'Affiliation': 'Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Verret', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Hack', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Spahn', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Liu', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Heba', 'Initials': 'H', 'LastName': 'Abdullah', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Yulei', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Genentech, South San Francisco, CA, USA.'}, {'ForeName': 'Aiwu Ruth', 'Initials': 'AR', 'LastName': 'He', 'Affiliation': 'Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.'}, {'ForeName': 'Kyung-Hun', 'Initials': 'KH', 'LastName': 'Lee', 'Affiliation': 'Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Electronic address: kyunghunlee@snu.ac.kr.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30156-X'] 1420,32507144,Osteopathic manipulative treatment combined with exercise improves pain and disability in individuals with non-specific chronic neck pain: A pragmatic randomized controlled trial.,"PURPOSE To determine effectiveness of osteopathic manipulative treatment combined with stretching and strengthening exercises in the cervical region on pain and disability in individuals with non-specific chronic neck pain. METHODS 90 adults with non-specific chronic neck pain were randomized to either exercises group (EG, n = 45) or osteopathic manipulative treatment associated with exercises group (OMT/EG, n = 45). The primary outcomes were obtained by the use of Numeric Pain-Rating Scale (NPRS), Pressure Pain Threshold (PPT) and Neck Disability Index (NDI). Secondary outcomes included range of motion (ROM) for cervical spine rotation, Fear-Avoidance Beliefs Questionnaire Work/Physical Activity (FABQ-W/PA) and Pain-self efficacy at two different moments: baseline and 4 weeks after the first treatment. Techniques and dosages of OMT were selected pragmatically by a registered osteopath. Generalized Estimating Equations model (GEE), complemented by the Least Significant Difference (LSD) and the intention-to-treat analysis, was used to assess the clinical outcomes. RESULTS Analysis with GEE indicated that OMT/EG reduced pain and disability more than the EG alone after 4 weeks of treatment with statistically significant difference (p < 0,05), as well as cervical active rotation was significantly improved (p = 0.03). There were no between-group differences observed in Pressure Pain Threshold (PPT) measure, Fear-Avoidance Beliefs Questionnaire and Pain-self efficacy. CONCLUSION The association between OMT and exercises reduces pain and improves functional disability more than only exercise for individuals with non-specific chronic neck pain.",2020,"There were no between-group differences observed in Pressure Pain Threshold (PPT) measure, Fear-Avoidance Beliefs Questionnaire and Pain-self efficacy. ","['individuals with non-specific chronic neck pain', '90 adults with non-specific chronic neck pain']","['OMT and exercises', 'osteopathic manipulative treatment combined with stretching and strengthening exercises', 'Osteopathic manipulative treatment combined with exercise', 'OMT', 'exercises group (EG, n\u202f=\u202f45) or osteopathic manipulative treatment associated with exercises group (OMT/EG, n\u202f=\u202f45']","['Numeric Pain-Rating Scale (NPRS), Pressure Pain Threshold (PPT) and Neck Disability Index (NDI', 'pain and disability', 'cervical active rotation', 'range of motion (ROM) for cervical spine rotation, Fear-Avoidance Beliefs Questionnaire Work/Physical Activity (FABQ-W/PA) and Pain-self efficacy', 'Pressure Pain Threshold (PPT) measure, Fear-Avoidance Beliefs Questionnaire and Pain-self efficacy', 'OMT/EG reduced pain and disability', 'functional disability']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205370', 'cui_str': 'Non-specific'}, {'cui': 'C0746815', 'cui_str': 'Chronic neck pain'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0949744', 'cui_str': 'Osteopathic manipulation'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0270814', 'cui_str': 'Spastic syndrome'}, {'cui': 'C0452260', 'cui_str': 'Muscular strength development exercise'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0728985', 'cui_str': 'Structure of cervical vertebral column'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]",90.0,0.103638,"There were no between-group differences observed in Pressure Pain Threshold (PPT) measure, Fear-Avoidance Beliefs Questionnaire and Pain-self efficacy. ","[{'ForeName': 'Sandro', 'Initials': 'S', 'LastName': 'Groisman', 'Affiliation': 'Graduate Program in Health Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil; Instituto Brasileiro de Osteopatia (IBO), Brazil. Electronic address: sandrogroisman@gmail.com.'}, {'ForeName': 'Tais', 'Initials': 'T', 'LastName': 'Malysz', 'Affiliation': 'Graduate Program in Neuroscience, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Department of Morphological Sciences, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.'}, {'ForeName': 'Luciano', 'Initials': 'L', 'LastName': 'de Souza da Silva', 'Affiliation': 'Instituto Brasileiro de Osteopatia (IBO), Brazil.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Rocha Ribeiro Sanches', 'Affiliation': 'Instituto Brasileiro de Osteopatia (IBO), Brazil.'}, {'ForeName': 'Karoline', 'Initials': 'K', 'LastName': 'Camargo Bragante', 'Affiliation': 'Graduate Program in Health Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil.'}, {'ForeName': 'Franciele', 'Initials': 'F', 'LastName': 'Locatelli', 'Affiliation': 'Instituto Brasileiro de Osteopatia (IBO), Brazil.'}, {'ForeName': 'Cleder', 'Initials': 'C', 'LastName': 'Pontel Vigolo', 'Affiliation': 'Instituto Brasileiro de Osteopatia (IBO), Brazil.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Vaccari', 'Affiliation': 'Instituto Brasileiro de Osteopatia (IBO), Brazil.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Homercher Rosa Francisco', 'Affiliation': 'Instituto Brasileiro de Osteopatia (IBO), Brazil.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Monteiro Steigleder', 'Affiliation': 'Instituto Brasileiro de Osteopatia (IBO), Brazil.'}, {'ForeName': 'Geraldo Pereira', 'Initials': 'GP', 'LastName': 'Jotz', 'Affiliation': 'Graduate Program in Health Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil; Department of Morphological Sciences, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2019.11.002'] 1421,32507145,Evaluating the short term effects of kinesiology taping and stretching of gastrocnemius on postural control: A randomized clinical trial.,"INTRODUCTION The ability to maintain balance is essential for both remaining in the standing position and preventing falls. Physical therapy techniques such as kinesiology taping (KT) and stretching are considered to be effective measures in ameliorating balance issues. However, there is no available study comparing the effects of these two methods on postural control. Thus, the current study aims to investigate and compare the efficacy of interventions accomplished through these methods on young and elderly subjects. METHOD In a single-blind randomized clinical trial, 40 young subjects (<30 years) and 40 elderly subjects (>60 years) were randomly assigned to two groups of KT and stretching. In the first group, inhibitory tape was applied to the gastrocnemius muscle. In the second group, 60 s of stretch was repeated 4 times. The static balance was evaluated before and after the interventions using the single-leg standing (SLS) test along with measurements of the velocity and displacement of the center of pressure by the force plate. RESULTS Based on the Mann-Whitney test, there were no significant differences between the tape and stretching techniques in the study variables of either group of participants, before and after the interventions (p > 0.05). However, the results of the Wilcoxon test showed a significant increase in single-leg stance time in the stretching group in the elderly subjects (p = 0.03). MANOVA results demonstrated significant group and time effects only in the SLS parameter (p < 0.05). CONCLUSION Stretching the gastrocnemius seems to be more efficacious than KT for improving balance problems in older adults. LEVEL OF EVIDENCE II.",2020,"Based on the Mann-Whitney test, there were no significant differences between the tape and stretching techniques in the study variables of either group of participants, before and after the interventions (p > 0.05).","['young and elderly subjects', 'older adults', '40 young subjects (<30 years) and 40 elderly subjects (>60 years']","['KT and stretching', 'kinesiology taping and stretching of gastrocnemius', 'KT', 'Physical therapy techniques such as kinesiology taping (KT) and stretching']","['static balance', 'single-leg stance time']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0270814', 'cui_str': 'Spastic syndrome'}, {'cui': 'C0242691', 'cui_str': 'Gastrocnemius muscle structure'}, {'cui': 'C0949766', 'cui_str': 'Physical therapy procedure'}]","[{'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",40.0,0.0179115,"Based on the Mann-Whitney test, there were no significant differences between the tape and stretching techniques in the study variables of either group of participants, before and after the interventions (p > 0.05).","[{'ForeName': 'Zohreh', 'Initials': 'Z', 'LastName': 'Shafizadegan', 'Affiliation': 'Musculoskeletal Research Center, Department of Physiotherapy, School of Rehabilitation Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: z.shafizadegan@rehab.mui.ac.ir.'}, {'ForeName': 'Hamzeh', 'Initials': 'H', 'LastName': 'Baharlouei', 'Affiliation': 'Student Research Committee, Ahvaz Jundishapur Univesity of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Omid', 'Initials': 'O', 'LastName': 'Khoshavi', 'Affiliation': 'Musculoskeletal Research Center, Department of Physiotherapy, School of Rehabilitation Sciences, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Garmabi', 'Affiliation': 'Student Research Committee, Rehabilitation School, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Niloofar', 'Initials': 'N', 'LastName': 'Fereshtenejad', 'Affiliation': 'Musculoskeletal Research Center, Instructor at Isfahan University of Medical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2019.11.003'] 1422,32507146,Adding Temporomandibular joint treatments to routine physiotherapy for patients with non-specific chronic neck pain: A randomized clinical study.,"INTRODUCTION Neck Pain can be related to the disorders of other adjacent areas such as the Temporomandibular Joint (TMJ). This study aimed to investigate whether there is value in adding TMJ treatments to routine physiotherapy in patients with non-specific chronic neck pain compared with a control group. METHODS A randomized, single-blind, clinical study desined including two groups of patients. Group A (20 people) received routine physiotherapy for neck pain and group B (20 people) received TMJ manual therapy plus exercise therapy in addition to routine physiotherapy for neck pain. The Treatment program included six sessions for two days a week over a period of 21 days. Assessments were performed during the first session, in the last session and one month after treatment as a follow-up. Outcome measures included neck range of motion (ROM), neck disability index (NDI) and visual analogue scale (VAS). Before starting the study, the reliability of methods for measuring neck ROM was evaluated. RESULTS Participants were 21 women and 19 men. Initially, a pilot study was carried out on the 40 volunteers to assess the reliability of the measurement methods, and the results were acceptable. With both the control group and the intervention group, the indexes showed significant improvement (p < 0.001), although the intervention group showed more improvement (p < 0.001). CONCLUSION This result means adding treatments of TMJ to routine neck physiotherapy can magnify the effect of the intervention, a significant change still in evidence at follow up. Moreover, given the clinically important differences, our results for VAS and NDI were acceptable.",2020,"With both the control group and the intervention group, the indexes showed significant improvement (p < 0.001), although the intervention group showed more improvement (p < 0.001). ","['Participants were 21 women and 19 men', 'patients with non-specific chronic neck pain', '40 volunteers', 'patients with non-specific chronic neck pain compared with a control group', 'two groups of patients']","['TMJ', 'routine physiotherapy', 'TMJ manual therapy plus exercise therapy', 'Temporomandibular joint treatments', 'routine physiotherapy for neck pain']","['neck range of motion (ROM), neck disability index (NDI) and visual analogue scale (VAS']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205370', 'cui_str': 'Non-specific'}, {'cui': 'C0746815', 'cui_str': 'Chronic neck pain'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0039493', 'cui_str': 'Temporomandibular joint structure'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0454525', 'cui_str': 'Manual therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}]","[{'cui': 'C1319209', 'cui_str': 'Neck joint - range of movement'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",21.0,0.0405683,"With both the control group and the intervention group, the indexes showed significant improvement (p < 0.001), although the intervention group showed more improvement (p < 0.001). ","[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Ghodrati', 'Affiliation': 'Health and Rehabilitation Sciences Program, University of Western Ontario, London, Canada.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Mosallanezhad', 'Affiliation': 'Department of Physical Therapy and Research Center of Aging, University of Social Welfare and Rehabilitation Sciences (USWR), Tehran, Iran. Electronic address: zmosallanezhad@yahoo.com.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Shati', 'Affiliation': 'Mental Health Research Center, School of Behavioral Sciences and Mental Health, Tehran Institute of Psychiatry, Iran University of Medical Sciences (IUMS), Tehran, Iran.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Noroozi', 'Affiliation': 'Psychosis Research Center, University of Social Welfare and Rehabilitation Sciences (USWR), Tehran, Iran.'}, {'ForeName': 'Afsun Nodehi', 'Initials': 'AN', 'LastName': 'Moghadam', 'Affiliation': 'Department of Physical Therapy and Research Center of Aging, University of Social Welfare and Rehabilitation Sciences (USWR), Tehran, Iran.'}, {'ForeName': 'Mohamad', 'Initials': 'M', 'LastName': 'Rostami', 'Affiliation': 'Department of Physical Therapy and Research Center of Aging, University of Social Welfare and Rehabilitation Sciences (USWR), Tehran, Iran.'}, {'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Nourbakhsh', 'Affiliation': 'Department of Physical Therapy, University of the North Georgia, GA, USA.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2019.11.004'] 1423,32507149,Acute effects of whole-body vibration on spinal excitability level and ankle plantar flexion spasticity in post-stroke individuals: A randomized controlled trial.,"INTRODUCTION This study aimed to evaluate the acute effects (up to 30 min) of whole-body vibration (WBV) on spinal excitability level and ankle plantar flexion spasticity in chronic stroke subjects. METHODS Twenty-one subjects (age 30-70 years old) with chronic stroke and ankle plantar flexion spasticity were randomly assigned to the vibration group (VG, n = 11) or the control group (CG, n = 10). Subjects in the VG underwent 10 minutes of WBV with a frequency of 35 Hz and amplitude of 2 mm. Subjects in the CG remained on the platform for 10 min without receiving vibratory stimulus. The spinal excitability level was estimated by the Hmax/Mmax ratio extracted from the H-reflex with simple stimulus examination. The value of the second/first wave ratio (H2/H1 ratio) at the peak of the first facilitation was also considered through the recovery curve with double stimulation. Spasticity was estimated by the Modified Ashworth Scale (MAS) and global perception of change. All outcomes were assessed before and at 10, 20, and 30 min after the WBV, except for MAS, which was evaluated only 10 min after WBV. RESULTS No between-group differences were found in either the spinal excitability level or plantar flexor spasticity at the three evaluated moments after WBV. CONCLUSION These results suggest that WBV does not reduce spinal excitability level or spasticity of the plantar flexor muscles in chronic stroke patients in the first 30 min after vibratory stimulus.",2020,"No between-group differences were found in either the spinal excitability level or plantar flexor spasticity at the three evaluated moments after WBV. ","['post-stroke individuals', 'Twenty-one subjects (age 30-70 years old) with chronic stroke and ankle plantar flexion spasticity', 'chronic stroke subjects']","['whole-body vibration', 'vibration group (VG, n\u202f=\u202f11) or the control group (CG', 'WBV', 'whole-body vibration (WBV']","['spinal excitability level or spasticity of the plantar flexor muscles', 'spinal excitability level and ankle plantar flexion spasticity', 'Spasticity', 'spinal excitability level or plantar flexor spasticity', 'spinal excitability level', 'Modified Ashworth Scale (MAS) and global perception of change']","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0231784', 'cui_str': 'Plantar flexion'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}]","[{'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0231784', 'cui_str': 'Plantar flexion'}, {'cui': 'C4707572', 'cui_str': 'Modified Ashworth Scale'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",,0.0236033,"No between-group differences were found in either the spinal excitability level or plantar flexor spasticity at the three evaluated moments after WBV. ","[{'ForeName': 'Rafael Moreira', 'Initials': 'RM', 'LastName': 'Sales', 'Affiliation': 'Department of Physical Therapy, Federal University of Pernambuco, Recife, Brazil.'}, {'ForeName': 'Mikhail Santos', 'Initials': 'MS', 'LastName': 'Cerqueira', 'Affiliation': 'Department of Physical Therapy, Federal University of Pernambuco, Recife, Brazil. Electronic address: mikalsantosc@hotmail.com.'}, {'ForeName': 'André Terácio', 'Initials': 'AT', 'LastName': 'Bezerra de Morais', 'Affiliation': 'Department of Physical Therapy, Federal University of Pernambuco, Recife, Brazil.'}, {'ForeName': 'Claúdia Regina O', 'Initials': 'CRO', 'LastName': 'de Paiva Lima', 'Affiliation': 'Department of Statistics, Federal University of Pernambuco, Recife, Brazil.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Lemos', 'Affiliation': 'Department of Physical Therapy, Federal University of Pernambuco, Recife, Brazil.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Galvão de Moura Filho', 'Affiliation': 'Department of Physical Therapy, Federal University of Pernambuco, Recife, Brazil.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2019.05.018'] 1424,32511774,Dietary sodium intake and cortisol measurements.,"OBJECTIVES To assess the influence of a dietary sodium intake intervention on cortisol measurements within the general population. DESIGN Cross-over intervention. PATIENTS Six hundred thirty adults without known Cushing syndrome, cardiovascular or renal disease completed a restricted dietary sodium diet (10 mmol/d, 230 mg/d) followed by cross-over to a liberalized dietary sodium diet (200 mmol/d, 4600 mg/d). Twenty-four-hour urine collection and biochemical investigations were performed at the end of each dietary intervention. RESULTS Mean 24-hour urinary free cortisol increased with liberalized sodium intake when compared with restricted sodium intake (178.0 ± 89.7 vs 121.3 ± 65.6 nmol/d, P < .001). Nearly all participants (84%) had an increase in the urinary free cortisol following liberalized sodium intake. This translated to a substantial difference in the proportion of participants exceeding categorical thresholds of urinary cortisol on liberalized vs restricted sodium intake: 62% vs 27% for 138 nmol/d (50 mcg/d), 46% vs 17% for 166 nmol/d (60 mcg/d), 32% vs 10% for 193 nmol/d (70 mcg/d), 23% vs 6% for 221 nmol/d (80 mcg/d), 17% vs 4% for 248 nmol/d (90 mcg/d). In parallel, there was a small decrease in morning total serum cortisol with liberalized sodium intake (303.0 ± 117.3 vs 326.4 ± 162.5 nmol/L, P < .001). CONCLUSIONS Increased dietary sodium intake increases urinary free cortisol excretion and may increase the risk for false-positive results. Variations in dietary sodium intake may influence the interpretations of cortisol measurements performed to evaluate for hypercortisolism.",2020,"Mean 24-hour urinary free cortisol increased with liberalized sodium intake when compared with restricted sodium intake (178.0 ± 89.7 vs. 121.3 ± 65.6 nmol/day, p<0.001).","['630 adults without known Cushing syndrome, cardiovascular or renal disease completed a']","['restricted dietary sodium diet (10 mmol/day, 230 mg/day) followed by cross-over to a liberalized dietary sodium diet', 'dietary sodium intake intervention']","['Mean 24-hour urinary free cortisol', 'Dietary Sodium Intake and Cortisol Measurements', 'morning total serum cortisol', 'urinary free cortisol', 'cortisol measurements']","[{'cui': 'C4708165', 'cui_str': '630'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0010481', 'cui_str': ""Cushing's syndrome""}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0037570', 'cui_str': 'Dietary Sodium'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0439433', 'cui_str': 'mmol/24h'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0010366', 'cui_str': 'Genetic crossing over'}, {'cui': 'C0425433', 'cui_str': 'Dietary sodium intake'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0474662', 'cui_str': 'Cortisol measurement, free, urine'}, {'cui': 'C0425433', 'cui_str': 'Dietary sodium intake'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0236396', 'cui_str': 'Serum cortisol measurement'}]",630.0,0.0210742,"Mean 24-hour urinary free cortisol increased with liberalized sodium intake when compared with restricted sodium intake (178.0 ± 89.7 vs. 121.3 ± 65.6 nmol/day, p<0.001).","[{'ForeName': 'Angela X', 'Initials': 'AX', 'LastName': 'Chen', 'Affiliation': ""Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Andrea V', 'Initials': 'AV', 'LastName': 'Haas', 'Affiliation': ""Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Gordon H', 'Initials': 'GH', 'LastName': 'Williams', 'Affiliation': ""Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Vaidya', 'Affiliation': ""Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.""}]",Clinical endocrinology,['10.1111/cen.14262'] 1425,32512477,"Effect of a maximal exercise test on serum and urinary concentrations of magnesium, phosphorous, rubidium and strontium in athletes.","AIM This study aims to determine the changes induced by a maximal exercise test until exhaustion on the serum and urinary concentrations of Magnesium (Mg), Phosphorous (P), Rubidium (Rb) and Strontium (Sr) in athletes (AG) and sedentary students (SG). METHODS Fifty subjects participated in the study divided into two groups. In AG there were twenty-five male athletes and in SG there were twenty-five male sedentary students. Both groups performed an exercise test until exhaustion, starting at 8 or 10 km/h respectively, and increasing the speed at 1 km/h every 400 m. Serum and urine samples were obtained from all participants before and after the test. RESULTS Regarding the basal status, AG showed lower values of Mg in serum (p < 0.05) and urine (p < 0.01), but higher concentrations of serum P (p < 0.05) in comparison to SG. Comparing the pre and post-test values, corrected or non-corrected for hemoconcentration in serum and for creatinine in urine, AG showed a decrease in serum Mg (p < 0.05), in serum P (p < 0.01) and in urinary Sr (p < 0.01) while an increase was observed in urinary P (p < 0.05) and in urinary Rb (p < 0.05). CONCLUSIONS It can be concluded that a treadmill test until exhaustion leads to changes in serum and urinary concentrations of minerals in both AG and SG males. This may reflect an adaptive response of the body to overcome the physical stress and, in some cases, to avoid loss of these elements.",2020,"Regarding the basal status, AG showed lower values of Mg in serum (p < 0.05) and urine (p < 0.01), but higher concentrations of serum P (p < 0.05) in comparison to SG.","['athletes', 'athletes (AG) and sedentary students (SG', 'In AG there were twenty-five male athletes and in SG there were twenty-five male sedentary students', 'Fifty subjects participated in the study divided into two groups']",['maximal exercise test'],"['urinary Rb', 'serum and urinary concentrations of Magnesium (Mg), Phosphorous (P), Rubidium (Rb) and Strontium (Sr', 'urinary Sr', 'serum and urinary concentrations of magnesium, phosphorous, rubidium and strontium']","[{'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}]","[{'cui': 'C0035930', 'cui_str': 'Rubidium'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0232827', 'cui_str': 'Urinary concentration'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0031705', 'cui_str': 'Phosphorus'}, {'cui': 'C0038467', 'cui_str': 'Strontium'}]",25.0,0.0207851,"Regarding the basal status, AG showed lower values of Mg in serum (p < 0.05) and urine (p < 0.01), but higher concentrations of serum P (p < 0.05) in comparison to SG.","[{'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Muñoz', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: diegomun@unex.es.'}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'Grijota', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: fgrijota@gmail.com.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Siquier-Coll', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: jsiquier@alumnos.unex.es.'}, {'ForeName': 'Víctor', 'Initials': 'V', 'LastName': 'Toro-Román', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: vtororom@alumnos.unex.es.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Bartolomé', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: ignbs.1991@gmail.com.'}, {'ForeName': 'Marcos', 'Initials': 'M', 'LastName': 'Maynar-Mariño', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: mmaynar@unex.es.'}]",Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS),['10.1016/j.jtemb.2020.126572'] 1426,32514007,Prenatal consults with illustrated literature (PnCIL): a RCT studying visual aids during prenatal consults.,"OBJECTIVE We hypothesize that addition of illustrated handouts during prenatal consultations decreases maternal anxiety and improves maternal knowledge. STUDY DESIGN Inpatient gravid women at 25 0/7-34 6/7 weeks gestation were randomized to Standard or Illustrated consults, verbal consults supplemented with a visual handout. Post consult surveys were administered assessing maternal anxiety and knowledge acquisition. RESULT We enrolled 82 women; 54 to Standard Consult, 28 to Illustrated Consult. Consult duration was the same across arms. Anxiety and knowledge were not impacted by the intervention overall. We found higher mean knowledge by 17% for consults ≥31 min (P = 0.006; 95% CI 0.67-3.82), and 13% in primigravids (P = 0.032; 95% CI 0.15-3.21) in the intervention arm. CONCLUSIONS Using illustrated handouts is feasible and does not increase duration of prenatal consults. It may improve knowledge acquisition in long consults and in primigravida women, although it does not impact anxiety and knowledge overall.",2020,"We found higher mean knowledge by 17% for consults ≥31 min (P = 0.006; 95% CI 0.67-3.82), and 13% in primigravids (P = 0.032; 95% CI 0.15-3.21) in the intervention arm. ","['Inpatient gravid women at 25 0/7-34 6/7 weeks gestation', 'We enrolled 82 women; 54 to Standard Consult, 28 to Illustrated Consult']","['illustrated literature (PnCIL', 'Standard or Illustrated consults, verbal consults supplemented with a visual handout']","['Anxiety and knowledge', 'knowledge acquisition', 'maternal anxiety and knowledge acquisition', 'maternal\xa0anxiety and improves maternal knowledge', 'mean knowledge']","[{'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}]","[{'cui': 'C0023866', 'cui_str': 'Literature'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0234621', 'cui_str': 'Visual'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",82.0,0.0820501,"We found higher mean knowledge by 17% for consults ≥31 min (P = 0.006; 95% CI 0.67-3.82), and 13% in primigravids (P = 0.032; 95% CI 0.15-3.21) in the intervention arm. ","[{'ForeName': 'Namrita J', 'Initials': 'NJ', 'LastName': 'Odackal', 'Affiliation': 'Division of Neonatology, St. Vincent Hospital, Billings, MT, USA. namrita.j.odackal@gmail.com.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Conaway', 'Affiliation': 'Division of Translational Research and Applied Statistics, Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Juyoung', 'Initials': 'J', 'LastName': 'Cha', 'Affiliation': 'School of Arts and Sciences, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Jonathan R', 'Initials': 'JR', 'LastName': 'Swanson', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, University of Virginia, Charlottesville, VA, USA.'}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-020-0709-y'] 1427,32686502,Bone mineralisation adjacent to cemented and uncemented acetabular cups: analysis by [18F]-fluoride-PET in a randomised clinical trial.,"PURPOSE We present a randomised clinical trial using F-PET/CT to analyse new bone metabolic mineralisation adjacent to acetabular cups following total hip arthoplasty (THA). PATIENTS AND METHODS THA was performed on 26 patients (26 cases) with hip OA. Patients with hip osteoarthritis (OA) were randomly assigned to operations with cemented or uncemented acetabular components. The contralateral, healthy acetabulum was used as referent for normal bone metabolism. The patients were analysed with radiography, clinical scoring, and F-PET/CT preoperatively, and at 6 weeks and 6 months postoperatively. RESULTS No major complications were recorded, and clinical results were good in all patients. Radiography showed all cups to be stable. The bone-forming activity, as measured by F-PET/CT, was quantified as standardised uptake values (SUV). The mean SUV was 4.6 (6 weeks) and 3.5 (6 months) around the uncemented cups, and 4.8 and 4.0, respectively, for the cemented cups. Normal healthy bone metabolism in the referent was 2.8 and 2.7 SUV at 6 weeks and 6 months, respectively. P < 0.01 for the cemented group at 6 weeks and 6 months, for the uncemented group only at 6 weeks. INTERPRETATION An acetabulum affected by OA has elevated SUV activity. Both cemented and uncemented cups had elevated bone metabolic activity at 6 weeks. The raised activity was interpreted as an effect from bone mineralisation secondary to surgical trauma and healing, and to the OA. At 6 months, activity was more normalised for the uncemented group than for the cemented, suggesting healing may terminate faster in the uncemented group. Postoperative bone metabolic activity can be analysed in detail by F-PET/CT.ClinicalTrials.gov Identifier: NCT01623687.",2020,"P < 0.01 for the cemented group at 6 weeks and 6 months, for the uncemented group only at 6 weeks. ","['total hip arthoplasty (THA', '26 patients (26 cases) with hip OA', 'Patients with hip osteoarthritis (OA']","['Bone mineralisation adjacent to cemented and uncemented acetabular cups: analysis by [18F]-fluoride-PET', 'Radiography', 'operations with cemented or uncemented acetabular components', 'F-PET/CT']","['elevated SUV activity', 'Normal healthy bone metabolism', 'elevated bone metabolic activity', 'Postoperative bone metabolic activity', 'activity', 'mean SUV']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0029410', 'cui_str': 'Osteoarthritis of hip'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}]","[{'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0205117', 'cui_str': 'Juxta-posed'}, {'cui': 'C0011343', 'cui_str': 'Cementum structure'}, {'cui': 'C0220647', 'cui_str': 'Carcinoma of unknown primary'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0016327', 'cui_str': 'Fluoride'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C1699633', 'cui_str': 'Positron emission tomography with computed tomography'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",26.0,0.0403775,"P < 0.01 for the cemented group at 6 weeks and 6 months, for the uncemented group only at 6 weeks. ","[{'ForeName': 'Gösta', 'Initials': 'G', 'LastName': 'Ullmark', 'Affiliation': '¹Department of Orthopaedics, Gävle Hospital, Gävle, Sweden.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Sörensen', 'Affiliation': 'Department of Nuclear Medicine, Uppsala University Hospital, Uppsala, Sweden.'}, {'ForeName': 'Olle', 'Initials': 'O', 'LastName': 'Nilsson', 'Affiliation': 'Department of Orthopaedics, Uppsala University Hospital, Sweden.'}, {'ForeName': 'Enn', 'Initials': 'E', 'LastName': 'Maripuu', 'Affiliation': 'Department of Nuclear Medicine, Uppsala University Hospital, Uppsala, Sweden.'}]",Hip international : the journal of clinical and experimental research on hip pathology and therapy,['10.1177/1120700019861274'] 1428,32686552,An empirical examination of the biogenetic approach in schizophrenia stigma reduction through an attribution lens.,"BACKGROUND The biogenetic approach in mental health stigmatization reduction has received increased attention. Taking the perspective of Weiner's attribution theory, the biogenetic explanations can be helpful in reducing the perceptions of controllability of mental illnesses (e.g., schizophrenia). However, recent studies reveal that biogenetic explanations may increase social stigma and discrimination against people with schizophrenia. AIMS The current research, using Weiner's attribution theory, empirically examined the effects of biogenetic beliefs on the desire for social distance via perceptions of controllability and stability of schizophrenia using a Chinese sample. METHODS A cross-sectional study ( n  = 156) and an experiment ( n  = 124) were carried out. Participants were recruited from an urban city in China. In the experiment, participants were randomly assigned to receive a biogenetic/control lecture and filled out a survey. RESULTS Biogenetic beliefs had indirect effects on the desire for social distance via decreased perceived controllability and increased perceived stability, which resulted in little to no change on the desire for social distance. CONCLUSION The biogenetic approach could decrease the perceptions of controllability of schizophrenia which may reduce the desire for social distance; however, it could also increase the perceptions of stability which may increase the desire for social distance, especially among close others. Cautions are warranted when using and disseminating the biogenetic causes of schizophrenia amongin the general public.",2020,"RESULTS Biogenetic beliefs had indirect effects on the desire for social distance via decreased perceived controllability and increased perceived stability, which resulted in little to no change on the desire for social distance. ","['Participants were recruited from an urban city in China', 'A cross-sectional study ( n \u2009=\u2009156) and an experiment ( n \u2009=\u2009124']",['biogenetic/control lecture and filled out a survey'],['social stigma'],"[{'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C4517553', 'cui_str': '124'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0376683', 'cui_str': 'Lectures'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]","[{'cui': 'C0277787', 'cui_str': 'Stigma'}]",,0.0603998,"RESULTS Biogenetic beliefs had indirect effects on the desire for social distance via decreased perceived controllability and increased perceived stability, which resulted in little to no change on the desire for social distance. ","[{'ForeName': 'Elvin', 'Initials': 'E', 'LastName': 'Yao', 'Affiliation': 'Claremont Graduate University, Claremont, CA, USA.'}, {'ForeName': 'Chunhui', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Chinese Center for Disease Control and Prevention, Qingdao, China.'}, {'ForeName': 'Mengqi', 'Initials': 'M', 'LastName': 'Sun', 'Affiliation': 'Chinese Center for Disease Control and Prevention, Qingdao, China.'}]",The International journal of social psychiatry,['10.1177/0020764020944202'] 1429,32517353,Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients.,"COVID-19, the illness caused by infection with the novel coronavirus SARS-CoV-2, is a rapidly spreading global pandemic in urgent need of effective treatments. Here we present a comprehensive examination of the host- and virus-targeted functions of the flavonolignan silibinin, a potential drug candidate against COVID-19/SARS-CoV-2. As a direct inhibitor of STAT3-a master checkpoint regulator of inflammatory cytokine signaling and immune response-silibinin might be expected to phenotypically integrate the mechanisms of action of IL-6-targeted monoclonal antibodies and pan-JAK1/2 inhibitors to limit the cytokine storm and T-cell lymphopenia in the clinical setting of severe COVID-19. As a computationally predicted, remdesivir-like inhibitor of RNA-dependent RNA polymerase (RdRp)-the central component of the replication/transcription machinery of SARS-CoV-2-silibinin is expected to reduce viral load and impede delayed interferon responses. The dual ability of silibinin to target both the host cytokine storm and the virus replication machinery provides a strong rationale for the clinical testing of silibinin against the COVID-19 global public health emergency. A randomized, open-label, phase II multicentric clinical trial (SIL-COVID19) will evaluate the therapeutic efficacy of silibinin in the prevention of acute respiratory distress syndrome in moderate-to-severe COVID-19-positive onco-hematological patients at the Catalan Institute of Oncology in Catalonia, Spain.",2020,"COVID-19, the illness caused by infection with the novel coronavirus SARS-CoV-2, is a rapidly spreading global pandemic in urgent need of effective treatments.","['COVID-19 Patients', 'acute respiratory distress syndrome in moderate-to-severe COVID-19-positive onco-hematological patients at the Catalan Institute of Oncology in Catalonia, Spain']","['Silibinin and SARS-CoV-2', 'silibinin']",[],"[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0007366', 'cui_str': 'Catalan language'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0037747', 'cui_str': 'Spain'}]","[{'cui': 'C0600334', 'cui_str': 'silybin'}]",[],,0.028084,"COVID-19, the illness caused by infection with the novel coronavirus SARS-CoV-2, is a rapidly spreading global pandemic in urgent need of effective treatments.","[{'ForeName': 'Joaquim', 'Initials': 'J', 'LastName': 'Bosch-Barrera', 'Affiliation': 'Medical Oncology, Catalan Institute of Oncology (ICO), Dr. Josep Trueta Hospital of Girona, 17007 Girona, Spain.'}, {'ForeName': 'Begoña', 'Initials': 'B', 'LastName': 'Martin-Castillo', 'Affiliation': 'Unit of Clinical Research, Catalan Institute of Oncology, 17007 Girona, Spain.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Buxó', 'Affiliation': 'Girona Biomedical Research Institute, 17190 Salt, Girona, Spain.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Brunet', 'Affiliation': 'Medical Oncology, Catalan Institute of Oncology (ICO), Dr. Josep Trueta Hospital of Girona, 17007 Girona, Spain.'}, {'ForeName': 'José Antonio', 'Initials': 'JA', 'LastName': 'Encinar', 'Affiliation': 'Institute of Research, Development and Innovation in Biotechnology of Elche (IDiBE) and Molecular and Cell Biology Institute (IBMC), Miguel Hernández University (UMH), 03202 Elche, Spain.'}, {'ForeName': 'Javier A', 'Initials': 'JA', 'LastName': 'Menendez', 'Affiliation': 'Girona Biomedical Research Institute, 17190 Salt, Girona, Spain.'}]",Journal of clinical medicine,['10.3390/jcm9061770'] 1430,32517490,Effect of Baduanjin exercise on cognitive function in patients with post-stroke cognitive impairment: a randomized controlled trial.,"OBJECTIVE To investigate the effectiveness and safety of Baduanjin training on the cognitive function in stroke survivors with cognitive impairment. DESIGN A randomized, two-arm parallel controlled trial with allocation concealment and assessors blinding. SETTING Community centre of Fuzhou city, China. SUBJECTS A total of 48 participants were recruited and randomly allocated into the Baduanjin exercise intervention or control group. INTERVENTIONS The control group maintained original medication and rehabilitation treatment. The Baduanjin training group received 24-week Baduanjin training with a frequency of three days a week and 40 minutes a day based on original medication and rehabilitation treatment. MAIN OUTCOME MEASURES The primary outcome was global cognitive function. Secondary outcome measures included the specific domains of cognition (i.e. memory, processing speed, execution, attention and visuospatial ability) and activities daily living. RESULTS In total, 41 (Baduanjin n  = 22, control n  = 19) participants completed 24-week treatment and data collection. Mean differences between groups at 24-week treatment were statistically significant for global cognitive function (MoCA: 2.54 (0.91 to 4.16)), execution (TMT-A: -42.4 (-75.0 to -9.8); TMT-B: -71.3 (-130.6 to -12.1)), memory (immediate recall: 2.11 (0.49 to 3.73); short-term delayed recognition: 2.47 (0.58 to 4.35) and long-term delayed recognition: 1.68(0.18 to 3.17)), attention (response time of alertness: -245.5 (-387 to -104)) and activities of daily living (modified Barthel Index). CONCLUSION Regular Baduanjin training is associated with less loss of cognitive function in patients after stroke.",2020,"Mean differences between groups at 24-week treatment were statistically significant for global cognitive function (MoCA: 2.54 (0.91 to 4.16)), execution (TMT-A: -42.4 (-75.0 to -9.8); TMT-B: -71.3 (-130.6 to -12.1)), memory (immediate recall: 2.11 (0.49 to 3.73); short-term delayed recognition: 2.47 (0.58 to 4.35) and long-term delayed recognition: 1.68(0.18 to 3.17)), attention (response time of alertness: -245.5 (-387 to -104)) and activities of daily living (modified Barthel Index). ","['A total of 48 participants', 'patients with post-stroke cognitive impairment', 'patients after stroke', 'stroke survivors with cognitive impairment', 'Community centre of Fuzhou city, China']","['Baduanjin training', 'control group maintained original medication and rehabilitation treatment', 'Regular Baduanjin training', 'Baduanjin exercise intervention or control group', 'Baduanjin exercise']","['activities of daily living (modified Barthel Index', 'global cognitive function', 'specific domains of cognition (i.e. memory, processing speed, execution, attention and visuospatial ability) and activities daily living', 'cognitive function']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C1278561', 'cui_str': 'Judicial execution'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",48.0,0.0905076,"Mean differences between groups at 24-week treatment were statistically significant for global cognitive function (MoCA: 2.54 (0.91 to 4.16)), execution (TMT-A: -42.4 (-75.0 to -9.8); TMT-B: -71.3 (-130.6 to -12.1)), memory (immediate recall: 2.11 (0.49 to 3.73); short-term delayed recognition: 2.47 (0.58 to 4.35) and long-term delayed recognition: 1.68(0.18 to 3.17)), attention (response time of alertness: -245.5 (-387 to -104)) and activities of daily living (modified Barthel Index). ","[{'ForeName': 'Guohua', 'Initials': 'G', 'LastName': 'Zheng', 'Affiliation': 'College of Nursing and Health Management, Shanghai University of Medicine & Health Sciences, Shanghai, China.'}, {'ForeName': 'Yuhui', 'Initials': 'Y', 'LastName': 'Zheng', 'Affiliation': 'College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.'}, {'ForeName': 'Zhenyu', 'Initials': 'Z', 'LastName': 'Xiong', 'Affiliation': 'College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.'}, {'ForeName': 'Bingzhao', 'Initials': 'B', 'LastName': 'Ye', 'Affiliation': 'College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.'}]",Clinical rehabilitation,['10.1177/0269215520930256'] 1431,32521394,Effects of perioperative magnesium sulfate infusion on intraoperative blood loss and postoperative analgesia in patients undergoing posterior lumbar spinal fusion surgery: A randomized controlled trial.,"OBJECTIVE Many studies have suggested the anti-nociceptive role for magnesium either as an adjunct for postoperative pain. Although several studies have been carried out to evaluate the anti-nociceptive effect of magnesium, there is still considerable uncertainty. PATIENTS AND METHODS Eighty patients who underwent posterior spinal fusion were randomly divided into two groups (magnesium and saline). Changes in cell count, magnesium concentration and coagulation status were assessed one hour after operation at both group and compared to baseline. At recovery room, their pain score was assessed according to 10 points visual analogue scale (VAS). Morphine consumption was evaluated at regular times after the surgery by patient controlled analgesia (PCA) device. RESULTS VAS scores were significantly lower in the magnesium group. Cumulative PCA morphine consumption after the surgery was significantly lower in the magnesium group. Pre and postoperative values for haemoglobin, platelet count, Prothrombin Time (PT), fibrinogen were not significantly different. There was a significant increase in activated Partial Thromboplastin Time (aPTT), International Normalized Ratio (INR), and bleeding time (BT), one hour after the operation in the magnesium group but intraoperative blood loss was similar in both groups. CONCLUSIONS Perioperative magnesium sulfate infusion improves the postoperative analgesia, decreases the amount of morphine consumption after the operation and does not change the intraoperative bleeding in patients undergoing posterior spinal fusion surgery.",2020,"Pre and postoperative values for haemoglobin, platelet count, Prothrombin Time (PT), fibrinogen were not significantly different.","['patients undergoing posterior spinal fusion surgery', 'Eighty patients who underwent posterior spinal fusion', 'patients undergoing posterior lumbar spinal fusion surgery']","['Perioperative magnesium sulfate infusion', 'magnesium and saline', 'magnesium', 'perioperative magnesium sulfate infusion']","['postoperative analgesia', 'intraoperative bleeding', 'Pre and postoperative values for haemoglobin, platelet count, Prothrombin Time (PT), fibrinogen', 'morphine consumption', 'cell count, magnesium concentration and coagulation status', 'Morphine consumption', 'intraoperative blood loss', 'pain score', 'activated Partial Thromboplastin Time (aPTT), International Normalized Ratio (INR), and bleeding time (BT', 'Cumulative PCA morphine consumption', 'intraoperative blood loss and postoperative analgesia', 'VAS scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0919636', 'cui_str': 'Spinal fusion surgery'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0037935', 'cui_str': 'Spinal arthrodesis'}, {'cui': 'C0186045', 'cui_str': 'Lumbar spinal fusion'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0024480', 'cui_str': 'Magnesium Sulfate'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0033707', 'cui_str': 'Prothrombin time'}, {'cui': 'C0016006', 'cui_str': 'Fibrinogen'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0030605', 'cui_str': 'Partial thromboplastin time, activated'}, {'cui': 'C0525032', 'cui_str': 'International normalized ratio'}, {'cui': 'C0005729', 'cui_str': 'Bleeding time'}, {'cui': 'C0078944', 'cui_str': 'Patient controlled analgesia'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",80.0,0.140799,"Pre and postoperative values for haemoglobin, platelet count, Prothrombin Time (PT), fibrinogen were not significantly different.","[{'ForeName': 'Masih Ebrahimy', 'Initials': 'ME', 'LastName': 'Dehkordy', 'Affiliation': 'Department of Anesthesiology, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Roozbeh', 'Initials': 'R', 'LastName': 'Tavanaei', 'Affiliation': 'Shohada Tajrish Neurosurgical Center of Excellence, Functional Neurosurgery Research Center, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Elahe', 'Initials': 'E', 'LastName': 'Younesi', 'Affiliation': 'Department of Anesthesiology, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Shayesteh', 'Initials': 'S', 'LastName': 'Khorasanizade', 'Affiliation': 'Department of Anesthesiology, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hamidreza Azizi', 'Initials': 'HA', 'LastName': 'Farsani', 'Affiliation': 'Department of Anesthesiology, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Oraee-Yazdani', 'Affiliation': 'Shohada Tajrish Neurosurgical Center of Excellence, Functional Neurosurgery Research Center, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: Saeed_o_yazdani@sbmu.ac.ir.'}]",Clinical neurology and neurosurgery,['10.1016/j.clineuro.2020.105983'] 1432,32521448,Design cues for tobacco communication: Heuristic interpretations and usability of online health information about harmful chemicals.,"OBJECTIVE Many people have a poor understanding of the numerous chemicals in tobacco products that cause severe health harms. The US government must display a list of these harmful chemicals for the public. Online disclosures are one promising solution, but evidence is needed for effective design strategies to encourage interpretation and use of information as intended. METHOD To examine the impact of website designs for the activation of heuristics and usability perceptions, a national probability sample of US adolescents and adults (n = 1441) was randomized in a 3 (chemical format) × 2 (webpage layout) between-subjects online experiment. Chemicals were displayed as names only, with a visual risk indicator, or with numerical ranges. Layouts displayed health harms at the top of the webpage separate from chemicals or the chemicals grouped by associated health harms. Participants viewed a webpage and reported activated heuristics, usability (perceived ease of use and usefulness), and intentions to use the website. RESULTS Displaying risk indicators increased website usability by encouraging users to rely on colors to interpret the risk of the chemicals (all p < .01). Website designs that grouped chemicals with harms allowed users to link the chemicals to harms they cause and increased perceived usability and intentions to use the website (all p < .001). CONCLUSION Assessing heuristics gives insights for how US adolescents and adults interpret chemical information and the impact of design strategies on usability. Public disclosures of chemicals in tobacco products could be optimized with color-coded risk indicators and layouts placing chemicals near the harms they cause.",2020,"Website designs that grouped chemicals with harms allowed users to link the chemicals to harms they cause and increased perceived usability and intentions to use the website (all p < .001). ",['US adolescents and adults (n = 1441'],[],['website usability'],"[{'cui': 'C0002838', 'cui_str': 'Andorra'}]",[],[],1441.0,0.0625486,"Website designs that grouped chemicals with harms allowed users to link the chemicals to harms they cause and increased perceived usability and intentions to use the website (all p < .001). ","[{'ForeName': 'Allison J', 'Initials': 'AJ', 'LastName': 'Lazard', 'Affiliation': 'School of Media and Journalism, University of North Carolina at Chapel Hill, NC 27599-3365, United States; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27599-3365, United States. Electronic address: lazard@unc.edu.'}]",International journal of medical informatics,['10.1016/j.ijmedinf.2020.104177'] 1433,32521472,Improvement of dynamic postural stability by an exercise program.,"BACKGROUND Central processing of multi-sensory feedback and motor commands responsible for force production are critical for postural control. An exercise program was developed to realign spinal curvature, but its effect on postural control is unknown. RESEARCH QUESTION To what extent would the exercise program influence on center of pressure (CoP) sway on stable and unstable surfaces? METHODS Subjects (n = 30) were randomly assigned into one of three groups: exercise on a cylinder-shaped tube (98-cm length, 15-cm diameter, n = 10), exercise on a flat surface (n = 10), and a control group that laid supine on a flat surface (n = 10). Standing posture of each subject was quantified using anterior-, posterior-, and lateral-view photography. Each subject's CoP sway was measured while standing on a static and dynamic platform with eyes open and eyes closed. Subjects were instructed to stand still when the platform was held stationary (e.g., no tilt) during the static condition. During the dynamic condition the platform was allowed to tilt in response to changes of CoP and subjects were instructed to maintain the platform in a horizontal position. RESULTS Only when subjects performed the exercise program on the tube, the angles of neck flexion and pelvis tilt decreased, and CoP sway in the sagittal, but not frontal plane, decreased during the dynamic platform conditions with both eyes open and eyes closed (p < 0.05). SIGNIFICANCE It is speculated that performing the exercise program on the tube might enhance a) central processing of somatosensory and vestibular inputs, b) motor commands responsible for force production in postural control, and c) biomechanical advantage by the realigned posture. The exercise program can be used by a variety of populations as home-exercise to realign the neck and pelvic posture and improve dynamic postural stability.",2020,"Only when subjects performed the exercise program on the tube, the angles of neck flexion and pelvis tilt decreased, and CoP sway in the sagittal, but not frontal plane, decreased during the dynamic platform conditions with both eyes open and eyes closed (p < 0.05). ",['Subjects (n\u202f=\u202f30'],"['exercise on a cylinder-shaped tube (98-cm length, 15-cm diameter, n\u202f=\u202f10), exercise on a flat surface (n\u202f=\u202f10), and a control group that laid supine']","['dynamic postural stability', 'neck flexion and pelvis tilt decreased, and CoP sway']",[],"[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0181797', 'cui_str': 'Medical gas cylinder'}, {'cui': 'C0332479', 'cui_str': 'Shape finding'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0205324', 'cui_str': 'Flat'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038846', 'cui_str': 'Supine body position'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0445088', 'cui_str': 'Neck flexion'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}]",30.0,0.0135493,"Only when subjects performed the exercise program on the tube, the angles of neck flexion and pelvis tilt decreased, and CoP sway in the sagittal, but not frontal plane, decreased during the dynamic platform conditions with both eyes open and eyes closed (p < 0.05). ","[{'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Shibata', 'Affiliation': 'Athletic Training Education Program, Department of Health Exercise and Sports Sciences, University of New Mexico, New Mexico, USA. Electronic address: diceshibata@unm.edu.'}]",Gait & posture,['10.1016/j.gaitpost.2020.05.044'] 1434,31298571,Comparison of Diode Laser (980 nm) Enucleation vs Holmium Laser Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia: A Randomized Controlled Trial with 12-Month Follow-Up.,"Objective: To compare the clinical efficacy and safety between diode laser (980 nm) enucleation of the prostate (DiLEP) and holmium laser enucleation of the prostate (HoLEP) for treating benign prostatic hyperplasia (BPH). Patients and Methods: One hundred twenty-six BPH patients in our hospital from December 2016 to December 2017 were enrolled in this study. They were randomized to the DiLEP group or HoLEP group, which were administrated with DiLEP and HoLEP treatment, respectively. The patient's characteristics, such as age, body mass index, comorbidities, prostate volume, and prostate-specific antigen, were recorded before surgery. The perioperative outcomes and complications were also compared. The maximum flow rate (Qmax), postvoid residual (PVR), international prostate symptom score (IPSS), and quality-of-life (QoL) score were assessed at baseline and 3, 6, and 12 months postoperatively. Results: No significant differences were observed for the patient's baseline characteristics between both groups. For the perioperative outcomes, including operative time, resected tissue weight, catheter duration, and hospital stay, no significant difference was found between the two groups. However, the DiLEP group showed less blood loss and decrease in hemoglobin compared with the HoLEP group. The incidence of early or late complications was similar for both groups. The Qmax, PVR, IPSS, and QoL for both groups of patients were dramatically improved after surgery. By comparing the Qmax, PVR, IPSS, and QoL between the two groups, no significant differences were detected in the 3-, 6-, or 12-month follow-up. Conclusions: This study demonstrated that both DiLEP and HoLEP are efficient and safe treatments for BPH patients. DiLEP showed less blood loss and decrease in hemoglobin than HoLEP, which indicated that the diode laser (980 nm) generates a better hemostasis effect.",2019,"By comparing the Qmax, PVR, IPSS, and QoL between the two groups, no significant differences were detected in the 3-, 6-, or 12-month follow-up. ","['One hundred twenty-six BPH patients in our hospital from December 2016 to December 2017 were enrolled in this study', 'treating benign prostatic hyperplasia (BPH', 'Benign Prostatic Hyperplasia', 'BPH patients']","['diode laser', 'Diode Laser (980\u2009nm) Enucleation vs Holmium Laser Enucleation', 'DiLEP and HoLEP', 'DiLEP', 'HoLEP', 'diode laser (980\u2009nm) enucleation of the prostate (DiLEP) and holmium laser enucleation of the prostate (HoLEP']","['incidence of early or late complications', 'blood loss', 'maximum flow rate (Qmax), postvoid residual (PVR), international prostate symptom score (IPSS), and quality-of-life (QoL) score', 'hemostasis effect', 'operative time, resected tissue weight, catheter duration, and hospital stay', 'perioperative outcomes and complications', 'Qmax, PVR, IPSS, and QoL', 'hemoglobin', 'clinical efficacy and safety']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}, {'cui': 'C0005001', 'cui_str': 'Benign enlargement of prostate'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital (finding)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C1704272', 'cui_str': 'Benign Prostatic Hyperplasia'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0392254', 'cui_str': 'Semiconductor Diode Lasers'}, {'cui': 'C0014392', 'cui_str': 'Enucleation'}, {'cui': 'C1955839', 'cui_str': 'Holmium Lasers'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C1998280', 'cui_str': 'International prostate symptom score (assessment scale)'}, {'cui': 'C0034380'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0740166', 'cui_str': 'Haemostasis'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0087113', 'cui_str': 'Treatment Efficacy'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",126.0,0.0557834,"By comparing the Qmax, PVR, IPSS, and QoL between the two groups, no significant differences were detected in the 3-, 6-, or 12-month follow-up. ","[{'ForeName': 'Gaofei', 'Initials': 'G', 'LastName': 'He', 'Affiliation': 'Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Shu', 'Affiliation': 'Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Bohan', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': 'Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Chuanjun', 'Initials': 'C', 'LastName': 'Du', 'Affiliation': 'Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Jimin', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Jiaming', 'Initials': 'J', 'LastName': 'Wen', 'Affiliation': 'Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}]",Journal of endourology,['10.1089/end.2019.0341'] 1435,32685788,The role of Visual Evoked Potential (VEP) in monitoring the progression and in guiding the treatment of glaucoma patients with poor compliance.,"Objectives: The objectives of the present study were to analyze the possibility of using pattern VEPs (VEP of pattern type) in glaucoma patients and their role in the follow-up and coordination/ management of anti-glaucoma treatment. Patients and Methods: This is a prospective study on 54 eyes of 30 consecutive glaucoma patients, whose compliance capacity did not allow automatic perimetry and OCT scan to be carried out. The patients were divided into two groups: group A - the study group and group B - the control group. All patients underwent FO exam and pachymetry, plus VEP exam for group A patients. Patients were analyzed at the initial visit and at 1 month, 3, 6, 12 months. Statistical analysis was made using t-test, ANOVA, Fisher test and Pearson correlation coefficient. Results: These participants presented a positive correlation between C/ D ratio and the latency of the P100 wave at 1 degree and a negative correlation between C/ D ratio and the amplitude of the P100 wave both at 1 degree (60 arc minutes) and at 0.25 degrees (15 arc minutes). During the study, the values of the latent P100 changed statistically at 6 months and at 1 year. Using all the data, the authors of the study considered it necessary to modify the treatment for 2 patients out of 13 in group B and for 9 patients out of 16 in group A (p = 0,02892). Conclusions: VEP supplies additional/ further data that significantly help guiding the treatment and monitoring the progression, therefore, it should be part of the routine examination for these patients. Further studies are necessary to deepen our understanding of the visual evoked potentials utility.",2020,These participants presented a positive correlation between C/ D ratio and the latency of the P100 wave at 1 degree and a negative correlation between C/ D ratio and the amplitude of the P100 wave both at 1 degree (60 arc minutes) and at 0.25 degrees (15 arc minutes).,"['54 eyes of 30 consecutive glaucoma patients, whose compliance capacity did not allow automatic perimetry and OCT scan to be carried out', 'glaucoma patients with poor compliance', 'glaucoma patients and their role in the follow-up and coordination/ management of anti-glaucoma treatment']","['FO exam and pachymetry, plus VEP exam', 'pattern VEPs (VEP of pattern type', 'Visual Evoked Potential (VEP']",[],"[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0031061', 'cui_str': 'Perimetry'}, {'cui': 'C0029279', 'cui_str': 'Ornithine carbamoyltransferase'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C1515995', 'cui_str': 'Antiglaucoma agent'}]","[{'cui': 'C0582103', 'cui_str': 'Medical assessment'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0546834', 'cui_str': 'Visual evoked potential study'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0015217', 'cui_str': 'Visual evoked potential'}]",[],,0.011245,These participants presented a positive correlation between C/ D ratio and the latency of the P100 wave at 1 degree and a negative correlation between C/ D ratio and the amplitude of the P100 wave both at 1 degree (60 arc minutes) and at 0.25 degrees (15 arc minutes).,"[{'ForeName': 'Anne Marie', 'Initials': 'AM', 'LastName': 'Firan', 'Affiliation': 'Barnsley District Hospital, NHS trust, England.'}, {'ForeName': 'Raluca Claudia', 'Initials': 'RC', 'LastName': 'Iancu', 'Affiliation': 'Department of Ophthalmology, University Emergency Hospital, Bucharest, Romania.'}, {'ForeName': 'Inna Adriana', 'Initials': 'IA', 'LastName': 'Bujor', 'Affiliation': 'Department of Ophthalmology, University Emergency Hospital, Bucharest, Romania.'}, {'ForeName': 'Radu Constantin', 'Initials': 'RC', 'LastName': 'Ciuluvică', 'Affiliation': '""Carol Davila"" University of Medicine and Pharmacy, Bucharest, Romania.'}, {'ForeName': 'Ruxandra', 'Initials': 'R', 'LastName': 'Tudosescu', 'Affiliation': 'Department of Ophthalmology, ""Regina Maria"" Private Health Care, Bucharest, Romania.'}, {'ForeName': 'Emil', 'Initials': 'E', 'LastName': 'Ungureanu', 'Affiliation': 'Department of Ophthalmology, University Emergency Hospital, Bucharest, Romania.'}, {'ForeName': 'Irena Gabriela', 'Initials': 'IG', 'LastName': 'Pașca', 'Affiliation': 'Department of Ophthalmology, University Emergency Hospital, Bucharest, Romania.'}, {'ForeName': 'Liliana', 'Initials': 'L', 'LastName': 'Voinea', 'Affiliation': 'Department of Ophthalmology, University Emergency Hospital, Bucharest, Romania.'}, {'ForeName': 'Sînziana', 'Initials': 'S', 'LastName': 'Istrate', 'Affiliation': 'Department of Ophthalmology, ""Regina Maria"" Private Health Care, Bucharest, Romania.'}]",Romanian journal of ophthalmology,[] 1436,32685899,"The Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease.","Background Little evidence is available for treatment of pediatric venous thromboembolism (VTE). Large randomized controlled trials are challenging in children. Current antithrombotic agents have many limitations, including nonoral administration and frequent monitoring. Edoxaban is an oral direct inhibitor of factor Xa without need of monitoring. In adults with VTE, edoxaban has shown to be effective and safe. Objectives The Edoxaban Hokusai VTE PEDIATRICS Study is an open-label, randomized clinical trial to evaluate pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and whether edoxaban is noninferior to standard of care in treatment of pediatric VTE. Methods A goal of 274 patients will be recruited in 5 age categories. A multidose PK/PD assessment on day 5 in the first 12 patients of each age group is incorporated into this study. The primary composite efficacy outcome comprises symptomatic recurrent VTE, death due to VTE, and no change or extension of thrombotic burden. The principal safety end point is a combination of major and clinically relevant nonmajor bleeding. PK end points include apparent systemic clearance and volume of distribution of edoxaban. PD end points include prothrombin time, activated partial thromboplastin time, and anti-factor Xa level for the edoxaban treatment arm. Results To increase feasibility, the multidose PK/PD study is integrated in the phase 3 trial. In addition, thrombotic burden, which is a prognostic factor for post thrombotic syndrome in children, is one of the components of the primary composite efficacy outcome. Conclusion This study will increase the level of evidence for treatment in pediatric VTE.",2020,"PD end points include prothrombin time, activated partial thromboplastin time, and anti-factor Xa level for the edoxaban treatment arm. ","['Study', 'pediatric venous thromboembolic disease', '274 patients will be recruited in 5 age categories']","['edoxaban', 'Edoxaban']","['systemic clearance and volume of distribution of edoxaban', 'symptomatic recurrent VTE, death due to VTE, and no change or extension of thrombotic burden', 'prothrombin time, activated partial thromboplastin time, and anti-factor Xa level']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C1997614', 'cui_str': 'Thromboembolism of vein'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C2975435', 'cui_str': 'edoxaban'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C2975435', 'cui_str': 'edoxaban'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0442739', 'cui_str': 'No status change'}, {'cui': 'C0439792', 'cui_str': 'Extent'}, {'cui': 'C0033707', 'cui_str': 'Prothrombin time'}, {'cui': 'C0030605', 'cui_str': 'Partial thromboplastin time, activated'}, {'cui': 'C0427612', 'cui_str': 'Anti factor Xa measurement'}]",274.0,0.0840701,"PD end points include prothrombin time, activated partial thromboplastin time, and anti-factor Xa level for the edoxaban treatment arm. ","[{'ForeName': 'Cornelia Heleen', 'Initials': 'CH', 'LastName': 'van Ommen', 'Affiliation': ""Department Pediatric Hematology/Oncology Erasmus MC Sophia Children's Hospital Rotterdam The Netherlands.""}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Albisetti', 'Affiliation': ""Hematology Department University Children's Hospital Zürich Switzerland.""}, {'ForeName': 'Anthony K', 'Initials': 'AK', 'LastName': 'Chan', 'Affiliation': ""McMaster Children's Hospital Hamilton ON Canada.""}, {'ForeName': 'Jeremie', 'Initials': 'J', 'LastName': 'Estepp', 'Affiliation': ""Department of Hematology St Jude Children's Research Hospital Memphis TN USA.""}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Jaffray', 'Affiliation': ""Division of Hematology, Oncology BMT Department of Pediatrics Children's Hospital Los Angeles University of Southern California Keck School of Medicine Los Angeles USA.""}, {'ForeName': 'Gili', 'Initials': 'G', 'LastName': 'Kenet', 'Affiliation': 'Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Young', 'Affiliation': ""Children's Hospital Los Angeles University of Southern California Keck School of Medicine Los Angeles USA.""}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Dave', 'Affiliation': 'Daiichi Sankyo Basking Ridge NJ USA.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Grosso', 'Affiliation': 'Daiichi Sankyo Basking Ridge NJ USA.'}, {'ForeName': 'Anil', 'Initials': 'A', 'LastName': 'Duggal', 'Affiliation': 'Daiichi Sankyo Basking Ridge NJ USA.'}]",Research and practice in thrombosis and haemostasis,['10.1002/rth2.12352'] 1437,32685910,Machine learning through cryptographic glasses: combating adversarial attacks by key-based diversified aggregation.,"In recent years, classification techniques based on deep neural networks (DNN) were widely used in many fields such as computer vision, natural language processing, and self-driving cars. However, the vulnerability of the DNN-based classification systems to adversarial attacks questions their usage in many critical applications. Therefore, the development of robust DNN-based classifiers is a critical point for the future deployment of these methods. Not less important issue is understanding of the mechanisms behind this vulnerability. Additionally, it is not completely clear how to link machine learning with cryptography to create an information advantage of the defender over the attacker. In this paper, we propose a key-based diversified aggregation (KDA) mechanism as a defense strategy in a gray- and black-box scenario. KDA assumes that the attacker (i) knows the architecture of classifier and the used defense strategy, (ii) has an access to the training data set, but (iii) does not know a secret key and does not have access to the internal states of the system. The robustness of the system is achieved by a specially designed key-based randomization. The proposed randomization prevents the gradients' back propagation and restricts the attacker to create a ""bypass"" system. The randomization is performed simultaneously in several channels. Each channel introduces its own randomization in a special transform domain. The sharing of a secret key between the training and test stages creates an information advantage to the defender. Finally, the aggregation of soft outputs from each channel stabilizes the results and increases the reliability of the final score. The performed experimental evaluation demonstrates a high robustness and universality of the KDA against state-of-the-art gradient-based gray-box transferability attacks and the non-gradient-based black-box attacks (The results reported in this paper have been partially presented in CVPR 2019 (Taran et al., Defending against adversarial attacks by randomized diversification, 2019) & ICIP 2019 (Taran et al., Robustification of deep net classifiers by key-based diversified aggregation with pre-filtering, 2019)).",2020,"Defending against adversarial attacks by randomized diversification, 2019) & ICIP 2019",[],"['ICIP 2019', 'Machine learning']",[],[],"[{'cui': 'C0376284', 'cui_str': 'Machine Learning'}]",[],,0.0199395,"Defending against adversarial attacks by randomized diversification, 2019) & ICIP 2019","[{'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Taran', 'Affiliation': 'Stochastic Information Processing Group, Department of Computer Science, University of Geneva, 7 Route de Drize, Carouge, GE Switzerland.'}, {'ForeName': 'Shideh', 'Initials': 'S', 'LastName': 'Rezaeifar', 'Affiliation': 'Stochastic Information Processing Group, Department of Computer Science, University of Geneva, 7 Route de Drize, Carouge, GE Switzerland.'}, {'ForeName': 'Taras', 'Initials': 'T', 'LastName': 'Holotyak', 'Affiliation': 'Stochastic Information Processing Group, Department of Computer Science, University of Geneva, 7 Route de Drize, Carouge, GE Switzerland.'}, {'ForeName': 'Slava', 'Initials': 'S', 'LastName': 'Voloshynovskiy', 'Affiliation': 'Stochastic Information Processing Group, Department of Computer Science, University of Geneva, 7 Route de Drize, Carouge, GE Switzerland.'}]",EURASIP journal on information security,['10.1186/s13635-020-00106-x'] 1438,32686050,Comparing remifentanil and sufentanil in stress reduction during neurosurgery: a randomised controlled trial.,"Background In most scenarios, anaesthesiologists titrate opioids to control nociceptive surgical stress based on intraoperative haemodynamic changes. Remifentanil was reported to cause more profound cardiovascular depression than sufentanil. A concern is that this direct cardiovascular depression might counteract the hypertension and tachycardia caused by surgical manipulation and mask inadequate analgesia. Objective To compare remifentanil and sufentanil, titrated to maintain a comparable haemodynamic range (within 20% of baseline) and combined with the same propofol regimen, in stress reduction measured as plasma levels of putative mediators of surgical stress. Setting Huashan Hospital of Fudan University, Shanghai, China. Method Forty-five patients undergoing supratentorial glioma resection were randomised to the remifentanil group or the sufentanil group. Main outcome measures Plasma concentrations of cortisol, epinephrine, norepinephrine, interleukin-6, interleukin-10 and lymphocyte counts were analysed before anaesthesia, 1 h after incision, at the end of surgery and 24 h after incision using enzyme-linked immunosorbent assay and an automatic haematology analyser. Recovery profiles during emergence from anaesthesia were also compared. Results Except for a lower epinephrine concentration in the remifentanil group 24 h after incision (median [interquartile range], 4.2 [3.4-6.1] vs. 8.4 [4.8-12.5] ng/ml; P = 0.003), stress biomarkers were not significantly different between the two groups. Patients in the sufentanil group had lower grades in coughing, restlessness (P = 0.001 and < 0.001, respectively) and a lower incidence of postoperative shivering (P = 0.007). Conclusion Compared to that of sufentanil, the direct cardiovascular depression of remifentanil does not mask the clinical manifestation of inadequate analgesia when both drugs are titrated according to haemodynamic variables in neurosurgery.",2020,"Patients in the sufentanil group had lower grades in coughing, restlessness (P = 0.001 and < 0.001, respectively) and a lower incidence of postoperative shivering (P = 0.007).","['Setting Huashan Hospital of Fudan University, Shanghai, China', 'stress reduction during neurosurgery', 'Method Forty-five patients undergoing supratentorial glioma resection']","['sufentanil', 'Remifentanil', 'remifentanil', 'remifentanil and sufentanil']","['plasma levels of putative mediators of surgical stress', 'coughing, restlessness', 'Plasma concentrations of cortisol, epinephrine, norepinephrine, interleukin-6, interleukin-10 and lymphocyte counts', 'postoperative shivering', 'stress biomarkers', 'epinephrine concentration', 'cardiovascular depression']","[{'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0027926', 'cui_str': 'Neurosurgery'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441938', 'cui_str': 'Supratentorial'}, {'cui': 'C0017638', 'cui_str': 'Glioma'}, {'cui': 'C0015252', 'cui_str': 'Removal'}]","[{'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0200635', 'cui_str': 'Lymphocyte count'}, {'cui': 'C1736186', 'cui_str': 'Postoperative shivering'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",45.0,0.12145,"Patients in the sufentanil group had lower grades in coughing, restlessness (P = 0.001 and < 0.001, respectively) and a lower incidence of postoperative shivering (P = 0.007).","[{'ForeName': 'Yi-Heng', 'Initials': 'YH', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, Huashan Hospital of Fudan University, No. 12 Middle Wulumuqi Road, Shanghai, 200040, China.'}, {'ForeName': 'Xiao-Bing', 'Initials': 'XB', 'LastName': 'Hu', 'Affiliation': 'Department of Anesthesiology, Huashan Hospital of Fudan University, No. 12 Middle Wulumuqi Road, Shanghai, 200040, China.'}, {'ForeName': 'Xia-Min', 'Initials': 'XM', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, Huashan Hospital of Fudan University, No. 12 Middle Wulumuqi Road, Shanghai, 200040, China.'}, {'ForeName': 'Ying-Wei', 'Initials': 'YW', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Huashan Hospital of Fudan University, No. 12 Middle Wulumuqi Road, Shanghai, 200040, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Deng', 'Affiliation': 'Department of Anesthesiology, Huashan Hospital of Fudan University, No. 12 Middle Wulumuqi Road, Shanghai, 200040, China. dengmeng05@163.com.'}]",International journal of clinical pharmacy,['10.1007/s11096-020-01094-1'] 1439,32686116,Comparative cost-effectiveness of mailed fecal immunochemical testing (FIT)-based interventions for increasing colorectal cancer screening in the Medicaid population.,"BACKGROUND Mailed reminders to promote colorectal cancer (CRC) screening by fecal immunochemical testing (FIT) have been shown to be effective in the Medicaid population, in which screening is underused. However, little is known regarding the cost-effectiveness of these interventions, with or without an included FIT kit. METHODS The authors conducted a cost-effectiveness analysis of a randomized controlled trial that compared the effectiveness of a reminder + FIT intervention versus a reminder-only intervention in increasing FIT screening. The analysis compared the costs per person screened for CRC screening associated with the reminder + FIT versus the reminder-only alternative using a 1-year time horizon. Input data for a cohort of 35,000 unscreened North Carolina Medicaid enrollees ages 52 to 64 years were derived from the trial and microcosting. Inputs and outputs were estimated from 2 perspectives-the Medicaid/state perspective and the health clinic/facility perspective-using probabilistic sensitivity analysis to evaluate uncertainty. RESULTS The anticipated number of CRC screenings, including both FIT and screening colonoscopies, was higher for the reminder + FIT alternative (n = 8131; 23.2%) than for the reminder-only alternative (n = 5533; 15.8%). From the Medicaid/state perspective, the reminder + FIT alternative dominated the reminder-only alternative, with lower costs and higher screening rates. From the health clinic/facility perspective, the reminder + FIT versus the reminder-only alternative resulted in an incremental cost-effectiveness ratio of $116 per person screened. CONCLUSIONS The reminder + FIT alternative was cost saving per additional Medicaid enrollee screened compared with the reminder-only alternative from the Medicaid/state perspective and likely cost-effective from the health clinic/facility perspective. The results also demonstrate that health departments and state Medicaid programs can efficiently mail FIT kits to large numbers of Medicaid enrollees to increase CRC screening completion.",2020,The reminder + FIT alternative was cost saving per additional Medicaid enrollee screened compared with the reminder-only alternative from the Medicaid/state perspective and likely cost-effective from the health clinic/facility perspective.,"['35,000 unscreened North Carolina Medicaid enrollees ages 52 to 64 years', 'colorectal cancer screening in the medicaid population']","['mailed fecal immunochemical testing (FIT)-based interventions', 'reminder + FIT intervention']",[],"[{'cui': 'C0028407', 'cui_str': 'North Carolina'}, {'cui': 'C0025071', 'cui_str': 'Medicaid coverage'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.0385864,The reminder + FIT alternative was cost saving per additional Medicaid enrollee screened compared with the reminder-only alternative from the Medicaid/state perspective and likely cost-effective from the health clinic/facility perspective.,"[{'ForeName': 'Stephanie B', 'Initials': 'SB', 'LastName': 'Wheeler', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Meghan C', 'Initials': 'MC', 'LastName': ""O'Leary"", 'Affiliation': 'Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Jewels', 'Initials': 'J', 'LastName': 'Rhode', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Jeff Y', 'Initials': 'JY', 'LastName': 'Yang', 'Affiliation': 'Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Drechsel', 'Affiliation': 'Mecklenburg County Public Health Department, Charlotte, North Carolina.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Plescia', 'Affiliation': 'Association of State and Territorial Health Officials, Charlotte, North Carolina.'}, {'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Reuland', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Alison T', 'Initials': 'AT', 'LastName': 'Brenner', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}]",Cancer,['10.1002/cncr.32992'] 1440,32686119,Hand-arm bimanual intensive therapy and daily functioning of children with bilateral cerebral palsy: a randomized controlled trial.,"AIM To examine the efficacy of Hand-Arm Bimanual Intensive Therapy (HABIT) on daily functioning, unimanual dexterity, and bimanual performance of children with bilateral cerebral palsy (CP) compared with customary care. METHOD Forty-one children with bilateral CP, aged 4 to 16 years, classified in levels I to III of the Manual Ability Classification System, were randomly assigned to HABIT (90h) (n=21) or to customary care (4.5h) (n=20). Participants' daily functioning (Pediatric Evaluation of Disability Inventory [PEDI], Canadian Occupational Performance Measure [COPM]), unimanual dexterity (Jebsen-Taylor Test of Hand Function, Box and Blocks Test [BBT]), and bimanual performance (Both Hands Assessment) were assessed pre-, post-, and 6 months after the intervention. Linear mixed-effects models were used for inferential analysis. RESULTS Children participating in HABIT showed greater improvements in daily functioning (COPM performance : χ 1 2 =9.50, p<0.01; COPM satisfaction : χ 1 2 =5.07, p<0.05; PEDI functional skills : χ 1 2 =6.81, p<0.01; PEDI caregiver assistance : χ 1 2 =6.23, p<0.05) and in the dexterity of the dominant hand (BBT: χ 1 2 =3.99, p<0.05) compared with children maintaining customary care. Group or time effects did not explain any variance in bimanual performance or in the dexterity of the non-dominant hand. INTERPRETATION HABIT may be beneficial for children with bilateral CP, with benefits evidenced for daily functioning outcomes.",2020,"RESULTS Children participating in HABIT showed greater improvements in daily functioning (COPM performance : χ 1 2 =9.50, p<0.01; COPM satisfaction : χ 1 2 =5.07, p<0.05; PEDI functional skills : χ ","['children with bilateral cerebral palsy (CP', 'Forty-one children with bilateral CP, aged 4 to 16 years, classified in levels I to III of the Manual Ability Classification System, were randomly assigned to HABIT (90h) (n=21) or to customary care (4.5h) (n=20', 'children with bilateral CP', 'children with bilateral cerebral palsy', 'PEDI caregiver assistance : χ 1 2 =6.23, p<0.05) and in the dexterity of the dominant hand']","['Hand-arm bimanual intensive therapy', 'Hand-Arm Bimanual Intensive Therapy (HABIT']","['bimanual performance', 'daily functioning, unimanual dexterity, and bimanual performance', 'daily functioning (COPM performance', ""Participants' daily functioning (Pediatric Evaluation of Disability Inventory [PEDI], Canadian Occupational Performance Measure [COPM]), unimanual dexterity (Jebsen-Taylor Test of Hand Function, Box and Blocks Test [BBT]), and bimanual performance (Both Hands Assessment""]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C3838784', 'cui_str': 'Bilateral cerebral palsy'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0441925', 'cui_str': 'Level I'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0565699', 'cui_str': 'Ability to perform general manipulative activities'}, {'cui': 'C0449722', 'cui_str': 'Dominant hand'}]","[{'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0565699', 'cui_str': 'Ability to perform general manipulative activities'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C2585956', 'cui_str': 'Canadian occupational performance measure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0562230', 'cui_str': 'Hand functions'}, {'cui': 'C0006080', 'cui_str': 'Boxing'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0230377', 'cui_str': 'Both hands'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",41.0,0.115674,"RESULTS Children participating in HABIT showed greater improvements in daily functioning (COPM performance : χ 1 2 =9.50, p<0.01; COPM satisfaction : χ 1 2 =5.07, p<0.05; PEDI functional skills : χ ","[{'ForeName': 'Priscilla R P', 'Initials': 'PRP', 'LastName': 'Figueiredo', 'Affiliation': 'Graduate Program in Rehabilitation Sciences, Universidade Federal de Minas Gerais, Associação Mineira de Reabilitação, Belo Horizonte, Brazil.'}, {'ForeName': 'Marisa C', 'Initials': 'MC', 'LastName': 'Mancini', 'Affiliation': 'Department of Occupational Therapy, Graduate Program in Rehabilitation Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'Aline M', 'Initials': 'AM', 'LastName': 'Feitosa', 'Affiliation': 'Graduate Program in Rehabilitation Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.'}, {'ForeName': 'Claudia M M F', 'Initials': 'CMMF', 'LastName': 'Teixeira', 'Affiliation': 'Associação Mineira de Reabilitação, Belo Horizonte, Brazil.'}, {'ForeName': 'Vanessa P D', 'Initials': 'VPD', 'LastName': 'Guerzoni', 'Affiliation': 'Associação Mineira de Reabilitação, Belo Horizonte, Brazil.'}, {'ForeName': 'Ann-Kristin G', 'Initials': 'AG', 'LastName': 'Elvrum', 'Affiliation': 'Department of Clinical Services, St Olavs Hospital, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Claudio L', 'Initials': 'CL', 'LastName': 'Ferre', 'Affiliation': 'Department of Occupational Therapy, Boston University, Boston, USA.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Gordon', 'Affiliation': 'Department of Biobehavioral Sciences, Columbia University, New York, USA.'}, {'ForeName': 'Marina B', 'Initials': 'MB', 'LastName': 'BrandÃo', 'Affiliation': 'Department of Occupational Therapy, Graduate Program in Rehabilitation Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}]",Developmental medicine and child neurology,['10.1111/dmcn.14630'] 1441,32503243,Randomized Trial of General Strength and Conditioning Versus Motor Control and Manual Therapy for Chronic Low Back Pain on Physical and Self-Report Outcomes.,"Exercise and spinal manipulative therapy are commonly used for the treatment of chronic low back pain (CLBP) in Australia. Reduction in pain intensity is a common outcome; however, it is only one measure of intervention efficacy in clinical practice. Therefore, we evaluated the effectiveness of two common clinical interventions on physical and self-report measures in CLBP. Participants were randomized to a 6‑month intervention of general strength and conditioning (GSC; n = 20; up to 52 sessions) or motor control exercise plus manual therapy (MCMT; n =20; up to 12 sessions). Pain intensity was measured at baseline and fortnightly throughout the intervention. Trunk extension and flexion endurance, leg muscle strength and endurance, paraspinal muscle volume, cardio‑respiratory fitness and self-report measures of kinesiophobia, disability and quality of life were assessed at baseline and 3- and 6-month follow-up. Pain intensity differed favoring MCMT between-groups at week 14 and 16 of treatment (both, p = 0.003), but not at 6-month follow‑up. Both GSC (mean change (95%CI): -10.7 (-18.7, -2.8) mm; p = 0.008) and MCMT (-19.2 (-28.1, -10.3) mm; p < 0.001) had within-group reductions in pain intensity at six months, but did not achieve clinically meaningful thresholds (20mm) within- or between‑group. At 6-month follow-up, GSC increased trunk extension (mean difference (95% CI): 81.8 (34.8, 128.8) s; p = 0.004) and flexion endurance (51.5 (20.5, 82.6) s; p = 0.004), as well as leg muscle strength (24.7 (3.4, 46.0) kg; p = 0.001) and endurance (9.1 (1.7, 16.4) reps; p = 0.015) compared to MCMT. GSC reduced disability (-5.7 (‑11.2, -0.2) pts; p = 0.041) and kinesiophobia (-6.6 (-9.9, -3.2) pts; p < 0.001) compared to MCMT at 6‑month follow-up. Multifidus volume increased within-group for GSC ( p = 0.003), but not MCMT or between-groups. No other between-group changes were observed at six months. Overall, GSC improved trunk endurance, leg muscle strength and endurance, self-report disability and kinesiophobia compared to MCMT at six months. These results show that GSC may provide a more diverse range of treatment effects compared to MCMT.",2020,"Overall, GSC improved trunk endurance, leg muscle strength and endurance, self-report disability and kinesiophobia compared to MCMT at six months.",['chronic low back pain (CLBP) in Australia'],"['GSC', 'Exercise and spinal manipulative therapy', '6‑month intervention of general strength and conditioning (GSC; n = 20; up to 52 sessions) or motor control exercise plus manual therapy (MCMT', 'General Strength and Conditioning Versus Motor Control and Manual Therapy']","['MCMT', 'endurance', 'Multifidus volume', 'flexion endurance', 'pain intensity', 'Trunk extension and flexion endurance, leg muscle strength and endurance, paraspinal muscle volume, cardio‑respiratory fitness and self-report measures of kinesiophobia, disability and quality of life', 'Pain intensity', 'Overall, GSC improved trunk endurance, leg muscle strength and endurance, self-report disability and kinesiophobia', 'kinesiophobia', 'leg muscle strength', 'GSC reduced disability', 'trunk extension']","[{'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0949742', 'cui_str': 'Therapy, Manipulation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0454525', 'cui_str': 'Manual therapy'}, {'cui': 'C1621352', 'cui_str': 'DNMT1 Enzyme'}]","[{'cui': 'C1621352', 'cui_str': 'DNMT1 Enzyme'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0224319', 'cui_str': 'Structure of multifidus muscle'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0224456', 'cui_str': 'Skeletal muscle structure of lower leg'}, {'cui': 'C0448353', 'cui_str': 'Deep muscle of back'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C4285782', 'cui_str': 'Kinesiophobia'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",,0.0653155,"Overall, GSC improved trunk endurance, leg muscle strength and endurance, self-report disability and kinesiophobia compared to MCMT at six months.","[{'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Tagliaferri', 'Affiliation': 'Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC 3220, Australia.'}, {'ForeName': 'Clint T', 'Initials': 'CT', 'LastName': 'Miller', 'Affiliation': 'Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC 3220, Australia.'}, {'ForeName': 'Jon J', 'Initials': 'JJ', 'LastName': 'Ford', 'Affiliation': 'Advance HealthCare, 157 Scoresby Rd, Boronia, VIC 3155, Australia.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Hahne', 'Affiliation': 'Low Back Research Team, College of Science, Health & Engineering, La Trobe University, Bundoora, VIC 3083, Australia.'}, {'ForeName': 'Luana C', 'Initials': 'LC', 'LastName': 'Main', 'Affiliation': 'Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC 3220, Australia.'}, {'ForeName': 'Timo', 'Initials': 'T', 'LastName': 'Rantalainen', 'Affiliation': 'Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC 3220, Australia.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Connell', 'Affiliation': 'Imaging@Olympic Park, AAMI Park, 60 Olympic Boulevard, Melbourne, VIC 3004, Australia.'}, {'ForeName': 'Katherine J', 'Initials': 'KJ', 'LastName': 'Simson', 'Affiliation': 'School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC 3220, Australia.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Owen', 'Affiliation': 'Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC 3220, Australia.'}, {'ForeName': 'Daniel L', 'Initials': 'DL', 'LastName': 'Belavy', 'Affiliation': 'Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC 3220, Australia.'}]",Journal of clinical medicine,['10.3390/jcm9061726'] 1442,32507128,Evaluation of the effect of naltrexone coadministration on the pharmacokinetics of oxycodone in a randomized phase 1 clinical trial
.,"OBJECTIVE Oxycodone is a centrally acting µ-opioid agonist used as a strong analgesic. The opioid receptor antagonist -naltrexone is often coadministered to healthy subjects in clinical trials evaluating the pharmacokinetics (PK) of oxycodone to minimize its pharmacodynamic opioid effects. One objective of this relative bioavailability trial in healthy subjects was to investigate the effect of naltrexone on the PK of oxycodone. MATERIALS AND METHODS A randomized, single-dose, parallel-group, within-groups crossover, clinical trial was conducted in 24 healthy subjects. 12 subjects were to receive a new oxycodone prolonged-release (PR) tablet (test) with naltrexone (T+) and without naltrexone (T) in the fasted state. Additionally, 12 subjects were to receive an Oxygesic PR tablet (reference) with naltrexone (R+) and without naltrexone (R) in the fasted state. Naltrexone was given orally 1.5 hours prior to each oxycodone administration. Pharmacokinetics, safety, and tolerability were assessed. RESULTS The PK parameters of either oxycodone formulation were not changed with naltrexone administration under fasted conditions (point estimate T+/T (corresponding 90% confidence interval): C max : 103% (88 - 119%), AUC 0-t : 97% (87 - 108%), AUC: 97% (88 - 108%); point estimate R+/R (corresponding 90% confidence interval): C max : 104% (97 - 112%), AUC 0-t : 95% (88 - 102%), AUC: 94% (87 - 100%)). The safety and tolerability of both formulations was not qualitatively affected by naltrexone coadministration; however, treatment with naltrexone coadministration showed lower frequencies of adverse events. CONCLUSION Oral naltrexone does not affect the PK of oral oxycodone under fasted conditions. A naltrexone block can be applied in oxycodone PK trials to minimize adverse opioid effects.",2020,"The PK parameters of either oxycodone formulation were not changed with naltrexone administration under fasted conditions (point estimate T+/T (corresponding 90% confidence interval): C max : 103% (88 - 119%), AUC 0-t : 97% (87 - 108%), AUC: 97% (88 - 108%); point estimate R+/R (corresponding 90% confidence interval): C max : 104% (97 - 112%), AUC 0-t : 95% (88 - 102%), AUC: 94% (87 - 100%)).","['24 healthy subjects', 'healthy subjects', '12 subjects']","['naltrexone', 'Naltrexone', 'Oxygesic PR tablet (reference) with naltrexone (R+) and without naltrexone (R', 'new oxycodone prolonged-release (PR) tablet (test) with naltrexone (T+) and without naltrexone (T', 'naltrexone coadministration']","['frequencies of adverse events', 'safety and tolerability', 'Pharmacokinetics, safety, and tolerability']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C4544856', 'cui_str': 'Prolonged-release'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0030049', 'cui_str': 'Oxycodone'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0991507', 'cui_str': 'Prolonged-release oral tablet'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}]",24.0,0.0949344,"The PK parameters of either oxycodone formulation were not changed with naltrexone administration under fasted conditions (point estimate T+/T (corresponding 90% confidence interval): C max : 103% (88 - 119%), AUC 0-t : 97% (87 - 108%), AUC: 97% (88 - 108%); point estimate R+/R (corresponding 90% confidence interval): C max : 104% (97 - 112%), AUC 0-t : 95% (88 - 102%), AUC: 94% (87 - 100%)).","[{'ForeName': 'Elke', 'Initials': 'E', 'LastName': 'Kleideiter', 'Affiliation': ''}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Buller', 'Affiliation': ''}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Nemeth', 'Affiliation': ''}, {'ForeName': 'Rolf', 'Initials': 'R', 'LastName': 'Terlinden', 'Affiliation': ''}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Rengelshausen', 'Affiliation': ''}]",International journal of clinical pharmacology and therapeutics,['10.5414/CP203706'] 1443,32507132,Whole body vibration improves symptoms of diabetic peripheral neuropathy.,"Whole Body Vibration (WBV) is an innovative therapy that may be effective for reducing chronic pain associated with diabetic peripheral neuropathy (DPN), Current treatments for DPN pain have demonstrated questionable efficacy and significant risk of adverse events. Preliminary research has indicated that WBV may be effective for controlling chronic pain symptoms of DPN. METHODS 20 participants (9 male, 11 female), 58.51 ± 10.69 years old, and BMI of 33.60 ± 8.20 kg/m2 were randomly assigned to a sham-treatment (n = 8) or WBV treatment (n = 12) group in a pre-post design. Pain was assessed with a 10-point verbal analog pain scale (VAS). Treatment consisted of three sessions/week with at least one day between sessions, 12 min/session (four bouts of 3 min), for four weeks. Control was established with a sham vibration protocol for two weeks in which the participants were blinded to the treatment. RESULTS VAS scores of the treatment group decreased significantly at both 2 and 4 weeks (p = 0.019). The treatment group was found to have a significantly lower VAS score than the controls at two weeks (p = 0.033). After cessation of WBV vibration treatment, participants reported reduced DPN-related pain from 1 to 5 weeks later. CONCLUSION WBV is effective for reducing DPN-associated pain over a two- and four-week interval. This was the first study to demonstrate this using a sham vibration control. We further saw a persistence in pain reduction beyond the day of treatment, indicating a potential chronic effect of WBV treatment.",2020,"RESULTS VAS scores of the treatment group decreased significantly at both 2 and 4 weeks (p = 0.019).","[' 58.51\xa0±\xa010.69 years old, and BMI of 33.60\xa0±\xa08.20\xa0kg/m2', '20 participants (9 male, 11 female']","['Whole body vibration', 'sham-treatment (n\xa0=\xa08) or WBV treatment', 'WBV vibration', 'Whole Body Vibration (WBV']","['reduced DPN-related pain', 'VAS score', 'pain reduction', '10-point verbal analog pain scale (VAS', 'Pain', 'DPN-associated pain', 'VAS scores']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0740447', 'cui_str': 'Diabetic peripheral neuropathy'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0002777', 'cui_str': 'Analog Pain Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}]",20.0,0.0384436,"RESULTS VAS scores of the treatment group decreased significantly at both 2 and 4 weeks (p = 0.019).","[{'ForeName': 'Nathan J', 'Initials': 'NJ', 'LastName': 'Kessler', 'Affiliation': 'Department of Exercise and Health Science, Willamette University, USA; Western University of the Health Sciences COMP-NW, USA.'}, {'ForeName': 'Michael M', 'Initials': 'MM', 'LastName': 'Lockard', 'Affiliation': 'Department of Exercise and Health Science, Willamette University, USA. Electronic address: mlockard@willamette.edu.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Fischer', 'Affiliation': 'Western University of the Health Sciences COMP-NW, USA.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2020.01.004'] 1444,32507135,Effect of Pilates Method on muscular trunk endurance and hamstring extensibility in adolescents during twelve weeks training and detraining.,"BACKGROUND Thoracic hyperkyphosis and lumbar hyperlordosis have been associated with low values of flexibility in the hamstring muscle and endurance of the trunk musculature. These are areas that are worked using the Pilates Method (PM), however, there are only two studies that assess its effect on these variables in adolescence, and none that measure the retention time of the acquired improvements. The main objective of this research was to assess the effect of 10 min of adapted exercise program from PM in a Physical Education class (PE) for 12 weeks, on trunk muscle endurance and hamstring flexibility, and to evaluate the retention of resulting changes. METHODS The sample consisted of 441 adolescents (age = 13.9 ± 1.3 years). The experimental group (EG) performed two weekly 10-min sessions of PM for 12 weeks. The control group (CG) performed its usual sessions of PE. The endurance of the trunk flexor muscles and trunk extensor muscles, toe touch test (TT), bench trunk curl test (BTC) and the Biering-Sörensen test (SOR), were used to evaluate hamstring flexibility, before application of the program, at the end, 12 weeks later. RESULTS A significant improvement was found in the EG for all variables analyzed, with an average improvement of 9.37 repetitions in the BTC test, 19.4 s in the SOR test and 2.75 in the TT test. The CG did not show significant changes. The EG's improvements were retained 12 weeks later, except in the SOR test. CONCLUSION The inclusion of 10 min of adapted exercise program from PM in PE classes, for two weekly sessions over 12 weeks, produces improvements in trunk muscle endurance and hamstring flexibility, and these gains are retained in the flexor and hamstring muscles 12 weeks later.",2020,"A significant improvement was found in the EG for all variables analyzed, with an average improvement of 9.37 repetitions in the BTC test, 19.4 s in the SOR test and 2.75 in the TT test.","['441 adolescents (age\xa0=\xa013.9\xa0±\xa01.3 years', 'adolescents during twelve weeks training and detraining']","['10\xa0min of adapted exercise program', 'control group (CG) performed its usual sessions of PE', 'Pilates Method']","['trunk muscle endurance and hamstring flexibility', 'endurance of the trunk flexor muscles and trunk extensor muscles, toe touch test (TT), bench trunk curl test (BTC) and the Biering-Sörensen test (SOR', 'muscular trunk endurance and hamstring extensibility']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517562', 'cui_str': '13.9'}, {'cui': 'C4517499', 'cui_str': '1.3'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0031805', 'cui_str': 'Education, Physical'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0581755', 'cui_str': 'Skeletal muscle structure of trunk'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0040357', 'cui_str': 'Toe structure'}, {'cui': 'C0152054', 'cui_str': 'Touch'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0010474', 'cui_str': ""Curling's ulcers""}, {'cui': 'C0442025', 'cui_str': 'Muscular'}]",441.0,0.0226033,"A significant improvement was found in the EG for all variables analyzed, with an average improvement of 9.37 repetitions in the BTC test, 19.4 s in the SOR test and 2.75 in the TT test.","[{'ForeName': 'Noelia', 'Initials': 'N', 'LastName': 'González-Gálvez', 'Affiliation': 'Catholic University San Antonio of Murcia (UCAM), Murcia, Spain.'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Vaquero-Cristóbal', 'Affiliation': 'Catholic University San Antonio of Murcia (UCAM), Murcia, Spain.'}, {'ForeName': 'Pablo Jorge', 'Initials': 'PJ', 'LastName': 'Marcos-Pardo', 'Affiliation': 'Catholic University San Antonio of Murcia (UCAM), Murcia, Spain. Electronic address: pmarcos@ucam.edu.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2020.02.002'] 1445,32507136,Effects of the Russian current in the treatment of low back pain in women: A randomized clinical trial.,"BACKGROUND Low back pain (LBP) is a high impact condition that affects the working population, generating social and economic repercussions, the most relevant symptoms being pain and functional disability. Conservative treatment is often based on stabilizing spinal muscles with exercises: the Russian current (RC) is reported as an alternative, because it promotes muscle contraction, providing muscle strengthening and hypertrophy. OBJECTIVE To assess the effectiveness of the RC in aiding the treatment of low back pain. METHODS This randomized study included 23 women aged 18-30 years, divided into two groups: the control group (CG) and the Russian current group (RCG), for four weeks. Pain (visual analogue scale, VAS; pressure algometer, PA), function (Oswestry Low Back Disability Index), resistance (trunk resistance [TR] test) and thickness changes in the muscle (ultrasound image) were evaluated before and after the RC protocol and at one-month follow-up. RESULTS There were significant VAS reductions in both groups, but at follow-up these had only been maintained in the RCG, which presented lower values than the CG in the second evaluation. For PA, Oswestry and TR, there were differences only in the RCG. In a comparison of LBP between the groups, the initial difference disappeared in subsequent evaluations; TR presented higher values in evaluation 2 and 3 in the RCG group. In terms of thickness changes, differences between the groups were reduced after treatment. CONCLUSION The proposed treatment was effective in the reduction of LBP, with short-term improvement in resistance and thickness changes of the multifidus.",2020,"There were significant VAS reductions in both groups, but at follow-up these had only been maintained in the RCG, which presented lower values than the CG in the second evaluation.","['23 women aged 18-30 years', 'low back pain in women']","['control group (CG) and the Russian current group (RCG', 'Russian current']","['Pain (visual analogue scale, VAS; pressure algometer, PA), function (Oswestry Low Back Disability Index), resistance (trunk resistance [TR] test) and thickness changes in the muscle (ultrasound image', 'VAS reductions']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0035967', 'cui_str': 'Russian language'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",23.0,0.0336222,"There were significant VAS reductions in both groups, but at follow-up these had only been maintained in the RCG, which presented lower values than the CG in the second evaluation.","[{'ForeName': 'Carla Elis', 'Initials': 'CE', 'LastName': 'Batistella', 'Affiliation': 'Universidade Estadual Do Oeste Do Paraná - UNIOESTE, Universitaria St. 2069, Cascavel, Paraná, 85819-110, Brazil. Electronic address: c-arlaeli-s@hotmail.com.'}, {'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'Bidin', 'Affiliation': 'Universidade Estadual Do Oeste Do Paraná - UNIOESTE, Universitaria St. 2069, Cascavel, Paraná, 85819-110, Brazil. Electronic address: fernandabidin@hotmail.com.'}, {'ForeName': 'Isabela', 'Initials': 'I', 'LastName': 'Giacomelli', 'Affiliation': 'Universidade Estadual Do Oeste Do Paraná - UNIOESTE, Universitaria St. 2069, Cascavel, Paraná, 85819-110, Brazil. Electronic address: isabela.giacomelli1997@gmail.com.'}, {'ForeName': 'Milena Aparecida', 'Initials': 'MA', 'LastName': 'Nunez', 'Affiliation': 'Universidade Estadual Do Oeste Do Paraná - UNIOESTE, Universitaria St. 2069, Cascavel, Paraná, 85819-110, Brazil. Electronic address: milenaapnunez@gmail.com.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Gasoto', 'Affiliation': 'Universidade Estadual Do Oeste Do Paraná - UNIOESTE, Universitaria St. 2069, Cascavel, Paraná, 85819-110, Brazil. Electronic address: eduardo_gmoreira@outlook.com.'}, {'ForeName': 'Carlos Eduardo de', 'Initials': 'CE', 'LastName': 'Albuquerque', 'Affiliation': 'Universidade Estadual Do Oeste Do Paraná - UNIOESTE, Universitaria St. 2069, Cascavel, Paraná, 85819-110, Brazil. Electronic address: ceafit@yahoo.com.'}, {'ForeName': 'Lucinar Jupir Forner', 'Initials': 'LJF', 'LastName': 'Flores', 'Affiliation': 'Universidade Estadual Do Oeste Do Paraná - UNIOESTE, Universitaria St. 2069, Cascavel, Paraná, 85819-110, Brazil. Electronic address: lucinar05@gmail.com.'}, {'ForeName': 'Gladson Ricardo Flor', 'Initials': 'GRF', 'LastName': 'Bertolini', 'Affiliation': 'Universidade Estadual Do Oeste Do Paraná - UNIOESTE, Universitaria St. 2069, Cascavel, Paraná, 85819-110, Brazil. Electronic address: gladson.bertolini@unioeste.br.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2019.10.009'] 1446,32686435,Prophylactic HIPEC with oxaliplatin might be of benefit in T4 and perforated colon cancer: another possible interpretation of the COLOPEC results.,"The COLOPEC trial failed to show evidence for improved relapse-free survival (RFS) between the two study groups: 80,9% (95% CI 73.3-88.5) in the experimental group and 76.2 % (68.0-84.4) in the control group (one-sided log-rank p = 0.28). Nevertheless only 87 patients received the adjuvant HIPEC treatment in the experimental arm (n = 100). This group had a peritoneal relapse of 19 %, but only 10 % had a truly peritoneal relapse as 9 of them had stablished peritoneal carcinomatosis and 1 case was a peritoneal recurrence but did not receive adjuvant HIPEC. We conducted a per-protocol analysis comparing the 87 patients which truly received the adjuvant HIPEC to the 102 patients in the control arm and obtained an OR 0.396 (95 % CI 0.17-0.91) with a (Pearson Chi-Square p = 0.026, two-tailed Fisher exact test p = 0.032). This contradicts the COLOPEC reported conclusions and shows that adjuvant HIPEC could have an important protective role against peritoneal recurrence.",2020,"The COLOPEC trial failed to show evidence for improved relapse-free survival (RFS) between the two study groups: 80,9% (95% CI 73.3-88.5) in the experimental group and 76.2 % (68.0-84.4) in the control group (one-sided log-rank p = 0.28).","['T4 and perforated colon cancer', '87 patients which truly received the adjuvant HIPEC to the 102 patients in the control arm and obtained an OR 0.396', '87 patients received the']","['oxaliplatin', 'adjuvant HIPEC']","['peritoneal relapse', 'relapse-free survival (RFS', 'truly peritoneal relapse', 'peritoneal recurrence']","[{'cui': 'C0347646', 'cui_str': 'Perforation of colon'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C1868801', 'cui_str': 'Hyperthermic Intraperitoneal Chemotherapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}]","[{'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C1868801', 'cui_str': 'Hyperthermic Intraperitoneal Chemotherapy'}]","[{'cui': 'C0031153', 'cui_str': 'Peritoneum (serous membrane) structure'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",,0.173321,"The COLOPEC trial failed to show evidence for improved relapse-free survival (RFS) between the two study groups: 80,9% (95% CI 73.3-88.5) in the experimental group and 76.2 % (68.0-84.4) in the control group (one-sided log-rank p = 0.28).","[{'ForeName': 'Juan José', 'Initials': 'JJ', 'LastName': 'Segura-Sampedro', 'Affiliation': 'Cirugía General y del Aparato Digestivo, Hospital Universitario Son Espases, España.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Morales-Soriano', 'Affiliation': 'Cirugía General y del Aparato Digestivo, Hospital Universitario Son Espases.'}]",Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva,['10.17235/reed.2020.6755/2019'] 1447,32506135,Effects of Potassium or Sodium Supplementation on Mineral Homeostasis: A Controlled Dietary Intervention Study.,"CONTEXT Although dietary potassium and sodium intake may influence calcium-phosphate metabolism and bone health, the effects on bone mineral parameters, including fibroblast growth factor 23 (FGF23), are unclear. OBJECTIVE Here, we investigated the effects of potassium or sodium supplementation on bone mineral parameters. DESIGN, SETTING, PARTICIPANTS We performed a post hoc analysis of a dietary controlled randomized, blinded, placebo-controlled crossover trial. Prehypertensive individuals not using antihypertensive medication (n = 36) received capsules containing potassium chloride (3 g/d), sodium chloride (3 g/d), or placebo. Linear mixed-effect models were used to estimate treatment effects. RESULTS Potassium supplementation increased plasma phosphate (from 1.10 ± 0.19 to 1.15 ± 0.19 mmol/L, P = 0.004), in line with an increase in tubular maximum of phosphate reabsorption (from 0.93 ± 0.21 to 1.01 ± 0.20 mmol/L, P < 0.001). FGF23 decreased (114.3 [96.8-135.0] to 108.5 [93.5-125.9] RU/mL, P = 0.01), without change in parathyroid hormone and 25-hydroxy vitamin D3. Fractional calcium excretion decreased (from 1.25 ± 0.50 to 1.11 ± 0.46 %, P = 0.03) without change in plasma calcium. Sodium supplementation decreased both plasma phosphate (from 1.10 ± 0.19 to 1.06 ± 0.21 mmol/L, P = 0.03) and FGF23 (from 114.3 [96.8-135.0] to 108.7 [92.3-128.1] RU/mL, P = 0.02). Urinary and fractional calcium excretion increased (from 4.28 ± 1.91 to 5.45 ± 2.51 mmol/24 hours, P < 0.001, and from 1.25 ± 0.50 to 1.44 ± 0.54 %, P = 0.004, respectively). CONCLUSIONS Potassium supplementation led to a decrease in FGF23, which was accompanied by increase in plasma phosphate and decreased calcium excretion. Sodium supplementation reduced FGF23, but this was accompanied by decrease in phosphate and increase in fractional calcium excretion. Our results indicate distinct effects of potassium and sodium intake on bone mineral parameters, including FGF23. CLINICAL TRIAL REGISTRATION NUMBER NCT01575041.",2020,"Sodium supplementation decreased both plasma phosphate (from 1.10±0.19 to 1.06±0.21 mmol/L, P=0.03) and FGF23 (from 114.3 [96.8-135.0] to 108.7 [92.3-128.1] RU/mL, P=0.02).",['hypertensive individuals not using antihypertensive medication (n=36) received'],"['Potassium or Sodium Supplementation', 'sodium chloride', 'capsules containing potassium chloride', 'Potassium supplementation', 'dietary potassium and sodium intake', 'potassium and sodium intake', 'potassium or sodium supplementation', 'Sodium supplementation', 'placebo']","['parathyroid hormone and 25(OH)-vitamin D3', 'Fractional calcium excretion', 'bone mineral parameters, including FGF23', 'Mineral Homeostasis', 'Urinary and fractional calcium excretion', 'plasma calcium', 'bone mineral parameters', 'plasma phosphate', 'FGF23', 'plasma phosphate and decreased calcium excretion', 'tubular maximum of phosphate reabsorption', 'fractional calcium excretion']","[{'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0445107', 'cui_str': 'Not used'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0032821', 'cui_str': 'Potassium'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0037494', 'cui_str': 'Sodium Chloride'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0032825', 'cui_str': 'Potassium Chloride'}, {'cui': 'C0561938', 'cui_str': 'Potassium supplementation'}, {'cui': 'C0162800', 'cui_str': 'Dietary Potassium'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0020063', 'cui_str': 'PTH protein, human'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0962301', 'cui_str': 'Fibroblast growth factor 23'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C1272114', 'cui_str': 'Plasma calcium level'}, {'cui': 'C0858147', 'cui_str': 'Plasma phosphate'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0332208', 'cui_str': 'Tubular'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0031603', 'cui_str': 'Phosphate'}]",,0.11207,"Sodium supplementation decreased both plasma phosphate (from 1.10±0.19 to 1.06±0.21 mmol/L, P=0.03) and FGF23 (from 114.3 [96.8-135.0] to 108.7 [92.3-128.1] RU/mL, P=0.02).","[{'ForeName': 'Jelmer K', 'Initials': 'JK', 'LastName': 'Humalda', 'Affiliation': 'Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, RB Groningen, the Netherlands.'}, {'ForeName': 'Stanley M H', 'Initials': 'SMH', 'LastName': 'Yeung', 'Affiliation': 'Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, RB Groningen, the Netherlands.'}, {'ForeName': 'Johanna M', 'Initials': 'JM', 'LastName': 'Geleijnse', 'Affiliation': 'Division of Human Nutrition and Health, Wageningen University, HB Wageningen, the Netherlands.'}, {'ForeName': 'Lieke', 'Initials': 'L', 'LastName': 'Gijsbers', 'Affiliation': 'Division of Human Nutrition and Health, Wageningen University, HB Wageningen, the Netherlands.'}, {'ForeName': 'Ineke J', 'Initials': 'IJ', 'LastName': 'Riphagen', 'Affiliation': 'Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, RB Groningen, the Netherlands.'}, {'ForeName': 'Ewout J', 'Initials': 'EJ', 'LastName': 'Hoorn', 'Affiliation': 'Department of Internal Medicine, Division of Nephrology & Transplantation, Erasmus Medical Center, University Medical Center Rotterdam, CA Rotterdam, The Netherlands.'}, {'ForeName': 'Joris I', 'Initials': 'JI', 'LastName': 'Rotmans', 'Affiliation': 'Department of Internal Medicine, Leiden University Medical Center, RC Leiden, the Netherlands.'}, {'ForeName': 'Liffert', 'Initials': 'L', 'LastName': 'Vogt', 'Affiliation': 'Department of Internal Medicine, Section of Nephrology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, DD Amsterdam Zuidoost, the Netherlands.'}, {'ForeName': 'Gerjan', 'Initials': 'G', 'LastName': 'Navis', 'Affiliation': 'Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, RB Groningen, the Netherlands.'}, {'ForeName': 'Stephan J L', 'Initials': 'SJL', 'LastName': 'Bakker', 'Affiliation': 'Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, RB Groningen, the Netherlands.'}, {'ForeName': 'Martin H', 'Initials': 'MH', 'LastName': 'de Borst', 'Affiliation': 'Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, RB Groningen, the Netherlands.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgaa359'] 1448,32533785,"Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial.","LESSONS LEARNED The efficacy of second-line treatment for advanced non-small cell lung carcinoma (NSCLC) without a sensitizing driver gene mutation is still unsatisfactory. The combination of apatinib and chemotherapy improved progression-free survival in the second-line therapy of advanced NSCLC without a sensitizing mutation. This study offers a new treatment strategy for second-line treatment of such patients but requires confirmation in a larger multi-institutional trial. BACKGROUND This study explored the efficacy and safety of apatinib combined with single-agent chemotherapy versus single-agent chemotherapy in the second-line treatment of advanced non-small-cell lung carcinoma (NSCLC) without driver mutations. METHODS In this double-arm, open label, exploratory clinical study, we enrolled patients with unresectable locally advanced or advanced NSCLC without driver mutations that had progressed following first-line chemotherapy. The subjects were allocated into an experimental group and a control group by 2:1. The experimental group received apatinib combined with four cycles of docetaxel or pemetrexed until disease progression, intolerable toxicity, or discontinuation at the patient' request. The control group only received four cycles of docetaxel or pemetrexed. The primary endpoints were progression-free survival (PFS), and the secondary endpoints were overall survival (OS), disease control rate (DCR), and safety. RESULTS Thirty-seven patients were enrolled. The efficacy of 33 patients was evaluated. The median PFS was 5.47 versus 2.97 months, the DCR was 95% versus 73%, and the objective response rate (ORR) was 27% versus 9% in the experimental versus control group. The OS was still under follow-up. The most common adverse effects included hypertension, hand-foot skin reaction (HFSR), and fatigue. CONCLUSION Apatinib combined with single-agent chemotherapy may be a novel option for second-line treatment of advanced NSCLC.",2020,"The median PFS was 5.47 versus 2.97 months, the DCR was 95% versus 73%, and the objective response rate (ORR) was 27% versus 9% in the experimental versus control group.","['advanced non-small-cell lung carcinoma (NSCLC) without driver mutations', '33 patients', 'advanced non-small cell lung carcinoma (NSCLC', 'Unresectable Non-Small Cell Lung Carcinoma', 'enrolled patients with unresectable locally advanced or advanced NSCLC without driver mutations that had progressed following first-line chemotherapy', 'Thirty-seven patients were enrolled']","['docetaxel or pemetrexed', 'apatinib combined with single-agent chemotherapy versus single-agent chemotherapy', 'apatinib combined with four cycles of docetaxel or pemetrexed', 'second-line treatment', 'Apatinib plus Chemotherapy', 'apatinib and chemotherapy', 'Apatinib combined with single-agent chemotherapy']","['objective response rate (ORR', 'progression-free survival', 'efficacy and safety', 'overall survival (OS), disease control rate (DCR), and safety', 'hypertension, hand-foot skin reaction (HFSR), and fatigue', 'progression-free survival (PFS', 'DCR', 'median PFS']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0684312', 'cui_str': 'Vehicle driver'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C4319569', 'cui_str': '37'}]","[{'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C2346836', 'cui_str': 'apatinib'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1710038', 'cui_str': 'Second line treatment'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0222289', 'cui_str': 'Skin structure of foot'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",37.0,0.11037,"The median PFS was 5.47 versus 2.97 months, the DCR was 95% versus 73%, and the objective response rate (ORR) was 27% versus 9% in the experimental versus control group.","[{'ForeName': 'Zongyang', 'Initials': 'Z', 'LastName': 'Yu', 'Affiliation': ""The 900th Hospital of Joint Logistic Support Force, PLA, Fujian Medical University, Fuzhou, People' Republic of China.""}, {'ForeName': 'Xiuyu', 'Initials': 'X', 'LastName': 'Cai', 'Affiliation': 'Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Zhengwu', 'Initials': 'Z', 'LastName': 'Xu', 'Affiliation': ""Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, People' Republic of China.""}, {'ForeName': 'Zhiyong', 'Initials': 'Z', 'LastName': 'He', 'Affiliation': ""Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, People' Republic of China.""}, {'ForeName': 'Jinhuo', 'Initials': 'J', 'LastName': 'Lai', 'Affiliation': ""Affiliated Union Hospital of Fujian Medical University, Fuzhou, People' Republic of China.""}, {'ForeName': 'Wenwu', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': ""The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, People' Republic of China.""}, {'ForeName': 'Wencui', 'Initials': 'W', 'LastName': 'Kong', 'Affiliation': ""The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China.""}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': ""The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China.""}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': ""The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China.""}, {'ForeName': 'Yanhong', 'Initials': 'Y', 'LastName': 'Shi', 'Affiliation': ""The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China.""}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Shi', 'Affiliation': ""First Affiliated Hospital of Fujian Medical University, Fuzhou, People' Republic of China.""}, {'ForeName': 'Zhongquan', 'Initials': 'Z', 'LastName': 'Zhao', 'Affiliation': ""The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China.""}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Ni', 'Affiliation': ""The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China.""}, {'ForeName': 'Xiangwu', 'Initials': 'X', 'LastName': 'Lin', 'Affiliation': ""The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China.""}, {'ForeName': 'Siyu', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': ""The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China.""}, {'ForeName': 'Xiaolong', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': ""The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, People' Republic of China.""}, {'ForeName': 'Wujin', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': ""Fujian People's Hospital, Fuzhou, People' Republic of China.""}, {'ForeName': 'Zhengbo', 'Initials': 'Z', 'LastName': 'Song', 'Affiliation': ""Zhejiang Cancer Hospital, Hangzhou, People' Republic of China.""}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Huang', 'Affiliation': ""Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, People' Republic of China.""}]",The oncologist,['10.1634/theoncologist.2020-0519'] 1449,32498269,"Effects of Porphyra tenera Supplementation on the Immune System: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial.","OBJECTIVE The purpose of this study was to determine if Porphyra tenera extract (PTE) has immune-enhancing effects and is safe in healthy adults. METHODS Subjects who met the inclusion criteria (3 × 10 3 ≤ peripheral blood leukocyte level ≥ 8 × 10 3 cells/µL) were recruited for this study. Enrolled subjects ( n = 120) were randomly assigned to either the PTE group ( n = 60) and were given 2.5 g/day of PTE (as PTE) in capsule form or the placebo group ( n = 60) and were given crystal cellulose capsules with the identical appearance, weight, and flavor as the PTE capsules for 8 weeks. Outcomes were assessed based on measuring natural killer (NK) cell activity, cytokines level, and upper respiratory infection (URI), and safety parameters were assessed at baseline and 8 weeks. RESULTS Compared with baseline, NK cell activity (%) increased for all effector cell-to-target cell ratios in the PTE group after 8 weeks; however, changes were not observed in the placebo group ( p < 0.10). Subgroup analysis of 101 subjects without URI showed that NK cell activity in the PTE group tended to increase for all effector cell/target cell (E:T) ratios (E:T = 12.5:1 p = 0.068; E:T = 25:1 p = 0.036; E:T = 50:1 p = 0.081) compared with the placebo group. A significant difference between the two groups was observed for the E:T = 25:1 ratio, which increased from 20.3 ± 12.0% at baseline to 23.2 ± 12.4% after 8 weeks in the PTE group ( p = 0.036). A significant difference was not observed in cytokine between the two groups. CONCLUSION PTE supplementation appears to enhance immune function by improving NK cell activity without adverse effects in healthy adults.",2020,"Compared with baseline, NK cell activity (%) increased for all effector cell-to-target cell ratios in the PTE group after 8 weeks; however, changes were not observed in the placebo group ( p < 0.10).","['Enrolled subjects ( n = 120', 'Subjects who met the inclusion criteria (3 × 10 3 ≤ peripheral blood leukocyte level ≥ 8 × 10 3 cells/µL', 'healthy adults']","['PTE supplementation', 'Placebo', 'PTE', 'PTE (as PTE) in capsule form or the placebo', 'crystal cellulose capsules with the identical appearance, weight, and flavor as the PTE capsules', 'Porphyra tenera Supplementation', 'Porphyra tenera extract (PTE', 'placebo']","['natural killer (NK) cell activity, cytokines level, and upper respiratory infection (URI), and safety parameters', 'effector cell/target cell (E:T) ratios (E:T', 'cytokine', 'effector cell-to-target cell ratios', 'NK cell activity']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0007648', 'cui_str': 'Cellulose'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0682897', 'cui_str': 'Flavor Enhancers'}, {'cui': 'C0996258', 'cui_str': 'Porphyra'}, {'cui': 'C4283088', 'cui_str': 'Porphyra tenera extract'}]","[{'cui': 'C0022688', 'cui_str': 'NK-cell'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0041912', 'cui_str': 'Upper respiratory infection'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0312740', 'cui_str': 'Immune effector cell'}, {'cui': 'C0221284', 'cui_str': 'Leptocyte'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",120.0,0.381579,"Compared with baseline, NK cell activity (%) increased for all effector cell-to-target cell ratios in the PTE group after 8 weeks; however, changes were not observed in the placebo group ( p < 0.10).","[{'ForeName': 'Su-Jin', 'Initials': 'SJ', 'LastName': 'Jung', 'Affiliation': 'Clinical Trial Center for Functional Foods, Chonbuk National University Hospital, Jeonju 54907, Korea.'}, {'ForeName': 'Hui-Yeon', 'Initials': 'HY', 'LastName': 'Jang', 'Affiliation': 'Clinical Trial Center for Functional Foods, Chonbuk National University Hospital, Jeonju 54907, Korea.'}, {'ForeName': 'Eun-Soo', 'Initials': 'ES', 'LastName': 'Jung', 'Affiliation': 'Clinical Trial Center for Functional Foods, Chonbuk National University Hospital, Jeonju 54907, Korea.'}, {'ForeName': 'Soon-Ok', 'Initials': 'SO', 'LastName': 'Noh', 'Affiliation': 'Clinical Trial Center for Functional Foods, Chonbuk National University Hospital, Jeonju 54907, Korea.'}, {'ForeName': 'Sang-Wook', 'Initials': 'SW', 'LastName': 'Shin', 'Affiliation': 'Department of Medical Nutrition Therapy, Jeonbuk National University, Jeonju 54896, Korea.'}, {'ForeName': 'Ki-Chan', 'Initials': 'KC', 'LastName': 'Ha', 'Affiliation': 'Healthcare Claims & Management Incorporation, Jeonju 54858, Korea.'}, {'ForeName': 'Hyang-Im', 'Initials': 'HI', 'LastName': 'Baek', 'Affiliation': 'Healthcare Claims & Management Incorporation, Jeonju 54858, Korea.'}, {'ForeName': 'Byung-Jae', 'Initials': 'BJ', 'LastName': 'Ahn', 'Affiliation': 'Marine Biotechnology Research Center, Jeonnam Bioindustry Foundation, Wando 59108, Korea.'}, {'ForeName': 'Tae-Hwan', 'Initials': 'TH', 'LastName': 'Oh', 'Affiliation': 'Marine Biotechnology Research Center, Jeonnam Bioindustry Foundation, Wando 59108, Korea.'}, {'ForeName': 'Soo-Wan', 'Initials': 'SW', 'LastName': 'Chae', 'Affiliation': 'Clinical Trial Center for Functional Foods, Chonbuk National University Hospital, Jeonju 54907, Korea.'}]",Nutrients,['10.3390/nu12061642'] 1450,32498372,"A Double-Blind, Randomized Placebo-Controlled Trial of Probiotic Lactobacillus casei Shirota in Stable Cirrhotic Patients.","Background : In cirrhosis, a pathological gut microbiome has been linked with immune dysfunction. A pilot study of probiotic Lactobacillus casei Shirota (LcS) in alcoholic cirrhosis demonstrated significant improvement in neutrophil function. This study aimed to evaluate the efficacy of LcS on neutrophil function and significant infection rates in patients with cirrhosis. Methods : 92 cirrhotic patients (Child-Pugh score ≤10) were randomized to receive LcS or placebo, three times daily for six months. Primary end-points were incidence of significant infection and neutrophil function. Secondary end-points were cytokine profile, endotoxin, bacterial DNA positivity, intestinal permeability and quality of life. Results : Rates of infection, decompensation or neutrophil function did not differ between placebo and probiotic groups. LcS significantly reduced plasma monocyte chemotactic protein-1 and, on subgroup analysis, plasma interleukin-1β (alcoholic cirrhosis), interleukin-17a and macrophage inflammatory protein-1β (non-alcoholic cirrhosis), compared with placebo. No significant differences in intestinal permeability, bacterial translocation or metabolomic profile were observed. Conclusion : LcS supplementation in patients with early cirrhosis is safe. Although no significant infections were observed in either group, LcS improved cytokine profile towards an anti-inflammatory phenotype, an effect which appears to be independent of bacterial translocation.",2020,"LcS significantly reduced plasma monocyte chemotactic protein-1 and, on subgroup analysis, plasma interleukin-1β (alcoholic cirrhosis), interleukin-17a and macrophage inflammatory protein-1β (non-alcoholic cirrhosis), compared with placebo.","['Pugh score ≤10', 'Stable Cirrhotic Patients', 'patients with cirrhosis', '92 cirrhotic patients (Child', 'patients with early cirrhosis is safe']","['Placebo', 'LcS supplementation', 'LcS or placebo', 'Probiotic Lactobacillus casei Shirota', 'probiotic Lactobacillus casei Shirota (LcS', 'LcS', 'placebo']","['incidence of significant infection and neutrophil function', 'neutrophil function', 'neutrophil function and significant infection rates', 'cytokine profile, endotoxin, bacterial DNA positivity, intestinal permeability and quality of life', 'subgroup analysis, plasma interleukin-1β (alcoholic cirrhosis), interleukin-17a and macrophage inflammatory protein-1β (non-alcoholic cirrhosis', 'intestinal permeability, bacterial translocation or metabolomic profile', 'plasma monocyte chemotactic protein-1', 'Rates of infection, decompensation or neutrophil function']","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0439686', 'cui_str': 'Cirrhotic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1299579', 'cui_str': 'Early cirrhosis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0268314', 'cui_str': 'Cholestasis-edema syndrome, Norwegian type'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0022940', 'cui_str': 'Lactobacillus casei'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0014264', 'cui_str': 'Bacterial endotoxin'}, {'cui': 'C0012924', 'cui_str': 'Bacterial DNA'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0031164', 'cui_str': 'Permeability'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0023891', 'cui_str': 'Alcoholic cirrhosis'}, {'cui': 'C1701790', 'cui_str': 'IL17A protein, human'}, {'cui': 'C0376579', 'cui_str': 'Macrophage Inflammatory Proteins'}, {'cui': 'C0400943', 'cui_str': 'Cirrhosis - non-alcoholic'}, {'cui': 'C0282583', 'cui_str': 'Bacterial translocation'}, {'cui': 'C1328813', 'cui_str': 'Metabolomics'}, {'cui': 'C0128897', 'cui_str': 'Monocyte Chemoattractant Protein-1'}, {'cui': 'C0231187', 'cui_str': 'Decompensation'}]",92.0,0.471678,"LcS significantly reduced plasma monocyte chemotactic protein-1 and, on subgroup analysis, plasma interleukin-1β (alcoholic cirrhosis), interleukin-17a and macrophage inflammatory protein-1β (non-alcoholic cirrhosis), compared with placebo.","[{'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Macnaughtan', 'Affiliation': 'UCL Institute for Liver and Digestive Health, Division of Medicine, University College London, London NW3 2PF, UK.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Figorilli', 'Affiliation': 'UCL Institute for Liver and Digestive Health, Division of Medicine, University College London, London NW3 2PF, UK.'}, {'ForeName': 'Elisabet', 'Initials': 'E', 'LastName': 'García-López', 'Affiliation': 'Data Management Centre, European Foundation for the Study of Chronic Liver Failure (EF-CLIF), 08021 Barcelona, Spain.'}, {'ForeName': 'Haw', 'Initials': 'H', 'LastName': 'Lu', 'Affiliation': 'UCL Institute for Liver and Digestive Health, Division of Medicine, University College London, London NW3 2PF, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Jones', 'Affiliation': 'UCL Institute for Liver and Digestive Health, Division of Medicine, University College London, London NW3 2PF, UK.'}, {'ForeName': 'Rohit', 'Initials': 'R', 'LastName': 'Sawhney', 'Affiliation': 'UCL Institute for Liver and Digestive Health, Division of Medicine, University College London, London NW3 2PF, UK.'}, {'ForeName': 'Kaori', 'Initials': 'K', 'LastName': 'Suzuki', 'Affiliation': 'Yakult Europe B.V., 1332 EN Almere, The Netherlands.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Fairclough', 'Affiliation': 'Mid and South Essex NHS Foundation Trust, Basildon & Thurrock University Hospitals NHS Foundation Trust, Basildon, SS16 5NL, UK.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Marsden', 'Affiliation': ""Department of Biochemistry, Bessemer Wing, King's College Hospital, London SE5 9RS, UK.""}, {'ForeName': 'Alba', 'Initials': 'A', 'LastName': 'Moratella', 'Affiliation': 'UCL Institute for Liver and Digestive Health, Division of Medicine, University College London, London NW3 2PF, UK.'}, {'ForeName': 'I Jane', 'Initials': 'IJ', 'LastName': 'Cox', 'Affiliation': 'Institute of Hepatology London, Foundation for Liver Research, London SE5 9NT, UK.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Thomas', 'Affiliation': 'Yakult Europe B.V., 1332 EN Almere, The Netherlands.'}, {'ForeName': 'Nathan', 'Initials': 'N', 'LastName': 'Davies', 'Affiliation': 'UCL Institute for Liver and Digestive Health, Division of Medicine, University College London, London NW3 2PF, UK.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Williams', 'Affiliation': 'Institute of Hepatology London, Foundation for Liver Research, London SE5 9NT, UK.'}, {'ForeName': 'Raj', 'Initials': 'R', 'LastName': 'Mookerjee', 'Affiliation': 'UCL Institute for Liver and Digestive Health, Division of Medicine, University College London, London NW3 2PF, UK.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Wright', 'Affiliation': 'UCL Institute for Liver and Digestive Health, Division of Medicine, University College London, London NW3 2PF, UK.'}, {'ForeName': 'Rajiv', 'Initials': 'R', 'LastName': 'Jalan', 'Affiliation': 'UCL Institute for Liver and Digestive Health, Division of Medicine, University College London, London NW3 2PF, UK.'}]",Nutrients,['10.3390/nu12061651'] 1451,32502908,Effects of 1 mA and 2 mA transcranial direct current stimulation on working memory performance in healthy participants.,"Anodal transcranial current stimulation (tDCS) to the left dorsolateral prefrontal cortex (DLPFC) has been shown to enhance working memory (WM) in neuropsychiatric patients. In healthy populations, however, tDCS obtains inconclusive results, mostly due to heterogeneous study and stimulation protocols. Here, we approached these issues by investigating effects of tDCS intensity on simultaneous WM performance with three cognitive loads by directly comparing findings of two double-blind, cross-over, sham-controlled experiments. TDCS was administrated to the left DLPFC at intensity of 1 mA (Experiment 1) or 2 mA (Experiment 2), while participants completed a verbal n-back paradigm (1-, 2-, 3-back). Analysis showed no overall effects of tDCS on WM, but a significant interaction with cognitive load. The present study suggests that cognitive load rather than tDCS intensity could be a decisive factor for effects on WM. Moreover, it emphasizes the need of thorough investigation on study parameters to develop more efficient stimulation protocols.",2020,"Analysis showed no overall effects of tDCS on WM, but a significant interaction with cognitive load.","['healthy participants', 'neuropsychiatric patients']","['1\xa0mA and 2\xa0mA transcranial direct current stimulation', 'TDCS', 'Anodal transcranial current stimulation (tDCS']",['working memory performance'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1172076', 'cui_str': '1-(1-phenylethyl)-2-methyleneaziridine'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0442348', 'cui_str': 'Transcranial approach'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0025265', 'cui_str': 'Immediate memory'}]",,0.0450811,"Analysis showed no overall effects of tDCS on WM, but a significant interaction with cognitive load.","[{'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Papazova', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany. Electronic address: Irina.papazova@med.uni-muenchen.de.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Strube', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany.'}, {'ForeName': 'Aida', 'Initials': 'A', 'LastName': 'Wienert', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Henning', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Schwippel', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Neurophysiology & Interventional Neuropsychiatry, University of Tübingen, Germany.'}, {'ForeName': 'Andreas J', 'Initials': 'AJ', 'LastName': 'Fallgatter', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Neurophysiology & Interventional Neuropsychiatry, University of Tübingen, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Padberg', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Falkai', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Plewnia', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Neurophysiology & Interventional Neuropsychiatry, University of Tübingen, Germany.'}, {'ForeName': 'Alkomiet', 'Initials': 'A', 'LastName': 'Hasan', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany; Department of Psychiatry, Psychotherapy and Psychosomatics, BKH Augsburg, Medical Faculty, University of Augsburg, Germany.'}]",Consciousness and cognition,['10.1016/j.concog.2020.102959'] 1452,32502923,"A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer.","OBJECTIVES Efficacy, safety, pharmacokinetics (PK), and immunogenicity of the biosimilar candidate SB8 was compared to its reference product bevacizumab (BEV) in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. METHODS Patients were randomized (1:1) in a phase III, double-blind study to receive intravenous SB8 or BEV 15 mg/kg with paclitaxel/carboplatin every 3 weeks for 24 weeks, followed by SB8 or BEV maintenance monotherapy. The primary endpoint was best overall response rate (ORR) by 24 weeks. Secondary endpoints included survival outcomes, safety, PK, and immunogenicity. RESULTS 763 patients (SB8, n = 379; BEV, n = 384) were randomized; baseline characteristics were well balanced. Best ORR in the FAS was 47.6% and 42.8%, and best ORR in the PPS was 50.1% and 44.8% for SB8 and BEV, respectively. The risk ratio of best ORR was 1.11 (90% CI, 0.975-1.269), and the risk difference in best ORR was 5.3% (95% CI, -2.2%-12.9%). Median survival outcomes were comparable between SB8 and BEV: progression-free survival was 8.50 vs 7.90 months, respectively (HR [95% CI], 0.99 [0.83-1.18]; p = 0.9338); overall survival was 14.90 vs 15.80 months, respectively (HR [95% CI], 1.03 [0.83-1.28]; p = 0.7713); and duration of response was 7.70 vs 7.00 months, respectively (HR [95% CI], 1.05 [0.81-1.37]; p = 0.6928). Severity and incidence of treatment-emergent adverse events, PK, and immunogenicity were comparable between SB8 and BEV. CONCLUSION This study demonstrated equivalence between SB8 and BEV in terms of best ORR risk ratio, with comparable safety, PK, and immunogenicity.",2020,"Severity and incidence of treatment-emergent adverse events, PK, and immunogenicity were comparable between SB8 and BEV. ","['763 patients (SB8, n\u2009=\u2009379; BEV, n\u2009=\u2009384', 'Patients', 'patients with metastatic or recurrent nonsquamous non-small cell lung cancer']","['paclitaxel/carboplatin', 'bevacizumab (BEV', 'bevacizumab', 'intravenous SB8 or BEV 15']","['duration of response', 'Efficacy, safety, pharmacokinetics (PK), and immunogenicity', 'risk ratio of best ORR', 'Median survival outcomes', 'safety, PK, and immunogenicity', 'overall response rate (ORR', 'overall survival', 'Severity and incidence of treatment-emergent adverse events, PK, and immunogenicity', 'FAS', 'efficacy, safety, pharmacokinetics, and immunogenicity', 'SB8 and BEV: progression-free survival', 'survival outcomes, safety, PK, and immunogenicity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}]","[{'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",763.0,0.560036,"Severity and incidence of treatment-emergent adverse events, PK, and immunogenicity were comparable between SB8 and BEV. ","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Reck', 'Affiliation': 'Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Lung Clinic, Woehrendamm 80, 22927 Grosshansdorf, Germany. Electronic address: m.reck@lungenclinic.de.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Luft', 'Affiliation': 'Department of Thoracic Surgery, Leningrad Regional Clinical Hospital, St. Petersburg, Russian Federation. Electronic address: alexander_luft@mail.ru.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Bondarenko', 'Affiliation': 'Oncology and Medical Radiology Department, Dnipropetrovsk Medical Academy, Dnipro, Ukraine. Electronic address: oncology@dsma.dp.ua.'}, {'ForeName': 'Serhii', 'Initials': 'S', 'LastName': 'Shevnia', 'Affiliation': 'Department of Chemotherapy, Podillia Regional Oncology Center, Vinnytsia, Ukraine. Electronic address: shevnia1969@gmail.com.'}, {'ForeName': 'Dmytro', 'Initials': 'D', 'LastName': 'Trukhin', 'Affiliation': 'Oncology Department, Odessa Regional Oncology Center, Odessa, Ukraine. Electronic address: dtrukhin39@gmail.com.'}, {'ForeName': 'Nadezhda V', 'Initials': 'NV', 'LastName': 'Kovalenko', 'Affiliation': 'Oncology, Volgograd Regional Clinical Oncology Dispensary, Volgograd, Russian Federation. Electronic address: kovalenkost@yandex.ru.'}, {'ForeName': 'Kakha', 'Initials': 'K', 'LastName': 'Vacharadze', 'Affiliation': 'Department of Phthisiatry, Research Institute of Clinical Medicine, Tbilisi, Georgia. Electronic address: kakhavacharadze@yahoo.com.'}, {'ForeName': 'Fülöp', 'Initials': 'F', 'LastName': 'Andrea', 'Affiliation': 'Department of Pulmonary Class and Bronchology, Országos Korányi TBC és Pulmonológiai Intézet, Budapest, Hungary. Electronic address: afulop64@gmail.com.'}, {'ForeName': 'Anatoliy', 'Initials': 'A', 'LastName': 'Hontsa', 'Affiliation': 'Day Staing Department, Chernivtsi Regional Oncology Center, Chernivtsi, Ukraine. Electronic address: anatoliyhontsa@gmail.com.'}, {'ForeName': 'Jihye', 'Initials': 'J', 'LastName': 'Choi', 'Affiliation': 'Biometrics, Samsung Bioepis Co., Ltd., Suwon, Republic of Korea. Electronic address: jihye24.choi@samsung.com.'}, {'ForeName': 'Donghoon', 'Initials': 'D', 'LastName': 'Shin', 'Affiliation': 'Clinical Development, Samsung Bioepis Co., Ltd., Suwon, Republic of Korea. Electronic address: dh01.shin@samsung.com.'}]","Lung cancer (Amsterdam, Netherlands)",['10.1016/j.lungcan.2020.05.027'] 1453,32507151,Contract-relax technique compared to static stretching in treating migraine in women: A randomized pilot trial.,"INTRODUCTION Physical therapy is often used by patients with headache, including modalities such as muscle stretching exercises. OBJECTIVES To evaluate the feasibility of a pilot trial aimed at determining the efficacy of the proprioceptive neuromuscular facilitation (PNF) contract-relax technique compared to static stretching for treating migraineurs. METHODS This pilot trial allocated 30 migraineur women (23 ± 4 years) into PNF (n = 15) and static stretching groups (n = 15). The interventions were performed twice a week (16 sessions, 8 weeks). The feasibility outcomes included successful random allocation of 30 patients during a 12-month period, the proportion of eligible patients randomly assigned to each group, and the proportion of those who completed the 30-day follow-up. The outcomes of headache characteristics; medication intake; severity of migraine-related disability; neck disability; cervical mobility; pressure pain threshold; adverse effects and global perception of change were evaluated at baseline, after the end of treatment and after 30-day follow-up. RESULTS The recruitment rate was 4.66% participants/month. The proportion of eligible patients randomly assigned to each group and for those who completed the 30-day follow-up was 88.23% and 100%, respectively. Both groups improved in headache-related outcomes. The perception of change was important for 67% of the PNF group and 47% of the static stretching group. No differences were found between groups regarding the studied outcomes. CONCLUSION This is a feasible pilot trial. The PNF contract-relax technique was no more effective than static stretching for treating migraine, but both techniques improved the headache, the severity of migraine-related disability and the satisfaction after treatment.",2020,"The PNF contract-relax technique was no more effective than static stretching for treating migraine, but both techniques improved the headache, the severity of migraine-related disability and the satisfaction after treatment.","['30 migraineur women (23\u202f±\u202f4 years) into', 'women']","['Contract-relax technique', 'static stretching', 'PNF', 'proprioceptive neuromuscular facilitation (PNF) contract-relax technique']","['recruitment rate', 'headache characteristics; medication intake; severity of migraine-related disability; neck disability; cervical mobility; pressure pain threshold; adverse effects and global perception of change']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0454483', 'cui_str': 'Contract relax technique'}, {'cui': 'C1720875', 'cui_str': 'Static Stretching'}, {'cui': 'C0037415', 'cui_str': 'Social Facilitation'}]","[{'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",30.0,0.0423781,"The PNF contract-relax technique was no more effective than static stretching for treating migraine, but both techniques improved the headache, the severity of migraine-related disability and the satisfaction after treatment.","[{'ForeName': 'Débora', 'Initials': 'D', 'LastName': 'Wanderley', 'Affiliation': 'Physical Therapy Department, Universidade Federal de Pernambuco, Recife, PE, Brazil. Electronic address: deborawanderley84@hotmail.com.'}, {'ForeName': 'Marcelo Moraes', 'Initials': 'MM', 'LastName': 'Valença', 'Affiliation': 'Neuropsychiatry Department, Universidade Federal de Pernambuco, Recife, PE, Brazil. Electronic address: mmvalenca@yahoo.com.br.'}, {'ForeName': 'Joaquim José', 'Initials': 'JJ', 'LastName': 'de Souza Costa Neto', 'Affiliation': 'Clinic Medicine Department, Universidade de Pernambuco, Recife, PE, Brazil. Electronic address: joaqcosta@yahoo.com.br.'}, {'ForeName': 'José Vicente', 'Initials': 'JV', 'LastName': 'Martins', 'Affiliation': 'Physical Therapy Department, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil. Electronic address: josevicentepnf@terra.com.br.'}, {'ForeName': 'Maria Cristina Falcão', 'Initials': 'MCF', 'LastName': 'Raposo', 'Affiliation': 'Statistic Department, Universidade Federal de Pernambuco, Recife, PE, Brazil. Electronic address: cristina@de.ufpe.br.'}, {'ForeName': 'Daniella Araújo', 'Initials': 'DA', 'LastName': 'de Oliveira', 'Affiliation': 'Physical Therapy Department, Universidade Federal de Pernambuco, Recife, PE, Brazil. Electronic address: sabinodaniellaufpe@gmail.com.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2019.05.023'] 1454,32507152,Does whole body vibration training improve heart rate variability in kidney transplants patients? A randomized clinical trial.,"BACKGROUND Whole-body vibration (WBV) is an exercise modality that can promote improvements in heart rate variability (HRV) with lower patient overload, and consequently reduce cardiovascular risk in renal transplant patients. The aim of this study was to evaluate the effects of a 12-week WBV training program of two weekly sessions on HRV. METHODS A double-blind, randomized controlled clinical trial with 12 kidney transplant recipients of both genders who underwent WBV training (35 Hz) twice a week for 12 weeks on alternate days (WBV Group) and training with sub-therapeutic WBV (8 Hz) (Sham Group). Variables were evaluated in time and frequency domains of HRV through the 24-h Holter monitor, heart rate (HR), blood pressure (BP) and maximum oxygen consumption (VO 2max ) through an exercise stress test. RESULTS The delta between Sham and WBV groups showed an increase in the low frequency (Δ = 959.05 Hz; p = 0.01) and in the high frequency (Δ = 204.42 Hz; p = 0.04) of the HRV compared to Sham group. No changes in the ergometric variables were observed for any of the groups. CONCLUSION The present study evidenced an increase in the low and high frequency of HRV in individuals who participated in the Sham WBV group. There was no improvement in the autonomic balance in the groups, in the other HRV parameters, or the exercise test after the WBV training period.",2020,"There was no improvement in the autonomic balance in the groups, in the other HRV parameters, or the exercise test after the WBV training period.","['renal transplant patients', 'kidney transplants patients', 'individuals who participated in the Sham WBV group', '12 kidney transplant recipients of both genders who underwent']","['body vibration training', 'Whole-body vibration (WBV', 'WBV training (35\u202fHz) twice a week for 12 weeks on alternate days (WBV Group) and training with sub-therapeutic WBV (8\u202fHz) (Sham Group']","['time and frequency domains of HRV through the 24-h Holter monitor, heart rate (HR), blood pressure (BP) and maximum oxygen consumption (VO 2max ) through an exercise stress test', 'ergometric variables', 'low frequency', 'heart rate variability (HRV', 'heart rate variability', 'autonomic balance']","[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0079399', 'cui_str': 'Gender'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0556985', 'cui_str': 'Twice weekly'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0558287', 'cui_str': 'Alternate days'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0013801', 'cui_str': 'Electrocardiography, Holter'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0205213', 'cui_str': 'Low frequency'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]",,0.066364,"There was no improvement in the autonomic balance in the groups, in the other HRV parameters, or the exercise test after the WBV training period.","[{'ForeName': 'Tuíra O', 'Initials': 'TO', 'LastName': 'Maia', 'Affiliation': 'Post-Graduation Program Health Sciences, Universidade Federal de Pernambuco, Recife, PE, Brazil. Electronic address: tuiraomaia@gmail.com.'}, {'ForeName': 'Dulciane N', 'Initials': 'DN', 'LastName': 'Paiva', 'Affiliation': 'Post-Graduation Program in Health Promotion, Universidade de Santa Cruz do Sul, Santa Cruz do Sul, RS, Brazil. Electronic address: dulciane@unisc.br.'}, {'ForeName': 'Dário C', 'Initials': 'DC', 'LastName': 'Sobral Filho', 'Affiliation': 'Coronary Care Unit of Pernambuco Cardiac Emergency Hospital, Universidade de Pernambuco, Recife, PE, Brazil. Electronic address: dsobral@uol.com.br.'}, {'ForeName': 'Frederico C B', 'Initials': 'FCB', 'LastName': 'Cavalcanti', 'Affiliation': 'Real Portuguese Hospital of Beneficence of Pernambuco, Recife, PE, Brazil. Electronic address: frcastelo@uol.com.br.'}, {'ForeName': 'Lívia G', 'Initials': 'LG', 'LastName': 'Rocha', 'Affiliation': 'Post-Graduation Program in Physical Therapy, Universidade Federal de Pernambuco, Recife, Brazil. Electronic address: liviagomesrocha@hotmail.com.'}, {'ForeName': 'Camila C A', 'Initials': 'CCA', 'LastName': 'Andrade', 'Affiliation': 'Integrated Multiprofessional Residency Program in Health, Clinics Hospital of Universidade Federal de Pernambuco, Brazil. Electronic address: camilaalvesccaa@gmail.com.'}, {'ForeName': 'Aluísio R A', 'Initials': 'ARA', 'LastName': 'Macedo Júnior', 'Affiliation': 'Clinics Hospital of Universidade Federal de Pernambuco, Recife, PE, Brazil. Electronic address: alumacedojr@hotmail.com.'}, {'ForeName': 'Patrícia E M', 'Initials': 'PEM', 'LastName': 'Marinho', 'Affiliation': 'Post-Graduation Program Health Sciences, Universidade Federal de Pernambuco, Recife, PE, Brazil; Post-Graduation Program in Physical Therapy, Universidade Federal de Pernambuco, Recife, Brazil. Electronic address: patmarinho@yahoo.com.br.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2019.05.031'] 1455,32507154,The effect of 8 weeks proprioception training without visual input on single-limb standing balance time in deaf students: A randomized controlled trial.,"INTRODUCTION The aim of this study was to determine the effects of 8 weeks proprioception training without visual input on the proprioception of the knee and ankle and single standing balance time in deaf students. METHODS Twenty male deaf students participated in this study and were randomly assigned into control (n = 10) and experimental (n = 10) groups. Subjects' proprioception was measured using an electrogoniometer. In addition, balance performance was evaluated through single-limb standing performance test under four sensory conditions (condition 1: eyes open on one leg; condition 2: eyes closed on one leg; condition 3: eyes open on foam; condition 4: eyes closed on foam). RESULTS The findings showed that proprioception training without visual input induced meaningful, significant effects in knee and ankle proprioception (p ≤ 0.001), and single-limb standing time of deaf students at condition 1 (p ≤ 0.03) and 2 (p ≤ 0.001). However, training programs did not have any significant effects on single-limb standing time in conditions 3 (p ≤ 0.41) and 4(p ≤ 0.22). CONCLUSIONS Proprioception training without visual input improves proprioception of ankle, knee and single-limb standing balance time in deaf students.",2020,"The findings showed that proprioception training without visual input induced meaningful, significant effects in knee and ankle proprioception (p ≤ 0.001), and single-limb standing time of deaf students at condition 1 (p ≤ 0.03) and 2 (p ≤ 0.001).","['Twenty male deaf students', 'deaf students']","['Proprioception training without visual input', 'proprioception training without visual input', 'single-limb standing performance test under four sensory conditions (condition 1: eyes open on one leg; condition 2: eyes closed on one leg; condition 3: eyes open on foam; condition 4: eyes closed on foam']","['proprioception of ankle, knee and single-limb standing balance time', 'knee and ankle proprioception', 'single-limb standing time of deaf students', 'single-limb standing time']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0525064', 'cui_str': 'Hearing Impaired Persons'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0033499', 'cui_str': 'Proprioception'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0266574', 'cui_str': 'Ablepharon'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0991510', 'cui_str': 'Foam'}]","[{'cui': 'C0033499', 'cui_str': 'Proprioception'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0525064', 'cui_str': 'Hearing Impaired Persons'}, {'cui': 'C0038492', 'cui_str': 'Student'}]",20.0,0.0367565,"The findings showed that proprioception training without visual input induced meaningful, significant effects in knee and ankle proprioception (p ≤ 0.001), and single-limb standing time of deaf students at condition 1 (p ≤ 0.03) and 2 (p ≤ 0.001).","[{'ForeName': 'Hamed', 'Initials': 'H', 'LastName': 'Zarei', 'Affiliation': 'Master of Physical Education (corrective Exercise and Sport Injuries), Corrective Exercises and Sports Injury Department, Faculty of Physical Education & Sport Sciences, University of Guilan, Rasht, Postcode No. 4199613776, Iran. Electronic address: Zareei.h@yahoo.com.'}, {'ForeName': 'Ali Asghar', 'Initials': 'AA', 'LastName': 'Norasteh', 'Affiliation': 'Corrective Exercises and Sports Injury Department, Faculty of Physical Education & Sport Sciences, University of Guilan, Rasht, Postcode No. 4199613776, Iran. Electronic address: Asgharnorasteh@yahoo.com.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2019.09.002'] 1456,32507156,Effect of push-up variations performed with Swiss ball on muscle electromyographic amplitude in trained men: A cross-sectional study.,"PURPOSE To compare the use of three variations of push-ups: traditional (stable surface), performed with hands on the Swiss ball (Swiss ball-hands), and performed with feet on the Swiss ball (Swiss ball-feet) on surface electromyography activity (sEMG) in the agonist and stabilizer muscles. METHODS Ten trained men (26 ± 5 years, 76.8 ± 8.7 kg, 1.70 ± 0.06 m) performed one experimental protocol within-subjects in a randomized design. Each subject performed one set of 10 of each of the push-up variations (5-min rest between sets). The sEMG activity was assessed for pectoralis major, triceps brachii, anterior deltoids, and rectus abdominis. One-way repeated-measures ANOVA (Bonferroni) compared push-up variations within-muscles (p < 0.05). RESULTS Pectoralis major sEMG was similar between exercises. Anterior deltoid sEMG activity was greater for stable surface than for Swiss ball-hands (p = 0.001). Triceps brachii sEMG activity was greater during Swiss ball-hands than during stable surface (p = 0.001) and Swiss ball-feet (p = 0.043), and Swiss ball-feet was greater than stable surface (p = 0.001). Rectus abdominis sEMG activity was greater during Swiss ball-hands than during stable surface (p = 0.0001) and Swiss ball-feet (p = 0.036), while Swiss ball-feet was greater than stable surface (p = 0.046). CONCLUSIONS Push-ups performed with hands on the Swiss ball may be considered an advanced variation that should be used when the goal is to achieve greater challenge of the rectus abdominis and triceps brachii. Novice subjects or those with weakness/injury should perform push-ups with hands on a stable surface, and with progression, push-ups with feet on Swiss ball could be adopted before hands on Swiss ball.",2020,"Triceps brachii sEMG activity was greater during Swiss ball-hands than during stable surface (p = 0.001) and Swiss ball-feet (p = 0.043), and Swiss ball-feet was greater than stable surface (p = 0.001).","['trained men', 'Ten trained men (26\u202f±\u202f5 years, 76.8\u202f±\u202f8.7\u202fkg']","['push-up variations performed with Swiss ball', 'push-ups: traditional (stable surface), performed with hands on the Swiss ball (Swiss ball-hands']","['surface electromyography activity (sEMG', 'Rectus abdominis sEMG activity', 'muscle electromyographic amplitude', 'Triceps brachii sEMG activity', 'Anterior deltoid sEMG activity']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517880', 'cui_str': '8.7'}]","[{'cui': 'C0580841', 'cui_str': 'Does push'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C2721273', 'cui_str': 'Balance ball exerciser'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0018563', 'cui_str': 'Hand'}]","[{'cui': 'C0430815', 'cui_str': 'Surface EMG'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0224234', 'cui_str': 'Structure of deltoid muscle'}]",10.0,0.0148488,"Triceps brachii sEMG activity was greater during Swiss ball-hands than during stable surface (p = 0.001) and Swiss ball-feet (p = 0.043), and Swiss ball-feet was greater than stable surface (p = 0.001).","[{'ForeName': 'Ewertton de Souza', 'Initials': 'ES', 'LastName': 'Bezerra', 'Affiliation': 'Laboratório de Estudo do Desempenho Humano, Faculdade de Educação Física e Fisioterapia, Universidade Federal do Amazonas, Manaus, Brazil.'}, {'ForeName': 'Lucas Bet da Rosa', 'Initials': 'LBDR', 'LastName': 'Orssatto', 'Affiliation': 'School of Exercise and Nutrition Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia; Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia. Electronic address: l.betdarosaorssatto@qut.edu.au.'}, {'ForeName': 'Leonardo C', 'Initials': 'LC', 'LastName': 'Werlang', 'Affiliation': 'Laboratório de Biomecânica, Centro de Desportos, Universidade Federal de Santa Catarina, Florianópolis, Brazil.'}, {'ForeName': 'Arthur Miranda', 'Initials': 'AM', 'LastName': 'Generoso', 'Affiliation': 'Laboratório de Biomecânica, Centro de Desportos, Universidade Federal de Santa Catarina, Florianópolis, Brazil.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Moraes', 'Affiliation': 'Extreme Performance LTDA, Manaus, Brazil.'}, {'ForeName': 'Raphael L', 'Initials': 'RL', 'LastName': 'Sakugawa', 'Affiliation': 'Laboratório de Biomecânica, Centro de Desportos, Universidade Federal de Santa Catarina, Florianópolis, Brazil.'}]",Journal of bodywork and movement therapies,['10.1016/j.jbmt.2019.09.004'] 1457,32505485,Neuroplastic changes in resting-state functional connectivity after rTMS intervention for methamphetamine craving.,"Amphetamine-type stimulants are the second most commonly abused illicit drug worldwide, with no effective medical treatments currently available. Previous studies have demonstrated that high frequency repetitive transcranial magnetic stimulation (rTMS) over the left dorsolateral prefrontal cortex (DLPFC) reduced cue-induced craving in patients with methamphetamine dependence. However, the neuroplastic mechanism underlying rTMS intervention in methamphetamine users remains to be elucidated. Sixty participants (40 males) with severe methamphetamine use disorder according to DSM-5 were randomized to receive either intermittent theta burst protocols (iTBS) (short bursts of 50 Hz rTMS repeated at a rate in the theta range (5 Hz), 2-sec on, 8-sec off for 5 min; 900 pulses) or sham rTMS over the DLPFC over four weeks (20 daily sessions). Resting state functional connectivity magnetic resonance imaging was acquired before and after rTMS intervention. Participants received drug related cue exposure and rated their craving before and after stimulation. Seed-based functional connectivity analysis was performed to probe rTMS-induced neuroplastic reorganization of brain functional networks. Results showed that twenty daily rTMS sessions decreased craving, increased functional connectivity between left DLPFC and inferior parietal lobule, and decreased functional connectivity between insula and inferior parietal lobule, medial temporal lobe and precuneus. Moreover, the increase of functional connectivity between DLPFC and inferior parietal lobule correlated with craving reduction. This study suggests that neuroplastic changes of frontoparietal functional connectivity contributes to craving reduction, shedding light on the therapeutic effect of rTMS on methamphetamine use disorder. This article is part of the special issue on Stress, Addiction and Plasticity.",2020,"Results showed that twenty daily rTMS sessions decreased craving, increased functional connectivity between left DLPFC and inferior parietal lobule, and decreased functional connectivity between insula and inferior parietal lobule, medial temporal lobe and precuneus.","['patients with methamphetamine dependence', 'Sixty participants (40 males) with severe methamphetamine use disorder according to DSM-5']","['intermittent theta burst protocols (iTBS) (short bursts of 50\u202fHz rTMS repeated at a rate in the theta range (5\u202fHz), 2-sec on, 8-sec off for 5\u202fmin; 900 pulses) or sham rTMS', 'rTMS', 'rTMS intervention', 'repetitive transcranial magnetic stimulation (rTMS', 'Amphetamine-type stimulants']","['craving, increased functional connectivity between left DLPFC and inferior parietal lobule, and decreased functional connectivity between insula and inferior parietal lobule, medial temporal lobe and precuneus', 'functional connectivity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1533217', 'cui_str': 'Methamphetamine dependence'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0059387', 'cui_str': 'staphylococcal enterotoxin C'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4517900', 'cui_str': '900'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002658', 'cui_str': 'Amphetamine'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0002763', 'cui_str': 'Central stimulant'}]","[{'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0152304', 'cui_str': 'Inferior parietal lobule structure'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0021640', 'cui_str': 'Insular structure'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0039485', 'cui_str': 'Temporal lobe structure'}]",60.0,0.0225991,"Results showed that twenty daily rTMS sessions decreased craving, increased functional connectivity between left DLPFC and inferior parietal lobule, and decreased functional connectivity between insula and inferior parietal lobule, medial temporal lobe and precuneus.","[{'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Su', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Yilin', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, State Key Laboratory of Neuroscience, CAS Key Laboratory of Primate Neurobiology, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China.'}, {'ForeName': 'Dazhi', 'Initials': 'D', 'LastName': 'Yin', 'Affiliation': 'School of Psychology and Cognitive Science, East China Normal University, Shanghai, China.'}, {'ForeName': 'Tianzhen', 'Initials': 'T', 'LastName': 'Chen', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Xiaotong', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Zhong', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Haifeng', 'Initials': 'H', 'LastName': 'Jiang', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Jijun', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Jiang', 'Initials': 'J', 'LastName': 'Du', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Xiao', 'Affiliation': 'Shanghai Drug Rehabilitation Administration Bureau, Shanghai, China.'}, {'ForeName': 'Ding', 'Initials': 'D', 'LastName': 'Xu', 'Affiliation': 'Shanghai Drug Rehabilitation Administration Bureau, Shanghai, China.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Zeljic', 'Affiliation': 'Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, State Key Laboratory of Neuroscience, CAS Key Laboratory of Primate Neurobiology, Chinese Academy of Sciences, Shanghai, China.'}, {'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, State Key Laboratory of Neuroscience, CAS Key Laboratory of Primate Neurobiology, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, 200031, China. Electronic address: zheng.wang@ion.ac.cn.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Zhao', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, 200031, China; Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China; Institute of Psychological and Behavioral Science, Shanghai Jiao Tong University, Shanghai, China. Electronic address: drminzhao@smhc.org.cn.'}]",Neuropharmacology,['10.1016/j.neuropharm.2020.108177'] 1458,32505660,Frontal-midline theta frequency and probabilistic learning: A transcranial alternating current stimulation study.,"Probabilistic learning is a fundamental cognitive ability that extracts and represents regularities of our environment enabling predictive processing during perception and acquisition of perceptual, motor, cognitive, and social skills. Previous studies show competition between neural networks related to executive function/working memory vs. probabilistic learning. Theta synchronization has been associated with the former while desynchronization with the latter in correlational studies. In the present paper our aim was to test causal relationship between fronto-parietal midline theta synchronization and probabilistic learning with non-invasive transcranial alternating current (tACS) stimulation. We hypothesize that theta synchronization disrupts probabilistic learning performance by modulating the competitive relationship. Twenty-six young adults performed the Alternating Serial Reaction Time (ASRT) task to assess probabilistic learning in two sessions that took place one week apart. Stimulation was applied in a double-blind cross-over within-subject design with an active theta tACS and a sham stimulation in a counter-balanced order between participants. Sinusoidal current was administered with 1 mA peak-to-peak intensity throughout the task (approximately 20 min) for the active stimulation and 30 s for the sham. We did not find an effect of fronto-parietal midline theta tACS on probabilistic learning comparing performance during active and sham stimulation. To influence probabilistic learning, we suggest applying higher current intensity and stimulation parameters more precisely aligned to endogenous brain activity for future studies.",2020,We did not find an effect of fronto-parietal midline theta tACS on probabilistic learning comparing performance during active and sham stimulation.,['Twenty-six young adults'],"['fronto-parietal midline theta synchronization and probabilistic learning with non-invasive transcranial alternating current (tACS) stimulation', 'probabilistic learning', 'fronto-parietal midline theta tACS', 'Probabilistic learning', 'Alternating Serial Reaction Time (ASRT) task to assess probabilistic learning']",['probabilistic learning performance'],"[{'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0442030', 'cui_str': 'Parietal'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439580', 'cui_str': 'Synchronous'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C3852966', 'cui_str': 'Transcranial Alternating Current Stimulation'}, {'cui': 'C3489891', 'cui_str': 'TAC Alternate'}, {'cui': 'C0332270', 'cui_str': 'Alternating'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}]",26.0,0.103353,We did not find an effect of fronto-parietal midline theta tACS on probabilistic learning comparing performance during active and sham stimulation.,"[{'ForeName': 'Zsófia', 'Initials': 'Z', 'LastName': 'Zavecz', 'Affiliation': 'Doctoral School of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Brain, Memory and Language Research Group, Institute of Cognitive Neuroscience and Psychology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.'}, {'ForeName': 'Kata', 'Initials': 'K', 'LastName': 'Horváth', 'Affiliation': 'Doctoral School of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Brain, Memory and Language Research Group, Institute of Cognitive Neuroscience and Psychology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.'}, {'ForeName': 'Péter', 'Initials': 'P', 'LastName': 'Solymosi', 'Affiliation': 'Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary.'}, {'ForeName': 'Karolina', 'Initials': 'K', 'LastName': 'Janacsek', 'Affiliation': 'Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Brain, Memory and Language Research Group, Institute of Cognitive Neuroscience and Psychology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary; Centre of Thinking and Learning, Institute for Lifecourse Development, School of Human Sciences, University of Greenwich, London, United Kingdom.'}, {'ForeName': 'Dezso', 'Initials': 'D', 'LastName': 'Nemeth', 'Affiliation': 'Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Brain, Memory and Language Research Group, Institute of Cognitive Neuroscience and Psychology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary; Lyon Neuroscience Research Center (CRNL), INSERM, CNRS, Université Claude Bernard Lyon 1, Lyon, France. Electronic address: dezso.nemeth@univ-lyon1.fr.'}]",Behavioural brain research,['10.1016/j.bbr.2020.112733'] 1459,32512184,"Accelerated iTBS treatment applied to the left DLPFC in depressed patients results in a rapid volume increase in the left hippocampal dentate gyrus, not driven by brain perfusion.","BACKGROUND Accelerated intermittent Theta Burst Stimulation (aiTBS) has been shown to be an effective antidepressant treatment. Although neurobiological changes shortly after this intervention have been reported, whether aiTBS results in structural brain changes must still be determined. Furthermore, it possible that rapid volumetric changes are driven by factors other than neurotrophic processes. OBJECTIVES We examined whether possible grey matter volumetric (GMV) increases after aiTBS treatment could be driven by increased brain perfusion, measured by Arterial Spin Labeling (ASL). METHODS 46 treatment-resistant depressed patients were randomized to receive 20 sessions of active or sham iTBS applied to the left dorsolateral prefrontal cortex. All sessions were delivered over 4 days at 5 sessions per day (trial registration: http://clinicaltrials.gov/show/NCT01832805). Patients were scanned the day before starting stimulation and three days after aiTBS. RESULTS There was a significant cluster of increased left hippocampal GMV in the dentate gyrus related to HRSD changes after active aiTBS, but not after sham stimulation. These GMV increases became more pronounced when accounting for changes in cerebral perfusion. CONCLUSIONS Active, but not sham, aiTBS, resulted in acute volumetric changes in parts of the left dentate gyrus, suggesting a connection with adult neurogenesis. Furthermore, taking cerebral perfusion measurements into account impacts on detection of the GMV changes. Whether these hippocampal volumetric changes produced by active aiTBS are necessary for long-term clinical improvement remains to be determined.",2020,"There was a significant cluster of increased left hippocampal GMV in the dentate gyrus related to HRSD changes after active aiTBS, but not after sham stimulation.",['46 treatment-resistant depressed patients'],"['Accelerated intermittent Theta Burst Stimulation (aiTBS', '20 sessions of active or sham iTBS']","['Arterial Spin Labeling (ASL', 'left hippocampal GMV']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0445383', 'cui_str': 'Volumetric'}]",46.0,0.102893,"There was a significant cluster of increased left hippocampal GMV in the dentate gyrus related to HRSD changes after active aiTBS, but not after sham stimulation.","[{'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Baeken', 'Affiliation': 'Ghent University, Department of Psychiatry and Medical Psychology, Ghent Experimental Psychiatry (GHEP) Lab, Ghent, Belgium; Vrije Universiteit Brussel (VUB), Department of Psychiatry, Universitair Ziekenhuis Brussel (UZBrussel), Laarbeeklaan 101, 1090, Brussels, Belgium; Eindhoven University of Technology, Department of Electrical Engineering, Eindhoven, the Netherlands.'}, {'ForeName': 'GuoRong', 'Initials': 'G', 'LastName': 'Wu', 'Affiliation': 'Key Laboratory of Cognition and Personality, Faculty of Psychology, Southwest University, Chongqing, China. Electronic address: guorongwu@swu.edu.cn.'}, {'ForeName': 'Harold A', 'Initials': 'HA', 'LastName': 'Sackeim', 'Affiliation': 'Columbia University, Department of Psychiatry, New York, NY, USA; Columbia University, Department of Radiology, New York, NY, USA.'}]",Brain stimulation,['10.1016/j.brs.2020.05.015'] 1460,32512234,Oxygen supplementation increases the total work and muscle damage markers but reduces the inflammatory response in COPD patients.,"INTRODUCTION Oxygen supplementation (O 2 -Suppl) is recommended for pulmonary rehabilitation with higher exercise intensities. However, high-intensity exercise tends toward muscle damage and a greater inflammatory response. We aimed to investigate the effect of O 2 -Suppl during exercise test (EET) on CRP level and muscle damage (CPK, LDH, lactate) in non-hypoxemic COPD patients. METHODS Eleven non-depleted patients with COPD (FEV 1 65.5 ± 4.3 %) performed two EET (room-air or O 2 -Suppl-100 %), through a blind, randomized, and placebo-controlled crossover design. CPK, LDH and CRP were measured before, immediately after and 24 h after EET. RESULTS Exercise time was higher with O 2 -Suppl (49.9 ± 37.3 %; p = 0.001) and increases in CPK and LDH were observed compared to basal values in the O 2 -Suppl (28.4UI/L and 28.3 UI/L). The O 2 -Suppl protocol resulted in a lower increase in CRP (92.1 ± 112.4 % vs. 400.1 ± 384.9 %; p = 0.003). CONCLUSIONS O 2 -Suppl increases exercise-tolerance, resulting in increased muscle injury markers in COPD. However, oxygen supplementation attenuates the inflammatory response, even upon increased physical exercise.",2020,"RESULTS Exercise time was higher with O 2 -Suppl (49.9 ± 37.3%; p = 0.001) and increases in CPK and LDH were observed compared to basal values in the O 2 -Suppl (28.4UI/L and 28.3 UI/L).","['Eleven non-depleted patients with COPD (FEV 1 65.5\u2009±\u20094.3%) performed two EET (room-air or O 2 -Suppl-100', 'COPD patients', 'non-hypoxemic COPD patients']","['oxygen supplementation', 'Oxygen supplementation (O 2 -Suppl', 'O 2 -Suppl during exercise test (EET', 'Oxygen supplementation', 'placebo']","['Exercise time', 'CRP', 'CPK and LDH', 'CPK, LDH and CRP', 'total work and muscle damage markers', 'physical exercise', 'exercise-tolerance', 'CRP level and muscle damage (CPK, LDH, lactate', 'inflammatory response']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C4517759', 'cui_str': '4.3'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C0919655', 'cui_str': 'Oxygen supplementation'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0587107', 'cui_str': 'During exercise'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439587', 'cui_str': 'Exercise time'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0022917', 'cui_str': 'Lactate dehydrogenase'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage NOS'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}]",11.0,0.185322,"RESULTS Exercise time was higher with O 2 -Suppl (49.9 ± 37.3%; p = 0.001) and increases in CPK and LDH were observed compared to basal values in the O 2 -Suppl (28.4UI/L and 28.3 UI/L).","[{'ForeName': 'Daniela Rodrigues', 'Initials': 'DR', 'LastName': 'Andrade', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Kelly Critine', 'Initials': 'KC', 'LastName': 'Pinto', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Julia Sampel', 'Initials': 'JS', 'LastName': 'de Castro', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Daniela Kuguimoto', 'Initials': 'DK', 'LastName': 'Andaku', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Viviani Aparecida', 'Initials': 'VA', 'LastName': 'Lara', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Fabio Augusto', 'Initials': 'FA', 'LastName': 'de Luca', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Gun', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Felipe Augusto Rodrigues', 'Initials': 'FAR', 'LastName': 'Mendes', 'Affiliation': 'Department of Physiotherapy, Ibirapuera University (UNIB), São Paulo, Brazil.'}, {'ForeName': 'Mayron F', 'Initials': 'MF', 'LastName': 'Oliveira', 'Affiliation': 'Pulmonary Function and Clinical Exercise Physiology Unit (SEFICE), Respiratory Division, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil; VO2Care Research Group, Research Physiotherapy Coordinator of Vila Nova Star Hospital, São Paulo, SP, Brazil.'}, {'ForeName': 'Wladimir Musetti', 'Initials': 'WM', 'LastName': 'Medeiros', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil; Department of Physiotherapy, Ibirapuera University (UNIB), São Paulo, Brazil; Pulmonary Function and Clinical Exercise Physiology Unit (SEFICE), Respiratory Division, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil; HEART - Institute of Cardiology, Department of Education and Research, São Paulo, Brazil. Electronic address: wmusettimedeiros@hotmail.com.'}]",Respiratory physiology & neurobiology,['10.1016/j.resp.2020.103475'] 1461,32507551,Prevalence of NAFLD in Guatemala following exposure to a protein-energy nutrition intervention in early life.,"INTRODUCTION AND OBJECTIVES The global prevalence of non-alcoholic fatty liver disease (NAFLD) is approximately 25%, with Hispanic populations at greatest risk. We describe the prevalence of NAFLD in a cohort of Guatemalan adults and examine whether exposure to a protein-energy supplement from conception to two years is associated with lower prevalence of NAFLD. MATERIALS AND METHODS From 1969 to 1977, four villages in Guatemala were cluster-randomized to receive a protein-energy supplement (Atole) or a no-protein, low-energy beverage (Fresco). We conducted a follow-up of participants from 2015 to 2017. We assessed blood samples (n=1093; 61.1% women; aged 37-53 years) for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and estimated NAFLD prevalence using the liver fat score. We used generalized linear and logistic models to estimate the difference-in-difference effect of Atole from conception to two years on NAFLD. RESULTS Median ALT and AST were 19.7U/L (interquartile range, IQR: 14.1, 27.4) and 26.0U/L (IQR: 21.4, 32.8), respectively. The median NAFLD liver fat score was 0.2 (IQR: -1.2, 1.6) in women and -1.2 (IQR: -2.2, 0.5) in men (p<0.0001). The prevalence of NAFLD was 67.4% among women and 39.5% among men (p<0.0001). The association between Atole exposure from conception to two years and NAFLD was not significant (OR: 0.90, 95% CI: 0.50-1.63). CONCLUSIONS NAFLD prevalence among Guatemalan adults exceeds the global average. Protein-energy supplementation in early life was not associated with later NAFLD. There is a need for further studies on the causes and onset of NAFLD throughout the life course.",2020,"The median NAFLD liver fat score was 0.2 (IQR: -1.2, 1.6) in women and -1.2 (IQR: -2.2, 0.5) in men (p<0.0001).","['participants from 2015 to 2017', 'From 1969 to 1977, four villages in Guatemala', 'n=1093; 61.1% women; aged 37-53 years) for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and estimated NAFLD prevalence using the liver fat score']","['Protein-energy supplementation', 'protein-energy nutrition intervention', 'protein-energy supplement (Atole) or a no-protein, low-energy beverage (Fresco']","['blood samples', 'prevalence of NAFLD', 'median NAFLD liver fat score']","[{'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0018367', 'cui_str': 'Guatemala'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0556077', 'cui_str': 'Energy supplementation'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}]","[{'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0835527,"The median NAFLD liver fat score was 0.2 (IQR: -1.2, 1.6) in women and -1.2 (IQR: -2.2, 0.5) in men (p<0.0001).","[{'ForeName': 'Ahlia', 'Initials': 'A', 'LastName': 'Sekkarie', 'Affiliation': 'Nutrition and Health Sciences Program, Laney Graduate School, Emory University, Atlanta, GA, United States. Electronic address: asekkar@emory.edu.'}, {'ForeName': 'Siran', 'Initials': 'S', 'LastName': 'He', 'Affiliation': 'Nutrition and Health Sciences Program, Laney Graduate School, Emory University, Atlanta, GA, United States.'}, {'ForeName': 'Jean A', 'Initials': 'JA', 'LastName': 'Welsh', 'Affiliation': 'Department of Pediatrics, Emory School of Medicine, Atlanta, GA, United States.'}, {'ForeName': 'Usha', 'Initials': 'U', 'LastName': 'Ramakrishnan', 'Affiliation': 'Nutrition and Health Sciences Program, Laney Graduate School, Emory University, Atlanta, GA, United States; Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, United States.'}, {'ForeName': 'Aryeh D', 'Initials': 'AD', 'LastName': 'Stein', 'Affiliation': 'Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, United States.'}, {'ForeName': 'Miriam B', 'Initials': 'MB', 'LastName': 'Vos', 'Affiliation': 'Department of Pediatrics, Emory School of Medicine, Atlanta, GA, United States.'}]",Annals of hepatology,['10.1016/j.aohep.2020.04.004'] 1462,32508323,Volume Analysis of Brain Cognitive Areas in Alzheimer's Disease: Interim 3-Year Results from the ASCOMALVA Trial.,"BACKGROUND Cerebral atrophy is a common feature of several neurodegenerative disorders, including Alzheimer's disease (AD). In AD, brain atrophy is associated with loss of gyri and sulci in the temporal and parietal lobes, and in parts of the frontal cortex and cingulate gyrus. OBJECTIVE The ASCOMALVA trial has assessed, in addition to neuropsychological analysis, whether the addition of the cholinergic precursor choline alphoscerate to treatment with donepezil has an effect on brain volume loss in patients affected by AD associated with cerebrovascular injury. METHODS 56 participants to the randomized, placebo-controlled, double-blind ASCOMALVA trial were assigned to donepezil + placebo (D + P) or donepezil + choline alphoscerate (D + CA) treatments and underwent brain magnetic resonance imaging and neuropsychological tests every year for 4 years. An interim analysis of 3-year MRI data was performed by voxel morphometry techniques. RESULTS The D + P group (n = 27) developed atrophy of the gray and white matter with concomitant increase in ventricular space volume. In the D + CA group (n = 29) the gray matter atrophy was less pronounced compared to the D + P group in frontal and temporal lobes, hippocampus, and amygdala. These morphological data are consistent with the results of the neuropsychological tests. CONCLUSION Our findings indicate that the addition of choline alphoscerate to standard treatment with the cholinesterase inhibitor donepezil counters to some extent the loss in volume occurring in some brain areas of AD patients. The observation of parallel less pronounced decrease in cognitive and functional tests in patients with the same treatment suggests that the morphological changes observed may have functional relevance.",2020,"In the D + CA group (n = 29) the gray matter atrophy was less pronounced compared to the D + P group in frontal and temporal lobes, hippocampus, and amygdala.","['patients affected by AD associated with cerebrovascular injury', '56 participants to the randomized', ""Alzheimer's Disease""]","['donepezil\u200a+\u200aplacebo (D\u200a+\u200aP) or donepezil\u200a+\u200acholine alphoscerate (D\u200a+\u200aCA) treatments and underwent brain magnetic resonance imaging and neuropsychological tests', 'donepezil', 'placebo']","['ventricular space volume', 'cognitive and functional tests', 'brain volume loss', 'gray matter atrophy']","[{'cui': 'C0522476', 'cui_str': 'Patient affected'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}]","[{'cui': 'C0527316', 'cui_str': 'donepezil'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0017889', 'cui_str': 'choline alfoscerate'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}]","[{'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0026846', 'cui_str': 'Muscle atrophy'}]",56.0,0.228653,"In the D + CA group (n = 29) the gray matter atrophy was less pronounced compared to the D + P group in frontal and temporal lobes, hippocampus, and amygdala.","[{'ForeName': 'Enea', 'Initials': 'E', 'LastName': 'Traini', 'Affiliation': 'Clinical Research, Telemedicine and Telepharmacy Centre, University of Camerino, Camerino, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Carotenuto', 'Affiliation': 'Clinical Research, Telemedicine and Telepharmacy Centre, University of Camerino, Camerino, Italy.'}, {'ForeName': 'Angiola Maria', 'Initials': 'AM', 'LastName': 'Fasanaro', 'Affiliation': 'Neurology Unit, National Hospital ""A. Cardarelli"", Naples, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Amenta', 'Affiliation': 'Clinical Research, Telemedicine and Telepharmacy Centre, University of Camerino, Camerino, Italy.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-190623'] 1463,32508327,"Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.","BACKGROUND Open-HART was an open-label extension of HART, a randomized, double-blind, placebo-controlled study of pridopidine in Huntington disease (HD). Previously, we reported safety and exploratory efficacy data after 36 months of treatment with pridopidine 45 mg twice daily. In the interim, emerging data suggests pridopidine may have neuroprotective effects mediated by sigma-1 receptor agonism. OBJECTIVE To report additional safety and exploratory efficacy data for continued open-label use of 45 mg BID pridopidine at 48 and 60 months. METHODS Patients in Open-HART were followed up to or greater than 60 months. Adverse events, concomitant medications, vital signs, laboratory values, and ECG data were monitored. Rates of decline in total functional capacity (TFC) and total motor score (TMS) over 60 months were evaluated in an exploratory analysis and compared between Open-HART and placebo recipients from the 2CARE trial. To account for missing data, sensitivity analyses were performed. RESULTS Of the original Open-HART baseline cohort (N = 118), 40 remained in the study at 48 months and 33 at 60 months. Pridopidine remained safe and well tolerated over the 60-month interval. TFC and TMS at 48 and 60 months remained stable, showing less decline at these timepoints compared to historical placebo controls from the 2CARE trial. TFC differences at 48 and 60 months observed remained nominally significant after sensitivity analysis. CONCLUSION The 45 mg BID pridopidine dosage remained safe and tolerable over 60 months. Exploratory analyses show TFC and TMS stability at 48 and 60 months, in contrast to placebo historical controls from the 2CARE trial. Results are consistent with data reported from the recent Phase 2 PRIDE-HD trial showing less functional decline in the pridopidine 45 mg BID treated group at 52 weeks.",2020,"TFC and TMS at 48 and 60 months remained stable, showing less decline at these timepoints compared to historical placebo controls from the 2CARE trial.","['Huntington disease (HD', 'N\u200a=\u200a118', 'Patients in Open-HART were followed up to or greater than 60 months', 'in Huntington Disease']","['TFC and TMS', '45\u200amg BID pridopidine', 'pridopidine', 'Pridopidine', 'placebo']","['TFC and TMS stability', 'total functional capacity (TFC) and total motor score (TMS', 'safe and well tolerated', 'TFC differences', 'Adverse events, concomitant medications, vital signs, laboratory values, and ECG data']","[{'cui': 'C0020179', 'cui_str': ""Huntington's chorea""}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0048106', 'cui_str': ""4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate""}, {'cui': 'C1741584', 'cui_str': 'pridopidine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}]",,0.101185,"TFC and TMS at 48 and 60 months remained stable, showing less decline at these timepoints compared to historical placebo controls from the 2CARE trial.","[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'McGarry', 'Affiliation': 'Cooper University Health Care at Rowan University, Camden, NJ, USA.'}, {'ForeName': 'Peggy', 'Initials': 'P', 'LastName': 'Auinger', 'Affiliation': 'University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Karl', 'Initials': 'K', 'LastName': 'Kieburtz', 'Affiliation': 'University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Geva', 'Affiliation': 'Prilenia Therapeutics, Herzliya, Israel.'}, {'ForeName': 'Munish', 'Initials': 'M', 'LastName': 'Mehra', 'Affiliation': 'Tigermed Data Solutions, Bengaluru, Karnataka, India.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Abler', 'Affiliation': 'Teva Pharmaceutical Industries, Kansas City, MO, USA.'}, {'ForeName': 'Igor D', 'Initials': 'ID', 'LastName': 'Grachev', 'Affiliation': 'Teva Pharmaceutical Industries, Kansas City, MO, USA.'}, {'ForeName': 'Mark Forrest', 'Initials': 'MF', 'LastName': 'Gordon', 'Affiliation': 'Teva Pharmaceutical Industries, Kansas City, MO, USA.'}, {'ForeName': 'Juha-Matti', 'Initials': 'JM', 'LastName': 'Savola', 'Affiliation': 'Teva Pharmaceuticals International GmbH, Basel, Switzerland.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Gandhi', 'Affiliation': 'Teva Pharmaceutical Industries, Kansas City, MO, USA.'}, {'ForeName': 'Spyridon', 'Initials': 'S', 'LastName': 'Papapetropoulos', 'Affiliation': 'Teva Pharmaceutical Industries, Frazer, PA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hayden', 'Affiliation': 'Prilenia Therapeutics, Herzliya, Israel.'}]",Journal of Huntington's disease,['10.3233/JHD-190393'] 1464,32406064,Short-term skin reactions following use of N95 respirators and medical masks.,"BACKGROUND In the context of the COVID-19 pandemic, cases of adverse skin reactions related to the wearing of masks have been observed. OBJECTIVES To analyze the short-term effects of N95 respirators and medical masks, respectively, on skin physiological properties and to report adverse skin reactions caused by the protective equipment. METHODS This study used a randomized crossover design with repeated measurements. Twenty healthy Chinese volunteers were recruited. Skin parameters were measured on areas covered by the respective masks and on uncovered skin 2 and 4 hours after donning, and 0.5 and 1 hour after removing the masks, including skin hydration, transepidermal water loss (TEWL), erythema, pH, and sebum secretion. Adverse reactions were clinically assessed, and perceived discomfort and non-compliance measured. RESULTS Skin hydration, TEWL, and pH increased significantly with wearing the protective equipment. Erythema values increased from baseline. Sebum secretion increased both on the covered and uncovered skin with equipment-wearing. There was no significant difference in physiological values between the two types of equipment. More adverse reactions were reported following a N95 mask use than the use of a medical mask, with a higher score of discomfort and non-compliance. CONCLUSIONS This study demonstrates that skin biophysical characters change as a result of wearing a mask or respirator. N95 respirators were associated with more skin reactions than medical masks.",2020,"More adverse reactions were reported following a N95 mask use than the use of a medical mask, with a higher score of discomfort and",['Twenty healthy Chinese volunteers'],['N95 respirators and medical masks'],"['skin reactions', 'Sebum secretion', 'Skin hydration, TEWL, and pH increased significantly with wearing the protective equipment', 'perceived discomfort and non-compliance measured', 'physiological values', 'Erythema values', 'adverse reactions', 'Skin parameters', 'Adverse reactions', 'skin hydration, transepidermal water loss (TEWL), erythema, pH, and sebum secretion']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0429406', 'cui_str': 'Pattern ERG N95'}, {'cui': 'C0035208', 'cui_str': 'Air-purifying respirator'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0024861', 'cui_str': 'Mask'}]","[{'cui': 'C0221743', 'cui_str': 'Skin reaction'}, {'cui': 'C0232436', 'cui_str': 'Sebaceous gland activity'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C1321013', 'cui_str': 'Hydration status'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0221106', 'cui_str': 'Alkalemia'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0457432', 'cui_str': 'Non-compliant'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0031845', 'cui_str': 'Physiological process'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",20.0,0.0210399,"More adverse reactions were reported following a N95 mask use than the use of a medical mask, with a higher score of discomfort and","[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Hua', 'Affiliation': 'Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zuo', 'Affiliation': 'Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Ruoyu', 'Initials': 'R', 'LastName': 'Wan', 'Affiliation': 'Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Lidan', 'Initials': 'L', 'LastName': 'Xiong', 'Affiliation': 'Cosmetic Safety and Efficacy Evaluation Center of West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': 'Cosmetic Safety and Efficacy Evaluation Center of West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Zou', 'Affiliation': 'Cosmetic Safety and Efficacy Evaluation Center of West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Xiaohong', 'Initials': 'X', 'LastName': 'Shu', 'Affiliation': 'Cosmetic Safety and Efficacy Evaluation Center of West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, China.'}]",Contact dermatitis,['10.1111/cod.13601'] 1465,32686440,[Effect of a Mediterranean-pattern diet on the metabolic response secondary to weight loss; role of the single nucleotide polymorphism (rs16147) of neuropeptide Y].,"BACKGROUND AND AIMS intervention studies that evaluate the effect of rs16147 on metabolic response and weight change after dietary intervention are scarce. We propose to evaluate the role of the rs16147 genetic variant in the metabolic effects produced by a hypocaloric Mediterranean-pattern diet with high content of omega-9. MATERIAL AND METHODS a sample of 363 obese subjects was recruited. At the baseline visit the patients were randomly assigned to one of two hypocaloric diets for 12 weeks (diet M, Mediterranean pattern; diet C, standard hypocaloric). All patients, at baseline and at 12 weeks, had biochemical and anthropometric variables measured, and genotyping performed for the rs16147 variant. RESULTS in all subjects, and with both diets, the parameters of adiposity, blood pressure, and circulating leptin improved. In obese subjects with allele (A) insulin levels (GG vs. GA + AA) (-0.9 ± 1.1 IU/L vs. -4.4 ± 1.0 IU/L; p = 0.01) and HOMA-IR (-0.3 ± 0.1 units vs. -1.2 ± 0.3 units; p = 0.02) decreased significantly with diet M. Subjects carrying the minor allele showed a significant decrease in basal insulin levels (GG vs. GA + AA) (0.7 ± 0.3 IU/L vs. -2.2 ± 0.9 IU/L: p = 0.02) and HOMA-IR (-0.3 ± 0.2 units vs. -0.7 ± 0.1 units: p = 0.01) after diet C. This decrease in circulating insulin and HOMA-IR levels in patients with allele A was significantly higher with diet M than with diet C. CONCLUSIONS the A allele of the rs16147 variant produces a better metabolic response in terms of insulin resistance and basal insulin secondary to weight loss with two different hypocaloric diets in obese subjects, with improvement being higher with the Mediterranean diet.",2020,"This decrease in circulating insulin and HOMA-IR levels in patients with allele A was significantly higher with diet M than with diet C. CONCLUSIONS the A allele of the rs16147 variant produces a better metabolic response in terms of insulin resistance and basal insulin secondary to weight loss with two different hypocaloric diets in obese subjects, with improvement being higher with the Mediterranean diet.","['obese subjects', 'a sample of 363 obese subjects was recruited']","['Mediterranean-pattern diet', 'hypocaloric Mediterranean-pattern diet with high content of omega-9', 'hypocaloric diets for 12 weeks (diet M, Mediterranean pattern; diet C, standard hypocaloric']","['circulating insulin and HOMA-IR levels', 'adiposity, blood pressure, and circulating leptin improved', 'basal insulin levels', 'metabolic response and weight change']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C1719844', 'cui_str': 'Omega'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}]",363.0,0.0271651,"This decrease in circulating insulin and HOMA-IR levels in patients with allele A was significantly higher with diet M than with diet C. CONCLUSIONS the A allele of the rs16147 variant produces a better metabolic response in terms of insulin resistance and basal insulin secondary to weight loss with two different hypocaloric diets in obese subjects, with improvement being higher with the Mediterranean diet.","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Primo Martín', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Olatz', 'Initials': 'O', 'LastName': 'Izaola Jáuregui', 'Affiliation': 'Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Juan José', 'Initials': 'JJ', 'LastName': 'López Gómez', 'Affiliation': 'Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Gómez Hoyos', 'Affiliation': 'Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Ortolá Buigues', 'Affiliation': 'Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Delgado', 'Affiliation': 'Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Gonzalo', 'Initials': 'G', 'LastName': 'Díaz', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'de Luis Román', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}]",Nutricion hospitalaria,['10.20960/nh.02941'] 1466,32686444,ACYL-CoA synthetase long-chain 5 polymorphism is associated with weight loss and metabolic changes in response to a partial meal-replacement hypocaloric diet.,"AIMS to analyze the effects of the rs2419621 genetic variant of the ACSL5 gene on weight change and metabolic parameters after a partial meal-replacement hypocaloric diet. METHODS this was a non-randomized, single-treatment study with a formula-diet in 44 obese subjects with body mass index (BMI) greater than 35 kg/m2. Patients received nutritional education and a modified diet with two intakes of a normocaloric hyperproteic formula during 3 months. Anthropometric parameters and biochemical profile were measured at baseline and after 3 months. The rs2419621 variant of the ACSL5 gene was assessed using real-time polymerase chain reaction. RESULTS T-allele carriers showed greater improvement in body weight (CC vs. CT + TT; -7.4 ± 2.1 kg vs. -9.3 ± 1.8 kg; p = 0.01), body mass index (-3.1 ± 0.4 kg/m2 vs. -3.4 ± 0.5 kg/m2; p = 0.02), fat mass (-5.2 ± 1.4 kg vs. -6.4 ± 1.2 kg; p = 0.01) and waist circumference (-6.1 ± 1.1 cm vs. -8.6 ± 0.8 cm; p = 0.02) than non-T-allele carriers. Only subjects with the T allele showed significant improvement in triglyceride levels (-4.6 ± 2.4 md/dL vs. -14.4 ± 2.3 mg/dL; p = 0.01). Finally, improvements in insulin (-2.0 ± 0.3 mU/L vs. -4.5 ± 0.5 mU/L; p = 0.01) and HOMA-IR (-0.4 ± 0.2 units vs. -1.3 ± 0.3 units; p = 0.02) were higher in T-allele carriers than in non-T-allele carriers. CONCLUSIONS our data suggest that the genetic variant (rs2419621) of the ACSL5 gene is associated with diet response after a partial-meal replacement intervention, with greater improvements in adiposity and biochemical parameters in subjects with the T allele.",2020,"RESULTS T-allele carriers showed greater improvement in body weight (CC vs. CT + TT; -7.4 ± 2.1 kg vs. -9.3 ± 1.8 kg; p = 0.01), body mass index (-3.1 ± 0.4 kg/m2 vs. -3.4 ± 0.5 kg/m2; p = 0.02), fat mass (-5.2 ± 1.4 kg vs. -6.4 ± 1.2 kg; p = 0.01) and waist circumference (-6.1 ± 1.1 cm vs. -8.6 ± 0.8 cm; p = 0.02) than non-T-allele carriers.","['44 obese subjects with body mass index (BMI) greater than 35 kg/m2', 'subjects with the T allele']","['formula-diet', 'nutritional education and a modified diet with two intakes of a normocaloric hyperproteic formula']","['waist circumference', 'Anthropometric parameters and biochemical profile', 'body mass index', 'body weight', 'triglyceride levels', 'HOMA-IR', 'adiposity and biochemical parameters', 'weight change and metabolic parameters']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0002085', 'cui_str': 'Genetic alleles'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0204934', 'cui_str': 'Nutrition education'}, {'cui': 'C0452264', 'cui_str': 'Therapeutic diet'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}]","[{'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0202236', 'cui_str': 'Triglycerides measurement'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}]",44.0,0.114747,"RESULTS T-allele carriers showed greater improvement in body weight (CC vs. CT + TT; -7.4 ± 2.1 kg vs. -9.3 ± 1.8 kg; p = 0.01), body mass index (-3.1 ± 0.4 kg/m2 vs. -3.4 ± 0.5 kg/m2; p = 0.02), fat mass (-5.2 ± 1.4 kg vs. -6.4 ± 1.2 kg; p = 0.01) and waist circumference (-6.1 ± 1.1 cm vs. -8.6 ± 0.8 cm; p = 0.02) than non-T-allele carriers.","[{'ForeName': 'Olatz', 'Initials': 'O', 'LastName': 'Izaola Jáuregui', 'Affiliation': 'Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Juan José', 'Initials': 'JJ', 'LastName': 'López Gómez', 'Affiliation': 'Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Primo Martín', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Torres Torres', 'Affiliation': 'Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Gómez Hoyos', 'Affiliation': 'Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Ortolá Buigues', 'Affiliation': 'Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Delgado', 'Affiliation': 'Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'de Luis Román', 'Affiliation': 'Centro de Investigación de Endocrinología y Nutrición. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Valladolid.'}]",Nutricion hospitalaria,['10.20960/nh.03019'] 1467,32686487,A neuropsychologically-based intervention with increased follow-up support for employed women with multiple sclerosis: a pilot randomized controlled trial.,"OBJECTIVE To evaluate feasibility and acceptability of a neuropsychologically-based vocational intervention with increased follow-up support for women with multiple sclerosis. DESIGN Single-blinded parallel-group randomized controlled trial with 12-month follow-up. SETTING Tertiary-care multiple sclerosis center. PARTICIPANTS Forty-nine employed women with multiple sclerosis meeting criteria on measures of cognitive dysfunction (Symbol Digit Modalities Test), fatigue (Fatigue Severity Scale), and/or depression (Beck Depression Inventory/Patient Health Questionnaire). INTERVENTIONS Participants received either neuropsychological testing and phone feedback regarding findings and tailored recommendations (standard-care treatment), or testing, in-person feedback, and two calls from a care-coordinator (experimental treatment). MEASURES Feasibility measures included enrollment and attrition rates, and compliance to recommendations at 12-months between groups. Acceptability was evaluated by participants' report of benefit from interventions. Secondary analyses included evaluation of symptom changes (cognition, fatigue, depression) from baseline to 12-months. RESULTS Of 49 women meeting screening measure thresholds, 44 were randomized to treatment groups (attrition: standard-care = 8, experimental = 6), and 30 completed the study (standard-care = 14, experimental = 16). Recommendation adherence rates did not significantly differ between standard-care and experimental groups (31% vs 49%). However, 16/16 experimental participants at least partially completed given recommendations as compared to 8/14 in the standard-care group. Participants across groups (97%) reported benefit from participation. No significant differences in symptom outcomes between groups at 12-months. CONCLUSION In-person feedback and care-coordinator calls were feasible and acceptable additions to a neuropsychological intervention and may serve to increase recommendation adherence. Given high drop-out rate, particularly prior to testing, future research may explore avenues to improve completion rates and maximize benefits of such interventions.",2020,Recommendation adherence rates did not significantly differ between standard-care and experimental groups (31% vs 49%).,"['Forty-nine employed women with multiple sclerosis meeting criteria on measures of', '16/16 experimental participants at least partially completed given recommendations as compared to 8/14 in the standard-care group', 'Tertiary-care multiple sclerosis center', 'women with multiple sclerosis']","['neuropsychologically-based vocational intervention', 'neuropsychologically-based intervention with increased follow-up support', 'neuropsychological testing and phone feedback regarding findings and tailored recommendations (standard-care treatment), or testing, in-person feedback, and two calls from a care-coordinator (experimental treatment']","['Acceptability', 'Recommendation adherence rates', 'enrollment and attrition rates, and compliance to recommendations', 'symptom outcomes', 'cognitive dysfunction (Symbol Digit Modalities Test), fatigue (Fatigue Severity Scale), and/or depression (Beck Depression Inventory/Patient Health Questionnaire', 'evaluation of symptom changes (cognition, fatigue, depression']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0450328', 'cui_str': '16/16'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C4708569', 'cui_str': 'Care coordinator'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0451522', 'cui_str': 'Symbol digit modalities test'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",49.0,0.10343,Recommendation adherence rates did not significantly differ between standard-care and experimental groups (31% vs 49%).,"[{'ForeName': 'Marnina B', 'Initials': 'MB', 'LastName': 'Stimmel', 'Affiliation': 'Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA.'}, {'ForeName': 'Jenna N', 'Initials': 'JN', 'LastName': 'Cohen', 'Affiliation': 'Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA.'}, {'ForeName': 'Shonna J', 'Initials': 'SJ', 'LastName': 'Schneider', 'Affiliation': 'Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA.'}, {'ForeName': 'Jeffrey G', 'Initials': 'JG', 'LastName': 'Portnoy', 'Affiliation': 'Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA.'}, {'ForeName': 'Elizabeth K', 'Initials': 'EK', 'LastName': 'Seng', 'Affiliation': 'Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA.'}, {'ForeName': 'Frederick W', 'Initials': 'FW', 'LastName': 'Foley', 'Affiliation': 'Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA.'}]",Clinical rehabilitation,['10.1177/0269215520940353'] 1468,32515134,"Effectiveness of Natural Frequency Technology ® on cognition, sleep, and mood of adults with high perceived stress: A randomized, double-blind, placebo-controlled crossover study.","INTRODUCTION NexQuest Natural Frequency Technology ® (NFT ® ), intended to enhance biological function using naturally occurring frequencies, may be a nonpharmacological intervention to improve stress and health. The study purpose was to determine the effectiveness of NFT ® for improving stress, sleep quality, mood, and cognition in adults. METHODS Using a double-blind placebo-controlled crossover design, participants with high perceived stress (N = 42, M age = 43.8) were assessed at baseline (BL) and assigned to either the Placebo Watch (PW) or Wellness Watch (WW) condition for 2 weeks, and then 2 weeks in the alternate condition. Participants completed the following self-report surveys of Perceived Stress Scale, Pittsburgh Sleep Quality Index, Insomnia Severity Index, Food Craving Questionnaire, and Profile of Mood States, as well as the CNS Vital Signs neurocognitive test at BL and following each condition. RESULTS The WW condition had significant improvements in sleep duration and Complex Attention compared to the PW group. Compared to BL, both conditions had significant improvements for perceived stress, food cravings, mood, sleep quality, and several cognitive tests, p's < .05. CONCLUSION Despite the placebo effect, NFT ® may be a natural alterative for improving stress and health. Research is needed examining the efficacy of NFT ® in a variety of populations and environments.",2020,"Compared to BL, both conditions had significant improvements for perceived stress, food cravings, mood, sleep quality, and several cognitive tests, p's < .05. ","['in adults', 'adults with high perceived stress', 'participants with high perceived stress (N\xa0=\xa042, M age\xa0=\xa043.8']","['Placebo Watch (PW) or Wellness Watch (WW) condition', 'Natural Frequency Technology ®', 'NFT ®', 'placebo']","['Perceived Stress Scale, Pittsburgh Sleep Quality Index, Insomnia Severity Index, Food Craving Questionnaire, and Profile of Mood States, as well as the CNS Vital Signs neurocognitive test', 'sleep duration and Complex Attention', 'perceived stress, food cravings, mood, sleep quality, and several cognitive tests', 'stress, sleep quality, mood, and cognition', 'cognition, sleep, and mood']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205296', 'cui_str': 'Natural'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0085400', 'cui_str': 'Neurofibrillary degeneration'}]","[{'cui': 'C0582653', 'cui_str': 'Perceived stress scale'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C4520529', 'cui_str': 'Insomnia severity index'}, {'cui': 'C0872380', 'cui_str': 'Food craving'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451394', 'cui_str': 'Profile of mood states'}, {'cui': 'C0028654', 'cui_str': 'Clinical nurse specialist'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0872227', 'cui_str': 'Neurocognitive Tests'}, {'cui': 'C0424574', 'cui_str': 'Duration of sleep'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}]",,0.209476,"Compared to BL, both conditions had significant improvements for perceived stress, food cravings, mood, sleep quality, and several cognitive tests, p's < .05. ","[{'ForeName': 'Heather A', 'Initials': 'HA', 'LastName': 'Hausenblas', 'Affiliation': 'Center for Health and Human Performance, Jacksonville University, Jacksonville, FL, USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Hooper', 'Affiliation': 'Center for Health and Human Performance, Jacksonville University, Jacksonville, FL, USA.'}, {'ForeName': 'Ashlyn', 'Initials': 'A', 'LastName': 'Knight', 'Affiliation': 'Center for Health and Human Performance, Jacksonville University, Jacksonville, FL, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Hooper', 'Affiliation': 'Center for Health and Human Performance, Jacksonville University, Jacksonville, FL, USA.'}]",Brain and behavior,['10.1002/brb3.1712'] 1469,32517192,Effect of Magnesium Supplementation on Circulating Biomarkers of Cardiovascular Disease.,"(1) Background: Magnesium supplementation may be effective for the prevention of cardiometabolic diseases, but the mechanisms are unclear. Proteomic approaches can assist in identifying the underlying mechanisms. (2) Methods: We collected repeated blood samples from 52 individuals enrolled in a double-blind trial which randomized participants 1:1 to oral magnesium supplementation (400 mg magnesium/day in the form of magnesium oxide) or a matching placebo for 10 weeks. Plasma levels of 91 proteins were measured at baseline with follow-up samples using the Olink Cardiovascular Disease III proximity extension assay panel and were modeled as arbitrary units in a log 2 scale. We evaluated the effect of oral magnesium supplementation for changes in protein levels and the baseline association between serum magnesium and protein levels. The Holm procedure was used to adjust for multiple comparisons. (3) Results: Participants were 73% women, 94% white, and had a mean age of 62. Changes in proteins did not significantly differ between the two intervention groups after correction for multiple comparisons. The most statistically significant effects were on myoglobin [difference -0.319 log 2 units, 95% confidence interval (CI) (-0.550, -0.088), p = 0.008], tartrate-resistant acid phosphatase type 5 (-0.187, (-0.328, -0.045), p = 0.011), tumor necrosis factor ligand superfamily member 13B (-0.181, (-0.332, -0.031), p = 0.019), ST2 protein (-0.198, (-0.363, -0.032), p = 0.020), and interleukin-1 receptor type 1 (-0.144, (-0.273, -0.015), p = 0.029). Similarly, none of the associations of baseline serum magnesium with protein levels were significant after correction for multiple comparisons. (4) Conclusions: Although we did not identify statistically significant effects of oral magnesium supplementation in this relatively small study, this study demonstrates the value of proteomic approaches for the investigation of mechanisms underlying the beneficial effects of magnesium supplementation. Clinical Trials Registration: ClinicalTrials.gov NCT02837328.",2020,"The most statistically significant effects were on myoglobin [difference -0.319 log 2 units, 95% confidence interval (CI) (-0.550, -0.088), p = 0.008], tartrate-resistant acid phosphatase type 5 (-0.187, (-0.328, -0.045), p = 0.011), tumor necrosis factor ligand superfamily member 13B (-0.181, (-0.332, -0.031), p = 0.019), ST2 protein (-0.198, (-0.363, -0.032), p = 0.020), and interleukin-1 receptor type 1 (-0.144, (-0.273, -0.015), p = 0.029).","['Participants were 73% women, 94% white, and had a mean age of 62', '52 individuals enrolled']","['Magnesium Supplementation', 'oral magnesium supplementation (400 mg magnesium/day in the form of magnesium oxide) or a matching placebo', 'oral magnesium supplementation', 'Magnesium supplementation']","['Plasma levels of 91 proteins', 'Circulating Biomarkers of Cardiovascular Disease', 'ST2 protein', 'tartrate-resistant acid phosphatase type']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C1096534', 'cui_str': 'Magnesium supplement therapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0024477', 'cui_str': 'Magnesium Oxide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0450499', 'cui_str': 'ST2'}, {'cui': 'C0297331', 'cui_str': 'Acid phosphatase bone isoenzyme'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]",73.0,0.469746,"The most statistically significant effects were on myoglobin [difference -0.319 log 2 units, 95% confidence interval (CI) (-0.550, -0.088), p = 0.008], tartrate-resistant acid phosphatase type 5 (-0.187, (-0.328, -0.045), p = 0.011), tumor necrosis factor ligand superfamily member 13B (-0.181, (-0.332, -0.031), p = 0.019), ST2 protein (-0.198, (-0.363, -0.032), p = 0.020), and interleukin-1 receptor type 1 (-0.144, (-0.273, -0.015), p = 0.029).","[{'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Alonso', 'Affiliation': 'Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.'}, {'ForeName': 'Lin Y', 'Initials': 'LY', 'LastName': 'Chen', 'Affiliation': 'Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Kyle D', 'Initials': 'KD', 'LastName': 'Rudser', 'Affiliation': 'Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Faye L', 'Initials': 'FL', 'LastName': 'Norby', 'Affiliation': 'Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55454, USA.'}, {'ForeName': 'Mary R', 'Initials': 'MR', 'LastName': 'Rooney', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21287, USA.'}, {'ForeName': 'Pamela L', 'Initials': 'PL', 'LastName': 'Lutsey', 'Affiliation': 'Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55454, USA.'}]",Nutrients,['10.3390/nu12061697'] 1470,32686617,Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials.,"BACKGROUND Four new agents (elotuzumab, ixazomib, panobinostat, and daratumumab) were approved by the US Food and Drug Administration (FDA) in 2015 for the treatment of multiple myeloma. Our objective was to compare the safety profiles of these new medications in real-world settings and their randomized controlled trial(s). MATERIAL AND METHODS An analysis was conducted of the FDA Adverse Event Reporting System (FAERS) for each drug consisting of the quarter that the drug received its FDA approval and the eight subsequent quarters. Reporting odds ratios and corresponding 95% confidence intervals were then calculated for each drug for each of the 10 most frequent adverse drug reactions. The randomized controlled trials that led to initial FDA approval for these medications were subsequently reviewed to assess the 10 most frequently reported adverse drug reactions in these trials. RESULTS There were only two adverse drug reactions in the top 10 of both FAERS and its randomized controlled trials for elotuzumab (anaemia, diarrhoea) and for daratumumab (cough, back pain), five for ixazomib (diarrhoea, constipation, fatigue, nausea, peripheral neuropathy), and four panobinostat (diarrhoea, fatigue, nausea, constipation). Ixazomib had two adverse drug reactions with a significant reporting odds ratios greater than a 10-fold increased risk (plasma cell myeloma, peripheral neuropathy); elotuzumab had three adverse drug reactions (infusion site reaction, malignant neoplasm progression, deep vein thrombosis); daratumumab had three adverse drug reactions (infusion site reaction, bronchospasm, chills), while panobinostat had four (malignant neoplasm progression, decreased platelet count, diarrhoea, increased blood creatinine). CONCLUSION This analysis helps to highlight the importance of conducting postmarketing pharmacovigilance studies to better understand the potential adverse reactions of these medications.",2020,"There were only two adverse drug reactions in the top 10 of both FAERS and its randomized controlled trials for elotuzumab (anaemia, diarrhoea) and for daratumumab (cough, back pain), five for ixazomib (diarrhoea, constipation, fatigue, nausea, peripheral neuropathy), and four panobinostat (diarrhoea, fatigue, nausea, constipation).",[],['Ixazomib'],"['risk (plasma cell myeloma, peripheral neuropathy', 'adverse drug reactions', 'elotuzumab (anaemia, diarrhoea) and for daratumumab (cough, back pain), five for ixazomib (diarrhoea, constipation, fatigue, nausea, peripheral neuropathy), and four panobinostat (diarrhoea, fatigue, nausea, constipation', 'platelet count, diarrhoea, increased blood creatinine', 'adverse drug reactions (infusion site reaction, malignant neoplasm progression, deep vein thrombosis); daratumumab had three adverse drug reactions (infusion site reaction, bronchospasm, chills']",[],"[{'cui': 'C3273711', 'cui_str': 'ixazomib'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}, {'cui': 'C0041755', 'cui_str': 'Adverse reaction to drug'}, {'cui': 'C1832049', 'cui_str': 'elotuzumab'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C2346801', 'cui_str': 'daratumumab'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C3273711', 'cui_str': 'ixazomib'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C1998098', 'cui_str': 'panobinostat'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0201975', 'cui_str': 'Creatinine measurement'}, {'cui': 'C1096343', 'cui_str': 'Infusion site reaction'}, {'cui': 'C0948048', 'cui_str': 'Malignant neoplasm progression'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0006266', 'cui_str': 'Bronchospasm'}, {'cui': 'C0085593', 'cui_str': 'Chill'}]",,0.166994,"There were only two adverse drug reactions in the top 10 of both FAERS and its randomized controlled trials for elotuzumab (anaemia, diarrhoea) and for daratumumab (cough, back pain), five for ixazomib (diarrhoea, constipation, fatigue, nausea, peripheral neuropathy), and four panobinostat (diarrhoea, fatigue, nausea, constipation).","[{'ForeName': 'Eric P', 'Initials': 'EP', 'LastName': 'Borrelli', 'Affiliation': 'Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, Kingston, RI, USA.'}, {'ForeName': 'Conor G', 'Initials': 'CG', 'LastName': 'McGladrigan', 'Affiliation': 'Department of Pharmacy, Mass General/North Shore Cancer Center, Danvers, MA, USA.'}]",Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,['10.1177/1078155220941937'] 1471,32521736,"The Effect of Escitalopram on Central Serotonergic and Dopaminergic Systems in Patients with Cervical Dystonia, and Its Relationship with Clinical Treatment Effects: A Double-Blind Placebo-Controlled Trial.","Purpose: The pathophysiology of cervical dystonia (CD) is thought to be related to changes in dopamine and serotonin levels in the brain. We performed a double-blind trial with escitalopram (selective serotonin reuptake inhibitor; SSRI) in patients with CD. Here, we report on changes in dopamine D 2/3 receptor (D2/3R), dopamine transporter (DAT) and serotonin transporter (SERT) binding potential (BP ND ) after a six-week treatment course with escitalopram or placebo. Methods: CD patients had [123I]FP-CIT SPECT (I-123 fluoropropyl carbomethoxy-3 beta-(4-iodophenyltropane) single-photon emission computed tomography) scans, to quantify extrastriatal SERT and striatal DAT, and [123I]IBZM SPECT (I-123 iodobenzamide SPECT) scans to quantify striatal D2/3R BPND before and after six weeks of treatment with either escitalopram or placebo. Treatment effect was evaluated with the Clinical Global Impression scale for dystonia, jerks and psychiatric symptoms, both by physicians and patients. Results: In both patients treated with escitalopram and placebo there were no significant differences after treatment in SERT, DAT or D2/3R BP ND . Comparing scans after treatment with escitalopram (n = 8) to placebo (n = 8) showed a trend ( p = 0.13) towards lower extrastriatal SERT BPND in the SSRI group (median SERT occupancy of 64.6%). After treatment with escitalopram, patients who reported a positive effect on dystonia or psychiatric symptoms had significantly higher SERT occupancy compared to patients who did not experience an effect. Conclusion: Higher extrastriatal SERT occupancy after treatment with escitalopram is associated with a trend towards a positive subjective effect on dystonia and psychiatric symptoms in CD patients.",2020,"In both patients treated with escitalopram and placebo there were no significant differences after treatment in SERT, DAT or D2/3R BP ND .","['patients with CD', 'Patients with Cervical Dystonia, and Its Relationship with Clinical Treatment Effects', 'cervical dystonia (CD', 'CD patients']","['Placebo', '123I]FP-CIT SPECT (I-123 fluoropropyl carbomethoxy-3 beta-(4-iodophenyltropane) single-photon emission computed tomography) scans', 'escitalopram', 'escitalopram or placebo', 'escitalopram (selective serotonin reuptake inhibitor; SSRI', 'Escitalopram', 'placebo']","['SERT, DAT or D2/3R BP ND ', 'Clinical Global Impression scale for dystonia, jerks and psychiatric symptoms', 'Central Serotonergic and Dopaminergic Systems', 'dystonia and psychiatric symptoms', 'dystonia or psychiatric symptoms', 'SERT occupancy', 'extrastriatal SERT BPND', 'extrastriatal SERT occupancy', 'dopamine D 2/3 receptor (D2/3R), dopamine transporter (DAT) and serotonin transporter (SERT) binding potential (BP ND ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0949445', 'cui_str': 'Cervical Dystonia'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0008864', 'cui_str': 'Citrulline'}, {'cui': 'C0040399', 'cui_str': 'Single photon emission computerized tomography'}, {'cui': 'C3495673', 'cui_str': 'IODIDE ION I-123'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C1099456', 'cui_str': 'Escitalopram'}, {'cui': 'C0360105', 'cui_str': 'Selective serotonin re-uptake inhibitor'}]","[{'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C3639708', 'cui_str': 'Clinical global impression scale'}, {'cui': 'C0013421', 'cui_str': 'Dystonia'}, {'cui': 'C0231530', 'cui_str': 'Muscle twitch'}, {'cui': 'C0233401', 'cui_str': 'Psychiatric symptom'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0178601', 'cui_str': 'Dopamine receptor agonist'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0114838', 'cui_str': 'Dopamine Transporter'}, {'cui': 'C0170657', 'cui_str': 'Serotonin Transporter'}, {'cui': 'C0332297', 'cui_str': 'Bounded by'}]",,0.388244,"In both patients treated with escitalopram and placebo there were no significant differences after treatment in SERT, DAT or D2/3R BP ND .","[{'ForeName': 'Evelien', 'Initials': 'E', 'LastName': 'Zoons', 'Affiliation': 'Department of Neurology, Zaans Medisch Centrum, 1502 DV Zaandam, The Netherlands.'}, {'ForeName': 'Marina A J', 'Initials': 'MAJ', 'LastName': 'Tijssen', 'Affiliation': 'Department of Neurology, University Medical Centre, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Yasmine E M', 'Initials': 'YEM', 'LastName': 'Dreissen', 'Affiliation': 'Department of Neurosurgery, Amsterdam University Medical Centre, location Academic Medical Centre, 1100 DD Amsterdam, The Netherlands.'}, {'ForeName': 'Marenka', 'Initials': 'M', 'LastName': 'Smit', 'Affiliation': 'Department of Neurology, University Medical Centre, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Booij', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Amsterdam UMC, location Academic Medical Centre, 1100 DD Amsterdam, The Netherlands.'}]",Biomolecules,['10.3390/biom10060880'] 1472,32524827,An integrated videoconferencing intervention for chronic pain and heavy drinking among patients in HIV-care: a proof-of-concept study.,"Chronic pain and heavy drinking are common comorbid conditions among people living with HIV/AIDS (PLWHA). An integrated approach to address these co-occurring conditions in a manner that facilitates treatment utilization would represent an important advance in HIV-care. This study examined the acceptability and feasibility of a tailored, videoconferencing intervention to reduce chronic pain and heavy drinking among PLWHA. Participants in HIV-care (n = 8) completed baseline assessments and an in-person intervention session followed by 6 videoconferencing sessions. Acceptability and feasibility were assessed with patient satisfaction ratings and interview responses 8 weeks following baseline along with videoconferencing use during the intervention period. Treatment satisfaction and comprehensibility ratings were high and supported by interview responses indicating the value of the intervention content, treatment alliance, and format. All participants successfully enabled videoconferencing on their own smartphones and completed a median number of 4.5 (out of 6) video-sessions. Changes in heavy drinking and pain provided additional support for the potential utility of this approach. Results suggest that this videoconferencing intervention is an acceptable and feasible method of addressing chronic pain and heavy drinking among PLWHA. Findings provide the basis for future work to examine the efficacy of this approach in a Stage 1b trial.",2020,"Treatment satisfaction and comprehensibility ratings were high and supported by interview responses indicating the value of the intervention content, treatment alliance, and format.","['patients in HIV-care', 'Participants in HIV-care (n\u2009=\u20098) completed', 'people living with HIV/AIDS (PLWHA']","['integrated videoconferencing intervention', 'baseline assessments and an in-person intervention session followed by 6 videoconferencing sessions', 'videoconferencing intervention']","['Acceptability and feasibility', 'chronic pain and heavy drinking', 'Chronic pain and heavy drinking', 'Treatment satisfaction and comprehensibility ratings']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}]","[{'cui': 'C1450048', 'cui_str': 'Videoconferencing'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",,0.0421099,"Treatment satisfaction and comprehensibility ratings were high and supported by interview responses indicating the value of the intervention content, treatment alliance, and format.","[{'ForeName': 'Tibor P', 'Initials': 'TP', 'LastName': 'Palfai', 'Affiliation': 'Department of Psychological and Brain Sciences, Boston University, Boston, MA, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Saitz', 'Affiliation': 'Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA, USA.'}, {'ForeName': 'Maya P L', 'Initials': 'MPL', 'LastName': 'Kratzer', 'Affiliation': 'Department of Psychological and Brain Sciences, Boston University, Boston, MA, USA.'}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Taylor', 'Affiliation': 'Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA, USA.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Otis', 'Affiliation': 'Department of Psychological and Brain Sciences, Boston University, Boston, MA, USA.'}, {'ForeName': 'Judith A', 'Initials': 'JA', 'LastName': 'Bernstein', 'Affiliation': 'Department of Community Health Sciences, Boston University School of Public Health, Boston, MA, USA.'}]",AIDS care,['10.1080/09540121.2020.1776825'] 1473,32526153,"Compared to conventional physiotherapy, does the use of an ankle trainer device after Weber B ankle fracture operation improve outcome and shorten hospital stay? A randomized controlled trial.","OBJECTIVE To compare the functional outcomes and length of hospital stay for patients treated with conventional physiotherapy compared to a new ankle trainer device after Weber B ankle fractures. DESIGN The patients were randomized, and then followed up at 3, 6, 12 and 52 weeks by a blinded physiotherapist. SETTING This study was done at a level 1 trauma centre. SUBJECTS One hundred and forty consecutive patients with Weber B ankle fractures that were operated on were screened for eligibility, of whom 113 were included in the study. INTERVENTIONS Conventional physiotherapy with stretching exercises, using a non-elastic band or using new ankle trainer. MAIN MEASURES Outcomes were evaluated with Olerud-Molander ankle score, Visual analogue scale for pain and ankle dorsiflexion at 3, 6, 12 and 52 weeks follow-up. Time of hospitalization and complications were registered. RESULTS Superior Olerud-Molander ankle scores were observed at three weeks follow-up in the ankle trainer group 40.9 (10.8), compared to the conventional group 35.3 (14.2) ( P  = 0.021). At one-year follow-up, there was no difference between the groups ( P  = 0.386). The ankle trainer group had a shorter hospital stay with a mean 2.6 days (0.98) compared to 3.2 days (1.47) in the conventional group ( P  = 0.026). CONCLUSION The patients who were treated with the new ankle trainer device recovered more rapidly, evaluated by the Olerud-Molander ankle score and had a shorter stay in hospital compared to the conventional physiotherapy group. No between group differences could be observed at long-term follow-up.",2020,"RESULTS Superior Olerud-Molander ankle scores were observed at three weeks follow-up in the ankle trainer group 40.9 (10.8), compared to the conventional group 35.3 (14.2) ( P  = 0.021).","['patients treated with', 'One hundred and forty consecutive patients with Weber B ankle fractures that were operated on were screened for eligibility, of whom 113 were included in the study']","['Conventional physiotherapy with stretching exercises, using a non-elastic band or using new ankle trainer', 'conventional physiotherapy']","['Time of hospitalization and complications', 'shorter hospital stay', 'Superior Olerud-Molander ankle scores', 'Olerud-Molander ankle score, Visual analogue scale for pain and ankle dorsiflexion', 'functional outcomes and length of hospital stay']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0582525', 'cui_str': 'weber'}, {'cui': 'C0159877', 'cui_str': 'Fracture of ankle'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0600080', 'cui_str': 'Stretching exercises'}, {'cui': 'C0221839', 'cui_str': 'Orthodontic band, elastic'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0453962', 'cui_str': 'Trainers'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231770', 'cui_str': 'Dorsiflexion of foot'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}]",140.0,0.117407,"RESULTS Superior Olerud-Molander ankle scores were observed at three weeks follow-up in the ankle trainer group 40.9 (10.8), compared to the conventional group 35.3 (14.2) ( P  = 0.021).","[{'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Molund', 'Affiliation': 'Department of Orthopaedic, Sykehuset Østfold HF, Grålum, Norway.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Hellesnes', 'Affiliation': 'Department of Orthopaedic, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Gøran', 'Initials': 'G', 'LastName': 'Berdal', 'Affiliation': 'Department of Orthopaedic, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Bernt Stray', 'Initials': 'BS', 'LastName': 'Andreassen', 'Affiliation': 'Department of Orthopaedic, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Geir Stray', 'Initials': 'GS', 'LastName': 'Andreassen', 'Affiliation': 'Department of Orthopaedic, Oslo University Hospital, Oslo, Norway.'}]",Clinical rehabilitation,['10.1177/0269215520929727'] 1474,32516894,Effectiveness of a Real-Time Ventilation Feedback Device for Guiding Adequate Minute Ventilation: A Manikin Simulation Study.,"Background and objectives: It is often challenging even for skilled rescuers to provide adequate positive pressure ventilation consistently. This study aimed to investigate the effectiveness of a newly developed real-time ventilation feedback device (RTVFD) that estimates tidal volume (TV) and ventilation interval (VI) in real time. Materials and methods: We conducted a randomised, crossover, manikin simulation study. A total of 26 medical providers were randomly assigned to the RTVFD-assisted ventilation (RAV) first group ( n = 13) and the non-assisted ventilation (NV) first group ( n = 13). Participants provided ventilation using adult and paediatric bag valves (BVs) for 2 min each. After a washout period, the simulation was repeated by exchanging the participants' groups. Results: The primary outcome was optimal TV in the RAV and NV groups using adult and paediatric BVs. A secondary outcome was optimal VI in the RAV and NV groups using adult and paediatric BVs. The proportions of optimal TV values were higher for the RAVs when using both adult and paediatric BVs (adult BV: 47.29% vs. 18.46%, p < 0.001; paediatric BV: 89.51% vs. 72.66%, p < 0.001) than for the NVs. The proportions of optimal VI were significantly higher in RAVs when using both adult and paediatric BVs than that in NVs (adult BV: 95.64% vs. 50.20%, p < 0.001; paediatric BV: 95.83% vs. 57.14%, p < 0.001). Additionally, we found that with paediatric BVs, the simulation had a higher OR for both optimal TV (13.26; 95% CI, 9.96-17.65; p < 0.001) and VI (1.32; 1.08-1.62, p = 0.007), regardless of RTVFD use. Conclusion: Real-time feedback using RTVFD significantly improves the TV and VI in both adult and paediatric BVs in a manikin simulation study.",2020,Conclusion: Real-time feedback using RTVFD significantly improves the TV and VI in both adult and paediatric BVs in a manikin simulation study.,['26 medical providers'],"['RTVFD', 'newly developed real-time ventilation feedback device (RTVFD', 'Real-Time Ventilation Feedback Device', 'RTVFD-assisted ventilation (RAV) first group ( n = 13) and the non-assisted ventilation (NV) first group']","['optimal VI in the RAV and NV groups using adult and paediatric BVs', 'estimates tidal volume (TV) and ventilation interval (VI) in real time', 'proportions of optimal TV values', 'optimal TV in the RAV and NV groups using adult and paediatric BVs']","[{'cui': 'C0199168', 'cui_str': 'Medical service'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0554804', 'cui_str': 'Assisted breathing'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",26.0,0.166221,Conclusion: Real-time feedback using RTVFD significantly improves the TV and VI in both adult and paediatric BVs in a manikin simulation study.,"[{'ForeName': 'Sejin', 'Initials': 'S', 'LastName': 'Heo', 'Affiliation': 'Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.'}, {'ForeName': 'Sun Young', 'Initials': 'SY', 'LastName': 'Yoon', 'Affiliation': 'Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.'}, {'ForeName': 'Jongchul', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Biomedical Engineering, Samsung Medical Center, Seoul 06351, Korea.'}, {'ForeName': 'Hye Seung', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': 'Biostatistics and Clinical Epidemiology Center, Samsung Medical Center, Seoul 06351, Korea.'}, {'ForeName': 'Kyunga', 'Initials': 'K', 'LastName': 'Kim', 'Affiliation': 'Biostatistics and Clinical Epidemiology Center, Samsung Medical Center, Seoul 06351, Korea.'}, {'ForeName': 'Hee', 'Initials': 'H', 'LastName': 'Yoon', 'Affiliation': 'Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.'}, {'ForeName': 'Sung Yeon', 'Initials': 'SY', 'LastName': 'Hwang', 'Affiliation': 'Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.'}, {'ForeName': 'Won Chul', 'Initials': 'WC', 'LastName': 'Cha', 'Affiliation': 'Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.'}, {'ForeName': 'Taerim', 'Initials': 'T', 'LastName': 'Kim', 'Affiliation': 'Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.'}]","Medicina (Kaunas, Lithuania)",['10.3390/medicina56060278'] 1475,32517513,The effects of a dialogue-based intervention to promote psychosocial well-being after stroke: a randomized controlled trial.,"OBJECTIVE To evaluate the effect of a dialogue-based intervention targeting psychosocial well-being at 12 months post-stroke. DESIGN Multicenter, prospective, randomized, assessor-blinded, controlled trial with two parallel groups. SETTING Community. SUBJECTS Three-hundred and twenty-two adults (⩾18 years) with stroke within the last four weeks were randomly allocated into intervention group ( n  = 166) or control group ( n  = 156). INTERVENTIONS The intervention group received a dialogue-based intervention to promote psychosocial well-being, comprising eight individual 1-1½ hour sessions delivered during the first six months post-stroke. MAIN MEASURES The primary outcome measure was the General Health Questionnaire-28 (GHQ-28). Secondary outcome measures included the Stroke and Aphasia Quality of Life Scale-39g, the Sense of Coherence scale, and the Yale Brown single-item questionnaire. RESULTS The mean (SD) age of the participants was 66.8 (12.1) years in the intervention group and 65.7 (13.3) years in the control group. At 12 months post-stroke, the mean (SE) GHQ-28 score was 20.6 (0.84) in the intervention group and 19.9 (0.85) in the control group. There were no between-group differences in psychosocial well-being at 12 months post-stroke (mean difference: -0.74, 95% confidence interval (CI): -3.08, 1.60). The secondary outcomes showed no statistically significant between-group difference in health-related quality of life, sense of coherence, or depression at 12 months. CONCLUSION The results of this trial did not demonstrate lower levels of emotional distress and anxiety or higher levels of health-related quality of life in the intervention group (dialogue-based intervention) as compared to the control group (usual care) at 12 months post-stroke.",2020,The results of this trial did not demonstrate lower levels of emotional distress and anxiety or higher levels of health-related quality of life in the intervention group (dialogue-based intervention) as compared to the control group (usual care) at 12 months post-stroke.,"['The mean (SD) age of the participants was 66.8 (12.1) years in the intervention group and 65.7 (13.3) years in the control group', 'Three-hundred and twenty-two adults (⩾18\u2009years) with stroke within the last four weeks', 'Community']","['dialogue-based intervention to promote psychosocial well-being', 'dialogue-based intervention']","['health-related quality of life, sense of coherence, or depression', 'emotional distress and anxiety or higher levels of health-related quality of life', 'Stroke and Aphasia Quality of Life Scale-39g, the Sense of Coherence scale, and the Yale Brown single-item questionnaire', 'General Health Questionnaire-28 (GHQ-28', 'mean (SE) GHQ-28 score']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517844', 'cui_str': '66.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517712', 'cui_str': '322'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C3178983', 'cui_str': 'Salutogenesis'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0700361', 'cui_str': 'Emotional distress'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0003537', 'cui_str': 'Aphasia'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0155339', 'cui_str': ""Brown's tendon sheath syndrome""}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451182', 'cui_str': 'General health questionnaire'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",322.0,0.103993,The results of this trial did not demonstrate lower levels of emotional distress and anxiety or higher levels of health-related quality of life in the intervention group (dialogue-based intervention) as compared to the control group (usual care) at 12 months post-stroke.,"[{'ForeName': 'Line Kildal', 'Initials': 'LK', 'LastName': 'Bragstad', 'Affiliation': 'Research Center for Habilitation and Rehabilitation Services and Models (CHARM), Institute of Health and Society, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Ellen Gabrielsen', 'Initials': 'EG', 'LastName': 'Hjelle', 'Affiliation': 'Research Center for Habilitation and Rehabilitation Services and Models (CHARM), Institute of Health and Society, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Zucknick', 'Affiliation': 'Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Unni', 'Initials': 'U', 'LastName': 'Sveen', 'Affiliation': 'Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Bente', 'Initials': 'B', 'LastName': 'Thommessen', 'Affiliation': 'Department of Neurology, Akershus University Hospital, Lørenskog, Norway.'}, {'ForeName': 'Berit Arnesveen', 'Initials': 'BA', 'LastName': 'Bronken', 'Affiliation': 'Department of Health and Nursing Sciences, Faculty of Social and Health Sciences, Inland Norway University of Applied Sciences, Elverum, Norway.'}, {'ForeName': 'Randi', 'Initials': 'R', 'LastName': 'Martinsen', 'Affiliation': 'Department of Health and Nursing Sciences, Faculty of Social and Health Sciences, Inland Norway University of Applied Sciences, Elverum, Norway.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Kitzmüller', 'Affiliation': 'Department of Health and Care Sciences, Faculty of Health Sciences, UiT, The Arctic University of Norway, Narvik, Norway.'}, {'ForeName': 'Margrete', 'Initials': 'M', 'LastName': 'Mangset', 'Affiliation': 'Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Kari Johanne', 'Initials': 'KJ', 'LastName': 'Kvigne', 'Affiliation': 'Department of Health and Nursing Sciences, Faculty of Social and Health Sciences, Inland Norway University of Applied Sciences, Elverum, Norway.'}, {'ForeName': 'Katerina', 'Initials': 'K', 'LastName': 'Hilari', 'Affiliation': 'Centre for Language and Communication Sciences Research, School of Health Sciences, City, University of London, London, UK.'}, {'ForeName': 'C Elizabeth', 'Initials': 'CE', 'LastName': 'Lightbody', 'Affiliation': 'School of Nursing, University of Central Lancashire, Lancashire, UK.'}, {'ForeName': 'Marit', 'Initials': 'M', 'LastName': 'Kirkevold', 'Affiliation': 'Research Center for Habilitation and Rehabilitation Services and Models (CHARM), Institute of Health and Society, University of Oslo, Oslo, Norway.'}]",Clinical rehabilitation,['10.1177/0269215520929737'] 1476,32517596,Comparing Blended Learning with Faculty-Led Ultrasound Training: Protocol for a Randomised Controlled Trial (The SIGNATURE Trial).,"Background: Ultrasound is increasingly used in clinical practice as a bedside tool. As medical graduates first encounter the technique in early residency, ultrasound training needs to be integrated into the undergraduate curriculum. In Switzerland, abdominal ultrasound skills have been taught by a faculty-led, 21-hour course. However, this course does not have sufficient capacity to meet the increasing demand, and there have been doubts about its effectiveness as a teaching method. We therefore developed a 21-hour blended-learning course, comprising five hours of e-learning and 16 hours of near-peer tutoring. This study investigates whether this new teaching format is as good as, or superior to, the faculty-led method. Methods: The SIGNATURE study is an investigator-initiated, two-arm, randomised controlled trial, enrolling 152 medical students at the Universities of Bern, Fribourg and Zurich. Stratified by study site, students are 1:1 randomised to either the blended-learning course or the faculty-led 2.5-day ultrasound course. Students undergo a six-station objective structured clinical examination (OSCE) and complete an online questionnaire immediately after the course and 6 months later. Discussion: If demonstrated to be effective, the blended-learning course would allow an increase in the number of undergraduate medical students that can acquire ultrasound skills before starting their residencies.",2020,"If demonstrated to be effective, the blended-learning course would allow an increase in the number of undergraduate medical students that can acquire ultrasound skills before starting their residencies.","['enrolling 152 medical students at the Universities of Bern, Fribourg and Zurich', 'Discussion']",['blended-learning course or the faculty-led 2.5-day ultrasound course'],[],"[{'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0015535', 'cui_str': 'Faculty'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}]",[],152.0,0.0832832,"If demonstrated to be effective, the blended-learning course would allow an increase in the number of undergraduate medical students that can acquire ultrasound skills before starting their residencies.","[{'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Hari', 'Affiliation': 'Institute of Primary Health Care (BIHAM), University of Bern, Switzerland.'}, {'ForeName': 'Kaspar', 'Initials': 'K', 'LastName': 'Kälin', 'Affiliation': 'Institute of Primary Health Care (BIHAM), University of Bern, Switzerland.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Harris', 'Affiliation': 'Institute of Primary Health Care (BIHAM), University of Bern, Switzerland.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Walter', 'Affiliation': 'Institute of Primary Health Care (BIHAM), University of Bern, Switzerland.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Serra', 'Affiliation': 'Clinic of General Internal Medicine and Nephrology, Klinik Hirslanden Zurich, Switzerland.'}]",Praxis,['10.1024/1661-8157/a003497'] 1477,32521605,"Growth, Physiology and Nutrient Use Efficiency in Eugenia dysenterica DC under Varying Rates of Nitrogen and Phosphorus.","The production of high-quality seedlings and their use in commercial planting reduce pressure on natural areas. Eugenia dysenterica DC is a native fruit tree from the Brazilian Cerrado, whose nutritional requirements are still unclear. This study aimed to evaluate the effects of nitrogen (N) and phosphorus (P) supplementation on the physiology, growth and nutrient uptake, and use efficiencies of E. dysenterica seedlings grown in glasshouse conditions. The following rates were used in separate experiments: 0, 50, 100, 200, and 400 mg dm -3 N and 0, 100, 200, 400, and 600 mg dm -3 P. The experiment was conducted in a randomized block with four replications. The lowest N rate (50 mg dm -3 ) increased the stomatal conductance (g S ) and, consequently, resulted in the highest transpiration ( E ), electron transport (ETR), and photosynthetic ( A ) rates. Also, rates of 50 mg dm -3 and 100 mg dm -3 N increased the Root Uptake Efficiency (RUE) and plant Nutrient Use Efficiency (NUE) for macronutrients and the RUE for micronutrients, stimulating plant growth. Phosphorous fertilization resulted in the maximum values for photosynthesis, electron transport rate, total dry mass, and NUE at the 200 mg dm -3 rate. The results of this study suggest that fertilization with 50 mg dm -3 N and 200 mg dm -3 P is suitable for the development of E. dysenterica seedlings.",2020,"N increased the Root Uptake Efficiency (RUE) and plant Nutrient Use Efficiency (NUE) for macronutrients and the RUE for micronutrients, stimulating plant growth.",[],['nitrogen (N) and phosphorus (P) supplementation'],"['stomatal conductance', 'maximum values for photosynthesis, electron transport rate, total dry mass, and NUE', 'highest transpiration ( E ), electron transport (ETR), and photosynthetic ( A ) rates', 'Root Uptake Efficiency (RUE) and plant Nutrient Use Efficiency (NUE) for macronutrients and the RUE for micronutrients, stimulating plant growth', 'Eugenia dysenterica']",[],"[{'cui': 'C0028158', 'cui_str': 'Nitrogen'}, {'cui': 'C0031705', 'cui_str': 'Phosphorus'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0031764', 'cui_str': 'Photosynthesis'}, {'cui': 'C0013846', 'cui_str': 'Electron transfer'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0011682', 'cui_str': 'Desiccation - action'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0763953', 'cui_str': 'NUE protein, silkworm'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0032098', 'cui_str': 'Kingdom Viridiplantae'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C0330928', 'cui_str': 'Ruta'}, {'cui': 'C0040577', 'cui_str': 'Trace element'}, {'cui': 'C0597252', 'cui_str': 'Plant Development'}, {'cui': 'C1186984', 'cui_str': 'Eugenia'}]",,0.0481211,"N increased the Root Uptake Efficiency (RUE) and plant Nutrient Use Efficiency (NUE) for macronutrients and the RUE for micronutrients, stimulating plant growth.","[{'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Nogueira Dos Reis', 'Affiliation': 'Plant Tissue Culture Laboratory, Goiano Federal Institute of Science and Technology-Campus Rio Verde, P.O. Box 66, 75901-970 Rio Verde, GO, Brazil.'}, {'ForeName': 'Fabiano', 'Initials': 'F', 'LastName': 'Guimarães Silva', 'Affiliation': 'Plant Tissue Culture Laboratory, Goiano Federal Institute of Science and Technology-Campus Rio Verde, P.O. Box 66, 75901-970 Rio Verde, GO, Brazil.'}, {'ForeName': 'Reginaldo', 'Initials': 'R', 'LastName': 'da Costa Santana', 'Affiliation': 'Plant Tissue Culture Laboratory, Goiano Federal Institute of Science and Technology-Campus Rio Verde, P.O. Box 66, 75901-970 Rio Verde, GO, Brazil.'}, {'ForeName': 'Thales', 'Initials': 'T', 'LastName': 'Caetano de Oliveira', 'Affiliation': 'Plant Tissue Culture Laboratory, Goiano Federal Institute of Science and Technology-Campus Rio Verde, P.O. Box 66, 75901-970 Rio Verde, GO, Brazil.'}, {'ForeName': 'Mariângela', 'Initials': 'M', 'LastName': 'Brito Freiberger', 'Affiliation': 'Plant Tissue Culture Laboratory, Goiano Federal Institute of Science and Technology-Campus Rio Verde, P.O. Box 66, 75901-970 Rio Verde, GO, Brazil.'}, {'ForeName': 'Fábia', 'Initials': 'F', 'LastName': 'Barbosa da Silva', 'Affiliation': 'Plants Stress Study Laboratory, University of São Paulo, Luiz de QueirózAgriculture School, P.O. Box 9, 13418-900 Piracicaba, SP, Brazil.'}, {'ForeName': 'Elídio', 'Initials': 'E', 'LastName': 'Monteiro Júnior', 'Affiliation': 'Biodiversity Laboratory, Minas South Federal Institute of Science and Technology-Campus Poços de Caldas, 37713-100 Poços de Caldas, MG, Brazil.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Müller', 'Affiliation': 'Ecophysiology and Plant Productivity Laboratory, Goiano Federal Institute of Science and Technology-Campus Rio Verde, P.O. Box 66, 75901-970 Rio Verde, GO, Brazil.'}]","Plants (Basel, Switzerland)",['10.3390/plants9060722'] 1478,32522591,Mothers' DASH diet adherence and food purchases after week-long episodic future thinking intervention.,"Prospection has helped participants forego the temptation to buy and eat higher calorie nutrient poor foods in favor of buying and eating fewer calories and healthier macronutrient profiles in laboratory tasks and brief field studies. This pilot study examines whether episodic future thinking (EFT) improves mothers' dietary behavior and food purchasing over a longer 7-10-day period. The study utilized a 2 × 2 factorial design with mothers (N = 60) randomized to EFT or standardized episodic thinking (SET) crossed with dietary approaches to stop hypertension (DASH) diet education or a food safety education control. Participants listened to their cues (e.g., recordings of themselves imagining a future event or recalling a past episode) using a mobile ecological momentary intervention (EMI) tool and returned to complete a follow-up dietary recall and submit food receipts. Results showed diets of mothers in the EFT groups became more concordant with the DASH diet (η p 2  = 0.08, p < .05) than mothers in the SET group. When considering food purchases for the family, there was an EFT effect on milligrams of sodium purchased (η p 2  = 0.07, p < .05) and a trend towards a decrease in grams of fat purchased (η p 2  = 0.06, p = .06), however, these findings were no longer significant after correcting for multiple comparisons. There were no DASH education effects and no DASH by EFT interactions observed. The dietary intake and food purchasing results should be replicated in larger more representative samples.",2020,"Results showed diets of mothers in the EFT groups became more concordant with the DASH diet (η p 2  = 0.08, p < .05) than mothers in the SET group.",['2\u202f×\u202f2 factorial design with mothers (N\u202f=\u202f60) randomized to'],"['episodic future thinking (EFT', 'EFT or standardized episodic thinking (SET) crossed with dietary approaches to stop hypertension (DASH) diet education or a food safety education control', 'mobile ecological momentary intervention (EMI) tool and returned to complete a follow-up dietary recall and submit food receipts']","['DASH education effects', ""mothers' dietary behavior and food purchasing"", 'grams of fat purchased']","[{'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]","[{'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0016884', 'cui_str': 'Future'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C4053458', 'cui_str': 'Dietary Approaches to Stop Hypertension diet'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C1456535', 'cui_str': 'Food Safety'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0016452', 'cui_str': 'Foods'}]","[{'cui': 'C4053458', 'cui_str': 'Dietary Approaches to Stop Hypertension diet'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C0015677', 'cui_str': 'Fat'}]",60.0,0.0401892,"Results showed diets of mothers in the EFT groups became more concordant with the DASH diet (η p 2  = 0.08, p < .05) than mothers in the SET group.","[{'ForeName': 'Kelseanna', 'Initials': 'K', 'LastName': 'Hollis-Hansen', 'Affiliation': 'Department of Population Health, University of Texas at Austin, Dell Medical School, Austin, TX, USA; University of Texas at Austin, Steve Hicks School of Social Work, Austin, TX, USA. Electronic address: kelseanna.hollishansen@austin.utexas.edu.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Seidman', 'Affiliation': 'Department of Pediatrics, Division of Behavioral Medicine, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': ""O'Donnell"", 'Affiliation': 'Department of Pediatrics, Division of Behavioral Medicine, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.'}, {'ForeName': 'Leonard H', 'Initials': 'LH', 'LastName': 'Epstein', 'Affiliation': 'Department of Pediatrics, Division of Behavioral Medicine, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.'}]",Appetite,['10.1016/j.appet.2020.104757'] 1479,32525048,"Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study.","PURPOSE To evaluate changes in ocular biometrics in groups receiving 0.05%, 0.025%, and 0.01% atropine compared with placebo over 1 year based on the Low-Concentration Atropine for Myopia Progression (LAMP) study. DESIGN Double-blinded, randomized, placebo-controlled trial. PARTICIPANTS Three hundred eighty-three children aged 4 to 12 years who were assigned randomly to receive 0.05%, 0.025%, 0.01% atropine, or placebo once daily in both eyes and completed the first year of the LAMP study. METHODS Cycloplegic spherical equivalent (SE), axial length (AL), corneal curvature (K), and anterior chamber depth (ACD) were measured by IOLMaster. Corneal astigmatism and lens power were calculated. The ocular biometric parameter changes were compared among groups. Contributions to SE progression from ocular parameters were determined and compared among groups. MAIN OUTCOME MEASURES Changes in ocular biometrics and their associations with the changes in SE. RESULTS Over 1 year, changes in AL were 0.20 ± 0.25 mm, 0.29 ± 0.20 mm, 0.36 ± 0.29 mm, and 0.41 ± 0.22 mm in the 0.05% atropine, 0.025% atropine, 0.01% atropine, and placebo groups, respectively (P < 0.001), with a concentration-dependent response. Corneal power remained stable, and its changes were similar across all atropine concentrations: -0.02 ± 0.14 diopter (D), -0.01 ± 0.14 D, -0.01 ± 0.12 D, and 0.01 ± 0.14 D in the 0.05% atropine, 0.025% atropine, 0.01% atropine, and placebo groups, respectively (P = 0.10). Lens power decreased over time in each concentration, but its changes also were similar across all concentrations: -0.31 ± 0.43 D, -0.38 ± 0.47 D, -0.40 ± 0.43 D, and -0.41 ± 0.43 D in the 0.05% atropine, 0.025% atropine, 0.01% atropine, and placebo groups, respectively (P = 0.24). Changes in ACD remained similar across all concentrations (P = 0.41). The contributions to SE progression from the ocular biometric changes after adjusting for age and gender in each concentration were similar across all groups (P > 0.05). CONCLUSIONS Low-concentrations of atropine (0.05%, 0.025%, and 0.01%) have no clinical effect on corneal or lens power. Antimyopic effects of low-concentration atropine act mainly on reducing AL elongation, and therefore could reduce the risk of subsequent myopia complications.",2020,"BACKGROUND Anti-myopia effect of 0.01% atropine over placebo affected spherical equivalent (SE) but not axial length (AL) elongation in both ATOM2 study and LAMP study.",['383 children aged 4 to 12 years'],"['atropine, or placebo', 'Atropine: Low-concentration Atropine', 'low-concentration atropine', 'atropine', 'placebo']","['Ocular Biometrics', 'changes of K, AL, and lens power', 'ocular biometric parameters changes', 'ocular biometrics', 'Corneal astigmatism and lens power', 'ocular biometrics and their associations with the changes in SE', 'AL, corneal curvatures, and anterior chamber depth (ACD', 'corneal power and lens power', 'Corneal power']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0004259', 'cui_str': 'Atropine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205131', 'cui_str': 'Axial'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0023317', 'cui_str': 'Lens clear'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0339682', 'cui_str': 'Regular astigmatism - corneal'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0429492', 'cui_str': 'Depth of anterior chamber'}]",383.0,0.359246,"BACKGROUND Anti-myopia effect of 0.01% atropine over placebo affected spherical equivalent (SE) but not axial length (AL) elongation in both ATOM2 study and LAMP study.","[{'ForeName': 'Fen Fen', 'Initials': 'FF', 'LastName': 'Li', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.'}, {'ForeName': 'Ka Wai', 'Initials': 'KW', 'LastName': 'Kam', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Yuzhou', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.'}, {'ForeName': 'Shu Min', 'Initials': 'SM', 'LastName': 'Tang', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Ophthalmology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.'}, {'ForeName': 'Alvin L', 'Initials': 'AL', 'LastName': 'Young', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Li Jia', 'Initials': 'LJ', 'LastName': 'Chen', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Clement C', 'Initials': 'CC', 'LastName': 'Tham', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Hong Kong SAR, China; Hong Kong Eye Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Chi Pui', 'Initials': 'CP', 'LastName': 'Pang', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.'}, {'ForeName': 'Jason C', 'Initials': 'JC', 'LastName': 'Yam', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Hong Kong SAR, China; Hong Kong Eye Hospital, Hong Kong SAR, China. Electronic address: yamcheuksing@cuhk.edu.hk.'}]",Ophthalmology,['10.1016/j.ophtha.2020.06.004'] 1480,32472686,Can social accountability mechanisms using community scorecards improve quality of pediatric care in rural Cambodia?,"OBJECTIVE To determine the effect of social accountability strategies on pediatric quality of care. DESIGN AND SETTING A non-randomized quasi experimental study was conducted in four districts in Cambodia and all operational public health facilities were included. PARTICIPANTS Five patients under 5 years and their caretakers were randomly selected in each facility. INTERVENTIONS To determine the effect of maternal and child health interventions integrating citizen voice and action using community scorecards on quality of pediatric care. OUTCOME MEASURES Patient observations were conducted to determine quality of screening and counseling, followed by exit interviews with caretakers. RESULTS Results indicated significant differences between intervention and comparison facilities; screening by Integrated Management of Childhood Illness (IMCI) trained providers (100% vs 67%, P < 0.019), screening for danger signs; ability to drink/breastfeed (100% vs 86.7%, P < 0.041), lethargy (86.7% vs 40%, P < 0.004) and convulsions (83.3 vs 46.7%, P < 0.023). Screening was significantly higher for patients in the intervention facilities for edema (56.7% vs 6.7%, P < 0.000), immunization card (90% vs 40%, P < 0.002), child weight (100 vs 86.7, P < 0.041) and checking growth chart (96.7% vs 66.7%, P < 0.035). The IMCI index, constructed from key performance indicators, was significantly higher for patients in the intervention facilities than comparison facilities (screening index 8.8 vs 7.0, P < 0.018, counseling index 2.7 vs 1.5, P < 0.001). Predictors of screening quality were child age, screening by IMCI trained provider, wealthier quintiles and intervention facilities. CONCLUSION The institution of social accountability mechanisms to engage communities and facility providers showed some improvements in quality of care for common pediatric conditions, but socioeconomic disparities were evident.",2020,"The IMCI index, constructed from key performance indicators, was significantly higher for patients in the intervention facilities than comparison facilities (screening index 8.8 vs 7.0, P ","['Five patients under 5\xa0years and their caretakers', 'A non-randomized quasi experimental study was conducted in four districts in Cambodia and all operational public health facilities were included']",['social accountability strategies'],"['IMCI index', 'Childhood Illness (IMCI) trained providers', 'quality of screening and counseling, followed by exit interviews with caretakers', 'edema', 'screening for danger signs; ability to drink/breastfeed', 'pediatric quality of care', 'child weight', 'lethargy', 'checking growth chart', 'convulsions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0335350', 'cui_str': 'Building caretaker'}, {'cui': 'C2985410', 'cui_str': 'Controlled Clinical Trials, Non-Randomized'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0006797', 'cui_str': 'Cambodia'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0037394', 'cui_str': 'Social Accountability'}]","[{'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0337094', 'cui_str': 'Exit'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0335350', 'cui_str': 'Building caretaker'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0566274', 'cui_str': 'Ability to drink'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0034379', 'cui_str': 'Quality of Care'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0023380', 'cui_str': 'Lethargy'}, {'cui': 'C1283174', 'cui_str': 'Checking - action'}, {'cui': 'C2718056', 'cui_str': 'Growth Charts'}, {'cui': 'C0036572', 'cui_str': 'Seizure'}]",5.0,0.0304983,"The IMCI index, constructed from key performance indicators, was significantly higher for patients in the intervention facilities than comparison facilities (screening index 8.8 vs 7.0, P ","[{'ForeName': 'Anbrasi', 'Initials': 'A', 'LastName': 'Edward', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD 21205, USA.'}, {'ForeName': 'Younghee', 'Initials': 'Y', 'LastName': 'Jung', 'Affiliation': 'Neglected Tropical Disease, WHO Timor-Leste Office United Nations House Caicoli street, Dili, Timor-Leste.'}, {'ForeName': 'Chea', 'Initials': 'C', 'LastName': 'Chhorvann', 'Affiliation': 'National Institute of Public Health, N° 2, Sena Pramuk Kim Il Sung (St. 289), Phnom Penh, Cambodia.'}, {'ForeName': 'Annette E', 'Initials': 'AE', 'LastName': 'Ghee', 'Affiliation': 'Department of Global Health, University of Washington Harris Hydraulics Laboratory 1510 San Juan Rd NE, Seattle, WA 98195-7965 USA.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Chege', 'Affiliation': 'Monitoring & Evaluation, Ministry Strategy and Evidence, World Vision International, 34834 Weyerhaeuser Way S, Federal Way, Washington, DC 98001, USA.'}]",International journal for quality in health care : journal of the International Society for Quality in Health Care,['10.1093/intqhc/mzaa052'] 1481,31806484,Efficacy of open reduction and internal fixation in achieving bony union of comminuted mandibular fractures caused by civilian gunshot injuries.,"INTRODUCTION Comminuted fractures of the mandible caused by gunshot injuries were traditionally treated with closed reduction using maxillo-mandibular fixation (MMF). 2,3 Open reduction and internal fixation (ORIF) has become a valuable treatment modality in the management of comminuted mandibular fractures due to low rate of complications and predictable healing 4, 5 . OBJECTIVE To compare the efficacy of ORIF compared with MMF in achieving bony union of comminuted mandibular fractures in gunshot injury patients. METHOD ology: Randomized controlled trial conducted at the department of Oral & Maxillofacial Surgery, Abbasi Shaheed Hospital for a period of 3 years; total of 40 patients divided equally into two groups. Group A were treated with ORIF and group B were treated with MMF. Callus formation radiographically was confirmed by 8th week post operatively. Data was collected using proforma, entered on a statistical software SPSS version 20. Frequency percentages were computed for age and gender. Chi square and Fisher's exact tests were applied. P value ≤ 0.05 considered significant. RESULT A total of 40 patients of gunshot injuries were included in this study. 37 (92.5%) were males and 3 (7.5%) were Females with mean age of 36.35 ± 12.9 years SD. 19 (47.5%) patients showed callus formation, whereas, 21 (52.5%) did not. Out of 19 patients, 14 (70%) belonged to group A, and 5 (25%) from group B. The final healing considered by 8th week was in 16 (80%) of ORIF group A, and 8 (40%) group B (MMF) after calculating the clinical and radiographic evidences. CONCLUSION Comparative clinical trials have proven that ORIF is superior to MMF in the management of comminuted mandibular fractures. Early primary repair and internal fixation provides predictable and cost effective results.",2020,"CONCLUSION Comparative clinical trials have proven that ORIF is superior to MMF in the management of comminuted mandibular fractures.","['gunshot injury patients', 'department of Oral & Maxillofacial Surgery, Abbasi Shaheed Hospital for a period of 3 years; total of 40 patients divided equally into two groups', 'ology', '37 (92.5%) were males and 3 (7.5%) were Females with mean age of 36.35\xa0±', '2,3', '40 patients of gunshot injuries']","['MMF', 'ORIF', 'open reduction and internal fixation', 'internal fixation (ORIF']","['callus formation', 'final healing', 'Callus formation radiographically']","[{'cui': 'C0043252', 'cui_str': 'Gunshot wound'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0812928', 'cui_str': 'Oral and maxillofacial surgery'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0185373', 'cui_str': 'Open reduction of fracture'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}]","[{'cui': 'C0006767', 'cui_str': 'Callus of bone'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}]",40.0,0.019335,"CONCLUSION Comparative clinical trials have proven that ORIF is superior to MMF in the management of comminuted mandibular fractures.","[{'ForeName': 'Saad-Ud-Din', 'Initials': 'SU', 'LastName': 'Siddiqui', 'Affiliation': 'Civil Hospital Karachi, Opposite Allawala Market, M.A. Jinnah Road, Baba-e-Urdu Road, Nanakwara, Karachi, Pakistan. Electronic address: drsaadsiddiqui@hotmail.com.'}, {'ForeName': 'Naveed', 'Initials': 'N', 'LastName': 'Iqbal', 'Affiliation': 'Fatima Jinnah Dental College & Hospital Trust, Building No. 1, Street No. 1, 100 Foot Road, Azam Town, Karachi, Pakistan. Electronic address: naveedsyed1@hotmail.com.'}, {'ForeName': 'Mirza Hamid', 'Initials': 'MH', 'LastName': 'Baig', 'Affiliation': 'Fatima Jinnah Dental College & Hospital Trust, Building No. 1, Street No. 1, 100 Foot Road, Azam Town, Karachi, Pakistan. Electronic address: dr_hamidbaig@hotmail.com.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Mehdi', 'Affiliation': 'Fatima Jinnah Dental College & Hospital Trust, Building No. 1, Street No. 1, 100 Foot Road, Azam Town, Karachi, Pakistan. Electronic address: hassanmzaidi@msn.com.'}, {'ForeName': 'Syed', 'Initials': 'S', 'LastName': 'Mahmood Haider', 'Affiliation': 'Principal Karachi Medical & Dental College, Consultant OMS Abbasi Shaheed Hospital, Pakistan. Electronic address: mhaider@kmdc.edu.pk.'}]",The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland,['10.1016/j.surge.2019.10.004'] 1482,32682929,"Antioxidant supplementation, redox deficiencies and exercise performance: A falsification design.","The aim of the present study was to validate the idea of personalized redox supplementation by subjecting individuals to targeted and non-targeted antioxidant supplementation schemes. Seventy-three volunteers were screened for plasma vitamin C and erythrocyte glutathione levels. Three groups were formed: i) the ""low vitamin C″ group (12 individuals with the lowest vitamin C levels; Low VitC), ii) the ""low glutathione"" group (12 individuals with the lowest glutathione levels; Low GSH) and iii) a control group (12 individuals with moderate vitamin C and glutathione levels). The three groups received 1 g of vitamin C or 1.2 g of NAC daily for 30 days in a crossover design with a wash-out period of 30 days. Both antioxidant treatments reduced the increased resting systemic oxidative stress levels, assessed via urine F 2 -isoprostanes, in the Low VitC and Low GSH groups (P < .05). A significant group × time interaction (P < .05) was found for VO 2 max and isometric peak torque after both treatments, with the Low VitC and Low GSH groups exhibiting improved performance only after the targeted treatment (vitamin C and NAC, respectively). A significant group × time interaction (P < .05) was found for fatigue index after NAC treatment, but not after vitamin C treatment. No interaction was found for the Wingate test after both treatments. Most of the evidence verifies the idea that antioxidant supplementation increases performance when a particular deficiency is reversed. This indicates that the presence of oxidative stress per se does not rationalize the use of antioxidants and emphasizes the need to identify ""responsive"" phenotypes.",2020,"A significant group × time interaction (P<.05) was found for VO 2 max and isometric peak torque after both treatments, with the Low VitC and Low GSH groups exhibiting improved performance only after the targeted treatment (vitamin C and NAC, respectively).",[],"['low vitamin C"" group (12 individuals with the lowest vitamin C levels; Low VitC), ii) the ""low glutathione"" group (12 individuals with the lowest glutathione levels; Low GSH) and iii) a control group (12 individuals with moderate vitamin C and glutathione levels', 'antioxidant supplementation', 'personalized redox supplementation', 'vitamin C or 1.2g of NAC']","['Antioxidant supplementation, redox deficiencies and exercise performance', 'fatigue index', 'resting systemic oxidative stress levels', 'VO 2 max and isometric peak torque', 'plasma vitamin C and erythrocyte glutathione levels']",[],"[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0201898', 'cui_str': 'Ascorbic acid measurement'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0202053', 'cui_str': 'Glutathione measurement'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0030012', 'cui_str': 'Oxidation-reduction'}, {'cui': 'C4068880', 'cui_str': '1.2'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}]","[{'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0030012', 'cui_str': 'Oxidation-reduction'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0202053', 'cui_str': 'Glutathione measurement'}]",73.0,0.0729379,"A significant group × time interaction (P<.05) was found for VO 2 max and isometric peak torque after both treatments, with the Low VitC and Low GSH groups exhibiting improved performance only after the targeted treatment (vitamin C and NAC, respectively).","[{'ForeName': 'Nikos V', 'Initials': 'NV', 'LastName': 'Margaritelis', 'Affiliation': 'Department of Physical Education and Sport Science at Serres, Aristotle University of Thessaloniki, Serres, Greece; Dialysis Unit, 424 General Military Hospital of Thessaloniki, Thessaloniki, Greece. Electronic address: nvmargar@auth.gr.'}, {'ForeName': 'Vassilis', 'Initials': 'V', 'LastName': 'Paschalis', 'Affiliation': 'School of Physical Education and Sport Science, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: vpaschalis@phed.uoa.gr.'}, {'ForeName': 'Anastasios A', 'Initials': 'AA', 'LastName': 'Theodorou', 'Affiliation': 'Department of Health Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus. Electronic address: a.theodorou@euc.ac.cy.'}, {'ForeName': 'Antonios', 'Initials': 'A', 'LastName': 'Kyparos', 'Affiliation': 'Department of Physical Education and Sport Science at Serres, Aristotle University of Thessaloniki, Serres, Greece. Electronic address: akyparos@auth.gr.'}, {'ForeName': 'Michalis G', 'Initials': 'MG', 'LastName': 'Nikolaidis', 'Affiliation': 'Department of Physical Education and Sport Science at Serres, Aristotle University of Thessaloniki, Serres, Greece. Electronic address: nikolaidis@auth.gr.'}]",Free radical biology & medicine,['10.1016/j.freeradbiomed.2020.06.029'] 1483,32682938,Comparison of corticosteroid injection dosages in mild to moderate idiopathic carpal tunnel syndrome: A randomized controlled trial.,"OBJECTIVES To evaluate whether the therapeutic effect of ultrasound-guided injections with 10 mg or 40 mg triamcinolone acetonide (TA) was dose-dependent in patients with idiopathic mild to moderate carpal tunnel syndrome (CTS). DESIGN Prospective, double-blinded, randomized controlled study with 12 weeks of follow-up. SETTING Rehabilitation outpatient clinic of a single medical center. PARTICIPANTS Patients with CTS (N=56). INTERVENTION Participants were randomly assigned to two treatment groups for injection: (A) 40 mg TA + 2% lidocaine hydrochloride or (B) 10 mg TA + 2% lidocaine hydrochloride. MAIN OUTCOME MEASURES Participants were evaluated using Visual Analogue Scale (VAS) and Boston Carpal Tunnel Questionnaire (BCTQ, including Symptom Severity Scale (SSS) and Functional Status Scale (FSS)) at baseline, 6 and 12 weeks after injection). Nerve conduction studies (NCS), including parameters of distal motor latency, amplitude of compound motor action potential, amplitude of sensory nerve action potential and sensory nerve conduction velocity of median nerve, and the patient's subjective impression of improvement were recorded before injection and 6 and 12 weeks after injection. RESULTS No significant differences were observed in baseline demographic characteristics and clinical evaluations. The parameters in group A and B at the baseline, 6, and 12 weeks were: (1) SSS: 2.17±0.14, 1.19±0.04, and 1.34±0.09 and 1.87±0.11, 1.21±0.07, and 1.26±0.04; (2) FSS: 1.63±0.07, 1.27±0.06, and 1.33±0.08 and 1.50±0.10, 1.18±0.05, and 1.26±0.05; VAS: 6.4±0.3, 2.2±0.3, and 3.0±0.1 and 6.7±0.3, 2.0±0.3, and 3.1±0.3, respectively, and significantly decreased after 6 and 12 weeks in both treatment groups (p<0.05). All parameters of NCS improved in both groups after 12 weeks (p<0.05). VAS, BCTQ, and NCS did not show significant inter-group differences after 6 and 12 weeks. CONCLUSION In patients with idiopathic mild to moderate CTS, ultrasound-guided injection with 10 and 40 mg TA yield similar improvements in BCTQ, VAS, and NCS at the 12-week follow-up.",2020,All parameters of NCS improved in both groups after 12 weeks (p<0.05).,"['patients with idiopathic mild to moderate CTS', 'Patients with CTS (N=56', 'Rehabilitation outpatient clinic of a single medical center', 'patients with idiopathic mild to moderate carpal tunnel syndrome (CTS', 'mild to moderate idiopathic carpal tunnel syndrome']","['corticosteroid injection dosages', 'injection: (A) 40 mg TA + 2% lidocaine hydrochloride or (B) 10 mg TA + 2% lidocaine hydrochloride', 'ultrasound-guided injections with 10 mg or 40 mg triamcinolone acetonide (TA']","['Visual Analogue Scale (VAS) and Boston Carpal Tunnel Questionnaire (BCTQ, including Symptom Severity Scale (SSS) and Functional Status Scale (FSS', ""parameters of distal motor latency, amplitude of compound motor action potential, amplitude of sensory nerve action potential and sensory nerve conduction velocity of median nerve, and the patient's subjective impression of improvement"", 'baseline demographic characteristics and clinical evaluations', 'NCS', 'BCTQ, VAS, and NCS', 'VAS, BCTQ, and NCS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0007286', 'cui_str': 'Carpal tunnel syndrome'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}]","[{'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0040866', 'cui_str': 'Triamcinolone acetonide'}, {'cui': 'C0546869', 'cui_str': 'Lidocaine hydrochloride'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0006037', 'cui_str': 'Boston'}, {'cui': 'C0007286', 'cui_str': 'Carpal tunnel syndrome'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0265224', 'cui_str': 'Freeman-Sheldon syndrome'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0242465', 'cui_str': 'Response Latency'}, {'cui': 'C0205198', 'cui_str': 'Compound'}, {'cui': 'C0001272', 'cui_str': 'Action Potentials'}, {'cui': 'C0522219', 'cui_str': 'Sensory potential'}, {'cui': 'C0457378', 'cui_str': 'Sensory nerve conduction velocity'}, {'cui': 'C0025058', 'cui_str': 'Structure of median nerve'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C1261322', 'cui_str': 'Evaluation procedure'}]",,0.0597336,All parameters of NCS improved in both groups after 12 weeks (p<0.05).,"[{'ForeName': 'Po-Cheng', 'Initials': 'PC', 'LastName': 'Hsu', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital, Bei-Hu Branch, Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Kwong-Kum', 'Initials': 'KK', 'LastName': 'Liao', 'Affiliation': 'Department of Neurology, Taipei Veterans General Hospital, Taipei; Department of Neurology, National Yang-Ming University School of Medicine, Taipei.'}, {'ForeName': 'Kon-Ping', 'Initials': 'KP', 'LastName': 'Lin', 'Affiliation': 'Department of Neurology, Taipei Veterans General Hospital, Taipei; Department of Neurology, National Yang-Ming University School of Medicine, Taipei.'}, {'ForeName': 'Jan-Wei', 'Initials': 'JW', 'LastName': 'Chiu', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Taipei Veterans General Hospital, Taipei.'}, {'ForeName': 'Pin-Yi', 'Initials': 'PY', 'LastName': 'Wu', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Taipei Veterans General Hospital, Taipei.'}, {'ForeName': 'Chen-Liang', 'Initials': 'CL', 'LastName': 'Chou', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Taipei Veterans General Hospital, Taipei; Department of Physical Medicine and Rehabilitation, School of Medicine, National Yang Ming University, Taipei.'}, {'ForeName': 'Nin-Yi', 'Initials': 'NY', 'LastName': 'Wang', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Taipei Veterans General Hospital, Taipei.'}, {'ForeName': 'Jia-Chi', 'Initials': 'JC', 'LastName': 'Wang', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Taipei Veterans General Hospital, Taipei; Department of Physical Medicine and Rehabilitation, School of Medicine, National Yang Ming University, Taipei. Electronic address: jcwang0726@gmail.com.'}]",Archives of physical medicine and rehabilitation,['10.1016/j.apmr.2020.06.018'] 1484,32525761,A prospective quasi-experimental controlled study evaluating the use of dynamic elastomeric fabric orthoses to manage common postpartum ailments during postnatal care.,"OBJECTIVE To evaluate the effectiveness of a postnatal dynamic elastomeric fabric orthoses to manage postpartum pain, improve functional capacity and enhance the quality of life arising from postnatal ailments immediately to an 8-week postpartum, compared with patients who did not wear dynamic elastomeric fabric orthoses. METHOD A total of 51 postpartum women were recruited (day 0 to 10 days post-delivery) from hospitals and community-based health clinics to participate in a prospective quasi-experimental controlled study using parallel groups without random allocation. The subgroup of the compression shorts group wore SRC recovery shorts and received standard postnatal care. The comparison group received standard postnatal care alone. Wear compliance was monitored throughout the study. Primary outcome measure, Numeric Pain Rating Scale, and secondary outcome measures, Roland Morris Disability Questionnaire, Pelvic Floor Impact Questionnaire-7, and Short Form (SF-36) were assessed fortnightly over 8 weeks for both groups. RESULTS The compression shorts group reported a larger reduction in mean (SD) Numeric Pain Rating Scale score (-3.09 (2.20)) from baseline to 8 weeks, compared to the comparison group (-2.00 (1.41)). However, there was insufficient evidence of a statistical difference in Numeric Pain Rating Scale score at 8 weeks when comparing the compression shorts group and comparison group (-1.17; 95%CI: (-2.35, -0.01), R 2 = .19, p  = .050). The compression shorts group met the wear compliance of the dynamic elastomeric fabric orthoses and reported an average wear of the dynamic elastomeric fabric orthoses as 9 out of 14 days for 11 h per day (SD 4.8 h) between the fortnightly timepoints. CONCLUSION The use of dynamic elastomeric fabric orthoses may be considered during postnatal care as a non-pharmacological therapeutic intervention to manage pain resulting from common postpartum ailments. While the dynamic elastomeric fabric orthoses was clinically well accepted by participants with high wearing compliance, future research with larger population samples are needed to enable statistical conclusions on the effectiveness of a dynamic elastomeric fabric orthoses in postnatal care to be made. REGISTRATION Trial registration was not required as per the Australian Government Department of Health, Therapeutic Goods Administration.",2020,"The compression shorts group reported a larger reduction in mean (SD) Numeric Pain Rating Scale score (-3.09 (2.20)) from baseline to 8 weeks, compared to the comparison group (-2.00 (1.41)).","['51 postpartum women were recruited (day 0 to 10 days post-delivery) from hospitals and community-based health clinics to participate in a prospective quasi-experimental controlled study using parallel groups without random allocation', 'patients who did not wear dynamic elastomeric fabric orthoses']","['95%CI', 'postnatal dynamic elastomeric fabric orthoses', 'dynamic elastomeric fabric orthoses', 'standard postnatal care alone']","['Numeric Pain Rating Scale, and secondary outcome measures, Roland Morris Disability Questionnaire, Pelvic Floor Impact Questionnaire-7, and Short Form (SF-36', 'Numeric Pain Rating Scale score', 'Wear compliance', 'mean (SD) Numeric Pain Rating Scale score']","[{'cui': 'C0032804', 'cui_str': 'Postpartum Women'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0020003', 'cui_str': 'Community hospital'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0039717', 'cui_str': 'Textiles'}]","[{'cui': 'C0443281', 'cui_str': 'Postnatal'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0039717', 'cui_str': 'Textiles'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0032782', 'cui_str': 'Postpartum care'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",51.0,0.0465939,"The compression shorts group reported a larger reduction in mean (SD) Numeric Pain Rating Scale score (-3.09 (2.20)) from baseline to 8 weeks, compared to the comparison group (-2.00 (1.41)).","[{'ForeName': 'Jaclyn Michele', 'Initials': 'JM', 'LastName': 'Szkwara', 'Affiliation': 'Physiotherapy Program, Bond Institute of Health and Sport, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, QLD, Australia.'}, {'ForeName': 'Nikki', 'Initials': 'N', 'LastName': 'Milne', 'Affiliation': 'Physiotherapy Program, Bond Institute of Health and Sport, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, QLD, Australia.'}, {'ForeName': 'Evelyne', 'Initials': 'E', 'LastName': 'Rathbone', 'Affiliation': 'Faculty of Health Sciences and Medicine, Bond University, Gold Coast, QLD, Australia.'}]","Women's health (London, England)",['10.1177/1745506520927196'] 1485,32526490,Creativity on tap 2: Investigating dose effects of alcohol on cognitive control and creative cognition.,"This preregistered study aimed to replicate and extend research on the role of cognitive control in creative cognition by examining dose effects of alcohol in a randomized controlled trial. A sample of 125 participants was randomly assigned to three experimental groups, either drinking alcoholic beer (BAC = 0.03 or 0.06) or drinking non-alcoholic beer (placebo-control group). Before and after the alcohol intervention, participants completed two tests of cognitive control and two established creative thinking tasks. A BAC of 0.06 led to an impairment of verbal fluency, while working memory performance was unaffected at both alcohol levels. Alcohol had no facilitative or detrimental effects on creative thinking performance, neither in terms of RAT performance, divergent thinking fluency or divergent thinking creativity. These results indicate that moderate alcohol levels have dose-dependent, selective effects on cognitive control, and that minor impairments of cognitive control do not generally increase or attenuate creative thinking performance.",2020,"Alcohol had no facilitative or detrimental effects on creative thinking performance, neither in terms of RAT performance, divergent thinking fluency or divergent thinking creativity.",['A sample of 125 participants'],"['drinking alcoholic beer (BAC\xa0=\xa00.03 or 0.06) or drinking non-alcoholic beer (placebo-control group', 'alcohol', 'cognitive control and two established creative thinking tasks']","['creative thinking performance', 'verbal fluency, while working memory performance', 'RAT performance, divergent thinking fluency or divergent thinking creativity', 'cognitive control and creative cognition']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C4319551', 'cui_str': '125'}]","[{'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0687725', 'cui_str': 'Problem drinker'}, {'cui': 'C0004922', 'cui_str': 'Beer'}, {'cui': 'C0004599', 'cui_str': 'Bacitracin'}, {'cui': 'C4517402', 'cui_str': '0.03'}, {'cui': 'C4517412', 'cui_str': '0.06'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0010297', 'cui_str': 'Creative thought'}]","[{'cui': 'C0010297', 'cui_str': 'Creative thought'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",125.0,0.0319793,"Alcohol had no facilitative or detrimental effects on creative thinking performance, neither in terms of RAT performance, divergent thinking fluency or divergent thinking creativity.","[{'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Benedek', 'Affiliation': 'Institute of Psychology, University of Graz, Austria. Electronic address: mathias.benedek@uni-graz.at.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Zöhrer', 'Affiliation': 'Institute of Psychology, University of Graz, Austria.'}]",Consciousness and cognition,['10.1016/j.concog.2020.102972'] 1486,32526929,Pain Neuroscience Education for Children with Functional Abdominal Pain Disorders: A Randomized Comparative Pilot Study.,"This article explores the effectiveness of a newly developed Pain Neuroscience Education program for children (PNE4Kids) with functional abdominal pain disorder (FAPD). Children (6-12 years) with FAPD were randomly assigned to 1) the experimental group ( n = 14), participating in one hypnotherapy session (i.e., usual care) and one additional PNE4Kids session, or 2) the control group ( n = 14), participating in two hypnotherapy sessions. Parental pain catastrophizing, the child's functional disability (parental-proxy), pain-related fear (parent-proxy) and pain intensity, were assessed at baseline and one and three weeks after each therapy session. Pressure algometry and a conditioned pain modulation paradigm were performed at baseline and three weeks after completion of the last therapy session. Parents from both the experimental as well as the control group showed significantly less parental pain catastrophizing ( p < 0.01). Children showed significantly less functional disability ( p < 0.05), pain-related fear ( p < 0.01) and local pressure pain sensitivity ( p < 0.05) at short-term follow-up (three weeks after last intervention) in both groups. No significant ( p > 0.05) between-group differences were found. Hypnotherapy combined with PNE4Kids did not result in better clinical outcomes compared to hypnotherapy alone. Study limitations include the application of one single PNE4Kids session and the short follow-up time.",2020,Hypnotherapy combined with PNE4Kids did not result in better clinical outcomes compared to hypnotherapy alone.,"['children (PNE4Kids) with functional abdominal pain disorder (FAPD', 'Children (6-12 years) with FAPD', 'Children with Functional Abdominal Pain Disorders']","['Pain Neuroscience Education program', 'participating in one hypnotherapy session (i.e., usual care) and one additional PNE4Kids session, or 2) the control group', 'Pain Neuroscience Education', 'Hypnotherapy combined with PNE4Kids']","['parental pain catastrophizing', 'pain-related fear', 'local pressure pain sensitivity', ""Parental pain catastrophizing, the child's functional disability (parental-proxy), pain-related fear (parent-proxy) and pain intensity"", 'functional disability']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1609533', 'cui_str': 'Functional abdominal pain'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0027910', 'cui_str': 'Neurosciences'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0020587', 'cui_str': 'Hypnotherapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600420', 'cui_str': 'Proxy'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",,0.0325116,Hypnotherapy combined with PNE4Kids did not result in better clinical outcomes compared to hypnotherapy alone.,"[{'ForeName': 'Roselien', 'Initials': 'R', 'LastName': 'Pas', 'Affiliation': 'Pain in Motion Research Group (PAIN), Department of Physiotherapy, Human Physiology and Anatomy, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Rheel', 'Affiliation': 'Pain in Motion Research Group (PAIN), Department of Physiotherapy, Human Physiology and Anatomy, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Van Oosterwijck', 'Affiliation': 'Pain in Motion International Research Group.'}, {'ForeName': 'Anthe', 'Initials': 'A', 'LastName': 'Foubert', 'Affiliation': 'Department of Rehabilitation Sciences and Physiotherapy, Faculty of Medicine and Health Sciences, University of Antwerp (UA), D.S.022, 2610 Wilrijk, Belgium.'}, {'ForeName': 'Robby', 'Initials': 'R', 'LastName': 'De Pauw', 'Affiliation': 'Department of Rehabilitation Sciences, Faculty of Medicine and Health Sciences, Ghent University, Campus UZ, Corneel Heymanslaan 10, 9000 Ghent, Belgium.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Leysen', 'Affiliation': 'Pain in Motion Research Group (PAIN), Department of Physiotherapy, Human Physiology and Anatomy, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Roete', 'Affiliation': 'Antwerp University Hospital, department of Pediatrics, 2610 Wilrijk, Belgium.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Nijs', 'Affiliation': 'Pain in Motion Research Group (PAIN), Department of Physiotherapy, Human Physiology and Anatomy, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.'}, {'ForeName': 'Mira', 'Initials': 'M', 'LastName': 'Meeus', 'Affiliation': 'Pain in Motion Research Group (PAIN), Department of Physiotherapy, Human Physiology and Anatomy, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Ickmans', 'Affiliation': 'Pain in Motion Research Group (PAIN), Department of Physiotherapy, Human Physiology and Anatomy, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.'}]",Journal of clinical medicine,['10.3390/jcm9061797'] 1487,32526849,Therapeutic Atmosphere in Psychotherapy Sessions.,"There is uncertainty concerning what the active ingredients in psychotherapy are. The First Experimental Study of Transference interpretations (FEST) was a randomized controlled trial of the effects of transference work (TW) in psychodynamic psychotherapy. Women with low quality of object relations (QOR) showed a large positive effect of transference work, while men with high QOR showed a slight negative effect. The present study aimed to expand the knowledge from the FEST by investigating the therapeutic atmosphere with Structural Analysis of Social Behavior (SASB). Two-way ANOVAs were conducted to investigate differences between SASB cluster scores between subgroups. The therapeutic atmosphere was characterized by Protect-Trust, Affirm-Disclose and Control-Submit. Multilevel modeling was used to assess the relationship between a therapist variable and outcomes for men and women. Contrary to expectations, no significant differences in therapeutic atmosphere between subgroups (with or without TW in women with low QOR and men with high QOR) were observed using the process measure SASB.",2020,"Contrary to expectations, no significant differences in therapeutic atmosphere between subgroups (with or without TW in women with low QOR and men with high QOR) were observed using the process measure SASB.","['Women with low quality of object relations (QOR', 'women with low QOR and men with high QOR', 'men and women']","['Transference interpretations (FEST', 'transference work (TW']","['therapeutic atmosphere', 'SASB cluster scores']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0205864', 'cui_str': 'Object Relations'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C0040678', 'cui_str': 'Transference'}, {'cui': 'C0459471', 'cui_str': 'Interpretation'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0043227', 'cui_str': 'Working'}]","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0004178', 'cui_str': 'Atmosphere'}, {'cui': 'C0204514', 'cui_str': 'Structural analysis'}, {'cui': 'C0037397', 'cui_str': 'Social behavior'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0323645,"Contrary to expectations, no significant differences in therapeutic atmosphere between subgroups (with or without TW in women with low QOR and men with high QOR) were observed using the process measure SASB.","[{'ForeName': 'Marte L', 'Initials': 'ML', 'LastName': 'Siegel', 'Affiliation': 'Department of Psychology, University of Oslo, Forskningsveien 3A, 0373 Oslo, Norway.'}, {'ForeName': 'Eva M', 'Initials': 'EM', 'LastName': 'Gullestad Binder', 'Affiliation': 'Department of Psychology, University of Oslo, Forskningsveien 3A, 0373 Oslo, Norway.'}, {'ForeName': 'Hanne Sofie J', 'Initials': 'HSJ', 'LastName': 'Dahl', 'Affiliation': 'Department of Psychology, University of Oslo, Forskningsveien 3A, 0373 Oslo, Norway.'}, {'ForeName': 'Nikolai O', 'Initials': 'NO', 'LastName': 'Czajkowski', 'Affiliation': 'Department of Psychology, University of Oslo, Forskningsveien 3A, 0373 Oslo, Norway.'}, {'ForeName': 'Kenneth L', 'Initials': 'KL', 'LastName': 'Critchfield', 'Affiliation': 'Department of Graduate Psychology, James Madison University, Harrisonburg, VA 22807, USA.'}, {'ForeName': 'Per A', 'Initials': 'PA', 'LastName': 'Høglend', 'Affiliation': 'Division of Mental Health and Addiction, University of Oslo, Kirkeveien 166, 0450 Oslo, Norway.'}, {'ForeName': 'Randi', 'Initials': 'R', 'LastName': 'Ulberg', 'Affiliation': 'Division of Mental Health and Addiction, University of Oslo, Kirkeveien 166, 0450 Oslo, Norway.'}]",International journal of environmental research and public health,['10.3390/ijerph17114105'] 1488,32526852,"Prebiotic Therapy with Inulin Associated with Low Protein Diet in Chronic Kidney Disease Patients: Evaluation of Nutritional, Cardiovascular and Psychocognitive Parameters.","A relationship between dysbiotic gut microbiome and chronic kidney disease (CKD) has been recently documented; it contributes to CKD-related complications, including cardiovascular disease. Aim: We tested how a low-protein diet (LPD)-with or without oral inulin supplementation as a prebiotic-modulates some inflammatory, atherosclerosis and endothelial dysfunction indices and nutritional markers, as well as psychocognitive functions in CKD patients. We conducted a prospective, case-control study on CKD patients on conservative therapy, divided in two groups: the intervention group treated with LPD (0.6 g/kg/day) plus inulin (19 g/day) and a control group treated with LPD without inulin, for six consecutive months. Clinical and hematochemical parameters as well as instrumental, and psychocognitive assessments (by SF-36 survey and MMSE, HAM-D, BDI-II) were recorded in all the participants at baseline (T0), at three months (T1) and at six months (T2). A total of 41 patients were enrolled: 18 in the intervention group and 23 in the control group. At T2, in both groups, we observed a significant reduction of serum nitrogen and phosphorus ( p ≤ 0.01) and serum uric acid ( p ≤ 0.03), and an improvement in metabolic acidosis (bicarbonates, p ≤ 0.01; base excess, p ≤ 0.02). Moreover, at T2 the intervention group showed a reduction in serum insulin ( p = 0.008) and fasting glucose levels ( p = 0.022), HOMA-IR ( p = 0.004), as well as lower total serum cholesterol ( p = 0.012), triglycerides ( p = 0.016), C-reactive protein ( p = 0.044) and homocysteine ( p = 0.044) and higher HDL ( p < 0.001) with respect to baseline. We also observed a significant amelioration of some quality of life and functional status indices (SF-36 survey) among the intervention group compared to controls, without a significant improvement in the cognitive state (MMSE). On the other hand, an amelioration in mood (by HAM-D and BDI-II) was found in the intervention group and in controls (only by BID-II). In conclusion, LPD in association with oral inulin supplementation improved glycemic and lipid metabolism and ameliorated the systemic inflammatory state, likely reducing cardiovascular risk in CKD patients and this may represent a promising therapeutic option, also improving quality of life and mood.",2020,"Moreover, at T2 the intervention group showed a reduction in serum insulin ( p = 0.008) and fasting glucose levels ( p = 0.022), HOMA-IR ( p = 0.004), as well as lower total serum cholesterol ( p = 0.012), triglycerides ( p = 0.016), C-reactive protein ( p = 0.044) and homocysteine ( p = 0.044) and higher HDL ( p < 0.001) with respect to baseline.","['Chronic Kidney Disease Patients', 'chronic kidney disease (CKD', 'CKD patients', '41 patients were enrolled: 18 in the intervention group and 23 in the control group']","['CKD', 'Prebiotic Therapy with Inulin Associated with Low Protein Diet', 'low-protein diet (LPD)-with or without oral inulin supplementation', 'LPD', 'oral inulin supplementation', 'control group treated with LPD without inulin']","['serum nitrogen and phosphorus', 'fasting glucose levels', 'total serum cholesterol', 'triglycerides', 'cardiovascular risk', 'HOMA-IR', 'quality of life and functional status indices (SF-36 survey', 'metabolic acidosis', 'instrumental, and psychocognitive assessments (by SF-36 survey and MMSE, HAM-D, BDI-II', 'cognitive state (MMSE', 'homocysteine', 'reduction in serum insulin', 'serum uric acid', 'C-reactive protein', 'quality of life and mood', 'glycemic and lipid metabolism']","[{'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0021936', 'cui_str': 'Inulin'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0242972', 'cui_str': 'Low protein diet'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0028158', 'cui_str': 'Nitrogen'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}, {'cui': 'C1445957', 'cui_str': 'Serum total cholesterol measurement'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0451175', 'cui_str': 'Functional status index'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0220981', 'cui_str': 'Metabolic acidosis'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0030481', 'cui_str': 'Human T-cell lymphotropic virus 1-associated myelopathy'}, {'cui': 'C0006448', 'cui_str': 'Burundi'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0019878', 'cui_str': 'Homocysteine'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0455272', 'cui_str': 'Serum urate measurement'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}]",41.0,0.0147668,"Moreover, at T2 the intervention group showed a reduction in serum insulin ( p = 0.008) and fasting glucose levels ( p = 0.022), HOMA-IR ( p = 0.004), as well as lower total serum cholesterol ( p = 0.012), triglycerides ( p = 0.016), C-reactive protein ( p = 0.044) and homocysteine ( p = 0.044) and higher HDL ( p < 0.001) with respect to baseline.","[{'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Lai', 'Affiliation': 'Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.'}, {'ForeName': 'Sandro', 'Initials': 'S', 'LastName': 'Mazzaferro', 'Affiliation': 'Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Muscaritoli', 'Affiliation': 'Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Mastroluca', 'Affiliation': 'Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Testorio', 'Affiliation': 'Department of Obstetrical-Gynecological Sciences and Urologic Sciences, Unit of Nephrology, Sapienza University of Rome, 00161 Rome, Italy.'}, {'ForeName': 'Adolfo', 'Initials': 'A', 'LastName': 'Perrotta', 'Affiliation': 'Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.'}, {'ForeName': 'Ylenia', 'Initials': 'Y', 'LastName': 'Esposito', 'Affiliation': 'Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Carta', 'Affiliation': 'Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Campagna', 'Affiliation': 'Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Di Grado', 'Affiliation': 'Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.'}, {'ForeName': 'Cesarina', 'Initials': 'C', 'LastName': 'Ramaccini', 'Affiliation': 'Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'De Leo', 'Affiliation': 'Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Galani', 'Affiliation': 'Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy.'}, {'ForeName': 'Maria Ida', 'Initials': 'MI', 'LastName': 'Amabile', 'Affiliation': 'Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.'}, {'ForeName': 'Alessio', 'Initials': 'A', 'LastName': 'Molfino', 'Affiliation': 'Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.'}]",Toxins,['10.3390/toxins12060381'] 1489,32526892,Immediate Effect of Balance Taping Using Kinesiology Tape on Dynamic and Static Balance after Ankle Muscle Fatigue.,"The objective of this study was to investigate whether ankle balance taping (ABT) applied after muscle fatigue-inducing exercise can cause immediate improvements in dynamic and static balance. A total of 31 adults (16 males and 15 females) met the inclusion criteria. The experiment was designed using a single-blinded, randomized controlled trial. Changes in static and dynamic balance were measured before and after inducing muscle fatigue in the ankles and after ABT or ankle placebo taping (APT). After ankle muscle fatigue-inducing exercise, both the ABT and APT groups showed significant increases in surface area ellipses in the static state with eyes open ( p < 0.05), and significant increases in surface area ellipses in the static and dynamic states with eyes closed (both p < 0.05). After taping of the fatigued ankle, surface area ellipses decreased significantly when eyes were open and closed in the static and dynamic states, but only in the ABT group ( p < 0.05). Static balance was significantly different between groups (eyes open, 36.2 ± 86; eyes closed, 22.9 ± 46.7). Dynamic balance was significantly different between groups (eyes open, 68.6 ± 152.1; eyes closed, 235.8 ± 317.6). ABT may help prevent ankle injuries in individuals who experience muscle fatigue around the ankles after sports and daily activities.",2020,"After ankle muscle fatigue-inducing exercise, both the ABT and APT groups showed significant increases in surface area ellipses in the static state with eyes open ( p < 0.05), and significant increases in surface area ellipses in the static and dynamic states with eyes closed (both p < 0.05).","['31 adults (16 males and 15 females) met the inclusion criteria', 'after Ankle Muscle Fatigue']","['Balance Taping Using Kinesiology Tape', 'ABT', 'ankle balance taping (ABT']","['surface area ellipses', 'Static balance', 'static and dynamic balance', 'Dynamic and Static Balance', 'Dynamic balance']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0242979', 'cui_str': 'Muscle fatigue'}]","[{'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0034115', 'cui_str': 'Centesis'}, {'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}]","[{'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}]",31.0,0.0281186,"After ankle muscle fatigue-inducing exercise, both the ABT and APT groups showed significant increases in surface area ellipses in the static state with eyes open ( p < 0.05), and significant increases in surface area ellipses in the static and dynamic states with eyes closed (both p < 0.05).","[{'ForeName': 'Hyun-Su', 'Initials': 'HS', 'LastName': 'Choi', 'Affiliation': 'Department of Biomedical Health Science, Graduate School, Dong-Eui University, Busan 47340, Korea.'}, {'ForeName': 'Jung-Hoon', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Therapy, College of Nursing, Healthcare Sciences and Human Ecology, Dong-Eui University, Busan 47340, Korea.'}]","Healthcare (Basel, Switzerland)",['10.3390/healthcare8020162'] 1490,32533548,The Effectiveness of Acceptance and Commitment Therapy on Pain Acceptance and Pain Perception in Patients with Painful Diabetic Neuropathy: A Randomized Controlled Trial.,"INTRODUCTION Neuropathic pain is a complex phenomenon in patients with diabetes. These patients have many problems, such as psychological problems, high-level pain perception, and pain acceptance. This study aimed to evaluate the effectiveness of acceptance and commitment therapy on pain acceptance and pain perception in patients with painful diabetic neuropathy. METHODS This study was performed according to the clinical trial method. The sample size was 50 participants. In this study, participants were divided into interventional and control groups. According to the diagnosis of neurologists, all participants received conventional medications to manage neuropathic pain. The intervention group received acceptance and commitment therapy for eight sessions. The results in the three phases of pre-test, post-test, and follow-up were evaluated. After completing the study, to comply with ethical standards, the control group received psycho-education. The tools used were the McGill Pain Questionnaire (MPQ) and the Chronic Pain Acceptance Questionnaire (CPAQ). Statistical analysis includes mean, standard deviation, and repeated-measures (ANOVA) conducted by SPSS software version 22. RESULTS The results demonstrated that in the post-test and follow-up phases, acceptance and commitment therapy could improve pain acceptance and reduce pain perception in the intervention group compared to the control group (P < 0.01). CONCLUSION The results indicated that acceptance and commitment therapy could be used as a psychological intervention besides pharmacotherapy to improve pain acceptance and reduce pain perception in patients with painful diabetic neuropathy. CLINICAL TRAIL REGISTRATION This study was registered at the Iranian Registry of Clinical Trials (IRCT20180205038630N4).",2020,"The results demonstrated that in the post-test and follow-up phases, acceptance and commitment therapy could improve pain acceptance and reduce pain perception in the intervention group compared to the control group (P < 0.01). ","['patients with diabetes', 'Patients with Painful Diabetic Neuropathy', 'patients with painful diabetic neuropathy']","['psycho-education', 'acceptance and commitment therapy', 'conventional medications', 'Acceptance and Commitment Therapy']","['pain acceptance and reduce pain perception', 'Pain Acceptance and Pain Perception', 'McGill Pain Questionnaire (MPQ) and the Chronic Pain Acceptance Questionnaire (CPAQ', 'pain\xa0acceptance and pain perception']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751074', 'cui_str': 'Neuralgia, Diabetic'}]","[{'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0024985', 'cui_str': 'McGill pain chart questionnaire'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",50.0,0.0546189,"The results demonstrated that in the post-test and follow-up phases, acceptance and commitment therapy could improve pain acceptance and reduce pain perception in the intervention group compared to the control group (P < 0.01). ","[{'ForeName': 'Amir Abbas', 'Initials': 'AA', 'LastName': 'Taheri', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Ali Akbar', 'Initials': 'AA', 'LastName': 'Foroughi', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran. aliakbar.Foroughi@kums.ac.ir.'}, {'ForeName': 'Youkhabeh', 'Initials': 'Y', 'LastName': 'Mohammadian', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Seyed Mojtaba', 'Initials': 'SM', 'LastName': 'Ahmadi', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Khatereh', 'Initials': 'K', 'LastName': 'Heshmati', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Leila Afshar', 'Initials': 'LA', 'LastName': 'Hezarkhani', 'Affiliation': 'Department of Neurology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Ali Akbar', 'Initials': 'AA', 'LastName': 'Parvizifard', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00851-9'] 1491,32533796,Attachment & Child Health (ATTACH) pilot trials: Effect of parental reflective function intervention for families affected by toxic stress.,"Toxic stressors (e.g., parental violence, depression, low income) place children at risk for insecure attachment. Parental reflective function-parents' capacity to understand their own and their child's mental states and thus regulate their own feelings and behavior toward their child-may buffer the negative effects of toxic stress on attachment. Our objective was to test the effectiveness of the Attachment and Child Health (ATTACH) intervention, focusing on improving reflective function and children's attachment security, for at-risk mothers and children <36 months of age. Three pilot studies were conducted with women and children from an inner city agency serving vulnerable, low-income families and a family violence shelter. Randomized control trial (n = 20, n = 10 at enrollment) and quasi-experimental (n = 10 at enrollment) methods tested the effect of the ATTACH intervention on the primary outcome of reflective function scores, from transcribed Parent Development Interviews. Our secondary outcome was children's attachment patterns from Ainsworth's Strange Situation Procedure. Despite some attrition, mixed methods analysis of covariance and t tests revealed significant differences in maternal, child, and overall reflective function, with moderate effect sizes. While more children whose mothers received the ATTACH program were securely attached posttreatment, as compared with controls, significant differences were not observed, which may be due to missing observations (n = 5 cases). Understanding the effectiveness of programs like the ATTACH intervention contributes to improved programs and services to promote healthy development of children affected by toxic stress.",2020,Understanding the effectiveness of programs like the ATTACH intervention contributes to improved programs and services to promote healthy development of children affected by toxic stress.,"['risk mothers and children <36 months of age', 'families affected by toxic stress', 'women and children from an inner city agency serving vulnerable, low-income families and a family violence shelter']","['parental reflective function intervention', 'ATTACH intervention', 'Attachment and Child Health (ATTACH) intervention']","['Toxic stressors (e.g., parental violence, depression, low income) place children at risk for insecure attachment']","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0557849', 'cui_str': 'Inner city'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0206072', 'cui_str': 'Family Violence'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0008078', 'cui_str': 'Child health care'}]","[{'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0425119', 'cui_str': 'Child at risk'}, {'cui': 'C0582758', 'cui_str': 'Insecure attachment'}]",,0.0662825,Understanding the effectiveness of programs like the ATTACH intervention contributes to improved programs and services to promote healthy development of children affected by toxic stress.,"[{'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Letourneau', 'Affiliation': 'Faculty of Nursing and Cumming School of Medicine, Departments of Pediatrics, Psychiatry, & Community Health Sciences, University of Calgary, Calgary, Alberta, Canada, T2N 1N4.'}, {'ForeName': 'Lubna', 'Initials': 'L', 'LastName': 'Anis', 'Affiliation': ""Owerko Centre at the Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada, T2N 1N4.""}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Ntanda', 'Affiliation': ""Owerko Centre at the Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada, T2N 1N4.""}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Novick', 'Affiliation': ""Owerko Centre at the Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada, T2N 1N4.""}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Steele', 'Affiliation': 'Department of Psychology, The New School, New York City, NY, 1011.'}, {'ForeName': 'Howard', 'Initials': 'H', 'LastName': 'Steele', 'Affiliation': 'Department of Psychology, The New School, New York City, NY, 1011.'}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Hart', 'Affiliation': ""Owerko Centre at the Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada, T2N 1N4.""}]",Infant mental health journal,['10.1002/imhj.21833'] 1492,32682992,Characterizing the analgesic effects of real and imagined acupuncture using functional and structure MRI.,"Acupuncture and imagery interventions for pain management have a long history. The present study comparatively investigated whether acupuncture and video-guided acupuncture imagery treatment (VGAIT, watching a video of acupuncture on the participant's own body while imagining it being applied) could modulate brain regional connectivity to produce analgesic effects. The study also examined whether pre-intervention brain functional and structural features could be used to predict the magnitude of analgesic effects. Twenty-four healthy participants were recruited and received four different interventions (real acupuncture, sham acupuncture, VGAIT, and VGAIT control) in random order using a cross-over design. Pain thresholds and magnetic resonance imaging (MRI) data were collected before and after each intervention. We first compared the modulatory effects of real acupuncture and VGAIT on intra- and inter-regional intrinsic brain connectivity and found that real acupuncture decreased regional homogeneity (ReHo) and functional connectivity (FC) in sensorimotor areas, whereas VGAIT increased ReHo in basal ganglia (BG) (i.e., putamen) and FC between the BG subcortical network and default mode network. The altered ReHo and FC were associated with changes in pain threshold after real acupuncture and VGAIT, respectively. A multimodality fusion approach with pre-intervention ReHo and grey matter volume (GMV) as features was used to explore the brain profiles underlying individual variability of pain threshold changes by real acupuncture and VGAIT. Variability in acupuncture responses was associated with ReHo and GMV in BG, whereas VGAIT responses were associated with ReHo and GMV in the anterior insula. These results suggest that through different pathways both real acupuncture and VGAIT can modulate brain systems to produce analgesic effects.",2020,"The altered ReHo and FC were associated with changes in pain threshold after real acupuncture and VGAIT, respectively.",['Twenty-four healthy participants'],"['real acupuncture and VGAIT', 'acupuncture and video-guided acupuncture imagery treatment (VGAIT, watching a video of acupuncture', 'pre-intervention ReHo and grey matter volume (GMV', 'interventions (real acupuncture, sham acupuncture, VGAIT, and VGAIT control', 'Acupuncture and imagery interventions']","['pain threshold', 'Pain thresholds and magnetic resonance imaging (MRI) data', 'regional homogeneity (ReHo) and functional connectivity (FC']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]",24.0,0.0799386,"The altered ReHo and FC were associated with changes in pain threshold after real acupuncture and VGAIT, respectively.","[{'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Cao', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.'}, {'ForeName': 'Yiheng', 'Initials': 'Y', 'LastName': 'Tu', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.'}, {'ForeName': 'Georgia', 'Initials': 'G', 'LastName': 'Wilson', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.'}, {'ForeName': 'Scott P', 'Initials': 'SP', 'LastName': 'Orr', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Kong', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA; Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. Electronic address: jkong2@mgh.harvard.edu.'}]",NeuroImage,['10.1016/j.neuroimage.2020.117176'] 1493,32531982,"Intestinal Permeability in Children with Celiac Disease after the Administration of Oligofructose-Enriched Inulin into a Gluten-Free Diet-Results of a Randomized, Placebo-Controlled, Pilot Trial.","Abnormalities in the intestinal barrier are a possible cause of celiac disease (CD) development. In animal studies, the positive effect of prebiotics on the improvement of gut barrier parameters has been observed, but the results of human studies to date remain inconsistent. Therefore, this study aimed to evaluate the effect of twelve-week supplementation of a gluten-free diet (GFD) with prebiotic oligofructose-enriched inulin (10 g per day) on the intestinal permeability in children with CD treated with a GFD. A pilot, randomized, placebo-controlled nutritional intervention was conducted in 34 children with CD, being on a strict GFD. Sugar absorption test (SAT) and the concentrations of intestinal permeability markers, such as zonulin, intestinal fatty acid-binding protein, claudin-3, calprotectin, and glucagon-like peptide-2, were measured. We found that the supplementation with prebiotic did not have a substantial effect on barrier integrity. Prebiotic intake increased excretion of mannitol, which may suggest an increase in the epithelial surface. Most children in our study seem to have normal values for intestinal permeability tests before the intervention. For individuals with elevated values, improvement in calprotectin and SAT was observed after the prebiotic intake. This preliminary study suggests that prebiotics may have an impact on the intestinal barrier, but it requires confirmation in studies with more subjects with ongoing leaky gut.",2020,"Sugar absorption test (SAT) and the concentrations of intestinal permeability markers, such as zonulin, intestinal fatty acid-binding protein, claudin-3, calprotectin, and glucagon-like peptide-2, were measured.","['subjects with ongoing leaky gut', 'children with CD treated with a GFD', '34 children with CD, being on a strict GFD', 'Children with Celiac Disease after the Administration of Oligofructose-Enriched Inulin into a Gluten-Free Diet']","['placebo-controlled nutritional intervention', 'Placebo', 'gluten-free diet (GFD) with prebiotic oligofructose-enriched inulin']","['calprotectin and SAT', 'Intestinal Permeability', 'barrier integrity', 'Sugar absorption test (SAT) and the concentrations of intestinal permeability markers, such as zonulin, intestinal fatty acid-binding protein, claudin-3, calprotectin, and glucagon-like peptide-2']","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0007570', 'cui_str': 'Celiac disease'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0344351', 'cui_str': 'Gluten free diet'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0907858', 'cui_str': 'oligofructose'}, {'cui': 'C0021936', 'cui_str': 'Inulin'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0344351', 'cui_str': 'Gluten free diet'}, {'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C0907858', 'cui_str': 'oligofructose'}, {'cui': 'C0021936', 'cui_str': 'Inulin'}]","[{'cui': 'C0950624', 'cui_str': 'Calprotectin'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0031164', 'cui_str': 'Permeability'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0914216', 'cui_str': 'zonulin'}, {'cui': 'C0163314', 'cui_str': 'Intestinal Fatty Acid-Binding Protein'}, {'cui': 'C0912332', 'cui_str': 'Glucagon-like peptide 2'}]",34.0,0.205677,"Sugar absorption test (SAT) and the concentrations of intestinal permeability markers, such as zonulin, intestinal fatty acid-binding protein, claudin-3, calprotectin, and glucagon-like peptide-2, were measured.","[{'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Drabińska', 'Affiliation': 'Department of Chemistry and Biodynamics of Food, Institute of Animal Reproduction and Food Research of Polish Academy of Sciences, 10-748 Olsztyn, Poland.'}, {'ForeName': 'Urszula', 'Initials': 'U', 'LastName': 'Krupa-Kozak', 'Affiliation': 'Department of Chemistry and Biodynamics of Food, Institute of Animal Reproduction and Food Research of Polish Academy of Sciences, 10-748 Olsztyn, Poland.'}, {'ForeName': 'Elżbieta', 'Initials': 'E', 'LastName': 'Jarocka-Cyrta', 'Affiliation': 'Department of Pediatrics, Gastroenterology, and Nutrition, Collegium Medicum, University of Warmia & Mazury, 10-719 Olsztyn, Poland.'}]",Nutrients,['10.3390/nu12061736'] 1494,32532631,Lower donor site morbidity and higher patient satisfaction with epidermal grafting in comparison to split thickness skin grafting: A randomized controlled trial (EPIGRAAFT Trial).,"BACKGROUND Split thickness skin grafting (SSG) is an important modality for wound coverage; however, it leads to donor site morbidity. Epidermal grafting (EG) is a promising option for autologous skin grafting which offers minimal donor site morbidity, though it is not known if EG is an effective clinical alternative for SSG. This study compared the efficacy of EG as an alternative to SSG in terms of wound healing outcomes, donor site morbidity, patient satisfaction and adverse events. METHODS EPIGRAAFT is a Phase 2, randomized, open-label trial with two parallel groups: EG and SSG. Patients referred for skin grafting with a healthy granulating wound bed were included. The co-primary endpoints were the proportion of wounds healed and donor site healing time. The secondary endpoints include donor site morbidity measured using Vancouver Scar Scale, mean time for complete wound healing, patient satisfaction assessed using a validated skin grafting questionnaire and incidence of adverse events. RESULTS Of the 61 patients screened, 44 patients were randomized. There was no difference in the proportion of wounds healed at 6 weeks (p=0.366) and 3 months(p=0.24) as well as the mean time for wound healing (p=0.12). EG resulted in lower donor site morbidity (p=0.001), faster donor site healing time (EG: 4.86 days vs. SSG: 21.32 days) (p<0.0001), and higher overall satisfaction (p<0.001). There were no adverse events reported. CONCLUSION This study demonstrated that EG has superior donor site outcomes with faster donor site healing and lower morbidity compared to SSG, while having comparable wound healing outcomes. Patients receiving EG also experienced higher donor site satisfaction compared to SSG. ClinicalTrials.gov identifier: NCT02535481.",2020,"EG resulted in lower donor site morbidity (p=0.001), faster donor site healing time (EG: 4.86 days vs. SSG: 21.32 days) (p<0.0001), and higher overall satisfaction (p<0.001).","['Patients referred for skin grafting with a healthy granulating wound bed were included', '61 patients screened, 44 patients were randomized']","['Split thickness skin grafting (SSG', 'split thickness skin grafting', 'Epidermal grafting (EG']","['overall satisfaction', 'mean time for wound healing', 'lower donor site morbidity', 'faster donor site healing time', 'proportion of wounds healed and donor site healing time', 'higher donor site satisfaction', 'wound healing outcomes, donor site morbidity, patient satisfaction and adverse events', 'donor site morbidity measured using Vancouver Scar Scale, mean time for complete wound healing, patient satisfaction assessed using a validated skin grafting questionnaire and incidence of adverse events', 'proportion of wounds healed', 'Lower donor site morbidity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0037297', 'cui_str': 'Grafting to skin'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0423756', 'cui_str': 'Thickness of skin'}, {'cui': 'C0439061', 'cui_str': 'Split thickness skin graft (procedure)'}, {'cui': 'C0014520', 'cui_str': 'Epidermis structure'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1444716', 'cui_str': 'Donor site'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0037297', 'cui_str': 'Grafting to skin'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",44.0,0.0865935,"EG resulted in lower donor site morbidity (p=0.001), faster donor site healing time (EG: 4.86 days vs. SSG: 21.32 days) (p<0.0001), and higher overall satisfaction (p<0.001).","[{'ForeName': 'Muholan', 'Initials': 'M', 'LastName': 'Kanapathy', 'Affiliation': 'Division of Surgery & Interventional Science, University College London, United Kingdom; Department of Plastic and Reconstructive Surgery, Royal Free NHS Foundation Trust Hospital, London, United Kingdom.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Bystrzonowski', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Royal Free NHS Foundation Trust Hospital, London, United Kingdom.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Hachach-Haram', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Royal Free NHS Foundation Trust Hospital, London, United Kingdom.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Twyman', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Royal Free NHS Foundation Trust Hospital, London, United Kingdom.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Becker', 'Affiliation': 'Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Institute of Medical Biology, A*Star, Immunos, Biomedical Grove, Singapore.'}, {'ForeName': 'Toby', 'Initials': 'T', 'LastName': 'Richards', 'Affiliation': 'Division of Surgery & Interventional Science, University College London, United Kingdom; Faculty of Health and Medical Sciences, University of Western Australia. Electronic address: toby.richards@uwa.edu.au.'}, {'ForeName': 'Afshin', 'Initials': 'A', 'LastName': 'Mosahebi', 'Affiliation': 'Division of Surgery & Interventional Science, University College London, United Kingdom; Department of Plastic and Reconstructive Surgery, Royal Free NHS Foundation Trust Hospital, London, United Kingdom.'}]","Journal of plastic, reconstructive & aesthetic surgery : JPRAS",['10.1016/j.bjps.2020.03.006'] 1495,32534250,External trigeminal nerve stimulation for drug resistant epilepsy: A randomized controlled trial.,"BACKGROUND External trigeminal nerve stimulation (ETNS) is an emergent, non-invasive neurostimulation therapy delivered bilaterally with adhesive skin electrodes. In previous studies, ETNS was associated to a decrease in seizure frequency in patients with focal drug-resistant epilepsy (DRE). OBJECTIVE To determine the long-term efficacy and tolerability of ETNS in patients with focal DRE. Moreover, to explore whether its efficacy depends on the epileptogenic zone (frontal or temporal), and its impact on mood, cognitive function, quality of life, and trigeminal nerve excitability. METHODS Forty consecutive patients with frontal or temporal DRE, unsuitable for surgery, were randomized to ETNS or usual medical treatment. Participants were evaluated at 3, 6 and 12 months for efficacy, side effects, mood scales, neuropsychological tests and trigeminal nerve excitability. RESULTS Subjects had a median of 15 seizures per month and had tried a median of 12.5 antiepileptic drugs. At 12 months, percentage of responders was 50% in ETNS group and 0% in control group. Seizure frequency in ETNS group decreased by -43.5% from baseline. Temporal epilepsy subgroup responded better than frontal epilepsy subgroup (55.56% vs. 45.45%, respectively). Median stimulation intensity was 6.2 mA. ETNS improved quality of life, but not anxiety or depression. Long-term ETNS affected neither neuropsychological function, nor trigeminal nerve excitability. No relevant adverse events were observed. CONCLUSIONS ETNS is an effective and well-tolerated therapy for focal DRE. Patients with temporal epilepsy showed a better response than those with frontal epilepsy. Future studies with larger populations may define its role compared to other neurostimulation techniques. CLASSIFICATION OF EVIDENCE This study provides Class II evidence that ETNS reduces seizure frequency in patients with focal DRE.",2020,"Temporal epilepsy subgroup responded better than frontal epilepsy subgroup (55.56% vs. 45.45%, respectively).","['Patients with temporal epilepsy', 'Subjects had a median of 15 seizures per month and had tried a median of 12.5 antiepileptic drugs', 'patients with focal drug-resistant epilepsy (DRE', 'drug resistant epilepsy', 'Forty consecutive patients with frontal or temporal DRE, unsuitable for surgery', 'patients with focal DRE']","['ETNS or usual medical treatment', 'External trigeminal nerve stimulation (ETNS', 'ETNS', 'External trigeminal nerve stimulation']","['quality of life', 'seizure frequency', 'neuropsychological function, nor trigeminal nerve excitability', 'efficacy, side effects, mood scales, neuropsychological tests and trigeminal nerve excitability', 'Seizure frequency', 'Median stimulation intensity', 'adverse events', 'anxiety or depression', 'mood, cognitive function, quality of life, and trigeminal nerve excitability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442043', 'cui_str': 'Temporal'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C0003299', 'cui_str': 'ANTIEPILEPTICS'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C1096063', 'cui_str': 'Refractory epilepsy'}, {'cui': 'C0205123', 'cui_str': 'Coronal'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0040996', 'cui_str': 'Trigeminal nerve structure'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0149775', 'cui_str': 'Fit frequency'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0040996', 'cui_str': 'Trigeminal nerve structure'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",40.0,0.130105,"Temporal epilepsy subgroup responded better than frontal epilepsy subgroup (55.56% vs. 45.45%, respectively).","[{'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Gil-López', 'Affiliation': ""Epilepsy Unit, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain, Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. Electronic address: fran.gil.lopez@gmail.com.""}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Boget', 'Affiliation': 'Epilepsy Unit, Department of Neuropsychology, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Manzanares', 'Affiliation': ""Epilepsy Unit, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain, Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.""}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Donaire', 'Affiliation': ""Epilepsy Unit, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain, Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.""}, {'ForeName': 'Estefanía', 'Initials': 'E', 'LastName': 'Conde-Blanco', 'Affiliation': ""Epilepsy Unit, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain, Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.""}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Baillés', 'Affiliation': 'Epilepsy Unit, Department of Psychiatry, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Pintor', 'Affiliation': 'Epilepsy Unit, Department of Psychiatry, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Setoaín', 'Affiliation': 'Epilepsy Unit, Department of Nuclear Medicine, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Núria', 'Initials': 'N', 'LastName': 'Bargalló', 'Affiliation': 'Epilepsy Unit, Department of Neurorradiology, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Navarro', 'Affiliation': 'Electromyography Unit, Neurophysiology, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Casanova', 'Affiliation': 'Electromyography Unit, Neurophysiology, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Valls', 'Affiliation': 'Electromyography Unit, Neurophysiology, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Roldán', 'Affiliation': 'Epilepsy Unit, Department of Neurosurgery, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Rumià', 'Affiliation': 'Epilepsy Unit, Department of Neurosurgery, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Georgina', 'Initials': 'G', 'LastName': 'Casanovas', 'Affiliation': 'Medical Statistics Core Facility, IDIBAPS-Hospital Clínic, Barcelona, Spain.'}, {'ForeName': 'Gema', 'Initials': 'G', 'LastName': 'Domenech', 'Affiliation': 'Medical Statistics Core Facility, IDIBAPS-Hospital Clínic, Barcelona, Spain.'}, {'ForeName': 'Ferrán', 'Initials': 'F', 'LastName': 'Torres', 'Affiliation': 'Medical Statistics Core Facility, IDIBAPS-Hospital Clínic, Barcelona, Spain.'}, {'ForeName': 'Mar', 'Initials': 'M', 'LastName': 'Carreño', 'Affiliation': ""Epilepsy Unit, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain, Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.""}]",Brain stimulation,['10.1016/j.brs.2020.06.005'] 1496,32534252,"Two weeks of image-guided left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation improves smoking cessation: A double-blind, sham-controlled, randomized clinical trial.","BACKGROUND Previous studies have found that repetitive transcranial magnetic stimulation (rTMS) to the left dorsal lateral prefrontal cortex (LDLPFC) transiently reduces smoking craving, decreases cigarette consumption, and increases abstinence rates. OBJECTIVE We investigated whether 10 daily MRI-guided rTMS sessions over two weeks to the LDLPFC paired with craving cues could reduce cigarette consumption and induce smoking cessation. METHODS We enrolled 42 treatment-seeking nicotine-dependent smokers (≥10 cigarettes per day) in a randomized, double-blind, sham-controlled trial. Participants received 10 daily sessions over 2 weeks of either active or sham MRI-guided rTMS (10Hz, 3000 pulses each session) to the LDLPFC concurrently with video smoking cues. The primary outcome was a reduction in biochemically confirmed cigarette consumption with a secondary outcome of abstinence on the target quit date. We also recorded cue-induced craving and withdrawal symptoms. RESULTS Compared to sham (n = 17), participants receiving active rTMS (n = 21) smoked significantly fewer cigarettes per day during the 2-week treatment (mean [SD], 13.73[9.18] vs. 11.06[9.29], P < .005) and at 1-month follow-up (12.78[9.53] vs. 7.93[7.24], P < .001). Active rTMS participants were also more likely to quit by their target quit rate (23.81%vs. 0%, OR 11.67, 90% CL, 0.96-141.32, x 2  = 4.66, P = .031). Furthermore, rTMS significantly reduced mean craving throughout the treatments and at follow-up (29.93[13.12] vs. 25.01[14.45], P < .001). Interestingly across the active treatment sample, more lateral coil location was associated with more success in quitting (-43.43[0.40] vs. -41.79[2.24], P < .013). CONCLUSIONS Daily MRI-guided rTMS to the LDLPFC for 10 days reduces cigarette consumption and cued craving for up to one month and also increases the likelihood of smoking cessation. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02401672.",2020,"Compared to sham (n=17), participants receiving active rTMS (n=21) smoked significantly fewer cigarettes per day during the 2-week treatment (mean [SD], 13.73[9.18] vs. 11.06[9.29], P<.005) and at 1-month follow-up (12.78[9.53] vs. 7.93[7.24], P<.001).",['enrolled 42 treatment-seeking nicotine-dependent smokers (≥10 cigarettes per day'],"['rTMS', 'Image-guided Left Dorsolateral Prefrontal Cortex Repetitive Transcranial Magnetic Stimulation Improves Smoking Cessation', 'active rTMS', 'repetitive transcranial magnetic stimulation (rTMS', 'LDLPFC paired with craving cues', 'active or sham MRI-guided rTMS (10Hz, 3000 pulses each session) to the LDLPFC concurrently with video smoking cues']","['abstinence on the target quit date', 'likelihood of smoking cessation', 'lateral coil location', 'cigarette consumption and cued craving', 'mean craving', 'likely to quit by their target quit rate']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0439505', 'cui_str': '/day'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0470279', 'cui_str': '3000'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0450424', 'cui_str': 'To the left'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}]","[{'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0011008', 'cui_str': 'Date'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0337671', 'cui_str': 'Ex-smoker'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0419518', 'cui_str': 'Contraceptive coil'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0459840', 'cui_str': 'Cigarette consumption'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}]",42.0,0.428626,"Compared to sham (n=17), participants receiving active rTMS (n=21) smoked significantly fewer cigarettes per day during the 2-week treatment (mean [SD], 13.73[9.18] vs. 11.06[9.29], P<.005) and at 1-month follow-up (12.78[9.53] vs. 7.93[7.24], P<.001).","[{'ForeName': 'Xingbao', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA; Center for Biomedical Imaging, Medical University of South Carolina, Charleston, SC, 29425, USA. Electronic address: lixi@musc.edu.'}, {'ForeName': 'Karen J', 'Initials': 'KJ', 'LastName': 'Hartwell', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, 29401, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Henderson', 'Affiliation': 'Center for Biomedical Imaging, Medical University of South Carolina, Charleston, SC, 29425, USA.'}, {'ForeName': 'Bashar W', 'Initials': 'BW', 'LastName': 'Badran', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA.'}, {'ForeName': 'Kathleen T', 'Initials': 'KT', 'LastName': 'Brady', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, 29401, USA.'}, {'ForeName': 'Mark S', 'Initials': 'MS', 'LastName': 'George', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, 29401, USA.'}]",Brain stimulation,['10.1016/j.brs.2020.06.007'] 1497,32534376,Fatty acid desaturation in red blood cell membranes of patients with type 2 diabetes is improved by zinc supplementation.,"BACKGROUND/OBJECTIVE Membrane flexibility can be a determining factor in pathophysiological mechanisms of type 2 diabetes (T2D). As a cofactor of delta-5 desaturase (D5D) and delta-6 desaturase (D6D), and gene expression regulator, zinc may play a role modulating membrane flexibility by increasing membrane polyunsaturated fatty acids (PUFA) abundance. The objective of this study was to evaluate the effect of a 24-month zinc supplementation (30 mg elemental zinc) on membrane fatty acid composition in patients with T2D. SUBJECTS/METHODS Sixty patients with T2D were evaluated. Thirty were randomly assigned to the zinc supplemented group and thirty to the placebo group. Fatty acid composition in red blood cell (RBC) membranes was determined by gas chromatography. Expression of gene encoding for D5D (FADS1), and D6D (FADS2) were evaluated in peripheral blood mononuclear cells by real-time polymerase chain reaction. RESULTS After 24 months of supplementation, a greater abundance of docosapentaenoic acid (C22:5 n-3), arachidonic acid (C20:4 n-6), adrenic acid (C22:4 n-6), and total n-6 PUFA was found (p = 0.001, p = 0.007, p = 0.033, p = 0.048, respectively). The unsaturated fatty acids/saturated fatty acids ratio, and unsaturation index was increased in the zinc supplemented group at month 24 (p = 0.003 and p  = 0.000, respectively). FADS1 gene was upregulated in the zinc group in relation to placebo at month 12 (p = 0.020). CONCLUSIONS Supplementation with 30 mg/d elemental zinc during 24 months in patients with T2D had an effect on the composition of RBC membranes increasing PUFA abundance and in turn, improving membrane flexibility. This effect may be mediated by induction of D5D gene expression.",2020,"FADS1 gene was upregulated in the zinc group in relation to placebo at month 12 (p = 0.020). ","['patients with T2D', 'Sixty patients with T2D were evaluated', 'patients with type 2 diabetes']","['Fatty acid desaturation', 'zinc supplementation (30\u202fmg elemental zinc', 'placebo']","['membrane flexibility', 'Expression of gene encoding for D5D (FADS1), and D6D (FADS2', 'Fatty acid composition in red blood cell (RBC) membranes', 'abundance of docosapentaenoic acid (C22:5 n-3), arachidonic acid (C20:4 n-6), adrenic acid (C22:4 n-6), and total n-6 PUFA', 'FADS1 gene', 'unsaturated fatty acids/saturated fatty acids ratio, and unsaturation index', 'membrane fatty acid composition']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}, {'cui': 'C4524022', 'cui_str': 'Zinc supplementation'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0057338', 'cui_str': 'delta-5 fatty acid desaturase'}, {'cui': 'C0065017', 'cui_str': 'Linoleoyl-CoA desaturase'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0058624', 'cui_str': 'docosapentaenoic acid'}, {'cui': 'C0003695', 'cui_str': 'Arachidonic acid'}, {'cui': 'C0050877', 'cui_str': 'adrenic acid'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1276035', 'cui_str': 'Pena-Shokeir syndrome type I'}, {'cui': 'C0015690', 'cui_str': 'Unsaturated fatty acid'}, {'cui': 'C0597423', 'cui_str': 'Saturated fat'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",60.0,0.126956,"FADS1 gene was upregulated in the zinc group in relation to placebo at month 12 (p = 0.020). ","[{'ForeName': 'María Catalina', 'Initials': 'MC', 'LastName': 'Hernández', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Rojas', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Carrasco', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Basfi-Fer', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Valenzuela', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Juana', 'Initials': 'J', 'LastName': 'Codoceo', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Inostroza', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Ruz', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile. Electronic address: mruz@med.uchile.cl.'}]",Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS),['10.1016/j.jtemb.2020.126571'] 1498,32539487,Cognition test battery: Adjusting for practice and stimulus set effects for varying administration intervals in high performing individuals.,"INTRODUCTION Practice effects associated with the repeated administration of cognitive tests often confound true therapeutic or experimental effects. Alternate test forms help reduce practice effects, but generating stimulus sets with identical properties can be difficult. The main objective of this study was to disentangle practice and stimulus set effects for Cognition , a battery of 10 brief cognitive tests specifically designed for high-performing populations with 15 unique versions for repeated testing. A secondary objective was to investigate the effects of test-retest interval on practice effects. METHODS The 15 versions of Cognition were administered in three groups of 15-16 subjects (total N = 46, mean±SD age 32.5 ± 7.2 years, range 25-54 years, 23 male) in a randomized but balanced fashion with administration intervals of ≥10 days, ≤5 days, or 4 times per day. Mixed effect models were used to investigate linear and logarithmic trends across repeated administrations in key speed and accuracy outcomes, whether these trends differed significantly between administration interval groups, and whether stimulus sets differed significantly in difficulty. RESULTS Protracted, non-linear practice effects well beyond the second administration were observed for most of the 10 Cognition tests both in accuracy and speed, but test-retest administration interval significantly affected practice effects only for 3 out of the 10 tests and only in the speed domain. Stimulus set effects were observed for the 6 Cognition tests that use unique sets of stimuli. Factors were established that allow for correcting for both practice and stimulus set effects. CONCLUSIONS Practice effects are pronounced and probably under-appreciated in cognitive testing. The correction factors established in this study are a unique feature of the Cognition battery that can help avoid masking practice effects, address noise generated by differences in stimulus set difficulty, and facilitate interpretation of results from studies with repeated assessments.",2020,"RESULTS Protracted, non-linear practice effects well beyond the second administration were observed for most of the 10 Cognition tests both in accuracy and speed, but test-retest administration interval significantly affected practice effects only for 3 out of the 10 tests and only in the speed domain.","['high-performing populations with 15 unique versions for repeated testing', '15 versions of Cognition were administered in three groups of 15-16 subjects (total N =\xa046, mean±SD age 32.5\xa0±\xa07.2\xa0years, range 25-54\xa0years, 23 male']",[],['Cognition test battery'],"[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517710', 'cui_str': '32.5'}, {'cui': 'C4517857', 'cui_str': '7.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0086582', 'cui_str': 'Male'}]",[],"[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}]",,0.0386009,"RESULTS Protracted, non-linear practice effects well beyond the second administration were observed for most of the 10 Cognition tests both in accuracy and speed, but test-retest administration interval significantly affected practice effects only for 3 out of the 10 tests and only in the speed domain.","[{'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Basner', 'Affiliation': 'Unit for Experimental Psychiatry, Division of Sleep and Chronobiology, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA.'}, {'ForeName': 'Emanuel', 'Initials': 'E', 'LastName': 'Hermosillo', 'Affiliation': 'Unit for Experimental Psychiatry, Division of Sleep and Chronobiology, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA.'}, {'ForeName': 'Jad', 'Initials': 'J', 'LastName': 'Nasrini', 'Affiliation': 'Unit for Experimental Psychiatry, Division of Sleep and Chronobiology, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA.'}, {'ForeName': 'Salil', 'Initials': 'S', 'LastName': 'Saxena', 'Affiliation': 'Unit for Experimental Psychiatry, Division of Sleep and Chronobiology, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA.'}, {'ForeName': 'David F', 'Initials': 'DF', 'LastName': 'Dinges', 'Affiliation': 'Unit for Experimental Psychiatry, Division of Sleep and Chronobiology, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA.'}, {'ForeName': 'Tyler M', 'Initials': 'TM', 'LastName': 'Moore', 'Affiliation': 'Brain Behavior Laboratory, Neuropsychiatry Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA.'}, {'ForeName': 'Ruben C', 'Initials': 'RC', 'LastName': 'Gur', 'Affiliation': 'Brain Behavior Laboratory, Neuropsychiatry Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA.'}]",Journal of clinical and experimental neuropsychology,['10.1080/13803395.2020.1773765'] 1499,32540134,Event-related desynchronization of alpha and beta band neural oscillations predicts speech and limb motor timing deficits in normal aging.,"Normal aging is associated with decline of motor timing mechanisms implicated in planning and execution of movement. Evidence from previous studies has highlighted the relationship between neural oscillatory activities and motor timing processing in neurotypical younger adults; however, it remains unclear how normal aging affects the underlying neural mechanisms of movement in older populations. In the present study, we recorded EEG activities in two groups of younger and older adults while they performed randomized speech and limb motor reaction time tasks cued by temporally predictable and unpredictable sensory stimuli. Our data showed that older adults were significantly slower than their younger counterparts during speech production and limb movement, especially in response to temporally unpredictable sensory stimuli. This behavioral effect was accompanied by significant desynchronization of alpha (7-12 Hz) and beta (13-25 Hz) band neural oscillatory activities in older compared with younger adults, primarily during the preparatory pre-motor phase of responses for speech production and limb movement. In addition, we found that faster motor reaction times in younger adults were significantly correlated with weaker desynchronization of pre-motor alpha and beta band neural activities irrespective of stimulus timing and response modality. However, the pre-motor components of alpha and beta activities were timing-specific in older adults and were more strongly desynchronized in response to temporally predictable sensory stimuli. These findings highlight the role of alpha and beta band neural oscillations in motor timing processing mechanisms and reflect their functional deficits during the planning phase of speech production and limb movement in normal aging.",2020,"Our data showed that older adults were significantly slower than their younger counterparts during speech production and limb movement, especially in response to temporally unpredictable sensory stimuli.","['Normal Aging', 'neurotypical younger adults', 'two groups of younger and older adults', 'older adults']",['randomized speech and limb motor reaction time tasks cued by temporally predictable and unpredictable sensory stimuli'],['faster motor reaction times'],"[{'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}]",,0.0320888,"Our data showed that older adults were significantly slower than their younger counterparts during speech production and limb movement, especially in response to temporally unpredictable sensory stimuli.","[{'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Johari', 'Affiliation': 'Speech Neuroscience Lab, Department of Communication Sciences and Disorders, University of South Carolina, Columbia, SC, United States; Department of Psychology, University of South Carolina, Columbia, SC, United States.'}, {'ForeName': 'Roozbeh', 'Initials': 'R', 'LastName': 'Behroozmand', 'Affiliation': 'Speech Neuroscience Lab, Department of Communication Sciences and Disorders, University of South Carolina, Columbia, SC, United States. Electronic address: r-behroozmand@sc.edu.'}]",Behavioural brain research,['10.1016/j.bbr.2020.112763'] 1500,32540553,Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM).,"BACKGROUND The combination of chemotherapy plus anti HER-2 agents is the mainstay of HER-2 positive advanced breast cancer (ABC) therapy. We conducted a phase II trial testing activity and safety of trastuzumab and metronomic capecitabine/cyclophosphamide (HEX) as first-line therapy in HER-2 positive ABC.
Methods. Patients at first relapse or with synchronous metastasis were treated with trastuzumab (4 mg/kg, biweekly) plus oral capecitabine (1500 mg/daily) and cyclophosphamide (50 mg/daily). Primary endpoint was objective response rate (ORR), secondary endpoints progression-free survival (PFS), clinical benefit rate (CBR; PR + CR + SD for ≥ 24 weeks) and tolerability. Optimal two-stage design was applied. RESULTS Sixty patients with measurable ABC, tumors scored as +3 for HER-2 or FISH +, untreated for advanced disease were enrolled. Median age was 62.5 years, visceral metastases were present in most patients (57.9%). Median number of cycles was 16 (range 1-98). ORR was 56.7% (95% CI, 44.1-68.4%), with 5 CR (8.3%) and 29 PR (48.3%). Fifteen patients had SD (25%). The CBR was 78.2%. Nine progressions were observed (15%). Median PFS was 11 months. One year PFS was 47.7%. Median OS was 45.9 months. Worst toxicities were grade 3 hand-foot syndrome in 2 pts (3.3%), grade 3 anaemia in 2 pts (3.3%), grade 2 nausea in 2 pts (3.3%) and grade 3-4 diarrhea in 2 pts (3.3%). Cardiac toxicity grade 1 was reported in 1 pt. CONCLUSIONS Combination of trastuzumab and metronomic oral chemotherapy has clinical activity. The tolerability was excellent and allowed the prolonged delivery of treatment.",2020,"ORR was 56.7% (95% CI, 44.1-68.4%), with 5 CR (8.3%) and 29 PR (48.3%).","['Patients at first relapse or with synchronous metastasis', 'HER-2 positive advanced breast cancer', 'HER-2 positive advanced breast cancer (ABC) therapy', 'Sixty patients with measurable ABC, tumors scored as\xa0+3 for HER-2 or FISH\xa0+, untreated for advanced disease were enrolled', 'Fifteen patients had SD (25']","['trastuzumab', 'cyclophosphamide', 'chemotherapy plus anti HER-2 agents', 'trastuzumab and metronomic capecitabine/cyclophosphamide (HEX', 'trastuzumab and metronomic oral chemotherapy', 'oral capecitabine', 'Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX']","['Median PFS', 'grade 2 nausea', 'Median OS', 'Worst toxicities', 'grade 3 anaemia', 'ORR', 'objective response rate (ORR), secondary endpoints progression-free survival (PFS), clinical benefit rate (CBR; PR\xa0+\xa0CR\xa0+\xa0SD for\xa0≥\xa024 weeks) and tolerability', 'Cardiac toxicity grade 1', 'tolerability', 'Median number of cycles', 'visceral metastases', 'grade 3-4 diarrhea']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0439580', 'cui_str': 'Synchronous'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}]","[{'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0419073', 'cui_str': 'Oral chemotherapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0475270', 'cui_str': 'G2 grade'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0876994', 'cui_str': 'Cardiotoxicity'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",9.0,0.0480206,"ORR was 56.7% (95% CI, 44.1-68.4%), with 5 CR (8.3%) and 29 PR (48.3%).","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Orlando', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy. Electronic address: laura.orlando68@gmail.com.'}, {'ForeName': 'Vito', 'Initials': 'V', 'LastName': 'Lorusso', 'Affiliation': 'Medical Oncology, Istituto Tumori Giovanni Paolo II, IRCCS, Bari, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Giotta', 'Affiliation': 'Medical Oncology, Istituto Tumori Giovanni Paolo II, IRCCS, Bari, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Di Maio', 'Affiliation': 'Department of Oncology, University of Turin at Ordine Mauriziano Hospital, Turin, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Schiavone', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Palma', 'Initials': 'P', 'LastName': 'Fedele', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Annamaria', 'Initials': 'A', 'LastName': 'Quaranta', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Caliolo', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Mariangela', 'Initials': 'M', 'LastName': 'Ciccarese', 'Affiliation': 'Medical Oncology, Ospedale Vito Fazzi, Lecce, Italy.'}, {'ForeName': 'Margherita', 'Initials': 'M', 'LastName': 'Cinefra', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Sante', 'Initials': 'S', 'LastName': 'Romito', 'Affiliation': 'Medical Oncology, Ospedali Riuniti, Foggia, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Pisconti', 'Affiliation': 'Medical Oncology, Ospedale Moscato, Taranto, Italy.'}, {'ForeName': 'Salvatore Del', 'Initials': 'SD', 'LastName': 'Prete', 'Affiliation': 'Medical Oncology, Ospedale San Giovanni di Dio, Frattamaggiore, Napoli, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Aieta', 'Affiliation': 'Medical Oncology, Ospedale Oncologico Regionale, Rionero in Vulture, Potenza, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Rizzi', 'Affiliation': 'Medical Oncology, Istituto Tumori Giovanni Paolo II, IRCCS, Bari, Italy.'}, {'ForeName': 'Evaristo', 'Initials': 'E', 'LastName': 'Maiello', 'Affiliation': 'Medical Oncology, Ospedale Sollievo Della Sofferenza, IRCCS, San Giovanni Rotondo, Foggia, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Colucci', 'Affiliation': 'Medical Oncology, Istituto Tumori Giovanni Paolo II, IRCCS, Bari, Italy.'}, {'ForeName': 'Saverio', 'Initials': 'S', 'LastName': 'Cinieri', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.06.002'] 1501,32540624,Effects of night-time bicycling visibility aids on vehicle passing distance.,"Bicycling at night is dangerous, with vehicle passing distances being a key concern, given that the main cause of night-time bicycling fatalities is from motorists hitting bicyclists from behind. However, little is known about vehicle passing distances at night or how they are affected by bicyclist visibility. This study assessed the impact of different bicyclist visibility configurations on vehicle passing distances at night-time. Fourteen licenced drivers with normal vision (age 24.2 ± 3.7 years) drove an experimental vehicle with low-beam headlights around a 1-km section of a closed-road circuit at night. Each lap involved passing two bicyclists displaying one of four visibility configurations: Control (red rear-facing light and reflector), Handlebars (control plus two red rear-facing lights on each handlebar), Helmet (control plus one red rear-facing light on the helmet), and Leg Retro-reflectors (control plus retro-reflective strips positioned on the knees and ankles). Participants were instructed to pass each bicyclist at a distance of 1-metre at a speed no greater than 50 km/hr, consistent with Queensland's Minimum Passing Distance rule. Participants completed eight laps, two for each configuration, in a randomised sequence. Passing distance was measured using a vehicle-mounted ultra-sonic sensor (ToughSonic14; Senix). Following each lap, participants rated the difficulty level in judging the 1-metre passing distance, as well as their estimated passing distance. Visibility configuration significantly affected passing distance (p = 0.001), with wider passing distances for the Handlebar configuration (1.54 ± 0.62 m), followed by the Helmet (1.51 ± 0.63 m), Leg Retro-reflectors (1.50 ± 0.62 m) which were all significantly greater than the Control (1.42 ± 0.57 m), but not significantly different from each other. There was also a significant effect of visibility configuration on difficulty rating (p = 0.035), with the Control rated as the most difficult, followed by Helmet, Handlebars and Leg Retro-reflectors. Overall, additional visibility aids resulted in wider vehicle passing distances, likely due to enhanced visual cues for drivers. The findings suggest that bicyclists should incorporate additional visibility aids to encourage safer passing distances of vehicles at night-time.",2020,"Visibility configuration significantly affected passing distance (p = 0.001), with wider passing distances for the Handlebar configuration (1.54 ± 0.62 m), followed by the Helmet (1.51 ± 0.63 m), Leg Retro-reflectors (1.50 ± 0.62 m) which were all significantly greater than the Control (1.42 ± 0.57 m), but not significantly different from each other.",['Fourteen licenced drivers with normal vision (age 24.2\u202f±\u202f3.7 years) drove an experimental vehicle with low-beam headlights around a 1-km section of a closed-road circuit at night'],"['visibility configurations: Control (red rear-facing light and reflector), Handlebars (control plus two red rear-facing lights on each handlebar), Helmet (control plus one red rear-facing light on the helmet), and Leg Retro-reflectors (control plus retro-reflective strips positioned on the knees and ankles', 'night-time bicycling visibility aids']","['visibility configuration on difficulty rating', 'Leg Retro-reflectors']","[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0684312', 'cui_str': 'Vehicle driver'}, {'cui': 'C0234622', 'cui_str': 'Normal vision'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517696', 'cui_str': '3.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0442650', 'cui_str': 'Road'}, {'cui': 'C0240526', 'cui_str': 'Night time'}]","[{'cui': 'C0449830', 'cui_str': 'With configuration'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332575', 'cui_str': 'Red color'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0018884', 'cui_str': 'Helmet'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0185047', 'cui_str': 'Stripping'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0005375', 'cui_str': 'Bicycle'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}]","[{'cui': 'C0449830', 'cui_str': 'With configuration'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}]",,0.0635457,"Visibility configuration significantly affected passing distance (p = 0.001), with wider passing distances for the Handlebar configuration (1.54 ± 0.62 m), followed by the Helmet (1.51 ± 0.63 m), Leg Retro-reflectors (1.50 ± 0.62 m) which were all significantly greater than the Control (1.42 ± 0.57 m), but not significantly different from each other.","[{'ForeName': 'Alex A', 'Initials': 'AA', 'LastName': 'Black', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia. Electronic address: aa.black@qut.edu.au.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Duff', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Madeline', 'Initials': 'M', 'LastName': 'Hutchinson', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Ng', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Kirby', 'Initials': 'K', 'LastName': 'Phillips', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Katelyn', 'Initials': 'K', 'LastName': 'Rose', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Abby', 'Initials': 'A', 'LastName': 'Ussher', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Joanne M', 'Initials': 'JM', 'LastName': 'Wood', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}]",Accident; analysis and prevention,['10.1016/j.aap.2020.105636'] 1502,32540878,Ultrasonographic needle tip tracking for in-plane infraclavicular brachialis plexus blocks: a randomized controlled volunteer study.,"BACKGROUND Onvision is a new technology for needle tip detection and tracking in ultrasound-guided regional anesthesia. The system consists of a piezoelectric sensor close to the needle tip and an electronic console integrated in the ultrasound system. The needle tip is visualized by a green circle on the ultrasound screen. The aim of the study was to investigate the effect of the new needle tip tracking technology on in-plane infraclavicular plexus blocks. METHODS The study was a randomized, controlled, observer blinded cross-over trial in 26 healthy volunteers. Two specialists in anesthesiology performed an ultrasound-guided infraclavicular lateral sagittal brachial plexus block with and without needle tip tracking. Primary outcome was procedure time, measured from insertion of the needle until local anesthesia injection was completed. Secondary outcome measures included the number of hand movements and path lengths (assessed by hand motion analysis), block success rate, onset time and duration, discomfort experienced by the volunteers, and the anesthesiologists' confidence as to whether their block would be successful or not. RESULTS Mean (SD) procedure time was 183.0 (56.1) s with and 206.8 (56.2) s without needle tip tracking (p=0.16). There were no significant differences in any of the secondary outcomes. Two volunteers' experienced Horner syndrome after blocks without needle tip tracking. No other adverse events occurred during the study. CONCLUSION Our study on needle tip tracking for infraclavicular blocks did not reveal any significant differences between active needle tip tracking and the control procedures, neither for primary outcome nor secondary outcome measurements. TRIAL REGISTRATION NUMBER NCT03631914.",2020,"Our study on needle tip tracking for infraclavicular blocks did not reveal any significant differences between active needle tip tracking and the control procedures, neither for primary outcome nor secondary outcome measurements. ",['26 healthy volunteers'],"['new needle tip tracking technology', 'Ultrasonographic needle tip tracking', 'ultrasound-guided infraclavicular lateral sagittal brachial plexus block with and without needle tip tracking']","['Horner syndrome', 'Mean (SD) procedure time', 'adverse events', ""number of hand movements and path lengths (assessed by hand motion analysis), block success rate, onset time and duration, discomfort experienced by the volunteers, and the anesthesiologists' confidence as to whether their block would be successful or not"", 'procedure time, measured from insertion of the needle until local anesthesia injection']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0339897', 'cui_str': 'Transjugular intrahepatic portosystemic shunt'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0230108', 'cui_str': 'Infraclavicular region structure'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0205129', 'cui_str': 'Sagittal'}, {'cui': 'C0394697', 'cui_str': 'Injection of anesthetic agent into brachial plexus'}]","[{'cui': 'C0019937', 'cui_str': 'Cervical sympathetic paralysis'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0449244', 'cui_str': 'Time of onset'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0449770', 'cui_str': 'Measured from'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]",26.0,0.0592287,"Our study on needle tip tracking for infraclavicular blocks did not reveal any significant differences between active needle tip tracking and the control procedures, neither for primary outcome nor secondary outcome measurements. ","[{'ForeName': 'Trine', 'Initials': 'T', 'LastName': 'Kåsine', 'Affiliation': 'Division of Emergencies and Critical Care, Department of Research and Development, Oslo University Hospital, Oslo, Norway trikaa@ous-hf.no.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Romundstad', 'Affiliation': 'Division of Emergencies and Critical Care, Department of Anesthesiology, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'L A', 'Initials': 'LA', 'LastName': 'Rosseland', 'Affiliation': 'Division of Emergencies and Critical Care, Department of Research and Development, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Morten Wang', 'Initials': 'MW', 'LastName': 'Fagerland', 'Affiliation': 'Oslo Centre for Biostatics and Epidemiology (OCBE) Research Support Services, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Kessler', 'Affiliation': 'Department of Anesthesiology, Intensive Care and Pain Medicine, Orthopedic University Hospital Friedrichsheim, Frankfurt am Main, Hessen, Germany.'}, {'ForeName': 'Ivar Nagelgaard', 'Initials': 'IN', 'LastName': 'Omenås', 'Affiliation': 'Division of Emergencies and Critical Care, Department of Anesthesiology, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Holmberg', 'Affiliation': 'Division of Emergencies and Critical Care, Department of Anesthesiology, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Axel R', 'Initials': 'AR', 'LastName': 'Sauter', 'Affiliation': 'Division of Emergencies and Critical Care, Department of Research and Development, Oslo University Hospital, Oslo, Norway.'}]",Regional anesthesia and pain medicine,['10.1136/rapm-2020-101349'] 1503,32542431,"Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled Trial.","INTRODUCTION Diabetic macular edema (DME) threatens daily life activities such as reading and driving and reduces the patients' quality-of-life. Recently, anti-vascular endothelial growth factor (VEGF) agents have become a first-line therapy in DME. However, therapy with anti-VEGF agents has several problems: repeated invasive injections are required; medical costs are high; and a certain proportion of patients with DME are resistant to treatment with anti-VEGF agents. While sodium-glucose co-transporter 2 (SGLT2) inhibitors have been widely used for the treatment of type 2 diabetes mellitus (T2DM), the effects of a combination therapy with anti-VEGF agent and SGLT2 inhibitor on DME are not yet known. METHODS This study enrolls subjects with T2DM and DME, randomizes them into either a study agent treatment group (treated with ranibizumab as anti-VEGF agent and luseogliflozin as SGLT2 inhibitor) or a control group (treated with ranibizumab and glimepiride), and observes the subjects for 52 weeks after initiation of treatment. Planned outcomes: The primary endpoint is intergroup difference in the number of intravitreal anti-VEGF injections to the study eye from baseline to week 48. Secondary and exploratory endpoints include safety and ophthalmologic and internal medical clinical parameters. REGISTRATION This study is registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN000033961) and Japan Registry of Clinical Trials (jRCTs031180210).",2020,The primary endpoint is intergroup difference in the number of intravitreal anti-VEGF injections to the study eye from baseline to week 48.,"['Patients with Diabetic Macular Edema', 'enrolls subjects with T2DM and DME, randomizes them into either a study agent treatment group (treated with']","['sodium-glucose co-transporter\xa02 (SGLT2) inhibitors', 'ranibizumab as anti-VEGF agent and luseogliflozin as SGLT2 inhibitor) or a control group (treated with ranibizumab and glimepiride', 'Ranibizumab and Luseogliflozin Combination Therapy']","['safety and ophthalmologic and internal medical clinical parameters', 'Safety and Efficacy', 'number of intravitreal anti-VEGF injections']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0730285', 'cui_str': 'Macular edema due to diabetes mellitus'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0598849', 'cui_str': 'Co-Transporters'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C2933904', 'cui_str': '1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol'}, {'cui': 'C4301634', 'cui_str': 'Sodium-glucose co-transporter 2 (SGLT2) inhibitors'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0061323', 'cui_str': 'glimepiride'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0029087', 'cui_str': 'Ophthalmology'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]",,0.0283211,The primary endpoint is intergroup difference in the number of intravitreal anti-VEGF injections to the study eye from baseline to week 48.,"[{'ForeName': 'Ryoichi', 'Initials': 'R', 'LastName': 'Ishibashi', 'Affiliation': 'Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, 1010 Sakurai, Kisarazu, Chiba, 292-8535, Japan. ishibashi-cib@umin.net.'}, {'ForeName': 'Yoko', 'Initials': 'Y', 'LastName': 'Takatsuna', 'Affiliation': 'Department of Ophthalmology, Chiba Rosai Hospital, 2-16 Tatsumidai-Higashi, Ichihara, Chiba, 290-0003, Japan.'}, {'ForeName': 'Masaya', 'Initials': 'M', 'LastName': 'Koshizaka', 'Affiliation': 'Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan.'}, {'ForeName': 'Tomoaki', 'Initials': 'T', 'LastName': 'Tatsumi', 'Affiliation': 'Department of Ophthalmology and Vision Science, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan.'}, {'ForeName': 'Sho', 'Initials': 'S', 'LastName': 'Takahashi', 'Affiliation': 'Clinical Research Support Center, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-8461, Japan.'}, {'ForeName': 'Kengo', 'Initials': 'K', 'LastName': 'Nagashima', 'Affiliation': 'Research Center for Medical and Health Data Science, The Institute of Statistical Mathematics, 10-3 Midori-cho, Tachikawa, Tokyo, 190-8562, Japan.'}, {'ForeName': 'Noriko', 'Initials': 'N', 'LastName': 'Asaumi', 'Affiliation': 'Department of Ophthalmology, Kimitsu Chuo Hospital, 1010 Sakurai, Kisarazu, Chiba, 292-8535, Japan.'}, {'ForeName': 'Miyuki', 'Initials': 'M', 'LastName': 'Arai', 'Affiliation': 'Department of Ophthalmology, National Hospital Organization Chiba Medical Center, Tsubakimori 4-1-2, Chuo-ku, Chiba, Chiba, 260-8606, Japan.'}, {'ForeName': 'Fumio', 'Initials': 'F', 'LastName': 'Shimada', 'Affiliation': 'Department of Diabetes and Metabolism, National Hospital Organization Chiba Medical Center, Tsubakimori 4-1-2, Chuo-ku, Chiba, Chiba, 260-8606, Japan.'}, {'ForeName': 'Kaori', 'Initials': 'K', 'LastName': 'Tachibana', 'Affiliation': 'Department of Diabetes, Metabolic Diseases, Endocrinology, Japanese Red Cross Narita Hospital, 90-1, Iida-cho, Narita, Chiba, 286-8523, Japan.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Watanabe', 'Affiliation': 'Department of Ophthalmology, Japanese Red Cross Narita Hospital, 90-1, Iida-cho, Narita, Chiba, 286-8523, Japan.'}, {'ForeName': 'Ko', 'Initials': 'K', 'LastName': 'Ishikawa', 'Affiliation': 'Department of Internal Medicine, Chiba Rosai Hospital, Tatsumidai-Higashi 2-16, Ichihara, Chiba, 290-0003, Japan.'}, {'ForeName': 'Akiko', 'Initials': 'A', 'LastName': 'Hoshino', 'Affiliation': 'Department of Ophthalmology, Chiba Aoba Municipal Hospital, Aoba-cho 1273-2, Chuo-ku, Chiba, Chiba, 260-0852, Japan.'}, {'ForeName': 'Kyohei', 'Initials': 'K', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Internal Medicine, Chiba Aoba Municipal Hospital, Aoba-cho 1273-2, Chuo-ku, Chiba, Chiba, 260-0852, Japan.'}, {'ForeName': 'Mariko', 'Initials': 'M', 'LastName': 'Kubota-Taniai', 'Affiliation': 'Department of Ophthalmology, Chiba Kaihin Municipal Hospital, Isobe 3-31-1, Mihama-ku, Chiba, Chiba, 261-0012, Japan.'}, {'ForeName': 'Takafumi', 'Initials': 'T', 'LastName': 'Mayama', 'Affiliation': 'Department of Internal Medicine, Chiba Kaihin Municipal Hospital, Isobe 3-31-1, Mihama-ku, Chiba, Chiba, 261-0012, Japan.'}, {'ForeName': 'Shuichi', 'Initials': 'S', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Ophthalmology and Vision Science, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan.'}, {'ForeName': 'Koutaro', 'Initials': 'K', 'LastName': 'Yokote', 'Affiliation': 'Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00854-6'] 1504,32543020,Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF).,"AIMS Hyponatremia is associated with poorer outcomes and diuretic response in patients hospitalized for heart failure. This study compared a tolvaptan-based vs. furosemide-based diuretic regimen on short-term clinical responses in hyponatremic acute heart failure. METHODS AND RESULTS Prospective, randomized, open-label, parallel-group, single-centre study comparing oral tolvaptan vs. continuous infusion furosemide. Thirty-three subjects requiring hospitalization for acute congestive heart failure, and a serum sodium < 135 mmol/L, were randomized to tolvaptan 30 mg orally daily or furosemide 5 mg/h intravenously for initial 24 h, after which treatments could be escalated. Median daily dose throughout was tolvaptan 30 mg and furosemide 120 mg, with four subjects in each group requiring dose escalation. Urine output and net fluid balance were not different between groups at 24 h or subsequent time points up to 96 h. Changes in estimated glomerular filtration rate were comparable. Cystatin C improved at 24 h with tolvaptan compared with furosemide (-6.4 ± 11.8 vs. 4.1 ± 17.2% change, P = 0.036), but the effect was transient. No significant between group differences were seen for NT-proBNP, plasma renin activity, or urinary neutrophil gelatinase-associated lipocalin:Cr. Serum sodium, as well as copeptin levels, increased with tolvaptan compared with furosemide. CONCLUSIONS Oral tolvaptan was associated with similar, but not superior, diuresis compared with intravenous furosemide for acute heart failure with concomitant hyponatremia.",2020,"No significant between group differences were seen for NT-proBNP, plasma renin activity, or urinary neutrophil gelatinase-associated lipocalin:Cr.","['patients hospitalized for heart failure with hyponatremia (AQUA-AHF', 'patients hospitalized for heart failure', 'Thirty-three subjects requiring hospitalization for acute congestive heart failure, and a serum sodium', 'hyponatremic acute heart failure']","['Tolvaptan vs. furosemide-based diuretic regimens', 'tolvaptan-based vs. furosemide-based diuretic regimen', 'tolvaptan vs. continuous infusion furosemide', 'furosemide', 'tolvaptan', 'tolvaptan 30\xa0mg orally daily or furosemide']","['Urine output and net fluid balance', 'Serum sodium', 'Cystatin C', 'glomerular filtration rate', 'NT-proBNP, plasma renin activity, or urinary neutrophil gelatinase-associated lipocalin:Cr']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0020625', 'cui_str': 'Hyponatremia'}, {'cui': 'C0015506', 'cui_str': 'Factor VIII'}, {'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0264719', 'cui_str': 'Acute congestive heart failure'}, {'cui': 'C0523891', 'cui_str': 'Sodium measurement, serum'}, {'cui': 'C0857122', 'cui_str': 'Hyponatraemic'}, {'cui': 'C0264714', 'cui_str': 'Acute heart failure'}]","[{'cui': 'C1176308', 'cui_str': 'tolvaptan'}, {'cui': 'C0016860', 'cui_str': 'Furosemide'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0012798', 'cui_str': 'Diuretic'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0444889', 'cui_str': 'Continuous infusion'}, {'cui': 'C2684746', 'cui_str': 'tolvaptan 30 MG'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0016284', 'cui_str': 'Fluid balance'}, {'cui': 'C0523891', 'cui_str': 'Sodium measurement, serum'}, {'cui': 'C0071744', 'cui_str': 'Cystatin C'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0035094', 'cui_str': 'Renin'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0206528', 'cui_str': 'Gelatinase'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1956074', 'cui_str': 'Lipocalin'}]",33.0,0.0461433,"No significant between group differences were seen for NT-proBNP, plasma renin activity, or urinary neutrophil gelatinase-associated lipocalin:Cr.","[{'ForeName': 'Tien M H', 'Initials': 'TMH', 'LastName': 'Ng', 'Affiliation': 'School of Pharmacy, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Luanda P', 'Initials': 'LP', 'LastName': 'Grazette', 'Affiliation': 'Division of Cardiovascular Medicine, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Fong', 'Affiliation': 'Division of Cardiovascular Medicine, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Yoon', 'Affiliation': 'Division of Cardiovascular Medicine, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Mimi', 'Initials': 'M', 'LastName': 'Lou', 'Affiliation': 'School of Pharmacy, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Allen', 'Initials': 'A', 'LastName': 'Kuo', 'Affiliation': 'Division of Cardiovascular Medicine, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Rani Y', 'Initials': 'RY', 'LastName': 'Upadhyay', 'Affiliation': 'Division of Cardiovascular Medicine, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Emily E', 'Initials': 'EE', 'LastName': 'Han', 'Affiliation': 'School of Pharmacy, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Anilkumar', 'Initials': 'A', 'LastName': 'Mehra', 'Affiliation': 'Division of Cardiovascular Medicine, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Uri', 'Initials': 'U', 'LastName': 'Elkayam', 'Affiliation': 'Division of Cardiovascular Medicine, University of Southern California, Los Angeles, CA, USA.'}]",ESC heart failure,['10.1002/ehf2.12783'] 1505,32535263,Effects of edaravone on postoperative cognitive function in elderly patients undergoing hip joint replacement surgery: A randomized controlled trial.,"BACKGROUND Postoperative cognitive dysfunction (POCD) is a complication of central nervous system in patients after surgery. Edaravone as a brain-protective agent may have protective effect on postoperative cognitive function. The study was designed to explore the effects of edaravone on postoperative cognitive function in elderly patients undergoing hip joint replacement surgery and potential mechanism. PATIENTS AND METHODS Patients undergoing hip joint replacement surgery were randomly allocated into 2 groups: the edaravone group (group E) and the control group (group C). Group E received intravenous edaravone at a dose of 0.5 mg/kg after induction of anesthesia, while group C received normal saline. The cognitive function was evaluated with the Mini-Mental State Examination (MMSE) 1day before surgery,3 days and the 7 days after surgery. Patients' plasma samples were collected to detect the levels of S100β protein (S100β), interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9), superoxide dismutase (SOD) and malondialdehyde (MDA) before the induction of anesthesia, at the end of surgery and on postoperative day 3. RESULTS The MMSE scores in group E were higher than those of group C 3 days after surgery (25.98 ± 1.99 vs 24.86 ± 1.86, p = 0.003). There were remarkable rises (p < 0.05) in plasma IL-6, S100βand MMP-9 levels at the end of surgery and on postoperative day 3 in the two groups, however, edaravone pretreatment could reduce these levels to a certain extent compared with group C (p < 0.05).In group E, the SOD concentration was higher at the end of surgery (16.03 ± 2.46U/ml vs. 13.65 ± 2.53U/ml, p = 0.0001), while the MDA level was lower on postoperative day 3 than those in group C (7.01 ± 2.37 nmol/ml vs. 11.34 ± 3.18 nmol/ml, p = 0.0001). CONCLUSION The results indicated that preoperative intervention with edaravone may improve the postoperative cognitive function in elderly patients undergoing hip joint replacement surgery.",2020,"There were remarkable rises (p< 0.05) in plasma IL-6, S100βand MMP-9 levels at the end of surgery and on postoperative day 3 in the two groups, however, edaravone pretreatment could reduce these levels to a certain extent compared with group C (p< 0.05).In group E, the SOD concentration was higher at the end of surgery (16.03±2.46U/ml vs. 13.65±2.53U/ml, p = 0.0001), while the MDA level was lower on postoperative day 3 than those in group C (7.01±2.37nmol/ml vs. 11.34±3.18nmol/ml, p = 0.0001). ","['eldely patients undergoing hip joint replacement surgery and potential mechanism', 'Patients undergoing hip joint replacement surgery', 'patients after surgery', 'elderly patients undergoing hip joint replacement surgery']","['intravenous edaravone', 'normal saline', 'edaravone', 'Edaravone']","['MDA level', 'MMSE scores', 'cognitive function', 'SOD concentration', 'levels of S100β protein (S100β), interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9), superoxide dismutase (SOD) and malondialdehyde (MDA', 'postoperative cognitive function', 'plasma IL-6, S100βand MMP-9 levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019558', 'cui_str': 'Hip joint structure'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0070694', 'cui_str': 'edaravone'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}]","[{'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2960235', 'cui_str': 'Mini-mental state examination score'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0165519', 'cui_str': 'Gelatinase B'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}]",,0.097904,"There were remarkable rises (p< 0.05) in plasma IL-6, S100βand MMP-9 levels at the end of surgery and on postoperative day 3 in the two groups, however, edaravone pretreatment could reduce these levels to a certain extent compared with group C (p< 0.05).In group E, the SOD concentration was higher at the end of surgery (16.03±2.46U/ml vs. 13.65±2.53U/ml, p = 0.0001), while the MDA level was lower on postoperative day 3 than those in group C (7.01±2.37nmol/ml vs. 11.34±3.18nmol/ml, p = 0.0001). ","[{'ForeName': 'Nan-Nan', 'Initials': 'NN', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Huinan Town, Pudong, Shanghai, 201399, China.'}, {'ForeName': 'Long', 'Initials': 'L', 'LastName': 'Sun', 'Affiliation': 'Department of Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of Chinese Traditional Medicine, 528 Zhangheng Road, Pudong, Shanghai, 201203, China. Electronic address: sun_long2@163.com.'}, {'ForeName': 'Wen-Ting', 'Initials': 'WT', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of Chinese Traditional Medicine, 528 Zhangheng Road, Pudong, Shanghai, 201203, China.'}, {'ForeName': 'Yang-Liang', 'Initials': 'YL', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Huinan Town, Pudong, Shanghai, 201399, China.'}, {'ForeName': 'Yi-Ming', 'Initials': 'YM', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Huinan Town, Pudong, Shanghai, 201399, China. Electronic address: nange1984@sina.com.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2020.05.092'] 1506,32535338,A serious-game for child sexual abuse prevention: An evaluation of orbit.,"BACKGROUND Greater public and professional awareness of the extent and impact of child sexual abuse (CSA) has prompted the inclusions of prevention initiatives within school curricula. However CSA education is not always soundly grounded in empirical evidence, and evaluations of the impact of programs often inadequate. OBJECTIVE This paper reports on a randomized-control trial of an empirically informed serious-game for CSA prevention, for children aged 8-10 years. The study also evaluates the impact on learning of complementary classroom lessons and part completion of the Orbit game. PARTICIPANTS AND SETTING The evaluation involved 139 students (female = 78; male = 61) aged 8-10 years (Mage = 9.64, SD = 0.33), from an elementary school in Queensland, Australia. METHOD All children were pre-tested and post-tested (at 3 months) for knowledge of abuse prevention using the Children's Knowledge of Abuse Questionnaire-Revised (CKAQ-R-III), and a short form (SF) mapped to the learning objectives of Orbit . Children were assigned to one of three groups; i) play Orbit (n = 50); ii) play Orbit and CSA lessons (n = 55); and iii) control (n = 34). RESULTS Children in the Orbit play, and Orbit play and lesson groups, significantly (p < .001) increased their CKAQ SF scores, whereas those in the control group did not. Furthermore, those children who completed all of Orbit significantly (p < .001) increased their post-test CKAQ scores, whereas those who didn't complete the game did not. CONCLUSIONS This study shows the strength of a serious-games approach for school CSA prevention whilst reporting how child completion can impact learnings.",2020,"RESULTS Children in the Orbit play, and Orbit play and lesson groups, significantly (p < .001) increased their CKAQ SF scores, whereas those in the control group did not.","['child sexual abuse (CSA', 'child sexual abuse prevention', ""All children were pre-tested and post-tested (at 3 months) for knowledge of abuse prevention using the Children's Knowledge of Abuse Questionnaire-Revised (CKAQ-R-III), and a short form (SF) mapped to the learning objectives of Orbit "", 'The evaluation involved 139 students (female\u202f=\u202f78; male\u202f=\u202f61) aged 8-10 years (Mage\u202f=\u202f9.64, SD\u202f=\u202f0.33), from an elementary school in Queensland, Australia', 'children aged 8-10 years']",['play Orbit (n\u202f=\u202f50); ii) play Orbit and CSA lessons (n\u202f=\u202f55); and iii) control'],"['post-test CKAQ scores', 'CKAQ SF scores']","[{'cui': 'C0008062', 'cui_str': 'Sexual Abuse of Child'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C1261558', 'cui_str': 'Abuse prevention'}, {'cui': 'C0562381', 'cui_str': 'Victim of abuse'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0024779', 'cui_str': 'Maps'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0029180', 'cui_str': 'Orbital cavity'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C5191072', 'cui_str': '139'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517449', 'cui_str': '0.33'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0034391', 'cui_str': 'Queensland'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0029180', 'cui_str': 'Orbital cavity'}, {'cui': 'C0008062', 'cui_str': 'Sexual Abuse of Child'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",139.0,0.0282223,"RESULTS Children in the Orbit play, and Orbit play and lesson groups, significantly (p < .001) increased their CKAQ SF scores, whereas those in the control group did not.","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Jones', 'Affiliation': 'School of Social Sciences, University of the Sunshine Coast, Queensland, Australia. Electronic address: cmjones@usc.edu.au.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Scholes', 'Affiliation': 'Institute for Learning Sciences & Teacher Education, Australian Catholic University, Queensland, Australia. Electronic address: laura.scholes@acu.edu.au.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Rolfe', 'Affiliation': 'Ecoludology Games, Queensland, Australia. Electronic address: ben@ecoludology.com.'}, {'ForeName': 'Colleen', 'Initials': 'C', 'LastName': 'Stieler-Hunt', 'Affiliation': 'School of Creative Industries, University of the Sunshine Coast, Queensland, Australia. Electronic address: cstieler@usc.edu.au.'}]",Child abuse & neglect,['10.1016/j.chiabu.2020.104569'] 1507,32536195,Canakinumab After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation: A Pilot Randomized Trial.,,2020,,['Patients with Persistent Atrial Fibrillation'],['Canakinumab after Electrical Cardioversion'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}]","[{'cui': 'C2718773', 'cui_str': 'canakinumab'}, {'cui': 'C0013778', 'cui_str': 'Cardioversion'}]",[],,0.0404341,,"[{'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Krisai', 'Affiliation': 'Department of Cardiology (P.K., S.B., C.S., M.K.), University Hospital Basel, Switzerland.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Blum', 'Affiliation': 'Department of Cardiology (P.K., S.B., C.S., M.K.), University Hospital Basel, Switzerland.'}, {'ForeName': 'Renate B', 'Initials': 'RB', 'LastName': 'Schnabel', 'Affiliation': 'Department of General and Interventional Cardiology, University Heart and Vascular Center Hamburg, Germany (R.B.S.).'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Sticherling', 'Affiliation': 'Department of Cardiology (P.K., S.B., C.S., M.K.), University Hospital Basel, Switzerland.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kühne', 'Affiliation': 'Department of Cardiology (P.K., S.B., C.S., M.K.), University Hospital Basel, Switzerland.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'von Felten', 'Affiliation': 'German Center for Cardiovascular Research, Partner Site Hamburg/Kiel/Luebeck (R.B.S.).'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Ammann', 'Affiliation': 'Department of Cardiology, Kantonsspital St. Gallen, Switzerland (P.A.).'}, {'ForeName': 'Etienne', 'Initials': 'E', 'LastName': 'Pruvot', 'Affiliation': 'Department of Cardiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (E.P.).'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Albert', 'Affiliation': 'Department of Cardiology, Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA (C.M.A.).'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Conen', 'Affiliation': 'Population Health Research Institute, McMaster University and Hamilton Health Sciences, Canada (D.C.).'}]",Circulation. Arrhythmia and electrophysiology,['10.1161/CIRCEP.119.008197'] 1508,32686643,Long term oral appliance therapy decreases stress symptoms in patients with upper airway resistance syndrome.,"STUDY OBJECTIVES To evaluate the long-term effects of a mandibular advancement device (MAD) on stress symptoms and cognitive function in patients with UARS compared with placebo. METHODS This study was a randomized placebo-controlled clinical trial. Thirty UARS patients were randomized into two groups: placebo and MAD groups. UARS criteria were the presence of sleepiness (Epworth Sleepiness Scale ≥ 10) and/or fatigue (Modified Fatigue Impact Scale ≥ 38) associated with an apnea/hypopnea index (AHI) ≤ 5 and a respiratory disturbance index (RDI) > 5 events/hour of sleep, and/or flow limitation in more than 30% of total sleep time. All patients completed the Rey Auditory-Verbal Learning Test (RAVLT), the Logical Memory Test, the Stroop Color Test, the Trail Making Test, the Digit Symbol Substitution Test and Inventory of Stress Symptoms (ISSL). Cognition protocol was defined based on the most used neuropsychological tests in the literature. Evaluations were performed before and after 1.5 years of treatment. RESULTS Mean adherence to placebo and to MAD was 6.6 ± 2.6 and 6.1 ± 2.4 hours/night, respectively. Side effects reported by MAD group were minor and short-term. There was no statistically significant difference in RAVLT, Logical Memory Test, Stroop Color Test, Trail Making Test, Digit Symbol Substitution Test before and after 1.5 years of treatment in both groups. ISSL score decreased at the alert phase and the resistance phase after 1.5 years of MAD treatment compared to the placebo. CONCLUSIONS Mandibular advancement device was effective in decreasing stress symptoms in UARS patients after 1.5-years of treatment. CLINICAL TRIAL REGISTRATION Registry: ClinicalTrials.gov; Title: Efficacy of Oral Appliance for Upper Airway Resistance Syndrome: Randomized, Parallel, Placebo, Controlled Study; Identifier: NTC02636621; URL: https://clinicaltrials.gov/ct2/show/record/NCT02636621.",2020,"There was no statistically significant difference in RAVLT, Logical Memory Test, Stroop Color Test, Trail Making Test, Digit Symbol Substitution Test before and after 1.5 years of treatment in both groups.","['UARS patients after 1.5-years of treatment', 'Thirty UARS patients', 'Upper Airway Resistance Syndrome', 'patients with upper airway resistance syndrome', 'patients with UARS compared with placebo']","['Placebo', 'mandibular advancement device (MAD', 'appliance therapy', 'placebo and MAD', 'Oral Appliance', 'MAD', 'placebo']","['stress symptoms and cognitive function', 'RAVLT, Logical Memory Test, Stroop Color Test, Trail Making Test, Digit Symbol Substitution Test', 'stress symptoms', 'ISSL score', 'Rey Auditory-Verbal Learning Test (RAVLT), the Logical Memory Test, the Stroop Color Test, the Trail Making Test, the Digit Symbol Substitution Test and Inventory of Stress Symptoms (ISSL', 'Side effects', 'Mean adherence', 'presence of sleepiness (Epworth Sleepiness Scale ≥ 10) and/or fatigue (Modified Fatigue Impact Scale ≥ 38) associated with an apnea/hypopnea index (AHI) ≤ 5 and a respiratory disturbance index (RDI) > 5 events/hour of sleep, and/or flow limitation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C1319384', 'cui_str': 'Upper airway resistance syndrome'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2091299', 'cui_str': 'Mandibular Advancement Devices'}, {'cui': 'C1542418', 'cui_str': 'Appliance'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C4505058', 'cui_str': 'Rey Auditory Verbal Learning Test'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0040604', 'cui_str': 'Trail making test'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C3541276', 'cui_str': 'Epworth Sleepiness Scale'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2733557', 'cui_str': 'Fatigue impact scale'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0235546', 'cui_str': 'Slow shallow breathing'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439084', 'cui_str': '>5'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0521112', 'cui_str': 'Bedtime'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}]",30.0,0.120518,"There was no statistically significant difference in RAVLT, Logical Memory Test, Stroop Color Test, Trail Making Test, Digit Symbol Substitution Test before and after 1.5 years of treatment in both groups.","[{'ForeName': 'Luciana B M', 'Initials': 'LBM', 'LastName': 'de Godoy', 'Affiliation': 'Departamento de Psicobiologia, Universidade Federal de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Ksdy M M', 'Initials': 'KMM', 'LastName': 'Sousa', 'Affiliation': 'Departamento de Psicobiologia, Universidade Federal de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Luciana', 'Initials': 'L', 'LastName': 'de O Palombini', 'Affiliation': 'Departamento de Psicobiologia, Universidade Federal de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Dalva', 'Initials': 'D', 'LastName': 'Poyares', 'Affiliation': 'Departamento de Psicobiologia, Universidade Federal de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Cibele', 'Initials': 'C', 'LastName': 'Dal-Fabbro', 'Affiliation': 'Instituto do Sono, São Paulo, Brazil.'}, {'ForeName': 'Thais M', 'Initials': 'TM', 'LastName': 'Guimarães', 'Affiliation': 'Departamento de Psicobiologia, Universidade Federal de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Tufik', 'Affiliation': 'Departamento de Psicobiologia, Universidade Federal de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Sonia M', 'Initials': 'SM', 'LastName': 'Togeiro', 'Affiliation': 'Departamento de Psicobiologia, Universidade Federal de São Paulo, São Paulo, Brazil.'}]",Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine,['10.5664/jcsm.8698'] 1509,32535135,Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy.,"BACKGROUND While desensitization and sustained unresponsiveness (SU) have been shown with egg oral immunotherapy (OIT), the benefits of baked egg (BE) therapy for egg allergy have not been well studied. OBJECTIVES This study sought to evaluate the safety and efficacy of BE ingestion compared with egg OIT in participants allergic to unbaked egg but tolerant to BE. METHODS Children who are BE-tolerant but unbaked egg reactive ages 3 to 16 years were randomized to 2 years of treatment with either BE or egg OIT. Double-blind, placebo-controlled food challenges were conducted after 1 and 2 years of treatment to assess for desensitization, and after 2 years of treatment followed by 8 to 10 weeks off of treatment to assess for SU. Mechanistic studies were conducted to assess for immune modulation. A cohort of participants who are BE-reactive underwent egg OIT and identical double-blind, placebo-controlled food challenges as a comparator group. RESULTS Fifty participants (median age 7.3 years) were randomized and initiated treatment. SU was achieved in 3 of 27 participants assigned to BE (11.1%) versus 10 of 23 participants assigned to egg OIT (43.5%) (P = .009). In the BE-reactive comparator group, 7 of 39 participants (17.9%) achieved SU. More participants who are BE-tolerant withdrew from BE versus from egg OIT (29.6% vs 13%). Dosing symptom frequency in participants who are BE-tolerant was similar with BE and egg OIT, but more frequent in participants who are BE-reactive. Egg white-specific IgE, skin testing, and basophil activation decreased similarly after BE and egg OIT. CONCLUSIONS Among children allergic to unbaked egg but tolerant to BE, those treated with egg OIT were significantly more likely to achieve SU than were children ingesting BE.",2020,"Egg white-specific IgE, skin testing and basophil activation decreased similarly after BE and egg OIT. ","['BE tolerant but unbaked egg reactive children ages 3-16 years', 'participants allergic to unbaked egg but tolerant to BE', 'egg-allergic children', 'Fifty participants (median age 7.3 years']","['baked egg therapy', 'egg oral immunotherapy (OIT', 'BE or egg OIT', 'placebo-controlled food challenges (DBPCFC', 'egg OIT and identical DBPCFCs']","['SU', 'Egg white-specific IgE, skin testing and basophil activation']","[{'cui': 'C0013710', 'cui_str': 'Eggs (edible)'}, {'cui': 'C0205332', 'cui_str': 'Reactive'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]","[{'cui': 'C0013710', 'cui_str': 'Eggs (edible)'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0205280', 'cui_str': 'Identical'}]","[{'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C1270739', 'cui_str': 'Egg white specific immunoglobulin E'}, {'cui': 'C0037296', 'cui_str': 'Hypersensitivity skin testing'}, {'cui': 'C0004827', 'cui_str': 'Basophils'}]",50.0,0.291217,"Egg white-specific IgE, skin testing and basophil activation decreased similarly after BE and egg OIT. ","[{'ForeName': 'Edwin H', 'Initials': 'EH', 'LastName': 'Kim', 'Affiliation': 'Department of Medicine and Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC. Electronic address: edwinkim@email.unc.edu.'}, {'ForeName': 'Tamara T', 'Initials': 'TT', 'LastName': 'Perry', 'Affiliation': ""Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark.""}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Wood', 'Affiliation': 'Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Rockville.'}, {'ForeName': 'Donald Y M', 'Initials': 'DYM', 'LastName': 'Leung', 'Affiliation': 'Department of Pediatrics, National Jewish Health, Denver, Colo.'}, {'ForeName': 'M Cecilia', 'Initials': 'MC', 'LastName': 'Berin', 'Affiliation': 'Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'A Wesley', 'Initials': 'AW', 'LastName': 'Burks', 'Affiliation': 'Department of Medicine and Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC.'}, {'ForeName': 'Christine B', 'Initials': 'CB', 'LastName': 'Cho', 'Affiliation': 'Department of Pediatrics, National Jewish Health, Denver, Colo.'}, {'ForeName': 'Stacie M', 'Initials': 'SM', 'LastName': 'Jones', 'Affiliation': ""Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark.""}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Scurlock', 'Affiliation': ""Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark.""}, {'ForeName': 'Scott H', 'Initials': 'SH', 'LastName': 'Sicherer', 'Affiliation': 'Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Alice K', 'Initials': 'AK', 'LastName': 'Henning', 'Affiliation': 'Emmes, Rockville, Md.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Dawson', 'Affiliation': 'Emmes, Rockville, Md.'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Lindblad', 'Affiliation': 'Emmes, Rockville, Md.'}, {'ForeName': 'Marshall', 'Initials': 'M', 'LastName': 'Plaut', 'Affiliation': 'National Institutes of Health/National Institutes of Allergy and Infectious Diseases, Bethesda, Md.'}, {'ForeName': 'Hugh A', 'Initials': 'HA', 'LastName': 'Sampson', 'Affiliation': 'Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Journal of allergy and clinical immunology,['10.1016/j.jaci.2020.05.040'] 1510,32536331,A clinical method of evaluating simple reaction time and reaction accuracy is sensitive to a single dose of lorazepam.,"RATIONALE Benzodiazepines are useful and commonly prescribed. Unfortunately, they are associated with subtle but functionally significant neurocognitive side effects that increase the risk of motor vehicle accidents and falls. OBJECTIVE The objective of this study was to determine whether clinically feasible measures of simple reaction time and reaction accuracy are sensitive to a single dose of lorazepam. METHODS Using a randomized, double-blind, crossover design, 26 healthy adults (13 women; age = 26.9 ± 8.2 yr) were given 1.0 mg lorazepam or placebo 90 minutes prior to two data collection sessions. Participants completed simple and reaction accuracy tasks using a standardized ""ruler drop"" testing paradigm during each session. Outcomes were mean and variability of simple reaction time and reaction accuracy, which evaluates a participant's ability to catch the device solely on the random 50% of trials that lights affixed to it illuminate on release. Reaction accuracy requires a go/no-go decision within 420 ms before the falling device strikes the floor. RESULTS As compared with placebo, lorazepam increased simple reaction time variability (range = 43 ± 18 vs. 60 ± 23 ms, respectively; p = 0.004 and standard deviation = 14.6 ± 5.7 vs. 19.7 ± 7.3 ms, respectively; = 0.006) and decreased reaction accuracy (90 ± 7% vs. 84 ± 11%, respectively; p = 0.010). CONCLUSION Given prior work demonstrating associations between simple reaction time and reaction accuracy and functional outcomes such as self-protection, response to perturbations, and fall risk, these clinically available measures may have a role in identifying subtle, functionally significant cognitive changes related to short-term benzodiazepine use.",2020,"RESULTS As compared with placebo, lorazepam increased simple reaction time variability (range = 43 ± 18 vs. 60 ± 23 ms, respectively; p = 0.004 and standard deviation = 14.6 ± 5.7 vs. 19.7 ± 7.3 ms, respectively; = 0.006) and decreased reaction accuracy (90 ± 7% vs. 84 ± 11%, respectively; p = 0.010). ",['26 healthy adults (13 women; age = 26.9 ± 8.2\u2009yr'],"['lorazepam', 'lorazepam or placebo', 'placebo, lorazepam']","['mean and variability of simple reaction time and reaction accuracy', 'simple reaction time variability', 'simple reaction time and reaction accuracy and functional outcomes such as self-protection, response to perturbations, and fall risk', 'reaction accuracy']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0024002', 'cui_str': 'Lorazepam'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C1268740', 'cui_str': 'At risk for falls'}]",26.0,0.207435,"RESULTS As compared with placebo, lorazepam increased simple reaction time variability (range = 43 ± 18 vs. 60 ± 23 ms, respectively; p = 0.004 and standard deviation = 14.6 ± 5.7 vs. 19.7 ± 7.3 ms, respectively; = 0.006) and decreased reaction accuracy (90 ± 7% vs. 84 ± 11%, respectively; p = 0.010). ","[{'ForeName': 'James K', 'Initials': 'JK', 'LastName': 'Richardson', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, USA.'}, {'ForeName': 'James T', 'Initials': 'JT', 'LastName': 'Eckner', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, USA.'}, {'ForeName': 'Hogene', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Mechanical Engineering, University of Michigan, Ann Arbor, USA.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Ashton-Miller', 'Affiliation': 'Department of Mechanical Engineering, University of Michigan, Ann Arbor, USA.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881120915409'] 1511,32532068,Beneficial Molecular Adaptations In BRCA -Mutation Carriers By Combined HIT/HIRT Intervention: Results From A Pilot Study.,": Based on growing evidence that breast cancer (BRCA) also plays a pivotal role in the regulation of skeletal muscle metabolism and the response to anti-oxidative stress, we examined the influence of regular exercise in human BRCA mutation carriers on their BRCA1 gene/protein expression and inflammatory/oxidative response. Sixteen BRCA -mutation carriers were assigned to an intervention (IG) or control group (CG). IG received a combination of high-intensity interval endurance (HIT) and strength training (HIRT) for six weeks, whereas CG received a low-intensity activity program. Before (T0) and at the end of the intervention (T1), muscle biopsy, physiological performance, blood withdrawal and anthropometry were obtained. Parameters included: Muscle BRCA1 gene/protein expression, inflammatory/oxidative stress, anti-oxidative capacity, peak oxygen capacity (VO 2 peak) and 1-repetition maximum (1-RM) at six different training machines. VO 2 peak and 1-RM of IG were increased at T1 compared to T0, whereas CG performance, physiological and molecular parameters remained unchanged. IG showed increased BRCA1 protein concentration as well as anti-oxidative capacity, whereas gene expression was unaltered. IG inflammatory and oxidative damage did not differ between time points. Combined HIT/HIRT increases aerobic and strength performance of BRCA -mutation carriers with up regulated BRCA1 protein expression and improved anti-oxidative status without showing an increased inflammatory response.",2020,Combined HIT/HIRT increases aerobic and strength performance of BRCA -mutation carriers with up regulated BRCA1 protein expression and improved anti-oxidative status without showing an increased inflammatory response.,['Sixteen BRCA -mutation carriers'],"['combination of high-intensity interval endurance (HIT) and strength training (HIRT', 'HIT/HIRT Intervention', 'Combined HIT/HIRT']","['muscle biopsy, physiological performance, blood withdrawal and anthropometry', 'IG inflammatory and oxidative damage', 'aerobic and strength performance', 'VO 2 peak and 1-RM of IG', 'CG performance, physiological and molecular parameters', 'Muscle BRCA1 gene/protein expression, inflammatory/oxidative stress, anti-oxidative capacity, peak oxygen capacity (VO 2 peak) and 1-repetition maximum (1-RM', 'BRCA1 protein concentration', 'inflammatory response']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}]","[{'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0272285', 'cui_str': 'Heparin-induced thrombocytopenia'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0185283', 'cui_str': 'Biopsy of muscle'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1528558', 'cui_str': 'BRCA1 protein, human'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0259275', 'cui_str': 'Breast cancer type 1 susceptibility protein'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",,0.037094,Combined HIT/HIRT increases aerobic and strength performance of BRCA -mutation carriers with up regulated BRCA1 protein expression and improved anti-oxidative status without showing an increased inflammatory response.,"[{'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Bizjak', 'Affiliation': 'Ulm University Hospital, Division of Sports and Rehabilitation Medicine, 89075 Ulm, Germany.'}, {'ForeName': 'Sebastian V W', 'Initials': 'SVW', 'LastName': 'Schulz', 'Affiliation': 'Ulm University Hospital, Division of Sports and Rehabilitation Medicine, 89075 Ulm, Germany.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Schumann', 'Affiliation': 'Ulm University Hospital, Division of Sports and Rehabilitation Medicine, 89075 Ulm, Germany.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Otto', 'Affiliation': 'Ulm University Hospital, Division of Sports and Rehabilitation Medicine, 89075 Ulm, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Kirsten', 'Affiliation': 'Ulm University Hospital, Division of Sports and Rehabilitation Medicine, 89075 Ulm, Germany.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Ebner', 'Affiliation': 'Ulm University Hospital, Department of Gynecology and Obstetrics, 89075 Ulm, Germany.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Leinert', 'Affiliation': 'Ulm University Hospital, Department of Gynecology and Obstetrics, 89075 Ulm, Germany.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Huober', 'Affiliation': 'Ulm University Hospital, Department of Gynecology and Obstetrics, 89075 Ulm, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Janni', 'Affiliation': 'Ulm University Hospital, Department of Gynecology and Obstetrics, 89075 Ulm, Germany.'}, {'ForeName': 'Jürgen Michael', 'Initials': 'JM', 'LastName': 'Steinacker', 'Affiliation': 'Ulm University Hospital, Division of Sports and Rehabilitation Medicine, 89075 Ulm, Germany.'}]",Cancers,['10.3390/cancers12061526'] 1512,32532097,"A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults.","This study describes a double-blind randomized placebo-controlled phase I clinical trial in healthy adults of a new potential pandemic H7N9 live attenuated influenza vaccine (LAIV) based on the human influenza virus of Yangtze River Delta hemagglutinin lineage (ClinicalTrials.gov Identifier: NCT03739229). Two doses of H7N9 LAIV or placebo were administered intranasally to 30 and 10 subjects, respectively. The vaccine was well-tolerated and not associated with increased rates of adverse events or with any serious adverse events. Vaccine virus was detected in nasal swabs during the 6 days after vaccination or revaccination. A lower frequency of shedding was observed after the second vaccination. Twenty-five clinical viral isolates obtained after the first and second doses of vaccine retained the temperature-sensitive and cold-adapted phenotypic characteristics of LAIV. There was no confirmed transmission of the vaccine strain from vaccinees to placebo recipients. After the two H7N9 LAIV doses, an immune response was observed in 96.6% of subjects in at least one of the assays conducted.",2020,The vaccine was well-tolerated and not associated with increased rates of adverse events or with any serious adverse events.,"['healthy adults of a new potential pandemic H7N9 live attenuated', 'Healthy Adults']","['Placebo', 'New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine', 'influenza vaccine (LAIV', 'H7N9 LAIV or placebo', 'placebo']","['frequency of shedding', 'Safety, Immunogenicity and Genetic Stability', 'immune response', 'rates of adverse events']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}, {'cui': 'C0016627', 'cui_str': 'Avian influenza'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}, {'cui': 'C0016627', 'cui_str': 'Avian influenza'}, {'cui': 'C3652556', 'cui_str': 'influenza, live attenuated'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0021403', 'cui_str': 'Influenza virus vaccine'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0017296', 'cui_str': 'Gene therapy'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0301872', 'cui_str': 'Immune response'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.409709,The vaccine was well-tolerated and not associated with increased rates of adverse events or with any serious adverse events.,"[{'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Kiseleva', 'Affiliation': 'Federal State Budgetary Scientific Institution ""Institute of Experimental Medicine"", 197376 St Petersburg, Russia.'}, {'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Isakova-Sivak', 'Affiliation': 'Federal State Budgetary Scientific Institution ""Institute of Experimental Medicine"", 197376 St Petersburg, Russia.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Stukova', 'Affiliation': 'Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, 197376 St Petersburg, Russia.'}, {'ForeName': 'Marianna', 'Initials': 'M', 'LastName': 'Erofeeva', 'Affiliation': 'Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, 197376 St Petersburg, Russia.'}, {'ForeName': 'Svetlana', 'Initials': 'S', 'LastName': 'Donina', 'Affiliation': 'Federal State Budgetary Scientific Institution ""Institute of Experimental Medicine"", 197376 St Petersburg, Russia.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Larionova', 'Affiliation': 'Federal State Budgetary Scientific Institution ""Institute of Experimental Medicine"", 197376 St Petersburg, Russia.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Krutikova', 'Affiliation': 'Federal State Budgetary Scientific Institution ""Institute of Experimental Medicine"", 197376 St Petersburg, Russia.'}, {'ForeName': 'Ekaterina', 'Initials': 'E', 'LastName': 'Bazhenova', 'Affiliation': 'Federal State Budgetary Scientific Institution ""Institute of Experimental Medicine"", 197376 St Petersburg, Russia.'}, {'ForeName': 'Ekaterina', 'Initials': 'E', 'LastName': 'Stepanova', 'Affiliation': 'Federal State Budgetary Scientific Institution ""Institute of Experimental Medicine"", 197376 St Petersburg, Russia.'}, {'ForeName': 'Kirill', 'Initials': 'K', 'LastName': 'Vasilyev', 'Affiliation': 'Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, 197376 St Petersburg, Russia.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Matyushenko', 'Affiliation': 'Federal State Budgetary Scientific Institution ""Institute of Experimental Medicine"", 197376 St Petersburg, Russia.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Krylova', 'Affiliation': 'The Federal State Unitary Enterprise ""Scientific and Production Association for Immunological Preparations ""Microgen"", Ministry of Health of Russian Federation, 127473 Moscow, Russia.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Galatonova', 'Affiliation': 'The Federal State Unitary Enterprise ""Scientific and Production Association for Immunological Preparations ""Microgen"", Ministry of Health of Russian Federation, 127473 Moscow, Russia.'}, {'ForeName': 'Aleksey', 'Initials': 'A', 'LastName': 'Ershov', 'Affiliation': 'The Federal State Unitary Enterprise ""Scientific and Production Association for Immunological Preparations ""Microgen"", Ministry of Health of Russian Federation, 127473 Moscow, Russia.'}, {'ForeName': 'Dmitry', 'Initials': 'D', 'LastName': 'Lioznov', 'Affiliation': 'Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, 197376 St Petersburg, Russia.'}, {'ForeName': 'Erin Grace', 'Initials': 'EG', 'LastName': 'Sparrow', 'Affiliation': 'World Health Organization, 1211 Geneva, Switzerland.'}, {'ForeName': 'Guido', 'Initials': 'G', 'LastName': 'Torelli', 'Affiliation': 'World Health Organization, 1211 Geneva, Switzerland.'}, {'ForeName': 'Larisa', 'Initials': 'L', 'LastName': 'Rudenko', 'Affiliation': 'Federal State Budgetary Scientific Institution ""Institute of Experimental Medicine"", 197376 St Petersburg, Russia.'}]",Vaccines,['10.3390/vaccines8020296'] 1513,32532564,"Corrigendum to 'Is regional ankle block needed in conjunction with general anaesthesia for first ray surgery? A randomised controlled trial of ultrasound guided ankle block versus ""blind"" local infiltration' [Foot and Ankle Surgery 26 (2020) 66-70].",,2020,,[],"['ultrasound guided ankle block versus ""blind"" local infiltration\' [Foot and Ankle Surgery']",[],[],"[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0394745', 'cui_str': 'Local anesthetic ankle block'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0188412', 'cui_str': 'Operative procedure on ankle'}]",[],,0.104726,,"[{'ForeName': 'Veronica I', 'Initials': 'VI', 'LastName': 'Roberts', 'Affiliation': 'Orthopaedic Surgery, Leicester General Hospital, University Hospitals of Leicester, Leicester, England, UK.'}, {'ForeName': 'Randeep S', 'Initials': 'RS', 'LastName': 'Aujla', 'Affiliation': 'Orthopaedic Surgery, Leicester General Hospital, University Hospitals of Leicester, Leicester, England, UK. Electronic address: Randeep.aujla@hotmail.co.uk.'}, {'ForeName': 'Sheela', 'Initials': 'S', 'LastName': 'Vinay', 'Affiliation': 'Orthopaedic Surgery, Leicester General Hospital, University Hospitals of Leicester, Leicester, England, UK.'}, {'ForeName': 'Felix N', 'Initials': 'FN', 'LastName': 'Fombon', 'Affiliation': 'Orthopaedic Surgery, Leicester General Hospital, University Hospitals of Leicester, Leicester, England, UK.'}, {'ForeName': 'Harvinder', 'Initials': 'H', 'LastName': 'Singh', 'Affiliation': 'Orthopaedic Surgery, Leicester General Hospital, University Hospitals of Leicester, Leicester, England, UK.'}, {'ForeName': 'Maneesh', 'Initials': 'M', 'LastName': 'Bhatia', 'Affiliation': 'Orthopaedic Surgery, Leicester General Hospital, University Hospitals of Leicester, Leicester, England, UK.'}]",Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons,['10.1016/j.fas.2020.05.006'] 1514,32534120,Effect of traditional Chinese medicine formula GeGen decoction on primary dysmenorrhea: A randomized controlled trial study.,"ETHNOPHARMACOLOGICAL RELEVANCE GeGen Decoction, a well-known Chinese herbal formula, is widely used in China and other Asian countries to treat gynecological diseases, including primary dysmenorrhea. Pharmacological studies have confirmed that GeGen Decoction is able to inhibit spasmodic contractions of the uterus in vivo and in vitro. AIM OF THE STUDY The objective of this study is to examine the efficacy and safety of GeGen Decoction on primary dysmenorrheic patients. METHODS This was a randomized, double-blinded, placebo-controlled trial. GeGen Decoction or placebo was administered a week before the expected start of each cycle for three consecutive menstrual periods. Between-group differences in pain intensity were detected by visual analogue scale (VAS). In addition, serum levels of arginine vasopressin (AVP) and estrogen (E) were examined by enzyme-linked immunosorbent assay. Metabolomic analysis was further used to evaluate the influence of GeGen Decoction on the metabolomics of primary dysmenorrheic patients. RESULTS A total of 71 primary dysmenorrheic women were recruited and 30 participants met the criteria were randomized into GeGen Decoction or placebo group. After three consecutive menstrual cycles' treatments, the VAS score of the GeGen Decoction group was significantly lower than that of the placebo group. Both serum levels of AVP and E decreased after GeGen Decoction administration, while the placebo seemed to have little effect on either of the index. Moreover, after GeGen Decoction treatment, seven important metabolites were identified by metabolomic analysis compared to the placebo group. No abnormalities in blood biochemical and routine physical examination pre and post GeGen Decoction intervention were observed. CONCLUSIONS GeGen Decoction can remarkably relieve the severity of menstrual pain without obvious adverse effects. Its therapeutic effect on primary dysmenorrhea might be related to the regulation of pituitary hypothalamic ovarian hormones, and interfering with the metabolic change.",2020,"After three consecutive menstrual cycles' treatment, the VAS score of the GeGen Decoction group was significantly lower than that of the placebo group.","['primary dysmenorrhea', 'primary dysmenorrheic patients', '71 primary dysmenorrheic women were recruited and 30 participants met the criteria']","['GeGen Decoction', 'traditional Chinese medicine formula GeGen decoction', 'GeGen Decoction or placebo', 'placebo']","['VAS score', 'pain intensity', 'blood biochemical and routine physical examination pre and post GeGen Decoction intervention', 'visual analogue scale (VAS', 'serum levels of arginine vasopressin (AVP) and estrogen (E', 'serum levels of AVP and E', 'efficacy and safety', 'severity of menstrual pain']","[{'cui': 'C0149875', 'cui_str': 'Primary dysmenorrhea'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003779', 'cui_str': 'Argipressin'}, {'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0013390', 'cui_str': 'Dysmenorrhea'}]",71.0,0.369829,"After three consecutive menstrual cycles' treatment, the VAS score of the GeGen Decoction group was significantly lower than that of the placebo group.","[{'ForeName': 'Chengzhi', 'Initials': 'C', 'LastName': 'Chai', 'Affiliation': 'Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, PR China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Hong', 'Affiliation': 'Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, PR China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': 'Shanxi University, Taiyuan, Shanxi Province, PR China.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, PR China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zong', 'Affiliation': 'Hospital Affiliated to Shanxi University of Traditional Chinese Medicine, Taiyuan, Shanxi Province, PR China.'}, {'ForeName': 'Changsong', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Traditional Chinese Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu Province, PR China.'}, {'ForeName': 'Zhigang', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of Traditional Chinese Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu Province, PR China. Electronic address: liuzhigang729@seu.edu.cn.'}, {'ForeName': 'Boyang', 'Initials': 'B', 'LastName': 'Yu', 'Affiliation': 'Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, PR China. Electronic address: boyangyu59@163.com.'}]",Journal of ethnopharmacology,['10.1016/j.jep.2020.113053'] 1515,32534175,"Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials.","PURPOSE Asymptomatic or minimally symptomatic infection with COVID-19 can result in silent transmission to large numbers of individuals, resulting in expansion of the pandemic with a global increase in morbidity and mortality. New ways of screening the general population for COVID-19 are urgently needed along with novel effective prevention and treatment strategies. HYPOTHESIS A hypothetical three-part prevention, diagnostic, and treatment approach based on an up-to-date scientific literature review for COVID-19 is proposed. Regarding diagnosis, a validated screening questionnaire and digital app for COVID-19 could help identify individuals who are at risk of transmitting the disease, as well as those at highest risk for poor clinical outcomes. Global implementation and online tracking of vital signs and scored questionnaires that are statistically validated would help health authorities properly allocate essential health care resources to test and isolate those at highest risk for transmission and poor outcomes. Second, regarding prevention, no validated protocols except for physical distancing, hand washing, and isolation exist, and recently ivermectin has been published to have anti-viral properties against COVID-19. A randomized trial of ivermectin, and/or nutraceuticals that have been published to support immune function including glutathione, vitamin C, zinc, and immunomodulatory supplements (3,6 Beta glucan) could be beneficial in preventing transmission or lessening symptomatology but requires statistical validation. Third, concerning treatment, COVID-19 induced inflammation and ""cytokine storm syndrome"" with hemophagocytic lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS) have resulted in extreme morbidity and mortality in those with certain comorbidities, secondary to ""acute respiratory distress syndrome"" (ARDS) and multiorgan dysfunction with disseminated intravascular coagulation (DIC). Deficiency in red blood cell, serum and alveolar glutathione has been published in the medical literature for ARDS, as well as viral and bacterial pneumonias, resulting from increased levels of free radical/oxidative stress. A randomized controlled trial of blocking NF-κB and cytokine formation using glutathione precursors (N-acetyl-cysteine [NAC] and alpha lipoic acid) and PO/IV glutathione with associated anti-viral effects should be performed, along with an evaluation of Nrf2 activators (curcumin, sulforaphane glucosinolate) which have been scientifically proven to lower inflammation. Since high mortality rates from sepsis induced DIC due to COVID-19 infection has also been associated with thrombotic events and elevated levels of D-dimer, randomized controlled trials of using anticoagulant therapy with heparin is urgently required. This is especially important in patients on ventilators who have met certain sepsis induced coagulopathy (SIC) criteria. The use of acetazolamide with or without sildenafil also needs to be explored with or without heparin, since increased oxygen delivery to vital organs through prevention of thrombosis/pulmonary emboli along with carbonic anhydrase inhibition may help increase oxygenation and prevent adverse clinical outcomes. CONCLUSION AND IMPLICATIONS A three-part prevention, diagnostic, and treatment plan is proposed for addressing the severe complications of COVID-19. Digital monitoring of symptoms to clinically diagnose early exposure and response to treatment; prevention with ivermectin as well as nutritional therapies that support a healthy immune response; treatment with anti-inflammatory therapies that block NF-κB and activate Nrf2 pathways, as well as novel therapies that address COVID-19 pneumonia and ARDS with DIC including anticoagulation and/or novel respiratory therapies with or without acetazolamide and sildenafil. These three broad-based interventions urgently need to be subjected to randomized, controlled trials.",2020,"New ways of screening the general population for COVID-19 are urgently needed along with novel effective prevention and treatment strategies. ",['patients on ventilators who have met certain sepsis induced coagulopathy (SIC) criteria'],"['ivermectin', 'acetazolamide and sildenafil', 'heparin', 'hemophagocytic lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS', 'acetazolamide with or without sildenafil', 'blocking NF-κB and cytokine formation using glutathione precursors (N-acetyl-cysteine [NAC] and alpha lipoic acid) and PO/IV glutathione']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2603364', 'cui_str': 'On ventilator'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0205423', 'cui_str': 'Certain'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0005779', 'cui_str': 'Blood coagulation disorder'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0022322', 'cui_str': 'Ivermectin'}, {'cui': 'C0000981', 'cui_str': 'Acetazolamide'}, {'cui': 'C0529793', 'cui_str': 'sildenafil'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0024291', 'cui_str': 'Hemophagocytic lymphohistiocytosis'}, {'cui': 'C1868709', 'cui_str': 'Activation syndrome'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C0023791', 'cui_str': 'thioctic acid'}]",[],,0.0711722,"New ways of screening the general population for COVID-19 are urgently needed along with novel effective prevention and treatment strategies. ","[{'ForeName': 'Richard I', 'Initials': 'RI', 'LastName': 'Horowitz', 'Affiliation': 'HHS Babesia and Tickborne Pathogen Subcommittee, Washington, D.C. 20201, USA; Hudson Valley Healing Arts Center, 4232 Albany Post Road, Hyde Park, NY 12538, USA. Electronic address: medical@hvhac.com.'}, {'ForeName': 'Phyllis R', 'Initials': 'PR', 'LastName': 'Freeman', 'Affiliation': 'Hudson Valley Healing Arts Center, 4232 Albany Post Road, Hyde Park, NY 12538, USA.'}]",Medical hypotheses,['10.1016/j.mehy.2020.109851'] 1516,32534221,The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.,"INTRODUCTION In women with postmenopausal osteoporosis denosumab discontinuation is associated with rapid bone loss that could be potentially prevented by a single zoledronate infusion for two years. The longer-term effects, however, of zoledronate treatment are unknown. We aimed to study the effect of a single zoledronate infusion during the third year following denosumab discontinuation, in initially treatment-naive postmenopausal women who became osteopenic after 2.4 ± 0.2 years of denosumab therapy. METHODS We report the 1-year follow-up results of a single arm observational extension of a previously reported 2-year multicenter prospective randomized clinical trial. The primary endpoint of this extension was the change in lumbar spine bone mineral density (LS-BMD); secondary endpoints were changes in femoral neck (FN)-BMD and markers of bone turnover (BTM) during the 3rd year from the zoledronate infusion. Changes are presented as mean and SEM. RESULTS LS-BMD did not change significantly at year 3 compared to year 2 (-1.35 ± 1.1%, p = 1.00) and compared to baseline (-1.96 ± 1.44%, p = 1.00). FN-BMD values did not change while serum P1NP values decreased and CTX values remained unchanged during the third-year of the follow-up. In 4 of the 23 studied women BMD values returned to the osteoporotic range at 3 years. CONCLUSIONS A single i.v. infusion of zoledronate 5 mg, given 6 months after the last injection of denosumab therapy maintains for three years BMD gains in the majority of patients previously treated with denosumab for an approximate period of 2.5 years. Follow-up of patients is, however, recommended because about one-fifth of treated women will require additional antiosteoporotic treatment.",2020,FN-BMD values did not change while serum P1NP values decreased and CTX values remained unchanged during the third-year of the follow-up.,"['women with postmenopausal osteoporosis', 'initially treatment-naive postmenopausal women who became osteopenic after 2.4\u202f±\u202f0.2\u202fyears of denosumab therapy']","['single zoledronate infusion', 'zoledronate infusion', 'denosumab', 'zoledronate', 'denosumab discontinuation']","['CTX values', 'femoral neck (FN)-BMD and markers of bone turnover (BTM', 'FN-BMD values', 'lumbar spine bone mineral density (LS-BMD', 'bone mineral density and bone turnover markers', 'LS-BMD']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0029458', 'cui_str': 'Postmenopausal osteoporosis'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C4517631', 'cui_str': '2.4'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3839270', 'cui_str': 'Denosumab therapy'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0392938', 'cui_str': 'Zoledronate'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}]","[{'cui': 'C0010377', 'cui_str': 'Crotoxin'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0015815', 'cui_str': 'Structure of neck of femur'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0085268', 'cui_str': 'Bone remodeling'}, {'cui': 'C0024091', 'cui_str': 'Bone structure of lumbar vertebra'}]",23.0,0.0926873,FN-BMD values did not change while serum P1NP values decreased and CTX values remained unchanged during the third-year of the follow-up.,"[{'ForeName': 'Polyzois', 'Initials': 'P', 'LastName': 'Makras', 'Affiliation': 'Department of Endocrinology and Diabetes and Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.'}, {'ForeName': 'Socrates E', 'Initials': 'SE', 'LastName': 'Papapoulos', 'Affiliation': 'Center for Bone Quality, Department of Internal Medicine, Section Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Stergios A', 'Initials': 'SA', 'LastName': 'Polyzos', 'Affiliation': 'First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Natasha M', 'Initials': 'NM', 'LastName': 'Appelman-Dijkstra', 'Affiliation': 'Center for Bone Quality, Department of Internal Medicine, Section Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Athanasios D', 'Initials': 'AD', 'LastName': 'Anastasilakis', 'Affiliation': 'Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece. Electronic address: a.anastasilakis@gmail.com.'}]",Bone,['10.1016/j.bone.2020.115478'] 1517,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: results of a multicenter randomized placebo-controlled clinical trial.,"BACKGROUND Surgical site infections (SSIs) are common complications after colorectal surgery. Oral non-absorbable antibiotic prophylaxis (OAP) can be administered preoperatively to reduce the risk of SSIs. Its efficacy without simultaneous mechanical cleaning is unknown. METHODS The Precaution trial was a double-blind, placebo-controlled randomized clinical trial conducted in six Dutch hospitals. Adult patients who underwent elective colorectal surgery were randomized to receive either a three-day course of preoperative OAP with tobramycin and colistin or placebo. The primary composite endpoint was the incidence of deep SSI or mortality within 30 days after surgery. Secondary endpoints included both infectious and non-infectious complications at 30 days and six months after surgery. RESULTS The study was prematurely ended due to the loss of clinical equipoise. At that time, 39 patients had been randomized to active OAP and 39 to placebo, which reflected 8.1% of the initially pursued sample size. Nine (11.5%) patients developed the primary outcome, of whom four had been randomized to OAP (4/39; 10.3%) and five to placebo (5/39; 12.8%). This corresponds to a risk ratio in the intention-to-treat analysis of 0.80 (95% confidence interval (CI) 0.23-2.78). In the per-protocol analysis, the relative risk was 0.64 (95% CI 0.12-3.46). CONCLUSIONS Observational data emerging during the study provided new evidence for the effectiveness of OAP that changed both the clinical and medical ethical landscape for infection prevention in colorectal surgery. We therefore consider it unethical to continue randomizing patients to placebo. We recommend the implementation of OAP in clinical practice and continuing monitoring of infection rates and antibiotic susceptibilities. TRIAL REGISTRATION The PreCaution trial is registered in the Netherlands Trial Register under NL5932 (previously: NTR6113) as well as in the EudraCT register under 2015-005736-17.",2020,This corresponds to a risk ratio in the intention-to-treat analysis of 0.80 (95% confidence interval (CI) 0.23-2.78).,"['Adult patients who underwent elective colorectal surgery', 'six Dutch hospitals', '39 patients had been randomized to active OAP and 39 to']","['OAP', 'colorectal surgery using oral non-absorbable antimicrobial prophylaxis', 'preoperative OAP with tobramycin and colistin or placebo', 'Oral non-absorbable antibiotic prophylaxis (OAP', 'placebo']","['infectious and non-infectious complications', 'incidence of deep SSI or mortality', 'relative risk']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0009369', 'cui_str': 'Colorectal surgery'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0282638', 'cui_str': 'Antibiotic prophylaxis'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0282638', 'cui_str': 'Antibiotic prophylaxis'}, {'cui': 'C0009369', 'cui_str': 'Colorectal surgery'}, {'cui': 'C1527415', 'cui_str': 'Oral route'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0040341', 'cui_str': 'Tobramycin'}, {'cui': 'C0009316', 'cui_str': 'Colistin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}]",,0.768962,This corresponds to a risk ratio in the intention-to-treat analysis of 0.80 (95% confidence interval (CI) 0.23-2.78).,"[{'ForeName': 'Tessa', 'Initials': 'T', 'LastName': 'Mulder', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.'}, {'ForeName': 'Marjolein', 'Initials': 'M', 'LastName': 'Kluytmans-van den Bergh', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.'}, {'ForeName': 'Bart', 'Initials': 'B', 'LastName': 'Vlaminckx', 'Affiliation': 'Department of Medical Microbiology, St. Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'Daphne', 'Initials': 'D', 'LastName': 'Roos', 'Affiliation': 'Department of Surgery, Reinier de Graaf Gasthuis, Delft, The Netherlands.'}, {'ForeName': 'Anne Marie', 'Initials': 'AM', 'LastName': 'de Smet', 'Affiliation': 'Department of Intensive Care Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'de Vos Tot Nederveen Cappel', 'Affiliation': 'Department of Surgery, Admiraal de Ruyter Hospital, Goes, The Netherlands.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Verheijen', 'Affiliation': 'Department of Surgery, Meander Medical Center, Amersfoort, The Netherlands.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Brandt', 'Affiliation': 'Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Anke', 'Initials': 'A', 'LastName': 'Smits', 'Affiliation': 'Department of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'van der Vorm', 'Affiliation': 'Department of Medical Microbiology, Reinier de Graaf Gasthuis, Delft, The Netherlands.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Bathoorn', 'Affiliation': 'Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Boudewijn', 'Initials': 'B', 'LastName': 'van Etten', 'Affiliation': 'Department of Surgery, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Jacobien', 'Initials': 'J', 'LastName': 'Veenemans', 'Affiliation': 'Department of Medical Microbiology, Admiraal de Ruyter Hospital, Goes, the Netherlands.'}, {'ForeName': 'Annemarie', 'Initials': 'A', 'LastName': 'Weersink', 'Affiliation': 'Department of Medical Microbiology, Meander Medical Center, Amersfoort, The Netherlands.'}, {'ForeName': 'Margreet', 'Initials': 'M', 'LastName': 'Vos', 'Affiliation': 'Department of Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Nils', 'Initials': 'N', 'LastName': ""van 't Veer"", 'Affiliation': 'Department of Clinical Pharmacy, Amphia Hospital, Breda, The Netherlands.'}, {'ForeName': 'Stavros', 'Initials': 'S', 'LastName': 'Nikolakopoulos', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Bonten', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Kluytmans', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. jankluytmans@gmail.com.'}]",Antimicrobial resistance and infection control,['10.1186/s13756-020-00745-2'] 1518,32540210,Does accreditation affect the job satisfaction of general practitioners? A combined panel data survey and cluster randomised field experiment.,"A critical question for policy makers in health care is whether external interventions have unintended consequences such as lowering professionals' job satisfaction. We investigate whether a non-monetary incentive, in the form of mandatory accreditation, affects the job satisfaction of Danish GPs. Accreditation of general practice in Denmark was introduced as a cluster randomised stepwise implementation from 2016 to 2018. We measure job satisfaction at three time points: before the randomisation took place, one year into the accreditation process and two years into the accreditation process. We use a balanced panel of GPs who have completed all three waves of the survey (n = 846) and estimate a series of random and mixed effects ordered logit models. Despite many GPs having negative attitudes towards accreditation, we find no evidence of accreditation affecting GP job satisfaction. However, there are negative associations between job satisfaction and perceiving accreditation as a tool for external control. Policy makers are therefore encouraged to carefully inform about new interventions and identify barriers to diminish pre-existing negative perceptions about the incentive.",2020,"We investigate whether a non-monetary incentive, in the form of mandatory accreditation, affects the job satisfaction of Danish GPs.",[],[],['job satisfaction'],[],[],"[{'cui': 'C0022397', 'cui_str': 'Work Satisfaction'}]",,0.0348546,"We investigate whether a non-monetary incentive, in the form of mandatory accreditation, affects the job satisfaction of Danish GPs.","[{'ForeName': 'Line Bjørnskov', 'Initials': 'LB', 'LastName': 'Pedersen', 'Affiliation': 'DaCHE - Danish Centre for Health Economics, Institute of Public Health, University of Southern Denmark, J.B. Winsløwsvej 9B, 5000 Odense C, Denmark; Research Unit for General Practice, Institute of Public Health, University of Southern Denmark, J.B. Winsløwsvej 9A, 5000 Odense C, Denmark. Electronic address: lib@sdu.dk.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Allen', 'Affiliation': 'Manchester Centre for Health Economics, University of Manchester, Oxford Road, Manchester M13 9PL, UK.'}, {'ForeName': 'Frans Boch', 'Initials': 'FB', 'LastName': 'Waldorff', 'Affiliation': 'Research Unit for General Practice, Institute of Public Health, University of Southern Denmark, J.B. Winsløwsvej 9A, 5000 Odense C, Denmark.'}, {'ForeName': 'Merethe Kirstine Kousgaard', 'Initials': 'MKK', 'LastName': 'Andersen', 'Affiliation': 'Research Unit for General Practice, Institute of Public Health, University of Southern Denmark, J.B. Winsløwsvej 9A, 5000 Odense C, Denmark.'}]","Health policy (Amsterdam, Netherlands)",['10.1016/j.healthpol.2020.04.002'] 1519,32540277,High blood pressure responders show largest increase in heartbeat perception accuracy after post-learning stress following a cardiac interoceptive learning task.,"Mental disorders with physical symptoms, e.g. somatic symptom disorder, are characterized by altered interoceptive accuracy (IAc), which can be explained by individual differences in interoceptive learning (IL). We investigated if stress facilitates IL. Seventy-three healthy participants performed a heartbeat counting task (HCT: T1) and a heartbeat perception training (HBPT). After exposure to a socially-evaluated cold pressor stress test (SECPT; n = 48) or a control condition (n = 25), two more HCTs were performed (T2: 30 min after SECPT; T3: 24 h later). After the HBPT, all participants showed an increase in IAc. We separated the stress group into high vs. low systolic blood pressures (SBP) responders (n = 24 each), with high SBP responders showing the largest IAc increases. Only SBP, but not cortisol responsiveness significantly predicted IAc increase from T1 to T2. Our results indicate that post-learning autonomic stress response facilitates IL, whereas the HPA axis response may be less important for this effect.",2020,"Only SBP, but not cortisol responsiveness significantly predicted IAc increase from T1 to T2.","['Seventy-three healthy participants', 'Mental disorders with physical symptoms, e.g. somatic symptom disorder']","['heartbeat counting task (HCT: T1) and a heartbeat perception training (HBPT', 'SECPT']","['HPA axis response', 'IAc', 'systolic blood pressures (SBP) responders', 'heartbeat perception accuracy']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4087321', 'cui_str': 'Somatic symptom disorder'}]","[{'cui': 'C0425583', 'cui_str': 'Heart beat'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0085355', 'cui_str': 'Platelet-specific antigen'}, {'cui': 'C0004457', 'cui_str': 'Bone structure of axis'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0425583', 'cui_str': 'Heart beat'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]",73.0,0.014762,"Only SBP, but not cortisol responsiveness significantly predicted IAc increase from T1 to T2.","[{'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Schenk', 'Affiliation': 'Clinical Psychophysiology Laboratory, Department of Behavioural and Cognitive Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg.'}, {'ForeName': 'Jean T M', 'Initials': 'JTM', 'LastName': 'Fischbach', 'Affiliation': 'Clinical Psychophysiology Laboratory, Department of Behavioural and Cognitive Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg.'}, {'ForeName': 'Ruta', 'Initials': 'R', 'LastName': 'Müller', 'Affiliation': 'Clinical Psychophysiology Laboratory, Department of Behavioural and Cognitive Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Vögele', 'Affiliation': 'Clinical Psychophysiology Laboratory, Department of Behavioural and Cognitive Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Witthöft', 'Affiliation': 'Division of Clinical Psychology, Department of Psychology, Johannes Gutenberg University of Mainz, Mainz, Germany.'}, {'ForeName': 'Ilse', 'Initials': 'I', 'LastName': 'Van Diest', 'Affiliation': 'Department of Health Psychology, Catholic University of Leuven, Leuven, Belgium.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Schulz', 'Affiliation': 'Clinical Psychophysiology Laboratory, Department of Behavioural and Cognitive Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg. Electronic address: andre.schulz@uni.lu.'}]",Biological psychology,['10.1016/j.biopsycho.2020.107919'] 1520,32540779,Comparison of simple frenotomy with 4-flap Z-frenuloplasty in treatment for ankyloglossia with articulation difficulty: A prospective randomized study.,"OBJECTIVE To compare the surgical outcomes of simple frenotomy and the 4-flap Z-frenuloplasty according to the articulation test values and tongue-tie classification in patients with ankyloglossia with articulation difficulty. STUDY DESIGN prospective randomized study. SETTING Tertiary academic center. SUBJECTS and methods: Children with ankyloglossia with articulation difficulty were randomly divided into 2 groups for surgical treatment. Patients were evaluated for the tongue-tie classification and articulation test before surgery. Three months after the operation, the frenulum classification and articulation test were re-evaluated to compare the differences in surgical outcome between the two surgical methods. RESULTS Out of 37 patients, 19 underwent the 4-flap Z-frenuloplasty and 18, the simple frenotomy. No differences were observed in the baseline characteristics of the patients assigned to both groups. Changes in the tongue-tie classification and improvement in the articulation test results were observed with both the surgical methods. Both surgical groups had significant improvement in the speech articulation test (consonants) but there was no difference in the speech outcomes between the surgical groups. CONCLUSION Although there was no significant difference in the surgical outcome between the two surgical methods, ankyloglossia patients showed improvement in a Korean speech articulation test 3 months after undergoing surgery to release the lingual frenulum.",2020,"Both surgical groups had significant improvement in the speech articulation test (consonants) but there was no difference in the speech outcomes between the surgical groups. ","['patients with ankyloglossia with articulation difficulty', 'ankyloglossia with articulation difficulty', 'and methods', 'Children with ankyloglossia with articulation difficulty', 'Tertiary academic center', '37 patients, 19 underwent the 4-flap Z-frenuloplasty and 18, the simple frenotomy']","['simple frenotomy and the 4-flap Z-frenuloplasty', 'simple frenotomy with 4-flap Z-frenuloplasty']","['speech articulation test', 'speech outcomes', 'surgical outcome', 'Korean speech articulation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0152415', 'cui_str': 'Tongue tie'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0038925', 'cui_str': 'Flap'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0192139', 'cui_str': 'Incision of lingual frenum'}]","[{'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0192139', 'cui_str': 'Incision of lingual frenum'}, {'cui': 'C0038925', 'cui_str': 'Flap'}]","[{'cui': 'C0037819', 'cui_str': 'Speech Articulation Tests'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}]",37.0,0.0322658,"Both surgical groups had significant improvement in the speech articulation test (consonants) but there was no difference in the speech outcomes between the surgical groups. ","[{'ForeName': 'Tae Hoon', 'Initials': 'TH', 'LastName': 'Kim', 'Affiliation': 'Department of Otorhinolaryngology - Head & Neck Surgery, School of Medicine, Kyung Hee University, Seoul, Republic of Korea.'}, {'ForeName': 'Young Chan', 'Initials': 'YC', 'LastName': 'Lee', 'Affiliation': 'Department of Otorhinolaryngology - Head & Neck Surgery, School of Medicine, Kyung Hee University, Seoul, Republic of Korea.'}, {'ForeName': 'Seung Don', 'Initials': 'SD', 'LastName': 'Yoo', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.'}, {'ForeName': 'Seung Ah', 'Initials': 'SA', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.'}, {'ForeName': 'Young-Gyu', 'Initials': 'YG', 'LastName': 'Eun', 'Affiliation': 'Department of Otorhinolaryngology - Head & Neck Surgery, School of Medicine, Kyung Hee University, Seoul, Republic of Korea. Electronic address: ygeun@khu.ac.kr.'}]",International journal of pediatric otorhinolaryngology,['10.1016/j.ijporl.2020.110146'] 1521,32542627,Vitamin D in Type 2 Diabetes: Genetic Susceptibility and the Response to Supplementation.,"Variants of vitamin D metabolism-genes may predispose to type 2 diabetes (T2D). This study investigated the impact of these variants on disease susceptibility, Vitamin D, parathyroid hormone, C-peptide and HbA1c levels before and after cholecalciferol supplementation in patients with T2D.Twelve polymorphisms within CYP2R1, CYP27B1, DBP, VDR and CYP24A1 were genotyped in 553 T2D patients and 916 controls. In addition 65 patients receiving either cholecalciferol or placebo were analyzed during 6 months intervention and 6 months follow-up.T2D risk alleles are VDR rs7975232 ""G"" (p c =0.031), rs1544410 ""G"" (p c =0.027) and CYP2R1 rs10741657 ""A"" (p c =0.016). Patients with genotypes CYP27B1 rs10877012 ""CC"" (p c =4x10 -5 ), DBP rs7041 ""GG"" (p c =0.003), rs4588 ""CC"" (p c  = 3x10 -4 ), CYP24A1 rs2585426 ""CG"" (p c =0.006) and rs2248137 ""CG"" (p c =0.001) showed lower 25(OH)D3 and DBP rs4588 ""CC"" lower 1,25(OH)2D3 levels (p c =0.005). Whereas DBP rs4588 ""CC"" (p c =0.009), CYP27B1 rs10877012 ""AC"" (p c =0.059), VDR rs7975323 ""AG"" (p c =0.033) and rs1544410 ""GG"" (p c =0.013) are associated with higher 25(OH)D3 levels at 6 months' follow-up. Significant PTH suppression was detected for CYP2R1 ""AG"" (p c =0.002), DBP rs4588 ""CC"" (p c <0.001), VDR rs110735810 ""CT"" (p c <0.001) and CYP24A1 rs2248137 ""GG"" (p c =0.021).Genetic variants of the vitamin D system predispose to type 2 diabetes and regulate - partially - vitamin D metabolism, concentrations and the vitamin D status. Vitamin D insufficiency is a T2D risk factor. The response to cholecalciferol supplementation can be measured as 25(OH)D3 increment and PTH suppression. This process is regulated by genes of the vitamin D system conferring modest T2D risk.",2020,"Significant PTH suppression was detected for CYP2R1 ""AG"" (p c =0.002), DBP rs4588 ""CC"" (p c <0.001), VDR rs110735810 ""CT"" (p c <0.001) and CYP24A1 rs2248137 ""GG"" (p c =0.021).Genetic variants of the vitamin D system predispose to type 2 diabetes and regulate - partially - vitamin D metabolism, concentrations and the vitamin D status.","['Type 2 Diabetes', 'Patients with genotypes', 'patients with T2D.Twelve polymorphisms within CYP2R1, CYP27B1, DBP, VDR and CYP24A1 were genotyped in 553 T2D patients and 916 controls', '65 patients receiving either']","['cholecalciferol supplementation', 'cholecalciferol or placebo', 'Vitamin D']","['DBP rs4588 ""CC', '25(OH)D3 levels', 'VDR rs7975323 ""AG', 'CYP2R1 ""AG', '25(OH)D3 and DBP rs4588 ""CC"" lower 1,25(OH)2D3 levels', '25(OH)D3 increment and PTH suppression', 'CYP27B1 rs10877012 ""AC', 'disease susceptibility, Vitamin D, parathyroid hormone, C-peptide and HbA1c levels', 'VDR rs110735810 ""CT', 'Significant PTH suppression']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0032529', 'cui_str': 'Genetic polymorphism'}, {'cui': 'C1827418', 'cui_str': 'Cytochrome p450 CYP2R1 enzyme'}, {'cui': 'C0000340', 'cui_str': 'Calcidiol 1-monooxygenase'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C3657722', 'cui_str': 'VDR protein, human'}, {'cui': 'C0283470', 'cui_str': '1 alpha,25-Dihydroxycholecalciferol-24-Hydroxylase'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C3657722', 'cui_str': 'VDR protein, human'}, {'cui': 'C1827418', 'cui_str': 'Cytochrome p450 CYP2R1 enzyme'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0020063', 'cui_str': 'PTH protein, human'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0000340', 'cui_str': 'Calcidiol 1-monooxygenase'}, {'cui': 'C0012655', 'cui_str': 'Diathesis'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0750502', 'cui_str': 'Significant'}]",,0.0456524,"Significant PTH suppression was detected for CYP2R1 ""AG"" (p c =0.002), DBP rs4588 ""CC"" (p c <0.001), VDR rs110735810 ""CT"" (p c <0.001) and CYP24A1 rs2248137 ""GG"" (p c =0.021).Genetic variants of the vitamin D system predispose to type 2 diabetes and regulate - partially - vitamin D metabolism, concentrations and the vitamin D status.","[{'ForeName': 'Edith', 'Initials': 'E', 'LastName': 'Klahold', 'Affiliation': 'Department of Internal Medicine I, Division of Endocrinology, Diabetes and Metabolism, Goethe-University Hospital, Frankfurt/Main, Germany.'}, {'ForeName': 'Marissa', 'Initials': 'M', 'LastName': 'Penna-Martinez', 'Affiliation': 'Department of Internal Medicine I, Division of Endocrinology, Diabetes and Metabolism, Goethe-University Hospital, Frankfurt/Main, Germany.'}, {'ForeName': 'Franziska', 'Initials': 'F', 'LastName': 'Bruns', 'Affiliation': 'Department of Internal Medicine I, Division of Endocrinology, Diabetes and Metabolism, Goethe-University Hospital, Frankfurt/Main, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Seidl', 'Affiliation': 'German Red Cross Blood Donor Service, Institute for Transfusion Medicine and Immunohaematology, Frankfurt/Main, Germany.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Wicker', 'Affiliation': 'Occupational Health Service, Goethe-University Hospital, Frankfurt/Main, Germany.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Badenhoop', 'Affiliation': 'Department of Internal Medicine I, Division of Endocrinology, Diabetes and Metabolism, Goethe-University Hospital, Frankfurt/Main, Germany.'}]",Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,['10.1055/a-1157-0026'] 1522,32535742,Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects.,"INTRODUCTION Ultra rapid lispro (URLi) is a novel insulin lispro formulation that was developed to more closely match physiological insulin secretion. The aims of this study were to demonstrate the bioequivalence (BE) of a concentrated formulation (U200) of URLi to the U100 formulation of URLi after subcutaneous (SC) administration and to evaluate the glucodynamics (GD) of these formulations. METHODS This phase 1, randomized, two-sequence, four-period, double-blind, replicate crossover study was conducted in 68 healthy subjects. At each dosing visit, subjects received a 15-U SC dose of either U100 URLi or U200 URLi followed by a 10-h euglycemic clamp procedure. Serum insulin lispro and blood glucose concentrations were measured, and the glucose infusion rate was continuously adjusted during the clamp to maintain the target blood glucose. RESULTS Bioequivalence of U200 URLi relative to U100 URLi was demonstrated. The 90% confidence intervals (CIs) of the ratios of geometric least squares (LS) means for the maximum insulin concentration and total exposure were within the BE limits of 0.80-1.25. Additionally, the 90% CIs for the ratios of geometric LS means for maximum glucose infusion rate and total glucose infused were within the BE limits. The early 50% t max occurred at approximately the same time for the U100 and U200 URLi formulations, and the insulin exposure within the first 15 min was similar for both formulations. The tolerability of the two URLi formulations was comparable. CONCLUSIONS This study demonstrated that the U100 and U200 URLi formulations are bioequivalent. The accelerated insulin absorption observed for the U100 formulation was maintained with the U200 URLi formulation. Further, the GD were similar for both formulations, supporting the ability of individuals to transfer from U100 to U200 URLi in a 1:1 unit conversion. TRIAL REGISTRATION NCT03616977.",2020,"The tolerability of the two URLi formulations was comparable. ","['68 healthy subjects', 'Healthy Subjects']","['Ultra Rapid Lispro (URLi) U100 and U200 Formulations', 'Ultra rapid lispro (URLi', '15-U SC dose of either U100 URLi or U200 URLi followed by a 10-h euglycemic clamp procedure']","['accelerated insulin absorption', 'maximum glucose infusion rate and total glucose', 'Serum insulin lispro and blood glucose concentrations', 'glucose infusion rate']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0293359', 'cui_str': 'Insulin Lispro'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0079318', 'cui_str': 'Euglycaemic Clamp'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0521110', 'cui_str': 'Accelerated'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0293359', 'cui_str': 'Insulin Lispro'}, {'cui': 'C2585282', 'cui_str': 'Blood glucose concentration'}]",68.0,0.0625239,"The tolerability of the two URLi formulations was comparable. ","[{'ForeName': 'Helle', 'Initials': 'H', 'LastName': 'Linnebjerg', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Elizabeth Smith', 'Initials': 'ES', 'LastName': 'LaBell', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Mary Anne', 'Initials': 'MA', 'LastName': 'Dellva', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Coutant', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Leohr', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA. leohr_jennifer_k@lilly.com.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00848-4'] 1523,32546645,Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.,"PURPOSE In the S-TRAC trial, adjuvant sunitinib improved disease-free survival (DFS) compared with placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence. This post hoc exploratory analysis investigated the neutrophil-to-lymphocyte ratio (NLR) for predictive and prognostic significance in the RCC adjuvant setting. EXPERIMENTAL DESIGN Kaplan-Meier estimates and Cox proportional analyses were performed on baseline NLR and change from baseline at week 4 to assess their association with DFS. Univariate P values were two-sided and based on an unstratified log-rank test. RESULTS 609 of 615 patients had baseline NLR values; 574 patients had baseline and week 4 values. Sunitinib-treated patients with baseline NLR <3 had longer DFS versus placebo (7.1 vs. 4.7; HR, 0.71; P = 0.02). For baseline NLR ≥3, DFS was similar regardless of treatment (sunitinib 6.8 vs. placebo not reached; HR, 1.03; P = 0.91). A ≥25% NLR decrease at week 4 was associated with longer DFS versus no change (6.8 vs. 5.3 years; HR, 0.71; P = 0.01). A greater proportion of sunitinib-treated patients had ≥25% NLR decrease at week 4 (71.2%) versus placebo (17.4%). Patients with ≥25% NLR decrease at week 4 received a higher median cumulative sunitinib dose (10,137.5 mg) versus no change (8,168.8 mg) or ≥25% increase (6,712.5 mg). CONCLUSIONS In the postnephrectomy high-risk RCC patient cohort, low baseline NLR may help identify those most suitable for adjuvant sunitinib. A ≥25% NLR decrease at week 4 may be an early indicator of those most likely to tolerate treatment and derive DFS benefit.",2020,"For baseline NLR ≥3, DFS was similar regardless of treatment (sunitinib 6.8 vs. placebo not reached; HR, 1.03; P = 0.91).",['patients with loco-regional renal cell carcinoma (RCC) at high risk of recurrence'],['placebo'],"['neutrophil-to-lymphocyte ratio (NLR', 'disease-free survival (DFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0007134', 'cui_str': 'Renal cell carcinoma'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0024264', 'cui_str': 'Lymphocyte'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}]",,0.276738,"For baseline NLR ≥3, DFS was similar regardless of treatment (sunitinib 6.8 vs. placebo not reached; HR, 1.03; P = 0.91).","[{'ForeName': 'Anup', 'Initials': 'A', 'LastName': 'Patel', 'Affiliation': 'London, United Kingdom. anuppatel666@gmail.com.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Ravaud', 'Affiliation': 'Bordeaux University Hospital, Bordeaux, France.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Motzer', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Allan J', 'Initials': 'AJ', 'LastName': 'Pantuck', 'Affiliation': 'Ronald Reagan UCLA Medical Center, Los Angeles, California.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Staehler', 'Affiliation': 'University Hospital of Munich, Munich, Germany.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Escudier', 'Affiliation': 'Institut Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Jean-François', 'Initials': 'JF', 'LastName': 'Martini', 'Affiliation': 'Pfizer Inc, La Jolla, California.'}, {'ForeName': 'Mariajose', 'Initials': 'M', 'LastName': 'Lechuga', 'Affiliation': 'Pfizer S.r.L, Milan, Italy.'}, {'ForeName': 'Xun', 'Initials': 'X', 'LastName': 'Lin', 'Affiliation': 'Pfizer Inc, La Jolla, California.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'George', 'Affiliation': 'Duke Cancer Institute, Durham, North Carolina.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-0704'] 1524,32683063,Pharmacological dilutional therapy using the vasopressin antagonist tolvaptan for young patients with cystinuria: a pilot investigation.,"OBJECTIVE To perform a pilot study of short-term safety, tolerability, and impact on urinary stone risk parameters of the vasopressin V2-receptor antagonist tolvaptan (which increases urinary excretion of free water) among adolescents and young adults with cystinuria. MATERIALS AND METHODS We enrolled cystinuria patients age 12-25 yrs. Subjects were treated for 4 days at low dose tolvaptan (0.3 mg/kg/day, maximum 30 mg) and 4 days at high dose (0.6 mg/kg/day, maximum 60 mg). 24 hour urine collections were done at baseline, day 3-4 of the dosing period, day 7-8 of the dosing period, and 3-6 days after washout. Primary outcome was cystine capacity (mg/L, target capacity > 0). Secondary outcomes included other urinary/serum parameters, tolerability, and thirst response. RESULTS 2 females (17, 23 yrs) and 2 males (13, 24 yrs) were enrolled. Cystine capacity respectively went from baseline of -312, -82, -353 and -628 mg/L to 97, 111, 75 and -3 mg/L on high dose (Figure 1). 24-hour volume went from 1.96, 3.0, 2.1 and 0.91 L to 11.74, 6.5, 9.9 and 2.8 L on high dose (Figure 2). There were no abnormalities in serum electrolytes or liver enzymes. Subjects did experience extreme thirst (9/10 on visual scale), but none discontinued treatment or reduced dose. CONCLUSIONS Dilutional therapy with tolvaptan increased both cystine capacity and urinary volumes. This treatment approach has the potential to reduce recurrence of stones in this population. Further investigation should study longer term effects and safety, and determine optimal dosing to improve tolerability.",2020,There were no abnormalities in serum electrolytes or liver enzymes.,"['adolescents and young adults with cystinuria', '2 females (17, 23 yrs) and 2 males (13, 24 yrs) were enrolled', 'We enrolled cystinuria patients age 12-25 yrs', 'young patients with cystinuria']","['tolvaptan', 'Pharmacological dilutional therapy', 'vasopressin antagonist tolvaptan', 'vasopressin V2-receptor antagonist tolvaptan']","['24-hour volume', 'serum electrolytes or liver enzymes', 'Cystine capacity', 'urinary/serum parameters, tolerability, and thirst response', 'tolerability', 'cystine capacity and urinary volumes', 'cystine capacity (mg/L, target capacity > 0', 'urinary excretion of free water']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0010691', 'cui_str': 'Cystinuria'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332239', 'cui_str': 'Young'}]","[{'cui': 'C1176308', 'cui_str': 'tolvaptan'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C3537128', 'cui_str': 'Vasopressin receptor antagonist'}, {'cui': 'C0162829', 'cui_str': 'V2 Receptors'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}]","[{'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0587355', 'cui_str': 'Electrolytes measurement, serum'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme'}, {'cui': 'C0010682', 'cui_str': 'Cystine'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0039971', 'cui_str': 'Thirst'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0439268', 'cui_str': 'mg/L'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}]",,0.0469341,There were no abnormalities in serum electrolytes or liver enzymes.,"[{'ForeName': 'Caleb P', 'Initials': 'CP', 'LastName': 'Nelson', 'Affiliation': ""Department of Urology, Boston Children's Hospital and Harvard Medical School, Boston, MA USA.. Electronic address: caleb.nelson@childrens.harvard.edu.""}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Kurtz', 'Affiliation': ""Department of Urology, Boston Children's Hospital and Harvard Medical School, Boston, MA USA.""}, {'ForeName': 'Alyssia', 'Initials': 'A', 'LastName': 'Venna', 'Affiliation': ""Department of Urology, Boston Children's Hospital and Harvard Medical School, Boston, MA USA.""}, {'ForeName': 'Bartley G', 'Initials': 'BG', 'LastName': 'Cilento', 'Affiliation': ""Department of Urology, Boston Children's Hospital and Harvard Medical School, Boston, MA USA.""}, {'ForeName': 'Michelle A', 'Initials': 'MA', 'LastName': 'Baum', 'Affiliation': ""Division of Nephrology, Boston Children's Hospital and Harvard Medical School, Boston, MA USA.""}]",Urology,['10.1016/j.urology.2020.07.002'] 1525,32513018,The effect of high-intensity versus low-level laser therapy in the management of plantar fasciitis: randomized participant blind controlled trial.,"OBJECTIVES To evaluate and compare the efficacy of high-intensity laser therapy (HILT) and low-level laser therapy (LLLT) for plantar fasciitis. DESIGN A participant blind randomized controlled trial with parallel group design and an active comparator with follow-up at four weeks. SETTINGS Outpatient, University hospital. SUBJECTS Unilateral plantar fasciitis participants ( n  = 102) were randomly assigned into two groups. Recruitment period was from January 2017 to April 2019. INTERVENTIONS Interventions included eight sessions of laser therapy over three weeks and single session of patient education. The HILT group ( n  = 51) received HILT and the LLLT group ( n  = 51) received LLLT. MAIN MEASURES Primary outcomes: visual analogue scale; secondary outcomes: pressure algometry, sonography of plantar fascia thickness (time frame: baseline to three-week and four-week follow-up) and numeric rating scale (0%-100%) for opinion of participants on effect of treatment (time frame: three weeks). Data presented: mean (SD) or n (%). RESULTS There was no statistically significant difference between the groups according to visual analogue scale (pain in general reduction in three weeks: 2.57(3.45) vs. 2.88(3.28) cm), pressure algometry (pain threshold difference between healthy and affected heel reduction in three weeks: 1.80(6.39) vs. 1.77(2.85) kg) and sonography measurements (plantar fascia thickness difference between healthy and affected heel reduction in three weeks: 0.19(0.56) vs. 0.30(0.57) mm). There was a statistically significant difference between the groups in participants' opinion in favor to HILT group (efficacy of treatment better than 50%: 26(51%) vs. 37(73%)). CONCLUSION No statistically significant difference between groups was observed.",2020,"There was a statistically significant difference between the groups in participants' opinion in favor to HILT group (efficacy of treatment better than 50%: 26(51%) vs. 37(73%)). ","['Outpatient, University hospital', 'plantar fasciitis', 'Unilateral plantar fasciitis participants ( n \u2009=\u2009102']","['Interventions included eight sessions of laser therapy', 'LLLT', 'high-intensity versus low-level laser therapy', 'HILT and the LLLT', 'high-intensity laser therapy (HILT) and low-level laser therapy (LLLT']","['visual analogue scale (pain in general reduction', 'visual analogue scale; secondary outcomes: pressure algometry, sonography of plantar fascia thickness (time frame: baseline to three-week and four-week follow-up) and numeric rating scale', 'pressure algometry (pain threshold difference between healthy and affected heel reduction']","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0149756', 'cui_str': 'Plantar fasciitis'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0549109', 'cui_str': 'Plantar fascia structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0332168', 'cui_str': 'Time frame'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4082109', 'cui_str': 'Three weeks'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0392760', 'cui_str': 'Affecting'}, {'cui': 'C0018870', 'cui_str': 'Heel structure'}]",,0.152495,"There was a statistically significant difference between the groups in participants' opinion in favor to HILT group (efficacy of treatment better than 50%: 26(51%) vs. 37(73%)). ","[{'ForeName': 'Dovile', 'Initials': 'D', 'LastName': 'Naruseviciute', 'Affiliation': 'Department of Rehabilitation, The Lithuanian University of Health Sciences, Kaunas, Lithuania.'}, {'ForeName': 'Raimondas', 'Initials': 'R', 'LastName': 'Kubilius', 'Affiliation': 'Department of Rehabilitation, The Lithuanian University of Health Sciences, Kaunas, Lithuania.'}]",Clinical rehabilitation,['10.1177/0269215520929073'] 1526,32535161,Urethra-Sparing Stereotactic Body Radiation Therapy for Prostate Cancer: Quality Assurance of a Randomized Phase 2 Trial.,"PURPOSE To present the radiation therapy quality assurance results from a prospective multicenter phase 2 randomized trial of short versus protracted urethra-sparing stereotactic body radiation therapy (SBRT) for localized prostate cancer. METHODS AND MATERIALS Between 2012 and 2015, 165 patients with prostate cancer from 9 centers were randomized and treated with SBRT delivered either every other day (arm A, n = 82) or once a week (arm B, n = 83); 36.25 Gy in 5 fractions were prescribed to the prostate with (n = 92) or without (n = 73) inclusion of the seminal vesicles (SV), and the urethra planning-risk volume received 32.5 Gy. Patients were treated either with volumetric modulated arc therapy (VMAT; n = 112) or with intensity modulated radiation therapy (IMRT; n = 53). Deviations from protocol dose constraints, planning target volume (PTV) homogeneity index, PTV Dice similarity coefficient, and number of monitor units for each treatment plan were retrospectively analyzed. Dosimetric results of VMAT versus IMRT and treatment plans with versus without inclusion of SV were compared. RESULTS At least 1 major protocol deviation occurred in 51 patients (31%), whereas none was observed in 41. Protocol violations were more frequent in the IMRT group (P < .001). Furthermore, the use of VMAT yielded better dosimetric results than IMRT for urethra planning-risk volume D 98% (31.1 vs 30.8 Gy, P < .0001), PTV D 2% (37.9 vs 38.7 Gy, P < .0001), homogeneity index (0.09 vs 0.10, P < .0001), Dice similarity coefficient (0.83 vs 0.80, P < .0001), and bladder wall V 50% (24.5% vs 33.5%, P = .0001). To achieve its goals volumetric modulated arc therapy required fewer monitor units than IMRT (2275 vs 3378, P <.0001). The inclusion of SV in the PTV negatively affected the rectal wall V 90% (9.1% vs 10.4%, P = .0003) and V 80% (13.2% vs 15.7%, P = .0003). CONCLUSIONS Protocol deviations with potential impact on tumor control or toxicity occurred in 31% of patients in this prospective clinical trial. Protocol deviations were more frequent with IMRT. Prospective radiation therapy quality assurance protocols should be strongly recommended for SBRT trials to minimize potential protocol deviations.",2020,"To achieve its goals VMAT required less MU than IMRT (2275 vs. 3378, p<0.0001).","['Between 2012 and 2015, 165 PCa patients from nine centers', 'localized prostate cancer (PCa', 'prostate cancer']","['radiotherapy quality assurance (RTQA', 'IMRT', 'Urethra-sparing stereotactic body radiotherapy', 'SBRT', 'VMAT vs. IMRT', 'protracted urethra-sparing stereotactic body radiotherapy (SBRT', 'VMAT']","['PTV homogeneity index (HI), PTV Dice similarity coefficient (DSC), and number of monitor units (MU', 'toxicity', 'DSC']","[{'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C1512814', 'cui_str': 'Intensity modulated radiation therapy'}, {'cui': 'C0041967', 'cui_str': 'Urethral'}, {'cui': 'C1843661', 'cui_str': 'Spastic Paraplegia, Ataxia, And Mental Retardation'}, {'cui': 'C1720823', 'cui_str': 'Stereotactic Body Radiotherapy'}, {'cui': 'C3489631', 'cui_str': 'Intensity-Modulated Arc Therapy'}]","[{'cui': 'C0454199', 'cui_str': 'Planning target volume'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0040539', 'cui_str': 'TO'}]",165.0,0.0661156,"To achieve its goals VMAT required less MU than IMRT (2275 vs. 3378, p<0.0001).","[{'ForeName': 'Maud', 'Initials': 'M', 'LastName': 'Jaccard', 'Affiliation': 'Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland. Electronic address: maud.jaccard@hcuge.ch.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Zilli', 'Affiliation': 'Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland; Faculty of Medicine, Geneva University, Geneva, Switzerland.'}, {'ForeName': 'Angèle', 'Initials': 'A', 'LastName': 'Dubouloz', 'Affiliation': 'Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Lluís', 'Initials': 'L', 'LastName': 'Escude', 'Affiliation': 'Radiation Oncology, Teknon Oncologic Institute, Barcelona, Spain.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Jorcano', 'Affiliation': 'Radiation Oncology, Teknon Oncologic Institute, Barcelona, Spain.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Linthout', 'Affiliation': 'Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Bral', 'Affiliation': 'Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium.'}, {'ForeName': 'Wilko', 'Initials': 'W', 'LastName': 'Verbakel', 'Affiliation': 'Radiation Oncology Amsterdam UMC, Amsterdam, the Netherlands.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Bruynzeel', 'Affiliation': 'Radiation Oncology Amsterdam UMC, Amsterdam, the Netherlands.'}, {'ForeName': 'Mikko', 'Initials': 'M', 'LastName': 'Björkqvist', 'Affiliation': 'Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland; Department of Medical Physics, Division of Medical Imaging, Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Heikki', 'Initials': 'H', 'LastName': 'Minn', 'Affiliation': 'Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Lev', 'Initials': 'L', 'LastName': 'Tsvang', 'Affiliation': 'Sheba Medical Center, Ramat Gan, Israel.'}, {'ForeName': 'Zvi', 'Initials': 'Z', 'LastName': 'Symon', 'Affiliation': 'Sheba Medical Center, Ramat Gan, Israel.'}, {'ForeName': 'Joana', 'Initials': 'J', 'LastName': 'Lencart', 'Affiliation': 'Faculty of Medicine, Geneva University, Geneva, Switzerland.'}, {'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Oliveira', 'Affiliation': 'Portuguese Institut of Oncology, Porto, Portugal.'}, {'ForeName': 'Zeynep', 'Initials': 'Z', 'LastName': 'Ozen', 'Affiliation': 'Neolife Medical Center, Istanbul, Turkey.'}, {'ForeName': 'Ufuk', 'Initials': 'U', 'LastName': 'Abacioglu', 'Affiliation': 'Neolife Medical Center, Istanbul, Turkey.'}, {'ForeName': 'Juan María', 'Initials': 'JM', 'LastName': 'Pérez-Moreno', 'Affiliation': 'Hospital Universitario Sanchinarro, Madrid, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Rubio', 'Affiliation': 'Hospital Universitario Sanchinarro, Madrid, Spain.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Rouzaud', 'Affiliation': 'Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Miralbell', 'Affiliation': 'Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland; Faculty of Medicine, Geneva University, Geneva, Switzerland; Radiation Oncology, Teknon Oncologic Institute, Barcelona, Spain.'}]","International journal of radiation oncology, biology, physics",['10.1016/j.ijrobp.2020.06.002'] 1527,32536000,Impact of inferior caval valve implantation on severity of tricuspid regurgitation and right heart function.,"AIMS Severe tricuspid regurgitation (TR) is a common finding in heart failure patients and associated with increased mortality. New interventional therapeutic options are needed as many heart failure patients are unfit for surgery. The TRICAVAL study compared valve implantation into the inferior vena cava (CAVI) with optimal medical therapy (OMT) in patients with severe TR. Here, we report details on the impact of CAVI on TR severity as well as right heart function and morphology. METHODS AND RESULTS We randomized 28 patients with severe TR to CAVI (n = 14) with transfemoral implantation of an Edwards Sapien XT valve into the inferior vena cava or OMT (n = 14). Inclusion and exclusion criteria were based on anatomical and clinical parameters. Echocardiographic measurements were performed at baseline, at the first postoperative day and one, three, and twelve months after randomization. As proof of concept of an effective sealing of the inferior vena cava, we detected a significant decrease in systolic hepatic vein reflux volume (11.0 [6.2-21.9] mL vs 3.5 [0.6-8.5] mL, P = .016) and hepatic vein diameter (11.5 [10.0-14.8] mm vs 10.0 [9.3-11.8] mm, P = .034) at thirty-day follow-up. However, CAVI had no significant impact on TR, cardiac function, and morphology. CONCLUSIONS Caval valve implantation significantly reduced systolic reflux into the hepatic veins but was not associated with an improvement in cardiac function, morphology, or TR severity.",2020,"CONCLUSIONS Caval valve implantation significantly reduced systolic reflux into the hepatic veins but was not associated with an improvement in cardiac function, morphology, or TR severity.","['heart failure patients', 'patients with severe TR', '28 patients with severe TR to CAVI (n\xa0=\xa014) with', 'n\xa0=\xa014']","['valve implantation into the inferior vena cava (CAVI) with optimal medical therapy (OMT', 'inferior caval valve implantation', 'transfemoral implantation of an Edwards Sapien XT valve into the inferior vena cava or OMT']","['Echocardiographic measurements', 'hepatic vein diameter', 'Severe tricuspid regurgitation (TR', 'systolic reflux', 'severity of tricuspid regurgitation and right heart function', 'systolic hepatic vein reflux volume', 'TR, cardiac function, and morphology', 'cardiac function, morphology, or TR severity']","[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0040961', 'cui_str': 'Tricuspid valve regurgitation'}, {'cui': 'C0085979', 'cui_str': 'Genus Cavia'}]","[{'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0042458', 'cui_str': 'Inferior vena cava structure'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0152096', 'cui_str': 'Complete trisomy 18 syndrome'}]","[{'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0019155', 'cui_str': 'Structure of hepatic vein'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0040961', 'cui_str': 'Tricuspid valve regurgitation'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C4317146', 'cui_str': 'Acid reflux'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0225808', 'cui_str': 'Structure of right side of heart'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0332437', 'cui_str': 'Associated morphology'}]",28.0,0.0584031,"CONCLUSIONS Caval valve implantation significantly reduced systolic reflux into the hepatic veins but was not associated with an improvement in cardiac function, morphology, or TR severity.","[{'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Mattig', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Fabian', 'Initials': 'F', 'LastName': 'Knebel', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Hewing', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Verena', 'Initials': 'V', 'LastName': 'Stangl', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Karl', 'Initials': 'K', 'LastName': 'Stangl', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Laule', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Henryk', 'Initials': 'H', 'LastName': 'Dreger', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}]","Echocardiography (Mount Kisco, N.Y.)",['10.1111/echo.14760'] 1528,32682994,Time limited eating in adolescents with obesity (time LEAd): Study protocol.,"BACKGROUND Time limited eating (TLE) has been shown to be effective for weight loss and improvement of glycemic control in adults with obesity and type 2 diabetes (T2D), but has not been well studied in adolescents. TLE may be a more feasible, flexible and effective dietary intervention for adolescents because it removes the need for intensive counting of calories or macronutrients, and emphasizes eating during a specified time period. OBJECTIVES The aim of this study is to assess the feasibility of a TLE approach in adolescents with obesity using a continuous glucose monitor (CGM) to promote adherence to the intervention. METHODS We propose a prospective, randomized controlled trial, in 60 adolescents (ages 14-18) with obesity (BMI% ≥ 95th percentile). Youth will be randomized to one of three treatment groups for a 12-week intervention: Group 1) Low sugar and carbohydrate education (LSC, 5% of total daily calories from sugar (<35 g)/day; <90 g carbohydrate (CHO)/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback), Group 2) LSC + TLE (16-h fast/8-h feed for 5 days per week) + blinded CGM, and Group 3) LSC + TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy). Outcomes will include change in total body fat (TBF) percentage measured on DEXA scan, BMI status and fasting blood glucose at 12 weeks compared to baseline. CONCLUSIONS TLE is a potentially powerful lifestyle intervention that could be readily integrated into pediatric weight management programs to optimize their impact and accelerate healthy changes. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT03954223.",2020,"TLE may be a more feasible, flexible and effective dietary intervention for adolescents because it removes the need for intensive counting of calories or macronutrients, and emphasizes eating during a specified time period. ","['60 adolescents (ages 14-18) with obesity (BMI%\u202f≥\u202f95th percentile', 'adolescents with obesity (time LEAd', 'adolescents with obesity using a', 'adults with obesity and type 2 diabetes (T2D']","['TLE approach', 'LSC\u202f+\u202fTLE', 'TLE', 'Low sugar and carbohydrate education (LSC, 5% of total daily calories from sugar (<35\u202fg)/day; <90\u202fg carbohydrate (CHO)/day)\u202f+\u202fblinded CGM', 'continuous glucose monitor (CGM']","['total body fat (TBF) percentage measured on DEXA scan, BMI status and fasting blood glucose']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0332186', 'cui_str': 'Definite time'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0439175', 'cui_str': '% of total'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0439087', 'cui_str': '<90'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}]","[{'cui': 'C0424677', 'cui_str': 'Total body fat'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}]",,0.0740017,"TLE may be a more feasible, flexible and effective dietary intervention for adolescents because it removes the need for intensive counting of calories or macronutrients, and emphasizes eating during a specified time period. ","[{'ForeName': 'Alaina P', 'Initials': 'AP', 'LastName': 'Vidmar', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America. Electronic address: avidmar@chla.usc.edu.""}, {'ForeName': 'Michael I', 'Initials': 'MI', 'LastName': 'Goran', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Naguib', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Cassandra', 'Initials': 'C', 'LastName': 'Fink', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Choo Phei', 'Initials': 'CP', 'LastName': 'Wee', 'Affiliation': 'CTSI Biostatics Core, Saban Research Institute, Los Angeles, CA, United States of America.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Hegedus', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Kelleen', 'Initials': 'K', 'LastName': 'Lopez', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Janelle', 'Initials': 'J', 'LastName': 'Gonzalez', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}, {'ForeName': 'Jennifer K', 'Initials': 'JK', 'LastName': 'Raymond', 'Affiliation': ""Diabetes & Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, United States of America.""}]",Contemporary clinical trials,['10.1016/j.cct.2020.106082'] 1529,32682995,The impact of narratives and active video games on long-term moderate-to-vigorous physical activity: A randomized controlled trial protocol.,"BACKGROUND Although physical activity (PA) has been shown in helping prevent and treat obesity, current PA interventions are still not effective in ameliorating the obesity epidemic. Additional forms of PA need to be investigated to improve PA engagement and outcomes. We hypothesize that pairing a narrative (i.e., story) with an active video game (AVG), a less traditional form of PA, will increase participant engagement in PA. This paper presents the rationale, implementation, and pilot results of a study assessing the effect of narrative's impact on PA and a series of other health outcomes. METHODS/DESIGN The Active Video Game Study is a six-month randomized controlled single-blind trial projected to include 210 participants. The intervention strategy will pair a narrative to an active video game (AVG). Participants will be randomized into 3 groups: condition A [Narrative + AVG], condition B [AVG Only], and condition C [Control]. Participants will undergo three in-person data collection visits over the course of six months. Inclusion criteria are that children are between the ages of 8-12 and have a BMI ≥ 85%. The primary outcome is change in moderate to vigorous physical activity (MVPA). Secondary outcome measures include change in BMI percentile, fasting insulin and glucose, lipid panel, C-reactive protein, and cognitive function. A pilot trial of n = 6 was conducted to help develop procedures and address problems that could arise in the main trial. DISCUSSION Successful completion of this study will provide the empirical basis for novel intervention and design strategies to enhance the impact of AVGs on long-term MVPA.",2020,Successful completion of this study will provide the empirical basis for novel intervention and design strategies to enhance the impact of AVGs on long-term MVPA.,"['210 participants', 'long-term moderate-to-vigorous physical activity']","['physical activity (PA', 'narratives and active video games', 'condition A [Narrative + AVG], condition B [AVG Only], and condition C [Control']","['change in moderate to vigorous physical activity (MVPA', 'change in BMI percentile, fasting insulin and glucose, lipid panel, C-reactive protein, and cognitive function']","[{'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0042649', 'cui_str': 'Video Games'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C1135957', 'cui_str': 'Narration'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0200382', 'cui_str': 'Lipid panel'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",210.0,0.130661,Successful completion of this study will provide the empirical basis for novel intervention and design strategies to enhance the impact of AVGs on long-term MVPA.,"[{'ForeName': 'Dar', 'Initials': 'D', 'LastName': 'Alon', 'Affiliation': 'Health Technology Lab, College of Arts, Media, and Design, Bouvé College of Health Sciences, Northeastern University, 360 Huntington Ave, Boston, MA 02115, United States.'}, {'ForeName': 'Caio', 'Initials': 'C', 'LastName': 'Sousa', 'Affiliation': 'Health Technology Lab, College of Arts, Media, and Design, Bouvé College of Health Sciences, Northeastern University, 360 Huntington Ave, Boston, MA 02115, United States.'}, {'ForeName': 'Romina', 'Initials': 'R', 'LastName': 'Cabrera-Perez', 'Affiliation': 'Health Technology Lab, College of Arts, Media, and Design, Bouvé College of Health Sciences, Northeastern University, 360 Huntington Ave, Boston, MA 02115, United States.'}, {'ForeName': 'Austin', 'Initials': 'A', 'LastName': 'Fernandez', 'Affiliation': 'Health Technology Lab, College of Arts, Media, and Design, Bouvé College of Health Sciences, Northeastern University, 360 Huntington Ave, Boston, MA 02115, United States.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Lee', 'Affiliation': 'Health Technology Lab, College of Arts, Media, and Design, Bouvé College of Health Sciences, Northeastern University, 360 Huntington Ave, Boston, MA 02115, United States.'}, {'ForeName': 'Aika', 'Initials': 'A', 'LastName': 'Misawa', 'Affiliation': 'Health Technology Lab, College of Arts, Media, and Design, Bouvé College of Health Sciences, Northeastern University, 360 Huntington Ave, Boston, MA 02115, United States.'}, {'ForeName': 'Kyung Jin', 'Initials': 'KJ', 'LastName': 'Sun', 'Affiliation': 'Health Technology Lab, College of Arts, Media, and Design, Bouvé College of Health Sciences, Northeastern University, 360 Huntington Ave, Boston, MA 02115, United States.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Baranowski', 'Affiliation': 'Baylor College of Medicine, 1100 Bates St, Houston, TX 77030, United States.'}, {'ForeName': 'Tiago V', 'Initials': 'TV', 'LastName': 'Barreira', 'Affiliation': 'Exercise Science Department, Syracuse University, 820 Comstock Ave, Syracuse, NY 13244, United States.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Chiu', 'Affiliation': 'Harvard Medical School, Primary Care Martha Eliot, 75 Bickford St, Jamaica Plain, MA 02478, United States.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Fleischman', 'Affiliation': ""Harvard Medical School, Optimal Wellness for Life Clinic, Boston Children's Hospital, Boston, MA 02115, United States.""}, {'ForeName': 'Shirley', 'Initials': 'S', 'LastName': 'Huang', 'Affiliation': 'Division of General Pediatrics and Adolescent Medicine, Floating Hospital for Children at Tufts Medical Center, Boston, MA 02111, United States.'}, {'ForeName': 'Jungyun', 'Initials': 'J', 'LastName': 'Hwang', 'Affiliation': 'Department of Medicine, Stanford University Medical Center, Palo Alto, CA 94304, United States.'}, {'ForeName': 'Melanie C', 'Initials': 'MC', 'LastName': 'Green', 'Affiliation': 'Department of Communication, University at Buffalo, 359 Baldy Hall, Buffalo, NY 14260, United States.'}, {'ForeName': 'I Min', 'Initials': 'IM', 'LastName': 'Lee', 'Affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.""}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Lessard', 'Affiliation': 'Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02215, United States.'}, {'ForeName': 'Lynne L', 'Initials': 'LL', 'LastName': 'Levitsky', 'Affiliation': ""Joslin Diabetes Center, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, United States.""}, {'ForeName': 'Farzad', 'Initials': 'F', 'LastName': 'Noubary', 'Affiliation': 'Pediatric Endocrinology, Massachusetts General Hospital, Harvard Medical School, 175 Cambridge St 5(th) Floor, Boston, MA 02114, United States; Department of Health Sciences, Bouvé College of Health Sciences, Northeastern University, 360 Huntington Ave, Boston, MA 02115, United States.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Samuels', 'Affiliation': ""Children's Hospital Primary Care Center, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, United States of America.""}, {'ForeName': 'Debbe', 'Initials': 'D', 'LastName': 'Thompson', 'Affiliation': ""Scientist/Research Nutritionist, USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine, 1100 Bates Avenue, Houston, TX 77030, United States.""}, {'ForeName': 'Amy S', 'Initials': 'AS', 'LastName': 'Lu', 'Affiliation': 'Health Technology Lab, Department of Communication Studies, College of Arts, Media, and Design, United States; Department of Health Sciences, Bouvé College of Health Sciences, Northeastern University, 360 Huntington Ave, Boston, MA 02115, United States. Electronic address: a.lu@northeastern.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106087'] 1530,32548299,Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer.,"This retrospective study examined magnetic resonance imaging (MRI)-derived tumor sphericity (SPH) as a quantitative measure of breast tumor morphology, and investigated the association between SPH and reader-assessed morphological pattern (MP). In addition, association of SPH with pathologic complete response was evaluated in patients enrolled in an adaptively randomized clinical trial designed to rapidly identify new agents for breast cancer. All patients underwent MRI examinations at multiple time points during the treatment. SPH values from pretreatment (T0) and early-treatment (T1) were investigated in this study. MP on T0 dynamic contrast-enhanced MRI was ranked from 1 to 5 in 220 patients. Mean SPH values decreased with the increased order of MP. SPH was higher in patients with pathologic complete response than in patients without (difference at T0: 0.04, 95% confidence interval [CI]: 0.02-0.05, P < .001; difference at T1: 0.03, 95% CI: 0.02-0.04, P < .001). The area under the receiver operating characteristic curve was estimated as 0.61 (95% CI, 0.57-0.65) at T0 and 0.58 (95% CI, 0.55-0.62) at T1. When the analysis was performed by cancer subtype defined by hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, highest area under the receiver operating characteristic curve were observed in HR-/HER2+: 0.67 (95% CI, 0.54-0.80) at T0, and 0.63 (95% CI, 0.51-0.76) at T1. Tumor SPH showed promise to quantify MRI MPs and as a biomarker for predicting treatment outcome at pre- or early-treatment time points.",2020,Tumor SPH showed promise to quantify MRI MPs and as a biomarker for predicting treatment outcome at pre- or early-treatment time points.,['Invasive Breast Cancer'],"['Neoadjuvant Chemotherapy', 'magnetic resonance imaging (MRI)-derived tumor sphericity (SPH']","['SPH', 'MP on T0 dynamic contrast-enhanced MRI', 'SPH values', 'area under the receiver operating characteristic curve', 'Mean SPH values', 'hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, highest area under the receiver operating characteristic curve']","[{'cui': 'C0853879', 'cui_str': 'Invasive carcinoma of breast'}]","[{'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}]","[{'cui': 'C0543482', 'cui_str': 'morphology'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0034772', 'cui_str': 'Receiver Operating Characteristic'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205250', 'cui_str': 'High'}]",220.0,0.0801601,Tumor SPH showed promise to quantify MRI MPs and as a biomarker for predicting treatment outcome at pre- or early-treatment time points.,"[{'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Newitt', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Bo La', 'Initials': 'B', 'LastName': 'Yun', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Ella F', 'Initials': 'EF', 'LastName': 'Jones', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Vignesh', 'Initials': 'V', 'LastName': 'Arasu', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Lisa J', 'Initials': 'LJ', 'LastName': 'Wilmes', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Gibbs', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Alex Anh-Tu', 'Initials': 'AA', 'LastName': 'Nguyen', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Natsuko', 'Initials': 'N', 'LastName': 'Onishi', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Kornak', 'Affiliation': 'Departments of Epidemiology and Biostatistics; and.'}, {'ForeName': 'Bonnie N', 'Initials': 'BN', 'LastName': 'Joe', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Esserman', 'Affiliation': 'Surgery, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Nola M', 'Initials': 'NM', 'LastName': 'Hylton', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}]","Tomography (Ann Arbor, Mich.)",['10.18383/j.tom.2020.00016'] 1531,32544283,Restored pelvic anatomy is preserved after laparoscopic and robot-assisted ventral rectopexy: MRI-based 5-year follow-up of a randomized controlled trial.,"AIM Our aim was to compare the long-term anatomical outcomes between robot-assisted ventral mesh rectopexy (RVMR) and laparoscopic ventral mesh rectopexy (LVMR) for external or internal rectal prolapse. METHOD This study is a follow-up of a single-centre randomized controlled trial (RCT). Thirty patients were randomly allocated to RVMR (n = 16) or LVMR (n = 14). The primary end-point was maintenance of the restored pelvic anatomy 5 years after the operation, as assessed by magnetic resonance (MR) defaecography. Secondary outcome measures included the Pelvic Organ Prolapse Quantification (POP-Q) measures and functional results assessed using symptom questionnaires. RESULTS Twenty-six patients (14 RVMR and 12 LVMR) completed the 5-year follow-up and were included in the study. The MRI results, POP-Q measurements and symptom-specific quality of life measures did not differ between the RVMR and LVMR groups. The MRI measurements of the total study population remained unchanged between 3 months and 5 years. In the Pelvic Floor Distress Inventory (PFDI-20), the RVMR group had lower symptom scores (mean 96.0, SD 70.7) than the LVMR group (mean 160.6, SD 58.9; P = 0.004). In the subscales of pelvic organ prolapse (POPDI-6) (mean 23.2, SD 24.3 vs mean 52.4, SD 22.4; P = 0.001) and the Colorectal-Anal Distress Inventory (CRADI-8) (mean 38.4, SD 23.3 vs mean 58.6, SD 25.4; P = 0.009), the patients in the RVMR group had significantly better outcomes. CONCLUSION After VMR, the corrected anatomy was preserved. There were no clinically significant differences in anatomical results between the RVMR and LVMR procedures 5 years after surgery based on MR defaecography. However, functional outcomes were better after RMVR.",2020,"The MR imaging (MRI) results, POP-Q measurements and symptom-specific quality of life measures did not differ between the RVMR and LVMR groups.","['Twenty-six patients (14 RVMR and 12 LVMR) completed the 5-year follow-up and were included in the study', 'Thirty patients']","['RVMR', 'robot-assisted (RVMR) and laparoscopic ventral mesh rectopexy (LVMR', 'LVMR']","['maintenance of the restored pelvic anatomy 5 years after the operation as assessed by magnetic resonance (MR) defaecography', 'colorectal-anal distress inventory (CRADI-8', 'pelvic organ prolapse (POPDI-6', 'Pelvic Organ Prolapse Quantification (POP-Q) measures and functional results assessed using symptom questionnaires', 'MR imaging (MRI) results, POP-Q measurements and symptom-specific quality of life measures', 'symptom scores']","[{'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C1704448', 'cui_str': 'Ventral'}, {'cui': 'C0400222', 'cui_str': 'Mesh rectopexy'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C3816446', 'cui_str': '30'}]","[{'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C1704448', 'cui_str': 'Ventral'}, {'cui': 'C0400222', 'cui_str': 'Mesh rectopexy'}]","[{'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0030797', 'cui_str': 'Pelvic'}, {'cui': 'C0002808', 'cui_str': 'Anatomy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0028580', 'cui_str': 'Nuclear Magnetic Resonance'}, {'cui': 'C0524966', 'cui_str': 'Defecography'}, {'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C0003461', 'cui_str': 'Anal structure'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0877015', 'cui_str': 'Urogenital prolapse'}, {'cui': 'C0033377', 'cui_str': 'Prolapse'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",30.0,0.123838,"The MR imaging (MRI) results, POP-Q measurements and symptom-specific quality of life measures did not differ between the RVMR and LVMR groups.","[{'ForeName': 'K E', 'Initials': 'KE', 'LastName': 'Laitakari', 'Affiliation': 'Department of Surgery, Division of Gastroenterology, Oulu University Hospital, Oulu, Finland.'}, {'ForeName': 'J K', 'Initials': 'JK', 'LastName': 'Mäkelä-Kaikkonen', 'Affiliation': 'Department of Surgery, Division of Gastroenterology, Oulu University Hospital, Oulu, Finland.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Pääkkö', 'Affiliation': 'Department of Radiology, Oulu University Hospital, Oulu, Finland.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Kata', 'Affiliation': 'Department of Radiology, Oulu University Hospital, Oulu, Finland.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Ohtonen', 'Affiliation': 'Medical Research Center Oulu, Center of Surgical Research, University of Oulu, Oulu, Finland.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Mäkelä', 'Affiliation': 'Department of Surgery, Division of Gastroenterology, Oulu University Hospital, Oulu, Finland.'}, {'ForeName': 'T T', 'Initials': 'TT', 'LastName': 'Rautio', 'Affiliation': 'Department of Surgery, Division of Gastroenterology, Oulu University Hospital, Oulu, Finland.'}]",Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland,['10.1111/codi.15195'] 1532,32545579,Effects of Four-Week Rehabilitation Program on Hemostasis Disorders in Patients with Spinal Cord Injury.,"BACKGROUND Patients with spinal cord injury (SCI) exhibit hemostasis disorders. This study aims at assessing the effects of a 4-week rehabilitation program on hemostasis disorders in patients with SCI. METHODS Seventy-eight in-patients undergoing a 4-week rehabilitation were divided into three groups based on time elapsed since SCI: I (3 weeks-3 months), II (3-6 months), and III (>6 months). Tissue factor (TF), tissue factor pathway inhibitor (TFPI), thrombin-antithrombin complex (TAT) and D-dimer levels, antithrombin activity (AT), and platelet count (PLT) were measured on admission and after rehabilitation. RESULTS Rehabilitation resulted in an increase in TF in group III ( p < 0.050), and decrease in TFPI ( p < 0.022) and PLT ( p < 0.042) in group II as well as AT in group I ( p < 0.009). Compared to control group without SCI, TF, TFPI, and TAT were significantly higher in all SCI groups both before and after rehabilitation. All SCI groups had elevated D-dimer, which decreased after rehabilitation in the whole study group ( p < 0.001) and group I ( p < 0.001). CONCLUSION No decrease in activation of TF-dependent coagulation was observed after a 4-week rehabilitation regardless of time elapsed since SCI. However, D-dimer levels decreased significantly, which may indicate reduction of high fibrinolytic potential, especially when rehabilitation was done <3 months after SCI.",2020,No decrease in activation of TF-dependent coagulation was observed after a 4-week rehabilitation regardless of time elapsed since SCI.,"['patients with SCI.\nMETHODS\n\n\nSeventy-eight in-patients undergoing a 4-week rehabilitation', 'Patients with spinal cord injury (SCI) exhibit hemostasis disorders', 'Patients with Spinal Cord Injury']","['4-week rehabilitation program', 'Four-Week Rehabilitation Program']","['PLT', 'TF', 'hemostasis disorders', 'Tissue factor (TF), tissue factor pathway inhibitor (TFPI), thrombin-antithrombin complex (TAT) and D-dimer levels, antithrombin activity (AT), and platelet count (PLT', 'TFPI', 'activation of TF-dependent coagulation', 'Hemostasis Disorders', 'SCI, TF, TFPI, and TAT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0015272', 'cui_str': 'Exhibits as Topic'}, {'cui': 'C0005779', 'cui_str': 'Blood coagulation disorder'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}]","[{'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0040048', 'cui_str': 'Thromboplastin'}, {'cui': 'C0005779', 'cui_str': 'Blood coagulation disorder'}, {'cui': 'C0164707', 'cui_str': 'Tissue factor pathway inhibitor'}, {'cui': 'C0052128', 'cui_str': 'Thrombin-antithrombin complex'}, {'cui': 'C0060323', 'cui_str': 'D-dimer'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0200416', 'cui_str': 'Antithrombin III assay'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}]",,0.0100283,No decrease in activation of TF-dependent coagulation was observed after a 4-week rehabilitation regardless of time elapsed since SCI.,"[{'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Mackiewicz-Milewska', 'Affiliation': 'Department of Rehabilitation, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland.'}, {'ForeName': 'Małgorzata', 'Initials': 'M', 'LastName': 'Cisowska-Adamiak', 'Affiliation': 'Department of Rehabilitation, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland.'}, {'ForeName': 'Danuta', 'Initials': 'D', 'LastName': 'Rość', 'Affiliation': 'Department of Pathophysiology, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland.'}, {'ForeName': 'Iwona', 'Initials': 'I', 'LastName': 'Głowacka-Mrotek', 'Affiliation': 'Department of Rehabilitation, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland.'}, {'ForeName': 'Iwona', 'Initials': 'I', 'LastName': 'Świątkiewicz', 'Affiliation': 'Department of Cardiology and Internal Medicine, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland.'}]",Journal of clinical medicine,['10.3390/jcm9061836'] 1533,32544854,Effect of ZNF804A gene polymorphism (rs1344706) on the plasticity of the functional coupling between the right dorsolateral prefrontal cortex and the contralateral hippocampal formation.,"ZNF804A has now been recognized as a schizophrenia risk gene by multiple genome-wide association studies with its intronic polymorphism rs1344706 being reported as the first genome-wide significant risk variant for schizophrenia. Although the functional impact of this gene is still unknown, rs1344706's contribution to the functional coupling between the right dorsolateral prefrontal cortex (DLPFC) and the contralateral hippocampal formation (HF) has been reported by several studies. The current study tested whether the right DLPFC-left HF functional coupling showed plasticity during cognitive training (Study I) and whether rs1344706 affected the plasticity (Study II). In Study I, we conducted a randomized controlled trial with 30 subjects receiving 20 sessions of adaptive training on a memory span task (the training group) and 30 subjects practicing on a non-adaptive easy version of the same memory span task for 20 sessions (the control group). All subjects were scanned using fMRI before and after the training. Analyses of resting-state and task-state fMRI data consistently showed that the adaptive memory span training significantly strengthened the right DLPFC-left HF functional coupling. In Study II, we conducted a genetic association study with 101 subjects (combining the data from the training group in Study I with those from an additional subsequent sample of 71 subjects who received the same training and fMRI scans). Results showed that rs1344706 was significantly associated with training-induced changes in functional coupling. Subjects carrying the non-risk allele (C) of rs1344706 showed greater training-induced plasticity than the risk allele (A) homozygotes. These findings expanded our current understanding of the functional impact of the schizophrenia risk variant of ZNF804A gene and suggested that the ZNF804A gene could be used as a prospective target for future antipsychotic drugs and clinical research.",2020,Subjects carrying the non-risk allele (C) of rs1344706 showed greater training-induced plasticity than the risk allele (A) homozygotes.,"['101 subjects (combining the data from the training group in Study', '71 subjects who received the same training and fMRI scans', '30 subjects receiving 20 sessions of adaptive training on a memory span task (the training group) and 30 subjects practicing on a non-adaptive easy version of the same memory span task for 20 sessions (the control group']","['ZNF804A', 'ZNF804A gene polymorphism (rs1344706']",['functional coupling'],"[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0332219', 'cui_str': 'Easy'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0032529', 'cui_str': 'Genetic polymorphism'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}]",101.0,0.0118036,Subjects carrying the non-risk allele (C) of rs1344706 showed greater training-induced plasticity than the risk allele (A) homozygotes.,"[{'ForeName': 'Wan', 'Initials': 'W', 'LastName': 'Zhao', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China.'}, {'ForeName': 'Xiongying', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders & Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing 100088, PR China.'}, {'ForeName': 'Qiumei', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China; School of Mental Health, Jining Medical University, 45# Jianshe South Road, Jining 272013, Shandong Province, PR China.'}, {'ForeName': 'Boqi', 'Initials': 'B', 'LastName': 'Du', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China.'}, {'ForeName': 'Xiaoxiang', 'Initials': 'X', 'LastName': 'Deng', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Ji', 'Affiliation': 'School of Mental Health, Jining Medical University, 45# Jianshe South Road, Jining 272013, Shandong Province, PR China.'}, {'ForeName': 'Yu-Tao', 'Initials': 'YT', 'LastName': 'Xiang', 'Affiliation': 'Faculty of Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macau, PR China.'}, {'ForeName': 'Chuanyue', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders & Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing 100088, PR China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Dong', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China.'}, {'ForeName': 'Chuansheng', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Department of Psychological Science, University of California, Irvine, CA 92697, United States.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China. Electronic address: lijundp@bnu.edu.cn.'}]",NeuroImage. Clinical,['10.1016/j.nicl.2020.102279'] 1534,32545600,"Variations in Values of State, Response Entropy and Haemodynamic Parameters Associated with Development of Different Epileptiform Patterns during Volatile Induction of General Anaesthesia with Two Different Anaesthetic Regimens Using Sevoflurane in Comparison with Intravenous Induct: A Comparative Study.","BACKGROUND AND OBJECTIVES Raw electroencephalographic (EEG) signals are rarely used to monitor the depth of volatile induction of general anaesthesia (VIGA) with sevoflurane, even though EEG-based indices may show aberrant values. We aimed to identify whether response (RE) and state entropy (SE) variations reliably reflect the actual depth of general anaesthesia in the presence of different types of epileptiform patterns (EPs) in EEGs during induction of general anaesthesia. MATERIALS AND METHODS A randomized, prospective clinical study was performed with 60 patients receiving VIGA using sevoflurane with the increasing concentrations (group VIMA) or the vital capacity (group VCRII) technique or an intravenous single dose of propofol (group PROP). Facial electromyography (fEMG), fraction of inspired sevoflurane (FiAA), fraction of expired sevoflurane (FeAA), minimal alveolar concentration (MAC) of sevoflurane, RE and SE, and standard electroencephalographic evaluations were performed in these patients. RESULTS In contrast to periodic epileptiform discharges, erroneous SE and RE values in the patients' EEGs were associated with the presence of polyspikes (PS) and rhythmic polyspikes (PSR), which were more likely to indicate toxic depth rather than false emergence from anaesthesia with no changes in the FiAA, FeAA, and MAC of sevoflurane. CONCLUSION Calculated RE and SE values may be misleading during VIGA when EPs are present in patients' EEGs. During VIGA with sevoflurane, we recommend monitoring raw EEG data in scientific studies to correlate it with potentially erroneous RE and SE values and the end-tidal concentration of sevoflurane in everyday clinical practice, when monitoring raw EEG is not available, because they can mislead anaesthesiologists to reduce sevoflurane levels in the ventilation gas and result in unintentional true emergence from anaesthesia. Further studies are required to investigate the behaviour of EEG-based indices during rapid changes in sevoflurane concentrations at different stages of VIGA and the influence of polyspikes and rhythmic polyspikes on the transformation of EEG signals into a digital form.",2020,"In contrast to periodic epileptiform discharges, erroneous SE and RE values in the patients' EEGs were associated with the presence of polyspikes (PS) and rhythmic polyspikes (PSR), which were more likely to indicate toxic depth rather than false emergence from anaesthesia with no changes in the FiAA, FeAA, and MAC of sevoflurane. ","['60 patients receiving VIGA using sevoflurane with the increasing concentrations (group VIMA) or the', 'group PROP']","['sevoflurane', 'vital capacity (group VCRII) technique or an intravenous single dose of propofol', 'Sevoflurane']","['erroneous SE and RE values', 'presence of polyspikes (PS) and rhythmic polyspikes (PSR', 'Facial electromyography (fEMG), fraction of inspired sevoflurane (FiAA), fraction of expired sevoflurane (FeAA), minimal alveolar concentration (MAC) of sevoflurane, RE and SE, and standard electroencephalographic evaluations']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0443769', 'cui_str': 'Volatile agent'}, {'cui': 'C0473960', 'cui_str': 'Induction of general anesthesia'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0042834', 'cui_str': 'Vital capacity'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}]","[{'cui': 'C3541364', 'cui_str': 'Erroneous'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0376522', 'cui_str': 'Entropy'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}]",60.0,0.0448379,"In contrast to periodic epileptiform discharges, erroneous SE and RE values in the patients' EEGs were associated with the presence of polyspikes (PS) and rhythmic polyspikes (PSR), which were more likely to indicate toxic depth rather than false emergence from anaesthesia with no changes in the FiAA, FeAA, and MAC of sevoflurane. ","[{'ForeName': 'Michał', 'Initials': 'M', 'LastName': 'Stasiowski', 'Affiliation': 'Department of Anaesthesiology and Intensive Therapy, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Duława', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Railway District Hospital Katowice, 40-055 Katowice, Poland.'}, {'ForeName': 'Izabela', 'Initials': 'I', 'LastName': 'Szumera', 'Affiliation': 'Department of Anaesthesiology and Intensive Therapy, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.'}, {'ForeName': 'Radosław', 'Initials': 'R', 'LastName': 'Marciniak', 'Affiliation': 'Department of Anaesthesiology and Intensive Therapy, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.'}, {'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Niewiadomska', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health in Bytom, Medical University of Silesia, 40-055 Katowice, Poland.'}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Kaspera', 'Affiliation': 'Department of Neurosurgery, Regional Hospital in Sosnowiec, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.'}, {'ForeName': 'Lech', 'Initials': 'L', 'LastName': 'Krawczyk', 'Affiliation': 'Department of Anaesthesiology and Intensive Therapy, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Ładziński', 'Affiliation': 'Department of Neurosurgery, Regional Hospital in Sosnowiec, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.'}, {'ForeName': 'Beniamin Oskar', 'Initials': 'BO', 'LastName': 'Grabarek', 'Affiliation': 'Department of Clinical Trials, Maria Sklodowska-Curie National Research Institute of Oncology Krakow Branch, 31-115 Katowice, Poland.'}, {'ForeName': 'Przemysław', 'Initials': 'P', 'LastName': 'Jałowiecki', 'Affiliation': 'Department of Anaesthesiology and Intensive Therapy, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.'}]",Brain sciences,['10.3390/brainsci10060366'] 1535,32682996,THR1VE! Positive psychology intervention to treat diabetes distress in teens with type 1 diabetes: Rationale and trial design.,"Adolescents with type 1 diabetes (T1D) experience high rates of diabetes distress, which negatively influence self-management and glycemic control. Building on effective positive psychology interventions to improve adherence in adults, as well as our pilot work to adapt these interventions for adolescents, we developed a positive psychology intervention for adolescents with T1D. The goal of THR1VE! is to reduce diabetes distress in adolescents with T1D and improve their diabetes outcomes. This multi-site randomized controlled trial compares a Diabetes Education + text-message-based Positive Affect intervention, to a Diabetes Education control condition. In the ongoing trial, we are evaluating the effects of the intervention on adolescents' diabetes distress, self-management, and glycemic control. This paper describes the rationale, trial design, and methodology of the THR1VE! Study.",2020,"Adolescents with type 1 diabetes (T1D) experience high rates of diabetes distress, which negatively influence self-management and glycemic control.","['Adolescents with type 1 diabetes (T1D) experience high rates of diabetes distress', 'teens with type 1 diabetes', 'adolescents with T1D']","['Diabetes Education + text-message-based Positive Affect intervention', 'Positive psychology intervention']","[""adolescents' diabetes distress, self-management, and glycemic control"", 'diabetes distress']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0231303', 'cui_str': 'Distress'}]","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1510628', 'cui_str': 'Positive Psychology'}]","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",,0.0417244,"Adolescents with type 1 diabetes (T1D) experience high rates of diabetes distress, which negatively influence self-management and glycemic control.","[{'ForeName': 'Sarah S', 'Initials': 'SS', 'LastName': 'Jaser', 'Affiliation': 'Vanderbilt University Medical Center, USA. Electronic address: sarah.jaser@vumc.org.'}, {'ForeName': 'Karishma', 'Initials': 'K', 'LastName': 'Datye', 'Affiliation': 'Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Troy', 'Initials': 'T', 'LastName': 'Morrow', 'Affiliation': 'Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Sinisterra', 'Affiliation': ""Children's National Hospital, USA.""}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'LeStourgeon', 'Affiliation': 'Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Fayo', 'Initials': 'F', 'LastName': 'Abadula', 'Affiliation': 'Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Grace E', 'Initials': 'GE', 'LastName': 'Bell', 'Affiliation': 'Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Randi', 'Initials': 'R', 'LastName': 'Streisand', 'Affiliation': ""Children's National Hospital, USA.""}]",Contemporary clinical trials,['10.1016/j.cct.2020.106086'] 1536,32544572,"A 10-week yoga practice has no effect on cognition, but improves balance and motor learning by attenuating brain-derived neurotrophic factor levels in older adults.","Despite studies investigating the effect of yoga on cognitive and motor functioning in older adults, the effect on dual-task performance and motor learning and the specific mechanisms underlying the positive effect of yoga remain unclear. Thus, the aim of this study was to investigate the effects of yoga on cognition, balance under single- and dual-task conditions, and motor learning. The potential role of brain-derived neurotrophic factor (BDNF) in induced improvement was also explored. Participants aged 60-79 years were randomized to either a control group (n = 15) or a yoga group (n = 18) for a 10-week period. The yoga group received 90-min duration yoga classes two times per week. Changes in cognition, balance under single- and dual-task conditions, and learning fast and accurate reaching movements were assessed. Yoga practice decreased (P < 0.05) the velocity vector of the center of pressure under single- and dual-task conditions, whereas no changes in cognitive performance were observed. Although reaction and movement times during learning were decreased in both groups (P < 0.05), a faster reaction time (P < 0.05) and shorter movement time (P < 0.05) were observed in the yoga group than in the control group. Significant moderate relationships (P < 0.05) between changes in BDNF levels and functional improvements were observed. Thus, 10 weeks of yoga practice resulted in improved balance and learning in the speed-accuracy motor task that were mediated by increased BDNF levels, but had no impact on cognition in older adults.",2020,"Although reaction and movement times during learning were decreased in both groups (P < 0.05), a faster reaction time (P < 0.05) and shorter movement time (P < 0.05) were observed in the yoga group than in the control group.","['Participants aged 60-79\u202fyears', 'older adults']","['brain-derived neurotrophic factor (BDNF', 'control group (n\u202f=\u202f15) or a yoga group']","['cognitive performance', 'Yoga practice', 'BDNF levels', 'shorter movement time', 'reaction and movement times during learning', 'velocity vector of the center of pressure under single- and dual-task conditions', 'Changes in cognition, balance under single- and dual-task conditions, and learning fast and accurate reaching movements', 'balance and learning', 'cognition, balance under single- and dual-task conditions, and motor learning', 'BDNF levels and functional improvements', 'faster reaction time']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0012656', 'cui_str': 'Infectious Disease Vectors'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}]",,0.0174528,"Although reaction and movement times during learning were decreased in both groups (P < 0.05), a faster reaction time (P < 0.05) and shorter movement time (P < 0.05) were observed in the yoga group than in the control group.","[{'ForeName': 'Agnė', 'Initials': 'A', 'LastName': 'Čekanauskaitė', 'Affiliation': 'Department of Health Promotion and Rehabilitation, Lithuanian Sports University, Kaunas, Lithuania. Electronic address: agne.cekanauskaite@lsu.lt.'}, {'ForeName': 'Albertas', 'Initials': 'A', 'LastName': 'Skurvydas', 'Affiliation': 'Department of Health Promotion and Rehabilitation, Lithuanian Sports University, Kaunas, Lithuania; Institute of Sports Science and Innovations, Lithuanian Sports University, Kaunas, Lithuania.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Žlibinaitė', 'Affiliation': 'Department of Health Promotion and Rehabilitation, Lithuanian Sports University, Kaunas, Lithuania.'}, {'ForeName': 'Dalia', 'Initials': 'D', 'LastName': 'Mickevičienė', 'Affiliation': 'Department of Health Promotion and Rehabilitation, Lithuanian Sports University, Kaunas, Lithuania; Institute of Sports Science and Innovations, Lithuanian Sports University, Kaunas, Lithuania.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Kilikevičienė', 'Affiliation': 'Department of Health Promotion and Rehabilitation, Lithuanian Sports University, Kaunas, Lithuania; Institute of Sports Science and Innovations, Lithuanian Sports University, Kaunas, Lithuania.'}, {'ForeName': 'Rima', 'Initials': 'R', 'LastName': 'Solianik', 'Affiliation': 'Department of Health Promotion and Rehabilitation, Lithuanian Sports University, Kaunas, Lithuania; Institute of Sports Science and Innovations, Lithuanian Sports University, Kaunas, Lithuania.'}]",Experimental gerontology,['10.1016/j.exger.2020.110998'] 1537,32544602,Clinician-Patient Movement Synchrony Mediates Social Group Effects on Interpersonal Trust and Perceived Pain.,"Pain is an unfortunate consequence of many medical procedures, which in some patients becomes chronic and debilitating. Among the factors affecting medical pain, clinician-patient (C-P) similarity and nonverbal communication are particularly important for pain diagnosis and treatment. Participants (N = 66) were randomly assigned to clinician and patient roles and were grouped into C-P dyads. Clinicians administered painful stimuli to patients as an analogue of a painful medical procedure. We manipulated the perceived C-P similarity of each dyad using groups ostensibly based on shared beliefs and values, and each patient was tested twice: Once with a same group clinician (concordant, CC) and once with a clinician from the other group (discordant, DC). Movement synchrony was calculated as a marker of nonverbal communication. We tested whether movement synchrony mediated the effects of group concordance on patients' pain and trust in the clinician. Movement synchrony was higher in CC than DC dyads. Higher movement synchrony predicted reduced pain and increased trust in the clinician. Movement synchrony also formally mediated the group concordance effects on pain and trust. These findings increase our understanding of the role of nonverbal C-P communication on pain and related outcomes. Interpersonal synchrony may be associated with better pain outcomes, independent of the specific treatment provided. PERSPECTIVE: This article demonstrates that movement synchrony in C-P interactions is an unobtrusive measure related to their relationship quality, trust toward the clinician, and pain. These findings suggest that interpersonal synchrony may be associated with better patient outcomes, independent of the specific treatment provided.",2020,Movement synchrony was higher in CC than DC dyads.,['Participants (N=66'],[],"['pain and trust', 'interpersonal trust and perceived pain', 'Movement synchrony', 'pain']",[],[],"[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0026649', 'cui_str': 'Movement'}]",66.0,0.0401092,Movement synchrony was higher in CC than DC dyads.,"[{'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Goldstein', 'Affiliation': 'Institute of Cognitive Science, University of Colorado, Boulder, Colorado; The School of Public Health, University of Haifa, Israel.'}, {'ForeName': 'Elizabeth A Reynolds', 'Initials': 'EAR', 'LastName': 'Losin', 'Affiliation': 'Department of Psychology, University of Miami, Florida.'}, {'ForeName': 'Steven R', 'Initials': 'SR', 'LastName': 'Anderson', 'Affiliation': 'Department of Psychology, University of Miami, Florida.'}, {'ForeName': 'Victoria R', 'Initials': 'VR', 'LastName': 'Schelkun', 'Affiliation': 'Department of Psychological and Brain Sciences, Dartmouth College, Hanover, New Hampshire.'}, {'ForeName': 'Tor D', 'Initials': 'TD', 'LastName': 'Wager', 'Affiliation': 'Department of Psychological and Brain Sciences, Dartmouth College, Hanover, New Hampshire; Department of Psychology and Neuroscience, University of Colorado, Boulder, Colorado. Electronic address: tor.d.wager@dartmouth.edu.'}]",The journal of pain : official journal of the American Pain Society,['10.1016/j.jpain.2020.03.001'] 1538,32544700,Time course of drug-related treatment-emergent adverse side effects of brivaracetam.,"OBJECTIVE Treatment-emergent adverse events (TEAEs) in clinical trials are typically reported for the full duration of the treatment period including titration and maintenance. Drug-related central nervous system (CNS) TEAEs are common with antiseizure medications (ASMs) and can affect drug tolerability. In this report, we test the hypothesis that drug-related CNS TEAEs have early onset and decrease with time. Unlike prior ASM clinical trials, a novel design was used for brivaracetam (BRV) without initial drug titration allowing assessment of habituation to TEAEs separate from dose titration. METHODS Data were pooled from three studies (N01252 [NCT00490035], N01253 [NCT00464269], N01358 [NCT01261325]) in adult patients (≥16 years of age) with focal seizures receiving BRV adjunctive therapy. This post hoc analysis reports data on the prevalence and incidence of all drug-related CNS TEAEs and all TEAEs over time in patients who received BRV doses of 50-200 mg/day (without titration) vs. placebo during a 12-week treatment period. RESULTS A total of 1262 patients received the following: placebo (n = 459), BRV 50 mg/day (n = 200), BRV 100 mg/day (n = 353), and BRV 200 mg/day (n = 250). Both the incidence (p < .0001) and prevalence (p < .0001) of drug-related CNS TEAEs (all with frequency ≥ 5%) changed across time with peak TEAEs in week 1 then significantly reducing over the first 6 weeks for prevalence and the first 3 weeks for incidence. CONCLUSIONS Drug-related CNS TEAEs occurred early and substantially habituated over several weeks. TEAEs of ASMs might be better represented by division into early and late phases to guide clinician monitoring and patient expectations.",2020,"Both the incidence (p < .0001) and prevalence (p < .0001) of drug-related CNS TEAEs (all with frequency ≥ 5%) changed across time with peak TEAEs in week 1 then significantly reducing over the first 6 weeks for prevalence and the first 3 weeks for incidence. ","['1262 patients', 'adult patients (≥16\u202fyears of age) with focal seizures receiving BRV adjunctive therapy']","['Drug-related central nervous system (CNS', 'brivaracetam', 'placebo']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C1699861', 'cui_str': 'Brivaracetam'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C1699861', 'cui_str': 'Brivaracetam'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],1262.0,0.10034,"Both the incidence (p < .0001) and prevalence (p < .0001) of drug-related CNS TEAEs (all with frequency ≥ 5%) changed across time with peak TEAEs in week 1 then significantly reducing over the first 6 weeks for prevalence and the first 3 weeks for incidence. ","[{'ForeName': 'Kimford J', 'Initials': 'KJ', 'LastName': 'Meador', 'Affiliation': 'Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA. Electronic address: kmeador@stanford.edu.'}, {'ForeName': 'Cedric', 'Initials': 'C', 'LastName': 'Laloyaux', 'Affiliation': 'UCB Pharma, Brussels, Belgium. Electronic address: cedric.laloyaux@ucb.com.'}, {'ForeName': 'Sami', 'Initials': 'S', 'LastName': 'Elmoufti', 'Affiliation': 'UCB Pharma, Raleigh, NC, USA. Electronic address: sami.elmoufti@ucb.com.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Gasalla', 'Affiliation': 'UCB Pharma, Monheim am Rhein, Germany. Electronic address: teresa.gasalla@ucb.com.'}, {'ForeName': 'Jesse', 'Initials': 'J', 'LastName': 'Fishman', 'Affiliation': 'UCB Pharma, Smyrna, GA, USA. Electronic address: jfishman@its.jnj.com.'}, {'ForeName': 'Melinda S', 'Initials': 'MS', 'LastName': 'Martin', 'Affiliation': 'UCB Pharma, Smyrna, GA, USA. Electronic address: melinda.martin@ucb.com.'}, {'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Klein', 'Affiliation': 'Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA. Electronic address: kleinp@epilepsydc.com.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2020.107212'] 1539,32544794,Acute aerobic exercise enhances pleasant compared to unpleasant visual scene processing.,"Although acute aerobic exercise benefits different aspects of emotional functioning, it is unclear how exercise influences the processing of emotional stimuli and which brain mechanisms support this relationship. We assessed the influence of acute aerobic exercise on valence biases (preferential processing of negative/positive pictures) by performing source reconstructions of participants' brain activity after they viewed emotional scenes. Twenty-four healthy participants (12 women) were tested in a randomized and counterbalanced design that consisted of three experimental protocols, each lasting 30 min: low-intensity exercise (Low-Int); moderate-intensity exercise (Mod-Int); and a seated rest condition (REST). After each of the protocols, participants viewed negative and positive pictures, during which event-related magnetic fields were recorded. Analyses revealed that exercise strongly impacted the valence processing of emotional scenes within a widely distributed left hemispheric spatio-temporal cluster between 190 and 310 ms after picture onset. Brain activity in this cluster showed that a negativity bias at REST (negative > positive picture processing) diminished after the Low-Int condition (positive = negative) and even reversed to a positivity bias after the Mod-Int condition (positive > negative). Thus, acute aerobic exercise of low and moderate intensities induces a positivity bias which is reflected in early, automatic processes.",2020,Analyses revealed that exercise strongly impacted the valence processing of emotional scenes within a widely distributed left hemispheric spatio-temporal cluster between 190 and 310 ms after picture onset.,"['Twenty-four healthy participants (12 women', ""participants' brain activity after they viewed emotional scenes""]","['Acute aerobic exercise enhances pleasant', 'lasting 30\xa0min: low-intensity exercise (Low-Int); moderate-intensity exercise (Mod-Int); and a seated rest condition (REST', 'acute aerobic exercise']","['valence processing of emotional scenes', 'Brain activity']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0443158', 'cui_str': 'Brain activity'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0277814', 'cui_str': 'Sitting position'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0443158', 'cui_str': 'Brain activity'}]",24.0,0.139816,Analyses revealed that exercise strongly impacted the valence processing of emotional scenes within a widely distributed left hemispheric spatio-temporal cluster between 190 and 310 ms after picture onset.,"[{'ForeName': 'Tomasz S', 'Initials': 'TS', 'LastName': 'Ligeza', 'Affiliation': 'Psychophysiology Laboratory, Institute of Psychology, Jagiellonian University, Kraków, Poland. Electronic address: tomasz.ligeza@uj.edu.pl.'}, {'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Maciejczyk', 'Affiliation': 'Department of Physiology and Biochemistry, Faculty of Physical Education and Sport, University of Physical Education, Kraków, Poland.'}, {'ForeName': 'Miroslaw', 'Initials': 'M', 'LastName': 'Wyczesany', 'Affiliation': 'Psychophysiology Laboratory, Institute of Psychology, Jagiellonian University, Kraków, Poland.'}, {'ForeName': 'Heiko', 'Initials': 'H', 'LastName': 'Wagner', 'Affiliation': 'Institute for Sports Science, University of Muenster, Muenster, Germany; Otto Creutzfeldt Center for Cognitive and Behavioral Neuroscience, University of Muenster, Muenster, Germany.'}, {'ForeName': 'Kati', 'Initials': 'K', 'LastName': 'Roesmann', 'Affiliation': 'Otto Creutzfeldt Center for Cognitive and Behavioral Neuroscience, University of Muenster, Muenster, Germany; Institute for Clinical Psychology, University of Siegen, Siegen, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Junghofer', 'Affiliation': 'Institute for Biomagnetism and Biosignalanalysis, University of Muenster, Muenster, Germany; Otto Creutzfeldt Center for Cognitive and Behavioral Neuroscience, University of Muenster, Muenster, Germany.'}]",Brain and cognition,['10.1016/j.bandc.2020.105595'] 1540,32545872,"Exercise before, during, and after Hospitalization for Allogeneic Hematological Stem Cell Transplant: A Feasibility Randomized Controlled Trial.","People with cancer who undergo allogeneic hematological stem cell transplant (allo-HSCT) experience significant deconditioning that can compromise quality of life. Exercise has shown to be beneficial before or after allo-HSCT; however, little is known about exercise therapy delivered across the continuum of care. We conducted a feasibility randomized controlled trial of exercise delivered prior to admission, during the inpatient stay, and after discharge versus control in people with planned allo-HSCT. Feasibility was assessed via recruitment and retention rates, the incidence of adverse events, and adherence to the exercise prescription. Estimates of efficacy were measured at baseline, one week prior to hospital admission, and 100 days and one year after transplant. The recruitment and retention rates were 20% and 33%, respectively. One serious adverse event occurred during the baseline six-minute walk test that precluded participation in the study and no adverse events were associated with the intervention. From baseline to pre-transplant, the intervention group improved six-minute walk test distances by 45 m (95% CI: -18.0 to 108.7)-a finding that warrants further investigation with an adequately powered trial. Our study contributes important feasibility considerations and pilot data for future exercise intervention research in allo-HSCT recipients.",2020,"From baseline to pre-transplant, the intervention group improved six-minute walk test distances by 45 m (95% CI: -18.0 to 108.7)-a finding that warrants further investigation with an adequately powered trial.","['People with cancer who undergo allogeneic hematological stem cell transplant (allo-HSCT) experience significant deconditioning', 'people with planned allo-HSCT', 'Allogeneic Hematological Stem Cell Transplant', 'allo-HSCT recipients']",[],"['via recruitment and retention rates, the incidence of adverse events, and adherence to the exercise prescription', 'recruitment and retention rates']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0750502', 'cui_str': 'Significant'}]",[],"[{'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0588464', 'cui_str': 'Exercise on prescription'}]",,0.163626,"From baseline to pre-transplant, the intervention group improved six-minute walk test distances by 45 m (95% CI: -18.0 to 108.7)-a finding that warrants further investigation with an adequately powered trial.","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Santa Mina', 'Affiliation': 'Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON M5S 2W6, Canada.'}, {'ForeName': 'Lianne B', 'Initials': 'LB', 'LastName': 'Dolan', 'Affiliation': 'Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada.'}, {'ForeName': 'Jeffrey H', 'Initials': 'JH', 'LastName': 'Lipton', 'Affiliation': 'Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.'}, {'ForeName': 'Darren', 'Initials': 'D', 'LastName': 'Au', 'Affiliation': 'Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON M5S 2W6, Canada.'}, {'ForeName': 'Encarna', 'Initials': 'E', 'LastName': 'Camacho Pérez', 'Affiliation': 'Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON M5S 2W6, Canada.'}, {'ForeName': 'Alyssa', 'Initials': 'A', 'LastName': 'Franzese', 'Affiliation': 'Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada.'}, {'ForeName': 'Shabbir M H', 'Initials': 'SMH', 'LastName': 'Alibhai', 'Affiliation': 'Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Jones', 'Affiliation': 'Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada.'}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Chang', 'Affiliation': 'Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada.'}]",Journal of clinical medicine,['10.3390/jcm9061854'] 1541,32683106,Effect of combined exercise training on pentraxins and pro- inflammatory cytokines in people with multiple sclerosis as a function of disability status.,"OBJECTIVES There is some evidence for beneficial effects of exercise on cytokines in people with multiple sclerosis (MS), but it is unclear if such effects differ by disability status (i.e., stage of the disease). This study investigated the effect of combined exercise training on pentraxins and pro- inflammatory cytokines in people with multiple sclerosis as a function of disability status. METHODS This randomized control trial included 94 women with MS who were randomly assigned into exercise or control conditions with randomization stratified by Expanded Disability Status Scale (EDSS) scores of low (EDSS < 4.5), moderate (4.5 ≤ EDSS ≤ 6), or high (EDSS ≥ 6.5) disability. The exercise program lasted 12 weeks and comprised resistance, endurance, Pilates, balance and stretch exercises performed? days/week; the control condition involved a waitlist control. We measured resting levels of inflammatory factors, functional capacity, and lipid profile before and after the 12-week intervention period. RESULTS Combined exercise training significantly decreased hs-CRP (p = 0.029) and IL-6 (p = 0.001) and increased PTX-3 (p = 0.001) and IFN-ƴ (p = 0.001), but there was no significant change in Fibrin D-dimer (FDD) (p = 0.876) compared with control, and those effects were independent of disability status. 1RM for lat pull-down, knee extension, and seated row and 6MWT (i.e., walking further) significantly increased and TUG performance significantly decreased (i.e., faster performance) (all, p < 0.001) after combined exercise compared with control, and this too was independent of disability status. CONCLUSIONS Exercise may stimulate anti-inflammatory effects in MS, and this is generally not influenced by disability status. Exercise training may be an adjuvant for disease-modifying therapy among people with MS, and such effects might not be moderated by disability status.",2020,"RESULTS Combined exercise training significantly decreased hs-CRP (p = 0.029) and IL-6 (p = 0.001) and increased PTX-3 (p = 0.001) and IFN-ƴ (p = 0.001), but there was no significant change in Fibrin D-dimer (FDD) (p = 0.876) compared with control, and those effects were independent of disability status.","['people with multiple sclerosis', '94 women with MS', 'people with multiple sclerosis (MS']","['Combined exercise training', 'exercise or control conditions with randomization stratified by Expanded Disability Status Scale (EDSS) scores of low (EDSS\xa0<\xa04.5), moderate (4.5\xa0≤', 'exercise program lasted 12\xa0weeks and comprised resistance, endurance, Pilates, balance and stretch exercises performed', 'Exercise training', 'combined exercise training']","['Fibrin D-dimer (FDD', 'resting levels of inflammatory factors, functional capacity, and lipid profile', 'faster performance', 'TUG performance', 'pentraxins and pro- inflammatory cytokines', 'PTX-3', 'IL-6', 'hs-CRP']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C3844009', 'cui_str': '4.5'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0600080', 'cui_str': 'Stretching exercises'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0060323', 'cui_str': 'D-dimer'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0030899', 'cui_str': 'Pentoxifylline'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}]",94.0,0.0328348,"RESULTS Combined exercise training significantly decreased hs-CRP (p = 0.029) and IL-6 (p = 0.001) and increased PTX-3 (p = 0.001) and IFN-ƴ (p = 0.001), but there was no significant change in Fibrin D-dimer (FDD) (p = 0.876) compared with control, and those effects were independent of disability status.","[{'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Faramarzi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran. Electronic address: farmarzi@sku.ac.ir.'}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Banitalebi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Raisi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Masoumeh', 'Initials': 'M', 'LastName': 'Samieyan', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Saberi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Mardaniyan Ghahfarrokhi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Raoof', 'Initials': 'R', 'LastName': 'Negaresh', 'Affiliation': 'Department of Physical Education & Sport Sciences, Faculty of Humanities, Tarbiat Modares University, Tehran, Iran.'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Motl', 'Affiliation': 'Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, USA.'}]",Cytokine,['10.1016/j.cyto.2020.155196'] 1542,32545353,Long-Term Effects in Bone Mineral Density after Different Bariatric Procedures in Patients with Type 2 Diabetes: Outcomes of a Randomized Clinical Trial.,"There is scant evidence of the long-term effects of bariatric surgery on bone mineral density (BMD). We compared BMD changes in patients with severe obesity and type 2 diabetes (T2D) 5 years after randomization to metabolic gastric bypass (mRYGB), sleeve gastrectomy (SG) and greater curvature plication (GCP). We studied the influence of first year gastrointestinal hormone changes on final bone outcomes. Forty-five patients, averaging 49.4 (7.8) years old and body mass index (BMI) 39.4 (1.9) kg/m 2 , were included. BMD at lumbar spine (LS) was lower after mRYGB compared to SG and GCP: 0.89 [0.82;0.94] vs. 1.04 [0.91;1.16] vs. 0.99 [0.89;1.12], p = 0.020. A higher percentage of LS osteopenia was present after mRYGB 78.6% vs. 33.3% vs. 50.0%, respectively. BMD reduction was greater in T2D remitters vs. non-remitters. Weight at fifth year predicted BMD changes at the femoral neck (FN) (adjusted R 2 : 0.3218; p = 0.002), and type of surgery (mRYGB) and menopause predicted BMD changes at LS (adjusted R 2 : 0.2507; p < 0.015). In conclusion, mRYGB produces higher deleterious effects on bone at LS compared to SG and GCP in the long-term. Women in menopause undergoing mRYGB are at highest risk of bone deterioration. Gastrointestinal hormone changes after surgery do not play a major role in BMD outcomes.",2020,"BMD at lumbar spine (LS) was lower after mRYGB compared to SG and GCP: 0.89 [0.82;0.94] vs. 1.04 [0.91;1.16] vs. 0.99 [0.89;1.12], p = 0.020.","['Forty-five patients, averaging 49.4 (7.8) years old and body mass index (BMI) 39.4 (1.9) kg/m 2 , were included', 'patients with severe obesity and type 2 diabetes (T2D) 5 years after randomization to', 'Patients with Type 2 Diabetes']","['metabolic gastric bypass (mRYGB), sleeve gastrectomy (SG) and greater curvature plication (GCP', 'bariatric surgery']","['BMD at lumbar spine (LS', 'bone deterioration', 'BMD reduction', 'bone mineral density (BMD', 'Bone Mineral Density', 'LS osteopenia', 'type of surgery (mRYGB) and menopause predicted BMD changes']","[{'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517517', 'cui_str': '1.9'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0028756', 'cui_str': 'Morbid obesity'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0017125', 'cui_str': 'Bypass of stomach'}, {'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}, {'cui': 'C0227223', 'cui_str': 'Structure of greater curvature of stomach'}, {'cui': 'C0185026', 'cui_str': 'Plication'}, {'cui': 'C1456587', 'cui_str': 'Metabolic surgery'}]","[{'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0024091', 'cui_str': 'Bone structure of lumbar vertebra'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",45.0,0.0884541,"BMD at lumbar spine (LS) was lower after mRYGB compared to SG and GCP: 0.89 [0.82;0.94] vs. 1.04 [0.91;1.16] vs. 0.99 [0.89;1.12], p = 0.020.","[{'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Guerrero-Pérez', 'Affiliation': ""Department of Endocrinology and Nutrition, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Casajoana', 'Affiliation': ""Bariatric Surgery Unit, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.""}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Gómez-Vaquero', 'Affiliation': ""Department of Rheumatology, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.""}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Virgili', 'Affiliation': ""Department of Endocrinology and Nutrition, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.""}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'López-Urdiales', 'Affiliation': ""Department of Endocrinology and Nutrition, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Hernández-Montoliu', 'Affiliation': ""Department of Endocrinology and Nutrition, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.""}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Pujol-Gebelli', 'Affiliation': ""Bariatric Surgery Unit, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.""}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Osorio', 'Affiliation': ""Bariatric Surgery Unit, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Prats', 'Affiliation': ""Clinical Nutrition Unit, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Vidal-Alabró', 'Affiliation': ""Instituto de Investigación Biomédica-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.""}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Pérez-Maraver', 'Affiliation': ""Department of Endocrinology and Nutrition, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.""}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Fernández-Veledo', 'Affiliation': 'CIBERDEM-CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, 28014 Madrid, Spain.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Vendrell', 'Affiliation': 'CIBERDEM-CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, 28014 Madrid, Spain.'}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Vilarrasa', 'Affiliation': ""Department of Endocrinology and Nutrition, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.""}]",Journal of clinical medicine,['10.3390/jcm9061830'] 1543,32683099,"Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.","BACKGROUND & AIMS Vedolizumab is a gut-selective monoclonal antibody for treatment of moderately to severely active Crohn's disease (CD). We performed a prospective study of endoscopic, radiologic, and histologic healing in patients with CD who received vedolizumab therapy METHODS: We performed a phase 3b, open-label, single-group study of 101 patients with at least 3 months of active CD (a CD Activity Index score of 220-450, a simple endoscopic score for CD [SES-CD] of 7 or more, 1 or more mucosal ulcerations [identified by endoscopy], and failure of conventional therapy) from March 2015 through December 2017. Among the patients enrolled, 54.5% had previous failure of 1 or more tumor necrosis factor (TNF) antagonist and 44.6% had severe endoscopic disease activity (SES-CD scores above 15) at baseline. Participants received vedolizumab (300 mg intravenously) at weeks 0, 2, and 6, and then every 8 weeks thereafter, for 26 weeks (primary study) or 52 weeks (sub-study, 56 patients). The primary endpoint at week 26 was endoscopic remission (SES-CD score of 4 or less); other endpoints included endoscopic response (50% reduction in SES-CD), radiologic remission (magnetic resonance index of activity score below 7), and histologic response (modified-global histologic disease activity score of 4 or less). RESULTS At week 26, 11.9% of patients were in endoscopic remission (95% CI, 6.3%-9.8%); at week 52, 17.9% of the patients were in endoscopic remission (95% CI, 8.9%-30.4%). Higher proportions of patients naïve to TNF antagonists achieved endoscopic remission than patients with TNF antagonist failure at weeks 26 and 52. Higher proportion of patients with moderate CD (SES-CD scores, 7-15) achieved endoscopic remission at weeks 26 and 52 than patients with severe CD (SES-CD scores above 15). The proportion of patients with complete mucosal healing increased over time, with greater rates of healing in the colon than in the ileum. Remission was detected by magnetic resonance enterography in 21.9% of patients at week 26 (95% CI, 9.3%-40.0%) and in 38.1% at week 52 (95% CI, 18.1%-61.6%). At week 26, 24.4% of patients had a histologic response in the colon (95% CI, 15.3%-35.4%) and 28.3% of patients had a histologic response in the ileum (95% CI, 17.5%-41.4%). At week 52, 20.5% of patients had a histologic response in the colon (95% CI, 9.8%-35.3%) and 34.3% of patients had a histologic response in the ileum (95% CI, 19.1%-52.2%). There were no notable safety issues, including worsening of extraintestinal manifestations. CONCLUSIONS In a phase 3b trial, we found that 26 and 52 weeks of treatment with vedolizumab (300 mg, at weeks 0, 2, and 6, and then every 8 weeks thereafter) induces endoscopic, radiologic, and histologic healing in patients with moderately to severely active CD.",2020,"The proportion of patients with complete mucosal healing increased over time, with greater rates of healing in the colon than in the ileum.","[""moderately to severely active Crohn's disease (CD"", 'patients with moderately to severely active CD', '101 patients with at least 3 months of active CD (a CD Activity Index score of 220-450, a simple endoscopic score for CD [SES-CD] of 7 or more, 1 or more mucosal ulcerations [identified by endoscopy], and failure of conventional therapy) from March 2015 through December 2017', ""Patients With Active Crohn's Disease"", 'patients with CD who received']","['vedolizumab therapy', 'vedolizumab', 'Vedolizumab']","['worsening of extraintestinal manifestations', 'proportion of patients with complete mucosal healing', 'rates of healing', 'endoscopic, radiologic, and histologic healing', 'previous failure of 1 or more tumor necrosis factor (TNF', 'Endoscopic, Radiologic, and Histologic Healing', 'endoscopic remission (SES-CD score of 4 or less); other endpoints included endoscopic response', 'histologic response', 'Remission', 'severe endoscopic disease activity (SES-CD scores', 'endoscopic remission', 'SES-CD), radiologic remission (magnetic resonance index of activity score below 7), and histologic response (modified-global histologic disease activity score of 4 or less', 'magnetic resonance enterography']","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0451071', 'cui_str': ""Crohn's disease activity index""}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C3844104', 'cui_str': '450'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0236053', 'cui_str': 'Mucosal ulcer'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C5190551', 'cui_str': 'Vedolizumab therapy'}, {'cui': 'C2742797', 'cui_str': 'vedolizumab'}]","[{'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0205319', 'cui_str': 'Manifest'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0034599', 'cui_str': 'Radiology - specialty'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0028580', 'cui_str': 'Nuclear Magnetic Resonance'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C4274338', 'cui_str': 'Magnetic resonance enterography'}]",101.0,0.144412,"The proportion of patients with complete mucosal healing increased over time, with greater rates of healing in the colon than in the ileum.","[{'ForeName': 'Tarun', 'Initials': 'T', 'LastName': 'Chhibba', 'Affiliation': 'Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Guizzetti', 'Affiliation': 'Alimentiv (formerly Robarts Clinical Trials, Inc.), London, Ontario, Canada.'}, {'ForeName': 'Cynthia H', 'Initials': 'CH', 'LastName': 'Seow', 'Affiliation': 'Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Cathy', 'Initials': 'C', 'LastName': 'Lu', 'Affiliation': 'Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Kerri L', 'Initials': 'KL', 'LastName': 'Novak', 'Affiliation': 'Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Ashwin N', 'Initials': 'AN', 'LastName': 'Ananthakrishnan', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, United States.'}, {'ForeName': 'Charles N', 'Initials': 'CN', 'LastName': 'Bernstein', 'Affiliation': 'Inflammatory Bowel Disease Clinical and Research Centre, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Gilaad G', 'Initials': 'GG', 'LastName': 'Kaplan', 'Affiliation': 'Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Remo', 'Initials': 'R', 'LastName': 'Panaccione', 'Affiliation': 'Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Ma', 'Affiliation': 'Alimentiv (formerly Robarts Clinical Trials, Inc.), London, Ontario, Canada; Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada. Electronic address: christopher.ma@ucalgary.ca.'}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2020.07.020'] 1544,32557382,Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.,"BACKGROUND Management of moderate-to-severe atopic dermatitis (AD) commonly requires long-term treatment. OBJECTIVE The aim of this study was to report the safety and efficacy of dupilumab treatment for up to 3 years in adults with moderate-to-severe AD. METHODS This ongoing, multicenter, open-label extension study (LIBERTY AD OLE; NCT01949311) assessed dupilumab treatment in adults previously enrolled in dupilumab trials. Patients received dupilumab 300 mg weekly up to 148 weeks. The primary outcome was safety. RESULTS Of 2677 patients enrolled and treated, 347 reached week 148. Mean self-reported drug compliance was 98.2%. Safety data were consistent with previously reported trials (270.1 adverse events [AEs]/100 patient-years; 6.9 serious AEs/100 patient-years) and the known dupilumab safety profile. Common AEs (≥ 5% of patients) included nasopharyngitis, AD, upper respiratory tract infection, conjunctivitis, headache, oral herpes, and injection-site reactions. AD signs and symptoms showed sustained improvements during treatment with mean (standard deviation, mean percentage change from parent study baseline) Eczema Area and Severity Index 1.4 (3.2, - 95.4%) and weekly Pruritus Numerical Rating Scale 2.2 (1.8, - 65.4%) at week 148. LIMITATIONS No control arm; fewer patients at later time points; regimen different from the approved 300 mg every 2 weeks dose. CONCLUSION These safety and efficacy results support dupilumab as a continuous long-term treatment for adults with moderate-to-severe AD. TRIAL REGISTRATION ClinicalTrials.gov: NCT01949311. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis (MP4  139831 kb).",2020,"Eczema Area and Severity Index 1.4 (3.2, - 95.4%) and weekly Pruritus Numerical Rating Scale 2.2 (1.8, - 65.4%) at week 148. ","['Adults with Moderate-to-Severe Atopic Dermatitis', 'adults with moderate-to-severe atopic dermatitis (MP4 \xa0139831 kb', 'adults previously enrolled in dupilumab trials', '2677 patients enrolled and treated, 347 reached week 148', 'adults with moderate-to-severe AD']","['dupilumab 300\xa0mg weekly up to 148\xa0weeks', 'dupilumab']","['weekly Pruritus Numerical Rating Scale', 'Mean self-reported drug compliance', 'nasopharyngitis, AD, upper respiratory tract infection, conjunctivitis, headache, oral herpes, and injection-site reactions', 'safety', 'safety and efficacy', 'Eczema Area and Severity Index']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C3660996', 'cui_str': 'dupilumab'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C3660996', 'cui_str': 'dupilumab'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C0041912', 'cui_str': 'Upper respiratory infection'}, {'cui': 'C0009763', 'cui_str': 'Conjunctivitis'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0341012', 'cui_str': 'Oral herpes simplex infection'}, {'cui': 'C0151735', 'cui_str': 'Injection site reaction'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0013595', 'cui_str': 'Eczema'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",2677.0,0.0596092,"Eczema Area and Severity Index 1.4 (3.2, - 95.4%) and weekly Pruritus Numerical Rating Scale 2.2 (1.8, - 65.4%) at week 148. ","[{'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Beck', 'Affiliation': 'Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Diamant', 'Initials': 'D', 'LastName': 'Thaçi', 'Affiliation': 'University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'Mette', 'Initials': 'M', 'LastName': 'Deleuran', 'Affiliation': 'Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Blauvelt', 'Affiliation': 'Oregon Medical Research, Portland, OR, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Bissonnette', 'Affiliation': 'Innovaderm Research, Montreal, QC, Canada.'}, {'ForeName': 'Marjolein', 'Initials': 'M', 'LastName': 'de Bruin-Weller', 'Affiliation': 'National Expertise Center of Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Michihiro', 'Initials': 'M', 'LastName': 'Hide', 'Affiliation': 'Department of Dermatology, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Sher', 'Affiliation': 'Peninsula Research Associates, Rolling Hills Estates, CA, USA.'}, {'ForeName': 'Iftikhar', 'Initials': 'I', 'LastName': 'Hussain', 'Affiliation': 'Vital Prospects Clinical Research Institute, PC, Tulsa, OK, USA.'}, {'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY, 10591, USA.'}, {'ForeName': 'Faisal A', 'Initials': 'FA', 'LastName': 'Khokhar', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY, 10591, USA.'}, {'ForeName': 'Bethany', 'Initials': 'B', 'LastName': 'Beazley', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY, 10591, USA.'}, {'ForeName': 'Marcella', 'Initials': 'M', 'LastName': 'Ruddy', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY, 10591, USA.'}, {'ForeName': 'Naimish', 'Initials': 'N', 'LastName': 'Patel', 'Affiliation': 'Sanofi, Bridgewater, NJ, USA.'}, {'ForeName': 'Neil M H', 'Initials': 'NMH', 'LastName': 'Graham', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY, 10591, USA.'}, {'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Ardeleanu', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY, 10591, USA.'}, {'ForeName': 'Brad', 'Initials': 'B', 'LastName': 'Shumel', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY, 10591, USA. brad.shumel@regeneron.com.'}]",American journal of clinical dermatology,['10.1007/s40257-020-00527-x'] 1545,32549135,Double-blind trial of solid lipid Boswellia serrata particles (SLBSP) vs. standardized Boswellia serrata gum extract (BSE) for osteoarthritis of knee.,"Objectives The present study was planned to investigate the efficacy of SLBSP vs. standardized BSE for symptomatic knee osteoarthritis (OA) treatment. Methods It was a prospective, randomized, double-blind, double-dummy, placebo-controlled, and single-centre clinical trial for symptomatic osteoarthritis of knee. Subjects were randomized to receive SLBSP capsule+BSE Placebo or BSE tablet+SLBSP placebo for two months. Patients were allowed to take rescue analgesics (Acelofenac 100 mg). Improvement in pain and function was assessed utilizing WOMAC, VAS. Level of CTX-II in urine and serum levels of inflammatory cytokines including IL-2, IL-4, IL-6, TNF-α, and IFN-γ was measured initially and at end of treatment. Results and conclusions Western Ontario and McMaster Universities osteoarthritis index (WOMAC) and Visual Analog Scale score improved markedly in SLBSP as well as in BSE arm (p < 0.05). Difference in VAS and WOMAC scores between the two arms was not statistically significant. Most significant effect was observed in the need for rescue analgesics. SLBSP caused marked lowering of pro-inflammatory cytokines levels whereas a several fold increase was noted in the BSE arm (p < 0.05). Both groups showed marked improvement in pain, SLBSP being superior to BSE with respect to reducing the need for rescue analgesics in addition to modulating inflammatory cytokines.",2020,SLBSP caused marked lowering of pro-inflammatory cytokines levels whereas a several fold increase was noted in the BSE arm (p < 0.05).,"['symptomatic knee osteoarthritis (OA) treatment', 'osteoarthritis of knee', 'symptomatic osteoarthritis of knee']","['solid lipid Boswellia serrata particles (SLBSP) vs. standardized Boswellia serrata gum extract (BSE', 'SLBSP capsule\xa0+\xa0BSE Placebo or BSE tablet\xa0+\xa0SLBSP placebo', 'SLBSP', 'SLBSP vs. standardized BSE', 'placebo']","['WOMAC and VAS score', 'pain and function', 'VAS and WOMAC scores', 'Level of CTX-II in urine and serum levels of inflammatory cytokines including IL-2, IL-4, IL-6, TNF-α, and IFN-γ', 'pain, SLBSP', 'lowering of pro-inflammatory cytokines levels']","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0205208', 'cui_str': 'Solid'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0873038', 'cui_str': 'boswellia preparation'}, {'cui': 'C0085105', 'cui_str': 'Breast self-examination'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0010377', 'cui_str': 'Crotoxin'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0021756', 'cui_str': 'Interleukin-2'}, {'cui': 'C0021758', 'cui_str': 'Interleukin-4'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0033382', 'cui_str': 'Proline'}]",,0.428873,SLBSP caused marked lowering of pro-inflammatory cytokines levels whereas a several fold increase was noted in the BSE arm (p < 0.05).,"[{'ForeName': 'Preeti D', 'Initials': 'PD', 'LastName': 'Kulkarni', 'Affiliation': 'School of Pharmacy and Medical Science, Singhania University, Pacheri Bari, Jhunjhunu, 333515,Rajasthan, India.'}, {'ForeName': 'Neena D', 'Initials': 'ND', 'LastName': 'Damle', 'Affiliation': 'Department of Kaya Chikitsa, DY Patil University, School of Ayurveda, Navi Mumbai, India.'}, {'ForeName': 'Sumer', 'Initials': 'S', 'LastName': 'Singh', 'Affiliation': 'School of Life Sciences, Singhania University, Jhunjhunu, Rajasthan, India.'}, {'ForeName': 'Krishnat S', 'Initials': 'KS', 'LastName': 'Yadav', 'Affiliation': 'Department of Biochemistry, Padmashree Dr. D Y Patil Medical College and Hospital, Navi Mumbai, India.'}, {'ForeName': 'Minal R', 'Initials': 'MR', 'LastName': 'Ghante', 'Affiliation': 'Sinhgad Technical Education Society, Smt. Kashibai Navale College of Pharmacy [Kondhwa], S. P. Pune University, Pune, India.'}, {'ForeName': 'Vaidhun H', 'Initials': 'VH', 'LastName': 'Bhaskar', 'Affiliation': 'Gahlot Institute of Pharmacy, Koparkhairane, Navi Mumbai, India.'}, {'ForeName': 'Lal', 'Initials': 'L', 'LastName': 'Hingorani', 'Affiliation': 'Pharmanza Herbal Pvt. Ltd., Dharmaj, Gujarat, India.'}, {'ForeName': 'Vikram S', 'Initials': 'VS', 'LastName': 'Gota', 'Affiliation': 'Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi-Mumbai, India.'}]",Drug metabolism and personalized therapy,['10.1515/dmpt-2020-0104'] 1546,32557731,Impact of minimal invasive extracorporeal circulation on atrial fibrillation after coronary artery bypass surgery.,"Postoperative atrial fibrillation (POAF) is the most common arrhythmia after cardiac surgery with an incidence between 15% and 50% and pathophysiology not fully known. By choosing the method of extracorporeal circulation with focus on the reduction of systemic inflammatory response, one can potentially decrease the risk of POAF. In this prospective, randomized trial, we compared minimal invasive extracorporeal circulation (MiECC) with conventional extracorporeal circulation (CECC) in the prevention of POAF after coronary artery bypass surgery (CABG). A total of 240 patients who were scheduled for their first on-pump CABG, were randomized to MiECC or CECC. The primary outcome measure was the incidence of first POAF during the first 84 hours after surgery. POAF occurred in 42/120 (35.0%) MiECC patients and 43/120 (35.8%) CECC patients with nonsignificant difference between the groups (OR 1.043, 95% CI 0.591-1.843, P = .884). The first postoperative creatine kinase-MB mass (CK-MBm) value was lower in the MiECC group, 13.95 [10.5-16.7] (median [IQR]) than in the CECC group, 15.30 [11.4-18.9] (P = .036), whereas the use of perioperative dobutamine was higher in the MiECC group, 18/120 (15.0%), than in the CECC group 8/120 (6.7%) (P = .038). The incidence of a stroke, perioperative myocardial infarction, and resternotomy caused by bleeding did not differ in the MiECC and CECC groups. Age (OR 1.08, 95% CI 1.04-1.13, P = .000) and peak postoperative CK-MBm (OR 1.57, 95% CI 1.06-2.37, P = .026) were independent predictors of POAF. MiECC compared to CECC was not effective in reducing the incidence of POAF in patients undergoing CABG.",2020,"The first postoperative creatine kinase-MB mass (CK-MBm) value was lower in the MiECC group, 13.95","['POAF after coronary artery bypass surgery (CABG', 'patients undergoing CABG', 'atrial fibrillation after coronary artery bypass surgery', '240 patients who were scheduled for their first on-pump CABG']","['minimal invasive extracorporeal circulation', 'MiECC', 'minimal invasive extracorporeal circulation (MiECC) with conventional extracorporeal circulation (CECC', 'CECC', 'MiECC or CECC']","['postoperative creatine kinase-MB mass (CK-MBm) value', 'POAF', 'peak postoperative CK-MBm', 'risk of POAF', 'incidence of first POAF', 'perioperative dobutamine', 'incidence of a stroke, perioperative myocardial infarction and resternotomy caused by bleeding', 'incidence of POAF']","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}]","[{'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0015354', 'cui_str': 'Extracorporeal circulation procedure'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0010290', 'cui_str': 'Creatine kinase isoenzyme, MB fraction'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0012963', 'cui_str': 'Dobutamine'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]",240.0,0.0559402,"The first postoperative creatine kinase-MB mass (CK-MBm) value was lower in the MiECC group, 13.95","[{'ForeName': 'Sten', 'Initials': 'S', 'LastName': 'Ellam', 'Affiliation': 'Department of Anesthesiology and Operative Services, Kuopio University Hospital, Kuopio, Finland.'}, {'ForeName': 'Juha', 'Initials': 'J', 'LastName': 'Hartikainen', 'Affiliation': 'Heart Center, Kuopio University Hospital, and School of Medicine, University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Pekka', 'Initials': 'P', 'LastName': 'Korvenoja', 'Affiliation': 'Acute Care, South Karelia Central Hospital, Lappeenranta, Finland.'}, {'ForeName': 'Otto', 'Initials': 'O', 'LastName': 'Pitkänen', 'Affiliation': 'Department of Anesthesiology and Operative Services, Kuopio University Hospital, Kuopio, Finland.'}, {'ForeName': 'Esko', 'Initials': 'E', 'LastName': 'Tyrväinen', 'Affiliation': 'Department of Anesthesiology and Operative Services, Kuopio University Hospital, Kuopio, Finland.'}, {'ForeName': 'Antti', 'Initials': 'A', 'LastName': 'Valtola', 'Affiliation': 'Heart Center, Kuopio University Hospital, and School of Medicine, University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Jari', 'Initials': 'J', 'LastName': 'Halonen', 'Affiliation': 'Heart Center, Kuopio University Hospital, and School of Medicine, University of Eastern Finland, Kuopio, Finland.'}]",Artificial organs,['10.1111/aor.13756'] 1547,32549724,Intraoperative Evaluation of Phacoemulsification Cataract Surgery with and without the Use of Ophthalmic Viscosurgical Devices.,"PURPOSE The purpose of this study was to compare the efficacy and safety of cataract surgery by the phacoemulsification technique with and without the use of ophthalmic viscosurgical devices (OVDs). SETTING This study was conducted at a tertiary eye care center in a rural area of Central India. DESIGN This was a prospective, randomized, observational study. METHODS In this study, 220 patients underwent phacoemulsification for cataract surgery with OVDs (OVD group) or without OVDs (BSS group) ( n = 110 in each group). Patients with operable, nuclear Grade 2-4 cataracts were included in the study. The study was conducted from June 2017 to September 2018. The frequency of intraoperative complications, surgical time, and ease of the surgical procedure (easy, difficult, or very difficult) were recorded. RESULTS There was no statistically significant difference in the nuclear opalescence, axial length, and intraocular lens (IOL) power between the two groups. Capsulorhexis extension was seen in two eyes in the OVD group and none of the eyes in the BSS group. The problems that occurred during IOL implantation included flip (OVD group, 2; BSS group, 1), haptic breakage (OVD group, 1; BSS group, 1), sulcus implantation (OVD group, 0; BSS group, 2), and stuck haptic (OVD group, 1; BSS group, 3). The total surgical time was almost equal in the two groups (OVD group, 9.2 min ± 3; BSS group, 9.5 min ± 3.5; P = 0.521). None of the patients had iris trauma or posterior capsular rupture. CONCLUSIONS OVD-less phacoemulsification surgery is a safe and effective technique for treating age-related cataracts that requires no additional instrumentation and saves the cost of the OVD.",2020,"There was no statistically significant difference in the nuclear opalescence, axial length, and intraocular lens (IOL) power between the two groups.","['This study was conducted at a tertiary eye care center in a rural area of Central India', 'Patients with operable, nuclear Grade 2-4 cataracts', 'June 2017 to September 2018', '220 patients underwent']","['Phacoemulsification Cataract Surgery', 'Ophthalmic Viscosurgical Devices', 'OVD-less phacoemulsification surgery', 'ophthalmic viscosurgical devices (OVDs', 'cataract surgery', 'phacoemulsification for cataract surgery with OVDs (OVD group) or without OVDs (BSS group) ( n']","['iris trauma or posterior capsular rupture', 'nuclear opalescence, axial length, and intraocular lens (IOL) power', 'efficacy and safety', 'total surgical time', 'Capsulorhexis extension', 'frequency of intraoperative complications, surgical time, and ease of the surgical procedure (easy, difficult, or very difficult']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0885957', 'cui_str': 'Eye care'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205188', 'cui_str': 'Operable'}, {'cui': 'C0475270', 'cui_str': 'G2 grade'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C4517650', 'cui_str': '220'}]","[{'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0005129', 'cui_str': 'Bernard Soulier syndrome'}]","[{'cui': 'C0022077', 'cui_str': 'Iris structure'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C1626910', 'cui_str': 'Posterior capsular rupture'}, {'cui': 'C0296695', 'cui_str': 'tooth-bleaching agent, Opalescence'}, {'cui': 'C0205131', 'cui_str': 'Axial'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0023311', 'cui_str': 'Insertion of intraocular lens'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0525027', 'cui_str': 'Anterior capsulorrhexis'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0021890', 'cui_str': 'Intraoperative complication'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0332219', 'cui_str': 'Easy'}, {'cui': 'C0332218', 'cui_str': 'Difficult'}]",220.0,0.0458724,"There was no statistically significant difference in the nuclear opalescence, axial length, and intraocular lens (IOL) power between the two groups.","[{'ForeName': 'Rajesh Subhash', 'Initials': 'RS', 'LastName': 'Joshi', 'Affiliation': 'Department of Ophthalmology, Vasantrao Naik Government Medical College, Yavatmal, Maharashtra, India.'}, {'ForeName': 'Sanoja Rangnath', 'Initials': 'SR', 'LastName': 'Naik', 'Affiliation': 'Department of Ophthalmology, Vasantrao Naik Government Medical College, Yavatmal, Maharashtra, India.'}]",Middle East African journal of ophthalmology,['10.4103/meajo.MEAJO_140_19'] 1548,32683215,Intensive upper extremity training improved whole body movement control for children with unilateral spastic cerebral palsy.,"BACKGROUND Children with unilateral spastic cerebral palsy (USCP) exhibit impaired bimanual coordination, gait control, and whole body movement control. Intensive upper extremity training has been found to be effective for improving upper extremity function. However, the effectiveness of the intensive upper extremity training on whole body movement control is not known. RESEARCH QUESTION The present study aimed to evaluate the effects of Constraint Induced Movement Therapy (CIMT) and Hand Arm Bimanual Intensive Therapy (HABIT) on bimanual coordination and gait control during a complex whole body task. METHODS Sixteen children with congenital hemiplegia (age 6-12 years; GMFCS: I-II, MACS: I-II) were randomly assigned to either CIMT or HABIT for 6 h per day training for 15 days. Children were asked to perform two whole body tasks (walking with and without a tray carrying) while 3-D kinematic analysis was performed before and after training. RESULTS After training, the HABIT group increased the symmetry in height of their hands during tray carrying (more leveled tray). Both CIMT and HABIT groups decreased the lateral motion of the tray. The CIMT group increased speed and stride length after training in both the walking and tray carrying tasks. Both groups also increased their minimum toe clearance (all p < 0.05). SIGNIFICANCE Two types of intensive upper extremity training have provided significant improvements to whole body movement control for children with USCP. Adhering to the specificity of practice concept, HABIT improved bimanual coordination after training during the whole body tray carrying tasks. Given extensive interactions between the upper and lower extremities in real-world activities, future studies should focus on the effects of such combined training.",2020,"Both groups also increased their minimum toe clearance (all p < 0.05). ","['children with unilateral spastic cerebral palsy', 'Children with unilateral spastic cerebral palsy (USCP', 'children with USCP', 'Sixteen children with congenital hemiplegia (age 6-12 years; GMFCS']","['CIMT or HABIT', 'Intensive upper extremity training improved whole body movement control', 'CIMT', 'Constraint Induced Movement Therapy (CIMT) and Hand Arm Bimanual Intensive Therapy (HABIT', 'intensive upper extremity training', 'Intensive upper extremity training']","['bimanual coordination and gait control', 'symmetry in height of their hands', 'speed and stride length', 'lateral motion of the tray', 'minimum toe clearance']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0338596', 'cui_str': 'Spastic cerebral palsy'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0270805', 'cui_str': 'Hemiplegic cerebral palsy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0454279', 'cui_str': 'Movement therapy'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0427083', 'cui_str': 'Control of movement'}]","[{'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332516', 'cui_str': 'Symmetrical'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0184054', 'cui_str': 'Tray'}, {'cui': 'C0040357', 'cui_str': 'Toe structure'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}]",16.0,0.0108967,"Both groups also increased their minimum toe clearance (all p < 0.05). ","[{'ForeName': 'Ya-Ching', 'Initials': 'YC', 'LastName': 'Hung', 'Affiliation': 'Department of Family, Nutrition, and Exercise Sciences, Queens College, City University of New York, 65-30 Kissena Blvd, Flushing, NY 11367, USA. Electronic address: yaching.hung@qc.cuny.edu.'}, {'ForeName': 'Fawzia', 'Initials': 'F', 'LastName': 'Shirzad', 'Affiliation': 'Department of Family, Nutrition, and Exercise Sciences, Queens College, City University of New York, 65-30 Kissena Blvd, Flushing, NY 11367, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Saleem', 'Affiliation': 'Department of Family, Nutrition, and Exercise Sciences, Queens College, City University of New York, 65-30 Kissena Blvd, Flushing, NY 11367, USA.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Gordon', 'Affiliation': 'Department of Biobehavioral Sciences, Teachers College, Columbia University, 525 West 120th Street, Box 199, NY 10027, USA.'}]",Gait & posture,['10.1016/j.gaitpost.2020.07.009'] 1549,32683383,Efficacy of ozonized water for the treatment of erosive oral lichen planus: a randomized controlled study.,"BACKGROUND Management of erosive Oral Lichen Planus (eOLP) is challenging. Currently, topical corticosteroids are widely used as first-line therapy, but they might be associated with side-effects and incomplete clinical response. Among non-pharmacological strategies, ozone at low medical concentration has proven to induce a mild activation of protective anti-oxidant pathways, thus exerting therapeutic effects in many inflammatory diseases. The aim of this randomized controlled study was to investigate the effectiveness of ozonized water in association with conventional topical corticosteroids for the treatment of eOLP. MATERIAL AND METHODS Fifty-one patients were included in the study and randomized into 2 groups: study group (n=26) included patients receiving ozonized water treatment; control group (n=25) included patients receiving placebo treatment (i.e. double-distilled water). Treatment protocol consisted of 1-minute oral rinses, repeated for 4 times, twice a week for 4 weeks. All patients received conventional corticosteroid topical therapy (betamethasone soluble tablets, 2 rinses/day for 4 weeks). Assessment of size of lesions, sign and pain scores was performed before treatment, after 2 weeks of treatment (T1) and at the end of 4-week treatment (T2). Efficacy Index (EI) of treatment, candidiasis and relapse rates were also recorded. RESULTS All patients experienced significant improvement of sign and pain scores with a higher rate of improvement in ozone-treated group (T1 improvement rates: Thongprasom 92.2% vs 28%; VAS pain 76.9% vs 32%; p<0.05). Pain and size reduction were significantly higher in ozone-treated group both at T1 and T2 (p<0.05). Ozone-treated group showed a higher EI at every time point (T0-T2: 72.77% vs 37.66%, p<0.01). Candidiasis (32% vs 11.5%) and relapse (40% vs 34.6%) rates were higher in control group, however the differences were not statistically significant. CONCLUSIONS Within the limitations of this study, ozonized water seems to be effective as an adjunct therapy, in combination with topical corticosteroids, for the treatment of eOLP.",2020,Pain and size reduction were significantly higher in ozone-treated group both at T1 and T2 (p<0.05).,"['Fifty-one patients were included in the study and randomized into 2 groups: study group (n=26) included patients receiving', 'erosive oral lichen planus', 'erosive Oral Lichen Planus']","['conventional corticosteroid topical therapy (betamethasone soluble tablets', 'ozonized water treatment; control group', 'placebo treatment (i.e. double-distilled water', 'ozonized water']","['size of lesions, sign and pain scores', 'Candidiasis', 'sign and pain scores', 'Efficacy Index (EI) of treatment, candidiasis and relapse rates', 'relapse', 'Pain and size reduction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0406378', 'cui_str': 'Erosive oral lichen planus'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0005308', 'cui_str': 'Betamethasone'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0597684', 'cui_str': 'Water Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0790233', 'cui_str': 'Distilled water'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}]","[{'cui': 'C0449453', 'cui_str': 'Lesion size'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0006840', 'cui_str': 'Candidiasis'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",51.0,0.0461569,Pain and size reduction were significantly higher in ozone-treated group both at T1 and T2 (p<0.05).,"[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Veneri', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Bardellini', 'Affiliation': 'Dental Clinic, p.le Spedali Civili n.1 25133 Brescia elena.bardellini@unibs.it.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Amadori', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Conti', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Majorana', 'Affiliation': ''}]","Medicina oral, patologia oral y cirugia bucal",['10.4317/medoral.23693'] 1550,32552711,Effect of symmetrical restoration for the migration of uncemented total hip arthroplasty: a randomized RSA study with 75 patients and 5-year follow-up.,"BACKGROUND Inferior placement of a femoral stem is predictive for early loosening and failure, but does restoration of the original hip anatomy benefit the function and survival of a total hip replacement? METHODS Seventy-five patients with primary unilateral hip osteoarthritis operated with an uncemented anatomical stem were randomized for either standard or modular stems. We used 50 ABG II stems with modular necks and 25 standard stems (control group). We measured the symmetry in hip anatomy between healthy and operated side. The anatomical restoration variables were anteversion, global offset, and femoral offset/acetabular offset (FO/AO) quota. We performed measurements using a CT-based 3D templating and measuring software. Migratory behavior of the stems was then measured postoperatively with repeated radiostereometry (RSA) examinations over 5 years. RESULTS Both stem types showed an early (within 3 months) good stabilization after an initial slight rotation into retroversion and subsidence. There were no significant differences in RSA migration between modular and standard stems. Postoperative anteversion and FO/AO quota had no impact on stem migration. The standard stem tended to result in insufficient global offset (GO), whereas the modular stem did not. CONCLUSIONS The modular stem gave good symmetrical anatomical restoration and, like the standard version, a benign migratory behavior. Anteversion, GO, and FO/AO quota had no significant impact on stem migration. It therefore seems to be of no importance whether we choose a modular or a standard stem with regard to postoperative stem migration for this stem type. We overestimated the effect anatomical parameters have on stem movement; hence, we believe the study to be underpowered. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT01512550. Registered 19 January 2012-retrospectively registered.",2020,There were no significant differences in RSA migration between modular and standard stems.,"['uncemented total hip arthroplasty', 'hip anatomy between healthy and operated side', 'Seventy-five patients with primary unilateral hip osteoarthritis operated with an uncemented anatomical stem', '75 patients and 5-year follow-up']","['standard or modular stems', 'symmetrical restoration']","['RSA migration', 'stem migration', 'anteversion, global offset, and femoral offset/acetabular offset (FO/AO) quota']","[{'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0002808', 'cui_str': 'Anatomy'}, {'cui': 'C4319621', 'cui_str': '75'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0029410', 'cui_str': 'Osteoarthritis of hip'}, {'cui': 'C0220784', 'cui_str': 'Anatomic'}, {'cui': 'C0162731', 'cui_str': 'STEM'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0162731', 'cui_str': 'STEM'}, {'cui': 'C0332516', 'cui_str': 'Symmetrical'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}]","[{'cui': 'C0237731', 'cui_str': 'Human Migration'}, {'cui': 'C0162731', 'cui_str': 'STEM'}, {'cui': 'C0333053', 'cui_str': 'Anteversion'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}]",75.0,0.0588382,There were no significant differences in RSA migration between modular and standard stems.,"[{'ForeName': 'Sverrir', 'Initials': 'S', 'LastName': 'Kiernan', 'Affiliation': 'Department of Orthopedics, Skåne University Hospital, Clinical Sciences, Lund University, Lund, Sweden. Sverrir.Kiernan@med.lu.se.'}, {'ForeName': 'Mats', 'Initials': 'M', 'LastName': 'Geijer', 'Affiliation': 'Department of Radiology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Sundberg', 'Affiliation': 'Department of Orthopedics, Skåne University Hospital, Clinical Sciences, Lund University, Lund, Sweden.'}, {'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Flivik', 'Affiliation': 'Department of Orthopedics, Skåne University Hospital, Clinical Sciences, Lund University, Lund, Sweden.'}]",Journal of orthopaedic surgery and research,['10.1186/s13018-020-01736-0'] 1551,32552523,Cooling as an Adjunctive Therapy to Percutaneous Intervention in Acute Myocardial Infarction: COOL-MI InCor Trial.,"Endovascular Therapeutic hypothermia (ETH) reduces the damage caused by postischemia reperfusion injury syndrome in cardiopulmonary arrest and has already established its role in patients with sudden death; however, its role in ST-segment elevation myocardial infarction (STEMI) remains controversial. The objectives of this study were to investigate the safety, feasibility, and 30-day efficacy of rapid induction of therapeutic hypothermia as adjunctive therapy to percutaneous coronary intervention (PCI) in patients with anterior and inferior STEMIs. This was a prospective, controlled, randomized, two-arm, prospective, interventional study of patients admitted to the emergency department within 6 hours of angina onset, with anterior or inferior STEMI eligible for PCI. Subjects were randomized to the hypothermia group (primary PCI+ETH) or to the control group (primary PCI) at a 4:1 ratio. The ETH was induced by 1 L cold saline (1-4°C) associated with the Proteus™ System, by cooling for at least 18 minutes before coronary reperfusion with a target temperature of 32°C ± 1°C. Maintenance of ETH was conducted for 1-3 hours, and active reheating was done at a rate of 1°C/h for 4 hours. Primary safety outcomes were the feasibility of ETH in the absence of (1) door-to-balloon (DTB) delay; (2) major adverse cardiac events (MACE) within 30 days after randomization. The primary outcomes of effectiveness were infarct size (IS) and left ventricular ejection fraction (LVEF) at 30 days. An as-treated statistical analysis was performed. Fifty patients were included: 35 (70%) randomized to the hypothermia group and 15 (30%) to the control group. The mean age was 58 ± 12 years; 78% were men; and associated diseases were 60% hypertension, 42% diabetes, and 72% dyslipidemia. The compromised myocardial wall was anterior in 38% and inferior in 62%, and the culprit vessels were left anterior descending artery (LAD) (40%), right coronary artery (38%), and left circumflex (18%). All 35 patients who attempted ETH (100%) had successful cooling, with a mean endovascular coronary reperfusion temperature of 33.1°C ± 0.9°C. The mean ischemic time was 375 ± 89.4 minutes in the hypothermia group and 359.5 ± 99.4 minutes in the control group. The mean DTB was 92.1 ± 20.5 minutes in the hypothermia group and 87 ± 24.4 minutes in the control group. The absolute difference of 5.1 minutes was not statistically significant ( p  = 0.509). The MACE rates were similar between both groups (21.7% vs. 20% respectively, p  = 0.237). In the comparison between the hypothermia and control groups, no statistically significant differences were observed at 30 days between mean IS (13.9% ± 8% vs. 13.8% ± 10.8%, respectively, p  = 0.801) and mean final LVEF (43.3% ± 11.2% vs. 48.3 ± 10.9%, respectively; p  = 0.194). Hypothermia as an adjunctive therapy to primary PCI in STEMI is feasible and can be implemented without delay in coronary reperfusion. Hypothermia was safe regarding the incidence of MACE at 30 days. However, there was a higher incidence of arrhythmia and in-hospital infection in the hypothermia group, with no increase in mortality. Regarding efficacy, there was no difference in IS or LVEF at 30 days that would suggest additional myocardial protection with ETH. ClinicalTrials.gov: NCT02664194.",2020,"The MACE rates were similar between both groups (21.7% vs. 20% respectively, p  = 0.237).","['All 35 patients who attempted ETH (100%) had successful cooling, with a mean endovascular coronary reperfusion temperature of 33.1°C\u2009±\u20090.9°C', 'patients admitted to the emergency department within 6 hours of angina onset, with anterior or inferior STEMI eligible for PCI', 'Fifty patients were included: 35 (70%) randomized to the', 'patients with sudden death', 'Acute Myocardial Infarction', 'patients with anterior and inferior STEMIs', 'The mean age was 58\u2009±\u200912 years; 78% were men; and associated diseases were 60% hypertension, 42% diabetes, and 72% dyslipidemia']","['percutaneous coronary intervention (PCI', 'hypothermia', 'Percutaneous Intervention', 'Endovascular Therapeutic hypothermia (ETH', 'hypothermia group (primary PCI+ETH', 'control group (primary PCI']","['arrhythmia and in-hospital infection', 'MACE rates', 'mean DTB', 'mean ischemic time', 'mean final LVEF', 'mortality', 'safety, feasibility, and 30-day efficacy', 'feasibility of ETH in the absence of (1) door-to-balloon (DTB) delay; (2) major adverse cardiac events (MACE', 'infarct size (IS) and left ventricular ejection fraction (LVEF']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020674', 'cui_str': 'Induction of hypothermia'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0027054', 'cui_str': 'Reperfusion, Myocardial'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C4068881', 'cui_str': '0.9'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C1292428', 'cui_str': '6 hours'}, {'cui': 'C0002962', 'cui_str': 'Angina pectoris'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0011071', 'cui_str': 'Sudden death'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}]","[{'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0020672', 'cui_str': 'Hypothermia'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0020674', 'cui_str': 'Induction of hypothermia'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0003811', 'cui_str': 'Cardiac arrhythmia'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0557698', 'cui_str': 'Door'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0020674', 'cui_str': 'Induction of hypothermia'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0021308', 'cui_str': 'Infarct'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}]",50.0,0.0457433,"The MACE rates were similar between both groups (21.7% vs. 20% respectively, p  = 0.237).","[{'ForeName': 'Luis Augusto Palma', 'Initials': 'LAP', 'LastName': 'Dallan', 'Affiliation': 'Department of Cardiology, InCor, Heart Institute, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Natali Schiavo', 'Initials': 'NS', 'LastName': 'Giannetti', 'Affiliation': 'Department of Cardiology, InCor, Heart Institute, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Carlos Eduardo', 'Initials': 'CE', 'LastName': 'Rochitte', 'Affiliation': 'Department of Cardiology, InCor, Heart Institute, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Thatiane Facholi', 'Initials': 'TF', 'LastName': 'Polastri', 'Affiliation': 'Department of Cardiology, InCor, Heart Institute, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Claudia Yanet', 'Initials': 'CY', 'LastName': 'Bernoche San Martin', 'Affiliation': 'Department of Cardiology, InCor, Heart Institute, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Ludhmila Abrahao', 'Initials': 'LA', 'LastName': 'Hajjar', 'Affiliation': 'Department of Cardiology, InCor, Heart Institute, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Jose Carlos', 'Initials': 'JC', 'LastName': 'Nicolau', 'Affiliation': 'Department of Cardiology, InCor, Heart Institute, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Mucio Tavares de', 'Initials': 'MT', 'LastName': 'Oliveira', 'Affiliation': 'Department of Cardiology, InCor, Heart Institute, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Dae', 'Affiliation': 'Department of Radiology, UCSF, University of California, San Francisco, California, USA.'}, {'ForeName': 'Expedito Eustaquio', 'Initials': 'EE', 'LastName': 'Ribeiro da Silva', 'Affiliation': 'Department of Cardiology, InCor, Heart Institute, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Kalil Filho', 'Affiliation': 'Department of Cardiology, InCor, Heart Institute, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Pedro Alves', 'Initials': 'PA', 'LastName': 'Lemos Neto', 'Affiliation': 'Department of Cardiology, InCor, Heart Institute, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Timerman', 'Affiliation': 'Department of Cardiology, InCor, Heart Institute, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.'}]",Therapeutic hypothermia and temperature management,['10.1089/ther.2020.0018'] 1552,32552387,Aspirin enhances the clinical efficacy of anti-tuberculosis therapy in pulmonary tuberculosis in patients with type 2 diabetes mellitus.,"Background: Tuberculosis in patients with diabetes mellitus is characterised by rapid disease progression, poor treatment efficacy, poor prognosis and poses a new challenge in tuberculosis treatment and control. Methods: Patients with pulmonary TB and type 2 DM were recruited at Yijishan Hospital of Wannan Medical College. A total of 348 patients were randomly assigned to two groups. The aspirin group (aspirin + TB/DM) included 174 patients who received anti-TB therapy and enteric-coated aspirin tablets (100 mg/tablet). The control group (placebo + TB/DM) included 174 patients who received anti-TB therapy and enteric-coated placebo tablets (an identical tablet containing no drug). Eighty-two patients in the aspirin group and 86 in the control group completed the trial and were included in the analysis. Clinical characteristics, laboratory test results, imaging data and side effects of aspirin were monitored. Results: Aspirin treatment affect certain signs and symptoms. The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were lower in the aspirin group than in the control group after treatment (Both p  = .000). The sputum-negative conversion rate was 86.7% in the aspirin group, significantly higher than in the control group (53.8%) ( p  = .031). After two months of treatment, the differences in the number of cases with cavities, the number of cavities, and maximum diameter of cavities in the aspirin group were statistically significant ( p  = .003, p  = .023 and p  = .015 respectively). Conclusion: Our findings suggest that aspirin may improve treatment in patients with pulmonary TB and type 2 DM.",2020,The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were lower in the aspirin group than in the control group after treatment (,"['348 patients', 'patients with type 2 diabetes mellitus', '174 patients who received', 'patients with diabetes mellitus', 'patients with pulmonary TB and type 2\u2009DM', 'Patients with pulmonary TB and type 2\u2009DM were recruited at Yijishan Hospital of Wannan Medical College', 'an identical tablet containing no drug', '174 patients who received anti-TB therapy and enteric-coated aspirin tablets (100\u2009mg/tablet']","['control group (placebo\u2009+\u2009TB/DM', 'anti-tuberculosis therapy', 'Aspirin', 'aspirin group (aspirin\u2009+\u2009TB/DM', 'aspirin', 'anti-TB therapy and enteric-coated placebo tablets']","['certain signs and symptoms', 'sputum-negative conversion rate', 'number of cases with cavities, the number of cavities, and maximum diameter of cavities', 'erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels']","[{'cui': 'C4517733', 'cui_str': '348'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0041327', 'cui_str': 'Pulmonary tuberculosis'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1304890', 'cui_str': 'Enteral'}, {'cui': 'C0453946', 'cui_str': 'Coat'}, {'cui': 'C1244632', 'cui_str': 'Aspirin Oral Tablet'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0041296', 'cui_str': 'Tuberculosis'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1304890', 'cui_str': 'Enteral'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}]","[{'cui': 'C0205423', 'cui_str': 'Certain'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement'}]",348.0,0.0578305,The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were lower in the aspirin group than in the control group after treatment (,"[{'ForeName': 'Wenjie', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Infectious Diseases, Yijishan Hospital of Wannan Medical College, Wuhu, P. R. China.'}, {'ForeName': 'Zhixiang', 'Initials': 'Z', 'LastName': 'Du', 'Affiliation': ""Department of Infectious Diseases, The People's Hospital of Taizhou, Taizhou, P. R. China.""}, {'ForeName': 'Mingyue', 'Initials': 'M', 'LastName': 'Ni', 'Affiliation': 'Department of Infectious Diseases, Yijishan Hospital of Wannan Medical College, Wuhu, P. R. China.'}, {'ForeName': 'Zijian', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Department of Infectious Diseases, Yijishan Hospital of Wannan Medical College, Wuhu, P. R. China.'}, {'ForeName': 'Manman', 'Initials': 'M', 'LastName': 'Liang', 'Affiliation': 'Department of Infectious Diseases, Yijishan Hospital of Wannan Medical College, Wuhu, P. R. China.'}, {'ForeName': 'Haoyu', 'Initials': 'H', 'LastName': 'Sheng', 'Affiliation': 'Department of Infectious Diseases, Yijishan Hospital of Wannan Medical College, Wuhu, P. R. China.'}, {'ForeName': 'Aiping', 'Initials': 'A', 'LastName': 'Zhang', 'Affiliation': 'Department of Infectious Diseases, Yijishan Hospital of Wannan Medical College, Wuhu, P. R. China.'}, {'ForeName': 'Jianghua', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Department of Infectious Diseases, Yijishan Hospital of Wannan Medical College, Wuhu, P. R. China.'}]","Infectious diseases (London, England)",['10.1080/23744235.2020.1778177'] 1553,32688398,Effect of Steroid in Local Infiltration Analgesia in One-Stage Bilateral Total Knee Arthroplasty: A Paired-Randomized Controlled Study.,"Although local infiltration analgesia (LIA) is effective in relieving pain after total knee arthroplasty (TKA), its effect is short lasting and the optimal combination of drugs is unknown. Steroids being a potent and long-acting anti-inflammatory drug might extend LIA's effect. This study aims to evaluate the role of steroids in LIA. This is a paired-randomized controlled study involving one-stage bilateral TKA patients. LIA containing ropivacaine, ketorolac, and adrenaline with or without triamcinolone was given. One knee was randomized to receive LIA with steroids, while the other received LIA without steroids. The primary outcome was knee pain in terms of the visual analog scale (VAS). Secondary outcomes were rehabilitation progress, functional scores, and complications. Outcomes were compared between the knees of the same patient and documented up to 1 year. A total of 45 patients (90 TKAs) were included. LIA with steroid knees showed lower VAS score at rest and during activity from postoperation day 1 to 5 and at 6 weeks ( p  < 0.05). Passive and active range of movement was also greater in LIA with steroid group from day 1 to 7 and day 2 to 5, respectively ( p  < 0.05). Steroid-treated knees also achieved active straight leg raise earlier (1.2 vs. 2.0 days, p  < 0.05). No differences in Knee Society Score and complication rates between both groups. Steroids in LIA offer additional and extended benefit in pain control and rehabilitation after TKA, while no adverse effects were found up to 1-year follow-up.",2020,No differences in Knee Society Score and complication rates between both groups.,"['45 patients (90 TKAs) were included', 'One-Stage Bilateral Total Knee Arthroplasty', 'pain after total knee arthroplasty (TKA', 'one-stage bilateral TKA patients']","['LIA with steroids', 'local infiltration analgesia (LIA', 'ropivacaine, ketorolac, and adrenaline with or without triamcinolone', 'LIA without steroids', 'Steroid']","['knee pain in terms of the visual analog scale (VAS', 'Passive and active range of movement', 'VAS score', 'active straight leg raise earlier', 'rehabilitation progress, functional scores, and complications', 'Knee Society Score and complication rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0073631', 'cui_str': 'Ketorolac'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0040864', 'cui_str': 'Triamcinolone'}]","[{'cui': 'C0231749', 'cui_str': 'Knee pain'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0422926', 'cui_str': 'Straight leg raise test response'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0037455', 'cui_str': 'Societies'}]",45.0,0.0949757,No differences in Knee Society Score and complication rates between both groups.,"[{'ForeName': 'Vincent Wai Kwan', 'Initials': 'VWK', 'LastName': 'Chan', 'Affiliation': ""Division of Joint Replacement Surgery, Department of Orthopaedics and Traumatology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, SAR, People's Republic of China.""}, {'ForeName': 'Ping Keung', 'Initials': 'PK', 'LastName': 'Chan', 'Affiliation': ""Division of Joint Replacement Surgery, Department of Orthopaedics and Traumatology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, SAR, People's Republic of China.""}, {'ForeName': 'Chun Hoi', 'Initials': 'CH', 'LastName': 'Yan', 'Affiliation': ""Division of Joint Replacement Surgery, Department of Orthopaedics and Traumatology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, SAR, People's Republic of China.""}, {'ForeName': 'Chun Him', 'Initials': 'CH', 'LastName': 'Henry', 'Affiliation': ""Division of Joint Replacement Surgery, Department of Orthopaedics and Traumatology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, SAR, People's Republic of China.""}, {'ForeName': 'Chi Wing', 'Initials': 'CW', 'LastName': 'Chan', 'Affiliation': ""Department of Anaesthesiology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, SAR, People's Republic of China.""}, {'ForeName': 'Kwong Yuen', 'Initials': 'KY', 'LastName': 'Chiu', 'Affiliation': ""Division of Joint Replacement Surgery, Department of Orthopaedics and Traumatology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, SAR, People's Republic of China.""}]",The journal of knee surgery,['10.1055/s-0040-1713811'] 1554,32556356,Erratum: Efficacy and Safety of Oral Administration of a Mixture of Probiotic Strains in Patients with Psoriasis: A Randomized Controlled Clinical Trial.,,2020,,['Patients with Psoriasis'],['Oral Administration of a Mixture of Probiotic Strains'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}]","[{'cui': 'C0001563', 'cui_str': 'Medication administration: oral'}, {'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}]",[],,0.0730396,,[],Acta dermato-venereologica,['10.2340/00015555-3529'] 1555,32553642,Love at first taste: Activation in reward-related brain regions during single-trial naturalistic appetitive conditioning in humans.,"Palatable food can trigger appetitive responses, such as salivation and approach tendencies. Though evolutionarily functional, these conditioned responses can encourage overeating and obesity when food is abundant. The current study examines the neural correlates of 'denovo' Pavlovian appetitive conditioning, pairing one class of unknown objects (conditioned stimuli, CS) with their sweet taste (unconditioned stimulus, US) during a single trial. To do so, 23 participants consumed unknown (marzipan) objects of one particular color (CS+) while only interacting with control stimuli of different color and shape (CS-). After this single-trial conditioning procedure, participants viewed and rated images of the marzipan figures and the control objects during functional magnetic resonance imaging (fMRI). Relative to the CS-, the CS+ elicited stronger activation in the dorsal striatum, a brain region associated with cue-reward coupling. Furthermore, conditioning effects in subjective 'craving', defined as increased palatability and desire to eat, were observed, and these were positively related to conditioning effects in the amygdala, a brain region associated with the need-dependent value of a reward. Thus, the study identified reward-related brain regions involved in single-trial appetitive learning, thereby providing a potential mechanism that contributes to the etiology of food craving. These findings might help to understand clinically relevant food cravings in individuals with eating or weight related concerns and might support the development of extinction based treatments.",2020,"Relative to the CS-, the CS+ elicited stronger activation in the dorsal striatum, a brain region associated with cue-reward coupling.","['23 participants consumed unknown (marzipan) objects of one particular color (CS+) while only interacting with control stimuli of different color and shape (CS', 'humans']","[""denovo' Pavlovian appetitive conditioning, pairing one class of unknown objects (conditioned stimuli, CS) with their sweet taste (unconditioned stimulus, US""]","[""subjective 'craving"", 'palatability and desire to eat']","[{'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0347997', 'cui_str': 'Physical object'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0332479', 'cui_str': 'Shape finding'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0347997', 'cui_str': 'Physical object'}, {'cui': 'C0234404', 'cui_str': 'Conditioned stimulus'}, {'cui': 'C0858600', 'cui_str': 'Taste sweet'}, {'cui': 'C0234403', 'cui_str': 'Unconditioned stimulus'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}]",23.0,0.0298472,"Relative to the CS-, the CS+ elicited stronger activation in the dorsal striatum, a brain region associated with cue-reward coupling.","[{'ForeName': 'Lender', 'Initials': 'L', 'LastName': 'A', 'Affiliation': 'Department of Psychology, Centre for Cognitive Neuroscience, Paris-Lodron-University of Salzburg, Hellbrunner Str. 34, 5020 Salzburg, Austria. Electronic address: anja.lender@sbg.ac.at.'}, {'ForeName': 'Miedl', 'Initials': 'M', 'LastName': 'Sf', 'Affiliation': 'Department of Psychology, Division of Clinical Psychology and Psychopathology, Paris-Lodron-University of Salzburg, Hellbrunner Str. 34, 15020 Salzburg, Austria.'}, {'ForeName': 'Wilhelm', 'Initials': 'W', 'LastName': 'Fh', 'Affiliation': 'Department of Psychology, Division of Clinical Psychology and Psychopathology, Paris-Lodron-University of Salzburg, Hellbrunner Str. 34, 15020 Salzburg, Austria.'}, {'ForeName': 'Miller', 'Initials': 'M', 'LastName': 'J', 'Affiliation': 'Department of Psychology, Centre for Cognitive Neuroscience, Paris-Lodron-University of Salzburg, Hellbrunner Str. 34, 5020 Salzburg, Austria.'}, {'ForeName': 'Blechert', 'Initials': 'B', 'LastName': 'J', 'Affiliation': 'Department of Psychology, Centre for Cognitive Neuroscience, Paris-Lodron-University of Salzburg, Hellbrunner Str. 34, 5020 Salzburg, Austria.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113014'] 1556,32688414,Effects of Three Resistance Exercise Orders on Muscular Function and Body Composition in Older Women.,"The purpose of the present study was to compare the effects of three resistance exercise orders on muscular strength, body composition, and functional fitness in trained older women. Forty-five women (aged ≥60 years), after performing 12 weeks of a pre-conditioning resistance-training program were randomly assigned in one of the following groups that performed the exercises in the following orders: multi-joint to single-joint order (MJ-SJ, n=15), single-joint to multi-joint order (SJ-MJ, n=15), and alternating between upper and lower body order (ALT, n=15). Specific training intervention lasted 12 weeks (3x/week) and was composed of eight exercises performed in three sets of 15/10/5 repetitions, with increasing load through the sets. Muscular strength was estimated by one-repetition maximum tests; body composition was assessed by whole-body dual-energy x-ray absorptiometry, and functional fitness was analyzed with a sequence of four motor tests. All groups improved similarly in muscular strength (Cohen's effect size: MJ-SJ=0.45; SJ-MJ=0.48; ALT=0.45), skeletal muscle mass (MJ-SJ=0.08; SJ-MJ=0.07; ALT=0.09), and functional test performance (MJ-SJ=0.38; SJ-MJ=0.20; ALT=0.31), but no change was observed for body fat ( P >0.05). The results suggest that 12 weeks of resistance training induce positive changes in muscle morphofunctionality, regardless of the exercise order employed in trained older women.",2020,"All groups improved similarly in muscular strength (Cohen's effect size: MJ-SJ=0.45; SJ-MJ=0.48; ALT=0.45), skeletal muscle mass (MJ-SJ=0.08; SJ-MJ=0.07; ALT=0.09), and functional test performance (MJ-SJ=0.38; SJ-MJ=0.20; ALT=0.31), but no change was observed for body fat ( P >0.05).","['trained older women', 'Older Women', 'Forty-five women (aged ≥60 years), after performing 12 weeks of a pre-conditioning resistance-training program']","['Specific training intervention', 'Three Resistance Exercise Orders', 'multi-joint to single-joint order (MJ-SJ, n=15), single-joint to multi-joint order (SJ-MJ', 'resistance training']","['Muscular strength', 'muscular strength', 'muscular strength, body composition, and functional fitness', 'skeletal muscle mass', 'functional test performance', 'Muscular Function and Body Composition', 'body fat']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1709632', 'cui_str': 'Precondition'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}]",45.0,0.0183531,"All groups improved similarly in muscular strength (Cohen's effect size: MJ-SJ=0.45; SJ-MJ=0.48; ALT=0.45), skeletal muscle mass (MJ-SJ=0.08; SJ-MJ=0.07; ALT=0.09), and functional test performance (MJ-SJ=0.38; SJ-MJ=0.20; ALT=0.31), but no change was observed for body fat ( P >0.05).","[{'ForeName': 'Márcia M', 'Initials': 'MM', 'LastName': 'Dib', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, PR, Brazil.'}, {'ForeName': 'Crisieli M', 'Initials': 'CM', 'LastName': 'Tomeleri', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, PR, Brazil.'}, {'ForeName': 'João Pedro', 'Initials': 'JP', 'LastName': 'Nunes', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, PR, Brazil.'}, {'ForeName': 'Paolo M', 'Initials': 'PM', 'LastName': 'Cunha', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, PR, Brazil.'}, {'ForeName': 'Alex S', 'Initials': 'AS', 'LastName': 'Ribeiro', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, PR, Brazil.'}, {'ForeName': 'Durcelina', 'Initials': 'D', 'LastName': 'Schiavoni', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, PR, Brazil.'}, {'ForeName': 'Edilaine F', 'Initials': 'EF', 'LastName': 'Cavalcante', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, PR, Brazil.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Kunevaliki', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, PR, Brazil.'}, {'ForeName': 'Denilson C', 'Initials': 'DC', 'LastName': 'Teixeira', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, PR, Brazil.'}, {'ForeName': 'Arli R', 'Initials': 'AR', 'LastName': 'de Oliveira', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, PR, Brazil.'}, {'ForeName': 'Ezequiel M', 'Initials': 'EM', 'LastName': 'Gonçalves', 'Affiliation': 'Department of Pediatrics, University of Campinas, Campinas, SP, Brazil.'}, {'ForeName': 'Luís A', 'Initials': 'LA', 'LastName': 'Gobbo', 'Affiliation': 'School of Science and Technology, São Paulo State University, Presidente Prudente, SP, Brazil.'}, {'ForeName': 'Analiza M', 'Initials': 'AM', 'LastName': 'Silva', 'Affiliation': 'Exercise and Health Laboratory, CIPER, Faculdade de Motricidade Humana, Universidade de Lisboa, Lisboa, Portugal.'}, {'ForeName': 'Luís B', 'Initials': 'LB', 'LastName': 'Sardinha', 'Affiliation': 'Exercise and Health Laboratory, CIPER, Faculdade de Motricidade Humana, Universidade de Lisboa, Lisboa, Portugal.'}, {'ForeName': 'Edilson S', 'Initials': 'ES', 'LastName': 'Cyrino', 'Affiliation': 'Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, PR, Brazil.'}]",International journal of sports medicine,['10.1055/a-1192-5205'] 1557,32550739,Intravaginal isonicotinic acid hydrazide (INH) versus misoprostol for cervical ripening prior to hysteroscopy.,"OBJECTIVE The aim of the present study was to compare the efficacy of vaginal isoniazid (isonicotinic acid hydrazide [INH]) and vaginal misoprostol in cervical ripening before hysteroscopic surgery. METHODS This randomized controlled trial included patients scheduled for hysteroscopic surgery during April 2016 and June 2017. The inclusion criteria were as follows: postmenopausal women or those at premenopausal age who had not had a vaginal delivery and candidate for diagnostic or operative hysteroscopy with closed cervix before intervention. The INH group (intervention group) received 900 mg of vaginal isoniazid (three 300-mg pills) 6-8 hours before hysteroscopic surgery. The misoprostol group (control group) received 400 micrograms of vaginal misoprostol 6-8 hours before hysteroscopic surgery. Finally, the efficacy of the 2 agents was comparatively analyzed. RESULTS Baseline characteristics were comparable between the groups. In 67 cases in the INH group (95%) and 45 in the misoprostol group (50%), hysteroscopic entry was successful without additional mechanical dilation, and this difference was statistically significant (P=0.001). The odds ratio (OR) obtained in this study was 0.57 for both INH and misoprostol groups (OR, 0.57; 95% confidence interval, 0.43-0.75). Further, 19 cases in the INH group vs. 45 cases in the misoprostol group did not respond to the intervention, indicating statistically significance (P=0.001). CONCLUSION Vaginal INH is more effective than misoprostol in cervical ripening before hysteroscopic surgery and can be a good alternative to misoprostol. TRIAL REGISTRATION Iranian Registry Clinical Trial (IRCT) Identifier: IRCT2015112821506N4.",2020,Baseline characteristics were comparable between the groups.,"['cervical ripening prior to hysteroscopy', 'patients scheduled for hysteroscopic surgery during April 2016 and June 2017', 'postmenopausal women or those at premenopausal age who had not had a vaginal delivery and candidate for diagnostic or operative hysteroscopy with closed cervix before intervention']","['vaginal isoniazid (isonicotinic acid hydrazide [INH]) and vaginal misoprostol', '400 micrograms of vaginal misoprostol 6-8 hours before hysteroscopic surgery', 'misoprostol', 'Intravaginal isonicotinic acid hydrazide (INH', 'vaginal isoniazid']","['hysteroscopic entry', 'odds ratio (OR']","[{'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0020710', 'cui_str': 'Hysteroscopy'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0751614', 'cui_str': 'Surgical Procedures, Hysteroscopic'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0567179', 'cui_str': 'Cervix undilated'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0022209', 'cui_str': 'isoniazid'}, {'cui': 'C0085174', 'cui_str': 'Misoprostol'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0439211', 'cui_str': 'mcg'}, {'cui': 'C1292429', 'cui_str': '8 hours'}, {'cui': 'C0751614', 'cui_str': 'Surgical Procedures, Hysteroscopic'}, {'cui': 'C0442122', 'cui_str': 'Intravaginal'}]","[{'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}]",,0.183447,Baseline characteristics were comparable between the groups.,"[{'ForeName': 'Ladan', 'Initials': 'L', 'LastName': 'Haghighi', 'Affiliation': 'Department of Obstetrics and Gynecology, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Najmi', 'Affiliation': 'Department of Obstetrics and Gynecology, Zanjan University of Medical Sciences, Zanjan, Iran.'}, {'ForeName': 'Samaneh', 'Initials': 'S', 'LastName': 'Rokhgireh', 'Affiliation': 'Endometriosis Research Center,Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Yousef', 'Initials': 'Y', 'LastName': 'Moradi', 'Affiliation': 'Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}]",Obstetrics & gynecology science,['10.5468/ogs.19170'] 1558,32553888,Effect of practical hyperoxic high-intensity interval training on exercise performance.,"This study investigated the effect of a practical hyperoxic high-intensity interval training (HIIT) on aerobic and anaerobic exercise capacity. Sixteen male athletes were randomized into 2 groups: normoxic HIIT (NHIIT, n = 8) group or hyperoxic HIIT (HHIIT, n = 8) group and trained for 3 weeks (2 days/week) on a cycle ergometer (2-min intervals, with 2-min rest between intervals) at maximal workload, which was obtained during a maximal graded exercise test under normoxia. All training sessions were performed until exhaustion. Participants performed maximal graded exercise, submaximal exercise, and 90-s maximal exercise tests before and after the training period. Maximal oxygen uptake (P < 0.01) increased significantly in both groups. Blood lactate curve during submaximal exercise improved significantly only in the HHIIT group (P < 0.01). Mean power output during maximal exercise increased significantly only in the HHIIT group (P = 0.02). This study demonstrated that a practical hyperoxic HHIIT might be effective for improving aerobic capacity and anaerobic performance.",2020,Blood lactate curve during submaximal exercise improved significantly only in the HHIIT group (P <  0.01).,['Sixteen male athletes'],"['normoxic HIIT (NHIIT, n\u2009=\u20098) group or hyperoxic HIIT (HHIIT, n\u2009=\u20098) group and trained for 3 weeks (2 days/week) on a cycle ergometer (2-min intervals, with 2-min rest between intervals) at maximal workload, which was obtained during a maximal graded exercise test under normoxia', 'maximal graded exercise, submaximal exercise, and 90-s maximal exercise tests', 'practical hyperoxic high-intensity interval training', 'practical hyperoxic high-intensity interval training (HIIT']","['Mean power output during maximal exercise', 'Blood lactate curve during submaximal exercise', 'Maximal oxygen uptake', 'aerobic capacity and anaerobic performance', 'aerobic and anaerobic exercise capacity', 'exercise performance']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0677547', 'cui_str': 'days/week'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}]",16.0,0.0253253,Blood lactate curve during submaximal exercise improved significantly only in the HHIIT group (P <  0.01).,"[{'ForeName': 'Michihiro', 'Initials': 'M', 'LastName': 'Kon', 'Affiliation': 'School of International Liberal Studies, Chukyo University, 101-2 Yagotohonmachi, Showa-ku, Nagoya, 466-8666, Japan; Department of Sports Sciences, Japan Institute of Sports Sciences, 3-15-1 Nishigaoka, Kita-ku, Tokyo, 115-0056, Japan. Electronic address: kon.michihiro@gmail.com.'}, {'ForeName': 'Kohei', 'Initials': 'K', 'LastName': 'Nakagaki', 'Affiliation': 'Department of Sports Sciences, Japan Institute of Sports Sciences, 3-15-1 Nishigaoka, Kita-ku, Tokyo, 115-0056, Japan; Department of Sports Sciences, Yamanashi Gakuin University, 2-4-5 Sakaori, Kofu, Yamanashi, 400-8575, Japan.'}, {'ForeName': 'Yoshiko', 'Initials': 'Y', 'LastName': 'Ebi', 'Affiliation': 'Department of Sports Sciences, Japan Institute of Sports Sciences, 3-15-1 Nishigaoka, Kita-ku, Tokyo, 115-0056, Japan.'}]",Respiratory physiology & neurobiology,['10.1016/j.resp.2020.103481'] 1559,32551725,Patterns of change and their relationship to outcome and follow-up in group and individual psychotherapy for depression.,"OBJECTIVE The study explored the presence of different patterns of change in a sample of patients who received cognitive therapy for depression sequentially in two different formats: group and individual. Our hypothesis was that patients' baseline characteristics (e.g., symptom severity, self-esteem) would discriminate patterns of response to group and individual therapy. METHOD 108 adults who met criteria for depression and completed the treatments included in a randomized controlled trial (RCT) were assessed with the Beck Depression Inventory-II (BDI-II), the Clinical Outcome in Routine Evaluation-Short Form B (CORE-SFB), the Global Assessment of Functioning (GAF), and the repertory grid technique. Growth mixture modeling was carried out to identify the patterns of change. Mixed linear models and repeated measures analysis of variance were performed to compare patients' characteristics in each pattern. Multinomial logistic regression was used to compute predictive models for the patterns from patients' characteristics. Finally, hierarchical linear regression was used to establish the power of each pattern to predict treatment outcome. RESULTS A 3-class solution was obtained: group therapy improvers, individual therapy improvers, and nonimprovers. Group therapy improvers started therapy with less severe levels of depression and psychological distress, higher functioning and self-esteem, lower perceived social isolation, and lower dilemmatic construction of the self than the other groups. Individual therapy improvers and nonimprovers presented similar characteristics at baseline. However, a significant proportion of nonimprovers presented a concurrent diagnosis of fibromyalgia. CONCLUSION The greater the impairment that patients present at baseline, the more likely they are to benefit from individual therapy after group therapy. A diagnosis of fibromyalgia can be considered a risk factor for therapy failure in the treatment of depression. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"Group therapy improvers started therapy with less severe levels of depression and psychological distress, higher functioning and self-esteem, lower perceived social isolation, and lower dilemmatic construction of the self than the other groups.",['108 adults who met criteria for depression and completed the treatments'],"['Routine Evaluation-Short Form B (CORE-SFB', 'cognitive therapy']","['severe levels of depression and psychological distress, higher functioning and self-esteem, lower perceived social isolation, and lower dilemmatic construction of the self', 'Beck Depression Inventory-II (BDI-II']","[{'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1319226', 'cui_str': 'Level of depression'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0037421', 'cui_str': 'Social isolation'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0403066', 'cui_str': 'Construction worker'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}]",108.0,0.0521554,"Group therapy improvers started therapy with less severe levels of depression and psychological distress, higher functioning and self-esteem, lower perceived social isolation, and lower dilemmatic construction of the self than the other groups.","[{'ForeName': 'Danilo', 'Initials': 'D', 'LastName': 'Moggia', 'Affiliation': 'Department of Clinical Psychology and Psychobiology.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Lutz', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Arndt', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy.'}, {'ForeName': 'Guillem', 'Initials': 'G', 'LastName': 'Feixas', 'Affiliation': 'Department of Clinical Psychology and Psychobiology.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000562'] 1560,32556324,Dry Cupping Therapy for Improving Nonspecific Neck Pain and Subcutaneous Hemodynamics.,"CONTEXT Dry cupping therapy is a noninvasive treatment commonly used to reduce pain and promote the healing process in various populations, including those with nonspecific neck pain; however, no data are available to support most of this method's true physiological benefits. OBJECTIVE To determine if dry cupping therapy decreased pain and increased subcutaneous blood flow compared with sham cupping and control conditions. DESIGN Controlled laboratory study. SETTING Laboratory. PATIENTS OR OTHER PARTICIPANTS A total of 32 participants (age = 22.5 ± 2.8 years, height = 173.3 ± 10.1 cm, mass = 76.6 ± 18.7 kg) with self-reported nonspecific neck pain. INTERVENTION(S) We used dry cupping and sham cupping interventions and a control condition. For the dry cupping intervention, 1 stationary cup was placed directly over the most painful area for 8 minutes. The sham cupping intervention followed the same procedures as the dry cupping intervention except a sham cup was applied. For the control condition, participants received no treatment. MAIN OUTCOME MEASURE(S) Subjective pain intensity (visual analog scale); pain-pressure threshold; subcutaneous hemodynamics, including superficial and deep oxygenated, deoxygenated, and total hemoglobin levels; and tissue saturation index. RESULTS We observed differences in the visual analog scale score and the superficial and deep oxygenated and total hemoglobin levels (P values ≤ .002) immediately postintervention compared with baseline. Post hoc tests revealed that the dry cupping group had less pain than the sham cupping and control groups and higher superficial and deep oxygenated and total hemoglobin levels (P values ≤ .008). No differences were found between baseline and 24 hours postintervention. CONCLUSIONS A single session of dry cupping therapy may be an effective short-term treatment method for immediately reducing pain and increasing oxygenated and total hemoglobin levels in patients with nonspecific neck pain.",2020,Post hoc tests revealed that the dry cupping group had less pain than the sham cupping and control groups and higher superficial and deep oxygenated and total hemoglobin levels (P values ≤ .008).,"['patients with nonspecific neck pain', 'A total of 32 participants (age = 22.5 ± 2.8 years, height = 173.3 ± 10.1 cm, mass = 76.6 ± 18.7 kg) with self-reported nonspecific neck pain']","['dry cupping and sham cupping interventions', 'Dry Cupping Therapy', 'sham cupping intervention']","['higher superficial and deep oxygenated and total hemoglobin levels', 'Subcutaneous Hemodynamics and Pain Associated With Nonspecific Neck Pain', 'Subjective pain intensity (visual analog scale); pain-pressure threshold; subcutaneous hemodynamics, including superficial and deep oxygenated, deoxygenated, and total hemoglobin levels; and tissue saturation index', 'pain and increased subcutaneous blood flow', 'pain and increasing oxygenated and total hemoglobin levels', 'pain', 'visual analog scale score and the superficial and deep oxygenated and total hemoglobin levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517649', 'cui_str': '22.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}]","[{'cui': 'C0011682', 'cui_str': 'Desiccation - action'}, {'cui': 'C0220647', 'cui_str': 'Carcinoma of unknown primary'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C5197695', 'cui_str': 'Cupping Treatment'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0475206', 'cui_str': '% total hemoglobin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",32.0,0.0555464,Post hoc tests revealed that the dry cupping group had less pain than the sham cupping and control groups and higher superficial and deep oxygenated and total hemoglobin levels (P values ≤ .008).,"[{'ForeName': 'Stephanie L', 'Initials': 'SL', 'LastName': 'Stephens', 'Affiliation': 'School of Kinesiology and Recreation, Illinois State University, Normal.'}, {'ForeName': 'Noelle M', 'Initials': 'NM', 'LastName': 'Selkow', 'Affiliation': 'School of Kinesiology and Recreation, Illinois State University, Normal.'}, {'ForeName': 'Nicole L', 'Initials': 'NL', 'LastName': 'Hoffman', 'Affiliation': 'School of Kinesiology and Recreation, Illinois State University, Normal.'}]",Journal of athletic training,['10.4085/1062-6050-236-19'] 1561,32550738,Comparison of pain and proper sample status according to usage of tenaculum and analgesia: a randomized clinical trial.,"OBJECTIVE Colposcopic biopsy is a discomfortable procedure. Additionally, it creates negative influence on sexuality. This study aimed to investigate the relationships among tenaculum, pain perception, and biopsy size during colposcopy. METHODS In total, 228 patients who underwent colposcopy-directed biopsy were included, and randomized into 4 groups based on whether analgesic and tenaculum were used and replaced (tenaculum with n=58/without analgesic n=56, no tenaculum replacement with n=57/without analgesic n=57). Lidocaine hydrochloride (40 mg) plus adrenaline (0.025 mg) was administered in the analgesic groups. The pain was assessed using a linear visual analog scale. The biopsy specimen size was measured in millimeters. RESULTS The mean age of the patients was 42.85±8.88 years. The most frequent colposcopy indications were atypical squamous cells of undetermined significance and human papilloma virus-positive results on cervical cytology (30.2%; n=69). Low- and high-grade intraepithelial lesions were noted in 14.91% (n=34) and 10.96% (n=25) women through colposcopy-directed biopsy results, respectively. Tenaculum replacement increased pain perception in the without analgesic group; however, no statistically significant differences were noted between of the groups with and without tenaculum replacement with analgesic. The size and number of biopsy specimens were not associated with tenaculum replacement and analgesic use. CONCLUSION Administration of analgesics decreased discomfort and pain in patients. Tenaculum replacement aided colposcopists in manipulating the cervix. Additionally, administration of analgesics relieved pain in the tenaculum replacement group. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03279666.",2020,"Tenaculum replacement increased pain perception in the without analgesic group; however, no statistically significant differences were noted between of the groups with and without tenaculum replacement with analgesic.","['228 patients who underwent colposcopy-directed biopsy', 'patients']","['adrenaline', 'tenaculum and analgesia', 'Lidocaine hydrochloride', 'analgesic and tenaculum were used and replaced (tenaculum with n=58/without analgesic n=56, no tenaculum replacement with n=57/without analgesic n=57']","['Low- and high-grade intraepithelial lesions', 'biopsy specimen size', 'sexuality', 'cervical cytology', 'discomfort and pain', 'pain', 'pain perception']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009417', 'cui_str': 'Colposcopy'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}]","[{'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0180964', 'cui_str': 'Tenaculum'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0546869', 'cui_str': 'Lidocaine hydrochloride'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0856201', 'cui_str': 'Cervical cytology'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}]",228.0,0.0996657,"Tenaculum replacement increased pain perception in the without analgesic group; however, no statistically significant differences were noted between of the groups with and without tenaculum replacement with analgesic.","[{'ForeName': 'Cihan', 'Initials': 'C', 'LastName': 'Comba', 'Affiliation': 'Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of Health Sciences, Sultangazi Haseki Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Gökhan', 'Initials': 'G', 'LastName': 'Demirayak', 'Affiliation': 'Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Sakir Volkan', 'Initials': 'SV', 'LastName': 'Erdogan', 'Affiliation': 'Department of Gynecology and Obstetrics, University of Health Sciences, Bagcilar Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Karaca', 'Affiliation': 'Department of Gynecology and Obstetrics, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey.'}, {'ForeName': 'Omer', 'Initials': 'O', 'LastName': 'Demir', 'Affiliation': 'Department of Gynecology and Obstetrics, Karadeniz Technical University, Trabzon, Turkey.'}, {'ForeName': 'Oguz', 'Initials': 'O', 'LastName': 'Guler', 'Affiliation': 'Department of Gynecology and Obstetrics, Kucukkoy Bilge Hospital, Istanbul, Turkey.'}, {'ForeName': 'Isa Aykut', 'Initials': 'IA', 'LastName': 'Ozdemir', 'Affiliation': 'Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Medipol University Mega Hospital, Istanbul, Turkey.'}]",Obstetrics & gynecology science,['10.5468/ogs.19185'] 1562,32554025,swCRTdesign: An R Package for Stepped Wedge Trial Design and Analysis.,"BACKGROUND AND OBJECTIVE Stepped wedge trials (SWTs) are a type of cluster-randomized trial that are commonly used to evaluate health care interventions. Most SWT-related software packages have restrictive assumptions about the study design and correlation structure of the data. The objective of this paper is to present a package and corresponding web-based graphical user interface (GUI) that provide researchers with another, more flexible option for SWT design and analysis. METHODS We developed an R package swCRTdesign ('stepped wedge Cluster Randomized Trial design'), which uses a random effects model to account for correlation in the data induced by a SWT design. Possible sources of correlation include clusters, time within clusters, and treatment within clusters. RESULTS swCRTdesign allows a user to calculate power, simulate SWT data to streamline simulation studies (e.g. to estimate power), and create descriptive summaries and plots. Additionally, a GUI, developed using shiny, is available to calculate power and create power curves and design plots. CONCLUSIONS The swCRTdesign package accommodates a wide variety of SWT designs, and makes it easy to account for some sources of correlation which are not found in other packages. The user-friendly web-based GUI makes some swCRTdesign features accessible to researchers not familiar with R. These two resources will make appropriately complex SWT calculations more accessible to scientists from a wide variety of backgrounds.",2020,"We developed an R package swCRTdesign ('stepped wedge Cluster Randomized Trial design'), which uses a random effects model to account for correlation in the data induced by a SWT design.",[],['swCRTdesign'],[],[],[],[],,0.150645,"We developed an R package swCRTdesign ('stepped wedge Cluster Randomized Trial design'), which uses a random effects model to account for correlation in the data induced by a SWT design.","[{'ForeName': 'Emily C', 'Initials': 'EC', 'LastName': 'Voldal', 'Affiliation': 'Department of Biostatistics, University of Washington, Box 357232, Seattle, WA 98195, United States. Electronic address: voldal@uw.edu.'}, {'ForeName': 'Navneet R', 'Initials': 'NR', 'LastName': 'Hakhu', 'Affiliation': 'Department of Statistics, University of California, Irvine, Irvine, CA 92697, United States.'}, {'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Xia', 'Affiliation': 'Department of Biostatistics, University of Washington, Box 357232, Seattle, WA 98195, United States.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Heagerty', 'Affiliation': 'Department of Biostatistics, University of Washington, Box 357232, Seattle, WA 98195, United States.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Hughes', 'Affiliation': 'Department of Biostatistics, University of Washington, Box 357232, Seattle, WA 98195, United States.'}]",Computer methods and programs in biomedicine,['10.1016/j.cmpb.2020.105514'] 1563,32554067,Dexmedetomidine Provides Fewer Respiratory Events Compared With Propofol and Fentanyl During Third Molar Surgery: A Randomized Clinical Trial.,"PURPOSE Propofol and fentanyl can cause airway obstruction and respiratory depression when used together for intravenous sedation. This study investigated whether dexmedetomidine and midazolam would decrease respiratory events requiring intervention during deep sedation compared with propofol, fentanyl, and midazolam. PATIENTS AND METHODS A prospective, randomized, double-blinded, controlled trial was designed to assess 2 intravenous treatment groups during third molar surgery. Patients were randomized into 2 groups. The control group (group P) received 0.8 μg/kg of fentanyl followed by propofol infusion at 125 μg/kg per minute over a 10-minute period with intraoperative boluses of 0.1 μg/kg. The study group (group D) received dexmedetomidine bolus infusion of 1 μg/kg over a 10-minute period followed by maintenance infusion at 0.5 μg/kg per hour. Both groups were given 0.03 mg/kg of midazolam before infusion. Scorers, masked to group, viewed the procedure remotely and evaluated the primary outcome variable of respiratory events requiring intervention. Secondary outcome variables evaluated by the scorers included the Behavioral Pain Scale for non-intubated patients at initial injection, cooperation score at 5 and 15 minutes, and time to ambulation and discharge. Patient satisfaction and hemodynamic stability were measured. The difference between groups regarding the occurrence of respiratory events was tested using the Fisher exact test, and mixed-effects models were used to compare repeated vital signs. RESULTS The sample was composed of 141 patients randomly assigned to either group P (n = 67) or group D (n = 74). No statistically significant differences in the distribution of study variables were found between groups at baseline. A statistically significant difference in respiratory events requiring deliberate intervention existed between group P (25.4%) and group D (2.7%) (P < .0001). No statistically significant difference was found between groups for Behavioral Pain Scale score, cooperation score, time to ambulation or discharge, and patient satisfaction. CONCLUSIONS Using dexmedetomidine and midazolam for outpatient surgery resulted in fewer respiratory events requiring deliberate intervention compared with propofol, fentanyl, and midazolam. Ambulation and discharge times were not prolonged using dexmedetomidine.",2020,"No statistically significant difference was found between groups for Behavioral Pain Scale score, cooperation score, time to ambulation or discharge, and patient satisfaction. ",['141 patients randomly assigned to either group P (n\xa0=\xa067) or group D'],"['dexmedetomidine bolus infusion of 1\xa0μg/kg over a 10-minute period followed by maintenance infusion', 'Dexmedetomidine', 'Propofol and Fentanyl', 'Propofol and fentanyl', 'fentanyl followed by propofol infusion', 'propofol, fentanyl, and midazolam', 'dexmedetomidine and midazolam', 'midazolam', 'dexmedetomidine']","['occurrence of respiratory events', 'Respiratory Events', 'respiratory events', 'Patient satisfaction and hemodynamic stability', 'Behavioral Pain Scale score, cooperation score, time to ambulation or discharge, and patient satisfaction', 'Behavioral Pain Scale for non-intubated patients at initial injection, cooperation score at 5 and 15\xa0minutes, and time to ambulation and discharge', 'Ambulation and discharge times']","[{'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0441849', 'cui_str': 'Group P'}, {'cui': 'C0441838', 'cui_str': 'Group D'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}]","[{'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C1320717', 'cui_str': 'Respiratory event'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C1442447', 'cui_str': 'Fifteen minutes'}]",141.0,0.396816,"No statistically significant difference was found between groups for Behavioral Pain Scale score, cooperation score, time to ambulation or discharge, and patient satisfaction. ","[{'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Nolan', 'Affiliation': 'Assistant Professor, Division of Oral and Maxillofacial Surgery, Department of Dentistry, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY. Electronic address: PNOLAN@montefiore.org.'}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Delgadillo', 'Affiliation': 'Resident, Division of Oral and Maxillofacial Surgery, Department of Dentistry, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Joseph M', 'Initials': 'JM', 'LastName': 'Youssef', 'Affiliation': 'Resident, Division of Oral and Maxillofacial Surgery, Department of Dentistry, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Freeman', 'Affiliation': 'Professor of Biomedical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Jones', 'Affiliation': 'Former Resident, Division of Oral and Maxillofacial Surgery, Department of Dentistry, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Arian', 'Initials': 'A', 'LastName': 'Chehrehsa', 'Affiliation': 'Former Resident, Division of Oral and Maxillofacial Surgery, Department of Dentistry, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2020.05.015'] 1564,32554218,Potential benefits of environmental volunteering programs of the health of older adults: a pilot study.,"PURPOSE To study the effects of participating in a 12-week environmental volunteering program on the physical performance of older adults across different age groups MATERIALS AND METHODS: We conducted a pretest-posttest pilot study with a single group. The intervention consisted of twice-weekly recycling activities and once-weekly rehabilitation exercise at community-based care centers. The recycling activities of the environmental volunteering program included sorting and handling paper products, plastics, and metals; disposing electronic products; and sorting clothes. The rehabilitation exercise program comprised a 90-min course for special needs and 30 min of health education. The evaluation tools were the handgrip strength, five-times-sit-to-stand test, sit-and-reach test, Timed Up and Go (TUG) test and usual and fast gait speeds. RESULTS In total, 45 participants completed the program. After the program, the participants showed significantly great improvements compared to baseline in all outcome measures. We further divided these participants into two age subgroups [65-75 years (n = 31) and >75 years (n = 14)]. The 65-75-year subgroup only showed significant improvements in handgrip strength, TUG and usual gait speed. However, the >75-year subgroup showed significant improvements in all outcome measures. CONCLUSIONS This innovative environmental volunteering program conducted in a local Taiwanese community can be a sustainable and feasible model to improve physical performance in the participants, the subgroup aged >75 years in particular. It also provides a potential avenue for researchers and policymakers to address environmental and aging-related issues.",2020,"The 65-75-year subgroup only showed significant improvements in handgrip strength, TUG and usual gait speed.","['older adults across different age groups', 'older adults', 'participants into two age subgroups [65-75 years (n\u2009=\u200931) and >75 years (n\u2009=\u200914', 'participants, the subgroup aged >75 years in particular', '45 participants completed the program']","['twice-weekly recycling activities and once-weekly rehabilitation exercise at community-based care centers', 'rehabilitation exercise program', 'environmental volunteering program', 'environmental volunteering programs']","['handgrip strength, TUG and usual gait speed', 'handgrip strength, five-times-sit-to-stand test, sit-and-reach test, Timed Up and Go (TUG) test and usual and fast gait speeds']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0556985', 'cui_str': 'Twice weekly'}, {'cui': 'C0282114', 'cui_str': 'Recycling'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0558293', 'cui_str': 'Once a week'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0014406', 'cui_str': 'Environment'}]","[{'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0560801', 'cui_str': 'Does stand from sitting'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}]",45.0,0.0265483,"The 65-75-year subgroup only showed significant improvements in handgrip strength, TUG and usual gait speed.","[{'ForeName': 'Jia-Ching', 'Initials': 'JC', 'LastName': 'Chen', 'Affiliation': 'Department of Rehabilitation Medicine, Buddhist Tzu Chi General Hospital, Hualien, Taiwan; Department of Physical Therapy, Tzu Chi University, Hualien, Taiwan.'}, {'ForeName': 'Qi-Xing', 'Initials': 'QX', 'LastName': 'Chang', 'Affiliation': 'Department of Rehabilitation Medicine, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.'}, {'ForeName': 'Chung-Chao', 'Initials': 'CC', 'LastName': 'Liang', 'Affiliation': 'Department of Rehabilitation Medicine, Buddhist Tzu Chi General Hospital, Hualien, Taiwan; Department of Medicine, Tzu Chi University, Hualien, Taiwan.'}, {'ForeName': 'Jyh-Gang', 'Initials': 'JG', 'LastName': 'Hsieh', 'Affiliation': 'Department of Family Medicine, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.'}, {'ForeName': 'Peter Pin-Sung', 'Initials': 'PP', 'LastName': 'Liu', 'Affiliation': 'Center for Aging and Health, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.'}, {'ForeName': 'Chia-Feng', 'Initials': 'CF', 'LastName': 'Yen', 'Affiliation': 'Department of Public Health, Tzu Chi University, Hualien, Taiwan. Electronic address: mapleyeng@gmail.com.'}, {'ForeName': 'Ching-Hui', 'Initials': 'CH', 'LastName': 'Loh', 'Affiliation': 'Department of Family Medicine, Buddhist Tzu Chi General Hospital, Hualien, Taiwan; Center for Aging and Health, Buddhist Tzu Chi General Hospital, Hualien, Taiwan. Electronic address: twdoc1960@gmail.com.'}]",Archives of gerontology and geriatrics,['10.1016/j.archger.2020.104113'] 1565,32554291,Community level interventions for pre-eclampsia (CLIP) in India: A cluster randomised controlled trial.,"OBJECTIVES Pregnancy hypertension is associated with 7.1% of maternal deaths in India. The objective of this trial was to assess whether task-sharing care might reduce adverse pregnancy outcomes related to delays in triage, transport, and treatment. STUDY DESIGN The Indian Community-Level Interventions for Pre-eclampsia (CLIP) open-label cluster randomised controlled trial (NCT01911494) recruited pregnant women in 12 clusters (initial four-cluster internal pilot) in Belagavi and Bagalkote, Karnataka. The CLIP intervention (6 clusters) consisted of community engagement, community health workers (CHW) provided mobile health (mHeath)-guided clinical assessment, initial treatment, and referral to facility either urgently (<4 h) or non-urgently (<24 h), dependent on algorithm-defined risk. Treatment effect was estimated by multi-level logistic regression modelling, adjusted for prognostically-significant baseline variables. Predefined secondary analyses included safety and evaluation of the intensity of mHealth-guided CHW-provided contacts. MAIN OUTCOME MEASURES 20% reduction in composite of maternal, fetal, and newborn mortality and major morbidity. RESULTS All 14,783 recruited pregnancies (7839 intervention, 6944 control) were followed-up. The primary outcome did not differ between intervention and control arms (adjusted odds ratio (aOR) 0.92 [95% confidence interval 0.74, 1.15]; p = 0.47; intraclass correlation coefficient 0.013). There were no intervention-related safety concerns following administration of either methyldopa or MgSO 4 , and 401 facility referrals. Compared with intervention arm women without CLIP contacts, those with ≥8 contacts suffered fewer stillbirths (aOR 0.19 [0.10, 0.35]; p < 0.001), at the probable expense of survivable neonatal morbidity (aOR 1.39 [0.97, 1.99]; p = 0.072). CONCLUSIONS As implemented, solely community-level interventions focussed on pre-eclampsia did not improve outcomes in northwest Karnataka.",2020,"There were no intervention-related safety concerns following administration of either methyldopa or MgSO 4 , and 401 facility referrals.","['All 14,783 recruited pregnancies (7839 intervention, 6944 control) were followed-up', 'pregnant women in 12 clusters (initial four-cluster internal pilot) in Belagavi and Bagalkote, Karnataka', 'pre-eclampsia (CLIP) in India']","['CLIP intervention (6 clusters) consisted of community engagement, community health workers (CHW) provided mobile health (mHeath)-guided clinical assessment, initial treatment, and referral to facility either urgently (<4\xa0h) or non-urgently', 'task-sharing care', 'Community level interventions', 'methyldopa']","['safety and evaluation of the intensity of mHealth-guided CHW-provided contacts', 'survivable neonatal morbidity', 'composite of maternal, fetal, and newborn mortality and major morbidity']","[{'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021201', 'cui_str': 'India'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C0025741', 'cui_str': 'Methyldopa'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0015965', 'cui_str': 'Fetuses'}, {'cui': 'C0027616', 'cui_str': 'Neonatal Mortality'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",,0.32665,"There were no intervention-related safety concerns following administration of either methyldopa or MgSO 4 , and 401 facility referrals.","[{'ForeName': 'Mrutunjaya B', 'Initials': 'MB', 'LastName': 'Bellad', 'Affiliation': ""KLE Academy of Higher Education and Research's J N Medical College, Nehru Nagar, Belagavi, 590010 Karnataka, India. Electronic address: mbbellad@hotmail.com.""}, {'ForeName': 'Shivaprasad S', 'Initials': 'SS', 'LastName': 'Goudar', 'Affiliation': ""KLE Academy of Higher Education and Research's J N Medical College, Nehru Nagar, Belagavi, 590010 Karnataka, India.""}, {'ForeName': 'Ashalata A', 'Initials': 'AA', 'LastName': 'Mallapur', 'Affiliation': 'S Nijalingappa Medical College, HSK (Hanagal Shree Kumareshwar) Hospital and Research Centre, Navanagar, Bagalkot, 587102 Karnataka, India.'}, {'ForeName': 'Sumedha', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Bone', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada.'}, {'ForeName': 'Umesh S', 'Initials': 'US', 'LastName': 'Charantimath', 'Affiliation': ""KLE Academy of Higher Education and Research's J N Medical College, Nehru Nagar, Belagavi, 590010 Karnataka, India.""}, {'ForeName': 'Geetanjali M', 'Initials': 'GM', 'LastName': 'Katageri', 'Affiliation': 'S Nijalingappa Medical College, HSK (Hanagal Shree Kumareshwar) Hospital and Research Centre, Navanagar, Bagalkot, 587102 Karnataka, India.'}, {'ForeName': 'Umesh Y', 'Initials': 'UY', 'LastName': 'Ramadurg', 'Affiliation': 'S Nijalingappa Medical College, HSK (Hanagal Shree Kumareshwar) Hospital and Research Centre, Navanagar, Bagalkot, 587102 Karnataka, India.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Mark Ansermino', 'Affiliation': 'Centre for International Child Health, 305 - 4088 Cambie Street, Vancouver V5Z 2X8, Canada.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Derman', 'Affiliation': 'Global Affairs, 1020 Walnut Street, Thomas Jefferson University, Philadelphia 19107, USA.'}, {'ForeName': 'Dustin T', 'Initials': 'DT', 'LastName': 'Dunsmuir', 'Affiliation': 'Centre for International Child Health, 305 - 4088 Cambie Street, Vancouver V5Z 2X8, Canada.'}, {'ForeName': 'Narayan V', 'Initials': 'NV', 'LastName': 'Honnungar', 'Affiliation': ""KLE Academy of Higher Education and Research's J N Medical College, Nehru Nagar, Belagavi, 590010 Karnataka, India.""}, {'ForeName': 'Chandrashekhar', 'Initials': 'C', 'LastName': 'Karadiguddi', 'Affiliation': ""KLE Academy of Higher Education and Research's J N Medical College, Nehru Nagar, Belagavi, 590010 Karnataka, India.""}, {'ForeName': 'Avinash J', 'Initials': 'AJ', 'LastName': 'Kavi', 'Affiliation': ""KLE Academy of Higher Education and Research's J N Medical College, Nehru Nagar, Belagavi, 590010 Karnataka, India.""}, {'ForeName': 'Bhalachandra S', 'Initials': 'BS', 'LastName': 'Kodkany', 'Affiliation': ""KLE Academy of Higher Education and Research's J N Medical College, Nehru Nagar, Belagavi, 590010 Karnataka, India.""}, {'ForeName': 'Tang', 'Initials': 'T', 'LastName': 'Lee', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada.'}, {'ForeName': 'Hannah L', 'Initials': 'HL', 'LastName': 'Nathan', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, St. Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK.""}, {'ForeName': 'Beth A', 'Initials': 'BA', 'LastName': 'Payne', 'Affiliation': 'Centre for International Child Health, 305 - 4088 Cambie Street, Vancouver V5Z 2X8, Canada.'}, {'ForeName': 'Amit P', 'Initials': 'AP', 'LastName': 'Revankar', 'Affiliation': ""KLE Academy of Higher Education and Research's J N Medical College, Nehru Nagar, Belagavi, 590010 Karnataka, India.""}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Shennan', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, St. Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK.""}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Singer', 'Affiliation': ""Centre for Health Evaluation and Outcome Sciences, Providence Health Care Research Institute, University of British Columbia, 588 - 1081 Burrard Street, St. Paul's Hospital, Vancouver V6Z 1Y6, Canada.""}, {'ForeName': 'Domena K', 'Initials': 'DK', 'LastName': 'Tu', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Vidler', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada; Centre for International Child Health, 305 - 4088 Cambie Street, Vancouver V5Z 2X8, Canada.'}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'Wong', 'Affiliation': ""Centre for Health Evaluation and Outcome Sciences, Providence Health Care Research Institute, University of British Columbia, 588 - 1081 Burrard Street, St. Paul's Hospital, Vancouver V6Z 1Y6, Canada.""}, {'ForeName': 'Zulfiqar A', 'Initials': 'ZA', 'LastName': 'Bhutta', 'Affiliation': 'Centre for Global Child Health, Hospital for Sick Children, 525 University Avenue, Suite 702, Toronto M5G 2L3, Canada; Aga Khan University, Stadium Road, P.O. Box 3500, Karachi 74800, Pakistan.'}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Magee', 'Affiliation': ""Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada; Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, St. Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK.""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'von Dadelszen', 'Affiliation': ""Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver, BC V6Z 2K8, Canada; Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, St. Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Pregnancy hypertension,['10.1016/j.preghy.2020.05.008'] 1566,32555029,The Effects of L-Carnitine on Echocardiographic Changes in Patients With β-Thalassemia Major and Intermedia.,"INTRODUCTION Heart failure, fatal arrhythmias, and cardiac dilatation because of anemia are common causes of β-thalassemia major-related deaths. The aim of this study was to determine the effect of L-carnitine on echocardiographic changes in β-thalassemia major and intermedia patients in Besat Hospital in Sanandaj, Iran. METHODS In a randomized clinical trial, 60 β-thalassemia patients who were eligible for L-carnitine administration were randomly divided into 2 placebo and study drug groups. The duration of the study was 6 months. Using echocardiography and blood tests, cardiac parameters including left ventricular dilatation, left ventricular hypertrophy, and a number of cardiac blood indices were examined before and after the intervention. The data were analyzed using SPSS V.23 software, χ, and covariance statistical tests. RESULTS There was no significant difference between the 2 groups in terms of age and sex. Patients treated with L-carnitine have a reduced rate of left ventricular dilatation, left ventricular hypertrophy, and systolic blood pressure compared with controls (P<0.05). Cardiac output increased from 43.5 to 56.5 (P=0.002). CONCLUSIONS The results of this study showed that the drug has a positive effect on the improvement of cardiac indices in β-thalassemia patients. Therefore, we suggest that further studies with more samples and other diagnostic modalities of the drug's effect be investigated.",2020,"Cardiac output increased from 43.5 to 56.5 (P=0.002). ","['Patients With β-Thalassemia Major and Intermedia', '60 β-thalassemia patients who were eligible for L-carnitine administration', 'β-thalassemia major and intermedia patients in Besat Hospital in Sanandaj, Iran.\nMETHODS', 'β-thalassemia patients']","['placebo', 'L-Carnitine', 'L-carnitine']","['echocardiography and blood tests, cardiac parameters including left ventricular dilatation, left ventricular hypertrophy, and a number of cardiac blood indices', 'Cardiac output', 'rate of left ventricular dilatation, left ventricular hypertrophy, and systolic blood pressure', 'cardiac indices', 'Echocardiographic Changes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002875', 'cui_str': 'Homozygous beta thalassemia'}, {'cui': 'C0446035', 'cui_str': 'Candida intermedia'}, {'cui': 'C0039730', 'cui_str': 'Thalassemia'}, {'cui': 'C0087163', 'cui_str': 'Levocarnitine'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0087163', 'cui_str': 'Levocarnitine'}]","[{'cui': 'C0013516', 'cui_str': 'Echocardiography'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0344911', 'cui_str': 'Left cardiac ventricular dilatation'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0340279', 'cui_str': 'Ventricular hypertrophy'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0007165', 'cui_str': 'Cardiac output'}, {'cui': 'C0264733', 'cui_str': 'Cardiac ventricular dilatation'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428776', 'cui_str': 'Cardiac index'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",60.0,0.0649836,"Cardiac output increased from 43.5 to 56.5 (P=0.002). ","[{'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Shahidi', 'Affiliation': 'Department of Cardiology, Besat Hospital.'}, {'ForeName': 'Sayedeh Rozhin', 'Initials': 'SR', 'LastName': 'Hashemi', 'Affiliation': 'Faculty of Medicine.'}, {'ForeName': 'Nima', 'Initials': 'N', 'LastName': 'Fattahi', 'Affiliation': 'Non-Communicable Diseases Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Daem', 'Initials': 'D', 'LastName': 'Roshani', 'Affiliation': 'Social Determinants of Health Research Center, Research Institute for Health Development.'}, {'ForeName': 'Siamak', 'Initials': 'S', 'LastName': 'Vahedi', 'Affiliation': 'Cardiology Department.'}, {'ForeName': 'Pezhman', 'Initials': 'P', 'LastName': 'Sharifi', 'Affiliation': 'Liver and Digestive Research Center.'}, {'ForeName': 'Borhan', 'Initials': 'B', 'LastName': 'Moradveisi', 'Affiliation': 'Cancer and Immunology Research Center, Kurdistan University of Medical Sciences, Sanandaj.'}]",Journal of pediatric hematology/oncology,['10.1097/MPH.0000000000001850'] 1567,32345594,Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak.,"The novel COVID-19 outbreak has affected more than 200 countries and territories as of March 2020. Given that patients with cancer are generally more vulnerable to infections, systematic analysis of diverse cohorts of patients with cancer affected by COVID-19 is needed. We performed a multicenter study including 105 patients with cancer and 536 age-matched noncancer patients confirmed with COVID-19. Our results showed COVID-19 patients with cancer had higher risks in all severe outcomes. Patients with hematologic cancer, lung cancer, or with metastatic cancer (stage IV) had the highest frequency of severe events. Patients with nonmetastatic cancer experienced similar frequencies of severe conditions to those observed in patients without cancer. Patients who received surgery had higher risks of having severe events, whereas patients who underwent only radiotherapy did not demonstrate significant differences in severe events when compared with patients without cancer. These findings indicate that patients with cancer appear more vulnerable to SARS-CoV-2 outbreak. SIGNIFICANCE: Because this is the first large cohort study on this topic, our report will provide much-needed information that will benefit patients with cancer globally. As such, we believe it is extremely important that our study be disseminated widely to alert clinicians and patients. This article is highlighted in the In This Issue feature, p. 747 .",2020,"Patients who received surgery had higher risks of having severe events, whereas patients who underwent only radiotherapy did not demonstrate significant differences in severe events when compared with patients without cancer.","['patients with cancer', 'Patients with nonmetastatic cancer', '105 patients with cancer and 536 age-matched noncancer patients confirmed with COVID-19', 'patients with cancer globally', 'Patients with Cancer Appear More Vulnerable to SARS-CoV-2', 'Patients with hematologic cancer, lung cancer, or with metastatic cancer (stage IV']",['radiotherapy'],"['severe events', 'higher risks of having severe events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0376545', 'cui_str': 'Hematologic neoplasm'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}]",105.0,0.0266972,"Patients who received surgery had higher risks of having severe events, whereas patients who underwent only radiotherapy did not demonstrate significant differences in severe events when compared with patients without cancer.","[{'ForeName': 'Mengyuan', 'Initials': 'M', 'LastName': 'Dai', 'Affiliation': 'Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.'}, {'ForeName': 'Dianbo', 'Initials': 'D', 'LastName': 'Liu', 'Affiliation': ""Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Miao', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': ""Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. chb21051@163.com msantill@g.harvard.edu mliu0@bwh.harvard.edu.""}, {'ForeName': 'Fuxiang', 'Initials': 'F', 'LastName': 'Zhou', 'Affiliation': 'Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China.'}, {'ForeName': 'Guiling', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Cancer Center, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Department of Emergency, The Central Hospital of Wuhan affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'ForeName': 'Zhian', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Department of Gynecology, The Central Hospital of Huanggang, Huanggang, Hubei, China.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'You', 'Affiliation': 'Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong Province, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'Department of Ultrasound, Zhongnan Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Qichao', 'Initials': 'Q', 'LastName': 'Zheng', 'Affiliation': 'Department of Ultrasound, Zhongnan Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Xiong', 'Affiliation': 'Department of Infectious Disease, Zhongnan Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Huihua', 'Initials': 'H', 'LastName': 'Xiong', 'Affiliation': 'Cancer Center, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'ForeName': 'Chun', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Oncology, The Central Hospital of Wuhan affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'ForeName': 'Changchun', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Department of Radiology, Hubei Cancer Hospital, Wuhan, Hubei, China.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Xiong', 'Affiliation': 'Department of Thoracic Surgery, Hubei Cancer Hospital, Wuhan, Hubei, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Yaqin', 'Initials': 'Y', 'LastName': 'Peng', 'Affiliation': 'Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Siping', 'Initials': 'S', 'LastName': 'Ge', 'Affiliation': 'Department of Oncology, Wuhan Puren Hospital, Wuhan, Hubei, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Zhen', 'Affiliation': 'Department of Obstetrics and Gynecology, The Central Hospital of Xianning, Xianning, Hubei, China.'}, {'ForeName': 'Tingting', 'Initials': 'T', 'LastName': 'Yu', 'Affiliation': 'Department of Oncology, The Central Hospital of Xiaogan, Xiaogan, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': ""Department of Obstetrics and Gynecology, The People's Hospital of Huangmei, Huangmei, Hubei, China.""}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': ""Department of Obstetrics and Gynecology, Xiangyang First People's Hospital affiliated to Hubei University of Medicine, Xiangyang, Hubei, China.""}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China.'}, {'ForeName': 'Yeshan', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Cancer Center, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'ForeName': 'Junhua', 'Initials': 'J', 'LastName': 'Mei', 'Affiliation': 'Department of Gynecology, The Central Hospital of Huanggang, Huanggang, Hubei, China.'}, {'ForeName': 'Xiaojia', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': 'Department of Oncology, The Central Hospital of Wuhan affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'ForeName': 'Zhuyan', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': ""Department of Obstetrics and Gynecology, The People's Hospital of Shiyan, Shiyan, Hubei, China.""}, {'ForeName': 'Lijuan', 'Initials': 'L', 'LastName': 'Gan', 'Affiliation': 'Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.'}, {'ForeName': 'Can', 'Initials': 'C', 'LastName': 'He', 'Affiliation': 'Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.'}, {'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.'}, {'ForeName': 'Yuying', 'Initials': 'Y', 'LastName': 'Shi', 'Affiliation': 'Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.'}, {'ForeName': 'Yuwen', 'Initials': 'Y', 'LastName': 'Qi', 'Affiliation': 'Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.'}, {'ForeName': 'Daniel G', 'Initials': 'DG', 'LastName': 'Tenen', 'Affiliation': 'Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Chai', 'Affiliation': ""Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Lorelei A', 'Initials': 'LA', 'LastName': 'Mucci', 'Affiliation': 'Harvard T.H. Chan School of Public Health, Dana-Farber, Harvard Cancer Center, Boston, Massachusetts.'}, {'ForeName': 'Mauricio', 'Initials': 'M', 'LastName': 'Santillana', 'Affiliation': ""Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts. chb21051@163.com msantill@g.harvard.edu mliu0@bwh.harvard.edu.""}, {'ForeName': 'Hongbing', 'Initials': 'H', 'LastName': 'Cai', 'Affiliation': 'Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. chb21051@163.com msantill@g.harvard.edu mliu0@bwh.harvard.edu.'}]",Cancer discovery,['10.1158/2159-8290.CD-20-0422'] 1568,32554380,"Effectiveness of an 8-Week Web-Based Mindfulness Virtual Community Intervention for University Students on Symptoms of Stress, Anxiety, and Depression: Randomized Controlled Trial.","BACKGROUND A student mental health crisis is increasingly acknowledged and will only intensify with the COVID-19 crisis. Given accessibility of methods with demonstrated efficacy in reducing depression and anxiety (eg, mindfulness meditation and cognitive behavioral therapy [CBT]) and limitations imposed by geographic obstructions and localized expertise, web-based alternatives have become vehicles for scaled-up delivery of benefits at modest cost. Mindfulness Virtual Community (MVC), a web-based program informed by CBT constructs and featuring online videos, discussion forums, and videoconferencing, was developed to target depression, anxiety, and experiences of excess stress among university students. OBJECTIVE The aim of this study was to assess the effectiveness of an 8-week web-based mindfulness and CBT program in reducing symptoms of depression, anxiety, and stress (primary outcomes) and increasing mindfulness (secondary outcome) within a randomized controlled trial (RCT) with undergraduate students at a large Canadian university. METHODS An RCT was designed to assess undergraduate students (n=160) who were randomly allocated to a web-based guided mindfulness-CBT condition (n=80) or to a waitlist control (WLC) condition (n=80). The 8-week intervention consisted of a web-based platform comprising (1) 12 video-based modules with psychoeducation on students' preidentified life challenges and applied mindfulness practice; (2) anonymous peer-to-peer discussion forums; and (3) anonymous, group-based, professionally guided 20-minute live videoconferences. The outcomes (depression, anxiety, stress, and mindfulness) were measured via an online survey at baseline and at 8 weeks postintervention using the Patient Health Questionnaire-9 (PHQ9), the Beck Anxiety Inventory (BAI), the Perceived Stress Scale (PSS), and the Five Facets Mindfulness Questionnaire Short Form (FFMQ-SF). Analyses employed generalized estimation equation methods with AR(1) covariance structures and were adjusted for possible covariates (gender, age, country of birth, ethnicity, English as first language, paid work, unpaid work, relationship status, physical exercise, self-rated health, and access to private mental health counseling). RESULTS Of the 159 students who provided T1 data, 32 were males and 125 were females with a mean age of 22.55 years. Participants in the MVC (n=79) and WLC (n=80) groups were similar in sociodemographic characteristics at T1 with the exception of gender and weekly hours of unpaid volunteer work. At postintervention follow-up, according to the adjusted comparisons, there were statistically significant between-group reductions in depression scores (β=-2.21, P=.01) and anxiety scores (β=-4.82, P=.006), and a significant increase in mindfulness scores (β=4.84, P=.02) compared with the WLC group. There were no statistically significant differences in perceived stress for MVC (β=.64, P=.48) compared with WLC. CONCLUSIONS With the MVC intervention, there were significantly reduced depression and anxiety symptoms but no significant effect on perceived stress. Online mindfulness interventions can be effective in addressing common mental health conditions among postsecondary populations on a large scale, simultaneously reducing the current burden on traditional counseling services. TRIAL REGISTRATION ISRCTN Registry ISRCTN12249616; http://www.isrctn.com/ISRCTN12249616.",2020,"There were no statistically significant differences in perceived stress for MVC (β = .64, P = .48) compared to WLC. ","['32 were males and 125 were females with a mean age of 22.55 years', 'undergraduate students at a large Canadian university', 'undergraduate students (n = 160', '159 students who provided T1 data', 'Participants in the MVC (n = 79) and WLC (n = 80) groups were similar in sociodemographic characteristics at T1 with the exception of gender and weekly hours of unpaid volunteer work', 'University Students on Symptoms of Stress, Anxiety, and Depression', 'university students']","['web-based guided mindfulness-CBT condition (n = 80) or to a waitlist control condition (WLC', 'Eight-Week Web-Based Mindfulness Virtual Community Intervention', 'mindfulness meditation and cognitive behavioural therapy [CBT', 'Mindfulness Virtual Community (MVC), a web-based program informed by cognitive behavioral therapy (CBT) constructs and featuring online videos, discussion forums, and videoconferencing', 'eight-week web-based mindfulness and cognitive behavioural therapy (CBT) program', 'Online mindfulness interventions', ""web-based platform consisting of (1) 12 video-based modules with psycho-education on students' preidentified life challenges and applied mindfulness practice; (2) anonymous peer-to-peer discussion forums; and (3) anonymous, group-based, professionally guided 20-minute live videoconferences""]","['mindfulness scores', 'outcomes (depression, anxiety, stress, and mindfulness', 'depression scores', 'Patient Health Questionniare-9 (PHQ9), the Beck Anxiety Inventory (BAI), the Perceived Stress Scale (PSS), and the Five Facets Mindfulness Questionnaire Short Form (FFMQ-SF', 'depression and anxiety symptoms', 'anxiety scores', 'symptoms of depression, anxiety, and stress (primary outcomes', 'perceived stress for MVC']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0700287', 'cui_str': 'Informing'}, {'cui': 'C0012931', 'cui_str': 'Recombinant DNA'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}, {'cui': 'C1450048', 'cui_str': 'Videoconferencing'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C1450049', 'cui_str': 'Videoconference'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory'}, {'cui': 'C0582653', 'cui_str': 'Perceived stress scale'}, {'cui': 'C0222679', 'cui_str': 'Structure of articular surface of bone'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0009462', 'cui_str': 'Community'}]",160.0,0.0566538,"There were no statistically significant differences in perceived stress for MVC (β = .64, P = .48) compared to WLC. ","[{'ForeName': 'Christo', 'Initials': 'C', 'LastName': 'El Morr', 'Affiliation': 'School of Health Policy and Management, York University, Toronto, ON, Canada.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Ritvo', 'Affiliation': 'School of Kinesiology and Health Science, York University, Toronto, ON, Canada.'}, {'ForeName': 'Farah', 'Initials': 'F', 'LastName': 'Ahmad', 'Affiliation': 'School of Health Policy and Management, York University, Toronto, ON, Canada.'}, {'ForeName': 'Rahim', 'Initials': 'R', 'LastName': 'Moineddin', 'Affiliation': 'Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': 'School of Health Policy and Management, York University, Toronto, ON, Canada.'}]",JMIR mental health,['10.2196/18595'] 1569,32683390,"Efficacy of a topical gel containing chitosan, chlorhexidine, allantoin and dexpanthenol for pain and inflammation control after third molar surgery: A randomized and placebo-controlled clinical trial.","BACKGROUND The aim of this study was to evaluate and compare the postoperative effect of a topic gel containing chlorhexidine, chitosan, allantoine and dexpanthenol versus a placebo for pain and inflammation control after third molar surgery. MATERIAL AND METHODS A gel combining 0.2% chlorhexdine, 0.5% chitosan, 5% dexpanthenol, 0.15% allantoin and 0.01% sodium saccharin was selected for this split mouth randomized controlled and double-blind trial including 36 patients with bilaterally and symmetrically impacted lower third molars. The teeth (n=72) were randomly divided into two groups before surgical removal: control group (CG; in which a placebo was given) and experimental group (EG). Swelling, trismus, postoperative pain, wound healing and complications were measured and recorded in order to evaluate differences between the placebo and experimental product. RESULTS Five patients suffered from an alveolitis in the CG (13.9%), and none in the study group (0%), but no statistically significant difference was found (p=0.063). From day 0 to day 7, trismus and swelling were significantly less pronounced in the EG, and wound healing was considered 'good' in 22.2% for the CG and 97.2% for the EG (p<0.001). Mean VAS scores during the seven postoperative days were statistically lower in the study (2.56±1,19) compared to the placebo group (3.25±1.6) (p=0.002). The mean consumption of analgesic pills during the first 92 hours was also statistically lower in the EG (0.26±0.51) in comparison to the CG (0.56±0.67) (p=0.003). CONCLUSIONS The use of an experimental gel containing chlorhexidine, chitosan, allantoine and dexpanthenol seems to significantly reduce postoperative pain, trismus and signs of inflammation. Future studies should further evaluate, if the gel is effective in dry socket preventing after third molar removal.",2020,"From day 0 to day 7, trismus and swelling were significantly less pronounced in the EG, and wound healing was considered 'good' in 22.2% for the CG and 97.2% for the EG (p<0.001).","['36 patients with bilaterally and symmetrically impacted lower third molars', 'pain and inflammation control after third molar surgery', 'The teeth (n=72']","['topical gel containing chitosan, chlorhexidine, allantoin and dexpanthenol', 'placebo', 'surgical removal: control group (CG; in which a placebo', 'gel combining 0.2% chlorhexdine, 0.5% chitosan, 5% dexpanthenol, 0.15% allantoin and 0.01% sodium saccharin', 'chlorhexidine, chitosan, allantoine and dexpanthenol']","['trismus and swelling', 'mean consumption of analgesic pills', 'wound healing', 'Mean VAS scores', 'Swelling, trismus, postoperative pain, wound healing and complications', 'postoperative pain, trismus and signs of inflammation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0227191', 'cui_str': 'Structure of lower third of esophagus'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0026369', 'cui_str': 'Structure of wisdom tooth'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}]","[{'cui': 'C1160728', 'cui_str': 'Cutaneous gel'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0162969', 'cui_str': 'Chitosan'}, {'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C0002083', 'cui_str': 'Allantoin'}, {'cui': 'C0057610', 'cui_str': 'dexpanthenol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C4068886', 'cui_str': '0.15'}, {'cui': 'C4517393', 'cui_str': '0.01'}, {'cui': 'C0917900', 'cui_str': 'Saccharin sodium'}]","[{'cui': 'C0041105', 'cui_str': 'Trismus'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",36.0,0.206127,"From day 0 to day 7, trismus and swelling were significantly less pronounced in the EG, and wound healing was considered 'good' in 22.2% for the CG and 97.2% for the EG (p<0.001).","[{'ForeName': 'L-M', 'Initials': 'LM', 'LastName': 'Sáez-Alcaide', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Molinero-Mourelle', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'González-Serrano', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Rubio-Alonso', 'Affiliation': ''}, {'ForeName': 'M-M', 'Initials': 'MM', 'LastName': 'Bornstein', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'López-Quiles', 'Affiliation': ''}]","Medicina oral, patologia oral y cirugia bucal",['10.4317/medoral.23661'] 1570,32554133,A video-game based cognitive training for breast cancer survivors with cognitive impairment: A prospective randomized pilot trial.,"INTRODUCTION We investigated whether a web-based cognitive training video game is an effective approach to improve cognitive decline in combination with our standard of care for rehabilitation of breast cancer (BC) patients. MATERIALS AND METHODS Self-selected BC patients between 18 and 71 years old complaining of disturbing cognitive impairment were studied. The patients received access to a web-based internet video game and online cognitive assessments (Aquasnap, Cambridge, MyCQ™). The early intervention group (n = 23) had a training program of 6 months of at least three times a week for a minimum of 60 min of game playing per week at home in addition to standard of care rehabilitation. The delayed intervention (n = 23) received standard of care for three months, followed by three months of similar MyCQ training. Outcome measures were the MyCQ (sub)scores and Activity of Daily Life (ADL), mood, subjective cognition and functional cognitive status measured by classic neuropsychological tests. RESULTS At baseline the means for CFQ (a measure of self-reported cognitive failure), anxiety, PSQI and self-reflectiveness were beyond normal range in both groups. CFQ improved significantly better in the intervention group (p = 0.029). Combining the evolution over time in the entire population a significant improvement was seen for overall MyCQ score, level of fear, physical and emotional role limitation, and health change (all p < 0.05), but self-reflectivess deteriorated (p < 0.05)). Significant differences in the various MyCQ subtests over time were: improved speed in choice reaction time, visual memory recognition, N back 1 and 2, coding, trail making test B, improved accuracy of N back 1 and 2 (all p < 0.05). CONCLUSION A program of cognitive training improves cognitive functioning over time. ""Aquasnap"" has a beneficial effect on the perception of subjective cognitive functioning (CFQ) but the exact role of video gaming in this process remains uncertain.",2020,"Significant differences in the various MyCQ subtests over time were: improved speed in choice reaction time, visual memory recognition, N back 1 and 2, coding, trail making test B, improved accuracy of N","['Self-selected BC patients between 18 and 71 years old complaining of disturbing cognitive impairment were studied', 'breast cancer (BC) patients', 'breast cancer survivors with cognitive impairment']","['video-game based cognitive training', 'cognitive training', 'web-based cognitive training video game', 'MyCQ training', 'access to a web-based internet video game and online cognitive assessments (Aquasnap, Cambridge, MyCQ™']","['speed in choice reaction time, visual memory recognition, N back 1 and 2, coding, trail making test B, improved accuracy of N', 'cognitive failure), anxiety, PSQI and self-reflectiveness', 'cognitive functioning', 'MyCQ (sub)scores and Activity of Daily Life (ADL), mood, subjective cognition and functional cognitive status measured by classic neuropsychological tests', 'overall MyCQ score, level of fear, physical and emotional role limitation, and health change', 'CFQ']","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]","[{'cui': 'C0042649', 'cui_str': 'Video Games'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0542316', 'cui_str': 'Visual memory'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439658', 'cui_str': 'Classic'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1319227', 'cui_str': 'Level of fear'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",,0.0411642,"Significant differences in the various MyCQ subtests over time were: improved speed in choice reaction time, visual memory recognition, N back 1 and 2, coding, trail making test B, improved accuracy of N","[{'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Bellens', 'Affiliation': 'Multidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, Edegem, B2650, Belgium; Centre for Oncological Research (CORE), University of Antwerp, Wilrijk, B2610, Belgium.'}, {'ForeName': 'Ella', 'Initials': 'E', 'LastName': 'Roelant', 'Affiliation': 'Clinical Trial Center (CTC), CRC Antwerp, Antwerp University Hospital, University of Antwerp, Edegem, B2650, Belgium; StatUa, Center for Statistics, University of Antwerp, Antwerp, B2000, Belgium.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Sabbe', 'Affiliation': 'Department of Psychiatry, Antwerp University, Wilrijk, Belgium.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Peeters', 'Affiliation': 'Multidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, Edegem, B2650, Belgium; Centre for Oncological Research (CORE), University of Antwerp, Wilrijk, B2610, Belgium.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'van Dam', 'Affiliation': 'Multidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, Edegem, B2650, Belgium; Centre for Oncological Research (CORE), University of Antwerp, Wilrijk, B2610, Belgium. Electronic address: peter.vandam@telenet.be.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.06.003'] 1571,32554135,The relationship between the tympanostomy tube extrusion time and viscosity.,"OBJECTIVE The purpose of the study was to assess the correlation between the tympanostomy tube extrusion time and the viscosity of the middle ear fluid. METHODS Thirty-three patients who were scheduled for a tympanostomy tube (TT) insertion were included in the study. During the paracentesis procedure, fluid from the middle ear was obtained, and the viscosity was measured with a viscometer. Patients with effusion values below and above the median viscosity value of 439 cP (cP) were assigned to Group 1 and Group 2, respectively. After the surgery, the patients were followed up monthly until the tubes were observed to be extruded. RESULTS The analysis of the correlation between the tube extrusion time and the viscosity was statistically insignificant (p > 0.05). The mean tube extrusion time of Group 1 (12.65 ± 4.152 months) was slightly lower than that of Group 2 (13.81 ± 4.43 months); however, the difference was not statistically significant. CONCLUSION The tube extrusion time can be longer or shorter and is independent of the effusion viscosity. Further studies are needed to clarify the factors that affect the TT extrusion time. TRIAL REGISTRATION NUMBER NCT03848026.",2020,The analysis of the correlation between the tube extrusion time and the viscosity was statistically insignificant (p > 0.05).,"['Patients with effusion values below and above the median viscosity value of 439\xa0cP (cP', 'Thirty-three patients who were scheduled for a tympanostomy tube (TT) insertion were included in the study']",[],"['mean tube extrusion time', 'tube extrusion time and the viscosity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013687', 'cui_str': 'Effusion'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0042784', 'cui_str': 'Viscosity'}, {'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0850121', 'cui_str': 'Tympanic ventilation tube'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0443213', 'cui_str': 'Extrusion'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0042784', 'cui_str': 'Viscosity'}]",33.0,0.0301946,The analysis of the correlation between the tube extrusion time and the viscosity was statistically insignificant (p > 0.05).,"[{'ForeName': 'Nazan', 'Initials': 'N', 'LastName': 'Degirmenci', 'Affiliation': 'Bezmialem Vakif University, Department of Otorhinolaryngology and Head and Neck Surgery, Istanbul, Turkey. Electronic address: ndegirmenci@bezmialem.edu.tr.'}, {'ForeName': 'Selahattin', 'Initials': 'S', 'LastName': 'Tugrul', 'Affiliation': 'Bezmialem Vakif University, Department of Otorhinolaryngology and Head and Neck Surgery, Istanbul, Turkey. Electronic address: selahattintugrul@yahoo.com.'}, {'ForeName': 'Seda Sezen', 'Initials': 'SS', 'LastName': 'Goktas', 'Affiliation': '75. Yil Boyabat State Hospital, Department of Otorhinolaryngology and Head and Neck Surgery, Sinop, Turkey. Electronic address: sedasezengoktas@gmail.com.'}, {'ForeName': 'Erol', 'Initials': 'E', 'LastName': 'Senturk', 'Affiliation': 'Bezmialem Vakif University, Department of Otorhinolaryngology and Head and Neck Surgery, Istanbul, Turkey. Electronic address: erolsent@gmail.com.'}, {'ForeName': 'Omer Faruk', 'Initials': 'OF', 'LastName': 'Calim', 'Affiliation': 'Bezmialem Vakif University, Department of Otorhinolaryngology and Head and Neck Surgery, Istanbul, Turkey. Electronic address: omercalim@yahoo.com.'}, {'ForeName': 'Remzi', 'Initials': 'R', 'LastName': 'Dogan', 'Affiliation': 'Bezmialem Vakif University, Department of Otorhinolaryngology and Head and Neck Surgery, Istanbul, Turkey. Electronic address: dr.remzidogan@hotmail.com.'}, {'ForeName': 'Alper', 'Initials': 'A', 'LastName': 'Yenigun', 'Affiliation': 'Bezmialem Vakif University, Department of Otorhinolaryngology and Head and Neck Surgery, Istanbul, Turkey. Electronic address: alperyenigun@gmail.com.'}, {'ForeName': 'Orhan', 'Initials': 'O', 'LastName': 'Ozturan', 'Affiliation': 'Bezmialem Vakif University, Department of Otorhinolaryngology and Head and Neck Surgery, Istanbul, Turkey. Electronic address: orhanent@yahoo.com.'}]",International journal of pediatric otorhinolaryngology,['10.1016/j.ijporl.2020.110140'] 1572,32555939,"Randomized, double-blind, placebo-controlled study of the analgesic effect of intraoperative esmolol for laparoscopic gastroplasty.","PURPOSE To evaluate the analgesic effect of esmolol in patients submitted to laparoscopic gastroplasty. METHODS Forty patients aged between 18 and 50 years with American Society of Anesthesiologists (ASA) physical status scores of II and III who underwent gastric bypass were allocated to two groups. Group 1 patients received a 0.5-mg/kg bolus of esmolol in 30 mL of saline before induction of anesthesia, followed by an infusion at 15 µg/kg/min until the end of surgery. Group 2 patients received 30 mL of saline as a bolus and then an infusion of saline. Anesthesia included fentanyl (3 µg/kg), propofol (2-4 mg/kg), rocuronium (0.6 mg/kg), and 2% sevoflurane, with remifentanil if necessary. The following parameters were evaluated: pain intensity over 24h, remifentanil consumption, the first analgesic request, morphine consumption, and side effects. RESULTS Pain intensity was lower in the esmolol group except at T0 (after extubation) and 12h postoperatively. Remifentanil supplementation, recovery time, and postoperative morphine supplementation were lower in the esmolol group. No differences in the time to the first analgesic request or side effects were found between the groups. CONCLUSION Intraoperative esmolol promotes reductions in pain intensity and the need for analgesic supplementation without adverse effects, thus representing an effective drug for multimodal analgesia in gastroplasty.",2020,"RESULTS Pain intensity was lower in the esmolol group except at T0 (after extubation) and 12h postoperatively.","['Forty patients aged between 18 and 50 years with American Society of Anesthesiologists (ASA) physical status scores of II and III who underwent gastric bypass', 'patients submitted to laparoscopic gastroplasty', 'laparoscopic gastroplasty']","['rocuronium', 'sevoflurane, with remifentanil', 'Remifentanil', 'Intraoperative esmolol', 'intraoperative esmolol', 'esmolol', '30 mL of saline', 'propofol', 'placebo']","['pain intensity', 'analgesic effect', 'Pain intensity', 'time to the first analgesic request or side effects', 'recovery time, and postoperative morphine supplementation', 'pain intensity over 24h, remifentanil consumption, the first analgesic request, morphine consumption, and side effects']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0017125', 'cui_str': 'Bypass of stomach'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0017193', 'cui_str': 'Gastroplasty'}]","[{'cui': 'C0209337', 'cui_str': 'Rocuronium'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0116569', 'cui_str': 'esmolol'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0420259', 'cui_str': 'Analgesics requested'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]",40.0,0.357074,"RESULTS Pain intensity was lower in the esmolol group except at T0 (after extubation) and 12h postoperatively.","[{'ForeName': 'Vinicius Barros Duarte de', 'Initials': 'VBD', 'LastName': 'Morais', 'Affiliation': 'MD, Pain Sector, Department of Surgery, Universidade Federal de São Paulo (UNIFESP), Brazil, Design of the study, acquisition of data, final approval.'}, {'ForeName': 'Rioko Kimiko', 'Initials': 'RK', 'LastName': 'Sakata', 'Affiliation': 'PhD, Pain Sector, Department of Surgery, UNIFESP, Sao Paulo-SP, Brazil, Design of the study, manuscript writing, critical revision, final approval.'}, {'ForeName': 'Ana Paula Santana', 'Initials': 'APS', 'LastName': 'Huang', 'Affiliation': 'Master, Pain Sector, Department of Surgery, UNIFESP, Sao Paulo-SP, Brazil. Acquisition of data, final approval.'}, {'ForeName': 'Leonardo Henrique da Cunha', 'Initials': 'LHDC', 'LastName': 'Ferraro', 'Affiliation': 'PhD, Pain Sector, Department of Surgery, UNIFESP, Sao Paulo-SP, Brazil. Manuscript writing, final approval.'}]",Acta cirurgica brasileira,['10.1590/s0102-865020200040000008'] 1573,32559474,"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.","BACKGROUND SGLT2 inhibition decreases albuminuria and reduces the risk of kidney disease progression in patients with type 2 diabetes. These benefits are unlikely to be mediated by improvements in glycaemic control alone. Therefore, we aimed to examine the kidney effects of the SGLT2 inhibitor dapagliflozin in patients with proteinuric kidney disease without diabetes. METHODS DIAMOND was a randomised, double-blind, placebo-controlled crossover trial done at six hospitals in Canada, Malaysia, and the Netherlands. Eligible participants were adult patients (aged 18-75 years) with chronic kidney disease, without a diagnosis of diabetes, with a 24-h urinary protein excretion greater than 500 mg and less than or equal to 3500 mg and an estimated glomerular filtration rate (eGFR) of at least 25 mL/min per 1·73 m 2 , and who were on stable renin-angiotensin system blockade. Participants were randomly assigned (1:1) to receive placebo and then dapagliflozin 10 mg per day or vice versa. Each treatment period lasted 6 weeks with a 6-week washout period in between. Participants, investigators, and study personnel were masked to assignment throughout the trial and analysis. The primary outcome was percentage change from baseline in 24-h proteinuria during dapagliflozin treatment relative to placebo. Secondary outcomes were changes in measured GFR (mGFR; via iohexol clearance), bodyweight, blood pressure, and concentrations of neurohormonal biomarkers. Analyses were done in accordance with the intention-to-treat principle. This study is registered with ClinicalTrials.gov, NCT03190694. FINDINGS Between Nov 22, 2017, and April 5, 2019, 58 patients were screened, of whom 53 (mean age 51 years [SD 13]; 32% women) were randomly assigned (27 received dapagliflozin then placebo and 26 received placebo then dapagliflozin). One patient discontinued during the first treatment period. All patients were included in the analysis. Mean baseline mGFR was 58·3 mL/min per 1·73 m 2 (SD 23), median proteinuria was 1110 mg per 24 h (IQR 730-1560), and mean HbA 1c was 5·6% (SD 0·4). The difference in mean proteinuria change from baseline between dapagliflozin and placebo was 0·9% (95% CI -16·6 to 22·1; p=0·93). Compared with placebo, mGFR was changed with dapagliflozin treatment by -6·6 mL/min per 1·73 m 2 (-9·0 to -4·2; p<0·0001) at week 6. This reduction was fully reversible within 6 weeks after dapagliflozin discontinuation. Compared with placebo, bodyweight was reduced by 1·5 kg (0·03-3·0; p=0·046) with dapagliflozin; changes in systolic and diastolic blood pressure and concentrations of neurohormonal biomarkers did not differ significantly between dapagliflozin and placebo treatment. The numbers of patients who had one or more adverse events during dapagliflozin treatment (17 [32%] of 53) and during placebo treatment (13 [25%] of 52) were similar. No hypoglycaemic events were reported and no deaths occurred. INTERPRETATION 6-week treatment with dapagliflozin did not affect proteinuria in patients with chronic kidney disease without diabetes, but did induce an acute and reversible decline in mGFR and a reduction in bodyweight. Long-term clinical trials are underway to determine whether SGLT2 inhibitors can safely reduce the rate of major clinical kidney outcomes in patients with chronic kidney disease with and without diabetes. FUNDING AstraZeneca.",2020,"Compared with placebo, mGFR was changed with dapagliflozin treatment by -6·6 mL/min per 1·73 m 2 (-9·0 to -4·2; p<0·0001) at week 6.","['Eligible participants were adult patients (aged 18-75 years) with chronic kidney disease, without a diagnosis of diabetes, with a 24-h urinary protein excretion greater than 500 mg and less than or equal to 3500 mg and an estimated glomerular filtration rate (eGFR) of at least 25 mL/min per 1·73 m 2 , and who were on stable renin-angiotensin system blockade', '58 patients were screened, of whom 53 (mean age 51 years [SD 13]; 32% women', 'patients with chronic kidney disease with and without diabetes', 'Between Nov 22, 2017, and April 5, 2019', 'patients with proteinuric kidney disease without diabetes', 'patients with type 2 diabetes', 'non-diabetic patients with chronic kidney disease (DIAMOND', 'patients with chronic kidney disease without diabetes', 'six hospitals in Canada, Malaysia, and the Netherlands']","['dapagliflozin then placebo', 'dapagliflozin', 'SGLT2 inhibitors', 'placebo and then dapagliflozin 10 mg per day or vice versa', 'SGLT2 inhibitor dapagliflozin', 'placebo then dapagliflozin', 'dapagliflozin and placebo', 'placebo']","['systolic and diastolic blood pressure and concentrations of neurohormonal biomarkers', 'median proteinuria', 'percentage change from baseline in 24-h proteinuria', 'mean proteinuria change', 'adverse events', 'hypoglycaemic events', 'changes in measured GFR (mGFR; via iohexol clearance), bodyweight, blood pressure, and concentrations of neurohormonal biomarkers', 'Mean baseline mGFR']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0439090', 'cui_str': '<='}, {'cui': 'C4517736', 'cui_str': '3500'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0439445', 'cui_str': 'mL/min'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0035094', 'cui_str': 'Renin'}, {'cui': 'C0003018', 'cui_str': 'Angiotensin'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0057717', 'cui_str': 'Diamond'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0024552', 'cui_str': 'Malaysia'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}]","[{'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3273807', 'cui_str': 'SGLT2 Inhibitors'}, {'cui': 'C3709918', 'cui_str': 'dapagliflozin 10 MG'}, {'cui': 'C0439505', 'cui_str': '/day'}]","[{'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic agent'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0022005', 'cui_str': 'Iohexol'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",58.0,0.624837,"Compared with placebo, mGFR was changed with dapagliflozin treatment by -6·6 mL/min per 1·73 m 2 (-9·0 to -4·2; p<0·0001) at week 6.","[{'ForeName': 'David Z I', 'Initials': 'DZI', 'LastName': 'Cherney', 'Affiliation': 'Division of Nephrology, Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Claire C J', 'Initials': 'CCJ', 'LastName': 'Dekkers', 'Affiliation': 'Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.'}, {'ForeName': 'Sean J', 'Initials': 'SJ', 'LastName': 'Barbour', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Cattran', 'Affiliation': 'Division of Nephrology, Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Abdul Halim', 'Initials': 'AH', 'LastName': 'Abdul Gafor', 'Affiliation': 'Department of Medicine, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Greasley', 'Affiliation': 'Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Gozewijn D', 'Initials': 'GD', 'LastName': 'Laverman', 'Affiliation': 'Department of Internal Medicine, ZGT Hospital, Almelo and Hengelo, Netherlands.'}, {'ForeName': 'Soo Kun', 'Initials': 'SK', 'LastName': 'Lim', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Gian Luca', 'Initials': 'GL', 'LastName': 'Di Tanna', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Heather N', 'Initials': 'HN', 'LastName': 'Reich', 'Affiliation': 'Division of Nephrology, Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Marc G', 'Initials': 'MG', 'LastName': 'Vervloet', 'Affiliation': 'Department of Nephrology and Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, Amsterdam, Netherlands.'}, {'ForeName': 'Muh Geot', 'Initials': 'MG', 'LastName': 'Wong', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia; Royal North Shore Hospital, St Leonards, NSW, Australia.'}, {'ForeName': 'Ron T', 'Initials': 'RT', 'LastName': 'Gansevoort', 'Affiliation': 'Department of Nephrology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.'}, {'ForeName': 'Hiddo J L', 'Initials': 'HJL', 'LastName': 'Heerspink', 'Affiliation': 'Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands. Electronic address: h.j.lambers.heerspink@umcg.nl.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The lancet. Diabetes & endocrinology,['10.1016/S2213-8587(20)30162-5'] 1574,32559515,Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis.,"Gait dysfunction is common in patients with multiple sclerosis (PwMS). Treatment with prolonged-release fampridine (PR-fampridine) improves walking ability in some PwMS. Associated fampridine-induced changes in the walking pattern are still poorly understood but may provide a better understanding of the mechanisms underlying the beneficial drug effects. 61 PwMS were treated with PR-fampridine in a randomized, monocentric, double-blind and placebo-controlled clinical trial with crossover design (FAMPKIN). Drug-induced improvements in walking speed (Timed-25-Foot Walk; T25FW) and endurance (6-Minute Walk Test; 6MWT) were quantified. In this sub-study of the FAMPKIN trial, fampridine-induced changes in kinetic gait patterns were analyzed by pressure-based foot print analysis during treadmill walking. Vertical ground reaction forces were analyzed during different gait phases. Kinetic data of 44 PwMS was eligible for analysis. During double-blind treatment with PR-fampridine, patients performed significantly better in the T25FW and 6MWT than during placebo treatment (p < 0.0001 for both). At the group level (n = 44), there were no significant changes of gait kinetics under PR-fampridine vs. placebo. However, we found relevant changes of walking kinetics regarding forces during loading, single limb and pre-swing phase in a patient sub-group (n = 8). Interestingly, this sub-group demonstrated superior responsiveness to PR-fampridine in the clinical walking tests compared to those patients without any fampridine-induced changes in kinetics (n = 36). Our results demonstrate fampridine-induced changes in gait kinetics in a sub-group of PwMS. These gait pattern changes were accompanied by improved clinical walking performance under PR-fampridine. These results shed some light on the biomechanical changes in walking patterns underlying enhanced fampridine-induced gait performance.",2020,"At the group level (n = 44), there were no significant changes of gait kinetics under PR-fampridine vs. placebo.","['patients with multiple sclerosis', 'patients with multiple sclerosis (PwMS']","['PR-fampridine', 'prolonged-release fampridine (PR-fampridine', 'placebo']","['clinical walking performance', 'Vertical ground reaction forces', 'walking kinetics', 'gait kinetics', 'Gait dysfunction', 'walking speed (Timed-25-Foot Walk; T25FW) and endurance (6-Minute Walk Test; 6MWT', 'kinetic gait patterns', 'T25FW and 6MWT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}]","[{'cui': 'C0000477', 'cui_str': 'dalfampridine'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0430515', 'cui_str': '6-minute walk test'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}]",61.0,0.124543,"At the group level (n = 44), there were no significant changes of gait kinetics under PR-fampridine vs. placebo.","[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Weller', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Lörincz', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Sutter', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Reuter', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Linnebank', 'Affiliation': 'Department of Neurology, University Witten/Herdecke and Evangelische Kliniken Gelsenkirchen, Munckelstraße 32, 45879 Gelsenkirchen, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Weller', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Zörner', 'Affiliation': 'Spinal Cord Injury Center, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Filli', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland; Spinal Cord Injury Center, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland; Swiss Center for clinical Movement Analysis (SCMA), Balgrist Campus AG, Lengghalde 5, 8008 Zurich, Switzerland. Electronic address: linard.filli@balgrist.ch.'}]",Journal of the neurological sciences,['10.1016/j.jns.2020.116978'] 1575,32559601,Cardiovascular responses to pelvic floor muscle contraction in healthy women: Prospective study.,"OBJECTIVE Analyze the acute heart rate and blood pressure responses to two protocols of pelvic floor muscles contractions in premenopausal and postmenopausal women. METHODS Fifty-four women without pelvic floor muscles disorders were eligible and allocated into two groups: premenopausal and postmenopausal. The groups underwent two protocols and the pelvic floor muscle endurance, heart rate, and blood pressure values were monitored. Both protocols included 10 pelvic floor muscles contractions; one series contained contractions lasting 5 s with 5 s of rest between each contraction and the other series contained contractions lasting 10 s with 10 s of rest. RESULTS In both groups, there was a significant increase in the heart rate during pelvic floor muscles contractions (premenopausal: 71.0 ± 7.3 and 80.3 ± 7.7; postmenopausal: 65.4 ± 6.6 and 73.6 ± 6.6, at rest and contractions peak, respectively) and in systolic blood pressure immediately after the contractions. The observed values during exercise returned to basal values seconds after the contractions. A positive correlation between heart rate and vaginal squeeze pressure (r = 0.45, p = 0.0007 and r = 0.48, p = 0.0003, 5- and 10-s series, respectively) was observed. CONCLUSION The proposed protocol of isometric pelvic floor muscles contractions caused an increase in heart rate and blood pressure within the normal range and might not represent a cardiovascular risk for healthy postmenopausal women without urinary incontinence and without cardiovascular dysfunctions.",2020,The proposed protocol of isometric pelvic floor muscles contractions caused an increase in heart rate and blood pressure within the normal range and might not represent a cardiovascular risk for healthy postmenopausal women without urinary incontinence and without cardiovascular dysfunctions.,"['premenopausal and postmenopausal women', 'healthy women', 'healthy postmenopausal women without urinary incontinence and without cardiovascular dysfunctions', 'Fifty-four women without pelvic floor muscles disorders were eligible and allocated into two groups: premenopausal and postmenopausal']",['pelvic floor muscles contractions'],"['heart rate and blood pressure', 'pelvic floor muscle endurance, heart rate, and blood pressure values', 'heart rate', 'Cardiovascular responses', 'systolic blood pressure', 'heart rate and vaginal squeeze pressure']","[{'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026848', 'cui_str': 'Disorder of muscle'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026820', 'cui_str': 'Muscle contraction'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0413258', 'cui_str': 'Barotrauma of descent'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}]",54.0,0.0281104,The proposed protocol of isometric pelvic floor muscles contractions caused an increase in heart rate and blood pressure within the normal range and might not represent a cardiovascular risk for healthy postmenopausal women without urinary incontinence and without cardiovascular dysfunctions.,"[{'ForeName': 'Alana Maria G', 'Initials': 'AMG', 'LastName': 'Bastos', 'Affiliation': ""Women's Health Research Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.""}, {'ForeName': 'Aparecida M', 'Initials': 'AM', 'LastName': 'Catai', 'Affiliation': 'Cardiovascular Physical Therapy Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.'}, {'ForeName': 'Soraia P', 'Initials': 'SP', 'LastName': 'Jürgensen', 'Affiliation': ""Women's Health Research Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.""}, {'ForeName': 'Grasiela N', 'Initials': 'GN', 'LastName': 'Correia', 'Affiliation': ""Women's Health Research Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.""}, {'ForeName': 'Vanessa S', 'Initials': 'VS', 'LastName': 'Pereira-Baldon', 'Affiliation': ""Women's Health Research Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.""}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Perseguini', 'Affiliation': 'Cardiovascular Physical Therapy Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Borghi-Silva', 'Affiliation': 'Cardiovascular Physical Therapy Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Driusso', 'Affiliation': ""Women's Health Research Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil. Electronic address: pdriusso@ufscar.br.""}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.05.050'] 1576,32560472,Repeated Menthol Mouth Swilling Affects Neither Strength nor Power Performance.,"This study aimed to assess the effects of repeated menthol mouth swilling upon strength and power performance. Nineteen (10 male) participants completed familiarisation and experimental trials of repeated menthol mouth swilling (0.1% concentration) or control (no swill) in a randomised crossover design. Participants performed an isometric mid-thigh pull (IMTP; peak and mean force; N), vertical jump (peak; cm) and six second sprint (peak and mean power; W) under each condition. Participants completed three efforts per exercise task interspersed with three-minute recoveries. Mean best values were analysed via a two-way mixed repeated measures ANOVA, and differences reported as effect sizes ± 95% confidence intervals, with accompanying descriptors and p values. Differences in peak IMTP values were unclear between familiarisation and experimental trials, and between menthol and control conditions. Mean IMTP force differed between familiarisation and control (0.51; -0.15 to 1.14; p = 0.001) and familiarisation and menthol conditions (0.50; -0.15 to 1.14; p = 0.002) by a small degree, but were unclear between control and menthol conditions. Unclear differences were also noted on vertical jump performance compared to familiarisation and between experimental conditions, with repeated six second peak and average power performance also showing unclear effects across all comparisons. We conclude that repeated menthol mouth swilling does not improve strength or power performance.",2020,"Mean IMTP force differed between familiarisation and control (0.51; -0.15 to 1.14; p = 0.001) and familiarisation and menthol conditions (0.50; -0.15 to 1.14; p = 0.002) by a small degree, but were unclear between control and menthol conditions.",['Nineteen (10 male) participants completed familiarisation and experimental trials of repeated'],['menthol mouth swilling (0.1% concentration) or control (no swill'],"['peak IMTP values', 'strength or power performance', 'vertical jump performance', 'strength and power performance', 'Strength nor Power Performance', 'Mean IMTP force']","[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}]","[{'cui': 'C0025368', 'cui_str': 'Menthol'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0580846', 'cui_str': 'Does pull'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0443221', 'cui_str': 'Forced'}]",,0.128886,"Mean IMTP force differed between familiarisation and control (0.51; -0.15 to 1.14; p = 0.001) and familiarisation and menthol conditions (0.50; -0.15 to 1.14; p = 0.002) by a small degree, but were unclear between control and menthol conditions.","[{'ForeName': 'Russ', 'Initials': 'R', 'LastName': 'Best', 'Affiliation': 'Centre for Sport Science and Human Performance, Wintec, Hamilton 3200, New Zealand.'}, {'ForeName': 'Dani', 'Initials': 'D', 'LastName': 'Temm', 'Affiliation': 'Centre for Sport Science and Human Performance, Wintec, Hamilton 3200, New Zealand.'}, {'ForeName': 'Holly', 'Initials': 'H', 'LastName': 'Hucker', 'Affiliation': 'Centre for Sport Science and Human Performance, Wintec, Hamilton 3200, New Zealand.'}, {'ForeName': 'Kerin', 'Initials': 'K', 'LastName': 'McDonald', 'Affiliation': 'Centre for Sport Science and Human Performance, Wintec, Hamilton 3200, New Zealand.'}]","Sports (Basel, Switzerland)",['10.3390/sports8060090'] 1577,32683384,Effect of lingual-based flap design on postoperative pain of impacted mandibular third molar surgery: Split-mouth randomized clinical trial.,"BACKGROUND The extraction of third molars is one of the most common procedures in oral and maxillofacial surgery clinic. Surgical extraction involves the manipulation of both soft and hard tissues, so the patient usually experiences pain, swelling, and trismus in the immediate post-operative period. Several studies have been conducted using different types of surgical flaps to provide access with the least possible damage of soft tissues. Designing and implementing an optimum flap, which provides easier technique, better visibility, minimal post-operative complications, and best healing, is an aspired goal of every oral surgeon. This study aimed to compare lingual-based four-cornered flap with conventional triangular flap, and to evaluate its effect on post-operative pain after surgical extraction of impacted lower third molars. MATERIAL AND METHODS Seventeen patients (age ranged from 19 to 26 years) with bilateral, symmetrical impacted lower third molars (n=34) were included in the study. This was a randomized clinical trial with a split-mouth design. The impacted molars were assigned randomly, by coin flipping, to two groups: Case side with lingual-based four-cornered flap (Group A), and control side with conventional triangular flap (Group B). Away from the incision, the prognosis, surgical intervention, and postoperative procedures were exactly the same for the two groups. Postsurgical pain was assessed for 5 days using visual analogue scale (VAS) and by recording patients need for analgesics on a daily basis. Patients were also evaluated via a self-reporting questionnaire, i.e. Postoperative Symptoms Severity (PoSSe) scale, administered on the seventh postoperative day. RESULTS Pain scores recorded in Group A were found to be significantly lower as compared to pain scores in Group B in the 5 postoperative days (P<0.05). Total analgesic intake in Group B was significantly higher (P<0.05). PoSSe scores were lower in Group A, however, this difference was insignificant (P>0.05). CONCLUSIONS According to the data of the current study and within its limits, it appeared that lingual-based four-cornered flap design was superior to the conventional triangular flap regarding the postsurgical discomfort and pain.",2020,Total analgesic intake in Group B was significantly higher (P<0.05).,"['Seventeen patients (age ranged from 19 to 26 years) with bilateral, symmetrical impacted lower third molars (n=34) were included in the study', 'postoperative pain of impacted mandibular third molar surgery']","['Case side with lingual-based four-cornered flap (Group A), and control side with conventional triangular flap', 'lingual-based flap design', 'lingual-based four-cornered flap with conventional triangular flap']","['pain scores', 'Total analgesic intake', 'PoSSe scores', 'visual analogue scale (VAS', 'Postsurgical pain', 'self-reporting questionnaire, i.e. Postoperative Symptoms Severity (PoSSe) scale', 'Pain scores']","[{'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0332516', 'cui_str': 'Symmetrical'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0227191', 'cui_str': 'Structure of lower third of esophagus'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026369', 'cui_str': 'Structure of wisdom tooth'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0040408', 'cui_str': 'Tongue structure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038925', 'cui_str': 'Flap'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0205119', 'cui_str': 'Triangular'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",34.0,0.119895,Total analgesic intake in Group B was significantly higher (P<0.05).,"[{'ForeName': 'B', 'Initials': 'B', 'LastName': 'Hassan', 'Affiliation': 'Department of Oral and Maxillofacial Surgery Faculty of Dentistry, Syrian Private University P.O. Box 36822, Damascus, Syria nuraldeen.alkhanati@gmail.com.'}, {'ForeName': 'N-M', 'Initials': 'NM', 'LastName': 'Al-Khanati', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Bahhah', 'Affiliation': ''}]","Medicina oral, patologia oral y cirugia bucal",['10.4317/medoral.23666'] 1578,32683388,Hemostatic agents in endodontic surgery of maxillary molars: A randomized controlled pilot study of polytetrafluoroethylene (PTFE) strips as an adjunct to epinephrine impregnated gauze versus aluminum chloride.,"BACKGROUND Hemostasis is of critical importance in endodontic surgery. Studies on bleeding control in maxillary molars are scarce. The present study compares the efficacy of two hemostatic techniques in controlling bleeding in endodontic surgery. MATERIAL AND METHODS A randomized two-arm pilot study involving 30 patients with peri-radicular lesions in maxillary molars (first and second molars) was carried out including the following hemostatic agents: polytetrafluoroethylene (PTFE) strips as an adjunct to epinephrine impregnated gauze (test group; n = 15) and aluminum chloride (Expasyl™) (control; n = 15). Bleeding control was independently assessed by the surgeon and by two blinded observers before and after application of the hemostatic agent, and was classified as either adequate (complete bleeding control) or inadequate (incomplete bleeding control). RESULTS Bleeding control was similar in both groups. Simple binary logistic regression analysis failed to identify variables affecting bleeding control. Only the height of the keratinized mucosal band (≥ 2 mm) suggested a decreased risk of inadequate bleeding control of up to 89% (OR=0.11; p=0.06). CONCLUSIONS No difference in the efficacy of bleeding control was observed between PTFE strips as an adjunct to epinephrine impregnated gauze and aluminum chloride in maxillary molars.",2020,No difference in the efficacy of bleeding control was observed between PTFE strips as an adjunct to epinephrine impregnated gauze and aluminum chloride in maxillary molars.,"['30 patients with peri-radicular lesions in maxillary molars (first and second molars', 'endodontic surgery of maxillary molars']","['epinephrine impregnated gauze (test group; n = 15) and aluminum chloride (Expasyl™', 'polytetrafluoroethylene (PTFE) strips', 'epinephrine impregnated gauze and aluminum chloride', 'Hemostatic agents', 'hemostatic agents: polytetrafluoroethylene (PTFE) strips', 'hemostatic techniques', 'epinephrine impregnated gauze versus aluminum chloride']","['Bleeding control', 'efficacy of bleeding control', 'risk of inadequate bleeding control']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0332274', 'cui_str': 'Endodontic'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0590323', 'cui_str': 'Gauzes'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0019120', 'cui_str': 'Hemostatic agent'}, {'cui': 'C0032611', 'cui_str': 'Polytetrafluoroethylene'}, {'cui': 'C0185047', 'cui_str': 'Stripping'}, {'cui': 'C0051512', 'cui_str': 'Aluminum chloride hexahydrate'}, {'cui': 'C0019119', 'cui_str': 'Hemostatic Technics'}]","[{'cui': 'C0149533', 'cui_str': 'Control of hemorrhage'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",30.0,0.0325652,No difference in the efficacy of bleeding control was observed between PTFE strips as an adjunct to epinephrine impregnated gauze and aluminum chloride in maxillary molars.,"[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Peñarrocha-Oltra', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Soto-Peñaloza', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Peñarrocha-Diago', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Cervera-Ballester', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Cabanes-Gumbau', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Peñarrocha-Diago', 'Affiliation': ''}]","Medicina oral, patologia oral y cirugia bucal",['10.4317/medoral.23652'] 1579,32559734,"Effects of low fructose diet on glycemic control, lipid profile and systemic inflammation in patients with type 2 diabetes: A single-blind randomized controlled trial.","BACKGROUND AND AIM Type 2 diabetes is one of the global epidemic disorders, which causes many side effects on the body. Fructose is a lipogenic monosaccharide. Recent studies have reported the adverse effects of this carbohydrate on diabetes. This study aimed to evaluate the clinical efficacy of a low-fructose diet on the metabolic alterations in patients with type 2 diabetes. METHODS This study was a randomized, single-blind clinical trial on 50 patients with type 2 diabetes. Participants randomly allocated to two groups, to receive either diabetic-diet or diabetic-diet with low-fructose for 8-weeks. Anthropometric measurements, systolic blood pressure (SBP), Diastolic blood pressure (DBP) and metabolic factors were assessed at baseline and the end of the trial. RESULTS At the end of trial, reduction in body weight, waist circumference, and blood pressure were not significant except for DBP (P = 0.013). Statistical analysis showed that low-fructose diet compared to control group significantly declined fasting blood glucose (FBG), Hemoglobin A1c (HbA1c), Triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C) and high-sensitivity C-reactive protein (hs-CRP) (P = 0.015, P = 0.001, P=<0.0001, P= <0.0001 and P= <0.0001 respectively). CONCLUSION Our results showed that eight weeks of low-fructose diet results in a significant improvement in FBG, HbA1c, TG, HDL-C and hs-CRP in patients with type 2 diabetes.",2020,"At the end of trial, reduction in body weight, waist circumference, and blood pressure were not significant except for DBP (P = 0.013).","['50 patients with type 2 diabetes', 'patients with type 2 diabetes']","['diabetic-diet or diabetic-diet with low-fructose for 8-weeks', 'low-fructose diet', 'Fructose', 'low fructose diet']","['fasting blood glucose (FBG), Hemoglobin A1c (HbA1c), Triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C) and high-sensitivity C-reactive protein (hs-CRP', 'Anthropometric measurements, systolic blood pressure (SBP), Diastolic blood pressure (DBP) and metabolic factors', 'glycemic control, lipid profile and systemic inflammation', 'body weight, waist circumference, and blood pressure', 'metabolic alterations', 'FBG, HbA1c, TG, HDL-C and hs-CRP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0011878', 'cui_str': 'Diabetic diet'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0016745', 'cui_str': 'Fructose'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0452314', 'cui_str': 'Low fructose diet'}]","[{'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",50.0,0.074236,"At the end of trial, reduction in body weight, waist circumference, and blood pressure were not significant except for DBP (P = 0.013).","[{'ForeName': 'Arman', 'Initials': 'A', 'LastName': 'Jalilvand', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, ShahidBeheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Vahideh', 'Initials': 'V', 'LastName': 'Behrouz', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, ShahidBeheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Omid', 'Initials': 'O', 'LastName': 'Nikpayam', 'Affiliation': 'Student Research Committee, Tabriz University of Medical Science, Tabriz, Iran; Department of Clinical Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Golbon', 'Initials': 'G', 'LastName': 'Sohrab', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, ShahidBeheshti University of Medical Sciences, Tehran, Iran. Electronic address: golbonsohrab@yahoo.com.'}, {'ForeName': 'Azita', 'Initials': 'A', 'LastName': 'Hekmatdoost', 'Affiliation': 'Department of Clinical Nutrition and Dietetics, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, ShahidBeheshti University of Medical Sciences, Tehran, Iran.'}]",Diabetes & metabolic syndrome,['10.1016/j.dsx.2020.04.003'] 1580,32559735,Improving clinical outcomes of diabetic foot ulcers by the 3-month self- and family management support programs in Indonesia: A randomized controlled trial study.,"BACKGROUND AND AIMS Diabetic foot ulcers are the leading cause of lower extremity amputations, which require more effective prevention. Even though previous nursing studies on diabetic foot ulcers have been well performed, programs implementing self- and family management are limited and even underexplored. Therefore, the purpose of the study was to investigate the effect of 3-month self- and family management support programs on clinical outcomes among Indonesians with diabetic foot ulcers. METHOD The randomized controlled trial design was used to answer the research question of the study. A total of 56 eligible participants were enrolled, with 27 in the experimental group and 29 in the control group. The experimental group received self- and family management support programs for three months. Meanwhile, the control group received usual care. Descriptive statistics, multivariate analysis of variance, and Generalized Estimating Equations were used to analyze the data. The significance level was considered at .05 for hypothesis testing. RESULTS The study showed that there were statistically significant improvements in self-management, family supports, hemoglobin A1c, and wound size after implemented the programs for three months (p < .05). CONCLUSIONS With regard to the result of the study, implementing the 3-month self- and family management support programs improves the patients' and families' abilities to perform diabetic foot ulcer care at home.",2020,"The study showed that there were statistically significant improvements in self-management, family supports, hemoglobin A1c, and wound size after implemented the programs for three months (p < .05). ","['A total of 56 eligible participants were enrolled, with 27 in the experimental group and 29 in the control group', 'Indonesia', 'Indonesians with diabetic foot ulcers']","['usual care', 'self- and family management support programs']","['self-management, family supports, hemoglobin A1c, and wound size']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021247', 'cui_str': 'Indonesia'}, {'cui': 'C0021248', 'cui_str': 'Indonesian language'}, {'cui': 'C1456868', 'cui_str': 'Diabetic foot ulcer'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0150232', 'cui_str': 'Family support'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0456389', 'cui_str': 'Size'}]",56.0,0.0239313,"The study showed that there were statistically significant improvements in self-management, family supports, hemoglobin A1c, and wound size after implemented the programs for three months (p < .05). ","[{'ForeName': 'Sumarno Adi', 'Initials': 'SA', 'LastName': 'Subrata', 'Affiliation': 'Ramathibodi School of Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand; Department of Nursing and Wound Research Center, Faculty of Health Sciences, Universitas Muhammadiyah Magelang, Indonesia.'}, {'ForeName': 'Rutja', 'Initials': 'R', 'LastName': 'Phuphaibul', 'Affiliation': 'Ramathibodi School of Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand. Electronic address: ruja.phu@mahidol.ac.th.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Grey', 'Affiliation': 'Yale University School of Nursing, United States.'}, {'ForeName': 'Apinya', 'Initials': 'A', 'LastName': 'Siripitayakunkit', 'Affiliation': 'Ramathibodi School of Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand.'}, {'ForeName': 'Noppawan', 'Initials': 'N', 'LastName': 'Piaseu', 'Affiliation': 'Ramathibodi School of Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand.'}]",Diabetes & metabolic syndrome,['10.1016/j.dsx.2020.05.028'] 1581,32560171,Long-Term Socioeconomic Impact of Informal Care Provided to Patients with Pacemakers: Remote vs. Conventional Monitoring.,"The impact of informal care immediately after pacemaker (PM) implantation has been well established; however, not much is known about its long-term effects. The present study compared personal characteristics, associated problems, workloads, time, and costs related to informal care provided to patients with PM under remote monitoring (RM) vs. conventional monitoring (CM) in the hospital, five years after implantation. The PONIENTE study was a controlled, non-randomized or masked clinical trial conducted with information obtained from the perspective of informal caregivers. Data were collected at 12 and 60 months after PM implantation. The patients in the study were assigned to two different groups: remote monitoring (RM) and conventional monitoring (CM). The ""Disability, personal autonomy, and dependency situations survey"" (EDAD) was administered to collect information on sociodemographic characteristics, time, care difficulties, health status, professional aspects, and impact on economic, family, or leisure aspects of the main caregivers providing care to patients with pacemakers. After five years, 55 patients completed the study (RM = 21; CM = 34). The average age was 63.14 years (SD = 14.90), 96% of them were women, and the most predominant marital status was married (72%). Informal caregivers lived in the homes of the patients in 70% of cases, and 88% indicated that they had to provide care six to seven days a week. The average cost per patient during the monitoring period studied was 13.17% lower in the RM group than in the CM group, and these differences were not statistically significant ( p = 0.35). This study found similar results in the two groups under study with respect to sociodemographic characteristics, workload, time, and problems associated with health, leisure and family members. The costs associated with care were higher in the CM group; however, these differences were not statistically significant.",2020,"The average cost per patient during the monitoring period studied was 13.17% lower in the RM group than in the CM group, and these differences were not statistically significant ( p = 0.35).","['The average age was 63.14 years (SD = 14.90), 96% of them were women, and the most predominant marital status was married (72', 'patients with pacemakers']","['remote monitoring (RM) and conventional monitoring (CM', 'Informal Care', 'PM under remote monitoring (RM) vs. conventional monitoring (CM', 'informal care immediately after pacemaker (PM) implantation']","['average cost per patient', 'personal characteristics, associated problems, workloads, time, and costs related to informal care', 'sociodemographic characteristics, time, care difficulties, health status, professional aspects, and impact on economic, family, or leisure aspects of the main caregivers providing care']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0024819', 'cui_str': 'Marital status'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030163', 'cui_str': 'Cardiac pacemaker'}]","[{'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C3494177', 'cui_str': 'Informal care'}, {'cui': 'C0030163', 'cui_str': 'Cardiac pacemaker'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3494177', 'cui_str': 'Informal care'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0013556', 'cui_str': 'Economics'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0086542', 'cui_str': 'Leisure'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}]",,0.0284831,"The average cost per patient during the monitoring period studied was 13.17% lower in the RM group than in the CM group, and these differences were not statistically significant ( p = 0.35).","[{'ForeName': 'Cesar', 'Initials': 'C', 'LastName': 'Leal-Costa', 'Affiliation': 'Nursing Department, University of Murcia, 30003 Murcia, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Lopez-Villegas', 'Affiliation': 'Social Involvement of Critical and Emergency Medicine, CTS-609 Research Group, Hospital de Poniente, 04700 El Ejido-Almería, Spain.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Catalan-Matamoros', 'Affiliation': 'Department of Journalism and Communication, Universidad Carlos III de Madrid, 28903 Madrid, Spain.'}, {'ForeName': 'Emilio', 'Initials': 'E', 'LastName': 'Robles-Musso', 'Affiliation': 'Intensive Care Unit, Hospital de Poniente, 04700 El Ejido-Almería, Spain.'}, {'ForeName': 'Knut Tore', 'Initials': 'KT', 'LastName': 'Lappegård', 'Affiliation': 'Institute of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, 9019 Tromsø, Norway.'}, {'ForeName': 'Rafael Jesus', 'Initials': 'RJ', 'LastName': 'Bautista-Mesa', 'Affiliation': 'Management Unit, Hospital de Poniente, 04700 El Ejido-Almería, Spain.'}, {'ForeName': 'Salvador', 'Initials': 'S', 'LastName': 'Peiró', 'Affiliation': 'Health Services Research Unit, FISABIO-PUBLIC HEALTH, 46020 Valencia, Spain.'}, {'ForeName': 'Remedios', 'Initials': 'R', 'LastName': 'Lopez-Liria', 'Affiliation': 'Department of Nursing Science, Physiotherapy and Medicine, Hum-498 Research Team, Health Research Centre, University of Almería, 04120 El Ejido-Almería, Spain.'}]","Healthcare (Basel, Switzerland)",['10.3390/healthcare8020175'] 1582,32560256,Gait Event Detection for Stroke Patients during Robot-Assisted Gait Training.,"Functional electrical stimulation and robot-assisted gait training are techniques which are used in a clinical routine to enhance the rehabilitation process of stroke patients. By combining these technologies, therapy effects could be further improved and the rehabilitation process can be supported. In order to combine these technologies, a novel algorithm was developed, which aims to extract gait events based on movement data recorded with inertial measurement units. In perspective, the extracted gait events can be used to trigger functional electrical stimulation during robot-assisted gait training. This approach offers the possibility of equipping a broad range of potential robot-assisted gait trainers with functional electrical stimulation. In particular, the aim of this study was to test the robustness of the previously developed algorithm in a clinical setting with patients who suffered a stroke. A total amount of N = 10 stroke patients participated in the study, with written consent. The patients were assigned to two different robot-assisted gait trainers (Lyra and Lokomat) according to their performance level, resulting in five recording sessions for each gait-trainer. A previously developed algorithm was applied and further optimized in order to extract the gait events. A mean detection rate across all patients of 95.8% ± 7.5% for the Lyra and 98.7% ± 2.6% for the Lokomat was achieved. The mean type 1 error across all patients was 1.0% ± 2.0% for the Lyra and 0.9% ± 2.3% for the Lokomat. As a result, the developed algorithm was robust against patient specific movements, and provided promising results for the further development of a technique that can detect gait events during robot-assisted gait training, with the future aim to trigger functional electrical stimulation.",2020,This approach offers the possibility of equipping a broad range of potential robot-assisted gait trainers with functional electrical stimulation.,"['A total amount of N = 10 stroke patients participated in the study, with written consent', 'stroke patients', 'Stroke Patients during Robot-Assisted Gait Training', 'patients who suffered a stroke']","['robot-assisted gait trainers (Lyra and Lokomat', 'Functional electrical stimulation and robot-assisted gait training']",['mean detection rate'],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}]","[{'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0453962', 'cui_str': 'Trainers'}, {'cui': 'C0228287', 'cui_str': 'Structure of hippocampal commissure'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}]",10.0,0.0230811,This approach offers the possibility of equipping a broad range of potential robot-assisted gait trainers with functional electrical stimulation.,"[{'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Schicketmueller', 'Affiliation': 'HASOMED GmbH, Paul-Ecke-Str. 1, 39114 Magdeburg, Germany.'}, {'ForeName': 'Juliane', 'Initials': 'J', 'LastName': 'Lamprecht', 'Affiliation': 'MEDIAN Neurological Rehabilitation Center Magdeburg, Gustav-Ricker-Str. 4, 39120 Magdeburg, Germany.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Hofmann', 'Affiliation': 'HASOMED GmbH, Paul-Ecke-Str. 1, 39114 Magdeburg, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Sailer', 'Affiliation': 'MEDIAN Neurological Rehabilitation Center Magdeburg, Gustav-Ricker-Str. 4, 39120 Magdeburg, Germany.'}, {'ForeName': 'Georg', 'Initials': 'G', 'LastName': 'Rose', 'Affiliation': 'Institute for Medical Engineering and Research Campus STIMULATE, University of Magdeburg, Universitaetsplatz 2, 39106 Magdeburg, Germany.'}]","Sensors (Basel, Switzerland)",['10.3390/s20123399'] 1583,32561426,Recombinant human thrombopoietin in critically ill patients with sepsis-associated thrombocytopenia: A clinical study.,"BACKGROUND Sepsis causes varying degrees of thrombocytopenia that are closely related to the likelihood of patient mortality. This study analysed the effect of recombinant human thrombopoietin (rhTPO) on the platelet count in critically ill patients with sepsis-associated thrombocytopenia and provided a reference for its treatment. MATERIAL/METHODS The study was a retrospective analysis of the clinical data of patients. Patients were divided into an rhTPO group and control group according to rhTPO use during treatment. Demographical and clinical data (age, sex, history of hypertension, diabetes, platelet counts, mortality rate, etc.) of the patients were collected and analysed using statistical software; p < 0.05 was considered statistically significant. RESULTS Of 213 patients, 84 constituted the rhTPO group and 129 constituted the control group. The increase in platelet counts was significantly higher in the rhTPO group than in the control group on the third day (43.01 ± 18.23 × 10 9 /L vs. 36.31 ± 14.17 × 10 9 /L, p = 0.003), fifth day (71.51 ± 39.59 × 10 9 /L vs. 42.95 ± 20.48 × 10 9 /L, p < 0.001) and seventh day (115.36 ± 69.41 × 10 9 /L vs. 62.54 ± 42.70 × 10 9 /L, p < 0.001). Further statistical analysis of the data of patients with platelet counts ≤30 × 10 9 /L and >30 × 10 9 /L and APACHE II scores >15 and ≤15 at the time of diagnosis showed that the increase in platelet counts in the rhTPO group was greater. There was no significant between-group difference in volume of platelet transfusions (rhTPO group 15.42 ± 17.20 vs. control group 10.93 ± 17.48, p = 0.068). The cost of ICU treatment in patients with rhTPO was higher (RMB 126,936.21 ± 86,548.27 vs. 101,685.28 ± 77,291.75, p = 0.027); however, the ICU stay time was shorter (9.20 ± 5.38 vs. 10.88 ± 6.82, p = 0.047). There was no significant difference in 28-day mortality (rhTPO group: 25.0% vs. control group: 34.1%, p = 0.158) between the two groups. CONCLUSION For patients with severe thrombocytopenia or severe sepsis, rhTPO was efficacious in increasing their platelet counts, resulting in a shorter ICU stay time.",2020,The increase in platelet counts was significantly higher in the rhTPO group than in the control group on the third day (43.01±18.23×10 9,"['patients with severe thrombocytopenia or patients with severe sepsis', 'patients with platelet counts', 'critically ill patients with sepsis-associated thrombocytopenia and provided a reference for its treatment', '213 patients', '84 patients constituted the rhTPO group and 129 constituted the control group', 'critically ill patients with sepsis-associated thrombocytopenia', '≤30×10 9']","['recombinant human thrombopoietin (rhTPO', 'Recombinant human thrombopoietin', 'rhTPO']","['ICU stay time', 'platelet counts', 'volume of platelet transfusions', 'cost of ICU treatment', '28-days mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}, {'cui': 'C1719672', 'cui_str': 'Severe Sepsis'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0040052', 'cui_str': 'Thrombopoietin'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0040052', 'cui_str': 'Thrombopoietin'}]","[{'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0086818', 'cui_str': 'Platelet transfusion'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",213.0,0.0258731,The increase in platelet counts was significantly higher in the rhTPO group than in the control group on the third day (43.01±18.23×10 9,"[{'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': ""Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Jin', 'Affiliation': ""Emergency Department, Xi'an Aerospace General Hospital, Xi'an, China.""}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': ""Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ""Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: wangxuejd2008@126.com.""}, {'ForeName': 'Litao', 'Initials': 'L', 'LastName': 'Guo', 'Affiliation': ""Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: glt2002@xjtu.edu.cn.""}]",International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,['10.1016/j.ijid.2020.06.045'] 1584,32561466,A randomized clinical trial of a collaborative home-based diabetes intervention to reduce emergency department visits and hospitalizations in black individuals with diabetes.,"The prevalence of diabetes mellitus (DM) in black individuals (blacks) is twice that of white individuals (whites), and blacks are more likely to have worse glycemic control, less optimal medication regimens, and higher levels of mistrust in the medical system. These three factors account for higher rates of acute medical care use in blacks with DM. To address this disparity, we developed DM I-TEAM (Diabetes Interprofessional Team to Enhance Adherence to Medical Care), a home-based multidisciplinary behavioral intervention that integrates care from a community health worker (CHW), the participant's primary care physician (PCP), a DM nurse educator, and a clinical pharmacist. Treatment is delivered during 9 sessions over 1 year, and includes diabetes education and goal setting, telehealth visits with participants' PCP and a DM nurse educator, and comprehensive medication reviews by a pharmacist. We describe the rationale and methods for a randomized controlled trial to test the efficacy of DM I-TEAM to reduce emergency department (ED) visits and hospitalizations. We are enrolling 200 blacks with DM during an ED visit. Participants are randomized to DM I-TEAM or Usual Medical Care (UMC). Follow-up assessments are conducted at 6 and 12 months. The primary outcome is the number of ED visits and hospitalizations over 12 months, and is measured by participant self-report and medical record review. Secondary outcomes include hemoglobin A1c (HbA1c), number of potentially inappropriate medications (PIMs), and trust in health care.",2020,"The prevalence of diabetes mellitus (DM) in black individuals (blacks) is twice that of white individuals (whites), and blacks are more likely to have worse glycemic control, less optimal medication regimens, and higher levels of mistrust in the medical system.","['200 blacks with DM during an ED visit', 'blacks with DM', 'black individuals (blacks', 'black individuals with diabetes']","['DM I-TEAM', 'collaborative home-based diabetes intervention', 'DM I-TEAM or Usual Medical Care (UMC']","['hemoglobin A1c (HbA1c), number of potentially inappropriate medications (PIMs), and trust in health care', 'emergency department (ED) visits and hospitalizations', 'prevalence of diabetes mellitus (DM', 'number of ED visits and hospitalizations over 12\u202fmonths, and is measured by participant self-report and medical record review']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}]","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0496675', 'cui_str': 'Medical care'}]","[{'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C4042848', 'cui_str': 'PIM List'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0730229', 'cui_str': 'Medical records review'}]",200.0,0.0803291,"The prevalence of diabetes mellitus (DM) in black individuals (blacks) is twice that of white individuals (whites), and blacks are more likely to have worse glycemic control, less optimal medication regimens, and higher levels of mistrust in the medical system.","[{'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Casten', 'Affiliation': 'Department of Psychiatry and Human Behavior, Sidney Kimmel Medical College at Thomas, Jefferson University, United States of America. Electronic address: Robin.Casten@Jefferson.edu.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Rovner', 'Affiliation': 'Departments of Neurology, Psychiatry, and Ophthalmology, Sidney Kimmel Medical College at Thomas Jefferson University, United States of America.'}, {'ForeName': 'Anna Marie', 'Initials': 'AM', 'LastName': 'Chang', 'Affiliation': 'Department of Emergency Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, United States of America.'}, {'ForeName': 'Judd E', 'Initials': 'JE', 'LastName': 'Hollander', 'Affiliation': 'Department of Emergency Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, United States of America.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Kelley', 'Affiliation': 'Department of Neurology, Sidney Kimmel Medical College at Thomas Jefferson University, United States of America.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Leiby', 'Affiliation': 'Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College at Thomas Jefferson University, United States of America.'}, {'ForeName': 'Ginah', 'Initials': 'G', 'LastName': 'Nightingale', 'Affiliation': 'Jefferson College of Pharmacy at Thomas Jefferson University, United States of America.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Pizzi', 'Affiliation': 'Center for Health Outcomes, Policy, and Economics, Ernest Mario School of Pharmacy, Rutgers University, United States of America.'}, {'ForeName': 'Neva', 'Initials': 'N', 'LastName': 'White', 'Affiliation': 'Center for Urban Health, Thomas Jefferson University Hospital, United States of America.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Rising', 'Affiliation': 'Department of Emergency Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106069'] 1585,32561467,A randomized comparison trial of culturally adapted HIV prevention approaches for Native Americans reducing trauma symptoms versus substance misuse: The Healing Seasons protocol.,"Native Americans (NA) experience interrelated risks of trauma exposure, substance use, and HIV risk behaviors that put them at increased risk for HIV infection. Despite these known risk factors, there are very few published randomized trials testing interventions to reduce trauma-related symptoms and substance misuse among NA. METHODS The Healing Seasons study is a randomized comparsion trial of two counseling strategies, Narrative Exposure Therapy (NET) addressing PTSD or Motivational interviewing with cognitive behavioral therapy skills training (MIST) addressing substance misuse as a means to prevent HIV among NA. Using a community-based participatory research approach, we adapted both evidence-based interventions to be specific to the risk contexts and realities of NA and to include psychoeducational and skill-building components that include cultural-specific stories, virtues, and traditional treatment strategies. Participants, 16 years and older, were recruited from a Pacific Northwest tribal community, screened over the phone, enrolled in person, and randomized in equal numbers to NET or MIST. We stratified by age (16-29 years and 30 or older) and gender (male or female identified) to ensure balance between treatment arms. The primary outcomes were number of sex partners and frequency of sexual acts (with and without condoms), sex under the influence of substances, frequency of substance use, and PTSD severity. DISCUSSION Behavioral interventions for NA are needed to prevent HIV risk behaviors when faced with trauma symptoms and substance misuse. This study will provide evidence to determine feasibility and efficacy of addressing related risk factors as part of counseling-based HIV prevention intervention to reduce sexual risk among this population. TRIAL REGISTRATION ClinicalTrials.gov number, NCT03112369, registered April 12, 2017.",2020,"Using a community-based participatory research approach, we adapted both evidence-based interventions to be specific to the risk contexts and realities of NA and to include psychoeducational and skill-building components that include cultural-specific stories, virtues, and traditional treatment strategies.","['Native Americans reducing trauma symptoms versus substance misuse', 'We stratified by age (16-29\u202fyears and 30 or older) and gender (male or female identified', 'Participants, 16\u202fyears and older, were recruited from a Pacific Northwest tribal community, screened over the phone, enrolled in person']","['NET or MIST', 'culturally adapted HIV prevention approaches', 'Narrative Exposure Therapy (NET) addressing PTSD or Motivational interviewing with cognitive behavioral therapy skills training (MIST', 'counseling-based HIV prevention intervention']","['number of sex partners and frequency of sexual acts (with and without condoms), sex under the influence of substances, frequency of substance use, and PTSD severity', 'HIV risk behaviors']","[{'cui': 'C0282204', 'cui_str': 'Native Americans'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030170', 'cui_str': 'Pacific Northwest'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C1135957', 'cui_str': 'Narration'}, {'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0036911', 'cui_str': 'Sexual partners'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0086931', 'cui_str': 'Risk Behavior'}]",,0.0757073,"Using a community-based participatory research approach, we adapted both evidence-based interventions to be specific to the risk contexts and realities of NA and to include psychoeducational and skill-building components that include cultural-specific stories, virtues, and traditional treatment strategies.","[{'ForeName': 'C R', 'Initials': 'CR', 'LastName': 'Pearson', 'Affiliation': 'Indigenous Wellness Research Institute, School of Social Work, University of Washington, Seattle, WA, USA. Electronic address: pearsonc@uw.edu.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Kaysen', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Huh', 'Affiliation': 'Indigenous Wellness Research Institute, School of Social Work, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bedard-Gillgan', 'Affiliation': 'Department of Psychiatry, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Walker', 'Affiliation': 'Innovative Programs Research Group, School of Social Work, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Marin', 'Affiliation': 'Indigenous Wellness Research Institute, School of Social Work, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Saluskin', 'Affiliation': 'Yakama Nation Behavioral Health Services, Toppenish, WA, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106070'] 1586,32559602,Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2.,"OBJECTIVE To assess the efficacy of vilaprisan compared with placebo in the management of the symptoms of uterine fibroids (UF), with a secondary objective to provide a descriptive comparison with ulipristal acetate. STUDY DESIGN The randomized, parallel-group, double-blind, placebo- and active-controlled, multicenter ASTEROID 2 trial assessed the efficacy and safety of vilaprisan versus placebo and ulipristal acetate for two 12-week treatment periods in women with ≥1 UF experiencing heavy menstrual bleeding (HMB). The primary endpoint compared the efficacy of vilaprisan with placebo at 12 weeks, assessed as the absence of bleeding/spotting by bleeding diary. Secondary endpoints compared the efficacy of vilaprisan with ulipristal acetate. Results of the first 12-week treatment period are reported here. RESULTS Women (mean age 42.5 years) were enrolled from 1 June 2015. At baseline, mean menstrual blood loss per 28 days was 214.1 mL and the volume of the three largest UF was 106.2 mL. In total, 155 women completed the initial 12-week treatment period. Complete absence of bleeding/spotting until the end of the 12-week treatment period was achieved by 62.9 % of women receiving vilaprisan versus 0.0 % with placebo (p < .001); 55.4 % of women treated with ulipristal acetate reported absence of bleeding/spotting. The predefined HMB response (<80 mL and >50 % reduction from baseline during the last 28 days of treatment) was observed in 95.7 % of subjects treated with vilaprisan and 86.5 % of subjects treated with ulipristal acetate. Vilaprisan and ulipristal acetate treatment reduced the sum of the volume of the three largest UF by 29.9 % and 23.8 %, respectively, whereas an increase of 6.3 % was observed in the placebo group. No safety concerns, including multiple laboratory parameters, were identified. CONCLUSION Daily administration of vilaprisan 2 mg induced amenorrhea, controlled bleeding, decreased UF size, and was well tolerated in women with HMB associated with UF. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov number: NCT02465814 https://clinicaltrials.gov/ct2/show/NCT02465814.",2020,"Vilaprisan and ulipristal acetate treatment reduced the sum of the volume of the three largest UF by 29.9 % and 23.8 %, respectively, whereas an increase of 6.3 % was observed in the placebo group.","['women with ≥1 UF experiencing heavy menstrual bleeding (HMB', 'women with uterine fibroids', 'Women (mean age 42.5 years) were enrolled from 1 June 2015', '155 women completed the initial 12-week treatment period']","['Vilaprisan and ulipristal acetate', 'ulipristal acetate', 'vilaprisan versus placebo and ulipristal acetate', 'vilaprisan', 'placebo']","['mean menstrual blood loss', 'HMB response', 'Efficacy and safety', 'absence of bleeding/spotting by bleeding diary', 'Complete absence of bleeding/spotting', 'efficacy and safety', 'amenorrhea, controlled bleeding, decreased UF size', 'efficacy of vilaprisan', 'efficacy of vilaprisan with ulipristal acetate', 'absence of bleeding/spotting']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042133', 'cui_str': 'Leiomyoma'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0025323', 'cui_str': 'Menorrhagia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C4508937', 'cui_str': 'vilaprisan'}, {'cui': 'C2723461', 'cui_str': 'Ulipristal acetate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0694689', 'cui_str': 'Menstrual blood'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0002453', 'cui_str': 'Amenorrhea'}, {'cui': 'C0149533', 'cui_str': 'Control of hemorrhage'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0042133', 'cui_str': 'Leiomyoma'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C4508937', 'cui_str': 'vilaprisan'}, {'cui': 'C2723461', 'cui_str': 'Ulipristal acetate'}]",155.0,0.413833,"Vilaprisan and ulipristal acetate treatment reduced the sum of the volume of the three largest UF by 29.9 % and 23.8 %, respectively, whereas an increase of 6.3 % was observed in the placebo group.","[{'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Gemzell-Danielsson', 'Affiliation': ""Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet, and Karolinska University Hospital, S-171 76, Stockholm, Sweden. Electronic address: Kristina.Gemzell@ki.se.""}, {'ForeName': 'Oskari', 'Initials': 'O', 'LastName': 'Heikinheimo', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, PO Box 140, 00029-HUS, Helsinki, Finland. Electronic address: oskari.heikinheimo@helsinki.fi.'}, {'ForeName': 'Janos', 'Initials': 'J', 'LastName': 'Zatik', 'Affiliation': 'Szent Anna Szuleszeti, Nogyogyaszati es Ultrahang Magan Rendelo, 48 Szent Anna utca, Debrecen, Hungary. Electronic address: jzatik@yahoo.com.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Poka', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Debrecen, Nagyerdei krt. 98, 4032, Debrecen, Hungary. Electronic address: pokar@med.unideb.hu.'}, {'ForeName': 'Tomasz', 'Initials': 'T', 'LastName': 'Rechberger', 'Affiliation': 'II Department of Gynecology, Medical University of Lublin, Racławickie 1 Street, 20-059, Lublin, Poland. Electronic address: rechbergt@yahoo.com.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Hudecek', 'Affiliation': 'Department of Obstetrics and Gynecology, Brno University Hospital and Masaryk University Medical School, Jihlavská 20, CZ - 625 00, Brno, Czech Republic. Electronic address: hudecek.robert@fnbrno.cz.'}, {'ForeName': 'Kathrin', 'Initials': 'K', 'LastName': 'Petersdorf', 'Affiliation': 'Bayer AG, Müllerstraße 178, 13342, Berlin, Germany. Electronic address: Kathrin.petersdorf@bayer.com.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Ramirez', 'Affiliation': 'Syneos Health, Frankfurter StraBe 233 Triforum, Haus C1 Neu-Isenburg, 63263, Germany. Electronic address: francisco.ramirez1.ext@bayer.com.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Faustmann', 'Affiliation': 'Bayer AG, Müllerstraße 178, 13342, Berlin, Germany. Electronic address: thomas.faustmann@bayer.com.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Groettrup-Wolfers', 'Affiliation': 'Bayer AG, Müllerstraße 178, 13342, Berlin, Germany. Electronic address: Esther.groettrup-wolfers@bayer.com.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Seitz', 'Affiliation': 'Bayer AG, Müllerstraße 178, 13342, Berlin, Germany. Electronic address: Christian.seitz@bayer.com.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.05.043'] 1587,32559644,Compensation of stochastic time-continuous perturbations during walking in healthy young adults: An analysis of the structure of gait variability.,"BACKGROUND During everyday locomotion, we cope with various internal or external perturbations (e.g. uneven surface). Uncertainty exists on how unpredictable external perturbations increase noise within the motor system and if they are compensated by employing covariation of the limb joints or rather due to decreased sensitivity of an altered posture. RESEARCH QUESTION Do continuous stochastic perturbations affect the structure of gait variability in young and healthy adults? METHODS In a cross-over study, gait kinematics of 21 healthy young sports students were registered during treadmill walking with and without continuous stochastic perturbations. Using the TNC method, the following aspects were analyzed: (a) the sensitivity of body posture to perturbations ('tolerance') decreasing gait variability, (b) the unstructured motor 'noise' increasing gait variability and (c) the amount of 'covariation' of the limb joints. RESULTS Compared to normal walking, gait variability was significantly increased (p < .001) during walking with perturbations. The negative effect of noise was partly compensated by improved 'covariation' of leg joints (p < .001). The aspect 'tolerance' had a small effect on increasing gait variability during stance phase (p < .001) and decreasing gait variability during swing phase (p < .001). SIGNIFICANCE Increased motor noise due to external perturbations is partly compensated by improved covariation of the limb joints. However, the effect of an altered posture slightly affects gait variability. Further studies should focus on different populations (e.g. older participants) to see if they use the same mechanism (improved covariation) to compensate for stochastic perturbations.",2020,"The aspect 'tolerance' had a small effect on increasing gait variability during stance phase (p < .001) and decreasing gait variability during swing phase (p < .001). ","['young and healthy adults', '21 healthy young sports students', 'healthy young adults']",['treadmill walking with and without continuous stochastic perturbations'],"[""sensitivity of body posture to perturbations ('tolerance') decreasing gait variability, (b) the unstructured motor 'noise' increasing gait variability and (c) the amount of 'covariation' of the limb joints"", 'gait variability', 'normal walking, gait variability', ""covariation' of leg joints""]","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}]","[{'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C1262869', 'cui_str': 'Body position'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}]",21.0,0.0319459,"The aspect 'tolerance' had a small effect on increasing gait variability during stance phase (p < .001) and decreasing gait variability during swing phase (p < .001). ","[{'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Koch', 'Affiliation': 'Institute of Sports Science, Friedrich Schiller University of Jena, Jena, Germany. Electronic address: mq.koch@gmx.de.'}, {'ForeName': 'Nils', 'Initials': 'N', 'LastName': 'Eckardt', 'Affiliation': 'Department of Sport and Movement Science, Institute of Sport Science, Carl von Ossietzky University of Oldenburg, Oldenburg, Germany; Department for Exercise & Health, Institute of Sport Science, Leibniz University Hannover, Hannover, Germany. Electronic address: nils.eckardt@uni-oldenburg.de.'}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Zech', 'Affiliation': 'Institute of Sports Science, Friedrich Schiller University of Jena, Jena, Germany. Electronic address: astrid.zech@uni-jena.de.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Hamacher', 'Affiliation': 'Institute of Sports Science, Friedrich Schiller University of Jena, Jena, Germany. Electronic address: daniel.hamacher@uni-jena.de.'}]",Gait & posture,['10.1016/j.gaitpost.2020.05.040'] 1588,32560099,Temperament and Character Profile and Its Clinical Correlates in Male Patients with Dual Schizophrenia.,"Personality traits are relevant in understanding substance use disorders (SUD) and schizophrenia (SZ), but few works have also included patients with dual schizophrenia (SZ+) and personality traits. We explored personality profile in a sample of 165 male patients under treatment, using the Temperament and Character Inventory-Revised. The participants were assigned to three groups of 55 patients each, according to previous diagnosis: SUD, SZ- and SZ+ (without/with SUD). We analyzed their clinical characteristics, relating them to personality dimensions. The SUD and SZ+ groups scored higher than SZ- in Novelty/Sensation Seeking. SZ- and SZ+ presented higher Harm Avoidance and lower Persistence than the SUD group. SZ+ patients showed the lowest levels of Self-directedness, while SZ- and SZ+ had higher scores in Self-transcendence than the SUD group. Several clinical characteristics were associated with personality dimensions depending on diagnosis, and remarkably so for psychiatric symptoms in the SZ- and SZ+ groups. The three groups had a maladaptive personality profile compared to general population. Our results point to different profiles for SUD versus SZ, while both profiles appear combined in the SZ+ group, with extreme scores in some traits. Thus, considering personality endophenotypes in SZ+ could help in designing individualized interventions for this group.",2020,"SZ+ patients showed the lowest levels of Self-directedness, while SZ- and SZ+ had higher scores in Self-transcendence than the SUD group.","['patients with dual schizophrenia (SZ+) and personality traits', 'Male Patients with Dual Schizophrenia', '165 male patients under treatment, using the Temperament and Character Inventory-Revised', '55 patients each, according to previous diagnosis']","['SUD, SZ- and SZ', 'SZ', 'SZ- and SZ']","['maladaptive personality profile', 'lowest levels of Self-directedness', 'Self-transcendence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0233849', 'cui_str': 'Character trait finding'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0039474', 'cui_str': 'Temperament'}, {'cui': 'C0007952', 'cui_str': 'Character'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0332132', 'cui_str': 'Prior diagnosis'}]","[{'cui': 'C0038586', 'cui_str': 'Substance use disorder'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}]","[{'cui': 'C0003944', 'cui_str': 'As If Personality'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0036588', 'cui_str': 'Self'}]",165.0,0.0165927,"SZ+ patients showed the lowest levels of Self-directedness, while SZ- and SZ+ had higher scores in Self-transcendence than the SUD group.","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Río-Martínez', 'Affiliation': ""Department of Clinical Psychology and Psychobiology, School of Psychology, University of Barcelona, Passeig de la Vall d'Hebrón 171, 08035 Barcelona, Spain.""}, {'ForeName': 'Julia E', 'Initials': 'JE', 'LastName': 'Marquez-Arrico', 'Affiliation': ""Department of Clinical Psychology and Psychobiology, School of Psychology, University of Barcelona, Passeig de la Vall d'Hebrón 171, 08035 Barcelona, Spain.""}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Prat', 'Affiliation': ""Department of Clinical Psychology and Psychobiology, School of Psychology, University of Barcelona, Passeig de la Vall d'Hebrón 171, 08035 Barcelona, Spain.""}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Adan', 'Affiliation': ""Department of Clinical Psychology and Psychobiology, School of Psychology, University of Barcelona, Passeig de la Vall d'Hebrón 171, 08035 Barcelona, Spain.""}]",Journal of clinical medicine,['10.3390/jcm9061876'] 1589,32560125,"The Effect of Loving-Kindness Meditation on Flight Attendants' Spirituality, Mindfulness and Subjective Well-Being.","Background : This study investigated: (1) the effects of the loving-kindness meditation (LKM) on mindfulness, subjective well-being (SWB), and spirituality and (2) the relationships between mindfulness, spirituality, and SWB. Methods : 98 flight attendants from Xiamen Airlines in China were recruited and randomly assigned to the LKM training group ( n = 49) or the waiting control group ( n = 49). The LKM training group underwent an 8-week LKM training intervention, and the control group did not undergo intervention. The three main variables (SWB, mindfulness, and spirituality) were measured both before (pre-test) and after (post-test) the LKM training intervention. Results : In the experimental group, SWB and spirituality increased significantly. In the control group, no significant differences were observed for the three variables between the pre-test and post-test. Conclusions : Our results indicated that LKM may help to improve SWB and spirituality. However, the mechanisms which underlie the effects of the LKM on mindfulness, spirituality, SWB, and other psychological constructs require further elucidation.",2020,"In the control group, no significant differences were observed for the three variables between the pre-test and post-test. ",['Methods : 98 flight attendants from Xiamen Airlines in China'],"[' ', 'waiting control group', 'LKM', 'loving-kindness meditation (LKM', 'LKM training intervention, and the control group did not undergo intervention', 'LKM training', 'Loving-Kindness Meditation']","['mindfulness, subjective well-being (SWB), and spirituality and (2) the relationships between mindfulness, spirituality, and SWB', 'SWB and spirituality', 'variables (SWB, mindfulness, and spirituality']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024028', 'cui_str': 'Love'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1299585', 'cui_str': 'Does not'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0237104', 'cui_str': 'Spirituality'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0439828', 'cui_str': 'Variable'}]",,0.0166254,"In the control group, no significant differences were observed for the three variables between the pre-test and post-test. ","[{'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'College of Aviation, Hua Qiao University, Xiamen 361021, China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Graduate Institute of Business and Management, Chang Gung University, Taoyuan 33302, Taiwan.'}, {'ForeName': 'Chia-Yi', 'Initials': 'CY', 'LastName': 'Liu', 'Affiliation': 'Department of Psychiatry, Chang Gung Memorial Hospital, Taipei 10507, Taiwan.'}, {'ForeName': 'Rung-Tai', 'Initials': 'RT', 'LastName': 'Lin', 'Affiliation': 'Graduate School of Creative Industry Design, National Taiwan University of Arts, New Taipei 22058, Taiwan.'}, {'ForeName': 'Wen-Ko', 'Initials': 'WK', 'LastName': 'Chiou', 'Affiliation': 'Department of Psychiatry, Chang Gung Memorial Hospital, Taipei 10507, Taiwan.'}]","Healthcare (Basel, Switzerland)",['10.3390/healthcare8020174'] 1590,32562206,Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial.,"BACKGROUND AND OBJECTIVE In patients with atrial fibrillation following percutaneous coronary intervention, if a proton pump inhibitor is used, could that allow the use of warfarin triple therapy, or is there additional reduction in bleeding while using it with dual therapy? METHODS The RE-DUAL PCI trial randomized 2725 patients with atrial fibrillation post-percutaneous coronary intervention to dabigatran dual therapy (110 or 150 mg twice daily, with clopidogrel or ticagrelor) or warfarin triple therapy (with clopidogrel or ticagrelor, and aspirin for 1-3 months). This prespecified subgroup analysis evaluated risks of a first major bleeding event or clinically relevant non-major bleeding event, all gastrointestinal bleeding, and a composite efficacy endpoint of all-cause mortality/thromboembolic event or unplanned revascularization according to baseline use of a proton pump inhibitor. RESULTS Of 2678 analyzed patients, 1641 (61.3%) were receiving a proton pump inhibitor at baseline. Dabigatran 110 and 150 mg dual therapy reduced the risk of major bleeding events or clinically relevant non-major bleeding events vs warfarin triple therapy regardless of proton pump inhibitor use, with comparable risk of the composite efficacy endpoint (all interaction p values > 0.05). For gastrointestinal bleeding, no interaction was observed between study treatment and proton pump inhibitor use (interaction p values 0.84 and 0.62 for dabigatran 110 and 150 mg dual therapy, respectively, vs warfarin triple therapy). CONCLUSIONS Dabigatran 110 and 150 mg dual therapy reduced the risk of major bleeding events or clinically relevant non-major bleeding events vs warfarin triple therapy, regardless of proton pump inhibitor use at baseline, in patients with atrial fibrillation who underwent percutaneous coronary intervention. Risk of the composite efficacy endpoint appeared to be similar for dabigatran dual therapy vs warfarin triple therapy in patients receiving/not receiving a proton pump inhibitor. CLINICALTRIALS. GOV UNIQUE IDENTIFIER NCT02164864.",2020,"Dabigatran 110 and 150 mg dual therapy reduced the risk of major bleeding events or clinically relevant non-major bleeding events vs warfarin triple therapy regardless of proton pump inhibitor use, with comparable risk of the composite efficacy endpoint (all interaction p values > 0.05).","['patients with atrial fibrillation who underwent percutaneous coronary intervention', 'patients receiving/not receiving a proton pump inhibitor', 'Patients with Atrial Fibrillation', 'patients with atrial fibrillation following percutaneous coronary intervention', 'Of 2678 analyzed patients, 1641 (61.3%) were receiving a proton pump inhibitor at baseline', '2725 patients with atrial fibrillation post-percutaneous coronary intervention to']","['warfarin triple therapy', 'dabigatran dual therapy', 'Dabigatran', 'clopidogrel or ticagrelor', 'Proton Pump Inhibitor', 'warfarin triple therapy (with clopidogrel or ticagrelor, and aspirin', 'proton pump inhibitor', 'Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention']","['risk of major bleeding events', 'risks of a first major bleeding event or clinically relevant non-major bleeding event, all gastrointestinal bleeding, and a composite efficacy endpoint of all-cause mortality/thromboembolic event or unplanned revascularization']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0358591', 'cui_str': 'H+/K+-exchanging ATPase inhibitor'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0687676', 'cui_str': 'After values'}]","[{'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C2348066', 'cui_str': 'dabigatran'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0358591', 'cui_str': 'H+/K+-exchanging ATPase inhibitor'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0017181', 'cui_str': 'Gastrointestinal hemorrhage'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}]",2725.0,0.0706981,"Dabigatran 110 and 150 mg dual therapy reduced the risk of major bleeding events or clinically relevant non-major bleeding events vs warfarin triple therapy regardless of proton pump inhibitor use, with comparable risk of the composite efficacy endpoint (all interaction p values > 0.05).","[{'ForeName': 'José C', 'Initials': 'JC', 'LastName': 'Nicolau', 'Affiliation': 'Instituto do Coracao (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Enéas Carvalho Aguiar, 44, Sao Paulo, SP, 05403-000, Brazil. jose.nicolau@incor.usp.br.'}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""Brigham and Women's Hospital and Heart and Vascular Center, and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Stefan H', 'Initials': 'SH', 'LastName': 'Hohnloser', 'Affiliation': 'Johann Wolfgang Goethe University, Frankfurt am Main, Germany.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Kimura', 'Affiliation': 'Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Gregory Y H', 'Initials': 'GYH', 'LastName': 'Lip', 'Affiliation': 'Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, UK.'}, {'ForeName': 'Corinna', 'Initials': 'C', 'LastName': 'Miede', 'Affiliation': 'Mainanalytics ma GmbH, Sulzbach (Taunus), Germany.'}, {'ForeName': 'Matias', 'Initials': 'M', 'LastName': 'Nordaby', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Oldgren', 'Affiliation': 'Uppsala Clinical Research Center, and Department of Medical Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Philippe Gabriel', 'Initials': 'PG', 'LastName': 'Steg', 'Affiliation': 'Université de Paris, FACT, INSERM U_1148, Paris, France.'}, {'ForeName': 'Jurriën M', 'Initials': 'JM', 'LastName': 'Ten Berg', 'Affiliation': 'St. Antonius Ziekenhuis, Nieuwegein, the Netherlands.'}, {'ForeName': 'Lucas C', 'Initials': 'LC', 'LastName': 'Godoy', 'Affiliation': 'Instituto do Coracao (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Enéas Carvalho Aguiar, 44, Sao Paulo, SP, 05403-000, Brazil.'}, {'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Cannon', 'Affiliation': ""Brigham and Women's Hospital and Heart and Vascular Center, and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Drugs,['10.1007/s40265-020-01323-x'] 1591,32562747,Effects of an 8-week resistance training intervention on plantar flexor muscle quality and functional capacity in older women: A randomised controlled trial.,"The present study examined 8 weeks of resistance training and its effects on muscle quality measures, plantar flexor muscle strength, muscle thickness and functional capacity in older women. Moreover, we tested if changes in muscle quality were associated with functional capacity. Twenty-four older women (66.3 ± 5.8 years; 69.0 ± 3.0 kg; 25.3 ± 1.4 kg·m -2 ) were recruited to the study. After completion of the baseline assessment, participants were randomly assigned to either the resistance training (RET, n = 12) or an active control group (CTR, n = 12). Muscle quality was evaluated through muscle echo intensity (MQ EI ) and specific tension (MQ ST ). Muscle thickness, unilateral plantar flexor muscle strength and functional tests were evaluated at baseline and after the training period. After 8 weeks, both MQ EI and MQ ST did not respond to the intervention. Furthermore, significant changes in stair climb performance (P < 0.05) were not associated with plantar flexor-derived muscle quality (P > 0.05). Finally, significant gains in muscle hypertrophy were observed in the RET group (P < 0.01), while muscle strength failed to change significantly (P > 0.05). In conclusion, a resistance training program provided significant benefits in the stair climb test, unrelated to plantar flexor-derived muscle quality measures as previously demonstrated in quadriceps femoris.",2020,"Furthermore, significant changes in stair climb performance (P < 0.05) were not associated with plantar flexor-derived muscle quality (P > 0.05).","['older women', 'Twenty-four older women (66.3\u202f±\u202f5.8\u202fyears; 69.0\u202f±\u202f3.0\u202fkg; 25.3\u202f±\u202f1.4\u202fkg·m -2 ']","['8-week resistance training intervention', 'resistance training (RET, n\u202f=\u202f12) or an active control', 'resistance training']","['stair climb performance', 'Muscle quality', 'plantar flexor-derived muscle quality', 'muscle quality', 'plantar flexor muscle quality and functional capacity', 'Muscle thickness, unilateral plantar flexor muscle strength and functional tests', 'muscle hypertrophy', 'muscle strength', 'muscle echo intensity (MQ EI ) and specific tension (MQ ST ', 'muscle quality measures, plantar flexor muscle strength, muscle thickness and functional capacity']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C4517796', 'cui_str': '5.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517503', 'cui_str': '1.4'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0389252', 'cui_str': 'RET protein, human'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0432601', 'cui_str': 'Stairs climbed'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0236033', 'cui_str': 'Muscle hypertrophy'}, {'cui': 'C0013520', 'cui_str': 'Doppler Echocardiography'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0233494', 'cui_str': 'Tension'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",24.0,0.0161992,"Furthermore, significant changes in stair climb performance (P < 0.05) were not associated with plantar flexor-derived muscle quality (P > 0.05).","[{'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Lopez', 'Affiliation': 'Exercise Medicine Research Institute, Edith Cowan University, Perth, Western Australia, Australia. Electronic address: p.lopezda@our.ecu.edu.au.'}, {'ForeName': 'Brendan James', 'Initials': 'BJ', 'LastName': 'Crosby', 'Affiliation': 'Exercise Medicine Research Institute, Edith Cowan University, Perth, Western Australia, Australia.'}, {'ForeName': 'Bruna Patrícia', 'Initials': 'BP', 'LastName': 'Robetti', 'Affiliation': 'Universidade de Caxias do Sul, Caxias do Sul, Rio Grande do Sul, Brazil.'}, {'ForeName': 'Douglas Jean Preussler', 'Initials': 'DJP', 'LastName': 'Turella', 'Affiliation': 'Centro Clínico UCS, Universidade de Caxias do Sul, Caxias do Sul, Rio Grande do Sul, Brazil.'}, {'ForeName': 'Thaís Andréia Schepa', 'Initials': 'TAS', 'LastName': 'Weber', 'Affiliation': 'Universidade de Caxias do Sul, Caxias do Sul, Rio Grande do Sul, Brazil.'}, {'ForeName': 'Morgana Lima', 'Initials': 'ML', 'LastName': 'de Oliveira', 'Affiliation': 'Universidade de Caxias do Sul, Caxias do Sul, Rio Grande do Sul, Brazil.'}, {'ForeName': 'Anderson', 'Initials': 'A', 'LastName': 'Rech', 'Affiliation': 'Universidade de Caxias do Sul, Caxias do Sul, Rio Grande do Sul, Brazil.'}]",Experimental gerontology,['10.1016/j.exger.2020.111003'] 1592,32562877,Efficacy of Reslizumab Treatment in Exacerbation-Prone Patients with Severe Eosinophilic Asthma.,"BACKGROUND Patients with severe eosinophilic asthma have increased risk of clinical asthma exacerbations (CAEs), impaired lung function, and lower quality of life (QoL) compared with patients with noneosinophilic asthma. The efficacy and safety of intravenous reslizumab have been demonstrated in 2 duplicate, randomized, double-blind, placebo-controlled, phase 3 studies. OBJECTIVE We present findings from post hoc analyses of the subgroup of patients from the phase 3 studies with severe (Global Initiative for Asthma [GINA] Step 4 or 5) eosinophilic asthma who had ≥2 or ≥3 CAEs in the 12 months before screening. METHODS Patients aged ≥12 years with severe eosinophilic asthma were randomized (1:1) to reslizumab 3.0 mg/kg or placebo every 4 weeks for 1 year. Outcomes assessed included CAEs, forced expiratory volume in 1 second (FEV 1 ), and Asthma Control Questionnaire 6 (ACQ-6) and Asthma QoL Questionnaire (AQLQ) scores. RESULTS Of 953 patients randomized, 318 (reslizumab: n = 156; placebo: n = 162) and 164 (reslizumab: n = 72; placebo: n = 92) were GINA 4/5 with ≥2 CAEs in the prior year and ≥3 CAEs in the prior year, respectively. Reslizumab significantly improved CAE rate, time to first CAE, and the proportion of patients who experienced ≥1 CAE versus placebo in both CAE subgroups. Improvements in FEV 1 , ACQ-6 and AQLQ scores, and systemic corticosteroid burden were also observed with reslizumab versus placebo after 52 weeks of treatment in both CAE subgroups. CONCLUSION Reslizumab reduced CAE frequency and improved lung function, asthma control, and QoL versus placebo in patients with severe eosinophilic asthma with a high CAE rate before treatment.",2020,"Improvements in FEV 1 , ACQ-6 and AQLQ scores, and systemic corticosteroid burden were also observed with reslizumab versus placebo after 52 weeks of treatment in both CAE subgroups. ","['exacerbation-prone patients with severe eosinophilic asthma', 'patients with severe eosinophilic asthma with a high CAE rate prior to treatment', '953 patients randomized, 318 (reslizumab: n=156', 'subgroup of patients from the Phase 3 studies with severe (Global Initiative for Asthma Step 4 or 5) eosinophilic asthma who had ≥2 or ≥3 CAEs in the 12 months prior to screening', 'Patients aged ≥12 years with severe eosinophilic asthma', 'Patients with severe eosinophilic asthma', 'patients with non-eosinophilic asthma']","['Reslizumab', 'reslizumab 3.0 mg/kg or placebo', 'reslizumab', 'reslizumab versus placebo', 'placebo']","['CAEs, forced expiratory volume in 1 second (FEV 1 ), and Asthma Control Questionnaire 6 (ACQ-6) and Asthma QoL Questionnaire (AQLQ) scores', 'CAE frequency and improved lung function, asthma control and QoL', 'CAE rate, time to first CAE', 'efficacy and safety', 'FEV 1 , ACQ-6 and AQLQ scores, and systemic corticosteroid burden']","[{'cui': 'C0033422', 'cui_str': 'Prone body position'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0034068', 'cui_str': 'Eosinophilic asthma'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0108844', 'cui_str': 'CDE protocol'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1869620', 'cui_str': 'reslizumab'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0349790', 'cui_str': 'Exacerbation of asthma'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1869620', 'cui_str': 'reslizumab'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0349790', 'cui_str': 'Exacerbation of asthma'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C2919686', 'cui_str': 'Asthma control questionnaire'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0108844', 'cui_str': 'CDE protocol'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}]",953.0,0.216782,"Improvements in FEV 1 , ACQ-6 and AQLQ scores, and systemic corticosteroid burden were also observed with reslizumab versus placebo after 52 weeks of treatment in both CAE subgroups. ","[{'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Wechsler', 'Affiliation': 'Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colo. Electronic address: WechslerM@NJHealth.org.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Hickey', 'Affiliation': 'Teva Branded Pharmaceuticals R&D Inc., West Chester, Pa.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Garin', 'Affiliation': 'Teva Branded Pharmaceuticals R&D Inc., West Chester, Pa.'}, {'ForeName': 'Anoop', 'Initials': 'A', 'LastName': 'Chauhan', 'Affiliation': 'Respiratory Department, Portsmouth Hospitals NHS Trust, Portsmouth, Hampshire, United Kingdom.'}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2020.06.009'] 1593,32567357,Efficacy of shortwave diathermy in ulnar nerve entrapment at the elbow: a double-blind randomized controlled clinical trial.,"OBJECTIVE To investigate the efficacy of shortwave diathermy in treatment of ulnar nerve entrapment at the elbow. DESIGN The study was a double blind, randomized controlled clinical trial. SETTING, PARTICIPANTS A total of 76 adult patients diagnosed with ulnar nerve entrapment at the elbow clinically and electrophysiologically, were randomly assigned into two groups. Patients were evaluated at baseline, after completing treatment and 1 and 3 months after treatment. Physical examination, quick-DASH (disabilities of arm, shoulder, hand) and SF-36 (short form) questionnaires for daily life activities, dynamometer for grip strength, and visual analog scale for pain were used. INTERVENTION A total of 10 sessions of shortwave diathermy were applied to patients in treatment group as five sessions/week, 2 weeks. Control group was given placebo shortwave diathermy. Both groups were given elbow splints and informed to avoid symptom provoking activities. MAIN OUTCOME MEASURES Visual analog scale, grip strength, SF-36, and quick-DASH results. RESULTS Out of 76 patients, 61 of them completed the study where n  = 31 for treatment group and n  = 30 for control group. Mean age was 46.18 ± 13.45 years. There were 32 (52.5%) women and 29 (47.5%) men. The p values between groups 3 months after intervention for visual analog scale, quick-DASH, SF-36 questionnaire, and dynamometer were 0.669, 0.277, 0.604, and 0.126, respectively ( p  > 0.05). CONCLUSION Application of shortwave diathermy to patients with ulnar nerve neuropathy at the elbow was not associated with any difference in outcome.",2020,"The p values between groups 3 months after intervention for visual analog scale, quick-DASH, SF-36 questionnaire, and dynamometer were 0.669, 0.277, 0.604, and 0.126, respectively ( p  > 0.05). ","['A total of 76 adult patients diagnosed with ulnar nerve entrapment at the elbow clinically and electrophysiologically', '76 patients, 61 of them completed the study where n \u2009=\u200931 for treatment group and n \u2009=\u200930 for control group', 'Mean age was 46.18\u2009±\u200913.45\u2009years', 'ulnar nerve entrapment at the elbow']","['shortwave diathermy', 'placebo shortwave diathermy', 'elbow splints']","['Physical examination, quick-DASH (disabilities of arm, shoulder, hand) and SF-36 (short form) questionnaires for daily life activities, dynamometer for grip strength, and visual analog scale for pain', 'visual analog scale, quick-DASH, SF-36 questionnaire, and dynamometer', 'Visual analog scale, grip strength, SF-36, and quick-DASH results']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0751658', 'cui_str': 'Ulnar nerve entrapment'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0012002', 'cui_str': 'Diathermy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0038009', 'cui_str': 'Splint'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C1997924', 'cui_str': 'Disability of arm'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0180572', 'cui_str': 'Dynamometer'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0678226', 'cui_str': 'Due to'}]",76.0,0.139331,"The p values between groups 3 months after intervention for visual analog scale, quick-DASH, SF-36 questionnaire, and dynamometer were 0.669, 0.277, 0.604, and 0.126, respectively ( p  > 0.05). ","[{'ForeName': 'Naciye', 'Initials': 'N', 'LastName': 'Bilgin Badur', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Sureyyapasa Chest Diseases and Thoracic Surgery Education and Training Hospital, Istanbul, Turkey.'}, {'ForeName': 'Feyza', 'Initials': 'F', 'LastName': 'Unlu Ozkan', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Istanbul Fatih Sultan Mehmet Education and Training Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ilknur', 'Initials': 'I', 'LastName': 'Aktas', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Istanbul Fatih Sultan Mehmet Education and Training Hospital, Istanbul, Turkey.'}]",Clinical rehabilitation,['10.1177/0269215520930062'] 1594,32683460,Kirschner wire versus Herbert screw fixation for the treatment of unstable scaphoid waist fracture nonunion using corticocancellous iliac bone graft: randomized clinical trial.,"PURPOSE The study compared the impact of the Kirschner wires versus Herbert screw fixation on the rate of union, time to union, correction of deformity, and clinical outcome in adults with unstable scaphoid waist fracture nonunions without avascular necrosis. METHODS We prospectively randomized 122 patients to undergo corticocancellous iliac bone grafting and internal fixation either with multiple Kirschner wires or Herbert screw. Radiographs, clinical outcome measures (pain, range of motion, and grip strength), and the Quick DASH score were taken pre- and post-operatively. RESULTS The rate of the scaphoid union in the Kirschner wire group was 91% versus 88% in the Herbert group. No difference was detected between the two groups with respect to the time to union, deformity correction, pain analysis, range of motion, grip strength, return to work, and complications. CONCLUSION Using of multiple Kirschner wires as a fixation method for unstable scaphoid waist fracture nonunion that was treated by open reduction and corticocancellous iliac bone grafting had a shorter operative time and lower cost as compared with the Herbert screw fixation. Herbert screw fixation was technically more demanding in terms of technique than K-wires. However, because of easy application of Kirschner wires, and low cost, especially in developing countries, it may be a good alternative to Herbert screw.",2020,"No difference was detected between the two groups with respect to the time to union, deformity correction, pain analysis, range of motion, grip strength, return to work, and complications. ","['unstable scaphoid waist fracture nonunion using corticocancellous iliac bone graft', 'adults with unstable scaphoid waist fracture nonunions without avascular necrosis', '122 patients to undergo']","['multiple Kirschner wires', 'Herbert screw fixation', 'corticocancellous iliac bone grafting and internal fixation either with multiple Kirschner wires or Herbert screw', 'Kirschner wires versus Herbert screw fixation', 'Kirschner wire versus Herbert screw fixation']","['Radiographs, clinical outcome measures (pain, range of motion, and grip strength), and the Quick DASH score', 'rate of the scaphoid union', 'rate of union, time to union, correction of deformity, and clinical outcome', 'time to union, deformity correction, pain analysis, range of motion, grip strength, return to work, and complications']","[{'cui': 'C0443343', 'cui_str': 'Unstable status'}, {'cui': 'C0448063', 'cui_str': 'Entire waist of scaphoid bone'}, {'cui': 'C0016665', 'cui_str': 'Fracture, ununited'}, {'cui': 'C0020889', 'cui_str': 'Bone structure of ilium'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0027543', 'cui_str': 'Avascular necrosis of bone'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0086510', 'cui_str': 'K-wire'}, {'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0020889', 'cui_str': 'Bone structure of ilium'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}]","[{'cui': 'C1306645', 'cui_str': 'Plain radiography'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0223724', 'cui_str': 'Bone structure of scaphoid'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0425105', 'cui_str': 'Returned to work'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",122.0,0.0353334,"No difference was detected between the two groups with respect to the time to union, deformity correction, pain analysis, range of motion, grip strength, return to work, and complications. ","[{'ForeName': 'Galal', 'Initials': 'G', 'LastName': 'Hegazy', 'Affiliation': 'Orthopedic Department, Faculty of Medicine, AL-Azhar University, Nasr City, Cairo, 11884, Egypt. glalhegazy@azhar.edu.eg.'}, {'ForeName': 'Ehab', 'Initials': 'E', 'LastName': 'Alshal', 'Affiliation': 'Orthopedic Department, Faculty of Medicine, AL-Azhar University, Assiut, 71524, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Abdelaal', 'Affiliation': 'Orthopedic Department, Faculty of Medicine, AL-Azhar University, Nasr City, Cairo, 11884, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Abdelaziz', 'Affiliation': 'Orthopedic Department, Faculty of Medicine, AL-Azhar University, Nasr City, Cairo, 11884, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Moawad', 'Affiliation': 'Orthopedic Department, Faculty of Medicine, AL-Azhar University, Nasr City, Cairo, 11884, Egypt.'}, {'ForeName': 'Yasser M', 'Initials': 'YM', 'LastName': 'Saqr', 'Affiliation': 'Orthopedic Department, Faculty of Medicine, Port Said University, Port Said, 11884, Egypt.'}, {'ForeName': 'Ibrahem', 'Initials': 'I', 'LastName': 'El-Sebaey', 'Affiliation': 'Orthopedic Department, Faculty of Medicine, AL-Azhar University, Nasr City, Cairo, 11884, Egypt.'}, {'ForeName': 'Mokhtar', 'Initials': 'M', 'LastName': 'Abdelazeem', 'Affiliation': 'Orthopedic Department, Faculty of Medicine, AL-Azhar University, Nasr City, Cairo, 11884, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'El-Barody', 'Affiliation': 'Radiodiagnosis Department, South Egypt Cancer Institute, Assiut University, Assiut, 71524, Egypt.'}]",International orthopaedics,['10.1007/s00264-020-04730-7'] 1595,32561662,"Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer.","PURPOSE Invasive lobular carcinoma (ILC) accounts for approximately 5%-15% of all invasive breast cancer cases. Most of the correlations between multigene assays and patient outcome were derived from studies based on patients with invasive ductal carcinoma (IDC) or without distinction between the subtypes. Here, we investigate the prognostic value of EndoPredict (EPclin) in a large cohort of ILCs pooled from three phase III randomized trials (ABCSG-6, ABCSG-8, TransATAC). EXPERIMENTAL DESIGN The primary objective of this analysis was to determine the prognostic value of EPclin for distant recurrence (DR) in years 0-10 in postmenopausal women with ILC. The primary outcome was DR. RESULTS 470 women (17.9%) presented with ILC, 1,944 (73.9%) with IDC, and 216 (8.2%) with other histologic types. EPclin was highly prognostic in women with ILC [HR = 3.32 (2.54-4.34)] and provided more prognostic value than the Clinical Treatment Score [CTS; HR = 2.17 (1.73-2.72)]. 63.4% of women were categorized into the low EPclin risk group and they had a 10-year DR of 4.8% (2.7-8.4) compared with 36.6% of women in the high-risk group with a 10-year DR risk of 26.6% (20.0-35.0). EPclin also provided highly prognostic information in women with node-negative disease [HR = 2.56 (1.63-4.02)] and node-positive disease [HR = 3.70 (2.49-5.50)]. CONCLUSIONS EPclin provided highly significant prognostic value and significant risk stratification for women with ILC. Ten-year DR risk in the EPclin low-risk groups were similar between ILC and IDC. Our results show that EPclin is informative in women with ILC and suggest that it is equally valid in both histologic subtypes.",2020,"CONCLUSIONS EPclin provided highly significant prognostic value and significant risk stratification for women with ILC","['Women with Hormone Receptor Positive, HER2-Negative Invasive Lobular Breast Cancer', 'women with ILC', 'distant recurrence in years 0-10 in postmenopausal women with ILC', 'patients with invasive ductal carcinoma (IDC', '470 women (17.9%) presented with ILC, 1944 (73.9%) with IDC, and 216 (8.2%) had other histological types']","['EndoPredict (EPclin', 'EPclin']","[' 10-year DR risk', '10-year DR risk', '10-year DR', 'node-positive disease', 'distant recurrence (DR']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C4087376', 'cui_str': 'HER2 negative'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0205417', 'cui_str': 'Lobular'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0206692', 'cui_str': 'Lobular carcinoma'}, {'cui': 'C0443203', 'cui_str': 'Distant'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1134719', 'cui_str': 'Infiltrating ductular carcinoma'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C4708905', 'cui_str': '216'}, {'cui': 'C0449574', 'cui_str': 'Histologic type'}]",[],"[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0443203', 'cui_str': 'Distant'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",470.0,0.177538,"CONCLUSIONS EPclin provided highly significant prognostic value and significant risk stratification for women with ILC","[{'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Sestak', 'Affiliation': 'Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University London, London, United Kingdom. i.sestak@qmul.ac.uk.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Filipits', 'Affiliation': 'Medical University of Vienna, Cancer Research Institute, Department for Internal Medicine I and Comprehensive Cancer Centre, Vienna, Austria.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Buus', 'Affiliation': 'The Breast Cancer Now Research Centre, Institute of Cancer, London, United Kingdom.'}, {'ForeName': 'Margaretha', 'Initials': 'M', 'LastName': 'Rudas', 'Affiliation': 'Medical University of Vienna, Cancer Research Institute, Department for Internal Medicine I and Comprehensive Cancer Centre, Vienna, Austria.'}, {'ForeName': 'Marija', 'Initials': 'M', 'LastName': 'Balic', 'Affiliation': 'Department of Internal Medicine, Division of Oncology and Comprehensive Cancer Centre Graz, Medical University of Graz, Graz, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Knauer', 'Affiliation': 'Kantonsspital St. Gallen, St. Gallen, Switzerland.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Kronenwett', 'Affiliation': 'Myriad International GmbH, Cologne, Germany.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Fitzal', 'Affiliation': 'Medical University of Vienna, Department of Surgery and Comprehensive Cancer Centre, Vienna, Austria.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Cuzick', 'Affiliation': 'Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University London, London, United Kingdom.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Gnant', 'Affiliation': 'Medical University of Vienna, Comprehensive Cancer Centre, Vienna, Austria.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Greil', 'Affiliation': 'Department of Internal Medicine III, Oncologic Center, Salzburg Cancer Research Institute, Paracelsus Medical University Salzburg, Salzburg, Austria.'}, {'ForeName': 'Mitch', 'Initials': 'M', 'LastName': 'Dowsett', 'Affiliation': 'The Breast Cancer Now Research Centre, Institute of Cancer, London, United Kingdom.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Dubsky', 'Affiliation': 'Medical University of Vienna, Department of Surgery and Comprehensive Cancer Centre, Vienna, Austria.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-0260'] 1596,32563116,Screening and brief intervention for lower-risk drug use in primary care: A pilot randomized trial.,"AIMS The efficacy of screening and brief intervention for lower-risk drug use is unknown. This pilot study tested the efficacy of two brief interventions (BIs) for drug use compared to no BI in primary care patients with lower-risk drug use identified by screening. METHODS We randomly assigned participants identified by screening with Alcohol Smoking and Substance Involvement Screening Test (ASSIST) drug specific scores of 2 or 3 to: no BI, a brief negotiated interview (BNI), or an adaptation of motivational interviewing (MOTIV). Primary outcome was number of days use of main drug in the past 30 as determined by validated calendar method at 6 months. Analyses were performed using negative binomial regression adjusted for baseline use and main drug. RESULTS Of 142 eligible adults, 61(43 %) consented and were randomized. Participant characteristics were: mean age 41; 54 % male; 77 % black. Main drug was cannabis 70 %, cocaine 15 %, prescription opioid 10 %; 7% reported injection drug use and mean days use of main drug (of 30) was 3.4. At 6 months, 93 % completed follow-up and adjusted mean days use of main drug were 6.4 (no BI) vs 2.1 (BNI) (incidence rate ratio, IRR 0.33[0.15-0.74]) and 2.3 (MOTIV) (IRR 0.36[0.15-0.85]). CONCLUSIONS BI appears to have efficacy for preventing an increase in drug use in primary care patients with lower-risk use identified by screening. These findings raise the potential that less severe patterns of drug use in primary care may be uniquely amenable to brief intervention and warrant replication.",2020,"This pilot study tested the efficacy of two brief interventions (BIs) for drug use compared to no BI in primary care patients with lower-risk drug use identified by screening. ","['Of 142 eligible adults, 61(43 %) consented and were randomized', 'Participant characteristics were: mean age 41; 54 % male; 77 % black', 'lower-risk drug use in primary care', 'primary care patients with lower-risk drug use identified by screening', 'primary care patients with lower-risk use identified by screening']","['brief interventions (BIs', 'screening with Alcohol Smoking and Substance Involvement Screening Test (ASSIST) drug specific scores of 2 or 3 to: no BI, a brief negotiated interview (BNI), or an adaptation of motivational interviewing (MOTIV', 'screening and brief intervention']",['number of days use of main drug in the past 30 as determined by validated calendar method'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0449889', 'cui_str': 'Drug used'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0871311', 'cui_str': 'Screening test'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0680727', 'cui_str': 'Mediation'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0035513', 'cui_str': 'Contraceptive rhythm method'}]",142.0,0.0558587,"This pilot study tested the efficacy of two brief interventions (BIs) for drug use compared to no BI in primary care patients with lower-risk drug use identified by screening. ","[{'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Bertholet', 'Affiliation': 'Addiction Medicine, Department of Psychiatry, Lausanne University Hospital and University of Lausanne, Bugnon 23A, Lausanne, 1011, Switzerland. Electronic address: Nicolas.Bertholet@chuv.ch.'}, {'ForeName': 'Seville', 'Initials': 'S', 'LastName': 'Meli', 'Affiliation': 'Upstream USA, Cambridge, MA 02140, USA.'}, {'ForeName': 'Tibor P', 'Initials': 'TP', 'LastName': 'Palfai', 'Affiliation': 'Department of Psychology, Boston University, 900 Commonwealth Avenue, Boston, MA 02215, USA. Electronic address: palfai@bu.edu.'}, {'ForeName': 'Debbie M', 'Initials': 'DM', 'LastName': 'Cheng', 'Affiliation': 'Department of Biostatistics, Boston University School of Public Health, Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, and the Grayken Center for Addiction, Boston Medical Center and Boston University School of Medicine, Boston, MA 02118, USA. Electronic address: dmcheng@bu.edu.'}, {'ForeName': 'Daniel P', 'Initials': 'DP', 'LastName': 'Alford', 'Affiliation': 'Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, and the Grayken Center for Addiction, Boston Medical Center and Boston University School of Medicine, Boston, MA 02118, USA. Electronic address: Dan.Alford@bmc.org.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Bernstein', 'Affiliation': 'Department of Community Health Sciences, Boston University School of Public Health, Boston, MA 02118, USA. Electronic address: jbernste@bu.edu.'}, {'ForeName': 'Jeffrey H', 'Initials': 'JH', 'LastName': 'Samet', 'Affiliation': 'Department of Community Health Sciences, Boston University School of Public Health, Boston, MA, USA, and Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, and the Grayken Center for Addiction, Boston Medical Center and Boston University School of Medicine, Boston, MA 02118, USA. Electronic address: jsamet@bu.edu.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Lloyd-Travaglini', 'Affiliation': 'Data Coordinating Center, Boston University School of Public Health, Boston, MA 02118, USA. Electronic address: clloyd@bu.edu.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Saitz', 'Affiliation': 'Department of Community Health Sciences, Boston University School of Public Health, Boston, MA, USA, and Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, and the Grayken Center for Addiction, Boston Medical Center and Boston University School of Medicine, Boston, MA 02118, USA. Electronic address: rsaitz@bu.edu.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108001'] 1597,32563171,Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy.,"PURPOSE This post hoc analysis assessed the effects of adjunctive perampanel on myoclonic and absence seizure outcomes in patients (aged ≥12 years) with idiopathic generalized epilepsy (IGE) and generalized tonic-clonic seizures during the double-blind (up to 8 mg/day) and open-label extension (OLEx; up to 12 mg/day) phases of Study 332. METHODS Patients experiencing myoclonic and/or absence seizures during study baseline were included. Assessments for myoclonic and absence seizures included: median percent change in seizure frequency, number of seizure days and seizure-free days (all per 28 days), 50 % and 75 % responder rates, seizure-freedom rates, seizure worsening, and monitoring of treatment-emergent adverse events (TEAEs). RESULTS During the double-blind phase, myoclonic and/or absence seizures were reported in 47/163 and 60/163 patients, respectively. Median percent reductions in seizure frequency per 28 days from study baseline were 52.5% and 24.5% (myoclonic seizures) and 7.6 % and 41.2 % (absence seizures) for placebo and perampanel, respectively; seizure-freedom rates were 13.0 % and 16.7 % (myoclonic seizures) and 12.1 % and 22.2 % (absence seizures), respectively. During the OLEx phase, 46/138 and 52/138 patients experienced myoclonic and/or absence seizures, respectively. Responses during the double-blind phase were maintained during long-term (>104 weeks) adjunctive perampanel treatment. The frequency/type of TEAEs was consistent with the known safety profile of perampanel. CONCLUSION In this post hoc analysis, adjunctive perampanel was not associated with any overall worsening of absence seizures. Further research is needed to investigate the effect of adjunctive perampanel in IGE patients with myoclonic and/or absence seizures.",2020,"In this post hoc analysis, adjunctive perampanel was not associated with any overall worsening of absence seizures.","['and myoclonic and absence seizures', 'patients (aged ≥12 years) with idiopathic generalized epilepsy (IGE) and generalized tonic-clonic seizures during the double-blind (up to 8 mg/day) and open-label extension (OLEx; up to 12 mg/day) phases of Study 332', 'Patients experiencing myoclonic and/or absence seizures during study baseline were included', 'patients with idiopathic generalized epilepsy', 'IGE patients with myoclonic and/or absence seizures']","['Adjunctive perampanel', 'adjunctive perampanel', 'placebo']","['responder rates, seizure-freedom rates, seizure worsening, and monitoring of treatment-emergent adverse events (TEAEs', 'seizure frequency', 'overall worsening of absence seizures', 'myoclonic and/or absence seizures', 'seizure frequency, number of seizure days and seizure-free days', 'seizure-freedom rates', 'myoclonic and absence seizure outcomes']","[{'cui': 'C0014553', 'cui_str': 'Absence seizure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0270850', 'cui_str': 'Idiopathic generalized epilepsy'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0494475', 'cui_str': 'Tonic-clonic seizure'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C2698764', 'cui_str': 'perampanel'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0149775', 'cui_str': 'Fit frequency'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0014553', 'cui_str': 'Absence seizure'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1299590', 'cui_str': 'Seizure free'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.383148,"In this post hoc analysis, adjunctive perampanel was not associated with any overall worsening of absence seizures.","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Brandt', 'Affiliation': 'Bethel Epilepsy Centre, Maraweg 21, 33617, Bielefeld, Germany. Electronic address: Christian.Brandt@mara.de.'}, {'ForeName': 'Robert T', 'Initials': 'RT', 'LastName': 'Wechsler', 'Affiliation': 'Idaho Comprehensive Epilepsy Center, 1499 West Hays St., Boise, ID, 83702, USA. Electronic address: rtw@idahoepilepsy.com.'}, {'ForeName': 'Terence J', 'Initials': 'TJ', 'LastName': ""O'Brien"", 'Affiliation': 'The Department of Neuroscience, The Central Clinical School, Monash University, The Alfred Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia; The Departments of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Grattan St., Parkville, VIC, 3010, Australia. Electronic address: terence.obrien@monash.edu.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Patten', 'Affiliation': 'Eisai Ltd., Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK. Electronic address: Anna_Patten@eisai.net.'}, {'ForeName': 'Manoj', 'Initials': 'M', 'LastName': 'Malhotra', 'Affiliation': 'Eisai Inc., 100 Tice Blvd, Woodcliff Lake, NJ, 07677, USA. Electronic address: Manoj_Malhotra@eisai.com.'}, {'ForeName': 'Leock Y', 'Initials': 'LY', 'LastName': 'Ngo', 'Affiliation': 'Eisai Inc., 100 Tice Blvd, Woodcliff Lake, NJ, 07677, USA. Electronic address: Stella_Ngo@eisai.com.'}, {'ForeName': 'Bernhard J', 'Initials': 'BJ', 'LastName': 'Steinhoff', 'Affiliation': 'Kork Epilepsy Centre, Landstraße 1, 77694, Kehl-Kork, Germany. Electronic address: BSteinhoff@epilepsiezentrum.de.'}]",Seizure,['10.1016/j.seizure.2020.06.011'] 1598,32564058,Pregnancy outcomes of women conceiving on antiretroviral therapy (ART) compared to those commenced on ART during pregnancy.,"BACKGROUND Globally, the number of HIV-infected women of child-bearing age conceiving on ART is increasing. Evidence of ART safety at conception and during pregnancy and adverse pregnancy outcomes remains conflicting. The PROMISE 1077 breastfeeding (BF) and formula feeding (FF) international multisite trials provide an opportunity to examine the impact of ART at conception on pregnancy outcomes with subsequent pregnancies. METHODS The PROMISE 1077BF/1077FF trials were designed to address key questions in the management of HIV-infected women who did not meet clinical guidelines for ART treatment during the time of the trials. After the period of risk of mother-to-child transmission was over, women were randomized to either continue or discontinue ART. We compared subsequent pregnancy outcomes of non-breastfeeding women randomized to continue ART following delivery, or breastfeeding women randomized to continue ART following breastfeeding cessation who conceived while on ART to women randomized to discontinue ART, who re-started ART after pregnancy was diagnosed. RESULTS Pregnancy outcomes of 939 subsequent pregnancies of 826 mothers were recorded. The intention-to-treat analyses showed increased incidence of low birth weight (<2500gm) for women who conceived while on ART {relative risk 2.65 (95% CI 1.20, 5.81)}, and also a higher risk of spontaneous abortion, stillbirth, or neonatal death {hazard ratio 1.40 (0.99, 1.98)} compared to women who re-started ART after they were found to be pregnant during trial follow up. CONCLUSIONS We found an increased risk for adverse pregnancy outcomes in women conceiving on ART emphasising the need for improved obstetric and neonatal care for this group.",2020,"The intention-to-treat analyses showed increased incidence of low birth weight (<2500gm) for women who conceived while on ART {relative risk 2.65 (95% CI 1.20, 5.81)}, and also a higher risk of spontaneous abortion, stillbirth, or neonatal death {hazard ratio 1.40 (0.99, 1.98)} compared to women who re-started ART after they were found to be pregnant during trial follow up. ",['939 subsequent pregnancies of 826 mothers'],"['discontinue ART', 'women conceiving on antiretroviral therapy (ART']","['incidence of low birth weight', 'risk of spontaneous abortion, stillbirth, or neonatal death {hazard ratio']","[{'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]","[{'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0410916', 'cui_str': 'Newborn death'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",826.0,0.235655,"The intention-to-treat analyses showed increased incidence of low birth weight (<2500gm) for women who conceived while on ART {relative risk 2.65 (95% CI 1.20, 5.81)}, and also a higher risk of spontaneous abortion, stillbirth, or neonatal death {hazard ratio 1.40 (0.99, 1.98)} compared to women who re-started ART after they were found to be pregnant during trial follow up. ","[{'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Theron', 'Affiliation': 'Department of Obstetrics and Gynaecology, Stellenbosch University, Cape Town, South Africa.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Brummel', 'Affiliation': 'Harvard T. H. Chan School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, USA.'}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Fairlie', 'Affiliation': 'Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Mauricio', 'Initials': 'M', 'LastName': 'Pinilla', 'Affiliation': 'Harvard T. H. Chan School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, USA.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'McCarthy', 'Affiliation': 'FHI 360, Durham, NC, USA.'}, {'ForeName': 'Maxensia', 'Initials': 'M', 'LastName': 'Owor', 'Affiliation': 'MUJHU Research Collaboration, Kampala, Uganda.'}, {'ForeName': 'Lameck', 'Initials': 'L', 'LastName': 'Chinula', 'Affiliation': 'UNC Project-Malawi CRS; University of North Carolina at Chapel Hill, Department of Obstetrics and Gynaecology, Division of Global Women Health, Lilongwe, Malawi.'}, {'ForeName': 'Bonus', 'Initials': 'B', 'LastName': 'Makanani', 'Affiliation': 'College of Medicine-Johns Hopkins Research Project, Blantyre, Malawi.'}, {'ForeName': 'Avy', 'Initials': 'A', 'LastName': 'Violari', 'Affiliation': 'Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Dhayendre', 'Initials': 'D', 'LastName': 'Moodley', 'Affiliation': 'Centre for AIDS Research in South Africa and Department of Obstetrics and Gynecology, School of Clinical Medicine, University of KwaZulu Natal, Durban, South Africa.'}, {'ForeName': 'Nahida', 'Initials': 'N', 'LastName': 'Chakhtoura', 'Affiliation': 'Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Browning', 'Affiliation': 'National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.'}, {'ForeName': 'Risa', 'Initials': 'R', 'LastName': 'Hoffman', 'Affiliation': 'Division of Infectious Diseases , David Geffer School of Medicine at the University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Mary Glenn', 'Initials': 'MG', 'LastName': 'Fowler', 'Affiliation': 'Johns Hopkins University, Department of Pathology, Baltimore, MD, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciaa805'] 1599,32563188,"GnRH agonist and hCG (dual trigger) versus hCG trigger for final follicular maturation: a double-blinded, randomized controlled study.","STUDY QUESTION Does co-administration of GnRH agonist and Human chorionic gonadotropin (hCG; dual trigger) in IVF cycles improve the number of mature oocytes and pregnancy outcome compared to hCG alone? SUMMARY ANSWER Using the dual trigger for final follicular maturation increases the number of oocytes, mature oocytes and number of blastocysts (total and top-quality) compared to triggering with hCG alone. WHAT IS KNOWN ALREADY hCG is used at the end of controlled ovarian hyperstimulation as a surrogate LH surge to induce final oocyte maturation. Recently, based on retrospective studies, the co-administration of GnRH agonist and hCG for final oocyte maturation (dual trigger) has been suggested to improve IVF outcome and pregnancy rates. STUDY DESIGN, SIZE, DURATION A single center, randomized controlled, double-blinded clinical trial between May 2016 and June 2018 analyzed by intention to treat (ITT). PARTICIPANTS/MATERIALS, SETTINGS, METHODS One hundred and fifty-five normal responder patients were randomized either to receive hCG or dual trigger for final oocyte maturation. Data on patients age, BMI, AMH, number of oocytes retrieved, number of metaphase 2 (MII) oocytes, zygotes and blastocysts, clinical pregnancy rate and live birth rate were assessed and compared between the dual trigger group and the hCG group. We performed a planned interim analysis after the recruitment of 50% of the patients. Based on the totality of outcomes at the interim analysis we decided to discontinue further recruitment. MAIN RESULTS AND THE ROLE OF CHANCE One hundred and fifty-five patients were included in the study. The age (36 years versus 35.3 years P = NS), BMI (24 kg/m2 versus 23.7 kg/m2) and the AMH (20.1 pmol/l versus 22.4 pmol/l) were comparable between the two groups. Based on ITT analysis, the number of eggs retrieved (11.1 versus 13.4, P = 0.002), the MII oocytes (8.6 versus 10.3, P = 0.009), total number of blastocysts (2.9 versus 3.9, P = 0.01) and top-quality blastocysts transferred (44.7% versus 64.9%; P = 0.003) were significantly higher in the dual trigger group compared to the hCG group. The clinical pregnancy rate (24.3% versus 46.1%, OR 2.65 (1.43-1.93), P = 0.009) and the live birth rate per transfer (22% versus 36.2%, OR= 1.98 (1.05-3.75), P = 0.03) were significantly higher in the dual trigger group compared to the hCG group. LIMITATIONS, REASONS FOR CAUTION None. WIDER IMPLICATIONS OF THE FINDINGS The enhanced response observed with the dual trigger might lead to better IVF outcomes were it used more widely. STUDY FUNDING/COMPETING INTEREST(S) The study was funded by TRIO Fertility. There are no conflicts of interest to declare. TRIAL REGISTRATION NUMBER ClinicalTrials.gov identifier: NCT02703584. DATE OF TRIAL REGISTRATION March 2016. DATE OF FIRST PATIENT'S ENROLLMENT May 2016.",2020,"Based on ITT analysis, the number of eggs retrieved (11.1 versus 13.4, P = 0.002), the MII oocytes (8.6 versus 10.3, P = 0.009), total number of blastocysts (2.9 versus 3.9, P = 0.01) and top-quality blastocysts transferred (44.7% versus 64.9%; P = 0.003) were significantly higher in the dual trigger group compared to the hCG group.","['One hundred and fifty-five normal responder patients', 'One hundred and fifty-five patients were included in the study', 'May 2016 and June 2018 analyzed by intention to treat (ITT', 'The age (36 years versus 35.3 years P = NS), BMI (24 kg/m2 versus 23.7 kg/m2) and the AMH (20.1 pmol/l versus 22.4 pmol/l']","['GnRH agonist and Human chorionic gonadotropin (hCG', 'hCG', 'GnRH agonist and hCG (dual trigger) versus hCG', 'GnRH agonist and hCG']","['number of oocytes, mature oocytes and number of blastocysts (total and top-quality', 'total number of blastocysts', 'clinical pregnancy rate', 'BMI, AMH, number of oocytes retrieved, number of metaphase 2 (MII) oocytes, zygotes and blastocysts, clinical pregnancy rate and live birth rate', 'IVF outcome and pregnancy rates', 'live birth rate per transfer', 'MII oocytes']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0162874', 'cui_str': 'Amharic language'}, {'cui': 'C0439284', 'cui_str': 'pmol/L'}]","[{'cui': 'C1518041', 'cui_str': 'Gonadotropin releasing hormone analogues'}, {'cui': 'C0428402', 'cui_str': 'Human chorionic gonadotropin measurement'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0032930', 'cui_str': 'Precipitating Factors'}]","[{'cui': 'C0449803', 'cui_str': 'Number of oocytes'}, {'cui': 'C0205286', 'cui_str': 'Mature'}, {'cui': 'C0029045', 'cui_str': 'Oocyte'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1281743', 'cui_str': 'Blastocyst structure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rates'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0162874', 'cui_str': 'Amharic language'}, {'cui': 'C1621812', 'cui_str': 'Metaphase'}, {'cui': 'C0043544', 'cui_str': 'Structure of zygote'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}]",155.0,0.308413,"Based on ITT analysis, the number of eggs retrieved (11.1 versus 13.4, P = 0.002), the MII oocytes (8.6 versus 10.3, P = 0.009), total number of blastocysts (2.9 versus 3.9, P = 0.01) and top-quality blastocysts transferred (44.7% versus 64.9%; P = 0.003) were significantly higher in the dual trigger group compared to the hCG group.","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Haas', 'Affiliation': 'TRIO Fertility, Toronto, ON, Canada.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Bassil', 'Affiliation': 'TRIO Fertility, Toronto, ON, Canada.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Samara', 'Affiliation': 'TRIO Fertility, Toronto, ON, Canada.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Zilberberg', 'Affiliation': 'TRIO Fertility, Toronto, ON, Canada.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Mehta', 'Affiliation': 'TRIO Fertility, Toronto, ON, Canada.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Orvieto', 'Affiliation': 'IVF Unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel-Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'R F', 'Initials': 'RF', 'LastName': 'Casper', 'Affiliation': 'TRIO Fertility, Toronto, ON, Canada.'}]","Human reproduction (Oxford, England)",['10.1093/humrep/deaa107'] 1600,32562573,"Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population.","The platelet endothelial aggregation receptor-1 (PEAR1) rs12041331 variant has been identified as a genetic determinant of platelet aggregation in response to antiplatelet therapies, including aspirin. However, association with atherothrombotic cardiovascular events is less clear, with limited evidence from large trials. Here, we tested association of rs12041331 with cardiovascular events and aspirin use in a randomized trial population of healthy older individuals. We undertook post hoc analysis of 13,547 participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial, median age 74 years. Participants had no previous diagnosis of atherothrombotic cardiovascular disease at enrollment, and were randomized to either 100 mg daily low-dose aspirin or placebo for median 4.7 years follow-up. We used Cox proportional hazard regression to model the relationship between rs12041331 and the ASPREE primary cardiovascular disease (CVD) end point, and composites of major adverse cardiovascular events (MACE) and ischemic stroke (STROKE); and bleeding events; major hemorrhage (MHEM) and intracranial bleeding (ICB). We performed whole-population analysis using additive and dominant inheritance models, then stratified by treatment group. Interaction effects between genotypes and treatment group were examined. We observed no statistically significant association (P < 0.05) in the population, or by treatment group, between rs12041331 and cardiovascular or bleeding events in either model. We also found no significant interaction effects between rs12041331-A and treatment group, for CVD (P = 0.65), MACE (P = 0.32), STROKE (P = 0.56), MHEM (P = 0.59), or ICB (P = 0.56). The genetic variant PEAR1 rs12041331 is not associated with cardiovascular events in response to low-dose aspirin in a healthy elderly population.",2020,The genetic variant PEAR1 rs12041331 is not associated with cardiovascular events in response to low-dose aspirin in a healthy elderly population.,"['healthy older individuals', 'Participants had no previous diagnosis of atherothrombotic cardiovascular disease at enrolment', 'healthy elderly population', 'N=13,547 participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial, median age 74 years']","['aspirin', 'aspirin or placebo']","['cardiovascular disease endpoint (CVD), and composites of major adverse cardiovascular events (MACE) and ischaemic stroke (STROKE); and bleeding events; major hemorrhage (MHEM) and intracranial bleeding (ICB', 'Interaction effects', 'rs12041331 and cardiovascular or bleeding events']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332132', 'cui_str': 'Prior diagnosis'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0151699', 'cui_str': 'Intracranial hemorrhage'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}]",13547.0,0.0373115,The genetic variant PEAR1 rs12041331 is not associated with cardiovascular events in response to low-dose aspirin in a healthy elderly population.,"[{'ForeName': 'Joshua P', 'Initials': 'JP', 'LastName': 'Lewis', 'Affiliation': 'Department of Medicine, Program for Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Moeen', 'Initials': 'M', 'LastName': 'Riaz', 'Affiliation': 'Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Xie', 'Affiliation': 'Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Galina', 'Initials': 'G', 'LastName': 'Polekhina', 'Affiliation': 'Department of Medicine, Program for Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Rory', 'Initials': 'R', 'LastName': 'Wolfe', 'Affiliation': 'Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Nelson', 'Affiliation': 'Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Tonkin', 'Affiliation': 'Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Reid', 'Affiliation': 'Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Murray', 'Affiliation': 'Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute, Hennepin Healthcare, Minneapolis, Minnesota, USA.'}, {'ForeName': 'John J', 'Initials': 'JJ', 'LastName': 'McNeil', 'Affiliation': 'Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Alan R', 'Initials': 'AR', 'LastName': 'Shuldiner', 'Affiliation': 'Department of Medicine, Program for Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Lacaze', 'Affiliation': 'Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}]",Clinical pharmacology and therapeutics,['10.1002/cpt.1959'] 1601,32568464,Effects of Empagliflozin Treatment on Glycerol-Derived Hepatic Gluconeogenesis in Adults with Obesity: A Randomized Clinical Trial.,"OBJECTIVE The aim of this study was to determine the effects of empagliflozin on glycerol-derived hepatic gluconeogenesis in adults with obesity without type 2 diabetes mellitus (T2DM) using oral carbon 13 ( 13 C)-labeled glycerol. METHODS A randomized, double-blind, placebo-controlled trial was performed in participants with magnetic resonance imaging assessment of body fat and measurement of glycerol-derived 13 C enrichment in plasma glucose by nuclear magnetic resonance spectroscopy following ingestion of [U- 13 C 3 ]glycerol. Participants were randomized to oral empagliflozin 10 mg once daily or placebo for 3 months. Glycerol-derived 13 C enrichment studies were repeated, and treatment differences in the mean percentage of 13 C glycerol enrichment in glucose were compared using mixed linear models. RESULTS Thirty-five participants completed the study. Empagliflozin increased glycerol-derived 13 C enrichment between baseline and follow-up by 6.5% (P = 0.005), consistent with less glycerol from visceral adipose tissue (VAT). No difference was found with placebo. Glycerol-derived 13 C enrichment was lower in participants with high VAT compared with low VAT by 12.6% (P = 0.04), but there was no heterogeneity of the treatment effect by baseline VAT. Glycerol-derived 13 C enrichment was inversely correlated with VAT but was not correlated with weight loss. CONCLUSIONS VAT is associated with endogenous glycerol-derived hepatic gluconeogenesis, and empagliflozin reduces endogenous glycerol gluconeogenesis in adults with obesity without T2DM. These findings suggest a mechanism by which sodium-glucose cotransporter 2 inhibitors may prevent T2DM in obesity.",2020,"Empagliflozin increased glycerol-derived 13 C enrichment between baseline and follow-up by 6.5% (P = 0.005), consistent with less glycerol from visceral adipose tissue (VAT).","['Adults with Obesity', 'adults with obesity without type 2 diabetes mellitus (T2DM) using oral carbon 13 ( 13 C)-labeled glycerol', 'Thirty-five participants completed the study', 'adults with obesity without T2DM', 'participants with magnetic resonance imaging assessment of body fat and measurement of']","['empagliflozin', 'glycerol-derived 13 C enrichment in plasma glucose by nuclear magnetic resonance spectroscopy following ingestion of [U- 13 C 3 ]glycerol', 'glycerol-derived hepatic gluconeogenesis', 'oral empagliflozin 10 mg once daily or placebo', 'Empagliflozin', 'placebo']",['weight loss'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C1527415', 'cui_str': 'Oral route'}, {'cui': 'C0729631', 'cui_str': 'Carbon-13'}, {'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]","[{'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C0729631', 'cui_str': 'Carbon-13'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0877853', 'cui_str': 'Spectroscopy, NMR'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0017715', 'cui_str': 'Gluconeogenesis'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3848773', 'cui_str': 'empagliflozin 10 MG [Jardiance]'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}]",35.0,0.48677,"Empagliflozin increased glycerol-derived 13 C enrichment between baseline and follow-up by 6.5% (P = 0.005), consistent with less glycerol from visceral adipose tissue (VAT).","[{'ForeName': 'Ian J', 'Initials': 'IJ', 'LastName': 'Neeland', 'Affiliation': 'Division of Cardiology, University of Texas Medical Center, Dallas, Texas, USA.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'de Albuquerque Rocha', 'Affiliation': 'Division of Cardiology, University of Texas Medical Center, Dallas, Texas, USA.'}, {'ForeName': 'Connor', 'Initials': 'C', 'LastName': 'Hughes', 'Affiliation': 'Division of Cardiology, University of Texas Medical Center, Dallas, Texas, USA.'}, {'ForeName': 'Colby R', 'Initials': 'CR', 'LastName': 'Ayers', 'Affiliation': 'Division of Cardiology, University of Texas Medical Center, Dallas, Texas, USA.'}, {'ForeName': 'Craig R', 'Initials': 'CR', 'LastName': 'Malloy', 'Affiliation': 'Department of Internal Medicine, University of Texas Medical Center, Dallas, Texas, USA.'}, {'ForeName': 'Eunsook S', 'Initials': 'ES', 'LastName': 'Jin', 'Affiliation': 'Department of Internal Medicine, University of Texas Medical Center, Dallas, Texas, USA.'}]","Obesity (Silver Spring, Md.)",['10.1002/oby.22854'] 1602,32564334,Long-Term Cilostazol Treatment and Predictive Factors on Outcomes of Endovascular Intervention in Patients with Diabetes Mellitus and Critical Limb Ischemia.,"INTRODUCTION Despite improvements in endovascular interventions and multidisciplinary approaches, improving clinical outcomes and increasing limb salvage have become increasingly challenging. This prospective study investigated the associations of cilostazol treatment with clinical outcomes and predictive factors in patients with diabetes mellitus (DM) and critical limb ischemia (CLI) after endovascular revascularization of the affected angiosome. METHODS In this study, 172 consecutive patients with CLI (Fontaine levels III-IV) received cilostazol treatment after successful endovascular intervention according to the angiosome concept, and their primary patency rates and cardiovascular and amputation events during a 24-month follow-up period were assessed. RESULT The 24-month primary patency rate, mortality rate, and amputation rate were better in the patients under long-term cilostazol treatment (P < 0.001, P = 0.029, and P = 0.014). Weighted multivariate Cox analyses with a propensity scoring-based method showed that long-term cilostazol treatment [hazard ratio (HR) 0.2, 95% confidence interval (CI) 0.11-0.36, P < 0.001], direct revascularization (DR) (HR 0.46, 95% CI 0.28-0.74, P = 0.002), and supervised exercise (HR 0.4, 95% CI 0.24-0.66, P < 0.001) were independently associated with primary patency. Patients with lower-extremity amputation (LEA) had a higher risk of coronary artery disease (CAD) and mortality. Cellulitis and neuropathy were independently associated with LEA events (cellulitis: HR 2.89, 95% CI 1.66-5.05, P < 0.001; neuropathy: HR 2.2, 95% CI 1.31-3.7, P = 0.003). CONCLUSION Our results showed that patients with DM who received cilostazol treatment for more than 3 months had significantly better outcomes and decreased amputation and mortality rates after DR, and cellulitis and neuropathy were highly associated with the risk of limb loss. A large-scale randomized trial should be conducted in the future to confirm these results. TRIAL REGISTRATION Taipei Veterans General Hospital (TVGH) IRB no. 2013-08-020B. Registered 30 August 2013.",2020,"The 24-month primary patency rate, mortality rate, and amputation rate were better in the patients under long-term cilostazol treatment (P < 0.001, P = 0.029, and P = 0.014).","['2013-08-020B', '172 consecutive patients with CLI (Fontaine levels\xa0III-IV) received', 'Patients with lower-extremity amputation (LEA', 'Patients with Diabetes Mellitus and Critical Limb Ischemia', 'Taipei Veterans General Hospital', 'patients with diabetes mellitus (DM) and critical limb ischemia (CLI) after endovascular revascularization of the affected angiosome']","['cilostazol', 'TVGH', 'cilostazol treatment', 'Endovascular Intervention']","['supervised exercise', 'direct revascularization (DR', 'risk of coronary artery disease (CAD) and mortality', 'Cellulitis and neuropathy', 'amputation and mortality rates after DR, and cellulitis and neuropathy', '24-month primary patency rate, mortality rate, and amputation rate', 'risk of limb loss']","[{'cui': 'C4517601', 'cui_str': '172'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1142264', 'cui_str': 'Critical limb ischemia'}, {'cui': 'C0441927', 'cui_str': 'Level III'}, {'cui': 'C0337308', 'cui_str': 'Amputation of lower limb'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0020008', 'cui_str': 'Hospitals, General'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0392760', 'cui_str': 'Affecting'}]","[{'cui': 'C0055729', 'cui_str': 'cilostazol'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0020008', 'cui_str': 'Hospitals, General'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0411282', 'cui_str': 'Endovascular radiological intervention'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0007642', 'cui_str': 'Cellulitis'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0002695', 'cui_str': 'Amputee'}]",172.0,0.0628399,"The 24-month primary patency rate, mortality rate, and amputation rate were better in the patients under long-term cilostazol treatment (P < 0.001, P = 0.029, and P = 0.014).","[{'ForeName': 'Chiu-Yang', 'Initials': 'CY', 'LastName': 'Lee', 'Affiliation': 'Division of Cardiovascular Surgery, Department of Surgery, Taipei Veterans General Hospital, No. 201, Section\xa02 Shih-Pai Road, Beitou District, Taipei, 11217, Taiwan.'}, {'ForeName': 'Tao-Cheng', 'Initials': 'TC', 'LastName': 'Wu', 'Affiliation': 'Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. dcwu@vghtpe.gov.tw.'}, {'ForeName': 'Shing-Jong', 'Initials': 'SJ', 'LastName': 'Lin', 'Affiliation': 'Institute of Clinical Medicine, School of Medicine, National Yang Ming University, Taipei, Taiwan. shingjong88@gmail.com.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00860-8'] 1603,32564705,The microbial biofilm composition on peripherally inserted central catheters: A comparison of polyurethane and hydrophobic catheters collected from paediatric patients.,"BACKGROUND Peripherally inserted central catheters are susceptible to microbial colonisation and subsequent biofilm formation, leading to central line-associated bloodstream infection, a serious peripherally inserted central catheter-related complication. Next-generation peripherally inserted central catheter biomaterials, such as hydrophobic materials (e.g. Endexo ® ), may reduce microbial biofilm formation or attachment, consequently reducing the potential for central line-associated bloodstream infection. METHODS Within a randomised controlled trial, culture-dependent and culture-independent methods were used to determine if the biomaterials used in traditional polyurethane peripherally inserted central catheters and hydrophobic peripherally inserted central catheters impacted microbial biofilm composition. This study also explored the impact of other clinical characteristics including central line-associated bloodstream infection, antibiotic therapy and dwell time on the microbial biofilm composition of peripherally inserted central catheters. RESULTS From a total of 32 patients, one peripherally inserted central catheter was determined to be colonised with Staphylococcus aureus , and on further analysis, the patient was diagnosed with central line-associated bloodstream infection. All peripherally inserted central catheters ( n = 17 polyurethane vs n = 15 hydrophobic) were populated with complex microbial communities, including peripherally inserted central catheters considered non-colonised. The two main microbial communities observed included Staphylococcus spp., dominant on the colonised peripherally inserted central catheter, and Enterococcus , dominant on non-colonised peripherally inserted central catheters. Both the peripherally inserted central catheter biomaterial design and antibiotic therapy had no significant impact on microbial communities. However, the diversity of microbial communities significantly decreased with dwell time. CONCLUSION More diverse pathogens were present on the colonised peripherally inserted central catheter collected from the patient with central line-associated bloodstream infection. Microbial biofilm composition did not appear to be affected by the design of peripherally inserted central catheter biomaterials or antibiotic therapy. However, the diversity of the microbial communities appeared to decrease with dwell time.",2020,Microbial biofilm composition did not appear to be affected by the design of peripherally inserted central catheter biomaterials or antibiotic therapy.,['paediatric patients'],"['polyurethane and hydrophobic catheters', 'central catheters ( n = 17 polyurethane vs n = 15 hydrophobic) were populated with complex microbial communities, including peripherally inserted central catheters considered non-colonised']","['microbial biofilm composition', 'microbial communities', 'diversity of microbial communities', 'Microbial biofilm composition']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0032616', 'cui_str': 'Polyisocyanate'}, {'cui': 'C0598629', 'cui_str': 'Hydrophobicity'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0179740', 'cui_str': 'Peripherally inserted central catheter'}]","[{'cui': 'C0081786', 'cui_str': 'Biofilm'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}]",32.0,0.0689821,Microbial biofilm composition did not appear to be affected by the design of peripherally inserted central catheter biomaterials or antibiotic therapy.,"[{'ForeName': 'Maddie', 'Initials': 'M', 'LastName': 'Higgins', 'Affiliation': 'School of Environment and Science, Griffith University, Brisbane, QLD, Australia.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'School of Dentistry and Oral Health, Gold Coast Campus, Griffith University, QLD, Australia.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Ford', 'Affiliation': 'School of Environment and Science, Griffith University, Brisbane, QLD, Australia.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Brownlie', 'Affiliation': 'School of Environment and Science, Griffith University, Brisbane, QLD, Australia.'}, {'ForeName': 'Tricia', 'Initials': 'T', 'LastName': 'Kleidon', 'Affiliation': 'School of Nursing and Midwifery, Griffith University, Brisbane, QLD, Australia.'}, {'ForeName': 'Claire M', 'Initials': 'CM', 'LastName': 'Rickard', 'Affiliation': 'Alliance for Vascular Access Teaching and Research (AVATAR), Menzies Health Institute Queensland, Griffith University, Brisbane, QLD, Australia.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Ullman', 'Affiliation': 'Alliance for Vascular Access Teaching and Research (AVATAR), Menzies Health Institute Queensland, Griffith University, Brisbane, QLD, Australia.'}]",The journal of vascular access,['10.1177/1129729820932423'] 1604,32563846,Depression history as a predictor of outcomes during buprenorphine-naloxone treatment of prescription opioid use disorder.,"BACKGROUND In the multi-site Prescription Opioid Addiction Treatment Study (POATS), the best predictor of successful opioid use outcome was lifetime diagnosis of major depressive disorder. The primary aim of this secondary analysis of data from POATS was to empirically assess two explanations for this counterintuitive finding. METHODS The POATS study was a national, 10-site randomized controlled trial (N = 360 enrolled in the 12-week buprenorphine-naloxone maintenance treatment phase) sponsored by the NIDA Clinical Trials Network. We evaluated how the presence of a history of depression influences opioid use outcome (negative urine drug assays). Using adjusted logistic regression models, we tested the hypotheses that 1) a reduction in depressive symptoms and 2) greater motivation and engagement in treatment account for the association between depression history and good treatment outcome. RESULTS Although depressive symptoms decreased significantly throughout treatment (p <.001), this improvement was not associated with opioid outcomes (aOR = 0.98, ns). Reporting a goal of opioid abstinence at treatment entry was also not associated with outcomes (aOR = 1.39, ns); however, mutual-help group participation was associated with good treatment outcomes (aOR = 1.67, p <.05). In each of these models, lifetime major depressive disorder remained associated with good outcomes (aORs = 1.63-1.82, ps = .01-.055). CONCLUSIONS Findings are consistent with the premise that greater engagement in treatment is associated with good opioid outcomes. Nevertheless, depression history continues to be associated with good opioid outcomes in adjusted models. More research is needed to understand how these factors could improve treatment outcomes for those with opioid use disorder.",2020,"Although depressive symptoms decreased significantly throughout treatment (p <.001), this improvement was not associated with opioid outcomes (aOR = 0.98, ns).","['prescription opioid use disorder', '360 enrolled in the 12-week', 'maintenance treatment phase) sponsored by the NIDA Clinical Trials Network']",['buprenorphine-naloxone'],"['lifetime major depressive disorder', 'depressive symptoms']","[{'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0068218', 'cui_str': 'N-nitrosoiminodiacetic acid'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}]","[{'cui': 'C1169989', 'cui_str': 'Buprenorphine- and naloxone-containing product'}]","[{'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",360.0,0.0809725,"Although depressive symptoms decreased significantly throughout treatment (p <.001), this improvement was not associated with opioid outcomes (aOR = 0.98, ns).","[{'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'Peckham', 'Affiliation': 'Department of Psychiatry, McLean Hospital and Harvard Medical School, Belmont, MA, USA. Electronic address: adpeckham@mclean.harvard.edu.'}, {'ForeName': 'Margaret L', 'Initials': 'ML', 'LastName': 'Griffin', 'Affiliation': 'Department of Psychiatry, McLean Hospital and Harvard Medical School, Belmont, MA, USA.'}, {'ForeName': 'R Kathryn', 'Initials': 'RK', 'LastName': 'McHugh', 'Affiliation': 'Department of Psychiatry, McLean Hospital and Harvard Medical School, Belmont, MA, USA.'}, {'ForeName': 'Roger D', 'Initials': 'RD', 'LastName': 'Weiss', 'Affiliation': 'Department of Psychiatry, McLean Hospital and Harvard Medical School, Belmont, MA, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108122'] 1605,32563847,Longitudinal analysis of alcohol use and intimate partner violence perpetration among men with HIV in northern Vietnam.,"BACKGROUND Alcohol use is a known risk factor for male-perpetrated intimate partner violence (IPV), although few studies have been conducted globally and among men with HIV (MWH). We estimated the longitudinal effects of alcohol use on IPV perpetration among MWH. METHODS This study is a secondary analysis of randomized controlled trial data among male and female antiretroviral treatment patients with hazardous alcohol use in Thai Nguyen, Vietnam. Analyses were restricted to male participants who were married/cohabitating (N = 313). Alcohol use was assessed as proportion days alcohol abstinent, heavy drinking, and alcohol use disorder (AUD) using the Timeline Followback and Mini International Neuropsychiatric Interview questionnaire. Multilevel modeling was used to estimate the effects of higher versus lower average alcohol use on IPV perpetration (between-person effects) and the effects of time-specific deviations in alcohol use on IPV perpetration (within-person effects). RESULTS Participants with higher average proportion days alcohol abstinent had decreased odds of IPV perpetration (adjusted Odds Ratio [aOR] = 0.43, p = 0.03) and those with higher average heavy drinking and AUD had increased odds of IPV perpetration (Heavy drinking: aOR = 1.05, p = 0.002; AUD: aOR = 4.74, p < 0.0001). Time-specific increases in proportion days alcohol abstinent were associated with decreased odds of IPV perpetration (aOR = 0.39, p = 0.02) and time-specific increases in AUD were associated with increased odds of IPV perpetration (aOR = 2.95, p = 0.001). Within-person effects for heavy drinking were non-significant. CONCLUSIONS Alcohol use is associated with IPV perpetration among Vietnamese men with HIV. In this context, AUD and frequent drinking are stronger correlates of IPV perpetration as compared to heavy drinking.",2020,"Within-person effects for heavy drinking were non-significant. CONCLUSIONS Alcohol use is associated with IPV perpetration among Vietnamese men with HIV.","['men with HIV in northern Vietnam', 'men with HIV (MWH', 'Vietnamese men with HIV', 'male participants who were married/cohabitating (N = 313', 'male and female antiretroviral treatment patients with hazardous alcohol use in Thai Nguyen, Vietnam', 'male-perpetrated intimate partner violence (IPV']",[],"['proportion days alcohol abstinent, heavy drinking, and alcohol use disorder (AUD) using the Timeline Followback and Mini International Neuropsychiatric Interview questionnaire', 'time-specific increases in AUD', 'Time-specific increases in proportion days alcohol abstinent', 'IPV perpetration']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0042658', 'cui_str': 'Vietnam'}, {'cui': 'C0042660', 'cui_str': 'Vietnamese language'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0024841', 'cui_str': 'Marriage'}, {'cui': 'C4517707', 'cui_str': '313'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0599685', 'cui_str': 'Antiretroviral-containing product'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0039724', 'cui_str': 'Thai language'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}]",[],"[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0457801', 'cui_str': 'Non - drinker'}, {'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0145943', 'cui_str': 'TimeLine'}, {'cui': 'C4505426', 'cui_str': 'Mini International Neuropsychiatric Interview'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}]",313.0,0.0196213,"Within-person effects for heavy drinking were non-significant. CONCLUSIONS Alcohol use is associated with IPV perpetration among Vietnamese men with HIV.","[{'ForeName': 'Rebecca B', 'Initials': 'RB', 'LastName': 'Hershow', 'Affiliation': 'University of North Carolina at Chapel Hill Gillings School of Global Public Health, 135 Dauer Drive, 302 Rosenau Hall, Chapel Hill, NC, 27599, USA. Electronic address: rhershow@live.unc.edu.'}, {'ForeName': 'H Luz McNaughton', 'Initials': 'HLM', 'LastName': 'Reyes', 'Affiliation': 'University of North Carolina at Chapel Hill Gillings School of Global Public Health, 135 Dauer Drive, 302 Rosenau Hall, Chapel Hill, NC, 27599, USA.'}, {'ForeName': 'Tran Viet', 'Initials': 'TV', 'LastName': 'Ha', 'Affiliation': 'UNC Project Vietnam, Yen Hoa Health Clinic, Lot E2, Duong Dinh Nghe Street, Hanoi, Viet Nam.'}, {'ForeName': 'Geetanjali', 'Initials': 'G', 'LastName': 'Chander', 'Affiliation': 'Johns Hopkins University Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD, 21205, USA; Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD, 21205, USA.'}, {'ForeName': 'Nguyen Vu Tuyet', 'Initials': 'NVT', 'LastName': 'Mai', 'Affiliation': 'UNC Project Vietnam, Yen Hoa Health Clinic, Lot E2, Duong Dinh Nghe Street, Hanoi, Viet Nam.'}, {'ForeName': 'Teerada', 'Initials': 'T', 'LastName': 'Sripaipan', 'Affiliation': 'University of North Carolina at Chapel Hill Gillings School of Global Public Health, 135 Dauer Drive, 302 Rosenau Hall, Chapel Hill, NC, 27599, USA.'}, {'ForeName': 'Constantine', 'Initials': 'C', 'LastName': 'Frangakis', 'Affiliation': 'Johns Hopkins University Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD, 21205, USA; Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD, 21205, USA.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Dowdy', 'Affiliation': 'Johns Hopkins University Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD, 21205, USA; Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD, 21205, USA.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Latkin', 'Affiliation': 'Johns Hopkins University Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD, 21205, USA; Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD, 21205, USA.'}, {'ForeName': 'Heidi E', 'Initials': 'HE', 'LastName': 'Hutton', 'Affiliation': 'Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD, 21205, USA.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Pettifor', 'Affiliation': 'University of North Carolina at Chapel Hill Gillings School of Global Public Health, 135 Dauer Drive, 302 Rosenau Hall, Chapel Hill, NC, 27599, USA.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Maman', 'Affiliation': 'University of North Carolina at Chapel Hill Gillings School of Global Public Health, 135 Dauer Drive, 302 Rosenau Hall, Chapel Hill, NC, 27599, USA.'}, {'ForeName': 'Vivian F', 'Initials': 'VF', 'LastName': 'Go', 'Affiliation': 'University of North Carolina at Chapel Hill Gillings School of Global Public Health, 135 Dauer Drive, 302 Rosenau Hall, Chapel Hill, NC, 27599, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108098'] 1606,32563858,Capitalizing on cross-language similarities in intervention with bilingual children.,"PURPOSE This study examined the effects of a vocabulary intervention for bilingual children that was conducted in children's first language, Spanish, and included explicit instruction on cognates. We measured effects in terms of change from pre- to post-intervention in Spanish as well as associations with the non-target language, English. METHOD Participants were 12 Spanish-English bilingual children, aged 6-8 years, with and without Developmental Language Disorder. Children completed the intervention in pairs (one child with DLD and a typically developing peer) for 70-minute sessions, 3 days a week, for four weeks. Intervention targeted 32 words (16 cognates, 16 non-cognates) using four storybooks (8 words/book) and interactive activities that highlighted similarities across languages. Pre- and post-intervention measures in Spanish and English included tasks of word definition and cognate facilitation. RESULTS As a group, children showed improvement in definition quality and cognate naming in Spanish. There was a positive correlation between definition quality and cognate naming for the typically developing children, but not for the children with DLD. All children showed positive cross-language correlations on post-intervention measures. CONCLUSIONS Bilingual children, with and without DLD, have the capacity to improve in their awareness and use of cognates. Explicit teaching of cognates can be an effective tool for building vocabulary skills. Children with DLD may need additional time and support to apply their knowledge of cognates to vocabulary learning.",2020,"There was a positive correlation between definition quality and cognate naming for the typically developing children, but not for the children with DLD.","[""bilingual children that was conducted in children's first language, Spanish, and included explicit instruction on cognates"", 'Children with DLD', 'Participants were 12 Spanish-English bilingual children, aged 6-8 years, with and without Developmental Language Disorder', 'Spanish and English']",['vocabulary intervention'],"['included tasks of word definition and cognate facilitation', 'definition quality and cognate naming', 'positive cross-language correlations']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0557073', 'cui_str': 'First language'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0023014', 'cui_str': 'Developmental language disorder'}]","[{'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C0037415', 'cui_str': 'Social Facilitation'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0010101', 'cui_str': 'Correlation Studies'}]",,0.0437372,"There was a positive correlation between definition quality and cognate naming for the typically developing children, but not for the children with DLD.","[{'ForeName': 'Quynh', 'Initials': 'Q', 'LastName': 'Dam', 'Affiliation': 'San Diego State University, 5500 Campanile Drive, San Diego, CA 92182, United States; University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, United States. Electronic address: qdam@sdsu.edu.'}, {'ForeName': 'Giang T', 'Initials': 'GT', 'LastName': 'Pham', 'Affiliation': 'San Diego State University, 5500 Campanile Drive, San Diego, CA 92182, United States. Electronic address: gpham@sdsu.edu.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Pruitt-Lord', 'Affiliation': 'San Diego State University, 5500 Campanile Drive, San Diego, CA 92182, United States. Electronic address: spruitt@sdsu.edu.'}, {'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Limon-Hernandez', 'Affiliation': 'San Diego State University, 5500 Campanile Drive, San Diego, CA 92182, United States. Electronic address: jlimon-hernandez@sdsu.edu.'}, {'ForeName': 'Carrie', 'Initials': 'C', 'LastName': 'Goodwiler', 'Affiliation': 'San Diego State University, 5500 Campanile Drive, San Diego, CA 92182, United States. Electronic address: cgoodwiler@sdsu.edu.'}]",Journal of communication disorders,['10.1016/j.jcomdis.2020.106004'] 1607,32565123,An acute bout of swimming increases post-exercise energy intake in young healthy men and women.,"Single bouts of land-based exercise (for example, walking, running, cycling) do not typically alter post-exercise energy intake on the day of exercise. However, anecdotal and preliminary empirical evidence suggests that swimming may increase appetite and energy intake. This study compared the acute effects of swimming on appetite, energy intake, and food preference and reward, versus exertion-matched cycling and a resting control. Thirty-two men (n = 17; mean ± SD age 24 ± 2 years, body mass index [BMI] 25.0 ± 2.6 kg/m 2 ) and women (n = 15; age 22 ± 3 years, BMI 22.8 ± 2.3 kg/m 2 ) completed three experimental trials (swimming, cycling, control) in a randomised, crossover design. The exercise trials involved 60-min of 'hard' exercise (self-selected rating of perceived exertion: 15) performed 90-min after a standardised breakfast. Food preference and reward were assessed via the Leeds Food Preference Questionnaire 15-min after exercise, whilst ad libitum energy intake was determined 30-min after exercise. The control trial involved identical procedures except no exercise was performed. Compared with control (3259 ± 1265 kJ), swimming increased ad libitum energy intake (3857 ± 1611 kJ; ES = 0.47, 95% CI of the mean difference between trials 185, 1010 kJ, P = 0.005); the magnitude of increase was smaller after cycling (3652 ± 1619 kJ; ES = 0.31, 95% CI -21, 805 kJ, P = 0.062). Ad libitum energy intake was similar between swimming and cycling (ES = 0.16, 95% CI -207, 618 kJ, P = 0.324). This effect was consistent across sexes and unrelated to food preference and reward which were similar after swimming and cycling compared with control. This study has identified an orexigenic effect of swimming. Further research is needed to identify the responsible mechanism(s), including the relevance of water immersion and water temperature per se.",2020,This effect was consistent across sexes and unrelated to food preference and reward which were similar after swimming and cycling compared with control.,"['young healthy men and women', 'Thirty-two men (n\u202f=\u202f17; mean\u202f±\u202fSD age 24\u202f±\u202f2 years, body mass index [BMI] 25.0\u202f±\u202f2.6\u202fkg/m 2 ) and women (n\u202f=\u202f15', 'age 22\u202f±\u202f3 years, BMI 22.8\u202f±\u202f2.3\u202fkg/m 2 ']","[""60-min of 'hard' exercise (self-selected rating of perceived exertion: 15) performed 90-min after a standardised breakfast"", 'Single bouts of land-based exercise']","['appetite, energy intake, and food preference and reward, versus exertion-matched cycling', 'Ad libitum energy intake', 'appetite and energy intake']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517633', 'cui_str': '2.6'}]","[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0018599', 'cui_str': 'Hard'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0557668', 'cui_str': 'Landing'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0016483', 'cui_str': 'Food Preferences'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]",,0.135485,This effect was consistent across sexes and unrelated to food preference and reward which were similar after swimming and cycling compared with control.,"[{'ForeName': 'Alice E', 'Initials': 'AE', 'LastName': 'Thackray', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. Electronic address: A.E.Thackray@lboro.ac.uk.'}, {'ForeName': 'Scott A', 'Initials': 'SA', 'LastName': 'Willis', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. Electronic address: S.Willis2@lboro.ac.uk.'}, {'ForeName': 'Aron P', 'Initials': 'AP', 'LastName': 'Sherry', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. Electronic address: A.P.Sherry@lboro.ac.uk.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Clayton', 'Affiliation': 'School of Science and Technology, Nottingham Trent University, UK. Electronic address: David.Clayton@ntu.ac.uk.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Broom', 'Affiliation': 'Centre for Sport, Exercise and Life Sciences, Coventry University, UK. Electronic address: ad5173@coventry.ac.uk.'}, {'ForeName': 'Mayada', 'Initials': 'M', 'LastName': 'Demashkieh', 'Affiliation': 'Department of Physical Education and Sport Science, Nanyang Technological University, Singapore. Electronic address: Mayada.Demashkieh@nie.edu.sg.'}, {'ForeName': 'Jack A', 'Initials': 'JA', 'LastName': 'Sargeant', 'Affiliation': 'National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK; Diabetes Research Centre, University of Leicester, UK. Electronic address: js928@leicester.ac.uk.'}, {'ForeName': 'Lewis J', 'Initials': 'LJ', 'LastName': 'James', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK. Electronic address: L.James@lboro.ac.uk.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Finlayson', 'Affiliation': 'Faculty of Medicine and Health, University of Leeds, UK. Electronic address: G.S.Finlayson@leeds.ac.uk.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Stensel', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. Electronic address: D.J.Stensel@lboro.ac.uk.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'King', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. Electronic address: j.a.king@lboro.ac.uk.'}]",Appetite,['10.1016/j.appet.2020.104785'] 1608,32526634,"Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).","BACKGROUND Cetuximab has been shown to be clinically active when given in combination with irinotecan in patients with irinotecan-refractory metastatic colorectal cancer (mCRC). However, it has remained unclear whether panitumumab is effective when combined with irinotecan. We compared efficacies of both regimens in this randomised phase II study. PATIENTS AND METHODS Patients with wild-type KRAS exon 2 mCRC previously treated with fluorouracil-, oxaliplatin- and irinotecan-based chemotherapies were randomised (1:1) to either panitumumab plus irinotecan (panitumumab arm) or cetuximab plus irinotecan (cetuximab arm). The primary end-point was progression-free survival (PFS). The planned sample size was 120, expecting a hazard ratio (HR) of 1.0 with non-inferiority margin of 1.3 (one-sided alpha error 0.2 and power 0.7). Major secondary end-points were overall survival (OS), response rate and safety. RESULTS From December 2011 to September 2014, 121 patients were enrolled, and 61 and 59 patients were randomised to the panitumumab and cetuximab arms, respectively (1 patient excluded). Most patients (97%) had received prior chemotherapies containing bevacizumab. The median PFS was 5.42 months in the panitumumab arm and 4.27 months in the cetuximab arm (HR = 0.64, 95% confidence interval [CI] = 0.44-0.94, P < 0.001 for non-inferiority, P = 0.058 for superiority), and median OS was 14.85 and 11.53 months (HR = 0.66, 95% CI = 0.44-1.00, P = 0.050 for superiority), respectively. The incidence of grade 3 or 4 hypomagnesaemia was higher in the panitumumab arm than that in the cetuximab arm (17% vs. 7%). CONCLUSION Panitumumab may be non-inferior to cetuximab in combination with irinotecan in survival of patients with irinotecan-refractory mCRC.",2020,"CONCLUSION Panitumumab may be non-inferior to cetuximab in combination with irinotecan in survival of patients with irinotecan-refractory mCRC.","['patients with KRAS wild-type metastatic colorectal cancer refractory to', 'patients with irinotecan-refractory metastatic colorectal cancer (mCRC', 'From December 2011 to September 2014', 'patients with irinotecan-refractory mCRC', '121 patients were enrolled, and 61 and 59 patients', 'Patients with wild-type KRAS exon 2 mCRC previously treated with']","['panitumumab plus irinotecan versus cetuximab plus irinotecan', 'fluoropyrimidine, irinotecan\xa0and oxaliplatin (WJOG 6510G', 'panitumumab', 'panitumumab and cetuximab', 'panitumumab plus irinotecan (panitumumab arm) or cetuximab plus irinotecan (cetuximab arm', 'irinotecan', 'bevacizumab', 'fluorouracil-, oxaliplatin-\xa0and irinotecan-based chemotherapies']","['median OS', 'incidence of grade 3 or 4 hypomagnesaemia', 'overall survival (OS), response rate\xa0and safety', 'progression-free survival (PFS', 'median PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0445392', 'cui_str': 'Wild'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0015295', 'cui_str': 'Exons'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0879427', 'cui_str': 'panitumumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0995188', 'cui_str': 'cetuximab'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0151723', 'cui_str': 'Hypomagnesemia'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",121.0,0.220477,"CONCLUSION Panitumumab may be non-inferior to cetuximab in combination with irinotecan in survival of patients with irinotecan-refractory mCRC.","[{'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Sakai', 'Affiliation': 'Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan. Electronic address: dsakai@cfs.med.osaka-u.ac.jp.'}, {'ForeName': 'Hiroya', 'Initials': 'H', 'LastName': 'Taniguchi', 'Affiliation': 'Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'Naotoshi', 'Initials': 'N', 'LastName': 'Sugimoto', 'Affiliation': 'Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.'}, {'ForeName': 'Takao', 'Initials': 'T', 'LastName': 'Tamura', 'Affiliation': 'Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.'}, {'ForeName': 'Tomohiro', 'Initials': 'T', 'LastName': 'Nishina', 'Affiliation': 'Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Hara', 'Affiliation': 'Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.'}, {'ForeName': 'Taito', 'Initials': 'T', 'LastName': 'Esaki', 'Affiliation': 'Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.'}, {'ForeName': 'Tadamichi', 'Initials': 'T', 'LastName': 'Denda', 'Affiliation': 'Division of Gastroenterology, Chiba Cancer Center, Chiba, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Sakamoto', 'Affiliation': 'Department of Gastroetererological Oncology, Hyogo Cancer Center, Akashi, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Okuda', 'Affiliation': 'Department of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan.'}, {'ForeName': 'Taroh', 'Initials': 'T', 'LastName': 'Satoh', 'Affiliation': 'Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Tsushima', 'Affiliation': 'Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.'}, {'ForeName': 'Akitaka', 'Initials': 'A', 'LastName': 'Makiyama', 'Affiliation': 'Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Tsuda', 'Affiliation': 'Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.'}, {'ForeName': 'Ayumu', 'Initials': 'A', 'LastName': 'Hosokawa', 'Affiliation': 'Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Toyama, Japan.'}, {'ForeName': 'Hidekazu', 'Initials': 'H', 'LastName': 'Kuramochi', 'Affiliation': ""Department of Chemotherapy, Tokyo Women's Medical University, Yachiyo Medical Center, Yachiyo, Japan.""}, {'ForeName': 'Shinya', 'Initials': 'S', 'LastName': 'Tokunaga', 'Affiliation': 'Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan.'}, {'ForeName': 'Toshikazu', 'Initials': 'T', 'LastName': 'Moriwaki', 'Affiliation': 'Division of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.'}, {'ForeName': 'Hisateru', 'Initials': 'H', 'LastName': 'Yasui', 'Affiliation': 'Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.'}, {'ForeName': 'Hiroyasu', 'Initials': 'H', 'LastName': 'Ishida', 'Affiliation': 'Department of Gastroenterology, National Hospital Organization Mito Medical Center, Mito, Japan.'}, {'ForeName': 'Akihito', 'Initials': 'A', 'LastName': 'Tsuji', 'Affiliation': 'Department of Clinical Oncology, Kagawa University Faculty of Medicine, Kagawa, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Otsu', 'Affiliation': 'Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.'}, {'ForeName': 'Hozumi', 'Initials': 'H', 'LastName': 'Shimokawa', 'Affiliation': 'Department of Medical Oncology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Japan.'}, {'ForeName': 'Eishi', 'Initials': 'E', 'LastName': 'Baba', 'Affiliation': 'Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Japan.'}, {'ForeName': 'Mikio', 'Initials': 'M', 'LastName': 'Sato', 'Affiliation': 'Department of Gastroenterology and Hepatology, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan.'}, {'ForeName': 'Shigemi', 'Initials': 'S', 'LastName': 'Matsumoto', 'Affiliation': 'Department of Medical Oncology, Kyoto University Hospital, Kyoto, Japan.'}, {'ForeName': 'Yukinori', 'Initials': 'Y', 'LastName': 'Ozaki', 'Affiliation': 'Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.'}, {'ForeName': 'Katsunori', 'Initials': 'K', 'LastName': 'Shinozaki', 'Affiliation': 'Division of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Tamagawa', 'Affiliation': 'Department of Surgery, Osaka General Medical Center, Osaka, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Goto', 'Affiliation': 'Cancer Chemotherapy Center, Osaka Medical College, Osaka, Japan.'}, {'ForeName': 'Shigenori', 'Initials': 'S', 'LastName': 'Kadowaki', 'Affiliation': 'Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'Hirofumi', 'Initials': 'H', 'LastName': 'Fujii', 'Affiliation': 'Department of Clinical Oncology, Jichi Medical University Hospital, Tochigi, Japan.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Koh', 'Affiliation': 'Internal Medicine III, Wakayama Medical University, Wakayama, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Yamazaki', 'Affiliation': 'Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.'}, {'ForeName': 'Shuichi', 'Initials': 'S', 'LastName': 'Hironaka', 'Affiliation': 'Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.'}, {'ForeName': 'Junji', 'Initials': 'J', 'LastName': 'Kishimoto', 'Affiliation': 'Center for Clinical and Translational Research, Kyushu University Hospital, Japan.'}, {'ForeName': 'Narikazu', 'Initials': 'N', 'LastName': 'Boku', 'Affiliation': 'Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Ichinosuke', 'Initials': 'I', 'LastName': 'Hyodo', 'Affiliation': 'Division of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.'}, {'ForeName': 'Kei', 'Initials': 'K', 'LastName': 'Muro', 'Affiliation': 'Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.04.014'] 1609,32526688,Examining the effect of a brief psychoeducation intervention based on self-regulation model on sexual satisfaction for women with breast cancer: A randomized controlled trial.,"PURPOSE The main goal of this study was to investigate whether the Self-Regulation Model could improve sexual satisfaction for women diagnosed with breast cancer. METHODS Adult women diagnosed with breast cancer were recruited from a hospital in Qazvin, Iran. Participants were randomly assigned to either an intervention group (n = 40) or a control group (n = 40). All participants were administered a demographic questionnaire and an Index of Sexual Satisfaction (ISS) pre-intervention, immediately post-intervention, and 1, 2, and 3 months following the intervention. The control group completed the assessments along the same time line as the intervention group. Women in the experimental group were provided three sessions of a psychological individual intervention which included psychoeducation regarding their diagnosis and personalized intervention strategies to improve their overall sexual satisfaction with sexual intercourse. Each intervention took between 60 and 90 min to administer. RESULTS The experimental and control group participants were well balanced in terms of demographic characteristics and sexual satisfaction scores before the intervention. The intervention group showed a positive increasing trend in the sexual satisfaction scores over time while the control group participants had a negative trend (p < 0.05). There were also statistical differences in the sexual satisfaction scores at each follow-up month (p < 0.05) adjusted for the baseline score and relevant demographical variables, showing longer term effects with a significant increase in sexual satisfaction over time. CONCLUSION Providing a psychoeducational based intervention provided an increase of sexual satisfaction during intercourse for women diagnosed with breast cancer. The psychoeducation based intervention provided an opportunity for participants to dispel common myths regarding their disease and obtain new strategies and skills to improve their sexual satisfaction from intercourse with their partners.",2019,"There were also statistical differences in the sexual satisfaction scores at each follow-up month (p < 0.05) adjusted for the baseline score and relevant demographical variables, showing longer term effects with a significant increase in sexual satisfaction over time. ","['women diagnosed with breast cancer', 'Adult women diagnosed with breast cancer were recruited from a hospital in Qazvin, Iran', 'women with breast cancer']","['psychoeducational based intervention', 'Self-Regulation Model', 'psychological individual intervention which included psychoeducation regarding their diagnosis and personalized intervention strategies', 'psychoeducation intervention based on self-regulation model']","['demographic characteristics and sexual satisfaction scores', 'sexual satisfaction scores', 'sexual satisfaction']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022065', 'cui_str': 'Iran'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0684274', 'cui_str': 'Self-control'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0871356', 'cui_str': 'Sexual Gratification'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0482538,"There were also statistical differences in the sexual satisfaction scores at each follow-up month (p < 0.05) adjusted for the baseline score and relevant demographical variables, showing longer term effects with a significant increase in sexual satisfaction over time. ","[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Abedini', 'Affiliation': 'Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran.'}, {'ForeName': 'Frouzan', 'Initials': 'F', 'LastName': 'Olfati', 'Affiliation': 'Metabolic Diseases Research Center, School of Nursing and Midwifery, Qazvin University of Medical Sciences, Qazvin, Iran. Electronic address: folfati@qums.ac.ir.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Oveisi', 'Affiliation': 'Metabolic Disease Research Center, School of Medicine, Qazvin University of Medical Science, Qazvin, Iran. Electronic address: soveysi@qums.ac.ir.'}, {'ForeName': 'Nasim', 'Initials': 'N', 'LastName': 'Bahrami', 'Affiliation': 'Social Determinants of Health Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran. Electronic address: nbahrami@qums.ac.ir.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Astrologo', 'Affiliation': 'Interpersonal Relationships & Development Laboratory, Centre for Research in Human Development, Department of Psychology, Concordia University, Montréal, QC, Canada. Electronic address: lisa.astrologo@live.ca.'}, {'ForeName': 'Yiong Huak', 'Initials': 'YH', 'LastName': 'Chan', 'Affiliation': 'Biostatistics Unit, Yong Loo Lin School of Medicine, National University Health System, Singapore. Electronic address: yiong_huak_chan@nuhs.edu.sg.'}]",European journal of oncology nursing : the official journal of European Oncology Nursing Society,['10.1016/j.ejon.2019.101673'] 1610,32564661,Transcutaneous electrical nerve stimulation is superior than placebo and control for postoperative pain relief.,"Aim: To determine whether transcutaneous electrical nerve stimulation (TENS) is more efficient than placebo TENS and control groups for pain relief. Design: Randomized, single-blinded, placebo-controlled trial.  Setting & participants:  A total of 78 adults with postoperative pain, after cholecystectomy, at the University Hospital. They were randomized into active TENS, placebo TENS and control. Intervention: A total of 30-min interventions applied in the first 24 h after the surgery. Outcome: Pain intensity. Results: Pain significantly decreased for both TENS; however, the active TENS was better. A decrease of 2 points or more on the visual analog scale for 53.8% active TENS and 11.5% placebo. Conclusion: There was a greater reduction in pain of important clinical relevance in the active TENS group. Clinical Trial registration: Brazilian Clinical Trial (REBEC): RBR-6cgx2k.",2020,"Pain significantly decreased for both TENS, however the active TENS was better.","['78 adults with postoperative pain, after cholecystectomy, at the University Hospital', 'Setting & participants']","['placebo TENS', 'Transcutaneous electrical nerve stimulation', 'active TENS, placebo TENS and control', 'transcutaneous electrical nerve stimulation (TENS', 'placebo']","['Pain', 'Pain intensity', 'visual analog scale', 'postoperative pain relief', 'pain of important clinical relevance']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0008320', 'cui_str': 'Cholecystectomy'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0014518', 'cui_str': 'Lyell syndrome'}, {'cui': 'C0040654', 'cui_str': 'Percutaneous electrical nerve stimulation'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",78.0,0.564169,"Pain significantly decreased for both TENS, however the active TENS was better.","[{'ForeName': 'Maraísa Rodrigues', 'Initials': 'MR', 'LastName': 'Borges', 'Affiliation': 'Department of Applied Physiotherapy, Federal University of Triangulo Mineiro, Uberaba, MG, Brazil.'}, {'ForeName': 'Nuno Miguel Lopes', 'Initials': 'NML', 'LastName': 'de Oliveira', 'Affiliation': 'Medical School, Federal University of Triangulo Mineiro, Uberaba, MG, Brazil.'}, {'ForeName': 'Izabella Barberato Silva', 'Initials': 'IBS', 'LastName': 'Antonelli', 'Affiliation': 'Department of Applied Physiotherapy, Federal University of Triangulo Mineiro, Uberaba, MG, Brazil.'}, {'ForeName': 'Maristella Borges', 'Initials': 'MB', 'LastName': 'Silva', 'Affiliation': 'The study was performed at Clinics Hospital of the Federal University of Triangulo Mineiro, Uberaba, MG, Brazil.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Crema', 'Affiliation': 'Medical School, Federal University of Triangulo Mineiro, Uberaba, MG, Brazil.'}, {'ForeName': 'Luciane Fernanda Rodrigues Martinho', 'Initials': 'LFRM', 'LastName': 'Fernandes', 'Affiliation': 'Medical School, Federal University of Triangulo Mineiro, Uberaba, MG, Brazil.'}]",Pain management,['10.2217/pmt-2019-0063'] 1611,32683489,A brief bout of exercise in hypoxia reduces ventricular filling rate and stroke volume response during muscle metaboreflex activation.,"PURPOSE The hemodynamic consequences of exercise in hypoxia have not been completely investigated. The present investigation aimed at studying the hemodynamic effects of contemporary normobaric hypoxia and metaboreflex activation. METHODS Eleven physically active, healthy males (age 32.7 ± 7.2 years) completed a cardiopulmonary test on an electromagnetically braked cycle-ergometer to determine their maximum workload (W max ). On separate days, participants performed two randomly assigned exercise sessions (3 minutes pedalling at 30% of W max ): (1) one in normoxia (NORMO), and (2) one in normobaric hypoxia with FiO 2 set to 13.5% (HYPO). After each session, the following protocol was randomly assigned: either (1) post-exercise muscle ischemia (PEMI) to study the metaboreflex, or (2) a control exercise recovery session, i.e., without metaboreflex activation. Hemodynamics were assessed with impedance cardiography. RESULTS The main result was that the HYPO session impaired the ventricular filling rate (measured as stroke volume/diastolic time) response during PEMI versus control condition in comparison to the NORMO test (31.33 ± 68.03 vs. 81.52 ± 49.23 ml·s -1 ,respectively, p = 0.003). This caused a reduction in the stroke volume response (1.45 ± 9.49 vs. 10.68 ± 8.21 ml, p = 0.020). As a consequence, cardiac output response was impaired during the HYPO test. CONCLUSIONS The present investigation suggests that a brief exercise bout in hypoxia is capable of impairing cardiac filling rate as well as stroke volume during the metaboreflex. These results are in good accordance with recent findings showing that among hemodynamic modulators, ventricular filling is the most sensible variable to hypoxic stimuli.",2020,"This caused a reduction in the stroke volume response (1.45 ± 9.49 vs. 10.68 ± 8.21 ml, p = 0.020).","['Eleven physically active, healthy males (age 32.7\u2009±\u20097.2\xa0years) completed a']","['post-exercise muscle ischemia (PEMI) to study the metaboreflex, or (2) a control exercise recovery session, i.e., without metaboreflex activation', 'cardiopulmonary test on an electromagnetically braked cycle-ergometer to determine their maximum workload (W max ', 'exercise sessions (3 minutes pedalling at 30% of W max ): (1) one in normoxia (NORMO), and (2) one in normobaric hypoxia with FiO 2 set to 13.5% (HYPO']","['stroke volume/diastolic time) response', 'cardiac output response', 'ventricular filling rate', 'stroke volume response']","[{'cui': 'C0556453', 'cui_str': 'Physically active'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517857', 'cui_str': '7.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0337108', 'cui_str': 'Brake'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C4517559', 'cui_str': '13.5'}]","[{'cui': 'C0038455', 'cui_str': 'Stroke volume'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0007165', 'cui_str': 'Cardiac output'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}]",11.0,0.067047,"This caused a reduction in the stroke volume response (1.45 ± 9.49 vs. 10.68 ± 8.21 ml, p = 0.020).","[{'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Mulliri', 'Affiliation': 'Sports Physiology Laboratory, Department of Medical Sciences and Public Health, University of Cagliari, Via Porcell 4, 09124, Cagliari, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Magnani', 'Affiliation': 'Sports Physiology Laboratory, Department of Medical Sciences and Public Health, University of Cagliari, Via Porcell 4, 09124, Cagliari, Italy.'}, {'ForeName': 'Silvana', 'Initials': 'S', 'LastName': 'Roberto', 'Affiliation': 'Sports Physiology Laboratory, Department of Medical Sciences and Public Health, University of Cagliari, Via Porcell 4, 09124, Cagliari, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Sechi', 'Affiliation': 'Sports Physiology Laboratory, Department of Medical Sciences and Public Health, University of Cagliari, Via Porcell 4, 09124, Cagliari, Italy.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Ghiani', 'Affiliation': 'Sports Physiology Laboratory, Department of Medical Sciences and Public Health, University of Cagliari, Via Porcell 4, 09124, Cagliari, Italy.'}, {'ForeName': 'Gianmarco', 'Initials': 'G', 'LastName': 'Sainas', 'Affiliation': 'Sports Physiology Laboratory, Department of Medical Sciences and Public Health, University of Cagliari, Via Porcell 4, 09124, Cagliari, Italy.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Nughedu', 'Affiliation': 'Sports Physiology Laboratory, Department of Medical Sciences and Public Health, University of Cagliari, Via Porcell 4, 09124, Cagliari, Italy.'}, {'ForeName': 'Seyed Alireza', 'Initials': 'SA', 'LastName': 'Hosseini Kakhak', 'Affiliation': 'Faculty of Physical Education and Sport Sciences, Hakim Sabzevari University, Sabzevar, Iran.'}, {'ForeName': 'Pier Paolo', 'Initials': 'PP', 'LastName': 'Bassareo', 'Affiliation': 'University College of Dublin, Mater Misericordiae University Teaching Hospital, Dublin, Ireland.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Crisafulli', 'Affiliation': 'Sports Physiology Laboratory, Department of Medical Sciences and Public Health, University of Cagliari, Via Porcell 4, 09124, Cagliari, Italy. crisafulli@tiscali.it.'}]",European journal of applied physiology,['10.1007/s00421-020-04435-0'] 1612,32573271,Effects of two different types of ankle-foot orthoses on gait outcomes in patients with subacute stroke: a randomized crossover trial.,"OBJECTIVE To identify whether patients in the subacute stage of stroke, with foot drop, would have better gait outcomes when using a double-adjustable AFO (DA AFO) or a posterior leaf spring AFO (PLS AFO) at baseline without practice and to determine whether one week of practice would significantly change gait outcomes with either of the AFOs. DESIGN Within-subject 2 × 2 repeated measures design. SETTING Postacute and outpatient rehabilitation center. PARTICIPANTS Twenty individuals with mean age of 57 years (SD: 12.0 years) with subacute stroke. INTERVENTIONS Participants were measured using DA AFO and PLS AFO at baseline. Follow-up measurements were taken after one week of practice with each type of AFO in randomly assigned order. OUTCOME MEASURES Gait endurance (6-Minute Walk Test (6MWT)), gait symmetry, and gait velocity at self-selected and fast-paced velocity measured using GAITRite gait analysis system and patient report of AFO preference. RESULTS At baseline, no significant differences were found between the 2 AFOs ( P  > 0.05). There was no significant interaction ( P  > 0.05) of AFO and practice for gait endurance, symmetry, and velocity. Main effect of practice was significant for gait endurance ( P  < 0.001), self-selected velocity ( P  = 0.001), and fast-paced velocity ( P  < 0.001). In all, 16 participants preferred using DA AFO for walking. CONCLUSIONS No difference between DA AFO and PLS AFO was found on measures of gait endurance, symmetry, and velocity at baseline or after practice. With practice over time, participants improved in gait endurance and velocity regardless of AFO type.",2020,"There was no significant interaction ( P  > 0.05) of AFO and practice for gait endurance, symmetry, and velocity.","['Postacute and outpatient rehabilitation center', 'Twenty individuals with mean age of 57\u2009years (SD: 12.0 years) with subacute stroke', '16 participants preferred using DA AFO for walking', 'patients in the subacute stage of stroke, with foot drop', 'patients with subacute stroke']",['ankle-foot orthoses'],"['Gait endurance (6-Minute Walk Test (6MWT)), gait symmetry, and gait velocity at self-selected and fast-paced velocity measured using GAITRite gait analysis system and patient report of AFO preference', 'gait endurance, symmetry, and velocity', 'fast-paced velocity', 'gait endurance and velocity regardless of AFO type', 'self-selected velocity', 'DA AFO and PLS AFO', 'gait endurance', 'gait outcomes']","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0034993', 'cui_str': 'Centers, Rehabilitation'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205365', 'cui_str': 'Subacute'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0085684', 'cui_str': 'Foot-drop'}]","[{'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0430515', 'cui_str': '6-minute walk test'}, {'cui': 'C0332516', 'cui_str': 'Symmetrical'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C3874714', 'cui_str': 'Gait analysis system'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0242724', 'cui_str': 'Leaves'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",20.0,0.0698814,"There was no significant interaction ( P  > 0.05) of AFO and practice for gait endurance, symmetry, and velocity.","[{'ForeName': 'Priya Sibi', 'Initials': 'PS', 'LastName': 'Karakkattil', 'Affiliation': 'Baylor Scott & White Institute for Rehabilitation, Frisco, TX, USA.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'Trudelle-Jackson', 'Affiliation': ""School of Physical Therapy, Texas Woman's University Institute of Health Sciences, Dallas, TX, USA.""}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Medley', 'Affiliation': ""School of Physical Therapy, Texas Woman's University Institute of Health Sciences, Dallas, TX, USA.""}, {'ForeName': 'Chad', 'Initials': 'C', 'LastName': 'Swank', 'Affiliation': 'Baylor Scott & White Institute for Rehabilitation, Dallas, TX, USA.'}]",Clinical rehabilitation,['10.1177/0269215520927738'] 1613,32569239,Efficiency and safety evaluation of prophylaxes for venous thrombosis after gynecological surgery.,"BACKGROUND In this study, we investigate the incidence of venous thrombosis (VT), and evaluate the effectiveness and safety of 3 major thromboprophylaxes and the potential risk factors for VT in women undergoing surgery for a gynecological malignancy. METHODS We performed a randomized controlled trial of 307 patients undergoing laparoscopic surgery for gynecological malignancies at a single institution from January 2016 to October 2017. Patients were divided into 3 groups: one receiving a half dose of low-molecular-weight heparin sodium injection (FLUXUM, Alfa Wassermann, Italy) delivered by injection, one receiving a full dose of FLUXUM, and a third group receiving an Argatroban injection. RESULTS None of the patients in our study developed a pulmonary embolism, bleeding, or infectious complications. There were no statistical differences in the rate of deep venous thrombosis (DVT) (0%, 0%, and 2.38%) and the superficial venous thromboembolism (SVT) (15.66%, 8.97%, and 18.6%) among the 3 groups. None of the patients developed symptomatic VT. The effect of treatment on alanine aminotransferase and aspartate aminotransferase differed between the groups, with a minimal effect in the Argatroban group, and all 3 methods resulted in minimal impairment of renal function. Decreased hemoglobin, elevated levels of D-dimer, and prothrombin time were closely related to thrombogenesis. CONCLUSION In conclusion, the incidence of postoperative thrombosis in gynecological malignancy among these Chinese people is not as low as we had originally presumed. Argatroban is not more effective than Parnaparin as a direct thrombin inhibitor, but it has less influence on liver function, which is beneficial for patients undergoing chemotherapy. Hemoglobin, D-dimer, and prothrombin time may be used to predict or detect thrombogenesis.",2020,"There were no statistical differences in the rate of deep venous thrombosis (DVT) (0%, 0%, and 2.38%) and the superficial venous thromboembolism (SVT) (15.66%, 8.97%, and 18.6%) among the 3 groups.","['venous thrombosis after gynecological surgery', 'women undergoing surgery for a gynecological malignancy', 'patients undergoing chemotherapy', '307 patients undergoing laparoscopic surgery for gynecological malignancies at a single institution from January 2016 to October 2017']","['low-molecular-weight heparin sodium injection (FLUXUM, Alfa Wassermann, Italy) delivered by injection, one receiving a full dose of FLUXUM, and a third group receiving an Argatroban injection', 'prophylaxes', 'Argatroban']","['pulmonary embolism, bleeding, or infectious complications', 'alanine aminotransferase and aspartate aminotransferase', 'rate of deep venous thrombosis (DVT', 'Hemoglobin, D-dimer, and prothrombin time', 'minimal impairment of renal function', 'superficial venous thromboembolism (SVT', 'symptomatic VT', 'Decreased hemoglobin, elevated levels of D-dimer, and prothrombin time']","[{'cui': 'C0042487', 'cui_str': 'Venous thrombosis'}, {'cui': 'C0038902', 'cui_str': 'Operation on female genital organs'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0018417', 'cui_str': 'Gynecology'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}]","[{'cui': 'C0019139', 'cui_str': 'Low molecular weight heparin'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0212082', 'cui_str': 'Fluxum'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C1828121', 'cui_str': 'Injections'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4255162', 'cui_str': 'argatroban Injection'}, {'cui': 'C0048470', 'cui_str': 'argatroban'}]","[{'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0060323', 'cui_str': 'D-dimer'}, {'cui': 'C0033707', 'cui_str': 'Prothrombin time'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0042487', 'cui_str': 'Venous thrombosis'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",307.0,0.125385,"There were no statistical differences in the rate of deep venous thrombosis (DVT) (0%, 0%, and 2.38%) and the superficial venous thromboembolism (SVT) (15.66%, 8.97%, and 18.6%) among the 3 groups.","[{'ForeName': 'Ruidi', 'Initials': 'R', 'LastName': 'Yu', 'Affiliation': 'Department of Obstetrics and Gynecology.'}, {'ForeName': 'Faridah', 'Initials': 'F', 'LastName': 'Nansubuga', 'Affiliation': 'Department of Obstetrics and Gynecology.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': ""Division of Vascular Surgery, Hepatic Surgery Center, Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.""}, {'ForeName': 'Wencheng', 'Initials': 'W', 'LastName': 'Ding', 'Affiliation': 'Department of Obstetrics and Gynecology.'}, {'ForeName': 'Kezhen', 'Initials': 'K', 'LastName': 'Li', 'Affiliation': 'Department of Obstetrics and Gynecology.'}, {'ForeName': 'Danhui', 'Initials': 'D', 'LastName': 'Weng', 'Affiliation': 'Department of Obstetrics and Gynecology.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Wu', 'Affiliation': 'Department of Obstetrics and Gynecology.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Department of Obstetrics and Gynecology.'}, {'ForeName': 'Ding', 'Initials': 'D', 'LastName': 'Ma', 'Affiliation': 'Department of Obstetrics and Gynecology.'}, {'ForeName': 'Juncheng', 'Initials': 'J', 'LastName': 'Wei', 'Affiliation': 'Department of Obstetrics and Gynecology.'}]",Medicine,['10.1097/MD.0000000000020928'] 1614,32570930,Long-Term Efficacy of the Workshop Vs. Online SUCCEAT (Supporting Carers of Children and Adolescents with Eating Disorders) Intervention for Parents: A Quasi-Randomised Feasibility Trial.,"Interventions for main carers of adult patients with anorexia nervosa (AN) can reduce the caregiving burden and increase caregiver skills. However, the effectiveness and feasibility for carers of adolescent patients, the optimal form of the intervention and long-term outcomes are largely unknown. We evaluated the efficacy and feasibility of the ""Supporting Carers of Children and Adolescents with Eating Disorders in Austria"" (SUCCEAT) workshop vs. online intervention. Main caregivers (parents) of adolescent patients with AN were randomly allocated to a workshop ( n = 50) or online version ( n = 50). Participants were compared to a non-randomised comparison group ( n = 49) receiving multi-family or systemic family therapy. Primary (General Health Questionnaire) and secondary outcomes were obtained at baseline, three-month and 12-month follow-up. Adherence was high for workshop and online participants (6.2 and 6.7 sessions completed out of 8). Intention-to-treat analyses revealed significant pre-post reductions in the primary outcome for the workshop (d = 0.87 (95%conficence interval (CI): 0.48; 1.26)) and online (d = 0.65 (95%CI: 0.31; 0.98)) intervention that were sustained at the 12-month follow-up. There was no significant group difference ( p = 0.473). Parental psychopathology and burden decreased and caregiver skills increased in all groups; the improvement of caregiver skills was significantly higher in SUCCEAT participants than in the comparison group. Online interventions for parents of adolescents with AN were equally effective as workshops. The improvements remained stable over time.",2020,Parental psychopathology and burden decreased and caregiver skills increased in all groups; the improvement of caregiver skills was significantly higher in SUCCEAT participants than in the comparison group.,"['Supporting Carers of Children and Adolescents with Eating Disorders in Austria"" (SUCCEAT) workshop vs. online intervention', 'carers of adolescent patients', 'Supporting Carers of Children and Adolescents with Eating Disorders', 'Parents', 'adult patients with anorexia nervosa (AN', 'parents of adolescents with AN', 'Main caregivers (parents) of adolescent patients with AN']","['multi-family or systemic family therapy', 'Online SUCCEAT', 'workshop ( n = 50) or online version']","['efficacy and feasibility', 'Parental psychopathology and burden decreased and caregiver skills', 'improvement of caregiver skills', 'Adherence']","[{'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0013473', 'cui_str': 'Eating disorder'}, {'cui': 'C0004348', 'cui_str': 'Austria'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C3898714', 'cui_str': 'Internet Intervention'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0003125', 'cui_str': 'Anorexia nervosa'}, {'cui': 'C0205225', 'cui_str': 'Principal'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0015618', 'cui_str': 'Family therapy'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0013473', 'cui_str': 'Eating disorder'}, {'cui': 'C0004348', 'cui_str': 'Austria'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C2607870', 'cui_str': 'Version'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",,0.108054,Parental psychopathology and burden decreased and caregiver skills increased in all groups; the improvement of caregiver skills was significantly higher in SUCCEAT participants than in the comparison group.,"[{'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Truttmann', 'Affiliation': 'Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, 1090 Vienna, Austria.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Philipp', 'Affiliation': 'Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, 1090 Vienna, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Zeiler', 'Affiliation': 'Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, 1090 Vienna, Austria.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Franta', 'Affiliation': 'Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, 1090 Vienna, Austria.'}, {'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Wittek', 'Affiliation': 'Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, 1090 Vienna, Austria.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Merl', 'Affiliation': 'Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, 1090 Vienna, Austria.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Schöfbeck', 'Affiliation': 'Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, 1090 Vienna, Austria.'}, {'ForeName': 'Doris', 'Initials': 'D', 'LastName': 'Koubek', 'Affiliation': 'Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, 1090 Vienna, Austria.'}, {'ForeName': 'Clarissa', 'Initials': 'C', 'LastName': 'Laczkovics', 'Affiliation': 'Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, 1090 Vienna, Austria.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Imgart', 'Affiliation': 'Parkland Clinic, Clinic for Psychosomatic Medicine and Psychotherapy, 34537 Bad Wildungen, Germany.'}, {'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Zanko', 'Affiliation': 'Parkland Clinic, Clinic for Psychosomatic Medicine and Psychotherapy, 34537 Bad Wildungen, Germany.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Auer-Welsbach', 'Affiliation': 'Department for Neurology and child and adolescents Psychiatry, 9020 Klagenfurt am Wörthersee, Austria.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Treasure', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London WC2R 2LS, UK.""}, {'ForeName': 'Andreas F K', 'Initials': 'AFK', 'LastName': 'Karwautz', 'Affiliation': 'Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, 1090 Vienna, Austria.'}, {'ForeName': 'Gudrun', 'Initials': 'G', 'LastName': 'Wagner', 'Affiliation': 'Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, 1090 Vienna, Austria.'}]",Journal of clinical medicine,['10.3390/jcm9061912'] 1615,32571614,Effects of diet and exercise on adipocytokine levels in patients with moderate to severe chronic kidney disease.,"BACKGROUND AND AIMS Obesity is a pro-inflammatory risk factor for progression of CKD and cardiovascular disease. We hypothesized that implementation of caloric restriction and endurance exercise would improve adipocytokine profiles in patients with moderate to severe CKD. METHODS AND RESULTS We enrolled patients with moderate to severe CKD through a multi-center pilot randomized trial of diet and exercise in a 4-arm design (dietary restriction of 10%-15% reduction in caloric intake, exercise three times/week, combined diet and exercise, and control) (NCT01150851). Adipocytokines (adiponectin and leptin) were measured at the beginning and end of the study period as secondary outcomes. Treatment effect was analyzed in a multivariable model adjusted for baseline outcome values, age, gender, site and diabetes. A total of 122 participants were consented, 111 were randomized (42% female, 25% diabetic, and 91% hypertensive), 104 started intervention and 92 completed the study (Figure 1). Plasma adiponectin levels increased significantly in response to diet by 23% (95% CI: 0.2%, 49.8%, p = 0.048) among participants randomized to the caloric restriction and usual activity arm but not to exercise, whereas circulating leptin did not change by either treatment. CONCLUSION Our data suggest that dietary caloric restriction increases plasma adiponectin levels in stage 3-4 CKD patients, with limited effect on leptin levels. These findings suggest the potential for improving the metabolic milieu of CKD with moderate calorie restriction.",2020,"Plasma adiponectin levels increased significantly in response to diet by 23% (95% CI: 0.2%, 49.8%, p = 0.048) among participants randomized to the caloric restriction and usual activity arm but not to exercise, whereas circulating leptin did not change by either treatment. ","['A total of 122 participants were consented, 111 were randomized (42% female, 25% diabetic, and 91% hypertensive), 104 started intervention and 92 completed the study (Figure\xa01', 'enrolled patients with moderate to severe CKD through a multi-center pilot randomized trial of', 'patients with moderate to severe CKD', 'patients with moderate to severe chronic kidney disease']","['diet and exercise', 'dietary caloric restriction', 'diet and exercise in a 4-arm design (dietary restriction of 10%-15% reduction in caloric intake, exercise three times/week, combined diet and exercise, and control) (NCT01150851', 'caloric restriction and endurance exercise']","['Adipocytokines (adiponectin and leptin', 'plasma adiponectin levels', 'adipocytokine levels', 'Plasma adiponectin levels', 'circulating leptin', 'adipocytokine profiles', 'leptin levels']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1135809', 'cui_str': 'Decreased energy diet'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0456698', 'cui_str': 'times/week'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0419120', 'cui_str': 'Muscular endurance development exercise'}]","[{'cui': 'C1955907', 'cui_str': 'Adipokine'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}]",122.0,0.0257898,"Plasma adiponectin levels increased significantly in response to diet by 23% (95% CI: 0.2%, 49.8%, p = 0.048) among participants randomized to the caloric restriction and usual activity arm but not to exercise, whereas circulating leptin did not change by either treatment. ","[{'ForeName': 'Nihal', 'Initials': 'N', 'LastName': 'Aydemir', 'Affiliation': 'Hitit University Medical School, Nephrology Department, Corum, Turkey.'}, {'ForeName': 'Mindy M', 'Initials': 'MM', 'LastName': 'Pike', 'Affiliation': ""Vanderbilt O'Brien Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.""}, {'ForeName': 'Aseel', 'Initials': 'A', 'LastName': 'Alsouqi', 'Affiliation': ""Vanderbilt O'Brien Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.""}, {'ForeName': 'Samuel A E', 'Initials': 'SAE', 'LastName': 'Headley', 'Affiliation': 'Department of Exercise Science and Athletic Training, Springfield College, Springfield, MA, USA.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Tuttle', 'Affiliation': 'Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA, USA; Providence Medical Research Center, Providence Health Care, Spokane, WA, USA.'}, {'ForeName': 'Elizabeth E', 'Initials': 'EE', 'LastName': 'Evans', 'Affiliation': 'Department of Exercise Science and Athletic Training, Springfield College, Springfield, MA, USA.'}, {'ForeName': 'Charles M', 'Initials': 'CM', 'LastName': 'Milch', 'Affiliation': 'Department of Exercise Science and Athletic Training, Springfield College, Springfield, MA, USA.'}, {'ForeName': 'Kelsey A', 'Initials': 'KA', 'LastName': 'Moody', 'Affiliation': 'Department of Exercise Science and Athletic Training, Springfield College, Springfield, MA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Germain', 'Affiliation': 'Department of Nephrology, Bay State Medical Center, Springfield, MA, USA.'}, {'ForeName': 'Loren', 'Initials': 'L', 'LastName': 'Lipworth', 'Affiliation': ""Vanderbilt O'Brien Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.""}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Himmelfarb', 'Affiliation': 'Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'T A', 'Initials': 'TA', 'LastName': 'Ikizler', 'Affiliation': ""Vanderbilt O'Brien Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.""}, {'ForeName': 'Cassianne', 'Initials': 'C', 'LastName': 'Robinson-Cohen', 'Affiliation': ""Vanderbilt O'Brien Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: cassianne.robinson-cohen@vumc.edu.""}]","Nutrition, metabolism, and cardiovascular diseases : NMCD",['10.1016/j.numecd.2020.04.012'] 1616,32563939,Association of Meteorin-Like Hormone with insulin resistance and body composition in healthy Iranian adults.,"BACKGROUND AND AIMS Sedentary behavior and/or physical inactivity are modifiable risk factors for noncommunicable diseases. Myokines are one of the mediators of physical activity health benefits. Relationship between regular physical activity (RPA) and baseline plasma Meteorin-Like Hormone (Metrnl) has not been explored in human. Hence, we compared baseline plasma Metrnl between sedentary individuals and ones with recreational physical activities, and role of Metrnl as a biological messenger between physical activity and insulin resistance and body composition was also explored. METHODS Forty healthy young men (aged: 21 ± 2.1 yrs; BMI: 23 ± 3.44 kg/m 2 ) completed the study. Participants were equally assigned into two groups of control (sedentary) and case (recreational athletes). Baseline plasma Metrnl, glucose, insulin and body composition components and insulin resistance index (HOMA-IR) were assessed under resting conditions. RESULTS Except for baseline blood glucose, baseline plasma Metrnl, insulin, HOMA-IR and body mass index and body fat percentage were similar between two groups (P > 0.05). However, after Metrnl correction for the degree of insulin resistance index (Metrnl/HOMA-IR), recreational athletes showed a significantly greater baseline compared to sedentary subjects (P < 0.05). Baseline blood glucose showed a negative and significant correlation with baseline plasma Metrnl (P < 0.05). CONCLUSIONS Baseline plasma Metrnl is correlated with regular physical activity and insulin sensitivity, but not with body composition parameters. Metrnl may be one possible mediator of the beneficial effects of PA on insulin sensitivity in healthy humans. Hence, increasing awareness of the benefits of physical activity and incorporating physical activity into lifestyle are of great importance for people with non-communicable diseases.",2020,"Baseline plasma Metrnl, glucose, insulin and body composition components and insulin resistance index (HOMA-IR) were assessed under resting conditions. ","['healthy humans', 'Forty healthy young men (aged: 21\xa0±\xa02.1\xa0yrs', 'people with non-communicable diseases', 'healthy Iranian adults']","['Meteorin-Like Hormone with insulin resistance and body composition', 'regular physical activity (RPA) and baseline plasma Meteorin-Like Hormone (Metrnl']","['Baseline blood glucose', 'degree of insulin resistance index (Metrnl/HOMA-IR', 'baseline plasma Metrnl', 'baseline blood glucose, baseline plasma Metrnl, insulin, HOMA-IR and body mass index and body fat percentage', 'Baseline plasma Metrnl, glucose, insulin and body composition components and insulin resistance index (HOMA-IR']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4068876', 'cui_str': '2.1'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4505065', 'cui_str': 'Non-infectious Diseases'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0449432', 'cui_str': 'Component'}]",40.0,0.0269477,"Baseline plasma Metrnl, glucose, insulin and body composition components and insulin resistance index (HOMA-IR) were assessed under resting conditions. ","[{'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Alizadeh', 'Affiliation': 'Faculty of Sport Sciences, University of Mazandaran, Babolsar, Mazandaran, Iran. Electronic address: h.alizadeh.aw@gmail.com.'}, {'ForeName': 'Aliakbar', 'Initials': 'A', 'LastName': 'Alizadeh', 'Affiliation': 'Department of Sport Physiology, Faculty of Sport Sciences, Shahid Chamran University of Ahvaz, Ahvaz, Iran. Electronic address: aliakbar.alizadeh1984@gmail.com.'}]",Diabetes & metabolic syndrome,['10.1016/j.dsx.2020.05.031'] 1617,32564042,Analysis of scoliosis deformation in the Zebris computer study as an assessment of the effectiveness of the FED method in the treatment of idiopathic scolioses.,"Idiopathic scoliosis is one of the most difficult problems of contemporary orthopaedics and physiotherapy, and its unknown etiology hinders initiation of effective causative therapy. A tendency for progression of scoliosis, and failure of many conservative treatment methods stimulated a search for new and more effective methods which will not only stop a progress of the deformation, but actually correct it. The FED method is a relatively new, but promising method used for conservative treatment of idiopathic scoliosis. It is based on the use of a special device, which enables corrective forces to act at a level of the scoliotic curve. AIM The aim of this study was a comparative analysis of effectiveness of idiopathic scoliosis treatment using the FED method versus FITS, during 3 weeks of observations of girls aged 11 to 15 years. MATERIALS AND METHODS The study was conducted in 60 girls, aged from 11 to 15 years (mean 13.58 ± 1.33 years) randomly qualified which were suffered with double-curve scoliosis of the 2nd degree according to Cobb. According to the randomization, the girls were assigned to two groups based on the therapeutic strategy, the study group of patients treated with the FED method, and the control group treated with the FITS method. The therapy results were evaluated by computer examination of the posture using the Zebris CMS10 system. The degree of the spine deformity in the frontal plane was described with the total scoliotic deformation (SD) angle. RESULTS In the conducted study, no statistically significant difference was noted between groups for any of the analyzed variables. It means that these groups did not differ statistically in terms of subjects' number, age, type of scoliosis, Cobb angle value for primary and secondary scoliosis, Risser sign, Raimondi rotation, and scoliosis type. Statistically significant differences were found between the two groups for the scoliosis degree, however, after the therapy, the girls treated with the FED method were characterized by a greater improvement in this parameter versus the control group. CONCLUSIONS Both FED and FITS methods significantly influence the improvement in the scoliotic deformation degree in the Zebris computer examination during a 3-week follow-up; however, when both treatment methods are compared, it can be concluded that the therapy by the FED method is statistically more effective. The treatment of the 2nd degree scolioses with the FED method requires further analyses supplemented with other parameters of postural examination, as well as long-term diagnostics in a larger group of patients.",2020,"Both FED and FITS methods significantly influence the improvement in the scoliotic deformation degree in the Zebris computer examination during a 3-week follow-up; however, when both treatment methods are compared, it can be concluded that the therapy by the FED method is statistically more effective.","['girls aged 11 to 15 years', 'idiopathic scolioses', '60 girls, aged from 11 to 15 years (mean 13.58 ± 1.33 years) randomly qualified which were suffered with double-curve scoliosis of the 2nd degree according to Cobb']",['FED method versus FITS'],"['total scoliotic deformation (SD) angle', 'scoliotic deformation degree']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4517500', 'cui_str': '1.33'}, {'cui': 'C0443205', 'cui_str': 'Double curve'}, {'cui': 'C0036439', 'cui_str': 'Scoliosis deformity of spine'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]","[{'cui': 'C0342895', 'cui_str': 'Fish-eye disease'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0036572', 'cui_str': 'Seizure'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",60.0,0.0228685,"Both FED and FITS methods significantly influence the improvement in the scoliotic deformation degree in the Zebris computer examination during a 3-week follow-up; however, when both treatment methods are compared, it can be concluded that the therapy by the FED method is statistically more effective.","[{'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Trzcińska', 'Affiliation': 'Orthopaedic-Rehabilitation Centre for Children and Youth in Chylice, Mazovian Center of Rehabilitation ""STOCER"", Konstancin-Jeziorna, Poland.'}, {'ForeName': 'Zbigniew', 'Initials': 'Z', 'LastName': 'Nowak', 'Affiliation': 'Orthopaedic-Rehabilitation Centre for Children and Youth in Chylice, Mazovian Center of Rehabilitation ""STOCER"", Konstancin-Jeziorna, Poland.'}]",Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,[] 1618,32565388,A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial.,"INTRODUCTION Receptor activator of NF-kB ligand stimulates NF-kB-dependent cell signaling and acts as the primary signal for bone resorption. Retrospective analysis of a large trial comparing denosumab versus zoledronic acid in bone metastatic solid tumors suggested significant overall survival (OS) advantage for patients with lung cancer with denosumab (p = 0.01). The randomized open-label phase III SPLENDOUR trial was designed to evaluate whether the addition of denosumab to standard first-line platinum-based doublet chemotherapy improved OS in advanced NSCLC. METHODS Patients with stage IV NSCLC were randomized in a 1:1 ratio to either chemotherapy with or without denosumab (120 mg every 3-4 wks), stratified by the presence of bone metastases (at diagnosis), Eastern Cooperative Oncology Group performance status, histology, and region. To detect an OS increase from 9 to 11.25 months (hazard ratio [HR] = 0.80), 847 OS events were required. The trial closed prematurely owing to decreasing accrual rate. RESULTS A total of 514 patients were randomized, with 509 receiving one or more doses of the assigned treatment (chemotherapy: 252, chemotherapy-denosumab: 257). The median age was 66.1 years, 71% were men, and 59% were former smokers. Bone metastases were identified in 275 patients (53%). Median OS (95% confidence interval [CI]) was 8.7 (7.6-11.0) months in the control arm versus 8.2 (7.5-10.4) months in the chemotherapy-denosumab arm (HR = 0.96; 95% CI: 0.78-1.19; one-sided p = 0.36). For patients with bone metastasis, HR was 1.02 (95% CI: 0.77-1.35), whereas for those without, HR was 0.90 (95% CI: 0.66-1.23). Adverse events grade 3 or greater were observed in 40.9%, 5.2%, 8.7% versus 45.5%, 10.9%, 10.5% of patients. Conditional power for OS benefit was less than or equal to 10%. CONCLUSIONS Denosumab was well-tolerated without unexpected safety concerns. There was no OS improvement for denosumab when added to chemotherapy in the intention-to-treat population and the subgroups with and without bone metastases. Our data do not provide evidence of a clinical benefit for denosumab in patients with NSCLC without bone metastases.",2020,"Median OS(95%CI) was 8.7(7.6-11.0) in the control versus 8.2(7.5-10.4) months in the chemotherapy-denosumab-arm,","['Median age was 66.1 years, 71% male, 59% former smokers', 'lung cancer patients with denosumab', '514 patients', 'NSCLC patients without bone metastases', 'Stage IV NSCLC patients']","['chemotherapy with or without denosumab', '509 receiving ≥1 dose of assigned treatment (chemotherapy:252, chemotherapy-denosumab:257', 'denosumab to standard first-line treatment', 'denosumab versus zoledronic acid', 'denosumab to standard first-line platinum-based doublet chemotherapy', 'Denosumab']","['Median OS(95%CI', 'Bone metastases', 'OS improvement', 'overall survival (OS) advantage', 'Conditional power for OS benefit', 'Grade≥3 adverse events']","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0337671', 'cui_str': 'Ex-smoker'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0153690', 'cui_str': 'Secondary malignant neoplasm of bone'}, {'cui': 'C0278987', 'cui_str': 'Metastatic non-small cell lung cancer'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1708063', 'cui_str': 'First line treatment'}, {'cui': 'C0257685', 'cui_str': 'zoledronic acid'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0153690', 'cui_str': 'Secondary malignant neoplasm of bone'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",514.0,0.243713,"Median OS(95%CI) was 8.7(7.6-11.0) in the control versus 8.2(7.5-10.4) months in the chemotherapy-denosumab-arm,","[{'ForeName': 'Solange', 'Initials': 'S', 'LastName': 'Peters', 'Affiliation': 'Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Electronic address: Solange.Peters@chuv.ch.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Danson', 'Affiliation': 'Department of Oncology and Metabolism & Sheffield Experimental Cancer Medicine Centre, University of Sheffield, Weston Park Hospital, Sheffield, United Kingdom.'}, {'ForeName': 'Baktiar', 'Initials': 'B', 'LastName': 'Hasan', 'Affiliation': 'European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium.'}, {'ForeName': 'Urania', 'Initials': 'U', 'LastName': 'Dafni', 'Affiliation': 'School of Health Sciences, National and Kapodistrian University of Athens & Frontier Science Foundation-Hellas, Athens, Greece.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Reinmuth', 'Affiliation': 'Asklepios Kliniken GmbH, Asklepios Fachkliniken Muenchen, Gauting, Germany.'}, {'ForeName': 'Margarita', 'Initials': 'M', 'LastName': 'Majem', 'Affiliation': 'Department of Medical Oncology, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain.'}, {'ForeName': 'Kurt G', 'Initials': 'KG', 'LastName': 'Tournoy', 'Affiliation': 'Faculty of Medicine and Life Sciences, Ghent University and Onze-Lieve-Vrouwziekenhuis (OLV), Aalst, Belgium.'}, {'ForeName': 'Michael T', 'Initials': 'MT', 'LastName': 'Mark', 'Affiliation': 'Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department of Medical Oncology, Cantonal Hospital Graubuenden, Chur, Switzerland.'}, {'ForeName': 'Miklos', 'Initials': 'M', 'LastName': 'Pless', 'Affiliation': 'Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department of Medical Oncology and Hematology, Cantonal Hospital Winterthur, Winterthur, Switzerland.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Cobo', 'Affiliation': 'Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Unidad Gestion Intercentros of Medical Oncology. Regional and Virgen de la Victoria University Hospitals (IBIMA), Málaga, Spain.'}, {'ForeName': 'Delvys', 'Initials': 'D', 'LastName': 'Rodriguez-Abreu', 'Affiliation': 'Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain.'}, {'ForeName': 'Lionel', 'Initials': 'L', 'LastName': 'Falchero', 'Affiliation': 'Department of Pneumology and Thoracic Oncology, Hopital Nord-Ouest, Villefranche-sur-Saône Cedex, France.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Moran', 'Affiliation': ""Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Department of Medical Oncology, Institut Català d'Oncologia (ICO) Badalona, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona Applied Research Group in Oncology (B-ARGO), Barcelona, Spain.""}, {'ForeName': 'Ana Laura', 'Initials': 'AL', 'LastName': 'Ortega Granados', 'Affiliation': 'Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Department of Medical Oncology, Hospital Universitario de Jaén, Jaén, Spain.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Monnet', 'Affiliation': 'Department of Pneumology, Centre Hopitalier Intercommunal De Créteil, Créteil, France.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Mohorcic', 'Affiliation': 'Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia.'}, {'ForeName': 'Bartomeu Massutí', 'Initials': 'BM', 'LastName': 'Sureda', 'Affiliation': 'Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; El Instituto de Investigación Sanitaria y Biomédica de Alicante (SABIAL), Hospital Universitario Alicante, Alicante, Spain.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Betticher', 'Affiliation': 'Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department of Medical Oncology, Fribourg Cantonal Hospital (HFR), Fribourg, Switzerland.'}, {'ForeName': 'Ingel', 'Initials': 'I', 'LastName': 'Demedts', 'Affiliation': 'Department of Pulmonary Diseases, AZ Delta, Roeselare, Belgium.'}, {'ForeName': 'Jose Antionio', 'Initials': 'JA', 'LastName': 'Macias', 'Affiliation': 'Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Department of Hematology and Oncology, Hospital General Universitario Morales Meseguer, Murcia, Spain.'}, {'ForeName': 'Sinead', 'Initials': 'S', 'LastName': 'Cuffe', 'Affiliation': ""Cancer Trials Ireland, Dublin, Ireland; Department of Medical Oncology, St. James's Hospital, Dublin, Ireland.""}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Luciani', 'Affiliation': 'Department of Medical Oncology, Ospedale San Paolo, Milano, Italy.'}, {'ForeName': 'Jose Garcia', 'Initials': 'JG', 'LastName': 'Sanchez', 'Affiliation': 'Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Department of Medical Oncology, University Hospital Arnau de Vilanova, Valencia, Spain.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Curioni-Fontecedro', 'Affiliation': 'Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department for Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Gautschi', 'Affiliation': 'Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Cantonal Hospital Lucerne, Lucern, Switzerland.'}, {'ForeName': 'Gillian', 'Initials': 'G', 'LastName': 'Price', 'Affiliation': 'Department of Medical Oncology, Aberdeen Royal Infirmary NHS Grampian, Aberdeen, United Kingdom.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Coate', 'Affiliation': 'Cancer Trials Ireland, Dublin, Ireland; Mid-Western Cancer Centre, University Hospital Limerick, Limerick, Ireland.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'von Moos', 'Affiliation': 'Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department of Medical Oncology, Cantonal Hospital Graubuenden, Chur, Switzerland.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Zielinski', 'Affiliation': 'Clinical Division of Oncology, Medical University Vienna, Vienna, Austria; Central European Cooperative Oncology Group, Vienna, Austria.'}, {'ForeName': 'Mariano', 'Initials': 'M', 'LastName': 'Provencio', 'Affiliation': 'Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Department of Medical Oncology, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Menis', 'Affiliation': 'European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology Department, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padova, Italy.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Ruepp', 'Affiliation': 'European Thoracic Oncology Platform (ETOP), Bern, Switzerland.'}, {'ForeName': 'Alessia', 'Initials': 'A', 'LastName': 'Pochesci', 'Affiliation': 'European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Roschitzki-Voser', 'Affiliation': 'European Thoracic Oncology Platform (ETOP), Bern, Switzerland.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Besse', 'Affiliation': 'European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium; Gustave Roussy Cancer Center Villejuif, Paris Saclay University, Orsay, France.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Rabaglio', 'Affiliation': 'European Thoracic Oncology Platform (ETOP), Bern, Switzerland.'}, {'ForeName': 'Mary E R', 'Initials': 'MER', 'LastName': ""O'Brien"", 'Affiliation': 'Department of Medical Oncology, Royal Marsden Hospital, Sutton, United Kingdom.'}, {'ForeName': 'Rolf A', 'Initials': 'RA', 'LastName': 'Stahel', 'Affiliation': 'Department for Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.'}]",Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,['10.1016/j.jtho.2020.06.011'] 1619,32569934,Metabolic tracking of isoflavones in soybean products and biosamples from healthy adults after fermented soybean consumption.,"Fermentation may enhance the nutritional properties of foods by increasing metabolite bioactivity or bioavailability. This study explored the effect of fermentation on isoflavone bioavailability and metabolism. Isoflavone metabolites were tracked in foods and biospecimens of healthy adults after fermented soybean (FS) or non-fermented soybean (NFS) consumption in a randomized, controlled, crossover intervention study. The change in soybean isoflavones caused by fermentation resulted in faster absorption and higher bioavailability after consumption of FS. Although the urinary level of total isoflavone metabolites was similar after the consumption of the two diets, urinary genistein 7-O-sulfate was derived as a discriminant metabolite for the FS diet by partial least squares discriminant analysis. This study suggests that an isoflavone conjugate profile might be a more appropriate marker than total isoflavone levels for discriminating between the consumption of FS and NFS diets.",2020,"Although the urinary level of total isoflavone metabolites was similar after the consumption of the two diets, urinary genistein 7-O-sulfate was derived as a discriminant metabolite for the FS diet by partial least squares discriminant analysis.","['healthy adults after', 'healthy adults after fermented soybean consumption']","['fermented soybean (FS) or non-fermented soybean (NFS) consumption', 'isoflavones', 'Isoflavone metabolites']","['faster absorption and higher bioavailability', 'urinary level of total isoflavone metabolites', 'metabolite bioactivity or bioavailability', 'isoflavone bioavailability and metabolism']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0037733', 'cui_str': 'Soya bean'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0037733', 'cui_str': 'Soya bean'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0022179', 'cui_str': 'Isoflavone Derivatives'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0243173', 'cui_str': 'urinary levels'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0022179', 'cui_str': 'Isoflavone Derivatives'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}]",,0.0552057,"Although the urinary level of total isoflavone metabolites was similar after the consumption of the two diets, urinary genistein 7-O-sulfate was derived as a discriminant metabolite for the FS diet by partial least squares discriminant analysis.","[{'ForeName': 'Hwan-Hee', 'Initials': 'HH', 'LastName': 'Jang', 'Affiliation': 'National Institute of Agricultural Sciences, Rural Development Administration, Wanju, South Korea; Department of Nutritional Science and Food Management, Ewha Womans University, Seoul, South Korea.'}, {'ForeName': 'Hwayoung', 'Initials': 'H', 'LastName': 'Noh', 'Affiliation': 'Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France.'}, {'ForeName': 'Heon-Woong', 'Initials': 'HW', 'LastName': 'Kim', 'Affiliation': 'National Institute of Agricultural Sciences, Rural Development Administration, Wanju, South Korea.'}, {'ForeName': 'Su-Yeon', 'Initials': 'SY', 'LastName': 'Cho', 'Affiliation': 'National Institute of Agricultural Sciences, Rural Development Administration, Wanju, South Korea.'}, {'ForeName': 'Hyeon-Jeong', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'National Institute of Agricultural Sciences, Rural Development Administration, Wanju, South Korea.'}, {'ForeName': 'Seon-Hye', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'National Institute of Agricultural Sciences, Rural Development Administration, Wanju, South Korea.'}, {'ForeName': 'Sung-Hyen', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'National Institute of Agricultural Sciences, Rural Development Administration, Wanju, South Korea.'}, {'ForeName': 'Marc J', 'Initials': 'MJ', 'LastName': 'Gunter', 'Affiliation': 'Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France.'}, {'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Ferrari', 'Affiliation': 'Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France.'}, {'ForeName': 'Augustin', 'Initials': 'A', 'LastName': 'Scalbert', 'Affiliation': 'Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France.'}, {'ForeName': 'Heinz', 'Initials': 'H', 'LastName': 'Freisling', 'Affiliation': 'Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France.'}, {'ForeName': 'Jung-Bong', 'Initials': 'JB', 'LastName': 'Kim', 'Affiliation': 'National Institute of Agricultural Sciences, Rural Development Administration, Wanju, South Korea.'}, {'ForeName': 'Jeong-Sook', 'Initials': 'JS', 'LastName': 'Choe', 'Affiliation': 'National Institute of Agricultural Sciences, Rural Development Administration, Wanju, South Korea. Electronic address: swany@korea.kr.'}, {'ForeName': 'Oran', 'Initials': 'O', 'LastName': 'Kwon', 'Affiliation': 'Department of Nutritional Science and Food Management, Ewha Womans University, Seoul, South Korea. Electronic address: orank@ewha.ac.kr.'}]",Food chemistry,['10.1016/j.foodchem.2020.127317'] 1620,32570015,Lactobacillus rhamnosus GG and HbA1c in middle age and older adults without type 2 diabetes mellitus: A preliminary randomized study.,"BACKGROUND AND AIMS Probiotic supplementation improves glycemic control in persons with diabetes and the current study examined whether these benefits extend to healthy individuals. METHODS The current study was a 90-day placebo-controlled, double-blind, randomized clinical trial of Lactobacillus rhamnosus GG in healthy middle-aged and older adults. Fasting blood glucose and HbA1c were quantified at baseline and follow up. RESULTS ANCOVA controlling for baseline values showed group differences in follow up HbA1c [F (1,90) = 8.44, p = 0.005]; HbA1c values increased in the placebo group, though remained stable in the probiotic group. CONCLUSIONS If replicated, Lactobacillus rhamnosus GG may protect against changes in glycemic control.",2020,"RESULTS ANCOVA controlling for baseline values showed group differences in follow up HbA1c [F (1,90) = 8.44, p = 0.005]; HbA1c values increased in the placebo group, though remained stable in the probiotic group. ","['middle age and older adults without type 2 diabetes mellitus', 'healthy middle-aged and older adults', 'persons with diabetes']","['placebo', 'Lactobacillus rhamnosus GG', 'Lactobacillus rhamnosus GG and HbA1c', 'Probiotic supplementation']","['glycemic control', 'HbA1c values', 'Fasting blood glucose and HbA1c']","[{'cui': 'C0026062', 'cui_str': 'Middle-age'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1629836', 'cui_str': 'Lactobacillus rhamnosus GG'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}]",,0.163147,"RESULTS ANCOVA controlling for baseline values showed group differences in follow up HbA1c [F (1,90) = 8.44, p = 0.005]; HbA1c values increased in the placebo group, though remained stable in the probiotic group. ","[{'ForeName': 'Victoria E', 'Initials': 'VE', 'LastName': 'Sanborn', 'Affiliation': 'Department of Psychological Sciences, Kent State University, USA. Electronic address: vsanborn@kent.edu.'}, {'ForeName': 'M Andrea', 'Initials': 'MA', 'LastName': 'Azcarate-Peril', 'Affiliation': 'Department of Medicine, Division of Gastroenterology and Hepatology, and UNC Microbiome Core, Center for Gastrointestinal Biology and Disease, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Gunstad', 'Affiliation': 'Department of Psychological Sciences, Kent State University, USA; Brain Health Research Institute, Kent State University, USA.'}]",Diabetes & metabolic syndrome,['10.1016/j.dsx.2020.05.034'] 1621,32570059,"Effect of photobiomodulation on salivary flow and composition, xerostomia and quality of life of patients during head and neck radiotherapy in short term follow-up: A randomized controlled clinical trial.","Xerostomia and hyposalivation are frequent conditions in patients undergoing head and neck radiotherapy, which usually lead to a worsening of quality of life. This study aimed to assess whether photobiomodulation (PBM) can minimize hyposalivation, xerostomia and qualitative changes on saliva and improve quality of life in patients undergoing radiotherapy in short-term follow-up. Twenty-one patients were randomly divided into two groups: sham group (SG) and laser group (LG). A diode laser was used for intra- (660 nm, 10 J/cm 2 , 0.28 J per point, 40 mW) and extra-oral (810 nm, 25 J/cm 2 , 0.7 J per point, 40 mW) applications over the salivary glands, three times a week, during the entire radiotherapy period. In SG, the tip of the instrument was sealed with blue rubber to prevent the passage of light. Xerostomia and pH were evaluated and unstimulated and stimulated salivary flow was determined before the start of radiotherapy (T1), after the 15th session (T2), after the end of radiotherapy (T3) and 60 days after radiotherapy (T4). Concentrations of calcium, total proteins, chloride, sodium, potassium and amylase and catalase activities were evaluated in stimulated saliva samples. Quality of life was assessed at times T1 and T4. Generalized estimating equations were used to assess differences in the outcome between times and groups. All patients showed worsening in unstimulated (p = .003) and stimulated (p < .001) salivary flow, xerostomia (p < .05) and quality of life during radiotherapy (p = .001). An increase in chloride concentrations was observed at times T3 and T4 (p < 0,05), and a reduction in amylase activity at T3 (p < .05). Unstimulated saliva pH was higher in LG than SG at T3 (p = .037). No difference between groups was noted in relation to salivary flow and composition, xerostomia or quality of life. Our results suggest that PBM may help in preserving salivary pH during radiotherapy.",2020,"All patients showed worsening in unstimulated (p = .003) and stimulated (p < .001) salivary flow, xerostomia (p < .05) and quality of life during radiotherapy (p = .001).","['patients undergoing head and neck', 'patients during head and neck radiotherapy in short term follow-up', 'patients undergoing radiotherapy in short-term follow-up', 'Twenty-one patients']","['radiotherapy', 'photobiomodulation (PBM', 'photobiomodulation', 'sham group (SG) and laser group (LG', 'diode laser', 'PBM']","['quality of life', 'Concentrations of calcium, total proteins, chloride, sodium, potassium and amylase and catalase activities', 'Unstimulated saliva pH', 'relation to salivary flow and composition, xerostomia or quality of life', 'amylase activity', 'Quality of life', 'salivary flow and composition, xerostomia and quality of life', 'chloride concentrations', 'Xerostomia and pH', 'salivary flow, xerostomia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0460004', 'cui_str': 'Structure of head and/or neck'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C3715213', 'cui_str': '21'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0392254', 'cui_str': 'Semiconductor laser device'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0555903', 'cui_str': 'Total protein measurement'}, {'cui': 'C0008203', 'cui_str': 'Chloride salt'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0032821', 'cui_str': 'Potassium'}, {'cui': 'C0002712', 'cui_str': 'Amylases'}, {'cui': 'C0007367', 'cui_str': 'CATALASE'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0439819', 'cui_str': 'Unstimulated'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0043352', 'cui_str': 'Xerostomia'}]",21.0,0.0663906,"All patients showed worsening in unstimulated (p = .003) and stimulated (p < .001) salivary flow, xerostomia (p < .05) and quality of life during radiotherapy (p = .001).","[{'ForeName': 'Gabriel Campos', 'Initials': 'GC', 'LastName': 'Louzeiro', 'Affiliation': 'School of Health and Life Sciences, Oral Medicine Division, Pontifical Catholic University of Rio Grande do Sul- PUCRS, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Cherubini', 'Affiliation': 'School of Health and Life Sciences, Oral Medicine Division, Pontifical Catholic University of Rio Grande do Sul- PUCRS, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'ForeName': 'Maria Antonia Zancanaro', 'Initials': 'MAZ', 'LastName': 'de Figueiredo', 'Affiliation': 'School of Health and Life Sciences, Oral Medicine Division, Pontifical Catholic University of Rio Grande do Sul- PUCRS, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'ForeName': 'Fernanda Gonçalves', 'Initials': 'FG', 'LastName': 'Salum', 'Affiliation': 'School of Health and Life Sciences, Oral Medicine Division, Pontifical Catholic University of Rio Grande do Sul- PUCRS, Porto Alegre, Rio Grande do Sul, Brazil. Electronic address: fernanda.salum@pucrs.br.'}]","Journal of photochemistry and photobiology. B, Biology",['10.1016/j.jphotobiol.2020.111933'] 1622,32569429,A Pilot Trial of Topical Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome.,"OBJECTIVES Patients with cannabinoid hyperemesis syndrome (CHS) present frequently to the emergency department. Previous case studies suggest dramatic symptomatic improvement with topical capsaicin treatment. This exploratory study examined the potential effectiveness of topical capsaicin in patients with nausea and vomiting due to a suspected CHS exacerbation. METHODS This was a double-blind, randomized placebo-controlled pilot trial. Adults who presented with vomiting suspected to be from CHS were eligible for enrollment. We excluded pregnant women and those with resolution of symptoms. Following randomization, topical 0.1% capsaicin or placebo cream was applied to the anterior abdomen in a uniform manner. The primary outcome was the severity of nausea on a visual analog scale (VAS) of 0 to 10 cm assessed at 30 minutes. Secondary outcomes were adverse events, occurrence of posttreatment vomiting, nausea by VAS at 60 minutes, and hospital admission. RESULTS This pilot trial enrolled 30 patients, 17 in the capsaicin arm and 13 in the placebo arm. One patient in the capsaicin arm did not tolerate treatment due to skin irritation. Mean ± SD nausea severity at 30 minutes was 4.1 ± 2.3 cm in the capsaicin arm and 6.1 ± 3.3 cm in the placebo arm (difference = -2.0 cm, 95% confidence interval [CI] = 0.2 to -4.2 cm). At 60 minutes, mean ± SD nausea severity was 3.2 ± 3.2 cm versus 6.4 ± 2.8 cm (difference = -3.2 cm, 95% CI = -0.9 to -5.4 cm). The percent reduction in nausea at 60 minutes from baseline was 46.0% in the capsaicin arm and 24.9% in the placebo arm (difference = 21.1%, 95% CI = -5.6% to 47.9%). A higher proportion of capsaicin group patients (29.4% vs. 0%) had complete resolution of nausea (relative risk = 3.4, 95% CI = 1.6 to 7.1). CONCLUSION In this pilot trial, the application of topical capsaicin cream was associated with a significant reduction in nausea at 60 minutes but not at 30 minutes and provided more complete relief of nausea.",2020,"The percent reduction in nausea at 60 minutes from baseline was 46.0% in the capsaicin arm and 24.9% in the placebo arm (difference 21.1%, 95% CI, -5.6% to 47.9%).","['Adults who presented with vomiting suspected to be from CHS were eligible for enrollment', 'patients with nausea and vomiting due to a suspected CHS exacerbation', 'pregnant women and those with resolution of symptoms', '30 patients; 17 in the capsaicin arm and 13 in the placebo arm', 'Patients with cannabinoid hyperemesis syndrome (CHS', 'Cannabinoid Hyperemesis Syndrome']","['Topical Capsaicin Cream', 'topical capsaicin', 'topical 0.1% capsaicin or placebo cream', 'topical capsaicin cream', 'capsaicin', 'placebo']","['skin irritation', 'severity of nausea on a visual analog scale (VAS) of 0-10 cm assessed at 30 minutes', 'Mean nausea severity', 'complete resolution of nausea', 'complete relief of nausea', 'nausea', 'adverse events, occurrence of post-treatment vomiting, nausea by VAS at 60 minutes, and hospital admission', 'mean nausea severity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0006864', 'cui_str': 'cannabinoids'}, {'cui': 'C0020450', 'cui_str': 'Hyperemesis gravidarum'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0006931', 'cui_str': 'Capsaicin'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C3210186', 'cui_str': 'Capsaicin-containing product in transdermal dose form'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C0006931', 'cui_str': 'Capsaicin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0152030', 'cui_str': 'Skin irritation'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C3853333', 'cui_str': 'Sixty minutes'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]",30.0,0.533538,"The percent reduction in nausea at 60 minutes from baseline was 46.0% in the capsaicin arm and 24.9% in the placebo arm (difference 21.1%, 95% CI, -5.6% to 47.9%).","[{'ForeName': 'Diana J', 'Initials': 'DJ', 'LastName': 'Dean', 'Affiliation': 'From the, Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA.'}, {'ForeName': 'Noor', 'Initials': 'N', 'LastName': 'Sabagha', 'Affiliation': 'From the, Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA.'}, {'ForeName': 'Kaitlin', 'Initials': 'K', 'LastName': 'Rose', 'Affiliation': 'From the, Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Weiss', 'Affiliation': 'From the, Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'France', 'Affiliation': 'the, Wayne State University, Detroit, MI, USA.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Asmar', 'Affiliation': 'From the, Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA.'}, {'ForeName': 'Jo-Ann', 'Initials': 'JA', 'LastName': 'Rammal', 'Affiliation': 'From the, Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Beyer', 'Affiliation': 'From the, Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Bussa', 'Affiliation': 'From the, Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Ross', 'Affiliation': 'From the, Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA.'}, {'ForeName': 'Kaleem', 'Initials': 'K', 'LastName': 'Chaudhry', 'Affiliation': 'From the, Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Smoot', 'Affiliation': 'and the, Frederick Memorial Hospital, Frederick, MD, USA.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Wilson', 'Affiliation': 'From the, Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Miller', 'Affiliation': 'From the, Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA.'}]",Academic emergency medicine : official journal of the Society for Academic Emergency Medicine,['10.1111/acem.14062'] 1623,32569112,The Effect of Evaluator Training on Inter- and Intrarater Reliability in High-Stakes Assessment in Simulation.,"AIM The aim of this study was to evaluate the effectiveness of a training intervention in achieving inter- and intrarater reliability among faculty raters conducting high-stakes assessment of clinical performance in simulation. BACKGROUND High-stakes assessment of simulation performance is being adopted in nursing education. However, limited research exists to guide best practices in training raters, which is essential to ensure fair and defensible assessment. METHOD A nationwide sample of 75 prelicensure RN program faculty participated in an experimental, randomized, controlled study. RESULTS Participants completing a training intervention achieved higher inter- and intrarater reliability than control group participants when using a checklist evaluation tool. Mixed results were achieved by participants when completing a global competency assessment. CONCLUSION The training intervention was effective in helping participants to achieve a shared mental model for use of a checklist, but more time may be necessary to achieve consistent global competence decisions.",2020,"RESULTS Participants completing a training intervention achieved higher inter- and intrarater reliability than control group participants when using a checklist evaluation tool.","['A nationwide sample of 75 prelicensure RN program faculty participated in an experimental, randomized, controlled study']","['Evaluator Training', 'training intervention']",['higher inter- and intrarater reliability'],"[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0015535', 'cui_str': 'Faculty'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}]",,0.0219438,"RESULTS Participants completing a training intervention achieved higher inter- and intrarater reliability than control group participants when using a checklist evaluation tool.","[{'ForeName': 'Ann E', 'Initials': 'AE', 'LastName': 'Holland', 'Affiliation': 'About the Authors Ann E. Holland, PhD, RN, is a professor, Bethel University, St. Paul, Minnesota. Jone Tiffany, DNP, RN, CNE, CHSE, ANEF, is a professor, Bethel University. Linda Blazovich, DNP, RN, CNE, is an associate professor, St. Catherine University, St. Paul, Minnesota. Deborah Bambini, PhD, RN, WHNP-BC, CNE, CHSE, ANEF, is a professor, Grand Valley State University, Grand Rapids, Michigan. Vicki Schug, PhD, RN, CNE, is a professor, St. Catherine University. This study was supported by the National League for Nursing, with funding from Laerdal Medical. The authors acknowledge the work of their research assistant, Dorie Fritz, MSN, RN, and statistician, Joel Frederickson, PhD. For more information, contact Dr. Holland at ann-holland@bethel.edu.'}, {'ForeName': 'Jone', 'Initials': 'J', 'LastName': 'Tiffany', 'Affiliation': ''}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Blazovich', 'Affiliation': ''}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Bambini', 'Affiliation': ''}, {'ForeName': 'Vicki', 'Initials': 'V', 'LastName': 'Schug', 'Affiliation': ''}]",Nursing education perspectives,['10.1097/01.NEP.0000000000000619'] 1624,32570152,To study the changes in maternal hemodynamics with intravenous labetalol or nifedipine in acute severe hypertension.,"OBJECTIVE To study the maternal hemodynamic changes in acute severe hypertension after treatment with intravenous labetalol or oral nifedipine using color doppler ultrasound. STUDY DESIGN We evaluated thirty pregnant women with gestational age between 28 and 40 weeks in acute severe hypertension (more than or equal to 160/105 mmHg) which were randomly allocated to receive either intravenous labetalol or oral nifedipine until blood pressure was lowered to less than or equal to 140/90 mmHg. Doppler vascular indices namely pulsatility index, resistance index, S/D ratio of bilateral uterine arteries and maternal renal artery were measured baseline at the time of acute severe hypertension and repeated after control of blood pressure, to assess the changes in maternal hemodynamics if any with labetalol or nifedipine. RESULTS When evaluating right uterine artery Doppler parameters, a trend to increase in PI and RI was observed in those who received labetalol and nifedipine however the difference was not statistically significant. Whereas, while evaluating left uterine artery indices a trend to decrease PI was seen in nifedipine group but the difference was not statistically significant. On intergroup comparison there was no any significant change in any of uterine artery as well as renal artery indices in either group. CONCLUSION The use of labetalol and nifedipine were not related to any significant changes in maternal Doppler, which is reassuring about the safety of these drugs when treating acute severe hypertension in pregnancy.",2020,"On intergroup comparison there was no any significant change in any of uterine artery as well as renal artery indices in either group. ","['thirty pregnant women with gestational age between 28 and 40\xa0weeks in acute severe hypertension (more than or equal to 160/105\xa0mmHg', 'acute severe hypertension', 'acute severe hypertension after treatment with intravenous']","['labetalol or nifedipine', 'nifedipine', 'labetalol or oral nifedipine', 'intravenous labetalol or oral nifedipine', 'labetalol and nifedipine', 'labetalol']","['renal artery indices', 'Doppler vascular indices namely pulsatility index, resistance index, S/D ratio of bilateral uterine arteries and maternal renal artery', 'PI and RI']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0022860', 'cui_str': 'Labetalol'}, {'cui': 'C0028066', 'cui_str': 'Nifedipine'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0035065', 'cui_str': 'Structure of renal artery'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0554756', 'cui_str': 'Doppler studies'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0429863', 'cui_str': 'Pulsatility index, arterial velocity waveform'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0226378', 'cui_str': 'Structure of uterine artery'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]",30.0,0.0341283,"On intergroup comparison there was no any significant change in any of uterine artery as well as renal artery indices in either group. ","[{'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Thakur', 'Affiliation': 'Department of Obstetrics & Gynaecology, YSPGMC, Nahan, India. Electronic address: thakurmonika126@gmail.com.'}, {'ForeName': 'Shalini', 'Initials': 'S', 'LastName': 'Gainder', 'Affiliation': 'Department of Obstetrics & Gynaecology, PGIMER, Chandigarh, India.'}, {'ForeName': 'S C', 'Initials': 'SC', 'LastName': 'Saha', 'Affiliation': 'Department of Obstetrics & Gynaecology, PGIMER, Chandigarh, India.'}, {'ForeName': 'Mahesh', 'Initials': 'M', 'LastName': 'Prakash', 'Affiliation': 'Department of Radiodiagnosis, PGIMER, Chandigarh, India.'}]",Pregnancy hypertension,['10.1016/j.preghy.2020.05.014'] 1625,32570178,Effects of a 10-week multimodal dance and art intervention program leading to a public performance in persons with multiple sclerosis - A controlled pilot-trial.,"BACKGROUND Dance therapy is increasingly reported in neurological diseases for improving several motor and cognitive functions, but was mostly studied in partner dance. No individual choreo-based dance program has ever been reported in MS. OBJECTIVES The aim of this pilot study is to investigate effects of a ten-week choreo-based dance intervention on different impairments in MS. PARTICIPANTS Seventeen participants with MS were allocated to a dance group (DG) or an art group (AG) for a ten-week intervention program, with a public live performance at the end of the intervention. METHODS The DG received choreo-based dance courses twice a week for 90 min, while the active control AG weekly contributed to the production by painting, music, spoken word and photo- or videography. Measurements for fatigue and fatigability, physical capacity and coordination, sensory function, cognitive capacity, quality of life and dual task performance took place before and after the intervention. Differences were analysed with Wilcoxon Signed Rank test. RESULTS Both groups improved significantly on executive cognitive performance during dual task and fatigue. Only the DG improved significantly on functional lower limb strength, hand function, coordination, self-reported balance and walking, and showed a trend towards improving on cognition (PASAT). The AG showed significant improvements in on cognitive function (SDMT). CONCLUSION A ten-week multimodal dance intervention has positive effects on impact of fatigue, physical capacity and coordination, and cognitive performance during a dual task. Larger samples, follow-up measurements and research in different disability groups is recommended.",2020,"Only the DG improved significantly on functional lower limb strength, hand function, coordination, self-reported balance and walking, and showed a trend towards improving on cognition (PASAT).","['persons with multiple sclerosis', 'Seventeen participants with MS']","['active control AG weekly contributed to the production by painting, music, spoken word and photo- or videography', 'ten-week choreo-based dance intervention', 'multimodal dance and art intervention program', 'dance group (DG) or an art group (AG']","['functional lower limb strength, hand function, coordination, self-reported balance and walking, and showed a trend towards improving on cognition (PASAT', 'impact of fatigue, physical capacity and coordination, and cognitive performance', 'executive cognitive performance', 'fatigue and fatigability, physical capacity and coordination, sensory function, cognitive capacity, quality of life and dual task performance took place', 'cognitive function (SDMT']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0450331', 'cui_str': '17'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0030208', 'cui_str': 'Paintings'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0010963', 'cui_str': 'Dance'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0562230', 'cui_str': 'Hand functions'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040833', 'cui_str': 'trends'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0231230', 'cui_str': 'Fatigability'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0442504', 'cui_str': 'Place'}]",17.0,0.0172608,"Only the DG improved significantly on functional lower limb strength, hand function, coordination, self-reported balance and walking, and showed a trend towards improving on cognition (PASAT).","[{'ForeName': 'Fanny', 'Initials': 'F', 'LastName': 'Van Geel', 'Affiliation': 'REVAL Rehabilitation Research Center, Faculty of Rehabilitation Sciences, Hasselt University, Belgium. Electronic address: fanny.vangeel@uhasselt.be.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Van Asch', 'Affiliation': 'Fit Up Neurological and Sport Physiotherapy, Antwerp, Belgium; Move to Sport Foundation, Mechelsesteenweg, Kontich, Belgium.'}, {'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Veldkamp', 'Affiliation': 'REVAL Rehabilitation Research Center, Faculty of Rehabilitation Sciences, Hasselt University, Belgium. Electronic address: renee.veldkamp@uhasselt.be.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Feys', 'Affiliation': 'REVAL Rehabilitation Research Center, Faculty of Rehabilitation Sciences, Hasselt University, Belgium. Electronic address: peter.feys@uhasselt.be.'}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2020.102256'] 1626,32574844,"Effect of soluble corn fiber supplementation for 1 year on bone metabolism in children, the MetA-bone trial: Rationale and design.","Calcium intake is critical for adequate bone mineralization in adolescence, but it is usually inadequate in US adolescents. A strategy to maximize bone mineralization is to increase calcium absorption, which could be achieved by soluble corn fiber (SCF). There are no studies determining the long-term effects of SCF on bone mass in children. OBJECTIVES To determine the effect of one-year SCF supplementation compared to placebo on bone mass and bone biomarkers in children with low habitual calcium intake. We hypothesize that SCF supplementation will result in a higher bone mineral content and higher levels of bone formation and lower bone resorption biomarkers. METHODS 240 healthy children (10-13 years), with usual low calcium intake, will be randomized to four experimental groups for 1 year: (1) SCF (12 g/d); (2) SCF (12 g/d) + 600 mg/d of calcium; (3) Placebo (maltodextrin); and (4) Placebo +600 mg/d of calcium. The supplements have been pre-mixed with a flavored powder beverage and participants will only need to dilute it in water and drink this twice per day. Bone will be measured using dual energy x-ray absorptiometry (DXA) at baseline, 6 and 12 months. Serum bone biomarkers will be measured at baseline and at 12 months. CONCLUSIONS If supplementing diets with SCF lead to higher bone mass during adolescence, this could help achieve the genetic potential for PBM and to start adult life with stronger bones. If successful, SCF can be incorporated into diets for promoting bone health in adolescents.",2020,"We hypothesize that SCF supplementation will result in a higher bone mineral content and higher levels of bone formation and lower bone resorption biomarkers. ","['240 healthy children (10-13\u202fyears', 'adolescents', 'children with low habitual calcium intake', 'children']","['SCF', 'usual low calcium intake', 'soluble corn fiber supplementation', 'calcium; (3) Placebo (maltodextrin', 'Calcium intake', 'SCF supplementation', 'Placebo +600\u202fmg/d of calcium', 'placebo']","['bone metabolism', 'Serum bone biomarkers', 'bone mineral content and higher levels of bone formation and lower bone resorption biomarkers', 'bone mass and bone biomarkers']","[{'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0489458', 'cui_str': 'Calcium intake'}]","[{'cui': 'C0010028', 'cui_str': 'Zea mays'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0860967', 'cui_str': 'Calcium low'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0489458', 'cui_str': 'Calcium intake'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}]","[{'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005963', 'cui_str': 'Bone Mineral Content'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0029433', 'cui_str': 'Bone formation'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0005974', 'cui_str': 'Bone resorption'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}]",240.0,0.314368,"We hypothesize that SCF supplementation will result in a higher bone mineral content and higher levels of bone formation and lower bone resorption biomarkers. ","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Palacios', 'Affiliation': 'Dietetics and Nutrition Department, Robert Stempel College of Public Health & Social Work, Florida International University, 11200 SW 8th Street, Miami, FL\xa033199, United States of America. Electronic address: cristina.palacios@fiu.edu.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Trak-Fellermeier', 'Affiliation': 'Dietetics and Nutrition Department, Robert Stempel College of Public Health & Social Work, Florida International University, 11200 SW 8th Street, Miami, FL\xa033199, United States of America.'}, {'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Pérez', 'Affiliation': 'Department of Biostatistics and Epidemiology, Graduate School of Public Health, Medical Sciences Campus, University of Puerto Rico, 11200 SW 8th Street, Miami, FL\xa033199, United States of America.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Huffman', 'Affiliation': 'Dietetics and Nutrition Department, Robert Stempel College of Public Health & Social Work, Florida International University, 11200 SW 8th Street, Miami, FL\xa033199, United States of America.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Hernandez Suarez', 'Affiliation': 'Vice Provost for Population Health and Well-being, Florida International University, 11200 SW 8th Street, Miami, FL\xa033199, United States of America.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Bursac', 'Affiliation': 'Department of Biostatistics, Robert Stempel College of Public Health, Florida International University, 11200 SW 8th Street, Miami, FL\xa033199, United States of America.'}, {'ForeName': 'T B', 'Initials': 'TB', 'LastName': 'Gambon', 'Affiliation': 'Pediatrician, Citrus Health Network, 551 W 51st Pl, Hialeah, FL 33012, United States of America.'}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Nakatsu', 'Affiliation': 'Department of Agronomy, College of Agriculture, Purdue University, 915 West State Street, West Lafayette, IN 47907-2053, United States of America.'}, {'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Weaver', 'Affiliation': 'Distinguished Professor emerita, Purdue University, 610 Purdue Mall, West Lafayette, IN 47907, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106061'] 1627,32575439,Immunoadsorption for Treatment of Patients with Suspected Alzheimer Dementia and Agonistic Autoantibodies against Alpha1a-Adrenoceptor-Rationale and Design of the IMAD Pilot Study.,"BACKGROUND agonistic autoantibodies (agAABs) against G protein-coupled receptors (GPCR) have been linked to cardiovascular disease. In dementia patients, GPCR-agAABs against the α1- and ß2-adrenoceptors (α1AR- and ß2AR) were found at a prevalence of 50%. Elimination of agAABs by immunoadsorption (IA) was successfully applied in cardiovascular disease. The IMAD trial (Efficacy of immunoadsorption for treatment of persons with Alzheimer dementia and agonistic autoantibodies against alpha1A-adrenoceptor) investigates whether the removal of α1AR-AABs by a 5-day IA procedure has a positive effect (improvement or non-deterioration) on changes of hemodynamic, cognitive, vascular and metabolic parameters in patients with suspected Alzheimer's clinical syndrome within a one-year follow-up period. METHODS the IMAD trial is designed as an exploratory monocentric interventional trial corresponding to a proof-of-concept phase-IIa study. If cognition capacity of eligible patients scores 19-26 in the Mini Mental State Examination (MMSE), patients are tested for the presence of agAABs by an enzyme-linked immunosorbent assay (ELISA)-based method, followed by a bioassay-based confirmation test, further screening and treatment with IA and intravenous immunoglobulin G (IgG) replacement. We aim to include 15 patients with IA/IgG and to complete follow-up data from at least 12 patients. The primary outcome parameter of the study is uncorrected mean cerebral perfusion measured in mL/min/100 gr of brain tissue determined by magnetic resonance imaging with arterial spin labeling after 12 months. CONCLUSION IMAD is an important pilot study that will analyze whether the removal of α1AR-agAABs by immunoadsorption in α1AR-agAAB-positive patients with suspected Alzheimer's clinical syndrome may slow the progression of dementia and/or may improve vascular functional parameters.",2020,"The IMAD trial (Efficacy of immunoadsorption for treatment of persons with Alzheimer dementia and agonistic autoantibodies against alpha1A-adrenoceptor) investigates whether the removal of α1AR-AABs by a 5-day IA procedure has a positive effect (improvement or non-deterioration) on changes of hemodynamic, cognitive, vascular and metabolic parameters in patients with suspected Alzheimer's clinical syndrome within a one-year follow-up period. ","['eligible patients scores 19-26 in the Mini Mental State Examination (MMSE), patients are tested for the presence of agAABs by an enzyme-linked immunosorbent assay (ELISA)-based method, followed by a bioassay-based confirmation test, further screening and treatment with', 'persons with Alzheimer dementia and agonistic autoantibodies against alpha1A-adrenoceptor', '15 patients with IA/IgG and to complete follow-up data from at least 12 patients', 'Patients with Suspected Alzheimer Dementia and Agonistic Autoantibodies against Alpha1a-Adrenoceptor-Rationale and Design of the IMAD Pilot Study', ""patients with suspected Alzheimer's clinical syndrome within a one-year follow-up period""]","['IA and intravenous immunoglobulin G (IgG) replacement', 'immunoadsorption', 'IMAD']","['uncorrected mean cerebral perfusion measured in mL/min/100 gr of brain tissue determined by magnetic resonance imaging with arterial spin labeling', 'GPCR-agAABs against the α1- and ß2-adrenoceptors (α1AR- and ß2AR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0521091', 'cui_str': 'Confirmation of'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0004358', 'cui_str': 'Autoantibody'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0031928', 'cui_str': 'Pilot Study'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C4082117', 'cui_str': 'One year'}]","[{'cui': 'C0085297', 'cui_str': 'Intravenous Immunoglobulins'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0440746', 'cui_str': 'Brain tissue'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0537408', 'cui_str': 'ORF74 protein, Human herpesvirus 8'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}]",15.0,0.184026,"The IMAD trial (Efficacy of immunoadsorption for treatment of persons with Alzheimer dementia and agonistic autoantibodies against alpha1A-adrenoceptor) investigates whether the removal of α1AR-AABs by a 5-day IA procedure has a positive effect (improvement or non-deterioration) on changes of hemodynamic, cognitive, vascular and metabolic parameters in patients with suspected Alzheimer's clinical syndrome within a one-year follow-up period. ","[{'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Stracke', 'Affiliation': 'Department for Internal Medicine A, Nephrology, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Lange', 'Affiliation': 'Institute of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, 17475 Greifswald, Germany.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Bornmann', 'Affiliation': 'Department of Neurology, University Medicine Greifswald, 17475 Greifswald, Germany.'}, {'ForeName': 'Holger', 'Initials': 'H', 'LastName': 'Kock', 'Affiliation': 'Strategic Research Management, University Medicine Greifswald, 17475 Greifswald, Germany.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Schulze', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17475 Greifswald, Germany.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Klinger-König', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17475 Greifswald, Germany.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Böhm', 'Affiliation': 'Coordinating Centre for Clinical Trials, University Medicine Greifswald, 17475 Greifswald, Germany.'}, {'ForeName': 'Antje', 'Initials': 'A', 'LastName': 'Vogelgesang', 'Affiliation': 'Department of Neurology, University Medicine Greifswald, 17475 Greifswald, Germany.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'von Podewils', 'Affiliation': 'Department of Neurology, University Medicine Greifswald, 17475 Greifswald, Germany.'}, {'ForeName': 'Agnes', 'Initials': 'A', 'LastName': 'Föel', 'Affiliation': 'Department of Neurology, University Medicine Greifswald, 17475 Greifswald, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Gross', 'Affiliation': 'Department of Internal Medicine B, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Wenzel', 'Affiliation': 'Berlin Cures GmbH, 13125 Berlin, Germany.'}, {'ForeName': 'Gerd', 'Initials': 'G', 'LastName': 'Wallukat', 'Affiliation': 'Berlin Cures GmbH, 13125 Berlin, Germany.'}, {'ForeName': 'Harald', 'Initials': 'H', 'LastName': 'Prüss', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE) Berlin, 10117 Berlin, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Dressel', 'Affiliation': 'Department of Neurology, Carl-Thiem-Klinikum, 03048 Cottbus, Germany.'}, {'ForeName': 'Rudolf', 'Initials': 'R', 'LastName': 'Kunze', 'Affiliation': 'Science Office, Hessenhagen 2, 17268 Flieth-Stegelitz, Germany.'}, {'ForeName': 'Hans J', 'Initials': 'HJ', 'LastName': 'Grabe', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17475 Greifswald, Germany.'}, {'ForeName': 'Sönke', 'Initials': 'S', 'LastName': 'Langner', 'Affiliation': 'Institute of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, 17475 Greifswald, Germany.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Dörr', 'Affiliation': 'Department of Internal Medicine B, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany.'}]",Journal of clinical medicine,['10.3390/jcm9061919'] 1628,32576214,Tracking implementation strategies in the randomized rollout of a Veterans Affairs national opioid risk management initiative.,"BACKGROUND In 2018, the Department of Veterans Affairs (VA) issued Notice 2018-08 requiring facilities to complete ""case reviews"" for Veterans identified in the Stratification Tool for Opioid Risk Mitigation (STORM) dashboard as high risk for adverse outcomes among patients prescribed opioids. Half of the facilities were randomly assigned to a Notice version including additional oversight. We evaluated implementation strategies used, whether strategies differed by randomization arm, and which strategies were associated with case review completion rates. METHODS Facility points of contact completed a survey assessing their facility's use of 68 implementation strategies based on the Expert Recommendations for Implementing Change taxonomy. We collected respondent demographic information, facility-level characteristics, and case review completion rates (percentage of high-risk patients who received a case review). We used Kruskal-Wallis tests and negative binomial regression to assess strategy use and factors associated with case reviews. RESULTS Contacts at 89 of 140 facilities completed the survey (64%) and reported using a median of 23 (IQR 16-31) strategies. The median case review completion rate was 71% (IQR 48-95%). Neither the number or types of strategies nor completion rates differed by randomization arm. The most common strategies were using the STORM dashboard (97%), working with local opinion leaders (80%), and recruiting local partners (80%). Characteristics associated with case review completion rates included respondents being ≤ 35 years old (incidence rate ratio, IRR 1.35, 95% CI 1.09-1.67) and having < 5 years in their primary role (IRR 1.23; 95% CI 1.01-1.51), and facilities having more prior academic detailing around pain and opioid safety (IRR 1.40, 95% CI 1.12-1.75). Controlling for these characteristics, implementation strategies associated with higher completion rates included (1) monitoring and adjusting practices (adjusted IRR (AIRR) 1.40, 95% CI 1.11-1.77), (2) identifying adaptations while maintaining core components (AIRR 1.28, 95% CI 1.03-1.60), (3) conducting initial training (AIRR 1.16, 95% CI 1.02-1.50), and (4) regularly sharing lessons learned (AIRR 1.32, 95% CI 1.09-1.59). CONCLUSIONS In this national evaluation of strategies used to implement case reviews of patients at high risk of opioid-related adverse events, point of contact age and tenure in the current role, prior pain-related academic detailing at the facility, and four specific implementation strategies were associated with case review completion rates, while randomization to additional centralized oversight was not. TRIAL REGISTRATION This project is registered at the ISRCTN Registry with number ISRCTN16012111. The trial was first registered on May 3, 2017.",2020,"Characteristics associated with case review completion rates included respondents being ≤ 35 years old (incidence rate ratio, IRR 1.35, 95% CI 1.09-1.67) and having < 5 years in their primary role (IRR 1.23; 95% CI 1.01-1.51), and facilities having more prior academic detailing around pain and opioid safety (IRR 1.40, 95% CI 1.12-1.75).","[""Facility points of contact completed a survey assessing their facility's use of 68 implementation strategies based on the Expert Recommendations for Implementing Change taxonomy""]",[],"['number or types of strategies nor completion rates', 'median case review completion rate', 'facilities having more prior academic detailing around pain and opioid safety']","[{'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0008903', 'cui_str': 'classification'}]",[],"[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.246501,"Characteristics associated with case review completion rates included respondents being ≤ 35 years old (incidence rate ratio, IRR 1.35, 95% CI 1.09-1.67) and having < 5 years in their primary role (IRR 1.23; 95% CI 1.01-1.51), and facilities having more prior academic detailing around pain and opioid safety (IRR 1.40, 95% CI 1.12-1.75).","[{'ForeName': 'Shari S', 'Initials': 'SS', 'LastName': 'Rogal', 'Affiliation': 'Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA. shari.rogal@va.gov.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Chinman', 'Affiliation': 'Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.'}, {'ForeName': 'Walid F', 'Initials': 'WF', 'LastName': 'Gellad', 'Affiliation': 'Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.'}, {'ForeName': 'Maria K', 'Initials': 'MK', 'LastName': 'Mor', 'Affiliation': 'Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.'}, {'ForeName': 'Hongwei', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.'}, {'ForeName': 'Sharon A', 'Initials': 'SA', 'LastName': 'McCarthy', 'Affiliation': 'Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.'}, {'ForeName': 'Genna T', 'Initials': 'GT', 'LastName': 'Mauro', 'Affiliation': 'Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.'}, {'ForeName': 'Jennifer A', 'Initials': 'JA', 'LastName': 'Hale', 'Affiliation': 'Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.'}, {'ForeName': 'Eleanor T', 'Initials': 'ET', 'LastName': 'Lewis', 'Affiliation': 'VA Office of Mental Health and Suicide Prevention, VA Palo Alto Healthcare System, Menlo Park, CA, USA.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Oliva', 'Affiliation': 'VA Office of Mental Health and Suicide Prevention, VA Palo Alto Healthcare System, Menlo Park, CA, USA.'}, {'ForeName': 'Jodie A', 'Initials': 'JA', 'LastName': 'Trafton', 'Affiliation': 'VA Office of Mental Health and Suicide Prevention, VA Palo Alto Healthcare System, Menlo Park, CA, USA.'}, {'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Yakovchenko', 'Affiliation': 'Center for Healthcare Organization & Implementation Research, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, USA.'}, {'ForeName': 'Adam J', 'Initials': 'AJ', 'LastName': 'Gordon', 'Affiliation': 'Program for Addiction Research, Clinical Care, Knowledge, and Advocacy, University of Utah School of Medicine, Salt Lake City, UT, USA.'}, {'ForeName': 'Leslie R M', 'Initials': 'LRM', 'LastName': 'Hausmann', 'Affiliation': 'Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.'}]",Implementation science : IS,['10.1186/s13012-020-01005-y'] 1629,32576297,Comparison of whole egg v . egg white ingestion during 12 weeks of resistance training on skeletal muscle regulatory markers in resistance-trained men.,"Eggs are considered a high-quality protein source for their complete amino acid profile and digestibility. Therefore, this study aimed to compare the effects of whole egg (WE) v. egg white (EW) ingestion during 12 weeks of resistance training (RT) on the skeletal muscle regulatory markers and body composition in resistance-trained men. Thirty resistance-trained men (mean age 24·6 (sd 2·7) years) were randomly assigned into the WE + RT (WER, n 15) or EW + RT (EWR, n 15) group. The WER group ingested three WE, while the EWR group ingested an isonitrogenous quantity of six EW per d immediately after the RT session. Serum concentrations of regulatory markers and body composition were measured at baseline and after 12 weeks. Significant main effects of time were observed for body weight (WER 1·7, EWR 1·8 kg), skeletal muscle mass (WER 2·9, EWR 2·7 kg), fibroblast growth factor-2 (WER 116·1, EWR 83·2 pg/ml) and follistatin (WER 0·05, EWR 0·04 ng/ml), which significantly increased (P < 0·05), and for fat mass (WER -1·9, EWR -1·1 kg), transforming growth factor-β1 (WER -0·5, EWR -0·1 ng/ml), activin A (WER -6·2, EWR -4·5 pg/ml) and myostatin (WER -0·1, EWR -0·06 ng/ml), which significantly decreased (P < 0·05) in both WER and EWR groups. The consumption of eggs absent of yolk during chronic RT resulted in similar body composition and functional outcomes as WE of equal protein value. EW or WE may be used interchangeably for the dietary support of RT-induced muscular hypertrophy when protein intake is maintained.",2020,"ng.ml], which significantly decreased (p ˂ 0.05) in both the WER and EWR groups.","['resistance-trained men', 'Thirty resistance-trained men (24.6 ± 2.7 years']","['whole egg (WE) vs. egg white (EW) ingestion', 'whole egg vs. egg white ingestion', 'resistance training (RT', 'resistance training', 'EW + RT (EWR']","['Serum concentrations of regulatory markers and body composition', 'myostatin [WER', 'Fibroblast growth factor', 'skeletal muscle regulatory markers', 'skeletal muscle mass', 'Transforming growth factor-β1']","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C4517635', 'cui_str': '2.7'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0013710', 'cui_str': 'Eggs (edible)'}, {'cui': 'C0013704', 'cui_str': 'Egg white'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0538238', 'cui_str': 'GDF8 protein, human'}, {'cui': 'C0016026', 'cui_str': 'Fibroblast growth factor'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0040691', 'cui_str': 'Transforming Growth Factor'}]",,0.133598,"ng.ml], which significantly decreased (p ˂ 0.05) in both the WER and EWR groups.","[{'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Bagheri', 'Affiliation': 'Department of Exercise Physiology, University of Isfahan, Isfahan, 8174673441, Iran.'}, {'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Hooshmand Moghadam', 'Affiliation': 'Department of Exercise Physiology, Ferdowsi university of Mashhad, Mashhad, 9177948974, Iran.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Jo', 'Affiliation': 'Kinesiology & Health Promotion Department, California State Polytechnic University Pomona, Pomona, CA91768-2557, USA.'}, {'ForeName': 'Grant M', 'Initials': 'GM', 'LastName': 'Tinsley', 'Affiliation': 'Department of Kinesiology & Sport Management, Texas Tech University, Lubbock, TX79409, USA.'}, {'ForeName': 'Matthew T', 'Initials': 'MT', 'LastName': 'Stratton', 'Affiliation': 'Department of Kinesiology & Sport Management, Texas Tech University, Lubbock, TX79409, USA.'}, {'ForeName': 'Damoon', 'Initials': 'D', 'LastName': 'Ashtary-Larky', 'Affiliation': 'Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, 61357-15794, Iran.'}, {'ForeName': 'Mozhgan', 'Initials': 'M', 'LastName': 'Eskandari', 'Affiliation': 'Department of Exercise Physiology, University of Birjand, Birjand, 9717434765, Iran.'}, {'ForeName': 'Alexei', 'Initials': 'A', 'LastName': 'Wong', 'Affiliation': 'Department of Health and Human Performance, Marymount University, Arlington, TX22207, USA.'}]",The British journal of nutrition,['10.1017/S0007114520002238'] 1630,32577819,Switching from Warfarin to rivaroxaban induces sufficiency of vitamin K and reduction of arterial stiffness in patients with atrial fibrillation.,"Use of chronic vitamin K antagonist (VKA) induces a long-term deficiency of vitamin K, which may cause arterial stiffness and bone-related disease. Switching from VKA to rivaroxaban could induce rapid sufficiency of vitamin K and improvement of arterial stiffness. The K2 SUMMIT-3 study is a multicenter, open-label, prospective, and randomized design. Patients with atrial fibrillation who have been taking VKA for more than 6 months but less than 10 years were randomly assigned to two groups; those switching from VKA to rivaroxaban and those continuing with VKA medication. The primary endpoint was the percentage difference of brachial-ankle pulse wave velocity (baPWV) in 3 months. A total of 77 patients were randomly assigned to receive rivaroxaban (n = 38) or VKA (n = 39). The average age was 74 ± 9 years. The duration for which VKA was prescribed prior to randomization was 90 ± 87 months.Abnormally high levels of Des-gamma carboxyprothrombin (PIVKA-II) or uncarboxylated osteocalcin (ucOC) indicating vitamin K insufficiency were observed in 100% or 82% of the patients at baseline but it reduced to 2% (p < 0.0001) or 55% (p = 0.01) at 3 months in the rivaroxaban group. To the contrary, theses data had no changes in the VKA group. The percentage difference in baPWV was - 1.4 ± 10.0% vs. 3.5 ± 14.7% in the rivaroxaban and the VKA groups, respectively. (p = 0.02). Switching from VKA to rivaroxaban resulted in rapid sufficiency of vitamin K and reduction of arterial stiffness in 3 months.",2020,Switching from VKA to rivaroxaban resulted in rapid sufficiency of vitamin K and reduction of arterial stiffness in 3 months.,"['Patients with atrial fibrillation who have been taking VKA for more than 6\xa0months but less than 10\xa0years', 'A total of 77 patients', 'patients with atrial fibrillation']","['rivaroxaban', 'VKA', 'chronic vitamin K antagonist (VKA']","['Abnormally high levels of Des-gamma carboxyprothrombin (PIVKA-II) or uncarboxylated osteocalcin (ucOC) indicating vitamin K insufficiency', 'arterial stiffness', 'rapid sufficiency of vitamin K and reduction of arterial stiffness', 'percentage difference of brachial-ankle pulse wave velocity (baPWV', 'baPWV']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C1096489', 'cui_str': 'Vitamin K antagonist'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C1096489', 'cui_str': 'Vitamin K antagonist'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}]","[{'cui': 'C1299351', 'cui_str': 'Abnormally high'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017011', 'cui_str': 'Gamma radiation'}, {'cui': 'C0950248', 'cui_str': 'Des-gamma-carboxy prothrombin'}, {'cui': 'C0029419', 'cui_str': 'Osteocalcin'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0042878', 'cui_str': 'Vitamin K'}, {'cui': 'C0231179', 'cui_str': 'Insufficiency'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0232154', 'cui_str': 'Ankle pulse'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}]",77.0,0.0510437,Switching from VKA to rivaroxaban resulted in rapid sufficiency of vitamin K and reduction of arterial stiffness in 3 months.,"[{'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Ikari', 'Affiliation': 'Department of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan. ikari@is.icc.u-tokai.ac.jp.'}, {'ForeName': 'Fumie', 'Initials': 'F', 'LastName': 'Saito', 'Affiliation': 'Department of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan.'}, {'ForeName': 'Takahiko', 'Initials': 'T', 'LastName': 'Kiyooka', 'Affiliation': 'Tokai University Oiso Hospital, Oiso, Japan.'}, {'ForeName': 'Masakazu', 'Initials': 'M', 'LastName': 'Nagaoka', 'Affiliation': 'Ebina General Hospital, Ebina, Japan.'}, {'ForeName': 'Manabu', 'Initials': 'M', 'LastName': 'Kimura', 'Affiliation': 'Tokai University Tokyo Hospital, Tokyo, Japan.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Furuki', 'Affiliation': 'Hadano South Gate Clinic, Hadano, Japan.'}, {'ForeName': 'Shigemitsu', 'Initials': 'S', 'LastName': 'Tanaka', 'Affiliation': 'Tokai University Oiso Hospital, Oiso, Japan.'}]",Heart and vessels,['10.1007/s00380-020-01651-8'] 1631,32575705,"Effects of Oral Antihistamines on Tear Volume, Tear Stability, and Intraocular Pressure.","The goal of this study was to investigate the effects of two commonly used oral antihistamines-diphenhydramine and loratadine-on tear volume, tear breakup time, and intraocular pressure. Placebo, diphenhydramine, and loratadine were administered for one week to 33 subjects experimentally blind to the treatment given. All the subjects received all three treatments over a period of six weeks. The outcome measures were the change in phenol red thread test (PRT), the tear breakup time (TBUT), and the intraocular pressure (IOP) of both eyes evaluated by experimentally masked observers. Neither of the mean changes in TBUT or IOP depended on the treatment given, but there was a significant monocular decrease in tear volume from diphenhydramine use. While we used an adequate treatment washout period of seven days, our investigation was limited by the short treatment times and inclusion of only young healthy patients. Overall, however, these results suggest that systemic diphenhydramine use should be limited to increase the effectiveness of conventional therapies. Clinicians should have fewer reservations about recommending the use of loratadine concurrent with dry eye treatments.",2020,"Neither of the mean changes in TBUT or IOP depended on the treatment given, but there was a significant monocular decrease in tear volume from diphenhydramine use.",['young healthy patients'],"['Oral Antihistamines', 'loratadine', 'Placebo, diphenhydramine, and loratadine', 'antihistamines-diphenhydramine and loratadine', 'diphenhydramine']","['tear volume, tear breakup time, and intraocular pressure', 'change in phenol red thread test (PRT), the tear breakup time (TBUT), and the intraocular pressure (IOP) of both eyes evaluated by experimentally masked observers', 'Tear Volume, Tear Stability, and Intraocular Pressure', 'mean changes in TBUT or IOP']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0019590', 'cui_str': 'Histamine receptor antagonist'}, {'cui': 'C0065180', 'cui_str': 'Loratadine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0012522', 'cui_str': 'Diphenhydramine'}]","[{'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0031430', 'cui_str': 'Phenolsulfonphthalein'}, {'cui': 'C4319672', 'cui_str': 'Thread'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0229118', 'cui_str': 'Structure of both eyes'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",33.0,0.0262061,"Neither of the mean changes in TBUT or IOP depended on the treatment given, but there was a significant monocular decrease in tear volume from diphenhydramine use.","[{'ForeName': 'Brian K', 'Initials': 'BK', 'LastName': 'Foutch', 'Affiliation': 'Rosenberg School of Optometry, University of the Incarnate Word, San Antonio, TX 78229, USA.'}, {'ForeName': 'Kyle A', 'Initials': 'KA', 'LastName': 'Sandberg', 'Affiliation': 'Rosenberg School of Optometry, University of the Incarnate Word, San Antonio, TX 78229, USA.'}, {'ForeName': 'Edward S', 'Initials': 'ES', 'LastName': 'Bennett', 'Affiliation': 'College of Optometry, University of Missouri-St Louis, St. Louis, MO 63121, USA.'}, {'ForeName': 'Leonard L', 'Initials': 'LL', 'LastName': 'Naeger', 'Affiliation': 'College of Optometry, University of Missouri-St Louis, St. Louis, MO 63121, USA.'}]","Vision (Basel, Switzerland)",['10.3390/vision4020032'] 1632,32575829,Benefits of High-Flow Nasal Cannula Therapy for Acute Pulmonary Edema in Patients with Heart Failure in the Emergency Department: A Prospective Multi-Center Randomized Controlled Trial.,"Heart failure patients with pulmonary edema presenting to the emergency department (ED) require an effective approach to deliver sufficient oxygen and reduce the rate of intubation and mechanical ventilation in the ED; conventional oxygen therapy has proven ineffective in delivering enough oxygen to the tissues. We aimed to identify whether high-flow nasal cannula (HFNC) therapy over time improved the respiratory rate (RR), lactate clearance, and certain arterial blood gas (ABG) parameters, in comparison with conventional oxygen therapy, in patients with cardiogenic pulmonary edema. This prospective, multi-institutional, and interventional study (clinical trial, reference KCT0004578) conducted between 2016 and 2019 included adult patients diagnosed with heart failure within the previous year and pulmonary edema confirmed at admission. Patients were randomly assigned to the conventional or HFNC group and treated with the goal of maintaining oxygen saturation (SpO 2 ) ≥ 93. We obtained RR, SpO 2 , lactate levels, and ABG parameters at baseline and 30 and 60 min after randomization. All parameters showed greater improvement with HFNC therapy than with conventional therapy. Significant changes in ABG parameters were achieved within 30 min. HFNC therapy could therefore be considered as initial oxygen therapy. Physicians may consider advanced ventilation if there is no significant improvement in ABG parameters within 30 min of HFNC therapy.",2020,All parameters showed greater improvement with HFNC therapy than with conventional therapy.,"['2016 and 2019 included adult patients diagnosed with heart failure within the previous year and pulmonary edema confirmed at admission', 'Patients with Heart Failure in the Emergency Department', 'patients with cardiogenic pulmonary edema', 'Heart failure patients with pulmonary edema presenting to the emergency department (ED']","['conventional oxygen therapy', 'high-flow nasal cannula (HFNC) therapy', 'High-Flow Nasal Cannula Therapy', 'HFNC therapy', 'conventional or HFNC']","['ABG parameters', 'RR, SpO 2 , lactate levels, and ABG parameters', 'respiratory rate (RR), lactate clearance, and certain arterial blood gas (ABG) parameters']","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0034063', 'cui_str': 'Pulmonary edema'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0398350', 'cui_str': 'Acute cardiac pulmonary edema'}, {'cui': 'C0150312', 'cui_str': 'Present'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0150411', 'cui_str': 'Analysis of arterial blood gases and pH'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0428445', 'cui_str': 'D-lactate measurement'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0205423', 'cui_str': 'Certain'}]",,0.038284,All parameters showed greater improvement with HFNC therapy than with conventional therapy.,"[{'ForeName': 'Dong Ryul', 'Initials': 'DR', 'LastName': 'Ko', 'Affiliation': 'Department of Emergency Medicine, Yonsei University College of Medicine, Seoul 06273, Korea.'}, {'ForeName': 'Jinho', 'Initials': 'J', 'LastName': 'Beom', 'Affiliation': 'Department of Emergency Medicine, Yonsei University College of Medicine, Seoul 06273, Korea.'}, {'ForeName': 'Hye Sun', 'Initials': 'HS', 'LastName': 'Lee', 'Affiliation': 'Department of Research Affairs, Biostatistics Collaboration Unit, College of Medicine, Yonsei University, Seoul 06273, Korea.'}, {'ForeName': 'Je Sung', 'Initials': 'JS', 'LastName': 'You', 'Affiliation': 'Department of Emergency Medicine, Yonsei University College of Medicine, Seoul 06273, Korea.'}, {'ForeName': 'Hyun Soo', 'Initials': 'HS', 'LastName': 'Chung', 'Affiliation': 'Department of Emergency Medicine, Yonsei University College of Medicine, Seoul 06273, Korea.'}, {'ForeName': 'Sung Phil', 'Initials': 'SP', 'LastName': 'Chung', 'Affiliation': 'Department of Emergency Medicine, Yonsei University College of Medicine, Seoul 06273, Korea.'}]",Journal of clinical medicine,['10.3390/jcm9061937'] 1633,32583957,A Pooled Analysis of Three Randomized Phase I/IIa Clinical Trials Confirms Absence of a Clinically Relevant Effect on the QTc Interval by Umibecestat.,"Umibecestat, an orally active β-secretase inhibitor, reduces the production of amyloid beta-peptide that accumulates in the brain of patients with Alzheimer's disease. The echocardiogram effects of umibecestat, on QTcF (Fridericia-corrected QT), on PR and QRS and heart rate (HR), were estimated by concentration-effect modeling. Three phase I/II studies with durations up to 3 months, with 372 healthy subjects over a wide age range, including both sexes and 2 ethnicities, were pooled, providing a large data set with good statistical power. No clinically relevant effect on QTcF, PR interval, QRS duration, or HR were observed up to supratherapeutic doses. The upper bound of 90% confidence intervals of the ∆QTcF was below the 10 ms threshold of regulatory concern for all concentrations measured. Prespecified sensitivity analysis confirmed the results in both sexes, in those over and below 60 years, and in Japanese subjects. All conclusions were endorsed by the US Food and Drug Administration (FDA).",2020,"No clinically relevant effect on QTcF, PR interval, QRS duration or HR were observed up to supratherapeutic doses.","[""patients with Alzheimer's disease"", '372 healthy subjects over a wide age range, including both sexes and two ethnicities']",[],"['QTcF, PR interval, QRS duration or HR', 'ECG effects of umibecestat, on QTcF (Fridericia-corrected QT), on PR and QRS and heart rate (HR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}]",[],"[{'cui': 'C0429087', 'cui_str': 'PR interval - finding'}, {'cui': 'C0429025', 'cui_str': 'QRS complex duration'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}]",372.0,0.0353681,"No clinically relevant effect on QTcF, PR interval, QRS duration or HR were observed up to supratherapeutic doses.","[{'ForeName': 'Stefan Viktor', 'Initials': 'SV', 'LastName': 'Vormfelde', 'Affiliation': 'Department of Translational Medicine, Novartis Institutes for BioMedical Research, Basel, Switzerland.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Pezous', 'Affiliation': 'Department of Translational Medicine, Novartis Institutes for BioMedical Research, Basel, Switzerland.'}, {'ForeName': 'Gilbert', 'Initials': 'G', 'LastName': 'Lefèvre', 'Affiliation': 'Department of Translational Medicine, Novartis Institutes for BioMedical Research, Basel, Switzerland.'}, {'ForeName': 'Carine', 'Initials': 'C', 'LastName': 'Kolly', 'Affiliation': 'Department of Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland.'}, {'ForeName': 'Ulf', 'Initials': 'U', 'LastName': 'Neumann', 'Affiliation': 'Department of Neuroscience, Novartis Institutes for BioMedical Research, Basel, Switzerland.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Jordaan', 'Affiliation': 'Cardiovascular Safety Expert - CMO and Patient Safety - Oncology, Novartis Pharma, Basel, Switzerland.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Ufer', 'Affiliation': 'Department of Translational Medicine, Novartis Institutes for BioMedical Research, Basel, Switzerland.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Legangneux', 'Affiliation': 'Department of Translational Medicine, Novartis Institutes for BioMedical Research, Basel, Switzerland.'}]",Clinical and translational science,['10.1111/cts.12832'] 1634,32584519,Development and assessment of a formal learning module to educate veterinary students in an intensive care unit about transfusion reactions.,"OBJECTIVE To develop and assess the instructional efficacy of an online learning module on transfusion reactions in small animals and to evaluate participants' satisfaction of the module. DESIGN Randomized controlled trial. SETTING University teaching hospital. SUBJECTS A total of 55, fourth-year veterinary students, 27 in a treatment group that received the learning module plus standard rotation training and 28 in a control group (no module) who received only standard training INTERVENTIONS: Students received a pretest on transfusion reactions followed by administration of a transfusion reaction learning module covering recognition, treatment, prevention, case examples, and self-assessment questions for 6 common transfusion reactions. Students also received a module satisfaction survey, a post-test at 2 weeks post-module, and a retention test at 6 weeks post-module. MEASUREMENTS AND MAIN RESULTS Previous transfusion medicine exposure did not affect pretest scores and there was no difference in pretest scores between groups. The module group scored higher on the post-test (P < 0.001) and retention test (P = 0.002) than the control group. Mean post-test scores were 74.4% and 57.7% and mean retention test scores were 80.6% and 56.5% for the module and control groups, respectively. The module group scored higher on posttest and retention questions involving reaction recognition (P < 0.001). Students were overall very satisfied with the module with an average score of 4.8 (1-5). CONCLUSIONS A transfusion reaction instructional module can be delivered successfully to veterinary students on an ICU-based clinical rotation. Students taking the module scored significantly better on post-assessments up to 6 weeks after module administration as compared to students receiving only conventional clinical rotation training.",2020,The module group scored higher on the post-test (P < 0.001) and retention test (P = 0.002) than the control group.,"['educate veterinary students in an intensive care unit about transfusion reactions', 'University teaching hospital']","['online learning module', 'conventional clinical rotation training', 'learning module plus standard rotation training and 28 in a control group (no module) who received only standard training']","['posttest and retention questions involving reaction recognition', 'retention test', 'Mean post-test scores', 'mean retention test scores', 'transfusion reactions', 'instructional efficacy']","[{'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0042614', 'cui_str': 'veterinary'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0274435', 'cui_str': 'Blood transfusion reaction'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}]","[{'cui': 'C4505477', 'cui_str': 'Online Education'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0274435', 'cui_str': 'Blood transfusion reaction'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",55.0,0.0618456,The module group scored higher on the post-test (P < 0.001) and retention test (P = 0.002) than the control group.,"[{'ForeName': 'Jillian M', 'Initials': 'JM', 'LastName': 'Haines', 'Affiliation': 'Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington, USA.'}, {'ForeName': 'K Jane', 'Initials': 'KJ', 'LastName': 'Wardrop', 'Affiliation': 'Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington, USA.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Lindberg', 'Affiliation': 'Oregon State University Extended Campus, Oregon State University, Corvallis, Oregon, USA.'}, {'ForeName': 'Kira J', 'Initials': 'KJ', 'LastName': 'Carbonneau', 'Affiliation': 'Department of Educational Leadership, Sports Sciences, and Educational Psychology, College of Education, Washington State University, Pullman, Washington, USA.'}, {'ForeName': 'Thandeka R', 'Initials': 'TR', 'LastName': 'Ngwenyama', 'Affiliation': 'Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington, USA.'}, {'ForeName': 'Linda G', 'Initials': 'LG', 'LastName': 'Martin', 'Affiliation': 'Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington, USA.'}]","Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)",['10.1111/vec.12983'] 1635,32575151,Virtual reality for acute pain in outpatient hysteroscopy: a randomised controlled trial.,"OBJECTIVE To evaluate the effectiveness of virtual reality as a distraction technique in the management of acute pain and anxiety during outpatient hysteroscopy. DESIGN Parallel group, prospective randomised controlled trial. SETTING UK University Hospital. METHODS Forty consenting, eligible women were randomised to virtual reality intervention (immersive video content as a distraction method) or standard care during outpatient hysteroscopy from August to October 2018. MAIN OUTCOME MEASURES Pain and anxiety outcomes were measured as a numeric rating score (scale 0-10). RESULTS Compared with standard care, women with virtual reality intervention experienced less average pain (score 6.0 versus 3.7, mean difference 2.3, 95% CI 0.61-3.99, P = 0.009) and anxiety (score 5.45 versus 3.3, mean difference 2.15, 95% CI 0.38-3.92, P = 0.02). CONCLUSION Virtual reality was effective in reducing pain and anxiety during outpatient hysteroscopy in a mixed-methods randomised control trial. Its wide potential role in ambulatory gynaecological procedures needs further evaluation. TWEETABLE ABSTRACT Virtual reality can be used as a part of a multimodal strategy to reduce acute pain and anxiety in patients undergoing outpatient hysteroscopy.",2020,"Compared to standard care, women with virtual reality intervention experienced less average pain (score 6.0 vs. 3.7, mean difference 2.3, 95% CI 0.61-3.99, p=0.009) and anxiety (score 5.45 vs. 3.3, mean difference 2.15, 95% CI 0.38-3.92, p=0.02). ","['UK University Hospital', 'Forty consenting, eligible women', 'Outpatient Hysteroscopy']","['virtual reality intervention (immersive video content as a distraction method) or standard care', 'virtual reality as a distraction technique', 'Virtual Reality']","['anxiety', 'Pain and anxiety outcomes', 'average pain', 'pain and anxiety', 'numeric rating score (scale of 0-10', 'acute pain and anxiety']","[{'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0020710', 'cui_str': 'Hysteroscopy'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0150189', 'cui_str': 'Distraction training'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0184567', 'cui_str': 'Acute pain'}]",,0.217682,"Compared to standard care, women with virtual reality intervention experienced less average pain (score 6.0 vs. 3.7, mean difference 2.3, 95% CI 0.61-3.99, p=0.009) and anxiety (score 5.45 vs. 3.3, mean difference 2.15, 95% CI 0.38-3.92, p=0.02). ","[{'ForeName': 'N', 'Initials': 'N', 'LastName': 'Deo', 'Affiliation': 'Imperial College London, London, UK.'}, {'ForeName': 'K S', 'Initials': 'KS', 'LastName': 'Khan', 'Affiliation': 'Queen Mary University, London, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Mak', 'Affiliation': 'Queen Mary University, London, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Allotey', 'Affiliation': 'The London School of Medicine and Dentistry, London, UK.'}, {'ForeName': 'F J', 'Initials': 'FJ', 'LastName': 'Gonzalez Carreras', 'Affiliation': 'The London School of Medicine and Dentistry, London, UK.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Fusari', 'Affiliation': 'Helix Centre, Imperial College London and the Royal College of Art, London, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Benn', 'Affiliation': 'School of Psychology, University of Leeds, Leeds, UK.'}]",BJOG : an international journal of obstetrics and gynaecology,['10.1111/1471-0528.16377'] 1636,32575350,Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients.,"Corona Virus Disease 2019 (COVID-19) has affected over 8 million people worldwide. We underscore the potential benefits of conducting a randomized open-label unblinded clinical trial to evaluate the role of ursodeoxycholic acid (UDCA) in the treatment of COVID-19. Some COVID-19 patients are characterized with cytokine storm syndrome that can cause severe and irreversible damage to organs leading to multi-organ failure and death. Therefore, it is critical to control both programmed cell death (apoptosis) and the hyper-immune inflammatory response in COVID-19 patients to reduce the rising morbidity and mortality. UDCA is an existing drug with proven safety profiles that can reduce inflammation and prevent cell death. National Geographic reported that, ""China Promotes Bear Bile as Coronavirus Treatment"". Bear bile is rich in UDCA, comprising up to 40-50% of the total bile acid. UDCA is a logical and attainable replacement for bear bile that is available in pill form and merits clinical trial consideration.",2020,Corona Virus Disease 2019 (COVID-19) has affected over 8 million people worldwide.,['COVID-19 Patients'],"['Ursodeoxycholic Acid', 'ursodeoxycholic acid (UDCA', 'UDCA']",[],"[{'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0042105', 'cui_str': 'ursodeoxycholic acid'}]",[],,0.0492605,Corona Virus Disease 2019 (COVID-19) has affected over 8 million people worldwide.,"[{'ForeName': 'Subbaya', 'Initials': 'S', 'LastName': 'Subramanian', 'Affiliation': 'Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Tinen', 'Initials': 'T', 'LastName': 'Iles', 'Affiliation': 'Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Sayeed', 'Initials': 'S', 'LastName': 'Ikramuddin', 'Affiliation': 'Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Clifford J', 'Initials': 'CJ', 'LastName': 'Steer', 'Affiliation': 'Departments of Medicine and Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455, USA.'}]",Vaccines,['10.3390/vaccines8020320'] 1637,32683565,"Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).","PURPOSE Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, approved in combination with endocrine therapy for the treatment of women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC). In the phase 2, open-label, PALOMA-1 trial, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) versus letrozole alone (hazard ratio, 0.488; 95% CI 0.319‒0.748; P = 0.0004; median PFS, 20.2 vs 10.2 months, respectively) in postmenopausal women with estrogen receptor-positive (ER+)/HER2- ABC. Here, we present the final overall survival (OS) and updated safety results. METHODS Postmenopausal women with ER+/HER2- ABC were randomized 1:1 to receive either palbociclib (125 mg/day, 3/1 schedule) plus letrozole (2.5 mg/day, continuous) or letrozole alone (2.5 mg/day, continuous). The primary endpoint was investigator-assessed PFS; secondary endpoints included OS and safety. RESULTS A total of 165 patients were randomized. At the data cutoff date of December 30, 2016 (median duration of follow-up, 64.7 months), the stratified hazard ratio for OS was 0.897 (95% CI 0.623-1.294; P = 0.281); median OS in the palbociclib plus letrozole and letrozole alone arms was 37.5 and 34.5 months, respectively. The median time from randomization to first subsequent chemotherapy use was longer with palbociclib plus letrozole than letrozole alone (26.7 and 17.7 months, respectively). The most frequently reported adverse event in the palbociclib plus letrozole arm was neutropenia (any grade, 75%; grade 3 or 4, 59%). CONCLUSIONS Palbociclib plus letrozole treatment led to a numerical but not statistically significant improvement in median OS. Pfizer Inc (NCT00721409).",2020,"CONCLUSIONS Palbociclib plus letrozole treatment led to a numerical but not statistically significant improvement in median OS.","['women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC', '165 patients were randomized', 'postmenopausal women with estrogen receptor-positive (ER+)/HER2- ABC', 'Postmenopausal women with ER+/HER2- ABC']","['letrozole versus letrozole', 'endocrine therapy', 'letrozole', 'palbociclib', 'letrozole alone', 'palbociclib plus letrozole', 'Palbociclib plus letrozole']","['median time', 'neutropenia', 'median OS', 'Overall survival', 'stratified hazard ratio for OS', 'investigator-assessed PFS; secondary endpoints included OS and safety', 'final overall survival (OS) and updated safety results', 'prolonged progression-free survival (PFS']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0152244', 'cui_str': 'Aneurysmal bone cyst'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0279754', 'cui_str': 'ESR1 positive'}]","[{'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C3853822', 'cui_str': 'palbociclib'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}]",165.0,0.0903289,"CONCLUSIONS Palbociclib plus letrozole treatment led to a numerical but not statistically significant improvement in median OS.","[{'ForeName': 'Richard S', 'Initials': 'RS', 'LastName': 'Finn', 'Affiliation': 'David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, USA. RFinn@mednet.ucla.edu.'}, {'ForeName': 'Katalin', 'Initials': 'K', 'LastName': 'Boer', 'Affiliation': 'Onkologia, Szent Margit Korhaz, Budapest, Hungary.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Bondarenko', 'Affiliation': 'Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine.'}, {'ForeName': 'Ravindranath', 'Initials': 'R', 'LastName': 'Patel', 'Affiliation': 'Comprehensive Blood and Cancer Center, Bakersfield, CA, USA.'}, {'ForeName': 'Tamas', 'Initials': 'T', 'LastName': 'Pinter', 'Affiliation': 'Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Schmidt', 'Affiliation': 'Department of Obstetrics and Gynecology, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Yaroslav V', 'Initials': 'YV', 'LastName': 'Shparyk', 'Affiliation': 'Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.'}, {'ForeName': 'Anu', 'Initials': 'A', 'LastName': 'Thummala', 'Affiliation': 'Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.'}, {'ForeName': 'Nataliia', 'Initials': 'N', 'LastName': 'Voitko', 'Affiliation': 'Kyiv City Clinical Oncology Center, Kyiv, Ukraine.'}, {'ForeName': 'Eustratios', 'Initials': 'E', 'LastName': 'Bananis', 'Affiliation': 'Pfizer Inc, New York, NY, USA.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'McRoy', 'Affiliation': 'Pfizer Inc, New York, NY, USA.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Wilner', 'Affiliation': 'Pfizer Inc, San Diego, CA, USA.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Pfizer Inc, San Diego, CA, USA.'}, {'ForeName': 'Sindy', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Pfizer Inc, San Diego, CA, USA.'}, {'ForeName': 'Dennis J', 'Initials': 'DJ', 'LastName': 'Slamon', 'Affiliation': 'David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, USA.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Ettl', 'Affiliation': 'Department of Obstetrics and Gynecology, Klinikum Rechts Der Isar, Technische Universität München, München, Germany.'}]",Breast cancer research and treatment,['10.1007/s10549-020-05755-7'] 1638,32579567,School-based intervention to address self-regulation and executive functioning in children attending primary schools in remote Australian Aboriginal communities.,"Executive functioning and self-regulation influence a range of outcomes across the life course including physical and mental health, educational success, and employment. Children prenatally exposed to alcohol or early life trauma (ELT) are at higher risk of impairment of these skills and may require intervention to address self-regulation deficits. Researchers partnered with the local Aboriginal health organization and schools to develop and pilot a manualized version of the Alert Program® in the Fitzroy Valley, north Western Australia, a region with documented high rates of fetal alcohol spectrum disorder and ELT. This self-controlled cluster randomized trial evaluated the effect of an 8-week Alert Program® intervention on children's executive functioning and self-regulation skills. Following parent or caregiver consent (referred to hereafter as parent), 271 students were enrolled in the study. This reflects a 75% participation rate and indicates the strong community support that exists for the study. Teachers from 26 primary school classrooms across eight Fitzroy Valley schools received training to deliver eight, one-hour Alert Program® lessons over eight-weeks to students. Student outcomes were measured by parent and teacher ratings of children's behavioral, emotional, and cognitive regulation. The mean number of lessons attended by children was 4.2. Although no significant improvements to children's executive functioning skills or behavior were detected via the teacher-rated measures as hypothesized, statistically significant improvements were noted on parent-rated measures of executive functioning and behavior. The effectiveness of future self-regulation programs may be enhanced through multimodal delivery through home, school and community based settings to maximize children's exposure to the intervention. Despite mixed findings of effect, this study was an important first step in adapting and evaluating the Alert Program® for use in remote Australian Aboriginal community schools, where access to self-regulation interventions is limited.",2020,"Although no significant improvements to children's executive functioning skills or behavior were detected via the teacher-rated measures as hypothesized, statistically significant improvements were noted on parent-rated measures of executive functioning and behavior.","['Following parent or caregiver consent (referred to hereafter as parent), 271 students were enrolled in the study', 'children attending primary schools in remote Australian Aboriginal communities', ""children's executive functioning and self-regulation skills"", 'Teachers from 26 primary school classrooms across eight Fitzroy Valley schools', 'remote Australian Aboriginal community schools']","['alcohol or early life trauma (ELT', 'School-based intervention to address self-regulation and executive functioning', '8-week Alert Program® intervention']","[""parent and teacher ratings of children's behavioral, emotional, and cognitive regulation"", 'executive functioning and behavior', ""children's executive functioning skills or behavior"", 'physical and mental health, educational success, and employment']","[{'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0557296', 'cui_str': 'Attending primary school'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0684274', 'cui_str': 'Self-control'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0563004', 'cui_str': 'Valley'}, {'cui': 'C0036375', 'cui_str': 'School'}]","[{'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0684274', 'cui_str': 'Self-control'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0014003', 'cui_str': 'Employment'}]",271.0,0.0226753,"Although no significant improvements to children's executive functioning skills or behavior were detected via the teacher-rated measures as hypothesized, statistically significant improvements were noted on parent-rated measures of executive functioning and behavior.","[{'ForeName': 'Bree', 'Initials': 'B', 'LastName': 'Wagner', 'Affiliation': 'Alcohol and Pregnancy and Fetal Alcohol Spectrum Disorder Research Team, Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Latimer', 'Affiliation': 'Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Adams', 'Affiliation': 'Alcohol and Pregnancy and Fetal Alcohol Spectrum Disorder Research Team, Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Carmichael Olson', 'Affiliation': ""Seattle Children's Research Institute, Seattle, Washington, United States of America.""}, {'ForeName': 'Martyn', 'Initials': 'M', 'LastName': 'Symons', 'Affiliation': 'National Health and Medical Research Council FASD Research Australia Centre of Research Excellence, Perth, Western Australia, Australia.'}, {'ForeName': 'Trevor G', 'Initials': 'TG', 'LastName': 'Mazzucchelli', 'Affiliation': 'Child and Family Research Group, School of Psychology, Curtin University, Perth, Western Australia, Australia.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Jirikowic', 'Affiliation': 'Division of Occupational Therapy, Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, Washington, United States of America.'}, {'ForeName': 'Rochelle', 'Initials': 'R', 'LastName': 'Watkins', 'Affiliation': 'National Health and Medical Research Council FASD Research Australia Centre of Research Excellence, Perth, Western Australia, Australia.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Cross', 'Affiliation': 'Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Carapetis', 'Affiliation': 'Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Boulton', 'Affiliation': 'The University of Newcastle, Newcastle, New South Wales, Australia.'}, {'ForeName': 'Edie', 'Initials': 'E', 'LastName': 'Wright', 'Affiliation': 'Western Australian Department of Education Kimberley Education Region, Broome, Western Australia, Australia.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'McRae', 'Affiliation': 'Alcohol and Pregnancy and Fetal Alcohol Spectrum Disorder Research Team, Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Carter', 'Affiliation': 'Nindilingarri Cultural Health Services, Fitzroy Crossing, Western Australia, Australia.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Fitzpatrick', 'Affiliation': 'Alcohol and Pregnancy and Fetal Alcohol Spectrum Disorder Research Team, Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia.'}]",PloS one,['10.1371/journal.pone.0234895'] 1639,30685685,Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.,"BACKGROUND High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European and American Osteosarcoma Study (EURAMOS)-1 is a collaboration of four study groups aiming to improve outcomes of this rare disease by facilitating randomised controlled trials. METHODS Patients eligible for EURAMOS-1 were aged ≤40 years with M0 or M1 skeletal high-grade osteosarcoma in which case complete surgical resection at all sites was deemed to be possible. A three-drug combination with methotrexate, doxorubicin and cisplatin was defined as standard chemotherapy, and between April 2005 and June 2011, 2260 patients were registered. We report survival outcomes and prognostic factors in the full cohort of registered patients. RESULTS For all registered patients at a median follow-up of 54 months (interquartile range: 38-73) from biopsy, 3-year and 5-year event-free survival were 59% (95% confidence interval [CI]: 57-61%) and 54% (95% CI: 52-56%), respectively. Multivariate analyses showed that the most adverse factors at diagnosis were pulmonary metastases (hazard ratio [HR] = 2.34, 95% CI: 1.95-2.81), non-pulmonary metastases (HR = 1.94, 95% CI: 1.38-2.73) or an axial skeleton tumour site (HR = 1.53, 95% CI: 1.10-2.13). The histological subtypes telangiectatic (HR = 0.52, 95% CI: 0.33-0.80) and unspecified conventional (HR = 0.67, 95% CI: 0.52-0.88) were associated with a favourable prognosis compared with chondroblastic subtype. The 3-year and 5-year overall survival from biopsy were 79% (95% CI: 77-81%) and 71% (95% CI: 68-73%), respectively. For patients with localised disease at presentation and in complete remission after surgery, having a poor histological response was associated with worse outcome after surgery (HR = 2.13, 95% CI: 1.76-2.58). In radically operated patients, there was no good evidence that axial tumour site was associated with worse outcome. CONCLUSIONS In conclusion, data from >2000 patients registered to EURAMOS-1 demonstrated survival rates in concordance with institution- or group-level osteosarcoma trials. Further efforts are required to drive improvements for patients who can be identified to be at higher risk of adverse outcome. This trial reaffirms known prognostic factors, and owing to the large numbers of patients registered, it sheds light on some additional factors to consider.",2019,"The histological subtypes telangiectatic (HR = 0.52, 95% CI: 0.33-0.80) and unspecified conventional (HR = 0.67, 95% CI: 0.52-0.88) were associated with a favourable prognosis compared with chondroblastic subtype.","['April 2005 and June 2011, 2260 patients were registered', 'full cohort of registered patients', 'children and young adults', 'Patients eligible for EURAMOS-1 were aged ≤40 years with M0 or M1 skeletal high-grade osteosarcoma in which case complete surgical resection at all sites was deemed to be possible', '2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort']","['methotrexate, doxorubicin and cisplatin']","['3-year and 5-year overall survival', 'biopsy, 3-year and 5-year event-free survival', 'histological subtypes telangiectatic', 'survival rates']","[{'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0029463', 'cui_str': 'Osteosarcoma'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0332149', 'cui_str': 'Possible'}, {'cui': 'C0470277', 'cui_str': '2000'}]","[{'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0449560', 'cui_str': 'Subtype'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",2260.0,0.415819,"The histological subtypes telangiectatic (HR = 0.52, 95% CI: 0.33-0.80) and unspecified conventional (HR = 0.67, 95% CI: 0.52-0.88) were associated with a favourable prognosis compared with chondroblastic subtype.","[{'ForeName': 'Sigbjørn', 'Initials': 'S', 'LastName': 'Smeland', 'Affiliation': 'SSG Oslo University Hospital and Scandinavian Sarcoma Group and Institute for Clinical Medicine, University of Oslo, Norway. Electronic address: ssm@ous-hf.no.'}, {'ForeName': 'Stefan S', 'Initials': 'SS', 'LastName': 'Bielack', 'Affiliation': 'COSS Klinikum Stuttgart - Olgahospital Stuttgart, Germany.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Whelan', 'Affiliation': 'EOI University College Hospital, London, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Bernstein', 'Affiliation': 'COG IWK Health Center, Dalhousie University, Halifax, NS, Canada.'}, {'ForeName': 'Pancras', 'Initials': 'P', 'LastName': 'Hogendoorn', 'Affiliation': 'TMG Path Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Mark D', 'Initials': 'MD', 'LastName': 'Krailo', 'Affiliation': ""COG Children's Oncology Group, Arcadia, CA, USA.""}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Gorlick', 'Affiliation': 'COG the University of Texas M D Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Janeway', 'Affiliation': 'COG Dana-Farber Cancer Institute, Boston, MA, USA.'}, {'ForeName': 'Fiona C', 'Initials': 'FC', 'LastName': 'Ingleby', 'Affiliation': 'CDC MRC Clinical Trials Unit at UCL, London, UK.'}, {'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Anninga', 'Affiliation': 'EOI, Netherlands.'}, {'ForeName': 'Imre', 'Initials': 'I', 'LastName': 'Antal', 'Affiliation': 'COSS Semmelweis Egyetem Budapest, Budapest, Hungary.'}, {'ForeName': 'Carola', 'Initials': 'C', 'LastName': 'Arndt', 'Affiliation': 'COG Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Ken L B', 'Initials': 'KLB', 'LastName': 'Brown', 'Affiliation': 'COG University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Trude', 'Initials': 'T', 'LastName': 'Butterfass-Bahloul', 'Affiliation': 'EISD Centre for Clinical Trials, University Hospital Muenster, Muenster, Germany.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Calaminus', 'Affiliation': 'QLCC Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Bonn, Bonn, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Capra', 'Affiliation': ""EOI Our Lady's Children's Hospital, Dublin, Ireland.""}, {'ForeName': 'Catharina', 'Initials': 'C', 'LastName': 'Dhooge', 'Affiliation': 'EOI University Hospital Ghent, Gent, Belgium.'}, {'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Eriksson', 'Affiliation': 'SSG Lund University, Lund, Sweden.'}, {'ForeName': 'Adrienne M', 'Initials': 'AM', 'LastName': 'Flanagan', 'Affiliation': 'EOI Royal National Orthopaedic Hospital, Stanmore; Cancer Institute, University College London, London, UK.'}, {'ForeName': 'Godehard', 'Initials': 'G', 'LastName': 'Friedel', 'Affiliation': 'COSS Klinik Schillerhöhe - Thoraxchirurgie Gerlingen, Germany.'}, {'ForeName': 'Mark C', 'Initials': 'MC', 'LastName': 'Gebhardt', 'Affiliation': 'COG Dana-Farber Cancer Institute, Boston, MA, USA.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Gelderblom', 'Affiliation': 'EOI Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Goldsby', 'Affiliation': 'COG UCSF Medical Center-Mission Bay, Pediatric Oncology, San Francisco, CA, USA.'}, {'ForeName': 'Holcombe E', 'Initials': 'HE', 'LastName': 'Grier', 'Affiliation': 'COG Dana-Farber Cancer Institute, Boston, MA, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Grimer', 'Affiliation': 'EOI Royal Orthopaedic Hospital, Birmingham, UK.'}, {'ForeName': 'Douglas S', 'Initials': 'DS', 'LastName': 'Hawkins', 'Affiliation': 'COG University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Hecker-Nolting', 'Affiliation': 'COSS Klinikum Stuttgart - Olgahospital Stuttgart, Germany.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Sundby Hall', 'Affiliation': 'SSG Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Isakoff', 'Affiliation': ""COG Connecticut Children's Medical Center, Hartford, CT, USA.""}, {'ForeName': 'Gordana', 'Initials': 'G', 'LastName': 'Jovic', 'Affiliation': 'CDC MRC Clinical Trials Unit at UCL, London, UK.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Kühne', 'Affiliation': 'COSS Universitätsspital Basel, Basel, Switzerland.'}, {'ForeName': 'Leo', 'Initials': 'L', 'LastName': 'Kager', 'Affiliation': 'COSS St. Anna Kinderspital /CCRI, Wien, Austria.'}, {'ForeName': 'Thekla', 'Initials': 'T', 'LastName': 'von Kalle', 'Affiliation': 'COSS Klinikum Stuttgart - Olgahospital Stuttgart, Germany.'}, {'ForeName': 'Edita', 'Initials': 'E', 'LastName': 'Kabickova', 'Affiliation': 'COSS University Hospital MOTOL, Praha, Czech Republic.'}, {'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Lang', 'Affiliation': 'COSS Medizinische Universität Wien, Vienna, Austria.'}, {'ForeName': 'Ching C', 'Initials': 'CC', 'LastName': 'Lau', 'Affiliation': 'COG Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Leavey', 'Affiliation': ""COG Southwestern and Children's Medical Center, Dallas, TX, USA.""}, {'ForeName': 'Stephen L', 'Initials': 'SL', 'LastName': 'Lessnick', 'Affiliation': ""COG Nationwide Children's Hospital and the Ohio State University, Columbus, OH, USA.""}, {'ForeName': 'Leo', 'Initials': 'L', 'LastName': 'Mascarenhas', 'Affiliation': 'COG Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Regine', 'Initials': 'R', 'LastName': 'Mayer-Steinacker', 'Affiliation': 'COSS Universitätsklinikum Ulm, Ulm, Germany.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Meyers', 'Affiliation': 'COG Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Raj', 'Initials': 'R', 'LastName': 'Nagarajan', 'Affiliation': ""COG Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'R Lor', 'Initials': 'RL', 'LastName': 'Randall', 'Affiliation': 'COG Primary Childrens Hospital, The University of Utah, Salt Lake City, UT, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Reichardt', 'Affiliation': 'COSS Helios Kliniken Berlin-Buch, Berlin, Germany.'}, {'ForeName': 'Marleen', 'Initials': 'M', 'LastName': 'Renard', 'Affiliation': 'EOI University Hospital Leuven, Leuven, Belgium.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Rechnitzer', 'Affiliation': 'SSG Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Cindy L', 'Initials': 'CL', 'LastName': 'Schwartz', 'Affiliation': 'COG the University of Texas M D Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Strauss', 'Affiliation': 'EOI University College Hospital, London, UK.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Teot', 'Affiliation': ""COG Boston Children's Hospital, Boston, MA, USA.""}, {'ForeName': 'Beate', 'Initials': 'B', 'LastName': 'Timmermann', 'Affiliation': 'COSS Universitätsklinikum Essen, Essen, Germany.'}, {'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Sydes', 'Affiliation': 'CDC MRC Clinical Trials Unit at UCL, London, UK. Electronic address: mrcctu.euramos@ucl.ac.uk.'}, {'ForeName': 'Neyssa', 'Initials': 'N', 'LastName': 'Marina', 'Affiliation': 'COG Five Prime Therapeutics, Inc South San Francisco, CA, USA.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2018.11.027'] 1640,32442353,A randomized controlled clinical trial comparing the use of displacement cords and aluminum chloride paste.,"OBJECTIVES This clinical study measured the change in opening and height of the displaced gingiva using paste and cord retraction materials for definitive impression making of natural teeth and assessed if they were comparable and clinically acceptable. METHODS Impressions of 4 maxilla premolars from 10 participants were taken using a split-mouth protocol. All participants were free of periodontal disease, had a thick biotype, a minimal of 3 mm height of keratinized gingival tissue and gingival sulci depths of 2 mm. The bleeding index (BI), gingival index (GI) plaque index (PI), sulcular depth, level of attachment and tooth sensitivity were recorded at baseline, just after retraction, at 24 hours and at 2 weeks. Impressions were poured in stone and then after initial analysis were cross-sectioned to allow measurements of the gingival height change and gap size to be recorded. RESULTS The paste produced a slightly smaller gap compared to the cord (0.041 mm less, P = .014) whilst the mean displacement for the cord was 0.282 mm and paste was 0.241 mm respectively. Gingival height with the paste was 0.047 mm lower than that achieved by the cord (P = .208). CONCLUSIONS Cord and paste retraction produced comparable clinically acceptable gingival gaps, with the cord producing statistically larger gap size. CLINICAL SIGNIFICANCE The cord and paste retraction materials produced comparable clinically acceptable gingival retraction.",2020,"The paste produced a slightly smaller gap compared to the cord (0.041 mm less, P = .014) whilst the mean displacement for the cord was 0.282 mm and paste was 0.241 mm respectively.","['All participants were free of periodontal disease, had a thick biotype, a minimal of 3\u2009mm height of keratinized gingival tissue and gingival sulci depths of 2\u2009mm', 'Impressions of 4 maxilla premolars from 10 participants were taken using a split-mouth protocol']",['displacement cords and aluminum chloride paste'],"['bleeding index (BI), gingival index (GI) plaque index (PI), sulcular depth, level of attachment and tooth sensitivity', 'acceptable gingival retraction', 'Gingival height']","[{'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0031090', 'cui_str': 'Periodontal disease'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0441707', 'cui_str': 'Biotyping'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0017562', 'cui_str': 'Gingival structure'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0317562', 'cui_str': 'Eubacterium sulci'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C1704302', 'cui_str': 'Structure of premolar tooth'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C3489532', 'cui_str': 'Cone-Rod Dystrophy 2'}, {'cui': 'C0051512', 'cui_str': 'Aluminum chloride hexahydrate'}, {'cui': 'C0030634', 'cui_str': 'Pastes'}]","[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0011432', 'cui_str': 'Sensitive dentin'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C0017562', 'cui_str': 'Gingival structure'}, {'cui': 'C0332523', 'cui_str': 'Retraction'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}]",10.0,0.0760322,"The paste produced a slightly smaller gap compared to the cord (0.041 mm less, P = .014) whilst the mean displacement for the cord was 0.282 mm and paste was 0.241 mm respectively.","[{'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Bennani', 'Affiliation': 'Department of Oral Rehabilitation, Faculty of Dentistry, University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Aarts', 'Affiliation': 'Department of Oral Rehabilitation, Faculty of Dentistry, University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Brunton', 'Affiliation': 'Pro Vice Chancellor Health Sciences, University of Otago, Dunedin, New Zealand.'}]",Journal of esthetic and restorative dentistry : official publication of the American Academy of Esthetic Dentistry ... [et al.],['10.1111/jerd.12581'] 1641,32442673,Salivary oxytocin after oxytocin administration: Examining the moderating role of childhood trauma.,"Although oxytocin administration influences behavior, its effects on peripheral oxytocin concentrations are mixed and derived from studies on healthy subjects. Additionally, trauma attenuates the behavioral effects of oxytocin, but it is unknown whether it also influences its effect on peripheral circulation. This study examined whether salivary oxytocin increased after oxytocin administration and whether trauma attenuated this effect. We conducted a randomized, double-blind, placebo-controlled, within-subjects study in 100 male adolescents living in residential youth care facilities. Participants self-administered intranasally 24 IU of oxytocin and placebo (one week later) and provided a saliva sample before and 15 min after administration. Salivary oxytocin increased significantly after oxytocin administration, but this effect might be inflated by exogenous oxytocin reaching the throat. Trauma did not moderate this effect. Our findings suggest that trauma did not attenuate the effect of oxytocin administration on salivary oxytocin, but more robust methodologies are recommended to draw more solid conclusions.",2020,Trauma did not moderate this effect.,"['100 male adolescents living in residential youth care facilities', 'healthy subjects']","['oxytocin', 'salivary oxytocin', 'Salivary oxytocin', 'oxytocin and placebo', 'placebo']","['Salivary oxytocin', 'peripheral oxytocin concentrations']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0001589', 'cui_str': 'Adolescents, Male'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",100.0,0.442201,Trauma did not moderate this effect.,"[{'ForeName': 'Iro', 'Initials': 'I', 'LastName': 'Fragkaki', 'Affiliation': 'Radboud University, Behavioural Science Institute, Montessorilaan 3, 6525 HR, Nijmegen, the Netherlands. Electronic address: i.fragkaki@pwo.ru.nl.'}, {'ForeName': 'Jeffrey C', 'Initials': 'JC', 'LastName': 'Glennon', 'Affiliation': 'Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands.'}, {'ForeName': 'Maaike', 'Initials': 'M', 'LastName': 'Cima', 'Affiliation': 'Radboud University, Behavioural Science Institute, Montessorilaan 3, 6525 HR, Nijmegen, the Netherlands.'}]",Biological psychology,['10.1016/j.biopsycho.2020.107903'] 1642,32442189,Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.,"BACKGROUND Women living with HIV (WLHIV) have lower rates of contraceptive use than noninfected peers, yet concerns regarding contraceptive efficacy and interaction with antiretroviral therapy (ART) complicate counseling. Hormonal contraceptives may increase genital tract HIV viral load (gVL) and sexual transmission risk to male partners. We compared gVL, plasma VL (pVL), and intrauterine contraceptive (IUC) continuation between the levonorgestrel intrauterine system (LNG-IUS) and copper intrauterine device (C-IUD) in Cape Town, South Africa. METHODS AND FINDINGS In this double-masked, randomized controlled noninferiority trial, eligible WLHIV were ages 18-40, not pregnant or desiring pregnancy within 30 months, screened and treated (as indicated) for reproductive tract infections (RTIs) within 1 month of enrollment, and virologically suppressed using ART or above treatment threshold at enrollment (non-ART). Between October 2013, and December 2016, we randomized consenting women within ART groups, using 1:1 permuted block randomization stratified by ART use, age (18-23, 24-31, 32-40), and recent injectable progestin contraceptive (IPC) exposure, and provided the allocated IUC. At all visits, participants provided specimens for gVL (primary outcome), pVL, RTI, and pregnancy testing. We assessed gVL and pVL across 6 and 24 months controlling for enrollment measures, ART group, age, and RTI using generalized estimating equation and generalized linear models (non-ART group pVL and hemoglobin) in as-treated analyses. We measured IUC discontinuation rates with Kaplan-Meier estimates and Cox proportional hazards models. We enrolled 71 non-ART (36 LNG-IUS, 31 C-IUD; 2 declined and 2 were ineligible) and 134 ART-using (65 LNG-IUS, 67 C-IUD; 1 declined and 1 could not complete IUC insertion) women. Participant median age was 31 years, and 95% had 1 or more prior pregnancies. Proportions of women with detectable gVL were not significantly different comparing LNG-IUS to C-IUD across 6 (adjusted odds ratio [AOR]: 0.78, 95% confidence interval [CI] 0.44-1.38, p = 0.39) and 24 months (AOR: 1.03, 95% CI: 0.68-1.57, p = 0.88). Among ART users, proportions with detectable pVL were not significantly different at 6 (AOR = 0.83, 95% CI 0.37-1.86, p = 0.65) and 24 months (AOR = 0.94, 95% CI 0.49-1.81, p = 0.85), whereas among non-ART women, mean pVL was not significantly different at 6 months (-0.10 log10 copies/mL, 95% CI -0.29 to 0.10, p = 0.50) between LNG-IUS and C-IUD users. IUC continuation was 78% overall; C-IUD users experienced significantly higher expulsion (8% versus 1%, p = 0.02) and elective discontinuation (adjusted hazard ratio: 8.75, 95% CI 3.08-24.8, p < 0.001) rates. Sensitivity analysis adjusted for differential IUC discontinuation found similar gVL results. There were 39 serious adverse events (SAEs); SAEs believed to be directly related to IUC use (n = 7) comprised 3 pelvic inflammatory disease (PID) cases and 4 pregnancies with IUC in place with no discernible trend by IUC arm. Mean hemoglobin change was significantly higher among LNG-IUS users across 6 (0.57 g/dL, 95% CI 0.24-0.90; p < 0.001) and 24 months (0.71 g/dL, 95% CI 0.47-0.95; p < 0.001). Limitations included not achieving non-ART group sample size following change in ART treatment guidelines and truncated 24 months' outcome data, as 17 women were not yet eligible for their 24-month visit at study closure. Also, a change in VL assay during the study may have caused some discrepancy in VL values because of different limits of detection. CONCLUSIONS In this study, we found that the LNG-IUS did not increase gVL or pVL and had low levels of contraceptive failure and associated PID compared with the C-IUD among WLHIV. LNG-IUS users were significantly more likely to continue IUC use and had higher hemoglobin levels over time. The LNG-IUS appears to be a safe contraceptive with regard to HIV disease and may be a highly acceptable option for WLHIV. TRIAL REGISTRATION ClinicalTrials.gov NCT01721798.",2020,"Proportions of women with detectable gVL were not significantly different comparing LNG-IUS to C-IUD across 6 (adjusted odds ratio [AOR]: 0.78, 95% confidence interval [CI] 0.44-1.38, p = 0.39) and 24 months (AOR: 1.03, 95% CI: 0.68-1.57, p = 0.88).","['women living with HIV in South Africa', 'Participant median age was 31 years, and 95% had 1 or more prior pregnancies', 'male partners', 'We enrolled 71 non-ART (36 LNG-IUS, 31 C-IUD; 2 declined and 2 were ineligible) and 134 ART-using (65 LNG-IUS, 67 C-IUD; 1 declined and 1 could not complete IUC insertion) women', 'Cape Town, South Africa', 'eligible WLHIV were ages 18-40, not pregnant or desiring pregnancy within 30 months, screened and treated (as indicated) for reproductive tract infections (RTIs) within 1 month of enrollment, and virologically suppressed using ART or above treatment threshold at enrollment (non-ART', 'Between October 2013, and December 2016, we randomized consenting women within ART groups, using 1:1 permuted block randomization stratified by ART use, age (18-23, 24-31, 32-40), and recent', 'Women living with HIV (WLHIV']","['Hormonal contraceptives', 'levonorgestrel intrauterine system', 'injectable progestin contraceptive (IPC) exposure, and provided the allocated IUC', 'levonorgestrel intrauterine system (LNG-IUS) and copper intrauterine device (C-IUD']","['39 serious adverse events (SAEs); SAEs', 'gVL or pVL and had low levels of contraceptive failure and associated PID', 'Mean hemoglobin change', 'elective discontinuation', 'hemoglobin levels', 'pVL, RTI, and pregnancy testing', 'genital tract HIV viral load (gVL) and sexual transmission risk', 'mean pVL', 'gVL, plasma VL (pVL), and intrauterine contraceptive (IUC) continuation', 'expulsion']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0037712', 'cui_str': 'South Africa'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C4293465', 'cui_str': 'Levonorgestrel Intrauterine System [Kyleena]'}, {'cui': 'C0021901', 'cui_str': 'Copper Intrauterine Devices'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C1444661', 'cui_str': 'Stopped before completion'}, {'cui': 'C3653534', 'cui_str': 'Intrauterine contraceptives'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0054434', 'cui_str': 'caffeic acid phenethyl ester'}, {'cui': 'C0557750', 'cui_str': 'Town environment'}, {'cui': 'C0232973', 'cui_str': 'Not pregnant'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C2314882', 'cui_str': 'Genital Tract Infections'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C1260953', 'cui_str': 'Suppressed'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0332185', 'cui_str': 'Recent'}]","[{'cui': 'C0458083', 'cui_str': 'Hormonal'}, {'cui': 'C0009871', 'cui_str': 'Contraceptive agent'}, {'cui': 'C4293465', 'cui_str': 'Levonorgestrel Intrauterine System [Kyleena]'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}, {'cui': 'C0033306', 'cui_str': 'Progestational hormone'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C3653534', 'cui_str': 'Intrauterine contraceptives'}, {'cui': 'C0021901', 'cui_str': 'Copper Intrauterine Devices'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0017420', 'cui_str': 'Reproductive System'}, {'cui': 'C1168369', 'cui_str': 'HIV viral load'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0009866', 'cui_str': 'Contraception failure'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0031406', 'cui_str': 'Phenindione'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0035243', 'cui_str': 'Respiratory tract infection'}, {'cui': 'C0032976', 'cui_str': 'Pregnancy detection examination'}, {'cui': 'C1519279', 'cui_str': 'Sexual transmission'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C3653534', 'cui_str': 'Intrauterine contraceptives'}, {'cui': 'C1293107', 'cui_str': 'Expulsion'}]",71.0,0.642316,"Proportions of women with detectable gVL were not significantly different comparing LNG-IUS to C-IUD across 6 (adjusted odds ratio [AOR]: 0.78, 95% confidence interval [CI] 0.44-1.38, p = 0.39) and 24 months (AOR: 1.03, 95% CI: 0.68-1.57, p = 0.88).","[{'ForeName': 'Catherine S', 'Initials': 'CS', 'LastName': 'Todd', 'Affiliation': 'Maternal and Child Health and Nutrition Department, Global Health, Population, and Nutrition, Durham, North Carolina, United States of America.'}, {'ForeName': 'Heidi E', 'Initials': 'HE', 'LastName': 'Jones', 'Affiliation': 'Department of Epidemiology and Biostatistics, City University of New York School of Public Health, New York, New York, United States of America.'}, {'ForeName': 'Nontokozo', 'Initials': 'N', 'LastName': 'Langwenya', 'Affiliation': 'Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Observatory, Cape Town, South Africa.'}, {'ForeName': 'Donald R', 'Initials': 'DR', 'LastName': 'Hoover', 'Affiliation': 'Department of Statistics and Institute for Health Care Policy and Aging Research, Rutgers University, Piscataway, New Jersey, United States of America.'}, {'ForeName': 'Pai-Lien', 'Initials': 'PL', 'LastName': 'Chen', 'Affiliation': 'Global Population and Health Research Department, Global Health, Population, and Nutrition, Durham, North Carolina, United States of America.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Petro', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Cape Town, Observatory, Cape Town, South Africa.'}, {'ForeName': 'Landon', 'Initials': 'L', 'LastName': 'Myer', 'Affiliation': 'Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Observatory, Cape Town, South Africa.'}]",PLoS medicine,['10.1371/journal.pmed.1003110'] 1643,32443179,A polling experiment on public opinion on the future expansion of Medicare and Medicaid.,"OBJECTIVE To conduct a polling experiment to understand the possible framing effects that drive constituents' views around Medicare For All (MFA) and Medicaid Buy-In (MBI). DATA SOURCES AND STUDY SETTING Five thousand and fifty-one US adults aged 18 and older were recruited to participate in an online poll conducted between September 12, 2018, and September 26, 2018. STUDY DESIGN Participants were randomized to receive one of four polls: (a) a poll measuring respondent approval for MFA, with the name of the proposal stated with a description; (b) a poll measuring approval for MFA, with only a description of the proposal; (c) a poll measuring approval for MBI, with the name stated with a description; or (d) a poll measuring approval for MBI, with only a description. PRINCIPAL FINDINGS Including the names ""Medicare For All"" and ""Medicaid Buy-In"" increases approval by 3.4 (from 32.7 percent to 36.1 percent) and 5.0 (from 50.1 percent to 55.1 percent) percentage points, respectively. Support varies by age, where MBI is most strongly supported by Millennials, while Baby Boomers and those older than 65 are more likely to support MFA. CONCLUSIONS Constituents are more likely to support a proposal when given the names of the proposal. Approval is also higher for health policies that are framed as expansions of existing policies than as new programs.",2020,"Support varies by age, where MBI is most strongly supported by Millennials, while Baby Boomers and those older than 65 are more likely to support MFA. ","['Participants', 'Five thousand and fifty-one US adults aged 18 and older were recruited to participate in an online poll conducted between September 12, 2018, and September 26, 2018']","['poll measuring respondent approval for MFA, with the name of the proposal stated with a description; (b) a poll measuring approval for MFA, with only a description of the proposal; (c) a poll measuring approval for MBI, with the name stated with a description; or (d) a poll measuring approval for MBI, with only a description']",[],"[{'cui': 'C4319610', 'cui_str': '5000'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}]","[{'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0018717', 'cui_str': 'Health Insurance for Aged and Disabled, Title 18'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0025071', 'cui_str': 'Medicaid coverage'}]",[],5051.0,0.0357672,"Support varies by age, where MBI is most strongly supported by Millennials, while Baby Boomers and those older than 65 are more likely to support MFA. ","[{'ForeName': 'Mahesh', 'Initials': 'M', 'LastName': 'Karra', 'Affiliation': 'Frederick S. Pardee School of Global Studies, Boston University, Boston, Massachusetts, USA.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Sandoe', 'Affiliation': 'Graduate School of Arts and Sciences, Harvard University, Cambridge, Massachusetts, USA.'}]",Health services research,['10.1111/1475-6773.13295'] 1644,32442195,Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.,"BACKGROUND DNA plasmids promise a pragmatic alternative to viral vectors for prime-boost HIV-1 vaccines. We evaluated DNA plasmid versus canarypox virus (ALVAC) primes in 2 randomized, double-blind, placebo-controlled trials in southern Africa with harmonized trial designs. HIV Vaccine Trials Network (HVTN) 111 tested DNA plasmid prime by needle or needleless injection device (Biojector) and DNA plasmid plus gp120 protein plus MF59 adjuvant boost. HVTN 100 tested ALVAC prime and ALVAC plus gp120 protein plus MF59 adjuvant boost (same protein/adjuvant as HVTN 111) by needle. METHODS AND FINDINGS The primary endpoints for this analysis were binding antibody (bAb) responses to HIV antigens (gp120 from strains ZM96, 1086, and TV1; variable 1 and 2 [V1V2] regions of gp120 from strains TV1, 1086, and B.CaseA, as 1086 V1V2 and B.CaseA were correlates of risk in the RV144 efficacy trial), neutralizing antibody (nAb) responses to pseudoviruses TV1c8.2 and MW925.26, and cellular responses to vaccine-matched antigens (envelope [Env] from strains ZM96, 1086, and TV1; and Gag from strains LAI and ZM96) at month 6.5, two weeks after the fourth vaccination. Per-protocol cohorts included vaccine recipients from HVTN 100 (n = 186, 60% male, median age 23 years) enrolled between February 9, 2015, and May 26, 2015 and from HVTN 111 (n = 56, 48% male, median age 24 years) enrolled between June 21, 2016, and July 13, 2017. IgG bAb response rates were 100% to 3 Env gp120 antigens in both trials. Response rates to V1V2 were lower and similar in both trials except to vaccine-matched 1086 V1V2, with rates significantly higher for the DNA-primed regimen than the ALVAC-primed regimen: 96.6% versus 72.7% (difference = 23.9%, 95% CI 15.6%-32.2%, p < 0.001). Among positive responders, bAb net mean fluorescence intensity (MFI) was significantly higher with the DNA-primed regimen than ALVAC-primed for 1086 V1V2 (geometric mean [GM] 2,833.3 versus 1,200.9; ratio = 2.36, 95% CI 1.42-3.92, p < 0.001) and B.CaseA V1V2 (GM 2314.0 versus 744.6, ratio = 3.11, 95% CI 1.51-6.38, p = 0.002). nAb response rates were >98% in both trials, with significantly higher 50% inhibitory dilution (ID50) among DNA-primed positive responders (n = 53) versus ALVAC-primed (n = 182) to tier 1A MW965.26 (GM 577.7 versus 265.7, ratio = 2.17, 95% CI 1.67-2.83, p < 0.001) and to TV1c8.2 (GM 187.3 versus 100.4, ratio = 1.87, 95% CI 1.48-2.35, p < 0.001). CD4+ T-cell response rates were significantly higher with DNA plasmid prime via Biojector than ALVAC prime (91.4% versus 52.8%, difference = 38.6%, 95% CI 20.5%-56.6%, p < 0.001 for ZM96.C; 88.0% versus 43.1%, difference = 44.9%, 95% CI 26.7%-63.1%, p < 0.001 for 1086.C; 55.5% versus 2.2%, difference = 53.3%, 95% CI 23.9%-82.7%, p < 0.001 for Gag LAI/ZM96). The study's main limitations include the nonrandomized comparison of vaccines from 2 different trials, the lack of data on immune responses to other non-vaccine-matched antigens, and the uncertain clinical significance of the observed immunological effects. CONCLUSIONS In this study, we found that further investigation of DNA/protein regimens is warranted given enhanced immunogenicity to the V1V2 correlates of decreased HIV-1 acquisition risk identified in RV144, the only HIV vaccine trial to date to show any efficacy.",2020,"Response rates to V1V2 were lower and similar in both trials except to vaccine-matched 1086 V1V2, with rates significantly higher for the DNA-primed regimen than the ALVAC-primed regimen: 96.6% versus 72.7% (difference = 23.9%, 95% CI 15.6%-32.2%, p < 0.001).","['Per-protocol cohorts included vaccine recipients from HVTN 100', 'southern Africa with harmonized trial designs', 'n = 186, 60% male, median age 23 years) enrolled between February 9, 2015, and May 26, 2015 and from HVTN 111 (n = 56, 48% male, median age 24 years) enrolled between June 21, 2016, and July 13, 2017']","['placebo', 'ALVAC priming', 'DNA plasmid versus canarypox virus (ALVAC']","['IgG bAb response rates', 'nAb response rates', 'Response rates to V1V2', 'binding antibody (bAb) responses to HIV antigens (gp120 from strains ZM96, 1086, and TV1; variable 1 and 2 [V1V2] regions of gp120 from strains TV1, 1086, and B.CaseA, as 1086 V1V2 and B.CaseA were correlates of risk in the RV144 efficacy trial), neutralizing antibody (nAb) responses to pseudoviruses TV1c8.2 and MW925.26, and cellular responses to vaccine-matched antigens (envelope [Env] from strains ZM96, 1086, and TV1; and Gag from strains LAI and ZM96', 'bAb net mean fluorescence intensity (MFI', 'CD4+ T-cell response rates']","[{'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0001746', 'cui_str': 'Southern Africa'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517538', 'cui_str': '111'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0211671', 'cui_str': 'ALVAC vaccine'}, {'cui': 'C0331021', 'cui_str': 'Ligustrum vulgare'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}, {'cui': 'C0032136', 'cui_str': 'Plasmid'}, {'cui': 'C0282472', 'cui_str': 'Canarypox virus'}]","[{'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0282682', 'cui_str': 'Blocking antibody'}, {'cui': 'C0332297', 'cui_str': 'Bounded by'}, {'cui': 'C0003261', 'cui_str': 'Antibody Production'}, {'cui': 'C0019686', 'cui_str': 'AIDS Antigens'}, {'cui': 'C0019691', 'cui_str': 'env Protein gp120, HIV'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0003320', 'cui_str': 'Antigen'}, {'cui': 'C0016927', 'cui_str': 'Gagging'}, {'cui': 'C0443021', 'cui_str': 'Lai'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0016315', 'cui_str': 'Fluorescence'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}]",,0.585483,"Response rates to V1V2 were lower and similar in both trials except to vaccine-matched 1086 V1V2, with rates significantly higher for the DNA-primed regimen than the ALVAC-primed regimen: 96.6% versus 72.7% (difference = 23.9%, 95% CI 15.6%-32.2%, p < 0.001).","[{'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Moodie', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.'}, {'ForeName': 'Stephen R', 'Initials': 'SR', 'LastName': 'Walsh', 'Affiliation': ""Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.""}, {'ForeName': 'Fatima', 'Initials': 'F', 'LastName': 'Laher', 'Affiliation': 'Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Maganga', 'Affiliation': 'NIMR-Mbeya Medical Research Center, Mbeya, Tanzania.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Herce', 'Affiliation': 'University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.'}, {'ForeName': 'Sarita', 'Initials': 'S', 'LastName': 'Naidoo', 'Affiliation': 'HIV Prevention Research Unit, South African Medical Research Council, Durban, South Africa.'}, {'ForeName': 'Mina C', 'Initials': 'MC', 'LastName': 'Hosseinipour', 'Affiliation': 'UNC Project Malawi, Lilongwe, Malawi.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Innes', 'Affiliation': 'Aurum Institute, Klerksdorp, South Africa.'}, {'ForeName': 'Linda-Gail', 'Initials': 'LG', 'LastName': 'Bekker', 'Affiliation': 'Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Grunenberg', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Mann', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.'}, {'ForeName': 'Chenchen', 'Initials': 'C', 'LastName': 'Yu', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.'}, {'ForeName': 'Allan C', 'Initials': 'AC', 'LastName': 'deCamp', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.'}, {'ForeName': 'Maurine D', 'Initials': 'MD', 'LastName': 'Miner', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.'}, {'ForeName': 'Nicole L', 'Initials': 'NL', 'LastName': 'Yates', 'Affiliation': 'Duke Human Vaccine Institute, Department of Surgery Duke University, Durham, North Carolina, United States of America.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Heptinstall', 'Affiliation': 'Duke Human Vaccine Institute, Department of Surgery Duke University, Durham, North Carolina, United States of America.'}, {'ForeName': 'Nonhlanhla N', 'Initials': 'NN', 'LastName': 'Mkhize', 'Affiliation': 'National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.'}, {'ForeName': 'One', 'Initials': 'O', 'LastName': 'Dintwe', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Frahm', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.'}, {'ForeName': 'Kristen W', 'Initials': 'KW', 'LastName': 'Cohen', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Allen', 'Affiliation': 'National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland United States of America.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Hutter', 'Affiliation': 'National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland United States of America.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Wagner', 'Affiliation': 'Institute of Medical Microbiology and Hygiene, University of Regensberg, Regensberg, Germany.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Pantaleo', 'Affiliation': 'Swiss Vaccine Research Institute, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'M Juliana', 'Initials': 'MJ', 'LastName': 'McElrath', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.'}, {'ForeName': 'Georgia D', 'Initials': 'GD', 'LastName': 'Tomaras', 'Affiliation': 'Duke Human Vaccine Institute, Department of Surgery Duke University, Durham, North Carolina, United States of America.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Morris', 'Affiliation': 'National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Montefiori', 'Affiliation': 'Duke Human Vaccine Institute, Department of Surgery Duke University, Durham, North Carolina, United States of America.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Andersen-Nissen', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.'}, {'ForeName': 'Glenda E', 'Initials': 'GE', 'LastName': 'Gray', 'Affiliation': 'South African Medical Research Council, Cape Town, South Africa.'}, {'ForeName': 'Peter B', 'Initials': 'PB', 'LastName': 'Gilbert', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.'}, {'ForeName': 'James G', 'Initials': 'JG', 'LastName': 'Kublin', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",PLoS medicine,['10.1371/journal.pmed.1003117'] 1645,32444149,Transition to forefoot strike reduces load rates more effectively than altered cadence.,"BACKGROUND Excessive vertical impacts at landing are associated with common running injuries. Two primary gait-retraining interventions aimed at reducing impact forces are transition to forefoot strike and increasing cadence. The objective of this study was to compare the short- and long-term effects of 2 gait-retraining interventions aimed at reducing landing impacts. METHODS A total of 39 healthy recreational runners using a rearfoot strike and a cadence of ≤170 steps/min were randomized into cadence (CAD) or forefoot strike (FFS) groups. All participants performed 4 weeks of strengthening followed by 8 sessions of gait-retraining using auditory feedback. Vertical average load rates (VALR) and vertical instantaneous load rates (VILR) were calculated from the vertical ground reaction force curve. Both cadence and foot strike angle were measured using 3D motion analysis and an instrumented treadmill at baseline and at 1 week, 1 month, and 6 months post retraining. RESULTS ANOVA revealed that the FFS group had significant reductions in VALR (49.7%) and VILR (41.7%), and changes were maintained long term. Foot strike angle in the FFS group changed from 14.2° dorsiflexion at baseline to 3.4° plantarflexion, with changes maintained long term. The CAD group exhibited significant reduction only in VALR (16%) and only at 6 months. Both groups had significant and similar increases in cadence at all follow-ups (CAD, +7.2% to 173 steps/min; and FFS, +6.1% to 172 steps/min). CONCLUSION Forefoot strike gait-retraining resulted in significantly greater reductions in VALR and similar increases in cadence compared to cadence gait-retraining in the short and long term. Cadence gait-retraining resulted in small reductions in VALR at only the 6-month follow-up.",2020,"RESULTS ANOVA revealed that the FFS group had significant reductions in VALR (49.7%) and VILR (41.7%), and changes were maintained long term.",['39 healthy recreational runners using a rearfoot strike and a cadence of ≤170 steps/min were randomized into'],"['2 gait-retraining interventions', 'cadence (CAD) or forefoot strike (FFS', 'gait-retraining using auditory feedback', 'Cadence gait-retraining']","['VALR', 'VILR', 'Vertical average load rates (VALR) and vertical instantaneous load rates (VILR', 'Foot strike angle', 'cadence']","[{'cui': 'C0038452', 'cui_str': 'Employee Strikes'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0439232', 'cui_str': 'min'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1510667', 'cui_str': 'Forefoot region of foot'}, {'cui': 'C0038452', 'cui_str': 'Employee Strikes'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}]","[{'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0038452', 'cui_str': 'Employee Strikes'}, {'cui': 'C0205143', 'cui_str': 'Angular'}]",39.0,0.0737562,"RESULTS ANOVA revealed that the FFS group had significant reductions in VALR (49.7%) and VILR (41.7%), and changes were maintained long term.","[{'ForeName': 'Erin E', 'Initials': 'EE', 'LastName': 'Futrell', 'Affiliation': 'Department of Physical Therapy, Springfield College, Springfield, MA 01109, USA; Spaulding National Running Center, Harvard Medical School, Cambridge, MA 02138, USA. Electronic address: efutrell@springfieldcollege.edu.'}, {'ForeName': 'K Douglas', 'Initials': 'KD', 'LastName': 'Gross', 'Affiliation': 'Department of Physical Therapy, MGH Institute of Health Professions, Boston, MA 02129, USA.'}, {'ForeName': 'Darcy', 'Initials': 'D', 'LastName': 'Reisman', 'Affiliation': 'Department of Physical Therapy, University of Delaware, Newark, DE 19713, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Mullineaux', 'Affiliation': 'School of Sport and Exercise Science, University of Lincoln, Brayford Pool, Lincoln, Lincolnshire, Brayford Pool, LN6 7TS, UK.'}, {'ForeName': 'Irene S', 'Initials': 'IS', 'LastName': 'Davis', 'Affiliation': 'Spaulding National Running Center, Harvard Medical School, Cambridge, MA 02138, USA; Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA 02115, USA.'}]",Journal of sport and health science,['10.1016/j.jshs.2019.07.006'] 1646,32445295,The effectiveness of an interactive audio-tactile map for the process of cognitive mapping and recall among people with visual impairments.,"BACKGROUND People with visual impairments can experience numerous challenges navigating unfamiliar environments. Systems that operate as prenavigation tools can assist such individuals. This mixed-methods study examined the effectiveness of an interactive audio-tactile map tool on the process of cognitive mapping and recall, among people who were blind or had visual impairments. The tool was developed with the involvement of visually impaired individuals who additionally provided further feedback throughout this research. METHODS A mixed-methods experimental design was employed. Fourteen participants were allocated to either an experimental group who were exposed to an audio-tactile map, or a control group exposed to a verbally annotated tactile map. After five minutes' exposure, multiple-choice questions examined participants' recall of the spatial and navigational content. Subsequent semi-structured interviews were conducted to examine their views surrounding the study and the product. RESULTS The experimental condition had significantly better overall recall than the control group and higher average scores in all four areas examined by the questions. The interviews suggested that the interactive component offered individuals the freedom to learn the map in several ways and did not restrict them to a sequential and linear approach to learning. CONCLUSION Assistive technology can reduce challenges faced by people with visual impairments, and the flexible learning approach offered by the audio-tactile map may be of particular value. Future researchers and assistive technology developers may wish to explore this further.",2020,The experimental condition had significantly better overall recall than the control group and higher average scores in all four areas examined by the questions.,"['People with visual impairments', 'people who were blind or had visual impairments', 'Fourteen participants', 'people with visual impairments']","['interactive audio-tactile map tool', 'Assistive technology', 'interactive audio-tactile map', 'audio-tactile map, or a control group exposed to a verbally annotated tactile map']",['overall recall'],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0042798', 'cui_str': 'Dim vision'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C3715152', 'cui_str': '14'}]","[{'cui': 'C3876816', 'cui_str': 'Tactile map'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0036605', 'cui_str': 'Assistive equipment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}]",14.0,0.016012,The experimental condition had significantly better overall recall than the control group and higher average scores in all four areas examined by the questions.,"[{'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Griffin', 'Affiliation': 'School of Nursing and Midwifery, De Montfort University, Leicester, UK.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Picinali', 'Affiliation': 'Dyson School of Design Engineering, Imperial College London, London, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Scase', 'Affiliation': 'Division of Psychology, De Montfort University, Leicester, UK.'}]",Brain and behavior,['10.1002/brb3.1650'] 1647,32444457,Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.,"OBJECTIVE Type 2 diabetes is a leading cause of kidney failure, but few outcome trials proactively enrolled individuals with chronic kidney disease (CKD). We performed secondary analyses of cardiovascular (CV) and kidney outcomes across baseline estimated glomerular filtration rate (eGFR) categories (≥60, 45 to <60, 30 to <45, and <30 mL/min/1.73 m 2 ) in Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA), a cardiorenal placebo-controlled outcome trial of the dipeptidyl peptidase 4 inhibitor linagliptin (NCT01897532). RESEARCH DESIGN AND METHODS Participants with CV disease and/or CKD were included. The primary outcome was time to first occurrence of CV death, nonfatal myocardial infarction, or nonfatal stroke (three-point major adverse CV event [3P-MACE]), with a secondary outcome of renal death, end-stage kidney disease, or sustained ≥40% decrease in eGFR from baseline. Other end points included progression of albuminuria, change in HbA 1c , and adverse events (AEs) including hypoglycemia. RESULTS A total of 6,979 subjects (mean age 65.9 years; eGFR 54.6 mL/min/1.73 m 2 ; 80.1% albuminuria) were followed for 2.2 years. Across eGFR categories, linagliptin as compared with placebo did not affect the risk for 3P-MACE (hazard ratio 1.02 [95% CI 0.89, 1.17]) or the secondary kidney outcome (1.04 [0.89, 1.22]) (interaction P values >0.05). Regardless of eGFR, albuminuria progression was reduced with linagliptin, as was HbA 1c , without increasing risk for hypoglycemia. AEs were balanced among groups overall and across eGFR categories. CONCLUSIONS Across all GFR categories, in participants with type 2 diabetes and CKD and/or CV disease, there was no difference in risk for linagliptin versus placebo on CV and kidney events. Significant reductions in risk for albuminuria progression and HbA 1c and no difference in AEs were observed.",2020,"Across eGFR categories, linagliptin as compared with placebo did not affect the risk for 3P-MACE (hazard ratio 1.02 [95% CI 0.89, 1.17]) or the secondary kidney outcome (1.04 [0.89, 1.22]) (interaction P values >0.05).","['enrolled individuals with chronic kidney disease (CKD', '6,979 subjects (mean age 65.9 years; eGFR 54.6 mL/min/1.73 m 2 ; 80.1% albuminuria', 'People With Normal and Reduced Kidney Function', 'Participants with CV disease and/or CKD were included']","['placebo', 'Linagliptin', 'linagliptin']","['risk for 3P-MACE', 'time to first occurrence of CV death, nonfatal myocardial infarction, or nonfatal stroke', 'cardiovascular (CV) and kidney outcomes across baseline estimated glomerular filtration rate (eGFR) categories', 'progression of albuminuria, change in HbA 1c , and adverse events (AEs) including hypoglycemia', 'eGFR, albuminuria progression', 'CV and kidney events', 'risk for albuminuria progression and HbA 1c and no difference in AEs', 'Cardiovascular and Kidney Outcomes', 'secondary kidney outcome', 'renal death, end-stage kidney disease, or sustained ≥40% decrease in eGFR']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0001925', 'cui_str': 'Albuminuria'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0232804', 'cui_str': 'Renal function'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2746078', 'cui_str': 'Linagliptin'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0286421', 'cui_str': 'ACE protocol 2'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0001925', 'cui_str': 'Albuminuria'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}]",6979.0,0.362961,"Across eGFR categories, linagliptin as compared with placebo did not affect the risk for 3P-MACE (hazard ratio 1.02 [95% CI 0.89, 1.17]) or the secondary kidney outcome (1.04 [0.89, 1.22]) (interaction P values >0.05).","[{'ForeName': 'Vlado', 'Initials': 'V', 'LastName': 'Perkovic', 'Affiliation': 'Faculty of Medicine, The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia vlado.perkovic@unsw.edu.au.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Toto', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Cooper', 'Affiliation': 'Department of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Johannes F E', 'Initials': 'JFE', 'LastName': 'Mann', 'Affiliation': 'Kuratorium für Dialyse Kidney Centre, Munich, Germany.'}, {'ForeName': 'Julio', 'Initials': 'J', 'LastName': 'Rosenstock', 'Affiliation': 'Dallas Diabetes Research Center, Dallas, TX.'}, {'ForeName': 'Darren K', 'Initials': 'DK', 'LastName': 'McGuire', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'Steven E', 'Initials': 'SE', 'LastName': 'Kahn', 'Affiliation': 'Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, WA.'}, {'ForeName': 'Nikolaus', 'Initials': 'N', 'LastName': 'Marx', 'Affiliation': 'Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Alexander', 'Affiliation': 'Duke Clinical Research Institute, Duke Health, Durham, NC.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Zinman', 'Affiliation': 'Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'Egon', 'Initials': 'E', 'LastName': 'Pfarr', 'Affiliation': 'Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Schnaidt', 'Affiliation': 'Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Meinicke', 'Affiliation': 'Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.'}, {'ForeName': 'Maximillian', 'Initials': 'M', 'LastName': 'von Eynatten', 'Affiliation': 'Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.'}, {'ForeName': 'Jyothis T', 'Initials': 'JT', 'LastName': 'George', 'Affiliation': 'Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.'}, {'ForeName': 'Odd Erik', 'Initials': 'OE', 'LastName': 'Johansen', 'Affiliation': 'Boehringer Ingelheim Norway KS, Asker, Norway.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Wanner', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes care,['10.2337/dc20-0279'] 1648,31626688,"Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.",,2020,,['Community-acquired Bacterial Pneumonia'],"['Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic']",[],"[{'cui': 'C0456394', 'cui_str': 'Community acquired'}, {'cui': 'C0004626', 'cui_str': 'Bacterial pneumonia'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0071283', 'cui_str': 'Pleuromutilin'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}]",[],,0.017979,,"[{'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'File', 'Affiliation': ''}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Goldberg', 'Affiliation': ''}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Das', 'Affiliation': ''}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Sweeney', 'Affiliation': ''}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Saviski', 'Affiliation': ''}, {'ForeName': 'Steven P', 'Initials': 'SP', 'LastName': 'Gelone', 'Affiliation': ''}, {'ForeName': 'Elyse', 'Initials': 'E', 'LastName': 'Seltzer', 'Affiliation': ''}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Paukner', 'Affiliation': ''}, {'ForeName': 'Wolfgang W', 'Initials': 'WW', 'LastName': 'Wicha', 'Affiliation': ''}, {'ForeName': 'George H', 'Initials': 'GH', 'LastName': 'Talbot', 'Affiliation': ''}, {'ForeName': 'Leanne B', 'Initials': 'LB', 'LastName': 'Gasink', 'Affiliation': ''}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciz710'] 1649,32579859,Voice Therapy for Benign Voice Disorders in the Elderly: A Randomized Controlled Trial Comparing Telepractice and Conventional Face-to-Face Therapy.,"Purpose Previous studies have reported that voice therapy via telepractice is useful for patients with nodules and muscle tension dysphonia. Nevertheless, telepractice for elderly patients with voice disorders has not yet been investigated. We conducted this study to examine the hypothesis that voice therapy via telepractice is not inferior to conventional voice therapy. Method Eighty patients with dysphonia aged more than 55 years participated in this study from September 2016 to June 2018. After screening the inclusion and the exclusion criteria, 69 patients were randomized into telepractice (33 patients) and conventional (36 patients) groups. The outcome measurements included Voice Handicap Index-10, videolaryngostroboscopy, maximum phonation time, auditory-perceptual evaluation, and acoustic analysis. Paired t test, Wilcoxon signed-ranks test, and repeated measures analysis of variance were used to examine treatment outcomes. Results The diagnoses of voice disorders included atrophy ( n = 33), unilateral vocal paralysis ( n = 13), muscle tension dysphonia ( n = 7), nodules ( n = 6), and polyps ( n = 10). No significant differences were observed in age, sex, and baseline measurements between the two groups. Twenty-five patients in the telepractice group and 24 patients in the control group completed at least four weekly sessions. Significant improvements were observed for all the outcome measures ( p < .05) in both groups. Improvements in Voice Handicap Index-10 in the telepractice group (24.84 ± 5.49 to 16.80 ± 8.94) were comparable to those in the conventional group (22.17 ± 7.29 to 13.46 ± 9.95, p = .764). Other parameters also showed comparable improvements between the two groups without statistically significant differences. Conclusions This is the first randomized controlled trial comparing telepractice and conventional voice therapy in elderly patients with voice disorders. The results showed that the effectiveness of voice therapy via telepractice was not inferior to that of conventional voice therapy, indicating that telepractice can be used as an alternative to provide voice care for elderly patients with vocal disorders.",2020,"Improvements in Voice Handicap Index-10 in the telepractice group (24.84 ± 5.49 to 16.80 ± 8.94) were comparable to those in the conventional group (22.17 ± 7.29 to 13.46 ± 9.95, p = .764).","['Method Eighty patients with dysphonia aged more than 55 years participated in this study from September 2016 to June 2018', 'voice disorders included atrophy ( n = 33), unilateral vocal paralysis ( n = 13), muscle tension dysphonia ( n = 7), nodules ( n = 6), and polyps ( n = 10', 'Benign Voice Disorders in the Elderly', 'elderly patients with vocal disorders', 'elderly patients with voice disorders', 'patients with nodules and muscle tension dysphonia', '69 patients were randomized into telepractice (33 patients) and conventional (36 patients) groups']","['Voice Therapy', 'Telepractice and Conventional Face-to-Face Therapy', 'telepractice and conventional voice therapy']","['Voice Handicap Index-10', 'Voice Handicap Index-10, videolaryngostroboscopy, maximum phonation time, auditory-perceptual evaluation, and acoustic analysis']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019825', 'cui_str': 'Hoarse'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0042940', 'cui_str': 'Voice Disorders'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0026846', 'cui_str': 'Muscle atrophy'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0237766', 'cui_str': 'Hysterical paralysis'}, {'cui': 'C4728018', 'cui_str': 'Muscle tension dysphonia'}, {'cui': 'C0028259', 'cui_str': 'Nodule'}, {'cui': 'C0032584', 'cui_str': 'Polyp'}, {'cui': 'C0205183', 'cui_str': 'Benign'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C2202690', 'cui_str': 'Voice therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C2985106', 'cui_str': 'Voice handicap index'}, {'cui': 'C0234778', 'cui_str': 'Maximum phonation time'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0001166', 'cui_str': 'Acoustics'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]",80.0,0.0331451,"Improvements in Voice Handicap Index-10 in the telepractice group (24.84 ± 5.49 to 16.80 ± 8.94) were comparable to those in the conventional group (22.17 ± 7.29 to 13.46 ± 9.95, p = .764).","[{'ForeName': 'Feng-Chuan', 'Initials': 'FC', 'LastName': 'Lin', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Far Eastern Memorial Hospital, Taipei, Taiwan.'}, {'ForeName': 'Hsin-Yu', 'Initials': 'HY', 'LastName': 'Chien', 'Affiliation': 'Department of Audiology and Speech-Language Pathology, Asia University, Taichung, Taiwan.'}, {'ForeName': 'Sheng Hwa', 'Initials': 'SH', 'LastName': 'Chen', 'Affiliation': 'Department of Audiology and Speech-Language Pathology, Asia University, Taichung, Taiwan.'}, {'ForeName': 'Yi-Chia', 'Initials': 'YC', 'LastName': 'Kao', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Far Eastern Memorial Hospital, Taipei, Taiwan.'}, {'ForeName': 'Po-Wen', 'Initials': 'PW', 'LastName': 'Cheng', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Far Eastern Memorial Hospital, Taipei, Taiwan.'}, {'ForeName': 'Chi-Te', 'Initials': 'CT', 'LastName': 'Wang', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Far Eastern Memorial Hospital, Taipei, Taiwan.'}]","Journal of speech, language, and hearing research : JSLHR",['10.1044/2020_JSLHR-19-00364'] 1650,32580032,Design of a cluster-randomized trial of the effectiveness and cost-effectiveness of metformin on prevention of type 2 diabetes among prediabetic Mexican adults (the PRuDENTE initiative of Mexico City).,"INTRODUCTION Type 2 diabetes (T2D) is a global epidemic, and nations are struggling to implement effective healthcare strategies to reduce the burden. While efficacy studies demonstrate that metformin can reduce incident T2D by half among younger, obese adults with prediabetes, its real-world effectiveness are understudied, and its use for T2D prevention in primary care is low. We describe the design of a pragmatic trial to evaluate the incremental effectiveness of metformin, as an adjunct to a simple lifestyle counseling. METHODS The ""Prevención de la Diabetes con Ejercicio, Nutrición y Tratamiento"" [Diabetes Prevention with Exercise, Nutrition and Treatment; PRuDENTE, (Spanish acronym)] is a cluster-randomized trial in Mexico City's public primary healthcare system. The study randomly assigns 51 clinics to deliver one of two interventions for 36 months: 1) lifestyle only; 2) lifestyle plus metformin, to 3060 patients ages 30-65 with impaired fasting glucose and obesity. The primary endpoint is incident T2D (fasting glucose ≥126 mg/dL, or HbA1c ≥6.5%). We will also measure a range of implementation-related process outcomes at the clinic-, clinician- and patient-levels to inform interpretations of effectiveness and enable efforts to refine, adapt, adopt and disseminate the model. We will also estimate the cost-effectiveness of metformin as an adjunct to lifestyle counseling in Mexico. DISCUSSION Findings from this pragmatic trial will generate new translational knowledge in Mexico and beyond, both with respect to metformin's real-world effectiveness among an 'at-risk' population, and uncovering facilitators and barriers to the reach, adoption and implementation of metformin preventive therapy in public primary care settings. TRIAL REGISTRATION This trial is registered at Clinicaltrials.gov (NCT03194009).",2020,Nutrición y,"['prediabetic Mexican adults (the PRuDENTE initiative of Mexico City', '3060 patients ages 30-65 with impaired fasting glucose and obesity', 'Nutrición y']","['lifestyle only; 2) lifestyle plus metformin', 'metformin']","['incident T2D (fasting glucose ≥126\u202fmg/dL, or HbA1c ≥6.5']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0025885', 'cui_str': 'Mexico'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1272092', 'cui_str': 'Impaired fasting glycaemia'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]",3060.0,0.0429361,Nutrición y,"[{'ForeName': 'Luis A', 'Initials': 'LA', 'LastName': 'Rodríguez', 'Affiliation': 'Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA. Electronic address: Luis.Rodriguez@ucsf.edu.'}, {'ForeName': 'Simón', 'Initials': 'S', 'LastName': 'Barquera', 'Affiliation': 'Nutrition and Health Research Center, National Institute of Public Health, Cuernavaca, Mexico.'}, {'ForeName': 'Carlos A', 'Initials': 'CA', 'LastName': 'Aguilar-Salinas', 'Affiliation': 'Division of Nutrition, Salvador Zubiran National Institute of Medical Sciences and Nutrition, Mexico City, Mexico.'}, {'ForeName': 'Jaime', 'Initials': 'J', 'LastName': 'Sepúlveda-Amor', 'Affiliation': 'Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA; Institute for Global Health Sciences, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Luz María', 'Initials': 'LM', 'LastName': 'Sánchez-Romero', 'Affiliation': 'Nutrition and Health Research Center, National Institute of Public Health, Cuernavaca, Mexico.'}, {'ForeName': 'Edgar', 'Initials': 'E', 'LastName': 'Denova-Gutiérrez', 'Affiliation': 'Nutrition and Health Research Center, National Institute of Public Health, Cuernavaca, Mexico.'}, {'ForeName': 'Nydia', 'Initials': 'N', 'LastName': 'Balderas', 'Affiliation': 'Nutrition and Health Research Center, National Institute of Public Health, Cuernavaca, Mexico.'}, {'ForeName': 'Lizbeth', 'Initials': 'L', 'LastName': 'Moreno-Loaeza', 'Affiliation': 'Research Unit on Metabolic Diseases, Salvador Zubiran National Institute of Medical Sciences and Nutrition, Mexico City, Mexico; Medical, Dental and Health Sciences, National Autonomous University of Mexico, Mexico City, Mexico.'}, {'ForeName': 'Margaret A', 'Initials': 'MA', 'LastName': 'Handley', 'Affiliation': 'Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA; Division of General Internal Medicine at San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA; UCSF Center for Vulnerable Populations, San Francisco General Hospital, San Francisco, CA, USA.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Basu', 'Affiliation': 'Department of Medicine, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Oliva', 'Initials': 'O', 'LastName': 'López-Arellano', 'Affiliation': 'Ministry of Health, Mexico City, Mexico.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Gallardo-Hernández', 'Affiliation': 'Ministry of Health, Mexico City, Mexico.'}, {'ForeName': 'Dean', 'Initials': 'D', 'LastName': 'Schillinger', 'Affiliation': 'Division of General Internal Medicine at San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA; UCSF Center for Vulnerable Populations, San Francisco General Hospital, San Francisco, CA, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106067'] 1651,32444152,Land-walking vs. water-walking interventions in older adults: Effects on aerobic fitness.,"BACKGROUND Low cardiorespiratory fitness is an independent predictor of all-cause and cardiovascular mortality, and interventions that increase fitness reduce risk. Water-walking decreases musculoskeletal impact and risk of falls in older individuals, but it is unclear whether water-walking improves aerobic fitness in the same way as weight-dependent land-walking. This randomized controlled trial involved 3 intervention groups-a no-exercise control group (CG), a land-walking (LW) group, and a water-walking (WW) group-to investigate the comparative impacts of LW and WW to CG on fitness. METHODS Both exercise groups attended individually tailored, center-based, intensity-matched 3 × weekly sessions for 24 weeks, which progressed to 150 min of exercise per week. This was followed by a 24-week no-intervention period. Maximal graded exercise tests were performed on a treadmill at Weeks 0, 24, and 48. RESULTS Maximal oxygen uptake increased from Week 0 to Week 24 in both exercise groups (0.57 ± 0.62 mL/kg/min, 0.03 ± 0.04 L/min for LW; 0.93 ± 0.75 mL/kg/min, 0.06 ± 0.06 L/min for WW, mean ± SE) compared to the CG (-1.75 ± 0.78 mL/kg/min, -0.16 ± 0.05 L/min) (group × time, p < 0.05). Time to exhaustion increased significantly following LW only (123.4 ± 25.5 s), which was significantly greater (p = 0.001) than the CG (24.3 ± 18.5 s). By Week 48, the training-induced adaptations in the exercise groups returned to near baseline levels. CONCLUSION Our study supports current physical-activity recommendations that 150 min/week of moderate-intensity exercise produces improvements in fitness in previously sedentary older individuals. Also, LW and WW elicit similar improvements in fitness if conducted at the same relative intensities. Exercise-naïve older individuals can benefit from the lower impact forces and decreased risk of falls associated with WW without compromising improvements in cardiorespiratory fitness.",2020,"Time to exhaustion increased significantly following LW only (123.4 ± 25.5 s), which was significantly greater (p = 0.001) than the CG (24.3 ± 18.5 s).","['older individuals', 'Exercise-naïve older individuals', 'previously sedentary older individuals', 'older adults']","['moderate-intensity exercise', 'no-exercise control group (CG), a land-walking (LW) group, and a water-walking (WW', 'Land-walking vs. water-walking interventions', 'Water-walking']","['aerobic fitness', 'Maximal oxygen uptake', 'Time to exhaustion']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0557668', 'cui_str': 'Landing'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}]",,0.0350292,"Time to exhaustion increased significantly following LW only (123.4 ± 25.5 s), which was significantly greater (p = 0.001) than the CG (24.3 ± 18.5 s).","[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Haynes', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'Louise H', 'Initials': 'LH', 'LastName': 'Naylor', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'Howard H', 'Initials': 'HH', 'LastName': 'Carter', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'Angela L', 'Initials': 'AL', 'LastName': 'Spence', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, WA 6102, Australia.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Robey', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'Kay L', 'Initials': 'KL', 'LastName': 'Cox', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia; School of Medicine, The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Maslen', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'Nicola T', 'Initials': 'NT', 'LastName': 'Lautenschlager', 'Affiliation': 'Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Melbourne, VIC 3010, Australia; North Western Mental Health, Melbourne Health, Melbourne, VIC 3010, Australia; Division of Psychiatry, WA Centre for Health & Ageing, The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'Nicola D', 'Initials': 'ND', 'LastName': 'Ridgers', 'Affiliation': 'Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC 3125, Australia.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Green', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia. Electronic address: danny.green@uwa.edu.au.'}]",Journal of sport and health science,['10.1016/j.jshs.2019.11.005'] 1652,32446170,"Independent and combined effect of home-based progressive resistance training and nutritional supplementation on muscle strength, muscle mass and physical function in dynapenic older adults with low protein intake: A randomized controlled trial.","BACKGROUND With the aging phenomenon, there is growing interest in developing effective strategies to counteract dynapenia, the age-related loss of muscle strength. The positive effect of progressive resistance training on muscle strength is well known, however, the effect of nutritional supplementation or its synergistic effect along with exercise on muscle strength is not a consensus in the literature, especially in populations with low protein intake. METHODS We analyzed the muscle strength (handgrip strength and sit-to-stand test), muscle mass, body mass index, insulin resistance, and physical function (gait speed, timed up & go test, and single-leg-stance test) of 69 dynapenic older adults with low protein intake, before and after the intervention period of three months. The participants were randomly allocated into four groups: resistance training, supplementation, resistance training plus supplementation, and control. RESULTS There was a significant group x time interaction on the following outcome measures: handgrip strength (p <  0.001), gait speed (p =  0.023), and sit-to-stand test (p <  0.001). Considering the outcomes that showed a significant difference between and within groups, only the resistance training group and the resistance training plus supplementation group showed a large effect size in handgrip strength, gait speed, and sit-to-stand test, whereas the supplementation group showed a moderate effect size in gait speed. After the intervention period, there was no difference between the resistance training and the resistance training plus supplementation groups. CONCLUSION This study reinforces the value of resistance training in improving muscle strength. The nutritional supplementation added no further benefits in this specific population. Registration number at the Brazilian registry of clinical trials: RBR-4HRQJF.",2020,"There was a significant group x time interaction on the following outcome measures: handgrip strength (p <  0.001), gait speed (p =  0.023), and sit-to-stand test (","['dynapenic older adults with low protein intake', '69 dynapenic older adults with low protein intake, before and after the intervention period of three months']","['home-based progressive resistance training and nutritional supplementation', 'progressive resistance training', 'resistance training, supplementation, resistance training plus supplementation, and control']","['muscle strength (handgrip strength and sit-to-stand test), muscle mass, body mass index, insulin resistance, and physical function (gait speed, timed up & go test, and single-leg-stance test', 'gait speed', 'sit-to-stand test ', 'muscle strength, muscle mass and physical function', 'handgrip strength', 'moderate effect size in gait speed', 'handgrip strength, gait speed, and sit-to-stand test']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0242972', 'cui_str': 'Low protein diet'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4082119', 'cui_str': 'Three months'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0560801', 'cui_str': 'Does stand from sitting'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}]",,0.0382378,"There was a significant group x time interaction on the following outcome measures: handgrip strength (p <  0.001), gait speed (p =  0.023), and sit-to-stand test (","[{'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'de Carvalho Bastone', 'Affiliation': 'Postgraduate Program in Reabilitation and Functional Performance, Department of Physical Therapy - Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Minas Gerais, Brazil. Electronic address: ale.bastone@gmail.com.'}, {'ForeName': 'Luciana Neri', 'Initials': 'LN', 'LastName': 'Nobre', 'Affiliation': 'Department of Nutrition - Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Minas Gerais, Brazil. Electronic address: lunerinobre@yahoo.com.br.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'de Souza Moreira', 'Affiliation': 'Postgraduate Program in Public Health - Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. Electronic address: onurbsm@yahoo.com.br.'}, {'ForeName': 'Iramaya Francielle', 'Initials': 'IF', 'LastName': 'Rosa', 'Affiliation': 'Department of Physical Therapy - Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Minas Gerais, Brazil. Electronic address: iramayafranciellerosa@hotmail.com.'}, {'ForeName': 'Gabrielle Bemfica', 'Initials': 'GB', 'LastName': 'Ferreira', 'Affiliation': 'Department of Nutrition - Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Minas Gerais, Brazil. Electronic address: gabi_bferreira@hotmail.com.'}, {'ForeName': 'Dayane Deyse Lee', 'Initials': 'DDL', 'LastName': 'Santos', 'Affiliation': 'Department of Physical Therapy - Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Minas Gerais, Brazil. Electronic address: dayanedls@hotmail.com.'}, {'ForeName': 'Nancy Krysna Sancha Silva', 'Initials': 'NKSS', 'LastName': 'Monteiro', 'Affiliation': 'Department of Nutrition - Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Minas Gerais, Brazil. Electronic address: krysnancymonteiro@gmail.com.'}, {'ForeName': 'Michelle Dullya', 'Initials': 'MD', 'LastName': 'Alves', 'Affiliation': 'Department of Nutrition - Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Minas Gerais, Brazil. Electronic address: mih.dullya@gmail.com.'}, {'ForeName': 'Rômulo Amaral', 'Initials': 'RA', 'LastName': 'Gandra', 'Affiliation': 'Department of Physical Therapy - Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Minas Gerais, Brazil. Electronic address: romulogandra@yahoo.com.br.'}, {'ForeName': 'Elane Marinho', 'Initials': 'EM', 'LastName': 'de Lira', 'Affiliation': 'Postgraduate Program in Reabilitation and Functional Performance, Department of Physical Therapy - Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Minas Gerais, Brazil. Electronic address: e.lira.fisio@gmail.com.'}]",Archives of gerontology and geriatrics,['10.1016/j.archger.2020.104098'] 1653,32446172,Effects of 'participatory group-based care management' on wellbeing of older people living alone: a randomized controlled trial.,"BACKGROUND AND OBJECTIVES More knowledge is needed of the effectiveness of complex interventions that aim to promote the wellbeing of older people. This study examines the effects of 'participatory group-based care management' conducted among community-dwelling older adults living alone in Central and Eastern Finland. The intervention aimed to promote wellbeing and quality of life (QoL) using a needs-based and participatory approach. METHODS The study was carried out as a randomized control trial (intervention group n = 185, control group n = 207). In this article, baseline and 6-month follow-up surveys were used. QoL (WHOQOL-Bref instrument), loneliness (Revised UCLA Loneliness Scale; single-item question), and trust (two items of generalized trust and six items of institutional trust) were used as outcome measurements, and generalized estimating equations (GEE) modeling as the analysis method. Both per-protocol and intention-to-treat analyses were applied. RESULTS According to the per-protocol analysis, the intervention had no effects on QoL. Loneliness decreased among older people with poor QoL at the baseline. Additionally, the intervention enhanced trust in other people and some dimensions of institutional trust. The intention-to-treat analysis did not result in any significant effects on QoL or loneliness, but some small positive changes in institutional trust were found. CONCLUSIONS Based on some evidence of small positive effects, the intervention may be beneficial in alleviating loneliness and enhancing trust among older people living alone. Because of the contradictory results, more research is needed to examine the complexity of 'participatory group-based care management´ from the perspective of process evaluation.",2020,"According to the per-protocol analysis, the intervention had no effects on QoL. Loneliness decreased among older people with poor QoL at the baseline.","['older people', 'community-dwelling older adults living alone in Central and Eastern Finland', 'older people living alone']",['participatory group-based care management'],"['QoL or loneliness', 'wellbeing and quality of life (QoL', 'QoL. Loneliness', 'QoL (WHOQOL-Bref instrument), loneliness (Revised UCLA Loneliness Scale; single-item question), and trust (two items of generalized trust and six items of institutional trust']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439044', 'cui_str': 'Lives alone'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0016132', 'cui_str': 'Finland'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0023974', 'cui_str': 'Feeling lonely'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}]",,0.0856593,"According to the per-protocol analysis, the intervention had no effects on QoL. Loneliness decreased among older people with poor QoL at the baseline.","[{'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Ristolainen', 'Affiliation': 'Department of Social Sciences, University of Eastern Finland, Finland.'}, {'ForeName': 'Sirpa', 'Initials': 'S', 'LastName': 'Kannasoja', 'Affiliation': 'Department of Social Sciences and Philosophy, University of Jyväskylä, Finland.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Tiilikainen', 'Affiliation': 'Department of Social Sciences, University of Eastern Finland, Finland.'}, {'ForeName': 'Mari', 'Initials': 'M', 'LastName': 'Hakala', 'Affiliation': 'Department of Social Sciences and Philosophy, University of Jyväskylä, Finland.'}, {'ForeName': 'Kati', 'Initials': 'K', 'LastName': 'Närhi', 'Affiliation': 'Department of Social Sciences and Philosophy, University of Jyväskylä, Finland.'}, {'ForeName': 'Sari', 'Initials': 'S', 'LastName': 'Rissanen', 'Affiliation': 'Department of Social Sciences, University of Eastern Finland, Finland.'}]",Archives of gerontology and geriatrics,['10.1016/j.archger.2020.104095'] 1654,32446752,Adding Financial Incentives to Online Group-Based Behavioral Weight Control: An RCT.,"INTRODUCTION Internet-delivered behavioral weight control is promising for expanding the reach and availability of weight management, but online programs produce lower weight losses than typically achieved in person. Financial incentives have been shown to increase weight losses. This study examined whether adding financial incentives for self-monitoring and achieving target weight losses increases weight losses attained in a fully online, group-based behavioral weight management program compared with the same program alone. STUDY DESIGN This study was an RCT. SETTING/PARTICIPANTS Adults with overweight and obesity (n=418; 91% female; 28% minority) were recruited from 2 clinical centers. INTERVENTION The intervention was a 24-session online group-based behavioral weight control program with weekly synchronous chat sessions (Internet-only) or the same program with weekly financial incentives for self-monitoring body weight and dietary intake daily and for achieving target weight losses at 2 and 6 months (Internet + incentives). MAIN OUTCOME MEASURES This study measured weight loss at 6 months and treatment engagement (attendance, self-monitoring of body weight, dietary intake, and physical activity). Data were collected between February 2016 and August 2018, and analyses were completed in 2019. RESULTS Participants randomized to the Internet + incentives group lost more weight (-6.4 [SD=5.5] kg) than those in the Internet-only group (-4.7 [SD=6.6] kg; p<0.01). Further, a higher proportion of the Internet + incentives group achieved ≥5% weight loss (55%) than those in the Internet-only group (40%; p<0.05). Treatment engagement was higher in the Internet + incentives condition, with greater self-monitoring of behaviors targeted by incentives, as well as higher rates of behaviors not targeted and higher self-reported physical activity. Study retention was higher among those in the Internet + incentives condition (91%) than those in the Internet-only condition (81%; p=0.003). CONCLUSIONS Adding financial incentives to a program delivered fully online increases weight losses compared with the program alone and can achieve weight losses comparable to in-person programs, offering potential for substantial geographic reach. TRIAL REGISTRATION This study is registered at www.clinicaltrials.gov NCT02688621.",2020,"Study retention was higher among those in the Internet + incentives condition (91%) than those in the Internet-only condition (81%; p=0.003). ","['Adults with overweight and obesity (n=418; 91% female; 28% minority) were recruited from 2 clinical centers', 'Data were collected between February 2016 and August 2018, and analyses were completed in 2019']",['24-session online group-based behavioral weight control program with weekly synchronous chat sessions (Internet-only) or the same program with weekly financial incentives for self-monitoring body weight and dietary intake daily and for achieving target weight losses at 2 and 6 months (Internet\u202f+\u202fincentives'],"['weight', 'Study retention', 'weight loss at 6 months and treatment engagement (attendance, self-monitoring of body weight, dietary intake, and physical activity', 'weight losses', 'weight loss']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0026192', 'cui_str': 'Minority Groups'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0439580', 'cui_str': 'Synchronous'}, {'cui': 'C0124604', 'cui_str': 'Catha edulis'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1272247', 'cui_str': 'Target weight'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0376283,"Study retention was higher among those in the Internet + incentives condition (91%) than those in the Internet-only condition (81%; p=0.003). ","[{'ForeName': 'Delia S', 'Initials': 'DS', 'LastName': 'West', 'Affiliation': 'Arnold School of Public Health, University of South Carolina, Columbia, South Carolina. Electronic address: westds@mailbox.sc.edu.'}, {'ForeName': 'Rebecca A', 'Initials': 'RA', 'LastName': 'Krukowski', 'Affiliation': 'Department of Preventive Medicine, University of Tennessee Health Sciences Center, Memphis, Tennessee.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Finkelstein', 'Affiliation': 'Duke-NUS Medical School and Duke University Global Health Institute, Singapore and Durham, North Carolina.'}, {'ForeName': 'Melissa L', 'Initials': 'ML', 'LastName': 'Stansbury', 'Affiliation': 'Arnold School of Public Health, University of South Carolina, Columbia, South Carolina.'}, {'ForeName': 'Doris E', 'Initials': 'DE', 'LastName': 'Ogden', 'Affiliation': 'Department of Nutrition and Food Sciences, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Courtney M', 'Initials': 'CM', 'LastName': 'Monroe', 'Affiliation': 'Arnold School of Public Health, University of South Carolina, Columbia, South Carolina.'}, {'ForeName': 'Chelsea A', 'Initials': 'CA', 'LastName': 'Carpenter', 'Affiliation': 'Arnold School of Public Health, University of South Carolina, Columbia, South Carolina.'}, {'ForeName': 'Shelly', 'Initials': 'S', 'LastName': 'Naud', 'Affiliation': 'Biomedical Statistics, Larner College of Medicine, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Jean R', 'Initials': 'JR', 'LastName': 'Harvey', 'Affiliation': 'Department of Nutrition and Food Sciences, University of Vermont, Burlington, Vermont.'}]",American journal of preventive medicine,['10.1016/j.amepre.2020.03.015'] 1655,32247794,Subperiosteal versus Subdural Drain After Burr-hole Drainage Under Blood Thinners: A Subanalysis of the cSDH-Drain RCT.,"OBJECTIVE The chronic subdural hematoma (cSDH)-Drain trial compared recurrence rates and clinical outcome associated with the use of subperiosteal drain (SPD) and subdural drain (SDD) after burr-hole drainage for cSDH. This subgroup analysis aimed to determine whether one drain type is preferable for patients treated with platelet inhibitors (PI) or anticoagulants (AC). METHODS This subanalysis included 133 patients treated with PI/AC of the 220 patients from the preceding cSDH-Drain trial. For these patients the association between the drain type used and recurrence rates, mortality, as well as clinical outcome at 6 weeks and 12 months follow-up were analyzed using a logistic regression analysis model. Additionally, recurrence rates, clinical outcome, and mortality were assessed for each PI or AC type separately. RESULTS The insertion of SPD was associated with 7.35% recurrence rates compared to 13.85% with SDD in patients treated with PI or AC (OR 0.41, 95% CI 0.06-2.65, P = 0.36). Outcome measurements and mortality did not differ significantly between both groups at 6-week and 12-month follow-up. In addition, there was no statistically significant association between drain type and recurrence rate or mortality when comparing data for each PI or AC type. At 24 hours postoperatively, significantly more patients under phenprocoumon and natrium-dalteparin had a Glasgow Coma Scale score between 13 and 15 in the SDD group compared with the SPD group (P = 0.006), whereaas at 6-week follow-up significantly more patients in the SDD group treated with ASA had a good modified Rankin scale score (P = 0.01). At 12 months, no significant difference in outcome measurements was seen for all PI and AC types. CONCLUSIONS In patients treated with PI or AC, the insertion of SPD after burr-hole drainage of cSDH showed comparable recurrence, mortality, and long term outcome rates when compared with SDD.",2020,"The insertion of SPD was associated with 7.35% recurrence rates compared to 13.85% with SDD in patients treated with PI or AC (OR 0.41, 95% CI 0.06-2.65, P = 0.36).","['133 patients treated with PI/AC of the 220 patients from the preceding cSDH-Drain trial', 'After Burr-hole Drainage Under Blood Thinners']","['Subperiosteal versus Subdural Drain', 'ASA', 'subperiosteal drain (SPD) and subdural drain (SDD', 'cSDH-Drain RCT', 'platelet inhibitors (PI) or anticoagulants (AC']","['good modified Rankin scale score', 'Glasgow Coma Scale score', 'recurrence, mortality', 'recurrence rates, mortality', 'mortality', 'recurrence rates', 'recurrence rates, clinical outcome, and mortality', 'drain type and recurrence rate or mortality']","[{'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0032188', 'cui_str': 'Platelet Inhibitors'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0749095', 'cui_str': 'Subdural Hematoma, Chronic'}, {'cui': 'C0013103', 'cui_str': 'Drainage procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0040836', 'cui_str': 'Trephination of cranium'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]","[{'cui': 'C0038541', 'cui_str': 'Subdural space structure'}, {'cui': 'C0013103', 'cui_str': 'Drainage procedure'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0749095', 'cui_str': 'Subdural Hematoma, Chronic'}, {'cui': 'C0032188', 'cui_str': 'Platelet Inhibitors'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}]","[{'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0017594', 'cui_str': 'Glasgow coma scale'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0013103', 'cui_str': 'Drainage procedure'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]",220.0,0.201965,"The insertion of SPD was associated with 7.35% recurrence rates compared to 13.85% with SDD in patients treated with PI or AC (OR 0.41, 95% CI 0.06-2.65, P = 0.36).","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Kamenova', 'Affiliation': 'Department of Neurosurgery, University Hospital of Basel, Basel, Switzerland.'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Lutz', 'Affiliation': 'Faculty of Medicine, University of Basel, Basel, Switzerland; Department of Neurosurgery, Inselspital Bern, Bern, Switzerland.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Schaedelin', 'Affiliation': 'Clinical Trial Unit, University of Basel, Switzerland.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Fandino', 'Affiliation': 'Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Mariani', 'Affiliation': 'Department of Neurosurgery, University Hospital of Basel, Basel, Switzerland; Faculty of Medicine, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Jehuda', 'Initials': 'J', 'LastName': 'Soleman', 'Affiliation': 'Department of Neurosurgery, University Hospital of Basel, Basel, Switzerland; Faculty of Medicine, University of Basel, Basel, Switzerland. Electronic address: jehuda.soleman@gmail.com.'}]",World neurosurgery,['10.1016/j.wneu.2020.03.134'] 1656,32459377,Validation of the 7-item Functional Assessment of Cancer Therapy-General (FACT-G7) as a short measure of quality of life in patients with advanced cancer.,"BACKGROUND Assessing quality of life is essential for individuals with advanced cancer, but lengthy assessments can be burdensome. The authors investigated the psychometric characteristics of the FACT-G7, a 7-item quality-of-life measure derived from the Functional Assessment of Cancer Therapy-General (FACT-G) scale, in advanced cancer. METHODS Data were obtained from outpatients with advanced cancer who were enrolled in a randomized controlled trial of early palliative care. At baseline, 228 intervention participants and 233 control participants (N = 461) completed the FACT-G and measures of symptom severity, quality of life near the end of life, problematic medical communication, and satisfaction with care. Follow-up measures were administered monthly for 4 months. RESULTS The FACT-G7 showed good internal consistency (Cronbach α = .72-.80), and its single-factor structure was supported. It correlated strongly with the FACT-G total, physical, and functional indices and with symptom severity (absolute r = 0.73-0.92); more moderately with the FACT-G emotional index and with symptom impact and preparation for the end of life (r = .40-.71); and least with the FACT-G social/family index and with relationship with health care provider, life completion, problematic medical communication, and care satisfaction measures (absolute r = .26-.44). Eastern Cooperative Oncology Group performance status groups differed on FACT-G7 scores, as expected (all P < .001). Improvements in FACT-G7 scores in the intervention group compared with the control group at 3-month (P = .049) and 4-month (P = .034) follow-up supported responsiveness to change and somewhat greater sensitivity than the FACT-G scores. CONCLUSIONS The FACT-G7 is a valid, brief measure particularly of the physical and functional facets of quality of life. It may enable rapid quality-of-life assessments in patients with advanced cancer.",2020,"(P = .034) follow-up supported responsiveness to change and somewhat greater sensitivity than the FACT-G scores. ","['individuals with advanced cancer', '228 intervention participants and 233 control participants (N\xa0=\xa0461', 'Data were obtained from outpatients with advanced cancer who were enrolled in a randomized controlled trial of early palliative care', 'patients with advanced cancer']",['Cancer Therapy-General'],"['quality of life', 'Functional Assessment of Cancer Therapy-General (FACT-G) scale', 'FACT-G total, physical, and functional indices and with symptom severity', 'FACT-G and measures of symptom severity, quality of life near the end of life, problematic medical communication, and satisfaction with care', 'FACT-G7 scores']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",461.0,0.0598682,"(P = .034) follow-up supported responsiveness to change and somewhat greater sensitivity than the FACT-G scores. ","[{'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Mah', 'Affiliation': 'Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Swami', 'Affiliation': 'Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Lisa W', 'Initials': 'LW', 'LastName': 'Le', 'Affiliation': 'Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Chow', 'Affiliation': 'Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Breffni L', 'Initials': 'BL', 'LastName': 'Hannon', 'Affiliation': 'Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Rodin', 'Affiliation': 'Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Zimmermann', 'Affiliation': 'Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.'}]",Cancer,['10.1002/cncr.32981'] 1657,32459394,Parent reports of sun safety communication and behaviour for students in a randomised trial on a school policy implementation intervention.,"OBJECTIVE Schools are an important setting for skin cancer prevention. An intervention for implementation of school sun safety policy, Sun Safety Schools (SSS), was evaluated. METHODS Primary schools (n=118) in California school districts that had already adopted a sun safety policy were enrolled in a study with a randomised controlled design. Half of the schools were randomised to SSS intervention (N=58). Parents completed an online post-test. RESULTS More parents in intervention schools received information about sun safety (mean=26.3%, sd=3.1%, p=0.017) and children more frequently wore sun-protective clothing when not at school (mean=2.93, sd=0.03, p=0.033) than in control schools (mean=18.0%, sd=2.5%; mean=2.83, sd=0.03, respectively). In schools where principals reported implementing sun safety practices, parents reported that children spent less time outdoors at midday (mean=14.78 hours, sd=0.25, p=0.033) and fewer were sunburned (mean=12.7%, sd=1.1%, p=0.009) than in non-implementing schools (M=16.3 hours, sd=0.67; mean=21.2%, sd=3.8%, respectively). Parents who received sun safety information (mean=3.08, sd=0.04, p=0.008) reported more child sun protection than parents not receiving information (mean=2.96, sd=0.02). CONCLUSIONS A school district sun protection policy and support for implementation increased dissemination of sun safety information to parents and student sun safety. Implications for public health: Technical assistance for sun safety policies may increase sun protection of children.",2020,"More parents in intervention schools received information about sun safety (mean=26.3%, sd=3.1%, p=0.017) and children more frequently wore sun-protective clothing when not at school (mean=2.93, sd=0.03, p=0.033) than in control schools (mean=18.0%, sd=2.5%; mean=2.83, sd=0.03, respectively).","['Primary schools (n=118) in California school districts that had already adopted a sun safety policy', 'public health', 'children']","['SSS intervention', 'sun safety information']","['children spent less time outdoors at midday', 'information about sun safety', 'child sun protection']","[{'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0425382', 'cui_str': 'Adopted'}, {'cui': 'C0038817', 'cui_str': 'Sunlight'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0242456', 'cui_str': 'Policy'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0038817', 'cui_str': 'Sunlight'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0585020', 'cui_str': 'Noon'}, {'cui': 'C0038817', 'cui_str': 'Sunlight'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.152215,"More parents in intervention schools received information about sun safety (mean=26.3%, sd=3.1%, p=0.017) and children more frequently wore sun-protective clothing when not at school (mean=2.93, sd=0.03, p=0.033) than in control schools (mean=18.0%, sd=2.5%; mean=2.83, sd=0.03, respectively).","[{'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Buller', 'Affiliation': 'Klein Buendel Inc., Colorado, US.'}, {'ForeName': 'Kim D', 'Initials': 'KD', 'LastName': 'Reynolds', 'Affiliation': 'School of Community and Global Health, Claremont Graduate University, California, US.'}, {'ForeName': 'Mary K', 'Initials': 'MK', 'LastName': 'Buller', 'Affiliation': 'Klein Buendel Inc., Colorado, US.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Massie', 'Affiliation': 'School of Community and Global Health, Claremont Graduate University, California, US.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Berteletti', 'Affiliation': 'Klein Buendel Inc., Colorado, US.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Ashley', 'Affiliation': 'Sun Safety for Kids, California, US.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Meenan', 'Affiliation': 'Kaiser Permanente Center for Health Research, Oregon, US.'}]",Australian and New Zealand journal of public health,['10.1111/1753-6405.12987'] 1658,32457106,Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Conventional Itraconazole Capsules in Healthy Adults.,"Super bioavailability (SUBA) itraconazole (S-ITZ), which releases drug in the duodenum, and conventional itraconazole (C-ITZ), which releases drug in the stomach, were compared in two pharmacokinetic (PK) studies: a 3-day loading dose study and a 15-day steady-state administration study. These were crossover oral bioequivalence studies performed under fed conditions in healthy adult volunteers. In the loading dose study, C-ITZ (two doses of 100 mg each) and S-ITZ (two doses of 65 mg each) were administered three times daily for 3 days and once on day 4 ( n  = 15). For the steady-state administration study, C-ITZ (two doses of 100 mg each) and S-ITZ (two doses of 65 mg each) were administered twice daily for 14 days and a last dose was administered 30 min after a meal on day 15 ( n  = 16). Blood samples collected throughout both studies were analyzed for ITZ and hydroxy-ITZ (OH-ITZ) levels. Least-squares geometric means were used to compare the maximum peak concentration of drug after administration at steady state prior to administration of the subsequent dose ( C max_ss ), the minimum drug level after administration prior to the subsequent dose ( C trough ), and the area under the curve over the dosing interval (AUC tau ) of each formulation. The ratios of itraconazole (ITZ) and OH-ITZ for S-ITZ to C-ITZ were between 107% and 118% in both studies for C max_ss , C trough , and AUC tau , which were within the U.S. FDA-required bioequivalence range of 80% to 125%. At the end of the steady-state administration study, 13 of 16 volunteers obtained higher mean ITZ blood C trough levels of >1,000 ng/ml when they were administered S-ITZ (81%) than when they were administered C-ITZ (44%). The study drugs were well tolerated in both studies, with similar adverse events (AEs). All treatment-emergent AEs resolved after study completion. One volunteer receiving C-ITZ discontinued due to a treatment-unrelated AE in the steady-state administration study. No serious AEs were reported. Total, trough, and peak ITZ and OH-ITZ exposures were similar between the two formulations. Therefore, SUBA-ITZ, which has 35% less drug than C-ITZ, was bioequivalent to C-ITZ in healthy adult volunteers and exhibited a safety profile similar to that of C-ITZ.",2020,"Total, trough and peak ITZ and OH-ITZ exposure were similar between formulations.","['healthy adult volunteers', 'Healthy Adults']","['SUBA™-Itraconazole and Conventional Itraconazole Capsules', 'C-ITZ (2x100 mg) and S-ITZ', 'conventional ITZ (C-ITZ', 'SUBA™-itraconazole']","['mean C trough ITZ blood levels ', 'Total, trough and peak ITZ and OH-ITZ exposure', 'Ratios of ITZ and OH-ITZ for S-ITZ to C-ITZ']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0064113', 'cui_str': 'Itraconazole'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C1244751', 'cui_str': 'Itraconazole Oral Capsule'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0444506', 'cui_str': 'Trough'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0064113', 'cui_str': 'Itraconazole'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]",,0.0196089,"Total, trough and peak ITZ and OH-ITZ exposure were similar between formulations.","[{'ForeName': 'George R', 'Initials': 'GR', 'LastName': 'Thompson', 'Affiliation': 'UC Davis School of Medicine, Department of Internal Medicine, Division of Infectious Diseases, Sacramento, California, USA.'}, {'ForeName': 'Phoebe', 'Initials': 'P', 'LastName': 'Lewis', 'Affiliation': 'Department of Medical Affairs, Mayne Pharma, Inc., Raleigh, North Carolina, USA.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Mudge', 'Affiliation': 'Department of Medical Affairs, Mayne Pharma, LLC, Melbourne, Australia.'}, {'ForeName': 'Thomas F', 'Initials': 'TF', 'LastName': 'Patterson', 'Affiliation': 'University of Texas Health Science Center, Division of Infectious Diseases, San Antonio, Texas, USA.'}, {'ForeName': 'Bruce P', 'Initials': 'BP', 'LastName': 'Burnett', 'Affiliation': 'Department of Medical Affairs, Mayne Pharma, Inc., Raleigh, North Carolina, USA bruce.burnett@maynepharma.com.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.00400-20'] 1659,32579810,Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.,"BACKGROUND Higher serum urate levels are associated with an increased risk of diabetic kidney disease. Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes and early-to-moderate diabetic kidney disease. METHODS In a double-blind trial, we randomly assigned participants with type 1 diabetes, a serum urate level of at least 4.5 mg per deciliter, an estimated GFR of 40.0 to 99.9 ml per minute per 1.73 m 2 of body-surface area, and evidence of diabetic kidney disease to receive allopurinol or placebo. The primary outcome was the baseline-adjusted GFR, as measured with iohexol, after 3 years plus a 2-month washout period. Secondary outcomes included the decrease in the iohexol-based GFR per year and the urinary albumin excretion rate after washout. Safety was also assessed. RESULTS A total of 267 patients were assigned to receive allopurinol and 263 to receive placebo. The mean age was 51.1 years, the mean duration of diabetes 34.6 years, and the mean glycated hemoglobin level 8.2%. The mean baseline iohexol-based GFR was 68.7 ml per minute per 1.73 m 2 in the allopurinol group and 67.3 ml per minute per 1.73 m 2 in the placebo group. During the intervention period, the mean serum urate level decreased from 6.1 to 3.9 mg per deciliter with allopurinol and remained at 6.1 mg per deciliter with placebo. After washout, the between-group difference in the mean iohexol-based GFR was 0.001 ml per minute per 1.73 m 2 (95% confidence interval [CI], -1.9 to 1.9; P = 0.99). The mean decrease in the iohexol-based GFR was -3.0 ml per minute per 1.73 m 2 per year with allopurinol and -2.5 ml per minute per 1.73 m 2 per year with placebo (between-group difference, -0.6 ml per minute per 1.73 m 2 per year; 95% CI, -1.5 to 0.4). The mean urinary albumin excretion rate after washout was 40% (95% CI, 0 to 80) higher with allopurinol than with placebo. The frequency of serious adverse events was similar in the two groups. CONCLUSIONS We found no evidence of clinically meaningful benefits of serum urate reduction with allopurinol on kidney outcomes among patients with type 1 diabetes and early-to-moderate diabetic kidney disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; PERL ClinicalTrials.gov number, NCT02017171.).",2020,"The mean urinary albumin excretion rate after washout was 40% (95% CI, 0 to 80) higher with allopurinol than with placebo.","['persons with type 1 diabetes and early-to-moderate diabetic kidney disease', 'Type 1 Diabetes', 'patients with type 1 diabetes and early-to-moderate diabetic kidney disease', '267 patients']","['placebo', 'allopurinol or placebo', 'allopurinol', 'Allopurinol']","['Safety', 'frequency of serious adverse events', 'baseline-adjusted GFR', 'iohexol-based GFR per year and the urinary albumin excretion rate', 'mean baseline iohexol-based GFR', 'mean serum urate level', 'iohexol-based GFR', 'kidney outcomes', 'mean urinary albumin excretion rate', 'mean iohexol-based GFR', 'glomerular filtration rate (GFR']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0011881', 'cui_str': 'Kidney disorder due to diabetes mellitus'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517672', 'cui_str': '267'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0002144', 'cui_str': 'Allopurinol'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0022005', 'cui_str': 'Iohexol'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439508', 'cui_str': '/year'}, {'cui': 'C0585937', 'cui_str': 'Albumin excretion rate measurement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0455272', 'cui_str': 'Serum urate measurement'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",267.0,0.615998,"The mean urinary albumin excretion rate after washout was 40% (95% CI, 0 to 80) higher with allopurinol than with placebo.","[{'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Doria', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Andrzej T', 'Initials': 'AT', 'LastName': 'Galecki', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Cathie', 'Initials': 'C', 'LastName': 'Spino', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Rodica', 'Initials': 'R', 'LastName': 'Pop-Busui', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'David Z', 'Initials': 'DZ', 'LastName': 'Cherney', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Ildiko', 'Initials': 'I', 'LastName': 'Lingvay', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Afshin', 'Initials': 'A', 'LastName': 'Parsa', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Rossing', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Ronald J', 'Initials': 'RJ', 'LastName': 'Sigal', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Afkarian', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Ronnie', 'Initials': 'R', 'LastName': 'Aronson', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'M Luiza', 'Initials': 'ML', 'LastName': 'Caramori', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Jill P', 'Initials': 'JP', 'LastName': 'Crandall', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Ian H', 'Initials': 'IH', 'LastName': 'de Boer', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Thomas G', 'Initials': 'TG', 'LastName': 'Elliott', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Allison B', 'Initials': 'AB', 'LastName': 'Goldfine', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'J Sonya', 'Initials': 'JS', 'LastName': 'Haw', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Irl B', 'Initials': 'IB', 'LastName': 'Hirsch', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Amy B', 'Initials': 'AB', 'LastName': 'Karger', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Maahs', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Janet B', 'Initials': 'JB', 'LastName': 'McGill', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Molitch', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Bruce A', 'Initials': 'BA', 'LastName': 'Perkins', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Sarit', 'Initials': 'S', 'LastName': 'Polsky', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Marlon', 'Initials': 'M', 'LastName': 'Pragnell', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'William N', 'Initials': 'WN', 'LastName': 'Robiner', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Sylvia E', 'Initials': 'SE', 'LastName': 'Rosas', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Senior', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Katherine R', 'Initials': 'KR', 'LastName': 'Tuttle', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Guillermo E', 'Initials': 'GE', 'LastName': 'Umpierrez', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Amisha', 'Initials': 'A', 'LastName': 'Wallia', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Ruth S', 'Initials': 'RS', 'LastName': 'Weinstock', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Chunyi', 'Initials': 'C', 'LastName': 'Wu', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Mauer', 'Affiliation': 'From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston (A.D., A.B.G., S.E.R.); the Division of Geriatrics, Institute of Gerontology (A.T.G., C.W.), the Department of Biostatistics, School of Public Health (A.T.G., C.S.), Statistical Analysis of Biomedical and Educational Research (SABER) (C.S.), and the Department of Internal Medicine, Metabolism, Endocrinology, and Diabetes (R.P.-B.), University of Michigan, Ann Arbor; the Departments of Medicine, Physiology, and Pharmacology and Toxicology (D.Z.C.) and the Division of Endocrinology and Metabolism (B.A.P.), University of Toronto, the Division of Nephrology, University Health Network (D.Z.C.), LMC Diabetes and Endocrinology (R.A.), and Lunenfeld-Tanenbaum Research Institute, Sinai Health System (B.A.P.), Toronto, the Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, AB (R.J.S.), BCDiabetes, Vancouver (T.G.E.), and the Division of Endocrinology, University of Alberta, Edmonton (P.S.) - all in Canada; the Departments of Medicine and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas (I.L.); the Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (A.P.); Steno Diabetes Center, and the Department of Clinical Medicine, University Copenhagen, Copenhagen (P.R.); the Division of Nephrology, Department of Medicine, University of California, Davis (M.A.), and the Department of Pediatrics and Stanford Diabetes Research Center, Stanford University, Palo Alto (D.M.M.) - both in California; the Departments of Medicine and Pediatrics (M.L.C., W.N.R.. M.M.) and Laboratory Medicine and Pathology (A.B.K.), University of Minnesota, Minneapolis; the Division of Endocrinology and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine (J.P.C.), and JDRF (Juvenile Diabetes Research Foundation) (M.P.), New York; the Department of Medicine (I.H.B., I.B.H.) and the Nephrology Division (K.R.T.), University of Washington, and the Institute of Translational Health Sciences, Kidney Research Institute (K.R.T.), Seattle, and Providence Health Care, Spokane (K.R.T.) - both in Washington; the Department of Medicine, Emory University, Atlanta (J.S.H., G.E.U.); the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis (J.B.M.); the Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago (M.E.M., A.W.); the Barbara Davis Center for Diabetes, University of Colorado, Aurora (S.P.); and the Department of Medicine, State University of New York Upstate Medical University, Syracuse (R.S.W.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1916624'] 1660,32447634,Gut Microbial Predictors of Type 2 Diabetes Remission Following Bariatric Surgery.,"PURPOSE Distinct anatomical rearrangements of the gastrointestinal tract achieved by various types of bariatric surgery cause changes in nutrient intake and gut microbiota. The contribution of such gut microbiota changes to remission of type 2 diabetes (T2D) remains unclear. AIM We examined gut microbiota changes following banded Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) in a randomised study, in relation to T2D remission. MATERIALS AND METHODS Whole-metagenome shotgun sequencing was carried out on paired stool samples at pre- and 1-year post-surgery collected from 44 participants with T2D randomised to banded Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG). Taxonomic composition and predicted functional potential of the gut bacteria were identified using HUMANn2, and annotated using MetaCyc. Five-day dietary records (analysed using FoodWorks v8.0), body weight and diabetes status were recorded at both time points. RESULTS RYGB participants had higher percentage excess weight loss than SG (p = 0.01), even though dietary intake was similar at 1-year post-surgery. Similar proportions achieved diabetes remission (HbA1c < 48 mmol/mol without medications) after either RYGB (68%) or SG (59%). RYGB resulted in increased abundances of Firmicutes and Proteobacteria, while SG resulted in increased Bacteroidetes. Pre-surgery, an increased abundance of Eubacteriaceae (p = 0.01) and Alistipes putredinis (p = 0.01) was observed in those who went on to remit from T2D post-surgery. Following surgery, Lachnospiraceae (p = 0.04) and Roseburia (p = 0.01) species were more abundant in those who had achieved T2D remission. CONCLUSIONS Specific stool bacterial taxa may signal likelihood of T2D remission after bariatric surgery which is potentially mediated by increases in Lachnospiraceae and Roseburia.",2020,"Pre-surgery, an increased abundance of Eubacteriaceae (p = 0.01) and Alistipes putredinis (p = 0.01) was observed in those who went on to remit from T2D post-surgery.","['Type 2 Diabetes Remission Following Bariatric Surgery', '44 participants with T2D randomised to']",['banded Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG'],"['body weight and diabetes status', 'abundances of Firmicutes and Proteobacteria, while SG resulted in increased Bacteroidetes', 'diabetes remission', 'Alistipes putredinis', 'abundance of Eubacteriaceae', 'Taxonomic composition and predicted functional potential of the gut bacteria', 'percentage excess weight loss']","[{'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C1456587', 'cui_str': 'Metabolic surgery'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0399839', 'cui_str': 'Bypass gastrojejunostomy'}, {'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0751985', 'cui_str': 'Proteobacteria'}, {'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C1490417', 'cui_str': 'Alistipes'}, {'cui': 'C1210566', 'cui_str': 'Eubacteriaceae'}, {'cui': 'C0008903', 'cui_str': 'classification'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]",44.0,0.0200876,"Pre-surgery, an increased abundance of Eubacteriaceae (p = 0.01) and Alistipes putredinis (p = 0.01) was observed in those who went on to remit from T2D post-surgery.","[{'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Davies', 'Affiliation': 'Department of Medicine, Faculty of medical and health sciences, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Justin M', 'Initials': 'JM', 'LastName': ""O'Sullivan"", 'Affiliation': 'Maurice Wilkins Centre, The University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Lindsay D', 'Initials': 'LD', 'LastName': 'Plank', 'Affiliation': 'Department of Surgery, The University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Rinki', 'Initials': 'R', 'LastName': 'Murphy', 'Affiliation': 'Department of Medicine, Faculty of medical and health sciences, University of Auckland, Auckland, New Zealand. r.murphy@auckland.ac.nz.'}]",Obesity surgery,['10.1007/s11695-020-04684-0'] 1661,32462607,Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO ® and OTEMTO ® Studies.,"INTRODUCTION The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report recommends long-acting muscarinic antagonists (LAMA) or long-acting β 2 -agonists (LABA) as first-line treatment for chronic obstructive pulmonary disease (COPD), but many patients remain symptomatic on monotherapy and escalation to dual-bronchodilator therapy may be warranted. METHODS TONADO ® 1&2 and OTEMTO ® 1&2 assessed lung function and patient-reported outcomes in patients with moderate-to-severe (OTEMTO) or moderate-to-very-severe (TONADO) COPD. This pooled post hoc analysis included patients treated with LAMA monotherapy at baseline who were randomised to receive either 5 µg tiotropium (LAMA) or 5/5 µg tiotropium/olodaterol (LAMA/LABA). We assessed changes from baseline and responder rates for trough forced expiratory volume in 1 s (FEV 1 ), St. George's Respiratory Questionnaire (SGRQ) and the Transition Dyspnoea Index (TDI). RESULTS Overall, 151 patients received tiotropium; 148 received tiotropium/olodaterol. Mean differences from baseline with tiotropium/olodaterol versus tiotropium were + 0.074 l (95% confidence interval [CI] 0.033, 0.115; P = 0.0004) for trough FEV 1 , - 2.675 (95% CI - 5.060, - 0.291; P = 0.0280) for SGRQ and 1.148 (95% CI 0.564, 1.732; P = 0.0001) for TDI. Patients were more likely to respond when treated with tiotropium/olodaterol versus tiotropium for trough FEV 1 (odds ratio [OR] 3.14, 95% CI 1.94, 5.06; P < 0.0001), SGRQ (OR 1.49, 95% CI 0.93, 2.40; P = 0.0980) and TDI (OR 2.81, 95% CI 1.71, 4.60; P < 0.0001). Minimum clinically important difference from baseline in any of the analysed outcomes (FEV 1  ≥ 0.1 l, SGRQ ≥ 4.0 points or TDI ≥ 1.0 point) was more likely in patients treated with tiotropium/olodaterol versus tiotropium (OR 2.43, 95% CI 1.32, 4.51; P = 0.0046). CONCLUSION In patients with COPD receiving only LAMA monotherapy, treatment escalation to tiotropium/olodaterol resulted in statistically significant and clinically relevant improvements in lung function, health status and breathlessness. These results support early therapy optimisation to dual bronchodilation with tiotropium/olodaterol in patients receiving tiotropium alone. TRIAL REGISTRATION TONADO ® 1 was registered in the US National Library of Medicine on 9 September 2011 (Clinicaltrials.gov: NCT01431274). TONADO ® 2 was registered in the US National Library of Medicine on 9 September 2011 (Clinicaltrials.gov: NCT01431287). OTEMTO ® 1 was registered in the US National Library of Medicine on 17 October 2013 (Clinicaltrials.gov: NCT01964352). OTEMTO ® 2 was registered in the US National Library of Medicine on 10 December 2013 (Clinicaltrials.gov: NCT02006732).",2020,"Minimum clinically important difference from baseline in any of the analysed outcomes (FEV 1  ≥ 0.1 l, SGRQ ≥ 4.0 points or TDI ≥ 1.0 point) was more likely in patients treated with tiotropium/olodaterol versus tiotropium (OR 2.43, 95% CI 1.32, 4.51; P = 0.0046). ","['® 2 was registered in the US National Library of Medicine on 10 December 2013', 'patients with COPD receiving only', 'Patients with COPD Receiving only LAMA at Baseline', 'patients receiving tiotropium alone', '® 1 was registered in the US National Library of Medicine on 17 October 2013', 'patients with moderate-to-severe (OTEMTO) or moderate-to-very-severe (TONADO) COPD', 'chronic obstructive pulmonary disease (COPD']","['tiotropium (LAMA) or 5/5\xa0µg tiotropium/olodaterol (LAMA/LABA', 'Tiotropium/Olodaterol', 'muscarinic antagonists (LAMA) or long-acting β 2 -agonists (LABA', 'tiotropium/olodaterol', 'LAMA monotherapy', 'tiotropium/olodaterol versus tiotropium', 'Tiotropium', 'tiotropium']","['SGRQ', 'lung function, health status and breathlessness', ""trough forced expiratory volume in 1\xa0s (FEV 1 ), St. George's Respiratory Questionnaire (SGRQ) and the Transition Dyspnoea Index (TDI""]","[{'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0027470', 'cui_str': 'National Library of Medicine'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0003385', 'cui_str': 'Muscarinic receptor antagonist'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0213771', 'cui_str': 'tiotropium'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C3641272', 'cui_str': 'Very severe'}]","[{'cui': 'C0213771', 'cui_str': 'tiotropium'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0003385', 'cui_str': 'Muscarinic receptor antagonist'}, {'cui': 'C2934193', 'cui_str': 'olodaterol'}, {'cui': 'C0243192', 'cui_str': 'agonists'}]","[{'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0444506', 'cui_str': 'Trough'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205976', 'cui_str': 'Toluene di-isocyanate-containing product'}]",,0.511381,"Minimum clinically important difference from baseline in any of the analysed outcomes (FEV 1  ≥ 0.1 l, SGRQ ≥ 4.0 points or TDI ≥ 1.0 point) was more likely in patients treated with tiotropium/olodaterol versus tiotropium (OR 2.43, 95% CI 1.32, 4.51; P = 0.0046). ","[{'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Buhl', 'Affiliation': 'Pulmonary Department, Johannes Gutenberg University Hospital, Mainz, Germany. Roland.Buhl@unimedizin-mainz.de.'}, {'ForeName': 'Dave', 'Initials': 'D', 'LastName': 'Singh', 'Affiliation': 'Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'de la Hoz', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.'}, {'ForeName': 'Wenqiong', 'Initials': 'W', 'LastName': 'Xue', 'Affiliation': 'Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.'}, {'ForeName': 'Gary T', 'Initials': 'GT', 'LastName': 'Ferguson', 'Affiliation': 'Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA.'}]",Advances in therapy,['10.1007/s12325-020-01373-3'] 1662,31388184,Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel.,"BACKGROUND An early detection tool for EOC was constructed from analysis of biomarker expression data from serum collected during the UKCTOCS. METHODS This study included 49 EOC cases (19 Type I and 30 Type II) and 31 controls, representing 482 serial samples spanning seven years pre-diagnosis. A logit model was trained by analysis of dysregulation of expression data of four putative biomarkers, (CA125, phosphatidylcholine-sterol acyltransferase, vitamin K-dependent protein Z and C-reactive protein); by scoring the specificity associated with dysregulation from the baseline expression for each individual. RESULTS The model is discriminatory, passes k-fold and leave-one-out cross-validations and was further validated in a Type I EOC set. Samples were analysed as a simulated annual screening programme, the algorithm diagnosed cases with >30% PPV 1-2 years pre-diagnosis. For Type II cases (~80% were HGS) the algorithm classified 64% at 1 year and 28% at 2 years tDx as severe. CONCLUSIONS The panel has the potential to diagnose EOC one-two years earlier than current diagnosis. This analysis provides a tangible worked example demonstrating the potential for development as a screening tool and scrutiny of its properties. Limits on interpretation imposed by the number of samples available are discussed.",2019,"The model is discriminatory, passes k-fold and leave-one-out cross-validations and was further validated in a Type I EOC set.","['For Type II cases (~80% were HGS', '49 EOC cases (19 Type I and 30 Type II) and 31 controls, representing 482 serial samples spanning seven years pre-diagnosis']",[],[],"[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C1568891', 'cui_str': 'HGS protein, human'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]",[],[],49.0,0.0221786,"The model is discriminatory, passes k-fold and leave-one-out cross-validations and was further validated in a Type I EOC set.","[{'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Russell', 'Affiliation': 'Stoller Biomarker Discovery Centre and Manchester Molecular Pathology Innovation Centre, Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Ciaren', 'Initials': 'C', 'LastName': 'Graham', 'Affiliation': 'School of Biological Sciences, Queens University Belfast, Chlorine Gardens, Belfast, BT9 5DL, UK.'}, {'ForeName': 'Alfonsina', 'Initials': 'A', 'LastName': ""D'Amato"", 'Affiliation': 'Department of Pharmaceutical Sciences, University of Milan, Milano, Lombardy, Italy.'}, {'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Gentry-Maharaj', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London, UK.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Ryan', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London, UK.'}, {'ForeName': 'Jatinderpal K', 'Initials': 'JK', 'LastName': 'Kalsi', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London, UK.'}, {'ForeName': 'Anthony D', 'Initials': 'AD', 'LastName': 'Whetton', 'Affiliation': 'Stoller Biomarker Discovery Centre and Manchester Molecular Pathology Innovation Centre, Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Usha', 'Initials': 'U', 'LastName': 'Menon', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Jacobs', 'Affiliation': 'Stoller Biomarker Discovery Centre and Manchester Molecular Pathology Innovation Centre, Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK. i.jacobs@unsw.edu.au.'}, {'ForeName': 'Robert L J', 'Initials': 'RLJ', 'LastName': 'Graham', 'Affiliation': 'School of Biological Sciences, Queens University Belfast, Chlorine Gardens, Belfast, BT9 5DL, UK. r.graham@qub.ac.uk.'}]",British journal of cancer,['10.1038/s41416-019-0544-0'] 1663,31388185,Tumour-infiltrating CD8 + lymphocytes and colorectal cancer recurrence by tumour and nodal stage.,"BACKGROUND Intratumoural T-cell infiltrate intensity cortes wrelaith clinical outcome in stage II/III colorectal cancer (CRC). We aimed to determine whether this association varies across this heterogeneous group. METHODS We performed a pooled analysis of 1804 CRCs from the QUASAR2 and VICTOR trials. Intratumoural CD8 + and CD3 + densities were quantified by immunohistochemistry in tissue microarray (TMA) cores, and their association with clinical outcome analysed by Cox regression. We validated our results using publicly available gene expression data in a pooled analysis of 1375 CRCs from seven independent series. RESULTS In QUASAR2, intratumoural CD8 + was a stronger predictor of CRC recurrence than CD3 + and showed similar discriminative ability to both markers in combination. Pooled multivariable analysis of both trials showed increasing CD8 + density was associated with reduced recurrence risk independent of confounders including DNA mismatch repair deficiency, POLE mutation and chromosomal instability (multivariable hazard ratio [HR] for each two-fold increase = 0.92, 95%CI = 0.87-0.97, P = 3.6 × 10 -3 ). This association was not uniform across risk strata defined by tumour and nodal stage: absent in low-risk (pT3,N0) cases (HR = 1.03, 95%CI = 0.87-1.21, P = 0.75), modest in intermediate-risk (pT4,N0 or pT1-3,N1-2) cases (HR = 0.92, 95%CI = 0.86-1.0, P = 0.046) and strong in high-risk (pT4,N1-2) cases (HR = 0.87, 95%CI = 0.79-0.97, P = 9.4 × 10 -3 ); P INTERACTION  = 0.090. Analysis of tumour CD8A expression in the independent validation cohort revealed similar variation in prognostic value across risk strata (P INTERACTION  = 0.048). CONCLUSIONS The prognostic value of intratumoural CD8 + cell infiltration in stage II/III CRC varies across tumour and nodal risk strata.",2019,"This association was not uniform across risk strata defined by tumour and nodal stage: absent in low-risk (pT3,N0) cases (HR = 1.03, 95%CI = 0.87-1.21, P = 0.75), modest in intermediate-risk (pT4,N0 or pT1-3,N1-2) cases (HR = 0.92, 95%CI = 0.86-1.0, P = 0.046) and strong in high-risk (pT4,N1-2) cases (HR = 0.87, 95%CI = 0.79-0.97, P = 9.4 × 10 -3 ); P INTERACTION  = 0.090.",['stage II/III colorectal cancer (CRC'],[],"['tumour CD8A expression', 'CRC recurrence', 'Tumour-infiltrating CD8 + lymphocytes and colorectal cancer recurrence', 'CD8 + density', 'DNA mismatch repair deficiency, POLE mutation and chromosomal instability', 'Intratumoural CD8 + and CD3 + densities']","[{'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}]",[],"[{'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0242629', 'cui_str': 'Lymphocyte positive for CD8 antigen'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C1155661', 'cui_str': 'DNA mismatch repair'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0337815', 'cui_str': 'Poles'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C1257806', 'cui_str': 'Chromosome Instability'}, {'cui': 'C0108779', 'cui_str': 'Lymphocyte antigen CD3'}]",1804.0,0.198792,"This association was not uniform across risk strata defined by tumour and nodal stage: absent in low-risk (pT3,N0) cases (HR = 1.03, 95%CI = 0.87-1.21, P = 0.75), modest in intermediate-risk (pT4,N0 or pT1-3,N1-2) cases (HR = 0.92, 95%CI = 0.86-1.0, P = 0.046) and strong in high-risk (pT4,N1-2) cases (HR = 0.87, 95%CI = 0.79-0.97, P = 9.4 × 10 -3 ); P INTERACTION  = 0.090.","[{'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Glaire', 'Affiliation': 'Cancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK.'}, {'ForeName': 'Enric', 'Initials': 'E', 'LastName': 'Domingo', 'Affiliation': 'Cancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Sveen', 'Affiliation': 'Department of Molecular Oncology, Institute for Cancer Research & K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Jarle', 'Initials': 'J', 'LastName': 'Bruun', 'Affiliation': 'Department of Molecular Oncology, Institute for Cancer Research & K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Arild', 'Initials': 'A', 'LastName': 'Nesbakken', 'Affiliation': 'Department of Gastroenterological Surgery & K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Nicholson', 'Affiliation': 'Department of Statistics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Novelli', 'Affiliation': 'Department of Histopathology, UCL, Rockefeller Building, University Street, London, WC1E 6JJ, UK.'}, {'ForeName': 'Kay', 'Initials': 'K', 'LastName': 'Lawson', 'Affiliation': 'Department of Histopathology, UCL, Rockefeller Building, University Street, London, WC1E 6JJ, UK.'}, {'ForeName': 'Dahmane', 'Initials': 'D', 'LastName': 'Oukrif', 'Affiliation': 'Department of Histopathology, UCL, Rockefeller Building, University Street, London, WC1E 6JJ, UK.'}, {'ForeName': 'Wanja', 'Initials': 'W', 'LastName': 'Kildal', 'Affiliation': 'Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Havard E', 'Initials': 'HE', 'LastName': 'Danielsen', 'Affiliation': 'Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Kerr', 'Affiliation': 'Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals Foundation NHS Trust, Oxford, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kerr', 'Affiliation': 'Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, OX3 9 DU, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Tomlinson', 'Affiliation': 'Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.'}, {'ForeName': 'Ragnhild A', 'Initials': 'RA', 'LastName': 'Lothe', 'Affiliation': 'Department of Molecular Oncology, Institute for Cancer Research & K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'David N', 'Initials': 'DN', 'LastName': 'Church', 'Affiliation': 'Cancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK. dchurch@well.ox.ac.uk.'}]",British journal of cancer,['10.1038/s41416-019-0540-4'] 1664,32466168,Targeted Nutritional Intervention for Patients with Mild Cognitive Impairment: The Cognitive impAiRmEnt Study (CARES) Trial 1.,"Omega-3 fatty acids (ω-3FAs), carotenoids, and vitamin E are important constituents of a healthy diet. While they are present in brain tissue, studies have shown that these key nutrients are depleted in individuals with mild cognitive impairment (MCI) in comparison to cognitively healthy individuals. Therefore, it is likely that these individuals will benefit from targeted nutritional intervention, given that poor nutrition is one of the many modifiable risk factors for MCI. Evidence to date suggests that these nutritional compounds can work independently to optimize the neurocognitive environment, primarily due to their antioxidant and anti-inflammatory properties. To date, however, no interventional studies have examined the potential synergistic effects of a combination of ω-3FAs, carotenoids and vitamin E on the cognitive function of patients with MCI. Individuals with clinically confirmed MCI consumed an ω-3FA plus carotenoid plus vitamin E formulation or placebo for 12 months. Cognitive performance was determined from tasks that assessed global cognition and episodic memory. Ω-3FAs, carotenoids, and vitamin E were measured in blood. Carotenoid concentrations were also measured in tissue (skin and retina). Individuals consuming the active intervention ( n = 6; median [IQR] age 73.5 [69.5-80.5] years; 50% female) exhibited statistically significant improvements ( p < 0.05, for all) in tissue carotenoid concentrations, and carotenoid and ω-3FA concentrations in blood. Trends in improvements in episodic memory and global cognition were also observed in this group. In contrast, the placebo group ( n = 7; median [IQR] 72 (69.5-75.5) years; 89% female) remained unchanged or worsened for all measurements ( p > 0.05). Despite a small sample size, this exploratory study is the first of its kind to identify trends in improved cognitive performance in individuals with MCI following supplementation with ω-3FAs, carotenoids, and vitamin E.",2020,Trends in improvements in episodic memory and global cognition were also observed in this group.,"['patients with MCI', 'individuals with mild cognitive impairment (MCI) in comparison to cognitively healthy individuals', 'Patients with Mild Cognitive Impairment']","['Omega-3 fatty acids (ω-3FAs), carotenoids, and vitamin E', 'Targeted Nutritional Intervention', 'ω-3FAs, carotenoids and vitamin E', 'placebo']","['cognitive performance', 'episodic memory and global cognition', 'global cognition and episodic memory', 'tissue carotenoid concentrations, and carotenoid and ω-3FA concentrations in blood', 'Carotenoid concentrations', 'Ω-3FAs, carotenoids, and vitamin E', 'Cognitive performance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0007271', 'cui_str': 'Carotinoid'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0007271', 'cui_str': 'Carotinoid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}]",,0.037783,Trends in improvements in episodic memory and global cognition were also observed in this group.,"[{'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Power', 'Affiliation': 'Nutrition Research Centre Ireland, School of Health Sciences, Carriganore House, Waterford Institute of Technology West Campus, X91 K0EK Waterford, Ireland.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Nolan', 'Affiliation': 'Nutrition Research Centre Ireland, School of Health Sciences, Carriganore House, Waterford Institute of Technology West Campus, X91 K0EK Waterford, Ireland.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Prado-Cabrero', 'Affiliation': 'Nutrition Research Centre Ireland, School of Health Sciences, Carriganore House, Waterford Institute of Technology West Campus, X91 K0EK Waterford, Ireland.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Coen', 'Affiliation': ""Mercer's Institute for Research on Ageing, St. James's Hospital, D08 NHY1 Dublin, Ireland.""}, {'ForeName': 'Warren', 'Initials': 'W', 'LastName': 'Roche', 'Affiliation': 'Nutrition Research Centre Ireland, School of Health Sciences, Carriganore House, Waterford Institute of Technology West Campus, X91 K0EK Waterford, Ireland.'}, {'ForeName': 'Tommy', 'Initials': 'T', 'LastName': 'Power', 'Affiliation': 'Nutrition Research Centre Ireland, School of Health Sciences, Carriganore House, Waterford Institute of Technology West Campus, X91 K0EK Waterford, Ireland.'}, {'ForeName': 'Alan N', 'Initials': 'AN', 'LastName': 'Howard', 'Affiliation': 'Howard Foundation, 7 Marfleet Close, Great Shelford, Cambridge CB22 5LA, UK.'}, {'ForeName': 'Ríona', 'Initials': 'R', 'LastName': 'Mulcahy', 'Affiliation': 'Age-Related Care Unit, Health Service Executive, University Hospital Waterford, Dunmore Road, X91 ER8E Waterford, Ireland.'}]",Journal of personalized medicine,['10.3390/jpm10020043'] 1665,32466528,Analysis of Usage Data from a Self-Guided App-Based Virtual Reality Cognitive Behavior Therapy for Acrophobia: A Randomized Controlled Trial.,"This study examined user engagement with ZeroPhobia, a self-guided app-based virtual reality (VR) Cognitive Behavior Therapy for acrophobia symptoms using cardboard VR viewers. Dutch acrophobic adults ( n = 96) completed assessments at baseline and immediately following treatment. Primary outcome measures were the Acrophobia Questionnaire (AQ) and the Igroup Presence Questionnaire (IPQ). Usage data consisted of number of VR sessions practiced, practice time, and fear ratings directly after practicing. Results show that of the 66 participants who played at least one level, the majority continued to finish all levels, spending on average 24.4 min in VR. Self-reported fear consistently decreased between the start and finish of levels. Post-test AQ scores depended quadratically on time spent in VR. Higher pre-test AQ scores were significantly associated with subjective anxiety after the first level and a reduction of post-test AQ scores, but not with number of sessions, suggesting it might be more beneficial to play one level for a longer time period instead of practicing many VR levels. Results also show an optimum exposure level at which increasing practice time does not result in increased benefit. Self-guided VR acrophobia treatment is effective and leads to consistent reductions in self-reported anxiety both between levels and after treatment. Most participants progressed effectively to the highest self-exposure level, despite the absence of a therapist.",2020,Self-guided VR acrophobia treatment is effective and leads to consistent reductions in self-reported anxiety both between levels and after treatment.,"['Dutch acrophobic adults ( n = 96', 'Acrophobia']","['Self-Guided App-Based Virtual Reality Cognitive Behavior Therapy', 'ZeroPhobia, a self-guided app-based virtual reality (VR) Cognitive Behavior Therapy']","['time spent in VR', 'Acrophobia Questionnaire (AQ) and the Igroup Presence Questionnaire (IPQ', 'subjective anxiety']","[{'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0233701', 'cui_str': 'Fear of heights'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0233701', 'cui_str': 'Fear of heights'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",,0.01595,Self-guided VR acrophobia treatment is effective and leads to consistent reductions in self-reported anxiety both between levels and after treatment.,"[{'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Donker', 'Affiliation': 'Department of Clinical, Neuro and Developmental Psychology, Section Clinical Psychology, Vrije Universiteit Amsterdam, Van der Boechorststraat 1, 1081 BT Amsterdam, The Netherlands.'}, {'ForeName': 'Chris van', 'Initials': 'CV', 'LastName': 'Klaveren', 'Affiliation': 'Department of Education Sciences, Section Methods and Statistics and Amsterdam Center for Learning Analytics, Vrije Universiteit Amsterdam, Van der Boechorststraat 1, 1081 BT Amsterdam, The Netherlands.'}, {'ForeName': 'Ilja', 'Initials': 'I', 'LastName': 'Cornelisz', 'Affiliation': 'Department of Education Sciences, Section Methods and Statistics and Amsterdam Center for Learning Analytics, Vrije Universiteit Amsterdam, Van der Boechorststraat 1, 1081 BT Amsterdam, The Netherlands.'}, {'ForeName': 'Robin N', 'Initials': 'RN', 'LastName': 'Kok', 'Affiliation': 'Department of Psychology, University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark.'}, {'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'van Gelder', 'Affiliation': 'Institute of Education and Child Studies, Leiden University, Pieter de la Court Building, 4th floor, Wassenaarseweg 52, 2333 AK Leiden, The Netherlands.'}]",Journal of clinical medicine,['10.3390/jcm9061614'] 1666,32469305,Bioavailability study of two 81-mg coated tablet formulations of acetylsalicylic acid in fed healthy subjects
.,"OBJECTIVE To perform a comparative bioavailability study between a test (re-formulation) and a reference acetylsalicylic acid formulation (Ecasil-81, 81 mg coated tablet) in healthy subjects under fed condition. MATERIALS AND METHODS Healthy subjects (n = 48) were included in this monocentric, open-label, randomized, two-way crossover pharmacokinetic study. They received a single 81-mg oral dose of a test or a reference formulation of acetylsalicylic acid under fed condition, with a 7-day washout period between the treatments. Blood samples were collected over a period of 36 hours. The salicylic acid plasma concentration was measured by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Pharmacokinetic analysis was performed using WinNonlin software. RESULTS The geometric mean and 90% confidence interval of test/reference formulation ratios were 109.32% (102.54 - 116.54%) and 106.94% (102.97 - 111.07%) for salicylic acid C max and AUC 0-last , respectively. Food decreased the AUC and C max (p < 0.001) and delayed the t max (p = 0.0077). The investigated women presented higher AUC 0-∞ and C max values (p < 0.001) than men. The clinical and laboratory exams did not show significant alterations. CONCLUSION The re-formulation is bioequivalent to the reference formulation regarding the absorption extent and rate in fed healthy subjects. The administration of acetylsalicylic acid with food decreased its bioavailability. Moreover, differences in salicylic acid disposition related to sex were observed. The treatments were well tolerated by the investigated subjects.",2020,The investigated women presented higher AUC 0-∞ and C max values (p < 0.001) than men.,"['healthy subjects under fed condition', 'fed\xa0healthy subjects\u2029', 'fed healthy subjects', 'Healthy subjects (n\xa0=\xa048']","['acetylsalicylic acid', 'acetylsalicylic acid formulation (Ecasil-81, 81\xa0mg coated tablet']","['salicylic acid disposition', 'Blood samples', 'bioavailability', 'geometric mean and 90% confidence interval of test/reference formulation ratios', 'salicylic acid plasma concentration', 'AUC and C max']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}]","[{'cui': 'C0036079', 'cui_str': 'Salicylic Acid'}, {'cui': 'C0184758', 'cui_str': 'Patient disposition'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0009667', 'cui_str': 'Confidence Intervals'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}]",48.0,0.0240262,The investigated women presented higher AUC 0-∞ and C max values (p < 0.001) than men.,"[{'ForeName': 'Raul Cleverson', 'Initials': 'RC', 'LastName': 'Dolores', 'Affiliation': ''}, {'ForeName': 'Natalícia de Jesus', 'Initials': 'NJ', 'LastName': 'Antunes', 'Affiliation': ''}, {'ForeName': 'Alexandre Scremin', 'Initials': 'AS', 'LastName': 'Czezacki', 'Affiliation': ''}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Previato', 'Affiliation': ''}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Campos', 'Affiliation': ''}, {'ForeName': 'Ronilson A', 'Initials': 'RA', 'LastName': 'Moreno', 'Affiliation': ''}, {'ForeName': 'Gustavo D', 'Initials': 'GD', 'LastName': 'Mendes', 'Affiliation': ''}, {'ForeName': 'Gilberto', 'Initials': 'G', 'LastName': 'De Nucci', 'Affiliation': ''}]",International journal of clinical pharmacology and therapeutics,['10.5414/CP203575'] 1667,32470515,Ramipril in High-Risk Patients With COVID-19.,"BACKGROUND Coronavirus disease-2019 (COVID-19) is caused by severe acute respiratory-syndrome coronavirus-2 that interfaces with the renin-angiotensin-aldosterone system (RAAS) through angiotensin-converting enzyme 2. This interaction has been proposed as a potential risk factor in patients treated with RAAS inhibitors. OBJECTIVES This study analyzed whether RAAS inhibitors modify the risk for COVID-19. METHODS The RASTAVI (Renin-Angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation) trial is an ongoing randomized clinical trial randomly allocating subjects to ramipril or control groups after successful transcatheter aortic valve replacement at 14 centers in Spain. A non-pre-specified interim analysis was performed to evaluate ramipril's impact on COVID-19 risk in this vulnerable population. RESULTS As of April 1, 2020, 102 patients (50 in the ramipril group and 52 in the control group) were included in the trial. Mean age was 82.3 ± 6.1 years, 56.9% of the participants were male. Median time of ramipril treatment was 6 months (interquartile range: 2.9 to 11.4 months). Eleven patients (10.8%) have been diagnosed with COVID-19 (6 in control group and 5 receiving ramipril; hazard ratio: 1.150; 95% confidence interval: 0.351 to 3.768). The risk of COVID-19 was increased in older patients (p = 0.019) and those with atrial fibrillation (p = 0.066), lower hematocrit (p = 0.084), and more comorbidities according to Society of Thoracic Surgeons score (p = 0.065). Admission and oxygen supply was required in 4.9% of patients (2 in the ramipril group and 3 in the control group), and 4 of them died (2 in each randomized group). A higher body mass index was the only factor increasing the mortality rate (p = 0.039). CONCLUSIONS In a high-risk population of older patients with cardiovascular disease, randomization to ramipril had no impact on the incidence or severity of COVID-19. This analysis supports the maintenance of RAAS inhibitor treatment during the COVID-19 crisis. (Renin-Angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation [RASTAVI]; NCT03201185).",2020,"The risk of COVID-19 was increased in older patients (p=0.019), those with atrial fibrillation (p=0.066), lower hematocrit (p=0.084), and more comorbidities according to Society of thoracic surgeons score (p=0.065).","['High Risk Patients with COVID-19', 'patients treated with RAAS-inhibitors', '102 patients (50 Ramipril and 52 controls) were included in the trial', 'Mean age was 82.3±6.1 years, 56.9% males']",['Ramipril'],"['Admission and oxygen supply', 'mortality rate', 'risk of COVID-19', 'atrial fibrillation', 'incidence or severity of COVID-19', 'Median time']","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0086907', 'cui_str': 'Renin-Angiotensin-Aldosterone System'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0072973', 'cui_str': 'Ramipril'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0072973', 'cui_str': 'Ramipril'}]","[{'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0429622', 'cui_str': 'Oxygen delivery'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",,0.117341,"The risk of COVID-19 was increased in older patients (p=0.019), those with atrial fibrillation (p=0.066), lower hematocrit (p=0.084), and more comorbidities according to Society of thoracic surgeons score (p=0.065).","[{'ForeName': 'Ignacio J', 'Initials': 'IJ', 'LastName': 'Amat-Santos', 'Affiliation': 'Cardiology Department, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Hospital Clínico Universitario, Valladolid, Spain. Electronic address: ijamat@gmail.com.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Santos-Martinez', 'Affiliation': 'Cardiology Department, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Hospital Clínico Universitario, Valladolid, Spain.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'López-Otero', 'Affiliation': 'CIBERCV, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Nombela-Franco', 'Affiliation': 'Cardiovascular Institute, Hospital Clínico San Carlos, El Instituto de Investigación Sanitaria San Carlos, Madrid, Spain.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Gutiérrez-Ibanes', 'Affiliation': 'CIBERCV, Hospital General Gregorio Marañón and Universidad Carlos III, Madrid, Spain.'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Del Valle', 'Affiliation': 'Hospital Universitario Central de Asturias, Oviedo, Spain.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Muñoz-García', 'Affiliation': 'CIBERCV, Hospital Virgen de la Victoria, Málaga, Spain.'}, {'ForeName': 'Víctor A', 'Initials': 'VA', 'LastName': 'Jiménez-Diaz', 'Affiliation': 'Hospital Universitario de Vigo, Vigo, Spain.'}, {'ForeName': 'Ander', 'Initials': 'A', 'LastName': 'Regueiro', 'Affiliation': 'Hospital Clinic Univeristari, Barcelona, Spain.'}, {'ForeName': 'Rocío', 'Initials': 'R', 'LastName': 'González-Ferreiro', 'Affiliation': 'Hospital Clínico Universitario, Salamanca, Spain.'}, {'ForeName': 'Tomás', 'Initials': 'T', 'LastName': 'Benito', 'Affiliation': 'Hospital Universitario de León, León, Spain.'}, {'ForeName': 'Xoan Carlos', 'Initials': 'XC', 'LastName': 'Sanmartin-Pena', 'Affiliation': 'CIBERCV, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Catalá', 'Affiliation': 'Cardiology Department, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Hospital Clínico Universitario, Valladolid, Spain.'}, {'ForeName': 'Tania', 'Initials': 'T', 'LastName': 'Rodríguez-Gabella', 'Affiliation': 'Cardiology Department, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Hospital Clínico Universitario, Valladolid, Spain.'}, {'ForeName': 'Jose Raúl', 'Initials': 'JR', 'LastName': 'Delgado-Arana', 'Affiliation': 'Cardiology Department, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Hospital Clínico Universitario, Valladolid, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Carrasco-Moraleja', 'Affiliation': 'Cardiology Department, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Hospital Clínico Universitario, Valladolid, Spain.'}, {'ForeName': 'Borja', 'Initials': 'B', 'LastName': 'Ibañez', 'Affiliation': 'CIBERCV, Centro Nacional de Investigaciones Cardiovasculares, IIS-Hospital Fundación Jimenez Diaz, Madrid, Spain.'}, {'ForeName': 'J Alberto', 'Initials': 'JA', 'LastName': 'San Román', 'Affiliation': 'Cardiology Department, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Hospital Clínico Universitario, Valladolid, Spain.'}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2020.05.040'] 1668,32473365,Central nervous system activities of extract Mangifera indica L.,"ETHNOBOTANICAL RELEVANCE Leaves of Mangifera indica L. have folk-uses in tropical regions of the world as health teas, as a remedy for exhaustion and fatigue, as a vegetable, and as a medicine. Mangifera indica leaf extract (MLE) had previously been demonstrated to alter brain electrical activity in-vivo. The aim of the present series of studies was to investigate whether mangiferin, a major compound in leaves and in MLE, is responsible for the neurocognitive activity of MLE, and if the CNS activities of MLE have translational potential. MATERIALS AND METHODS MLE, tradename Zynamite, is produced by Nektium Pharma, Spain. Isolated mangiferin was tested in-vitro in radioligand binding and enzyme inhibition studies against 106 CNS targets. Changes in the electroencephalograms (EEG's) of MLE and mangiferin were recorded in-vivo from four brain regions. Two double blind randomized placebo-controlled crossover clinical trials were conducted, each with 16 subjects. At 90 min and at 60 min respectively, after oral intake of 500 mg MLE, EEG recordings, psychometric tests, mood state, and tolerability were studied. RESULTS Isolated mangiferin is a selective inhibitor of catechol-O-methyltransferase (COMT) with an IC50 of 1.1 μM, with no activity on the CNS targets of caffeine. Both mangiferin and MLE induce similar changes in long-term potentiation (LTP) in the hippocampus in-vitro, and induce a similar pattern of EEG changes in-vivo. In both translational clinical trials MLE was well tolerated, with no cardiovascular side-effects. In both studies MLE caused significant spectral changes in brain electrical activity in cortical regions during cognitive challenges, different to the attenuated spectral changes induced by caffeine. There were no significant changes in the psychometric tests other than reaction time for all groups. In the second study there was a trend to faster reaction time within group for MLE (p = 0.066) and the percentage improvement in reaction time for MLE compared to placebo was significant (p = 0.049). In the first study MLE improved all scores for Profile of Mood States (POMS), with the score for ""fatigue"" significantly improved (p = 0.015); in the second study the POMS score for ""dejection"" was improved in the caffeine group, p = 0.05. CONCLUSIONS Mangiferin is a COMT inhibitor of moderate potency and is the major CNS-active compound in MLE. Both mangiferin and MLE increase hippocampal LTP in-vitro, and induce a similar pattern of changes in brain electrical activity in-vivo. While the translational clinical trials of MLE are limited by being single dose studies in a small number of subjects, they provide the first clinical evidence that the extract is well tolerated with no cardiovascular side-effects, can induce changes in brain electrical activity, may give a faster reaction time, and decrease fatigue. These CNS activities support the reported folk-uses use of mango leaf tea as a substitute for tea and as a traditional remedy for fatigue and exhaustion. Extract Mangifera indica L., Zynamite, has nootropic potential, and larger clinical studies are needed to realise this potential.",2020,"Both mangiferin and MLE induce similar changes in long term potentiation (LTP) in the hippocampus in-vitro, and induce a similar pattern of EEG changes in-vivo.",['16 subjects'],"['Mangifera indica leaf extract (MLE', 'caffeine', 'mangiferin and MLE', 'MLE', 'extract Mangifera indica L', 'placebo']","['fatigue', 'POMS score for ""dejection', 'Profile of Mood States (POMS', 'brain electrical activity', 'psychometric tests, mood state, and tolerability', 'reaction time for MLE', 'faster reaction time']",[],"[{'cui': 'C4081111', 'cui_str': 'mango leaf extract'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0065654', 'cui_str': 'mangiferin'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0330955', 'cui_str': 'Mangifera indica'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0451394', 'cui_str': 'Profile of mood states'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0234388', 'cui_str': 'Electrical activity of brain'}, {'cui': 'C0033920', 'cui_str': 'Psychometric testing'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C4081111', 'cui_str': 'mango leaf extract'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}]",,0.0364453,"Both mangiferin and MLE induce similar changes in long term potentiation (LTP) in the hippocampus in-vitro, and induce a similar pattern of EEG changes in-vivo.","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'López-Ríos', 'Affiliation': 'Department of Research, Development and Innovation, Nektium Pharma SL, 35118, Las Palmas de Gran Canaria, Spain. Electronic address: llopez@nektium.com.'}, {'ForeName': 'Julia C', 'Initials': 'JC', 'LastName': 'Wiebe', 'Affiliation': 'Department of Research, Development and Innovation, Nektium Pharma SL, 35118, Las Palmas de Gran Canaria, Spain. Electronic address: jwiebe@nektium.com.'}, {'ForeName': 'Tanausú', 'Initials': 'T', 'LastName': 'Vega-Morales', 'Affiliation': 'Department of Research, Development and Innovation, Nektium Pharma SL, 35118, Las Palmas de Gran Canaria, Spain. Electronic address: tvega@nektium.com.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Gericke', 'Affiliation': 'Department of Research, Development and Innovation, Nektium Pharma SL, 35118, Las Palmas de Gran Canaria, Spain; Department of Botany and Plant Biotechnology, University of Johannesburg, Auckland Park, 2006, Johannesburg, South Africa. Electronic address: ngericke@nektium.com.'}]",Journal of ethnopharmacology,['10.1016/j.jep.2020.112996'] 1669,32473403,Testing a self-directed lifestyle intervention among veterans: The D-ELITE pragmatic clinical trial.,"Nearly half of Veterans have obesity, fueling chronic diseases. The Department of Veterans Affairs (VA) offers an evidence-based behavioral weight management intervention called MOVE!, mostly delivered through in-person group sessions. Few eligible Veterans participate due to factors like distance and preferences, mirroring barriers in the general population. Practical alternatives to standard in-person programs are needed to improve access and engagement. A self-directed lifestyle intervention called D-ELITE-delivered through pre-recorded videos by DVD or online streaming-previously efficacious in a general primary care population, may provide such an alternative. This pragmatic clinical trial will evaluate whether D-ELITE improves weight and general health status among Veterans with obesity, relative to VA usual care. The yearlong intervention includes one orientation by phone, supplemental lifestyle coaching primarily via technology-based messages, 12 DVD or online streaming sessions over 3 months, and continued self-directed weight management for months 4-12. Participants use MyFitnessPal.com or paper booklets for self-monitoring weight, diet, and physical activity. Follow-up assessments at 12 and 24 months are administered by mail or phone. The study hypothesis is that compared with usual care, D-ELITE will lead to greater improvements in 12-month weight loss, per VA electronic health records, and general physical health status, assessed using the self-reported SF-12 physical composite score. We will also explore D-ELITE's effects on secondary biometric (e.g., HbA1c) and intermediate (e.g., diet) outcomes, reach, and budget impact. If effective, D-ELITE will offer a potentially scalable, low-cost alternative to VA's existing weight loss interventions by mitigating barriers presented by distance and technology.",2020,"If effective, D-ELITE will offer a potentially scalable, low-cost alternative to VA's existing weight loss interventions by mitigating barriers presented by distance and technology.","['veterans', 'Veterans with obesity, relative to VA usual care']","['supplemental lifestyle coaching primarily via technology-based messages, 12 DVD or online streaming sessions', 'self-directed lifestyle intervention', 'self-directed lifestyle intervention called D-ELITE-delivered through pre-recorded videos by DVD or online streaming-previously efficacious']","['secondary biometric (e.g., HbA1c) and intermediate (e.g., diet) outcomes, reach, and budget impact', 'weight and general health status']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0750927', 'cui_str': 'Developmental verbal dyspraxia'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0006347', 'cui_str': 'Budgets'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",,0.02449,"If effective, D-ELITE will offer a potentially scalable, low-cost alternative to VA's existing weight loss interventions by mitigating barriers presented by distance and technology.","[{'ForeName': 'Katherine D', 'Initials': 'KD', 'LastName': 'Hoerster', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States; VA Puget Sound Healthcare System, Seattle Division, Mental Health Service, 1660 South Columbian Way (S-116), Seattle, WA 98108, United States; University of Washington, Department of Psychiatry and Behavioral Sciences, 1100 NE 45(th) Street, Suite 300, Seattle, WA 98105, United States. Electronic address: Katherine.Hoerster@va.gov.'}, {'ForeName': 'Margaret P', 'Initials': 'MP', 'LastName': 'Collins', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Margaret.Collins@va.gov.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Au', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States; University of Washington, Department of Medicine, 1959 NE Pacific St, Seattle, WA 98195, United States. Electronic address: David.Au@va.gov.'}, {'ForeName': 'Amber', 'Initials': 'A', 'LastName': 'Lane', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Amber.Lane2@va.gov.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Epler', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Eric.Epler@va.gov.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'McDowell', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Jennifer.McDowell@va.gov.'}, {'ForeName': 'Anna E', 'Initials': 'AE', 'LastName': 'Barón', 'Affiliation': 'Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, 13001 E. 17(th) Place, Aurora, CO 80045, United States. Electronic address: Anna.Baron@cuanschutz.edu.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Rise', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Peter.Rise@va.gov.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Plumley', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Robert.Plumley@va.gov.'}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Nguyen', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Tanya.Nguyen@va.gov.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Schooler', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Mary.Schooler@va.gov.'}, {'ForeName': 'Linnaea', 'Initials': 'L', 'LastName': 'Schuttner', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States; University of Washington, Department of Medicine, 1959 NE Pacific St, Seattle, WA 98195, United States. Electronic address: Linnaea.Schuttner@va.gov.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'University of Illinois at Chicago, Department of Medicine, 1747 W. Roosevelt Rd, Room 586 (MC 275), Chicago, IL 60608, United States. Electronic address: maj2015@uic.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106045'] 1670,32474130,Randomized controlled trial protocol for project BRIDGE: A telephone-administered motivational interviewing intervention targeting risky sexual behavior in older people living with HIV.,"PURPOSE By 2020, 70% of people living with HIV in the United States will be greater than 50 years of age. As many as 37% of sexually active older people living with HIV (OPLWH) engage in HIV transmission sexual behaviors. In spite of repeated calls for secondary prevention interventions to reduce condomless sex in OPLWH, no age-appropriate, evidence-based secondary prevention interventions exist for this group. Furthermore, many OPLWH face barriers to engaging in face-to-face secondary prevention services because of HIV- and age-related stigma, comorbid mental and physical health conditions that complicate travel, or geographic isolation. High rates of depression in OPLWH may further complicate engagement in interventions intended to reduce HIV transmissions. Telephone-administered motivational interviewing may be a feasible and efficacious intervention for this population. METHODS This randomized controlled trial will test the efficacy of a 5-session telephone-administered motivational interviewing plus behavioral skills training (teleMI+BST) intervention versus a 5-session telephone-administered coping effectiveness training (teleCET) control intervention to reduce condomless sex in OPLWH. A diverse sample of 336 OPLWH will be recruited across the U.S. The primary analysis will test the efficacy of teleMI+BST to reduce occasions of non-condom protected anal and vaginal intercourse with HIV serodiscordant sex partners. Secondary analyses will examine the efficacy of teleMI+BST to reduce depressive symptoms in mildly depressed OPLWH. CONCLUSION This is the first large-scale RCT intended to reduce HIV sexual transmission risk behavior in OPLWH and will add to the literature on secondary prevention telehealth interventions for people living with HIV. ClinicalTrials.gov Identifier: NCT03004170. This trial has been conducted by the approval of the Institutional Review Board. Participants provided verbal consent to participate in this trial.",2020,The primary analysis will test the efficacy of teleMI+BST to reduce occasions of non-condom protected anal and vaginal intercourse with HIV serodiscordant sex partners.,"['older people living with HIV', 'people living with HIV', 'A diverse sample of 336 OPLWH will be recruited across the U.S']","['teleMI+BST', 'Telephone-administered motivational interviewing', '5-session telephone-administered motivational interviewing plus behavioral skills training (teleMI+BST) intervention versus a 5-session telephone-administered coping effectiveness training (teleCET) control intervention', 'telephone-administered motivational interviewing intervention']",['depressive symptoms'],"[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",336.0,0.216379,The primary analysis will test the efficacy of teleMI+BST to reduce occasions of non-condom protected anal and vaginal intercourse with HIV serodiscordant sex partners.,"[{'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Kahler', 'Affiliation': 'Center to Improve Veteran Involvement in Care, VA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA.'}, {'ForeName': 'Timothy G', 'Initials': 'TG', 'LastName': 'Heckman', 'Affiliation': 'College of Public Health, University of Georgia, 100 Foster Road, Athens, GA 30606, USA.'}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Shen', 'Affiliation': 'College of Public Health, University of Georgia, 100 Foster Road, Athens, GA 30606, USA.'}, {'ForeName': 'Marilyn S', 'Initials': 'MS', 'LastName': 'Huckans', 'Affiliation': 'Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.'}, {'ForeName': 'Sarah W', 'Initials': 'SW', 'LastName': 'Feldstein Ewing', 'Affiliation': 'Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.'}, {'ForeName': 'Jeffrey T', 'Initials': 'JT', 'LastName': 'Parsons', 'Affiliation': 'Mindful Designs, 791 Salem Street, Teaneck, NJ 07666, USA.'}, {'ForeName': 'Alissa', 'Initials': 'A', 'LastName': 'Phelps', 'Affiliation': 'Center to Improve Veteran Involvement in Care, VA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA; Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Sutton', 'Affiliation': 'College of Public Health, University of Georgia, 100 Foster Road, Athens, GA 30606, USA.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Holloway', 'Affiliation': 'Center to Improve Veteran Involvement in Care, VA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA; Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.'}, {'ForeName': 'Travis I', 'Initials': 'TI', 'LastName': 'Lovejoy', 'Affiliation': 'Center to Improve Veteran Involvement in Care, VA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA; Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. Electronic address: lovejoy@ohsu.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106047'] 1671,32475048,Effect of High-Intensity Interval Training on Visceral and Liver Fat in Cardiac Rehabilitation: A Randomized Controlled Trial.,"OBJECTIVE This study aimed to investigate the effect of exercise intensity on visceral adipose tissue (VAT) and liver fat reduction in patients with coronary artery disease (CAD) over 3 months and the maintenance of improvements over 12 months. METHODS Forty-two participants with CAD were randomized to three sessions/week of either 4 × 4-minute high-intensity interval training (HIIT) or 40 minutes of usual care moderate-intensity continuous training (MICT) for a 4-week supervised cardiac rehabilitation program, followed by three home-based sessions/week for 11 months. Liver fat (as intrahepatic lipid) and VAT were measured via magnetic resonance techniques. Data are mean change (95% CI). RESULTS HIIT and MICT significantly reduced VAT over 3 months (-350 [-548 to -153] cm 3 vs. -456 [-634 to -278] cm 3 ; time × group effect: P = 0.421), with further improvement over 12 months (-545 [-818 to -271] cm 3 vs. -521 [-784 to -258] cm 3 ; time × group effect: P = 0.577) and no differences between groups. Both groups improved liver fat over 3 months, with HIIT tending to show greater reduction than MICT (-2.8% [-4.0% to -1.6%] vs. -1.4% [-2.4% to -0.4%]; time × group effect: P = 0.077). After 12 months, improvements were maintained to a similar degree. Higher exercise intensity predicted liver fat reduction (β = -0.3 [-0.7 to 0.0]; P = 0.042). CONCLUSIONS HIIT and MICT reduced VAT over 3 and 12 months. For liver fat, HIIT tended to provide a slightly greater reduction compared with MICT. These findings support HIIT as a beneficial adjunct or alternative to MICT for reducing visceral and liver fat in patients with CAD.",2020,"RESULTS HIIT and MICT significantly reduced VAT over 3 months (-350 [-548 to -153]","['Forty-two participants with CAD', 'Cardiac Rehabilitation', 'patients with CAD', 'patients with coronary artery disease (CAD']","['exercise intensity', 'High-Intensity Interval Training', '4\u2009×\u20094-minute high-intensity interval training (HIIT) or 40 minutes of usual care moderate-intensity continuous training (MICT']","['VAT', 'Liver fat (as intrahepatic lipid) and VAT', 'liver fat', 'visceral adipose tissue (VAT) and liver fat reduction', 'Visceral and Liver Fat']","[{'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C1563740', 'cui_str': 'Abdominal Visceral Fat'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}]",42.0,0.032867,"RESULTS HIIT and MICT significantly reduced VAT over 3 months (-350 [-548 to -153]","[{'ForeName': 'Jenna L', 'Initials': 'JL', 'LastName': 'Taylor', 'Affiliation': 'Centre for Research on Exercise, Physical Activity, and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Holland', 'Affiliation': 'Centre for Research on Exercise, Physical Activity, and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Gregore I', 'Initials': 'GI', 'LastName': 'Mielke', 'Affiliation': 'Centre for Research on Exercise, Physical Activity, and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Tom G', 'Initials': 'TG', 'LastName': 'Bailey', 'Affiliation': 'Centre for Research on Exercise, Physical Activity, and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Nathan A', 'Initials': 'NA', 'LastName': 'Johnson', 'Affiliation': 'Faculty of Health Sciences, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Leveritt', 'Affiliation': 'Centre for Research on Exercise, Physical Activity, and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Sjaan R', 'Initials': 'SR', 'LastName': 'Gomersall', 'Affiliation': 'Centre for Research on Exercise, Physical Activity, and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Alex V', 'Initials': 'AV', 'LastName': 'Rowlands', 'Affiliation': 'Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK.'}, {'ForeName': 'Jeff S', 'Initials': 'JS', 'LastName': 'Coombes', 'Affiliation': 'Centre for Research on Exercise, Physical Activity, and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Shelley E', 'Initials': 'SE', 'LastName': 'Keating', 'Affiliation': 'Centre for Research on Exercise, Physical Activity, and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}]","Obesity (Silver Spring, Md.)",['10.1002/oby.22833'] 1672,32476881,Measuring activity in patients with sarcoidosis - a pilot trial of two wrist-worn accelerometer devices.,"Introduction: Increasing physical activity is associated with health benefits. Reduced physical activity has been noted in sarcoidosis, particularly where fatigue co-exists. Monitoring physical activity is possible with wrist-worn devices. This study compared two available devices to determine patient preference and compare wear-time, with a secondary outcome of comparing device outputs with fatigue scores. Methods: Patients with sarcoidosis wore two wrist-worn activity monitors (GENEActiv actiwatch and Actigraph GT3X-bt) separately for seven days each. Participants were randomly allocated to receive either device first. Participants completed the Fatigue Assessment Scale (FAS) questionnaire immediately before wearing the first device. All participants completed a questionnaire of their perception regarding each device after the wear period. Data from the devices was analysed for total wear time, time spent in moderate or vigorous activity (MVPA) and for time spent in sedentary behaviours. Results: Twelve patients with sarcoidosis were included. The GENEActiv device was preferred by ten (83.3%) participants. Wear time was greater with the GENEActiv device (1354 minutes/day vs 1079 minutes/day). Time spent in MVPA was slightly higher when recorded by the GENEActiv compared with the Actigraph. Moderately strong correlation was seen between FAS scores and sedentary time (r=-0.554), light activity (r=-0.585) and moderate activity (r=0.506). Discussion: A clear preference was demonstrated for the GENEActiv. This was reflected in higher wear time and suggests the device can be comfortably worn 24 hours per day. Data from this small cohort also suggests there is correlation between fatigue and activity scores in patients with sarcoidosis. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 62-68) .",2018,Wear time was greater with the GENEActiv device (1354 minutes/day vs 1079 minutes/day).,"['Twelve patients with sarcoidosis were included', 'patients with sarcoidosis - a pilot trial of two wrist-worn accelerometer devices', 'Patients with sarcoidosis', 'patients with sarcoidosis']",[],"['total wear time, time spent in moderate or vigorous activity (MVPA) and for time spent in sedentary behaviours', 'Time spent in MVPA', 'Wear time', 'physical activity', 'fatigue and activity scores', 'Fatigue Assessment Scale (FAS) questionnaire', 'FAS scores and sedentary time (r=-0.554), light activity (r=-0.585) and moderate activity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036202', 'cui_str': 'Sarcoidosis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]",[],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0015683', 'cui_str': 'Fatty-acid synthase'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C4517464', 'cui_str': '0.585'}]",12.0,0.0600001,Wear time was greater with the GENEActiv device (1354 minutes/day vs 1079 minutes/day).,"[{'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Atkins', 'Affiliation': 'Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK, NR4 7TJ.'}, {'ForeName': 'Andy P', 'Initials': 'AP', 'LastName': 'Jones', 'Affiliation': 'Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK, NR4 7TJ.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Wilson', 'Affiliation': 'Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK, NR4 7TJ.'}]","Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG",['10.36141/svdld.v35i1.5848'] 1673,32448020,Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study.,"AIMS 22q11.2 deletion syndrome (22q11.2DS) is associated with impaired cognitive functioning. Glutamatergic pathways have been linked with cognition and are hypothesized to be disrupted in 22q11.2DS patients, possibly 'shifting' the excitatory (glutamate)/inhibitory (GABA) balance. Hence, the glutamate/GABA balance may constitute a target for pharmacological treatment. We aimed to examine alterations of glutamate/GABA metabolites in 22q11.2DS in vivo using riluzole, a compound with glutamate/GABA-modulating action, as pharmacological challenge. METHODS Seventeen 22q11.2DS patients and 20 matched healthy controls were enrolled in this randomized double-blind placebo-controlled crossover study. Glutamate and glutamine concentrations in the anterior cingulate cortex (ACC) and striatum, as well as ACC GABA concentrations were obtained after placebo and after a single dose of 50 mg riluzole using 7-Tesla magnetic resonance spectroscopy (MRS). Within the 22q11.2DS group, the relationship between metabolite concentrations and cognition was examined. RESULTS No group differences were found in ACC and striatal metabolite concentrations following placebo. Riluzole numerically decreased ACC ( η 2 = 0.094 ) but not striatal glutamate concentrations as well as ACC GABA concentrations ( η 2 = 0.176 ) in all subjects. In both regions, riluzole did not alter glutamine concentration. No interaction effects were found. Although not significant after Bonferroni correction, ACC glutamate concentrations were inversely correlated with cognitive functions in 22q11.2DS patients. DISCUSSION We did not demonstrate altered ACC and striatal metabolite concentrations in 22q11.2DS. Nevertheless, these results suggest that glutamate and GABA can be modulated with a single dose of riluzole. Possibly, riluzole may have memory-enhancing effects in 22q11.2DS. Future studies should examine the long-term effects of riluzole on cognition.",2020,Riluzole numerically decreased ACC ( η 2 = 0.094 ) but not striatal glutamate concentrations as well as ACC GABA concentrations ( η 2 = 0.176 ) in all subjects.,"['Seventeen 22q11.2DS patients and 20 matched healthy controls', '22q11.2 deletion syndrome and healthy volunteers', '22q11.2DS patients']","['Riluzole', 'riluzole', 'placebo']","['ACC GABA concentrations', 'ACC glutamate concentrations', 'ACC and striatal metabolite concentrations', 'cognitive functions', 'ACC', 'glutamine concentration']","[{'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0220704', 'cui_str': 'Velo-cardio-facial syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0012236', 'cui_str': ""DiGeorge's syndrome""}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0073379', 'cui_str': 'Riluzole'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C0016904', 'cui_str': 'Gamma-aminobutyric acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0017789', 'cui_str': 'Glutamates'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0017797', 'cui_str': 'Glutamine'}]",,0.0789898,Riluzole numerically decreased ACC ( η 2 = 0.094 ) but not striatal glutamate concentrations as well as ACC GABA concentrations ( η 2 = 0.176 ) in all subjects.,"[{'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Vingerhoets', 'Affiliation': 'Department of Psychiatry & Neuropsychology, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Desmond Hy', 'Initials': 'DH', 'LastName': 'Tse', 'Affiliation': 'Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Mathilde', 'Initials': 'M', 'LastName': 'van Oudenaren', 'Affiliation': 'Department of Psychiatry & Neuropsychology, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'Hernaus', 'Affiliation': 'Department of Psychiatry & Neuropsychology, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'van Duin', 'Affiliation': 'Department of Psychiatry & Neuropsychology, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Janneke', 'Initials': 'J', 'LastName': 'Zinkstok', 'Affiliation': 'Department of Psychiatry & UMC Utrecht Brain Center, University Medical Center, Utrecht, the Netherlands.'}, {'ForeName': 'Johannes G', 'Initials': 'JG', 'LastName': 'Ramaekers', 'Affiliation': 'Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Jacobus Fa', 'Initials': 'JF', 'LastName': 'Jansen', 'Affiliation': 'Department of Radiology, Maastricht University Medical Center, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Grainne', 'Initials': 'G', 'LastName': 'McAlonan', 'Affiliation': ""The Sackler Institute for Translational Neurodevelopment, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Therese', 'Initials': 'T', 'LastName': 'van Amelsvoort', 'Affiliation': 'Department of Psychiatry & Neuropsychology, Maastricht University, Maastricht, the Netherlands.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881120922977'] 1674,32448552,Randomized Trial of a Physical Activity Intervention for Latino Men: Activo.,"INTRODUCTION Latino men experience disproportionately high rates of diseases related to low physical activity, yet they are poorly represented in physical activity intervention trials. Efforts to promote physical activity in Latina women show promising results, yet such interventions are yet to be extended to Latino men. This study tested a computer expert system‒tailored, text messaging-supported physical activity intervention for underactive Spanish-speaking Latino men compared with a control group matched for contact time. Potential predictors of intervention success were also explored. STUDY DESIGN Randomized trial. Participants were randomized to receive a Tailored Physical Activity Intervention (Intervention) or a Wellness Control (Control). Data were collected in 2015-2017 and analyzed in 2018-2019. SETTING/PARTICIPANTS Insufficiently active Latino men (n=46). INTERVENTION Intervention participants received a baseline counseling session and then, individually tailored print materials and text messages on a tapered schedule for 6 months. Control participants received printed wellness materials and text messages on the same schedule. MAIN OUTCOME MEASURES Primary outcome was a change in weekly moderate to vigorous physical activity from baseline to 6 months measured by accelerometers. Self-reported moderate to vigorous physical activity measured by the 7-day Physical Activity Recall Interview was a secondary outcome. RESULTS For Intervention participants, median accelerometer-measured moderate to vigorous physical activity increased from 10.0 minutes/week at baseline to 57.5 minutes/week at 6 months, whereas for Control participants, it increased from 21.0 minutes/week at baseline to 23.0 minutes/week at 6 months (p<0.05). Similar results were found for self-reported moderate to vigorous physical activity. At 6 months, 47% of Intervention participants met national guidelines of 150 minutes/week versus 25% of Control participants (p=0.15, not significant). CONCLUSIONS Findings suggest that an individually tailored intervention can successfully increase moderate to vigorous physical activity in underactive Latino men. Such technology-supported interventions have the potential for broad dissemination. TRIAL REGISTRATION This study is registered at www.clinicaltrials.gov NCT02512419.",2020,"This study tested a computer expert system‒tailored, text messaging-supported physical activity intervention for underactive Spanish-speaking Latino men compared with a control group matched for contact time.","['Insufficiently active Latino men (n=46', 'underactive Spanish-speaking Latino men', 'Latina women', 'Latino Men', 'underactive Latino men', 'Data were collected in 2015-2017 and analyzed in 2018-2019']","['Intervention participants received a baseline counseling session', 'Physical Activity Intervention', 'computer expert system‒tailored, text messaging-supported physical activity intervention', 'Tailored Physical Activity Intervention (Intervention) or a Wellness Control (Control', 'printed wellness materials and text messages']","['vigorous physical activity', 'median accelerometer-measured moderate to vigorous physical activity', '7-day Physical Activity Recall Interview', 'change in weekly moderate to vigorous physical activity']","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0391853', 'cui_str': 'Underactive'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0949335', 'cui_str': 'Latinas'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0033161', 'cui_str': 'Printing'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}]",,0.0298802,"This study tested a computer expert system‒tailored, text messaging-supported physical activity intervention for underactive Spanish-speaking Latino men compared with a control group matched for contact time.","[{'ForeName': 'Britta A', 'Initials': 'BA', 'LastName': 'Larsen', 'Affiliation': 'Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, California. Electronic address: blarsen@ucsd.edu.'}, {'ForeName': 'Tanya J', 'Initials': 'TJ', 'LastName': 'Benitez', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island.'}, {'ForeName': 'Andrea S', 'Initials': 'AS', 'LastName': 'Mendoza-Vasconez', 'Affiliation': 'Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, California.'}, {'ForeName': 'Sheri J', 'Initials': 'SJ', 'LastName': 'Hartman', 'Affiliation': 'Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, California.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Linke', 'Affiliation': 'Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, California.'}, {'ForeName': 'Dori J', 'Initials': 'DJ', 'LastName': 'Pekmezi', 'Affiliation': 'Department of Health Behavior, School of Public Health at University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Shira I', 'Initials': 'SI', 'LastName': 'Dunsiger', 'Affiliation': 'Centers for Behavioral and Preventive Medicine, Department of Psychiatry and Human Behavior, Miriam Hospital, Providence, Rhode Island.'}, {'ForeName': 'Jesse N', 'Initials': 'JN', 'LastName': 'Nodora', 'Affiliation': 'Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, California.'}, {'ForeName': 'Kim M', 'Initials': 'KM', 'LastName': 'Gans', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island; Department of Human Development and Family Studies, University of Connecticut, Storrs, Connecticut.'}, {'ForeName': 'Bess H', 'Initials': 'BH', 'LastName': 'Marcus', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island.'}]",American journal of preventive medicine,['10.1016/j.amepre.2020.03.007'] 1675,32450979,Impact of visual inspection and radiographs for caries detection in children through a 2-year randomized clinical trial: The Caries Detection in Children-1 study.,"BACKGROUND Visual inspection (VIS) with radiographic examination (RAD) is the recommended diagnostic strategy for detecting caries in children; however, this recommendation is based on accuracy studies. The authors conducted a clinical trial to compare the detection and subsequent treatment of carious lesions in primary molars performed with VIS alone and with RAD. METHODS Children (3-6 years old) were randomly assigned to 2 groups according to the diagnostic strategy used for caries detection on primary molars: VIS or RAD. Participants were diagnosed and treated according to the management plan related to the allocated group. The primary outcome was the number of new operative interventions during the 2-year follow-up period. Other secondary outcomes were also compared. Comparisons were performed with Mann-Whitney test using an intention-to-treat approach. RESULTS Of the 252 children included and randomized, 216 were followed-up after 2 years (14.3% attrition rate). There was no difference between the groups for the primary outcome (P = .476). For the secondary outcomes, the RAD group had more restoration replacements (P = .038) and more restorations performed since the beginning of the study (P = .038) compared with the VIS group. In addition, the RAD group had a higher number of false-positive results than the VIS group (P < .001). CONCLUSIONS Simultaneous use of VIS and RAD for caries diagnosis in primary molars of children who seek dental treatment does not provide additional benefits compared with VIS alone. PRACTICAL IMPLICATIONS Dentists should perform VIS only, not RAD, for detecting carious lesions in preschool-aged children. ClinicalTrials.gov: NCT02078453.",2020,"For the secondary outcomes, the RAD group had more restoration replacements (P = .038) and more restorations performed since the beginning of the study (P = .038) compared with the VIS group.","['caries in children', 'Children (3-6 years old', 'children through a 2-year randomized clinical trial', '252 children', 'preschool-aged children']","['diagnostic strategy used for caries detection on primary molars: VIS or RAD', 'VIS and RAD', 'Visual inspection (VIS) with radiographic examination (RAD', 'VIS alone and with RAD', 'visual inspection and radiographs']","['restoration replacements', 'number of false-positive results', 'number of new operative interventions']","[{'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0442759', 'cui_str': '3/6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0199219', 'cui_str': 'Inspection'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1306645', 'cui_str': 'Plain radiography'}]","[{'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205557', 'cui_str': 'False positive'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",252.0,0.157572,"For the secondary outcomes, the RAD group had more restoration replacements (P = .038) and more restorations performed since the beginning of the study (P = .038) compared with the VIS group.","[{'ForeName': 'Laura R A', 'Initials': 'LRA', 'LastName': 'Pontes', 'Affiliation': ''}, {'ForeName': 'Tatiane F', 'Initials': 'TF', 'LastName': 'Novaes', 'Affiliation': ''}, {'ForeName': 'Juan S', 'Initials': 'JS', 'LastName': 'Lara', 'Affiliation': ''}, {'ForeName': 'Thais', 'Initials': 'T', 'LastName': 'Gimenez', 'Affiliation': ''}, {'ForeName': 'Bruna L P', 'Initials': 'BLP', 'LastName': 'Moro', 'Affiliation': ''}, {'ForeName': 'Lucila B', 'Initials': 'LB', 'LastName': 'Camargo', 'Affiliation': ''}, {'ForeName': 'Edgard', 'Initials': 'E', 'LastName': 'Michel-Crosato', 'Affiliation': ''}, {'ForeName': 'Claudio M', 'Initials': 'CM', 'LastName': 'Pannuti', 'Affiliation': ''}, {'ForeName': 'Daniela P', 'Initials': 'DP', 'LastName': 'Raggio', 'Affiliation': ''}, {'ForeName': 'Mariana M', 'Initials': 'MM', 'LastName': 'Braga', 'Affiliation': ''}, {'ForeName': 'Fausto M', 'Initials': 'FM', 'LastName': 'Mendes', 'Affiliation': ''}]",Journal of the American Dental Association (1939),['10.1016/j.adaj.2020.02.008'] 1676,32458473,Effectiveness of nurse-led group CBT for hot flushes and night sweats in women with breast cancer: Results of the MENOS4 randomised controlled trial.,"OBJECTIVE Troublesome hot flushes and night sweats (HFNS) are experienced by many women after treatment for breast cancer, impacting significantly on sleep and quality of life. Cognitive behavioural therapy (CBT) is known to be effective for the alleviation of HFNS. However, it is not known if it can effectively be delivered by specialist nurses. We investigated whether group CBT, delivered by breast care nurses (BCNs), can reduce the impact of HFNS. METHODS We recruited women with primary breast cancer following primary treatment with seven or more HFNS/week (including 4/10 or above on the HFNS problem rating scale), from six UK hospitals to an open, randomised, phase 3 effectiveness trial. Participants were randomised to Group CBT or usual care (UC). The primary endpoint was HFNS problem rating at 26 weeks after randomisation. Secondary outcomes included sleep, depression, anxiety and quality of life. RESULTS Between 2017 and 2018, 130 participants were recruited (CBT:63, control:67). We found a 46% (6.9-3.7) reduction in the mean HFNS problem rating score from randomisation to 26 weeks in the CBT arm and a 15% (6.5-5.5) reduction in the UC arm (adjusted mean difference -1.96, CI -3.68 to -0.23, P = .039). Secondary outcomes, including frequency of HFNS, sleep, anxiety and depression all improved significantly. CONCLUSION Our results suggest that specialist nurses can be trained to deliver CBT effectively to alleviate troublesome menopausal hot flushes in women following breast cancer in the NHS setting.",2020,Our results suggest that specialist nurses can be trained to deliver CBT effectively to alleviate troublesome menopausal hot flushes in women following breast cancer in the NHS setting.,"['130 participants were recruited (CBT:63, control:67', 'Between 2017-2018', 'recruited women with primary breast cancer following primary treatment with seven or more HFNS/week (including 4/10 or above on the HFNS problem rating scale), from six UK hospitals to an open, randomised, phase 3 effectiveness trial', 'women with breast cancer']","['nurse-led group CBT', 'Group CBT or usual care (UC', 'CBT delivered by breast care nurses (BCNs', 'Cognitive behavioural therapy (CBT']","['frequency of HFNS, sleep, anxiety and depression all improved significantly', 'mean HFNS problem rating score', 'HFNS problem rating', 'sleep, depression, anxiety and quality of life']","[{'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C1708063', 'cui_str': 'First line treatment'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0600142', 'cui_str': 'Menopausal flushing'}, {'cui': 'C0028081', 'cui_str': 'Night sweats'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0600142', 'cui_str': 'Menopausal flushing'}, {'cui': 'C0028081', 'cui_str': 'Night sweats'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",130.0,0.118211,Our results suggest that specialist nurses can be trained to deliver CBT effectively to alleviate troublesome menopausal hot flushes in women following breast cancer in the NHS setting.,"[{'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Fenlon', 'Affiliation': 'Department Nursing, College of Human and Health Sciences, Swansea University, Swansea, UK.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Maishman', 'Affiliation': 'Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Day', 'Affiliation': 'Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine , London, UK.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Nuttall', 'Affiliation': 'Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'May', 'Affiliation': 'Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine , London, UK.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Ellis', 'Affiliation': 'Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Raftery', 'Affiliation': 'Primary Care and Population Sciences, University of Southampton, Southampton, UK.'}, {'ForeName': 'Lesley', 'Initials': 'L', 'LastName': 'Turner', 'Affiliation': 'Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Fields', 'Affiliation': 'Ladybird Unit, Poole Hospital NHS Trust, Poole, UK.'}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Griffiths', 'Affiliation': 'Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Myra S', 'Initials': 'MS', 'LastName': 'Hunter', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}]",Psycho-oncology,['10.1002/pon.5432'] 1677,32460997,An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275.,"OBJECTIVES Methotrexate and actinomycin-D are both effective first-line drugs for low-risk (WHO score 0-6) Gestational Trophoblastic Neoplasia (GTN) with considerable debate about which is more effective, less toxic, and better tolerated. The primary trial objective was to test if treatment with multi-day methotrexate (MTX) was inferior to pulse actinomycin-D (ACT-D). Secondary objectives included evaluation of severity and frequency of adverse events, and impact on quality of life (QOL). METHODS This was a prospective international cooperative group randomized phase III two arm non-inferiority study (Clinical Trials Identifier: (NCT01535053). The control arm was ACT-D; the experimental arm was multi-day MTX regimen (institutional preference of 5 or 8 day). Outcome measures included complete response rate, recurrence rate, toxicity, and QOL as measured by FACT-G and FACIT supplemental items. RESULTS The complete response rates for multi-day methotrexate and pulse actinomycin-D were 88% (23/26 patients) and 79% (22/28 patients) (p = NS) respectively, there were two recurrences in each arm, and 100% of patients survived. Significant toxicity was minimal, but mouth sores (mucositis), and eye pain were significantly more common in the MTX arm (p = 0.001 and 0.01 respectively). Quality of life showed no significant difference in overall quality of life, body image, sexual function, or treatment related side effects. The study was closed for low accrual rate (target 384, actual accrual 57), precluding statistical analysis of the primary objective. CONCLUSIONS The complete response rate for multi-day methotrexate was higher than actinomycin-D, but did not reach statistical significance. The multi-day MTX regimens were associated with significantly more mucositis and were significantly less convenient.",2020,"The complete response rate for multi-day methotrexate was higher than actinomycin-D, but did not reach statistical significance.",['low risk gestational trophoblastic neoplasia; NRG/GOG 275'],"['pulse actinomycin-D (ACT-D', 'pulse actinomycin-D versus multi-day methotrexate', 'MTX', 'multi-day methotrexate (MTX', 'Methotrexate and actinomycin-D']","['complete response rates', 'mouth sores (mucositis), and eye pain', 'mucositis', 'evaluation of severity and frequency of adverse events, and impact on quality of life (QOL', 'Significant toxicity', 'overall quality of life, body image, sexual function, or treatment related side effects', 'complete response rate, recurrence rate, toxicity, and QOL as measured by FACT-G and FACIT supplemental items', 'complete response rate']","[{'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C1135868', 'cui_str': 'Gestational trophoblastic neoplasia'}, {'cui': 'C4517676', 'cui_str': '275'}]","[{'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0010934', 'cui_str': 'Dactinomycin'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}]","[{'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0149745', 'cui_str': 'Ulcer of mouth'}, {'cui': 'C0151827', 'cui_str': 'Pain in eye'}, {'cui': 'C0333355', 'cui_str': 'Inflammatory disease of mucous membrane'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C0278092', 'cui_str': 'Sexual function'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",,0.121683,"The complete response rate for multi-day methotrexate was higher than actinomycin-D, but did not reach statistical significance.","[{'ForeName': 'Julian C', 'Initials': 'JC', 'LastName': 'Schink', 'Affiliation': 'Cancer Treatment Centers of America, Comprehensive Care and Research Center, Chicago, IL, USA. Electronic address: Julian.schink@CTCA-hope.com.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Filiaci', 'Affiliation': 'NRG Oncology Statistics and Data Management Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Electronic address: FiliaciV@NRGOncology.org.'}, {'ForeName': 'Helen Q', 'Initials': 'HQ', 'LastName': 'Huang', 'Affiliation': 'NRG Oncology Statistics and Data Management Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Electronic address: HuangH@NRGOncology.org.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Tidy', 'Affiliation': 'Sheffield Teaching Hospitals, NHS Trust, Royal Hallamshire Hospital, Glossop Rd, Sheffield S10 2JF, UK. Electronic address: John.Tidy@sth.nhs.uk.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Winter', 'Affiliation': 'Sheffield Teaching Hospitals, NHS Trust, Royal Hallamshire Hospital, Glossop Rd, Sheffield S10 2JF, UK. Electronic address: matthew.winter@sth.nhs.uk.'}, {'ForeName': 'Jeanne', 'Initials': 'J', 'LastName': 'Carter', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, 641 Lexington Avenue, New York, NY, USA. Electronic address: carterj@mskcc.org.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Anderson', 'Affiliation': 'Northwestern University, Chicago, IL, USA. Electronic address: naanders@nm.org.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Moxley', 'Affiliation': 'Oklahoma University Health Science Center, Oklahoma City, OK, USA. Electronic address: Katherine-Moxley@ouhsc.edu.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Yabuno', 'Affiliation': 'Saitama Medical University International Medical Center, Saitama, Japan. Electronic address: yabunoakira@yahoo.co.jp.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Taylor', 'Affiliation': 'Gynecologic Oncology, Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address: taylorse@upmc.edu.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Kushnir', 'Affiliation': ""Gynecologic Oncology, Women's Cancer Center of Nevada, Las Vegas, NV, USA. Electronic address: ckushnir@wccenter.com.""}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Horowitz', 'Affiliation': 'Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA. Electronic address: nhorowitz@partners.org.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Miller', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: david.miller@utsouthwestern.edu.'}]",Gynecologic oncology,['10.1016/j.ygyno.2020.05.013'] 1678,32466360,"Effects of Anesthesia Techniques on Outcomes after Hip Fracture Surgery in Elderly Patients: A Prospective, Randomized, Controlled Trial.","The superiority of distinct anesthesia methods for geriatric hip fracture surgery remains unclear. We evaluated high mobility group box-1 (HMGB1) and interleukin-6 (IL-6) with three different anesthesia methods in elderly patients undergoing hip fracture surgery. Routine blood test findings, postoperative morbidity, and mortality were assessed as secondary outcome. In total, 176 patients were randomized into desflurane ( n = 60), propofol ( n = 58), or spinal groups ( n = 58) that received desflurane-based balanced anesthesia, propofol-based total intravenous anesthesia (TIVA), or spinal anesthesia, respectively. The spinal group required less intraoperative vasopressors ( p < 0.001) and fluids ( p = 0.006). No significant differences in HMGB1 ( p group×time = 0.863) or IL-6 ( p group×time = 0.575) levels were noted at baseline, postoperative day (POD) 1, or POD2. Hemoglobin, albumin, creatinine, total lymphocyte count, potassium, troponin T, and C-reactive protein were comparable among groups at all time-points. No significant differences in postoperative hospital stay, intensive care unit (ICU) stay, and ventilator use among groups were observed. Postoperative pulmonary, cardiac, and neurologic complications; and in-hospital, 30-day, and 90-day mortality were not significantly different among groups ( p = 0.974). In conclusion, HMGB1 and IL-6, and all secondary outcomes, were not significantly different between desflurane anesthesia, propofol TIVA, and spinal anesthesia.",2020,"No significant differences in postoperative hospital stay, intensive care unit (ICU) stay, and ventilator use among groups were observed.","['Elderly Patients', 'geriatric hip fracture surgery', '176 patients were randomized into', 'elderly patients undergoing hip fracture surgery']","['desflurane', 'Anesthesia Techniques', 'high mobility group box-1 (HMGB1) and interleukin-6 (IL-6) with three different anesthesia methods', 'propofol', 'desflurane-based balanced anesthesia, propofol-based total intravenous anesthesia (TIVA), or spinal anesthesia, respectively']","['HMGB1', 'intraoperative vasopressors', 'postoperative hospital stay, intensive care unit (ICU) stay, and ventilator use', 'IL-6', 'Hemoglobin, albumin, creatinine, total lymphocyte count, potassium, troponin T, and C-reactive protein', 'Postoperative pulmonary, cardiac, and neurologic complications; and in-hospital, 30-day, and 90-day mortality', 'postoperative morbidity, and mortality', 'desflurane anesthesia, propofol TIVA, and spinal anesthesia']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0063252', 'cui_str': 'desflurane'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0019796', 'cui_str': 'HMG-1 Protein'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C2936341', 'cui_str': 'Balanced Anesthesia'}, {'cui': 'C0473965', 'cui_str': 'Total intravenous anesthesia'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}]","[{'cui': 'C0019796', 'cui_str': 'HMG-1 Protein'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0042397', 'cui_str': 'Vasoconstrictor agent'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0087153', 'cui_str': 'Ventilator'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0200635', 'cui_str': 'Lymphocyte count'}, {'cui': 'C0032821', 'cui_str': 'Potassium'}, {'cui': 'C0077404', 'cui_str': 'Troponin T'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0063252', 'cui_str': 'desflurane'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C3854651', 'cui_str': 'TIVA'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}]",176.0,0.0595164,"No significant differences in postoperative hospital stay, intensive care unit (ICU) stay, and ventilator use among groups were observed.","[{'ForeName': 'Seokyung', 'Initials': 'S', 'LastName': 'Shin', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul 03722, Korea.'}, {'ForeName': 'Seung Hyun', 'Initials': 'SH', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul 03722, Korea.'}, {'ForeName': 'Kwan Kyu', 'Initials': 'KK', 'LastName': 'Park', 'Affiliation': 'Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul 03722, Korea.'}, {'ForeName': 'Seon Ju', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, National Health Insurance Service Ilsan Hospital, Goyang 10444, Korea.'}, {'ForeName': 'Jae Chan', 'Initials': 'JC', 'LastName': 'Bae', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, National Health Insurance Service Ilsan Hospital, Goyang 10444, Korea.'}, {'ForeName': 'Yong Seon', 'Initials': 'YS', 'LastName': 'Choi', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul 03722, Korea.'}]",Journal of clinical medicine,['10.3390/jcm9061605'] 1679,32466854,Preoperative Vitamin D Supplementation in Patients With Vitamin D Deficiency Undergoing Total Thyroidectomy.,"BACKGROUND Transient hypocalcemia due to parathyroid gland or vessel manipulation is a common complication following thyroidectomy. Considering the role of 25-hydroxyvitamin D (25(OH)D) in calcium hemostasis, this study aimed to evaluate the effect of preoperative vitamin D supplementation on hypocalcemia incidence in thyroidectomy patients. METHODS In this randomized clinical trial, 100 patients scheduled for total thyroidectomy and suffering from preoperative moderate or severe vitamin D deficiency were enrolled. Patients were randomly allocated to either study or control groups using the sealed envelope method. Patients in the study group received vitamin D3 50,000-unit pearl weekly for 4 weeks prior to the operation. The control group received placebo. Total and ionized serum calcium levels were checked before surgery, the day after surgery, and 2 weeks postoperatively. RESULTS No significant difference was observed in terms of demographic data. During serial total calcium checks (5 episodes), total calcium levels changed significantly in patients who had received vitamin D supplements compared to the control group (P = 0.043). Symptomatic hypocalcemia incidence was significantly lower in patients supplemented with 25-hydroxyvitamin D (25(OH)D) (P = 0.04). Also, the requirement for intravenous calcium administration in order to treat the hypocalcemia symptoms was significantly lower in the study in comparison to the control group (P = 0.03). CONCLUSIONS Vitamin D supplementation in patients with vitamin D deficiency might lead to a lower incidence of early-onset symptomatic hypocalcemia; hence, requiring less calcium supplementation for the management of hypocalcemia.",2020,Symptomatic hypocalcemia incidence was significantly lower in patients supplemented with 25-hydroxyvitamin D (25(OH)D),"['100 patients scheduled for total thyroidectomy and suffering from preoperative moderate or severe vitamin D deficiency were enrolled', 'thyroidectomy patients', 'Patients With Vitamin D Deficiency Undergoing Total Thyroidectomy', 'patients with vitamin D deficiency']","['vitamin D supplements', 'preoperative vitamin D supplementation', 'Vitamin D supplementation', '25-hydroxyvitamin D (25(OH)D', 'Preoperative Vitamin D Supplementation', 'vitamin D3', 'placebo']","['Total and ionized serum calcium levels', 'demographic data', 'Symptomatic hypocalcemia incidence', 'total calcium levels', 'hypocalcemia symptoms', 'hypocalcemia incidence']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0193788', 'cui_str': 'Total thyroidectomy'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0042870', 'cui_str': 'Vitamin D deficiency'}, {'cui': 'C0040145', 'cui_str': 'Thyroidectomy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0420176', 'cui_str': 'Vitamin D supplement therapy'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0728876', 'cui_str': 'Serum calcium measurement'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0020598', 'cui_str': 'Hypocalcemia'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0201925', 'cui_str': 'Calcium measurement'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",100.0,0.0588547,Symptomatic hypocalcemia incidence was significantly lower in patients supplemented with 25-hydroxyvitamin D (25(OH)D),"[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ramouz', 'Affiliation': 'Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Mahdie', 'Initials': 'M', 'LastName': 'Hosseini', 'Affiliation': 'Department of Cardiothoracic Surgery, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Cardiothoracic Surgery, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Seyedeh Shaghayegh', 'Initials': 'SS', 'LastName': 'Hosseinzadeh', 'Affiliation': 'Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Seyed Ziaeddin', 'Initials': 'SZ', 'LastName': 'Rasihashemi', 'Affiliation': 'Department of Cardiothoracic Surgery, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: zia.hashemi@yahoo.com.'}]",The American journal of the medical sciences,['10.1016/j.amjms.2020.04.036'] 1680,32464527,Community-level interventions for pre-eclampsia (CLIP) in Mozambique: A cluster randomised controlled trial.,"OBJECTIVES Pregnancy hypertension is the third leading cause of maternal mortality in Mozambique and contributes significantly to fetal and neonatal mortality. The objective of this trial was to assess whether task-sharing care might reduce adverse pregnancy outcomes related to delays in triage, transport, and treatment. STUDY DESIGN The Mozambique Community-Level Interventions for Pre-eclampsia (CLIP) cluster randomised controlled trial (NCT01911494) recruited pregnant women in 12 administrative posts (clusters) in Maputo and Gaza Provinces. The CLIP intervention (6 clusters) consisted of community engagement, community health worker-provided mobile health-guided clinical assessment, initial treatment, and referral to facility either urgently (<4hrs) or non-urgently (<24hrs), dependent on algorithm-defined risk. Treatment effect was estimated by multi-level logistic regression modelling, adjusted for prognostically-significant baseline variables. Predefined secondary analyses included safety and evaluation of the intensity of CLIP contacts. MAIN OUTCOME MEASURES 20% reduction in composite of maternal, fetal, and newborn mortality and major morbidity. RESULTS 15,013 women (15,123 pregnancies) were recruited in intervention (N = 7930; 2·0% loss to follow-up (LTFU)) and control (N = 7190; 2·8% LTFU) clusters. The primary outcome did not differ between intervention and control clusters (adjusted odds ratio (aOR) 1·31, 95% confidence interval (CI) [0·70, 2·48]; p = 0·40). Compared with intervention arm women without CLIP contacts, those with ≥8 contacts experienced fewer primary outcomes (aOR 0·79 (95% CI 0·63, 0·99); p = 0·041), primarily due to improved maternal outcomes (aOR 0·72 (95% CI 0·53, 0·97); p = 0·033). INTERPRETATION As generally implemented, the CLIP intervention did not improve pregnancy outcomes; community implementation of the WHO eight contact model may be beneficial. FUNDING The University of British Columbia (PRE-EMPT), a grantee of the Bill & Melinda Gates Foundation (OPP1017337).",2020,"The primary outcome did not differ between intervention and control clusters (adjusted odds ratio (aOR) 1·31, 95% confidence interval (CI) [0·70, 2·48]; p = 0·40).","['pre-eclampsia (CLIP) in Mozambique', 'pregnant women in 12 administrative posts (clusters) in Maputo and Gaza Provinces', '15,013 women (15,123 pregnancies']","['CLIP intervention', 'task-sharing care', 'CLIP intervention (6 clusters) consisted of community engagement, community health worker-provided mobile health-guided clinical assessment, initial treatment, and referral to facility either urgently (<4hrs) or non-urgently', 'Community-level interventions', 'Mozambique Community-Level Interventions']","['maternal outcomes', 'composite of maternal, fetal, and newborn mortality and major morbidity', 'safety and evaluation of the intensity of CLIP contacts']","[{'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0026655', 'cui_str': 'Mozambique'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C1292785', 'cui_str': 'Administrative action'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C0026655', 'cui_str': 'Mozambique'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0015965', 'cui_str': 'Fetuses'}, {'cui': 'C0027616', 'cui_str': 'Neonatal Mortality'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}]",15013.0,0.295538,"The primary outcome did not differ between intervention and control clusters (adjusted odds ratio (aOR) 1·31, 95% confidence interval (CI) [0·70, 2·48]; p = 0·40).","[{'ForeName': 'Esperança', 'Initials': 'E', 'LastName': 'Sevene', 'Affiliation': 'Centro de Investigação em Saúde da Manhiça (CISM), Rua 12, Cambeve, Manhiça, CP 1929 Maputo, Mozambique; Faculdade de Medicina, Universidade Eduardo Mondlane, Av. Salvador Allende nr. 702, Maputo, Mozambique. Electronic address: esperanca.sevene@manhica.net.'}, {'ForeName': 'Sumedha', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver V6Z 2K8, Canada.'}, {'ForeName': 'Khátia', 'Initials': 'K', 'LastName': 'Munguambe', 'Affiliation': 'Centro de Investigação em Saúde da Manhiça (CISM), Rua 12, Cambeve, Manhiça, CP 1929 Maputo, Mozambique; Faculdade de Medicina, Universidade Eduardo Mondlane, Av. Salvador Allende nr. 702, Maputo, Mozambique.'}, {'ForeName': 'Charfudin', 'Initials': 'C', 'LastName': 'Sacoor', 'Affiliation': 'Centro de Investigação em Saúde da Manhiça (CISM), Rua 12, Cambeve, Manhiça, CP 1929 Maputo, Mozambique.'}, {'ForeName': 'Anifa', 'Initials': 'A', 'LastName': 'Vala', 'Affiliation': 'Centro de Investigação em Saúde da Manhiça (CISM), Rua 12, Cambeve, Manhiça, CP 1929 Maputo, Mozambique.'}, {'ForeName': 'Salésio', 'Initials': 'S', 'LastName': 'Macuacua', 'Affiliation': 'Centro de Investigação em Saúde da Manhiça (CISM), Rua 12, Cambeve, Manhiça, CP 1929 Maputo, Mozambique; Direcção Provincial de Saúde, Ministério da Saúde, Av. Eduardo Mondlane n(o) 1008, CP 264 Maputo, Mozambique.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Boene', 'Affiliation': 'Centro de Investigação em Saúde da Manhiça (CISM), Rua 12, Cambeve, Manhiça, CP 1929 Maputo, Mozambique.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Mark Ansermino', 'Affiliation': 'Centre for International Child Health, University of British Columbia, 305 - 4088 Cambie Street, Vancouver V5Z 2X8, Canada.'}, {'ForeName': 'Orvalho', 'Initials': 'O', 'LastName': 'Augusto', 'Affiliation': 'Centro de Investigação em Saúde da Manhiça (CISM), Rua 12, Cambeve, Manhiça, CP 1929 Maputo, Mozambique; Faculdade de Medicina, Universidade Eduardo Mondlane, Av. Salvador Allende nr. 702, Maputo, Mozambique.'}, {'ForeName': 'Cassimo', 'Initials': 'C', 'LastName': 'Bique', 'Affiliation': 'Departamento de Ginecologia e Obstetrícia, Hospital Central de Maputo, Av. Agostinho Neto n(o) 167, CP 1164 Maputo, Mozambique.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Bone', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver V6Z 2K8, Canada.'}, {'ForeName': 'Dustin T', 'Initials': 'DT', 'LastName': 'Dunsmuir', 'Affiliation': 'Centre for International Child Health, University of British Columbia, 305 - 4088 Cambie Street, Vancouver V5Z 2X8, Canada.'}, {'ForeName': 'Tang', 'Initials': 'T', 'LastName': 'Lee', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver V6Z 2K8, Canada.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver V6Z 2K8, Canada.'}, {'ForeName': 'Eusébio', 'Initials': 'E', 'LastName': 'Macete', 'Affiliation': 'Centro de Investigação em Saúde da Manhiça (CISM), Rua 12, Cambeve, Manhiça, CP 1929 Maputo, Mozambique; Instituto Nacional de Saúde, Ministério da Saúde, Distrito de Marracuene, Estrada Nacional N(o) 1, Maputo, Mozambique.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Singer', 'Affiliation': ""Centre for Health Evaluation and Outcome Sciences, Providence Health Care Research Institute, University of British Columbia, 588 - 1081 Burrard Street, St. Paul's Hospital, Vancouver V6Z 1Y6, Canada.""}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'Wong', 'Affiliation': ""Centre for Health Evaluation and Outcome Sciences, Providence Health Care Research Institute, University of British Columbia, 588 - 1081 Burrard Street, St. Paul's Hospital, Vancouver V6Z 1Y6, Canada.""}, {'ForeName': 'Hannah L', 'Initials': 'HL', 'LastName': 'Nathan', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, Faculty of Medicine and Life Sciences, King's College London, 1 Lambeth Place Road, London SE1 7EH, UK.""}, {'ForeName': 'Beth A', 'Initials': 'BA', 'LastName': 'Payne', 'Affiliation': 'Centre for International Child Health, University of British Columbia, 305 - 4088 Cambie Street, Vancouver V5Z 2X8, Canada.'}, {'ForeName': 'Mohsin', 'Initials': 'M', 'LastName': 'Sidat', 'Affiliation': 'Faculdade de Medicina, Universidade Eduardo Mondlane, Av. Salvador Allende nr. 702, Maputo, Mozambique.'}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Shennan', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, Faculty of Medicine and Life Sciences, King's College London, 1 Lambeth Place Road, London SE1 7EH, UK.""}, {'ForeName': 'Corssino', 'Initials': 'C', 'LastName': 'Tchavana', 'Affiliation': 'Centro de Investigação em Saúde da Manhiça (CISM), Rua 12, Cambeve, Manhiça, CP 1929 Maputo, Mozambique.'}, {'ForeName': 'Domena K', 'Initials': 'DK', 'LastName': 'Tu', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver V6Z 2K8, Canada.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Vidler', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver V6Z 2K8, Canada.'}, {'ForeName': 'Zulfiqar A', 'Initials': 'ZA', 'LastName': 'Bhutta', 'Affiliation': 'Centre for Global Child Health, Hospital for Sick Children, 525 University Avenue, Suite 702, Toronto M5G 2L3, Canada.'}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Magee', 'Affiliation': ""Department of Obstetrics and Gynaecology, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver V6Z 2K8, Canada; Department of Women and Children's Health, School of Life Course Sciences, Faculty of Medicine and Life Sciences, King's College London, 1 Lambeth Place Road, London SE1 7EH, UK.""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'von Dadelszen', 'Affiliation': ""Department of Obstetrics and Gynaecology, University of British Columbia, Suite 930, 1125 Howe Street, Vancouver V6Z 2K8, Canada; Department of Women and Children's Health, School of Life Course Sciences, Faculty of Medicine and Life Sciences, King's College London, 1 Lambeth Place Road, London SE1 7EH, UK.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Pregnancy hypertension,['10.1016/j.preghy.2020.05.006'] 1681,32472742,"Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.","NEPA is the only fixed combination antiemetic, comprised of an NK 1 RA (netupitant) and a 5-HT 3 RA (palonosetron). In the first head-to-head trial to compare NK 1 RA-containing regimens, a single oral dose of NEPA was non-inferior to a 3-day aprepitant/granisetron (APR/GRAN) regimen for the primary endpoint of overall (0-120 hours) complete response (no emesis/no rescue). This pre-specified analysis evaluates the efficacy of NEPA versus APR/GRAN in the subset of Chinese patients in the study. In addition, efficacy in patients at greatest emetic risk receiving high-dose cisplatin (≥70 mg/m 2 ) was explored. Chemotherapy-naïve patients with solid tumors in this randomized, double-blind study received either a single dose of NEPA prior to cisplatin-based chemotherapy or a 3-day regimen of APR/GRAN, both with dexamethasone on Days 1-4. Efficacy was evaluated through complete response, no emesis, and no significant nausea rates during the acute (0-24 hours), delayed (25-120 hours) and overall phases as well as individual days post-chemotherapy, as the daily course of CINV protection is often unstudied. The Chinese subset included 667 patients; of these, 363 (54%) received high-dose cisplatin. Baseline characteristics were comparable. While response rates were similar for NEPA and APR/GRAN during the acute, delayed and overall phases, significantly fewer NEPA patients experienced breakthrough CINV on individual Days 3-5 in both the Chinese patients and also in those receiving high-dose cisplatin. As a fixed oral NK 1 RA/5HT 3 RA combination given once/cycle, NEPA is a convenient highly effective prophylactic antiemetic that may offer better protection from CINV than a 3-day APR/GRAN regimen on Days 3-5 following highly emetogenic chemotherapy.",2020,"While response rates were similar for NEPA and APR/GRAN during the acute, delayed and overall phases, significantly fewer NEPA patients experienced breakthrough CINV on individual Days 3-5 in both the Chinese patients and also in those receiving high-dose cisplatin.","['The Chinese subset included 667 patients; of these, 363 (54%) received', 'naïve patients with solid tumors', 'Chinese patients in the study', 'Chinese patients receiving highly']","['NEPA prior to cisplatin-based chemotherapy', 'granisetron (APR/GRAN', 'Chemotherapy', 'high-dose cisplatin', 'dexamethasone', 'NEPA', 'cisplatin', 'NEPA versus APR/GRAN', 'emetogenic chemotherapy (HEC']","['breakthrough CINV', 'nausea and vomiting (CINV', 'response rates', 'Efficacy', 'complete response, no emesis', 'nausea rates']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517851', 'cui_str': '667'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0061863', 'cui_str': 'Granisetron'}, {'cui': 'C2004459', 'cui_str': 'Abdominoperineal resection'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0013973', 'cui_str': 'Emetic'}, {'cui': 'C0318598', 'cui_str': 'Human enteric calicivirus'}]","[{'cui': 'C0444503', 'cui_str': 'Breakthrough'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",5.0,0.202667,"While response rates were similar for NEPA and APR/GRAN during the acute, delayed and overall phases, significantly fewer NEPA patients experienced breakthrough CINV on individual Days 3-5 in both the Chinese patients and also in those receiving high-dose cisplatin.","[{'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Chang', 'Affiliation': 'Fudan University Shanghai Cancer Center, Shanghai, China.'}, {'ForeName': 'Gongyan', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Affiliated Tumour Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'The Third Affiliated Hospital of Third Military Medical University, Chongqing, China.'}, {'ForeName': 'Guihua', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'Changsha Central Hospital, Changsha, China.'}, {'ForeName': 'Shun', 'Initials': 'S', 'LastName': 'Lu', 'Affiliation': 'Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.'}, {'ForeName': 'Jifeng', 'Initials': 'J', 'LastName': 'Feng', 'Affiliation': 'Jiangsu Cancer Hospital, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'The First Affiliated Hospital of Jilin University, Changchun, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': 'West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Corinna', 'Initials': 'C', 'LastName': 'Lanzarotti', 'Affiliation': 'Helsinn Healthcare, Lugano, Switzerland.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Chessari', 'Affiliation': 'Helsinn Healthcare, Lugano, Switzerland.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Sun Yat-sen University Cancer Center, Guangzhou, China.'}]",Cancer medicine,['10.1002/cam4.3123'] 1682,32470370,Effect of Diclofenac Potassium Premedication on Postendodontic Pain in Mandibular Molars with Symptomatic Irreversible Pulpitis: A Randomized Placebo-Controlled Double-Blind Trial.,"INTRODUCTION The aim of this prospective, randomized, double-blind clinical trial was to evaluate the effect of a preoperative, single, oral dose of diclofenac potassium (DFK) on postoperative pain and rescue analgesic intake in patients with symptomatic irreversible pulpitis in mandibular molars treated in 1 visit. METHODS Seventy emergency patients with moderate to severe preoperative pain randomly received either 50 mg DFK or placebo tablets 1 hour before starting endodontic treatment (n = 35 per group). Patients recorded their pain level 6, 12, 24, and 48 hours after treatment on a 170-mm Heft-Parker visual analog scale. The incidence of rescue analgesic intake was also recorded. Outcome data were statistically analyzed using Mann-Whitney U, Friedman, Wilcoxon signed rank, and chi-square tests. Binary logistic regression assessed the association of predisposing factors with postoperative pain. The significance level (α) was set at 0.05. RESULTS Of the 70 patients, 68 were analyzed (n = 34 per group). Both groups had similar baseline characteristics (P > .05). DFK showed significantly less pain incidence and intensity than the placebo at 48 hours only (P < .05). A significant decrease occurred from 24 to 48 hours with DFK (P < .05), which was not recorded with the placebo (P > .05). No difference in the incidence of rescue analgesic intake was reported between groups (P > .05). Food intake timing, sex, and rescue analgesic intake were associated with postoperative pain (P < .05). CONCLUSIONS Premedication by a single, oral dose of 50 mg DFK could be effective in reducing postendodontic pain at 48 hours after 1-visit endodontic treatment in mandibular molars with symptomatic irreversible pulpitis.",2020,"Food-intake timing, gender, and rescue-analgesic intake were associated with postoperative pain (p<0.05). ","['70 patients', 'Mandibular Molars with Symptomatic Irreversible Pulpitis', 'patients with symptomatic irreversible pulpitis (SIP) in mandibular molars treated in one visit', 'Seventy emergency patients with moderate-to-severe preoperative pain randomly received either']","['Placebo', '50mg DFK or placebo tablets (PLC', 'diclofenac potassium', 'DFK', 'diclofenac potassium (DFK', 'Diclofenac Potassium Premedication']","['Postendodontic Pain', 'pain level', 'postoperative pain and rescue-analgesic intake', 'pain incidence and intensity', 'postendodontic pain', 'incidence of rescue-analgesic intake', '170-mm Heft-Parker visual analogue scale']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0282131', 'cui_str': 'Diclofenac potassium'}, {'cui': 'C0033045', 'cui_str': 'Premedication'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",70.0,0.553297,"Food-intake timing, gender, and rescue-analgesic intake were associated with postoperative pain (p<0.05). ","[{'ForeName': 'Amatallah Hussein', 'Initials': 'AH', 'LastName': 'Al-Rawhani', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Shaimaa Ismail', 'Initials': 'SI', 'LastName': 'Gawdat', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Suzan Abdul', 'Initials': 'SA', 'LastName': 'Wanees Amin', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Cairo University, Cairo, Egypt. Electronic address: suzan.wanis@dentistry.cu.edu.eg.'}]",Journal of endodontics,['10.1016/j.joen.2020.05.008'] 1683,32445440,Remdesivir for the Treatment of Covid-19 - Preliminary Report.,"BACKGROUND Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious. METHODS We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. RESULTS A total of 1063 patients underwent randomization. The data and safety monitoring board recommended early unblinding of the results on the basis of findings from an analysis that showed shortened time to recovery in the remdesivir group. Preliminary results from the 1059 patients (538 assigned to remdesivir and 521 to placebo) with data available after randomization indicated that those who received remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who received placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). The Kaplan-Meier estimates of mortality by 14 days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). Serious adverse events were reported for 114 of the 541 patients in the remdesivir group who underwent randomization (21.1%) and 141 of the 522 patients in the placebo group who underwent randomization (27.0%). CONCLUSIONS Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACCT-1 ClinicalTrials.gov number, NCT04280705.).",2020,"CONCLUSIONS Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection.","['1059 patients (538 assigned to remdesivir and 521 to', 'adults hospitalized with Covid-19 and evidence of lower respiratory tract infection', '1063 patients underwent randomization', 'adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement']","['remdesivir', 'intravenous remdesivir', 'placebo']","['median recovery time', 'time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only', 'Serious adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C4726677', 'cui_str': 'remdesivir'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0149725', 'cui_str': 'Lower respiratory tract infection'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0458579', 'cui_str': 'Lower respiratory tract structure'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}]","[{'cui': 'C4726677', 'cui_str': 'remdesivir'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0085557', 'cui_str': 'Infection control procedure'}, {'cui': 'C1285529', 'cui_str': 'Purpose'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",1063.0,0.687871,"CONCLUSIONS Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection.","[{'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Beigel', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Kay M', 'Initials': 'KM', 'LastName': 'Tomashek', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Lori E', 'Initials': 'LE', 'LastName': 'Dodd', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Aneesh K', 'Initials': 'AK', 'LastName': 'Mehta', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Barry S', 'Initials': 'BS', 'LastName': 'Zingman', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Andre C', 'Initials': 'AC', 'LastName': 'Kalil', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Hohmann', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Helen Y', 'Initials': 'HY', 'LastName': 'Chu', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Annie', 'Initials': 'A', 'LastName': 'Luetkemeyer', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Kline', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Lopez de Castilla', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Finberg', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Kerry', 'Initials': 'K', 'LastName': 'Dierberg', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Tapson', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Lanny', 'Initials': 'L', 'LastName': 'Hsieh', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Thomas F', 'Initials': 'TF', 'LastName': 'Patterson', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Paredes', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Sweeney', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'William R', 'Initials': 'WR', 'LastName': 'Short', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Giota', 'Initials': 'G', 'LastName': 'Touloumi', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'David Chien', 'Initials': 'DC', 'LastName': 'Lye', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Norio', 'Initials': 'N', 'LastName': 'Ohmagari', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Myoung-Don', 'Initials': 'MD', 'LastName': 'Oh', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Guillermo M', 'Initials': 'GM', 'LastName': 'Ruiz-Palacios', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Benfield', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Gerd', 'Initials': 'G', 'LastName': 'Fätkenheuer', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Mark G', 'Initials': 'MG', 'LastName': 'Kortepeter', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Atmar', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'C Buddy', 'Initials': 'CB', 'LastName': 'Creech', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Lundgren', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Abdel G', 'Initials': 'AG', 'LastName': 'Babiker', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Pett', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Neaton', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Timothy H', 'Initials': 'TH', 'LastName': 'Burgess', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Tyler', 'Initials': 'T', 'LastName': 'Bonnett', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Green', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Mat', 'Initials': 'M', 'LastName': 'Makowski', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Anu', 'Initials': 'A', 'LastName': 'Osinusi', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Seema', 'Initials': 'S', 'LastName': 'Nayak', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'H Clifford', 'Initials': 'HC', 'LastName': 'Lane', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa2007764'] 1684,32467339,Particle depletion of diesel exhaust restores allergen-induced lung-protective surfactant protein D in human lungs.,"RATIONALE Exposure to air pollution is linked with increased asthma morbidity and mortality. To understand pathological processes linking air pollution and allergen exposures to asthma pathophysiology, we investigated the effect of coexposure to diesel exhaust (DE) and aeroallergen on immune regulatory proteins in human airways. METHODS Fourteen allergen-sensitised participants completed this randomised, double-blinded, cross-over, controlled exposure study. Each participant underwent four exposures (allergen-alone exposure, DE and allergen coexposure, particle-depleted DE (PDDE) and allergen coexposure, and sham exposure) on different order-randomised dates, each separated by a 4-week washout. Serum and bronchoalveolar lavage (BAL) were assayed for pattern recognition molecules, cytokines, chemokines and inflammatory mediators. RESULTS In human airways, allergen-alone exposure led to accumulation of surfactant protein D (SPD; p=0.02). Coexposure to allergen and DE did not elicit the same increase of SPD as did allergen alone; diesel particulate reduction restored allergen-induced SPD accumulation. Soluble receptor for advanced glycation end products was higher with particle reduction than without it. In the systemic circulation, there was a transient increase in SPD and club cell protein 16 (CC16) 4 hours after allergen alone. CC16 was augmented by PDDE, but not DE. % eosinophils in BAL (p<0.005), eotaxin-3 (p<0.0001), interleukin 5 (IL-5; p<0.0001) and thymus and activation regulated chemokine (p=0.0001) were each increased in BAL by allergen. IL-5, SPD and % eosinophils in BAL were correlated with decreased FEV 1 . CONCLUSION Short-term coexposure to aeroallergen and DE alters immune regulatory proteins in lungs; surfactant levels are dependent on particle depletion. TRIAL REGISTRATION NUMBER NCT02017431.",2020,"% eosinophils in BAL (p<0.005), eotaxin-3 (p<0.0001), interleukin 5 (IL-5; p<0.0001) and thymus and activation regulated chemokine (p=0.0001) were each increased in BAL by allergen.","['human airways', 'Fourteen allergen-sensitised participants', 'human lungs']","['four exposures (allergen-alone exposure, DE and allergen coexposure, particle-depleted DE (PDDE) and allergen coexposure, and sham exposure', 'coexposure to diesel exhaust (DE', 'diesel exhaust restores allergen-induced lung-protective surfactant protein D']","['CC16', 'asthma morbidity and mortality', 'IL-5, SPD and % eosinophils in BAL', 'Serum and bronchoalveolar lavage (BAL', 'SPD and club cell protein']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0002092', 'cui_str': 'Allergen'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}]","[{'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0002092', 'cui_str': 'Allergen'}, {'cui': 'C0012151', 'cui_str': 'Diesel Exhaust'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0084692', 'cui_str': 'Surfactant Protein D'}]","[{'cui': 'C0225668', 'cui_str': 'Clara cell of bronchiole'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0021759', 'cui_str': 'Interleukin-5'}, {'cui': 'C0084692', 'cui_str': 'Surfactant Protein D'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil'}, {'cui': 'C1535502', 'cui_str': 'Bronchoalveolar lavage'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",,0.106351,"% eosinophils in BAL (p<0.005), eotaxin-3 (p<0.0001), interleukin 5 (IL-5; p<0.0001) and thymus and activation regulated chemokine (p=0.0001) were each increased in BAL by allergen.","[{'ForeName': 'Min Hyung', 'Initials': 'MH', 'LastName': 'Ryu', 'Affiliation': 'Air Pollution Exposure Laboratory, Department of Medicine, Vancouver Coastal Health Research Institute, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Kevin Soon-Keen', 'Initials': 'KS', 'LastName': 'Lau', 'Affiliation': 'Air Pollution Exposure Laboratory, Department of Medicine, Vancouver Coastal Health Research Institute, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Denise Jill', 'Initials': 'DJ', 'LastName': 'Wooding', 'Affiliation': 'Air Pollution Exposure Laboratory, Department of Medicine, Vancouver Coastal Health Research Institute, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Shuyu', 'Initials': 'S', 'LastName': 'Fan', 'Affiliation': 'Air Pollution Exposure Laboratory, Department of Medicine, Vancouver Coastal Health Research Institute, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Don D', 'Initials': 'DD', 'LastName': 'Sin', 'Affiliation': ""Centre for Heart Lung Innovation, St. Paul's Hospital, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada.""}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Carlsten', 'Affiliation': 'Air Pollution Exposure Laboratory, Department of Medicine, Vancouver Coastal Health Research Institute, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada carlsten@mail.ubc.ca.'}]",Thorax,['10.1136/thoraxjnl-2020-214561'] 1685,32463741,Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.,"PURPOSE NCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile-driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with tumors harboring actionable aberration(s) in fibroblast growth factor receptor ( FGFR ) 1-3 were treated with AZD4547, an oral FGFR1-3 inhibitor. METHODS Patients' tumors were screened by next-generation sequencing for predefined FGFR amplification, activating mutations, or fusions. Patients were treated with AZD4547, 80 mg orally twice daily until progression of disease or drug intolerance. A response rate of 16% was considered promising. RESULTS Between July 2016 and June 2017, 70 patients were assigned and 48 received protocol therapy and are eligible for analysis. Patients' tumors harbored FGFR1 or FGFR2 amplification (n = 20), FGFR2 or FGFR3 single-nucleotide variants (n = 19), or FGFR1 or FGFR3 fusions (n = 9). The most common primary tumors were breast (33.3%), urothelial (12.5%), and cervical cancer (10.4%).Grade 3 adverse events were consistent with those described in previous clinical trials. Confirmed partial responses were seen in 8% (90% CI, 3% to 18%) and were observed only in patients whose tumors harbored FGFR1-3 point mutations or fusions. Stable disease was observed in 37.5% (90% CI, 25.8% to 50.4%). The median progression-free survival (PFS) was 3.4 months, and the 6-month PFS rate was 15% (90% CI, 8% to 31%). For patients with tumors harboring FGFR fusions, the response rate was 22% (90% CI, 4.1% to 55%), and 6-month PFS rate was 56% (90% CI, 31% to 100%). CONCLUSION Preliminary signals of activity appeared to be limited to cancers harboring FGFR activating mutations and fusions, although AZD4547 did not meet the primary end point. Different FGFR somatic alterations may confer different levels of signaling potency and/or oncogene dependence.",2020,FGFR3 ,"[""Patients' tumors were screened by next-generation sequencing for predefined FGFR amplification, activating mutations, or fusions"", 'Patients With Tumors Harboring Aberrations in the FGFR Pathway', ""Patients' tumors harbored FGFR1 or FGFR2 amplification (n = 20), FGFR2 or"", 'patients with refractory cancers, lymphomas, or myelomas', 'Patients with tumors harboring actionable aberration(s', 'Between July 2016 and June 2017, 70 patients were assigned and 48 received']","['FGFR1 or FGFR3 fusions', 'AZD4547', 'protocol therapy', 'FGFR3', 'AZD4547, an oral FGFR1-3 inhibitor', 'fibroblast growth factor receptor']","['Stable disease', 'median progression-free survival (PFS', 'cervical cancer', '6-month PFS rate', 'response rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C2936621', 'cui_str': 'Next-Generation Sequencing'}, {'cui': 'C0060369', 'cui_str': 'Fibroblast Growth Factor Receptors'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0475311', 'cui_str': 'Harbor'}, {'cui': 'C1527757', 'cui_str': 'FGFR1 protein, human'}, {'cui': 'C0209706', 'cui_str': 'Fibroblast Growth Factor Receptor 2'}, {'cui': 'C0677936', 'cui_str': 'Refractory cancer'}, {'cui': 'C0024299', 'cui_str': 'Malignant lymphoma'}, {'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C1527757', 'cui_str': 'FGFR1 protein, human'}, {'cui': 'C0527057', 'cui_str': 'FGFR3 protein, human'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C2981795', 'cui_str': 'AZD4547'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0060369', 'cui_str': 'Fibroblast Growth Factor Receptors'}]","[{'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",70.0,0.037636,FGFR3 ,"[{'ForeName': 'Young K', 'Initials': 'YK', 'LastName': 'Chae', 'Affiliation': 'Northwestern University, Chicago, IL.'}, {'ForeName': 'Fangxin', 'Initials': 'F', 'LastName': 'Hong', 'Affiliation': 'Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.'}, {'ForeName': 'Christos', 'Initials': 'C', 'LastName': 'Vaklavas', 'Affiliation': 'University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Heather H', 'Initials': 'HH', 'LastName': 'Cheng', 'Affiliation': 'Seattle Cancer Center Alliance, Seattle, WA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hammerman', 'Affiliation': 'Dana Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Edith P', 'Initials': 'EP', 'LastName': 'Mitchell', 'Affiliation': 'Thomas Jefferson University Hospital, Philadelphia, PA.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Zwiebel', 'Affiliation': 'Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.'}, {'ForeName': 'S Percy', 'Initials': 'SP', 'LastName': 'Ivy', 'Affiliation': 'Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Gray', 'Affiliation': 'Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.'}, {'ForeName': 'Shuli', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.'}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'McShane', 'Affiliation': 'Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.'}, {'ForeName': 'Larry V', 'Initials': 'LV', 'LastName': 'Rubinstein', 'Affiliation': 'Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Patton', 'Affiliation': 'Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.'}, {'ForeName': 'P Mickey', 'Initials': 'PM', 'LastName': 'Williams', 'Affiliation': 'Frederick National Laboratory for Cancer Research, Frederick, MD.'}, {'ForeName': 'Stanley R', 'Initials': 'SR', 'LastName': 'Hamilton', 'Affiliation': 'MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Mansfield', 'Affiliation': 'Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Conley', 'Affiliation': 'Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.'}, {'ForeName': 'Carlos L', 'Initials': 'CL', 'LastName': 'Arteaga', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'Lyndsay N', 'Initials': 'LN', 'LastName': 'Harris', 'Affiliation': 'Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': ""O'Dwyer"", 'Affiliation': 'University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Alice P', 'Initials': 'AP', 'LastName': 'Chen', 'Affiliation': 'Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.'}, {'ForeName': 'Keith T', 'Initials': 'KT', 'LastName': 'Flaherty', 'Affiliation': 'Massachusetts General Hospital, Boston, MA.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.02630'] 1686,32472801,Prophylactic Intrathecal Morphine and Prevention of Post-Dural Puncture Headache: A Randomized Double-blind Trial: Erratum.,,2020,,['Post-Dural Puncture Headache'],['Prophylactic Intrathecal Morphine'],[],"[{'cui': 'C0270697', 'cui_str': 'Headache following lumbar puncture'}]","[{'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0677897', 'cui_str': 'Intrathecal route'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]",[],,0.674421,,[],Anesthesiology,['10.1097/ALN.0000000000003411'] 1687,32471186,Vitamin E-Bonded Membranes Do Not Influence Markers of Oxidative Stress in Hemodialysis Patients with Homozygous Glutathione Transferase M1 Gene Deletion.,"BACKGROUND Increased oxidative stress is a hallmark of end-stage renal disease. Hemodialysis (HD) patients lacking glutathione transferase M1 (GSTM1) enzyme activity exhibit enhanced oxidative DNA damage and higher mortality rate than those with active GSTM1 enzyme. To our knowledge, this is the first study to use the vitamin E-bonded membranes (VEM) in patients with homozygous GSTM1 gene deletion, and we aimed to determine the effect of VEM on oxidative and inflammatory status in HD patients with homozygous GSTM1 gene deletion. METHODS GSTM1 genotypes were determined by polymerase chain reaction (PCR) in 170 chronic HD patients. Those with GSTM1-null genotype were randomized and 80 were included in the study. Forty of them were dialyzed for three months with VEM, while the other forty were dialyzed with high-flux same-surface polysulfone dialyzers. Markers of protein and lipid oxidative damage and inflammation (thiol groups, malondialdehyde (MDA), Interleukin-6 (IL-6)), together with plasma antioxidant activity (glutathione peroxidase (GPX), superoxide dismutase (SOD)) were determined. RESULTS Seventy-five patients finished the study. There were no differences at baseline in markers of protein and lipid oxidative damage, inflammation and plasma antioxidant activity. After three months of therapy, GPX, MDA, and thiol groups increased significantly in both groups, but without statistical significance between groups. SOD and C reactive protein (CRP) did not change significantly during the three-month period. IL-6 increased in the control group, and at the same time, decreased in the VEM group, but without statistical significance. Hemoglobin (Hb) value, red blood cells, erythropoiesis resistance index (ERI), serum ferritin and iron did not change significantly within or between groups. Regarding other laboratory parameters, proteins, albumins, triglycerides, serum phosphorus, serum bicarbonate and Kt/V showed significant improvements within groups but with no significant difference between groups. CONCLUSIONS Our data shows that therapy with VEM over three months had no benefit over standard polysulfone membrane in decreasing by-products of oxidative stress and inflammation in dialysis patients lacking GSTM1 enzyme activity.",2020,"After three months of therapy, GPX, MDA, and thiol groups increased significantly in both groups, but without statistical significance between groups.","['Seventy-five patients finished the study', '170 chronic HD patients', 'Hemodialysis Patients with Homozygous Glutathione Transferase M1 Gene Deletion', 'patients with homozygous GSTM1 gene deletion', 'Those with GSTM1-null genotype were randomized and 80 were included in the study', 'HD patients with homozygous GSTM1 gene deletion']","['VEM', 'Vitamin E-Bonded Membranes', 'polymerase chain reaction (PCR', 'vitamin E-bonded membranes (VEM']","['Hemoglobin (Hb) value, red blood cells, erythropoiesis resistance index (ERI), serum ferritin and iron', 'Markers of protein and lipid oxidative damage and inflammation (thiol groups, malondialdehyde (MDA), Interleukin-6 (IL-6)), together with plasma antioxidant activity (glutathione peroxidase (GPX), superoxide dismutase (SOD', 'Oxidative Stress', 'SOD and C reactive protein (CRP', 'markers of protein and lipid oxidative damage, inflammation and plasma antioxidant activity', 'IL-6', 'triglycerides, serum phosphorus, serum bicarbonate and Kt/V']","[{'cui': 'C4319621', 'cui_str': '75'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1706059', 'cui_str': 'Finish'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C1740835', 'cui_str': 'Chronic haemodialysis'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0019904', 'cui_str': 'Homozygote'}, {'cui': 'C0017837', 'cui_str': 'Glutathione transferase'}, {'cui': 'C0017260', 'cui_str': 'Gene deletion'}, {'cui': 'C1738886', 'cui_str': 'GSTM1 protein, human'}, {'cui': 'C0456148', 'cui_str': 'Null'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0014819', 'cui_str': 'Erythrocyte production'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0696113', 'cui_str': 'Serum ferritin measurement'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0038734', 'cui_str': 'Sulfhydryls'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0017822', 'cui_str': 'Glutathione peroxidase'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0428301', 'cui_str': 'Serum bicarbonate measurement'}, {'cui': 'C0429662', 'cui_str': 'kt/V'}]",170.0,0.0267835,"After three months of therapy, GPX, MDA, and thiol groups increased significantly in both groups, but without statistical significance between groups.","[{'ForeName': 'Petar', 'Initials': 'P', 'LastName': 'Djuric', 'Affiliation': 'Clinical Department for Renal Diseases, Zvezdara University Medical Center, 11000 Belgrade, Serbia.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Suvakov', 'Affiliation': 'Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.'}, {'ForeName': 'Tatjana', 'Initials': 'T', 'LastName': 'Simic', 'Affiliation': 'Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.'}, {'ForeName': 'Dragana', 'Initials': 'D', 'LastName': 'Markovic', 'Affiliation': 'Clinical Department for Renal Diseases, Zvezdara University Medical Center, 11000 Belgrade, Serbia.'}, {'ForeName': 'Djurdja', 'Initials': 'D', 'LastName': 'Jerotic', 'Affiliation': 'Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.'}, {'ForeName': 'Aleksandar', 'Initials': 'A', 'LastName': 'Jankovic', 'Affiliation': 'Clinical Department for Renal Diseases, Zvezdara University Medical Center, 11000 Belgrade, Serbia.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Bulatovic', 'Affiliation': 'Clinical Department for Renal Diseases, Zvezdara University Medical Center, 11000 Belgrade, Serbia.'}, {'ForeName': 'Jelena', 'Initials': 'J', 'LastName': 'Tosic Dragovic', 'Affiliation': 'Clinical Department for Renal Diseases, Zvezdara University Medical Center, 11000 Belgrade, Serbia.'}, {'ForeName': 'Tatjana', 'Initials': 'T', 'LastName': 'Damjanovic', 'Affiliation': 'Clinical Department for Renal Diseases, Zvezdara University Medical Center, 11000 Belgrade, Serbia.'}, {'ForeName': 'Jelena', 'Initials': 'J', 'LastName': 'Marinkovic', 'Affiliation': 'Institute of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.'}, {'ForeName': 'Radomir', 'Initials': 'R', 'LastName': 'Naumovic', 'Affiliation': 'Clinical Department for Renal Diseases, Zvezdara University Medical Center, 11000 Belgrade, Serbia.'}, {'ForeName': 'Nada', 'Initials': 'N', 'LastName': 'Dimkovic', 'Affiliation': 'Clinical Department for Renal Diseases, Zvezdara University Medical Center, 11000 Belgrade, Serbia.'}]",Toxins,['10.3390/toxins12060352'] 1688,31811497,"Comparison of the effect of photobiomodulation therapy and Ibuprofen on postoperative pain after endodontic treatment: randomized, controlled, clinical study.","The aim of the study was to compare the effect of Ibuprofen and the application of photobiomodulation therapy protocol on the reduction of postoperative pain in endodontically treated teeth using a randomized clinical trial design. Seventy patients, diagnosed with symptomatic irreversible pulpitis, were selected. Treatment was performed by a single operator; a reciprocal system was used to prepare the canals; they were obturated using the Tagger's hybrid technique and coronally sealed with glass-ionomer cement. After treatment, patients were randomly divided into 2 groups. In the active control group, two Ibuprofen 600 mg tablets were administered within a 12-h interval. In the photobiomodulation therapy group, the irradiation was applied after treatment. The evaluation of postoperative pain was performed by another researcher blinded to the groups at 6, 12, 24, and 72 h intervals after treatment. To measure the outcome, two pain scales were used: numerical rate scale (NRS) and verbal rate scale (VRS). Data were analyzed using the chi-square, Mann-Whitney, and Wilcoxon paired tests. Outcome was superior with photobiomodulation therapy at 6 h (p < 0.001), 12 h (p = 0.005), and 24 h (p < 0.001) intervals compared with Ibuprofen. The results for the 72 h (p = 0.317) interval were similar, both in the VRS and NRS scales. It may be concluded that the use of photobiomodulation therapy was effective in reducing pain within the first 24 h when compared with the administration of Ibuprofen 600 mg.",2020,"Outcome was superior with photobiomodulation therapy at 6 h (p < 0.001), 12 h (p = 0.005), and 24 h (p < 0.001) intervals compared with Ibuprofen.","['Seventy patients, diagnosed with symptomatic irreversible pulpitis']","['photobiomodulation therapy protocol', 'Ibuprofen', 'photobiomodulation therapy', 'photobiomodulation therapy and Ibuprofen', ""Tagger's hybrid technique and coronally sealed with glass-ionomer cement""]","['postoperative pain', 'numerical rate scale (NRS) and verbal rate scale (VRS', 'pain']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}]","[{'cui': 'C4019433', 'cui_str': 'Photobiomodulation Therapy'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0007597', 'cui_str': 'Cell hybridization'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0036492', 'cui_str': 'Seal'}, {'cui': 'C0017597', 'cui_str': 'Glass-ionomer dental material'}]","[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.0399194,"Outcome was superior with photobiomodulation therapy at 6 h (p < 0.001), 12 h (p = 0.005), and 24 h (p < 0.001) intervals compared with Ibuprofen.","[{'ForeName': 'Eduardo Costa', 'Initials': 'EC', 'LastName': 'Nunes', 'Affiliation': 'Dental School, Federal University of Amazonas, R. Mins Waldemar Pedrosa, n. 1539, Praça 14 de Janeiro, Manaus, AM, 69025-050, Brazil.'}, {'ForeName': 'Fernando José', 'Initials': 'FJ', 'LastName': 'Herkrath', 'Affiliation': 'Leônidas & Maria Deane Institute, Oswaldo Cruz Foundation, Manaus, Brazil.'}, {'ForeName': 'Eduardo Hideki', 'Initials': 'EH', 'LastName': 'Suzuki', 'Affiliation': 'Dental School, Federal University of Amazonas, R. Mins Waldemar Pedrosa, n. 1539, Praça 14 de Janeiro, Manaus, AM, 69025-050, Brazil.'}, {'ForeName': 'Erivan Clementino', 'Initials': 'EC', 'LastName': 'Gualberto Júnior', 'Affiliation': 'Dental School, Federal University of Amazonas, R. Mins Waldemar Pedrosa, n. 1539, Praça 14 de Janeiro, Manaus, AM, 69025-050, Brazil.'}, {'ForeName': 'André Augusto Franco', 'Initials': 'AAF', 'LastName': 'Marques', 'Affiliation': 'Dental School, Federal University of Amazonas, R. Mins Waldemar Pedrosa, n. 1539, Praça 14 de Janeiro, Manaus, AM, 69025-050, Brazil.'}, {'ForeName': 'Emílio Carlos', 'Initials': 'EC', 'LastName': 'Sponchiado Júnior', 'Affiliation': 'Dental School, Federal University of Amazonas, R. Mins Waldemar Pedrosa, n. 1539, Praça 14 de Janeiro, Manaus, AM, 69025-050, Brazil. spemilio@ufam.edu.br.'}]",Lasers in medical science,['10.1007/s10103-019-02929-8'] 1689,32478879,Pigmentation effects of blue light irradiation on skin and how to protect against them.,"BACKGROUND Visible light, in particular blue light, has been identified as an additional contributor to cutaneous photoageing. However, clinical studies demonstrating the clear effect of blue light on photoageing are still scarce, and so far, most studies have focused on broad-spectrum visible light. Although there is evidence for increased skin pigmentation, the underlying mechanisms of photoageing in vivo are still unclear. Furthermore, there is still a need for active ingredients to significantly protect against blue light-induced hyperpigmentation in vivo. Our study had two aims: to detect visible changes in skin pigmentation following repeated irradiation of the skin with LED-based blue light and to reduce pigmentation using suitable active ingredients. METHOD We conducted a randomized, double-blind and placebo-controlled clinical study on 33 female volunteers with skin phototypes III and IV. We used a repetitive blue light (4 × 60 J cm -2 , 450 nm) irradiation protocol on the volunteers' inner forearms. Using hyperspectral imaging, we assessed chromophore status. In addition, we took chromameter measurements and photographs to assess visible hyperpigmentation. RESULTS We measured significant changes in chromophore status (P < 0.001 vs baseline), that is of melanin, haemoglobin and oxygen saturation, immediately after blue light irradiation. In addition, we found visible skin colour changes which were expressed by a significant decrease in ITA° values (delta ITA° = -16.89, P < 0.001 vs baseline for the placebo group) and an increase in a* (delta a* = +3.37, P < 0.001 vs baseline for the placebo group) 24 h post-irradiation. Hyperpigmentation and skin reddening were mitigated by both a formulation containing 3% of a microalgal product and a formulation containing 3% niacinamide. CONCLUSION Our study sets out an efficient and robust protocol for investigating both blue light-induced cutaneous alterations, such as changes in skin chromophores, and signs of photoageing, such as hyperpigmentation. Moreover, we have shown evidence that both an extract of the microalga Scenedesmus rubescens and niacinamide (vitamin B3) have the potential to protect against blue light-induced hyperpigmentation.",2020,"Hyperpigmentation and skin reddening were mitigated by both a formulation containing 3% of a microalgal product and a formulation containing 3% niacinamide. ",['33 female volunteers with skin phototypes III and IV'],"['placebo', 'repeated irradiation of the skin with LED-based blue light', 'repetitive blue light (4x 60 J cm -2 , 450 nm) irradiation protocol', 'blue light irradiation']","['ITA° values (delta ITA° ', 'skin pigmentation', 'chromophore status', 'Hyperpigmentation and skin reddening', 'melanin, hemoglobin and oxygen saturation', 'visible skin color changes']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0303896', 'cui_str': 'Blue light'}, {'cui': 'C3844104', 'cui_str': '450'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0022275', 'cui_str': 'Italian language'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0037290', 'cui_str': 'Skin pigmentation'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0162834', 'cui_str': 'Hyperpigmentation'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0025196', 'cui_str': 'Melanin'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0205379', 'cui_str': 'Visible'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",33.0,0.0481121,"Hyperpigmentation and skin reddening were mitigated by both a formulation containing 3% of a microalgal product and a formulation containing 3% niacinamide. ","[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Campiche', 'Affiliation': 'DSM Nutritional Products, Personal Care & Aroma, Wurmisweg 576, Kaiseraugst, 4303, Switzerland.'}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Curpen', 'Affiliation': 'Centre International de Développement Pharmaceutique (CIDP), BioPark Mauritius, SOCOTA Phoenicia, Sayed Hossen Road, Phoenix, 73408, Mauritius.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Lutchmanen-Kolanthan', 'Affiliation': 'Centre International de Développement Pharmaceutique (CIDP), BioPark Mauritius, SOCOTA Phoenicia, Sayed Hossen Road, Phoenix, 73408, Mauritius.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Gougeon', 'Affiliation': 'Newtone Technologies, 13 bis Place Jules Ferry, Lyon, 69006, France.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Cherel', 'Affiliation': 'Newtone Technologies, 13 bis Place Jules Ferry, Lyon, 69006, France.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Laurent', 'Affiliation': 'DSM Nutritional Products, Personal Care & Aroma, Wurmisweg 576, Kaiseraugst, 4303, Switzerland.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gempeler', 'Affiliation': 'DSM Nutritional Products, Personal Care & Aroma, Wurmisweg 576, Kaiseraugst, 4303, Switzerland.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Schuetz', 'Affiliation': 'DSM Nutritional Products, Personal Care & Aroma, Wurmisweg 576, Kaiseraugst, 4303, Switzerland.'}]",International journal of cosmetic science,['10.1111/ics.12637'] 1690,32683574,Intimate Partner Violence and Food Insecurity Predict Early Behavior Problems Among South African Children over 5-years Post-Birth.,"Households experiencing intimate partner violence (IPV) and food insecurity are at high risk of lifelong physical and behavioral difficulties. Longitudinal data from a perinatal home-visiting cluster-randomized controlled intervention trial in South Africa townships were used to examine the relationships between household settings and mothers' histories of risk and children's behavior problems at 3 and 5 years of age. IPV, food insecurity, maternal depressed mood, and geriatric pregnancy (at age of 35 or older) were consistently associated with children's internalizing and externalizing behavior problems. Aggressive behavior was more prevalent among 3- and 5-year olds boys, and was associated with maternal alcohol use. The effects of these factors on child behavior were more prominent than maternal HIV status. There is a continuing need to reduce IPV and household food insecurity, as well as supporting older, depressed, alcohol using mothers in order to address children's behavioral needs.",2020,"Aggressive behavior was more prevalent among 3- and 5-year olds boys, and was associated with maternal alcohol use.","['South African Children over 5-years Post-Birth', 'Households experiencing intimate partner violence (IPV', ""mothers' histories of risk and children's behavior problems at 3 and 5\xa0years of age"", 'Longitudinal data from a perinatal home-visiting cluster-randomized controlled intervention trial in South Africa townships']",[],"[""children's internalizing and externalizing behavior problems"", 'IPV, food insecurity, maternal depressed mood, and geriatric pregnancy', 'child behavior', 'Aggressive behavior']","[{'cui': 'C0027567', 'cui_str': 'African race'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0474413', 'cui_str': 'Problematic behavior in children'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0178795', 'cui_str': 'Perinatal period'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0037712', 'cui_str': 'South Africa'}]",[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C3494174', 'cui_str': 'Food insecurity'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0344315', 'cui_str': 'Depressed mood'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0008065', 'cui_str': 'Behavior, Child'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}]",,0.0324837,"Aggressive behavior was more prevalent among 3- and 5-year olds boys, and was associated with maternal alcohol use.","[{'ForeName': 'Panteha', 'Initials': 'P', 'LastName': 'Hayati Rezvan', 'Affiliation': 'Global Centre for Children and Families, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, The University of California, 10920 Wilshire Blvd., Los Angeles, USA. phayatirevan@mednet.ucla.edu.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Tomlinson', 'Affiliation': 'Department of Global Health, Institute for Life Course Health Research, Stellenbosch University, Cape Town, South Africa.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Christodoulou', 'Affiliation': 'Global Centre for Children and Families, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, The University of California, 10920 Wilshire Blvd., Los Angeles, USA.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Almirol', 'Affiliation': 'Global Centre for Children and Families, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, The University of California, 10920 Wilshire Blvd., Los Angeles, USA.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Stewart', 'Affiliation': 'Department of Global Health, Institute for Life Course Health Research, Stellenbosch University, Cape Town, South Africa.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Gordon', 'Affiliation': 'Department of Global Health, Institute for Life Course Health Research, Stellenbosch University, Cape Town, South Africa.'}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Belin', 'Affiliation': 'Global Centre for Children and Families, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, The University of California, 10920 Wilshire Blvd., Los Angeles, USA.'}, {'ForeName': 'Mary Jane', 'Initials': 'MJ', 'LastName': 'Rotheram-Borus', 'Affiliation': 'Global Centre for Children and Families, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, The University of California, 10920 Wilshire Blvd., Los Angeles, USA.'}]",Child psychiatry and human development,['10.1007/s10578-020-01025-1'] 1691,32477208,Training Positive Rumination in Expressive Writing to Enhance Psychological Adjustment and Working Memory Updating for Maladaptive Ruminators.,"Rumination is associated with psychological adjustment and working memory (WM) capacity. Studies have shown that psychological interventions can reduce negative rumination and improve psychological adjustment and WM capacity. The present study investigated the effect of positive rumination training in expressive writing on psychological adjustment and WM updating capacity. Within an experimental design, positive rumination was manipulated for 10 participants who were maladaptive ruminators in an experiment using a 5-week training compared to the control group with nine participants. Results revealed significant enhancement of psychological adjustment and the response time (RT) of WM updating in the experimental group but not in the control group. The two groups did not show significant difference of all the variables in pretest. However, the experimental group showed significantly better outcomes than the control group in posttest. The results suggest that positive rumination training in expressive writing is effective and rumination has a causal influence on WM updating capacity.",2020,Results revealed significant enhancement of psychological adjustment and the response time (RT) of WM updating in the experimental group but not in the control group.,['10 participants who were maladaptive ruminators in an experiment using a 5-week training compared to the control group with nine participants'],['positive rumination training'],"['psychological adjustment and working memory (WM) capacity', 'psychological adjustment and the response time (RT) of WM updating', 'negative rumination and improve psychological adjustment and WM capacity']","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0557904', 'cui_str': 'Emotional adjustment'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",10.0,0.0192719,Results revealed significant enhancement of psychological adjustment and the response time (RT) of WM updating in the experimental group but not in the control group.,"[{'ForeName': 'Hongfei', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Department of Psychology and Behavioral Sciences, Zhejiang University, Hangzhou, China.'}, {'ForeName': 'Huizhong', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Psychology and Behavioral Sciences, Zhejiang University, Hangzhou, China.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.00789'] 1692,32483056,Acupuncture of different treatment frequencies in knee osteoarthritis: a pilot randomised controlled trial.,"This 16-week randomised controlled trial (8-week treatment followed by 8-week follow-up) evaluated the symptomatic improvement in patients with knee osteoarthritis on 3 sessions per week of acupuncture (TSWA) compared to 1 session per week of acupuncture (OSWA). Sixty participants were randomised to either the TSWA or the OSWA group in a 1:1 ratio. The primary outcome was response rate, defined as the percentage of participants achieving ≥2 points decrease on the numerical rating scale (NRS) and ≥6 points decrease in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function score at week 8 compared with baseline. Additional outcomes included response rates at weeks 4 and 16, NRS, WOMAC, Patient Global Assessment, 12-item Short Form Health Survey (SF-12), and treatment credibility and expectancy. No significant difference was seen in response rate between TSWA and OSWA groups at week 8 (64.7% vs 50.0%; difference, 14.7 percentage points [95% CI, -10.1 to 39.4 percentage points], P = 0.435). At weeks 4 and 16, the TSWA group had higher response rates than the OSWA group (week-4: difference, 44.7 percentage points [95% CI, 23.2-66.1 percentage points], P = 0.001; week-16: difference, 46.0 percentage points [95% CI, 24.4-67.6 percentage points], P < 0.001). Participants in the TSWA group experienced significantly greater improvements in NRS, WOMAC function, and Patient Global Assessment than those in the OSWA group. There were no significant between-group differences in WOMAC stiffness and SF-12. In summary, TSWA immediately improved knee pain and dysfunction compared with OSWA. In addition, the benefit of TSWA persists throughout follow-up.",2020,"Participants in TSWA group experienced significantly greater improvements in NRS, WOMAC function and PGA than OSWA group.","['knee osteoarthritis', 'Sixty participants', 'patients with knee osteoarthritis (KOA']","['OSWA', 'acupuncture (OSWA', 'Acupuncture', 'TSWA', 'acupuncture (TSWA']","['response rate, defined as the percentage of participants achieving ≥2 points decrease on the numerical rating scale (NRS) and ≥6 points decrease in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function score', 'response rates', 'response rates at weeks 4 and 16, NRS, WOMAC, Patient Global Assessment (PGA), 12-item', 'knee pain and dysfunction', 'NRS, WOMAC function and PGA', 'response rate', 'WOMAC stiffness and SF-12']","[{'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}]","[{'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C3472647', 'cui_str': 'Western Ontario and McMaster Universities osteoarthritis index'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0231749', 'cui_str': 'Knee pain'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}]",60.0,0.126622,"Participants in TSWA group experienced significantly greater improvements in NRS, WOMAC function and PGA than OSWA group.","[{'ForeName': 'Lu-Lu', 'Initials': 'LL', 'LastName': 'Lin', 'Affiliation': 'Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Jian-Feng', 'Initials': 'JF', 'LastName': 'Tu', 'Affiliation': 'Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, affiliated with Capital Medical University, Beijing, China.'}, {'ForeName': 'Li-Qiong', 'Initials': 'LQ', 'LastName': 'Wang', 'Affiliation': 'Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Jing-Wen', 'Initials': 'JW', 'LastName': 'Yang', 'Affiliation': 'Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Guang-Xia', 'Initials': 'GX', 'LastName': 'Shi', 'Affiliation': 'Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Jin-Ling', 'Initials': 'JL', 'LastName': 'Li', 'Affiliation': 'Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Zhang', 'Affiliation': 'Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Jia-Kai', 'Initials': 'JK', 'LastName': 'Shao', 'Affiliation': 'Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, affiliated with Capital Medical University, Beijing, China.'}, {'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Zou', 'Affiliation': 'Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Cun-Zhi', 'Initials': 'CZ', 'LastName': 'Liu', 'Affiliation': 'Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}]",Pain,['10.1097/j.pain.0000000000001940'] 1693,32483861,"L-Dex, arm volume, and symptom trajectories 24 months after breast cancer surgery.","PURPOSE Study objectives were to examine: (a) biomarker trajectories (change from presurgical baseline values of Lymphedema index (L-Dex) units and arm volume difference) and symptom cluster scores 24 months after breast cancer surgery and (b) associations of these objective biomarkers and symptom cluster scores. Patient/treatment characteristics influencing trajectories were also evaluated. METHODS A secondary analysis of data from the published interim analysis of a randomized parent study was undertaken using trajectory analysis. Five hundred and eight participants included in the prior analysis with 24 months of postsurgical follow-up were initially measured with bioelectric impedance spectroscopy (BIS) and tape measure (TM) and completed self-report measures. Patients were reassessed postsurgery for continuing eligibility and then randomized to either BIS or TM groups and measured along with self-report data at regular and optional* visits 3, 6,12,15*,18, 21*, and 24-months. RESULTS Three subclinical trajectories were identified for each biomarker (decreasing, stable, increasing) and symptom cluster scores (stable, slight increase/decrease, increasing). Subclinical lymphedema was identified throughout the 24-month period by each biomarker. An L-Dex increase at 15 months in the BIS group was noted. The self-report sets demonstrated contingency coefficients of 0.20 (LSIDS-A soft tissue, P = .031) and 0.19 (FACTB+4, P = .044) with the L-Dex unit change trajectories. CONCLUSIONS These data support the need for long-term (24 months) prospective surveillance with frequent assessments (every 3 months) at least 15 months after surgery. Statistically significant convergence of symptom cluster scores with L-Dex unit change supports BIS as beneficial in the early identification of subclinical lymphedema.",2020,Statistically significant convergence of symptom cluster scores with L-Dex unit change supports BIS as beneficial in the early identification of subclinical lymphedema.,['Five hundred and eight participants included in the prior analysis with 24\xa0months of postsurgical follow-up were initially measured with'],['BIS or TM'],"['bioelectric impedance spectroscopy (BIS) and tape measure (TM) and completed self-report measures', 'Subclinical lymphedema']","[{'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]","[{'cui': 'C2936361', 'cui_str': 'Impedance Spectroscopy'}, {'cui': 'C0336570', 'cui_str': 'Measuring tape'}]","[{'cui': 'C2936361', 'cui_str': 'Impedance Spectroscopy'}, {'cui': 'C0336570', 'cui_str': 'Measuring tape'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205211', 'cui_str': 'Subclinical'}, {'cui': 'C0024236', 'cui_str': 'Lymphedema'}]",508.0,0.0250319,Statistically significant convergence of symptom cluster scores with L-Dex unit change supports BIS as beneficial in the early identification of subclinical lymphedema.,"[{'ForeName': 'Sheila H', 'Initials': 'SH', 'LastName': 'Ridner', 'Affiliation': 'Vanderbilt University School of Nursing, Nashville, TN, USA.'}, {'ForeName': 'Chirag', 'Initials': 'C', 'LastName': 'Shah', 'Affiliation': 'Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Boyages', 'Affiliation': 'Australian Lymphoedema Education, Research, and Treatment (ALERT) Program, Faculty of Medicine & Health Sciences, Macquarie University, Sydney, NSW, Australia.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Koelmeyer', 'Affiliation': 'ALERT Program, Faculty of Medicine & Health Sciences, Macquarie University, Sydney, NSW, Australia.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Ajkay', 'Affiliation': 'Breast Surgical Oncology, University of Louisville, Louisville, KY, USA.'}, {'ForeName': 'Sarah M', 'Initials': 'SM', 'LastName': 'DeSnyder', 'Affiliation': 'Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'McLaughlin', 'Affiliation': 'Surgery, Mayo Clinic, Jacksonville, FL, USA.'}, {'ForeName': 'Mary S', 'Initials': 'MS', 'LastName': 'Dietrich', 'Affiliation': 'Vanderbilt University School of Nursing and Vanderbilt University School of Medicine, Nashville, TN, USA.'}]",Cancer medicine,['10.1002/cam4.3188'] 1694,32480319,Effectiveness of an app-based cognitive behavioral therapy program for postpartum depression in primary care: A randomized controlled trial.,"OBJECTIVE The objective of this study was to examine the effect of mobile phone applications (App) based cognitive behavioral therapy (CBT) on postpartum depression. METHOD A non-blinded parallel-group randomized controlled trial was conducted. The study population consisted of women attended to three health care centers in Kerman, Iran. Participants were recruited between September and November 2018, and randomized 1:1 to either the intervention group (mobile application access) or control group (no mobile application access). All participants completed the Edinburgh Postnatal Depression Scale (EPDS) at the baseline and 2 months after baseline. Data were analyzed using inferential statistics including chi-square, independent sample t-test, paired t-test and linear regression. RESULTS A total of 75 women with an average age of 27 years participated in this study. Before the intervention, there was no statistically significant difference between the EPDS score between the two groups (p > 0.001). However, in the intervention group, the average EPDS score after intervention was 8.18 and in the control group was 15.05, which was statistically significant (p < 0.001). CONCLUSION These findings provide proof that providing a CBT program using a mobile application can lead to clinically important improvements in outcomes for mothers who suffer from postpartum depression.",2020,"Before the intervention, there was no statistically significant difference between the EPDS score between the two groups (p > 0.001).","['Participants were recruited between September and November 2018', 'postpartum depression in primary care', 'women attended to three health care centers in Kerman, Iran', 'mothers who suffer from postpartum depression', '75 women with an average age of 27 years participated in this study']","['intervention group (mobile application access) or control group (no mobile application access', 'app-based cognitive behavioral therapy program', 'mobile phone applications (App) based cognitive behavioral therapy (CBT']","['Edinburgh Postnatal Depression Scale (EPDS', 'average EPDS score', 'EPDS score']","[{'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C0451144', 'cui_str': 'Edinburgh postnatal depression scale'}, {'cui': 'C3472185', 'cui_str': 'Edinburgh postnatal depression scale score'}]",75.0,0.174326,"Before the intervention, there was no statistically significant difference between the EPDS score between the two groups (p > 0.001).","[{'ForeName': 'Nazanin', 'Initials': 'N', 'LastName': 'Jannati', 'Affiliation': 'Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Shahrzad', 'Initials': 'S', 'LastName': 'Mazhari', 'Affiliation': 'Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Ahmadian', 'Affiliation': 'Medical Informatics Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. Electronic address: ahmadianle@yahoo.com.'}, {'ForeName': 'Moghaddameh', 'Initials': 'M', 'LastName': 'Mirzaee', 'Affiliation': 'Epidemiology and Biostatistics, Kerman University of Medical Sciences, Kerman, Iran.'}]",International journal of medical informatics,['10.1016/j.ijmedinf.2020.104145'] 1695,32486104,Non-Steroidal Anti-Inflammatory Drug Etoricoxib Facilitates the Application of Individualized Exercise Programs in Patients with Ankylosing Spondylitis.,"Background and objectives: The main objective of this study is to highlight the efficiency of different therapeutic means in patients with ankylosing spondylitis, resulting in the improvement of their quality of life. Materials and Methods: We conducted a randomized, longitudinal, controlled trial on 92 patients with ankylosing spondylitis over a period of 6 years. Disease activity was assessed using the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) score. The assessment of functional disabilities was performed using BASFI (Bath Ankylosing Spondylitis Functional Index). We assessed the quality of life using the HAQ questionnaire (Health Assessment Questionnaire). Based on the HAQ, we calculated the minimum number of patients to be treated for 52 weeks to prevent a decrease in the quality of life for at least one of them (the number needed to treat (NNT)). Results: For the combination therapy group, the result we obtained was 2, lower than the other therapies compared (the medication group and the group with physical exercise). We point out a correlation between the improvement of the functional status (BASFI) and the increase of the quality of life (HAQ), estimated as moderately high (0.8). The superiority of the effects of the combined treatment, in which we combined a nonsteroidal anti-inflammatory drug (etoricoxib) to the exercise program, is reflected by the model of the significant improvements ( p < 0.05) obtained for the functional status and quality of life scores (BASFI and HAQ). Conclusions: The nonsteroidal anti-inflammatory drugs, in our case, etoricoxib, facilitate the application of individualized exercise programs in patients with ankylosing spondylitis.",2020,"For the combination therapy group, the result we obtained was 2, lower than the other therapies compared (the medication group and the group with physical exercise).","['Patients with Ankylosing Spondylitis', 'patients with ankylosing spondylitis', '92 patients with ankylosing spondylitis over a period of 6 years']","['Etoricoxib', 'individualized exercise programs', 'nonsteroidal anti-inflammatory drug (etoricoxib', 'etoricoxib']","['quality of life', 'BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) score', 'functional status and quality of life scores (BASFI and HAQ', 'Disease activity', 'quality of life using the HAQ questionnaire (Health Assessment Questionnaire', 'functional status (BASFI', 'quality of life (HAQ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038013', 'cui_str': 'Ankylosing spondylitis'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0972314', 'cui_str': 'etoricoxib'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1998004', 'cui_str': 'Bath ankylosing spondylitis disease activity index'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0102923', 'cui_str': 'ametantrone'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451208', 'cui_str': 'Health assessment questionnaire'}]",92.0,0.0280411,"For the combination therapy group, the result we obtained was 2, lower than the other therapies compared (the medication group and the group with physical exercise).","[{'ForeName': 'Iulia Rahela', 'Initials': 'IR', 'LastName': 'Marcu', 'Affiliation': 'Department of Physical and Rehabilitation Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.'}, {'ForeName': 'Dalia', 'Initials': 'D', 'LastName': 'Dop', 'Affiliation': 'Department of Pediatrics, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania.'}, {'ForeName': 'Vlad', 'Initials': 'V', 'LastName': 'Padureanu', 'Affiliation': 'Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.'}, {'ForeName': 'Stefan Adrian', 'Initials': 'SA', 'LastName': 'Niculescu', 'Affiliation': 'Department of Orthopedics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.'}, {'ForeName': 'Rodica', 'Initials': 'R', 'LastName': 'Padureanu', 'Affiliation': 'Department of Biochemistry, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.'}, {'ForeName': 'Carmen Elena', 'Initials': 'CE', 'LastName': 'Niculescu', 'Affiliation': 'Department of Pediatrics, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania.'}, {'ForeName': 'Otilia Constantina', 'Initials': 'OC', 'LastName': 'Rogoveanu', 'Affiliation': 'Department of Physical and Rehabilitation Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.'}]","Medicina (Kaunas, Lithuania)",['10.3390/medicina56060270'] 1696,32583313,"Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A Single-Center, Open-Label, Randomized Controlled Trial.","INTRODUCTION Allisartan isoproxil is a novel angiotensin II type 1 receptor antagonist that has been confirmed to lower blood pressure and protect target organs effectively. However, its role in improving endothelial function and vascular damage has not been investigated yet. METHODS Patients with initially diagnosed mild essential hypertension (BP ranging from 140/90 to 159/99 mmHg) with age from 25-75 years were randomly assigned 1:1 to either the allisartan group (allisartan 240 mg/day and lifestyle modification) or the lifestyle modification group and were followed up for 30 days. Flow-mediated dilation (FMD), brachial-ankle pulse wave velocity (baPWV) and endothelial microparticles (EMPs) were measured for evaluation of endothelial function and vascular damage. In addition, we enrolled 36 normotensive individuals as healthy control. RESULTS Seventy-two mildly hypertensive patients were enrolled in this study. After 30 days of treatment, a significant increase in FMD was observed in the allisartan group (0.9 ± 0.7%, p < 0.001) and remained unchanged in the lifestyle modification group, but the difference between the two groups did not reach statistical significance (p = ns). EMPs, baPWV, SBP and DBP decreased by 251.0 ± 255.9 counts/μl (p < 0.001), 102.8 ± 84.2 cm/s (p < 0.001), 13.20 ± 3.9 mmHg (p < 0.001) and 9.35 ± 2.5 mmHg (p < 0.001), respectively, in the allisartan group, while by 21.3 ± 84.3 counts/μl (p = ns), 0.4 ± 22.0 cm/s (p = ns), 3.2 ± 6.0 mmHg (p < 0.01) and 1.0 ± 2.5 mmHg (p = ns), respectively, in the lifestyle modification group. All of the indexes above achieved statistical significance between the allisartan and lifestyle modification groups (p < 0.05). Besides, after 30 days of allisartan administration baPWV and EMPs were comparable to those measured in the healthy control group, while the difference in SBP, DBP and FMD remained significant between the allisartan and healthy control groups (p < 0.05). CONCLUSION The present study demonstrates for the first time that allisartan isoproxil exerts a favorable effect on improving endothelial function and vascular damage in patients with mild EH, making it a promising drug for management of EH. CLINICAL TRIAL REGISTRATION ChiCTR2000032332.",2020,"Flow-mediated dilation (FMD), brachial-ankle pulse wave velocity (baPWV) and endothelial microparticles (EMPs) were measured for evaluation of endothelial function and vascular damage.","['patients with mild EH', 'Seventy-two mildly hypertensive patients', 'Patients with Essential Hypertension', 'Patients with initially diagnosed mild essential hypertension (BP ranging from 140/90 to 159/99\xa0mmHg) with age from 25-75\xa0years', '36 normotensive individuals as healthy control']","['allisartan group (allisartan 240\xa0mg/day and lifestyle modification) or the lifestyle modification', 'Allisartan Isoproxil']","['EMPs, baPWV, SBP and DBP', 'Endothelial Function and Vascular Damage', 'FMD', 'SBP, DBP and FMD', 'Flow-mediated dilation (FMD), brachial-ankle pulse wave velocity (baPWV) and endothelial\xa0microparticles (EMPs', 'endothelial function and vascular damage']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C4319632', 'cui_str': '72'}, {'cui': 'C2945599', 'cui_str': 'Mild'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0085580', 'cui_str': 'Essential hypertension'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C2712122', 'cui_str': 'Normal blood pressure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C3849367', 'cui_str': 'allisartan isoproxil'}]","[{'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C2350307', 'cui_str': 'Microparticles, Cell-Derived'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0232154', 'cui_str': 'Ankle pulse'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}]",36.0,0.0670531,"Flow-mediated dilation (FMD), brachial-ankle pulse wave velocity (baPWV) and endothelial microparticles (EMPs) were measured for evaluation of endothelial function and vascular damage.","[{'ForeName': 'Gaoxing', 'Initials': 'G', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology, The Jiangmen Central Hospital, Jiangmen, China.'}, {'ForeName': 'Yongqiang', 'Initials': 'Y', 'LastName': 'Fan', 'Affiliation': 'Department of Cardiology, The Jiangmen Central Hospital, Jiangmen, China.'}, {'ForeName': 'Yumin', 'Initials': 'Y', 'LastName': 'Qiu', 'Affiliation': 'Department of Hypertension and Vascular Disease, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'Department of Hypertension and Vascular Disease, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Jianning', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Hypertension and Vascular Disease, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Zhichao', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Department of Hypertension and Vascular Disease, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Yuanya', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Cardiology, The Jiangmen Central Hospital, Jiangmen, China.'}, {'ForeName': 'Xing', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Hypertension and Vascular Disease, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Tao', 'Affiliation': 'Department of Hypertension and Vascular Disease, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China. taojungz123@163.com.'}]",Advances in therapy,['10.1007/s12325-020-01413-y'] 1697,32580399,"A Randomized Trial of Deep Brain Stimulation to the Subcallosal Cingulate and Nucleus Accumbens in Patients with Treatment-Refractory, Chronic, and Severe Anorexia Nervosa: Initial Results at 6 Months of Follow Up.","BACKGROUND The main objective of this study was to assess the safety and efficacy of deep brain stimulation (DBS) in patients with severe anorexia nervosa (AN). METHODS Eight participants received active DBS to the subcallosal cingulate (SCC) or nucleus accumbens (NAcc) depending on comorbidities (affective or anxiety disorders, respectively) and type of AN. The primary outcome measure was body mass index (BMI). RESULTS Overall, we found no significant difference ( p = 0.84) between mean preoperative and postoperative (month 6) BMI. A BMI reference value (BMI-RV) was calculated. In patients that received preoperative inpatient care to raise the BMI, the BMI-RV was defined as the mean BMI value in the 12 months prior to surgery. In patients that did not require inpatient care, the BMI-RV was defined as the mean BMI in the 3-month period before surgery. This value was compared to the postoperative BMI (month 6), revealing a significant increase ( p = 0.02). After 6 months of DBS, five participants showed an increase of ≥10% in the BMI-RV. Quality of life was improved ( p = 0.03). Three cases presented cutaneous complications. CONCLUSION DBS may be effective for some patients with severe AN. Cutaneous complications were observed. Longer term data are needed.",2020,"Overall, we found no significant difference ( p = 0.84) between mean preoperative and postoperative (month 6) BMI.","['Patients with Treatment-Refractory, Chronic, and Severe Anorexia Nervosa', 'patients with severe anorexia nervosa (AN', 'Eight participants received', 'patients with severe AN']","['deep brain stimulation (DBS', 'active DBS to the subcallosal cingulate (SCC) or nucleus accumbens (NAcc', 'DBS', 'Deep Brain Stimulation']","['postoperative BMI', 'BMI-RV', 'safety and efficacy', 'mean BMI', 'Quality of life', 'Cutaneous complications', 'A BMI reference value (BMI-RV', 'mean BMI value', 'body mass index (BMI']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0003125', 'cui_str': 'Anorexia nervosa'}]","[{'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0007610', 'cui_str': 'Nucleus'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0086715', 'cui_str': 'Normal range'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.0312145,"Overall, we found no significant difference ( p = 0.84) between mean preoperative and postoperative (month 6) BMI.","[{'ForeName': 'Gloria', 'Initials': 'G', 'LastName': 'Villalba Martínez', 'Affiliation': 'Department of Neurosurgery, Hospital del Mar, 08003 Barcelona, Spain.'}, {'ForeName': 'Azucena', 'Initials': 'A', 'LastName': 'Justicia', 'Affiliation': 'Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.'}, {'ForeName': 'Purificación', 'Initials': 'P', 'LastName': 'Salgado', 'Affiliation': 'Institut de Neuropsiquiatria i Adiccions (INAD), Hospital del Mar, 08003 Barcelona, Spain.'}, {'ForeName': 'José María', 'Initials': 'JM', 'LastName': 'Ginés', 'Affiliation': 'Institut de Neuropsiquiatria i Adiccions (INAD), Hospital del Mar, 08003 Barcelona, Spain.'}, {'ForeName': 'Rocío', 'Initials': 'R', 'LastName': 'Guardiola', 'Affiliation': 'Institut de Neuropsiquiatria i Adiccions (INAD), Hospital del Mar, 08003 Barcelona, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Cedrón', 'Affiliation': 'Institut de Neuropsiquiatria i Adiccions (INAD), Hospital del Mar, 08003 Barcelona, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Polo', 'Affiliation': 'Institut de Neuropsiquiatria i Adiccions (INAD), Hospital del Mar, 08003 Barcelona, Spain.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Delgado-Martínez', 'Affiliation': 'Department of Neurosurgery, Hospital del Mar, 08003 Barcelona, Spain.'}, {'ForeName': 'Santiago', 'Initials': 'S', 'LastName': 'Medrano', 'Affiliation': 'Department of Radiology, Hospital del Mar, 08003 Barcelona, Spain.'}, {'ForeName': 'Rosa María', 'Initials': 'RM', 'LastName': 'Manero', 'Affiliation': 'Department of Neurology, Hospital del Mar, 08003 Barcelona, Spain.'}, {'ForeName': 'Gerardo', 'Initials': 'G', 'LastName': 'Conesa', 'Affiliation': 'Department of Neurosurgery, Hospital del Mar, 08003 Barcelona, Spain.'}, {'ForeName': 'Gustavo', 'Initials': 'G', 'LastName': 'Faus', 'Affiliation': 'ITA, Mental Health Specialists, 08036 Barcelona, Spain.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Grau', 'Affiliation': 'ITA, Mental Health Specialists, 08036 Barcelona, Spain.'}, {'ForeName': 'Matilde', 'Initials': 'M', 'LastName': 'Elices', 'Affiliation': 'Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.'}, {'ForeName': 'Víctor', 'Initials': 'V', 'LastName': 'Pérez', 'Affiliation': 'Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, 08193 Barcelona, Spain.'}]",Journal of clinical medicine,['10.3390/jcm9061946'] 1698,32459776,Comparison of Treatment Outcomes after Collagenase Injection and Percutaneous Needle Fasciotomy for Dupuytren's Contracture: Objective and Subjective Comparisons with a 3-Year Follow-Up.,"BACKGROUND This study compared the effectiveness of injectable collagenase clostridium histolyticum and percutaneous needle fasciotomy in the treatment of Dupuytren's contracture. METHODS Patients with a total passive extension deficit of 30 degrees or more in a single digital ray were enrolled and assigned randomly to receive either collagenase clostridium histolyticum injections or percutaneous needle fasciotomy. Preoperative severity of proximal interphalangeal joint contracture for Dupuytren's disease was classified according to the British Society for Surgery of the Hand as less than 30 degrees (stage I) or 30 degrees or more (stage II). RESULTS Of the 70 patients enrolled, 36 patients with 46 joints received collagenase clostridium histolyticum injections and 34 patients with 48 joints received percutaneous needle fasciotomy. At day 30, successful corrections were obtained in only 50 percent of the injection group and 67 percent of the fasciotomy group for stage II proximal interphalangeal joints. Recurrences were frequent among patients with stage II joint contractures. The mean Quick Disabilities of the Arm, Shoulder and Hand questionnaire score at day 30 was significantly higher in the injection group compared with the fasciotomy group (7.5 versus 4.2, respectively). In the injection group, adverse events were reported for all patients. In the fasciotomy group, complications were reported for 15 percent of patients. CONCLUSIONS The collagenase clostridium histolyticum and percutaneous needle fasciotomy groups had similar outcomes for Dupuytren's contracture with 3 years' follow-up. Recurrences were frequent among patients with stage II proximal interphalangeal joint contractures. The Unité Rhumatologique des Affections de la Main scale and Quick Disabilities of the Arm, Shoulder and Hand questionnaire score decreased significantly for both groups at final follow-up. CLINICAL QUESTION/LEVEL OF EVIDENCE Therapeutic, II.",2020,"The mean Quick Disabilities of the Arm, Shoulder and Hand questionnaire score at day 30 was significantly higher in the injection group compared with the fasciotomy group (7.5 versus 4.2, respectively).","['36 patients with 46 joints received', 'and 34 patients with 48 joints received', 'Patients with a total passive extension deficit of 30 degrees or more in a single digital ray', ""Dupuytren's Contracture"", 'patients with stage II proximal interphalangeal joint contractures', 'patients with stage II joint contractures', '70 patients enrolled', ""Dupuytren's contracture""]","['percutaneous needle fasciotomy', 'collagenase clostridium histolyticum injections', 'collagenase clostridium histolyticum injections or percutaneous needle fasciotomy', 'injectable collagenase clostridium histolyticum and percutaneous needle fasciotomy', 'Collagenase Injection and Percutaneous Needle Fasciotomy']","['mean Quick Disabilities of the Arm, Shoulder and Hand questionnaire score', 'Unité Rhumatologique des Affections de la Main scale and Quick Disabilities of the Arm, Shoulder and Hand questionnaire score', 'complications', 'adverse events', 'Recurrences']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0086894', 'cui_str': 'Rajiformes'}, {'cui': 'C0013312', 'cui_str': ""Dupuytren's contracture""}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C1563055', 'cui_str': 'Interphalangeal joint structure'}, {'cui': 'C0009917', 'cui_str': 'Contracture'}, {'cui': 'C0009918', 'cui_str': 'Contracture of joint'}]","[{'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0185188', 'cui_str': 'Division of fascia'}, {'cui': 'C4301823', 'cui_str': 'collagenase Clostridium histolyticum Injection'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}, {'cui': 'C0009053', 'cui_str': 'collagenase Clostridium histolyticum'}, {'cui': 'C0162745', 'cui_str': 'COLLAGENASE'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011702', 'cui_str': '4-(4-Amino-4-Carboxybutyl)-1-(5-Amino-5-Carboxypentyl)-3,5-bis(3-Amino-3-Carboxypropyl)pyridinium'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",70.0,0.038712,"The mean Quick Disabilities of the Arm, Shoulder and Hand questionnaire score at day 30 was significantly higher in the injection group compared with the fasciotomy group (7.5 versus 4.2, respectively).","[{'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Abe', 'Affiliation': 'Ichihara City, Japan From the Department of Orthopedic Surgery, Chiba Rosai Hospital.'}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000006828'] 1699,32459919,Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.,"BACKGROUND Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19). METHODS We conducted a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia. Patients were randomly assigned in a 1:1 ratio to receive intravenous remdesivir for either 5 days or 10 days. All patients received 200 mg of remdesivir on day 1 and 100 mg once daily on subsequent days. The primary end point was clinical status on day 14, assessed on a 7-point ordinal scale. RESULTS In total, 397 patients underwent randomization and began treatment (200 patients for 5 days and 197 for 10 days). The median duration of treatment was 5 days (interquartile range, 5 to 5) in the 5-day group and 9 days (interquartile range, 5 to 10) in the 10-day group. At baseline, patients randomly assigned to the 10-day group had significantly worse clinical status than those assigned to the 5-day group (P = 0.02). By day 14, a clinical improvement of 2 points or more on the ordinal scale occurred in 64% of patients in the 5-day group and in 54% in the 10-day group. After adjustment for baseline clinical status, patients in the 10-day group had a distribution in clinical status at day 14 that was similar to that among patients in the 5-day group (P = 0.14). The most common adverse events were nausea (9% of patients), worsening respiratory failure (8%), elevated alanine aminotransferase level (7%), and constipation (7%). CONCLUSIONS In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined. (Funded by Gilead Sciences; GS-US-540-5773 ClinicalTrials.gov number, NCT04292899.).",2020,"By day 14, a clinical improvement of 2 points or more on the ordinal scale occurred in 64% of patients in the 5-day group and in 54% in the 10-day group.","['patients with severe Covid-19 not requiring mechanical ventilation', 'hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia', 'Patients with Severe Covid-19', '397 patients underwent randomization and began treatment (200 patients for 5 days and 197 for 10 days']",['intravenous remdesivir'],"['worsening respiratory failure', 'ordinal scale', 'distribution in clinical status', 'clinical status on day 14, assessed on a 7-point ordinal scale', 'elevated alanine aminotransferase level', 'nausea', 'constipation', 'clinical status', 'median duration of treatment']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C4726677', 'cui_str': 'remdesivir'}]","[{'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}, {'cui': 'C0439080', 'cui_str': 'Ordinal number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0449440', 'cui_str': 'Clinical status'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0163299', 'cui_str': 'A 7'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment'}]",397.0,0.213119,"By day 14, a clinical improvement of 2 points or more on the ordinal scale occurred in 64% of patients in the 5-day group and in 54% in the 10-day group.","[{'ForeName': 'Jason D', 'Initials': 'JD', 'LastName': 'Goldman', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'David C B', 'Initials': 'DCB', 'LastName': 'Lye', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Hui', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Kristen M', 'Initials': 'KM', 'LastName': 'Marks', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Raffaele', 'Initials': 'R', 'LastName': 'Bruno', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Rocio', 'Initials': 'R', 'LastName': 'Montejano', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Christoph D', 'Initials': 'CD', 'LastName': 'Spinner', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Galli', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Mi-Young', 'Initials': 'MY', 'LastName': 'Ahn', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Ronald G', 'Initials': 'RG', 'LastName': 'Nahass', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Yao-Shen', 'Initials': 'YS', 'LastName': 'Chen', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Devi', 'Initials': 'D', 'LastName': 'SenGupta', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Robert H', 'Initials': 'RH', 'LastName': 'Hyland', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Anu O', 'Initials': 'AO', 'LastName': 'Osinusi', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Huyen', 'Initials': 'H', 'LastName': 'Cao', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Christiana', 'Initials': 'C', 'LastName': 'Blair', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Xuelian', 'Initials': 'X', 'LastName': 'Wei', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Anuj', 'Initials': 'A', 'LastName': 'Gaggar', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Diana M', 'Initials': 'DM', 'LastName': 'Brainard', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Towner', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Muñoz', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Mullane', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Francisco M', 'Initials': 'FM', 'LastName': 'Marty', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Karen T', 'Initials': 'KT', 'LastName': 'Tashima', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Diaz', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': 'Aruna', 'Initials': 'A', 'LastName': 'Subramanian', 'Affiliation': ""From the Swedish Center for Research and Innovation, Swedish Medical Center, and the University of Washington, Seattle (J.D.G.), and Providence Regional Medical Center, Everett (G.D.) - both in Washington; the National Center for Infectious Diseases, Lee Kong Chian School of Medicine, Tan Tock Seng Hospital, Singapore (D.C.B.L.); the Chinese University of Hong Kong-Prince of Wales Hospital, Hong Kong (D.S.H.); NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York (K.M. Marks); Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia-Università di Pavia, Pavia (R.B.), and Università di Milano, Department of Biomedical and Clinical Sciences, L. Sacco Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan (M.G.) - both in Italy; Hospital Universitario La Paz, IdiPAZ, Madrid (R.M.), and Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Barcelona (J.M.); Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (C.D.S.); Seoul Medical Center, Seoul, South Korea (M.-Y.A.); ID Care, Hillsborough, and Robert Wood Johnson University Hospital Somerset, Somerville - both in New Jersey (R.G.N.); Kaohsiung Veterans General Hospital, Taiwan (Y.-S.C.); Gilead Sciences, Foster City (D.S., R.H.H., A.O.O., H.C., C.B., X.W., A.G., D.M.B.), Kaiser Permanente, Los Angeles (W.J.T.), and Stanford University, Palo Alto (A.S.) - all in California; University of Chicago, Chicago (K.M. Mullane); Brigham and Women's Hospital and Harvard Medical School, Boston (F.M.M.); and Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI (K.T.T.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa2015301'] 1700,31806881,"OPRM1, OPRK1, and COMT genetic polymorphisms associated with opioid effects on experimental pain: a randomized, double-blind, placebo-controlled study.","Genetic polymorphisms have been shown to affect opioid requirement for pain relief. However, true genetic effect is often difficult to assess due to underlying pain conditions and placebo effects. The goal of this study was to understand how common polymorphisms affect opioid effects while controlling for these factors. A randomized, double-blind, placebo-controlled study was implemented to assess how opioid effects are modulated by COMT (rs6269, rs4633, rs4848, rs4680), OPRM1 (A118G), and OPRK1 (rs1051660, rs702764, rs16918875). One hundred and eight healthy subjects underwent experimental pain testing before and after morphine, butorphanol, and placebo (saline). Association analysis was performed between polymorphisms/haplotypes and opioid response, while correcting for race, gender, placebo effects, and multiple comparisons. Pressure pain was significantly associated with rs6269 and rs4633 following butorphanol. The AA genotype of rs4680 or A_T_C_A/ A_T_C_A (rs6269_rs4633_ rs4818_rs4680) diplotype of COMT, combined with the AG genotype of OPRM1 A118G, showed significantly increased pressure pain threshold from butorphanol. Opioid effects on pressure, ischemic, heat pain, and side effects were nominally associated with several SNPs and haplotypes. Effects were often present in one opioid but not the other. This indicates that these polymorphisms affect pain relief from opioids, and that their effects are opioid and pain modality specific.",2020,Pressure pain was significantly associated with rs6269 and rs4633 following butorphanol.,['One hundred and eight healthy subjects'],"['butorphanol', 'morphine, butorphanol, and placebo (saline', 'placebo']","['Pressure pain', 'pressure, ischemic, heat pain, and side effects', 'pressure pain', 'experimental pain']","[{'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0006491', 'cui_str': 'Butorphanol'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",108.0,0.58088,Pressure pain was significantly associated with rs6269 and rs4633 following butorphanol.,"[{'ForeName': 'Kwo Wei David', 'Initials': 'KWD', 'LastName': 'Ho', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, Division of Pain Medicine, Stanford University, Redwood City, CA, USA. kwoweiho@stanford.edu.'}, {'ForeName': 'Margaret R', 'Initials': 'MR', 'LastName': 'Wallace', 'Affiliation': 'Department of Molecular Genetics & Microbiology, and UF Genetics Institute, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Staud', 'Affiliation': 'Department of Medicine, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Roger B', 'Initials': 'RB', 'LastName': 'Fillingim', 'Affiliation': 'Department of Community Dentistry and Behavioral Science, University of Florida, Gainesville, FL, USA.'}]",The pharmacogenomics journal,['10.1038/s41397-019-0131-z'] 1701,32470863,The effect of Korean Red Ginseng on sarcopenia biomarkers in type 2 diabetes patients.,"BACKGROUND The elderly population is growing rapidly worldwide and sarcopenia, which is considered as a new geriatric syndrome has become an important issue. In particular, diabetes is known to be an important risk factor for sarcopenia. In this study, we investigated the effects of Korean Red Ginseng (KRG) on biomarkers of sarcopenia in middle and old age diabetes patients. PATIENTS AND METHODS This study was a randomized, double-blind, placebo-controlled trial. Participants were randomly allocated to either the placebo or KRG group and took corresponding tablets for 24 weeks. The primary outcomes were changes in sarcopenia biomarkers at week 24. Secondary outcomes were changes in inflammatory and antioxidant markers and lean body mass at week 24. RESULTS Fifty-nine patients completed the study. Follistatin and sex hormone binding globulin (SHBG) were significantly improved in KRG group. In the subgroup analysis, female postmenopausal patients over the age of 55 showed a significant improvement in serum SHBG, follistatin, and growth differentiation factor 15 (GDF-15) and an attenuated reduction in Troponin T (TNT) after the administration of KRG. CONCLUSION Twenty-four week administration of KRG in diabetes patients resulted in a significant improvement in follistatin and SHBG levels, especially in old postmenopausal women. A further, larger population study with a longer follow-up period is warranted to verify and understand the effects of KRG on sarcopenia.",2020,"Twenty-four week administration of KRG in diabetes patients resulted in a significant improvement in follistatin and SHBG levels, especially in old postmenopausal women.","['type 2 diabetes patients', 'Fifty-nine patients completed the study', 'middle and old age diabetes patients', 'old postmenopausal women']","['placebo or KRG', 'Korean Red Ginseng (KRG', 'KRG', 'Korean Red Ginseng', 'placebo']","['serum SHBG, follistatin, and growth differentiation factor 15 (GDF-15) and an attenuated reduction in Troponin T (TNT', 'sarcopenia biomarkers', 'changes in inflammatory and antioxidant markers and lean body mass', 'changes in sarcopenia biomarkers', 'follistatin and SHBG levels', 'Follistatin and sex hormone binding globulin (SHBG']","[{'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3830128', 'cui_str': '59'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0231337', 'cui_str': 'Senility'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0873137', 'cui_str': 'Korean ginseng preparation'}]","[{'cui': 'C0455307', 'cui_str': 'Serum sex hormone binding globulin measurement'}, {'cui': 'C0060623', 'cui_str': 'Activin-Binding Protein'}, {'cui': 'C0668195', 'cui_str': 'Macrophage Inhibitory Cytokine 1'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0077404', 'cui_str': 'Troponin T'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenia'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass'}, {'cui': 'C0202218', 'cui_str': 'Sex hormone binding globulin measurement'}, {'cui': 'C0036883', 'cui_str': 'Sex steroid binding globulin'}]",59.0,0.135337,"Twenty-four week administration of KRG in diabetes patients resulted in a significant improvement in follistatin and SHBG levels, especially in old postmenopausal women.","[{'ForeName': 'Kahui', 'Initials': 'K', 'LastName': 'Park', 'Affiliation': 'Department of Internal Medicine, Yonsei University College of Medicine, 63 gil 20, Eonguro, Gangnam-gu, Seoul, 06229, Republic of Korea.'}, {'ForeName': 'Chul Woo', 'Initials': 'CW', 'LastName': 'Ahn', 'Affiliation': 'Department of Internal Medicine, Yonsei University College of Medicine, 63 gil 20, Eonguro, Gangnam-gu, Seoul, 06229, Republic of Korea; Severance Institute for Vascular and Metabolic Research, College of Medicine, Yonsei University, 211 Eonguro, Gangnam-gu, Seoul, 06288, Republic of Korea.'}, {'ForeName': 'YuSik', 'Initials': 'Y', 'LastName': 'Kim', 'Affiliation': 'Severance Institute for Vascular and Metabolic Research, College of Medicine, Yonsei University, 211 Eonguro, Gangnam-gu, Seoul, 06288, Republic of Korea. Electronic address: cromoton@yuhs.ac.'}, {'ForeName': 'Ji Sun', 'Initials': 'JS', 'LastName': 'Nam', 'Affiliation': 'Department of Internal Medicine, Yonsei University College of Medicine, 63 gil 20, Eonguro, Gangnam-gu, Seoul, 06229, Republic of Korea; Severance Institute for Vascular and Metabolic Research, College of Medicine, Yonsei University, 211 Eonguro, Gangnam-gu, Seoul, 06288, Republic of Korea. Electronic address: jisunn@yuhs.ac.'}]",Archives of gerontology and geriatrics,['10.1016/j.archger.2020.104108'] 1702,32527049,Impact of a Catch-Up Strategy of DT-IPV Vaccination during Hospitalization on Vaccination Coverage among People Over 65 Years of Age in France: The HOSPIVAC Study (Vaccination during Hospitalization).,"In France, diphtheria tetanus and inactivated polio vaccine (DT-IPV) coverage and immunization are insufficient in the elderly and decrease with age. The principal objective of this study was to assess the impact of a strategy of catch-up DT-IPV vaccination during hospitalization in people over the age of 65 years in central France (the Sarthe region). We performed a prospective, single-center, cluster-randomized study (four hospital wards). We included patients aged ≥65 years, without mental impairment, contraindication and who accepted to participate, hospitalized in the internal medicine wards in Le Mans Hospital from 28 May 2018 to 27 May 2019. The DT-IPV vaccination status of the patients was determined at inclusion and the wards were randomized (intervention and control). In the intervention group, vaccination was up-dated during hospitalization. In case of temporary contraindication, vaccination was prescribed at hospital discharge. Patients hospitalized in the control wards received oral information only. Final immunization status was determined by calling the patient's general practitioner two months after hospital discharge. One hundred and fifty seven patients were included: 73 in the intervention and 84 in the control arm. Baseline immunization coverage was 46.5%. Vaccination coverage increased from 56.2% to 80.8% in the intervention group and from 38.1% to 40.5% in the control group ( p < 0.001). Having received sufficient information from the general practitioner was the only factor associated with vaccination being up-to-date in uni- and multivariate analysis: OR = 5.07 [2.45-10.51]. In a setting of low vaccination coverage DT-IPV vaccination during hospitalization is an effective catch-up strategy.",2020,Vaccination coverage increased from 56.2% to 80.8% in the intervention group and from 38.1% to 40.5% in the control group ( p < 0.001).,"['people over the age of 65 years in central France (the Sarthe region', 'One hundred and fifty seven patients were included: 73 in the intervention and 84 in the control arm', 'People Over 65 Years of Age in France', 'patients aged ≥65 years, without mental impairment, contraindication and who accepted to participate, hospitalized in the internal medicine wards in Le Mans Hospital from 28 May 2018 to 27 May 2019']","['catch-up DT-IPV vaccination', 'DT-IPV Vaccination', 'diphtheria tetanus and inactivated polio vaccine (DT-IPV']","['Vaccination coverage', 'Baseline immunization coverage']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0278061', 'cui_str': 'Altered mental status'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0021782', 'cui_str': 'Internal medicine'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0231617', 'cui_str': 'Catch'}, {'cui': 'C0012546', 'cui_str': 'Diphtheria'}, {'cui': 'C0039614', 'cui_str': 'Tetanus'}, {'cui': 'C0718003', 'cui_str': 'Inactivated Poliovirus vaccine'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C4505148', 'cui_str': 'Vaccination Coverage'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4505149', 'cui_str': 'Immunization Coverage'}]",157.0,0.0446113,Vaccination coverage increased from 56.2% to 80.8% in the intervention group and from 38.1% to 40.5% in the control group ( p < 0.001).,"[{'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Blanchi', 'Affiliation': 'Department of Infectious Diseases, Le Mans Hospital, 72000 Le Mans, France.'}, {'ForeName': 'Justine', 'Initials': 'J', 'LastName': 'Vaux', 'Affiliation': 'Department of Infectious Diseases, Le Mans Hospital, 72000 Le Mans, France.'}, {'ForeName': 'Jean Marc', 'Initials': 'JM', 'LastName': 'Toqué', 'Affiliation': 'Department of Internal Medecine, Le Mans Hospital, 72000 Le Mans, France.'}, {'ForeName': 'Ludovic', 'Initials': 'L', 'LastName': 'Hery', 'Affiliation': 'Department of Internal Medecine, Le Mans Hospital, 72000 Le Mans, France.'}, {'ForeName': 'Servane', 'Initials': 'S', 'LastName': 'Laforest', 'Affiliation': 'Department of Internal Medecine, Le Mans Hospital, 72000 Le Mans, France.'}, {'ForeName': 'Giorgina Barbara', 'Initials': 'GB', 'LastName': 'Piccoli', 'Affiliation': 'Department of Nephrology, Le Mans Hospital, 72000 Le Mans, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Crochette', 'Affiliation': 'Department of Infectious Diseases, Le Mans Hospital, 72000 Le Mans, France.'}]",Vaccines,['10.3390/vaccines8020292'] 1703,31806214,Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.,"OBJECTIVES The aim of this study was to assess if prior oral anticoagulant agent (OAC) use modifies the lower bleeding risk observed with dabigatran dual therapy (dabigatran twice daily plus a P2Y 12 inhibitor) versus warfarin triple therapy (warfarin plus a P2Y 12 inhibitor plus aspirin) in patients with atrial fibrillation who underwent percutaneous coronary intervention (PCI). BACKGROUND In the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial, the primary outcome of major bleeding or clinically relevant nonmajor bleeding was lower with dabigatran dual therapy versus warfarin triple therapy in patients with atrial fibrillation who underwent PCI. METHODS A total of 2,725 patients were randomized to dual therapy with dabigatran (110 or 150 mg twice daily) plus clopidogrel or ticagrelor or triple therapy with warfarin plus aspirin and clopidogrel or ticagrelor. Subgroup analysis compared risk for major bleeding or clinically relevant nonmajor bleeding and a composite thromboembolic endpoint in patients with prior OAC use and in those who were OAC treatment naive. RESULTS Risk for major bleeding or clinically relevant nonmajor bleeding was reduced with both dabigatran dual therapies compared with warfarin triple therapy in both the prior OAC use group (hazard ratios: 0.58 [95% confidence interval (CI): 0.42 to 0.81] and 0.61 [95% CI: 0.41 to 0.92] with 110 and 150 mg dabigatran, respectively) and the OAC-naive group (hazard ratios: 0.49 [95% CI: 0.38 to 0.63] and 0.76 [95% CI: 0.59 to 0.97] with 110 and 150 mg dabigatran) (p for interaction = 0.42 and 0.37, 110 and 150 mg dabigatran, respectively). The risk for thromboembolic events seemed similar with dabigatran dual therapy (both doses) and warfarin triple therapy across subgroups. CONCLUSIONS Bleeding risk was reduced with dabigatran dual therapy versus warfarin triple therapy in patients with atrial fibrillation after PCI, regardless of whether they were prior OAC users or OAC treatment naive. These results suggest that it is also safe to switch patients on OAC pre-PCI to dabigatran dual therapy post-PCI.",2019,"RESULTS Risk for major bleeding or clinically relevant nonmajor bleeding was reduced with both dabigatran dual therapies compared with warfarin triple therapy in both the prior OAC use group (hazard ratios: 0.58 [95% confidence interval (CI): 0.42 to 0.81] and 0.61 [95% CI: 0.41 to 0.92] with 110 and 150 mg dabigatran, respectively) and the OAC-naive group (hazard ratios: 0.49 [95% CI: 0.38 to 0.63] and 0.76 [95% ","['Patients With Atrial Fibrillation', 'patients\xa0with atrial\xa0fibrillation after PCI, regardless of whether they were prior OAC users or OAC treatment naive', 'patients with atrial fibrillation who underwent percutaneous coronary intervention (PCI', 'patients with atrial fibrillation who underwent PCI', '2,725 patients', 'Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention']","['warfarin triple therapy', 'clopidogrel or ticagrelor or triple therapy with warfarin plus aspirin and clopidogrel or ticagrelor', 'dabigatran dual therapy (dabigatran twice daily plus a P2Y 12 inhibitor) versus warfarin triple therapy (warfarin plus a P2Y 12 inhibitor plus aspirin', 'Oral Anticoagulation Therapy', 'dual therapy with dabigatran', 'oral anticoagulant agent (OAC', 'Dabigatran Versus Triple Therapy With Warfarin']","['risk for thromboembolic events', 'Bleeding risk', 'Risk for major bleeding or clinically relevant nonmajor bleeding']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C2348066', 'cui_str': 'dabigatran'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",2725.0,0.0648341,"RESULTS Risk for major bleeding or clinically relevant nonmajor bleeding was reduced with both dabigatran dual therapies compared with warfarin triple therapy in both the prior OAC use group (hazard ratios: 0.58 [95% confidence interval (CI): 0.42 to 0.81] and 0.61 [95% CI: 0.41 to 0.92] with 110 and 150 mg dabigatran, respectively) and the OAC-naive group (hazard ratios: 0.49 [95% CI: 0.38 to 0.63] and 0.76 [95% ","[{'ForeName': 'Jurrien M', 'Initials': 'JM', 'LastName': 'Ten Berg', 'Affiliation': 'St. Antonius Ziekenhuis, Nieuwegein, the Netherlands. Electronic address: jurtenberg@gmail.com.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'de Veer', 'Affiliation': 'St. Antonius Ziekenhuis, Nieuwegein, the Netherlands.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Oldgren', 'Affiliation': 'Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Philippe Gabriel', 'Initials': 'PG', 'LastName': 'Steg', 'Affiliation': 'French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, Paris, France; Université de Paris, Paris, France; INSERM U-1148, Paris, France; Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Dmitry A', 'Initials': 'DA', 'LastName': 'Zateyshchikov', 'Affiliation': 'Primary Vascular Department, City Clinic Hospital #51, Moscow, Russian Federation.'}, {'ForeName': 'Petr', 'Initials': 'P', 'LastName': 'Jansky', 'Affiliation': 'Department of Cardiovascular Surgery, Faculty Hospital Motol, Prague, Czech Republic.'}, {'ForeName': 'Ki-Bae', 'Initials': 'KB', 'LastName': 'Seung', 'Affiliation': 'The Catholic University of Korea, Seoul, Korea.'}, {'ForeName': 'Stefan H', 'Initials': 'SH', 'LastName': 'Hohnloser', 'Affiliation': 'Johann Wolfgang Goethe University, Frankfurt am Main, Germany.'}, {'ForeName': 'Gregory Y H', 'Initials': 'GYH', 'LastName': 'Lip', 'Affiliation': 'Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.'}, {'ForeName': 'Matias', 'Initials': 'M', 'LastName': 'Nordaby', 'Affiliation': 'Boehringer Ingelheim International, Ingelheim, Germany.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Kleine', 'Affiliation': 'Boehringer Ingelheim International, Ingelheim, Germany.'}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Cannon', 'Affiliation': ""Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2019.08.039'] 1704,31806216,Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.,"OBJECTIVES The aim of this study was to evaluate dabigatran dual therapy versus warfarin triple therapy in patients with or without diabetes mellitus in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial. BACKGROUND It is unclear whether dual therapy is as safe and efficacious as triple therapy in patients with atrial fibrillation with diabetes following percutaneous coronary intervention. METHODS In RE-DUAL PCI, 2,725 patients with atrial fibrillation (993 with diabetes) who had undergone PCI were assigned to warfarin triple therapy (warfarin, clopidogrel or ticagrelor, and aspirin) or dabigatran dual therapy (dabigatran 110 mg or 150 mg twice daily and clopidogrel or ticagrelor). Median follow-up was 13 months. The primary outcome was the composite of major bleeding or clinically relevant nonmajor bleeding, and the main efficacy outcome was the composite of death, thromboembolic events, or unplanned revascularization. RESULTS Among patients with diabetes, the incidence of major bleeding or clinically relevant nonmajor bleeding was 15.2% in the dabigatran 110 mg dual therapy group versus 27.5% in the warfarin triple therapy group (hazard ratio [HR]: 0.48; 95% confidence interval [CI] 0.35 to 0.67) and 23.8% in the dabigatran 150 mg dual therapy group versus 25.1% in the warfarin triple therapy group (HR: 0.87; 95% CI: 0.62 to 1.22). Risk for major bleeding or clinically relevant nonmajor bleeding was also reduced with both dabigatran doses among patients without diabetes (dabigatran 110 mg dual therapy: HR: 0.54; 95% CI: 0.42 to 0.70; dabigatran 150 mg dual therapy: HR: 0.63; 95% CI: 0.48 to 0.83). Risk for the efficacy endpoint was comparable between treatment groups for both patients with and those without diabetes. No interaction between treatment and diabetes subgroup could be observed, either for bleeding or for composite efficacy endpoints. CONCLUSIONS In this subgroup analysis, dabigatran dual therapy had a lower risk for bleeding and a comparable rate of the efficacy endpoint compared with warfarin triple therapy in patients with atrial fibrillation with or without diabetes following percutaneous coronary intervention.",2019,Risk for major bleeding or clinically relevant nonmajor bleeding was also reduced with both dabigatran doses among patients without diabetes (dabigatran 110 mg dual therapy: HR: 0.54; 95% CI: 0.42 to 0.70; dabigatran 150 mg dual therapy: HR: 0.63; 95% CI: 0.48 to 0.83).,"['patients with diabetes', '2,725 patients with atrial fibrillation (993 with diabetes) who had undergone PCI', 'Patients With Nonvalvular Atrial Fibrillation', 'Patients', 'patients with or without diabetes mellitus in the RE-DUAL PCI (Randomized Evaluation of', 'patients with atrial fibrillation with diabetes following percutaneous coronary intervention', 'patients with atrial fibrillation with or without diabetes following percutaneous coronary intervention']","['Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI', 'warfarin triple therapy (warfarin, clopidogrel or ticagrelor, and aspirin) or dabigatran dual therapy (dabigatran 110\xa0mg or 150\xa0mg twice daily and clopidogrel or ticagrelor', 'Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With Warfarin', 'warfarin triple therapy']","['composite of major bleeding or clinically relevant nonmajor bleeding, and the main efficacy outcome was the composite of death, thromboembolic events, or unplanned revascularization', 'Risk for major bleeding or clinically relevant nonmajor bleeding', 'incidence of major bleeding or clinically relevant nonmajor bleeding', 'risk for bleeding']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C2348066', 'cui_str': 'dabigatran'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",2725.0,0.0743746,Risk for major bleeding or clinically relevant nonmajor bleeding was also reduced with both dabigatran doses among patients without diabetes (dabigatran 110 mg dual therapy: HR: 0.54; 95% CI: 0.42 to 0.70; dabigatran 150 mg dual therapy: HR: 0.63; 95% CI: 0.48 to 0.83).,"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Maeng', 'Affiliation': 'Aarhus University Hospital, Aarhus, Denmark. Electronic address: michael.maeng@ki.au.dk.'}, {'ForeName': 'Philippe Gabriel', 'Initials': 'PG', 'LastName': 'Steg', 'Affiliation': 'FACT, an F-CRIN Network, DHU FIRE, Hôpital Bichat, Paris, France; Université Paris Diderot, Paris, France; INSERM U_1148, Paris, France; Hôpital Bichat Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""Brigham and Women's Hospital and Heart and Vascular Center Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Stefan H', 'Initials': 'SH', 'LastName': 'Hohnloser', 'Affiliation': 'Johann Wolfgang Goethe University, Frankfurt am Main, Germany.'}, {'ForeName': 'Matias', 'Initials': 'M', 'LastName': 'Nordaby', 'Affiliation': 'Boehringer Ingelheim International, Ingelheim, Germany.'}, {'ForeName': 'Corinna', 'Initials': 'C', 'LastName': 'Miede', 'Affiliation': 'HMS Analytical Software, Weimar (Lahn), Germany.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Kimura', 'Affiliation': 'Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Gregory Y H', 'Initials': 'GYH', 'LastName': 'Lip', 'Affiliation': 'Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Oldgren', 'Affiliation': 'Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Jurriën M', 'Initials': 'JM', 'LastName': 'Ten Berg', 'Affiliation': 'St. Antonius Ziekenhuis, Nieuwegein, the Netherlands.'}, {'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Cannon', 'Affiliation': ""Brigham and Women's Hospital and Heart and Vascular Center Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2019.07.059'] 1705,32474473,Supplementation with Matured Hop Bitter Acids Improves Cognitive Performance and Mood State in Healthy Older Adults with Subjective Cognitive Decline.,"BACKGROUND Prevention of age-related cognitive decline and depression is becoming urgent because of rapid growing aging populations. Effects of vagal nerve activation on brain function by food ingredients are inadequately investigated; matured hop bitter acid (MHBA) administration reportedly improves cognitive function and depression via vagal nerve activation in model mice. OBJECTIVE We investigated the effects of MHBA supplementation on cognitive function and mood state in healthy older adults with perceived subjective cognitive decline. METHODS Using a randomized double-blind placebo-controlled trial design, 100 subjects (aged 45-69 years) were randomly assigned into placebo (n = 50) and MHBA (n = 50) groups, and received placebo or MHBA capsules daily for 12 weeks. RESULTS Symbol Digit Modalities Test (SDMT) score assessing divided attention at week 12 was significantly higher (p = 0.045) and β-endorphin at week 12 was significantly lower (p = 0.043) in the subjects receiving MHBA. Transthyretin in serum, a putative mild cognitive impairment marker, was significantly higher at week 12 in the MHBA group than in the placebo group (p = 0.048). Subgroup analysis classified by the subjective cognitive decline questionnaire revealed that in addition to improved SDMT scores, memory retrieval assessed using the standard verbal paired-associate learning tests and the Ray Verbal Learning Test at week 12 had significantly improved in the subgroup with perceived subjective cognitive decline and without requirement for medical assistance in the MHBA group compared with that in the placebo group. CONCLUSION This study suggested that MHBA intake improves cognitive function, attention, and mood state in older adults.",2020,"Transthyretin in serum, a putative mild cognitive impairment marker, was significantly higher at week 12 in the MHBA group than in the placebo group (p = 0.048).","['100 subjects (aged 45-69 years', 'older adults', 'healthy older adults with perceived subjective cognitive decline', 'Healthy Older Adults with Subjective Cognitive Decline']","['vagal nerve activation', 'MHBA supplementation', 'placebo or MHBA capsules daily for 12 weeks', 'Supplementation with Matured Hop Bitter Acids', 'MHBA', 'placebo']","['Symbol Digit Modalities Test (SDMT) score assessing divided attention', 'SDMT scores, memory retrieval assessed using the standard verbal paired-associate learning tests and the Ray Verbal Learning Test', 'cognitive function, attention, and mood state', 'subjective cognitive decline and without requirement for medical assistance', 'cognitive function and mood state', 'Transthyretin in serum, a putative mild cognitive impairment marker', 'Cognitive Performance and Mood State', 'β-endorphin']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0234985', 'cui_str': 'Mental Deterioration'}]","[{'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0205286', 'cui_str': 'Mature'}, {'cui': 'C0078040', 'cui_str': 'VAP protocol'}, {'cui': 'C0235290', 'cui_str': 'Taste bitter'}, {'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0451522', 'cui_str': 'Symbol digit modalities test'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0589101', 'cui_str': 'Divided attention'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0030210', 'cui_str': 'Paired-Associate Learning'}, {'cui': 'C0086894', 'cui_str': 'Rajiformes'}, {'cui': 'C0042531', 'cui_str': 'Verbal learning'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0234985', 'cui_str': 'Mental Deterioration'}, {'cui': 'C0025070', 'cui_str': 'Assistance, Medical'}, {'cui': 'C0032923', 'cui_str': 'Prealbumin'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0014242', 'cui_str': 'Endorphin'}]",100.0,0.48803,"Transthyretin in serum, a putative mild cognitive impairment marker, was significantly higher at week 12 in the MHBA group than in the placebo group (p = 0.048).","[{'ForeName': 'Takafumi', 'Initials': 'T', 'LastName': 'Fukuda', 'Affiliation': 'KIRIN Central Research Institute, Kirin Holdings Company, Ltd., Kanagawa, Japan.'}, {'ForeName': 'Tohru', 'Initials': 'T', 'LastName': 'Ohnuma', 'Affiliation': 'Department of Psychiatry, Juntendo University Faculty of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kuniaki', 'Initials': 'K', 'LastName': 'Obara', 'Affiliation': 'KIRIN Central Research Institute, Kirin Holdings Company, Ltd., Kanagawa, Japan.'}, {'ForeName': 'Sumio', 'Initials': 'S', 'LastName': 'Kondo', 'Affiliation': 'Fukushima Healthcare Center, Osaka, Japan.'}, {'ForeName': 'Heii', 'Initials': 'H', 'LastName': 'Arai', 'Affiliation': 'Department of Psychiatry, Juntendo University Faculty of Medicine, Tokyo, Japan.'}, {'ForeName': 'Yasuhisa', 'Initials': 'Y', 'LastName': 'Ano', 'Affiliation': 'KIRIN Central Research Institute, Kirin Holdings Company, Ltd., Kanagawa, Japan.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-200229'] 1706,32475085,The Weight Optimization Revamping Lifestyle using the Dietary Guidelines (WORLD) Study: Sustained Weight Loss Over 12 Months.,"OBJECTIVE This study aimed to compare two energy-restricted, nutrient-dense diets at the upper or lower ends of the dietary fat recommendation range (lower fat [20% energy from fat] versus moderate fat [35%]) on weight loss using behavioral theory-based nutrition education. METHODS A total of 101 premenopausal women with overweight or obesity were randomized to an energy-restricted lower-fat or moderate-fat diet for 1 year. Interventions included 28 behavioral theory-based nutrition education sessions plus weekly exercise sessions. RESULTS Both treatment groups experienced weight loss (-5.0 kg for lower fat and -4.3 kg for moderate fat; P < 0.0001), but there was no difference in weight loss or fat intake between groups. Total and low-density lipoprotein cholesterol decreased (-3. 4 mg/dL and -3.8 mg/dL; P < 0.05), and high-density lipoprotein cholesterol increased (1.9 mg/dL; P < 0.05) in both groups at 12 months. Diet quality, assessed by the Healthy Eating Index, increased significantly at 4 months versus baseline (70.8 [0.9] vs. 77.8 [1.0]) and was maintained through 12 months. Higher Healthy Eating Index scores were associated with greater weight loss at 4 months (r = -0.2; P < 0.05). CONCLUSIONS In the context of a well-resourced, free-living weight-loss intervention, total fat intake did not change; however, theory-based nutrition education underpinned by food-based recommendations resulted in caloric deficits, improvements in diet quality, and weight loss that was sustained for 1 year.",2020,"Higher Healthy Eating Index scores were associated with greater weight loss at 4 months (r = -0.2; P < 0.05). ",['101 premenopausal women with overweight or obesity'],"['28 behavioral theory-based nutrition education sessions plus weekly exercise sessions', 'energy-restricted lower-fat or moderate-fat diet for 1 year']","['Weight Loss', 'Diet quality', 'diet quality, and weight loss', 'high-density lipoprotein cholesterol', 'weight loss', 'Healthy Eating Index', 'weight loss or fat intake', 'Higher Healthy Eating Index scores', 'Total and low-density lipoprotein cholesterol']","[{'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0242970', 'cui_str': 'Low fat diet'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0301585', 'cui_str': 'Fat diet'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C4280021', 'cui_str': 'Healthy Eating Index'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}]",101.0,0.0236992,"Higher Healthy Eating Index scores were associated with greater weight loss at 4 months (r = -0.2; P < 0.05). ","[{'ForeName': 'Tricia L', 'Initials': 'TL', 'LastName': 'Psota', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania, USA.'}, {'ForeName': 'Alyssa M', 'Initials': 'AM', 'LastName': 'Tindall', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania, USA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Lohse', 'Affiliation': 'Wegmans School of Health and Nutrition, Rochester Institute of Technology, Rochester, New York, USA.'}, {'ForeName': 'Paige E', 'Initials': 'PE', 'LastName': 'Miller', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania, USA.'}, {'ForeName': 'Kristina S', 'Initials': 'KS', 'LastName': 'Petersen', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania, USA.'}, {'ForeName': 'Penny M', 'Initials': 'PM', 'LastName': 'Kris-Etherton', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania, USA.'}]","Obesity (Silver Spring, Md.)",['10.1002/oby.22824'] 1707,32475095,Efficacy and Safety of Abdominal Trunk Muscle Strengthening Using an Innovative Device in Elderly Patients With Chronic Low Back Pain: A Pilot Study.,"OBJECTIVE To examine the efficacy and safety of an innovative, device-driven abdominal trunk muscle strengthening program, with the ability to measure muscle strength, to treat chronic low back pain (LBP) in elderly participants. METHODS Seven women with non-specific chronic LBP, lasting at least 3 months, were enrolled and treated with the prescribed exercise regimen. Patients participated in a 12-week device-driven exercise program which included abdominal trunk muscle strengthening and 4 types of stretches for the trunk and lower extremities. Primary outcomes were adverse events associated with the exercise program, improvement in abdominal trunk muscle strength, as measured by the device, and improvement in the numerical rating scale (NRS) scores of LBP with the exercise. Secondary outcomes were improvement in the Roland-Morris Disability Questionnaire (RDQ) score and the results of the locomotive syndrome risk test, including the stand-up and two-step tests. RESULTS There were no reports of increased back pain or new-onset abdominal pain or discomfort during or after the device-driven exercise program. The mean abdominal trunk muscle strength, NRS, RDQ scores, and the stand-up and two-step test scores were significantly improved at the end of the trial compared to baseline. CONCLUSION No participants experienced adverse events during the 12-week strengthening program, which involved the use of our device and stretching, indicating the program was safe. Further, the program significantly improved various measures of LBP and physical function in elderly participants.",2020,There were no reports of increased back pain or new-onset abdominal pain or discomfort during or after the device-driven exercise program.,"['Elderly Patients With Chronic Low Back Pain', 'elderly participants', 'Seven women with non-specific chronic LBP, lasting at least 3 months, were enrolled and treated with the prescribed exercise regimen']","['innovative, device-driven abdominal trunk muscle strengthening program', 'Abdominal Trunk Muscle', 'device-driven exercise program which included abdominal trunk muscle strengthening and 4 types of stretches for the trunk and lower extremities', 'Strengthening Using an Innovative Device']","['back pain or new-onset abdominal pain or discomfort', 'Roland-Morris Disability Questionnaire (RDQ) score and the results of the locomotive syndrome risk test, including the stand-up and two-step tests', 'adverse events associated with the exercise program, improvement in abdominal trunk muscle strength, as measured by the device, and improvement in the numerical rating scale (NRS) scores of LBP with the exercise', 'LBP and physical function', 'efficacy and safety', 'mean abdominal trunk muscle strength, NRS, RDQ scores, and the stand-up and two-step test scores', 'adverse events']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205370', 'cui_str': 'Non-specific'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]","[{'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0581755', 'cui_str': 'Skeletal muscle structure of trunk'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0441732', 'cui_str': 'Type 4'}, {'cui': 'C0270814', 'cui_str': 'Spastic syndrome'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}]","[{'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C4087189', 'cui_str': 'Locomotive syndrome'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0444796', 'cui_str': 'Standing up'}, {'cui': 'C0087028', 'cui_str': 'Step Test'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0581755', 'cui_str': 'Skeletal muscle structure of trunk'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",7.0,0.0363891,There were no reports of increased back pain or new-onset abdominal pain or discomfort during or after the device-driven exercise program.,"[{'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Kato', 'Affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.'}, {'ForeName': 'Satoru', 'Initials': 'S', 'LastName': 'Demura', 'Affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Kurokawa', 'Affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Takahashi', 'Affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.'}, {'ForeName': 'Kazuya', 'Initials': 'K', 'LastName': 'Shinmura', 'Affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.'}, {'ForeName': 'Noriaki', 'Initials': 'N', 'LastName': 'Yokogawa', 'Affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.'}, {'ForeName': 'Noritaka', 'Initials': 'N', 'LastName': 'Yonezawa', 'Affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.'}, {'ForeName': 'Takaki', 'Initials': 'T', 'LastName': 'Shimizu', 'Affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.'}, {'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Kitagawa', 'Affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Tsuchiya', 'Affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.'}]",Annals of rehabilitation medicine,['10.5535/arm.19100'] 1708,32482541,"Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.","BACKGROUND In the phase III CASTOR study in relapsed or refractory multiple myeloma, daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical benefit versus Vd alone. Outcomes after 40.0 months of median follow-up are discussed. PATIENTS AND METHODS Eligible patients had received ≥ 1 line of treatment and were administered bortezomib (1.3 mg/m 2 ) and dexamethasone (20 mg) for 8 cycles with or without daratumumab (16 mg/kg) until disease progression. RESULTS Of 498 patients in the intent-to-treat (ITT) population (D-Vd, n = 251; Vd, n = 247), 47% had 1 prior line of treatment (1PL; D-Vd, n = 122; Vd, n = 113). Median progression-free survival (PFS) was significantly prolonged with D-Vd versus Vd in the ITT population (16.7 vs. 7.1 months; hazard ratio [HR], 0.31; 95% confidence interval [CI], 0.25-0.40; P < .0001) and the 1PL subgroup (27.0 vs. 7.9 months; HR, 0.22; 95% CI, 0.15-0.32; P < .0001). In lenalidomide-refractory patients, the median PFS was 7.8 versus 4.9 months (HR, 0.44; 95% CI, 0.28-0.68; P = .0002) for D-Vd (n = 60) versus Vd (n = 81). Minimal residual disease (MRD)-negativity rates (10 -5 ) were greater with D-Vd versus Vd (ITT: 14% vs. 2%; 1PL: 20% vs. 3%; both P < .0001). PFS2 was significantly prolonged with D-Vd versus Vd (ITT: HR, 0.48; 95% CI, 0.38-0.61; 1PL: HR, 0.35; 95% CI, 0.24-0.51; P < .0001). No new safety concerns were observed. CONCLUSION After 3 years, D-Vd maintained significant benefits in patients with relapsed or refractory multiple myeloma with a consistent safety profile. D-Vd provided the greatest benefit at first relapse and increased MRD-negativity rates.",2020,"PFS2 was significantly prolonged with D-Vd versus Vd (ITT: HR, 0.48; 95% CI, 0.38-0.61; 1PL: HR, 0.35; 95% CI, 0.24-0.51; P < .0001).","['Patients With Previously Treated Multiple Myeloma', 'patients with relapsed or refractory multiple myeloma', '498 patients in the intent-to-treat (ITT) population (D-Vd, n\xa0= 251; Vd, n\xa0= 247', 'Eligible patients had received\xa0≥ 1 line of treatment and were\xa0administered']","['Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone', 'bortezomib', 'dexamethasone']","['MRD-negativity rates', 'PFS2', 'Median progression-free survival (PFS', 'Minimal residual disease (MRD)-negativity rates', 'median PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C4551538', 'cui_str': 'Plasma cell myeloma refractory'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0761050', 'cui_str': '(GVGVP)251'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1533734', 'cui_str': 'Administration'}]","[{'cui': 'C2346801', 'cui_str': 'daratumumab'}, {'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}]","[{'cui': 'C0242596', 'cui_str': 'Minimal residual disease'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",-5.0,0.0659076,"PFS2 was significantly prolonged with D-Vd versus Vd (ITT: HR, 0.48; 95% CI, 0.38-0.61; 1PL: HR, 0.35; 95% CI, 0.24-0.51; P < .0001).","[{'ForeName': 'Maria-Victoria', 'Initials': 'MV', 'LastName': 'Mateos', 'Affiliation': 'Department of Hematology, University Hospital of Salamanca/IBSAL, Salamanca, Spain.'}, {'ForeName': 'Pieter', 'Initials': 'P', 'LastName': 'Sonneveld', 'Affiliation': 'Department of Hematology, Erasmus MC, Rotterdam, The Netherlands.'}, {'ForeName': 'Vania', 'Initials': 'V', 'LastName': 'Hungria', 'Affiliation': 'Irmandade Da Santa Casa De Misericordia De São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Ajay K', 'Initials': 'AK', 'LastName': 'Nooka', 'Affiliation': 'Winship Cancer Institute, Emory University, Atlanta, GA.'}, {'ForeName': 'Jane A', 'Initials': 'JA', 'LastName': 'Estell', 'Affiliation': 'Haematology Department, Concord Cancer Centre, Concord Hospital, University of Sydney, Concord NSW, Australia.'}, {'ForeName': 'Wolney', 'Initials': 'W', 'LastName': 'Barreto', 'Affiliation': 'Hospital Santa Marcelina, São Paulo, Brazil.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Corradini', 'Affiliation': 'Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Chang-Ki', 'Initials': 'CK', 'LastName': 'Min', 'Affiliation': ""Seoul St. Mary's Hospital, Seoul, The Republic of Korea.""}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Medvedova', 'Affiliation': 'Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Weisel', 'Affiliation': 'University Medical Center of Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Chiu', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA.'}, {'ForeName': 'Jordan M', 'Initials': 'JM', 'LastName': 'Schecter', 'Affiliation': 'Janssen Research & Development, LLC, Raritan, NJ.'}, {'ForeName': 'Himal', 'Initials': 'H', 'LastName': 'Amin', 'Affiliation': 'Janssen Research & Development, LLC, Raritan, NJ.'}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Qin', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Ukropec', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Kobos', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Spencer', 'Affiliation': 'Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia. Electronic address: aspencer@netspace.net.au.'}]","Clinical lymphoma, myeloma & leukemia",['10.1016/j.clml.2019.09.623'] 1709,32483186,The Help for Hay Fever community pharmacy-based pilot randomised controlled trial for intermittent allergic rhinitis.,"Management of intermittent allergic rhinitis (IAR) is suboptimal in the UK. An Australian community pharmacy-based intervention has been shown to help patients better self-manage their IAR. We conducted a pilot cluster RCT in 12 Scottish community pharmacies to assess transferability of the Australian intervention. Trained staff in intervention pharmacies delivered the intervention to eligible customers (n = 60). Non-intervention pharmacy participants (n = 65) received usual care. Outcome measures included effect size of change in the mini-Rhinoconjunctivitis Quality of Life Questionnaire (miniRQLQ) between baseline, 1-week and 6-week follow-up. Trial procedures were well received by pharmacy staff, and customer satisfaction with the intervention was high. The standardised effect size for miniRQLQ total score was -0.46 (95% CI, -1.05, 0.13) for all participants and -0.14 (95% CI,-0.86, 0.57) in the complete case analysis, suggesting a small overall treatment effect in the intervention group. A full-scale RCT is warranted to fully evaluate the effectiveness of this service.",2020,The standardised effect size for miniRQLQ total score was -0.46,"['12 Scottish community pharmacies to assess transferability of the Australian intervention', 'intermittent allergic rhinitis (IAR']",['usual care'],"['miniRQLQ total score', 'effect size of change in the mini-Rhinoconjunctivitis Quality of Life Questionnaire (miniRQLQ']","[{'cui': 'C0009478', 'cui_str': 'Community Pharmacies'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C2607914', 'cui_str': 'Allergic rhinitis'}]",[],"[{'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0861155', 'cui_str': 'Rhinoconjunctivitis'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",,0.163936,The standardised effect size for miniRQLQ total score was -0.46,"[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Smith', 'Affiliation': 'Institute of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK.'}, {'ForeName': 'Terry', 'Initials': 'T', 'LastName': 'Porteous', 'Affiliation': 'Institute of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK. t.porteous@abdn.ac.uk.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Bond', 'Affiliation': 'Institute of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Francis', 'Affiliation': 'School of Health Sciences, City, University of London, Northampton Square, London, EC1V 0HB, UK.'}, {'ForeName': 'Amanda J', 'Initials': 'AJ', 'LastName': 'Lee', 'Affiliation': 'Institute of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Lowrie', 'Affiliation': 'Pharmacy Research and Development Team, Pharmacy and Prescribing Support Unit, West Glasgow Ambulatory Care Hospital, Glasgow, G3 8SJ, UK.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Scotland', 'Affiliation': 'Institute of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK.'}, {'ForeName': 'Aziz', 'Initials': 'A', 'LastName': 'Sheikh', 'Affiliation': 'Allergy and Respiratory Research Group, Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG, UK.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Thomas', 'Affiliation': 'Primary Care and Population Sciences, University of Southampton, Aldermoor Health Centre, Aldermoor Close, Southampton, SO16 5ST, UK.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Wyke', 'Affiliation': 'Institute of Health and Wellbeing, College of Social Sciences, University of Glasgow, 27 Bute Gardens, Glasgow, G12 8RS, UK.'}, {'ForeName': 'Lorraine', 'Initials': 'L', 'LastName': 'Smith', 'Affiliation': 'Faculty of Pharmacy, Building A15, The University of Sydney, Camperdown, NSW, 2006, Australia.'}]",NPJ primary care respiratory medicine,['10.1038/s41533-020-0180-4'] 1710,32484259,Repositioning for pressure injury prevention in adults.,"BACKGROUND A pressure injury (PI), also referred to as a 'pressure ulcer', or 'bedsore', is an area of localised tissue damage caused by unrelieved pressure, friction, or shearing on any part of the body. Immobility is a major risk factor and manual repositioning a common prevention strategy. This is an update of a review first published in 2014. OBJECTIVES To assess the clinical and cost effectiveness of repositioning regimens(i.e. repositioning schedules and patient positions) on the prevention of PI in adults regardless of risk in any setting. SEARCH METHODS We searched the Cochrane Wounds Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Ovid Embase, and EBSCO CINAHL Plus on 12 February 2019. We also searched clinical trials registries for ongoing and unpublished studies, and scanned the reference lists of included studies as well as reviews, meta-analyses, and health technology reports to identify additional studies. There were no restrictions with respect to language, date of publication, or study setting. SELECTION CRITERIA Randomised controlled trials (RCTs), including cluster-randomised trials (c-RCTs), published or unpublished, that assessed the effects of any repositioning schedule or different patient positions and measured PI incidence in adults in any setting. DATA COLLECTION AND ANALYSIS Three review authors independently performed study selection, 'Risk of bias' assessment, and data extraction. We assessed the certainty of the evidence using GRADE. MAIN RESULTS We identified five additional trials and one economic substudy in this update, resulting in the inclusion of a total of eight trials involving 3941 participants from acute and long-term care settings and two economic substudies in the review. Six studies reported the proportion of participants developing PI of any stage. Two of the eight trials reported within-trial cost evaluations. Follow-up periods were short (24 hours to 21 days). All studies were at high risk of bias. Funding sources were reported in five trials. Primary outcomes: proportion of new PI of any stage Repositioning frequencies: three trials compared different repositioning frequencies We pooled data from three trials (1074 participants) comparing 2-hourly with 4-hourly repositioning frequencies (fixed-effect; I² = 45%; pooled risk ratio (RR) 1.06, 95% confidence interval (CI) 0.80 to 1.41). It is uncertain whether 2-hourly repositioning compared with 4-hourly repositioning used in conjunction with any support surface increases or decreases the incidence of PI. The certainty of the evidence is very low due to high risk of bias, downgraded twice for risk of bias, and once for imprecision. One of these trials had three arms (967 participants) comparing 2-hourly, 3-hourly, and 4-hourly repositioning regimens on high-density mattresses; data for one comparison was included in the pooled analysis. Another comparison was based on 2-hourly versus 3-hourly repositioning. The RR for PI incidence was 4.06 (95% CI 0.87 to 18.98). The third study comparison was based on 3-hourly versus 4-hourly repositioning (RR 0.20, 95% CI 0.04 to 0.92). The certainty of the evidence is low due to risk of bias and imprecision. In one c-RCT, 262 participants in 32 ward clusters were randomised between 2-hourly and 3-hourly repositioning on standard mattresses and 4-hourly and 6-hourly repositioning on viscoelastic mattresses. The RR for PI with 2-hourly repositioning compared with 3-hourly repositioning on standard mattress is imprecise (RR 0.90, 95% CI 0.69 to 1.16; very low-certainty evidence). The CI for PI include both a large reduction and no difference for the comparison of 4-hourly and 6-hourly repositioning on viscoelastic foam (RR 0.73, 95% CI 0.53 to 1.02). The certainty of the evidence is very low, downgraded twice due to high risk of bias, and once for imprecision. Positioning regimens: four trials compared different tilt positions We pooled data from two trials (252 participants) that compared a 30° tilt with a 90° tilt (random-effects; I² = 69%). There was no clear difference in the incidence of stage 1 or 2 PI. The effect of tilt is uncertain because the certainty of evidence is very low (pooled RR 0.62, 95% CI 0.10 to 3.97), downgraded due to serious design limitations and very serious imprecision. One trial involving 120 participants compared 30° tilt and 45° tilt with 'usual care' and reported no occurrence of PI events (low certainty evidence). Another trial involving 116 ICU patients compared prone with the usual supine positioning for PI. Reporting was incomplete and this is low certainty evidence. Secondary outcomes No studies reported health-related quality of life utility scores, procedural pain, or patient satisfaction. Cost analysis Two included trials also performed economic analyses. A cost-minimisation analysis compared the costs of 3-hourly and 4-hourly repositioning with 2-hourly repositioning schedule amongst nursing home residents. The cost of repositioning was estimated at CAD 11.05 and CAD 16.74 less per resident per day for the 3-hourly or 4-hourly regimen, respectively, compared with the 2-hourly regimen. The estimates of economic benefit were driven mostly by the value of freed nursing time. The analysis assumed that 2-, 3-, or 4-hourly repositioning is associated with a similar incidence of PI, as no difference in incidence was observed. A second study compared the nursing time cost of 3-hourly repositioning using a 30° tilt with standard care (6-hourly repositioning with a 90° lateral rotation) amongst nursing home residents. The intervention was reported to be cost-saving compared with standard care (nursing time cost per patient EUR 206.60 versus EUR 253.10, incremental difference EUR -46.50, 95% CI EUR -1.25 to EUR -74.60). AUTHORS' CONCLUSIONS Despite the addition of five trials, the results of this update are consistent with our earlier review, with the evidence judged to be of low or very low certainty. There remains a lack of robust evaluations of repositioning frequency and positioning for PI prevention and uncertainty about their effectiveness. Since all comparisons were underpowered, there is a high level of uncertainty in the evidence base. Given the limited data from economic evaluations, it remains unclear whether repositioning every three hours using the 30° tilt versus ""usual care"" (90° tilt) or repositioning 3-to-4-hourly versus 2-hourly is less costly relative to nursing time.",2020,"The CI for PI include both a large reduction and no difference for the comparison of 4-hourly and 6-hourly repositioning on viscoelastic foam (RR 0.73, 95% CI 0.53 to 1.02).","[""120 participants compared 30° tilt and 45° tilt with 'usual care' and reported no occurrence of PI events (low certainty evidence"", '3941 participants from acute and long-term care settings and two economic substudies in the review', '262 participants in 32 ward clusters', 'adults', 'adults in any setting', 'nursing home residents', 'adults regardless of risk in any setting', 'two trials (252 participants) that compared a 30° tilt with a 90° tilt (random-effects; I² = 69', '116 ICU patients']","['2-hourly and 3-hourly repositioning on standard mattresses and 4-hourly and 6-hourly repositioning on viscoelastic mattresses', '3-hourly repositioning using a 30° tilt with standard care (6-hourly repositioning with a 90° lateral rotation', 'tilt positions']","['health-related quality of life utility scores, procedural pain, or patient satisfaction', 'cost of repositioning', 'Cost analysis', 'incidence of stage 1 or 2 PI', 'proportion of new PI of any stage Repositioning frequencies', 'cost-saving', 'RR for PI incidence', 'incidence of PI']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0332679', 'cui_str': 'Crushing injury'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205423', 'cui_str': 'Certain'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0013556', 'cui_str': 'Economics'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C4517541', 'cui_str': '116'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0585322', 'cui_str': 'Every two hours'}, {'cui': 'C0585323', 'cui_str': 'Every three hours'}, {'cui': 'C0556030', 'cui_str': 'Repositioning'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0024940', 'cui_str': 'Mattress'}, {'cui': 'C0558292', 'cui_str': 'Hourly'}, {'cui': 'C0231462', 'cui_str': 'External rotation'}, {'cui': 'C0733755', 'cui_str': 'Position'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1619712', 'cui_str': 'Procedural pain'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0556030', 'cui_str': 'Repositioning'}, {'cui': 'C0010171', 'cui_str': 'Analysis, Cost'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0332679', 'cui_str': 'Crushing injury'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0085550', 'cui_str': 'Cost Savings'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}]",116.0,0.24709,"The CI for PI include both a large reduction and no difference for the comparison of 4-hourly and 6-hourly repositioning on viscoelastic foam (RR 0.73, 95% CI 0.53 to 1.02).","[{'ForeName': 'Brigid M', 'Initials': 'BM', 'LastName': 'Gillespie', 'Affiliation': 'School of Nursing and Midwifery, Griffith University, Brisbane, Australia.'}, {'ForeName': 'Rachel M', 'Initials': 'RM', 'LastName': 'Walker', 'Affiliation': 'School of Nursing and Midwifery, Griffith University, Brisbane, Australia.'}, {'ForeName': 'Sharon L', 'Initials': 'SL', 'LastName': 'Latimer', 'Affiliation': 'School of Nursing and Midwifery, Griffith University, Brisbane, Australia.'}, {'ForeName': 'Lukman', 'Initials': 'L', 'LastName': 'Thalib', 'Affiliation': 'Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.'}, {'ForeName': 'Jennifer A', 'Initials': 'JA', 'LastName': 'Whitty', 'Affiliation': 'Health Economics Group, Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'McInnes', 'Affiliation': ""Nursing Research Institute, St Vincent's Health Australia Sydney, St Vincent's Hospital Melbourne & Australian Catholic University, Fitzroy, Melbourne, Australia.""}, {'ForeName': 'Wendy P', 'Initials': 'WP', 'LastName': 'Chaboyer', 'Affiliation': 'School of Nursing and Midwifery, Griffith University, Brisbane, Australia.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD009958.pub3'] 1711,32481563,Effects of Ginseng Ingestion on Salivary Testosterone and DHEA Levels in Healthy Females: An Exploratory Study.,"Ginseng is a traditional herbal adaptogen that has been historically used in China and the Far East. Ginsenosides are the active component of ginseng known to exert several actions by targeting ""multi-receptor systems"", both extracellular and intracellular. In humans, ginseng effects remain unclear. This study aimed to investigate whether ginseng can influence salivary androgen levels (testosterone and dehydroepiandrosterone (DHEA)) in females. The study followed a parallel partially controlled design. Healthy women ( n = 24) were recruited and divided into two groups (A = 20-32 and B = 38-50 years). Volunteers were asked to maintain a food diary pre and post ginseng consumption and collected four salivary samples (7 a.m., 9 a.m., 12 p.m., and 5 p.m.) before and after ingesting 75 mg red Korean ginseng extract per day for seven days. Testosterone and DHEA were then assayed by ELISA methods. Group A's mean daily salivary testosterone pre ginseng ingestion increased from 76.3 ± 16.6 to 98.4 ± 21.1 pg/mL post ginseng (p < 0.01) with significant difference at all time points, and mean daily salivary DHEA increased from 1.53 ± 0.63 to 1.98 ± 0.89 ng/mL post ginseng ( p = 0.02). Group B's mean daily salivary testosterone pre ginseng ingestion was 61.2 ± 16.9 and post ginseng 68.1 ± 11.5 pg/mL ( p = 0.132), and daily salivary DHEA increased from 0.91 ± 0.32 to 1.62 ± 0.49 ng/mL post ginseng ( p = 0.014) with significant difference at all time points. In conclusion, it appears that ginseng intake significantly increased salivary testosterone levels in the younger women group, but only slightly in the older group. However, DHEA levels in the older women showed a marked and significant increase. These results suggest a potential role for ginseng in modulating salivary androgen levels and that such effect may be more evident in older women where the levels of androgens (DHEA) start to decline. However, it has to be stressed that our results are preliminary and further properly controlled trials are justified.",2020,"Group A's mean daily salivary testosterone pre ginseng ingestion increased from 76.3 ± 16.6 to 98.4 ± 21.1 pg/mL post ginseng (p < 0.01) with significant difference at all time points, and mean daily salivary DHEA increased from 1.53 ± 0.63 to 1.98 ± 0.89 ng/mL post ginseng ( p = 0.02).","['females', 'older women', 'Healthy women ( n = 24', 'Healthy Females']","['Ginseng', 'ginseng', 'Ginseng Ingestion']","['Salivary Testosterone and DHEA Levels', 'salivary androgen levels (testosterone and dehydroepiandrosterone (DHEA', 'mean daily salivary testosterone pre ginseng ingestion', 'daily salivary DHEA', 'DHEA levels', 'Testosterone and DHEA', 'salivary testosterone levels', 'mean daily salivary DHEA']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0086767', 'cui_str': 'Ginseng'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}]","[{'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0011185', 'cui_str': 'prasterone'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0919646', 'cui_str': 'Androgen level'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0086767', 'cui_str': 'Ginseng'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0523912', 'cui_str': 'Testosterone measurement'}]",24.0,0.121192,"Group A's mean daily salivary testosterone pre ginseng ingestion increased from 76.3 ± 16.6 to 98.4 ± 21.1 pg/mL post ginseng (p < 0.01) with significant difference at all time points, and mean daily salivary DHEA increased from 1.53 ± 0.63 to 1.98 ± 0.89 ng/mL post ginseng ( p = 0.02).","[{'ForeName': 'Emad A S', 'Initials': 'EAS', 'LastName': 'Al-Dujaili', 'Affiliation': ""Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK.""}, {'ForeName': 'Maha N', 'Initials': 'MN', 'LastName': 'Abu Hajleh', 'Affiliation': 'Department of Pharmaceutical sciences, Faculty of Pharmacy, University of Jordan, Amman 11942, Jordan.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Chalmers', 'Affiliation': 'Biological Sciences, Queen Margaret University, Edinburgh EH21 6UU, UK.'}]",Nutrients,['10.3390/nu12061582'] 1712,32482433,Effects of Exercise and an Integrated Neuromuscular Inhibition Technique Program in the Management of Chronic Mechanical Neck Pain: A Randomized Controlled Trial.,"OBJECTIVE The aim of this study was to evaluate the effect of adding the integrated neuromuscular inhibition technique (INIT) to therapeutic exercise (TE) in individuals with chronic mechanical neck pain (CMNP). METHODS In this 34-week, assessor-blind randomized controlled trial, 40 participants (men and women) with CMNP with active or latent myofascial trigger points on the neck muscles were divided into 2 groups. The participants followed 4 treatments per week for 10 weeks. The intervention group followed a TE program in combination with the INIT, whereas the control group followed the same program without the INIT. Both protocols were applied by physiotherapists. Pain, disability, pressure pain threshold, active range of motion, and health-related quality of life were evaluated before, during, and after the intervention, whereas patients were followed for 6 months after completion of treatment. Repeated-measures ANOVA was applied. RESULTS Both groups showed a significant improvement in all dependent measures after the intervention (P < .05). However, the intervention group showed greater improvement in the visual analog scale and neck disability index score, in the neck muscles pressure pain threshold, in the range of motion, and in the 36-Item Short Form Health Survey score, than the control group. In many of the above variables this improvement was seen from the second week and was maintained for 6 months after the intervention. CONCLUSION The results of this preliminary study suggest that the addition of the INIT to a TE program had a positive effect on pain, functionality, and the quality of life in individuals with CMNP.",2020,"However, the intervention group showed greater improvement in the visual analog scale and neck disability index score, in the neck muscles pressure pain threshold, in the range of motion, and in the 36-Item Short Form Health Survey score, than the control group.","['Chronic Mechanical Neck Pain', 'individuals with chronic mechanical neck pain (CMNP', '40 participants (men and women) with CMNP with active or latent myofascial trigger points on the neck muscles', 'individuals with CMNP']","['TE program in combination with the INIT, whereas the control group followed the same program without the INIT', 'integrated neuromuscular inhibition technique (INIT) to therapeutic exercise (TE', 'Exercise and an Integrated Neuromuscular Inhibition Technique Program']","['visual analog scale and neck disability index score, in the neck muscles pressure pain threshold, in the range of motion, and in the 36-Item Short Form Health Survey score', 'pain, functionality, and the quality of life', 'Pain, disability, pressure pain threshold, active range of motion, and health-related quality of life']","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205275', 'cui_str': 'Latent'}, {'cui': 'C0458343', 'cui_str': 'Trigger point'}, {'cui': 'C0027532', 'cui_str': 'Skeletal muscle structure of neck'}]","[{'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0234119', 'cui_str': 'Neuromuscular blockade'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C2959538', 'cui_str': 'Neck disability index score'}, {'cui': 'C0027532', 'cui_str': 'Skeletal muscle structure of neck'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}]",40.0,0.0689753,"However, the intervention group showed greater improvement in the visual analog scale and neck disability index score, in the neck muscles pressure pain threshold, in the range of motion, and in the 36-Item Short Form Health Survey score, than the control group.","[{'ForeName': 'Dimitrios E', 'Initials': 'DE', 'LastName': 'Lytras', 'Affiliation': 'Laboratory of Ergophysiology, Department of Physical Education and Sports Sciences, Aristotle University of Thessaloniki, Thermi Thessaloniki, Greece. Electronic address: lytrasde@gmail.com.'}, {'ForeName': 'Evaggelos I', 'Initials': 'EI', 'LastName': 'Sykaras', 'Affiliation': 'Laboratory of Ergophysiology, Department of Physical Education and Sports Sciences, Aristotle University of Thessaloniki, Thermi Thessaloniki, Greece.'}, {'ForeName': 'Kosmas I', 'Initials': 'KI', 'LastName': 'Christoulas', 'Affiliation': 'Laboratory of Ergophysiology, Department of Physical Education and Sports Sciences, Aristotle University of Thessaloniki, Thermi Thessaloniki, Greece.'}, {'ForeName': 'Ioannis S', 'Initials': 'IS', 'LastName': 'Myrogiannis', 'Affiliation': 'Laboratory of Hygiene-Medical Statistics, School of Medicine, Aristotle University of Thessaloniki, University Campus, Thessaloniki, Greece.'}, {'ForeName': 'Eleftherios', 'Initials': 'E', 'LastName': 'Kellis', 'Affiliation': 'Laboratory of Neuromechanics, Department of Physical Education and Sport Science at Serres, Aristotle University of Thessaloníki, Agios Ioannis Serres, Greece.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2019.03.011'] 1713,32485993,"Acute and Chronic Effects of Green Oat ( Avena sativa) Extract on Cognitive Function and Mood during a Laboratory Stressor in Healthy Adults: A Randomised, Double-Blind, Placebo-Controlled Study in Healthy Humans.","Green oat ( Avena sativa ) extracts contain several groups of potentially psychoactive phytochemicals. Previous research has demonstrated improvements in cognitive function following a single dose of these extracts, but not following chronic supplementation. Additionally, whilst green oat extracts contain phytochemicals that may improve mood or protect against stress, for instance species-specific triterpene saponins, to date this possibility has not been examined. The current study investigated the effects of a single dose and four weeks of administration of a novel, Avena sativa herbal extract (cognitaven ® ) on cognitive function and mood, and changes in psychological state during a laboratory stressor. The study adopted a dose-ranging, double-blind, randomised, parallel groups design in which 132 healthy males and females (35 to 65 years) received either 430 mg, 860 mg, 1290 mg green oat extract or placebo for 29 days. Assessments of cognitive function, mood and changes in psychological state during a laboratory stressor (Observed Multitasking Stressor) were undertaken pre-dose and at 2 h and 4 h post-dose on the first (Day 1) and last days (Day 29) of supplementation. The results showed that both a single dose of 1290 mg and, to a greater extent, supplementation for four weeks with both 430 mg and 1290 mg green oat extract resulted in significantly improved performance on a computerised version of the Corsi Blocks working memory task and a multitasking task (verbal serial subtractions and computerised tracking) in comparison to placebo. After four weeks, the highest dose also decreased the physiological response to the stressor in terms of electrodermal activity. There were no treatment-related effects on mood. These results confirm the acute cognitive effects of Avena sativa extracts and are the first to demonstrate that chronic supplementation can benefit cognitive function and modulate the physiological response to a stressor.",2020,"After four weeks, the highest dose also decreased the physiological response to the stressor in terms of electrodermal activity.","['Healthy Humans', '132 healthy males and females (35 to 65 years', 'Healthy Adults']","['Placebo', 'Green oat ( Avena sativa ) extracts', 'novel, Avena sativa herbal extract (cognitaven ® ', 'green oat extract or placebo', 'Green Oat ( Avena sativa) Extract', 'placebo']","['physiological response', 'cognitive function', 'performance on a computerised version of the Corsi Blocks working memory task and a multitasking task (verbal serial subtractions and computerised tracking', 'cognitive function and mood, and changes in psychological state', 'cognitive function, mood and changes in psychological state', 'Cognitive Function and Mood']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332583', 'cui_str': 'Green color'}, {'cui': 'C0028753', 'cui_str': 'Oats'}, {'cui': 'C0939905', 'cui_str': 'Oats preparation'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0376667', 'cui_str': 'Herbals'}, {'cui': 'C1364956', 'cui_str': 'Oat extract'}]","[{'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C1301808', 'cui_str': 'State'}]",132.0,0.197591,"After four weeks, the highest dose also decreased the physiological response to the stressor in terms of electrodermal activity.","[{'ForeName': 'David O', 'Initials': 'DO', 'LastName': 'Kennedy', 'Affiliation': 'Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle-upon-Tyne NE1 8ST, UK.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Bonnländer', 'Affiliation': 'Anklam Extrakt GmbH, Marienbergstr. 92, 90411 Nuremberg, Germany.'}, {'ForeName': 'Stefanie C', 'Initials': 'SC', 'LastName': 'Lang', 'Affiliation': 'Anklam Extrakt GmbH, Marienbergstr. 92, 90411 Nuremberg, Germany.'}, {'ForeName': 'Ivo', 'Initials': 'I', 'LastName': 'Pischel', 'Affiliation': 'Research Group Pharmacognosy and Phytotherapy, UCL School of Pharmacy, London WC1N 1AX, UK.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Forster', 'Affiliation': 'Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle-upon-Tyne NE1 8ST, UK.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Khan', 'Affiliation': 'Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle-upon-Tyne NE1 8ST, UK.'}, {'ForeName': 'Philippa A', 'Initials': 'PA', 'LastName': 'Jackson', 'Affiliation': 'Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle-upon-Tyne NE1 8ST, UK.'}, {'ForeName': 'Emma L', 'Initials': 'EL', 'LastName': 'Wightman', 'Affiliation': 'NUTRAN, Northumbria University, Newcastle NE1 8ST, UK.'}]",Nutrients,['10.3390/nu12061598'] 1714,32486864,Robot-Assisted Laparoscopic Partial Nephrectomy Vs Conventional Laparoscopic Partial Nephrectomy: Functional and Surgical Outcomes of a Prospective Single Surgeon Randomized Study.,"Background: Laparoscopic partial nephrectomy (LPN) and robot-assisted partial nephrectomy (RAPN) are commonly used techniques for treating small renal masses. Regarding renal function (RF) preservation, no superiority of one technique over the other has yet been definitely demonstrated. Objective: To compare functional and surgical outcomes of LPN and RAPN. Patients and Methods: Between 2015 and 2019, we prospectively randomized 115 patients with cT1-T2 renal masses to LPN in total ischemia or RAPN in selective ischemia. Primary endpoint was RF preservation, assessed by renal scintigraphy (RS). RS assessments were performed preoperatively and at 6 months follow-up. Secondary endpoints included clinical, histopathologic, and surgical outcomes. Results: One hundred eight patients were included in the final analysis. Patient and tumor characteristics were comparable. No significant difference in RS values after 6 months was observed between both groups. Median (interquartile range) RF change after 6 months was -18.0% (-26.5 to -11.0) in LPN group and -20.0 (-33.2 to -12.0) in RAPN group ( p  = 0.3). Mean (standard deviation [SD]) warm ischemia time was 21.1 (6.1) minutes in LPN group and 19.6 (7.7) minutes in RAPN group ( p  = 0.2). No positive surgical margins (PSMs) occurred in the LPN group, whereas RAPN group had PSM in 4.9% ( n  = 3); p  = 0.099. Renal volume loss after 6 months was 27.5% (22.7-45.7) in the LPN group vs 37.5 (13.7-54.2) in the RAPN group ( p  = 0.5). Mean operative times were lower in the LPN group (192.3 minutes [SD 44.5] vs 230.2 minutes [SD 59.6], p  = 0.001). More complications occurred in the LPN group (31% vs 21%, p  = 0.075). Transfusion rates were 15% for LPN and 11% for RAPN. Conclusions: In terms of preserving RF, LPN in total ischemia and RAPN in selective ischemia are comparable. In most patients, RF decrease of the affected kidney after PN seems to not exceed 25%, regardless of the surgical approach.",2020,"Mean operative times were lower in the LPN group (192.3 min (SD 44.5) versus 230.2 min (SD 59.6), p=0.001).","['115 patients with cT1-T2 renal masses to LPN in total ischemia or RAPN in selective ischemia', 'Total Ischemia', '108 patients were included in the final analysis', 'Patients/Methods Between 2015 and 2019']","['RAPN', 'LPN', ' Laparoscopic partial nephrectomy (LPN) and robot-assisted partial nephrectomy (RAPN', 'Conventional Laparoscopic Partial Nephrectomy', 'Robot-assisted Laparoscopic Partial Nephrectomy', 'LPN and RAPN']","['Mean (SD) warm ischemia time', 'More complications', 'Median (IQR) RF change', 'positive surgical margins (PSM', 'Renal volume loss', 'Mean operative times', 'RF preservation, assessed by renal scintigraphy (RS', 'clinical, histopathological and surgical outcomes', 'Transfusion rates', 'RS values']","[{'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1438035', 'cui_str': 'SLC6A8 protein, human'}, {'cui': 'C0262613', 'cui_str': 'Renal mass'}, {'cui': 'C1144661', 'cui_str': 'Laparoscopic partial nephrectomy'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C4039858', 'cui_str': 'Robot assisted laparoscopic partial nephrectomy'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C4039858', 'cui_str': 'Robot assisted laparoscopic partial nephrectomy'}, {'cui': 'C1144661', 'cui_str': 'Laparoscopic partial nephrectomy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1563923', 'cui_str': 'Warm Ischemic Time'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1709603', 'cui_str': 'Positive Surgical Margins'}, {'cui': 'C1310550', 'cui_str': 'Pteroylpoly-gamma-glutamate carboxypeptidase'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",115.0,0.0746323,"Mean operative times were lower in the LPN group (192.3 min (SD 44.5) versus 230.2 min (SD 59.6), p=0.001).","[{'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Würnschimmel', 'Affiliation': 'Klinik für Urologie, Luzerner Kantonsspital, Luzern, Switzerland.'}, {'ForeName': 'Giovanni Battista', 'Initials': 'GB', 'LastName': 'Di Pierro', 'Affiliation': 'Klinik für Urologie, Luzerner Kantonsspital, Luzern, Switzerland.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Moschini', 'Affiliation': 'Klinik für Urologie, Luzerner Kantonsspital, Luzern, Switzerland.'}, {'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Grande', 'Affiliation': 'Klinik für Urologie, Luzerner Kantonsspital, Luzern, Switzerland.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Baumeister', 'Affiliation': 'Klinik für Urologie, Luzerner Kantonsspital, Luzern, Switzerland.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Roth', 'Affiliation': 'Klinik für Radiologie, Luzerner Kantonsspital, Luzern, Switzerland.'}, {'ForeName': 'Livio', 'Initials': 'L', 'LastName': 'Mordasini', 'Affiliation': 'Klinik für Urologie, Luzerner Kantonsspital, Luzern, Switzerland.'}, {'ForeName': 'Agostino', 'Initials': 'A', 'LastName': 'Mattei', 'Affiliation': 'Klinik für Urologie, Luzerner Kantonsspital, Luzern, Switzerland.'}]",Journal of endourology,['10.1089/end.2020.0143'] 1715,32459643,Adherence to Blended or Face-to-Face Smoking Cessation Treatment and Predictors of Adherence: Randomized Controlled Trial.,"BACKGROUND Blended face-to-face and web-based treatment is a promising way to deliver smoking cessation treatment. Since adherence has been shown to be an indicator of treatment acceptability and a determinant for effectiveness, we explored and compared adherence and predictors of adherence to blended and face-to-face alone smoking cessation treatments with similar content and intensity. OBJECTIVE The objectives of this study were (1) to compare adherence to a blended smoking cessation treatment with adherence to a face-to-face treatment; (2) to compare adherence within the blended treatment to its face-to-face mode and web mode; and (3) to determine baseline predictors of adherence to both treatments as well as (4) the predictors to both modes of the blended treatment. METHODS We calculated the total duration of treatment exposure for patients (N=292) of a Dutch outpatient smoking cessation clinic who were randomly assigned either to the blended smoking cessation treatment (n=130) or to a face-to-face treatment with identical components (n=162). For both treatments (blended and face-to-face) and for the two modes of delivery within the blended treatment (face-to-face vs web mode), adherence levels (ie, treatment time) were compared and the predictors of adherence were identified within 33 demographic, smoking-related, and health-related patient characteristics. RESULTS We found no significant difference in adherence between the blended and the face-to-face treatments. Participants in the blended treatment group spent an average of 246 minutes in treatment (median 106.7% of intended treatment time, IQR 150%-355%) and participants in the face-to-face group spent 238 minutes (median 103.3% of intended treatment time, IQR 150%-330%). Within the blended group, adherence to the face-to-face mode was twice as high as that to the web mode. Participants in the blended group spent an average of 198 minutes (SD 120) in face-to-face mode (152% of the intended treatment time) and 75 minutes (SD 53) in web mode (75% of the intended treatment time). Higher age was the only characteristic consistently found to uniquely predict higher adherence in both the blended and face-to-face groups. For the face-to-face group, more social support for smoking cessation was also predictive of higher adherence. The variability in adherence explained by these predictors was rather low (blended R 2 =0.049; face-to-face R 2 =0.076). Within the blended group, living without children predicted higher adherence to the face-to-face mode (R 2 =0.034), independent of age. Higher adherence to the web mode of the blended treatment was predicted by a combination of an extrinsic motivation to quit, a less negative attitude toward quitting, and less health complaints (R 2 =0.164). CONCLUSIONS This study represents one of the first attempts to thoroughly compare adherence and predictors of adherence of a blended smoking cessation treatment to an equivalent face-to-face treatment. Interestingly, although the overall adherence to both treatments appeared to be high, adherence within the blended treatment was much higher for the face-to-face mode than for the web mode. This supports the idea that in blended treatment, one mode of delivery can compensate for the weaknesses of the other. Higher age was found to be a common predictor of adherence to the treatments. The low variance in adherence predicted by the characteristics examined in this study suggests that other variables such as provider-related health system factors and time-varying patient characteristics should be explored in future research. TRIAL REGISTRATION Netherlands Trial Register NTR5113; http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5113.",2020,"Within BSCT, adherence to the face-to-face mode was twice as high as to the web-mode.",['patients (N=292) of a Dutch outpatient smoking cessation clinic'],"['blended smoking cessation treatment (BSCT, N=162) or to a face-to-face treatment with identical ingredients', 'Blended Treatment with Face-To-Face Treatment', 'BSCT', 'blended smoking cessation treatment (BSCT) with adherence to a face-to-face treatment (F2F']","['adherence', 'adherence levels', 'negative attitude toward quitting and less health complaints']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}]","[{'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1262620', 'cui_str': 'Negative attitude'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}]",,0.0203694,"Within BSCT, adherence to the face-to-face mode was twice as high as to the web-mode.","[{'ForeName': 'Lutz', 'Initials': 'L', 'LastName': 'Siemer', 'Affiliation': 'Technology, Health & Care Research Group, Saxion University of Applied Sciences, Enschede, Netherlands.'}, {'ForeName': 'Marjolein G J', 'Initials': 'MGJ', 'LastName': 'Brusse-Keizer', 'Affiliation': 'Medical School Twente, Medisch Spectrum Twente, Enschede, Netherlands.'}, {'ForeName': 'Marloes G', 'Initials': 'MG', 'LastName': 'Postel', 'Affiliation': 'Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands.'}, {'ForeName': 'Somaya', 'Initials': 'S', 'LastName': 'Ben Allouch', 'Affiliation': 'Digital Life Research Group, Amsterdam University of Applied Science, Amsterdam, Netherlands.'}, {'ForeName': 'Robbert', 'Initials': 'R', 'LastName': 'Sanderman', 'Affiliation': 'Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands.'}, {'ForeName': 'Marcel E', 'Initials': 'ME', 'LastName': 'Pieterse', 'Affiliation': 'Centre for eHealth and Well-being Research, University of Twente, Enschede, Netherlands.'}]",Journal of medical Internet research,['10.2196/17207'] 1716,32460575,Working Memory and Response Inhibition Effects on At-Risk Youth's Willingness to Use Multiple Nicotine and Tobacco Products.,"Purpose: Past research has suggested that executive functions, such as working memory and response inhibition, predict the use of nicotine and tobacco products (NTPs). The current study extends prior research by assessing whether response inhibition and working memory are associated with at-risk youth's willingness to use NTPs. Methods: A sample of 1060 at-risk youth were recruited from alternative high schools in southern California. Participants were randomly assigned to complete the Symmetry Span Task, an indicator of working memory ability, or the cued Go/No-Go task, an indicator of response inhibition. Participants who reported never using NTPs ( n  = 348) indicated how willing they would be try NTPs. Results: Results from a cross-sectional zero-inflated negative binomial (ZINB) regression suggest that females with stronger working memory skills and individuals with weaker response inhibition skills were more likely to be unwilling to use NTPs. Conclusion: While further research is needed to determine whether executive functions can prospectively predict NTP use among at-risk youth, the current study indicates that both working memory and response inhibition may play a significant role.",2020,"Participants were randomly assigned to complete the Symmetry Span Task, an indicator of working memory ability, or the cued Go/","['Participants who reported never using NTPs ( n \u2009=\u2009348', 'sample of 1060 at-risk youth were recruited from alternative high schools in southern California']","['Symmetry Span Task, an indicator of working memory ability, or the cued Go']",['cross-sectional zero-inflated negative binomial (ZINB) regression'],"[{'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C4517733', 'cui_str': '348'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0006754', 'cui_str': 'California'}]","[{'cui': 'C0332516', 'cui_str': 'Symmetrical'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0010439', 'cui_str': 'Cues'}]","[{'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0919414', 'cui_str': '0'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0684321', 'cui_str': 'Regression - mental defense mechanism'}]",,0.0298494,"Participants were randomly assigned to complete the Symmetry Span Task, an indicator of working memory ability, or the cued Go/","[{'ForeName': 'Maya A', 'Initials': 'MA', 'LastName': 'Pilin', 'Affiliation': 'Psychology Department, University of British Columbia, Kelowna, British Columbia, Canada.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Pike', 'Affiliation': 'School of Community and Global Health, Claremont Graduate University, Claremont, California, USA.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Xie', 'Affiliation': 'School of Community and Global Health, Claremont Graduate University, Claremont, California, USA.'}, {'ForeName': 'Alan W', 'Initials': 'AW', 'LastName': 'Stacy', 'Affiliation': 'School of Community and Global Health, Claremont Graduate University, Claremont, California, USA.'}]",Substance use & misuse,['10.1080/10826084.2020.1771595'] 1717,32461554,Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial.,"OBJECTIVE Recent clinical trials have demonstrated that colchicine may have metabolic and cardiovascular and benefits in at-risk patients; however, the mechanisms through which colchicine may improve outcomes are still unclear. We sought to examine colchicine's effects on circulating inflammatory and metabolic molecules in adults with obesity and metabolic syndrome (MetS). METHODS Blood samples were collected pre- and post-intervention during a double-blind randomized controlled trial in which 40 adults with obesity and MetS were randomized to colchicine 0.6 mg or placebo twice-daily for 3 months. Serum samples were analyzed for 1305 circulating factors using the SomaScan Platform. The Benjamini-Hochberg procedure was used to adjust the false discovery rate (FDR) for multiple testing. RESULTS At baseline, age (48.0 ± 13.8 vs. 44.7 ± 10.3 years) and BMI (39.8 ± 6.4 vs. 41.8 ± 8.2 kg/m 2 ) were not different between groups. After controlling for the FDR, 34 molecules were significantly changed by colchicine. Colchicine decreased concentrations of multiple inflammatory molecules, including C-reactive protein, interleukin 6, and resistin, in addition to vascular-related proteins (e.g., oxidized low-density lipoprotein receptor, phosphodiesterase 5A). Conversely, relative to placebo, colchicine significantly increased concentrations of eight molecules including secreted factors associated with metabolism and anti-thrombosis. CONCLUSIONS In adults with obesity, colchicine significantly affected concentrations of proteins involved in the innate immune system, endothelial function and atherosclerosis, uncovering new mechanisms behind its cardiometabolic effects. Further research is warranted to investigate whether colchicine's IL-6 suppressive effects may be beneficial in COVID-19.",2020,"Colchicine decreased concentrations of multiple inflammatory molecules, including C-reactive protein, interleukin 6, and resistin, in addition to vascular-related proteins (e.g., oxidized low-density lipoprotein receptor, phosphodiesterase 5A).","['adults with obesity and metabolic syndrome', '40 adults with obesity and MetS', 'adults with obesity and metabolic syndrome (MetS', 'At baseline, age (48.0\u2009±\u200913.8 vs. 44.7\u2009±\u200910.3 years) and BMI (39.8\u2009±\u20096.4 vs. 41.8\u2009±\u20098.2\u2009kg/m 2 ']","['placebo, colchicine', 'Colchicine', 'colchicine', ""Colchicine's"", 'colchicine 0.6\u2009mg or placebo']","['concentrations of multiple inflammatory molecules, including C-reactive protein, interleukin 6, and resistin', 'metabolic and inflammatory molecules', 'circulating inflammatory and metabolic molecules', 'false discovery rate (FDR']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517561', 'cui_str': '13.8'}, {'cui': 'C4517519', 'cui_str': '10.3'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517822', 'cui_str': '6.4'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009262', 'cui_str': 'Colchicine'}, {'cui': 'C0985108', 'cui_str': 'Colchicine 0.6 MG'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0567416', 'cui_str': 'Molecule'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0963992', 'cui_str': 'Resistin'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0205557', 'cui_str': 'False positive'}]",40.0,0.602228,"Colchicine decreased concentrations of multiple inflammatory molecules, including C-reactive protein, interleukin 6, and resistin, in addition to vascular-related proteins (e.g., oxidized low-density lipoprotein receptor, phosphodiesterase 5A).","[{'ForeName': 'Andrew P', 'Initials': 'AP', 'LastName': 'Demidowich', 'Affiliation': 'Section on Growth and Obesity, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, 20892-1103, USA. ademido1@jh.edu.'}, {'ForeName': 'Jordan A', 'Initials': 'JA', 'LastName': 'Levine', 'Affiliation': 'Section on Growth and Obesity, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, 20892-1103, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Apps', 'Affiliation': 'Center for Human Immunology (CHI), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 20892, USA.'}, {'ForeName': 'Foo K', 'Initials': 'FK', 'LastName': 'Cheung', 'Affiliation': 'Center for Human Immunology (CHI), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 20892, USA.'}, {'ForeName': 'Jinguo', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Center for Human Immunology (CHI), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 20892, USA.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Fantoni', 'Affiliation': 'Center for Human Immunology (CHI), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 20892, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Tushar P', 'Initials': 'TP', 'LastName': 'Patel', 'Affiliation': 'Section on Growth and Obesity, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, 20892-1103, USA.'}, {'ForeName': 'Jack A', 'Initials': 'JA', 'LastName': 'Yanovski', 'Affiliation': 'Section on Growth and Obesity, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, 20892-1103, USA.'}]",International journal of obesity (2005),['10.1038/s41366-020-0598-3'] 1718,32461626,Timing of milk expression following delivery in mothers delivering preterm very low birth weight infants: a randomized trial.,"OBJECTIVE To determine the effect of timing of expression initiation on mother's own milk production and time to secretory activation in mothers of preterm infants. STUDY DESIGN 180 mothers delivering infants ≤1500 grams and ≤32 weeks gestation were randomized to begin expression within 60 (early), 61-180 (intermediate) or 181-360 (late) minutes following delivery. Milk volume was measured on days 1-7 and weekly for 6 weeks. Time to secretory activation was determined through self-report. RESULTS The late group produced more milk than the early group in the first 3 days (p = 0.015-0.031) and over 6 weeks (p = 0.045). The late group had more expressions on day 1 (early: p = 0.049; intermediate; p = 0.048). CONCLUSION Initiation of expression at 181-360 min following delivery was associated with increased milk production for 6 weeks following delivery. Further research is needed to determine the effect of expression frequency on milk production in the first days following birth.",2020,The late group produced more milk than the early group in the first 3 days (p = 0.015-0.031) and over 6 weeks (p = 0.045).,"['mothers of preterm infants', 'mothers delivering preterm very low birth weight infants', '180 mothers delivering infants', '≤1500 grams and ≤32 weeks gestation']",[],"['milk production', 'Milk volume', 'Time to secretory activation']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0566687', 'cui_str': 'Mother delivered'}, {'cui': 'C0282667', 'cui_str': 'Very low birth weight infant'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]",[],"[{'cui': 'C0558187', 'cui_str': 'Lactation established'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",180.0,0.11443,The late group produced more milk than the early group in the first 3 days (p = 0.015-0.031) and over 6 weeks (p = 0.045).,"[{'ForeName': 'Leslie A', 'Initials': 'LA', 'LastName': 'Parker', 'Affiliation': 'University of Florida, Gainesville, FL, USA. Parkela@ufl.edu.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Sullivan', 'Affiliation': 'University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Charlene', 'Initials': 'C', 'LastName': 'Kruger', 'Affiliation': 'University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Mueller', 'Affiliation': 'Medical University of South Carolina, Charleston, SC, USA.'}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-020-0688-z'] 1719,32471910,Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial.,"OBJECTIVE Limited information is available about glycemic outcomes with a closed-loop control (CLC) system compared with a predictive low-glucose suspend (PLGS) system. RESEARCH DESIGN AND METHODS After 6 months of use of a CLC system in a randomized trial, 109 participants with type 1 diabetes (age range, 14-72 years; mean HbA 1c , 7.1% [54 mmol/mol]) were randomly assigned to CLC ( N = 54, Control-IQ) or PLGS ( N = 55, Basal-IQ) groups for 3 months. The primary outcome was continuous glucose monitor (CGM)-measured time in range (TIR) for 70-180 mg/dL. Baseline CGM metrics were computed from the last 3 months of the preceding study. RESULTS All 109 participants completed the study. Mean ± SD TIR was 71.1 ± 11.2% at baseline and 67.6 ± 12.6% using intention-to-treat analysis (69.1 ± 12.2% using per-protocol analysis excluding periods of study-wide suspension of device use) over 13 weeks on CLC vs. 70.0 ± 13.6% and 60.4 ± 17.1% on PLGS (difference = 5.9%; 95% CI 3.6%, 8.3%; P < 0.001). Time >180 mg/dL was lower in the CLC group than PLGS group (difference = -6.0%; 95% CI -8.4%, -3.7%; P < 0.001) while time <54 mg/dL was similar (0.04%; 95% CI -0.05%, 0.13%; P = 0.41). HbA 1c after 13 weeks was lower on CLC than PLGS (7.2% [55 mmol/mol] vs. 7.5% [56 mmol/mol], difference -0.34% [-3.7 mmol/mol]; 95% CI -0.57% [-6.2 mmol/mol], -0.11% [1.2 mmol/mol]; P = 0.0035). CONCLUSIONS Following 6 months of CLC, switching to PLGS reduced TIR and increased HbA 1c toward their pre-CLC values, while hypoglycemia remained similarly reduced with both CLC and PLGS.",2020,HbA 1c after 13 weeks was lower on CLC than PLGS (,"['Type 1 Diabetes', 'All 109 participants completed the study', '109 participants with type 1 diabetes (age range, 14-72 years; mean HbA 1c , 7.1% [54 mmol/mol']","['CLC', 'CLC Versus PLGS', 'closed-loop control (CLC) system', 'CLC system', 'PLGS']","['continuous glucose monitor (CGM)-measured time in range (TIR', 'Mean ± SD TIR', 'TIR and increased HbA 1c toward their pre-CLC values, while hypoglycemia']","[{'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}]","[{'cui': 'C0443183', 'cui_str': 'Closed loop'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0860801', 'cui_str': 'Glucose low'}, {'cui': 'C0038959', 'cui_str': 'Suspending Agents'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0445022', 'cui_str': 'Loop'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0460094', 'cui_str': 'Within reference range'}, {'cui': 'C0574173', 'cui_str': 'Tigrinya language'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0443183', 'cui_str': 'Closed loop'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}]",109.0,0.176696,HbA 1c after 13 weeks was lower on CLC than PLGS (,"[{'ForeName': 'Sue A', 'Initials': 'SA', 'LastName': 'Brown', 'Affiliation': 'Division of Endocrinology and Center for Diabetes Technology, University of Virginia, Charlottesville, VA.'}, {'ForeName': 'Roy W', 'Initials': 'RW', 'LastName': 'Beck', 'Affiliation': 'Jaeb Center for Health Research, Tampa, FL.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Raghinaru', 'Affiliation': 'Jaeb Center for Health Research, Tampa, FL.'}, {'ForeName': 'Bruce A', 'Initials': 'BA', 'LastName': 'Buckingham', 'Affiliation': 'Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA.'}, {'ForeName': 'Lori M', 'Initials': 'LM', 'LastName': 'Laffel', 'Affiliation': 'Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, MA.'}, {'ForeName': 'R Paul', 'Initials': 'RP', 'LastName': 'Wadwa', 'Affiliation': 'Barbara Davis Center for Diabetes, Anschutz Medical Campus, University of Colorado, Aurora, CO.'}, {'ForeName': 'Yogish C', 'Initials': 'YC', 'LastName': 'Kudva', 'Affiliation': 'Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Carol J', 'Initials': 'CJ', 'LastName': 'Levy', 'Affiliation': 'Division of Endocrinology, Icahn School of Medicine at Mount Sinai, New York City, NY.'}, {'ForeName': 'Jordan E', 'Initials': 'JE', 'LastName': 'Pinsker', 'Affiliation': 'Sansum Diabetes Research Institute, Santa Barbara, CA.'}, {'ForeName': 'Eyal', 'Initials': 'E', 'LastName': 'Dassau', 'Affiliation': 'Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, MA.'}, {'ForeName': 'Francis J', 'Initials': 'FJ', 'LastName': 'Doyle', 'Affiliation': 'Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Ambler-Osborn', 'Affiliation': 'Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, MA.'}, {'ForeName': 'Stacey M', 'Initials': 'SM', 'LastName': 'Anderson', 'Affiliation': 'Division of Endocrinology and Center for Diabetes Technology, University of Virginia, Charlottesville, VA.'}, {'ForeName': 'Mei Mei', 'Initials': 'MM', 'LastName': 'Church', 'Affiliation': 'Sansum Diabetes Research Institute, Santa Barbara, CA.'}, {'ForeName': 'Laya', 'Initials': 'L', 'LastName': 'Ekhlaspour', 'Affiliation': 'Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA.'}, {'ForeName': 'Gregory P', 'Initials': 'GP', 'LastName': 'Forlenza', 'Affiliation': 'Barbara Davis Center for Diabetes, Anschutz Medical Campus, University of Colorado, Aurora, CO.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Levister', 'Affiliation': 'Division of Endocrinology, Icahn School of Medicine at Mount Sinai, New York City, NY.'}, {'ForeName': 'Vinaya', 'Initials': 'V', 'LastName': 'Simha', 'Affiliation': 'Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Marc D', 'Initials': 'MD', 'LastName': 'Breton', 'Affiliation': 'Division of Endocrinology and Center for Diabetes Technology, University of Virginia, Charlottesville, VA.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Kollman', 'Affiliation': 'Jaeb Center for Health Research, Tampa, FL.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Lum', 'Affiliation': 'Jaeb Center for Health Research, Tampa, FL jl_manuscripts@jaeb.org.'}, {'ForeName': 'Boris P', 'Initials': 'BP', 'LastName': 'Kovatchev', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes care,['10.2337/dc20-0124'] 1720,32471214,Total Hip Arthroplasty Using Imageless Computer-Assisted Navigation-2-Year Follow-Up of a Prospective Randomized Study.,"The purpose of this study is to compare computer-assisted to manual implantation-techniques in total hip arthroplasty (THA) and to find out if the computer-assisted surgery is able to improve the clinical and functional results and reduce the dislocation rate in short-terms after THA. We performed a concise minimum 2-year follow-up of the patient cohort of a prospective randomized study published in 2014 and evaluated if the higher implantation accuracy in the navigated group can be seen as an important determinant of success in total hip arthroplasty. Although a significant difference was found in mean postoperative acetabular component anteversion and in the outliers regarding inclination and anteversion (p < 0.05) between the computer-assisted and the manual-placed group, we could not find significant differences regarding clinical outcome or revision rates at 2-years follow-up. The implantation accuracy in the navigated group can be regarded as an important determinant of success in THA, although no significant differences in clinical outcome could be detected at short-term follow-up. Therefore, further long-term follow-up of our patient group is needed.",2020,"Although a significant difference was found in mean postoperative acetabular component anteversion and in the outliers regarding inclination and anteversion (p < 0.05) between the computer-assisted and the manual-placed group, we could not find significant differences regarding clinical outcome or revision rates at 2-years follow-up.","['total hip arthroplasty (THA', 'total hip arthroplasty']","['computer-assisted to manual implantation-techniques', 'computer-assisted surgery']","['dislocation rate', 'implantation accuracy', 'mean postoperative acetabular component anteversion', 'clinical outcome or revision rates', 'Total Hip Arthroplasty']","[{'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}]","[{'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0949696', 'cui_str': 'Computer-Assisted Surgery'}]","[{'cui': 'C0012691', 'cui_str': 'Dislocation'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0333053', 'cui_str': 'Anteversion'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0439616', 'cui_str': 'Revisions'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}]",,0.0177396,"Although a significant difference was found in mean postoperative acetabular component anteversion and in the outliers regarding inclination and anteversion (p < 0.05) between the computer-assisted and the manual-placed group, we could not find significant differences regarding clinical outcome or revision rates at 2-years follow-up.","[{'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Lass', 'Affiliation': 'Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Boris', 'Initials': 'B', 'LastName': 'Olischar', 'Affiliation': 'Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Kubista', 'Affiliation': 'Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Waldhoer', 'Affiliation': 'Department of Epidemiology, Center of Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Giurea', 'Affiliation': 'Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Windhager', 'Affiliation': 'Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.'}]",Journal of clinical medicine,['10.3390/jcm9061620'] 1721,32471226,Proximal Tibiofibular Dislocation in a Closing-Wedge High Tibial Osteotomy Causes Lateral Radiological Gapping of the Knee: A Prospective Randomized Study.,"BACKGROUND To determine whether a proximal tibiofibular joint dislocation (TFJD) increases lateral compartment gapping more than a fibular head osteotomy (FHO) during a closing-wedge high tibial osteotomy (CWHTO). The second objective was to determine whether lateral compartment gapping affects clinical outcomes. METHODS A prospective randomized clinical study was carried out that included 18 patients in Group 1 (FHO) and 18 in Group 2 (TFJD). Varus-stress radiographs of all the patients with both knees at full extension and at 30 ° of flexion were studied pre-operatively and 12 months post-operatively. Lateral compartment gapping was measured in millimeters. The Knee Society Score (KSS) was used to assess clinical stability. RESULTS The difference between the pre- and post-operative measurements relative to gapping in the lateral knee compartment at 0 ° of knee flexion was 1.3 mm (SD 1.8) in Group 1 and 4.5 mm (SD 2.4) in Group 2 ( p = 0.006). At 30 ° of knee flexion, this difference was 1.9 mm (SD 1.2) in Group 1 and 5.2 mm (SD 3.1) in Group 2 ( p = 0.01). No differences were observed in the pre- and post-operative period relative to gapping in healthy knees. Pre-operatively, both groups presented similar KSS knee values: Group 1 with 54.7 (SD 11.7), Group 2 with 54.8 (SD 11.1) (n.s.). Post-operatively, these values were also similar: Group 1 with 93.2 (SD 7.4), Group 2 with 93.5 (SD 5.5) (n.s.). CONCLUSIONS In patients who have undergone a CWHTO, TFJ dislocation increases knee lateral compartment gapping when compared to an FHO at 0 ° and 30 ° of knee flexion. However, this fact seems to have no repercussion on the functional status of the knees as measured with the KSS at the one-year follow-up.",2020,"At 30 ° of knee flexion, this difference was 1.9 mm (SD 1.2) in Group 1 and 5.2 mm (SD 3.1) in Group 2 ( p = 0.01).","['Proximal Tibiofibular Dislocation in a Closing-Wedge High Tibial Osteotomy Causes Lateral Radiological Gapping of the Knee', 'included 18 patients in Group 1 (FHO) and 18 in Group 2 (TFJD']","['proximal tibiofibular joint dislocation (TFJD', 'TFJ dislocation']",['Knee Society Score (KSS'],"[{'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0012691', 'cui_str': 'Dislocation'}, {'cui': 'C0439639', 'cui_str': 'Wedge'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0187826', 'cui_str': 'Osteotomy of tibia'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0223908', 'cui_str': 'Head of fibula structure'}, {'cui': 'C0029468', 'cui_str': 'Osteotomy'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0730180', 'cui_str': 'Tibiofibular joint structure'}]","[{'cui': 'C0022745', 'cui_str': 'Knee joint structure'}, {'cui': 'C0012691', 'cui_str': 'Dislocation'}, {'cui': 'C0730180', 'cui_str': 'Tibiofibular joint structure'}]","[{'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0935532,"At 30 ° of knee flexion, this difference was 1.9 mm (SD 1.2) in Group 1 and 5.2 mm (SD 3.1) in Group 2 ( p = 0.01).","[{'ForeName': 'Raúl', 'Initials': 'R', 'LastName': 'Torres-Claramunt', 'Affiliation': 'Orthopaedic Department, Hospital del Mar, Universitat Autònoma Barcelona, 08003 Barcelona, Spain.'}, {'ForeName': 'Juan Francisco', 'Initials': 'JF', 'LastName': 'Sánchez-Soler', 'Affiliation': 'Orthopaedic Department, Hospital del Mar, Universitat Autònoma Barcelona, 08003 Barcelona, Spain.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Hinarejos', 'Affiliation': 'Orthopaedic Department, Hospital del Mar, Universitat Autònoma Barcelona, 08003 Barcelona, Spain.'}, {'ForeName': 'Aleix', 'Initials': 'A', 'LastName': 'Sala-Pujals', 'Affiliation': 'Orthopaedic Department, Hospital del Mar, Universitat Autònoma Barcelona, 08003 Barcelona, Spain.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Leal-Blanquet', 'Affiliation': ""Orthopaedic Department, Hospital de Igualada, Consorci Sanitari de l'Anoia, 08700 Barcelona, Spain.""}, {'ForeName': 'Joan Carles', 'Initials': 'JC', 'LastName': 'Monllau', 'Affiliation': 'Orthopaedic Department, Hospital del Mar, Universitat Autònoma Barcelona, 08003 Barcelona, Spain.'}]",Journal of clinical medicine,['10.3390/jcm9061622'] 1722,32473556,Functional training with blood occlusion influences muscle quality indices in older adults.,"OBJECTIVES This study aimed to determine if functional training with blood flow restriction (BFR) has a greater effect on muscle quality indices and performance of older men when compared to functional training without BFR. MATERIALS AND METHODS Thirty men (67.7 ± 5.8 years) were randomly assigned to one of the following three groups: functional training (FT), functional training with blood flow restriction (FTBFR), and control (C). Participants in both experimental groups trained three sessions per week for six weeks. The training program included eleven body exercises, which were performed in 2-4 sets of 10 repetitions. FTBFR group wore pneumatic cuffs on their extremities that begun with 50 % of estimated arterial occlusion pressure and increased by 10 % every 2 weeks. Before and after the intervention period, subjects completed a series of tests to assess physical performances along with changes serum muscle quality indices. RESULTS A significant decrease in serum C-terminal Agrin Fragment (CAF) levels were observed in FT and FTBFR groups (p ≤ 0.05). In addition, the levels of CAF in FTBFR group was significantly lower compared to control group. Moreover, the circulatory levels of N-terminal propeptide type III collagen (P3NP) were reduced significantly in FT and C groups (p ≤ 0.05) but did not statistically differ from baseline in FTBFR group (p > 0.05). These changes were accompanied by significant improvements in dynamic strength, flexibility, static, and dynamic balance in both training groups (p ≤ 0.01). CONCLUSIONS The finding showed greater improvements in muscle quality indices and functional performance of older men when exercises performed with BFR.",2020,A significant decrease in serum C-terminal Agrin Fragment (CAF) levels were observed in FT and FTBFR groups (p ≤ 0.05).,"['Thirty men (67.7\u202f±\u202f5.8 years', 'older adults', 'older men']","['Functional training with blood occlusion', 'FTBFR group wore pneumatic cuffs', 'functional training with blood flow restriction (BFR', 'functional training (FT), functional training with blood flow restriction (FTBFR), and control (C']","['circulatory levels of N-terminal propeptide type III collagen (P3NP', 'dynamic strength, flexibility, static, and dynamic balance', 'serum C-terminal Agrin Fragment (CAF) levels', 'arterial occlusion pressure', 'muscle quality indices and functional performance', 'levels of CAF']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4517796', 'cui_str': '5.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441107', 'cui_str': 'Device cuff'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0005775', 'cui_str': 'Circulation, Blood'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0009332', 'cui_str': 'Collagen type III'}, {'cui': 'C0072054', 'cui_str': 'procollagen Type III-N-terminal peptide'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C4077009', 'cui_str': 'C-terminal agrin fragment'}, {'cui': 'C0264995', 'cui_str': 'Occlusion of artery'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]",,0.0143913,A significant decrease in serum C-terminal Agrin Fragment (CAF) levels were observed in FT and FTBFR groups (p ≤ 0.05).,"[{'ForeName': 'Sima', 'Initials': 'S', 'LastName': 'Bigdeli', 'Affiliation': 'Department of Exercise Physiology, Faculty of Physical Education and Sports Science, Kharazmi University, Tehran, Iran.'}, {'ForeName': 'Mohammad Hasan', 'Initials': 'MH', 'LastName': 'Dehghaniyan', 'Affiliation': 'Department of Exercise Physiology, Faculty of Physical Education and Sports Science, Kharazmi University, Tehran, Iran.'}, {'ForeName': 'Sadegh', 'Initials': 'S', 'LastName': 'Amani-Shalamzari', 'Affiliation': 'Department of Exercise Physiology, Faculty of Physical Education and Sports Science, Kharazmi University, Tehran, Iran. Electronic address: amani_sadegh@khu.ac.ir.'}, {'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Rajabi', 'Affiliation': 'Department of Exercise Physiology, Faculty of Physical Education and Sports Science, Kharazmi University, Tehran, Iran.'}, {'ForeName': 'Daniel E', 'Initials': 'DE', 'LastName': 'Gahreman', 'Affiliation': 'College of Health and Human Sciences, Charles Darwin University, Darwin, Northern Territory, Australia.'}]",Archives of gerontology and geriatrics,['10.1016/j.archger.2020.104110'] 1723,32473797,Prior Application of 10% Potassium Nitrate to Reduce Postbleaching Sensitivity: A Randomized Triple-Blind Clinical Trial.,"OBJECTIVE To evaluate if the topical application of 10% potassium nitrate applied before in-office bleaching is effective to reduce the risk and intensity of tooth sensitivity (TS), as well as to evaluate if its application can jeopardize color change. MATERIALS AND METHODS A randomized, split-mouth triple-blind clinical trial was conducted on 43 young patients with incisors A2 or darker. Half of the patient's upper arch received either the application of a 10% potassium nitrate or placebo gel for 10 min in a university setting. In-office bleaching was performed in three 15-min applications in two clinical sessions (1-week interval) using 35% hydrogen peroxide. Risk and intensity of TS was recorded with a 0-4 Numeric Rating Scale and a 0-10 Visual Analogue Scale during bleaching, 1 hour, 24 hours, and 48 hours after bleaching. Color was evaluated before and 1 month after bleaching with shade guides (Vita Classical and Vita Bleachedguide) and a spectrophotometer. The risk of TS (McNemar's test) and intensity of TS (Wilcoxon signed-rank for Numeric Rating Scale and paired t-test for Visual Analogue Scale) were statistically evaluated. Color change was compared using paired t-test. Significant level was set at 5%. RESULTS No significant difference was observed in the absolute risks of TS between groups (RR = 1.11; 95% CI 0.97 to 1.27; P = .12), which exceeded 87% for both groups. Similarly, no difference in TS intensities was detected (P > .05). Significant whitening was observed with all color measurement instruments with no difference between groups (P > .05). CONCLUSION The topical application of 10% potassium nitrate, before in-office bleaching, did not reduce the risk and intensity of TS and did not jeopardize color change.",2020,"Significant whitening was observed with all color measurement instruments with no difference between groups (P > .05). ",['43 young patients with incisors A2 or darker'],"['hydrogen peroxide', 'potassium nitrate or placebo gel', 'Potassium Nitrate', '10% potassium nitrate']","[""risk of TS (McNemar's test) and intensity of TS (Wilcoxon signed-rank for Numeric Rating Scale and paired t-test for Visual Analogue Scale"", 'risk and intensity of tooth sensitivity (TS', 'absolute risks of TS', 'risk and intensity of TS', 'Postbleaching Sensitivity', 'Risk and intensity of TS', 'TS intensities']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021156', 'cui_str': 'Structure of incisor tooth'}, {'cui': 'C0332582', 'cui_str': 'Dark color'}]","[{'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}, {'cui': 'C0071772', 'cui_str': 'potassium nitrate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0017243', 'cui_str': 'Gel'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0011432', 'cui_str': 'Sensitive dentin'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0667477', 'cui_str': 'TNFRSF11A protein, human'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]",43.0,0.123407,"Significant whitening was observed with all color measurement instruments with no difference between groups (P > .05). ","[{'ForeName': 'Márcia', 'Initials': 'M', 'LastName': 'Rezende', 'Affiliation': 'School of Dentistry, Paulo Picanço School of Dentistry, Fortaleza, Ceará, Brazil.'}, {'ForeName': 'Karine Leticia', 'Initials': 'KL', 'LastName': 'da Silva', 'Affiliation': 'State University of Ponta Grossa, Ponta Grossa, Paraná, Brazil.'}, {'ForeName': 'Thais Caroline', 'Initials': 'TC', 'LastName': 'Miguel', 'Affiliation': 'State University of Ponta Grossa, Ponta Grossa, Paraná, Brazil.'}, {'ForeName': 'Paulo Vitor', 'Initials': 'PV', 'LastName': 'Farago', 'Affiliation': 'School of Pharmacy, State University of Ponta Grossa, Ponta Grossa, Paraná, Brazil.'}, {'ForeName': 'Alessandro Dourado', 'Initials': 'AD', 'LastName': 'Loguercio', 'Affiliation': 'State University of Ponta Grossa, Ponta Grossa, Paraná, Brazil.'}, {'ForeName': 'Luciana Dorochenko', 'Initials': 'LD', 'LastName': 'Martins', 'Affiliation': 'State University of Ponta Grossa, Ponta Grossa, Paraná, Brazil.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Reis', 'Affiliation': 'State University of Ponta Grossa, Ponta Grossa, Paraná, Brazil. Electronic address: reis_ale@hotmail.com.'}]",The journal of evidence-based dental practice,['10.1016/j.jebdp.2020.101406'] 1724,32475989,A randomized placebo-controlled PET study of ketamine´s effect on serotonin 1B receptor binding in patients with SSRI-resistant depression.,"The glutamate N-methyl-D-aspartate receptor antagonist ketamine has a rapid antidepressant effect. Despite large research efforts, ketamine's mechanism of action in major depressive disorder (MDD) has still not been determined. In rodents, the antidepressant properties of ketamine were found to be dependent on both the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and the serotonin (5-HT) 1B receptor. Low 5-HT 1B receptor binding in limbic brain regions is a replicated finding in MDD. In non-human primates, AMPA-dependent increase in 5-HT 1B receptor binding in the ventral striatum (VST) has been demonstrated after ketamine infusion. Thirty selective serotonin reuptake inhibitor-resistant MDD patients were recruited via advertisement and randomized to double-blind monotherapy with 0.5 mg/kg ketamine or placebo infusion. The patients were examined with the 5-HT 1B receptor selective radioligand [ 11 C]AZ10419369 and positron emission tomography (PET) before and 24-72 h after treatment. 5-HT 1B receptor binding did not significantly alter in patients treated with ketamine compared with placebo. An increase in 5-HT 1B receptor binding with 16.7 % (p = 0.036) was found in the hippocampus after one ketamine treatment. 5-HT 1B receptor binding in VST at baseline correlated with MDD symptom ratings (r = -0.426, p = 0.019) and with reduction of depressive symptoms with ketamine (r = -0.644, p = 0.002). In conclusion, reduction of depressive symptoms in MDD patients after ketamine treatment is correlated inversely with baseline 5-HT 1B receptor binding in VST. Further studies examining the role of 5-HT 1B receptors in the antidepressant mechanism of action of ketamine should be conducted, homing in on the 5-HT 1B receptor as an MDD treatment response marker.",2020,An increase in 5-HT 1B receptor binding with 16.7 % (p = 0.036) was found in the hippocampus after one ketamine treatment.,"['Thirty selective serotonin reuptake inhibitor-resistant MDD patients', 'patients with SSRI-resistant depression']","['glutamate N-methyl-D-aspartate receptor antagonist ketamine', 'ketamine', 'ketamine or placebo infusion', 'placebo']","['MDD symptom ratings', 'depressive symptoms', '5-HT 1B receptor binding']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0360105', 'cui_str': 'Selective serotonin re-uptake inhibitor'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C0017789', 'cui_str': 'Glutamates'}, {'cui': 'C0598695', 'cui_str': 'NMDA receptor antagonist'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}]","[{'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0429688', 'cui_str': 'Symptom ratings'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0033482', 'cui_str': 'Propanoic Acids'}, {'cui': 'C0535025', 'cui_str': '5-HT1B Receptor'}]",30.0,0.0756628,An increase in 5-HT 1B receptor binding with 16.7 % (p = 0.036) was found in the hippocampus after one ketamine treatment.,"[{'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Tiger', 'Affiliation': 'Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Sweden. mikael.tiger@ki.se.'}, {'ForeName': 'Emma R', 'Initials': 'ER', 'LastName': 'Veldman', 'Affiliation': 'Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Sweden.'}, {'ForeName': 'Carl-Johan', 'Initials': 'CJ', 'LastName': 'Ekman', 'Affiliation': 'Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Sweden.'}, {'ForeName': 'Christer', 'Initials': 'C', 'LastName': 'Halldin', 'Affiliation': 'Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Sweden.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Svenningsson', 'Affiliation': 'Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Lundberg', 'Affiliation': 'Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Sweden.'}]",Translational psychiatry,['10.1038/s41398-020-0844-4'] 1725,32483675,Medical management of pediatric glaucoma: lessons learned from randomized clinical trials.,"PURPOSE To critically discuss the randomized clinical trials (RCTs) on glaucoma medical therapy for the management of pediatric glaucoma. METHODS RCTs on glaucoma drugs carried out on pediatric subjects with ocular hypertension and glaucoma were identified through systematic searches. The methods of the RCTs and the safety and the efficacy of the glaucoma drugs were reviewed and discussed. RESULTS We included five RCTs. One study compared dorzolamide with 0.5% timolol gel; one brinzolamide with 0.5% levobetaxolol; one 0.25% betaxolol, 0.25% timolol gel, and 0.5% timolol gel; one latanoprost with 0.5% timolol; and one travoprost with 0.5% timolol. The primary outcome was safety for two studies and efficacy for three studies. None of the RCTs was powered to detect statistically significant differences in intraocular pressure (IOP) between treatments. In total, 658 subjects received at least one dose of study medication. Beta-blockers were administered to 359 patients, carbonic anhydrase inhibitor (CAI) to 154, and prostaglandins to 145 patients. IOP-lowering efficacy ranged from 20 to 23% for CAI, from 9 to 36% for beta-blockers, and from 26 to 27% for prostaglandins. The percentage of responders was 50% for CAI, ranged from 38 to 74% for beta-blockers and from 60 to 83% for prostaglandins. Two patients receiving timolol experienced a systemic, drug-related serious adverse event (one patient bradycardia and one pneumonia). Systemic, nonserious drug-related events occurred in 15 patients randomized to beta-blockers and in 8 patients randomized to CAI. No adverse events occurred in children treated with prostaglandins. CONCLUSION RCTs that are available on medical therapy for glaucoma are few and underpowered. The proportion of responders is lower in children; however, in subjects who are responders, the efficacy of glaucoma drugs seemed to be comparable to that in adults. As systemic adverse events have been reported, including serious events with timolol, a particular attempt to minimize the absorption of the drug (using the lowest dose and the gel formulation of beta-blockers or considering the lacrimal punctum occlusion) and a follow-up that is more frequent and more focused on safety should be considered in pediatric subjects who are on topical glaucoma medications.",2020,"IOP-lowering efficacy ranged from 20 to 23% for CAI, from 9 to 36% for beta-blockers, and from 26 to 27% for prostaglandins.","['pediatric subjects who are on topical glaucoma medications', 'pediatric glaucoma', '359 patients', '658 subjects received at least one dose of study medication', 'pediatric subjects with ocular hypertension and glaucoma']","['betaxolol, 0.25% timolol gel, and 0.5% timolol gel; one latanoprost with 0.5% timolol', 'CAI', 'Beta-blockers', 'timolol gel; one brinzolamide with 0.5% levobetaxolol', 'glaucoma medical therapy', 'carbonic anhydrase inhibitor (CAI', 'timolol', 'dorzolamide']","['intraocular pressure (IOP', 'IOP-lowering efficacy', 'adverse events', 'systemic, drug-related serious adverse event (one patient bradycardia and one pneumonia']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C2981140', 'cui_str': 'Glaucoma of childhood'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0028840', 'cui_str': 'Ocular hypertension'}]","[{'cui': 'C0005320', 'cui_str': 'Betaxolol'}, {'cui': 'C4517443', 'cui_str': '0.25'}, {'cui': 'C0040233', 'cui_str': 'Timolol'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0090306', 'cui_str': 'latanoprost'}, {'cui': 'C0007036', 'cui_str': 'Carbonic anhydrase inhibitor'}, {'cui': 'C0001645', 'cui_str': 'Beta adrenergic receptor antagonist'}, {'cui': 'C0673966', 'cui_str': 'brinzolamide'}, {'cui': 'C1171274', 'cui_str': 'Levobetaxolol'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0165590', 'cui_str': 'dorzolamide'}]","[{'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}]",658.0,0.0368441,"IOP-lowering efficacy ranged from 20 to 23% for CAI, from 9 to 36% for beta-blockers, and from 26 to 27% for prostaglandins.","[{'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Sacchi', 'Affiliation': 'University Eye Clinic, San Giuseppe Hospital, University of Milan, Via San Vittore 12, 20123, Milan, Italy. matteosacchi.hsg@gmail.com.'}, {'ForeName': 'Rosario Alfio Umberto', 'Initials': 'RAU', 'LastName': 'Lizzio', 'Affiliation': 'University Eye Clinic, San Giuseppe Hospital, University of Milan, Via San Vittore 12, 20123, Milan, Italy.'}, {'ForeName': 'Edoardo', 'Initials': 'E', 'LastName': 'Villani', 'Affiliation': 'University Eye Clinic, San Giuseppe Hospital, University of Milan, Via San Vittore 12, 20123, Milan, Italy.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Monsellato', 'Affiliation': 'University Eye Clinic, San Giuseppe Hospital, University of Milan, Via San Vittore 12, 20123, Milan, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Lucentini', 'Affiliation': 'University Eye Clinic, San Giuseppe Hospital, University of Milan, Via San Vittore 12, 20123, Milan, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Cremonesi', 'Affiliation': 'University Eye Clinic, San Giuseppe Hospital, University of Milan, Via San Vittore 12, 20123, Milan, Italy.'}, {'ForeName': 'Saverio', 'Initials': 'S', 'LastName': 'Luccarelli', 'Affiliation': 'University Eye Clinic, San Giuseppe Hospital, University of Milan, Via San Vittore 12, 20123, Milan, Italy.'}, {'ForeName': 'Massimiliano', 'Initials': 'M', 'LastName': 'Serafino', 'Affiliation': 'University Eye Clinic, San Giuseppe Hospital, University of Milan, Via San Vittore 12, 20123, Milan, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Nucci', 'Affiliation': 'University Eye Clinic, San Giuseppe Hospital, University of Milan, Via San Vittore 12, 20123, Milan, Italy.'}]",Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,['10.1007/s00417-020-04767-9'] 1726,32487916,Effects of Adding Oxycodone to Ropivacaine on Labor Analgesia: A Randomized Controlled Trial: Erratum.,,2020,,[],"['Oxycodone', 'Ropivacaine']",['Labor Analgesia'],[],"[{'cui': 'C0030049', 'cui_str': 'Oxycodone'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}]","[{'cui': 'C1301740', 'cui_str': 'Analgesia in labor'}]",,0.180916,,[],The Clinical journal of pain,['10.1097/AJP.0000000000000836'] 1727,32683644,"Efficacy and Safety of Intravenously Administered Tramadol in Patients with Moderate to Severe Pain Following Bunionectomy: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study.","INTRODUCTION This study is part of the registrational program for intravenously administered (IV) tramadol in the USA and compared the analgesic benefit and tolerability of two doses of IV tramadol (50 mg and 25 mg) to placebo in adult patients undergoing bunionectomy, an orthopedic surgical model. METHODS This was a phase 3, multicenter, double-blind, three-arm, randomized, placebo-controlled, multiple-dose, parallel-group trial to evaluate IV tramadol in the management of postoperative pain following bunionectomy. Eligible patients were randomized (1:1:1 ratio) to IV tramadol 50 mg, 25 mg, or placebo. Primary endpoint was summary of pain intensity differences over 48 h (SPID48). Key secondary endpoints included SPID24, total consumption of rescue analgesia, and patient global assessment of efficacy (PGA). Safety assessments included treatment emergent adverse events (TEAEs), clinical laboratory tests, vital signs, and electrocardiograms (ECGs). Assessment of the dose-response was an important objective of the study. RESULTS The study established a dose response, with IV tramadol 50 mg demonstrating statistically significant benefit (p < 0.05) over placebo for primary and all key secondary efficacy endpoints, whereas tramadol 25 mg demonstrated intermediate results between the 50 mg and placebo arms. IV tramadol 50 mg was well tolerated; most common TEAEs were nausea and vomiting; and there were no meaningful differences among treatments for vital signs, ECG, and laboratory assessments. The largest proportion of patients completed tramadol 50 mg (98.6%) compared to tramadol 25 mg (91.8%) and placebo (88.2%). CONCLUSION IV tramadol 50 mg was effective and well tolerated as treatment for postoperative pain following bunionectomy surgery, while IV tramadol 25 mg, although well tolerated, was judged an ineffective dose for the treatment of pain in this setting. IV tramadol 50 mg was further developed in the registrational program for the USA. TRIAL REGISTRATION ClinicalTrials.gov identifier, NCT03290378.",2020,"mg was well tolerated; most common TEAEs were nausea and vomiting; and there were no meaningful differences among treatments for vital signs, ECG, and laboratory assessments.","['adult patients undergoing bunionectomy, an orthopedic surgical model', 'Eligible patients', 'Patients with Moderate to Severe Pain', 'postoperative pain following bunionectomy']","['Bunionectomy', 'Placebo', 'IV tramadol', 'Tramadol', 'tramadol', 'tramadol 50\xa0mg, 25\xa0mg, or placebo', 'placebo']","['Efficacy and Safety', 'nausea and vomiting', 'treatment emergent adverse events (TEAEs), clinical laboratory tests, vital signs, and electrocardiograms (ECGs', 'SPID24, total consumption of rescue analgesia, and patient global assessment of efficacy (PGA', 'effective and well tolerated', 'pain intensity differences over 48\xa0h (SPID48']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1542057', 'cui_str': 'Silver bunionectomy'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0887962', 'cui_str': 'Models, Surgical'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}]","[{'cui': 'C1542057', 'cui_str': 'Silver bunionectomy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0040610', 'cui_str': 'Tramadol'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4505474', 'cui_str': 'Clinical Laboratory Tests'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",,0.495008,"mg was well tolerated; most common TEAEs were nausea and vomiting; and there were no meaningful differences among treatments for vital signs, ECG, and laboratory assessments.","[{'ForeName': 'Neil K', 'Initials': 'NK', 'LastName': 'Singla', 'Affiliation': 'Lotus Clinical Research, Pasadena, CA, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Pollak', 'Affiliation': 'Evolution Research Group, New Providence, NJ, USA.'}, {'ForeName': 'Ira', 'Initials': 'I', 'LastName': 'Gottlieb', 'Affiliation': 'Chesapeake Research Group, Pasadena, MD, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Leiman', 'Affiliation': 'HD Research, Bellaire, TX, USA.'}, {'ForeName': 'Harold', 'Initials': 'H', 'LastName': 'Minkowitz', 'Affiliation': 'HD Research, Bellaire, TX, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Zimmerman', 'Affiliation': 'Trovare Clinical Research, Bakersfield, CA, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Harnett', 'Affiliation': 'Avenue Therapeutics, New York, NY, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Ryan', 'Affiliation': 'Avenue Therapeutics, New York, NY, USA.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Lu', 'Affiliation': 'Avenue Therapeutics, New York, NY, USA. llu@avenuetx.com.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Reines', 'Affiliation': 'Avenue Therapeutics, New York, NY, USA.'}]",Pain and therapy,['10.1007/s40122-020-00184-2'] 1728,32484914,A randomized phase 3 study of maintenance therapy with S-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L).,"BACKGROUND A randomized phase 3 study was performed to investigate the efficacy and safety of maintenance therapy with S-1 after induction therapy with carboplatin plus S-1 in patients with advanced squamous non-small cell lung cancer (NSCLC). METHODS Chemotherapy-naive patients with advanced or relapsed squamous NSCLC were treated with carboplatin (area under the curve of 5 on day 1 every 3 weeks) plus S-1 (40 mg/m 2 twice per day on days 1-14 every 3 weeks) as induction therapy. Patients who did not progress after 4 cycles of induction therapy were randomized to receive either S-1 plus best supportive care (BSC) or BSC alone. The primary objective of the study was to confirm the superiority of S-1 plus BSC in comparison with BSC alone with respect to progression-free survival. RESULTS Of the 365 patients enrolled in the study, 347 participated in the induction phase, and 131 of these individuals were randomized to receive S-1 plus BSC (n = 67) or BSC alone (n = 64). The risk of disease progression was significantly lower for patients in the S-1 plus BSC arm than those in the BSC-alone arm (hazard ratio, 0.548; 95% confidence interval, 0.374-0.802; P = .0019). The most common toxicities during maintenance therapy with S-1 included anorexia, anemia, and fatigue, but most cases were not severe. CONCLUSIONS Continued maintenance with S-1 plus BSC is an effective and well-tolerated treatment option for patients with advanced squamous NSCLC previously treated with carboplatin plus S-1.",2020,"The risk of disease progression was significantly lower for patients in the S-1 plus BSC arm than those in the BSC-alone arm (hazard ratio, 0.548; 95% confidence interval, 0.374-0.802; P = .0019).","['for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L', 'Chemotherapy-naive patients with advanced or relapsed squamous NSCLC', 'patients with advanced squamous NSCLC previously treated with', '365 patients enrolled in the study', 'patients with advanced squamous non-small cell lung cancer (NSCLC', '347 participated in the induction phase, and 131 of these individuals', 'Patients who did not progress after 4 cycles of induction therapy']","['BSC alone', 'S-1 plus best supportive care (BSC) or BSC alone', 'carboplatin (area under the curve of 5 on day 1 every 3\xa0weeks) plus S-1', 'S-1 plus BSC', 'carboplatin plus S-1']","['efficacy and safety', 'risk of disease progression', 'anorexia, anemia, and fatigue']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0149782', 'cui_str': 'Squamous cell carcinoma of lung'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4509816', 'cui_str': 'Squamous non-small cell lung cancer'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}]","[{'cui': 'C0879262', 'cui_str': 'S 1 (combination)'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0344211', 'cui_str': 'Support'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0585333', 'cui_str': 'Triweekly'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0003123', 'cui_str': 'Anorexia'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}]",365.0,0.0908591,"The risk of disease progression was significantly lower for patients in the S-1 plus BSC arm than those in the BSC-alone arm (hazard ratio, 0.548; 95% confidence interval, 0.374-0.802; P = .0019).","[{'ForeName': 'Kaoru', 'Initials': 'K', 'LastName': 'Tanaka', 'Affiliation': 'Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Morita', 'Affiliation': 'Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.'}, {'ForeName': 'Masahiko', 'Initials': 'M', 'LastName': 'Ando', 'Affiliation': 'Data Coordinating Center, Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.'}, {'ForeName': 'Takuma', 'Initials': 'T', 'LastName': 'Yokoyama', 'Affiliation': 'Department of Respiratory Medicine, Kyorin University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Nakamura', 'Affiliation': 'Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.'}, {'ForeName': 'Hiroshige', 'Initials': 'H', 'LastName': 'Yoshioka', 'Affiliation': 'Department of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Ishiguro', 'Affiliation': 'Division of Respiratory Medicine and Oncology, Gifu Municipal Hospital, Gifu, Japan.'}, {'ForeName': 'Satoru', 'Initials': 'S', 'LastName': 'Miura', 'Affiliation': 'Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.'}, {'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Toyozawa', 'Affiliation': 'Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Oguri', 'Affiliation': 'Department of Education and Research Center for Community Medicine, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.'}, {'ForeName': 'Haruko', 'Initials': 'H', 'LastName': 'Daga', 'Affiliation': 'Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan.'}, {'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Ko', 'Affiliation': 'Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Akihiro', 'Initials': 'A', 'LastName': 'Bessho', 'Affiliation': 'Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan.'}, {'ForeName': 'Motoko', 'Initials': 'M', 'LastName': 'Tachihara', 'Affiliation': 'Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Iwamoto', 'Affiliation': 'Department of Respiratory Medicine, Hiroshima City Hospital, Hiroshima, Japan.'}, {'ForeName': 'Katsuya', 'Initials': 'K', 'LastName': 'Hirano', 'Affiliation': 'Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.'}, {'ForeName': 'Yoichi', 'Initials': 'Y', 'LastName': 'Nakanishi', 'Affiliation': 'Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.'}, {'ForeName': 'Kazuhiko', 'Initials': 'K', 'LastName': 'Nakagawa', 'Affiliation': 'Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.'}, {'ForeName': 'Nobuyuki', 'Initials': 'N', 'LastName': 'Yamamoto', 'Affiliation': 'Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.'}, {'ForeName': 'Isamu', 'Initials': 'I', 'LastName': 'Okamoto', 'Affiliation': 'Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.'}]",Cancer,['10.1002/cncr.32987'] 1729,32485422,Utilizing the somatosensory system via vibratory stimulation to mitigate knee pain during walking: Randomized clinical trial.,"BACKGROUND Pain and proprioception deficits are often associated with knee pathologies and resultant quadriceps muscle inhibition. There is a need for new approaches to mitigate active knee pain and restore muscle function during walking. Activating properties of the somatosensory system with common pain and sensory pathways offers a novel opportunity to enhance quadriceps function during walking. RESEARCH QUESTION Conduct a controlled clinical trial that investigates the effects of applying intermittent vibrational cutaneous stimulation during walking on knee pain and symptoms and their correlations to gait parameters. METHODS This longitudinal controlled cross-over clinical study included thirty-two patients randomly and blindly assigned to active Treatment A and passive Treatment B for 4 weeks with a 2-week washout period between treatments. RESULTS Subjects when wearing active Treatment A for 4 weeks had significant (p = 0.04) improvement in patient reported outcomes, while they had no significant differences with passive Treatment B (p > 0.7) compared to the no treatment condition. For Treatment A, subjects with low knee flexion moment and knee flexion angle in no-treatment condition exhibited the greatest increase in knee flexion moment/angle in the active treatment condition (R > 0.57, p < 0.001). These changes in gait measures were correlated significantly to changes in pain. SIGNIFICANCE This clinical trial indicates that knee pain can be reduced, and gait improved in a manner that enhances quadriceps function by applying intermittent cutaneous stimulation during gait in patients following knee injury or disease. The correlation between decreased pain and improved gait suggests that rehabilitation and exercise therapy may benefit from this treatment.",2020,"RESULTS Subjects when wearing active Treatment A for 4 weeks had significant (p = 0.04) improvement in patient reported outcomes, while they had no significant differences with passive Treatment B (p > 0.7) compared to the no treatment condition.",['knee pain during walking'],"['somatosensory system via vibratory stimulation', 'intermittent vibrational cutaneous stimulation']","['knee flexion moment/angle', 'gait measures', 'pain']","[{'cui': 'C0231749', 'cui_str': 'Knee pain'}]","[{'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0150184', 'cui_str': 'Cutaneous stimulation'}]","[{'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",32.0,0.0771875,"RESULTS Subjects when wearing active Treatment A for 4 weeks had significant (p = 0.04) improvement in patient reported outcomes, while they had no significant differences with passive Treatment B (p > 0.7) compared to the no treatment condition.","[{'ForeName': 'Arielle G', 'Initials': 'AG', 'LastName': 'Fischer', 'Affiliation': 'BioMotion Laboratory, Department of Mechanical Engineering, Stanford University, Stanford, CA 94305, USA. Electronic address: ariellef@stanford.edu.'}, {'ForeName': 'Jennifer C', 'Initials': 'JC', 'LastName': 'Erhart-Hledik', 'Affiliation': 'BioMotion Laboratory, Department of Mechanical Engineering, Stanford University, Stanford, CA 94305, USA; Palo Alto Veterans Hospital, Palo Alto, CA, USA.'}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Asay', 'Affiliation': 'BioMotion Laboratory, Department of Mechanical Engineering, Stanford University, Stanford, CA 94305, USA; Palo Alto Veterans Hospital, Palo Alto, CA, USA.'}, {'ForeName': 'Constance R', 'Initials': 'CR', 'LastName': 'Chu', 'Affiliation': 'BioMotion Laboratory, Department of Mechanical Engineering, Stanford University, Stanford, CA 94305, USA; Palo Alto Veterans Hospital, Palo Alto, CA, USA.'}, {'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'Andriacchi', 'Affiliation': 'BioMotion Laboratory, Department of Mechanical Engineering, Stanford University, Stanford, CA 94305, USA.'}]",Gait & posture,['10.1016/j.gaitpost.2020.05.030'] 1730,32581009,Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial.,"Aspirin and statin use may lower risk of advanced/fatal prostate cancer, possibly by reducing intraprostatic inflammation. To test this hypothesis, we investigated the association of aspirin and statin use with the presence and extent of intraprostatic inflammation, and the abundance of specific immune cell types, in benign prostate tissue from a subset of men from the placebo arm of the Prostate Cancer Prevention Trial. Men were classified as aspirin or statin users if they reported use at baseline or during the seven-year trial. Presence and extent of inflammation were assessed, and markers of specific immune cell types (CD4, CD8, FoxP3, CD68, c-KIT) were scored, in slides from end-of-study prostate biopsies taken irrespective of clinical indication, per trial protocol. Logistic regression was used to estimate associations between medication use and inflammation measures, adjusted for potential confounders. Of 357 men included, 61% reported aspirin use and 32% reported statin use. Prevalence and extent of inflammation were not associated with medication use. However, aspirin users were more likely to have low FoxP3, a T regulatory cell marker (OR: 5.60, 95% CI: 1.16-27.07), and statin users were more likely to have low CD68, a macrophage marker (OR: 1.63, 95% CI: 0.81-3.27). If confirmed, these results suggest that these medications may alter the immune milieu of the prostate, which could potentially mediate effects of these medications on advanced/fatal prostate cancer risk.",2020,Prevalence and extent of inflammation were not associated with medication use.,"['benign prostate tissue from a subset of men from the placebo arm of the Prostate Cancer Prevention Trial', 'Men were classified as aspirin or statin users if they reported use at baseline or during the seven-year trial', 'Of 357 men included, 61% reported aspirin use and 32% reported statin use']","['aspirin and statin', 'aspirin', 'Aspirin and statin', 'Aspirin and Statins']","['specific immune cell types (CD4, CD8, FoxP3, CD68, c-KIT']","[{'cui': 'C0205183', 'cui_str': 'Benign'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0684224', 'cui_str': 'Report'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0108799', 'cui_str': 'Lymphocyte antigen CD68'}, {'cui': 'C0072470', 'cui_str': 'Lymphocyte antigen CD117'}]",357.0,0.0896527,Prevalence and extent of inflammation were not associated with medication use.,"[{'ForeName': 'Lauren M', 'Initials': 'LM', 'LastName': 'Hurwitz', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Kulac', 'Affiliation': 'Pathology, Koc University.'}, {'ForeName': 'Berrak', 'Initials': 'B', 'LastName': 'Gumuskaya', 'Affiliation': 'Pathology, Johns Hopkins University School of Medicine.'}, {'ForeName': 'Javier A', 'Initials': 'JA', 'LastName': 'Baena Del Valle', 'Affiliation': 'Fundacion Santa Fe de Bogota University Hospital.'}, {'ForeName': 'Ines', 'Initials': 'I', 'LastName': 'Benedetti', 'Affiliation': 'Basic Sciences, University of Cartagena.'}, {'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Pan', 'Affiliation': 'Immunology and Hematopoiesis Division, Department of Oncology, Johns Hopkins University School of Medicine.'}, {'ForeName': 'Jun O', 'Initials': 'JO', 'LastName': 'Liu', 'Affiliation': 'Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine.'}, {'ForeName': 'Michael T', 'Initials': 'MT', 'LastName': 'Marrone', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health.'}, {'ForeName': 'Kathryn B', 'Initials': 'KB', 'LastName': 'Arnold', 'Affiliation': 'SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center.'}, {'ForeName': 'Phyllis J', 'Initials': 'PJ', 'LastName': 'Goodman', 'Affiliation': 'SWOG Statistical Center, Fred Hutchinson Cancer Research Center.'}, {'ForeName': 'Catherine M', 'Initials': 'CM', 'LastName': 'Tangen', 'Affiliation': 'SWOG Statistical Center, Fred Hutchinson Cancer Research Center.'}, {'ForeName': 'M Scott', 'Initials': 'MS', 'LastName': 'Lucia', 'Affiliation': 'Department of Pathology, University of Colorado School of Medicine.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Thompson', 'Affiliation': 'Administration, CHRISTUS Santa Rosa Hospital - Medical Center.'}, {'ForeName': 'Charles G', 'Initials': 'CG', 'LastName': 'Drake', 'Affiliation': 'Department of Urology, and the Columbia Center for Translational Immunology (CCTI), Columbia University Herbert Irving Comprehensive Cancer Center.'}, {'ForeName': 'William B', 'Initials': 'WB', 'LastName': 'Isaacs', 'Affiliation': 'The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine.'}, {'ForeName': 'William G', 'Initials': 'WG', 'LastName': 'Nelson', 'Affiliation': 'Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University.'}, {'ForeName': 'Angelo M', 'Initials': 'AM', 'LastName': 'De Marzo', 'Affiliation': 'Department of Pathology, Johns Hopkins University School of Medicine.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Platz', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health eplatz1@jhu.edu.'}]","Cancer prevention research (Philadelphia, Pa.)",['10.1158/1940-6207.CAPR-19-0450'] 1731,32581041,Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication.,"BACKGROUND Previous studies have reported that the amplification of some genes, such as Murine Double Minute 2 or 4 and Epidermal Growth Factor Receptor ( EGFR ), may be related to hyperprogressive disease (HPD). Exploring somatic gene alterations might be an effective method to predict HPD. Herein we characterize the somatic alterations in a patient with esophageal squamous cell carcinoma (ESCC) who developed HPD to investigate the potential origins of HPD. CASE PRESENTATION A man in his mid-40s was diagnosed with ESCC. After the failure of first-line treatment with cisplatin and docetaxel, the patient participated in a phase III randomized, open, multicenter clinical trial (CTR20170307) and subsequently received camrelizumab. After 4 weeks of immunotherapy, the tumor size increased by 79% compared with baseline imaging; the progressive pace was 2.5-fold higher than preimmunotherapy, and a new liver metastasis appeared. A rare EGFR exon 2-28 duplication was discovered in both preimmunotherapy and postimmunotherapy tumor tissues. CONCLUSION This is the first report on a patient with ESCC harboring rare EGFR kinase domain duplication in exons 2-28 and developing HPD in the process of camrelizumab treatment. This case suggested that EGFR kinase domain duplication might be associated with HPD. Administration of immune checkpoint inhibitor monotherapy in this subgroup of patients harboring EGFR kinase domain duplication should be performed with caution. These results need to be further confirmed in a larger cohort of patients.",2020,"After 4 weeks of immunotherapy, the tumor size increased by 79% compared with baseline imaging; the progressive pace was 2.5-fold higher than preimmunotherapy, and a new liver metastasis appeared.","['A man in his mid-40s was diagnosed with ESCC', 'patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication', 'patient with esophageal squamous cell carcinoma (ESCC']","['Double Minute 2 or 4 and Epidermal Growth Factor Receptor ( EGFR ', 'camrelizumab', 'Hyperprogression to camrelizumab', 'cisplatin and docetaxel', 'immune checkpoint inhibitor monotherapy']","['tumor size', 'progressive pace']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0279626', 'cui_str': 'Squamous cell carcinoma of esophagus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0475311', 'cui_str': 'Harbor'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0031727', 'cui_str': 'Kinase'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0332597', 'cui_str': 'Duplication'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C4682408', 'cui_str': 'camrelizumab'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C1155874', 'cui_str': 'Cell Cycle Checkpoints'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0475440', 'cui_str': 'Tumor size'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0287990', 'cui_str': 'Furin'}]",,0.0305784,"After 4 weeks of immunotherapy, the tumor size increased by 79% compared with baseline imaging; the progressive pace was 2.5-fold higher than preimmunotherapy, and a new liver metastasis appeared.","[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Oncology, Changhai Hospital of Shanghai, Shanghai, China.'}, {'ForeName': 'Meihong', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'Department of Oncology, Changhai Hospital of Shanghai, Shanghai, China.'}, {'ForeName': 'Minglu', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': 'Department of Radiology, Changhai Hospital of Shanghai, Shanghai, China.'}, {'ForeName': 'Zhengqing', 'Initials': 'Z', 'LastName': 'Yan', 'Affiliation': 'The Medical Department, 3D Medicines Inc, Shanghai, China.'}, {'ForeName': 'Guoqiang', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'The Medical Department, 3D Medicines Inc, Shanghai, China.'}, {'ForeName': 'Dongliang', 'Initials': 'D', 'LastName': 'Mao', 'Affiliation': 'Department of Oncology, North Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'Department of Oncology, North Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China 13601810867@163.com.'}]",Journal for immunotherapy of cancer,['10.1136/jitc-2020-000793'] 1732,32581112,"A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data.","BACKGROUND A polygenic hazard score (PHS), the weighted sum of 54 SNP genotypes, was previously validated for association with clinically significant prostate cancer and for improved prostate cancer screening accuracy. Here, we assess the potential impact of PHS-informed screening. METHODS United Kingdom population incidence data (Cancer Research United Kingdom) and data from the Cluster Randomized Trial of PSA Testing for Prostate Cancer were combined to estimate age-specific clinically significant prostate cancer incidence (Gleason score ≥7, stage T3-T4, PSA ≥10, or nodal/distant metastases). Using HRs estimated from the ProtecT prostate cancer trial, age-specific incidence rates were calculated for various PHS risk percentiles. Risk-equivalent age, when someone with a given PHS percentile has prostate cancer risk equivalent to an average 50-year-old man (50-year-standard risk), was derived from PHS and incidence data. Positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was calculated using PHS-adjusted age groups. RESULTS The expected age at diagnosis of clinically significant prostate cancer differs by 19 years between the 1st and 99th PHS percentiles: men with PHS in the 1st and 99th percentiles reach the 50-year-standard risk level at ages 60 and 41, respectively. PPV of PSA was higher for men with higher PHS-adjusted age. CONCLUSIONS PHS provides individualized estimates of risk-equivalent age for clinically significant prostate cancer. Screening initiation could be adjusted by a man's PHS. IMPACT Personalized genetic risk assessments could inform prostate cancer screening decisions.",2020,"PPV of PSA was higher for men with higher PHS-adjusted age. ","['UK population incidence data (Cancer Research UK) and data from the Cluster Randomized Trial of PSA Testing for Prostate Cancer were combined to estimate age-specific clinically significant prostate cancer incidence (Gleason≥7, stage T3-T4, PSA ≥10, or nodal/distant metastases', 'men with higher PHS-adjusted age']",[],['PPV of PSA'],"[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0475374', 'cui_str': 'T3 category'}, {'cui': 'C0443268', 'cui_str': 'Nodal'}, {'cui': 'C1269798', 'cui_str': 'pM category'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}]",[],"[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}]",,0.0430511,"PPV of PSA was higher for men with higher PHS-adjusted age. ","[{'ForeName': 'Minh-Phuong', 'Initials': 'MP', 'LastName': 'Huynh-Le', 'Affiliation': 'Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California.'}, {'ForeName': 'Chun Chieh', 'Initials': 'CC', 'LastName': 'Fan', 'Affiliation': 'Center for Multimodal Imaging and Genetics, University of California San Diego, La Jolla, California.'}, {'ForeName': 'Roshan', 'Initials': 'R', 'LastName': 'Karunamuni', 'Affiliation': 'Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California.'}, {'ForeName': 'Eleanor I', 'Initials': 'EI', 'LastName': 'Walsh', 'Affiliation': 'Bristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, United Kingdom.'}, {'ForeName': 'Emma L', 'Initials': 'EL', 'LastName': 'Turner', 'Affiliation': 'Bristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, United Kingdom.'}, {'ForeName': 'J Athene', 'Initials': 'JA', 'LastName': 'Lane', 'Affiliation': 'Bristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, United Kingdom.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Martin', 'Affiliation': 'Bristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, United Kingdom.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Neal', 'Affiliation': 'Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Jenny L', 'Initials': 'JL', 'LastName': 'Donovan', 'Affiliation': 'School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom.'}, {'ForeName': 'Freddie C', 'Initials': 'FC', 'LastName': 'Hamdy', 'Affiliation': 'Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'J Kellogg', 'Initials': 'JK', 'LastName': 'Parsons', 'Affiliation': 'Department of Urology, University of California, San Diego, La Jolla, California.'}, {'ForeName': 'Rosalind A', 'Initials': 'RA', 'LastName': 'Eeles', 'Affiliation': 'The Institute of Cancer Research, London, United Kingdom.'}, {'ForeName': 'Douglas F', 'Initials': 'DF', 'LastName': 'Easton', 'Affiliation': 'Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.'}, {'ForeName': 'Zsofia', 'Initials': 'Z', 'LastName': 'Kote-Jarai', 'Affiliation': 'The Institute of Cancer Research, London, United Kingdom.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Amin Al Olama', 'Affiliation': 'Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Benlloch Garcia', 'Affiliation': 'Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Muir', 'Affiliation': 'Division of Population Health, Health Services Research and Primary Care, University of Manchester, Oxford Road, Manchester, United Kingdom.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Grönberg', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.'}, {'ForeName': 'Fredrik', 'Initials': 'F', 'LastName': 'Wiklund', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Aly', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Schleutker', 'Affiliation': 'Institute of Biomedicine, University of Turku, Turku, Finland.'}, {'ForeName': 'Csilla', 'Initials': 'C', 'LastName': 'Sipeky', 'Affiliation': 'Institute of Biomedicine, University of Turku, Turku, Finland.'}, {'ForeName': 'Teuvo Lj', 'Initials': 'TL', 'LastName': 'Tammela', 'Affiliation': 'Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University, Tampere, Finland.'}, {'ForeName': 'Børge Grønne', 'Initials': 'BG', 'LastName': 'Nordestgaard', 'Affiliation': 'Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'Key', 'Affiliation': 'University of Oxford, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Ruth C', 'Initials': 'RC', 'LastName': 'Travis', 'Affiliation': 'University of Oxford, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Paul D P', 'Initials': 'PDP', 'LastName': 'Pharoah', 'Affiliation': 'Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Cambridge, United Kingdom.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Pashayan', 'Affiliation': 'Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Cambridge, United Kingdom.'}, {'ForeName': 'Kay-Tee', 'Initials': 'KT', 'LastName': 'Khaw', 'Affiliation': 'Clinical Gerontology Unit, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Stephen N', 'Initials': 'SN', 'LastName': 'Thibodeau', 'Affiliation': 'Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Shannon K', 'Initials': 'SK', 'LastName': 'McDonnell', 'Affiliation': 'Division of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Schaid', 'Affiliation': 'Division of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Christiane', 'Initials': 'C', 'LastName': 'Maier', 'Affiliation': 'Humangenetik Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Walther', 'Initials': 'W', 'LastName': 'Vogel', 'Affiliation': 'Institute for Human Genetics, University Hospital Ulm, Ulm, Germany.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Luedeke', 'Affiliation': 'Humangenetik Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Herkommer', 'Affiliation': 'Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Urology, Munich, Germany.'}, {'ForeName': 'Adam S', 'Initials': 'AS', 'LastName': 'Kibel', 'Affiliation': 'Division of Urologic Surgery, Brigham and Womens Hospital, Boston, Massachusetts.'}, {'ForeName': 'Cezary', 'Initials': 'C', 'LastName': 'Cybulski', 'Affiliation': 'International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.'}, {'ForeName': 'Dominika', 'Initials': 'D', 'LastName': 'Wokolorczyk', 'Affiliation': 'International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.'}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Kluzniak', 'Affiliation': 'International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Cannon-Albright', 'Affiliation': 'Division of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah.'}, {'ForeName': 'Hermann', 'Initials': 'H', 'LastName': 'Brenner', 'Affiliation': 'Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Schöttker', 'Affiliation': 'Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Holleczek', 'Affiliation': 'Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Jong Y', 'Initials': 'JY', 'LastName': 'Park', 'Affiliation': 'Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.'}, {'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Sellers', 'Affiliation': 'Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.'}, {'ForeName': 'Hui-Yi', 'Initials': 'HY', 'LastName': 'Lin', 'Affiliation': 'School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana.'}, {'ForeName': 'Chavdar Kroumov', 'Initials': 'CK', 'LastName': 'Slavov', 'Affiliation': 'Department of Urology and Alexandrovska University Hospital, Medical University of Sofia, Sofia, Bulgaria.'}, {'ForeName': 'Radka P', 'Initials': 'RP', 'LastName': 'Kaneva', 'Affiliation': 'Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, Bulgaria.'}, {'ForeName': 'Vanio I', 'Initials': 'VI', 'LastName': 'Mitev', 'Affiliation': 'Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, Bulgaria.'}, {'ForeName': 'Jyotsna', 'Initials': 'J', 'LastName': 'Batra', 'Affiliation': 'Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.'}, {'ForeName': 'Judith A', 'Initials': 'JA', 'LastName': 'Clements', 'Affiliation': 'Australian Prostate Cancer Research @Centre-Qld, Translational Research Institute, Brisbane, Queensland, Australia.'}, {'ForeName': 'Amanda B', 'Initials': 'AB', 'LastName': 'Spurdle', 'Affiliation': ''}, {'ForeName': 'Manuel R', 'Initials': 'MR', 'LastName': 'Teixeira', 'Affiliation': 'Department of Genetics, Portuguese Oncology Institute, Porto, Portugal.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Paulo', 'Affiliation': 'Department of Genetics, Portuguese Oncology Institute, Porto, Portugal.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Maia', 'Affiliation': 'Department of Genetics, Portuguese Oncology Institute, Porto, Portugal.'}, {'ForeName': 'Hardev', 'Initials': 'H', 'LastName': 'Pandha', 'Affiliation': 'The University of Surrey, Guildford, Surrey, United Kingdom.'}, {'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Michael', 'Affiliation': 'The University of Surrey, Guildford, Surrey, United Kingdom.'}, {'ForeName': 'Ian G', 'Initials': 'IG', 'LastName': 'Mills', 'Affiliation': 'Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Ole A', 'Initials': 'OA', 'LastName': 'Andreassen', 'Affiliation': 'NORMENT, KG Jebsen Centre, Oslo University Hospital and University of Oslo, Oslo, Norway.'}, {'ForeName': 'Anders M', 'Initials': 'AM', 'LastName': 'Dale', 'Affiliation': 'Center for Multimodal Imaging and Genetics, University of California San Diego, La Jolla, California.'}, {'ForeName': 'Tyler M', 'Initials': 'TM', 'LastName': 'Seibert', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",['10.1158/1055-9965.EPI-19-1527'] 1733,32581121,Toward a science of delivering aid with dignity: Experimental evidence and local forecasts from Kenya.,"How can governments and nonprofits design aid programs that afford dignity and facilitate beneficial outcomes for recipients? We conceptualize dignity as a state that manifests when the stigma associated with receiving aid is countered and recipients are empowered, both in culturally resonant ways. Yet materials from the largest cash transfer programs in Africa predominantly characterize recipients as needy and vulnerable. Three studies examined the causal effects of alternative aid narratives on cash transfer recipients and donors. In study 1, residents of low-income settlements in Nairobi, Kenya ( N = 565) received cash-based aid accompanied by a randomly assigned narrative: the default deficit-focused ""Poverty Alleviation"" narrative, an ""Individual Empowerment"" narrative, or a ""Community Empowerment"" narrative. They then chose whether to spend time building business skills or watching leisure videos. Both empowerment narratives improved self-efficacy and anticipated social mobility, but only the ""Community Empowerment"" narrative significantly motivated recipients' choice to build skills and reduced stigma. Given the diverse settings in which aid is delivered, how can organizations quickly identify effective narratives in a context? We asked recipients to predict which narrative would best motivate skill-building in their community. In study 2, this ""local forecasting"" methodology outperformed participant evaluations and experimental pilots in accurately ranking treatments. Finally, study 3 confirmed that the narrative most effective for recipients did not undermine donors' willingness to contribute to the program. Together these studies show that responding to recipients' psychological and sociocultural realities in the design of aid can afford recipients dignity and help realize aid's potential.",2020,"Both empowerment narratives improved self-efficacy and anticipated social mobility, but only the ""Community Empowerment"" narrative significantly motivated recipients' choice to build skills and reduced stigma.","['residents of low-income settlements in Nairobi, Kenya ( N = 565) received']","['dignity', 'cash-based aid accompanied by a randomly assigned narrative: the default deficit-focused ""Poverty Alleviation"" narrative, an ""Individual Empowerment"" narrative, or a ""Community Empowerment"" narrative']",['self-efficacy and anticipated social mobility'],"[{'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0027345', 'cui_str': 'Nairobi sheep virus disease'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}]","[{'cui': 'C4704841', 'cui_str': 'Dignity'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C1135957', 'cui_str': 'Narration'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}]",,0.0181758,"Both empowerment narratives improved self-efficacy and anticipated social mobility, but only the ""Community Empowerment"" narrative significantly motivated recipients' choice to build skills and reduced stigma.","[{'ForeName': 'Catherine C', 'Initials': 'CC', 'LastName': 'Thomas', 'Affiliation': 'Department of Psychology, Stanford University, Stanford, CA 94305; ccthomas@stanford.edu hmarkus@stanford.edu.'}, {'ForeName': 'Nicholas G', 'Initials': 'NG', 'LastName': 'Otis', 'Affiliation': 'Division of Health Policy and Management, University of California, Berkeley, CA 94720.'}, {'ForeName': 'Justin R', 'Initials': 'JR', 'LastName': 'Abraham', 'Affiliation': 'Department of Economics, University of California, San Diego, CA 92161.'}, {'ForeName': 'Hazel Rose', 'Initials': 'HR', 'LastName': 'Markus', 'Affiliation': 'Department of Psychology, Stanford University, Stanford, CA 94305; ccthomas@stanford.edu hmarkus@stanford.edu.'}, {'ForeName': 'Gregory M', 'Initials': 'GM', 'LastName': 'Walton', 'Affiliation': 'Department of Psychology, Stanford University, Stanford, CA 94305.'}]",Proceedings of the National Academy of Sciences of the United States of America,['10.1073/pnas.1917046117'] 1734,32580655,Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials: Experience of the SHIFT Heart Failure Study.,"BACKGROUND The usefulness of adjudication by central end point committees (CECs) is poorly assessed in heart failure (HF) trials. We aimed to assess its impact on the outcome of the SHIFT trial (Systolic HF Treatment With the If Inhibitor Ivabradine Trial). METHODS SHIFT was a randomized placebo-controlled trial investigating the effect of ivabradine in 6505 HF patients with reduced ejection fraction. Prespecified end points, reported by investigators (all cardiologists) using specific case report form pages, included all-cause and specific causes of deaths and hospitalizations. The primary end point was a composite of cardiovascular deaths or hospitalizations for worsening HF. We compared the adjudication of prespecified end points made by investigators and by the CEC. RESULTS Investigators identified 7529 prespecified end points, 6793 of which were confirmed by the CEC: 98.1% of cardiovascular deaths, 88.6% of all hospitalizations, and 84.4% of hospitalizations for worsening HF. These differences had no meaningful impact on the study results; hazard ratio for the primary composite end point: investigators, 0.83 (95% CI, 0.76-0.91) versus CEC, 0.82 (95% CI, 0.75-0.90), with similar results for each component of the primary end point (hazard ratio of 0.92 versus 0.91 for cardiovascular death and 0.78 versus 0.74 for hospitalization for worsening HF). CONCLUSIONS Central adjudication by a CEC in the SHIFT study confirmed most of cardiovascular deaths and worsening HF hospitalizations assessed by cardiologists and did not result in a significant change of the final result as compared to investigator judgment. In this context, the benefits of CEC in blinded HF trials should be reconsidered. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02441218. URL: http://www.isrctn.com/ISRCTN70429960; Unique identifier: ISRCTN70429960.",2020,"These differences had no meaningful impact on the study results; hazard ratio for the primary composite end point: investigators, 0.83",['6505 HF patients with reduced ejection fraction'],"['ivabradine', 'placebo']","['cardiovascular deaths', 'cardiovascular deaths and worsening HF hospitalizations', 'composite of cardiovascular deaths or hospitalizations for worsening HF']","[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}]","[{'cui': 'C0257190', 'cui_str': 'ivabradine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0205199', 'cui_str': 'Composite'}]",6505.0,0.254635,"These differences had no meaningful impact on the study results; hazard ratio for the primary composite end point: investigators, 0.83","[{'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Tyl', 'Affiliation': 'CardioVascular & Metabolic Disease Center for Therapeutic Innovation (B.T., C.V.), Institut de Recherches Internationales Servier, Suresnes, France.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Lopez Sendon', 'Affiliation': 'Cardiology Department (J.L.S.), University Hospital La Paz, UAM, IdiPaz, CiberCV, Madrid, Spain.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Borer', 'Affiliation': 'College of Medicine, School of Public Health, SUNY Downstate Medical Center, Brooklyn, New York (J.S.B.).'}, {'ForeName': 'Esteban', 'Initials': 'E', 'LastName': 'Lopez De Sa', 'Affiliation': 'Acute Cardiac Care Unit (E.L.D.S.), University Hospital La Paz, UAM, IdiPaz, CiberCV, Madrid, Spain.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Lerebours', 'Affiliation': 'Health Value 92, Levallois-Perret, France (G.L.).'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Varin', 'Affiliation': 'CardioVascular & Metabolic Disease Center for Therapeutic Innovation (B.T., C.V.), Institut de Recherches Internationales Servier, Suresnes, France.'}, {'ForeName': 'Aurélie', 'Initials': 'A', 'LastName': 'De Montigny', 'Affiliation': 'Center of Excellence Methodology and Valorisation of Data (A.D.M., M.P.), Institut de Recherches Internationales Servier, Suresnes, France.'}, {'ForeName': 'Matthieu', 'Initials': 'M', 'LastName': 'Pannaux', 'Affiliation': 'Center of Excellence Methodology and Valorisation of Data (A.D.M., M.P.), Institut de Recherches Internationales Servier, Suresnes, France.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Komajda', 'Affiliation': 'Department of Cardiology, Hospital Saint Joseph, Paris, France (M.K.).'}]",Circulation. Heart failure,['10.1161/CIRCHEARTFAILURE.119.006720'] 1735,31810753,Efficacy of the presence of an emergency physician in prehospital major trauma care: Randomised control trial results are needed!,,2020,,['prehospital major trauma care'],['emergency physician'],[],"[{'cui': 'C0332677', 'cui_str': 'Major injury'}]","[{'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0031831', 'cui_str': 'Physician'}]",[],,0.0446977,,"[{'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Jouffroy', 'Affiliation': ""SAMU de Paris, Service d'Anesthésie Réanimation, Hôpital Universitaire Necker - Enfants Malades, Assistance Publique - Hôpitaux de Paris, and Université Paris Descartes - Paris 5, Paris, France. Electronic address: romain.jouffroy@aphp.fr.""}, {'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Vivien', 'Affiliation': ""SAMU de Paris, Service d'Anesthésie Réanimation, Hôpital Universitaire Necker - Enfants Malades, Assistance Publique - Hôpitaux de Paris, and Université Paris Descartes - Paris 5, Paris, France.""}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.11.033'] 1736,32683645,Biomarkers of platelet activation and cardiovascular risk in the DAPT trial.,"Prolonged use of dual antiplatelet therapy (DAPT) post-percutaneous coronary intervention (PCI) has been shown to reduce the risk of major adverse cardiovascular events (MACE), but with increased bleeding. It remains unknown whether biomarkers of platelet activation may be useful for identifying patients at increased risk of MACE. The DAPT study was a randomized trial of 12 versus 30 months of DAPT in patients who underwent PCI. Serum biomarkers [myeloid-related protein (MRP)-8/14, P-selectin, soluble CD-40 ligand (sCD40L)] were assessed in 1399 patients early post-PCI. On-treatment platelet reactivity index (PRI) using VASP phosphorylation was assessed in 443 patients randomized to continued DAPT at 1 year. MACE was defined as CV death, MI, or ischemic stroke. Multivariable models were adjusted for baseline characteristics, index event, and stent type. A stepwise increase in the risk of MACE was observed with increasing tertiles of both MRP-8/14 and P-selectin (p-trend = 0.04 for both). After multivariable adjustment, the adjusted HR (95% CI) for MACE in patients in the top tertile was 1.94 (1.14-3.30) for MRP-8/14 and 1.62 (0.99-2.64) for P-selectin. In contrast, baseline sCD40L was not associated with CV risk. Among patients randomized to continued DAPT, higher on-treatment platelet reactivity was not significantly associated with risk of MACE (p-trend = 0.32; adj-HR T3 vs. T1 1.54, 95% CI 0.20-12.18) or bleeding (P-trend = 0.17; adj-HR 0.25, 95% CI 0.05-1.21). MRP-8/14 and soluble P-selectin may be useful for identifying patients at increased risk of MACE after PCI. The utility of on-treatment platelet function testing requires further study.Clinical Trial Registration https://www.clinicaltrials.gov . Unique identifier NCT00977938.",2020,"Among patients randomized to continued DAPT, higher on-treatment platelet reactivity was not significantly associated with risk of MACE (p-trend = 0.32; adj-HR T3 vs. T1 1.54, 95% CI 0.20-12.18) or bleeding (P-trend = 0.17; adj-HR 0.25, 95% CI 0.05-1.21).","['443 patients randomized to continued DAPT at 1\xa0year', '1399 patients early post-PCI', 'patients who underwent PCI']","['dual antiplatelet therapy (DAPT) post-percutaneous coronary intervention (PCI', 'MACE', 'DAPT']","['Serum biomarkers [myeloid-related protein (MRP)-8/14, P-selectin, soluble CD-40 ligand (sCD40L', 'CV death, MI, or ischemic stroke', 'bleeding', 'risk of MACE', 'treatment platelet reactivity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0439677', 'cui_str': 'Myeloid'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0134835', 'cui_str': 'Lymphocyte antigen CD62'}, {'cui': 'C0023688', 'cui_str': 'Ligands'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}]",443.0,0.105176,"Among patients randomized to continued DAPT, higher on-treatment platelet reactivity was not significantly associated with risk of MACE (p-trend = 0.32; adj-HR T3 vs. T1 1.54, 95% CI 0.20-12.18) or bleeding (P-trend = 0.17; adj-HR 0.25, 95% CI 0.05-1.21).","[{'ForeName': 'David D', 'Initials': 'DD', 'LastName': 'Berg', 'Affiliation': ""TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. dberg1@bwh.harvard.edu.""}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Yeh', 'Affiliation': 'Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Mauri', 'Affiliation': 'Medtronic, Minneapolis, MN, USA.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Morrow', 'Affiliation': ""TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Dean J', 'Initials': 'DJ', 'LastName': 'Kereiakes', 'Affiliation': 'The Christ Hospital Heart and Vascular Center, The Lindner Research Center, Cincinnati, OH, USA.'}, {'ForeName': 'Donald E', 'Initials': 'DE', 'LastName': 'Cutlip', 'Affiliation': 'Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Gao', 'Affiliation': 'Baim Clinical Research Institute, Boston, MA, USA.'}, {'ForeName': 'Petr', 'Initials': 'P', 'LastName': 'Jarolim', 'Affiliation': ""Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Alan D', 'Initials': 'AD', 'LastName': 'Michelson', 'Affiliation': ""Center for Platelet Research Studies, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Andrew L', 'Initials': 'AL', 'LastName': 'Frelinger', 'Affiliation': ""Center for Platelet Research Studies, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Abby L', 'Initials': 'AL', 'LastName': 'Cange', 'Affiliation': ""TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Marc S', 'Initials': 'MS', 'LastName': 'Sabatine', 'Affiliation': ""TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Michelle L', 'Initials': 'ML', 'LastName': ""O'Donoghue"", 'Affiliation': ""TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}]",Journal of thrombosis and thrombolysis,['10.1007/s11239-020-02221-5'] 1737,32585185,"Effectiveness of a brief lay counsellor-delivered, problem-solving intervention for adolescent mental health problems in urban, low-income schools in India: a randomised controlled trial.","BACKGROUND Mental health problems are a leading cause of disability in adolescents worldwide. Problem solving is a well-tested mental health intervention in many populations. We aimed to investigate the effectiveness of a brief, transdiagnostic problem-solving intervention for common adolescent mental health problems when delivered by non-specialist school counsellors in New Delhi, India. METHODS This randomised trial was done in six government-run schools (three all-boys schools, two all-girls schools, and one co-educational school) that serve low-income communities. We recruited participants from grades 9 to 12 (ages 12-20 years) by selecting students with persistently elevated mental health symptoms accompanied by distress or functional impairment. Clinical eligibility criteria were assessed by research assistants using the Hindi-language version of the Strengths and Difficulties Questionnaire (SDQ), with reference to locally validated borderline cutoff scores of 19 or greater for boys and 20 or greater for girls on the SDQ Total Difficulties scale, an abnormal score of 2 or more on the SDQ Impact scale, and persistence of more than 1 month on the SDQ Chronicity index. Participants were randomly allocated (1:1) to problem solving delivered through a brief (2-3 week) counsellor-led intervention with supporting printed materials (intervention group), or problem solving delivered via printed booklets alone (control group). Primary outcomes were adolescent-reported mental health symptoms (SDQ Total Difficulties scale) and idiographic psychosocial problems (Youth Top Problems [YTP]) at 6 weeks. Primary analyses were done on an intention-to-treat basis at the 6-week endpoint. The trial is registered with ClinicalTrials.gov, NCT03630471. FINDINGS Participants were enrolled between Aug 20, and Dec 4, 2018. 283 eligible adolescents were referred to the trial, and 251 (89%) of these were enrolled (mean age 15·61 years; 174 [69%] boys). 125 participants were allocated to each group (after accounting for one participant in the intervention group who withdrew consent after randomisation). Primary outcome data were available for 245 (98%) participants. At 6 weeks, the mean YTP scores were 3·52 (SD 2·66) in the intervention group and 4·60 (2·75) in the control group (adjusted mean difference -1·01, 95% CI -1·63 to -0·38; adjusted effect size 0·36, 95% CI 0·11 to 0·61; p=0·0015). The mean SDQ Total Difficulties scores were 17·48 (5·45) in the intervention group and 18·33 (5·45) in the control group (-0·86, -2·14 to 0·41; 0·16, -0·09 to 0·41; p=0·18). We observed no adverse events. INTERPRETATION A brief lay counsellor-delivered problem-solving intervention combined with printed booklets seemed to have a modest effect on psychosocial outcomes among adolescents with diverse mental health problems compared with problem-solving booklets alone. This counsellor-delivered intervention might be a suitable first-line intervention in a stepped care approach, which is being evaluated in ongoing studies. FUNDING Wellcome Trust.",2020,"At 6 weeks, the mean YTP scores were 3·52 (SD 2·66) in the intervention group and 4·60 (2·75) in the control group (adjusted mean difference -1·01, 95% CI -1·63 to -0·38; adjusted effect size 0·36, 95% CI 0·11 to 0·61;","['125 participants', 'adolescent mental health problems in urban, low-income schools in India', 'common adolescent mental health problems when delivered by non-specialist school counsellors in New Delhi, India', '283 eligible adolescents were referred to the trial, and 251 (89%) of these were enrolled (mean age 15·61 years; 174 [69%] boys', 'adolescents with diverse mental health problems', 'participants from grades 9 to 12 (ages 12-20 years) by selecting students with persistently elevated mental health symptoms accompanied by distress or functional impairment', 'six government-run schools (three all-boys schools, two all-girls schools, and one co-educational school) that serve low-income communities', 'Participants were enrolled between Aug 20, and Dec 4, 2018']","['problem solving delivered through a brief (2-3 week) counsellor-led intervention with supporting printed materials (intervention group), or problem solving delivered via printed booklets alone (control group', 'lay counsellor-delivered problem-solving intervention combined with printed booklets', 'brief lay counsellor-delivered, problem-solving intervention', 'transdiagnostic problem-solving intervention']","['SDQ Total Difficulties scale', 'SDQ Chronicity index', 'psychosocial outcomes', 'mean YTP scores', 'mean SDQ Total Difficulties scores', 'adolescent-reported mental health symptoms (SDQ Total Difficulties scale) and idiographic psychosocial problems (Youth Top Problems [YTP']","[{'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1446377', 'cui_str': 'Mental health problem'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0557802', 'cui_str': 'Specialist school'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0086541', 'cui_str': 'Dry form of cutaneous leishmaniasis'}, {'cui': 'C4708786', 'cui_str': '283'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0761050', 'cui_str': '(GVGVP)251'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0018104', 'cui_str': 'Government'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0033211', 'cui_str': 'Problem solving'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0034036', 'cui_str': 'Printed material'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0033161', 'cui_str': 'Printing'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0023668', 'cui_str': 'Liechtenstein'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C3472494', 'cui_str': 'Strengths and difficulties questionnaire'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0547045', 'cui_str': 'Chronicity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}]",125.0,0.178681,"At 6 weeks, the mean YTP scores were 3·52 (SD 2·66) in the intervention group and 4·60 (2·75) in the control group (adjusted mean difference -1·01, 95% CI -1·63 to -0·38; adjusted effect size 0·36, 95% CI 0·11 to 0·61;","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Michelson', 'Affiliation': 'School of Psychology, University of Sussex, Brighton, UK.'}, {'ForeName': 'Kanika', 'Initials': 'K', 'LastName': 'Malik', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Rachana', 'Initials': 'R', 'LastName': 'Parikh', 'Affiliation': 'Sagath, New Delhi, India; Department of Clinical Psychology, Vrije Universiteit, Amsterdam, Netherlands.'}, {'ForeName': 'Helen A', 'Initials': 'HA', 'LastName': 'Weiss', 'Affiliation': 'Medical Research Council Tropical Epidemiology Group, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Aoife M', 'Initials': 'AM', 'LastName': 'Doyle', 'Affiliation': 'Medical Research Council Tropical Epidemiology Group, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Bhargav', 'Initials': 'B', 'LastName': 'Bhat', 'Affiliation': 'Sangath, Goa, India.'}, {'ForeName': 'Rooplata', 'Initials': 'R', 'LastName': 'Sahu', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Bhagwant', 'Initials': 'B', 'LastName': 'Chilhate', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Sonal', 'Initials': 'S', 'LastName': 'Mathur', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Madhuri', 'Initials': 'M', 'LastName': 'Krishna', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Rhea', 'Initials': 'R', 'LastName': 'Sharma', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Paulomi', 'Initials': 'P', 'LastName': 'Sudhir', 'Affiliation': 'Department of Clinical Psychology, National Institute of Mental Health and Neuro Sciences, Bengaluru, India.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'King', 'Affiliation': 'Division of Psychiatry, Faculty of Brain Sciences, University College London, London, UK.'}, {'ForeName': 'Pim', 'Initials': 'P', 'LastName': 'Cuijpers', 'Affiliation': 'Department of Clinical Psychology, Vrije Universiteit, Amsterdam, Netherlands.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Chorpita', 'Affiliation': 'Department of Psychology, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Christopher G', 'Initials': 'CG', 'LastName': 'Fairburn', 'Affiliation': 'Department of Psychiatry, University of Oxford, Oxford, UK.'}, {'ForeName': 'Vikram', 'Initials': 'V', 'LastName': 'Patel', 'Affiliation': 'Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA; Harvard TH Chan School of Public Health, Boston, MA, USA. Electronic address: vikram_patel@hms.harvard.edu.'}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(20)30173-5'] 1738,32585354,The benefits and costs of changing treatment technique in electroconvulsive therapy due to insufficient improvement of a major depressive episode.,"BACKGROUND Electroconvulsive therapy (ECT) technique is often changed after insufficient improvement, yet there has been little research on switching strategies. OBJECTIVE To document clinical outcome in ECT nonresponders who were received a second course using high dose, brief pulse, bifrontotemporal (HD BP BL) ECT, and compare relapse rates and cognitive effects relative to patients who received only one ECT course and as a function of the type of ECT first received. METHODS Patients were classified as receiving Weak, Strong, or HD BP BL ECT during three randomized trials at Columbia University. Nonresponders received HD BP BL ECT. In a separate multi-site trial, Optimization of ECT, patients were randomized to right unilateral or BL ECT and nonresponders also received further treatment with HD BP BL ECT. RESULTS Remission rates with a second course of HD BP BL ECT were high in ECT nonresponders, approximately 60% and 40% in the Columbia University and Optimization of ECT studies, respectively. Clinical outcome was independent of the type of ECT first received. A second course with HD BP BL ECT resulted in greater retrograde amnesia immediately, two months, and six months following ECT. CONCLUSIONS In the largest samples of ECT nonresponders studied to date, a second course of ECT had marked antidepressant effects. Since the therapeutic effects were independent of the technique first administered, it is possible that many patients may benefit simply from longer courses of ECT. Randomized trials are needed to determine whether, when, and how to change treatment technique in ECT.",2020,Clinical outcome was independent of the type of ECT first received.,"['Patients were classified as receiving Weak, Strong, or HD BP BL ECT during three randomized trials at Columbia University', 'patients who received only one ECT course and as a function of the type of ECT first received']","['Electroconvulsive therapy (ECT) technique', 'right unilateral or BL ECT', 'Electroconvulsive Therapy', 'HD BP BL ECT']","['retrograde amnesia', 'HD BP BL ECT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C1762617', 'cui_str': 'Weak'}, {'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}]","[{'cui': 'C0002624', 'cui_str': 'Retrograde amnesia'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}]",,0.0665526,Clinical outcome was independent of the type of ECT first received.,"[{'ForeName': 'Harold A', 'Initials': 'HA', 'LastName': 'Sackeim', 'Affiliation': 'Department of Psychiatry, Columbia University, NY, USA; Department of Radiology, Columbia University, NY, USA. Electronic address: has1@columbia.edu.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Prudic', 'Affiliation': 'Department of Psychiatry, Columbia University, NY, USA; New York State Psychiatric Institute, NY, USA.'}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Devanand', 'Affiliation': 'Department of Psychiatry, Columbia University, NY, USA; New York State Psychiatric Institute, NY, USA; Department of Neurology, Columbia University, NY, USA.'}, {'ForeName': 'Mitchell S', 'Initials': 'MS', 'LastName': 'Nobler', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, New York Medical College, NY, USA.'}, {'ForeName': 'Roger F', 'Initials': 'RF', 'LastName': 'Haskett', 'Affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Benoit H', 'Initials': 'BH', 'LastName': 'Mulsant', 'Affiliation': 'Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Centre for Addiction and Mental Health, Toronto, ON, Canada.'}, {'ForeName': 'Peter B', 'Initials': 'PB', 'LastName': 'Rosenquist', 'Affiliation': 'Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University, Augusta, GA, USA.'}, {'ForeName': 'William V', 'Initials': 'WV', 'LastName': 'McCall', 'Affiliation': 'Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University, Augusta, GA, USA.'}]",Brain stimulation,['10.1016/j.brs.2020.06.016'] 1739,32585438,Effect of in-bed cycling on acute muscle wasting in critically ill adults: A randomised clinical trial.,"PURPOSE To examine whether in-bed cycling assists critically ill adults to reduce acute muscle wasting, improve function and improve quality of life following a period of critical illness. MATERIALS AND METHODS A single-centre, two-group, randomised controlled trial with blinded assessment of the primary outcome was conducted in a tertiary ICU. Critically ill patients expected to be mechanically ventilated for at least 48 h were randomised to 30 min daily in-bed cycling in addition to usual-care physiotherapy (n = 37) or usual-care physiotherapy (n = 37). The primary outcome was muscle atrophy of rectus femoris cross-sectional area (RF CSA ) measured by ultrasound at Day 10 following study enrolment. Secondary outcomes included manual muscle strength, handgrip strength, ICU mobility score, six-minute walk test distance and health-related quality of life up to six-months following hospital admission. RESULTS Analysis included the 72 participants (mean age, 56-years; male, 68%) who completed the study. There were no significant between-group differences in muscle atrophy of RF CSA at Day 10 (mean difference 3.4, 95% CI -6.9% to 13.6%; p = .52), or for secondary outcomes (p-values ranged p = .11 to p = .95). CONCLUSIONS AND RELEVANCE In-bed cycling did not reduce muscle wasting in critically ill adults, but this study provides useful effect estimates for large-scale clinical trials. TRIAL REGISTRATION anzctr.org.au Identifier: ACTRN12616000948493.",2020,"There were no significant between-group differences in muscle atrophy of RF CSA at Day 10 (mean difference 3.4, 95% CI -6.9% to 13.6%; p = .52), or for secondary outcomes (p-values ranged p = .11 to p = .95). ","['72 participants (mean age, 56-years; male, 68%) who completed the study', 'critically ill adults', 'Critically ill patients expected to be mechanically ventilated for at least 48\xa0h']","['anzctr.org.au Identifier', '30\xa0min daily in-bed cycling in addition to usual-care physiotherapy (n\xa0=\xa037) or usual-care physiotherapy', 'bed cycling']","['quality of life', 'manual muscle strength, handgrip strength, ICU mobility score, six-minute walk test distance and health-related quality of life up to six-months following hospital admission', 'muscle atrophy of rectus femoris cross-sectional area (RF CSA ', 'muscle atrophy of RF CSA']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042491', 'cui_str': 'Ventilation'}]","[{'cui': 'C0600091', 'cui_str': 'Identifier'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0026846', 'cui_str': 'Muscle atrophy'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0584894', 'cui_str': 'Rectus femoris muscle structure'}]",,0.450536,"There were no significant between-group differences in muscle atrophy of RF CSA at Day 10 (mean difference 3.4, 95% CI -6.9% to 13.6%; p = .52), or for secondary outcomes (p-values ranged p = .11 to p = .95). ","[{'ForeName': 'Marc R', 'Initials': 'MR', 'LastName': 'Nickels', 'Affiliation': 'Physiotherapy Department, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia; Australian Centre for Health Services Innovation for Healthcare Transformation, School of Public Health & Social Work, Queensland University of Technology, Brisbane, Queensland, Australia; Centre for Functioning and Health Research, Metro South Health, Brisbane, Queensland, Australia; Intensive Care Unit, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia. Electronic address: marc.nickels@health.qld.gov.au.'}, {'ForeName': 'Leanne M', 'Initials': 'LM', 'LastName': 'Aitken', 'Affiliation': 'School of Health Sciences, City, University of London, London, United Kingdom; Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia. Electronic address: leanne.aitken.1@city.ac.uk.'}, {'ForeName': 'Adrian G', 'Initials': 'AG', 'LastName': 'Barnett', 'Affiliation': 'Australian Centre for Health Services Innovation for Healthcare Transformation, School of Public Health & Social Work, Queensland University of Technology, Brisbane, Queensland, Australia. Electronic address: a.barnett@qut.edu.au.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Walsham', 'Affiliation': 'Intensive Care Unit, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia; School of Medicine, University of Queensland, Brisbane, Queensland, Australia. Electronic address: james.walsham@health.qld.gov.au.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'King', 'Affiliation': 'Department of Radiology, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia. Electronic address: scott.king@health.qld.gov.au.'}, {'ForeName': 'Nicolette E', 'Initials': 'NE', 'LastName': 'Gale', 'Affiliation': 'Department of Radiology, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia. Electronic address: nicolette.gale@health.qld.gov.au.'}, {'ForeName': 'Alicia C', 'Initials': 'AC', 'LastName': 'Bowen', 'Affiliation': 'Physiotherapy Department, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia; Intensive Care Unit, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia. Electronic address: alicia.bowen@health.qld.gov.au.'}, {'ForeName': 'Brent M', 'Initials': 'BM', 'LastName': 'Peel', 'Affiliation': 'Physiotherapy Department, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia; Intensive Care Unit, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia. Electronic address: brent.peel@health.qld.gov.au.'}, {'ForeName': 'Samuel L', 'Initials': 'SL', 'LastName': 'Donaldson', 'Affiliation': 'Physiotherapy Department, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia; Intensive Care Unit, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia. Electronic address: samuel.donaldson2@health.qld.gov.au.'}, {'ForeName': 'Stewart T J', 'Initials': 'STJ', 'LastName': 'Mealing', 'Affiliation': 'Intensive Care Unit, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia. Electronic address: stewart.mealing@health.qld.gov.au.'}, {'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'McPhail', 'Affiliation': 'Australian Centre for Health Services Innovation for Healthcare Transformation, School of Public Health & Social Work, Queensland University of Technology, Brisbane, Queensland, Australia; Centre for Functioning and Health Research, Metro South Health, Brisbane, Queensland, Australia; Clinical Informatics, Metro South Health, Brisbane, Australia. Electronic address: steven.mcphail@qut.edu.au.'}]",Journal of critical care,['10.1016/j.jcrc.2020.05.008'] 1740,32585945,Metagenomic Characterization of Gut Microbiota of Carriers of Extended-Spectrum Beta-Lactamase or Carbapenemase-Producing Enterobacteriaceae Following Treatment with Oral Antibiotics and Fecal Microbiota Transplantation: Results from a Multicenter Randomized Trial.,"Background: The R-GNOSIS (Resistance in Gram-Negative Organisms: Studying Intervention Strategies) WP3 study was the first multicenter randomized clinical trial systematically investigating fecal microbiota transplantation (FMT) for intestinal decolonization of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE). Here, we characterized the temporal dynamics of fecal microbiota changes in a sub-cohort of the R-GNOSIS WP3 participants before and after antibiotics/FMT using whole metagenome shotgun sequencing. Methods: We sequenced fecal DNA obtained from 16 ESBL-E/CPE carriers having received oral colistin/neomycin followed by FMT and their corresponding seven donors. Ten treatment-naïve controls from the same trial were included. Fecal samples were collected at baseline (V0), after antibiotics but before FMT (V2) and three times after FMT (V3, V4 and V5). Results: Antibiotic treatment transiently decreased species richness and diversity and increased the abundance of antibiotic resistance determinants (ARDs). Bifidobacterium species, together with butyrate- and propionate-producing species from Lachnospiraceae and Ruminococcaceae families were significantly enriched in post-FMT microbiota of treated carriers. After FMT, the proportion of Enterobacteriaceae was lower compared to baseline but without statistical significance. Conclusions: Combined antibiotic and FMT treatment resulted in enrichment of species that are likely to limit the gut colonization by ESBL-E/CPE.",2020,"After FMT, the proportion of Enterobacteriaceae was lower compared to baseline but without statistical significance. ",['Gut Microbiota of Carriers of Extended-Spectrum Beta-Lactamase or Carbapenemase-Producing Enterobacteriaceae'],"['R-GNOSIS (Resistance in Gram-Negative Organisms', 'fecal microbiota transplantation (FMT', 'Oral Antibiotics and Fecal Microbiota Transplantation', 'antibiotic and FMT', 'CPE carriers', 'extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE', 'oral colistin/neomycin followed by FMT']","['Fecal samples', 'abundance of antibiotic resistance determinants (ARDs', 'fecal microbiota changes', 'proportion of Enterobacteriaceae']","[{'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}, {'cui': 'C0486433', 'cui_str': 'Extended-spectrum beta lactamase'}, {'cui': 'C4039163', 'cui_str': 'Carbapenem resistant Enterobacteriaceae'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0029235', 'cui_str': 'Organism'}, {'cui': 'C2242628', 'cui_str': 'Fecal microbiota transplantation'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0010827', 'cui_str': 'Cytopathic effect'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}, {'cui': 'C4511886', 'cui_str': 'ESBL (Extended spectrum beta-lactamase producing) Enterobacteriaceae'}, {'cui': 'C1444096', 'cui_str': 'ESBL'}, {'cui': 'C4039163', 'cui_str': 'Carbapenem resistant Enterobacteriaceae'}, {'cui': 'C0009316', 'cui_str': 'Colistin'}, {'cui': 'C0027603', 'cui_str': 'Neomycin'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0949285', 'cui_str': 'Antibiotic Resistance'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0014346', 'cui_str': 'Enterobacteriaceae'}]",,0.12825,"After FMT, the proportion of Enterobacteriaceae was lower compared to baseline but without statistical significance. ","[{'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Leo', 'Affiliation': 'Genomic Research Laboratory, Division of Infectious Diseases, University Hospitals and University of Geneva, Rue Michel Servet 1, 1211 Geneva, Switzerland.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Lazarevic', 'Affiliation': 'Genomic Research Laboratory, Division of Infectious Diseases, University Hospitals and University of Geneva, Rue Michel Servet 1, 1211 Geneva, Switzerland.'}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Girard', 'Affiliation': 'Genomic Research Laboratory, Division of Infectious Diseases, University Hospitals and University of Geneva, Rue Michel Servet 1, 1211 Geneva, Switzerland.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Gaïa', 'Affiliation': 'Genomic Research Laboratory, Division of Infectious Diseases, University Hospitals and University of Geneva, Rue Michel Servet 1, 1211 Geneva, Switzerland.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Schrenzel', 'Affiliation': 'Genomic Research Laboratory, Division of Infectious Diseases, University Hospitals and University of Geneva, Rue Michel Servet 1, 1211 Geneva, Switzerland.'}, {'ForeName': 'Victoire', 'Initials': 'V', 'LastName': 'de Lastours', 'Affiliation': 'Division of Internal Medicine, Beaujon Hospital, APHP, Boulevard du Général Leclerc 100, 92110 Clichy, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Fantin', 'Affiliation': 'Division of Internal Medicine, Beaujon Hospital, APHP, Boulevard du Général Leclerc 100, 92110 Clichy, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Bonten', 'Affiliation': 'Department of Medical Microbiology, University Medical Centre, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.'}, {'ForeName': 'Yehuda', 'Initials': 'Y', 'LastName': 'Carmeli', 'Affiliation': 'National Institute for Antibiotic Resistance and Infection Control, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Weizmann Street 6, 6423906 Tel Aviv, Israel.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Rondinaud', 'Affiliation': 'Department of Medical Microbiology, APHP, Bichat-Claude-Bernard Hospital, Rue Henri Huchard 46, 75018 Paris, France.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Harbarth', 'Affiliation': 'Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva, Switzerland.'}, {'ForeName': 'Benedikt D', 'Initials': 'BD', 'LastName': 'Huttner', 'Affiliation': 'Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva, Switzerland.'}]",Microorganisms,['10.3390/microorganisms8060941'] 1741,32588878,Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.,"PURPOSE The pharmacology, pharmacokinetics, efficacy, safety, dosing and administration, and place in therapy of caplacizumab, a novel antibody fragment that inhibits von Willebrand factor, for the treatment of acquired thrombotic thrombocytopenic purpura (TTP) are summarized. SUMMARY Caplacizumab is a humanized anti-von Willebrand factor monoclonal antibody fragment that inhibits the interaction between ultralarge von Willebrand factor multimers and platelets. Caplacizumab is indicated for use in combination with standard-of-care modalities such as plasma exchange and immunosuppressive therapy for the treatment of adults with acquired TTP. By inhibiting von Willebrand factor, caplacizumab offers a new approach to the management of TTP by preventing the development of potentially life-threatening microvascular thrombosis that can occur in the disease process. In a randomized, placebo-controlled phase 3 trial, patients with acquired TTP treated with caplacizumab had more rapid platelet level normalization than placebo users; caplacizumab use also resulted in lower rates of disease recurrence and TTP-related death. The most common adverse events associated with caplacizumab use are bleeding-related events. In a phase 3 trial, serious bleeding-related adverse events were reported in 8 patients (11%) in the caplacizumab group and 1 patient (1%) in the placebo group. Caplacizumab is administered as an 11-mg intravenous loading dose 15 minutes prior to plasma exchange, followed by administration of 11 mg subcutaneously daily after plasma exchange. Once-daily caplacizumab administration can be continued for 30 days after the last plasma exchange. The medication and supplies for administration are provided as a single-use kit; patients should be trained on proper reconstitution and self-administration technique prior to the use of caplacizumab in the ambulatory setting. CONCLUSION Caplacizumab is a first-in-class von Willebrand factor inhibitor approved for the treatment of adults with acquired TTP.",2020,"In a phase 3 trial, serious bleeding-related adverse events were reported in 8 patients (11%) in the caplacizumab group and 1 patient (1%) in the placebo group.","['adults with acquired TTP', 'thrombotic thrombocytopenic purpura', 'patients with acquired TTP treated with']","['Caplacizumab', 'caplacizumab', 'placebo']","['rapid platelet level normalization', 'serious bleeding-related adverse events', 'rates of disease recurrence and TTP-related death', 'pharmacology, pharmacokinetics, efficacy, safety']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439661', 'cui_str': 'Acquired'}, {'cui': 'C0857305', 'cui_str': 'Thrombocytopenic purpura'}, {'cui': 'C0034155', 'cui_str': 'Thrombotic thrombocytopenic purpura'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C3713057', 'cui_str': 'caplacizumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0679254', 'cui_str': 'Disease recurrence'}, {'cui': 'C0857305', 'cui_str': 'Thrombocytopenic purpura'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0342904,"In a phase 3 trial, serious bleeding-related adverse events were reported in 8 patients (11%) in the caplacizumab group and 1 patient (1%) in the placebo group.","[{'ForeName': 'Alyssa L', 'Initials': 'AL', 'LastName': 'Hollifield', 'Affiliation': 'High Point University Fred Wilson School of Pharmacy, High Point, NC.'}, {'ForeName': 'Justin R', 'Initials': 'JR', 'LastName': 'Arnall', 'Affiliation': 'Specialty Pharmacy, Atrium Health, Charlotte, NC.'}, {'ForeName': 'Donald C', 'Initials': 'DC', 'LastName': 'Moore', 'Affiliation': 'Department of Pharmacy, Levine Cancer Institute, Atrium Health, Concord, NC.'}]",American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,['10.1093/ajhp/zxaa151'] 1742,32584996,Safety and efficacy of 48 and 96 weeks of alendronate in children and adolescents with perinatal HIV infection and low bone mineral density for age.,"No safety concerns were identified in a randomized, crossover study of alendronate/placebo in youth with perinatal HIV-infection and low bone mineral density (BMD). BMD improved with 48 weeks of alendronate and continued to improve with an additional 48 weeks of therapy. Gains were largely maintained 48 weeks after stopping alendronate.",2020,"No safety concerns were identified in a randomized, crossover study of alendronate/placebo in youth with perinatal HIV-infection and low bone mineral density (BMD).","['children and adolescents with perinatal HIV infection and low bone mineral density for age', 'youth with perinatal HIV-infection and low bone mineral density (BMD']","['alendronate/placebo', 'alendronate']","['Safety and efficacy', 'BMD']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C3160847', 'cui_str': 'Perinatal HIV infection'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}]","[{'cui': 'C0102118', 'cui_str': 'Alendronate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}]",,0.0872012,"No safety concerns were identified in a randomized, crossover study of alendronate/placebo in youth with perinatal HIV-infection and low bone mineral density (BMD).","[{'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Lindsey', 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard TH Chan School of Public Health, Boston, United States.'}, {'ForeName': 'D L', 'Initials': 'DL', 'LastName': 'Jacobson', 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard TH Chan School of Public Health, Boston, United States.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Spiegel', 'Affiliation': 'Government Solutions, Contractor to National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA.'}, {'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Gordon', 'Affiliation': ""Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, MA, United States.""}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Hazra', 'Affiliation': 'Maternal and Pediatric Infectious Diseases Branch, Division of Extramural Research, Eunice Kennedy Shriver National Institute of Child Health and Development, National Institutes of Health, Department of Health and Human Services, Bethesda, United States.'}, {'ForeName': 'G K', 'Initials': 'GK', 'LastName': 'Siberry', 'Affiliation': 'Office of HIV/AIDS, United States Agency for International Development, Washington, DC, United States.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciaa861'] 1743,32683658,Extracorporeal shock wave lithotripsy for distal ureteric stones: which is the ideal approach?,"OBJECTIVE To compare the safety and efficacy of different approaches using ESWL for management of distal ureteric stone in an attempt to select the ideal one. PATIENTS AND METHODS This is a prospective randomized single-center study conducted on patients with lower third single radiopaque ureteric stone with size less than 15 mm. Patients were randomized into three groups, group A: Supine transgluteal, group B: Modified prone and group C: Prone position (80 patients each). The success of the procedure was assessed by NCCT and is defined as complete stone removal or had only clinically insignificant fragments (< 3 mm) for a maximum of three sessions. The success rate, rate of complications, pain intensity by visual pain scale and patients' satisfaction rate were compared among the three study groups. RESULTS Data of 240 patients were analyzed (80 in each group). Overall, no significant difference has been observed among all groups regarding demographic data, stone and treatment characteristics. The overall success rates for treatment after the last session were 86.3%, 65% and 62.5% in the three study groups, respectively, with a statistically significant difference for group A. Regarding pain perception and complication rate, all groups were comparable. Patient satisfaction is significantly better in group A versus the other two groups. CONCLUSION Our study has confirmed better efficacy profile and patients' satisfaction rate of ESWL in the supine position (transgluteal approach) than other different known approaches for the treatment of distal ureteral stones.",2020,"The overall success rates for treatment after the last session were 86.3%, 65% and 62.5% in the three study groups, respectively, with a statistically significant difference for group A. Regarding pain perception and complication rate, all groups were comparable.","['patients with lower third single radiopaque ureteric stone with size less than 15\xa0mm', 'distal ureteric stones', '240 patients were analyzed (80 in each group']","['Supine transgluteal, group B', 'Modified prone and group C', 'Extracorporeal shock wave lithotripsy', 'ESWL']","['Patient satisfaction', ""success rate, rate of complications, pain intensity by visual pain scale and patients' satisfaction rate"", 'overall success rates', 'safety and efficacy', 'pain perception and complication rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0227191', 'cui_str': 'Structure of lower third of esophagus'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0041952', 'cui_str': 'Ureteric stone'}, {'cui': 'C0522511', 'cui_str': 'With size'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0038846', 'cui_str': 'Supine body position'}, {'cui': 'C0444462', 'cui_str': 'Transgluteal approach'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0033422', 'cui_str': 'Prone body position'}, {'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0015359', 'cui_str': 'Extracorporeal shockwave lithotripsy'}]","[{'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}]",240.0,0.0735721,"The overall success rates for treatment after the last session were 86.3%, 65% and 62.5% in the three study groups, respectively, with a statistically significant difference for group A. Regarding pain perception and complication rate, all groups were comparable.","[{'ForeName': 'M Gaber', 'Initials': 'MG', 'LastName': 'Soliman', 'Affiliation': 'Urology Department, Faculty of Medicine, Tanta University, Tanta, Egypt. Mohagab2006@yahoo.com.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Gameel', 'Affiliation': 'Urology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'El-Tatawy', 'Affiliation': 'Urology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'A Shawky', 'Initials': 'AS', 'LastName': 'El-Abd', 'Affiliation': 'Urology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.'}]",International urology and nephrology,['10.1007/s11255-020-02572-1'] 1744,32589632,"A randomized controlled trial comparing the effectiveness of individual versus household treatment for Scabies in Lambaréné, Gabon.","BACKGROUND It is unclear whether individual treatment of scabies is similarly effective compared to household treatment. This study compared these two treatment strategies with topical benzyl benzoate for treating scabies in Lambaréné, Gabon. METHODS Participants presenting with uncomplicated scabies were randomized into either the Individual Treatment group, where only the affected participants received treatment, or the Household Treatment group, where all family members were treated in parallel to the affected participants regardless of signs and symptoms. The primary endpoint was clinical cure after 28 days; the secondary endpoint was the proportion of affected household members per household after 28 days. RESULTS After 28 days, from a total of 79 participants assessed, 67% (n = 53) were clinically cured; 59% (20/34) in the Individual Treatment group and 73% (33/45) in the Household Treatment group. Participants in the Household Treatment group had about twice the odds of being cured (odds ratio 1.9, 95% confidence interval: 0.8-4.9; p = 0.17). For the secondary outcome, an effect of similar size was observed. CONCLUSIONS Our findings show that treating close contacts of persons affected by scabies may be beneficial to patients and contacts, however, the benefit was less pronounced than anticipated and further research is needed to definitively answer this question.",2020,"Participants in the Household Treatment group had about twice the odds of being cured (odds ratio 1.9, 95% confidence interval: 0.8-4.9; p = 0.17).",['Participants presenting with uncomplicated scabies'],['topical benzyl benzoate'],['clinical cure'],"[{'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0443334', 'cui_str': 'Uncomplicated'}, {'cui': 'C0036262', 'cui_str': 'Infestation by Sarcoptes scabiei var hominis'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0053289', 'cui_str': 'benzyl benzoate'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}]",53.0,0.160026,"Participants in the Household Treatment group had about twice the odds of being cured (odds ratio 1.9, 95% confidence interval: 0.8-4.9; p = 0.17).","[{'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Matthewman', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Rella Zoleko', 'Initials': 'RZ', 'LastName': 'Manego', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Lia Betty', 'Initials': 'LB', 'LastName': 'Dimessa Mbadinga', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Hana', 'Initials': 'H', 'LastName': 'Šinkovec', 'Affiliation': 'Center for Medical Statistics, Informatics and Intelligent Systems, Institute of Clinical Biometrics, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Völker', 'Affiliation': 'Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, & I Dep. of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Malik', 'Initials': 'M', 'LastName': 'Akinosho', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Haedrich', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Jeanne', 'Initials': 'J', 'LastName': ""Tardif d'Hamonville"", 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Lell', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Ayola Akim', 'Initials': 'AA', 'LastName': 'Adegnika', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Ramharter', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Ghyslain', 'Initials': 'G', 'LastName': 'Mombo-Ngoma', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}]",PLoS neglected tropical diseases,['10.1371/journal.pntd.0008423'] 1745,32586939,Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab.,"PURPOSE We evaluated the prognostic and predictive value of circulating tumor cells (CTCs) hormone receptor-positive (HR + ) metastatic breast cancer (MBC) patients randomized to letrozole alone or letrozole plus bevacizumab in the first-line setting (CALGB 40503). EXPERIMENTAL DESIGN Blood samples were collected at pretreatment and three additional time points during therapy. The presence of ≥5 CTCs per 7.5 mL of blood was considered CTC positive. Association of CTCs with progression-free survival (PFS) and overall survival (OS) was assessed using Cox regression models. RESULTS Of 343 patients treated, 294 had CTC data and were included in this analysis. Median follow-up was 39 months. In multivariable analysis, CTC-positive patients at baseline (31%) had significantly reduced PFS [HR, 1.49; 95% confidence interval (CI), 1.12-1.97] and OS (HR, 2.08; 95% CI, 1.49-2.93) compared with CTC negative. Failure to clear CTCs during treatment was associated with significantly increased risk of progression (HR, 2.2; 95% CI, 1.58-3.07) and death (HR, 3.4; 95% CI, 2.36-4.88). CTC-positive patients who received only letrozole had the worse PFS (HR, 2.3; 95% CI, 1.54-3.47) and OS (HR, 2.6; 95% CI, 1.59-4.40). Median PFS in CTC-positive patients was significantly longer (18.0 vs. 7.0 months) in letrozole plus bevacizumab versus letrozole arm ( P = 0.0009). Restricted mean survival time analysis further revealed that addition of bevacizumab was associated with PFS benefit in both CTC-positive and CTC-negative patients, but OS benefit was only observed in CTC-positive patients. CONCLUSIONS CTCs were highly prognostic for the addition of bevacizumab to first-line letrozole in patients with HR+ MBC in CALGB 40503. Further research to determine the potential predictive value of CTCs in this setting is warranted.",2020,only Let had the worse PFS (HR=2.3; 95% CI: 1.54-3.47) and OS (HR=2.6; 95% CI: 1.59-4.40).,"['hormone receptor-positive metastatic breast cancer patients who received', 'CTC-positive patients who received', '343 patients treated, 294 had CTC data and were included in this analysis', 'patients with HR+ MBC']","['letrozole with or without bevacizumab', 'letrozole (Let) alone or letrozole plus bevacizumab (Let+Bev']","['OS benefit', 'Median PFS', 'PFS', 'death', 'Association of CTCs with progression-free survival (PFS) and overall survival (OS', 'risk of progression', 'worse PFS']","[{'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027625', 'cui_str': 'Circulating Neoplastic Cells'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0027625', 'cui_str': 'Circulating Neoplastic Cells'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}]",,0.146634,only Let had the worse PFS (HR=2.3; 95% CI: 1.54-3.47) and OS (HR=2.6; 95% CI: 1.59-4.40).,"[{'ForeName': 'Mark Jesus M', 'Initials': 'MJM', 'LastName': 'Magbanua', 'Affiliation': 'University of California at San Francisco, San Francisco, California. mark.magbanua@ucsf.edu.'}, {'ForeName': 'Oleksandr', 'Initials': 'O', 'LastName': 'Savenkov', 'Affiliation': 'Weill Medical College of Cornell University, New York, New York.'}, {'ForeName': 'Erik J', 'Initials': 'EJ', 'LastName': 'Asmus', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Karla V', 'Initials': 'KV', 'LastName': 'Ballman', 'Affiliation': 'Alliance Statistics and Data Center, Weill Medical College of Cornell University, New York, New York.'}, {'ForeName': 'Janet H', 'Initials': 'JH', 'LastName': 'Scott', 'Affiliation': 'University of California at San Francisco, San Francisco, California.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Park', 'Affiliation': 'University of California at San Francisco, San Francisco, California.'}, {'ForeName': 'Maura', 'Initials': 'M', 'LastName': 'Dickler', 'Affiliation': 'Lilly Oncology, Indianapolis, Indiana.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Partridge', 'Affiliation': 'Dana-Farber/Partners CancerCare, Boston, Massachusetts.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Carey', 'Affiliation': 'UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.'}, {'ForeName': 'Eric P', 'Initials': 'EP', 'LastName': 'Winer', 'Affiliation': 'Dana-Farber/Partners CancerCare, Boston, Massachusetts.'}, {'ForeName': 'Hope S', 'Initials': 'HS', 'LastName': 'Rugo', 'Affiliation': 'University of California at San Francisco, San Francisco, California.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-1329'] 1746,32588435,Ketogenic diets for drug-resistant epilepsy.,"BACKGROUND Ketogenic diets (KDs) are high in fat and low in carbohydrates and have been suggested to reduce seizure frequency in people with epilepsy. Such diets may be beneficial for children with drug-resistant epilepsy. This is an update of a review first published in 2003, and last updated in 2018. OBJECTIVES To assess the effects of ketogenic diets for people with drug-resistant epilepsy. SEARCH METHODS For this update, we searched the Cochrane Register of Studies (CRS Web) and MEDLINE (Ovid, 1946 to 26 April 2019) on 29 April 2019. The Cochrane Register of Studies includes the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), and randomised controlled trials (RCTs) from Embase, ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We imposed no language restrictions. We checked the reference lists of retrieved studies for additional relevant studies. SELECTION CRITERIA RCTs or quasi-RCTs of KDs for people of any age with drug-resistant epilepsy. DATA COLLECTION AND ANALYSIS Two review authors independently applied predefined criteria to extract data and evaluated study quality. We assessed the outcomes: seizure freedom, seizure reduction (50% or greater reduction in seizure frequency), adverse effects, cognition and behaviour, quality of life, and attrition rate. We incorporated a meta-analysis. We utilised an intention-to-treat (ITT) population for all primary analyses. We presented the results as risk ratios (RRs) with 95% confidence intervals (CIs). MAIN RESULTS We identified 13 studies with 932 participants; 711 children (4 months to 18 years) and 221 adults (16 years and over). We assessed all 13 studies to be at high risk of performance and detection bias, due to lack of blinding. Assessments varied from low to high risk of bias for all other domains. We rated the evidence for all outcomes as low to very low certainty. Ketogenic diets versus usual care for children Seizure freedom (RR 3.16, 95% CI 1.20 to 8.35; P = 0.02; 4 studies, 385 participants; very low-certainty evidence) and seizure reduction (RR 5.80, 95% CI 3.48 to 9.65; P < 0.001; 4 studies, 385 participants; low-certainty evidence) favoured KDs (including: classic KD, medium-chain triglyceride (MCT) KD combined, MCT KD only, simplified modified Atkins diet (MAD) compared to usual care for children. We are not confident that these estimated effects are accurate. The most commonly reported adverse effects were vomiting, constipation and diarrhoea for both the intervention and usual care group, but the true effect could be substantially different (low-certainty evidence). Ketogenic diet versus usual care for adults In adults, no participants experienced seizure freedom. Seizure reduction favoured KDs (MAD only) over usual care but, again, we are not confident that the effect estimated is accurate (RR 5.03, 95% CI 0.26 to 97.68; P = 0.29; 2 studies, 141 participants; very low-certainty evidence). Adults receiving MAD most commonly reported vomiting, constipation and diarrhoea (very low-certainty evidence). One study reported a reduction in body mass index (BMI) plus increased cholesterol in the MAD group. The other reported weight loss. The true effect could be substantially different to that reported. Ketogenic diet versus ketogenic diet for children Up to 55% of children achieved seizure freedom with a classical 4:1 KD after three months whilst up to 85% of children achieved seizure reduction (very low-certainty evidence). One trial reported a greater incidence of seizure reduction with gradual-onset KD, as opposed to fasting-onset KD. Up to 25% of children were seizure free with MAD and up to 60% achieved seizure reduction. Up to 25% of children became seizure free with MAD and up to 60% experienced seizure reduction. One study used a simplified MAD (sMAD) and reported that 15% of children gained seizure freedom rates and 56% achieved seizure reduction. We judged all the evidence described as very low certainty, thus we are very unsure whether the results are accurate. The most commonly reported adverse effects were vomiting, constipation and diarrhoea (5 studies, very low-certainty evidence). Two studies reported weight loss. One stated that weight loss and gastrointestinal disturbances were more frequent, with 4:1 versus 3:1 KD, whilst one reported no difference in weight loss with 20 mg/d versus 10 mg/d carbohydrates. In one study, there was a higher incidence of hypercalcuria amongst children receiving classic KD compared to MAD. All effects described are unlikely to be accurate. Ketogenic diet versus ketogenic diet for adults One study randomised 80 adults (aged 18 years and over) to either MAD plus KetoCal during the first month with MAD alone for the second month, or MAD alone for the first month followed by MAD plus KetoCal for the second month. No adults achieved seizure freedom. More adults achieved seizure reduction at one month with MAD alone (42.5%) compared to MAD plus KetoCal (32.5%), however, by three months only 10% of adults in both groups maintained seizure reduction. The evidence for both outcomes was of very low certainty; we are very uncertain whether the effects are accurate. Constipation was more frequently reported in the MAD plus KetoCal group (17.5%) compared to the MAD only group (5%) (1 study, very low-certainty evidence). Diarrhoea and increase/change in seizure pattern/semiology were also commonly reported (17.5% to 20% of participants). The true effects of the diets could be substantially different to that reported. AUTHORS' CONCLUSIONS The evidence suggests that KDs could demonstrate effectiveness in children with drug-resistant epilepsy, however, the evidence for the use of KDs in adults remains uncertain. We identified a limited number of studies which all had small sample sizes. Due to the associated risk of bias and imprecision caused by small study populations, the evidence for the use of KDs was of low to very low certainty. More palatable but related diets, such as the MAD, may have a similar effect on seizure control as the classical KD, but could be associated with fewer adverse effects. This assumption requires more investigation. For people who have drug-resistant epilepsy or who are unsuitable for surgical intervention, KDs remain a valid option. Further research is required, particularly for adults with drug-resistant epilepsy.",2020,"Constipation was more frequently reported in the MAD plus KetoCal group (17.5%) compared to the MAD only group (5%) (1 study, very low-certainty evidence).","['932 participants; 711 children (4 months to 18 years) and 221 adults (16 years and over', 'children with drug-resistant epilepsy', 'people of any age with drug-resistant epilepsy', '1946 to 26 April 2019) on 29 April 2019', 'people with epilepsy', 'adults with drug-resistant epilepsy', 'For people who have drug-resistant epilepsy or who are unsuitable for surgical intervention, KDs remain a valid option', 'adults One study randomised 80 adults (aged 18 years and over) to either', 'adults', 'Adults receiving', 'people with drug-resistant epilepsy']","['Ketogenic diets', 'Ketogenic diet versus usual care', 'Ketogenic diet versus ketogenic diet', 'ketogenic diets', 'simplified MAD (sMAD', 'MAD plus KetoCal', 'Ketogenic diets versus usual care', 'MAD']","['seizure frequency), adverse effects, cognition and behaviour, quality of life, and attrition rate', 'seizure freedom rates', 'Diarrhoea', 'body mass index (BMI) plus increased cholesterol', 'seizure free with MAD', 'Constipation', 'outcomes: seizure freedom, seizure reduction', 'vomiting, constipation and diarrhoea', 'weight loss', 'weight loss and gastrointestinal disturbances', 'seizure pattern/semiology', 'seizure reduction', 'seizure freedom']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1096063', 'cui_str': 'Refractory epilepsy'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0259972', 'cui_str': 'Ketogenic diet'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0259972', 'cui_str': 'Ketogenic diet'}, {'cui': 'C0002957', 'cui_str': 'Feeling angry'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0149775', 'cui_str': 'Fit frequency'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C1299590', 'cui_str': 'Seizure free'}, {'cui': 'C0002957', 'cui_str': 'Feeling angry'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0232459', 'cui_str': 'Abnormal digestive tract function'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}]",80.0,0.178047,"Constipation was more frequently reported in the MAD plus KetoCal group (17.5%) compared to the MAD only group (5%) (1 study, very low-certainty evidence).","[{'ForeName': 'Kirsty J', 'Initials': 'KJ', 'LastName': 'Martin-McGill', 'Affiliation': 'Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Bresnahan', 'Affiliation': 'Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Levy', 'Affiliation': 'The Croft Shifta Health Centre, Rochdale, UK.'}, {'ForeName': 'Paul N', 'Initials': 'PN', 'LastName': 'Cooper', 'Affiliation': 'Centre for Clinical Neurosciences, Salford Royal Hospitals NHS Trust, Salford, UK.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD001903.pub5'] 1747,32589613,Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial.,"More than half of community-dwelling individuals sixty years and older express concern about declining cognitive abilities. The current study's aim was to evaluate hyperbaric oxygen therapy (HBOT) effect on cognitive functions in healthy aging adults.A randomized controlled clinical trial randomized 63 healthy adults (>64) either to HBOT(n=33) or control arms(n=30) for three months. Primary endpoint included the general cognitive function measured post intervention/control. Cerebral blood flow (CBF) was evaluated by perfusion magnetic resonance imaging.There was a significant group-by-time interaction in global cognitive function post-HBOT compared to control (p=0.0017). The most striking improvements were in attention (net effect size=0.745) and information processing speed (net effect size=0.788).Voxel-based analysis showed significant cerebral blood flow increases in the HBOT group compared to the control group in the right superior medial frontal gyrus (BA10), right and left supplementary motor area (BA6), right middle frontal gyrus (BA6), left middle frontal gyrus (BA9), left superior frontal gyrus (BA8) and the right superior parietal gyrus (BA7).In this study, HBOT was shown to induce cognitive enhancements in healthy aging adults via mechanisms involving regional changes in CBF. The main improvements include attention, information processing speed and executive functions, which normally decline with aging.",2020,There was a significant group-by-time interaction in global cognitive function post-HBOT compared to control (p=0.0017).,"['63 healthy adults (>64) either to HBOT(n=33) or control arms(n=30) for three months', 'healthy older adults', 'healthy aging adults']","['hyperbaric oxygen', 'hyperbaric oxygen therapy (HBOT']","['global cognitive function post-HBOT', 'attention, information processing speed and executive functions, which normally decline with aging', 'Cerebral blood flow (CBF', 'right and left supplementary motor area (BA6), right middle frontal gyrus (BA6), left middle frontal gyrus (BA9), left superior frontal gyrus (BA8', 'cognitive functions', 'general cognitive function measured post intervention/control', 'cerebral blood flow increases']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4082119', 'cui_str': 'Three months'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0020431', 'cui_str': 'Hyperbaric oxygen therapy'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0020431', 'cui_str': 'Hyperbaric oxygen therapy'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0021420', 'cui_str': 'Information Processing'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C3496174', 'cui_str': 'Supplementary Motor Area'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0152297', 'cui_str': 'Structure of middle frontal gyrus'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0152296', 'cui_str': 'Structure of superior frontal gyrus'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",63.0,0.0790879,There was a significant group-by-time interaction in global cognitive function post-HBOT compared to control (p=0.0017).,"[{'ForeName': 'Hadanny', 'Initials': 'H', 'LastName': 'Amir', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Daniel-Kotovsky', 'Initials': 'DK', 'LastName': 'Malka', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Suzin', 'Initials': 'S', 'LastName': 'Gil', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Boussi-Gross', 'Initials': 'BG', 'LastName': 'Rahav', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Catalogna', 'Initials': 'C', 'LastName': 'Merav', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Dagan', 'Initials': 'D', 'LastName': 'Kobi', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Hachmo', 'Initials': 'H', 'LastName': 'Yafit', 'Affiliation': 'Research and Development Unit, Shamir Medical Center, Zerifin, Israel.'}, {'ForeName': 'Abu Hamed', 'Initials': 'AH', 'LastName': 'Ramzia', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Sasson', 'Initials': 'S', 'LastName': 'Efrat', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Fishlev', 'Initials': 'F', 'LastName': 'Gregory', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Lang', 'Initials': 'L', 'LastName': 'Erez', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Polak', 'Initials': 'P', 'LastName': 'Nir', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Doenyas', 'Initials': 'D', 'LastName': 'Keren', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Friedman', 'Initials': 'F', 'LastName': 'Mony', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Tal', 'Initials': 'T', 'LastName': 'Sigal', 'Affiliation': 'Radiology Department, Shamir Medical Center, Zerifin, Israel.'}, {'ForeName': 'Zemel', 'Initials': 'Z', 'LastName': 'Yonatan', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Bechor', 'Initials': 'B', 'LastName': 'Yair', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Efrati', 'Initials': 'E', 'LastName': 'Shai', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}]",Aging,['10.18632/aging.103571'] 1748,32590251,The treatment of V2 + V3 idiopathic trigeminal neuralgia using peripheral nerve radiofrequency thermocoagulation via the foramen rotundum and foramen ovale compared with semilunar ganglion radiofrequency thermocoagulation.,"OBJECTIVES To compare the advantages and disadvantages of V2 + V3 idiopathic trigeminal neuralgia using peripheral nerve radiofrequency (RF) thermocoagulation (PRF) via the foramen rotundum (FR) and foramen ovale (FO) with those of semilunar ganglion RF thermocoagulation (GRF) under local anesthesia, for exploring a new and available surgical method for patients with V2 + V3 idiopathic trigeminal neuralgia. PATIENTS AND METHODS 102 patients with V2 + V3 idiopathic trigeminal neuralgia were enrolled in this prospective randomized controlled clinical trial, and they were divided into the PRF and GRF group randomly (n = 51 in both groups). The outcome of pain relief was assessed using the Barrow Neurological Institute (BNI) pain score, and grouped as good (BNI Class I or II, no medication required) and bad (BNI Class III-V, medication required or failed). Recurrence was defined as a relapse to a previous lower level after attainment of any higher level of pain relief. The immediate effective rate, the 2-year postoperative effective rate, the 2-year postoperative recurrence rate, and the number of complications were observed and recorded. RESULTS Their basic conditions (age, gender ratio, side of pain, and disease duration) were similar. Furthermore, we found that the 2-year postoperative effective rate between them had no significant difference. By comparing the two groups, PRF group had the better immediate effective rate of the V2 branch and no severe complications such as corneal ulcer, however, GRF group had lower 2-year postoperative recurrence rate of the V3 branch and fewer facial swelling. CONCLUSION The PRF surgery, like GRF, is another prospective treatment for V2 + V3 idiopathic trigeminal neuralgia by virtue of its excellent immediate effect, accurate positioning and high safety.",2020,"The PRF surgery, like GRF, is another prospective treatment for V2 + V3 idiopathic trigeminal neuralgia by virtue of its excellent immediate effect, accurate positioning and high safety.","['patients with V2\u202f+\u202fV3 idiopathic trigeminal neuralgia', '102 patients with V2\u202f+\u202fV3 idiopathic trigeminal neuralgia']","['PRF and GRF', 'V2\u202f+\u202fV3 idiopathic trigeminal neuralgia using peripheral nerve radiofrequency thermocoagulation via the foramen rotundum and foramen ovale compared with semilunar ganglion radiofrequency thermocoagulation', 'semilunar ganglion RF thermocoagulation (GRF', 'V2\u202f+\u202fV3 idiopathic trigeminal neuralgia using peripheral nerve radiofrequency (RF) thermocoagulation (PRF) via the foramen rotundum (FR) and foramen ovale (FO']","['facial swelling', 'pain relief', 'Recurrence', 'immediate effective rate, the 2-year postoperative effective rate, the 2-year postoperative recurrence rate, and the number of complications', '2-year postoperative effective rate', 'immediate effective rate of the V2 branch and no severe complications such as corneal ulcer', 'Barrow Neurological Institute (BNI) pain score, and grouped as good (BNI Class I or II, no medication required) and bad (BNI Class III-V, medication required or failed', '2-year postoperative recurrence rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0393786', 'cui_str': 'Idiopathic trigeminal neuralgia'}]","[{'cui': 'C0031119', 'cui_str': 'Peripheral nerve structure'}, {'cui': 'C0013804', 'cui_str': 'Electrocoagulation'}, {'cui': 'C0017067', 'cui_str': 'Structure of nervous system ganglion'}, {'cui': 'C0393786', 'cui_str': 'Idiopathic trigeminal neuralgia'}, {'cui': 'C0016521', 'cui_str': 'Structure of foramen ovale of heart'}, {'cui': 'C0040995', 'cui_str': 'Structure of trigeminal ganglion'}]","[{'cui': 'C0151602', 'cui_str': 'Facial swelling'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205384', 'cui_str': 'Branching'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0010043', 'cui_str': 'Corneal ulcer'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0441885', 'cui_str': 'Class 1'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0441887', 'cui_str': 'Class 3'}]",102.0,0.0255936,"The PRF surgery, like GRF, is another prospective treatment for V2 + V3 idiopathic trigeminal neuralgia by virtue of its excellent immediate effect, accurate positioning and high safety.","[{'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Zeng', 'Affiliation': ""Department of Pain Clinic, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.""}, {'ForeName': 'Mengye', 'Initials': 'M', 'LastName': 'Zhu', 'Affiliation': ""Department of Pain Clinic, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.""}, {'ForeName': 'Quan', 'Initials': 'Q', 'LastName': 'Wan', 'Affiliation': ""Department of Pain Clinic, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, 310014, People's Republic of China.""}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': ""Department of Pain Clinic, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.""}, {'ForeName': 'Changxi', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': ""Department of Pain Clinic, Subei People's Hospital, Yangzhou, Jiangsu, 225002, People's Republic of China. Electronic address: 1714452550@qq.com.""}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ""Department of Pain Clinic, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China. Electronic address: zy830226@163.com.""}]",Clinical neurology and neurosurgery,['10.1016/j.clineuro.2020.106025'] 1749,32489001,Effects of lingual exercises on oral muscle strength and salivary flow rate in elderly adults: a randomized clinical trial.,"AIM The present study investigated the effects of two types of lingual exercise (tongue-hold swallowing and tongue-pressure resistance training) on oral muscle strength, salivary flow rate and subjective oral health of the elderly. METHODS We randomly assigned 74 elderly adults (≥65 years) to three groups (tongue-hold swallowing, tongue-pressure resistance training and control groups). Each group participated in 8 weeks of their appropriately prescribed intervention. We measured anterior tongue strength, posterior tongue strength, lip strength, salivary flow rate and Oral Health Impact Profile-14 score before and after 8 weeks. Differences before and after intervention were observed with a paired sample t-test. Moreover, analyses of covariance and variance were performed to determine the differences in the measured values between the groups. RESULTS The tongue-hold swallowing group showed improvement in both anterior and posterior tongue strength, while the tongue-pressure resistance training group showed a significant increase in only anterior tongue strength. Both the tongue-hold swallowing and tongue-pressure resistance training groups showed increased salivary secretion, with the tongue-pressure resistance training group showing a higher level of salivary secretion. However, the difference in the subjective oral health scores before and after the intervention was not significant. CONCLUSIONS The two lingual exercises strengthened some aspects of tongue muscles and increased the salivary flow rate, with more salivary secretion in the tongue-pressure resistance training group than in the tongue-hold swallowing group. Any evidence of the lingual exercises being able to enhance subjective oral health could not be found. Geriatr Gerontol Int 2020; ••: ••-••.",2020,"Both the tongue-hold swallowing and tongue-pressure resistance training groups showed increased salivary secretion, with the tongue-pressure resistance training group showing a higher level of salivary secretion.","['74 elderly adults (≥65\u2009years) to three groups ', 'elderly adults']","['tongue-hold swallowing, tongue-pressure resistance training', 'lingual exercises', 'lingual exercise (tongue-hold swallowing and tongue-pressure resistance training']","['anterior tongue strength, posterior tongue strength, lip strength, salivary flow rate and Oral Health Impact Profile-14 score', 'anterior tongue strength', 'subjective oral health scores', 'oral muscle strength and salivary flow rate', 'anterior and posterior tongue strength', 'salivary flow rate', 'oral muscle strength, salivary flow rate and subjective oral health of the elderly', 'salivary secretion']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0040408', 'cui_str': 'Tongue structure'}, {'cui': 'C0675390', 'cui_str': 'ARID1A protein, human'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0226945', 'cui_str': 'Structure of body of tongue'}, {'cui': 'C0226958', 'cui_str': 'Structure of root of tongue'}, {'cui': 'C0023759', 'cui_str': 'Lip structure'}, {'cui': 'C0429177', 'cui_str': 'Salivary flow rate'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0036104', 'cui_str': 'Salivary secretion'}]",74.0,0.0292108,"Both the tongue-hold swallowing and tongue-pressure resistance training groups showed increased salivary secretion, with the tongue-pressure resistance training group showing a higher level of salivary secretion.","[{'ForeName': 'Kyeong-Hee', 'Initials': 'KH', 'LastName': 'Lee', 'Affiliation': 'Department of Dental Hygiene, College of Bioecological Health, Shinhan University, Uijeongbu, Republic of Korea.'}, {'ForeName': 'Eun-Seo', 'Initials': 'ES', 'LastName': 'Jung', 'Affiliation': 'Department of Dental Hygiene, College of Bioecological Health, Shinhan University, Uijeongbu, Republic of Korea.'}, {'ForeName': 'Yoon-Young', 'Initials': 'YY', 'LastName': 'Choi', 'Affiliation': 'Artificial Intelligence Big Data Medical Center, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.'}]",Geriatrics & gerontology international,['10.1111/ggi.13944'] 1750,32590885,Effect of thickness and occlusal accommodation on the degree of satisfaction with mouthguard use among water polo players: A randomized crossover trial.,"BACKGROUND/AIM The optimal mouthguard type and design for each player and sport are currently unknown. The aim of this study was to assess the effect of using a thicker custom-made mouthguard with occlusal accommodation on the degree of satisfaction among water polo players. MATERIAL AND METHODS Twenty-five elite water polo players participated in this randomized four-period crossover trial conducted from February to May 2019. For each participant, two customized mouthguards were fabricated using 4-mm ethyl vinyl acetate foil: Type A included no occlusal accommodation, and Type B included a 2-mm occlusal accommodation. Players wore each mouthguard during training sessions and competitions for 2 weeks in one of two randomized sequences. After each match or training session, players were asked to evaluate the mouthguards on 10-point scales across three domains: discomfort or interference with function, protection, and general satisfaction. Mouthguard preference was also recorded. RESULTS The mouthguard with occlusal accommodation was reported to interfere more with speech and swallowing (P < .001) and with esthetics, breathing, and athletic performance (P < .05) compared with the conventional mouthguard. Although occlusal accommodation was associated with a higher perceived degree of protection (mean difference 0.5; 95% CI: 0.2-0.8), players were still more satisfied with the conventional mouthguard (mean difference 1.5; 95% CI: 0.8-2.3). Two players preferred the occlusal mouthguard, whereas 22 preferred the conventional mouthguard (P = .007). CONCLUSIONS Among water polo players, occlusal accommodation increasing the thickness of the custom-made mouthguards may offer a greater perceived sense of protection, but this comes at the cost of greater discomfort and reduced overall satisfaction. Dentists can recommend conventional mouthguards for most water polo players.",2020,"The mouthguard with occlusal accommodation was reported to interfere more with speech and swallowing (P < 0.001) and with aesthetics, breathing, and athletic performance (P < 0.05) compared with the conventional mouthguard.","['Twenty-five elite water polo players participated in this randomized four-period crossover trial conducted from February to May 2019', 'water polo players']","['thicker custom-made mouthguard with occlusal accommodation', 'thickness and occlusal accommodation']","['discomfort or interference with function, protection, and general satisfaction', 'speech and swallowing', 'aesthetics, breathing, and athletic performance']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C2712390', 'cui_str': 'Water Polo'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]","[{'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C3880278', 'cui_str': 'Mouthguard, custom-made'}, {'cui': 'C0447303', 'cui_str': 'Structure of occlusal surface of tooth'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}]","[{'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0871966', 'cui_str': 'Sports Performance'}]",,0.098461,"The mouthguard with occlusal accommodation was reported to interfere more with speech and swallowing (P < 0.001) and with aesthetics, breathing, and athletic performance (P < 0.05) compared with the conventional mouthguard.","[{'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Flores-Figueiras', 'Affiliation': 'Department of Prosthodontics, School of Dentistry, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Zamora-Olave', 'Affiliation': 'Department of Prosthodontics, School of Dentistry, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Willaert', 'Affiliation': 'Department of Prosthodontics, School of Dentistry, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Martinez-Gomis', 'Affiliation': 'Department of Prosthodontics, School of Dentistry, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.'}]",Dental traumatology : official publication of International Association for Dental Traumatology,['10.1111/edt.12583'] 1751,32590137,Bone turnover markers in children living with HIV remaining on ritonavir-boosted lopinavir or switching to efavirenz.,"INTRODUCTION We previously found lower bone mass but similar bone turnover in pre-pubertal children living with HIV (CLWH) on a ritonavir-boosted lopinavir (LPV/r)-based vs. efavirenz-based antiretroviral therapy regimen 2 years after switch. Here, we evaluate if bone turnover differed between the groups close to the time of switch. METHODS Samples from 108 children remaining on LPV/r and 104 children switched to efavirenz were available for analysis 8 weeks post-randomization. Bone turnover markers, including C-telopeptide of type 1 collagen (CTx), procollagen type-I N-terminal propeptide (P1NP), and osteocalcin were measured. Markers of immune activation were also measured, including IL-6, TNF-alpha, soluble CD14 and high-sensitivity C-reactive protein (CRP). RESULTS Eight weeks post-randomization, we did not detect differences in CTx (1.42 vs. 1.44 ng/mL, p = 0.85) or P1NP concentrations (622 vs. 513 ng/mL, p = 0.68) between treatment groups. At 8 weeks, the treatment groups also had similar levels of IL-6, TNF-alpha, soluble CD14 and high-sensitivity CRP. Osteocalcin (ng/mL) was higher in the LPV/r than efavirenz group both at 8 weeks (88.6 vs. 67.3, p = 0.001) and 2 years (67.6 vs. 49.8, p = 0.001). CONCLUSIONS Overall, we failed to detect difference in bone turnover by P1NP and CTx in virologically-suppressed CLWH on different regimens at a time point close to the switch. We did observe higher levels of total osteocalcin in children remaining on LPV/r compared to children switched to efavirenz. Future studies should focus on uncovering the mechanism and determining whether perturbation in undercarboxylated osteocalcin could explain some of the bone side effects noted with protease inhibitors.",2020,"At 8 weeks, the treatment groups also had similar levels of IL-6, TNF-alpha, soluble CD14 and high-sensitivity CRP.","['children living with HIV remaining on ritonavir-boosted lopinavir or switching to', 'Samples from 108 children remaining on LPV/r and 104 children switched to', 'pre-pubertal children living with HIV (CLWH) on a']","['efavirenz', 'ritonavir-boosted lopinavir (LPV/r)-based vs. efavirenz-based antiretroviral therapy']","['IL-6, TNF-alpha, soluble CD14 and high-sensitivity C-reactive protein (CRP', 'Bone turnover markers, including C-telopeptide of type 1 collagen (CTx), procollagen type-I N-terminal propeptide (P1NP), and osteocalcin', 'levels of IL-6, TNF-alpha, soluble CD14 and high-sensitivity CRP', 'Osteocalcin', 'bone turnover by P1NP and CTx', 'total osteocalcin', 'CTx', 'Bone turnover markers', 'bone turnover', 'P1NP concentrations', 'Markers of immune activation']","[{'cui': 'C0553288', 'cui_str': 'Lives with children'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0674432', 'cui_str': 'lopinavir'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C1628325', 'cui_str': 'Pre-pubertal'}]","[{'cui': 'C0674428', 'cui_str': 'efavirenz'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0674432', 'cui_str': 'lopinavir'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}]","[{'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1448177', 'cui_str': 'TNF protein, human'}, {'cui': 'C0108768', 'cui_str': 'Lymphocyte antigen CD14'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0085268', 'cui_str': 'Bone remodeling'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0631180', 'cui_str': 'C-telopeptide'}, {'cui': 'C0041455', 'cui_str': 'Collagen Type I'}, {'cui': 'C0041457', 'cui_str': 'Type I Procollagen'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0029419', 'cui_str': 'Osteocalcin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0072053', 'cui_str': 'Procollagen peptide, type 1 N-terminal'}, {'cui': 'C0010377', 'cui_str': 'Crotoxin'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439662', 'cui_str': 'Immune'}]",,0.0664262,"At 8 weeks, the treatment groups also had similar levels of IL-6, TNF-alpha, soluble CD14 and high-sensitivity CRP.","[{'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Shiau', 'Affiliation': 'Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA.'}, {'ForeName': 'Michael T', 'Initials': 'MT', 'LastName': 'Yin', 'Affiliation': 'Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.'}, {'ForeName': 'Renate', 'Initials': 'R', 'LastName': 'Strehlau', 'Affiliation': 'Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Department of Pediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Shen', 'Affiliation': 'Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA.'}, {'ForeName': 'Elaine J', 'Initials': 'EJ', 'LastName': 'Abrams', 'Affiliation': 'Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA; Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY, USA; ICAP at Columbia, Mailman School of Public Health, Columbia University, New York, NY, USA.'}, {'ForeName': 'Ashraf', 'Initials': 'A', 'LastName': 'Coovadia', 'Affiliation': 'Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Department of Pediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Kuhn', 'Affiliation': 'Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.'}, {'ForeName': 'Stephen M', 'Initials': 'SM', 'LastName': 'Arpadi', 'Affiliation': 'Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA; Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY, USA; ICAP at Columbia, Mailman School of Public Health, Columbia University, New York, NY, USA. Electronic address: sma2@columbia.edu.'}]",Bone,['10.1016/j.bone.2020.115500'] 1752,32590151,Cryoballoon ablation of pulmonary veins for persistent atrial fibrillation: Results from the multicenter STOP Persistent AF trial.,"BACKGROUND Pulmonary vein isolation (PVI) is the cornerstone of catheter ablation to treat patients with symptomatic drug-refractory atrial fibrillation (AF). OBJECTIVE The purpose of this study was to assess the safety and efficacy of PVI using the cryoballoon catheter to treat patients with persistent AF. METHODS STOP Persistent AF (ClinicalTrials.gov Identifier: NCT03012841) was a prospective, multicenter, single-arm, Food and Drug Administration-regulated trial designed to evaluate the safety and efficacy of PVI-only cryoballoon ablation for drug-refractory persistent AF (continuous episodes <6 months). The primary efficacy endpoint was 12-month freedom from ≥30 seconds of AF, atrial flutter (AFL), or atrial tachycardia (AT) after a 90-day blanking period. The prespecified performance goals were set at >40% and <13% for the primary efficacy and safety endpoints, respectively. Secondary endpoints assessed quality of life using the AFEQT (Atrial Fibrillation Effect on Quality of Life) and SF (Short Form)-12 questionnaires. RESULTS Of 186 total enrollments, 165 subjects (70% male; age 65 ± 9 years; left atrial diameter 4.2 ± 0.6 cm; body mass index 31 ± 6) were treated at 25 sites in the United States, Canada, and Japan. Total procedural, left atrial dwell, and fluoroscopy times were 121 ± 46 minutes, 102 ± 41 minutes, and 19 ± 16 minutes, respectively. At 12 months, the primary efficacy endpoint was 54.8% (95% confidence [CI] 46.7%-62.1%) freedom from AF, AFL, or AT. There was 1 primary safety event, translating to a rate of 0.6% (95% CI 0.1%-4.4%). AFEQT and SF-12 assessments demonstrated significant improvements from baseline to 12 months postablation (P <.001). CONCLUSION The STOP Persistent AF trial demonstrated cryoballoon ablation to be safe and effective in treating patients with drug-refractory persistent AF characterized by continuous AF episodes <6 months.",2020,"AFEQT and SF-12 assessments demonstrated significant improvements from baseline to 12 months post ablation (P<0.001). ","['Persistent Atrial Fibrillation', 'patients with symptomatic drug-refractory atrial fibrillation (AF', 'Of 186 total enrollments, 165 subjects (70% male, 65±9 years, left atrial diameter 4.2±0.6 cm, body mass index 31±6) were treated at 25 sites in the United States, Canada, and Japan']","['Cryoballoon Ablation of Pulmonary Veins', 'Pulmonary vein isolation (PVI', 'PVI-only cryoballoon ablation for drug-refractory persistent AF', 'PVI']","['Total procedure, left atrial dwell, and fluoroscopy times', 'safety and efficacy', 'quality of life using the AFEQT and SF-12 questionnaires', '12-month freedom from ≥30 sec of AF, atrial flutter (AFL), or atrial tachycardia (AT']","[{'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018792', 'cui_str': 'Atrial structure'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0034090', 'cui_str': 'Structure of vein of pulmonary circulation'}, {'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018792', 'cui_str': 'Atrial structure'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0059387', 'cui_str': 'staphylococcal enterotoxin C'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0004239', 'cui_str': 'Atrial flutter'}, {'cui': 'C0030587', 'cui_str': 'Atrial paroxysmal tachycardia'}]",,0.0320406,"AFEQT and SF-12 assessments demonstrated significant improvements from baseline to 12 months post ablation (P<0.001). ","[{'ForeName': 'Wilber W', 'Initials': 'WW', 'LastName': 'Su', 'Affiliation': 'Banner University Medical Center Phoenix, Phoenix, Arizona.'}, {'ForeName': 'Vivek Y', 'Initials': 'VY', 'LastName': 'Reddy', 'Affiliation': 'Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Kabir', 'Initials': 'K', 'LastName': 'Bhasin', 'Affiliation': 'Northwell Health-Lenox Hill Heart and Lung, New York, New York.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Champagne', 'Affiliation': 'Institut Universitaire de Cardiologie et du Pneumologie de Quebec, Quebec, Canada.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Sangrigoli', 'Affiliation': 'Doylestown Cardiology Associates, Doylestown, Pennsylvania.'}, {'ForeName': 'Kendra M', 'Initials': 'KM', 'LastName': 'Braegelmann', 'Affiliation': 'Medtronic, Inc., Minneapolis, Minnesota.'}, {'ForeName': 'Fred J', 'Initials': 'FJ', 'LastName': 'Kueffer', 'Affiliation': 'Medtronic, Inc., Minneapolis, Minnesota.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Novak', 'Affiliation': 'Royal Jubilee Hospital, Victoria, Canada.'}, {'ForeName': 'Sanjaya K', 'Initials': 'SK', 'LastName': 'Gupta', 'Affiliation': ""Saint Luke's Health System, Kansas City, Missouri.""}, {'ForeName': 'Teiichi', 'Initials': 'T', 'LastName': 'Yamane', 'Affiliation': 'Jikei University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hugh', 'Initials': 'H', 'LastName': 'Calkins', 'Affiliation': 'Johns Hopkins Medical Institutions, Baltimore, Maryland. Electronic address: hcalkins@jhmi.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Heart rhythm,['10.1016/j.hrthm.2020.06.020'] 1753,32590214,Perceived social support and posttraumatic stress symptoms in children and youth in therapy: A parallel process latent growth curve model.,"Many studies show that perceived social support protects against the development of posttraumatic stress symptoms (PTSS) in the aftermath of trauma, but less is known about support in relation to PTSS in trauma therapy. This study examined associations between perceived social support and PTSS in children and adolescents during trauma therapy. Parallel process latent growth curve modeling was used to examine trajectories of perceived social support and PTSS over five measurement waves in a sample of 156 patients, aged between 10 and 18 years (M age = 15.1, SD = 2.2, 79.5% girls), randomized to receive trauma-focused cognitive behavior therapy (TF-CBT) or therapy-as-usual (TAU). Across all participants there was an average decline in PTSS and increase of perceived social support from pre-therapy to 18 months after therapy. Most of the change occurred during therapy and was maintained after therapy. Higher levels of PTSS prior to therapy were associated with lower levels of perceived social support prior to therapy, and a decrease in PTSS was associated with increase in perceived social support. This co-development may have been directed by a third underlying factor or short-term temporal effects. Studies investigating within-person associations over shorter time intervals will benefit our understanding of possible temporal effects.",2020,Across all participants there was an average decline in PTSS and increase of perceived social support from pre-therapy to 18 months after therapy.,"['children and adolescents during trauma therapy', '156 patients, aged between 10 and 18 years (M age\xa0=\xa015.1, SD\xa0=\xa02.2, 79.5% girls', 'children and youth in therapy']",['trauma-focused cognitive behavior therapy (TF-CBT) or therapy-as-usual (TAU'],"['Perceived social support and posttraumatic stress symptoms', 'PTSS', 'perceived social support']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1320387', 'cui_str': 'Trauma therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}]",156.0,0.02545,Across all participants there was an average decline in PTSS and increase of perceived social support from pre-therapy to 18 months after therapy.,"[{'ForeName': 'Marianne S', 'Initials': 'MS', 'LastName': 'Birkeland', 'Affiliation': 'Norwegian Centre for Violence and Traumatic Stress Studies, Norway. Electronic address: Marianne.s.birkeland@gmail.com.'}, {'ForeName': 'Tonje', 'Initials': 'T', 'LastName': 'Holt', 'Affiliation': 'Division of Mental & Physical Health, Norwegian Institute of Public Health, Norway.'}, {'ForeName': 'Silje M', 'Initials': 'SM', 'LastName': 'Ormhaug', 'Affiliation': 'Norwegian Centre for Violence and Traumatic Stress Studies, Norway.'}, {'ForeName': 'Tine K', 'Initials': 'TK', 'LastName': 'Jensen', 'Affiliation': 'Norwegian Centre for Violence and Traumatic Stress Studies, Norway; Department of Psychology, University of Oslo, Norway.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103655'] 1754,32591310,Machine-learning-based in-hospital mortality prediction for transcatheter mitral valve repair in the United States.,"BACKGROUND Transcatheter mitral valve repair 2 utilization has increased significantly in the United States over the last years. Yet, a risk-prediction tool for adverse events has not been developed. We aimed to generate a machine-learning-based algorithm to predict in-hospital mortality after TMVR. METHODS Patients who underwent TMVR from 2012 through 2015 were identified using the National Inpatient Sample database. The study population was randomly divided into a training set (n = 636) and a testing set (n = 213). Prediction models for in-hospital mortality were obtained using five supervised machine-learning classifiers. RESULTS A total of 849 TMVRs were analyzed in our study. The overall in-hospital mortality was 3.1%. A naïve Bayes (NB) model had the best discrimination for fifteen variables, with an area under the receiver-operating curve (AUC) of 0.83 (95% CI, 0.80-0.87), compared to 0.77 for logistic regression (95% CI, 0.58-0.95), 0.73 for an artificial neural network (95% CI, 0.55-0.91), and 0.67 for both a random forest and a support-vector machine (95% CI, 0.47-0.87). History of coronary artery disease, of chronic kidney disease, and smoking were the three most significant predictors of in-hospital mortality. CONCLUSIONS We developed a robust machine-learning-derived model to predict in-hospital mortality in patients undergoing TMVR. This model is promising for decision-making and deserves further clinical validation.",2020,The overall in-hospital mortality was 3.1%.,"['A total of 849 TMVRs', 'Patients who underwent TMVR from 2012 through 2015 were identified using the National Inpatient Sample database', 'patients undergoing TMVR']","['machine-learning-based algorithm', 'Transcatheter mitral valve', 'repair']",['hospital mortality'],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}]","[{'cui': 'C0336779', 'cui_str': 'Machine'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0442343', 'cui_str': 'Transcatheter approach'}, {'cui': 'C0026264', 'cui_str': 'Mitral valve structure'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}]","[{'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}]",849.0,0.053033,The overall in-hospital mortality was 3.1%.,"[{'ForeName': 'Dagmar F', 'Initials': 'DF', 'LastName': 'Hernandez-Suarez', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, University of Puerto Rico School of Medicine, San Juan, PR, USA. Electronic address: dagmar.hernandez@upr.edu.'}, {'ForeName': 'Sagar', 'Initials': 'S', 'LastName': 'Ranka', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, University of Kansas School of Medicine, Kansas City, KS, USA.'}, {'ForeName': 'Yeunjung', 'Initials': 'Y', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Azeem', 'Initials': 'A', 'LastName': 'Latib', 'Affiliation': 'Division of Cardiology, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY, USA.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Wiley', 'Affiliation': 'Division of Cardiology, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY, USA.'}, {'ForeName': 'Angel', 'Initials': 'A', 'LastName': 'Lopez-Candales', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.'}, {'ForeName': 'Duane S', 'Initials': 'DS', 'LastName': 'Pinto', 'Affiliation': 'Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Maday C', 'Initials': 'MC', 'LastName': 'Gonzalez', 'Affiliation': 'Division of Cardiology, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY, USA.'}, {'ForeName': 'Harish', 'Initials': 'H', 'LastName': 'Ramakrishna', 'Affiliation': 'Division of Cardiovascular and Thoracic Anesthesiology, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Sanina', 'Affiliation': 'Division of Cardiology, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY, USA.'}, {'ForeName': 'Brenda G', 'Initials': 'BG', 'LastName': 'Nieves-Rodriguez', 'Affiliation': 'Center for Collaborative Research in Health Disparities, University of Puerto Rico School of Medicine, San Juan, PR, USA.'}, {'ForeName': 'Jovaniel', 'Initials': 'J', 'LastName': 'Rodriguez-Maldonado', 'Affiliation': 'Center for Collaborative Research in Health Disparities, University of Puerto Rico School of Medicine, San Juan, PR, USA.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Feliu Maldonado', 'Affiliation': 'Center for Collaborative Research in Health Disparities, University of Puerto Rico School of Medicine, San Juan, PR, USA.'}, {'ForeName': 'Israel J', 'Initials': 'IJ', 'LastName': 'Rodriguez-Ruiz', 'Affiliation': 'Center for Collaborative Research in Health Disparities, University of Puerto Rico School of Medicine, San Juan, PR, USA.'}, {'ForeName': 'Istoni', 'Initials': 'I', 'LastName': ""da Luz Sant'Ana"", 'Affiliation': 'Center for Collaborative Research in Health Disparities, University of Puerto Rico School of Medicine, San Juan, PR, USA.'}, {'ForeName': 'Karlo A', 'Initials': 'KA', 'LastName': 'Wiley', 'Affiliation': 'College of Agriculture and Life Sciences, Cornell University, Ithaca, NY, USA.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Cox-Alomar', 'Affiliation': 'Division of Cardiology, Department of Medicine, Louisiana State University, New Orleans, LA, USA.'}, {'ForeName': 'Pedro A', 'Initials': 'PA', 'LastName': 'Villablanca', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, Henry Ford Hospital, Detroit, MI, USA.'}, {'ForeName': 'Abiel', 'Initials': 'A', 'LastName': 'Roche-Lima', 'Affiliation': 'Center for Collaborative Research in Health Disparities, University of Puerto Rico School of Medicine, San Juan, PR, USA.'}]",Cardiovascular revascularization medicine : including molecular interventions,['10.1016/j.carrev.2020.06.017'] 1755,32592973,Impact of 80 kVp with iterative reconstruction algorithm and low-dose contrast medium on the image quality of craniocervical CT angiography.,"PURPOSE To assess the image quality of 80-kVp craniocervical CT angiography (CCCTA) protocol combined with adaptive statistical iterative reconstruction-V (ASIR-V) and low-dose contrast medium (CM). METHODS A total of 119 patients were randomly divided into three groups. For group A, 120-kVp protocol was followed with 60 ml CM and filtered back projection; for group B, 80-kVp protocol with 60 ml CM and ASIR-V; and for group C, 80-kVp protocol with 45 ml CM and ASIR-V. Both subjective and objective image quality and radiation doses were evaluated. RESULTS Arterial attenuation, signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) of the head, neck, and shoulder regions were significantly higher in groups B and C compared with group A. Group C yielded significantly better subjective image quality than that observed in groups A and B (both p < .05). As compared with group A, effective radiation dose and the iodine load of group C were reduced by 51.4% and 25%, respectively. CONCLUSIONS The CCCTA protocol with 80 kVp, ASIR-V, and 45 ml of CM injected at 3 ml/s significantly reduced the radiation dose, iodine load, and iodine delivery rate while providing better subjective and objective image quality, including higher arterial enhancement and a higher SNR and CNR compared with the 120-kVp protocol.",2020,"As compared with group A, effective radiation dose and the iodine load of group C were reduced by 51.4% and 25%, respectively. ",['A total of 119 patients'],"['80-kVp craniocervical CT angiography (CCCTA) protocol combined with adaptive statistical iterative reconstruction-V (ASIR-V) and low-dose contrast medium (CM', '80\xa0kVp with iterative reconstruction algorithm and low-dose contrast medium']","['image quality of craniocervical CT angiography', 'subjective image quality', 'radiation dose, iodine load, and iodine delivery rate', 'Arterial attenuation, signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) of the head, neck, and shoulder regions']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1536105', 'cui_str': 'CT angiography'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}]","[{'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C1536105', 'cui_str': 'CT angiography'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0021966', 'cui_str': 'Iodide salt'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C2986823', 'cui_str': 'Signal-To-Noise Ratio'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}]",119.0,0.0319457,"As compared with group A, effective radiation dose and the iodine load of group C were reduced by 51.4% and 25%, respectively. ","[{'ForeName': 'Po-An', 'Initials': 'PA', 'LastName': 'Chen', 'Affiliation': 'Department of Radiology, Kaohsiung Veterans General Hospital, No. 386, Ta-Chung 1st Road, Kaohsiung 81362, Taiwan; Faculty of Medicine, School of Medicine, National Yang Ming University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan.'}, {'ForeName': 'Chih-Wei', 'Initials': 'CW', 'LastName': 'Chen', 'Affiliation': 'Department of Radiology, Kaohsiung Veterans General Hospital, No. 386, Ta-Chung 1st Road, Kaohsiung 81362, Taiwan; Faculty of Medicine, School of Medicine, National Yang Ming University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan.'}, {'ForeName': 'Chiung-Chen', 'Initials': 'CC', 'LastName': 'Chou', 'Affiliation': 'Department of Radiology, Kaohsiung Veterans General Hospital, No. 386, Ta-Chung 1st Road, Kaohsiung 81362, Taiwan.'}, {'ForeName': 'Jui-Hsun', 'Initials': 'JH', 'LastName': 'Fu', 'Affiliation': 'Department of Radiology, Kaohsiung Veterans General Hospital, No. 386, Ta-Chung 1st Road, Kaohsiung 81362, Taiwan; Faculty of Medicine, School of Medicine, National Yang Ming University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan.'}, {'ForeName': 'Po-Chin', 'Initials': 'PC', 'LastName': 'Wang', 'Affiliation': 'Department of Radiology, Kaohsiung Veterans General Hospital, No. 386, Ta-Chung 1st Road, Kaohsiung 81362, Taiwan; Faculty of Medicine, School of Medicine, National Yang Ming University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan.'}, {'ForeName': 'Shuo-Hsiu', 'Initials': 'SH', 'LastName': 'Hsu', 'Affiliation': 'Department of Radiology, Kaohsiung Veterans General Hospital, No. 386, Ta-Chung 1st Road, Kaohsiung 81362, Taiwan.'}, {'ForeName': 'Ping-Hong', 'Initials': 'PH', 'LastName': 'Lai', 'Affiliation': 'Department of Radiology, Kaohsiung Veterans General Hospital, No. 386, Ta-Chung 1st Road, Kaohsiung 81362, Taiwan; Faculty of Medicine, School of Medicine, National Yang Ming University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan. Electronic address: pinghonglai@gmail.com.'}]",Clinical imaging,['10.1016/j.clinimag.2020.05.024'] 1756,32593123,Quality of life changes in response to yoga therapy in patients with schizophrenia: Reanalysis of Three randomized controlled trials.,,2020,,['patients with schizophrenia'],['yoga therapy'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}]",[],,0.0595902,,"[{'ForeName': 'Saeko', 'Initials': 'S', 'LastName': 'Ikai-Tani', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan; Faculty of Kinesiology & Physical Education, University of Toronto, 55 Harbord Street, M5S 2W6, Toronto, ON, Canada. Electronic address: sako0609@gmail.com.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Tani', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan; Kimel Family Translational Imaging-Genetics Laboratory, Centre for Addiction and Mental Health, 1001 Queen St W, M6J 1H4, Toronto, ON, Canada.'}, {'ForeName': 'Saki', 'Initials': 'S', 'LastName': 'Kamiyama', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan.'}, {'ForeName': 'Masaru', 'Initials': 'M', 'LastName': 'Mimura', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Uchida', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan; Geriatric Mental Health Program, Centre for Addiction and Mental Health, 1001 Queen St W, M6J 1H4, Toronto, ON, Canada.'}]",Asian journal of psychiatry,['10.1016/j.ajp.2020.102250'] 1757,32593154,Alpha-tACS effect on inhibitory control and feasibility of administration in community outpatient substance use treatment.,"BACKGROUND Deficits in inhibitory control (IC) and distress tolerance (DT) are associated with substance use disorders (SUD) and post-treatment return to substance use. Transcranial alternating current stimulation (tACS) modulates the neural oscillations that are associated with the cognitive and affective mechanisms contributing to IC and DT. The aims of the current study were to examine the feasibility and acceptability of administering tACS in a community-based SUD treatment setting, and to test the effect of alpha-tACS on IC and DT. METHOD A double-blind, randomized, active sham-controlled trial of treatment-seeking adults with a SUD (N = 30, Mean age = 43.2 years, 70.0% male). Participants attended two sessions and completed computerized inhibitory control and distress tolerance tasks while receiving tACS targeting the bilateral dorsolateral prefrontal cortex (DLPFC). Participants received sham-tACS and were then randomized to receive sham-, alpha-, or gamma-tACS within 2-3 days. RESULTS Treatment retention was 87%. Participant self-reported belief of having received tACS and mean side effect intensity ratings did not differ across conditions, with all side effect ratings in the absent to mild range. There was a large (d = 0.83) and significant effect of alpha-tACS on inhibitory control compared to sham-tACS (β = 1.78, SE = 0.65, 95 % CI: 0.41, 3.14, p<0.01). There were no significant effects of condition on distress tolerance. CONCLUSIONS To our knowledge, this is the first study of tACS in adults with a SUD. Our findings provide preliminary evidence for recruitment, retention, and administration feasibility of tACS in a community-based substance use treatment program and a beneficial effect of alpha-tACS on inhibitory control.",2020,Transcranial alternating current stimulation (tACS) modulates the neural oscillations that are associated with the cognitive and affective mechanisms contributing to IC and DT.,"['treatment-seeking adults with a SUD (N = 30, Mean age = 43.2 years, 70.0% male', 'adults with a SUD']","['Transcranial alternating current stimulation (tACS', 'sham-, alpha-, or gamma-tACS', 'alpha-tACS', 'tACS', 'sham-tACS', 'computerized inhibitory control and distress tolerance tasks while receiving tACS']","['feasibility and acceptability', 'distress tolerance']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0038586', 'cui_str': 'Substance use disorder'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C3852966', 'cui_str': 'Transcranial Alternating Current Stimulation'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0017011', 'cui_str': 'Gamma radiation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}]",,0.0861259,Transcranial alternating current stimulation (tACS) modulates the neural oscillations that are associated with the cognitive and affective mechanisms contributing to IC and DT.,"[{'ForeName': 'Stacey B', 'Initials': 'SB', 'LastName': 'Daughters', 'Affiliation': 'Department of Psychology & Neuroscience, University of North Carolina, Chapel Hill, NC, 27516, USA. Electronic address: daughter@unc.edu.'}, {'ForeName': 'Jennifer Y', 'Initials': 'JY', 'LastName': 'Yi', 'Affiliation': 'Department of Psychology & Neuroscience, University of North Carolina, Chapel Hill, NC, 27516, USA.'}, {'ForeName': 'Rachel D', 'Initials': 'RD', 'LastName': 'Phillips', 'Affiliation': 'Department of Psychology & Neuroscience, University of North Carolina, Chapel Hill, NC, 27516, USA.'}, {'ForeName': 'Regina M', 'Initials': 'RM', 'LastName': 'Carelli', 'Affiliation': 'Department of Psychology & Neuroscience, University of North Carolina, Chapel Hill, NC, 27516, USA.'}, {'ForeName': 'Flavio', 'Initials': 'F', 'LastName': 'Fröhlich', 'Affiliation': 'Carolina Center for Neurostimulation, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108132'] 1758,32592736,Challenges in Using Insurance Claims Data to Identify Palliative Care Patients for a Research Trial.,"BACKGROUND Little is known about strategies for enrolling patients in home-based palliative care programs despite the need to conduct effectiveness studies of this emerging industry. PURPOSE We used medical claims data from Accountable Care Organizations in California to identify patients for a randomized controlled trial of home-based palliative care. We report outcomes from this strategy and the implications for future research. RESULTS Claims data identified 1357 patients. Research assistants could not reach 986 patients (72.7%), usually because the phone calls went unanswered (38.5%) and many patients' phone numbers were missing or incorrect (16.3%). Of 371 patients reached, 163 opted out. Of 208 patients screened, 177 were ineligible for the trial. Just 10 patients were enrolled. RECOMMENDATIONS Our findings suggest that medical claims data may not be useful for engaging patients potentially eligible for palliative care research trials. We recommend that alternative identification and recruitment strategies be considered.",2020,"Research assistants could not reach 986 patients (72.7%), usually because the phone calls went unanswered (38.5%) and many patients' phone numbers were missing or incorrect (16.3%).","['371 patients reached, 163 opted out', 'Just 10 patients were enrolled', '1,357 patients', '208 patients screened, 177 were ineligible for the trial', 'enrolling patients in home-based palliative care (HBPC) programs']",['HBPC'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}]",[],10.0,0.055076,"Research assistants could not reach 986 patients (72.7%), usually because the phone calls went unanswered (38.5%) and many patients' phone numbers were missing or incorrect (16.3%).","[{'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Enguidanos', 'Affiliation': 'Leonard Davis School of Gerontology, University of Southern California, Los Angeles, California, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Rahman', 'Affiliation': 'Leonard Davis School of Gerontology, University of Southern California, Los Angeles, California, USA. Electronic address: anrahman@protonmail.com.'}, {'ForeName': 'Torrie', 'Initials': 'T', 'LastName': 'Fields', 'Affiliation': 'Blue Shield of California, San Francisco, California, USA; VotiveHealth, San Luis Obispo, California, USA.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Mack', 'Affiliation': 'Keck School of Medicine, University of Southern California, Los Angeles, California, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Brumley', 'Affiliation': 'Reliance Hospice and Palliative Care, Costa Mesa, California, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Rabow', 'Affiliation': 'University of California, San Francisco, California, USA.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Mert', 'Affiliation': 'Keck School of Medicine, University of Southern California, Los Angeles, California, USA.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2020.06.007'] 1759,32592830,Cluster-sets resistance training induce similar functional and strength improvements than the traditional method in postmenopausal and elderly women.,"OBJECTIVE The aim of this study was to compare the effects of 12 weeks of traditional resistance training (TRT) or resistance training using Cluster-set (CS) on functional performance and physical fitness of postmenopausal and elderly women. METHODS Participants (61.1 ± 4.9 years, body mass 64.5 ± 1.8 kg, height 155.7 ± 4.7 cm) were randomized to TRT (n = 35) or CS (n = 31). Anthropometric measures, muscle strength and power, gait speed, core stability, flexibility, and functional performance tests were performed before and after 12 weeks of training. The difference between protocols was the structure of rest intervals. The TRT group performed 120 s of rest between sets of 8 repetitions, while the CS performed 30 s of rest after every 2 repetitions. Two-way ANOVA with repeated measures was applied for each variable and, when needed, the Bonferroni post hoc was used. Statistical significance was set at p < 0.05. RESULTS No group by time interaction was found for any variable. Regarding between-moment comparisons, there were significant improvements for 1 repetition maximum (RM) bench press (F = 104.6; η p 2  = 0.62; p < 0.001), 1RM leg press (F = 74.6; η p 2  = 0.53; p < 0.001), medicine ball throw (F = 64.0; η p 2  = 0.26; p < 0.001), standing long jump (F = 27.6; η p 2  = 0.30; p < 0.001), countermovement jump (F = 17.4; η p 2  = 0.21; p < 0.001), squat jump (F = 23.2; η p 2  = 0.26; p < 0.001), plank time (F = 31.6; η p 2  = 0.33; p < 0.001), 6 m walking test (F = 18.0; η p 2  = 0.22; p < 0.001), sit-to-stand test (F = 20.4; η p 2  = 0.24; p < 0.001), sit and reach test (F = 56.8; η p 2  = 0.47; p < 0.001) and 2 kg elbow curls (F = 15.9; η p 2  = 0.19; p < 0.001). CONCLUSION Considering that both CS and TRT methods were equally effective to improve the physical fitness and functionality of elderly women, the decision of which protocol to use should be based on individual preferences and practical aspects.",2020,"Regarding between-moment comparisons, there were significant improvements for 1 repetition maximum (RM) bench press (F = 104.6; η p 2  = 0.62; p < 0.001), 1RM leg press (F = 74.6; η p 2  = 0.53; p < 0.001), medicine ball throw (F = 64.0; η p 2  = 0.26; p < 0.001), standing long jump (F = 27.6; η p 2  = 0.30; p < 0.001), countermovement jump (F = 17.4; η p 2  = 0.21; p < 0.001), squat jump (F = 23.2; η p 2  = 0.26; p < 0.001), plank time (F = 31.6; η p 2  = 0.33; p < 0.001), 6 m walking test (F = 18.0; η p 2  = 0.22; p < 0.001), sit-to-stand test (F = 20.4; η p 2  = 0.24; p < 0.001), sit and reach test (F = 56.8; η p 2  = 0.47; p < 0.001) and 2 kg elbow curls (F = 15.9; η p 2  = 0.19; p < 0.001). ","['Participants (61.1\u202f±\u202f4.9\u202fyears, body mass 64.5\u202f±\u202f1.8\u202fkg, height 155.7\u202f±\u202f4.7\u202fcm', 'postmenopausal and elderly women', 'elderly women']","['traditional resistance training (TRT) or resistance training using Cluster-set (CS', 'CS', 'Cluster-sets resistance training', 'TRT']","['Anthropometric measures, muscle strength and power, gait speed, core stability, flexibility, and functional performance tests', 'countermovement jump', '1 repetition maximum (RM) bench press', '1RM leg press', 'standing long jump', 'plank time', 'functional performance and physical fitness', 'squat jump']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0524338', 'cui_str': 'Elderly woman'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}]","[{'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0454326', 'cui_str': 'Bench press'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}]",,0.024454,"Regarding between-moment comparisons, there were significant improvements for 1 repetition maximum (RM) bench press (F = 104.6; η p 2  = 0.62; p < 0.001), 1RM leg press (F = 74.6; η p 2  = 0.53; p < 0.001), medicine ball throw (F = 64.0; η p 2  = 0.26; p < 0.001), standing long jump (F = 27.6; η p 2  = 0.30; p < 0.001), countermovement jump (F = 17.4; η p 2  = 0.21; p < 0.001), squat jump (F = 23.2; η p 2  = 0.26; p < 0.001), plank time (F = 31.6; η p 2  = 0.33; p < 0.001), 6 m walking test (F = 18.0; η p 2  = 0.22; p < 0.001), sit-to-stand test (F = 20.4; η p 2  = 0.24; p < 0.001), sit and reach test (F = 56.8; η p 2  = 0.47; p < 0.001) and 2 kg elbow curls (F = 15.9; η p 2  = 0.19; p < 0.001). ","[{'ForeName': 'Rayra Khalinka Neves', 'Initials': 'RKN', 'LastName': 'Dias', 'Affiliation': 'Faculdade de Educação Física, Universidade Federal do Pará, Castanhal, PA, Brasil.'}, {'ForeName': 'Eduardo Macedo', 'Initials': 'EM', 'LastName': 'Penna', 'Affiliation': 'Faculdade de Educação Física, Universidade Federal do Pará, Castanhal, PA, Brasil; Programa de Pós Graduação em Ciências do Movimento Humano, Universidade Federal do Pará.'}, {'ForeName': 'Adria Samara Negrão', 'Initials': 'ASN', 'LastName': 'Noronha', 'Affiliation': 'Faculdade de Educação Física, Universidade Federal do Pará, Castanhal, PA, Brasil.'}, {'ForeName': 'Antenor Barbosa Calandrini', 'Initials': 'ABC', 'LastName': 'de Azevedo', 'Affiliation': 'Faculdade de Educação Física, Universidade Federal do Pará, Castanhal, PA, Brasil.'}, {'ForeName': 'Matheus', 'Initials': 'M', 'LastName': 'Barbalho', 'Affiliation': 'Faculdade de Educação Física e Dança, Universidade Federal de Goiás, Goiânia, GO, Brasil.'}, {'ForeName': 'Paulo Viana', 'Initials': 'PV', 'LastName': 'Gentil', 'Affiliation': 'Faculdade de Educação Física e Dança, Universidade Federal de Goiás, Goiânia, GO, Brasil.'}, {'ForeName': 'Victor Silveira', 'Initials': 'VS', 'LastName': 'Coswig', 'Affiliation': 'Faculdade de Educação Física, Universidade Federal do Pará, Castanhal, PA, Brasil; Programa de Pós Graduação em Ciências do Movimento Humano, Universidade Federal do Pará. Electronic address: vcoswig@ufpa.br.'}]",Experimental gerontology,['10.1016/j.exger.2020.111011'] 1760,32592986,"A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.","OBJECTIVES Fruquintinib is an orally active kinase inhibitor that selectively targets the vascular endothelial growth factor (VEGF) receptor. A Phase II trial has demonstrated a significant benefit in progression-free survival (PFS) for fruquintinib-treated patients with locally advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have progressed after second-line chemotherapy. This Phase III trial is a randomized, double-blind, multicenter trial to confirm fruquintinib's efficacy in the same patient population. MATERIALS AND METHODS From December 2015 to February 2018, 730 patients were screened, of whom 527 were enrolled into the study. Participants were randomized 2:1 to receive fruquintinib (n = 354) or placebo (n = 173) once daily for 3 weeks on-treatment, and 1 week off-treatment. Patients were stratified according to epidermal growth factor receptor mutation status and prior use of VEGF inhibitors. Primary endpoint was overall survival (OS). RESULTS Median OS was 8.9 months for the fruquintinib group and 10.4 months for placebo group (hazard ratio [HR] 1.02; 95 % confidence interval [CI], 0.82-1.28; P = 0.841), with median PFS of 3.7 months and 1.0 months, respectively (HR 0.34; 95 % CI, 0.28-0.43; P < 0.001). Objective response rate and disease control rate were 13.8 % and 66.7 % for fruquintinib, and 0.6 % and 24.9 % for placebo, respectively (P < 0.001). Hypertension was the most frequent treatment-emergent adverse event (≥grade 3) observed in fruquintinib-treated patients (21.0 %). Post hoc analysis revealed that fruquintinib prolonged the median OS for patients who did not receive subsequent antitumor therapy: 7.0 months versus 5.1 months for placebo (HR 0.65; 95 % CI, 0.46-0.91; P = 0.012). Patients receiving fruquintinib also reported improvements in quality of life for most functional scales measured by EORTC QLQ-C30 and LC13 questionnaires. CONCLUSION Although the study did not meet its primary endpoint, fruquintinib could be effective in combination with other agents for the treatment of patients with NSCLC who have failed second-line chemotherapy.",2020,"Patients receiving fruquintinib also reported improvements in quality of life for most functional scales measured by EORTC QLQ-C30 and LC13 questionnaires. ","['patients with NSCLC who have failed second-line chemotherapy', 'Chinese patients with advanced nonsquamous non-small-cell lung cancer ', 'From December 2015 to February 2018, 730 patients were screened, of whom 527 were enrolled into the study', 'same patient population', 'fruquintinib-treated patients with locally advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have progressed after second-line chemotherapy']",['placebo'],"['Objective response rate and disease control rate', 'Median OS', 'Hypertension', 'fruquintinib prolonged the median OS', 'quality of life for most functional scales measured by EORTC QLQ-C30 and LC13 questionnaires', 'progression-free survival (PFS', 'overall survival (OS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4517805', 'cui_str': '527'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",730.0,0.694568,"Patients receiving fruquintinib also reported improvements in quality of life for most functional scales measured by EORTC QLQ-C30 and LC13 questionnaires. ","[{'ForeName': 'Shun', 'Initials': 'S', 'LastName': 'Lu', 'Affiliation': 'Shanghai Lung Cancer Center, Shanghai Chest Hospital, Jiao Tong University, China. Electronic address: shunlu@sjtu.edu.cn.'}, {'ForeName': 'Gongyan', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Harbin Medical University Cancer Hospital, China.'}, {'ForeName': 'Yuping', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': 'Jinan Central Hospital, China.'}, {'ForeName': 'Sanyuan', 'Initials': 'S', 'LastName': 'Sun', 'Affiliation': 'XuZhou Central Hospital, China.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Chang', 'Affiliation': 'Fudan University Shanghai Cancer Center, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Yao', 'Affiliation': ""The First Affiliated Hospital of Xi'an Jiaotong University, China.""}, {'ForeName': 'Zhendong', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'The Second Hospital of Anhui Medical University, China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Ye', 'Affiliation': 'Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, China.'}, {'ForeName': 'Junguo', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': 'Nantong Tumor Hospital, China.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': 'Linyi Cancer Hospital, China.'}, {'ForeName': 'Jianxing', 'Initials': 'J', 'LastName': 'He', 'Affiliation': 'The First Affiliated Hospital of Guangzhou Medical University, China.'}, {'ForeName': 'Xiaoqing', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': ""The Fifth Medical Center, General Hospital of the People's Liberation Army, China.""}, {'ForeName': 'Yiping', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Zhejiang Cancer Hospital, China.'}, {'ForeName': 'Zhihua', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Jiangxi Cancer Hospital, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Fang', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Cheng', 'Affiliation': 'Jilin Cancer Hospital, China.'}, {'ForeName': 'Chunhong', 'Initials': 'C', 'LastName': 'Hu', 'Affiliation': 'The Second Xiangya Hospital of Central South University, China.'}, {'ForeName': 'Weidong', 'Initials': 'W', 'LastName': 'Mao', 'Affiliation': ""Jiangyin People's Hospital, China.""}, {'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Hubei Cancer Hospital, China.'}, {'ForeName': 'Youling', 'Initials': 'Y', 'LastName': 'Gong', 'Affiliation': 'West China Hospital of Sichuan University, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Shan', 'Affiliation': 'Xinjiang Cancer Hospital, China.'}, {'ForeName': 'Zhixiong', 'Initials': 'Z', 'LastName': 'Yang', 'Affiliation': 'Affiliated Hospital of Guangdong Medical University, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': 'Jinling Hospital, Nanjing University School of Medicine, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'The First Hospital of Jilin University, China.'}, {'ForeName': 'Chong', 'Initials': 'C', 'LastName': 'Bai', 'Affiliation': 'Shanghai Changhai Hospital, China.'}, {'ForeName': 'Buhai', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': ""Northern Jiangsu People's Hospital, China.""}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Ma', 'Affiliation': 'Liaoning Cancer Hospital, China.'}, {'ForeName': 'Zhendong', 'Initials': 'Z', 'LastName': 'Zheng', 'Affiliation': 'General Hospital of Northern Theater Command, China.'}, {'ForeName': 'Mingfang', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': 'General Hospital of Ningxia Medical University, China.'}, {'ForeName': 'Zhijun', 'Initials': 'Z', 'LastName': 'Jie', 'Affiliation': ""The Fifth People's Hospital of Shanghai, China.""}, {'ForeName': 'Lejie', 'Initials': 'L', 'LastName': 'Cao', 'Affiliation': 'The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, China.'}, {'ForeName': 'Wangjun', 'Initials': 'W', 'LastName': 'Liao', 'Affiliation': 'Nanfang Hospital of Southern Medical University, China.'}, {'ForeName': 'Hongming', 'Initials': 'H', 'LastName': 'Pan', 'Affiliation': 'Sir Run Run Shaw Hospital Affiliated with School of Medicine, Zhejiang University, China.'}, {'ForeName': 'Dongning', 'Initials': 'D', 'LastName': 'Huang', 'Affiliation': 'The Fourth Affiliated Hospital of Guangxi Medical University, China.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Tongji Hospital, Tongji Medical College of Hust, China.'}, {'ForeName': 'Jinji', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': ""Guandong Provincial People's Hospital, China.""}, {'ForeName': 'Shukui', 'Initials': 'S', 'LastName': 'Qin', 'Affiliation': ""People's Liberation Army Cancer Center of Nanjing Jinling Hospital, China.""}, {'ForeName': 'Shenglin', 'Initials': 'S', 'LastName': 'Ma', 'Affiliation': ""Hangzhou First People's Hospital, China.""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Liang', 'Affiliation': 'Peking University Third Hospital, China.'}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Beijing Chest Hospital, Capital Medical University, China.'}, {'ForeName': 'Jianying', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': 'The First Affiliated Hospital, Zhejiang University, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Tao', 'Affiliation': 'The First Affiliated Hospital of Soochow University, China.'}, {'ForeName': 'Yijiang', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'Hainan General Hospital, China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Qiu', 'Affiliation': 'The First Affiliated Hospital of Nanchang University, China.'}, {'ForeName': 'Yunchao', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'Yunnan Cancer Hospital, China.'}, {'ForeName': 'Sha', 'Initials': 'S', 'LastName': 'Guan', 'Affiliation': 'Hutchison MediPharma, Shanghai, China.'}, {'ForeName': 'Mengye', 'Initials': 'M', 'LastName': 'Peng', 'Affiliation': 'Hutchison MediPharma, Shanghai, China.'}, {'ForeName': 'Weiguo', 'Initials': 'W', 'LastName': 'Su', 'Affiliation': 'Hutchison MediPharma, Shanghai, China.'}]","Lung cancer (Amsterdam, Netherlands)",['10.1016/j.lungcan.2020.06.016'] 1761,32592995,Proactive Integrated Consultation-Liaison Psychiatry: A new service model for the psychiatric care of general hospital inpatients.,"OBJECTIVE To describe a new service model for the psychiatric care of general hospital inpatients, called Proactive Integrated Consultation-Liaison Psychiatry ('Proactive Integrated Psychological Medicine' in the UK). METHOD The new service model was developed especially for general hospital inpatient populations with multimorbidity, such as older medical inpatients. Its design was informed by the published literature and the clinical experience of C-L psychiatrists. It was operationalized by a process of iterative piloting. RESULTS The rationale for the new model and the principles underpinning it are outlined. Details of how to implement it, including a service manual and associated workbook, are provided. The training of clinicians to deliver it is described. The effectiveness and cost-effectiveness of this new service model is being evaluated. Whilst we have found it feasible to deliver and well-accepted by ward teams, potential challenges to its wider implementation are discussed. CONCLUSION Proactive Integrated Consultation-Liaison Psychiatry (PICLP) is a fusion of proactive consultation and integrated care, operationalized in a field-tested service manual. Initial experience indicates that it is feasible to deliver. Its effectiveness and cost effectiveness for older patients on acute medical wards is currently being evaluated in a large multicentre randomized controlled trial (The HOME Study).",2020,"The new service model was developed especially for general hospital inpatient populations with multimorbidity, such as older medical inpatients.","['general hospital inpatient populations with multimorbidity, such as older medical inpatients', ""general hospital inpatients, called Proactive Integrated Consultation-Liaison Psychiatry ('Proactive Integrated Psychological Medicine' in the UK"", 'general hospital inpatients', 'older patients on acute medical wards']","['Proactive Integrated Consultation-Liaison Psychiatry (PICLP', 'Proactive Integrated Consultation-Liaison Psychiatry']",['effectiveness and cost-effectiveness'],"[{'cui': 'C0020008', 'cui_str': 'Hospitals, General'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1535889', 'cui_str': 'Multimorbidity'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C1305702', 'cui_str': 'Ward'}]","[{'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",,0.0145088,"The new service model was developed especially for general hospital inpatient populations with multimorbidity, such as older medical inpatients.","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Sharpe', 'Affiliation': 'Psychological Medicine Research, University of Oxford Department of Psychiatry, Warneford Hospital, Oxford, UK. Electronic address: michael.sharpe@psych.ox.ac.uk.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Toynbee', 'Affiliation': 'Psychological Medicine Research, University of Oxford Department of Psychiatry, Warneford Hospital, Oxford, UK.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Walker', 'Affiliation': 'Psychological Medicine Research, University of Oxford Department of Psychiatry, Warneford Hospital, Oxford, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': 'Psychological Medicine Research, University of Oxford Department of Psychiatry, Warneford Hospital, Oxford, UK.'}]",General hospital psychiatry,['10.1016/j.genhosppsych.2020.06.005'] 1762,32683735,Split-face comparison of grid fractional radiofrequency vs 1064-nm Nd-YAG laser treatment of periorbital rhytides among Filipino patients.,"BACKGROUND Despite multiple individual studies proving efficacy of grid fractional monopolar radiofrequency (Grid RF) and near-infrared irradiation 1064-nm long-pulsed neodymium:YAG laser (Laser Genesis), there is a lack of controlled comparative trials between these devices. OBJECTIVE To compare the efficacy and safety of Grid RF versus Laser Genesis in the treatment of periorbital rhytides METHODS: This is a randomized, single-blind, split-face, prospective study. Eight patients with moderate to severe periorbital rhytides were treated with either Grid RF or Laser Genesis on each side of the face. Photographic and live assessment with the Lemperle Wrinkle Assessment grading scale was compared after 2 months. Adverse events and patient satisfaction were also compared. RESULTS Difference in scores between Grid RF vs. Laser genesis groups after 2 months was not statistically significant (p=0.244) . Each group showed statistically significant improvement months post-procedure ( p< 0.05). Immediate adverse effects and satisfaction scale were similar for both groups (p> 0.05). At 2 months follow-up, no adverse effects were seen. CONCLUSION Grid monopolar radiofrequency (Grid RF) versus Near-infrared radiation 1064nm long-pulsed Nd-YAG laser (Laser Genesis) were equally efficacious, safe and well-tolerated among patients in the treatment of periorbital wrinkles (p >0.05). This article is protected by copyright. All rights reserved.",2020,"RESULTS Difference in scores between Grid RF vs. Laser genesis groups after 2 months was not statistically significant (p=0.244) .","['periorbital rhytides among Filipino patients', 'Eight patients with moderate to severe periorbital rhytides']","['Grid monopolar radiofrequency (Grid RF) versus Near-infrared radiation 1064nm long-pulsed Nd-YAG laser (Laser Genesis', 'Grid RF vs. Laser genesis', 'grid fractional radiofrequency vs 1064-nm Nd-YAG laser treatment', 'Grid RF or Laser Genesis', 'Grid RF versus Laser Genesis', 'grid fractional monopolar radiofrequency (Grid RF) and near-infrared irradiation 1064-nm long-pulsed neodymium:YAG laser (Laser Genesis']","['Adverse events and patient satisfaction', 'efficacious, safe and well-tolerated', 'Immediate adverse effects and satisfaction scale', 'efficacy and safety', 'adverse effects']","[{'cui': 'C0230064', 'cui_str': 'Periorbital'}, {'cui': 'C0037301', 'cui_str': 'Wrinkled skin'}, {'cui': 'C1556093', 'cui_str': 'Filipinos'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}]","[{'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C0021431', 'cui_str': 'Infrared radiation'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0392276', 'cui_str': 'Neodymium-YAG laser'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C4255166', 'cui_str': 'Genesis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1532326', 'cui_str': 'Infra-red'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0027599', 'cui_str': 'Neodymium'}, {'cui': 'C0587723', 'cui_str': 'YAG - laser'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",8.0,0.0201908,"RESULTS Difference in scores between Grid RF vs. Laser genesis groups after 2 months was not statistically significant (p=0.244) .","[{'ForeName': 'Riza', 'Initials': 'R', 'LastName': 'Milante', 'Affiliation': 'Department of Dermatology, Jose R. Reyes Memorial Medical Center, Manila, Philippines.'}, {'ForeName': 'Melanie Joy', 'Initials': 'MJ', 'LastName': 'Doria-Ruiz', 'Affiliation': 'Department of Dermatology, Jose R. Reyes Memorial Medical Center, Manila, Philippines.'}, {'ForeName': 'Mercedes Buenviaje', 'Initials': 'MB', 'LastName': 'Beloso', 'Affiliation': 'Department of Dermatology, Jose R. Reyes Memorial Medical Center, Manila, Philippines.'}, {'ForeName': 'Agnes', 'Initials': 'A', 'LastName': 'Espinoza-Thaebtharm', 'Affiliation': 'Department of Dermatology, Jose R. Reyes Memorial Medical Center, Manila, Philippines.'}]",Dermatologic therapy,['10.1111/dth.14031'] 1763,32683737,A randomised controlled trial of a relationship-focussed mobile phone application for improving adolescents' mental health.,"BACKGROUND This study evaluated the acceptability and effectiveness of a relationship-focussed mobile phone application (WeClick) for improving depressive symptoms and other mental health outcomes in adolescents. METHODS A randomised controlled trial involving 193 youth (M age: 14.82, SD: 0.94, 86.5% female) from Australia was conducted. Youth were recruited via the Internet and randomly allocated to the intervention or a 4-week wait list control condition, stratified for age and gender. The primary outcome was change in depressive symptom scores measured using the Patient Health Questionnaire for Adolescents (PHQ-A) at baseline, 4-week post-test and 12-week follow-up. Secondary outcomes included anxiety, psychological distress, wellbeing, help-seeking intentions for mental health, social self-efficacy and social support. Participants in the intervention condition received access to the intervention for four weeks. Thematic analysis was utilised to identify and examine acceptability. RESULTS The change in PHQ-A scores from baseline to 4-week post-test did not differ significantly (d = 0.26, p = .138) between the intervention (Mchange = -2.9, SD = 5.3) and wait list control conditions (Mchange = -1.7, SD = 4.3). However, significant between-group improvements were observed in wellbeing (d = 0.37, p = .023), help-seeking intentions (d = 0.36, p = .016) and professional help-seeking intentions for mental health problems (d = 0.36, p = .008). Increases in help-seeking intentions were sustained at follow-up in the intervention condition. No differential effects were found for generalised anxiety, separation anxiety, social self-efficacy or for any social support outcomes. Over 90% of participants indicated the app was enjoyable, interesting and easy to use. The app provided 'advice and direction' (n = 42; 46.15%), an 'opportunity for self-reflection' (n = 33; 36.3%) and 'normalised experiences' (n = 21; 23.1%). CONCLUSIONS The WeClick app was found to be effective for improving wellbeing and help-seeking intentions for mental health in adolescents. A larger, adequately powered trial is now required to establish differential effects on depressive symptoms. This trial was registered with the Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12618001982202.",2020,The WeClick app was found to be effective for improving wellbeing and help-seeking intentions for mental health in adolescents.,"[""adolescents' mental health"", '193 youth (M age: 14.82, SD: 0.94, 86.5% female) from Australia was conducted', 'adolescents']","['relationship-focussed mobile phone application', 'relationship-focussed mobile phone application (WeClick']","['generalised anxiety, separation anxiety, social self-efficacy', 'anxiety, psychological distress, wellbeing, help-seeking intentions for mental health, social self-efficacy and social support', 'Patient Health Questionnaire for Adolescents (PHQ-A', 'professional help-seeking intentions for mental health problems', 'wellbeing', 'help-seeking intentions', 'PHQ-A scores', 'acceptability and effectiveness', 'depressive symptom scores']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517487', 'cui_str': '0.94'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]","[{'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0003477', 'cui_str': 'Separation anxiety'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1446377', 'cui_str': 'Mental health problem'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",193.0,0.124213,The WeClick app was found to be effective for improving wellbeing and help-seeking intentions for mental health in adolescents.,"[{'ForeName': 'Bridianne', 'Initials': 'B', 'LastName': ""O'Dea"", 'Affiliation': 'Black Dog Institute, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Han', 'Affiliation': 'Black Dog Institute, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Batterham', 'Affiliation': 'Center for Mental Health Research, Research School of Population Health, The Australian National University, Canberra, ACT, Australia.'}, {'ForeName': 'Melinda R', 'Initials': 'MR', 'LastName': 'Achilles', 'Affiliation': 'Black Dog Institute, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Alison L', 'Initials': 'AL', 'LastName': 'Calear', 'Affiliation': 'Center for Mental Health Research, Research School of Population Health, The Australian National University, Canberra, ACT, Australia.'}, {'ForeName': 'Aliza', 'Initials': 'A', 'LastName': 'Werner-Seidler', 'Affiliation': 'Black Dog Institute, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Belinda', 'Initials': 'B', 'LastName': 'Parker', 'Affiliation': 'Black Dog Institute, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Shand', 'Affiliation': 'Black Dog Institute, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Christensen', 'Affiliation': 'Black Dog Institute, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.'}]","Journal of child psychology and psychiatry, and allied disciplines",['10.1111/jcpp.13294'] 1764,32593627,Modified Circumcision Using the Disposable Circumcision Suture Device in Children: A Randomized Controlled Trial.,"OBJECTIVE To evaluate and compare the surgical outcomes and complications of the modified circumcision using disposable circumcision suture device (device group) and the conventional dorsal slit circumcision (conventional group) in children. METHODS A total of 284 patients were randomized to either device group or conventional group. All patients were preoperatively assessed and evaluated at 4 weeks after surgery. The perioperative data and postoperative outcomes were compared between the 2 groups. RESULTS No statistical differences were observed in the average age and indications between the 2 groups preoperatively (P > .05). Compared with the conventional group, patients in the device group were shorter mean operative time, less blood loss, lower intraoperative and postoperative pain score, faster incision healing time and a higher satisfaction rate of penile cosmetic appearance (P < .01). Similarly, the incidences of complication were significantly lower in the device group than in the conventional group (4.3% vs 12.3%, P < .05). CONCLUSIONS The modified circumcision using disposable circumcision suture device is a simple, safe, faster, and effective procedure and may become the attractive alternative to the conventional technique for the children, with a relatively lower complication rate and better cosmetic results. With the improvement of disposable circumcision suture device, the modified circumcision using disposable circumcision suture device has the potential to be widely used in the world.",2020,No statistical differences were observed in the average age and indications between the two groups preoperatively (p>0.05).,"['284 patients', 'children']","['device group or conventional group', 'disposable circumcision suture device (device group) and the conventional dorsal slit circumcision (conventional group', 'Modified circumcision using the disposable circumcision suture device']","['perioperative data and postoperative outcomes', 'incidences of complication', 'shorter mean operative time, less blood loss, lower intraoperative and postoperative pain score, faster incision healing time and a higher satisfaction rate of penile cosmetic appearance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0008819', 'cui_str': 'Circumcision'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0184904', 'cui_str': 'Slitting'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030851', 'cui_str': 'Penile structure'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}]",284.0,0.0262913,No statistical differences were observed in the average age and indications between the two groups preoperatively (p>0.05).,"[{'ForeName': 'Jian-Ming', 'Initials': 'JM', 'LastName': 'Rao', 'Affiliation': ""Department of Urology, Fourth Hospital of Changsha, Hunan Normal University, Changsha, Hunan Province, China; Department of Urology, The Second Hunan Provincial People's Hospital, Hunan Traditional Chinese Medical University, Changsha, Hunan Province, China.""}, {'ForeName': 'He', 'Initials': 'H', 'LastName': 'Huang', 'Affiliation': 'Department of Urology, Fourth Hospital of Changsha, Hunan Normal University, Changsha, Hunan Province, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Chen', 'Affiliation': 'Department of Urology, Fourth Hospital of Changsha, Hunan Normal University, Changsha, Hunan Province, China. Electronic address: 516598806@qq.com.'}, {'ForeName': 'Chun-Gang', 'Initials': 'CG', 'LastName': 'Yang', 'Affiliation': 'Department of Urology, Fourth Hospital of Changsha, Hunan Normal University, Changsha, Hunan Province, China.'}, {'ForeName': 'Ci-Zhong', 'Initials': 'CZ', 'LastName': 'Pan', 'Affiliation': 'Department of Urology, Fourth Hospital of Changsha, Hunan Normal University, Changsha, Hunan Province, China.'}, {'ForeName': 'Guang-Cheng', 'Initials': 'GC', 'LastName': 'Deng', 'Affiliation': 'Department of Urology, Fourth Hospital of Changsha, Hunan Normal University, Changsha, Hunan Province, China.'}, {'ForeName': 'Long-Jiang', 'Initials': 'LJ', 'LastName': 'Shen', 'Affiliation': 'Department of Urology, Fourth Hospital of Changsha, Hunan Normal University, Changsha, Hunan Province, China.'}, {'ForeName': 'Xiao-Hui', 'Initials': 'XH', 'LastName': 'Qian', 'Affiliation': 'Department of Urology, Fourth Hospital of Changsha, Hunan Normal University, Changsha, Hunan Province, China.'}, {'ForeName': 'Mei-Kang', 'Initials': 'MK', 'LastName': 'Peng', 'Affiliation': 'Department of Urology, Fourth Hospital of Changsha, Hunan Normal University, Changsha, Hunan Province, China.'}, {'ForeName': 'Hui-Dong', 'Initials': 'HD', 'LastName': 'Zhou', 'Affiliation': 'Department of Urology, Fourth Hospital of Changsha, Hunan Normal University, Changsha, Hunan Province, China.'}, {'ForeName': 'Hong-Liang', 'Initials': 'HL', 'LastName': 'Peng', 'Affiliation': 'Department of Urology, Fourth Hospital of Changsha, Hunan Normal University, Changsha, Hunan Province, China.'}]",Urology,['10.1016/j.urology.2020.06.018'] 1765,32683741,Efficacy and safety of cross-cylinder photorefractive keratectomy versus single method in medium-high astigmatism: a randomized clinical trial.,"BACKGROUND To compare efficacy and safety of photorefractive keratectomy (PRK) by crosscylinder with single methods in medium-high astigmatism. DESIGN Randomized clinical trial study PARTICIPANTS: Fifty patients with medium-high compound myopic astigmatism were enrolled between September 2007 and September 2008. METHODS PRK was performed on 100 eyes of 50 patients with compound myopic astigmatism. Each patient underwent PRK by cross-cylinder approach in one eye and single method on the contralateral eye. Vector analysis was used to assess astigmatic results. MAIN OUTCOME MEASURES Improvement of visual acuity (snelen chart), refraction, aberrometry. RESULTS Uncorrected visual acuity (UCCA) equal to 20/40 or better after six months, was achieved in 98% of eyes in the cross-cylinder method versus 96% in single method.. Mean preoperative spherical equivalent(SE) was -5.2 ±2.1 D in the cross-cylinder method versus -5.1 ±0.5 D in the single method. At six months, the mean SE was - 0.5±0.4 D and -0.6±0.3 D, respectively. Mean IOS was 0.4±0.3 in the cross-cylinder group and 0.4±0.4 in the single group. Mean postoperative absolute change in total root-mean-square higher order aberrations in the cross-cylinder group and single group were 0.16 pm and 0.17 pm, respectively. Any of the mentioned differences didn't appear to be statistically significant. CONCLUSIONS Both PRK methods appeared to be safe and effective in correcting medium-high astigmatism.",2020,Mean preoperative spherical equivalent(SE) was -5.2 ±2.1 D in the cross-cylinder method versus -5.1 ±0.5 D in the single method.,"['medium-high astigmatism', 'Fifty patients with medium-high compound myopic astigmatism were enrolled between September 2007 and September 2008', '100 eyes of 50 patients with compound myopic astigmatism']","['cross-cylinder photorefractive keratectomy', 'photorefractive keratectomy (PRK']","['Mean postoperative absolute change in total root-mean-square higher order aberrations', 'Efficacy and safety', 'mean SE', 'Mean IOS', 'Mean preoperative spherical equivalent(SE', 'Uncorrected visual acuity (UCCA', 'visual acuity (snelen chart), refraction, aberrometry']","[{'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C3839737', 'cui_str': 'High astigmatism'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205198', 'cui_str': 'Compound'}, {'cui': 'C2363771', 'cui_str': 'Myopic astigmatism'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}]","[{'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0181797', 'cui_str': 'Medical gas cylinder'}, {'cui': 'C0395416', 'cui_str': 'Refractive keratoplasty by laser surgery'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332501', 'cui_str': 'Spherical shape'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0242753', 'cui_str': 'Io'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C1637380', 'cui_str': 'Uncorrected visual acuity'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0684240', 'cui_str': 'Chart'}, {'cui': 'C0429585', 'cui_str': 'Refraction measurement - finding'}, {'cui': 'C2717991', 'cui_str': 'Aberrometry'}]",50.0,0.141252,Mean preoperative spherical equivalent(SE) was -5.2 ±2.1 D in the cross-cylinder method versus -5.1 ±0.5 D in the single method.,"[{'ForeName': 'Mohammad R', 'Initials': 'MR', 'LastName': 'Sedghipour', 'Affiliation': 'Nikoukari University Hospital, Tabriz University of medical sciences, Tabriz, Iran.'}, {'ForeName': 'Afshin', 'Initials': 'A', 'LastName': 'Lotfi', 'Affiliation': 'Nikoukari University Hospital, Tabriz University of medical sciences, Tabriz, Iran.'}, {'ForeName': 'Ayaz', 'Initials': 'A', 'LastName': 'Sadeghilar', 'Affiliation': 'Nikoukari University Hospital, Tabriz University of medical sciences, Tabriz, Iran.'}, {'ForeName': 'Saeeid', 'Initials': 'S', 'LastName': 'Banan', 'Affiliation': 'Nikoukari University Hospital, Tabriz University of medical sciences, Tabriz, Iran.'}]",Clinical & experimental ophthalmology,['10.1111/ceo.13828'] 1766,32593791,Differential effects of modafinil on performance of low-performing and high-performing individuals during total sleep deprivation.,"BACKGROUND Individual responses to the effects of inadequate sleep have been well documented; some people are more vulnerable to the effects of sleep loss than others. Fatigue-vulnerable individuals generally require access to effective fatigue countermeasures; however, the question arises as to whether these fatigue-vulnerable individuals receive the same benefits shown in group efficacy data. The present study administered modafinil to individuals to determine its differential effects on performance of best and worst performers during sleep deprivation. METHODS A sample of 22 men, age 21-40 yrs., was tested on 2 separate occasions during which they were kept awake for 36 h. During one period they received 200 mg modafinil; during the other they received placebo. Participants were tested on a variety of tasks while rested and at 5-hr intervals across the continuous wakefulness period. Performance for each cognitive task and subjective measure of fatigue from the placebo period was used to group individuals into high (HP) or low performance (LP) groups to indicate fatigue vulnerability for each task. RESULTS Results indicated that on the MTS task, the HP group performed the same throughout the testing period, regardless of whether they received modafinil or not. However, the LP group significantly improved after receiving modafinil compared to placebo. Performance on the PVT showed the HP group had a small decrease in the number of lapses after receiving modafinil compared to placebo, whereas the LP group had a large decrease in lapses after receiving modafinil compared to placebo. Performance on the RDM showed no difference between groups, regardless of drug condition. Groups did not differ after receiving modafinil on subjective fatigue measured by the POMS. CONCLUSIONS Depending on the task, HP individuals did not benefit substantially when administered modafinil compared to placebo. However, the LP individuals improved after receiving modafinil compared to placebo.",2020,"Performance on the PVT showed the HP group had a small decrease in the number of lapses after receiving modafinil compared to placebo, whereas the LP group had a large decrease in lapses after receiving modafinil compared to placebo.","['low-performing and high-performing individuals during total sleep deprivation', 'group individuals into high (HP) or low performance (LP) groups to indicate fatigue vulnerability for each task', 'A sample of 22 men, age 21-40\u202fyrs., was tested on 2 separate occasions during which they were kept awake for 36\u202fh']","['modafinil', '200\u202fmg modafinil', 'placebo']","['subjective fatigue', 'lapses', 'number of lapses']","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037316', 'cui_str': 'Sleep deprivation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0012655', 'cui_str': 'Diathesis'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0234422', 'cui_str': 'Awake'}, {'cui': 'C0521125', 'cui_str': 'For'}]","[{'cui': 'C0066677', 'cui_str': 'modafinil'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",,0.090569,"Performance on the PVT showed the HP group had a small decrease in the number of lapses after receiving modafinil compared to placebo, whereas the LP group had a large decrease in lapses after receiving modafinil compared to placebo.","[{'ForeName': 'J Lynn', 'Initials': 'JL', 'LastName': 'Caldwell', 'Affiliation': 'Naval Medical Research Unit Dayton, United States of America. Electronic address: jo.caldwell@us.af.mil.'}, {'ForeName': 'Valarie M', 'Initials': 'VM', 'LastName': 'Schroeder', 'Affiliation': 'The Henry M. Jackson Foundation for the Advancement of Military Medicine, United States of America.'}, {'ForeName': 'Christina L', 'Initials': 'CL', 'LastName': 'Kunkle', 'Affiliation': 'The Henry M. Jackson Foundation for the Advancement of Military Medicine, United States of America.'}, {'ForeName': 'Henry G', 'Initials': 'HG', 'LastName': 'Stephenson', 'Affiliation': 'The Henry M. Jackson Foundation for the Advancement of Military Medicine, United States of America.'}]","Pharmacology, biochemistry, and behavior",['10.1016/j.pbb.2020.172968'] 1767,32593717,Caring for older veterans with chronic low back pain using a geriatric syndrome approach: Rationale and methods for the aging back clinics (ABC) trial.,"The purpose of the ongoing trial is to improve care of older Veterans with chronic low back pain (CLBP, i.e., low back pain for ≥6 months on ≥ half the days). Current CLBP care is limited by being either overly spine-focused or non-specifically prescribed and both approaches frequently lead to suboptimal reduction in pain and improvement in function. Through prior studies we have laid the foundation for a patient-centered approach to care for older Veterans with CLBP in which the spine is a source of vulnerability but not the sole treatment target. The approach considers CLBP a geriatric syndrome, a final common pathway for the expression of multiple contributors rather than a disease of the spine. We describe here the rationale and design of a randomized controlled trial to test the efficacy of an older Veteran-centered approach to CLBP care in ""Aging Back Clinics (ABCs)"" compared with Usual Care (UC). Three hundred thirty Veterans age 65-89 with CLBP will be randomized to ABCs or UC and followed for 12 months after randomization. We will assess the impact of ABCs on our primary outcome of pain-associated disability with the Oswestry Disability Index at 6 and 12 months, and secondary outcomes of pain intensity, health-related quality of life, balance confidence, mobility and healthcare utilization. If shown efficacious, the approach tested in ABCs has the potential to transform the care of older adults with CLBP by improving the quality of life for millions, reducing morbidity and saving substantial healthcare costs.",2020,"If shown efficacious, the approach tested in ABCs has the potential to transform the care of older adults with CLBP by improving the quality of life for millions, reducing morbidity and saving substantial healthcare costs.","['Three hundred thirty Veterans age 65-89 with CLBP', 'older Veterans with chronic low back pain (CLBP, i.e., low back pain for ≥6\u202fmonths on ≥ half the days', 'older veterans with chronic low back pain using a geriatric syndrome approach', 'older adults with CLBP']","['ABCs or UC', 'older Veteran-centered approach to CLBP care', 'Usual Care (UC']","['pain-associated disability with the Oswestry Disability Index', 'pain intensity, health-related quality of life, balance confidence, mobility and healthcare utilization']","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",330.0,0.0631505,"If shown efficacious, the approach tested in ABCs has the potential to transform the care of older adults with CLBP by improving the quality of life for millions, reducing morbidity and saving substantial healthcare costs.","[{'ForeName': 'Debra K', 'Initials': 'DK', 'LastName': 'Weiner', 'Affiliation': 'Geriatric Research, Education and Clinic Center, VA Pittsburgh Healthcare System, Pittsburgh, PA, United States of America; University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America. Electronic address: debra.weiner@va.gov.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Gentili', 'Affiliation': 'Central Virginia VA Health Care System, Richmond, VA, United States of America; Virginia Commonwealth University Health System, Richmond, VA.'}, {'ForeName': 'Meika A', 'Initials': 'MA', 'LastName': 'Fang', 'Affiliation': 'Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States of America; David Geffen School of Medicine at UCLA Los Angeles, Los Angeles, CA, United States of America.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Garay', 'Affiliation': 'VA Pittsburgh Healthcare System, Pittsburgh, PA, United States of America.'}, {'ForeName': 'Thiru', 'Initials': 'T', 'LastName': 'Annaswamy', 'Affiliation': 'VA North Texas Health Care System, Dallas, TX, United States of America; University of Texas Southwestern Medical Center, Dallas, TX, United States of America.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Castle', 'Affiliation': 'Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States of America; David Geffen School of Medicine at UCLA Los Angeles, Los Angeles, CA, United States of America.'}, {'ForeName': 'Lenore', 'Initials': 'L', 'LastName': 'Joseph', 'Affiliation': 'Central Virginia VA Health Care System, Richmond, VA, United States of America; Virginia Commonwealth University Health System, Richmond, VA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Lawson', 'Affiliation': 'Central Virginia VA Health Care System, Richmond, VA, United States of America; Virginia Commonwealth University Health System, Richmond, VA.'}, {'ForeName': 'Cathy C', 'Initials': 'CC', 'LastName': 'Lee', 'Affiliation': 'Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States of America; David Geffen School of Medicine at UCLA Los Angeles, Los Angeles, CA, United States of America.'}, {'ForeName': 'Una E', 'Initials': 'UE', 'LastName': 'Makris', 'Affiliation': 'VA North Texas Health Care System, Dallas, TX, United States of America; University of Texas Southwestern Medical Center, Dallas, TX, United States of America.'}, {'ForeName': 'Michelle I', 'Initials': 'MI', 'LastName': 'Rossi', 'Affiliation': 'Geriatric Research, Education and Clinic Center, VA Pittsburgh Healthcare System, Pittsburgh, PA, United States of America; University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America.'}, {'ForeName': 'Beverly', 'Initials': 'B', 'LastName': 'Thorn', 'Affiliation': 'University of Alabama, Tuscaloosa, AL, United States of America.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Clemens', 'Affiliation': 'Geriatric Research, Education and Clinic Center, VA Pittsburgh Healthcare System, Pittsburgh, PA, United States of America.'}, {'ForeName': 'Dave', 'Initials': 'D', 'LastName': 'Newman', 'Affiliation': 'Geriatric Research, Education and Clinic Center, VA Pittsburgh Healthcare System, Pittsburgh, PA, United States of America.'}, {'ForeName': 'Subashan', 'Initials': 'S', 'LastName': 'Perera', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America; University of Pittsburgh Graduate School of Public Health, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106077'] 1768,32593750,Effect of acute caffeine intake on hit accuracy and reaction time in professional e-sports players.,"Caffeine is considered a cognitive enhancer at low to moderate doses because it improves alertness, vigilance, attention, and reaction time. However, no previous investigation has assessed the effect of acute caffeine intake on e-sports-specific performance. The aim of this investigation was to determine the effect of the ingestion of 3 mg per kg of body mass on simple reaction time in a color test and on hit accuracy and reaction time during a first-person shooting game. Fifteen professional e-gamers (age= 22 ± 3 years) participated in a double-blind, cross-over, randomized experimental trial. In two trials 3 days apart, participants either ingested a placebo (cellulose) or 3 mg/kg of caffeine in an opaque and unidentifiable capsule. After a 45-min wait for substance absorption, participants performed 5 attempts at a simple reaction time test and completed a first-person shooting game that included 3 attempts at a 2-min game with 60 fixed targets (180 targets in total). Reaction times (in both tests) and accuracy in hitting the targets (only in the shooting game) were measured. In comparison to the placebo, caffeine decreased simple reaction time (0.20 ± 0.01 vs. 0.19 ± 0.01 s, P < 0.01), the mean time taken to hit the targets (0.92 ± 0.07 vs. 0.88 ± 0.07 s, P < 0.01) and enhanced hit accuracy (98.8 ± 0.92 vs. 99.8 ± 0.35% of targets hit, P < 0.01). In summary, the acute ingestion of 3 mg/kg of caffeine reduced the time taken to react to a simple stimulus, decreased the time taken to hit a fixed target and improved accuracy in hitting the target in a first-person shooting game in professional e-gamers. Thus, the caffeine ingestion (3 mg/kg) might be considered as an ergogenic aid for e-sports gamers based on its effect to enhance hit accuracy and time.",2020,"In comparison to the placebo, caffeine decreased simple reaction time (0.20 ± 0.01 vs. 0.19 ± 0.01 s, P < 0.01), the mean time taken to hit the targets (0.92 ± 0.07 vs. 0.88 ± 0.07 s, P < 0.01) and enhanced hit accuracy (98.8 ± 0.92 vs. 99.8 ± 0.35% of targets hit, P < 0.01).","['Fifteen professional e-gamers (age= 22 ± 3 years) participated in a double-blind, cross-over, randomized experimental trial', 'professional e-sports players']","['acute caffeine intake', 'caffeine ingestion', 'caffeine', 'placebo (cellulose) or 3 mg/kg of caffeine', 'Caffeine', 'placebo, caffeine']","['enhanced hit accuracy', 'time taken to hit a fixed target and improved accuracy', 'alertness, vigilance, attention, and reaction time', 'simple reaction time', 'Reaction times', 'hit accuracy and reaction time', 'mean time taken to hit the targets']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0010366', 'cui_str': 'Genetic crossing over'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0038039', 'cui_str': 'Sport'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}]","[{'cui': 'C0272285', 'cui_str': 'Heparin-induced thrombocytopenia'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0043012', 'cui_str': 'Wakefulness'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.0879569,"In comparison to the placebo, caffeine decreased simple reaction time (0.20 ± 0.01 vs. 0.19 ± 0.01 s, P < 0.01), the mean time taken to hit the targets (0.92 ± 0.07 vs. 0.88 ± 0.07 s, P < 0.01) and enhanced hit accuracy (98.8 ± 0.92 vs. 99.8 ± 0.35% of targets hit, P < 0.01).","[{'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Sainz', 'Affiliation': 'Team Queso, e-Gamers Club. Madrid, Spain. Electronic address: nachosainz10@gmail.com.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Collado-Mateo', 'Affiliation': 'Centre for Sport Studies, Rey Juan Carlos University, Fuenlabrada, Madrid, Spain. Electronic address: daniel.collado@urjc.es.'}, {'ForeName': 'Juan Del', 'Initials': 'JD', 'LastName': 'Coso', 'Affiliation': 'Centre for Sport Studies, Rey Juan Carlos University, Fuenlabrada, Madrid, Spain. Electronic address: juan.delcoso@urjc.es.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113031'] 1769,32594567,A computer-guided quality improvement tool for primary health care: cost-effectiveness analysis based on TORPEDO trial data.,"OBJECTIVE To assess the cost-effectiveness of a computer-guided quality improvement intervention for primary health care management of cardiovascular disease (CVD) in people at high risk. DESIGN Modelled cost-effectiveness analysis of the HealthTracker intervention and usual care for people with high CVD risk, based on TORPEDO trial data on prescribing patterns, changes in intermediate risk factors (low-density lipoprotein cholesterol, systolic blood pressure), and Framingham risk scores. PARTICIPANTS Hypothetical population of people with high CVD risk attending primary health care services in a New South Wales primary health network (PHN) of mean size. INTERVENTION HealthTracker, integrated into health care provider electronic health record systems, provides real time decision support, risk communication, a clinical audit tool, and a web portal for performance feedback. MAIN OUTCOME MEASURES Incremental cost-effectiveness ratios (ICERs): difference in costs of the intervention and usual care divided by number of CVD events averted with HealthTracker. RESULTS The estimated numbers of major CVD events over five years per 1000 patients at high CVD risk were lower in PHNs using HealthTracker, both for patients with prior CVD events (secondary prevention; 259 v 267 with usual care) and for those without prior events (primary prevention; 168 v 176). Medication costs were higher and hospitalisation costs lower with HealthTracker than with usual care for both primary and secondary prevention. The estimated ICER for one averted CVD event was $7406 for primary prevention and $17 988 for secondary prevention. CONCLUSION Modelled cost-effectiveness analyses provide information that can assist decisions about investing in health care quality improvement interventions. We estimate that HealthTracker could prevent major CVD events for less than $20 000 per event averted. TRIAL REGISTRATION (TORPEDO) Australian New Zealand Clinical Trials Registry, ACTRN 12611000478910.",2020,Medication costs were higher and hospitalisation costs lower with HealthTracker than with usual care for both primary and secondary prevention.,"['primary health care', 'primary health care management of cardiovascular disease (CVD) in people at high risk', 'people with high CVD risk', 'Hypothetical population of people with high CVD risk attending primary health care services in a New South Wales primary health network (PHN) of mean size']","['computer-guided quality improvement intervention', 'HealthTracker intervention and usual care']","['Medication costs', 'estimated numbers of major CVD events', 'major CVD events', 'intermediate risk factors (low-density lipoprotein cholesterol, systolic blood pressure), and Framingham risk scores', 'Incremental cost-effectiveness ratios (ICERs): difference in costs of the intervention and usual care divided by number of CVD events averted with HealthTracker', 'cost-effectiveness']","[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0043015', 'cui_str': 'Wales'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456389', 'cui_str': 'Size'}]","[{'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C2936612', 'cui_str': 'Quality Improvement'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332849', 'cui_str': 'Divide'}]",,0.109009,Medication costs were higher and hospitalisation costs lower with HealthTracker than with usual care for both primary and secondary prevention.,"[{'ForeName': 'Bindu', 'Initials': 'B', 'LastName': 'Patel', 'Affiliation': 'The George Institute for Global Health, UNSW Sydney, Sydney, NSW.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Peiris', 'Affiliation': 'The George Institute for Global Health, UNSW Sydney, Sydney, NSW.'}, {'ForeName': 'Anushka', 'Initials': 'A', 'LastName': 'Patel', 'Affiliation': 'The George Institute for Global Health, UNSW Sydney, Sydney, NSW.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Jan', 'Affiliation': 'The George Institute for Global Health, UNSW Sydney, Sydney, NSW.'}, {'ForeName': 'Mark F', 'Initials': 'MF', 'LastName': 'Harris', 'Affiliation': 'Centre for Primary Health Care and Equity, University of New South Wales, Sydney, NSW.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Usherwood', 'Affiliation': 'Sydney Medical School, the University of Sydney, Sydney, NSW.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Panaretto', 'Affiliation': 'Centre for Chronic Disease, University of Queensland, Brisbane, QLD.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Lung', 'Affiliation': 'The George Institute for Global Health, UNSW Sydney, Sydney, NSW.'}]",The Medical journal of Australia,['10.5694/mja2.50667'] 1770,32594587,Examining what factors mediate treatment effect in chronic low back pain: A mediation analysis of a Cognitive Functional Therapy clinical trial.,"BACKGROUND Cognitive Functional Therapy (CFT) is a physiotherapist-led individualized intervention for people with people with non-specific chronic low back pain (CLBP), involving biopsychosocial pain education, graded movement exposure and lifestyle coaching. METHODS A multicentre randomized controlled trial (RCT), including 206 participants with CLBP in Ireland, supported CFT's effectiveness for reducing disability, but not pain, compared to a group exercise and education intervention. In this study, causal mediation analysis was used to determine whether the effect of CFT on disability and the lack of effect on pain (relative to a group exercise and education intervention) is mediated by certain psychological and lifestyle factors. Hypothesized mediators measured were pain self-efficacy, stress, fear of physical activity, coping, depression, anxiety and sleep, at 6 months. The outcomes measured were functional disability and pain intensity at 12 months. RESULTS This causal mediation study shows that the majority of benefit of CFT (relative to a group exercise and education intervention) for disability is due to increasing pain self-efficacy. CONCLUSION Conclusion: CFT did not improve the majority of the hypothesized mediators (stress, fear of physical activity, coping, depression, anxiety and sleep) and these mediators were not associated with either disability or pain. Unfortunately, the proportion of missing data in this study is substantial and these findings can only be considered hypothesis-generating. Therefore, future research should examine replicating the results of this study to verify the role of self-efficacy and other proposed mediators (e.g. stress, coping, sleep, fear) on clinical outcomes. SIGNIFICANCE An exploration of seven potential mediators was undertaken to determine the effect of Cognitive Functional Therapy (CFT) on disability and pain intensity in individuals with chronic low back pain compared to a group exercise and education intervention. CFT improved pain self-efficacy, which was associated with disability and pain outcomes. CFT did not improve the other six potential mediators (stress, fear of physical activity, coping, depression, anxiety and sleep) and these were not associated with disability or pain. The proportion of missing data in this study is substantial and these findings should be considered hypothesis-generating only.",2020,"CFT did not improve the majority of the hypothesised mediators (stress, fear of physical activity, coping, depression, anxiety and sleep) and these mediators were not associated with either disability or pain.","[""206 participants with CLBP in Ireland, supported CFT's effectiveness for reducing disability, but not pain, compared to a group exercise and education intervention"", 'people with people with non-specific chronic low back pain (CLBP', 'chronic low back pain']","['CFT', 'Cognitive Functional Therapy (CFT']","['functional disability and pain intensity', 'pain self-efficacy, stress, fear of physical activity, coping, depression, anxiety, and sleep', 'majority of the hypothesised mediators (stress, fear of physical activity, coping, depression, anxiety and sleep', 'disability or pain']","[{'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0022067', 'cui_str': 'Republic of Ireland'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205370', 'cui_str': 'Non-specific'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}]",206.0,0.0973819,"CFT did not improve the majority of the hypothesised mediators (stress, fear of physical activity, coping, depression, anxiety and sleep) and these mediators were not associated with either disability or pain.","[{'ForeName': 'Aoife', 'Initials': 'A', 'LastName': ""O'Neill"", 'Affiliation': 'School of Allied Health, University of Limerick, Limerick, Ireland.'}, {'ForeName': 'Kieran', 'Initials': 'K', 'LastName': ""O'Sullivan"", 'Affiliation': 'School of Allied Health, University of Limerick, Limerick, Ireland.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': ""O'Sullivan"", 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, WA, Australia.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Purtill', 'Affiliation': 'Aging Research Centre, Health Research Institute, University of Limerick, Limerick, Ireland.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': ""O'Keeffe"", 'Affiliation': 'School of Allied Health, University of Limerick, Limerick, Ireland.'}]","European journal of pain (London, England)",['10.1002/ejp.1624'] 1771,32470421,"Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study.","BACKGROUND Deep brain stimulation (DBS) of the subthalamic nucleus is an established therapeutic option for managing motor symptoms of Parkinson's disease. We conducted a double-blind, sham-controlled, randomised controlled trial to assess subthalamic nucleus DBS, with a novel multiple independent contact current-controlled (MICC) device, in patients with Parkinson's disease. METHODS This trial took place at 23 implanting centres in the USA. Key inclusion criteria were age between 22 and 75 years, a diagnosis of idiopathic Parkinson's disease with over 5 years of motor symptoms, and stable use of anti-parkinsonian medications for 28 days before consent. Patients who passed screening criteria were implanted with the DBS device bilaterally in the subthalamic nucleus. Patients were randomly assigned in a 3:1 ratio to receive either active therapeutic stimulation settings (active group) or subtherapeutic stimulation settings (control group) for the 3-month blinded period. Randomisation took place with a computer-generated data capture system using a pre-generated randomisation table, stratified by site with random permuted blocks. During the 3-month blinded period, both patients and the assessors were masked to the treatment group while the unmasked programmer was responsible for programming and optimisation of device settings. The primary outcome was the difference in mean change from baseline visit to 3 months post-randomisation between the active and control groups in the mean number of waking hours per day with good symptom control and no troublesome dyskinesias, with no increase in anti-parkinsonian medications. Upon completion of the blinded phase, all patients received active treatment in the open-label period for up to 5 years. Primary and secondary outcomes were analysed by intention to treat. All patients who provided informed consent were included in the safety analysis. The open-label phase is ongoing with no new enrolment, and current findings are based on the prespecified interim analysis of the first 160 randomly assigned patients. The study is registered with ClinicalTrials.gov, NCT01839396. FINDINGS Between May 17, 2013, and Nov 30, 2017, 313 patients were enrolled across 23 sites. Of these 313 patients, 196 (63%) received the DBS implant and 191 (61%) were randomly assigned. Of the 160 patients included in the interim analysis, 121 (76%) were randomly assigned to the active group and 39 (24%) to the control group. The difference in mean change from the baseline visit (post-implant) to 3 months post-randomisation in increased ON time without troublesome dyskinesias between the active and control groups was 3·03 h (SD 4·52, 95% CI 1·3-4·7; p<0·0001). 26 serious adverse events in 20 (13%) patients occurred during the 3-month blinded period. Of these, 18 events were reported in the active group and 8 in the control group. One death was reported among the 196 patients before randomisation, which was unrelated to the procedure, device, or stimulation. INTERPRETATION This double-blind, sham-controlled, randomised controlled trial provides class I evidence of the safety and clinical efficacy of subthalamic nucleus DBS with a novel MICC device for the treatment of motor symptoms of Parkinson's disease. Future trials are needed to investigate potential benefits of producing a more defined current field using MICC technology, and its effect on clinical outcomes. FUNDING Boston Scientific.",2020,"One death was reported among the 196 patients before randomisation, which was unrelated to the procedure, device, or stimulation. ","['313 patients, 196 (63%) received the DBS implant and 191 (61%) were randomly assigned', '23 implanting centres in the USA', ""patients with Parkinson's disease"", ""motor symptoms of Parkinson's disease"", '160 patients included in the interim analysis, 121 (76', 'Between May 17, 2013, and Nov 30, 2017', '313 patients were enrolled across 23 sites', ""Parkinson's disease (INTREPID"", ""Key inclusion criteria were age between 22 and 75 years, a diagnosis of idiopathic Parkinson's disease with over 5 years of motor symptoms, and stable use of anti-parkinsonian medications for 28 days before consent""]","['subthalamic nucleus DBS with a novel MICC device', 'Subthalamic nucleus deep brain stimulation', 'Deep brain stimulation (DBS', 'active therapeutic stimulation settings (active group) or subtherapeutic stimulation settings (control group', 'novel multiple independent contact current-controlled (MICC) device']","['ON time without troublesome dyskinesias', 'anti-parkinsonian medications', 'mean number of waking hours per day with good symptom control and no troublesome dyskinesias', '26 serious adverse events', 'mean change from baseline visit to 3 months post-randomisation']","[{'cui': 'C4517707', 'cui_str': '313'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517625', 'cui_str': '196'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2711213', 'cui_str': 'Consented'}]","[{'cui': 'C0152355', 'cui_str': 'Nucleus of Luys'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0013384', 'cui_str': 'Dyskinesia'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C0556974', 'cui_str': 'hours/day'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1274136', 'cui_str': 'Symptom control'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0687676', 'cui_str': 'After values'}]",313.0,0.575314,"One death was reported among the 196 patients before randomisation, which was unrelated to the procedure, device, or stimulation. ","[{'ForeName': 'Jerrold L', 'Initials': 'JL', 'LastName': 'Vitek', 'Affiliation': 'Department of Neurology, University of Minnesota School of Medicine, Minneapolis, MN, USA. Electronic address: vitek004@umn.edu.'}, {'ForeName': 'Roshini', 'Initials': 'R', 'LastName': 'Jain', 'Affiliation': 'Division of Neuromodulation, Boston Scientific, Valencia, CA, USA.'}, {'ForeName': 'Lilly', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Division of Neuromodulation, Boston Scientific, Valencia, CA, USA.'}, {'ForeName': 'Alexander I', 'Initials': 'AI', 'LastName': 'Tröster', 'Affiliation': 'Department of Clinical Neuropsychology, Barrow Neurological Institute, Phoenix, AZ, USA.'}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Schrock', 'Affiliation': 'Department of Neurology, University of Minnesota School of Medicine, Minneapolis, MN, USA.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'House', 'Affiliation': 'Neurosurgical Associates, Murray, UT, USA.'}, {'ForeName': 'Monique L', 'Initials': 'ML', 'LastName': 'Giroux', 'Affiliation': 'Movement and Neuroperformance Center of Colorado, Englewood, CO, USA; Clinical Research Neurology, Eisai, Woodcliff Lake, NJ, USA.'}, {'ForeName': 'Adam O', 'Initials': 'AO', 'LastName': 'Hebb', 'Affiliation': 'Department of Neurological Surgery, Kaiser Permanente, Denver, CO, USA.'}, {'ForeName': 'Sierra M', 'Initials': 'SM', 'LastName': 'Farris', 'Affiliation': 'Division of Neuromodulation, Boston Scientific, Valencia, CA, USA; Movement and Neuroperformance Center of Colorado, Englewood, CO, USA.'}, {'ForeName': 'Donald M', 'Initials': 'DM', 'LastName': 'Whiting', 'Affiliation': 'Department of Neurosurgery, Allegheny General Hospital, Pittsburgh, PA, USA.'}, {'ForeName': 'Timothy A', 'Initials': 'TA', 'LastName': 'Leichliter', 'Affiliation': 'Department of Neurology, Allegheny General Hospital, Pittsburgh, PA, USA.'}, {'ForeName': 'Jill L', 'Initials': 'JL', 'LastName': 'Ostrem', 'Affiliation': 'Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'San Luciano', 'Affiliation': 'Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Galifianakis', 'Affiliation': 'Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Leo', 'Initials': 'L', 'LastName': 'Verhagen Metman', 'Affiliation': 'Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.'}, {'ForeName': 'Sepehr', 'Initials': 'S', 'LastName': 'Sani', 'Affiliation': 'Department of Neurological Surgery, Rush University Medical Center, Chicago, IL, USA.'}, {'ForeName': 'Jessica A', 'Initials': 'JA', 'LastName': 'Karl', 'Affiliation': 'Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.'}, {'ForeName': 'Mustafa S', 'Initials': 'MS', 'LastName': 'Siddiqui', 'Affiliation': 'Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'ForeName': 'Stephen B', 'Initials': 'SB', 'LastName': 'Tatter', 'Affiliation': 'Department of Neurosurgery, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'ForeName': 'Ihtsham', 'Initials': 'I', 'LastName': 'Ul Haq', 'Affiliation': 'Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'ForeName': 'Andre G', 'Initials': 'AG', 'LastName': 'Machado', 'Affiliation': 'Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Gostkowski', 'Affiliation': 'Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Tagliati', 'Affiliation': 'Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Adam N', 'Initials': 'AN', 'LastName': 'Mamelak', 'Affiliation': 'Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Okun', 'Affiliation': 'Department of Neurology, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Kelly D', 'Initials': 'KD', 'LastName': 'Foote', 'Affiliation': 'Department of Neurosurgery, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Moguel-Cobos', 'Affiliation': 'Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.'}, {'ForeName': 'Francisco A', 'Initials': 'FA', 'LastName': 'Ponce', 'Affiliation': 'Department of Neurosurgery, Barrow Neurological Institute, Phoenix, AZ, USA.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Pahwa', 'Affiliation': 'Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Jules M', 'Initials': 'JM', 'LastName': 'Nazzaro', 'Affiliation': 'Department of Neurosurgery, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Cathrin M', 'Initials': 'CM', 'LastName': 'Buetefisch', 'Affiliation': 'Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Gross', 'Affiliation': 'Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Corneliu C', 'Initials': 'CC', 'LastName': 'Luca', 'Affiliation': 'Department of Neurology, University of Miami School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Jonathan R', 'Initials': 'JR', 'LastName': 'Jagid', 'Affiliation': 'Department of Neurosurgery, University of Miami School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Gonzalo J', 'Initials': 'GJ', 'LastName': 'Revuelta', 'Affiliation': 'Department of Neurology, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Istvan', 'Initials': 'I', 'LastName': 'Takacs', 'Affiliation': 'Department of Neurosurgery, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Michael H', 'Initials': 'MH', 'LastName': 'Pourfar', 'Affiliation': 'Department of Neurology, New York University Medical Center, New York City, NY, USA.'}, {'ForeName': 'Alon Y', 'Initials': 'AY', 'LastName': 'Mogilner', 'Affiliation': 'Department of Neurosurgery, New York University Medical Center, New York City, NY, USA.'}, {'ForeName': 'Andrew P', 'Initials': 'AP', 'LastName': 'Duker', 'Affiliation': 'Department of Neurology, University of Cincinnati Medical Center, Cincinnati, OH, USA.'}, {'ForeName': 'George T', 'Initials': 'GT', 'LastName': 'Mandybur', 'Affiliation': 'Department of Neurosurgery, University of Cincinnati Medical Center, Cincinnati, OH, USA.'}, {'ForeName': 'Joshua M', 'Initials': 'JM', 'LastName': 'Rosenow', 'Affiliation': 'Department of Neurosurgery, Northwestern University School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Scott E', 'Initials': 'SE', 'LastName': 'Cooper', 'Affiliation': 'Department of Neurology, University of Minnesota School of Medicine, Minneapolis, MN, USA.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Park', 'Affiliation': 'Department of Neurosurgery, University of Minnesota School of Medicine, Minneapolis, MN, USA.'}, {'ForeName': 'Suketu M', 'Initials': 'SM', 'LastName': 'Khandhar', 'Affiliation': 'Department of Neurology, Kaiser Permanente Medical Center, Sacramento, CA, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Sedrak', 'Affiliation': 'Department of Neurosurgery, Kaiser Permanente Medical Center, Redwood City, CA, USA.'}, {'ForeName': 'Fenna T', 'Initials': 'FT', 'LastName': 'Phibbs', 'Affiliation': 'Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Julie G', 'Initials': 'JG', 'LastName': 'Pilitsis', 'Affiliation': 'Department of Neurosurgery, Albany Medical Center, Albany, NY, USA.'}, {'ForeName': 'Ryan J', 'Initials': 'RJ', 'LastName': 'Uitti', 'Affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.'}, {'ForeName': 'Philip A', 'Initials': 'PA', 'LastName': 'Starr', 'Affiliation': 'Department of Neurosurgery, University of California, San Francisco, San Francisco, CA, USA.'}]",The Lancet. Neurology,['10.1016/S1474-4422(20)30108-3'] 1772,32594854,"The impact of beetroot juice supplementation on muscular endurance, maximal strength and countermovement jump performance.","Purpose : Dietary nitrate has been shown to enhance muscle contractile function and has, therefore, been linked to increased muscle power and sprint exercise performance. However, the impact of dietary nitrate supplementation on maximal strength, performance and muscular endurance remains to be established. Methods : Fifteen recreationally active males (25 ± 4 y, BMI 24 ± 3 kg/m 2 ) participated in a randomized double-blinded cross-over study comprising two 6-d supplementation periods; 140 mL/d nitrate-rich (BR; 985 mg/d) and nitrate-depleted (PLA; 0.37 mg/d) beetroot juice. Three hours following the last supplement, we assessed countermovement jump (CMJ) performance, maximal strength and power of the upper leg by voluntary isometric (30° and 60° angle) and isokinetic contractions (60, 120, 180 and 300°·s -1 ), and muscular endurance (total workload) by 30 reciprocal isokinetic voluntary contractions at 180°·s -1 . Results : Despite differences in plasma nitrate (BR: 879 ± 239 vs. PLA: 33 ± 13 μmol/L, P  < 0.001) and nitrite (BR: 463 ± 217 vs. PLA: 176 ± 50 nmol/L, P  < 0.001) concentrations prior to exercise testing, CMJ height (BR: 39.3 ± 6.3 vs. PLA: 39.6 ± 6.3 cm; P  = 0.39) and muscular endurance (BR: 3.93 ± 0.69 vs. PLA: 3.90 ± 0.66 kJ; P  = 0.74) were not different between treatments. In line, isometric strength ( P  > 0.50 for both angles) and isokinetic knee extension power ( P  > 0.33 for all velocities) did not differ between treatments. Isokinetic knee flexion power was significantly higher following BR compared with PLA ingestion at 60°·s -1 ( P  = 0.001), but not at 120°·s -1 ( P  = 0.24), 180°·s -1 ( P  = 0.066), and 300°·s -1 ( P  = 0.36). Conclusion : Nitrate supplementation does not improve maximal strength, countermovement jump performance and muscular endurance in healthy, active males.",2020,"Isokinetic knee flexion power was significantly higher following BR compared with PLA ingestion at 60°·s -1 ( P =0.001), but not at 120°·s -1 ( P =0.24), 180°·s -1 ( P =0.066), and 300°·s -1 ( P =0.36). ","['healthy, active males', 'Fifteen recreationally active males (25±4 y']","['beetroot juice supplementation', 'dietary nitrate supplementation', 'PLA', 'Nitrate supplementation', 'nitrate-depleted (PLA; 0.37 mg/d) beetroot juice']","['muscular endurance (total workload) by 30 reciprocal isokinetic voluntary contractions', 'muscular endurance', 'CMJ height (BR', 'maximal strength, performance and muscular endurance', 'muscular endurance, maximal strength and countermovement jump performance', 'isokinetic knee extension power', 'Isokinetic knee flexion power', 'maximal strength, countermovement jump performance and muscular endurance', 'countermovement jump (CMJ) performance, maximal strength and power of the upper leg by voluntary isometric (30° and 60° angle) and isokinetic contractions', 'isometric strength', 'plasma nitrate']","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C1095905', 'cui_str': 'Beets preparation'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0456170', 'cui_str': 'Left atrial pressure'}, {'cui': 'C4517454', 'cui_str': '0.37'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}]","[{'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}]",2.0,0.0542704,"Isokinetic knee flexion power was significantly higher following BR compared with PLA ingestion at 60°·s -1 ( P =0.001), but not at 120°·s -1 ( P =0.24), 180°·s -1 ( P =0.066), and 300°·s -1 ( P =0.36). ","[{'ForeName': 'Kristin L', 'Initials': 'KL', 'LastName': 'Jonvik', 'Affiliation': 'School of Sport and Exercise, HAN University of Applied Sciences, Nijmegen, Netherlands.'}, {'ForeName': 'Daan', 'Initials': 'D', 'LastName': 'Hoogervorst', 'Affiliation': 'School of Sport and Exercise, HAN University of Applied Sciences, Nijmegen, Netherlands.'}, {'ForeName': 'Harmen B', 'Initials': 'HB', 'LastName': 'Peelen', 'Affiliation': 'Department of Movement and Sports Science, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'de Niet', 'Affiliation': 'School of Sport and Exercise, HAN University of Applied Sciences, Nijmegen, Netherlands.'}, {'ForeName': 'Lex B', 'Initials': 'LB', 'LastName': 'Verdijk', 'Affiliation': 'Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, Netherlands.'}, {'ForeName': 'Luc J C', 'Initials': 'LJC', 'LastName': 'van Loon', 'Affiliation': 'School of Sport and Exercise, HAN University of Applied Sciences, Nijmegen, Netherlands.'}, {'ForeName': 'Jan-Willem', 'Initials': 'JW', 'LastName': 'van Dijk', 'Affiliation': 'School of Sport and Exercise, HAN University of Applied Sciences, Nijmegen, Netherlands.'}]",European journal of sport science,['10.1080/17461391.2020.1788649'] 1773,32683790,"Oxidative stress and nitrate/nitrite (NOx) status following citrulline supplementation in type 2 diabetes: a randomised, double-blind, placebo-controlled trial.","BACKGROUND The pathogenesis of diabetes is accompanied by oxidative stress. Citrulline can be considered as a potent antioxidant. The present study aimed to examine the effects of citrulline supplementation on the status of oxidative stress and serum levels of nitrite/nitrate (NOx) in patients suffering from type 2 diabetes (T2DM). METHODS The present study comprises a double-blind placebo-controlled randomised clinical trial. The study subjects include 54 patients with T2DM chosen from specialised clinics of Tabriz University of Medical Sciences. The patients were allocated to one of the placebo or intervention groups. The patients in the placebo and the intervention group received one sachet of microcrystalline cellulose or l-citrulline (3 g), respectively, every day for 2 months. Malondialdehyde (MDA), glutathione peroxidase (GPx), total antioxidant capacity (TAC), superoxide dismutase (SOD), serum levels of fasting blood sugar (FBS), citrulline and NOx were assessed before and after the intervention. RESULTS Forty-five patients completed the trial. Significant decreases were found in serum levels of FBS and MDA. Serum levels of TAC, citrulline and NOx in the intervention group increased compared to those of the placebo group, after adjusting the data for the baseline values and confounders. Differences between and within the two groups were statistically nonsignificant for GPx and SOD at the end of the study. Body mass index and energy intake were not changed significantly after the intervention. CONCLUSIONS The results of the present study show the positive effects of citrulline supplementation with respect to attenuating FBS levels and oxidative stress, as well as boosting NOx status, in patients with T2DM.",2020,"Serum levels of TAC, citrulline and NOx in the intervention group increased compared to those of the placebo group, after adjusting the data for the baseline values and confounders.","['54 patients with T2DM chosen from specialised clinics of Tabriz University of Medical Sciences', 'patients suffering from type 2 diabetes (T2DM', 'Forty-five patients completed the trial', 'patients with T2DM', 'type 2 diabetes']","['citrulline supplementation', 'sachet of microcrystalline cellulose or l-citrulline', 'placebo']","['FBS levels and oxidative stress', 'oxidative stress and serum levels of nitrite/nitrate (NOx', 'GPx and SOD', 'Malondialdehyde (MDA), glutathione peroxidase (GPx), total antioxidant capacity (TAC), superoxide dismutase (SOD), serum levels of fasting blood sugar (FBS), citrulline and NOx', 'serum levels of FBS and MDA', 'Body mass index and energy intake', 'Serum levels of TAC, citrulline and NOx', 'Oxidative stress and nitrate/nitrite (NOx) status']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0008864', 'cui_str': 'Citrulline'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C2348127', 'cui_str': 'Sachet - unit of product usage'}, {'cui': 'C0669247', 'cui_str': 'microcrystalline cellulose'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0028137', 'cui_str': 'Nitrite salt'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0017822', 'cui_str': 'Glutathione peroxidase'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0008864', 'cui_str': 'Citrulline'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",54.0,0.210972,"Serum levels of TAC, citrulline and NOx in the intervention group increased compared to those of the placebo group, after adjusting the data for the baseline values and confounders.","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Azizi', 'Affiliation': 'Student Research Committee, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ebrahimi-Mameghani', 'Affiliation': 'Nutrition Research Center, Department of Biochemistry and Diet Therapy, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Mobasseri', 'Affiliation': 'Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Karamzad', 'Affiliation': 'Student Research Committee, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Mahdavi', 'Affiliation': 'Nutrition Research Center, Department of Biochemistry and Diet Therapy, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.'}]",Journal of human nutrition and dietetics : the official journal of the British Dietetic Association,['10.1111/jhn.12792'] 1774,32683992,Monopolar dielectric diathermy by emission of radiofrequency in Patellofemoral pain. A single-blind-randomized clinical trial.,"Despite the high incidence of patellofemoral pain syndrome (PFPS), few studies show the effects of radiofrequency on pain and functionality in these patients. For this reason, the aim of this study was to determine the efficacy of monopolar dielectric diathermy by emission of radiofrequency (MDR) in dynamic applications aimed at treating pain and improving function in patients with PFPS. For this purpose, a single-blind randomized clinical trial was conducted. Eighty-four participants with PFPS were evenly divided into an experimental group (EG) and a control group (CG). All subjects receive 10 min of daily home exercises along 3 weeks, and in addition, the subjects of the EG received 10 sessions based on the dynamic application of MDR. Variables measured included Visual Analogue Scale (VAS), DN4 questionnaire, Lower Extremity Functionality Scale (LEFS), Kujala scale, Range of Movement (ROM) in knee flexion and extension and drug intake. The EG showed a statistically significant reduction in pain (VAS = 4.8 [5.5-4.1] [ p < .001]; DN4 = 3.8 [4.4-3.2] [ p < .001]), and an increase in functionality (LEFS = 16 [19-13] [ p < .001]; Kujala = 19 [23-14] [ p < .001]) and in ROM (flexion 18º [21º-16º] [ p < .001]). No statistically significant changes in drug intake were found. Based on this data, the dynamic application of MDR seems effective in reducing pain and increasing functionality and flexion in patients with PFPS. Diathermy by emission of radiofrequency could be recommended as complement or main therapy in the treatment of PFPS.",2020,The EG showed a statistically significant reduction in pain (VAS = 4.8 [5.5-4.1] [ p < .001],"['patients with PFPS', 'Eighty-four participants with PFPS', 'Patellofemoral pain']","['Monopolar dielectric diathermy by emission of radiofrequency', 'monopolar dielectric diathermy by emission of radiofrequency (MDR', 'radiofrequency']","['pain and increasing functionality and flexion', 'drug intake', 'pain', 'Visual Analogue Scale (VAS), DN4 questionnaire, Lower Extremity Functionality Scale (LEFS), Kujala scale, Range of Movement (ROM) in knee flexion and extension and drug intake', 'pain and functionality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0877149', 'cui_str': 'Patellofemoral pain syndrome'}, {'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0012002', 'cui_str': 'Diathermy'}, {'cui': 'C0233929', 'cui_str': 'Emission'}, {'cui': 'C0242640', 'cui_str': 'Multiple-drug resistance'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231448', 'cui_str': 'Extension'}]",84.0,0.0504602,The EG showed a statistically significant reduction in pain (VAS = 4.8 [5.5-4.1] [ p < .001],"[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Albornoz-Cabello', 'Affiliation': 'Physiotherapy Department, University of Seville , Seville, Spain.'}, {'ForeName': 'A J', 'Initials': 'AJ', 'LastName': 'Ibáñez-Vera', 'Affiliation': 'Health Sciences Department, University of Jaen , Jaen, Spain.'}, {'ForeName': 'M E', 'Initials': 'ME', 'LastName': 'Aguilar-Ferrándiz', 'Affiliation': 'Physiotherapy Department, University of Granada , Granada, Spain.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Espejo-Antúnez', 'Affiliation': 'Department of Medical-Surgical Therapy, University of Extremadura , Badajoz, Spain.'}]",Electromagnetic biology and medicine,['10.1080/15368378.2020.1793169'] 1775,32683997,Managing Cancer and Living Meaningfully (CALM) Intervention on Chemotherapy-Related Cognitive Impairment in Breast Cancer Survivors.,"Objective: To evaluate the effectiveness and feasibility of Managing Cancer and Living Meaningfully (CALM), which is used to reduce chemotherapy-related cognitive impairment (CRCI), relieve psychological distress, and improve quality of life (QOL) in Chinese breast cancer survivors (BCs). Methods: Seventy-four BCs were enrolled in this study. All patients were randomly assigned to either the CALM group or the care as usual (CAU) group. All patients were evaluated by the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), Distress Thermometer (DT), and the Functional Assessment of Cancer Therapy-Breast (FACT-B) before and after CALM or CAU application to BCs with CRCI. We compared the differences in all these scores between the CALM group and the control group and analyzed the correlation between cognitive function and QOL. Results: Compared with the CAU group, the performance of the CALM group on the FACT-Cog, DT, and FACT-B showed significant differences before and after CALM ( t = -18.909, -5.180, -32.421, P = .000, .000, .000, respectively). Finally, there was a positive correlation between cognitive function and QOL in breast cancer patients before ( r = 0.579, P = .000) and after ( r = 0.797, P = .000) treatment. Conclusions: The present results indicated that CALM has salutary effects on the improvement of cognitive impairment and QOL and relieves psychological distress in breast cancer patients, which may be due to a positive correlation between psychological distress and cognitive function or QOL.",2020,"Compared with the CAU group, the performance of the CALM group on the FACT-Cog, DT, and FACT-B showed significant differences before and after CALM ( t = -18.909,","['Breast Cancer Survivors', 'breast cancer patients', 'Methods: Seventy-four BCs were enrolled in this study', 'Chinese breast cancer survivors (BCs']","['CALM', 'Managing Cancer and Living Meaningfully (CALM', 'Managing Cancer and Living Meaningfully (CALM) Intervention', 'CAU', 'CALM group or the care as usual (CAU']","['quality of life (QOL', 'cognitive impairment and QOL and relieves psychological distress', 'cognitive function and QOL', 'Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), Distress Thermometer (DT), and the Functional Assessment of Cancer Therapy-Breast']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4517867', 'cui_str': '74'}, {'cui': 'C0917927', 'cui_str': 'Breast conserving surgery'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}]","[{'cui': 'C0150157', 'cui_str': 'Calming'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0444892', 'cui_str': 'CAU'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0332303', 'cui_str': 'Relieved by'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0009738', 'cui_str': 'Congo'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0039818', 'cui_str': 'Thermometer'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}]",74.0,0.0371166,"Compared with the CAU group, the performance of the CALM group on the FACT-Cog, DT, and FACT-B showed significant differences before and after CALM ( t = -18.909,","[{'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Ding', 'Affiliation': 'The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.'}, {'ForeName': 'Xiuqing', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.'}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.'}, {'ForeName': 'He', 'Initials': 'H', 'LastName': 'Zuo', 'Affiliation': 'The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.'}, {'ForeName': 'Ziran', 'Initials': 'Z', 'LastName': 'Bi', 'Affiliation': 'The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.'}, {'ForeName': 'Huaidong', 'Initials': 'H', 'LastName': 'Cheng', 'Affiliation': 'The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.'}]",Integrative cancer therapies,['10.1177/1534735420938450'] 1776,32594615,"Reducing car idling at primary schools: An intervention study of parent behaviour change in Perth, Western Australia.","ISSUED ADDRESSED There is increasing evidence that exposure to traffic-related air pollution is related to childhood respiratory symptoms. This study demonstrated the effectiveness of an anti-idling behavioural intervention targeting parents at primary schools. METHODS Based on two focus group discussions with parents, a low-intensity 4-week anti-idling intervention was developed, comprising onsite signage, four newsletters, and two fact sheets. Exposure to selected air pollutants was assessed during pick-up and drop-off times pre- and postintervention at 12 randomly selected independent schools (10 intervention and 2 control) across the Perth metropolitan area. RESULTS The study results showed that a low-intensity behavioural intervention can be an effective strategy to affect parents' attitude towards vehicle idling. This was demonstrated by the reduced number of idling vehicles observed in 8 of the 10 intervention schools and decreased overall particulate matter concentration after the anti-idling intervention. CONCLUSION Anti-idling education can be effective in promoting clean travel behaviours and has potential health benefits for school children. SO WHAT?: This intervention study provides insights on the significant effect of anti-idling education on parents' behaviour towards air quality and children's health. These promising findings warrant further rigorous actions on anti-idling education and enforcement.",2020,The study results showed that a low-intensity behavioural intervention can be an effective strategy to affect parents' attitude towards vehicle idling.,"[""parents 'behaviour towards air quality and children's health"", 'parents at primary schools', 'school children']","['anti-idling education', 'anti-idling behavioural intervention targeting']","['overall particulate matter concentration', 'reduced number of idling vehicles', 'clean travel behaviours']","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C2371710', 'cui_str': 'Air Quality'}, {'cui': 'C0008078', 'cui_str': 'Child health care'}, {'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0260267', 'cui_str': 'School child'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1720884', 'cui_str': 'Particulate Matter'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle'}, {'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0040802', 'cui_str': 'Travel'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",12.0,0.0255061,The study results showed that a low-intensity behavioural intervention can be an effective strategy to affect parents' attitude towards vehicle idling.,"[{'ForeName': 'Krassi', 'Initials': 'K', 'LastName': 'Rumchev', 'Affiliation': 'School of Public Health, Curtin University, Perth, WA, Australia.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Lee', 'Affiliation': 'School of Public Health, Curtin University, Perth, WA, Australia.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Maycock', 'Affiliation': 'School of Public Health, Curtin University, Perth, WA, Australia.'}, {'ForeName': 'Jonine', 'Initials': 'J', 'LastName': 'Jancey', 'Affiliation': 'School of Public Health, Curtin University, Perth, WA, Australia.'}]",Health promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals,['10.1002/hpja.381'] 1777,32595244,"SAFETY AND EFFECTS OF CRATAEGUS EXTRACT WS 1442 AND NORDIC WALKING ON LIPID PROFILE AND ENDOTHELIAL FUNCTION: A RANDOMIZED, PARTIALLY BLINDED PILOT STUDY IN OVERWEIGHT VOLUNTEERS.","Overweight and physical inactivity adversely affect endothelial function and are risk factors for atherosclerosis and cardiovascular disease. Both Crataegus extract WS 1442 and physical exercise exert beneficial effects on endothelial function. We investigated whether WS 1442 and Nordic walking (NW) had comparable effects on endothelial function and lipid profile in overweight subjects. In this partially blinded pilot study, overweight, otherwise healthy volunteers aged 45-75 years were randomized into four groups as follows: WS 1442 2x450 mg/day (WS-standard), WS 1442 2x900 mg/day (WS-double), exercise 2x30 minutes/week (NW-low), and exercise 4x45 minutes/week (NW-high) for 12 weeks. Safety was assessed based on adverse events. Endothelial function testing (EndoPAT ® ), assessment of endothelial progenitor cells, lipid profiles, and treadmill testing were performed. Sixty subjects participated in the study. At baseline, subjects in WS-standard/-double groups had higher lipid levels and greater impairment of endothelial function. Subjects with impaired endothelial function showed improvement regardless of the type of intervention. Subjects in WS-standard and WS-double groups showed a trend towards modest decrease in triglycerides and modest increase in HDL-cholesterol; most changes were within the normal limits. In NW-low/-high groups, values also remained within the normal range. Exercise capacity improved in both NW groups. WS-double showed no additional benefits over WS-standard. All adverse events were unrelated or improbably related to treatment. In conclusion, WS 1442 and exercise training were safe and showed beneficial effects on endothelial function and lipid profile in overweight but otherwise healthy volunteers; exercise capacity improved only by Nordic walking.",2019,Exercise capacity improved in both NW groups.,"['overweight subjects', 'overweight, otherwise healthy volunteers aged 45-75 years', 'overweight but otherwise healthy volunteers', 'Sixty subjects participated in the study']","['WS 1442 and Nordic walking (NW', 'WS 1442 and exercise training', 'physical exercise']","['endothelial function', 'triglycerides', 'Endothelial function testing (EndoPAT ® ), assessment of endothelial progenitor cells, lipid profiles, and treadmill testing', 'Exercise capacity', 'exercise capacity', 'HDL-cholesterol', 'endothelial function and lipid profile', 'lipid levels']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0964758', 'cui_str': 'WS 1442'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C3850017', 'cui_str': 'Circulating Endothelial Progenitor Cells'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol in high density lipoprotein subfraction 2'}, {'cui': 'C0428460', 'cui_str': 'Lipid level - finding'}]",60.0,0.0554614,Exercise capacity improved in both NW groups.,"[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Niederseer', 'Affiliation': '1University Institute of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University, Institute of Sports Medicine of the State of Salzburg, Salzburg, Austria; 2Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.'}, {'ForeName': 'Eveline', 'Initials': 'E', 'LastName': 'Ledl-Kurkowski', 'Affiliation': '1University Institute of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University, Institute of Sports Medicine of the State of Salzburg, Salzburg, Austria; 2Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.'}, {'ForeName': 'Klara', 'Initials': 'K', 'LastName': 'Kvita', 'Affiliation': '1University Institute of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University, Institute of Sports Medicine of the State of Salzburg, Salzburg, Austria; 2Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Funk', 'Affiliation': '1University Institute of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University, Institute of Sports Medicine of the State of Salzburg, Salzburg, Austria; 2Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.'}, {'ForeName': 'Josef', 'Initials': 'J', 'LastName': 'Niebauer', 'Affiliation': '1University Institute of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University, Institute of Sports Medicine of the State of Salzburg, Salzburg, Austria; 2Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.'}]",Acta clinica Croatica,['10.20471/acc.2019.58.04.06'] 1778,32593918,Early initiated postoperative rehabilitation enhances quality of life in patients with operable lung cancer: Secondary outcomes from a randomized trial.,"INTRODUCTION Patients with lung cancer report a lower degree of Health Related Quality of Life (HRQoL) compared with other cancer patients. HRQoL reflects how patients experience the impact of their disease and its treatment on their quality of daily living. A widely used questionnaire in lung cancer patients is the Functional Assessment of Cancer Therapy - Lung (FACT-L) questionnaire. Here we report the secondary outcomes on FACT-L data from the Postoperative Rehabilitation in Operation for Lung CAncer (PROLUCA) study, which describes the effect of early (14 days) versus late initiated (14 weeks) postoperative rehabilitation. MATERIALS AND METHODS The PROLUCA study was designed as a two-armed randomized controlled trial with an early rehabilitation group (14 days after surgery (ERG)) or a control arm with a late rehabilitation group (14 weeks after surgery (LRG)). The results for seven domain scores obtained using the FACT-L at the following time-points: baseline, 14 weeks, 26 weeks and 52 weeks after surgery are presented here. RESULTS 119 patients were randomized to the ERG and 116 to the LRG. In the ERG, HRQoL measured by both FACT-L and FACT-G (general core instrument) showed a continuous improvement up to 26 weeks after which HRQoL decreased after further 26 weeks without structured intervention. In the LRG a non-significant deterioration was detected over the first 14 weeks after surgery. After participation in the 12 weeks rehabilitation program, an increase in HRQoL was seen, without reaching the same level as the early group. CONCLUSION Analyses of the seven domain scores obtained using FACT-L and FACT-G reflect the importance of starting exercise early after surgery since the ERG avoid a temporary decrease in HRQoL. It is therefore recommended to start up a structured rehabilitation program 14 days after surgery, containing high intensity interval training and strength exercise twice a week for 12 weeks.",2020,"After participation in the 12 weeks rehabilitation program, an increase in HRQoL was seen, without reaching the same level as the early group. ","['lung cancer patients', 'patients with operable lung cancer', '119 patients']","['postoperative rehabilitation', 'early rehabilitation group (14 days after surgery (ERG)) or a control arm with a late rehabilitation group']","['quality of life', 'Health Related Quality of Life (HRQoL', 'HRQoL']","[{'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205188', 'cui_str': 'Operable'}]","[{'cui': 'C0877071', 'cui_str': 'Postoperative rehabilitation'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0205087', 'cui_str': 'Late'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}]",119.0,0.0636671,"After participation in the 12 weeks rehabilitation program, an increase in HRQoL was seen, without reaching the same level as the early group. ","[{'ForeName': 'Maja Schick', 'Initials': 'MS', 'LastName': 'Sommer', 'Affiliation': 'Copenhagen Centre for Cancer and Health, Denmark. Electronic address: mss@kraeftcenter-kbh.dk.'}, {'ForeName': 'Jette', 'Initials': 'J', 'LastName': 'Vibe-Petersen', 'Affiliation': 'Copenhagen Centre for Cancer and Health, Denmark.'}, {'ForeName': 'Maja Bohlbro', 'Initials': 'MB', 'LastName': 'Stærkind', 'Affiliation': 'The University Hospitals for Health Sciences, University Hospital of Copenhagen, Denmark.'}, {'ForeName': 'Seppo W', 'Initials': 'SW', 'LastName': 'Langer', 'Affiliation': 'Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Denmark.'}, {'ForeName': 'Klaus Richter', 'Initials': 'KR', 'LastName': 'Larsen', 'Affiliation': 'Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Denmark.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Trier', 'Affiliation': 'Copenhagen Centre for Cancer and Health, Denmark.'}, {'ForeName': 'Merete', 'Initials': 'M', 'LastName': 'Christensen', 'Affiliation': 'Department of Cardiothoracic Surgery, Copenhagen University Hospital, Rigshospitalet, Denmark.'}, {'ForeName': 'Paul F', 'Initials': 'PF', 'LastName': 'Clementsen', 'Affiliation': 'Department of Internal Medicine, Zealand University Hospital, Roskilde, Denmark; Copenhagen Academy for Medical Education and Simulation, University of Copenhagen and the Capital Region of Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark.'}, {'ForeName': 'Malene', 'Initials': 'M', 'LastName': 'Missel', 'Affiliation': 'Department of Cardiothoracic Surgery, Copenhagen University Hospital, Rigshospitalet, Denmark.'}, {'ForeName': 'Karl Bang', 'Initials': 'KB', 'LastName': 'Christensen', 'Affiliation': 'Section of Biostatistics, Department of Public Health, University of Copenhagen, Denmark.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Lillelund', 'Affiliation': 'The University Hospitals for Health Sciences, University Hospital of Copenhagen, Denmark.'}, {'ForeName': 'Henning', 'Initials': 'H', 'LastName': 'Langberg', 'Affiliation': 'Department of Public Health, Faculty of Health, University of Copenhagen, Denmark.'}, {'ForeName': 'Jesper H', 'Initials': 'JH', 'LastName': 'Pedersen', 'Affiliation': 'Department of Cardiothoracic Surgery, Copenhagen University Hospital, Rigshospitalet, Denmark.'}, {'ForeName': 'Morten', 'Initials': 'M', 'LastName': 'Quist', 'Affiliation': 'The University Hospitals for Health Sciences, University Hospital of Copenhagen, Denmark.'}]","Lung cancer (Amsterdam, Netherlands)",['10.1016/j.lungcan.2020.06.023'] 1779,32593936,Endometrial scratch injury with office hysteroscopy before IVF/ICSI: A randomised controlled trial.,"OBJECTIVE Endometrial scratch injury (ESI) has been proposed to improve endometrial receptivity and thereby increase implantation rates in assisted reproductive technology (ART) treatment. ESI has been widely incorporated into clinical practice despite inconclusive evidence of its effect on reproductive outcomes. We aimed to assess pregnancy and live birth rates in subfertile women receiving ESI before IVF treatment in comparison to controls. STUDY DESIGN This was a randomised controlled trial (RCT) with no blinding of participants, investigators or health care personnel. Women in ART treatment were allocated to either office hysteroscopy with ESI (ESI group) or no intervention (control group). In total 184 women in IVF/ICSI treatment with minimum one previous failed IVF/ICSI cycle, were included in the final analysis. The primary outcome was positive serum hCG (s-hCG). Secondary outcomes were ongoing pregnancy and live birth rate. Only per-protocol analyses were performed as all patients included at one centre had to be excluded. The trial is registered at ClinicalTrials.gov, NCT01743391. RESULTS Our results showed a non-significant increase in positive s-hCG (OR 1.23, 95 % CI (0.65-2.33)), ongoing pregnancy (OR 1.52, 95 % CI (0.73-3.17)), and live birth rates (OR 1.69, 95 % CI (0.78-3.64)) per randomised woman between the ESI and the control group. CONCLUSION We observed no significant differences in positive s-hCG or other reproductive outcomes in the ESI vs. the control group. While the crude estimates of positive reproductive outcomes were higher in the ESI group, statistical significance was not reached, and the study was not powered to show smaller differences. However, data from this study will be re-evaluated in the context of an individual participant data meta-analysis (IPD-MA) of RCTs on ESI.",2020,Women in ART treatment were allocated to either office hysteroscopy with ESI (ESI group) or no intervention (control group).,"['In total 184 women in IVF/ICSI treatment with minimum one previous failed IVF/ICSI cycle, were included in the final analysis', 'Endometrial scratch injury with office hysteroscopy before IVF/ICSI', 'subfertile women receiving ESI before IVF treatment in comparison to controls', 'Women in ART treatment', 'participants, investigators or health care personnel']","['office hysteroscopy with ESI (ESI group) or no intervention (control group', 'ESI']","['positive reproductive outcomes', 'live birth rates', 'ongoing pregnancy and live birth rate', 'ongoing pregnancy', 'positive s-hCG', 'pregnancy and live birth rates', 'positive serum hCG (s-hCG']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517616', 'cui_str': '184'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C0455164', 'cui_str': 'IVF - In vitro fertilization with intracytoplasmic sperm injection (ICSI)'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0311213', 'cui_str': 'Dermatitis verrucosa'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0020710', 'cui_str': 'Hysteroscopy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0035157', 'cui_str': 'Reproductive Technologies'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}]","[{'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0020710', 'cui_str': 'Hysteroscopy'}, {'cui': 'C0311213', 'cui_str': 'Dermatitis verrucosa'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0035150', 'cui_str': 'Reproduction'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1141639', 'cui_str': 'Human chorionic gonadotropin'}]",184.0,0.498981,Women in ART treatment were allocated to either office hysteroscopy with ESI (ESI group) or no intervention (control group).,"[{'ForeName': 'Sine', 'Initials': 'S', 'LastName': 'Berntsen', 'Affiliation': 'Department of Obstetrics and Gynaecology, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark; The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark. Electronic address: sine.berntsen.01@regionh.dk.'}, {'ForeName': 'Kristine Juul', 'Initials': 'KJ', 'LastName': 'Hare', 'Affiliation': 'Department of Obstetrics and Gynaecology, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Løssl', 'Affiliation': 'The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark; The Fertility Clinic, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.'}, {'ForeName': 'Jeanette', 'Initials': 'J', 'LastName': 'Bogstad', 'Affiliation': 'The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark; The Fertility Clinic, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Palmø', 'Affiliation': 'Department of Obstetrics and Gynaecology, Holbaek Hospital, Smedelundsgade 60, 4300 Holbaek, Denmark.'}, {'ForeName': 'Lisbeth', 'Initials': 'L', 'LastName': 'Prætorius', 'Affiliation': 'The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Zedeler', 'Affiliation': 'The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Pinborg', 'Affiliation': 'The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark; The Fertility Clinic, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.06.034'] 1780,32601123,Does screening for adverse effects improve health outcomes in epilepsy? A randomized trial.,"OBJECTIVE To determine whether systematic screening for adverse effects of antiepileptic drugs (AEDs) reduces toxicity burden and improves health-related quality of life in patients with epilepsy. METHODS Consecutive patients with uncontrolled seizures aged ≥16 years and a high Adverse Event Profile (AEP) score were randomized to 2 groups and followed up for 18 months at 11 referral centers. AEP scores were made available to treating physicians at all visits in the intervention group, but not in the control group. Co-primary endpoints were changes in AEP scores and Quality of Life Inventory for Epilepsy-31 (QOLIE-31) scores. RESULTS Of 809 enrolled patients able to complete the AEP questionnaire, 222 had AEP scores ≥45 and were randomized to the intervention (n = 111) or control group (n = 111). A total of 206 patients completed the 18-month follow-up. Compared with baseline, AEP scores decreased on average by 7.2% at 6 months, 12.1% at 12 months, and 13.8% at 18 months in the intervention group ( p < 0.0001), and by 7.7% at 6 months, 9.2% at 12 months, and 12.0% at 18 months in controls ( p < 0.0001). QOLIE-31 scores also improved from baseline to final visit, with a mean 20.7% increase in the intervention group and a mean 24.9% increase in the control group ( p < 0.0001). However, there were no statistically significant differences in outcomes between groups for the 2 co-primary variables. CONCLUSIONS Contrary to findings from a previous study, systematic screening for adverse effects of AEDs using AEP scores did not lead to a reduced burden of toxicity over usual physician treatment. ITALIAN MEDICINES AGENCY AIFA IDENTIFIER FARM52K2WM_003. CLINICALTRIALSGOV IDENTIFIER NCT03939507 (registered retrospectively in 2019; the study was conducted during the 2006-2009 period and registration of clinical trials was not a widely established practice when this study was initiated). CLASSIFICATION OF EVIDENCE This study provides Class II evidence that the additional collection of formal questionnaires regarding adverse effects of AEDs does not reduce toxicity burden over usual physician treatment.",2020,"AEP scores were made available to treating physicians at all visits in the intervention group, but not in the control group.","['206 patients completed the 18-month follow-up', 'Consecutive patients with uncontrolled seizures aged ≥16 years and a high Adverse Event Profile (AEP) score were randomized to 2 groups and followed up for 18 months at 11 referral centers', '809 enrolled patients able to complete the AEP questionnaire, 222 had AEP scores ≥45', 'patients with epilepsy', 'NCT03939507 (registered retrospectively in 2019; the study was conducted during the 2006-2009 period and registration of clinical trials was not a widely established practice when this study was initiated']",['antiepileptic drugs (AEDs'],"['toxicity burden', 'toxicity', 'toxicity burden and improves health-related quality of life', 'AEP scores and Quality of Life Inventory for Epilepsy-31 (QOLIE-31) scores', 'QOLIE-31 scores', 'AEP scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0443211', 'cui_str': 'Established'}]","[{'cui': 'C0003299', 'cui_str': 'ANTIEPILEPTICS'}]","[{'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}]",809.0,0.161817,"AEP scores were made available to treating physicians at all visits in the intervention group, but not in the control group.","[{'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Franco', 'Affiliation': 'From the Clinical Pharmacology Unit (V.F., G.G., E.P.), University of Pavia; IRCCS Mondino Foundation (V.F., C.F., C.A.G., E.P.), Pavia; Epilepsy Center (M.P.C.), San Paolo Hospital, Milan; Magna Graecia University (G.D.S.), Catanzaro; School of Hospital Pharmacy (G.F.), University of Milan; Epilepsy Center (A.L.N.), Neurology Hospital ""Amaducci,"" University of Bari; Unit of Neurology (E.R.), Usl Centro Toscana Health Authority, Prato; University of Foggia (L.M.S.); Epilepsy Center (S.S.), Federico II University, Naples; and IRCCS (P.T.), Institute of Neurological Sciences of Bologna and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy. valentina.franco@unipv.it.'}, {'ForeName': 'Maria Paola', 'Initials': 'MP', 'LastName': 'Canevini', 'Affiliation': 'From the Clinical Pharmacology Unit (V.F., G.G., E.P.), University of Pavia; IRCCS Mondino Foundation (V.F., C.F., C.A.G., E.P.), Pavia; Epilepsy Center (M.P.C.), San Paolo Hospital, Milan; Magna Graecia University (G.D.S.), Catanzaro; School of Hospital Pharmacy (G.F.), University of Milan; Epilepsy Center (A.L.N.), Neurology Hospital ""Amaducci,"" University of Bari; Unit of Neurology (E.R.), Usl Centro Toscana Health Authority, Prato; University of Foggia (L.M.S.); Epilepsy Center (S.S.), Federico II University, Naples; and IRCCS (P.T.), Institute of Neurological Sciences of Bologna and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.'}, {'ForeName': 'Giovambattista', 'Initials': 'G', 'LastName': 'De Sarro', 'Affiliation': 'From the Clinical Pharmacology Unit (V.F., G.G., E.P.), University of Pavia; IRCCS Mondino Foundation (V.F., C.F., C.A.G., E.P.), Pavia; Epilepsy Center (M.P.C.), San Paolo Hospital, Milan; Magna Graecia University (G.D.S.), Catanzaro; School of Hospital Pharmacy (G.F.), University of Milan; Epilepsy Center (A.L.N.), Neurology Hospital ""Amaducci,"" University of Bari; Unit of Neurology (E.R.), Usl Centro Toscana Health Authority, Prato; University of Foggia (L.M.S.); Epilepsy Center (S.S.), Federico II University, Naples; and IRCCS (P.T.), Institute of Neurological Sciences of Bologna and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.'}, {'ForeName': 'Cinzia', 'Initials': 'C', 'LastName': 'Fattore', 'Affiliation': 'From the Clinical Pharmacology Unit (V.F., G.G., E.P.), University of Pavia; IRCCS Mondino Foundation (V.F., C.F., C.A.G., E.P.), Pavia; Epilepsy Center (M.P.C.), San Paolo Hospital, Milan; Magna Graecia University (G.D.S.), Catanzaro; School of Hospital Pharmacy (G.F.), University of Milan; Epilepsy Center (A.L.N.), Neurology Hospital ""Amaducci,"" University of Bari; Unit of Neurology (E.R.), Usl Centro Toscana Health Authority, Prato; University of Foggia (L.M.S.); Epilepsy Center (S.S.), Federico II University, Naples; and IRCCS (P.T.), Institute of Neurological Sciences of Bologna and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.'}, {'ForeName': 'Guido', 'Initials': 'G', 'LastName': 'Fedele', 'Affiliation': 'From the Clinical Pharmacology Unit (V.F., G.G., E.P.), University of Pavia; IRCCS Mondino Foundation (V.F., C.F., C.A.G., E.P.), Pavia; Epilepsy Center (M.P.C.), San Paolo Hospital, Milan; Magna Graecia University (G.D.S.), Catanzaro; School of Hospital Pharmacy (G.F.), University of Milan; Epilepsy Center (A.L.N.), Neurology Hospital ""Amaducci,"" University of Bari; Unit of Neurology (E.R.), Usl Centro Toscana Health Authority, Prato; University of Foggia (L.M.S.); Epilepsy Center (S.S.), Federico II University, Naples; and IRCCS (P.T.), Institute of Neurological Sciences of Bologna and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.'}, {'ForeName': 'Carlo Andrea', 'Initials': 'CA', 'LastName': 'Galimberti', 'Affiliation': 'From the Clinical Pharmacology Unit (V.F., G.G., E.P.), University of Pavia; IRCCS Mondino Foundation (V.F., C.F., C.A.G., E.P.), Pavia; Epilepsy Center (M.P.C.), San Paolo Hospital, Milan; Magna Graecia University (G.D.S.), Catanzaro; School of Hospital Pharmacy (G.F.), University of Milan; Epilepsy Center (A.L.N.), Neurology Hospital ""Amaducci,"" University of Bari; Unit of Neurology (E.R.), Usl Centro Toscana Health Authority, Prato; University of Foggia (L.M.S.); Epilepsy Center (S.S.), Federico II University, Naples; and IRCCS (P.T.), Institute of Neurological Sciences of Bologna and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.'}, {'ForeName': 'Giuliana', 'Initials': 'G', 'LastName': 'Gatti', 'Affiliation': 'From the Clinical Pharmacology Unit (V.F., G.G., E.P.), University of Pavia; IRCCS Mondino Foundation (V.F., C.F., C.A.G., E.P.), Pavia; Epilepsy Center (M.P.C.), San Paolo Hospital, Milan; Magna Graecia University (G.D.S.), Catanzaro; School of Hospital Pharmacy (G.F.), University of Milan; Epilepsy Center (A.L.N.), Neurology Hospital ""Amaducci,"" University of Bari; Unit of Neurology (E.R.), Usl Centro Toscana Health Authority, Prato; University of Foggia (L.M.S.); Epilepsy Center (S.S.), Federico II University, Naples; and IRCCS (P.T.), Institute of Neurological Sciences of Bologna and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'La Neve', 'Affiliation': 'From the Clinical Pharmacology Unit (V.F., G.G., E.P.), University of Pavia; IRCCS Mondino Foundation (V.F., C.F., C.A.G., E.P.), Pavia; Epilepsy Center (M.P.C.), San Paolo Hospital, Milan; Magna Graecia University (G.D.S.), Catanzaro; School of Hospital Pharmacy (G.F.), University of Milan; Epilepsy Center (A.L.N.), Neurology Hospital ""Amaducci,"" University of Bari; Unit of Neurology (E.R.), Usl Centro Toscana Health Authority, Prato; University of Foggia (L.M.S.); Epilepsy Center (S.S.), Federico II University, Naples; and IRCCS (P.T.), Institute of Neurological Sciences of Bologna and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.'}, {'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Rosati', 'Affiliation': 'From the Clinical Pharmacology Unit (V.F., G.G., E.P.), University of Pavia; IRCCS Mondino Foundation (V.F., C.F., C.A.G., E.P.), Pavia; Epilepsy Center (M.P.C.), San Paolo Hospital, Milan; Magna Graecia University (G.D.S.), Catanzaro; School of Hospital Pharmacy (G.F.), University of Milan; Epilepsy Center (A.L.N.), Neurology Hospital ""Amaducci,"" University of Bari; Unit of Neurology (E.R.), Usl Centro Toscana Health Authority, Prato; University of Foggia (L.M.S.); Epilepsy Center (S.S.), Federico II University, Naples; and IRCCS (P.T.), Institute of Neurological Sciences of Bologna and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.'}, {'ForeName': 'Luigi Maria', 'Initials': 'LM', 'LastName': 'Specchio', 'Affiliation': 'From the Clinical Pharmacology Unit (V.F., G.G., E.P.), University of Pavia; IRCCS Mondino Foundation (V.F., C.F., C.A.G., E.P.), Pavia; Epilepsy Center (M.P.C.), San Paolo Hospital, Milan; Magna Graecia University (G.D.S.), Catanzaro; School of Hospital Pharmacy (G.F.), University of Milan; Epilepsy Center (A.L.N.), Neurology Hospital ""Amaducci,"" University of Bari; Unit of Neurology (E.R.), Usl Centro Toscana Health Authority, Prato; University of Foggia (L.M.S.); Epilepsy Center (S.S.), Federico II University, Naples; and IRCCS (P.T.), Institute of Neurological Sciences of Bologna and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Striano', 'Affiliation': 'From the Clinical Pharmacology Unit (V.F., G.G., E.P.), University of Pavia; IRCCS Mondino Foundation (V.F., C.F., C.A.G., E.P.), Pavia; Epilepsy Center (M.P.C.), San Paolo Hospital, Milan; Magna Graecia University (G.D.S.), Catanzaro; School of Hospital Pharmacy (G.F.), University of Milan; Epilepsy Center (A.L.N.), Neurology Hospital ""Amaducci,"" University of Bari; Unit of Neurology (E.R.), Usl Centro Toscana Health Authority, Prato; University of Foggia (L.M.S.); Epilepsy Center (S.S.), Federico II University, Naples; and IRCCS (P.T.), Institute of Neurological Sciences of Bologna and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Tinuper', 'Affiliation': 'From the Clinical Pharmacology Unit (V.F., G.G., E.P.), University of Pavia; IRCCS Mondino Foundation (V.F., C.F., C.A.G., E.P.), Pavia; Epilepsy Center (M.P.C.), San Paolo Hospital, Milan; Magna Graecia University (G.D.S.), Catanzaro; School of Hospital Pharmacy (G.F.), University of Milan; Epilepsy Center (A.L.N.), Neurology Hospital ""Amaducci,"" University of Bari; Unit of Neurology (E.R.), Usl Centro Toscana Health Authority, Prato; University of Foggia (L.M.S.); Epilepsy Center (S.S.), Federico II University, Naples; and IRCCS (P.T.), Institute of Neurological Sciences of Bologna and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.'}, {'ForeName': 'Emilio', 'Initials': 'E', 'LastName': 'Perucca', 'Affiliation': 'From the Clinical Pharmacology Unit (V.F., G.G., E.P.), University of Pavia; IRCCS Mondino Foundation (V.F., C.F., C.A.G., E.P.), Pavia; Epilepsy Center (M.P.C.), San Paolo Hospital, Milan; Magna Graecia University (G.D.S.), Catanzaro; School of Hospital Pharmacy (G.F.), University of Milan; Epilepsy Center (A.L.N.), Neurology Hospital ""Amaducci,"" University of Bari; Unit of Neurology (E.R.), Usl Centro Toscana Health Authority, Prato; University of Foggia (L.M.S.); Epilepsy Center (S.S.), Federico II University, Naples; and IRCCS (P.T.), Institute of Neurological Sciences of Bologna and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Neurology,['10.1212/WNL.0000000000009880'] 1781,32599215,Who Enrolls in an Online Cancer Survivorship Program? Reach of the INSPIRE Randomized Controlled Trial for Hematopoietic Cell Transplantation Survivors.,"The Internet can be a valuable tool in delivering survivorship care to hematopoietic cell transplantation (HCT) cancer survivors. We describe the reach of INSPIRE, an Internet and social media-based randomized controlled trial, to address healthcare and psychosocial needs of HCT survivors. All survivors 2-10 years after HCT for hematologic malignancy or myelodysplasia from 6 transplantation centers in the US were approached by mail and follow-up calls. Eligible participants had access to the Internet, an email address, and did not have active disease in the past 2 years. We used logistic regression to determine characteristics of eligible survivors who were more or less likely to enroll. Of 2578 eligible HCT survivors, 1065 (41%) enrolled in the study. The mean age of enrollees was 56.3 ± 12.6 years (range, 19 to 89 years), 52% were male, and 94% were white. Survivors less likely to enroll included those who were male, age <40 years, and who received an autologous transplant (all P < .001). Compared with white survivors, African Americans were less likely to enroll (P < .001), whereas Native Americans/Alaska Natives were more likely to join the study (P = .03). The reach of the INSPIRE program was broad, including to survivors who traditionally have less access to resources, such as Native Americans/Alaskan Natives and rural residents. Strategies are still needed to improve the enrollment of online studies of survivorship resources for males, young adults, African American, and autologous HCT survivors, because their use may improve outcomes.",2020,"Compared with survivors of white race, African Americans were less likely to enroll (P<.001) while Native Americans/Alaska Natives were more likely to join the study (P=.03). ","['eligible survivors who were more or less likely to enroll', 'Survivors less likely to enroll included those who were male, age younger than 40, and who received an autologous transplant (all P<.001', 'hematopoietic cell transplantation survivors', 'Native Americans/Alaskan Natives and rural residents', 'hematopoietic cell transplantation (HCT) cancer survivors', 'Eligible participants had access to the internet, an email address, and did not have active disease in the past two years', '2578 eligible HCT survivors, 1065 (41%) enrolled in the study', 'Mean age of enrollees was 56.3 (SD=12.6; age range 19 to 89 years), 52% were male, and 94% were White']",['HCT'],[],"[{'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0040736', 'cui_str': 'Autogenous transplantation'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0282204', 'cui_str': 'Native Americans'}, {'cui': 'C0682125', 'cui_str': 'Native Alaskians'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}]","[{'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}]",[],2578.0,0.117693,"Compared with survivors of white race, African Americans were less likely to enroll (P<.001) while Native Americans/Alaska Natives were more likely to join the study (P=.03). ","[{'ForeName': 'Jean C', 'Initials': 'JC', 'LastName': 'Yi', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address: jyi@fredhutch.org.'}, {'ForeName': 'Brie', 'Initials': 'B', 'LastName': 'Sullivan', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Wendy M', 'Initials': 'WM', 'LastName': 'Leisenring', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Navneet S', 'Initials': 'NS', 'LastName': 'Majhail', 'Affiliation': 'Clevel and Clinic, Cleveland, Ohio.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Jim', 'Affiliation': 'Moffitt Cancer Center, Tampa, Florida.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Loren', 'Affiliation': 'University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Uberti', 'Affiliation': 'Barbara Ann Karmanos Cancer Institute, Detroit, Michigan.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Whalen', 'Affiliation': 'University of Nebraska, Omaha, Nebraska.'}, {'ForeName': 'Mary E D', 'Initials': 'MED', 'LastName': 'Flowers', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; University of Washington School of Medicine, Seattle, Washington.'}, {'ForeName': 'Stephanie J', 'Initials': 'SJ', 'LastName': 'Lee', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; University of Washington School of Medicine, Seattle, Washington.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Maynard', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Karen L', 'Initials': 'KL', 'LastName': 'Syrjala', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; University of Washington School of Medicine, Seattle, Washington.'}]",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,['10.1016/j.bbmt.2020.06.017'] 1782,32684055,A Pragmatic Study of the Impact of a Brief Mindfulness Intervention on Prisoners and Staff in a Category B Prison and Men Subject to Community-Based Probation Supervision.,"OBJECTIVES This article presents two studies assessing the impact of mindfulness in prison (prisoners and staff) and non-custodial settings. METHOD Study 1-prisoners ( n  = 17) and staff ( n  = 15) in a UK prison completed a mindfulness program; 16 individuals acted as a single time point comparison. Data were collected using self-report, computer based and physiological measurement. Study 2-men under community probation supervision were allocated to mindfulness (completed, n  = 28) or TAU ( n  = 27). Data were collected using self-report mindfulness measures. RESULTS Study 1-statistically significant (increases in mindfulness skills (η 2 p  = .234 to η 2 p  = .388), cognitive control (η 2 p  = .28), and heart rate variability (SDNN; η 2 p  = .41) along with significant decreases in stress (η 2 p  = .398) were found. In study 2, the mindfulness group showed non-significant improvements in mindfulness skills. CONCLUSION The findings suggest brief mindfulness interventions could make an important contribution to offender rehabilitation and custodial staff wellbeing.",2020,"RESULTS Study 1-statistically significant (increases in mindfulness skills (η 2 p  = .234 to η 2 p  = .388), cognitive control (η 2 p  = .28), and heart rate variability (SDNN; η 2 p  = .41) along with significant decreases in stress (η 2 p  = .398) were found.","['Study 2-men under community probation supervision', 'Study 1-prisoners ( n \u2009=\u200917) and staff ( n \u2009=\u200915) in a UK prison completed a mindfulness program; 16 individuals acted as a single time point comparison', 'prison (prisoners and staff) and non-custodial settings', 'Prisoners and Staff in a Category B Prison and Men Subject to Community-Based Probation Supervision']","['TAU', 'Brief Mindfulness Intervention']","['cognitive control', 'heart rate variability', 'mindfulness skills', 'stress']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C0033167', 'cui_str': 'Prisoners'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0033168', 'cui_str': 'Prisons'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0557638', 'cui_str': 'Category B prison'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]",,0.0124414,"RESULTS Study 1-statistically significant (increases in mindfulness skills (η 2 p  = .234 to η 2 p  = .388), cognitive control (η 2 p  = .28), and heart rate variability (SDNN; η 2 p  = .41) along with significant decreases in stress (η 2 p  = .398) were found.","[{'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Davies', 'Affiliation': 'Swansea University, Swansea, UK.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Ugwudike', 'Affiliation': 'University of Southampton, UK.'}, {'ForeName': 'Hayley', 'Initials': 'H', 'LastName': 'Young', 'Affiliation': 'Swansea University, Swansea, UK.'}, {'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Hurrell', 'Affiliation': 'Swansea University, Swansea, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Raynor', 'Affiliation': 'Swansea University, Swansea, UK.'}]",International journal of offender therapy and comparative criminology,['10.1177/0306624X20944664'] 1783,32684076,Video-guided exercise after stroke: a feasibility randomised controlled trial.,"BACKGROUND Facilitating self-directed upper-limb exercise in people after a stroke whilst not in therapy sessions may increase therapy intensity and improve outcomes. Objectives: To investigate the feasibility and acceptability of video-guided exercise for facilitating upper-limb exercise after stroke. METHODS A single-blind feasibility randomized controlled trial with embedded qualitative study in stroke wards at a large teaching hospital in the United Kingdom. Fourteen participants with stroke were randomized to either video-guided exercise intervention or a ""treatment-as-usual"" control group. Intervention participants received a computer tablet containing filmed individualized exercises to guide out of therapy practice. The primary outcome measure was the Motor status scale (MSS) for the upper limb, which was used to guide possible sample sizes for a future main trial. Qualitative focus group and interview data on feasibility/acceptability were collected and analyzed. RESULTS The intervention was acceptable, but the need for motivation/support to exercise was highlighted. Based on similar assumptions to the feasibility study, circa ninety-two patients in each group would be needed to detect a difference of 5 in upper-limb motor status for a main trial. CONCLUSION A trial of video-guided exercise is feasible, although an optimal main trial would require some relatively minor changes to design, outcome measures, eligibility, and the intervention.",2020,"Fourteen participants with stroke were randomized to either video-guided exercise intervention or a ""treatment-as-usual"" control group.","['Fourteen participants with stroke', 'stroke wards at a large teaching hospital in the United Kingdom']","['computer tablet containing filmed individualized exercises', 'Video-guided exercise', 'video-guided exercise', 'video-guided exercise intervention or a ""treatment-as-usual"" control group']","['Motor status scale (MSS', 'feasibility/acceptability']","[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom of Great Britain and Northern Ireland'}]","[{'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",14.0,0.115007,"Fourteen participants with stroke were randomized to either video-guided exercise intervention or a ""treatment-as-usual"" control group.","[{'ForeName': 'Madeleine', 'Initials': 'M', 'LastName': 'Kenny', 'Affiliation': 'G Floor Physiotherapy Department, Leeds Teaching Hospitals Trust , Leeds, UK.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Gilmartin', 'Affiliation': 'School of Healthcare, University of Leeds , Leeds, UK.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Thompson', 'Affiliation': 'School of Healthcare, University of Leeds , Leeds, UK.'}]",Physiotherapy theory and practice,['10.1080/09593985.2020.1790072'] 1784,32684094,Piloting a Dementia Caregiver Intervention in a Primary Care Setting.,"OBJECTIVES The purpose of this pilot study is to examine the efficacy of a theoretically based, 6-week dementia caregiver support group in a primary care setting. METHODS Using a quasi-experimental design, 22 participants completed the caregiver support group. Participants were mostly in their mid-60 s ( M  = 63 years old), female ( n  = 19), Caucasian ( n  = 14), and identified as either the care recipient's child or spouse ( n  = 19). At baseline and 6 weeks, participants completed self-report measures related to demographic information, caregiver preparedness, strain, and depressive symptoms, and care recipient's neuropsychiatric symptoms. Participants also completed a satisfaction survey. Within-subjects t -tests were run to determine if participants' scores changed over time. RESULTS Results revealed that participants demonstrated a significant increase in mean caregiver preparedness scores. No significant effects were found for caregiver strain, depressive symptoms, and distress related to neuropsychiatric symptoms. Participants rated being largely satisfied with the program. CONCLUSIONS Results suggest that this 6-week caregiver support group may be a promising caregiver intervention in primary care clinics. CLINICAL IMPLICATIONS Findings support the importance of caregiver support for persons with dementia in primary care.",2020,"No significant effects were found for caregiver strain, depressive symptoms, and distress related to neuropsychiatric symptoms.","[""63\xa0years old), female ( n \xa0=\xa019), Caucasian ( n \xa0=\xa014), and identified as either the care recipient's child or spouse ( n \xa0=\xa019"", 'persons with dementia in primary care', '22 participants completed the caregiver support group']",[],"['caregiver strain, depressive symptoms, and distress related to neuropsychiatric symptoms', ""demographic information, caregiver preparedness, strain, and depressive symptoms, and care recipient's neuropsychiatric symptoms"", 'mean caregiver preparedness scores']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0162409', 'cui_str': 'Spouse'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0150162', 'cui_str': 'Caregiver support'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",[],"[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C4285807', 'cui_str': 'Behavioral and psychological symptoms of dementia'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",22.0,0.039451,"No significant effects were found for caregiver strain, depressive symptoms, and distress related to neuropsychiatric symptoms.","[{'ForeName': 'Mona Shah', 'Initials': 'MS', 'LastName': 'Barman', 'Affiliation': 'Department of Psychology, University of Central Florida , Orlando, Florida, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Paulson', 'Affiliation': 'Department of Psychology, University of Central Florida , Orlando, Florida, USA.'}]",Clinical gerontologist,['10.1080/07317115.2020.1791294'] 1785,32605501,Randomised controlled trial of 1% and 5% 5-fluorouracil creams compared with 90% trichloroacetic acid solution for anogenital wart treatment.,"To evaluate the efficacy and safety of 1% and 5% 5-fluorouracil (5-FU) creams compared with 90% trichloroacetic acid (TCA) for the treatment of anogenital warts. we conducted a randomised controlled study in 72 subjects allocated to three groups: 1% 5-FU, 90% TCA and 5% 5-FU; 90% TCA was administered once a week, whereas 5-FU cream was applied three times a week. Response to therapy and side-effects were evaluated weekly for seven weeks. Evaluation at week 7 demonstrated that there was no significant difference in the efficacy between 1% 5-FU cream and 90% TCA ( p  =   0.763) or between 5% 5-FU cream and 90% TCA ( p  =   0.274). Subjective side-effects with 1% 5-FU were significantly milder than 90% TCA; however, significantly milder objective side-effects were observed only at weeks 2, 6 and 7. The subjective side-effects with 5% 5-FU were also significantly milder than 90% TCA; however, significantly milder objective side-effects were observed only at week 2. 5-FU may become an alternative topical therapy as it offers the benefit of self-application; furthermore, a concentration of 1% 5-FU cream is recommended due to milder side-effects.",2020,Evaluation at week 7 demonstrated that there was no significant difference in the efficacy between 1% 5-FU cream and 90% TCA ( p  =   0.763) or between 5% 5-FU cream and 90% TCA ( p  =   0.274).,"['anogenital warts', '72 subjects allocated to three groups: 1']","['trichloroacetic acid (TCA', '5-FU cream', 'TCA', '90% trichloroacetic acid solution', '5-FU, 90% TCA and 5% 5-FU', '5-fluorouracil (5-FU) creams', '5-fluorouracil creams', '5-FU']","['Subjective side-effects', 'subjective side-effects', 'efficacy and safety', 'efficacy', 'milder objective side-effects']","[{'cui': 'C0009663', 'cui_str': 'Genital warts'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0040900', 'cui_str': 'Trichloroacetic acid'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018017', 'cui_str': 'Goal'}]",,0.0163803,Evaluation at week 7 demonstrated that there was no significant difference in the efficacy between 1% 5-FU cream and 90% TCA ( p  =   0.763) or between 5% 5-FU cream and 90% TCA ( p  =   0.274).,"[{'ForeName': 'Ika', 'Initials': 'I', 'LastName': 'Anggraini', 'Affiliation': 'Department of Dermatology and Venereology, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.'}, {'ForeName': 'Aida Sd', 'Initials': 'AS', 'LastName': 'Hoemardani', 'Affiliation': 'Department of Dermatology and Venereology, Dharmais Cancer National Hospital, Jakarta, Indonesia.'}, {'ForeName': 'Hanny', 'Initials': 'H', 'LastName': 'Nilasari', 'Affiliation': 'Department of Dermatology and Venereology, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.'}, {'ForeName': 'Wresti', 'Initials': 'W', 'LastName': 'Indriatmi', 'Affiliation': 'Department of Dermatology and Venereology, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.'}]",International journal of STD & AIDS,['10.1177/0956462420925250'] 1786,32683755,First-trimester screening based on cell-free DNA vs combined screening: a randomized clinical trial on women's experience.,"OBJECTIVE To compare women's experience of first-trimester combined screening (FTCS), with women's experience of an approach that uses the combination of a detailed early anatomy scan and cell-free DNA (cfDNA) analysis. METHODS This was single-center, open label, parallel group, randomized clinical trial. Pregnant women were randomized at the time of their first prenatal visit to either a policy of first-trimester risk assessment based on FTCS, or to a policy of first-trimester risk assessment based on ultrasound findings and cfDNA. Control group included first-trimester risk assessment based on FTCS. FTCS included ultrasound evaluation with crown-rump length, nuchal translucency (NT) measurement, and a detailed ultrasound scan, along with biochemistry (PAPP-A and free beta hCG). In this group, diagnostic testing was offered to patients with risk >1 in 100, or NT >3.5 mm, or any fetal abnormalities on ultrasound. Women randomized in the intervention group received an approach of first-trimester risk assessment based on ultrasound findings and cfDNA. cfDNA analysis included a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. In the intervention group, diagnostic testing was offered to patients with abnormal cfDNA screening results, or NT >3.5 mm, or any fetal abnormalities on ultrasound. Participants received pre-test and post-test questionnaires regarding to measure reassurance, satisfaction, and anxiety. The primary outcome was the post-test reassurance, defined as mean score of reassurance post-test questionnaire. The effect of the assigned screening test on the cumulative incidence or on the mean of each outcome was quantified as the relative risk (RR) or mean difference (MD) with 95% confidence interval (CI). RESULTS 40 women with singleton gestations were included in the trial. Mean score for reassurance was significantly higher in the cfDNA group compared to the FTCS group in the pre-test questionnaire (MD 0.80 points, 95% CI 0.27 to 1.33) and in the post-test questionnaire (MD 16.50 points, 95% CI 2.18 to 30.82). Women randomized to the cfDNA group had higher satisfication and lower mean anxiety score as assessed in the STAI pre-test questionnaire. CONCLUSIONS First-trimester risk assessment for trisomy 21 with a combination of a detailed ultrasound examination and cfDNA is associated with better maternal reassurance and better maternal satisfaction compared to the standard first-trimester combined screening with nuchal trasclucency, and maternal serum free beta-human chorionic gonadotrophin (FbetahCG) and pregnancy-associated plasma protein A (PAPP-A). This article is protected by copyright. All rights reserved.",2020,"Women randomized to the cfDNA group had higher satisfication and lower mean anxiety score as assessed in the STAI pre-test questionnaire. ","['Pregnant women', '40 women with singleton gestations', ""women's experience""]","['cfDNA', 'first-trimester combined screening (FTCS', 'FTCS', 'approach of first-trimester risk assessment based on ultrasound findings and cfDNA', 'First-trimester screening based on cell-free DNA vs combined screening', 'policy of first-trimester risk assessment based on FTCS, or to a policy of first-trimester risk assessment based on ultrasound findings and cfDNA']","['ultrasound evaluation with crown-rump length, nuchal translucency (NT) measurement', 'Mean score for reassurance', 'maternal reassurance and better maternal satisfaction', 'post-test reassurance, defined as mean score of reassurance post-test questionnaire', 'mean anxiety score']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]","[{'cui': 'C4289789', 'cui_str': 'Cell free DNA'}, {'cui': 'C0032979', 'cui_str': 'First trimester pregnancy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0086930', 'cui_str': 'Risk assessment'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1299966', 'cui_str': 'Ultrasound scan finding'}, {'cui': 'C0242456', 'cui_str': 'Policy'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C2825540', 'cui_str': 'Crown rump length'}, {'cui': 'C1449855', 'cui_str': 'Nuchal Fold'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0204558', 'cui_str': 'Group reassurance'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",40.0,0.147153,"Women randomized to the cfDNA group had higher satisfication and lower mean anxiety score as assessed in the STAI pre-test questionnaire. ","[{'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Migliorini', 'Affiliation': 'Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Saccone', 'Affiliation': 'Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Fiora', 'Initials': 'F', 'LastName': 'Silvestro', 'Affiliation': 'Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Massaro', 'Affiliation': 'Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Arduino', 'Affiliation': 'Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Pietro', 'Initials': 'P', 'LastName': ""D'Alessandro"", 'Affiliation': 'Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Maria Teresa', 'Initials': 'MT', 'LastName': 'Petti', 'Affiliation': 'Department of Molecular Medicine and Medical Biotechnologies, School of Medicine, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Jessica Anna Cinzia', 'Initials': 'JAC', 'LastName': 'Paino', 'Affiliation': 'Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Guida', 'Affiliation': 'Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Mariavittoria', 'Initials': 'M', 'LastName': 'Locci', 'Affiliation': 'Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.'}, {'ForeName': 'Fulvio', 'Initials': 'F', 'LastName': 'Zullo', 'Affiliation': 'Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.'}]",Prenatal diagnosis,['10.1002/pd.5800'] 1787,32595959,The effects of a temporal processing-based auditory training program on the auditory skills of elderly users of hearing aids: a study protocol for a randomized clinical trial.,"Background : One of the most important effects of age-related declines in neural processing speed is the impairment of temporal resolution, which leads to difficulty hearing in noisy environments. Since the central auditory system is highly plastic, by designing and implementing a temporal processing-based auditory training program, we can help the elderly improve their listening skills and speech understanding in noisy environments. Methods: In the first phase of this research, based on the theoretical framework of temporal processing, an auditory training solution was developed as a software program. In the second phase, which will be described in the present study, the effects of the designed program on the listening skills of the elderly users of hearing aids (age: 60-75 years) will be studied in the control and intervention groups. In the intervention group, the auditory training program will be implemented for three months (36 sessions), and the results of central tests (GIN, DPT, QuickSIN) and the electrophysiological speech-ABR test will be compared in both groups before, immediately and one month after the intervention. Discussion : Since temporal processing is not sufficient in auditory training programs for the elderly with hearing impairments, implementation of a temporal processing-based auditory training program can reduce hearing problems in noisy environments among elderly users of hearing aids. Trial registration: This study was registered as a clinical trial in the Iranian Registry of Clinical Trials ( IRCT20190921044838N1) on December 25, 2019.",2020,"In the first phase of this research, based on the theoretical framework of temporal processing, an auditory training solution was developed as a software program.","['elderly users of hearing aids (age: 60-75 years', 'elderly users of hearing aids', 'elderly with hearing impairments']","[' ', 'temporal processing-based auditory training program', 'auditory training program']",['auditory skills'],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0018768', 'cui_str': 'Hearing aid'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}]","[{'cui': 'C0442043', 'cui_str': 'Temporal'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0439825', 'cui_str': 'Auditory'}]",,0.027288,"In the first phase of this research, based on the theoretical framework of temporal processing, an auditory training solution was developed as a software program.","[{'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Sattari', 'Affiliation': 'Department of Audiology, Rehabilitation Research Center, School of Rehabilitation Sciences, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Nariman', 'Initials': 'N', 'LastName': 'Rahbar', 'Affiliation': 'Department of Audiology, Rehabilitation Research Center, School of Rehabilitation Sciences, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Ahadi', 'Affiliation': 'Department of Audiology, Rehabilitation Research Center, School of Rehabilitation Sciences, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Haghani', 'Affiliation': 'Department of Biostatistics, School of Management and Information Technology, Iran University of Medical Sciences, Tehran, Iran.'}]",F1000Research,['10.12688/f1000research.22757.2'] 1788,32602148,Antacid Monotherapy Is More Effective in Relieving Epigastric Pain Than in Combination With Lidocaine: A Randomized Double-blind Clinical Trial.,,2020,"This was a double-blind, randomized clinical trial comparing three different solutions for the treatment of adults with epigastric pain or dyspepsia presenting to the emergency department (ED).","['Royal Melbourne Hospital, a tertiary, adult-only, inner-city center in Melbourne with 75,000 annual ED visits', 'adults with epigastric pain or dyspepsia presenting to the emergency department (ED']","['Antacid monotherapy', 'lidocaine']",['epigastric pain'],"[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0557849', 'cui_str': 'Inner city'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0232493', 'cui_str': 'Epigastric pain'}, {'cui': 'C0013395', 'cui_str': 'Indigestion'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}]","[{'cui': 'C0003138', 'cui_str': 'Antacid'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}]","[{'cui': 'C0232493', 'cui_str': 'Epigastric pain'}]",,0.679809,"This was a double-blind, randomized clinical trial comparing three different solutions for the treatment of adults with epigastric pain or dyspepsia presenting to the emergency department (ED).","[{'ForeName': 'Jaimee', 'Initials': 'J', 'LastName': 'Warren', 'Affiliation': 'From the, Emergency Department, Royal Melbourne Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Blake', 'Initials': 'B', 'LastName': 'Cooper', 'Affiliation': 'From the, Emergency Department, Royal Melbourne Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Jermakoff', 'Affiliation': 'From the, Emergency Department, Royal Melbourne Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Jonathan C', 'Initials': 'JC', 'LastName': 'Knott', 'Affiliation': 'From the, Emergency Department, Royal Melbourne Hospital, Melbourne, Victoria, Australia.'}]",Academic emergency medicine : official journal of the Society for Academic Emergency Medicine,['10.1111/acem.14069'] 1789,32601973,Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.,"PURPOSE The aim of the current study was to evaluate the effect of N-acetylcysteine (NAC) on the incidence and severity of paclitaxel-induced peripheral neuropathy (PIPN) in breast cancer patients. METHOD A prospective randomized controlled open label study was conducted on 75 breast cancer patients receiving adjuvant paclitaxel 80 mg/m 2 weekly for 12 weeks. Eligible patients were randomized to either the low dose group; 1200 mg daily NAC, the high dose group; 1200 mg NAC twice daily or the control group; received paclitaxel only. The primary endpoint was the incidence of different grades of PIPN using National Cancer Institute's common toxicity criteria for adverse event (NCI-CTCAE) while secondary endpoints were the severity of PIPN using modified total neuropathy score (mTNS), quality of life (QOL) using Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT-GOG-NTX) subscale, serum nerve growth factor (NGF), and serum malondialdehyde (MDA). RESULTS At the end of the 12-week period, the incidence of grade (2, 3) peripheral neuropathy was significantly lower in the high dose group (28.6%) compared to the low dose group (61.9%) and the control group (100%), p value < 0.001. A significant improvement in the mTNS and QOL scores was observed after 6 and 12 weeks in the high dose group and the low dose group compared to the control, p value < 0.001. Significantly higher levels of serum NGF in the high dose group and lower level of serum MDA in the high dose and the low dose group were observed. CONCLUSION Oral NAC (1200 mg once and twice daily) might reduce the incidence and severity of PIPN and improve the patients' QOL. TRIAL REGISTRY Clinical Trial.gov registration number: NCT03492047.",2020,"Significantly higher levels of serum NGF in the high dose group and lower level of serum MDA in the high dose and the low dose group were observed. ","['breast cancer patients', '75 breast cancer patients receiving', 'Eligible patients', '80\xa0mg/m 2 weekly for 12\xa0weeks']","['N-acetylcysteine (NAC', 'adjuvant paclitaxel', 'Oral NAC', 'low dose group; 1200\xa0mg daily NAC, the high dose group; 1200\xa0mg NAC twice daily or the control group; received paclitaxel only', 'N-acetylcysteine']","['serum NGF', 'mTNS and QOL scores', ""incidence and severity of PIPN and improve the patients' QOL"", 'severity of PIPN using modified total neuropathy score (mTNS), quality of life (QOL) using Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity', 'incidence of grade (2, 3) peripheral neuropathy', 'FACT-GOG-NTX) subscale, serum nerve growth factor (NGF), and serum malondialdehyde (MDA', 'level of serum MDA', ""incidence of different grades of PIPN using National Cancer Institute's common toxicity criteria for adverse event (NCI-CTCAE""]","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517548', 'cui_str': '1200'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0027752', 'cui_str': 'Nerve Growth Factor'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C4727882', 'cui_str': 'Total neuropathy score'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1321164', 'cui_str': 'Gynecological oncology'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0235032', 'cui_str': 'Neurotoxicity'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0000379', 'cui_str': 'Methylenedioxyamphetamine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1513882', 'cui_str': 'National Cancer Institute'}, {'cui': 'C1516728', 'cui_str': 'National Cancer Institute common terminology criteria for adverse events'}, {'cui': 'C0560007', 'cui_str': 'nCi'}]",75.0,0.0327264,"Significantly higher levels of serum NGF in the high dose group and lower level of serum MDA in the high dose and the low dose group were observed. ","[{'ForeName': 'Hadeer G', 'Initials': 'HG', 'LastName': 'Khalefa', 'Affiliation': 'Oncology Clinical Pharmacy Department, Nasser Institute for Research and Treatment, Cairo, Egypt.'}, {'ForeName': 'May A', 'Initials': 'MA', 'LastName': 'Shawki', 'Affiliation': 'Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. mayahmed@pharma.asu.edu.eg.'}, {'ForeName': 'Rasha', 'Initials': 'R', 'LastName': 'Aboelhassan', 'Affiliation': 'Nasser Institute for Research and Treatment, Cairo, Egypt.'}, {'ForeName': 'Lamia M', 'Initials': 'LM', 'LastName': 'El Wakeel', 'Affiliation': 'Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.'}]",Breast cancer research and treatment,['10.1007/s10549-020-05762-8'] 1790,32598941,Unskilled shooters improve both accuracy and grouping shot having as reference skilled shooters cortical area: An EEG and tDCS study.,"Transcranial direct current stimulation (tDCS) has been used as a non-invasive method for enhanced motor and cognitive abilities. However, no previous study has investigated if the tDCS application in unskilled shooters on cortical sites, selected based on the cortical activity of skilled shooters, improves the accuracy and shot grouping. Sixty participants were selected, which included 10 skilled shooters and 50 unskilled shooters. After we identified the right dorsolateral prefrontal cortex (DLPFC) as the area with the highest activity in skilled shooters, we applied anodal tDCS over the right DLPFC in the unskilled shooters under two conditions: sham-tDCS (placebo) and real-tDCS (anodal tDCS). We also analyzed electroencephalography. Our results indicated that anodal tDCS application enhanced the shot accuracy (p = 0.001). Furthermore, the beta power in the EEG recording was higher in the left DLPFC, left and right parietal cortex (p = 0,001) after applying anodal tDCS, while the low-gamma power was higher in the right DLPFC in sham-tDCS (p = 0.001) and right parietal cortex after anodal-tDCS (p = 0.001). Our findings indicate that anodal tDCS can improve accuracy and shot grouping when applied over the unskilled shooters' right DLPFC. Furthermore, beta and low-gamma bands are influenced by anodal tDCS over the right DLPFC, which may be predictive of skill improvement.",2020,Our findings indicate that anodal tDCS can improve accuracy and shot grouping when applied over the unskilled shooters' right DLPFC.,"['Sixty participants were selected, which included 10 skilled shooters and 50 unskilled shooters']","['tDCS (placebo) and real-tDCS (anodal tDCS', 'Transcranial direct current stimulation (tDCS', 'anodal tDCS']",['beta power in the EEG recording'],"[{'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}]",60.0,0.0141525,Our findings indicate that anodal tDCS can improve accuracy and shot grouping when applied over the unskilled shooters' right DLPFC.,"[{'ForeName': 'Kaline', 'Initials': 'K', 'LastName': 'Rocha', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil; The Northeast Biotechnology Network, Federal University of Piauí, Teresina, Brazil. Electronic address: kalinemrocha@gmail.com.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Marinho', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil; The Northeast Biotechnology Network, Federal University of Piauí, Teresina, Brazil.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Magalhães', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil; The Northeast Biotechnology Network, Federal University of Piauí, Teresina, Brazil.'}, {'ForeName': 'Valécia', 'Initials': 'V', 'LastName': 'Carvalho', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil; The Northeast Biotechnology Network, Federal University of Piauí, Teresina, Brazil.'}, {'ForeName': 'Thayaná', 'Initials': 'T', 'LastName': 'Fernandes', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil.'}, {'ForeName': 'Marcos', 'Initials': 'M', 'LastName': 'Ayres', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil; The Northeast Biotechnology Network, Federal University of Piauí, Teresina, Brazil.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Crespo', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil.'}, {'ForeName': 'Bruna', 'Initials': 'B', 'LastName': 'Velasques', 'Affiliation': 'Brain Mapping and Sensory Motor Integration Laboratory, Institute of Psychiatry of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Ribeiro', 'Affiliation': 'Brain Mapping and Sensory Motor Integration Laboratory, Institute of Psychiatry of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Mauricio', 'Initials': 'M', 'LastName': 'Cagy', 'Affiliation': 'Biomedical Engineering Program, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Victor Hugo', 'Initials': 'VH', 'LastName': 'Bastos', 'Affiliation': 'The Northeast Biotechnology Network, Federal University of Piauí, Teresina, Brazil; Brain Mapping and Functionality Laboratory, Federal University of Delta do Parnaíba, Parnaíba, Brazil.'}, {'ForeName': 'Daya S', 'Initials': 'DS', 'LastName': 'Gupta', 'Affiliation': 'Department of Biology, Camden County College, Blackwood, NJ, United States.'}, {'ForeName': 'Silmar', 'Initials': 'S', 'LastName': 'Teixeira', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil; The Northeast Biotechnology Network, Federal University of Piauí, Teresina, Brazil.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113036'] 1791,32599697,Osteopathic Manipulative Treatment in Neonatal Intensive Care Units.,"The aim of this study was to assess the impact of osteopathic manipulative treatment (OMT) on newborn babies admitted at a neonatal intensive care unit (NICU). This was an observational, longitudinal, retrospective study. All consecutive admitted babies were analyzed by treatment (OMT vs. usual care). Treatment group was randomly assigned. Between-group differences in weekly weight change and length of stay (LOS) were evaluated in the overall and preterm populations. Among 1249 babies (48.9% preterm) recorded, 652 received usual care and 597 received OMT. Weight increase was more marked in the OMT group than in the control group (weekly change: +83 g vs. +35 g; p < 0.001). Similar trends were found in the subgroup of preterm babies. A shorter LOS was found in the OMT group vs. the usual care group both in overall population (average mean difference: -7.9 days, p = 0.15) and in preterm babies (-12.3 days; p = 0.04). In severe preterm babies, mean LOS was more than halved as compared to the control group. OMT was associated with a more marked weekly weight increase and, especially in preterm babies, to a relevant LOS reduction: OMT may represent an efficient support to usual care in newborn babies admitted at a NICU.",2020,"A shorter LOS was found in the OMT group vs. the usual care group both in overall population (average mean difference: -7.9 days, p = 0.15) and in preterm babies (-12.3 days; p = 0.04).","['Neonatal Intensive Care Units', '1249 babies (48.9% preterm) recorded, 652 received usual care and 597 received', 'newborn babies admitted at a NICU', 'newborn babies admitted at a neonatal intensive care unit (NICU']","['osteopathic manipulative treatment (OMT', 'OMT', 'Osteopathic Manipulative Treatment']","['weekly weight change and length of stay (LOS', 'mean LOS', 'Weight increase', 'LOS']","[{'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0949744', 'cui_str': 'Osteopathic manipulation'}]","[{'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}]",,0.0615084,"A shorter LOS was found in the OMT group vs. the usual care group both in overall population (average mean difference: -7.9 days, p = 0.15) and in preterm babies (-12.3 days; p = 0.04).","[{'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Cicchitti', 'Affiliation': 'A.I.O.T-Traditional Osteopathy Italian Academy, 65125 Pescara, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Di Lelio', 'Affiliation': 'CORESEARCH-Center for Outcomes Research and Clinical Epidemiology, 65124 Pescara, Italy.'}, {'ForeName': 'Gina', 'Initials': 'G', 'LastName': 'Barlafante', 'Affiliation': 'A.I.O.T-Traditional Osteopathy Italian Academy, 65125 Pescara, Italy.'}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Cozzolino', 'Affiliation': 'A.I.O.T-Traditional Osteopathy Italian Academy, 65125 Pescara, Italy.'}, {'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Di Valerio', 'Affiliation': 'Neonatal Intensive Care Unit, Santo Spirito Hospital, 65126 Pescara, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Fusilli', 'Affiliation': 'Neonatal Intensive Care Unit, Santo Spirito Hospital, 65126 Pescara, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Lucisano', 'Affiliation': 'CORESEARCH-Center for Outcomes Research and Clinical Epidemiology, 65124 Pescara, Italy.'}, {'ForeName': 'Cinzia', 'Initials': 'C', 'LastName': 'Renzetti', 'Affiliation': 'A.I.O.T-Traditional Osteopathy Italian Academy, 65125 Pescara, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Verzella', 'Affiliation': 'A.I.O.T-Traditional Osteopathy Italian Academy, 65125 Pescara, Italy.'}, {'ForeName': 'Maria Chiara', 'Initials': 'MC', 'LastName': 'Rossi', 'Affiliation': 'CORESEARCH-Center for Outcomes Research and Clinical Epidemiology, 65124 Pescara, Italy.'}]","Medical sciences (Basel, Switzerland)",['10.3390/medsci8020024'] 1792,32609018,Erratum: Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial.,,2020,,['Patients with Obstructive Sleep Apnea'],[],['Daytime Sleepiness'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}]",[],"[{'cui': 'C0541854', 'cui_str': 'Daytime sleepiness'}]",,0.0148899,,[],American journal of respiratory and critical care medicine,['10.1164/rccm.v202erratum1'] 1793,32603873,An Initial Psychometric Evaluation of the Pain Concepts Questionnaire in a Low-SES Setting.,"The examination of pain beliefs for chronic pain assessment and treatment has been a growing area of interest. A variety of questionnaires have been developed to assess pain beliefs, however, these questionnaires often require high levels of literacy and education. The pain concepts questionnaire (PCQ) was developed with literacy-adaptations to better evaluate pain beliefs in a low socioeconomic (SES) population. This study is an initial exploratory evaluation of the PCQ in a sample of patients with chronic pain and multiple disparities as part of the learning about my pain (LAMP) trial, a randomized controlled trial comparing literacy-adapted psychosocial treatments for chronic pain. All data were collected at pretreatment. Exploratory factor analysis was performed to examine the underlying factor structure of the PCQ and cross-sectional correlational analyses examined relationships between pain beliefs with sociodemographic factors and chronic pain-related variables. Results suggested a 2-factor solution with a Biopsychosocial factor and Biomedical factor. Consistent with the literature, correlational analyses highlighted racial and SES disparities in pain beliefs and the importance of beliefs in pain- and cognitive/affective-related functioning. The study emphasizes the importance of pain beliefs in chronic pain management and recommends future research to further examine additional psychometric properties of the PCQ. PERSPECTIVE: This study is an initial evaluation of the psychometric properties of a new measure of chronic pain beliefs, the pain concepts questionnaire (PCQ). The PCQ is literacy-adapted and was assessed within a low-SES population. Psychometric proprieties of this measure were promising and could be useful in pain assessment and interventions.",2020,"Consistent with the literature, correlational analyses highlighted racial and SES disparities in pain beliefs and the importance of beliefs in pain- and cognitive/affective-related functioning.","['patients with chronic pain and multiple disparities as part of the Learning About My Pain (LAMP) trial', 'chronic pain']","['literacy-adapted psychosocial treatments', 'PCQ']","['pain beliefs', 'Pain Concepts Questionnaire (PCQ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.0609843,"Consistent with the literature, correlational analyses highlighted racial and SES disparities in pain beliefs and the importance of beliefs in pain- and cognitive/affective-related functioning.","[{'ForeName': 'Andrea K', 'Initials': 'AK', 'LastName': 'Newman', 'Affiliation': 'Department of Psychology, University of Alabama, Tuscaloosa, Alabama. Electronic address: anewman@crimson.ua.edu.'}, {'ForeName': 'Calia A', 'Initials': 'CA', 'LastName': 'Morais', 'Affiliation': 'Department of Community Dentistry and Behavioral Science & Pain Research and Intervention Center of Excellence, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Benjamin P', 'Initials': 'BP', 'LastName': 'Van Dyke', 'Affiliation': 'Department of Psychology, Young Harris College, Young Harris, Georgia.'}, {'ForeName': 'Beverly E', 'Initials': 'BE', 'LastName': 'Thorn', 'Affiliation': 'Department of Psychology, University of Alabama, Tuscaloosa, Alabama.'}]",The journal of pain : official journal of the American Pain Society,['10.1016/j.jpain.2020.05.002'] 1794,32605106,Hemodynamic Adaptations Induced by Short-Term Run Interval Training in College Students.,"Perceived lack of time is one of the most often cited barriers to exercise participation. High intensity interval training has become a popular training modality that incorporates intervals of maximal and low-intensity exercise with a time commitment usually shorter than 30 min. The purpose of this study was to examine the effects of short-term run interval training (RIT) on body composition (BC) and cardiorespiratory responses in undergraduate college students. Nineteen males (21.5 ± 1.6 years) were randomly assigned to a non-exercise control (CON, n = 10) or RIT ( n = 9). Baseline measurements of systolic and diastolic blood pressure, resting heart rate (HRrest), double product (DP) and BC were obtained from both groups. VO 2max and running speed associated with VO 2peak (sVO 2peak ) were then measured. RIT consisted of three running treadmill sessions per week over 4 weeks (intervals at 100% sVO 2peak , recovery periods at 40% sVO 2peak ). There were no differences in post-training BC or VO 2 max between groups ( p > 0.05). HRrest ( p = 0.006) and DP ( p ≤ 0.001) were lower in the RIT group compared to CON at completion of the study. RIT lowered HRrest and DP in the absence of appreciable BC and VO 2max changes. Thereby, RIT could be an alternative model of training to diminish health-related risk factors in undergraduate college students.",2020,HRrest ( p = 0.006) and DP ( p ≤ 0.001) were lower in the RIT group compared to CON at completion of the study.,"['undergraduate college students', 'College Students', 'Nineteen males (21.5 ± 1.6 years']","['non-exercise control (CON, n = 10) or RIT', 'Short-Term Run Interval Training', 'High intensity interval training', 'short-term run interval training (RIT']","['body composition (BC) and cardiorespiratory responses', 'VO 2max and running speed associated with VO 2peak (sVO 2peak ', 'systolic and diastolic blood pressure, resting heart rate (HRrest), double product (DP) and BC']","[{'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4517508', 'cui_str': '1.6'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C1821417', 'cui_str': 'Resting heart rate'}, {'cui': 'C0205173', 'cui_str': 'Double'}]",3.0,0.0570308,HRrest ( p = 0.006) and DP ( p ≤ 0.001) were lower in the RIT group compared to CON at completion of the study.,"[{'ForeName': 'Patricia C', 'Initials': 'PC', 'LastName': 'García-Suárez', 'Affiliation': 'Facultad de Deportes, Universidad Autónoma de Baja California-Ensenada, Boulevard Zertuche s/n. Fraccionamiento Valle Dorado, Ensenada 22890, Baja California, Mexico.'}, {'ForeName': 'Iván', 'Initials': 'I', 'LastName': 'Rentería', 'Affiliation': 'Facultad de Deportes, Universidad Autónoma de Baja California-Ensenada, Boulevard Zertuche s/n. Fraccionamiento Valle Dorado, Ensenada 22890, Baja California, Mexico.'}, {'ForeName': 'Priscilla', 'Initials': 'P', 'LastName': 'García Wong-Avilés', 'Affiliation': 'Facultad de Deportes, Universidad Autónoma de Baja California-Ensenada, Boulevard Zertuche s/n. Fraccionamiento Valle Dorado, Ensenada 22890, Baja California, Mexico.'}, {'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'Franco-Redona', 'Affiliation': 'Facultad de Deportes, Universidad Autónoma de Baja California-Ensenada, Boulevard Zertuche s/n. Fraccionamiento Valle Dorado, Ensenada 22890, Baja California, Mexico.'}, {'ForeName': 'Luis M', 'Initials': 'LM', 'LastName': 'Gómez-Miranda', 'Affiliation': 'Facultad de Deportes Tijuana, Universidad Autónoma de Baja California, Avenida Maclovio Herrera #4080, Colonia Francisco Villa, Tijuana 22615, Baja California, Mexico.'}, {'ForeName': 'Jorge A', 'Initials': 'JA', 'LastName': 'Aburto-Corona', 'Affiliation': 'Facultad de Deportes Tijuana, Universidad Autónoma de Baja California, Avenida Maclovio Herrera #4080, Colonia Francisco Villa, Tijuana 22615, Baja California, Mexico.'}, {'ForeName': 'Eric P', 'Initials': 'EP', 'LastName': 'Plaisance', 'Affiliation': 'Department of Human Studies, University of Alabama at Birmingham, Education Building 901, 13th Street South, Birmingham, AL 35294, USA.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Moncada-Jiménez', 'Affiliation': 'Human Movement Sciences Research Center (CIMOHU), University of Costa Rica, Ave. 31 Pavas, San José 1200, Costa Rica.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Jiménez-Maldonado', 'Affiliation': 'Facultad de Deportes, Universidad Autónoma de Baja California-Ensenada, Boulevard Zertuche s/n. Fraccionamiento Valle Dorado, Ensenada 22890, Baja California, Mexico.'}]",International journal of environmental research and public health,['10.3390/ijerph17134636'] 1795,32684108,Resistance training-induced improvement in exercise tolerance is not dependent on muscle mass gain in post-menopausal women.,"Menopause transition may impair muscle function, decreasing exercise tolerance. The torque-duration relationship (hyperbolic curve) forms a practical framework within which exercise tolerance may be explored. In this regard, resistance training (RT) increases the curvature constant of this relationship (W'). Muscle hypertrophy and strength gains have been suggested as possible mediators of RT-induced improvement in W', however, it is unclear what the main mediator is. Higher-volume RT (HV-RT), beyond that recommended by RT-guidelines (i.e. three sets per exercise), may promote greater hypertrophy, but not higher strength gains. Hence, this study aimed to investigate whether greater hypertrophy in HV-RT maximizes W' gain when compared to LVRT in postmenopausal women (PW). Fifty-eight PW were randomized to the control group (CTRL), HV-RT (six sets per exercise) or LV-RT (three sets per exercise). They underwent a 12-week RT program and were assessed for W', thigh lean body mass (TLBM) and maximal isometric voluntary contraction (MIVC). The TLBM gain was higher (P < 0.001) in the HV-RT (9.4%) than LV-RT (3.7%). However, both HV-RT and LV-RT similarly increased MIVC (9.7% vs. 16.5%, P= 0.063) and W' (26.4 % vs. 34.6 % P= 0.163). Additionally, the changes in W' were associated with the changes in TLBM (31%, P= 0.003) and MIVC (52%, P= <0.001). However, when the changes in TLBM and MIVC were inserted into the predictive model, only the MIVC (33%, P= 0.002) was a predictor of W'. Thus, although HV-RT promoted greater hypertrophy than LV-RT, HV-RT does not seem to maximize W' in PW.",2020,The TLBM gain was higher (P < 0.001) in the HV-RT (9.4%) than LV-RT (3.7%).,"['postmenopausal women (PW', 'Fifty-eight PW', 'post-menopausal women']","['resistance training (RT', 'LVRT', 'control group (CTRL), HV-RT (six sets per exercise) or LV-RT']","['thigh lean body mass (TLBM) and maximal isometric voluntary contraction (MIVC', 'MIVC', 'TLBM', 'TLBM gain', 'TLBM and MIVC']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}]",58.0,0.0180164,The TLBM gain was higher (P < 0.001) in the HV-RT (9.4%) than LV-RT (3.7%).,"[{'ForeName': 'Gersiel Nascimento', 'Initials': 'GN', 'LastName': 'de Oliveira Júnior', 'Affiliation': 'Exercise Biology Research Group (BioEx), Federal University of Triangulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.'}, {'ForeName': 'Jairo de Freitas Rodrigues', 'Initials': 'JFR', 'LastName': 'de Sousa', 'Affiliation': 'Exercise Biology Research Group (BioEx), Federal University of Triangulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.'}, {'ForeName': 'Marcelo Augusto da Silva', 'Initials': 'MADS', 'LastName': 'Carneiro', 'Affiliation': 'Exercise Biology Research Group (BioEx), Federal University of Triangulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.'}, {'ForeName': 'Fernanda Maria', 'Initials': 'FM', 'LastName': 'Martins', 'Affiliation': 'Exercise Biology Research Group (BioEx), Federal University of Triangulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.'}, {'ForeName': 'Samarita Beraldo', 'Initials': 'SB', 'LastName': 'Santagnello', 'Affiliation': 'Exercise Biology Research Group (BioEx), Federal University of Triangulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.'}, {'ForeName': 'Fábio Lera', 'Initials': 'FL', 'LastName': 'Orsatti', 'Affiliation': 'Exercise Biology Research Group (BioEx), Federal University of Triangulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil.'}]",European journal of sport science,['10.1080/17461391.2020.1798511'] 1796,32599496,Randomized controlled three-arm study of NADA acupuncture for alcohol addiction.,"INTRODUCTION Alcohol addiction compromises cardiovascular health, possibly due to impaired control of the heart and vasculature by the autonomic nervous system. We aimed to assess the effects of National Acupuncture Detoxification Association (NADA) acupuncture on cardiovascular autonomic functions, psychiatric comorbidities and abstinence in patients addicted to alcohol. MATERIAL AND METHODS A randomized sham controlled three-arm study was undertaken in 72 patients (nine females, aged 43.7 ± 9.2 years, mean ± SD) undergoing in-patient rehabilitation for alcohol addiction. Patients were randomly allocated (1:1:1) to receive twenty 30-minute NADA or sham acupuncture sessions within six weeks or no intervention. They were evaluated for craving, depression, anxiety and autonomic control of the heart (heart rate variability, HRV), vasculature (laser Doppler flowmetry) and sweat glands (sympathetic skin response). Testing was performed at baseline, immediately post intervention (sham intervention or control period, respectively) and another four weeks later. Abstinence was assessed one year after study completion. RESULTS Patients in the NADA arm displayed increased HRV immediately post-intervention compared to baseline (SDNN: 72.8 ms ± 34.2 ms vs. 57.9 ms ± 31.2 ms, p = 0.001). This increase was sustained four weeks later (66.2 ms ± 32.4 ms, p = 0.015). HRV remained unaltered following sham or no acupuncture (p = n.s.). Autonomic function of vasculature and sweat glands, psychiatric comorbidities and one-year abstinence did not differ between study arms. CONCLUSIONS NADA acupuncture may improve autonomic cardiac function. However, this improvement appears not to translate into alleviation of psychiatric comorbidities or sustained abstinence.",2020,"This increase was sustained four weeks later (66.2 ms ± 32.4 ms, p = 0.015).","['patients addicted to alcohol', '72 patients (nine females, aged 43.7\xa0±\xa09.2\xa0years, mean\xa0±\xa0SD) undergoing in-patient rehabilitation for alcohol addiction', '34.2']","['NADA or sham acupuncture sessions within six weeks or no intervention', 'National Acupuncture Detoxification Association (NADA) acupuncture', 'sham or no acupuncture', 'NADA acupuncture']","['HRV', 'Autonomic function of vasculature and sweat glands, psychiatric comorbidities and one-year abstinence', 'craving, depression, anxiety and autonomic control of the heart (heart rate variability, HRV), vasculature (laser Doppler flowmetry) and sweat glands (sympathetic skin response', 'autonomic cardiac function', 'cardiovascular autonomic functions, psychiatric comorbidities and abstinence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001973', 'cui_str': 'Alcohol dependence'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C5191219', 'cui_str': '9.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C5191359', 'cui_str': '34.2'}]","[{'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0025516', 'cui_str': 'Detoxication, Drug, Metabolic'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0010343', 'cui_str': 'Croatia'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0005839', 'cui_str': 'blood supply'}, {'cui': 'C0038989', 'cui_str': 'Sweat gland structure'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0162520', 'cui_str': 'Laser doppler flowmetry'}, {'cui': 'C0312646', 'cui_str': 'Finding related to response to skin test'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}]",72.0,0.09429,"This increase was sustained four weeks later (66.2 ms ± 32.4 ms, p = 0.015).","[{'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Krause', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Ana Isabel', 'Initials': 'AI', 'LastName': 'Penzlin', 'Affiliation': 'Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Ritschel', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Barlinn', 'Affiliation': 'Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Heinz', 'Initials': 'H', 'LastName': 'Reichmann', 'Affiliation': 'Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Kerstin', 'Initials': 'K', 'LastName': 'Weidner', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Siepmann', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Timo', 'Initials': 'T', 'LastName': 'Siepmann', 'Affiliation': 'Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. Electronic address: timo.siepmann@ukdd.de.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106488'] 1797,32599644,The Effects of Performing Mental Exertion during Cycling Exercise on Fatigue Indices.,"This study investigated the effect of performing prolonged mental exertion during submaximal cycling exercise on exercise tolerance and fatigue. Participants performed 5 experimental sessions. Session 1: determination of cycling peak power output. Sessions 2 and 3: cycling to exhaustion at 65% peak power output with mental exertion or watching a movie. Sessions 4 and 5: cycling for 45 min at 65% peak power output with mental exertion or while watching a movie. During sessions 2-5, rate of perceived exertion and heart rate were recorded while cycling and cortisol and prolactin concentrations, psychomotor vigilance task performance, and maximal voluntary contraction were measured pre-and post-sessions. During sessions 2 and 3, time to exhaustion was reduced ( p <0.01) and rate of perceived exertion was increased ( p <0.01) in session 2 compared to 3. Cortisol, prolactin and heart rate increased and psychomotor vigilance task and maximal voluntary contraction decreased from pre-to post-sessions with no difference between sessions. Cortisol, prolactin and rate of perceived exertion were higher ( p <0.03) in session 4 than 5. Heart rate increased and maximal voluntary contraction decreased from pre-to post-sessions with no difference between sessions. Prolonged mental exertion during cycling exercise reduces exercise tolerance, which appears to be mediated psychologically rather than physiologically.",2020,"Cortisol, prolactin and rate of perceived exertion were higher ( p <0.03) in session 4 than 5.",[],"['Performing Mental Exertion during Cycling Exercise', 'Sessions 2 and 3: cycling to exhaustion at 65% peak power output with mental exertion or watching a movie', 'Sessions 4 and 5: cycling for 45 min at 65% peak power output with mental exertion or while watching a movie', 'performing prolonged mental exertion during submaximal cycling exercise']","['Cortisol, prolactin and heart rate increased and psychomotor vigilance task and maximal voluntary contraction', 'rate of perceived exertion and heart rate', 'Heart rate increased and maximal voluntary contraction', 'cycling and cortisol and prolactin concentrations, psychomotor vigilance task performance, and maximal voluntary contraction', 'time to exhaustion', 'exercise tolerance and fatigue', 'rate of perceived exertion', 'Cortisol, prolactin and rate of perceived exertion', 'Fatigue Indices']",[],"[{'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0681495', 'cui_str': 'Movies'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}]","[{'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0033371', 'cui_str': 'Prolactin'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C0043012', 'cui_str': 'Wakefulness'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.0531489,"Cortisol, prolactin and rate of perceived exertion were higher ( p <0.03) in session 4 than 5.","[{'ForeName': 'Hamidreza', 'Initials': 'H', 'LastName': 'Barzegarpoor', 'Affiliation': 'Sport Sciences and Health, Shahid Beheshti University, Tehran, Iran (the Islamic Republic of).'}, {'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Amoozi', 'Affiliation': 'Sport Sciences and Health, Shahid Beheshti University, Tehran, Iran (the Islamic Republic of).'}, {'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Rajabi', 'Affiliation': 'Sport sciences, Kharazmi University, Tehran, Iran (the Islamic Republic of).'}, {'ForeName': 'Duane', 'Initials': 'D', 'LastName': 'Button', 'Affiliation': ""School of Human Kinetics and Recreation, Memorial University of Newfoundland, St. John's, Canada.""}, {'ForeName': 'Rana', 'Initials': 'R', 'LastName': 'Fayazmilani', 'Affiliation': 'Department of Biological Sciences in Sport, Faculty of Sports Sciences and Health, Shahid Beheshti University, Tehran, Iran.'}]",International journal of sports medicine,['10.1055/a-1179-8326'] 1798,32684099,"The effect of canola, sesame and sesame-canola oils on body fat and composition in adults: a triple-blind, three-way randomised cross-over clinical trial.","The present study aimed to examine the effect of replacing edible oils with sesame oil (SO), canola oil (CO) and sesame-canola oil (SCO) on body weight and composition in adults. Adults without any chronic diseases ( n  = 77) were entered a 4-week run-in period and then were randomised to receive SO, CO and SCO for their household use in 9-week intervention periods (separated by 4-week washout intervals). Anthropometric measurements, as well as body composition markers, were assessed at baseline, middle and after each intervention period. In total, 73 participants completed the study. Although significant time effects were seen for waist and hip circumference, waist-to-hip ratio, central obesity index, body adiposity index, muscle mass and body fat percent ( p time <.05), the treatment and treatment × time effects were not significant ( p >.05). The present clinical trial revealed that CO, SO and SCO might not differently affect body fat and composition. Trial registration code: IRCT2016091312571N6 (http://en.irct.ir/trial/12622).",2020,"Although significant time effects were seen for waist and hip circumference, waist-to-hip ratio, central obesity index, body adiposity index, muscle mass and body fat percent ( p time <.05), the treatment and treatment × time effects were not significant ( p >.05).","['Adults without any chronic diseases ( n \u2009=\u200977', '73 participants completed the study', 'adults']","['SO, CO and SCO', 'canola, sesame and sesame-canola oils', 'replacing edible oils with sesame oil (SO), canola oil (CO) and sesame-canola oil (SCO']","['body weight and composition', 'waist and hip circumference, waist-to-hip ratio, central obesity index, body adiposity index, muscle mass and body fat percent']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0036845', 'cui_str': 'Sesame Oil'}, {'cui': 'C0054599', 'cui_str': 'canola oil'}, {'cui': 'C1123051', 'cui_str': 'Sesame'}, {'cui': 'C0330502', 'cui_str': 'Brassica napus'}, {'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C0028908', 'cui_str': 'Oil'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0230097', 'cui_str': 'Structure of waist (surface region)'}, {'cui': 'C0562350', 'cui_str': 'Hip circumference'}, {'cui': 'C0205682', 'cui_str': 'Waist/hip ratio'}, {'cui': 'C0311277', 'cui_str': 'Abdominal Obesity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439165', 'cui_str': 'Percent'}]",77.0,0.100148,"Although significant time effects were seen for waist and hip circumference, waist-to-hip ratio, central obesity index, body adiposity index, muscle mass and body fat percent ( p time <.05), the treatment and treatment × time effects were not significant ( p >.05).","[{'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Moghtaderi', 'Affiliation': 'Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Mojgan', 'Initials': 'M', 'LastName': 'Amiri', 'Affiliation': 'Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Zimorovat', 'Affiliation': 'Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Hamidreza', 'Initials': 'H', 'LastName': 'Raeisi-Dehkordi', 'Affiliation': 'Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Rahmanian', 'Affiliation': 'Diabetes Research Center, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Mahdieh', 'Initials': 'M', 'LastName': 'Hosseinzadeh', 'Affiliation': 'Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Fallahzadeh', 'Affiliation': 'Research Center of Prevention and Epidemiology of Non-Communicable Disease, Department of Biostatistics and Epidemiology, School of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Salehi-Abargouei', 'Affiliation': 'Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}]",International journal of food sciences and nutrition,['10.1080/09637486.2020.1786024'] 1799,32609412,"Multifactorial Intervention on Type 2 Diabetes (MIDiab) Study: A multicenter, open-label, randomized, parallel controlled, community trial.",,2020,,[],['Multifactorial Intervention'],[],[],"[{'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.0248914,,"[{'ForeName': 'Yupeng', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Qingbo', 'Initials': 'Q', 'LastName': 'Guan', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Hou', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Haiqing', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Jing', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Shizhan', 'Initials': 'S', 'LastName': 'Ma', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Shanshan', 'Initials': 'S', 'LastName': 'Shao', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Zhao', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Qingling', 'Initials': 'Q', 'LastName': 'Guo', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Zhong', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Gao', 'Affiliation': 'Shandong Provincial Key Laboratory of Endocrinology and Lipid Metabolism, Institute of Endocrinology and Metabolism, Shandong Academy of Clinical Medicine, Jinan, China.'}, {'ForeName': 'Jiajun', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of diabetes,['10.1111/1753-0407.13081'] 1800,32605614,"A randomized controlled trial of a virtual reality based, approach-avoidance training program for alcohol use disorder: a study protocol.","BACKGROUND The approach-avoidance training program (AATP) has shown preliminary promise as an add-on to standard treatment for alcohol dependence. However, knowledge is lacking as to whether the effectiveness of AATP can be enhanced further when performed in a typical drinking situation. The main aim of this study is to investigate whether approach-avoidance training implemented in a virtual reality bar environment is superior to the classical joystick PC-version of the AATP. METHODS The study will be implemented as a randomized controlled trial. A total of 204consecutively enrolled alcohol use disorder (AUD) patients, recruited from alcohol inpatient clinics in Germany, Poland and Denmark, will be randomized into one of three groups at the start of standard alcohol treatment: group A) stimuli-relevant AATP + treatment as usual (TAU); group B) stimuli-relevant AATP in virtual reality + TAU, and group C) TAU only (control group). Treatment outcomes will be assessed at pre-treatment, post-treatment and 3-month follow-up. Repeated-measures ANOVA will be applied to compare the trajectories of the groups over time on drinking, craving and impulsiveness outcomes. It is hypothesized that the two experimental groups will achieve better treatment outcomes compared to group C and that group B will achieve better outcomes than group A. DISCUSSION This study is the first trial examining the effectiveness of stimuli-relevant AATP delivered in a VR environment. The use of VR has shown promise in enhancing the effectiveness of other psychological treatments and since AATP has already been shown effective as add-on treatment, it is of interest to investigate whether these effects can be further enhanced by implementing the program in more ecologically valid environments. If proven effective, the AATP-VR can, like the AATP, be implemented easily and cheaply as add-on treatment or continued care to enhance the effectiveness of current evidence-based treatment. TRIAL REGISTRATION ClinicalTrials.gov ID: NCT04283305 Registration date: 24.02.20.",2020,"If proven effective, the AATP-VR can, like the AATP, be implemented easily and cheaply as add-on treatment or continued care to enhance the effectiveness of current evidence-based treatment. ","['A total of 204consecutively enrolled alcohol use disorder (AUD) patients, recruited from alcohol inpatient clinics in Germany, Poland and Denmark']","['AATP', 'standard alcohol treatment: group A) stimuli-relevant AATP + treatment as usual (TAU); group B) stimuli-relevant AATP in virtual reality + TAU, and group C', 'TAU', 'approach-avoidance training', 'virtual reality based, approach-avoidance training program', 'avoidance training program (AATP', 'stimuli-relevant AATP']",[],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0032356', 'cui_str': 'Poland'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]",[],,0.0360521,"If proven effective, the AATP-VR can, like the AATP, be implemented easily and cheaply as add-on treatment or continued care to enhance the effectiveness of current evidence-based treatment. ","[{'ForeName': 'Angelina Isabella', 'Initials': 'AI', 'LastName': 'Mellentin', 'Affiliation': 'Unit for Clinical Alcohol Research, Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark, J. B. Winsløwsvej 18, 5000, Odense Center, Denmark. amellentin@health.sdu.dk.'}, {'ForeName': 'Anette Søgaard', 'Initials': 'AS', 'LastName': 'Nielsen', 'Affiliation': 'Unit for Clinical Alcohol Research, Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark, J. B. Winsløwsvej 18, 5000, Odense Center, Denmark.'}, {'ForeName': 'Leonie', 'Initials': 'L', 'LastName': 'Ascone', 'Affiliation': 'Neuroplasticity Research Group, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Janina', 'Initials': 'J', 'LastName': 'Wirtz', 'Affiliation': 'Neuroplasticity Research Group, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Jerzy', 'Initials': 'J', 'LastName': 'Samochowiec', 'Affiliation': 'Department of Psychiatry Pomeranian Medical University in Szczecin Poland, Szczecin, Poland.'}, {'ForeName': 'Jolanta', 'Initials': 'J', 'LastName': 'Kucharska-Mazur', 'Affiliation': 'Department of Psychiatry Pomeranian Medical University in Szczecin Poland, Szczecin, Poland.'}, {'ForeName': 'Friedrich', 'Initials': 'F', 'LastName': 'Schadow', 'Affiliation': 'Neuroplasticity Research Group, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Zofia', 'Initials': 'Z', 'LastName': 'Lebiecka', 'Affiliation': 'Department of Psychiatry Pomeranian Medical University in Szczecin Poland, Szczecin, Poland.'}, {'ForeName': 'Tomasz', 'Initials': 'T', 'LastName': 'Skoneczny', 'Affiliation': 'Department of Psychiatry Pomeranian Medical University in Szczecin Poland, Szczecin, Poland.'}, {'ForeName': 'Nicolai', 'Initials': 'N', 'LastName': 'Mistarz', 'Affiliation': 'Unit for Clinical Alcohol Research, Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark, J. B. Winsløwsvej 18, 5000, Odense Center, Denmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Bremer', 'Affiliation': 'Neuroplasticity Research Group, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Kühn', 'Affiliation': 'Neuroplasticity Research Group, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}]",BMC psychiatry,['10.1186/s12888-020-02739-1'] 1801,32684100,Spatial exploration strategy training for spatial neglect: A pilot study.,"Spatial neglect is a syndrome due to impaired neural networks critical for spatial attention and related cognitive and motor functions. Affected individuals also have impaired self-awareness of their own neglect symptoms. The present randomized controlled study was the first proof-of-concept pilot examining the multi-context treatment approach using a protocol of spatial exploration strategy training in one brief session (20-30 minutes). The therapist provided supportive feedback and semi-structured guidance to promote strategy learning and self-discovery of omission errors. 40 patients with left-sided neglect after right brain stroke were included. The results showed that the treatment reduced lateralized bias toward the ipsilesional side of space but did not improve overall detection performance. Impaired general self-awareness of daily-life spatial difficulties was found independent of treatment outcome. This implies that judgment regarding responsiveness to treatment should not be made based on an awareness interview or the severity of neglect symptoms. Lastly, the treatment showed the potential of improving online contextual self-awareness of spatial abilities. A collaborative and interactive approach that focuses on helping the patient self-discover, monitor and self-manage their errors, appears to have a potential for decreasing neglect symptoms. Future studies are required to examine additional aspects of the multi-context treatment approach.",2020,The results showed that the treatment reduced lateralized bias toward the ipsilesional side of space but did not improve overall detection performance.,['40 patients with left-sided neglect after right brain stroke'],"['spatial exploration strategy training', 'Spatial exploration strategy training']","['lateralized bias', 'overall detection performance', 'general self-awareness of daily-life spatial difficulties', 'online contextual self-awareness of spatial abilities']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0576479', 'cui_str': 'Neglect of left side of body'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C1280903', 'cui_str': 'Exploration procedure'}, {'cui': 'C0589105', 'cui_str': 'Strategy training'}]","[{'cui': 'C0005346', 'cui_str': 'Biases'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C3146223', 'cui_str': 'Awareness of self'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0679024', 'cui_str': 'Spatial Ability'}]",40.0,0.026707,The results showed that the treatment reduced lateralized bias toward the ipsilesional side of space but did not improve overall detection performance.,"[{'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Toglia', 'Affiliation': 'School of Health and Natural Sciences, Mercy College, Dobbs Ferry, NY, USA.'}, {'ForeName': 'Peii', 'Initials': 'P', 'LastName': 'Chen', 'Affiliation': 'Kessler Foundation, West Orange, NJ, USA.'}]",Neuropsychological rehabilitation,['10.1080/09602011.2020.1790394'] 1802,32604756,Assessing the Implementation of a Behavior Change Intervention: Process Evaluation of a Stepped-Wedge Cluster Randomized Controlled Trial for Newborn Health.,"Maternal and under five-year-old mortality rates have reduced in the last two decades globally due to concerted effort, yet newborn deaths remain unacceptably prevalent. Behavior change is an important component of interventions to address newborn health problems in low-income countries. In Cambodia, maternal and newborn mortality has markedly decreased, and continued improvements will allow the country to achieve further reduction in newborn morbidity. The results of an implementation study of the Newborn Care and Infection Control Initiative using process evaluation are presented to provide insight into the trial implementation and context of the program that may have contributed to intervention results. The study utilized a mixed method process to explore the context, mechanisms, and implementation of intervention components: training of village health support group volunteers to provide home visits, training of midwives on infection prevention and control around the perinatal period, counseling on newborn care, and provision of training materials for counseling and intervention. Implementation was evaluated through quantitative and qualitative data collection including surveys, observation, semi-structured interviews, focus groups, and visual media. Descriptive statistics summarized the quantitative data and thematic analysis was used to explore the qualitative data. The evaluation identified several factors that might have influenced the outcomes of the trial: continuity of health center staff communication, timing and ability to complete home visits, and training quality. Additional support for parents in the perinatal period, preferably provided at the community level, will contribute to further improvement in health outcomes for newborns in this area. Researchers in this context should consider mechanisms to improve the coordination of health facility staff counseling while providing support and resources to ensure home visits to families with newborns are made on time. Attention to staffing, training, and quality of newborn health interventions is critical in planning for the scaling-up of newborn health programming.",2020,"Maternal and under five-year-old mortality rates have reduced in the last two decades globally due to concerted effort, yet newborn deaths remain unacceptably prevalent.",['Newborn Health'],"['village health support group volunteers to provide home visits, training of midwives on infection prevention and control around the perinatal period, counseling on newborn care, and provision of training materials for counseling and intervention']",['newborn morbidity'],"[{'cui': 'C4042838', 'cui_str': 'Neonatal Health'}]","[{'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036606', 'cui_str': 'Support Groups'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0026083', 'cui_str': 'Professional midwife'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0178795', 'cui_str': 'Perinatal period'}, {'cui': 'C0341618', 'cui_str': 'Counsel'}, {'cui': 'C0204792', 'cui_str': 'Routine care of newborn'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}]",,0.0147921,"Maternal and under five-year-old mortality rates have reduced in the last two decades globally due to concerted effort, yet newborn deaths remain unacceptably prevalent.","[{'ForeName': 'Alessandra N', 'Initials': 'AN', 'LastName': 'Bazzano', 'Affiliation': 'Department of Global Community Health and Behavioral Sciences, Tulane School Public Health and Tropical Medicine, New Orleans, 70112 LA, USA.'}, {'ForeName': 'Jeni A', 'Initials': 'JA', 'LastName': 'Stolow', 'Affiliation': 'Department of Global Community Health and Behavioral Sciences, Tulane School Public Health and Tropical Medicine, New Orleans, 70112 LA, USA.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Duggal', 'Affiliation': 'School of Medicine, Tulane University, New Orleans, 70112 LA, USA.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Oberhelman', 'Affiliation': 'Department of Global Community Health and Behavioral Sciences, Tulane School Public Health and Tropical Medicine, New Orleans, 70112 LA, USA.'}, {'ForeName': 'Yaoyao', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': 'Department of Global Community Health and Behavioral Sciences, Tulane School Public Health and Tropical Medicine, New Orleans, 70112 LA, USA.'}, {'ForeName': 'Chivorn', 'Initials': 'C', 'LastName': 'Var', 'Affiliation': 'Reproductive Health Association of Cambodia, Phnom Penh 905, Cambodia.'}]","Healthcare (Basel, Switzerland)",['10.3390/healthcare8020187'] 1803,32684181,"A brief clinical report documenting a novel therapeutic technique (MEmory Specificity Training, MEST) for depression: a summary of two pilot randomized controlled trials.","BACKGROUND Depression has a profound effect on quality of life (QoL) and is associated with rumination, hopelessness and social difficulties. It is important to explore novel intervention techniques that may reduce depression, and also improve rumination, hope and QoL. AIMS In this brief clinical report, we report the findings of two pilot randomized controlled trials examining the feasibility of a potentially important novel clinical technique (MEmory Specificity Training, MEST) on depression, social problem-solving (Study 1), rumination, hope and QoL (Study 2). METHOD In Study 1, Iranian women with depression (n = 24) completed the Beck Depression Inventory-II and Means-Ends Problem-Solving test at baseline, post-training and 2-month follow-up. In Study 2, female students with moderate depression (n = 24) completed the Ruminative Response Scale, Adult Hope Scale and Short-Form Health Survey at baseline and post-training. Assessors were blind to group allocation. In both studies participants were randomly assigned to MEST or a non-active control group. RESULTS In both studies, MEST was found to be feasible and associated with low drop-out rates and high rates of self-reported patient and group facilitator satisfaction. There was preliminary evidence that MEST may bring about clinical benefit in terms of depression, social problem-solving (Study 1), QoL, rumination and hope (Study 2). CONCLUSIONS MEST is a promising technique in the treatment of depression.",2020,"There was preliminary evidence that MEST may bring about clinical benefit in terms of depression, social problem-solving (Study 1), QoL, rumination and hope (Study 2). ","['Iranian women with depression (n = 24', 'depression', 'female students with moderate depression (n = 24']","['MEST', 'novel therapeutic technique (MEmory Specificity Training, MEST', 'potentially important novel clinical technique (MEmory Specificity Training, MEST', 'MEST or a non-active control group']","['Beck Depression Inventory-II and Means-Ends Problem-Solving test', 'quality of life (QoL', 'Ruminative Response Scale, Adult Hope Scale and Short-Form Health Survey', 'depression, social problem-solving (Study 1), rumination, hope and QoL (Study 2']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0588007', 'cui_str': 'Moderate depression'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0033211', 'cui_str': 'Problem solving'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0392347', 'cui_str': 'Hope'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0037431', 'cui_str': 'Social problem'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}]",24.0,0.0903422,"There was preliminary evidence that MEST may bring about clinical benefit in terms of depression, social problem-solving (Study 1), QoL, rumination and hope (Study 2). ","[{'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Sadat Zia', 'Affiliation': 'Department of Psychology, University of Isfahan, Isfahan, Iran.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Afkhami', 'Affiliation': 'Department of Psychology, University of Isfahan, Isfahan, Iran.'}, {'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Taher Neshat-Doost', 'Affiliation': 'Department of Psychology, University of Isfahan, Isfahan, Iran.'}, {'ForeName': 'Mahgol', 'Initials': 'M', 'LastName': 'Tavakoli', 'Affiliation': 'Department of Psychology, University of Isfahan, Isfahan, Iran.'}, {'ForeName': 'Hossein Ali', 'Initials': 'HA', 'LastName': 'Mehrabi Kooshki', 'Affiliation': 'Department of Psychology, University of Isfahan, Isfahan, Iran.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Jobson', 'Affiliation': 'School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia.'}]",Behavioural and cognitive psychotherapy,['10.1017/S1352465820000417'] 1804,32684216,[Effect of positive end expiratory pressure level selection in prone position ventilation on lung recruitment and inflammatory factors in patients with severe acute respiratory distress syndrome].,"OBJECTIVE To investigate the effect of positive end expiratory pressure (PEEP) level selection on prone position ventilation and inflammatory factors in patients with severe acute respiratory distress syndrome (ARDS). METHODS A prospective randomized controlled study was conducted. The 100 patients with severe ARDS admitted to Union Jiangbei Hospital, Huazhong University of Science and Technology from March 2016 to March 2019 were enrolled. Patients were divided into two groups according to the random number table method, with 50 cases in each group. All patients were given lung protective ventilation strategy and prone position ventilation treatment on the basis of treatment of primary disease. The lower level of PEEP [8-12 cmH 2 O (1 cmH 2 O = 0.098 kPa)] was the control group, and the higher level of PEEP (13-17 cmH 2 O) was the observation group. Patients' vital signs were continuously monitored during mechanical ventilation. The indexes of pulmonary recruitment were recorded, including the dynamic lung compliance (Cdyn), pulmonary drive pressure (DP), heart rate and lactate (Lac) levels before and 48 hours after the treatment. The levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), high sensitivity C-reaction protein (hs-CRP) in serum were detected by enzyme linked immunosorbent assay (ELISA). Arterial blood gas was detected, including arterial partial pressure of oxygen (PaO 2 ), oxygenation index (PaO 2 /FiO 2 ), and arterial partial pressure of carbon dioxide (PaCO 2 ). The occurrence of pleural effusion and heart, liver and kidney dysfunction were recorded. RESULTS In the control group, the PEEP level was (10.9±1.2) cmH 2 O, and the observation group PEEP level was (15.6±1.5) cmH 2 O. There was no significant difference in the index of lung recruitment, the levels of inflammatory factors and the arterial blood gas analysis index between the two groups before treatment. After prone ventilation, the index of lung recruitment and the arterial blood gas analysis index were much better in both groups. The effect of lung recruitment and oxygenation in the observation group with higher PEEP level were significantly superior to the control group with lower PEEP level [Cdyn (mL/cmH 2 O): 37.61±5.09 vs. 32.51±4.97, DP (cmH 2 O): 10.36±1.51 vs. 12.55±1.35, heart rate (bpm): 93.13±10.56 vs. 108.56±12.49, Lac (mmol/L): 2.34±0.41 vs. 3.41±0.57, PaO 2 (mmHg, 1 mmHg = 0.133 kPa): 95.13±3.33 vs. 91.81±2.75, PaO 2 /FiO 2 (mmHg): 180.12±7.25 vs. 150.29±8.52, PaCO 2 (mmHg): 38.31±2.13 vs. 45.22±2.61, all P < 0.05]. The levels of inflammatory factors after treatment were higher than before treatment in both groups. Higher PEEP level will cause increased inflammatory factor level than the control group [IL-6 (ng/L): 526.24±125.18 vs. 465.18±130.52, TNF-α (ng/L): 42.47±2.20 vs. 34.12±1.89, hs-CRP (mg/L): 101.24±23.26 vs. 83.56±25.51, all P < 0.05]. Furthermore, the occurrence of pleural effusion and heart, liver, kidney dysfunction in the observation group were lower than that of the control group (4.0% vs. 8.0%, 10.0% vs. 16.0%, 2.0% vs. 10.0%, 2.0% vs. 6.0%, respectively, all P < 0.05). CONCLUSIONS The higher PEEP level combined with prone position ventilation is beneficial to the severe ARDS patients with better lung recruitment effect and arterial blood gas improvement, thus promote the patients' recovery. But the higher initial PEEP will induce the release of inflammatory factors to a certain extent.",2020,"There was no significant difference in the index of lung recruitment, the levels of inflammatory factors and the arterial blood gas analysis index between the two groups before treatment.","['100 patients with severe ARDS admitted to Union Jiangbei Hospital, Huazhong University of Science and Technology from March 2016 to March 2019 were enrolled', 'patients with severe acute respiratory distress syndrome', 'patients with severe acute respiratory distress syndrome (ARDS']","['positive end expiratory pressure level selection', 'positive end expiratory pressure (PEEP) level selection', 'prone position ventilation', 'lung protective ventilation strategy and prone position ventilation treatment']","['inflammatory factor level', 'indexes of pulmonary recruitment', 'lower level of PEEP', 'Arterial blood gas', 'levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), high sensitivity C-reaction protein (hs-CRP', 'occurrence of pleural effusion and heart, liver, kidney dysfunction', 'arterial partial pressure of oxygen (PaO 2 ), oxygenation index (PaO 2 /FiO 2 ), and arterial partial pressure of carbon dioxide (PaCO 2 ', 'index of lung recruitment and the arterial blood gas analysis index', 'PEEP level', 'index of lung recruitment, the levels of inflammatory factors and the arterial blood gas analysis index', 'levels of inflammatory factors', 'lung recruitment and inflammatory factors', 'dynamic lung compliance (Cdyn), pulmonary drive pressure (DP), heart rate and lactate (Lac) levels', 'occurrence of pleural effusion and heart, liver and kidney dysfunction']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0032740', 'cui_str': 'Positive end-expiratory pressure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0031222', 'cui_str': 'Personnel Selection'}, {'cui': 'C0033422', 'cui_str': 'Prone body position'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0032740', 'cui_str': 'Positive end-expiratory pressure'}, {'cui': 'C0150411', 'cui_str': 'Analysis of arterial blood gases and pH'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0032227', 'cui_str': 'Pleural effusion'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0151746', 'cui_str': 'Abnormal renal function'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0202155', 'cui_str': 'Oxygen measurement, partial pressure, arterial'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output'}, {'cui': 'C1278185', 'cui_str': 'Oxygenation index measurement'}, {'cui': 'C0428190', 'cui_str': 'Measurement of arterial partial pressure of carbon dioxide'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0024112', 'cui_str': 'Lung compliance'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0428445', 'cui_str': 'D-lactate measurement'}]",100.0,0.0609105,"There was no significant difference in the index of lung recruitment, the levels of inflammatory factors and the arterial blood gas analysis index between the two groups before treatment.","[{'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Guo', 'Affiliation': 'Department of Critical Care Medicine, Union Jiangbei Hospital, Huazhong University of Science and Technology, Wuhan 430100, Hubei, China. Corresponding author: Guo Jun, Email: 625246269@qq.com.'}, {'ForeName': 'Jinglong', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': ''}]",Zhonghua wei zhong bing ji jiu yi xue,['10.3760/cma.j.cn121430-20200406-00290'] 1805,32613240,Varying levels of serum estradiol do not alter the timing of the early endometrial secretory transformation.,"STUDY QUESTION Do supraphysiologic estradiol (E2) levels in the ranges attained during normal and high response superovulation cycles modify the onset of endometrial secretory transformation? SUMMARY ANSWER Highly supraphysiologic levels of E2 do not alter the ability of physiologic levels of progesterone (P4) to induce secretory transformation. WHAT IS KNOWN ALREADY Previous studies have demonstrated that premature P4 elevations during IVF cycles are associated with a decrement in clinical pregnancy rates after fresh embryo transfer due to shifts in the window of implantation (WOI). However, alterations in the onset of secretory transformation may not apply uniformly to all patients. High responders with supraphysiologic E2 levels accompanied by similar subtle increases in P4 have not been shown to have decreased sustained implantation rates. This prospective investigation in which whole-genome transcriptomic and methylomic analysis of the endometrium is performed for individual patients under a range of E2 concentrations brings clarity to a long-debated issue. STUDY DESIGN, SIZE, DURATION A randomized, prospective and paired trial was conducted in which 10 participants were enrolled and randomized to the order in which they completed three distinct uterine stimulation cycles, each at a specific E2 concentration: physiologic (∼180 pg/ml), moderately supraphysiologic (600-800 pg/ml) or supraphysiologic (2000 pg/ml). Target E2 ranges were selected to mimic those seen in natural, controlled ovarian stimulation and IVF cycles. E2 valerate was administered in order to maintain stable E2 levels for 12 days followed by intramuscular P4 in oil 10 mg/day for two doses, after which an endometrial biopsy was performed. A total of 30 endometrial biopsies were included in a whole-genome transcriptomic and methylomic analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS Healthy volunteers without a history of infertility were included in this study at a single large infertility center. DNA was isolated from the endometrial biopsy specimens and bisulfite sequencing was performed to construct a methylation array. Differential methylation analysis was conducted based on differences in M-values of individuals across treatment groups for each probe as well as carrying out t-tests. RNA was isolated for RNA-Seq analysis and gene expression values were compared using DESeq2. All analyses were performed in a pairwise fashion to compare among the three stimulation cycles within individuals and secondarily to compare all participants in each of the cycles. MAIN RESULTS AND THE ROLE OF CHANCE The mean peak E2 and P4 levels were 275 pg/ml and 4.17 ng/ml in the physiologic group, 910 pg/ml and 2.69 ng/ml in the moderate group was, and 2043 pg/ml and 2.64 ng/ml in the supraphysiologic group, respectively. Principal component analysis of 834 913 CpG sites was performed on M-values of individuals within the low, moderate and supraphysiologic conditions in a paired approach. There were no differences in genome-wide methylation within participants across E2 groups. A paired analysis revealed that gene expression profiles did not differ within the same individual at each of the three E2 levels. No significant alterations in gene expression as related to endometrial physiology were identified between the low, moderate and supraphysiologic groups in an inter-participant analysis. LIMITATIONS, REASONS FOR CAUTION Although each participant completed a physiologic cycle in which E2 levels were maintained in a range that would simulate a natural cycle, our findings are limited by lack of an unmedicated control to assess if there was a potential effect from E2V. Additionally, our results were obtained in fertile individuals, who may have a different endometrial response compared to an infertile population. Despite the whole genomic endometrial assessment and rigorous, paired study design, the sample size was limited. WIDER IMPLICATIONS OF THE FINDINGS Given that the endometrial response to P4 is unaffected by E2 levels in the supraphysiologic range, diminutions in implantation seen in stimulated cycles may result from embryonic-endometrial dyssynchrony following early P4 elevations or slowly blastulating embryos, which occur independently of the magnitude of the E2 rise. STUDY FUNDING/COMPETING INTEREST(S) This study was funded by the Foundation for Embryonic Competence, Basking Ridge, NJ, USA. Dr E.S. reports consultancy work for The Foundation for Embryonic Competence, Basking Ridge, NJ, USA. The other authors declare no conflict of interests related to this topic. TRIAL REGISTRATION NUMBER NCT02458404.",2020,"No significant alterations in gene expression as related to endometrial physiology were identified between the low, moderate and supraphysiologic groups in an inter-participant analysis. ","['Healthy volunteers without a history of infertility were included in this study at a single large infertility center', '10 participants', 'A total of 30 endometrial biopsies were included in a whole-genome transcriptomic and methylomic analysis']","['specific E2 concentration: physiologic (∼180 pg/ml), moderately supraphysiologic (600-800 pg/ml) or supraphysiologic', 'E2 valerate']","['gene expression profiles', 'genome-wide methylation', 'endometrial physiology', 'Varying levels of serum estradiol', 'mean peak E2 and P4 levels', 'clinical pregnancy rates']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0021359', 'cui_str': 'Sterility'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0404066', 'cui_str': 'Endometrial scraping'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0439297', 'cui_str': 'ng/L'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0042280', 'cui_str': 'Pentanoates'}]","[{'cui': 'C1449575', 'cui_str': 'Microarray Analysis'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0025723', 'cui_str': 'Methylation'}, {'cui': 'C0031842', 'cui_str': 'Physiology'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0474672', 'cui_str': 'Serum estradiol measurement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rates'}]",10.0,0.203383,"No significant alterations in gene expression as related to endometrial physiology were identified between the low, moderate and supraphysiologic groups in an inter-participant analysis. ","[{'ForeName': 'E K', 'Initials': 'EK', 'LastName': 'Osman', 'Affiliation': 'IVI-RMA New Jersey, Basking Ridge, NJ, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Wang', 'Affiliation': 'The Foundation for Embryonic Competence, Basking Ridge, NJ, USA.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Zhan', 'Affiliation': 'The Foundation for Embryonic Competence, Basking Ridge, NJ, USA.'}, {'ForeName': 'C R', 'Initials': 'CR', 'LastName': 'Juneau', 'Affiliation': 'Audubon Fertility, New Orleans, LA, USA.'}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Morin', 'Affiliation': 'IVI-RMA Northern California, San Francisco, CA, USA.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Seli', 'Affiliation': 'IVI-RMA New Jersey, Basking Ridge, NJ, USA.'}, {'ForeName': 'R T', 'Initials': 'RT', 'LastName': 'Scott', 'Affiliation': 'IVI-RMA New Jersey, Basking Ridge, NJ, USA.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Franasiak', 'Affiliation': 'IVI-RMA New Jersey, Basking Ridge, NJ, USA.'}]","Human reproduction (Oxford, England)",['10.1093/humrep/deaa135'] 1806,32609647,The particulars of certain drugs' effect on the endogenous coenzyme Q10 plasma level in patients with cardiovascular diseases.,"Objectives Coenzyme Q10 (CoQ10) has many vital functions in human body and its endogenous level can be affected either by various diseases or by administrated drugs. This study reveals the effect of atorvastatin, amlodipine and ethoxidol on the endogenous CoQ10 plasma concentration. Methods It was determined the total plasma concentration of endogenous CoQ10 in the plasma of 54 healthy individuals and 62 patients with cardiovascular diseases during treatment with various drugs using high performance liquid chromatography with mass spectrometric detection (HPLC-MS/MS). Results It was found that CoQ10 plasma concentration in patients is statistically significantly lower (on average -49.0 Δ%) than in practically healthy individuals. The total CoQ10 plasma level in patients receiving atorvastatin in the complex therapy is statistically significantly lower (-15.2 Δ%), and in patients taking amlodipine or ethoxidol is statistically significantly higher (+18.2 and +20.2 Δ%, respectively) than in patients of control groups (a group of patients who receive the same drugs, except for the studied one). Conclusions The study showed that in patients with CVDs treated with various drugs the CoQ10 plasma level is statistically significantly lower than in practically healthy individuals. So, to avoid the adverse reactions connected with low CoQ10 plasma levels, it is recommended to adjust the therapy to maintain its constant level.",2020,It was found that CoQ10 plasma concentration in patients is statistically significantly lower (on average -49.0 Δ%) than in practically healthy individuals.,"['54 healthy individuals and 62 patients with cardiovascular diseases', 'patients with cardiovascular diseases']","['atorvastatin', 'atorvastatin, amlodipine and ethoxidol', 'amlodipine', 'Objectives Coenzyme Q10 (CoQ10']","['total plasma concentration of endogenous CoQ10', 'total CoQ10 plasma level', 'CoQ10 plasma level', 'CoQ10 plasma concentration', 'endogenous coenzyme Q10 plasma level']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}]","[{'cui': 'C0286651', 'cui_str': 'atorvastatin'}, {'cui': 'C0051696', 'cui_str': 'Amlodipine'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0056077', 'cui_str': 'Ubiquinone'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C0056077', 'cui_str': 'Ubiquinone'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",54.0,0.0159371,It was found that CoQ10 plasma concentration in patients is statistically significantly lower (on average -49.0 Δ%) than in practically healthy individuals.,"[{'ForeName': 'Evgenia', 'Initials': 'E', 'LastName': 'Shikh', 'Affiliation': '2.Sechenov First Moscow State Medical University, Trubetskaya 8, bld. 2, Moscow, 119991, Russian Federation.'}, {'ForeName': 'Vladlena', 'Initials': 'V', 'LastName': 'Zozina', 'Affiliation': 'I M Sechenov First Moscow State Medical University, Russian Federation.'}, {'ForeName': 'Svetlana', 'Initials': 'S', 'LastName': 'Kondratenko', 'Affiliation': '2.Sechenov First Moscow State Medical University, Trubetskaya 8, bld. 2, Moscow, 119991, Russian Federation.'}, {'ForeName': 'Evgeny', 'Initials': 'E', 'LastName': 'Melnikov', 'Affiliation': '2.Sechenov First Moscow State Medical University, Trubetskaya 8, bld. 2, Moscow, 119991, Russian Federation.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Kukes', 'Affiliation': '2.Sechenov First Moscow State Medical University, Trubetskaya 8, bld. 2, Moscow, 119991, Russian Federation.'}]",Drug metabolism and personalized therapy,['10.1515/dmpt-2020-0106'] 1807,32609651,Can insights from placebo and nocebo mechanisms studies improve the randomized controlled trial?,"Background and aims The randomized controlled trial (RCT) is currently facing several challenges, one of these being that the placebo response appears to be increasing in RCTs, thereby making it difficult to demonstrate an effect of potentially new treatments over placebo. This problem has primarily been approached by predicting the magnitude of the placebo response via stable factors, such as demographic variables, and/or by developing complex designs aimed at reducing the placebo response in the hope that it will improve the test of the active treatment. Yet, the success of this approach has so far been limited. Methods A new approach toward improving the RCT is put forward based on placebo and nocebo mechanism studies, i.e. studies that investigate the mechanisms underlying placebo analgesia and nocebo hyperalgesia. In a series of meta-analyses the magnitude of placebo and nocebo effects were determined. Experimental studies across nociplastic and neuropathic pain conditions and across pharmacological and acupuncture treatments investigated psychological and neurobiological mechanisms underlying these effects. The obtained results were used to make approximations of expectations to see if that could predict the placebo response in RCTs and function as a new way of tapping into the placebo component of treatment effects. Results The magnitude of placebo and nocebo effects is large and highly variable. Placebo effects exist across chronic pain conditions with varying degrees of known etiology as well as across pharmacological and non-pharmacological treatments. Patients' perception of the treatment, the verbal suggestions given for pain relief, and the patients' expectations toward pain relief contribute to the magnitude of the placebo effect and to pain relief following placebo interventions. Also, unintentional unblinding and patients' perception of a treatment markedly influence the treatment outcome. By making approximations of expectations toward treatment effects it was possible to predict the magnitude of the placebo response in RCTs. Conclusions and implications The new approach of tapping into or directly asking patients about their perception and expectations toward a treatment, along with the account of the natural history of pain, has the potential to improve the information that can be obtained from RCTs. Thus, by interfacing insights from placebo and nocebo mechanism studies, it may be possible to enhance the information that can be obtained from RCTs and to account for a large part of the variability in the placebo component of the overall treatment effect. This approach has the potential to improve the scientific evaluation of treatments, as well as to illustrate how the effect of treatments can be optimized in clinical practice, which is the crux of evidence-based medicine.",2020,"Patients' perception of the treatment, the verbal suggestions given for pain relief, and the patients' expectations toward pain relief contribute to the magnitude of the placebo effect and to pain relief following placebo interventions.",[],"['acupuncture', 'Placebo', 'placebo']",['pain relief'],[],"[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief'}]",,0.289856,"Patients' perception of the treatment, the verbal suggestions given for pain relief, and the patients' expectations toward pain relief contribute to the magnitude of the placebo effect and to pain relief following placebo interventions.","[{'ForeName': 'Lene', 'Initials': 'L', 'LastName': 'Vase', 'Affiliation': 'Department of Psychology and Behavioural Sciences, Aarhus University, Bartholins Allé 11, Building 1350, DK-8000 Aarhus C, Denmark.'}]",Scandinavian journal of pain,['10.1515/sjpain-2019-0183'] 1808,31427720,The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.,,2020,,['patients with relapsed chronic lymphocytic leukemia treated with'],"['idelalisib plus rituximab', 'complex karyotype']",['overall survival'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0023434', 'cui_str': 'Chronic lymphocytic leukemia'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C2698692', 'cui_str': 'idelalisib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0022526', 'cui_str': 'Karyotype determination'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.0533494,,"[{'ForeName': 'Karl-Anton', 'Initials': 'KA', 'LastName': 'Kreuzer', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany. karl-anton.kreuzer@uni-koeln.de.'}, {'ForeName': 'Richard R', 'Initials': 'RR', 'LastName': 'Furman', 'Affiliation': 'Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Stilgenbauer', 'Affiliation': 'Department III of Internal Medicine, Ulm University Medical Center, Ulm, Germany.'}, {'ForeName': 'Ronald L', 'Initials': 'RL', 'LastName': 'Dubowy', 'Affiliation': 'Gilead Sciences, Inc., Foster City, CA, USA.'}, {'ForeName': 'Yeonhee', 'Initials': 'Y', 'LastName': 'Kim', 'Affiliation': 'Gilead Sciences, Inc., Foster City, CA, USA.'}, {'ForeName': 'Veerendra', 'Initials': 'V', 'LastName': 'Munugalavadla', 'Affiliation': 'Gilead Sciences, Inc., Foster City, CA, USA.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Lilienweiss', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Hans Christian', 'Initials': 'HC', 'LastName': 'Reinhardt', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Cramer', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Eichhorst', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hillmen', 'Affiliation': ""St. James's University Hospital, Leeds, UK.""}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': ""O'Brien"", 'Affiliation': 'University of California-Irvine, Irvine Chao Family Comprehensive Cancer Center, Orange, CA, USA.'}, {'ForeName': 'Andrew R', 'Initials': 'AR', 'LastName': 'Pettitt', 'Affiliation': 'University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hallek', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany.'}]",Leukemia,['10.1038/s41375-019-0533-6'] 1809,32615109,"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.","BACKGROUND Indications for liver transplantation for hepatocellular carcinoma are evolving and so-called expanded criteria remain debated. Locoregional therapies are able to downstage hepatocellular carcinoma from beyond to within the Milan criteria. We aimed to investigate the efficacy of liver transplantation after successful hepatocellular carcinoma downstaging. METHODS We did an open-label, multicentre, randomised, controlled trial designed in two phases, 2b and 3, at nine Italian tertiary care and transplantation centres. Patients aged 18-65 years with hepatocellular carcinoma beyond the Milan criteria, absence of macrovascular invasion or extrahepatic spread, 5-year estimated post-transplantation survival of at least 50%, and good liver function (Child-Pugh A-B7) were recruited and underwent tumour downstaging with locoregional, surgical, or systemic therapies according to multidisciplinary decision. After an observation period of 3 months, during which sorafenib was allowed, patients with partial or complete responses according to modified Response Evaluation Criteria in Solid Tumors were randomly assigned (1:1) by an interactive web-response system to liver transplantation or non-transplantation therapies (control group). A block randomisation (block size of 2), stratified by centre and compliance to sorafenib treatment, was applied. Liver transplantation was done with whole or split organs procured from brain-dead donors. The control group received sequences of locoregional and systemic treatment at the time of demonstrated tumour progression. The primary outcomes were 5-year tumour event-free survival for phase 2b and overall survival for phase 3. Analyses were by intention to treat. Organ allocation policy changed during the course of the study and restricted patient accrual to 4 years. This trial is registered with ClinicalTrials.gov, NCT01387503. FINDINGS Between March 1, 2011, and March 31, 2015, 74 patients were enrolled. Median duration of downstaging was 6 months (IQR 4-11). 29 patients dropped out before randomisation and 45 were randomly assigned: 23 to the transplantation group versus 22 to the control group. At data cutoff on July 31, 2019, median follow-up was 71 months (IQR 60-85). 5-year tumour event-free survival was 76·8% (95% CI 60·8-96·9) in the transplantation group versus 18·3% (7·1-47·0) in the control group (hazard ratio [HR] 0·20, 95% CI 0·07-0·57; p=0·003). 5-year overall survival was 77·5% (95% CI 61·9-97·1) in the transplantation group versus 31·2% (16·6-58·5) in the control group (HR 0·32, 95% CI 0·11-0·92; p=0·035). The most common registered grade 3-4 serious adverse events were hepatitis C virus recurrence (three [13%] of 23 patients) and acute transplant rejection (two [9%]) in the transplantation group, and post-embolisation syndrome (two [9%] of 22 patients) in the control group. Treatment-related deaths occurred in four patients: two (8%) of 23 patients in the transplantation group (myocardial infarction and multi-organ failure) versus two (9%) of 22 patients in the control group (liver decompensation). INTERPRETATION Although results must be interpreted with caution owing to the early closing of the trial, after effective and sustained downstaging of eligible hepatocellular carcinomas beyond the Milan criteria, liver transplantation improved tumour event-free survival and overall survival compared with non-transplantation therapies Post-downstaging tumour response could contribute to the expansion of hepatocellular carcinoma transplantation criteria. FUNDING Italian Ministry of Health.",2020,"overall survival was 77·5% (95% CI 61·9-97·1) in the transplantation group versus 31·2% (16·6-58·5) in the control group (HR 0·32, 95% CI 0·11-0·92; p=0·035).","['two phases, 2b and 3, at nine Italian tertiary care and transplantation centres', '29 patients dropped out before randomisation and 45 were randomly assigned: 23 to the transplantation group versus 22 to the control group', 'Between March 1, 2011, and March 31, 2015, 74 patients were enrolled', 'hepatocellular carcinoma after tumour downstaging (XXL', '0·20', 'Patients aged 18-65 years with hepatocellular carcinoma beyond the Milan criteria, absence of macrovascular invasion or extrahepatic spread, 5-year estimated post-transplantation survival of at least 50%, and good liver function (Child-Pugh A-B7) were recruited and underwent tumour downstaging with locoregional, surgical, or systemic therapies according to multidisciplinary decision', 'patients with partial or complete responses according to modified Response Evaluation Criteria in Solid Tumors']","['liver transplantation', 'sorafenib', 'Liver transplantation', 'interactive web-response system to liver transplantation or non-transplantation therapies (control group']","['5-year tumour event-free survival for phase 2b and overall survival', 'overall survival', 'tumour event-free survival', 'hepatitis C virus recurrence', 'acute transplant rejection', 'Median duration of downstaging', '5-year', 'deaths']","[{'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0022275', 'cui_str': 'Italian language'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C1269955', 'cui_str': 'Tumour invasion'}, {'cui': 'C0332261', 'cui_str': 'Spreading'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0232741', 'cui_str': 'Liver function'}, {'cui': 'C4050412', 'cui_str': 'Child-Pugh score'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1709926', 'cui_str': 'RECIST'}]","[{'cui': 'C0023911', 'cui_str': 'Transplantation of liver'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0079500', 'cui_str': 'Hepacivirus'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0018129', 'cui_str': 'Graft rejection'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",74.0,0.208689,"overall survival was 77·5% (95% CI 61·9-97·1) in the transplantation group versus 31·2% (16·6-58·5) in the control group (HR 0·32, 95% CI 0·11-0·92; p=0·035).","[{'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Mazzaferro', 'Affiliation': 'Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy. Electronic address: vincenzo.mazzaferro@istitutotumori.mi.it.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Citterio', 'Affiliation': 'HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Sherrie', 'Initials': 'S', 'LastName': 'Bhoori', 'Affiliation': 'HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Bongini', 'Affiliation': 'HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Rosalba', 'Initials': 'R', 'LastName': 'Miceli', 'Affiliation': 'Clinical Epidemiology and Trial Organization, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Luciano', 'Initials': 'L', 'LastName': 'De Carlis', 'Affiliation': 'General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-CàGranda Hospital, Milan, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Colledan', 'Affiliation': 'Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Salizzoni', 'Affiliation': 'General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Cittàdella Salute e della Scienza di Torino, Turin, Italy.'}, {'ForeName': 'Renato', 'Initials': 'R', 'LastName': 'Romagnoli', 'Affiliation': 'General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Cittàdella Salute e della Scienza di Torino, Turin, Italy.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Antonelli', 'Affiliation': ""Liver Transplant Unit and Gastroenterology Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Vivarelli', 'Affiliation': 'Hepatobiliary and Abdominal Transplantation Surgery, Hepatology, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Tisone', 'Affiliation': 'Department of Surgical Sciences and Medical Sciences University of Rome-Tor Vergata, Rome, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Rossi', 'Affiliation': 'Department of General Surgery and Organ Transplantation, Sapienza University, Rome, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Gruttadauria', 'Affiliation': 'Abdominal Surgery and Organ Transplantation Unit, Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, ISMETT, Palermo, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Di Sandro', 'Affiliation': 'General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-CàGranda Hospital, Milan, Italy.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'De Carlis', 'Affiliation': 'General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-CàGranda Hospital, Milan, Italy.'}, {'ForeName': 'Maria Grazia', 'Initials': 'MG', 'LastName': 'Lucà', 'Affiliation': 'Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'De Giorgio', 'Affiliation': 'Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Mirabella', 'Affiliation': 'General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Cittàdella Salute e della Scienza di Torino, Turin, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Belli', 'Affiliation': 'General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-CàGranda Hospital, Milan, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Fagiuoli', 'Affiliation': 'Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Martini', 'Affiliation': 'General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Cittàdella Salute e della Scienza di Torino, Turin, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Iavarone', 'Affiliation': ""Liver Transplant Unit and Gastroenterology Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.""}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Svegliati Baroni', 'Affiliation': 'Hepatobiliary and Abdominal Transplantation Surgery, Hepatology, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Angelico', 'Affiliation': 'Department of Surgical Sciences and Medical Sciences University of Rome-Tor Vergata, Rome, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Ginanni Corradini', 'Affiliation': 'Department of General Surgery and Organ Transplantation, Sapienza University, Rome, Italy.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Volpes', 'Affiliation': 'Abdominal Surgery and Organ Transplantation Unit, Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, ISMETT, Palermo, Italy.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Mariani', 'Affiliation': 'Clinical Epidemiology and Trial Organization, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Regalia', 'Affiliation': 'HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Flores', 'Affiliation': 'HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Droz Dit Busset', 'Affiliation': 'HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Sposito', 'Affiliation': 'Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.'}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30224-2'] 1810,32615798,Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.,"BACKGROUND Peripheral artery disease (PAD) is associated with increased risk of mortality, cardiovascular morbidity, and major amputation. Data on major amputation from a large randomized trial that included a substantial cohort of patients without critical limb ischemia (CLI) have not been described. The objective was to describe the incidence and types of amputations in the EUCLID trial (Examining Use of Ticagrelor in Peripheral Artery Disease) population, subcategorize amputations in the CLI versus no CLI cohorts, and describe the events surrounding major amputation. METHODS AND RESULTS Postrandomization major amputation was analyzed in the EUCLID trial. Patients were stratified by baseline CLI status. The occurrence of major amputation was ascertained and defined as the highest level. Perioperative events surrounding major amputation were obtained including acute limb ischemia, revascularization, and all-cause mortality. All variables were assessed for significance in univariable and multivariable models. The rate of major amputation during the course of the trial was 1.6% overall, 8.4% in the CLI at baseline group, and 1.2% in the no CLI at baseline group. The annualized rate of major amputation was 0.6% in PAD overall, 3.9% in the CLI at baseline group, and 0.5% in the no CLI at baseline group. Several factors were associated with increased risk of major amputation, including history of amputation, the presence of diabetes mellitus, baseline Rutherford category 4 to 6, and an ankle-brachial index <0.8. Factors associated with a lower risk for major amputation included prior statin use. The 30-day mortality rate after major amputation was 6.5% overall, 5.6% in the CLI at baseline group, and 6.8% in the no CLI at baseline group. The annual mortality rate following major amputation was 22.8% in the CLI at baseline group and 16.0% in the no CLI at baseline group. CONCLUSIONS The risk factors for major amputation in EUCLID patients are similar to previous large registries' reports except for diabetes mellitus in patients with CLI. The mortality following major amputation is lower in the EUCLID trial compared with registry data. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01732822.",2020,"The 30-day mortality rate after major amputation was 6.5% overall, 5.6% in the CLI at baseline group, and 6.8% in the no CLI at baseline group.","['patients with CLI', 'patients without critical limb ischemia (CLI', 'Patients With Peripheral Artery Disease']",['Ticagrelor'],"['occurrence of major amputation', 'risk of major amputation, including history of amputation, the presence of diabetes mellitus', '30-day mortality rate after major amputation', 'annualized rate of major amputation', 'rate of major amputation', 'annual mortality rate following major amputation', 'risk of mortality, cardiovascular morbidity, and major amputation', 'acute limb ischemia, revascularization, and all-cause mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1142264', 'cui_str': 'Critical limb ischemia'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}]","[{'cui': 'C1999375', 'cui_str': 'Ticagrelor'}]","[{'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C1301700', 'cui_str': 'Cardiovascular morbidity'}, {'cui': 'C4049535', 'cui_str': 'Acute limb ischaemia'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}]",,0.0731566,"The 30-day mortality rate after major amputation was 6.5% overall, 5.6% in the CLI at baseline group, and 6.8% in the no CLI at baseline group.","[{'ForeName': 'Chandler A', 'Initials': 'CA', 'LastName': 'Long', 'Affiliation': 'Department of Surgery, Division of Vascular Surgery and Endovascular Surgery (C.A.L.), Duke University Health System, Durham, NC.'}, {'ForeName': 'Hillary', 'Initials': 'H', 'LastName': 'Mulder', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (H.M., F.W.R., M.R.P., W.S.J.).'}, {'ForeName': 'F Gerry R', 'Initials': 'FGR', 'LastName': 'Fowkes', 'Affiliation': 'Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, United Kingdom (F.G.R.F.).'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Baumgartner', 'Affiliation': 'Division of Angiology, Swiss Cardiovascular Centre, Inselspital, Bern University Hospital, University of Bern, Switzerland (I.B.).'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Berger', 'Affiliation': 'Departments of Medicine (J.S.B.), New York University School of Medicine.'}, {'ForeName': 'Brian G', 'Initials': 'BG', 'LastName': 'Katona', 'Affiliation': 'AstraZeneca, Gaithersburg, MD (B.G.K.).'}, {'ForeName': 'Kenneth W', 'Initials': 'KW', 'LastName': 'Mahaffey', 'Affiliation': 'Stanford Center for Clinical Research, Stanford University School of Medicine, CA (K.W.M.).'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Norgren', 'Affiliation': 'Faculty of Medicine and Health, Örebro University, Sweden (L.N.).'}, {'ForeName': 'Juuso I', 'Initials': 'JI', 'LastName': 'Blomster', 'Affiliation': 'Heart Centre, Turku University Hospital, University of Turku, Finland (J.I.B.).'}, {'ForeName': 'Frank W', 'Initials': 'FW', 'LastName': 'Rockhold', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (H.M., F.W.R., M.R.P., W.S.J.).'}, {'ForeName': 'William R', 'Initials': 'WR', 'LastName': 'Hiatt', 'Affiliation': 'Department of Medicine, Division of Cardiology (W.R.H.), University of Colorado School of Medicine and CPC Clinical Research, Aurora.'}, {'ForeName': 'Manesh R', 'Initials': 'MR', 'LastName': 'Patel', 'Affiliation': 'Department of Medicine, Division of Cardiology (M.R.P., W.S.J.), Duke University Health System, Durham, NC.'}, {'ForeName': 'W Schuyler', 'Initials': 'WS', 'LastName': 'Jones', 'Affiliation': 'Department of Medicine, Division of Cardiology (M.R.P., W.S.J.), Duke University Health System, Durham, NC.'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Nehler', 'Affiliation': ''}]",Circulation. Cardiovascular quality and outcomes,['10.1161/CIRCOUTCOMES.119.006399'] 1811,32618032,The role of novelty and fat and sugar concentration in food selection by captive tufted capuchins (Sapajus apella).,"Capuchins, like other primates, use feedback from sensory cues and digestion to make decisions about which foods to consume and which to avoid. However, little is known about how capuchins make consumption decisions when simultaneously presented with novel and familiar foods, or how food familiarity and macronutrient concentration together influence food choice, topics with potential implications for developmental and health research. In this study, we evaluated the role of familiarity, as well as fat and sugar concentration, in the food selections of captive tufted capuchins (Sapajus apella). In the first experiment, over 10 sessions, subjects were assigned to either a group that chose between one familiar and one novel food item both high in fat or sugar (high condition), or to a group that chose between one familiar and one novel food item both low in fat or sugar (low condition). In the second experiment, subjects were divided into three groups, familiarized with food over five feeding sessions, and then offered the familiarized food and a novel food that varied in fat or sugar for 10 sessions. When offered foods high in fat, capuchins showed no clear signs of neophobia, forming an initial preference for the novel food, rejecting foods less frequently, and selecting foods faster than when offered foods low in fat. These trends were generally not observed in response to foods with sugar. When presented with options that varied in macronutrient concentration, subjects showed an initial interest in the novel food irrespective of whether it was high in fat or sugar, yet formed a final preference for the higher-concentration item. Findings suggest that the concentration of fat or sugar in novel foods may be an important mediator of exploratory behavior and that capuchins rely on immediate feedback from taste and other sensory cues to make consumption decisions.",2020,"When offered foods high in fat, capuchins showed no clear signs of neophobia, forming an initial preference for the novel food, rejecting foods less frequently, and selecting foods faster than when offered foods low in fat.",[],"['familiarized with food over five feeding sessions, and then offered the familiarized food and a novel food that varied in fat or sugar for 10 sessions', 'one familiar and one novel food item both high in fat or sugar (high condition), or to a group that chose between one familiar and one novel food item both low in fat or sugar (low condition']",[],[],"[{'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",[],,0.0156631,"When offered foods high in fat, capuchins showed no clear signs of neophobia, forming an initial preference for the novel food, rejecting foods less frequently, and selecting foods faster than when offered foods low in fat.","[{'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Heuberger', 'Affiliation': 'Center on Social Dynamics and Policy, The Brookings Institution, Washington, District of Columbia.'}, {'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Paukner', 'Affiliation': 'School of Social Sciences, Nottingham Trent University, Nottingham, Nottingham, UK.'}, {'ForeName': 'Lauren J', 'Initials': 'LJ', 'LastName': 'Wooddell', 'Affiliation': 'Laboratory of Comparative Ethology, National Institute of Child Health and Human Development, Poolesville, Maryland.'}, {'ForeName': 'Matt', 'Initials': 'M', 'LastName': 'Kasman', 'Affiliation': 'Center on Social Dynamics and Policy, The Brookings Institution, Washington, District of Columbia.'}, {'ForeName': 'Ross A', 'Initials': 'RA', 'LastName': 'Hammond', 'Affiliation': 'Center on Social Dynamics and Policy, The Brookings Institution, Washington, District of Columbia.'}]",American journal of primatology,['10.1002/ajp.23165'] 1812,32619032,Designing a multi-component intervention (P3-MumBubVax) to promote vaccination in antenatal care in Australia.,"ISSUE ADDRESSED Coverage of maternal influenza and pertussis vaccines remains suboptimal in Australia, and pockets of low childhood vaccine coverage persist nationwide. Maternal vaccine uptake is estimated to be between 35% and 60% for influenza vaccination and between 65% and 80% for pertussis vaccination. Australian midwives are highly trusted and ideally placed to discuss vaccines with expectant parents, but there are no evidence-based interventions to optimise these discussions and promote maternal and childhood vaccine acceptance in the Australian public antenatal setting. METHODS We gathered qualitative data from Australian midwives, reviewed theoretical models, and adapted existing vaccine communication tools to develop the multi-component P3-MumBubVax intervention. Through 12 interviews at two Australian hospitals, we explored midwives' vaccination attitudes and values, perceived role in vaccine advocacy and delivery, and barriers and enablers to intervention implementation. Applying the theory-based P3 intervention model, we designed intervention components targeting the Practice, Provider and Parent levels. Midwives provided feedback on prototype intervention features through two focus groups. RESULTS The P3-MumBubVax intervention includes practice-level prompts and identification of a vaccine champion. Provider-level components are a vaccine communication training module, learning exercise, and website with printable fact sheets. Parent-level intervention components include text message reminders to receive influenza and pertussis vaccines in pregnancy, as well as online information on vaccine safety, effectiveness and disease severity. CONCLUSIONS The P3-MumBubVax intervention is the first Australian antenatal intervention designed to support both maternal and childhood vaccine uptake. A pilot study is underway to inform a planned cluster randomised controlled trial. SO WHAT?: Barriers to vaccine acceptance and uptake are complex. The P3 model is a promising evidence-informed multi-component intervention strategy targeting all three levels influencing health care decision-making.",2020,The P3-MumBubVax intervention is the first Australian antenatal intervention designed to support both maternal and childhood vaccine uptake.,['antenatal care in Australia'],"['multi-component intervention (P3-MumBubVax', 'P3-MumBubVax intervention']","['Maternal vaccine uptake', 'vaccine safety, effectiveness and disease severity']","[{'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",,0.0735001,The P3-MumBubVax intervention is the first Australian antenatal intervention designed to support both maternal and childhood vaccine uptake.,"[{'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Kaufman', 'Affiliation': ""Murdoch Children's Research Institute, Parkville, Australia.""}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Attwell', 'Affiliation': 'School of Social Sciences, University of Western Australia, Perth, Australia.'}, {'ForeName': 'Yvonne', 'Initials': 'Y', 'LastName': 'Hauck', 'Affiliation': 'School of Nursing, Midwifery & Paramedicine, Curtin University, Perth, Australia.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Leask', 'Affiliation': 'Faculty of Medicine and Health, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Saad B', 'Initials': 'SB', 'LastName': 'Omer', 'Affiliation': 'Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Regan', 'Affiliation': 'School of Public Health, Texas A&M University, College Station, TX, USA.'}, {'ForeName': 'Margie', 'Initials': 'M', 'LastName': 'Danchin', 'Affiliation': ""Murdoch Children's Research Institute, Parkville, Australia.""}]",Health promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals,['10.1002/hpja.382'] 1813,32598997,The effect of low-volume high-intensity interval training on cardiovascular health outcomes in type 2 diabetes: A randomised controlled trial.,"BACKGROUND Low-volume high-intensity interval training (HIIT) may be a time-efficient strategy that leads to similar or superior improvements in cardiorespiratory fitness (CRF) and cardiovascular disease (CVD) risk factors when compared with moderate-intensity continuous training (MICT). Our study investigated the effect of low-volume HIIT or MICT versus sham placebo-control (PLA) on central arterial stiffness, hemodynamic responses, and CVD risk factors in adults with obesity and type 2 diabetes (T2D). METHODS Eligible participants were previously inactive adults with obesity and T2D. Individuals were randomly allocated to: i) HIIT (1 × 4 min cycling at 90% peak oxygen consumption [V̇O 2peak ]); ii) MICT (45 min of cycling at 60% VO 2peak ); or PLA. Training groups exercised thrice weekly for 12 weeks. Central arterial stiffness, hemodynamics and CVD risk factors were assessed at baseline and post-intervention. Analysis of covariance (ANCOVA) was used to examine changes following HIIT, MICT and PLA. RESULTS Thirty-five participants (age: 55.1 ± 1.4 years, BMI: 36.1 ± 0.8 kg/m 2 ) completed the study. A significant intervention effect was found for changes in pulse wave velocity (PWV) (p = .03), which reduced with HIIT (-0.3 ± 0.9 m/s) and MICT (-0.1 ± 1.1 m/s) but increased with PLA (0.8 ± 1.6 m/s). There was a significant intervention effect for changes in V̇O 2peak (p < .01), glycosylated hemoglobin (p = .03), systolic blood pressure (p < .01), and waist circumference (p = .03), which all improved following MICT or HIIT but not PLA; there was no difference between MICT and HIIT. CONCLUSIONS Twelve minutes of low-volume HIIT per week leads to improvements in central arterial stiffness and cardiovascular health in inactive individuals with obesity and T2D.",2020,"A significant intervention effect was found for changes in pulse wave velocity (PWV) (p = .05), which reduced with HIIT (-0.3 ± 0.9 m/s) and MICT (-0.1 ± 1.1 m/s) but increased with PLA (0.8 ± 1.6 m/s).","['Eligible participants were previously inactive adults with obesity and T2D. Individuals', 'adults with obesity and type 2 diabetes (T2D', 'inactive individuals with obesity and T2D', 'Thirty-five participants (age: 55.1\u202f±\u202f1.4\u202fyears, BMI: 36.1\u202f±\u202f0.8\u202fkg/m 2 ) completed the study', 'type 2 diabetes']","['low-volume HIIT or MICT versus sham placebo-control (PLA', 'HIIT (1\u202f×\u202f4 min cycling at 90% peak oxygen consumption [V̇O 2peak ]); ii) MICT (45\u202fmin of cycling at 60% VO 2peak ); or PLA', 'low-volume high-intensity interval training', 'Low-volume high-intensity interval training (HIIT']","['waist circumference', 'Central arterial stiffness, hemodynamics and CVD risk factors', 'cardiovascular health outcomes', 'central arterial stiffness, hemodynamic responses, and CVD risk factors', 'cardiorespiratory fitness (CRF) and cardiovascular disease (CVD) risk factors', 'V̇O 2peak', 'glycosylated hemoglobin', 'systolic blood pressure', 'central arterial stiffness and cardiovascular health', 'pulse wave velocity (PWV']","[{'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517503', 'cui_str': '1.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}]","[{'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}]",,0.0978978,"A significant intervention effect was found for changes in pulse wave velocity (PWV) (p = .05), which reduced with HIIT (-0.3 ± 0.9 m/s) and MICT (-0.1 ± 1.1 m/s) but increased with PLA (0.8 ± 1.6 m/s).","[{'ForeName': 'Kimberley L', 'Initials': 'KL', 'LastName': 'Way', 'Affiliation': 'Faculty of Medicine and Health, Discipline of Exercise and Sports Science, University of Sydney, Camperdown, NSW, Australia; The Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, University of Sydney, Camperdown, NSW, Australia; The Charles Perkins Centre, University of Sydney, Camperdown, NSW, Australia. Electronic address: kim.way@deakin.edu.au.'}, {'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Sabag', 'Affiliation': 'Faculty of Medicine and Health, Discipline of Exercise and Sports Science, University of Sydney, Camperdown, NSW, Australia; The Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, University of Sydney, Camperdown, NSW, Australia; The Charles Perkins Centre, University of Sydney, Camperdown, NSW, Australia.'}, {'ForeName': 'Rachelle N', 'Initials': 'RN', 'LastName': 'Sultana', 'Affiliation': 'Faculty of Medicine and Health, Discipline of Exercise and Sports Science, University of Sydney, Camperdown, NSW, Australia; The Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, University of Sydney, Camperdown, NSW, Australia; The Charles Perkins Centre, University of Sydney, Camperdown, NSW, Australia.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Baker', 'Affiliation': 'School of Exercise Science, Australian Catholic University, Strathfield, NSW, Australia.'}, {'ForeName': 'Shelley E', 'Initials': 'SE', 'LastName': 'Keating', 'Affiliation': 'Centre for Research on Exercise, Physical Activity and Health, School of Human Movement, and Nutrition Sciences, The University of Queensland, St Lucia, QLD, Australia.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Lanting', 'Affiliation': 'School of Health Sciences, University of Newcastle, Ourimbah, NSW, Australia.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Gerofi', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, University of Sydney, Camperdown, NSW, Australia; The Charles Perkins Centre, University of Sydney, Camperdown, NSW, Australia.'}, {'ForeName': 'Vivienne H', 'Initials': 'VH', 'LastName': 'Chuter', 'Affiliation': 'Centre for Research on Exercise, Physical Activity and Health, School of Human Movement, and Nutrition Sciences, The University of Queensland, St Lucia, QLD, Australia.'}, {'ForeName': 'Ian D', 'Initials': 'ID', 'LastName': 'Caterson', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, University of Sydney, Camperdown, NSW, Australia; The Charles Perkins Centre, University of Sydney, Camperdown, NSW, Australia.'}, {'ForeName': 'Stephen M', 'Initials': 'SM', 'LastName': 'Twigg', 'Affiliation': 'The Charles Perkins Centre, University of Sydney, Camperdown, NSW, Australia; Central Clinical School, School of Medicine, University of Sydney, Camperdown, NSW, Australia.'}, {'ForeName': 'Nathan A', 'Initials': 'NA', 'LastName': 'Johnson', 'Affiliation': 'Faculty of Medicine and Health, Discipline of Exercise and Sports Science, University of Sydney, Camperdown, NSW, Australia; The Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, University of Sydney, Camperdown, NSW, Australia; The Charles Perkins Centre, University of Sydney, Camperdown, NSW, Australia.'}]",International journal of cardiology,['10.1016/j.ijcard.2020.06.019'] 1814,32604962,Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis.,"To date, the impact of background glucocorticoids (GC) on the efficacy and safety of abatacept or adalimumab in patients with active rheumatoid arthritis (RA) is not clearly established. This post hoc analysis of (AMPLE) trial (NCT00929864) compared efficacy and safety outcomes over 2 years in patients treated with abatacept or adalimumab plus background methotrexate (MTX), who continued GC (≤10 mg/day) versus those who were not receiving GC (no-GC). Of 646 randomized patients, 317 received abatacept + MTX (161 GC, 156 no-GC) and 326 received adalimumab + MTX (162 GC, 164 no-GC). At Year 2, the adjusted mean changes from baseline in Disease Activity Score (DAS28 C-reactive protein (CRP)) and Health Assessment Questionnaire-Disability Index (HAQ-DI) were not significantly different in the GC versus no-GC subgroups receiving abatacept or adalimumab. A similar proportion of patients achieved remission, HAQ-DI score improvement ≥0.3 and radiographic progression rates. No clinically meaningful safety differences were observed between GC versus no-GC subgroups either with abatacept or adalimumab. In patients with active RA of similar baseline disease activity treated with abatacept or adalimumab plus background MTX, there was no additional value of background GC on clinical, functional or radiographic outcomes over two years.",2020,No clinically meaningful safety differences were observed between GC versus no-GC subgroups either with abatacept or adalimumab.,"['Patients with Rheumatoid Arthritis', 'patients with active rheumatoid arthritis (RA', '646 randomized patients, 317 received', 'patients with active RA of similar baseline disease activity treated with', '≤10 mg/day) versus those who were not receiving GC (no-GC']","['adalimumab', 'adalimumab + MTX', 'abatacept or adalimumab plus background methotrexate (MTX), who continued GC', 'abatacept or adalimumab', 'background glucocorticoids (GC', 'abatacept or adalimumab plus background MTX', ' Glucocorticoid Therapy', 'abatacept + MTX', 'Abatacept or Adalimumab']","['efficacy and safety outcomes', 'remission, HAQ-DI score improvement ≥0.3 and radiographic progression rates', 'Disease Activity Score (DAS28 C-reactive protein (CRP)) and Health Assessment Questionnaire-Disability Index (HAQ-DI']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}]","[{'cui': 'C1122087', 'cui_str': 'adalimumab'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C1619966', 'cui_str': 'abatacept'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}, {'cui': 'C0744425', 'cui_str': 'Glucocorticoid therapy'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0451208', 'cui_str': 'Health assessment questionnaire'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}]",646.0,0.0507699,No clinically meaningful safety differences were observed between GC versus no-GC subgroups either with abatacept or adalimumab.,"[{'ForeName': 'Yannick', 'Initials': 'Y', 'LastName': 'Degboé', 'Affiliation': 'Rheumatology Centre, Toulouse University Hospital and University Toulouse III Paul Sabatier, 31059 Toulouse, France.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schiff', 'Affiliation': 'Rheumatology Division, University of Colorado, Denver, CO 80111, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Weinblatt', 'Affiliation': ""Department of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA 02115, USA.""}, {'ForeName': 'Roy', 'Initials': 'R', 'LastName': 'Fleischmann', 'Affiliation': 'Department of Internal Medicine, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX 75231, USA.'}, {'ForeName': 'Harris A', 'Initials': 'HA', 'LastName': 'Ahmad', 'Affiliation': 'Immunology, Bristol-Myers Squibb, Princeton, NJ 08540, USA.'}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Constantin', 'Affiliation': 'Rheumatology Centre, Toulouse University Hospital and University Toulouse III Paul Sabatier, 31059 Toulouse, France.'}]",Journal of clinical medicine,['10.3390/jcm9062017'] 1815,32611451,Effectiveness of reminders to sustain practice change among direct care providers in residential care facilities: a cluster randomized controlled trial.,"BACKGROUND The study purpose was to compare the effectiveness of monthly or quarterly peer reminder knowledge translation interventions, with monthly or quarterly paper-based reminders, to sustain a mobility innovation, the sit-to-stand activity. METHOD A cluster RCT using a stratified 2 × 2 factorial design was conducted in 24 Canadian residential care facilities with 416 residents and 54 peer reminder care aides. The 1-year intervention included two intensities of reminders (high: socially based peer reminders delivered by volunteer care aides to other care aides; low: paper-based reminders posted in residents' rooms), at two frequencies (monthly; every 3 months). Intervention fidelity was assessed using questionnaires and observations. Monthly sustainability rate of the sit-to-stand activity was calculated as the percentage of opportunities that residents successfully completed the activity in 30 days. Residents' sustainability rates were analyzed using a linear mixed model that mirrored the clustered repeated-measures factorial trial design. The model included a random intercept to account for clustering within sites. An unstructured covariance structure characterized the interdependence of repeated measures over time. RESULTS Twenty-four sites were randomized. One site was excluded because of falsifying data, leaving 23 sites and 349 residents for intention-to-treat analysis. Paper reminders were implemented with high fidelity across all arms (91.5% per protocol), while the peer reminders were implemented with moderate fidelity in the monthly group (81.0% per protocol) and poor fidelity in the quarterly group (51.7% per protocol). At month 1, mean sustainability ranged from 40.7 to 47.2 per 100 opportunities, across the four intervention arms (p = 0.43). Mean rate of sustainability in the high intensity, high frequency group diverged after randomization, yielding statistically significant differences among the groups at 4 months which persisted for the remainder of the trial. After 12 months, the mean sustainability in the high intensity, high frequency group was approximately twice that of the other three groups combined (64.1 versus 37.8 per 100 opportunities, p < 0.001). CONCLUSIONS A monthly peer reminder intervention was more effective than a quarterly peer reminder intervention, a monthly paper-based reminder intervention, and a quarterly paper-based reminder intervention, in supporting care aides to sustain a mobility innovation in residential care facilities over 1 year. TRIAL REGISTRATION ClinicalTrials.gov , NCT01746459. Registered 11 December 2012: https://clinicaltrials.gov/ct2/show/NCT01746459 .",2020,"After 12 months, the mean sustainability in the high intensity, high frequency group was approximately twice that of the other three groups combined (64.1 versus 37.8 per 100 opportunities, p < 0.001). ","['residential care facilities', 'Twenty-four sites were randomized', '24 Canadian residential care facilities with 416 residents and 54 peer reminder care aides']","[""intensities of reminders (high: socially based peer reminders delivered by volunteer care aides to other care aides; low: paper-based reminders posted in residents' rooms""]","['Monthly sustainability rate of the sit-to-stand activity', 'Mean rate of sustainability', 'Intervention fidelity', 'mean sustainability']","[{'cui': 'C0035186', 'cui_str': 'Residential Facilities'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}]","[{'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0560801', 'cui_str': 'Does stand from sitting'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",,0.0687829,"After 12 months, the mean sustainability in the high intensity, high frequency group was approximately twice that of the other three groups combined (64.1 versus 37.8 per 100 opportunities, p < 0.001). ","[{'ForeName': 'Susan E', 'Initials': 'SE', 'LastName': 'Slaughter', 'Affiliation': 'Faculty of Nursing, Edmonton Clinic Health Academy, University of Alberta, 11405 87 Avenue, Edmonton, T6G 1C9, Canada. susan.slaughter@ualberta.ca.'}, {'ForeName': 'Misha', 'Initials': 'M', 'LastName': 'Eliasziw', 'Affiliation': 'Department of Public Health and Community Medicine, Tufts University, Boston, USA.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Ickert', 'Affiliation': 'Faculty of Nursing, Edmonton Clinic Health Academy, University of Alberta, 11405 87 Avenue, Edmonton, T6G 1C9, Canada.'}, {'ForeName': 'C Allyson', 'Initials': 'CA', 'LastName': 'Jones', 'Affiliation': 'Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Carole A', 'Initials': 'CA', 'LastName': 'Estabrooks', 'Affiliation': 'Faculty of Nursing, Edmonton Clinic Health Academy, University of Alberta, 11405 87 Avenue, Edmonton, T6G 1C9, Canada.'}, {'ForeName': 'Adrian S', 'Initials': 'AS', 'LastName': 'Wagg', 'Affiliation': 'Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.'}]",Implementation science : IS,['10.1186/s13012-020-01012-z'] 1816,32609918,TMJ arthroscopy with hyaluronic acid: A 12-month randomized clinical trial.,"OBJECTIVES To determine the effects of hyaluronic acid (HA) as an adjunct to temporomandibular joint (TMJ) arthroscopy, relative to standard TMJ arthroscopy, in Wilkes stage-III and stage-IV patients. METHODS A randomized clinical trial design was utilized (ClinicalTrials.gov NCT04110587). 51 patients were allocated to a TMJ arthroscopy (n = 25) or a TMJ arthroscopy plus HA (n = 26) group. Visual analog scale joint pain scores, maximum mouth opening (MMO), and muscle pain were measured at baseline, and at 3, 6, 9, and 12 months. Disk position on magnetic resonance imaging was evaluated at baseline and 12 months. Oral health-related quality of life (OHRQoL) was assessed at baseline, and at 6 and 12 months. RESULTS No group differences were observed in clinical or radiographic measurements (p ≥ .05). The results do not indicate any benefit of HA as an adjuvant therapy to arthroscopy during follow-up months 3-12. TMJ arthroscopy improved OHRQoL at 6 and 12 months (Oral Health Impact Profile-14 questionnaire scores of -14.59 and -14.27, 95% confidence intervals = -17.55 to -11.63 and -17.27 to -11.27) respectively, as well as pain and MMO, at all follow-up time points (p < .001). CONCLUSIONS A beneficial effect of HA injection during TMJ arthroscopy after the 3-month follow-up was not observed.",2020,"TMJ arthroscopy improved OHRQoL at 6 and 12 months (Oral Health Impact Profile-14 questionnaire scores of -14.59 and -14.27, 95% confidence intervals = -17.55 to -11.63 and -17.27 to -11.27) respectively, as well as pain and MMO, at all follow-up time points (P<0.001). ","['51 patients', 'Wilkes stage-III and -IV patients']","['TMJ arthroscopy plus HA', 'hyaluronic acid (HA', 'hyaluronic acid', 'HA injection', 'TMJ arthroscopy', 'TMJ Arthroscopy with Hyaluronic Acid']","['Oral-health-related quality of life (OHRQoL', 'Visual analog scale joint pain scores, maximum mouth opening (MMO), and muscle pain', 'pain and MMO', 'clinical or radiographic measurements', 'TMJ arthroscopy improved OHRQoL at 6 and 12 months (Oral Health Impact Profile-14 questionnaire scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}]","[{'cui': 'C0039493', 'cui_str': 'Temporomandibular joint structure'}, {'cui': 'C0003904', 'cui_str': 'Arthroscopy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0003862', 'cui_str': 'Joint pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0240379', 'cui_str': 'Open mouth'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0039493', 'cui_str': 'Temporomandibular joint structure'}, {'cui': 'C0003904', 'cui_str': 'Arthroscopy'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",51.0,0.352357,"TMJ arthroscopy improved OHRQoL at 6 and 12 months (Oral Health Impact Profile-14 questionnaire scores of -14.59 and -14.27, 95% confidence intervals = -17.55 to -11.63 and -17.27 to -11.27) respectively, as well as pain and MMO, at all follow-up time points (P<0.001). ","[{'ForeName': 'Oscar Gabriel', 'Initials': 'OG', 'LastName': 'Castaño-Joaqui', 'Affiliation': 'Department of Conservative Dentistry and Bucofacial Prosthesis, Complutense University of Madrid, Madrid, Spain.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Cano-Sánchez', 'Affiliation': 'Department of Dental Clinical Specialties, Complutense University of Madrid, Madrid, Spain.'}, {'ForeName': 'Julián', 'Initials': 'J', 'LastName': 'Campo-Trapero', 'Affiliation': 'Department of Dental Clinical Specialties, Complutense University of Madrid, Madrid, Spain.'}, {'ForeName': 'Mario Fernando', 'Initials': 'MF', 'LastName': 'Muñoz-Guerra', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University Hospital of La Princesa, Madrid, Spain.'}]",Oral diseases,['10.1111/odi.13524'] 1817,32610487,A Three-Arm Randomised Controlled Trial of High- and Low-Intensity Implementation Strategies to Support Centre-Based Childcare Service Implementation of Nutrition Guidelines: 12-Month Follow-Up.,"The study aimed to compare the effectiveness of a suite of implementation strategies of varying intensities on centre-based childcare service implementation of nutrition guideline recommendations at 12-month follow-up. A six-month three-arm parallel group randomised controlled trial was undertaken with 69 services, randomised to one of three arms: high-intensity strategies (executive support; group face-to-face training; provision of resources; multiple rounds of audit and feedback; ongoing face-to-face and phone support); low-intensity strategies (group face-to-face training; provision of resources; single round of audit and feedback); or usual care control. Across all study arms, only three high-intensity services were compliant with overall nutrition guidelines. A significant group interaction was found between the three arms for compliance with individual food groups. Relative to control, a significantly greater proportion of low-intensity services were compliant with dairy, and a significantly greater proportion of high-intensity services were compliant with fruit, vegetables, dairy, breads and cereals, and discretionary foods. No significant differences between the high- and low-intensity for individual food group compliance were found. High-intensity implementation strategies may be effective in supporting childcare service implementation of individual food group recommendations. Further research is warranted to identify strategies effective in increasing overall nutrition compliance.",2020,"Relative to control, a significantly greater proportion of low-intensity services were compliant with dairy, and a significantly greater proportion of high-intensity services were compliant with fruit, vegetables, dairy, breads and cereals, and discretionary foods.",['to Support Centre-Based Childcare Service Implementation of Nutrition Guidelines'],"['high-intensity strategies (executive support; group face-to-face training; provision of resources; multiple rounds of audit and feedback; ongoing face-to-face and phone support); low-intensity strategies (group face-to-face training; provision of resources; single round of audit and feedback); or usual care control', 'High- and Low-Intensity Implementation Strategies']",[],"[{'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C3658297', 'cui_str': 'Dietary Guidelines'}]","[{'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0332490', 'cui_str': 'Round shape'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205250', 'cui_str': 'High'}]",[],,0.0519355,"Relative to control, a significantly greater proportion of low-intensity services were compliant with dairy, and a significantly greater proportion of high-intensity services were compliant with fruit, vegetables, dairy, breads and cereals, and discretionary foods.","[{'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Grady', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Callaghan 2308, Australia.'}, {'ForeName': 'Kirsty', 'Initials': 'K', 'LastName': 'Seward', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Callaghan 2308, Australia.'}, {'ForeName': 'Meghan', 'Initials': 'M', 'LastName': 'Finch', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Callaghan 2308, Australia.'}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Wolfenden', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Callaghan 2308, Australia.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Wyse', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Callaghan 2308, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Wiggers', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Callaghan 2308, Australia.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Lecathelinais', 'Affiliation': 'Hunter New England Local Health District, Population Health, Wallsend 2287, Australia.'}, {'ForeName': 'Sze Lin', 'Initials': 'SL', 'LastName': 'Yoong', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Callaghan 2308, Australia.'}]",International journal of environmental research and public health,['10.3390/ijerph17134664'] 1818,32615579,Developmental effects on sleep-wake patterns in infants receiving a cow's milk-based infant formula with an added prebiotic blend: a Randomized Controlled Trial.,"BACKGROUND Few studies have evaluated nutritive effects of prebiotics on infant behavior state, physiology, or metabolic status. METHODS In this double-blind randomized study, infants (n = 161) received cow's milk-based infant formula (Control) or similar formula with an added prebiotic blend (polydextrose and galactooligosaccharides [PDX/GOS]) from 14-35 to 112 days of age. Infant wake behavior (crying/fussing, awake/content) and 24-h sleep-wake actograms were analyzed (Baseline, Days 70 and 112). Salivary cortisol was immunoassayed (Days 70 and 112). In a subset, exploratory stool 16S ribosomal RNA-sequencing was analyzed (Baseline, Day 112). RESULTS One hundred and thirty-one infants completed the study. Average duration of crying/fussing episodes was similar at Baseline, significantly shorter for PDX/GOS vs. Control at Day 70, and the trajectory continued at Day 112. Latency to first and second nap was significantly longer for PDX/GOS vs. Control at Day 112. Cortisol awakening response was demonstrated at Days 70 and 112. Significant stool microbiome beta-diversity and individual taxa abundance differences were observed in the PDX/GOS group. CONCLUSIONS Results indicate faster consolidation of daytime waking state in infants receiving prebiotics and support home-based actigraphy to assess early sleep-wake patterns. A prebiotic effect on wake organization is consistent with influence on the gut-brain axis and warrants further investigation. IMPACT Few studies have evaluated nutritive effects of prebiotics on infant behavior state, cortisol awakening response, sleep-wake entrainment, and gut microbiome.Faster consolidation of daytime waking state was demonstrated in infants receiving a prebiotic blend in infant formula through ~4 months of age.Shorter episodes of crying were demonstrated at ~2 months of age (time point corresponding to age/developmental range associated with peak crying) in infants receiving formula with added prebiotics.Results support home-based actigraphy as a suitable method to assess early sleep-wake patterns.Prebiotic effect on wake organization is consistent with influence on the gut-brain axis and warrants further investigation.",2020,Latency to first and second nap was significantly longer for PDX/GOS vs. Control at Day 112.,"[""infants receiving a cow's milk-based infant formula with an added prebiotic blend"", 'One hundred and thirty-one infants completed the study', 'infants (n\u2009=\u2009161) received']","[""cow's milk-based infant formula (Control) or similar formula with an added prebiotic blend (polydextrose and galactooligosaccharides [PDX/GOS""]","['Latency to first and second nap', 'Average duration of crying/fussing episodes', 'Cortisol awakening response', 'Infant wake behavior (crying/fussing, awake/content) and 24-h sleep-wake actograms', 'sleep-wake patterns', 'Shorter episodes of crying', 'Salivary cortisol', 'Significant stool microbiome beta-diversity and individual taxa abundance differences', 'daytime waking state']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0349374', 'cui_str': ""Cow's milk""}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0150589', 'cui_str': 'Infant formula'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0349374', 'cui_str': ""Cow's milk""}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0150589', 'cui_str': 'Infant formula'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C0071545', 'cui_str': 'polydextrose'}, {'cui': 'C0332134', 'cui_str': 'Preliminary diagnosis'}]","[{'cui': 'C0242465', 'cui_str': 'Response Latency'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0067518', 'cui_str': 'N-(4-aminophenethyl)spiroperidol'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0010399', 'cui_str': 'Crying'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C1720052', 'cui_str': 'Awakening'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0234422', 'cui_str': 'Awake'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C1956108', 'cui_str': 'Microbiome'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C1301808', 'cui_str': 'State'}]",,0.101785,Latency to first and second nap was significantly longer for PDX/GOS vs. Control at Day 112.,"[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Colombo', 'Affiliation': 'Schiefelbusch Institute for Life Span Studies and Department of Psychology, University of Kansas, Lawrence, KS, USA. colombo@ku.edu.'}, {'ForeName': 'Susan E', 'Initials': 'SE', 'LastName': 'Carlson', 'Affiliation': 'Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Algarín', 'Affiliation': 'Sleep and Functional Neurobiology Laboratory, Institute of Nutrition and Food Technology (INTA), University of Chile, Santiago, Chile.'}, {'ForeName': 'Sussanne', 'Initials': 'S', 'LastName': 'Reyes', 'Affiliation': 'Sleep and Functional Neurobiology Laboratory, Institute of Nutrition and Food Technology (INTA), University of Chile, Santiago, Chile.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Chichlowski', 'Affiliation': 'Nutrition Science, Department of Medical Affairs, Mead Johnson Nutrition, 2400 West Lloyd Expy, Evansville, IN, 47721, USA.'}, {'ForeName': 'Cheryl L', 'Initials': 'CL', 'LastName': 'Harris', 'Affiliation': 'Clinical Research, Department of Medical Affairs, Mead Johnson Nutrition, 2400 West Lloyd Expy, Evansville, IN, 47721, USA.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Wampler', 'Affiliation': 'Clinical Research, Department of Medical Affairs, Mead Johnson Nutrition, 2400 West Lloyd Expy, Evansville, IN, 47721, USA.'}, {'ForeName': 'Patricio', 'Initials': 'P', 'LastName': 'Peirano', 'Affiliation': 'Sleep and Functional Neurobiology Laboratory, Institute of Nutrition and Food Technology (INTA), University of Chile, Santiago, Chile.'}, {'ForeName': 'Carol Lynn', 'Initials': 'CL', 'LastName': 'Berseth', 'Affiliation': 'Clinical Research, Department of Medical Affairs, Mead Johnson Nutrition, 2400 West Lloyd Expy, Evansville, IN, 47721, USA.'}]",Pediatric research,['10.1038/s41390-020-1044-x'] 1819,32618522,Investigating the learning curve in endoscopic compared to microscopic myringotomy and ventilation tube insertion.,"OBJECTIVE Rate of learning is often cited as a deterrent in the use of endoscopic ear surgery. This study investigated the learning curves of novice surgeons performing simulated ear surgery using either an endoscope or a microscope. METHODS A prospective multi-site clinical research study was conducted. Seventy-two medical students were randomly allocated to the endoscope or microscope group, and performed 10 myringotomy and ventilation tube insertions. Trial times were used to produce learning curves. From these, slope (learning rate) and asymptote (optimal proficiency) were ascertained. RESULTS There was no significant difference between the learning curves (p = 0.41). The learning rate value was 68.62 for the microscope group and 78.71 for the endoscope group. The optimal proficiency (seconds) was 32.83 for the microscope group and 27.87 for the endoscope group. CONCLUSION The absence of a significant difference shows that the learning rates of each technique are statistically indistinguishable. This suggests that surgeons are not justified when citing 'steep learning curve' in arguments against the use of endoscopes in middle-ear surgery.",2020,"The optimal proficiency (seconds) was 32.83 for the microscope group and 27.87 for the endoscope group. ",['Seventy-two medical students'],"['microscopic myringotomy and ventilation tube insertion', 'endoscope or microscope group, and performed 10 myringotomy and ventilation tube insertions', 'novice surgeons performing simulated ear surgery using either an endoscope or a microscope']","['learning curves', 'learning rates', 'learning rate value']","[{'cui': 'C4319632', 'cui_str': '72'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}]","[{'cui': 'C0205288', 'cui_str': 'Microscopic'}, {'cui': 'C0087123', 'cui_str': 'Tympanostomy'}, {'cui': 'C0850121', 'cui_str': 'Tympanic ventilation tube'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0014243', 'cui_str': 'Endoscope'}, {'cui': 'C0181839', 'cui_str': 'Microscope'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0038899', 'cui_str': 'Otologic Surgical Procedure'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",72.0,0.022179,"The optimal proficiency (seconds) was 32.83 for the microscope group and 27.87 for the endoscope group. ","[{'ForeName': 'O', 'Initials': 'O', 'LastName': 'Denton', 'Affiliation': 'Postgraduate Centre, Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Daglish', 'Affiliation': 'Postgraduate Medical Education Centre, Royal Berkshire NHS Foundation Trust, Reading, UK.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Smallman', 'Affiliation': 'School of Mathematics, Cardiff University, Wales, UK.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Fishpool', 'Affiliation': 'Department of ENT, Cwm Taf Morgannwg University Health Board, Ynysmaerdy, Wales, UK.'}]",The Journal of laryngology and otology,['10.1017/S0022215120001188'] 1820,32619619,"A commentary on ""Efficacy of single layered intestinal anastomosis over double layered intestinal anastomosis-an open labeled, randomized controlled trial"".",,2020,,[],['single layered intestinal anastomosis'],[],[],"[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0192711', 'cui_str': 'Anastomosis of intestine'}]",[],,0.130852,,"[{'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Liu', 'Affiliation': 'Department of Colorectal Surgery, Changhai Hospital, Second Military Medical University, 200433, Shanghai, China.'}, {'ForeName': 'Zubing', 'Initials': 'Z', 'LastName': 'Mei', 'Affiliation': 'Department of Anorectal Surgery, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China; Anorectal Disease Institute of Shuguang Hospital, 201203, Shanghai, China. Electronic address: herrmayor@126.com.'}, {'ForeName': 'Guixin', 'Initials': 'G', 'LastName': 'Shen', 'Affiliation': 'Department of General Surgery, The Second Affiliated Hospital of Jiaxing University, 314000, Jiaxing, Zhejiang Province, China. Electronic address: jxeysgx1191@163.com.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2020.06.036'] 1821,32619832,Definitive chemoradiotherapy plus cetuximab for cancer in the oesophagus or gastro-oesophageal junction.,"BACKGROUND Chemoradiotherapy is standard treatment for localized oesophageal cancer unsuitable for surgery. We aimed to evaluate the efficacy of cetuximab in combination with chemoradiotherapy. METHODS This non-randomised multicentre phase II trial recruited patients aged 18-75 with WHO performance status 0-2 having squamous cell carcinoma or adenocarcinoma in the oesophagus or gastro-oesophageal junction, T2-4, N0-3, M0 not suitable for surgery. Chemotherapy was three 21-day cycles of fluorouracil 750 mg/m2 D1-5 and oxaliplatin D1 (cycle 1:130mg/m 2, cycle 2-3:85 mg/m 2). Radiotherapy was 50Gy in 2Gy/fraction, 5 days a week, concurrent with cycle 2 and 3 and weekly cetuximab. The primary objective was loco-regional control at one year. RESULTS 52 patients were included. 51 were eligible for toxicity and survival analysis and 46 for recurrence analysis. Full radiotherapy dose was delivered to 80%, 75% received all three cycles of chemotherapy and 75% received four or more doses of cetuximab. The most common related grade III-IV adverse events were gastro-intestinal(16), hypersensitivity(6) and infection(5). There were two drug-related deaths. Within six months from the end of treatment, six patients died from complications from fistulas. The loco-regional control rate at one year was 47.3%(95%CI 30.9%-62.1%). Overall survival at three years was 29.1%(95% CI 17.4-41.9%). CONCLUSIONS Oxaliplatin and fluorouracil given concurrent with radiotherapy and cetuximab had an acceptable safety profile and showed a clinical response in patients with locoregionally advanced oesophageal cancer unsuitable for surgery. However, the primary end-point was not met, and the addition of cetuximab to definitive chemoradiotherapy cannot be recommended.",2020,"Overall survival at three years was 29.1%(95% CI 17.4-41.9%). ","['localized oesophageal cancer unsuitable for surgery', 'cancer in the oesophagus or gastro-oesophageal junction', 'patients with locoregionally advanced oesophageal cancer unsuitable for surgery', 'patients aged 18-75 with WHO performance status 0-2 having squamous cell carcinoma or adenocarcinoma in the oesophagus or gastro-oesophageal junction, T2-4, N0-3, M0 not suitable for surgery', '52 patients were included']","['radiotherapy and cetuximab', 'Chemotherapy', 'Definitive chemoradiotherapy plus cetuximab', 'Oxaliplatin and fluorouracil', 'Full radiotherapy', 'cetuximab', 'Chemoradiotherapy', 'fluorouracil 750 mg/m2 D1-5 and oxaliplatin D1 (cycle 1:130mg', 'Radiotherapy']","['toxicity and survival analysis', 'Overall survival', 'loco-regional control at one year', 'loco-regional control rate']","[{'cui': 'C0392752', 'cui_str': 'Localized'}, {'cui': 'C0546837', 'cui_str': 'Malignant tumor of esophagus'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0014876', 'cui_str': 'Esophageal structure'}, {'cui': 'C0014871', 'cui_str': 'Cardioesophageal junction structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0007137', 'cui_str': 'Squamous cell carcinoma'}, {'cui': 'C0001418', 'cui_str': 'Adenocarcinoma'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0995188', 'cui_str': 'cetuximab'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0443196', 'cui_str': 'Definitive'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C4517868', 'cui_str': '750'}, {'cui': 'C1319266', 'cui_str': 'mg/sq.m'}]","[{'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0038953', 'cui_str': 'Analysis, Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4082117', 'cui_str': 'One year'}]",52.0,0.16028,"Overall survival at three years was 29.1%(95% CI 17.4-41.9%). ","[{'ForeName': 'Gabriella Alexandersson', 'Initials': 'GA', 'LastName': 'von Döbeln', 'Affiliation': 'Theme Cancer, Karolinska University Hospital, Stockholm, Sweden. Electronic address: gabriella.alexandersson-vondobeln@sll.se.'}, {'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Wagenius', 'Affiliation': 'Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Holtved', 'Affiliation': 'Department of Oncology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Anne-Birgitte', 'Initials': 'AB', 'LastName': 'Jacobsen', 'Affiliation': 'Department of Oncology, Oslo University hospital, Oslo, Norway.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Nilsson', 'Affiliation': 'Department of Clinical Sciences Intervention and Technology Karolinska Institutet Division of Upper Abdominal Cancer, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Jingru', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Lene', 'Initials': 'L', 'LastName': 'Baeksgaard', 'Affiliation': 'Department of Oncology, Rigshospitalet, Copenhagen, Denmark.'}]",Cancer treatment and research communications,['10.1016/j.ctarc.2020.100187'] 1822,32621905,The ENGAGE-2 study: Engaging self-regulation targets to understand the mechanisms of behavior change and improve mood and weight outcomes in a randomized controlled trial (Phase 2).,"Despite evidence for effective integrated behavior therapy for treating comorbid obesity and depression, treatment response is highly variable and the underlying neurobiological mechanisms remain unknown. This hampers efforts to identify mechanistic targets in order to optimize treatment precision and potency. Funded within the NIH Science of Behavior Change (SOBC) Research Network, the 2-phased ENGAGE research project applies an experimental precision medicine approach to address this gap. The Phase 1 study focused on demonstrating technical feasibility, target engagement and potential neural mechanisms of responses to an integrated behavior therapy. This therapy combines a video-based behavioral weight loss program and problem-solving therapy for depression, with as-needed intensification of antidepressant medications, and its clinical effectiveness was demonstrated within a parent randomized clinical trial. Here, we describe the ENGAGE Phase 2 (ENGAGE-2) study protocol which builds on Phase 1 in 2 ways: (1) pilot testing of an motivational interviewing-enhanced, integrated behavior therapy in an independent, primarily minority patient sample, and (2) evaluation of a priori defined neural targets, specifically the negative affect (threat and sadness) circuits which demonstrated engagement and malleability in Phase 1, as mediators of therapeutic outcomes. Additionally, the Phase 2 study includes a conceptual and methodological extension to explore the role of microbiome-gut-brain and systemic immunological pathways in integrated behavioral treatment of obesity and depression. This protocol paper documents the conceptualization, design and the transdisciplinary methodologies in ENGAGE-2, which can inform future clinical and translational research in experimental precision medicine for behavior change and chronic disease management. Trial registration: ClinicalTrials.gov #NCT 03,841,682.",2020,"The Phase 1 study focused on demonstrating technical feasibility, target engagement and potential neural mechanisms of responses to an integrated behavior therapy.",[],"['motivational interviewing-enhanced, integrated behavior therapy', 'video-based behavioral weight loss program and problem-solving therapy']",[],[],"[{'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C3179079', 'cui_str': 'Weight Loss Programs'}, {'cui': 'C1303140', 'cui_str': 'Problem solving therapy'}]",[],,0.0347898,"The Phase 1 study focused on demonstrating technical feasibility, target engagement and potential neural mechanisms of responses to an integrated behavior therapy.","[{'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Lv', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, United States.'}, {'ForeName': 'Olusola A', 'Initials': 'OA', 'LastName': 'Ajilore', 'Affiliation': 'Department of Psychiatry, University of Illinois at Chicago, Chicago, IL 60612, United States.'}, {'ForeName': 'Corina R', 'Initials': 'CR', 'LastName': 'Ronneberg', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, United States.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Venditti', 'Affiliation': 'Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States.'}, {'ForeName': 'Mark B', 'Initials': 'MB', 'LastName': 'Snowden', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98104, United States.'}, {'ForeName': 'Philip W', 'Initials': 'PW', 'LastName': 'Lavori', 'Affiliation': 'Department of Biomedical Data Science, Stanford University, Stanford, CA 94305, United States.'}, {'ForeName': 'Lan', 'Initials': 'L', 'LastName': 'Xiao', 'Affiliation': 'Department of Epidemiology and Population Health, Stanford University, Palo Alto, CA 94304, United States.'}, {'ForeName': 'Andrea N', 'Initials': 'AN', 'LastName': 'Goldstein-Piekarski', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, United States; MIRECC VISN21, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, United States.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Wielgosz', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, United States.'}, {'ForeName': 'Nancy E', 'Initials': 'NE', 'LastName': 'Wittels', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, United States.'}, {'ForeName': 'Amruta', 'Initials': 'A', 'LastName': 'Barve', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, United States.'}, {'ForeName': 'Aashutos S', 'Initials': 'AS', 'LastName': 'Patel', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, United States.'}, {'ForeName': 'Tessa L', 'Initials': 'TL', 'LastName': 'Eckley', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, United States.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Stetz', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, United States.'}, {'ForeName': 'Ben S', 'Initials': 'BS', 'LastName': 'Gerber', 'Affiliation': 'Division of Academic Internal Medicine and Geriatrics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, United States.'}, {'ForeName': 'Joshua M', 'Initials': 'JM', 'LastName': 'Smyth', 'Affiliation': 'Departments of Biobehavioral Health and Medicine, Pennsylvania State University, University Park, PA 16802, United States.'}, {'ForeName': 'Janine M', 'Initials': 'JM', 'LastName': 'Simmons', 'Affiliation': 'National Institute of Mental Health (NIMH), National Institutes of Health, Bethesda, MD 20892, United States.'}, {'ForeName': 'Lisa G', 'Initials': 'LG', 'LastName': 'Rosas', 'Affiliation': 'Department of Epidemiology and Population Health, Stanford University, Palo Alto, CA 94304, United States; Department of Medicine, Stanford University, Palo Alto, CA 94304, United States.'}, {'ForeName': 'Leanne M', 'Initials': 'LM', 'LastName': 'Williams', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, United States; MIRECC VISN21, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, United States.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, United States; Department of Medicine, University of Illinois at Chicago, Chicago, IL 60608, United States. Electronic address: maj2015@uic.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106072'] 1823,32621918,Dexmedetomidine pretreatment attenuates myocardial ischemia reperfusion induced acute kidney injury and endoplasmic reticulum stress in human and rat.,"BACKGROUND Patients undergoing cardiopulmonary bypass (CPB) often develop acute kidney injury (AKI) caused by myocardial ischemia reperfusion (MI/R), and this renal injury can be resolved notably by dexmedetomidine. Endoplasmic reticulum (ER) stress was reported to get involved in organ injury including AKI. OBJECTIVES The current study aimed to address the correlation between MI/R induced AKI with ER stress and to assess the effects of dexmedetomidine pretreatment on AKI protection. METHOD Patients selected for heart valve replacement surgery were randomly assigned to NS group (pre-anesthesia with 0.9% NaCl) and DEX group (pre-anesthesia with dexmedetomidine). Rat MI/R model was induced by occluding coronary artery for 30 min followed by 48-hour reperfusion. Rats were randomized into Sham (0.9% NaCl), I/R (MI/R + 0.9% NaCl) and I/R + DEX (MI/R + dexmedetomidine). Organ function and ER stress condition were evaluated by blood chemistry, pathology, and molecular test. RESULTS Clinical data indicated dexmedetomidine pretreatment attenuated AKI and oxidative stress as well as postischemic myocardial injury in patients. Accordingly animal results suggested dexmedetomidine reduced cellular injury and improved postischemic myocardial and renal function. Dexmedetomidine also reduced myocardial and renal cells apoptosis and down-regulated ER stress. CONCLUSIONS These results suggested that dexmedetomidine pretreatment attenuates MI/R injury-induced AKI by relieving the ER stress.",2020,"Dexmedetomidine also reduced myocardial and renal cells apoptosis and down-regulated ER stress. ","['Patients undergoing', 'Patients selected for heart valve replacement surgery', 'human and rat']","['cardiopulmonary bypass (CPB', 'NS group (pre-anesthesia with 0.9% NaCl) and DEX group (pre-anesthesia with dexmedetomidine', 'Dexmedetomidine', '\u202fDEX (MI/R\u202f+\u202fdexmedetomidine', 'dexmedetomidine']","['MI/R injury-induced AKI', 'Endoplasmic reticulum (ER) stress', 'AKI and oxidative stress', 'myocardial and renal cells apoptosis and down-regulated ER stress', 'cellular injury and improved postischemic myocardial and renal function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0190173', 'cui_str': 'Heart valve replacement'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}]","[{'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0011816', 'cui_str': 'Dextromethorphan'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0035124', 'cui_str': 'Reperfusion'}]","[{'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0035126', 'cui_str': 'Ischemia-reperfusion injury'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0014239', 'cui_str': 'Endoplasmic reticulum'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0162638', 'cui_str': 'Apoptosis'}, {'cui': 'C0851285', 'cui_str': 'Regulation'}, {'cui': 'C3178870', 'cui_str': 'Stress, Endoplasmic Reticulum'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}]",,0.0396497,"Dexmedetomidine also reduced myocardial and renal cells apoptosis and down-regulated ER stress. ","[{'ForeName': 'Chaoliang', 'Initials': 'C', 'LastName': 'Tang', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, Anhui, China. Electronic address: chaolt@ustc.edu.cn.'}, {'ForeName': 'Yida', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Gao', 'Affiliation': 'Department of Anesthesia, Critical Care & Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02144, USA.'}, {'ForeName': 'Jiazhen', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': 'Department of Emergency, Huashan Hospital North, Fudan University, Shanghai, 201907, China.'}, {'ForeName': 'Si', 'Initials': 'S', 'LastName': 'Shi', 'Affiliation': 'Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China.'}, {'ForeName': 'Jiawu', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, Anhui, China.'}, {'ForeName': 'Qingtian', 'Initials': 'Q', 'LastName': 'Geng', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, Anhui, China.'}, {'ForeName': 'Xinghan', 'Initials': 'X', 'LastName': 'Liang', 'Affiliation': 'Department of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230000, Anhui, China.'}, {'ForeName': 'Xiaoqing', 'Initials': 'X', 'LastName': 'Chai', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, Anhui, China. Electronic address: xiaoqingchai@163.com.'}]",Life sciences,['10.1016/j.lfs.2020.118004'] 1824,32622071,Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolism.,"Vitamin D effects on bone and mineral metabolism are well recognized, and its anti-inflammatory actions are gaining particular interest. Delta-like 1 (DLK1) is a protein, expressed by progenitor cells of different tissues, and increases the size of progenitor cell population during the inflammatory phase of tissue regeneration. DLK1 also plays a role in energy metabolism as it antagonizes insulin signaling in bone. In this one-year randomized clinical trial of overweight elderly individuals that received either 600 or 3750 IU daily cholecalciferol we assessed the effect of vitamin D supplementation on pre-specified secondary outcomes: DLK1, leptin, adiponectin, C-Reactive Protein (CRP) and Vascular Cell Adhesion Molecule (VCAM). We also examined correlations between DLK1 and bone (BMD, bone markers), fat (adipokines, body composition), insulin sensitivity and inflammatory markers. Multivariate analyses were conducted to further explore these associations. Overall, there was a significant increase in serum DLK1 and leptin and a decrease in VCAM, but no change in CRP, after 12 months of vitamin D supplementation. DLK1 was negatively correlated with BMD and positively correlated with bone markers, associations that persisted after adjusting for age, gender and BMI. DLK1 was also positively associated with indices of insulin resistance and negatively with indices of insulin sensitivity. Correlations between DLK1 and fat parameters, such as adipokines, and DXA derived fat mass were less consistent. There were no correlations between DLK1 and inflammatory markers. In conclusion, twelve months supplementation of vitamin D3 increased serum DLK1. DLK1 was negatively associated with indices of bone health and fuel metabolism, and with 1,25(OH) 2 D levels. Similar to the role of DLK1 in animal models, our findings support the hypothesis that DLK1 can be targeted to regulate bone and energy metabolism and develop drugs to improve BMD and insulin sensitivity. However, further studies are needed to explore the role of DLK1 and its relationship to vitamin D metabolites in vivo.",2020,"Correlations between DLK1 and fat parameters, such as adipokines, and DXA derived fat mass were less consistent.",['overweight elderly individuals'],"['Vitamin D', 'Delta-like 1 (DLK1', '600 or 3750\u202fIU daily cholecalciferol', 'vitamin D supplementation', 'vitamin D3']","['bone health and fuel metabolism, and with 1,25(OH) 2 D levels', 'serum DLK1 and leptin', 'serum DLK1', 'DLK1 and inflammatory markers', 'DLK1', 'BMD and insulin sensitivity', 'leptin, adiponectin, C-Reactive Protein (CRP) and Vascular Cell Adhesion Molecule (VCAM', 'VCAM', 'DLK1and bone (BMD, bone markers), fat (adipokines, body composition), insulin sensitivity and inflammatory markers', 'bone and mineral metabolism', 'insulin resistance and negatively with indices of insulin sensitivity']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C4517746', 'cui_str': '3750'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}]","[{'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0556991', 'cui_str': 'Fuel'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0078056', 'cui_str': 'Lymphocyte antigen CD106'}, {'cui': 'C0181734', 'cui_str': 'Bone marker'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C1955907', 'cui_str': 'Adipokine'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.0714769,"Correlations between DLK1 and fat parameters, such as adipokines, and DXA derived fat mass were less consistent.","[{'ForeName': 'Aya', 'Initials': 'A', 'LastName': 'Bassatne', 'Affiliation': 'Calcium Metabolism and Osteoporosis Program, Division of Endocrinology and Metabolism, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.'}, {'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Jafari', 'Affiliation': 'Molecular Endocrinology and Stem Cell Research Unit (KMEB), Department of Endocrinology and Metabolism, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Cellular and Molecular Medicine, Novo Nordisk Foundation Center for Stem Cell Biology (DanStem), University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Moustapha', 'Initials': 'M', 'LastName': 'Kassem', 'Affiliation': 'Molecular Endocrinology and Stem Cell Research Unit (KMEB), Department of Endocrinology and Metabolism, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Christos', 'Initials': 'C', 'LastName': 'Mantzoros', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Rahme', 'Affiliation': 'Calcium Metabolism and Osteoporosis Program, Division of Endocrinology and Metabolism, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.'}, {'ForeName': 'Ghada', 'Initials': 'G', 'LastName': 'El-Hajj Fuleihan', 'Affiliation': 'Calcium Metabolism and Osteoporosis Program, Division of Endocrinology and Metabolism, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address: gf01@aub.edu.lb.'}]",Bone,['10.1016/j.bone.2020.115510'] 1825,32623343,"""Sushi roll"" technique for precise total tongue functional reconstruction using a pre-sutured femoral anterolateral myocutaneous flap.","OBJECTIVES Reconstruction of the total tongue after cancer resection remains one of the challenges in head and neck surgery. Inadequate reconstruction after subtotal or total glossectomy defects leads to poor quality of life. The aim of this study was to explore an economical, practical and effective flap design for functional tongue reconstruction. MATERIAL AND METHODS Sixty patients were randomly divided into two groups, namely, a ""Sushi roll"" technique group (30 patients) and a conventional surgery group (30 patients). Then, the patients underwent total or subtotal tongue reconstruction. Swallowing function, speech intelligibility, cosmetic results, and quality of life were assessed with the appropriate scales. Outcomes were analysed, and a p-value <0.05 was considered significant. RESULTS The perioperative recovery of the ""Sushi roll"" group was superior to that of the conventional group. Relative to patients in the conventional group, patients in the ""Sushi roll"" group showed significantly improved speech intelligibility (p = 0.025), cosmetic results (p < 0.001) and swallowing function (p < 0.001). CONCLUSION The innovative ""Sushi roll"" anterolateral thigh myocutaneous flap approach for total tongue reconstruction creates a free neotongue tip with adequate volume and protuberance and causes minimal damage to the donor site, producing acceptable swallowing function and speech intelligibility.",2020,"Relative to patients in the conventional group, patients in the ""Sushi roll"" group showed significantly improved speech intelligibility (p = 0.025), cosmetic results (p < 0.001) and swallowing function (p < 0.001). ","['head and neck surgery', 'Sixty patients']","['Sushi roll"" technique group', 'conventional surgery', 'Sushi roll"" technique', 'subtotal tongue reconstruction']","['speech intelligibility', 'swallowing function', 'Swallowing function, speech intelligibility, cosmetic results, and quality of life', 'perioperative recovery', 'cosmetic results']","[{'cui': 'C0460004', 'cui_str': 'Structure of head and/or neck'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C0399188', 'cui_str': 'Tongue reconstruction'}]","[{'cui': 'C0037824', 'cui_str': 'Speech Intelligibility'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",60.0,0.0201308,"Relative to patients in the conventional group, patients in the ""Sushi roll"" group showed significantly improved speech intelligibility (p = 0.025), cosmetic results (p < 0.001) and swallowing function (p < 0.001). ","[{'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'Lecturer, Discipline of Oral & Maxillofacial Surgery, The Second Xiangya Hospital, Central South University, Changsha, China. Electronic address: drzhouxi0504@csu.edu.cn.'}, {'ForeName': 'Zhi-Jing', 'Initials': 'ZJ', 'LastName': 'He', 'Affiliation': 'Lecturer, Discipline of Oral & Maxillofacial Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Yu-Xiong', 'Initials': 'YX', 'LastName': 'Su', 'Affiliation': 'Associate Professor, Discipline of Oral & Maxillofacial Surgery, Faculty of Dentistry, the University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Sheng', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': 'Professor and Chief, Discipline of Oral & Maxillofacial Surgery, The Second Xiangya hospital, Central South University, Changsha, China.'}, {'ForeName': 'Zhao Jian', 'Initials': 'ZJ', 'LastName': 'Gong', 'Affiliation': 'Associate Professor, Discipline of Oral & Maxillofacial Surgery, The Second Xiangya hospital, Central South University, Changsha, China.'}, {'ForeName': 'Han Jiang', 'Initials': 'HJ', 'LastName': 'Wu', 'Affiliation': 'Professor and Chief, Discipline of Oral & Maxillofacial Surgery, The Second Xiangya hospital, Central South University, Changsha, China.'}]",Oral oncology,['10.1016/j.oraloncology.2020.104866'] 1826,32623361,Immediate effects of valgus bracing on knee joint moments during walking in knee-healthy individuals: Potential modifying effects of body height.,"BACKGROUND The goal of valgus knee brace treatment is to reduce medial knee joint loading during walking, often indicated by external knee adduction moment (KAM) measures. However, existing healthy-subjects studies have been equivocal in demonstrating KAM reduction with valgus knee bracing. RESEARCH QUESTION What are the immediate effects of valgus bracing at different tension levels on KAM during walking at a controlled speed and does body height modify the brace-KAM associations? METHODS Data from 32 knee-healthy participants were analysed in this randomized crossover trial. Participants performed walking trials at controlled speed (1.3 ± 0.065 m/s) both with and without an Ossür Unloader One® brace. During the bracing condition, valgus tension was incrementally increased, from zero tension to normal tension and to maximum tolerable tension. RESULTS Valgus bracing minimally increased knee flexion at heel-strike (P < 0.001) in a dose-dependent manner and minimally reduced gait velocity (∼0.015m/s) across all tension levels. Valgus bracing, overall, did not significantly reduce the various KAM measures. However, brace use at maximal tension was associated with a 0.04Nm/kg (9.2 %) increase in first peak KAM amongst participants with a body height of 1.75 m and a 0.03Nm/kg (7.6 %) decrease in first peak KAM amongst participants with a body height of 1.55 m. SIGNIFICANCE Valgus bracing did not reduce the various KAM measures during walking; however, body height may play a moderating role. Given knee brace sizes vary more in circumference than length, this result may be due to the ratio between effective moment arm length relative to limb length. A deeper understanding of the potential neuro-biomechanical effects of valgus knee bracing and how these effects are potentially modified by body height may be critical to the design of effective knee braces.",2020,Valgus bracing minimally increased knee flexion at heel-strike (P < 0.001) in a dose-dependent manner and minimally reduced gait velocity (∼0.015m/s) across all tension levels.,"['Data from 32 knee-healthy participants', 'knee-healthy individuals']",['valgus bracing'],"['gait velocity', 'various KAM measures', 'knee joint moments', 'knee flexion at heel-strike']","[{'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0042282', 'cui_str': 'Valgus deformity'}, {'cui': 'C1828220', 'cui_str': 'Application of brace'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231457', 'cui_str': 'Adduction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0022745', 'cui_str': 'Knee joint structure'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0018870', 'cui_str': 'Heel structure'}, {'cui': 'C0038452', 'cui_str': 'Employee Strikes'}]",,0.0313931,Valgus bracing minimally increased knee flexion at heel-strike (P < 0.001) in a dose-dependent manner and minimally reduced gait velocity (∼0.015m/s) across all tension levels.,"[{'ForeName': 'Yong-Hao', 'Initials': 'YH', 'LastName': 'Pua', 'Affiliation': 'Department of Physiotherapy, Singapore General Hospital, Singapore. Electronic address: pua.yong.hao@sgh.com.sg.'}, {'ForeName': 'Hong-Han', 'Initials': 'HH', 'LastName': 'Tan', 'Affiliation': 'Department of Physiotherapy, Singapore General Hospital, Singapore. Electronic address: tan.hong.han@sgh.com.sg.'}, {'ForeName': 'Benjamin F', 'Initials': 'BF', 'LastName': 'Mentiplay', 'Affiliation': 'La Trobe Sport and Exercise Medicine Research Centre, La Trobe University, Victoria, Australia. Electronic address: b.mentiplay@latrobe.edu.au.'}, {'ForeName': 'Leon Zhi-Xia', 'Initials': 'LZ', 'LastName': 'Lim', 'Affiliation': 'Department of Health and Social Sciences, Singapore Institute of Technology, Singapore. Electronic address: leonlimzx@hotmail.com.'}, {'ForeName': 'Asher Chi-Weng', 'Initials': 'AC', 'LastName': 'Tham', 'Affiliation': 'Department of Health and Social Sciences, Singapore Institute of Technology, Singapore. Electronic address: ashertham@hotmail.com.'}, {'ForeName': 'Joshua Jia-En', 'Initials': 'JJ', 'LastName': 'Quek', 'Affiliation': 'Department of Health and Social Sciences, Singapore Institute of Technology, Singapore. Electronic address: Quek.joshua@gmail.com.'}, {'ForeName': 'Ee-Lin', 'Initials': 'EL', 'LastName': 'Woon', 'Affiliation': 'Department of Physiotherapy, Singapore General Hospital, Singapore. Electronic address: woon.ee.lin@sgh.com.sg.'}, {'ForeName': 'Ting-Ting', 'Initials': 'TT', 'LastName': 'Yeh', 'Affiliation': 'Department of Health and Social Sciences, Singapore Institute of Technology, Singapore. Electronic address: tingting.yeh@singaporetech.edu.sg.'}, {'ForeName': 'Celia Ia-Choo', 'Initials': 'CI', 'LastName': 'Tan', 'Affiliation': 'Department of Physiotherapy, Singapore General Hospital, Singapore; SingHealth Group Allied Health, Singapore. Electronic address: celia.tan.i.c@singhealth.com.sg.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Hunt', 'Affiliation': 'Department of Physical Therapy, University of British Columbia, Vancouver, Canada. Electronic address: michael.hunt@ubc.ca.'}, {'ForeName': 'Ross Allan', 'Initials': 'RA', 'LastName': 'Clark', 'Affiliation': 'Research Health Institute, University of the Sunshine Coast, Sunshine Coast, Australia. Electronic address: rclark@usc.edu.au.'}]",Gait & posture,['10.1016/j.gaitpost.2020.06.025'] 1827,32624429,Effect of Prior Formal Education on Successful Thoracic Epidural Placement By Anesthesia Residents.,"OBJECTIVE Catheter placement for thoracic epidural analgesia (TEA) is technically challenging; however, methods for teaching this technique to anesthesia residents have not been well-studied. The present study aimed to determine optimal teaching methods for proficient TEA catheter placement by comparing video-based formal resident education with traditional bedside training by attending physicians. DESIGN Prospective, randomized study. SETTING Large academic hospital, single institution. PARTICIPANTS The study comprised 76 postgraduate year 3 and 4 anesthesiology residents (38 intervention, 38 control). INTERVENTIONS Formal education included an instructional video on proper TEA technique. MEASUREMENTS AND MAIN RESULTS Measures of proficiency in TEA catheter placement included the time needed to complete the procedure successfully and the success of placement as indicated by patient confirmation. Residents who received formal video instruction had similar success in catheter placement and similar procedure times compared with the traditionally trained residents. The overall success rate was 99.2%, with faculty intervention required in only 17% of cases. More experienced residents (ie, having placed more epidural catheters) were faster at TEA catheter placement. CONCLUSIONS Formal video education for TEA catheter placement provided no additional improvement of resident proficiency compared with traditional training at a high-volume academic center. The success rate was very high in this group of residents; however, experiences at other institutions may vary. Future studies are needed to determine optimum teaching strategies for TEA.",2020,Residents who received formal video instruction had similar success in catheter placement and similar procedure times compared with the traditionally trained residents.,"['Large academic hospital, single institution', 'The study comprised 76 postgraduate year 3 and 4 anesthesiology residents (38 intervention, 38 control', 'Successful Thoracic Epidural Placement By Anesthesia Residents']","['Prior Formal Education', 'Formal education included an instructional video on proper TEA technique', 'TEA catheter placement', 'proficient TEA catheter placement by comparing video-based formal resident education with traditional bedside training', 'Catheter placement for thoracic epidural analgesia (TEA', 'formal video instruction']","['time needed to complete the procedure successfully and the success of placement', 'success rate', 'overall success rate']","[{'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0228134', 'cui_str': 'Structure of epidural space of spine'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}]","[{'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0002769', 'cui_str': 'Epidural analgesia'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0883301', 'cui_str': 'Catheter placement'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.072334,Residents who received formal video instruction had similar success in catheter placement and similar procedure times compared with the traditionally trained residents.,"[{'ForeName': 'Yar Luan', 'Initials': 'YL', 'LastName': 'Yeap', 'Affiliation': 'Department of Anesthesia, Indiana University School of Medicine, Indianapolis, IN. Electronic address: yyeap@iupui.edu.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Randolph', 'Affiliation': 'Anesthesia Consultants Of Indianapolis, Indianapolis, IN.'}, {'ForeName': 'Adam J', 'Initials': 'AJ', 'LastName': 'Lemmon', 'Affiliation': 'Department of Anesthesia, Indiana University School of Medicine, Indianapolis, IN.'}, {'ForeName': 'Miles D', 'Initials': 'MD', 'LastName': 'Mann', 'Affiliation': 'Indiana University School of Medicine, Indianapolis, IN.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Stewart', 'Affiliation': 'Department of Anesthesia, Indiana University School of Medicine, Indianapolis, IN.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Wolfe', 'Affiliation': 'Department of Anesthesia, Indiana University School of Medicine, Indianapolis, IN.'}]",Journal of cardiothoracic and vascular anesthesia,['10.1053/j.jvca.2020.06.023'] 1828,32473186,"The effects of GAMotion (a giant exercising board game) on physical capacity, motivation and quality of life among nursing home residents: A pilot interventional study.","BACKGROUND In 2017, our team highlighted promising results of a giant exercising board game on physical activity level and a broader array of physical and psychological outcomes among nursing home residents. However, some improvements of this game were needed to make it more suitable for nursing homes and more challenging in terms of exercises. Therefore, we decided to develop a new version of a giant exercising board game: the GAMotion. OBJECTIVES The primary objective of this pilot study was to assess the impact of the GAMotion on physical capacity among nursing home residents. The secondary aims were to assess the impact of the GAMotion on motivation and quality of life in this population. METHODS A one-month pilot interventional study was performed in two comparable nursing homes. Eleven participants meeting the inclusion criteria took part in the intervention in one nursing home, whereas 10 participants were assigned to the control group in the other institution. The GAMotion required participants to perform strength, flexibility, balance and endurance activities. The assistance provided by an exercising specialist decreased gradually during the intervention in an autonomy-oriented approach based on the self-determination theory. Physical capacity (i.e. fall risk using Tinetti test; dynamic balance using Timed Up and Go test (TUG); physical abilities using SPPB test; grip strength using Jamar dynamometer; isometric lower limb muscle strength using MicroFET2 and quantitative evaluation of walking using Locometrix), motivation (i.e. using Behavioral Regulation in Exercise Questionnaire-2) and quality of life (i.e. using EQ-5D questionnaire) were assessed at baseline and at the end of the intervention. A two-way repeated-measure analysis of variance (ANOVA) was used to assess time*group (intervention vs. control group) effects. All the analyses were adjusted on age, which differed significantly between the 2 groups at baseline. RESULTS During the intervention period, the experimental group displayed a greater improvement in Tinetti score (p < 0.0001), TUG (p = 0.02), SPPB (p < 0.0001), knee extensor isometric strength (p = 0.04), grip strength (p = 0.02), symmetry of steps (p = 0.04), 3 domains of the EQ-5D (i.e. mobility, self-care, usual activities: p < 0.0001) and intrinsic motivation (p = 0.02) compared to the control group. No significant improvement was demonstrated on the other parameters. CONCLUSION These promising results should be interpreted with caution because of certain limitations (e.g. small sample size, no blind assessment). Further investigation is required to confirm and evaluate the long-term effectiveness of the GAMotion in nursing homes.",2020,"During the intervention period, the experimental group displayed a greater improvement in Tinetti score (p < 0.0001), TUG (p = 0.02), SPPB (p < 0.0001), knee extensor isometric strength (p = 0.04), grip strength (p = 0.02), symmetry of steps (p = 0.04), 3 domains of the EQ-5D (i.e. mobility, self-care, usual activities: p < 0.0001) and intrinsic motivation (p = 0.02) compared to the control group.","['nursing home residents', 'Eleven participants meeting the inclusion criteria took part in the intervention in one nursing home, whereas 10 participants were assigned to the control group in the other institution', 'two comparable nursing homes']","['GAMotion', 'GAMotion (a giant exercising board game']","['SPPB', 'TUG', 'intrinsic motivation', 'knee extensor isometric strength', 'motivation and quality of life', 'grip strength', 'physical capacity, motivation and quality of life', 'physical capacity', 'strength, flexibility, balance and endurance activities', 'quality of life (i.e. using EQ-5D questionnaire', 'Tinetti score', 'Physical capacity']","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}]","[{'cui': 'C0017547', 'cui_str': 'Gigantism'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0392350', 'cui_str': 'Intrinsic motivation'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",2.0,0.028377,"During the intervention period, the experimental group displayed a greater improvement in Tinetti score (p < 0.0001), TUG (p = 0.02), SPPB (p < 0.0001), knee extensor isometric strength (p = 0.04), grip strength (p = 0.02), symmetry of steps (p = 0.04), 3 domains of the EQ-5D (i.e. mobility, self-care, usual activities: p < 0.0001) and intrinsic motivation (p = 0.02) compared to the control group.","[{'ForeName': 'Fanny', 'Initials': 'F', 'LastName': 'Buckinx', 'Affiliation': 'WHO Collaborating Center for Public Health aspects of musculo-skeletal health and ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Belgium. Electronic address: fanny.buckinx@uliege.be.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Bruyère', 'Affiliation': 'WHO Collaborating Center for Public Health aspects of musculo-skeletal health and ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Belgium; Department of Sport and Rehabilitation Sciences, Multidisciplinary Research Unit on Health and Society, University of Liège, Liège, Belgium.'}, {'ForeName': 'Laetitia', 'Initials': 'L', 'LastName': 'Lengelé', 'Affiliation': 'WHO Collaborating Center for Public Health aspects of musculo-skeletal health and ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Belgium.'}, {'ForeName': 'Jean-Yves', 'Initials': 'JY', 'LastName': 'Reginster', 'Affiliation': 'WHO Collaborating Center for Public Health aspects of musculo-skeletal health and ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Belgium.'}, {'ForeName': 'Quentin', 'Initials': 'Q', 'LastName': 'Marchal', 'Affiliation': 'Department of Sport and Rehabilitation Sciences, Multidisciplinary Research Unit on Health and Society, University of Liège, Liège, Belgium.'}, {'ForeName': 'Paulin', 'Initials': 'P', 'LastName': 'Hurtrez', 'Affiliation': 'Department of Sport and Rehabilitation Sciences, Multidisciplinary Research Unit on Health and Society, University of Liège, Liège, Belgium.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Mouton', 'Affiliation': 'Department of Sport and Rehabilitation Sciences, Multidisciplinary Research Unit on Health and Society, University of Liège, Liège, Belgium.'}]",Experimental gerontology,['10.1016/j.exger.2020.110983'] 1829,32632986,Effects of phosphodiesterase-5 inhibitor sildenafil on esophageal secondary peristalsis: Studies with high-resolution manometry.,"BACKGROUND AND AIM Secondary peristalsis contributes to the clearance of retained refluxate from the esophagus. Sildenafil, a phosphodiesterase-5 inhibitor, inhibits primary esophageal peristalsis, but its effects on secondary peristalsis remain unknown. This study sought to investigate whether sildenafil could influence physiological characteristics of secondary peristalsis by applying high-resolution manometry (HRM). METHODS Seventeen healthy volunteers (15 men and 2 women, aged 30.2 ± 6.4 years) underwent two HRM studies on separate days following the administration of either a placebo or 50 mg of sildenafil in a random order. Both studies were performed using a water-perfused HRM catheter containing one air injection channel positioned in the mid-esophagus. Secondary peristalsis was stimulated by a rapid mid-esophageal injection of 10 or 20 mL of air 1 h after the administration of either the placebo or sildenafil. The frequency and distal contractile integral of secondary peristalsis were then compared. RESULTS Complete secondary peristalsis triggered by the 20-mL air injection was more frequent than observed with the 10-mL air injection (P < 0.001). The vigor of secondary peristalsis triggered by the injection of either volume of air was lower than that of primary peristalsis (P < 0.001). Sildenafil significantly reduced the success rate (P ≤ 0.001) and vigor (P < 0.001) of secondary peristalsis relative to the effects of the placebo at both distension volumes. CONCLUSIONS Secondary peristalsis can be successfully triggered by rapid air injection during HRM. Sildenafil reduces both the success rate and the vigor of secondary peristalsis, similar to that seen with primary peristalsis.",2020,"Sildenafil significantly reduced the success rate (P ≤ 0.001) and vigor (P < 0.001) of secondary peristalsis relative to the effects of the placebo at both distension volumes. ","['Seventeen healthy volunteers (15 men and 2 women, aged 30.2 ± 6.4 years']","['phosphodiesterase-5 inhibitor sildenafil', 'placebo', 'placebo or sildenafil', 'placebo or 50 mg of sildenafil', 'Sildenafil', 'sildenafil']","['20-mL air injection', 'success rate and vigor of secondary peristalsis', 'frequency and distal contractile integral of secondary peristalsis', 'success rate']","[{'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517822', 'cui_str': '6.4'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1318700', 'cui_str': 'Phosphodiesterase 5 inhibitor'}, {'cui': 'C0529793', 'cui_str': 'sildenafil'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0184946', 'cui_str': 'Injection of air'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0031133', 'cui_str': 'Peristalsis'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0026820', 'cui_str': 'Muscle contraction'}, {'cui': 'C0443238', 'cui_str': 'Integral'}]",17.0,0.23457,"Sildenafil significantly reduced the success rate (P ≤ 0.001) and vigor (P < 0.001) of secondary peristalsis relative to the effects of the placebo at both distension volumes. ","[{'ForeName': 'Ming-Wun', 'Initials': 'MW', 'LastName': 'Wong', 'Affiliation': 'Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.'}, {'ForeName': 'Chih-Hsun', 'Initials': 'CH', 'LastName': 'Yi', 'Affiliation': 'Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.'}, {'ForeName': 'Tso-Tsai', 'Initials': 'TT', 'LastName': 'Liu', 'Affiliation': 'Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.'}, {'ForeName': 'Wei-Yi', 'Initials': 'WY', 'LastName': 'Lei', 'Affiliation': 'Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.'}, {'ForeName': 'Jui-Sheng', 'Initials': 'JS', 'LastName': 'Hung', 'Affiliation': 'Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.'}, {'ForeName': 'Chao-Zong', 'Initials': 'CZ', 'LastName': 'Liu', 'Affiliation': 'Department of Pharmacology, School of Medicine, Tzu Chi University, Hualien, Taiwan.'}, {'ForeName': 'Chien-Lin', 'Initials': 'CL', 'LastName': 'Chen', 'Affiliation': 'Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.'}]",Journal of gastroenterology and hepatology,['10.1111/jgh.15170'] 1830,32603956,Leptin mediates improvements in cognitive function following treatment with infliximab in adults with bipolar depression.,"A potential role for leptin in the pathophysiology of bipolar disorder (BD) has been proposed. We recently investigated the effects of the tumor necrosis factor-alpha (TNF-α) antagonist infliximab in individuals with bipolar depression. Leptin is known to interact with the TNF-α system. Herein, we aimed to explore infliximab's effects on leptin and its relationship with brain structure and function. Sixty adults with bipolar depression were enrolled in this randomized, double-blind, 12-week clinical trial of adjunctive infliximab (n = 29) and saline control (n = 31), which were administered intravenously at weeks 0, 2, and 6. Plasma concentrations of leptin, TNF-α and soluble TNF receptors (sTNFR) 1 and 2 were assessed at weeks 0, 2, 6, and 12. We observed a significant decrease in leptin levels in infliximab-treated patients, relative to placebo. Infliximab treatment also significantly reduced TNF-α and sTNFR2, but not sTNFR1 levels. Changes in sTNR2 levels at week 6 significantly determined changes in leptin at week 12 in infliximab-, but not placebo-treated participants. Improvements in verbal memory and increases in global cortical volume were associated with reduction in leptin levels in the treatment group. Mediation analysis indicated that cognitive improvement in infliximab-treated patients was mediated by reductions in leptin levels, which in its turn were determined by decreases in sTNR2 levels. In conclusion, infliximab treatment reduced plasma leptin levels in individuals with BD, through modulation of sTNFR2. Decreases in leptin signaling were associated with an increase in global cortical volume and better performance in a verbal memory task.",2020,"Infliximab treatment also significantly reduced TNF-α and sTNFR2, but not sTNFR1 levels.","['Sixty adults with bipolar depression', 'individuals with BD', 'adults with bipolar depression', 'individuals with bipolar depression']","['Leptin', 'saline control', 'adjunctive infliximab', 'infliximab', 'Infliximab', 'tumor necrosis factor-alpha (TNF-α) antagonist infliximab', 'placebo']","['leptin', 'cognitive improvement', 'global cortical volume and better performance in a verbal memory task', 'cognitive function', 'Plasma concentrations of leptin, TNF-α and soluble TNF receptors (sTNFR', 'verbal memory', 'plasma leptin levels', 'global cortical volume', 'leptin signaling', 'leptin levels', 'TNF-α and sTNFR2', 'sTNR2 levels']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0005587', 'cui_str': 'Bipolar affective disorder, current episode depression'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}]","[{'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0077503', 'cui_str': 'Tumor Necrosis Factor Receptor'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",60.0,0.149116,"Infliximab treatment also significantly reduced TNF-α and sTNFR2, but not sTNFR1 levels.","[{'ForeName': 'Rodrigo B', 'Initials': 'RB', 'LastName': 'Mansur', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Electronic address: rodrigo.mansur@uhn.ca.'}, {'ForeName': 'Mehala', 'Initials': 'M', 'LastName': 'Subramaniapillai', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.'}, {'ForeName': 'Yena', 'Initials': 'Y', 'LastName': 'Lee', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Zihang', 'Initials': 'Z', 'LastName': 'Pan', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.'}, {'ForeName': 'Nicole E', 'Initials': 'NE', 'LastName': 'Carmona', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychology, Ryerson University, Toronto, ON, Canada.'}, {'ForeName': 'Margarita', 'Initials': 'M', 'LastName': 'Shekotikhina', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; University of Ottawa, Department of Psychiatry, Ottawa, ON, Canada.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Iacobucci', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.'}, {'ForeName': 'Nelson', 'Initials': 'N', 'LastName': 'Rodrigues', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.'}, {'ForeName': 'Flora', 'Initials': 'F', 'LastName': 'Nasri', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.'}, {'ForeName': 'Houman', 'Initials': 'H', 'LastName': 'Rashidian', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Rosenblat', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Brietzke', 'Affiliation': ""Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Kingston General Hospital, Providence Care Hospital, Department of Psychiatry, Queen's University School of Medicine, Kingston, ON, Canada.""}, {'ForeName': 'Victoria E', 'Initials': 'VE', 'LastName': 'Cosgrove', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Stanford University, School of Medicine, Palo Alto, CA, USA.'}, {'ForeName': 'Nicole E', 'Initials': 'NE', 'LastName': 'Kramer', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Stanford University, School of Medicine, Palo Alto, CA, USA.'}, {'ForeName': 'Trisha', 'Initials': 'T', 'LastName': 'Suppes', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Stanford University, School of Medicine, Palo Alto, CA, USA.'}, {'ForeName': 'Roger S', 'Initials': 'RS', 'LastName': 'McIntyre', 'Affiliation': 'Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2020.104779'] 1831,32603994,A randomized-controlled examination of the effect of cognitive reappraisal instruction on maternal accommodation of child anxiety symptoms.,"Parental accommodation plays a key role in the maintenance of child anxiety, yet much of the research to date has been correlational, making it difficult to draw conclusions about underlying mechanisms. Given preliminary evidence that parental beliefs play a role in parental accommodation, the present study sought to experimentally reduce accommodation by targeting parental attitudes about child anxiety. Mothers of children ages 4-9 (N = 47) were randomly assigned to either receive brief instruction in cognitive reappraisal (EXP) or to a control intervention in which they received no instruction (CON). At pre- and post-intervention mothers were presented with bogus information that their child was experiencing varying levels of distress while completing a task in a nearby room. Maternal distress, negative affect and perceived likelihood of accommodation in the context of child distress were measured pre- and post-intervention. EXP mothers reported greater pre- to post-intervention decreases in distress and perceived likelihood of accommodation, compared to CON mothers. EXP and CON mothers showed similar changes in negative affect. Findings from this study provide preliminary experimental evidence that targeting maternal beliefs about child anxiety can result in changes in maternal distress and behavior following exposure to child distress. Implications for prevention and treatment are discussed.",2020,"EXP mothers reported greater pre- to post-intervention decreases in distress and perceived likelihood of accommodation, compared to CON mothers.",['Mothers of children ages 4-9 (N = 47'],"['cognitive reappraisal instruction', 'brief instruction in cognitive reappraisal (EXP) or to a control intervention in which they received no instruction (CON']","['distress and perceived likelihood of accommodation', 'Maternal distress, negative affect and perceived likelihood of accommodation in the context of child distress', 'maternal accommodation of child anxiety symptoms']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0473485', 'cui_str': 'Maternal distress'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0449255', 'cui_str': 'Context'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}]",47.0,0.050831,"EXP mothers reported greater pre- to post-intervention decreases in distress and perceived likelihood of accommodation, compared to CON mothers.","[{'ForeName': 'Erin E', 'Initials': 'EE', 'LastName': ""O'Connor"", 'Affiliation': 'Department of Psychological and Brain Sciences, Boston University, 900 Commonwealth Ave. #2, Boston, MA, 02215, United States.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Langer', 'Affiliation': 'Department of Psychological and Brain Sciences, Boston University, 900 Commonwealth Ave. #2, Boston, MA, 02215, United States.'}, {'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Comer', 'Affiliation': 'Department of Psychology, Florida International University, 11200 SW 8th Street, Miami, FL, 33199, United States.'}, {'ForeName': 'Martha C', 'Initials': 'MC', 'LastName': 'Tompson', 'Affiliation': 'Department of Psychological and Brain Sciences, Boston University, 900 Commonwealth Ave. #2, Boston, MA, 02215, United States.'}]",Journal of anxiety disorders,['10.1016/j.janxdis.2020.102260'] 1832,32605239,Efficacy of a U-Shaped Automatic Electric Toothbrush in Dental Plaque Removal: A Cross-Over Randomized Controlled Trial.,"BACKGROUND The aim of this single-use, four-treatment, four-period (visit), cross-over, mono-centered, examiner-blind, cross-over randomized controlled trial (RCT) was to evaluate the efficacy in dental plaque removal of a U-shaped automatic electric toothbrush (U) compared to a conventional powered toothbrush (P), a habitual toothbrushing procedure (H), and no brushing (N). METHODS Eligible participants were volunteer students. Primary outcome measure was the reduction in full-mouth plaque score (FMPS) after brushing. The secondary outcome variable was a visual analogic scale (VAS) on subjective clean mouth sensation. Mixed models were performed for difference in FMPS and VAS. RESULTS Twenty-two participants were randomized to the treatments in the four periods of the study. The differences between treatments in FMPS reduction after brushing were statistically significant ( p < 0.0001). The differences were statistically significant between the U and P groups (difference -48; 95% CI from -54 to -41) favoring the P group, and between the U and H groups (difference -45; 95% CI from -52 to -39) favoring the H group. On the contrary, the difference between the U and N groups was not significant (difference 5; 95% CI from -2 to 12) favoring the U group. The differences between treatments in clean mouth VAS was statistically significant ( p < 0.0001) favoring the P and H groups. CONCLUSIONS The U-shaped automatic electric toothbrush tested in this study proved to be not effective in removing dental plaque.",2020,"The differences between treatments in clean mouth VAS was statistically significant ( p < 0.0001) favoring the P and H groups. ","['Eligible participants were volunteer students', 'Dental Plaque Removal', 'Twenty-two participants']","['conventional powered toothbrush (P), a habitual toothbrushing procedure (H), and no brushing (N', 'U-Shaped Automatic Electric Toothbrush']","['visual analogic scale (VAS) on subjective clean mouth sensation', 'clean mouth VAS', 'reduction in full-mouth plaque score (FMPS', 'FMPS reduction']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C4284772', 'cui_str': '22'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0032863', 'cui_str': 'Power (Psychology)'}, {'cui': 'C0183975', 'cui_str': 'Toothbrush'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0332479', 'cui_str': 'Shape finding'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C1740271', 'cui_str': 'Electric toothbrush'}]","[{'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0221732', 'cui_str': 'Mouth plaque'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",22.0,0.133698,"The differences between treatments in clean mouth VAS was statistically significant ( p < 0.0001) favoring the P and H groups. ","[{'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Nieri', 'Affiliation': 'Department of Experimental and Clinical Medicine, Orthodontics, Università degli Studi di Firenze, 50127 Firenze, Italy.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Giuntini', 'Affiliation': 'School of Dentistry, Department of Experimental and Clinical Medicine, Università degli Studi di Firenze, 50127 Firenze, Italy.'}, {'ForeName': 'Umberto', 'Initials': 'U', 'LastName': 'Pagliaro', 'Affiliation': 'School of Dentistry, Department of Experimental and Clinical Medicine, Università degli Studi di Firenze, 50127 Firenze, Italy.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Giani', 'Affiliation': 'Private Practice, Campi Bisenzio, 50013 Firenze, Italy.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Franchi', 'Affiliation': 'School of Dentistry, Department of Experimental and Clinical Medicine, Università degli Studi di Firenze, 50127 Firenze, Italy.'}, {'ForeName': 'Debora', 'Initials': 'D', 'LastName': 'Franceschi', 'Affiliation': 'School of Dentistry, Department of Experimental and Clinical Medicine, Università degli Studi di Firenze, 50127 Firenze, Italy.'}]",International journal of environmental research and public health,['10.3390/ijerph17134649'] 1833,32684162,Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).,An amendment to this paper has been published and can be accessed via the original article.,2020,An amendment to this paper has been published and can be accessed via the original article.,"[""Alzheimer's disease""]",['novel GLP-1 analogue liraglutide'],[],"[{'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C1456408', 'cui_str': 'liraglutide'}]",[],,0.0782946,An amendment to this paper has been published and can be accessed via the original article.,"[{'ForeName': 'Grazia Daniela', 'Initials': 'GD', 'LastName': 'Femminella', 'Affiliation': 'Department of Medicine, Imperial College London, London, UK.'}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Frangou', 'Affiliation': 'Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Sharon B', 'Initials': 'SB', 'LastName': 'Love', 'Affiliation': 'Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Busza', 'Affiliation': 'Department of Medicine, Imperial College London, London, UK.'}, {'ForeName': 'Clive', 'Initials': 'C', 'LastName': 'Holmes', 'Affiliation': 'Southern Health NHS Foundation Trust, Havant, UK.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Ritchie', 'Affiliation': 'Department of Medicine, Imperial College London, London, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Lawrence', 'Affiliation': ""SW London and St George's Mental Health Trust, London, UK.""}, {'ForeName': 'Brady', 'Initials': 'B', 'LastName': 'McFarlane', 'Affiliation': 'Southern Health NHS Foundation Trust, Havant, UK.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Tadros', 'Affiliation': 'Aston Medical school, Aston University, Birmingham, UK.'}, {'ForeName': 'Basil H', 'Initials': 'BH', 'LastName': 'Ridha', 'Affiliation': 'Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Bannister', 'Affiliation': 'South London and Maudsley NHS Foundation Trust, London, UK.'}, {'ForeName': 'Zuzana', 'Initials': 'Z', 'LastName': 'Walker', 'Affiliation': 'University College London and Essex Partnership University NHS Foundation Trust, Runwell, UK.'}, {'ForeName': 'Hilary', 'Initials': 'H', 'LastName': 'Archer', 'Affiliation': 'North Bristol NHS Trust, Bristol, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Coulthard', 'Affiliation': 'North Bristol NHS Trust, Bristol, UK.'}, {'ForeName': 'Ben R', 'Initials': 'BR', 'LastName': 'Underwood', 'Affiliation': 'Cambridgeshire and Peterborough NHS Foundation Trust, Peterborough, UK.'}, {'ForeName': 'Aparna', 'Initials': 'A', 'LastName': 'Prasanna', 'Affiliation': 'Black Country Partnership NHS Foundation Trust, West Bromwich, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Koranteng', 'Affiliation': 'Northamptonshire Healthcare NHS Foundation Trust, Kettering, UK.'}, {'ForeName': 'Salman', 'Initials': 'S', 'LastName': 'Karim', 'Affiliation': 'Lancashire Care NHS Foundation Trust, Preston, UK.'}, {'ForeName': 'Kehinde', 'Initials': 'K', 'LastName': 'Junaid', 'Affiliation': 'Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, UK.'}, {'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'McGuinness', 'Affiliation': ""Centre for Public Health, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Ramin', 'Initials': 'R', 'LastName': 'Nilforooshan', 'Affiliation': 'Surrey and Borders Partnership NHS Foundation Trust, Leatherhead, UK.'}, {'ForeName': 'Ajay', 'Initials': 'A', 'LastName': 'Macharouthu', 'Affiliation': 'NHS Ayrshire and Arran, Crosshouse, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Donaldson', 'Affiliation': 'NHS Lanarkshire, Glasgow, UK.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Thacker', 'Affiliation': 'Derbyshire Healthcare NHS Foundation Trust, Derby, UK.'}, {'ForeName': 'Gregor', 'Initials': 'G', 'LastName': 'Russell', 'Affiliation': 'Bradford District Care NHS Foundation Trust, Bradford, UK.'}, {'ForeName': 'Naghma', 'Initials': 'N', 'LastName': 'Malik', 'Affiliation': '5 Boroughs Partnership NHS Foundation Trust, Warrington, UK.'}, {'ForeName': 'Vandana', 'Initials': 'V', 'LastName': 'Mate', 'Affiliation': 'Cornwall Partnership NHS Foundation Trust, Redruth, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Knight', 'Affiliation': 'Somerset Partnership NHS Foundation Trust, Bridgwater, UK.'}, {'ForeName': 'Sajeev', 'Initials': 'S', 'LastName': 'Kshemendran', 'Affiliation': 'South Staffordshire and Shropshire Healthcare NHS Foundation Trust, Stafford, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Harrison', 'Affiliation': 'Alzheimer Center VUmc Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Hölscher', 'Affiliation': 'Research Department, Henan University of Chinese Medicine, Zhengzhou, China.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Brooks', 'Affiliation': 'Department of Medicine, Imperial College London, London, UK.'}, {'ForeName': 'Anthony Peter', 'Initials': 'AP', 'LastName': 'Passmore', 'Affiliation': ""Centre for Public Health, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Clive', 'Initials': 'C', 'LastName': 'Ballard', 'Affiliation': 'South London and Maudsley NHS Foundation Trust, London, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Edison', 'Affiliation': 'Department of Medicine, Imperial College London, London, UK. paul.edison@imperial.ac.uk.'}]",Trials,['10.1186/s13063-020-04608-4'] 1834,32614141,Targeted Mass Spectrometry of a Clinically Relevant PSA Variant from Post-DRE Urines for Quantitation and Genotype Determination.,"PURPOSE The rs17632542 single nucleotide polymorphism (SNP) results in lower serum prostate specific antigen (PSA) levels which may further mitigate against its clinical utility as a prostate cancer biomarker. Post-digital rectal exam (post-DRE) urine is a minimally invasive fluid that is currently utilized in prostate cancer diagnosis. To detect and quantitate the variant protein in urine. EXPERIMENTAL DESIGN Fifty-three post-DRE urines from rs17632542 genotyped individuals processed and analyzed by liquid chromatography/mass spectrometry (LC-MS) in a double-blinded randomized study. The ability to distinguish between homozygous wild-type, heterozygous, or homozygous variant is examined before unblinding. RESULTS Stable-isotope labeled peptides are used in the detection and quantitation of three peptides of interest in each sample using parallel reaction monitoring (PRM). Using these data, groupings are predicted using hierarchical clustering in R. Accuracy of the predictions show 100% concordance across the 53 samples, including individuals homozygous and heterozygous for the SNP. CONCLUSIONS AND CLINICAL RELEVANCE The study demonstrates that MS based peptide variant quantitation in urine could be useful in determining patient genotype expression. This assay provides a tool to evaluate the utility of PSA variant (rs17632542) in parallel with current and forthcoming urine biomarker panels.",2020,"Using these data, groupings were predicted using hierarchical clustering in R. Accuracy of the predictions showed 100% concordance across the 53 samples, including individuals homozygous and heterozygous for the SNP. ",['Fifty-three post-DRE urines from rs17632542 genotyped individuals'],[],"['peak detection and area extraction', 'serum PSA levels']","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1384593', 'cui_str': 'Digital examination of rectum'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0027361', 'cui_str': 'Person'}]",[],"[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0201544', 'cui_str': 'Prostate specific antigen measurement'}]",,0.0364145,"Using these data, groupings were predicted using hierarchical clustering in R. Accuracy of the predictions showed 100% concordance across the 53 samples, including individuals homozygous and heterozygous for the SNP. ","[{'ForeName': 'Joseph J', 'Initials': 'JJ', 'LastName': 'Otto', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}, {'ForeName': 'Vanessa L', 'Initials': 'VL', 'LastName': 'Correll', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}, {'ForeName': 'Hampus A', 'Initials': 'HA', 'LastName': 'Engstroem', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}, {'ForeName': 'Naomi L', 'Initials': 'NL', 'LastName': 'Hitefield', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}, {'ForeName': 'Brian P', 'Initials': 'BP', 'LastName': 'Main', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}, {'ForeName': 'Brenna', 'Initials': 'B', 'LastName': 'Albracht', 'Affiliation': 'Department of Urology, The University of Texas Health San Antonio, San Antonio, TX, 78229, USA.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Johnson-Pais', 'Affiliation': 'Department of Urology, The University of Texas Health San Antonio, San Antonio, TX, 78229, USA.'}, {'ForeName': 'Li Fang', 'Initials': 'LF', 'LastName': 'Yang', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Liss', 'Affiliation': 'Department of Urology, The University of Texas Health San Antonio, San Antonio, TX, 78229, USA.'}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'Boutros', 'Affiliation': 'Departments of Human Genetics and Urology, Jonsson Comprehensive Cancer Center, Institute for Precision Health University of California Los Angeles, Los Angeles, CA, 90095, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Kislinger', 'Affiliation': 'University of Toronto, Department of Medical Biophysics, Toronto, ON M5G 1L7, Canada.'}, {'ForeName': 'Robin J', 'Initials': 'RJ', 'LastName': 'Leach', 'Affiliation': 'Department of Urology, The University of Texas Health San Antonio, San Antonio, TX, 78229, USA.'}, {'ForeName': 'Oliver J', 'Initials': 'OJ', 'LastName': 'Semmes', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}, {'ForeName': 'Julius O', 'Initials': 'JO', 'LastName': 'Nyalwidhe', 'Affiliation': 'Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA, 23507, USA.'}]",Proteomics. Clinical applications,['10.1002/prca.202000012'] 1835,32610246,Structure and process associated with the efficiency of intensive care units in low-resource settings: An analysis of the CHECKLIST-ICU trial database.,"PURPOSE Characteristics of structure and process impact ICU performance and the outcomes of critically ill patients. We sought to identify organizational characteristics associated with efficient ICUs in low-resource settings. MATERIALS AND METHODS This is a secondary analysis of a multicenter cluster-randomized clinical trial in Brazil (CHECKLIST-ICU). Efficient units were defined by standardized mortality ratio (SMR) and standardized resource use (SRU) lower than the overall medians and non-efficient otherwise. We used a regularized logistic regression model to evaluate associations between organizational factors and efficiency. RESULTS From 118 ICUs (13,635 patients), 47 units were considered efficient and 71 non-efficient. Efficient units presented lower incidence rates (median[IQR]) of central line-associated bloodstream infections (4.95[0.00-22.0] vs 6.29[0.00-25.6], p = .04), utilization rates of mechanical ventilation (0.41[0.07-0.73] vs 0.58[0.19-0.82], p < .001), central venous catheter (0.67[0.15-0.98] vs 0.78[0.33-0.98], p = .04), and indwelling urinary catheter (0.62[0.22-0.95] vs 0.76[0.32-0.98], p < .01) than non-efficient units. The reported active surveillance of ventilator-associated pneumonia (OR = 1.72; 95%CI, 1.16-2.57) and utilization of central venous catheters (OR = 1.94; 95%CI, 1.32-2.94) were associated with efficient ICUs. CONCLUSIONS In low-resource settings, active surveillance of nosocomial infections and the utilization of invasive devices were associated with efficiency, supporting the management and evaluation of performance indicators as a starting point for improvement in ICU.",2020,"The reported active surveillance of ventilator-associated pneumonia (OR = 1.72; 95%CI, 1.16-2.57) and utilization of central venous catheters (OR = 1.94; 95%CI, 1.32-2.94) were associated with efficient ICUs. ","['critically ill patients', 'low-resource settings', 'From 118 ICUs (13,635 patients']",[],"['utilization of central venous catheters', 'utilization rates of mechanical ventilation', 'central venous catheter', 'standardized mortality ratio (SMR) and standardized resource use (SRU', 'incidence rates (median[IQR]) of central line-associated bloodstream infections', 'indwelling urinary catheter']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C4517542', 'cui_str': '118'}]",[],"[{'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C1145640', 'cui_str': 'Central venous catheter'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3161235', 'cui_str': 'CLABSI - central line associated bloodstream infection'}, {'cui': 'C0521197', 'cui_str': 'Indwelling urinary catheter'}]",,0.219858,"The reported active surveillance of ventilator-associated pneumonia (OR = 1.72; 95%CI, 1.16-2.57) and utilization of central venous catheters (OR = 1.94; 95%CI, 1.32-2.94) were associated with efficient ICUs. ","[{'ForeName': 'Leonardo S L', 'Initials': 'LSL', 'LastName': 'Bastos', 'Affiliation': 'Department of Industrial Engineering, Pontifical Catholic University of Rio de Janeiro (PUC-Rio), Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Silvio', 'Initials': 'S', 'LastName': 'Hamacher', 'Affiliation': 'Department of Industrial Engineering, Pontifical Catholic University of Rio de Janeiro (PUC-Rio), Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Fernando G', 'Initials': 'FG', 'LastName': 'Zampieri', 'Affiliation': ""Research Institute, Hospital do Coração (HCor), São Paulo, Brazil; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Brazilian Research in Intensive Care Network (BRICNet), Brazil.""}, {'ForeName': 'Alexandre B', 'Initials': 'AB', 'LastName': 'Cavalcanti', 'Affiliation': 'Research Institute, Hospital do Coração (HCor), São Paulo, Brazil; Brazilian Research in Intensive Care Network (BRICNet), Brazil.'}, {'ForeName': 'Jorge I F', 'Initials': 'JIF', 'LastName': 'Salluh', 'Affiliation': ""D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Brazilian Research in Intensive Care Network (BRICNet), Brazil.""}, {'ForeName': 'Fernando A', 'Initials': 'FA', 'LastName': 'Bozza', 'Affiliation': ""D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Brazilian Research in Intensive Care Network (BRICNet), Brazil; Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil. Electronic address: fernando.bozza@ini.fiocruz.br.""}]",Journal of critical care,['10.1016/j.jcrc.2020.06.008'] 1836,32610511,Acute Effects of Open Kinetic Chain Exercise Versus Those of Closed Kinetic Chain Exercise on Quadriceps Muscle Thickness in Healthy Adults.,"This study aimed to compare immediate changes in the thickness of the rectus femoris (RF), vastus intermedius (VI), vastus lateralis (VL), vastus medialis (VM), and vastus medialis oblique (VMO) muscles after open kinetic chain exercise (OKCE) and closed kinetic chain exercise (CKCE) and identify the effect of both exercise types on each quadricep muscle for early rehabilitation to prevent knee joint injury. Twenty-six healthy participants (13 males and 13 females) were randomly divided into the OKCE ( n = 13) and CKCE ( n = 13) groups. The thickness of their quadriceps muscles was measured using a portable ultrasonic imaging device before and after exercise in the sequence RF, VI, VL, VM, and VMO. A two-way repeated measures analysis of variance was used to compare the thickness of each component of the quadriceps muscles between the two groups. The thickness of the RF, VL, VM, and VMO muscles increased after OKCE, and the thickness of the VI muscle showed the greatest increase with a medium-large effect size (F = 8.52, p = 0.01, and d = 0.53). The thickness of the VI, VL, VM, and VMO muscles increased after CKCE, and the VMO muscle had the largest effect size (F = 11.71, p = 0.00, and d = 1.02). These results indicate that the thickness of the quadriceps muscles can be selectively improved depending on the type of exercise.",2020,"The thickness of the VI, VL, VM, and VMO muscles increased after CKCE, and the VMO muscle had the largest effect size (F = 11.71, p = 0.00, and d = 1.02).","['Twenty-six healthy participants (13 males and 13 females', 'Healthy Adults']","['Open Kinetic Chain Exercise Versus', 'Closed Kinetic Chain Exercise', 'OKCE', 'CKCE', 'open kinetic chain exercise (OKCE) and closed kinetic chain exercise (CKCE']","['thickness of the RF, VL, VM, and VMO muscles', 'thickness of their quadriceps muscles', 'rectus femoris (RF), vastus intermedius (VI), vastus lateralis (VL), vastus medialis (VM), and vastus medialis oblique (VMO) muscles', 'thickness of the VI, VL, VM, and VMO muscles', 'Quadriceps Muscle Thickness']","[{'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0454289', 'cui_str': 'Open kinetic chain exercises'}, {'cui': 'C0454288', 'cui_str': 'Closed kinetic chain exercises'}]","[{'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0584894', 'cui_str': 'Rectus femoris muscle structure'}, {'cui': 'C0224445', 'cui_str': 'Structure of vastus medialis muscle'}, {'cui': 'C0205315', 'cui_str': 'Oblique'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0224448', 'cui_str': 'Structure of vastus intermedius muscle'}]",26.0,0.0226761,"The thickness of the VI, VL, VM, and VMO muscles increased after CKCE, and the VMO muscle had the largest effect size (F = 11.71, p = 0.00, and d = 1.02).","[{'ForeName': 'Soul', 'Initials': 'S', 'LastName': 'Cheon', 'Affiliation': 'Department of Kinesiology, Inha University, Incheon 22212, Korea.'}, {'ForeName': 'Joo-Hyun', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Department of Kinesiology, Inha University, Incheon 22212, Korea.'}, {'ForeName': 'Hyung-Pil', 'Initials': 'HP', 'LastName': 'Jun', 'Affiliation': 'Department of Physical Education, Dong-A University, Busan 49236, Korea.'}, {'ForeName': 'Yong Woo', 'Initials': 'YW', 'LastName': 'An', 'Affiliation': 'Department of Health and Human Sciences, Loyola Marymount University, Los Angeles, CA 90045, USA.'}, {'ForeName': 'Eunwook', 'Initials': 'E', 'LastName': 'Chang', 'Affiliation': 'Department of Kinesiology, Inha University, Incheon 22212, Korea.'}]",International journal of environmental research and public health,['10.3390/ijerph17134669'] 1837,32610568,The Acute Impact of External Compression on Back Squat Performance in Competitive Athletes.,"The aim of the present study was to evaluate the effects of external compression with blood flow restriction on power output and bar velocity changes during the back-squat exercise (SQ). The study included 10 judo athletes (age = 28.4 ± 5.8 years; body mass = 81.3 ± 13.1 kg; SQ one-repetition maximum (1-RM) 152 ± 34 kg; training experience 10.7 ± 2.3 years). METHODS The experiment was performed following a randomized crossover design, where each participant performed three different exercise protocols: (1) control, without external compression (CONT); (2) intermittent external compression with pressure of 100% arterial occlusion pressure (AOP) (EC-100); and (3) intermittent external compression with pressure of 150% AOP (EC-150). To assess the differences between conditions, the participants performed 3 sets of 3 repetitions of the SQ at 70% 1-RM. The differences in peak power output (PP), mean power output (MP), peak bar velocity (PV), and mean bar velocity (MV) between the three conditions were examined using repeated measures two-way ANOVA. RESULTS The post hoc analysis for the main effect of conditions showed a significant increase in PP ( p = 0.03), PV ( p = 0.02), MP ( p = 0.04), and MV ( p = 0.03), for the EC-150, compared to the CONT. Furthermore, a statistically significant increase in PP ( p = 0.04), PV ( p = 0.03), MP ( p = 0.02), and MV ( p = 0.01) were observed for the EC-150 compared to EC-100. There were no significant changes in PP, PV, MP, and MV, between EC-100 and CONT conditions. CONCLUSION The results indicate that the use of extremely high-pressure external compression (150% AOP) during high-loaded (70% 1-RM) lower limb resistance exercise elicits an acute increase in power output and bar velocity.",2020,"The post hoc analysis for the main effect of conditions showed a significant increase in PP ( p = 0.03),","['10 judo athletes (age = 28.4 ± 5.8 years; body mass = 81.3 ± 13.1 kg', 'Competitive Athletes']","['exercise protocols: (1) control, without external compression (CONT); (2) intermittent external compression with pressure of 100% arterial occlusion pressure (AOP) (EC-100); and (3) intermittent external compression with pressure of 150% AOP (EC-150', 'external compression with blood flow restriction', 'back-squat exercise (SQ', 'External Compression']","['PP', 'PV', 'PP, PV, MP, and MV, between EC-100 and CONT conditions', 'power output and bar velocity changes', 'power output and bar velocity', 'peak power output (PP), mean power output (MP), peak bar velocity (PV), and mean bar velocity (MV', 'Back Squat Performance']","[{'cui': 'C0079650', 'cui_str': 'Judo'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517796', 'cui_str': '5.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0425273', 'cui_str': 'Competitive athlete'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0264995', 'cui_str': 'Occlusion of artery'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0158996', 'cui_str': 'Anemia of prematurity'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}]","[{'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0001643', 'cui_str': 'Beta-2 adrenergic receptor'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0264995', 'cui_str': 'Occlusion of artery'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}]",10.0,0.0501652,"The post hoc analysis for the main effect of conditions showed a significant increase in PP ( p = 0.03),","[{'ForeName': 'Mariola', 'Initials': 'M', 'LastName': 'Gepfert', 'Affiliation': 'Institute of Sport Sciences, Jerzy Kukuczka Academy of Physical Education in Katowice, 40-065 Katowice, Poland.'}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Krzysztofik', 'Affiliation': 'Institute of Sport Sciences, Jerzy Kukuczka Academy of Physical Education in Katowice, 40-065 Katowice, Poland.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Kostrzewa', 'Affiliation': 'Institute of Sport Sciences, Jerzy Kukuczka Academy of Physical Education in Katowice, 40-065 Katowice, Poland.'}, {'ForeName': 'Jakub', 'Initials': 'J', 'LastName': 'Jarosz', 'Affiliation': 'Institute of Sport Sciences, Jerzy Kukuczka Academy of Physical Education in Katowice, 40-065 Katowice, Poland.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Trybulski', 'Affiliation': 'Department of Medical Sciences, The Wojciech Korfanty School of Economics, 40-065 Katowice, Poland.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Zajac', 'Affiliation': 'Institute of Sport Sciences, Jerzy Kukuczka Academy of Physical Education in Katowice, 40-065 Katowice, Poland.'}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Wilk', 'Affiliation': 'Institute of Sport Sciences, Jerzy Kukuczka Academy of Physical Education in Katowice, 40-065 Katowice, Poland.'}]",International journal of environmental research and public health,['10.3390/ijerph17134674'] 1838,32615697,Headache Relief Is Maintained 7 Years After Anterior Cervical Spine Surgery: Post Hoc Analysis From a Multicenter Randomized Clinical Trial and Cervicogenic Headache Hypothesis.,"OBJECTIVE To evaluate whether anterior cervical spine surgery offers sustained (7 years) relief in patients with cervicogenic headaches (CGHs), and evaluate the difference between cervical disc arthroplasty (CDA) and anterior cervical discectomy and fusion (ACDF) for 1 and 2-level surgeries from a multicenter randomized clinical trial. METHODS A post hoc analysis was performed of 575 patients who underwent one or 2-level CDA or ACDF for symptomatic cervical spondylosis as part of a prospective randomized clinical trial. Assessment of pain and functional outcome was done with the Neck Disability Index (NDI) in the trial. We used the NDI headache component to assess headache outcome. RESULTS For both 1- and 2-level CDA and ACDF groups, there was significant headache improvement from preoperative baseline out to 7 years (p < 0.0001). For 1-level surgeries, headache improvement was similar for both groups at the 7-year point. For 2-level treatment, CDA patients had significantly improved headache scores versus ACDF patients at the 7-year point (p = 0.016). CONCLUSION The headache improvement noted at early follow-up was sustained over the long-term period with ACDF and CDA populations. In the case of 2-level operations, CDA patients demonstrated significantly greater benefit compared to ACDF patients over the long-term. Sinuvertebral nerve irritation at the unco-vasculo-radicular junction and anterior dura may be the cause of CGH. Therefore, it is possible that improved cervical kinematics and preservation of range of motion at adjacent uncovertebral joints in CDA may contribute to the observed difference between the groups.",2020,The headache improvement noted at early follow-up was sustained over the long-term period with ACDF and CDA populations.,"['575 patients who underwent one or', 'patients with cervicogenic headaches (CGHs']","['2-level CDA or ACDF', 'anterior cervical spine surgery', 'ACDF', 'cervical disc arthroplasty (CDA) and anterior cervical discectomy and fusion (ACDF']","['Neck Disability Index (NDI', 'headache scores', 'Headache Relief', 'headache improvement', 'Sinuvertebral nerve irritation']","[{'cui': 'C3844102', 'cui_str': '575'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0458101', 'cui_str': 'Cervicogenic headache'}]","[{'cui': 'C0456948', 'cui_str': 'Level 2'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0003893', 'cui_str': 'Arthroplasty'}, {'cui': 'C4552416', 'cui_str': 'ACDF'}, {'cui': 'C0442011', 'cui_str': 'Anterior cervical spine approach'}, {'cui': 'C0920347', 'cui_str': 'Procedure on spinal cord'}, {'cui': 'C0206078', 'cui_str': 'Discectomy of spine'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}]","[{'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0228813', 'cui_str': 'Structure of spinal nerve meningeal branch'}, {'cui': 'C0441723', 'cui_str': 'Irritation'}]",575.0,0.0936108,The headache improvement noted at early follow-up was sustained over the long-term period with ACDF and CDA populations.,"[{'ForeName': 'Harjot', 'Initials': 'H', 'LastName': 'Thind', 'Affiliation': 'Department of Neurological Surgery, University of California Davis, Sacramento, CA, USA.'}, {'ForeName': 'Dinesh', 'Initials': 'D', 'LastName': 'Ramanathan', 'Affiliation': 'Department of Neurological Surgery, University of California Davis, Sacramento, CA, USA.'}, {'ForeName': 'Julius', 'Initials': 'J', 'LastName': 'Ebinu', 'Affiliation': 'Department of Neurological Surgery, University of California Davis, Sacramento, CA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Copenhaver', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, University of California Davis, Sacramento, CA, USA.'}, {'ForeName': 'Kee D', 'Initials': 'KD', 'LastName': 'Kim', 'Affiliation': 'Department of Neurological Surgery, University of California Davis, Sacramento, CA, USA.'}]",Neurospine,['10.14245/ns.2040004.002'] 1839,32684325,"Immediate Effects of Ankle Non-elastic Taping on Balance and Gait Ability in Patients With Chronic Stroke: A Randomized, Controlled Trial.","OBJECTIVE The purpose of this study was to determine the immediate effects of ankle non-elastic taping on balance and gait ability in patients with chronic stroke. METHODS Thirty patients (inpatients and outpatients) with stroke were randomly assigned to 2 groups: the non-elastic taping group (n = 15) and the placebo-taping group (n = 15). Patients in the non-elastic taping group received Endura sports taping for their ankle joint, and patients in the placebo-taping group received Endura fix tape for their ankle joint. The Balance System SD assessed balance, and the GAITRite system assessed gait ability. We recorded measurements before and after intervention. RESULTS The non-elastic taping group showed a significant improvement in static and dynamic standing balance (P ≤ .001) after intervention; in addition, this group showed significant increases in the velocity, cadence, step length, and stride length of gait (P ≤ .001) after intervention. However, the placebo-taping group showed no significant improvements in standing balance and gait ability after intervention (P >.05). Furthermore, significant differences in static and dynamic standing balance, cadence, and velocity were observed between the 2 groups after intervention (P ≤ .001). CONCLUSIONS Our results demonstrate that the application of ankle non-elastic taping is effective at improving balance and gait abilities in patients with stroke. Ankle non-elastic taping appears to be an effective method to facilitate active rehabilitation in patients with hemiplegia.",2020,"The non-elastic taping group showed a significant improvement in static and dynamic standing balance (P ≤ .001) after intervention; in addition, this group showed significant increases in the velocity, cadence, step length, and stride length of gait (P ≤ .001) after intervention.","['Patients With Chronic Stroke', 'Thirty patients (inpatients and outpatients) with stroke', 'patients with hemiplegia', 'patients with chronic stroke', 'patients with stroke']","['Ankle Non-elastic Taping', 'Endura sports taping', 'placebo-taping group received Endura fix tape for their ankle joint', 'ankle non-elastic taping', 'placebo-taping group', 'non-elastic taping group', 'Ankle non-elastic taping', 'placebo-taping']","['balance and gait ability', 'Balance and Gait Ability', 'velocity, cadence, step length, and stride length of gait', 'static and dynamic standing balance', 'Balance System SD assessed balance, and the GAITRite system assessed gait ability', 'static and dynamic standing balance, cadence, and velocity', 'balance and gait abilities', 'standing balance and gait ability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0018991', 'cui_str': 'Hemiplegia'}]","[{'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0221839', 'cui_str': 'Orthodontic band, elastic'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0034115', 'cui_str': 'Centesis'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0003087', 'cui_str': 'Ankle joint structure'}]","[{'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0427126', 'cui_str': 'Step length'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}]",30.0,0.0992531,"The non-elastic taping group showed a significant improvement in static and dynamic standing balance (P ≤ .001) after intervention; in addition, this group showed significant increases in the velocity, cadence, step length, and stride length of gait (P ≤ .001) after intervention.","[{'ForeName': 'Suk-Hun', 'Initials': 'SH', 'LastName': 'Choi', 'Affiliation': 'Department of Physical Therapy, Gyeongin Rehabilitation Center Hospital, Incheon, South Korea.'}, {'ForeName': 'Chae-Gil', 'Initials': 'CG', 'LastName': 'Lim', 'Affiliation': 'Department of Physical Therapy, College of Health Science, Gachon University, Incheon, South Korea. Electronic address: jgyim@gachon.ac.kr.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2019.12.007'] 1840,32684359,Improving Colorectal Cancer Screening in a Rural Setting: A Randomized Study.,"INTRODUCTION Colorectal cancer screening has been shown to prevent or detect early colorectal cancer and reduce mortality; yet, adherence to screening recommendations remains low, particularly in rural settings. STUDY DESIGN RCT. SETTING/PARTICIPANTS Adults (n=7,812) aged 50-75 years and due for colorectal cancer screening in a largely rural health system were randomly assigned to either the intervention (n=3,906) or the control (n=3,906) group in September 2016, with analysis following through 2018. INTERVENTION A mailed motivational messaging screening reminder letter with an option to call and request a free at-home fecal immunochemical screening test (intervention) or the standard invitation letter detailing that the individual was due for screening (control). Multifaceted motivational messaging emphasized colorectal cancer preventability and the ease and affordability of screening, and communicated a limited supply of test kits. MAIN OUTCOME MEASURES Colorectal cancer screening participation within 6 months after mailed invitation was ascertained from the electronic medical record. RESULTS Colorectal cancer screening participation was significantly improved in the intervention (30.1%) vs the usual care control group (22.5%; p<0.001). Individuals randomized to the intervention group had 49% higher odds of being screened over follow-up than those randomized to the control group (OR=1.49, 95% CI=1.34, 1.65). A total of 13.2 screening invitations were needed to accomplish 1 additional screening over the usual care. Of the 233 fecal immunochemical test kits mailed to participants, 154 (66.1%) were returned, and 18 (11.7%) tested positive. CONCLUSIONS A mailed motivational messaging letter with a low-cost screening alternative increased colorectal cancer screening in this largely rural community with generally poor adherence to screening recommendations. Mailed colorectal cancer screening reminders using motivational messaging may be an effective method for increasing screening and reducing rural colorectal cancer disparities.",2020,"RESULTS Colorectal cancer screening participation was significantly improved in the intervention (30.1%) vs the usual care control group (22.5%; p<0.001).","['Adults (n=7,812', 'aged 50-75 years and due for colorectal cancer screening in a largely rural health system']",['motivational messaging screening reminder letter with an option to call and request a free at-home fecal immunochemical screening test (intervention) or the standard invitation letter detailing that the individual was due for screening (control'],['Colorectal cancer screening participation'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C1272683', 'cui_str': 'Requested'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0871311', 'cui_str': 'Screening test'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]",7812.0,0.0487801,"RESULTS Colorectal cancer screening participation was significantly improved in the intervention (30.1%) vs the usual care control group (22.5%; p<0.001).","[{'ForeName': 'Kelly A', 'Initials': 'KA', 'LastName': 'Hirko', 'Affiliation': 'Department of Epidemiology and Biostatistics, College of Human Medicine, Michigan State University, East Lansing, Michigan. Electronic address: khirko@epi.msu.edu.'}, {'ForeName': 'Sue A', 'Initials': 'SA', 'LastName': 'Lennon', 'Affiliation': 'MidMichigan Health, Midland, Michigan.'}, {'ForeName': 'Todd', 'Initials': 'T', 'LastName': 'Lucas', 'Affiliation': 'Department of Epidemiology and Biostatistics, College of Human Medicine, Michigan State University, East Lansing, Michigan; Division of Public Health, College of Human Medicine, Michigan State University, Flint, Michigan.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Miller', 'Affiliation': 'Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan.'}, {'ForeName': 'Masahito', 'Initials': 'M', 'LastName': 'Jimbo', 'Affiliation': 'Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan; Department of Family Medicine, University of Michigan Medical School, Ann Arbor, Michigan.'}, {'ForeName': 'Stephanie J', 'Initials': 'SJ', 'LastName': 'Leibfritz', 'Affiliation': 'MidMichigan Health, Midland, Michigan.'}, {'ForeName': 'Suzanne J', 'Initials': 'SJ', 'LastName': 'Knoff', 'Affiliation': 'MidMichigan Health, Midland, Michigan.'}, {'ForeName': 'Carol A', 'Initials': 'CA', 'LastName': 'Janney', 'Affiliation': 'Department of Psychiatry, College of Human Medicine West Michigan, Michigan State University, Grand Rapids, Michigan; Pine Rest Christian Mental Health Services, Grand Rapids, Michigan.'}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Berg', 'Affiliation': 'MidMichigan Health, Midland, Michigan.'}]",American journal of preventive medicine,['10.1016/j.amepre.2020.03.019'] 1841,32684362,"Conjugated linoleic acid supplements preserve muscle in high-body-fat adults: A double-blind, randomized, placebo trial.","BACKGROUND AND AIMS Conjugated linoleic acid (CLA) has been used to improve body composition in weight management. However, clinical trial results are inconsistent and limited among Asians. We aimed to investigate the effect of CLA on body composition of Chinese adults with elevated body fat percentage. METHODS AND RESULTS In this double-blind, randomized, placebo-controlled trial, 66 Chinese adults (aged 18-45 years old, 37.9% male) with elevated body fat percentage were provided with 3.2 g/day CLA (n = 33) or 3.2 g/day placebo (sunflower oil; n = 33) for 12 weeks. Both groups received lifestyle counseling, featured with low fat and low sugar diet, and moderate physical activity. Body composition was measured using dual-energy X-ray absorptiometry at the baseline and end of the trial. Sixty-four participants finished this study. Compared with the placebo group, the CLA group showed increased trunk muscle mass (MM) (0.6 ± 1.7 vs. -0.3 ± 1.2 kg, P = 0.019). Among those with an adherence score higher than 0.80 (n = 56, 87.5%), a greater increase in both total and trunk MM was observed in the CLA group (both P < 0.05). Moreover, the effect on MM appeared to be more evident in men, those with a body mass index <25 kg/m 2 , or those with higher self-rated physical activity. CONCLUSIONS In Chinese adults with elevated body fat percentage, 3.2 g/day CLA supplementation may be effective in preserving MM, especially in the trunk region. REGISTRATION This study was registered at ClinicalTrials.gov as NCT03915808 on April 9, 2019.",2020,"Compared with the placebo group, the CLA group showed increased trunk muscle mass (MM) (0.6 ± 1.7 vs. -0.3 ± 1.2 kg, P = 0.019).","['high-body-fat adults', 'Chinese adults with elevated body fat percentage', '66 Chinese adults (aged 18-45 years old, 37.9% male) with elevated body fat percentage were provided with 3.2\xa0g/day']","['CLA', 'CLA supplementation', 'placebo', 'lifestyle counseling, featured with low fat and low sugar diet', 'Conjugated linoleic acid supplements', 'Conjugated linoleic acid (CLA']","['total and trunk MM', 'trunk muscle mass (MM', 'Body composition']","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4517687', 'cui_str': '3.2'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}]","[{'cui': 'C0050156', 'cui_str': '9,11-linoleic acid'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0730543', 'cui_str': 'Lifestyle education'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0242970', 'cui_str': 'Low fat diet'}, {'cui': 'C0452316', 'cui_str': 'Low sugar diet'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0581755', 'cui_str': 'Skeletal muscle structure of trunk'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}]",66.0,0.699676,"Compared with the placebo group, the CLA group showed increased trunk muscle mass (MM) (0.6 ± 1.7 vs. -0.3 ± 1.2 kg, P = 0.019).","[{'ForeName': 'Huan', 'Initials': 'H', 'LastName': 'Chang', 'Affiliation': ""Department of Nutrition and Food Safety, School of Public Health, Xi'an Jiaotong University Health Science Center, 76 West Yanta Road, 710061, Xi'an, Shaanxi, China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Gan', 'Affiliation': 'Medical Research Council Population Health Research Unit at the University of Oxford, Oxford, OX3 7LF, UK; Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Liao', 'Affiliation': ""Department of Nutrition, The First Affiliated Hospital, Xi'an Jiaotong University Health Science Center, 277 West Yanta Road, 710061, Xi'an, Shaanxi, China.""}, {'ForeName': 'Junxiang', 'Initials': 'J', 'LastName': 'Wei', 'Affiliation': ""Department of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, 76 West Yanta Road, 710061, Xi'an, Shaanxi, China.""}, {'ForeName': 'Mengnan', 'Initials': 'M', 'LastName': 'Lu', 'Affiliation': ""Xi'an Jiaotong University Health Science Center, 76 West Yanta Road, 710061, Xi'an, Shaanxi, China.""}, {'ForeName': 'Huangtao', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': ""Xi'an Jiaotong University Health Science Center, 76 West Yanta Road, 710061, Xi'an, Shaanxi, China.""}, {'ForeName': 'Shenglong', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': ""Xi'an Jiaotong University Health Science Center, 76 West Yanta Road, 710061, Xi'an, Shaanxi, China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': ""School of Sports and Health Sciences, Xi'an Physical Education University, 65 North Hanguang Road, 710068, Xi'an, Shaanxi, China.""}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Wu', 'Affiliation': ""Department of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, 76 West Yanta Road, 710061, Xi'an, Shaanxi, China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': ""Department of Nutrition and Food Safety, School of Public Health, Xi'an Jiaotong University Health Science Center, 76 West Yanta Road, 710061, Xi'an, Shaanxi, China. Electronic address: yuyan@xjtu.edu.cn.""}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': ""Department of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, 76 West Yanta Road, 710061, Xi'an, Shaanxi, China. Electronic address: xinliu@xjtu.edu.cn.""}]","Nutrition, metabolism, and cardiovascular diseases : NMCD",['10.1016/j.numecd.2020.05.029'] 1842,32621735,Expert advice about therapeutic exercise during pregnancy reduces the symptoms of sacroiliac dysfunction.,"Objectives There are growing evidence that exercise improves sacroiliac dysfunction symptoms in pregnant women; but no data about the effect of expert advice regarding this matter. The aim of this study was to assess the effectiveness of expert advice about therapeutic exercise on sacroiliac dysfunction in pregnancy. Methods A total of 500 women with sacroiliac dysfunction diagnosed in pregnancy were randomized in study and control group. Study group has conducted expert advice on therapeutic exercise; while control group continued with their normal lifestyle. Pain intensity by Visual Analog Scale (VAS) and degree of functional disability by Quebec scale were assessed at enrolment and after 3 and 6 weeks. Results Significantly better reduction in pain intensity assessed by VAS (p=0.001) and degree of functional disability assessed by Quebec scale (p=0.001) was noted in study compared to control group. Better results for both outcome measures were obtained if intervention was implemented earlier i.e., in second (p=0.001; p=0.001) compared to third (p=0.005; p=0.001) trimester. Strong positive correlation was found between pain intensity and degree of functional disability in both groups. Conclusions Expert advice on therapeutic exercise is effective in reduction of sacroiliac dysfunction symptoms during pregnancy. Trial registration ACTRN12617000556347.",2020,Results Significantly better reduction in pain intensity assessed by VAS (p=0.001) and degree of functional disability assessed by Quebec scale (p=0.001) was noted in study compared to control group.,"['sacroiliac dysfunction in pregnancy', '500 women with sacroiliac dysfunction diagnosed in pregnancy', 'pregnant women']","['expert advice about therapeutic exercise', 'exercise']","['degree of functional disability assessed by Quebec scale', 'Pain intensity by Visual Analog Scale (VAS) and degree of functional disability by Quebec scale', 'sacroiliac dysfunction symptoms', 'pain intensity assessed by VAS', 'pain intensity and degree of functional disability']","[{'cui': 'C0555898', 'cui_str': 'Sacroiliac'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}]","[{'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0034390', 'cui_str': 'Quebec'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0555898', 'cui_str': 'Sacroiliac'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",500.0,0.118531,Results Significantly better reduction in pain intensity assessed by VAS (p=0.001) and degree of functional disability assessed by Quebec scale (p=0.001) was noted in study compared to control group.,"[{'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Filipec', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Clinical hospital ""Sveti Duh"", Zagreb, Croatia.'}, {'ForeName': 'Ratko', 'Initials': 'R', 'LastName': 'Matijević', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Zagreb, Zagreb, Croatia.'}]",Journal of perinatal medicine,['10.1515/jpm-2020-0143'] 1843,32612333,The Effectiveness of Nurses Implemented Music Add-on Therapy in Children with Behavioral Problems.,"Background Increasing rates of behavioral problems among children in India necessitates newer ways of managing them with medical and nonmedical approaches. Music add-on therapy is a method for treating mental disturbances. This study examines the effectiveness of music add-on therapy in managing children with behavioral problems. Methods and Materials A randomized controlled design was adopted with a random allocation of 40 children (20 each in experimental and control groups) aged between 6 and 12 years with behavioral disorders as per the International Statistical Classification of Diseases and Related Health Problems (ICD)-10. After the pretest, both the groups received treatment as usual (TAU), while the experimental group alone additionally received music add-on intervention with eight Hindustani ragas for 3 weeks. As clinical outcome measures, we used the Childrens Global Assessment Scale, Nisonger Child Behavior Rating Form typical IQ (NCBRF-TIQ) version, and visual analogue scale (VAS) for a parent to monitor the behavioral improvement. Results Children exposed to the music add-on therapy had improved score in the Children Global Assessment Scale (CGAS) and the VAS as compared with the control group (F [2,76] = 34.307, P < 0.001 and F [2,76] = 72.4, P < 0.001, respectively). Further, the NCBRF-TIQ version revealed improvement in positive social behavior (F [2,76] = 13.089, P < 0.001) and reduction in problem behaviors in the experimental group. Conclusion Music add-on therapy is effective in improving positive social behavior and reducing problem behaviors among children.",2020,"Results Children exposed to the music add-on therapy had improved score in the Children Global Assessment Scale (CGAS) and the VAS as compared with the control group (F [2,76] = 34.307, P < 0.001 and F [2,76] = 72.4, P < 0.001, respectively).","['40 children (20 each in experimental and control groups) aged between 6 and 12 years with behavioral disorders as per the International Statistical Classification of Diseases and Related Health Problems (ICD)-10', 'managing children with behavioral problems', 'Children with Behavioral Problems', 'children']","['Nurses Implemented Music Add-on Therapy', 'usual (TAU), while the experimental group alone additionally received music add-on intervention with eight Hindustani ragas']","['Childrens Global Assessment Scale, Nisonger Child Behavior Rating Form typical IQ (NCBRF-TIQ) version, and visual analogue scale (VAS) for a parent to monitor the behavioral improvement', 'positive social behavior', 'problem behaviors', 'Children Global Assessment Scale (CGAS) and the VAS']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0004930', 'cui_str': 'Behaviour disorder'}, {'cui': 'C0870733', 'cui_str': 'International Statistical Classification of Diseases and Related Health Problems'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}]","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0008065', 'cui_str': 'Behavior, Child'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0037397', 'cui_str': 'Social behavior'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C3472495', 'cui_str': ""Children's global assessment scale""}]",40.0,0.0871176,"Results Children exposed to the music add-on therapy had improved score in the Children Global Assessment Scale (CGAS) and the VAS as compared with the control group (F [2,76] = 34.307, P < 0.001 and F [2,76] = 72.4, P < 0.001, respectively).","[{'ForeName': 'Radhakrishnan', 'Initials': 'R', 'LastName': 'Govindan', 'Affiliation': 'Department of Nursing, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'John V S', 'Initials': 'JVS', 'LastName': 'Kommu', 'Affiliation': 'Department of Child and Adolescent Psychiatry, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.'}, {'ForeName': 'Binukumar', 'Initials': 'B', 'LastName': 'Bhaskarapillai', 'Affiliation': 'Department of Biostatistics, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.'}]",Indian journal of psychological medicine,['10.4103/IJPSYM.IJPSYM_240_19'] 1844,32610640,Be a Mom 's Efficacy in Enhancing Positive Mental Health among Postpartum Women Presenting Low Risk for Postpartum Depression: Results from a Pilot Randomized Trial.,"In this study, we conducted a preliminary investigation of the efficacy of Be a Mom , a web-based self-guided intervention, in enhancing positive mental health among postpartum women at low risk for postpartum depression. Additionally, we examined Be a Mom 's efficacy regarding secondary outcomes as well as its acceptability and adherence. A total of 367 participants were randomly assigned to the Be a Mom group ( n = 191) or to the waiting-list control group ( n = 176) and completed baseline (T1) and postintervention (T2) assessments. The intervention group reported significant increases in positive mental health between T1 and T2 compared to the control group. Additionally, group effects were found for depressive and anxiety symptoms. A significantly higher proportion of participants in the Be a Mom group had an improvement trajectory (from not flourishing at T1 to flourishing at T2). A total of 62 (32.5%) women completed Be a Mom , and most would use it again if needed ( n = 82/113; 72.6%). This study provides preliminary evidence of Be a Mom 's efficacy in increasing positive mental health among low-risk postpartum women. Our findings support mental health promotion strategies in the postpartum period and highlight the important role of web-based CBT interventions.",2020,The intervention group reported significant increases in positive mental health between T1 and T2 compared to the control group.,"['Postpartum Women Presenting Low Risk for Postpartum Depression', 'postpartum women at low risk for postpartum depression', 'low-risk postpartum women', 'A total of 367 participants', 'A total of 62 (32.5%) women completed Be a Mom']",['waiting-list control group'],"['depressive and anxiety symptoms', 'acceptability and adherence', 'positive mental health']","[{'cui': 'C0032804', 'cui_str': 'Postpartum Women'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517710', 'cui_str': '32.5'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C1442163', 'cui_str': 'MoM'}]","[{'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]",367.0,0.0973773,The intervention group reported significant increases in positive mental health between T1 and T2 compared to the control group.,"[{'ForeName': 'Fabiana', 'Initials': 'F', 'LastName': 'Monteiro', 'Affiliation': 'Center for Research in Neuropsychology and Cognitive Behavioral Intervention (CINEICC), Faculty of Psychology and Educational Sciences, the University of Coimbra Rua do Colégio Novo, 3000-315 Coimbra, Portugal.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Pereira', 'Affiliation': 'Center for Research in Neuropsychology and Cognitive Behavioral Intervention (CINEICC), Faculty of Psychology and Educational Sciences, the University of Coimbra Rua do Colégio Novo, 3000-315 Coimbra, Portugal.'}, {'ForeName': 'Maria Cristina', 'Initials': 'MC', 'LastName': 'Canavarro', 'Affiliation': 'Center for Research in Neuropsychology and Cognitive Behavioral Intervention (CINEICC), Faculty of Psychology and Educational Sciences, the University of Coimbra Rua do Colégio Novo, 3000-315 Coimbra, Portugal.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Fonseca', 'Affiliation': 'Center for Research in Neuropsychology and Cognitive Behavioral Intervention (CINEICC), Faculty of Psychology and Educational Sciences, the University of Coimbra Rua do Colégio Novo, 3000-315 Coimbra, Portugal.'}]",International journal of environmental research and public health,['10.3390/ijerph17134679'] 1845,32684314,Comparison of intraoperative outcomes with single and double puncture techniques of arthrocentesis of the temporomandibular joint.,"Evidence of differences in operator-related outcomes between single and double puncture arthrocentesis is limited. The purpose of this prospective study was to compare intraoperative outcomes with single puncture types 1 and 2, and double puncture, arthrocentesis. A total of 59 patients with 60 temporomandibular joints (TMJ) were treated sequentially by single puncture type 1 (n=20), single puncture type 2 (n=20), and double puncture arthrocentesis (n=20). Total operating time, incidence of dislocation of the needle, preauricular swelling, and ease of operation were compared. Single puncture type 2 arthrocentesis took significantly less time than type 1 (p<0.0001) or double puncture arthrocentesis (p<0.0001), but there was no difference in operating time between single puncture type 1 and the double puncture technique (p=0.25). There were significantly fewer dislocations of the needle with single puncture type 1 (p=0.041) and single puncture type 2 (p=0.033) than with double arthrocentesis. Single puncture type 2 arthrocentesis was easier than the single puncture type 1 (p=0.001) or double puncture technique (p<0.0001). Extravasation of fluid caused swelling in seven patients after double puncture, and in three patients each after single puncture types 1 and 2, arthrocentesis. Our results indicate that the single puncture type 2 technique is easiest and requires the least operating time. There was no difference between single puncture type 1 and double puncture arthrocentesis in terms of operating time or ease of the procedure. There were fewer operative dislocations of the needle with the single than with the double puncture technique.",2020,Single puncture type 2 arthrocentesis was easier than the single puncture type 1 (p=0.001) or double puncture technique (p<0.0001).,"['59 patients with 60 temporomandibular joints (TMJ', 'arthrocentesis of the temporomandibular joint']","['single puncture type 2 (n=20), and double puncture arthrocentesis']","['operating time', 'Extravasation of fluid caused swelling', 'Total operating time, incidence of dislocation of the needle, preauricular swelling, and ease of operation', 'operative dislocations']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039493', 'cui_str': 'Temporomandibular joint structure'}, {'cui': 'C0204854', 'cui_str': 'Arthrocentesis'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0204854', 'cui_str': 'Arthrocentesis'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0015376', 'cui_str': 'Extravasation'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0012691', 'cui_str': 'Dislocation'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",59.0,0.258854,Single puncture type 2 arthrocentesis was easier than the single puncture type 1 (p=0.001) or double puncture technique (p<0.0001).,"[{'ForeName': 'Shakil Ahmed', 'Initials': 'SA', 'LastName': 'Nagori', 'Affiliation': 'Oral & Maxillofacial Surgeon, 21 Corps Dental Unit, c/o 56 APO. Electronic address: drshakilnagori@gmail.com.'}, {'ForeName': 'Anson', 'Initials': 'A', 'LastName': 'Jose', 'Affiliation': 'Faculty, Department of Oral & Maxillofacial Surgery, Army Dental Centre (Research & Referral), New Delhi.'}, {'ForeName': 'Ajoy', 'Initials': 'A', 'LastName': 'Roychoudhury', 'Affiliation': 'Professor & Head of Department, Department of Oral & Maxillofacial Surgery, All India Institute of Medical Sciences, New Delhi.'}]",The British journal of oral & maxillofacial surgery,['10.1016/j.bjoms.2020.04.011'] 1846,32615473,Acceptance and commitment therapy combined with vestibular rehabilitation for persistent postural-perceptual dizziness: A pilot study.,"PURPOSE This study investigated the feasibility of acceptance and commitment therapy for persistent postural-perceptual dizziness and preliminarily verified the long-term effectiveness of the therapy. MATERIALS AND METHODS This study implemented the within-group pre-post comparison design. We enrolled 27 adult patients who met the criteria of persistent postural-perceptual dizziness. They underwent a treatment program including acceptance and commitment therapy combined with vestibular rehabilitation once a week for a total of six sessions. The primary outcome was changes in the Dizziness Handicap Inventory score 6 months posttreatment. RESULTS All 27 patients completed the acceptance and commitment therapy + vestibular rehabilitation program, and 25 patients (92.6%) could be followed for 6 months posttreatment. For 27 participants, the scores from pretreatment to 6 months posttreatment significantly declined (P < .001), and the Dizziness Handicap Inventory effect size was 1.11 (95% confidence interval = 0.80-1.42). At 6 months posttreatment, 11 patients (40.7%) achieved remission (the score ≤ 14), 16 (59.3%) achieved treatment response (reduction in the score ≥ 18), and 20 (74.1%) achieved remission and/or treatment response. CONCLUSIONS Acceptance and commitment therapy is feasible for persistent postural-perceptual dizziness and might have long-term effectiveness. However, a randomized controlled trial is warranted.",2020,"For 27 participants, the scores from pretreatment to 6 months posttreatment significantly declined (P < .001), and the Dizziness Handicap Inventory effect size was 1.11 (95% confidence interval = 0.80-1.42).","['persistent postural-perceptual dizziness', '27 adult patients who met the criteria of persistent postural-perceptual dizziness']","['Acceptance and commitment therapy combined with vestibular rehabilitation', 'acceptance and commitment therapy', 'acceptance and commitment therapy combined with vestibular rehabilitation']","['Dizziness Handicap Inventory effect size', 'remission', 'Dizziness Handicap Inventory score 6\xa0months posttreatment', 'remission and/or treatment response']","[{'cui': 'C0522360', 'cui_str': 'Persistent postural perceptual dizziness'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0200324', 'cui_str': 'Vestibular rehabilitation'}]","[{'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0231172', 'cui_str': 'Handicap'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C4304791', 'cui_str': 'Dizziness Handicap Inventory score'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",27.0,0.176719,"For 27 participants, the scores from pretreatment to 6 months posttreatment significantly declined (P < .001), and the Dizziness Handicap Inventory effect size was 1.11 (95% confidence interval = 0.80-1.42).","[{'ForeName': 'Junya', 'Initials': 'J', 'LastName': 'Kuwabara', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: jurry7777@hotmail.co.jp.'}, {'ForeName': 'Masaki', 'Initials': 'M', 'LastName': 'Kondo', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: kondo-masaki@umin.ac.jp.'}, {'ForeName': 'Kayoko', 'Initials': 'K', 'LastName': 'Kabaya', 'Affiliation': 'Department of Otolaryngology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: kabaya@med.nagoya-cu.ac.jp.'}, {'ForeName': 'Wakako', 'Initials': 'W', 'LastName': 'Watanabe', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan; Kikuchi Mental Clinic, Ushikubo-cho, Toyokawa 442-0826, Japan. Electronic address: wakakoigarashi@gmail.com.'}, {'ForeName': 'Nao', 'Initials': 'N', 'LastName': 'Shiraishi', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: fecitanno@gmail.com.'}, {'ForeName': 'Mie', 'Initials': 'M', 'LastName': 'Sakai', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: mie.sakai.38@gmail.com.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Toshishige', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: yuu0323uchi@yahoo.co.jp.'}, {'ForeName': 'Keiko', 'Initials': 'K', 'LastName': 'Ino', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: miniture_flute@hotmail.com.'}, {'ForeName': 'Meiho', 'Initials': 'M', 'LastName': 'Nakayama', 'Affiliation': 'Department of Otolaryngology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan; Good Sleep Center, Nagoya City University Hospital, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: nakayama@med.nagoya-cu.ac.jp.'}, {'ForeName': 'Shinichi', 'Initials': 'S', 'LastName': 'Iwasaki', 'Affiliation': 'Department of Otolaryngology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: iwashin-tky@umin.ac.jp.'}, {'ForeName': 'Tatsuo', 'Initials': 'T', 'LastName': 'Akechi', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: takechi@med.nagoya-cu.ac.jp.'}]",American journal of otolaryngology,['10.1016/j.amjoto.2020.102609'] 1847,32619524,Design of a randomized placebo controlled trial of high dose intravenous thiamine for the prevention of delirium in allogeneic hematopoietic stem cell transplantation.,"BACKGROUND Delirium is a highly prevalent and preventable neuropsychiatric condition with major health consequences. Thiamine deficiency is a well-established cause of delirium in those with chronic, severe alcoholism, but there remains an underappreciation of its significance in non-alcoholic populations, including patients with cancer. Treatment of suspected thiamine-related mental status changes with high dose intravenous (IV) thiamine has preliminary evidence for improving a variety of cognitive symptoms in oncology inpatient settings but has never been studied for the prevention of delirium in any population. OBJECTIVES The primary objective of this clinical trial is to determine if high dose IV thiamine can prevent delirium in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) for treatment of cancer. Secondary objectives are to determine if thiamine status is predictive of delirium onset and if high dose IV thiamine can attenuate the deleterious impact of delirium on health-related quality of life (HRQOL), functional status, and long-term neuropsychiatric outcomes. METHODS In this phase II study, we are recruiting 60 patients undergoing allogeneic HSCT, randomizing them to treatment with high dose IV thiamine (n = 30) versus placebo (n = 30), and systematically evaluating all participants for delirium and related comorbidities. We use the Delirium Rating Scale to measure the severity and duration of delirium during hospitalization for HSCT. We obtain thiamine levels weekly during the transplantation hospitalization. We assess HRQOL, functional status, depression, post-traumatic stress symptoms, and cognitive function prior to and at one, three, and six months after transplantation.",2020,"Treatment of suspected thiamine-related mental status changes with high dose intravenous (IV) thiamine has preliminary evidence for improving a variety of cognitive symptoms in oncology inpatient settings but has never been studied for the prevention of delirium in any population. ","['60 patients undergoing allogeneic HSCT, randomizing them to treatment with high dose', 'patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) for treatment of cancer', 'Allogeneic Hematopoietic Stem Cell Transplantation', 'patients with cancer']","['Placebo', 'Thiamine', 'thiamine', 'intravenous (IV) thiamine', 'IV thiamine', 'placebo']","['HRQOL, functional status, depression, post-traumatic stress symptoms, and cognitive function', 'Delirium Rating Scale', 'health-related quality of life (HRQOL), functional status, and long-term neuropsychiatric outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039840', 'cui_str': 'Thiamine'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",60.0,0.367689,"Treatment of suspected thiamine-related mental status changes with high dose intravenous (IV) thiamine has preliminary evidence for improving a variety of cognitive symptoms in oncology inpatient settings but has never been studied for the prevention of delirium in any population. ","[{'ForeName': 'Zev M', 'Initials': 'ZM', 'LastName': 'Nakamura', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: zev_nakamura@med.unc.edu.'}, {'ForeName': 'Allison M', 'Initials': 'AM', 'LastName': 'Deal', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Donald L', 'Initials': 'DL', 'LastName': 'Rosenstein', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Quillen', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Stephanie A', 'Initials': 'SA', 'LastName': 'Chien', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'William A', 'Initials': 'WA', 'LastName': 'Wood', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Thomas C', 'Initials': 'TC', 'LastName': 'Shea', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Eliza M', 'Initials': 'EM', 'LastName': 'Park', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106076'] 1848,32619868,Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults.,"Few studies examine the effectiveness of treatments for opioid use disorder (OUD) among Black individuals despite recent evidence suggesting opioid overdose death rates are, in some cases, highest and increasing at a faster rate among Black people compared to other racial/ethnic groups. This secondary analysis study investigated treatment preference, retention, and relapse rates amongst a subgroup of 73 Black participants with OUD (81% male, mean age 39.05, SD = 11.80) participating in a 24-week multisite randomized clinical trial (""X:BOT"") comparing the effectiveness of extended-release naltrexone (XR-NTX) and sublingual buprenorphine-naloxone (BUP-NX) between 2014 and 2017. Chi-square analyses were used to investigate treatment preference assessed at baseline, and logistic regression analyses were used to investigate differences in the odds of retention and relapse assessed over the 24-week course of treatment between treatment groups. Our findings suggest no differences in preference for XR-NTX versus BUP-NX. However, similar to the parent trial, there was an induction hurdle such that only 59.5% of those randomized to XR-NTX successfully initiated medication compared to 91.6% of those randomized to BUP-NX (OR = 0.13, 95% CI = 0.04, 0.52). No significant differences were found in treatment retention (intention-to-treat: OR = 1.19, 95% CI = 0.43, 3.28; per-protocol [i.e., those who initiated medication]: OR = 0.60, 95% CI = 0.20, 1.82) or relapse rates between treatment groups (intention-to-treat: OR = 1.53, 95% CI = 0.57, 4.13; per-protocol: OR = 0.69, 95% CI = 0.23, 2.06). Although there is a significant initiation hurdle with XR-NTX, once inducted, both medications appear similar in effectiveness, but as in the main study, dropout rates were high. Future research is needed on how to improve adherence.",2020,"No significant differences were found in treatment retention (intention-to-treat: OR = 1.19, 95% CI = 0.43, 3.28; per-protocol","['black adults', '73 Black participants with OUD (81% male, mean age 39.05, SD\xa0=\xa011.80) participating']","['extended-release naltrexone (XR-NTX) and sublingual buprenorphine-naloxone (BUP-NX', 'naltrexone', 'buprenorphine-naloxone']",['relapse rates'],"[{'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C0001565', 'cui_str': 'Sublingual route'}, {'cui': 'C1169989', 'cui_str': 'Buprenorphine- and naloxone-containing product'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}]",73.0,0.101327,"No significant differences were found in treatment retention (intention-to-treat: OR = 1.19, 95% CI = 0.43, 3.28; per-protocol","[{'ForeName': 'Angela M', 'Initials': 'AM', 'LastName': 'Haeny', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 34 Park St., New Haven, CT 06511, United States. Electronic address: angela.haeny@yale.edu.'}, {'ForeName': 'LaTrice', 'Initials': 'L', 'LastName': 'Montgomery', 'Affiliation': 'University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience, 3131 Harvey Avenue., Cincinnati, OH 45229, United States.'}, {'ForeName': 'A Kathleen', 'Initials': 'AK', 'LastName': 'Burlew', 'Affiliation': 'University of Cincinnati, Department of Psychology, 2600 Clifton Ave., Cincinnati, OH 45221, United States.'}, {'ForeName': 'Aimee N C', 'Initials': 'ANC', 'LastName': 'Campbell', 'Affiliation': 'Columbia University Irving Medical Center, Department of Psychiatry and New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, United States.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Scodes', 'Affiliation': 'Columbia University Irving Medical Center, Department of Psychiatry and New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, United States.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Pavlicova', 'Affiliation': 'Columbia University Irving Medical Center, Department of Psychiatry and New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, United States.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Rotrosen', 'Affiliation': 'New York University Grossman School of Medicine, One Park Ave., New York, NY 10016, United States.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Nunes', 'Affiliation': 'Columbia University Irving Medical Center, Department of Psychiatry and New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, United States.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106514'] 1849,32622225,The impact of adult trauma triage training on decision-making skills and accuracy of triage decision at emergency departments in Malaysia: A randomized control trial.,"INTRODUCTION Patients who visit emergency departments need to undergo a precise assessment to determine their priority and accurate triage category to ensure they receive the right treatment. AIM To identify the effect of triage training on the skills and accuracy of triage decisions for adult trauma patients. METHOD A randomized controlled trial design was conducted in ten emergency department of public hospitals. A total of 143 registered nurses and medical officer assistants who performed triage roles were recruited for the control group (n = 74) and the intervention group (n = 69). The skill and accuracy of triage decisions were measured two weeks and four weeks after the intervention group were exposed to the intervention. RESULTS There was a significant effect on the skill of triage decision-making between the control and the intervention group p < 0.001, η 2 partial  = 0.31. Concerning the accuracy of triage decisions, the effect was significantly different between the control group and the intervention group p < 0.001, η 2 partial  = 0.66 across time. CONCLUSION The triage training improved the skills of the participants and the accuracy of triage decision-making across time.",2020,"There was a significant effect on the skill of triage decision-making between the control and the intervention group p < 0.001, η 2 partial  = 0.31.","['emergency departments in Malaysia', 'Patients who visit emergency departments', 'ten emergency department of public hospitals', '143 registered nurses and medical officer assistants who performed triage roles were recruited for the control group (n\xa0=\xa074) and the intervention group (n\xa0=\xa069', 'adult trauma patients']","['triage training', 'adult trauma triage training']","['skill and accuracy of triage decisions', 'skill of triage decision-making']","[{'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0024552', 'cui_str': 'Malaysia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020022', 'cui_str': 'Public Hospitals'}, {'cui': 'C4517573', 'cui_str': '143'}, {'cui': 'C0687673', 'cui_str': 'Registered nurse'}, {'cui': 'C0557516', 'cui_str': 'Medical officer'}, {'cui': 'C0011327', 'cui_str': 'Dental assistant'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0040861', 'cui_str': 'Triage'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}]","[{'cui': 'C0040861', 'cui_str': 'Triage'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}]","[{'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0040861', 'cui_str': 'Triage'}, {'cui': 'C0011109', 'cui_str': 'Decision making'}]",143.0,0.0515258,"There was a significant effect on the skill of triage decision-making between the control and the intervention group p < 0.001, η 2 partial  = 0.31.","[{'ForeName': 'Siti Aishah', 'Initials': 'SA', 'LastName': 'Ghazali', 'Affiliation': 'School of Health Sciences, Health Campus, Universiti Sains Malaysia, Kelantan, Malaysia; Department of Nursing Science, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. Electronic address: schah@usm.my.'}, {'ForeName': 'Khatijah Lim', 'Initials': 'KL', 'LastName': 'Abdullah', 'Affiliation': 'Department of Nursing Science, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. Electronic address: katlim@um.edu.my.'}, {'ForeName': 'Foong Ming', 'Initials': 'FM', 'LastName': 'Moy', 'Affiliation': 'Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. Electronic address: moyfm@ummc.edu.my.'}, {'ForeName': 'Rashidi', 'Initials': 'R', 'LastName': 'Ahmad', 'Affiliation': 'Department of Emergency Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. Electronic address: rashidi@ummc.edu.my.'}, {'ForeName': 'Emni Omar Daw', 'Initials': 'EOD', 'LastName': 'Hussin', 'Affiliation': 'Department of Nursing Science, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.'}]",International emergency nursing,['10.1016/j.ienj.2020.100889'] 1850,32622294,The effects of yoga on functionality appreciation and additional facets of positive body image.,"This study investigated the effects of yoga on functionality appreciation, and the potential mechanisms that could explain the impact of yoga on additional facets of positive body image. Young adult women (N = 114; M age  = 22.19) were randomised to a 10-week Hatha yoga programme or waitlist control group. Participants completed measures of functionality appreciation, body appreciation, body compassion, appearance evaluation, self-objectification, and embodiment at Pretest, Midtest, Posttest, and 1-month Follow-Up. Follow-up data could not be analysed due to high levels of attrition. The remaining data showed that, compared to the control group, women in the yoga programme experienced lower self-objectification at Midtest and greater embodiment over time. Further, all participants experienced improvements in body appreciation, body compassion, and appearance evaluation over time, regardless of their assigned group. Lower self-objectification contributed to improvements in body appreciation and body compassion. In addition, greater embodiment contributed to improvements in body appreciation, body compassion, and appearance evaluation. Contrary to our expectations, yoga did not lead to increased functionality appreciation, nor was functionality appreciation a mediator of the impact of yoga on positive body image. Instead, lower self-objectification, and greater embodiment, drove improvements in positive body image.",2020,"The remaining data showed that, compared to the control group, women in the yoga programme experienced lower self-objectification at Midtest and greater embodiment over time.",['Young adult women (N\u202f=\u202f114; M age \u202f=\u202f22.19'],['Hatha yoga programme or waitlist control group'],"['body appreciation and body compassion', 'functionality appreciation, body appreciation, body compassion, appearance evaluation, self-objectification, and embodiment at Pretest, Midtest, Posttest, and 1-month Follow-Up', 'body appreciation, body compassion, and appearance evaluation']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]",,0.0268438,"The remaining data showed that, compared to the control group, women in the yoga programme experienced lower self-objectification at Midtest and greater embodiment over time.","[{'ForeName': 'Jessica M', 'Initials': 'JM', 'LastName': 'Alleva', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, the Netherlands. Electronic address: Jessica.Alleva@maastrichtuniversity.nl.'}, {'ForeName': 'Tracy L', 'Initials': 'TL', 'LastName': 'Tylka', 'Affiliation': 'Department of Psychology, The Ohio State University, Columbus, OH, United States.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'van Oorsouw', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Montanaro', 'Affiliation': 'Department of Psychology, The University of North Carolina at Charlotte, Charlotte, NC, United States.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Perey', 'Affiliation': 'Chair of Sport and Health Management, Technical University of Munich, Germany.'}, {'ForeName': 'Cheyenne', 'Initials': 'C', 'LastName': 'Bolle', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Jantine', 'Initials': 'J', 'LastName': 'Boselie', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Madelon', 'Initials': 'M', 'LastName': 'Peters', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Jennifer B', 'Initials': 'JB', 'LastName': 'Webb', 'Affiliation': 'Department of Psychology, The University of North Carolina at Charlotte, Charlotte, NC, United States.'}]",Body image,['10.1016/j.bodyim.2020.06.003'] 1851,32623088,Effectiveness of Intramuscular Electrical Stimulation on Postsurgical Nociceptive Pain for Patients Undergoing Open Pancreaticoduodenectomy: A Randomized Clinical Trial.,"BACKGROUND After pylorus-preserving pancreaticoduodenectomy (PPPD), incision and suture of the abdominal muscles cause inflammatory changes and elicit somatic pain that deteriorates the quality of life. There have been no previous reports on needle electrical twitch obtaining intramuscular stimulation (NETOIMS) in abdominal open operation; this study aimed to apply NETOIMS for postoperative somatic pain in patients undergoing PPPD as a new treatment modality for pain control. METHODS Between June 2018 and January 2019, 44 patients who underwent PPPD were randomly assigned to a control group and the NETOIMS group. The NETOIMS group received NETOIMS in the transverse abdominis muscle under ultrasound guidance right after operation under general anesthesia. The pain score (visual analog scale), peak cough flow (PCF), and gait speed were repetitively measured from 1 day before operation to 2 weeks after discharge as scheduled. Data were analyzed by the linear mixed model and repeated-measures analysis of variance. RESULTS Of the 44 patients recruited, data from 38 patients were finally analyzed. The pain scores were significantly lower in the NETOIMS group after PPPD (p = 0.01). Although the PCF at each measuring time point did not show inter-group difference (p = 0.20), improvement of PCF from the second day after operation to discharge was greater (p = 0.02) and gait speed improved significantly faster (p < 0.01) in the NETOIMS group than in the control group. CONCLUSIONS NETOIMS helps in rapid reduction of postoperative somatic pain developed after PPPD and in improvement of PCF and gait speed.",2020,"Although the PCF at each measuring time point did not show inter-group difference (P = 0.20), improvement of PCF from the second day of surgery to discharge was greater (P = 0.02) and gait speed improved significantly faster (P < 0.01) in the NETOIMS group than in the control group. ","['44 patients recruited, data of 38 patients were finally analyzed', 'Patients Undergoing Open Pancreaticoduodenectomy', 'after surgery under general anesthesia', 'Between June 2018 and January 2019, 44 patients who underwent PPPD', 'patients undergoing PPPD as a new treatment modality for pain control']","['transverse abdominis muscle under ultrasound guidance right', 'Intramuscular Electrical Stimulation']","['pain scores', 'gait speed', 'PCF and gait speed', 'Postsurgical Nociceptive Pain', 'improvement of PCF', 'pain score (visual analog scale, VAS), peak cough flow (PCF), and gait speed']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0085162', 'cui_str': 'Pancreaticoduodenectomy'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]","[{'cui': 'C0205106', 'cui_str': 'Transverse plane'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C3178766', 'cui_str': 'Nociceptive Pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",38.0,0.0740017,"Although the PCF at each measuring time point did not show inter-group difference (P = 0.20), improvement of PCF from the second day of surgery to discharge was greater (P = 0.02) and gait speed improved significantly faster (P < 0.01) in the NETOIMS group than in the control group. ","[{'ForeName': 'Jinyoung', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': 'Rehabilitation Institute of Neuromuscular Disease, Department of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Hyung Sun', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': 'Pancreatobiliary Cancer Clinic, Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jung Hyun', 'Initials': 'JH', 'LastName': 'Park', 'Affiliation': 'Rehabilitation Institute of Neuromuscular Disease, Department of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Yoon Ghil', 'Initials': 'YG', 'LastName': 'Park', 'Affiliation': 'Rehabilitation Institute of Neuromuscular Disease, Department of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Sanghoon', 'Initials': 'S', 'LastName': 'Shin', 'Affiliation': 'Gangnam Severance Hospital, Department Rehabilitation Medicine, Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jae Eun', 'Initials': 'JE', 'LastName': 'Park', 'Affiliation': 'Gangnam Severance Hospital, Department Rehabilitation Medicine, Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Sangwon', 'Initials': 'S', 'LastName': 'Hwang', 'Affiliation': 'Gangnam Severance Hospital, Department Rehabilitation Medicine, Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'So Young', 'Initials': 'SY', 'LastName': 'Jun', 'Affiliation': 'Pancreatobiliary Cancer Clinic, Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Joon Seong', 'Initials': 'JS', 'LastName': 'Park', 'Affiliation': 'Pancreatobiliary Cancer Clinic, Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: jspark330@yuhs.ac.'}]",Journal of the American College of Surgeons,['10.1016/j.jamcollsurg.2020.06.008'] 1852,32623140,Emotion self-regulation training in major depressive disorder using simultaneous real-time fMRI and EEG neurofeedback.,"Simultaneous real-time fMRI and EEG neurofeedback (rtfMRI-EEG-nf) is an emerging neuromodulation approach, that enables simultaneous volitional regulation of both hemodynamic (BOLD fMRI) and electrophysiological (EEG) brain activities. Here we report the first application of rtfMRI-EEG-nf for emotion self-regulation training in patients with major depressive disorder (MDD). In this proof-of-concept study, MDD patients in the experimental group (n = 16) used rtfMRI-EEG-nf during a happy emotion induction task to simultaneously upregulate two fMRI and two EEG activity measures relevant to MDD. The target measures included BOLD activities of the left amygdala (LA) and left rostral anterior cingulate cortex (rACC), and frontal EEG asymmetries in the alpha band (FAA, [7.5-12.5] Hz) and high-beta band (FBA, [21-30] Hz). MDD patients in the control group (n = 8) were provided with sham feedback signals. An advanced procedure for improved real-time EEG-fMRI artifact correction was implemented. The experimental group participants demonstrated significant upregulation of the LA BOLD activity, FAA, and FBA during the rtfMRI-EEG-nf task, as well as significant enhancement in fMRI connectivity between the LA and left rACC. Average individual FAA changes during the rtfMRI-EEG-nf task positively correlated with depression and anhedonia severities, and negatively correlated with after-vs-before changes in depressed mood ratings. Temporal correlations between the FAA and FBA time courses and the LA BOLD activity were significantly enhanced during the rtfMRI-EEG-nf task. The experimental group participants reported significant mood improvements after the training. Our results suggest that the rtfMRI-EEG-nf may have potential for treatment of MDD.",2020,"The experimental group participants demonstrated significant upregulation of the LA BOLD activity, FAA, and FBA during the rtfMRI-EEG-nf task, as well as significant enhancement in fMRI connectivity between the LA and left rACC.",['patients with major depressive disorder (MDD'],"['Emotion self-regulation training', 'rtfMRI-EEG-nf for emotion self-regulation training']","['BOLD activities of the left amygdala (LA) and left rostral anterior cingulate cortex (rACC), and frontal EEG asymmetries in the alpha band (FAA, [7.5-12.5] Hz) and high-beta band (FBA, [21-30] Hz', 'Average individual FAA changes', 'depression and anhedonia severities', 'LA BOLD activity', 'fMRI connectivity', 'LA BOLD activity, FAA, and FBA during the rtfMRI-EEG-nf task']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}]","[{'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C3163631', 'cui_str': 'Rostral'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C0205123', 'cui_str': 'Coronal'}, {'cui': 'C0332514', 'cui_str': 'Asymmetry'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0060441', 'cui_str': 'flavone acetic acid'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0178417', 'cui_str': 'Anhedonia'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]",,0.014664,"The experimental group participants demonstrated significant upregulation of the LA BOLD activity, FAA, and FBA during the rtfMRI-EEG-nf task, as well as significant enhancement in fMRI connectivity between the LA and left rACC.","[{'ForeName': 'Vadim', 'Initials': 'V', 'LastName': 'Zotev', 'Affiliation': 'Laureate Institute for Brain Research, Tulsa, OK, USA. Electronic address: vzotev@laureateinstitute.org.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Mayeli', 'Affiliation': 'Laureate Institute for Brain Research, Tulsa, OK, USA; Electrical and Computer Engineering, University of Oklahoma, Tulsa, OK, USA.'}, {'ForeName': 'Masaya', 'Initials': 'M', 'LastName': 'Misaki', 'Affiliation': 'Laureate Institute for Brain Research, Tulsa, OK, USA.'}, {'ForeName': 'Jerzy', 'Initials': 'J', 'LastName': 'Bodurka', 'Affiliation': 'Laureate Institute for Brain Research, Tulsa, OK, USA; Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA. Electronic address: jbodurka@laureateinstitute.org.'}]",NeuroImage. Clinical,['10.1016/j.nicl.2020.102331'] 1853,32623182,"Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).","BACKGROUND Chemotherapy is effective in metastatic pancreatic adenocarcinoma (mPA), but new approaches are still needed to improve patients' survival and quality of life. We have previously published good efficacy and tolerability results on a sequential treatment strategy of gemcitabine followed by an intensified FOLFIRI (5FU+irinotecan) regimen. In the present study, we evaluated the same sequence but replaced gemcitabine by the new gemcitabine + nab-paclitaxel standard first-line combination. PATIENTS AND METHODS We randomised chemotherapy-naive patients with proven mPA, bilirubin levels ≤1.5 upper limit of normal values and performance status 0-2 to alternately receive gemcitabine + nab-paclitaxel for 2 months then FOLFIRI.3 for 2 months in arm A, or gemcitabine + nab-paclitaxel alone until progression in arm B. The primary objective was to increase the 6-month progression-free survival (PFS) rate from 40% (H 0 ) to 60% (H 1 ); using the binomial exact method, 124 patients were required. Analyses were carried out in preplanned modified intention-to-treat (mITT) and per-protocol (PP) populations. RESULTS Between November 2015 and November 2016, 127 patients were enrolled. Main grade III-IV toxicities (% in arm A/B) were: diarrhoea (12.5/1.7), neutropenia (46.9/31, including febrile neutropenia: 1.6/0), skin toxicity (6.3/13.8), and peripheral neuropathy (6.3/8.6). No toxic deaths occurred. The objective response rate was 40.3% (95% confidence interval [CI]: 28.1-53.6) in arm A and 26.7% (95% CI: 16.1-39.7) in arm B. The primary end-point (6-month PFS rate) was 45.2% [one-sided 95% CI: 34.3-56.4] in arm A and 23.3% in arm B [one-sided 95% CI: 14.3-32.3] in the mITT population. In the PP population, median PFS and OS were 7.6 months and 6 months and 14.5 months and 12.2 months in arm A and B, respectively. CONCLUSIONS The FIRGEMAX strategy with gemcitabine + nab-paclitaxel alternating with FOLFIRI.3 every 2 months, appears feasible and effective, with manageable toxicities, in patients able to reach >2mo of treatment. TRIAL REGISTRATION INFORMATION EudraCT: 2014-004449-28: NCT: 0282701.",2020,The objective response rate was 40.3% (95% confidence interval [CI]: 28.1-53.6) in arm A and 26.7% (95% CI: 16.1-39.7) in arm,"['We randomised chemotherapy-naive patients with proven mPA, bilirubin levels ≤1.5 upper limit of normal values and performance status\xa00-2 to alternately receive', 'metastatic pancreatic adenocarcinoma (mPA', 'patients with metastatic pancreatic adenocarcinoma', 'Between November 2015 and November 2016', '127 patients were enrolled']","['gemcitabine\xa0+\xa0nab-paclitaxel', 'Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3', 'gemcitabine\xa0+\xa0nab-paclitaxel standard first-line combination', 'gemcitabine\xa0+\xa0nab-paclitaxel alone until progression in arm B', 'gemcitabine', 'gemcitabine\xa0+\xa0nab-paclitaxel alternating with FOLFIRI.3']","['peripheral neuropathy', 'toxic deaths', 'neutropenia', 'diarrhoea', 'Main grade III-IV toxicities', 'median PFS and OS', 'skin toxicity', 'objective response rate', '6-month progression-free survival (PFS) rate']","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0861727', 'cui_str': 'Pancreatic adenocarcinoma metastatic'}, {'cui': 'C0344395', 'cui_str': 'Bilirubin measurement'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0086715', 'cui_str': 'Normal range'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0449438', 'cui_str': 'Status'}]","[{'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0332270', 'cui_str': 'Alternating'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205617', 'cui_str': 'Poorly differentiated'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1167791', 'cui_str': 'Skin toxicity'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",127.0,0.0595149,The objective response rate was 40.3% (95% confidence interval [CI]: 28.1-53.6) in arm A and 26.7% (95% CI: 16.1-39.7) in arm,"[{'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Rinaldi', 'Affiliation': 'Department of Hepato-gastroenterology, European Hospital, Marseille, France.'}, {'ForeName': 'Anne-Laure', 'Initials': 'AL', 'LastName': 'Pointet', 'Affiliation': 'Department of Hepato-gastroenterology, Georges Pompidou European Hospital, Paris, France.'}, {'ForeName': 'Faiza', 'Initials': 'F', 'LastName': 'Khemissa Akouz', 'Affiliation': 'Department of Hepato-gastroenterology, Saint Jean Hospital, Perpignan, France.'}, {'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Le Malicot', 'Affiliation': 'Biostatistics Department, Francophone Federation of Digestive Cancerology, EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France.'}, {'ForeName': 'Bidaut', 'Initials': 'B', 'LastName': 'Wahiba', 'Affiliation': 'Department of Hepato-gastroenterology, European Hospital, Marseille, France.'}, {'ForeName': 'Samy', 'Initials': 'S', 'LastName': 'Louafi', 'Affiliation': 'Department of Oncology, Sud Francilien Hospital Center, Corbeil-Essonnes, France.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Gratet', 'Affiliation': 'Oncology and Hematology ONCOSUD Unit, Clinic Pasteur, Toulouse, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Miglianico', 'Affiliation': 'Department of Radiotherapy, Private Hospital Center, Saint-Grégoire, France.'}, {'ForeName': 'Hortense', 'Initials': 'H', 'LastName': 'Laharie', 'Affiliation': 'Department of Oncology and Radiotherapy, Clinic Tivoli, Bordeaux, France.'}, {'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Bouhier Leporrier', 'Affiliation': 'Department of Hepato-gastroenterology, University Hospital, Caen, France.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Thirot Bidault', 'Affiliation': 'Department of Hepato-gastroenterology, Private Hospital, Antony, France.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Texereau', 'Affiliation': 'Department of Hepato-gastroenterology, Layne Hospital, Mont-De-Marsan, France.'}, {'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Coriat', 'Affiliation': 'Department of Hepato-gastroenterology, Cochin Hospital, APHP, Paris, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Terrebonne', 'Affiliation': 'Department of Hepato-gastroenterology, Haut Lévêque Hospital, Pessac, France.'}, {'ForeName': 'Marie-Claude', 'Initials': 'MC', 'LastName': 'Gouttebel', 'Affiliation': 'Department of Oncology, Drôme Nord Hospital, Romans Sur Isère, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Malka', 'Affiliation': 'Department of Hepato-gastroenterology, Gustave Roussy Cancer Campus, Villejuif, France.'}, {'ForeName': 'Jean-Baptiste', 'Initials': 'JB', 'LastName': 'Bachet', 'Affiliation': 'Department of Hepato-gastroenterology, Pitié-Salpêtrière Hospital, Paris, France.'}, {'ForeName': 'Côme', 'Initials': 'C', 'LastName': 'Lepage', 'Affiliation': 'Department of Hepato-gastroenterology, University Hospital of Dijon, EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Taieb', 'Affiliation': 'Department of Hepato-gastroenterology, Sorbonne Paris City, Paris Descartes University, Georges Pompidou European Hospital, Paris, France. Electronic address: jtaieb75@gmail.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.05.018'] 1854,32633157,Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study.,"OBJECTIVES In TRANSFORM, de novo kidney transplant recipients received either everolimus in combination with reduced-exposure calcineurin inhibitor (EVR+rCNI) at standard EVR pre-dose concentrations of 3-8 ng/mL or mycophenolic acid plus standard-exposure CNI (MPA+sCNI). The authors analyzed the incidence of wound healing adverse events (WHAEs) over the 2-year study period. METHODS Patients were randomized to either EVR+rCNI or MPA+sCNI, both combined with induction therapy and steroids. RESULTS The safety population consisted of 2,026 patients (EVR+rCNI: 1,014, MPA+sCNI: 1,012). The proportion of patients with at least 1 WHAE was comparable between EVR+rCNI and MPA+sCNI treatment groups [20.6% vs. 17.3%; risk ratio (RR): 1.19; 95% confidence interval (CI): 0.99, 1.43] at month 24. The numerical difference between EVR+rCNI and MPA+sCNI was mainly caused by an increased proportion of EVR patients with lymphocele and wound dehiscence [7.5% vs. 5.1% (RR: 1.46; 95% CI: 1.04, 2.05) and 3.9% vs. 1.8% (RR: 2.22; 95%CI: 1.28, 3.84), respectively]. CONCLUSION The immediate introduction of EVR+rCNI after kidney transplantation was associated with an overall comparable incidence of WHAEs versus current standard-of-care over the 24-month study period. There was an increased relative risk of experiencing lymphocele and wound dehiscence but the absolute risks were rather low in both groups. CT.GOV IDENTIFIER NCT01950819.",2020,"There was an increased relative risk of experiencing lymphocele and wound dehiscence but the absolute risks were rather low in both groups. ","['2,026 patients (EVR+rCNI: 1,014, MPA+sCNI: 1,012', 'kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care', 'Patients']","['everolimus in combination with reduced-exposure calcineurin inhibitor (EVR+rCNI', 'EVR+rCNI', 'EVR+rCNI or MPA+sCNI, both combined with induction therapy and steroids', 'mycophenolic acid plus standard-exposure CNI (MPA+sCNI']","['proportion of EVR patients with lymphocele and wound dehiscence', 'relative risk of experiencing lymphocele and wound dehiscence', 'Wound healing adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C1453118', 'cui_str': 'CABIN1 protein, human'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C1453118', 'cui_str': 'CABIN1 protein, human'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0026933', 'cui_str': 'Mycophenolic Acid'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1431767', 'cui_str': 'cni protein, Drosophila'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024248', 'cui_str': 'Lymphocele'}, {'cui': 'C0259768', 'cui_str': 'Wound dehiscence'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",2026.0,0.0583234,"There was an increased relative risk of experiencing lymphocele and wound dehiscence but the absolute risks were rather low in both groups. ","[{'ForeName': 'Franco', 'Initials': 'F', 'LastName': 'Citterio', 'Affiliation': 'Department of Surgery, Fondazione Policlinico Universitario A. Gemelli, IRCCS , Rome, Italy.'}, {'ForeName': 'Mitchell', 'Initials': 'M', 'LastName': 'Henry', 'Affiliation': 'Department of Surgery, The Comprehensive Transplant Center, The Ohio State University, Wexner Medical Center , Columbus, OH, USA.'}, {'ForeName': 'Dean Y', 'Initials': 'DY', 'LastName': 'Kim', 'Affiliation': 'Department of Transplant and Hepatobiliary Surgery, Henry Ford Hospital , Detroit, USA.'}, {'ForeName': 'Myoung Soo', 'Initials': 'MS', 'LastName': 'Kim', 'Affiliation': 'Department of Surgery, Yonsei University College of Medicine , Seoul, Republic of Korea.'}, {'ForeName': 'Duck-Jong', 'Initials': 'DJ', 'LastName': 'Han', 'Affiliation': 'Department of Surgery, Asan Medical Center , Seoul, Republic of South Korea.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Kenmochi', 'Affiliation': 'Department of Transplant Surgery, Fujita Health University , Toyoake, Japan.'}, {'ForeName': 'Eytan', 'Initials': 'E', 'LastName': 'Mor', 'Affiliation': 'Department of Surgery, Transplant Center at Sheba Medical Center , Ramat-Gan, Israel.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Tisone', 'Affiliation': 'Department of Surgery HPB and Transplant Unit, University of Tor Vergata , Rome, Italy.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Bernhardt', 'Affiliation': 'Department of Research and Development, Novartis Pharma AG , Basel, Switzerland.'}, {'ForeName': 'Maria Pilar', 'Initials': 'MP', 'LastName': 'Hernandez Gutierrez', 'Affiliation': 'Department of Research and Development, Novartis Pharma AG , Basel, Switzerland.'}, {'ForeName': 'Yoshihiko', 'Initials': 'Y', 'LastName': 'Watarai', 'Affiliation': 'Department of Transplant Surgery and Nephrology, Nagoya Daini Red Cross Hospital , Nagoya-City, Japan.'}]",Expert opinion on drug safety,['10.1080/14740338.2020.1792441'] 1855,32629403,Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate.,"BACKGROUND Monomethyl fumarate (MMF) is the pharmacologically active metabolite of dimethyl fumarate (DMF). MMF formulated as Bafiertam™ 190 mg and DMF formulated as Tecfidera 240 mg deliver bioequivalent exposure of MMF and therefore possess the same efficacy/safety profiles. DMF is a widely used oral treatment for relapsing-remitting forms of multiple sclerosis (RRMS) but is limited in some patients, primarily female, by issues with gastrointestinal (GI) tolerability. METHODS This was a randomized, double-blind, head-to-head, 5-week study evaluating the GI tolerability of MMF 190 mg vs DMF 240 mg, administered twice daily in healthy subjects, using a derivative of the self-administered Modified Overall Gastrointestinal Symptom Scale (MOGISS). Subjects were stratified (3:1, female:male) and randomized (1:1) to the treatments. The primary endpoint was the Area Under the Curve (AUC) in each of the individual symptoms in the MOGISS over the 5-week treatment period. Other endpoints included the AUC over the 5-week treatment period in the MOGISS composite and total scores; duration and severity of GI events; Number and percentage of subjects reporting GI events during the overall treatment period, and assessment of safety/tolerability. RESULTS Inferential analysis of the hierarchical testing of overall treatment differences in each MOGISS symptom AUC occurred in a predefined sequence starting with Abdominal Pain. For each symptom, LSMean AUC values were lower for MMF than DMF, however, the first primary endpoint, Abdominal Pain, was not statistically different between treatments; thus, all subsequent statistical analyses were considered exploratory. The side effects and safety profiles observed were consistent with the known profiles of DMF, with no new or unique safety concerns noted. CONCLUSIONS Bafiertam showed an improved gastrointestinal tolerability profile compared with Tecfidera, with less severe GI events and fewer days of self-assessed GI symptoms, fewer GI adverse events, and lower discontinuation rates because of GI adverse events.",2020,"The side effects and safety profiles observed were consistent with the known profiles of DMF, with no new or unique safety concerns noted. ",['healthy subjects'],"['DMF', 'Monomethyl fumarate (MMF', 'MMF 190 mg vs DMF']","['LSMean AUC values', 'MOGISS composite and total scores; duration and severity of GI events; Number and percentage of subjects reporting GI events', 'gastrointestinal tolerability profile', 'derivative of the self-administered Modified Overall Gastrointestinal Symptom Scale (MOGISS', 'Area Under the Curve (AUC', 'safety/tolerability', 'Abdominal Pain', 'GI tolerability', 'severe GI events and fewer days of self-assessed GI symptoms, fewer GI adverse events']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0058218', 'cui_str': 'dimethyl fumarate'}, {'cui': 'C3848524', 'cui_str': 'monomethyl fumarate'}, {'cui': 'C0083765', 'cui_str': 'NMF protocol'}, {'cui': 'C4517622', 'cui_str': '190'}]","[{'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0243072', 'cui_str': 'derivatives'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.0797155,"The side effects and safety profiles observed were consistent with the known profiles of DMF, with no new or unique safety concerns noted. ","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Wynn', 'Affiliation': 'Consultants in Neurology, Ltd, Northbrook, IL 60062, USA.'}, {'ForeName': 'Thomas W', 'Initials': 'TW', 'LastName': 'Lategan', 'Affiliation': 'Banner Life Sciences, 3890 Premier Dr., Suite 110, High Point, NC 27265, USA. Electronic address: Lategan@bannerls.com.'}, {'ForeName': 'Tiffany N', 'Initials': 'TN', 'LastName': 'Sprague', 'Affiliation': 'Banner Life Sciences, 3890 Premier Dr., Suite 110, High Point, NC 27265, USA.'}, {'ForeName': 'Franck S', 'Initials': 'FS', 'LastName': 'Rousseau', 'Affiliation': 'Banner Life Sciences, 3890 Premier Dr., Suite 110, High Point, NC 27265, USA.'}, {'ForeName': 'Edward J', 'Initials': 'EJ', 'LastName': 'Fox', 'Affiliation': 'Central Texas Neurology Consultants, Round Rock, TX 78681, USA.'}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2020.102335'] 1856,32630164,The Application of Intra-Articulr Injections for Management of the Consequences of Disc Displacement without Reduction.,"The aim of the study was to make a comparative studies on the effectiveness of platelet rich plasma (PRP) and hyaluronic acid (HA) in intra-articular injections to the temporomandibular joints-in double blind studies application-based on the analysis of selected clinical parameters of functional efficiency and the mean value of joint's pain intensity before and after management. The study enrolled a group of 100 patients, aged 21 to 43 years, of both sexes, who came for the prosthodontic treatment. All patients had II b group of disorder according to the Research Diagnostic Criteria/Temporomandibular Disorder, and were consecutively, alternately assigned to the groups, 50 patients in each. Study group PRP was treated with intra-articular injection of platelet rich plasma and study group HA had injection with hyaluronic acid. The examination was double-blind, so that the injecting physician and the patient were not informed what kind of medicinal substance they received in the joint injection. The final selected clinical parameters did not differ statistically significantly between the groups, what means that both administered substances were effective in the repair of intra-articular structures. The results of research showed that the use of PRP and HA in intraarticular joint's injections positively affects in selected clinical parameters and decrease of the pain in temporomandibular joints in the case of disc displacement without reduction.",2020,"The final selected clinical parameters did not differ statistically significantly between the groups, what means that both administered substances were effective in the repair of intra-articular structures.","['All patients had II b group of disorder according to the Research Diagnostic Criteria/Temporomandibular Disorder', '100 patients, aged 21 to 43 years, of both sexes, who came for the prosthodontic treatment']","['platelet rich plasma (PRP) and hyaluronic acid (HA', 'hyaluronic acid']","['pain in temporomandibular joints', 'repair of intra-articular structures']","[{'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0039494', 'cui_str': 'Temporomandibular joint disorder'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0960273', 'cui_str': 'CAME'}, {'cui': 'C0033590', 'cui_str': 'Prosthodontics'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}]","[{'cui': 'C0155943', 'cui_str': 'Arthralgia of temporomandibular joint'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0442108', 'cui_str': 'Intra-articular'}]",100.0,0.0469652,"The final selected clinical parameters did not differ statistically significantly between the groups, what means that both administered substances were effective in the repair of intra-articular structures.","[{'ForeName': 'Malgorzata', 'Initials': 'M', 'LastName': 'Pihut', 'Affiliation': 'Prosthodontics Department, Consulting Room of Temporomandibular Disorders, Jagiellonian University, Medical College, 4 Montelupich Str., 31-155 Krakow, Poland.'}, {'ForeName': 'Andrzej', 'Initials': 'A', 'LastName': 'Gala', 'Affiliation': 'Prosthodontics Department, Consulting Room of Temporomandibular Disorders, Jagiellonian University, Medical College, 4 Montelupich Str., 31-155 Krakow, Poland.'}]",International journal of environmental research and public health,['10.3390/ijerph17134726'] 1857,32630188,Comparison of Aquatic Therapy vs. Dry Land Therapy to Improve Mobility of Chronic Stroke Patients.,"One of the most serious and disabling problems of stroke is pain and a decrease in balance, with the consequent increased risk of falls. The aim of the randomized controlled trial study was to compare the efficacy of three different treatment proposals to improve pain, gait, and balance in chronic stroke patients. Forty patients diagnosed with stroke were divided into three groups: the dry-land therapy group (control group) received sessions that included walking exercises and trunk mobility. The experimental group received Ai Chi aquatic therapy, and the combined group received alternating dry-land therapy sessions and Ai Chi aquatic therapy. The measurement instruments used were: the Tinetti balance and gait scale, the visual analog scale (VAS), 360° turn, single leg stance, and the 30-s stand test (CS-30). After twelve weeks of treatment, the results were significantly better for the combined therapy group and the experimental group compared to the dry-land therapy group ( p < 0.01) in the VAS scale, CS-30, and 360° turn, although improvements were also found in the evaluations carried out in the aquatic therapy group. In total, for the Tinetti scale and single-leg stance, the differences between the groups were evident, although not statistically significant ( p = 0.001). Aquatic therapy with Ai Chi and the combination of aquatic therapy with dry-land therapy was effective in improving pain, balance, and gait in patients with chronic stroke, thus improving their functional capacity and quality of life.",2020,"After twelve weeks of treatment, the results were significantly better for the combined therapy group and the experimental group compared to the dry-land therapy group ( p < 0.01) in the VAS scale, CS-30, and 360° turn, although improvements were also found in the evaluations carried out in the aquatic therapy group.","['Chronic Stroke Patients', 'patients with chronic stroke', 'Forty patients diagnosed with stroke', 'chronic stroke patients']","['Aquatic Therapy vs. Dry Land Therapy', 'dry-land therapy group (control group) received sessions that included walking exercises and trunk mobility', 'Aquatic therapy with Ai Chi and the combination of aquatic therapy with dry-land therapy', 'Ai Chi aquatic therapy, and the combined group received alternating dry-land therapy sessions and Ai Chi aquatic therapy']","['pain, balance, and gait', 'Tinetti balance and gait scale, the visual analog scale (VAS), 360° turn, single leg stance, and the 30-s stand test (CS-30', 'Tinetti scale and single-leg stance', 'functional capacity and quality of life', 'pain, gait, and balance']","[{'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0011682', 'cui_str': 'Desiccation - action'}, {'cui': 'C0557668', 'cui_str': 'Landing'}, {'cui': 'C1527374', 'cui_str': 'Group Therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0376586', 'cui_str': 'Life-Breath (Philosophy)'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332270', 'cui_str': 'Alternating'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C2732846', 'cui_str': 'Tinetti balance and gait scale'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0541749', 'cui_str': 'Does turn'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.0139959,"After twelve weeks of treatment, the results were significantly better for the combined therapy group and the experimental group compared to the dry-land therapy group ( p < 0.01) in the VAS scale, CS-30, and 360° turn, although improvements were also found in the evaluations carried out in the aquatic therapy group.","[{'ForeName': 'Sagrario', 'Initials': 'S', 'LastName': 'Pérez-de la Cruz', 'Affiliation': 'Department of Nursing, Physiotherapy and Medicine, University of Almería, 04120 Almería, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17134728'] 1858,32630214,Effects of Exercise Training during Christmas on Body Weight and Cardiometabolic Health in Overweight Individuals.,": Individuals with abdominal obesity and metabolic syndrome (MetS) have augmented risk of all-cause mortality. Lifestyle interventions are effective to treat MetS, however, there are periods during the year in which exercise programs are discontinued and improper dietary habits reappear (e.g., Christmas holidays). We aimed to analyze if exercise-training during Christmas holidays would avoid body-weight gains and cardiometabolic deterioration in MetS individuals, using a randomized control trial. Thirty-eight men with MetS undergoing exercise training were randomly allocated to either continue (TRAIN group, n = 16) or discontinue (HOLID group, n = 22) training, during the three weeks of Christmas. Anthropometrics (body weight, fat, and waist circumference), fasting blood metabolites (glucose, insulin, triglycerides, and cholesterol concentrations) and exercise maximal fat oxidation (FO MAX ) and oxygen uptake (VO 2PEAK ) were determined before and after Christmas. Both groups were similar at baseline in all parameters ( p > 0.05). HOLID group increased body weight (91.3 ± 13.0 to 92.0 ± 13.4 kg, p = 0.004), mean arterial pressure (94.0 ± 10.6 to 97.1 ± 8.9 mmHg, p = 0.026), blood insulin (10.2 ± 3.8 to 12.5 ± 5.4 µIU·mL -1 , p = 0.003) and HOMA (3.2 ± 1.3 to 4.1 ± 2.3, p = 0.003). In contrast, TRAIN prevented those disarrangements and reduced total (170.6 ± 30.6 to 161.3 ± 31.3 mg·dL -1 , p = 0.026) and low-density lipoprotein cholesterol (i.e., LDL- C , 104.8 ± 26.1 to 95.6 ± 21.7 mg·dL -1 , p = 0.013). TRAIN also prevented the reductions in exercise FO MAX and VO 2PEAK that was observed in the HOLID group ( p = 0.002). In conclusion, exercise training during Christmas, prevents body weight gains and the associated cardiovascular (increase in blood pressure and LDL -C ) and metabolic (reduced insulin sensitivity) health risks are an optimal non-pharmacological therapy for that period of the year.",2020,Both groups were similar at baseline in all parameters ( p > 0.05).,"[' Individuals with abdominal obesity and metabolic syndrome (MetS', 'Overweight Individuals', 'Thirty-eight men with MetS undergoing exercise training']","['exercise training', 'Exercise Training', 'discontinue (HOLID group, n = 22) training', 'exercise-training']","['body weight gains', 'blood insulin', 'body weight', 'low-density lipoprotein cholesterol', 'Body Weight and Cardiometabolic Health', 'blood pressure and LDL -C ) and metabolic (reduced insulin sensitivity) health risks', 'exercise FO MAX and VO 2PEAK', 'mean arterial pressure', 'Anthropometrics (body weight, fat, and waist circumference), fasting blood metabolites (glucose, insulin, triglycerides, and cholesterol concentrations) and exercise maximal fat oxidation (FO MAX ) and oxygen uptake (VO 2PEAK ']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0311277', 'cui_str': 'Abdominal Obesity'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0450361', 'cui_str': '38'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0853230', 'cui_str': 'Blood insulin'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}]",38.0,0.0169114,Both groups were similar at baseline in all parameters ( p > 0.05).,"[{'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Ramirez-Jimenez', 'Affiliation': 'Exercise Physiology Lab at Toledo, University of Castilla-La Mancha, 45071 Toledo, Spain.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Morales-Palomo', 'Affiliation': 'Exercise Physiology Lab at Toledo, University of Castilla-La Mancha, 45071 Toledo, Spain.'}, {'ForeName': 'Juan Fernando', 'Initials': 'JF', 'LastName': 'Ortega', 'Affiliation': 'Exercise Physiology Lab at Toledo, University of Castilla-La Mancha, 45071 Toledo, Spain.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Moreno-Cabañas', 'Affiliation': 'Exercise Physiology Lab at Toledo, University of Castilla-La Mancha, 45071 Toledo, Spain.'}, {'ForeName': 'Valle', 'Initials': 'V', 'LastName': 'Guio de Prada', 'Affiliation': 'Exercise Physiology Lab at Toledo, University of Castilla-La Mancha, 45071 Toledo, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Alvarez-Jimenez', 'Affiliation': 'Exercise Physiology Lab at Toledo, University of Castilla-La Mancha, 45071 Toledo, Spain.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Mora-Rodriguez', 'Affiliation': 'Exercise Physiology Lab at Toledo, University of Castilla-La Mancha, 45071 Toledo, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17134732'] 1859,32634745,"Examining sex, adverse childhood experiences, and oxytocin on neuroendocrine reactivity in smokers.","Adverse childhood experiences (ACE) are associated with greater neuroendocrine responses to social stress in substance users. The neuropeptide oxytocin might attenuate this relationship. Given sex differences in ACE exposure and neuroendocrine stress reactivity, it is unknown whether this association is similar for males and females. Therefore, this secondary analysis evaluated the interactive effect of sex, ACE, and acute oxytocin administration on neuroendocrine stress responses in adult cigarette smokers (N = 144). Participants completed the Adverse Childhood Experiences Questionnaire at screening and were randomized to receive intranasal oxytocin or placebo before undergoing the Trier Social Stress Task (TSST). Cortisol levels were assessed at pre- and post-medication administration and at 20 and 40 min following the TSST. Generalized linear mixed models were developed to predict post-TSST cortisol levels. Predictors included treatment assignment (placebo vs. oxytocin), sex (male vs. female), ACE (0-10 total score), pre-medication cortisol levels, and minutes since medication administration. The hypothesized three-way interaction between sex, oxytocin, and ACE scores was significant. Linear associations between ACE scores and cortisol reactivity indicated higher ACE scores were associated with attenuated cortisol response in females, regardless of treatment condition. For males, higher ACE scores were associated with heightened cortisol response, an effect that was attenuated by oxytocin. Results indicate that the association between ACE and neuroendocrine reactivity to social stress, as well as the attenuating effect of oxytocin, is differentially impacted by sex. Males with greater childhood adversity may be more likely to benefit from oxytocin's anxiolytic properties.",2020,"For males, higher ACE scores were associated with heightened cortisol response, an effect that was attenuated by oxytocin.","['adult cigarette smokers (N\u2009=\u2009144', 'smokers', 'Participants completed the Adverse Childhood Experiences Questionnaire at screening']","['oxytocin', 'treatment assignment (placebo vs. oxytocin', 'neuropeptide oxytocin', 'intranasal oxytocin or placebo', 'oxytocin administration']","['sex (male vs. female), ACE (0-10 total score), pre-medication cortisol levels, and minutes since medication administration', 'cortisol response', 'ACE scores', 'Cortisol levels', 'ACE scores and cortisol reactivity indicated higher ACE scores']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337667', 'cui_str': 'Cigarette smoker'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C4284014', 'cui_str': 'Adverse Childhood Experience questionnaire'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0027895', 'cui_str': 'Neuropeptide'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4296616', 'cui_str': 'Adverse Childhood Experiences'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C3469597', 'cui_str': 'Administration of medication'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0205250', 'cui_str': 'High'}]",,0.0291417,"For males, higher ACE scores were associated with heightened cortisol response, an effect that was attenuated by oxytocin.","[{'ForeName': 'Caitlyn O', 'Initials': 'CO', 'LastName': 'Hood', 'Affiliation': 'Department of Psychology, College of Arts & Sciences, University of Kentucky, United States. Electronic address: caitlyn.hood@uky.edu.'}, {'ForeName': 'Rachel L', 'Initials': 'RL', 'LastName': 'Tomko', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Nathaniel L', 'Initials': 'NL', 'LastName': 'Baker', 'Affiliation': 'Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Breanna M', 'Initials': 'BM', 'LastName': 'Tuck', 'Affiliation': 'Steve Hicks School of Social Work, University of Texas at Austin, United States.'}, {'ForeName': 'Julianne C', 'Initials': 'JC', 'LastName': 'Flanagan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States; Ralph H. Johnson VA Medical Center, United States.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Carpenter', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'Gray', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Saladin', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States; Department of Health Sciences and Research, College of Health Professions, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Erin A', 'Initials': 'EA', 'LastName': 'McClure', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2020.104752'] 1860,32634760,Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.,"BACKGROUND Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Italiano Mammella 2 (GIM2) trial, we investigated DD efficacy according to luminal-like subtypes. METHODS Patients with node-positive early breast cancer were randomised to receive either DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel. In our analysis, luminal A-like cohort was identified as having a Ki67 < 20% and a progesterone receptor (PgR) ≥ 20%; luminal B-like cohort as having a Ki67 ≥ 20% and/or a PgR < 20%. RESULTS Out of 2003 patients enrolled in the GIM2 trial, 412 had luminal A-like and 638 luminal B-like breast cancer. After a median follow-up of 7.9 years, disease-free survival (DFS) was 80.8% (95% confidence interval [CI] 76.4-84.5) and 70.5% (66.5-74.2) in luminal A-like and luminal B-like cohorts; overall survival (OS) was 91.6% (88.2-94.1) and 85.1% (81.7-87.9), respectively. We found no significant interaction between treatment and luminal subtype (interaction p = 0.603 and 0.535 for DFS and OS, respectively). When DD efficacy was investigated separately in each cohort, luminal-B like cohort appeared to benefit more from the DD schedule both in terms of DFS (unadjusted hazard ratio [HR] 0.72 [95% CI 0.54-0.96]) and OS (unadjusted HR 0.61 [95% CI 0.40-0.94]), compared with the luminal A-like cohort (unadjusted HR for DFS 0.89 [95% CI 0.59-1.33]; unadjusted HR for OS 0.83 [95% CI 0.45-1.54]). CONCLUSIONS No significant interaction between luminal-like subtype and treatment was observed. Patients in the luminal B-like cohort seemed to benefit more from DD schedule.",2020,"We found no significant interaction between treatment and luminal subtype (interaction p = 0.603 and 0.535 for DFS and OS, respectively).","['2003 patients enrolled in the GIM2 trial, 412 had luminal A-like and 638 luminal B-like breast cancer', 'Patients with node-positive early breast cancer', 'hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype']","['DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel', 'progesterone receptor (PgR', 'dose-dense adjuvant chemotherapy']","['overall survival (OS', 'disease-free survival (DFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0699493', 'cui_str': 'Luminal'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C4087376', 'cui_str': 'HER2 negative'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0449560', 'cui_str': 'Subtype'}]","[{'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439794', 'cui_str': 'Dense'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0034833', 'cui_str': 'Progesterone receptor'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}]",2003.0,0.206045,"We found no significant interaction between treatment and luminal subtype (interaction p = 0.603 and 0.535 for DFS and OS, respectively).","[{'ForeName': 'Benedetta', 'Initials': 'B', 'LastName': 'Conte', 'Affiliation': 'Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Carrer de Rosselló, 149, 08036, Barcelona, Spain.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Bruzzone', 'Affiliation': 'Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Lambertini', 'Affiliation': 'Medical Oncology Department, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 1632, Genoa, GE, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Viale Benedetto XV, 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Poggio', 'Affiliation': 'Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Bighin', 'Affiliation': 'Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Blondeaux', 'Affiliation': 'Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Michelino', 'Initials': 'M', 'LastName': 'De Laurentiis', 'Affiliation': 'Breast Unit, Istituto Nazionale Tumori-Fondazione ""G. Pascale"", Via Mariano Semmola, 53, 80131, Naples, NA, Italy.'}, {'ForeName': 'Enrichetta', 'Initials': 'E', 'LastName': 'Valle', 'Affiliation': 'Department of Medical Oncology, Ospedale Businco, Via Edward Jenner, 1, 09121, Cagliari, CA, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Cognetti', 'Affiliation': 'Department of Clinical and Molecolar Medicine, La Sapienza University, Viale Regina Elena, 324, 00161, Rome, RM, Italy.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Nisticò', 'Affiliation': 'Department of Medical Oncology 1, Istituto Nazionale Tumori ""Regina Elena"", Via Elio Chianesi, 53, 00128, Rome, RM, Italy.'}, {'ForeName': 'Sabino', 'Initials': 'S', 'LastName': 'De Placido', 'Affiliation': 'Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini, 5, 80131, Naples, NA, Italy.'}, {'ForeName': 'Ornella', 'Initials': 'O', 'LastName': 'Garrone', 'Affiliation': 'Breast Unit, Department of Oncology, Azienda Ospedaliera Santa Croce e Carle, Via Michele Coppino, 26, 12100, Cuneo, CN, Italy.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Gamucci', 'Affiliation': 'Department of Medical Oncology, Ospedale Sandro Pertini, Via dei Monti Tiburtini, 385/389, 00157, Rome, RM, Italy; Department of Medical Oncology, Ospedale SS Trinità, Località San Marciano, 03039, Sora, FR, Italy.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Montemurro', 'Affiliation': 'Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale, 142, 10060, Turin, TO, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Puglisi', 'Affiliation': 'Department of Medicine, University of Udine, Piazzale Massimiliano Kolbe, 4, 33100, Udine, Italy; Department of Medical Oncology, IRCCS Centro di Riferimento Oncologico Aviano - National Cancer Institute, Via Franco Gallini, 2, 33081, Aviano, PN, Italy.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Cardinali', 'Affiliation': 'Breast Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Piero', 'Initials': 'P', 'LastName': 'Fregatti', 'Affiliation': 'Department of Surgical Sciences and Integrated Diagnostic (DISC), University of Genova, Viale Benedetto XV, 6, 1612, Genoa, GE, Italy; Department of Surgery, IRCCS Policlinico San Martino, Largo Rosanna Benzi 10, 1632, Genoa, GE, Italy.'}, {'ForeName': 'Loredana', 'Initials': 'L', 'LastName': 'Miglietta', 'Affiliation': 'Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Boccardo', 'Affiliation': 'Medical Oncology Department, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 1632, Genoa, GE, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Viale Benedetto XV, 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Marcello', 'Initials': 'M', 'LastName': 'Ceppi', 'Affiliation': 'Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Del Mastro', 'Affiliation': 'Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Viale Benedetto XV, 10, 16132, Genoa, GE, Italy; Breast Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy. Electronic address: lucia.delmastro@hsanmartino.it.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.05.007'] 1861,32619694,Alpha frequency rTMS modulates theta lagged nonlinear connectivity in dorsal attention network.,"Dorsolateral prefrontal cortex (DLPFC) is a key structure in dorsal attention network (DAN) that facilitates sustained attention by modulating activity in task related and unrelated regions of the brain. Alpha and theta frequency bands enhance connectivity among different parts of the attention network and these connections are facilitated by long-range nonlinear connectivity in theta and alpha frequency bands. This study is an investigation of the behavioral and electrophysiological effects of alpha and theta frequency repetitive transcranial magnetic stimulation (rTMS) over RDLPFC. 20 healthy participants were randomly assigned to two groups of theta (n = 11, f = 6 Hz) and alpha (n = 9, f = 10 Hz) rTMS. Electroencephalogram (EEG) was recorded before and after each session while resting and performing tasks. Current source density (CSD) and functional connectivity (FC) in DAN and default mode network (DMN) and their correlations with rapid visual information processing task (RVIP) scores were calculated . Alpha frequency rTMS resulted in significant changes in RVIP scores. Active theta rTMS caused an increase in CSD in Postcentral gyrus and active alpha rTMS resulted in significant CSD changes in inferior parietal lobule (IPL). Theta lagged nonlinear connectivity was mudulated by alpha rTMSand FC changes were observed in DAN and DMN. Positive correlations were observed between DAN regions and RVIP scores in the alpha rTMS group. Increased activity in theta frequency band in left aPFC and left DLPFC correlated positively with higher total hits in RVIP. This study showed for the first time that theta and alpha frequency rTMS are able to modulate FC in DAN and DMN in a way that results in better performance in a sustained attention task.",2020,Active theta rTMS caused an increase in CSD in Postcentral gyrus and active alpha rTMS resulted in significant CSD changed in inferior parietal lobule (IPL).,['20 healthy participants'],"['alpha and theta repetitive transcranial magnetic stimulation (rTMS', 'Alpha Frequency rTMS', 'Active alpha rTMS', 'alpha (n\u2009=\u20099, f\u2009=\u20096\u2009Hz) rTMS']","['rapid visual information processing task (RVIP) scores', 'Electroencephalogram (EEG', 'RVIP scores', 'FC changes', 'CSD', 'Current source density (CSD) and functional connectivity (FC']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205177', 'cui_str': 'Active'}]","[{'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0021420', 'cui_str': 'Information Processing'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0449416', 'cui_str': 'Source'}, {'cui': 'C0178587', 'cui_str': 'Density'}]",20.0,0.0387473,Active theta rTMS caused an increase in CSD in Postcentral gyrus and active alpha rTMS resulted in significant CSD changed in inferior parietal lobule (IPL).,"[{'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Kazemi', 'Affiliation': 'Cognitive Lab, Department of Psychology, University of Tehran, Tehran, Iran; Atieh Clinical Neuroscience Center, Tehran, Iran. Electronic address: rezakazemi@ut.ac.ir.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Rostami', 'Affiliation': 'Department of Psychology, University of Tehran, Tehran, Iran.'}, {'ForeName': 'Shouka', 'Initials': 'S', 'LastName': 'Dehghan', 'Affiliation': 'Atieh Clinical Neuroscience Center, Tehran, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Nasiri', 'Affiliation': 'Atieh Clinical Neuroscience Center, Tehran, Iran.'}, {'ForeName': 'Solmaz', 'Initials': 'S', 'LastName': 'Lotfollahzadeh', 'Affiliation': 'Atieh Clinical Neuroscience Center, Tehran, Iran.'}, {'ForeName': 'Abed', 'Initials': 'A', 'LastName': 'L Hadipour', 'Affiliation': 'Atieh Clinical Neuroscience Center, Tehran, Iran; Department of Psychology, University of Tehran, Tehran, Iran.'}, {'ForeName': 'Sanaz', 'Initials': 'S', 'LastName': 'Khomami', 'Affiliation': 'Atieh Clinical Neuroscience Center, Tehran, Iran.'}, {'ForeName': 'Ryouhei', 'Initials': 'R', 'LastName': 'Ishii', 'Affiliation': 'Smart Rehabilitation Research Center, Osaka Prefecture University, Graduate School of Comprehensive Rehabilitation, Habikino, Japan; Department of Psychiatry, Osaka University, Graduate School of Medicine, Osaka, Japan.'}, {'ForeName': 'Shunichiro', 'Initials': 'S', 'LastName': 'Ikeda', 'Affiliation': 'Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.'}]",Brain research bulletin,['10.1016/j.brainresbull.2020.06.018'] 1862,32621083,Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials.,"INTRODUCTION Gastrointestinal (GI) events are a common side effect of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) class. This post hoc analysis assessed the characteristics of GI adverse events in Chinese patients with type 2 diabetes (T2D) who were treated with once-weekly dulaglutide from two randomized clinical trials. METHODS Chinese patients with T2D, treated with once-weekly dulaglutide (1.5 mg and 0.75 mg) from two phase III multicenter trials (AWARD-CHN1 and AWARD-CHN2) were included. Descriptive statistics were used to present the data. The characteristics (incidence, severity, onset, duration, and time of occurrence) of GI adverse events reported through 26 weeks in a Chinese subpopulation from the two trials were investigated. RESULTS A total of 787 Chinese patients with T2D were included in this analysis. Up to week 26, 225 patients (28.6%) reported at least one GI treatment-emergent adverse event (TEAE). The most frequently reported GI TEAEs were diarrhea (13.1%), nausea (6.6%), abdominal distension (6.4%), and vomiting (3.0%), with most being categorized as mild to moderate in severity in proportions of 92%, 88%, 94%, and 83%, respectively. A total of 12 patients (1.5%) discontinued the dulaglutide treatment as a result of GI TEAEs. The median duration of the first reported GI TEAEs was 4.0, 5.0, 12.5, and 4.0 days for diarrhea, nausea, abdominal distension, and vomiting, respectively. The incidence of GI TEAEs was more frequent during the first 2 weeks of dulaglutide treatment; however, the incidence declined rapidly after 2 weeks and remained low until week 26. CONCLUSIONS Most of the GI TEAEs associated with once-weekly dulaglutide (1.5 mg and 0.75 mg) were mild to moderate in severity. The incidence of GI TEAEs was more pronounced during the first 2 weeks of dulaglutide treatment but declined rapidly as treatment continued, and was low at week 26, indicating that dulaglutide was well tolerated in Chinese patients with T2D. TRIAL REGISTRATION NCT01648582 and NCT01644500.",2020,"Up to week 26, 225 patients (28.6%) reported at least one GI treatment-emergent adverse event (TEAE).","['Chinese patients with T2D, treated with once-weekly dulaglutide (1.5\xa0mg and 0.75\xa0mg) from two phase\xa0III multicenter trials (AWARD-CHN1 and AWARD-CHN2) were included', 'Chinese patients with type\xa02 diabetes (T2D) who were treated with once-weekly dulaglutide from two randomized clinical trials', '787 Chinese patients with T2D', 'Chinese Patients with Type']",[],"['diarrhea', 'incidence of GI TEAEs', 'abdominal distension', 'median duration', 'characteristics (incidence, severity, onset, duration, and time of occurrence) of GI adverse events', 'vomiting', 'nausea', 'diarrhea, nausea, abdominal distension, and vomiting']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0558293', 'cui_str': 'Once a week'}, {'cui': 'C3179549', 'cui_str': 'dulaglutide'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C4068882', 'cui_str': '0.75'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0206012', 'cui_str': 'Multicentre Trials'}, {'cui': 'C0004446', 'cui_str': 'Awards'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],"[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0000731', 'cui_str': 'Swollen abdomen'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",787.0,0.0832677,"Up to week 26, 225 patients (28.6%) reported at least one GI treatment-emergent adverse event (TEAE).","[{'ForeName': 'Lixin', 'Initials': 'L', 'LastName': 'Guo', 'Affiliation': 'Department of Endocrinology, Beijing Hospital, National Center of Gerontology, No.1, Dahua Road, Dongcheng District, Beijing, 100730, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Zhang', 'Affiliation': 'Lilly Suzhou Pharmaceutical Co., Ltd, 19F, Tower 1 HKRI, Taikoo Hui, No. 288, Shi Men No. 1 Rd, Shanghai, 200041, China.'}, {'ForeName': 'Jianing', 'Initials': 'J', 'LastName': 'Hou', 'Affiliation': 'Lilly Suzhou Pharmaceutical Co., Ltd, 19F, Tower 1 HKRI, Taikoo Hui, No. 288, Shi Men No. 1 Rd, Shanghai, 200041, China. hou_jia_ning@lilly.com.'}, {'ForeName': 'Zhiguang', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, China. zhouzhiguang@csu.edu.cn.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00869-z'] 1863,32684465,Short communication: Effect of purple corn pigment on change of anthocyanin composition and unsaturated fatty acids during milk storage.,"Unsaturated fatty acids (UFA) in milk give rise to radicals and lead to lipid oxidation during storage, reducing the commercial value of milk. The objective of this study was to observe the effect of anthocyanins from purple corn pigment on the oxidation of UFA in milk. Milk samples were randomly divided into 2 groups: (1) the control (without purple corn pigment) and (2) treatment (0.3% purple corn pigment), using a completely randomized design. The milk samples were placed into plastic tubes and stored at 4°C for a period of 0, 1, 3, and 7 d. Individual anthocyanin composition and UFA were detected by HPLC-mass spectrometry and gas chromatography-mass spectrometry, respectively. The results indicated that pelargonidin (0.258 vs. 0.054 µg/mL), cyanidin (5.550 vs. 1.808 µg/mL), petunidin (0.464 vs. 0.107 µg/mL), delphinidin (2.061 vs. 0.123 µg/mL), and total anthocyanin (8.332 vs. 2.091 µg/mL) significantly decreased in response to increasing storage day. Of interest, purple corn pigment had a significant effect on most of the UFA (C14:1n-5, C16:1n-7, C18:1n-9, C18:2n-6, C18:3n-3, C18:3n-6, C20:2n-6, C20:3n-3, and C20:4n-6), except for C17:1n-7 and C20:3n-6. Specifically, various stronger positive correlations were noted for anthocyanin composition and UFA (pelargonidin and petunidin with C14:1n-5, C17:1n-7, C18:2n-6, C20:2n-6, C20:3n-3, and C20:4n-6; and cyanidin and total anthocyanins with C14:1n-5, C16:1n-7, C17:1n-7). Collectively, the current study suggested that the addition of anthocyanins from purple corn pigment had the potential to maintain UFA concentrations in milk during the storage period.",2020,"The results indicated that pelargonidin (0.258 vs. 0.054 µg/mL), cyanidin (5.550 vs. 1.808 µg/mL), petunidin (0.464 vs. 0.107 µg/mL), delphinidin (2.061 vs. 0.123 µg/mL), and total anthocyanin (8.332 vs. 2.091 µg/mL) significantly decreased in response to increasing storage day.",[],"['control (without purple corn pigment) and (2) treatment (0.3% purple corn pigment', 'purple corn pigment', 'anthocyanins from purple corn pigment', 'Unsaturated fatty acids (UFA', 'pelargonidin']","['delphinidin', 'total anthocyanin', 'cyanidin', 'anthocyanin composition and unsaturated fatty acids', 'anthocyanin composition and UFA (pelargonidin and petunidin with C14:1n-5, C17:1n-7, C18:2n-6, C20:2n-6, C20:3n-3, and C20:4n-6; and cyanidin and total anthocyanins with C14:1n-5, C16:1n-7, C17:1n-7']",[],"[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439542', 'cui_str': 'Purple'}, {'cui': 'C0010028', 'cui_str': 'Zea mays'}, {'cui': 'C0031911', 'cui_str': 'Pigmentation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4068885', 'cui_str': '0.3'}, {'cui': 'C0003161', 'cui_str': 'Anthocyanin'}, {'cui': 'C0015690', 'cui_str': 'Unsaturated fatty acid'}, {'cui': 'C0083970', 'cui_str': 'pelargonidin'}]","[{'cui': 'C0057304', 'cui_str': 'delphinidin'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003161', 'cui_str': 'Anthocyanin'}, {'cui': 'C0056650', 'cui_str': 'cyanidin'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0015690', 'cui_str': 'Unsaturated fatty acid'}, {'cui': 'C0083970', 'cui_str': 'pelargonidin'}, {'cui': 'C1175797', 'cui_str': 'petunidin'}]",,0.0240595,"The results indicated that pelargonidin (0.258 vs. 0.054 µg/mL), cyanidin (5.550 vs. 1.808 µg/mL), petunidin (0.464 vs. 0.107 µg/mL), delphinidin (2.061 vs. 0.123 µg/mL), and total anthocyanin (8.332 vs. 2.091 µg/mL) significantly decreased in response to increasing storage day.","[{'ForeName': 'X Z', 'Initials': 'XZ', 'LastName': 'Tian', 'Affiliation': 'College of Animal Science, Guizhou University, Guiyang, 550025, China; Institute of Animal Nutrition and Feed Science, Guizhou University, Guiyang, 550025, China. Electronic address: tianxingzhou@yeah.net.'}, {'ForeName': 'Q', 'Initials': 'Q', 'LastName': 'Lu', 'Affiliation': 'College of Animal Science, Guizhou University, Guiyang, 550025, China; Institute of Animal Nutrition and Feed Science, Guizhou University, Guiyang, 550025, China.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Paengkoum', 'Affiliation': 'School of Animal Technology and Innovation, Suranaree University of Technology, Nakhon Ratchasima, 30000, Thailand.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Paengkoum', 'Affiliation': 'Program in Agriculture, Faculty of Science and Technology, Nakhon Ratchasima Rajabhat University, Muang, Nakhon Ratchasima, 30000, Thailand.'}]",Journal of dairy science,['10.3168/jds.2020-18409'] 1864,32684486,Postprandial lipaemia following consumption of a meal enriched with medium chain saturated and/or long chain omega-3 polyunsaturated fatty acids. A randomised cross-over study.,"BACKGROUND & AIMS Postprandial lipaemic response has emerged as a risk factor for cardiovascular disease. Dietary fats such as medium-chain saturated fatty acids (MCSFA) and long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) are known to reduce postprandial lipaemic responses. The combination of the two could potentially have complementary and/or synergistic effects for optimising cardiovascular health. This study aims to investigate the effects of MCSFA (coconut oil) with or without LCn-3PUFA (fish oil) inclusion in the test meal on postprandial blood lipids in healthy adults. METHODS In a randomised, double-blinded, placebo-controlled, 2 × 2 factorial cross-over study, participants (n = 15) were randomised to receive four standardised isocaloric test meals. Test meals include: placebo [PL, containing no fish oil (0 g EPA & DHA) or coconut oil (0 g MCSFA)], fish oil [FO, 6 g fish oil (3.85 g EPA & DHA), containing no coconut oil (0 g MCSFA)], coconut oil [CO, 18.65 g coconut oil (15 g MCSFA), containing no fish oil (0 g EPA & DHA)] and coconut oil + fish oil [COFO, 18.65 g coconut oil (15 g MCSFA) + 6 g fish oil (3.85 g EPA & DHA)]; all providing a total fat content of 33.5 g. Participants received all four treatments on four separate test days with at least 3 days washout in between. Blood parameters were measured by finger pricks at 7 timepoints between 0 and 300min. The primary outcome of this study was the change in postprandial TG concentrations with secondary outcomes as total cholesterol, high-density lipoprotein cholesterol and blood glucose concentrations. RESULTS TG area under the curve (AUC) (mmol/L/min) was significantly lower for FO (383.67, p = 0.0125) and COFO (299.12, p = 0.0186) in comparison to PL (409.17) only. TG incremental area under the curve (iAUC) (mmol/L/min) was significantly lower with COFO (59.67) in comparison to CO (99.86), (p = 0.0480). Compared to PL, the change in absolute TG concentrations (mmol/L) from baseline to post TG peak time (180min) after FO were significantly less at 240min (0.39 vs 0.15), 270min (0.2 vs 0.1), and 300min (0.28 vs 0.06), and after COFO was significantly less at 300min (0.28 vs 0.16) (p < 0.05). No significant differences in postprandial AUC and iAUC for any other blood parameters were reported. CONCLUSIONS Our study demonstrated that MCSFA with or without LCn-3PUFA but not MCSFA alone are effective in reducing postprandial TG in healthy individuals.",2020,"TG incremental area under the curve (iAUC) (mmol/L/min) was significantly lower with COFO (59.67) in comparison to CO (99.86), (p = 0.0480).","['healthy adults', 'participants (n\xa0=\xa015', 'healthy individuals']","['MCSFA', 'standardised isocaloric test meals', 'Dietary fats such as medium-chain saturated fatty acids (MCSFA) and long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA', 'LCn-3PUFA', 'MCSFA (coconut oil) with or without LCn-3PUFA (fish oil', 'Postprandial lipaemia following consumption of a meal enriched with medium chain saturated and/or long chain omega-3 polyunsaturated fatty acids', 'placebo [PL, containing no fish oil (0\xa0g EPA & DHA) or coconut oil (0\xa0g MCSFA)], fish oil [FO, 6\xa0g fish oil (3.85\xa0g EPA & DHA), containing no coconut oil (0\xa0g MCSFA)], coconut oil [CO, 18.65\xa0g coconut oil (15\xa0g MCSFA), containing no fish oil', 'placebo']","['TG peak time (180min) after FO', 'postprandial TG', 'total cholesterol, high-density lipoprotein cholesterol and blood glucose concentrations', 'absolute TG concentrations', 'Blood parameters', 'COFO', 'postprandial AUC and iAUC', 'TG area under the curve (AUC', 'TG incremental area under the curve (iAUC', 'postprandial blood lipids', 'postprandial TG concentrations']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0597423', 'cui_str': 'Saturated fat'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0012171', 'cui_str': 'Dietary fat'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0056060', 'cui_str': 'Coconut Oil'}, {'cui': 'C0016157', 'cui_str': 'Fish Oils'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C1706412', 'cui_str': 'Lipemia'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}, {'cui': 'C0142831', 'cui_str': 'sodium dehydroacetate'}, {'cui': 'C1722869', 'cui_str': '(glycyl-prolyl-glycyl-glycyl-alanyl)6-glycine'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C2585282', 'cui_str': 'Blood glucose concentration'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}]",15.0,0.395872,"TG incremental area under the curve (iAUC) (mmol/L/min) was significantly lower with COFO (59.67) in comparison to CO (99.86), (p = 0.0480).","[{'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Austin', 'Affiliation': 'School of Health Sciences, Faculty of Health & Medicine, University of Newcastle, Callaghan, NSW, 2308, Australia; Nutraceuticals Research Program, School of Biomedical Sciences & Pharmacy, 305C Medical Sciences Building, University of Newcastle, Callaghan, NSW, 2308, Australia. Electronic address: Grace.Austin@uon.edu.au.'}, {'ForeName': 'Jessica Ja', 'Initials': 'JJ', 'LastName': 'Ferguson', 'Affiliation': 'Nutraceuticals Research Program, School of Biomedical Sciences & Pharmacy, 305C Medical Sciences Building, University of Newcastle, Callaghan, NSW, 2308, Australia. Electronic address: Jessica.Ferguson@newcastle.edu.au.'}, {'ForeName': 'Rohith N', 'Initials': 'RN', 'LastName': 'Thota', 'Affiliation': 'Nutraceuticals Research Program, School of Biomedical Sciences & Pharmacy, 305C Medical Sciences Building, University of Newcastle, Callaghan, NSW, 2308, Australia; Riddet Institute, Massey University, Palmerston North, New Zealand. Electronic address: R.Thota@massey.ac.nz.'}, {'ForeName': 'Harjinder', 'Initials': 'H', 'LastName': 'Singh', 'Affiliation': 'Riddet Institute, Massey University, Palmerston North, New Zealand. Electronic address: H.Singh@massey.ac.nz.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Burrows', 'Affiliation': 'School of Health Sciences, Faculty of Health & Medicine, University of Newcastle, Callaghan, NSW, 2308, Australia. Electronic address: Tracy.Burrows@newcastle.edu.au.'}, {'ForeName': 'Manohar L', 'Initials': 'ML', 'LastName': 'Garg', 'Affiliation': 'Nutraceuticals Research Program, School of Biomedical Sciences & Pharmacy, 305C Medical Sciences Building, University of Newcastle, Callaghan, NSW, 2308, Australia; Riddet Institute, Massey University, Palmerston North, New Zealand. Electronic address: Manohar.Garg@newcastle.edu.au.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.06.027'] 1865,32684500,Impact of a decision-aid tool on influenza vaccine coverage among HCW in two French hospitals: A cluster-randomized trial.,"INTRODUCTION Nosocomial outbreaks of seasonal influenza are frequent, and vaccination is largely recommended for healthcare workers (HCWs). Vaccine coverage in French HCWs does not exceed 20%. Decision-aids (DA) are potential useful interventions to increase vaccine coverage (VC). Our aim was to evaluate the impact of a DA on HCWs influenza vaccine coverage. MATERIAL AND METHODS Prospective cluster-randomized trial conducted in 83 departments in two public hospitals (a teaching and a non-teaching hospital) during the 2018-2019 flu season. Distribution of the DA and of questionnaire about decisional conflict and knowledge in the departments randomized in the intervention group. RESULTS A total number of 3 547 HCWs were concerned by the study (1 953 in the intervention group, 1 594 in the control group). Global VC was 35.6% during the 2018-2019 season, instead of 23.6% in the 2017-2018 season (p < 0.005). During the 2018-2019 season, VC was 31% (95% CI 28.7-33.3) in the control group and 38.7% (95% CI 36.5-40.9) in the intervention group (p < 0.005). Among the 158 HCWs exposed to the DA who answered the survey, 51.3% had no decisional conflict. HCWs without decisional conflict were more prone to get vaccinated before flu season. CONCLUSION The use of the DA was associated with a 25% relative increase in VC among HCWs against seasonal influenza. This modest increase remained far from the WHO 75% target, but may have reduced the number of nosocomial. Multi-component interventions are needed to increase VC in HCWs.",2020,The use of the DA was associated with a 25% relative increase in VC among HCWs against seasonal influenza.,"['HCW in two French hospitals', '83 departments in two public hospitals (a teaching and a non-teaching hospital) during the 2018-2019 flu season']","['Decision-aids (DA', 'decision-aid tool']","['total number of 3 547 HCWs', 'Global VC']","[{'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0020022', 'cui_str': 'Public Hospitals'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}]","[{'cui': 'C0086104', 'cui_str': 'Decision Aids'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]",3547.0,0.0318562,The use of the DA was associated with a 25% relative increase in VC among HCWs against seasonal influenza.,"[{'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Saunier', 'Affiliation': 'Department of Infectious Diseases, and Infection Control Unit, University Hospital of Saint-Etienne, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Berthelot', 'Affiliation': ""Department of Infectious Diseases, and Infection Control Unit, University Hospital of Saint-Etienne, France; Groupe Immunité des Muqueuses et Agents Pathogènes, Centre International de Recherche en Infectiologie, Université Jean Monnet, Université de Lyon, Saint-Etienne, France; Institut de Recherche PRESAGE, Chaire vaccination, Prévention et Contrôle de l'Infection, Université de Lyon Saint-Etienne, France.""}, {'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Mottet-Auselo', 'Affiliation': 'Infection Control Unit, Hospital of Roanne, France.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Pelissier', 'Affiliation': 'Department of occupational medicine, University Hospital of Saint-Etienne, France.'}, {'ForeName': 'Luc', 'Initials': 'L', 'LastName': 'Fontana', 'Affiliation': 'Department of occupational medicine, University Hospital of Saint-Etienne, France.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Botelho-Nevers', 'Affiliation': ""Department of Infectious Diseases, and Infection Control Unit, University Hospital of Saint-Etienne, France; Groupe Immunité des Muqueuses et Agents Pathogènes, Centre International de Recherche en Infectiologie, Université Jean Monnet, Université de Lyon, Saint-Etienne, France; Institut de Recherche PRESAGE, Chaire vaccination, Prévention et Contrôle de l'Infection, Université de Lyon Saint-Etienne, France.""}, {'ForeName': 'Amandine', 'Initials': 'A', 'LastName': 'Gagneux-Brunon', 'Affiliation': ""Department of Infectious Diseases, and Infection Control Unit, University Hospital of Saint-Etienne, France; Groupe Immunité des Muqueuses et Agents Pathogènes, Centre International de Recherche en Infectiologie, Université Jean Monnet, Université de Lyon, Saint-Etienne, France; Institut de Recherche PRESAGE, Chaire vaccination, Prévention et Contrôle de l'Infection, Université de Lyon Saint-Etienne, France. Electronic address: amandine.gagneux-brunon@chu-st-etienne.fr.""}]",Vaccine,['10.1016/j.vaccine.2020.07.011'] 1866,32622871,Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.,"Efficient therapies are available for the treatment of osteoporosis. Bisphosphonates and denosumab are the most commonly used antiresorptive therapies. Despite differences in the increase in bone mineral density seen with these drugs, the reductions in fracture risk are similar; 50-70%, 20%, and 40% for vertebral, non-vertebral and hip fractures, respectively. The bone-forming treatments; teriparatide and abaloparatide increase bone mineral density more than the antiresorptives and the reductions in fracture risk are 85% and 40-50% for vertebral and non-vertebral fractures, respectively, compared to placebo. The VERO study demonstrated a >50% reduction in vertebral and clinical fractures in women treated with teriparatide compared to risedronate. The dual-action treatment; romosozumab leads to more pronounced increases in BMD than other treatment modalities and reduces the risk of vertebral and clinical fractures by 73% and 36% compared to placebo after 12 months and the sequential treatment regime; romosozumab for 12 months followed by alendronate reduced the risk of vertebral, non-vertebral and hip fractures by 48%, 20% and 38%, respectively compared to alendronate after 2-3 years. The evidence for combination therapy targeting both resorption and formation is limited as only short-term studies with BMD as the endpoint have been performed. All bone-forming and dual-action treatments increase BMD and reduce the fracture risk, however, the effect wears off with time and treatment is therefore only temporary and should be followed by antiresorptive treatment with a bisphosphonate or denosumab. The sequence of treatment matters as the BMD response to teriparatide is reduced in patients previously treated with bisphosphonates; however, based on the findings of the VERO trial, the anti-fracture efficacy of bone-forming treatment in comparison with risedronate seems to be preserved after bisphosphonate therapy. The DATA study suggested that transitioning from denosumab to teriparatide is problematic due to the increase in bone resorption occurring after stopping denosumab. Studies have shown further improvements in BMD when transitioning from oral bisphosphonates to zoledronic acid or denosumab. Management of osteoporosis will in many patients include a long-term treatment plan. This will often include sequential therapy which in severe cases preferably should start with bone-forming followed by antiresorptive treatment. The severity of osteoporosis, reaching a treatment goal, and responding to treatment failure are important factors determining the treatment sequence in the individual patient.",2020,"The dual-action treatment; romosozumab leads to more pronounced increases in BMD than other treatment modalities and reduces the risk of vertebral and clinical fractures by 73% and 36% compared to placebo after 12 months and the sequential treatment regime; romosozumab for 12 months followed by alendronate reduced the risk of vertebral, non-vertebral and hip fractures by 48%, 20% and 38%, respectively compared to alendronate after 2-3 years.","['patients previously treated with', 'postmenopausal osteoporosis with bone-forming and antiresorptive treatments']","['teriparatide', 'zoledronic acid or denosumab', 'Bisphosphonates and denosumab', 'bisphosphonates', 'alendronate', 'bisphosphonate or denosumab', 'risedronate', 'placebo']","['bone mineral density', 'vertebral and clinical fractures', 'risk of vertebral, non-vertebral and hip fractures', 'BMD', 'risk of vertebral and clinical fractures', 'fracture risk', 'BMD response', 'bone resorption']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0029458', 'cui_str': 'Postmenopausal osteoporosis'}, {'cui': 'C1286272', 'cui_str': 'Form of bone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0070093', 'cui_str': 'Teriparatide'}, {'cui': 'C0257685', 'cui_str': 'zoledronic acid'}, {'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C0012544', 'cui_str': 'Bisphosphonate'}, {'cui': 'C0102118', 'cui_str': 'Alendronate'}, {'cui': 'C0246719', 'cui_str': 'Risedronate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0549207', 'cui_str': 'Bone structure of spine'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0005974', 'cui_str': 'Bone resorption'}]",,0.0195905,"The dual-action treatment; romosozumab leads to more pronounced increases in BMD than other treatment modalities and reduces the risk of vertebral and clinical fractures by 73% and 36% compared to placebo after 12 months and the sequential treatment regime; romosozumab for 12 months followed by alendronate reduced the risk of vertebral, non-vertebral and hip fractures by 48%, 20% and 38%, respectively compared to alendronate after 2-3 years.","[{'ForeName': 'Bente', 'Initials': 'B', 'LastName': 'Langdahl', 'Affiliation': 'Aarhus University Hospital, Endocrinology and Internal Medicine, Palle Juul Jensen Boulevard 115, DK8200 Aarhus N, Denmark. Electronic address: bente.langdahl@aarhus.rm.dk.'}]",Bone,['10.1016/j.bone.2020.115516'] 1867,32623833,"Efficacy and safety results of micellar water, cream and serum for rosacea in comparison to a control group.","BACKGROUND Rosacea is a common inflammatory skin disorder with centrofacial erythema, flushing, telangiectasia, papules/pustules, and possible ocular or phymatous manifestation. Patients' skin is particularly sensitive to chemical and physical stimuli leading to burning, stinging, dryness, and skin tightness. OBJECTIVE Dermatological evaluation of the efficacy and safety of skin care products designed for centrofacial erythema in rosacea patients, in comparison with a control group using objective measurements. Rosacea symptoms (itching, tension, warmth, burning, dryness) and quality of life were examined. METHODS Sixty Caucasians with centrofacial erythema were enrolled in an 8-week prospective study, fifty of them exclusively using the study products (micellar water, cream, and serum) with ten participants randomly assigned to a control group. Patients were evaluated at baseline (V0), at 4 weeks (V1), and at 8 weeks (V2). Three-dimensional objective measurements (VECTRA ® ) as well as standardized questionnaires were used. RESULTS Results were compared with the control group. A significant reduction of 16% in skin redness as indicated by VECTRA ® analysis was seen in the intervention group comparing V0-V2. Furthermore, rosacea-associated symptoms diminished by 57.1%, while life quality of affected patients within the intervention group improved by 54.5% comparing V0-V2, respectively. CONCLUSIONS A skin care regime suitable for sensitive and redness-prone skin led to an enhanced clinical appearance, to a decrease of associated symptoms in rosacea patients, and to an improved life quality.",2020,A significant reduction of 16% in skin redness as indicated by VECTRA® analysis was seen in the intervention group comparing V0 to V2.,"['rosacea patients', 'centrofacial erythema in rosacea patients', 'Sixty Caucasians with centrofacial erythema were enrolled in an eight-week prospective study, fifty of them exclusively using the study products (micellar water, cream and serum) with ten participants randomly assigned to a control group']","['Micellar Water, Cream', 'skin care products']","['life quality', 'Furthermore, rosacea associated symptoms', 'skin redness', 'Rosacea symptoms (itching, tension, warmth, burning, dryness) and quality of life']","[{'cui': 'C0035854', 'cui_str': 'Rosacea'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0033522', 'cui_str': 'Prospective Studies'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0150773', 'cui_str': 'Skin care'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0035854', 'cui_str': 'Rosacea'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0233494', 'cui_str': 'Tension'}, {'cui': 'C0006434', 'cui_str': 'Burn injury'}]",60.0,0.0224167,A significant reduction of 16% in skin redness as indicated by VECTRA® analysis was seen in the intervention group comparing V0 to V2.,"[{'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Guertler', 'Affiliation': 'Department of Dermatology and Allergy, University Hospital of Munich (LMU), Munich, Germany.'}, {'ForeName': 'Nora Marie', 'Initials': 'NM', 'LastName': 'Jøntvedt', 'Affiliation': 'Department of Dermatology and Allergy, University Hospital of Munich (LMU), Munich, Germany.'}, {'ForeName': 'Benjamin M', 'Initials': 'BM', 'LastName': 'Clanner-Engelshofen', 'Affiliation': 'Department of Dermatology and Allergy, University Hospital of Munich (LMU), Munich, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Cappello', 'Affiliation': 'LETI Pharma GmbH, Ismaning, Germany.'}, {'ForeName': 'Angelika', 'Initials': 'A', 'LastName': 'Sager', 'Affiliation': 'LETI Pharma GmbH, Ismaning, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Reinholz', 'Affiliation': 'Department of Dermatology and Allergy, University Hospital of Munich (LMU), Munich, Germany.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13591'] 1868,32684537,Clopidogrel Monotherapy vs. Aspirin Monotherapy Following Short-Term Dual Antiplatelet Therapy in Patients Receiving Everolimus-Eluting Coronary Stent Implantation.,"BACKGROUND There is a scarcity of data on short-duration dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy as compared with aspirin monotherapy after percutaneous coronary intervention (PCI).Methods and Results:STOPDAPT-1 is a prospective trial enrolling patients who agreed to 3-month DAPT followed by aspirin monotherapy after everolimus-eluting stent (EES) implantation. STOPDAPT-2 is a randomized trial comparing 1-month DAPT followed by clopidogrel monotherapy with 12-month DAPT after EES implantation. We compared the clinical outcomes of patients assigned to the 1-month DAPT group in STOPDAPT-2 and the 3-month DAPT group enrolled in STOPDAPT-1. The current study population consisted of 1,480 patients in STOPDAPT-2 and 1,339 patients in STOPDAPT-1. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, definite stent thrombosis and TIMI major/minor bleeding. Cumulative 1-year incidence of the primary endpoint was not significantly different between STOPDAPT-2 and STOPDAPT-1 (2.3% vs. 2.3%, P=0.98). After adjusting for confounders, there was no excess risk of STOPDAPT-2 relative to STOPDAPT-1 for the primary endpoint. Between 3 and 12 months, the cumulative incidence of primary endpoint was not significantly different between STOPDAPT-2 and STOPDAPT-1 (1.7% vs. 1.6%, P=0.77). CONCLUSIONS The effect of 1-month DAPT followed by clopidogrel monotherapy on clinical outcomes was similar to that of 3-month DAPT followed by aspirin monotherapy in patients receiving PCI.",2020,"Cumulative 1-year incidence of the primary endpoint was not significantly different between STOPDAPT-2 and STOPDAPT-1 (2.3% vs. 2.3%, P=0.98).","['patients assigned to the 1-month DAPT group in STOPDAPT-2 and the 3-month DAPT group enrolled in STOPDAPT-1', 'enrolling patients who agreed to 3-month DAPT followed by aspirin monotherapy after everolimus-eluting stent (EES) implantation', 'Patients', 'patients receiving PCI', '1,480 patients in STOPDAPT-2 and 1,339 patients in STOPDAPT-1']","['clopidogrel monotherapy', 'DAPT', 'aspirin monotherapy', 'Clopidogrel Monotherapy vs. Aspirin Monotherapy', 'Everolimus-Eluting Coronary Stent Implantation']","['cumulative incidence of primary endpoint', 'Cumulative 1-year incidence', 'composite of cardiovascular death, myocardial infarction, stroke, definite stent thrombosis and TIMI major/minor bleeding']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0687568', 'cui_str': 'Coronary artery stent'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0439544', 'cui_str': 'Definite'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0026193', 'cui_str': 'Minor'}]",1480.0,0.0987282,"Cumulative 1-year incidence of the primary endpoint was not significantly different between STOPDAPT-2 and STOPDAPT-1 (2.3% vs. 2.3%, P=0.98).","[{'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Natsuaki', 'Affiliation': 'Department of Cardiovascular Medicine, Saga University.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Morimoto', 'Affiliation': 'Department of Clinical Epidemiology, Hyogo College of Medicine.'}, {'ForeName': 'Hirotoshi', 'Initials': 'H', 'LastName': 'Watanabe', 'Affiliation': 'Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University.'}, {'ForeName': 'Mitsuru', 'Initials': 'M', 'LastName': 'Abe', 'Affiliation': 'Department of Cardiology, National Hospital Organization Kyoto Medical Center.'}, {'ForeName': 'Kazuya', 'Initials': 'K', 'LastName': 'Kawai', 'Affiliation': 'Department of Cardiology, Chikamori Hospital.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Nakao', 'Affiliation': 'Department of Cardiology, Saiseikai Kumamoto Hospital.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Ando', 'Affiliation': 'Department of Cardiology, Kokura Memorial Hospital.'}, {'ForeName': 'Kengo', 'Initials': 'K', 'LastName': 'Tanabe', 'Affiliation': 'Division of Cardiology, Mitsui Memorial Hospital.'}, {'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Ikari', 'Affiliation': 'Department of Cardiology, Tokai University Hospital.'}, {'ForeName': 'Keiichi', 'Initials': 'K', 'LastName': 'Igarashi Hanaoka', 'Affiliation': 'Hanaoka Seishu Memorial Cardiovascular Clinic.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Morino', 'Affiliation': 'Department of Cardiology, Iwate Medical University Hospital.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Kozuma', 'Affiliation': 'Department of Cardiology, Teikyo University Hospital.'}, {'ForeName': 'Kazushige', 'Initials': 'K', 'LastName': 'Kadota', 'Affiliation': 'Department of Cardiology, Kurashiki Central Hospital.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Kimura', 'Affiliation': 'Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Circulation journal : official journal of the Japanese Circulation Society,['10.1253/circj.CJ-20-0298'] 1869,32684549,[A PHASE III STUDY TO EVALUATE SAFETY AND EFFICACY OF FLUTICASONE/FORMOTEROL COMBINATION (FLUTIFORM ® AEROSOL) IN LONG-TERM ADMINISTRATION (24 WEEKS) IN JAPANESE PEDIATRIC PATIENTS WITH BRONCHIAL ASTHMA].,"BACKGROUND The combination drug of inhaled corticosteroid (ICS)/long-acting β2 agonist is being used as a long-term control medication for pediatric asthma patients for those who are poorly controlled by ICS alone. Long-term efficacy and safety of Fluticasone propionate/formoterol fumarate hydrate (FP/FM) was evaluated in pediatric patients with bronchial asthma. METHODS Two inhales of FP/FM (50/5μg) at one time, twice daily were administered for 24 weeks to Japanese asthma patients aged 5 to ＜16 years who had asthma symptoms during the observation period while using the same dosage of ICS during a certain period of time. Adverse drug reactions, morning peak flow (mPEF) and asthma symptoms were evaluated 24 weeks after administration. RESULTS FP/FM was administered to 53 subjects. 52 subjects completed the 24 week administration. The incidence of adverse drug reactions was 9.4% (5 of 53), and all of the adverse drug reactions were mild. The mPEF increased from the starting value and was maintained through the treatment period. The average change from baseline in the mPEF after 24 weeks of treatment was 21.39±2.93L/min (Least squares mean±standard error). Changes in asthma symptoms were similar to that of morning peak flow. CONCLUSION It was considered that FP/FM could be useful for long-term control of pediatric asthma.",2020,"The incidence of adverse drug reactions was 9.4% (5 of 53), and all of the adverse drug reactions were mild.","['pediatric asthma patients for those who are poorly controlled by ICS alone', '52 subjects completed the 24 week administration', 'pediatric patients with bronchial asthma', 'Two inhales of FP/FM (50/5μg) at one time, twice daily were administered for 24 weeks to Japanese asthma patients aged 5 to ＜16 years who had asthma symptoms during the observation period while using the same dosage of ICS during a certain period of time']","['Fluticasone propionate/formoterol fumarate hydrate (FP/FM', 'inhaled corticosteroid (ICS)/long-acting β2 agonist', 'FP/FM']","['adverse drug reactions', 'mPEF', 'Adverse drug reactions, morning peak flow (mPEF) and asthma symptoms']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0117996', 'cui_str': 'Fluticasone propionate'}, {'cui': 'C0771469', 'cui_str': 'Formoterol fumarate'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0205423', 'cui_str': 'Certain'}]","[{'cui': 'C0117996', 'cui_str': 'Fluticasone propionate'}, {'cui': 'C0771469', 'cui_str': 'Formoterol fumarate'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0243192', 'cui_str': 'agonists'}]","[{'cui': 'C0041755', 'cui_str': 'Adverse reaction to drug'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0857465', 'cui_str': 'Peak flow'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",53.0,0.068091,"The incidence of adverse drug reactions was 9.4% (5 of 53), and all of the adverse drug reactions were mild.","[{'ForeName': 'Toshio', 'Initials': 'T', 'LastName': 'Katsunuma', 'Affiliation': 'Department of Pediatrics, Daisan Hospital, The Jikei University School of Medicine.'}, {'ForeName': 'Miho', 'Initials': 'M', 'LastName': 'Kamata', 'Affiliation': 'Clinical Development Center, Kyorin Pharmaceutical Co., Ltd.'}, {'ForeName': 'Yasuyuki', 'Initials': 'Y', 'LastName': 'Ishikawa', 'Affiliation': 'Clinical Development Center, Kyorin Pharmaceutical Co., Ltd.'}]",Arerugi = [Allergy],['10.15036/arerugi.69.341'] 1870,32633801,Effect of Probiotic Use on Antibiotic Administration Among Care Home Residents: A Randomized Clinical Trial.,"Importance Probiotics are frequently used by residents in care homes (residential homes or nursing homes that provide residents with 24-hour support for personal care or nursing care), although the evidence on whether probiotics prevent infections and reduce antibiotic use in these settings is limited. Objective To determine whether a daily oral probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 compared with placebo reduces antibiotic administration in care home residents. Design, Setting, and Participants Placebo-controlled randomized clinical trial of 310 care home residents, aged 65 years and older, recruited from 23 care homes in the United Kingdom between December 2016 and May 2018, with last follow-up on October 31, 2018. Interventions Study participants were randomized to receive a daily capsule containing a probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 (total cell count per capsule, 1.3 × 1010 to 1.6 × 1010) (n = 155), or daily matched placebo (n = 155), for up to 1 year. Main Outcomes and Measures The primary outcome was cumulative antibiotic administration days for all-cause infections measured from randomization for up to 1 year. Results Among 310 randomized care home residents (mean age, 85.3 years; 66.8% women), 195 (62.9%) remained alive and completed the trial. Participant diary data (daily data including study product use, antibiotic administration, and signs of infection) were available for 98.7% randomized to the probiotic group and 97.4% randomized to placebo. Care home residents randomized to the probiotic group had a mean of 12.9 cumulative systemic antibiotic administration days (95% CI, 0 to 18.05), and residents randomized to placebo had a mean of 12.0 days (95% CI, 0 to 16.95) (absolute difference, 0.9 days [95% CI, -3.25 to 5.05]; adjusted incidence rate ratio, 1.13 [95% CI, 0.79 to 1.63]; P = .50). A total of 120 care home residents experienced 283 adverse events (150 adverse events in the probiotic group and 133 in the placebo group). Hospitalizations accounted for 94 of the events in probiotic group and 78 events in the placebo group, and deaths accounted for 33 of the events in the probiotic group and 32 of the events in the placebo group. Conclusions and Relevance Among care home residents in the United Kingdom, a daily dose of a probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 did not significantly reduce antibiotic administration for all-cause infections. These findings do not support the use of probiotics in this setting. Trial Registration ISRCTN Identifier:16392920.",2020,"Care home residents randomized to the probiotic group had a mean of 12.9 cumulative systemic antibiotic administration days (95% CI, 0 to 18.05), and residents randomized to placebo had a mean of 12.0 days (95% CI, 0 to 16.95) (absolute difference, 0.9 days [95% CI, -3.25 to 5.05]; adjusted incidence rate ratio, 1.13 [95% CI, 0.79 to 1.63]; P = .50).","['120 care home residents experienced 283 adverse events (150 adverse events in the probiotic group and 133 in the placebo group', '310 randomized care home residents (mean age, 85.3 years; 66.8% women), 195 (62.9%) remained alive and completed the trial', 'care home residents', 'Care Home Residents', 'residents in care homes (residential homes or nursing homes that provide residents with 24-hour support for personal care or nursing care', '310 care home residents, aged 65 years and older, recruited from 23 care homes in the United Kingdom between December 2016 and May 2018, with last follow-up on October 31, 2018']","['Lactobacillus rhamnosus GG', 'Probiotic', 'Placebo', 'daily capsule containing a probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12', 'placebo']","['Antibiotic Administration', 'Participant diary data (daily data including study product use, antibiotic administration, and signs of infection', 'deaths', 'cumulative antibiotic administration days for all-cause infections', 'Hospitalizations']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C4708786', 'cui_str': '283'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C5191352', 'cui_str': '310'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517844', 'cui_str': '66.8'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C2584946', 'cui_str': 'Alive'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0580931', 'cui_str': 'In care'}, {'cui': 'C0338046', 'cui_str': 'Residential home'}, {'cui': 'C0038931', 'cui_str': 'Nursing, Perioperative'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom of Great Britain and Northern Ireland'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C1629836', 'cui_str': 'Lactobacillus rhamnosus GG'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}]","[{'cui': 'C0199779', 'cui_str': 'Administration of antibiotic'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",,0.418672,"Care home residents randomized to the probiotic group had a mean of 12.9 cumulative systemic antibiotic administration days (95% CI, 0 to 18.05), and residents randomized to placebo had a mean of 12.0 days (95% CI, 0 to 16.95) (absolute difference, 0.9 days [95% CI, -3.25 to 5.05]; adjusted incidence rate ratio, 1.13 [95% CI, 0.79 to 1.63]; P = .50).","[{'ForeName': 'Christopher C', 'Initials': 'CC', 'LastName': 'Butler', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, Radcliffe Primary Care Bldg, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Mandy', 'Initials': 'M', 'LastName': 'Lau', 'Affiliation': 'Centre for Trials Research, Cardiff University, Heath Park, Cardiff, United Kingdom.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Gillespie', 'Affiliation': 'Centre for Trials Research, Cardiff University, Heath Park, Cardiff, United Kingdom.'}, {'ForeName': 'Eleri', 'Initials': 'E', 'LastName': 'Owen-Jones', 'Affiliation': 'Centre for Trials Research, Cardiff University, Heath Park, Cardiff, United Kingdom.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Lown', 'Affiliation': 'Primary Care and Population Sciences Unit, University of Southampton, Aldermoor Health Centre, Aldermoor Close, Southampton, United Kingdom.'}, {'ForeName': 'Mandy', 'Initials': 'M', 'LastName': 'Wootton', 'Affiliation': 'Specialist Antimicrobial Chemotherapy Unit, Public Health Wales Microbiology, University Hospital of Wales, Heath Park, Cardiff, United Kingdom.'}, {'ForeName': 'Philip C', 'Initials': 'PC', 'LastName': 'Calder', 'Affiliation': 'NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, United Kingdom.'}, {'ForeName': 'Antony J', 'Initials': 'AJ', 'LastName': 'Bayer', 'Affiliation': 'Division of Population Medicine, School of Medicine, Neuadd Meirionnydd, Cardiff University, Cardiff, United Kingdom.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Moore', 'Affiliation': 'Primary Care and Population Sciences Unit, University of Southampton, Aldermoor Health Centre, Aldermoor Close, Southampton, United Kingdom.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Little', 'Affiliation': 'Primary Care and Population Sciences Unit, University of Southampton, Aldermoor Health Centre, Aldermoor Close, Southampton, United Kingdom.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Davies', 'Affiliation': 'Centre for Trials Research, Cardiff University, Heath Park, Cardiff, United Kingdom.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Edwards', 'Affiliation': 'Centre for Trials Research, Cardiff University, Heath Park, Cardiff, United Kingdom.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Shepherd', 'Affiliation': 'Centre for Trials Research, Cardiff University, Heath Park, Cardiff, United Kingdom.'}, {'ForeName': 'Kerenza', 'Initials': 'K', 'LastName': 'Hood', 'Affiliation': 'Centre for Trials Research, Cardiff University, Heath Park, Cardiff, United Kingdom.'}, {'ForeName': 'F D Richard', 'Initials': 'FDR', 'LastName': 'Hobbs', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, Radcliffe Primary Care Bldg, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Mina', 'Initials': 'M', 'LastName': 'Davoudianfar', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, Radcliffe Primary Care Bldg, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Rutter', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, Radcliffe Primary Care Bldg, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Stanton', 'Affiliation': 'Centre for Trials Research, Cardiff University, Heath Park, Cardiff, United Kingdom.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Lowe', 'Affiliation': 'Centre for Trials Research, Cardiff University, Heath Park, Cardiff, United Kingdom.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Fuller', 'Affiliation': 'Primary Care and Population Sciences Unit, University of Southampton, Aldermoor Health Centre, Aldermoor Close, Southampton, United Kingdom.'}, {'ForeName': 'Nick A', 'Initials': 'NA', 'LastName': 'Francis', 'Affiliation': 'Primary Care and Population Sciences Unit, University of Southampton, Aldermoor Health Centre, Aldermoor Close, Southampton, United Kingdom.'}]",JAMA,['10.1001/jama.2020.8556'] 1871,32629657,Therapeutic effect of percutaneous vertebroplasty and nonoperative treatment on osteoporotic vertebral compression fracture: A randomized controlled trial protocol.,"BACKGROUND Osteoporosis and related complications have been increasing with the aging population. Osteoporotic vertebral compression fractures (OVCFs) are the most common among all osteoporotic fractures. The purpose of this study was performed to compare the efficiency and safety of vertebroplasty versus conservative treatment for acute OVCFs. METHODS The conduct of this study followed the Declaration of Helsinki principles and the reporting of this study adhered to the Consolidated Standards of Reporting Trials guidelines for randomized controlled trials. Written informed consent was obtained from every participant. Participants were randomly assigned (1:1) to receive either vertebroplasty or control group. The primary outcome was pain relief at 1 month and 1 year, measured with a Visual Analogue Scale score. The secondary outcomes were Roland-Morris Disability Questionnaire, short form score, European Quality of Life-5 Dimensions, and postoperative complications. RESULTS We hypothesize that vertebroplasty will provide a rapid decrease of pain and an early return to daily life activities compared with the control group. TRIAL REGISTRATION This study protocol was registered in Research Registry (researchregistry5624).",2020,"The secondary outcomes were Roland-Morris Disability Questionnaire, short form score, European Quality of Life-5 Dimensions, and postoperative complications. ",['osteoporotic vertebral compression fracture'],"['percutaneous vertebroplasty and nonoperative treatment', 'vertebroplasty or control group', 'vertebroplasty']","['Osteoporotic vertebral compression fractures (OVCFs', 'efficiency and safety', 'pain and an early return to daily life activities', 'Roland-Morris Disability Questionnaire, short form score, European Quality of Life-5 Dimensions, and postoperative complications', 'pain relief at 1 month and 1 year, measured with a Visual Analogue Scale score']","[{'cui': 'C0262431', 'cui_str': 'Compression fracture of vertebral column'}]","[{'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C1303192', 'cui_str': 'Vertebroplasty'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0262431', 'cui_str': 'Compression fracture of vertebral column'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",,0.164349,"The secondary outcomes were Roland-Morris Disability Questionnaire, short form score, European Quality of Life-5 Dimensions, and postoperative complications. ","[{'ForeName': 'Dongliang', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': ""Department of Spinal Surgery, Yancheng NO.1 People's Hospital, Jiang Su, China.""}, {'ForeName': 'Dingwei', 'Initials': 'D', 'LastName': 'Cang', 'Affiliation': ''}, {'ForeName': 'Ya', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Siqing', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000020770'] 1872,32629706,The evaluation of a nurse-led hypertension management model in an urban community healthcare: A randomized controlled trial.,"BACKGROUND Hypertension is a silent disease of the masses with an increasing prevalence and poor control rates. This study aims to establish and test the efficacy of a nurse-led hypertension management model in the community. METHODS A single-blind, randomized controlled trial was performed. 156 hypertensive patients with uncontrolled blood pressure were equally and randomly allocated into 2 groups. Patients in the study group received a 12-week period of hypertension management. Blood pressure, self-care behaviors, self-efficacy, and satisfaction were assessed at the start of recruitment, 12 and 16 weeks thereafter. RESULTS After the intervention, blood pressure of patients in the study group had greater improvement in self-care behaviors and a higher level of satisfaction with the hypertensive care compared to the control group (both P < .05). CONCLUSIONS The nurse-led hypertension management model is feasible and effective for patients with uncontrolled blood pressure in the community.",2020,"After the intervention, blood pressure of patients in the study group had greater improvement in self-care behaviors and a higher level of satisfaction with the hypertensive care compared to the control group (both P < .05). ","['156 hypertensive patients with uncontrolled blood pressure', 'patients with uncontrolled blood pressure in the community', 'urban community healthcare']","['nurse-led hypertension management model', 'hypertension management']","['Blood pressure, self-care behaviors, self-efficacy, and satisfaction', 'blood pressure', 'level of satisfaction with the hypertensive care', 'self-care behaviors']","[{'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0086034', 'cui_str': 'Community Healthcare'}]","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0474417', 'cui_str': 'Self-care behavior'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}]",156.0,0.035059,"After the intervention, blood pressure of patients in the study group had greater improvement in self-care behaviors and a higher level of satisfaction with the hypertensive care compared to the control group (both P < .05). ","[{'ForeName': 'Jian-Hong', 'Initials': 'JH', 'LastName': 'Miao', 'Affiliation': ""Tangshan Worker's Hospital, Tangshan.""}, {'ForeName': 'Hai-Shan', 'Initials': 'HS', 'LastName': 'Wang', 'Affiliation': 'TangShan FuYou BaoJianYuan.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Liu', 'Affiliation': 'TangShan Chinese Medicine Hospital, Heibei, P.R. China.'}]",Medicine,['10.1097/MD.0000000000020967'] 1873,32630387,"The Efficacy of Rotary, Reciprocating, and Combined Non-Surgical Endodontic Retreatment Techniques in Removing a Carrier-Based Root Canal Filling Material from Straight Root Canal Systems: A Micro-Computed Tomography Analysis.","The aim of this study is to analyze and compare the efficacy of three non-surgical endodontic retreatment techniques in removing a carrier-based root canal filling material from straight root canal systems. The study was performed on 99 single-rooted extracted teeth using the ProTaper Gold endodontic rotary system up to the F2 file (Dentsply Maillefer, Baillagues, Switzerland), which were sealed with GuttaCore (Dentsply Maillefer, Ballaigues, Switzerland) and AH plus epoxy resin sealer (Dentsply DeTrey, Konstanz, Germany) and randomly assigned to the following non-surgical retreatment techniques: ProTaper Retreatment endodontic rotary instruments (D1-D3 files, Dentsply Maillefer, Ballaigues, Switzerland; n = 33, PTR), Reciproc Blue endodontic reciprocating instrument (R50, VDW, Munich, Germany; n = 33, RCB50), and a combined root canal retreatment technique between Gates-Glidden drills (sizes #3 and #2, Dentsply Maillefer, Ballaigues, Switzerland) and Hedstrom files (file size 35, 30, and 25, Dentsply Maillefer, Ballaigues, Switzerland; n = 33; H-GG). All of the teeth were submitted twice to a micro-computed tomography (micro-CT) scan, before and after non-surgical endodontic retreatment procedures. The volume of root canal filling material (mm 3 ), volume of remaining root canal filling material (mm 3 ), non-surgical endodontic retreatment working time (min), proportion of remaining root canal filling material (%), and efficacy of root canal filling material removal between the non-surgical endodontic retreatment techniques were analyzed using ANOVA one-way statistical analysis. Statistically significant differences were observed between the proportions of remaining root canal filling material of PTR and H-GG ( p = 0.018), between the non-surgical endodontic retreatment working times (min; p < 0.001), and between the efficacies of root canal filling material removal by the non-surgical endodontic retreatment techniques ( p = 0.009). However, the non-surgical endodontic retreatment systems allow for similar carrier-based root canal filling material removal.",2020,"Statistically significant differences were observed between the proportions of remaining root canal filling material of PTR and H-GG ( p = 0.018), between the non-surgical endodontic retreatment working times (min; p < 0.001), and between the efficacies of root canal filling material removal by the non-surgical endodontic retreatment techniques ( p = 0.009).","['Removing a Carrier-Based Root Canal Filling Material from Straight Root Canal Systems', '99 single-rooted extracted teeth using the']","['ProTaper Gold endodontic rotary system up to the F2 file (Dentsply Maillefer, Baillagues, Switzerland), which were sealed with GuttaCore (Dentsply Maillefer, Ballaigues, Switzerland) and AH plus epoxy resin sealer (Dentsply DeTrey, Konstanz, Germany) and randomly assigned to the following non-surgical retreatment techniques: ProTaper Retreatment endodontic rotary instruments (D1-D3 files, Dentsply Maillefer, Ballaigues, Switzerland; n = 33, PTR), Reciproc Blue endodontic reciprocating instrument (R50, VDW, Munich, Germany; n = 33, RCB50), and a combined root canal retreatment technique between Gates-Glidden drills', 'Rotary, Reciprocating, and Combined Non-Surgical Endodontic Retreatment Techniques']","['volume of root canal filling material (mm 3 ), volume of remaining root canal filling material (mm 3 ), non-surgical endodontic retreatment working time (min), proportion of remaining root canal filling material (%), and efficacy of root canal filling material removal', 'proportions of remaining root canal filling material of PTR and H-GG', 'efficacies of root canal filling material removal']","[{'cui': 'C1883720', 'cui_str': 'Removes'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0440137', 'cui_str': 'Filling material'}, {'cui': 'C0019421', 'cui_str': 'Heterosexuality'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0040440', 'cui_str': 'Tooth extraction'}]","[{'cui': 'C0018026', 'cui_str': 'Gold'}, {'cui': 'C0332274', 'cui_str': 'Endodontic'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0016094', 'cui_str': 'Filing'}, {'cui': 'C0112984', 'cui_str': 'Dentsply'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}, {'cui': 'C0036492', 'cui_str': 'Seal'}, {'cui': 'C0673096', 'cui_str': 'AH Plus'}, {'cui': 'C0014631', 'cui_str': 'Epoxy resin'}, {'cui': 'C0449942', 'cui_str': 'Sealer'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0376495', 'cui_str': 'Retreatments'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0206711', 'cui_str': 'Pilomatrixoma'}, {'cui': 'C1260957', 'cui_str': 'Blue color'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0237633', 'cui_str': 'Sensory Filtering'}, {'cui': 'C0324815', 'cui_str': 'Mandrillus leucophaeus'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0398946', 'cui_str': 'Periapical surgery of tooth'}]","[{'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0440137', 'cui_str': 'Filling material'}, {'cui': 'C0398946', 'cui_str': 'Periapical surgery of tooth'}, {'cui': 'C0376495', 'cui_str': 'Retreatments'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0206711', 'cui_str': 'Pilomatrixoma'}]",99.0,0.0221559,"Statistically significant differences were observed between the proportions of remaining root canal filling material of PTR and H-GG ( p = 0.018), between the non-surgical endodontic retreatment working times (min; p < 0.001), and between the efficacies of root canal filling material removal by the non-surgical endodontic retreatment techniques ( p = 0.009).","[{'ForeName': 'Tarek-Fahed', 'Initials': 'TF', 'LastName': 'Alakabani', 'Affiliation': 'Department of Stomatology, Faculty of Medicine and Dentistry, University of Valencia, 46010 Valencia, Spain.'}, {'ForeName': 'Vicente', 'Initials': 'V', 'LastName': 'Faus-Llácer', 'Affiliation': 'Department of Stomatology, Faculty of Medicine and Dentistry, University of Valencia, 46010 Valencia, Spain.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Faus-Matoses', 'Affiliation': 'Department of Stomatology, Faculty of Medicine and Dentistry, University of Valencia, 46010 Valencia, Spain.'}, {'ForeName': 'Celia', 'Initials': 'C', 'LastName': 'Ruiz-Sánchez', 'Affiliation': 'Department of Stomatology, Faculty of Medicine and Dentistry, University of Valencia, 46010 Valencia, Spain.'}, {'ForeName': 'Álvaro', 'Initials': 'Á', 'LastName': 'Zubizarreta-Macho', 'Affiliation': 'Department of Endodontics, Faculty of Health Sciences, Alfonso X El Sabio University, 28691 Madrid, Spain.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Sauro', 'Affiliation': 'Department of Dentistry, Faculty of Health Sciences, CEU Cardenal Herrera University, 46115 Valencia, Spain.'}, {'ForeName': 'Vicente', 'Initials': 'V', 'LastName': 'Faus-Matoses', 'Affiliation': 'Department of Stomatology, Faculty of Medicine and Dentistry, University of Valencia, 46010 Valencia, Spain.'}]",Journal of clinical medicine,['10.3390/jcm9061989'] 1874,32629226,Occurrence of c.976 G>T (p.Val326Leu) and c.452 G>A (p.Trp151Ter) variants in DHCR7 gene in population of polish women with recurrent miscarriage.,"INTRODUCTION Recurrent miscarriage is a serious clinical problem that affects 1-5 % of all couples trying to conceive. Although the incidence of Smith-Lemli-Opitz Syndrome (SLOS, OMIM #270400), an autosomal recessive condition caused by variants in the DHCR7 gene, is very low, (1:83 000), the observed carrier frequency of DHCR7 gene variants in the Polish population is high, ranging from 1:24 to 1:31. It is possible that this carriage may be responsible for early pregnancy loss. OBJECTIVES The aim of the study is to determine the carrier frequency of the p c.976 G>T (p.Val326Leu) and c.452 G>A (p.Trp151Ter) variants in the DHCR7 gene in patients experiencing recurrent miscarriage. METHODS The study group included 480 patients: a study group of 380 with at least 2 miscarriages before the 20th week of pregnancy, and a control group of 100 who had not experienced miscarriage. The variants were identified by genotyping: c.976 G>T (p.Val326Leu) by the TaqMan® SNP Genotyping Assay system, and c.452 G>A (p.Trp151Ter) using the BfaI restriction enzyme. Statistical analysis was performed using R software. RESULTS No examples of c.976 G>T (p.Val326Leu) were found in either group. c.452 G>A (p.Trp151Ter) was found in 22 participants from the study group and 4 from the control group; however, this difference was not significant (Chi2 test p = 0.61). CONCLUSIONS Being a carrier of the c.976 G>T (p.Val326Leu) and c.452 G>A (p.Trp151Ter) variants in theDHCR7 gene is not a risk factor for recurrent miscarriage in the Polish population.",2020,A (p.Trp151Ter) variants in theDHCR7 gene is not a risk factor for recurrent miscarriage in the Polish population.,"['population of polish women with recurrent miscarriage', 'patients experiencing recurrent miscarriage', '480 patients: a study group of 380 with at least 2 miscarriages before the 20th week of pregnancy, and a control group of 100 who had not experienced miscarriage']","['Val326Leu) and c.452 G', 'G']",[],"[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0032376', 'cui_str': 'Polish language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0000809', 'cui_str': 'Recurrent miscarriage'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C4319609', 'cui_str': '480'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319693', 'cui_str': '380'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1704407', 'cui_str': '100'}]",[],[],,0.0226355,A (p.Trp151Ter) variants in theDHCR7 gene is not a risk factor for recurrent miscarriage in the Polish population.,"[{'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Chrzanowska-Steglińska', 'Affiliation': 'Department of Fetal Medicine and Gynaecology, the Medical University of Lodz, Poland. Electronic address: marta.chrzanowska85@interia.pl.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Moczulska', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland; Clinical Genetics Clinic, Central Clinical Hospital of the Medical University of Lodz, Poland.'}, {'ForeName': 'Beata', 'Initials': 'B', 'LastName': 'Skoczylas', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland.'}, {'ForeName': 'Michał', 'Initials': 'M', 'LastName': 'Pietrusiński', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland.'}, {'ForeName': 'Karolina', 'Initials': 'K', 'LastName': 'Antosik', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland.'}, {'ForeName': 'Paulina', 'Initials': 'P', 'LastName': 'Jakiel', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Kacprzak', 'Affiliation': 'Department of Fetal Medicine and Gynaecology, the Medical University of Lodz, Poland.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Borowiec', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Sieroszewski', 'Affiliation': 'Department of Fetal Medicine and Gynaecology, the Medical University of Lodz, Poland.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.05.063'] 1875,32629291,A randomised double-blind trial of cognitive training for the prevention of psychopathology in at-risk youth.,"BACKGROUND The aim of this study was to evaluate the effectiveness of online cognitive training as a means of reducing psychopathology in at-risk youth. METHODS In a double-blind randomised controlled trial, 228 youths (mean age = 18.6, 74.6% female) were randomly allocated to either an intervention group (n = 114; online cognitive training focused on executive functioning) and a control group (n = 114; online cognitive training focused on other cognitive abilities). Participants were assessed online at baseline, post-training, 3-, 6- and 12-month follow-up. The primary outcome of the study was overall psychopathology as measured by the Strengths and Difficulties Questionnaire. Secondary outcomes were executive functioning ability (assessed using the n-back, trail-making and Stroop tasks), day-to-day functioning and risky drinking. RESULTS Mixed model intention-to-treat analyses indicated that psychopathology increased and day-to-day functioning decreased, regardless of intervention group. Those in the intervention group improved more than those in the control group in terms of the n-back task, but this was not statistically significant after adjusting for multiple comparisons. There were no statistically significant effects on risky drinking, or the trail-making and Stroop tasks. CONCLUSION This study failed to provide evidence for the efficacy of cognitive training as a stand-alone intervention for psychopathology.",2020,"Those in the intervention group improved more than those in the control group in terms of the n-back task, but this was not statistically significant after adjusting for multiple comparisons.","['psychopathology in at-risk youth', '228 youths (mean age\xa0=\xa018.6, 74.6% female']","['cognitive training', 'intervention group (n\xa0=\xa0114; online cognitive training focused on executive functioning) and a control group (n\xa0=\xa0114; online cognitive training focused on other cognitive abilities', 'online cognitive training']","['psychopathology increased and day-to-day functioning', 'executive functioning ability (assessed using the n-back, trail-making and Stroop tasks), day-to-day functioning and risky drinking', 'risky drinking, or the trail-making and Stroop tasks', 'overall psychopathology as measured by the Strengths and Difficulties Questionnaire']","[{'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}]","[{'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C2718024', 'cui_str': 'Stroop Task'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C3472494', 'cui_str': 'Strengths and difficulties questionnaire'}]",228.0,0.191026,"Those in the intervention group improved more than those in the control group in terms of the n-back task, but this was not statistically significant after adjusting for multiple comparisons.","[{'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Mewton', 'Affiliation': 'Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia. Electronic address: louisem@unsw.edu.au.'}, {'ForeName': 'Antoinette', 'Initials': 'A', 'LastName': 'Hodge', 'Affiliation': ""Child Development Unit, The Children's Hospital, Westmead, Australia.""}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Gates', 'Affiliation': 'Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Visontay', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Briana', 'Initials': 'B', 'LastName': 'Lees', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Maree', 'Initials': 'M', 'LastName': 'Teesson', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, Australia.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103672'] 1876,32629336,"The effects of a virtual learning environment compared with an individual handheld device on pharmacology knowledge acquisition, satisfaction and comfort ratings.","BACKGROUND Virtual reality is reported to improve post-intervention knowledge and skills outcomes of health professionals compared to traditional teaching methods or digital online media. However, providing equitable access to high quality virtual reality resources for large, diverse nursing and midwifery student cohorts within multi-campus settings remains challenging. OBJECTIVES This study compared the effect on student learning, satisfaction and comfort following exposure to a three-dimensional pharmacology artefact in a virtual facility (CAVE2™) 1 with viewing of the same artefact using a mobile handheld device with stereoscopic lenses attached. DESIGN The study used a pretest-posttest design. SETTING School of Nursing and Midwifery in a regional university in Southeast Queensland, Australia. PARTICIPANTS Two hundred and forty-nine second year undergraduate nursing and midwifery students. METHODS Online multiple choice tests were deployed to measure knowledge acquisition. Self-reported satisfaction scores and comfort ratings were collected using questionnaires. RESULTS Participants were not disadvantaged in terms of knowledge acquisition by using either CAVE2™ or the mobile handheld visualisation mode (P = 0.977). Significant differences in favour of the CAVE2™ environment were found in between students' satisfaction scores for clinical reasoning (P = 0.013) and clinical learning (P < 0.001) compared to the handheld mode, and there were no significant differences in their satisfaction with debriefing and reflective practice processes (P = 0.377) related to undertaking visualisation activities. A small number of students using handheld devices with stereoscopic lenses reported greater discomfort in relation to the visualisation that negatively impacted their learning (P = 0.001). CONCLUSION Three-dimensional artefacts using mobile devices is promising in terms of cost-effectiveness and accessibility for students with restricted access to on-campus teaching modes.",2020,"CONCLUSION Three-dimensional artefacts using mobile devices is promising in terms of cost-effectiveness and accessibility for students with restricted access to on-campus teaching modes.","['Two hundred and forty-nine second year undergraduate nursing and midwifery students', 'School of Nursing and Midwifery in a regional university in Southeast Queensland, Australia']","['virtual learning environment', 'stereoscopic lenses']","['Self-reported satisfaction scores and comfort ratings', 'satisfaction with debriefing and reflective practice processes', 'knowledge acquisition', 'satisfaction scores for clinical reasoning', 'clinical learning', 'pharmacology knowledge acquisition, satisfaction and comfort ratings']","[{'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0026082', 'cui_str': 'Midwifery'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0034391', 'cui_str': 'Queensland'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0023317', 'cui_str': 'Lens clear'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}]",,0.0701285,"CONCLUSION Three-dimensional artefacts using mobile devices is promising in terms of cost-effectiveness and accessibility for students with restricted access to on-campus teaching modes.","[{'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Hanson', 'Affiliation': 'School of Nursing, Midwifery and Paramedicine, University of the Sunshine Coast, Locked Bag 4, Maroochydore DC, QLD 4558, Australia. Electronic address: jhanson@usc.edu.au.'}, {'ForeName': 'Patrea', 'Initials': 'P', 'LastName': 'Andersen', 'Affiliation': 'School of Nursing, Midwifery and Paramedicine, University of the Sunshine Coast, Locked Bag 4, Maroochydore DC, QLD 4558, Australia. Electronic address: panders1@usc.edu.au.'}, {'ForeName': 'Peter K', 'Initials': 'PK', 'LastName': 'Dunn', 'Affiliation': 'School Health and Sports Science, Locked Bag 4, Maroochydore DC 4558, Australia. Electronic address: pdunn2@usc.edu.au.'}]",Nurse education today,['10.1016/j.nedt.2020.104518'] 1877,32630511,Abnormalities on Perfusion CT and Intervention for Intracranial Hypertension in Severe Traumatic Brain Injury.,"The role of invasive intracranial pressure (ICP) monitoring in patients with severe traumatic brain injury (STBI) remain unclear. Perfusion computed tomography (CTP) provides crucial information about the cerebral perfusion status in these patients. We hypothesised that CTP abnormalities would be associated with the severity of intracranial hypertension (ICH). To investigate this hypothesis, twenty-eight patients with STBI and ICP monitors were investigated with CTP within 48 h from admission. Treating teams were blind to these results. Patients were divided into five groups based on increasing intervention required to control ICH and were compared. Group I required no intervention above routine sedation, group II required a single first tier intervention, group III required multiple different first-tier interventions, group IV required second-tier medical therapy and group V required second-tier surgical therapy. Analysis of the results showed demographics and injury severity did not differ among groups. In group I no patients showed CTP abnormality, while patients in all other groups had abnormal CTP ( p = 0.003). Severe ischaemia observed on CTP was associated with increasing intervention for ICH. This study, although limited by small sample size, suggests that CTP abnormalities are associated with the need to intervene for ICH. Larger scale assessment of our results is warranted to potentially avoid unnecessary invasive procedures in head injury patients.",2020,"In group I no patients showed CTP abnormality, while patients in all other groups had abnormal CTP ( p = 0.003).","['Severe Traumatic Brain Injury', 'head injury patients', 'patients with severe traumatic brain injury (STBI', 'twenty-eight patients with STBI and ICP monitors']","['invasive intracranial pressure (ICP) monitoring', 'CTP', 'no intervention above routine sedation, group II required a single first tier intervention, group III required multiple different first-tier interventions, group IV required second-tier medical therapy and group V required second-tier surgical therapy', 'Perfusion CT and Intervention', 'Perfusion computed tomography (CTP']","['abnormal CTP', 'demographics and injury severity', 'CTP abnormality', 'severity of intracranial hypertension (ICH', 'Severe ischaemia']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0018674', 'cui_str': 'Injury of head'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0150260', 'cui_str': 'Intracranial pressure monitoring regime'}]","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0021880', 'cui_str': 'Intracranial pressure'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0441855', 'cui_str': 'Group V'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}]","[{'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0151740', 'cui_str': 'Raised intracranial pressure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}]",28.0,0.0145531,"In group I no patients showed CTP abnormality, while patients in all other groups had abnormal CTP ( p = 0.003).","[{'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Cooper', 'Affiliation': 'Department of Traumatology, John Hunter Hospital Newcastle, Newcastle, NSW 2305, Australia.'}, {'ForeName': 'Cino', 'Initials': 'C', 'LastName': 'Bendinelli', 'Affiliation': 'Department of Traumatology, John Hunter Hospital Newcastle, Newcastle, NSW 2305, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Bivard', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Newcastle, NSW 2300, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Parsons', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Newcastle, NSW 2300, Australia.'}, {'ForeName': 'Zsolt J', 'Initials': 'ZJ', 'LastName': 'Balogh', 'Affiliation': 'Department of Traumatology, John Hunter Hospital Newcastle, Newcastle, NSW 2305, Australia.'}]",Journal of clinical medicine,['10.3390/jcm9062000'] 1878,32634486,Team clinic: Expansion of a multidisciplinary care model for adolescents with type 1 diabetes.,"BACKGROUND Adolescent and young adults (AYA) with Type 1 Diabetes (T1D) experience more difficulty with glycemic control than patients in all other age groups. The shared medical appointment (SMA) model has been effective in multiple healthcare populations, but the feasibility and effectiveness of SMA in AYA patients with T1D is unclear. METHODS This research leverages the team's multidisciplinary expertise to develop an engaging intervention toolkit and test the implementation of the Team Clinic care model for the treatment of T1D among middle school adolescents in a large urban children's hospital serving an economically, racially and ethnically diverse population. In Phase 1, the team will manualize the Team Clinic care model into an engaging, age-appropriate educational and intervention toolkit. In Phase 2, the team will conduct a randomized clinical trial to test the feasibility and usability of the toolkit from the provider perspective (team member satisfaction; clinical efficiency; compliance with American Diabetes Association, American Association of Diabetes Educators, and California Children's Services standards; and payor-level cost data) and the preliminary efficacy of the intervention toolkit on patient- and family-level outcomes (attendance, acceptability/satisfaction with care, patient-level cost data, diabetes outcomes, diabetes family conflict, diabetes distress, and depression). DISCUSSION AYA patients with T1D often receive care in clinics and institutions with limited resources and time. This research tests the feasibility and efficacy of an innovative and potentially cost-effective SMA model to address the unique needs of underserved populations, while meeting national and state clinical standards. Trial registration The study is registered with ClinicalTrials.gov (Protocol Record: NCT04190368).",2020,"This research tests the feasibility and efficacy of an innovative and potentially cost-effective SMA model to address the unique needs of underserved populations, while meeting national and state clinical standards.","['Adolescent and young adults (AYA) with Type 1 Diabetes (T1D) experience more difficulty with glycemic control than patients in all other age groups', 'adolescents with type 1 diabetes', 'patients with T1D often receive care in clinics and institutions with limited resources and time', ""middle school adolescents in a large urban children's hospital serving an economically, racially and ethnically diverse population""]",[],"['patient- and family-level outcomes (attendance, acceptability/satisfaction with care, patient-level cost data, diabetes outcomes, diabetes family conflict, diabetes distress, and depression']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0332218', 'cui_str': 'Difficult'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0557797', 'cui_str': 'Middle school'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0013556', 'cui_str': 'Economics'}, {'cui': 'C0032659', 'cui_str': 'Population'}]",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0233542', 'cui_str': 'Family conflict'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",,0.0267749,"This research tests the feasibility and efficacy of an innovative and potentially cost-effective SMA model to address the unique needs of underserved populations, while meeting national and state clinical standards.","[{'ForeName': 'Sarah-Jeanne', 'Initials': 'SJ', 'LastName': 'Salvy', 'Affiliation': 'Research Center for Health Equity, Cedars-Sinai Medical Center, United States of America.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Ruelas', 'Affiliation': 'Keck School of Medicine, University of Southern California, United States of America.'}, {'ForeName': 'Shideh', 'Initials': 'S', 'LastName': 'Majidi', 'Affiliation': 'School of Medicine, University of Colorado Anschutz Medical Campus, United States of America.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Thomas', 'Affiliation': 'Booster Shot Media, United States of America.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Ashwal', 'Affiliation': 'Booster Shot Media, United States of America.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Reid', 'Affiliation': ""The Vision Center, Children's Hospital Los Angeles, United States of America.""}, {'ForeName': 'D Steven', 'Initials': 'DS', 'LastName': 'Fox', 'Affiliation': 'School of Pharmacy, University of Southern California, United States of America.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'McClain', 'Affiliation': 'School of Social Work, University of Southern California, United States of America.'}, {'ForeName': 'Jennifer K', 'Initials': 'JK', 'LastName': 'Raymond', 'Affiliation': ""Center for Endocrinology, Diabetes, & Metabolism, Children's Hospital Los Angeles, United States of America. Electronic address: jraymond@chla.usc.edu.""}]",Contemporary clinical trials,['10.1016/j.cct.2020.106079'] 1879,32634551,Effects of resistance training on hepcidin levels and iron bioavailability in older individuals with end-stage renal disease: A randomized controlled trial.,"Anemia is an inherent complication of older individuals with end-stage renal disease (ESRD) that is associated with inflammation which in turn is an important factor in the activation of hepcidin that contributes to the decrease in serum iron. Athough resistance training (RT) seems to reduce inflammation in ESRD, its influence on hepcidin and iron availability in hemodialysis patients is unclear. Therefore, the aim of this study was to exemine the effects of RT in on inflammatory profile, hepcidin, and iron status in older individuals with ESRD. End-stage renal disease patients (N: 157, age: 66.8 ± 3.6; body mass: 73 ± 15 body mass index:27 ± 3), were assigned to control (CTL n: 76) and exercise groups (RT n: 81). RT consisted of 24 weeks/3 days per week of a moderate intensity. There was an increase in the bioavailability of iron (ΔRT: 22.2; ΔCTL: -1 μg/dL, p < 0.0001), a decrease in hepcidin levels (ΔRT: -7.9; ΔCTL: 0.2 ng/mL, p < 0.0001),and an improvement of the inflammatory profile. These novel findings show that RT is a potential coadjuvant to reduce iron deficiency by decreasing the levels of hepcidin and pro-inflammatory markers in older patients undergoing hemodialysis.",2020,"There was an increase in the bioavailability of iron (ΔRT: 22.2; ΔCTL: -1 μg/dL, p < 0.0001), a decrease in hepcidin levels (ΔRT: -7.9; ΔCTL: 0.2 ng/mL, p < 0.0001),and an improvement of the inflammatory profile.","['N: 157, age: 66.8\u202f±\u202f3.6; body mass: 73\u202f±\u202f15 body mass index:27\u202f±\u202f3', 'older individuals with ESRD', 'older individuals with end-stage renal disease', 'older individuals with end-stage renal disease (ESRD', 'older patients undergoing hemodialysis', 'hemodialysis patients', 'End-stage renal disease patients']","['Athough resistance training (RT', 'RT', 'resistance training']","['inflammatory profile, hepcidin, and iron status', 'hepcidin levels and iron bioavailability', 'hepcidin levels', 'bioavailability of iron']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517844', 'cui_str': '66.8'}, {'cui': 'C4517694', 'cui_str': '3.6'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}]",157.0,0.0490397,"There was an increase in the bioavailability of iron (ΔRT: 22.2; ΔCTL: -1 μg/dL, p < 0.0001), a decrease in hepcidin levels (ΔRT: -7.9; ΔCTL: 0.2 ng/mL, p < 0.0001),and an improvement of the inflammatory profile.","[{'ForeName': 'Sting Ray Gouveia', 'Initials': 'SRG', 'LastName': 'Moura', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Hugo Luca', 'Initials': 'HL', 'LastName': 'Corrêa', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil. Electronic address: hugo.efucb@gmail.com.'}, {'ForeName': 'Rodrigo Vanerson Passos', 'Initials': 'RVP', 'LastName': 'Neves', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Cláudio Avelino Rodrigues', 'Initials': 'CAR', 'LastName': 'Santos', 'Affiliation': 'Federal University of Tocantins, Medicine Department, Tocantins, Brazil.'}, {'ForeName': 'Luiz Sinésio Silva', 'Initials': 'LSS', 'LastName': 'Neto', 'Affiliation': 'Federal University of Tocantins, Medicine Department, Tocantins, Brazil.'}, {'ForeName': 'Victor Lopes', 'Initials': 'VL', 'LastName': 'Silva', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Michel Kendy', 'Initials': 'MK', 'LastName': 'Souza', 'Affiliation': 'Federal University of Tocantins, Medicine Department, Tocantins, Brazil.'}, {'ForeName': 'Lysleine Alves', 'Initials': 'LA', 'LastName': 'Deus', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Andrea Lucena', 'Initials': 'AL', 'LastName': 'Reis', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Herbert Gustavo', 'Initials': 'HG', 'LastName': 'Simões', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Fabiani Lage Rodrigues', 'Initials': 'FLR', 'LastName': 'Beal', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Milton Rocha', 'Initials': 'MR', 'LastName': 'Moraes', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'Navalta', 'Affiliation': 'University of Nevada, Las Vegas, Department of Kinesiology and Nutrition Sciences, Las Vegas, NV, USA.'}, {'ForeName': 'Jonato', 'Initials': 'J', 'LastName': 'Prestes', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'André Bonadias', 'Initials': 'AB', 'LastName': 'Gadelha', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil; Federal Institute of Education, Science and Technology Goiano, Goiás, Brazil.'}, {'ForeName': 'Thiago Dos Santos', 'Initials': 'TDS', 'LastName': 'Rosa', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}]",Experimental gerontology,['10.1016/j.exger.2020.111017'] 1880,32634820,Serial assessment of fat and fat-free mass accretion in very preterm infants: a randomized trial.,"BACKGROUND Clinicians could modify dietary interventions during early infancy by monitoring fat and fat-free mass accretion in very preterm infants. METHODS Preterm infants were randomly assigned to either having reports on infant body composition available to the clinicians caring for them (intervention group) or not having reports available (control group). All infants underwent serial assessments of body composition by air-displacement plethysmography before 32 weeks of postmenstrual age (PMA) and at 36 weeks PMA. The primary outcome was percent body fat (%BF) at 3 months of corrected age (CA). RESULTS Fifty infants were randomized (median gestational age: 30 weeks; mean ± SD birth weight: 1387 ± 283 g). The mean %BF increased from 7 ± 4 before 32 weeks PMA to 20 ± 5 at 3 months CA. The differences in mean %BF between the intervention group and the control group were not statistically significant at 36 weeks PMA (14.5 vs. 13.6) or 3 months CA (20.8 vs. 19.4). Feeding practices and anthropometric measurements during hospitalization did not differ between groups. CONCLUSIONS Serial assessments of body composition in both intervention and control groups showed consistent increments in %BF. However, providing this information to clinicians did not influence nutritional practices or growth. IMPACT Serial assessments of body composition in preterm infants at 32 and 36 weeks postmenstrual age show consistent increments in % body fat up to 3 months of corrected age.However, providing this information to the clinician did not influence nutritional practices or growth.",2020,The differences in mean %BF between the intervention group and the control group were not statistically significant at 36 weeks PMA (14.5 vs. 13.6) or 3 months CA (20.8 vs. 19.4).,"['very preterm infants', 'Fifty infants were randomized (median gestational age: 30 weeks; mean\u2009±\u2009SD birth weight: 1387\u2009±\u2009283\u2009g', 'Preterm infants', 'preterm infants at 32 and 36 weeks postmenstrual age']","['Serial assessment of fat and fat-free mass accretion', 'having reports on infant body composition available to the clinicians caring for them (intervention group) or not having reports available (control group']","['body composition', 'mean %BF', 'percent body fat (%BF']","[{'cui': 'C3897192', 'cui_str': 'Very preterm infant'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C4708786', 'cui_str': '283'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass'}, {'cui': 'C0333038', 'cui_str': 'Accretion'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}]",50.0,0.0677656,The differences in mean %BF between the intervention group and the control group were not statistically significant at 36 weeks PMA (14.5 vs. 13.6) or 3 months CA (20.8 vs. 19.4).,"[{'ForeName': 'Ariel A', 'Initials': 'AA', 'LastName': 'Salas', 'Affiliation': 'Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 35249, USA. asalas@peds.uab.edu.'}, {'ForeName': 'Maggie L', 'Initials': 'ML', 'LastName': 'Jerome', 'Affiliation': 'Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, 35249, USA.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Chandler-Laney', 'Affiliation': 'Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, 35249, USA.'}, {'ForeName': 'Namasivayam', 'Initials': 'N', 'LastName': 'Ambalavanan', 'Affiliation': 'Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 35249, USA.'}, {'ForeName': 'Waldemar A', 'Initials': 'WA', 'LastName': 'Carlo', 'Affiliation': 'Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 35249, USA.'}]",Pediatric research,['10.1038/s41390-020-1052-x'] 1881,32635281,"Influence of an Aquatic Therapy Program on Perceived Pain, Stress, and Quality of Life in Chronic Stroke Patients: A Randomized Trial.","Pain and depressive states may have a negative impact on the quality of life of individuals with stroke. The aim of this study was to evaluate the effects of a program of Ai Chi aquatic therapy on pain, depression, and quality of life in a sample of people with stroke. Forty-five participants received physiotherapy treatment on dry land (control group), an experimental group received aquatic Ai Chi therapy, and a combined therapy group received alternating sessions of physiotherapy on dry land and aquatic Ai Chi therapy. The Visual Analog Scale (VAS) scale for pain, the resilience scale, and the SF-36 quality of life scale were used as outcome measures. Statistically significant differences were found in the experimental group and the combined intervention group for post treatment pain and resilience ( p < 0.001). Concerning the SF-36, statistically significant changes ( p < 0.01) were found in the experimental group and the combined therapy group for all items except general health, vitality, and social function, where no between group differences were observed ( p = 0.001). In conclusion, physical exercise performed in water has positive effects on several factors that contribute towards improving the mood and quality of life of people with acquired brain injury.",2020,"Concerning the SF-36, statistically significant changes ( p < 0.01) were found in the experimental group and the combined therapy group for all items except general health, vitality, and social function, where no between group differences were observed ( p = 0.001).","['Chronic Stroke Patients', 'people with stroke']","['Aquatic Therapy Program', 'physiotherapy treatment on dry land (control group), an experimental group received aquatic Ai Chi therapy, and a combined therapy group received alternating sessions of physiotherapy on dry land and aquatic Ai Chi therapy', 'Ai Chi aquatic therapy', 'physical exercise']","['general health, vitality, and social function', 'Perceived Pain, Stress, and Quality of Life', 'Pain and depressive states', 'mood and quality of life', 'Visual Analog Scale (VAS) scale for pain, the resilience scale, and the SF-36 quality of life scale', 'pain, depression, and quality of life']","[{'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011682', 'cui_str': 'Desiccation - action'}, {'cui': 'C0557668', 'cui_str': 'Landing'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0376586', 'cui_str': 'Life-Breath (Philosophy)'}, {'cui': 'C0033972', 'cui_str': 'Combined therapy'}, {'cui': 'C0332270', 'cui_str': 'Alternating'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale'}]",45.0,0.0453378,"Concerning the SF-36, statistically significant changes ( p < 0.01) were found in the experimental group and the combined therapy group for all items except general health, vitality, and social function, where no between group differences were observed ( p = 0.001).","[{'ForeName': 'Sagrario', 'Initials': 'S', 'LastName': 'Pérez-de la Cruz', 'Affiliation': 'Department of Nursing, Physiotherapy and Medicine, University of Almería, La Cañada de San Urbano, 04120 Almería, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17134796'] 1882,32635352,Everyday Pedelec Use and Its Effect on Meeting Physical Activity Guidelines.,"Pedelecs (e-bikes with electrical support up to 25 km·h -1 ) are important in active transportation. Yet, little is known about physiological responses during their everyday use. We compared daily pedelec (P) and bicycle (B) use to determine if pedelecs are a suitable tool to enhance physical activity. In 101 employees, cycling duration and intensity, heart rate (HR) during P and B were recorded via a smartphone app. Each recording period was a randomized crossover design and lasted two weeks. The ride quantity was higher in P compared to B (5.3 ± 4.3 vs. 3.2 ± 4.0 rides·wk -1 ; p < 0.001) resulting in a higher total cycling time per week for P (174 ± 146 min·wk -1 ) compared to B (99 ± 109 min·wk -1 ; p < 0.001). The mean HR during P was lower than B (109 ± 14 vs. 118 ± 17 bpm; p < 0.001). The perceived exertion was lower in P (11.7 ± 1.8 vs. 12.8 ± 2.1 in B; p < 0.001). The weekly energy expenditure was higher during P than B (717 ± 652 vs. 486 ± 557 metabolic equivalents of the task [MET]·min·wk -1 ; p < 0.01). Due to a sufficient HR increase in P, pedelecs offer a more active form of transportation to enhance physical activity.",2020,p < 0.001) resulting in a higher total cycling time per week for P (174 ± 146 min·wk -1 ) compared to B (99 ±,[],[],"['total cycling time', 'weekly energy expenditure', 'ride quantity', 'perceived exertion', 'cycling duration and intensity, heart rate (HR', 'mean HR during P']",[],[],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.0676234,p < 0.001) resulting in a higher total cycling time per week for P (174 ± 146 min·wk -1 ) compared to B (99 ±,"[{'ForeName': 'Hedwig T', 'Initials': 'HT', 'LastName': 'Stenner', 'Affiliation': 'Institute of Sports Medicine, Hannover Medical School, 30625 Hanover, Germany.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Boyen', 'Affiliation': 'Institute of Sports Medicine, Hannover Medical School, 30625 Hanover, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Hein', 'Affiliation': 'Institute of Sports Medicine, Hannover Medical School, 30625 Hanover, Germany.'}, {'ForeName': 'Gudrun', 'Initials': 'G', 'LastName': 'Protte', 'Affiliation': 'Institute of Sports Medicine, Hannover Medical School, 30625 Hanover, Germany.'}, {'ForeName': 'Momme', 'Initials': 'M', 'LastName': 'Kück', 'Affiliation': 'Institute of Sports Medicine, Hannover Medical School, 30625 Hanover, Germany.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Finkel', 'Affiliation': 'Institute of Sports Medicine, Hannover Medical School, 30625 Hanover, Germany.'}, {'ForeName': 'Alexander A', 'Initials': 'AA', 'LastName': 'Hanke', 'Affiliation': 'Institute of Sports Medicine, Hannover Medical School, 30625 Hanover, Germany.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Tegtbur', 'Affiliation': 'Institute of Sports Medicine, Hannover Medical School, 30625 Hanover, Germany.'}]",International journal of environmental research and public health,['10.3390/ijerph17134807'] 1883,32684719,Comparative Study of the Effect of Resistance Exercises versus Aerobic Exercises in Postmenopausal Women Suffering from Insomnia.,"Study Objectives The main objective of the study is to compare the effectiveness of resistance exercises versus aerobic exercises in postmenopausal women suffering from insomnia using the Pittsburgh Sleep Quality Index (PSQI). Materials and Methods Sixty postmenopausal women with menopause <10 years, suffering from insomnia for >1 month and on no supplementary exercises were recruited and categorized conveniently into two groups of 30 each. Group A received resistance exercises and Group B aerobic exercises. PSQI was used to screen postmenopausal women. Women on hormone replacement therapy, with artificial menopause, with diagnosed osteoporosis ( t > 2) were excluded. Group A underwent general strengthening program in the form of closed-chain exercise. Group B received aerobic exercises after calculating target heart rate (HR) using Karvonen's formula in the form of brisk walking three times a week at 30%-60% of HRmax. Results Paired t -test done to evaluate pre- and postmean values of PSQI for Group A. P < 0.001 which is highly statistically significant. Paired t -test done to evaluate pre- and postmean values of PSQI for Group B. P < 0.001, which is highly statistically significant. Unpaired t -test was carried out to compare the mean difference (pre-post) of PSQI values of both the groups. P < 0.001 which is highly significant. The mean difference of Group A (i.e., 4) is more than the mean difference of Group B (i.e., 2.63) indicating that the intervention of resistance exercises is more effective. Conclusion Aerobic exercises and resistance exercises, both are effective in reducing insomnia in postmenopausal women, but resistance exercises are more beneficial than aerobic exercises.",2020,"Paired t -test done to evaluate pre- and postmean values of PSQI for Group B. P < 0.001, which is highly statistically significant.","['postmenopausal women suffering from insomnia using the Pittsburgh Sleep Quality Index (PSQI', 'screen postmenopausal women', 'Women on hormone replacement therapy, with artificial menopause, with diagnosed osteoporosis ( t > 2) were excluded', 'Postmenopausal Women Suffering from Insomnia', 'postmenopausal women', 'Sixty postmenopausal women with menopause <10 years, suffering from insomnia for >1 month and on no supplementary exercises were recruited and categorized conveniently into two groups of 30 each']","['general strengthening program in the form of closed-chain exercise', 'PSQI', 'resistance exercises and Group B aerobic exercises', 'Resistance Exercises versus Aerobic Exercises', 'resistance exercises versus aerobic exercises', 'Aerobic exercises and resistance exercises', 'aerobic exercises']",[],"[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0282402', 'cui_str': 'Hormone replacement therapy'}, {'cui': 'C0232972', 'cui_str': 'Postartificial menopausal syndrome'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4280965', 'cui_str': 'Greater than one'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}]",[],60.0,0.0435829,"Paired t -test done to evaluate pre- and postmean values of PSQI for Group B. P < 0.001, which is highly statistically significant.","[{'ForeName': 'Gayatri', 'Initials': 'G', 'LastName': 'Karandikar-Agashe', 'Affiliation': 'Department of Musculoskeletal Sciences, M A Rangoonwala College of Physiotherapy and Research, Pune, Maharashtra, India.'}, {'ForeName': 'Ronika', 'Initials': 'R', 'LastName': 'Agrawal', 'Affiliation': 'Department of Musculoskeletal Sciences, M A Rangoonwala College of Physiotherapy and Research, Pune, Maharashtra, India.'}]",Journal of mid-life health,['10.4103/jmh.JMH_35_19'] 1884,32629091,Early-onset pneumonia following bag-mask ventilation versus endotracheal intubation during cardiopulmonary resuscitation: A substudy of the CAAM trial.,"AIM Early-onset pneumonia (EOP) is a common in-hospital complication in survivors of out-of-hospital cardiac arrest. In this substudy of the CAAM trial, we aimed to compare whether bag mask ventilation (BMV) compared to endotracheal intubation (ETI) performed during cardiopulmonary resuscitation increases the risk of developing EOP. METHODS Adult patients from the CAAM trial that survived beyond 12 h of hospitalization were included. Information about in-hospital management and outcome of study subjects was systematically collected. Our primary aim was to compare the incidence of EOP in the BMV and ETI group using a series of bivariate analysis adjusting for one variable at a time and a logistic regression controlled for survival beyond 96 h, age, gender, catecholamine administration, no flow time, and initial shockable rhythm. RESULTS Of 627 patients from the CAAM trial that survived to hospital admission, 409 patients were hospitalized beyond 12 h and thus included (202 randomized to BMV and 20 7 randomized to ETI). Patients in the BMV group had a significantly longer period of unsecured airway during prehospital cardiopulmonary resuscitation (BMV (median): 33 min; ETI (median): 17 min, p < 0.0001). No significant difference in the development of EOP according to airway management was identified on univariate analysis (BMV: 53%, ETI: 53%, Odds Ratio 1.0 [0.7-1.5], p = 1.0). We found no difference in the development of EOP according to airway management in the series of bivariate analyses or in the multivariable regression analysis either. CONCLUSION In this substudy of the CAAM trial, development of early-onset pneumonia in out-of-hospital cardiac arrest survivors did not depend on airway management technique during CPR.",2020,"No significant difference in the development of EOP according to airway management was identified on univariate analysis (BMV: 53%, ETI: 53%, Odds Ratio 1.0 [0.7 - 1.5], p = 1.0).","['cardiopulmonary resuscitation', 'Adult patients from the CAAM trial that survived beyond 12\u2009hours of hospitalization were included', '627 patients from the CAAM trial that survived to hospital admission', '409 patients were hospitalized beyond 12\u2009hours and thus included (202 randomized to BMV and 20 7 randomized to ETI']","['endotracheal intubation (ETI', 'bag-mask ventilation versus endotracheal intubation', 'bag mask ventilation (BMV']","['development of EOP according to airway management', 'risk of developing EOP', 'incidence of EOP']","[{'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1292430', 'cui_str': '12 hours'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0179196', 'cui_str': 'Bag'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}]","[{'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C0179196', 'cui_str': 'Bag'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}]","[{'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0150126', 'cui_str': 'Airway management'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",627.0,0.0603892,"No significant difference in the development of EOP according to airway management was identified on univariate analysis (BMV: 53%, ETI: 53%, Odds Ratio 1.0 [0.7 - 1.5], p = 1.0).","[{'ForeName': 'Josefine S', 'Initials': 'JS', 'LastName': 'Baekgaard', 'Affiliation': 'Department of Anesthesia, Centre of Head and Orthopaedics, Rigshospitalet, University of Copenhagen, Denmark; Urgences et Samu 93, AP-HP, Hôpital Avicenne, Inserm U942, 93000 Bobigny, France. Electronic address: josefine.stokholm.baekgaard.01@regionh.dk.'}, {'ForeName': 'Mohamed N', 'Initials': 'MN', 'LastName': 'Triba', 'Affiliation': ""Sorbonne Paris Cité, Equipe Nanomédecine Biomarqueurs Détection, Laboratoire de Chimie, Structures et Propriétés de Biomateriaux et d'Agents Therapeutiques, UMR CNRS 7244, University Paris 13 Bobigny, France.""}, {'ForeName': 'Morgane', 'Initials': 'M', 'LastName': 'Brandeis', 'Affiliation': 'Service des Urgences, Hopital Ballanger, 93600 Aulnays, France.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Steinmetz', 'Affiliation': 'Department of Anesthesia, Centre of Head and Orthopaedics, Rigshospitalet, University of Copenhagen, Denmark.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Cohen', 'Affiliation': 'Intensive Care Unit, AP-HP, Hôpital Avicenne, Inserm U942, 93000 Bobigny, France.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Gorlicki', 'Affiliation': 'Urgences et Samu 93, AP-HP, Hôpital Avicenne, Inserm U942, 93000 Bobigny, France.'}, {'ForeName': 'Lars S', 'Initials': 'LS', 'LastName': 'Rasmussen', 'Affiliation': 'Department of Anesthesia, Centre of Head and Orthopaedics, Rigshospitalet, University of Copenhagen, Denmark.'}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Deltour', 'Affiliation': 'Urgences et Samu 93, AP-HP, Hôpital Avicenne, Inserm U942, 93000 Bobigny, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Lapostolle', 'Affiliation': 'Urgences et Samu 93, AP-HP, Hôpital Avicenne, Inserm U942, 93000 Bobigny, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Adnet', 'Affiliation': 'Urgences et Samu 93, AP-HP, Hôpital Avicenne, Inserm U942, 93000 Bobigny, France.'}]",Resuscitation,['10.1016/j.resuscitation.2020.06.011'] 1885,32629997,The UK Pregnancies Better Eating and Activity Trial (UPBEAT); Pregnancy Outcomes and Health Behaviours by Obesity Class.,"The effectiveness of antenatal intervention in women with increasing obesity is unknown. This study investigated whether there was a differential effect of antenatal intervention on diet, physical activity and pregnancy outcomes in women stratified by obesity class using data from the UK Pregnancies Better Eating and Activity Trial (UPBEAT) ( n = 1555). The stratification was by World Health Organization classifications: Class I, II and III (30-34.9 kg/m 2 , 35-39.9 kg/m 2 and ≥40 kg/m 2 ). Using linear and logistic regression, adjusted for confounders, outcomes were assessed post-intervention (27 +0 -28 +6 weeks' gestation) and in late pregnancy (34 +0 -36 +0 weeks' gestation). Interactions between obesity class and the intervention were explored. Compared to the standard care arm, class III intervention women had lower gestational weight gain (GWG) (-1.87 kg; 95% CI -3.29 to -0.47, p = 0.009), and the effect of the intervention was greater in class III compared to class I, by -2.01 kg (95% CI -3.45 to -0.57, p = 0.006). Class I and II intervention women reported significantly lower dietary glycaemic load and saturated fat intake across their pregnancy. This differential effect of the intervention suggests antenatal interventions for women with obesity should stratify outcomes by obesity severity. This would inform evidence-based antenatal strategies for high-risk groups, including women with a BMI ≥ 40 kg/m 2 .",2020,"Compared to the standard care arm, class III intervention women had lower gestational weight gain (GWG) (-1.87 kg; 95% CI -3.29 to -0.47, p = 0.009), and the effect of the intervention was greater in class III compared to class","['women with obesity', 'women stratified by obesity class using data from the UK Pregnancies Better Eating and Activity Trial (UPBEAT) ( n = 1555', 'women with increasing obesity is unknown']",['antenatal intervention'],"['gestational weight gain (GWG', 'diet, physical activity and pregnancy outcomes', 'dietary glycaemic load and saturated fat intake']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}]","[{'cui': 'C2828394', 'cui_str': 'Antenatal'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C1398625', 'cui_str': 'Maternal Weight Gain'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0032972', 'cui_str': 'Outcomes, Pregnancy'}, {'cui': 'C0556120', 'cui_str': 'Saturated fat intake'}]",,0.0574858,"Compared to the standard care arm, class III intervention women had lower gestational weight gain (GWG) (-1.87 kg; 95% CI -3.29 to -0.47, p = 0.009), and the effect of the intervention was greater in class III compared to class","[{'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Peacock', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, King's College London, 10th Floor North Wing, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK.""}, {'ForeName': 'Paul T', 'Initials': 'PT', 'LastName': 'Seed', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, King's College London, 10th Floor North Wing, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK.""}, {'ForeName': 'Kathryn V', 'Initials': 'KV', 'LastName': 'Dalrymple', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, King's College London, 10th Floor North Wing, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK.""}, {'ForeName': 'Sara L', 'Initials': 'SL', 'LastName': 'White', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, King's College London, 10th Floor North Wing, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK.""}, {'ForeName': 'Lucilla', 'Initials': 'L', 'LastName': 'Poston', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, King's College London, 10th Floor North Wing, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK.""}, {'ForeName': 'Angela C', 'Initials': 'AC', 'LastName': 'Flynn', 'Affiliation': ""Department of Women and Children's Health, School of Life Course Sciences, King's College London, 10th Floor North Wing, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK.""}]",International journal of environmental research and public health,['10.3390/ijerph17134712'] 1886,32684633,"Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.","Intensive upfront therapy in newly-diagnosed multiple myeloma (MM) including induction therapy (IT), high-dose melphalan (MEL200), and autologous blood stem cell transplantation (ASCT) followed by consolidation and/or maintenance is mostly restricted to patients up to 65 years of age. Prospective phase III trial data in the era of novel agents for patients up to 70 years of age are not available. The GMMG-MM5 trial included 601 patients between 18 and 70 years of age, divided in three groups for the present analysis: ≤60 years (S1, n = 353), 61-65 years (S2, n = 107) and 66-70 years (S3, n = 141). Treatment consisted of a bortezomib-containing IT, MEL200/ASCT, consolidation, and maintenance with lenalidomide. Adherence to treatment was similar among patients of the three age groups. Overall toxicity during all treatment phases was increased in S2 and S3 compared to S1 (any adverse event/any serious adverse event: S1:81.7/41.8% vs. S2:90.7/56.5% vs. S3:87.2/68.1%, p = 0.05/<0.001). With respect to progression-free survival (log-rank p = 0.73), overall survival (log-rank p = 0.54) as well as time-to-progression (Gray's p = 0.83) and non-relapse mortality (Gray's p = 0.25), no differences were found between the three age groups. Our results imply that an intensive upfront therapy with a bortezomib-containing IT, MEL200/ASCT, lenalidomide consolidation, and maintenance should be applied to transplant-eligible MM patients up to 70 years of age.",2020,"Overall toxicity during all treatment phases was increased in S2 and S3 compared to S1 (any adverse event/any serious adverse event: S1:81.7/41.8% vs. S2:90.7/56.5% vs. S3:87.2/68.1%, p = 0.05/<0.001).","['601 patients between 18 and 70 years of age, divided in three groups for the present analysis: ≤60 years (S1, n\u2009=\u2009353), 61-65 years (S2, n\u2009=\u2009107) and 66-70 years (S3, n\u2009=\u2009141', 'patients up to 70 years of age are not available', 'myeloma up to 70 years of age', 'newly-diagnosed multiple myeloma (MM) including induction therapy (IT), high-dose']","['bortezomib-containing IT, MEL200/ASCT, consolidation, and maintenance with lenalidomide', 'Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance', 'bortezomib-containing IT, MEL200/ASCT, lenalidomide consolidation', 'melphalan (MEL200), and autologous blood stem cell transplantation (ASCT', 'Intensive upfront therapy']","['progression-free survival', 'overall survival', 'Overall toxicity', 'non-relapse mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0686905', 'cui_str': 'Unavailability'}, {'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0444956', 'cui_str': 'High dose'}]","[{'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0521530', 'cui_str': 'Lung consolidation'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C1144149', 'cui_str': 'lenalidomide'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0025241', 'cui_str': 'Melphalan'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",601.0,0.0313945,"Overall toxicity during all treatment phases was increased in S2 and S3 compared to S1 (any adverse event/any serious adverse event: S1:81.7/41.8% vs. S2:90.7/56.5% vs. S3:87.2/68.1%, p = 0.05/<0.001).","[{'ForeName': 'Elias K', 'Initials': 'EK', 'LastName': 'Mai', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Kaya', 'Initials': 'K', 'LastName': 'Miah', 'Affiliation': 'Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Uta', 'Initials': 'U', 'LastName': 'Bertsch', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Dürig', 'Affiliation': 'Department of Hematology, University Clinic Essen, Essen, Germany.'}, {'ForeName': 'Christof', 'Initials': 'C', 'LastName': 'Scheid', 'Affiliation': 'Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.'}, {'ForeName': 'Katja C', 'Initials': 'KC', 'LastName': 'Weisel', 'Affiliation': 'Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Kunz', 'Affiliation': 'Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Munder', 'Affiliation': 'Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Hans-Walter', 'Initials': 'HW', 'LastName': 'Lindemann', 'Affiliation': 'Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany.'}, {'ForeName': 'Maximilian', 'Initials': 'M', 'LastName': 'Merz', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Hose', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Jauch', 'Affiliation': 'Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Seckinger', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Luntz', 'Affiliation': 'Coordination Centre for Clinical Trials, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Sauer', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Fuhrmann', 'Affiliation': 'Department of Hematology and Oncology, Helios Hospital Berlin Buch, Berlin, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Brossart', 'Affiliation': 'University Hospital Bonn, Bonn, Germany.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Elmaagacli', 'Affiliation': 'Department of Hematology and Oncology, Asklepios Hospital Hamburg St. Georg, Hamburg, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Goerner', 'Affiliation': 'Department of Hematology, Oncology and Palliative Care, Klinikum Bielefeld, Bielefeld, Germany.'}, {'ForeName': 'Helga', 'Initials': 'H', 'LastName': 'Bernhard', 'Affiliation': 'Department of Internal Medicine V, Klinikum Darmstadt, Darmstadt, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hoffmann', 'Affiliation': 'Medical Clinic A, Klinikum Ludwigshafen, Ludwigshafen, Germany.'}, {'ForeName': 'Marc S', 'Initials': 'MS', 'LastName': 'Raab', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Igor W', 'Initials': 'IW', 'LastName': 'Blau', 'Affiliation': 'Medical Clinic, Charité University Medicine Berlin, Berlin, Germany.'}, {'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Hänel', 'Affiliation': 'Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Benner', 'Affiliation': 'Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'ForeName': 'Hans J', 'Initials': 'HJ', 'LastName': 'Salwender', 'Affiliation': 'Department of Hematology and Oncology, Asklepios Hospital Hamburg Altona, Hamburg, Germany.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Goldschmidt', 'Affiliation': 'Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany. hartmut.goldschmidt@med.uni-heidelberg.de.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Leukemia,['10.1038/s41375-020-0976-9'] 1887,32631102,A cluster-randomised trial to evaluate an intervention to promote handwashing in rural Nigeria.,"Handwashing with soap at critical times helps prevent diarrhoeal diseases. Changing handwashing practices through behaviour change communication remains a challenge. This study designed and tested a scalable intervention to promote handwashing with soap. A cluster-randomised, controlled trial compared our intervention against standard practice. Subjects were men, women and children in 14 villages in Cross-River state, Nigeria. The primary outcome was the proportion of observed key events on which hands were washed with soap. Binomial regression analysis calculated prevalence differences between study arms. The intervention had minimal effect on the primary outcome (+2.4%, p = 0.096). The intervention was associated with increased frequency of handwashes without soap before food contact (+13%, p = 0.017). The intervention failed to produce significant changes in handwashing with soap at key times. The low dose delivered (two contact points) may have increased scalability at the cost of effectiveness, particularly in the challenging context of inconvenient water access.",2020,"The intervention had minimal effect on the primary outcome (+2.4%, p = 0.096).","['Subjects were men, women and children in 14 villages in Cross-River state, Nigeria', 'rural Nigeria']",[],"['handwashing with soap at key times', 'frequency of handwashes without soap before food contact', 'diarrhoeal diseases', 'proportion of observed key events']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0337050', 'cui_str': 'River'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0028075', 'cui_str': 'Nigeria'}]",[],"[{'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0037392', 'cui_str': 'Soap'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C1550738', 'cui_str': 'Before food'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C1290807', 'cui_str': 'Diarrheal disorder'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",,0.0660822,"The intervention had minimal effect on the primary outcome (+2.4%, p = 0.096).","[{'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Biran', 'Affiliation': 'Disease Control Department, London School of Hygiene and Tropical Medicine , London, UK.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'White', 'Affiliation': 'Disease Control Department, London School of Hygiene and Tropical Medicine , London, UK.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Awe', 'Affiliation': 'United Purpose Nigeria , Calabar, Nigeria.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Greenland', 'Affiliation': 'Disease Control Department, London School of Hygiene and Tropical Medicine , London, UK.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Akabike', 'Affiliation': 'EpiAFRIC , Abuja, Nigeria.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Chuktu', 'Affiliation': 'United Purpose Nigeria , Calabar, Nigeria.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Aunger', 'Affiliation': 'Disease Control Department, London School of Hygiene and Tropical Medicine , London, UK.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Curtis', 'Affiliation': 'Disease Control Department, London School of Hygiene and Tropical Medicine , London, UK.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Schmidt', 'Affiliation': 'Disease Control Department, London School of Hygiene and Tropical Medicine , London, UK.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Van der Voorden', 'Affiliation': 'Technical Support Unit, Water Supply and Sanitation Collaborative Council , Geneva, Switzerland.'}]",International journal of environmental health research,['10.1080/09603123.2020.1788712'] 1888,32634485,Virtual mind-body treatment for adolescents with neurofibromatosis: Study protocol for a single-blind randomized controlled trial.,"BACKGROUND Neurofibromatoses (NF) are a group of genetically distinct disorders of the nervous system unified by the predisposition to nerve sheath tumors. Although adolescents with NF types 1 and 2 (NF1 and NF2) report poor quality of life and high psychosocial burden, there are no evidence-based interventions to address these needs. This paper presents the study design and protocol for the first randomized controlled trial (RCT) of a mind-body intervention for adolescents with NF, Resilient Youth with NF (RY-NF), versus an educational control group, Health Education for NF (HE-NF), both delivered in groups via secure live video. METHODS This is an ongoing, single-blind efficacy RCT. Recruitment began in November 2019 and will continue until March 2022. We will enroll 200 English-speaking, geographically diverse adolescents (ages 12-17) with NF1 and NF2 who report significant distress or difficulty coping with their NF symptoms. We will use a shared-baseline, linear mixed model to compare the effect of RY-NF versus HE-NF on changes in quality of life (QoL) and psychosocial outcomes from baseline to post-intervention, and 6- and 12-month follow-ups. We will also develop NF-specific minimal clinically important difference (MCID) for QoL variables, and conduct mediation and moderation analyses to understand mechanisms of improvement. DISCUSSION This study has important clinical and public health implications for the psychosocial functioning of adolescents with NF. It provides a model for efficient delivery of virtual psychosocial care for adolescents with rare diseases. Plans for dissemination and implementation of the RY-NF should efficacy be ascertained are also discussed.",2020,"Although adolescents with NF types 1 and 2 (NF1 and NF2) report poor quality of life and high psychosocial burden, there are no evidence-based interventions to address these needs.","['adolescents with NF, Resilient Youth with NF (RY-NF', 'adolescents with neurofibromatosis', 'adolescents with NF', 'adolescents with rare diseases', '200 English-speaking, geographically diverse adolescents (ages 12-17) with NF1 and NF2 who report significant distress or difficulty coping with their NF symptoms']","['educational control group, Health Education for NF (HE-NF', 'Virtual mind-body treatment', 'mind-body intervention', 'RY-NF versus HE-NF']",['quality of life (QoL) and psychosocial outcomes'],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0027831', 'cui_str': 'Neurofibromatosis type 1'}, {'cui': 'C0678236', 'cui_str': 'Rare Diseases'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0027832', 'cui_str': 'Neurofibromatosis type 2'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0582154', 'cui_str': 'Difficulty coping'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1513305', 'cui_str': 'Mind-Body Medicine'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0666435,"Although adolescents with NF types 1 and 2 (NF1 and NF2) report poor quality of life and high psychosocial burden, there are no evidence-based interventions to address these needs.","[{'ForeName': 'Mira', 'Initials': 'M', 'LastName': 'Reichman', 'Affiliation': 'Integrated Brain Health Clinical and Research Program, Psychiatry Department, Massachusetts General Hospital, One Bowdoin, Square, 1st floor Boston, 02114 Boston, MA, United States of America. Electronic address: mreichman@mgh.harvard.edu.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Riklin', 'Affiliation': 'Department of Psychology, Fordham University, Dealy 336, 441 East Fordham Rd, Bronx, NY 10458, United States of America. Electronic address: eriklin@fordham.edu.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Macklin', 'Affiliation': 'Biostatistics Center, Massachusetts General Hospital, 50 Staniford Street, St 560, Boston, MA 02114, United States of America. Electronic address: emacklin@mgh.harvard.edu.'}, {'ForeName': 'Ana-Maria', 'Initials': 'AM', 'LastName': 'Vranceanu', 'Affiliation': 'Integrated Brain Health Clinical and Research Program, Psychiatry Department, Massachusetts General Hospital, One Bowdoin, Square, 1st floor Boston, 02114 Boston, MA, United States of America; Harvard Medical School, One Bowdoin Square, 1st floor Boston, 02114 Boston, MA, United States of America. Electronic address: avranceanu@mgh.harvard.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106078'] 1889,32634642,Evaluation of the perioperative effects of dexmedetomidine on tympanoplasty operations.,"PURPOSE This randomized double-blind study aimed to evaluate the effects of dexmedetomidine on hemodynamic parameters and the quality of surgery and recovery criteria in tympanoplasty operations. MATERIALS AND METHODS A total of 75 patients 18-55 years undergoing tympanoplasty, who were graded as American Society of Anesthesiologists physical status I-II, were randomly divided into three groups. Group 1 included patients receiving remifentanil alone, Group 2 included patients receiving dexmedetomidine + remifentanil and Group 3 included patients receiving dexmedetomidine + ½ remifentanil. Anesthesia was induced with propofol and cisatracurium. For maintenance of anesthesia, a mixture of 2-2.5% sevoflurane, 40-60% oxygen/air was used. The groups were compared in terms of hemodynamic parameters, surgical area, recovery criteria, modified Aldrete, pain scores, additional analgesic requirements and adverse effects. RESULTS Mean arterial pressure and heart rate values of Group 1 were higher at the time of intubation, incision, spontaneous breathing and extubation compared to Group 2 and Group 3. Surgical field satisfaction was higher in Group 2 and Group 3 than Group 1. Spontaneous breathing, eye opening and verbal cooperation times were shorter in Group 3 compared to Group 2. Eye opening and verbal cooperation times were longer in Group 2 compared to Group 1. The 30-minute modified Aldrete scores was higher in Group 3 compared to Group 1. There was no difference between the groups in terms of postoperative pain and adverse effects. CONCLUSION The use of dexmedetomidine during tympanoplasty operations may provide better hemodynamic control and surgical view, may provide faster recovery and may reduce remifentanil consumption.",2020,"Mean arterial pressure and heart rate values of Group 1 were higher at the time of intubation, incision, spontaneous breathing and extubation compared to Group 2 and Group 3.","['75 patients 18-55\xa0years undergoing tympanoplasty, who were graded as American Society of Anesthesiologists physical status I-II']","['dexmedetomidine + ½ remifentanil', 'remifentanil alone', 'propofol and cisatracurium', 'sevoflurane', 'dexmedetomidine', 'dexmedetomidine + remifentanil']","['Eye opening and verbal cooperation times', 'Mean arterial pressure and heart rate values', 'Surgical field satisfaction', 'Spontaneous breathing, eye opening and verbal cooperation times', 'postoperative pain and adverse effects', 'hemodynamic parameters, surgical area, recovery criteria, modified Aldrete, pain scores, additional analgesic requirements and adverse effects', 'tympanoplasty operations']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0041447', 'cui_str': 'Repair of middle ear'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449438', 'cui_str': 'Status'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C1096766', 'cui_str': 'Cisatracurium'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}]","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0041447', 'cui_str': 'Repair of middle ear'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",75.0,0.0542959,"Mean arterial pressure and heart rate values of Group 1 were higher at the time of intubation, incision, spontaneous breathing and extubation compared to Group 2 and Group 3.","[{'ForeName': 'Muge', 'Initials': 'M', 'LastName': 'Kosucu', 'Affiliation': 'Medical School of Karadeniz Technical University, Department of Anaesthesiology, 61080 Trabzon, Turkey. Electronic address: mugekk73@hotmail.com.'}, {'ForeName': 'Ersagun', 'Initials': 'E', 'LastName': 'Tugcugil', 'Affiliation': 'Medical School of Karadeniz Technical University, Department of Anaesthesiology, 61080 Trabzon, Turkey.'}, {'ForeName': 'Bengu', 'Initials': 'B', 'LastName': 'Cobanoglu', 'Affiliation': 'Medical School of Karadeniz Technical University, Department of Otorhinolaryngology, 61080 Trabzon, Turkey.'}, {'ForeName': 'Erhan', 'Initials': 'E', 'LastName': 'Arslan', 'Affiliation': 'Medical School of Karadeniz Technical University, Department of Neurosurgery, 61080 Trabzon, Turkey.'}]",American journal of otolaryngology,['10.1016/j.amjoto.2020.102619'] 1890,32634673,Ulipristal acetate versus gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): Long term results of a double-blind randomized controlled trial.,"OBJECTIVE The aim of this study was to compare the effect of ulipristal acetate (UPA) and gonadotropin-releasing hormone agonists (GnRHa) before laparoscopic myomectomy on long term secondary outcomes of the MYOMEX-trial, regarding quality of life, ultrasound characteristics, hemoglobin levels 6 weeks post-operative, sexual function and menstrual bleeding control. A cost-analysis was also performed. Short-term primary and secondary outcomes are reported elsewhere. STUDY DESIGN A double-blind, randomized, controlled, non-inferiority trial in nine hospitals in the Netherlands. Participants were randomized in a 1:1 ratio (block size of four, stratified per hospital) to either UPA or GnRHa pre-treatment. Additional placebo injections containing saline, respectively daily placebo tablets were given to both groups to ensure double-blinding. Surgery was performed within a month after the last tablet. Women were followed up until six months post-surgery. RESULTS A total of 55 participants were randomized: 30 to the UPA- and 25 to the GnRHa-group between May 2015 and July 2017. Uterine volume at six weeks post-operative did not differ significantly between both pre-treatment groups with 170.1 cm 3 (106.8-243.5; N = 29) vs. 152.8 cm 3 (92.3-205.6; N = 23) for the UPA- and GnRHa-group respectively (p = 0.423). Hemoglobin levels six weeks post-operatively recovered back to baseline and were not significantly different between groups with 7.7 mmol/L for the UPA- vs. 8.1 mmol/L for the GnRHa-group (p = 0.157; mean difference -0.4 (CI -0.9, 0.2). Menstrual bleeding pattern, quality of life, effects on general and sexual health showed a significant improvement compared to baseline in both groups without any differences between the treatment groups. Symptom severity scores also decreased significantly at 6 week post-operatively compared to baseline, but did not differ between the treatment groups. Fibroid characteristics at baseline (e.g. mean diameter of largest fibroid) appeared not to be a confounding factor. An exploratory cost analysis showed no significant differences in absenteeism costs, total healthcare and societal costs, after adjustment for confounding factors. CONCLUSION Pre-treatment prior to laparoscopic myomectomy with UPA compared to GnRHa has similar effects on bleeding pattern, menopausal symptoms, sexual functioning, symptom severity and quality of life from baseline up to six months post-operative. Due to the small sample size, these findings should be interpreted with caution. Also, no firm conclusions on costs could be made.",2020,"Menstrual bleeding pattern, quality of life, effects on general and sexual health showed a significant improvement compared to baseline in both groups without any differences between the treatment groups.","['prior to laparoscopic myomectomy (MYOMEX trial', 'A total of 55 participants were randomized: 30 to the UPA- and 25 to the GnRHa-group between May 2015 and July 2017', 'nine hospitals in the Netherlands']","['UPA or GnRHa pre-treatment', 'Ulipristal acetate versus gonadotropin-releasing hormone agonists', 'ulipristal acetate (UPA) and gonadotropin-releasing hormone agonists (GnRHa) before laparoscopic myomectomy', 'placebo injections containing saline, respectively daily placebo tablets']","['Fibroid characteristics', 'Hemoglobin levels', 'Menstrual bleeding pattern, quality of life, effects on general and sexual health', 'absenteeism costs, total healthcare and societal costs', 'bleeding pattern, menopausal symptoms, sexual functioning, symptom severity and quality of life', 'Symptom severity scores', 'Uterine volume', 'quality of life, ultrasound characteristics, hemoglobin levels 6 weeks post-operative, sexual function and menstrual bleeding control']","[{'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C2111517', 'cui_str': 'Laparoscopic myomectomy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C2723461', 'cui_str': 'Ulipristal acetate'}, {'cui': 'C1518041', 'cui_str': 'Gonadotropin releasing hormone analogues'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}]","[{'cui': 'C2723461', 'cui_str': 'Ulipristal acetate'}, {'cui': 'C1518041', 'cui_str': 'Gonadotropin releasing hormone analogues'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C2111517', 'cui_str': 'Laparoscopic myomectomy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}]","[{'cui': 'C0023267', 'cui_str': 'Leiomyofibroma'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0025344', 'cui_str': 'Menstruation'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C2362326', 'cui_str': 'Sexual Health'}, {'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0236075', 'cui_str': 'Menopausal symptom'}, {'cui': 'C0278092', 'cui_str': 'Sexual function'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",55.0,0.659859,"Menstrual bleeding pattern, quality of life, effects on general and sexual health showed a significant improvement compared to baseline in both groups without any differences between the treatment groups.","[{'ForeName': 'Inge', 'Initials': 'I', 'LastName': 'De Milliano', 'Affiliation': 'Amsterdam University Medical Center, Department of Obstetrics and Gynecology, Amsterdam Reproduction and Development, De Boelelaan 1117, Amsterdam, The Netherlands.'}, {'ForeName': 'Mei-An', 'Initials': 'MA', 'LastName': 'Middelkoop', 'Affiliation': 'Amsterdam University Medical Center, Department of Obstetrics and Gynecology, Amsterdam Reproduction and Development, De Boelelaan 1117, Amsterdam, The Netherlands. Electronic address: m.middelkoop@amsterdamumc.nl.'}, {'ForeName': 'Judith A F', 'Initials': 'JAF', 'LastName': 'Huirne', 'Affiliation': 'Amsterdam University Medical Center, Department of Obstetrics and Gynecology, Amsterdam Reproduction and Development, De Boelelaan 1117, Amsterdam, The Netherlands.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Kwee', 'Affiliation': 'OLVG, Department of Obstetrics and Gynecology, Jan Tooropstraat 164, Amsterdam, The Netherlands.'}, {'ForeName': 'Peggy M A J', 'Initials': 'PMAJ', 'LastName': 'Geomini', 'Affiliation': 'Máxima Medisch Centrum, Department of Obstetrics and Gynecology, De Run 4600, Veldhoven, The Netherlands.'}, {'ForeName': 'Benedictus C', 'Initials': 'BC', 'LastName': 'Schoot', 'Affiliation': 'Catharina Ziekenhuis, Department of Obstetrics and Gynecology, Michelangelolaan 2, Eindhoven, The Netherlands.'}, {'ForeName': 'Marchien', 'Initials': 'M', 'LastName': 'Van Baal', 'Affiliation': 'Flevoziekenhuis, Department Obstetrics and Gynecology, Hospitaalweg 1, Almere, The Netherlands.'}, {'ForeName': 'Judith E', 'Initials': 'JE', 'LastName': 'Bosmans', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Wouter J K', 'Initials': 'WJK', 'LastName': 'Hehenkamp', 'Affiliation': 'Amsterdam University Medical Center, Department of Obstetrics and Gynecology, Amsterdam Reproduction and Development, De Boelelaan 1117, Amsterdam, The Netherlands. Electronic address: w.hehenkamp@amsterdamumc.nl.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.06.035'] 1891,32635650,Mind over Matter: Testing the Efficacy of an Online Randomized Controlled Trial to Reduce Distraction from Smartphone Use.,"Evidence suggests a growing call for the prevention of excessive smartphone and social media use and the ensuing distraction that arises affecting academic achievement and productivity. A ten-day online randomized controlled trial with the use of smartphone apps, engaging participants in mindfulness exercises, self-monitoring and mood tracking, was implemented amongst UK university students ( n = 143). Participants were asked to complete online pre- and post-intervention assessments. Results indicated high effect sizes in reduction of smartphone distraction and improvement scores on a number of self-reported secondary psychological outcomes. The intervention was not effective in reducing habitual behaviours, nomophobia, or time spent on social media. Mediation analyses demonstrated that: (i) emotional self-awareness but not mindful attention mediated the relationship between intervention effects and smartphone distraction, and (ii) online vigilance mediated the relationship between smartphone distraction and problematic social media use. The present study provides preliminary evidence of the efficacy of an intervention for decreased smartphone distraction and highlights psychological processes involved in this emergent phenomenon in the smartphone literature. Online interventions may serve as complementary strategies to reduce distraction levels and promote insight into online engagement. More research is required to elucidate the mechanisms of digital distraction and assess its implications in problematic use.",2020,Results indicated high effect sizes in reduction of smartphone distraction and improvement scores on a number of self-reported secondary psychological outcomes.,['UK university students ( n = 143'],"['smartphone apps, engaging participants in mindfulness exercises, self-monitoring and mood tracking', 'Mind over Matter']","['smartphone distraction and improvement scores', 'habitual behaviours, nomophobia, or time spent on social media']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C4517573', 'cui_str': '143'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0026516', 'cui_str': 'Mood'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0150189', 'cui_str': 'Distraction training'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3179065', 'cui_str': 'Social Medium'}]",,0.0449527,Results indicated high effect sizes in reduction of smartphone distraction and improvement scores on a number of self-reported secondary psychological outcomes.,"[{'ForeName': 'Melina A', 'Initials': 'MA', 'LastName': 'Throuvala', 'Affiliation': 'International Gaming Research Unit, Psychology Department, Nottingham Trent University, Nottingham NG1 4FQ, UK.'}, {'ForeName': 'Mark D', 'Initials': 'MD', 'LastName': 'Griffiths', 'Affiliation': 'International Gaming Research Unit, Psychology Department, Nottingham Trent University, Nottingham NG1 4FQ, UK.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Rennoldson', 'Affiliation': 'Psychology Department, Nottingham Trent University, Nottingham NG1 4FQ, UK.'}, {'ForeName': 'Daria J', 'Initials': 'DJ', 'LastName': 'Kuss', 'Affiliation': 'International Gaming Research Unit, Psychology Department, Nottingham Trent University, Nottingham NG1 4FQ, UK.'}]",International journal of environmental research and public health,['10.3390/ijerph17134842'] 1892,32638409,Dietary macronutrient regulation of acyl and desacyl ghrelin concentrations in children with Prader-Willi syndrome (PWS).,"BACKGROUND The effects of dietary macronutrients on orexigenic and anorexigenic hormones in children are poorly understood. OBJECTIVE To explore effects of varying dietary macronutrients on appetite-regulating hormones [acyl ghrelin (AG) and desacyl ghrelin (DAG), glucagon-like peptide 1 (GLP-1), peptide tyrosine tyrosine (PYY) and insulin] in children with PWS and healthy children (HC). DESIGN Randomized, cross-over experiments compared two test diets [high protein-low carbohydrate (HP-LC) and high protein-low fat (HP-LF)] to a STANDARD meal (55% carbohydrate, 30% fat, 15% protein). Experiment 1 included ten children with PWS (median age 6.63 years; BMI z 1.05); experiment 2 had seven HC (median age 12.54 years; BMI z 0.95). Blood samples were collected at baseline and at 60-minute intervals for 4 hours. Independent linear mixed models were adjusted for age, sex and BMI z-score. RESULTS Fasting and post-prandial AG and DAG concentrations are elevated in PWS children; the ratio of AG/DAG is normal. Food consumption reduced AG and DAG concentrations in both PWS and HC. GLP-1 levels were higher in PWS after the HP-LC and HP-LF meals than the STANDARD meal (P = .02-0.04). The fasting proinsulin to insulin ratio (0.08 vs 0.05) was higher in children with PWS (P = .05) than in HC. Average appetite scores in HC declined after all three meals (P = .02) but were lower after the HP-LC and HP-LF meals than the STANDARD meal. CONCLUSION Altered processing of proinsulin and increased GLP-1 secretion in children with PWS after a high protein meal intake might enhance satiety and reduce energy intake.",2020,GLP-1 levels were higher in PWS after the HP-LC and HP-LF meals than the STANDARD meal (p = 0.02- 0.04).,"['children with PWS', 'children with Prader-Willi syndrome (PWS', 'children with PWS and healthy children (HC', 'Experiment 1 included ten children with PWS (median age 6.63y; BMI z 1.05); experiment 2 had seven HC (median age 12.54y; BMI z 0.95']","['varying dietary macronutrients', 'diets [High Protein-Low Carbohydrate (HP-LC) and High Protein-Low Fat (HP-LF', 'dietary macronutrients']","['Fasting and post-prandial AG and DAG concentrations', 'Blood samples', 'GLP-1 levels', 'GLP-1 secretion', 'fasting proinsulin to insulin ratio', 'Average appetite scores in HC', 'AG and DAG concentrations', 'satiety and reduce energy intake', 'appetite-regulating hormones [acyl ghrelin (AG) and desacyl ghrelin (DAG), glucagon-like peptide\xa01 (GLP-1), peptide tyrosine tyrosine (PYY), and insulin']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0032897', 'cui_str': 'Prader-Willi syndrome'}, {'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4068754', 'cui_str': '1.05'}, {'cui': 'C0205453', 'cui_str': '7'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0242970', 'cui_str': 'Low fat diet'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0011967', 'cui_str': '1,2,5,6-Dianhydrogalactitol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0033362', 'cui_str': 'Proinsulin'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0911014', 'cui_str': 'Ghrelin'}, {'cui': 'C0965048', 'cui_str': 'ghrelin, des-n-octanoyl'}, {'cui': 'C0077599', 'cui_str': 'tyrosyltyrosine'}]",10.0,0.035134,GLP-1 levels were higher in PWS after the HP-LC and HP-LF meals than the STANDARD meal (p = 0.02- 0.04).,"[{'ForeName': 'Maha', 'Initials': 'M', 'LastName': 'Alsaif', 'Affiliation': 'Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, AL, Canada.'}, {'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Pakseresht', 'Affiliation': 'Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, AL, Canada.'}, {'ForeName': 'Michelle L', 'Initials': 'ML', 'LastName': 'Mackenzie', 'Affiliation': 'Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, AL, Canada.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Gaylinn', 'Affiliation': 'Division of Endocrinology, Department of Medicine, School of Medicine, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Michael O', 'Initials': 'MO', 'LastName': 'Thorner', 'Affiliation': 'Division of Endocrinology, Department of Medicine, School of Medicine, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Freemark', 'Affiliation': 'Duke Molecular Physiology Institute, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Catherine J', 'Initials': 'CJ', 'LastName': 'Field', 'Affiliation': 'Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, AL, Canada.'}, {'ForeName': 'Carla M', 'Initials': 'CM', 'LastName': 'Prado', 'Affiliation': 'Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, AL, Canada.'}, {'ForeName': 'Andrea M', 'Initials': 'AM', 'LastName': 'Haqq', 'Affiliation': 'Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, AL, Canada.'}]",Clinical endocrinology,['10.1111/cen.14279'] 1893,32639946,A validated survival nomogram for early-onset diffuse gastric cancer.,"This study aimed to establish and independently validate a prognostic nomogram for individual risk prediction in patients with early-onset diffuse gastric cancer (EODGC). Data for 794 patients with EODGC from the SEER database were randomly assigned to training (N=558) and internal validation (N=236) sets, and data for 82 patients from the Renmin Hospital of Wuhan University (RMHWHU) were used as an independent validation cohort. Our LASSO regression analyses of the training set yielded five clinicopathological features (race, AJCC stage, surgery for primary site, chemotherapy and tumor size), which were used to create a survival nomogram. Our survival nomogram achieved better predictive performance than the AJCC staging system, the current standard. Additionally, the calibration curves of the prognostic nomogram revealed good agreement between the predicted survival probabilities and the ground truth values. Indeed, our nomogram, which estimates individualized survival probabilities for patients with EODGC, shows good predictive accuracy and calibration ability for both the SEER and RMHWHU cohorts. These results suggest that a survival nomogram may be better at predicting OS for EODGC patients than the AJCC staging system.",2020,"Additionally, the calibration curves of the prognostic nomogram revealed good agreement between the predicted survival probabilities and the ground truth values.","['82 patients from the Renmin Hospital of Wuhan University (RMHWHU) were used as an independent validation cohort', '794 patients with EODGC from the SEER database', 'early-onset diffuse gastric cancer', 'patients with early-onset diffuse gastric cancer (EODGC']",[],"['survival probabilities', 'individualized survival probabilities']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0242638', 'cui_str': 'Surveillance, Epidemiology, and End Results Program'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}]",[],"[{'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0033204', 'cui_str': 'Probability'}]",794.0,0.0291444,"Additionally, the calibration curves of the prognostic nomogram revealed good agreement between the predicted survival probabilities and the ground truth values.","[{'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Liao', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430061, Hubei Province, China.'}, {'ForeName': 'Xufeng', 'Initials': 'X', 'LastName': 'Guo', 'Affiliation': 'Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430061, Hubei Province, China.'}, {'ForeName': 'Xiaohong', 'Initials': 'X', 'LastName': 'Lu', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430061, Hubei Province, China.'}, {'ForeName': 'Weiguo', 'Initials': 'W', 'LastName': 'Dong', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430061, Hubei Province, China.'}]",Aging,['10.18632/aging.103406'] 1894,32640411,"The experience of trial participation, treatment approaches and perceptions of change among participants with dissociative seizures within the CODES randomized controlled trial: A qualitative study.","BACKGROUND Nested within a large, multicenter randomized controlled trial (RCT) for people with dissociative seizures (DS), the study used purposive sampling to explore participants' experience of participating in an RCT, their experience of DS-specific cognitive behavioral therapy (CBT) and another component of the RCT, Standardized Medical Care (SMC) and their perceptions of and reflections on seizure management and change. METHODS A qualitative study using semistructured interviews was conducted with 30 participants in an RCT (the COgnitive behavioral therapy vs standardized medical care for adults with Dissociative non-Epileptic Seizures (CODES) Trial) investigating the effectiveness of two treatments for DS. Key themes and subthemes were identified using thematic framework analysis (TFA). RESULTS Analysis yielded three overarching themes: taking part in a treatment trial - ""the only thing out there"", the experience of treatment techniques that were perceived to help with seizure management, and reflections on an ""unpredictable recovery"". CONCLUSIONS People with DS are amenable to participating in a psychotherapy RCT and described a largely positive experience. They also described the applicability of aspects of DS-specific CBT and SMC in the management of their DS, received within the confines of the CODES trial. Factors that appeared to account for the variability in response to treatment delivery included individual preferences for the nature of sessions, the nature of therapeutic relationships, readiness to discuss trauma, other aspects of emotional avoidance, and whether therapy provided something new.",2020,"Factors that appeared to account for the variability in response to treatment delivery included individual preferences for the nature of sessions, the nature of therapeutic relationships, readiness to discuss trauma, other aspects of emotional avoidance, and whether therapy provided something new.","['participants with dissociative seizures', 'adults with Dissociative non-Epileptic Seizures (CODES) Trial', '30 participants in an', 'people with dissociative seizures (DS']","['DS-specific cognitive behavioral therapy (CBT) and another component of the RCT, Standardized Medical Care (SMC', 'RCT (the COgnitive behavioral therapy vs standardized medical care']",[],"[{'cui': 'C0349245', 'cui_str': 'Dissociative convulsions'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3495874', 'cui_str': 'Non-Epileptic Seizures'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0349245', 'cui_str': 'Dissociative convulsions'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0496675', 'cui_str': 'Medical care'}]",[],30.0,0.0596229,"Factors that appeared to account for the variability in response to treatment delivery included individual preferences for the nature of sessions, the nature of therapeutic relationships, readiness to discuss trauma, other aspects of emotional avoidance, and whether therapy provided something new.","[{'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Read', 'Affiliation': ""King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK.""}, {'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'Jordan', 'Affiliation': ""King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK.""}, {'ForeName': 'Iain', 'Initials': 'I', 'LastName': 'Perdue', 'Affiliation': ""King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK.""}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Purnell', 'Affiliation': ""King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK.""}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Murray', 'Affiliation': ""King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK.""}, {'ForeName': 'Trudie', 'Initials': 'T', 'LastName': 'Chalder', 'Affiliation': ""King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK.""}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Reuber', 'Affiliation': 'Academic Neurology Unit, University of Sheffield, Royal Hallamshire Hospital, Sheffield S10 2JF, UK.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Stone', 'Affiliation': 'Department of Clinical Neuroscience, Centre for Clinical Brain Sciences, University of Edinburgh, UK.'}, {'ForeName': 'Laura H', 'Initials': 'LH', 'LastName': 'Goldstein', 'Affiliation': ""King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK. Electronic address: laura.goldstein@kcl.ac.uk.""}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2020.107230'] 1895,32640554,Psychological and Physiological Responses in Patients with Generalized Anxiety Disorder: The Use of Acute Exercise and Virtual Reality Environment.,"Virtual exercise therapy is considered a useful method by which to encourage patients with generalized anxiety disorder (GAD) to engage in aerobic exercise in order to reduce stress. This study was intended to explore the psychological and physiological responses of patients with GAD after cycling in a virtual environment containing natural images. Seventy-seven participants with GAD were recruited in the present study and randomly assigned to a virtual nature (VN) or a virtual abstract painting (VAP) group. Their electroencephalogram alpha activity, perceived stress, and levels of restorative quality and satisfaction were assessed at baseline and after an acute bout of 20 min of moderate-intensity aerobic exercise. The results showed that both the VN and VAP groups showed significantly higher alpha activity post-exercise as compared to pre-exercise. The VN group relative to the VAP group exhibited higher levels of stress-relief, restorative quality, and personal satisfaction. These findings imply that a virtual exercise environment is an effective way to induce a relaxing effect in patients with GAD. However, they exhibited more positive psychological responses when exercising in such an environment with natural landscapes.",2020,"The VN group relative to the VAP group exhibited higher levels of stress-relief, restorative quality, and personal satisfaction.","['Seventy-seven participants with GAD', 'Patients with Generalized Anxiety Disorder', 'patients with GAD', 'patients with GAD after cycling in a virtual environment containing natural images', 'patients with generalized anxiety disorder (GAD']","['VAP', 'virtual nature (VN) or a virtual abstract painting (VAP', 'Acute Exercise and Virtual Reality Environment', 'Virtual exercise therapy', 'virtual exercise environment']","['alpha activity post-exercise', 'Psychological and Physiological Responses', 'positive psychological responses', 'stress-relief, restorative quality, and personal satisfaction', 'electroencephalogram alpha activity, perceived stress, and levels of restorative quality and satisfaction']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0205296', 'cui_str': 'Natural'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}]","[{'cui': 'C0000857', 'cui_str': 'Abstracting as Topic'}, {'cui': 'C0030208', 'cui_str': 'Paintings'}, {'cui': 'C0349590', 'cui_str': 'Nature'}, {'cui': 'C4279937', 'cui_str': 'Acute Exercise'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0031206', 'cui_str': 'Personal wellbeing status'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",77.0,0.0381468,"The VN group relative to the VAP group exhibited higher levels of stress-relief, restorative quality, and personal satisfaction.","[{'ForeName': 'Tsai-Chiao', 'Initials': 'TC', 'LastName': 'Wang', 'Affiliation': 'Institute of Physical Education, Health & Leisure Studies, National Cheng Kung University, Tainan 701, Taiwan.'}, {'ForeName': 'Cindy Hui-Ping', 'Initials': 'CH', 'LastName': 'Sit', 'Affiliation': 'Department of Sports Science and Physical Education, The Chinese University of Hong Kong, Hong Kong.'}, {'ForeName': 'Ta-Wei', 'Initials': 'TW', 'LastName': 'Tang', 'Affiliation': 'Department of Leisure and Recreation Management, Asia University, Taichung 413, Taiwan.'}, {'ForeName': 'Chia-Liang', 'Initials': 'CL', 'LastName': 'Tsai', 'Affiliation': 'Institute of Physical Education, Health & Leisure Studies, National Cheng Kung University, Tainan 701, Taiwan.'}]",International journal of environmental research and public health,['10.3390/ijerph17134855'] 1896,32640602,"Efficacy of a Six-Week Dispersed Wingate-Cycle Training Protocol on Peak Aerobic Power, Leg Strength, Insulin Sensitivity, Blood Lipids and Quality of Life in Healthy Adults.","BACKGROUND The aim of this study was to evaluate the efficacy of a six-week dispersed Wingate Anaerobic test (WAnT) cycle exercise training protocol on peak aerobic power (VO 2peak ), isokinetic leg strength, insulin sensitivity, lipid profile and quality of life, in healthy adults. Methods : We conducted a match-controlled cohort trial and participants were assigned to either the training (intervention, INT, N = 16) or non-training (control, CON, N = 17) group. INT performed 30-s WAnT bouts three times a day in the morning, afternoon and evening with each bout separated by ~4 h of rest, performed for 3 days a week for 6 weeks. Criterion measures of peak oxygen uptake (VO 2peak ), leg strength, insulin markers such as homeostatic model assessment (HOMA) and quantitative insulin-sensitivity check index (QUICKI), blood lipids profile and health-related quality of life (HRQL) survey were assessed before and after 6 weeks in both groups. Results : Absolute VO 2peak increased by 8.3 ± 7.0% ( p < 0.001) after INT vs . 0.9 ± 6.1% in CON ( p = 0.41) group. Maximal voluntary contraction at 30°·s -1 of the dominant lower-limb flexors in INT increased significantly post-training ( p = 0.03). There were no changes in the INT individuals' other cardiorespiratory markers, HOMA, QUICKI, blood lipids, and HRQL measures (all p > 0.05) between pre- and post-training; but importantly, no differences were observed between INT and CON groups (all p > 0.05). Conclusion s : The results indicate that 6 weeks of dispersed sprint cycle training increased cardiorespiratory fitness and dynamic leg strength but had minimal impact on insulin sensitivity, blood lipids and quality of life in the exercising individuals.",2020,"There were no changes in the INT individuals' other cardiorespiratory markers, HOMA, QUICKI, blood lipids, and HRQL measures (all p > 0.05) between pre- and post-training; but importantly, no differences were observed between INT and CON groups (all p > 0.05). ","['Healthy Adults', 'healthy adults']","['Six-Week Dispersed Wingate-Cycle Training Protocol', 'training (intervention, INT, N = 16) or non-training (control, CON, N = 17) group', 'dispersed sprint cycle training', 'CON', 'six-week dispersed Wingate Anaerobic test (WAnT) cycle exercise training protocol']","['Peak Aerobic Power, Leg Strength, Insulin Sensitivity, Blood Lipids and Quality of Life', 'peak oxygen uptake (VO 2peak ), leg strength, insulin markers such as homeostatic model assessment (HOMA) and quantitative insulin-sensitivity check index (QUICKI), blood lipids profile and health-related quality of life (HRQL) survey', 'cardiorespiratory fitness and dynamic leg strength', 'peak aerobic power (VO 2peak ), isokinetic leg strength, insulin sensitivity, lipid profile and quality of life', 'cardiorespiratory markers, HOMA, QUICKI, blood lipids, and HRQL measures', 'insulin sensitivity, blood lipids and quality of life', 'Absolute VO 2peak', 'Maximal voluntary contraction']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332624', 'cui_str': 'Dispersion'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C1283174', 'cui_str': 'Checking - action'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}]",,0.019415,"There were no changes in the INT individuals' other cardiorespiratory markers, HOMA, QUICKI, blood lipids, and HRQL measures (all p > 0.05) between pre- and post-training; but importantly, no differences were observed between INT and CON groups (all p > 0.05). ","[{'ForeName': 'Chun Hou', 'Initials': 'CH', 'LastName': 'Wun', 'Affiliation': 'Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.'}, {'ForeName': 'Mandy Jiajia', 'Initials': 'MJ', 'LastName': 'Zhang', 'Affiliation': 'Changi Sports Medicine Centre, Changi General Hospital, Singapore 529889, Singapore.'}, {'ForeName': 'Boon Hor', 'Initials': 'BH', 'LastName': 'Ho', 'Affiliation': 'Changi Sports Medicine Centre, Changi General Hospital, Singapore 529889, Singapore.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'McGeough', 'Affiliation': 'ActiveSG, Active Health Division, Sport Singapore, Singapore 397630, Singapore.'}, {'ForeName': 'Frankie', 'Initials': 'F', 'LastName': 'Tan', 'Affiliation': 'Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.'}, {'ForeName': 'Abdul Rashid', 'Initials': 'AR', 'LastName': 'Aziz', 'Affiliation': 'Sport Science and Sport Medicine, Singapore Sport Institute, Sport Singapore, Singapore 397630, Singapore.'}]",International journal of environmental research and public health,['10.3390/ijerph17134860'] 1897,32485656,Impulsiveness as a moderator of amphetamine treatment response for cocaine use disorder among ADHD patients.,"BACKGROUND Amphetamines are a first-line treatment for ADHD and have shown promise for the treatment of cocaine use disorder (CUD), both alone and with comorbid ADHD. Impulsiveness is a key aspect of both ADHD and substance use disorders. We sought to understand the role of baseline impulsiveness in the treatment of comorbid CUD and ADHD. METHODS In a post hoc analysis (N = 76) of a 14-week, double-blind, randomized, placebo-controlled trial of mixed amphetamine salts-extended release (MAS-ER) for comorbid ADHD and CUD, we examined the relationship between treatment response and participants' baseline Barratt Impulsiveness Scale (BIS-11) score by comparing those with scores below versus above the median. In the original trial, participants received daily 60 mg MAS-ER, 80 mg MAS-ER, or placebo, in conjunction with cognitive behavioral therapy. RESULTS The odds of a cocaine-abstinent week over time were significantly greater in the high BIS group compared to the low BIS group, both when missing data was treated as missing (p = .0155; OR = 1.23, 95% CI: 1.13, 1.35 versus OR = 1.04, 95% CI: 0.95, 1.15) and when missing data was treated as cocaine-positive (p = .003; OR = 1.15, 95% CI: 1.06, 1.24 versus OR = 0.96, 95% CI: 0.88, 1.05). CONCLUSIONS The results show an association between higher within-group trait impulsiveness, as measured by the BIS-11, and response to MAS-ER for CUD in a cohort with comorbid ADHD. This result further demonstrates that impulsiveness is an important factor when considering treatment options for patients with CUD and that higher baseline impulsiveness may predict response to treatment with psychostimulants for CUD.",2020,"The odds of a cocaine-abstinent week over time were significantly greater in the high BIS group compared to the low BIS group, both when missing data was treated as missing (p = .0155; OR = 1.23, 95% CI: 1.13, 1.35 versus OR = 1.04, 95% CI: 0.95, 1.15) and when missing data was treated as cocaine-positive (p = .003; OR = 1.15, 95% CI: 1.06, 1.24 versus OR = 0.96, 95% CI: 0.88, 1.05). ","['ADHD patients', 'patients with CUD']","['mixed amphetamine salts-extended release (MAS-ER', 'daily 60\u2009mg MAS-ER, 80\u2009mg\u2009MAS-ER, or placebo, in conjunction with cognitive behavioral therapy', 'amphetamine', 'placebo']",['baseline Barratt Impulsiveness Scale (BIS-11) score'],"[{'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0002658', 'cui_str': 'Amphetamine'}, {'cui': 'C0036140', 'cui_str': 'Salts'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0564567', 'cui_str': 'Impulsive character'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0053723', 'cui_str': 'bis(cyclohexylammonium)'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.145481,"The odds of a cocaine-abstinent week over time were significantly greater in the high BIS group compared to the low BIS group, both when missing data was treated as missing (p = .0155; OR = 1.23, 95% CI: 1.13, 1.35 versus OR = 1.04, 95% CI: 0.95, 1.15) and when missing data was treated as cocaine-positive (p = .003; OR = 1.15, 95% CI: 1.06, 1.24 versus OR = 0.96, 95% CI: 0.88, 1.05). ","[{'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'Blevins', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, United States; Division on Substance Use Disorders, New York State Psychiatric Institute, New York, NY, United States. Electronic address: derek.blevins@nyspi.columbia.edu.'}, {'ForeName': 'C Jean', 'Initials': 'CJ', 'LastName': 'Choi', 'Affiliation': 'Mental Health Data Science, New York State Psychiatric Institute, New York, NY, United States.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Pavlicova', 'Affiliation': 'Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY, United States.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Martinez', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, United States; Division on Substance Use Disorders, New York State Psychiatric Institute, New York, NY, United States.'}, {'ForeName': 'John J', 'Initials': 'JJ', 'LastName': 'Mariani', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, United States; Division on Substance Use Disorders, New York State Psychiatric Institute, New York, NY, United States.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Grabowski', 'Affiliation': 'Department of Psychiatry, University of Minnesota Twin Cities, Minneapolis, MN, United States.'}, {'ForeName': 'Frances R', 'Initials': 'FR', 'LastName': 'Levin', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, United States; Division on Substance Use Disorders, New York State Psychiatric Institute, New York, NY, United States.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108082'] 1898,32485734,Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.,"CONTEXT Control of multiple cardiovascular (CV) risk factors reduces CV events in individuals with type 2 diabetes. OBJECTIVE To investigate this association in a contemporary clinical trial population, including how CV risk factor control affects the CV benefits of empagliflozin, a sodium-glucose cotransporter-2 inhibitor. DESIGN Post hoc analysis. SETTING Randomized CV outcome trial (EMPA-REG OUTCOME). PARTICIPANTS Type 2 diabetes patients with established CV disease. INTERVENTION Empagliflozin or placebo. MAIN OUTCOME MEASURES Risk of CV outcomes-including the treatment effect of empagliflozin-by achieving 7 goals for CV risk factor control at baseline: (1) glycated hemoglobin <7.5%, (2) low-density lipoprotein cholesterol <100 mg/dL or statin use, (3) systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg, (4) pharmacological renin-angiotensin-aldosterone system blockade, (5) normoalbuminuria, (6) aspirin use, (7) nonsmoking. RESULTS In the placebo group, the hazard ratio (HR) for CV death was 4.00 (95% CI, 2.26-7.11) and 2.48 (95% CI, 1.52-4.06) for patients achieving only 0-3 or 4-5 risk factor goals at baseline, respectively, compared with those achieving 6-7 goals. Participants achieving 0-3 or 4-5 goals also had increased risk for the composite outcome of hospitalization for heart failure or CV death (excluding fatal stroke) (HR 2.89 [1.82-4.57] and 1.90 [1.31-2.78], respectively) and 3-point major adverse CV events (HR 2.21 [1.53-3.19] and 1.42 [1.06-1.89]). Empagliflozin significantly reduced these outcomes across all risk factor control categories (P > 0.05 for treatment-by-subgroup interactions). CONCLUSIONS Cardiovascular risk in EMPA-REG OUTCOME was inversely associated with baseline CV risk factor control. Empagliflozin's cardioprotective effect was consistent regardless of multiple baseline risk factor control.",2020,"Participants achieving 0-3 or 4-5 goals also had increased risk for the composite outcome of hospitalization for heart failure or CV death (excluding fatal stroke) (HR 2.89 [1.82-4.57] and 1.90 [1.31-2.78], respectively) and 3-point major adverse CV events (HR 2.21 [1.53-3.19] and 1.42 [1.06-1.89]).",['individuals with type 2 diabetes (T2D'],"['empagliflozin', 'Empagliflozin or placebo', 'Empagliflozin', 'EMPA', 'placebo']","['hazard ratio (HR) for CV death', 'risk for the composite outcome of hospitalization for heart failure or CV death (excluding fatal stroke', 'risk factor control categories', 'baseline CV risk factor control', '3-point major adverse CV events', 'Risk of CV outcomes - including treatment effect of empagliflozin - by achievement of seven goals for CV risk factor control at baseline: glycated hemoglobin <7.5%, low-density lipoprotein cholesterol <100 mg/dL or statin use, systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg, pharmacological renin-angiotensin-aldosterone system blockade, normoalbuminuria, aspirin use, non-smoking.\nRESULTS']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0439087', 'cui_str': '<90'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0086907', 'cui_str': 'Renin-Angiotensin-Aldosterone System'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0678226', 'cui_str': 'Due to'}]",,0.196854,"Participants achieving 0-3 or 4-5 goals also had increased risk for the composite outcome of hospitalization for heart failure or CV death (excluding fatal stroke) (HR 2.89 [1.82-4.57] and 1.90 [1.31-2.78], respectively) and 3-point major adverse CV events (HR 2.21 [1.53-3.19] and 1.42 [1.06-1.89]).","[{'ForeName': 'Silvio E', 'Initials': 'SE', 'LastName': 'Inzucchi', 'Affiliation': 'Section of Endocrinology, Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Kamlesh', 'Initials': 'K', 'LastName': 'Khunti', 'Affiliation': 'Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Fitchett', 'Affiliation': ""Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Wanner', 'Affiliation': 'Division of Nephrology, Würzburg University Clinic, Würzburg, Germany.'}, {'ForeName': 'Michaela', 'Initials': 'M', 'LastName': 'Mattheus', 'Affiliation': 'Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany.'}, {'ForeName': 'Jyothis T', 'Initials': 'JT', 'LastName': 'George', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Anne Pernille', 'Initials': 'AP', 'LastName': 'Ofstad', 'Affiliation': 'Boehringer Ingelheim Norway KS, Asker, Norway.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Zinman', 'Affiliation': 'Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgaa321'] 1899,32641966,A Randomized Clinical Trial of Elemental Zinc Add-on Therapy on Clinical Outcomes of Patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP).,"Recent studies suggest a relationship between zinc deficiency and inflammation. In the present study, we studied the effect of oral zinc supplementation on clinical improvement of chronic rhinosinusitis with nasal polyposis. In this single-blind randomized controlled trial, 44 patients with chronic rhinosinusitis with polyposis referring to ENT clinic of the Loghman Hakim hospital during 2013-2014 were randomly allocated in two groups. The treatment group (n = 28) was treated with a four-drug fixed-dose regimen (FD_FDR) consisting of oral dexamethasone (0.02 mg/kg), fluticasone nasal spray, fexophenadine 60 mg daily, montelukast 10 mg daily plus 220mg zinc sulfate capsules containing 55 mg elemental zinc, b.d., and the control group (n = 16) received the FD_FDR without supplemental zinc, for six weeks. After sixth week, two groups were compared regarding clinical outcomes based on theSNOT20 (Sinonasal outcome test) questionnaire, the general health questionnaire (SF12), the Lund-Mackay, and the Lund-Kennedy scoring systems. In the treatment group, serum zinc levels were significantly increased compared to those at the baseline (1.33 fold-increase; p = 0.0002). Within groups analysis revealed a significant reduction ( p < 0.01) in LM and LK in both treatment (55% LM; 50% LK) and control groups (45% LM; 53% LK). Incontrast, between groups analysis revealed no significant differences in the LM and LK. The treatment group showed a mild superiority in general health improvement compared to that of the control group. Add-on therapy with supplemental zinc sulfate was not associated with significant improvement in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). The advantage of zinc supplementation on the general health improvement of the patients with CRSwNP requires further assessments.",2019,Within groups analysis revealed a significant reduction ( p < 0.01) in LM and LK in both treatment (55% LM; 50% LK) and control groups (45% LM; 53% LK).,"['chronic rhinosinusitis with nasal polyposis', 'Patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP', 'patients with chronic rhinosinusitis with nasal polyposis (CRSwNP', '44 patients with chronic rhinosinusitis with polyposis referring to ENT clinic of the Loghman Hakim hospital during 2013-2014']","['FD_FDR without supplemental zinc', 'supplemental zinc sulfate', 'oral zinc supplementation', 'zinc supplementation', 'oral dexamethasone', 'fluticasone nasal spray, fexophenadine 60 mg daily, montelukast 10 mg daily plus 220mg zinc sulfate capsules containing 55 mg elemental zinc', 'Elemental Zinc Add-on Therapy']","['general health improvement', 'serum zinc levels', 'clinical outcomes based on theSNOT20 (Sinonasal outcome test) questionnaire, the general health questionnaire (SF12), the Lund-Mackay, and the Lund-Kennedy scoring systems', 'LM and LK']","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0027430', 'cui_str': 'Polyp of nasal cavity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0334108', 'cui_str': 'Multiple polyps'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0150934', 'cui_str': 'Ear, nose and throat structure'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0078794', 'cui_str': 'Zinc Sulfate'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C4524022', 'cui_str': 'Zinc supplementation'}, {'cui': 'C0360528', 'cui_str': 'Dexamethasone-containing product in oral dose form'}, {'cui': 'C0360577', 'cui_str': 'Fluticasone-containing product in nasal dose form'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1145935', 'cui_str': 'montelukast 10 MG'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C1318315', 'cui_str': 'Serum zinc measurement'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C5197689', 'cui_str': 'Sinonasal Outcome Test'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451182', 'cui_str': 'General health questionnaire'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]",44.0,0.132435,Within groups analysis revealed a significant reduction ( p < 0.01) in LM and LK in both treatment (55% LM; 50% LK) and control groups (45% LM; 53% LK).,"[{'ForeName': 'Nader', 'Initials': 'N', 'LastName': 'Akbari Dilmaghani', 'Affiliation': 'Department of Otolaryngology, Head and Neck Surgery, Loghman Hakim Educational Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Nadereh', 'Initials': 'N', 'LastName': 'Alani', 'Affiliation': 'Department of Otolaryngology, Head and Neck Surgery, Loghman Hakim Educational Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Sepideh', 'Initials': 'S', 'LastName': 'Fazeli', 'Affiliation': 'Department of Otolaryngology, Head and Neck Surgery, Loghman Hakim Educational Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}]",Iranian journal of pharmaceutical research : IJPR,['10.22037/ijpr.2019.1100767'] 1900,32641967,"Effect of a Natural Eye Drop, Made of Plantago Ovata Mucilage on Improvement of Dry Eye Symptoms: A Randomized, Double-blind Clinical Trial.","Dry eye disease is a relatively common eye disorder associated with decrease in quality of life. In this study, efficacy of an eye drop of Plantago ovata mucilage on symptoms of dry eye disease was evaluated. In a randomized, double-blind, placebo-controlled clinical trial, sixty dry eye patients with ocular symptoms and total Ocular Surface Disease Index (OSDI) score of ≥12 were randomly assigned to receive either a natural ophthalmic drop, made of Plantago ovata mucilage or placebo 4 times a day for 6 weeks. The patients were evaluated at pretreatment (baseline), weeks 4 and 6 post-treatment. The evaluation of the efficacy and safety were conducted based on the OSDI questionnaire, the noninvasive tear film break-up time (NI-BUT) with keratograph, the Schirmer test without anesthesia, and the osmolarity test, as well as by monitoring possible adverse events. After 6 weeks, within group analysis showed a significant improvement in total OSDI score ( p < 0.001). In addition, between group comparison revealed a significant improvement in the OSDI score of the intervention group ( p < 0.001). Although, NI-BUT was significantly improved in the Plantago ovata group ( p = 0.004), however no statistically significant difference was observed in between group analysis. There were no significant differences between two groups, or significant changes within the groups in the Schirmer test without anesthesia and the osmolarity test. No serious adverse events were reported. In conclusion, P. ovata mucilage is a natural, inexpensiveness, and safe lubricant polymer that could have beneficial ocular effects on subjective symptoms of the patients with dry eye disease.",2019,"There were no significant differences between two groups, or significant changes within the groups in the Schirmer test without anesthesia and the osmolarity test.","['patients with dry eye disease', 'sixty dry eye patients with ocular symptoms and total Ocular Surface Disease Index (OSDI) score of ≥12']","['Natural Eye Drop, Made of Plantago Ovata Mucilage', 'natural ophthalmic drop, made of Plantago ovata mucilage or placebo', 'placebo']","['quality of life', 'total OSDI score', 'NI-BUT', 'OSDI score', 'efficacy and safety', 'serious adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013238', 'cui_str': 'Dry Eye Disease'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1557335', 'cui_str': 'Ocular surface disease'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0205296', 'cui_str': 'Natural'}, {'cui': 'C0015399', 'cui_str': 'Eye drops'}, {'cui': 'C1209192', 'cui_str': 'Plantago ovata'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",60.0,0.268929,"There were no significant differences between two groups, or significant changes within the groups in the Schirmer test without anesthesia and the osmolarity test.","[{'ForeName': 'Neda', 'Initials': 'N', 'LastName': 'Haji-Ali-Nili', 'Affiliation': 'Traditional Medicine Clinical Trial Research Center, Shahed University, Tehran, Iran.'}, {'ForeName': 'Fariba', 'Initials': 'F', 'LastName': 'Khoshzaban', 'Affiliation': 'Traditional Medicine Clinical Trial Research Center, Shahed University, Tehran, Iran.'}, {'ForeName': 'Mehrdad', 'Initials': 'M', 'LastName': 'Karimi', 'Affiliation': 'Department of Iranian Traditional Medicine, School of Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Roja', 'Initials': 'R', 'LastName': 'Roja', 'Affiliation': 'Department of Traditional Pharmacy, School of Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Ashrafi', 'Affiliation': 'Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Ghaffari', 'Affiliation': 'Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ghobadi', 'Affiliation': 'Department of Traditional Pharmacy, School of Traditional Medicine, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Jabarvand Behrouz', 'Affiliation': 'Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}]",Iranian journal of pharmaceutical research : IJPR,['10.22037/ijpr.2019.1100717'] 1901,32641968,Comparative Study of the Effects of Chamomile ( Matricaria Chamomilla L.) and Cabergoline on Idiopathic Hyperprolactinemia: A Pilot Randomized Controlled Trial.,"Chamomile is a fascinating plant quoted in several traditional medicine texts, which has broad-spectrum pharmacological activity and medicinal uses. The aim of this study was to assess the efficacy of chamomile syrup in reducing serum prolactin in women with idiopathic hyperprolactinemia. The study was a randomized, controlled clinical trial that was conducted on 56 women with idiopathic hyperprolactinemia for a study period of four weeks. Patients were randomly enrolled in two parallel arms and were treated by chamomile syrup at a dose of 5 mL twice daily or cabergoline tablet orally at a dose of 0.25 mg twice weekly. Serum prolactin levels were measured at baseline and the end of the 4-week study period. Any report of adverse events was also recorded. Results revealed that within the cabergoline group the reduction in the mean prolactin level was significantly greater than that of the chamomile group ( p <0.0001). It was also found that decline in the mean prolactin level was statistically significant within the chamomile group ( p <0.0001). Chamomile syrup seems to be effective on serum prolactin reduction in women with idiopathic hyperprolactinemia. However, studies with a larger sample size and for a longer follow-up period are recommended.",2019,Results revealed that within the cabergoline group the reduction in the mean prolactin level was significantly greater than that of the chamomile group ( p <0.0001).,"['Idiopathic Hyperprolactinemia', 'women with idiopathic hyperprolactinemia', '56 women with idiopathic hyperprolactinemia for a study period of four weeks']","['chamomile syrup', 'Chamomile ( Matricaria Chamomilla L.) and Cabergoline', 'cabergoline tablet', 'cabergoline']","['serum prolactin reduction', 'adverse events', 'mean prolactin level', 'Serum prolactin levels', 'serum prolactin']","[{'cui': 'C0271552', 'cui_str': 'Idiopathic hyperprolactinemia'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0439963', 'cui_str': 'Chamomile extract'}, {'cui': 'C0458173', 'cui_str': 'Syrup'}, {'cui': 'C0939806', 'cui_str': 'Matricaria recutita extract'}, {'cui': 'C0107994', 'cui_str': 'cabergoline'}, {'cui': 'C1245215', 'cui_str': 'cabergoline Oral Tablet'}]","[{'cui': 'C1277972', 'cui_str': 'Serum prolactin measurement'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0033371', 'cui_str': 'Prolactin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",56.0,0.043982,Results revealed that within the cabergoline group the reduction in the mean prolactin level was significantly greater than that of the chamomile group ( p <0.0001).,"[{'ForeName': 'Marya', 'Initials': 'M', 'LastName': 'Kabiri', 'Affiliation': 'School of Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Kamalinejad', 'Affiliation': 'School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Soodabeh', 'Initials': 'S', 'LastName': 'Bioos', 'Affiliation': 'School of Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mamak', 'Initials': 'M', 'LastName': 'Shariat', 'Affiliation': 'Institute of Family Health, Maternal, Fetal and Neonatal Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Farnaz', 'Initials': 'F', 'LastName': 'Sohrabvand', 'Affiliation': 'Vali-e-Asr Hospital, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.'}]",Iranian journal of pharmaceutical research : IJPR,['10.22037/ijpr.2019.1100758'] 1902,32641970,A Comparison Study of Efficacy and Safety of a Biosimilar Form of Intramuscular Βeta-interferon I-a Versus the Reference Product: A Randomized Controlled Clinical Trial in Iran.,"We compared the efficacy and safety of a biosimilar form of beta-interferon-1a (Actovex) versus the reference product in the treatment of relapsing remitting multiple sclerosis (RRMS). In a double blind, randomized phase 3 clinical trial, we evaluated 138 patients with RRMS that were allocated to receive the biosimilar medication and the reference treatment (30 μg intramuscular, weekly for one year). We investigated changes in EDSS, relapse rate and MRI changes within one year. In sixty-nine patients who were allocated to each arm and analyzed mean age and its standard deviation was 32.4 ± 8.8 and 31.5 ± 8 for the biosimilar medication and the reference arm respectively. One-year follow-up revealed a mean difference of 0.084 in EDSS (95% CI: 0.069-0.237) between the two groups in favor of the biosimilar medication. This value did not exceed the predefined non-inferiority margin of 0.1. There were no statistically significant differences in relapse rate and systemic and local adverse events of the two groups. The results show that the biosimilar interferon 1-a is non-inferior to the reference product in terms of efficacy while it demonstrates comparable safety. In conclusion the biosimilar interferon 1-a can be considered as an effective and safe alternative to the reference product due to lower cost and more availability.",2019,The results show that the biosimilar interferon 1-a is non-inferior to the reference product in terms of efficacy while it demonstrates comparable safety.,"['relapsing remitting multiple sclerosis (RRMS', 'In sixty-nine patients who were allocated to each arm and analyzed mean age and its standard deviation was 32.4 ± 8.8 and 31.5 ± 8 for the biosimilar medication and the reference arm respectively', '138 patients with RRMS']","['Biosimilar Form of Intramuscular Βeta-interferon I', 'biosimilar medication', 'biosimilar form of beta-interferon-1a (Actovex']","['efficacy and safety', 'relapse rate and systemic and local adverse events', 'EDSS, relapse rate and MRI changes']","[{'cui': 'C0751967', 'cui_str': 'Relapsing remitting multiple sclerosis'}, {'cui': 'C0450388', 'cui_str': '69'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C4517882', 'cui_str': '8.8'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C4045974', 'cui_str': 'Biosimilars'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0015980', 'cui_str': 'Interferon-beta'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",138.0,0.0550926,The results show that the biosimilar interferon 1-a is non-inferior to the reference product in terms of efficacy while it demonstrates comparable safety.,"[{'ForeName': 'Seyed Massood', 'Initials': 'SM', 'LastName': 'Nabavi', 'Affiliation': 'Department of Brain and Cognitive Sciences, Royan Institute for Stem Cell Biology and Technology, Tehran, Iran.'}, {'ForeName': 'Roya', 'Initials': 'R', 'LastName': 'Abolfazli', 'Affiliation': 'Department of Neurology, Amir Alam Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Etemadrezaei', 'Affiliation': 'Actoverco Pharmaceuticals, Tehran, Iran.'}, {'ForeName': 'Hamed', 'Initials': 'H', 'LastName': 'Hosseini', 'Affiliation': 'Clinical Trial Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Nahid', 'Initials': 'N', 'LastName': 'Moradi', 'Affiliation': 'Shefa Neuroscience Research Center, Tehran, Iran.'}, {'ForeName': 'Sanaz', 'Initials': 'S', 'LastName': 'Shahriari', 'Affiliation': 'Actoverco Pharmaceuticals, Tehran, Iran.'}, {'ForeName': 'Baharak', 'Initials': 'B', 'LastName': 'Mehdipour', 'Affiliation': 'Actoverco Pharmaceuticals, Tehran, Iran.'}, {'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Shekarchi', 'Affiliation': 'Department of Radiology, School of Medicine, Aja University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Akbar', 'Initials': 'A', 'LastName': 'Soltanzadeh', 'Affiliation': 'Department of Neurology, Faculty of Medical, Tehran University of Medical Sciences, Tehran, Iran.'}]",Iranian journal of pharmaceutical research : IJPR,['10.22037/ijpr.2019.14503.12441'] 1903,32684807,Efficacy of Albendazole-Pyrantel Pamoate Compared to Albendazole Alone for Trichuris trichiura Infection in Children: A Double Blind Randomised Controlled Trial.,"Background Soil transmitted helminths (STH) are intestinal nematodes and constitute one of the most neglected tropical diseases to exist. Objective : This study determined the efficacy of albendazole-pyrantel pamoate compared to albendazole in 8-12 years old children with Trichuris trichiura infection. Methods A randomised controlled trial was conducted between October 2017 and February 2018 on participants whose stool examinations confirmed the presence of Trichuris trichiura infection. The subjects were randomised into two groups. The statistical analysis used Chi-square test. Results There were 392 of 600 children at five public elementary schools in Bangli and Bali and were infected with Trichuris trichiura . The cure rate of Trichuris trichiura infection seven days following treatment was lower with the combination of albendazole and pyrantel pamoate compared to that of albendazole. The egg reduction rate of Trichuris trichiura infection was lower with the combination of albendazole and pyrantel pamoate compared to albendazole. Conclusion The study indicated that a combination of albendazole and pyrantel pamoate does not improve cure rate or egg reduction rate in 8-12 years old children with Trichuris trichiura infection.",2020,The cure rate of Trichuris trichiura infection seven days following treatment was lower with the combination of albendazole and pyrantel pamoate compared to that of albendazole.,"['8-12 years old children with Trichuris trichiura infection', 'October 2017 and February 2018 on participants whose stool examinations confirmed the presence of Trichuris trichiura infection', 'Trichuris trichiura Infection in Children', '600 children at five public elementary schools in Bangli and Bali and were infected with Trichuris trichiura ']","['albendazole', 'albendazole-pyrantel pamoate', 'Albendazole-Pyrantel Pamoate', 'albendazole and pyrantel pamoate', 'Albendazole Alone']","['cure rate', 'cure rate or egg reduction rate', 'egg reduction rate of Trichuris trichiura infection']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0040954', 'cui_str': 'Infection by Trichuris trichiura'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0454738', 'cui_str': 'Bali'}, {'cui': 'C0040913', 'cui_str': 'Trichuris trichiura'}]","[{'cui': 'C0001911', 'cui_str': 'Albendazole'}, {'cui': 'C0034237', 'cui_str': 'Pyrantel pamoate'}]","[{'cui': 'C0013710', 'cui_str': 'Eggs (edible)'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0040954', 'cui_str': 'Infection by Trichuris trichiura'}]",,0.11064,The cure rate of Trichuris trichiura infection seven days following treatment was lower with the combination of albendazole and pyrantel pamoate compared to that of albendazole.,"[{'ForeName': 'Eva Jacomina Jemima', 'Initials': 'EJJ', 'LastName': 'Sapulete', 'Affiliation': 'Department of Child Health-Medical School of Udayana University and Sanglah Hospital Denpasar, Bali, Indonesia.'}, {'ForeName': 'I Made G', 'Initials': 'IMG', 'LastName': 'de Dwi Lingga Utama', 'Affiliation': 'Department of Child Health-Medical School of Udayana University and Sanglah Hospital Denpasar, Bali, Indonesia.'}, {'ForeName': 'I Gusti Ngurah', 'Initials': 'IGN', 'LastName': 'Sanjaya Putra', 'Affiliation': 'Department of Child Health-Medical School of Udayana University and Sanglah Hospital Denpasar, Bali, Indonesia.'}, {'ForeName': 'Dyah', 'Initials': 'D', 'LastName': 'Kanya Wati', 'Affiliation': 'Department of Child Health-Medical School of Udayana University and Sanglah Hospital Denpasar, Bali, Indonesia.'}, {'ForeName': 'I Made', 'Initials': 'IM', 'LastName': 'Arimbawa', 'Affiliation': 'Department of Child Health-Medical School of Udayana University and Sanglah Hospital Denpasar, Bali, Indonesia.'}, {'ForeName': 'I Wayan', 'Initials': 'IW', 'LastName': 'Gustawan', 'Affiliation': 'Department of Child Health-Medical School of Udayana University and Sanglah Hospital Denpasar, Bali, Indonesia.'}]",The Malaysian journal of medical sciences : MJMS,['10.21315/mjms2020.27.3.7'] 1904,32684809,Effectiveness of an Antenatal-Exercise Counseling Module on Knowledge and Self-Efficacy of Nurses in Northeast Peninsular Malaysia: A Quasi-Experimental Study.,"Background Because of their frequent, regular contact with antenatal mothers, healthcare providers play an important role in promoting the health benefits of antenatal exercise. This study aimed to determine the effectiveness of an antenatal-exercise counseling module on knowledge and self-efficacy of staff nurses. Methods A quasi-experimental design was conducted. The intervention and control groups consisted of 66 nurses randomly selected from the Tumpat and Pasir Mas districts, respectively, in Kelantan. The intervention group received an antenatal-exercise counseling module, and the control group performed counseling based on self-reading. Knowledge and self-efficacy were assessed at the baseline and at week 4. Analysis of variance and repeated measure analysis of covariance were performed using SPSS. Results There was a significant difference in the knowledge scores [estimated marginal mean (95% confidence interval, CI): 33.9 (33.29, 34.53) versus 27.4 (26.52, 28.29); P < 0.001)] and the self-efficacy scores [estimated marginal mean (95% CI): 31.3 (30.55, 32.03) versus 27.4 (26.03, 28.74); P = 0.005)] between intervention and control groups at week 4 after adjusting for duration of practice and formal training. Conclusion The antenatal-exercise counseling module is recommended for use in routine counseling in health centers to promote healthy lifestyles among pregnant women.",2020,"There was a significant difference in the knowledge scores [estimated marginal mean (95% confidence interval, CI): 33.9 (33.29, 34.53) versus 27.4 (26.52, 28.29); ","['Nurses in Northeast Peninsular Malaysia', 'pregnant women', '66 nurses randomly selected from the Tumpat and Pasir Mas districts, respectively, in Kelantan']","['antenatal-exercise counseling module, and the control group performed counseling based on self-reading', 'Antenatal-Exercise Counseling Module', 'antenatal-exercise counseling module']","['self-efficacy scores', 'Knowledge and Self-Efficacy', 'Knowledge and self-efficacy', 'knowledge scores', 'knowledge and self-efficacy']","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0454750', 'cui_str': 'Peninsular Malaysia'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}]","[{'cui': 'C0419126', 'cui_str': 'Antenatal exercises'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0034754', 'cui_str': 'Reading'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",66.0,0.0295318,"There was a significant difference in the knowledge scores [estimated marginal mean (95% confidence interval, CI): 33.9 (33.29, 34.53) versus 27.4 (26.52, 28.29); ","[{'ForeName': 'Ismail', 'Initials': 'I', 'LastName': 'Nor Azura', 'Affiliation': 'Department of Family Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.'}, {'ForeName': 'Ishak', 'Initials': 'I', 'LastName': 'Azlina', 'Affiliation': 'Department of Family Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.'}, {'ForeName': 'Zakaria', 'Initials': 'Z', 'LastName': 'Rosnani', 'Affiliation': 'Department of Family Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.'}, {'ForeName': 'Mohd Noor', 'Initials': 'MN', 'LastName': 'Norhayati', 'Affiliation': 'Department of Family Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.'}]",The Malaysian journal of medical sciences : MJMS,['10.21315/mjms2020.27.3.9'] 1905,32684989,A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial.,"Background Prognosis of patients affected by metastatic esophageal-gastric junction (EGJ) or gastric cancer (GC) remains dismal. Trastuzumab, an anti-HER2 monoclonal antibody, is the only targeted agent approved for the first-line treatment of patients with HER2-overexpressing advanced EGJ or GC in combination with chemotherapy. However, patients invariably become resistant during this treatment. We recently identified the overexpression of fibroblast growth factor (FGF) receptor 3 (FGFR3) as a molecular mechanism responsible for trastuzumab resistance in GC models, providing the rationale for the inhibition of this receptor as a potential second-line strategy in this disease. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3. Methods The FiGhTeR trial is a phase II, single-arm, open-label study to assess safety and activity of the FGFR inhibitor pemigatinib as second-line treatment strategy in metastatic EGJ/GC patients progressing under trastuzumab-containing therapies. The primary endpoint is the 12-week progression-free survival rate. Plasma and tumor tissue samples will be collected for translational research analyses at baseline, during treatment, and at progression on pemigatinib. Discussion Co-alterations in genes coding for different tyrosine-kinase receptors are emerging as relevant mechanisms of acquired resistance to anti-HER2 therapeutic strategies in GC. In particular, our group has recently identified that in GC models the overexpression of FGFR3 sustains the acquired resistance to trastuzumab. This trial aims to assess the safety, tolerability and activity of the FGFR inhibitor pemigatinib as a second-line treatment in metastatic EGJ/GC patients refractory to first-line trastuzumab-containing therapies. Furthermore, this study offers the opportunity to prospectively study mechanisms and pathways involved in trastuzumab resistance. Protocol number CRC2017_02. EudraCT Number 2017-004522-14.",2020,"Trastuzumab, an anti-HER2 monoclonal antibody, is the only targeted agent approved for the first-line treatment of patients with HER2-overexpressing advanced EGJ or GC in combination with chemotherapy.","['metastatic EGJ/GC patients refractory to first-line trastuzumab-containing therapies', 'patients with HER2-overexpressing advanced EGJ or GC in combination with chemotherapy', 'metastatic EGJ/GC patients progressing under trastuzumab-containing therapies', 'patients affected by metastatic esophageal-gastric junction (EGJ) or gastric cancer (GC', 'patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant']","['Trastuzumab', 'FGFR inhibitor pemigatinib']","['Plasma and tumor tissue samples', '12-week progression-free survival rate', 'safety, tolerability and activity']","[{'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0205144', 'cui_str': 'Junctional'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0522476', 'cui_str': 'Patient affected'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}]","[{'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C0060369', 'cui_str': 'Fibroblast Growth Factor Receptors'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0475358', 'cui_str': 'Tumor tissue sample'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",,0.027516,"Trastuzumab, an anti-HER2 monoclonal antibody, is the only targeted agent approved for the first-line treatment of patients with HER2-overexpressing advanced EGJ or GC in combination with chemotherapy.","[{'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Merz', 'Affiliation': 'Digestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli studi di Verona, Verona, Italy.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Zecchetto', 'Affiliation': 'Digestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli studi di Verona, Verona, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Simionato', 'Affiliation': 'Digestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli studi di Verona, Verona, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Cavaliere', 'Affiliation': 'Digestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli studi di Verona, Verona, Italy.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Casalino', 'Affiliation': 'Digestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli studi di Verona, Verona, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Pavarana', 'Affiliation': 'Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Giacopuzzi', 'Affiliation': 'Esophageal and Gastric Surgery Unit, Department of Surgery, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Bencivenga', 'Affiliation': 'Esophageal and Gastric Surgery Unit, Department of Surgery, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Tomezzoli', 'Affiliation': 'Anatomical Pathology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.'}, {'ForeName': 'Raffaela', 'Initials': 'R', 'LastName': 'Santoro', 'Affiliation': 'Digestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli studi di Verona, Verona, Italy.'}, {'ForeName': 'Vita', 'Initials': 'V', 'LastName': 'Fedele', 'Affiliation': 'Digestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli studi di Verona, Verona, Italy.'}, {'ForeName': 'Serena', 'Initials': 'S', 'LastName': 'Contarelli', 'Affiliation': 'Digestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli studi di Verona, Verona, Italy.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Rossi', 'Affiliation': 'Centro Ricerche Cliniche di Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.'}, {'ForeName': 'Serena', 'Initials': 'S', 'LastName': 'Giacomazzi', 'Affiliation': 'Centro Ricerche Cliniche di Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Pasquato', 'Affiliation': 'Centro Ricerche Cliniche di Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.'}, {'ForeName': 'Cristiana', 'Initials': 'C', 'LastName': 'Piazzola', 'Affiliation': 'Centro Ricerche Cliniche di Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Milleri', 'Affiliation': 'Centro Ricerche Cliniche di Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'de Manzoni', 'Affiliation': 'Esophageal and Gastric Surgery Unit, Department of Surgery, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Melisi', 'Affiliation': 'Digestive Molecular Clinical Oncology unit, Section of Medical Oncology, Department of Medicine, University of Verona, AOUI Verona - Policlinico ""G.B. Rossi"", Piazzale L.A. Scuro,10, Verona, 37134, Italy.'}]",Therapeutic advances in medical oncology,['10.1177/1758835920937889'] 1906,32648108,Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials.,"INTRODUCTION This post hoc exploratory analysis examined the effects of ertugliflozin on liver enzymes in patients with type 2 diabetes mellitus (T2DM). METHODS Data were pooled from seven randomized, double-blind VERTIS phase 3 trials that evaluated ertugliflozin (5 mg and 15 mg) versus non-ertugliflozin (placebo, glimepiride, or sitagliptin) treatment in patients with T2DM. Change from baseline at week 52 of treatment in alanine and aspartate aminotransferase (ALT and AST, respectively) serum levels (overall and categorized into tertiles by baseline ALT and AST), Fibrosis-4 Index (FIB-4), glycated hemoglobin (HbA1c), and body weight were evaluated, along with the association between changes in ALT and AST and changes in HbA1c and body weight by treatment. RESULTS Baseline characteristics were balanced across treatment groups (ertugliflozin 5 mg, n = 1716; ertugliflozin 15 mg, n = 1693; non-ertugliflozin, n = 1450). At week 52 of treatment, serum levels of ALT and AST were reduced in patients in the ertugliflozin treatment groups (5 and 15 mg, respectively) compared with those in the non-ertugliflozin group. The comparator-adjusted mean (95% confidence interval [CI]) difference in change from baseline at week 52 for ALT was - 3.35 (- 4.40, - 2.31) IU/L for ertugliflozin 5 mg and - 4.08 (- 5.13, - 3.03) IU/L for ertugliflozin 15 mg; for AST, the respective values were - 1.81 (- 2.50, - 1.11) IU/L and - 2.12 (- 2.82, - 1.42) IU/L. The effects of ertugliflozin were detected across all baseline ALT and AST tertiles, with the highest tertile showing the greatest treatment differences. No meaningful differences were observed between treatment groups for FIB-4. Changes in ALT and AST showed a weak but statistically significant association with changes in HbA1c and body weight in all treatment groups. CONCLUSIONS Treatment with ertugliflozin resulted in a reduction in the levels of hepatic transaminases compared with the non-ertugliflozin group after 52 weeks of treatment. Changes in body weight and HbA1c contributed at least in part to the effects of ertugliflozin on liver enzymes. TRIAL REGISTRATION Clinicaltrials.gov registry numbers: NCT02033889, NCT01958671, NCT02036515, NCT01986855, NCT02099110, NCT02226003, NCT01999218.",2020,"At week 52 of treatment, serum levels of ALT and AST were reduced in patients in the ertugliflozin treatment groups (5 and 15 mg, respectively) compared with those in the non-ertugliflozin group.","['patients with T2DM', 'patients with type 2 diabetes mellitus (T2DM', 'Patients with Type 2 Diabetes']","['ertugliflozin', 'ertugliflozin (5 mg and 15\xa0mg) versus non-ertugliflozin (placebo, glimepiride, or sitagliptin', 'Ertugliflozin', 'IU/L']","['serum levels of ALT and AST', 'alanine and aspartate aminotransferase (ALT and AST, respectively) serum levels (overall and categorized into tertiles by baseline ALT and AST), Fibrosis-4 Index (FIB-4), glycated hemoglobin (HbA1c), and body weight', 'Liver Enzymes', 'levels of hepatic transaminases', 'liver enzymes', 'HbA1c and body weight', 'body weight and HbA1c']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}]","[{'cui': 'C4079805', 'cui_str': 'ertugliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0061323', 'cui_str': 'glimepiride'}, {'cui': 'C1565750', 'cui_str': 'sitagliptin'}, {'cui': 'C0439457', 'cui_str': 'mIU/mL'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0001898', 'cui_str': 'Alanine'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4304377', 'cui_str': 'Fibrosis-4 index'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0002594', 'cui_str': 'Aminotransferase'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]",,0.085715,"At week 52 of treatment, serum levels of ALT and AST were reduced in patients in the ertugliflozin treatment groups (5 and 15 mg, respectively) compared with those in the non-ertugliflozin group.","[{'ForeName': 'Silvina', 'Initials': 'S', 'LastName': 'Gallo', 'Affiliation': 'Pfizer Pharma GmbH, Berlin, Germany.'}, {'ForeName': 'Roberto A', 'Initials': 'RA', 'LastName': 'Calle', 'Affiliation': 'Pfizer Inc., Cambridge, MA, USA.'}, {'ForeName': 'Steven G', 'Initials': 'SG', 'LastName': 'Terra', 'Affiliation': 'Pfizer Inc., Andover, MA, USA.'}, {'ForeName': 'Annpey', 'Initials': 'A', 'LastName': 'Pong', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Tarasenko', 'Affiliation': 'Pfizer Inc., New York, NY, USA.'}, {'ForeName': 'Annaswamy', 'Initials': 'A', 'LastName': 'Raji', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA. annaswamy.raji@merck.com.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00867-1'] 1907,32648508,Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation.,"Background Left ventricular assist device (LVAD) thrombosis is clinically devastating and impacts the cost effectiveness of LVAD therapy for advanced heart failure. Anticoagulation and antiplatelet therapies represent the standard of care to mitigate LVAD thrombosis. Phosphodiesterase type 5 inhibitors (PDE-5is) exhibit hemodynamic, antiplatelet, and antithrombotic effects. Using a national registry, we examined the relationship of PDE-5i use on thrombotic events in patients with continuous-flow LVADs. Methods and Results We obtained data from 13 772 patients with continuous flow LVADs participating in a national registry. Patients implanted with primary LVADs from 2012 to 2017 were included in the analysis. The primary end point was a composite of LVAD thrombosis and ischemic stroke. Patients were analyzed according to any use of PDE-5i after LVAD implantation (PDE-5i group) versus no use after LVAD implantation (no PDE-5i group). The primary end point was significantly lower in the PDE-5i group compared with the no PDE-5i group (hazard ratio [HR], 0.84; 95% CI, 0.77-0.91; P <0.001) at 48 months. The components of the primary end point (LVAD thrombosis: HR, 0.82; 95% CI, 0.74-0.90; P <0.001; and ischemic stroke: HR, 0.85; 95% CI, 0.75-0.97; P =0.019), as well as the secondary end point all-cause mortality (HR, 0.86; 95% CI, 0.79-0.93; P <0.001) were lower in the PDE-5i group versus the no PDE-5i at 48 months post LVAD. The favorable results observed with postimplant PDE-5i use were consistent with both axial and centrifugal flow devices. Conclusions The postimplant use of PDE-5i was associated with fewer thrombotic events and improved survival in LVAD patients. A randomized clinical trial is warranted to confirm these findings.",2020,"The primary end point was significantly lower in the PDE-5i group compared with the no PDE-5i group (hazard ratio [HR], 0.84; 95% CI, 0.77-0.91; P <0.001) at 48 months.","['patients with continuous-flow LVADs', 'Patients implanted with primary LVADs from 2012 to 2017 were included in the analysis', '772 patients with continuous flow LVADs participating in a national registry', 'advanced heart failure']","['PDE-5i after LVAD implantation (PDE-5i group) versus no use after LVAD implantation', 'Phosphodiesterase type 5 inhibitors (PDE-5is', 'LVAD therapy']","['thrombotic events and improved survival', 'ischemic stroke', 'Thrombotic Events', 'composite of LVAD thrombosis and ischemic stroke']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0181598', 'cui_str': 'Left ventricular assist device'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}]","[{'cui': 'C0031640', 'cui_str': 'Phosphoric diester hydrolase'}, {'cui': 'C0181598', 'cui_str': 'Left ventricular assist device'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C1318700', 'cui_str': 'Phosphodiesterase 5 inhibitor'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0085842', 'cui_str': 'Ventricular assist device'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}]",13772.0,0.0719794,"The primary end point was significantly lower in the PDE-5i group compared with the no PDE-5i group (hazard ratio [HR], 0.84; 95% CI, 0.77-0.91; P <0.001) at 48 months.","[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Xanthopoulos', 'Affiliation': 'Kaufman Center for Heart Failure, Heart and Vascular Institute Cleveland Clinic Cleveland OH.'}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Tryposkiadis', 'Affiliation': 'Independent Biostatistician Athens Greece.'}, {'ForeName': 'Filippos', 'Initials': 'F', 'LastName': 'Triposkiadis', 'Affiliation': 'Department of Cardiology University General Hospital of Larissa Greece.'}, {'ForeName': 'Kiyotaka', 'Initials': 'K', 'LastName': 'Fukamachi', 'Affiliation': 'Kaufman Center for Heart Failure, Heart and Vascular Institute Cleveland Clinic Cleveland OH.'}, {'ForeName': 'Edward G', 'Initials': 'EG', 'LastName': 'Soltesz', 'Affiliation': 'Kaufman Center for Heart Failure, Heart and Vascular Institute Cleveland Clinic Cleveland OH.'}, {'ForeName': 'James B', 'Initials': 'JB', 'LastName': 'Young', 'Affiliation': 'Kaufman Center for Heart Failure, Heart and Vascular Institute Cleveland Clinic Cleveland OH.'}, {'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Wolski', 'Affiliation': 'Kaufman Center for Heart Failure, Heart and Vascular Institute Cleveland Clinic Cleveland OH.'}, {'ForeName': 'Eugene H', 'Initials': 'EH', 'LastName': 'Blackstone', 'Affiliation': 'Kaufman Center for Heart Failure, Heart and Vascular Institute Cleveland Clinic Cleveland OH.'}, {'ForeName': 'Randall C', 'Initials': 'RC', 'LastName': 'Starling', 'Affiliation': 'Kaufman Center for Heart Failure, Heart and Vascular Institute Cleveland Clinic Cleveland OH.'}]",Journal of the American Heart Association,['10.1161/JAHA.119.015897'] 1908,32648861,Effect of coconut oil on weight loss and metabolic parameters in men with obesity: a randomized controlled clinical trial.,"Coconut oil appears to help in weight loss and improve metabolic parameters associated with obesity. We evaluate the influence of coconut oil on the body composition, lipid profile and glycemia in men with obesity. A controlled, randomized clinical trial was performed with 29 adult men affected by obesity. They were randomized between two groups receiving a daily intake of 1 tablespoon (12 mL) of extra virgin coconut oil (CO, n = 15) or soybean oil (SO, n = 14), and an isoenergetic balanced diet. The anthropometric profile, lipid profile and glycaemia were evaluated at the baseline and 45 days after intervention. The Mann-Whitney test was performed to compare the groups, and the Wilcoxon test was performed to compare the times. We considered a value of p < 0.05 as significant. There was no difference in anthropometric variables between the groups before and after intervention. The level of HDL cholesterol increased (3.67 ± 8.08 versus-3.79 ± 10.98, p = 0.02) and the TC/HDL cholesterol ratio decreased (-0.63 ± 0.82 versus 0.23 ± 0.80, p = 0.03) in the CO group, compared to the SO group. Coconut oil included in the isoenergetic balanced diet could increase HDL cholesterol and decrease the TC/HDL cholesterol ratio in men with obesity.",2020,"The level of HDL cholesterol increased (3.67 ± 8.08 versus -3.79 ± 10.98, p = 0.02) and the TC/HDL cholesterol ratio decreased (-0.63 ± 0.82 versus 0.23 ± 0.80, p = 0.03) in the CO group, compared to the SO group.","['29 adult men affected by obesity', 'men with obesity']","['isoenergetic balanced diet', 'coconut oil', 'Coconut oil', 'daily intake of 1 tablespoon (12 mL) of extra virgin coconut oil (CO, n = 15) or soybean oil']","['weight loss and metabolic parameters', 'level of HDL cholesterol', 'anthropometric variables', 'anthropometric profile, lipid profile and glycaemia', 'body composition, lipid profile and glycemia', 'HDL cholesterol', 'weight loss', 'TC/HDL cholesterol ratio']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0452410', 'cui_str': 'Balanced diet'}, {'cui': 'C0056060', 'cui_str': 'Coconut Oil'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C1532188', 'cui_str': 'Tablespoonful - unit of product usage'}, {'cui': 'C0555061', 'cui_str': 'Virgin'}, {'cui': 'C0037732', 'cui_str': 'Soybean Oil'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol in high density lipoprotein subfraction 2'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",29.0,0.0269566,"The level of HDL cholesterol increased (3.67 ± 8.08 versus -3.79 ± 10.98, p = 0.02) and the TC/HDL cholesterol ratio decreased (-0.63 ± 0.82 versus 0.23 ± 0.80, p = 0.03) in the CO group, compared to the SO group.","[{'ForeName': 'Christine Érika', 'Initials': 'CÉ', 'LastName': 'Vogel', 'Affiliation': 'Department of Nutrition and Dietetics, Nutrition Institute Josué de Castro, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. louisecrovesy@yahoo.com.br.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Crovesy', 'Affiliation': ''}, {'ForeName': 'Eliane Lopes', 'Initials': 'EL', 'LastName': 'Rosado', 'Affiliation': ''}, {'ForeName': 'Márcia', 'Initials': 'M', 'LastName': 'Soares-Mota', 'Affiliation': ''}]",Food & function,['10.1039/d0fo00872a'] 1909,32645079,Cardiopulmonary bypass and internal thoracic artery: Can roller or centrifugal pumps change vascular reactivity of the graft? The IPITA study: A randomized controlled clinical trial.,"BACKGROUND Cardiopulmonary bypass (CPB) induces a systemic inflammatory response (SIRS) and affects the organ vascular bed. Experimentally, the lack of pulsatility alters myogenic tone of resistance arteries and increases the parietal inflammatory response. The purpose of this study was to compare the vascular reactivity of the internal thoracic arteries (ITAs) due to the inflammatory response between patients undergoing coronary artery bypass grafting (CABG) under CPB with a roller pump or with a centrifugal pump. METHODS Eighty elective male patients undergoing CABG were selected using one or two internal thoracic arteries under CPB with a roller pump (RP group) or centrifugal pump (CFP group). ITA samples were collected before starting CPB (Time 1) and before the last coronary anastomosis during aortic cross clamping (Time 2). The primary endpoint was the endothelium-dependent relaxation of ITAs investigated using wire-myography. The secondary endpoint was the parietal inflammatory response of arteries defined by the measurements of superoxide levels, leukocytes and lymphocytes rate and gene expression of inflammatory proteins using. Terminal complement complex activation (SC5b-9) and neutrophil activation (elastase) analysis were performed on arterial blood at the same times. RESULTS Exposure time of ITAs to the pump flow was respectively 43.3 minutes in the RP group and 45.7 minutes in the CFP group. Acetylcholine-dependent relaxation was conserved in the two groups whatever the time. Gene expression of C3 and C4a in the artery wall decreased from Time 1 to Time 2. No oxidative stress was observed in the graft. There was no difference between the groups concerning the leukocytes and lymphocytes rate. SC5b-9 and elastase increased between Time 1 and Time 2. CONCLUSION Endothelium-dependent relaxation of the internal thoracic arteries was preserved during CPB whatever the type of pump used. The inflammatory response observed in the blood was not found in the graft wall within this time frame. TRIAL REGISTRATION Name of trial study protocol: IPITA Registration number (ClinicalTrials.gov): NCT04168853.",2020,"Terminal complement complex activation (SC5b-9) and neutrophil activation (elastase) analysis were performed on arterial blood at the same times. ","['patients undergoing coronary artery bypass grafting (CABG) under CPB with a roller pump or with a centrifugal pump', 'Eighty elective male patients undergoing CABG were selected using one or two internal thoracic arteries under']","['internal thoracic arteries (ITAs', 'Cardiopulmonary bypass (CPB', 'Cardiopulmonary bypass and internal thoracic artery', 'CPB with a roller pump (RP group) or centrifugal pump (CFP group', 'Acetylcholine']","['leukocytes and lymphocytes rate', 'parietal inflammatory response of arteries defined by the measurements of superoxide levels, leukocytes and lymphocytes rate and gene expression of inflammatory proteins using', 'oxidative stress', 'parietal inflammatory response', 'vascular reactivity', 'Gene expression of C3 and C4a', 'SC5b-9 and elastase', 'Exposure time of ITAs to the pump flow', 'endothelium-dependent relaxation of ITAs investigated using wire-myography', 'inflammatory response']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0326180', 'cui_str': 'Coraciidae'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0444755', 'cui_str': 'Centrifugal pump'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0226276', 'cui_str': 'Structure of internal thoracic artery'}]","[{'cui': 'C0226276', 'cui_str': 'Structure of internal thoracic artery'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0326180', 'cui_str': 'Coraciidae'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444755', 'cui_str': 'Centrifugal pump'}, {'cui': 'C0055162', 'cui_str': 'CFP protocol'}, {'cui': 'C0001041', 'cui_str': 'Acetylcholine'}]","[{'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0442030', 'cui_str': 'Parietal'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0038836', 'cui_str': 'Superoxide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0523345', 'cui_str': 'Complement C4a measurement'}, {'cui': 'C0074124', 'cui_str': 'SC5b-9 protein complex'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0009545', 'cui_str': 'Active C5b6789'}, {'cui': 'C0242599', 'cui_str': 'Neutrophil Activation'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0226276', 'cui_str': 'Structure of internal thoracic artery'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}, {'cui': 'C0005978', 'cui_str': 'Bone wire'}, {'cui': 'C0027081', 'cui_str': 'Myography'}]",80.0,0.0607982,"Terminal complement complex activation (SC5b-9) and neutrophil activation (elastase) analysis were performed on arterial blood at the same times. ","[{'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Fouquet', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, University Hospital, Angers, France.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Dang Van', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, University Hospital, Angers, France.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Baudry', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, University Hospital, Angers, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Meisnerowski', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, University Hospital, Angers, France.'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Robert', 'Affiliation': 'MITOVASC Institute CNRS UMR 6214, INSERM U1083, University of Angers, Angers, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Pinaud', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, University Hospital, Angers, France.'}, {'ForeName': 'Patrice', 'Initials': 'P', 'LastName': 'Binuani', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, University Hospital, Angers, France.'}, {'ForeName': 'Jean-Marie', 'Initials': 'JM', 'LastName': 'Chrétien', 'Affiliation': 'Clinical Research Department, University Hospital, Angers, France.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Henrion', 'Affiliation': 'MITOVASC Institute CNRS UMR 6214, INSERM U1083, University of Angers, Angers, France.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Baufreton', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, University Hospital, Angers, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Loufrani', 'Affiliation': 'MITOVASC Institute CNRS UMR 6214, INSERM U1083, University of Angers, Angers, France.'}]",PloS one,['10.1371/journal.pone.0235604'] 1910,32645213,Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies.,"OBJECTIVE This post hoc analysis evaluated long-term efficacy and safety in patients with focal to bilateral tonic-clonic seizures (FBTCS) or generalized tonic-clonic seizures (GTCS) who entered open-label extension (OLEx) studies to receive long-term adjunctive perampanel. METHODS Patients aged 12 years and older who completed phase II or III randomized, double-blind, placebo-controlled studies could enter an OLEx study, each comprising a blinded conversion period followed by an open-label maintenance period (32-424 weeks; maximum perampanel dose = 12 mg/d). Exposure, seizure outcomes, and treatment-emergent adverse events (TEAEs) were analyzed. RESULTS Baseline characteristics were generally balanced between patients with FBTCS (n = 720) and GTCS (n = 138). Mean (standard deviation) cumulative duration of perampanel exposure was 102.3 (70.3) weeks (FBTCS) and 83.9 (38.4) weeks (GTCS). Retention rates were 50.0% for up to 4 years (FBTCS) and 49.2% for up to 2 years (GTCS). Across OLEx treatment durations, median reductions in seizure frequency per 28 days were 66.7% (FBTCS) and 80.6% (GTCS). Fifty percent and 75% responder and seizure-freedom rates were 59.5%, 45.3%, and 18.4%, respectively (FBTCS), and 72.5%, 51.5%, and 16.7%, respectively (GTCS). Efficacy was sustained for up to 4 years (FBTCS) and up to 3 years (GTCS), even when accounting for early dropouts. TEAE incidence was highest during Year 1 (FBTCS, 85.3%; GTCS, 86.2%); most common were dizziness and somnolence. During Year 1, serious TEAEs were reported in 81 (11.3%; FBTCS) and 10 (7.2%; GTCS) patients. TEAEs were consistent with the known safety profile of perampanel; no new safety signals were identified with long-term treatment. SIGNIFICANCE This post hoc analysis suggests long-term (up to 4 years) adjunctive perampanel (up to 12 mg/d) is efficacious and well tolerated in patients (aged 12 years and older) with FBTCS or GTCS.",2020,"Efficacy was sustained for up to 4 years (FBTCS) and up to 3 years (GTCS), even when accounting for early dropouts.","['patients (aged 12\xa0years and older) with FBTCS or GTCS', 'patients with focal to bilateral tonic-clonic seizures (FBTCS) or generalized tonic-clonic seizures (GTCS) who entered open-label extension (OLEx) studies', 'tonic-clonic seizures', 'Patients aged 12\xa0years and older who completed phase II or III randomized']","['GTCS', 'perampanel', 'FBTCS', 'adjunctive perampanel', 'placebo']","['efficacious and well tolerated', 'Retention rates', 'seizure frequency', 'Exposure, seizure outcomes, and treatment-emergent adverse events (TEAEs', 'seizure-freedom rates', 'Efficacy', 'Mean (standard deviation) cumulative duration of perampanel exposure', 'TEAE incidence', 'dizziness and somnolence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0494475', 'cui_str': 'Tonic-clonic seizure'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0494475', 'cui_str': 'Tonic-clonic seizure'}, {'cui': 'C2698764', 'cui_str': 'perampanel'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0149775', 'cui_str': 'Fit frequency'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C2698764', 'cui_str': 'perampanel'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}]",720.0,0.190572,"Efficacy was sustained for up to 4 years (FBTCS) and up to 3 years (GTCS), even when accounting for early dropouts.","[{'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Rektor', 'Affiliation': 'Brno Epilepsy Center and Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.'}, {'ForeName': 'Gregory L', 'Initials': 'GL', 'LastName': 'Krauss', 'Affiliation': 'Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Yushi', 'Initials': 'Y', 'LastName': 'Inoue', 'Affiliation': 'National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan.'}, {'ForeName': 'Sunao', 'Initials': 'S', 'LastName': 'Kaneko', 'Affiliation': 'North Tohoku Epilepsy Center, Minato Hospital, Hachinohe, Japan.'}, {'ForeName': 'Betsy', 'Initials': 'B', 'LastName': 'Williams', 'Affiliation': 'Formerly: Eisai Inc., Woodcliff Lake, New Jersey, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Patten', 'Affiliation': 'Eisai Ltd., Hatfield, UK.'}, {'ForeName': 'Manoj', 'Initials': 'M', 'LastName': 'Malhotra', 'Affiliation': 'Eisai Inc., Woodcliff Lake, New Jersey, USA.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Laurenza', 'Affiliation': 'Formerly: Eisai Inc., Woodcliff Lake, New Jersey, USA.'}, {'ForeName': 'Robert T', 'Initials': 'RT', 'LastName': 'Wechsler', 'Affiliation': 'Idaho Comprehensive Epilepsy Center, Boise, Idaho, USA.'}]",Epilepsia,['10.1111/epi.16573'] 1911,32645227,Effectiveness of blood flow-restricted slow walking on mobility in severe multiple sclerosis: A pilot randomized trial.,"OBJECTIVE We tested the safety, feasibility, and effectiveness of blood flow restriction-empowered low-intensity interval walking exercise (BFR-W) compared with conventional intensive overground walking (CON-W) at improving gait speed and functional capacity in patients with multiple sclerosis (MS) and severe gait disabilities. METHODS 24 patients (58 ± 5 years; 7 males) with progressive MS (Expanded Disability Status Scale 5.5 - 6.5) were randomized to receive 12 rehabilitation sessions over 6 weeks. The BFR-W group (n = 12) performed interval walking (speed paced by a metronome that increased weekly) with BFR bands at the thighs. The CON-W group (n = 12) received physiotherapist-assisted overground walking therapy. The primary outcome was gait speed, measured by the timed 25-foot walk test. Secondary outcomes included walking endurance, balance, strength, fatigue, and quality of life. The measurements were collected at baseline, at the end of training, and a 6-week follow-up. RESULTS The two groups did not present any baseline difference. BFR-W group safely walked without limitations due to sleeve compression, with lower increase in perceived exertion (RPE) (P < .001) and heart rate (P = .031) compared with the CON-W. Gait speed improved significantly in both groups (BFR-W + 13%; CON-W + 5%) with greater increases in the BFR-W group at end of the training (P = .001) and at the follow-up (P = .041). Most of the secondary outcomes significantly improved in the two groups, without between-group differences. CONCLUSIONS Slow interval walking with moderate BFR to the lower limbs was superior to overground walking in improving gait speed in patients with MS with a lower training load and a more durable clinical benefit.",2020,"BFR-W group safely walked without limitations due to sleeve compression, with lower increase of perceived exertion (RPE) (p<0.001) and heart rate (p=0.031) compared with the CON-W. Gait speed improved significantly in both groups (BFR-W +13%; CON-W +5%) with greater increases in the BFR-W group at end of the training (p=0.001) and at the follow-up (p=0.041).","['24 patients (58±5 years; 7 males) with progressive MS (Expanded Disability Status Scale 5.5-6.5', 'severe multiple sclerosis', 'patients with multiple sclerosis (MS) and severe gait disabilities']","['conventional intensive overground walking (CON-W', 'physiotherapist-assisted overground walking therapy', 'blood flow restriction-empowered low-intensity interval walking exercise (BFR-W', 'blood flow-restricted slow walking']","['gait speed, measured by the timed 25-foot walk test', 'gait speed', 'gait speed and functional capacity', 'walking endurance, balance, strength, fatigue and quality of life', 'heart rate', 'CON-W. Gait speed', 'perceived exertion (RPE']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C1095979', 'cui_str': 'Progressive multiple sclerosis'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale'}, {'cui': 'C3844008', 'cui_str': '5.5'}, {'cui': 'C3844007', 'cui_str': '6.5'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0231170', 'cui_str': 'Disability'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0562342', 'cui_str': 'Empowered'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439834', 'cui_str': 'Slow'}]","[{'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0035322', 'cui_str': 'Structure of retinal pigment epithelium'}]",24.0,0.0478559,"BFR-W group safely walked without limitations due to sleeve compression, with lower increase of perceived exertion (RPE) (p<0.001) and heart rate (p=0.031) compared with the CON-W. Gait speed improved significantly in both groups (BFR-W +13%; CON-W +5%) with greater increases in the BFR-W group at end of the training (p=0.001) and at the follow-up (p=0.041).","[{'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Lamberti', 'Affiliation': 'Department of Biomedical and Surgical Specialties Sciences, Section of Sport Sciences, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Straudi', 'Affiliation': 'Neuroscience and Rehabilitation Department, Ferrara University Hospital, Ferrara, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Donadi', 'Affiliation': 'Neuroscience and Rehabilitation Department, Ferrara University Hospital, Ferrara, Italy.'}, {'ForeName': 'Hirofumi', 'Initials': 'H', 'LastName': 'Tanaka', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Nino', 'Initials': 'N', 'LastName': 'Basaglia', 'Affiliation': 'Neuroscience and Rehabilitation Department, Ferrara University Hospital, Ferrara, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Manfredini', 'Affiliation': 'Department of Biomedical and Surgical Specialties Sciences, Section of Sport Sciences, University of Ferrara, Ferrara, Italy.'}]",Scandinavian journal of medicine & science in sports,['10.1111/sms.13764'] 1912,32645830,Randomized Clinical Trial: The Effect of Exercise of the Intrinsic Muscle on Foot Pronation.,"Background: There is little scientific evidence regarding the effectiveness of strengthening exercises on the foot's intrinsic musculature in improving the lower limb on the statics and dynamics in healthy individuals. Method: To evaluate the effect on foot posture with regard to the reinforcement of the short foot exercise (SFE) compared to another without a recognized biomechanical action, which we called the ""non-biomechanical function"" (NBF) exercise. A randomized clinical trial was carried out with 85 asymptomatic participants with a bilateral Foot Posture Index (FPI) greater than 6 points. An experimental group ( n = 42) did SFE training and a control group ( n = 43) carried out NBF exercises. The foot posture was evaluated twice via the navicular drop (ND) test, and the FPI was assessed on the day of inclusion in the study (pre-intervention) and after four weeks of training (post-intervention). Results: Statistically significant values were not found in foot posture between the experimental and the control groups when comparing before and after the training. However, the foot posture was modified in both groups with respect to its initial state, and the ND value decreased. Conclusions: SFE could be considered a useful tool to deal with pathologies whose etiology includes excessive pronation of the foot.",2020,Results: Statistically significant values were not found in foot posture between the experimental and the control groups when comparing before and after the training.,"['85 asymptomatic participants with a bilateral Foot Posture Index (FPI) greater than 6 points', 'healthy individuals']","['strengthening exercises', 'SFE training and a control group ( n = 43) carried out NBF exercises', 'short foot exercise (SFE', 'SFE']",['foot posture'],"[{'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0230473', 'cui_str': 'Both feet'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0452260', 'cui_str': 'Muscular strength development exercise'}, {'cui': 'C1870204', 'cui_str': '(18F)1-(2-fluoroethyl)-4-((4-cyanophenoxy)methyl)piperidine'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0576226', 'cui_str': 'Short foot'}]","[{'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}]",85.0,0.0321686,Results: Statistically significant values were not found in foot posture between the experimental and the control groups when comparing before and after the training.,"[{'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Pabón-Carrasco', 'Affiliation': 'Cruz Roja, Nursing Department, University of Seville, 41009 Seville, Spain.'}, {'ForeName': 'Aurora', 'Initials': 'A', 'LastName': 'Castro-Méndez', 'Affiliation': 'Podiatry Department, University of Seville, 41009 Seville, Spain.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Vilar-Palomo', 'Affiliation': 'Virgen del Rocío Hospital, 41013 Seville, Spain.'}, {'ForeName': 'Ana María', 'Initials': 'AM', 'LastName': 'Jiménez-Cebrián', 'Affiliation': 'Nursing and Podiatry Department, University of Malaga, 29071 Malaga, Spain.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'García-Paya', 'Affiliation': 'Nursing and Podiatry Department, University of Malaga, 29071 Malaga, Spain.'}, {'ForeName': 'Inmaculada C', 'Initials': 'IC', 'LastName': 'Palomo-Toucedo', 'Affiliation': 'Podiatry Department, University of Seville, 41009 Seville, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17134882'] 1913,32638615,The Feasibility and Efficacy of a Brief Integrative Treatment for Adults With Depression and/or Anxiety: A Randomized Controlled Trial.,"The aim of this study was to investigate the efficacy and suitability of a brief integrative intervention, Personalized Integrative Therapy (PI Therapy), for the treatment of adult depression and/or anxiety. In this 6-week, 3-arm, parallel-group, randomized trial, PI Therapy delivered alone or with nutritional supplements (PI Therapy + Supps) was compared to cognitive behavior therapy (CBT) in 48 adults with depression and/or anxiety. All treatments were delivered as a 1-day workshop plus 6 weeks of reminder phone text messages to reinforce topics and skills covered in the workshop. Affective symptoms decreased significantly and to the same extent in all 3 conditions. At the end of treatment, 33% to 58% of participants reported levels of depressive symptoms in the normal range, and 50% to 58% reported nonclinical levels of anxiety. Compared to CBT and PI Therapy, PI Therapy + Supps was associated with significantly greater improvements in sleep quality. These findings suggest that a brief integrative intervention with or without supplements was comparable to CBT in reducing affective symptoms in adults with depression and/or anxiety. However, sleep quality improved only in the PI Therapy + Supps condition. These findings will require replication with a larger cohort.",2020,Affective symptoms decreased significantly and to the same extent in all 3 conditions.,"['adult depression and/or anxiety', 'adults with depression and/or anxiety', '48 adults with depression and/or anxiety', 'Adults With Depression and/or Anxiety']","['CBT', 'integrative intervention, Personalized Integrative Therapy (PI Therapy', 'PI Therapy delivered alone or with nutritional supplements (PI Therapy + Supps', 'Brief Integrative Treatment', 'cognitive behavior therapy (CBT']","['levels of depressive symptoms', 'affective symptoms', 'nonclinical levels of anxiety', 'Affective symptoms', 'sleep quality']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0038854', 'cui_str': 'Suppository'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0001726', 'cui_str': 'Affective Symptoms'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}]",48.0,0.0323079,Affective symptoms decreased significantly and to the same extent in all 3 conditions.,"[{'ForeName': 'Adrian L', 'Initials': 'AL', 'LastName': 'Lopresti', 'Affiliation': 'Murdoch University, Perth, Western Australia, Australia.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Smith', 'Affiliation': 'Murdoch University, Perth, Western Australia, Australia.'}, {'ForeName': 'Alexandra P', 'Initials': 'AP', 'LastName': 'Metse', 'Affiliation': 'Murdoch University, Perth, Western Australia, Australia.'}, {'ForeName': 'Tiffany', 'Initials': 'T', 'LastName': 'Foster', 'Affiliation': 'Murdoch University, Perth, Western Australia, Australia.'}, {'ForeName': 'Peter D', 'Initials': 'PD', 'LastName': 'Drummond', 'Affiliation': 'Murdoch University, Perth, Western Australia, Australia.'}]",Journal of evidence-based integrative medicine,['10.1177/2515690X20937997'] 1914,32640124,Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.,"BACKGROUND Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear. METHODS We conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the postexposure prophylactic efficacy of baloxavir in household contacts of index patients with confirmed influenza during the 2018-2019 season in Japan. The participants were assigned in a 1:1 ratio to receive either a single dose of baloxavir or placebo. The primary end point was clinical influenza, as confirmed by reverse-transcriptase-polymerase-chain-reaction testing, over a period of 10 days. The occurrence of baloxavir-selected PA substitutions associated with reduced susceptibility was assessed. RESULTS A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza A virus infection, 73.6% were younger than 12 years of age, and 52.7% received baloxavir. Among the participants who could be evaluated (374 in the baloxavir group and 375 in the placebo group), the percentage in whom clinical influenza developed was significantly lower in the baloxavir group than in the placebo group (1.9% vs. 13.6%) (adjusted risk ratio, 0.14; 95% confidence interval [CI], 0.06 to 0.30; P<0.001). Baloxavir was effective in high-risk, pediatric, and unvaccinated subgroups of participants. The risk of influenza infection, regardless of symptoms, was lower with baloxavir than with placebo (adjusted risk ratio, 0.43; 95% CI, 0.32 to 0.58). The incidence of adverse events was similar in the two groups (22.2% in the baloxavir group and 20.5% in the placebo group). In the baloxavir group, the viral PA substitutions I38T/M or E23K were detected in 10 (2.7%) and 5 (1.3%) participants, respectively. No transmission of these variants from baloxavir-treated index patients to participants in the placebo group was detected; however, several instances of transmission to participants in the baloxavir group could not be ruled out. CONCLUSIONS Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza. (Funded by Shionogi; Japan Primary Registries Network number, JapicCTI-184180.).",2020,"CONCLUSIONS Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza.","['A total of 752 household contacts of 545 index patients', 'household contacts of index patients with confirmed influenza during the 2018-2019 season in Japan', 'Household Contacts', 'household contacts of patients with influenza']","['Baloxavir', 'baloxavir', 'Baloxavir Marboxil', 'Baloxavir marboxil (baloxavir', 'baloxavir or placebo', 'placebo']","['postexposure prophylactic efficacy', 'clinical influenza, as confirmed by reverse-transcriptase-polymerase-chain-reaction testing', 'clinical influenza', 'viral PA substitutions I38T/M or E23K', 'incidence of adverse events']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C4517809', 'cui_str': '545'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C4734224', 'cui_str': 'baloxavir'}, {'cui': 'C4688747', 'cui_str': 'Baloxavir marboxil'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0599161', 'cui_str': 'Polymerase Chain Reaction, Reverse Transcriptase'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.380895,"CONCLUSIONS Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza.","[{'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Ikematsu', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Frederick G', 'Initials': 'FG', 'LastName': 'Hayden', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Keiko', 'Initials': 'K', 'LastName': 'Kawaguchi', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Kinoshita', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Menno D', 'Initials': 'MD', 'LastName': 'de Jong', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Nelson', 'Initials': 'N', 'LastName': 'Lee', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Satoru', 'Initials': 'S', 'LastName': 'Takashima', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Noshi', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Tsuchiya', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Takeki', 'Initials': 'T', 'LastName': 'Uehara', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}]",The New England journal of medicine,['10.1056/NEJMoa1915341'] 1915,32640755,A New Nasal Restriction Device Called FeelBreathe ® Improves Breathing Patterns in Chronic Obstructive Pulmonary Disease Patients during Exercise.,"A device called FeelBreathe (FB) ® was designed, developed, and patented for inspiratory muscle training. The main aim was to determine the acute responses on lung ventilation, gas exchange, and heart rate during exercise in patients with chronic obstructive pulmonary disease (COPD) with and without the use of FB. In this study, a randomized cross-over trial was performed with 18 men diagnosed with COPD (FEV 1 between 30% and 70% of its predicted value). Each participant randomly conducted two trials with 30 min of rest between them with the same protocol on a treadmill for 10 min at a constant rate of 50% of VO 2peak . Each test was performed randomly and in a crossover randomized design in two different conditions: (1) oronasal breathing; and (2) nasal breathing with FB (nasal ventilatory flow restriction device). It was observed that FB had positive effects on dynamic hyperinflation, breathing pattern, and breathing efficiency, with higher expiratory and inspiratory time. Despite these differences, blood oxygen saturation percentage, oxygen uptake, and heart rate showed a similar response for both conditions during exercise. The results suggest that exercise performed with FB improved ventilatory responses compared to the oronasal mode in COPD patients. This new tool could be used during most daily tasks and exercise programs.",2020,"Despite these differences, blood oxygen saturation percentage, oxygen uptake, and heart rate showed a similar response for both conditions during exercise.","['patients with chronic obstructive pulmonary disease (COPD) with and without the use of FB', '18 men diagnosed with COPD (FEV 1 between 30% and 70% of its predicted value', 'Chronic Obstructive Pulmonary Disease Patients during Exercise']","['Nasal Restriction Device Called FeelBreathe ®', 'oronasal breathing; and (2) nasal breathing with FB (nasal ventilatory flow restriction device']","['ventilatory responses', 'blood oxygen saturation percentage, oxygen uptake, and heart rate', 'acute responses on lung ventilation, gas exchange, and heart rate', 'dynamic hyperinflation, breathing pattern, and breathing efficiency, with higher expiratory and inspiratory time']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0587107', 'cui_str': 'During exercise'}]","[{'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C1720420', 'cui_str': 'Call'}]","[{'cui': 'C0428174', 'cui_str': 'Hemoglobin saturation with oxygen'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0554804', 'cui_str': 'Assisted breathing'}, {'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0020449', 'cui_str': 'Hyperdistention'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0428686', 'cui_str': 'Inspiratory time'}]",,0.10336,"Despite these differences, blood oxygen saturation percentage, oxygen uptake, and heart rate showed a similar response for both conditions during exercise.","[{'ForeName': 'José L', 'Initials': 'JL', 'LastName': 'Gonzalez-Montesinos', 'Affiliation': 'Department of Physical Education, Faculty of Education Sciences, University of Cádiz, 11519 Cádiz, Spain.'}, {'ForeName': 'Aurelio', 'Initials': 'A', 'LastName': 'Arnedillo', 'Affiliation': 'University Hospital Puerta del Mar. Pneumology, Allergy and Thoracic Surgery Department, 11009 Cádiz, Spain.'}, {'ForeName': 'Jorge R', 'Initials': 'JR', 'LastName': 'Fernandez-Santos', 'Affiliation': 'Biomedical Research and Innovation Institute of Cádiz (INiBICA) Research Unit, 11009 Cádiz, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Vaz-Pardal', 'Affiliation': 'Bahía Sur Andalusian Center for Sports Medicine, 11100 Cádiz, Spain.'}, {'ForeName': 'Pelayo A', 'Initials': 'PA', 'LastName': 'García', 'Affiliation': 'Center Sport Iberia, 29007 Málaga, Spain.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Castro-Piñero', 'Affiliation': 'Biomedical Research and Innovation Institute of Cádiz (INiBICA) Research Unit, 11009 Cádiz, Spain.'}, {'ForeName': 'Jesús G', 'Initials': 'JG', 'LastName': 'Ponce-González', 'Affiliation': 'Biomedical Research and Innovation Institute of Cádiz (INiBICA) Research Unit, 11009 Cádiz, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17134876'] 1916,32641226,Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.,"The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial reported that sacubitril/valsartan (S/V), an angiotensin receptor-neprilysin inhibitor, significantly reduced mortality and heart failure (HF) hospitalization in HF patients with a reduced ejection fraction (HFrEF). However, fewer than 1% of patients in the PARADIGM-HF study had New York Heart Association (NYHA) functional class IV symptoms. Accordingly, data that informed the use of S/V among patients with advanced HF were limited. The LIFE (LCZ696 in Hospitalized Advanced Heart Failure) study was a 24-week prospective, multicenter, double-blinded, double-dummy, active comparator trial that compared the safety, efficacy, and tolerability of S/V with those of valsartan in patients with advanced HFrEF. The trial planned to randomize 400 patients ≥18 years of age with advanced HF, defined as an EF ≤35%, New York Heart Association functional class IV symptoms, elevated natriuretic peptide concentration (B-type natriuretic peptide [BNP] ≥250 pg/ml or N-terminal pro-B-type natriuretic peptide [NT-proBNP] ≥800 pg/ml), and ≥1 objective finding of advanced HF. Following a 3- to 7-day open label run-in period with S/V (24 mg/26 mg twice daily), patients were randomized 1:1 to S/V titrated to 97 mg/103 mg twice daily versus 160 mg of V twice daily. The primary endpoint was the proportional change from baseline in the area under the curve for NT-proBNP levels measured through week 24. Secondary and tertiary endpoints included clinical outcomes and safety and tolerability. Because of the COVID-19 pandemic, enrollment in the LIFE trial was stopped prematurely to ensure patient safety and data integrity. The primary analysis consists of the first 335 randomized patients whose clinical follow-up examination results were not severely impacted by COVID-19. (Entresto [LCZ696] in Advanced Heart Failure [LIFE STUDY] [HFN-LIFE]; NCT02816736).",2020,The primary endpoint was the proportional change from baseline in the area under the curve for NT-proBNP levels measured through week 24.,"['400 patients\xa0≥18 years of age with advanced HF, defined as an EF\xa0≤35%, New York Heart Association functional class IV symptoms, elevated natriuretic peptide concentration (B-type natriuretic peptide [BNP]\xa0≥250 pg/ml or N-terminal pro-B-type natriuretic peptide [NT-proBNP]\xa0≥800 pg/ml), and\xa0≥1 objective finding of advanced HF', 'patients with advanced HF', 'Failure With Reduced Ejection Fraction', 'Heart\xa0Failure', 'Advanced Heart\xa0Failure [LIFE STUDY', 'HF patients with a reduced ejection fraction (HFrEF', 'Advanced Heart', 'patients with advanced HFrEF']","['Entresto [LCZ696', 'valsartan', 'Angiotensin II Receptor Blocker Neprilysin Inhibitor', 'Angiotensin-Converting Enzyme Inhibitor', 'sacubitril/valsartan', 'Sacubitril/Valsartan', 'LIFE (LCZ696']","['mortality and heart failure (HF) hospitalization', 'proportional change from baseline in the area under the curve for NT-proBNP levels', 'Global Mortality and Morbidity', 'safety, efficacy, and tolerability', 'clinical outcomes and safety and tolerability']","[{'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0441888', 'cui_str': 'Class 4'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1144709', 'cui_str': 'Natriuretic Peptide Hormones'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0054015', 'cui_str': 'Nesiritide'}, {'cui': 'C0439297', 'cui_str': 'ng/L'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C4033616', 'cui_str': 'Entresto'}, {'cui': 'C2933615', 'cui_str': 'LCZ 696'}, {'cui': 'C0216784', 'cui_str': 'valsartan'}, {'cui': 'C0521942', 'cui_str': 'Angiotensin II receptor antagonist'}, {'cui': 'C4760695', 'cui_str': 'Neprilysin inhibitor'}, {'cui': 'C0003015', 'cui_str': 'Angiotensin-converting enzyme inhibitor'}, {'cui': 'C4033631', 'cui_str': 'valsartan and sacubitril'}, {'cui': 'C0376558', 'cui_str': 'Life'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0205351', 'cui_str': 'Proportional'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",335.0,0.331951,The primary endpoint was the proportional change from baseline in the area under the curve for NT-proBNP levels measured through week 24.,"[{'ForeName': 'Douglas L', 'Initials': 'DL', 'LastName': 'Mann', 'Affiliation': 'Department of Medicine, Washington University, St. Louis, Missouri. Electronic address: dmann@wustl.edu.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Greene', 'Affiliation': 'Department of Medicine, Duke University, Durham, North Carolina; Duke Clinical Research Institute, Duke University, Durham, North Carolina.'}, {'ForeName': 'Michael M', 'Initials': 'MM', 'LastName': 'Givertz', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Justin M', 'Initials': 'JM', 'LastName': 'Vader', 'Affiliation': 'Department of Medicine, Washington University, St. Louis, Missouri.'}, {'ForeName': 'Randall C', 'Initials': 'RC', 'LastName': 'Starling', 'Affiliation': 'Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Andrew P', 'Initials': 'AP', 'LastName': 'Ambrosy', 'Affiliation': 'Division of Research, Kaiser Permanente Northern California, Oakland, California.'}, {'ForeName': 'Palak', 'Initials': 'P', 'LastName': 'Shah', 'Affiliation': 'Inova Heart and Vascular Institute, Falls Church, Virginia.'}, {'ForeName': 'Steven E', 'Initials': 'SE', 'LastName': 'McNulty', 'Affiliation': 'Duke Clinical Research Institute, Duke University, Durham, North Carolina.'}, {'ForeName': 'Claudius', 'Initials': 'C', 'LastName': 'Mahr', 'Affiliation': 'Department of Medicine, University of Washington, Seattle, Washington.'}, {'ForeName': 'Divya', 'Initials': 'D', 'LastName': 'Gupta', 'Affiliation': 'Department of Medicine, Emory University, Atlanta, Georgia.'}, {'ForeName': 'Margaret M', 'Initials': 'MM', 'LastName': 'Redfield', 'Affiliation': 'Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Anuradha', 'Initials': 'A', 'LastName': 'Lala', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Gregory D', 'Initials': 'GD', 'LastName': 'Lewis', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Selma F', 'Initials': 'SF', 'LastName': 'Mohammed', 'Affiliation': 'MedStar Washington Hospital Center, Washington, DC.'}, {'ForeName': 'Nisha A', 'Initials': 'NA', 'LastName': 'Gilotra', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Adam D', 'Initials': 'AD', 'LastName': 'DeVore', 'Affiliation': 'Department of Medicine, Duke University, Durham, North Carolina; Duke Clinical Research Institute, Duke University, Durham, North Carolina.'}, {'ForeName': 'Eiran Z', 'Initials': 'EZ', 'LastName': 'Gorodeski', 'Affiliation': 'Department of Medicine, Harrington Heart and Vascular Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.'}, {'ForeName': 'Patrice', 'Initials': 'P', 'LastName': 'Desvigne-Nickens', 'Affiliation': 'Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Baltimore, Maryland.'}, {'ForeName': 'Adrian F', 'Initials': 'AF', 'LastName': 'Hernandez', 'Affiliation': 'Department of Medicine, Duke University, Durham, North Carolina; Duke Clinical Research Institute, Duke University, Durham, North Carolina.'}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Braunwald', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JACC. Heart failure,['10.1016/j.jchf.2020.05.005'] 1917,32684741,Rapid rehabilitation technique with integrated traditional Chinese and Western medicine promotes postoperative gastrointestinal function recovery.,"BACKGROUND During the perioperative period, the characteristic therapy of traditional Chinese medicine is effective in improving postoperative rehabilitation. In large-scale hospitals practicing traditional Chinese medicine, there is accumulating experience related to the promotion of fast recovery in the perioperative period. AIM To evaluate the efficacy and safety of Yikou-Sizi powder hot compress on Shenque acupuncture point combined with rapid rehabilitation technique. METHODS This prospective, multicenter, randomized, controlled study included two groups: Treatment group and control group. The patients in the treatment group and control group received Yikou-Sizi powder hot compress on Shenque acupuncture point combined with rapid rehabilitation technique and routine treatment, respectively. Clinical observation regarding postoperative recovery of gastrointestinal function was performed, including the times to first passage of flatus, first defecation, and first normal bowel sounds. The comparison between groups was conducted through descriptive analysis, χ 2 , t, F , and rank-sum tests. RESULTS There was a statistically significant difference in the time to postoperative first defecation between the treatment and control group (87.16 ± 32.09 vs 109.79 ± 40.25 h, respectively; P < 0.05). Similarly, the time to initial recovery of bowel sounds in the treatment group was significantly shorter than that in the control group (61.17 ± 26.75 vs 79.19 ± 33.35 h, respectively; P < 0.05). However, there was no statistically significant difference in the time to initial exhaust between the treatment and control groups (51.54 ± 23.66 vs 62.24 ± 25.95 h, respectively; P > 0.05). The hospitalization expenses for the two groups of patients were 62283.45 ± 12413.90 and 62059.42 ± 11350.51 yuan, respectively. Although the cost of hospitalization was decreased in the control group, the difference was not statistically significant ( P > 0.05). This clinical trial was safe without reports of any adverse reaction or event. CONCLUSION The rapid rehabilitation technique with integrated traditional Chinese and Western medicine promotes the recovery of postoperative gastrointestinal function and is significantly better than standard approach for patients after colorectal surgery.",2020,"Similarly, the time to initial recovery of bowel sounds in the treatment group was significantly shorter than that in the control group (61.17 ± 26.75 vs 79.19 ± 33.35 h, respectively; P < 0.05).",['patients after colorectal surgery'],"['Rapid rehabilitation technique with integrated traditional Chinese and Western medicine', 'Yikou-Sizi powder hot compress', 'rapid rehabilitation technique with integrated traditional Chinese and Western medicine', 'Yikou-Sizi powder hot compress on Shenque acupuncture point combined with rapid rehabilitation technique and routine treatment']","['time to initial recovery of bowel sounds', 'efficacy and safety', 'cost of hospitalization', 'time to initial exhaust', 'hospitalization expenses', 'postoperative gastrointestinal function', 'time to postoperative first defecation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009369', 'cui_str': 'Colorectal surgery'}]","[{'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0032861', 'cui_str': 'Powder'}, {'cui': 'C0444519', 'cui_str': 'Hot'}, {'cui': 'C0332260', 'cui_str': 'Compressing'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0232693', 'cui_str': 'Bowel sounds'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}]",,0.0262552,"Similarly, the time to initial recovery of bowel sounds in the treatment group was significantly shorter than that in the control group (61.17 ± 26.75 vs 79.19 ± 33.35 h, respectively; P < 0.05).","[{'ForeName': 'Li-Xing', 'Initials': 'LX', 'LastName': 'Cao', 'Affiliation': 'Perioperative Research Team, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong Province, China.'}, {'ForeName': 'Zhi-Qiang', 'Initials': 'ZQ', 'LastName': 'Chen', 'Affiliation': 'Perioperative Research Team, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong Province, China. weishoushuqi@163.com.'}, {'ForeName': 'Zhi', 'Initials': 'Z', 'LastName': 'Jiang', 'Affiliation': 'Perioperative Research Team, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong Province, China.'}, {'ForeName': 'Qi-Cheng', 'Initials': 'QC', 'LastName': 'Chen', 'Affiliation': 'Perioperative Research Team, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong Province, China.'}, {'ForeName': 'Xiao-Hua', 'Initials': 'XH', 'LastName': 'Fan', 'Affiliation': 'Perioperative Research Team, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong Province, China.'}, {'ForeName': 'Shi-Jun', 'Initials': 'SJ', 'LastName': 'Xia', 'Affiliation': 'Perioperative Research Team, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong Province, China.'}, {'ForeName': 'Jin-Xuan', 'Initials': 'JX', 'LastName': 'Lin', 'Affiliation': 'The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong province, China.'}, {'ForeName': 'Hua-Chan', 'Initials': 'HC', 'LastName': 'Gan', 'Affiliation': 'Perioperative Research Team, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong Province, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Wang', 'Affiliation': 'The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong province, China.'}, {'ForeName': 'Yang-Xue', 'Initials': 'YX', 'LastName': 'Huang', 'Affiliation': 'The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong province, China.'}]",World journal of gastroenterology,['10.3748/wjg.v26.i23.3271'] 1918,32648810,Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: Post-hoc analysis of short- and long-term studies.,"BACKGROUND The treatment of patients with severe schizophrenia symptoms can be complicated and expensive. AIMS The purpose of this study was to evaluate the short- and long-term effects of brexpiprazole in patients with schizophrenia presenting with severe symptoms. METHODS Data were pooled from three six-week, randomized, double-blind, placebo-controlled studies and two 52-week, open-label extension studies. In the short-term studies, 1405 patients received placebo or brexpiprazole 2-4 mg/day; 412 brexpiprazole-treated patients rolled over into the long-term studies and received brexpiprazole 1-4 mg/day. More severe symptoms were defined as a Positive and Negative Syndrome Scale Total score >95 (median score at baseline). Outcomes included change in Positive and Negative Syndrome Scale Total and Personal and Social Performance scale scores. RESULTS Brexpiprazole improved Positive and Negative Syndrome Scale Total score over 6 weeks among more severely ill patients, with a least squares mean difference versus placebo of -6.76 (95% confidence limits: -9.80, -3.72; p <0.0001; Cohen's d : 0.43). Brexpiprazole also improved Personal and Social Performance scale score over 6 weeks in more severely ill patients (least squares mean difference: 4.38; limits: 2.14, 6.62; p =0.0001; Cohen's d : 0.38). Improvement of functioning was greatest in the 'Self-care' domain, followed by 'Personal and social relationships'. Among less severely ill patients, brexpiprazole was superior to placebo on Positive and Negative Syndrome Scale Total and Personal and Social Performance scale at Week 6. Improvements were maintained over 58 weeks. No new safety or tolerability concerns were observed. CONCLUSIONS Brexpiprazole is an efficacious and well-tolerated treatment for schizophrenia in patients with more severe, and less severe, symptoms.",2020,"Among less severely ill patients, brexpiprazole was superior to placebo on Positive and Negative Syndrome Scale Total and Personal and Social Performance scale at Week 6.","['patients with schizophrenia presenting with severe symptoms', '1405 patients received', 'patients with severe schizophrenia symptoms']","['brexpiprazole-treated patients rolled over into the long-term studies and received brexpiprazole 1-4 mg/day', 'Brexpiprazole', 'brexpiprazole', 'placebo or brexpiprazole', 'placebo']","['change in Positive and Negative Syndrome Scale Total and Personal and Social Performance scale scores', 'Positive and Negative Syndrome Scale Total and Personal and Social Performance scale', 'Personal and Social Performance scale score', 'severe symptoms', 'Efficacy and safety', 'Positive and Negative Syndrome Scale Total score', 'new safety or tolerability concerns']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0436345', 'cui_str': 'Symptom severe'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C3885614', 'cui_str': 'brexpiprazole'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0543436', 'cui_str': 'Does roll over'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0436345', 'cui_str': 'Symptom severe'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205314', 'cui_str': 'New'}]",1405.0,0.236428,"Among less severely ill patients, brexpiprazole was superior to placebo on Positive and Negative Syndrome Scale Total and Personal and Social Performance scale at Week 6.","[{'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Meade', 'Affiliation': 'Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, USA.'}, {'ForeName': 'Lily', 'Initials': 'L', 'LastName': 'Shi', 'Affiliation': 'Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, USA.'}, {'ForeName': 'Stine R', 'Initials': 'SR', 'LastName': 'Meehan', 'Affiliation': 'H. Lundbeck A/S, Valby, Copenhagen, Denmark.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Weiss', 'Affiliation': 'Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, USA.'}, {'ForeName': 'Zahinoor', 'Initials': 'Z', 'LastName': 'Ismail', 'Affiliation': 'Department of Psychiatry and Hotchkiss Brain Institute, University of Calgary, Calgary, Canada.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881120936485'] 1919,32645111,The effects of ten weeks resistance training on sticking region in chest-press exercises.,"The aim of the study was to compare the effects of a 10-week chest-press resistance training on lifting regions in a trained exercise and a none-trained exercise; the barbell bench press (BBP). Thirty-five resistance trained men with 4.2 (± 2.3) years of resistance training experience were recruited. The participants were randomized to attend a resistance program, performing the chest-press, twice per week using either, Smith machine, dumbbells or laying on Swiss ball using a barbell. A six-repetitions maximum (6RM) test was conducted pre- and post-training in the trained chest-press exercise and non-trained BBP to examine lifting velocity, load displacement and the time of the pre-sticking, sticking and post-sticking regions. Additionally, the muscle activity in pectoralis major, triceps brachii, biceps brachii and deltoid anterior was examined. In the post-test, all three chest-press groups decreased lifting velocity and increased the time to reach the sticking- and post-sticking region. Independent of the type of chest-press exercise trained, no differences were observed in vertical displacement or in the muscle activity for the three lifting regions. In general, similar changes in kinematics in trained exercise and those observed in the BBP were observed for all three groups. This indicates that none of the three chest-press exercises (Swiss ball, Smith machine or dumbbells) were specific regarding the lifting regions but displaced a transferability towards the non-trained BBP. However, improved strength altered the sticking region among resistance trained men.",2020,"In the post-test, all three chest-press groups decreased lifting velocity and increased the time to reach the sticking- and post-sticking region.",['Thirty-five resistance trained men with 4.2 (± 2.3) years of resistance training experience were recruited'],"['10-week chest-press resistance training', 'Smith machine, dumbbells or laying on Swiss ball using a barbell', 'resistance training']","['lifting velocity', 'muscle activity in pectoralis major, triceps brachii, biceps brachii and deltoid anterior', 'BBP']","[{'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4517758', 'cui_str': '4.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0347795', 'cui_str': ""Reversed Colles' fracture""}, {'cui': 'C0336779', 'cui_str': 'Machine'}, {'cui': 'C2721273', 'cui_str': 'Balance ball exerciser'}]","[{'cui': 'C0181620', 'cui_str': 'Hoist'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0559499', 'cui_str': 'Biceps brachii muscle structure'}, {'cui': 'C0224234', 'cui_str': 'Structure of deltoid muscle'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0454326', 'cui_str': 'Bench press'}]",35.0,0.0227159,"In the post-test, all three chest-press groups decreased lifting velocity and increased the time to reach the sticking- and post-sticking region.","[{'ForeName': 'Atle Hole', 'Initials': 'AH', 'LastName': 'Saeterbakken', 'Affiliation': 'Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}, {'ForeName': 'Vidar', 'Initials': 'V', 'LastName': 'Andersen', 'Affiliation': 'Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'van den Tillaar', 'Affiliation': 'Department of Sport Science and Physical Education, Nord University, Levanger, Norway.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Joly', 'Affiliation': 'Rennes School of Sports, Rennes, France.'}, {'ForeName': 'Nicolay', 'Initials': 'N', 'LastName': 'Stien', 'Affiliation': 'Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}, {'ForeName': 'Helene', 'Initials': 'H', 'LastName': 'Pedersen', 'Affiliation': 'Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}, {'ForeName': 'Matthew Peter', 'Initials': 'MP', 'LastName': 'Shaw', 'Affiliation': 'Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}, {'ForeName': 'Tom Erik Jorung', 'Initials': 'TEJ', 'LastName': 'Solstad', 'Affiliation': 'Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}]",PloS one,['10.1371/journal.pone.0235555'] 1920,32645452,Surrogate Decision Maker Stress in Advance Care Planning Conversations: A Mixed-Methods Analysis from a Randomized Controlled Trial.,"CONTEXT Spokespersons serving as surrogate decision-makers for their loved ones report high levels of stress. Despite known benefits, advance care planning (ACP) conversations often do not occur. More information is needed to understand spokesperson stress during ACP. OBJECTIVES To: 1) explore if and how spokespersons perceive stress related to ACP conversations; 2) compare factors related to stress; and 3) assess whether ACP intervention impacted stress. METHODS Secondary, mixed methods analysis with data transformation of semi-structured interviews occurring during a 2x2 factorial (four armed), randomized controlled trial that compared standard online ACP to a comprehensive, online ACP decision aid. Tools were completed by patients with advanced illness (n=285) alone or with their spokesperson (n=285). 200 spokesperson interviews were purposively sampled from each of the 4 arms (50 per arm). RESULTS ACP conversations were reported as stressful by 54.41% (74/136), and non-stressful by 45.59% (62/136). Five themes impacting spokesperson stress were: (1) the nature of the relationship with their loved one, (2) self-described personality and belief systems, (3) knowledge and experience with illness and ACP conversations, (4) attitude toward ACP conversations, and (5) social support in caregiving and decision making. No significant differences in stress were associated with arm assignment. CONCLUSION Identifying what factors impact spokesperson stress in ACP conversations can be used to help design ACP interventions to more appropriately address the needs and concerns of spokespersons.",2020,"RESULTS ACP conversations were reported as stressful by 54.41% (74/136), and non-stressful by 45.59% (62/136).","['Advance Care Planning Conversations', 'Secondary, mixed methods analysis with data transformation of semi-structured interviews occurring during a 2x2 factorial (four armed', '200 spokesperson interviews were purposively sampled from each of the 4 arms (50 per arm', 'patients with advanced illness (n=285) alone or with their spokesperson (n=285']",['standard online ACP'],"['stress', 'nature of the relationship with their loved one, (2) self-described personality and belief systems, (3) knowledge and experience with illness and ACP conversations, (4) attitude toward ACP conversations, and (5) social support in caregiving and decision making']","[{'cui': 'C0600371', 'cui_str': 'Advance care planning'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C3714584', 'cui_str': 'Transformation'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0221423', 'cui_str': 'Illness'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0600371', 'cui_str': 'Advance care planning'}]","[{'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0349590', 'cui_str': 'Nature'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0205447', 'cui_str': '1'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0003944', 'cui_str': 'As If Personality'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0600371', 'cui_str': 'Advance care planning'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0011109', 'cui_str': 'Decision making'}]",,0.0799872,"RESULTS ACP conversations were reported as stressful by 54.41% (74/136), and non-stressful by 45.59% (62/136).","[{'ForeName': 'Daniella', 'Initials': 'D', 'LastName': 'Lipnick', 'Affiliation': 'Penn State College of Medicine. Electronic address: dlipnick@pennstatehealth.psu.edu.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Green', 'Affiliation': 'Department of Humanities; Department of Medicine.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Thiede', 'Affiliation': 'Penn State College of Nursing, University Park, PA, USA.'}, {'ForeName': 'Theresa J', 'Initials': 'TJ', 'LastName': 'Smith', 'Affiliation': 'Department of Humanities.'}, {'ForeName': 'Erik B', 'Initials': 'EB', 'LastName': 'Lehman', 'Affiliation': 'Department of Humanities; Department of Public Health Sciences at Penn State College of Medicine, Penn State Milton S. Hershey Medical Center; Hershey, PA, USA.'}, {'ForeName': 'Ms Rhonda', 'Initials': 'MR', 'LastName': 'Johnson', 'Affiliation': 'Department of Humanities.'}, {'ForeName': 'In Seo', 'Initials': 'IS', 'LastName': 'La', 'Affiliation': 'University of Maryland School of Nursing, Baltimore, MD, USA.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Wiegand', 'Affiliation': 'University of Maryland School of Nursing, Baltimore, MD, USA.'}, {'ForeName': 'Benjamin H', 'Initials': 'BH', 'LastName': 'Levi', 'Affiliation': 'Department of Humanities; Department of Pediatrics.'}, {'ForeName': 'Lauren Jodi', 'Initials': 'LJ', 'LastName': 'Van Scoy', 'Affiliation': 'Department of Humanities; Department of Medicine; Department of Public Health Sciences at Penn State College of Medicine, Penn State Milton S. Hershey Medical Center; Hershey, PA, USA.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2020.07.001'] 1921,32645640,The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.,"OBJECTIVE Ocrelizumab inhibits relapsing multiple sclerosis when administered every six months. Based on potential similar memory B cell depletion mechanisms with cladribine and alemtuzumab, we hypothesised that CD20-depletion of B cells by ocrelizumab may exhibit a duration of response exceeding the current licenced treatment interval. METHODS Internet-located information from regulatory submissions and meeting reports relating to the unpublished open-label, phase II ocrelizumab extension trial (NCT00676715) were reviewed. This followed people (54-55/arm) with MS, who switched from placebo or interferon-beta to ocrelizumab for three 600 mg treatment cycles (week 24, 48, 72) or people treated with ocrelizumab for four 600 mg treatment cycles (week 0-72), followed by an 18 month treatment-free period. RESULTS CD19+ B cells were rapidly depleted within 2 weeks and slow CD19+ B cell repopulation began about 6 months after the last infusion with median-repletion of over 15 months. The reduced annualized relapse rate during the published efficacy study appeared to be maintained in the extension study and there were no new T1 gadolinium-enhancing or T2 lesions detected in the treatment-free period. Importantly, within these extension cohorts, there appeared to be fewer adverse events and infections events. CONCLUSIONS Ocrelizumab appears to induce durable relapsing disease inhibition, within 3 treatment cycles Therefore, it may be possible to reduce the frequency of dosing to maintain efficacy, whilst limiting infection and other risks associated with continuous immunosuppression and could allow more effective vaccination against new pathogens. Further studies are now clearly required to determine whether this data is robust.",2020,"CONCLUSIONS Ocrelizumab appears to induce durable relapsing disease inhibition, within 3 treatment cycles",[],"['placebo or interferon-beta to ocrelizumab', 'cladribine and alemtuzumab', 'Ocrelizumab', 'ocrelizumab']","['annualized relapse rate', 'new T1 gadolinium-enhancing or T2 lesions']",[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0015980', 'cui_str': 'Interferon-beta'}, {'cui': 'C1882138', 'cui_str': 'ocrelizumab'}, {'cui': 'C0092801', 'cui_str': 'Cladribine'}, {'cui': 'C0383429', 'cui_str': 'alemtuzumab'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0016911', 'cui_str': 'Gadolinium'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",,0.0255681,"CONCLUSIONS Ocrelizumab appears to induce durable relapsing disease inhibition, within 3 treatment cycles","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Baker', 'Affiliation': 'Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, United Kingdom. Electronic address: david.baker@qmul.ac.uk.'}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Pryce', 'Affiliation': 'Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, United Kingdom.'}, {'ForeName': 'Louisa K', 'Initials': 'LK', 'LastName': 'James', 'Affiliation': 'Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, United Kingdom.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Marta', 'Affiliation': 'Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, United Kingdom; Clinical Board:Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London E1 1BB, United Kingdom.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Schmierer', 'Affiliation': 'Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, United Kingdom; Clinical Board:Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London E1 1BB, United Kingdom.'}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2020.102279'] 1922,32645683,Eye tracking of smoking-related stimuli in tobacco use disorder: A proof-of-concept study combining attention bias modification with alpha-transcranial alternating current stimulation.,"BACKGROUND Tobacco use disorder (TUD) is characterized by the presence of an attentional bias (AB) towards smoking-related stimuli. We investigated whether combining an AB modification paradigm (ABM) with transcranial alternating current stimulation (tACS) applied over the dorsolateral prefrontal cortex (DLPFC) reduces the AB towards smoking-related stimuli, as well as craving level and impulsive choices. METHODS In a sham-controlled, crossover preliminary study, 19 subjects with TUD received two stimulation arms: 1) active tACS (10 Hz, 2 mA, 30 min) combined with ABM and 2) sham tACS combined with ABM, in a randomized order, separated by one week. AB towards smoking cues during passive observation of smoking and neutral cues was assessed with an eye-tracking device and reactions times at a visual-probe task. Craving level was measured with the Questionnaire of Smoking Urges. Impulsive choices were assessed with the delay discounting task. RESULTS Active tACS combined with ABM reduced the amount of time spent looking at smoking-related pictures (p = 0.03), prevented the increase of self-reported desire to smoke (p = 0.026), and reduced the proportion of impulsive choices (p = 0.049), compared to sham tACS combined with ABM. No significant effects were reported on other craving dimensions and on AB based on reaction times. CONCLUSIONS These preliminary findings suggest that combining tACS with ABM may help smokers who wish to quit by reducing the desire to smoke, attention to smoking-cues, and impulsive decision-making.",2020,"RESULTS Active tACS combined with ABM reduced the amount of time spent looking at smoking-related pictures (p = 0.03), prevented the increase of self-reported desire to smoke (p = 0.026), and reduced the proportion of impulsive choices (p = 0.049), compared to sham tACS combined with ABM.","['19 subjects with TUD received two stimulation arms: 1', 'tobacco use disorder']","['tACS with ABM', 'alpha-transcranial alternating current stimulation', 'active tACS (10 Hz, 2 mA, 30 min) combined with ABM and 2) sham tACS combined with ABM', 'AB modification paradigm (ABM) with transcranial alternating current stimulation (tACS']","['Impulsive choices', 'increase of self-reported desire to smoke', 'delay discounting task', 'proportion of impulsive choices', 'craving dimensions and on AB based on reaction times', 'Craving level', 'time spent looking at smoking-related pictures']","[{'cui': 'C0040336', 'cui_str': 'Tobacco abuse'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C3852966', 'cui_str': 'Transcranial Alternating Current Stimulation'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C4277667', 'cui_str': 'Attentional Biases'}]","[{'cui': 'C0021125', 'cui_str': 'Impulsive behaviour'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C3850035', 'cui_str': 'Intertemporal Preferences'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C4277667', 'cui_str': 'Attentional Biases'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}]",19.0,0.0484381,"RESULTS Active tACS combined with ABM reduced the amount of time spent looking at smoking-related pictures (p = 0.03), prevented the increase of self-reported desire to smoke (p = 0.026), and reduced the proportion of impulsive choices (p = 0.049), compared to sham tACS combined with ABM.","[{'ForeName': 'Marine', 'Initials': 'M', 'LastName': 'Mondino', 'Affiliation': ""Department of Psychiatry and Neurosciences, Medical School, Université Laval, CERVO Brain Research Center, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, 2325 rue de l'Université, Quebec City, QC, G1V 0A6, Canada.""}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Lenglos', 'Affiliation': ""Department of Psychiatry and Neurosciences, Medical School, Université Laval, CERVO Brain Research Center, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, 2325 rue de l'Université, Quebec City, QC, G1V 0A6, Canada.""}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Cinti', 'Affiliation': ""Department of Psychiatry and Neurosciences, Medical School, Université Laval, CERVO Brain Research Center, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, 2325 rue de l'Université, Quebec City, QC, G1V 0A6, Canada.""}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Renauld', 'Affiliation': ""Department of Psychiatry and Neurosciences, Medical School, Université Laval, CERVO Brain Research Center, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, 2325 rue de l'Université, Quebec City, QC, G1V 0A6, Canada.""}, {'ForeName': 'Shirley', 'Initials': 'S', 'LastName': 'Fecteau', 'Affiliation': ""Department of Psychiatry and Neurosciences, Medical School, Université Laval, CERVO Brain Research Center, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, 2325 rue de l'Université, Quebec City, QC, G1V 0A6, Canada. Electronic address: shirley.fecteau@fmed.ulaval.ca.""}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108152'] 1923,32646037,Crying Therapy Intervention for Breast Cancer Survivors: Development and Effects.,"BACKGROUND crying therapy is currently being applied in some countries to treat cancer patients, manage pain, and promote mental health. However, little nursing and medical research on the effects of crying therapy has been conducted in other parts of the world. This study aimed to develop a crying therapy program for breast cancer survivors and assess its effects. Interventions/method: data from 27 breast cancer survivors in South Korea were analyzed. The intervention, employing a single group, pre-post-test quasi-experimental design, was divided into three phases, and effects were verified for emotional (distress, fatigue, and mood conditions) and physiological (cortisol, immunoglobulin G, and blood pressure) variables. RESULTS there were significant changes in distress, mood changes, and immunoglobulin G and smaller changes in blood pressure postintervention. Fatigue and cortisol showed no significant changes. CONCLUSIONS this study demonstrated the effectiveness of a short-term crying therapy program that can induce positive emotional changes and physiological effects in breast cancer survivors. This intervention can improve quality of life, indicating its value as a self-care program for cancer survivors.",2020,"Fatigue and cortisol showed no significant changes. ","['Breast Cancer Survivors', 'breast cancer survivors', 'cancer survivors', '27 breast cancer survivors in South Korea']","['short-term crying therapy program', 'Crying Therapy Intervention', 'crying therapy program']","['quality of life', 'Fatigue and cortisol', 'distress, mood changes, and immunoglobulin G and smaller changes in blood pressure postintervention', 'positive emotional changes and physiological effects', 'emotional (distress, fatigue, and mood conditions) and physiological (cortisol, immunoglobulin G, and blood pressure) variables']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0010399', 'cui_str': 'Crying'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0085633', 'cui_str': 'Mood swings'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C1268766', 'cui_str': 'Blood pressure alteration'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0439828', 'cui_str': 'Variable'}]",27.0,0.0200838,"Fatigue and cortisol showed no significant changes. ","[{'ForeName': 'Hye-Sun', 'Initials': 'HS', 'LastName': 'Byun', 'Affiliation': 'School of Nursing, Yeungnam University College, Daegu 42415, Korea.'}, {'ForeName': 'Hyenam', 'Initials': 'H', 'LastName': 'Hwang', 'Affiliation': 'Department of Nursing, Daegu University, Daegu 42400, Korea.'}, {'ForeName': 'Gyung-Duck', 'Initials': 'GD', 'LastName': 'Kim', 'Affiliation': 'Department of Nursing, Dongyang University, Kyungpook 36040, Korea.'}]",International journal of environmental research and public health,['10.3390/ijerph17134911'] 1924,32191814,"Ferrous sulfate oral solution in young children with iron deficiency anemia: An open-label trial of efficacy, safety, and acceptability.","BACKGROUND This study evaluated the efficacy, safety, and acceptability of a new ferrous sulfate oral solution (Tardyferon® 20 mg/mL) in young children with mild or moderate iron deficiency anemia (IDA). METHODS This was a multicenter, national, single-arm, open-label study. Children aged 6-53 months presenting with mild or moderate IDA (i.e., blood hemoglobin (Hb) ranging from 7.0 to 10.9 g/dL and serum ferritin <12 ng/mL) were eligible for inclusion. The ferrous sulfate heptahydrate solution (2 mg/kg/day) was administered orally for 3 months. If normalization of either Hb or ferritin was not achieved at month 3 the treatment was continued for another 3 months. RESULTS Of the 100 children screened, 21 aged 6-17 months were included and received the study treatment, and 19 were analyzed for hematologic outcomes at month 3. Only one patient continued treatment for the additional 3 months. At month 3, mean ± SD Hb and ferritin levels were 12.0 ± 0.7 g/dL and 31.5 ± 19.4 ng/mL, respectively. Hemoglobin and ferritin levels were normalized in 95% (18/19) and 84% (16/19) of the patients, respectively. Treatment compliance and levels of satisfaction of both the parents and the investigators were high. Overall, 33.3% of patients (7/21) experienced at least one adverse event. Only one patient (4.8%) experienced a drug-related adverse event (upper abdominal pain). CONCLUSIONS A 2 mg/kg daily dose of the new oral ferrous sulfate heptahydrate solution provides substantial therapeutic benefit with high levels of tolerability in young children who have mild or moderate IDA.",2020,"Hemoglobin and ferritin levels were normalized in 95% (18/19) and 84% (16/19) of the patients, respectively.","['100 children screened, 21 aged 6-17\xa0months', 'Children aged 6-53\xa0months presenting with mild or moderate IDA (i.e.,\xa0blood hemoglobin (Hb) ranging from\xa07.0\xa0to\xa010.9\xa0g/dL and serum ferritin <12\xa0ng/mL) were eligible for inclusion', 'young children with mild or moderate iron deficiency anemia (IDA', 'young children who have mild or moderate IDA', 'young children with iron deficiency anemia']","['new ferrous sulfate oral solution (Tardyferon® 20\xa0mg/mL', 'Ferrous sulfate oral solution', 'ferrous sulfate heptahydrate solution']","['Hemoglobin and ferritin levels', 'efficacy, safety, and acceptability', 'mean ± SD Hb and ferritin levels', 'drug-related adverse event (upper abdominal pain']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439267', 'cui_str': 'g/dL'}, {'cui': 'C0696113', 'cui_str': 'Serum ferritin measurement'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C1246232', 'cui_str': 'ferrous sulfate Oral Solution'}, {'cui': 'C0075817', 'cui_str': 'tardyferon'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C0970110', 'cui_str': 'Ferrous sulfate heptahydrate'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0373607', 'cui_str': 'Ferritin measurement'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0232492', 'cui_str': 'Upper abdominal pain'}]",21.0,0.0787444,"Hemoglobin and ferritin levels were normalized in 95% (18/19) and 84% (16/19) of the patients, respectively.","[{'ForeName': 'Lidia', 'Initials': 'L', 'LastName': 'Pachuta Węgier', 'Affiliation': 'Lidia Pachuta Węgier Medical Services, Lublin, Poland.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Kubiak', 'Affiliation': 'Tolek Clinic for Children, Lesznowola, Poland.'}, {'ForeName': 'Agata', 'Initials': 'A', 'LastName': 'Liebert', 'Affiliation': 'Tolek Clinic for Children, Lesznowola, Poland.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Clavel', 'Affiliation': 'TCC Consulting, Revel, France.'}, {'ForeName': 'Agnès', 'Initials': 'A', 'LastName': 'Montagne', 'Affiliation': 'Clinical Development Department, Institut de Recherche Pierre Fabre, CRDPF, Toulouse, France.'}, {'ForeName': 'Aline', 'Initials': 'A', 'LastName': 'Stennevin', 'Affiliation': 'Clinical Development Department, Institut de Recherche Pierre Fabre, CRDPF, Toulouse, France.'}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Roye', 'Affiliation': 'Clinical Development Department, Institut de Recherche Pierre Fabre, CRDPF, Toulouse, France.'}, {'ForeName': 'Asmaa', 'Initials': 'A', 'LastName': 'Boudribila', 'Affiliation': 'Clinical Development Department, Institut de Recherche Pierre Fabre, CRDPF, Toulouse, France.'}]",Pediatrics international : official journal of the Japan Pediatric Society,['10.1111/ped.14237'] 1925,32639610,Long-term outcomes of anterior cruciate ligament reconstruction surgery: 2020 OREF clinical research award paper.,"ACL injuries place the knee at risk for post-traumatic osteoarthritis (PTOA) despite surgical anterior cruciate ligament (ACL) reconstruction. One parameter thought to affect PTOA risk is the initial graft tension. This randomized controlled trial (RCT) was designed to compare outcomes between two graft tensioning protocols that bracket the range commonly used. At 7 years postsurgery, we determined that most outcomes between the two tension groups were not significantly different, that they were inferior to an uninjured matched control group, and that PTOA was progressing in both groups relative to controls. The trial database was also leveraged to gain insight into mechanisms of PTOA following ACL injury. We determined that the inflammatory response at the time of injury undermines one of the joint's lubricating mechanisms. We learned that patients continue to protect their surgical knee 5 years postinjury compared to controls during a jump-pivot activity. We also established that presurgical knee function and mental health were correlated with symptomatic PTOA at 7 years, that there were specific anatomical factors associated with poor outcomes, and that there were no changes in outcomes due to tunnel widening in patients receiving hamstring tendon autografts. We also validated a magnetic resonance imaging technique to noninvasively assess graft strength. In conclusion, the RCT determined that initial graft tensioning does not have a major influence on 7-year outcomes. Therefore, surgeons can reconstruct the ACL using a graft tensioning protocol that is within the window of the two graft tensioning techniques evaluated in this RCT.",2020,"At 7-years post-surgery, we determined that most outcomes between the two tension groups were not significantly different, that they were inferior to an uninjured matched control group, and that PTOA was progressing in the both groups relative to controls.",['patients receiving hamstring tendon autografts'],"['surgical ACL reconstruction (ACLR', 'Anterior Cruciate Ligament Reconstruction Surgery']",['pre-surgical knee function and mental health'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039508', 'cui_str': 'Tendon structure'}, {'cui': 'C0040736', 'cui_str': 'Autogenous transplantation'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0162596', 'cui_str': 'Cardiolipin antibody'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]",,0.0307706,"At 7-years post-surgery, we determined that most outcomes between the two tension groups were not significantly different, that they were inferior to an uninjured matched control group, and that PTOA was progressing in the both groups relative to controls.","[{'ForeName': 'Braden C', 'Initials': 'BC', 'LastName': 'Fleming', 'Affiliation': 'Department of Orthopaedics, Warren Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island.'}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Fadale', 'Affiliation': 'Department of Orthopaedics, Warren Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Hulstyn', 'Affiliation': 'Department of Orthopaedics, Warren Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Shalvoy', 'Affiliation': 'Department of Orthopaedics, Warren Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island.'}, {'ForeName': 'Glenn A', 'Initials': 'GA', 'LastName': 'Tung', 'Affiliation': 'Department of Orthopaedics, Warren Alpert Medical School of Brown University/Rhode Island Hospital, Providence, Rhode Island.'}, {'ForeName': 'Gary J', 'Initials': 'GJ', 'LastName': 'Badger', 'Affiliation': 'Department of Medical Biostatistics, University of Vermont, Burlington, Vermont.'}]",Journal of orthopaedic research : official publication of the Orthopaedic Research Society,['10.1002/jor.24794'] 1926,32645840,Effect of a Game-Based Physical Education Program on Physical Fitness and Mental Health in Elementary School Children.,"Promotion of healthy active behaviors should start from early ages, as behaviors learned in youth are more likely to endure. A fundamental body of research in this field focuses on the implementation of programs within physical education (PE), thanks to its favorable characteristics. However, traditional PE based on exercise training and controlling styles seems to have weaker association with students' health benefits. For this reason, the aim of this study was to assess the effects of a game-based PE program on physical fitness and psychological health in schoolchildren aged 10 to 12 years old. A total of 252 students were distributed in experimental (EG, games-centered activities) and control (CG, traditional exercise training activities) groups. The program lasted 6 months. Health-related physical fitness components, psychological wellbeing, self-esteem, stress, and anxiety were assessed before and after the treatment. Both groups increased physical fitness at post-test; however, cardiorespiratory fitness did not improve. No differences were found between the groups at post-test. Our results show that games may be as effective as traditional training methods; yet, they suggest that PE alone may be insufficient for obtaining substantive benefits in cardiorespiratory fitness, regardless of the type of task presented.",2020,No differences were found between the groups at post-test.,"['Elementary School Children', 'A total of 252 students', 'schoolchildren aged 10 to 12 years old']","['exercise training', 'control (CG, traditional exercise training activities', 'Game-Based Physical Education Program', 'game-based PE program']","['Physical Fitness and Mental Health', 'physical fitness', 'Health-related physical fitness components, psychological wellbeing, self-esteem, stress, and anxiety', 'physical fitness and psychological health', 'cardiorespiratory fitness']","[{'cui': 'C0260267', 'cui_str': 'School child'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0031805', 'cui_str': 'Education, Physical'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}]",252.0,0.0137873,No differences were found between the groups at post-test.,"[{'ForeName': 'Armando', 'Initials': 'A', 'LastName': 'Cocca', 'Affiliation': 'Department of Sport Science, University of Innsbruck, 6020 Innsbruck, Tirol, Austria.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Espino Verdugo', 'Affiliation': 'School of Sports Organization, Autonomous University of Nuevo Leon, San Nicolás de los Garza 66455, Mexico.'}, {'ForeName': 'Luis Tomás', 'Initials': 'LT', 'LastName': 'Ródenas Cuenca', 'Affiliation': 'School of Sports Organization, Autonomous University of Nuevo Leon, San Nicolás de los Garza 66455, Mexico.'}, {'ForeName': 'Michaela', 'Initials': 'M', 'LastName': 'Cocca', 'Affiliation': 'School of Sports Organization, Autonomous University of Nuevo Leon, San Nicolás de los Garza 66455, Mexico.'}]",International journal of environmental research and public health,['10.3390/ijerph17134883'] 1927,32645890,The Effect of Different Cadence on Paddling Gross Efficiency and Economy in Stand-Up Paddle Boarding.,"Background: Due to the importance of energy efficiency and economy in endurance performance, it is important to know the influence of different paddling cadences on these variables in the stand-up paddleboarding (SUP). The purpose of this study was to determine the effect of paddling at different cadences on the energy efficiency, economy, and physiological variables of international SUP race competitors. Methods: Ten male paddlers (age 28.8 ± 11.0 years; height 175.4 ± 5.1 m; body mass 74.2 ± 9.4 kg) participating in international tests carried out two test sessions. In the first one, an incremental exercise test was conducted to assess maximal oxygen uptake and peak power output (PPO). On the second day, they underwent 3 trials of 8 min each at 75% of PPO reached in the first test session. Three cadences were carried out in different trials randomly assigned between 45-55 and 65 strokes-min -1 (spm). Heart rate (HR), blood lactate, perceived sense of exertion (RPE), gross efficiency, economy, and oxygen uptake (VO 2 ) were measured in the middle (4-min) and the end (8-min) of each trial. Results: Economy (45.3 ± 5.7 KJ·l -1 at 45 spm vs. 38.1 ± 5.3 KJ·l -1 at 65 spm; p = 0.010) and gross efficiency (13.4 ± 2.3% at 45 spm vs. 11.0 ± 1.6% at 65 spm; p = 0.012) was higher during de 45 spm condition than 65 spm in the 8-min. Respiratory exchange ratio (RER) presented a lower value at 4-min than at 8-min in 55 spm (4-min, 0.950 ± 0.065 vs. 8-min, 0.964 ± 0.053) and 65 spm cadences (4-min, 0.951 ± 0.030 vs. 8-min, 0.992 ± 0.047; p < 0.05). VO 2 , HR, lactate, and RPE were lower ( p < 0.05) at 45 spm (VO 2 , 34.4 ± 6.0 mL·kg -1 ·min -1 ; HR, 161.2 ± 16.4 beats·min -1 ; lactate, 3.5 ± 1.0 mmol·l -1 ; RPE, 6.0 ± 2.1) than at 55 spm (VO 2 , 38.6 ± 5.2 mL·kg -1 ·min -1 ; HR, 168.1 ± 15.1 beats·min -1 ; lactate, 4.2 ± 1.2 mmol·l -1 ; RPE, 6.9 ± 1.4) and 65 spm (VO 2 , 38.7 ± 5.9 mL·kg -1 ·min -1 ; HR, 170.7 ± 13.0 beats·min -1 ; 5.3 ± 1.8 mmol·l -1 ; RPE, 7.6 ± 1.4) at 8-min. Moreover, lactate and RPE at 65 spm was greater than 55 spm ( p < 0.05) at 8-min. Conclusion: International male SUP paddlers were most efficient and economical when paddling at 45 spm vs. 55 or 65 spm, confirmed by lower RPE values, which may likely translate to faster paddling speed and greater endurance.",2020,"VO 2 , HR, lactate, and RPE were lower ( p < 0.05) at 45 spm (VO 2 , 34.4 ± 6.0 mL·kg -1 ·min -1 ; HR, 161.2 ± 16.4 beats·min -1 ; lactate, 3.5 ± 1.0 mmol·l -1 ; RPE, 6.0 ± 2.1) than at 55 spm (VO 2 , 38.6 ± 5.2 mL·kg -1 ·min -1 ; HR, 168.1 ± 15.1 beats·min -1 ; lactate, 4.2 ± 1.2 mmol·l -1 ; RPE, 6.9 ± 1.4) and 65 spm (VO 2 , 38.7 ± 5.9 mL·kg -1 ·min -1 ; HR, 170.7 ± 13.0 beats·min -1 ; 5.3 ± 1.8 mmol·l -1 ; RPE, 7.6 ± 1.4) at 8-min.",['Methods: Ten male paddlers (age 28.8 ± 11.0 years; height 175.4 ± 5.1 m; body mass 74.2 ± 9.4 kg) participating in international tests carried out two test sessions'],[],"['Respiratory exchange ratio (RER', 'lactate and RPE', 'maximal oxygen uptake and peak power output (PPO', 'Heart rate (HR), blood lactate, perceived sense of exertion (RPE), gross efficiency, economy, and oxygen uptake (VO 2 ', 'gross efficiency', 'VO 2 , HR, lactate, and RPE']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}]",[],"[{'cui': 'C0429702', 'cui_str': 'Respiratory quotient'}, {'cui': 'C0230779', 'cui_str': 'Granular endoplasmic reticulum'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0035322', 'cui_str': 'Structure of retinal pigment epithelium'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0032956', 'cui_str': 'Preferred Provider Organization'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}]",2.0,0.0798461,"VO 2 , HR, lactate, and RPE were lower ( p < 0.05) at 45 spm (VO 2 , 34.4 ± 6.0 mL·kg -1 ·min -1 ; HR, 161.2 ± 16.4 beats·min -1 ; lactate, 3.5 ± 1.0 mmol·l -1 ; RPE, 6.0 ± 2.1) than at 55 spm (VO 2 , 38.6 ± 5.2 mL·kg -1 ·min -1 ; HR, 168.1 ± 15.1 beats·min -1 ; lactate, 4.2 ± 1.2 mmol·l -1 ; RPE, 6.9 ± 1.4) and 65 spm (VO 2 , 38.7 ± 5.9 mL·kg -1 ·min -1 ; HR, 170.7 ± 13.0 beats·min -1 ; 5.3 ± 1.8 mmol·l -1 ; RPE, 7.6 ± 1.4) at 8-min.","[{'ForeName': 'Arkaitz', 'Initials': 'A', 'LastName': 'Castañeda-Babarro', 'Affiliation': 'Health, Physical Activity and Sports Science Laboratory, Department of Physical Activity and Sports, Faculty of Psychology and Education, University of Deusto, 48007 Bizkaia, Spain.'}, {'ForeName': 'Jordan', 'Initials': 'J', 'LastName': 'Santos-Concejero', 'Affiliation': 'Department of Physical Education and Sport, Faculty of Education and Sport, University of the Basque Country UPV/EHU, 01007 Vitoria-Gasteiz, Spain.'}, {'ForeName': 'Aitor', 'Initials': 'A', 'LastName': 'Viribay', 'Affiliation': 'Glut4Science, Physiology, Nutrition and Sport, 01004 Vitoria-Gasteiz, Spain.'}, {'ForeName': 'Borja', 'Initials': 'B', 'LastName': 'Gutiérrez-Santamaría', 'Affiliation': 'Health, Physical Activity and Sports Science Laboratory, Department of Physical Activity and Sports, Faculty of Psychology and Education, University of Deusto, 48007 Bizkaia, Spain.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Mielgo-Ayuso', 'Affiliation': 'Department of Biochemistry, Molecular Biology and Physiology, Faculty of Health Sciences, University of Valladolid, 42004 Soria, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17134893'] 1928,32645892,Analysis of Motor Intervention Program on the Development of Gross Motor Skills in Preschoolers.,"This study aimed to investigate the influence of a structured movement activity program on the motor development of children aged three to five years attending preschool. Participants were 136 preschool students with normative development at three to four years old who lived in the Region of Murcia (Spain). The McCarthy Children's Psychomotricity and Aptitude Scales (MSCA) battery of psychomotor tests was used to evaluate the motor development profiles of preschoolers before and after the intervention. The sample was divided into two groups: an intervention group (28 students) and a comparison group (108 students). A structured 24 week physical education program was used in the intervention group. An experiential program based on free play was used in the comparison group during the same period. Preschoolers in both groups got a significant improvement in the contrast of pre-intervention with post-intervention in limb coordination. Statistically significant differences in the post-intervention measurements between the comparison group and the intervention group on arm and leg coordination were observed, whereby the intervention group presented higher arm coordination values ( F 1,134 = 14,389, p = 0.000, η 2 = 0.097) and higher leg coordination values ( F 1,134 = 19,281, p = 0.000, η 2 = 0.126) than the comparison group. It was pointed out that structured physical activity education is better educational methodology than free play to achieve adequate motor development in preschool children.",2020,Preschoolers in both groups got a significant improvement in the contrast of pre-intervention with post-intervention in limb coordination.,"['Participants were 136 preschool students with normative development at three to four years old who lived in the Region of Murcia (Spain', 'children aged three to five years attending preschool', 'Preschoolers', 'preschool children']","['structured movement activity program', 'Motor Intervention Program']","[""McCarthy Children's Psychomotricity and Aptitude Scales (MSCA) battery of psychomotor tests"", 'higher arm coordination values', 'higher leg coordination values', 'leg coordination']","[{'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1456498', 'cui_str': 'Attended'}]","[{'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0003646', 'cui_str': 'Aptitude'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}]",136.0,0.015633,Preschoolers in both groups got a significant improvement in the contrast of pre-intervention with post-intervention in limb coordination.,"[{'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Ruiz-Esteban', 'Affiliation': 'Department of Evolutionary and Educational Psychology, Campus Regional Excellence Mare Nostrum, University of Murcia, 30100 Murcia, Spain.'}, {'ForeName': 'Jaime', 'Initials': 'J', 'LastName': 'Terry Andrés', 'Affiliation': 'Department of Evolutionary and Educational Psychology, Campus Regional Excellence Mare Nostrum, University of Murcia, 30100 Murcia, Spain.'}, {'ForeName': 'Inmaculada', 'Initials': 'I', 'LastName': 'Méndez', 'Affiliation': 'Department of Evolutionary and Educational Psychology, Campus Regional Excellence Mare Nostrum, University of Murcia, 30100 Murcia, Spain.'}, {'ForeName': 'Ángela', 'Initials': 'Á', 'LastName': 'Morales', 'Affiliation': 'Department of Music, Autonomous University of Madrid, 28049 Madrid, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17134891'] 1929,32646041,Effects of Neuromuscular Electrical Stimulation Synchronized with Chewing Exercises on Bite Force and Masseter Muscle Thickness in Community-Dwelling Older Adults in South Korea: A Randomized Controlled Trial.,"This study is aimed at investigating the effects of synchronized neuromuscular electrical stimulation (NMES) and chewing exercises on bite force and the masseter muscle thickness in community-dwelling older adults. Material and methods: Forty older adults were enrolled in South Korea and randomly assigned to either an experimental or control group. The experimental group performed chewing exercises using the No-Sick Exerciser equipment synchronized with NMES applied to the bilateral masseter muscles, while the control group performed only chewing exercises. Both groups received interventions for 20 min/day, 5 days/week, for 6 weeks. Bite force was measured using the OCCLUZER device, and masseter muscle thickness was measured using a portable ultrasound. Results: Both groups showed a significant increase in bite force and masseter muscle thickness compared to baseline measurements ( p < 0.05). The experimental group showed a significantly higher increase in bite force and masseter muscle thickness than the control group after combined intervention ( p < 0.05). Conclusion: This study demonstrates that NMES synchronized with chewing exercises is more efficient in increasing bite force and masseter muscle thickness than chewing exercises alone in community-dwelling older adults.",2020,The experimental group showed a significantly higher increase in bite force and masseter muscle thickness than the control group after combined intervention ( p < 0.05). ,"['community-dwelling older adults', 'Community-Dwelling Older Adults in South Korea', 'Forty older adults were enrolled in South Korea']","['Neuromuscular Electrical Stimulation Synchronized with Chewing Exercises', 'NMES synchronized with chewing exercises', 'chewing exercises using the No-Sick Exerciser equipment synchronized with NMES applied to the bilateral masseter muscles, while the control group performed only chewing exercises', 'synchronized neuromuscular electrical stimulation (NMES) and chewing exercises']","['Bite force', 'Bite Force and Masseter Muscle Thickness', 'bite force and masseter muscle thickness']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}]","[{'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0439580', 'cui_str': 'Synchronous'}, {'cui': 'C0589278', 'cui_str': 'Chewing exercises'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0180776', 'cui_str': 'Exerciser'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0024876', 'cui_str': 'Masseter muscle structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0005654', 'cui_str': 'Masticatory Force'}, {'cui': 'C0024876', 'cui_str': 'Masseter muscle structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}]",40.0,0.0185005,The experimental group showed a significantly higher increase in bite force and masseter muscle thickness than the control group after combined intervention ( p < 0.05). ,"[{'ForeName': 'Ji-Su', 'Initials': 'JS', 'LastName': 'Park', 'Affiliation': 'Advanced Human Resource Development Project Group for Health Care in Aging Friendly Industry, Dongseo University, Busan 47011, Korea.'}, {'ForeName': 'Young-Jin', 'Initials': 'YJ', 'LastName': 'Jung', 'Affiliation': 'Advanced Human Resource Development Project Group for Health Care in Aging Friendly Industry, Dongseo University, Busan 47011, Korea.'}, {'ForeName': 'Min-Ji', 'Initials': 'MJ', 'LastName': 'Kim', 'Affiliation': 'Department of Dental Hygiene, DongSeo University, Busan 47011, Korea.'}]",International journal of environmental research and public health,['10.3390/ijerph17134902'] 1930,32646264,Bias and Loss to Follow-Up in Cardiovascular Randomized Trials: A Systematic Review.,"Background Loss to follow-up (LTFU) is common in randomized controlled trials. However, its potential impact on primary outcomes from cardiovascular randomized controlled trials is not known. Methods and Results We conducted a prospective systematic review (PROSPERO: CRD42019121959) for randomized controlled trials published in 8 leading journals over 5 years from January 2014 to December 2018. Extent, reporting, and handling of LTFU data were recorded, and the proportion of a trial's primary outcome results that lose statistical significance was calculated after making plausible assumptions for the intervention and control arms. These assumptions could drive differential treatment effects between the groups considering relative event incidence between LTFU participants and those included in the primary outcome. We identified 117 randomized controlled trials of which 91 (78%) trials reported LTFU, 23 (20%) reported no LTFU, and 3 (3%) trials did not report on whether LTFU occurred. The median percentage of study participants lost to follow-up was 2% (interquartile range, 0.33%-5.3%). Only 10 trials (9%) had a low cluster of risk factors for impairment in trial quality. The percentage of trials losing statistical significance varied from 2% when the relative event incidence for LTFU between the randomized groups was 1 for the intervention arm and 1.5 for the control arm to 16% when the relative event incidence was 3 for the intervention arm and 1 for the control arm. Conclusions Almost 1 in 6 (16%) cardiovascular randomized trials published in leading journals may have a change in the primary outcome if plausible assumptions are made about differential event rates of participants lost to follow up. There is scope for improvement arising from LTFU in randomized trials in cardiovascular medicine. Registration URL: https://www.crd.york.ac.uk/prospero; Unique identifier: CRD42019121959.",2020,The percentage of trials losing statistical significance varied from 2% when the relative event incidence for LTFU between the randomized groups was 1 for the intervention arm and 1.5 for the control arm to 16% when the relative event incidence was 3 for the intervention arm and 1 for the control arm.,"['117 randomized controlled trials of which 91 (78', '8 leading journals over 5\xa0years from January 2014 to December 2018']",[' Loss to follow-up (LTFU'],[],"[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0162443', 'cui_str': 'Journals as Topic'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0589120', 'cui_str': 'Follow-up status'}]",[],,0.329949,The percentage of trials losing statistical significance varied from 2% when the relative event incidence for LTFU between the randomized groups was 1 for the intervention arm and 1.5 for the control arm to 16% when the relative event incidence was 3 for the intervention arm and 1 for the control arm.,"[{'ForeName': 'Lucas Chun Wah', 'Initials': 'LCW', 'LastName': 'Fong', 'Affiliation': 'West of Scotland Heart and Lung Centre Golden Jubilee National Hospital Glasgow Scotland.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Ford', 'Affiliation': 'British Heart Foundation Glasgow Cardiovascular Research Centre Institute of Cardiovascular and Medical Sciences University of Glasgow United Kingdom.'}, {'ForeName': 'Bruno R', 'Initials': 'BR', 'LastName': 'da Costa', 'Affiliation': 'Institute of Health Policy, Management, and Evaluation Dalla Lana School of Public Health University of Toronto.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Jüni', 'Affiliation': 'Department of Medicine University of Toronto Canada.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Berry', 'Affiliation': 'West of Scotland Heart and Lung Centre Golden Jubilee National Hospital Glasgow Scotland.'}]",Journal of the American Heart Association,['10.1161/JAHA.119.015361'] 1931,32651582,Injuries on the Youth Soccer (Football) Field: Do Additional Referees Reduce Risk? Randomized Crossover Trial.,"OBJECTIVE Youth soccer injury can be prevented through various means, but few studies consider the role of referees. Following previous research suggesting children take fewer risks when supervised intensely, this randomized crossover trial evaluated whether risky play and injuries decrease under supervision from three referees instead of one referee. METHODS Youth soccer clubs serving a metropolitan U.S. area participated. Boys' and girls' clubs at under age 10 (U10) and under age 11 (U11) levels were randomly assigned such that when the same clubs played each other twice in the same season, they played once with one referee and once with three referees. A total of 98 games were videotaped and subsequently coded to obtain four outcomes: collisions between players, aggressive fouls (involving physical player-to-player contact) called by the referee(s) on the field, aggressive fouls judged by trained coders, and injuries requiring adult attention or play stoppage. RESULTS Poisson mixed model results suggest players in the 98 games committed fewer aggressive fouls, as identified independently by referees (rate ratio [RR] 0.58; 95% confidence interval [CI] 0.35-0.96) and by researchers (RR 0.67; 95% CI 0.50-0.90), when there were three referees versus one referee. Collisions (RR 0.98; 95% CI 0.86-1.12) and injury rates (RR 1.15; 95% CI 0.60-2.19) were similar across conditions. CONCLUSION When the same youth soccer clubs played with three referees rather than one, they committed fewer aggressive fouls. More intense supervision created better rule adherence. Injury rates were unchanged with increased supervision. Results raise questions concerning whether financial investment in additional referees on youth soccer fields yields safety benefits.",2020,"Collisions (RR 0.98; 95% CI 0.86-1.12) and injury rates (RR 1.15; 95% CI 0.60-2.19) were similar across conditions. ","['Youth soccer clubs serving a metropolitan U.S. area participated', ""Boys' and girls' clubs at under age 10 (U10) and under age 11 (U11) levels""]","['videotaped and subsequently coded to obtain four outcomes: collisions between players, aggressive fouls (involving physical player-to-player contact) called by the referee(s) on the field, aggressive fouls judged by trained coders, and injuries requiring adult attention or play stoppage']","['injury rates', 'Injury rates', 'aggressive fouls']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0149651', 'cui_str': 'Clubbing'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0007465', 'cui_str': 'Cause of death'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0221191', 'cui_str': 'Judge'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0032214', 'cui_str': 'Play'}]","[{'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}]",98.0,0.150697,"Collisions (RR 0.98; 95% CI 0.86-1.12) and injury rates (RR 1.15; 95% CI 0.60-2.19) were similar across conditions. ","[{'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Schwebel', 'Affiliation': 'Department of Psychology, University of Alabama at Birmingham.'}, {'ForeName': 'D Leann', 'Initials': 'DL', 'LastName': 'Long', 'Affiliation': 'Department of Biostatistics, University of Alabama at Birmingham.'}, {'ForeName': 'Leslie A', 'Initials': 'LA', 'LastName': 'McClure', 'Affiliation': 'Department of Epidemiology and Biostatistics, Drexel University.'}]",Journal of pediatric psychology,['10.1093/jpepsy/jsaa050'] 1932,32651585,Music Therapy to Regulate Arousal and Attention in Patients With Substance Use Disorder and Posttraumatic Stress Disorder: A Feasibility Study.,"Patients diagnosed with both substance use disorder (SUD) and posttraumatic stress disorder (PTSD) often experience hypervigilance, increased fear, and difficulties regulating emotions. This dual diagnosis increases treatment complexity. Recently, a short-term music therapy intervention for arousal and attention regulation (the SMAART intervention) was designed based on neurobiological findings. Twelve patients with SUD and PTSD (50% females) in outpatient treatment participated in six weekly one-hour sessions of the SMAART intervention. Six patients completed the study. PTSD symptom severity was evaluated with the Posttraumatic Stress Disorder Symptom Scale Interview for DSM-5 (PSSI-5) pre- and post-intervention, and sustained attention was evaluated with the Bourdon-Wiersma (BW) test. A significant difference in measurements for the PSSI-5 overall symptom severity was found pre- and post-intervention. Furthermore, participants showed significant improvement on subscales of hyperarousal, mood and cognition, and attention. The BW test completion time decreased significantly. Two participants dropped out before the end of the intervention due to craving. Concerning future research, it is recommended to define the role of the music more explicitly and to change the design to a randomized controlled trial. A risk for future larger studies is a high dropout rate (50%). Several limitations of the study are discussed.",2020,A significant difference in measurements for the PSSI-5 overall symptom severity was found pre- and post-intervention.,"['Six patients completed the study', 'Posttraumatic Stress Disorder', 'Patients', 'Patients diagnosed with both substance use disorder (SUD) and posttraumatic stress disorder (PTSD', 'Twelve patients with SUD and PTSD (50% females']",['Music Therapy'],"['PTSD symptom severity', 'BW test completion time', 'subscales of hyperarousal, mood and cognition, and attention', 'PSSI-5 overall symptom severity', 'Posttraumatic Stress Disorder Symptom Scale Interview for DSM-5']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0038586', 'cui_str': 'Substance use disorder'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0026868', 'cui_str': 'Music therapy'}]","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C4552570', 'cui_str': 'Hyperarousal'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",12.0,0.0188963,A significant difference in measurements for the PSSI-5 overall symptom severity was found pre- and post-intervention.,"[{'ForeName': 'Laurien', 'Initials': 'L', 'LastName': 'Hakvoort', 'Affiliation': 'ArtEZ University of the Artsm, Enschede, The Netherlands.'}, {'ForeName': 'Sirik', 'Initials': 'S', 'LastName': 'de Jong', 'Affiliation': 'ArtEZ University of the Artsm, Enschede, The Netherlands.'}, {'ForeName': 'Maartje', 'Initials': 'M', 'LastName': 'van de Ree', 'Affiliation': 'ArtEZ University of the Artsm, Enschede, The Netherlands.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Kok', 'Affiliation': 'Tactus, Addiction Care Twente, Enschede, The Netherlands.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Macfarlane', 'Affiliation': 'Penitentiary Psychiatric Center Institution Vught & Vrije Universiteit, Amsterdam, The Netherlands.'}, {'ForeName': 'Hein', 'Initials': 'H', 'LastName': 'de Haan', 'Affiliation': 'Tactus, Addiction Care Twente, Enschede, The Netherlands.'}]",Journal of music therapy,['10.1093/jmt/thaa007'] 1933,32651812,Psychophysiological Analysis of Thymoleptic Effects of Xenon in Humans.,"This pilot study was aimed at evaluation of the translational potential of xenon as a potential antidepressant. In placebo-controlled double-blind study, 14 healthy right-handed volunteers were randomly assigned to 15-min inhalation session of either gas mixture with xenon (25%Хе/30%О 2 /45%N 2 ) or placebo (70%N 2 /30%О 2 ) with simultaneous recording of 64-channel EEG. To assess the dynamics and nature of emotional activation in response to xenon and placebo, we analyzed both the intensity of positive and negative emotions and individual alpha peak frequency (iAPF) of EEG. We found that xenon in sub-anesthetic doses promoted positive emotional arousal, and that emotional response to xenon depended on individual neurophysiological endophenotype of alpha-activity (iAPF). The authors suggest that iAPF shifts can be used as a neurophysiological predictor of individual thymoleptic response to xenon.",2020,"We found that xenon in sub-anesthetic doses promoted positive emotional arousal, and that emotional response to xenon depended on individual neurophysiological endophenotype of alpha-activity (iAPF).","['14 healthy right-handed volunteers', 'Humans']","['gas mixture with xenon (25%Хе/30%О 2 /45%N 2 ) or placebo (70%N 2 /30%О 2 ) with simultaneous recording of 64-channel EEG', 'placebo']","['intensity of positive and negative emotions and individual alpha peak frequency (iAPF) of EEG', 'positive emotional arousal', 'individual neurophysiological endophenotype of alpha-activity (iAPF']","[{'cui': 'C0230370', 'cui_str': 'Structure of right hand'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0581444', 'cui_str': 'Gas mixture'}, {'cui': 'C0043339', 'cui_str': 'Xenon'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0439799', 'cui_str': 'Channel'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}]","[{'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C2936327', 'cui_str': 'Endophenotypes'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}]",14.0,0.125353,"We found that xenon in sub-anesthetic doses promoted positive emotional arousal, and that emotional response to xenon depended on individual neurophysiological endophenotype of alpha-activity (iAPF).","[{'ForeName': 'L I', 'Initials': 'LI', 'LastName': 'Aftanas', 'Affiliation': 'Reasearch Institute of Physiology and Fundamental Medicine, Novosibirsk, Russia.'}, {'ForeName': 'O M', 'Initials': 'OM', 'LastName': 'Bazanova', 'Affiliation': 'Reasearch Institute of Physiology and Fundamental Medicine, Novosibirsk, Russia. bazanovaom@physiol.ru.'}, {'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Khabarov', 'Affiliation': 'Reasearch Institute of Physiology and Fundamental Medicine, Novosibirsk, Russia.'}, {'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Pustovoyt', 'Affiliation': 'Reasearch Institute of Physiology and Fundamental Medicine, Novosibirsk, Russia.'}]",Bulletin of experimental biology and medicine,['10.1007/s10517-020-04846-1'] 1934,32649708,Feasibility and acceptability of a milk and resistance exercise intervention to improve muscle function in community-dwelling older adults (MIlkMAN): Pilot study.,"BACKGROUND Dietary protein supplementation combined with resistance exercise (RE) may counteract declines in muscle strength, mass, and function (sarcopenia), but the role of whole foods rich in protein, such as milk, is less well understood. In the MIlkMAN study, we aimed to examine the feasibility and acceptability of milk+RE as an intervention for muscle function in community-dwelling older adults, and provide exploratory pilot data for future substantive research in population at risk of sarcopenia. METHODS In a parallel groups design, 30 older adults (71.7±3.6 years; 12 women) were randomised into three groups: WM (whole milk 3.6% fat)+RE, SM (skimmed milk 0.3% fat)+RE, and C (isocaloric carbohydrate drink)+RE. RE was performed twice-weekly over 6 weeks in a community gym, followed by the consumption of 500 ml of milk (~20 g protein) or carbohydrate drink immediately after exercise and a further 500 ml at home within the following 4-5 hours. The feasibility and acceptability of the study was determined by calculating recruitment and attendance rates, compliance with the intervention, rating participants' experiences, and recording adverse health events. RESULTS The response rate was 49% (out of 400 invitations sent), and the recruitment rate was 73.2% (30 participants recruited out of 41 screened for eligibility). Twenty-nine participants completed the intervention-an attendance rate of 97.1%; 89.7% rated their experience as 'excellent'/very good'. Compliance with taking the drinks was 97.1% (WM), 98.3% (SM), and 95.0% (C); 93.1% rated their drink intake as 'easy'/'very easy' with no adverse effects. Collection of exploratory pilot data to inform future trials was successful. Mean change in grip strength, 5-chair rises, and gait speed were 0.9±3.4 kg, 1.8±2.2 s, 0.1±0.1 m/s, respectively with no differences between the groups. CONCLUSIONS This community-based milk+RE intervention was feasible and acceptable to older adults. The study successfully collected pilot data for future substantive research.",2020,"Mean change in grip strength, 5-chair rises, and gait speed were 0.9±3.4 kg, 1.8±2.2 s, 0.1±0.1 m/s, respectively with no differences between the groups. ","['30 older adults (71.7±3.6 years; 12 women', 'older adults', 'community-dwelling older adults', '20', 'community-dwelling older adults (MIlkMAN']","['milk and resistance exercise intervention', 'milk+RE', 'carbohydrate drink', 'WM (whole milk 3.6% fat)+RE, SM (skimmed milk 0.3% fat)+RE, and C (isocaloric carbohydrate drink)+RE', 'Dietary protein supplementation combined with resistance exercise (RE', 'milk+RE intervention']","['attendance rate', 'muscle function', 'Mean change in grip strength, 5-chair rises, and gait speed', ""calculating recruitment and attendance rates, compliance with the intervention, rating participants' experiences, and recording adverse health events"", 'response rate', 'Feasibility and acceptability']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0402554', 'cui_str': 'Milkman'}]","[{'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0452717', 'cui_str': 'Whole milk'}, {'cui': 'C4517694', 'cui_str': '3.6'}, {'cui': 'C0349375', 'cui_str': 'Skim milk'}, {'cui': 'C4068885', 'cui_str': '0.3'}, {'cui': 'C0012177', 'cui_str': 'Proteins, Dietary'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0231484', 'cui_str': 'Muscle function'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",30.0,0.0398701,"Mean change in grip strength, 5-chair rises, and gait speed were 0.9±3.4 kg, 1.8±2.2 s, 0.1±0.1 m/s, respectively with no differences between the groups. ","[{'ForeName': 'Antoneta', 'Initials': 'A', 'LastName': 'Granic', 'Affiliation': 'AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Hurst', 'Affiliation': 'AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'Lorelle', 'Initials': 'L', 'LastName': 'Dismore', 'Affiliation': 'Northumbria Healthcare NHS Foundation Trust, Research and Development, North Tyneside General Hospital, North Shields, United Kingdom.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Stevenson', 'Affiliation': 'Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'Avan A', 'Initials': 'AA', 'LastName': 'Sayer', 'Affiliation': 'AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'Terry', 'Initials': 'T', 'LastName': 'Aspray', 'Affiliation': 'AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}]",PloS one,['10.1371/journal.pone.0235952'] 1935,32649717,Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: A randomized controlled trial.,"OBJECTIVE Intranasal fentanyl (INF) quickly and noninvasively relieves severe pain, whereas intravenous hydromorphone (IVH) reliably treats severe cancer pain but requires vascular access. The trial evaluated the efficacy of INF relative to IVH for treating cancer patients with severe pain in an emergency department (ED) setting. METHODS We randomized 82 patients from a comprehensive cancer center ED to receive INF (n = 42) or IVH (n = 40). Eligible patients reported severe pain at randomization (≥7, scale: 0 ""none"" to 10 ""worst pain""). We conducted non-inferiority comparisons (non-inferiority margin = 0.9) of pain change from treatment initiation (T0) to one hour later (T60). T0 pain ratings were unavailable; therefore, we estimated T0 pain by comparing 1) T60 ratings, assuming similar group T0 ratings; 2) pain change, estimating T0 pain = randomization ratings, and 3) pain change, with T0 pain = 10 (IVH group) or T0 pain = randomization rating (INF group). RESULTS At T60, the upper 90% confidence limit (CL) of the mean log-transformed pain ratings for the INF group exceeded the mean IVH group rating by 0.16 points (>pain). Substituting randomization ratings for T0 pain, the lower 90% CL of mean pain change in the INF group extended 0.32 points below ( 0.05). However, Group II showed improvements in total Motor Activity Log scores at both follow-up visits (p < 0.05). No serious adverse events were reported. Conclusion The results of this study indicate that tDCS therapy is a potential treatment in pediatric patients with chronic stroke. Furthermore, our data indicate that botulinum toxin A and peripheral neuromuscular electrical stimulation combined therapy may enhance the efficacy of tDCS on motor function.",2020,"In addition, Group II showed significant improvement in total FMA-UE scores in the 2-week follow-up (p < 0.05) but not on the ARAT scores (p > 0.05).","['Eleven patients were recruited, and classified into three groups', 'pediatric patients', 'chronic stroke in adult and pediatric patients', 'adult patients with chronic stroke', 'adult patients', 'pediatric patients with chronic stroke', 'chronic stroke']","['transcranial direct current stimulation (tDCS', 'transcranial direct current stimulation', 'bilateral tDCS and intensive occupational therapy', 'botulinum toxin A and peripheral neuromuscular electrical stimulation combined therapy', 'tDCS therapy', 'bilateral tDCS, peripheral neuromuscular electrical stimulation, and intensive occupational therapy after botulinum toxin A injection', 'bilateral transcranial direct current stimulation and intensive occupational therapy']","['Action Research Arm Test (ARAT) scores', 'total Motor Activity Log scores', 'safety and efficacy', 'serious adverse events', 'ARAT scores', 'headache, redness, pain, itching, and fever', 'total FMA-UE scores', 'total Fugl-Meyer Assessment Upper Extremity (FMA-UE) scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C1318464', 'cui_str': 'Occupational therapy'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0033972', 'cui_str': 'Combined therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C4720875', 'cui_str': 'Action research arm test'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}]",11.0,0.0409638,"In addition, Group II showed significant improvement in total FMA-UE scores in the 2-week follow-up (p < 0.05) but not on the ARAT scores (p > 0.05).","[{'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Hyakutake', 'Affiliation': 'Department of Neurosurgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Morishita', 'Affiliation': 'Department of Neurosurgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.'}, {'ForeName': 'Kazuya', 'Initials': 'K', 'LastName': 'Saita', 'Affiliation': 'Department of Neurosurgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.'}, {'ForeName': 'Toshiyasu', 'Initials': 'T', 'LastName': 'Ogata', 'Affiliation': 'Department of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.'}, {'ForeName': 'Yoshinari', 'Initials': 'Y', 'LastName': 'Uehara', 'Affiliation': 'Center for Preventive, Anti-aging Regenerative Medicine, Fukuoka University Hospital, Fukuoka, Japan.'}, {'ForeName': 'Etsuji', 'Initials': 'E', 'LastName': 'Shiota', 'Affiliation': 'Department of Rehabilitation Medicine, Fukuoka University Hospital, Fukuoka, Japan.'}, {'ForeName': 'Tooru', 'Initials': 'T', 'LastName': 'Inoue', 'Affiliation': 'Department of Neurosurgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.'}]",SAGE open medicine,['10.1177/2050312120940546'] 1952,32685183,Efficacy of different load intensity and time-under-tension calf loading protocols for Achilles tendinopathy (the LOADIT trial): protocol for a randomised pilot study.,"Background Modifying variables in exercise prescription can produce specific effects on Achilles tendinopathy outcomes. This study aims to determine the feasibility of conducting an adequately powered randomised trial in the future to assess the efficacy of different load intensity and time-under-tension exercise parameters for improving pain and function in individuals with persistent midportion Achilles tendinopathy. Methods The trial is designed as prospective, four-armed feasibility and randomised pilot trial with 3 months follow-up. Interventions will be provided in a gym setting. The investigator, who will be blind to the allocation of participants, will conduct all pre- and post-intervention assessments. Forty-eight male participants with Achilles tendinopathy will be recruited from the community. We will use a 2 × 2 factorial design with factors of load intensity (six or eighteen repetitions maximum) and time-under-tension (two or six second repetitions). Participants will be randomised into one of the testing groups: six RM with two second repetitions, six RM with six second repetitions, eighteen RM with two second repetitions or eighteen RM with six second repetitions. Trial feasibility will be indicated by the rate of conversion, recruitment and retention, adherence to the interventions by participants, the utility of videoconferencing mode for weekly exercise supervision, incidence of adverse events, and feasibility of future economic evaluation. The secondary clinical outcomes will assess pain and disability, participant impression of change, satisfaction, health-related quality of life, physical activity, work absenteeism, psychological measures at baseline, 6 and 12 weeks, and plantarflexor contractile dysfunction (torque, rate of force development and muscle force steadiness) at baseline and 12 weeks. These clinical outcomes are primarily measured to provide information regarding potential treatment effects and trends. Discussion The proposed study and follow-up powered randomised trial will be a first step towards determining exercise dose parameters that may optimise outcomes for Achilles tendinopathy. We have chosen to focus on load intensity and time-under-tension, as these parameters are important for tendon adaptation. This work has the potential to lead to more effective exercise loading interventions for Achilles tendinopathy. Trial registration Australian New Zealand Clinical Trials Registry, ACTRN12618001315202. Registered retrospectively on August 6th, 2018.",2020,"Trial feasibility will be indicated by the rate of conversion, recruitment and retention, adherence to the interventions by participants, the utility of videoconferencing mode for weekly exercise supervision, incidence of adverse events, and feasibility of future economic evaluation.","['individuals with persistent midportion Achilles tendinopathy', 'Forty-eight male participants with Achilles tendinopathy will be recruited from the community']","['load intensity and time-under-tension calf loading protocols', 'load intensity and time-under-tension exercise parameters']","['pain and disability, participant impression of change, satisfaction, health-related quality of life, physical activity, work absenteeism, psychological measures at baseline, 6 and 12\u2009weeks, and plantarflexor\xa0contractile dysfunction (torque, rate of force development and muscle force steadiness', 'pain and function', 'rate of conversion, recruitment and retention, adherence']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0001074', 'cui_str': 'Structure of Achilles tendon'}, {'cui': 'C0151936', 'cui_str': 'Disorder of tendon'}, {'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0233494', 'cui_str': 'Tension'}, {'cui': 'C0230445', 'cui_str': 'Structure of calf of leg'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0026820', 'cui_str': 'Muscle contraction'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",48.0,0.17682,"Trial feasibility will be indicated by the rate of conversion, recruitment and retention, adherence to the interventions by participants, the utility of videoconferencing mode for weekly exercise supervision, incidence of adverse events, and feasibility of future economic evaluation.","[{'ForeName': 'Fatmah', 'Initials': 'F', 'LastName': 'Hasani', 'Affiliation': 'Physiotherapy Department, School of Primary and Allied Health Care, Faculty of Medicine Nursing and Health Sciences, Monash University, Frankston, Victoria 3199 Australia.'}, {'ForeName': 'Terry P', 'Initials': 'TP', 'LastName': 'Haines', 'Affiliation': 'School of Primary and Allied Health Care, Faculty of Medicine Nursing and Health Sciences, Monash University, Frankston, Victoria 3199 Australia.'}, {'ForeName': 'Shannon E', 'Initials': 'SE', 'LastName': 'Munteanu', 'Affiliation': 'Discipline of Podiatry, School of Allied Health, Human Services and Sport, College of Science, Health and Engineering, La Trobe University, Melbourne, Victoria 3086 Australia.'}, {'ForeName': 'Bill', 'Initials': 'B', 'LastName': 'Vicenzino', 'Affiliation': 'Sports Injuries Rehabilitation and Prevention for Health Research Unit, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Queensland Australia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Malliaras', 'Affiliation': 'Physiotherapy Department, School of Primary and Allied Health Care, Faculty of Medicine Nursing and Health Sciences, Monash University, Frankston, Victoria 3199 Australia.'}]",Pilot and feasibility studies,['10.1186/s40814-020-00639-5'] 1953,32685184,"Internet-based cognitive behavioural therapy programme as an intervention for people diagnosed with adult-onset, focal, isolated, idiopathic cervical dystonia: a feasibility study protocol.","Background Dystonia is one of the most common forms of movement disorder, caused by the co-contraction of antagonistic muscles, leading to abnormal postures and considerable disability. Non-motor symptoms, notably psychiatric disorders, are well recognised comorbid features of the disorder. However, there is no standardised model for the management of these symptoms in dystonia, with them frequently going undiagnosed and untreated. An internet-based cognitive behavioural therapy programme may provide a future model of care that also maximises available resources. Methods This study represents a two-armed randomised feasibility trail, aiming to recruit a total of 20 participants with a diagnosis of adult-onset primary focal cervical dystonia. Participants will be recruited from the Global Myoclonus Dystonia Registry and Dystonia Non-Motor Symptom Study (conducted at Cardiff University) based on presence of moderate symptoms of anxiety/depression as indicated by standardised questionnaires. All participants will undergo assessment at baseline, 3 and 6 months, with this including questionnaires for assessment of non-motor symptoms and clinical assessment of motor symptom severity. Participants will be randomised to either the control ( n = 10) or treatment ( n = 10) groups. The treatment group will be asked to complete one session of the online CBT program a week, for 8 weeks. The primary outcome measure will be the engagement of participants with the programme, with secondary outcomes of non-motor and motor symptom scores. Discussion Promising results have been shown using face-to-face cognitive behavioural therapy to reduce levels of anxiety and depression in individuals with a diagnosis of dystonia. However, no studies to date have sought to determine the feasibility of an internet-delivered cognitive behavioural therapy programme. A number of effective internet-based programmes have been developed that combat anxiety and depression in the general population, suggesting the potential for its effectiveness in cervical dystonia patients. Success with this study would significantly impact the clinical care delivery for patients with cervical dystonia, as well as widening potential access to effective treatment. Trial registration This feasibility trial has been registered with Health and Care Research Wales Research Directory. Trial registration number 44245. Date of registration: 21 November 2019. https://www.healthandcareresearch.gov.wales/research-studies-in-wales/.",2020,"Discussion Promising results have been shown using face-to-face cognitive behavioural therapy to reduce levels of anxiety and depression in individuals with a diagnosis of dystonia.","['cervical dystonia patients', '20 participants with a diagnosis of adult-onset primary focal cervical dystonia', 'people diagnosed with adult-onset, focal, isolated, idiopathic cervical dystonia', 'individuals with a diagnosis of dystonia', 'patients with cervical dystonia', 'Participants will be recruited from the Global Myoclonus Dystonia Registry and Dystonia Non-Motor Symptom Study (conducted at Cardiff University']","['internet-based cognitive behavioural therapy programme', 'Internet-based cognitive behavioural therapy programme']","['engagement of participants with the programme, with secondary outcomes of non-motor and motor symptom scores', 'questionnaires for assessment of non-motor symptoms and clinical assessment of motor symptom severity']","[{'cui': 'C0949445', 'cui_str': 'Cervical Dystonia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0013421', 'cui_str': 'Dystonia'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C1834570', 'cui_str': 'Myoclonic dystonia'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",20.0,0.142498,"Discussion Promising results have been shown using face-to-face cognitive behavioural therapy to reduce levels of anxiety and depression in individuals with a diagnosis of dystonia.","[{'ForeName': 'Megan E', 'Initials': 'ME', 'LastName': 'Wadon', 'Affiliation': 'Neuroscience and Mental Health Research Institute, Hadyn Ellis Building, Cardiff University, Cardiff, UK.'}, {'ForeName': 'Mia', 'Initials': 'M', 'LastName': 'Winter', 'Affiliation': 'Department of Clinical Neuropsychology, University Hospital of Wales, Cardiff, UK.'}, {'ForeName': 'Kathryn J', 'Initials': 'KJ', 'LastName': 'Peall', 'Affiliation': 'Neuroscience and Mental Health Research Institute, Hadyn Ellis Building, Cardiff University, Cardiff, UK.'}]",Pilot and feasibility studies,['10.1186/s40814-020-00641-x'] 1954,32657457,Glycopyrrolate Improves Disability from Sialorrhea in Parkinson's Disease: A 12-Week Controlled Trial.,"OBJECTIVE The objective of this study was to assess the 12-week efficacy and safety of oral glycopyrrolate for moderate-to-severe sialorrhea in Parkinson's disease (PD). BACKGROUND Chronic moderate-to-severe sialorrhea has a negative impact on quality of life in PD. There is no robust evidence for oral treatments for sialorrhea longer than 1 week. METHODS This was a 12-week, double-blinded, placebo-controlled, parallel phase II study in patients with PD and Movement Disorder Society-Unified Parkinson's Disease Rating Scale item 2.2 > 2. The intervention was glycopyrrolate up to 4.5 mg/d; the primary outcome was sialorrhea related-disability (Radboud Oral Motor Inventory for Parkinson's Disease-Saliva). We used an intention-to-treat analysis. A P < 0.05 was deemed significant. RESULTS We recruited 28 patients (age, 71.1 ± 6.9 years; PD duration, 11.4 ± 7.2 years; Radboud Oral Motor Inventory for Parkinson's Disease-Saliva, 22.4 ± 5.7). Glycopyrrolate was superior to placebo at 12 weeks in the Radboud Oral Motor Inventory for Parkinson's Disease-Saliva (between-group difference, 5.3; 95% confidence interval, 1.0-9.6). Dry mouth was the most common adverse event (glycopyrrolate, n = 6; placebo, n = 2). CONCLUSIONS The results support the efficacy of glycopyrrolate to treat sialorrhea-related disability up to 12 weeks and contribute to addressing unmet nonmotor care needs in PD. © 2020 International Parkinson and Movement Disorder Society.",2020,"Glycopyrrolate was superior to placebo at 12 weeks in the Radboud Oral Motor Inventory for Parkinson's Disease-Saliva (between-group difference, 5.3; 95% confidence interval, 1.0-9.6).","[""28 patients (age, 71.1\u2009±\u20096.9\u2009years; PD duration, 11.4\u2009±\u20097.2\u2009years; Radboud Oral Motor Inventory for Parkinson's Disease-Saliva, 22.4\u2009±\u20095.7"", ""Parkinson's Disease"", ""moderate-to-severe sialorrhea in Parkinson's disease (PD"", ""patients with PD and Movement Disorder Society-Unified Parkinson's Disease Rating Scale item 2.2\u2009>\u20092""]","['glycopyrrolate', 'oral glycopyrrolate', 'Glycopyrrolate', 'placebo']","['12-week efficacy and safety', ""sialorrhea related-disability (Radboud Oral Motor Inventory for Parkinson's Disease-Saliva""]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517826', 'cui_str': '6.9'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C4517533', 'cui_str': '11.4'}, {'cui': 'C4517857', 'cui_str': '7.2'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C4517795', 'cui_str': '5.7'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0037036', 'cui_str': 'Excessive salivation'}, {'cui': 'C0026650', 'cui_str': 'Movement disorder'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4517629', 'cui_str': '2.2'}]","[{'cui': 'C0017970', 'cui_str': 'Glycopyrrolate'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0037036', 'cui_str': 'Excessive salivation'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0036087', 'cui_str': 'Saliva'}]",,0.205804,"Glycopyrrolate was superior to placebo at 12 weeks in the Radboud Oral Motor Inventory for Parkinson's Disease-Saliva (between-group difference, 5.3; 95% confidence interval, 1.0-9.6).","[{'ForeName': 'Tiago A', 'Initials': 'TA', 'LastName': 'Mestre', 'Affiliation': 'University of Ottawa Brain and Mind Research Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'Eliza', 'Initials': 'E', 'LastName': 'Freitas', 'Affiliation': 'Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Basndwah', 'Affiliation': 'University of Ottawa Brain and Mind Research Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'Marta Ruiz', 'Initials': 'MR', 'LastName': 'Lopez', 'Affiliation': 'Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'Lais Machado', 'Initials': 'LM', 'LastName': 'de Oliveira', 'Affiliation': 'Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'Duha Mohammed', 'Initials': 'DM', 'LastName': 'Al-Shorafat', 'Affiliation': 'Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'Tinghua', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Ottawa Methods Center, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'Jane P', 'Initials': 'JP', 'LastName': 'Lui', 'Affiliation': 'Department of Pharmacy, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Grimes', 'Affiliation': 'University of Ottawa Brain and Mind Research Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'Susan H', 'Initials': 'SH', 'LastName': 'Fox', 'Affiliation': 'Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada.'}]",Movement disorders : official journal of the Movement Disorder Society,['10.1002/mds.28196'] 1955,32657704,Predischarge transcutaneous bilirubin screening reduces readmission rate for hyperbilirubinaemia in diverse South African newborns: A randomised controlled trial.,"BACKGROUND In South Africa (SA), healthy term newborns are usually discharged ˂72 hours after delivery. Discharged babies remain at risk for severe hyperbilirubinaemia if it is not identified early. Hyperbilirubinaemia is an important cause of readmission, and also leads to neonatal mortality and morbidity. Use of transcutaneous bilirubin (TcB) screening before hospital discharge has been controversial. OBJECTIVES To test the clinical benefits of TcB screening of healthy newborns before discharge for the outcomes of readmission for jaundice and severe hyperbilirubinaemia in a randomised controlled trial (RCT). METHODS This was a RCT. We compared predischarge TcB screening with visual assessment (alone) for jaundice in apparently healthy newborns at a public tertiary hospital in Cape Town, SA. Patients or study participants were not involved in the study design and implementation. RESULTS Of the 1 858 infants, 63% were black, 35% of mixed race and 1% white. There was a significant reduction in the rate of readmission for jaundice (risk ratio (RR) 0.25; 95% confidence interval (CI) 0.14 - 0.46; p<0.0001) and in the incidence of severe hyperbilirubinaemia (RR 0.27; 95% CI 0.08 - 0.97; p=0.05) with the use of TcB screening compared with visual inspection. CONCLUSIONS Predischarge TcB screening is superior in identifying newborns at risk of severe hyperbilirubinaemia compared with visual inspection. We recommend that every newborn, regardless of skin pigmentation, should receive objective bilirubin screening before hospital discharge. Universal bilirubin screening in newborns could potentially reduce hyperbilirubinaemia-related morbidity and mortality.",2020,"There was a significant reduction in the rate of readmission for jaundice (risk ratio (RR) 0.25; 95% confidence interval (CI) 0.14 - 0.46; p<0.0001) and in the incidence of severe hyperbilirubinaemia (RR 0.27; 95% CI 0.08 - 0.97; p=0.05) with the use of TcB screening compared with visual inspection. ","['Of the 1 858 infants, 63% were black, 35% of mixed race and 1% white', 'hyperbilirubinaemia in diverse South African newborns', 'apparently healthy newborns at a public tertiary hospital in Cape Town, SA', 'healthy newborns']","['TcB screening', 'transcutaneous bilirubin (TcB) screening', 'Predischarge transcutaneous bilirubin screening', 'predischarge TcB screening with visual assessment (alone']","['incidence of severe hyperbilirubinaemia', 'rate of readmission for jaundice']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0020433', 'cui_str': 'Hyperbilirubinemia'}, {'cui': 'C0027567', 'cui_str': 'African race'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0578757', 'cui_str': 'Good neonatal condition at birth'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0054434', 'cui_str': 'caffeic acid phenethyl ester'}, {'cui': 'C0557750', 'cui_str': 'Town environment'}, {'cui': 'C0037712', 'cui_str': 'South Africa'}]","[{'cui': 'C0005437', 'cui_str': 'Bilirubin'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0020433', 'cui_str': 'Hyperbilirubinemia'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0022346', 'cui_str': 'Jaundice'}]",63.0,0.285629,"There was a significant reduction in the rate of readmission for jaundice (risk ratio (RR) 0.25; 95% confidence interval (CI) 0.14 - 0.46; p<0.0001) and in the incidence of severe hyperbilirubinaemia (RR 0.27; 95% CI 0.08 - 0.97; p=0.05) with the use of TcB screening compared with visual inspection. ","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Okwundu', 'Affiliation': 'Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. charlesokwundu@gmail.com.'}, {'ForeName': 'V K', 'Initials': 'VK', 'LastName': 'Bhutani', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Smith', 'Affiliation': ''}, {'ForeName': 'T M', 'Initials': 'TM', 'LastName': 'Esterhuizen', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Wiysonge', 'Affiliation': ''}]",South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,['10.7196/SAMJ.2020.v110i3.14186'] 1956,32657740,Water-wise hand preparation - the true impact of our practice: A controlled before-and-after study.,"BACKGROUND South Africa (SA) and other countries worldwide are experiencing extreme drought conditions. Since the start of the drought in SA, many ways of saving water have been proposed and innovative water-saving mechanisms have become part of the lives of communities. We investigated water use during surgical scrubbing procedures and possible interventions to reduce water consumption. OBJECTIVES To compare water use during surgical hand preparation before and after the implementation of specific water-saving interventions. METHODS This was a non-randomised controlled study, following a before-and-after design, of orthopaedic theatre personnel scrubbing for surgical cases at Tygerberg Hospital, Cape Town. A control (CON) group (n=32) was established to observe standard practice for baseline measurements including total amount of water used, wash time and water flow rate during surgical hand preparation. After this, three interventions were randomly assigned to a single theatre each, where the same variables were measured. Intervention AS entailed using an alcohol scrub (n=18), intervention SN (n=12) had a dedicated assistant to open and close taps during scrubbing, and intervention SW (n=12) made use of adjusted tap levers to allow the surgeon to open and close taps more easily. Analysis of variance was used to detect global differences between groups, and Tukey's post hoc test was performed to detect differences between groups. RESULTS Significant differences in water use (p<0.001), wash time (p<0.001) and water flow rate (p<0.001) were observed between the four groups. On average, the AS group used the least water per scrub (mean (standard deviation) 0.82 (1.43) L), which was significantly less than the CON (5.56 (1.79) L; p<0.001) and SN (2.29 (0.37) L; p=0.002) groups. The amount of time spent per scrub was significantly less in the AS group than all the other groups (p<0.05 for all comparisons), with no significant differences observed between the CON, SN and SW groups independently. The SW group had the lowest mean water flow rate (0.73 (0.22) L/min), which was significantly lower than the CON group (2.19 (0.84) L/min; p<0.001). The flow rate of the SN group (1.36 (0.66) L/min) was also significantly lower than that of the CON group (p=0.005). CONCLUSIONS Water use during surgical hand preparation can easily be reduced by implementing easy and effective interventions. The practicality of interventions may differ between institutions, and their acceptance by surgical staff is important to ensure compliance. However, ensuring that alternative scrubbing options are available to surgical staff would equate to substantial savings over time.",2020,"RESULTS Significant differences in water use (p<0.001), wash time (p<0.001) and water flow rate (p<0.001) were observed between the four groups.","['surgical cases at Tygerberg Hospital, Cape Town']","['alcohol scrub (n=18), intervention SN (n=12) had a dedicated assistant to open and close taps during scrubbing, and intervention SW (n=12) made use of adjusted tap levers to allow the surgeon to open and close taps more easily', 'control (CON', 'CON', 'orthopaedic theatre personnel scrubbing']","['flow rate', 'water flow rate', 'lowest mean water flow rate', 'amount of time spent per scrub']","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0054434', 'cui_str': 'caffeic acid phenethyl ester'}, {'cui': 'C0557750', 'cui_str': 'Town environment'}]","[{'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C2946035', 'cui_str': 'Scrubs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0011327', 'cui_str': 'Dental assistant'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0034115', 'cui_str': 'Centesis'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0332219', 'cui_str': 'Easy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0475307', 'cui_str': 'Theatre'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}]","[{'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C2946035', 'cui_str': 'Scrubs'}]",,0.0399163,"RESULTS Significant differences in water use (p<0.001), wash time (p<0.001) and water flow rate (p<0.001) were observed between the four groups.","[{'ForeName': 'M S W', 'Initials': 'MSW', 'LastName': 'Potgieter', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. Mswpot@yahoo.com.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Faisal', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ikram', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Burger', 'Affiliation': ''}]",South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,['10.7196/SAMJ.2020.v110i4.14044'] 1957,32653571,Brain MR imaging and spectroscopy for outcome prognostication after pediatric cardiac arrest.,"AIM Children surviving cardiac arrest are at high risk of neurological morbidity and mortality; however, there is a lack of validated prognostic biomarkers. We aimed to evaluate brain magnetic resonance imaging (MRI) and spectroscopy (MRS) as predictors of death and disability. Secondly, we evaluated whether MRI/S by randomized group. METHODS This single center study analyzed clinically indicated brain MRI/S data from children enrolled in a randomized controlled trial of 24 vs. 72 h of hypothermia following cardiac arrest. Two pediatric radiologists scored conventional MRIs. Lactate and N-acetyl-aspartate (NAA) concentrations (mmol/kg) were determined from spectra acquired from the basal ganglia, thalamus, parietal white matter and parietooccipital gray matter. Mortality and neurological outcomes (favorable = Pediatric Cerebral Performance Category [PCPC] 1, 2, 3 or increase < 2) were assessed at hospital discharge. Non-parametric tests were used to test for associations between MRI/S biomarkers and outcome and randomized group. RESULTS 23 children with (median [interquartile range]) age of 1.5 (0.3-4.0) years. Ten (44%) had favorable outcome. There were more T2 brain lesions in the lentiform nuclei in children with unfavorable 12 (92%) vs. favorable 3 (33%) outcome, p = 0.007. Increased lactate and decreased NAA concentrations in the parietooccipital gray matter and decreased NAA in the parietal white matter were associated with unfavorable outcome (p's < 0.05). There were no differences for any biomarker by randomized group. CONCLUSION Regional cerebral and metabolic MRI/S biomarkers are predictive of neurological outcomes at hospital discharge in pediatric cardiac arrest and should undergo validation testing in a large sample.",2020,Increased lactate and decreased NAA concentrations in the parietooccipital gray matter and decreased NAA in the parietal white matter were associated with unfavorable outcome (p's<.05).,"['pediatric cardiac arrest', '23 children with (median [interquartile range]) age of 1.5 (0.3-4.0) years', 'children enrolled in a randomized controlled trial of 24 versus 72\u2009hours of hypothermia following cardiac arrest']","['brain magnetic resonance imaging (MRI) and spectroscopy (MRS', 'Brain MR imaging and spectroscopy', 'PCPC']","['Lactate and N-acetyl-aspartate (NAA) concentrations (mmol/kg', 'Increased lactate and decreased NAA concentrations', 'Mortality and neurological outcomes', 'T2 brain lesions']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C4068885', 'cui_str': '0.3'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C0020672', 'cui_str': 'Hypothermia'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0037812', 'cui_str': 'Analysis, Spectrum'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}]","[{'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0067684', 'cui_str': 'N-acetyl-L-aspartate'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439291', 'cui_str': 'mmol/kg'}, {'cui': 'C0392691', 'cui_str': 'Increased lactic acid level'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0221505', 'cui_str': 'Lesion of brain'}]",23.0,0.15601,Increased lactate and decreased NAA concentrations in the parietooccipital gray matter and decreased NAA in the parietal white matter were associated with unfavorable outcome (p's<.05).,"[{'ForeName': 'Ericka L', 'Initials': 'EL', 'LastName': 'Fink', 'Affiliation': ""Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA; Department of Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; Safar Center for Resuscitation Research, Pittsburgh, PA, USA. Electronic address: finkel@ccm.upmc.edu.""}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Wisnowski', 'Affiliation': ""Children's Hospital of Los Angeles, Los Angeles, CA, USA.""}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Clark', 'Affiliation': ""Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA; Department of Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; Safar Center for Resuscitation Research, Pittsburgh, PA, USA.""}, {'ForeName': 'Rachel P', 'Initials': 'RP', 'LastName': 'Berger', 'Affiliation': ""Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA; Safar Center for Resuscitation Research, Pittsburgh, PA, USA.""}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Fabio', 'Affiliation': 'Department of Epidemiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}, {'ForeName': 'Andre', 'Initials': 'A', 'LastName': 'Furtado', 'Affiliation': ""Department of Radiology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.""}, {'ForeName': 'Srikala', 'Initials': 'S', 'LastName': 'Narayan', 'Affiliation': ""Department of Radiology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.""}, {'ForeName': 'Derek C', 'Initials': 'DC', 'LastName': 'Angus', 'Affiliation': 'Department of Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, Pittsburgh, PA, USA.'}, {'ForeName': 'R Scott', 'Initials': 'RS', 'LastName': 'Watson', 'Affiliation': ""Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA; Center for Child Health, Behavior, and Development, Seattle Children's Research Institute, Seattle, WA, USA.""}, {'ForeName': 'Chunyan', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Epidemiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}, {'ForeName': 'Clifton W', 'Initials': 'CW', 'LastName': 'Callaway', 'Affiliation': 'Emergency Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; Safar Center for Resuscitation Research, Pittsburgh, PA, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Bell', 'Affiliation': ""Children's National Medical Center, Washington, DC, USA.""}, {'ForeName': 'Patrick M', 'Initials': 'PM', 'LastName': 'Kochanek', 'Affiliation': ""Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA; Department of Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; Safar Center for Resuscitation Research, Pittsburgh, PA, USA.""}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Bluml', 'Affiliation': ""Children's Hospital of Los Angeles, Los Angeles, CA, USA.""}, {'ForeName': 'Ashok', 'Initials': 'A', 'LastName': 'Panigrahy', 'Affiliation': ""Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA; Department of Radiology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.""}]",Resuscitation,['10.1016/j.resuscitation.2020.06.033'] 1958,32640882,Atrial fibrillation trial to evaluate real-world procedures for their utility in helping to lower stroke events: A randomized clinical trial.,"BACKGROUND Enhancing detection of unrecognized atrial fibrillation among acute ischemic stroke patients is crucial for secondary stroke prevention. AIM To evaluate whether the detection rate of new atrial fibrillation in acute ischemic stroke patients without known atrial fibrillation could be improved by doing serial 12-lead electrocardiograms once daily for five days, compared with conventional 24-h Holter monitoring (24-h Holter). METHODS We conducted a randomized clinical trial to compare the detection rates of paroxysmal atrial fibrillation between serial electrocardiograms versus 24-h Holter from October 2015 to October 2018 at six hospitals. Eligible participants were acute ischemic stroke patients with aged ≥65 years, with neither atrial fibrillation history nor any presence of atrial fibrillation on baseline electrocardiogram at admission. The primary outcome was newly detected electrocardiogram in the serial electrocardiograms and 24-h Holter group. RESULTS Among 826 patients, baseline characteristics were similar between both groups. In the intention-to-treat analysis, there was no statistical difference between serial electrocardiograms versus 24-Holter to detect atrial fibrillation (8.4% vs. 6.9%; adjusted odds ratio 1.17, 95% confidence interval 0.69-2.01). Stepwise multivariate logistic regression revealed age ≥80 years and history of heart failure were associated with detection of paroxysmal atrial fibrillation whereas patients with lacunar infarction had lower odds for detection of paroxysmal atrial fibrillation. CONCLUSIONS Serial electrocardiograms had comparable detection rate of paroxysmal atrial fibrillation compared with 24-h Holter and might be a viable alternative to 24-h Holter as a first-line approach to survey for potential paroxysmal atrial fibrillation among elderly patients with acute ischemic stroke. Clinical Trial Registration: URL https://clinicaltrials.gov/ct2/show/NCT02578979Unique Identifiers: NCT02578979.",2020,"Stepwise multivariate logistic regression revealed age ≥80 years and history of heart failure were associated with detection of paroxysmal atrial fibrillation whereas patients with lacunar infarction had lower odds for detection of paroxysmal atrial fibrillation. ","['elderly patients with acute ischemic stroke', 'from October 2015 to October 2018 at six hospitals', 'acute ischemic stroke patients', 'Eligible participants were acute ischemic stroke patients with aged ≥65 years, with neither atrial fibrillation history nor any presence of atrial fibrillation on baseline electrocardiogram at admission', 'acute ischemic stroke patients without known atrial fibrillation']",['serial electrocardiograms versus 24-h Holter'],"['newly detected electrocardiogram in the serial electrocardiograms and 24-h Holter group', 'detection rates of paroxysmal atrial fibrillation', 'detection of paroxysmal atrial fibrillation', 'atrial fibrillation', 'detection rate of paroxysmal atrial fibrillation']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0205309', 'cui_str': 'Known'}]","[{'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}]","[{'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0235480', 'cui_str': 'Paroxysmal atrial fibrillation'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}]",,0.248161,"Stepwise multivariate logistic regression revealed age ≥80 years and history of heart failure were associated with detection of paroxysmal atrial fibrillation whereas patients with lacunar infarction had lower odds for detection of paroxysmal atrial fibrillation. ","[{'ForeName': 'Wen-Yi', 'Initials': 'WY', 'LastName': 'Huang', 'Affiliation': 'Department of Neurology, Chang Gung University College of Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Lee', 'Affiliation': 'Department of Neurology, Chang Gung University College of Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.'}, {'ForeName': 'Sheng-Feng', 'Initials': 'SF', 'LastName': 'Sung', 'Affiliation': 'Division of Neurology, Department of Internal Medicine, Ditmanson Medical Foundation, Chia-Yi Christian Hospital, Chiayi, Taiwan.'}, {'ForeName': 'Sung-Chun', 'Initials': 'SC', 'LastName': 'Tang', 'Affiliation': 'Stroke Center and Department of Neurology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Kuo-Hsuan', 'Initials': 'KH', 'LastName': 'Chang', 'Affiliation': 'Department of Neurology, Chang Gung University College of Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.'}, {'ForeName': 'Yung-Sung', 'Initials': 'YS', 'LastName': 'Huang', 'Affiliation': 'Division of Neurology, Department of Internal Medicine, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan.'}, {'ForeName': 'Jiann-Der', 'Initials': 'JD', 'LastName': 'Lee', 'Affiliation': 'Department of Neurology, Chang Gung University College of Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.'}, {'ForeName': 'Tsong-Hai', 'Initials': 'TH', 'LastName': 'Lee', 'Affiliation': 'Department of Neurology, Chang Gung University College of Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.'}, {'ForeName': 'Jiann-Shing', 'Initials': 'JS', 'LastName': 'Jeng', 'Affiliation': 'Stroke Center and Department of Neurology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Chang-Min', 'Initials': 'CM', 'LastName': 'Chung', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Chang Gung University College of Medicine, Chang Gung Memorial Hospital, Chiayi Branch, Chiayi, Taiwan.'}, {'ForeName': 'Yi-Ling', 'Initials': 'YL', 'LastName': 'Wu', 'Affiliation': 'Institute of Population Health Sciences, National Health Research Institutes, Miaoli County, Taiwan.'}, {'ForeName': 'Tsung-Ta', 'Initials': 'TT', 'LastName': 'Hsieh', 'Affiliation': 'Department of Neurology, Chang Gung University College of Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Ovbiagele', 'Affiliation': 'Department of Neurology, University of California, San Francisco, CA, USA.'}]",International journal of stroke : official journal of the International Stroke Society,['10.1177/1747493020938297'] 1959,32658385,Randomized trial of lung hyperinflation therapy in children with congenital muscular dystrophy.,"OBJECTIVE Respiratory compromise in congenital muscular dystrophy (CMD) occurs, in part, from chest wall contractures. Passive stretch with hyperinsufflation therapy could reduce related costo-vertebral joint contractures. We sought to examine the impact of hyperinsufflation use on lung function and quality of life in children with CMD. STUDY DESIGN We conducted a randomized controlled trial on hyperinsufflation therapy in children with CMD at two centers. An individualized hyperinsufflation regimen of 15 minutes twice daily using a cough assist device over a 12 months period was prescribed. We measured lung function, quality of life, and adherence. To demonstrate reproducibility, pulmonary function was measured twice on the same day. A mixed-effects regression model adjusting for confounders was used to assess the effects of hyperinsufflation. RESULTS We enrolled 34 participants in the study; 31 completed the trial (n = 17 treatment group and n = 14 controls). Participants in the treatment group demonstrated a relative gain in lung volume measured at 4 and 8 months, but not at 12 months. The control group required increases in the maximum insufflation pressures to achieve maximum lung volumes while the treatment group did not. Adherence was best early in the study, peaking at the first visit and decreasing at subsequent visits. Caregiver-reported quality of life was higher in the treatment group. CONCLUSION Hyperinsufflation therapy is effective in increasing and sustaining lung volume over time. Adherence, however, was inconsistent and difficult to maintain. Further research should determine if improved adherence leads to sustained benefits of hyperinsufflation.",2020,"Participants in the treatment group demonstrated a relative gain in lung volume measured at 4 and 8 months, but not at 12 months.","['34 participants in the study; 31 completed the trial (n=17 treatment group and n=14 controls', 'children with congenital muscular dystrophy', 'Children with Congenital Muscular Dystrophy', 'children with congenital muscular dystrophy at two centers']","['hyperinsufflation', 'Hyperinsufflation therapy', 'hyperinsufflation therapy', 'Lung Hyperinflation Therapy']","['lung function, quality of life and adherence', 'costo-vertebral joint contractures', 'relative gain in lung volume', 'reproducibility, pulmonary function', 'Caregiver-reported quality of life', 'lung function and quality of life', 'maximum insufflation pressures', 'Adherence']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0009678', 'cui_str': 'congenital'}, {'cui': 'C0026850', 'cui_str': 'Muscular dystrophy'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1167782', 'cui_str': 'Lung hyperinflation'}]","[{'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0549207', 'cui_str': 'Bone structure of spine'}, {'cui': 'C0009918', 'cui_str': 'Contracture of joint'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0231953', 'cui_str': 'Lung volume'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0021634', 'cui_str': 'Insufflation'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}]",34.0,0.0666038,"Participants in the treatment group demonstrated a relative gain in lung volume measured at 4 and 8 months, but not at 12 months.","[{'ForeName': 'Hemant', 'Initials': 'H', 'LastName': 'Sawnani', 'Affiliation': ""Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Oscar H', 'Initials': 'OH', 'LastName': 'Mayer', 'Affiliation': ""Division of Pulmonary Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.""}, {'ForeName': 'Avani C', 'Initials': 'AC', 'LastName': 'Modi', 'Affiliation': 'Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}, {'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Pascoe', 'Affiliation': ""Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'McConnell', 'Affiliation': ""Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Joseph M', 'Initials': 'JM', 'LastName': 'McDonough', 'Affiliation': ""Division of Pulmonary Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.""}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Rutkowski', 'Affiliation': 'Cure CMD Foundation and Kaiser SCPMG, Los Angeles, California.'}, {'ForeName': 'Md Monir', 'Initials': 'MM', 'LastName': 'Hossain', 'Affiliation': 'Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}, {'ForeName': 'Rhonda', 'Initials': 'R', 'LastName': 'Szczesniak', 'Affiliation': 'Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}, {'ForeName': 'Dawit G', 'Initials': 'DG', 'LastName': 'Tadesse', 'Affiliation': ""Division of Epidemiology and Biostatistics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Christine L', 'Initials': 'CL', 'LastName': 'Schuler', 'Affiliation': 'Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}, {'ForeName': 'Raouf', 'Initials': 'R', 'LastName': 'Amin', 'Affiliation': ""Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}]",Pediatric pulmonology,['10.1002/ppul.24954'] 1960,32653604,"Impact of bupivacaine injection to trocar sites on postoperative pain following laparoscopic hysterectomy: Results from a prospective, multicentre, double-blind randomized controlled trial.","OBJECTIVES Laparoscopic surgery has numerous advantages over open surgery in view of postoperative pain. In this context, to elevate its benefits and patient satisfaction, different pain management interventions have been used so far. This study aimed to evaluate the effect of bupivacaine injection to trocar sites following laparoscopic hysterectomy for the management of postoperative pain. STUDY DESIGN In this study, patients were randomized into two groups (56 cases; 52 controls). A single injection of bupivacaine (0.5 %, 5 mg/mL) was introduced to trocar sites under subcutaneous tissue at a dose of 4 ml for the umbilicus and 2 ml for each 5-mm ancillary trocar site in the study group. No bupivacaine was administered to the control group. The primary aim was to measure differences in 2 -h postoperative numerical rating scale (NRS) pain scores between the two groups. The secondary aims were to evaluate differences between 1-, 4-, 6-, 24- and 48 -h postoperative NRS pain scores, surgical complications, estimated blood loss, duration of operation and analgesic consumption. RESULTS The number of postoperative rescue doses of analgesics was found to be lower in the study group compared to the control group (median of 2 vs. 4; p < 0.01). The 1-, 4-, 6-, 24- and 48-hour postoperative NRS pain scores were also found to be lower in the study group compared to the control group (p < 0.01 at each follow-up). The mean duration of surgery and uterus removal, as well as the estimated blood loss, were not significantly different between the two groups. CONCLUSIONS The present study suggests that bupivacaine injection to trocar sites is an effective and safe method for reducing pain following laparoscopic hysterectomy.",2020,The number of postoperative rescue doses of analgesics was found to be lower in the study group compared to the control group (median of 2 vs. 4; p < 0.01).,['laparoscopic hysterectomy'],"['laparoscopic hysterectomy', 'Laparoscopic surgery', 'bupivacaine injection to trocar sites', 'bupivacaine']","['48-hour postoperative NRS pain scores', '2 -h postoperative numerical rating scale (NRS) pain scores', 'mean duration of surgery and uterus removal', 'postoperative pain', 'postoperative NRS pain scores, surgical complications, estimated blood loss, duration of operation and analgesic consumption', 'estimated blood loss', 'pain', 'number of postoperative rescue doses of analgesics']","[{'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}]","[{'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C4060211', 'cui_str': 'Bupivacaine Injection [Sensorcaine]'}, {'cui': 'C0041158', 'cui_str': 'Trocar'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]","[{'cui': 'C0439586', 'cui_str': '48 hours'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C1443559', 'cui_str': 'Estimated blood loss'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.144145,The number of postoperative rescue doses of analgesics was found to be lower in the study group compared to the control group (median of 2 vs. 4; p < 0.01).,"[{'ForeName': 'Ismet', 'Initials': 'I', 'LastName': 'Hortu', 'Affiliation': 'Department of Obstetrics and Gynaecology, Ege University School of Medicine, Izmir, Turkey; Department of Stem Cell, Ege University Institute of Health Sciences, Izmir, Turkey. Electronic address: ismethortu@yahoo.com.'}, {'ForeName': 'Unal', 'Initials': 'U', 'LastName': 'Turkay', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Hasan', 'Initials': 'H', 'LastName': 'Terzi', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Kale', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Mehmet', 'Initials': 'M', 'LastName': 'Yılmaz', 'Affiliation': 'Department of Anaesthesiology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Canan', 'Initials': 'C', 'LastName': 'Balcı', 'Affiliation': 'Department of Anaesthesiology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Umit', 'Initials': 'U', 'LastName': 'Aydın', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Antonio Simone', 'Initials': 'AS', 'LastName': 'Laganà', 'Affiliation': 'Department of Obstetrics and Gynaecology, ""Filippo Del Ponte"" Hospital, University of Insubria, Varese, Italy.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.07.007'] 1961,32653606,Effects of the levonorgestrel intrauterine system on the endometrium after long-term exposure to mifepristone: Secondary outcomes of a randomized controlled trial.,"OBJECTIVE Long-term treatment with progesterone receptor modulators (PRM) is associated with a distinct histological entity termed progesterone receptor modulator associated endometrial changes (PAEC). While accumulating evidence implies that these changes are benign and reversible after cessation of treatment, there are currently no data underpinning their development. Consequently, as a precaution, endometrial shedding is recommended after long-term PRM intake. Avoiding endometrial shedding after treatment with a PRM and prior to the start of a progestin treatment would be beneficial for women in reproductive age to avoid pregnancy and bleeding. However, the endometrial morphology with such a treatment regimen is unknown. The aim of this study was to delineate the endometrial morphology following continuous long-term treatment with the PRM mifepristone and subsequent placement of a levonorgestrel intrauterine system (LNG-IUS) without prior shedding of the endometrium. STUDY DESIGN This study reports the secondary outcome from a double-blinded randomized controlled trial conducted at Karolinska University Hospital, Sweden, November 2009 to January 2015. Healthy women aged 18-43 years with regular menstrual cycles were included. Eligible women were randomized to receive either 50 mg of mifepristone (n = 29) or a comparator (n = 29), every other day for two months followed by insertion of an LNG-IUS 52 mg. Endometrial biopsies were obtained at baseline and three months after placement of the device. The samples were histologically assessed. The main outcome measure of this sub-study was the endometrial morphology including presence of PAEC three months after LNG-IUS insertion. RESULTS Nine and eight paired biopsies from the mifepristone and comparator group, respectively, were included in the histological analysis. There were no differences in baseline characteristics between the groups and all baseline endometrial biopsies were physiological. Three months after LNG-IUS placement the endometrial morphology was still benign without PAEC in all samples treated with either mifepristone or comparator. A progestin effect on the endometrium was seen in all samples. CONCLUSIONS Placement of an LNG-IUS immediately following two months' treatment with the PRM mifepristone, without any prior shedding of the endometrium, may represent a feasible approach in terms of endometrial safety. However, larger studies are needed to confirm our results.",2020,Three months after LNG-IUS placement the endometrial morphology was still benign without PAEC in all samples treated with either mifepristone or comparator.,"['Karolinska University Hospital, Sweden, November 2009 to January 2015', 'Eligible women', 'Healthy women aged 18-43 years with regular menstrual cycles']","['progesterone receptor modulators (PRM', 'mifepristone', 'PRM mifepristone', 'levonorgestrel intrauterine system', 'progestin treatment', 'PRM mifepristone and subsequent placement of a levonorgestrel intrauterine system (LNG-IUS']",['Endometrial biopsies'],"[{'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0025329', 'cui_str': 'Normal menstrual cycle'}]","[{'cui': 'C3653463', 'cui_str': 'Progesterone receptor modulators'}, {'cui': 'C0026088', 'cui_str': 'Mifepristone'}, {'cui': 'C4293465', 'cui_str': 'Levonorgestrel Intrauterine System [Kyleena]'}, {'cui': 'C0033306', 'cui_str': 'Progestational hormone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0404066', 'cui_str': 'Endometrial scraping'}]",,0.419988,Three months after LNG-IUS placement the endometrial morphology was still benign without PAEC in all samples treated with either mifepristone or comparator.,"[{'ForeName': 'Kiriaki', 'Initials': 'K', 'LastName': 'Papaikonomou', 'Affiliation': ""Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. Electronic address: kiriaki.papaikonomou@ki.se.""}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Frisendahl', 'Affiliation': ""Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.""}, {'ForeName': 'Alistair R W', 'Initials': 'ARW', 'LastName': 'Williams', 'Affiliation': 'Division of Pathology, The Royal Infirmary of Edinburgh, The University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Gemzell-Danielsson', 'Affiliation': ""Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.""}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.06.056'] 1962,32653721,Leveraging immersive technology to expand access to opioid overdose reversal training in community settings: Results from a randomized controlled equivalence trial.,"BACKGROUND Immersive video (e.g. virtual reality) poses a promising and engaging alternative to standard in-person trainings and can potentially increase access to evidence-based opioid overdose prevention programs (OOPPs). Therefore, the objective of this equivalence study was to test whether the immersive video OOPP was equivalent to a standard in-person OOPP for changes in opioid overdose knowledge and attitudes. METHODS A team of nurses and communication researchers developed a 9-minute immersive video OOPP. To test whether this immersive video OOPP (treatment) demonstrated equivalent gains in opioid overdose response knowledge and attitudes as in-person OOPPs (standard of care control), researchers deployed a two-day field experiment in Philadelphia, Pennsylvania, USA. In this equivalence trial, 9 libraries were randomly assigned to offer treatment or control OOPP to community members attending naloxone giveaway events. In this equivalence design, a difference between treatment and control groups pre- to post-training scores within -1.0 to 1.0 supports equivalence between the trainings. RESULTS Results demonstrate participants (N = 94) exposed to the immersive video OOPP had equivalent improvements on posttest knowledge (β=-0.18, p = .61) and more favorable attitudes about responding to an opioid overdose (β=0.26, p = .02) than those exposed to the standard OOPP. However, these minor differences in knowledge and attitudes were within the equivalence interval indicating that the immersive video OOPP remained equivalently effective for community members. CONCLUSIONS Community partnerships, like those between public health departments and libraries, can provide opportunities for deploying novel immersive video OOPP that, alongside standard offerings, can strengthen community response to the opioid crisis.",2020,"RESULTS Results demonstrate participants (N = 94) exposed to the immersive video OOPP had equivalent improvements on posttest knowledge (β=-0.18, p = .61) and more favorable attitudes about responding to an opioid overdose (β=0.26, p = .02) than those exposed to the standard OOPP.",['community settings'],"['immersive video OOPP (treatment', 'immersive video OOPP', 'control OOPP']","['posttest knowledge', 'favorable attitudes about responding to an opioid overdose']","[{'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0029944', 'cui_str': 'Drug overdose'}]",9.0,0.046718,"RESULTS Results demonstrate participants (N = 94) exposed to the immersive video OOPP had equivalent improvements on posttest knowledge (β=-0.18, p = .61) and more favorable attitudes about responding to an opioid overdose (β=0.26, p = .02) than those exposed to the standard OOPP.","[{'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Herbert', 'Affiliation': 'Woods Institute for the Environment, Stanford University, 473 Via Ortega, Stanford, CA, USA.'}, {'ForeName': 'Sydney', 'Initials': 'S', 'LastName': 'Axson', 'Affiliation': 'School of Nursing, University of Pennsylvania, 418 Curie Boulevard, Philadelphia, PA, USA.'}, {'ForeName': 'Leeann', 'Initials': 'L', 'LastName': 'Siegel', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania, 620 Walnut Street, Philadelphia, PA, USA.'}, {'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Cassidy', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania, 620 Walnut Street, Philadelphia, PA, USA.'}, {'ForeName': 'Ann Marie', 'Initials': 'AM', 'LastName': 'Hoyt-Brennan', 'Affiliation': 'School of Nursing, University of Pennsylvania, 418 Curie Boulevard, Philadelphia, PA, USA.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Whitney', 'Affiliation': 'School of Nursing, University of Pennsylvania, 418 Curie Boulevard, Philadelphia, PA, USA.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Herens', 'Affiliation': 'Division of Substance Use Prevention and Harm Reduction, Philadelphia Department of Public Health, 1101 Market Street, 13th Floor, Suite 1320, Philadelphia PA, USA.'}, {'ForeName': 'Nicholas A', 'Initials': 'NA', 'LastName': 'Giordano', 'Affiliation': 'Nell Hodgson Woodruff School of Nursing, Emory University, 1520 Clifton Road, Atlanta, GA, USA. Electronic address: ngiorda@emory.edu.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108160'] 1963,32654902,Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series.,"BACKGROUND Concomitant administration of vaccines simplifies delivery. DTaP5-HB-IPV-Hib is a fully liquid, combination vaccine against 6 diseases. This study evaluated the compatibility of DTaP5-HB-IPV-Hib with 2 different meningococcus group C conjugate (MCC) vaccines in infants. METHODS In a phase 3, open-label study, 284 healthy infants from 11 UK centres received DTaP5-HB-IPV-Hib at age 2, 3, and 4 months; 13-valent pneumococcal conjugate vaccine (PCV13) at 2 and 4 months; a Haemophilus influenzae type b (Hib)-MCC vaccine and a measles/mumps/rubella vaccine at 12 months. Participants were randomised 1:1 to receive either an MCC-detoxified tetanus toxin vaccine (MCC-TT; n = 141) or an MCC-Corynebacterium diphtheriae CRM 197 protein vaccine (MCC-CRM; n = 143) at 3 and 4 months. The primary outcome was seroprotection rate (SPR) to MCC (percent with rabbit complement serum bactericidal antibody titer ≥8). RESULTS Per protocol analysis, MCC SPRs were 100 and 96.4 one month after the first dose, 100 and 99.1 after the second dose, and 100 and 97.3 after the third (booster) dose of MCC in the MCC-TT and MCC-CRM groups, respectively. One month after all 3 doses of DTaP5-HB-IPV-Hib, immunoglobulin G anti-polyribosylribitol phosphate SPRs (% ≥0.15 µg/mL) were 97.8 in the MCC-TT group and 100 in the MCC-CRM group; anti-hepatitis B antigen SPRs (% ≥10 mIU/mL) were 96.8 and 96.3 in the MCC-TT and MCC-CRM groups, respectively. All participants were seroprotected against diphtheria and tetanus (≥0.01 IU/mL) and poliovirus types 1, 2, and 3 (≥8 dilution), and seroresponse rates to all pertussis antigens were ≥90.4%. Two vaccine-related serious adverse events (transient severe abdominal pain and crying) occurred concomitantly in 1 participant in the MCC-CRM group. Adverse event rates were similar to other studies of DTaP5-HB-IPV-Hib, with pyrexia ≥38 °C in 10.9% of participants following any dose. CONCLUSIONS DTaP5-HB-IPV-Hib can be effectively used in a 2-, 3-, and 4-month infant priming schedule when given with 2 doses of MCC.",2020,"All participants were seroprotected against diphtheria and tetanus (≥0.01 IU/mL) and poliovirus types 1, 2, and 3 (≥8 dilution), and seroresponse rates to all pertussis antigens were ≥90.4%.","['284 healthy infants from 11 UK centres received', 'infants']","['DTaP5-HB-IPV-Hib with 2 different meningococcus group C conjugate (MCC) vaccines', 'MCC-detoxified tetanus toxin vaccine (MCC-TT; n\xa0=\xa0141) or an MCC-Corynebacterium diphtheriae CRM 197 protein vaccine (MCC-CRM', 'DTaP5-HB-IPV-Hib at age 2, 3, and 4\xa0months; 13-valent pneumococcal conjugate vaccine (PCV13) at 2 and 4\xa0months; a Haemophilus influenzae type b (Hib)-MCC vaccine and a measles/mumps/rubella vaccine', 'DTaP5-HB-IPV-Hib, immunoglobulin G anti-polyribosylribitol phosphate SPRs', 'DTaP5-HB-IPV-Hib vaccine']","['Adverse event rates', 'seroprotection rate (SPR) to MCC (percent with rabbit complement serum bactericidal antibody titer\xa0≥8', 'serious adverse events (transient severe abdominal pain and crying']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0718003', 'cui_str': 'Inactivated Poliovirus vaccine'}, {'cui': 'C0121772', 'cui_str': 'Haemophilus influenzae type b'}, {'cui': 'C0027575', 'cui_str': 'Neisseria meningitidis'}, {'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0301869', 'cui_str': 'Conjugate'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0025516', 'cui_str': 'Detoxication, Drug, Metabolic'}, {'cui': 'C0039617', 'cui_str': 'tetanus toxin'}, {'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0010150', 'cui_str': 'Corynebacterium diphtheriae'}, {'cui': 'C0056499', 'cui_str': 'CRM197 (non-toxic variant of diphtheria toxin)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C3152625', 'cui_str': 'Pneumococcal 13-valent conjugate vaccine'}, {'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}, {'cui': 'C0025007', 'cui_str': 'Measles'}, {'cui': 'C0035923', 'cui_str': 'Rubella virus vaccine'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0031603', 'cui_str': 'Phosphate'}, {'cui': 'C0626314', 'cui_str': 'sperm releasing substance'}, {'cui': 'C0062086', 'cui_str': 'Haemophilus influenzae Type b vaccine'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0027575', 'cui_str': 'Neisseria meningitidis'}, {'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0301869', 'cui_str': 'Conjugate'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0324889', 'cui_str': 'Oryctolagus cuniculus'}, {'cui': 'C0009498', 'cui_str': 'Complement'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0474643', 'cui_str': 'Antibody titer measurement'}, {'cui': 'C0040704', 'cui_str': 'Transients'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}]",284.0,0.0936911,"All participants were seroprotected against diphtheria and tetanus (≥0.01 IU/mL) and poliovirus types 1, 2, and 3 (≥8 dilution), and seroresponse rates to all pertussis antigens were ≥90.4%.","[{'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Oliver', 'Affiliation': ""Bristol Children's Vaccine Centre, University of Bristol & University Hospitals Bristol NHS Foundation Trust, Bristol, UK.""}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Sadorge', 'Affiliation': 'Sanofi Pasteur MSD, Lyon, France.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Boisnard', 'Affiliation': 'Sanofi Pasteur MSD, Lyon, France.'}, {'ForeName': 'Matthew D', 'Initials': 'MD', 'LastName': 'Snape', 'Affiliation': 'Oxford Vaccine Group, University of Oxford Department of Paediatrics and the NIHR Oxford Biomedical Research Council, Oxford, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Tomlinson', 'Affiliation': 'Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Mann', 'Affiliation': 'Taunton and Somerset NHS Foundation Trust, Somerset, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Rudd', 'Affiliation': 'Royal Hospitals Bath NHS Foundation Trust, Bath, UK.'}, {'ForeName': 'Shyam', 'Initials': 'S', 'LastName': 'Bhakthavalsala', 'Affiliation': 'Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK.'}, {'ForeName': 'Saul N', 'Initials': 'SN', 'LastName': 'Faust', 'Affiliation': 'NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Paul T', 'Initials': 'PT', 'LastName': 'Heath', 'Affiliation': ""St George's, University of London and St George's University Hospitals NHS Foundation Trust, London, UK.""}, {'ForeName': 'Stephen M', 'Initials': 'SM', 'LastName': 'Hughes', 'Affiliation': 'Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Ray', 'Initials': 'R', 'LastName': 'Borrow', 'Affiliation': 'Public Health England, Manchester Royal Infirmary, Manchester, UK.'}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Thomas', 'Affiliation': 'Sanofi Pasteur MSD, Lyon, France.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Finn', 'Affiliation': ""Bristol Children's Vaccine Centre, University of Bristol & University Hospitals Bristol NHS Foundation Trust, Bristol, UK. Electronic address: Adam.Finn@bristol.ac.uk.""}]",Vaccine,['10.1016/j.vaccine.2020.06.015'] 1964,32658765,Assessment of stress markers in restrained individuals following physical stress with and without sham CED activation.,"INTRODUCTION Law enforcement and pre-hospital care personnel often confront individuals who must be physically restrained. Many are under the influence of illicit substances, and law enforcement officers may need to use a controlled electrical device (CED) to gain control of the individual and they are often placed into the prone maximum restraint (PMR) position. These techniques have previously been evaluated for their physiologic effects. The purpose of this study was to investigate the psychological effects of anticipating and experiencing a sham CED activation in healthy human subjects who were exercised and restrained compared with no sham activation by assessing the differences in a panel of several known biomarkers of stress. METHODS We performed a randomized, crossover controlled human subject trial to study the stress associated with exercise, physical exhaustion, and restraint with and without an added psychological stress simulating the field use of a CED. Twenty five total subjects; each subject performed two different trials each consisting of a brief period of intense exercise on a treadmill to exhaustion followed by placement in the PMR with and without induced psychological stress. Blood samples were collected for analysis pre and post exercise, as well as 10 min after completion of the exercise. A panel of hormones and stress markers were measured. RESULTS We found no significant differences in any of the stress biomarkers measured between the two study groups. A trend towards higher levels of copeptin was measured in the sham CED activation arm. CONCLUSION During a brief period of intense exercise followed by the psychological stress of anticipated CED application, there did not appear to be statistically significant changes in the stress panel of biomarkers measured, only a trend towards significance for higher copeptin levels in the patients exposed to the psychological stress.",2020,We found no significant differences in any of the stress biomarkers measured between the two study groups.,"['healthy human subjects', 'Twenty five total subjects']",['intense exercise on a treadmill to exhaustion followed by placement in the PMR with and without induced psychological stress'],"['stress biomarkers', 'levels of copeptin']","[{'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0033422', 'cui_str': 'Prone body position'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0035260', 'cui_str': 'Physical restraint'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0038443', 'cui_str': 'Psychological Stress'}]","[{'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0056279', 'cui_str': 'copeptins'}]",25.0,0.0515782,We found no significant differences in any of the stress biomarkers measured between the two study groups.,"[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Sloane', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA. Electronic address: csloane@ucsd.edu.'}, {'ForeName': 'Deborah C', 'Initials': 'DC', 'LastName': 'Mash', 'Affiliation': 'Department of Neurology, Molecular and Cellular Pharmacology, University of Miami, Miami, FL, USA.'}, {'ForeName': 'Theodore C', 'Initials': 'TC', 'LastName': 'Chan', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA.'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Kolkhorst', 'Affiliation': 'School of Exercise and Nutritional Sciences, San Diego State University San Diego, CA, USA.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Neuman', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA.'}, {'ForeName': 'Edward M', 'Initials': 'EM', 'LastName': 'Castillo', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Lasoff', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Wardi', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA; Division of Pulmonary, Critical Care, and Sleep Medicine, University of California, San Diego, San Diego, CA, USA.'}, {'ForeName': 'Xiaobin', 'Initials': 'X', 'LastName': 'Xie', 'Affiliation': 'Department of Neurology, Molecular and Cellular Pharmacology, University of Miami, Miami, FL, USA.'}, {'ForeName': 'Gary M', 'Initials': 'GM', 'LastName': 'Vilke', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA.'}]",Journal of forensic and legal medicine,['10.1016/j.jflm.2020.101982'] 1965,32658797,Addition of dexmedetomidine to ropivacaine for local infiltration anaesthesia improves analgesic efficacy after tonsillectomy and adenoidectomy: A randomized controlled trial.,"OBJECTIVES The aim of this study was to determine whether the addition of dexmedetomidine to ropivacaine for local infiltration anaesthesia was more effective than ropivacaine alone in attenuating pain after tonsillectomy and adenoidectomy. METHODS This was a double-blind randomized clinical trial. One hundred and twenty children scheduled for tonsillectomy and adenoidectomy using a combination of general anaesthesia and local infiltration anaesthesia were randomized into the dexmedetomidine plus ropivacaine group (DR) and ropivacaine group (R). The children were locally infiltrated with 1 μg kg -1 dexmedetomidine and 0.25% ropivacaine in the DR group or 0.25% ropivacaine alone in the R group. In both groups, local infiltration anaesthesia was performed using 5 ml of solution. The pain scores were recorded at the 1st, 4th, 8th, 12th, 16th, 20th, and 24th hours after surgery using the Face Legs Activity Cry Consolability (FLACC) scale. When the pain score exceeded 4, paracetamol syrup (15 mg kg -1 ) was administered as a rescue analgesic. Time to the first administration of analgesic was recorded. RESULTS 8th, 16th, 20th, and 24th hours after surgery, the children in the DR group had lower pain scores than those in the R group (P<0.05). The time to the first administration of analgesic was significantly longer in the DR group (mean: 10.4 h, range: 9.4-11.4 h) than in the R group (mean: 8.1 h, range: 7.3-8.8 h) (P < 0.001). CONCLUSION The addition of dexmedetomidine to ropivacaine for local infiltration anaesthesia effectively improved the efficacy of analgesia and extended the duration of analgesia after tonsillectomy and adenoidectomy.",2020,The addition of dexmedetomidine to ropivacaine for local infiltration anaesthesia effectively improved the efficacy of analgesia and extended the duration of analgesia after tonsillectomy and adenoidectomy.,['One hundred and twenty children scheduled for tonsillectomy and adenoidectomy using a combination of general anaesthesia and local infiltration anaesthesia'],"['dexmedetomidine plus ropivacaine', 'tonsillectomy and adenoidectomy', 'ropivacaine', 'paracetamol syrup', 'dexmedetomidine']","['pain scores', 'Face Legs Activity Cry Consolability (FLACC) scale', 'efficacy of analgesia and extended the duration of analgesia', 'time to the first administration of analgesic', 'analgesic efficacy', 'pain', 'pain score', 'lower pain scores']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0193959', 'cui_str': 'Tonsillectomy and adenoidectomy'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0198813', 'cui_str': 'Local anesthesia, by infiltration'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0193959', 'cui_str': 'Tonsillectomy and adenoidectomy'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0458173', 'cui_str': 'Syrup'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0010399', 'cui_str': 'Crying'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0262176', 'cui_str': 'Administration of analgesic'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",120.0,0.171204,The addition of dexmedetomidine to ropivacaine for local infiltration anaesthesia effectively improved the efficacy of analgesia and extended the duration of analgesia after tonsillectomy and adenoidectomy.,"[{'ForeName': 'Jianhong', 'Initials': 'J', 'LastName': 'Hao', 'Affiliation': ""Department of Anesthesiology, HongHui Hospital, Xi'an JiaoTong University, Xi'an, China.""}, {'ForeName': 'Zanqing', 'Initials': 'Z', 'LastName': 'Wu', 'Affiliation': ""Department of Anesthesiology, HongHui Hospital, Xi'an JiaoTong University, Xi'an, China.""}, {'ForeName': 'Zhenguo', 'Initials': 'Z', 'LastName': 'Luo', 'Affiliation': ""Department of Anesthesiology, HongHui Hospital, Xi'an JiaoTong University, Xi'an, China.""}, {'ForeName': 'Buhuai', 'Initials': 'B', 'LastName': 'Dong', 'Affiliation': ""Department of Anesthesiology, HongHui Hospital, Xi'an JiaoTong University, Xi'an, China. Electronic address: dongbuhai@sina.com.""}]",International journal of pediatric otorhinolaryngology,['10.1016/j.ijporl.2020.110168'] 1966,32658817,Effects of family-focused therapy on suicidal ideation and behavior in youth at high risk for bipolar disorder.,"BACKGROUND Youth who are at clinical and familial risk for bipolar disorder (BD) often have significant suicidal ideation (SI). In a randomized trial, we examined whether family-focused therapy (FFT) is associated with reductions in SI and suicidal behaviors in high-risk youth. METHODS Participants (ages 9-17 years) met diagnostic criteria for unspecified BD or major depressive disorder with active mood symptoms and had at least one relative with BD type I or II. Participants were randomly allocated to 12 sessions in 4 months of FFT or 6 sessions in 4 months of psychoeducation (enhanced care, EC), with pharmacotherapy as needed. Clinician- and child-rated assessments of mood, suicidal thoughts and behaviors, and family conflict were obtained at baseline and 4-6 month intervals over 1-4 years. RESULTS Participants (N=127; mean 13.2±2.6 yrs., 82 female) were followed over an average of 105.9±64.0 weeks. Youth with high baseline levels of SI who received FFT had lower levels of (and fewer weeks with) SI at follow-up compared to youth with high baseline SI who received EC. Participants in FFT had longer intervals without suicidal behaviors than participants in EC. Youths' ratings of family conflict significantly mediated the effects of treatment on SI at follow-up. LIMITATIONS Family conflict was based on questionnaires rather than observer ratings of family interactions. CONCLUSIONS Family psychoeducation with skill training can be an effective deterrent to suicidal thoughts and behaviors in youth at high risk for BD. Reducing parent/offspring conflict should be a central objective of psychosocial interventions for high-risk youth with SI.",2020,"Youths' ratings of family conflict significantly mediated the effects of treatment on SI at follow-up. ","['Youth who are at clinical and familial risk for bipolar disorder (BD', 'youth at high risk for bipolar disorder', 'Participants (N=127; mean 13.2±2.6 yrs., 82 female', 'high-risk youth with SI', 'Participants (ages 9-17 years) met diagnostic criteria for unspecified BD or major depressive disorder with active mood symptoms and had at least one relative with BD type I or II', 'Youth with high baseline levels of SI who received']","['FFT or 6 sessions in 4 months of psychoeducation (enhanced care, EC', 'family-focused therapy', 'FFT', 'skill training', 'family-focused therapy (FFT']","['longer intervals without suicidal behaviors', 'SI and suicidal behaviors', 'mood, suicidal thoughts and behaviors, and family conflict', 'suicidal ideation and behavior']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C1760428', 'cui_str': 'Suicidal behavior'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0233542', 'cui_str': 'Family conflict'}]",127.0,0.111281,"Youths' ratings of family conflict significantly mediated the effects of treatment on SI at follow-up. ","[{'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Miklowitz', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Los Angeles (UCLA) School of Medicine, University of California, 760 Westwood Plaza Rm A8-256, Los Angeles, 90024-1759 CA, USA. Electronic address: dmiklowitz@mednet.ucla.edu.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Merranko', 'Affiliation': 'Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA.'}, {'ForeName': 'Marc J', 'Initials': 'MJ', 'LastName': 'Weintraub', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Los Angeles (UCLA) School of Medicine, University of California, 760 Westwood Plaza Rm A8-256, Los Angeles, 90024-1759 CA, USA.'}, {'ForeName': 'Patricia D', 'Initials': 'PD', 'LastName': 'Walshaw', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Los Angeles (UCLA) School of Medicine, University of California, 760 Westwood Plaza Rm A8-256, Los Angeles, 90024-1759 CA, USA.'}, {'ForeName': 'Manpreet K', 'Initials': 'MK', 'LastName': 'Singh', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Kiki D', 'Initials': 'KD', 'LastName': 'Chang', 'Affiliation': 'Private Practice, Menlo Park, CA, USA.'}, {'ForeName': 'Christopher D', 'Initials': 'CD', 'LastName': 'Schneck', 'Affiliation': 'Department of Psychiatry, University of Colorado Anschutz Medical Campus, Denver, CO, USA.'}]",Journal of affective disorders,['10.1016/j.jad.2020.06.015'] 1967,32658822,Improvements in irritability with sertraline versus placebo: Findings from the EMBARC study.,"BACKGROUND This report seeks to evaluate improvements in symptoms of irritability with sertraline (a selective serotonin reuptake inhibitor antidepressant) versus placebo. METHODS Participants of Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study who were randomized to 8 weeks of treatment with either sertraline or placebo and completed 5-item irritability domain of Concise Associated Symptom Tracking scale (CAST-IRR) at baseline were included (n = 292). Repeated measures mixed model analysis with CAST-IRR as the outcome variable and treatment arm-by-time interaction as the independent variable of interest evaluated whether changes in irritability with treatment differed between sertraline and placebo arms. A separate analysis controlled for levels of overall depression severity (17-item Hamilton Depression Rating Scale). Covariates included age, sex, race, ethnicity, and site. RESULTS There was a significant treatment arm-by-time interaction (F = 6.96, df = 6, 1418, p <0.0001) suggesting that changes in irritability with sertraline differed from placebo. The magnitude of reduction in irritability from baseline to week-8 was greater with sertraline than with placebo (Cohen's d effect size = 0.56). After controlling for levels of overall depression severity at each visit, reduction in irritability with time continued to be significant with sertraline but not with placebo. LIMITATIONS Secondary analysis, limited generalizability, lack of non-serotonergic antidepressants. DISCUSSION There is greater improvement in irritability with sertraline than with placebo. Improvement in irritability with sertraline was independent of its effects on overall depression severity. CLINICALTRIALS. GOV IDENTIFIER NCT01407094.",2020,The magnitude of reduction in irritability from baseline to week-8 was greater with sertraline than with placebo (Cohen's d effect size = 0.56).,['Participants of Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study who'],"['sertraline or placebo', 'sertraline', 'placebo']","['5-item irritability domain of Concise Associated Symptom Tracking scale (CAST-IRR', 'reduction in irritability', 'overall depression severity', 'irritability', 'overall depression severity (17-item Hamilton Depression Rating Scale']","[{'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0022107', 'cui_str': 'Feeling irritable'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0521989', 'cui_str': 'Associated symptom'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0179686', 'cui_str': 'Cast'}, {'cui': 'C0083017', 'cui_str': 'insulin receptor-related receptor'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}]",,0.370511,The magnitude of reduction in irritability from baseline to week-8 was greater with sertraline than with placebo (Cohen's d effect size = 0.56).,"[{'ForeName': 'Manish K', 'Initials': 'MK', 'LastName': 'Jha', 'Affiliation': 'Center for Depression Research and Clinical Care, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9119, United States; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, United States.'}, {'ForeName': 'Abu', 'Initials': 'A', 'LastName': 'Minhajuddin', 'Affiliation': 'Center for Depression Research and Clinical Care, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9119, United States.'}, {'ForeName': 'Cherise', 'Initials': 'C', 'LastName': 'Chin Fatt', 'Affiliation': 'Center for Depression Research and Clinical Care, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9119, United States.'}, {'ForeName': 'Madhukar H', 'Initials': 'MH', 'LastName': 'Trivedi', 'Affiliation': 'Center for Depression Research and Clinical Care, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9119, United States. Electronic address: madhukar.trivedi@utsouthwestern.edu.'}]",Journal of affective disorders,['10.1016/j.jad.2020.06.021'] 1968,32658830,The feasibility of acupuncture as an adjunct intervention for antenatal depression: a pragmatic randomised controlled trial.,"BACKGROUND Antenatal depression is common and associated with adverse consequences for mothers, babies, and future generations. Limitations with conventional approaches has resulted in additional therapies being considered. This study examined the feasibility and effectiveness of acupuncture for improving mental health. METHODS Fifty-seven pregnant women with depressive symptomologies were randomised to acupuncture (n=19) plus treatment as usual (TAU), progressive muscle relaxation (PMR, n=19) plus TAU or TAU (n=19). Treatments were conducted from 24 to 31 weeks gestation. Clinical assessments were performed throughout the intervention, as well as at a six-week postnatal follow-up. The primary outcome measure was depression. Secondary outcome measurements were stress, anxiety, psychological distress, quality of life and adjustment to mothering. Intention to treat (ITT), Linear Mixed Model (LMM) repeated measures and per protocol (PP) analyses were conducted. RESULTS At end-of-intervention there were significantly lower depression scores in the acupuncture group versus TAU and PMR respectively [ITT p<0.001, mean difference (MD) -5.84 (95% CI -9.10 to -2.58); MD -3.42 (95% CI -6.64 to -0.20)]. LMM repeated measures analysis (including postnatal follow-up) also demonstrated significantly lowered acupuncture group scores for stress (p=0.006) and psychological distress (p<0.001) when compared to PMR and TAU. Between group differences were not significant at six-weeks postnatal. No adverse events were reported. LIMITATIONS Main limitations are small sample size and the use of self-reported outcome measures. CONCLUSION Prenatal acupuncture reduced depression, stress and distress, whilst also being well-tolerated and free from adverse events. Further research is warranted.",2020,"At end-of-intervention there were significantly lower depression scores in the acupuncture group versus TAU and PMR respectively [ITT p<0.001, mean difference (MD)","['Fifty-seven pregnant women with depressive symptomologies', 'antenatal depression']","['acupuncture', 'acupuncture (n=19) plus treatment as usual (TAU), progressive muscle relaxation (PMR, n=19) plus TAU or TAU']","['mean difference (MD', 'depression scores', 'depression', 'adverse events', 'depression, stress and distress, whilst also being well-tolerated and free from adverse events', 'psychological distress', 'stress, anxiety, psychological distress, quality of life and adjustment to mothering']","[{'cui': 'C4517815', 'cui_str': '57'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C2828394', 'cui_str': 'Antenatal'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0454043', 'cui_str': 'Jacobson technique'}, {'cui': 'C0032533', 'cui_str': 'Polymyalgia rheumatica'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]",57.0,0.185105,"At end-of-intervention there were significantly lower depression scores in the acupuncture group versus TAU and PMR respectively [ITT p<0.001, mean difference (MD)","[{'ForeName': 'Simone M', 'Initials': 'SM', 'LastName': 'Ormsby', 'Affiliation': 'Adjunct Fellow, NICM Health Research Institute, Level 1, Building J, Western Sydney University, Westmead Campus, Locked Bag 1797, Penrith, NSW 2751, Australia. Electronic address: simone.ormsby@westernsydney.edu.au.'}, {'ForeName': 'Caroline A', 'Initials': 'CA', 'LastName': 'Smith', 'Affiliation': 'Professor of Clinical Research, NICM Health Research Institute, Level 1, Building J, Western Sydney University, Westmead Campus, Locked Bag 1797, Penrith, NSW, 2751, Australia. Electronic address: caroline.smith@westernsydney.edu.au.edu.au.'}, {'ForeName': 'Hannah G', 'Initials': 'HG', 'LastName': 'Dahlen', 'Affiliation': 'Professor of Midwifery, Associate Dean Research and HDR, Midwifery Discipline, Building EB, UWS Parramatta Campus, Locked Bag 1797, Penrith, NSW 2751, Australia. Electronic address: H.Dahlen@westernsydney.edu.au.'}, {'ForeName': 'Phillipa J', 'Initials': 'PJ', 'LastName': 'Hay', 'Affiliation': 'Professor of Mental Health, Translational Health Research Institute, School of Medicine Western Sydney University and Camden and Campbelltown Hospitals SWSLHD, Locked Bag 1797, Penrith, NSW 2751, Australia. Electronic address: P.Hay@westernsydney.edu.au.'}]",Journal of affective disorders,['10.1016/j.jad.2020.05.089'] 1969,32659699,A web-based daily care training to improve the quality of life of mothers of children with cerebral palsy: A randomized controlled trial.,"BACKGROUND Mothers of moderately to severely affected children with cerebral palsy (CP) have to spend a long time to take care of their children. This time-consuming responsibility affects their physical and psychosocial health. Therefore, mothers as caregivers are required to receive special training to take care of their children. AIMS The aim of this study was to evaluate the effectiveness of a developed web-based intervention for daily care training of children with CP on their mothers' quality of life (QOL), anxiety, depression, stress, and their musculoskeletal pain. METHODS AND PROCEDURES This study was a single blind randomized controlled trial. 91 mothers of children with CP with Gross Motor Function Classification System (GMFCS) levels III, IѴ, and Ѵ, who aged from 4 to 12 years were assigned to the intervention and control groups using block randomization. Mothers in the control group received their routine face to face occupational therapy intervention and mothers in the intervention group received 12 weeks web-based intervention. QOL, depression, anxiety, stress, and pain were measured before and after the intervention in both groups. OUTCOMES AND RESULTS The results of analysis of covariance showed that after controlling the mean score of pretest of pain, the mean score of post-tests in the intervention and control groups was significantly different (P < 0.05). The mean scores of physical health and total QOL scores of post-tests in the intervention group were significantly higher than the control group with controlling pretest scores. CONCLUSIONS AND IMPLICATIONS Designed web-based intervention affects the caregivers' QOL and pain significantly. This intervention can be used to provide daily care training for mothers of children with CP.",2020,"The mean scores of physical health and total QOL scores of post-tests in the intervention group were significantly higher than the control group with controlling pretest scores. ","['91 mothers of children with CP with Gross Motor Function Classification System (GMFCS) levels III, IѴ, and Ѵ, who aged from 4 to 12 years', 'mothers of children with cerebral palsy', 'Mothers of moderately to severely affected children with cerebral palsy (CP', 'mothers of children with CP', 'children with CP on their mothers']","['special training', 'A web-based daily care training', 'routine face to face occupational therapy intervention and mothers in the intervention group received 12 weeks web-based intervention']","['quality of life', 'QOL, depression, anxiety, stress, and pain', 'mean score of pretest of pain', 'quality of life (QOL), anxiety, depression, stress, and their musculoskeletal pain', 'mean scores of physical health and total QOL scores of post-tests']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0677549', 'cui_str': 'Gross motor functions'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0441927', 'cui_str': 'Level III'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C1318464', 'cui_str': 'Occupational therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C3898714', 'cui_str': 'Internet Intervention'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026858', 'cui_str': 'Musculoskeletal pain'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",91.0,0.0560542,"The mean scores of physical health and total QOL scores of post-tests in the intervention group were significantly higher than the control group with controlling pretest scores. ","[{'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Nobakht', 'Affiliation': 'Pediatric Neurorehabilitation Research Center and Occupational Therapy Department, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Rassafiani', 'Affiliation': 'Occupational Therapy Department, Faculty of Allied Health Sciences, Kuwait University, Kuwait. Pediatric Neurorehabilitation Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. Electronic address: mrassafiani@yahoo.com.'}, {'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Hosseini', 'Affiliation': 'Social Determinants of Health Research Center and Occupational Therapy Department, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Hosseinzadeh', 'Affiliation': 'Biosatistics Department, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.'}]",Research in developmental disabilities,['10.1016/j.ridd.2020.103731'] 1970,32659714,The effect of web-based training on life quality and spousal adjustment for women with breast cancer and their spouses.,"PURPOSE The aim of the study was to examine the effects of web-based training that was structured in line with Roy's Adaptation Model on the ""life quality"" of women with breast cancer, and on the ""spousal adjustment"" of women and their spouses. METHOD The study used a pretest-posttest, quasi-experimental controlled group design and 83 women with breast cancer and their spouses were enrolled. The data were collected at baseline and again three months later using the Functional Assessment of Cancer Therapy-breast cancer scale and the Dyadic Adjustment Scale as data collection tools. RESULTS The average scores of life quality and agreement between spouses in the web-based training group were higher than in the control group. More specifically, the physical well-being (p=0.002), emotional well-being (p<0.001), functional well-being (p=0.001), breast cancer module scores (p<0.001) and dyadic cohesion (p=0.003) and dyadic consensus (p<0.001) sub-dimension scores of the women in the intervention group were higher than those in the control group in the third month. Similarly, the third month mean score of dyadic consensus (p<0.001) and affectional expression (p=0.023) of the spouses in the intervention group were higher than those in the control group. CONCLUSIONS The web-based training programme that was prepared by nurses in line with Roy's Adaptation Model improved the life quality and couples' adjustment in women with breast cancer. Web-based training can be used to improve patient care outcomes because of the continuity of training for women and their spouses.",2020,"Similarly, the third month mean score of dyadic consensus (p<0.001) and affectional expression (p=0.023) of the spouses in the intervention group were higher than those in the control group. ","['women with breast cancer', '83 women with breast cancer and their spouses were enrolled', 'women with breast cancer, and on the ""spousal adjustment"" of women and their spouses', 'women with breast cancer and their spouses']",['web-based training'],"['dyadic consensus (p<0.001) sub-dimension scores', 'life quality and spousal adjustment', 'Functional Assessment of Cancer Therapy-breast cancer scale and the Dyadic Adjustment Scale', 'life quality', 'average scores of life quality', 'emotional well-being (p<0.001), functional well-being (p=0.001), breast cancer module scores (p<0.001) and dyadic cohesion', 'mean score of dyadic consensus (p<0.001) and affectional expression']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0162409', 'cui_str': 'Spouse'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0376298', 'cui_str': 'Consensus'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}]",83.0,0.0223756,"Similarly, the third month mean score of dyadic consensus (p<0.001) and affectional expression (p=0.023) of the spouses in the intervention group were higher than those in the control group. ","[{'ForeName': 'Saadet', 'Initials': 'S', 'LastName': 'Çömez', 'Affiliation': 'Mehmet Akif Ersoy University, Faculty of Health Sciences, Department of Nursing, Burdur, Turkey. Electronic address: saadet.andic@gmail.com.'}, {'ForeName': 'Özgül', 'Initials': 'Ö', 'LastName': 'Karayurt', 'Affiliation': 'Izmir University of Economics, Faculty of Health Sciences, Department of Nursing, Izmir, Turkey.'}]",European journal of oncology nursing : the official journal of European Oncology Nursing Society,['10.1016/j.ejon.2020.101758'] 1971,32685186,Effectiveness of a brief lifestyle intervention targeting mental health staff: analysis of physical fitness and activity in the Keeping Our Staff in Mind study.,"Background People with mental illness die on average 15 years less than the general population, primarily to cardiometabolic disease. Lifestyle interventions are effective in reducing cardiometabolic risk but are not routinely provided to mental health consumers. Lifestyle interventions targeting mental health staff may be beneficial in changing culture surrounding physical health and subsequently improving consumer outcomes. This study examines exercise and fitness outcomes of a targeted lifestyle intervention directed at Australian mental health staff. Methods A pragmatic single-arm intervention study was conducted within an Australian public mental health service. Mental health staff were provided a five-session individualised lifestyle intervention (incorporating exercise and nutritional counselling) over 5 weeks. Two waves of the programme were delivered between 2015 and 2016. This paper examines the exercise and fitness outcomes of the second wave of the study. Participants were assessed at baseline and at a 16-week follow-up. The primary exercise outcome was a measurement of cardiorespiratory fitness. Secondary outcomes included self-reported physical activity and a measurement of handgrip strength. Results A total of 106 staff participated in this component of the study. Cardiorespiratory fitness increased significantly from baseline to follow-up (p<0.001). Significant improvements to physical activity occurred with decreases in sedentary time (p<0.0005) and increases in moderate-to-vigorous physical activity (p<0.005). Conclusion Lifestyle interventions incorporating exercise counselling may improve the physical health of mental health staff. Such strategies may be effective in improving culture surrounding physical health and/or increasing the effectiveness of lifestyle interventions targeting mental health consumers.",2020,"Significant improvements to physical activity occurred with decreases in sedentary time (p<0.0005) and increases in moderate-to-vigorous physical activity (p<0.005). ","['\n\n\nPeople with mental illness die on average 15 years less than the general population, primarily to cardiometabolic disease', 'Mental health staff', 'Australian public mental health service', 'A total of 106 staff participated in this component of the study']","['brief lifestyle intervention', 'Lifestyle interventions']","['sedentary time', 'physical health of mental health staff', 'physical activity', 'measurement of cardiorespiratory fitness', 'cardiometabolic risk', 'Cardiorespiratory fitness', 'self-reported physical activity and a measurement of handgrip strength', 'moderate-to-vigorous physical activity']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0025355', 'cui_str': 'Mental health service'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}]",106.0,0.0407121,"Significant improvements to physical activity occurred with decreases in sedentary time (p<0.0005) and increases in moderate-to-vigorous physical activity (p<0.005). ","[{'ForeName': 'Hamish', 'Initials': 'H', 'LastName': 'Fibbins', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Philip B', 'Initials': 'PB', 'LastName': 'Ward', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Jackie', 'Initials': 'J', 'LastName': 'Curtis', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Watkins', 'Affiliation': 'Keeping the Body in Mind Program, South Eastern Sydney Local Health District, Sydney, New South Wales, Australia.'}, {'ForeName': 'Oscar', 'Initials': 'O', 'LastName': 'Lederman', 'Affiliation': 'Keeping the Body in Mind Program, South Eastern Sydney Local Health District, Sydney, New South Wales, Australia.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Morell', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Rosenbaum', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia.'}]",BMJ open sport & exercise medicine,['10.1136/bmjsem-2020-000761'] 1972,32685258,Does intravenous tranexamic acid reduce bleeding during mastoidectomy?,"Mastoidectomy is one of the important head and neck surgeries which is mostly performed due to complications of otitis media. This procedure is performed under microscopic surgery and as a result, a clean visual field is required for surgeons. Bleeding is one of the important issues during microscopic surgeries which reduces visualization. In this clinical trial, we aimed to examine effects of tranexamic acid in reducing bleeding during mastoidectomy. Here we investigated 69 patients who were candidates of mastoidectomy. Patients were randomized into two groups. In group 1, patients received tranexamic acid (10 mg/kg) at the beginning of surgeries along with other anesthetic drugs. In group 2, patients received normal saline as placebo with the same volume. Data regarding to bleeding, duration of surgeries, heart rate and blood pressure of patients were collected and analyzed. We indicated that administration of tranexamic acid is associated with significant reduced bleeding and also reduced blood pressure during surgeries (P<0.001). Taken together, we suggest that otolaryngologists should administer tranexamic acid during microscopic surgeries in order to reduce bleeding and provide a better visual field.",2020,We indicated that administration of tranexamic acid is associated with significant reduced bleeding and also reduced blood pressure during surgeries (P<0.001).,['69 patients who were candidates of mastoidectomy'],"['tranexamic acid', 'normal saline as placebo']","['blood pressure', 'bleeding, duration of surgeries, heart rate and blood pressure']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0198154', 'cui_str': 'Mastoidectomy'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}]",69.0,0.140275,We indicated that administration of tranexamic acid is associated with significant reduced bleeding and also reduced blood pressure during surgeries (P<0.001).,"[{'ForeName': 'Samaneh', 'Initials': 'S', 'LastName': 'Ziaei', 'Affiliation': 'DDS, MS. Assistant Professor, Dept. of Dral and Maxillofacial Medicine, Faculty of Dentistry, Sharekord Branch Shahrekord, Iran.'}, {'ForeName': 'Saeid Sadeghi', 'Initials': 'SS', 'LastName': 'Joni', 'Affiliation': 'Department of Radiology, Razi Hospital, Guilan University of Medical Sciences Rasht, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Shahriar', 'Affiliation': 'School of Medicine, Tehran University of Medical Sciences Tehran, Iran.'}, {'ForeName': 'Mehran', 'Initials': 'M', 'LastName': 'Shahzamani', 'Affiliation': 'Department of Surgery, Chamran Heart Center and University Hospital, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.'}]",American journal of blood research,[] 1973,32659437,Testing the effectiveness of physical activity advice delivered via text messaging vs. human phone advisors in a Latino population: The On The Move randomized controlled trial design and methods.,"Physical inactivity is a key risk factor for a range of chronic diseases and conditions, yet, approximately 50% of U.S. adults fall below recommended levels of regular aerobic physical activity (PA). This is particularly true for ethnic minority populations such as Latino adults for whom few culturally adapted programs have been developed and tested. Text messaging (SMS) represents a convenient and accessible communication channel for delivering targeted PA information and support, but has not been rigorously evaluated against standard telehealth advising programs. The objective of the On The Move randomized controlled trial is to test the effectiveness of a linguistically and culturally targeted SMS PA intervention (SMS PA Advisor) versus two comparison conditions: a) a standard, staff-delivered phone PA intervention (Telephone PA Advisor) and b) an attention-control arm consisting of a culturally targeted SMS intervention to promote a healthy diet (SMS Nutrition Advisor). The study sample (N = 350) consists of generally healthy, insufficiently active Latino adults ages 35 years and older living in five northern California counties. Study assessments occur at baseline, 6, and 12 months, with a subset of participants completing 18-month assessments. The primary outcome is 12-month change in walking, and secondary outcomes include other forms of PA, assessed via validated self-report measures and supported by accelerometry, and physical function and well-being variables. Potential mediators and moderators of intervention success will be explored to better determine which subgroups do best with which type of intervention. Here we present the study design and methods, including recruitment strategies and yields. Trial Registration: clinicaltrial.gov Identifier = NCT02385591.",2020,Potential mediators and moderators of intervention success will be explored to better determine which subgroups do best with which type of intervention.,"['Latino population', 'The study sample (N\u202f=\u202f350) consists of generally healthy, insufficiently active Latino adults ages 35\u202fyears and older living in five northern California counties']","['phone PA intervention (Telephone PA Advisor) and b) an attention-control arm consisting of a culturally targeted SMS intervention', 'linguistically and culturally targeted SMS PA intervention (SMS PA Advisor', 'Text messaging (SMS', 'physical activity advice delivered via text messaging vs. human phone advisors']","['12-month change in walking, and secondary outcomes include other forms of PA, assessed via validated self-report measures and supported by accelerometry, and physical function and well-being variables']","[{'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C4517735', 'cui_str': '350'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0006754', 'cui_str': 'California'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0441677', 'cui_str': 'Accelerometry'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439828', 'cui_str': 'Variable'}]",,0.0964757,Potential mediators and moderators of intervention success will be explored to better determine which subgroups do best with which type of intervention.,"[{'ForeName': 'Abby C', 'Initials': 'AC', 'LastName': 'King', 'Affiliation': 'Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA 94305, United States of America; Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: king@stanford.edu.'}, {'ForeName': 'Ines', 'Initials': 'I', 'LastName': 'Campero', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: icampero@stanford.edu.'}, {'ForeName': 'Jylana L', 'Initials': 'JL', 'LastName': 'Sheats', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: JSheats@tulane.edu.'}, {'ForeName': 'Cynthia M', 'Initials': 'CM', 'LastName': 'Castro Sweet', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: cynthia@omadahealth.com.'}, {'ForeName': 'Patricia Rodriguez', 'Initials': 'PR', 'LastName': 'Espinosa', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: prespinosa@stanford.edu.'}, {'ForeName': 'Dulce', 'Initials': 'D', 'LastName': 'Garcia', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: dgarcia3@stanford.edu.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Hauser', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: mehauser@stanford.edu.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Done', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: mdone@stanford.edu.'}, {'ForeName': 'Michele L', 'Initials': 'ML', 'LastName': 'Patel', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: michele.patel@stanford.edu.'}, {'ForeName': 'Nina M', 'Initials': 'NM', 'LastName': 'Parikh', 'Affiliation': 'CareMessage, Inc., San Francisco, California 94115, United States of America. Electronic address: nparikh@caremessage.org.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Corral', 'Affiliation': 'CareMessage, Inc., San Francisco, California 94115, United States of America. Electronic address: ccorral@caremessage.org.'}, {'ForeName': 'David K', 'Initials': 'DK', 'LastName': 'Ahn', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America. Electronic address: dahn@stanford.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106084'] 1974,32659480,Effectiveness of a physiologic voice therapy program based on different semioccluded vocal tract exercises in subjects with behavioral dysphonia: A randomized controlled trial.,"PURPOSE The present study aimed to assess the effectiveness of a physiologic voice therapy program based on different semioccluded vocal tract exercises in subjects with behavioral dysphonia. METHODS Thirty-four participants with behavioral dysphonia were randomly assigned to one of two treatment groups: 1) voice treatment with physiologic voice therapy plus vocal hygiene program (n=20), and 2) vocal hygiene program only (n=14). Laryngoscopic assessment was performed in all subjects. Before and after voice therapy, participants underwent aerodynamic, electroglottographic, and acoustic assessment. The Voice Handicap Index (VHI), Voice symptom scale (VoiSs), Vocal tract discomfort scale (VTDS), and self-assessment of resonant voice quality were also performed. The treatment included eight voice therapy sessions. For the experimental group, the exercises consisted of a sequence of seven phonatory tasks performed with four different semioccluded vocal tract exercises (SOVTE). Comparison for all variables were performed between experimental group and control group. RESULTS Wilcoxon test showed significant improvements for experimental group for VHI, VoiSs, VTDS (decrease), and self-perception of resonant voice quality (increase). Significant decrease for experimental groups was observed on subglottic pressure, phonation threshold pressure, and glottal airflow across the implemented tasks. CONCLUSION Physiologic voice therapy based on semioccluded vocal tract exercises seems to be an effective tool to improve voice in subjects diagnosed with behavioral dysphonia. Apparently, most changes should be expected in variables related to physical and functional aspects compared to objective variables. Subglottic pressure and phonation threshold pressure seem to be the most change-sensitive parameters and they may reflect a reduction in phonatory effort reported by patients after voice therapy.",2020,"Significant decrease for experimental groups was observed on subglottic pressure, phonation threshold pressure, and glottal airflow across the implemented tasks. ","['subjects diagnosed with behavioral dysphonia', 'Thirty-four participants with behavioral dysphonia', 'subjects with behavioral dysphonia']","['physiologic voice therapy program', 'phonatory tasks performed with four different semioccluded vocal tract exercises (SOVTE', 'voice treatment with physiologic voice therapy plus vocal hygiene program (n=20), and 2) vocal hygiene program', 'Physiologic voice therapy']","['VHI, VoiSs, VTDS (decrease), and self-perception of resonant voice quality (increase', 'Subglottic pressure and phonation threshold pressure', 'Laryngoscopic assessment', 'Voice Handicap Index (VHI), Voice symptom scale (VoiSs), Vocal tract discomfort scale (VTDS), and self-assessment of resonant voice quality', 'subglottic pressure, phonation threshold pressure, and glottal airflow across the implemented tasks']","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0019825', 'cui_str': 'Hoarse'}, {'cui': 'C3816446', 'cui_str': '30'}]","[{'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C2202690', 'cui_str': 'Voice therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0020405', 'cui_str': 'Hygiene'}]","[{'cui': 'C2985106', 'cui_str': 'Voice handicap index'}, {'cui': 'C0242498', 'cui_str': 'Self-image'}, {'cui': 'C0577554', 'cui_str': 'Resonant'}, {'cui': 'C0042943', 'cui_str': 'Vocal quality'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0234833', 'cui_str': 'Subglottic pressure'}, {'cui': 'C0031577', 'cui_str': 'Laryngeal voice function'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0036591', 'cui_str': 'Self Assessment'}, {'cui': 'C0231999', 'cui_str': 'Airflow'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}]",34.0,0.0112718,"Significant decrease for experimental groups was observed on subglottic pressure, phonation threshold pressure, and glottal airflow across the implemented tasks. ","[{'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Guzman', 'Affiliation': 'Department of Communication Sciences and Disorders, Universidad de los Andes, Chile; Department of Otolaryngology, Las Condes Clinic, Santiago, Chile. Electronic address: guzmann.marcoa@gmail.com.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Bertucci', 'Affiliation': 'Department of Communication Sciences and Disorders, University of Chile, Av. Independencia 1027, Santiago, Chile. Electronic address: terebertucci@gmail.com.'}, {'ForeName': 'Constanza', 'Initials': 'C', 'LastName': 'Pacheco', 'Affiliation': 'Department of Otolaryngology, Las Condes Clinic, Av. Estoril 850, Santiago, Chile. Electronic address: cpachecob@clinicalascondes.cl.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Leiva', 'Affiliation': 'Department of Communication Sciences and Disorders, Universidad Pedro de Valdivia, Vicuña Mackena 44, Santiago, Chile. Electronic address: fernando.leiva.solari@gmail.com.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Quintana', 'Affiliation': 'Department of Communication Sciences and Disorders, University of Chile, Av. Independencia 1027, Santiago, Chile. Electronic address: quintana.b.felipe@gmail.com.'}, {'ForeName': 'Romina', 'Initials': 'R', 'LastName': 'Ansaldi', 'Affiliation': 'Facultad de Ciencias de la Salud, Universidad de las Américas, Santiago, Chile. Electronic address: romina.ansaldi@gmail.com.'}, {'ForeName': 'Camilo', 'Initials': 'C', 'LastName': 'Quezada', 'Affiliation': 'Department of Communication Sciences and Disorders, University of Chile, Av. Independencia 1027, Santiago, Chile. Electronic address: cequezad@uc.cl.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Muñoz', 'Affiliation': 'Department of Otolaryngology, University of Chile, Av. Independencia 1027, Santiago, Chile. Electronic address: daniel.uchile@gmail.com.'}]",Journal of communication disorders,['10.1016/j.jcomdis.2020.106023'] 1975,32659483,Non-invasive vagal nerve stimulation decreases brain activity during trauma scripts.,"BACKGROUND Traumatic stress can have lasting effects on neurobiology and result in psychiatric conditions such as posttraumatic stress disorder (PTSD). We hypothesize that non-invasive cervical vagal nerve stimulation (nVNS) may alleviate trauma symptoms by reducing stress sympathetic reactivity. This study examined how nVNS alters neural responses to personalized traumatic scripts. METHODS Nineteen participants who had experienced trauma but did not have the diagnosis of PTSD completed this double-blind sham-controlled study. In three sequential time blocks, personalized traumatic scripts were presented to participants immediately followed by either sham stimulation (n = 8; 0-14 V, 0.2 Hz, pulse width = 5s) or active nVNS (n = 11; 0-30 V, 25 Hz, pulse width = 40 ms). Brain activity during traumatic scripts was assessed using High Resolution Positron Emission Tomography (HR-PET) with radiolabeled water to measure brain blood flow. RESULTS Traumatic scripts resulted in significant activations within the bilateral medial and orbital prefrontal cortex, premotor cortex, anterior cingulate, thalamus, insula, hippocampus, right amygdala, and right putamen. Greater activation was observed during sham stimulation compared to nVNS within the bilateral prefrontal and orbitofrontal cortex, premotor cortex, temporal lobe, parahippocampal gyrus, insula, and left anterior cingulate. During the first exposure to the trauma scripts, greater activations were found in the motor cortices and ventral visual stream whereas prefrontal cortex and anterior cingulate activations were more predominant with later script presentations for those subjects receiving sham stimulation. CONCLUSION nVNS decreases neural reactivity to an emotional stressor in limbic and other brain areas involved in stress, with changes over repeated exposures suggesting a shift from scene appraisal to cognitively processing the emotional event.",2020,"Greater activation was observed during sham stimulation compared to nVNS within the bilateral prefrontal and orbitofrontal cortex, premotor cortex, temporal lobe, parahippocampal gyrus, insula, and left anterior cingulate.",['Nineteen participants who had experienced trauma but did not have the diagnosis of PTSD completed this double-blind sham-controlled study'],"['invasive cervical vagal nerve stimulation (nVNS', 'active nVNS', 'nVNS']","['bilateral medial and orbital prefrontal cortex, premotor cortex, anterior cingulate, thalamus, insula, hippocampus, right amygdala, and right putamen', 'motor cortices and ventral visual stream whereas prefrontal cortex and anterior cingulate activations', 'Greater activation', 'Brain activity']","[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0205177', 'cui_str': 'Active'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0699036', 'cui_str': 'Orbital'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0228202', 'cui_str': 'Premotor cortex'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C0039729', 'cui_str': 'Thalamic structure'}, {'cui': 'C0021640', 'cui_str': 'Insular structure'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid structure'}, {'cui': 'C0026607', 'cui_str': 'Motor cortex'}, {'cui': 'C1704448', 'cui_str': 'Ventral'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0442540', 'cui_str': 'Stream'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0443158', 'cui_str': 'Brain activity'}]",19.0,0.0708328,"Greater activation was observed during sham stimulation compared to nVNS within the bilateral prefrontal and orbitofrontal cortex, premotor cortex, temporal lobe, parahippocampal gyrus, insula, and left anterior cingulate.","[{'ForeName': 'Matthew T', 'Initials': 'MT', 'LastName': 'Wittbrodt', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: mattwittbrodt@emory.edu.'}, {'ForeName': 'Nil Z', 'Initials': 'NZ', 'LastName': 'Gurel', 'Affiliation': 'Department of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, USA.'}, {'ForeName': 'Jonathon A', 'Initials': 'JA', 'LastName': 'Nye', 'Affiliation': 'Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Stacy', 'Initials': 'S', 'LastName': 'Ladd', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Md Mobashir H', 'Initials': 'MMH', 'LastName': 'Shandhi', 'Affiliation': 'Department of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, USA.'}, {'ForeName': 'Minxuan', 'Initials': 'M', 'LastName': 'Huang', 'Affiliation': 'Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Amit J', 'Initials': 'AJ', 'LastName': 'Shah', 'Affiliation': 'Department of Medicine (Cardiology), Emory University School of Medicine, Atlanta, GA, USA; Atlanta VA Medical Center, Decatur, GA, USA.'}, {'ForeName': 'Bradley D', 'Initials': 'BD', 'LastName': 'Pearce', 'Affiliation': 'Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Zuhayr S', 'Initials': 'ZS', 'LastName': 'Alam', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Mark H', 'Initials': 'MH', 'LastName': 'Rapaport', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Murrah', 'Affiliation': 'Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Yi-An', 'Initials': 'YA', 'LastName': 'Ko', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Ammer A', 'Initials': 'AA', 'LastName': 'Haffer', 'Affiliation': 'Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Lucy H', 'Initials': 'LH', 'LastName': 'Shallenberger', 'Affiliation': 'Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Viola', 'Initials': 'V', 'LastName': 'Vaccarino', 'Affiliation': 'Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA; Department of Medicine (Cardiology), Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Omer T', 'Initials': 'OT', 'LastName': 'Inan', 'Affiliation': 'Department of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.'}, {'ForeName': 'J Douglas', 'Initials': 'JD', 'LastName': 'Bremner', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA; Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA; Atlanta VA Medical Center, Decatur, GA, USA.'}]",Brain stimulation,['10.1016/j.brs.2020.07.002'] 1976,32659637,Cost and cost-effectiveness of three strategies for implementing motivational interviewing for substance misuse on medical inpatient units.,"BACKGROUND This study conducted cost and cost-effectiveness analyses of three strategies for implementing motivational interviewing for substance misuse on general medical inpatient units: workshop, apprenticeship, and consult. METHODS The economic analyses were conducted prospectively alongside a type 3 hybrid effectiveness-implementation randomized trial comprising 38 medical providers, 1173 inpatients, and four consultation-liaison motivational interviewing experts. The trial took place in a university affiliated teaching hospital in New Haven, CT, USA. After completing a 1-day workshop on motivational interviewing, providers were randomized to conditions. The primary outcome measure was the number of study-eligible patients who received a motivational interview. The economic analyses included the costs of both start-up and on-going activities in each condition. Incremental cost-effectiveness ratios were used to determine cost effectiveness. Results are presented from the healthcare provider (i.e., hospital) perspective in 2018 US dollars. RESULTS The total cost per patient receiving a motivational interview averaged $804.53, $606.52, and $185.65 for workshop, apprenticeship, and consult, respectively. Workshop and apprenticeship were extended dominated by the combination of consult and doing nothing. Doing nothing is cost effective when the willingness-to-pay for an additional patient receiving a motivational interview is less than $185.65, and consult is cost-effective when the willingness-to-pay for an additional patient receiving a motivational interview is greater than $185.65. CONCLUSIONS Given that typical reimbursements for brief intervention services for substance misuse are $35-$65, none of the three implementation strategies is likely to be economically viable from the healthcare provider perspective.",2020,"The total cost per patient receiving a motivational interview averaged $804.53, $606.52, and $185.65 for workshop, apprenticeship, and consult, respectively.","['substance misuse on medical inpatient units', '38 medical providers, 1173 inpatients, and four consultation-liaison motivational interviewing experts', 'university affiliated teaching hospital in New Haven, CT, USA']",['implementing motivational interviewing'],"['Cost and cost-effectiveness', 'Incremental cost-effectiveness ratios', 'total cost per patient receiving a motivational interview']","[{'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}]",38.0,0.0294972,"The total cost per patient receiving a motivational interview averaged $804.53, $606.52, and $185.65 for workshop, apprenticeship, and consult, respectively.","[{'ForeName': 'Todd A', 'Initials': 'TA', 'LastName': 'Olmstead', 'Affiliation': 'The University of Texas at Austin, Lyndon B. Johnson School of Public Affairs, Sid Richardson Hall, Unit 3, Austin, TX, 78712, USA. Electronic address: tolmstead@austin.utexas.edu.'}, {'ForeName': 'Kimberly A', 'Initials': 'KA', 'LastName': 'Yonkers', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA; Yale School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, 333 Cedar Street, New Haven, CT, 06510, USA; Yale School of Epidemiology and Public Health Division of Chronic Disease, 60 College Street, New Haven, CT, 06520, USA.'}, {'ForeName': 'Ariadna', 'Initials': 'A', 'LastName': 'Forray', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Zimbrean', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Gilstad-Hayden', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Martino', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA; VA Connecticut Healthcare System, Psychology Service, 950 Campbell Avenue (116B), West Haven, CT, 06516, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108156'] 1977,32659641,A comparative study of autologous rectus fascia pubovaginal sling surgery and synthetic transobturator vaginal tape procedure in treatment of women with urodynamic stress urinary incontinence.,"OBJECTIVE To compare short term results of autologous rectus fascia pubovaginal sling surgery with synthetic transobturator vaginal tape procedure in treatment of female stress urinary incontinence (SUI) STUDY DESIGN: It was a comparative study on 30 women between 25-65 years of age with urodynamic proven SUI who were randomly allocated to autologous rectus fascia pubovaginal sling surgery (Group I)(15 women) and synthetic transobturator vaginal tape procedure (Group II) (15 women). Preoperative and postoperative ICIQ (International Consultation on Incontinence Questionnaire) score, urodynamic study and serum CRP and IL-6 were done in all cases. RESULTS The baseline characteristics in terms of age, body mass index (BMI), parity, mean ICIQ score and mean preoperative CRP and IL-6 levels were similar in two groups. Mean operative time was significantly longer (55.60 ± 5.77 vs 25.27 ± 4.32 minutes, p = 0.001) in group I than group II. Mean hospital stay of 7.1 ± 1.2 vs 1.2 ± 0.4 days, mean duration of catheterization 5.8 vs 1.2 day (<0.01) and postoperative urinary retention requiring recathterization were all significantly higher in group I than II. Wound infection was more in group I than in group II (p = 0.01) while groin pain was significantly more in group II (p = 0.01). One patient developed vesicovaginal fistula, while one patient required cutting of tape in group I. Pdet at Q max (Detrusor pressure at peak urine flow) increased significantly in both the groups after surgery. ICIQ score was zero in both the groups indicating 100 % success. Surgical trauma was more in group I as shown by significantly higher CRP levels. CONCLUSION The success rate of the two groups was similar but, autologous rectus fascia sling surgery took longer, had more complications and urinary retention as compared to transobturator vaginal tape procedure.",2020,"Mean operative time was significantly longer (55.60 ± 5.77 vs 25.27 ± 4.32 minutes, p = 0.001) in group I than group II.","['Group II) (15 women', 'women with urodynamic stress urinary incontinence', '30 women between 25-65 years of age with urodynamic proven SUI', 'female stress urinary incontinence']","['autologous rectus fascia pubovaginal sling surgery (Group I)(15 women) and synthetic transobturator vaginal tape procedure', 'autologous rectus fascia pubovaginal sling surgery and synthetic transobturator vaginal tape procedure', 'autologous rectus fascia pubovaginal sling surgery with synthetic transobturator vaginal tape procedure']","['Preoperative and postoperative ICIQ ', 'Mean operative time', 'Mean hospital stay', 'ICIQ score', 'Surgical trauma', 'CRP and IL-6', 'Wound infection', 'postoperative urinary retention requiring recathterization', 'CRP levels', 'complications and urinary retention', 'groin pain', 'vesicovaginal fistula', 'mean duration of catheterization', 'success rate', 'body mass index (BMI), parity, mean ICIQ score and mean preoperative CRP and IL-6 levels', 'Incontinence Questionnaire) score, urodynamic study and serum']","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042059', 'cui_str': 'Urodynamics'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0456369', 'cui_str': 'Proven'}]","[{'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0225234', 'cui_str': 'Structure of fascia of rectus abdominis muscle'}, {'cui': 'C0183346', 'cui_str': 'Sling'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0043241', 'cui_str': 'Local infection of wound'}, {'cui': 'C0080274', 'cui_str': 'Bladder retention of urine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0239783', 'cui_str': 'Inguinal pain'}, {'cui': 'C0042582', 'cui_str': 'Vesicovaginal fistula'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0030563', 'cui_str': 'Parity'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0042059', 'cui_str': 'Urodynamics'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",30.0,0.0224989,"Mean operative time was significantly longer (55.60 ± 5.77 vs 25.27 ± 4.32 minutes, p = 0.001) in group I than group II.","[{'ForeName': 'J B', 'Initials': 'JB', 'LastName': 'Sharma', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: jbsharma@aiims.ac.in.'}, {'ForeName': 'Manasi Kamalakar', 'Initials': 'MK', 'LastName': 'Deoghare', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Neerja', 'Initials': 'N', 'LastName': 'Bhatla', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Garima', 'Initials': 'G', 'LastName': 'Kachhawa', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Reeta', 'Initials': 'R', 'LastName': 'Mahey', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Kumari', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Amlesh', 'Initials': 'A', 'LastName': 'Seth', 'Affiliation': 'Department of Urology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Alpana', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.06.062'] 1978,32660211,Manual versus automated image fusion of real-time ultrasonography and MR/CT images for radiofrequency ablation of hepatic tumors: results of a randomized prospective trial (NCT02705118).,"PURPOSE This study compared the technical parameters and clinical outcomes of manual and automatic image fusion techniques of ultrasonography and magnetic resonance imaging/computed tomography for radiofrequency ablation (RFA) of hepatic tumors. METHODS Seventy consecutive patients (male:female=47:23, 67.1±10.9 years old) who underwent RFA for hepatic tumors were prospectively enrolled and randomly assigned to the manual or automatic registration group. Two operators performed RFA with one of two imaging fusion techniques. Technical parameters (the registration error, time required for image registration, number of point registrations) and clinical outcomes (technical success, technical effectiveness, local tumor progression [LTP]-free survival, and progression-free survival [PFS]) were compared. RESULTS The automatic group contained 35 patients with hepatocellular carcinoma, while the manual group included 34 hepatocellular carcinoma patients and a patient with colon cancer liver metastasis. The registration error, time required for registration, and number of point registrations were 5.7±4.3 mm, 147.8±78.2 seconds, and 3.26±1.20 in the automatic group, and 6.3±5.0 mm, 150.3±89.7 seconds, and 3.20±1.13 in the manual group, respectively. The technical success and effectiveness rates were both 97.1% in the automatic group and both 100.0% in the manual group. The above differences were not significant. The LTP-free survival and PFS (28.3 and 21.2 months in the automatic group, and 29.0 and 24.9 months in the manual group, respectively) showed no significant between-group differences during a median 20.1-month follow-up period. CONCLUSION The technical parameters and clinical outcomes of automatic image fusion were not significantly different from those of manual image fusion for RFA of hepatic tumors.",2020,Technical success and effectiveness rate were both 97.1% for automatic group and both 100.0% for manual group without any significant difference.,"['34 patients with hepatocellular carcinoma and a patient with colon cancer liver metastasis', 'hepatic tumors', 'Thirty-five patients with hepatocellular carcinoma', 'Seventy consecutive patients (M:F=47:23, 67.1±10.9 years old) who performed RFA for hepatic tumors']","['automatic registration (automatic group', 'manual or automatic registration group', 'Manual versus automated image fusion of real-time ultrasonography and MR/CT images', 'ultrasonography and MRI/CT for radiofrequency ablation (RFA']","['Technical success and effectiveness rate', 'registration error, time required for registration and number of point registrations', 'LTP-free survival and PFS', 'registration error, time required for image registration, number of point registrations and clinical outcomes including technical success, technical effectiveness, local tumor progression (LTP) free survival and progression free survival (PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C0494165', 'cui_str': 'Secondary malignant neoplasm of liver'}, {'cui': 'C0023903', 'cui_str': 'Neoplasm of liver'}, {'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}]","[{'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}]","[{'cui': 'C0449851', 'cui_str': 'Technique'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0449956', 'cui_str': 'Number of points'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0178874', 'cui_str': 'Tumor progression'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}]",70.0,0.0620668,Technical success and effectiveness rate were both 97.1% for automatic group and both 100.0% for manual group without any significant difference.,"[{'ForeName': 'Moon Hyung', 'Initials': 'MH', 'LastName': 'Choi', 'Affiliation': ""Department of Radiology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Joon-Il', 'Initials': 'JI', 'LastName': 'Choi', 'Affiliation': 'Cancer Research Institute of the Catholic University of Korea, Seoul, Korea.'}, {'ForeName': 'Young Joon', 'Initials': 'YJ', 'LastName': 'Lee', 'Affiliation': ""Department of Radiology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}]","Ultrasonography (Seoul, Korea)",['10.14366/usg.20052'] 1979,32660604,Effects of virtual reality associated with serious games for upper limb rehabilitation inpatients with multiple sclerosis: randomized controlled trial.,"BACKGROUND Dexterity and activities of daily living limitations on the upper limb (UL) represent one of the most common problems in patients with multiple sclerosis (MS). The aim of this study was to evaluate the effectiveness of the specially developed Serious Games that make use of the Leap Motion Controller (LMC) as main user interface for improving UL grip muscle strength, dexterity, fatigue, quality of life, satisfaction and compliance. METHODS A single-blinded randomized controlled trial was conducted. The sample was randomized into two groups: an experimental group who received treatment based on serious games designed by the research team using the developed LMC based Serious Games for the UL plus conventional rehabilitation, and a control group who received the same conventional rehabilitation for the UL. Both groups received two 60 min sessions per week over a ten-week period. Grip muscle strength, coordination, speed of movements, fine and gross UL dexterity, fatigue, quality of life, satisfaction and compliance were assessed in both groups pre-treatment, post-treatment and in a follow-up period of 1 month without receiving any treatment. RESULTS In the experimental group compared to the control group, significant improvements were observed in the post-treatment assessment for coordination, speed of movements, fine and gross UL dexterity. Also, significant results were found in the follow-up in coordination, speed of movements, fine and gross for the more affected side. CONCLUSIONS An experimental protocol using an LMC based Serious Games designed for UL rehabilitation showed improvements for unilateral gross manual dexterity, fine manual dexterity, and coordination in MS patients with high satisfaction and excellent compliance. TRIAL REGISTRATION This randomized controlled trial has been registered at ClinicalTrials.gov Identifier: NCT04171908 , Nov 2019.",2020,"An experimental protocol using an LMC based Serious Games designed for UL rehabilitation showed improvements for unilateral gross manual dexterity, fine manual dexterity, and coordination in MS patients with high satisfaction and excellent compliance. ","['upper limb rehabilitation inpatients with multiple sclerosis', 'patients with multiple sclerosis (MS']","['virtual reality associated with serious games', 'serious games designed by the research team using the developed LMC based Serious Games for the UL plus conventional rehabilitation, and a control group who received the same conventional rehabilitation for the UL', 'LMC based Serious Games designed for UL rehabilitation', 'Leap Motion Controller (LMC']","['unilateral gross manual dexterity, fine manual dexterity, and coordination', 'post-treatment assessment for coordination, speed of movements, fine and gross UL dexterity', 'Grip muscle strength, coordination, speed of movements, fine and gross UL dexterity, fatigue, quality of life, satisfaction and compliance', 'follow-up in coordination, speed of movements, fine and gross for the more affected side', 'UL grip muscle strength, dexterity, fatigue, quality of life, satisfaction and compliance']","[{'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0565699', 'cui_str': 'Ability to perform general manipulative activities'}, {'cui': 'C0205232', 'cui_str': 'Fine'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0220843', 'cui_str': 'Grasp'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0392760', 'cui_str': 'Affecting'}]",,0.0783139,"An experimental protocol using an LMC based Serious Games designed for UL rehabilitation showed improvements for unilateral gross manual dexterity, fine manual dexterity, and coordination in MS patients with high satisfaction and excellent compliance. ","[{'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Cuesta-Gómez', 'Affiliation': 'Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Faculty of Health Sciences, Rey Juan Carlos University, Avenida de Atenas s/n 28922 Alcorcón, Madrid, Spain.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Sánchez-Herrera-Baeza', 'Affiliation': 'Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Faculty of Health Sciences, Rey Juan Carlos University, Avenida de Atenas s/n 28922 Alcorcón, Madrid, Spain. patricia.sanchezherrera@urjc.es.'}, {'ForeName': 'Edwin Daniel', 'Initials': 'ED', 'LastName': 'Oña-Simbaña', 'Affiliation': 'Robotics Lab. University Carlos III of Madrid, Leganés, Madrid, Spain.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Martínez-Medina', 'Affiliation': 'Asociación de Esclerosis Múltiple de Toledo (ADEMTO), Toledo, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Ortiz-Comino', 'Affiliation': 'Asociación de Esclerosis Múltiple de Toledo (ADEMTO), Toledo, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Balaguer-Bernaldo-de-Quirós', 'Affiliation': 'Robotics Lab. University Carlos III of Madrid, Leganés, Madrid, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Jardón-Huete', 'Affiliation': 'Robotics Lab. University Carlos III of Madrid, Leganés, Madrid, Spain.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Cano-de-la-Cuerda', 'Affiliation': 'Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Faculty of Health Sciences, Rey Juan Carlos University, Avenida de Atenas s/n 28922 Alcorcón, Madrid, Spain.'}]",Journal of neuroengineering and rehabilitation,['10.1186/s12984-020-00718-x'] 1980,32662862,Effect of Maternal Docosahexaenoic Acid Supplementation on Bronchopulmonary Dysplasia-Free Survival in Breastfed Preterm Infants: A Randomized Clinical Trial.,"Importance Maternal docosahexaenoic acid (DHA) supplementation may prevent bronchopulmonary dysplasia, but evidence remains inconclusive. Objective To determine whether maternal DHA supplementation during the neonatal period improves bronchopulmonary dysplasia-free survival in breastfed infants born before 29 weeks of gestation. Design, Setting, and Participants Superiority, placebo-controlled randomized clinical trial at 16 Canadian neonatal intensive care units (June 2015-April 2018 with last infant follow-up in July 2018). Lactating women who delivered before 29 weeks of gestation were enrolled within 72 hours of delivery. The trial intended to enroll 800 mothers, but was stopped earlier. Interventions There were 232 mothers (273 infants) assigned to oral capsules providing 1.2 g/d of DHA from randomization to 36 weeks' postmenstrual age and 229 mothers (255 infants) assigned to placebo capsules. Main Outcomes and Measures The primary outcome was bronchopulmonary dysplasia-free survival in infants at 36 weeks' postmenstrual age. There were 22 secondary outcomes, including mortality and bronchopulmonary dysplasia. Results Enrollment was stopped early due to concern for harm based on interim data from this trial and from another trial that was published during the course of this study. Among 461 mothers and their 528 infants (mean gestational age, 26.6 weeks [SD, 1.6 weeks]; 253 [47.9%] females), 375 mothers (81.3%) and 523 infants (99.1%) completed the trial. Overall, 147 of 268 infants (54.9%) in the DHA group vs 157 of 255 infants (61.6%) in the placebo group survived without bronchopulmonary dysplasia (absolute difference, -5.0% [95% CI, -11.6% to 2.6%]; relative risk, 0.91 [95% CI, 0.80 to 1.04], P = .18). Mortality occurred in 6.0% of infants in the DHA group vs 10.2% of infants in the placebo group (absolute difference, -3.9% [95% CI, -6.8% to 1.4%]; relative risk, 0.61 [95% CI, 0.33 to 1.13], P = .12). Bronchopulmonary dysplasia occurred in 41.7% of surviving infants in the DHA group vs 31.4% in the placebo group (absolute difference, 11.5% [95% CI, 2.3% to 23.2%]; relative risk, 1.36 [95% CI, 1.07 to 1.73], P = .01). Of 22 prespecified secondary outcomes, 19 were not significantly different. Conclusions and Relevance Among breastfed preterm infants born before 29 weeks of gestation, maternal docosahexaenoic acid supplementation during the neonatal period did not significantly improve bronchopulmonary dysplasia-free survival at 36 weeks' postmenstrual age compared with placebo. Study interpretation is limited by early trial termination. Trial Registration ClinicalTrials.gov Identifier: NCT02371460.",2020,"Mortality occurred in 6.0% of infants in the DHA group vs 10.2% of infants in the placebo group (absolute difference, -3.9% [95% CI, -6.8% to 1.4%]; relative risk, 0.61 [95% CI, 0.33 to 1.13], P = .12).","[""232 mothers (273 infants) assigned to oral capsules providing 1.2 g/d of DHA from randomization to 36 weeks' postmenstrual age and 229 mothers (255 infants) assigned to"", 'enroll 800 mothers, but was stopped earlier', 'Lactating women who delivered before 29 weeks of gestation were enrolled within 72 hours of delivery', 'breastfed preterm infants born before 29 weeks of gestation, maternal', 'Breastfed Preterm Infants', 'breastfed infants born before 29 weeks of gestation', '461 mothers and their 528 infants (mean gestational age, 26.6 weeks', '375 mothers (81.3%) and 523 infants (99.1%) completed the trial', '16 Canadian neonatal intensive care units (June 2015-April 2018 with last infant follow-up in July 2018']","['Maternal docosahexaenoic acid (DHA) supplementation', 'placebo capsules', 'maternal DHA supplementation', 'Maternal Docosahexaenoic Acid Supplementation', 'docosahexaenoic acid supplementation', 'placebo']","['bronchopulmonary dysplasia', 'Bronchopulmonary dysplasia', 'mortality and bronchopulmonary dysplasia', 'Mortality', 'Bronchopulmonary Dysplasia-Free Survival', 'bronchopulmonary dysplasia-free survival']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0991533', 'cui_str': 'Oral capsule'}, {'cui': 'C4068880', 'cui_str': '1.2'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0450446', 'cui_str': 'Stops'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C4517745', 'cui_str': '375'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0556102', 'cui_str': 'Docosahexaenoic acid supplementation'}]","[{'cui': 'C0006287', 'cui_str': 'Bronchopulmonary dysplasia of newborn'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.79265,"Mortality occurred in 6.0% of infants in the DHA group vs 10.2% of infants in the placebo group (absolute difference, -3.9% [95% CI, -6.8% to 1.4%]; relative risk, 0.61 [95% CI, 0.33 to 1.13], P = .12).","[{'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Marc', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Quebec, Canada.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Piedboeuf', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Quebec, Canada.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Lacaze-Masmonteil', 'Affiliation': 'Department of Pediatrics, Cumming School of Medicine, University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Fraser', 'Affiliation': 'Department of Obstetrics and Gynecology, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada.'}, {'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Mâsse', 'Affiliation': 'School of Public Health, Université de Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Mohamed', 'Affiliation': 'Department of Pediatrics, Université de Montréal, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.'}, {'ForeName': 'Mosarrat', 'Initials': 'M', 'LastName': 'Qureshi', 'Affiliation': 'Division of Neonatology, Royal Alexandra Hospital, Edmonton, Alberta, Canada.'}, {'ForeName': 'Jehier', 'Initials': 'J', 'LastName': 'Afifi', 'Affiliation': 'Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Brigitte', 'Initials': 'B', 'LastName': 'Lemyre', 'Affiliation': ""Division of Neonatology, Children's Hospital of Eastern Ontario, Ottawa, Canada.""}, {'ForeName': 'Georges', 'Initials': 'G', 'LastName': 'Caouette', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Quebec, Canada.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Bartholomew', 'Affiliation': 'Department of Neonatology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.'}, {'ForeName': 'Anne Monique', 'Initials': 'AM', 'LastName': 'Nuyt', 'Affiliation': 'Department of Pediatrics, Université de Montréal, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Julien', 'Affiliation': 'Department of Endocrinology and Nephrology, Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Quebec, Canada.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Synnes', 'Affiliation': 'Department of Pediatrics, Division of Neonatology, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Lucas', 'Affiliation': 'Department of Social and Preventive Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Hôpital du Saint-Sacrement, Quebec City, Quebec, Canada.'}, {'ForeName': 'Thérèse', 'Initials': 'T', 'LastName': 'Perreault', 'Affiliation': ""Division of Neonatology, Montréal Children's Hospital, McGill University, Montreal, Quebec, Canada.""}, {'ForeName': 'Lannae', 'Initials': 'L', 'LastName': 'Strueby', 'Affiliation': 'Department of Pediatrics, University of Saskatchewan, Saskatoon, Canada.'}, {'ForeName': 'Zenon', 'Initials': 'Z', 'LastName': 'Cieslak', 'Affiliation': 'Department of Pediatrics, Royal Columbian Hospital, New Westminster, British Columbia, Canada.'}, {'ForeName': 'Kamran', 'Initials': 'K', 'LastName': 'Yusuf', 'Affiliation': 'Department of Pediatrics, Section of Neonatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Gustavo', 'Initials': 'G', 'LastName': 'Pelligra', 'Affiliation': 'Department of Maternity Care and Pediatrics, Victoria General Hospital, Island Health, Victoria, British Columbia, Canada.'}, {'ForeName': 'Edith', 'Initials': 'E', 'LastName': 'Massé', 'Affiliation': 'Department of Pediatrics, Université de Sherbrooke, Hôpital Fleurimont, Sherbrooke, Quebec, Canada.'}, {'ForeName': 'Bodil', 'Initials': 'B', 'LastName': 'Larsen', 'Affiliation': 'Faculty of Agricultural, Life, and Environmental Sciences, University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'de Cabo', 'Affiliation': 'Department of Pediatrics and Child Health, Max Rady School of Medicine, University of Manitoba, Winnipeg, Canada.'}, {'ForeName': 'Chelsea', 'Initials': 'C', 'LastName': 'Ruth', 'Affiliation': 'Department of Pediatrics and Child Health, Max Rady School of Medicine, University of Manitoba, Winnipeg, Canada.'}, {'ForeName': 'Faiza', 'Initials': 'F', 'LastName': 'Khurshid', 'Affiliation': ""Department of Pediatrics, Queen's University, Kingston, Ontario, Canada.""}, {'ForeName': 'Pascal M', 'Initials': 'PM', 'LastName': 'Lavoie', 'Affiliation': 'Department of Pediatrics, Division of Neonatology, University of British Columbia, Vancouver, Canada.'}]",JAMA,['10.1001/jama.2020.8896'] 1981,32662323,A randomized controlled trial of a smartphone-based application for the treatment of anxiety.,"Abstract Introduction: Generalized anxiety disorder (GAD) is prevalent among college students. Smartphone-based interventions may be a low-cost treatment method. Method: College students with self-reported GAD were randomized to receive smartphone-based guided self-help ( n  = 50), or no treatment ( n  = 50). Post-treatment and six-month follow-up outcomes included the Depression Anxiety Stress Scales-Short Form Stress Subscale (DASS Stress), the Penn State Worry Questionnaire (PSWQ-11), and the State-Trait Anxiety Inventory-Trait (STAI-T), as well as diagnostic status assessed by the GAD-Questionnaire, 4th edition. Results: From pre- to post-treatment, participants who received guided self-help (vs. no treatment) experienced significantly greater reductions on the DASS Stress ( d  = -0.408) and a greater probability of remission from GAD ( d  = -0.445). There was no significant between-group difference in change on the PSWQ-11 ( d  = -0.208) or STAI-T ( d  = -0.114). From post to six-month follow-up there was no significant loss of gains on DASS Stress scores ( d  = -0.141) and of those who had remitted, 78.6% remained remitted. Yet rates of remitted participants no longer differed significantly between conditions at follow-up ( d  = -0.229). Conclusion: Smartphone-based interventions may be efficacious in treating some aspects of GAD. Methods for improving symptom reduction and long-term outcome are discussed.",2020,"From post to six-month follow-up there was no significant loss of gains on DASS Stress scores ( d  = -0.141) and of those who had remitted, 78.6% remained remitted.","['college students', 'Method: College students with self-reported GAD']","['Smartphone-based interventions', 'smartphone-based guided self-help ( n \u2009=\u200950), or no treatment', 'smartphone-based application']","['probability of remission from GAD', 'DASS Stress scores', 'PSWQ-11', 'Depression Anxiety Stress Scales-Short Form Stress Subscale (DASS Stress), the Penn State Worry Questionnaire (PSWQ-11), and the State-Trait Anxiety Inventory-Trait (STAI-T), as well as diagnostic status assessed by the GAD-Questionnaire, 4th edition', 'DASS Stress']","[{'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0270549', 'cui_str': 'Generalized anxiety disorder'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0270549', 'cui_str': 'Generalized anxiety disorder'}, {'cui': 'C1832594', 'cui_str': 'Verloes Bourguignon syndrome'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0338908', 'cui_str': 'Mixed anxiety and depressive disorder'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C2959752', 'cui_str': 'Penn State worry questionnaire'}, {'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205438', 'cui_str': 'Fourth'}, {'cui': 'C0441792', 'cui_str': 'Editions'}]",,0.0274946,"From post to six-month follow-up there was no significant loss of gains on DASS Stress scores ( d  = -0.141) and of those who had remitted, 78.6% remained remitted.","[{'ForeName': 'Michelle G', 'Initials': 'MG', 'LastName': 'Newman', 'Affiliation': 'Department of Psychology, the Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Nicholas C', 'Initials': 'NC', 'LastName': 'Jacobson', 'Affiliation': 'Department of Psychology, the Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Gavin N', 'Initials': 'GN', 'LastName': 'Rackoff', 'Affiliation': 'Department of Psychology, the Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Megan Jones', 'Initials': 'MJ', 'LastName': 'Bell', 'Affiliation': 'Headspace, Inc., San Francisco, CA, USA.'}, {'ForeName': 'C Barr', 'Initials': 'CB', 'LastName': 'Taylor', 'Affiliation': 'Department of Psychiatry, Stanford University, Stanford, CA, USA.'}]",Psychotherapy research : journal of the Society for Psychotherapy Research,['10.1080/10503307.2020.1790688'] 1982,32667635,Nasogastric Decompression vs No Decompression After Pancreaticoduodenectomy: The Randomized Clinical IPOD Trial.,"Importance Although standardization of pancreaticoduodenectomy (PD) has improved postoperative outcomes, morbidity remains high. Fast-track surgery programs appear to improve morbidity, and avoiding nasogastric tube decompression (NGTD), already outdated in most major abdominal surgery, is strongly suggested after PD by fast-track surgery programs but lacks high-level evidence, especially regarding safety. Objective To assess in a randomized clinical trial whether the absence of systematic NGTD after PD reduces postoperative complications. Design, Setting, and Participants The IPOD study (Impact of the Absence of Nasogastric Decompression After Pancreaticoduodenectomy) was an open-label, prospective, single-center, randomized clinical trial conducted at a high-volume pancreatic surgery university hospital in France. In total, 155 patients who were 18 to 75 years of age and required PD for benign or malignant disease were screened for study eligibility. Key exclusion criteria were previous gastric or esophageal surgery and severe comorbidities. Patients were randomly assigned (1:1) to systematic NGTD or to no nasogastric decompression and were followed up until 90 days after surgery. Interventions For patients without NGTD, the NGT was removed immediately after surgery, whereas for patients with NGTD, the NGT was removed 3 to 5 days after surgery. Main Outcomes and Measures The primary end point was the occurrence of postoperative complications grade II or higher using the Clavien-Dindo classification. The primary end point and safety were evaluated in the intent-to-treat population. Results From January 2016 to August 2018, 125 screened patients were considered eligible for the study, and 111 were randomized to no NGTD (n = 52) or to NGTD (n = 59). No patient was lost to follow-up. The 2 groups had similar patient demographic and clinical characteristics at baseline. The median (interquartile range) age was 63.0 (57.0-66.5) years in the group with NGTD (38 [64.4%] were males) and 64.0 (58.0-68.0) years in the group without NGTD (31 [59.6%] were males). The postoperative complication rates grade II or higher were similar between the 2 groups (risk ratio, 0.99; 95% CI, 0.66-1.47; P > .99). Pulmonary complication rates (risk ratio, 0.59; 95% CI, 0.18-1.95; P = .44) and delayed gastric emptying rates (risk ratio, 1.07; 95% CI, 0.52-2.21; P > .99) were not significantly different between the groups. Median (interquartile) length of hospital stay for patients without NGTD was not significantly different compared with those with NGTD (10.0 [9.0-16.3] vs 12.0 [10.0-16.0] days; P = .14). Conclusions and Relevance The present study found no significant difference in postoperative complication occurrence of Clavien-Dindo classification grade II or higher between systematic NGTD and no NGTD after PD, suggesting that avoiding systematic nasogastric decompression is safe for this indication. Trial Registration ClinicalTrials.gov Identifier: NCT02594956.",2020,"Pulmonary complication rates (risk ratio, 0.59; 95% CI, 0.18-1.95; P = .44) and delayed gastric emptying rates (risk ratio, 1.07; 95% CI, 0.52-2.21; P > .99) were not significantly different between the groups.","['patients without NGTD', '155 patients who were 18 to 75 years of age and required PD for benign or malignant disease were screened for study eligibility', 'From January 2016 to August 2018, 125 screened patients were considered eligible for the study, and 111 were randomized to no NGTD (n\u2009=\u200952) or to NGTD (n\u2009=\u200959', 'high-volume pancreatic surgery university hospital in France', 'The median (interquartile range) age was 63.0 (57.0-66.5) years in the group with NGTD (38 [64.4%] were males) and 64.0 (58.0-68.0) years in the group without NGTD (31 [59.6%] were males']","['pancreaticoduodenectomy (PD', 'Nasogastric Decompression vs No Decompression', 'Nasogastric Decompression', 'systematic NGTD or to no nasogastric decompression', 'Fast-track surgery programs']","['Pulmonary complication rates', 'Median (interquartile) length of hospital stay', 'occurrence of postoperative complications grade II or higher using the Clavien-Dindo classification', 'delayed gastric emptying rates', 'postoperative complication rates grade II or higher']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085678', 'cui_str': 'Nasogastric tube'}, {'cui': 'C0011117', 'cui_str': 'Decompression'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0085162', 'cui_str': 'Pancreaticoduodenectomy'}, {'cui': 'C0205183', 'cui_str': 'Benign'}, {'cui': 'C0205282', 'cui_str': 'Malignant'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0030274', 'cui_str': 'Pancreatic structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0085162', 'cui_str': 'Pancreaticoduodenectomy'}, {'cui': 'C0694637', 'cui_str': 'Nasogastric route'}, {'cui': 'C0011117', 'cui_str': 'Decompression'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0085678', 'cui_str': 'Nasogastric tube'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}]",155.0,0.200993,"Pulmonary complication rates (risk ratio, 0.59; 95% CI, 0.18-1.95; P = .44) and delayed gastric emptying rates (risk ratio, 1.07; 95% CI, 0.52-2.21; P > .99) were not significantly different between the groups.","[{'ForeName': 'Damien', 'Initials': 'D', 'LastName': 'Bergeat', 'Affiliation': 'Service de Chirurgie Hépatobiliaire et Digestive, Hôpital Pontchaillou, Centre Hospitalier Universitaire (CHU Rennes), Université de Rennes 1 Centre, Rennes, France.'}, {'ForeName': 'Aude', 'Initials': 'A', 'LastName': 'Merdrignac', 'Affiliation': 'Service de Chirurgie Hépatobiliaire et Digestive, Hôpital Pontchaillou, Centre Hospitalier Universitaire (CHU Rennes), Université de Rennes 1 Centre, Rennes, France.'}, {'ForeName': 'Fabien', 'Initials': 'F', 'LastName': 'Robin', 'Affiliation': 'Service de Chirurgie Hépatobiliaire et Digestive, Hôpital Pontchaillou, Centre Hospitalier Universitaire (CHU Rennes), Université de Rennes 1 Centre, Rennes, France.'}, {'ForeName': 'Elodie', 'Initials': 'E', 'LastName': 'Gaignard', 'Affiliation': 'Service de Chirurgie Hépatobiliaire et Digestive, Hôpital Pontchaillou, Centre Hospitalier Universitaire (CHU Rennes), Université de Rennes 1 Centre, Rennes, France.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Rayar', 'Affiliation': 'Service de Chirurgie Hépatobiliaire et Digestive, Hôpital Pontchaillou, Centre Hospitalier Universitaire (CHU Rennes), Université de Rennes 1 Centre, Rennes, France.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Meunier', 'Affiliation': 'Service de Chirurgie Hépatobiliaire et Digestive, Hôpital Pontchaillou, Centre Hospitalier Universitaire (CHU Rennes), Université de Rennes 1 Centre, Rennes, France.'}, {'ForeName': 'Hélène', 'Initials': 'H', 'LastName': 'Beloeil', 'Affiliation': 'University of Rennes, Rennes, France.'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Boudjema', 'Affiliation': 'Service de Chirurgie Hépatobiliaire et Digestive, Hôpital Pontchaillou, Centre Hospitalier Universitaire (CHU Rennes), Université de Rennes 1 Centre, Rennes, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Laviolle', 'Affiliation': 'University of Rennes, Rennes, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Sulpice', 'Affiliation': 'Service de Chirurgie Hépatobiliaire et Digestive, Hôpital Pontchaillou, Centre Hospitalier Universitaire (CHU Rennes), Université de Rennes 1 Centre, Rennes, France.'}]",JAMA surgery,['10.1001/jamasurg.2020.2291'] 1983,32667636,Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial.,"Importance Long-acting injectable antipsychotics (LAIs) can potentially reduce hospitalization risk by enhancing medication adherence but are rarely considered for early-phase schizophrenia treatment. Objective To determine whether encouraging use of a LAI compared with usual care delays the time to first hospitalization with patients with early-phase illness. Design, Setting, and Participants The Prevention of Relapse in Schizophrenia (PRELAPSE) trial was cluster randomized with a follow-up duration of 2 years. The study began in December 2014, was completed in March 2019, and was conducted in 39 mental health centers in 19 US states. Site randomization assigned 19 clinics to encourage treatment with long-acting aripiprazole monohydrate (aripiprazole once monthly [AOM] condition) and 20 to provide treatment as usual (clinician's choice [CC] condition). Participant eligibility criteria included (1) schizophrenia diagnosis confirmed by a structured clinical interview, (2) fewer than 5 years of lifetime antipsychotic use, and (3) age 18 to 35 years. The AOM sites identified 576 potentially eligible participants, of whom 234 (40.6%) enrolled; CC sites identified 685 potentially eligible participants, of whom 255 (37.2%) enrolled. Interventions There were no restrictions on treatment at CC sites (including using LAIs) or at AOM sites with the exception that aripiprazole monohydrate had to be prescribed within US Food and Drug Administration-approved guidelines. Main Outcomes and Measures The primary outcome was time to first psychiatric hospitalization based on participant interviews every 2 months, the service use resource form administered every 4 months, and other sources (eg, health records) as available. Potential events were adjudicated by an independent committee masked to treatment assignment. Results The 489 participants (368 men [55.3%]) had a mean (SD) age of 25.2 (4.2) years and 225 (46.0%) had 1 year or less lifetime antipsychotic use. Fifty-two AOM (22%) and 91 CC participants (36%) had at least 1 hospitalization. The mean survival time until first hospitalization was 613.7 days (95% CI, 582.3-645.1 days) for AOM participants and 530.6 days (95% CI, 497.3-563.9 days) for CC participants. For time to first hospitalization, the hazard ratio was 0.56 (95% CI, 0.34- 0.92; P = .02), favoring AOM. Survival probabilities were 0.73 (95% CI, 0.65-0.83) for AOM participants and 0.58 (95% CI, 0.50-0.67) for CC participants. The number needed to treat to prevent 1 additional hospitalization was 7 participants treated with AOM compared with CC. Conclusions and Relevance Long-acting injectable antipsychotic use by patients with early-phase schizophrenia can significantly delay time to hospitalization, a personally and economically important outcome. Clinicians should more broadly consider LAI treatment for patients with early-phase illness. Trial Registration ClinicalTrials.gov Identifier: NCT02360319.",2020,"Survival probabilities were 0.73 (95% CI, 0.65-0.83) for AOM participants and 0.58 (95% CI, 0.50-0.67) for CC participants.","['489 participants (368 men [55.3%]) had a mean (SD) age of 25.2 (4.2) years and 225 (46.0%) had 1 year or less lifetime antipsychotic use', '576 potentially eligible participants, of whom 234 (40.6%) enrolled; CC sites identified 685 potentially eligible participants, of whom 255 (37.2%) enrolled', 'patients with early-phase illness', 'The study began in December 2014, was completed in March 2019, and was conducted in 39 mental health centers in 19 US states', 'Early-Phase Schizophrenia', 'Participant eligibility criteria included (1) schizophrenia diagnosis confirmed by a structured clinical interview, (2) fewer than 5 years of lifetime antipsychotic use, and (3) age 18 to 35 years', 'patients with early-phase schizophrenia']","['Long-Acting Injectable Antipsychotics vs Usual Care', 'aripiprazole monohydrate', 'aripiprazole monohydrate (aripiprazole', 'Importance\n\n\nLong-acting injectable antipsychotics (LAIs']","['mean survival time until first hospitalization', 'time to first psychiatric hospitalization based on participant interviews every 2 months, the service use resource form administered every 4 months, and other sources (eg, health records) as available', 'Survival probabilities']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517758', 'cui_str': '4.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517652', 'cui_str': '225'}, {'cui': 'C0040615', 'cui_str': 'Antipsychotic agent'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0009474', 'cui_str': 'CMHC'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0199182', 'cui_str': 'History taking'}, {'cui': 'C0205388', 'cui_str': 'Few'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}, {'cui': 'C0040615', 'cui_str': 'Antipsychotic agent'}, {'cui': 'C0299792', 'cui_str': 'aripiprazole'}]","[{'cui': 'C0086595', 'cui_str': 'Mean Survival Time'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0585338', 'cui_str': 'Every four months'}, {'cui': 'C0449416', 'cui_str': 'Source'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0033204', 'cui_str': 'Probability'}]",,0.152895,"Survival probabilities were 0.73 (95% CI, 0.65-0.83) for AOM participants and 0.58 (95% CI, 0.50-0.67) for CC participants.","[{'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Kane', 'Affiliation': 'Departments of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.'}, {'ForeName': 'Nina R', 'Initials': 'NR', 'LastName': 'Schooler', 'Affiliation': 'SUNY Downstate Health Sciences University, Brooklyn, New York.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Marcy', 'Affiliation': 'Vanguard Research Group, Glen Oaks, New York.'}, {'ForeName': 'Christoph U', 'Initials': 'CU', 'LastName': 'Correll', 'Affiliation': 'Departments of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.'}, {'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Achtyes', 'Affiliation': 'Cherry Health, Grand Rapids, Michigan.'}, {'ForeName': 'Robert D', 'Initials': 'RD', 'LastName': 'Gibbons', 'Affiliation': 'University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Delbert G', 'Initials': 'DG', 'LastName': 'Robinson', 'Affiliation': 'Departments of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.'}]",JAMA psychiatry,['10.1001/jamapsychiatry.2020.2076'] 1984,32667654,Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial.,"Importance Impairment of dopaminergic transmission may contribute to cognitive dysfunction in Alzheimer disease (AD). Objective To investigate whether therapy with dopaminergic agonists may affect cognitive functions in patients with AD. Design, Setting, and Participants This phase 2, monocentric, randomized, double-blind, placebo-controlled trial was conducted in Italy. Patients with mild to moderate AD were enrolled between September 1, 2017, and December 31, 2018. Data were analyzed from July 1 to September 1, 2019. Interventions A rotigotine 2 mg transdermal patch for 1 week followed by a 4 mg patch for 23 weeks (n = 47) or a placebo transdermal patch for 24 weeks (n = 47). Main Outcomes and Measures The primary end point was change from baseline on the Alzheimer Disease Assessment Scale-Cognitive Subscale. Secondary end points were changes in Frontal Assessment Battery, Alzheimer Disease Cooperative Study-Activities of Daily Living, and Neuropsychiatric Inventory scores. Prefrontal cortex activity was evaluated by transcranial magnetic stimulation combined with electroencephalography. Results Among 94 patients randomized (mean [SD] age, 73.9 [5.6] years; 58 [62%] women), 78 (83%) completed the study. Rotigotine, as compared with placebo, had no significant effect on the primary end point: estimated mean change in Alzheimer Disease Assessment Scale-Cognitive Subscale score was 2.92 (95% CI, 2.51-3.33) for the rotigotine group and 2.66 (95% CI, 2.31-3.01) for the placebo group. For the secondary outcomes, there were significant estimated mean changes between groups for Alzheimer Disease Cooperative Study-Activities of Daily Living score (-3.32 [95% CI, -4.02 to -2.62] for rotigotine and -7.24 [95% CI, -7.84 to -6.64] for placebo) and Frontal Assessment Battery score (0.48 [95% CI, 0.31 to 0.65] for rotigotine and -0.66 [95% CI, -0.80 to -0.52] for placebo). There was no longitudinal change in Neuropsychiatric Inventory scores (1.64 [95% CI, 1.06-2.22] for rotigotine and 1.26 [95% CI, 0.77-1.75] for placebo group). Neurophysiological analysis of electroencephalography results indicated that prefrontal cortical activity increased in rotigotine but not in the placebo group. Adverse events were more common in the rotigotine group, with 11 patients dropping out compared with 5 in the placebo group. Conclusions and Relevance In this randomized clinical trial, rotigotine treatment did not significantly affect global cognition in patients with mild to moderate AD; however, improvement was observed in cognitive functions highly associated with the frontal lobe and in activities of daily living. These findings suggest that treatment with the dopaminergic agonist rotigotine may reduce symptoms associated with frontal lobe cognitive dysfunction and thus may delay the impairment of activities of daily living. Trial Registration ClinicalTrials.gov Identifier: NCT03250741.",2020,"For the secondary outcomes, there were significant estimated mean changes between groups for Alzheimer Disease Cooperative Study-Activities of Daily Living score (-3.32 [95% CI, -4.02 to -2.62] for rotigotine and -7.24","['patients with AD', 'Patients with mild to moderate AD were enrolled between September 1, 2017, and December 31, 2018', 'patients with mild to moderate AD', '94 patients randomized (mean [SD] age, 73.9 [5.6] years; 58 [62%] women), 78 (83%) completed the study', 'Patients With Mild to Moderate Alzheimer Disease', 'Alzheimer disease (AD']","['dopaminergic agonist rotigotine', 'placebo transdermal patch', 'rotigotine 2 mg transdermal patch', 'Rotigotine vs Placebo', 'Rotigotine', 'rotigotine', 'transcranial magnetic stimulation combined with electroencephalography', 'placebo']","['Adverse events', 'mean change in Alzheimer Disease Assessment Scale-Cognitive Subscale score', 'Neuropsychiatric Inventory scores', 'Prefrontal cortex activity', 'Cognitive Functions', 'Alzheimer Disease Cooperative Study-Activities of Daily Living score', 'global cognition', 'cognitive functions', 'prefrontal cortical activity', 'Alzheimer Disease Assessment Scale-Cognitive Subscale', 'Frontal Assessment Battery score', 'changes in Frontal Assessment Battery, Alzheimer Disease Cooperative Study-Activities of Daily Living, and Neuropsychiatric Inventory scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517794', 'cui_str': '5.6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0178601', 'cui_str': 'Dopamine receptor agonist'}, {'cui': 'C1700683', 'cui_str': 'Rotigotine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0991556', 'cui_str': 'Prolonged-release transdermal patch'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0450989', 'cui_str': ""Alzheimer's Disease Assessment Scale""}, {'cui': 'C0459443', 'cui_str': 'Subscale score'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C2960460', 'cui_str': 'Frontal assessment battery score'}, {'cui': 'C2732353', 'cui_str': 'Frontal assessment battery'}]",94.0,0.720977,"For the secondary outcomes, there were significant estimated mean changes between groups for Alzheimer Disease Cooperative Study-Activities of Daily Living score (-3.32 [95% CI, -4.02 to -2.62] for rotigotine and -7.24","[{'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Koch', 'Affiliation': 'Department of Behavioral and Clinical Neurology, Santa Lucia Foundation Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.'}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Motta', 'Affiliation': 'Department of Behavioral and Clinical Neurology, Santa Lucia Foundation Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Bonnì', 'Affiliation': 'Department of Behavioral and Clinical Neurology, Santa Lucia Foundation Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.'}, {'ForeName': 'Maria Concetta', 'Initials': 'MC', 'LastName': 'Pellicciari', 'Affiliation': 'Department of Behavioral and Clinical Neurology, Santa Lucia Foundation Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Picazio', 'Affiliation': 'Department of Behavioral and Clinical Neurology, Santa Lucia Foundation Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.'}, {'ForeName': 'Elias Paolo', 'Initials': 'EP', 'LastName': 'Casula', 'Affiliation': 'Department of Behavioral and Clinical Neurology, Santa Lucia Foundation Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Maiella', 'Affiliation': 'Department of Behavioral and Clinical Neurology, Santa Lucia Foundation Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Di Lorenzo', 'Affiliation': 'Department of Behavioral and Clinical Neurology, Santa Lucia Foundation Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.'}, {'ForeName': 'Viviana', 'Initials': 'V', 'LastName': 'Ponzo', 'Affiliation': 'Department of Behavioral and Clinical Neurology, Santa Lucia Foundation Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.'}, {'ForeName': 'Clarissa', 'Initials': 'C', 'LastName': 'Ferrari', 'Affiliation': 'Unit of Statistics, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.'}, {'ForeName': 'Eugenia', 'Initials': 'E', 'LastName': 'Scaricamazza', 'Affiliation': 'Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Caltagirone', 'Affiliation': 'Department of Behavioral and Clinical Neurology, Santa Lucia Foundation Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Martorana', 'Affiliation': 'Department of Behavioral and Clinical Neurology, Santa Lucia Foundation Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.'}]",JAMA network open,['10.1001/jamanetworkopen.2020.10372'] 1985,32666060,Clinical Performance of Posterior Microhybrid Resin Composite Restorations Applied Using Regular and High-Power Mode Polymerization Protocols According to USPHS and SQUACE Criteria: 10-Year Randomized Controlled Split-Mouth Trial.,"PURPOSE This randomized, split-mouth clinical study evaluated the marginal quality of direct class-I and class-II restorations made of microhybrid composite that were applied using two polymerization protocols and two marginal evaluation criteria. MATERIALS AND METHODS A total of 50 patients (mean age: 33 years) received 100 direct class-I or class-II restorations in premolars or molars. Three calibrated operators made the restorations. After conditioning the tooth with 2-step etch-and-rinse adhesive, restorations were made incrementally using microhybrid composite. Each layer was polymerized using a polymerization device operated either in regular mode (600-650 mW/cm2 for 20 s) (RM) or high-power (1200-1300 mW/cm2 for 10 s) mode (HPM). Two independent, calibrated operators evaluated the restorations 1 week (baseline) and 6 months after restoration placement, and thereafter annually up to 10 years using modified USPHS and SQUACE criteria. Data were analyzed using the Mann-Whitney U-test (α = 0.05). RESULTS Alpha scores (USPHS) for marginal adaptation (76% and 74% for RM and HPM, respectively) and marginal discoloration (70% and 72%, for RM and HPM, respectively) did not show significant differences between the two polymerization protocols (p > 0.05). Alpha scores (SQUACE) for marginal adaptation (78% and 74% for RM and HPM, respectively) and marginal discoloration (70% for both RM and HPM) were also not significantly different at the 10-year year follow-up (p > 0.05). CONCLUSION Regular and high-power polymerization protocols had no influence on the stability of marginal quality of the microhybrid composite tested up to 10 years. Both modified USPHS and SQUACE criteria confirmed that regardless of the polymerization mode, marginal quality of the restorations deteriorated significantly compared to baseline (p < 0.05).",2020,"Both modified USPHS and SQUACE criteria confirmed that regardless of the polymerization mode, marginal quality of the restorations deteriorated significantly compared to baseline (p < 0.05).",['50 patients (mean age: 33 years'],['100 direct class-I or class-II restorations in premolars or molars'],"['stability of marginal quality', 'Alpha scores (SQUACE) for marginal adaptation', 'Alpha scores (USPHS) for marginal adaptation', 'marginal discoloration']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0441885', 'cui_str': 'Class 1'}, {'cui': 'C0441886', 'cui_str': 'Class 2'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C1704302', 'cui_str': 'Structure of premolar tooth'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}]","[{'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0332572', 'cui_str': 'Abnormal color'}]",50.0,0.0306194,"Both modified USPHS and SQUACE criteria confirmed that regardless of the polymerization mode, marginal quality of the restorations deteriorated significantly compared to baseline (p < 0.05).","[{'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Cerutti', 'Affiliation': ''}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Barabanti', 'Affiliation': ''}, {'ForeName': 'Mutlu', 'Initials': 'M', 'LastName': 'Özcan', 'Affiliation': ''}]",The journal of adhesive dentistry,['10.3290/j.jad.a44865'] 1986,32663699,A randomized control trial of activity scheduling for caring for older adults with dementia and its impact on their spouse care-givers.,"INTRODUCTION Participating in meaningful activities is important for any individual's wellbeing. Activity scheduling enables older adults with dementia and their spouse caregivers to structure their activities in accordance with the things they value. METHODS In examining the effectiveness of activity scheduling, this report details the results of a 12-week single-blinded randomized control trial using a parallel group experimental design. RESULTS From August 2018 to August 2019, 100 community-dwelling older adults with mild to moderate dementia and their spouses completed this study. The experimental group (n = 50) practicing activity scheduling showed improvements than in control group (n = 50), with respect to alleviating the impact of the caregiving role, reducing the behavioural and psychological symptoms of dementia, decreasing the caring demand and generally improving the quality of life, with Cohen's d = .61, .45, .50 and 43 respectively. Moreover, there were significant differences between the groups indicated that over time, the experimental group showed an improvement with regard to alleviating the role of caring, with Cohen's d = .64, and alleviating disruptive and depressive behavior, with an effect size of .45 and .50 respectively. The number of caring hours needed dropped from 6.98 to 5.98 h in the experimental group. DISCUSSION & CONCLUSION There were more activities that older adults with dementia and their spouse caregivers would like to do, and could participate in, than we had expected. Activity scheduling can facilitate their participation. This is a very important topic as non-pharmacological interventions are needed for this even-growing segment of the population.",2020,"The experimental group (n = 50) practicing activity scheduling showed improvements than in control group (n = 50), with respect to alleviating the impact of the caregiving role, reducing the behavioural and psychological symptoms of dementia, decreasing the caring demand and generally improving the quality of life, with Cohen's d = .61, .45, .50 and 43 respectively.","['older adults with dementia and its impact on their spouse care-givers', 'older adults with dementia and their spouse caregivers', 'From August 2018 to August 2019, 100 community-dwelling older adults with mild to moderate dementia and their spouses completed this study']",[],"['number of caring hours needed', 'alleviating disruptive and depressive behavior']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0087015', 'cui_str': 'Spouse Caregivers'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],"[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",,0.0283988,"The experimental group (n = 50) practicing activity scheduling showed improvements than in control group (n = 50), with respect to alleviating the impact of the caregiving role, reducing the behavioural and psychological symptoms of dementia, decreasing the caring demand and generally improving the quality of life, with Cohen's d = .61, .45, .50 and 43 respectively.","[{'ForeName': 'Frank Ho-Yin', 'Initials': 'FH', 'LastName': 'Lai', 'Affiliation': 'Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong. Electronic address: frank.hy.lai@polyu.edu.hk.'}, {'ForeName': 'Elaine Wai-Hung', 'Initials': 'EW', 'LastName': 'Yan', 'Affiliation': 'Occupational Therapy Department, Kowloon Hospital, Hong Kong.'}, {'ForeName': 'Wing-Sze', 'Initials': 'WS', 'LastName': 'Tsui', 'Affiliation': ""Chung Hok Elderly Centre, Women's Welfare Club Western District, Hong Kong.""}, {'ForeName': 'Kathy Ka-Ying', 'Initials': 'KK', 'LastName': 'Yu', 'Affiliation': 'Tai Po Integrated Service for Senior Citizens, The Salvation Army Hong Kong & Macau Command, Hong Kong.'}]",Archives of gerontology and geriatrics,['10.1016/j.archger.2020.104167'] 1987,32664046,Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer.,,2014,,['metastatic colorectal cancer'],['FOLFIRI ± panitumumab'],[],"[{'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}]","[{'cui': 'C0879427', 'cui_str': 'panitumumab'}]",[],,0.0213531,,[],Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdu002'] 1988,32664145,A randomized double-blind placebo-controlled multicenter trial of Bushen Yisui and Ziyin Jiangzhuo formula for constipation in Parkinson disease.,"INTRODUCTION Constipation is a common nonmotor symptom of Parkinson disease (PD). Constipation can also impact patient's quality of life. Chinese herbal medicines have been used for the treatment of constipation in PD. This trial will evaluate the efficacy and safety of a Chinese herbal formula Bushen Yisui and Ziyin Jiangzhuo (BYZJ) for the treatment of constipation in PD. METHODS AND ANALYSIS This randomized, double-blind, placebo-controlled, multicenter clinical trial will involve 4 hospitals in Beijing, China. The study will aim to recruit 90 PD patients with constipation between 30 and 80 years-of age with a score of 1 - 4 on the Hoehn and Yahr scale. Once recruited, Patients will be randomized into a BYZJ group or a placebo group in a 2:1 ratio. The trial will include a 1-week run-in period, a 4-week double-blind treatment period, a 4-week and a 12-week follow-up period. All patients will be educated about PD-related constipation during the run-in period. BYZJ granules and simulated granules will be administered twice daily for 4 weeks to the BYZJ group and the placebo group respectively. Assessments will be performed during run-in period, before the start of treatment (baseline, week 0), and at 4, 8, and 16 weeks. The primary outcome will be measured with the Constipation Severity Instrument, and secondary outcomes will be evaluated with the Patient Assessment of Constipation Quality of Life questionnaire, Bristol Stool Form Scale, Movement Disorders-Unified Parkinson Disease Rating Scale, Nonmotor Symptoms Scale, PD Sleep Scale, Parkinson Fatigue Scale-16. Laxative use (dose and frequency) will also be recorded. Intention-to-treat and per-protocol set analyses will be used to compare symptom improvement between the 2 groups. Any adverse events will be recorded. DISCUSSION If found effective and safe, BYZJ formula will be one of Chinese herb to treat constipation and even other nonmotor or motor symptoms in PD patients. The results will sustain the broader use of BYZJ formula in PD.",2020,BYZJ granules and simulated granules will be administered twice daily for 4 weeks to the BYZJ group and the placebo group respectively.,"['constipation in Parkinson disease', '90 PD patients with constipation between 30 and 80 years-of age with a score of 1 - 4 on the Hoehn and Yahr scale', '4 hospitals in Beijing, China', 'constipation in PD']","['Bushen Yisui and Ziyin Jiangzhuo formula', 'Chinese herbal formula Bushen Yisui and Ziyin Jiangzhuo (BYZJ', 'Chinese herbal medicines', 'placebo']","['efficacy and safety', 'Constipation Severity Instrument, and secondary outcomes will be evaluated with the Patient Assessment of Constipation Quality of Life questionnaire, Bristol Stool Form Scale, Movement Disorders-Unified Parkinson Disease Rating Scale, Nonmotor Symptoms Scale, PD Sleep Scale, Parkinson Fatigue Scale-16']","[{'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4274667', 'cui_str': 'Hoehn and Yahr Scale'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C2352031', 'cui_str': 'bushen yisui'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0376667', 'cui_str': 'Herbals'}, {'cui': 'C1273412', 'cui_str': 'Chinese herbal medicine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1997606', 'cui_str': 'Bristol stool form scale'}, {'cui': 'C0026650', 'cui_str': 'Movement disorder'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}]",,0.305455,BYZJ granules and simulated granules will be administered twice daily for 4 weeks to the BYZJ group and the placebo group respectively.,"[{'ForeName': 'Zhaohui', 'Initials': 'Z', 'LastName': 'Jin', 'Affiliation': 'Parkinson Medical Center, Beijing Rehabilitation Hospital, Capital Medical University.'}, {'ForeName': 'Zhengtang', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Geriatrics Department, China Academy of Chinese Medical Sciences Xiyuan Hospital.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Kang', 'Affiliation': 'Medical Insurance Office, Dongzhimen Hospital of Beijing University of Chinese Medicine.'}, {'ForeName': 'Aoran', 'Initials': 'A', 'LastName': 'Yang', 'Affiliation': 'Traditional Chinese Medicine Rehabilitation Center, Beijing Rehabilitation Hospital, Capital Medical University.'}, {'ForeName': 'Hongbo', 'Initials': 'H', 'LastName': 'Zhao', 'Affiliation': 'Traditional Chinese Medicine Rehabilitation Center, Beijing Rehabilitation Hospital, Capital Medical University.'}, {'ForeName': 'XiaoYan', 'Initials': 'X', 'LastName': 'Yan', 'Affiliation': 'Peking University Clinical Research Institute, Peking University First Hospital.'}, {'ForeName': 'Tianqing', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Neurology Department, Beijing Longfu Hospital, Beijing, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Gao', 'Affiliation': 'Parkinson Medical Center, Beijing Rehabilitation Hospital, Capital Medical University.'}, {'ForeName': 'Aixian', 'Initials': 'A', 'LastName': 'Liu', 'Affiliation': 'Parkinson Medical Center, Beijing Rehabilitation Hospital, Capital Medical University.'}, {'ForeName': 'Boyan', 'Initials': 'B', 'LastName': 'Fang', 'Affiliation': 'Parkinson Medical Center, Beijing Rehabilitation Hospital, Capital Medical University.'}]",Medicine,['10.1097/MD.0000000000021145'] 1989,32664149,"Exploring the efficacy and safety of herbal medicine on Korean obese women with or without metabolic syndrome risk factors: A study protocol for a double-blind, randomized, multi-center, placebo-controlled clinical trial.","BACKGROUND The prevalence of obesity among women is increasing. Obesity is associated with various metabolic syndromes; conventional treatments are limited and may induce serious adverse events due to polytherapy regimens. Currently, demands for complementary and alternative medicine that has a proven safety profile for the treatment of obesity with or without metabolic risk factors are increasing.Our team of preclinical experts reported a significant anti-obesity effect of the Korean herbal medicine, Galgeun-tang (GGT). Thus, we designed this trial to explore the effects of GGT among obese women to accumulate optimal clinical evidence.Obesity is not only a component of metabolic syndrome and a factor associated with an increased risk of cardiovascular disease but is also related to insulin resistance. Previous research has confirmed that an increasing body mass index is highly related with increased risk of metabolic syndrome among overweight and obese individuals. The effectiveness of the Korean medicine herbal formula, GGT on obesity has been previously reported. The objective of this study is to assess the efficacy and safety of GGT for weight loss among obese Korean women with or without high risk for metabolic syndrome. METHODS/DESIGN This study is a randomized, double-blinded, placebo-controlled, multi-center clinical trial. A total of 160 participants will be randomly distributed in 2 groups, the GGT group or the placebo group in a 1:1 ratio using a web-based randomization system. Each group will be administered GGT or placebo 3 times a day for 12 weeks. The primary endpoint is to assess the change in weight from baseline. The secondary endpoints are the following: the changes in body composition measurements, anthropomorphic measurements, obesity screening Laboratory tests, patient self-reported questionnaires, and economic evaluation outcomes. Adverse events will also be reported. DISCUSSION The findings of this study will confirm methodologies regarding the efficacy and safety of GGT for weight loss among obese Korean women with or without metabolic risk factors.",2020,"Our team of preclinical experts reported a significant anti-obesity effect of the Korean herbal medicine, Galgeun-tang (GGT).","['160 participants', 'overweight and obese individuals', 'Korean obese women with or without metabolic syndrome risk factors', 'obese Korean women with or without high risk for metabolic syndrome', 'obese Korean women with or without metabolic risk factors', 'obese women']","['GGT', 'GGT or placebo', 'herbal medicine', 'placebo']","['body composition measurements, anthropomorphic measurements, obesity screening Laboratory tests, patient self-reported questionnaires, and economic evaluation outcomes', 'efficacy and safety', 'change in weight from baseline', 'weight loss']","[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]","[{'cui': 'C0017040', 'cui_str': 'Gamma-glutamyltransferase'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0025125', 'cui_str': 'Herbs, Medicinal'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0740216', 'cui_str': 'Obesity screening'}, {'cui': 'C0022885', 'cui_str': 'Laboratory procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0150099', 'cui_str': 'Economic Evaluation'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]",160.0,0.388628,"Our team of preclinical experts reported a significant anti-obesity effect of the Korean herbal medicine, Galgeun-tang (GGT).","[{'ForeName': 'Youme', 'Initials': 'Y', 'LastName': 'Ko', 'Affiliation': 'Department of Korean Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul.'}, {'ForeName': 'Hyun-Ju', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Oriental Medicine Research Institute, College of Korean Medicine, Gachon University, Seongnam.'}, {'ForeName': 'Hojun', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Korean Rehabilitation Medicine, College of Korean Medicine, Dongguk University, Seoul.'}, {'ForeName': 'Jin-Bong', 'Initials': 'JB', 'LastName': 'Choi', 'Affiliation': 'Department of Oriental Rehabilitation Medicine, Gwangju Oriental Hospital of Dongshin University, Gwangju.'}, {'ForeName': 'Young-Dal', 'Initials': 'YD', 'LastName': 'Kwon', 'Affiliation': 'Department of Korean Medicine Rehabilitation, Gwangju Medical Center, College of Korean Medicine, Wonkwang University, Gwangju.'}, {'ForeName': 'Won-Seok', 'Initials': 'WS', 'LastName': 'Jung', 'Affiliation': 'Department of Korean Rehabilitation Medicine, College of Korean Medicine, Kyung Hee University, Seoul.'}, {'ForeName': 'Bo-Hyoung', 'Initials': 'BH', 'LastName': 'Jang', 'Affiliation': 'Department of Korean Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul.'}, {'ForeName': 'NamKwen', 'Initials': 'N', 'LastName': 'Kim', 'Affiliation': 'Center for Comparative Effectiveness Research & Economic Evaluation in Korean Medicine, Pusan National University, Yangsan.'}, {'ForeName': 'Yun-Kyung', 'Initials': 'YK', 'LastName': 'Song', 'Affiliation': 'Department of Korean Rehabilitation Medicine, College of Korean Medicine, Gachon University, Seongnam, Republic of Korea.'}, {'ForeName': 'Seong-Gyu', 'Initials': 'SG', 'LastName': 'Ko', 'Affiliation': 'Department of Korean Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul.'}]",Medicine,['10.1097/MD.0000000000021153'] 1990,32662184,Effects of caregiver dementia training in caregiver-patient dyads: A randomized controlled study.,"OBJECTIVES Caregivers for people with dementia (PWD) have reported needing emotional and social support, improved coping strategies, and better information about the illness and available support services. In this study, we aimed to determine the effectiveness of an Australian multicomponent community-based training program that we adapted and implemented in a non-medical Dutch health care setting. METHODS AND DESIGN A randomized controlled trial was performed: 142 dyads of cohabiting caregivers and PwD were randomized to control (care as usual) or intervention (training program) groups and outcomes were compared. Programs lasted 1 week, comprised 14 sessions, and were delivered by specialist staff. We included 16 groups of two to six caregivers. The primary outcome was care-related quality of life (CarerQol-7D) at 3 months. The main secondary outcomes for caregivers were self-rated burden, health and mood symptoms, and for PwD were neuropsychiatric symptoms, quality of life, and agitation. RESULTS No significant difference was observed for the primary outcome. However, caregivers experienced fewer role limitations due to physical function (adjusted mean difference, 13.04; 95% confidence interval [95%CI], 3.15-22.93), emotional function (13.52; 95%CI, 3.76-23.28), and pain reduction (9.43; 95%CI, 1.00-17.86). Positive outcomes identified by qualitative analysis included better acceptance and coping and improved knowledge of dementia and available community services and facilities. CONCLUSION Quantitative analysis showed that the multicomponent course did not affect care-related quality of life but did have a positive effect on experienced role limitations and pain. Qualitative analysis showed that the course met the needs of participating dyads.",2020,"However, caregivers experienced fewer role limitations due to physical function (adjusted mean difference, 13.04; 95% confidence interval [95%CI], 3.15-22.93), emotional function (13.52; 95%CI, 3.76-23.28), and pain reduction (9.43; 95%CI, 1.00-17.86).","['Caregiver-Patient Dyads', 'Caregivers for people with dementia (PWD', '142 dyads of cohabiting caregivers and PwD', '16 groups of two to six caregivers']","['control (care as usual) or intervention (training program', 'Australian multicomponent community-based training program', 'Caregiver Dementia Training']","['emotional function', 'care-related quality of life (CarerQol-7D', 'pain reduction', 'self-rated burden, health and mood symptoms, and for PwD were neuropsychiatric symptoms, quality of life, and agitation', 'acceptance and coping and improved knowledge of dementia and available community services and facilities']","[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0032861', 'cui_str': 'Powder'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0032861', 'cui_str': 'Powder'}, {'cui': 'C4285807', 'cui_str': 'Behavioral and psychological symptoms of dementia'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0009482', 'cui_str': 'Community Services'}]",142.0,0.20068,"However, caregivers experienced fewer role limitations due to physical function (adjusted mean difference, 13.04; 95% confidence interval [95%CI], 3.15-22.93), emotional function (13.52; 95%CI, 3.76-23.28), and pain reduction (9.43; 95%CI, 1.00-17.86).","[{'ForeName': 'Elizabeth G', 'Initials': 'EG', 'LastName': 'Birkenhäger-Gillesse', 'Affiliation': 'Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Wilco P', 'Initials': 'WP', 'LastName': 'Achterberg', 'Affiliation': 'Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Sarah I M', 'Initials': 'SIM', 'LastName': 'Janus', 'Affiliation': 'Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Boudewijn J', 'Initials': 'BJ', 'LastName': 'Kollen', 'Affiliation': 'Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Sytse U', 'Initials': 'SU', 'LastName': 'Zuidema', 'Affiliation': 'Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}]",International journal of geriatric psychiatry,['10.1002/gps.5378'] 1991,32664934,Protect MSM from HIV and other sexually transmitted diseases by providing mobile health services of partner notification: protocol for a pragmatic stepped wedge cluster randomized controlled trial.,"BACKGROUND Recently, more and more men who have sex with men (MSM) look for casual partners through online dating platforms in China. However, most are unable to know their partners' HIV and other sexually transmitted diseases (STD) statuses, leading to the rapid increase in HIV infection among Chinese MSM. Effective partner notification is urgently needed to increase the risk awareness of MSM and prevent HIV and other STDs transmission. However, the traditional intervention mainly targets to the HIV-positive MSM and the effect is not promising. Our study aims to provide Internet-based partner notification, along with a series of health services for HIV-negative MSM to protect them from HIV and other STDs. METHODS A pragmatic stepped wedge cluster randomized controlled trial design is used to evaluate the effectiveness of a new intervention paradigm, which aims to reduce HIV and other STDs incidences among MSM in China. Through integrating a mobile health (mHealth) service application (app) to the current HIV and other STDs prevention and control methods, the new paradigm provides partner notification of HIV, syphilis, hepatitis B, and hepatitis C statuses. A total of 6172 MSM in 16 districts of Beijing, China will be recruited and randomized to sequentially receive partner notification intervention through the app at 6-month intervals. The primary outcomes are HIV incidence and the additional cost of the intervention. The secondary outcomes include incidences of syphilis, hepatitis B, and hepatitis C, disease transmission social networks, testing adherence, knowledge of HIV and STDs control, health self-responsibility awareness, changes of high risk behaviors and other related outcomes. The generalized linear mixed models (GLMM) will be used to analyze the differences of outcomes in the control period and in the intervention period. DISCUSSION We expect that the HIV incidence will be significantly lower and the secondary outcomes will also be improved with providing health service of partner notification through mhealth intervention. The feasible and affordable public health intervention paradigm will have implications for HIV and STDs prevention and control among MSM and other key populations. TRIAL REGISTRATION ClinicalTrials.gov, NCT04349748 . Registered on 16 April 2020.",2020,"The feasible and affordable public health intervention paradigm will have implications for HIV and STDs prevention and control among MSM and other key populations. ","['men who have sex with men (MSM) look for casual partners through online dating platforms in China', 'A total of 6172 MSM in 16 districts of Beijing, China']",[],"['HIV incidence and the additional cost of the intervention', 'incidences of syphilis, hepatitis B, and hepatitis C, disease transmission social networks, testing adherence, knowledge of HIV and STDs control, health self-responsibility awareness, changes of high risk behaviors and other related outcomes']","[{'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4042832', 'cui_str': 'Peking'}]",[],"[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0039128', 'cui_str': 'Syphilis'}, {'cui': 'C0019163', 'cui_str': 'Type B viral hepatitis'}, {'cui': 'C0019196', 'cui_str': 'Viral hepatitis C'}, {'cui': 'C0242781', 'cui_str': 'Communicable Disease Transmission'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0036916', 'cui_str': 'Sexually transmitted infectious disease'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",6172.0,0.127014,"The feasible and affordable public health intervention paradigm will have implications for HIV and STDs prevention and control among MSM and other key populations. ","[{'ForeName': 'Xiangyu', 'Initials': 'X', 'LastName': 'Yan', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.'}, {'ForeName': 'Yongjie', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.'}, {'ForeName': 'Hexuan', 'Initials': 'H', 'LastName': 'Su', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Xing', 'Affiliation': 'Institute of Child and Adolescent Health, School of Public Health, Peking University, Beijing, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Zhang', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.'}, {'ForeName': 'Zuhong', 'Initials': 'Z', 'LastName': 'Lu', 'Affiliation': 'State Key Laboratory for Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.'}, {'ForeName': 'Zhongwei', 'Initials': 'Z', 'LastName': 'Jia', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China. urchinjj@163.com.'}]",BMC public health,['10.1186/s12889-020-09162-x'] 1992,32665218,"Robotic versus laparoscopic ventral hernia repair: multicenter, blinded randomized controlled trial.","OBJECTIVE To determine whether robotic ventral hernia repair is associated with fewer days in the hospital 90 days after surgery compared with laparoscopic repair. DESIGN Pragmatic, blinded randomized controlled trial. SETTING Multidisciplinary hernia clinics in Houston, USA. PARTICIPANTS 124 patients, deemed appropriate candidates for elective minimally invasive ventral hernia repair, consecutively presenting from April 2018 to February 2019. INTERVENTIONS Robotic ventral hernia repair (n=65) versus laparoscopic ventral hernia repair (n=59). MAIN OUTCOME MEASURES The primary outcome was number of days in hospital within 90 days after surgery. Secondary outcomes included emergency department visits, operating room time, wound complications, hernia recurrence, reoperation, abdominal wall quality of life, and costs from the healthcare system perspective. Outcomes were pre-specified before data collection began and analyzed as intention to treat. RESULTS Patients from both groups were similar at baseline. Ninety day follow-up was completed in 123 (99%) patients. No evidence was seen of a difference in days in hospital between the two groups (median 0 v 0 days; relative rate 0.90, 95% confidence interval 0.37 to 2.19; P=0.82). For secondary outcomes, no differences were noted in emergency department visits, wound complications, hernia recurrence, or reoperation. However, robotic repair had longer operative duration (141 v 77 min; mean difference 62.89, 45.75 to 80.01; P≤0.001) and increased healthcare costs ($15 865 (£12 746; €14 125) v $12 955; cost ratio 1.21, 1.07 to 1.38; adjusted absolute cost difference $2767, $910 to $4626; P=0.004). Among patients with robotic ventral hernia repair, two had an enterotomy compared none with laparoscopic repair. The median one month postoperative improvement in abdominal wall quality of life was 3 with robotic ventral hernia repair compared with 15 following laparoscopic repair. CONCLUSION This study found no evidence of a difference in 90 day postoperative hospital days between robotic and laparoscopic ventral hernia repair. However, robotic repair increased operative duration and healthcare costs. TRIAL REGISTRATION Clinicaltrials.gov NCT03490266.",2020,"However, robotic repair had longer operative duration (141 v 77 min; mean difference 62.89, 45.75 to 80.01; P≤0.001) and increased healthcare costs ($15 865 (£12 746; €14 125) v $12 955; cost ratio 1.21, 1.07 to 1.38; adjusted absolute cost difference $2767, $910 to $4626; P=0.004).","['patients with robotic ventral hernia repair, two had an enterotomy compared none with laparoscopic repair', '124 patients, deemed appropriate candidates for elective minimally invasive ventral hernia repair, consecutively presenting from April 2018 to February 2019', 'Multidisciplinary hernia clinics in Houston, USA', 'n=59']","['laparoscopic ventral hernia repair', 'Robotic versus laparoscopic ventral hernia repair', 'robotic ventral hernia repair', 'Robotic ventral hernia repair', 'laparoscopic repair', 'robotic and laparoscopic ventral hernia repair']","['abdominal wall quality of life', 'healthcare costs', 'emergency department visits, operating room time, wound complications, hernia recurrence, reoperation, abdominal wall quality of life, and costs from the healthcare system perspective', 'operative duration and healthcare costs', 'operative duration', 'number of days in hospital within 90 days after surgery', 'emergency department visits, wound complications, hernia recurrence, or reoperation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0019334', 'cui_str': 'Repair of ventral hernia'}, {'cui': 'C0192579', 'cui_str': 'Incision of intestine'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0019334', 'cui_str': 'Repair of ventral hernia'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}]","[{'cui': 'C0836916', 'cui_str': 'Abdominal wall structure'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0085552', 'cui_str': 'Health Costs'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0018696', 'cui_str': 'Healthcare Systems'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]",,0.631683,"However, robotic repair had longer operative duration (141 v 77 min; mean difference 62.89, 45.75 to 80.01; P≤0.001) and increased healthcare costs ($15 865 (£12 746; €14 125) v $12 955; cost ratio 1.21, 1.07 to 1.38; adjusted absolute cost difference $2767, $910 to $4626; P=0.004).","[{'ForeName': 'Oscar A', 'Initials': 'OA', 'LastName': 'Olavarria', 'Affiliation': 'Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, Houston, TX 77026, USA oscarolavarria@hotmail.com.'}, {'ForeName': 'Karla', 'Initials': 'K', 'LastName': 'Bernardi', 'Affiliation': 'Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, Houston, TX 77026, USA.'}, {'ForeName': 'Shinil K', 'Initials': 'SK', 'LastName': 'Shah', 'Affiliation': 'Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, Houston, TX 77026, USA.'}, {'ForeName': 'Todd D', 'Initials': 'TD', 'LastName': 'Wilson', 'Affiliation': 'Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, Houston, TX 77026, USA.'}, {'ForeName': 'Shuyan', 'Initials': 'S', 'LastName': 'Wei', 'Affiliation': 'Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, Houston, TX 77026, USA.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Pedroza', 'Affiliation': 'Department of Pediatrics, McGovern Medical School at UTHealth, Houston, TX, USA.'}, {'ForeName': 'Elenir B', 'Initials': 'EB', 'LastName': 'Avritscher', 'Affiliation': 'Department of Pediatrics, McGovern Medical School at UTHealth, Houston, TX, USA.'}, {'ForeName': 'Michele M', 'Initials': 'MM', 'LastName': 'Loor', 'Affiliation': 'Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Tien C', 'Initials': 'TC', 'LastName': 'Ko', 'Affiliation': 'Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, Houston, TX 77026, USA.'}, {'ForeName': 'Lillian S', 'Initials': 'LS', 'LastName': 'Kao', 'Affiliation': 'Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, Houston, TX 77026, USA.'}, {'ForeName': 'Mike K', 'Initials': 'MK', 'LastName': 'Liang', 'Affiliation': 'Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, Houston, TX 77026, USA.'}]",BMJ (Clinical research ed.),['10.1136/bmj.m2457'] 1993,32663977,Combined treatment with escitalopram and memantine increases gray matter volume and cortical thickness compared to escitalopram and placebo in a pilot study of geriatric depression.,"BACKGROUND Geriatric depression with subjective cognitive complaints increases the risk of Alzheimer's Disease (AD). Memantine is a cognitive enhancer used to treat AD. In a 6-month double-blind randomized placebo-controlled trial of escitalopram and memantine (ESC/MEM), ESC/MEM improved cognition at 12 month in geriatric depression (NCT01902004). We now investigated structural neuroplastic changes at 3 months. METHODS Forty-one older depressed adults (mean age=70.43, SD=7.33, 26 female) were randomized to receive ESC/MEM or ESC/PBO. Mood scores (Hamilton Depression Rating Scale, HAMD) and high-resolution structural T1-weighted images were acquired at baseline and 3 months. Freesurfer 6.0 for image processing and General Linear Models was used to examine group differences in symmetrized percent change gray matter volume (GMV) and cortical thickness, controlling for age and intracranial volume. Nonparametric tests were used to investigate group differences in mood and subcortical volume change. RESULTS Among 27 completers (ESC/MEM n = 13; ESC/PBO n = 14), 62% achieved remission (HAMD≤6) with ESC/MEM and 43% with ESC/PBO (Fisher's exact p=.45). Change in HAMD did not differ between groups (F(1,23)=0.14, p=.7). GMV and thickness increased more with ESC/MEM than with ESC/PBO in the left middle and inferior temporal lobe, right medial, and lateral orbito-frontal cortex (OFC). LIMITATIONS included small sample size, dropout, and the lack of cognitive data at 3 months. CONCLUSIONS Although significant group differences in mood improvement were not observed, ESC/MEM resulted in increased GMV and cortical thickness in several brain regions compared to placebo. Larger longitudinal clinical trials can further examine the neuroprotective effect of memantine in geriatric depression.",2020,"Although significant group differences in mood improvement were not observed, ESC/MEM resulted in increased GMV and cortical thickness in several brain regions compared to placebo.","['geriatric depression', 'Forty-one older depressed adults (mean age=70.43, SD=7.33, 26 female']","['escitalopram and memantine (ESC/MEM), ESC/MEM', 'ESC/MEM or ESC/PBO', 'memantine', 'Memantine', 'escitalopram and placebo', 'escitalopram and memantine', 'placebo']","['GMV and thickness', 'left middle and inferior temporal lobe, right medial, and lateral orbito-frontal cortex (OFC', 'Change in HAMD', 'Mood scores (Hamilton Depression Rating Scale, HAMD) and high-resolution structural T1-weighted images', 'mood improvement', 'gray matter volume (GMV) and cortical thickness, controlling for age and intracranial volume', 'mood and subcortical volume change', 'GMV and cortical thickness', 'gray matter volume and cortical thickness']","[{'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0344315', 'cui_str': 'Depressed mood'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C1099456', 'cui_str': 'Escitalopram'}, {'cui': 'C0025242', 'cui_str': 'Memantine'}, {'cui': 'C0031962', 'cui_str': 'Piperonyl Butoxide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0039485', 'cui_str': 'Temporal lobe structure'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0016733', 'cui_str': 'Frontal lobe structure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0524466', 'cui_str': 'Intracranial'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",41.0,0.0984536,"Although significant group differences in mood improvement were not observed, ESC/MEM resulted in increased GMV and cortical thickness in several brain regions compared to placebo.","[{'ForeName': 'Beatrix', 'Initials': 'B', 'LastName': 'Krause-Sorio', 'Affiliation': 'Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095, USA. Electronic address: bkrause@ucla.edu.'}, {'ForeName': 'Prabha', 'Initials': 'P', 'LastName': 'Siddarth', 'Affiliation': 'Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095, USA. Electronic address: PSiddarth@mednet.ucla.edu.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Kilpatrick', 'Affiliation': 'Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095, USA. Electronic address: lakilpatrick@mednet.ucla.edu.'}, {'ForeName': 'Kelsey T', 'Initials': 'KT', 'LastName': 'Laird', 'Affiliation': 'Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095, USA.'}, {'ForeName': 'Michaela M', 'Initials': 'MM', 'LastName': 'Milillo', 'Affiliation': 'Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Ercoli', 'Affiliation': 'Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095, USA. Electronic address: LErcoli@mednet.ucla.edu.'}, {'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Narr', 'Affiliation': 'Department of Neurology, 635 Charles E. Young Drive South, Los Angeles, CA 90095, USA. Electronic address: knarr@ucla.edu.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Lavretsky', 'Affiliation': 'Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095, USA. Electronic address: hlavretsky@mednet.ucla.edu.'}]",Journal of affective disorders,['10.1016/j.jad.2020.05.092'] 1994,32687788,Self-Management Training in Chronic Obstructive Lung Disease Improves the Quality of Life.,"OBJECTIVES Management of chronic obstructive pulmonary disease (COPD) includes interventions such as improving skills in coping with the disease. We aimed to examine the effect of self-management training on the quality of life and functional parameters in patients with moderate to severe COPD. MATERIALS AND METHODS Sixty-one consecutive patients with COPD were recruited in the study prospectively. The patients were randomized into two groups: self-management training (n=31) and standard care (n=30). Each patient was evaluated by spirometry, COPD assessment test (CAT), St George's respiratory questionnaire (SGRQ), hospital anxiety and depression scale (HADS), modified British Medical Research Council (mMRC) dyspnea scale, and short form-36 (SF-36). A team of physiotherapists, psychologists, pulmonary disease specialists, and dietitians provided self-management training and biweekly counseling via phone. At the end of three months, both the groups were re-evaluated using the same assessment parameters. RESULTS We found no significant difference between the baseline demographic characteristics of the self-management training and standard care groups. We observed a reduction in CAT (p<0.001), SGRQ impact (p=0.013), activity subscales (p<0.001) and the total scores (p=0.020), and HADS anxiety (p=0.012) and depression (p=0.014) scores in the self-management training group after the education session. A significant increase in SF-36 physical function score was also observed (p=0.008). No significant improvement in the functional parameters was observed in either group; however, the change in FEV1 was more pronounced in the self-management training group than in the control group (p=0.017). The hospital readmissions and 1-year survival rates were similar for both the groups after receiving education (p>0.05). CONCLUSION Our results suggest that the self-management training of the patients with COPD improves the quality of life and reduces the symptoms of depression and anxiety. Therefore, at the least, self-management training should be done as the first step of pulmonary rehabilitation in patients with COPD who cannot access pulmonary rehabilitation facilities.",2020,"The hospital readmissions and 1-year survival rates were similar for both the groups after receiving education (p>0.05). ","['patients with COPD who cannot access pulmonary rehabilitation facilities', 'patients with moderate to severe COPD', 'Sixty-one consecutive patients with COPD were recruited in the study prospectively', 'chronic obstructive pulmonary disease (COPD']","['self-management training', 'self-management training (n=31) and standard care', 'Self-Management Training']","['quality of life', 'hospital readmissions and 1-year survival rates', 'Quality of Life', 'quality of life and functional parameters', 'functional parameters', 'activity subscales', 'reduction in CAT (p<0.001), SGRQ impact', 'SF-36 physical function score', 'symptoms of depression and anxiety', ""spirometry, COPD assessment test (CAT), St George's respiratory questionnaire (SGRQ), hospital anxiety and depression scale (HADS), modified British Medical Research Council (mMRC) dyspnea scale, and short form-36 (SF-36"", 'change in FEV1', 'total scores (p=0.020), and HADS anxiety', 'depression']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C4517832', 'cui_str': '61'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C4284282', 'cui_str': 'COPD assessment test'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0037981', 'cui_str': 'Spirometry'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0079816', 'cui_str': 'Research, Medical'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",61.0,0.0197593,"The hospital readmissions and 1-year survival rates were similar for both the groups after receiving education (p>0.05). ","[{'ForeName': 'Betül Özdel', 'Initials': 'BÖ', 'LastName': 'Öztürk', 'Affiliation': 'Clinic of Pulmonary Diseases, İzzet Baysal State Hospital, Bolu, Turkey.'}, {'ForeName': 'Aylin Özgen', 'Initials': 'AÖ', 'LastName': 'Alpaydın', 'Affiliation': 'Department of Pulmonary Diseases, Dokuz Eylül University School of Medicine, İzmir, Turkey.'}, {'ForeName': 'Sevgi', 'Initials': 'S', 'LastName': 'Özalevli', 'Affiliation': 'Department of Pulmonary Rehabilitation, Dokuz Eylül University, Izmir, Turkey.'}, {'ForeName': 'Nurcan', 'Initials': 'N', 'LastName': 'Güler', 'Affiliation': 'Department of Pulmonary Diseases, Dokuz Eylül University School of Medicine, İzmir, Turkey.'}, {'ForeName': 'Can', 'Initials': 'C', 'LastName': 'Cimilli', 'Affiliation': 'Department of Psychiatry, Dokuz Eylül University School of Medicine, İzmir, Turkey.'}]",Turkish thoracic journal,['10.5152/TurkThoracJ.2019.19015'] 1995,32660769,"Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta® in Healthy Subjects: a Randomized, Double-blind Trial.","PURPOSE MSB11455 is a proposed biosimilar to the reference pegfilgrastim (Neulasta®). This pivotal equivalence study (NCT03251248) assessed the pharmacokinetic and pharmacodynamic equivalence of MSB11455 to the reference product. METHODS This 2-way, 2-sequence, group-sequential, crossover study was conducted in healthy subjects. Subjects received a single subcutaneous dose of MSB11455 or the reference product (both 6 mg/0.6 mL) on Day 1 of each study period. Pharmacokinetic and pharmacodynamic (absolute neutrophil count; ANC) samples were taken predose and up to day 16 post-dose. Non-compartmental parameters were calculated. Immunogenicity samples were taken pre-dose and up to day 84 after the first dose. Safety was assessed throughout the study. FINDINGS A total of 292 subjects were randomized to therapy and treated; 244 received both treatments. For all primary pharmacokinetic and pharmacodynamic parameters, 90% repeated confidence intervals of geometric means ratio of MSB11455 to the reference product were within the pre-defined equivalence range (80.00%-125.00%) for AUC 0-∞ (96.59-112.82); AUC 0-last (97.29-113.96), C max (97.13-114.99), maximum observed effect on ANC (98.74-102.39), and area under the effect-time curve from time zero to time to last quantifiable concentration (97.30-100.23). Safety, tolerability, and immunogenicity were comparable between treatments. No filgrastim-specific neutralizing antibodies were detected with either treatment sequence. IMPLICATIONS Pharmacokinetic and pharmacodynamic equivalence of MSB11455 and the reference product was shown, with comparable immunogenicity, safety, and tolerability between treatments. The study supports the biosimilarity of MSB11455 to the reference product. ClinicalTrials.gov identifier: NCT03251248.",2020,"Safety, tolerability, and immunogenicity were comparable between treatments.","['292 subjects', 'healthy subjects', 'Healthy Subjects']","['MSB11455', 'Pegfilgrastim Biosimilar MSB11455']","['Safety', 'Safety, tolerability, and immunogenicity', 'immunogenicity, safety, and tolerability', 'Immunogenicity samples', 'Pharmacokinetic and pharmacodynamic (absolute neutrophil count; ANC) samples']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C1136535', 'cui_str': 'pegfilgrastim'}, {'cui': 'C4045974', 'cui_str': 'Biosimilars'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0948762', 'cui_str': 'Absolute neutrophil count'}]",292.0,0.056325,"Safety, tolerability, and immunogenicity were comparable between treatments.","[{'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Lickliter', 'Affiliation': 'Nucleus Network, Melbourne, Australia.'}, {'ForeName': 'Radmila', 'Initials': 'R', 'LastName': 'Kanceva', 'Affiliation': 'Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland. Electronic address: Radmila.Kanceva@fresenius-kabi.com.'}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Vincent', 'Affiliation': 'Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Schueler', 'Affiliation': 'Biostatistics, Merck Healthcare, Darmstadt, Germany.'}, {'ForeName': 'Eleanor', 'Initials': 'E', 'LastName': 'Harrison-Moench', 'Affiliation': 'Quantitative Pharmacology, Merck Healthcare, Darmstadt, Germany.'}, {'ForeName': 'Corinne Seng', 'Initials': 'CS', 'LastName': 'Yue', 'Affiliation': 'Learn and Confirm, Inc., St-Laurent, Québec, Canada.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Stahl', 'Affiliation': 'Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Ullmann', 'Affiliation': 'Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland.'}, {'ForeName': 'Vishal', 'Initials': 'V', 'LastName': 'Ghori', 'Affiliation': 'Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Griffin', 'Affiliation': 'School of Medicine, University of Queensland, Brisbane, Australia; Department of Medicine and Infectious Diseases, Mater Hospital and Mater Medical Research Institute, Brisbane, Queensland, Australia.'}]",Clinical therapeutics,['10.1016/j.clinthera.2020.05.020'] 1996,32661681,Effects of hesperidin in orange juice on blood and pulse pressures in mildly hypertensive individuals: a randomized controlled trial (Citrus study).,"PURPOSE To assess the sustained and acute effects, as well as the influence of sustained consumption on the acute effects, of orange juice (OJ) with a natural hesperidin content and hesperidin-enriched OJ (EOJ) on blood (BP) and pulse (PP) pressures in pre- and stage-1 hypertensive individuals. METHODS In a randomized, parallel, double-blind, placebo-controlled trial, participants (n = 159) received 500 mL/day of control drink, OJ, or EOJ for 12 weeks. Two dose-response studies were performed at baseline and after 12 weeks. RESULTS A single EOJ dose (500 mL) reduced systolic BP (SBP) and PP, with greater changes after sustained treatment where a decrease in diastolic BP (DBP) also occurred (P < 0.05). SBP and PP decreased in a dose-dependent manner relative to the hesperidin content of the beverages throughout the 12 weeks (P < 0.05). OJ and EOJ decreased homocysteine levels at 12 weeks versus the control drink (P < 0.05). After 12 weeks of EOJ consumption, four genes related to hypertension (PTX3, NLRP3, NPSR1 and NAMPT) were differentially expressed in peripheral blood mononuclear cells (P < 0.05). CONCLUSION Hesperidin in OJ reduces SBP and PP after sustained consumption, and after a single dose, the chronic consumption of EOJ enhances its postprandial effect. Decreases in systemic and transcriptomic biomarkers were concomitant with BP and PP changes. EOJ could be a useful co-adjuvant tool for BP and PP management in pre- and stage-1 hypertensive individuals.",2020,OJ and EOJ decreased homocysteine levels at 12 weeks versus the control drink (P < 0.05).,"['mildly hypertensive individuals', 'participants (n\u2009=\u2009159) received', 'pre- and stage-1 hypertensive individuals']","['500\xa0mL/day of control drink, OJ, or EOJ', 'EOJ', 'orange juice (OJ) with a natural hesperidin content and hesperidin-enriched OJ (EOJ', 'hesperidin', 'placebo']","['OJ and EOJ decreased homocysteine levels', 'hypertension (PTX3, NLRP3, NPSR1 and NAMPT', 'peripheral blood mononuclear cells', 'systemic and transcriptomic biomarkers', 'diastolic BP (DBP', 'reduced systolic BP (SBP) and PP', 'blood and pulse pressures', 'blood (BP) and pulse (PP) pressures', 'SBP and PP']","[{'cui': 'C2945599', 'cui_str': 'Mild'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}]","[{'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0439446', 'cui_str': 'mL/24h'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0452458', 'cui_str': 'Orange juice'}, {'cui': 'C0205296', 'cui_str': 'Natural'}, {'cui': 'C0019392', 'cui_str': 'Hesperidin'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0452458', 'cui_str': 'Orange juice'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C2242817', 'cui_str': 'Homocysteine measurement'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C1571622', 'cui_str': 'nicotinamide phosphoribosyltransferase, human'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0949236', 'cui_str': 'Pulse Pressure'}]",,0.134296,OJ and EOJ decreased homocysteine levels at 12 weeks versus the control drink (P < 0.05).,"[{'ForeName': 'Rosa M', 'Initials': 'RM', 'LastName': 'Valls', 'Affiliation': 'Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Universitat Rovira i Virgili, Facultat de Medicina i Ciències de La Salut, Reus, Spain.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Pedret', 'Affiliation': 'Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Universitat Rovira i Virgili, Facultat de Medicina i Ciències de La Salut, Reus, Spain. anna.pedret@eurecat.org.'}, {'ForeName': 'Lorena', 'Initials': 'L', 'LastName': 'Calderón-Pérez', 'Affiliation': 'Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Universitat Rovira i Virgili, Facultat de Medicina i Ciències de La Salut, Reus, Spain.'}, {'ForeName': 'Elisabet', 'Initials': 'E', 'LastName': 'Llauradó', 'Affiliation': 'Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Universitat Rovira i Virgili, Facultat de Medicina i Ciències de La Salut, Reus, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Pla-Pagà', 'Affiliation': 'Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Universitat Rovira i Virgili, Facultat de Medicina i Ciències de La Salut, Reus, Spain.'}, {'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Companys', 'Affiliation': 'Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Universitat Rovira i Virgili, Facultat de Medicina i Ciències de La Salut, Reus, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Moragas', 'Affiliation': 'Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Martín-Luján', 'Affiliation': 'Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain.'}, {'ForeName': 'Yolanda', 'Initials': 'Y', 'LastName': 'Ortega', 'Affiliation': ""Institut Universitari d'Investigació en Atenció Primària-IDIAP Jordi Gol, Tarragona, Spain.""}, {'ForeName': 'Montse', 'Initials': 'M', 'LastName': 'Giralt', 'Affiliation': 'Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Universitat Rovira i Virgili, Facultat de Medicina i Ciències de La Salut, Reus, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Romeu', 'Affiliation': 'Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Universitat Rovira i Virgili, Facultat de Medicina i Ciències de La Salut, Reus, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Rubió', 'Affiliation': 'Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Universitat Rovira i Virgili, Facultat de Medicina i Ciències de La Salut, Reus, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Mayneris-Perxachs', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Av. de La Universitat, 1, 43204, Reus, Spain.'}, {'ForeName': 'Núria', 'Initials': 'N', 'LastName': 'Canela', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Centre for Omic Sciences, Reus, Spain.'}, {'ForeName': 'Francesc', 'Initials': 'F', 'LastName': 'Puiggrós', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Av. de La Universitat, 1, 43204, Reus, Spain.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Caimari', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Av. de La Universitat, 1, 43204, Reus, Spain.'}, {'ForeName': 'Josep M', 'Initials': 'JM', 'LastName': 'Del Bas', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Av. de La Universitat, 1, 43204, Reus, Spain.'}, {'ForeName': 'Lluís', 'Initials': 'L', 'LastName': 'Arola', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Av. de La Universitat, 1, 43204, Reus, Spain.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Solà', 'Affiliation': 'Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Universitat Rovira i Virgili, Facultat de Medicina i Ciències de La Salut, Reus, Spain.'}]",European journal of nutrition,['10.1007/s00394-020-02279-0'] 1997,32687588,Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial.,"Importance Fluorouracil-based chemotherapy combined with anti-epidermal growth factor receptor/vascular endothelial growth factor therapy is the standard first-line treatment for metastatic colorectal cancer followed by low-intensity maintenance therapy to balance the clinical efficacy and adverse effects (AEs). However, there have been concerns about the AEs of capecitabine plus cetuximab as a maintenance therapy in patients with RAS wild-type metastatic colorectal cancer. Objective To evaluate the biological activity and safety of capecitabine plus cetuximab as a novel maintenance therapy for RAS wild-type metastatic colorectal cancer. Design, Setting, and Participants This phase 2 prospective clinical trial was conducted from April 29, 2016, to April 29, 2019, at 5 centers in China. Patients diagnosed as having RAS wild-type metastatic colorectal cancer were recruited to receive fluorouracil-based cytotoxic agents combined with cetuximab followed by capecitabine plus cetuximab for maintenance therapy. Forty-seven patients with histologically confirmed metastatic colorectal cancer and genetic test results showing a wild-type RAS were enrolled in maintenance therapy. Interventions Induction therapy for patients with RAS wild-type metastatic colorectal cancer was 8 to 12 cycles of fluorouracil-based chemotherapy combined with cetuximab. After stable disease status or better was achieved, reduced-dose capecitabine plus cetuximab was administered for maintenance therapy. Main Outcomes and Measures The primary end point was progression-free survival during maintenance therapy. The secondary end points were total progression-free survival, overall survival, quality of life, safety, and toxic effects of treatment. Results Forty-seven patients were enrolled in maintenance therapy, with a median age of 52 years (range, 25-81 years) and 32 (68%) of them being men. The median maintenance progression-free survival was 7.2 (95% CI, 5.8-8.6) months. The median progression-free survival was 12.7 (95% CI, 11.8-15.4) months. The median overall survival was 27.4 (95% CI, 21.4-35.5) months. Grade 3 to 4 AEs during induction therapy included neutropenia (4 patients [9%]), diarrhea (4 patients [9%]), nausea or vomiting (3 patients [6%]), rash acneiform (10 patients [21%]), and hand-foot syndrome (8 patients [17%]). Grade 3 to 4 AEs during maintenance therapy included diarrhea (2 patients [4%]), rash acneiform (8 patients [17%]), and hand-foot syndrome (5 patients [11%]). Conclusions and Relevance Reduced-dose capecitabine plus cetuximab after initial chemotherapy is a novel maintenance therapy for patients with RAS wild-type metastatic colorectal cancer that achieved good outcomes and tolerable nonserious AEs. Trial Registration ClinicalTrials.gov Identifier: NCT02717923.",2020,"The median maintenance progression-free survival was 7.2 (95% CI, 5.8-8.6) months.","['RAS wild-type metastatic colorectal cancer', 'Forty-seven patients with histologically confirmed metastatic colorectal cancer and genetic test results showing a wild-type RAS were enrolled in maintenance therapy', 'April 29, 2016, to April 29, 2019, at 5 centers in China', 'RAS Wild-Type Metastatic Colorectal Cancer', 'Results\n\n\nForty-seven patients were enrolled in maintenance therapy, with a median age of 52 years (range, 25-81 years) and 32 (68%) of them being men', 'Patients diagnosed as having RAS wild-type metastatic colorectal cancer', 'patients with RAS wild-type metastatic colorectal cancer']","['fluorouracil-based cytotoxic agents combined with cetuximab followed by capecitabine plus cetuximab', 'fluorouracil-based chemotherapy combined with cetuximab', 'Reduced-Dose Capecitabine Plus Cetuximab', 'Fluorouracil-based chemotherapy combined with anti-epidermal growth factor receptor/vascular endothelial growth factor therapy', 'capecitabine plus cetuximab', 'Interventions\n\n\nInduction therapy']","['diarrhea', 'median progression-free survival', 'neutropenia', 'progression-free survival', 'nausea or vomiting', 'total progression-free survival, overall survival, quality of life, safety, and toxic effects of treatment', 'median overall survival', 'median maintenance progression-free survival', 'rash acneiform']","[{'cui': 'C0445392', 'cui_str': 'Wild'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0679560', 'cui_str': 'Genetic test'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}]","[{'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0010868', 'cui_str': 'Cytotoxin'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0995188', 'cui_str': 'cetuximab'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0175167', 'cui_str': 'Acneiform eruption'}]",47.0,0.0582028,"The median maintenance progression-free survival was 7.2 (95% CI, 5.8-8.6) months.","[{'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Medical Oncology of Zhengzhou University Affiliated Cancer Hospital, Henan Cancer Hospital, Zhengzhou, Henan, China.'}, {'ForeName': 'Xianli', 'Initials': 'X', 'LastName': 'Yin', 'Affiliation': 'Gastroenterology and Urology Department, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Weijia', 'Initials': 'W', 'LastName': 'Fang', 'Affiliation': 'Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.'}, {'ForeName': 'Jianping', 'Initials': 'J', 'LastName': 'Xiong', 'Affiliation': 'Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Zhao', 'Affiliation': 'Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'ForeName': 'Mingsheng', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'ForeName': 'Yanmei', 'Initials': 'Y', 'LastName': 'Zou', 'Affiliation': 'Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Qiu', 'Affiliation': 'Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'ForeName': 'Xianglin', 'Initials': 'X', 'LastName': 'Yuan', 'Affiliation': 'Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.'}]",JAMA network open,['10.1001/jamanetworkopen.2020.11036'] 1998,32664987,"Effectiveness of the baby-friendly community initiative in promoting exclusive breastfeeding among HIV negative and positive mothers: a randomized controlled trial in Koibatek Sub-County, Baringo, Kenya.","BACKGROUND Although the baby-friendly community initiative (BFCI) has been proposed as a community-level approach to improve infant feeding practices, there is little data on its variation in effectiveness by HIV status. We conducted a study to determine the effectiveness of BFCI in changing knowledge and attitudes towards exclusive breastfeeding (EBF) and increasing the rates among HIV negative and HIV positive women in rural Kenya. METHODS A community-based cluster-randomized controlled trial was implemented from April 2015 to December 2016 among 901 women enrolled across 13 clusters. The intervention groups received a minimum of 12 personalized home-based counselling sessions on infant feeding by trained community health volunteers from their first or second trimester of pregnancy until 6 months postpartum. Other interventions included education sessions at maternal child clinics, mother-to-mother support group meetings and bi-monthly baby-friendly gatherings targeting influencers. The control group received standard health education at the facility and during monthly routine home visits by community health volunteers not trained on BFCI. Primary outcome measures were the rates of EBF at week 1, months 2, 4 and 6 postpartum. Secondary outcomes included knowledge and attitudes regarding breastfeeding for HIV-exposed infants. Statistical methods included analysis of covariance and logistic regression. RESULTS At 6 months, EBF rates among HIV negative mothers were significantly higher in the BFCI intervention arm compared to the control arm (81.7% versus 42.2% p = 0.001). HIV positive mothers in the intervention arm had higher EBF rates at 6 months than the control but the difference was not statistically significant (81.8% versus 58.4%; p = 0.504). In HIV negative group, there was greater knowledge regarding EBF for HIV-exposed infants in the intervention arm than in the control (92.1% versus 60.7% p = 0.001). Among HIV positive mothers, such knowledge was high among both the intervention and control groups (96% versus 100%, p > 0.1). HIV negative and positive mothers in the intervention arm had more favourable attitudes regarding EBF for HIV-exposed infants than the control (84.5% versus 62.1%, p = 0.001) and (94.6% versus 53.8% to p = 0.001) respectively. CONCLUSIONS BFCI interventions can complement facility-based interventions to improve exclusive and continued breastfeeding knowledge, attitudes, and behaviours among HIV negative and positive women.",2020,HIV positive mothers in the intervention arm had higher EBF rates at 6 months than the control but the difference was not statistically significant (81.8% versus 58.4%; p = 0.504).,"['HIV negative and positive mothers', 'A community-based cluster-randomized controlled trial was implemented from April 2015 to December 2016 among 901 women enrolled across 13 clusters', 'HIV negative and HIV positive women in rural Kenya']","['minimum of 12 personalized home-based counselling sessions', 'BFCI', 'standard health education at the facility and during monthly routine home visits by community health volunteers\xa0not trained on BFCI', 'education sessions at maternal child clinics, mother-to-mother support group meetings and bi-monthly baby-friendly gatherings targeting influencers', 'baby-friendly community initiative']","['rates of EBF', 'knowledge regarding EBF', 'EBF rates', 'knowledge and attitudes regarding breastfeeding for HIV-exposed infants']","[{'cui': 'C0481430', 'cui_str': 'HIV negative'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0019699', 'cui_str': 'HIV positive'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0036606', 'cui_str': 'Support Groups'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}]","[{'cui': 'C0242205', 'cui_str': 'Breastfeeding, Exclusive'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]",901.0,0.0667188,HIV positive mothers in the intervention arm had higher EBF rates at 6 months than the control but the difference was not statistically significant (81.8% versus 58.4%; p = 0.504).,"[{'ForeName': 'Betty Mogesi', 'Initials': 'BM', 'LastName': 'Samburu', 'Affiliation': 'Formerly Division of Nutrition and Dietetics, Ministry of Health in Kenya, Nairobi, Kenya. betsamburu@gmail.com.'}, {'ForeName': 'Sera Lewise', 'Initials': 'SL', 'LastName': 'Young', 'Affiliation': 'Institute of Policy Research, Northwestern University, Evanston, USA.'}, {'ForeName': 'Frederick Murunga', 'Initials': 'FM', 'LastName': 'Wekesah', 'Affiliation': 'Maternal and Child Wellbeing Unit, African Population and Health Research Center, Nairobi, Kenya.'}, {'ForeName': 'Milkah Njeri', 'Initials': 'MN', 'LastName': 'Wanjohi', 'Affiliation': 'Maternal and Child Wellbeing Unit, African Population and Health Research Center, Nairobi, Kenya.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Kimiywe', 'Affiliation': 'Department of Foods, Nutrition and Dietetics, Kenyatta University, Nairobi, Kenya.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Muriuki', 'Affiliation': 'Maternal and Child Wellbeing Unit, African Population and Health Research Center, Nairobi, Kenya.'}, {'ForeName': 'Paula L', 'Initials': 'PL', 'LastName': 'Griffiths', 'Affiliation': 'School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.'}, {'ForeName': 'Stephen T', 'Initials': 'ST', 'LastName': 'McGarvey', 'Affiliation': 'International Health Institute, Brown University School of Public Health, Providence, USA.'}, {'ForeName': 'Nyovani Janet', 'Initials': 'NJ', 'LastName': 'Madise', 'Affiliation': 'African Institute for Development Policy, Lilongwe, Malawi.'}, {'ForeName': 'Elizabeth W', 'Initials': 'EW', 'LastName': 'Kimani-Murage', 'Affiliation': 'Maternal and Child Wellbeing Unit, African Population and Health Research Center, Nairobi, Kenya.'}]",International breastfeeding journal,['10.1186/s13006-020-00299-4'] 1999,32663102,Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium versus tiotropium: the RED trial.,"BACKGROUND Exertional dyspnea is a cardinal feature of chronic obstructive pulmonary disease (COPD) and a major cause of activity limitation. Although dual bronchodilation is more effective than bronchodilator monotherapy at improving resting pulmonary function, it is unclear to which extent this translates into superior relief of exertional dyspnea. METHODS We conducted a randomized controlled, double-blind, cross-over trial comparing indacaterol 110 µg/glycopyrronium 50 µg once daily (OD) with tiotropium 50 µg OD in patients with moderate to severe COPD and resting hyperinflation (functional residual capacity >120% of predicted value). The primary outcome was Borg dyspnea score at the end of a 3-min constant speed shuttle test after 3 weeks of treatment. Secondary outcomes included changes in Borg dyspnea score after the first dose of study medication, expiratory flows and lung volumes. Statistical analysis was conducted using a cross-over analysis of variance model with repeated measurements. RESULTS A total of 50 patients with COPD and a mean forced expiratory volume in 1 s of 54 ± 11% (mean ± SEM) predicted participated in the cross-over phase of the trial. Compared with baseline, there was a decrease in dyspnea after the first dose of medication with indacaterol/glycopyrronium [mean -1.00, 95% confidence interval (CI) -1.49 to -0.52] but not with tiotropium alone (mean -0.36, 95% CI -0.81 to 0.08). The reduction in dyspnea after the first dose was statistically significant between the two treatments (mean difference of -0.64, 95% CI -1.11 to -0.17). Despite indacaterol/glycopyrronium providing further bronchodilation and lung deflation throughout the trial, the reduction in dyspnea was not sustained at 3 weeks of treatment (mean between-treatment difference at 3 weeks of 0.09, 95% CI -0.44 to 0.61). CONCLUSION In comparison with bronchodilator monotherapy, indacaterol/glycopyrronium provided greater immediate exertional dyspnea relief, although this difference was not sustained after 3 weeks of therapy despite evidence of further bronchodilation and lung deflation. The reviews of this paper are available via the supplemental material section.",2020,"The reduction in dyspnea after the first dose was statistically significant between the two treatments (mean difference of -0.64, 95% CI -1.11 to -0.17).","['patients with moderate to severe COPD and resting hyperinflation (functional residual capacity >120% of predicted value', '50 patients with COPD and a mean forced expiratory volume in 1\u2009s of 54\u2009±\u200911% (mean\u2009±\u2009SEM) predicted participated in the cross-over phase of the trial', 'patients with COPD with']","['indacaterol/glycopyrronium versus tiotropium', 'bronchodilator monotherapy, indacaterol/glycopyrronium', 'indacaterol 110\u2009µg/glycopyrronium 50\u2009µg once daily (OD) with tiotropium', 'tiotropium']","['changes in Borg dyspnea score after the first dose of study medication, expiratory flows and lung volumes', 'reduction in dyspnea', 'Borg dyspnea score', 'Relieving exertional dyspnea', 'bronchodilation and lung deflation', 'immediate exertional dyspnea relief', 'dyspnea']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0020449', 'cui_str': 'Hyperdistention'}, {'cui': 'C0016815', 'cui_str': 'Functional residual capacity'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0262878', 'cui_str': 'Scanning electron microscope'}, {'cui': 'C0010366', 'cui_str': 'Genetic crossing over'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C1722260', 'cui_str': 'indacaterol'}, {'cui': 'C3814772', 'cui_str': 'glycopyrronium'}, {'cui': 'C0213771', 'cui_str': 'tiotropium'}, {'cui': 'C0006280', 'cui_str': 'Bronchodilator agent'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0231953', 'cui_str': 'Lung volume'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0332303', 'cui_str': 'Relieved by'}, {'cui': 'C0231807', 'cui_str': 'Dyspnea on exertion'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}]",50.0,0.452807,"The reduction in dyspnea after the first dose was statistically significant between the two treatments (mean difference of -0.64, 95% CI -1.11 to -0.17).","[{'ForeName': 'Jessie', 'Initials': 'J', 'LastName': 'Beaulieu', 'Affiliation': 'Centre de recherche, Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval, Québec, QC, Canada.'}, {'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'Jensen', 'Affiliation': 'Clinical Exercise and Respiratory Physiology Laboratory, Department of Kinesiology and Physical Education, Faculty of Education, McGill University, Montréal, QC, Canada.'}, {'ForeName': 'Denis E', 'Initials': 'DE', 'LastName': ""O'Donnell"", 'Affiliation': ""Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.""}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Brouillard', 'Affiliation': 'Centre de recherche, Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval, Québec, QC, Canada.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Tracey', 'Affiliation': 'Clinical Exercise and Respiratory Physiology Laboratory, Department of Kinesiology and Physical Education, Faculty of Education, McGill University, Montréal, QC, Canada.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Vincent', 'Affiliation': ""Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.""}, {'ForeName': 'Éric', 'Initials': 'É', 'LastName': 'Nadreau', 'Affiliation': 'Centre de recherche, Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval, Québec, QC, Canada.'}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Bernard', 'Affiliation': 'Centre de recherche, Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval, Québec, QC, Canada.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Bernard', 'Affiliation': 'Centre de recherche, Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval, Québec, QC, Canada.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Maltais', 'Affiliation': 'Centre de pneumologie, Institut universitaire de cardiologie et de pneumologie de Québec, 2725 chemin Ste-Foy, QC G1V 4G5, Canada.'}]",Therapeutic advances in respiratory disease,['10.1177/1753466620939507'] 2000,32664047,"Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.",,2014,,['patients receiving high-dose'],"['cisplatin', 'single-dose fosaprepitant', 'placebo']","['nausea and vomiting', 'Efficacy and safety']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444956', 'cui_str': 'High dose'}]","[{'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C2349941', 'cui_str': 'fosaprepitant'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.638118,,[],Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdt534'] 2001,32669161,[Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial].,"OBJECTIVE To compare the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants. METHODS A total of 98 preterm infants with a gestational age of 28 - <34 weeks between April 2018 and December 2019 were enrolled. They were randomly administered with domestic (n=48) or imported caffeine citrate (n=50) within 6 hours after birth. The therapeutic effects, complications, adverse effects and clinical outcomes were compared between the two groups. RESULTS There were no significant differences in the incidence of apnea within 7 days after birth, daily frequency of apnea, the time of apnea disappearance, the failure rate of intubation-surfactant-extubation strategy, the time of non-invasive assisted ventilation, the duration of oxygen therapy, the duration of caffeine citrate therapy, the length of hospital stay, blood gas analysis results, liver and kidney function testing results between the two groups (P>0.05). There were no significant differences in the incidence of complications and the mortality rate between the two groups (P>0.05). There was no significant difference in the incidence of adverse effects between the two groups (P>0.05). CONCLUSIONS The efficacy and safety of domestic caffeine citrate in the treatment of apnea are similar to those of imported caffeine citrate in preterm infants.",2020,The efficacy and safety of domestic caffeine citrate in the treatment of apnea are similar to those of imported caffeine citrate in preterm infants.,"['98 preterm infants with a gestational age of 28\u2009-\u2009<34 weeks between April 2018 and December 2019 were enrolled', 'apnea in preterm infants', 'preterm infants']","['domestic caffeine citrate', 'domestic (n=48) or imported caffeine citrate', 'domestic and imported caffeine citrate']","['incidence of apnea within 7 days after birth, daily frequency of apnea, the time of apnea disappearance, the failure rate of intubation-surfactant-extubation strategy, the time of non-invasive assisted ventilation, the duration of oxygen therapy, the duration of caffeine citrate therapy, the length of hospital stay, blood gas analysis results, liver and kidney function testing results', 'incidence of adverse effects', 'therapeutic effects, complications, adverse effects and clinical outcomes', 'incidence of complications and the mortality rate']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}]","[{'cui': 'C0003063', 'cui_str': 'Domestic Animals'}, {'cui': 'C0054436', 'cui_str': 'Caffeine citrate'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0034085', 'cui_str': 'Lung surfactant'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0554804', 'cui_str': 'Assisted breathing'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}, {'cui': 'C0054436', 'cui_str': 'Caffeine citrate'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0005800', 'cui_str': 'Blood gas analysis'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0232804', 'cui_str': 'Renal function'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",98.0,0.0280981,The efficacy and safety of domestic caffeine citrate in the treatment of apnea are similar to those of imported caffeine citrate in preterm infants.,"[{'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'He', 'Affiliation': 'Department of Neonatology, Xiangya Hospital, Central South University, Changsha 410008, China. shaojieyue@163.com.'}, {'ForeName': 'Zheng-Chang', 'Initials': 'ZC', 'LastName': 'Liao', 'Affiliation': ''}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': ''}, {'ForeName': 'Ming-Jie', 'Initials': 'MJ', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Ji-Min', 'Initials': 'JM', 'LastName': 'Gan', 'Affiliation': ''}, {'ForeName': 'Shao-Jie', 'Initials': 'SJ', 'LastName': 'Yue', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 2002,32672570,Outcomes of the Shunt Tube Exposure Prevention Study: A Randomized Clinical Trial.,"PURPOSE To compare the long-term safety and efficacy of amniotic membrane-umbilical cord (AM-UC) and pericardium patch grafts in reducing glaucoma shunt tube exposure. DESIGN Multicenter, prospective, randomized clinical trial. PARTICIPANTS Adults with uncontrolled glaucoma undergoing glaucoma drainage device (GDD) implantation. METHODS Patients were randomized to receive GDD with either AM-UC or pericardium patch grafts to cover GDD tubes. Patients were followed up clinically with anterior segment (AS) OCT to assess patch graft stability and host-tissue integration prospectively. MAIN OUTCOME MEASURES Tube exposure, graft thinning, and graft-related complications. RESULTS A total of 81 eyes of 81 patients (50 women, 31 men) with a mean age of 67±13 years underwent GGD implantation using Baerveldt (n = 72) or Ahmed valve (n = 9). Tubes were inserted in the anterior chamber (n = 71), sulcus (n = 6), or pars plana (n = 4). Tube ligation was performed with Baerveldt GDD along with fenestration (n = 51) or orphan trabeculectomy (n = 21). Tubes were covered with AM-UC (n = 41) or pericardium (n = 40). The mean follow-up time was 29±8 months (range, 13-40 months). Tube exposure occurred in 1 eye (2%) in the AM-UC group at 3 months and in 2 eyes (5%) in the pericardium group at 2 and 6 months (P = 0.54). Sequential AS OCT showed better host-tissue integration and significantly less graft thinning in the AM-UC group. Early graft thinning (≤3 months) occurred in 5 eyes (12%) in the AM-UC group and in 17 eyes (43%) in the pericardium group (P = 0.002). Late thinning occurred in 2 eyes (5%) and 11 eyes (28%) in the AM-UC and pericardium groups, respectively (P = 0.007). Graft translucency and cosmetic appearance of the AM-UC graft were superior to those of the pericardium graft. No evidence of graft rejection or infection was associated with the patch grafts in either group. CONCLUSIONS Amniotic membrane-umbilical cord grafts are well tolerated and offer an alternative to pericardium for safe and stable tube shunt coverage. Its high-tensile strength, low immunogenicity, and excellent host-tissue integration significantly reduced graft thinning.",2019,Graft translucency and cosmetic appearance of the AM-UC graft were superior to those of the pericardium graft.,"['Adults with uncontrolled glaucoma undergoing glaucoma drainage device (GDD) implantation', 'Patients', 'A total of 81 eyes of 81 patients (50 women, 31 men) with a mean age of 67±13 years underwent GGD implantation using Baerveldt (n\xa0= 72) or Ahmed valve (n']","['amniotic membrane-umbilical cord (AM-UC) and pericardium patch grafts', 'AM-UC', 'Tube ligation was performed with Baerveldt GDD along with fenestration (n\xa0= 51) or orphan trabeculectomy', 'GDD with either AM-UC or pericardium patch grafts to cover GDD tubes']","['graft rejection or infection', 'Tube exposure, graft thinning, and graft-related complications', 'graft thinning', 'Tube exposure', 'Early graft thinning', 'host-tissue integration', 'Late thinning', 'Graft translucency and cosmetic appearance']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0181041', 'cui_str': 'Glaucoma drainage device'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}]","[{'cui': 'C0002630', 'cui_str': 'Structure of amnion'}, {'cui': 'C0041633', 'cui_str': 'Umbilical cord structure'}, {'cui': 'C0031050', 'cui_str': 'Pericardial sac structure'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0023690', 'cui_str': 'Ligation'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0181041', 'cui_str': 'Glaucoma drainage device'}, {'cui': 'C0015825', 'cui_str': 'Inner ear fenestration'}, {'cui': 'C0242299', 'cui_str': 'Orphan'}, {'cui': 'C0040574', 'cui_str': 'Trabeculoplasty'}, {'cui': 'C0439844', 'cui_str': 'Covered'}]","[{'cui': 'C0018129', 'cui_str': 'Graft rejection'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0522503', 'cui_str': 'Translucent'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}]",81.0,0.0452362,Graft translucency and cosmetic appearance of the AM-UC graft were superior to those of the pericardium graft.,"[{'ForeName': 'Hosam', 'Initials': 'H', 'LastName': 'Sheha', 'Affiliation': 'Department of Ophthalmology, Manhattan Eye, Ear & Throat Hospital, New York, New York; Hofstra Northwell Zucker School of Medicine, Hempstead, New York; Herbert Wertheim College of Medicine, Florida International University, Miami, Florida. Electronic address: hsheha@northwell.edu.'}, {'ForeName': 'Celso', 'Initials': 'C', 'LastName': 'Tello', 'Affiliation': 'Department of Ophthalmology, Manhattan Eye, Ear & Throat Hospital, New York, New York; Hofstra Northwell Zucker School of Medicine, Hempstead, New York.'}, {'ForeName': 'Lama A', 'Initials': 'LA', 'LastName': 'Al-Aswad', 'Affiliation': 'Harkness Eye Institute, Columbia University, New York, New York.'}, {'ForeName': 'Mohamed S', 'Initials': 'MS', 'LastName': 'Sayed', 'Affiliation': 'Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Richard K', 'Initials': 'RK', 'LastName': 'Lee', 'Affiliation': 'Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida. Electronic address: rlee@med.miami.edu.'}]",Ophthalmology. Glaucoma,['10.1016/j.ogla.2019.08.003'] 2003,32667923,WaSH CQI: Applying continuous quality improvement methods to water service delivery in four districts of rural northern Ghana.,"Continuous, safely managed water is critical to health and development, but rural service delivery faces complex challenges in low- and middle-income countries (LMICs). We report the first application of continuous quality improvement (CQI) methods to improve the microbial quality of household water for consumption (HWC) and the functionality of water sources in four rural districts of northern Ghana. We further report on the impacts of interventions developed through these methods. A local CQI team was formed and trained in CQI methods. Baseline data were collected and analyzed to identify determinants of service delivery problems and microbial safety. The CQI team randomized communities, developed an improvement package, iteratively piloted it in intervention communities, and used uptake survey data to refine the package. The final improvement package comprised safe water storage containers, refresher training for community WaSH committees and replacement of missing maintenance tools. This package significantly reduced contamination of HWC (p<0.01), and significant reduction in contamination persisted two years after implementation. Repair times in both intervention and control arms decreased relative to baseline (p<0.05), but differences between intervention and control arms were not significant at endline. Further work is needed to build on the gains in household water quality observed in this work, sustain and scale these improvements, and explore applications of CQI to other aspects of water supply and sanitation.",2020,"This package significantly reduced contamination of HWC (p<0.01), and significant reduction in contamination persisted two years after implementation.","['four rural districts of northern Ghana', 'four districts of rural northern Ghana']","['WaSH CQI', 'continuous quality improvement (CQI']","['Repair times', 'microbial quality of household water for consumption (HWC', 'contamination of HWC']","[{'cui': 'C0017516', 'cui_str': 'Ghana'}]","[{'cui': 'C1547959', 'cui_str': 'Wash'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C2936612', 'cui_str': 'Quality Improvement'}]","[{'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]",4.0,0.0294095,"This package significantly reduced contamination of HWC (p<0.01), and significant reduction in contamination persisted two years after implementation.","[{'ForeName': 'Michael B', 'Initials': 'MB', 'LastName': 'Fisher', 'Affiliation': 'Department of Environmental Sciences and Engineering, The Water Institute at UNC, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.'}, {'ForeName': 'Leslie', 'Initials': 'L', 'LastName': 'Danquah', 'Affiliation': 'School of Geosciences, University of Energy and Natural Resources, Sunyani, Ghana.'}, {'ForeName': 'Zakaria', 'Initials': 'Z', 'LastName': 'Seidu', 'Affiliation': 'West African Centre for Cell Biology of Infectious Pathogens, University of Ghana, Legon, Ghana.'}, {'ForeName': 'Allison N', 'Initials': 'AN', 'LastName': 'Fechter', 'Affiliation': 'The Water Project, Concord, NH, United States of America.'}, {'ForeName': 'Bansaga', 'Initials': 'B', 'LastName': 'Saga', 'Affiliation': 'Solidarites International, Clichy, France.'}, {'ForeName': 'Jamie K', 'Initials': 'JK', 'LastName': 'Bartram', 'Affiliation': 'Department of Environmental Sciences and Engineering, The Water Institute at UNC, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.'}, {'ForeName': 'Kaida M', 'Initials': 'KM', 'LastName': 'Liang', 'Affiliation': 'Department of Environmental Sciences and Engineering, The Water Institute at UNC, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.'}, {'ForeName': 'Rohit', 'Initials': 'R', 'LastName': 'Ramaswamy', 'Affiliation': 'Public Health Leadership Program, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, United States of America.'}]",PloS one,['10.1371/journal.pone.0233679'] 2004,32668323,A randomized controlled trial of lung ultrasound-guided therapy in heart failure (CLUSTER-HF study).,"BACKGROUND Lung ultrasound (LUS) has emerged as a new tool for the evaluation of congestion in heart failure (HF); incorporation of LUS during follow-up may detect congestion earlier and prompt interventions to prevent hospitalizations. The aim of this study was to test the hypothesis that the incorporation of LUS during follow-up of patients with HF may reduce the rate of adverse events compared with usual care. METHODS In this single-blinded, randomized controlled trial, patients were randomized into an LUS-guided arm or control arm. Patients were followed in 4 prespecified visits during a 6-month period. LUS was performed in every patient visit in both groups; however, LUS results were available for the treating physician only in the LUS group. The primary outcome was the composite of urgent HF visits, rehospitalization for worsening HF, and death from any cause. RESULTS One hundred twenty-six patients were randomized to either LUS (n = 63) or control (n = 63) (age 62.5 ± 10 years, median left ventricular ejection fraction 31%). The primary end point occurred in 30 (47.6%) patients in the control group and 20 (31.7%) patients in the LUS group (P = .041). LUS-guided treatment was associated with a 45% risk reduction in the primary end point (hazard ratio 0.55, 95% CI 0.31-0.98, P = .044), mainly driven by a reduction in urgent HF visits (hazard ratio 0.28, 95% CI 0.13-0.62, P = .001). No significant differences in rehospitalizations for HF or death were found. CONCLUSIONS Incorporation of LUS into clinical follow-up of patients with HF significantly reduced the risk of urgent visits for worsening HF.",2020,"LUS-guided treatment was associated with a 45% risk reduction in the primary end point (hazard ratio 0.55, 95% CI 0.31-0.98, P = .044), mainly driven by a reduction in urgent HF visits (hazard ratio 0.28, 95% CI 0.13-0.62, P = .001).",['One hundred twenty-six patients'],"['LUS-guided arm or control arm', 'lung ultrasound-guided therapy', 'Lung ultrasound (LUS', 'LUS']","['rate of adverse events', 'urgent HF visits', 'rehospitalizations for HF or death', 'composite of urgent HF visits, rehospitalization for worsening HF, and death from any cause', 'risk of urgent visits']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4286019', 'cui_str': 'Lung ultrasound'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",126.0,0.114217,"LUS-guided treatment was associated with a 45% risk reduction in the primary end point (hazard ratio 0.55, 95% CI 0.31-0.98, P = .044), mainly driven by a reduction in urgent HF visits (hazard ratio 0.28, 95% CI 0.13-0.62, P = .001).","[{'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Araiza-Garaygordobil', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico. Electronic address: dargaray@gmail.com.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Gopar-Nieto', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Martinez-Amezcua', 'Affiliation': 'Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Cabello-López', 'Affiliation': 'Centro Médico Nacional ""Siglo XXI,"" Instituto Mexicano del Seguro Social, Mexico City, Mexico.'}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Alanis-Estrada', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Abraham', 'Initials': 'A', 'LastName': 'Luna-Herbert', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Héctor', 'Initials': 'H', 'LastName': 'González-Pacheco', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Cynthia Paola', 'Initials': 'CP', 'LastName': 'Paredes-Paucar', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Martinez Daniel', 'Initials': 'MD', 'LastName': 'Sierra-Lara', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Jose Luis', 'Initials': 'JL', 'LastName': 'Briseño-De la Cruz', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Hugo', 'Initials': 'H', 'LastName': 'Rodriguez-Zanella', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Marco Antonio', 'Initials': 'MA', 'LastName': 'Martinez-Rios', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Arias-Mendoza', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}]",American heart journal,['10.1016/j.ahj.2020.06.003'] 2005,32669121,A Combined Randomised and Observational Study of Surgery for Fractures In the distal Radius in the Elderly (CROSSFIRE): a statistical analyses plan.,"BACKGROUND We are performing a combined randomised and observational study comparing internal fixation to non-surgical management for common wrist fractures in older patients. This paper describes the statistical analysis plan. METHODS/DESIGN A Combined Randomised and Observational Study of Surgery for Fractures In the distal Radius in the Elderly (CROSSFIRE) is a randomised controlled trial comparing two types of usual care for treating wrist fractures in older patients, surgical fixation using volar locking plates and non-surgical treatment using closed reduction and plaster immobilisation. The primary aim of this comparative-effectiveness study is to determine whether surgery is superior to non-surgical treatment with respect to patient-reported wrist function at 12 months post treatment. The secondary outcomes include radiographic outcomes, complication rates and patient-reported outcomes including quality of life, pain, treatment success and cosmesis. Primary analysis will use a two-sample t test and an intention-to-treat analysis using the randomised arm of the study. Statistical analyses will be two-tailed and significance will be determined by p < 0.05. Sensitivity analyses will be conducted to assess for differences in intention-to-treat, per-protocol and as-treated analyses. Sensitivity analyses will also be conducted to assess selection bias by evaluating differences in participants between the randomised and observational study arms, and for bias relating to any missing data. An economic analysis will be conducted separately if surgery is shown to provide superior outcomes to a level of clinical significance. DISCUSSION This statistical analysis plan describes the analysis of the CROSSFIRE study which aims to provide evidence to aid clinical decision-making in the treatment of distal radius fractures in older patients. TRIAL REGISTRATION CROSSFIRE was approved by The Hunter New England Human Research Ethics Committee (HNEHREC Reference No: 16/02/17/3.04). Registered on 22 July 2016 with The Australian and New Zealand Clinical Trials Registry (ANZCTR Number; ACTRN12616000969460 ). This manuscript is based on v.11 of the statistical analysis plan. A copy of v.11, signed by the chief investigator and the senior statistician is kept at the administering institution.",2020,"In the distal Radius in the Elderly (CROSSFIRE) is a randomised controlled trial comparing two types of usual care for treating wrist fractures in older patients, surgical fixation using volar locking plates and non-surgical treatment using closed reduction and plaster immobilisation.","['older patients', 'Surgery for Fractures']","['surgical fixation using volar locking plates and non-surgical treatment using closed reduction and plaster immobilisation', 'internal fixation to non-surgical management']","['radiographic outcomes, complication rates and patient-reported outcomes including quality of life, pain, treatment success and cosmesis']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0443349', 'cui_str': 'Volar'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C2363849', 'cui_str': 'Non-surgical treatment'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0460977', 'cui_str': 'Plasters'}, {'cui': 'C0020944', 'cui_str': 'Immobilization - action'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",,0.126119,"In the distal Radius in the Elderly (CROSSFIRE) is a randomised controlled trial comparing two types of usual care for treating wrist fractures in older patients, surgical fixation using volar locking plates and non-surgical treatment using closed reduction and plaster immobilisation.","[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Lawson', 'Affiliation': 'Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical Research, Sydney, NSW, Australia. aalawson@tpg.com.au.'}, {'ForeName': 'Justine', 'Initials': 'J', 'LastName': 'Naylor', 'Affiliation': 'Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.'}, {'ForeName': 'Rachelle', 'Initials': 'R', 'LastName': 'Buchbinder', 'Affiliation': 'Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Ivers', 'Affiliation': 'School of Public Health and Community Medicine, UNSW Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Zsolt', 'Initials': 'Z', 'LastName': 'Balogh', 'Affiliation': 'John Hunter Hospital, Newcastle, NSW, Australia.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Smith', 'Affiliation': 'Canberra Hospital, Canberra, ACT, Australia.'}, {'ForeName': 'Rajat', 'Initials': 'R', 'LastName': 'Mittal', 'Affiliation': 'South Western Sydney Clinical School, UNSW, Sydney, NSW, Australia.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Xuan', 'Affiliation': 'Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Howard', 'Affiliation': 'Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Arezoo', 'Initials': 'A', 'LastName': 'Vafa', 'Affiliation': 'Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.'}, {'ForeName': 'Piers', 'Initials': 'P', 'LastName': 'Yates', 'Affiliation': 'Fiona Stanley Hospital, Perth, WA, Australia.'}, {'ForeName': 'Bertram', 'Initials': 'B', 'LastName': 'Rieger', 'Affiliation': 'Fiona Stanley Hospital, Perth, WA, Australia.'}, {'ForeName': 'Geoff', 'Initials': 'G', 'LastName': 'Smith', 'Affiliation': 'St George and Sutherland Hospitals, Sydney, NSW, Australia.'}, {'ForeName': 'Ilia', 'Initials': 'I', 'LastName': 'Elkinson', 'Affiliation': 'Wellington Hospital, Wellington, New Zealand.'}, {'ForeName': 'Woosung', 'Initials': 'W', 'LastName': 'Kim', 'Affiliation': 'Wellington Hospital, Wellington, New Zealand.'}, {'ForeName': 'Jai', 'Initials': 'J', 'LastName': 'Sungaran', 'Affiliation': 'Concord Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Latendresse', 'Affiliation': 'Nambour Hospital and Sunshine Coast University Hospital, Nambour, QLD, Australia.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Wong', 'Affiliation': 'Westmead Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Sameer', 'Initials': 'S', 'LastName': 'Viswanathan', 'Affiliation': 'Campbelltown Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Landale', 'Affiliation': 'Campbelltown Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Herwig', 'Initials': 'H', 'LastName': 'Drobetz', 'Affiliation': 'Mackay Base Hospital, Mackay, QLD, Australia.'}, {'ForeName': 'Phong', 'Initials': 'P', 'LastName': 'Tran', 'Affiliation': 'Western Health, Melbourne, VIC, Australia.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Page', 'Affiliation': 'University Hospital Geelong, Barwon Health, Geelong, NSW, Australia.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Hau', 'Affiliation': 'Northern Health, Melbourne, VIC, Australia.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Mulford', 'Affiliation': 'Launceston Hospital, Launceston, TAS, Australia.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Incoll', 'Affiliation': 'Gosford and Wyong Hospitals, Gosford, NSW, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kale', 'Affiliation': 'Gosford and Wyong Hospitals, Gosford, NSW, Australia.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Schick', 'Affiliation': 'Prince of Wales Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Higgs', 'Affiliation': ""St Vincent's Hospital, Sydney, NSW, Australia.""}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Oppy', 'Affiliation': 'Royal Melbourne Hospital, Melbourne, VIC, Australia.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Perriman', 'Affiliation': 'Canberra Hospital, Canberra, ACT, Australia.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Harris', 'Affiliation': 'Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.'}]",Trials,['10.1186/s13063-020-4228-0'] 2006,32687804,"Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study.","BACKGROUND Long-term protection and herd immunity induced by existing pertussis vaccines are imperfect, and a need therefore exists to develop new pertussis vaccines. This study aimed to investigate the safety, colonisation, and immunogenicity of the new, live attenuated pertussis vaccine, BPZE1, when given intranasally. METHODS This phase 1b, double-blind, randomised, placebo-controlled, dose-escalation study was done at the phase 1 unit, Karolinska Trial Alliance, Karolinska University Hospital, Stockholm, Sweden. Healthy adults (18-32 years) were screened and included sequentially into three groups of increasing BPZE1 dose strength (10 7 colony-forming units [CFU], 10 8 CFU, and 10 9 CFU), and were randomly assigned (3:1 within each group) to receive vaccine or placebo. Vaccine and placebo were administered in phosphate-buffered saline contained 5% saccharose as 0·4 mL in each nostril. The primary outcome was solicited and unsolicited adverse events between day 0 and day 28. The analysis included all randomised participants who received a vaccine dose. Colonisation with BPZE1 was determined by repeatedly culturing nasopharyngeal aspirates at day 4, day 7, day 11, day 14, day 21, and day 28 after vaccination. Immunogenicity, as serum IgG and IgA responses were assessed at day 0, day 7, day 14, day 21, day 28, 6 months, and 12 months after vaccination. This trial is registered at Clinicaltrials.gov, NCT02453048. FINDINGS Between Sept 1, 2015, and Feb 3, 2016, 120 participants were assessed for eligibility, 48 of whom were enrolled and randomly assigned (3:1) to receive vaccine or placebo, with 12 participants each in a low-dose, medium-dose, and high-dose vaccine group. Adverse events between day 0 and day 28 were reported by one (8%, 95% CI 0-39) of 12 participants in both the placebo and low-dose groups, and two (17%; 2-48) of 12 participants in both the medium-dose and high-dose groups, including cough of grade 2 or more, oropharyngeal pain, and rhinorrhoea and nasal congestion. During this time, none of the participants experienced any spasmodic cough, difficulties in breathing, or adverse events following immunisation concerning vital signs. The tested doses of BPZE1 or placebo were well tolerated, with no apparent difference in solicited or unsolicited adverse events following immunisation between groups. Colonisation at least once after vaccination was observed in 29 (81%; 68-93) of 36 vaccinated participants. The tested vaccine doses were immunogenic, with increases in serum IgG and IgA titres against the four B pertussis antigens from baseline to 12 months. INTERPRETATION The tested vaccine was safe, induced a high colonisation rate in an adult population, and was immunogenic at all doses. These findings justify further clinical development of BPZE1 to ultimately be used as a priming vaccine for neonates or a booster vaccine for adolescents and adults, or both. FUNDING ILiAD Biotechnologies.",2020,"The tested vaccine doses were immunogenic, with increases in serum IgG and IgA titres against the four B pertussis antigens from baseline to 12 months. ","['Between Sept 1, 2015, and Feb 3, 2016, 120 participants were assessed for eligibility, 48 of whom were enrolled and randomly assigned (3:1) to receive', 'Healthy adults (18-32 years']","['vaccine or placebo', 'BPZE1 or placebo', 'Vaccine and placebo', 'live attenuated intranasal pertussis vaccine BPZE1', 'phosphate-buffered saline contained 5% saccharose as 0·4', 'placebo']","['spasmodic cough, difficulties in breathing, or adverse events', 'Safety and immunogenicity', 'Adverse events', 'Immunogenicity, as serum IgG and IgA responses', 'solicited and unsolicited adverse events', 'safety, colonisation, and immunogenicity', 'cough of grade 2 or more, oropharyngeal pain, and rhinorrhoea and nasal congestion', 'serum IgG and IgA titres', 'solicited or unsolicited adverse events', 'Colonisation']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0031237', 'cui_str': 'Pertussis Vaccine'}, {'cui': 'C0031603', 'cui_str': 'Phosphate'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}]","[{'cui': 'C0277870', 'cui_str': 'Spasmodic cough'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0475270', 'cui_str': 'G2 grade'}, {'cui': 'C2363731', 'cui_str': 'Oropharyngeal pain'}, {'cui': 'C1260880', 'cui_str': 'Nasal discharge'}, {'cui': 'C0027424', 'cui_str': 'Nasal congestion'}, {'cui': 'C0475208', 'cui_str': 'Titer'}]",120.0,0.664209,"The tested vaccine doses were immunogenic, with increases in serum IgG and IgA titres against the four B pertussis antigens from baseline to 12 months. ","[{'ForeName': 'Maja', 'Initials': 'M', 'LastName': 'Jahnmatz', 'Affiliation': 'Public Health Agency of Sweden, Solna, Sweden.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Richert', 'Affiliation': 'University of Bordeaux, National Institute for Health and Medical Research (Inserm), Bordeaux Population Health Research Center, Bordeaux, France; University Hospital Centre CHU, Bordeaux, France; EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France; Inria SISTM team, F-33405, Talence, France.'}, {'ForeName': 'Nabil', 'Initials': 'N', 'LastName': 'Al-Tawil', 'Affiliation': 'Karolinska Trial Alliance, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Jann', 'Initials': 'J', 'LastName': 'Storsaeter', 'Affiliation': 'Public Health Agency of Sweden, Solna, Sweden.'}, {'ForeName': 'Céline', 'Initials': 'C', 'LastName': 'Colin', 'Affiliation': 'University of Bordeaux, National Institute for Health and Medical Research (Inserm), Bordeaux Population Health Research Center, Bordeaux, France; University Hospital Centre CHU, Bordeaux, France; EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Bauduin', 'Affiliation': 'University of Bordeaux, National Institute for Health and Medical Research (Inserm), Bordeaux Population Health Research Center, Bordeaux, France; University Hospital Centre CHU, Bordeaux, France; EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.'}, {'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Thalen', 'Affiliation': 'ILiAD Biotechnologies, New York, NY, USA.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Solovay', 'Affiliation': 'ILiAD Biotechnologies, New York, NY, USA.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Rubin', 'Affiliation': 'ILiAD Biotechnologies, New York, NY, USA.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Mielcarek', 'Affiliation': 'University of Lille, National Centre for Scientific Research (CNRS), National Institute for Health and Medical Research (Inserm), University Hospital Centre CHU Lille, Lille, France; Center for Infection and Immunity of Lille, Institut Pasteur de Lille, Lille, France.'}, {'ForeName': 'Rigmor', 'Initials': 'R', 'LastName': 'Thorstensson', 'Affiliation': 'Public Health Agency of Sweden, Solna, Sweden.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Locht', 'Affiliation': 'University of Lille, National Centre for Scientific Research (CNRS), National Institute for Health and Medical Research (Inserm), University Hospital Centre CHU Lille, Lille, France; Center for Infection and Immunity of Lille, Institut Pasteur de Lille, Lille, France. Electronic address: camille.locht@pasteur-lille.fr.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(20)30274-7'] 2007,32687819,"Weight Loss Prior to Pregnancy and Subsequent Gestational Weight Gain: Prepare, a Randomized Clinical Trial.","OBJECTIVE Women with elevated body mass index are encouraged to lose weight before pregnancy, but no trials have tested the effects of pre-pregnancy weight loss on health outcomes. Our objective was to determine whether pre-pregnancy weight loss reduces gestational weight gain and improves pregnancy outcomes. STUDY DESIGN Pragmatic randomized clinical trial conducted between May 2015 and October 2019 at Kaiser Permanente Northwest, an integrated health system. Data collection was blind to condition assignment. Eligible participants were women aged 18-40 years with BMI ≥27 kg/m 2 who were planning pregnancy within 2 years. Recruitment contacts were sent to 27,665 health system members who met age and BMI criteria; 329 women attended screening visits and 326 were randomized. They were randomized to either a behavioral weight loss intervention or usual care control. The intervention consisted of health-coaching phone sessions weekly for 6 months and then monthly for 18 months or until pregnancy end. We used logistic regression to examine the a priori primary hypothesis that participants in the intervention would be less likely to exceed National Academy of Medicine guidelines for gestational weight gain during each trimester and overall. Secondary and exploratory outcomes included absolute weight gain before and during pregnancy and perinatal and newborn outcomes. RESULTS Of the 326 participants, 169 had singleton pregnancies lasting ≥14 weeks (analytic cohort: intervention n=89, control n=80). At baseline, mean age was 31.3±3.5 years and BMI was 34.8±5.8 kg/m 2 . Intervention participants lost more weight before pregnancy than controls (-0.25±0.51 vs -0.03±0.21 kg/week, P<0.001). However, intervention participants gained more weight than controls in the second (0.42±0.26 vs. 0.33±0.28 kg/week; P=0.04) and third trimesters (0.56±0.37 vs 0.43±0.33 kg/week; P=0.02) and overall (13.2±8.20 vs 10.3±7.41 kg; P=0.03). Nevertheless, arms did not differ in rates of exceeding gestational weight gain guidelines at any time point. Spontaneous pregnancy loss was less common in the intervention than control arm (8 [4.9%] vs 19 [11.8%]; OR 0.39 [0.16, 0.92]) but we found no other differences in secondary or exploratory outcomes. INTERPRETATION Participation in the pre-pregnancy weight loss intervention had no effect on women's likelihood of exceeding gestational weight gain guidelines. While the intervention group successfully lost weight prior to conception, the intervention was associated with greater weight gain in late pregnancy. In order to effectively reduce weight throughout pregnancy and improve maternal and child outcomes, pre-pregnancy weight loss interventions may need to be combined with intensive weight management that continues through delivery.",2020,"Intervention participants lost more weight before pregnancy than controls (-0.25±0.51 vs -0.03±0.21 kg/week, P<0.001).","['326 participants', '27,665 health system members who met age and BMI criteria; 329 women attended screening visits and 326 were randomized', '169 had singleton pregnancies lasting ≥14 weeks', 'Women with elevated body mass index', 'Eligible participants were women aged 18-40 years with BMI ≥27 kg/m 2 who were planning pregnancy within 2 years', 'May 2015 and October 2019 at Kaiser Permanente Northwest, an integrated health system']","['behavioral weight loss intervention or usual care control', 'health-coaching phone sessions']","['rates of exceeding gestational weight gain guidelines', 'weight', 'Weight Loss', 'absolute weight gain before and during pregnancy and perinatal and newborn outcomes', 'weight gain', 'weight before pregnancy', 'gestational weight gain and improves pregnancy outcomes', 'Spontaneous pregnancy loss', 'gestational weight gain']","[{'cui': 'C5191353', 'cui_str': '326'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032992', 'cui_str': 'Pregnant - planned'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}]","[{'cui': 'C1398625', 'cui_str': 'Maternal Weight Gain'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0178795', 'cui_str': 'Perinatal period'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0032972', 'cui_str': 'Outcomes, Pregnancy'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0156543', 'cui_str': 'Pregnancy with abortive outcome'}]",,0.162714,"Intervention participants lost more weight before pregnancy than controls (-0.25±0.51 vs -0.03±0.21 kg/week, P<0.001).","[{'ForeName': 'Erin S', 'Initials': 'ES', 'LastName': 'Leblanc', 'Affiliation': 'Kaiser Permanente, Center for Health Research, 3800 N. Interstate Ave Portland, OR 97227.'}, {'ForeName': 'Ning X', 'Initials': 'NX', 'LastName': 'Smith', 'Affiliation': 'Kaiser Permanente, Center for Health Research, 3800 N. Interstate Ave Portland, OR 97227.'}, {'ForeName': 'Kimberly K', 'Initials': 'KK', 'LastName': 'Vesco', 'Affiliation': 'Kaiser Permanente, Center for Health Research, 3800 N. Interstate Ave Portland, OR 97227.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Paul', 'Affiliation': 'Penn State College of Medicine, 500 University Drive, Hershey, PA 17033-0850.'}, {'ForeName': 'Victor J', 'Initials': 'VJ', 'LastName': 'Stevens', 'Affiliation': 'Kaiser Permanente, Center for Health Research, 3800 N. Interstate Ave Portland, OR 97227.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.07.027'] 2008,32685315,Multi-Community Cardiopulmonary Resuscitation Education by Medical Students.,"Introduction One purpose of the hands-only cardiopulmonary resuscitation (HOCPR) program is to simplify CPR instruction to encourage more bystanders to take action during cardiac arrest. Although the program has been successfully implemented in traditional classroom settings, the utility of large-scale training events has not been well-explored. We hypothesized that CPR knowledge and comfort levels would increase through a large-scale, multi-community HOCPR training event. We also explored what effect this training event had on perceived barriers to bystander-performed CPR. Methods A convenience sample participated in HOCPR training on a single day across 10 Texas cities. A sub-sample completed training questionnaires, including a five-item CPR pre- and post-test. A follow-up questionnaire was conducted two years after the event. The primary outcome of interest was the difference in cardiopulmonary resuscitation (CPR) knowledge and comfort level between pre- and post-event questionnaires. Demographic contributions were also assessed. Results A total of 4,253 participants were trained, 1,416 were enrolled upon submitting matching pre- and post-event questionnaires, and 101 (14%) submitted follow-up questionnaires. Mean knowledge scores increased from pre-training (2.7 ± 1.6 standard deviation (SD)) to post-training (4.7 ± 0.76 SD) (p < 0.001). Follow-up test scores (3.8 ± 1.1 SD) remained higher than pre-test scores (p < 0.001). Comfort with HOCPR increased from 59% (95% confidence interval (CI) 56 - 61) to 96% (95% CI 95 - 97). Pre- and post-knowledge scores differed significantly by education level (p < 0.001), ethnicity (p < 0.001), and income (p < 0.001). Education contributed significantly to comfort at both pre- (p = 0.015) and post-training (p = 0.026), but ethnicity and income did not. Before training, the most common barrier to performing CPR was lack of knowledge 59% (95% CI 55 - 62); after training, the most common barrier was fear of causing harm 34% (95% CI 29 - 40). Conclusions This study demonstrated that medical students were successfully able to conduct large-scale HOCPR training that improved CPR knowledge and comfort levels among participants across multiple metropolitan areas. Knowledge retention remained higher at two-years for participants of a follow-up questionnaire. Medical students can use the experiences from this training event as a template to organize similar large-scale training events in the future.",2020,This study demonstrated that medical students were successfully able to conduct large-scale HOCPR training that improved CPR knowledge and comfort levels among participants across multiple metropolitan areas. ,"['medical students', 'Multi-Community Cardiopulmonary Resuscitation Education by Medical Students', '4,253 participants were trained, 1,416 were enrolled upon submitting matching pre- and post-event questionnaires, and 101 (14%) submitted follow-up questionnaires', 'convenience sample participated in HOCPR training on a single day across 10 Texas cities', 'participants across multiple metropolitan areas']",['hands-only cardiopulmonary resuscitation (HOCPR) program'],"['CPR knowledge and comfort levels', 'Knowledge retention', 'Mean knowledge scores', 'Comfort with HOCPR', 'cardiopulmonary resuscitation (CPR) knowledge and comfort level between pre- and post-event questionnaires']","[{'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0204928', 'cui_str': 'CPR education'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0039711', 'cui_str': 'Texas'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0517225', 'cui_str': 'Comfort level'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",4253.0,0.0261916,This study demonstrated that medical students were successfully able to conduct large-scale HOCPR training that improved CPR knowledge and comfort levels among participants across multiple metropolitan areas. ,"[{'ForeName': 'Kenton L', 'Initials': 'KL', 'LastName': 'Anderson', 'Affiliation': 'Emergency Medicine, Stanford University School of Medicine, Palo Alto, USA.'}, {'ForeName': 'Kian', 'Initials': 'K', 'LastName': 'Niknam', 'Affiliation': 'Emergency Medicine, Stanford University School of Medicine, Palo Alto, USA.'}, {'ForeName': 'Larry', 'Initials': 'L', 'LastName': 'Laufman', 'Affiliation': 'Medicine, Baylor College of Medicine, Houston, USA.'}, {'ForeName': 'Stefanie S', 'Initials': 'SS', 'LastName': 'Sebok-Syer', 'Affiliation': 'Emergency Medicine, Stanford University, Palo Alto, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Andrabi', 'Affiliation': 'Emergency Medicine, Baylor College of Medicine, Houston, USA.'}]",Cureus,['10.7759/cureus.8647'] 2009,32687612,"Interaction of Ethanol and Oral ANS-6637, a Selective ALDH2 Inhibitor in Males: A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Cohort Study.","BACKGROUND ANS-6637, an orally bioavailable selective and reversible aldehyde dehydrogenase-2 (ALDH2) inhibitor, is under development for drug and alcohol use disorders. During the elimination of alcohol, ALDH2 metabolizes acetaldehyde to acetate; inhibiting this enzyme can lead to aversive reactions due to the accumulation of acetaldehyde. Thus, understanding the safety and tolerability of ANS-6637 in combination with alcohol is essential. TRIAL DESIGN AND METHODS 48 healthy males participated in a randomized, double-blind, placebo-controlled, single-ascending dose cohort study of oral ANS-6637. Eligible participants were randomized to ANS-6637 (n=36) or placebo (n=12) in a 3:1 fashion in each of 6 dose cohorts (8 per cohort; ANS-6637 dose levels were 25mg, 50mg, 100mg, 200mg, 400mg, and 600mg). Two hours after receiving study drug, participants drank up to 5 standard drinks, one every 30 minutes. Safety assessments, pharmacodynamic measures and pharmacokinetic blood samples were obtained. RESULTS Flushing was the most common adverse event (AE) associated with ANS-6637 (24 of 36 participants) compared to placebo (3 of 12). Statistically significant, but modest, increases in heart rate (HR) occurred (+10.5 bpm after 2 drinks; +16.9 to +20.5 bpm after 3 rd through 5 th drink). No participant met HR or systolic blood pressure criteria for stopping ethanol administration. There were no clinically significant QTc interval prolongations. Individuals receiving ANS-6637 reported lower ratings of liking, alcohol effects, and feeling drunk. CONCLUSIONS A single oral dose of ANS-6637 with up to 5 standards drinks over 2.5 hrs was generally well tolerated in healthy males. The most common pharmacological response was flushing and an increase in HR, which are known effects of acetaldehyde accumulation and consistent with inhibition of ADLH2 with oral ANS-6637 in combination with alcohol. The results of this alcohol interaction study support further testing of ANS-6637 in individuals with substance use disorders who may consume alcohol.",2020,"Individuals receiving ANS-6637 reported lower ratings of liking, alcohol effects, and feeling drunk. ","['Eligible participants', 'healthy males', '48 healthy males', 'Males', 'individuals with substance use disorders who may consume alcohol']","['Placebo', 'Ethanol and Oral ANS-6637, a Selective ALDH2 Inhibitor', 'ANS-6637', 'oral ANS-6637', 'placebo']","['safety and tolerability', 'ratings of liking, alcohol effects, and feeling drunk', 'heart rate (HR', 'HR or systolic blood pressure criteria', 'Safety assessments, pharmacodynamic measures and pharmacokinetic blood samples']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038586', 'cui_str': 'Substance use disorder'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0001985', 'cui_str': 'Aldehyde dehydrogenase (NAD^+^)'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0522172', 'cui_str': 'Feeling intoxicated'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}]",48.0,0.210466,"Individuals receiving ANS-6637 reported lower ratings of liking, alcohol effects, and feeling drunk. ","[{'ForeName': 'Stephanie S', 'Initials': 'SS', 'LastName': ""O'Malley"", 'Affiliation': 'Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Megan J', 'Initials': 'MJ', 'LastName': 'Shram', 'Affiliation': 'Altreos Research Partners, Toronto, CA, USA.'}, {'ForeName': 'Naama', 'Initials': 'N', 'LastName': 'Levy-Cooperman', 'Affiliation': 'Altreos Research Partners, Toronto, CA, USA.'}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Vince', 'Affiliation': 'Altasciences/Vince Associates, Overland Park, KS, USA.'}, {'ForeName': 'Peter M', 'Initials': 'PM', 'LastName': 'Strumph', 'Affiliation': 'Amygdala Neurosciences, Inc, San Francisco, CA, USA.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Diamond', 'Affiliation': 'Amygdala Neurosciences, Inc, San Francisco, CA, USA.'}, {'ForeName': 'Brent K', 'Initials': 'BK', 'LastName': 'Blackburn', 'Affiliation': 'Amygdala Neurosciences, Inc, San Francisco, CA, USA.'}]","Alcoholism, clinical and experimental research",['10.1111/acer.14416'] 2010,32664997,Where is an emotion? Using targeted visceroception as a method of improving emotion regulation in healthy participants to inform suicide prevention initiatives: a randomised controlled trial.,"BACKGROUND William James' 1884 paper ""What is an emotion?"" has generated much recent interest in affective science regarding somatic contributions to emotion. Studies of interoception (""sensing the physiological condition of the body"") suggest that sensing specific parts of the body contributes to the production of emotion, namely when sensing the viscera (i.e. ""visceroception"" of the heart, gut or lungs). Improved visceroception has, for instance, been linked to increased emotional intensity, suggesting a role for interoception in emotion regulation that may pertain specifically to visceral bodily locations. Thus, in addition to asking James' question, ""What is an emotion?"", we ask, ""Where is an emotion?"". Further, there is an evidence base pointing to the connections between emotion regulation and suicide, and between interoception and suicide. This is a preliminary trial investigating whether targeted interoception/visceroception improves emotion regulation. Ultimately, the overall project aims to inform suicide prevention efforts. METHODS The trial utilises a pre-test/post-test control group design, with two experimental groups undergoing visceroceptive interventions (focussing on areas pertaining to the gut or heart) and a control group. The interventions will run for 8 weeks. A spatial cueing task will measure reaction times to bodily changes relating to lower abdomen or chest focus. A stop/signal task will measure emotional inhibition, which is hypothesised to obscure awareness of active bodily locations. Visceroceptive ability will be tracked using a heartbeat estimation task, a water load test, and by self-report questionnaire. The sample will consist of healthcare professionals and healthcare students. Despite these being groups that represent a relatively high suicide risk among professional and student groups, all participants will be healthy, given the preliminary nature of this trial. DISCUSSION To our knowledge, this will be the first project to address whether emotional feeling presents as a localised bodily phenomenon and whether trained awareness of emotional localisation can improve emotion regulation. It will also be the first to investigate relationships between interoception and emotional inhibition (i.e. whether a sustained interoceptive practice leads to the disinhibition of bodily emotional sensations, which can positively contribute to emotion regulation). These empirical findings on emotion regulation from a healthy sample will be used to inform a desk-based enquiry into the role of embodied emotion in suicide prevention, which may make a significant contribution to a growing evidence base on interoception and suicide. TRIAL REGISTRATION ACTR N12619000324112 . Registered on 4 March 2019. Universal Trial Number (UTN): U1111-1221-0201.",2020,"Improved visceroception has, for instance, been linked to increased emotional intensity, suggesting a role for interoception in emotion regulation that may pertain specifically to visceral bodily locations.","['healthy participants', ""William James' 1884 paper ""]",['visceroceptive interventions (focussing on areas pertaining to the gut or heart) and a control group'],['emotion regulation'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030351', 'cui_str': 'Paper'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}]",,0.0367685,"Improved visceroception has, for instance, been linked to increased emotional intensity, suggesting a role for interoception in emotion regulation that may pertain specifically to visceral bodily locations.","[{'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Davey', 'Affiliation': 'Suicide and Mental Health Research Group, University of Otago, Wellington, PO Box 7343, Wellington, Newtown, 6242, New Zealand. davst397@student.otago.ac.nz.'}, {'ForeName': 'Elliot', 'Initials': 'E', 'LastName': 'Bell', 'Affiliation': 'Department of Psychological Medicine, University of Otago, Wellington, New Zealand.'}, {'ForeName': 'Jamin', 'Initials': 'J', 'LastName': 'Halberstadt', 'Affiliation': 'Department of Psychology, University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'Sunny', 'Initials': 'S', 'LastName': 'Collings', 'Affiliation': 'Suicide and Mental Health Research Group, University of Otago, Wellington, New Zealand.'}]",Trials,['10.1186/s13063-020-04479-9'] 2011,32665034,"Effect of intraoperative dexmedetomidine infusion on delirium in adult patients following cardiac valve surgery: a protocol of a randomized, double-blinded, and placebo-controlled study.","BACKGROUND Delirium is an acute status of brain dysfunction that commonly occurs in patients who have undergone cardiac surgery, and increases morbidity and mortality. It is associated with risk factors, such as older age, use of narcotics, cardiopulmonary bypass, and hypothermia. Dexmedetomidine infusion might exert a neuroprotective effect. However, the effect of perioperative administration of dexmedetomidine on the incidence of postoperative delirium (POD) in patients undergoing cardiac or non-cardiac surgery is yet controversial. The present study aimed to reveal the effect of intraoperative dexmedetomidine administration on the incidence of delirium in adult patients following cardiac surgery. METHODS This single-center, randomized, double-blinded, and placebo-controlled trial consisted of 652 patients randomly divided into two groups: dexmedetomidine and placebo. 0.6 μg/kg dexmedetomidine will be infused 10 min after central vein catheterization, followed by a continuous infusion at a speed of 0.4 μg/kg/h until the end of surgery in the dexmedetomidine group, while normal saline will be administered at the same rate in the placebo group. The primary outcome is the incidence of POD during the first 7 days post-surgery. The secondary outcomes include duration of mechanical ventilation after surgery, duration of stay in the intensive care unit and the hospital after surgery, incidence of hypotension during or after dexmedetomidine infusion, acute kidney injury and sudden arrhythmia during the hospital stay postoperatively, and all-cause mortality in 30 and 90 days after surgery, respectively. DISCUSSION This study was approved by the Ethics Committee of the Chinese Academy of Medical Sciences Fuwai Hospital on 6 March 2019 (2019-1180). The results will be disseminated at academic conferences and submitted to peer-reviewed publications. Either positive or negative results will provide guidance for clinical practice. TRIAL REGISTRATION The Chinese Clinical Trial Registry ( http://www.chictr.org.cn ) ChiCTR1900022583. Registered on 17 April 2019.",2020,"It is associated with risk factors, such as older age, use of narcotics, cardiopulmonary bypass, and hypothermia.","['patients undergoing cardiac or non-cardiac surgery', 'adult patients following cardiac surgery', 'adult patients following cardiac valve surgery', 'patients who have undergone cardiac surgery', 'Chinese Academy of Medical Sciences Fuwai Hospital on 6 March 2019 (2019-1180', '652 patients randomly divided into two groups']","['intraoperative dexmedetomidine infusion', 'Dexmedetomidine', 'dexmedetomidine and placebo', 'dexmedetomidine', 'intraoperative dexmedetomidine', 'placebo']","['incidence of POD during the first 7\u2009days post-surgery', 'morbidity and mortality', 'duration of mechanical ventilation after surgery, duration of stay in the intensive care unit and the hospital after surgery, incidence of hypotension during or after dexmedetomidine infusion, acute kidney injury and sudden arrhythmia during the hospital stay postoperatively, and all-cause mortality', 'postoperative delirium (POD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0018825', 'cui_str': 'Cardiac valve prosthesis'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0000876', 'cui_str': 'Academies'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C4721772', 'cui_str': 'Postoperative delirium'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C1276802', 'cui_str': 'Sudden'}, {'cui': 'C0003811', 'cui_str': 'Cardiac arrhythmia'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",652.0,0.710088,"It is associated with risk factors, such as older age, use of narcotics, cardiopulmonary bypass, and hypothermia.","[{'ForeName': 'Hong-Bai', 'Initials': 'HB', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, No. 167 North Lishi Road, Xicheng District, Beijing, China.'}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Chongqing Traditional Chinese Medicine Hospital, Chongqing, No. 6, 7 Branch Road, Panxi, Jiangbei District, Chongqing, China.'}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, No. 167 North Lishi Road, Xicheng District, Beijing, China.'}, {'ForeName': 'Su', 'Initials': 'S', 'LastName': 'Yuan', 'Affiliation': 'Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, No. 167 North Lishi Road, Xicheng District, Beijing, China. fuwaiys@126.com.'}, {'ForeName': 'Fu-Xia', 'Initials': 'FX', 'LastName': 'Yan', 'Affiliation': 'Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, No. 167 North Lishi Road, Xicheng District, Beijing, China.'}, {'ForeName': 'Qi-Peng', 'Initials': 'QP', 'LastName': 'Luo', 'Affiliation': 'Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, No. 167 North Lishi Road, Xicheng District, Beijing, China.'}]",Trials,['10.1186/s13063-020-04574-x'] 2012,32665381,"Oral switch versus standard intravenous antibiotic therapy in left-sided endocarditis due to susceptible staphylococci, streptococci or enterococci (RODEO): a protocol for two open-label randomised controlled trials.","INTRODUCTION Left-sided infective endocarditis (IE) is a serious infection with a heavy burden for patients and healthcare system. Oral switch after initial intravenous antibiotic therapy may reduce costs and improve patients' discomfort without increasing unfavourable outcomes. We describe the methodology of two simultaneously conducted open-label randomised trials aiming to assess non-inferiority of oral switch as compared with entirely intravenous antibiotic therapy for the treatment of left-sided IE. METHODS AND ANALYSIS Two simultaneous multicentre open-label prospective randomised trials assessing non-inferiority of oral switch during antibiotic treatment as compared with entirely intravenous therapy in patients with left-sided IE are ongoing. One trial is dedicated to left-sided IE caused by multisusceptible staphylococci (Relais Oral Dans le traitement des Endocardites à staphylocoques ou streptOcoques (RODEO)-1) and the other is dedicated to left-sided IE caused by susceptible streptococci or enterococci (RODEO-2). It is planned to randomise 324 patients in each trial after an initial course of at least 10 days of intravenous antibiotic therapy either to continue intravenous antibiotic therapy or to switch to oral antibiotic therapy. The primary outcome is treatment failure within 3 months after the end of antibiotic treatment, a composite outcome defined by all-cause death and/or symptomatic embolic events and/or unplanned valvular surgery and/or microbiological relapse (with the primary pathogen). Secondary outcomes include patient quality of life, echocardiographic outcome, costs and efficiency associated with IE care. Statistical analysis will be performed with a non-inferiority margin of 10% and a one-sided 2.5% type I error. ETHICS AND DISSEMINATION Written informed consent will be obtained from all participants. This study was approved by Tours Research ethics committee (CPP TOURS-Region Centre-Ouest 1, 2015-R26, 23 February 2016). Study findings will be published in peer-reviewed journals and disseminated through presentation at relevant national and international conferences. TRIAL REGISTRATION NUMBER EudraCT Number: 2015-002371-16 and NCT02701608; NCT02701595.",2020,"METHODS AND ANALYSIS Two simultaneous multicentre open-label prospective randomised trials assessing non-inferiority of oral switch during antibiotic treatment as compared with entirely intravenous therapy in patients with left-sided IE are ongoing.",['patients with left-sided IE are ongoing'],"['intravenous antibiotic therapy', 'Oral switch versus standard intravenous antibiotic therapy', 'entirely intravenous antibiotic therapy', 'oral switch during antibiotic treatment']","['treatment failure within 3 months after the end of antibiotic treatment, a composite outcome defined by all-cause death and/or symptomatic embolic events and/or unplanned valvular surgery and/or microbiological relapse (with the primary pathogen', 'patient quality of life, echocardiographic outcome, costs and efficiency associated with IE care']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1827151', 'cui_str': 'Left sided infective endocarditis'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}]","[{'cui': 'C0559680', 'cui_str': 'Intravenous antibiotic therapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0025953', 'cui_str': 'microbiology'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0450254', 'cui_str': 'Pathogenic organism'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0014121', 'cui_str': 'Bacterial endocarditis'}]",,0.161677,"METHODS AND ANALYSIS Two simultaneous multicentre open-label prospective randomised trials assessing non-inferiority of oral switch during antibiotic treatment as compared with entirely intravenous therapy in patients with left-sided IE are ongoing.","[{'ForeName': 'Adrien', 'Initials': 'A', 'LastName': 'Lemaignen', 'Affiliation': 'Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Régional Universitaire de Tours, Tours, France.'}, {'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'Bernard', 'Affiliation': 'Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Régional Universitaire de Tours, Tours, France louis.bernard@univ-tours.fr.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Tattevin', 'Affiliation': 'Service de Maladies Infectieuses et de Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.'}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Bru', 'Affiliation': ""Service d'infectiologie et de médecine interne, Centre Hospitalier Annecy-Genevois, Epagny Metz-Tessy, Rhône-Alpes, France.""}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Duval', 'Affiliation': 'INSERM Clinical Investigation Center 1425, IAME 1138, Universite Paris Diderot, Sorbonne Paris-Cité, Paris, Île-de-France, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Hoen', 'Affiliation': 'Service de Maladies Infectieuses et Tropicales, CHRU de Nancy, Vandoeuvre-les-Nancy, France.'}, {'ForeName': 'Solène', 'Initials': 'S', 'LastName': 'Brunet-Houdard', 'Affiliation': ""Unité d'Evaluation Médico-Economique, EA7505, Education Ethique, Santé, Centre Hospitalier Régional Universitaire de Tours, Université de Tours, Tours, Centre, France.""}, {'ForeName': 'Jean-Luc', 'Initials': 'JL', 'LastName': 'Mainardi', 'Affiliation': 'Service de Microbiologie, APHP, Hôpital Européen Georges Pompidou, Paris, France.'}, {'ForeName': 'Agnes', 'Initials': 'A', 'LastName': 'Caille', 'Affiliation': ""Unité d'Evaluation Médico-Economique, EA7505, Education Ethique, Santé, Centre Hospitalier Régional Universitaire de Tours, Université de Tours, Tours, Centre, France.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2019-033540'] 2013,32665394,Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly (ACP-PEACE): the study protocol for a pragmatic stepped-wedge trial of older patients with cancer.,"INTRODUCTION Advance care planning (ACP) is associated with improved health outcomes for patients with cancer, and its absence is associated with unfavourable outcomes for patients and their caregivers. However, older adults do not complete ACP at expected rates due to patient and clinician barriers. We present the original design, methods and rationale for a trial aimed at improving ACP for older patients with advanced cancer and the modified protocol in response to changes brought by the COVID-19 pandemic. METHODS AND ANALYSIS The Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly study is a pragmatic, stepped-wedge cluster randomised trial examining a Comprehensive ACP Program. The programme combines two complementary evidence-based interventions: clinician communication skills training (VitalTalk) and patient video decision aids (ACP Decisions). We will implement the programme at 36 oncology clinics across three unique US health systems. Our primary outcome is the proportion of eligible patients with ACP documentation completed in the electronic health record. Our secondary outcomes include resuscitation preferences, palliative care consultations, death, hospice use and final cancer-directed therapy. From a subset of our patient population, we will collect surveys and video-based declarations of goals and preferences. We estimate 11 000 patients from the three sites will be enrolled in the study. ETHICS AND DISSEMINATION Regulatory and ethical aspects of this trial include Institutional Review Board (IRB) approval via single IRB of record mechanism at Dana-Farber Cancer Institute, Data Use Agreements among partners and a Data Safety and Monitoring Board. We plan to present findings at national meetings and publish the results. TRIAL REGISTRATION NUMBER NCT03609177; Pre-results.",2020,"INTRODUCTION Advance care planning (ACP) is associated with improved health outcomes for patients with cancer, and its absence is associated with unfavourable outcomes for patients and their caregivers.","['older adults', '11 000 patients from the three sites will be enrolled in the study', 'patients with cancer', 'older patients with cancer', 'older patients with advanced cancer']","['complementary evidence-based interventions: clinician communication skills training (VitalTalk) and patient video decision aids (ACP Decisions', 'Advance care planning (ACP', 'Advance Care Planning']","['proportion of eligible patients with ACP documentation', 'resuscitation preferences, palliative care consultations, death, hospice use and final cancer-directed therapy']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0588407', 'cui_str': 'Communication skills training'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0086104', 'cui_str': 'Decision Aids'}, {'cui': 'C0600371', 'cui_str': 'Advance care planning'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0600371', 'cui_str': 'Advance care planning'}, {'cui': 'C0175636', 'cui_str': 'Documentation procedure'}, {'cui': 'C0035273', 'cui_str': 'Resuscitation'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019947', 'cui_str': 'Hospice'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",11000.0,0.103925,"INTRODUCTION Advance care planning (ACP) is associated with improved health outcomes for patients with cancer, and its absence is associated with unfavourable outcomes for patients and their caregivers.","[{'ForeName': 'Joshua R', 'Initials': 'JR', 'LastName': 'Lakin', 'Affiliation': 'Department of Psychosocial Oncology and Palliative Care, Dana Farber Cancer Institute, Boston, Massachusetts, USA jlakin@partners.org.'}, {'ForeName': 'Elise N', 'Initials': 'EN', 'LastName': 'Brannen', 'Affiliation': 'Department of Psychosocial Oncology and Palliative Care, Dana Farber Cancer Institute, Boston, Massachusetts, USA.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Tulsky', 'Affiliation': 'Department of Psychosocial Oncology and Palliative Care, Dana Farber Cancer Institute, Boston, Massachusetts, USA.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Paasche-Orlow', 'Affiliation': 'Department of General Internal Medicine, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Charlotta', 'Initials': 'C', 'LastName': 'Lindvall', 'Affiliation': 'Department of Psychosocial Oncology and Palliative Care, Dana Farber Cancer Institute, Boston, Massachusetts, USA.'}, {'ForeName': 'Yuchiao', 'Initials': 'Y', 'LastName': 'Chang', 'Affiliation': 'Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Gundersen', 'Affiliation': 'Department of Survey and Data Management Core, Dana Farber Cancer Institute, Boston, Massachusetts, USA.'}, {'ForeName': 'Areej', 'Initials': 'A', 'LastName': 'El-Jawahri', 'Affiliation': 'Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Volandes', 'Affiliation': 'Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2020-040999'] 2014,32663638,"Better off at home? Effects of nursing home eligibility on costs, hospitalizations and survival.","Encouraging and helping elderly to postpone a nursing home admission appears to be a win-win that keeps long-term care spending in check and is in line with the target population's preferences, but there is little evidence about its effects. We study the causal impact of nursing home admission eligibility using Dutch administrative data and exploiting variation between randomly assigned assessors in their tendency to grant eligibility for a nursing home admission. We find a drop in medical care use when eligibility is granted, especially in hospital admissions, while total healthcare spending is unaffected. This suggests that postponing an admission may not always be a win-win after all.",2020,"We find a drop in medical care use when eligibility is granted, especially in hospital admissions, while total healthcare spending is unaffected.",[],[],"['costs, hospitalizations and survival']",[],[],"[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.0493303,"We find a drop in medical care use when eligibility is granted, especially in hospital admissions, while total healthcare spending is unaffected.","[{'ForeName': 'Pieter', 'Initials': 'P', 'LastName': 'Bakx', 'Affiliation': 'Erasmus School of Health Policy and Management, the Netherlands; Network for Studies on Pensions, Ageing and Retirement, the Netherlands. Electronic address: bakx@eshpm.eur.nl.'}, {'ForeName': 'Bram', 'Initials': 'B', 'LastName': 'Wouterse', 'Affiliation': 'Erasmus School of Health Policy and Management, the Netherlands; Network for Studies on Pensions, Ageing and Retirement, the Netherlands.'}, {'ForeName': 'Eddy', 'Initials': 'E', 'LastName': 'van Doorslaer', 'Affiliation': 'Erasmus School of Health Policy and Management, the Netherlands; Network for Studies on Pensions, Ageing and Retirement, the Netherlands; Erasmus School of Economics, Erasmus University Rotterdam, the Netherlands; Tinbergen Institute, the Netherlands.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Wong', 'Affiliation': 'Network for Studies on Pensions, Ageing and Retirement, the Netherlands; RIVM National Institute for Public Health and the Environment, the Netherlands.'}]",Journal of health economics,['10.1016/j.jhealeco.2020.102354'] 2015,32663640,"A commentary on ""Effects of edaravone on postoperative cognitive function in elderly patients undergoing hip joint replacement surgery: A randomized controlled trial"" (Int J Surg 2020;80:13-18).",,2020,,['Elderly Patients undergoing Hip Joint Replacement Surgery'],['Edaravone'],['Postoperative Cognitive Function'],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019558', 'cui_str': 'Hip joint structure'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0070694', 'cui_str': 'edaravone'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",,0.104829,,"[{'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Woo', 'Affiliation': 'School of Medicine, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, United Kingdom. Electronic address: wootk@cardiff.ac.uk.'}, {'ForeName': 'Sashiananthan', 'Initials': 'S', 'LastName': 'Ganesananthan', 'Affiliation': 'National Heart and Lung Institute, Imperial College London, United Kingdom.'}, {'ForeName': 'ChunHei', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Surgery and Cancer, Imperial College London, United Kingdom.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2020.07.001'] 2016,32663660,"Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.","BACKGROUND Current guidelines recommend anticoagulation therapy during primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI). However, whether anticoagulation should be continued after pPCI has not been well investigated. METHODS/DESIGN The RIGHT trial is a prospective, multicenter, randomized, double-blind, placebo-controlled trial in STEMI patients treated with pPCI evaluating the prolongation of anticoagulation after the procedure. Patients are randomized in a 1:1 fashion to receive either prolonged anticoagulant or matching placebo (no anticoagulation) for at least 48 hours after the procedure. When randomized to anticoagulation prolongation, the patient is assigned to intravenous unfractionated heparin (UFH) or subcutaneous enoxaparin or intravenous bivalirudin (same drug and same regimen at each center). The primary efficacy endpoint is the composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel) at 30 days. The primary safety endpoint is major bleeding (BARC 3-5) at 30 days. Based on a superiority design and assuming a 35% relative risk reduction (from 7% to 4.5%), 2856 patients will be enrolled, accounting for a 5% drop-out rate (α = 0.05 and power = 80%). CONCLUSION The RIGHT trial tests the hypothesis that post-procedural anticoagulation is superior to no anticoagulation in reducing ischemic events in STEMI patients undergoing pPCI.",2020,"The primary efficacy endpoint is the composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel) at 30 days.","['STEMI patients undergoing pPCI', 'STEMI patients treated with pPCI evaluating the prolongation of anticoagulation after the procedure', 'after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction']","['prolonged anticoagulant or matching placebo (no anticoagulation', 'unfractionated heparin (UFH) or subcutaneous enoxaparin or intravenous bivalirudin', 'anticoagulation prolongation versus no anticoagulation', 'placebo']","['composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel', 'major bleeding (BARC 3-5', 'ischemic events']","[{'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1536220', 'cui_str': 'ST Segment Elevation Myocardial Infarction'}]","[{'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0206460', 'cui_str': 'Enoxaparin'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0168273', 'cui_str': 'bivalirudin'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0442758', 'cui_str': '3/5'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",2856.0,0.600901,"The primary efficacy endpoint is the composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel) at 30 days.","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: eva3321@sina.com.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: spaceeye123@126.com.'}, {'ForeName': 'Jincheng', 'Initials': 'J', 'LastName': 'Guo', 'Affiliation': 'Beijing Luhe Hospital, Capital Medical University, Beijing, China. Electronic address: guojcmd@126.com.'}, {'ForeName': 'Yongjun', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'The Second Hospital of Hebei Medical University, Shijiazhuang, China. Electronic address: lyjbs2009@yeah.net.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Ai', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: aihui0814@126.com.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Gong', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: tjmusky@126.com.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Que', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: quebin@sohu.com.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhen', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: 13439546840@yeah.net.'}, {'ForeName': 'Jiapeng', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': 'National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: jiapeng.lu@fwoxford.org.'}, {'ForeName': 'Changsheng', 'Initials': 'C', 'LastName': 'Ma', 'Affiliation': 'Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Electronic address: chshma@vip.sina.com.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Montalescot', 'Affiliation': 'Sorbonne University, ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. Electronic address: gilles.montalescot@aphp.fr.'}, {'ForeName': 'Shaoping', 'Initials': 'S', 'LastName': 'Nie', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: spnie@ccmu.edu.cn.'}]",American heart journal,['10.1016/j.ahj.2020.06.005'] 2017,32687741,Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes: Results From a Randomized Trial.,"BACKGROUND The efficacy and safety of a reduced dose of prasugrel versus a standard dose of ticagrelor in elderly patients or those with a low body weight presenting with an acute coronary syndrome (ACS) are unknown. OBJECTIVE To investigate the effect of an age- and weight-adapted dose of prasugrel versus a standard dose of ticagrelor in patients with ACS. (ClinicalTrials.gov: NCT01944800). DESIGN Prespecified analysis of the multicenter, randomized ISAR-REACT 5 trial. SETTING 23 centers in Germany and Italy. PATIENTS 3997 patients with ACS planned for invasive management. INTERVENTION Participants were randomly assigned to receive a standard dose of ticagrelor or prasugrel (reduced dose in the elderly or low-weight group and standard dose in the neither elderly nor low-weight group). MEASUREMENTS The efficacy end point was a composite of death, myocardial infarction, or stroke, and the safety end point was bleeding, both at 12 months. RESULTS In the elderly or low-weight group, the efficacy end point occurred in 12.7% of patients assigned to receive prasugrel and 14.6% of those assigned to receive ticagrelor (hazard ratio [HR], 0.82 [95% CI, 0.60 to 1.14]); in the neither elderly nor low-weight group, the efficacy end point occurred in 4.8% of patients assigned to receive prasugrel and 7.3% of those assigned to receive ticagrelor (HR, 0.65 [CI, 0.48 to 0.88]; P for interaction > 0.2). In the elderly or low-weight group, Bleeding Academic Research Consortium type 3 to 5 bleeding occurred in 8.1% of patients assigned to receive prasugrel and 10.6% of those assigned to receive ticagrelor (HR, 0.72 [0.46 to 1.12]), and in 3.7% and 3.8%, respectively, of patients in the neither elderly nor low-weight group (HR, 0.98 [CI, 0.65 to 1.47]; P for interaction > 0.2). LIMITATION The study is a subgroup analysis. CONCLUSION In elderly or low-weight patients with ACS, a reduced dose of prasugrel compared with the standard dose of ticagrelor is associated with maintained anti-ischemic efficacy while protecting these patients against the excess risk for bleeding. PRIMARY FUNDING SOURCE German Center for Cardiovascular Research and Deutsches Herzzentrum München.",2020,"In the elderly or low-weight group, Bleeding Academic Research Consortium type 3 to 5 bleeding occurred in 8.1% of patients assigned to receive prasugrel and 10.6% of those assigned to receive ticagrelor (HR, 0.72 [0.46 to 1.12]), and in 3.7% and 3.8%, respectively, of patients in the neither elderly nor low-weight group (HR, 0.98 [CI, 0.65 to 1.47]; P for interaction > 0.2). ","['23 centers in Germany and Italy', 'Patients With Acute Coronary Syndromes', 'elderly patients or those with a low body weight presenting with an acute coronary syndrome (ACS', 'patients with ACS', '3997 patients with ACS planned for invasive management', 'In elderly or low-weight patients with ACS']","['Prasugrel Versus Standard Dose of Ticagrelor', 'prasugrel', 'ticagrelor or prasugrel (reduced dose in the elderly or low-weight group and standard dose in the neither elderly nor low-weight group', 'ticagrelor']","['efficacy end point', 'composite of death, myocardial infarction, or stroke, and the safety end point was bleeding']","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C1620287', 'cui_str': 'prasugrel'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]",3997.0,0.113308,"In the elderly or low-weight group, Bleeding Academic Research Consortium type 3 to 5 bleeding occurred in 8.1% of patients assigned to receive prasugrel and 10.6% of those assigned to receive ticagrelor (HR, 0.72 [0.46 to 1.12]), and in 3.7% and 3.8%, respectively, of patients in the neither elderly nor low-weight group (HR, 0.98 [CI, 0.65 to 1.47]; P for interaction > 0.2). ","[{'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Menichelli', 'Affiliation': 'Ospedale Fabrizio Spaziani, Cardiology, Frosinone, Italy (M.M.).'}, {'ForeName': 'Franz-Josef', 'Initials': 'FJ', 'LastName': 'Neumann', 'Affiliation': 'University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany (F.N., D.T.).'}, {'ForeName': 'Gjin', 'Initials': 'G', 'LastName': 'Ndrepepa', 'Affiliation': 'Deutsches Herzzentrum München and Technische Universität München, Munich, Germany (G.N., K.M., S.G., S.L.).'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Mayer', 'Affiliation': 'Deutsches Herzzentrum München and Technische Universität München, Munich, Germany (G.N., K.M., S.G., S.L.).'}, {'ForeName': 'Jochen', 'Initials': 'J', 'LastName': 'Wöhrle', 'Affiliation': 'Medical Campus Lake Constance, Friedrichshafen, Germany (J.W.).'}, {'ForeName': 'Isabell', 'Initials': 'I', 'LastName': 'Bernlochner', 'Affiliation': 'Medizinische Klinik und Poliklinik Innere Medizin I (Kardiologie, Angiologie, Pneumologie), Klinikum rechts der Isar, Munich, Germany, and German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (I.B.).'}, {'ForeName': 'Gert', 'Initials': 'G', 'LastName': 'Richardt', 'Affiliation': 'Heart Center Bad Segeberg, Bad Segeberg, Germany (G.R.).'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Witzenbichler', 'Affiliation': 'Helios Amper-Klinikum Dachau, Dachau, Germany (B.W.).'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Sibbing', 'Affiliation': 'Klinik der Universität München, Ludwig-Maximilians-Universität, Munich, Germany, and German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (D.S.).'}, {'ForeName': 'Senta', 'Initials': 'S', 'LastName': 'Gewalt', 'Affiliation': 'Deutsches Herzzentrum München and Technische Universität München, Munich, Germany (G.N., K.M., S.G., S.L.).'}, {'ForeName': 'Dominick J', 'Initials': 'DJ', 'LastName': 'Angiolillo', 'Affiliation': 'University of Florida College of Medicine, Jacksonville, Florida (D.J.A.).'}, {'ForeName': 'Shqipdona', 'Initials': 'S', 'LastName': 'Lahu', 'Affiliation': 'Deutsches Herzzentrum München and Technische Universität München, Munich, Germany (G.N., K.M., S.G., S.L.).'}, {'ForeName': 'Christian W', 'Initials': 'CW', 'LastName': 'Hamm', 'Affiliation': 'Heart Center, Campus Kerckhoff of Justus-Liebig-University, Giessen, Germany, and German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Germany (C.W.H.).'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Hapfelmeier', 'Affiliation': 'Technical University of Munich, School of Medicine, Institute of Medical Informatics, Statistics and Epidemiology, Munich, Germany (A.H.).'}, {'ForeName': 'Dietmar', 'Initials': 'D', 'LastName': 'Trenk', 'Affiliation': 'University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany (F.N., D.T.).'}, {'ForeName': 'Karl-Ludwig', 'Initials': 'KL', 'LastName': 'Laugwitz', 'Affiliation': 'Medizinische Klinik und Poliklinik Innere Medizin I, Klinikum rechts der Isar, Munich, Germany, and German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (K.L.).'}, {'ForeName': 'Heribert', 'Initials': 'H', 'LastName': 'Schunkert', 'Affiliation': 'Deutsches Herzzentrum München and Technische Universität München, Munich, Germany, and German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (H.S., S.S., A.K.).'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Schüpke', 'Affiliation': 'Deutsches Herzzentrum München and Technische Universität München, Munich, Germany, and German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (H.S., S.S., A.K.).'}, {'ForeName': 'Adnan', 'Initials': 'A', 'LastName': 'Kastrati', 'Affiliation': 'Deutsches Herzzentrum München and Technische Universität München, Munich, Germany, and German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (H.S., S.S., A.K.).'}]",Annals of internal medicine,['10.7326/M20-1806'] 2018,32687757,Gabapentin reduced drinking in patients with alcohol use disorder and alcohol withdrawal symptoms.,"SOURCE CITATION Anton RF, Latham P, Voronin K, et al. Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med. 2020;180:1-9. 32150232.",2020,Efficacy of gabapentin for the treatment of alcohol,"['patients with alcohol withdrawal symptoms', 'patients with alcohol use disorder and alcohol withdrawal symptoms']","['gabapentin', 'Gabapentin', 'alcohol']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0236663', 'cui_str': 'Alcohol withdrawal syndrome'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}]","[{'cui': 'C0060926', 'cui_str': 'gabapentin'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}]",[],,0.0263875,Efficacy of gabapentin for the treatment of alcohol,"[{'ForeName': 'Mat', 'Initials': 'M', 'LastName': 'Rose', 'Affiliation': 'Boyle McCauley Health Centre/University of Alberta, Edmonton, Alberta, Canada (M.R.).'}]",Annals of internal medicine,['10.7326/ACPJ202007210-006'] 2019,32687762,"In patients with CKD having CT with contrast media, no prehydration and prehydration did not differ for AKI.","SOURCE CITATION Timal RJ, Kooiman J, Sijpkens YWJ, et al. Effect of no prehydration vs sodium bicarbonate prehydration prior to contrast-enhanced computed tomography in the prevention of postcontrast acute kidney injury in adults with chronic kidney disease: the Kompas randomized clinical trial. JAMA Intern Med. 2020;180:533-41. 32065601.",2020,"SOURCE CITATION Timal RJ, Kooiman J, Sijpkens YWJ, et al. ",['adults with chronic kidney disease'],['no prehydration vs sodium bicarbonate prehydration prior to contrast-enhanced computed tomography'],[],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}]","[{'cui': 'C0074722', 'cui_str': 'Sodium Bicarbonate'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}]",[],,0.0187791,"SOURCE CITATION Timal RJ, Kooiman J, Sijpkens YWJ, et al. ","[{'ForeName': 'Neesh', 'Initials': 'N', 'LastName': 'Pannu', 'Affiliation': 'University of Alberta, Edmonton, Alberta, Canada (N.P.).'}]",Annals of internal medicine,['10.7326/ACPJ202007210-009'] 2020,32687763,Guselkumab safely improved clinical outcomes in biologic-naive patients with psoriatic arthritis.,"SOURCE CITATION Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1126-36. 32178766.",2020,"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. ","['biologic-naive patients with active psoriatic arthritis (DISCOVER-2', 'biologic-naive patients with psoriatic arthritis']","['Guselkumab', 'Guselkumab safely', 'placebo']",[],"[{'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0003872', 'cui_str': 'Psoriatic arthritis'}]","[{'cui': 'C3852217', 'cui_str': 'guselkumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.386249,"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. ","[{'ForeName': 'Ami', 'Initials': 'A', 'LastName': 'Schattner', 'Affiliation': 'Hebrew University Hadassah, Jerusalem, Israel (A.S.).'}]",Annals of internal medicine,['10.7326/ACPJ202007210-007'] 2021,32669487,Core Stability and Hip Exercises Improve Physical Function and Activity in Patients with Non-Specific Low Back Pain: A Randomized Controlled Trial.,"Approximately 90% of low back pain (LBP) diagnoses are non-specific (NSLBP; i.e. with unknown cause). In NSLBP patients, the hamstrings, iliopsoas, piriformis, and tensor fasciae latae are overactive due to weak hip abductor, extensor, and core muscles. Core stability is essential for proper load balance within the pelvis, spine, and kinetic chain, and core stability exercise (CSE) is an exercise treatment regimen for LBP conditions. We investigated how core stability and hip muscle stretching exercises affected NSLBP patients' physical function and activity. Patients were randomly allocated to three groups. The Stretch group (n = 24) performed exercises for hip muscle stretching for maximal motion; the Strengthen group (n = 22) performed exercises for hip muscle strengthening while maintaining the maximal isometric contraction. The Sham group (n = 20) received gentle palpation of the skin. Therapy was conducted thrice weekly for 6 weeks. Pain intensity, lower back instability, and hip muscle flexibility were measured to assess physical function. Disability level, balance ability, and quality of life were measured to assess physical activity. Data were collected prior to intervention and at 6-week follow-up. There were significant within-group changes for all measurements (P < 0.05). The Stretch and Strengthen groups had greater improvements in pain intensity, disability level, balance ability, and quality of life than the Sham group. Lower back instability and hip muscle flexibility had the greatest improvement in the Stretch group. In conclusion, CSE and hip muscle stretching are effective at improving physical function and activity in NSLBP patients.",2020,"The Stretch and Strengthen groups had greater improvements in pain intensity, disability level, balance ability, and quality of life than the Sham group.","['NSLBP patients', 'Patients with Non-Specific Low Back Pain']","['Core Stability and Hip Exercises', 'exercises for hip muscle stretching for maximal motion; the Strengthen group (n = 22) performed exercises for hip muscle strengthening while maintaining the maximal isometric contraction', 'gentle palpation of the skin']","['Pain intensity, lower back instability, and hip muscle flexibility', 'Lower back instability and hip muscle flexibility', 'Disability level, balance ability, and quality of life', 'pain intensity, disability level, balance ability, and quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205370', 'cui_str': 'Non-specific'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}]","[{'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0454362', 'cui_str': 'Hip exercises'}, {'cui': 'C0407178', 'cui_str': 'Stretching of muscle'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0022205', 'cui_str': 'Muscle isometric contraction'}, {'cui': 'C0030247', 'cui_str': 'Palpation'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0085633', 'cui_str': 'Mood swings'}, {'cui': 'C0224415', 'cui_str': 'Skeletal muscle structure of hip'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0560184', 'cui_str': 'Ability to balance'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.0585005,"The Stretch and Strengthen groups had greater improvements in pain intensity, disability level, balance ability, and quality of life than the Sham group.","[{'ForeName': 'Beomryong', 'Initials': 'B', 'LastName': 'Kim', 'Affiliation': 'Department of Physical Therapy, The Graduate School of Sahmyook University.'}, {'ForeName': 'Jongeun', 'Initials': 'J', 'LastName': 'Yim', 'Affiliation': 'Department of Physical Therapy, The Graduate School of Sahmyook University.'}]",The Tohoku journal of experimental medicine,['10.1620/tjem.251.193'] 2022,32669521,Comparative efficacy and safety of Verbascox ® - a proprietary herbal extract capable of inhibiting human cyclooxygenase-2 - and celecoxib for knee osteoarthritis.,"The aim of this randomized, single-blind, active-controlled pilot study was to investigate the clinical efficacy of oral supplementation with Verbascox ® , a proprietary herbal extract capable of inhibiting human cyclooxygenase-2 (COX-2), in patients with mild-to-moderate osteoarthritis (OA) of the knee. Patients in the control group (n = 50) did not undergo any treatment (watchful waiting). Patients in the Verbascox ® group (n = 50) received oral supplementation (800 mg/day) with the herbal extract for 2 weeks. The final study group consisted of patients (n = 50) who received celecoxib, a known pharmacological inhibitor of COX-2, 200 mg/day for 2 weeks. Examining physicians and laboratory personnel were blinded to group assignment, whereas patients were unblinded. All participants were evaluated using standard measures of pain relief and improvement in functional capacity at baseline, after 1 week, and at the end of the 2-week treatment course. Moreover, serum levels of substance P (SP), a member of the tachykinin family of neuropeptides involved in pain perception, were measured at the three time points. Both Verbascox ® and celecoxib reduced pain, improved functional capacity, and lowered serum SP levels at 2 weeks compared with baseline, without significant inter-arm differences. Both Verbascox ® and celecoxib showed a limited number of treatment-emergent adverse events. In summary, oral supplementation with Verbascox ® (800 mg/day) in patients with mild-to-moderate OA of the knee is as effective and safe as a standard therapeutic dose of celecoxib in terms of pain relief and improvement in functional capacity after a 2-week treatment course.",2020,"Both Verbascox ® and celecoxib reduced pain, improved functional capacity, and lowered serum SP levels at 2 weeks compared with baseline, without significant inter-arm differences.","['knee osteoarthritis', 'patients with mild-to-moderate osteoarthritis (OA) of the knee']","['oral supplementation with Verbascox ®', 'herbal extract', 'celecoxib, a known pharmacological inhibitor of COX-2', 'Verbascox ®', 'oral supplementation', 'celecoxib']","['serum levels of substance P (SP), a member of the tachykinin family of neuropeptides involved in pain perception', 'pain, improved functional capacity, and lowered serum SP levels', 'pain relief and improvement in functional capacity']","[{'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0376667', 'cui_str': 'Herbals'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0538927', 'cui_str': 'celecoxib'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0387583', 'cui_str': 'Cyclooxygenase 2'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0038585', 'cui_str': 'Substance P'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0039241', 'cui_str': 'Tachykinin'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0027895', 'cui_str': 'Neuropeptide'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}]",,0.0756157,"Both Verbascox ® and celecoxib reduced pain, improved functional capacity, and lowered serum SP levels at 2 weeks compared with baseline, without significant inter-arm differences.","[{'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Nannoni', 'Affiliation': 'R&D, LaBiotre srl, Tavarnelle Val di Pesa (FI), Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Volterrani', 'Affiliation': 'R&D, LaBiotre srl, Tavarnelle Val di Pesa (FI), Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Mattarocci', 'Affiliation': 'R&D, LaBiotre srl, Tavarnelle Val di Pesa (FI), Italy.'}, {'ForeName': 'Piercarlo', 'Initials': 'P', 'LastName': 'Minoretti', 'Affiliation': 'Studio Minoretti, Oggiono (LC), Italy.'}, {'ForeName': 'Enzo', 'Initials': 'E', 'LastName': 'Emanuele', 'Affiliation': '2E Science, Via Monte Grappa, Robbio (PV), Italy.'}]",Drug discoveries & therapeutics,['10.5582/ddt.2020.03034'] 2023,32672806,Effectiveness of a Multimedia Educational Intervention to Improve Understanding of the Risks and Benefits of Palliative Chemotherapy in Patients With Advanced Cancer: A Randomized Clinical Trial.,"Importance Despite requirements of informed consent, patients with advanced cancer often receive palliative chemotherapy (PC) without understanding that the likelihood of cure is remote. Objective To determine whether a PC educational video and booklet at treatment initiation could improve patients' understanding of its benefits and risks. Interventions Regimen-specific PC videos and booklets presenting information about logistics, potential benefits, life expectancy (optional), adverse effects, and alternatives. Videos featured authentic patients sharing diverse experiences. After receiving treatment recommendations, research assistants distributed materials to patients for independent review. Design, Setting, and Participants Multicenter randomized clinical trial of patients with advanced colorectal or pancreatic cancer starting first-line or second-line PC in 5 US cancer centers with enrollment from June 2015 to September 2017 and follow-up to December 2019. Main Outcomes and Measures The primary outcome was accurate expectations of chemotherapy benefits at 3 months, defined as responding ""not at all likely"" to ""What is your understanding of how likely the chemotherapy is to cure your cancer?"" (from the Cancer Care Outcomes Research and Surveillance study). Secondary outcomes included understanding of adverse effects, decisional conflict (SURE test), regret (Decisional Regret Scale), and distress (Functional Assessment of Cancer Therapy-General emotional well-being subscale). Results Among 186 patients with advanced colorectal or pancreatic cancer who were starting first-line or second-line PC (94 randomized to usual care, 92 to intervention; mean [SD] age, 59.3 [12.6] [range, 28-86] years; 107 [58%] male; 118 [63.4%] colorectal and 68 [36.6%] pancreatic cancer), most patients wanted ""a lot"" of information or ""as much information as possible"" about adverse effects (149, 80.1%), likelihood of cure (148, 79.6%), and prognosis (148, 79.6%). Among the intervention arm, 59 (78%) reviewed the booklet and 30 (40%) reviewed the video within 2 weeks. The primary outcome did not differ between intervention and control arms (52.6%; 95% CI, 40.3%-65.0%; vs 55.5%; 95% CI, 45.1%-66.0%). Accurate adverse effect understanding was more common among intervention than control patients (56.0%; 95% CI, 44.3%-67.7%; vs 40.2%; 95% CI, 29.5%-50.9%; P = .05), although this did not meet the threshold for statistical significance. The intervention did not increase distress, despite frank prognostic information. Other secondary outcomes were similar. Conclusions and Relevance Provision of an educational video and booklet did not alter patients' expectation of cure from PC. Alternative delivery strategies, such as integration with nurse teaching, could be explored in future studies. Trial Registration ClinicalTrials.gov Identifier: NCT02282722.",2020,"Accurate adverse effect understanding was more common among intervention than control patients (56.0%; 95% CI, 44.3%-67.7%; vs 40.2%; 95% CI, 29.5%-50.9%; P = .05), although this did not meet the threshold for statistical significance.","['Patients With Advanced Cancer', 'patients with advanced cancer often receive', 'patients with advanced colorectal or pancreatic cancer starting first-line or second-line PC in 5 US cancer centers with enrollment from June 2015 to September 2017 and follow-up to December 2019', '186 patients with advanced colorectal or pancreatic cancer who were starting first-line or second-line PC (94 randomized to usual care, 92 to intervention; mean [SD] age, 59.3 [12.6] [range, 28-86] years; 107 [58%] male; 118 [63.4%] colorectal and 68']","['Palliative Chemotherapy', 'palliative chemotherapy (PC', 'PC educational video and booklet', 'Multimedia Educational Intervention']","['likelihood of cure', 'understanding of adverse effects, decisional conflict (SURE test), regret (Decisional Regret Scale), and distress (Functional Assessment of Cancer Therapy-General emotional well-being subscale', 'accurate expectations of chemotherapy benefits', 'distress, despite frank prognostic information', 'pancreatic cancer']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C0235974', 'cui_str': 'Carcinoma of pancreas'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0587605', 'cui_str': 'Palliative care service'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517545', 'cui_str': '12.6'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4517542', 'cui_str': '118'}]","[{'cui': 'C0587605', 'cui_str': 'Palliative care service'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0376478', 'cui_str': 'Multimedium'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0231394', 'cui_str': 'Decisional conflict'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0080101', 'cui_str': 'Regret'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0398650', 'cui_str': 'Idiopathic thrombocytopenic purpura'}, {'cui': 'C0235974', 'cui_str': 'Carcinoma of pancreas'}]",186.0,0.171388,"Accurate adverse effect understanding was more common among intervention than control patients (56.0%; 95% CI, 44.3%-67.7%; vs 40.2%; 95% CI, 29.5%-50.9%; P = .05), although this did not meet the threshold for statistical significance.","[{'ForeName': 'Andrea C', 'Initials': 'AC', 'LastName': 'Enzinger', 'Affiliation': 'Division of Population Sciences, Dana-Farber/Partners CancerCare, Boston, Massachusetts.'}, {'ForeName': 'Hajime', 'Initials': 'H', 'LastName': 'Uno', 'Affiliation': 'Division of Population Sciences, Dana-Farber/Partners CancerCare, Boston, Massachusetts.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'McCleary', 'Affiliation': 'Division of Gastrointestinal Oncology, Dana-Farber/Partners CancerCare, Boston, Massachusetts.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Frank', 'Affiliation': ""Susan F. Smith Center for Women's Cancers, Dana-Farber/Partners CancerCare, Boston, Massachusetts.""}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Sanoff', 'Affiliation': 'Division of Medical Oncology, University of North Carolina Lineberger Cancer Center, Chapel Hill.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Van Loon', 'Affiliation': 'Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco.'}, {'ForeName': 'Khalid', 'Initials': 'K', 'LastName': 'Matin', 'Affiliation': 'Division of Medical Oncology, Virginia Commonwealth University, Richmond.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Bullock', 'Affiliation': 'Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Cronin', 'Affiliation': 'Division of Population Sciences, Dana-Farber/Partners CancerCare, Boston, Massachusetts.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Cibotti', 'Affiliation': 'Department of Nursing, Dana-Farber/Partners CancerCare, Boston, Massachusetts.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Bagley', 'Affiliation': 'Department of Nursing, Dana-Farber/Partners CancerCare, Boston, Massachusetts.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Schrag', 'Affiliation': 'Division of Population Sciences, Dana-Farber/Partners CancerCare, Boston, Massachusetts.'}]",JAMA oncology,['10.1001/jamaoncol.2020.1921'] 2024,32672829,Effect of Cold Atmospheric Plasma Therapy vs Standard Therapy Placebo on Wound Healing in Patients With Diabetic Foot Ulcers: A Randomized Clinical Trial.,"Importance Diabetic foot ulcers are a common complication of diabetes and require specialized treatment. Cold atmospheric plasma (CAP) has been associated with benefits in wound infection and healing in previous smaller series of case reports. Yet the effect of CAP compared with standard care therapy in wound healing in diabetic foot ulcers remains to be studied. Objective To determine whether the application of CAP accelerates wound healing in diabetic foot ulcers compared with standard care therapy. Design, Setting, and Participants A prospective, randomized, placebo-controlled, patient-blinded clinical trial was conducted at 2 clinics with recruitment from August 17, 2016, to April 20, 2019. Patients were scheduled to remain in follow-up until April 30, 2024. Patients with diabetes and diabetic foot ulcers described using the combined Wagner-Armstrong classification of 1B or 2B (superficial or infected diabetic foot ulcers extending to tendon) were eligible. A patient could participate with 1 or more wounds in both groups in both intervention and control groups. Wounds were randomized separately, allowing a participant to be treated several times within the study following a 2 × 2 × 2 randomization strata considering sex, smoking status, and age (≤68 years and >68 years). Interventions Standard care treatment with 8 applications of either CAP generated from argon gas in an atmospheric pressure plasma jet or 8 applications of placebo treatment in a patient-blinded manner. Main Outcomes and Measures Primary end points were reduction in wound size, clinical infection, and microbial load compared with treatment start. Secondary end points were time to relevant wound reduction (>10%), reduction of infection, parameters of patient's well-being, and treatment-associated adverse events. Results Of 65 diabetic foot ulcer wounds from 45 patients assessed for study, 33 wounds from 29 patients were randomized to CAP and 32 wounds from 28 to placebo, with 62 wounds from 43 patients (31 wounds per group) included for final evaluation (mean [SD] age, 68.5 [9.1] years for full sample). Four patients with 5 wounds of 31 (16.1%) wounds in the CAP group and 3 patients with 4 wounds of 31 (13%) wounds in the placebo group were active smokers. CAP therapy yielded a significant increase in wound healing, both in total mean (SD) area reduction (CAP vs placebo relative units, -26.31 [11.72]; P = .03) and mean (SD) time to relevant wound area reduction (CAP vs placebo relative units, 10% from baseline, 1.60 [0.58]; P = .009). Reduction of infection and microbial load was not significantly different between CAP and placebo. No therapy-related adverse events occurred during therapy; patient's perceptions during therapy were comparable. Conclusions and Relevance In this randomized clinical trial, CAP therapy resulted in beneficial effects in chronic wound treatment in terms of wound surface reduction and time to wound closure independent from background infection. Trial Registration ClinicalTrials.gov Identifier: NCT04205942.",2020,"CAP therapy yielded a significant increase in wound healing, both in total mean (SD) area reduction (CAP vs placebo relative units, -26.31 [11.72]; P = .03) and mean (SD) time to relevant wound area reduction (CAP vs placebo relative units, 10% from baseline, 1.60 [0.58]; P = .009).","['Patients were scheduled to remain in follow-up until April 30, 2024', ' with 62 wounds from 43 patients (31 wounds per group) included for final evaluation (mean [SD] age, 68.5 [9.1] years for full sample', 'Patients With Diabetic Foot Ulcers', '2 clinics with recruitment from August 17, 2016, to April 20, 2019', 'diabetic foot ulcers', '65 diabetic foot ulcer wounds from 45 patients assessed for study, 33 wounds from 29 patients', 'Patients with diabetes and diabetic foot ulcers described using the combined Wagner-Armstrong classification of 1B or 2B (superficial or infected diabetic foot ulcers extending to tendon) were eligible']","['CAP therapy', 'Cold Atmospheric Plasma Therapy vs Standard Therapy Placebo', 'Cold atmospheric plasma (CAP', 'standard care therapy', 'CAP', 'placebo']","[""reduction of infection, parameters of patient's well-being, and treatment-associated adverse events"", 'time to relevant wound reduction', 'Wound Healing', 'total mean (SD) area reduction', 'wound healing', 'adverse events', 'reduction in wound size, clinical infection, and microbial load', 'Reduction of infection and microbial load']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C1456868', 'cui_str': 'Diabetic foot ulcer'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0439792', 'cui_str': 'Extent'}, {'cui': 'C0039508', 'cui_str': 'Tendon structure'}]","[{'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0456389', 'cui_str': 'Size'}]",4.0,0.164355,"CAP therapy yielded a significant increase in wound healing, both in total mean (SD) area reduction (CAP vs placebo relative units, -26.31 [11.72]; P = .03) and mean (SD) time to relevant wound area reduction (CAP vs placebo relative units, 10% from baseline, 1.60 [0.58]; P = .009).","[{'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Stratmann', 'Affiliation': 'Diabeteszentrum, Herz- und Diabeteszentrum Nordrhein Westfalen (NRW), Ruhr Universität Bochum, Bad Oeynhausen, Germany.'}, {'ForeName': 'Tania-Cristina', 'Initials': 'TC', 'LastName': 'Costea', 'Affiliation': 'Diabeteszentrum, Herz- und Diabeteszentrum Nordrhein Westfalen (NRW), Ruhr Universität Bochum, Bad Oeynhausen, Germany.'}, {'ForeName': 'Catharina', 'Initials': 'C', 'LastName': 'Nolte', 'Affiliation': 'Diabeteszentrum, Herz- und Diabeteszentrum Nordrhein Westfalen (NRW), Ruhr Universität Bochum, Bad Oeynhausen, Germany.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Hiller', 'Affiliation': 'Diabeteszentrum, Herz- und Diabeteszentrum Nordrhein Westfalen (NRW), Ruhr Universität Bochum, Bad Oeynhausen, Germany.'}, {'ForeName': 'Jörn', 'Initials': 'J', 'LastName': 'Schmidt', 'Affiliation': 'Klinikum Karlsburg der Klinikgruppe Dr Guth GmbH & Co KG, Karlsburg, Germany.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Reindel', 'Affiliation': 'Klinikum Karlsburg der Klinikgruppe Dr Guth GmbH & Co KG, Karlsburg, Germany.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Masur', 'Affiliation': 'Leibniz-Institut für Plasmaforschung und Technologie, Greifswald, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Motz', 'Affiliation': 'Klinikum Karlsburg der Klinikgruppe Dr Guth GmbH & Co KG, Karlsburg, Germany.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Timm', 'Affiliation': 'Competence Center for Clinical Studies Bremen, Bremen, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Kerner', 'Affiliation': 'Klinikum Karlsburg der Klinikgruppe Dr Guth GmbH & Co KG, Karlsburg, Germany.'}, {'ForeName': 'Diethelm', 'Initials': 'D', 'LastName': 'Tschoepe', 'Affiliation': 'Diabeteszentrum, Herz- und Diabeteszentrum Nordrhein Westfalen (NRW), Ruhr Universität Bochum, Bad Oeynhausen, Germany.'}]",JAMA network open,['10.1001/jamanetworkopen.2020.10411'] 2025,32668482,Erratum: Effects of Sustained Inflation or Positive Pressure Ventilation on the Release of Adrenomedullin in Preterm Infants with Respiratory Failure at Birth.,,2019,,['Preterm Infants with Respiratory Failure at Birth'],['Sustained Inflation or Positive Pressure Ventilation'],[],"[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}, {'cui': 'C1744681', 'cui_str': 'Congenital'}]","[{'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0021398', 'cui_str': 'Economic Inflation'}, {'cui': 'C0021778', 'cui_str': 'Intermittent positive pressure ventilation'}]",[],,0.0385335,,"[{'ForeName': 'Azzurra La', 'Initials': 'A', 'LastName': 'Verde', 'Affiliation': ""Neonatal Intensive Care Unit, V. Buzzi Children's Hospital, ASST-FBFSacco, Milan, Italy.""}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Franchini', 'Affiliation': ""Neonatal Intensive Care Unit, G. D'Annunzio University of Chieti, Chieti, Italy.""}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Lapergola', 'Affiliation': ""Neonatal Intensive Care Unit, G. D'Annunzio University of Chieti, Chieti, Italy.""}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Lista', 'Affiliation': ""Neonatal Intensive Care Unit, V. Buzzi Children's Hospital, ASST-FBFSacco, Milan, Italy.""}, {'ForeName': 'Ignazio', 'Initials': 'I', 'LastName': 'Barbagallo', 'Affiliation': 'Department of Biomedical and Biotechnological Sciences Section of Biochemistry, University of Catania, Catania, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Livolti', 'Affiliation': 'Department of Biomedical and Biotechnological Sciences Section of Biochemistry, University of Catania, Catania, Italy.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Gazzolo', 'Affiliation': ""Neonatal Intensive Care Unit, G. D'Annunzio University of Chieti, Chieti, Italy.""}]",American journal of perinatology,['10.1055/s-0040-1714104'] 2026,32675042,"Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.","OBJECTIVES This study evaluated the efavirenz (EFV) mid-dose plasma concentration (C12), clinical efficacy, and safety after the switch to a single-tablet regimen containing tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and 400-mg EFV in virally suppressed HIV-positive Taiwanese who were receiving co-formulated TDF, emtricitabine (FTC), and 600-mg EFV. METHODS In this single-arm, open-label study, HIV-positive adults who had undetectable plasma HIV RNA load (<50 copies/ml) for 6 months or longer while receiving co-formulated TDF, FTC, and 600-mg EFV with EFV C12 of ≥1 mg/L were enrolled. The participants were switched to co-formulated TDF, 3TC, and 400-mg EFV and followed for 24 weeks. The primary endpoint was the proportion of participants with EFV C12 ≥ 1 mg/L at Week 4. The secondary endpoints included virologic response and change of CD4 lymphocyte count up to Week 24. Specific adverse effects associated with EFV were recorded before and after the switch. RESULTS From December 2018 to January 2019, 50 participants were enrolled. EFV C12 remained ≥1 mg/L in 48 (96.0%) participants with a median reduction of 38.9% (interquartile range 29.0-44.4) at Week 4 after switch. All participants had undetectable plasma HIV RNA by Week 12, whereas 96.0% of them remained so at Week 24. Significant increases of CD4 lymphocyte count were observed at Weeks 12 and 24. Thirty-three participants (66.0%) reported improvement of pre-existing adverse effects. CONCLUSION Switch to coformulated TDF, 3TC, and 400-mg EFV in virally suppressed HIV-positive Taiwanese maintained effective EFV concentration and viral suppression while the adverse effects were reduced.",2020,"All participants had undetectable plasma HIV RNA by Week 12, whereas 96.0% of them remained so at Week 24.","['HIV-positive adults who had undetectable plasma HIV RNA load (<50 copies/ml) for 6 months or longer while receiving co-formulated TDF, FTC, and 600-mg EFV with EFV C12 of ≥1\xa0mg/L were enrolled', 'From December 2018 to January 2019, 50 participants were enrolled', 'HIV-positive patients with viral suppression', 'virally suppressed HIV-positive Taiwanese who were receiving co-formulated']","['tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and 400-mg EFV', 'TDF, 3TC, and 400-mg EFV', 'EFV C12', 'TDF, emtricitabine (FTC', 'efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine']","['efavirenz (EFV) mid-dose plasma concentration (C12), clinical efficacy, and safety', 'HIV-positive Taiwanese maintained effective EFV concentration and viral suppression', 'undetectable plasma HIV RNA', 'CD4 lymphocyte count', 'virologic response and change of CD4 lymphocyte count', 'proportion of participants with EFV C12', 'improvement of pre-existing adverse effects']","[{'cui': 'C0019699', 'cui_str': 'HIV positive'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0674428', 'cui_str': 'efavirenz'}, {'cui': 'C0439268', 'cui_str': 'mg/L'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C1260953', 'cui_str': 'Suppressed'}, {'cui': 'C1556096', 'cui_str': 'Taiwanese'}]","[{'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0209738', 'cui_str': 'Lamivudine'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0674428', 'cui_str': 'efavirenz'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}]","[{'cui': 'C0674428', 'cui_str': 'efavirenz'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0019699', 'cui_str': 'HIV positive'}, {'cui': 'C1556096', 'cui_str': 'Taiwanese'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Cell Counts'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",50.0,0.126093,"All participants had undetectable plasma HIV RNA by Week 12, whereas 96.0% of them remained so at Week 24.","[{'ForeName': 'Wei-Chieh', 'Initials': 'WC', 'LastName': 'Huang', 'Affiliation': 'School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Chun-Kai', 'Initials': 'CK', 'LastName': 'Huang', 'Affiliation': 'Department of Internal Medicine, I-Da Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Sung-Hsi', 'Initials': 'SH', 'LastName': 'Huang', 'Affiliation': 'Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan; Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Shu-Wen', 'Initials': 'SW', 'LastName': 'Lin', 'Affiliation': 'Department of Pharmacy, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Graduate Institute of Clinical Pharmacy, National Taiwan University College of Medicine, Taipei, Taiwan; School of Pharmacy, National Taiwan University, Taipei, Taiwan.'}, {'ForeName': 'Shyh-Tyan', 'Initials': 'ST', 'LastName': 'Ou', 'Affiliation': 'Department of Statistics, National Taipei University, Taipei, Taiwan.'}, {'ForeName': 'Yi-Ting', 'Initials': 'YT', 'LastName': 'Chen', 'Affiliation': 'Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Ya-Wen', 'Initials': 'YW', 'LastName': 'Chen', 'Affiliation': 'Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Shu-Yuan', 'Initials': 'SY', 'LastName': 'Chang', 'Affiliation': 'Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Wen-Chun', 'Initials': 'WC', 'LastName': 'Liu', 'Affiliation': 'Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Hsin-Yun', 'Initials': 'HY', 'LastName': 'Sun', 'Affiliation': 'Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: hysun@ntu.edu.tw.'}, {'ForeName': 'Chien-Ching', 'Initials': 'CC', 'LastName': 'Hung', 'Affiliation': 'Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.'}]","Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi",['10.1016/j.jmii.2020.06.010'] 2027,32675229,Safety decision-making and planning mobile app for intimate partner violence prevention and response: randomised controlled trial in Kenya.,"INTRODUCTION Intimate partner violence (IPV) threatens women's health and safety globally, yet services remain underdeveloped and inaccessible. Technology-based resources exist, however, few have been adapted and tested in low-resource settings. We evaluate the efficacy of a community-partnered technology solution: culturally and linguistically adapted version of the myPlan app, a tailored safety decision-making and planning intervention, administrated by trained lay professionals. METHODS This randomised, controlled, participant-blinded superiority trial compares safety-related outcomes at baseline, immediate post intervention and 3-month follow-up among women at risk of and experiencing IPV in Nairobi, Kenya. Women were randomised (1:1 ratio) to: (1) myPlan Kenya (intervention); or (2) standard IPV referrals (control). Primary outcomes were safety preparedness, safety behaviour and IPV; secondary outcomes include resilience, mental health, service utilisation and self-blame. RESULTS Between April 2018 and October 2018, 352 participants (n=177 intervention, n=175 control) were enrolled and randomly assigned; 312 (88.6%, n=157 intervention, n=155 control) were retained at 3 months. Intervention participants demonstrated immediate postintervention improvement in safety preparedness relative to control participants (p=0.001). At 3 months, intervention participants reported increased helpfulness of safety strategies used relative to control participants (p=0.004); IPV reduced in both groups. Among women reporting the highest level of IPV severity, intervention participants had significant increase in resilience (p<0.01) compared with controls, and significantly decreased risk for lethal violence (p<0.01). CONCLUSIONS Facilitated delivery of a technology-based safety intervention appropriately adapted to the context demonstrates promise in improving women's IPV-related health and safety in a low-resource, urban setting. TRIAL REGISTRATION NUMBER Pan African Clinical Trial Registry (PACTR201804003321122).",2020,Intervention participants demonstrated immediate postintervention improvement in safety preparedness relative to control participants (p=0.001).,"['women at risk of and experiencing IPV in Nairobi, Kenya', 'Between April 2018 and October 2018, 352 participants (n=177 intervention, n=175 control) were enrolled and randomly assigned; 312 (88.6%, n=157 intervention, n=155 control']","['community-partnered technology solution', 'myPlan Kenya (intervention); or (2) standard IPV referrals (control']","['immediate postintervention improvement in safety preparedness', 'risk for lethal violence', 'IPV', 'safety preparedness, safety behaviour and IPV; secondary outcomes include resilience, mental health, service utilisation and self-blame', 'helpfulness of safety strategies']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0027345', 'cui_str': 'Nairobi sheep virus disease'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C4517706', 'cui_str': '312'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C1321226', 'cui_str': 'Safety behavior'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0018379', 'cui_str': 'Feeling guilt'}]",,0.174925,Intervention participants demonstrated immediate postintervention improvement in safety preparedness relative to control participants (p=0.001).,"[{'ForeName': 'Michele R', 'Initials': 'MR', 'LastName': 'Decker', 'Affiliation': 'Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA mdecker@jhu.edu.'}, {'ForeName': 'Shannon N', 'Initials': 'SN', 'LastName': 'Wood', 'Affiliation': 'Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Zaynab', 'Initials': 'Z', 'LastName': 'Hameeduddin', 'Affiliation': 'Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'S Rachel', 'Initials': 'SR', 'LastName': 'Kennedy', 'Affiliation': 'Johns Hopkins University School of Nursing, Baltimore, Maryland, USA.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Perrin', 'Affiliation': 'Johns Hopkins University School of Nursing, Baltimore, Maryland, USA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Tallam', 'Affiliation': 'Ujamaa Africa, Nairobi, Kenya.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Akumu', 'Affiliation': 'Ujamaa Africa, Nairobi, Kenya.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Wanjiru', 'Affiliation': 'Ujamaa Africa, Nairobi, Kenya.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Asira', 'Affiliation': 'Ujamaa Africa, Nairobi, Kenya.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Frankel', 'Affiliation': 'International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Omondi', 'Affiliation': 'Ujamaa Africa, Nairobi, Kenya.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Case', 'Affiliation': 'Johns Hopkins University School of Nursing, Baltimore, Maryland, USA.'}, {'ForeName': 'Amber', 'Initials': 'A', 'LastName': 'Clough', 'Affiliation': 'Johns Hopkins University School of Nursing, Baltimore, Maryland, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Otieno', 'Affiliation': 'Ujamaa Africa, Nairobi, Kenya.'}, {'ForeName': 'Morris', 'Initials': 'M', 'LastName': 'Mwiti', 'Affiliation': 'Ujamaa Africa, Nairobi, Kenya.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Glass', 'Affiliation': 'Johns Hopkins University School of Nursing, Baltimore, Maryland, USA.'}]",BMJ global health,['10.1136/bmjgh-2019-002091'] 2028,32675585,Minimal Pain Decrease Between 2 and 4 Weeks after Nonoperative Management of a Displaced Midshaft Clavicle Fracture Is Associated with a High Risk of Symptomatic Nonunion.,"BACKGROUND The main long-term benefit of operative treatment of displaced midshaft clavicular fractures is the reduction in nonunion risk, and as this risk is generally low, the ideal approach would be to operate only patients at high risk of nonunion. However, most current surgical decision models use baseline variables to estimate the nonunion risk, and the value of these models remains unclear. Pain in the early weeks after fracture could be potentially be an indirect measurement of fracture healing, and so it is a potential proxy variable that could lead to simpler prediction models. QUESTIONS/PURPOSES (1) Is pain a possible proxy variable for the development of symptomatic nonunion after nonoperative treatment of midshaft clavicular fractures? (2) How reliable is the model we created that uses pain as a proxy variable for symptomatic nonunion of nonoperatively treated clavicle fractures? METHODS In this secondary retrospective analysis of an earlier randomized trial, we studied prospectively collected data from 64 nonoperatively treated patients aged 18 years to 60 years. In the original randomized trial, we compared operative and nonoperative treatment of displaced midshaft clavicular fractures. In all, 150 patients were included in the study, of whom 71 received nonoperative treatment. Patients were predominantly males (75%, 48 of 64) with a mean age of 38 ± SD 12 years; most fractures were comminuted and shortened more than 1 cm. All 71 patients who were nonoperatively treated were potentially eligible for this secondary analysis; of those, 11% (8 of 71) were lost to follow-up, leaving 63 patients from the nonoperative treatment arm and one patient from the operative treatment arm (who declined surgical treatment after randomization but was followed in this group according to the intention-to-treat principle) for analysis here. Nonunion was defined as lack of callus formation, persistent fracture lines and/or sclerotic edges of the bones at the fracture site on plain radiographs at 6 months follow-up. Nonunions were regarded as symptomatic if pain, tenderness, and local crepitation were present at the fracture site. Seventeen percent (11 of 64) of patients had symptomatic nonunions. After investigating differences in early pain scores between the union and nonunion groups, we defined the VASratio as the VAS pain score at 4 weeks divided by the VAS pain score at 2 weeks. Week 2 VAS pain score was chosen as baseline after visual inspection of a linear mixed model that showed increased divergence in pain scores between union and nonunion group at 2 weeks after fracture. Week 4 was chosen as the cutoff because we wanted a reasonable time frame for the detection of pain reduction and did not want to delay surgical treatment more than necessary. Odds ratios for various risk factors were calculated using logistic regression analyses. We used a receiver operating characteristic curve analysis to identify cutoff values for the VASratio. RESULTS An increase in absolute pain score at 4 weeks after fracture (odds ratio 1.8 per 1 point increase [95% confidence interval 1.1 to 3.4]) was associated with an increased risk of nonunion 6 months after fracture. Likewise, we found that an increasing VASratio (OR 1.02 per 0.01 point increase [95% CI 1.002 to 1.06]) was also associated with nonunion. Receiver operating curve analysis found that the best cutoff value of VASratio was about 0.6. Patients with a VASratio above 0.6 had a relative risk of developing nonunion of 18 (95% CI 2 to 130) compared with patients with a VASratio below 0.6. Sparse-data bias could be present, as is evident from this wide confidence interval, though even at the low end of the confidence interval, the relative risk was 2, which may still improve surgical decision-making. CONCLUSIONS A pain score that exhibits no or minimal change from 2 to 4 weeks after nonoperative treatment of a displaced midshaft fracture of the clavicle is associated with a high risk that symptomatic nonunion will develop. Patients with no or minimal change in pain in the early weeks may be candidates for surgery to reduce the risk of symptomatic nonunion. As this was a retrospective study, with a risk of sparse-data bias, the predictive value of the VASratio needs to be further investigated in large prospective studies before clinical use. LEVEL OF EVIDENCE Level III, diagnostic study.",2020,An increase in absolute pain score at 4 weeks after fracture (odds ratio 1.8 per 1 point increase,"['All 71 patients who were nonoperatively treated were potentially eligible for this secondary analysis; of those, 11% (8 of 71) were lost to follow-up, leaving 63 patients from the nonoperative treatment arm and one patient from the operative treatment arm (who declined surgical treatment after randomization but was followed in this group according to the intention-to-treat principle) for analysis here', 'displaced midshaft clavicular fractures', '64 nonoperatively treated patients aged 18 years to 60 years', 'Patients were predominantly males (75%, 48 of 64) with a mean age of 38 ± SD 12 years', '150 patients were included in the study, of whom 71 received nonoperative treatment']",[],"['pain scores', 'VASratio', 'VAS pain score', 'symptomatic if pain, tenderness, and local crepitation', 'Minimal Pain Decrease', 'early pain scores', 'Pain', 'relative risk of developing nonunion', 'pain', 'absolute pain score', 'symptomatic nonunions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1302313', 'cui_str': 'Lost to follow-up'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0012727', 'cui_str': 'Displacement'}, {'cui': 'C0159658', 'cui_str': 'Fracture of clavicle'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],"[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0234233', 'cui_str': 'Soreness'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0034642', 'cui_str': 'Respiratory crackles'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}]",150.0,0.130969,An increase in absolute pain score at 4 weeks after fracture (odds ratio 1.8 per 1 point increase,"[{'ForeName': 'Andreas H', 'Initials': 'AH', 'LastName': 'Qvist', 'Affiliation': 'A. H. Qvist, Department of Orthopaedics, Aarhus University Hospital, Arhus, Denmark A. H. Qvist, T. Jakobsen, S. L. Jensen, Interdisciplinary Orthopaedics, Department of Orthopaedics, Aalborg University Hospital, Denmark A. H. Qvist, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark M. T. Væsel, Department of Orthopaedics, Viborg Regional Hospital, Viborg, Denmark C. M. Jensen, Department of Orthopaedics, Randers Regional Hospital, Randers, Denmark T. Jakobsen, S. L. Jensen, Department of Orthopaedics, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Michael T', 'Initials': 'MT', 'LastName': 'Væsel', 'Affiliation': ''}, {'ForeName': 'Carsten M', 'Initials': 'CM', 'LastName': 'Jensen', 'Affiliation': ''}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Jakobsen', 'Affiliation': ''}, {'ForeName': 'Steen L', 'Initials': 'SL', 'LastName': 'Jensen', 'Affiliation': ''}]",Clinical orthopaedics and related research,['10.1097/CORR.0000000000001411'] 2029,32676868,Colchicine ameliorates the chronic inflammatory state in patients with chronic rheumatic valvular heart disease: a pilot study.,"BACKGROUND Inflammation is an important contributor to the pathogenesis of rheumatic heart disease (RHD). High serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6) are commonly seen in patients with chronic (RHD) and indicate the presence of a chronic inflammatory state. The aim of this study was to assess the effect of colchicine as anti-inflammatory drug on the serum levels of the inflammatory markers (CRP) and (IL-6) in patients with chronic (RHD). RESULTS This is a prospective controlled study that enrolled thirty-five patients with chronic (RHD) visiting Ain Shams University Hospital's outpatient clinic for receiving regular long acting penicillin as rheumatic fever prophylaxis. Ten matched healthy individuals were taken as control group. Blood samples for serum levels of CRP and IL-6 were collected before and 1 month after receiving colchicine 0.5 mg BID. Mean (CRP) level was 6.09 ± 4.39 IU/ml versus 0 IU/ml in the control group respectively (P = 0.0001). Mean (IL-6) level was 113.57 ± 37.41 ng/l versus 10.50 ± 5.99 ng/l, in the control group (p = 0.0001). Mean (CRP) was 6.09 ± 4.39 IU/ml before and became 3.34 ± 3.07I U/ml 1 month after colchicine therapy. Mean (IL-6) level was 113.57 ± 37.4 ng/l before and became 45.57 ± 20.39 ng/l 1 month after colchicine therapy (P = 0.001). CONCLUSION In this pilot study, using colchicine as anti-inflammatory drug in patients with chronic (RHD) significantly reduced the serum inflammatory markers (CRP) and (IL-6), thus helping in ameliorating their chronic inflammatory state.",2020,"Mean (IL-6) level was 113.57 ± 37.41 ng/l versus 10.50 ± 5.99 ng/l, in the control group (p = 0.0001).","['Ten matched healthy individuals', 'patients with chronic rheumatic valvular heart disease', ""enrolled thirty-five patients with chronic (RHD) visiting Ain Shams University Hospital's outpatient clinic for receiving regular long acting penicillin as rheumatic fever prophylaxis"", 'patients with chronic (RHD']","['Colchicine', 'colchicine']","['serum inflammatory markers (CRP) and (IL-6', 'Mean (IL-6) level', 'Mean (CRP) level', 'High serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6', 'chronic inflammatory state', 'serum levels of the inflammatory markers (CRP) and (IL-6', 'Mean (CRP', 'Blood samples for serum levels of CRP and IL-6']","[{'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0264757', 'cui_str': 'Rheumatic disease of heart valve'}, {'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0035439', 'cui_str': 'Rheumatic heart disease'}, {'cui': 'C0347129', 'cui_str': 'Dysplasia of anus'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0030842', 'cui_str': 'Penicillin'}, {'cui': 'C0035436', 'cui_str': 'Rheumatic fever'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}]","[{'cui': 'C0009262', 'cui_str': 'Colchicine'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}]",35.0,0.042829,"Mean (IL-6) level was 113.57 ± 37.41 ng/l versus 10.50 ± 5.99 ng/l, in the control group (p = 0.0001).","[{'ForeName': 'Osama', 'Initials': 'O', 'LastName': 'Rifaie', 'Affiliation': 'Department of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Badr', 'Affiliation': 'Department of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Ahmed Abdel', 'Initials': 'AA', 'LastName': 'Salam', 'Affiliation': 'Department of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Haitham', 'Initials': 'H', 'LastName': 'Galal', 'Affiliation': 'Department of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. haitham-w@hotmail.com.'}]",The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology,['10.1186/s43044-020-00080-2'] 2030,32628146,The ISCHEMIA trial: Implications for non-invasive imaging.,"Coronary artery disease (CAD) is highly prevalent and constitutes the single most common cause of death worldwide. However, the diagnosis of CAD remains challenging. There are two ways to approach the diagnosis of CAD, namely (1) by a functional non-invasive stress test to detect ischemia (stress echocardiography, stress cardiovascular magnetic resonance, single-photon emission computed tomography, positron emission tomography) or (2) by imaging for stenosis visualization (coronary computed tomography angiography or invasive coronary angiography). There are also two approaches for treatment: medical treatment and revascularization. The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial investigated the outcome differences of patients who had moderate to severe ischemia on stress testing and who, after CT angiography, had ruled out left main stenosis and demonstrated at least 1 coronary artery stenosis exceeding 50%. The patients were randomized to an initially conservative treatment versus immediate revascularization. No difference in hard outcomes was found, but angina relief was more effective in the revascularization group. In this article, we explore the implications of the ISCHEMIA trial for non-invasive testing in suspected CAD.",2020,"No difference in hard outcomes was found, but angina relief was more effective in the revascularization group.","['patients who had moderate to severe ischemia on stress testing and who, after CT angiography, had ruled out left main stenosis and demonstrated at least 1 coronary artery stenosis exceeding 50']","['Medical and Invasive Approaches (ISCHEMIA', 'imaging for stenosis visualization (coronary computed tomography angiography or invasive coronary angiography', 'initially conservative treatment versus immediate revascularization']",['angina relief'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C1536105', 'cui_str': 'CT angiography'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0678234', 'cui_str': 'Form of stenosis'}, {'cui': 'C0242231', 'cui_str': 'Coronary artery stenosis'}]","[{'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0678234', 'cui_str': 'Form of stenosis'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}, {'cui': 'C0085532', 'cui_str': 'Coronary angiography'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0459914', 'cui_str': 'Conservative therapy'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}]","[{'cui': 'C0002962', 'cui_str': 'Angina pectoris'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}]",,0.049503,"No difference in hard outcomes was found, but angina relief was more effective in the revascularization group.","[{'ForeName': 'Amina', 'Initials': 'A', 'LastName': 'Rakisheva', 'Affiliation': 'Department of Cardiology, Friedrich Alexander University Erlangen-Nürnberg (FAU); Erlangen-Germany.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Marwan', 'Affiliation': 'Department of Cardiology, Friedrich Alexander University Erlangen-Nürnberg (FAU); Erlangen-Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Achenbach', 'Affiliation': 'Department of Cardiology, Friedrich Alexander University Erlangen-Nürnberg (FAU); Erlangen-Germany.'}]",Anatolian journal of cardiology,['10.14744/AnatolJCardiol.2020.82428'] 2031,32677911,The WOMAN trial: clinical and contextual factors surrounding the deaths of 483 women following post-partum haemorrhage in developing countries.,"BACKGROUND Post-partum haemorrhage (PPH) is a leading cause of maternal death worldwide. The WOMAN trial assessed the effects of tranexamic acid (TXA) on death and surgical morbidity in women with PPH. The trial recorded 483 maternal deaths. We report the circumstances of the women who died. METHODS The WOMAN trial recruited 20,060 women with a clinical diagnosis of PPH after a vaginal birth or caesarean section. We randomly allocated women to receive TXA or placebo. When a woman died, we asked participating clinicians to report the cause of death and to provide a short narrative of the events surrounding the death. We collated and edited for clarity the narrative data. RESULTS Case fatality rates were 3.0% in Africa and 1.7% in Asia. Nearly three quarters of deaths were within 3 h of delivery and 91% of these deaths were from bleeding. Women who delivered outside a participating hospital (12%) were three times more likely to die (OR = 3.12, 95%CI 2.55-3.81) than those who delivered in hospital. Blood was often unavailable due to shortages or because relatives could not afford to buy it. Clinicians highlighted late presentation, maternal anaemia and poor infrastructure as key contributory factors. CONCLUSIONS Although TXA use reduces bleeding deaths by almost one third, mortality rates similar to those in high income countries will not be achieved without tackling late presentation, maternal anaemia, availability of blood for transfusion and poor infrastructure.",2020,"Women who delivered outside a participating hospital (12%) were three times more likely to die (OR = 3.12, 95%CI 2.55-3.81) than those who delivered in hospital.","['women with PPH', 'Women who delivered outside a participating hospital (12%) were three times more likely to die (OR\u2009=\u20093.12, 95%CI 2.55-3.81) than those who delivered in hospital', '483 women following post-partum haemorrhage in developing countries', '20,060 women with a clinical diagnosis of PPH after a vaginal birth or caesarean section']","['tranexamic acid (TXA', 'TXA', 'TXA or placebo']","['mortality rates', 'bleeding deaths', 'death and surgical morbidity', 'Case fatality rates']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032797', 'cui_str': 'Postpartum hemorrhage'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0011750', 'cui_str': 'Less-Developed Countries'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0282250', 'cui_str': 'Case fatality rate'}]",20060.0,0.192909,"Women who delivered outside a participating hospital (12%) were three times more likely to die (OR = 3.12, 95%CI 2.55-3.81) than those who delivered in hospital.","[{'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Picetti', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. roberto.picetti@lshtm.ac.uk.'}, {'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Miller', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.'}, {'ForeName': 'Haleema', 'Initials': 'H', 'LastName': 'Shakur-Still', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.'}, {'ForeName': 'Tracey', 'Initials': 'T', 'LastName': 'Pepple', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Beaumont', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.'}, {'ForeName': 'Eni', 'Initials': 'E', 'LastName': 'Balogun', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.'}, {'ForeName': 'Etienne', 'Initials': 'E', 'LastName': 'Asonganyi', 'Affiliation': 'Maternity Unit, Kumba District Hospital, Kumba, Southwest Province, Cameroon.'}, {'ForeName': 'Rizwana', 'Initials': 'R', 'LastName': 'Chaudhri', 'Affiliation': 'Holy Family Hospital, Gynaecology & Obstetrics Unit 1, F-762 Said Pur Road, Satellite Town, Rawalpindi, Pakistan.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'El-Sheikh', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Khartoum, Khartoum, Sudan.'}, {'ForeName': 'Bellington', 'Initials': 'B', 'LastName': 'Vwalika', 'Affiliation': 'Department of Obstetrics and Gynaecology, School of Medicine, University of Zambia, Lusaka, Zambia.'}, {'ForeName': 'Sabaratnam', 'Initials': 'S', 'LastName': 'Arulkumaran', 'Affiliation': ""St George's University of London, Room 1.126, First Floor, Jenner Wing, Cranmer Terrace, London, SW17 0RE, UK.""}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Roberts', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMC pregnancy and childbirth,['10.1186/s12884-020-03091-8'] 2032,32677982,"A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis.","BACKGROUND Toremifene (TOR) is a selective oestrogen receptor modulator (SERM) and has comparable efficacy to that of tamoxifen (TAM) in breast cancer patients. Herein, we compared the safety of TOR to that of TAM in the adjuvant treatment of premenopausal breast cancer. METHODS This was a prospective randomized and open-label clinical study. Premenopausal patients with hormonal receptor (HR)-positive early breast cancer were randomly assigned (1:1) to receive TOR) or TAM treatment. The follow-up period was 1 year. The primary end point was the incidence of ovarian cysts, and secondary end points were the incidence of endometrial thickening, changes in female hormones, the incidence of fatty liver, changes in the modified Kupperman index (mKMI) and changes in quality of life. RESULTS There were 92 patients in the final analysis. The incidences of ovarian cysts were 42.6% in the TOR group and 51.1% in the TAM group (p = 0.441). Forty-one patients (87.2%) in the TOR group and 36 patients (80.0%) in the TAM group experienced endometrial thickening (p = 0.348). The proportions of patients with fatty liver were 31.9% in the TOR group and 26.7% in the TAM group (p = 0.581). No significant differences in the mKMI or quality of life were observed between the two groups. CONCLUSIONS TOR and TAM have similar side effects on the female genital system and quality of life in premenopausal early breast cancer patients. TRIAL REGISTRATION ClinicalTrials.gov NCT02344940. Registered 26 January 2015 (retrospectively registered).",2020,The incidences of ovarian cysts were 42.6% in the TOR group and 51.1% in the TAM group (p = 0.441).,"['Premenopausal patients with hormonal receptor (HR)-positive early breast cancer', 'premenopausal early breast cancer patients', 'breast cancer patients', 'Registered 26 January 2015 (retrospectively registered', 'premenopausal breast cancer']","['Toremifene vs. tamoxifen', 'tamoxifen (TAM', 'TOR) or TAM treatment', 'TAM', 'TOR and TAM']","['incidence of ovarian cysts', 'mKMI or quality of life', 'endometrial thickening', 'incidence of endometrial thickening, changes in female hormones, the incidence of fatty liver, changes in the modified Kupperman index (mKMI) and changes in quality of life', 'incidences of ovarian cysts', 'female genital system and quality of life', 'proportions of patients with fatty liver']","[{'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0458083', 'cui_str': 'Hormonal'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0741682', 'cui_str': 'Premenopausal breast cancer'}]","[{'cui': 'C0076836', 'cui_str': 'Toremifene'}, {'cui': 'C0039286', 'cui_str': 'Tamoxifen'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0029927', 'cui_str': 'Cyst of ovary'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0743516', 'cui_str': 'Endometrial thickening'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0015695', 'cui_str': 'Fatty Liver'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0017421', 'cui_str': 'Female genital'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",,0.0561431,The incidences of ovarian cysts were 42.6% in the TOR group and 51.1% in the TAM group (p = 0.441).,"[{'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Hong', 'Affiliation': 'Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China.'}, {'ForeName': 'Jiahui', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China.'}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Shen', 'Affiliation': 'Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China.'}, {'ForeName': 'Siji', 'Initials': 'S', 'LastName': 'Zhu', 'Affiliation': 'Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China.'}, {'ForeName': 'Weiqi', 'Initials': 'W', 'LastName': 'Gao', 'Affiliation': 'Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China.'}, {'ForeName': 'Jiayi', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China.'}, {'ForeName': 'Ou', 'Initials': 'O', 'LastName': 'Huang', 'Affiliation': 'Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China.'}, {'ForeName': 'Jianrong', 'Initials': 'J', 'LastName': 'He', 'Affiliation': 'Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhu', 'Affiliation': 'Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China.'}, {'ForeName': 'Weiguo', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': 'Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China.'}, {'ForeName': 'Yafen', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China.'}, {'ForeName': 'Xiaosong', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China.'}, {'ForeName': 'Kunwei', 'Initials': 'K', 'LastName': 'Shen', 'Affiliation': 'Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China. kwshen@medmail.com.cn.'}]",BMC cancer,['10.1186/s12885-020-07156-x'] 2033,32677987,Establishing cross-systems collaborations for implementation: protocol for a longitudinal mixed methods study.,"BACKGROUND Cross-system interventions can help integrate services across different service delivery systems but require organizations to establish strong collaborative relationships for implementation. Contingency theory suggests that the effectiveness of different collaborative strategies (i.e. specific ways organizations align operations and services) varies by context. This paper describes a study of different strategies for fostering collaboration between child welfare and substance abuse treatment agencies and the conditions under which they are effective for implementation. We also describe the development and piloting of the Collaborating Across Systems for Program Implementation (CASPI) tool-a decision-making guide intended to help researchers and organizational leaders identify and use appropriate collaborative strategies for their context. METHODS/DESIGN This multisite longitudinal, mixed methods study, leverages a naturally occurring implementation initiative -- in up to 17 Ohio counties -- to implement Ohio START (Sobriety Treatment and Reducing Trauma). START is a child welfare model that requires strong collaboration with local substance use treatment organizations to promote integrated services. During the first two years, we will identify collaborative strategies associated with improved START implementation (penetration and fidelity) and service delivery outcomes (timeliness), given system, and organizational features. We will conduct a convergent mixed methods study drawing on worker surveys, agency documents, administrative data, formal partner agreements, and group interviews. Data will be integrated and analyzed using Qualitative Comparative Analysis (QCA). To develop the CASPI, an expert panel comprised of implementation experts, and community stakeholders will convene to synthesize our findings and develop contents (including a decision tree). During the final year of the study, we will assess the acceptability, appropriateness, and feasibility of the CASPI in a randomized vignette experiment, and a pilot-test with 3 child welfare agencies that have not yet implemented START. DISCUSSION Our results will lay the groundwork for a larger controlled trial that will test the CASPI's effectiveness for supporting effective and efficient implementation of cross-system interventions like START. The CASPI is expected to help leaders and researchers select and use collaboration strategies tailored to their context and be applicable in a wide range of settings including rural communities. Our work also advances system-level implementation strategies. TRIAL REGISTRATION NCT03931005 , Registered April 29, 2019.",2020,"During the first two years, we will identify collaborative strategies associated with improved START implementation (penetration and fidelity) and service delivery outcomes (timeliness), given system, and organizational features.",['leverages a naturally occurring implementation initiative -- in up to 17 Ohio counties -- to implement Ohio START (Sobriety Treatment and Reducing Trauma'],[],"['START implementation (penetration and fidelity) and service delivery outcomes (timeliness), given system, and organizational features']","[{'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0028905', 'cui_str': 'Ohio'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}]",[],"[{'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0205321', 'cui_str': 'Penetrating'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0029246', 'cui_str': 'Organizations'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]",,0.0363623,"During the first two years, we will identify collaborative strategies associated with improved START implementation (penetration and fidelity) and service delivery outcomes (timeliness), given system, and organizational features.","[{'ForeName': 'Alicia C', 'Initials': 'AC', 'LastName': 'Bunger', 'Affiliation': 'College of Social Work, The Ohio State University, 1947 College Road, Columbus, OH, 43210, USA. Bunger.5@osu.edu.'}, {'ForeName': 'Emmeline', 'Initials': 'E', 'LastName': 'Chuang', 'Affiliation': 'School of Social Welfare, University of California Berkeley, 120 Haviland Hall, Berkeley, CA, 94720, USA.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Girth', 'Affiliation': 'John Glenn College of Public Affairs, The Ohio State University, 1810 College Road, Columbus, OH, 43210, USA.'}, {'ForeName': 'Kathryn E', 'Initials': 'KE', 'LastName': 'Lancaster', 'Affiliation': 'College of Public Health, The Ohio State University, 1841 Neil Avenue, Columbus, OH, 43210, USA.'}, {'ForeName': 'Fawn', 'Initials': 'F', 'LastName': 'Gadel', 'Affiliation': 'Public Children Services Association of Ohio (PCSAO), 37 West Broad Street, Suite 1100, Columbus, OH, 43215, USA.'}, {'ForeName': 'Marla', 'Initials': 'M', 'LastName': 'Himmeger', 'Affiliation': 'Public Children Services Association of Ohio (PCSAO), 37 West Broad Street, Suite 1100, Columbus, OH, 43215, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Saldana', 'Affiliation': 'Oregon Social Learning Center, 10 Shelton McMurphey Blvd., Eugene, OR, 97405, USA.'}, {'ForeName': 'Byron J', 'Initials': 'BJ', 'LastName': 'Powell', 'Affiliation': 'Brown School, Washington University in St. Louis, One Brookings Drive, St. Louis, MO, 63130, USA.'}, {'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Aarons', 'Affiliation': 'UC San Diego, Department of Psychiatry, 9500 Gilman Drive (0812), La Jolla, San Diego, CA, 92093, USA.'}]",Implementation science : IS,['10.1186/s13012-020-01016-9'] 2034,32677992,Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.,"BACKGROUND There is limited evidence that rituximab, a B cell depletion therapy, is an effective treatment for systemic lupus erythematosus (SLE). Data on the mechanisms of B cell depletion in SLE indicate that the combination of rituximab and belimumab may be more effective than rituximab alone. The safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial aims to determine whether belimumab is superior to placebo, when given 4-8 weeks after treatment with rituximab. This article describes the statistical analysis plan for this trial as an update to the published protocol. It is written prior to the end of patient follow-up, while the outcome of the trial is still unknown. DESIGN AND METHODS BEAT-LUPUS is a randomised, double-blind, phase II trial of 52 weeks of belimumab versus placebo, initiated 4-8 weeks after rituximab treatment. The primary outcome is anti-dsDNA antibodies at 52 weeks post randomisation. Secondary outcomes include lupus flares and damage, adverse events, doses of concomitant medications, quality of life, and clinical biomarkers. We describe the trial's clinical context, outcome measures, sample size calculation, and statistical modelling strategy, and the supportive analyses planned to evaluate for mediation of the treatment effect through changes in concomitant medication doses and bias from missing data. DISCUSSION The analysis will provide detailed information on the safety and effectiveness of belimumab. It will be implemented from July 2020 when patient follow-up and data collection is complete. TRIAL REGISTRATION ISRCTN: 47873003 . Registered on 28 November 2016. EudracT: 2015-005543-14 . Registered on 19 November 2018.",2020,"The safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial aims to determine whether belimumab is superior to placebo, when given 4-8 weeks after treatment with rituximab.",[],"['belimumab versus placebo', 'belimumab after B cell depletion therapy', 'rituximab', 'placebo']","['anti-dsDNA antibodies', 'safety and efficacy', 'Safety and efficacy', 'lupus flares and damage, adverse events, doses of concomitant medications, quality of life, and clinical biomarkers']",[],"[{'cui': 'C1723401', 'cui_str': 'belimumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1171324', 'cui_str': 'B-cell depletion therapy'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}]","[{'cui': 'C2747926', 'cui_str': 'Anti-dsDNA antibody'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0024131', 'cui_str': 'Lupus vulgaris'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",,0.396122,"The safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial aims to determine whether belimumab is superior to placebo, when given 4-8 weeks after treatment with rituximab.","[{'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Muller', 'Affiliation': 'Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK. p.muller@ucl.ac.uk.'}, {'ForeName': 'Kashfia', 'Initials': 'K', 'LastName': 'Chowdhury', 'Affiliation': 'Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Gordon', 'Affiliation': 'Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Ehrenstein', 'Affiliation': 'Centre for Rheumatology, Division of Medicine, University College London, London, UK.'}, {'ForeName': 'Caroline J', 'Initials': 'CJ', 'LastName': 'Doré', 'Affiliation': 'Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.'}]",Trials,['10.1186/s13063-020-04391-2'] 2035,32678082,Vagus nerve stimulation boosts the drive to work for rewards.,"Interoceptive feedback transmitted via the vagus nerve plays a vital role in motivation by tuning actions according to physiological needs. Whereas vagus nerve stimulation (VNS) reinforces actions in animals, motivational effects elicited by VNS in humans are still largely elusive. Here, we applied non-invasive transcutaneous auricular VNS (taVNS) on the left or right ear while participants exerted effort to earn rewards using a randomized cross-over design (vs. sham). In line with preclinical studies, acute taVNS enhances invigoration of effort, and stimulation on the left side primarily facilitates invigoration for food rewards. In contrast, we do not find conclusive evidence that acute taVNS affects effort maintenance or wanting ratings. Collectively, our results suggest that taVNS enhances reward-seeking by boosting invigoration, not effort maintenance and that the stimulation side affects generalization beyond food reward. Thus, taVNS may enhance the pursuit of prospective rewards which may pave avenues to treat motivational deficiencies.",2020,"In line with preclinical studies, acute taVNS enhances invigoration of effort, and stimulation on the left side primarily facilitates invigoration for food rewards.",[],"['vagus nerve stimulation (VNS', 'invasive transcutaneous auricular VNS (taVNS']",[],[],"[{'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C1522191', 'cui_str': 'Otic route'}]",[],,0.0294214,"In line with preclinical studies, acute taVNS enhances invigoration of effort, and stimulation on the left side primarily facilitates invigoration for food rewards.","[{'ForeName': 'Monja P', 'Initials': 'MP', 'LastName': 'Neuser', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Tübingen, Calwerstraße 14, 72076, Tübingen, Germany.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Teckentrup', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Tübingen, Calwerstraße 14, 72076, Tübingen, Germany.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Kühnel', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Tübingen, Calwerstraße 14, 72076, Tübingen, Germany.'}, {'ForeName': 'Manfred', 'Initials': 'M', 'LastName': 'Hallschmid', 'Affiliation': 'Department of Medical Psychology and Behavioral Neurobiology, University of Tübingen, Otfried-Müller-Straße 25, 72076, Tübingen, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Walter', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Tübingen, Calwerstraße 14, 72076, Tübingen, Germany.'}, {'ForeName': 'Nils B', 'Initials': 'NB', 'LastName': 'Kroemer', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Tübingen, Calwerstraße 14, 72076, Tübingen, Germany. nils.kroemer@uni-tuebingen.de.'}]",Nature communications,['10.1038/s41467-020-17344-9'] 2036,32678131,Clinical efficacy of eyelid hygiene in blepharitis and meibomian gland dysfunction after cataract surgery: a randomized controlled pilot trial.,"The purpose of this randomized clinical trial is to evaluate the effect of eyelid hygiene on subjective symptoms, anterior blepharitis, and meibomian gland dysfunction (MGD) after cataract surgery. Subjects with obstructive MGD who underwent cataract surgery were randomly divided into two groups. In the eyelid hygiene group, eyelid hygiene was performed twice a day for 10 days from 3 days before to 1 week after cataract surgery. The control group did not perform eyelid hygiene. A subjective symptom questionnaire of SPEED, anterior blepharitis grade, and meibum quality and quantity was evaluated at baseline and at postoperative 1 and 4 weeks. The eyelid hygiene group (n = 36) showed decreased SPEED score after cataract surgery and the control group (n = 33) did not. Anterior blepharitis grade was worse 1 week after surgery in the control group but not in the eyelid hygiene group. The control group had significantly decreased meibum quality and quantity in both the upper and lower eyelids after cataract surgery, but the eyelid hygiene group did not. Eyelid hygiene before/after cataract surgery improved postoperative subjective symptoms and prevented postoperative exacerbation of anterior blepharitis and MGD. Thus, perioperative eyelid hygiene is recommended for patients with obstructive MGD who undergo cataract surgery.",2020,"The control group had significantly decreased meibum quality and quantity in both the upper and lower eyelids after cataract surgery, but the eyelid hygiene group did not.","['Subjects with obstructive MGD who underwent cataract surgery', 'patients with obstructive MGD who undergo cataract surgery', 'cataract surgery', 'blepharitis and meibomian gland dysfunction after cataract surgery']",['eyelid hygiene'],"['Anterior blepharitis grade', 'subjective symptoms, anterior blepharitis, and meibomian gland dysfunction (MGD', 'meibum quality and quantity in both the upper and lower eyelids', 'postoperative subjective symptoms', 'subjective symptom questionnaire of SPEED, anterior blepharitis grade, and meibum quality and quantity', 'postoperative exacerbation of anterior blepharitis and MGD', 'eyelid hygiene', 'Eyelid hygiene', 'SPEED score']","[{'cui': 'C1275684', 'cui_str': 'Meibomian gland dysfunction'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005741', 'cui_str': 'Blepharitis'}, {'cui': 'C1306068', 'cui_str': 'Secondary cataract'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0015426', 'cui_str': 'Eyelid structure'}, {'cui': 'C0020405', 'cui_str': 'Hygiene'}]","[{'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0005741', 'cui_str': 'Blepharitis'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1275684', 'cui_str': 'Meibomian gland dysfunction'}, {'cui': 'C5197842', 'cui_str': 'Meibomian Lipids'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0229258', 'cui_str': 'Lower eyelid structure'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0015426', 'cui_str': 'Eyelid structure'}, {'cui': 'C0020405', 'cui_str': 'Hygiene'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0203607,"The control group had significantly decreased meibum quality and quantity in both the upper and lower eyelids after cataract surgery, but the eyelid hygiene group did not.","[{'ForeName': 'Youngsub', 'Initials': 'Y', 'LastName': 'Eom', 'Affiliation': 'Department of Ophthalmology, Korea University Ansan Hospital, Korea University College of Medicine, Gyeonggi-do, South Korea.'}, {'ForeName': 'Kyung Sun', 'Initials': 'KS', 'LastName': 'Na', 'Affiliation': ""Department of Ophthalmology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.""}, {'ForeName': 'Ho Sik', 'Initials': 'HS', 'LastName': 'Hwang', 'Affiliation': ""Department of Ophthalmology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.""}, {'ForeName': 'Kyong Jin', 'Initials': 'KJ', 'LastName': 'Cho', 'Affiliation': 'Department of Ophthalmology, Dankook University College of Medicine, Cheonan, South Korea.'}, {'ForeName': 'Tae-Young', 'Initials': 'TY', 'LastName': 'Chung', 'Affiliation': 'Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Roo Min', 'Initials': 'RM', 'LastName': 'Jun', 'Affiliation': ""Department of Ophthalmology, Ewha Woman's University School of Medicine, Seoul, South Korea.""}, {'ForeName': 'Byung Yi', 'Initials': 'BY', 'LastName': 'Ko', 'Affiliation': 'Department of Ophthalmology, Konyang University College of Medicine, Daejeon, Republic of Korea.'}, {'ForeName': 'Yeoun Sook', 'Initials': 'YS', 'LastName': 'Chun', 'Affiliation': 'Department of Ophthalmology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Hyun Seung', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': ""Department of Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.""}, {'ForeName': 'Jong Suk', 'Initials': 'JS', 'LastName': 'Song', 'Affiliation': 'Department of Ophthalmology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea. crisim@korea.ac.kr.'}]",Scientific reports,['10.1038/s41598-020-67888-5'] 2037,32678132,"Resistance training improves sleep quality, redox balance and inflammatory profile in maintenance hemodialysis patients: a randomized controlled trial.","Patients in maintenance hemodialisys (HD) present sleep disorders, increased inflammation, unbalanced redox profiles, and elevated biomarkers representing endothelial dysfunction. Resistance training (RT) has shown to mitigate the loss of muscle mass, strength, improve inflammatory profiles, and endothelial function while decreasing oxidative stress for those in HD. However, the relation between those factors and sleep quality are inadequately described. The aim of this study was to verify the effects of 3 months of RT on sleep quality, redox balance, nitric oxide (NO) bioavailability, inflammation profile, and asymmetric dimethylarginine (ADMA) in patients undergoing HD. Our primary goal was to describe the role of RT on sleep quality. Our secondary goal was to evaluate the effect of RT on NO, metabolism markers, and inflammatory and redox profiles as potential mechanisms to explain RT-induced sleep quality changes. Fifty-five men undergoing maintenance hemodialysis were randomized into either a control (CTL, n = 25) and RT group (RTG; n = 30). Participants in the RT group demonstrated an improvement in sleep pattern, redox, inflammatory profiles, and biomarkers of endothelial function (NO 2 - and ADMA). This group also increased muscle strength (total workload in RT exercises of upper and lower limbs). These findings support that RT may improve the clinical status of HD patients by improving their sleep quality, oxidative and inflammatory parameters.",2020,"Participants in the RT group demonstrated an improvement in sleep pattern, redox, inflammatory profiles, and biomarkers of endothelial function (NO 2 - and ADMA).","['Fifty-five men undergoing maintenance hemodialysis', 'patients undergoing HD', 'maintenance hemodialysis patients']","['control (CTL, n\u2009=\u200925) and RT', 'Resistance training', 'Resistance training (RT']","['sleep pattern, redox, inflammatory profiles, and biomarkers of endothelial function (NO 2 - and ADMA', 'sleep quality, redox balance, nitric oxide (NO) bioavailability, inflammation profile, and asymmetric dimethylarginine (ADMA', 'muscle strength (total workload in RT exercises of upper and lower limbs', 'sleep quality, redox balance and inflammatory profile', 'sleep quality', 'sleep quality, oxidative and inflammatory parameters']","[{'cui': 'C0450382', 'cui_str': '55'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4040576', 'cui_str': 'Maintenance hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039195', 'cui_str': 'Cytotoxic T lymphocyte'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0474396', 'cui_str': 'Sleep behavior finding'}, {'cui': 'C0030012', 'cui_str': 'Oxidation-reduction'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0067385', 'cui_str': 'N,N-dimethylarginine'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",55.0,0.0171028,"Participants in the RT group demonstrated an improvement in sleep pattern, redox, inflammatory profiles, and biomarkers of endothelial function (NO 2 - and ADMA).","[{'ForeName': 'Hugo Luca', 'Initials': 'HL', 'LastName': 'Corrêa', 'Affiliation': 'Graduate Program of Physical Education, Catholic University of Brasilia (USB), EPTC, QS07, LT1 s/n. Bloco G Sala 117, Águas Claras, Taguatinga, Brasília, DF, 71966-700, Brazil. hugo.efucb@gmail.com.'}, {'ForeName': 'Sting Ray Gouveia', 'Initials': 'SRG', 'LastName': 'Moura', 'Affiliation': 'Graduate Program of Physical Education, Catholic University of Brasilia (USB), EPTC, QS07, LT1 s/n. Bloco G Sala 117, Águas Claras, Taguatinga, Brasília, DF, 71966-700, Brazil.'}, {'ForeName': 'Rodrigo Vanerson Passos', 'Initials': 'RVP', 'LastName': 'Neves', 'Affiliation': 'Graduate Program of Physical Education, Catholic University of Brasilia (USB), EPTC, QS07, LT1 s/n. Bloco G Sala 117, Águas Claras, Taguatinga, Brasília, DF, 71966-700, Brazil.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Tzanno-Martins', 'Affiliation': 'HDC RenalClass, São Paulo, SP, Brazil.'}, {'ForeName': 'Michel Kendy', 'Initials': 'MK', 'LastName': 'Souza', 'Affiliation': 'Department of Nephrology, Federal University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Anderson Sola', 'Initials': 'AS', 'LastName': 'Haro', 'Affiliation': 'Department of Nephrology, Federal University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Costa', 'Affiliation': 'Department of Nephrology, Federal University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'José Adeirton Bezerra', 'Initials': 'JAB', 'LastName': 'Silva', 'Affiliation': 'HDC RenalClass, São Paulo, SP, Brazil.'}, {'ForeName': 'Whitley', 'Initials': 'W', 'LastName': 'Stone', 'Affiliation': 'School of Kinesiology, Recreation, and Sport, Western Kentucky University, Bowling Green, KY, USA.'}, {'ForeName': 'Fernando Sousa', 'Initials': 'FS', 'LastName': 'Honorato', 'Affiliation': 'Graduate Program of Physical Education, Catholic University of Brasilia (USB), EPTC, QS07, LT1 s/n. Bloco G Sala 117, Águas Claras, Taguatinga, Brasília, DF, 71966-700, Brazil.'}, {'ForeName': 'Lysleine Alves', 'Initials': 'LA', 'LastName': 'Deus', 'Affiliation': 'Graduate Program of Physical Education, Catholic University of Brasilia (USB), EPTC, QS07, LT1 s/n. Bloco G Sala 117, Águas Claras, Taguatinga, Brasília, DF, 71966-700, Brazil.'}, {'ForeName': 'Jonato', 'Initials': 'J', 'LastName': 'Prestes', 'Affiliation': 'Graduate Program of Physical Education, Catholic University of Brasilia (USB), EPTC, QS07, LT1 s/n. Bloco G Sala 117, Águas Claras, Taguatinga, Brasília, DF, 71966-700, Brazil.'}, {'ForeName': 'Herbert Gustavo', 'Initials': 'HG', 'LastName': 'Simões', 'Affiliation': 'Graduate Program of Physical Education, Catholic University of Brasilia (USB), EPTC, QS07, LT1 s/n. Bloco G Sala 117, Águas Claras, Taguatinga, Brasília, DF, 71966-700, Brazil.'}, {'ForeName': 'Elaine Cristina', 'Initials': 'EC', 'LastName': 'Vieira', 'Affiliation': 'Graduate Program of Physical Education, Catholic University of Brasilia (USB), EPTC, QS07, LT1 s/n. Bloco G Sala 117, Águas Claras, Taguatinga, Brasília, DF, 71966-700, Brazil.'}, {'ForeName': 'Gislane Ferreira', 'Initials': 'GF', 'LastName': 'de Melo', 'Affiliation': 'Graduate Program of Physical Education, Catholic University of Brasilia (USB), EPTC, QS07, LT1 s/n. Bloco G Sala 117, Águas Claras, Taguatinga, Brasília, DF, 71966-700, Brazil.'}, {'ForeName': 'Milton Rocha', 'Initials': 'MR', 'LastName': 'Moraes', 'Affiliation': 'Graduate Program of Physical Education, Catholic University of Brasilia (USB), EPTC, QS07, LT1 s/n. Bloco G Sala 117, Águas Claras, Taguatinga, Brasília, DF, 71966-700, Brazil.'}, {'ForeName': 'Thiago Santos', 'Initials': 'TS', 'LastName': 'Rosa', 'Affiliation': 'Graduate Program of Physical Education, Catholic University of Brasilia (USB), EPTC, QS07, LT1 s/n. Bloco G Sala 117, Águas Claras, Taguatinga, Brasília, DF, 71966-700, Brazil.'}]",Scientific reports,['10.1038/s41598-020-68602-1'] 2038,32678200,Individual versus team heart rate variability responsiveness analyses in a national soccer team during training camps.,"Heart rate variability (HRV) analyses can be performed using group or individual changes. Individual changes could be of potential interest during training camps for national soccer teams. The purpose of this study was to compare whether analysis of individual daily HRV could detect changes in cardiac autonomic responses during training camps for national soccer teams. During two different training camps, 34 professional soccer players were monitored daily over 9 days, using heart rate monitors. Players were divided into First Eleven (those who participated in the main squad) or Reserves. Daily HRV was individually analyzed using a day-to-day method or a baseline (days prior to first match) method, using the smallest worthwhile change and the typical error in the estimate to establish a trivial (random change) zone. Group changes were also analyzed using an ANOVA one-way repeated measures test. Players' responsiveness was classified as High-, Low- or Non-response depending on individual changes. Both analyses showed substantial daily individual changes after playing a soccer match, regardless of the group. However, group changes showed that only First Eleven players had significant changes after playing a soccer match. In conclusion, individual daily HRV analyses are useful in detecting individual changes in professional soccer players.",2020,"Both analyses showed substantial daily individual changes after playing a soccer match, regardless of the group.","['Players were divided into First Eleven (those who participated in the main squad) or Reserves', 'national soccer teams', 'professional soccer players', '34 professional soccer players']",[],"['Daily HRV', 'Heart rate variability (HRV) analyses', 'cardiac autonomic responses']","[{'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}]",[],"[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}]",34.0,0.0198656,"Both analyses showed substantial daily individual changes after playing a soccer match, regardless of the group.","[{'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Muñoz-López', 'Affiliation': 'Departamento de Motricidad Humana y Rendimiento Deportivo, Education Sciences School, University of Seville, Desk 4.78, c/Pirotecnica s/n, 41013, Seville, Spain. amunlop@gmail.com.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Naranjo-Orellana', 'Affiliation': 'Sports and Computers Department, University Pablo de Olavide, Seville, Spain.'}]",Scientific reports,['10.1038/s41598-020-68698-5'] 2039,32673766,Making sense of cross-trial comparisons for the frontline treatment of advanced-stage Hodgkin lymphoma.,,2020,,['advanced-stage Hodgkin lymphoma'],[],[],"[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0019829', 'cui_str': 'Hodgkin lymphoma'}]",[],[],,0.0468669,,"[{'ForeName': 'Deepesh P', 'Initials': 'DP', 'LastName': 'Lad', 'Affiliation': 'Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India. Electronic address: deepesh.lad12@gmail.com.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.05.012'] 2040,32673830,Accelerated treatment of endocarditis-The POET II trial: Rationale and design of a randomized controlled trial.,"BACKGROUND The optimal antibiotic treatment length for infective endocarditis (IE) is uncertain. International guidelines recommend treatment duration of up to 6 weeks for patients with left-sided IE but are primarily based on historical data and expert opinion. Efficacies of modern therapies, fast recovery seen in many patients with IE, and complications to long hospital stays challenge the rationale for fixed treatment durations in all patients. OBJECTIVE The objective was to conduct a noninferiority randomized controlled trial (acronym POET II) investigating the safety of accelerated (shortened) antibiotic therapy as compared to standard duration in patients with left-sided IE. METHODS The POET II trial is a multicenter, multinational, open-label, noninferiority randomized controlled trial. Patients with definite left-sided IE due to Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis will be eligible for enrolment. Each patient will be randomized to accelerated antibiotic treatment or standard-length treatment (1:1) following clinical stabilization as defined by clinical parameters, laboratory values, and transesophageal echocardiography findings. Accelerated treatment will be between 2 and 4 weeks, whereas standard-length treatment will be between 4 and 6 weeks, depending on microbiologic etiology, complications, need for valve surgery, and prosthetic versus native valve endocarditis. The primary outcome is a composite of all-cause mortality, unplanned cardiac surgery, relapse of bacteremia, or embolization within 6 months of randomization. CONCLUSIONS The POET II trial will investigate the safety of accelerated antibiotic therapy for patients with left-sided IE caused by Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis. The results of the POET II trial will improve the evidence base of treatment recommendations, and clinical practice may be altered.",2020,"The POET II trial will investigate the safety of accelerated antibiotic therapy for patients with left-sided IE caused by Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis.","['patients with left-sided IE caused by Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis', 'patients with left-sided IE']","['accelerated (shortened) antibiotic therapy', 'accelerated antibiotic therapy']","['microbiologic etiology, complications, need for valve surgery, and prosthetic versus native valve endocarditis', 'composite of all-cause mortality, unplanned cardiac surgery, relapse of bacteremia, or embolization within 6\u202fmonths of randomization']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1827151', 'cui_str': 'Left sided infective endocarditis'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0074992', 'cui_str': 'sphingosine 1-phosphate'}, {'cui': 'C0038172', 'cui_str': 'Staphylococcus aureus'}, {'cui': 'C0085494', 'cui_str': 'Genus Enterococcus'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}]","[{'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1142550', 'cui_str': 'Native valve endocarditis'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0013931', 'cui_str': 'Embolization - action'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]",,0.224308,"The POET II trial will investigate the safety of accelerated antibiotic therapy for patients with left-sided IE caused by Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis.","[{'ForeName': 'Lauge', 'Initials': 'L', 'LastName': 'Østergaard', 'Affiliation': 'The Heart Center, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Mia Marie', 'Initials': 'MM', 'LastName': 'Pries-Heje', 'Affiliation': 'The Heart Center, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Rasmus Bo', 'Initials': 'RB', 'LastName': 'Hasselbalch', 'Affiliation': 'Department of Cardiology, Herlev-Gentofte Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Rasmussen', 'Affiliation': 'Department of Infectious Diseases, Skåne University Hospital, Lund, Sweden.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Åkesson', 'Affiliation': 'Department of Infectious Diseases, Skåne University Hospital, Lund, Sweden.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Horvath', 'Affiliation': 'Department of Infectious Diseases, The Prince Charles Hospital, Brisbane, Australia.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Povlsen', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Gill', 'Affiliation': 'Department of Cardiology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Niels Eske', 'Initials': 'NE', 'LastName': 'Bruun', 'Affiliation': 'Department of Cardiology, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Katrine', 'Initials': 'K', 'LastName': 'Müllertz', 'Affiliation': 'Department of Cardiology, Nordsjællands Hospital, Hillerød, Denmark.'}, {'ForeName': 'Christian Ditlev', 'Initials': 'CD', 'LastName': 'Tuxen', 'Affiliation': 'Department of Cardiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Nikolaj', 'Initials': 'N', 'LastName': 'Ihlemann', 'Affiliation': 'The Heart Center, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Jannik', 'Initials': 'J', 'LastName': 'Helweg-Larsen', 'Affiliation': 'Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Moser', 'Affiliation': 'Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Emil Loldrup', 'Initials': 'EL', 'LastName': 'Fosbøl', 'Affiliation': 'The Heart Center, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Henning', 'Initials': 'H', 'LastName': 'Bundgaard', 'Affiliation': 'The Heart Center, Rigshospitalet, Copenhagen, Denmark. Electronic address: Henning.Bundgaard@regionh.dk.'}, {'ForeName': 'Kasper', 'Initials': 'K', 'LastName': 'Iversen', 'Affiliation': 'Department of Cardiology, Herlev-Gentofte Hospital, Copenhagen, Denmark.'}]",American heart journal,['10.1016/j.ahj.2020.05.012'] 2041,32674009,Extracorporeal shockwave therapy in the management of plantar fasciitis: A randomized controlled trial.,"BACKGROUND This study aimed at estimating the extent to which a combination therapy of extracorporeal shockwave therapy (ESWT) with usual care (exercise and orthotic support) improve functional ability in the patient with plantar fasciitis when compared to usual care alone. METHODS Participants with plantar fasciitis were randomly allocated into two groups: ESWT (n=23), and control (n=21). All participants received home exercise program with orthotic support. In addition, ESWT group received 2000 shock waves with 0.02 mJ/mm 2 for three sessions. Functional outcomes were measured by function subscale of American orthopedic foot and ankle society (AOFAS-F) score and 12 minutes walking test including walking speed, cadence. The scores were recorded at baseline, third week and third month after the treatment. Analysis was performed using repeated measures ANOVA, and an intention to treat approach using multiple imputations. RESULTS Results showed that there was a significant improvement in AOFAS-F total score and walking speed over three months in both groups (p<0.001, p=0.04 respectively); improvements in AOFAS-F were particularly in activity limitation (p=0.001), walking distance (p=0.02) and walking surface (p=0.02). Groups were comparable with each other for both walking speed and AOFAS-F in any assessment time (p>0.05). However, groups performed differently in cadence where there was an increase in cadence in ESWT group whereas a decline in control at the third month (p=0.07). CONCLUSION The results revealed that ESWT did not have an additive benefit over usual care to improve foot function and walking performance in patient with plantar fasciitis over three months post-treatment.",2020,Groups were comparable with each other for both walking speed and AOFAS-F in any assessment time (p>0.05).,"['Participants with plantar fasciitis', 'plantar fasciitis', 'patient with plantar fasciitis']","['ESWT', 'extracorporeal shockwave therapy (ESWT) with usual care (exercise and orthotic support', 'Extracorporeal shockwave therapy', 'home exercise program with orthotic support']","['foot function and walking performance', 'walking surface', 'AOFAS-F total score and walking speed', 'AOFAS-F', 'function subscale of American orthopedic foot and ankle society (AOFAS-F) score and 12 minutes walking test including walking speed, cadence', 'cadence', 'walking distance', 'activity limitation', 'functional ability']","[{'cui': 'C0149756', 'cui_str': 'Plantar fasciitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1737238', 'cui_str': 'Extracorporeal shock wave therapy'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0029365', 'cui_str': 'Orthotic device'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program'}]","[{'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0430516', 'cui_str': '12-minute walk test'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}]",,0.0431827,Groups were comparable with each other for both walking speed and AOFAS-F in any assessment time (p>0.05).,"[{'ForeName': 'Eda', 'Initials': 'E', 'LastName': 'Cinar', 'Affiliation': 'School of Physical and Occupational Therapy, McGill University, 8852 Saint Hubert, Montreal, QC, H2M 1Y5, Canada. Electronic address: edaccinar@gmail.com.'}, {'ForeName': 'Shikha', 'Initials': 'S', 'LastName': 'Saxena', 'Affiliation': 'School of Physical and Occupational Therapy, McGill University, 8852 Saint Hubert, Montreal, QC, H2M 1Y5, Canada. Electronic address: shikha.saxena@mail.mcgill.ca.'}, {'ForeName': 'Halil Ekrem', 'Initials': 'HE', 'LastName': 'Akkurt', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Konya Training and Research Hospital, Konya Eğitim ve Araştırma Hastanesi Fiziksel Tıp ve Rehabilitasyon Kliniği, Meram, Konya, 42090, Turkey. Electronic address: ekremakkurt@yahoo.com.'}, {'ForeName': 'Fatma', 'Initials': 'F', 'LastName': 'Uygur', 'Affiliation': 'Department of Physical Therapy and Rehabilitation, Faculty of Health Science Cyprus International University, via Mersin 10, 99258 Lefkoşa, Turkey. Electronic address: fztuygur@yahoo.com.'}]","Foot (Edinburgh, Scotland)",['10.1016/j.foot.2020.101679'] 2042,32674036,Effects of a nurse-led medication self-management programme in women with oral treatments for metastatic breast cancer: A mixed-method randomised controlled trial.,"PURPOSE Adherence to medication is the most important challenge facing patients receiving oral anticancer treatment. This study aimed to evaluate the effects of a patient-centred medication self-management support programme in patients with metastatic breast cancer undergoing oral anticancer treatment. METHODS This trial was a two-phased mixed-method randomised controlled study. Eligible participants were 155 patients with metastatic breast cancer newly prescribed an oral chemotherapy or targeted therapy agent. The intervention group received the patient-centred medication self-management support programme conducted by trained nurses. Primary outcome was adherence to medication at three months after the commencement of treatment, calculated by medication possession ratio (MPR). Secondary outcomes included self-efficacy, functional assessment, psychological distress, symptom severity and symptom interference, and patient satisfaction. After the completion of the intervention study, focus group interviews were conducted among intervention nurses. RESULTS Both intervention and control groups maintained more than 90% of MPR and no significant difference was observed in the primary outcome. Regarding secondary outcomes, only general self-efficacy was significantly different in the two groups. In the qualitative study, the intervention nurses perceived improvement in the patients' self-efficacy, ability to anticipate the impact of treatment and adjust to life, and avoidance of loneliness. CONCLUSIONS A significant effect of the programme was not found in the program because the adherence rate was high in both groups. Improvement in the patients' self-efficacy was observed both quantitatively and qualitatively. TRIAL REGISTRATION UMIN Clinical Trials Registry (UMIN-CTR), Japan, UMIN000016597. (27 February 2015).",2020,Both intervention and control groups maintained more than 90% of MPR and no significant difference was observed in the primary outcome.,"['patients receiving oral anticancer treatment', 'Eligible participants were 155 patients with metastatic breast cancer newly prescribed an oral chemotherapy or targeted therapy agent', 'patients with metastatic breast cancer undergoing oral anticancer treatment', 'women with oral treatments for metastatic breast cancer']","['patient-centred medication self-management support programme', 'patient-centred medication self-management support programme conducted by trained nurses', 'nurse-led medication self-management programme']","['self-efficacy, functional assessment, psychological distress, symptom severity and symptom interference, and patient satisfaction', 'adherence to medication', 'adherence rate', 'medication possession ratio (MPR', 'general self-efficacy']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0419073', 'cui_str': 'Oral chemotherapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0036600', 'cui_str': 'Self-medication'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0023175', 'cui_str': 'Lead'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}]",155.0,0.0763852,Both intervention and control groups maintained more than 90% of MPR and no significant difference was observed in the primary outcome.,"[{'ForeName': 'Hiroko', 'Initials': 'H', 'LastName': 'Komatsu', 'Affiliation': 'Japanese Red Cross Kyushu International College of Nursing, 1-1 Asty Munakata-City, Fukuoka-Prefecture, 811-4157, Japan. Electronic address: h-komatsu@jrckicn.ac.jp.'}, {'ForeName': 'Kaori', 'Initials': 'K', 'LastName': 'Yagasaki', 'Affiliation': 'Faculty of Nursing and Medical Care, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. Electronic address: yagasaki@sfc.keio.ac.jp.'}, {'ForeName': 'Takuhiro', 'Initials': 'T', 'LastName': 'Yamaguchi', 'Affiliation': 'Division of Biostatistics, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. Electronic address: yamaguchi@med.tohoku.ac.jp.'}, {'ForeName': 'Ayako', 'Initials': 'A', 'LastName': 'Mori', 'Affiliation': 'Division of Nursing, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. Electronic address: aymori@ncc.go.jp.'}, {'ForeName': 'Hiromi', 'Initials': 'H', 'LastName': 'Kawano', 'Affiliation': 'Nursing Department, Kanagawa Cancer Center, 2-3-1 Nakao, Yokohamashi, Kanagawa, 241-8515, Japan. Electronic address: gairai@kcch.jp.'}, {'ForeName': 'Noriko', 'Initials': 'N', 'LastName': 'Minamoto', 'Affiliation': 'Nursing Division, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba-ken, 277-8577, Japan. Electronic address: nminamot@east.ncc.go.jp.'}, {'ForeName': 'Orie', 'Initials': 'O', 'LastName': 'Honma', 'Affiliation': 'Division of Nursing, Showa University Hospital, 1-5-8, Hatanodai, Shinagawaku, Tokyo, 142-8666, Japan. Electronic address: ori-miya20@cmed.showa-u.ac.jp.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Tamura', 'Affiliation': 'Department of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. Electronic address: ketamura@ncc.go.jp.'}]",European journal of oncology nursing : the official journal of European Oncology Nursing Society,['10.1016/j.ejon.2020.101780'] 2043,32674048,"Cyclosporine or methotrexate, which one is more promising in the treatment of lichen planopilaris?; A comparative clinical trial.","BACKGROUND Lichen Planopilaris (LPP) is a primary scarring alopecia with unknown etiology and its management is a challenge for dermatologists. We aimed to compare the safety and efficacy of methotrexate and cyclosporine in LPP patients. METHODS In a randomized clinical trials, 33 patients were randomly allocated to receive either 15-mg oral methotrexate per week or 3-5-mg/kg/day cyclosporine for six months. During the treatment course, side effects, signs/symptoms and laboratory test were assessed periodically. Lichen planopilaris activity index (LPPAI) was measured at baseline and 2, 4, and 6 months after the intervention. Score of both photography and patient's opinion were also obtained. The collected data were analyzed in SPSS software (Ver.25.0. Armonk, NY: IBM Corp). RESULTS Both medications had positive effects on the signs and symptoms of LPP with a significant difference between the variables (p < 0.05), and the results showed similar efficacy at the end of 6th months of the therapy with both cyclosporine and methotrexate (p > 0.05). CONCLUSIONS Regarding the results of the present study, both cyclosporine and methotrexate are effective in treating refractory lichen planopilaris and we propose methotrexate as a possible earlier choice over cyclosporine. This study was registered in Iranian Registry of Clinical Trials (IRCT20190717044256N1).",2020,"Both medications had positive effects on the signs and symptoms of LPP with a significant difference between the variables (p < 0.05), and the results showed similar efficacy at the end of 6th months of the therapy with both cyclosporine and methotrexate (p > 0.05). ","['LPP patients', '33 patients']","['Lichen Planopilaris (LPP', 'cyclosporine and methotrexate', '15-mg oral methotrexate per week or 3-5-mg/kg/day cyclosporine', 'Cyclosporine or methotrexate', 'methotrexate and cyclosporine', 'cyclosporine']","['side effects, signs/symptoms and laboratory test', 'safety and efficacy', 'Lichen planopilaris activity index (LPPAI', 'signs and symptoms of LPP']","[{'cui': 'C0023645', 'cui_str': 'Lichen planopilaris'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0023645', 'cui_str': 'Lichen planopilaris'}, {'cui': 'C0010592', 'cui_str': 'Cyclosporine'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0442758', 'cui_str': '3/5'}, {'cui': 'C3665414', 'cui_str': 'mg/kg/day'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0022885', 'cui_str': 'Laboratory procedure'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0023645', 'cui_str': 'Lichen planopilaris'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",33.0,0.113439,"Both medications had positive effects on the signs and symptoms of LPP with a significant difference between the variables (p < 0.05), and the results showed similar efficacy at the end of 6th months of the therapy with both cyclosporine and methotrexate (p > 0.05). ","[{'ForeName': 'Farahnaz', 'Initials': 'F', 'LastName': 'Fatemi Naeini', 'Affiliation': 'Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: fatemi@med.mui.ac.ir.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Mohaghegh', 'Affiliation': 'Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: f.mohaghegh@med.mui.ac.ir.'}, {'ForeName': 'Minoo', 'Initials': 'M', 'LastName': 'Jelvan', 'Affiliation': 'Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: minoo.jelvan@gmail.com.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Asilian', 'Affiliation': 'Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: asilian@med.mui.ac.ir.'}, {'ForeName': 'Mina', 'Initials': 'M', 'LastName': 'Saber', 'Affiliation': 'Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: mi.saber@med.mui.ac.ir.'}]",International immunopharmacology,['10.1016/j.intimp.2020.106765'] 2044,32673060,Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.,"BACKGROUND No effective oral therapy exists for early coronavirus disease 2019 (COVID-19). OBJECTIVE To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients. DESIGN Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668). SETTING Internet-based trial across the United States and Canada (40 states and 3 provinces). PARTICIPANTS Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset. INTERVENTION Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo. Measures : Symptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale. The primary end point was change in overall symptom severity over 14 days. RESULTS Of 491 patients randomly assigned to a group, 423 contributed primary end point data. Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting. Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, -0.27 points [95% CI, -0.61 to 0.07 points]; P  = 0.117). At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo ( P  = 0.21). Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo ( P  < 0.001). With placebo, 10 hospitalizations occurred (2 non-COVID-19-related), including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death ( P  = 0.29). LIMITATIONS Only 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages. CONCLUSION Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19. PRIMARY FUNDING SOURCE Private donors.",2020,"With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death ( P  = 0.29). ","['outpatients with early, mild COVID-19', 'Nonhospitalized Adults', '22 March through 20 May 2020', '341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting', 'Internet-based trial across the United States and Canada', 'Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset', 'adult outpatients', '491 patients randomly assigned to a group, 423 contributed primary end point data']","['hydroxychloroquine', 'Hydroxychloroquine', 'Early COVID-19', 'Oral hydroxychloroquine', 'placebo']","['ongoing symptoms', 'overall symptom severity', '10-point visual analogue scale', 'Medication adverse effects', 'symptom severity', 'hospitalized death', 'Change in symptom severity', 'COVID-19 severity']","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0444930', 'cui_str': 'End'}]","[{'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0041755', 'cui_str': 'Adverse reaction to drug'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",423.0,0.761778,"With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death ( P  = 0.29). ","[{'ForeName': 'Caleb P', 'Initials': 'CP', 'LastName': 'Skipper', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Katelyn A', 'Initials': 'KA', 'LastName': 'Pastick', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Nicole W', 'Initials': 'NW', 'LastName': 'Engen', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Ananta S', 'Initials': 'AS', 'LastName': 'Bangdiwala', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Abassi', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Sarah M', 'Initials': 'SM', 'LastName': 'Lofgren', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Darlisha A', 'Initials': 'DA', 'LastName': 'Williams', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Okafor', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Matthew F', 'Initials': 'MF', 'LastName': 'Pullen', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Melanie R', 'Initials': 'MR', 'LastName': 'Nicol', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Alanna A', 'Initials': 'AA', 'LastName': 'Nascene', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Kathy H', 'Initials': 'KH', 'LastName': 'Hullsiek', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Cheng', 'Affiliation': 'Research Institute of the McGill University Health Centre and McGill University, Montréal, Quebec, Canada (M.P.C., E.G.M., T.C.L.).'}, {'ForeName': 'Darlette', 'Initials': 'D', 'LastName': 'Luke', 'Affiliation': 'M Health Fairview Investigational Drug Service Pharmacy, Minneapolis, Minnesota (D.L.).'}, {'ForeName': 'Sylvain A', 'Initials': 'SA', 'LastName': 'Lother', 'Affiliation': 'University of Manitoba, Winnipeg, Manitoba, Canada (S.A.L., L.J.M., G.D., R.Z.).'}, {'ForeName': 'Lauren J', 'Initials': 'LJ', 'LastName': 'MacKenzie', 'Affiliation': 'University of Manitoba, Winnipeg, Manitoba, Canada (S.A.L., L.J.M., G.D., R.Z.).'}, {'ForeName': 'Glen', 'Initials': 'G', 'LastName': 'Drobot', 'Affiliation': 'University of Manitoba, Winnipeg, Manitoba, Canada (S.A.L., L.J.M., G.D., R.Z.).'}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Kelly', 'Affiliation': 'George & Fay Yee Centre for Healthcare Innovation, Winnipeg, Manitoba, Canada (L.E.K.).'}, {'ForeName': 'Ilan S', 'Initials': 'IS', 'LastName': 'Schwartz', 'Affiliation': 'University of Alberta, Edmonton, Alberta, Canada (I.S.S.).'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Zarychanski', 'Affiliation': 'University of Manitoba, Winnipeg, Manitoba, Canada (S.A.L., L.J.M., G.D., R.Z.).'}, {'ForeName': 'Emily G', 'Initials': 'EG', 'LastName': 'McDonald', 'Affiliation': 'Research Institute of the McGill University Health Centre and McGill University, Montréal, Quebec, Canada (M.P.C., E.G.M., T.C.L.).'}, {'ForeName': 'Todd C', 'Initials': 'TC', 'LastName': 'Lee', 'Affiliation': 'Research Institute of the McGill University Health Centre and McGill University, Montréal, Quebec, Canada (M.P.C., E.G.M., T.C.L.).'}, {'ForeName': 'Radha', 'Initials': 'R', 'LastName': 'Rajasingham', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Boulware', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}]",Annals of internal medicine,['10.7326/M20-4207'] 2045,32673082,Massage Compared with Massage Plus Acupuncture for Breast Cancer Patients Undergoing Reconstructive Surgery.,"Objectives: Integrative therapies have been incorporated increasingly into health and wellness in the United States in recent decades. Their potential benefits are under evaluation in various situations, including pain and symptom relief for cancer patients and survivors. This pilot study evaluated whether combining two integrative complementary approaches augments a patient's benefit by reducing postoperative stress, pain, anxiety, muscle tension, and fatigue compared with one integrative complementary approach alone. Design: Patients undergoing autologous tissue breast reconstruction were randomly assigned to one of two postoperative complementary alternative therapies for three consecutive days. All participants were observed for up to 3 months. Subjects: Forty-two participants were recruited from January 29, 2016 to July 11, 2018. Interventions: Twenty-one participants were randomly assigned to massage alone and 21 to massage and acupuncture. Outcome measures: Stress, anxiety, relaxation, nausea, fatigue, pain, and mood (score 0-10) were measured at enrollment before surgery and postoperative days 1, 2, and 3 before and after the intervention. Patient satisfaction was evaluated. Results: Stress decreased from baseline for both Massage-Only Group and Massage+Acupuncture Group after each treatment intervention. Change in stress score from baseline decreased significantly more in the Massage-Only Group at pretreatment and posttreatment ( p  = 0.03 and p  = 0.04). After adjustment for baseline values, change in fatigue, anxiety, relaxation, nausea, pain, and mood scores did not differ between groups. When patients were asked whether they would recommend the study, 100% (19/19) of Massage-Only Group and 94% (17/18) of Massage+Acupuncture Group responded yes ( p  = 0.49). Conclusion: No additive beneficial effects were observed with addition of acupuncture to massage for pain, anxiety, relaxation, nausea, fatigue, and mood. Combined massage and acupuncture was not as effective in reducing stress as massage alone, although both groups had significant stress reduction. These findings indicate a need for larger studies to explore these therapies further.",2020,"No additive beneficial effects were observed with addition of acupuncture to massage for pain, anxiety, relaxation, nausea, fatigue, and mood.","['Patients undergoing autologous tissue breast reconstruction', 'cancer patients and survivors', 'Interventions: Twenty-one participants', 'Subjects: Forty-two participants were recruited from January 29, 2016 to July 11, 2018', 'Breast Cancer Patients Undergoing Reconstructive Surgery']","['Combined massage and acupuncture', 'acupuncture', 'massage alone and 21 to massage and acupuncture', 'Massage+Acupuncture', 'Massage', 'Massage Plus Acupuncture']","['Patient satisfaction', 'pain, anxiety, relaxation, nausea, fatigue, and mood', 'Change in stress score', 'Outcome measures: Stress, anxiety, relaxation, nausea, fatigue, pain, and mood', 'pain and symptom relief', 'Stress', 'fatigue, anxiety, relaxation, nausea, pain, and mood scores', 'postoperative stress, pain, anxiety, muscle tension, and fatigue']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0085076', 'cui_str': 'Mammoplasty'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0524865', 'cui_str': 'Reconstruction - action'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0026841', 'cui_str': 'Muscle Tension'}]",42.0,0.0842268,"No additive beneficial effects were observed with addition of acupuncture to massage for pain, anxiety, relaxation, nausea, fatigue, and mood.","[{'ForeName': 'Christina A', 'Initials': 'CA', 'LastName': 'Dilaveri', 'Affiliation': 'Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Ivana T', 'Initials': 'IT', 'LastName': 'Croghan', 'Affiliation': 'Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Molly J', 'Initials': 'MJ', 'LastName': 'Mallory', 'Affiliation': 'Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Liza J', 'Initials': 'LJ', 'LastName': 'Dion', 'Affiliation': 'Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Karen M', 'Initials': 'KM', 'LastName': 'Fischer', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Darrell R', 'Initials': 'DR', 'LastName': 'Schroeder', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Jorys', 'Initials': 'J', 'LastName': 'Martinez-Jorge', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Minh-Doan T', 'Initials': 'MT', 'LastName': 'Nguyen', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Shawn C', 'Initials': 'SC', 'LastName': 'Fokken', 'Affiliation': 'Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Brent A', 'Initials': 'BA', 'LastName': 'Bauer', 'Affiliation': 'Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Dietlind L', 'Initials': 'DL', 'LastName': 'Wahner-Roedler', 'Affiliation': 'Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.'}]","Journal of alternative and complementary medicine (New York, N.Y.)",['10.1089/acm.2019.0479'] 2046,32673517,Splanchnic Venous Compression Enhances the Effects of ß-Blockade in the Treatment of Postural Tachycardia Syndrome.,"Background Splanchnic venous pooling induced by upright posture triggers a compensatory increase in heart rate (HR), a response that is exaggerated in patients with postural tachycardia syndrome. To assess whether abdominal compression attenuates orthostatic tachycardia and improves symptoms, 18 postural tachycardia syndrome patients (32±2 years) were randomized to receive either abdominal compression (40 mm Hg applied with an inflatable binder ≈2 minutes before standing) or propranolol (20 mg) in a placebo-controlled, crossover study. Methods and Results Systolic blood pressure, HR, and symptoms were assessed while seated and standing, before and 2 hours postdrug. As expected, propranolol decreased standing HR compared with placebo (81±2 versus 98±4 beats per minute; P <0.001) and was associated with lower standing systolic blood pressure (93±2 versus 100±2 mm Hg for placebo; P =0.002). Compression had no effect on standing HR (96±4 beats per minute) but increased standing systolic blood pressure compared with placebo and propranolol (106±2 mm Hg; P <0.01). Neither propranolol nor compression improved symptoms compared with placebo. In 16 patients we compared the combination of abdominal compression and propranolol with propranolol alone. The combination had no additional effect on standing HR (81±2 beats per minute for both interventions) but prevented the decrease in standing systolic blood pressure produced by propranolol (98±2 versus 93±2 mm Hg for propranolol; P =0.029), and significantly improved total symptom burden (-6±2 versus -1±2 for propranolol; P =0.041). Conclusions Splanchnic venous compression alone did not improve HR or symptoms but prevented the blood pressure decrease produced by propranolol. The combination was more effective in improving symptoms than either alone. Splanchnic venous compression can be a useful adjuvant therapy to propranolol in postural tachycardia syndrome. Registration URL: https://www.clini​caltr​ials.gov; Unique identifier: NCT00262470.",2020,"As expected, propranolol decreased standing HR compared with placebo (81±2 versus 98±4 beats per minute; P <0.001) and was associated with lower standing systolic blood pressure (93±2 versus 100±2 mm ","['Postural Tachycardia Syndrome', '18 postural tachycardia syndrome patients (32±2\xa0years', 'patients with postural tachycardia syndrome']","['placebo and propranolol', 'Splanchnic venous compression', 'propranolol with propranolol alone', 'abdominal compression (40\xa0mm', 'abdominal compression attenuates orthostatic tachycardia', 'propranolol', 'placebo']","['HR or symptoms', 'total symptom burden', 'blood pressure', 'Systolic blood pressure, HR, and symptoms', 'standing systolic blood pressure', 'heart rate (HR', 'standing HR']","[{'cui': 'C1299624', 'cui_str': 'Postural orthostatic tachycardia syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0033497', 'cui_str': 'Propranolol'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0450402', 'cui_str': '40mm'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C1303018', 'cui_str': 'Standing systolic blood pressure'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}]",,0.169521,"As expected, propranolol decreased standing HR compared with placebo (81±2 versus 98±4 beats per minute; P <0.001) and was associated with lower standing systolic blood pressure (93±2 versus 100±2 mm ","[{'ForeName': 'Emily C', 'Initials': 'EC', 'LastName': 'Smith', 'Affiliation': 'Vanderbilt Autonomic Dysfunction Center Vanderbilt University School of Medicine Nashville TN.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Diedrich', 'Affiliation': 'Vanderbilt Autonomic Dysfunction Center Vanderbilt University School of Medicine Nashville TN.'}, {'ForeName': 'Satish R', 'Initials': 'SR', 'LastName': 'Raj', 'Affiliation': 'Vanderbilt Autonomic Dysfunction Center Vanderbilt University School of Medicine Nashville TN.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Gamboa', 'Affiliation': 'Vanderbilt Autonomic Dysfunction Center Vanderbilt University School of Medicine Nashville TN.'}, {'ForeName': 'Cyndya A', 'Initials': 'CA', 'LastName': 'Shibao', 'Affiliation': 'Vanderbilt Autonomic Dysfunction Center Vanderbilt University School of Medicine Nashville TN.'}, {'ForeName': 'Bonnie K', 'Initials': 'BK', 'LastName': 'Black', 'Affiliation': 'Vanderbilt Autonomic Dysfunction Center Vanderbilt University School of Medicine Nashville TN.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Peltier', 'Affiliation': 'Vanderbilt Autonomic Dysfunction Center Vanderbilt University School of Medicine Nashville TN.'}, {'ForeName': 'Sachin Y', 'Initials': 'SY', 'LastName': 'Paranjape', 'Affiliation': 'Vanderbilt Autonomic Dysfunction Center Vanderbilt University School of Medicine Nashville TN.'}, {'ForeName': 'Italo', 'Initials': 'I', 'LastName': 'Biaggioni', 'Affiliation': 'Vanderbilt Autonomic Dysfunction Center Vanderbilt University School of Medicine Nashville TN.'}, {'ForeName': 'Luis E', 'Initials': 'LE', 'LastName': 'Okamoto', 'Affiliation': 'Vanderbilt Autonomic Dysfunction Center Vanderbilt University School of Medicine Nashville TN.'}]",Journal of the American Heart Association,['10.1161/JAHA.120.016196'] 2047,32678777,The intraocular pressure responses to oral academic examination: The influence of perceived levels of public speaking anxiety.,"We examined the intraocular pressure responsiveness to oral examination stress, as well as the mediating role of the perceived levels of public speaking anxiety on intraocular pressure changes. Thirty-two university students (intervention group) publicly defended their degree final project, and intraocular pressure and perceived levels of stress were measured before and after the oral presentation, and after 10 min of recovery. The control group (n = 32) was not exposed to any stressful situation, and the dependent measures were taken at the same time points. All participants completed the public speaking anxiety scale. The intervention group exhibited higher intraocular pressure values before the oral presentation (corrected p-values<0.001), with these changes being positively associated with the perceived levels of public speaking anxiety (p < 0.001, r = 0.71). Our results reveal a mediating role of public speaking anxiety on the intraocular pressure responsiveness to oral examination stress, and highlight the utility of intraocular pressure as an indicator of stress in applied situations.",2020,"The intervention group exhibited higher intraocular pressure values before the oral presentation (corrected p-values<0.001), with these changes being positively associated with the perceived levels of public speaking anxiety (p < 0.001, r = 0.71).",['Thirty-two university students (intervention group) publicly defended their'],[],"['intraocular pressure responses', 'degree final project, and intraocular pressure and perceived levels of stress', 'perceived levels of public speaking anxiety', 'public speaking anxiety scale', 'intraocular pressure values']","[{'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",[],"[{'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}, {'cui': 'C0234856', 'cui_str': 'Speaking'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.0271671,"The intervention group exhibited higher intraocular pressure values before the oral presentation (corrected p-values<0.001), with these changes being positively associated with the perceived levels of public speaking anxiety (p < 0.001, r = 0.71).","[{'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Vera', 'Affiliation': 'Department of Optics, Faculty of Sciences, University of Granada, Spain.'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Redondo', 'Affiliation': 'Department of Optics, Faculty of Sciences, University of Granada, Spain. Electronic address: beadondo@correo.ugr.es.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Álvarez-Rodríguez', 'Affiliation': 'Department of Optics, Faculty of Sciences, University of Granada, Spain.'}, {'ForeName': 'Rubén', 'Initials': 'R', 'LastName': 'Molina', 'Affiliation': 'Department of Optics, Faculty of Sciences, University of Granada, Spain.'}, {'ForeName': 'Raimundo', 'Initials': 'R', 'LastName': 'Jiménez', 'Affiliation': 'Department of Optics, Faculty of Sciences, University of Granada, Spain.'}]",Applied ergonomics,['10.1016/j.apergo.2020.103158'] 2048,32678808,[Letter to the editor - Participation of medical students from Latin America in the COVID-19 pandemic].,,2020,,[],[],[],[],[],[],,0.0151271,,"[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Ponce-Torres', 'Affiliation': 'Facultad de Medicina Humana, Universidad de San Martín de Porres, Lima, Perú. Address: Alameda del Corregidor 1531, La Molina, Lima, Perú. Email: christianfpt01@gmail.com. ORCID: 0000-0002-7745-8875.'}]",Medwave,['10.5867/medwave.2020.06.7968'] 2049,32678852,The effect of comprehensive intervention for childhood obesity on dietary diversity among younger children: Evidence from a school-based randomized controlled trial in China.,"BACKGROUND Little evidence from developing countries on dietary transition demonstrates the effects of comprehensive childhood obesity interventions on dietary diversity and food variety among younger children. This study aimed to evaluate the effects of comprehensive childhood obesity interventions on dietary diversity among younger children. METHODS A total of 4846 children aged 7-13 years were included based on a multicenter randomized controlled trial for childhood obesity interventions in 38 primary schools. Nutrition education intervention (NE), physical activity intervention (PA) and comprehensive intervention including both NE and PA (CNP) were carried out separately for 2 semesters. Dietary Diversity Score (DDS9 and DDS28 for 9 and 28 food groupings, respectively), Food Variety Score (FVS, the number of food items) and the proportions of different foods consumed were calculated according to the food intake records collected with the 24-h dietary recall method. RESULTS The intervention effects per day of comprehensive intervention group were 0 (95% Confidence Interval (CI): 0, 0.1; p = 0.382) on DDS9, 0.1 (95% CI: -0.1, 0.2; p = 0.374) on DDS28 and 0.1 (95% CI: -0.1, 0.3; p = 0.186) on FVS of overall diet, which was 0.1 (95% CI: 0, 0.1; p < 0.001) on DDS9, 0 (95% CI: 0, 0.1; p = 0.168) on DDS28 and 0.1 (95% CI: 0, 0.1; p = 0.067) on FVS of dietary scores of breakfast only. Additionally, CNP group had greater increases in cereals, meat and fruits, and more decreases in eggs, fish and dried legumes consumption proportions as compared with the control group. Decreasing side effect on dietary diversity and food variety were found for PA intervention, but not for NE intervention only. CONCLUSIONS Though the comprehensive obesity intervention didn't improve the overall dietary diversity per day, the positive intervention effects were observed on breakfast foods and some foods' consumption.",2020,"Additionally, CNP group had greater increases in cereals, meat and fruits, and more decreases in eggs, fish and dried legumes consumption proportions as compared with the control group.","['younger children', '4846 children aged 7-13 years', '38 primary schools']","['comprehensive childhood obesity interventions', 'childhood obesity interventions', 'comprehensive intervention', 'Nutrition education intervention (NE), physical activity intervention (PA) and comprehensive intervention including both NE and PA (CNP', 'CNP']","['Dietary Diversity Score (DDS9 and DDS28', 'FVS of dietary scores', 'dietary diversity', 'Food Variety Score ', 'cereals, meat and fruits, and more decreases in eggs, fish and dried legumes consumption proportions', 'FVS of overall diet', 'overall dietary diversity']","[{'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0033145', 'cui_str': 'Primary school'}]","[{'cui': 'C2362324', 'cui_str': 'Childhood obesity'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1511518', 'cui_str': 'Copy Number Polymorphisms'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0236026', 'cui_str': 'Fetal valproate syndrome'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0007757', 'cui_str': 'Cereal'}, {'cui': 'C0025017', 'cui_str': 'Meat'}, {'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0013710', 'cui_str': 'Eggs (edible)'}, {'cui': 'C0016163', 'cui_str': 'Fish'}, {'cui': 'C0011682', 'cui_str': 'Desiccation - action'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",4846.0,0.0989589,"Additionally, CNP group had greater increases in cereals, meat and fruits, and more decreases in eggs, fish and dried legumes consumption proportions as compared with the control group.","[{'ForeName': 'Haiquan', 'Initials': 'H', 'LastName': 'Xu', 'Affiliation': 'Institute of Food and Nutrition Development, Ministry of Agriculture and Rural Affairs, Beijing, China.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Ecker', 'Affiliation': 'International Food Policy Research Institute, Washington, DC, United States of America.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing, China.'}, {'ForeName': 'Songming', 'Initials': 'S', 'LastName': 'Du', 'Affiliation': 'Chinese Nutrition Society, Beijing, China.'}, {'ForeName': 'Ailing', 'Initials': 'A', 'LastName': 'Liu', 'Affiliation': 'National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing, China.'}, {'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Xiaoqi', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing, China.'}, {'ForeName': 'Tingyu', 'Initials': 'T', 'LastName': 'Li', 'Affiliation': ""Chongqing Children's Hospital, Chongqing, China.""}, {'ForeName': 'Hongwei', 'Initials': 'H', 'LastName': 'Guo', 'Affiliation': 'School of Public Health, Fudan University, Shanghai, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Harbin Medical University, Harbin, China.'}, {'ForeName': 'Guifa', 'Initials': 'G', 'LastName': 'Xu', 'Affiliation': 'Department of Public Health, Shandong University, Jinan, China.'}, {'ForeName': 'Weijia', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'Guangzhou Center for Disease Control and Prevention, Guangzhou, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'Institute of Child and Adolescent Health, School of Public Health, Peking University, Beijing, China.'}, {'ForeName': 'Junmao', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': 'Institute of Food and Nutrition Development, Ministry of Agriculture and Rural Affairs, Beijing, China.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Chen', 'Affiliation': 'International Food Policy Research Institute, Washington, DC, United States of America.'}, {'ForeName': 'Guansheng', 'Initials': 'G', 'LastName': 'Ma', 'Affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China.'}]",PloS one,['10.1371/journal.pone.0235951'] 2050,32679434,"Diet-induced differences in estimated plasma glucose concentrations in healthy, non-diabetic adults are detected by continuous glucose monitoring-a randomized crossover trial.","Continuous glucose monitors (CGMs) have been developed for diabetic patients for estimating and controlling plasma glucose changes throughout the day. However, elevated postprandial glucose concentrations may also be detrimental for non-diabetic subjects by increasing the risk of developing vascular complications and type 2 diabetes. Therefore, CGMs may also be valuable in clinical research and we hypothesized that diet-induced differences in estimated plasma glucose concentrations in healthy, non-diabetic adults could be detected by the Abbott FreeStyle Libre Pro CGM. In this single-blind randomized cross-over trial, 23 healthy but overweight or obese men and women therefore consumed two diets differing in glycemic load in randomized order for three consecutive days. Based on the CGM measurements, two-hour total areas under the curve (tAUCs) after breakfast, lunch and dinner were calculated. Additionally, postprandial glucose was measured with the CGM and in plasma during a rice meal challenge. The average tAUC was significantly lower on the low GL diet compared to the high GL diet (P < .0001). The same conclusions were drawn when tAUCs for breakfast (P < .0001), lunch (P < .0001) and dinner (P < .0001) were analyzed separately. During the rice meal challenge, significantly higher glucose responses were observed after the low GL period, as monitored by both the CGM device (P < .0001) and the plasma glucose analysis (P < .0001). The difference between the means of both methods was 0.11 mmol/L (1.78%) with a higher glucose value in plasma. The absolute mean difference was 0.66 mmol/L (10.5%). We conclude that the CGM detected diet-induced differences in estimated plasma glucose concentrations, which supports its use not only in clinical practice, but also for research purposes during dietary interventions in non-diabetic participants.",2020,The average tAUC was significantly lower on the low GL diet compared to the high GL diet (P < .0001).,"['healthy, non-diabetic adults', '23 healthy but overweight or obese men and women', 'non-diabetic participants', 'diabetic patients']",['Continuous glucose monitors (CGMs'],"['elevated postprandial glucose concentrations', 'average tAUC', 'glucose responses', 'plasma glucose analysis', 'plasma glucose concentrations', 'postprandial glucose']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0427743', 'cui_str': 'Glucose concentration, test strip measurement'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C2584434', 'cui_str': 'Plasma glucose concentration'}]",23.0,0.0315526,The average tAUC was significantly lower on the low GL diet compared to the high GL diet (P < .0001).,"[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Fechner', 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, PO Box 616, 6200, MD, Maastricht, The Netherlands. Electronic address: eva.fechner@outlook.com.'}, {'ForeName': 'Cara', 'Initials': 'C', 'LastName': ""Op 't Eyndt"", 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, PO Box 616, 6200, MD, Maastricht, The Netherlands. Electronic address: cara.opteyndt@mumc.nl.'}, {'ForeName': 'Theo', 'Initials': 'T', 'LastName': 'Mulder', 'Affiliation': 'Unilever Foods Innovation Center - Hive, Bronland 14, 6708, WH, Wageningen, The Netherlands. Electronic address: theo.mulder@unilever.com.'}, {'ForeName': 'Ronald P', 'Initials': 'RP', 'LastName': 'Mensink', 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, PO Box 616, 6200, MD, Maastricht, The Netherlands. Electronic address: r.mensink@maastrichtuniversity.nl.'}]","Nutrition research (New York, N.Y.)",['10.1016/j.nutres.2020.06.001'] 2051,32679537,Blood pressure postpartum (BP 2 ) RCT protocol: Follow-up and lifestyle behaviour change strategies in the first 12 months after hypertensive pregnancy.,"OBJECTIVES Women who had hypertensive disorders of pregnancy (HDP) are twice as likely to experience maternal cardiovascular disease later in life. The primary aim of this study (BP 2 ) is to compare outcomes of 3 different management strategies, including lifestyle behaviour change (LBC), in the first 12 months postpartum in women who had HDP in their preceding pregnancy. Secondary aims include assessing the effects on other cardiometabolic parameters. STUDY DESIGN Three-arm multicentre randomised trial in metropolitan Australian hospitals, (registration: ACTRN12618002004246) target sample size 480. Participants are randomised to one of three groups: 1) Optimised usual care: information package and family doctor follow-up 6 months postpartum 2) Brief intervention: information package as per group 1, plus assessment and brief LBC counselling at a specialised clinic with an obstetric physician and dietitian 6 months postpartum 3) Extended intervention: as per group 2 plus enrolment into a 6 month telephone-based LBC program from 6 to 12 months postpartum. All women have an outcome assessment at 12 months. MAIN OUTCOME MEASURES Primary outcomes: (a) BP change or (b) weight change and/or waist circumference change. SECONDARY OUTCOMES maternal health-related quality of life, engagement and retention in LBC program, biochemical markers, vascular function testing, infant weight trajectory, incremental cost-effectiveness ratios. The study is powered to detect a 4 mmHg difference in systolic BP between groups, or a 4 kg weight loss difference/2cm waist circumference change. CONCLUSIONS BP 2 will provide evidence regarding the feasibility and effectiveness of postpartum LBC interventions and structured clinical follow-up in improving cardiovascular health markers after HDP.",2020,Participants are randomised to one of three groups: 1) Optimised usual care: information package and family doctor follow-up 6 months postpartum 2),"['women who had HDP in their preceding pregnancy', 'Three-arm multicentre randomised trial in metropolitan Australian hospitals, (registration: ACTRN12618002004246) target sample size 480', 'Women who had hypertensive disorders of pregnancy (HDP']","['LBC counselling at a specialised clinic with an obstetric physician and dietitian 6\xa0months postpartum 3) Extended intervention: as per group 2 plus enrolment into a 6\xa0month telephone-based LBC program', 'Optimised usual care: information package and family doctor follow-up 6\xa0months postpartum 2']","['Blood pressure postpartum (BP 2 ', 'BP change or (b) weight change and/or waist circumference change', 'maternal health-related quality of life, engagement and retention in LBC program, biochemical markers, vascular function testing, infant weight trajectory, incremental cost-effectiveness ratios', 'systolic BP', 'lifestyle behaviour change (LBC']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0852260', 'cui_str': 'Hypertension associated disorders of pregnancy'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C4319609', 'cui_str': '480'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0334932', 'cui_str': 'Dietitian (general)'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C1704221', 'cui_str': 'Family medicine specialist'}, {'cui': 'C0589124', 'cui_str': 'Follow-up 6 months'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C1268766', 'cui_str': 'Blood pressure alteration'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0024921', 'cui_str': 'Maternal Health'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Markers'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C4704805', 'cui_str': 'Weight Trajectory'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",480.0,0.118249,Participants are randomised to one of three groups: 1) Optimised usual care: information package and family doctor follow-up 6 months postpartum 2),"[{'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Henry', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia; The George Institute for Global Health, Sydney, Australia. Electronic address: Amanda.Henry@unsw.edu.au.""}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Arnott', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia; Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Faculty of Medicine, University of New South Wales, Sydney, Australia; Sydney Medical School, University of Sydney, Australia.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Makris', 'Affiliation': 'Faculty of Medicine, University of New South Wales, Sydney, Australia; School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Davis', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Annemarie', 'Initials': 'A', 'LastName': 'Hennessy', 'Affiliation': 'School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Beech', 'Affiliation': 'Royal Hospital for Women, Randwick, New South Wales, Australia.'}, {'ForeName': 'Franziska', 'Initials': 'F', 'LastName': 'Pettit', 'Affiliation': 'Department of Renal Medicine, St George Hospital, Kogarah, New South Wales, Australia; St George and Sutherland Clinical School, UNSW Medicine, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Se Homer', 'Affiliation': 'Burnet Institute, Melbourne, Victoria, Australia; Faculty of Health, University of Technology, Sydney, New South Wales, Australia.'}, {'ForeName': 'Maria E', 'Initials': 'ME', 'LastName': 'Craig', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Lynne', 'Initials': 'L', 'LastName': 'Roberts', 'Affiliation': ""Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia; St George and Sutherland Clinical School, UNSW Medicine, University of New South Wales, Sydney, Australia.""}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Hyett', 'Affiliation': 'Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Sydney Medical School, University of Sydney, Australia.'}, {'ForeName': 'Georgina', 'Initials': 'G', 'LastName': 'Chambers', 'Affiliation': ""National Perinatal Epidemiology and Statistics Unit, School of Women's and Children's Health and Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW, Australia.""}, {'ForeName': 'Oisin', 'Initials': 'O', 'LastName': 'Fitzgerald', 'Affiliation': ""National Perinatal Epidemiology and Statistics Unit, School of Women's and Children's Health and Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW, Australia.""}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Gow', 'Affiliation': 'Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Mann', 'Affiliation': 'General Practitioner, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Challis', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Royal Hospital for Women, Randwick, New South Wales, Australia.""}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Gale', 'Affiliation': 'New South Wales Ministry of Health, North Sydney, New South Wales, Australia.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Ruhotas', 'Affiliation': ""Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Emilee', 'Initials': 'E', 'LastName': 'Kirwin', 'Affiliation': ""Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Denney-Wilson', 'Affiliation': 'Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Brown', 'Affiliation': 'Department of Renal Medicine, St George Hospital, Kogarah, New South Wales, Australia; St George and Sutherland Clinical School, UNSW Medicine, University of New South Wales, Sydney, Australia.'}]",Pregnancy hypertension,['10.1016/j.preghy.2020.07.001'] 2052,32679728,Effects of 120 vs. 60 and 90 g/h Carbohydrate Intake during a Trail Marathon on Neuromuscular Function and High Intensity Run Capacity Recovery.,"BACKGROUND Current carbohydrate (CHO) intake recommendations for ultra-trail activities lasting more than 2.5 h is 90 g/h. However, the benefits of ingesting 120 g/h during a mountain marathon in terms of post-exercise muscle damage have been recently demonstrated. Therefore, the aim of this study was to analyze and compare the effects of 120 g/h CHO intake with the recommendations (90 g/h) and the usual intake for ultra-endurance athletes (60 g/h) during a mountain marathon on internal exercise load, and post-exercise neuromuscular function and recovery of high intensity run capacity. METHODS Twenty-six elite trail-runners were randomly distributed into three groups: LOW (60 g/h), MED (90 g/h) and HIGH (120 g/h), according to CHO intake during a 4000-m cumulative slope mountain marathon. Runners were measured using the Abalakov Jump test, a maximum a half-squat test and an aerobic power-capacity test at baseline (T1) and 24 h after completing the race (T2). RESULTS Changes in Abalakov jump time (ABK JT ), Abalakov jump height (ABK H ), half-squat test 1 repetition maximum (HST 1RM ) between T1 and T2 showed significant differences by Wilcoxon signed rank test only in LOW and MED ( p < 0.05), but not in the HIGH group ( p > 0.05). Internal load was significantly lower in the HIGH group ( p = 0.017) regarding LOW and MED by Mann Whitney u test. A significantly lower change during the study in ABK JT ( p = 0.038), ABK H ( p = 0.038) HST 1RM ( p = 0.041) and in terms of fatigue ( p = 0.018) and lactate ( p = 0.012) within the aerobic power-capacity test was presented in HIGH relative to LOW and MED. CONCLUSIONS 120 g/h CHO intake during a mountain marathon might limit neuromuscular fatigue and improve recovery of high intensity run capacity 24 h after a physiologically challenging event when compared to 90 g/h and 60 g/h.",2020,Internal load was significantly lower in the HIGH group ( p = 0.017) regarding LOW and MED by Mann Whitney u test.,['Twenty-six elite trail-runners'],[],"['Abalakov jump time (ABK JT ', 'fatigue', 'Abalakov jump height (ABK H ), half-squat test 1 repetition maximum (HST 1RM ', 'Wilcoxon signed rank test only in LOW and MED', 'ABK H ', 'Internal load', 'Neuromuscular Function and High Intensity Run Capacity Recovery']","[{'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}]",[],"[{'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0667477', 'cui_str': 'TNFRSF11A protein, human'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",,0.0286564,Internal load was significantly lower in the HIGH group ( p = 0.017) regarding LOW and MED by Mann Whitney u test.,"[{'ForeName': 'Aritz', 'Initials': 'A', 'LastName': 'Urdampilleta', 'Affiliation': 'Centro Investigación y Formación ElikaSport, Cerdanyola del Valles, 08290 Barcelona, Spain.'}, {'ForeName': 'Soledad', 'Initials': 'S', 'LastName': 'Arribalzaga', 'Affiliation': 'Institute of Biomedicine (IBIOMED), Physiotherapy Department, University of Leon, Campus de Vegazana, 24071 Leon, Spain.'}, {'ForeName': 'Aitor', 'Initials': 'A', 'LastName': 'Viribay', 'Affiliation': 'Glut4Science, Physiology, Nutrition and Sport, 01004 Vitoria-Gasteiz, Spain.'}, {'ForeName': 'Arkaitz', 'Initials': 'A', 'LastName': 'Castañeda-Babarro', 'Affiliation': 'Health, Physical Activity and Sports Science Laboratory, Department of Physical Activity and Sports, Faculty of Psychology and Education, University of Deusto, 48007 Bizkaia, Spain.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Seco-Calvo', 'Affiliation': 'Institute of Biomedicine (IBIOMED), Physiotherapy Department, University of Leon, Researcher at the Basque Country University, Campus de Vegazana, 24071 Leon, Spain.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Mielgo-Ayuso', 'Affiliation': 'Department of Biochemistry, Molecular Biology and Physiology, Faculty of Health Sciences, University of Valladolid, 42004 Soria, Spain.'}]",Nutrients,['10.3390/nu12072094'] 2053,32679755,Effects of 3D Moving Platform Exercise on Physiological Parameters and Pain in Patients with Chronic Low Back Pain.,"Background and objectives: Patient-handling activities predispose women to chronic low back pain (CLBP), but sufficient evidence is not available on whether a 3D moving platform, made for core stability exercise, affects pain, trunk flexibility, and static/dynamic muscle contractions in CLBP patients. Materials and Methods: The participants were twenty-nine women who were randomly divided into a control group (CON) and a 3D exercise group (3DEG), which took part in 3D moving exercise three times a week for 8 weeks. Both groups measured a visual analog scale (VAS) about their CLBP. Body composition, forward and backward trunk flexibilities, static muscle contraction property in rectus abdominis, and erector spinae were measured by tensiomyography, which found contraction time (Tc) and maximal displacement (Dm). Dynamic muscle contraction property in the abdomen and back were measured with an isokinetic device, which could measure peak torque (Pt) and work per repetition (Wr), before and after the trial. Results: The 3DEG had a significantly decreased fat mass and waist/hip ratio, as well as improved static muscle contractions of the erector spinae. The Wr of trunk extensor of 3D exercise group were also significantly increased. In the VAS, although the scores showed a significant change in some variables, while others did not. The Δ% in feeling pain at rest or at night, during exercise, walking, sitting in a hard chair, sitting in a soft chair, and lying down in 3DEG were significantly changed after 8 weeks. This indicates that the platform exercise provided a greater reduction of pain for activities that are done on a daily basis. Conclusions : This study confirms that the 3D moving platform exercise can provide the similar effect of the core stability exercise used in previous studies. Moreover, this study suggests that 3D moving platform exercise is a suitable means to reduce fatness, to increase trunk extensor, and to increase trunk backward flexibility, which led to reduced back pain in the women with CLBP.",2020,"The 3DEG had a significantly decreased fat mass and waist/hip ratio, as well as improved static muscle contractions of the erector spinae.","['CLBP patients', 'women with CLBP', 'participants were twenty-nine women', 'Patients with Chronic Low Back Pain', 'Patient-handling activities predispose women to chronic low back pain (CLBP']","['3D Moving Platform Exercise', 'control group (CON) and a 3D exercise group (3DEG']","['pain for activities', 'fat mass and waist/hip ratio', 'visual analog scale (VAS', 'trunk backward flexibility', 'back pain', 'peak torque (Pt) and work per repetition (Wr', 'contraction time (Tc) and maximal displacement (Dm', 'static muscle contractions', 'Physiological Parameters and Pain', 'Body composition, forward and backward trunk flexibilities, static muscle contraction property in rectus abdominis, and erector spinae']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0450351', 'cui_str': '29'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C2350569', 'cui_str': 'Patient Handling'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]","[{'cui': 'C0578671', 'cui_str': 'Does move'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0205682', 'cui_str': 'Waist/hip ratio'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0439781', 'cui_str': 'Backward'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0026820', 'cui_str': 'Muscle contraction'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0439780', 'cui_str': 'Forward'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0224301', 'cui_str': 'Structure of erector spinae muscle'}]",29.0,0.0385122,"The 3DEG had a significantly decreased fat mass and waist/hip ratio, as well as improved static muscle contractions of the erector spinae.","[{'ForeName': 'Soochul', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Department of Education Major of Physical Education, Graduate School of Education of Hanseo University, Hanseo 1-Ro, Haemi-myeon, Seosan 31962, Korea.'}, {'ForeName': 'Yongseok', 'Initials': 'Y', 'LastName': 'Jee', 'Affiliation': 'Department of Education Major of Physical Education, Graduate School of Education of Hanseo University, Hanseo 1-Ro, Haemi-myeon, Seosan 31962, Korea.'}]","Medicina (Kaunas, Lithuania)",['10.3390/medicina56070351'] 2054,32679757,Characterizing the Heart Rate Response to the 4 × 4 Interval Exercise Protocol.,"High intensity interval training is frequently implemented using the 4 × 4 protocol where four 4-min bouts are performed at heart rate (HR) between 85 and 95% HR max. This study identified the HR and power output response to the 4 × 4 protocol in 39 active men and women (age and VO 2 max = 26.0 ± 6.1 years and 37.0 ± 5.4 mL/kg/min). Initially, participants completed incremental cycling to assess VO 2 max, HR max, and peak power output (PPO). They subsequently completed the 4 × 4 protocol, during which HR and power output were monitored. Data showed that 12.9 ± 0.4 min of 16 min were spent between 85 and 95% HR max, with time spent significantly lower in interval 1 (2.7 ± 0.6 min) versus intervals 2-4 (3.4 ± 0.4 min, 3.4 ± 0.3 min, and 3.5 ± 0.3 min, d = 2.4-2.7). Power output was highest in interval 1 (75% PPO) and significantly declined in intervals 2-4 (63 to 54% PPO, d = 0.7-1.0). To enhance time spent between 85 and 95% HR max for persons with higher fitness, we recommend immediate allocation of supramaximal intensities in interval one.",2020,"Power output was highest in interval 1 (75% PPO) and significantly declined in intervals 2-4 (63 to 54% PPO, d = 0.7-1.0).",['39 active men and women (age and VO 2 max = 26.0 ± 6.1 years and 37.0 ± 5.4 mL/kg/min'],['High intensity interval training'],"['VO 2 max, HR max, and peak power output (PPO', 'Power output', 'Heart Rate Response']","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517792', 'cui_str': '5.4'}, {'cui': 'C0439402', 'cui_str': 'mL/min/kg'}]","[{'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}]","[{'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0032956', 'cui_str': 'Preferred Provider Organization'}, {'cui': 'C1997754', 'cui_str': 'Heart rate response'}]",,0.0733088,"Power output was highest in interval 1 (75% PPO) and significantly declined in intervals 2-4 (63 to 54% PPO, d = 0.7-1.0).","[{'ForeName': 'Justin J', 'Initials': 'JJ', 'LastName': 'Acala', 'Affiliation': 'Department of Kinesiology, California State University, San Marcos, CA 92096-0001, USA.'}, {'ForeName': 'Devyn', 'Initials': 'D', 'LastName': 'Roche-Willis', 'Affiliation': 'Department of Kinesiology, California State University, San Marcos, CA 92096-0001, USA.'}, {'ForeName': 'Todd A', 'Initials': 'TA', 'LastName': 'Astorino', 'Affiliation': 'Department of Kinesiology, California State University, San Marcos, CA 92096-0001, USA.'}]",International journal of environmental research and public health,['10.3390/ijerph17145103'] 2055,32679839,Effect of Viewing Video Representation of the Urban Environment and Forest Environment on Mood and Level of Procrastination.,"A common problem among students is the problem of delaying important work activities, which is conceptualized as procrastination. Since procrastination can cause considerable costs for society, we would like to find a method to effectively alleviate the symptoms of this conditioning. It has been proven in an earlier study that staying in the forest environment increases vitality and reduces anxiety, and the negative state of these features can be associated with the intensification of procrastination symptoms. Therefore, it is likely that watching a forest video may decrease the probability or intensity of procrastination. To measure the impact of the forest environment on the level of procrastination of the subjects, a randomized experiment was carried out, in which the subjects watched in random order (on different days) one of two 15-min videos: one showing a walk in the forest area and one showing a walk in an urban environment (control). We measured the level of so-called 'fluid procrastination' including three aspects: 'lack of energy to do the work', 'inability to get to work' and 'pessimistic attitude to do the work' with a set of questions the respondents completed before and after the experiment. The results showed that one aspect of fluid procrastination ('pessimistic attitude to do the work') can be effectively lowered by watching a video showing the forest environment. In contrast, watching a video of an urban environment increased the procrastination levels for two other aspects of procrastination ('lack of energy to do the work', 'inability to get to work'). We also measured three other parameters before and after the experiment: mood state, restoration and vitality. Watching the video from forest area raised mood and restoration and watching the video from urban area, decreased mood, vitality and restoration. The study suggests that watching a video showing forest landscapes could be used as an effective remedy for problems related to procrastination among students.",2020,"Watching the video from forest area raised mood and restoration and watching the video from urban area, decreased mood, vitality and restoration.",[],"['Viewing Video Representation of the Urban Environment and Forest Environment', '15-min videos: one showing a walk in the forest area and one showing a walk in an urban environment (control']","['Mood and Level of Procrastination', 'mood state, restoration and vitality']",[],"[{'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0086312', 'cui_str': 'Forest'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0871142', 'cui_str': 'Procrastination'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}]",,0.0230505,"Watching the video from forest area raised mood and restoration and watching the video from urban area, decreased mood, vitality and restoration.","[{'ForeName': 'Ernest', 'Initials': 'E', 'LastName': 'Bielinis', 'Affiliation': 'Department of Forestry and Forest Ecology, Faculty of Environmental Management and Agriculture, University of Warmia and Mazury, Pl. Łódzki 2, 10-727 Olsztyn, Poland.'}, {'ForeName': 'Jenni', 'Initials': 'J', 'LastName': 'Simkin', 'Affiliation': 'Natural Resources Institute Finland, Latokartanonkaari 9, 00790 Helsinki, Finland.'}, {'ForeName': 'Pasi', 'Initials': 'P', 'LastName': 'Puttonen', 'Affiliation': 'Department of Forest Sciences, University of Helsinki, Latokartanonkaari 7, 00014 Helsinki, Finland.'}, {'ForeName': 'Liisa', 'Initials': 'L', 'LastName': 'Tyrväinen', 'Affiliation': 'Natural Resources Institute Finland, Latokartanonkaari 9, 00790 Helsinki, Finland.'}]",International journal of environmental research and public health,['10.3390/ijerph17145109'] 2056,32679866,The Effect of a Pulmonary Rehabilitation on Lung Function and Exercise Capacity in Patients with Burn: A Prospective Randomized Single-Blind Study.,"We performed pulmonary function (PF) tests and factors affecting PF evaluation in 120 patients with inhalation injury to evaluate the effects of pulmonary rehabilitation (PR) in burn patients with inhalation injury. Patients were randomized into pulmonary rehabilitation (PR) group and conventional rehabilitation (CON) group. PF tests, including forced vital capacity (FVC), 1-s forced expiratory volume FEV1), maximum voluntary ventilation (MVV), and respiratory muscles strength (maximal expiratory pressure (MEP) and maximal inspiratory pressure (MIP)), were measured by mouth pressure meter in the sitting position. Diffusing capacity for carbon monoxide (DLco) was determined by the single-breath carbon monoxide technique. Peak cough flow (PCF) was measured by a peak flow meter. Diaphragmatic mobility (DM) was evaluated on anteroposterior fluoroscopy. All evaluations were performed in all groups at baseline and after 12 weeks. There were no differences in evaluations between the PR group and CON group before the intervention. There were significant improvements in the PCF and MIP (%) changes, taken before and after rehabilitation in the PR group, compared with the changes in the CON group ( p = 0.01, and p = 0.04). There were no significant changes in the other parameters in the PR group compared with the changes in the CON group ( p > 0.05). There were significant differences in DLco (%), MIP, MIP (%), and DM between the PR group and the CON group ( p = 0.02, p = 0.005, and p = 0.001) after 12 weeks of rehabilitation. There were no differences between the PR group and CON group after 12 weeks rehabilitation in the other parameters ( p > 0.05). PR for patients with major burns and smoke inhalation induced improved PCF, MIP, MIP (%), DLco (%), and DM. These results show that PR should be a fundamental component of the treatment program for patients with burns.",2020,There were no differences between the PR group and CON group after 12 weeks rehabilitation in the other parameters ( p > 0.05).,"['patients with major burns and smoke inhalation', '120 patients with inhalation injury', 'Patients with Burn', 'burn patients with inhalation injury', 'patients with burns']","['pulmonary rehabilitation (PR) group and conventional rehabilitation (CON', 'CON', 'pulmonary rehabilitation (PR', 'Pulmonary Rehabilitation']","['forced vital capacity (FVC', 'Lung Function and Exercise Capacity', 'Diaphragmatic mobility (DM', 'PCF, MIP, MIP (%), DLco (%), and DM', 'PCF and MIP', 'mouth pressure meter in the sitting position', '1-s forced expiratory volume FEV1), maximum voluntary ventilation (MVV), and respiratory muscles strength (maximal expiratory pressure (MEP) and maximal inspiratory pressure (MIP', 'Peak cough flow (PCF', 'DLco (%), MIP, MIP (%), and DM', 'Diffusing capacity for carbon monoxide (DLco']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0000912', 'cui_str': 'Accident caused by unspecified fire'}, {'cui': 'C0037367', 'cui_str': 'Smoke inhalation injury'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0745334', 'cui_str': 'Inhalation injury'}]","[{'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}]","[{'cui': 'C0430511', 'cui_str': 'Vital capacity test'}, {'cui': 'C3714541', 'cui_str': 'Forced vital capacity'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0011980', 'cui_str': 'Diaphragm structure'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0376579', 'cui_str': 'Macrophage Inflammatory Proteins'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0441074', 'cui_str': 'Meters'}, {'cui': 'C0277814', 'cui_str': 'Sitting position'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0024967', 'cui_str': 'Maximum voluntary ventilation'}, {'cui': 'C0021724', 'cui_str': 'Structure of intercostal muscle'}, {'cui': 'C4082175', 'cui_str': 'Maximum Expiratory Pressure'}, {'cui': 'C4083126', 'cui_str': 'Maximum Inspiratory Pressure'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C1280474', 'cui_str': 'Transfer factor (respiratory measure)'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}]",120.0,0.0139461,There were no differences between the PR group and CON group after 12 weeks rehabilitation in the other parameters ( p > 0.05).,"[{'ForeName': 'Yu Hui', 'Initials': 'YH', 'LastName': 'Won', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907 Korea.'}, {'ForeName': 'Yoon Soo', 'Initials': 'YS', 'LastName': 'Cho', 'Affiliation': 'Department of Rehabilitation Medicine, Hangang Sacred Heart Hospital, College of Medicine, Hallym University, 94-200 Yeongdeungpo-Dong Yeongdeungpo-Ku, Seoul 07247, Korea.'}, {'ForeName': 'So Young', 'Initials': 'SY', 'LastName': 'Joo', 'Affiliation': 'Department of Rehabilitation Medicine, Hangang Sacred Heart Hospital, College of Medicine, Hallym University, 94-200 Yeongdeungpo-Dong Yeongdeungpo-Ku, Seoul 07247, Korea.'}, {'ForeName': 'Cheong Hoon', 'Initials': 'CH', 'LastName': 'Seo', 'Affiliation': 'Department of Rehabilitation Medicine, Hangang Sacred Heart Hospital, College of Medicine, Hallym University, 94-200 Yeongdeungpo-Dong Yeongdeungpo-Ku, Seoul 07247, Korea.'}]",Journal of clinical medicine,['10.3390/jcm9072250'] 2057,32680067,Random phase-shifting digital holography based on a self-calibrated system.,"Random phase-shifting digital holography based on a self-calibrated system is proposed. In the proposed method, the hologram and the calibration interference fringes can be recorded simultaneously in a single image based on the space-division-multiplexing technique. Three randomly phase-shifted holograms and corresponding interference fringes are recorded, and the phase-shifting amount between each two adjacent holograms is calculated by the sampling Moiré method from the calibration interference fringes. A reflective object is used to demonstrate the effectiveness of the proposed method in the numerical and experiment.",2020,"In the proposed method, the hologram and the calibration interference fringes can be recorded simultaneously in a single image based on the space-division-multiplexing technique.",[],[],[],[],[],[],3.0,0.0128143,"In the proposed method, the hologram and the calibration interference fringes can be recorded simultaneously in a single image based on the space-division-multiplexing technique.","[{'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Xia', 'Affiliation': ''}, {'ForeName': 'Qinghua', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Shien', 'Initials': 'S', 'LastName': 'Ri', 'Affiliation': ''}]",Optics express,['10.1364/OE.395819'] 2058,32680328,Taming the adolescent mind: a randomised controlled trial examining clinical efficacy of an adolescent mindfulness-based group programme.,"BACKGROUND Mindfulness interventions with adolescents are in the early stages of development. This study sought to establish efficacy of a mindfulness-based group intervention for adolescents with mixed mental health disorders. METHOD One hundred and eight adolescents (ages 13-18) were recruited from community mental health clinics and randomised into two groups (control vs. treatment). All participants received treatment-as-usual (TAU) from clinic-based therapists independent of the study. Adolescents in the treatment condition received TAU plus a 5-week mindfulness-training programme (TAU+Mi); adolescents in the control group received only TAU. Assessments including parent/carer reports were conducted at baseline, postintervention and 3-month follow-up. RESULTS At postintervention, adolescents in the mindfulness condition experienced significant decrease in mental distress (measured with the DASS-21) compared to the control group (Cohen's d = 0.43), and these gains were enhanced at 3-month follow-up (Cohen's d = 0.78). Overall outcomes at 3 months showed significant improvement for adolescents in the mindfulness condition; in self-esteem, mindfulness, psychological inflexibility and mental health, but not resilience. Parents/carers also reported significant improvement in their adolescent's psychological functioning (using the CBCL). Mediation analyses concluded mindfulness mediated mental health outcomes. CONCLUSIONS Increase in mindful awareness after training leads to improvement in mental health and this is consistent with mindfulness theory. The mindfulness group programme appears to be a promising adjunctive therapeutic approach for clinic-based adolescents with mental health problems.",2015,"Overall outcomes at 3 months showed significant improvement for adolescents in the mindfulness condition; in self-esteem, mindfulness, psychological inflexibility and mental health, but not resilience.","['adolescents with mixed mental health disorders', 'clinic-based adolescents with mental health problems', 'One hundred and eight adolescents (ages 13-18) were recruited from community mental health clinics']","['mindfulness-based group intervention', 'adolescent mindfulness-based group programme', 'TAU plus a 5-week mindfulness-training programme (TAU+Mi); adolescents in the control group received only TAU']","['mental distress', ""adolescent's psychological functioning"", 'self-esteem, mindfulness, psychological inflexibility and mental health']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1446377', 'cui_str': 'Mental health problem'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C3839912', 'cui_str': 'Mental health clinic'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0235109', 'cui_str': 'Mental distress'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]",108.0,0.0333644,"Overall outcomes at 3 months showed significant improvement for adolescents in the mindfulness condition; in self-esteem, mindfulness, psychological inflexibility and mental health, but not resilience.","[{'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Tan', 'Affiliation': 'Department of Psychiatry, Principal Clinical Psychologist, Tan Psychological Services, RBWH, Herston Rd, Brisbane, Queensland, Australia.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Martin', 'Affiliation': 'Psychiatry, The University of Queensland, Brisbane, Queensland, Australia.'}]",Child and adolescent mental health,['10.1111/camh.12057'] 2059,32680330,"A controlled evaluation of the 'FRIENDS for Life' emotional resiliency programme on overall anxiety levels, anxiety subtype levels and school adjustment.","BACKGROUND Anxiety constitutes the most common form of psychopathology in childhood and adolescence. METHODS This randomised controlled study evaluated the 'FRIENDS for Life' school-based Cognitive Behavioural Therapy programme on overall anxiety, anxiety subtypes and school adjustment. Sixty-two students aged 12-13 completed measures of anxiety and school adjustment before, immediately after and 4 months after completing the programme. Parents and teachers also rated the students on overall anxiety levels and school adjustment respectively. RESULTS The intervention group's 'overall anxiety' and specifically 'separation anxiety' reduced significantly during the programme and continued to decrease at the 4-month follow-up. CONCLUSIONS A significant negative correlation was found between anxiety and school adjustment. The professional implications of these findings are discussed.",2015,"The intervention group's 'overall anxiety' and specifically 'separation anxiety' reduced significantly during the programme and continued to decrease at the 4-month follow-up. ","['Sixty-two students aged 12-13 completed measures of anxiety and school adjustment before, immediately after and 4\xa0months after completing the programme']",['Cognitive Behavioural Therapy programme'],"['overall anxiety levels, anxiety subtype levels and school adjustment', 'overall anxiety levels and school adjustment respectively', ""overall anxiety' and specifically 'separation anxiety"", 'overall anxiety, anxiety subtypes and school adjustment']","[{'cui': 'C4517835', 'cui_str': '62'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449560', 'cui_str': 'Subtype'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0003477', 'cui_str': 'Separation anxiety'}]",62.0,0.0251054,"The intervention group's 'overall anxiety' and specifically 'separation anxiety' reduced significantly during the programme and continued to decrease at the 4-month follow-up. ","[{'ForeName': 'Alish', 'Initials': 'A', 'LastName': 'Rodgers', 'Affiliation': 'National Behaviour Support Service, Navan Education Centre, Navan, Ireland.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Dunsmuir', 'Affiliation': 'University College London, London, UK.'}]",Child and adolescent mental health,['10.1111/camh.12030'] 2060,32680337,Innovations in Practice: a pilot study of interpersonal psychotherapy for depressed adolescents and their parents.,"BACKGROUND Problems in adolescents' relationships with their parents are a significant risk factor for the development and maintenance of depression. The purpose of this pilot study was to examine the feasibility and acceptability of an adaptation of interpersonal psychotherapy for depressed adolescents (IPT-A) who were also experiencing problems in their relationships with parents. The adaptation includes greater and more structured parent involvement in the treatment (IPT-AP). METHOD Fifteen adolescents (age 12-17) who were diagnosed with depression and were also experiencing conflictual or emotionally disengaged relationships with their parents (based on adolescent or parent report on the Conflict Behavior Questionnaire) participated in a 16 week randomized clinical trial of individually delivered IPT-A versus IPT-AP. Data regarding the feasibility and acceptability of IPT-AP were collected. Assessments of depression and family functioning were completed at baseline and weeks 4, 8, 12, and 16 by evaluators blind to treatment condition. RESULTS IPT-AP was feasible to implement, and adolescents and parents reported high treatment satisfaction. Adolescents demonstrated significant improvements in depressive symptoms, general functioning, and family functioning. IPT-AP was more efficacious than individual IPT-A in improving adolescents' perceptions of father-adolescent relations and mothers' perceptions of mother-adolescent relations. CONCLUSIONS Interpersonal psychotherapy for depressed adolescents and their parents was feasible to implement and acceptable to families, indicating that a full-scale randomized controlled trial to evaluate its efficacy is warranted.",2016,"IPT-AP was more efficacious than individual IPT-A in improving adolescents' perceptions of father-adolescent relations and mothers' perceptions of mother-adolescent relations. ","['depressed adolescents (IPT-A) who were also experiencing problems in their relationships with parents', 'depressed adolescents and their parents', 'Fifteen adolescents (age 12-17) who were diagnosed with depression and were also experiencing conflictual or emotionally disengaged relationships with their parents (based on adolescent or parent report on the Conflict Behavior Questionnaire) participated in a 16\xa0week randomized clinical trial of individually delivered']","['IPT-A versus IPT-AP', 'IPT-AP', 'Interpersonal psychotherapy', 'interpersonal psychotherapy']","['feasibility and acceptability', 'depressive symptoms, general functioning, and family functioning', 'depression and family functioning']","[{'cui': 'C0344315', 'cui_str': 'Depressed mood'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0871787', 'cui_str': 'Interpersonal psychotherapy'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0871787', 'cui_str': 'Interpersonal psychotherapy'}, {'cui': 'C0344315', 'cui_str': 'Depressed mood'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0380193', 'cui_str': 'iodine-123-IPT'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0680051', 'cui_str': 'Family functioning capacity'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",,0.0529785,"IPT-AP was more efficacious than individual IPT-A in improving adolescents' perceptions of father-adolescent relations and mothers' perceptions of mother-adolescent relations. ","[{'ForeName': 'Meredith', 'Initials': 'M', 'LastName': 'Gunlicks-Stoessel', 'Affiliation': 'Department of Psychiatry, University of Minnesota, 2450 Riverside Ave, F256/2B West, Minneapolis, MN, 55454, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Mufson', 'Affiliation': 'Division of Child & Adolescent Psychiatry, New York State Psychiatric Institute, Columbia University, New York City, NY, USA.'}]",Child and adolescent mental health,['10.1111/camh.12167'] 2061,32672800,Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.,"Importance The 2-year efficacy and safety of combination therapy of ranibizumab administered together with verteporfin photodynamic therapy (vPDT) compared with ranibizumab monotherapy in participants with polypoidal choroidal vasculopathy (PCV) are unclear. Objective To compare treatment outcomes of ranibizumab, 0.5 mg, plus prompt vPDT combination therapy with ranibizumab, 0.5 mg, monotherapy in participants with PCV for 24 months. Design, Setting, and Participants This 24-month, phase IV, double-masked, multicenter, randomized clinical trial (EVEREST II) was conducted among Asian participants from August 7, 2013, to March 2, 2017, with symptomatic macular PCV confirmed using indocyanine green angiography. Interventions Participants (N = 322) were randomized 1:1 to ranibizumab, 0.5 mg, plus vPDT (combination therapy group; n = 168) or ranibizumab, 0.5 mg, plus sham PDT (monotherapy group; n = 154). All participants received 3 consecutive monthly ranibizumab injections, followed by a pro re nata regimen. Participants also received vPDT (combination group) or sham PDT (monotherapy group) on day 1, followed by a pro re nata regimen based on the presence of active polypoidal lesions. Main Outcomes and Measures Evaluation of combination therapy vs monotherapy at 24 months in key clinical outcomes, treatment exposure, and safety. Polypoidal lesion regression was defined as the absence of indocyanine green hyperfluorescence of polypoidal lesions. Results Among 322 participants (mean [SD] age, 68.1 [8.8] years; 225 [69.9%] male), the adjusted mean best-corrected visual acuity (BCVA) gains at month 24 were 9.6 letters in the combination therapy group and 5.5 letters in the monotherapy group (mean difference, 4.1 letters; 95% CI, 1.0-7.2 letters; P = .005), demonstrating that combination therapy was superior to monotherapy by the BCVA change from baseline to month 24. Combination therapy was superior to monotherapy in terms of complete polypoidal lesion regression at month 24 (81 of 143 [56.6%] vs 23 of 86 [26.7%] participants; P < .001). Participants in the combination group received fewer ranibizumab injections (median, 6.0 [interquartile range (IQR), 4.0-11.0]) than the monotherapy group (median, 12.0 [IQR, 7.0-17.0]) up to month 24. The combination group required a median of 2.0 (IQR, 1.0-3.0) vPDT treatments for 24 months, with 75 of 168 participants (44.6%) requiring only 1 vPDT treatment. Conclusions and Relevance The 24-month data findings confirm that ranibizumab therapy, given as monotherapy or in combination with vPDT, is efficacious and safe for treatment of PCV. Combination therapy with vPDT added to ranibizumab achieved superior BCVA gain, increased odds of complete polypoidal lesion regression, and fewer treatment episodes compared with ranibizumab monotherapy. Trial Registration ClinicalTrials.gov Identifier: NCT01846273.",2020,Combination therapy was superior to monotherapy in terms of complete polypoidal lesion regression at month 24 (81 of 143 [56.6%] vs 23 of 86 [26.7%] participants; P < .001).,"['participants with polypoidal choroidal vasculopathy (PCV', 'Polypoidal Choroidal Vasculopathy', 'Asian participants from August 7, 2013, to March 2, 2017, with symptomatic macular PCV confirmed using indocyanine green angiography', '322 participants (mean [SD] age', 'Interventions\n\n\nParticipants (N\u2009=\u2009322', 'participants with PCV for 24 months']","['vPDT', 'vPDT (combination group) or sham PDT (monotherapy', 'ranibizumab injections', 'ranibizumab', 'ranibizumab, 0.5 mg, plus prompt vPDT combination therapy with ranibizumab, 0.5 mg, monotherapy', 'verteporfin photodynamic therapy (vPDT', 'ranibizumab, 0.5 mg, plus vPDT (combination therapy group; n\u2009=\u2009168) or ranibizumab, 0.5 mg, plus sham PDT (monotherapy', 'Ranibizumab With or Without Verteporfin Photodynamic Therapy', 'ranibizumab monotherapy']","['superior BCVA gain', 'key clinical outcomes, treatment exposure, and safety', 'visual acuity (BCVA) gains', '2-year efficacy and safety', 'complete polypoidal lesion regression']","[{'cui': 'C1504336', 'cui_str': 'Polypoidal choroidal vasculopathy'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0430879', 'cui_str': 'Indocyanine green angiography'}, {'cui': 'C4517712', 'cui_str': '322'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0387288', 'cui_str': 'Verteporfin'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C4050112', 'cui_str': 'ranibizumab Injection'}, {'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}, {'cui': 'C4319556', 'cui_str': '168'}]","[{'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C1690532', 'cui_str': 'Best corrected visual acuity'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0684321', 'cui_str': 'Regression - mental defense mechanism'}]",,0.24727,Combination therapy was superior to monotherapy in terms of complete polypoidal lesion regression at month 24 (81 of 143 [56.6%] vs 23 of 86 [26.7%] participants; P < .001).,"[{'ForeName': 'Tock H', 'Initials': 'TH', 'LastName': 'Lim', 'Affiliation': 'National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore.'}, {'ForeName': 'Timothy Y Y', 'Initials': 'TYY', 'LastName': 'Lai', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Kanji', 'Initials': 'K', 'LastName': 'Takahashi', 'Affiliation': 'Department of Ophthalmology, Kansai Medical University, Osaka, Japan.'}, {'ForeName': 'Tien Y', 'Initials': 'TY', 'LastName': 'Wong', 'Affiliation': 'Singapore Eye Research Institute, Singapore National Eye Centre, Duke-NUS Medical School, National University of Singapore, Singapore.'}, {'ForeName': 'Lee-Jen', 'Initials': 'LJ', 'LastName': 'Chen', 'Affiliation': 'Department of Ophthalmology, Mackay Memorial Hospital, Taipei, Taiwan.'}, {'ForeName': 'Paisan', 'Initials': 'P', 'LastName': 'Ruamviboonsuk', 'Affiliation': 'Department of Ophthalmology, Rajavithi Hospital, Bangkok, Thailand.'}, {'ForeName': 'Colin S', 'Initials': 'CS', 'LastName': 'Tan', 'Affiliation': 'National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore.'}, {'ForeName': 'Won Ki', 'Initials': 'WK', 'LastName': 'Lee', 'Affiliation': ""Department of Ophthalmology, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Chui Ming Gemmy', 'Initials': 'CMG', 'LastName': 'Cheung', 'Affiliation': 'Singapore Eye Research Institute, Singapore National Eye Centre, Duke-NUS Medical School, National University of Singapore, Singapore.'}, {'ForeName': 'Nor Fariza', 'Initials': 'NF', 'LastName': 'Ngah', 'Affiliation': 'Department of Ophthalmology, Hospital Shah Alam, Malaysia.'}, {'ForeName': 'Ramune', 'Initials': 'R', 'LastName': 'Patalauskaite', 'Affiliation': 'Novartis Ireland Ltd, Dublin, Ireland.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Margaron', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Koh', 'Affiliation': 'Eye & Retina Surgeons, Camden Medical Centre, Singapore.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA ophthalmology,['10.1001/jamaophthalmol.2020.2443'] 2062,32668039,Effectiveness of web-based distance education for parents in the prevention of emotional neglect and abuse: A randomized controlled study.,"PURPOSE The aim of this study was to determine the efficacy of web-based distance education for the prevention of child emotional neglect and abuse by increasing parental awareness of emotional abuse and appropriate attitudes toward child-rearing. DESIGN AND METHODS This study had a quasi-experimental, randomized controlled design. The study sample included a total of 60 parents who had taken their child to a pediatric outpatient clinic in Turkey. Of 60 parents, 30 were randomly assigned to an experimental group and 30 were randomly assigned to a control group. Data were collected using the Personal Characteristics Form, the Recognition of Emotional Maltreatment Scale (REMS) and the Parental Attitude Research Instrument (PARI). The experimental group was offered a 6-week web-based distance education program focusing on the prevention of child emotional neglect and abuse. FINDINGS There was no significant difference between the posttest scores of the experimental and control groups (P > .05). However, a significant difference was found between pretest and posttest scores of the experimental group for the REMS and its subscales and for the overprotective mothering and strict discipline subscales of the PARI (P < .05). CONCLUSION The 6-week web-based distance education has the potential to increase parental awareness of child-rearing and emotional abuse. PRACTICE IMPLICATIONS Web-based distance education has a positive effect on parenting attitudes and emotional abuse awareness levels. This form of parent education should, therefore, be utilized further in clinical practice.",2020,"The 6-week web-based distance education has the potential to increase parental awareness of child-rearing and emotional abuse. ","['parents in the prevention of emotional neglect and abuse', '60 parents', '60 parents who had taken their child to a pediatric outpatient clinic in Turkey', 'child emotional neglect and abuse by increasing parental awareness of emotional abuse and appropriate attitudes toward child-rearing']","['web-based distance education', '6-week web-based distance education program focusing on the prevention of child emotional neglect and abuse']","['Recognition of Emotional Maltreatment Scale (REMS) and the Parental Attitude Research Instrument (PARI', 'overprotective mothering and strict discipline subscales of the PARI']","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0521874', 'cui_str': 'Victim of neglect'}, {'cui': 'C0562381', 'cui_str': 'Victim of abuse'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0041400', 'cui_str': 'Turkey - country'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0730557', 'cui_str': 'Emotional abuse'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0008091', 'cui_str': 'Child Rearing'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0600562', 'cui_str': 'Distance Education'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0521874', 'cui_str': 'Victim of neglect'}, {'cui': 'C0562381', 'cui_str': 'Victim of abuse'}]","[{'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]",60.0,0.0313589,"The 6-week web-based distance education has the potential to increase parental awareness of child-rearing and emotional abuse. ","[{'ForeName': 'Kübra', 'Initials': 'K', 'LastName': 'Gülırmak', 'Affiliation': 'Department of Psychiatric Nursing Samsun, Ondokuz Mayıs University, Samsun, Turkey.'}, {'ForeName': 'Oya Sevcan', 'Initials': 'OS', 'LastName': 'Orak', 'Affiliation': 'Department of Psychiatric Nursing Samsun, Ondokuz Mayıs University, Samsun, Turkey.'}]",Perspectives in psychiatric care,['10.1111/ppc.12580'] 2063,32668087,Associations between resting-state functional connectivity and treatment response in a randomized clinical trial for posttraumatic stress disorder.,"BACKGROUND Alterations in resting-state functional connectivity (rsFC) have been reported in posttraumatic stress disorder (PTSD). Here, we examined pre- and post-treatment rsFC during a randomized clinical trial to characterize alterations and examine predictors of treatment response. METHODS Sixty-four combat veterans with PTSD were randomly assigned to prolonged exposure (PE) plus placebo, sertraline plus enhanced medication management, or PE plus sertraline. Symptom assessment and resting-state functional magnetic resonance imaging (fMRI) scans occurred before and after treatment. Twenty-nine trauma-exposed combat veterans without PTSD served as a control group at intake. Seed-based and region of interest (ROI)-to-ROI connectivities, as well as an exploratory connectome-based approach were used to analyze rsFC patterns. Based on previously reported findings, analyses focused on Salience Network (SN) and Default-Mode Network (DMN). RESULTS At intake, patients with PTSD showed greater DMN-dorsal attention network (DAN) connectivity (between ventromedial prefrontal cortex and superior parietal lobule; family-wise error corrected p = .011), greater SN-DAN connectivity (between insula and middle frontal gyrus; corrected p = .003), and a negative correlation between re-experiencing symptoms and within-DMN connectivity (between posterior cingulate cortex (PCC) and middle temporal gyrus; corrected p < .001). We also found preliminary evidence for associations between rsFC and treatment response. Specifically, high responders (≥50% PTSD symptom improvement), compared with low responders, had greater SN-DMN segregation (i.e., less pre-treatment amygdala-PCC connectivity; p = .011) and lower pre-treatment global centrality (p = .042). CONCLUSIONS Our findings suggest neural abnormalities in PTSD and may inform future research examining neural biomarkers of PTSD treatment response.",2020,"Specifically, high responders (≥50% PTSD symptom improvement), compared with low responders, had greater SN-DMN segregation (i.e., less pre-treatment amygdala-PCC connectivity; p = .011) and lower pre-treatment global centrality (p = .042). ","['Twenty-nine trauma-exposed combat veterans without PTSD served as a control group at intake', 'Sixty-four combat veterans with PTSD', 'posttraumatic stress disorder']","['prolonged exposure (PE) plus placebo, sertraline plus enhanced medication management, or PE plus sertraline']","['greater DMN-dorsal attention network (DAN) connectivity', 'Symptom assessment and resting-state functional magnetic resonance imaging (fMRI) scans', 'greater SN-DAN connectivity', 'SN-DMN segregation', 'Salience Network (SN) and Default-Mode Network (DMN']","[{'cui': 'C0450351', 'cui_str': '29'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C4517839', 'cui_str': '64'}]","[{'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C0150270', 'cui_str': 'Management of drug regimen'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}]","[{'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C3494437', 'cui_str': 'Symptom Assessment'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0080141', 'cui_str': 'Racial Segregation'}]",,0.0394609,"Specifically, high responders (≥50% PTSD symptom improvement), compared with low responders, had greater SN-DMN segregation (i.e., less pre-treatment amygdala-PCC connectivity; p = .011) and lower pre-treatment global centrality (p = .042). ","[{'ForeName': 'Jony', 'Initials': 'J', 'LastName': 'Sheynin', 'Affiliation': 'Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.'}, {'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Duval', 'Affiliation': 'Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.'}, {'ForeName': 'Anthony P', 'Initials': 'AP', 'LastName': 'King', 'Affiliation': 'Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Angstadt', 'Affiliation': 'Department of Psychiatry, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'K Luan', 'Initials': 'KL', 'LastName': 'Phan', 'Affiliation': 'Department of Psychiatry and Behavioral Health, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'Naomi M', 'Initials': 'NM', 'LastName': 'Simon', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Sheila A M', 'Initials': 'SAM', 'LastName': 'Rauch', 'Affiliation': 'Mental Health Service Line, Atlanta VA Healthcare System, Decatur, Georgia.'}, {'ForeName': 'Israel', 'Initials': 'I', 'LastName': 'Liberzon', 'Affiliation': 'Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.'}]",Depression and anxiety,['10.1002/da.23075'] 2064,32687836,Failure of tDCS to modulate motor excitability and speech motor learning.,"Transcranial direct current stimulation (tDCS) modulates cortical excitability in a polarity-specific way and, when used in combination with a behavioural task, it can alter performance. TDCS has the potential, therefore, for use as an adjunct to therapies designed to treat disorders affecting speech, including, but not limited to acquired aphasias and developmental stuttering. For this reason, it is important to conduct studies evaluating its effectiveness and the parameters optimal for stimulation. Here, we aimed to evaluate the effects of bi-hemispheric tDCS over speech motor cortex on performance of a complex speech motor learning task, namely the repetition of tongue twisters. A previous study in older participants showed that tDCS could modulate performance on a similar task. To further understand the effects of tDCS, we also measured the excitability of the speech motor cortex before and after stimulation. Three groups of 20 healthy young controls received: (i) anodal tDCS to the left IFG/LipM1 and cathodal tDCS to the right hemisphere homologue; or (ii) cathodal tDCS over the left and anodal over the right; or (iii) sham stimulation. Participants heard and repeated novel tongue twisters and matched simple sentences before, during and 10 min after the stimulation. One mA tDCS was delivered concurrent with task performance for 13 min. Motor excitability was measured using transcranial magnetic stimulation to elicit motor-evoked potentials in the lip before and immediately after tDCS. The study was double-blind, randomized, and sham-controlled; the design and analysis were pre-registered. Performance on the task improved from baseline to after stimulation but was not significantly modulated by tDCS. Similarly, a small decrease in motor excitability was seen in all three stimulation groups but did not differ among them and were unrelated to task performance. Bayesian analyses provide substantial evidence in support of the null hypotheses in both cases, namely that tongue twister performance and motor excitability were not affected by tDCS. We discuss our findings in the context of the previous positive results for a similar task. We conclude that tDCS may be most effective when brain function is sub-optimal due to age-related declines or pathology. Further study is required to determine why tDCS failed to modulate excitability in the speech motor cortex in the expected ways.",2020,"Similarly, a small decrease in motor excitability was seen in all three stimulation groups but did not differ among them and were unrelated to task performance.","['older participants', '20 healthy young controls received: (i']","['bi-hemispheric tDCS', 'Transcranial direct current stimulation (tDCS', 'TDCS', 'tDCS', 'anodal tDCS to the left IFG/LipM1 and cathodal tDCS to the right hemisphere homologue; or (ii) cathodal tDCS over the left and anodal over the right; or (iii) sham stimulation']","['tongue twister performance and motor excitability', 'motor excitability', 'Motor excitability']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205139', 'cui_str': 'Hemispheric'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0450424', 'cui_str': 'To the left'}, {'cui': 'C0546911', 'cui_str': 'To the right'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0040408', 'cui_str': 'Tongue structure'}, {'cui': 'C0335670', 'cui_str': 'Twister'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}]",20.0,0.046913,"Similarly, a small decrease in motor excitability was seen in all three stimulation groups but did not differ among them and were unrelated to task performance.","[{'ForeName': 'Charlotte E E', 'Initials': 'CEE', 'LastName': 'Wiltshire', 'Affiliation': 'Wellcome Centre for Integrative Neuroimaging, Department of Experimental Psychology, Radcliffe Observatory Quarter, University of Oxford, OX2 6GG, UK. Electronic address: charlotte.wiltshire@psy.ox.ac.uk.'}, {'ForeName': 'Kate E', 'Initials': 'KE', 'LastName': 'Watkins', 'Affiliation': 'Wellcome Centre for Integrative Neuroimaging, Department of Experimental Psychology, Radcliffe Observatory Quarter, University of Oxford, OX2 6GG, UK. Electronic address: kate.watkins@psy.ox.ac.uk.'}]",Neuropsychologia,['10.1016/j.neuropsychologia.2020.107568'] 2065,32675291,"Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation.","INTRODUCTION A growing body of evidence suggests that specific, naturally occurring gut bacteria are under-represented in the intestinal tracts of subjects with type 2 diabetes (T2D) and that their functions, like gut barrier stability and butyrate production, are important to glucose and insulin homeostasis. The objective of this study was to test the hypothesis that enteral exposure to microbes with these proposed functions can safely improve clinical measures of glycemic control and thereby play a role in the overall dietary management of diabetes. RESEARCH DESIGN AND METHODS We evaluated whether a probiotic comprised of these anaerobic bacteria would enhance dietary management by (1) manufacturing two novel probiotic formulations containing three (WBF-010) or five (WBF-011) distinct strains in a Current Good Manufacturing Practice (cGMP) facility, (2) establishing consistent live-cell concentrations, (3) confirming safety at target concentrations dispensed in both animal and human studies and (4) conducting a 12-week parallel, double-blind, placebo-controlled, proof-of-concept study in which subjects previously diagnosed with T2D (n=76) were randomly assigned to a two times a day regimen of placebo, WBF-010 or WBF-011. RESULTS No safety or tolerability issues were observed. Compared with the placebo group, subjects administered WBF-011 (which contains inulin, Akkermansia muciniphila, Clostridium beijerinckii, Clostridium butyricum, Bifidobacterium infantis and Anaerobutyricum hallii ) significantly improved in the primary outcome, glucose total area under the curve (AUC): -36.1 mg/dL/180 min, p=0.0500 and also improved in secondary outcomes, glycated hemoglobin (A1c): -0.6, glucose incremental-AUC: -28.6 mg/dL/180 min. CONCLUSIONS To our knowledge, this is the first randomized controlled trial to administer four of the five strains to human subjects with T2D. This proof-of-concept study (clinical trial number NCT03893422) shows that the intervention was safe and well tolerated and that supplementation with WBF-011 improves postprandial glucose control. The limited sample size and intersubject variability justifies future studies designed to confirm and expand on these observations.",2020,No safety or tolerability issues were observed.,"['human subjects with T2D', 'subjects with type 2 diabetes', 'subjects previously diagnosed with T2D (n=76']","['placebo, WBF-010 or WBF-011.\nRESULTS', 'WBF-011', 'placebo']","['glucose total area under the curve (AUC', 'postprandial glucose control', 'secondary outcomes, glycated hemoglobin (A1c): -0.6, glucose incremental-AUC', 'safe and well tolerated']","[{'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0678226', 'cui_str': 'Due to'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4068883', 'cui_str': '0.6'}]",76.0,0.155382,No safety or tolerability issues were observed.,"[{'ForeName': 'Fanny', 'Initials': 'F', 'LastName': 'Perraudeau', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'McMurdie', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Bullard', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Cheng', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'Colleen', 'Initials': 'C', 'LastName': 'Cutcliffe', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'Achal', 'Initials': 'A', 'LastName': 'Deo', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Eid', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Gines', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'Mohan', 'Initials': 'M', 'LastName': 'Iyer', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Justice', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'Wesley T', 'Initials': 'WT', 'LastName': 'Loo', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'Madeleine', 'Initials': 'M', 'LastName': 'Nemchek', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Schicklberger', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Souza', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'Brendon', 'Initials': 'B', 'LastName': 'Stoneburner', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'Surabhi', 'Initials': 'S', 'LastName': 'Tyagi', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA.'}, {'ForeName': 'Orville', 'Initials': 'O', 'LastName': 'Kolterman', 'Affiliation': 'Pendulum Therapeutics, Inc, San Francisco, California, USA orville.kolterman@pendulum.co.'}]",BMJ open diabetes research & care,['10.1136/bmjdrc-2020-001319'] 2066,32675297,Vitamin K for kidney transplant organ recipients: investigating vessel stiffness (ViKTORIES): study rationale and protocol of a randomised controlled trial.,"BACKGROUND Renal transplant recipients (RTRs) exhibit increased vascular stiffness and calcification; these parameters are associated with increased cardiovascular risk. Activity of endogenous calcification inhibitors such as matrix gla protein (MGP) is dependent on vitamin K. RTRs commonly have subclinical vitamin K deficiency. The Vitamin K in kidney Transplant Organ Recipients: Investigating vEssel Stiffness (ViKTORIES) study assesses whether vitamin K supplementation reduces vascular stiffness and calcification in a diverse population of RTR. METHODS AND ANALYSIS ViKTORIES (ISRCTN22012044) is a single-centre, phase II, parallel-group, randomised, double-blind, placebo-controlled trial of the effect of vitamin K supplementation in 90 prevalent RTR. Participants are eligible if they have a functioning renal transplant for > 1 year. Those on warfarin, with atrial fibrillation, estimated glomerular filtration rate <15 mL/min/1.73 m 2 or contraindications to MRI are excluded. Treatment is with vitamin K (menadiol diphosphate) 5 mg three times per week for 1 year or matching placebo. All participants have primary and secondary endpoint measures at 0 and 12 months. The primary endpoint is ascending aortic distensibility on cardiac MR imaging. Secondary endpoints include vascular calcification (coronary artery calcium score by CT), cardiac structure and function on MR, carotid-femoral pulse wave velocity, serum uncarboxylated MGP, transplant function, proteinuria and quality of life. The study is powered to detect 1.0×10 -3 mm Hg -1 improvement in ascending aortic distensibility in the vitamin K group relative to placebo at 12 months. Analyses will be conducted as between-group differences at 12 months by intention to treat. DISCUSSION This trial may identify a novel, inexpensive and low-risk treatment to improve surrogate markers of cardiovascular risk in RTR.",2020,The study is powered to detect 1.0×10 -3 mm Hg -1 improvement in ascending aortic distensibility in the vitamin K group relative to placebo at 12 months.,"['kidney Transplant Organ Recipients', '90 prevalent RTR', 'Participants are eligible if they have a functioning renal transplant for > 1 year', 'kidney transplant organ recipients']","['Vitamin K', 'vitamin K (menadiol diphosphate', 'vitamin K supplementation', 'placebo']","['glomerular filtration rate', 'ascending aortic distensibility on cardiac MR imaging', 'ascending aortic distensibility', 'vascular calcification (coronary artery calcium score by CT), cardiac structure and function on MR, carotid-femoral pulse wave velocity, serum uncarboxylated MGP, transplant function, proteinuria and quality of life']","[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0232804', 'cui_str': 'Renal function'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C4280965', 'cui_str': 'Greater than one'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0042878', 'cui_str': 'Vitamin K'}, {'cui': 'C0065933', 'cui_str': 'menadiol diphosphate'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0205385', 'cui_str': 'Ascending'}, {'cui': 'C0003483', 'cui_str': 'Aortic'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0342649', 'cui_str': 'Vascular calcification'}, {'cui': 'C2825178', 'cui_str': 'Coronary artery calcium score'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C5197774', 'cui_str': 'Carotid-Femoral Pulse Wave Velocities'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0065752', 'cui_str': 'matrix Gla protein'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",90.0,0.639054,The study is powered to detect 1.0×10 -3 mm Hg -1 improvement in ascending aortic distensibility in the vitamin K group relative to placebo at 12 months.,"[{'ForeName': 'Jennifer Susan', 'Initials': 'JS', 'LastName': 'Lees', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK jennifer.lees2@nhs.net.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Mangion', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'Rutherford', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Miles D', 'Initials': 'MD', 'LastName': 'Witham', 'Affiliation': 'AGE Research Group, NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Rosemary', 'Initials': 'R', 'LastName': 'Woodward', 'Affiliation': 'Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK.'}, {'ForeName': 'Giles', 'Initials': 'G', 'LastName': 'Roditi', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Tracey', 'Initials': 'T', 'LastName': 'Hopkins', 'Affiliation': 'Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK.'}, {'ForeName': 'Katriona', 'Initials': 'K', 'LastName': 'Brooksbank', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Alan G', 'Initials': 'AG', 'LastName': 'Jardine', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Patrick B', 'Initials': 'PB', 'LastName': 'Mark', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.'}]",Open heart,['10.1136/openhrt-2019-001070'] 2067,32677876,Intra-articular injections of allogeneic human adipose-derived mesenchymal progenitor cells in patients with symptomatic bilateral knee osteoarthritis: a Phase I pilot study.,"Aim: This study investigated the safety and clinical outcomes of expanded allogeneic human adipose-derived mesenchymal progenitor cells injected into patients with symptomatic, bilateral knee osteoarthritis. Design: In this single-site, randomized, double-blind, dose-ranging, Phase I study, patients were randomized to three treatment groups (low dose, 1 × 10 7 cells; medium dose, 2 × 10 7 cells; high dose, 5 × 10 7 cells). All patients received two bilateral intra-articular injections: week 0 (baseline) and week 3. The primary end point was adverse events within 48 weeks. Secondary end points were measured with Western Ontario and McMaster Universities Osteoarthritis index, visual analog scale, short form-36 at weeks 12, 24 and 48. Quantitative MRI measurements of cartilage volume were compared from baseline and week 48. Results:  A total of 22 subjects were enrolled of which 19 (86%) completed the study. Adverse events were transient, including mild to moderate pain and swelling of injection site. Improvements from baseline were measured in the secondary end points. MRI assessments showed slight improvements in the low-dose group. Conclusion: Safety and improvements in pain and function after intra-articular injections of allogeneic human adipose-derived mesenchymal progenitor cells into arthritic patients was demonstrated.",2020,"Secondary end points were measured with Western Ontario and McMaster Universities Osteoarthritis index, visual analog scale, short form-36 at weeks 12, 24 and 48.","['arthritic patients', 'A total of\xa022 subjects were enrolled of which\xa019 (86%) completed the study', 'patients with symptomatic, bilateral knee osteoarthritis', 'patients with symptomatic bilateral knee osteoarthritis']","['allogeneic human adipose-derived mesenchymal progenitor cells', 'expanded allogeneic human adipose-derived mesenchymal progenitor cells']","['Quantitative MRI measurements of cartilage volume', 'pain and function', 'adverse events', 'Western Ontario and McMaster Universities Osteoarthritis index, visual analog scale, short form-36']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}]","[{'cui': 'C3535670', 'cui_str': 'human adipose preparation'}, {'cui': 'C1257975', 'cui_str': 'Mesenchymal stem cell'}, {'cui': 'C0205229', 'cui_str': 'Expanding'}]","[{'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0007301', 'cui_str': 'Cartilage tissue'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C3472647', 'cui_str': 'Western Ontario and McMaster Universities osteoarthritis index'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}]",22.0,0.457349,"Secondary end points were measured with Western Ontario and McMaster Universities Osteoarthritis index, visual analog scale, short form-36 at weeks 12, 24 and 48.","[{'ForeName': 'Liangjing', 'Initials': 'L', 'LastName': 'Lu', 'Affiliation': 'Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai 200001, PR\xa0China.'}, {'ForeName': 'Chengxiang', 'Initials': 'C', 'LastName': 'Dai', 'Affiliation': 'Cellular Biomedicine Group, 333 Guiping Road, Bldg 1, 6th FI, Shanghai 200233, PR China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Du', 'Affiliation': 'Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai 200001, PR\xa0China.'}, {'ForeName': 'Suke', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Cellular Biomedicine Group, 333 Guiping Road, Bldg 1, 6th FI, Shanghai 200233, PR China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Ye', 'Affiliation': 'Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai 200001, PR\xa0China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Cellular Biomedicine Group, 333 Guiping Road, Bldg 1, 6th FI, Shanghai 200233, PR China.'}, {'ForeName': 'Xiaoying', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Cellular Biomedicine Group, 333 Guiping Road, Bldg 1, 6th FI, Shanghai 200233, PR China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': 'Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai 200001, PR\xa0China.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Togashi', 'Affiliation': 'Department of Orthopaedic Surgery, Keck School of Medicine, The University of Southern California, Los Angeles, CA 90033, USA.'}, {'ForeName': 'C Thomas', 'Initials': 'CT', 'LastName': 'Vangsness', 'Affiliation': 'Department of Orthopaedic Surgery, Keck School of Medicine, The University of Southern California, Los Angeles, CA 90033, USA.'}, {'ForeName': 'Chunde', 'Initials': 'C', 'LastName': 'Bao', 'Affiliation': 'Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai 200001, PR\xa0China.'}]",Regenerative medicine,['10.2217/rme-2019-0106'] 2068,32677891,Non-inferiority comparative clinical trial between early oral REFEEDING and usual oral REFEEDING in predicted mild acute biliary pancreatitis.,"BACKGROUND The aim of the study was to compare the onset of oral feeding in the first 24 h after hospital admission with usual oral refeeding and determine whether the timing of the onset of oral feeding influences the recurrence of pain or alters the blood levels of pancreatic enzymes in patients with predicted mild acute biliary pancreatitis. METHODS This non-inferiority randomized controlled trial was carried out between September 2018 and June 2019 after receiving authorization from the ethics committee for health research. Patients with a diagnosis of predicted mild acute biliary pancreatitis were divided into Group A (early oral refeeding, EOR) and Group B (usual oral refeeding, UOR). Outcome measures included pancreatic lipase levels, the systemic inflammatory response (concentrations of leukocytes), feasibility (evaluated by abdominal pain recurrence), the presence and recurrence of gastrointestinal symptoms and the length of hospital stay. RESULTS Two patients in the EOR group experienced pain relapse (3.2%), and four patients in the UOR group experienced pain relapse (6.77%) after oral refeeding (p = 0.379). The presence of nausea or vomiting after the onset of oral refeeding was not different between the two groups (p = 0.293). The onset of oral refeeding was approximately 48 h later in the UOR group. The length of hospital stay was 5 days in the EOR group and 8 days in the UOR group (p = 0.042), and this difference was also manifested in higher hospital costs in the UOR group (p = 0.0235). CONCLUSION Compared with usual oral refeeding, early oral refeeding is safe in predicted mild acute biliary pancreatitis patients, does not cause adverse gastrointestinal events, and reduces the length of hospital stay and costs. TRIAL REGISTRATION Early oral refeeding in mild acute pancreatitis (EORVsUOR). NCT04168801 , retrospectively registered (November 19, 2019).",2020,"Compared with usual oral refeeding, early oral refeeding is safe in predicted mild acute biliary pancreatitis patients, does not cause adverse gastrointestinal events, and reduces the length of hospital stay and costs. ","['patients with predicted mild acute biliary pancreatitis', 'predicted mild acute biliary pancreatitis', 'September 2018 and June 2019 after receiving authorization from the ethics committee for health research', 'mild acute biliary pancreatitis patients', 'Patients with a diagnosis of predicted mild acute biliary pancreatitis', 'mild acute pancreatitis (EORVsUOR']",[],"['higher hospital costs', 'pancreatic lipase levels, the systemic inflammatory response (concentrations of leukocytes), feasibility (evaluated by abdominal pain recurrence), the presence and recurrence of gastrointestinal symptoms and the length of hospital stay', 'length of hospital stay and costs', 'nausea or vomiting', 'pain relapse', 'length of hospital stay', 'onset of oral refeeding']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0747195', 'cui_str': 'Biliary pancreatitis'}, {'cui': 'C0085546', 'cui_str': 'Ethics Committees'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0001339', 'cui_str': 'Acute pancreatitis'}]",[],"[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0206174', 'cui_str': 'Cost, Hospital'}, {'cui': 'C0443469', 'cui_str': 'Pancreatic lipase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0332162', 'cui_str': 'Onset of'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]",,0.124806,"Compared with usual oral refeeding, early oral refeeding is safe in predicted mild acute biliary pancreatitis patients, does not cause adverse gastrointestinal events, and reduces the length of hospital stay and costs. ","[{'ForeName': 'Edgard Efrén', 'Initials': 'EE', 'LastName': 'Lozada-Hernández', 'Affiliation': 'Department of Surgery and Clinical Research, Hospital Regional de Alta Especialidad del Bajío, Circuito Quinta los Naranjos # 145 B. Colonia Quinta los Naranjos, León, Guanajuato, Mexico. edgardlozada@hotmail.com.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Barrón-González', 'Affiliation': 'Department of Surgery, Unidad Médica de Alta Especialidad Bajío, Instituto Mexicano del Seguro Social, León, Guanajuato, Mexico.'}, {'ForeName': 'Santa', 'Initials': 'S', 'LastName': 'Vázquez-Romero', 'Affiliation': 'Department of Surgery, Unidad Médica de Alta Especialidad Bajío, Instituto Mexicano del Seguro Social, León, Guanajuato, Mexico.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Cano-Rosas', 'Affiliation': 'Department of Surgery, Unidad Médica de Alta Especialidad Bajío, Instituto Mexicano del Seguro Social, León, Guanajuato, Mexico.'}, {'ForeName': 'Evelia', 'Initials': 'E', 'LastName': 'Apolinar-Jimenez', 'Affiliation': 'Department of Clinical Nutrition, Hospital Regional de Alta Especialidad del Bajío, León, Guanajuato, Mexico.'}]",BMC gastroenterology,['10.1186/s12876-020-01363-3'] 2069,32677897,Effects of a 16-week multimodal exercise program on gait performance in individuals with dementia: a multicenter randomized controlled trial.,"BACKGROUND There is a high prevalence of gait impairments in individuals with dementia (IWD). Gait impairments are associated with increased risk of falls, disability, and economic burden for health care systems. Only few studies have investigated the effectiveness of physical activity on gait performance in IWD, reporting promising but inconsistent results. Thus, this study aimed to investigate the effectiveness of a multimodal exercise program (MEP) on gait performance in IWD. METHODS In this parallel-group randomized controlled trial, we enrolled 319 IWD of mild to moderate severity, living in care facilities, aged ≥ 65 years, and being able to walk at least 10 m. The control group (n = 118) received conventional treatment, whereas the intervention group (n = 201) additionally participated in a 16-week MEP specifically tailored to IWD. We examined the effects of the MEP on spatiotemporal gait parameters and dual task costs by using the gait analysis system GAITRite. Additionally, we compared characteristics between positive, non-, and negative responders, and investigated the impact of changes in underlying motor and cognitive performance in the intervention group by conducting multiple regression analyses. RESULTS Two-factor analyses of variance with repeated measurements did not reveal any statistically significant time*group effects on either spatiotemporal gait parameters or dual task costs. Differences in baseline gait performance, mobility, lower limb strength, and severity of cognitive impairments were observed between positive, non-, and negative responders. Positive responders were characterized by lower motor performance compared to negative and non-responders, while non-responders showed better cognitive performance than negative responders. Changes in lower limb strength and function, mobility, executive function, attention, and working memory explained up to 39.4% of the variance of changes in gait performance. CONCLUSIONS The effectiveness of a standardized MEP on gait performance in IWD was limited, probably due to insufficient intensity and amount of specific walking tasks as well as the large heterogeneity of the sample. However, additional analyses revealed prerequisites of individual characteristics and impacts of changes in underlying motor and cognitive performance. Considering such factors may improve the effectiveness of a physical activity intervention among IWD. TRIAL REGISTRATION DRKS00010538 (German Clinical Trial Register, date of registration: 01 June 2016, retrospectively registered, https://www.drks.de/drks_web/setLocale_EN.do ).",2020,"Positive responders were characterized by lower motor performance compared to negative and non-responders, while non-responders showed better cognitive performance than negative responders.","['individuals with dementia', 'enrolled 319 IWD of mild to moderate severity, living in care facilities, aged ≥ 65\u2009years, and being able to walk at least 10\u2009m', 'individuals with dementia (IWD', '01 June 2016, retrospectively registered, https://www.drks.de/drks_web/setLocale_EN.do ']","['multimodal exercise program (MEP', 'multimodal exercise program', 'standardized MEP', 'MEP', 'conventional treatment, whereas the intervention group (n\u2009=\u2009201) additionally participated in a 16-week MEP specifically tailored to IWD']","['lower limb strength and function, mobility, executive function, attention, and working memory', 'cognitive performance', 'baseline gait performance, mobility, lower limb strength, and severity of cognitive impairments', 'gait performance', 'spatiotemporal gait parameters and dual task costs', 'spatiotemporal gait parameters or dual task costs']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0856538', 'cui_str': 'Living in care'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C2712089', 'cui_str': 'Able to walk'}, {'cui': 'C0600375', 'cui_str': 'Registers'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}]","[{'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",,0.0744723,"Positive responders were characterized by lower motor performance compared to negative and non-responders, while non-responders showed better cognitive performance than negative responders.","[{'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Trautwein', 'Affiliation': 'Karlsruhe Institute of Technology, Institute of Sports and Sports Science, Engler-Bunte-Ring 15, 76131, Karlsruhe, Germany. sandra.trautwein@kit.edu.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Barisch-Fritz', 'Affiliation': 'Karlsruhe Institute of Technology, Institute of Sports and Sports Science, Engler-Bunte-Ring 15, 76131, Karlsruhe, Germany.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Scharpf', 'Affiliation': 'Karlsruhe Institute of Technology, Institute of Sports and Sports Science, Engler-Bunte-Ring 15, 76131, Karlsruhe, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Ringhof', 'Affiliation': 'Karlsruhe Institute of Technology, Institute of Sports and Sports Science, Engler-Bunte-Ring 15, 76131, Karlsruhe, Germany.'}, {'ForeName': 'Thorsten', 'Initials': 'T', 'LastName': 'Stein', 'Affiliation': 'Karlsruhe Institute of Technology, Institute of Sports and Sports Science, Engler-Bunte-Ring 15, 76131, Karlsruhe, Germany.'}, {'ForeName': 'Janina', 'Initials': 'J', 'LastName': 'Krell-Roesch', 'Affiliation': 'Karlsruhe Institute of Technology, Institute of Sports and Sports Science, Engler-Bunte-Ring 15, 76131, Karlsruhe, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Woll', 'Affiliation': 'Karlsruhe Institute of Technology, Institute of Sports and Sports Science, Engler-Bunte-Ring 15, 76131, Karlsruhe, Germany.'}]",BMC geriatrics,['10.1186/s12877-020-01635-3'] 2070,32678053,Report of a Delphi exercise to inform the design of a research programme on screening for thoracic aortic disease.,"OBJECTIVES To inform the design of a clinical trial of a targeted screening programme for relatives of individuals affected by thoracic aortic disease, we performed a consensus exercise as to the acceptability of screening, the optimal sequence and choice of tests, long-term patient management, and choice of trial design. METHODS Working with the Aortic Dissection Awareness UK & Ireland patient association, we performed a Delphi exercise with clinical experts, patients, and carers, consisting of three rounds of consultation followed by a final multi-stakeholder face-to-face workshop. RESULTS Thirty-five experts and 84 members of the public took part in the surveys, with 164 patients and clinicians attending the final workshop. There was substantial agreement on the need for a targeted screening pathway that would employ a combined approach (imaging + genetic testing). The target population would include the first- and second-degree adult (> 15 years) relatives, with no upper age limit of affected patients. Disagreement persisted about the screening process, sequence, personnel, the imaging method to adopt, computed tomography (CT) scan vs magnetic resonance imaging (MRI), and the specifics of a potential trial, including willingness to undergo randomisation, and measures of effectiveness and acceptability. CONCLUSION A Delphi process, initiated by patients, identified areas of uncertainty with respect to behaviour, process, and the design of a targeted screening programme for thoracic aortic disease that requires further research prior to any future trial.",2020,"A Delphi process, initiated by patients, identified areas of uncertainty with respect to behaviour, process, and the design of a targeted screening programme for thoracic aortic disease that requires further research prior to any future trial.","['Thirty-five experts and 84 members of the public took part in the surveys, with 164 patients and clinicians attending the final workshop', 'relatives of individuals affected by thoracic aortic disease', 'Working with the Aortic Dissection Awareness UK & Ireland patient association']","['targeted screening programme', 'Delphi exercise', 'computed tomography (CT) scan vs magnetic resonance imaging (MRI']",[],"[{'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0003493', 'cui_str': 'Disorder of aorta'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0340643', 'cui_str': 'Dissection of aorta'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0022067', 'cui_str': 'Republic of Ireland'}, {'cui': 'C0004083', 'cui_str': 'Association'}]","[{'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]",[],164.0,0.030268,"A Delphi process, initiated by patients, identified areas of uncertainty with respect to behaviour, process, and the design of a targeted screening programme for thoracic aortic disease that requires further research prior to any future trial.","[{'ForeName': 'R G', 'Initials': 'RG', 'LastName': 'Abbasciano', 'Affiliation': 'Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, LE3 9QP, UK. rga8@leicester.ac.uk.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Barwell', 'Affiliation': 'Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, LE3 9QP, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Sayers', 'Affiliation': 'Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, LE3 9QP, UK.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bown', 'Affiliation': 'Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, LE3 9QP, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Milewicz', 'Affiliation': 'Division of Medical Genetics, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Cooper', 'Affiliation': 'Northern General Hospital, Herries Road, Sheffield, UK.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Mariscalco', 'Affiliation': 'Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, LE3 9QP, UK.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Wheeldon', 'Affiliation': 'Northern General Hospital, Herries Road, Sheffield, UK.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Fowler', 'Affiliation': '.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Owens', 'Affiliation': '.'}, {'ForeName': 'G J', 'Initials': 'GJ', 'LastName': 'Murphy', 'Affiliation': 'Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, LE3 9QP, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Trials,['10.1186/s13063-020-04562-1'] 2071,32678054,The effect of dexmedetomidine on vasopressor requirements in patients with septic shock: a subgroup analysis of the Sedation Practice in Intensive Care Evaluation [SPICE III] Trial.,"BACKGROUND Septic shock is associated with decreased vasopressor responsiveness. Experimental data suggest that central alpha2-agonists like dexmedetomidine (DEX) increase vasopressor responsiveness and reduce catecholamine requirements in septic shock. However, DEX may also cause hypotension and bradycardia. Thus, it remains unclear whether DEX is hemodynamically safe or helpful in this setting. METHODS In this post hoc subgroup analysis of the Sedation Practice in Intensive Care Evaluation (SPICE III) trial, an international randomized trial comparing early sedation with dexmedetomidine to usual care in critically patients receiving mechanical ventilation, we studied patients with septic shock admitted to two tertiary ICUs in Australia and Switzerland. The primary outcome was vasopressor requirements in the first 48 h after randomization, expressed as noradrenaline equivalent dose (NEq [μg/kg/min] = noradrenaline + adrenaline + vasopressin/0.4). RESULTS Between November 2013 and February 2018, 417 patients were recruited into the SPICE III trial at both sites. Eighty-three patients with septic shock were included in this subgroup analysis. Of these, 44 (53%) received DEX and 39 (47%) usual care. Vasopressor requirements in the first 48 h were similar between the two groups. Median NEq dose was 0.03 [0.01, 0.07] μg/kg/min in the DEX group and 0.04 [0.01, 0.16] μg/kg/min in the usual care group (p = 0.17). However, patients in the DEX group had a lower NEq/MAP ratio, indicating lower vasopressor requirements to maintain the target MAP. Moreover, on adjusted multivariable analysis, higher dexmedetomidine dose was associated with a lower NEq/MAP ratio. CONCLUSIONS In critically ill patients with septic shock, patients in the DEX group received similar vasopressor doses in the first 48 h compared to the usual care group. On multivariable adjusted analysis, dexmedetomidine appeared to be associated with lower vasopressor requirements to maintain the target MAP. TRIAL REGISTRATION The SPICE III trial was registered at ClinicalTrials.gov ( NCT01728558 ).",2020,Vasopressor requirements in the first 48 h were similar between the two groups.,"['critically ill patients with septic shock, patients in the', 'Intensive Care Evaluation [SPICE\xa0III', 'septic shock', 'patients with septic shock', 'Eighty-three patients with septic shock', 'Between November 2013 and February 2018, 417 patients were recruited into the SPICE III trial at both sites', 'critically patients receiving mechanical ventilation, we studied patients with septic shock admitted to two tertiary ICUs in Australia and Switzerland']","['dexmedetomidine (DEX', 'dexmedetomidine', 'DEX']","['catecholamine requirements', 'hypotension and bradycardia', 'Vasopressor requirements', 'vasopressor responsiveness', 'vasopressor requirements', 'lower NEq/MAP ratio']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036983', 'cui_str': 'Septic shock'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0037910', 'cui_str': 'Spice'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C4517888', 'cui_str': '83'}, {'cui': 'C5191297', 'cui_str': '417'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}]","[{'cui': 'C0007412', 'cui_str': 'Catecholamine'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0042397', 'cui_str': 'Vasoconstrictor agent'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0024779', 'cui_str': 'Maps'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",83.0,0.380463,Vasopressor requirements in the first 48 h were similar between the two groups.,"[{'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Cioccari', 'Affiliation': 'Department of Intensive Care, Austin Hospital, The University of Melbourne, Melbourne, Australia. luca.cioccari@insel.ch.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Luethi', 'Affiliation': 'Department of Intensive Care, Austin Hospital, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Bailey', 'Affiliation': 'Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.'}, {'ForeName': 'Yahya', 'Initials': 'Y', 'LastName': 'Shehabi', 'Affiliation': 'Critical Care and Perioperative Services, School of Clinical Sciences, Monash University, Monash Health, Melbourne, Australia.'}, {'ForeName': 'Belinda', 'Initials': 'B', 'LastName': 'Howe', 'Affiliation': 'Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.'}, {'ForeName': 'Anna S', 'Initials': 'AS', 'LastName': 'Messmer', 'Affiliation': 'Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Helena K', 'Initials': 'HK', 'LastName': 'Proimos', 'Affiliation': 'Department of Intensive Care, Austin Hospital, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Peck', 'Affiliation': 'Department of Intensive Care, Austin Hospital, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Young', 'Affiliation': 'Department of Intensive Care, Austin Hospital, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Glenn M', 'Initials': 'GM', 'LastName': 'Eastwood', 'Affiliation': 'Department of Intensive Care, Austin Hospital, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Tobias M', 'Initials': 'TM', 'LastName': 'Merz', 'Affiliation': 'Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Jukka', 'Initials': 'J', 'LastName': 'Takala', 'Affiliation': 'Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Stephan M', 'Initials': 'SM', 'LastName': 'Jakob', 'Affiliation': 'Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Rinaldo', 'Initials': 'R', 'LastName': 'Bellomo', 'Affiliation': 'Department of Intensive Care, Austin Hospital, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Critical care (London, England)",['10.1186/s13054-020-03115-x'] 2072,32678055,"10-year follow-up results of the prospective, double-blinded, randomized, controlled study on autologous bone marrow buffy coat grafting combined with core decompression in patients with avascular necrosis of the femoral head.","BACKGROUND Avascular necrosis of the femoral head (ANFH) is a severely disabling disease of the hip. Several clinical trials have shown promising outcomes on the use of mesenchymal stem cells for the treatment of ANFH, but long-term clinical assessments are lacking. Previously, we reported the 2-year follow-up results of a prospective, double-blinded, randomized, controlled study on autologous bone marrow buffy coat grafting combined with core decompression in patients with ANFH. Here, we report the 10-year follow-up results of this study. METHODS We recruited 43 (53 hips) patients from 2009 to 2010. The hips were randomly allocated to code decompression (CD) with or without bone marrow buffy coat (BBC) grafting. Participants underwent follow-up at 24, 60, and 120 months postoperatively. The visual analogue scale (VAS), Lequesne algofunctional index, and Western Ontario and McMaster Universities Arthritis Index (WOMAC) osteoarthritis scores were recorded. Survival rate analysis and prognostic factor analysis were performed. The endpoint was defined as progression to Ficat stage IV or conversion to hip arthroplasty. RESULTS A total of 31 patients (41 hips) were included in the final analysis. The CD + BBC group had better subjective assessment scores than the CD group. The average survival times were 102.3 months and 78.1 months in the CD + BBC group and CD group, respectively (log-rank test, P = 0.029). In the univariate Cox proportional hazards regression model, age [hazard ratio (HR) = 1.079, P = 0.047] and preoperative Ficat stage (HR = 3.283, P = 0.028) indicated a high risk for progression, while the use of BBC (HR = 0.332, P = 0.042) indicated a low risk. Preoperative Ficat stage III was isolated as an independent risk factor for clinical failure in the multivariate model (HR = 3.743, P = 0.018). CONCLUSION The 10-year follow-up results of this prospective, double-blinded, randomized, controlled study showed that the use of autologous BBC in combination with core decompression was more effective than the use of core decompression alone. TRIAL REGISTRATION ClinicalTrials.gov, NCT01613612 . Registered on 13 December 2011-retrospectively registered.",2020,"The average survival times were 102.3 months and 78.1 months in the CD + BBC group and CD group, respectively (log-rank test, P = 0.029).","['31 patients (41 hips', 'patients with avascular necrosis of the femoral head', 'We recruited 43 (53 hips) patients from 2009 to 2010', 'patients with ANFH']","['autologous BBC', 'code decompression (CD) with or without bone marrow buffy coat (BBC) grafting', 'CD + BBC', 'autologous bone marrow buffy coat grafting combined with core decompression']","['preoperative Ficat stage', 'visual analogue scale (VAS), Lequesne algofunctional index, and Western Ontario and McMaster Universities Arthritis Index (WOMAC) osteoarthritis scores', 'average survival times', 'subjective assessment scores', 'progression to Ficat stage IV or conversion to hip arthroplasty']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0410480', 'cui_str': 'Avascular necrosis of the head of femur'}]","[{'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0005953', 'cui_str': 'Bone marrow structure'}, {'cui': 'C0443089', 'cui_str': 'Leukocyte buffy coat'}, {'cui': 'C0009219', 'cui_str': 'Coding'}, {'cui': 'C0011117', 'cui_str': 'Decompression'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0444669', 'cui_str': 'Core'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0451868', 'cui_str': 'Localized osteoporosis - Lequesne'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0003864', 'cui_str': 'Arthritis'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2919552', 'cui_str': 'Survival time'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0186193', 'cui_str': 'Repair of hip'}]",31.0,0.241733,"The average survival times were 102.3 months and 78.1 months in the CD + BBC group and CD group, respectively (log-rank test, P = 0.029).","[{'ForeName': 'Mengyuan', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': ""Division of Joint Osteopathy and Traumatology, Center of Orthopedics Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, 106 Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, People's Republic of China.""}, {'ForeName': 'Yuanchen', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': ""Division of Joint Osteopathy and Traumatology, Center of Orthopedics Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, 106 Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, People's Republic of China.""}, {'ForeName': 'Guangtao', 'Initials': 'G', 'LastName': 'Fu', 'Affiliation': ""Division of Joint Osteopathy and Traumatology, Center of Orthopedics Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, 106 Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, People's Republic of China.""}, {'ForeName': 'Ruiying', 'Initials': 'R', 'LastName': 'Zhang', 'Affiliation': ""Division of Joint Osteopathy and Traumatology, Center of Orthopedics Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, 106 Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, People's Republic of China.""}, {'ForeName': 'Qingtian', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': ""Division of Joint Osteopathy and Traumatology, Center of Orthopedics Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, 106 Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, People's Republic of China.""}, {'ForeName': 'Zhantao', 'Initials': 'Z', 'LastName': 'Deng', 'Affiliation': ""Division of Joint Osteopathy and Traumatology, Center of Orthopedics Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, 106 Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, People's Republic of China.""}, {'ForeName': 'Minghao', 'Initials': 'M', 'LastName': 'Zheng', 'Affiliation': 'Centre for Orthopaedic Translational Research, School of Surgery, The University of Western Australia, M Block, QE2 Medical Centre, Monash Ave., Nedlands, WA, 6009, Australia. Minghao.zheng@uwa.edu.au.'}, {'ForeName': 'Qiujian', 'Initials': 'Q', 'LastName': 'Zheng', 'Affiliation': ""Division of Joint Osteopathy and Traumatology, Center of Orthopedics Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, 106 Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, People's Republic of China. zhengqiujian@gdph.org.cn.""}]",Stem cell research & therapy,['10.1186/s13287-020-01810-8'] 2073,32678062,Effectiveness of Interventions to Increase Colorectal Cancer Screening Among American Indians and Alaska Natives.,"INTRODUCTION Screening rates for colorectal cancer are low in many American Indian and Alaska Native (AI/AN) communities. Direct mailing of a fecal immunochemical test (FIT) kit can address patient and structural barriers to screening. Our objective was to determine if such an evidence-based intervention could increase colorectal cancer screening among AI/AN populations. METHODS We recruited study participants from 3 tribally operated health care facilities and randomly assigned them to 1 of 3 study groups: 1) usual care, 2) mailing of FIT kits, and 3) mailing of FIT kits plus follow-up outreach by telephone and/or home visit from an American Indian Community Health Representative (CHR). RESULTS Among participants who received usual care, 6.4% returned completed FIT kits. Among participants who were mailed FIT kits without outreach, 16.9% returned the kits - a significant increase over usual care (P < .01). Among participants who received mailed FIT kits plus CHR outreach, 18.8% returned kits, which was also a significant increase over usual care (P < .01) but not a significant increase compared with the mailed FIT kit-only group (P = .44). Of 165 participants who returned FIT kits during the study, 39 (23.6%) had a positive result and were referred for colonoscopy of which 23 (59.0%) completed the colonoscopy. Twelve participants who completed a colonoscopy had polyps, and 1 was diagnosed with colorectal cancer. CONCLUSION Direct mailing of FIT kits to eligible community members may be a useful, population-based strategy to increase colorectal cancer screening among AI/AN people.",2020,"Among participants who were mailed FIT kits without outreach, 16.9% returned the kits - a significant increase over usual care (P < .01).","['participants who received usual care, 6.4% returned completed FIT kits', 'Twelve participants who completed a colonoscopy had polyps, and 1 was diagnosed with colorectal cancer', 'American Indians and Alaska Natives', '165 participants who returned FIT kits during the study, 39 (23.6%) had a positive result and were referred for colonoscopy of which 23 (59.0%) completed the colonoscopy', 'study participants from 3 tribally operated health care facilities and randomly assigned them to 1 of 3 study groups: 1']","['usual care, 2) mailing of FIT kits, and 3) mailing of FIT kits plus follow-up outreach by telephone and/or home visit from an American Indian Community Health Representative (CHR']",['usual care'],"[{'cui': 'C4517822', 'cui_str': '6.4'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C1272835', 'cui_str': 'Test kit'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0032584', 'cui_str': 'Polyp'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0682125', 'cui_str': 'Native Alaskians'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C1272835', 'cui_str': 'Test kit'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0043459', 'cui_str': 'Zellweger syndrome'}]",[],165.0,0.0522286,"Among participants who were mailed FIT kits without outreach, 16.9% returned the kits - a significant increase over usual care (P < .01).","[{'ForeName': 'Donald', 'Initials': 'D', 'LastName': 'Haverkamp', 'Affiliation': 'Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Albuquerque, New Mexico.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'English', 'Affiliation': 'Albuquerque Area Indian Health Board, Albuquerque, New Mexico.'}, {'ForeName': 'Jasmine', 'Initials': 'J', 'LastName': 'Jacobs-Wingo', 'Affiliation': 'Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Albuquerque, New Mexico.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Tjemsland', 'Affiliation': 'Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Albuquerque, New Mexico.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Espey', 'Affiliation': 'Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Albuquerque, New Mexico.'}]",Preventing chronic disease,['10.5888/pcd17.200049'] 2074,32676897,Classifying the diagnosis of study participants in clinical trials: a structured and efficient approach.,"BACKGROUND A challenge in imaging research is a diagnostic classification of study participants. We hypothesised that a structured approach would be efficient and that classification by medical students, residents, and an expert panel whenever necessary would be as valid as classification of all patients by experts. METHODS OPTIMACT is a randomised trial designed to evaluate the effectiveness of replacing chest x-ray for ultra-low-dose chest computed tomography (CT) at the emergency department. We developed a handbook with diagnostic guidelines and randomly selected 240 cases from 2,418 participants enrolled in OPTIMACT. Each case was independently classified by two medical students and, if they disagreed, by the students and a resident in a consensus meeting. Cases without consensus and cases classified as complex were assessed by a panel of medical specialists. To evaluate the validity, 60 randomly selected cases not referred to the panel by the students and the residents were reassessed by the specialists. RESULTS Overall, the students and, if necessary, residents were able to assign a diagnosis in 183 of the 240 cases (76% concordance; 95% confidence interval [CI] 71-82%). We observed agreement between students and residents versus medical specialists in 50/60 cases (83% concordance; 95% CI 74-93%). CONCLUSIONS A structured approach in which study participants are assigned diagnostic labels by assessors with increasing levels of medical experience was an efficient and valid classification method, limiting the workload for medical specialists. We presented a viable option for classifying study participants in large-scale imaging trials (Netherlands National Trial Register number NTR6163).",2020,"We observed agreement between students and residents versus medical specialists in 50/60 cases (83% concordance; 95% CI 74-93%). ","['2,418 participants enrolled in OPTIMACT', '60 randomly selected cases not referred to the panel by the students and the residents were reassessed by the specialists']",['replacing chest x-ray for ultra-low-dose chest computed tomography (CT'],[],"[{'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}]","[{'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C0039985', 'cui_str': 'Plain chest X-ray'}, {'cui': 'C4075962', 'cui_str': 'Low dose computed tomography of thorax'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}]",[],60.0,0.0447482,"We observed agreement between students and residents versus medical specialists in 50/60 cases (83% concordance; 95% CI 74-93%). ","[{'ForeName': 'Tjitske S R', 'Initials': 'TSR', 'LastName': 'van Engelen', 'Affiliation': 'Department of Internal Medicine, Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Room: T1-0-240, Amsterdam, The Netherlands. t.s.vanengelen@amsterdamumc.nl.'}, {'ForeName': 'Maadrika M N P', 'Initials': 'MMNP', 'LastName': 'Kanglie', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'Inge A H', 'Initials': 'IAH', 'LastName': 'van den Berk', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'Merel L J', 'Initials': 'MLJ', 'LastName': 'Bouwman', 'Affiliation': 'Department of Internal Medicine, Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Room: T1-0-240, Amsterdam, The Netherlands.'}, {'ForeName': 'Hind J M', 'Initials': 'HJM', 'LastName': 'Suhooli', 'Affiliation': 'Department of Internal Medicine, Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Room: T1-0-240, Amsterdam, The Netherlands.'}, {'ForeName': 'Sascha L', 'Initials': 'SL', 'LastName': 'Heckert', 'Affiliation': 'Department of Internal Medicine, Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Room: T1-0-240, Amsterdam, The Netherlands.'}, {'ForeName': 'Jaap', 'Initials': 'J', 'LastName': 'Stoker', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'Patrick M M', 'Initials': 'PMM', 'LastName': 'Bossuyt', 'Affiliation': 'Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'Jan M', 'Initials': 'JM', 'LastName': 'Prins', 'Affiliation': 'Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European radiology experimental,['10.1186/s41747-020-00169-y'] 2075,32676976,Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.,"OBJECTIVES To develop a new Chinese medicine (CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome (ARDS) in COVID-19 patients. METHODS A putative ARDS-suppressing drug Keguan-1 was first developed and then evaluated by a randomized, controlled two-arm trial. The two arms of the trial consist of a control therapy (alpha interferon inhalation, 50 µg twice daily; and lopinavir/ritonavir, 400 and 100 mg twice daily, respectively) and a testing therapy (control therapy plus Keguan-1 19.4 g twice daily) by random number table at 1:1 ratio with 24 cases each group. After 2-week treatment, adverse events, time to fever resolution, ARDS development, and lung injury on newly diagnosed COVID-19 patients were assessed. RESULTS An analysis of the data from the first 30 participants showed that the control arm and the testing arm did not exhibit any significant differences in terms of adverse events. Based on this result, the study was expanded to include a total of 48 participants (24 cases each arm). The results show that compared with the control arm, the testing arm exhibited a significant improvement in time to fever resolution (P=0.035), and a significant reduction in the development of ARDS (P=0.048). CONCLUSIONS Keguan-1-based integrative therapy was safe and superior to the standard therapy in suppressing the development of ARDS in COVID-19 patients. (Trial registration No. NCT04251871 at www.clinicaltrials.gov ).",2020,"The results show that compared with the control arm, the testing arm exhibited a significant improvement in time to fever resolution (P=0.035), and a significant reduction in the development of ARDS (P=0.048). ","['48 participants (24 cases each arm', 'COVID-19 patients']","['control therapy (alpha interferon inhalation, 50 µg twice daily; and lopinavir/ritonavir', 'Keguan-1-based integrative therapy']","['adverse events', 'development of ARDS', 'adverse events, time to fever resolution, ARDS development, and lung injury', 'time to fever resolution']","[{'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0002199', 'cui_str': 'interferon alfa natural'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0939237', 'cui_str': 'lopinavir and ritonavir'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0273115', 'cui_str': 'Injury of lung'}]",48.0,0.271286,"The results show that compared with the control arm, the testing arm exhibited a significant improvement in time to fever resolution (P=0.035), and a significant reduction in the development of ARDS (P=0.048). ","[{'ForeName': 'Jia-Bo', 'Initials': 'JB', 'LastName': 'Wang', 'Affiliation': 'China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Zhong-Xia', 'Initials': 'ZX', 'LastName': 'Wang', 'Affiliation': 'Integrative Medical Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Jing', 'Affiliation': 'Integrative Medical Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Zhao', 'Affiliation': 'Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Jing-Hui', 'Initials': 'JH', 'LastName': 'Dong', 'Affiliation': 'Department of Radiology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Yong-Feng', 'Initials': 'YF', 'LastName': 'Zhou', 'Affiliation': 'China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Guang', 'Initials': 'G', 'LastName': 'Yang', 'Affiliation': 'Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Niu', 'Affiliation': 'China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Tian-Jun', 'Initials': 'TJ', 'LastName': 'Jiang', 'Affiliation': 'Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Jing-Feng', 'Initials': 'JF', 'LastName': 'Bi', 'Affiliation': 'Research Center for Clinical and Translational Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Xu', 'Affiliation': 'Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': 'Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Zhao-Fang', 'Initials': 'ZF', 'LastName': 'Bai', 'Affiliation': 'China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Yu-Ming', 'Initials': 'YM', 'LastName': 'Guo', 'Affiliation': 'China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Si-Miao', 'Initials': 'SM', 'LastName': 'Yu', 'Affiliation': 'Integrative Medical Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Yong-Qiang', 'Initials': 'YQ', 'LastName': 'Sun', 'Affiliation': 'Integrative Medical Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Zi-Teng', 'Initials': 'ZT', 'LastName': 'Zhang', 'Affiliation': 'China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Xiao-Yan', 'Initials': 'XY', 'LastName': 'Zhan', 'Affiliation': 'China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Peng-Yan', 'Initials': 'PY', 'LastName': 'Li', 'Affiliation': 'China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Jin-Biao', 'Initials': 'JB', 'LastName': 'Ding', 'Affiliation': 'Research Center for Clinical and Translational Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Peng-Fei', 'Initials': 'PF', 'LastName': 'Zhao', 'Affiliation': 'College of Life Science, Beijing University of Chinese Medicine, Beijing, 100029, China.'}, {'ForeName': 'Xue-Ai', 'Initials': 'XA', 'LastName': 'Song', 'Affiliation': 'Integrative Medical Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.'}, {'ForeName': 'Jian-Yuan', 'Initials': 'JY', 'LastName': 'Tang', 'Affiliation': 'Sichuan Evidence-Based Medicine Center of Traditional Chinese Medicine Affliated Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.'}, {'ForeName': 'Dong-Chu', 'Initials': 'DC', 'LastName': 'He', 'Affiliation': 'Department of Integrated Treatment, General Hospital of Central Theater Command, Wuhan, 430070, China.'}, {'ForeName': 'Zhu', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'National Clinical Research Center for Infectious Diseases, Beijing, 100039, China.'}, {'ForeName': 'En-Qiang', 'Initials': 'EQ', 'LastName': 'Qin', 'Affiliation': 'Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China. qeq2004@sina.com.'}, {'ForeName': 'Rui-Lin', 'Initials': 'RL', 'LastName': 'Wang', 'Affiliation': 'Integrative Medical Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China. wrl7905@163.com.'}, {'ForeName': 'Xiao-He', 'Initials': 'XH', 'LastName': 'Xiao', 'Affiliation': 'China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China. pharmacy302xxh@126.com.'}]",Chinese journal of integrative medicine,['10.1007/s11655-020-3426-7'] 2076,32677707,"Remimazolam tosilate in upper gastrointestinal endoscopy: A multicenter, randomized, non-inferiority, phase III trial.","BACKGROUND AND AIM Remimazolam tosilate (RT) is a new short-acting GABA(A) receptor agonist, having potential to be an effective option for procedural sedation. Here, we aimed to compare the efficacy and safety of RT with propofol in patients undergoing upper gastrointestinal endoscopy. METHODS This positive-controlled, non-inferiority, phase III trial recruited patients at 17 centers, between September 2017 and November 2017. A total of 384 patients scheduled to undergo upper gastrointestinal endoscopy were randomly assigned to receive RT or propofol. Primary endpoint was the success rate of sedation. Adverse events (AEs) were recorded to evaluate safety. RESULTS The success rate of sedation in the RT group was non-inferior to that in the propofol group (97.34% vs 100.00%; difference in rate -2.66%, 95% CI -4.96 to -0.36, meeting criteria for non-inferiority). Patients in the RT group had longer time to adequate sedation (P < 0.0001) but shorter time to fully alert (P < 0.0001) than that in the propofol group. The incidences of hypotension (13.04% vs 42.86%, P < 0.0001), treatment-related hypotension (0.54% vs 5.82%, P < 0.0001), and respiratory depression (1.09% vs 6.88%, P = 0.0064) were significantly lower in the RT group. AEs were reported in 74 (39.15%) patients in the RT group and 114 (60.32%) patients in the propofol group, with significant difference (P < 0.0001). CONCLUSION This trial established non-inferior sedation success rate of RT compared with propofol. RT allows faster recovery from sedation compared with propofol. The safety profile is favorable and appears to be superior to propofol, indicating that it was feasible and well tolerated for patients.",2020,"The incidences of hypotension (13.04% vs. 42.86%, p<0.0001), treatment-related hypotension (0.54% vs. 5.82%, p<0.0001) and respiratory depression (1.09% vs. 6.88%, p=0.0 064) were significantly lower in RT group.","['384 patients scheduled to undergo upper gastrointestinal endoscopy', 'patients undergoing upper gastrointestinal endoscopy', 'in Upper Gastrointestinal Endoscopy', 'patients at 17 centers, between September 2017 and November 2017']","['Remimazolam Tosilate', 'propofol', 'RT', 'RT with propofol', 'RT or propofol']","['success rate of sedation', 'shorter time to fully alert', 'respiratory depression', 'efficacy and safety', 'treatment-related hypotension', 'Adverse events (AEs', 'longer time to adequate sedation', 'incidences of hypotension']","[{'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0079304', 'cui_str': 'Esophagogastroduodenoscopy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0104487', 'cui_str': 'AT 17'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C3179470', 'cui_str': 'remimazolam'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}]","[{'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0235063', 'cui_str': 'Decreased respiratory function'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",384.0,0.115255,"The incidences of hypotension (13.04% vs. 42.86%, p<0.0001), treatment-related hypotension (0.54% vs. 5.82%, p<0.0001) and respiratory depression (1.09% vs. 6.88%, p=0.0 064) were significantly lower in RT group.","[{'ForeName': 'Shao-Hui', 'Initials': 'SH', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, Chinese Academy of Medical College and Peking Union Medical College Hospital, Beijing, China.'}, {'ForeName': 'Tang-Mi', 'Initials': 'TM', 'LastName': 'Yuan', 'Affiliation': 'Department of Anesthesiology, Chinese Academy of Medical College and Peking Union Medical College Hospital, Beijing, China.'}, {'ForeName': 'Jiao', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Chinese Academy of Medical College and Peking Union Medical College Hospital, Beijing, China.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Bai', 'Affiliation': 'Clinical Pharmacology Research Center, Chinese Academy of Medical College and Peking Union Medical College Hospital, Beijing, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Tian', 'Affiliation': 'Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Chu-Xiong', 'Initials': 'CX', 'LastName': 'Pan', 'Affiliation': 'Department of Anesthesiology, Beijing TongRen Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Hong-Guang', 'Initials': 'HG', 'LastName': 'Bao', 'Affiliation': 'Department of Anesthesiology, Nanjing First Hospital, Nanjing, China.'}, {'ForeName': 'Xiao-Ju', 'Initials': 'XJ', 'LastName': 'Jin', 'Affiliation': 'Department of Anesthesiology, Yijishan Hospital of Wannan Medical College, Wuhu, China.'}, {'ForeName': 'Fu-Hai', 'Initials': 'FH', 'LastName': 'Ji', 'Affiliation': 'Department of Anesthesiology, The First Hospital of Soochow University, Suzhou, China.'}, {'ForeName': 'Tai-Di', 'Initials': 'TD', 'LastName': 'Zhong', 'Affiliation': 'Department of Anesthesiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Jian-Rui', 'Initials': 'JR', 'LastName': 'Lv', 'Affiliation': ""Department of Anesthesiology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Sheng', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology, Guangdong Provincial People's Hospital, Guangzhou, China.""}, {'ForeName': 'Yu-Juan', 'Initials': 'YJ', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yong-Hao', 'Initials': 'YH', 'LastName': 'Yu', 'Affiliation': 'Department of Anesthesiology, Tianjin Medical University General Hospital, Tianjin, China.'}, {'ForeName': 'Ai-Lin', 'Initials': 'AL', 'LastName': 'Luo', 'Affiliation': 'Department of Anesthesiology, Tongji Hospital, Wuhan, China.'}, {'ForeName': 'Xiang-Kui', 'Initials': 'XK', 'LastName': 'Li', 'Affiliation': ""Department of Anesthesiology, Sichuan Provincial People's Hospital, Chengdu, China.""}, {'ForeName': 'Su', 'Initials': 'S', 'LastName': 'Min', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, The General Hospital of Northern Theater Command, Shenyang, China.'}, {'ForeName': 'Xiao-Hua', 'Initials': 'XH', 'LastName': 'Zou', 'Affiliation': 'Department of Anesthesiology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.'}, {'ForeName': 'Yu-Guang', 'Initials': 'YG', 'LastName': 'Huang', 'Affiliation': 'Department of Anesthesiology, Chinese Academy of Medical College and Peking Union Medical College Hospital, Beijing, China.'}]",Journal of gastroenterology and hepatology,['10.1111/jgh.15188'] 2077,32677999,"eTest: a limited-interaction, longitudinal randomized controlled trial of a mobile health platform that enables real-time phone counseling after HIV self-testing among high-risk men who have sex with men.","BACKGROUND HIV disproportionately affects men who have sex with men (MSM) in the USA, and new infections continue to increase, particularly among African American (AA) and Hispanic/Latino (H/L) MSM. Rates of HIV testing are particularly low among AA and H/L MSM, and innovative approaches to encourage testing may help address high incidence in these men. HIV self-testing (HST) may be an important tool for increasing rates and frequency of testing. HST may be particularly well-suited for AA and H/L MSM, given that stigma and mistrust of medical care contribute to low testing rates. Despite its promise, however, many are concerned that HST does not sufficiently connect users with critical post-testing resources, such as confirmatory testing and care among those who test positive, and that these limitations may result in delayed linkage to care. METHODS We developed a mobile health platform (eTest) that monitors when HST users open their tests in real time, allowing us to provide timely, ""active"" follow-up counseling and referral over the phone. In this study, 900 high-risk MSM (with targets of 40% AA, 35% H/L) who have not tested in the last year will be recruited from social media and other gay-oriented websites in several major cities. Over 12 months, participants will be randomly assigned to receive (1) HST with post-test phone counseling and referral (eTest condition), (2) HST without active follow-up (standard condition), or (3) reminders to get tested for HIV at a local clinic (control) every 3 months. Primary outcomes include rates of HIV testing, receipt of additional HIV prevention services, and PrEP initiation verified by clinical medical records. DISCUSSION This study tests whether providing more active counseling and referral after HST encourages more regular HIV testing and engagement with other prevention services among MSM, compared to more passive approaches or clinic-based testing alone. It will also explore the cost-effectiveness and emotional/behavioral effects of these two strategies. TRIAL REGISTRATION ClinicalTrials.gov identifier NCT03654690 . Registered on 31 August 2018.",2020,"This study tests whether providing more active counseling and referral after HST encourages more regular HIV testing and engagement with other prevention services among MSM, compared to more passive approaches or clinic-based testing alone.","['HIV disproportionately affects men who have sex with men (MSM', 'high-risk men who have sex with men', '900 high-risk MSM (with targets of 40% AA, 35% H/L) who have not tested in the last year will be recruited from social media and other gay-oriented websites in several major cities']","['HIV self-testing (HST', 'mobile health platform that enables real-time phone counseling', 'HST', 'HST with post-test phone counseling and referral (eTest condition), (2) HST without active follow-up (standard condition), or (3) reminders to get tested for HIV at a local clinic (control) every 3\xa0months']","['cost-effectiveness and emotional/behavioral effects', 'rates of HIV testing, receipt of additional HIV prevention services, and PrEP initiation verified by clinical medical records']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C4517900', 'cui_str': '900'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3179065', 'cui_str': 'Social Medium'}, {'cui': 'C0019898', 'cui_str': 'Queers'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0008848', 'cui_str': 'Cities'}]","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0562342', 'cui_str': 'Empowered'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C3850116', 'cui_str': 'Etest'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0332179', 'cui_str': 'Trimonthly'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0025102', 'cui_str': 'Medical record'}]",900.0,0.169923,"This study tests whether providing more active counseling and referral after HST encourages more regular HIV testing and engagement with other prevention services among MSM, compared to more passive approaches or clinic-based testing alone.","[{'ForeName': 'Tyler B', 'Initials': 'TB', 'LastName': 'Wray', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, USA. tyler_wray@brown.edu.'}, {'ForeName': 'Philip A', 'Initials': 'PA', 'LastName': 'Chan', 'Affiliation': 'Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, RI, USA.'}, {'ForeName': 'Jeffrey D', 'Initials': 'JD', 'LastName': 'Klausner', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Leandro A', 'Initials': 'LA', 'LastName': 'Mena', 'Affiliation': 'Department of Population Health Sciences, John D. Bower School of Population Health, University of Mississippi Medical Center, Jackson, MS, USA.'}, {'ForeName': 'James B', 'Initials': 'JB', 'LastName': 'Brock', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.'}, {'ForeName': 'Erik M', 'Initials': 'EM', 'LastName': 'Simpanen', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, USA.'}, {'ForeName': 'Lori M', 'Initials': 'LM', 'LastName': 'Ward', 'Affiliation': 'Department of Population Health Sciences, John D. Bower School of Population Health, University of Mississippi Medical Center, Jackson, MS, USA.'}, {'ForeName': 'Stafylis', 'Initials': 'S', 'LastName': 'Chrysovalantis', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, USA.'}]",Trials,['10.1186/s13063-020-04554-1'] 2078,32678005,Process evaluation of a complex intervention to promote advance care planning in community-dwelling older persons (the STADPLAN study)-study protocol.,"BACKGROUND Process evaluation addresses the implementation, mechanisms of impact, and context of participants in complex interventions. The STADPLAN study assesses the effects of conversations on advance care planning (ACP) led by trained nurse facilitators. The complex intervention consists of several components that may lead to various changes in attitude and behavior regarding personal ACP activities. With the process evaluation, we aim to assess how changes were achieved in the STADPLAN intervention. METHODS The planned process evaluation study will be conducted alongside a cluster-randomized controlled trial on ACP in home care services (HCS). Trained nurse facilitators will deliver the ACP intervention consisting of an information brochure and two ACP conversations. A logic model depicts the assumed change processes of the intervention: the educational program enables nurses to conduct ACP conversations with patients and their caregivers. Patients gain knowledge and reflect upon and engage in their own ACP. Caregivers better understand patients' wishes and feel reassured in their role as surrogates. Designation of a surrogate and communication on ACP are facilitated. We will assess the effects of the educational program with questionnaires and a focus group including all participating nurses. We will measure ACP engagement, and prevalence of advance directives in patients, and ask for their experiences with the intervention. We will conduct semi-structured interviews with caregivers about their expectations and experiences regarding ACP in general and the intervention. We will address context factors, e.g., basic characteristics of the HCS (such as ownership, number of clients, staff and qualification). Analysis will be based upon the logic model, integrating qualitative and quantitative data. DISCUSSION The comprehensive process evaluation will provide essential information on the feasibility of implementation strategies and the clinical relevance of a nurse-led ACP intervention in home care recipients and its generalizability and transferability to other settings. TRIAL REGISTRATION German Clinical Trials Register: DRKS00016886 . Registered retrospectively on June 4, 2019, first participant included on May 29, 2019.",2020,The STADPLAN study assesses the effects of conversations on advance care planning (ACP) led by trained nurse facilitators.,"['community-dwelling older persons', 'Registered retrospectively on June 4, 2019, first participant included on May 29, 2019']","['advance care planning (ACP', 'ACP', 'ACP intervention', 'complex intervention']",[],"[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0600371', 'cui_str': 'Advance care planning'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}]",[],,0.0454776,The STADPLAN study assesses the effects of conversations on advance care planning (ACP) led by trained nurse facilitators.,"[{'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Silies', 'Affiliation': 'Institute for Social Medicine and Epidemiology, Nursing Research Unit, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany. Katharina.silies@uksh.de.'}, {'ForeName': 'Rieke', 'Initials': 'R', 'LastName': 'Schnakenberg', 'Affiliation': 'Department for Health Services Research, Faculty of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Ammerländer Heerstraße 140, 26129, Oldenburg, Germany. rieke.schnakenberg@uni-oldenburg.de.'}, {'ForeName': 'Almuth', 'Initials': 'A', 'LastName': 'Berg', 'Affiliation': 'Medical Faculty, Institute for Health- and Nursing Science, Martin Luther University Halle-Wittenberg, Magdeburger Straße 8, 06112, Halle (Saale), Germany.'}, {'ForeName': 'Änne', 'Initials': 'Ä', 'LastName': 'Kirchner', 'Affiliation': 'Medical Faculty, Institute for Health- and Nursing Science, Martin Luther University Halle-Wittenberg, Magdeburger Straße 8, 06112, Halle (Saale), Germany.'}, {'ForeName': 'Henriette', 'Initials': 'H', 'LastName': 'Langner', 'Affiliation': 'Medical Faculty, Institute for Health- and Nursing Science, Martin Luther University Halle-Wittenberg, Magdeburger Straße 8, 06112, Halle (Saale), Germany.'}, {'ForeName': 'Juliane', 'Initials': 'J', 'LastName': 'Köberlein-Neu', 'Affiliation': 'Center for Health Economics and Health Services Research, Schumpeter School of Business and Economics, University of Wuppertal, Rainer-Gruenter-Straße 21, 42119, Wuppertal, Germany.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Meyer', 'Affiliation': 'Medical Faculty, Institute for Health- and Nursing Science, Martin Luther University Halle-Wittenberg, Magdeburger Straße 8, 06112, Halle (Saale), Germany.'}, {'ForeName': 'Falk', 'Initials': 'F', 'LastName': 'Hoffmann', 'Affiliation': 'Department for Health Services Research, Faculty of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Ammerländer Heerstraße 140, 26129, Oldenburg, Germany.'}, {'ForeName': 'Sascha', 'Initials': 'S', 'LastName': 'Köpke', 'Affiliation': 'Institute for Social Medicine and Epidemiology, Nursing Research Unit, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.'}]",Trials,['10.1186/s13063-020-04529-2'] 2079,32678026,"A trauma medical home, evaluating collaborative care for the older injured patient: study protocol for a randomized controlled trial.","BACKGROUND It is estimated that 55 million adults will be 65 years and older in the USA by 2020. These older adults are at increased risk for injury and their recovery is multi-faceted. A collaborative care model may improve psychological and functional outcomes of the non-neurologically impaired older trauma patient and reduce health care costs. METHODS This is a randomized controlled trial of 430 patients aged 50 and older who have suffered a non-neurologic injury and are admitted to a level one trauma center in Indianapolis, IN, or Madison, WI. Participants will be assigned to either the Trauma Medical Home (TMH) intervention or usual care. The TMH intervention is a collaborative care model that includes validated protocols addressing the multi-faceted needs of this population, with the help of care coordination software and a mobile office concept. The primary outcome is self-reported physical recovery at 6- and 12-month follow-up. Secondary outcomes include self-reported psychological recovery, acute health care utilization, and cost-effectiveness of the intervention at 6 and 12 months. The TMH collaborative care model will be delivered by a registered nurse care coordinator. The assessments will be completed by trained blinded research assistants. DISCUSSION The proposed study will evaluate a collaborative care model to help maximize psychological and functional recovery for non-neurologically injured older patients at four level one trauma centers in the Midwest. TRIAL REGISTRATION Clinical Trials. NCT03108820 . Registered on 11 April 2017. Protocol Version 6: Study # 1612690852. April 12, 2019. SPONSOR Indiana University. Human subjects and IRB contact information: irb@iu.edu Prospectively registered in the WHO ICTRP on 4 June 2017.",2020,"A collaborative care model may improve psychological and functional outcomes of the non-neurologically impaired older trauma patient and reduce health care costs. ","['non-neurologically injured older patients at four level one trauma centers in the Midwest', '430 patients aged 50 and older who have suffered a non-neurologic injury and are admitted to a level one trauma center in Indianapolis, IN, or Madison, WI', '55 million adults will be 65\u2009years and older in the USA by 2020', 'older injured patient', 'Human subjects and IRB contact information: irb@iu.edu Prospectively registered in the WHO ICTRP on 4 June 2017']","['Trauma Medical Home (TMH) intervention or usual care', 'TMH intervention']","['self-reported psychological recovery, acute health care utilization, and cost-effectiveness of the intervention at 6 and 12\xa0months', 'self-reported physical recovery']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040786', 'cui_str': 'Trauma center'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C1881839', 'cui_str': '1000000'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C0086911', 'cui_str': 'Ethics Committee, Research'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0600375', 'cui_str': 'Registers'}]","[{'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C2713310', 'cui_str': 'Medical Home'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0030672', 'cui_str': 'Health Care Utilization'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",430.0,0.125255,"A collaborative care model may improve psychological and functional outcomes of the non-neurologically impaired older trauma patient and reduce health care costs. ","[{'ForeName': 'Damaris', 'Initials': 'D', 'LastName': 'Ortiz', 'Affiliation': 'Division of Acute Care Surgery, Department of Surgery, Indiana University School of Medicine, 545 Barnhill Dr., Emerson Hall, Indianapolis, IN, 46202, USA. damaorti@iu.edu.'}, {'ForeName': 'Ashley D', 'Initials': 'AD', 'LastName': 'Meagher', 'Affiliation': 'Division of Acute Care Surgery, Department of Surgery, Indiana University School of Medicine, 545 Barnhill Dr., Emerson Hall, Indianapolis, IN, 46202, USA.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Lindroth', 'Affiliation': 'Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Department of Medicine, Indiana University School of Medicine, 1120 W. Michigan St., CL 260, Indianapolis, IN, 46202, USA.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Holler', 'Affiliation': 'Sidney & Lois Eskenazi Hospital Smith Level One Trauma Center, 720 Eskenazi Ave, Indianapolis, IN, 46202, USA.'}, {'ForeName': 'Sujuan', 'Initials': 'S', 'LastName': 'Gao', 'Affiliation': 'Center of Health Innovation and Implementation Science, Center for Translational Science and Innovation, 410 W. 10th St., Indianapolis, IN, 46202, USA.'}, {'ForeName': 'Babar', 'Initials': 'B', 'LastName': 'Khan', 'Affiliation': 'Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Department of Medicine, Indiana University School of Medicine, 1120 W. Michigan St., CL 260, Indianapolis, IN, 46202, USA.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Lasiter', 'Affiliation': 'School of Nursing and Health Studies, University of Missouri, 2464 Charlotte St, Kansas City, MO, 64108, USA.'}, {'ForeName': 'Malaz', 'Initials': 'M', 'LastName': 'Boustani', 'Affiliation': 'Center of Health Innovation and Implementation Science, Center for Translational Science and Innovation, 410 W. 10th St., Indianapolis, IN, 46202, USA.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Zarzaur', 'Affiliation': 'Department of Surgery, University of Wisconsin School of Medicine and Public Health-Madison, 600 Highland Ave., Madison, WI, 53792, USA.'}]",Trials,['10.1186/s13063-020-04582-x'] 2080,32678041,"Effect of electroacupuncture versus solifenacin for moderate and severe overactive bladder: a multi-centre, randomized controlled trial study protocol.","BACKGROUND Overactive bladder is defined as ""urgency, with or without urge incontinence, usually with frequency and nocturia"". Electroacupuncture may be a safe and an effective alternative therapy for overactive bladder, but the evidence is limited. METHODS We will conduct a three-arm, non-inferiority, multi-centre randomized controlled clinical trial. A total of 420 patients with moderate and severe overactive bladder will be randomly assigned to one of three groups: the electroacupuncture group (N = 140), sham electroacupuncture group (N = 140), and solifenacin group (N = 140). The primary outcome will be the change in the overactive bladder symptom score from baseline to the end of the 12-week treatment. The secondary outcomes will include the proportion of participants with a decrease in the overactive bladder symptom score ≥ 3 at weeks 4, 8, 12, 20, and 32; the change in average 24 h values of urination, nocturnal urination, urgency incontinence and urgency episodes from baseline to weeks 4, 8, 12, 20 and 32, and so forth. The adverse events will be recorded. Statistical analysis will include covariance analysis, nonparametric tests and descriptive statistics. DISCUSSION This study will answer the question of whether electroacupuncture is effective and non-inferior to solifenacin for improving the symptoms of overactive bladder patients. TRIAL REGISTRATION Chinese clinical trial registry ( ChiCTR1800019928 ).",2020,"Electroacupuncture may be a safe and an effective alternative therapy for overactive bladder, but the evidence is limited. ","['moderate and severe overactive bladder', 'overactive bladder patients', '420 patients with moderate and severe overactive bladder']","['electroacupuncture group (N\u2009=\u2009140), sham electroacupuncture', 'Electroacupuncture', 'electroacupuncture', 'solifenacin']","['adverse events', 'change in average 24\u2009h values of urination, nocturnal urination, urgency incontinence and urgency episodes', 'overactive bladder symptom score']","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0878773', 'cui_str': 'Overactive bladder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517774', 'cui_str': '420'}]","[{'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C1099677', 'cui_str': 'Solifenacin'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0042034', 'cui_str': 'Micturition'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0878773', 'cui_str': 'Overactive bladder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",420.0,0.206234,"Electroacupuncture may be a safe and an effective alternative therapy for overactive bladder, but the evidence is limited. ","[{'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Wen', 'Affiliation': 'Department of Integrated Traditional and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Department of Integrated Traditional and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Xueling', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Integrated Traditional and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Integrated Traditional and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Fengwei', 'Initials': 'F', 'LastName': 'Tian', 'Affiliation': 'Department of acupuncture and moxibustion, Chongqing hospital of traditional Chinese medicine, Chongqing, China.'}, {'ForeName': 'Weiwei', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': ""Department of acupuncture and moxibustion, Subei people's hospital of Jiangsu province, Yangzhou, China.""}, {'ForeName': 'Yanyan', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'Department of acupuncture and moxibustion, Jiangbin hospital of Guangxi Zhuang autonomous region, Nanning, China.'}, {'ForeName': 'Zhishun', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': ""Guang'anmen Hospital, China Academy of Chinese Medical Sciences, No.5 Beixiange Street, Beijing, Xicheng District, China. liuzhishun@aliyun.com.""}]",BMC complementary medicine and therapies,['10.1186/s12906-020-03018-y'] 2081,32678285,Cerebellar transcranial direct current stimulation for learning a novel split-belt treadmill task: a randomised controlled trial.,"This study aimed to examine the effect of repeated anodal cerebellar transcranial direct current stimulation (ctDCS) on learning a split-belt treadmill task. Thirty healthy individuals randomly received three consecutive sessions of active or sham anodal ctDCS during split-belt treadmill training. Motor performance and strides to steady-state performance were evaluated before (baseline), during (adaptation), and after (de-adaptation) the intervention. The outcomes were measured one week later to assess absolute learning and during the intervention to evaluate cumulative, consecutive, and session-specific effects. Data were analysed using linear mixed-effects regression models. During adaptation, there was no significant difference in absolute learning between the groups (p > 0.05). During de-adaptation, a significant difference in absolute learning between the groups (p = 0.03) indicated slower de-adaptation with anodal ctDCS. Pre-planned secondary analysis revealed that anodal ctDCS significantly reduced the cumulative (p = 0.01) and consecutive-session effect (p = 0.01) on immediate adaptation. There were significant cumulative (p = 0.02) and session-specific effects (p = 0.003) on immediate de-adaptation. Repeated anodal ctDCS does not enhance motor learning measured during adaptation to a split-belt treadmill task. However, it influences the maintenance of learnt walking patterns, suggesting that it may be beneficial in maintaining therapeutic effects.",2020,There were significant cumulative (p = 0.02) and session-specific effects (p = 0.003) on immediate de-adaptation.,['Thirty healthy individuals'],"['active or sham anodal ctDCS during split-belt treadmill training', 'anodal cerebellar transcranial direct current stimulation (ctDCS', 'Cerebellar transcranial direct current stimulation', 'anodal ctDCS']","['Motor performance and strides to steady-state performance', 'motor learning', 'absolute learning', 'session-specific effects']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0007765', 'cui_str': 'Cerebellar structure'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0452227', 'cui_str': 'Belt'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0205361', 'cui_str': 'Steady'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",30.0,0.0490166,There were significant cumulative (p = 0.02) and session-specific effects (p = 0.003) on immediate de-adaptation.,"[{'ForeName': 'Nitika', 'Initials': 'N', 'LastName': 'Kumari', 'Affiliation': 'Health and Rehabilitation Research Institute, Auckland University of Technology, Auckland, New Zealand. nitika.kumari@aut.ac.nz.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Taylor', 'Affiliation': 'Health and Rehabilitation Research Institute, Auckland University of Technology, Auckland, New Zealand.'}, {'ForeName': 'Usman', 'Initials': 'U', 'LastName': 'Rashid', 'Affiliation': 'Health and Rehabilitation Research Institute, Auckland University of Technology, Auckland, New Zealand.'}, {'ForeName': 'Alain C', 'Initials': 'AC', 'LastName': 'Vandal', 'Affiliation': 'Department of Statistics, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Paul F', 'Initials': 'PF', 'LastName': 'Smith', 'Affiliation': 'Department of Pharmacology and Toxicology, School of Biomedical Sciences, Brain Health Research Centre, University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'Nada', 'Initials': 'N', 'LastName': 'Signal', 'Affiliation': 'Health and Rehabilitation Research Institute, Auckland University of Technology, Auckland, New Zealand.'}]",Scientific reports,['10.1038/s41598-020-68825-2'] 2082,32678376,Weighted Blankets: Anxiety Reduction in Adult Patients Receiving Chemotherapy.,"BACKGROUND Weighted blankets have been used as a deep touch pressure (DTP) tool to alleviate anxiety in many patient populations. Patients with cancer can experience anxiety related to diagnosis and treatments, such as chemotherapy infusions. Research on the effectiveness of weighted blankets as a DTP tool to alleviate anxiety in patients receiving chemotherapy is limited. OBJECTIVES This study assessed the effectiveness of a medical-grade therapeutic weighted blanket on anxiety in patients receiving their first and second chemotherapy infusions at an outpatient infusion center. METHODS A randomized controlled trial with a crossover design was performed with new patients in the outpatient chemotherapy infusion center. Patients were randomized to one of two study arms (given the weighted blanket during their first infusion or given the weighted blanket during their second infusion). Anxiety was measured using an anxiety inventory and a visual analog scale. FINDINGS Anxiety was reduced among patients receiving chemotherapy when the weighted blanket was used. Based on the results, a standard-weight, medical-grade therapeutic weighted blanket can be safely used to reduce anxiety in patients of various weights, and a visual analog scale can be a reliable indicator of patients' state anxiety. ",2020,"This study assessed the effectiveness of a medical-grade therapeutic weighted blanket on anxiety in patients receiving their first and second chemotherapy infusions at an outpatient infusion center. ","['new patients in the outpatient chemotherapy infusion center', 'patients receiving chemotherapy is limited', 'patients receiving their first and second chemotherapy infusions at an outpatient infusion center', 'Patients with cancer', 'Adult Patients Receiving Chemotherapy']","['medical-grade therapeutic weighted blanket', 'weighted blankets']","['Anxiety', 'anxiety inventory and a visual analog scale']","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0179330', 'cui_str': 'Blanket'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",,0.0336687,"This study assessed the effectiveness of a medical-grade therapeutic weighted blanket on anxiety in patients receiving their first and second chemotherapy infusions at an outpatient infusion center. ","[{'ForeName': 'Jaime', 'Initials': 'J', 'LastName': 'Vinson', 'Affiliation': 'Parkview Health System.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Powers', 'Affiliation': 'Parkview Health System.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Mosesso', 'Affiliation': 'Indiana University.'}]",Clinical journal of oncology nursing,['10.1188/20.CJON.360-368'] 2083,32678377,Low-Dose Computed Tomography: Effects of Oncology Nurse Navigation on Lung Cancer Screening.,"BACKGROUND Low-dose computed tomography (LDCT) lung cancer screening is an evidence-based and reimbursable strategy to decrease lung cancer and all-cause mortality in qualifying patients, but there remains low use and variation in providers' LDCT screening, ordering, and referring knowledge. OBJECTIVES The purpose of this quality improvement project was to examine the effects of oncology nurse navigation on assisting patients and ensuring optimal LDCT lung cancer screening. METHODS Oncology nurse navigators conducted LDCT provider education and navigated 133 eligible patients to LDCT during a five-month intervention time period. FINDINGS Provider education resulted in improved documented tobacco cessation discussions and increased LDCT screening ordering fidelity. Mean days from LDCT to provider notification and mean days from LDCT to patient notification improved significantly. ",2020,"Mean days from LDCT to provider notification and mean days from LDCT to patient notification improved significantly. ","['Oncology nurse navigators conducted LDCT provider education and navigated 133 eligible patients to LDCT during a five-month intervention time period', 'Lung Cancer Screening']","['oncology nurse navigation', 'Low-dose computed tomography (LDCT) lung cancer screening', 'Oncology Nurse Navigation', 'Low-Dose Computed Tomography']",['tobacco cessation discussions'],"[{'cui': 'C0557529', 'cui_str': 'Oncology nurse'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1948053', 'cui_str': 'Time periods'}, {'cui': 'C0281477', 'cui_str': 'Screening for malignant neoplasm of lung'}]","[{'cui': 'C0557529', 'cui_str': 'Oncology nurse'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0281477', 'cui_str': 'Screening for malignant neoplasm of lung'}]","[{'cui': 'C0600549', 'cui_str': 'Tobacco Cessation'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}]",133.0,0.0540633,"Mean days from LDCT to provider notification and mean days from LDCT to patient notification improved significantly. ","[{'ForeName': 'Joni', 'Initials': 'J', 'LastName': 'Watson', 'Affiliation': 'Baylor Scott and White Medical Center.'}, {'ForeName': 'Marion E', 'Initials': 'ME', 'LastName': 'Broome', 'Affiliation': 'Duke University.'}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Schneider', 'Affiliation': 'Duke University.'}]",Clinical journal of oncology nursing,['10.1188/20.CJON.421-429'] 2084,32678452,Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease: A Randomized Clinical Trial.,"Importance Sickle cell disease (SCD) is characterized by chronic pain and episodic acute pain caused by vasoocclusive crises, often requiring high doses of opioids for prolonged periods. In humanized mouse models of SCD, a synthetic cannabinoid has been found to attenuate both chronic and acute hyperalgesia. The effect of cannabis on chronic pain in adults with SCD is unknown. Objective To determine whether inhaled cannabis is more effective than inhaled placebo in relieving chronic pain in adults with SCD. Design, Setting, and Participants This pilot randomized clinical trial included participants with SCD with chronic pain admitted to a single inpatient clinical research center for 2 separate 5-day stays from August 2014 to April 2017. Participants inhaled either vaporized cannabis (4.4% Δ-9-tetrahydrocannabinol to 4.9% cannabidiol) 3 times daily or vaporized placebo cannabis. Pain and pain interference ratings using the Brief Pain Inventory were assessed throughout each 5-day period. Participants with SCD and chronic pain on stable analgesics were eligible to enroll. A total of 90 participants were assessed for eligibility; 56 participants were deemed ineligible, and 34 participants were enrolled. Of these, 7 participants dropped out before randomization. Of 27 randomized participants, 23 completed both treatment arms of the crossover study and were included in the final per protocol analysis. Data analysis was completed in June 2019, with the sensitivity analysis conducted in April 2020. Interventions Inhalation of vaporized cannabis plant (4.4% Δ-9-tetrahydrocannbinol to 4.9% cannabidiol) or placebo cannabis plant using a vaporizer 3 times daily for 5 days. Main Outcomes and Measures Daily pain assessed with visual analog scale and Brief Pain Inventory. Results A total of 23 participants (mean [SD] age, 37.6 [11.4] years; 13 [56%] women) completed the trial. The mean (SD) difference in pain rating assessment between the cannabis and placebo groups was -5.3 (8.1) for day 1, -10.9 (7.0) for day 2, -16.5 (9.2) for day 3, -8.9 (6.7) for day 4, and -8.2 (8.1) for day 5; however, none of these differences were statistically significant. There was no statistically significant mean (SD) difference in pain interference ratings between cannabis and placebo between days 1 and 5 for interference in general activities (day 1: 0.27 [0.35]; day 5: -1.0 [0.5]), walking (day 1: 0.14 [0.73]; day 5: -0.87 [0.63]), sleep (day 1: 0.59 [0.74]; day 5: -1.3 [0.8]), or enjoyment (day 1: 0.23 [0.69]; day 5: -0.91 [0.48]), but there was a statistically significant mean (SD) difference in decrease in interference with mood (day 1: 0.96 [0.59]; day 5: -1.4 [0.6]; P = .02). No differences in treatment-related adverse effects were observed. Use of concomitant opioids was similar during both treatment periods. Conclusions and Relevance This randomized clinical trial found that, compared with vaporized placebo, vaporized cannabis did not statistically significantly reduce pain and associated symptoms, except interference in mood, in patients with SCD with chronic pain. Trial Registration ClinicalTrials.gov Identifier: NCT01771731.",2020,"There was no statistically significant mean (SD) difference in pain interference ratings between cannabis and placebo between days 1 and 5 for interference in general activities (day 1: 0.27 [0.35]; day 5: -1.0 [0.5]), walking (day 1: 0.14 [0.73];","['Adults With Sickle Cell Disease', 'A total of 90 participants were assessed for eligibility; 56 participants were deemed ineligible, and 34 participants were enrolled', '23 participants (mean [SD] age, 37.6 [11.4] years; 13 [56%] women) completed the trial', '27 randomized participants, 23 completed both treatment arms of the crossover study and were included in the final per protocol analysis', 'patients with SCD with chronic pain', 'Participants with SCD and chronic pain on stable analgesics were eligible to enroll', 'participants with SCD with chronic pain admitted to a single inpatient clinical research center for 2 separate 5-day stays from August 2014 to April 2017', 'adults with SCD']","['vaporized cannabis plant (4.4% Δ-9-tetrahydrocannbinol to 4.9% cannabidiol) or placebo cannabis plant', 'vaporized placebo', 'Inhaled Cannabis', 'vaporized cannabis (4.4% Δ-9-tetrahydrocannabinol to 4.9% cannabidiol) 3 times daily or vaporized placebo cannabis', 'cannabis', 'placebo']","['adverse effects', 'pain and associated symptoms', 'mean (SD) difference in pain rating assessment', 'chronic pain', 'Pain and pain interference ratings', 'pain interference ratings', 'sleep', 'Main Outcomes and Measures\n\n\nDaily pain assessed with visual analog scale and Brief Pain Inventory']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0002895', 'cui_str': 'Sickling disorder due to hemoglobin S'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517533', 'cui_str': '11.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0032098', 'cui_str': 'Kingdom Viridiplantae'}, {'cui': 'C4517761', 'cui_str': '4.4'}, {'cui': 'C0006863', 'cui_str': 'Cannabidiol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0556984', 'cui_str': 'Three times daily'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0521989', 'cui_str': 'Associated symptom'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",90.0,0.730869,"There was no statistically significant mean (SD) difference in pain interference ratings between cannabis and placebo between days 1 and 5 for interference in general activities (day 1: 0.27 [0.35]; day 5: -1.0 [0.5]), walking (day 1: 0.14 [0.73];","[{'ForeName': 'Donald I', 'Initials': 'DI', 'LastName': 'Abrams', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Couey', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco.'}, {'ForeName': 'Niharika', 'Initials': 'N', 'LastName': 'Dixit', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco.'}, {'ForeName': 'Varun', 'Initials': 'V', 'LastName': 'Sagi', 'Affiliation': 'Vascular Biology Center, Division of Hematology-Oncology-Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis.'}, {'ForeName': 'Ward', 'Initials': 'W', 'LastName': 'Hagar', 'Affiliation': ""UCSF Benioff Children's Hospital Oakland, Oakland, California.""}, {'ForeName': 'Elliott', 'Initials': 'E', 'LastName': 'Vichinsky', 'Affiliation': ""UCSF Benioff Children's Hospital Oakland, Oakland, California.""}, {'ForeName': 'Mary Ellen', 'Initials': 'ME', 'LastName': 'Kelly', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco.'}, {'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Connett', 'Affiliation': 'School of Public Health, University of Minnesota, Minneapolis.'}, {'ForeName': 'Kalpna', 'Initials': 'K', 'LastName': 'Gupta', 'Affiliation': 'Vascular Biology Center, Division of Hematology-Oncology-Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis.'}]",JAMA network open,['10.1001/jamanetworkopen.2020.10874'] 2085,32673939,Individualized PEEP ventilation between tumor resection and dural suture in craniotomy.,"OBJECTIVE Atelectasis, which affects oxygenation, is always occurred after craniotomy under general anesthesia. The commonly used protective ventilation strategy, which includes recruitment maneuver and higher level of positive end-expiratory pressure (PEEP), can effectively reduce atelectasis after heart and abdominal surgery, but increase intracranial pressure and reduce cerebral perfusion in patients undergoing craniotomy. We hypothesized individualized PEEP ventilation between tumor resection and dural suture in craniotomy could effectively reduce postoperative atelectasis, improve PaO 2 /FiO 2 ratio, and without reducing the regional cerebral oxygen saturation (rScO 2 ). PATIENTS AND METHODS 96 patients underwent tumor craniotomy in supine position were randomized into the control group (C group) and individualized PEEP group (P group). In the C group, the tidal volume (VT) was set at 8 mL/kg of predicted body weight, but PEEP were not used. In the P group, VT was set at 6 mL/kg of predicted body weight combined with individualized PEEP between tumor resection and dural suture, while in other periods of general anesthesia, VT was set at 8 mL/kg of predicted body weight. PaO 2 /FiO 2 ratio, lung ultrasound score (LUS) and rScO 2 were measured before induction, 1 h and 24 h after extubation. RESULTS Individual PEEP in the P group was 7.0 (4.0-9.0). The PaO 2 /FiO 2 ratio and rScO 2 in the P group were significantly higher than that of the C group (395 ± 62 vs. 344 ± 40, 67 ± 5 vs. 61 ± 4, respectively, p < 0.05) and the LUS of the experimental group was significantly lower than that of the C group [7.5 (5.3-8.3) vs. 10.0 (9.0-12.0), p < 0.05] 1 h after extubation. CONCLUSION Mechanical ventilation with individualized PEEP between tumor resection and dural suture in craniotomy can reduce atelectasis, improve PaO 2 /FiO 2 ratio and rScO 2 1 h after extubation.",2020,"The PaO 2 /FiO 2 ratio and rScO 2 in the P group were significantly higher than that of the C group (395 ± 62 vs. 344 ± 40, 67 ± 5 vs. 61 ± 4, respectively, p < 0.05) and the LUS of the experimental group was significantly lower than that of the C group [7.5 (5.3-8.3) vs. 10.0 (9.0-12.0), p < 0.05] 1 h after extubation. ","['patients undergoing craniotomy', '96 patients underwent tumor craniotomy in supine position']","['control group (C group) and individualized PEEP', 'Individualized PEEP ventilation']","['PaO 2 /FiO 2 ratio, lung ultrasound score (LUS) and rScO 2', 'tidal volume (VT', 'LUS', 'regional cerebral oxygen saturation (rScO 2 ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010280', 'cui_str': 'Craniotomy'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0038846', 'cui_str': 'Supine body position'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032740', 'cui_str': 'Positive end-expiratory pressure'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}]","[{'cui': 'C0232555', 'cui_str': 'Peak gastric acid output'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C4286019', 'cui_str': 'Lung ultrasound'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C4273907', 'cui_str': 'Cerebral oxygen saturation'}]",96.0,0.0496743,"The PaO 2 /FiO 2 ratio and rScO 2 in the P group were significantly higher than that of the C group (395 ± 62 vs. 344 ± 40, 67 ± 5 vs. 61 ± 4, respectively, p < 0.05) and the LUS of the experimental group was significantly lower than that of the C group [7.5 (5.3-8.3) vs. 10.0 (9.0-12.0), p < 0.05] 1 h after extubation. ","[{'ForeName': 'Hairui', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou 215004, China.'}, {'ForeName': 'Xuemei', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou 215004, China.'}, {'ForeName': 'Jinlu', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou 215004, China.'}, {'ForeName': 'Yueqin', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou 215004, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou 215004, China.'}, {'ForeName': 'Mingxia', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Department of Infection Control, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou 215004, China.'}, {'ForeName': 'Jiang', 'Initials': 'J', 'LastName': 'Zhu', 'Affiliation': 'Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou 215004, China.'}, {'ForeName': 'Peimin', 'Initials': 'P', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou 215004, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Xie', 'Affiliation': 'Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou 215004, China. Electronic address: xiehong_sz@hotmail.com.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Dong', 'Affiliation': 'Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou 215004, China. Electronic address: dongjun@suda.edu.cn.'}]",Clinical neurology and neurosurgery,['10.1016/j.clineuro.2020.106027'] 2086,32673969,A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization.,"PURPOSE To date, there has not been a single randomized controlled trial (RCT) conducted to directly compare the efficacy and safety of perampanel to brivaracetam in the adjunctive treatment of focal-onset seizures. This study makes these comparisons through the use of indirect treatment comparison (ITC) methods. METHODS A systematic review was conducted to identify RCTs that evaluated either one of perampanel or brivaracetam in the treatment of patients with focal-onset seizures. The Bucher ITC method was then used to compare efficacy and safety outcomes between perampanel and brivaracetam. Additional subgroup analyses, by levetiracetam usage (prior or concomitant), were conducted. RESULTS Eight RCTs (four comparing perampanel to placebo, four comparing brivaracetam to placebo) were included in the ITC. For patients taking concomitant levetiracetam, perampanel showed a significantly better responder rate compared to brivaracetam [relative risk (RR) and 95 % confidence interval (CI): 2.62 (1.15, 5.99)]. For patients who had previously, or never, taken levetiracetam, there was no difference in the responder rate. In the overall population, both perampanel and brivaracetam were more effective than placebo in terms of responder rate, seizure freedom, and secondarily generalized tonic-clonic seizure responder rate; however, for these outcomes, no evidence of a difference between perampanel and brivaracetam was found. Patients taking brivaracetam showed significantly less dizziness compared to patients taking perampanel. No differences for any other safety outcome were found. CONCLUSION Perampanel and brivaracetam are effective for the adjunctive treatment of focal-onset seizures and display similar adverse event profiles. Perampanel demonstrated an improved focal-onset seizure responder rate compared to brivaracetam in patients taking concomitant levetiracetam. This may be due to the similarity in the mechanism of action between brivaracetam and levetiracetam.",2020,"For patients who had previously, or never, taken levetiracetam, there was no difference in the responder rate.","['focal-onset seizures', 'patients with focal-onset seizures with or without secondary generalization', 'patients with focal-onset seizures']","['perampanel', 'perampanel versus brivaracetam', 'perampanel or brivaracetam', 'levetiracetam, perampanel', 'Perampanel', 'placebo']","['efficacy and safety outcomes', 'dizziness', 'responder rate', 'responder rate, seizure freedom, and secondarily generalized tonic-clonic seizure responder rate', 'efficacy and safety', 'focal-onset seizure responder rate']","[{'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0017324', 'cui_str': 'Generalization (Psychology)'}]","[{'cui': 'C2698764', 'cui_str': 'perampanel'}, {'cui': 'C1699861', 'cui_str': 'Brivaracetam'}, {'cui': 'C0377265', 'cui_str': 'Levetiracetam'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0494475', 'cui_str': 'Tonic-clonic seizure'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}]",,0.188512,"For patients who had previously, or never, taken levetiracetam, there was no difference in the responder rate.","[{'ForeName': 'Eugen', 'Initials': 'E', 'LastName': 'Trinka', 'Affiliation': 'FRCP Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University, Harrerstrasse 79, A-5020, Salzburg, Austria. Electronic address: eugen@trinka.at.'}, {'ForeName': 'Wan', 'Initials': 'W', 'LastName': 'Tsong', 'Affiliation': 'Formerly Eisai Inc, 100 Tice Blvd, Woodcliff Lake, NJ, 07677, United States. Electronic address: wtsong.esi@gmail.com.'}, {'ForeName': 'Sydney', 'Initials': 'S', 'LastName': 'Toupin', 'Affiliation': 'Quantics Biostatistics, Exchange Tower, 19 Canning Street Fourth Floor, Edinburgh, EH3 8EG, United Kingdom. Electronic address: sydney.toupin@outlook.com.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Patten', 'Affiliation': 'Eisai Ltd. European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, United Kingdom. Electronic address: Anna_Patten@eisai.net.'}, {'ForeName': 'Katy', 'Initials': 'K', 'LastName': 'Wilson', 'Affiliation': 'York Health Economics Consortium, Enterprise House, Innovation Way, University of York, York, YO10 5NQ, United Kingdom. Electronic address: katy.wilson@york.ac.uk.'}, {'ForeName': 'Jaana', 'Initials': 'J', 'LastName': 'Isojarvi', 'Affiliation': 'York Health Economics Consortium, Enterprise House, Innovation Way, University of York, York, YO10 5NQ, United Kingdom. Electronic address: jaana.isojarvi@york.ac.uk.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'James', 'Affiliation': 'Quantics Biostatistics, Exchange Tower, 19 Canning Street Fourth Floor, Edinburgh, EH3 8EG, United Kingdom. Electronic address: Daniel.James@quantics.co.uk.'}]",Epilepsy research,['10.1016/j.eplepsyres.2020.106403'] 2087,31822477,Implementing a junior high school-based programme to reduce sports injuries through neuromuscular training (iSPRINT): a cluster randomised controlled trial (RCT).,"OBJECTIVE To evaluate the effectiveness of a junior high school-based sports injury prevention programme to reduce injuries through neuromuscular training (NMT). METHODS This was a cluster randomised controlled trial. Students were recruited from 12 Calgary junior high schools (2014-2017). iSPRINT is a 15 min NMT warm-up including aerobic, agility, strength and balance exercises. Following a workshop, teachers delivered a 12-week iSPRINT NMT (six schools) or a standard-of-practice warm-up (six schools) in physical education classes. The definition of all recorded injuries included injuries that resulted in participants being unable to complete a sport and recreation (S&R) session, lost time from sport and/or seek medical attention. Incidence rate ratios (IRRs) were estimated based on multiple multilevel Poisson regression analyses (adjusting for sex (considering effect modification) and previous injury, offset by S&R participation hours, and school-level and class-level random effects were examined) for intent-to-treat analyses. RESULTS 1067 students (aged 11-16) were recruited across 12 schools (6 intervention schools (22 classes), 6 control schools (27 classes); 53.7% female, 46.3% male). The iSPRINT programme was protective of all recorded S&R injuries for girls (IRR=0.543, 95% CI 0.295 to 0.998), but not for boys (IRR=0.866, 95% CI 0.425 to 1.766). The iSPRINT programme was also protective of each of lower extremity injuries (IRR=0.357, 95% CI 0.159 to 0.799) and medical attention injuries (IRR=0.289, 95% CI 0.135 to 0.619) for girls, but not for boys (IRR=1.055, 95% CI 0.404 to 2.753 and IRR=0.639, 95% CI 0.266 to 1.532, respectively). CONCLUSION The iSPRINT NMT warm-up was effective in preventing each of all recorded injuries, lower extremity injuries and medically treated S&R injuries in female junior high school students. TRIAL REGISTRATION NUMBER NCT03312504.",2020,"The iSPRINT programme was protective of all recorded S&R injuries for girls (IRR=0.543, 95% CI 0.295 to 0.998), but not for boys (IRR=0.866, 95% CI 0.425 to 1.766).","['1067 students (aged 11-16) were recruited across 12 schools (6 intervention schools (22 classes), 6 control schools (27 classes); 53.7% female, 46.3% male', 'Students were recruited from 12 Calgary junior high schools (2014-2017', 'female junior high school students']","['neuromuscular training (iSPRINT', '12-week iSPRINT NMT (six schools) or a standard-of-practice warm-up (six schools) in physical education classes', 'junior high school-based sports injury prevention programme']","['medical attention injuries', 'extremity injuries', 'Incidence rate ratios (IRRs']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2350169', 'cui_str': 'Warming-Up Exercise'}, {'cui': 'C0031805', 'cui_str': 'Education, Physical'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0004161', 'cui_str': 'Sports injury'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]","[{'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0743668', 'cui_str': 'Limb injury'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.058628,"The iSPRINT programme was protective of all recorded S&R injuries for girls (IRR=0.543, 95% CI 0.295 to 0.998), but not for boys (IRR=0.866, 95% CI 0.425 to 1.766).","[{'ForeName': 'Carolyn A', 'Initials': 'CA', 'LastName': 'Emery', 'Affiliation': 'Sport Injury Prevention Research Centre, Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada caemery@ucalgary.ca.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'van den Berg', 'Affiliation': 'Sport Injury Prevention Research Centre, Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Sarah Ann', 'Initials': 'SA', 'LastName': 'Richmond', 'Affiliation': 'Health Promotion, Chronic Disease and Injury Prevention, Public Health Ontario, Toronto, Ontario, Canada.'}, {'ForeName': 'Luz', 'Initials': 'L', 'LastName': 'Palacios-Derflingher', 'Affiliation': 'Sport Injury Prevention Research Centre, Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Carly D', 'Initials': 'CD', 'LastName': 'McKay', 'Affiliation': 'Department for Health, University of Bath, Bath, UK.'}, {'ForeName': 'Patricia K', 'Initials': 'PK', 'LastName': 'Doyle-Baker', 'Affiliation': 'Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'McKinlay', 'Affiliation': 'Ever Active Schools, Calgary, Alberta, Canada.'}, {'ForeName': 'Clodagh M', 'Initials': 'CM', 'LastName': 'Toomey', 'Affiliation': 'Sport Injury Prevention Research Centre, Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Nettel-Aguirre', 'Affiliation': 'Departments of Pediatrics and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Evert', 'Initials': 'E', 'LastName': 'Verhagen', 'Affiliation': 'Department of Public and Occupational Health, Amsterdam Collaboration for Health and Safety in Sports, Amsterdam University Medical Center, Amsterdam, The Netherlands.'}, {'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Belton', 'Affiliation': 'School of Public Health, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Macpherson', 'Affiliation': 'Faculty of Health, York University, Toronto, Ontario, Canada.'}, {'ForeName': 'Brent E', 'Initials': 'BE', 'LastName': 'Hagel', 'Affiliation': 'Departments of Pediatrics and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.'}]",British journal of sports medicine,['10.1136/bjsports-2019-101117'] 2088,32682174,The renin secretion profile under the influence of sleep deprivation and the neuropeptides CRH and GHRH.,"It is already known that during normal sleep plasma renin activity (PRA) shows oscillations with decreases during rapid-eye-movement (REM) sleep and increases during non-REM (NREM) sleep. We also know that renin correlates positively with slow-wave sleep (SWS). Sleep deprivation is known to enhance significantly SWS and slow wave activity (SWA, known as δ power). Based on these findings we addressed the question whether and to which extent sleep deprivation may affect the synchronization found between PRA and REM sleep during normal sleep and whether this synchronization is affected by other sleep regulating factors. To investigate these questions we compared sleep EEG and sleep-related free renin levels in 48 normal women and men 19-69 years old between nights before and after 40 h of sleep deprivation. During the recovery night, four bolus injections of either GHRH, CRH or placebo were injected via long catheter around sleep onset. When compared to baseline after each of the treatments SWS, SWA and renin levels increased. The characteristical oscillation profiles of renin during normal sleep were also preserved after sleep deprivation. Similar to normal sleep our data support also a distinct link between nocturnal renin secretion and SWS after sleep deprivation and that independent of the applied treatments.",2020,"When compared to baseline after each of the treatments SWS, SWA and renin levels increased.",['48 normal women and men 19-69 years old between nights before and after 40\u2009h of sleep deprivation'],"['GHRH, CRH or placebo']","['renin correlates positively with slow-wave sleep (SWS', 'SWA and renin levels', 'sleep EEG and sleep-related free renin levels']","[{'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0037316', 'cui_str': 'Sleep deprivation'}]","[{'cui': 'C0037668', 'cui_str': 'Somatotropin releasing factor'}, {'cui': 'C0010132', 'cui_str': 'Corticotropin-Releasing Hormone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0035094', 'cui_str': 'Renin'}, {'cui': 'C0234451', 'cui_str': 'Non-rapid eye movement sleep'}, {'cui': 'C0038977', 'cui_str': 'Swahili language'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0200101', 'cui_str': 'Sleep electroencephalogram'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0332296', 'cui_str': 'Free of'}]",48.0,0.0236425,"When compared to baseline after each of the treatments SWS, SWA and renin levels increased.","[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Künzel', 'Affiliation': 'Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Germany; Max-Planck-Institut für Psychiatrie München, Germany. Electronic address: Heike.Kuenzel@med.uni-muenchen.de.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Schüssler', 'Affiliation': 'Max-Planck-Institut für Psychiatrie München, Germany; Universität Regensburg, Klinik und Poliklinik für Psychiatrie, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Yassouridis', 'Affiliation': 'Max-Planck-Institut für Psychiatrie München, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Uhr', 'Affiliation': 'Max-Planck-Institut für Psychiatrie München, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kluge', 'Affiliation': 'Max-Planck-Institut für Psychiatrie München, Germany; Universität Leipzig, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Steiger', 'Affiliation': 'Max-Planck-Institut für Psychiatrie München, Germany.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2020.104799'] 2089,32686744,The impact of vitamin D supplementation on VDR gene expression and body composition in monozygotic twins: randomized controlled trial.,"Vitamin D supplementation is widely used. However, there is no consensus on the use and dosage of this supplement and the existing recommendations arise from studies based on the benefits that this nutrient can facilitate in bones. In addition, individual genetics can influence the response to supplementation, therefore, research involving monozygotic twins aims to reduce these differences in phenotypic responses. The objective of this randomised controlled study is to examine the effect of vitamin D supplementation on body composition and the expression of the vitamin D receptor (VDR) mRNA. An intervention was performed through supplementation with cholecalciferol at the concentration of 2000 IU in 90 healthy adult monozygotic twins (male or female pairs) for 2 months. The findings showed that serum vitamin D concentration increased by 65% and VDR gene expression sixty times (p = 0.001). Changes in body composition parameters were observed regarding body fat and lean mass. Our results indicate that an increase in serum vitamin D concentration may have potential therapeutic implications.",2020,The findings showed that serum vitamin D concentration increased by 65% and VDR gene expression sixty times (p = 0.001).,"['monozygotic twins', '90 healthy adult monozygotic twins (male or female pairs) for 2\xa0months']","['cholecalciferol', 'vitamin D supplementation', 'Vitamin D supplementation']","['body composition and the expression of the vitamin D receptor (VDR) mRNA', 'VDR gene expression and body composition', 'serum vitamin D concentration', 'body composition parameters']","[{'cui': 'C0041432', 'cui_str': 'Monozygotic twins'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0108082', 'cui_str': 'Vitamin D3 Receptor'}, {'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0428586', 'cui_str': 'Serum vitamin D measurement'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",90.0,0.199654,The findings showed that serum vitamin D concentration increased by 65% and VDR gene expression sixty times (p = 0.001).,"[{'ForeName': 'Jeane Franco Pires', 'Initials': 'JFP', 'LastName': 'Medeiros', 'Affiliation': 'Department of Health Sciences, Federal University of Rio Grande Do Norte, Av. General Cordeiro de Farias, S/N - Petrópolis, Natal, RN, 59012-570, Brazil. jeanefpires@hotmail.com.'}, {'ForeName': 'Michelle Vasconcelos', 'Initials': 'MV', 'LastName': 'de Oliveira Borges', 'Affiliation': 'Department of Health Sciences, Federal University of Rio Grande Do Norte, Av. General Cordeiro de Farias, S/N - Petrópolis, Natal, RN, 59012-570, Brazil.'}, {'ForeName': 'Aline Alves', 'Initials': 'AA', 'LastName': 'Soares', 'Affiliation': 'Department of Health Sciences, Federal University of Rio Grande Do Norte, Av. General Cordeiro de Farias, S/N - Petrópolis, Natal, RN, 59012-570, Brazil.'}, {'ForeName': 'Jessica Cavalcante', 'Initials': 'JC', 'LastName': 'Dos Santos', 'Affiliation': 'Department of Pharmaceutical Sciences, Faculty of Pharmacy, Federal University of Rio Grande Do Norte, Natal, RN, Brazil.'}, {'ForeName': 'Ana Beatriz Bezerra', 'Initials': 'ABB', 'LastName': 'de Oliveira', 'Affiliation': 'Department of Pharmaceutical Sciences, Faculty of Pharmacy, Federal University of Rio Grande Do Norte, Natal, RN, Brazil.'}, {'ForeName': 'Conceição Horrana Belo', 'Initials': 'CHB', 'LastName': 'da Costa', 'Affiliation': 'Department of Pharmaceutical Sciences, Faculty of Pharmacy, Federal University of Rio Grande Do Norte, Natal, RN, Brazil.'}, {'ForeName': 'Marina Sampaio', 'Initials': 'MS', 'LastName': 'Cruz', 'Affiliation': 'Department of Health Sciences, Federal University of Rio Grande Do Norte, Av. General Cordeiro de Farias, S/N - Petrópolis, Natal, RN, 59012-570, Brazil.'}, {'ForeName': 'Raul Hernandes', 'Initials': 'RH', 'LastName': 'Bortolin', 'Affiliation': 'Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, SP, Brazil.'}, {'ForeName': 'Renata Caroline Costa', 'Initials': 'RCC', 'LastName': 'de Freitas', 'Affiliation': 'Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, SP, Brazil.'}, {'ForeName': 'Paulo Moreira Silva', 'Initials': 'PMS', 'LastName': 'Dantas', 'Affiliation': 'Department of Health Sciences, Federal University of Rio Grande Do Norte, Av. General Cordeiro de Farias, S/N - Petrópolis, Natal, RN, 59012-570, Brazil.'}, {'ForeName': 'Mario Hiroyuki', 'Initials': 'MH', 'LastName': 'Hirata', 'Affiliation': 'Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, SP, Brazil.'}, {'ForeName': 'Vivian Nogueira', 'Initials': 'VN', 'LastName': 'Silbiger', 'Affiliation': 'Graduate Program in Pharmaceutical Sciences, Faculty of Pharmacy, Federal University of Rio Grande Do Norte, Natal, RN, Brazil.'}, {'ForeName': 'André Ducati', 'Initials': 'AD', 'LastName': 'Luchessi', 'Affiliation': 'Department of Health Sciences, Federal University of Rio Grande Do Norte, Av. General Cordeiro de Farias, S/N - Petrópolis, Natal, RN, 59012-570, Brazil.'}]",Scientific reports,['10.1038/s41598-020-69128-2'] 2090,32686755,Embrace versus Cloth Wrap in preventing neonatal hypothermia during transport: a randomized trial.,"BACKGROUND We assessed the efficacy of Embrace Nest Infant Warmer versus Cloth Wrap in preventing hypothermia during short-term transport from the emergency department (ED) to the neonatal intensive care unit (NICU). METHODS Neonates weighing ≥1500 g coming to the ED were randomized for transport to the NICU. Axillary temperature was measured. RESULTS A total of 120 newborns (60 per group) were enrolled. From ED exit to NICU entry, the mean (SD) temperature increased in the Embrace group by 0.37 °C (0.54), whereas it reduced by 0.38 °C (0.80) in the Cloth group (p < 0.001). Hypothermia cases reduced in the Embrace group from 39 (65%) to 21 (35%), while it increased from 21 (35%) to 39 (65%) in the Cloth group (p = 0.001) from ED exit to NICU entry. The thermoregulation for 24 h after admission to the NICU was superior in the Embrace group. CONCLUSIONS Embrace showed significantly better thermoregulation in neonates. Further studies should be done to measure its effectiveness in different environments and distances.",2020,"Hypothermia cases reduced in the Embrace group from 39 (65%) to 21 (35%), while it increased from 21 (35%) to 39 (65%) in the Cloth group (p = 0.001) from ED exit to NICU entry.","['120 newborns (60 per group) were enrolled', 'Neonates weighing ≥1500']","['Embrace versus Cloth Wrap', 'Embrace Nest Infant Warmer versus Cloth Wrap']","['neonatal hypothermia', 'mean (SD) temperature', 'Axillary temperature', 'Hypothermia cases']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient'}]","[{'cui': 'C0039717', 'cui_str': 'Textiles'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0184348', 'cui_str': 'Warmer'}]","[{'cui': 'C0919592', 'cui_str': 'Hypothermia neonatal'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C1531924', 'cui_str': 'Axillary temperature'}, {'cui': 'C0020672', 'cui_str': 'Hypothermia'}, {'cui': 'C0868928', 'cui_str': 'Case'}]",120.0,0.0501065,"Hypothermia cases reduced in the Embrace group from 39 (65%) to 21 (35%), while it increased from 21 (35%) to 39 (65%) in the Cloth group (p = 0.001) from ED exit to NICU entry.","[{'ForeName': 'Vallaree Anant', 'Initials': 'VA', 'LastName': 'Morgaonkar', 'Affiliation': 'Department of Pediatrics, Deenanath Mangeshkar Hospital, Pune, India.'}, {'ForeName': 'Dipen Vasudev', 'Initials': 'DV', 'LastName': 'Patel', 'Affiliation': 'Department of Pediatrics, Pramukhswami Medical College, Karamsad, India. dipen_patel258@yahoo.co.in.'}, {'ForeName': 'Ajay Gajanan', 'Initials': 'AG', 'LastName': 'Phatak', 'Affiliation': 'Central Research Services, Charutar Arogya Mandal, Karamsad, India.'}, {'ForeName': 'Archana Somashekhar', 'Initials': 'AS', 'LastName': 'Nimbalkar', 'Affiliation': 'Department of Physiology, Pramukhswami Medical College, Karamsad, India.'}, {'ForeName': 'Somashekhar Marutirao', 'Initials': 'SM', 'LastName': 'Nimbalkar', 'Affiliation': 'Department of Pediatrics, Pramukhswami Medical College, Karamsad, India.'}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-020-0734-x'] 2091,32686874,Platelet function in stroke/transient ischemic attack patients treated with tocotrienol.,"The purpose of this study was to characterize the effects of tocotrienol form of vitamin E (TCT) on platelet function in patients with stroke or transient ischemic attack (TIA). A double blind, randomized, single center phase II clinical trial was conducted comparing placebo (PBO) and 400 and 800 mg TCT daily for a year in 150 patients with a sentinel ischemic stroke or TIA event in the prior 6 months. Platelet function was measured at baseline and then, at 3 month intervals for a year, using light transmission aggregometry. The incidence of aspirin resistance in aspirin-treated patients or platelet inhibition in patients on clopidogrel alone was compared between the three treatment groups. Results showed that in patients taking aspirin and clopidogrel, the incidence of aspirin resistance was significantly decreased from 40% in PBO-treated patients to 9% in the 400 mg TCT group and 25% in the TCT 800 mg group (P = .03). In conclusion, patients on aspirin and clopidogrel had a higher incidence of aspirin resistance than all patients treated with aspirin alone and TCT decreased the frequency of aspirin resistance in this group.",2020,The incidence of aspirin resistance in aspirin-treated patients or platelet inhibition in patients on clopidogrel alone was compared between the three treatment groups.,"['150 patients with a sentinel ischemic stroke or TIA event in the prior 6\xa0months', 'patients with stroke or transient ischemic attack (TIA', 'stroke/transient ischemic attack patients treated with']","['tocotrienol', 'TCT', 'vitamin E (TCT', 'aspirin and clopidogrel', 'aspirin', 'placebo (PBO) and 400 and 800\xa0mg TCT']","['incidence of aspirin resistance', 'aspirin resistance', 'platelet function', 'Platelet function', 'frequency of aspirin resistance']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0949647', 'cui_str': 'Tocotrienols'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C3844106', 'cui_str': '800'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0920267', 'cui_str': 'Platelet aggregation test'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}]",,0.0584769,The incidence of aspirin resistance in aspirin-treated patients or platelet inhibition in patients on clopidogrel alone was compared between the three treatment groups.,"[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Slivka', 'Affiliation': 'Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Cameron', 'Initials': 'C', 'LastName': 'Rink', 'Affiliation': 'Department of Neurosurgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Paoletto', 'Affiliation': 'Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}, {'ForeName': 'Chandan K', 'Initials': 'CK', 'LastName': 'Sen', 'Affiliation': 'Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.'}]",FASEB journal : official publication of the Federation of American Societies for Experimental Biology,['10.1096/fj.201902216RR'] 2092,32686972,Text message-based lifestyle intervention in primary care patients with hypertension: a randomized controlled pilot trial.,"OBJECTIVE To evaluate the feasibility of a randomized controlled pilot study with lifestyle-promoting text messages as a treatment for hypertension in primary care. DESIGN Randomized controlled pilot trial. SETTING Three primary health care centers in southern Sweden. SUBJECTS Sixty patients aged 40-80 years with hypertension were included. MAIN OUTCOME MEASURES Feasibility of the pilot study, i.e. recruitment rate, dropout rate and eligibility criteria. Secondary outcomes were change in blood pressure and other cardiovascular risk factors. METHODS Thirty participants were randomized to the intervention group with four lifestyle-promoting text messages sent every week for six months. The control group received usual care. The baseline and follow-up visits for all 60 patients included measurements of blood pressure, anthropometrics, blood tests and a self-reported questionnaire. RESULTS All feasibility criteria (recruitment rate (≥55%), dropout rate (≤15%) and eligibility (60 eligible patients during the four-month inclusion period) for the pilot study were fulfilled. This means that a larger study with a similar design may be conducted. After six months, there were no significant improvements in cardiovascular risk factors. However, we found favorable trends for all secondary outcomes in the intervention group as compared to the control group. CONCLUSION Lifestyle modification in patients with hypertension is important to reduce cardiovascular risk. However, primary healthcare has limited resources to work with modifying lifestyle habits. This is the first pilot study to test the feasibility of text message-based lifestyle intervention in patients with hypertension in Swedish primary healthcare. Whether significant improvement in cardiovascular risk factors may be achieved in a larger study population remains to be evaluated. Key points This pilot randomized controlled trial (RCT) is the first study to evaluate the feasibility of text message-based lifestyle advice to patients with hypertension in Swedish primary healthcare. •All feasibility criteria for the pilot study were fulfilled. This outcome means that a larger study with a similar design may be conducted. •The study was not powered to find significant changes in cardiovascular risk factors. Nevertheless, after six months we found favorable trends for all secondary outcomes in the intervention group compared to control. •If a future larger study can show significant results, this intervention could serve as a useful tool in everyday primary healthcare.",2020,"After six months, there were no significant improvements in cardiovascular risk factors.","['primary care patients with hypertension', 'hypertension in primary care', 'Sixty patients aged 40-80\u2009years with hypertension were included', 'patients with hypertension', 'patients with hypertension in Swedish primary healthcare', 'Three primary health care centers in southern Sweden', 'Thirty participants']","['text message-based lifestyle advice', 'text message-based lifestyle intervention', 'usual care', 'lifestyle-promoting text messages', 'Text message-based lifestyle intervention']","['dropout rate', 'blood pressure, anthropometrics, blood tests and a self-reported questionnaire', 'blood pressure and other cardiovascular risk factors', 'cardiovascular risk factors']","[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0038996', 'cui_str': 'Swedish language'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C3816446', 'cui_str': '30'}]","[{'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}]",30.0,0.0772197,"After six months, there were no significant improvements in cardiovascular risk factors.","[{'ForeName': 'Beata Borgström', 'Initials': 'BB', 'LastName': 'Bolmsjö', 'Affiliation': 'Department of Clinical Sciences Malmö, Lund University, Sweden.'}, {'ForeName': 'Moa', 'Initials': 'M', 'LastName': 'Wolff', 'Affiliation': 'Department of Clinical Sciences Malmö, Lund University, Sweden.'}, {'ForeName': 'Veronica Milos', 'Initials': 'VM', 'LastName': 'Nymberg', 'Affiliation': 'Department of Clinical Sciences Malmö, Lund University, Sweden.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Sandberg', 'Affiliation': 'Department of Health Sciences, Lund University, Sweden.'}, {'ForeName': 'Patrik', 'Initials': 'P', 'LastName': 'Midlöv', 'Affiliation': 'Department of Clinical Sciences Malmö, Lund University, Sweden.'}, {'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Calling', 'Affiliation': 'Department of Clinical Sciences Malmö, Lund University, Sweden.'}]",Scandinavian journal of primary health care,['10.1080/02813432.2020.1794392'] 2093,32687218,Feasibility of Clinicians Aligning Health Care with Patient Priorities in Geriatrics Ambulatory Care.,"BACKGROUND/OBJECTIVES Aligning healthcare decisions with patients' priorities may improve care for older adults with multiple chronic conditions (MCCs). We conducted a pilot study to assess the feasibility of identifying patient priorities in routine geriatrics care and to compare clinicians' recommendations for patients who did or did not have their priorities identified. DESIGN Retrospective chart review. SETTING Veterans Administration Medical Center Geriatrics Clinic. PARTICIPANTS Older adults with MCCs receiving Patient Priorities Care (PPC; n = 35) were matched with patients receiving usual care (UC; n = 35). Both PPC and UC patients were cared for by three primary care providers (PCPs) in an ambulatory geriatric clinic. INTERVENTION In the PPC group, a clinician facilitator met with each patient to identify their healthcare priorities and transmitted patients' priorities in the electronic health record (EHR). Trained PCPs then sought to align healthcare decisions with patients' priorities. In the UC group, patients received usual care from the same PCPs. MEASUREMENTS We matched patients by clinician seen, patient's age, number of active conditions, medications, hospitalizations, functional status, and prior hospitalizations. EHRs were reviewed to identify care decisions including medications added or stopped, referrals and consults added or avoided, referrals to community services and supports, self-management activities added or avoided, and total number of changes to care. Mean differences in recommended care between PPC and UC patients from the same PCPs were examined. RESULTS Clinician facilitators could identify patient priorities during routine clinic encounters. Compared with patients in the UC group, those in the PPC group had, on average, fewer medications added (P = .05), more referrals to community services and supports (P = .03), and more priorities-aligned self-management tasks added (P = .005). CONCLUSION These findings support the feasibility of identifying and documenting patient priorities during routine encounters. Results also suggest that clinicians use patient priorities in recommending care.",2020,"Compared with patients in the UC group, those in the PPC group had, on average, fewer medications added (P = .05), more referrals to community services and supports (P = .03), and more priorities-aligned self-management tasks added (P = .005). ","['older adults with multiple chronic conditions (MCCs', 'Both PPC and UC patients were cared for by three primary care providers (PCPs) in an ambulatory geriatric clinic', 'patients who did or did not have their priorities identified', 'Clinicians Aligning Health Care with Patient Priorities in Geriatrics Ambulatory Care', 'Older adults with MCCs receiving Patient Priorities Care (PPC; n\u2009=\u200935) were matched with patients receiving usual care (UC; n\u2009=\u200935', 'Veterans Administration Medical Center Geriatrics Clinic']",[],"['number of active conditions, medications, hospitalizations, functional status, and prior hospitalizations']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C3266262', 'cui_str': 'Multiple chronic diseases'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439607', 'cui_str': 'Priorities'}, {'cui': 'C2735026', 'cui_str': 'Primary care provider'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0555968', 'cui_str': 'Elderly assessment clinic'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C2369992', 'cui_str': 'Align'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0002423', 'cui_str': 'Outpatient Care'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}]",[],"[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0332152', 'cui_str': 'Before'}]",35.0,0.0183052,"Compared with patients in the UC group, those in the PPC group had, on average, fewer medications added (P = .05), more referrals to community services and supports (P = .03), and more priorities-aligned self-management tasks added (P = .005). ","[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Freytag', 'Affiliation': 'Center for Innovations in Quality, Effectiveness, and Safety, Houston, Texas, USA.'}, {'ForeName': 'Lilian', 'Initials': 'L', 'LastName': 'Dindo', 'Affiliation': 'Center for Innovations in Quality, Effectiveness, and Safety, Houston, Texas, USA.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Catic', 'Affiliation': 'Michael E. DeBakey VA Medical Center, Houston, Texas, USA.'}, {'ForeName': 'Adrienne L', 'Initials': 'AL', 'LastName': 'Johnson', 'Affiliation': 'Center for Tobacco Research and Intervention, University of Wisconsin-Madison, Madison, Wisconsin, USA.'}, {'ForeName': 'Amber', 'Initials': 'A', 'LastName': 'Bush Amspoker', 'Affiliation': 'Center for Innovations in Quality, Effectiveness, and Safety, Houston, Texas, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Gravier', 'Affiliation': 'Michael E. DeBakey VA Medical Center, Houston, Texas, USA.'}, {'ForeName': 'Darius B', 'Initials': 'DB', 'LastName': 'Dawson', 'Affiliation': 'Center for Innovations in Quality, Effectiveness, and Safety, Houston, Texas, USA.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Tinetti', 'Affiliation': 'Yale University School of Medicine (Geriatrics) and Yale School of Public Health, New Haven, Connecticut, USA.'}, {'ForeName': 'Aanand D', 'Initials': 'AD', 'LastName': 'Naik', 'Affiliation': 'Center for Innovations in Quality, Effectiveness, and Safety, Houston, Texas, USA.'}]",Journal of the American Geriatrics Society,['10.1111/jgs.16662'] 2094,32687220,Empathy as a buffer: How empathy moderates the emotional effects on Preschoolers' sharing.,"This study experimentally investigated how empathy moderated the influence of external emotional stimuli on preschoolers' subsequent sharing behaviour. Children aged 4-6 (N = 218) were randomly presented with one of the video clips that elicited sad, happy, or neutral emotion, and were then asked to play a dictator game with puppet partners. Results revealed that compared to the neutral condition, children with higher empathy increased sharing after induced happiness but did not change sharing after induced sadness; by contrast, children with lower empathy decreased sharing after induced sadness. It appears that empathy may enhance the positive effect of happiness while reducing the negative effect of sadness on sharing behaviour. These findings provide experimental evidence in early childhood to support approaches that emphasize the role of immediate emotions in moral decision-making; critically, such emotional effects vary with individual differences in dispositional empathy.",2020,"Results revealed that compared to the neutral condition, children with higher empathy increased sharing after induced happiness but did not change sharing after induced sadness; by contrast, children with lower empathy decreased sharing after induced sadness.","['Children aged 4-6 (N\xa0=\xa0218', ""preschoolers' subsequent sharing behaviour""]","['video clips that elicited sad, happy, or neutral emotion, and were then asked to play a dictator game with puppet partners', 'external emotional stimuli']",[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517647', 'cui_str': '218'}, {'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0175722', 'cui_str': 'Clip'}, {'cui': 'C0449265', 'cui_str': 'Elicited by'}, {'cui': 'C0085159', 'cui_str': 'Seasonal affective disorder'}, {'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C1172410', 'cui_str': 'ASK protein, human'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0034125', 'cui_str': 'Puppets'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}]",[],218.0,0.0222539,"Results revealed that compared to the neutral condition, children with higher empathy increased sharing after induced happiness but did not change sharing after induced sadness; by contrast, children with lower empathy decreased sharing after induced sadness.","[{'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Guo', 'Affiliation': 'Department of Psychology, School of Social Sciences, Tsinghua University, Beijing, China.'}, {'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Wu', 'Affiliation': 'Department of Psychology, School of Social Sciences, Tsinghua University, Beijing, China.'}]","British journal of psychology (London, England : 1953)",['10.1111/bjop.12466'] 2095,32687266,A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.,"Eflapegrastim (Rolontis ® ) is a novel, long-acting hematopoietic growth factor consisting of a recombinant human granulocyte-colony stimulating factor (rhG-CSF) analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker. We report results from a second pivotal, randomized, open-label, Phase 3 study comparing the efficacy and safety of eflapegrastim to pegfilgrastim for reducing the risk of chemotherapy-induced neutropenia. Patients with Stage I to IIIA early-stage breast cancer (ESBC) were randomized 1:1 to fixed-dose eflapegrastim 13.2 mg (3.6 mg G-CSF) or pegfilgrastim (6 mg G-CSF) administered one day after standard docetaxel/cyclophosphamide (TC) therapy for four cycles. The primary objective was to demonstrate noninferiority (NI) of eflapegrastim compared to pegfilgrastim in mean duration of severe neutropenia (DSN; Grade 4) in Cycle 1. A total of 237 eligible patients were randomized 1:1 to receive either eflapegrastim (n = 118) or pegfilgrastim (n = 119). Cycle 1 severe neutropenia was observed in 20.3% (n = 24) of patients receiving eflapegrastim and 23.5% (n = 28) receiving pegfilgrastim. The DSN of eflapegrastim in Cycle 1 was noninferior to pegfilgrastim with a mean difference of -0.074 days (NI P-value < .0001). Noninferiority was maintained throughout the four treatment cycles (P < .0001 in all cycles). Other efficacy endpoints results were comparable between treatment arms, and adverse events, irrespective of causality and grade, were comparable between treatment arms. The results demonstrate noninferior efficacy and comparable safety for eflapegrastim, at a lower G-CSF dose, vs pegfilgrastim. The potential for the increased potency of eflapegrastim to deliver improved clinical benefit warrants further clinical study.",2020,Noninferiority was maintained throughout the four treatment cycles (P < .0001 in all cycles).,"['Patients with Stage I to IIIA early-stage breast cancer (ESBC', 'patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER', '237 eligible patients']","['pegfilgrastim', 'pegfilgrastim (6\xa0mg G-CSF', 'Eflapegrastim (Rolontis ® ', 'eflapegrastim 13.2\xa0mg', 'docetaxel/cyclophosphamide (TC) therapy', 'eflapegrastim to pegfilgrastim', 'eflapegrastim']","['adverse events, irrespective of causality and grade', 'Cycle 1 severe neutropenia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0304497', 'cui_str': 'Cytotoxic agent'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0521108', 'cui_str': 'Recovering from'}]","[{'cui': 'C1136535', 'cui_str': 'pegfilgrastim'}, {'cui': 'C0079459', 'cui_str': 'Colony-stimulating factor, granulocytic'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C4076002', 'cui_str': 'Cyclophosphamide therapy'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}]",237.0,0.0235253,Noninferiority was maintained throughout the four treatment cycles (P < .0001 in all cycles).,"[{'ForeName': 'Patrick Wayne', 'Initials': 'PW', 'LastName': 'Cobb', 'Affiliation': ""St. Vincent's Frontier Cancer Center, Frontier Cancer Center, Billings, MT, USA.""}, {'ForeName': 'Yong Wha', 'Initials': 'YW', 'LastName': 'Moon', 'Affiliation': 'CHA Bundang Medical Center, Seongnam, Korea.'}, {'ForeName': 'Klára', 'Initials': 'K', 'LastName': 'Mezei', 'Affiliation': 'Szabolcs-Szatmár - Bereg County Hospital, Nyíregyháza, Hungary.'}, {'ForeName': 'István', 'Initials': 'I', 'LastName': 'Láng', 'Affiliation': 'National Institute of Oncology, Budapest, Hungary.'}, {'ForeName': 'Gajanan', 'Initials': 'G', 'LastName': 'Bhat', 'Affiliation': 'Spectrum Pharmaceuticals, Inc, Irvine, CA, USA.'}, {'ForeName': 'Shanta', 'Initials': 'S', 'LastName': 'Chawla', 'Affiliation': 'Spectrum Pharmaceuticals, Inc, Irvine, CA, USA.'}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Hasal', 'Affiliation': 'Spectrum Pharmaceuticals, Inc, Irvine, CA, USA.'}, {'ForeName': 'Lee S', 'Initials': 'LS', 'LastName': 'Schwartzberg', 'Affiliation': 'West Cancer Center, Germantown, TN, USA.'}]",Cancer medicine,['10.1002/cam4.3227'] 2096,32682394,Early versus delayed postoperative oral hydration in children following general anesthesia: a prospective randomized trial.,"BACKGROUND Oral hydration has typically not been administered for between 4 and 6 h postoperative for children's safety in China. But children are more likely to suffer from apnea, crying and agitation, wound bleeding, and other complications during the post-anesthesia recovery period because of thirsty and fear. This Prospective, randomized study sought to assess the compare the early and late oral hydration (EOH and DOH, respectively) in children following general anesthesia, with the goal of assessing relative safety and tolerability and thereby improving patient comfort. METHODS A total of 2000 children corresponding to the American Society of Anesthesiology (ASA) I-III were randomized into an EOH group (n = 1000) and a DOH group (n = 1000). For the former group, children were administered a small amount of drinking water following recovery of the swallowing reflex, and children's vital signs were monitored for 20 min in a postanesthesia care unit (PACU). DOH group patients received water at 4 h following general anesthesia). All patients underwent monitoring to assess their thirst, satisfaction, oropharyngeal discomfort, nausea, and vomiting. RESULTS Complete data were collected from a total of 1770 patients (EOH = 832, DOH = 938) and was compared via chi-squared and t-tests as appropriate. There was no hypoxemia in either group, nor did the incidence of nausea and vomiting differ between the two groups (P > 0.05). The thirst score of the EOH group was significantly decreased relative to the DOH group in the children over 5 years old after drinking for 10 to 20 min (P < 0.05). CONCLUSIONS For children undergoing general anesthesia, a small amount of drinking water in the early stages of recovery will not increase the incidence of nausea, vomiting, or hypoxemia, but will decrease thirst and improve satisfaction. It is important, however, that medical staff carefully monitor the swallowing reflex and vital signs of all children. TRIAL REGISTRATION This study was registered on the Chinese Clinical Trial Registry (ChiCTR-IOR-16008197) (http://www.chictr.org.cn/index.aspx. On April 2, 2016 the first patients was enrolled and on March 31, 2016 the trial was registered).",2020,"The thirst score of the EOH group was significantly decreased relative to the DOH group in the children over 5 years old after drinking for 10 to 20 min (P < 0.05). ","['On April 2, 2016 the first patients was enrolled and on March 31, 2016 the trial was registered', 'children undergoing general anesthesia', '2000 children corresponding to the American Society of Anesthesiology (ASA', 'children following general anesthesia']","['EOH', 'DOH']","['apnea, crying and agitation, wound bleeding', 'nausea, vomiting, or hypoxemia', 'hypoxemia', 'nausea and vomiting', 'thirst, satisfaction, oropharyngeal discomfort, nausea, and vomiting']","[{'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]",[],"[{'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0241742', 'cui_str': 'Wound hemorrhage'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0039971', 'cui_str': 'Thirst'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C2363730', 'cui_str': 'Oropharyngeal discomfort'}]",1770.0,0.080039,"The thirst score of the EOH group was significantly decreased relative to the DOH group in the children over 5 years old after drinking for 10 to 20 min (P < 0.05). ","[{'ForeName': 'Xiaorong', 'Initials': 'X', 'LastName': 'Yin', 'Affiliation': ""Department of Anesthesiology, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, Sichuan Province, 610041, People's Republic of China.""}, {'ForeName': 'Xiaoqi', 'Initials': 'X', 'LastName': 'Zeng', 'Affiliation': ""Department of Anesthesiology, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, Sichuan Province, 610041, People's Republic of China.""}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, Sichuan Province, 610041, People's Republic of China.""}, {'ForeName': 'Binbin', 'Initials': 'B', 'LastName': 'Dong', 'Affiliation': ""Department of Anesthesiology, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, Sichuan Province, 610041, People's Republic of China.""}, {'ForeName': 'Menghang', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': ""Department of Anesthesiology, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, Sichuan Province, 610041, People's Republic of China.""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Jia', 'Affiliation': ""Department of Anesthesiology, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, Sichuan Province, 610041, People's Republic of China.""}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Ye', 'Affiliation': ""Department of Pain Management, West China Hospital, Sichuan University, Chengdu, Sichuan Province, 610041, People's Republic of China. zerodq_hx@163.com.""}]",BMC anesthesiology,['10.1186/s12871-020-01086-8'] 2097,32682494,"Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).","BACKGROUND Glecaprevir-pibrentasvir results in high rates of sustained virological response in patients with chronic hepatitis C virus (HCV) genotype 1-6 infection. Data for glecaprevir-pibrentasvir in non-Japanese Asian patients have been minimal. The aim of these studies was to assess the efficacy and safety of glecaprevir-pibrentasvir in treatment-naive and treatment-experienced Asian patients with chronic HCV genotype 1-6 infection without cirrhosis (VOYAGE-1) and with compensated cirrhosis (VOYAGE-2). METHODS We did two phase 3 studies in treatment-naive and treatment-experienced patients with chronic HCV genotype 1-6 infection. VOYAGE-1 was a randomised, double-blind, placebo-controlled study that recruited patients without cirrhosis at 47 sites across China, South Korea, and Singapore. Randomisation was 2:1 with a fixed block size of three and stratified by geographical region and HCV genotype. Investigators, study site personnel, the study sponsor, and patients were masked to treatment allocation. VOYAGE-2 was a single-arm, open-label study that recruited patients with compensated cirrhosis at 34 sites across China and South Korea. Glecaprevir (300 mg) and pibrentasvir (120 mg) or placebo (VOYAGE-1, 2:1 ratio), administered as three tablets daily, was given for 8 weeks in patients without cirrhosis and for 12 weeks in those with cirrhosis (and for 16 weeks in treatment-experienced patients with genotype 3). The primary efficacy endpoint was the proportion of patients with a sustained virological response, defined as HCV RNA below the lower limit of quantification 12 weeks after the last dose of glecaprevir-pibrentasvir. We analysed efficacy and safety in all patients who received at least one dose of the study drug. These trials are registered with ClinicalTrials.gov, NCT03222583 (VOYAGE-1) and NCT03235349 (VOYAGE-2); both trials have been completed. This Article reports the results of the primary analysis for each study, undertaken when all patients who received glecaprevir-pibrentasvir (during the double-blind period in VOYAGE-1) had been followed up for 12 weeks following their last dose of study drug. Data from the double-blind period for placebo patients in VOYAGE-1 are also summarised. FINDINGS Between Oct 4, 2017, and April 20, 2018, 546 patients with chronic HCV without cirrhosis were randomly assigned to treatment (363 to glecaprevir-pibrentasvir, 183 to placebo) in VOYAGE-1. One patient withdrew consent and did not receive treatment with glecaprevir-pibrentasvir. 352 of 362 patients who received glecaprevir-pibrentasvir achieved SVR12 (97·2% [95% CI 95·5-98·9]). Of 160 patients with compensated cirrhosis who were enrolled in VOYAGE-2 between Sept 29, 2017, and June 14, 2018, 159 of 160 achieved SVR12 (99·4%, 95% CI 98·2-100·0). 20 patients with HCV genotype 3b across both trials received glecaprevir-pibrentasvir; six of these patients were among the 11 patients who did not achieve SVR12. Upper respiratory tract infection was the most common adverse event (35 [10%] of 362 receiving glecaprevir-pibrentasvir and 18 [10%] of 183 receiving placebo in VOYAGE-1; 19 [12%] of 160 in VOYAGE-2). For patients receiving glecaprevir-pibrentasvir, serious adverse events occurred in three (<1%) of 362 patients in VOYAGE-1 and five (3%) of 160 patients in VOYAGE-2. Grade 3-4 adverse events in patients receiving glecaprevir-pibrentasvir occurred in five (1%) of 362 patients in VOYAGE-1 and six (4%) of 160 patients in VOYAGE-2; each type of event was experienced by at most one patient within a study. One patient with cirrhosis discontinued study drug because of an adverse event. INTERPRETATION Glecaprevir-pibrentasvir showed high efficacy and an acceptable safety profile in these studies although responses were less common in the few patients with HCV genotype 3b. The results support the use of glecaprevir-pibrentasvir in these Asian populations. FUNDING AbbVie.",2020,Upper respiratory tract infection was the most common adverse event (35 [10%] of 362 receiving glecaprevir-pibrentasvir and 18 [10%] of 183 receiving placebo in VOYAGE-1; 19 [12%] of 160 in VOYAGE-2).,"['all patients who received at least one dose of the study drug', 'patients with chronic hepatitis C virus (HCV) genotype 1-6 infection', 'Asian patients with chronic HCV genotype 1-6 infection without cirrhosis (VOYAGE-1) and with compensated cirrhosis (VOYAGE-2', 'recruited patients without cirrhosis at 47 sites across China, South Korea, and Singapore', 'patients with compensated cirrhosis at 34 sites across China and South Korea', '546 patients with chronic HCV without cirrhosis', '352 of 362 patients who received', '160 patients with compensated cirrhosis who were enrolled in VOYAGE-2 between Sept 29, 2017, and June 14, 2018, 159 of 160 achieved SVR12 (99·4%, 95% CI 98·2-100·0', '20 patients with HCV genotype 3b across both trials received glecaprevir-pibrentasvir; six of these patients were among the 11 patients who did not achieve SVR12', 'non-Japanese Asian patients']","['glecaprevir-pibrentasvir', 'Glecaprevir', 'Glecaprevir-pibrentasvir', 'glecaprevir-pibrentasvir achieved SVR12', 'pibrentasvir (120 mg) or placebo', 'placebo']","['efficacy and safety', 'Upper respiratory tract infection', 'proportion of patients with a sustained virological response, defined as HCV RNA', 'serious adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0013175', 'cui_str': 'Clinical drug trial'}, {'cui': 'C0524910', 'cui_str': 'Chronic hepatitis C'}, {'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0079500', 'cui_str': 'Hepacivirus'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C3805156', 'cui_str': 'Chronic hepatitis C virus genotype 1'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}, {'cui': 'C1608426', 'cui_str': 'Compensated cirrhosis'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0037173', 'cui_str': 'Singapore'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0205432', 'cui_str': 'Compensated'}, {'cui': 'C1533728', 'cui_str': 'Hepatitis C virus genotype determination'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C4519575', 'cui_str': 'glecaprevir and pibrentasvir'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}]","[{'cui': 'C4519575', 'cui_str': 'glecaprevir and pibrentasvir'}, {'cui': 'C4519536', 'cui_str': 'glecaprevir'}, {'cui': 'C4519537', 'cui_str': 'pibrentasvir'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0041912', 'cui_str': 'Upper respiratory infection'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0369335', 'cui_str': 'Hepatitis C virus RNA'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",20.0,0.347295,Upper respiratory tract infection was the most common adverse event (35 [10%] of 362 receiving glecaprevir-pibrentasvir and 18 [10%] of 183 receiving placebo in VOYAGE-1; 19 [12%] of 160 in VOYAGE-2).,"[{'ForeName': 'Lai', 'Initials': 'L', 'LastName': 'Wei', 'Affiliation': ""Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China; Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.""}, {'ForeName': 'Guiqiang', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'Peking University First Hospital, Beijing, China.'}, {'ForeName': 'Negar N', 'Initials': 'NN', 'LastName': 'Alami', 'Affiliation': 'AbbVie, North Chicago, IL, USA.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Xie', 'Affiliation': 'Center of Liver Diseases, Beijing Di Tan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Jeong', 'Initials': 'J', 'LastName': 'Heo', 'Affiliation': 'Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Busan, South Korea.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Xie', 'Affiliation': 'Department of Infectious Diseases, Rui Jin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Mingxiang', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': ""Shenyang Sixth People's Hospital, Shenyang, China.""}, {'ForeName': 'Yoon Jun', 'Initials': 'YJ', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Seng Gee', 'Initials': 'SG', 'LastName': 'Lim', 'Affiliation': 'National University Healthcare System, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.'}, {'ForeName': 'Linda M', 'Initials': 'LM', 'LastName': 'Fredrick', 'Affiliation': 'AbbVie, North Chicago, IL, USA.'}, {'ForeName': 'Wenjing', 'Initials': 'W', 'LastName': 'Lu', 'Affiliation': 'AbbVie, North Chicago, IL, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'AbbVie, North Chicago, IL, USA.'}, {'ForeName': 'Hari V', 'Initials': 'HV', 'LastName': 'Kalluri', 'Affiliation': 'AbbVie, North Chicago, IL, USA.'}, {'ForeName': 'Preethi', 'Initials': 'P', 'LastName': 'Krishnan', 'Affiliation': 'AbbVie, North Chicago, IL, USA.'}, {'ForeName': 'Rakesh', 'Initials': 'R', 'LastName': 'Tripathi', 'Affiliation': 'AbbVie, North Chicago, IL, USA.'}, {'ForeName': 'Niloufar', 'Initials': 'N', 'LastName': 'Mobashery', 'Affiliation': 'AbbVie, North Chicago, IL, USA.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Burroughs', 'Affiliation': 'AbbVie, North Chicago, IL, USA.'}, {'ForeName': 'Armen', 'Initials': 'A', 'LastName': 'Asatryan', 'Affiliation': 'AbbVie, North Chicago, IL, USA.'}, {'ForeName': 'Jidong', 'Initials': 'J', 'LastName': 'Jia', 'Affiliation': 'Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Jinlin', 'Initials': 'J', 'LastName': 'Hou', 'Affiliation': 'Department of Infectious Diseases and Hepatology Unit, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China. Electronic address: jlhousmu@163.com.'}]",The lancet. Gastroenterology & hepatology,['10.1016/S2468-1253(20)30086-8'] 2098,32682507,Heated fennel therapy promotes the recovery of gastrointestinal function in patients after complex abdominal surgery: A single-center prospective randomized controlled trial in China.,"BACKGROUND Postoperative gastrointestinal dysfunction remains a major determinant of the duration of stay after complex abdominal surgery. This study was performed to evaluate the effectiveness of heated fennel therapy in accelerating the recovery of gastrointestinal function. METHODS This surgeon-blinded, prospective randomized controlled study included 381 patients with hepatobiliary, pancreatic, and gastric tumors who were divided into 2 groups. The patients in the experimental groups received heated fennel therapy, and those in the control groups received heated rice husk therapy. We compared the baseline characteristics, time to first postoperative flatus and defecation, fasting time, duration of postoperative hospital stay, grading of abdominal pain, classification of abdominal distension, inflammatory markers, and nutritional status indicators. RESULTS The time to first flatus and first defecation and the fasting time were statistically significantly less in the heated fennel therapy group than those in the control groups (P < .05 each); and abdominal distension was also relieved in the experimental groups (P < .001). Heated fennel therapy had no obvious beneficial effect on inflammatory markers but improved the serum albumin (ALB) level of the patients at postop day 9 (P < .001). Among the patients with alimentary tract reconstruction, those in the heated fennel therapy group had a clinically important, lesser hospital stay than those in the control group (9.2 5 ± 5.1 versus 11.1 ± 6.4; P < .023). CONCLUSION Heated fennel therapy facilitated the gastrointestinal motility function of patients early postoperatively.",2020,The time to first flatus and first defecation and the fasting time were statistically significantly less in the heated fennel therapy group than those in the control groups (P < .05 each); and abdominal distension was also relieved in the experimental groups (P < .001).,"['381 patients with hepatobiliary, pancreatic, and gastric tumors who were divided into 2 groups', 'patients after complex abdominal surgery']","['Heated fennel therapy', 'heated rice husk therapy', 'heated fennel therapy']","['time to first flatus and first defecation and the fasting time', 'gastrointestinal motility function', 'recovery of gastrointestinal function', 'abdominal distension', 'inflammatory markers', 'hospital stay', 'baseline characteristics, time to first postoperative flatus and defecation, fasting time, duration of postoperative hospital stay, grading of abdominal pain, classification of abdominal distension, inflammatory markers, and nutritional status indicators', 'serum albumin (ALB) level']","[{'cui': 'C4708787', 'cui_str': '381'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030274', 'cui_str': 'Pancreatic structure'}, {'cui': 'C0038356', 'cui_str': 'Neoplasm of stomach'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}]","[{'cui': 'C0015833', 'cui_str': 'Fennel extract'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0035567', 'cui_str': 'Rice'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0017184', 'cui_str': 'Gastrointestinal Motility'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0000731', 'cui_str': 'Swollen abdomen'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0523465', 'cui_str': 'Albumin measurement, serum'}]",381.0,0.0272158,The time to first flatus and first defecation and the fasting time were statistically significantly less in the heated fennel therapy group than those in the control groups (P < .05 each); and abdominal distension was also relieved in the experimental groups (P < .001).,"[{'ForeName': 'Baiyang', 'Initials': 'B', 'LastName': 'Chen', 'Affiliation': 'Department of General Surgery, Research Center of Digestive Diseases, Zhongnan Hospital of Wuhan University, Wuhan, PR China.'}, {'ForeName': 'Yukun', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': 'Department of General Surgery, Research Center of Digestive Diseases, Zhongnan Hospital of Wuhan University, Wuhan, PR China.'}, {'ForeName': 'Yusha', 'Initials': 'Y', 'LastName': 'Xiao', 'Affiliation': 'Department of General Surgery, Research Center of Digestive Diseases, Zhongnan Hospital of Wuhan University, Wuhan, PR China.'}, {'ForeName': 'Deliang', 'Initials': 'D', 'LastName': 'Guo', 'Affiliation': 'Department of General Surgery, Research Center of Digestive Diseases, Zhongnan Hospital of Wuhan University, Wuhan, PR China.'}, {'ForeName': 'Pengpeng', 'Initials': 'P', 'LastName': 'Liu', 'Affiliation': 'Department of General Surgery, Research Center of Digestive Diseases, Zhongnan Hospital of Wuhan University, Wuhan, PR China.'}, {'ForeName': 'Yueming', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': 'Department of General Surgery, Research Center of Digestive Diseases, Zhongnan Hospital of Wuhan University, Wuhan, PR China.'}, {'ForeName': 'Quan', 'Initials': 'Q', 'LastName': 'Sun', 'Affiliation': 'Department of General Surgery, Research Center of Digestive Diseases, Zhongnan Hospital of Wuhan University, Wuhan, PR China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Jiang', 'Affiliation': 'Department of General Surgery, Research Center of Digestive Diseases, Zhongnan Hospital of Wuhan University, Wuhan, PR China.'}, {'ForeName': 'Zhisu', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of General Surgery, Research Center of Digestive Diseases, Zhongnan Hospital of Wuhan University, Wuhan, PR China.'}, {'ForeName': 'Quanyan', 'Initials': 'Q', 'LastName': 'Liu', 'Affiliation': 'Department of General Surgery, General Hospital of Tianjin Medical University, Tianjin, PR China. Electronic address: spsslqy@vip.126.com.'}]",Surgery,['10.1016/j.surg.2020.05.040'] 2099,32682552,"Evaluation of the intratidal compliance profile at different PEEP levels in children with healthy lungs: a prospective, crossover study.","BACKGROUND Optimal intraoperative lung protective ventilation (LPV) strategies in young children are largely under-explored. Individualised PEEP levels are likely to contribute to optimal lung protection. We determined optimal PEEP levels in young children during general anaesthesia by evaluating changes in intratidal compliance with varying PEEP. METHODS Children aged ≤6 yr were enrolled in this prospective interventional study. After induction of general anaesthesia and neuromuscular block (rocuronium), children were randomly assigned to be mechanically ventilated at each of three PEEP levels for 15 min each: 5, 8, and 12 cm H 2 O PEEP (PEEP 5/8/12 ). Haemodynamic and respiratory data were recorded at each PEEP level. Intratidal volume-compliance was classified into one of six compliance profiles (increasing/decreasing/horizontal [plateau]/increasing-horizontal/horizontal-decreasing/increasing-horizontal-decreasing) at each PEEP level. The primary outcome was intratidal compliance at different PEEP levels. RESULTS Forty-seven children were enrolled (40% female; median age: 2.5 yr [0.9-3.7]). Mean airway pressure progressively increased from 7.6 cm H 2 O (0.5) at PEEP 5 , 10.5 cm H 2 O (0.9) at PEEP 8 to 14.3 cm H 2 O (0.5) PEEP 12 (P<0.001). Mean driving pressure was lower at PEEP 12 (6.3 cm H 2 O [1.1]), compared with PEEP 8 (6.5 cm H 2 O [1.1]) and PEEP 5 (7.0 cm H 2 O [1.5]; P=0.004 for trend). Intratidal compliance increased in 31/47 (66%) children at PEEP 5 , but was less likely with PEEP 8 (9/47; 19.1%) and was absent at PEEP 12 . At PEEP 8 , plateaued compliance was most frequent (16/46; 34.8%). At PEEP 12 , decreasing compliance occurred most frequently (32/46; 69.6%). CONCLUSIONS Intratidal compliance at different PEEP levels varied widely in young children under general anaesthesia. These data suggest that individualised PEEP levels are required for optimal lung protection in children. CLINICAL TRIAL REGISTRATION NCT03533296.",2020,"Mean airway pressure progressively increased from 7.6 cm H 2 O (0.5) at PEEP 5 , 10.5 cm H 2 O (0.9) at PEEP 8 to 14.3 cm","['young children under general anaesthesia', 'young children', 'Forty-seven children were enrolled (40% female; median age: 2.5 yr [0.9-3.7', 'children with healthy lungs', 'Children aged ≤6 yr']","['general anaesthesia and neuromuscular block (rocuronium', 'intraoperative lung protective ventilation (LPV']","['Intratidal compliance', 'Mean airway pressure progressively', 'Haemodynamic and respiratory data', 'Mean driving pressure', 'intratidal compliance at different PEEP levels']","[{'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C4068881', 'cui_str': '0.9'}, {'cui': 'C4517696', 'cui_str': '3.7'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}]","[{'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0235062', 'cui_str': 'Induction of neuromuscular blockade'}, {'cui': 'C0209337', 'cui_str': 'Rocuronium'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}]","[{'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0032740', 'cui_str': 'Positive end-expiratory pressure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",47.0,0.0709234,"Mean airway pressure progressively increased from 7.6 cm H 2 O (0.5) at PEEP 5 , 10.5 cm H 2 O (0.9) at PEEP 8 to 14.3 cm","[{'ForeName': 'Ji-Hyun', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Sang-Hwan', 'Initials': 'SH', 'LastName': 'Ji', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Hyung-Chul', 'Initials': 'HC', 'LastName': 'Lee', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Department of Anaesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Young-Eun', 'Initials': 'YE', 'LastName': 'Jang', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Eun-Hee', 'Initials': 'EH', 'LastName': 'Kim', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Hee-Soo', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Department of Anaesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jin-Tae', 'Initials': 'JT', 'LastName': 'Kim', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Department of Anaesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: jintae73@gmail.com.'}]",British journal of anaesthesia,['10.1016/j.bja.2020.06.046'] 2100,32682554,Evaluation of an enhanced pulse oximeter auditory display: a simulator study.,"BACKGROUND We compared anaesthetists' ability to identify haemoglobin oxygen saturation (SpO 2 ) levels using two auditory displays: one based on a standard pulse oximeter display (varying pitch plus alarm) and the other enhanced with additional sound properties (varying pitch plus tremolo and acoustic brightness) to differentiate SpO 2 ranges. METHODS In a counter-balanced crossover study in a simulator, 20 experienced anaesthetists supervised a junior colleague (an actor) managing two airway surgery scenarios: once while using the enhanced auditory display and once while using a standard auditory display. Participants were distracted with other tasks such as paperwork and workplace interruptions, but were required to identify when SpO 2 transitioned between pre-set ranges (target, low, critical) and when other vital signs transitioned out of a target range. They also identified the range once a transition had occurred. Visual displays were available for all monitored vital signs, but the numerical value for SpO 2 was excluded. RESULTS Participants were more accurate and faster at detecting transitions to and from the target SpO 2 range when using the enhanced display (100.0%, 3.3 s) than when using the standard display plus alarm (73.2%, 27.4 s) (P<0.001 and P=0.004, respectively). They were also more accurate at identifying the SpO 2 range once a transition had occurred when using the enhanced display (100.0%) than when using the standard display plus alarm (57.1%; P<0.001). CONCLUSIONS The enhanced auditory display helps anaesthetists judge SpO 2 levels more effectively than current auditory displays and may facilitate 'eyes-free' monitoring.",2020,"RESULTS Participants were more accurate and faster at detecting transitions to and from the target SpO 2 range when using the enhanced display (100.0%, 3.3 s) than when using the standard display plus alarm (73.2%, 27.4 s) (P<0.001 and P=0.004, respectively).",[],['anaesthetists supervised a junior colleague (an actor) managing two airway surgery scenarios'],['haemoglobin oxygen saturation (SpO 2 ) levels'],[],"[{'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0335083', 'cui_str': 'Actor'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0651879,"RESULTS Participants were more accurate and faster at detecting transitions to and from the target SpO 2 range when using the enhanced display (100.0%, 3.3 s) than when using the standard display plus alarm (73.2%, 27.4 s) (P<0.001 and P=0.004, respectively).","[{'ForeName': 'Estrella', 'Initials': 'E', 'LastName': 'Paterson', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Queensland, Australia. Electronic address: estrella.paterson@uqconnect.edu.au.'}, {'ForeName': 'Penelope M', 'Initials': 'PM', 'LastName': 'Sanderson', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Queensland, Australia; School of Information Technology and Electrical Engineering, The University of Queensland, St Lucia, Queensland, Australia; School of Clinical Medicine, The University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Isaac S', 'Initials': 'IS', 'LastName': 'Salisbury', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Felicity P', 'Initials': 'FP', 'LastName': 'Burgmann', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Ismail', 'Initials': 'I', 'LastName': 'Mohamed', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Loeb', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Queensland, Australia; Department of Anesthesiology, University of Florida College of Medicine, Gainesville, FL, USA.'}, {'ForeName': 'Neil A B', 'Initials': 'NAB', 'LastName': 'Paterson', 'Affiliation': ""School of Clinical Medicine, The University of Queensland, St Lucia, Queensland, Australia; Anaesthesia and Pain Management Services, Queensland Children's Hospital, South Brisbane, Queensland, Australia.""}]",British journal of anaesthesia,['10.1016/j.bja.2020.05.038'] 2101,32682669,Postsurgical Follow-Up Phone Calls: Worth the Investment?,"PURPOSE To analyze differences in health confidence levels regarding discharge instructions between two groups of same-day surgery patients. DESIGN Comparative and descriptive design. METHODS Phone surveys to two groups: those who received follow-up phone calls from a registered nurse (RN) and those who received standard care instructions at discharge only. FINDINGS In 74 same-day surgery patients (n = 37 per group), all participants expressed high health confidence in implementing discharge instructions. Results revealed no higher health confidence levels in patients who received RN follow-up phone calls, no difference between groups attending postoperative appointments, and no relationships between subject demographics, health confidence level, and postoperative complications between groups. CONCLUSIONS The use of specialized RNs to conduct postoperative phone calls may not be cost effective. When RNs provide excellent instructions to patients in person, it may lead to sufficient patient health confidence. Personal and nurse-provided education should be considered a standard, and the outcomes of costly follow-up phone calls should be examined.",2020,"Results revealed no higher health confidence levels in patients who received RN follow-up phone calls, no difference between groups attending postoperative appointments, and no relationships between subject demographics, health confidence level, and postoperative complications between groups. ","['two groups of same-day surgery patients', 'Phone surveys to two groups: those who received follow-up phone calls from a registered nurse (RN) and those who received standard care instructions at discharge only']",[],"['subject demographics, health confidence level, and postoperative complications', 'health confidence levels']","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0282046', 'cui_str': 'Day Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0687673', 'cui_str': 'Registered nurse'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C3871203', 'cui_str': 'At discharge'}]",[],"[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}]",,0.0468988,"Results revealed no higher health confidence levels in patients who received RN follow-up phone calls, no difference between groups attending postoperative appointments, and no relationships between subject demographics, health confidence level, and postoperative complications between groups. ","[{'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Berardinelli', 'Affiliation': 'Mather/MOSC/Seidman PACUs, University Hospitals Cleveland Medical Center, Cleveland, OH. Electronic address: amyberardinelli@icloud.com.'}, {'ForeName': 'Esther I', 'Initials': 'EI', 'LastName': 'Bernhofer', 'Affiliation': 'Frances Payne Bolton School of Nursing, Case Western Reserve University Samson Pavilion, Cleveland, OH.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.03.014'] 2102,32682696,Electronic Decision Support for Management of CKD in Primary Care: A Pragmatic Randomized Trial.,"RATIONALE & OBJECTIVE Most adults with chronic kidney disease (CKD) in the U.S. are cared for by primary care providers (PCP). We evaluated the feasibility and preliminary effectiveness of an electronic clinical decision support system (eCDSS) within the electronic health record (EHR) with or without pharmacist follow-up to improve management of CKD in primary care. STUDY DESIGN Pragmatic, cluster randomized trial SETTING & PARTICIPANTS: 524 adults with confirmed eGFRCr 30-59 mL/min/1.73m 2 cared for by 80 PCPs at the University of California San Francisco. EHR data were used for patient identification, intervention deployment, and outcomes ascertainment. INTERVENTIONS Each PCP's eligible patients were randomized as a group into one of three treatment arms: 1) usual care, 2) eCDSS: testing of creatinine, cystatin C and urinary albumin-to-creatinine ratio with individually tailored guidance for PCPs on blood pressure, potassium and proteinuria management, cardiovascular risk-reduction, and patient education, or 3) eCDSS plus pharmacist counseling (eCDSS-PLUS). OUTCOMES Primary clinical outcome was change in blood pressure over 12 months. Secondary outcomes were PCP awareness of CKD as well as use of ACEi/ARB and statin. RESULTS All 80 eligible PCPs participated. Mean patient age was 70, 47% were non-white, mean eGFRcr was 56 +/-0.6 mL/min/1.73m 2 . Among patients receiving eCDSS with or without pharmacist counseling (n=336), 178 (53%) completed labs and 138 (41%) had labs followed by a PCP visit with eCDSS deployment. eCDSS was opened by the PCP for 102 (74%) patients, with at least one suggested order signed for 83 of these 102 (81%). Changes in systolic blood pressure were -2.1 ± 1.5 mmHg with usual care, -2.8 ± 1.8 with eCDSS and -1.1 ± 1.1 with eCDSS-PLUS (p=0.69). PCP awareness of CKD was 16% with usual care, 26% with eCDSS, and 32% for eCDSS -PLUS (p=0.09). In as-treated analyses, PCP awareness of CKD was significantly greater with eCDSS and eCDSS-PLUS (73% and 69%) vs. usual care (47%), p<0.01. LIMITATIONS Recruitment of smaller than intended sample size, and limited uptake of the testing component of the intervention. CONCLUSIONS While we were unable to demonstrate the effectiveness of eCDSS to lower blood pressure, and uptake of the eCDSS was limited by low testing rates, eCDSS utilization was high once labs were available and was associated with higher PCP awareness of CKD.",2020,"PCP awareness of CKD was 16% with usual care, 26% with eCDSS, and 32% for eCDSS -PLUS (p=0.09).","[' 524 adults with confirmed eGFRCr 30-59 mL/min/1.73m 2 cared for by 80 PCPs at the University of California San Francisco', 'Mean patient age was 70, 47% were non-white, mean eGFRcr was 56 +/-0.6', 'Primary Care', 'All 80 eligible PCPs participated', 'patients receiving eCDSS with or without pharmacist counseling (n=336), 178 (53%) completed labs and 138 (41%) had labs followed by a PCP visit with eCDSS deployment', 'adults with chronic kidney disease (CKD) in the U.S. are cared for by primary care providers (PCP']","['eCDSS', 'electronic clinical decision support system (eCDSS', 'usual care, 2) eCDSS: testing of creatinine, cystatin C and urinary albumin-to-creatinine ratio with individually tailored guidance for PCPs on blood pressure, potassium and proteinuria management, cardiovascular risk-reduction, and patient education, or 3) eCDSS plus pharmacist counseling (eCDSS-PLUS']","['blood pressure', 'blood pressure, and uptake of the eCDSS', 'PCP awareness of CKD', 'systolic blood pressure', 'PCP awareness of CKD as well as use of ACEi/ARB and statin']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0036152', 'cui_str': 'San Francisco'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C4068883', 'cui_str': '0.6'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0525070', 'cui_str': 'Clinical Decision Support Systems'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C2735026', 'cui_str': 'Primary care provider'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0525070', 'cui_str': 'Clinical Decision Support Systems'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0071744', 'cui_str': 'Cystatin C'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0032821', 'cui_str': 'Potassium'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0030688', 'cui_str': 'Patient education'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0525070', 'cui_str': 'Clinical Decision Support Systems'}, {'cui': 'C2735026', 'cui_str': 'Primary care provider'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0521942', 'cui_str': 'Angiotensin II receptor antagonist'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}]",524.0,0.0628094,"PCP awareness of CKD was 16% with usual care, 26% with eCDSS, and 32% for eCDSS -PLUS (p=0.09).","[{'ForeName': 'Carmen A', 'Initials': 'CA', 'LastName': 'Peralta', 'Affiliation': 'Department of Medicine, University of California San Francisco; The Kidney Health Research Collaborative, University of California San Francisco; Cricket Health, Inc. Electronic address: carmenalicia.peralta@ucsf.edu.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Livaudais-Toman', 'Affiliation': 'Department of Medicine, University of California San Francisco; Multiethnic Health Equity Research Center, University of California San Francisco.'}, {'ForeName': 'Marilyn', 'Initials': 'M', 'LastName': 'Stebbins', 'Affiliation': 'Department of Clinical Pharmacy, University of California San Francisco.'}, {'ForeName': 'Lowell', 'Initials': 'L', 'LastName': 'Lo', 'Affiliation': 'Department of Medicine, University of California San Francisco.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Robinson', 'Affiliation': 'Department of Medicine, University of California San Francisco.'}, {'ForeName': 'Sarita', 'Initials': 'S', 'LastName': 'Pathak', 'Affiliation': 'Department of Medicine, University of California San Francisco; Multiethnic Health Equity Research Center, University of California San Francisco.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Scherzer', 'Affiliation': 'Department of Medicine, University of California San Francisco; The Kidney Health Research Collaborative, University of California San Francisco.'}, {'ForeName': 'Leah S', 'Initials': 'LS', 'LastName': 'Karliner', 'Affiliation': 'Department of Medicine, University of California San Francisco; Multiethnic Health Equity Research Center, University of California San Francisco.'}]",American journal of kidney diseases : the official journal of the National Kidney Foundation,['10.1053/j.ajkd.2020.05.013'] 2103,32682705,Evaluation of Three Field Rewarming Techniques During Cold Weather Military Training.,"INTRODUCTION The purpose of this work was to evaluate the effectiveness of 3 rewarming techniques to determine how warfighters, and perhaps other populations in wilderness environments, should prioritize field rewarming options after a brief accidental immersion in cold water. METHODS As part of a cold weather military training exercise, 31 military personnel (mean±SD age: 26±5 y, height: 180±10 cm, weight: 83.2±10.9 kg) completed a 10-min immersion in cold (0°C) water and subsequently rewarmed for 60 min using 3 different field rewarming techniques (sleeping bag, sleeping bag + warm fluids, or exercise). Heart rate, core and skin temperatures, thermal and shivering sensations, and manual dexterity (intravenous setup and insertion) were measured during the training exercise. RESULTS Cold water immersion decreased core temperature (pre: 37.4±0.4; post: 36.4±1.0°C; P<0.001) and mean skin temperature (pre: 27.9±1.3; post: 15.6±1.8°C; P<0.001) and impaired manual dexterity (intravenous insertion time, pre: 71±12, post: 166±48 s; P<0.001). Recovery from mild cold stress was similar among all 3 rewarming techniques for all measurements. CONCLUSIONS Findings suggesting similar rewarming responses in field settings are beneficial for the warfighter, and perhaps others, in that rewarming options exist and can be implemented with no compromise in recovery from cold stress.",2020,"RESULTS Cold water immersion decreased core temperature (pre: 37.4±0.4; post: 36.4±1.0°C; P<0.001) and mean skin temperature","['31 military personnel (mean±SD age: 26±5 y, height: 180±10 cm, weight: 83.2±10.9 kg) completed a']","['Field Rewarming Techniques', '10-min immersion in cold (0°C) water and subsequently rewarmed for 60 min using 3 different field rewarming techniques (sleeping bag, sleeping bag\xa0+ warm fluids, or exercise']","['core temperature', 'manual dexterity (intravenous insertion time, pre', 'mean skin temperature', 'Heart rate, core and skin temperatures, thermal and shivering sensations, and manual dexterity (intravenous setup and insertion']","[{'cui': 'C0026126', 'cui_str': 'Military personnel'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0020940', 'cui_str': 'Immersion'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0179196', 'cui_str': 'Bag'}, {'cui': 'C0184348', 'cui_str': 'Warmer'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0565699', 'cui_str': 'Ability to perform general manipulative activities'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037294', 'cui_str': 'Temperature of skin'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0036973', 'cui_str': 'Shivering or rigors'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}]",,0.0836842,"RESULTS Cold water immersion decreased core temperature (pre: 37.4±0.4; post: 36.4±1.0°C; P<0.001) and mean skin temperature","[{'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Jones', 'Affiliation': 'Leidos, Inc., San Diego, CA; Warfighter Performance Department, Naval Health Research Center, San Diego, CA. Electronic address: douglas.m.jones@leidos.com.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Bowles', 'Affiliation': 'Marine Corps Mountain Warfare Training Center, Bridgeport, CA.'}, {'ForeName': 'Dale', 'Initials': 'D', 'LastName': 'Bergquist-Turori', 'Affiliation': 'Leidos, Inc., San Diego, CA; Warfighter Performance Department, Naval Health Research Center, San Diego, CA.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Cooper', 'Affiliation': 'Leidos, Inc., San Diego, CA; Warfighter Performance Department, Naval Health Research Center, San Diego, CA.'}, {'ForeName': 'Kaitlyn', 'Initials': 'K', 'LastName': 'Rostomily', 'Affiliation': 'Leidos, Inc., San Diego, CA; Warfighter Performance Department, Naval Health Research Center, San Diego, CA.'}, {'ForeName': 'Carina', 'Initials': 'C', 'LastName': 'Pautz', 'Affiliation': 'Innovative Employee Solutions, San Diego, CA.'}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Heaney', 'Affiliation': 'Warfighter Performance Department, Naval Health Research Center, San Diego, CA.'}]",Wilderness & environmental medicine,['10.1016/j.wem.2020.04.002'] 2104,32682735,Effect of an Informative Video on Anxiety and Hemodynamic Parameters in Patients Requiring Mandibular Third Molar Extraction: A Randomized Clinical Trial.,"PURPOSE The purpose was to determine the effect of watching an informative video about mandibular third molar (M3M) removal on patient anxiety and hemodynamic parameters. PATIENTS AND METHODS A randomized controlled clinical trial was carried out in healthy patients (aged between 18 and 40 years) requiring M3M extraction under local anesthesia. Patients with previous tooth extractions, psychiatric disorders, or cardiac problems or patients undergoing anxiolytic or antidepressant drug treatment were excluded. Participants were randomized into 2 groups according to whether they watched an informative video about the surgical procedure (video group) or not (control group). The primary outcome variable was the difference between groups regarding patient anxiety assessed with the State-Trait Anxiety Inventory (STAI) and the Modified Dental Anxiety Scale (MDAS). The secondary outcome variables were hemodynamic parameters recorded during different moments of the surgical procedure. Descriptive, bivariate, and multivariate analyses were performed, and a repeated-measures mixed model was generated. Statistical significance was considered for P < .05. RESULTS Fifty patients referred for M3M extraction met the inclusion criteria. The final data analysis was based on 47 patients: 25 from the video group and 22 controls. The bivariate analysis showed the video group to have a significant decrease in anxiety as measured by the MDAS (P = .006; 95% confidence interval [CI], -4.1 to -0.7) and STAI-State (P = .003; 95% CI, -13.7 to -0.7). A significantly lower heart rate was likewise found in the video group (χ 2  = 4.30, df = 1, P = .038). The linear regression analysis adjusting for the STAI-Trait also showed lower dental anxiety measured by the MDAS in the video group (P = .023; 95% CI, 0.32 to 4.14). CONCLUSIONS Providing preoperative information through an informative video about M3M removal significantly reduces patient anxiety and heart rate during the surgical procedure.",2020,"A significantly lower heart rate was likewise found in the video group (χ 2  = 4.30, df = 1, P = .038).","['47 patients: 25 from the video group and 22 controls', 'Patients Requiring Mandibular Third Molar Extraction', 'Fifty patients referred for M3M extraction met the inclusion criteria', 'healthy patients (aged between 18 and 40\xa0years) requiring M3M extraction under local anesthesia', 'Patients with previous tooth extractions, psychiatric disorders, or cardiac problems or patients undergoing anxiolytic or antidepressant drug treatment were excluded']","['informative video about the surgical procedure (video group) or not (control group', 'watching an informative video about mandibular third molar (M3M) removal', 'Informative Video']","['patient anxiety and heart rate', 'anxiety', 'hemodynamic parameters recorded during different moments of the surgical procedure', 'Anxiety and Hemodynamic Parameters', 'dental anxiety', 'heart rate', 'patient anxiety assessed with the State-Trait Anxiety Inventory (STAI) and the Modified Dental Anxiety Scale (MDAS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026369', 'cui_str': 'Structure of wisdom tooth'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1720162', 'cui_str': 'Under local anesthesia'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0040440', 'cui_str': 'Tooth extraction'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0040616', 'cui_str': 'Anxiolytic agent'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026369', 'cui_str': 'Structure of wisdom tooth'}, {'cui': 'C0015252', 'cui_str': 'Removal'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0085380', 'cui_str': 'Dental phobia'}, {'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",50.0,0.095681,"A significantly lower heart rate was likewise found in the video group (χ 2  = 4.30, df = 1, P = .038).","[{'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Toledano-Serrabona', 'Affiliation': 'Fellow of the Master Degree of Oral Surgery and Implantology, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Alba', 'Initials': 'A', 'LastName': 'Sánchez-Torres', 'Affiliation': 'Associate Professor of Oral Surgery, Master Degree Program in Oral Surgery and Implantology, School of Medicine and Health Sciences, University of Barcelona; and Researcher, IDIBELL Institute, Barcelona, Spain.'}, {'ForeName': 'Octavi', 'Initials': 'O', 'LastName': 'Camps-Font', 'Affiliation': 'Associate Professor of Oral Surgery, Master Degree Program in Oral Surgery and Implantology, School of Medicine and Health Sciences, University of Barcelona; and Researcher, IDIBELL Institute, Barcelona, Spain.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Figueiredo', 'Affiliation': 'Lecturer in Oral Surgery and Coordinator, Master Degree Program in Oral Surgery and Implantology, School of Medicine and Health Sciences, University of Barcelona; and Researcher, IDIBELL Institute, Barcelona, Spain. Electronic address: ruipfigueiredo@hotmail.com.'}, {'ForeName': 'Cosme', 'Initials': 'C', 'LastName': 'Gay-Escoda', 'Affiliation': 'Chairman and Professor of Oral and Maxillofacial Surgery, School of Medicine and Health Sciences, University of Barcelona; Director, Master Degree Program in Oral Surgery and Implantology, EFHRE International University/FUCSO; Coordinator/Researcher, IDIBELL Institute; and Head, Department of Oral Surgery, Implantology and Maxillofacial Surgery, Teknon Medical Center, Barcelona, Spain.'}, {'ForeName': 'Eduard', 'Initials': 'E', 'LastName': 'Valmaseda-Castellón', 'Affiliation': 'Senior Lecturer in Oral Surgery and Director, Master Degree Program in Oral Surgery and Implantology, School of Medicine and Health Sciences, University of Barcelona; and Researcher, IDIBELL Institute, Barcelona, Spain.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2020.06.024'] 2105,32682770,"""A randomized trial of initiation of chronic non-invasive mechanical ventilation at home vs in-hospital in patients with Neuromuscular Disease and thoracic cage disorder"": The Dutch Homerun Trial.","BACKGROUND There is an increasing demand for Home Mechanical Ventilation (HMV) in patients with chronic respiratory insufficiency. At present, Non-invasive Ventilation (NIV) is exclusively initiated in a clinical setting at all 4 centres for HMV in The Netherlands. In addition to its high societal costs and patient discomfort, commencing HMV is often delayed due to lack of hospital bed capacity. RESEARCH QUESTION Is HMV initiation at home, by using telemonitoring, non-inferior to in-hospital initiation in a nationwide study? STUDY DESIGN AND METHODS We conducted a nationwide, randomised controlled non-inferiority trial, in which every HMV centre recruited 24 patients (home (n=12) vs hospital (n=12)) with a neuromuscular disease (NMD) or thoracic cage disorder, all with an indication to start HMV. Change of arterial carbon dioxide (PaCO₂) over a 6-months period was considered the primary outcome, while quality of life and costs were assessed as secondary outcomes. RESULTS A total of 96 patients were randomised, most of them diagnosed with NMD. We found a significant improvement of the PaCO₂ within both groups (home from 6.1 kPa to 5.6 kPa (p <0.01), hospital from 6.3 kPa to 5.6 kPa (p<0.01)), with no significant differences between groups. Health-Related Quality of life (HRQoL) showed significant improvement on various subscales; however, no significant differences were observed between the home and hospital groups. From a societal perspective, a cost reduction of over €3200- per patient was evident in the home group. INTERPRETATION This nationwide, multi-centre study shows that HMV initiation at home is non-inferior to hospital initiation, as it shows the same improvement in gas exchange and HRQoL. In fact, from a patient's perspective, it might even be a more attractive approach. In addition starting at home saves over €3200,- per patient over a 6-month period.",2020,"Health-Related Quality of life (HRQoL) showed significant improvement on various subscales; however, no significant differences were observed between the home and hospital groups.","['patients with Neuromuscular Disease and thoracic cage disorder', '96 patients', 'patients with chronic respiratory insufficiency', '24 patients (home (n=12) vs hospital (n=12)) with a neuromuscular disease (NMD) or thoracic cage disorder, all with an indication to start HMV']","['chronic non-invasive mechanical ventilation', 'Home Mechanical Ventilation (HMV']","['PaCO₂', 'quality of life and costs', 'Change of arterial carbon dioxide (PaCO₂', 'Health-Related Quality of life (HRQoL']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027868', 'cui_str': 'Myoneural disorder'}, {'cui': 'C0222762', 'cui_str': 'Thoracic cage structure'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1998122', 'cui_str': 'Chronic respiratory insufficiency'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}]","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}]",96.0,0.19593,"Health-Related Quality of life (HRQoL) showed significant improvement on various subscales; however, no significant differences were observed between the home and hospital groups.","[{'ForeName': 'Ries J M', 'Initials': 'RJM', 'LastName': 'van den Biggelaar', 'Affiliation': 'Department of Pulmonary Diseases/Department of Intensive Care Medicine and Home Mechanical Ventilation, Erasmus Medical Center Rotterdam, The Netherlands. Electronic address: r.vandenbiggelaar@erasmusmc.nl.'}, {'ForeName': 'Anda', 'Initials': 'A', 'LastName': 'Hazenberg', 'Affiliation': 'Department of Pulmonary Diseases/Home Mechanical Ventilation, University of Groningen, University Medical Center Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, the Netherlands.'}, {'ForeName': 'Nicolle A M', 'Initials': 'NAM', 'LastName': 'Cobben', 'Affiliation': 'Department of Pulmonary Diseases/Home Mechanical Ventilation, University Medical Center Maastricht, the Netherlands.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Gaytant', 'Affiliation': 'Department of Pulmonary Diseases/Home Mechanical Ventilation, University Medical Center Utrecht, the Netherlands.'}, {'ForeName': 'Karin M', 'Initials': 'KM', 'LastName': 'Vermeulen', 'Affiliation': 'Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Wijkstra', 'Affiliation': 'Department of Pulmonary Diseases/Home Mechanical Ventilation, University of Groningen, University Medical Center Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, the Netherlands.'}]",Chest,['10.1016/j.chest.2020.07.007'] 2106,32682793,New ultrasonic tip decreases uninstrumented surface and debris in flattened canals: a micro-computed tomographic study.,"INTRODUCTION Preparation of flattened root canals using reciprocating or rotary nickel-titanium (NiTi) instruments associated with the Flatsonic ultrasonic tip was evaluated by micro-computed tomographic (micro-CT). METHODS Twenty-four flattened distal canals of mandibular molars with a buccolingual diameter 4 or more times larger than the mesiodistal diameter were selected. The root canals were randomly divided into two experimental groups for preparation: Reciproc Blue (RB) 40/.06 file in reciprocating motion or ProDesign Logic (PDL) 40/.01 and 40/.05 files in rotary motion (n = 12). A complementary preparation was performed with the Flatsonic ultrasonic tip for both preparations. Micro-CT scanning at a resolution of 8.74 μm was performed before and after preparation with the NiTi instruments and after use of the Flatsonic tip. The percentages of increase in volume, debris and uninstrumented surface were analyzed. The data obtained were submitted to paired and unpaired t-test, ANOVA and Tukey (α = 5%). RESULTS The percentage increase in volume, debris and uninstrumented surface was similar between RB and PDL, in entire root canal (P > .05). PDL promoted a lower percentage of debris in the cervical third, and lower percentage of increase in volume in the apical third in comparison with RB (P < .05). Flatsonic decreased debris and uninstrumented surface after PDL preparation in all thirds (P < .05). After preparation with RB, the Flatsonic decreases the debris in cervical third and uninstrumented surface in the cervical and middle thirds (P < .05). CONCLUSIONS Preparation of flattened root canals using Reciproc Blue or ProDesign Logic produced high percentage of debris and uninstrumented surface. Flatsonic ultrasonic tip significantly improved the cleaning of flattened root canals.",2020,Flatsonic decreased debris and uninstrumented surface after PDL preparation in all thirds (P < .05).,['Twenty-four flattened distal canals of mandibular molars with a buccolingual diameter 4 or more times larger than the mesiodistal diameter were selected'],"['preparation: Reciproc Blue (RB', 'PDL', 'Micro-CT scanning', 'New ultrasonic tip', 'flattened root canals using reciprocating or rotary nickel-titanium (NiTi']","['Flatsonic decreased debris and uninstrumented surface', 'volume, debris and uninstrumented surface', 'Flatsonic ultrasonic tip']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0086881', 'cui_str': 'Pulp canal'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0549177', 'cui_str': 'Large'}]","[{'cui': 'C1260957', 'cui_str': 'Blue color'}, {'cui': 'C0023963', 'cui_str': 'Logic'}, {'cui': 'C2350281', 'cui_str': 'MicroCT'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0339897', 'cui_str': 'Transjugular intrahepatic portosystemic shunt'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0068790', 'cui_str': 'nitinol'}]","[{'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0440266', 'cui_str': 'Debris'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0339897', 'cui_str': 'Transjugular intrahepatic portosystemic shunt'}]",24.0,0.014489,Flatsonic decreased debris and uninstrumented surface after PDL preparation in all thirds (P < .05).,"[{'ForeName': 'Airton Oliveira', 'Initials': 'AO', 'LastName': 'Santos-Junior', 'Affiliation': 'Department of Restorative Dentistry, São Paulo State University (UNESP), School of Dentistry, Araraquara, SP, Brazil.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Tanomaru-Filho', 'Affiliation': 'Department of Restorative Dentistry, São Paulo State University (UNESP), School of Dentistry, Araraquara, SP, Brazil. Electronic address: tanomaru@uol.com.br.'}, {'ForeName': 'Jader Camilo', 'Initials': 'JC', 'LastName': 'Pinto', 'Affiliation': 'Department of Restorative Dentistry, São Paulo State University (UNESP), School of Dentistry, Araraquara, SP, Brazil.'}, {'ForeName': 'Karina Ines', 'Initials': 'KI', 'LastName': 'Medina Carita Tavares', 'Affiliation': 'Department of Restorative Dentistry, São Paulo State University (UNESP), School of Dentistry, Araraquara, SP, Brazil.'}, {'ForeName': 'Mariana Mena', 'Initials': 'MM', 'LastName': 'Barreto Pivoto-João', 'Affiliation': 'Department of Restorative Dentistry, São Paulo State University (UNESP), School of Dentistry, Araraquara, SP, Brazil.'}, {'ForeName': 'Juliane Maria', 'Initials': 'JM', 'LastName': 'Guerreiro-Tanomaru', 'Affiliation': 'Department of Restorative Dentistry, São Paulo State University (UNESP), School of Dentistry, Araraquara, SP, Brazil.'}]",Journal of endodontics,['10.1016/j.joen.2020.07.012'] 2107,32682815,Acceptance and Commitment Therapy for Primary Headache Sufferers: A Randomized Controlled Trial of Efficacy.,"Prevention of headaches via avoidance of triggers remains the main behavioral treatment suggestion for headache management despite trigger avoidance resulting in increases in potency, lifestyle restrictions, internal locus of control decreases, pain exacerbation and maintenance. New approaches, such as Acceptance and Commitment Therapy (ACT), instead emphasize acceptance and valued living as alternatives to avoidance. Though ACT is an empirically supported treatment for chronic pain, there is limited evidence for headache management whilst preliminary outcome studies are afflicted with methodological limitations. This study compared an ACT-based group headache-specific intervention to wait-list control, in a randomized clinical trial, on disability, distress, medical utilization, functioning and quality of life. 94 individuals with primary headache (84% women; Mage=43 years; 87.35% migraine diagnosis) were randomized into two groups (47 in each). Assessments occurred: before, immediately after, and at 3-months following treatment end. Only the ACT group was additionally assessed at 6- and 12-months follow-up. Results (intent to treat analyses corroborated by linear-mixed-model analyses) showed substantial improvements in favor of ACT compared to control, on disability, quality of life, functional status, and depression at 3-, 6-, and 12-month follow-up. Improvements were maintained in the ACT group at 6- and 12-month follow-up. At 3-month follow-up, clinical improvement occurred in headache-related disability (63%) and 65% in quality of life in ACT vs. 37% & 35% in control. These findings offer new evidence for the utility and efficacy of ACT in localized pain conditions and yields evidence for both statistical and clinical improvements over a years' period. Perspective: An Acceptance and Commitment Therapy approach focusing on acceptance and values-based activities, was found to improve disability, functioning and quality of life among patients with primary headaches. Trial registration: Clinical trials.gov registry (NCT02734992).",2020,"At 3-month follow-up, clinical improvement occurred in headache-related disability (63%) and 65% in quality of life in ACT vs. 37% & 35% in control.","['94 individuals with primary headache (84% women; Mage=43 years; 87.35% migraine diagnosis', 'Primary Headache Sufferers', 'patients with primary headaches']","['ACT-based group headache-specific intervention to wait-list control', 'ACT']","['quality of life', 'headache-related disability', 'disability, quality of life, functional status, and depression', 'disability, distress, medical utilization, functioning and quality of life', 'disability, functioning and quality of life']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0029917', 'cui_str': 'Outpatient Commitment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",94.0,0.0922623,"At 3-month follow-up, clinical improvement occurred in headache-related disability (63%) and 65% in quality of life in ACT vs. 37% & 35% in control.","[{'ForeName': 'Vasilis S', 'Initials': 'VS', 'LastName': 'Vasiliou', 'Affiliation': 'University College Cork, Department of Applied Psychology, Ireland.'}, {'ForeName': 'Evangelos C', 'Initials': 'EC', 'LastName': 'Karademas', 'Affiliation': 'University of Crete, Department of Psychology, Greece.'}, {'ForeName': 'Yiolanda', 'Initials': 'Y', 'LastName': 'Christou', 'Affiliation': ""Neurology Clinic B', The Cyprus Institute of Neurology and Genetics, Cyprus.""}, {'ForeName': 'Savvas', 'Initials': 'S', 'LastName': 'Papacostas', 'Affiliation': ""Neurology Clinic B', The Cyprus Institute of Neurology and Genetics, Cyprus.""}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Karekla', 'Affiliation': 'University of Cyprus, Department of Psychology, ACTHealthy laboratory, Cyprus. Electronic address: mkarekla@ucy.ac.cy.'}]",The journal of pain : official journal of the American Pain Society,['10.1016/j.jpain.2020.06.006'] 2108,32682856,A Prospective Randomized Trial Comparing Liposomal Bupivacaine vs. Standard Bupivacaine Wound Infiltration in Open Gynecologic Surgery On An Enhanced Recovery Pathway.,"BACKGROUND Value in healthcare is reflected by patient-centered outcomes of care per health dollar expended. Although more expensive, liposomal bupivacaine has been shown to provide prolonged analgesia (72 hours). OBJECTIVE To evaluate whether the addition of liposomal bupivacaine to standard bupivacaine could decrease opioid intake and improve pain control after laparotomy for gynecologic surgery compared to standard bupivacaine alone within an enhanced recovery after surgery (ERAS) pathway. STUDY DESIGN A prospective randomized control single-blinded trial of wound infiltration with liposomal bupivacaine plus 0.25% bupivacaine (study-arm) vs. 0.25% bupivacaine (control-arm) was performed at a National Cancer Institute designated tertiary referral cancer center. Participants were patients age 18 years or older undergoing exploratory laparotomy for a gynecologic indication. All patients were treated on an Enhanced Recovery pathway including local wound infiltration prior to closure. In the study arm: 266 mg of liposomal bupivacaine (free base; equal to 300 mg bupivacaine HCL) + 150 mg of bupivacaine mixed in the same syringe and in the control arm: 150 mg of bupivacaine. The primary outcome was the proportion of opioid-free patients within 48 hours after surgery. Secondary outcomes included number of opioid-free days from postoperative day 0-3, days to first opioid administration, morphine-equivalent daily dose (MEDD), patient-reported outcomes (PROs) collected with the MD-Anderson Symptom Inventory (MDASI). The MDASI was administered as a preoperative baseline, daily while hospitalized, and at least weekly for 8 weeks after discharge. All outcomes were pre-specified prior to data collection. RESULTS 102 patients were evaluable. 16.7% of patients in the study-arm received no opioids through 48 hours compared to 14.8% in the control-arm, (p=0.99). There were no significant differences in the amount of intraoperative opioids administered or days to first opioid use. There was no significant difference between the two arms in median cumulative MEDD, 21.3 (study-arm) vs. 33.8 (control-arm), p=0.36, nor between the groups in MEDD per individual day. There were no significant differences in patient-reported pain or interference with walking between the two arms nor other PROs. CONCLUSIONS Within an ERAS pathway, adding liposomal bupivacaine to 0.25% bupivacaine wound infiltration did not decrease the proportion of patients opioid free within 48 hours after surgery, opioid intake, or improve patient's self-reported pain and functional recovery compared to standard bupivacaine.",2020,"There were no significant differences in patient-reported pain or interference with walking between the two arms nor other PROs. ","['National Cancer Institute designated tertiary referral cancer center', 'Open Gynecologic Surgery', 'Participants were patients age 18 years or older undergoing exploratory laparotomy for a gynecologic indication', '102 patients were evaluable']","['bupivacaine HCL) + 150 mg of bupivacaine', 'bupivacaine', 'liposomal bupivacaine plus 0.25% bupivacaine', 'Liposomal Bupivacaine vs. Standard Bupivacaine', 'liposomal bupivacaine']","[""patient's self-reported pain and functional recovery"", 'number of opioid-free days from postoperative day 0-3, days to first opioid administration, morphine-equivalent daily dose (MEDD), patient-reported outcomes (PROs) collected with the MD-Anderson Symptom Inventory (MDASI', 'proportion of patients opioid free', 'median cumulative MEDD', 'opioid intake and improve pain control', 'proportion of opioid-free patients within 48 hours after surgery']","[{'cui': 'C1513882', 'cui_str': 'National Cancer Institute'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0038902', 'cui_str': 'Operation on female genital organs'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0085704', 'cui_str': 'Exploratory laparotomy'}, {'cui': 'C0205480', 'cui_str': 'Gynecologic'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}]","[{'cui': 'C0887621', 'cui_str': 'Bupivacaine hydrochloride'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0023828', 'cui_str': 'Liposomes'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C4517443', 'cui_str': '0.25'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0599766', 'cui_str': 'Recovery of Function'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0439586', 'cui_str': '48 hours'}]",102.0,0.14023,"There were no significant differences in patient-reported pain or interference with walking between the two arms nor other PROs. ","[{'ForeName': 'Larissa A', 'Initials': 'LA', 'LastName': 'Meyer', 'Affiliation': 'Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: lmeyer@mdanderson.org.'}, {'ForeName': 'Camila Corzo', 'Initials': 'CC', 'LastName': 'Casadiego', 'Affiliation': 'Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Maria D', 'Initials': 'MD', 'LastName': 'Iniesta', 'Affiliation': 'Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Munsell', 'Affiliation': 'Department of Biostatics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.'}, {'ForeName': 'Qiuling', 'Initials': 'Q', 'LastName': 'Shi', 'Affiliation': 'Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.'}, {'ForeName': 'Brandelyn', 'Initials': 'B', 'LastName': 'Pitcher', 'Affiliation': 'Department of Biostatics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Lasala', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Katherine E', 'Initials': 'KE', 'LastName': 'Cain', 'Affiliation': 'Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.'}, {'ForeName': 'Xin Shelly', 'Initials': 'XS', 'LastName': 'Wang', 'Affiliation': 'Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Mena', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Pedro T', 'Initials': 'PT', 'LastName': 'Ramirez', 'Affiliation': 'Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.07.017'] 2109,32685335,Photovoice as an intervention for college students living with mental illness: A pilot study.,"Introduction Photovoice is a participatory-action research method in which participants capture and collectively reflect upon photos of their lived experience. Photovoice participation may be beneficial for individuals living with mental illness, but its effects have not been quantitatively measured. Methods In this pilot study, 20 college students living with a mental illness and prescribed at least 1 medication were randomized to a Photovoice group intervention or usual group counseling, which was an active control. Participants completed the BURNS Anxiety Inventory, Beck Depression Inventory, and Medication Adherence Rating Scale at baseline and 8 weeks. Between-groups comparisons were conducted. Results Photovoice participants experienced a significantly greater reduction in the BURNS Anxiety Inventory (-8.5 vs -2.6; P  = .049) compared to control participants. No difference was seen in change in the Beck Depression Inventory (6.7 in the Photovoice group vs 0.2 among controls; P  = .26). Mean medication adherence scores worsened in both groups from baseline with no difference between the groups (1 vs 0.86; P  = .16). Discussion Photovoice may be a resource-efficient and effective intervention to reduce anxiety among college students with mental illness; however, it may be associated with poorer medication adherence. Further study is needed to evaluate these findings.",2020,"Mean medication adherence scores worsened in both groups from baseline with no difference between the groups (1 vs 0.86; P  = .16). ","['college students with mental illness', '20 college students living with a mental illness and prescribed at least 1 medication', 'college students living with mental illness', 'individuals living with mental illness']","['Photovoice', 'Photovoice group intervention or usual group counseling, which was an active control']","['BURNS Anxiety Inventory, Beck Depression Inventory, and Medication Adherence Rating Scale', 'BURNS Anxiety Inventory', 'Mean medication adherence scores', 'Beck Depression Inventory']","[{'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0237547', 'cui_str': 'Group counseling'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0000912', 'cui_str': 'Accident caused by unspecified fire'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",20.0,0.129172,"Mean medication adherence scores worsened in both groups from baseline with no difference between the groups (1 vs 0.86; P  = .16). ","[{'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Werremeyer', 'Affiliation': 'Associate Professor, Department of Pharmacy Practice, North Dakota State University, Fargo, North Dakota.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Skoy', 'Affiliation': 'Associate Professor, Department of Pharmacy Practice, North Dakota State University, Fargo, North Dakota.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Burns', 'Affiliation': 'Director, Counseling Center, North Dakota State University, Fargo, North Dakota.'}, {'ForeName': 'Amber', 'Initials': 'A', 'LastName': 'Bach-Gorman', 'Affiliation': 'Assistant Director, Clinical and Crisis Services, Counseling Center, North Dakota State University, Fargo, North Dakota.'}]",The mental health clinician,['10.9740/mhc.2020.07.237'] 2110,32685394,Medical treatment of inflammatory punctual stenosis monitored by anterior segment optical coherence tomography.,"AIM To evaluate the role of medical treatment in the management of inflammatory punctum stenosis guided by spectral domain anterior segment optical coherence tomography (OCT). METHODS This prospective study included 60 patients complaining of epiphora due to inflammatory punctual stenosis. They were divided into two groups: Group A (30 patients) treated with a combination of preservative free hydrocortisone sodium phosphate 3.35 mg/mL eye drops, and preservative free artificial tears based on sodium hyaluronate, polyethylene and propylene Glycol; Group B (30 patients) treated with the same preservative free artificial tears only. Thirty normal subjects were included for comparison of pre-treatment anatomical parameters. Before starting treatment, all patients underwent anterior segment assessment including slit lamp examination, measurement of intraocular pressure (IOP), fluorescein dye disappearance test, and measurement of the outer punctum diameter (OPD) by Spectral domain anterior segment OCT. All assessments were repeated at each follow up done at 1 and 3mo later, together with subjective evaluation of patient's satisfaction of the treatment outcome by simple rating questionnaire. RESULTS Punctual diameter increased significantly with treatment in both groups ( P <0.0001); although the widening was more in Group A as compared to group B (16.2% vs 8% of the original punctual size, mean difference of 28.933 µm, P =0.0076). Subjective satisfaction with treatment outcome was also better in group A (70% vs 40%, Chi-square P =0.0397). CONCLUSION A combination of preservative free steroid eye drops and artificial tears causes significant widening of inflammed stenotic punctae and improvement of the associated epiphora.",2020,"RESULTS Punctual diameter increased significantly with treatment in both groups ( P <0.0001); although the widening was more in Group A as compared to group B (16.2% vs 8% of the original punctual size, mean difference of 28.933 µm, P =0.0076).","['60 patients complaining of epiphora due to inflammatory punctual stenosis', 'Thirty normal subjects']","['spectral domain anterior segment optical coherence tomography (OCT', 'combination of preservative free hydrocortisone sodium phosphate 3.35 mg/mL eye drops, and preservative free artificial tears based on sodium hyaluronate, polyethylene and propylene Glycol; Group B (30 patients) treated with the same preservative free artificial tears only']","['Subjective satisfaction', 'Punctual diameter', 'slit lamp examination, measurement of intraocular pressure (IOP), fluorescein dye disappearance test, and measurement of the outer punctum diameter (OPD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0152227', 'cui_str': 'Epiphora'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0678234', 'cui_str': 'Form of stenosis'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0205307', 'cui_str': 'Normal'}]","[{'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0003153', 'cui_str': 'Anterior eyeball segment structure'}, {'cui': 'C0920367', 'cui_str': 'Optical coherence tomography'}, {'cui': 'C0033086', 'cui_str': 'Drug preservative'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0770559', 'cui_str': 'Hydrocortisone sodium phosphate'}, {'cui': 'C4517691', 'cui_str': '3.35'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C0015399', 'cui_str': 'Eye drops'}, {'cui': 'C2608262', 'cui_str': 'Artificial Tears'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0087000', 'cui_str': 'Hyaluronate sodium'}, {'cui': 'C0032487', 'cui_str': 'Polyethylenes'}, {'cui': 'C0033437', 'cui_str': 'Propanediols'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0419360', 'cui_str': 'Ocular slit lamp examination'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C1633730', 'cui_str': 'Fluorescein dye disappearance test'}, {'cui': 'C0205101', 'cui_str': 'External'}]",30.0,0.014987,"RESULTS Punctual diameter increased significantly with treatment in both groups ( P <0.0001); although the widening was more in Group A as compared to group B (16.2% vs 8% of the original punctual size, mean difference of 28.933 µm, P =0.0076).","[{'ForeName': 'Hanan Youssef', 'Initials': 'HY', 'LastName': 'Elalfy', 'Affiliation': 'Al Dorra Subspecialty Ophthalmology Centre, Cairo 11751, Egypt.'}, {'ForeName': 'Mahmoud A', 'Initials': 'MA', 'LastName': 'Elsamkary', 'Affiliation': 'Department of Ophthalmology, Ain Shams University, Cairo 11471, Egypt.'}, {'ForeName': 'Ahmed M Shafek', 'Initials': 'AMS', 'LastName': 'Elridy', 'Affiliation': 'Department of Ophthalmology, Ain Shams University, Cairo 11471, Egypt.'}, {'ForeName': 'Tarek M', 'Initials': 'TM', 'LastName': 'Saad', 'Affiliation': 'Department of Ophthalmology, Ain Shams University, Cairo 11471, Egypt.'}, {'ForeName': 'Saad Mohamed', 'Initials': 'SM', 'LastName': 'Rashad', 'Affiliation': 'Department of Ophthalmology, Ain Shams University, Cairo 11471, Egypt.'}, {'ForeName': 'Samah M', 'Initials': 'SM', 'LastName': 'Fawzy', 'Affiliation': 'Department of Ophthalmology, Ain Shams University, Cairo 11471, Egypt.'}]",International journal of ophthalmology,['10.18240/ijo.2020.07.09'] 2111,32685417,The Effect of Theory-Based HIV/AIDS Educational Program on Preventive Behaviors Among Female Adolescents in Tehran: A Randomized Controlled Trial.,"Background Adolescents are increasingly at risks of HIV infection through high-risk sexual behaviors. This paper aimed to assess the effectiveness of a HIV/AIDS educational intervention among female adolescents in Tehran. Methods A randomized controlled trial was conducted among high school girls aged 12-16 years studying in Tehran in 2016-17. The sample was selected using multistage random cluster sampling. Four schools per district were randomly selected using probability-proportional to size. Adolescents were randomly assigned to the experimental (n=289) and the control (n=289) groups. The theory of planned behavior (TPB) was the basis of both the intervention and the evaluation phase. Both experimental and control groups completed a questionnaire designed for HIV related behaviors for female adolescents (HBQFA) at baseline and after six months follow up. A theory-based educational program was implemented for the experimental group. Results The mean age of participants was 14.1 years (SD=0.96). In the experimental group, significant improvements were shown in adolescents' HIV knowledge (31.9%, 95% CI: 28.8-35.0), attitudes towards HIV (16.6%, 95% CI=14.4-18.8), subjective norm (16.8%, 95% CI=12.9-20.6) and perceived behavioral control (19.1%, 95% CI=16.2-22.1), perceived parental support (17%, 95% CI=13.8-20.2), behavioral intention to prevent HIV (19%, 95% CI=16.3-21.6), and HIV preventive behavior (17.3%, 95% CI=13.9-20.6) (p<0.001). Conclusion Theory-based educational intervention on HIV/AIDS prevention can significantly protect adolescents from misconceptions, wrong attitudes and risky behaviors and unsupportive social environment that expose them to greater HIV risk. Health policy -makers are advised to consider effective training programs related to HIV/AIDS prevention behaviors in the school system.",2020,Both experimental and control groups completed a questionnaire designed for HIV related behaviors for female adolescents (HBQFA) at baseline and after six months follow up.,"['Adolescents', 'Female Adolescents in Tehran', 'female adolescents in Tehran', 'high school girls aged 12-16 years studying in Tehran in 2016-17', 'Four schools per district']","['HIV/AIDS educational intervention', 'Theory-Based HIV/AIDS Educational Program']","['HIV preventive behavior', 'subjective norm', 'behavioral control', 'attitudes towards HIV', 'behavioral intention to prevent HIV', ""adolescents' HIV knowledge"", 'Preventive Behaviors']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",,0.118288,Both experimental and control groups completed a questionnaire designed for HIV related behaviors for female adolescents (HBQFA) at baseline and after six months follow up.,"[{'ForeName': 'Farideh', 'Initials': 'F', 'LastName': 'Khalajabadi Farahani', 'Affiliation': 'Department of Population and Health, National Population Studies and Comprehensive Management Institute, Tehran, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Darabi', 'Affiliation': 'Department of Public Health, Asadabad School of Medical Sciences, Asadabad, Iran.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Yaseri', 'Affiliation': 'Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran.'}]",Journal of reproduction & infertility,[] 2112,32685542,Evaluation of Microvascular Structure Changes after Conbercept Treatment on Macular Edema Secondary to Retinal Vein Occlusion.,"Aims To confirm the therapeutic efficacy of conbercept for the treatment of macular edema (ME) secondary to retinal vein occlusion (RVO) by using optical coherence tomography angiography (OCTA) and to find out the differences in therapeutic efficacy between ischemic and nonischemic retinal vein occlusion (iRVO or non-iRVO) after conbercept treatment. Methods In this prospective, randomized, and comparative study, 60 unilateral eyes suffered from RVO combined with macular edema were included and fellow eye as controls. After an initial intravitreal injection of conbercept (IVIC), a pro re nata (PRN) strategy was adopted, and the follow-up time was 6 months. The foveal avascular zone (FAZ), vascular density of superficial capillary plexus (SCP), and vascular density of deep retinal capillary plexus (DCP), nonperfused areas (NPAs) were evaluated with OCTA on baseline and after treatment. Results The mean intravitreal injection number was 2.9 ± 0.89 times during six months in iRVO patients and 2.1 ± 0.86 times in non-iRVO patients, with statistically significant difference ( p < 0.05). On baseline, central macular thickness (CMT) and FAZ were significantly thickened and enlarged compared to those of healthy fellow eyes; the vascular density of SCP and DCP were significantly decreased, and the differences were statistically significant ( p < 0.05). Compared to baseline, after treatment, the best-corrected visual acuity (BCVA) was improved in either iRVO or non-iRVO (-0.601 ± 0.387, -0.241 ± 0.341 logMAR, p < 0.05). In iRVO, the improvement was more substantial than that of the non-iRVO group. FAZ in the non-iRVO group had significantly decreased compared to that in iRVO group (-0.044 ± 0.040 versus 0.014 ± 0.043 mm 2 , p < 0.05). CMT, the vascular density of SCP, and DCP had no significant difference. Conclusions The changes of microvascular structure can be quantitatively evaluated by using OCTA for the patients with RVO. Conbercept had a significant effect on treatment of RVO with macular edema. A more profound effect was achieved in the iRVO group on visual improvement and FAZ reduction in the non-iRVO group after conbercept treatment.",2020,A more profound effect was achieved in the iRVO group on visual improvement and FAZ reduction in the non-iRVO group after conbercept treatment.,"['Macular Edema Secondary to Retinal Vein Occlusion', '60 unilateral eyes suffered from RVO combined with macular edema were included and fellow eye as controls']","['conbercept', 'optical coherence tomography angiography (OCTA', 'FAZ', 'Conbercept Treatment', 'conbercept (IVIC', 'nonischemic retinal vein occlusion (iRVO or non-iRVO']","['best-corrected visual acuity (BCVA', 'mean intravitreal injection number', 'visual improvement and FAZ reduction', 'foveal avascular zone (FAZ), vascular density of superficial capillary plexus (SCP), and vascular density of deep retinal capillary plexus (DCP), nonperfused areas (NPAs', 'RVO with macular edema', 'vascular density of SCP and DCP', 'central macular thickness (CMT) and FAZ']","[{'cui': 'C0271051', 'cui_str': 'Macular retinal edema'}, {'cui': 'C0175668', 'cui_str': 'Secondary'}, {'cui': 'C0035328', 'cui_str': 'Retinal vein occlusion'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2352201', 'cui_str': 'KH902 fusion protein'}, {'cui': 'C0920367', 'cui_str': 'Optical coherence tomography'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}, {'cui': 'C1275950', 'cui_str': 'Foveal avascular zone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1554888', 'cui_str': 'Intravitreal Injections'}, {'cui': 'C0035328', 'cui_str': 'Retinal vein occlusion'}]","[{'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1554888', 'cui_str': 'Intravitreal Injections'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C1275950', 'cui_str': 'Foveal avascular zone'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0006901', 'cui_str': 'Structure of capillary blood vessel (organ)'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0035328', 'cui_str': 'Retinal vein occlusion'}, {'cui': 'C0271051', 'cui_str': 'Macular retinal edema'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1280412', 'cui_str': 'Thick'}]",60.0,0.0342241,A more profound effect was achieved in the iRVO group on visual improvement and FAZ reduction in the non-iRVO group after conbercept treatment.,"[{'ForeName': 'Wenqi', 'Initials': 'W', 'LastName': 'Song', 'Affiliation': 'Shandong University of Traditional Chinese Medicine, Jinan, China.'}, {'ForeName': 'Wanzhen', 'Initials': 'W', 'LastName': 'Jiao', 'Affiliation': 'Department of Ophthalmology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.'}, {'ForeName': 'Fengjiao', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'Department of Ophthalmology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.'}, {'ForeName': 'Aihua', 'Initials': 'A', 'LastName': 'Ma', 'Affiliation': 'Department of Pediatric, Shandong Provincial Hospital affiliated to Shandong first Medical University, Jinan, China.'}, {'ForeName': 'Bojun', 'Initials': 'B', 'LastName': 'Zhao', 'Affiliation': 'Department of Ophthalmology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.'}]",BioMed research international,['10.1155/2020/9046781'] 2113,32685567,Evaluation of the Electromyographic Amplitude-to-Work Ratio in the Infraspinatus Muscle During External Shoulder Rotation Exercises: A Comparison of Concentric Isotonic and Isokinetic Exercises.,"Background Isotonic exercise is commonly adopted for shoulder rehabilitation, but the efficacy of isokinetic exercise for rehabilitation has not been evaluated. Purpose To evaluate the efficacy of isotonic and isokinetic external shoulder rotation exercises. Study Design Controlled laboratory study. Methods Using surface electromyography (EMG) and the Biodex system, we investigated the EMG amplitude of the infraspinatus (IS), total work (tWK), and EMG(IS)/tWK ratio and examined the relative IS and posterior deltoid (PD) contributions to all exercises. A total of 24 healthy participants without musculoskeletal injuries were included. Participants performed isotonic external shoulder rotation at 10%, 20%, 30%, 40%, and 50% of the maximum voluntary isometric contraction (MVIC) as well as isokinetic external shoulder rotation at angular velocities of 60, 120, 180, 240, and 300 deg/s. Levels of intensity were classified from 1 to 5: level 1 corresponded to 10% of the MVIC and a 300-deg/s angular velocity; level 2 corresponded to 20% MVIC and 240 deg/s; level 3 corresponded to 30% MVIC and 180 deg/s; level 4 corresponded to 40% MVIC and 120 deg/s; and level 5 corresponded to 50% MVIC and 60 deg/s. Normalized IS and tWK amplitudes were calculated for each exercise. Results During isotonic exercise, the EMG(IS)/tWK ratio significantly decreased from level 5 to 3, 2, and 1; from level 4 to 2 and 1; and from level 3 to 1. During isokinetic exercise, the EMG(IS)/tWK ratio at level 3 was greater than that at all other levels except level 1. Statistical differences were found between isotonic and isokinetic modes at levels 1, 2, and 3. The IS/PD activation ratios were not significantly different between exercise modes at any level. Conclusion Isokinetic resistance may provide more effective stimulation of the IS muscle compared with isotonic resistance. Clinical Relevance Isokinetic exercise needs to be considered as a method of rehabilitation that effectively increases infraspinatus muscle activity.",2020,"During isotonic exercise, the EMG(IS)/tWK ratio significantly decreased from level 5 to 3, 2, and 1; from level 4 to 2 and 1; and from level 3 to 1.",['24 healthy participants without musculoskeletal injuries'],"['External Shoulder Rotation Exercises', 'isotonic external shoulder rotation', '\n\n\nIsotonic exercise', 'isotonic and isokinetic external shoulder rotation exercises', 'Concentric Isotonic and Isokinetic Exercises', 'maximum voluntary isometric contraction (MVIC', 'isokinetic exercise']","['PD activation ratios', 'Normalized IS and tWK amplitudes', 'Levels of intensity', 'EMG amplitude of the infraspinatus (IS), total work (tWK), and EMG(IS)/tWK ratio and examined the relative IS and posterior deltoid (PD) contributions', 'Electromyographic Amplitude-to-Work Ratio']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0272448', 'cui_str': 'Injury of musculoskeletal system'}]","[{'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0454287', 'cui_str': 'Isotonic exercise'}, {'cui': 'C0439744', 'cui_str': 'Concentric'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0022205', 'cui_str': 'Muscle isometric contraction'}]","[{'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0224234', 'cui_str': 'Structure of deltoid muscle'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0454287', 'cui_str': 'Isotonic exercise'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0429340', 'cui_str': 'EMG amplitude'}, {'cui': 'C0584882', 'cui_str': 'Infraspinatus muscle structure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0080103', 'cui_str': 'Relative'}]",24.0,0.0335959,"During isotonic exercise, the EMG(IS)/tWK ratio significantly decreased from level 5 to 3, 2, and 1; from level 4 to 2 and 1; and from level 3 to 1.","[{'ForeName': 'Jung-Ho', 'Initials': 'JH', 'LastName': 'Park', 'Affiliation': 'Korea University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Seok Won', 'Initials': 'SW', 'LastName': 'Chung', 'Affiliation': 'Konkuk University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Seoung-Joon', 'Initials': 'SJ', 'LastName': 'Lee', 'Affiliation': 'Konkuk University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jong-Won', 'Initials': 'JW', 'LastName': 'Lee', 'Affiliation': 'Konkuk University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Kyung-Soo', 'Initials': 'KS', 'LastName': 'Oh', 'Affiliation': 'Konkuk University School of Medicine, Seoul, Republic of Korea.'}]",Orthopaedic journal of sports medicine,['10.1177/2325967120932459'] 2114,32685568,Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain.,"Purpose To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain. Design and methods A Markov model was developed to compare radium-223 versus BSC and to accrue the health outcomes and costs of a simulated cohort of mCRPC patients. Quality-adjusted life year (QALY) and life year (LY) were selected as health outcomes to measure the effectiveness of treatment alternatives. Main health resource use and efficacy inputs were obtained from a randomized controlled trial comparing radium-223 versus placebo. Unit costs were retrieved from Spanish databases and published sources. One-way and probabilistic sensitivity analyses were carried out to assess uncertainty. Results Total costs and QALYs were €65 067 and 1.12 QALYs for radium-223 and €55 437 and 0.77 QALYs for BSC. Therefore, incremental costs per QALY were €27 606. The sensitivity analysis showed that with a willingness-to-pay threshold of €30 000 per QALY, radium-223 would have a probability of 48% of being cost-effective compared to BSC. Conclusions Although results must be assessed with caution, from the Spanish National Health System perspective and based on the results of the present analysis, radium-223 could be a suitable option of health resources' utilization for end of life mCRPC without previous docetaxel treatment, subject to a moderate level of uncertainty.",2018,"Results Total costs and QALYs were €65 067 and 1.12 QALYs for radium-223 and €55 437 and 0.77 QALYs for BSC.","['Spain', 'patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain', 'Metastatic Castration-Resistant Prostate Cancer Patients']","['radium-223 versus placebo', 'Radium-223 Dichloride', 'radium-223 plus Best Supportive Care (BSC', 'BSC']","['Quality-adjusted life year (QALY) and life year (LY', 'Unit costs', 'Total costs and QALYs']","[{'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0303282', 'cui_str': 'Radium-223'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3541342', 'cui_str': 'RADIUM CHLORIDE RA-223'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0344211', 'cui_str': 'Support'}]","[{'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",,0.0630699,"Results Total costs and QALYs were €65 067 and 1.12 QALYs for radium-223 and €55 437 and 0.77 QALYs for BSC.","[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Tirado Mercier', 'Affiliation': 'Pharmaceuticals Division Bayer Hispania, SL, Barcelona, Spain.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Callejo Velasco', 'Affiliation': 'IQVIA, Madrid, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Rubio Cabezas', 'Affiliation': 'IQVIA, Madrid, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Moretones Agut', 'Affiliation': 'Pharmaceuticals Division Bayer Hispania, SL, Barcelona, Spain.'}, {'ForeName': 'Meritxell', 'Initials': 'M', 'LastName': 'Granell Villalón', 'Affiliation': 'Pharmaceuticals Division Bayer Hispania, SL, Barcelona, Spain.'}]",Journal of health economics and outcomes research,['10.36469/9777'] 2115,32685581,A Pragmatic Clinical Trial to Compare the Real-World Effectiveness of V-Go versus Standard Delivery of Insulin in Patients with Advanced Type 2 Diabetes.,"Background Many patients with type 2 diabetes mellitus (T2DM) do not have adequate glycemic control, leading to poor patient outcomes and high healthcare costs. Objective This prospective pragmatic clinical trial evaluated V-Go, a wearable insulin delivery device, compared with standard treatment optimization (STO) among insulin-treated patients with T2DM in a real-world, community-based practice setting. Methods Study sites, rather than individual patients, were randomized to V-Go or STO via cluster randomization. Patients were treated according to routine clinical practice and followed up to 4 months. T2DM medications and supplies were purchased utilizing usual insurance and co-pay systems. The primary analysis was an unadjusted treatment group comparison of glycosylated hemoglobinA1c (HbA1c) change from baseline to end of study (EOS). A cost of therapy analysis was completed on patients who had received comparable baseline T2DM treatment with multiple daily basal-bolus insulin injections (MDI). Results Analysis included 415 patients (169 V-Go, 246 STO) enrolled from 52 US sites. Mean baseline HbA1c (9.6%) was higher in V-Go (9.9%, range 8.0% - 14.2%) than STO (9.3%, range 7.9% - 13.9%, p <.001). HbA1c decreased from baseline to EOS in both V-Go (-1.0%, p<.001) and STO (-0.5%, p<.001); V-Go had significantly larger decrease (p=.002). V-Go had a significant reduction (p<.001) in mean insulin total daily dose (TDD; 0.76 U/kg baseline, 0.57 U/kg EOS), not seen in STO (0.72 U/kg baseline and EOS). The MDI group included 95 (56.2%) V-Go and 113 STO (45.9%) patients. Mean baseline HbA1c was significantly higher in V-Go (9.9%) than STO (9.4%). V-Go also experienced larger decrease in HbA1c from baseline (-1.0%) than STO (-0.36%) (p=.006) with a decrease in TDD, while STO TDD remained unchanged. EOS mean per patient per day cost of diabetes treatment was lower for V-Go ($30.59) vs STO ($32.20) (p=.006). V-Go was more cost effective than STO ($24.02 per 1% drop in HbA1c vs $58.86, respectively). Conclusions This pragmatic clinical trial demonstrated improved HbA1c levels, lower cost, and decreased insulin dose in patients with T2DM initiating V-Go vs STO in a real-world community-based practice setting. Observed baseline HbAlc indicated use of V-Go in more difficult to manage diabetes patients.",2019,"V-Go had a significant reduction (p<.001) in mean insulin total daily dose (TDD; 0.76 U/kg baseline, 0.57 U/kg EOS), not seen in STO (0.72 U/kg baseline and EOS).","['Patients with Advanced Type 2 Diabetes', '415 patients (169 V-Go, 246 STO) enrolled from 52 US sites', 'treated patients with T2DM in a real-world, community-based practice setting', 'patients who had received comparable baseline T2DM treatment with multiple daily basal-bolus insulin injections (MDI', 'patients with type 2 diabetes mellitus (T2DM']","['V-Go versus Standard Delivery of Insulin', 'standard treatment optimization (STO) among insulin']","['TDD, while STO TDD', 'HbA1c levels, lower cost, and decreased insulin dose', 'mean insulin total daily dose', 'glycosylated hemoglobinA1c (HbA1c) change from baseline to end of study (EOS', 'Mean baseline HbA1c', 'EOS mean per patient per day cost of diabetes treatment']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C4517772', 'cui_str': '415'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0199782', 'cui_str': 'Administration of insulin'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0183841', 'cui_str': 'TDD'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]",415.0,0.100947,"V-Go had a significant reduction (p<.001) in mean insulin total daily dose (TDD; 0.76 U/kg baseline, 0.57 U/kg EOS), not seen in STO (0.72 U/kg baseline and EOS).","[{'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Cziraky', 'Affiliation': 'HealthCore, Inc., Wilmington, DE.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Abbott', 'Affiliation': 'Valeritas, Inc., Bridgewater, NJ.'}, {'ForeName': 'Matt', 'Initials': 'M', 'LastName': 'Nguyen', 'Affiliation': 'Valeritas, Inc., Bridgewater, NJ.'}, {'ForeName': 'Kay', 'Initials': 'K', 'LastName': 'Larholt', 'Affiliation': 'Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Apgar', 'Affiliation': 'HealthCore, Inc., Wilmington, DE.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Wasser', 'Affiliation': 'HealthCore, Inc., Wilmington, DE.'}, {'ForeName': 'Poul', 'Initials': 'P', 'LastName': 'Strange', 'Affiliation': 'Integrated Medical Development, LLC, Princeton Junction, NJ.'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Shi', 'Affiliation': 'Integrated Medical Development, LLC, Princeton Junction, NJ.'}, {'ForeName': 'H Courtenay', 'Initials': 'HC', 'LastName': 'Harrison', 'Affiliation': 'Endocrinology Consultants, Virginia Beach, VA.'}, {'ForeName': 'Beverly', 'Initials': 'B', 'LastName': 'Everitt', 'Affiliation': 'Endocrinology Consultants, Virginia Beach, VA.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Nowak', 'Affiliation': 'HealthCore, Inc., Wilmington, DE at the time of the study.'}]",Journal of health economics and outcomes research,['10.36469/9731'] 2116,32685606,"Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials.","Background Renal impairment is not a consistently cited risk factor for recurrent Clostridioides difficile infection (rCDI). We examined the association between renal impairment and rCDI and the effect of bezlotoxumab, an anti-toxin B monoclonal antibody, in reducing rCDI in participants with renal impairment. Methods We pooled data from 2 randomized, double-blind, placebo-controlled, multicenter, phase 3 clinical trials conducted in participants receiving bezlotoxumab or placebo infusion during oral antibacterial drug treatment for CDI. We assessed the association between renal impairment and rCDI in placebo-treated participants and evaluated the effect of bezlotoxumab vs placebo in reducing rCDI among participants with renal impairment, defined as an estimated glomerular filtration rate <90 mL/min. Results The proportion of placebo-treated participants experiencing rCDI within 12 weeks was higher in those with renal impairment (n = 919) vs those without renal impairment (n = 612; 36.6% and 27.7%, respectively; difference, 8.9%; 95% CI, 1.3% to 16.3%). Renal impairment was significantly associated with a higher rate of recurrence in placebo-treated participants lacking commonly recognized risk factors for rCDI (renal impairment as only risk factor, 28.8%; vs normal renal function and no risk factors, 12.5%; difference, 16.3%; 95% CI, 3.4% to 28.8%). Among all participants with renal impairment, the rate of rCDI was 19.5% among bezlotoxumab-treated vs 36.6% among placebo-treated participants (difference, -17.1%; 95% CI, -23.4% to -10.6%). Conclusions This post hoc analysis adds to the literature suggesting an association of renal impairment as an independent risk factor for rCDI and provides preliminary evidence that patients with renal impairment who suffer with CDI may benefit from adjunctive treatment with bezlotoxumab.",2020,"Renal impairment was significantly associated with a higher rate of recurrence in placebo-treated participants lacking commonly recognized risk factors for rCDI (renal impairment as only risk factor, 28.8%; vs normal renal function and no risk factors, 12.5%; difference, 16.3%; 95% CI, 3.4% to 28.8%).","['infusion during oral antibacterial drug treatment for CDI', 'participants with renal impairment, defined as an estimated glomerular filtration rate <90 mL/min', 'patients with renal impairment who suffer with CDI', 'participants with renal impairment']","['bezlotoxumab or placebo', 'bezlotoxumab', 'Bezlotoxumab', 'bezlotoxumab vs placebo', 'placebo']","['Renal Impairment, C. difficile Recurrence', 'Renal impairment', 'rate of recurrence', 'rate of rCDI', 'renal impairment and rCDI']","[{'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0279516', 'cui_str': 'Antibacterial'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0282601', 'cui_str': 'Compact Disk Interactive'}, {'cui': 'C1565489', 'cui_str': 'Renal impairment'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0439087', 'cui_str': '<90'}, {'cui': 'C0439445', 'cui_str': 'mL/min'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4291320', 'cui_str': 'bezlotoxumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1565489', 'cui_str': 'Renal impairment'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",919.0,0.694603,"Renal impairment was significantly associated with a higher rate of recurrence in placebo-treated participants lacking commonly recognized risk factors for rCDI (renal impairment as only risk factor, 28.8%; vs normal renal function and no risk factors, 12.5%; difference, 16.3%; 95% CI, 3.4% to 28.8%).","[{'ForeName': 'Yoav', 'Initials': 'Y', 'LastName': 'Golan', 'Affiliation': 'Tufts Medical Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Herbert L', 'Initials': 'HL', 'LastName': 'DuPont', 'Affiliation': 'University of Texas School of Public Health, Houston, Texas, USA.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Aldomiro', 'Affiliation': 'Hospital Fernando Fonseca, EPE - Amadora/Sintra at Portugal, Area Metropolitana de Lisboa, Carnaxide, Portugal.'}, {'ForeName': 'Erin H', 'Initials': 'EH', 'LastName': 'Jensen', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey, USA.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Hanson', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey, USA.'}, {'ForeName': 'Mary Beth', 'Initials': 'MB', 'LastName': 'Dorr', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey, USA.'}]",Open forum infectious diseases,['10.1093/ofid/ofaa248'] 2117,32687801,"Lung recruitment before surfactant administration in extremely preterm neonates with respiratory distress syndrome (IN-REC-SUR-E): a randomised, unblinded, controlled trial.","BACKGROUND The importance of lung recruitment before surfactant administration has been shown in animal studies. Well designed trials in preterm infants are absent. We aimed to examine whether the application of a recruitment manoeuvre just before surfactant administration, followed by rapid extubation (intubate-recruit-surfactant-extubate [IN-REC-SUR-E]), decreased the need for mechanical ventilation during the first 72 h of life compared with no recruitment manoeuvre (ie, intubate-surfactant-extubate [IN-SUR-E]). METHODS We did a randomised, unblinded, controlled trial in 35 tertiary neonatal intensive care units in Italy. Spontaneously breathing extremely preterm neonates (24 + 0 to 27 + 6 weeks' gestation) reaching failure criteria for continuous positive airway pressure within the first 24 h of life were randomly assigned (1:1) with a minimisation algorithm to IN-REC-SUR-E or IN-SUR-E using an interactive web-based electronic system, stratified by clinical site and gestational age. The primary outcome was the need for mechanical ventilation in the first 72 h of life. Analyses were done in intention-to-treat and per-protocol populations, with a log-binomial regression model correcting for stratification factors to estimate adjusted relative risk (RR). This study is registered with ClinicalTrials.gov, NCT02482766. FINDINGS Of 556 infants assessed for eligibility, 218 infants were recruited from Nov 12, 2015, to Sept 23, 2018, and included in the intention-to-treat analysis. The requirement for mechanical ventilation during the first 72 h of life was reduced in the IN-REC-SUR-E group (43 [40%] of 107) compared with the IN-SUR-E group (60 [54%] of 111; adjusted RR 0·75, 95% CI 0·57-0·98; p=0·037), with a number needed to treat of 7·2 (95% CI 3·7-135·0). The addition of the recruitment manoeuvre did not adversely affect the safety outcomes of in-hospital mortality (19 [19%] of 101 in the IN-REC-SUR-E group vs 37 [33%] of 111 in the IN-SUR-E group), pneumothorax (four [4%] of 101 vs seven [6%] of 111), or grade 3 or worse intraventricular haemorrhage (12 [12%] of 101 vs 17 [15%] of 111). INTERPRETATION A lung recruitment manoeuvre just before surfactant administration improved the efficacy of surfactant treatment in extremely preterm neonates compared with the standard IN-SUR-E technique, without increasing the risk of adverse neonatal outcomes. The reduced need for mechanical ventilation during the first 72 h of life might facilitate implementation of a non-invasive respiratory support strategy. FUNDING None.",2020,"The requirement for mechanical ventilation during the first 72 h of life was reduced in the IN-REC-SUR-E group (43 [40%] of 107) compared with the IN-SUR-E group (60 [54%] of 111; adjusted RR 0·75, 95% CI 0·57-0·98; p=0·037), with a number needed to treat of 7·2","['extremely preterm neonates with respiratory distress syndrome (IN-REC-SUR-E', 'preterm infants', '35 tertiary neonatal intensive care units in Italy', 'extremely preterm neonates', '556 infants assessed for eligibility, 218 infants were recruited from Nov 12, 2015, to Sept 23, 2018, and included in the intention-to-treat analysis', ""Spontaneously breathing extremely preterm neonates (24\u2008+\u20080 to 27\u2008+\u20086 weeks' gestation) reaching failure criteria for continuous positive airway pressure within the first 24 h of life""]","['rapid extubation (intubate-recruit-surfactant-extubate [IN-REC-SUR-E', 'minimisation algorithm to IN-REC-SUR-E or IN-SUR-E using an interactive web-based electronic system']","['need for mechanical ventilation in the first 72 h of life', 'intraventricular haemorrhage', 'pneumothorax', 'mechanical ventilation', 'safety outcomes of in-hospital mortality']","[{'cui': 'C0205403', 'cui_str': 'Extreme'}, {'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0035220', 'cui_str': 'Respiratory distress syndrome in the newborn'}, {'cui': 'C2606415', 'cui_str': 'ZDHHC2 protein, human'}, {'cui': 'C0038944', 'cui_str': 'Suriname'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C4517811', 'cui_str': '556'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C4517647', 'cui_str': '218'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0376558', 'cui_str': 'Life'}]","[{'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0034085', 'cui_str': 'Lung surfactant'}, {'cui': 'C2606415', 'cui_str': 'ZDHHC2 protein, human'}, {'cui': 'C0038944', 'cui_str': 'Suriname'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0240059', 'cui_str': 'Ventricular hemorrhage'}, {'cui': 'C0032326', 'cui_str': 'Pneumothorax'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}]",218.0,0.367845,"The requirement for mechanical ventilation during the first 72 h of life was reduced in the IN-REC-SUR-E group (43 [40%] of 107) compared with the IN-SUR-E group (60 [54%] of 111; adjusted RR 0·75, 95% CI 0·57-0·98; p=0·037), with a number needed to treat of 7·2","[{'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Vento', 'Affiliation': 'Dipartimento Universitario Scienze della Vita e Sanità Pubblica, Unità Operativa Complessa di Neonatologia, Fondazione Policlinico Universitario A Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Rome, Italy. Electronic address: giovanni.vento@unicatt.it.'}, {'ForeName': 'Maria Luisa', 'Initials': 'ML', 'LastName': 'Ventura', 'Affiliation': 'Fondazione Monza e Brianza per il Bambino e la sua Mamma, Ospedale San Gerardo Monza, Italy.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Pastorino', 'Affiliation': 'Department of Woman and Child Health and Public Health, Public Health Area, Fondazione Policlinico Universitario A Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.'}, {'ForeName': 'Anton H', 'Initials': 'AH', 'LastName': 'van Kaam', 'Affiliation': ""Department of Neonatology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.""}, {'ForeName': 'Virgilio', 'Initials': 'V', 'LastName': 'Carnielli', 'Affiliation': 'Division of Neonatology, Department of Clinical Sciences, Polytechnic University of Marche and Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy.'}, {'ForeName': 'Filip', 'Initials': 'F', 'LastName': 'Cools', 'Affiliation': 'Department of Neonatology, Universitair Ziekenhuis Brussel, Brussels, Belgium.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Dani', 'Affiliation': 'Department of Mother and Child Health, Division of Neonatology and Neonatal Intensive Care Unit, Careggi University Hospital, Florence, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Mosca', 'Affiliation': 'Department of Clinical Sciences and Community Health, University of Milan, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'ForeName': 'Graeme', 'Initials': 'G', 'LastName': 'Polglase', 'Affiliation': 'The Ritchie Centre Hudson Institute of Medical Research and Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC, Australia.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Tagliabue', 'Affiliation': 'Fondazione Monza e Brianza per il Bambino e la sua Mamma, Ospedale San Gerardo Monza, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Boni', 'Affiliation': 'SC Epidemiologia Clinica Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genova, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Cota', 'Affiliation': 'Dipartimento Universitario Scienze della Vita e Sanità Pubblica, Unità Operativa Complessa di Neonatologia, Fondazione Policlinico Universitario A Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Rome, Italy.'}, {'ForeName': 'Milena', 'Initials': 'M', 'LastName': 'Tana', 'Affiliation': 'Dipartimento Universitario Scienze della Vita e Sanità Pubblica, Unità Operativa Complessa di Neonatologia, Fondazione Policlinico Universitario A Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Rome, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Tirone', 'Affiliation': 'Dipartimento Universitario Scienze della Vita e Sanità Pubblica, Unità Operativa Complessa di Neonatologia, Fondazione Policlinico Universitario A Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Rome, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Aurilia', 'Affiliation': 'Dipartimento Universitario Scienze della Vita e Sanità Pubblica, Unità Operativa Complessa di Neonatologia, Fondazione Policlinico Universitario A Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Rome, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Lio', 'Affiliation': 'Dipartimento Universitario Scienze della Vita e Sanità Pubblica, Unità Operativa Complessa di Neonatologia, Fondazione Policlinico Universitario A Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Rome, Italy.'}, {'ForeName': 'Simonetta', 'Initials': 'S', 'LastName': 'Costa', 'Affiliation': 'Dipartimento Universitario Scienze della Vita e Sanità Pubblica, Unità Operativa Complessa di Neonatologia, Fondazione Policlinico Universitario A Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Rome, Italy.'}, {'ForeName': 'Vito', 'Initials': 'V', 'LastName': ""D'Andrea"", 'Affiliation': 'Dipartimento Universitario Scienze della Vita e Sanità Pubblica, Unità Operativa Complessa di Neonatologia, Fondazione Policlinico Universitario A Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Rome, Italy.'}, {'ForeName': 'Mariella', 'Initials': 'M', 'LastName': 'Lucente', 'Affiliation': 'Azienda Ospedaliera Cosenza, Cosenza, Italy.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'Nigro', 'Affiliation': 'Azienda Ospedaliera Cosenza, Cosenza, Italy.'}, {'ForeName': 'Lucio', 'Initials': 'L', 'LastName': 'Giordano', 'Affiliation': 'Ospedale Pineta Grande, Castel Volturno, Italy.'}, {'ForeName': 'Vincenzina', 'Initials': 'V', 'LastName': 'Roma', 'Affiliation': 'Ospedale Pineta Grande, Castel Volturno, Italy.'}, {'ForeName': 'Paolo E', 'Initials': 'PE', 'LastName': 'Villani', 'Affiliation': 'Azienda Ospedaliera Carlo Poma, Mantova, Italy.'}, {'ForeName': 'Francesca P', 'Initials': 'FP', 'LastName': 'Fusco', 'Affiliation': 'Dipartimento Universitario Scienze della Vita e Sanità Pubblica, Unità Operativa Complessa di Neonatologia, Fondazione Policlinico Universitario A Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Rome, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy.'}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Fasolato', 'Affiliation': 'Azienda Ospedaliera Carlo Poma, Mantova, Italy.'}, {'ForeName': 'Maria Rosa', 'Initials': 'MR', 'LastName': 'Colnaghi', 'Affiliation': 'Department of Clinical Sciences and Community Health, University of Milan, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'ForeName': 'Piero G', 'Initials': 'PG', 'LastName': 'Matassa', 'Affiliation': 'Department of Clinical Sciences and Community Health, University of Milan, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Vendettuoli', 'Affiliation': 'Department of Clinical Sciences and Community Health, University of Milan, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Poggi', 'Affiliation': 'Department of Mother and Child Health, Division of Neonatology and Neonatal Intensive Care Unit, Careggi University Hospital, Florence, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Del Vecchio', 'Affiliation': 'Dipartimento Materno Infantile ASL Bari, Ospedale Di Venere, Bari, Italy.'}, {'ForeName': 'Flavia', 'Initials': 'F', 'LastName': 'Petrillo', 'Affiliation': 'Dipartimento Materno Infantile ASL Bari, Ospedale Di Venere, Bari, Italy.'}, {'ForeName': 'Pasqua', 'Initials': 'P', 'LastName': 'Betta', 'Affiliation': 'Azienda Ospedaliera-Universitaria Policlinico Vittorio Emanuele- Presidio Ospedaliero Gaspare Rodolico, Catania, Italy.'}, {'ForeName': 'Carmine', 'Initials': 'C', 'LastName': 'Mattia', 'Affiliation': 'Azienda Ospedaliera-Universitaria Policlinico Vittorio Emanuele- Presidio Ospedaliero Gaspare Rodolico, Catania, Italy.'}, {'ForeName': 'Giampaolo', 'Initials': 'G', 'LastName': 'Garani', 'Affiliation': 'Azienda Ospedaliera-Universitaria, Ferrara, Italy.'}, {'ForeName': 'Agostina', 'Initials': 'A', 'LastName': 'Solinas', 'Affiliation': 'Azienda Ospedaliera-Universitaria, Ferrara, Italy.'}, {'ForeName': 'Eloisa', 'Initials': 'E', 'LastName': 'Gitto', 'Affiliation': 'Università degli studi, Messina, Italy.'}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Salvo', 'Affiliation': 'Università degli studi, Messina, Italy.'}, {'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Gargano', 'Affiliation': 'Azienda Unità Sanitaria Locale, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy.'}, {'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Balestri', 'Affiliation': 'Azienda Unità Sanitaria Locale, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy.'}, {'ForeName': 'Fabrizio', 'Initials': 'F', 'LastName': 'Sandri', 'Affiliation': 'Ospedale Maggiore, Bologna, Italy.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Mescoli', 'Affiliation': 'Ospedale Maggiore, Bologna, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Martinelli', 'Affiliation': 'Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Ilardi', 'Affiliation': 'Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Ciarmoli', 'Affiliation': 'Fondazione Monza e Brianza per il Bambino e la sua Mamma, Ospedale San Gerardo Monza, Italy.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Di Fabio', 'Affiliation': ""Ospedale San Salvatore, L'Aquila, Italy.""}, {'ForeName': 'Eugenia', 'Initials': 'E', 'LastName': 'Maranella', 'Affiliation': ""Ospedale San Salvatore, L'Aquila, Italy.""}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Grassia', 'Affiliation': 'Azienda Ospedaliera S Anna e S Sebastiano, Caserta, Italy.'}, {'ForeName': 'Gaetano', 'Initials': 'G', 'LastName': 'Ausanio', 'Affiliation': 'Azienda Ospedaliera S Anna e S Sebastiano, Caserta, Italy.'}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Rossi', 'Affiliation': 'Azienda Ospedaliera S Anna e S Sebastiano, Caserta, Italy.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Motta', 'Affiliation': 'ARNAS Garibaldi, Catania, Italy.'}, {'ForeName': 'Lucia G', 'Initials': 'LG', 'LastName': 'Tina', 'Affiliation': 'ARNAS Garibaldi, Catania, Italy.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Maiolo', 'Affiliation': 'ARNAS Garibaldi, Catania, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Nobile', 'Affiliation': 'Dipartimento Universitario Scienze della Vita e Sanità Pubblica, Unità Operativa Complessa di Neonatologia, Fondazione Policlinico Universitario A Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Rome, Italy; Division of Neonatology, Department of Clinical Sciences, Polytechnic University of Marche and Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy.'}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'Messner', 'Affiliation': 'Ospedale di Bolzano, Novara, Italy.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Staffler', 'Affiliation': 'Ospedale di Bolzano, Novara, Italy.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Ferrero', 'Affiliation': 'Ospedale Maggiore, Novara, Italy.'}, {'ForeName': 'Ilaria', 'Initials': 'I', 'LastName': 'Stasi', 'Affiliation': 'Ospedale Maggiore, Novara, Italy.'}, {'ForeName': 'Luisa', 'Initials': 'L', 'LastName': 'Pieragostini', 'Affiliation': 'Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy; Dipartimento Materno Infantile, Unità Operativa Complessa Neonatologia e Pediatria, Ospedale Augusto Murri, Fermo, Italy.'}, {'ForeName': 'Isabella', 'Initials': 'I', 'LastName': 'Mondello', 'Affiliation': 'Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Haass', 'Affiliation': 'Ospedale Fatebenefratelli-San Pietro, Rome, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Consigli', 'Affiliation': 'Ospedale Fatebenefratelli-San Pietro, Rome, Italy.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Vedovato', 'Affiliation': 'Ospedale San Bortolo, Vicenza, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Grison', 'Affiliation': 'Ospedale San Bortolo, Vicenza, Italy.'}, {'ForeName': 'Gianfranco', 'Initials': 'G', 'LastName': 'Maffei', 'Affiliation': 'Azienda Ospedaliera-Universitaria Ospedali Riuniti, Foggia, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Presta', 'Affiliation': 'Azienda Ospedaliera Vito Fazzi, Lecce, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Perniola', 'Affiliation': 'Azienda Ospedaliera Vito Fazzi, Lecce, Italy.'}, {'ForeName': 'Marcello', 'Initials': 'M', 'LastName': 'Vitaliti', 'Affiliation': 'ARNAS Civico, Palermo, Italy.'}, {'ForeName': 'Maria P', 'Initials': 'MP', 'LastName': 'Re', 'Affiliation': 'ARNAS Civico, Palermo, Italy.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'De Curtis', 'Affiliation': 'Maternal and Child Health Department, University of Rome La Sapienza, Rome, Italy.'}, {'ForeName': 'Viviana', 'Initials': 'V', 'LastName': 'Cardilli', 'Affiliation': 'Maternal and Child Health Department, University of Rome La Sapienza, Rome, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Lago', 'Affiliation': 'Ospedale Cà Foncello, Treviso, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Tormena', 'Affiliation': 'Ospedale Cà Foncello, Treviso, Italy.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Orfeo', 'Affiliation': 'Ospedale ""San Giovanni Calibita"" Fatebenefratelli, Rome, Italy.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Gizzi', 'Affiliation': 'Ospedale ""San Giovanni Calibita"" Fatebenefratelli, Rome, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Massenzi', 'Affiliation': 'Ospedale ""San Giovanni Calibita"" Fatebenefratelli, Rome, Italy.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Gazzolo', 'Affiliation': 'Ospedale C Arrigo, Alessandria, Italy; Chieti University, Chieti, Italy.'}, {'ForeName': 'Maria Chiara M', 'Initials': 'MCM', 'LastName': 'Strozzi', 'Affiliation': 'Ospedale C Arrigo, Alessandria, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Bottino', 'Affiliation': 'Fondazione Poliambulanza, Brescia, Italy.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Pontiggia', 'Affiliation': 'Fondazione Poliambulanza, Brescia, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Berardi', 'Affiliation': 'Azienda Ospedaliera-Universitaria Policlinico, Modena, Italy.'}, {'ForeName': 'Isotta', 'Initials': 'I', 'LastName': 'Guidotti', 'Affiliation': 'Azienda Ospedaliera-Universitaria Policlinico, Modena, Italy.'}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Cacace', 'Affiliation': 'Ospedale Barone Romeo, Patti, Italy.'}, {'ForeName': 'Valerio', 'Initials': 'V', 'LastName': 'Meli', 'Affiliation': 'Ospedale Barone Romeo, Patti, Italy.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Quartulli', 'Affiliation': 'Azienda Ospedaliera ""Card G Panico"", Tricase, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Scorrano', 'Affiliation': 'Azienda Ospedaliera ""Card G Panico"", Tricase, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Casati', 'Affiliation': 'Ospedale Bel Colle, Viterbo, Italy.'}, {'ForeName': 'Lidia', 'Initials': 'L', 'LastName': 'Grappone', 'Affiliation': 'Azienda Ospedaliera G Rummo, Benevento, Italy.'}, {'ForeName': 'J Jane', 'Initials': 'JJ', 'LastName': 'Pillow', 'Affiliation': 'Centre for Child Health Research and School of Human Sciences, The University of Western Australia, Perth, WA, Australia.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(20)30179-X'] 2118,32681775,Self-estimation of phenylketonuria patients on therapeutic diet. Psychological support.,"Objectives Self-esteem is the degree to which the qualities and characteristics contained in one's self-concept are perceived to be positive. The aim of this study was to evaluate the self-esteem scores in phenylketonuria (PKU) patients on ""strict"", ""loos"" and ""off diet"". Sixty PKU patients were divided in three equal groups. Methods Group a: ""on strict"", group b: ""on loos"" and group c: ""off diet"". A special questionnaire for self-esteem scores was created for these patients. Results Before psychological support, group a patients demonstrated 6/20 (30%) very high self-esteem, 9/20 (45%) high and 5/25 (25%) moderate. After support 14/20 (70%) were turned to very high, 5/20 (25%) represented high except one whose degrees remained an altered. group b 4/20 (20%) were very high, 7/20 (35%) were high, 3/20 (15%) moderate and the rest of them showed low self-esteem degrees, after support, 10/20 (50%) showed very high, 5/20 (25%) became high, 3/20 (15%) turned to moderate and 2/20 (10%) remained unaltered. Group c, 1/20 (5%) were very high self-esteemed, 7/20 (35%) were high, 6/20 (30%) were moderate and 6/20 (30%) with low self-esteemed, at the end of support, 6/20 (30%) become very high, 8/20 (40%) with high, 4/20 (20.0%), moderate self-esteem whereas the rest were unaltered. Conclusions Very high and high self-esteem degrees were demonstrated in patients who follow their PKU diet. Moderate and low self-esteem degrees were predominantly found in patients on loos and or off diet. Psychological supports commonly result in amelioration of self-esteem degrees.",2020,Results Before psychological support,"['Sixty PKU patients', 'phenylketonuria (PKU) patients on ""strict"", ""loos"" and ""off diet']","['on loos"" and group c: ""off diet']","['high self-esteem', 'Moderate and low self-esteem degrees', 'moderate self-esteem', 'self-esteem scores']","[{'cui': 'C0031485', 'cui_str': 'Phenylketonuria'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C2712312', 'cui_str': 'High self-esteem'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0679136', 'cui_str': 'Low self-esteem'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",60.0,0.0184039,Results Before psychological support,"[{'ForeName': 'Kostas Konstantinos', 'Initials': 'KK', 'LastName': 'Iakovou', 'Affiliation': 'Institute of child health, Inborn Errors of Metabolism, Hivon & Papadiamantopoulou, 15773, Αthens, 11527, Attiki, Greece.'}, {'ForeName': 'Kleopatra', 'Initials': 'K', 'LastName': 'Schulpis', 'Affiliation': 'Institute of Child Health Athens, Inborn error of metabolism, Athens, Attiki, Greece.'}]",Drug metabolism and personalized therapy,['10.1515/dmpt-2020-0107'] 2119,32681816,"Novel approaches to behavioral management of vasovagal reactions and donor recruitment: comment on ""a randomized controlled trial of a table-based intervention to address predonation fears among high school donors"".",,2020,,['high school donors'],[],[],"[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0013018', 'cui_str': 'Donors'}]",[],[],,0.0449032,,"[{'ForeName': 'Blaine', 'Initials': 'B', 'LastName': 'Ditto', 'Affiliation': 'Department of Psychology, McGill University, Montreal, Québec, Canada.'}]",Transfusion,['10.1111/trf.15950'] 2120,32682049,"Employee perseverance in a ""no phone use while driving"" organizational road-safety intervention.","INTRODUCTION This interdisciplinary study explores factors that contribute to the perseverance of participants in an organizational ""no phone use while driving"" road-safety intervention. METHOD The study sample comprised 200 employees (mean age 43 years; 104 females [52 %], 96 males [48 %]) from 8 organizations in Israel. Subjects completed a 4-month organizational intervention using a smartphone application that monitored smartphone use, operationalized as taps per minute, where each tap represents a single instance of contact with the screen (e.g., touching, tapping or swiping). The app also silenced notifications during the intervention stage. Changes over time in tapping-while-driving behavior were examined through self-report questionnaires and objectively through the application's monitoring function. Validated measures were used to examine factors associated with perseverance in the program. RESULTS Organizational safety climate and gender (male) were positively related to perseverance in the intervention. Contrary to our hypothesis, safety motivation was not found to influence perseverance. CONCLUSIONS The present intervention is most effective for employees with high safety climate perceptions and for male employees. PRACTICAL APPLICATIONS The organizational intervention presented in the current study was shown to be effective in reducing smartphone use (touching, tapping or swiping) while driving. Our findings show that people will download and use an app that actively reduces their incentive to use their phones at the wheel by silencing incoming notifications. The findings support calls to harness the positive potential of information and communications technologies for organizational interventions.",2020,"The organizational intervention presented in the current study was shown to be effective in reducing smartphone use (touching, tapping or swiping) while driving.","['employees with high safety climate perceptions and for male employees', '200 employees (mean age 43 years; 104 females [52 %], 96 males [48 %]) from 8 organizations in Israel']",[],['safety motivation'],"[{'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0008946', 'cui_str': 'Climate'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0022271', 'cui_str': 'Israel'}]",[],"[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}]",200.0,0.0146053,"The organizational intervention presented in the current study was shown to be effective in reducing smartphone use (touching, tapping or swiping) while driving.","[{'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Rispler', 'Affiliation': 'Faculty of Welfare and Health Sciences, Department of Human Services, University of Haifa, Mount Carmel, Haifa, 31905, Israel. Electronic address: clararispler5510@gmail.com.'}, {'ForeName': 'Gil', 'Initials': 'G', 'LastName': 'Luria', 'Affiliation': 'Faculty of Welfare and Health Sciences, Department of Human Services, University of Haifa, Mount Carmel, Haifa, 31905, Israel. Electronic address: gluria@univ.haifa.ac.il.'}]",Accident; analysis and prevention,['10.1016/j.aap.2020.105689'] 2121,32686996,"Effects of two exercise programmes on joint position sense, dynamic balance and countermovement jump in male amateur football players. A randomised controlled trial.","INTRODUCTION The injury prevention and warm-up exercises programmes improve physical performance and injury ratio, but it is poorly investigated in amateur football. OBJECTIVES To assess the effects of two warm-up multi-station programmes (IAI-Programme and FIFA11+) through JPS, LSDT and CMJ. Study design: Randomised controlled trial. METHODS 36 football players were randomised into 2 groups: IAI-Programme (n = 18) and FIFA11+ (n = 18) and performed the intervention protocol for 6 weeks. JPS, LSDT and CMJ were measured at baseline, after 6, 10 and 18 weeks (from baseline). The inter-group and intra-group differences were assessed by repeated-measures analysis of variance test (ANOVA). RESULTS Significant differences between groups were found after 18 weeks in the absolute angular error (-2.18[-4.33,-0.047], d = 0.69, p < 0.05) of the JPS and in the CMJ (p = 0.001, ŋ 2 p=,0.298) in favour of IAI-Programme when compared to FIFA11 +. No significant differences between groups were found in the LSDT. There were also intra-group differences observed in the LSDT in both groups. CONCLUSIONS IAI-Programme can provide sensitive benefits with respect to the proprioceptive ability of knee flexion and CMJ than FIFA11 +. Both IAI-Programme and FIFA11+ present improvements in the dynamic postural control measured by the LSDT.",2020,"RESULTS Significant differences between groups were found after 18 weeks in the absolute angular error (-2.18[-4.33,-0.047], d = 0.69, p < 0.05) of the JPS and in the CMJ (p = 0.001, ŋ 2 p=,0.298) in favour of IAI-Programme when compared to FIFA11 +.","['36 football players', 'male amateur football players']","['IAI-Programme (n\xa0=\xa018) and FIFA11', 'JPS, LSDT and CMJ', 'exercise programmes']","['dynamic postural control', 'absolute angular error', 'JPS, LSDT and CMJ', 'joint position sense, dynamic balance and countermovement jump', 'physical performance and injury ratio']","[{'cui': 'C0016517', 'cui_str': 'American or Canadian football - sport'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0345893', 'cui_str': 'Juvenile polyposis syndrome'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C4760618', 'cui_str': 'Posture Control'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0345893', 'cui_str': 'Juvenile polyposis syndrome'}, {'cui': 'C0423561', 'cui_str': 'Joint position sense'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.082265,"RESULTS Significant differences between groups were found after 18 weeks in the absolute angular error (-2.18[-4.33,-0.047], d = 0.69, p < 0.05) of the JPS and in the CMJ (p = 0.001, ŋ 2 p=,0.298) in favour of IAI-Programme when compared to FIFA11 +.","[{'ForeName': 'Marcos J', 'Initials': 'MJ', 'LastName': 'Navarro-Santana', 'Affiliation': 'Health and Rehabilitation Center San Fernando (Centro Médico Rehabilitación San Fernando) , Madrid, Spain.'}, {'ForeName': 'Iván', 'Initials': 'I', 'LastName': 'Asín-Izquierdo', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Alcalá , Madrid, Spain.'}, {'ForeName': 'Guido F', 'Initials': 'GF', 'LastName': 'Gómez-Chiguano', 'Affiliation': 'Podiatry University Clinic, Complutense University of Madrid , Madrid, Spain.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Albert-Lucena', 'Affiliation': 'Mutua Universal , Madrid, Spain.'}, {'ForeName': 'Gustavo', 'Initials': 'G', 'LastName': 'Plaza-Manzano', 'Affiliation': 'Department of Radiology, Rehabilitation and Physiotherapy, Complutense University of Madrid , Madrid, Spain.'}, {'ForeName': 'Ángel', 'Initials': 'Á', 'LastName': 'Pérez-Silvestre', 'Affiliation': 'Centre for Sports Medicine, Spanish Agency for Health Protection in Sports (AEPSAD in its Spanish acronym) , Madrid, Spain.'}]",Journal of sports sciences,['10.1080/02640414.2020.1794472'] 2122,32687081,The role of entropy monitoring in reducing propofol requirements during open heart surgeries. A prospective randomized study.,"Background Hypotension, which is commonly associated with propofol induction of general anesthesia in coronary artery bypass grafting (CABG) surgery, may cause adverse consequences in patients with coronary artery diseases undergoing this type of surgeries. The clinical absence of verbal response and eyelash reflex was used as an endpoint for hypnosis. Spectral entropy, as a novel monitoring method for the endpoint of hypnosis, affect the dose of required anesthetic agents for induction as well as the hemodynamic profile during general anesthesia in CABG surgery. Aims We hypothesized that entropy monitoring might reduce the dose of propofol required for induction of anesthesia during CABG surgery and could maintain hemodynamic stability when compared with the conventional clinical monitoring. Materials and Methods Sixty adult patients of both sexes, aged 30-60 years, ASA II and III, and scheduled for CABG surgery were enrolled in this prospective, controlled, randomized, double-blind study. These patients were randomly divided into two equal groups to receive intravenous propofol for induction of anesthesia guided by either the patients' clinical response (Group I) or by entropy monitoring (Group II). The total dose of propofol used for induction of anesthesia was recorded. Hemodynamic parameters and entropy values were also recorded. Results Propofol consumption was significantly reduced in Group II than Group I (P = 0.000*). Heart rate showed no statistical significance between the two groups, whereas the mean arterial pressure significantly decreased at induction in group I compared to Group II (P = 0.000*). The entropy values were significantly lower in Group I than Group II at induction (P = 0.036* for state entropy; 0.002* for response entropy). However, during intubation, and after 1 and 5 min, entropy indices displayed a significant increase in Group I than Group II. Conclusions Entropy monitoring significantly reduced the dose of propofol required for induction of anesthesia and maintained hemodynamic stability compared to the conventional clinical monitoring during CABG surgeries.",2020,The entropy values were significantly lower in Group I than Group II at induction (P = 0.036,"['Sixty adult patients of both sexes, aged 30-60 years, ASA II and III, and scheduled for CABG surgery', 'open heart surgeries', 'patients with coronary artery diseases undergoing this type of surgeries']","['coronary artery bypass grafting (CABG) surgery', ""intravenous propofol for induction of anesthesia guided by either the patients' clinical response (Group I) or by entropy monitoring"", 'propofol', 'entropy monitoring']","['Propofol consumption', 'entropy values', 'propofol requirements', 'Heart rate', 'mean arterial pressure', 'verbal response and eyelash reflex', 'Hemodynamic parameters and entropy values']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0189745', 'cui_str': 'Open heart surgery'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]","[{'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0853212', 'cui_str': 'Induction of anaesthesia'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0441843', 'cui_str': 'Group I'}, {'cui': 'C0376522', 'cui_str': 'Entropy'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}]","[{'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0376522', 'cui_str': 'Entropy'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0422906', 'cui_str': 'Eyelash reflex'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",60.0,0.0314859,The entropy values were significantly lower in Group I than Group II at induction (P = 0.036,"[{'ForeName': 'Ahmed Said', 'Initials': 'AS', 'LastName': 'Elgebaly', 'Affiliation': 'Department of Anesthesia and PSICUD, Faculty of Medicine, Tanta University, Egypt.'}, {'ForeName': 'Mona B', 'Initials': 'MB', 'LastName': 'El Mourad', 'Affiliation': 'Department of Anesthesia and PSICUD, Faculty of Medicine, Tanta University, Egypt.'}, {'ForeName': 'Sameh Mohamad', 'Initials': 'SM', 'LastName': 'Fathy', 'Affiliation': 'Department of Anesthesia and PSICUD, Faculty of Medicine, Tanta University, Egypt.'}]",Annals of cardiac anaesthesia,['10.4103/aca.ACA_184_18'] 2123,32687088,"Comparison of postoperative cognitive decline in patients undergoing conventional vs miniaturized cardiopulmonary bypass: A randomized, controlled trial.","Background Neurocognitive dysfunction is a common complication of coronary artery bypass grafting (CABG) with incidence of 19-38%. The miniaturized cardiopulmonary bypass (MCPB) system was developed to reduce hemodilution and inflammation and provides better cerebral protection than conventional cardiopulmonary bypass (CCPB). In a meta-analysis, MCPB was associated with a 10-fold reduction in the incidence of strokes. However, its effect on postoperative cognitive decline (POCD) is unknown. We assessed if MCPB decreases POCD after CABG and compared the risk factors. Methods A total of 71 Asian patients presenting for elective CABG at a tertiary center were enrolled. They were randomly assigned to MCPB (n = 36) or CCPB group (n = 35) and followed up in a single-blinded, prospective, randomized controlled trial. The primary outcome was POCD as measured by the repeatable battery of neuropsychological status (RBANS). Inflammatory markers (tumor necrosis factor-alpha and interleukin-6), hematocrit levels, and neutron-specific enolase (NSE) levels were studied. Results Overall, the incidence of POCD at 3 months was 50%, and this was not significantly different between both groups (51.4 vs 50.0%, P = 0.90). Having <6 years of formal education [risk ratio (RR) = 3.014, 95% confidence interval (CI) = 1.054-8.618, P = 0.040] was significantly associated with POCD in the CCPB group, while the lowest hematocrit during cardiopulmonary bypass was independently associated with POCD in the MCPB group (RR = 0.931, 95% CI = 0.868-0.998, P = 0.044). The postoperative inflammatory markers and NSE levels were similar between the two groups. Conclusions This study shows that the MCPB was not superior to CCPB with cell salvage and biocompatible tubing with regard to the neurocognitive outcomes measured by the RBANS.",2020,This study shows that the MCPB was not superior to CCPB with cell salvage and biocompatible tubing with regard to the neurocognitive outcomes measured by the RBANS.,"['patients undergoing', '71 Asian patients presenting for elective CABG at a tertiary center were enrolled']","['conventional cardiopulmonary bypass (CCPB', 'MCPB', 'coronary artery bypass grafting (CABG', 'conventional vs miniaturized cardiopulmonary bypass', 'miniaturized cardiopulmonary bypass (MCPB) system', 'CCPB']","['POCD', 'postoperative cognitive decline (POCD', 'Inflammatory markers (tumor necrosis factor-alpha and interleukin-6), hematocrit levels, and neutron-specific enolase (NSE) levels', 'postoperative inflammatory markers and NSE levels', 'POCD as measured by the repeatable battery of neuropsychological status (RBANS', 'incidence of POCD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0234985', 'cui_str': 'Mental Deterioration'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0518014', 'cui_str': 'Hematocrit - finding'}, {'cui': 'C0027946', 'cui_str': 'Neutron'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0031691', 'cui_str': 'Enolase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",71.0,0.232063,This study shows that the MCPB was not superior to CCPB with cell salvage and biocompatible tubing with regard to the neurocognitive outcomes measured by the RBANS.,"[{'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Yuhe', 'Affiliation': 'Department of Anesthesiology, Singapore General Hospital, 20 College Road, Academia, Level 5, Singapore.'}, {'ForeName': 'Sophia Tsong', 'Initials': 'ST', 'LastName': 'Huey Chew', 'Affiliation': 'Department of Anesthesiology, Singapore General Hospital, 20 College Road, Academia, Level 5; Department of Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Graduate Medical School, 8 College Road, Singapore.'}, {'ForeName': 'An Shing', 'Initials': 'AS', 'LastName': 'Ang', 'Affiliation': 'Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, Level 11,, Singapore.'}, {'ForeName': 'Roderica Rui', 'Initials': 'RR', 'LastName': 'Ge Ng', 'Affiliation': 'Department of Anesthesiology, Singapore General Hospital, 20 College Road, Academia, Level 5; Department of Cardiac, Thoracic and Vascular Surgery, National University Hospital Singapore, 5 Lower Kent Ridge Road, Singapore.'}, {'ForeName': 'Nantawan', 'Initials': 'N', 'LastName': 'Boonkiangwong', 'Affiliation': 'Department of Cardiac, Thoracic and Vascular Surgery, National University Hospital Singapore, Singapore.'}, {'ForeName': 'Weiling', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, Level 11; Department of Anesthesia, National University Health System, 5 Lower Kent Ridge Road, Singapore.'}, {'ForeName': 'Anastasia Han', 'Initials': 'AH', 'LastName': 'Hao Toh', 'Affiliation': 'Department of Psychological Medicine, National University Health System, 5 Lower Kent Ridge Road, Singapore.'}, {'ForeName': 'Michael George', 'Initials': 'MG', 'LastName': 'Caleb', 'Affiliation': 'Department of Anesthesiology, Singapore General Hospital, 20 College Road, Academia, Level 5; Department of Cardiac, Thoracic and Vascular Surgery, National University Hospital Singapore, 5 Lower Kent Ridge Road, Singapore.'}, {'ForeName': 'Roger Chun', 'Initials': 'RC', 'LastName': 'Man Ho', 'Affiliation': 'Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, Level 11; Department of Psychological Medicine, National University Health System, 5 Lower Kent Ridge Road, Singapore.'}, {'ForeName': 'Lian Kah', 'Initials': 'LK', 'LastName': 'Ti', 'Affiliation': 'Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, Level 11; Department of Anesthesia, National University Health System, 5 Lower Kent Ridge Road, Singapore.'}]",Annals of cardiac anaesthesia,['10.4103/aca.ACA_192_18'] 2124,32687091,Pharmacological preconditioning with intralipid in patients undergoing off-pump coronary artery bypass surgery.,"Aims and Objectives The objective of the study was to determine the preconditioning myocardial protective effects of intralipid (IL) in off-pump coronary artery bypass (OPCAB) surgery by measuring highly sensitive troponin T (hsTnT) and cardiac-specific creatine kinase (CK-MB) as markers of myocardial injury. Materials and Methods : Thirty patients, scheduled to undergo elective OPCAB surgery, were randomly assigned to the IL group (n = 15) or control (C) group (n = 15); the IL group received an infusion of 20% IL 2 ml/kg, 30 min prior to revascularization and the control group received an equivalent volume of normal saline. Serum levels of hsTnT and CK-MB were measured before surgery and at 6 h, 24 h, 48 h, and 72 h postoperatively. Also, intraoperative hemodynamic parameters, inotrope use, ventilatory hours, ICU stay, postoperative left ventricular ejection fraction, postoperative lipid profile, renal and hepatic function tests were measured. Results The hsTnT values at the 24 h, 48 h, and 72 h in IL group were significantly lower as compared with the control group. The decline in plasma levels of CK-MB mirrored the hsTnT levels post revascularization at 24 h and 48 h in the IL group compared with the control group; however, at 72 h, level was comparable in both the groups. None of the treated patients had abnormal lipid metabolism, deranged renal, and hepatic function. Conclusion The study revealed Intralipid as a safe pharmacological preconditioning agent for OPCAB surgeries which can reduce the postischemic myocardial injury indicated by the reduction in postischemic cardiac enzymes hsTnT and CK-MB.",2020,"The hsTnT values at the 24 h, 48 h, and 72 h in IL group were significantly lower as compared with the control group.","['patients undergoing off-pump coronary artery bypass surgery', 'Thirty patients, scheduled to undergo elective OPCAB surgery']","['pump coronary artery bypass (OPCAB) surgery', 'intralipid (IL', 'Materials and Methods\n\n\n', 'IL group received an infusion of 20% IL 2 ml/kg, 30 min prior to revascularization and the control group received an equivalent volume of normal saline', 'Pharmacological preconditioning with intralipid']","['Serum levels of hsTnT and CK-MB', 'intraoperative hemodynamic parameters, inotrope use, ventilatory hours, ICU stay, postoperative left ventricular ejection fraction, postoperative lipid profile, renal and hepatic function tests', 'plasma levels of CK-MB', 'abnormal lipid metabolism, deranged renal, and hepatic function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1449706', 'cui_str': 'Off-pump coronary artery bypass'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}]","[{'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C1449706', 'cui_str': 'Off-pump coronary artery bypass'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0733854', 'cui_str': 'Intralipid'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C1300574', 'cui_str': 'mL/kg'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439822', 'cui_str': 'Highly sensitive'}, {'cui': 'C0077404', 'cui_str': 'Troponin T'}, {'cui': 'C0010290', 'cui_str': 'Creatine kinase isoenzyme, MB fraction'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0232741', 'cui_str': 'Liver function'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}]",,0.0830948,"The hsTnT values at the 24 h, 48 h, and 72 h in IL group were significantly lower as compared with the control group.","[{'ForeName': 'Gegal', 'Initials': 'G', 'LastName': 'Pruthi', 'Affiliation': 'Department of Cardiac Anaesthesiology, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Jayanagar, Karnataka, India.'}, {'ForeName': 'Naveen G', 'Initials': 'NG', 'LastName': 'Singh', 'Affiliation': 'Department of Cardiac Anaesthesiology, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Jayanagar, Karnataka, India.'}, {'ForeName': 'P S', 'Initials': 'PS', 'LastName': 'Nagaraja', 'Affiliation': 'Department of Cardiac Anaesthesiology, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Jayanagar, Karnataka, India.'}, {'ForeName': 'Rohini Mayur', 'Initials': 'RM', 'LastName': 'Balaji', 'Affiliation': 'Department of Cardiac Anaesthesiology, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Jayanagar, Karnataka, India.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Manjunatha', 'Affiliation': 'Department of Cardiac Anaesthesiology, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Jayanagar, Karnataka, India.'}, {'ForeName': 'P K', 'Initials': 'PK', 'LastName': 'Choudhary', 'Affiliation': 'Department of Sports Medicine, Sports Authority of Karnataka, Bengaluru, Karnataka, India.'}, {'ForeName': 'M Kurinchi', 'Initials': 'MK', 'LastName': 'Raja', 'Affiliation': 'Department of Cardiac Anaesthesiology, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Jayanagar, Karnataka, India.'}]",Annals of cardiac anaesthesia,['10.4103/aca.ACA_251_18'] 2125,32682395,"Effectiveness of wound infusion of 0.2% ropivacaine by patient control analgesia pump after minithoracotomy aortic valve replacement: a randomized, double-blind, placebo-controlled trial.","BACKGROUND Local anesthetic wound infusion has become an invaluable technique in multimodal analgesia. The effectiveness of wound infusion of 0.2% ropivacaine delivered by patient controlled analgesia (PCA) pump has not been evaluated in minimally invasive cardiac surgery. We tested the hypothesis that 0.2% ropivacaine wound infusion by PCA pump reduces the cumulative dose of opioid needed in the first 48 h after minithoracothomy aortic valve replacement (AVR). METHODS In this prospective, randomized, double-blind, placebo-controlled study, 70 adult patients (31 female and 39 male) were analyzed. Patients were randomized to receive 0.2% ropivacaine or 0.9% saline wound infusion by PCA pump for 48 h postoperatively. PCA pump was programmed at 5 ml h - 1 continuously and 5 ml of bolus with 60 min lockout. Pain levels were assessed and recorded hourly by Numeric Rating Scale (NRS). If NRS score was higher than three the patient was administered 3 mg of opioid piritramide repeated and titrated as needed until pain relief was achieved. The primary outcome was the cumulative dose of the opioid piritramide in the first 48 h after surgery. Secondary outcomes were frequency of NRS scores higher than three, patient's satisfaction with pain relief, hospital length of stay, side effects related to the local anesthetic and complications related to the wound catheter. RESULTS The cumulative dose of the opioid piritramide in the first 48 h after minithoracotomy AVR was significantly lower (p < 0.001) in the ropivacaine (R) group median 3 mg (IQR 6 mg) vs. 9 mg (IQR 9 mg). The number of episodes of pain where NRS score was greater than three median 2 (IQR 2), vs 3 (IQR 3), (p = 0.002) in the first 48 h after surgery were significantly lower in the ropivacaine group, compared to control. Patient satisfaction with pain relief in our study was high. There were no wound infections and no side-effects from the local anesthetic. CONCLUSIONS Wound infusion of local anesthetic by PCA pump significantly reduced opioid dose needed and improves pain control postoperatively. We have also shown that it is a feasible method of analgesia and it should be considered in the multimodal pain control strategy following minimally invasive cardiac surgery. TRIAL REGISTRATION ClinicalTrials.gov NCT03079830 , date of registration: March 15, 2017. Retrospecitvely registered.",2020,"There were no wound infections and no side-effects from the local anesthetic. ","['patient control analgesia pump after minithoracotomy aortic valve replacement', '70 adult patients (31 female and 39 male']","['PCA pump', 'opioid piritramide', 'ropivacaine', 'patient controlled analgesia (PCA) pump', 'wound infusion of 0.2% ropivacaine', 'ropivacaine wound infusion by PCA pump', 'ropivacaine or 0.9% saline wound infusion by PCA pump', 'placebo']","['Numeric Rating Scale (NRS', 'NRS score', 'pain relief', ""frequency of NRS scores higher than three, patient's satisfaction with pain relief, hospital length of stay, side effects related to the local anesthetic and complications related to the wound catheter"", 'number of episodes of pain where NRS score', 'cumulative dose of opioid needed', 'cumulative dose of the opioid piritramide', 'wound infections and no side-effects', 'Patient satisfaction with pain relief', 'Pain levels', 'opioid dose needed and improves pain control postoperatively']","[{'cui': 'C0078944', 'cui_str': 'Patient controlled analgesia'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0405917', 'cui_str': 'Limited thoracotomy'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0078944', 'cui_str': 'Patient controlled analgesia'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0031982', 'cui_str': 'Pirinitramide'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0031982', 'cui_str': 'Pirinitramide'}, {'cui': 'C0043241', 'cui_str': 'Local infection of wound'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]",70.0,0.699468,"There were no wound infections and no side-effects from the local anesthetic. ","[{'ForeName': 'Gordan', 'Initials': 'G', 'LastName': 'Mijovski', 'Affiliation': 'Department of Anaesthesiology and Surgical Intensive Therapy, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Zaloška cesta 2, 1000, Ljubljana, Slovenia. gord@healthgrouper.com.'}, {'ForeName': 'Matej', 'Initials': 'M', 'LastName': 'Podbregar', 'Affiliation': 'Department of Anaesthesiology and Surgical Intensive Therapy, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Zaloška cesta 2, 1000, Ljubljana, Slovenia.'}, {'ForeName': 'Juš', 'Initials': 'J', 'LastName': 'Kšela', 'Affiliation': 'Department of Cardiovascular Surgery, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Matej', 'Initials': 'M', 'LastName': 'Jenko', 'Affiliation': 'Department of Anaesthesiology and Surgical Intensive Therapy, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Zaloška cesta 2, 1000, Ljubljana, Slovenia.'}, {'ForeName': 'Maja', 'Initials': 'M', 'LastName': 'Šoštarič', 'Affiliation': 'Department of Anaesthesiology and Surgical Intensive Therapy, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Zaloška cesta 2, 1000, Ljubljana, Slovenia.'}]",BMC anesthesiology,['10.1186/s12871-020-01093-9'] 2126,32682397,Lung ultrasound score to determine the effect of fraction inspired oxygen during alveolar recruitment on absorption atelectasis in laparoscopic surgery: a randomized controlled trial.,"BACKGROUND Although the intraoperative alveolar recruitment maneuver (RM) efficiently treats atelectasis, the effect of FIO 2 on atelectasis during RM is uncertain. We hypothesized that a high FIO 2 (1.0) during RM would lead to a higher degree of postoperative atelectasis without benefiting oxygenation when compared to low FIO 2 (0.4). METHODS In this randomized controlled trial, patients undergoing elective laparoscopic surgery in the Trendelenburg position were allocated to low- (FIO 2 0.4, n = 44) and high-FIO 2 (FIO 2 1.0, n = 46) groups. RM was performed 1-min post tracheal intubation and post changes in supine and Trendelenburg positions during surgery. We set the intraoperative FIO 2 at 0.4 for both groups and calculated the modified lung ultrasound score (LUSS) to assess lung aeration after anesthesia induction and at surgery completion. The primary outcome was modified LUSS at the end of the surgery. The secondary outcomes were the intra- and postoperative PaO 2 to FIO 2 ratio and postoperative pulmonary complications. RESULTS The modified LUSS before capnoperitoneum and RM (P = 0.747) were similar in both groups. However, the postoperative modified LUSS was significantly lower in the low FIO 2 group (median difference 5.0, 95% CI 3.0-7.0, P < 0.001). Postoperatively, substantial atelectasis was more common in the high-FIO 2 group (relative risk 1.77, 95% CI 1.27-2.47, P < 0.001). Intra- and postoperative PaO 2 to FIO 2 were similar with no postoperative pulmonary complications. Atelectasis occurred more frequently when RM was performed with high than with low FIO 2 ; oxygenation was not benefitted by a high-FIO 2. CONCLUSIONS: In patients undergoing laparoscopic surgery in the Trendelenburg position, absorption atelectasis occurred more frequently with high rather than low FIO 2 . No oxygenation benefit was observed in the high-FIO 2 group. TRIAL REGISTRATION ClinicalTrials.gov, NCT03943433 . Registered 7 May 2019.",2020,Atelectasis occurred more frequently when RM was performed with high than with low FIO 2 ; oxygenation was not benefitted by a high-FIO 2. ,"['patients undergoing elective laparoscopic surgery in the Trendelenburg position were allocated to low- ', 'patients undergoing', 'laparoscopic surgery']","['laparoscopic surgery', 'fraction inspired oxygen during alveolar recruitment', 'intraoperative alveolar recruitment maneuver (RM']","['absorption atelectasis', 'Atelectasis', 'postoperative modified LUSS', 'substantial atelectasis', 'oxygenation benefit', 'modified LUSS', 'intra- and postoperative PaO 2 to FIO 2 ratio and postoperative pulmonary complications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C0277812', 'cui_str': 'Trendelenburg position'}, {'cui': 'C0205251', 'cui_str': 'Low'}]","[{'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C0428648', 'cui_str': 'Inspired oxygen concentration'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}]","[{'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0004144', 'cui_str': 'Atelectasis'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",,0.470857,Atelectasis occurred more frequently when RM was performed with high than with low FIO 2 ; oxygenation was not benefitted by a high-FIO 2. ,"[{'ForeName': 'Bo Rim', 'Initials': 'BR', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.'}, {'ForeName': 'Seohee', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.'}, {'ForeName': 'Hansu', 'Initials': 'H', 'LastName': 'Bae', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.'}, {'ForeName': 'Minkyoo', 'Initials': 'M', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.'}, {'ForeName': 'Jae-Hyon', 'Initials': 'JH', 'LastName': 'Bahk', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.'}, {'ForeName': 'Susie', 'Initials': 'S', 'LastName': 'Yoon', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. susiey87@gmail.com.'}]",BMC anesthesiology,['10.1186/s12871-020-01090-y'] 2127,32682408,"Evaluation of the impact of breastfeeding support groups in primary health CENTRES in Andalusia, Spain: a study protocol for a cluster randomized controlled trial (GALMA project).","BACKGROUND In 2003, the World Health Organization recommended exclusive breastfeeding (EB) during the newborn's first 6 months of life and, if possible, during the first 2 years. However, EB rates resist these recommendations. In developed countries, only 1 out of 3 babies is breastfed during its first 6 months of life, and great differences between areas and countries can be observed. Only 35% of the newborns receive breastfeeding at 3-4 months of age. There are diverse strategies described in the literature that have proven their efficiency in improving breastfeeding rates. It has also been proven that professional support is an effective tool to extend any kind of breastfeeding; besides, it has been observed that mother-to-mother support also increases breastfeeding initiation, sustainment, and exclusive duration. The overall aim of the study is to assess the impact of the support groups on the sustainment of exclusive breastfeeding until 6 months after birth. METHODS/DESIGN This study is a cluster-random multicentric clinical trial with a control group and an intervention group, without blinding because it is impossible to mask the intervention. A randomization by centres of primary health (clusters) will be carried out. The women allocated to the intervention or control group will be randomized with a simple randomization sampling. The participants' breastfeeding rate will be followed up at the first 10 days, and at 2, 4, and 6 months of their newborn's life. DISCUSSION There is a need to assess the impact of mother support groups on exclusive breastfeeding. This study aims to analyse the outcomes related to the support received and to identify what should the structure of these groups be; in other words, to describe factors related to a better breastfeeding experience in order to help women increase breastfeeding rates. TRIAL REGISTRATION The trial is prospectively recorded at the ISRCTN registry (Trial ID: ISRCTN17263529 ). Date recorded: 17/06/2020.",2020,"This study aims to analyse the outcomes related to the support received and to identify what should the structure of these groups be; in other words, to describe factors related to a better breastfeeding experience in order to help women increase breastfeeding rates. ","['primary health CENTRES in Andalusia, Spain']",[],['breastfeeding rate'],"[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0037747', 'cui_str': 'Spain'}]",[],"[{'cui': 'C0006147', 'cui_str': 'Breast fed'}]",,0.066185,"This study aims to analyse the outcomes related to the support received and to identify what should the structure of these groups be; in other words, to describe factors related to a better breastfeeding experience in order to help women increase breastfeeding rates. ","[{'ForeName': 'Rodríguez-Gallego', 'Initials': 'RG', 'LastName': 'Isabel', 'Affiliation': 'Virgen del Rocío University Hospital (Seville), Centro Universitario de Enfermería Cruz Roja, University of Seville, Sevilla, Spain.'}, {'ForeName': 'Leon-Larios', 'Initials': 'LL', 'LastName': 'Fatima', 'Affiliation': 'Nursing Department, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, Sevilla, Spain. fatimaleon@us.es.'}, {'ForeName': 'Ruiz-Ferron', 'Initials': 'RF', 'LastName': 'Cecilia', 'Affiliation': 'Nursing Department, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, Sevilla, Spain.'}, {'ForeName': 'Lomas-Campos', 'Initials': 'LC', 'LastName': 'Maria-de-Las-Mercedes', 'Affiliation': 'Nursing Department, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, Sevilla, Spain.'}]",BMC public health,['10.1186/s12889-020-09244-w'] 2128,32682416,Physical fitness in older women with osteoporosis and vertebral fracture after a resistance and balance exercise programme: 3-month post-intervention follow-up of a randomised controlled trial.,"BACKGROUND Exercise is recommended for individuals with vertebral fractures, but few studies have investigated the effect of exercise on outcomes of importance for this population. Post-intervention effects of exercise are even less studied. The objective of this study was to evaluate habitual walking speed and other health-related outcomes after cessation of a 3-month exercise intervention. METHODS This follow-up study was conducted 3 months post-intervention of a randomised controlled trial. A total of 149 community-dwelling Norwegian women aged 65 years or older, diagnosed with osteoporosis and vertebral fracture were randomised into either exercise or control group. Primary outcome was habitual walking speed at 3 months. Secondary outcomes were other measures of physical fitness - including the Four Square Step Test (FSST), functional reach, grip strength and Senior Fitness Test - measures of health-related quality of life and fear of falling. Herein we report secondary data analysis of all outcomes at 6 months (3 months post-intervention). Data were analysed according to the intention-to-treat principle, linear mixed regression models were employed. RESULTS For the primary outcome, habitual walking speed, there was no statistically significant difference between groups (0.03 m/s, 95%CI - 0.02 to 0.08, p = 0.271) at the 3-month post-intervention follow-up. For secondary outcomes of physical fitness, statistically significant differences in favour of the intervention group were found for balance using the FSST (- 0.68 s, 95%CI - 1.24 to - 0.11, p = 0.019), arm curl (1.3, 95%CI 0.25 to 2.29, p = 0.015), leg strength using the 30-s sit to stand (1.56, 95%CI 0.68 to 2.44, p = 0.001) and mobility using the 2.45-m up and go (- 0.38 s, 95%CI - 0.74 to - 0.02, p = 0.039). There was a statistically significant difference between the groups regarding fear of falling in favour of the intervention group (- 1.7, 95%CI - 2.97 to - 0.38, p = 0.011). No differences between groups were observed for health-related quality of life. CONCLUSION The results show the improved effects of a multicomponent exercise programme on outcomes like muscle strength, balance and mobility as well as fear of falling in a group of older women with osteoporosis and vertebral fracture 3 months post-intervention. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02781974 . Registered 25.05.16. Retrospectively registered.",2020,"For secondary outcomes of physical fitness, statistically significant differences in favour of the intervention group were found for balance using the FSST (- 0.68 s, 95%CI - 1.24 to - 0.11, p = ","['older women with osteoporosis and vertebral fracture after a resistance and balance exercise programme', '149 community-dwelling Norwegian women aged 65\u2009years or older, diagnosed with osteoporosis and vertebral fracture', 'individuals with vertebral fractures']","['exercise or control group', 'multicomponent exercise programme']","['outcomes like muscle strength, balance and mobility as well as fear of falling', 'habitual walking speed at 3\u2009months', 'habitual walking speed', 'leg strength', 'health-related quality of life', 'physical fitness - including the Four Square Step Test (FSST), functional reach, grip strength and Senior Fitness Test - measures of health-related quality of life and fear of falling', 'physical fitness', 'mobility', 'fear of falling', 'Physical fitness', 'balance using the FSST']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0080179', 'cui_str': 'Fracture of vertebral column'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0150219', 'cui_str': 'Balance exercises'}, {'cui': 'C5191071', 'cui_str': '149'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0028424', 'cui_str': 'Norwegian language'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0877040', 'cui_str': 'Fear of falling'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0087028', 'cui_str': 'Step Test'}, {'cui': 'C1321055', 'cui_str': 'Functional reach'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}]",149.0,0.13951,"For secondary outcomes of physical fitness, statistically significant differences in favour of the intervention group were found for balance using the FSST (- 0.68 s, 95%CI - 1.24 to - 0.11, p = ","[{'ForeName': 'Brita', 'Initials': 'B', 'LastName': 'Stanghelle', 'Affiliation': 'Institute of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway. bsugland@oslomet.no.'}, {'ForeName': 'Hege', 'Initials': 'H', 'LastName': 'Bentzen', 'Affiliation': 'Institute of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.'}, {'ForeName': 'Lora', 'Initials': 'L', 'LastName': 'Giangregorio', 'Affiliation': 'Department of Kinesiology, University of Waterloo and Schlegel-UW Research Institute for Aging, Waterloo, Canada.'}, {'ForeName': 'Are Hugo', 'Initials': 'AH', 'LastName': 'Pripp', 'Affiliation': 'Institute of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.'}, {'ForeName': 'Dawn A', 'Initials': 'DA', 'LastName': 'Skelton', 'Affiliation': 'School of Health and Life Sciences, Institute of Applied Health Research, Centre for Living, Glasgow Caledonian University, Glasgow, UK.'}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Bergland', 'Affiliation': 'Institute of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.'}]",BMC musculoskeletal disorders,['10.1186/s12891-020-03495-9'] 2129,32682429,A multimodal intervention to improve hand hygiene compliance in peripheral wards of a tertiary care university centre: a cluster randomised controlled trial.,"BACKGROUND Interventions to improve hand hygiene (HH) compliance are a key element in the practice infection prevention and control. It was our objective to assess the effect of a multimodal intervention on HH compliance at a tertiary care university hospital. As a secondary objective, we investigated the effect of the intervention on the occurrence of device-associated bloodstream infections. METHODS We performed a single centre cluster randomised controlled trial at a university hospital in Germany. Twenty peripheral wards were invited to participate and randomly assigned to either the intervention (n = 10) or control group (n = 10). Quarterly, specifically trained student employees conducted direct compliance observations in all twenty wards. The intervention entailed dissemination of teaching materials on aseptic procedures, equipment with flexibly mountable alcoholic hand rub dispensers, and quarterly feedback on HH compliance. RESULTS In total, 21,424 HH opportunities were observed. Overall, compliance did not change significantly in either group (intervention group: 59% vs. 61% (1482 HH actions for 2494 HH opportunities vs. 5033 HH actions for 8215 HH opportunities), odds ratio (OR) 1.08 (95% confidence interval (CI95) 0.88, 1.33)); control group: 59% vs. 60% (1457 HH actions for 2484 HH opportunities vs. 4948 HH actions for 8231 HH opportunities), OR 1.06 (CI95 0.84, 1.35)). Compliance prior to aseptic procedures improved significantly in the intervention group from 44% (168 HH actions for 380 HH opportunities) to 53% (764 HH actions for 1452 HH opportunities) (OR 1.40 (CI95 1.04, 1.89), p = 0.03), while no significant increase was noted in the control group. In the intervention group, significantly fewer device-associated bloodstream infections per 1000 patient-days occurred than in the control group (84 vs. 123, incidence rate ratio 0.61 (CI95 0.46, 0.81), p < 0.01). CONCLUSIONS The lack of a significant overall improvement of HH compliance demonstrated that comprehensive implementation of HH interventions in multiple wards simultaneously is difficult. However, through targeted intervention measures, we were able to significantly increase HH compliance before aseptic procedures.",2020,"In the intervention group, significantly fewer device-associated bloodstream infections per 1000 patient-days occurred than in the control group (84 vs. 123, incidence rate ratio 0.61 (CI95 0.46, 0.81), p < 0.01). ","['peripheral wards of a tertiary care university centre', 'Twenty peripheral wards', 'university hospital in Germany', 'HH compliance at a tertiary care university hospital']",['multimodal intervention'],"['Compliance prior to aseptic procedures', 'HH compliance', 'device-associated bloodstream infections']","[{'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C3494474', 'cui_str': 'Hand Hygiene'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0232920', 'cui_str': 'Sterile'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C3494474', 'cui_str': 'Hand Hygiene'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C2316160', 'cui_str': 'Infection of bloodstream'}]",21424.0,0.0706666,"In the intervention group, significantly fewer device-associated bloodstream infections per 1000 patient-days occurred than in the control group (84 vs. 123, incidence rate ratio 0.61 (CI95 0.46, 0.81), p < 0.01). ","[{'ForeName': 'Seven Johannes Sam', 'Initials': 'SJS', 'LastName': 'Aghdassi', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Hygiene and Environmental Medicine, Berlin, Germany. seven-johannes-sam.aghdassi@charite.de.'}, {'ForeName': 'Christin', 'Initials': 'C', 'LastName': 'Schröder', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Hygiene and Environmental Medicine, Berlin, Germany.'}, {'ForeName': 'Elke', 'Initials': 'E', 'LastName': 'Lemke', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Hygiene and Environmental Medicine, Berlin, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Behnke', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Hygiene and Environmental Medicine, Berlin, Germany.'}, {'ForeName': 'Patricia Manuela', 'Initials': 'PM', 'LastName': 'Fliss', 'Affiliation': 'BODE SCIENCE CENTER, BODE Chemie GmbH, Hamburg, Germany.'}, {'ForeName': 'Carolin', 'Initials': 'C', 'LastName': 'Plotzki', 'Affiliation': 'BODE SCIENCE CENTER, BODE Chemie GmbH, Hamburg, Germany.'}, {'ForeName': 'Janina', 'Initials': 'J', 'LastName': 'Wenk', 'Affiliation': 'BODE SCIENCE CENTER, BODE Chemie GmbH, Hamburg, Germany.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Gastmeier', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Hygiene and Environmental Medicine, Berlin, Germany.'}, {'ForeName': 'Tobias Siegfried', 'Initials': 'TS', 'LastName': 'Kramer', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Hygiene and Environmental Medicine, Berlin, Germany.'}]",Antimicrobial resistance and infection control,['10.1186/s13756-020-00776-9'] 2130,32640131,A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries.,"BACKGROUND Injuries from falls are major contributors to complications and death in older adults. Despite evidence from efficacy trials that many falls can be prevented, rates of falls resulting in injury have not declined. METHODS We conducted a pragmatic, cluster-randomized trial to evaluate the effectiveness of a multifactorial intervention that included risk assessment and individualized plans, administered by specially trained nurses, to prevent fall injuries. A total of 86 primary care practices across 10 health care systems were randomly assigned to the intervention or to enhanced usual care (the control) (43 practices each). The participants were community-dwelling adults, 70 years of age or older, who were at increased risk for fall injuries. The primary outcome, assessed in a time-to-event analysis, was the first serious fall injury, adjudicated with the use of participant report, electronic health records, and claims data. We hypothesized that the event rate would be lower by 20% in the intervention group than in the control group. RESULTS The demographic and baseline characteristics of the participants were similar in the intervention group (2802 participants) and the control group (2649 participants); the mean age was 80 years, and 62.0% of the participants were women. The rate of a first adjudicated serious fall injury did not differ significantly between the groups, as assessed in a time-to-first-event analysis (events per 100 person-years of follow-up, 4.9 in the intervention group and 5.3 in the control group; hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P = 0.25). The rate of a first participant-reported fall injury was 25.6 events per 100 person-years of follow-up in the intervention group and 28.6 events per 100 person-years of follow-up in the control group (hazard ratio, 0.90; 95% CI, 0.83 to 0.99; P = 0.004). The rates of hospitalization or death were similar in the two groups. CONCLUSIONS A multifactorial intervention, administered by nurses, did not result in a significantly lower rate of a first adjudicated serious fall injury than enhanced usual care. (Funded by the Patient-Centered Outcomes Research Institute and others; STRIDE ClinicalTrials.gov number, NCT02475850.).",2020,A total of 86 primary care practices across 10 health care systems were randomly assigned to the intervention or to enhanced usual care (the control) (43 practices each).,"['participants were similar in the intervention group (2802 participants) and the control group (2649 participants); the mean age was 80 years, and 62.0% of the participants were women', '86 primary care practices across 10 health care systems', 'older adults', 'participants were community-dwelling adults, 70 years of age or older, who were at increased risk for fall injuries']","['multifactorial intervention', 'intervention or to enhanced usual care (the control']","['time-to-event analysis, was the first serious fall injury, adjudicated with the use of participant report, electronic health records, and claims data', 'rate of a first adjudicated serious fall injury', 'rate of a first participant-reported fall injury', 'rates of hospitalization or death']","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0051533', 'cui_str': 'Am 80'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0018696', 'cui_str': 'Healthcare Systems'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C4045975', 'cui_str': 'Community Dwelling'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1268740', 'cui_str': 'At risk for falls'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0085639', 'cui_str': 'Falls'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",2802.0,0.136147,A total of 86 primary care practices across 10 health care systems were randomly assigned to the intervention or to enhanced usual care (the control) (43 practices each).,"[{'ForeName': 'Shalender', 'Initials': 'S', 'LastName': 'Bhasin', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Gill', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Reuben', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Nancy K', 'Initials': 'NK', 'LastName': 'Latham', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Ganz', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Erich J', 'Initials': 'EJ', 'LastName': 'Greene', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Dziura', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Shehzad', 'Initials': 'S', 'LastName': 'Basaria', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Jerry H', 'Initials': 'JH', 'LastName': 'Gurwitz', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Patricia C', 'Initials': 'PC', 'LastName': 'Dykes', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Siobhan', 'Initials': 'S', 'LastName': 'McMahon', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Thomas W', 'Initials': 'TW', 'LastName': 'Storer', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Priscilla', 'Initials': 'P', 'LastName': 'Gazarian', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Miller', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Thomas G', 'Initials': 'TG', 'LastName': 'Travison', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Esserman', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Martha B', 'Initials': 'MB', 'LastName': 'Carnie', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Goehring', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Fagan', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Greenspan', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Alexander', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Jocelyn', 'Initials': 'J', 'LastName': 'Wiggins', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Ko', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Albert L', 'Initials': 'AL', 'LastName': 'Siu', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Volpi', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Albert W', 'Initials': 'AW', 'LastName': 'Wu', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Rich', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Stephen C', 'Initials': 'SC', 'LastName': 'Waring', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Robert B', 'Initials': 'RB', 'LastName': 'Wallace', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Carri', 'Initials': 'C', 'LastName': 'Casteel', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Neil M', 'Initials': 'NM', 'LastName': 'Resnick', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Magaziner', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Charpentier', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Lu', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Katy', 'Initials': 'K', 'LastName': 'Araujo', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Haseena', 'Initials': 'H', 'LastName': 'Rajeevan', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Can', 'Initials': 'C', 'LastName': 'Meng', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Allore', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Brooke F', 'Initials': 'BF', 'LastName': 'Brawley', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Rich', 'Initials': 'R', 'LastName': 'Eder', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Joanne M', 'Initials': 'JM', 'LastName': 'McGloin', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Eleni A', 'Initials': 'EA', 'LastName': 'Skokos', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Pamela W', 'Initials': 'PW', 'LastName': 'Duncan', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Dorothy', 'Initials': 'D', 'LastName': 'Baker', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Chad', 'Initials': 'C', 'LastName': 'Boult', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Rosaly', 'Initials': 'R', 'LastName': 'Correa-de-Araujo', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Peduzzi', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa2002183'] 2131,32538148,An acute rise of plasma Na + concentration associates with syndecan-1 shedding during hemodialysis.,"Endothelial dysfunction (ED) contributes to the high incidence of cardiovascular events in patients undergoing hemodialysis. Syndecan-1 in the endothelial glycocalyx can be shed into the circulation, serving as a biomarker for ED. As Na + is a trigger for glycocalyx shedding, we now tested whether hemodialysis, with higher dialysate Na + concentrations, is associated with more syndecan-1 shedding compared with standard hemodialysis (SHD). In this crossover study in 29 patients, plasma syndecan-1 was repeatedly measured during SHD and during Hemocontrol hemodialysis (HHD), which is characterized by initially higher dialysate and plasma Na + levels. Courses of syndecan-1 were compared with linear mixed models. Syndecan-1 shedding was assessed by area under the curve analysis. Plasma Na + increased early after the start of SHD and HHD, with higher values during HHD (30 min: 142.3 vs. 139.9 mM, P < 0.001). Syndecan-1 increased significantly during both conditions, but the percent change was higher (42.9% vs. 19.5%) and occurred earlier (120 vs. 180 min) during HHD. Syndecan-1 levels were significantly higher at 120 min during HHD compared with SHD ( P < 0.05). Overall, syndecan-1 shedding was higher during HHD compared with SHD (means: 40.4 vs. 19.0 arbitrary units, P = 0.06). Lower predialysis plasma Na + and osmolality were associated with greater intradialytic increases in syndecan-1 levels (both groups, P = 0.001). The rise in plasma syndecan-1 levels was more pronounced and occurred earlier during hemodialysis with higher plasma Na + levels. Although we cannot prove that the rise in plasma syndecan-1 originates from the endothelial glycocalyx, our findings are compatible with Na + -driven endothelial glycocalyx-derived syndecan-1 shedding.",2020,The rise in plasma syndecan-1 levels was more pronounced and occurred earlier during hemodialysis with higher plasma Na + levels.,"['29 patients, plasma syndecan-1 was repeatedly measured during SHD and during Hemocontrol hemodialysis (HHD), which is characterized by initially higher dialysate and plasma Na + levels', 'patients undergoing hemodialysis']",[],"['Endothelial dysfunction (ED', 'Lower predialysis plasma Na + and osmolality', 'syndecan-1 levels', 'plasma syndecan-1 levels', 'syndecan-1 shedding', 'Plasma Na ', 'Syndecan-1 shedding', 'Syndecan-1 levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0753253', 'cui_str': 'SDC1 protein, human'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0011947', 'cui_str': 'Dialysis fluid'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",[],"[{'cui': 'C0856169', 'cui_str': 'Endothelial dysfunction'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0086741', 'cui_str': 'Osmolality'}, {'cui': 'C0753253', 'cui_str': 'SDC1 protein, human'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",29.0,0.028535,The rise in plasma syndecan-1 levels was more pronounced and occurred earlier during hemodialysis with higher plasma Na + levels.,"[{'ForeName': 'Josephine', 'Initials': 'J', 'LastName': 'Koch', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Nienke M A', 'Initials': 'NMA', 'LastName': 'Idzerda', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Esmée M', 'Initials': 'EM', 'LastName': 'Ettema', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Kuipers', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Dam', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'van den Born', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Casper F M', 'Initials': 'CFM', 'LastName': 'Franssen', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.'}]",American journal of physiology. Renal physiology,['10.1152/ajprenal.00005.2020'] 2132,32687890,The value of ultrasound guidance during IUD insertion in women with RVF uterus: A randomized controlled trial.,"OBJECTIVE The study objective is to evaluate the benefits of using ultrasound guidance during insertion of Intrauterine device IUD in women with retroverted flexed RVF uteri. STUDY DESIGN A randomized controlled trial conducted on 400 women with RVF uteri eligible for IUD insertion. They were randomly divided into 2 groups. Group 1 underwent IUD insertion under ultrasound guidance while in group 2 no ultrasound guidance was used. The primary outcome measure was the(Visual Analogue Scale) VAS pain score reported by the women during insertion. Other outcome included easiness of insertion, the procedure time and occurrence of complications as nausea, vomiting, abdominal cramps, failure of insertion, uterine perforation and bleeding. RESULTS The VAS pain score was significantly lower (2.36 ± 1.77 vs. 4.74 ± 2.35, p < 0.001), the insertion was much easier (score 4.0 ± 0.9 vs. 2.5 ± 1.27, p < 0.001) and the time needed for the procedure was significantly shorter (5.82 ± 2.56 vs. 9.4 ± 4.99 minutes, p < 0.001) in women within the ultrasound guided group when compared to control group. The total rate of complications was significantly lower (6 vs. 16%, p 0.001) especially bleeding (2 vs. 9%, p = 0.002), abdominal cramps (10.5 vs. 28%, p 0.012) and failure of the procedure (0 vs. 3%, p = 005) in ultrasound guided group women when compared to control. CONCLUSION Insertion of Intrauterine device IUD under ultrasound guidance in women with Retroverted flexed RVF uterus easier and less painful than the blind standard technique.",2020,"The total rate of complications was significantly lower (6 vs. 16%, p 0.001) especially bleeding (2 vs. 9%, p = 0.002), abdominal cramps (10.5 vs. 28%, p 0.012) and failure of the procedure (0 vs. 3%, p = 005) in ultrasound guided group women when compared to control. ","['women with RVF uterus', '400 women with RVF uteri eligible for IUD insertion', 'women with retroverted flexed RVF uteri']","['IUD insertion under ultrasound guidance while in group 2 no ultrasound guidance', 'ultrasound guidance', 'Insertion of Intrauterine device IUD under ultrasound guidance', 'Intrauterine device IUD', 'ultrasound guidance during IUD insertion']","['easiness of insertion, the procedure time and occurrence of complications as nausea, vomiting, abdominal cramps, failure of insertion, uterine perforation and bleeding', 'the(Visual Analogue Scale) VAS pain score', 'VAS pain score', 'bleeding', 'time needed for the procedure', 'failure of the procedure', 'abdominal cramps', 'total rate of complications']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0035613', 'cui_str': 'Rift valley fever'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0812450', 'cui_str': 'Insertion of intrauterine contraceptive device'}]","[{'cui': 'C0812450', 'cui_str': 'Insertion of intrauterine contraceptive device'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0015927', 'cui_str': 'Fetal death'}, {'cui': 'C0021900', 'cui_str': 'Intrauterine contraceptive device'}]","[{'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0000729', 'cui_str': 'Abdominal Cramps'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0042139', 'cui_str': 'Perforation of uterus'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",400.0,0.274029,"The total rate of complications was significantly lower (6 vs. 16%, p 0.001) especially bleeding (2 vs. 9%, p = 0.002), abdominal cramps (10.5 vs. 28%, p 0.012) and failure of the procedure (0 vs. 3%, p = 005) in ultrasound guided group women when compared to control. ","[{'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Maged', 'Affiliation': 'Obstetrics and Gynecology department Cairo University, Egypt. Electronic address: ahmedmaged@gmail.com.'}, {'ForeName': 'Adel M', 'Initials': 'AM', 'LastName': 'Nada', 'Affiliation': 'Obstetrics and Gynecology department Cairo University, Egypt. Electronic address: adel.nada29@gmail.com.'}, {'ForeName': 'Hala', 'Initials': 'H', 'LastName': 'Abdelwahab', 'Affiliation': 'Obstetrics and Gynecology department Cairo University, Egypt. Electronic address: halaabdelwahab@gmail.com.'}, {'ForeName': 'Emad', 'Initials': 'E', 'LastName': 'Salah', 'Affiliation': 'Obstetrics and Gynecology department Cairo University, Egypt. Electronic address: emadsalah148@gmail.com.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Soliman', 'Affiliation': 'Obstetrics and Gynecology department Cairo University, Egypt. Electronic address: dr_mahmoudsoliman@yahoo.com.'}, {'ForeName': 'Eman', 'Initials': 'E', 'LastName': 'A Hussein', 'Affiliation': 'Obstetrics and Gynecology department Cairo University, Egypt. Electronic address: emanalyhussein@yahoo.com.'}, {'ForeName': 'Aimy', 'Initials': 'A', 'LastName': 'Essam', 'Affiliation': 'Obstetrics and Gynecology department Cairo University, Egypt. Electronic address: aimyessam@hotmail.com.'}, {'ForeName': 'Hala', 'Initials': 'H', 'LastName': 'Nabil', 'Affiliation': 'Obstetrics and Gynecology department Cairo University, Egypt. Electronic address: Fawzy.Jana@yahoo.com.'}]",Journal of gynecology obstetrics and human reproduction,['10.1016/j.jogoh.2020.101875'] 2133,32687924,"Intake of Lactiplantibacillus plantarum HEAL9 reduces the inflammatory markers soluble fractalkine and CD163 during acute stress: A randomized, double blind, placebo-controlled study.","The intestine and the brain are connected via the brain-gut axis and the intestinal microbiota influences the immune activation and signaling molecules that are involved in the stress response. The aim of the study was to investigate if intake of the probiotic strain Lactiplantibacillus plantarum HEAL9 (LPHEAL9) for four weeks could counteract elevated cortisol and inflammation levels in subjects with chronic stress that are exposed to an acute stress test (Trier Social Stress Test, TSST). Seventy participants were included, and 63 participants completed the study (LPHEAL9, n = 32; placebo, n  =  31). Cardiovascular reactivity and cortisol levels were affected by the TSST, but no differences between the groups were observed. Intake of LPHEAL9 did, however, result in significantly decreased plasma levels of two inflammatory markers (soluble fractalkine and CD163) compared to placebo. In conclusion, intake of LPHEAL9 for four weeks may reduce inflammatory markers coupled to acute stress in chronically stressed individuals.",2020,"Intake of LPHEAL9 did, however, result in significantly decreased plasma levels of two inflammatory markers (soluble fractalkine and CD163) compared to placebo.","['acute stress', 'subjects with chronic stress', 'chronically stressed individuals', 'Seventy participants were included, and 63 participants completed the study (LPHEAL9, n=32; placebo, n=31']","['probiotic strain Lactobacillus plantarum HEAL9 (LPHEAL9', 'Lactobacillus plantarum HEAL9', 'placebo']","['elevated cortisol and inflammation levels', 'plasma levels', 'Cardiovascular reactivity and cortisol levels']","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0317608', 'cui_str': 'Lactobacillus plantarum'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}]",70.0,0.191303,"Intake of LPHEAL9 did, however, result in significantly decreased plasma levels of two inflammatory markers (soluble fractalkine and CD163) compared to placebo.","[{'ForeName': 'Gunilla', 'Initials': 'G', 'LastName': 'Önning', 'Affiliation': 'Biomedical Nutrition, Pure and Applied Biochemistry, Lund University, Lund, Sweden; Probi AB, Lund, Sweden. Electronic address: gunilla.onning@probi.com.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Hillman', 'Affiliation': 'Department of Clinical Sciences Lund, Diabetes Research Laboratory, Lund University, Lund, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Hedin', 'Affiliation': 'Department of Food Technology, Engineering and Nutrition, Lund University, Lund, Sweden.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Montelius', 'Affiliation': 'Probi AB, Lund, Sweden.'}, {'ForeName': 'Joakim', 'Initials': 'J', 'LastName': 'Eriksson', 'Affiliation': 'Ergonomics and Aerosol Technology, Department of Design Studies, Lund University, Lund, Sweden.'}, {'ForeName': 'Siv', 'Initials': 'S', 'LastName': 'Ahrné', 'Affiliation': 'Department of Food Technology, Engineering and Nutrition, Lund University, Lund, Sweden.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Jönsson', 'Affiliation': 'Department of Psychology, Faculty of Education, Kristianstad University, Kristianstad, Sweden.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113083'] 2134,32679281,"China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial.","Acute ST-segment elevation myocardial infarction (STEMI) remains a serious life-threatening event. Despite coronary revascularization, patients might still suffer from poor outcomes caused by myocardial no-reflow and ischemic/reperfusion injury. Tongxinluo (TXL), a traditional Chinese medicine, has been preliminarily demonstrated to reduce myocardial no-reflow and ischemic/reperfusion injury. We further hypothesize that TXL treatment is also effective in reducing clinical end points for the patients with STEMI. METHODS AND RESULTS: The CTS-AMI trial is a prospective, randomized, double-blind, placebo-controlled, multicenter clinical study in China. An estimated 3,796 eligible patients with STEMI from about 120 centers are randomized 1:1 ratio to TXL or placebo groups. All enrolled patients are orally administrated a loading dose of 8 capsules of TXL or placebo together with dual antiplatelet agents on admission followed by 4 capsules 3 times a day until 12 months. The primary end point is 30-day major adverse cardiovascular and cerebrovascular events, a composite of cardiac death, myocardial reinfarction, emergency coronary revascularization, and stroke. Secondary end points include each component of the primary end point, 1-year major adverse cardiovascular and cerebrovascular events, and other efficacy and safety parameters. CONCLUSIONS: Results of CTS-AMI trial will determine the clinical efficacy and safety of traditional Chinese medicine TXL capsule in the treatment of STEMI patients in the reperfusion era.",2020,"The primary end point is 30-day major adverse cardiovascular and cerebrovascular events, a composite of cardiac death, myocardial reinfarction, emergency coronary revascularization, and stroke.","['patients with Acute Myocardial Infarction (CTS-AMI', '3,796 eligible patients with STEMI from about 120 centers']","['Tongxinluo (TXL', 'TXL', 'TXL or placebo', 'placebo']","['each component of the primary end point, 1-year major adverse cardiovascular and cerebrovascular events, and other efficacy and safety parameters', '30-day major adverse cardiovascular and cerebrovascular events, a composite of cardiac death, myocardial reinfarction, emergency coronary revascularization, and stroke']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C1742872', 'cui_str': 'tongxinluo'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0376297', 'cui_str': 'Cardiac death'}, {'cui': 'C0948369', 'cui_str': 'Myocardial reinfarction'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]",3796.0,0.355531,"The primary end point is 30-day major adverse cardiovascular and cerebrovascular events, a composite of cardiac death, myocardial reinfarction, emergency coronary revascularization, and stroke.","[{'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Xiangdong', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Haitao', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Kefei', 'Initials': 'K', 'LastName': 'Dou', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Hongbing', 'Initials': 'H', 'LastName': 'Yan', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Shijie', 'Initials': 'S', 'LastName': 'You', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yanmin', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Liang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Lianjun', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Xiaojin', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Qiuting', 'Initials': 'Q', 'LastName': 'Dong', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Wenjia', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Guangyuan', 'Initials': 'G', 'LastName': 'Song', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Jiang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Guihao', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Ruijie', 'Initials': 'R', 'LastName': 'Tang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Jin', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jingang', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Yao', 'Affiliation': 'Peking University Clinical Research Institute, Peking University, Beijing, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Xian', 'Affiliation': 'Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Peterson', 'Affiliation': 'Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Runlin', 'Initials': 'R', 'LastName': 'Gao', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yuejin', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: yangyjfw@126.com.'}]",American heart journal,['10.1016/j.ahj.2020.06.011'] 2135,32689628,Effects of gait exercise assist robot (GEAR) on subjects with chronic stroke: A randomized controlled pilot trial.,"OBJECTIVE The aim of this study was to investigate whether gait training using the Gait Exercise Assist Robot (GEAR) is more effective for improving gait ability than treadmill gait training in chronic stroke subjects. DESIGN Subjects were randomly assigned to either the GEAR group (n = 8) or treadmill group (n = 11). Both groups received a training program of 20 sessions (5 days/week). The 10-m walk test, Timed Up and Go (TUG) test, 6-min walk test, the Medical Outcome Study 8-item Short Form Health Survey (SF-8), and Global Rating of Change (GRC) scales were administered at baseline (week 0), completion of training (week 4), 1-mo follow-up (week 8), and 3-mo follow-up (week 16). RESULTS Gait speed was significantly increased at completion of training and 1-mo follow-up compared with baseline in the GEAR group. Mean changes in TUG and 6-min walk were significantly greater in the GEAR group than in the treadmill group at completion of training compared to baseline. Furthermore, GRC scales were significantly increased at completion of training, 1-mo follow-up, and 3-mo follow-up compared with baseline in the GEAR group. CONCLUSION This study suggests that gait training using GEAR was more effective for improving gait ability than treadmill among subjects with chronic stroke. REGISTRATION OF CLINICAL TRIALS This study was registered with the University Hospital Medical Information Network (No. UMIN000028042).",2020,Gait speed was significantly increased at completion of training and 1-mo follow-up compared with baseline in the GEAR group.,"['Subjects', 'subjects with chronic stroke', 'chronic stroke subjects']","['gait training', 'Gait Exercise Assist Robot (GEAR', 'gait training using GEAR', 'GEAR', 'treadmill gait training', 'gait exercise assist robot (GEAR']","['gait ability', '10-m walk test, Timed Up and Go (TUG) test, 6-min walk test, the Medical Outcome Study 8-item Short Form Health Survey (SF-8), and Global Rating of Change ', 'GRC) scales', 'Gait speed', 'Furthermore, GRC scales', 'Mean changes in TUG and 6-min walk']","[{'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}]","[{'cui': 'C0085673', 'cui_str': 'Gait training procedure'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0543472', 'cui_str': 'Outcome Studies'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]",,0.0368056,Gait speed was significantly increased at completion of training and 1-mo follow-up compared with baseline in the GEAR group.,"[{'ForeName': 'Tomoyuki', 'Initials': 'T', 'LastName': 'Ogino', 'Affiliation': 'Department of Rehabilitation, Hyogo College of Medicine Sasayama Medical Center, Kurooka 5, Sasayama, Hyogo 669-2321, Japan. Electronic address: ogino0327@gmail.com.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Kanata', 'Affiliation': 'Department of Rehabilitation, Hyogo College of Medicine Sasayama Medical Center, Kurooka 5, Sasayama, Hyogo 669-2321, Japan. Electronic address: ym_kanata611@yahoo.co.jp.'}, {'ForeName': 'Ryota', 'Initials': 'R', 'LastName': 'Uegaki', 'Affiliation': 'Department of Rehabilitation, Hyogo College of Medicine Sasayama Medical Center, Kurooka 5, Sasayama, Hyogo 669-2321, Japan. Electronic address: ri-uegaki@hyo-med.ac.jp.'}, {'ForeName': 'Tatuya', 'Initials': 'T', 'LastName': 'Yamaguchi', 'Affiliation': 'Department of Rehabilitation, Hyogo College of Medicine Sasayama Medical Center, Kurooka 5, Sasayama, Hyogo 669-2321, Japan. Electronic address: tt-yamaguchi@hyo-med.ac.jp.'}, {'ForeName': 'Katuhisa', 'Initials': 'K', 'LastName': 'Morisaki', 'Affiliation': 'Department of Rehabilitation, Hyogo College of Medicine Sasayama Medical Center, Kurooka 5, Sasayama, Hyogo 669-2321, Japan. Electronic address: kindai_lacrosse_8@yahoo.co.jp.'}, {'ForeName': 'Shuhei', 'Initials': 'S', 'LastName': 'Nakano', 'Affiliation': 'Department of Rehabilitation, Hyogo College of Medicine Sasayama Medical Center, Kurooka 5, Sasayama, Hyogo 669-2321, Japan. Electronic address: stp.tig.6gd@gmail.com.'}, {'ForeName': 'Kazuhisa', 'Initials': 'K', 'LastName': 'Domen', 'Affiliation': 'Department of Rehabilitation Medicine, Hyogo College of Medicine, Japan. Electronic address: domen@hyo-med.ac.jp.'}]",Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association,['10.1016/j.jstrokecerebrovasdis.2020.104886'] 2136,32689752,[Application value of non-invasive ventilation combined with high flow nasal cannula oxygen therapy in sequential treatment of patients with chronic obstructive pulmonary disease after mechanical ventilation].,"Objective: To investigate the value of non-invasive ventilation (NIV) combined with high flow nasal cannula oxygen therapy (HFNCO) in sequential treatment of patients with chronic obstructive pulmonary disease after mechanical ventilation. Methods: Chronic obstructive pulmonary disease with acute exacerbation (AECOPD) patients with invasive mechanical ventilation (MV) and successful withdrawal admitted into Huxi Affiliated Hospital of Jining Medical College from January 2018 to December 2019 were enrolled for perspective study. The patients were divided into treatment group ( n= 40) and control group ( n= 33) by random number table method. The treatment group was given NIV and HFNCO, the control group was given NIV treatment alone. Bedside ultrasound was used to measure the patients' diaphragmatic motion, and the differences between the two groups of patients before treatment, 24, 48 and 72 h after treatment were compared in diaphragmatic excursions during quiet breathing (DEq), diaphragmatic excursions during deep breathing(DEd), diaphragmatic shallow fast breathing index (D-RSBI), arterial oxygen partial pressure (PaO(2)), arterial partial pressure of carbon dioxide (PaCO(2)), re-tracheal intubation rate, mortality rate for 28 days and average duration of NPPV treatment within 3 days. Results: There were no statistically significant differences in DEq, DEd, D-RSBI, PaO(2) and PaCO(2) between the two groups before treatment (all P> 0.05). After 24 h treatment, DEd decreased in both groups, D-RSBI increased in both groups, However, D-RSBI [(1.33±0.56) vs (1.62±0.59) times·min(-1)·mm(-1)] in the treatment group was significantly lower than the control group, P= 0.034. After 72 h treatment, DEd [(41.4±8.1) vs (37.8±6.0) mm] was significantly higher than the control group, D-RSBI [(1.02±0.27) vs (1.22±0.43) times·min(-1)·mm(-1)] was significantly lower than the control group (all P< 0.05). The average duration of NIV treatment time [(7.5±1.2) vs (9.3±2.6) h] in the treatment group was significantly shorter than that in the control group ( P< 0.01). There were no statistically significant differences in PaO(2), PCO(2), re-tracheal intubation rate and the mortality rate of 28 days. Conclusion: NIV combined with HFNCO sequential therapy can effectively relieve diaphragm fatigue and promote recovery of respiratory muscle strength, and it's better than NIV alone.",2020,"There were no statistically significant differences in DEq, DEd, D-RSBI, PaO(2) and PaCO(2) between the two groups before treatment (all P> 0.05).","['Chronic obstructive pulmonary disease with acute exacerbation (AECOPD) patients with invasive mechanical ventilation (MV) and successful withdrawal admitted into Huxi Affiliated Hospital of Jining Medical College from January 2018 to December 2019 were enrolled for perspective study', 'patients with chronic obstructive pulmonary disease after mechanical ventilation']","['non-invasive ventilation combined with high flow nasal cannula oxygen therapy', 'HFNCO sequential therapy', 'non-invasive ventilation (NIV) combined with high flow nasal cannula oxygen therapy (HFNCO', 'times·min(-1)·mm(-1']","['diaphragm fatigue and promote recovery of respiratory muscle strength', 'diaphragmatic excursions during quiet breathing (DEq), diaphragmatic excursions during deep breathing(DEd), diaphragmatic shallow fast breathing index (D-RSBI), arterial oxygen partial pressure (PaO(2)), arterial partial pressure of carbon dioxide (PaCO(2)), re-tracheal intubation rate, mortality rate for 28 days and average duration of NPPV treatment within 3 days', 'DEq, DEd, D-RSBI, PaO(2) and PaCO(2', 'PaO(2), PCO(2), re-tracheal intubation rate and the mortality rate of 28 days', 'average duration of NIV treatment time', 'DEd', 'D-RSBI']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}]","[{'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C4761117', 'cui_str': 'High-flow nasal cannula oxygen therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0011980', 'cui_str': 'Diaphragm structure'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0021724', 'cui_str': 'Structure of intercostal muscle'}, {'cui': 'C0232086', 'cui_str': 'Diaphragmatic excursion'}, {'cui': 'C0439654', 'cui_str': 'Quiet'}, {'cui': 'C1321587', 'cui_str': 'Excessively deep breathing'}, {'cui': 'C0231835', 'cui_str': 'Tachypnea'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0202155', 'cui_str': 'Oxygen measurement, partial pressure, arterial'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output'}, {'cui': 'C0428190', 'cui_str': 'Measurement of arterial partial pressure of carbon dioxide'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C0751673', 'cui_str': 'Nipah virus'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",,0.0241827,"There were no statistically significant differences in DEq, DEd, D-RSBI, PaO(2) and PaCO(2) between the two groups before treatment (all P> 0.05).","[{'ForeName': 'S Q', 'Initials': 'SQ', 'LastName': 'Yang', 'Affiliation': 'Department of Intensive Care Unit, Huxi Hospital Affiliated to Jining Medical College, Heze 274300, China.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of Pulmonary Medicine, Huxi Hospital Affiliated to Jining Medical College, Heze 274300, China.'}, {'ForeName': 'S Q', 'Initials': 'SQ', 'LastName': 'Meng', 'Affiliation': 'Department of Intensive Care Unit, Huxi Hospital Affiliated to Jining Medical College, Heze 274300, China.'}, {'ForeName': 'W B', 'Initials': 'WB', 'LastName': 'Yang', 'Affiliation': 'Department of Intensive Care Unit, Huxi Hospital Affiliated to Jining Medical College, Heze 274300, China.'}, {'ForeName': 'G Z', 'Initials': 'GZ', 'LastName': 'Zhang', 'Affiliation': 'Department of Intensive Care Unit, Huxi Hospital Affiliated to Jining Medical College, Heze 274300, China.'}, {'ForeName': 'Q B', 'Initials': 'QB', 'LastName': 'Shi', 'Affiliation': 'Department of Emergency, Huxi Hospital Affiliated to Jining Medical College, Heze 274300, China.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Zhang', 'Affiliation': 'Department of Intensive Care Unit, Huxi Hospital Affiliated to Jining Medical College, Heze 274300, China.'}]",Zhonghua yi xue za zhi,['10.3760/cma.j.cn112137-20200306-00616'] 2137,32689756,[Effect and underling mechanism of 6% hydroxyethyl starch 130/0.4 on serum albumen in trauma orthopedic patients during operation].,"Objective: To investigate the effect of 6% hydroxyethyl starch 130/0.4(HES) on protein in severe trauma orthopedic patients after acute hemodilution. Methods: Fourty-eight severe trauma patients who met the inclusion criteria were selected from June 2018 to December 2018 in Yantaishan Hospital, and were randomly divided into two groups ( n= 24): group A and group B. Group A was ringer's sodium lactate control group, and group B was HES treatment group. After the tracheal intubation, the patients of group A were infused with 10% blood volume of sodium lactate ringer at 0.5 ml·kg(-1)·min(-1), and the patients in group B were infused with 10% blood volume of HES at 0.5 ml·kg(-1)·min(-1). Total protein (TP), human serum albumin (HSA), numbers of circulating endothelium cells (CEC), C-reactive protein (CRP), and serum levels of tumor necrosis factor-alpha (TNF-α), interleukin (IL)-10 and IL-6 were measured immediately after acute hemodilution (T(0)), 24 hours (T(1)) and 48 hours (T(2)) after acute hemodilution. After infusion into human body, HES bond to HSA, and fluorescence spectroscopy was used to analyze the binding relationship between HES and HSA in order to further study the effects of HES on HSA. Results: The HSA, TP, CEC, TNF-α, IL-6, IL-10, CRP at T(0) of group A were (38±5) g/L, (66±5) g/L, (5.5±0.4)/0.9 μl, (24±5) μg/L, (8.9±0.8) μg/L, (44±6) μg/L, (13.6±1.4) mg/L; While at T(1) were (33±5) g/L, (60±6) g/L, (10.2±0.7)/0.9 μl, (87±9) μg/L, (38.8±2.3) μg/L, (57±7) μg/L, (23.4±2.4) mg/L. The HSA, TP, CEC, TNF-α, IL-6, IL-10, CRP at T(0) of group B were(38±4)g/L, (66±5) g/L, (5.4±0.6)/0.9 μl, (24±6) μg/L, (9.1±0.9) μg/L, (45±6) μg/L, (13.4±1.8) mg/L; While at T(1) were (35±5)g/L, (62±5)g/L, (7.4±0.6)/0.9 μl, (70±8) μg/L, (29.5±3.1) μg/L, (72±6) μg/L, (19.7±2.2) mg/L. HSA and TP decreased at T(1) in group A as compared with T(0) ( P< 0.05), contrarily CEC increased significantly at T(1), TNF-ɑ, IL-6, IL-10 and CRP augmented at T(1) and T(2) in two groups ( P< 0.05). In comparison with the patients of group A, CEC decreased significantly at T(1) ( P< 0.05). TNF-ɑ, IL-6, CRP reduced significantly at T(1) and T(2) ( P< 0.05), but IL-10 increased at T(1) and T(2) in group B ( P< 0.05). The secondary structure of HSA changed after HES was added in the HES solution. The fluorescence intensity of HSA decreased with the increase of HES concentration,which suggested that HES induced HSA fluorescence quenching. HES could bind to Trp-214 residue in HSA at a molecular ration of 1∶1. Conclusions: 6% HES reduces the occurrence of low protein level in severe trauma patients after operation. HES could bind to Trp-214 amino acid residue in HSA and form the complex at a molecular ratio of 1∶1. The formation of HES-HSA complex increases the volume of HES, avoids the vascular leakage, protects the vascular endothelial cells, and induces anti-inflammatory immunity in the patients with capillary syndrome.",2020,"TNF-ɑ, IL-6, CRP reduced significantly at T(1) and T(2)","['severe trauma orthopedic patients after acute hemodilution', 'severe trauma patients after operation', 'trauma orthopedic patients during operation', 'patients with capillary syndrome', 'Fourty-eight severe trauma patients who met the inclusion criteria were selected from June 2018 to December 2018 in Yantaishan Hospital']","['hydroxyethyl starch 130/0.4(HES', ""ringer's sodium lactate control group, and group B was HES treatment group"", 'HES', 'T(0', 'sodium lactate ringer at 0.5 ml·kg(-1)·min(-1', 'hydroxyethyl starch']","['serum albumen', 'CEC decreased significantly at T(1', 'Total protein (TP), human serum albumin (HSA), numbers of circulating endothelium cells (CEC), C-reactive protein (CRP), and serum levels of tumor necrosis factor-alpha (TNF-α), interleukin (IL)-10 and IL-6 were measured immediately after acute hemodilution (T(0)), 24 hours (T(1)) and 48 hours (T(2', 'contrarily CEC increased significantly at T(1), TNF-ɑ, IL-6, IL-10 and CRP augmented at T(1) and T(2', 'IL-10 increased at T(1) and T(2', 'TNF-ɑ, IL-6, CRP reduced significantly at T(1) and T(2', 'HSA, TP, CEC, TNF-α, IL-6, IL-10, CRP at T(0) of group B were(38±4)g/L, (66±5', 'fluorescence intensity of HSA', 'occurrence of low protein level', 'HSA, TP, CEC, TNF-α, IL-6, IL-10, CRP at T(0']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0019009', 'cui_str': 'Hemodilution'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0006901', 'cui_str': 'Structure of capillary blood vessel (organ)'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0020352', 'cui_str': 'Hetastarch'}, {'cui': 'C0142874', 'cui_str': 'Sodium lactate'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444500', 'cui_str': '0.5'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0318601', 'cui_str': 'Canine enteric calicivirus'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0555903', 'cui_str': 'Total protein measurement'}, {'cui': 'C0304925', 'cui_str': 'Albumin Human, USP'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0019009', 'cui_str': 'Hemodilution'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0439586', 'cui_str': '48 hours'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0018763', 'cui_str': 'Health Systems Agencies'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0016315', 'cui_str': 'Fluorescence'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0242972', 'cui_str': 'Low protein diet'}]",,0.0377761,"TNF-ɑ, IL-6, CRP reduced significantly at T(1) and T(2)","[{'ForeName': 'J Z', 'Initials': 'JZ', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Yantaishan Hospital, Yantai 264008, China.'}, {'ForeName': 'L Y', 'Initials': 'LY', 'LastName': 'Qu', 'Affiliation': 'Department of Anesthesiology, Yantaishan Hospital, Yantai 264008, China.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesiology, Yantaishan Hospital, Yantai 264008, China.'}, {'ForeName': 'X N', 'Initials': 'XN', 'LastName': 'Yi', 'Affiliation': 'Department of Anesthesiology, Yantaishan Hospital, Yantai 264008, China.'}, {'ForeName': 'K Y', 'Initials': 'KY', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Yantaishan Hospital, Yantai 264008, China.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Shao', 'Affiliation': 'Department of Anesthesiology, Yantaishan Hospital, Yantai 264008, China.'}, {'ForeName': 'S Y', 'Initials': 'SY', 'LastName': 'Huang', 'Affiliation': 'Department of Oncology, Yantaishan Hospital, Yantai 264008, China.'}]",Zhonghua yi xue za zhi,['10.3760/cma.j.cn112137-20191114-02475'] 2138,32689826,Prospective evaluation of Bilateral Retrograde Intrarenal Surgery: is it really safe?,"Introduction The aim of this study was to prospectively compare the outcomes of bilateral same session retrograde intrarenal surgery (BSS RIRS) to unilateral RIRS and to compare the outcomes of first to second operated kidney in BSS RIRS. Methods Consecutive symptomatic adult patients with kidney stones up to 20 mm that accepted to be treated by RIRS were prospectively studied. Stone-free rate (SFR) was evaluated by non-contrast computerized tomography for each renal unit and surgical complications were evaluated based on Clavien-Dindo classification. Results SFR (73.9% vs. 76.1%, p=0.830) and hospitalization time (14.43 ± 18.81 h vs. 13.00 ± 4.89 h, p=0.564) were similar between unilateral and BSS RIRS groups with less consumption of disposable devices in BSS RIRS (p=0.017). Operative time was longer in BSS RIRS (61.24 ± 26.62 min. vs. 88.65 ± 33.19 min. P<0.001). Bilateral group had significant more overall complications by Clavien-Dindo classification than unilateral (15.9% vs. 39.9%, p=0.030) and more emergency room visits (11.6% vs. 34.8%, p=0.026). Moreover, albeit both groups temporary increased creatinine levels, it was significantly higher in bilateral RIRS (p=0.019). First operated kidney outcomes were similar to second operated kidney of BSS RIRS. Conclusion Although BSS RIRS had similar SFR and consumed less disposable devices, it had higher overall complication rate, higher frequency of emergency room visits and higher creatinine levels during follow-up than unilateral RIRS. There is no significant outcome difference between first and second operated kidney in BSS RIRS.",2020,"Results SFR (73.9% vs. 76.1%, p=0.830) and hospitalization time (14.43 ± 18.81 h vs. 13.00 ± 4.89 h, p=0.564) were similar between unilateral and BSS RIRS groups with less consumption of disposable devices in BSS RIRS (p=0.017).",['Methods Consecutive symptomatic adult patients with kidney stones up to 20 mm that accepted to be treated by RIRS were prospectively studied'],"['bilateral same session retrograde intrarenal surgery (BSS RIRS', 'Bilateral Retrograde Intrarenal Surgery']","['Stone-free rate (SFR', 'overall complications', 'Operative time', 'hospitalization time', 'overall complication rate, higher frequency of emergency room visits and higher creatinine levels', 'emergency room visits', 'creatinine levels', 'bilateral RIRS']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022650', 'cui_str': 'Kidney stone'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0439784', 'cui_str': 'Retrograde direction'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0151578', 'cui_str': 'Creatinine increased'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0201975', 'cui_str': 'Creatinine measurement'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}]",,0.0533197,"Results SFR (73.9% vs. 76.1%, p=0.830) and hospitalization time (14.43 ± 18.81 h vs. 13.00 ± 4.89 h, p=0.564) were similar between unilateral and BSS RIRS groups with less consumption of disposable devices in BSS RIRS (p=0.017).","[{'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Danilovic', 'Affiliation': 'Universidade de Sao Paulo Hospital das Clinicas, 117265, Section of Endourology, Division of Urology São Paulo, Sao Paulo, São Paulo, Brazil; alexandre.danilovic@gmail.com.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Torricelli', 'Affiliation': 'Universidade de Sao Paulo Hospital das Clinicas, 117265, Section of Endourology, Division of Urology São Paulo, Sao Paulo, São Paulo, Brazil; fctorricelli@yahoo.com.br.'}, {'ForeName': 'Giovanni Scala', 'Initials': 'GS', 'LastName': 'Marchini', 'Affiliation': 'Universidade de Sao Paulo Hospital das Clinicas, 117265, Section of Endourology, Division of Urology, Sao Paulo, São Paulo, Brazil; marchinism@gmail.com.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Batagello', 'Affiliation': 'Universidade de Sao Paulo Hospital das Clinicas, 117265, Division of Urology, Section of Endourology, Sao Paulo, São Paulo, Brazil; carlosbatagello@hotmail.com.'}, {'ForeName': 'Fabio Carvalho', 'Initials': 'FC', 'LastName': 'Vicentini', 'Affiliation': 'Universidade de Sao Paulo Hospital das Clinicas, 117265, Urology, Sao Paulo, São Paulo, Brazil.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Traxer', 'Affiliation': 'Hopital Tenon, 55705, GRC n 20 Lithiase Renale, AP-HP, Paris, Île-de-France, France; olivier.traxer@aphp.fr.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Srougi', 'Affiliation': 'Universidade de Sao Paulo Hospital das Clinicas, 117265, Division of Urology, Sao Paulo, São Paulo, Brazil; srougi@terra.com.br.'}, {'ForeName': 'William Carlos', 'Initials': 'WC', 'LastName': 'Nahas', 'Affiliation': 'University of Sao Paulo, 28133, Av Dr Eneas Aguiar 256, Sao Paulo, Brazil, 05508-900; wnahas@uol.com.br.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Mazzucchi', 'Affiliation': 'Universidade de Sao Paulo Hospital das Clinicas, 117265, Division of Urology, Section of Endourology, Sao Paulo, São Paulo, Brazil; mazuchi@terra.com.br.'}]",Journal of endourology,['10.1089/end.2020.0611'] 2139,32690072,Use of olanzapine to treat agitation in traumatic brain injury: study protocol for a randomised controlled trial.,"BACKGROUND Agitation is common in the early stages of recovery from traumatic brain injury (TBI), when patients are in post-traumatic amnesia (PTA). Agitation is associated with risk of harm to patients and caregivers. Recent guidelines recommend that agitation during PTA is managed using environmental modifications. Agitation is also frequently treated pharmacologically, with the use of atypical antipsychotics such as olanzapine among the most common. This is despite a lack of well-designed studies to support the use of antipsychotics within this context. This study will be a double-blind, placebo-controlled randomised controlled trial. We will examine the efficacy, safety, cost-effectiveness and outcomes associated with the use of olanzapine for reducing agitation in patients in PTA following TBI over and above recommended environmental management. METHODS Fifty-eight TBI rehabilitation inpatients who are in PTA and are agitated will receive olanzapine or placebo for the duration of PTA. All participants will additionally receive optimal environmental management for agitation. Measures of agitation, PTA and health will be undertaken at baseline. Treatment administration will begin at a dose of 5 mg daily and may be escalated to a maximum dose of 20 mg per day. Throughout the treatment period, agitation and PTA will be measured daily, and adverse events monitored weekly. Efficacy will be assessed by treatment group comparison of average Agitated Behaviour Scale scores during PTA. Participants will cease treatment upon emergence from PTA. Agitation levels will continue to be monitored for a further 2 weeks, post-treatment measures of health will be undertaken and cognitive and functional status will be assessed. Level of agitation and functional health will be assessed at hospital discharge. At 3 months post-discharge, functional outcomes and health service utilisation will be measured. DISCUSSION This trial will provide crucial evidence to inform the management of agitation in patients in PTA following TBI. It will provide guidance as to whether olanzapine reduces agitation over and above recommended environmental management or conversely whether it increases or prolongs agitation and PTA, increases length of inpatient hospitalisation and impacts longer term cognitive and functional outcomes. It will also speak to the safety and cost-effectiveness of olanzapine use in this population. TRIAL REGISTRATION ANZCTR ACTRN12619000284167 . Registered on 25 February 2019.",2020,Efficacy will be assessed by treatment group comparison of average Agitated Behaviour Scale scores during PTA.,"['for the duration of PTA', 'patients in PTA following TBI over and above recommended environmental management', 'Fifty-eight TBI rehabilitation inpatients who are in PTA and are agitated will receive', 'traumatic brain injury']","['olanzapine', 'olanzapine or placebo', 'placebo']","['Agitation levels', 'agitation, PTA and health', 'Level of agitation and functional health', 'Efficacy', 'efficacy, safety, cost-effectiveness', 'length of inpatient hospitalisation', 'average Agitated Behaviour Scale scores', 'functional outcomes and health service utilisation']","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0002623', 'cui_str': 'Post-traumatic amnesia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0150211', 'cui_str': 'Environmental care procedure'}, {'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}]","[{'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2585388', 'cui_str': 'Level of agitation'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0002623', 'cui_str': 'Post-traumatic amnesia'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0018747', 'cui_str': 'Services, Health'}]",,0.410544,Efficacy will be assessed by treatment group comparison of average Agitated Behaviour Scale scores during PTA.,"[{'ForeName': 'Ruby K', 'Initials': 'RK', 'LastName': 'Phyland', 'Affiliation': 'Monash Epworth Rehabilitation Research Centre, 185-187 Hoddle Street, Richmond, Victoria, 3121, Australia. ruby.phyland@monash.edu.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'McKay', 'Affiliation': 'Monash Epworth Rehabilitation Research Centre, 185-187 Hoddle Street, Richmond, Victoria, 3121, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Olver', 'Affiliation': 'Rehabilitation Medicine, Epworth HealthCare, 89 Bridge Rd, Richmond, Victoria, 3121, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Walterfang', 'Affiliation': 'Department of Psychiatry, University of Melbourne, Royal Melbourne Hospital, Level 1 North Block, Grattan Street, Parkville, Victoria, 3052, Australia.'}, {'ForeName': 'Malcolm', 'Initials': 'M', 'LastName': 'Hopwood', 'Affiliation': 'Department of Psychiatry, University of Melbourne, Royal Melbourne Hospital, Level 1 North Block, Grattan Street, Parkville, Victoria, 3052, Australia.'}, {'ForeName': 'Amelia J', 'Initials': 'AJ', 'LastName': 'Hicks', 'Affiliation': 'Monash Epworth Rehabilitation Research Centre, 185-187 Hoddle Street, Richmond, Victoria, 3121, Australia.'}, {'ForeName': 'Duncan', 'Initials': 'D', 'LastName': 'Mortimer', 'Affiliation': 'Centre for Health Economics, Monash Business School, Monash University, Building H, Level 5, Caulfield Campus, Clayton, Victoria, 3145, Australia.'}, {'ForeName': 'Jennie L', 'Initials': 'JL', 'LastName': 'Ponsford', 'Affiliation': 'Monash Epworth Rehabilitation Research Centre, 185-187 Hoddle Street, Richmond, Victoria, 3121, Australia.'}]",Trials,['10.1186/s13063-020-04553-2'] 2140,32690074,Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial.,"OBJECTIVES To assess the efficacy of local intranasal treatment with budesonide (nasal irrigation), in addition to olfactory rehabilitation, in the management of loss of smell in COVID-19 patients without signs of severity and with persistent hyposmia 30 days after the onset of symptoms. To search for an association between the presence of an obstruction on MRI and the severity of olfactory loss, at inclusion and after 30 days of treatment. TRIAL DESIGN Two center, open-label, 2-arm (1:1 ratio) parallel group randomized controlled superiority trial. PARTICIPANTS Inclusion criteria - Patient over 18 years of age; - Patient with a suspected SARS-CoV-2 infection, whether or not confirmed by PCR, or close contact with a PCR-confirmed case, typical chest CT scan (unsystematic frosted glass patches with predominantly sub-pleural appearance, and at a later stage, alveolar condensation without excavation or nodules or masses) or positive serology ; - Patient with isolated sudden onset hyposmia persisting 30 days after the onset of symptoms of CoV-2 SARS infection; - Affiliate or beneficiary of a social security scheme; - Written consent to participate in the study. Non-inclusion criteria - Known hypersensitivity to budesonide or any of the excipients; - Hemostasis disorder or epistaxis; - Oral-nasal and ophthalmic herpes virus infection; - Long-term corticosteroid treatment; - Treatment with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and HIV protease inhibitors); - Severe forms of SARS-CoV-2 with respiratory or other signs; - Hyposmia persisting for more than 90 days after the onset of symptoms - Other causes of hyposmia found on interrogation or MRI; - Patient benefiting from a legal protection measure; - Pregnant or breastfeeding women. The participants will be recruited from: Hôpital Fondation Adolphe de Rothschild and Hôpital Lariboisière in Paris, France INTERVENTION AND COMPARATOR: Intervention: Experimental group: Nasal irrigation with budesonide and physiological saline (Budesonide 1mg/2mL diluted in 250mL of physiological saline 9°/00): 3 syringes of 20mL in each nasal cavity, morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day. CONTROL GROUP Nasal irrigation with physiological saline 9°/00 only: 3 syringes of 20cc in each nasal cavity, morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day. MAIN OUTCOMES Percentage of patients with an improvement of more than 2 points on the ODORATEST score after 30 days of treatment. RANDOMISATION Patients will be randomized (1:1) between the experimental and control groups, using the e-CRF. The randomization list will be stratified by centre. BLINDING (MASKING) Participants and caregivers are aware of the group assignment. People assessing the outcomes are blinded to the group assignment Numbers to be randomised (sample size) 120 patients are planned to be randomized into two groups of 60 patients. TRIAL STATUS MDL_2020_10. Version number 2, May 22, 2020. Recruitment started on May 22, 2020. The trial will finish recruiting by August 2020. TRIAL REGISTRATION EUDRACT number: 2020-001667-85; date of trial registration: 15 May 2020 Protocol registered on ClinicalTrial.gov, registration number: NCT04361474 ; date of trial registration: 24 April 2020. FULL PROTOCOL The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.",2020,"CONTROL GROUP ","['COVID-19 patients without signs of severity', ' Severe forms of SARS-CoV-2 with respiratory or other signs; - Hyposmia persisting for more than 90 days after the onset of symptoms - Other causes of hyposmia found on interrogation or MRI; - Patient benefiting from a legal protection measure; - Pregnant or breastfeeding women', 'COVID-19 patients without signs of severity and with persistent hyposmia 30 days after the onset of symptoms', 'Two center, open-label, 2-arm (1:1 ratio', 'participants will be recruited from: Hôpital Fondation Adolphe de Rothschild and Hôpital Lariboisière in Paris, France INTERVENTION AND COMPARATOR', 'Inclusion criteria - Patient over 18 years of age; - Patient with a suspected SARS-CoV-2 infection, whether or not confirmed by PCR, or close contact with a PCR-confirmed case, typical chest CT scan (unsystematic frosted glass patches with predominantly sub-pleural appearance, and at a later stage, alveolar condensation without excavation or nodules or masses) or positive serology ; - Patient with isolated sudden onset hyposmia persisting 30 days after the onset of symptoms of CoV-2 SARS infection; - Affiliate or beneficiary of a social security scheme; - Written consent to participate in the study. Non-inclusion criteria - Known hypersensitivity to budesonide or any of the excipients; - Hemostasis disorder or epistaxis; - Oral-nasal and ophthalmic herpes virus infection; - Long-term corticosteroid treatment; - Treatment with']","['Nasal irrigation with physiological saline', 'local budesonide therapy', 'potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and HIV protease inhibitors', 'budesonide (nasal irrigation', 'Intervention', 'GROUP', 'budesonide and physiological saline (Budesonide']",[],"[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C2364082', 'cui_str': 'Sense of smell impaired'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332162', 'cui_str': 'Onset of'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C1301860', 'cui_str': 'Legal'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0030561', 'cui_str': 'Paris'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0521094', 'cui_str': 'Not confirmed by'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0202823', 'cui_str': 'CT of chest'}, {'cui': 'C0015421', 'cui_str': 'Eyeglasses'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C1522720', 'cui_str': 'Pleural'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0233656', 'cui_str': 'Mental condensation'}, {'cui': 'C0028259', 'cui_str': 'Nodule'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0242089', 'cui_str': 'Serology positive'}, {'cui': 'C1272517', 'cui_str': 'Sudden onset'}, {'cui': 'C0037435', 'cui_str': 'Social Insurance'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C0015237', 'cui_str': 'Pharmaceutical excipient'}, {'cui': 'C0005779', 'cui_str': 'Blood coagulation disorder'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C2350442', 'cui_str': 'Nasal irrigation'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C3850053', 'cui_str': 'CYP3A4 Inhibitors'}, {'cui': 'C0022625', 'cui_str': 'Ketoconazole'}, {'cui': 'C0064113', 'cui_str': 'Itraconazole'}, {'cui': 'C0393080', 'cui_str': 'voriconazole'}, {'cui': 'C0936148', 'cui_str': 'posaconazole'}, {'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0907410', 'cui_str': 'telithromycin'}, {'cui': 'C0068485', 'cui_str': 'nefazodone'}, {'cui': 'C0162714', 'cui_str': 'HIV Protease Inhibitors'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",[],,0.347084,"CONTROL GROUP ","[{'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Daval', 'Affiliation': 'Hopital Fondation Adolphe de Rothschild, Paris, France. mdaval@for.paris.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Corré', 'Affiliation': 'Hopital Fondation Adolphe de Rothschild, Paris, France.'}, {'ForeName': 'Clement', 'Initials': 'C', 'LastName': 'Palpacuer', 'Affiliation': 'Hopital Fondation Adolphe de Rothschild, Paris, France.'}, {'ForeName': 'Juliette', 'Initials': 'J', 'LastName': 'Housset', 'Affiliation': 'Hopital Lariboisiere, Paris, France.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Poillon', 'Affiliation': 'Hopital Fondation Adolphe de Rothschild, Paris, France.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Eliezer', 'Affiliation': 'Hopital Lariboisiere, Paris, France.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Verillaud', 'Affiliation': 'Hopital Lariboisiere, Paris, France.'}, {'ForeName': 'Dorsaf', 'Initials': 'D', 'LastName': 'Slama', 'Affiliation': 'Hotel Dieu Hospital, Paris, France.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Ayache', 'Affiliation': 'Hopital Fondation Adolphe de Rothschild, Paris, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Herman', 'Affiliation': 'Hopital Lariboisiere, Paris, France.'}, {'ForeName': 'Clement', 'Initials': 'C', 'LastName': 'Jourdaine', 'Affiliation': 'Hopital Lariboisiere, Paris, France.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Hervé', 'Affiliation': 'Hopital Fondation Adolphe de Rothschild, Paris, France.'}, {'ForeName': 'Wissame', 'Initials': 'W', 'LastName': 'El Bakkouri', 'Affiliation': 'Hopital Fondation Adolphe de Rothschild, Paris, France.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Salmon', 'Affiliation': 'Hopital Fondation Adolphe de Rothschild, Paris, France.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Hautefort', 'Affiliation': 'Hopital Lariboisiere, Paris, France.'}]",Trials,['10.1186/s13063-020-04585-8'] 2141,32690103,Deep learning vs. atlas-based models for fast auto-segmentation of the masticatory muscles on head and neck CT images.,"BACKGROUND Impaired function of masticatory muscles will lead to trismus. Routine delineation of these muscles during planning may improve dose tracking and facilitate dose reduction resulting in decreased radiation-related trismus. This study aimed to compare a deep learning model with a commercial atlas-based model for fast auto-segmentation of the masticatory muscles on head and neck computed tomography (CT) images. MATERIAL AND METHODS Paired masseter (M), temporalis (T), medial and lateral pterygoid (MP, LP) muscles were manually segmented on 56 CT images. CT images were randomly divided into training (n = 27) and validation (n = 29) cohorts. Two methods were used for automatic delineation of masticatory muscles (MMs): Deep learning auto-segmentation (DLAS) and atlas-based auto-segmentation (ABAS). The automatic algorithms were evaluated using Dice similarity coefficient (DSC), recall, precision, Hausdorff distance (HD), HD95, and mean surface distance (MSD). A consolidated score was calculated by normalizing the metrics against interobserver variability and averaging over all patients. Differences in dose (∆Dose) to MMs for DLAS and ABAS segmentations were assessed. A paired t-test was used to compare the geometric and dosimetric difference between DLAS and ABAS methods. RESULTS DLAS outperformed ABAS in delineating all MMs (p < 0.05). The DLAS mean DSC for M, T, MP, and LP ranged from 0.83 ± 0.03 to 0.89 ± 0.02, the ABAS mean DSC ranged from 0.79 ± 0.05 to 0.85 ± 0.04. The mean value for recall, HD, HD95, MSD also improved with DLAS for auto-segmentation. Interobserver variation revealed the highest variability in DSC and MSD for both T and MP, and the highest scores were achieved for T by both automatic algorithms. With few exceptions, the mean ∆D98%, ∆D95%, ∆D50%, and ∆D2% for all structures were below 10% for DLAS and ABAS and had no detectable statistical difference (P > 0.05). DLAS based contours had dose endpoints more closely matched with that of the manually segmented when compared with ABAS. CONCLUSIONS DLAS auto-segmentation of masticatory muscles for the head and neck radiotherapy had improved segmentation accuracy compared with ABAS with no qualitative difference in dosimetric endpoints compared to manually segmented contours.",2020,Routine delineation of these muscles during planning may improve dose tracking and facilitate dose reduction resulting in decreased radiation-related trismus.,[],"['Deep learning auto-segmentation (DLAS) and atlas-based auto-segmentation (ABAS', 'deep learning model with a commercial atlas-based model for fast auto-segmentation of the masticatory muscles']","['Dice similarity coefficient (DSC), recall, precision, Hausdorff distance (HD), HD95, and mean surface distance (MSD', 'automatic delineation of masticatory muscles (MMs', 'Paired masseter (M), temporalis (T), medial and lateral pterygoid (MP, LP) muscles', 'mean value for recall, HD, HD95, MSD', 'segmentation accuracy', 'DLAS mean DSC for M, T, MP, and LP']",[],"[{'cui': 'C4704761', 'cui_str': 'Hierarchical Learning'}, {'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0024890', 'cui_str': 'Structure of muscle of mastication'}]","[{'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0024890', 'cui_str': 'Structure of muscle of mastication'}, {'cui': 'C0024876', 'cui_str': 'Masseter muscle structure'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0224145', 'cui_str': 'Structure of lateral pterygoid muscle'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C4704761', 'cui_str': 'Hierarchical Learning'}]",,0.0352222,Routine delineation of these muscles during planning may improve dose tracking and facilitate dose reduction resulting in decreased radiation-related trismus.,"[{'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': 'Department of Radiation Oncology, Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Yimin', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Radiation Oncology, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.'}, {'ForeName': 'Brandon A', 'Initials': 'BA', 'LastName': 'Dyer', 'Affiliation': 'Department of Radiation Oncology, University of California Davis Medical Center, 4501 X Street, Suite 0152, Sacramento, California, 95817, USA.'}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Feng', 'Affiliation': 'Carina Medical LLC, 145 Graham Ave, A168, Lexington, KY, 40536, USA.'}, {'ForeName': 'Shyam', 'Initials': 'S', 'LastName': 'Rao', 'Affiliation': 'Department of Radiation Oncology, University of California Davis Medical Center, 4501 X Street, Suite 0152, Sacramento, California, 95817, USA.'}, {'ForeName': 'Stanley H', 'Initials': 'SH', 'LastName': 'Benedict', 'Affiliation': 'Department of Radiation Oncology, University of California Davis Medical Center, 4501 X Street, Suite 0152, Sacramento, California, 95817, USA.'}, {'ForeName': 'Quan', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Carina Medical LLC, 145 Graham Ave, A168, Lexington, KY, 40536, USA. qchen@uky.edu.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Rong', 'Affiliation': 'Department of Radiation Oncology, University of California Davis Medical Center, 4501 X Street, Suite 0152, Sacramento, California, 95817, USA. yrong@ucdavis.edu.'}]","Radiation oncology (London, England)",['10.1186/s13014-020-01617-0'] 2142,32690105,"Impact of receiving recorded mental health recovery narratives on quality of life in people experiencing psychosis, people experiencing other mental health problems and for informal carers: Narrative Experiences Online (NEON) study protocol for three randomised controlled trials.","BACKGROUND Mental health recovery narratives have been defined as first-person lived experience accounts of recovery from mental health problems which refer to events or actions over a period of time and which include elements of adversity or struggle, and also self-defined strengths, successes or survival. They are readily available in invariant recorded form, including text, audio or video. Previous studies have provided evidence that receiving recorded recovery narratives can provide benefits to recipients. This protocol describes three pragmatic trials that will be conducted by the Narrative Experiences Online (NEON) study using the NEON Intervention, a web application that delivers recorded recovery narratives to its users. The aim of the NEON Trial is to understand whether receiving online recorded recovery narratives through the NEON Intervention benefits people with experience of psychosis. The aim of the NEON-O and NEON-C trials is to evaluate the feasibility of conducting a definitive trial on the use of the NEON Intervention with people experiencing non-psychosis mental health problems and those who care for others experiencing mental health problems respectively. METHODS The NEON Trial will recruit 683 participants with experience of psychosis. The NEON-O Trial will recruit at least 100 participants with experience of non-psychosis mental health problems. The NEON-C Trial will recruit at least 100 participants with experience of caring for others who have experienced mental health problems. In all three trials, participants will be randomly allocated into one of two arms. Intervention arm participants will receive treatment as usual plus immediate access to the NEON Intervention for 1 year. Control arm participants will receive treatment as usual plus access to the NEON Intervention after 1 year. All participants will complete demographics and outcome measures at baseline, 1 week, 12 weeks and 52 weeks. For the NEON Trial, the primary outcome measure is the Manchester Short Assessment of Quality of Life at 52 weeks, and secondary outcome measures are the CORE-10, Herth Hope Index, Mental Health Confidence Scale and Meaning in Life Questionnaire. A cost-effectiveness analysis will be conducted using data collected through the EQ-5D-5 L and the Client Service Receipt Inventory. DISCUSSION NEON Trial analyses will establish both effectiveness and cost-effectiveness of the NEON Intervention for people with experience of psychosis, and hence inform future clinical recommendations for this population. TRIAL REGISTRATION All trials were prospectively registered with ISRCTN. NEON Trial: ISRCTN11152837 . Registered on 13 August 2018. NEON-C Trial: ISRCTN76355273 . Registered on 9 January 2020. NEON-O Trial: ISRCTN63197153 . Registered on 9 January 2020.",2020,The aim of the NEON Trial is to understand whether receiving online recorded recovery narratives through the NEON Intervention benefits people with experience of psychosis.,"['100 participants with experience of caring for others who have experienced mental health problems', 'people with experience of psychosis', 'benefits people with experience of psychosis', 'people experiencing psychosis, people experiencing other mental health problems and for informal carers', '683 participants with experience of psychosis', '100 participants with experience of non-psychosis mental health problems', 'people experiencing non-psychosis mental health problems and those who care for others experiencing mental health problems respectively']","['EQ-5D-5', 'receiving recorded mental health recovery narratives', 'NEON Intervention']","['quality of life', 'Manchester Short Assessment of Quality of Life at 52\u2009weeks, and secondary outcome measures are the CORE-10, Herth Hope Index, Mental Health Confidence Scale and Meaning in Life Questionnaire']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C1446377', 'cui_str': 'Mental health problem'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C1319882', 'cui_str': 'Informal caregiver'}]","[{'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C4505046', 'cui_str': 'Mental Health Recovery'}, {'cui': 'C1135957', 'cui_str': 'Narration'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C3898714', 'cui_str': 'Internet Intervention'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0281588', 'cui_str': 'Assessment of quality of life'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0392347', 'cui_str': 'Hope'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",683.0,0.315777,The aim of the NEON Trial is to understand whether receiving online recorded recovery narratives through the NEON Intervention benefits people with experience of psychosis.,"[{'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Rennick-Egglestone', 'Affiliation': 'School of Health Sciences, Institute of Mental Health, University of Nottingham Innovation Park, Triumph Road, Nottingham, NG7 2TU, UK. stefan.egglestone@nottingham.ac.uk.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Elliott', 'Affiliation': 'Division of Population Health, Health Services Research & Primary Care, University of Manchester, Oxford Road, Manchester, M13 9PL, UK.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Smuk', 'Affiliation': 'London School of Hygiene and Tropical Medicine, Keppel St, Bloomsbury, London, WC1E 7HT, UK.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Robinson', 'Affiliation': 'Centre for Primary Care & Public Health, Pragmatic Clinical Trials Unit, Queen Mary University of London, 58 Turner St, London, E1 2AB, UK.'}, {'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Bailey', 'Affiliation': 'NEON Lived Experience Advisory Panel, Nottingham, UK.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Smith', 'Affiliation': 'NEON Lived Experience Advisory Panel, Nottingham, UK.'}, {'ForeName': 'Jeroen', 'Initials': 'J', 'LastName': 'Keppens', 'Affiliation': ""Department of Informatics, King's College London, Bush House, 30 Aldwych, London, WC2B 4BG, UK.""}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Hussain', 'Affiliation': 'Division of Population Health, Health Services Research & Primary Care, University of Manchester, Oxford Road, Manchester, M13 9PL, UK.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Pollock', 'Affiliation': 'School of Health Sciences, Queens Medical Centre, Nottingham, NG7 2UH, UK.'}, {'ForeName': 'Pim', 'Initials': 'P', 'LastName': 'Cuijpers', 'Affiliation': 'Department of Clinical, Neuro and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Joy', 'Initials': 'J', 'LastName': 'Llewellyn-Beardsley', 'Affiliation': 'School of Health Sciences, Institute of Mental Health, University of Nottingham Innovation Park, Triumph Road, Nottingham, NG7 2TU, UK.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Ng', 'Affiliation': 'School of Health Sciences, Institute of Mental Health, University of Nottingham Innovation Park, Triumph Road, Nottingham, NG7 2TU, UK.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Yeo', 'Affiliation': 'School of Health Sciences, Institute of Mental Health, University of Nottingham Innovation Park, Triumph Road, Nottingham, NG7 2TU, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Roe', 'Affiliation': 'National Institute for Health Research, ARC East Midlands, University of Nottingham, Triumph Road, Nottingham, NG7 2TU, UK.'}, {'ForeName': 'Ada', 'Initials': 'A', 'LastName': 'Hui', 'Affiliation': 'School of Health Sciences, Institute of Mental Health, University of Nottingham Innovation Park, Triumph Road, Nottingham, NG7 2TU, UK.'}, {'ForeName': 'Lian', 'Initials': 'L', 'LastName': 'van der Krieke', 'Affiliation': 'University Medical Center Groningen, University Center of Psychiatry, University of Groningen, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.'}, {'ForeName': 'Rianna', 'Initials': 'R', 'LastName': 'Walcott', 'Affiliation': ""Department of Digital Humanities, King's College London, Strand, London, WC2R 2LS, UK.""}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Slade', 'Affiliation': 'School of Health Sciences, Institute of Mental Health, University of Nottingham Innovation Park, Triumph Road, Nottingham, NG7 2TU, UK.'}]",Trials,['10.1186/s13063-020-04428-6'] 2143,32690388,Optimal strategy for side branch treatment in patients with left main coronary bifurcation lesions.,"INTRODUCTION AND OBJECTIVES There are no guidelines regarding the most appropriate approach for provisional side branch (SB) intervention in left main (LM) bifurcation lesions. METHODS The present prospective, randomized, open-label, multicenter trial compared conservative vs aggressive strategies for provisional SB intervention during LM bifurcation treatment. Although the trial was designed to enroll 700 patients, it was prematurely terminated due to slow enrollment. For 160 non-true bifurcation lesions, a 1-stent technique without kissing balloon inflation was applied in the conservative strategy, whereas a 1-stent technique with mandatory kissing balloon inflation was applied in the aggressive strategy. For 46 true bifurcation lesions, a stepwise approach was applied in the conservative strategy (after main vessel stenting, SB ballooning when residual stenosis> 75%; then, SB stenting if residual stenosis> 50% or there was a dissection). An elective 2-stent technique was applied in the aggressive strategy. The primary outcome was a 1-year target lesion failure (TLF) composite of cardiac death, myocardial infarction, or target lesion revascularization. RESULTS Among non-true bifurcation lesions, the conservative strategy group used a smaller amount of contrast dye than the aggressive strategy group. There were no significant differences in 1-year TLF between the 2 strategies among non-true bifurcation lesions (6.5% vs 4.9%; HR, 1.31; 95%CI, 0.35-4.88; P=.687) and true bifurcation lesions (17.6% vs 21.7%; HR, 0.76; 95%CI, 0.20-2.83; P=.683). CONCLUSIONS In patients with a LM bifurcation lesion, conservative and aggressive strategies for a provisional SB approach have similar 1-year TLF rates.",2020,"Among non-true bifurcation lesions, the conservative strategy group used a smaller amount of contrast dye than the aggressive strategy group.","['enroll 700 patients, it was prematurely terminated due to slow enrollment', 'patients with left main coronary bifurcation lesions']",[],"['1-year TLF rates', '1-year target lesion failure (TLF) composite of cardiac death, myocardial infarction, or target lesion revascularization', 'true bifurcation lesions', '1-year TLF']","[{'cui': 'C4517862', 'cui_str': '700'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0184906', 'cui_str': 'Bifurcation'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",[],"[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0014742', 'cui_str': 'Erythema multiforme'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0376297', 'cui_str': 'Cardiac death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0205238', 'cui_str': 'True'}, {'cui': 'C0184906', 'cui_str': 'Bifurcation'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",,0.0813169,"Among non-true bifurcation lesions, the conservative strategy group used a smaller amount of contrast dye than the aggressive strategy group.","[{'ForeName': 'Jihoon', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Joo Myung', 'Initials': 'JM', 'LastName': 'Lee', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Taek Kyu', 'Initials': 'TK', 'LastName': 'Park', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jeong Hoon', 'Initials': 'JH', 'LastName': 'Yang', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Joo-Yong', 'Initials': 'JY', 'LastName': 'Hahn', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jin-Ho', 'Initials': 'JH', 'LastName': 'Choi', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Seung-Hyuk', 'Initials': 'SH', 'LastName': 'Choi', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Ki Bae', 'Initials': 'KB', 'LastName': 'Seung', 'Affiliation': ""Division of Cardiology, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Seung-Ho', 'Initials': 'SH', 'LastName': 'Hur', 'Affiliation': 'Division of Cardiology, Keimyung University Dongsan Medical Center, Daegu, Republic of Korea.'}, {'ForeName': 'Seung-Woon', 'Initials': 'SW', 'LastName': 'Rha', 'Affiliation': 'Division of Cardiology, Korea University Guro Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'June-Hong', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology, Pusan National University Yangsan Hospital, Pusan, Republic of Korea.'}, {'ForeName': 'Rak Kyeong', 'Initials': 'RK', 'LastName': 'Choi', 'Affiliation': 'Division of Cardiology, Mediplex Sejong Hospital, Incheon, Republic of Korea.'}, {'ForeName': 'Ju Hyeon', 'Initials': 'JH', 'LastName': 'Oh', 'Affiliation': 'Division of Cardiology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.'}, {'ForeName': 'Hyo-Soo', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology, Seoul National University Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Seung-Hwan', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Division of Cardiology, Yonsei University Wonju Christian Hospital, Wonju, Republic of Korea.'}, {'ForeName': 'Jong-Seon', 'Initials': 'JS', 'LastName': 'Park', 'Affiliation': 'Division of Cardiology, Yeungnam University Medical Center, Daegu, Republic of Korea.'}, {'ForeName': 'Sung Yun', 'Initials': 'SY', 'LastName': 'Lee', 'Affiliation': 'Division of Cardiology, Inje University Ilsan Paik Hospital, Ilsan, Republic of Korea.'}, {'ForeName': 'Dong Woon', 'Initials': 'DW', 'LastName': 'Jeon', 'Affiliation': 'Division of Cardiology, National Health Insurance Service Ilsan Hospital, Ilsan, Republic of Korea.'}, {'ForeName': 'Myung Ho', 'Initials': 'MH', 'LastName': 'Jeong', 'Affiliation': 'Division of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea.'}, {'ForeName': 'Jae-Hwan', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Division of Cardiology, Chungnam National University Hospital, Daejeon, Republic of Korea.'}, {'ForeName': 'Sang Yeub', 'Initials': 'SY', 'LastName': 'Lee', 'Affiliation': 'Division of Cardiology, Chungbuk National University Hospital, Cheongju, Republic of Korea.'}, {'ForeName': 'Woo-Jung', 'Initials': 'WJ', 'LastName': 'Park', 'Affiliation': 'Division of Cardiology, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.'}, {'ForeName': 'Young Bin', 'Initials': 'YB', 'LastName': 'Song', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: youngbin.song@gmail.com.'}, {'ForeName': 'Hyeon-Cheol', 'Initials': 'HC', 'LastName': 'Gwon', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}]",Revista espanola de cardiologia (English ed.),['10.1016/j.rec.2020.06.011'] 2144,32690404,"Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomized, Multicenter Study. Lancet 2020;395:1208-16.",,2020,,['Patients with High-risk Cancer'],"['Curative-intent Surgery or Radiotherapy (proPSMA', 'Prostate-specific Membrane Antigen PET-CT']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]","[{'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0067685', 'cui_str': 'Glutamate carboxypeptidase II'}, {'cui': 'C1699633', 'cui_str': 'Positron emission tomography with computed tomography'}]",[],,0.0238972,,"[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Evangelista', 'Affiliation': 'Nuclear Medicine Unit, Department of Medicine, University of Padua, Padua, Italy. Electronic address: laura.evangelista@unipd.it.'}, {'ForeName': 'Gian Luca', 'Initials': 'GL', 'LastName': 'De Salvo', 'Affiliation': 'Clinical Trials and Biostatistics Unit, IRCCS Istituto Oncologico Veneto, Padova, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Zattoni', 'Affiliation': 'Urology Unit, Academic Medical Centre Hospital, Udine, Italy.'}, {'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Novara', 'Affiliation': 'Department of Surgery, Oncology, and Gastroenterology, Urology Clinic, University of Padua, Padua, Italy.'}]",European urology oncology,['10.1016/j.euo.2020.06.013'] 2145,32690406,"Comparison the effect of breast milk smell, white noise and facilitated tucking applied to Turkish preterm infants during endotracheal suctioning on pain and physiological parameters.","PURPOSE This study aimed to determine the effect of the breast milk smell, white noise and facilitated tucking during endotracheal suctioning (ES) on pain and physiological findings. DESIGN AND METHODS The present study was conducted as a randomized, controlled experimental trial study. The sample of the study was composed of a total of 80 preterm infants. Pain was measured with PIPP-R pain scale. rMANOVA and bonferroni tests were used in the comparison of the pain scores of the groups. RESULTS It was determined that white noise and facilitated tucking were more effective in relieving infants before ES procedure (p < .05). No statistically significant difference was found between the groups in reducing the pain during ES procedure (p > .05). After the procedure, facilitated tucking was determined more effective in the recovery of preterm infants (p < .05). PRACTICE IMPLICATIONS It is recommended to use facilitated tucking and white noise for decreasing pain of ventilated preterm infants during the ES procedure. CONCLUSIONS White noise and facilitated tucking were effective in relieving pain before procedure and facilitated tucking recovery in preterm infants after the ES procedure.",2020,"After the procedure, facilitated tucking was determined more effective in the recovery of preterm infants (p < .05). ","['ventilated preterm infants during the ES procedure', '80 preterm infants']","['endotracheal suctioning', 'breast milk smell, white noise and facilitated tucking during endotracheal suctioning (ES', 'breast milk smell, white noise and facilitated tucking']","['pain scores', 'pain and physiological findings', 'Pain', 'pain and physiological parameters', 'pain during ES procedure', 'relieving pain', 'PIPP-R pain scale']","[{'cui': 'C0042491', 'cui_str': 'Ventilation'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C1522653', 'cui_str': 'Intratracheal route'}, {'cui': 'C0038638', 'cui_str': 'Suction drainage'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C1522653', 'cui_str': 'Intratracheal route'}, {'cui': 'C0038638', 'cui_str': 'Suction drainage'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0037361', 'cui_str': 'Sense of smell, function'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0028263', 'cui_str': 'Noise'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1522653', 'cui_str': 'Intratracheal route'}, {'cui': 'C0038638', 'cui_str': 'Suction drainage'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0070798', 'cui_str': 'PtdIns(4,5)P2'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}]",80.0,0.0401671,"After the procedure, facilitated tucking was determined more effective in the recovery of preterm infants (p < .05). ","[{'ForeName': 'Ayşe Şener', 'Initials': 'AŞ', 'LastName': 'Taplak', 'Affiliation': 'PhD, Assist. Prof, RN. Yozgat Bozok University, Faculty of Health Sciences, Yozgat, Turkey. Electronic address: ayse.taplak@yobu.edu.tr.'}, {'ForeName': 'Meral', 'Initials': 'M', 'LastName': 'Bayat', 'Affiliation': 'PhD, Prof, RN. Erciyes University Faculty of Health Sciences, Kayseri, Turkey.'}]",Journal of pediatric nursing,['10.1016/j.pedn.2020.07.001'] 2146,32690472,Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial.,"BACKGROUND Past clinical trials of docosahexaenoic Acid (DHA) supplements for the prevention of Alzheimer's disease (AD) dementia have used lower doses and have been largely negative. We hypothesized that larger doses of DHA are needed for adequate brain bioavailability and that APOE4 is associated with reduced delivery of DHA and eicosapentaenoic acid (EPA) to the brain before the onset of cognitive impairment. METHODS 33 individuals were provided with a vitamin B complex (1 mg vitamin B12, 100 mg of vitamin B6 and 800 mcg of folic acid per day) and randomized to 2,152 mg of DHA per day or placebo over 6 months. 26 individuals completed both lumbar punctures and MRIs, and 29 completed cognitive assessments at baseline and 6 months. The primary outcome was the change in CSF DHA. Secondary outcomes included changes in CSF EPA levels, MRI hippocampal volume and entorhinal thickness; exploratory outcomes were measures of cognition. FINDINGS A 28% increase in CSF DHA and 43% increase in CSF EPA were observed in the DHA treatment arm compared to placebo (mean difference for DHA (95% CI): 0.08 µg/mL (0.05, 0.10), p<0.0001; mean difference for EPA: 0.008 µg/mL (0.004, 0.011), p<0.0001). The increase in CSF EPA in non-APOE4 carriers after supplementation was three times greater than APOE4 carriers. The change in brain volumes and cognitive scores did not differ between groups. INTERPRETATION Dementia prevention trials using omega-3 supplementation doses equal or lower to 1 g per day may have reduced brain effects, particularly in APOE4 carriers. TRIAL REGISTRATION NCT02541929. FUNDING HNY was supported by R01AG055770, R01AG054434, R01AG067063 from the National Institute of Aging and NIRG-15-361854 from the Alzheimer's Association, and MGH by the L. K. Whittier Foundation. This work was also supported by P50AG05142 (HCC) from the National Institutes of Health. Funders had no role in study design, data collection, data analysis, interpretation, or writing of the report.",2020,"The change in brain volumes and cognitive scores did not differ between groups. ","[""Alzheimer's disease (AD) dementia"", '26 individuals completed both lumbar punctures and MRIs, and 29 completed cognitive assessments at baseline and 6 months', '33 individuals']","['docosahexaenoic Acid (DHA) supplements', 'supplemental docosahexaenoic acid (DHA', 'vitamin B complex (1\xa0mg vitamin B12, 100\xa0mg of vitamin B6 and 800 mcg of folic acid per day) and randomized to 2,152 mg of DHA per day or placebo', 'placebo']","['change in brain volumes and cognitive scores', 'CSF DHA', 'change in CSF DHA', 'CSF EPA', 'changes in CSF EPA levels, MRI hippocampal volume and entorhinal thickness; exploratory outcomes were measures of cognition']","[{'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0037943', 'cui_str': 'Lumbar puncture'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0042845', 'cui_str': 'Vitamin B 12'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0034272', 'cui_str': 'pyridoxine'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0439211', 'cui_str': 'mcg'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",33.0,0.602306,"The change in brain volumes and cognitive scores did not differ between groups. ","[{'ForeName': 'Isabella C', 'Initials': 'IC', 'LastName': 'Arellanes', 'Affiliation': 'Department of Medicine, Keck School of Medicine USC, United States.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Choe', 'Affiliation': 'Department of Medicine, Keck School of Medicine USC, United States.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Solomon', 'Affiliation': 'Department of Medicine, Keck School of Medicine USC, United States.'}, {'ForeName': 'Xulei', 'Initials': 'X', 'LastName': 'He', 'Affiliation': 'Department of Medicine, Keck School of Medicine USC, United States.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Kavin', 'Affiliation': 'Department of Medicine, Keck School of Medicine USC, United States.'}, {'ForeName': 'Ashley E', 'Initials': 'AE', 'LastName': 'Martinez', 'Affiliation': 'Department of Medicine, Keck School of Medicine USC, United States.'}, {'ForeName': 'Naoko', 'Initials': 'N', 'LastName': 'Kono', 'Affiliation': 'Department of Preventive Medicine, Keck School of Medicine USC, United States.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Buennagel', 'Affiliation': 'Huntington Medical Research Institutes, CA, United States.'}, {'ForeName': 'Nalini', 'Initials': 'N', 'LastName': 'Hazra', 'Affiliation': 'Imaging Genetics Center, Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, USC, United States.'}, {'ForeName': 'Giselle', 'Initials': 'G', 'LastName': 'Kim', 'Affiliation': 'Imaging Genetics Center, Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, USC, United States.'}, {'ForeName': 'Lina M', 'Initials': 'LM', 'LastName': ""D'Orazio"", 'Affiliation': 'Department of Neurology, Keck School of Medicine USC, United States.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'McCleary', 'Affiliation': 'Department of Neurology, Keck School of Medicine USC, United States.'}, {'ForeName': 'Abhay', 'Initials': 'A', 'LastName': 'Sagare', 'Affiliation': 'Department of Physiology and Neuroscience, Keck School of Medicine USC, United States.'}, {'ForeName': 'Berislav V', 'Initials': 'BV', 'LastName': 'Zlokovic', 'Affiliation': 'Department of Physiology and Neuroscience, Keck School of Medicine USC, United States.'}, {'ForeName': 'Howard N', 'Initials': 'HN', 'LastName': 'Hodis', 'Affiliation': 'Department of Medicine, Keck School of Medicine USC, United States; Department of Preventive Medicine, Keck School of Medicine USC, United States.'}, {'ForeName': 'Wendy J', 'Initials': 'WJ', 'LastName': 'Mack', 'Affiliation': 'Department of Preventive Medicine, Keck School of Medicine USC, United States.'}, {'ForeName': 'Helena C', 'Initials': 'HC', 'LastName': 'Chui', 'Affiliation': 'Department of Neurology, Keck School of Medicine USC, United States.'}, {'ForeName': 'Michael G', 'Initials': 'MG', 'LastName': 'Harrington', 'Affiliation': 'Huntington Medical Research Institutes, CA, United States; Department of Neurology, Keck School of Medicine USC, United States.'}, {'ForeName': 'Meredith N', 'Initials': 'MN', 'LastName': 'Braskie', 'Affiliation': 'Imaging Genetics Center, Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, USC, United States.'}, {'ForeName': 'Lon S', 'Initials': 'LS', 'LastName': 'Schneider', 'Affiliation': 'Department of Neurology, Keck School of Medicine USC, United States; Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine USC, United States.'}, {'ForeName': 'Hussein N', 'Initials': 'HN', 'LastName': 'Yassine', 'Affiliation': 'Department of Medicine, Keck School of Medicine USC, United States; Department of Neurology, Keck School of Medicine USC, United States. Electronic address: hyassine@usc.edu.'}]",EBioMedicine,['10.1016/j.ebiom.2020.102883'] 2147,32690477,"Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice.","Despite their ubiquitous presence, placebos and placebo effects retain an ambiguous and unsettling presence in biomedicine. Specifically focused on chronic pain, this review examines the effect of placebo treatment under three distinct frameworks: double blind, deception, and open label honestly prescribed. These specific conditions do not necessarily differentially modify placebo outcomes. Psychological, clinical, and neurological theories of placebo effects are scrutinized. In chronic pain, conscious expectation does not reliably predict placebo effects. A supportive patient-physician relationship may enhance placebo effects. This review highlights ""predictive coding"" and ""bayesian brain"" as emerging models derived from computational neurobiology that offer a unified framework to explain the heterogeneous evidence on placebos. These models invert the dogma of the brain as a stimulus driven organ to one in which perception relies heavily on learnt, top down, cortical predictions to infer the source of incoming sensory data. In predictive coding/bayesian brain, both chronic pain (significantly modulated by central sensitization) and its alleviation with placebo treatment are explicated as centrally encoded, mostly non-conscious, bayesian biases. The review then evaluates seven ways in which placebos are used in clinical practice and research and their bioethical implications. In this way, it shows that placebo effects are evidence based, clinically relevant, and potentially ethical tools for relieving chronic pain.",2020,"In predictive coding/bayesian brain, both chronic pain (significantly modulated by central sensitization) and its alleviation with placebo treatment are explicated as centrally encoded, mostly non-conscious, bayesian biases.",['chronic pain'],"['Placebos', 'placebo']",['chronic pain'],"[{'cui': 'C0150055', 'cui_str': 'Chronic pain'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0150055', 'cui_str': 'Chronic pain'}]",,0.471247,"In predictive coding/bayesian brain, both chronic pain (significantly modulated by central sensitization) and its alleviation with placebo treatment are explicated as centrally encoded, mostly non-conscious, bayesian biases.","[{'ForeName': 'Ted J', 'Initials': 'TJ', 'LastName': 'Kaptchuk', 'Affiliation': 'Beth Israel Hospital/Harvard Medical School, Boston, MA 02139, USA.'}, {'ForeName': 'Christopher C', 'Initials': 'CC', 'LastName': 'Hemond', 'Affiliation': 'University of Massachusetts Medical School, Worcester, MA 01655, USA.'}, {'ForeName': 'Franklin G', 'Initials': 'FG', 'LastName': 'Miller', 'Affiliation': 'Weill Cornell Medicine, New York, NY 10065, USA.'}]",BMJ (Clinical research ed.),['10.1136/bmj.m1668'] 2148,32690591,Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE).,"BACKGROUND Observational studies have supported the practice of offering minimally invasive interval debulking surgery after neoadjuvant chemotherapy for well-selected patients with advanced epithelial ovarian cancer. However, there are no prospective randomized data comparing the oncologic efficacy of minimally invasive and open interval debulking surgery in epithelial ovarian cancer. PRIMARY OBJECTIVE The primary objective of this study is to examine whether minimally invasive surgery is non-inferior to laparotomy in terms of disease-free survival in women with advanced stage epithelial ovarian cancer that responded to three or four cycles of neoadjuvant chemotherapy. STUDY HYPOTHESIS We hypothesize that in patients who had a complete or partial response to neoadjuvant chemotherapy, minimally invasive interval debulking surgery is not inferior to laparotomy. TRIAL DESIGN The Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE) trial is an international, prospective, randomized, multicenter, non-inferiority phase III trial to compare minimally invasive surgery vs laparotomy in women with advanced stage high-grade epithelial ovarian cancer that had a complete or partial response to three or four cycles of neoadjuvant chemotherapy and normalization of CA-125. The first 100 participants will be enrolled into a pilot lead-in to determine feasibility. The study will be considered feasible and will continue to Phase III under the following conditions: the accrual rate reaches at least 80% of the target rate after all pilot sites are open; the crossover rate in the minimally invasive group is less than 25%; and the difference of complete gross resection between the minimally invasive and open group is less than 20%. If the study is determined to be feasible, all remaining participants will be enrolled into the Phase III stage. MAJOR INCLUSION/EXCLUSION CRITERIA Patients with stage IIIC or IV high-grade epithelial ovarian, primary peritoneal or fallopian tube carcinoma who had a complete or partial response to three or four cycles of neoadjuvant chemotherapy based on imaging and normalization of CA-125 will be enrolled. Patients with evidence of tumor not amenable to minimally invasive resection on pre-operative imaging will be excluded. PRIMARY ENDPOINT The primary endpoint is non-inferiority of disease-free survival in minimally invasive vs laparotomic interval debulking surgery. SAMPLE SIZE To demonstrate non-inferiority with a margin of 33% in the hazard ratio (HR=1.33), 549 patients will be randomized.",2020,"The primary endpoint is non-inferiority of disease-free survival in minimally invasive vs laparotomic interval debulking surgery. ","['100 participants', 'women with advanced stage high-grade epithelial ovarian cancer that had a complete or partial response to three or four cycles of neoadjuvant chemotherapy and normalization of CA-125', 'patients who had a complete or partial response to neoadjuvant chemotherapy, minimally invasive interval debulking surgery is not inferior to laparotomy', '549 patients will be randomized', 'women with advanced stage epithelial ovarian cancer', 'patients with advanced epithelial ovarian cancer', 'Patients with stage IIIC or IV high-grade epithelial ovarian, primary peritoneal or fallopian tube carcinoma who had a complete or partial response to three or four cycles of neoadjuvant chemotherapy based on imaging and normalization of CA-125 will be enrolled']","['minimally invasive and open interval debulking surgery', 'Laparoscopic cytoreduction', 'Neoadjuvant ChEmotherapy (LANCE', 'minimally invasive surgery', 'minimally invasive interval debulking surgery after neoadjuvant chemotherapy', 'minimally invasive surgery vs laparotomy', 'neoadjuvant chemotherapy']",['non-inferiority of disease-free survival'],"[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C4721610', 'cui_str': 'Epithelial Ovarian Carcinoma'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0006610', 'cui_str': 'Cancer antigen 125'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0023038', 'cui_str': 'Laparotomy'}, {'cui': 'C0456608', 'cui_str': 'Stage 3C'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0031153', 'cui_str': 'Peritoneum (serous membrane) structure'}, {'cui': 'C0238122', 'cui_str': 'Carcinoma of fallopian tube'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}]","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C3850079', 'cui_str': 'Cytoreductive surgery'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0282624', 'cui_str': 'Procedures, Minimally Invasive Surgical'}, {'cui': 'C0023038', 'cui_str': 'Laparotomy'}]","[{'cui': 'C0237666', 'cui_str': 'Inferiority feeling'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}]",549.0,0.355422,"The primary endpoint is non-inferiority of disease-free survival in minimally invasive vs laparotomic interval debulking surgery. ","[{'ForeName': 'Roni', 'Initials': 'R', 'LastName': 'Nitecki', 'Affiliation': 'Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Jose Alejandro', 'Initials': 'JA', 'LastName': 'Rauh-Hain', 'Affiliation': 'Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA jarauh@mdanderson.org.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Melamed', 'Affiliation': 'Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Scambia', 'Affiliation': ""Department of Women's and Children's Health, Policlinico A Gemelli, Rome, Italy.""}, {'ForeName': 'Rene', 'Initials': 'R', 'LastName': 'Pareja', 'Affiliation': 'Instituto Nacional de Cancerología, Bogotá, and Clínica de Oncología Astorga, Medellin, Colombia.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Coleman', 'Affiliation': 'The US Oncology Network, The Woodlands, Texas, USA.'}, {'ForeName': 'Pedro T', 'Initials': 'PT', 'LastName': 'Ramirez', 'Affiliation': 'Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Fagotti', 'Affiliation': ""Department of Women's and Children's Health, Policlinico A Gemelli, Rome, Italy.""}]",International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,['10.1136/ijgc-2020-001584'] 2149,32690640,Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Non-Severe Community-Acquired Pneumonia.,"Background. There remains an unmet need to address the substantial morbidity and mortality associated with severe community-acquired pneumonia (sCAP). Recombinant human plasma gelsolin (rhu-pGSN) improves disease outcomes in diverse animal models of infectious and non-infectious inflammation. Methods. This blinded dose-escalation safety study involved non-ICU patients admitted for mild CAP and randomized 3:1 to receive adjunctive rhu-pGSN or placebo intravenously. Thirty-three subjects were treated: 8 in the single-dose phase and 25 in the multi-dose phase. For the single-dose phase, rhu-pGSN 6 mg/kg was administered once. For the multi-dose phase, a daily rhu-pGSN dose of 6, 12, or 24 mg/kg was given on 3 consecutive days. Results Adverse events (AEs) were generally mild in both treatment groups irrespective of dose. The only serious (S)AE in the single-dose phase was a non-drug related pneumonia in a rhu-pGSN recipient who died after institution of comfort care. One single-dose placebo recipient had a drug-related AE (maculo-papular rash). In the multi-dose phase, there were 2 SAEs in 1 placebo recipient, including a fatal pulmonary embolism. In the 18 rhu-pGSN recipients in the multi-dose phase, there were no serious or drug-related AEs, and nausea and increased blood pressure were each reported in 2 patients. The median rhu-pGSN half-life exceeded 17 hours with all dosing regimens, and supraphysiologic levels were maintained throughout the 24-hour dosing interval in the 2 highest dosing arms. Conclusions Rhu-pGSN was well tolerated overall in CAP patients admitted to non-ICU beds, justifying a larger proof-of-concept trial in an ICU population admitted with sCAP.",2020,Recombinant human plasma gelsolin (rhu-pGSN) improves disease outcomes in diverse animal models of infectious and non-infectious inflammation.,"['Patients Hospitalized for Non-Severe Community-Acquired Pneumonia', 'Thirty-three subjects were treated: 8 in the single-dose phase and 25 in the multi-dose phase', 'non-ICU patients admitted for mild CAP']","['placebo', 'adjunctive rhu-pGSN or placebo', 'Recombinant human plasma gelsolin (rhu-pGSN', 'Recombinant Human Plasma Gelsolin']","['fatal pulmonary embolism', 'Adverse events (AEs', 'no serious or drug-related AEs, and nausea and increased blood pressure', 'supraphysiologic levels', 'median rhu-pGSN half-life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0694549', 'cui_str': 'Community acquired pneumonia'}, {'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0949898', 'cui_str': 'Sumac'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0061187', 'cui_str': 'Gelsolin'}]","[{'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0949898', 'cui_str': 'Sumac'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}]",33.0,0.124056,Recombinant human plasma gelsolin (rhu-pGSN) improves disease outcomes in diverse animal models of infectious and non-infectious inflammation.,"[{'ForeName': 'Abla', 'Initials': 'A', 'LastName': 'Tannous', 'Affiliation': 'BioAegis Therapeutics, North Brunswick, NJ atannous@bioaegistx.com.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Levinson', 'Affiliation': 'BioAegis Therapeutics, North Brunswick, NJ.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Bolognese', 'Affiliation': 'Cytel Corporation, Waltham, MA.'}, {'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'Opal', 'Affiliation': 'Alpert Medical School of Brown University, Providence, RI.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'DiNubile', 'Affiliation': 'BioAegis Therapeutics, North Brunswick, NJ.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.00579-20'] 2150,32690725,"Correction: Effects of programmed intermittent thoracic paravertebral bolus of levobupivacaine on the spread of sensory block: a randomized, controlled, double-blind study .",,2020,,[],['levobupivacaine'],['spread of sensory block'],[],"[{'cui': 'C0873118', 'cui_str': 'Levobupivacaine'}]","[{'cui': 'C0332261', 'cui_str': 'Spreading'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}]",,0.431649,,[],Regional anesthesia and pain medicine,['10.1136/rapm-2018-100021corr1'] 2151,32690730,Identifying significant contributors for smoking cessation among male prisoners in Australia: results from a randomised clinical trial.,"INTRODUCTION In Australia, an estimated 90% of those entering prison are current tobacco smokers and three-quarters of current prisoners are tobacco smokers. AIMS To identify factors and their relative contributions to smoking cessation among male prisoners. METHODS A total of 425 male tobacco smokers with a median age of 32 years in Australian prisons. The primary outcome was continuous abstinence at 3, 6 and 12 months. We measured various sociodemographic characteristics, drug use, psychological distress and the mental and physical health status of the participants. Multivariate logistic regression models and population attributable risks (PAR%) were used to identify the significant factors and their contributions to smoking cessation rates. RESULTS The median age of participants was 32 years (IQR 25-41 years). High smoking cessation rates were collectively associated with not using drugs, lower psychological distress, good mental health scores and better physical health (PAR%: 93%, 98% and 88% at 3, 6 and 12 months). CONCLUSION Our study suggests that not using drugs and being in good mental/physical health are the important contributors to continuous abstinence among prisoners. Thus, effective smoking cessation programmes require a multicomponent approach that includes addressing drug problems and mental health functioning. TRIAL REGISTRATION NUMBER 12606000229572.",2020,"High smoking cessation rates were collectively associated with not using drugs, lower psychological distress, good mental health scores and better physical health (PAR%: 93%, 98% and 88% at 3, 6 and 12 months). ","['425 male tobacco smokers with a median age of 32 years in Australian prisons', 'male prisoners', 'male prisoners in Australia']",[],"['psychological distress, good mental health scores and better physical health', 'continuous abstinence', 'High smoking cessation rates', 'various sociodemographic characteristics, drug use, psychological distress and the mental and physical health status']","[{'cui': 'C3844105', 'cui_str': '425'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4505217', 'cui_str': 'Smokers, Tobacco'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0033168', 'cui_str': 'Prisons'}, {'cui': 'C0033167', 'cui_str': 'Prisoners'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]",[],"[{'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0449889', 'cui_str': 'Drug used'}, {'cui': 'C0018759', 'cui_str': 'Health status'}]",425.0,0.0559297,"High smoking cessation rates were collectively associated with not using drugs, lower psychological distress, good mental health scores and better physical health (PAR%: 93%, 98% and 88% at 3, 6 and 12 months). ","[{'ForeName': 'Handan', 'Initials': 'H', 'LastName': 'Wand', 'Affiliation': 'Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Robyn', 'Initials': 'R', 'LastName': 'Richmond', 'Affiliation': 'School of Public Health and Community Medicine, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Armita', 'Initials': 'A', 'LastName': 'Adily', 'Affiliation': 'Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Le', 'Affiliation': 'Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Kay', 'Initials': 'K', 'LastName': 'Wilhelm', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, Australila.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Butler', 'Affiliation': 'Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia tbutler@kirby.unsw.edu.au.'}]",BMJ open,['10.1136/bmjopen-2019-034046'] 2152,32317371,Comparison of intra-aneurysmal flow modification using optical flow imaging to evaluate the performance of Evolve and Pipeline flow diverting stents.,"BACKGROUND Flow diverting stent (FDS) devices have revolutionized the treatment of large and complex brain aneurysms, but there is still room for improvement, particularly on the flow diversion properties and technical challenges associated with stent deployment. In this study we compared flow diversion properties between the new generation Surpass Evolve (Stryker) and the Pipeline Flex (Medtronic) devices by quantitatively evaluating intra-aneurysmal flow modification. METHODS An in vitro experimental set-up was used, consisting of four patient-specific silicone models with internal carotid aneurysms and a circulating hemodynamic simulation system with pulsatile flow. The Evolve and Pipeline stents were deployed across the neck of each aneurysm model, in a randomized fashion, for a total of eight device deployments. A 60 frames/s digital subtraction angiography run was acquired before and after placement of each FDS. An optical flow-analysis method was used to measure intra-aneurysmal flow modification induced by the stent by calculating a mean aneurysm flow amplitude (MAFA) before and after stent placement and computing a ratio. RESULTS Average MAFA ratio values calculated from pre- and post-stent placement were significantly lower after deployment of the Evolve (n=4, mean=0.62±0.09) compared with the Pipeline device (n=4, mean=0.71±0.06) (p=0.03). CONCLUSIONS Our in vitro results show that the Evolve stent had a superior flow diversion effect compared with the Pipeline stent, which-based on clinical evidence-suggest it may promote faster aneurysm occlusion rates in patients.",2020,"RESULTS Average MAFA ratio values calculated from pre- and post-stent placement were significantly lower after deployment of the Evolve (n=4, mean=0.62±0.09) compared with the Pipeline device (n=4, mean=0.71±0.06) (p=0.03). ",[],"['Flow diverting stent (FDS) devices', 'Evolve and Pipeline flow diverting stents']","['aneurysm occlusion rates', 'superior flow diversion effect', 'Average MAFA ratio values']",[],"[{'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0332253', 'cui_str': 'Evolving'}]","[{'cui': 'C0002940', 'cui_str': 'Aneurysm'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0185033', 'cui_str': 'Diversion procedure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1532109', 'cui_str': 'Ratio value'}]",,0.0326068,"RESULTS Average MAFA ratio values calculated from pre- and post-stent placement were significantly lower after deployment of the Evolve (n=4, mean=0.62±0.09) compared with the Pipeline device (n=4, mean=0.71±0.06) (p=0.03). ","[{'ForeName': 'Nicole Mariantonia', 'Initials': 'NM', 'LastName': 'Cancelliere', 'Affiliation': 'Division of Neuroradiology, Department of Medical Imaging, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Nicholson', 'Affiliation': 'Division of Neuroradiology, Department of Medical Imaging, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Radovanovic', 'Affiliation': 'Division of Neurosurgery, Department of Surgery, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Karla Mirella', 'Initials': 'KM', 'LastName': 'Mendes', 'Affiliation': 'Division of Neuroradiology, Department of Medical Imaging, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Emanuele', 'Initials': 'E', 'LastName': 'Orru', 'Affiliation': 'Division of Neuroradiology, Department of Medical Imaging, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Timo', 'Initials': 'T', 'LastName': 'Krings', 'Affiliation': 'Division of Neuroradiology, Department of Medical Imaging, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Vitor M', 'Initials': 'VM', 'LastName': 'Pereira', 'Affiliation': 'Division of Neuroradiology, Department of Medical Imaging, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada vitor.pereira@uhn.ca.'}]",Journal of neurointerventional surgery,['10.1136/neurintsurg-2019-015696'] 2153,30864748,"Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT.","Achieving blood pressure (BP) control is associated with lower cardiovascular disease (CVD) risk, but less is known about CVD risk associated with sustained BP control over time. This observational analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was restricted to participants with four to seven visits with systolic BP (SBP) measurements during a 22-month period (n = 24 309). The authors categorized participants as having sustained BP control (SBP < 140 mm Hg) at 100%, 75% to <100%, 50% to <75%, and <50% of visits during this period. Outcomes included fatal coronary heart disease (CHD)/nonfatal myocardial infarction (MI), stroke, heart failure (HF), a composite CVD outcome (fatal CHD/nonfatal MI, stroke, or HF), and mortality. Hazard ratios (HRs) for the association of category of sustained BP control for each outcome were obtained using proportional hazards models. SBP control was present among 20.0% of participants at 100%, 16.4% at 75% to less than 100%, 27.0% at 50% to less than 75%, and 36.6% at less than 50% of visits. Compared to those with SBP control at 100% visits, adjusted HR (95% CI) among those with SBP control at <50% of visits was 1.16 (0.93-1.44) for fatal CHD/nonfatal MI, 1.71 (1.26-2.32) for stroke, 1.63 (1.30-2.06) for HF, 1.39 (1.20-1.62) for the composite CVD outcome, and 1.14 (0.99-1.30) for mortality. Sustained SBP control may be beneficial for preventing stroke, HF, and CVD outcomes in adults taking antihypertensive medication.",2019,"SBP control was present among 20.0% of participants at 100%, 16.4% at 75% to less than 100%, 27.0% at 50% to less than 75%, and 36.6% at less than 50% of visits.","['adults taking antihypertensive medication', 'participants with four to seven visits with systolic BP (SBP) measurements during a 22-month period (n\xa0=\xa024\xa0309']",['Antihypertensive and Lipid-Lowering Treatment'],"['Hazard ratios (HRs', 'fatal coronary heart disease (CHD)/nonfatal myocardial infarction (MI), stroke, heart failure (HF), a composite CVD outcome (fatal CHD/nonfatal MI, stroke,\xa0or HF), and mortality', 'SBP control', 'Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality', 'mortality', 'fatal CHD/nonfatal MI', 'Achieving blood pressure (BP) control']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",,0.0580609,"SBP control was present among 20.0% of participants at 100%, 16.4% at 75% to less than 100%, 27.0% at 50% to less than 75%, and 36.6% at less than 50% of visits.","[{'ForeName': 'C Barrett', 'Initials': 'CB', 'LastName': 'Bowling', 'Affiliation': 'Durham Veterans Affairs Geriatric Research Education and Clinical Center, Durham Veterans Affairs Medical Center (VAMC), Durham, North Carolina.'}, {'ForeName': 'Barry R', 'Initials': 'BR', 'LastName': 'Davis', 'Affiliation': 'The University of Texas School of Public Health, Houston, Texas.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Luciano', 'Affiliation': 'Center for Study of Aging and Human Development, Duke University, Durham, North Carolina.'}, {'ForeName': 'Lara M', 'Initials': 'LM', 'LastName': 'Simpson', 'Affiliation': 'The University of Texas School of Public Health, Houston, Texas.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Sloane', 'Affiliation': 'Center for Study of Aging and Human Development, Duke University, Durham, North Carolina.'}, {'ForeName': 'Carl F', 'Initials': 'CF', 'LastName': 'Pieper', 'Affiliation': 'Center for Study of Aging and Human Development, Duke University, Durham, North Carolina.'}, {'ForeName': 'Paula T', 'Initials': 'PT', 'LastName': 'Einhorn', 'Affiliation': 'Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute of the National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Oparil', 'Affiliation': 'Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Muntner', 'Affiliation': 'Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama.'}]","Journal of clinical hypertension (Greenwich, Conn.)",['10.1111/jch.13515'] 2154,31054219,Ultrasound assessment of muscle mass in response to exercise training in chronic kidney disease: a comparison with MRI.,"BACKGROUND Chronic kidney disease (CKD) is a catabolic condition associated with muscle wasting and dysfunction, which associates with morbidity and mortality. There is a need for simple techniques capable of monitoring changes in muscle size with disease progression and in response to interventions aiming to increase muscle mass and function. Ultrasound is one such technique; however, it is unknown how well changes in muscle cross-sectional area (CSA) measured using ultrasound relate to changes in whole muscle volume measured using magnetic resonance imaging. We tested whether rectus femoris CSA (RF-CSA) could be used as a valid indication of changes in quadriceps muscle volume as a single measure of muscle size and following a 12 week exercise intervention that resulted in muscle hypertrophy. METHODS Secondary analysis of data was collected from the ExTra CKD study (ISRCTN 36489137). Quadriceps muscle size was assessed from 36 patients with non-dialysis CKD before and after 12 weeks of supervised exercise that resulted in muscle hypertrophy. RESULTS Strong positive correlations were observed between RF-CSA and quadriceps volume at baseline (r 2 = 0.815, CI 0.661 to 0.903; P < 0.001) and following 12 week exercise (r 2 = 0.845, CI 0.700 to 0.923; P < 0.001). A moderate positive association was also observed between changes in RF-CSA and quadriceps following exercise training (rho = 0.441, CI 0.085 to 0.697; P = 0.015). Bland-Altman analysis revealed a small bias (bias 0.6% ± 12.5) between the mean percentage changes in RF-CSA and quadriceps volume but wide limits of agreement from -24 to 25. CONCLUSIONS Rectus femoris CSA appears to be a reliable index of total quadriceps volume as a simple measure of muscle size, both as a single observation and in response to exercise training in non-dialysis CKD patients.",2019,"Strong positive correlations were observed between RF-CSA and quadriceps volume at baseline (r 2 = 0.815, CI 0.661 to 0.903; P < 0.001) and following 12 week exercise (r 2 = 0.845, CI 0.700 to 0.923; P < 0.001).","['Chronic kidney disease (CKD', '36 patients with non-dialysis CKD before and after 12 weeks of', 'chronic kidney disease']","['supervised exercise', 'exercise training', 'rectus femoris CSA (RF-CSA']","['RF-CSA and quadriceps', 'Quadriceps muscle size', 'RF-CSA and quadriceps volume']","[{'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",36.0,0.0238361,"Strong positive correlations were observed between RF-CSA and quadriceps volume at baseline (r 2 = 0.815, CI 0.661 to 0.903; P < 0.001) and following 12 week exercise (r 2 = 0.845, CI 0.700 to 0.923; P < 0.001).","[{'ForeName': 'Douglas W', 'Initials': 'DW', 'LastName': 'Gould', 'Affiliation': 'Department of Health Sciences, University of Leicester, Leicester, UK.'}, {'ForeName': 'Emma L', 'Initials': 'EL', 'LastName': 'Watson', 'Affiliation': 'Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Wilkinson', 'Affiliation': 'Department of Health Sciences, University of Leicester, Leicester, UK.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Wormleighton', 'Affiliation': 'Department of Imaging, Glenfield Hospital, Leicester, UK.'}, {'ForeName': 'Soteris', 'Initials': 'S', 'LastName': 'Xenophontos', 'Affiliation': 'Department of Respiratory Sciences, University of Leicester, Leicester, UK.'}, {'ForeName': 'Joao L', 'Initials': 'JL', 'LastName': 'Viana', 'Affiliation': 'Research Center in Sports Sciences, Health Sciences and Human Development, CIDESD, University Institute of Maia, ISMAI, Maia, Portugal.'}, {'ForeName': 'Alice C', 'Initials': 'AC', 'LastName': 'Smith', 'Affiliation': 'Department of Health Sciences, University of Leicester, Leicester, UK.'}]","Journal of cachexia, sarcopenia and muscle",['10.1002/jcsm.12429'] 2155,31308252,"Small-protein Enrichment Assay Enables the Rapid, Unbiased Analysis of Over 100 Low Abundance Factors from Human Plasma.","Unbiased and sensitive quantification of low abundance small proteins in human plasma ( e.g. hormones, immune factors, metabolic regulators) remains an unmet need. These small protein factors are typically analyzed individually and using antibodies that can lack specificity. Mass spectrometry (MS)-based proteomics has the potential to address these problems, however the analysis of plasma by MS is plagued by the extremely large dynamic range of this body fluid, with protein abundances spanning at least 13 orders of magnitude. Here we describe an enrichment assay (SPEA), that greatly simplifies the plasma dynamic range problem by enriching small-proteins of 2-10 kDa, enabling the rapid, specific and sensitive quantification of >100 small-protein factors in a single untargeted LC-MS/MS acquisition. Applying this method to perform deep-proteome profiling of human plasma we identify C5ORF46 as a previously uncharacterized human plasma protein. We further demonstrate the reproducibility of our workflow for low abundance protein analysis using a stable-isotope labeled protein standard of insulin spiked into human plasma. SPEA provides the ability to study numerous important hormones in a single rapid assay, which we applied to study the intermittent fasting response and observed several unexpected changes including decreased plasma abundance of the iron homeostasis regulator hepcidin.",2019,Applying this method to perform deep-proteome profiling of human plasma we identify C5ORF46 as a previously uncharacterized human plasma protein.,[],[],['Mass spectrometry '],[],[],"[{'cui': 'C0037813', 'cui_str': 'Mass spectrometry measurement'}]",,0.0181029,Applying this method to perform deep-proteome profiling of human plasma we identify C5ORF46 as a previously uncharacterized human plasma protein.,"[{'ForeName': 'Dylan J', 'Initials': 'DJ', 'LastName': 'Harney', 'Affiliation': '‡Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Amy T', 'Initials': 'AT', 'LastName': 'Hutchison', 'Affiliation': '¶Discipline of Medicine, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Zhiduan', 'Initials': 'Z', 'LastName': 'Su', 'Affiliation': '‡Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Hatchwell', 'Affiliation': '‡Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Leonie K', 'Initials': 'LK', 'LastName': 'Heilbronn', 'Affiliation': '¶Discipline of Medicine, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Hocking', 'Affiliation': '§Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'James', 'Affiliation': '‡Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Larance', 'Affiliation': '‡Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Sydney, Australia mark.larance@sydney.edu.au.'}]",Molecular & cellular proteomics : MCP,['10.1074/mcp.TIR119.001562'] 2156,31343520,Muscle Glycogen Content during Endurance Training under Low Energy Availability.,"PURPOSE The present study investigated the effects of three consecutive days of endurance training under conditions of low energy availability (LEA) on the muscle glycogen content, muscle damage markers, endocrine regulation, and endurance capacity in male runners. METHODS Seven male long-distance runners (19.9 ± 1.1 yr, 175.6 ± 4.7 cm, 61.4 ± 5.3 kg, maximal oxygen uptake [V˙O2max]: 67.5 ± 4.3 mL·kg·min) completed two trials consisting of three consecutive days of endurance training under LEA (18.9 ± 1.9 kcal·kg FFM·d) or normal energy availability (NEA) (52.9 ± 5.0 kcal·kg FFM·d). The order of the two trials was randomized, with a 2-wk interval between trials. The endurance training consisted of 75 min of treadmill running at 70% of V˙O2max. Muscle glycogen content, respiratory gas variables, and blood and urine variables were measured in the morning for three consecutive days of training (days 1-3) and on the following morning after training (day 4). As an indication of endurance capacity, time to exhaustion at 19.0 ± 0.8 km·h to elicit 90% of V˙O2max was evaluated on day 4. RESULTS During the training period, body weight, fat-free mass, and skeletal muscle volume were significantly reduced in LEA (P = 0.02 for body weight and skeletal muscle volume, P = 0.01 for fat-free mass). Additionally, muscle glycogen content was significantly reduced in LEA (~30%, P < 0.001), with significantly lower values than those in NEA (P < 0.001). Time to exhaustion was not significantly different between the two trials (~20 min, P = 0.39). CONCLUSIONS Three consecutive days of endurance training under LEA decreased muscle glycogen content with lowered body weight. However, endurance capacity was not significantly impaired.",2020,"Additionally, muscle glycogen content was significantly reduced in LEA (~30%, P < 0.001), with significantly lower values than those in NEA (P < 0.001).","['Seven male long-distance runners (19.9 ± 1.1 yr, 175.6 ± 4.7 cm, 61.4 ± 5.3 kg, maximal oxygen uptake [V˙O2max]: 67.5 ± 4.3 mL·kg·min', 'male runners']","['endurance training under conditions of low energy availability (LEA', 'endurance training under LEA (18.9 ± 1.9 kcal·kg FFM·d) or normal energy availability (NEA) (52.9 ± 5.0 kcal·kg FFM·d', 'endurance training consisted of 75 min of treadmill running at 70% of V˙O2max']","['Muscle glycogen content, respiratory gas variables, and blood and urine variables', 'muscle glycogen content, muscle damage markers, endocrine regulation, and endurance capacity', 'LEA', 'muscle glycogen content', 'endurance capacity', 'Time to exhaustion', 'body weight, fat-free mass, and skeletal muscle volume']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C4517491', 'cui_str': '1.1'}, {'cui': 'C4708663', 'cui_str': '5.3'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C4517759', 'cui_str': '4.3'}]","[{'cui': 'C4704697', 'cui_str': 'Endurance Training'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C4517517', 'cui_str': '1.9'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0017911', 'cui_str': 'Glycogen'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage NOS'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0014136', 'cui_str': 'Structure of endocrine system'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",7.0,0.123417,"Additionally, muscle glycogen content was significantly reduced in LEA (~30%, P < 0.001), with significantly lower values than those in NEA (P < 0.001).","[{'ForeName': 'Chihiro', 'Initials': 'C', 'LastName': 'Kojima', 'Affiliation': 'Graduate School of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, JAPAN.'}, {'ForeName': 'Aya', 'Initials': 'A', 'LastName': 'Ishibashi', 'Affiliation': 'Japan Institute of Sports Sciences, Nishigaoka, Kitaku, Tokyo, JAPAN.'}, {'ForeName': 'Yoko', 'Initials': 'Y', 'LastName': 'Tanabe', 'Affiliation': 'Japan Institute of Sports Sciences, Nishigaoka, Kitaku, Tokyo, JAPAN.'}, {'ForeName': 'Kaito', 'Initials': 'K', 'LastName': 'Iwayama', 'Affiliation': 'Department of Budo and Sport Studies, Tenri University, Tenri, Nara, JAPAN.'}, {'ForeName': 'Akiko', 'Initials': 'A', 'LastName': 'Kamei', 'Affiliation': 'Japan Institute of Sports Sciences, Nishigaoka, Kitaku, Tokyo, JAPAN.'}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Takahashi', 'Affiliation': 'Japan Institute of Sports Sciences, Nishigaoka, Kitaku, Tokyo, JAPAN.'}, {'ForeName': 'Kazushige', 'Initials': 'K', 'LastName': 'Goto', 'Affiliation': 'Graduate School of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, JAPAN.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002098'] 2157,31600823,The burden of and factors associated with misclassification of intrapartum stillbirth: Evidence from a large scale multicentric observational study.,"INTRODUCTION Global estimates suggest 2.6 million stillbirths and 2.5 million neonatal deaths occur annually worldwide. The majority of these deaths occur in low resource settings where analysis of health metrics and outcomes measurements may be challenging. We examined the misclassification of documented intrapartum stillbirth and factors associated with misclassification. MATERIAL AND METHODS A prospective observational study was performed in 12 public hospitals in Nepal. Data were extracted from the medical records of all births that occurred during the 6-month period of the study. For the study purpose, we classified birth outcome based on the presence of fetal heart sound (FHS) at admission and use of neonatal resuscitation. The health worker-documented intrapartum stillbirths were considered potentially misclassified when there were FHS present at admission and no resuscitation initiated after birth. The association between potentially misclassified intrapartum stillbirth and complications during labor, birthweight and gestational age was assessed using Pearson's chi-square test, bivariate and multivariate logistic regression. RESULTS A total of 39 562 mother-infant dyads were enrolled in the study, all of whom had FHS at admission. Among the 391 intrapartum stillbirths recorded during the study, 180 (46.0%) of them had FHS at admission with no resuscitation initiated after birth and were considered potentially misclassified intrapartum stillbirths. Among these potentially misclassified intrapartum stillbirths, 170 (43.5%) had FHS present 15 minutes before birth and 10 had no FHS 15 minutes before birth Among the potentially misclassified intrapartum stillbirths, 23.3% had complications during labor, 93.3% had birthweight less than 2500 g and 90.0% were born preterm. The risk of intrapartum misclassification was nearly four times higher among low birthweight babies (adjusted odds ratio [aOR] 3.5, 95% confidence interval [CI] 1.8 to 7.0, P < 0.001) and five times higher among preterm babies (aOR 5.3, 95% CI 3.0 to 9.3, P < 0.001). CONCLUSIONS We estimate that 46% of intrapartum stillbirths were potentially misclassified intrapartum stillbirths. Improving quality of both FHS monitoring and neonatal resuscitation as well as measurement of the care will reduce the risk of potentially misclassified intrapartum stillbirth and consequently intrapartum stillbirth.",2020,"< 0.001) and five times higher among preterm babies (aOR 5.3, 95% CI 3.0 to 9.3, P < 0.001). ","['12 public hospitals in Nepal', 'A total of 39\u2009562 mother-infant dyads were enrolled in the study, all of whom had FHS at admission']",[],['risk of intrapartum misclassification'],"[{'cui': 'C0020022', 'cui_str': 'Public Hospitals'}, {'cui': 'C0027689', 'cui_str': 'Nepal'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0426038', 'cui_str': 'Fetal heart sounds present'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]",[],"[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0456337', 'cui_str': 'Intrapartum'}]",39562.0,0.0415263,"< 0.001) and five times higher among preterm babies (aOR 5.3, 95% CI 3.0 to 9.3, P < 0.001). ","[{'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Kc', 'Affiliation': ""Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.""}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Berkelhamer', 'Affiliation': 'Department of Pediatrics, University at Buffalo, Buffalo, NY, USA.'}, {'ForeName': 'Rejina', 'Initials': 'R', 'LastName': 'Gurung', 'Affiliation': 'Golden Community, Lalitpur, Nepal.'}, {'ForeName': 'Zhou', 'Initials': 'Z', 'LastName': 'Hong', 'Affiliation': 'Department of Maternal and Child Health, Peking University of Health Sciences, Peking, China.'}, {'ForeName': 'Haijun', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Maternal and Child Health, Peking University of Health Sciences, Peking, China.'}, {'ForeName': 'Avinash K', 'Initials': 'AK', 'LastName': 'Sunny', 'Affiliation': 'Golden Community, Lalitpur, Nepal.'}, {'ForeName': 'Pratiksha', 'Initials': 'P', 'LastName': 'Bhattarai', 'Affiliation': 'Golden Community, Lalitpur, Nepal.'}, {'ForeName': 'Pragya G', 'Initials': 'PG', 'LastName': 'Poudel', 'Affiliation': 'Golden Community, Lalitpur, Nepal.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Litorp', 'Affiliation': ""Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.""}]",Acta obstetricia et gynecologica Scandinavica,['10.1111/aogs.13746'] 2158,32680341,"A pilot randomized controlled trial comparing computer-assisted cognitive rehabilitation, stimulant medication, and an active control in the treatment of ADHD.","BACKGROUND This research aimed to compare computer-assisted cognitive rehabilitation (CACR) psychostimulants (MED) and placebo CACR (PCACR) in the treatment of ADHD using a multiarm parallel design. METHODS Thirty-four boys with ADHD, aged 7-12, were randomly assigned to either CACR (n = 12), MED (n = 11), or PCACR (n = 11). However, the study was not blinded and medication doses might be suboptimal given the lack of titration. Continuous performance test, Tower-of-London, forward/backward digit span, span board, Raven's progressive matrices, and SNAP-IV were completed at baseline, posttest, and follow-up. RESULTS Computer-assisted cognitive rehabilitation outperformed both MED and PCACR on backward digit span at posttest and PCACR at follow-up. CACR outperformed PCACR and MED on forward digit span at posttest and PCACR at follow-up. CACR outperformed MED on span board at posttest. CACR outperformed PCACR and MED on Raven's matrices at posttest. CACR and PCACR scored lower than MED on ADHD-PHI at posttest. CACR scored lower than MED on ADHD-C at posttest. CONCLUSIONS Immediately after interventions, CACR improved certain simple executive functions (EFs) as much as active stimulant medication. On complex EFs, CACR was superior to active stimulant medication and PCACR. CACR reduced behavioral symptoms of ADHD more than active stimulant medication. However, at 3-month follow-up, maintenance of the CACR gains was weak.",2016,"RESULTS Computer-assisted cognitive rehabilitation outperformed both MED and PCACR on backward digit span at posttest and PCACR at follow-up.","['Thirty-four boys with ADHD, aged 7-12']","['CACR', 'computer-assisted cognitive rehabilitation (CACR) psychostimulants (MED) and placebo CACR (PCACR', 'PCACR', 'computer-assisted cognitive rehabilitation, stimulant medication']","['CACR outperformed PCACR and MED on forward digit span', ""Continuous performance test, Tower-of-London, forward/backward digit span, span board, Raven's progressive matrices, and SNAP-IV"", 'backward digit span', 'CACR and PCACR', 'CACR gains', 'behavioral symptoms of ADHD']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}]","[{'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C0304403', 'cui_str': 'Psychostimulant'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2732404', 'cui_str': 'Corrected measurement of calcium'}, {'cui': 'C0002763', 'cui_str': 'Central stimulant'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2732404', 'cui_str': 'Corrected measurement of calcium'}, {'cui': 'C0439780', 'cui_str': 'Forward'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0023973', 'cui_str': 'London'}, {'cui': 'C0439781', 'cui_str': 'Backward'}, {'cui': 'C0475506', 'cui_str': 'Ravens colored progressive matrices'}, {'cui': 'C1177045', 'cui_str': 'Snap'}, {'cui': 'C0004941', 'cui_str': 'Behavioral Symptoms'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}]",34.0,0.017074,"RESULTS Computer-assisted cognitive rehabilitation outperformed both MED and PCACR on backward digit span at posttest and PCACR at follow-up.","[{'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Azami', 'Affiliation': 'Department of Clinical and General Psychology, Allameh Tabatabai University, Tehran, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Moghadas', 'Affiliation': 'Department of Clinical and General Psychology, Allameh Tabatabai University, Tehran, Iran.'}, {'ForeName': 'Faramarz', 'Initials': 'F', 'LastName': 'Sohrabi-Esmrood', 'Affiliation': 'Department of Clinical and General Psychology, Allameh Tabatabai University, Tehran, Iran.'}, {'ForeName': 'Morteza', 'Initials': 'M', 'LastName': 'Nazifi', 'Affiliation': 'Department of Psychology, University of Bojnord, Bojnord, 9453155111, Iran.'}, {'ForeName': 'Mahdieh', 'Initials': 'M', 'LastName': 'Mirmohamad', 'Affiliation': 'Institute for Brain and Cognitive Sciences, Shahid-Beheshti University, Tehran, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Hemmati', 'Affiliation': 'Department of Psychology, Tarbiat Modares University, Tehran, Iran.'}, {'ForeName': 'Ameneh', 'Initials': 'A', 'LastName': 'Ahmadi', 'Affiliation': 'Department of Clinical and General Psychology, Allameh Tabatabai University, Tehran, Iran.'}, {'ForeName': 'Pariya', 'Initials': 'P', 'LastName': 'Hamzeh-Poor', 'Affiliation': 'Department of Clinical and General Psychology, Allameh Tabatabai University, Tehran, Iran.'}, {'ForeName': 'Saeedeh', 'Initials': 'S', 'LastName': 'Khari', 'Affiliation': 'Al-Zahra University, Tehran, Iran.'}, {'ForeName': 'Kimberley', 'Initials': 'K', 'LastName': 'Lakes', 'Affiliation': 'Department of Pediatrics, University of California, Irvine, CA, USA.'}]",Child and adolescent mental health,['10.1111/camh.12157'] 2159,32680363,"Effectiveness of brief school-based, group cognitive behavioural therapy for depressed adolescents in south west Nigeria.","BACKGROUND There is paucity of evidence-based psychological interventions for depressive disorders in Africa, more so among depressed children and adolescents. This study aimed to determine the effects of a school-based cognitive behavioural therapy programme (CBT) on depressed adolescents in South West Nigeria. METHODS Forty students who scored 18 or above on the Beck Depression Inventory (BDI) were recruited from two schools (20 from each school). One school was designated intervention and the other a wait-list control school. Five weekly sessions of group CBT programme were conducted in the intervention school. Primary outcome measure was the Beck Depression Inventory, and secondary outcome measures were the Short Mood and Feelings Questionnaire and the Impact Supplement of the Strengths and Difficulties Questionnaire. RESULTS Controlling for baseline scores and other confounders, the intervention group had significantly lower depressive symptoms scores on the BDI and SMFQ 1 week post intervention with large effect sizes. The intervention group maintained the treatment effect with significantly lower depression scores 16 weeks post intervention compared with their baseline scores. The effect sizes remained large. The intervention and control groups did not differ in their SDQ impact supplement scores post intervention, but the intervention group improved significantly on this measure at 16 weeks. CONCLUSIONS To our knowledge, this is the first study of a school-based group CBT programme for depressed adolescents in Africa. The programme showed good feasibility and promising effectiveness.",2016,"The intervention and control groups did not differ in their SDQ impact supplement scores post intervention, but the intervention group improved significantly on this measure at 16 weeks. ","['depressed adolescents in South West Nigeria', 'depressed adolescents in Africa', 'Forty students who scored 18 or above on the Beck Depression Inventory (BDI) were recruited from two schools (20 from each school', 'depressed children and adolescents', 'depressed adolescents in south west Nigeria']","['school-based cognitive behavioural therapy programme (CBT', 'brief school-based, group cognitive behavioural therapy']","['Short Mood and Feelings Questionnaire and the Impact Supplement of the Strengths and Difficulties Questionnaire', 'Beck Depression Inventory', 'depressive symptoms scores', 'depression scores']","[{'cui': 'C0344315', 'cui_str': 'Depressed mood'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0037769', 'cui_str': 'West syndrome'}, {'cui': 'C0028075', 'cui_str': 'Nigeria'}, {'cui': 'C0001737', 'cui_str': 'Africa'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C3472494', 'cui_str': 'Strengths and difficulties questionnaire'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",40.0,0.060686,"The intervention and control groups did not differ in their SDQ impact supplement scores post intervention, but the intervention group improved significantly on this measure at 16 weeks. ","[{'ForeName': 'Tolulope', 'Initials': 'T', 'LastName': 'Bella-Awusah', 'Affiliation': 'Centre for Child and Adolescent Mental Health, University of Ibadan, College of Medicine, University College Hospital, Ibadan, Nigeria.'}, {'ForeName': 'Cornelius', 'Initials': 'C', 'LastName': 'Ani', 'Affiliation': 'Academic Unit of Child and Adolescent Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'Ademola', 'Initials': 'A', 'LastName': 'Ajuwon', 'Affiliation': 'Department of Health Promotion and Education, University of Ibadan, Ibadan, Nigeria.'}, {'ForeName': 'Olayinka', 'Initials': 'O', 'LastName': 'Omigbodun', 'Affiliation': 'Centre for Child and Adolescent Mental Health, University of Ibadan, College of Medicine, University College Hospital, Ibadan, Nigeria.'}]",Child and adolescent mental health,['10.1111/camh.12104'] 2160,32680417,Mitigating depression among orphaned and vulnerable adolescents: a randomized controlled trial of interpersonal psychotherapy for groups in South Africa.,"BACKGROUND Children and adolescents affected by HIV are at elevated risk of depression, yet research on related interventions in this population is scarce in sub-Saharan Africa. This study sought to examine the effects of interpersonal psychotherapy for groups (IPTG) on depressive symptomology among orphaned and vulnerable adolescents in South Africa. METHOD A cluster randomized controlled trial wherein adolescents ages 14-17 enrolled in community-based programming for HIV-affected and vulnerable families were randomly assigned by geographic cluster to participate in a 16-session IPTG intervention or the standard of care (n = 489). Baseline and postintervention surveys conducted with enrollees included standardized depression screening. Utilizing an intent-to-treat design, mixed effects models were performed to examine treatment effects for all participants and potential moderators including gender and baseline depression level (Clinical Trials registration: ClinicalTrials.gov NCT02386878). RESULTS While 23% of adolescents in the intervention group did not attend any IPTG sessions, average attendance was 12 out of 16 possible sessions among participants. The intervention was not associated with changes in depression symptomology. CONCLUSIONS Results underscore the importance of mitigating participation barriers prior to intervention roll-out and the need for increased evidence for psychological health interventions to mitigate depression among orphaned and vulnerable adolescents. This intervention and the study selectively targeted at-risk adolescents versus using diagnostic mental health criteria for enrollment; more research is needed to identify the potential benefits and disadvantages of these approaches.",2017,"The intervention was not associated with changes in depression symptomology. ","['orphaned and vulnerable adolescents', 'adolescents ages 14-17 enrolled in community-based programming for HIV-affected and vulnerable families', 'groups in South Africa', 'orphaned and vulnerable adolescents in South Africa']","['interpersonal psychotherapy for groups (IPTG', '16-session IPTG intervention or the standard of care', 'interpersonal psychotherapy']","['depressive symptomology', 'depression symptomology']","[{'cui': 'C0242299', 'cui_str': 'Orphan'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0392760', 'cui_str': 'Affecting'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0037712', 'cui_str': 'South Africa'}]","[{'cui': 'C0871787', 'cui_str': 'Interpersonal psychotherapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}]",,0.171042,"The intervention was not associated with changes in depression symptomology. ","[{'ForeName': 'Tonya R', 'Initials': 'TR', 'LastName': 'Thurman', 'Affiliation': 'Tulane International LLC, 23 Belmont Road, 7700, Cape Town, South Africa.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Nice', 'Affiliation': 'Tulane School of Social Work, Highly Vulnerable Children Research Center, New Orleans, LA, USA.'}, {'ForeName': 'Tory M', 'Initials': 'TM', 'LastName': 'Taylor', 'Affiliation': 'Tulane School of Social Work, Highly Vulnerable Children Research Center, New Orleans, LA, USA.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Luckett', 'Affiliation': 'Tulane School of Social Work, Highly Vulnerable Children Research Center, New Orleans, LA, USA.'}]",Child and adolescent mental health,['10.1111/camh.12241'] 2161,32680419,The intersection of adolescent depression and peer violence: baseline results from a randomized controlled trial of 1752 youth in Pakistan.,"BACKGROUND Depression and peer violence are global issues impacting youth. We are presenting baseline data as part of a cluster randomized control trial underway, on adolescent depression, and associated factors among boys and girls in schools. METHOD Cluster randomized control trial is underway for measuring the effectiveness of school-based play intervention program of the NGO Right to Play, in a sample of 1752 grade 6 youth in 40 public schools of Hyderabad, Pakistan. Students responded to Child Depression Inventory (CDI-2), the Peer Victimization Scale (PVS), the Peer Perpetration Scale (PPS), and investigator-driven seven-item School Performance Scale. RESULTS We report baseline assessments to examine the prevalence of depressive symptoms, and associated occurrence of peer perpetration and victimization. Boys report significantly more depressive symptoms as well as perpetration and victimization compared to girls (p ≤ .0001). Our analysis indicates that among boys, depression was found associated with greater age, food insecurity, poorer school performance and working for money, as well as being beaten at home and witnessing beating of their mother by their father or other relatives. Among girls, depression was associated with a younger age, greater food insecurity and poorer school performance. Depression was also associated with a great likelihood of engagement in peer violence, experience of punishment at home, and witnessing their father fighting with other men or beating their mother. CONCLUSIONS Engagement in violent behaviors, exposure to violent acts and poverty surfaces as detrimental to mental health in youth age groups, suggesting strong measures to address youth violence, and poverty reduction for positive mental health outcomes in school age children.",2017,Boys report significantly more depressive symptoms as well as perpetration and victimization compared to girls (p ≤ .0001).,"['boys and girls in schools', 'school age children', '1752 grade 6 youth in 40 public schools of Hyderabad, Pakistan', '1752 youth in Pakistan']",['school-based play intervention program of the NGO'],"['Child Depression Inventory (CDI-2), the Peer Victimization Scale (PVS), the Peer Perpetration Scale (PPS), and investigator-driven seven-item School Performance Scale', 'depressive symptoms']","[{'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0557800', 'cui_str': 'Public school'}, {'cui': 'C0030211', 'cui_str': 'Pakistan'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0282601', 'cui_str': 'Compact Disk Interactive'}, {'cui': 'C0376695', 'cui_str': 'Victimization'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0036373', 'cui_str': 'Academic Test Performance'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",,0.0535244,Boys report significantly more depressive symptoms as well as perpetration and victimization compared to girls (p ≤ .0001).,"[{'ForeName': 'Nargis', 'Initials': 'N', 'LastName': 'Asad', 'Affiliation': 'Department of Psychiatry, The Aga Khan University, Karachi, 3500, Pakistan.'}, {'ForeName': 'Rozina', 'Initials': 'R', 'LastName': 'Karmaliani', 'Affiliation': 'School of Nursing & Midwifery, The Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'McFarlane', 'Affiliation': ""College of Nursing, Texas Woman's University, Houston, TX, USA.""}, {'ForeName': 'Shireen Shehzad', 'Initials': 'SS', 'LastName': 'Bhamani', 'Affiliation': 'School of Nursing & Midwifery, The Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Yasmeen', 'Initials': 'Y', 'LastName': 'Somani', 'Affiliation': 'School of Nursing & Midwifery, The Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Esnat', 'Initials': 'E', 'LastName': 'Chirwa', 'Affiliation': 'South African Medical Research Council, Pretoria, South Africa.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Jewkes', 'Affiliation': 'South African Medical Research Council, Pretoria, South Africa.'}]",Child and adolescent mental health,['10.1111/camh.12249'] 2162,32680456,A randomised crossover comparison of two endotracheal tube introducers: the FROVA and the Flexible Tip Bougie for GlideScope intubation of a difficult airway manikin by infrequent intubators.,"BACKGROUND This unblinded randomised crossover study compares two endotracheal tube introducers (ETIs): the FROVA and the ""Flexible Tip Bougie"" (FTB), in an airway manikin mimicking difficult intubation with a percentage of glottic opening view of 30%. Participants were Emergency Medicine and Anaesthesia trainees with recent experience of less than twenty patient intubations. The primary outcome was time to intubation, further divided into time taken to pass the ETI and time to railroad the endotracheal tube (ETT) over the ETI. The secondary outcome was the difficulty of intubation. RESULTS The median total time to ETT placement was significantly shorter with the FTB (37.5 s) compared with the FROVA ETI (63.0 s), P = 0.0006. The median difficulty reported (scores 0-10 with 0 being no difficulty) with the FTB was 2 compared with 5 for the FROVA, P < 0.0001. CONCLUSIONS The FTB enabled significantly faster and easier placement of the endotracheal tube compared with the FROVA in inexperienced hands intubating a difficult intubation manikin.",2020,The FTB enabled significantly faster and easier placement of the endotracheal tube compared with the FROVA in inexperienced hands intubating a difficult intubation manikin.,['Participants were Emergency Medicine and Anaesthesia trainees with recent experience of less than twenty patient intubations'],"['endotracheal tube introducers (ETIs', 'FTB', 'Flexible Tip Bougie"" (FTB', 'FROVA', 'endotracheal tube introducers: the FROVA and the Flexible Tip']","['median total time to ETT placement', 'time to intubation, further divided into time taken to pass the ETI and time to railroad the endotracheal tube (ETT) over the ETI', 'difficulty of intubation']","[{'cui': 'C0013964', 'cui_str': 'Emergency medicine'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}]","[{'cui': 'C0179390', 'cui_str': 'Bougie'}, {'cui': 'C0443220', 'cui_str': 'Flexible'}, {'cui': 'C0339897', 'cui_str': 'Transjugular intrahepatic portosystemic shunt'}, {'cui': 'C1099778', 'cui_str': 'Frova'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0336630', 'cui_str': 'Endotracheal tube'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0034638', 'cui_str': 'Railroads'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}]",,0.0429303,The FTB enabled significantly faster and easier placement of the endotracheal tube compared with the FROVA in inexperienced hands intubating a difficult intubation manikin.,"[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Cormack', 'Affiliation': 'The Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Building 181, Grattan St, Melbourne, 3010, Australia. cormackj@ozemail.com.au.'}, {'ForeName': 'Bridget', 'Initials': 'B', 'LastName': 'Langley', 'Affiliation': 'The Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Building 181, Grattan St, Melbourne, 3010, Australia.'}, {'ForeName': 'Louisa-Rose', 'Initials': 'LR', 'LastName': 'Bhanabhai', 'Affiliation': ""Department of Anaesthesia and Acute Pain Medicine, St Vincent's Hospital Melbourne, 41 Victoria Parade, PO Box 2900, Fitzroy, VIC 3065, Australia.""}, {'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Kluger', 'Affiliation': 'The Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Building 181, Grattan St, Melbourne, 3010, Australia.'}]",International journal of emergency medicine,['10.1186/s12245-020-00298-6'] 2163,32680465,Study protocol: older people in retirement villages. A survey and randomised trial of a multi-disciplinary invention designed to avoid adverse outcomes.,"BACKGROUND There is increasing interest among older people in moving into retirement villages (RVs), an attractive option for those seeking a supportive community as they age, while still maintaining independence. Currently in New Zealand there is limited knowledge of the medical, service supports, social status and needs of RV residents. The objective of this study is to explore RV facilities and services, the health and functional status of RV residents, prospectively study their healthcare trajectories and to implement a multidisciplinary team intervention to potentially decrease dependency and impact healthcare utilization. METHODS All RVs located in two large district health boards in Auckland, New Zealand were eligible to participate. This three-year project comprised three phases: The survey phase provided a description of RVs, residents' characteristics and health and functional status. RV managers completed a survey of size, facilities and recreational and healthcare services provided in the village. Residents were surveyed to establish reasons for entry to the village and underwent a Gerontology Nurse Specialist (GNS) assessment providing details of demographics, social engagement, health and functional status. The cohort study phase examines residents' healthcare trajectories and adverse outcomes, over three years. The final phase is a randomised controlled trial of a multidisciplinary team intervention aimed to improve health outcomes for more vulnerable residents. Residents who triggered potential unmet health needs during the assessment in the survey phase were randomised to intervention or usual care groups. Multidisciplinary team meetings included the resident and support person, a geriatrician or gerontology nurse practitioner, GNS, pharmacist and General Practitioner. The primary outcome of the randomised controlled trial will be first acute hospitalization. Secondary outcomes include all acute hospitalizations, long-term care admissions, and all-cause mortality. DISCUSSION This paper describes the study protocol of this complex study. The study aims to inform policies and practices around health care services for residents in retirement villages. The results of this trial are expected early 2020 with publication subsequently. TRIAL REGISTRATION Australia and New Zealand Clinical Trials Registry: ACTRN12616000685415 . Registered 25.5.2016. Universal Trial Number (UTN): U111-1173-6083.",2020,The final phase is a randomised controlled trial of a multidisciplinary team intervention aimed to improve health outcomes for more vulnerable residents.,"['Study protocol: older people in retirement villages', 'Residents were surveyed to establish reasons for entry to the village and underwent a Gerontology Nurse Specialist (GNS) assessment providing details of demographics, social engagement, health and functional status', 'All RVs located in two large district health boards in Auckland, New Zealand were eligible to participate', 'more vulnerable residents', 'residents in retirement villages', 'older people in moving into retirement villages (RVs', 'Residents who triggered potential unmet health needs during the assessment in the survey phase']",['multi-disciplinary invention'],"['acute hospitalizations, long-term care admissions, and all-cause mortality', 'health outcomes']","[{'cui': 'C2599718', 'cui_str': 'Clinical Trial Protocols'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0035345', 'cui_str': 'Retired'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C4277711', 'cui_str': 'Nurse Specialists'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0578671', 'cui_str': 'Does move'}, {'cui': 'C0032930', 'cui_str': 'Precipitating Factors'}, {'cui': 'C1273868', 'cui_str': 'Health needs (community)'}, {'cui': 'C0205390', 'cui_str': 'Phase'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C3494260', 'cui_str': 'Inventions'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.127928,The final phase is a randomised controlled trial of a multidisciplinary team intervention aimed to improve health outcomes for more vulnerable residents.,"[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Peri', 'Affiliation': 'School of Nursing, University of Auckland, Private Bag 92 019, Auckland, 1142, New Zealand.'}, {'ForeName': 'J B', 'Initials': 'JB', 'LastName': 'Broad', 'Affiliation': 'Department of Geriatric Medicine, University of Auckland, Level 1, Building 5, Waitemata District Health Board, PO Box 93 503, Auckland, Takapuna, 0740, New Zealand.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Hikaka', 'Affiliation': 'Waitemata District Health Board, PO Box 93 503, Auckland, Takapuna, 0740, New Zealand.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Boyd', 'Affiliation': 'School of Nursing, University of Auckland, Private Bag 92 019, Auckland, 1142, New Zealand.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Bloomfield', 'Affiliation': 'Department of Geriatric Medicine, University of Auckland, Level 1, Building 5, Waitemata District Health Board, PO Box 93 503, Auckland, Takapuna, 0740, New Zealand.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Wu', 'Affiliation': 'Department of Geriatric Medicine, University of Auckland, Level 1, Building 5, Waitemata District Health Board, PO Box 93 503, Auckland, Takapuna, 0740, New Zealand.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Calvert', 'Affiliation': 'Department of Geriatric Medicine, University of Auckland, Level 1, Building 5, Waitemata District Health Board, PO Box 93 503, Auckland, Takapuna, 0740, New Zealand.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Tatton', 'Affiliation': 'Department of Geriatric Medicine, University of Auckland, Level 1, Building 5, Waitemata District Health Board, PO Box 93 503, Auckland, Takapuna, 0740, New Zealand.'}, {'ForeName': 'A-M', 'Initials': 'AM', 'LastName': 'Higgins', 'Affiliation': 'Department of Geriatric Medicine, University of Auckland, Level 1, Building 5, Waitemata District Health Board, PO Box 93 503, Auckland, Takapuna, 0740, New Zealand.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Bramley', 'Affiliation': 'Waitemata District Health Board, PO Box 93 503, Auckland, Takapuna, 0740, New Zealand.'}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Connolly', 'Affiliation': 'Department of Geriatric Medicine, University of Auckland, Level 1, Building 5, Waitemata District Health Board, PO Box 93 503, Auckland, Takapuna, 0740, New Zealand. martin.connolly@waitematadhb.govt.nz.'}]",BMC geriatrics,['10.1186/s12877-020-01640-6'] 2164,32680475,Impact of a smoking cessation program on smoking prevalence and food security among food pantry users - a study protocol for a pragmatic cluster randomised controlled trial.,"BACKGROUND Among food pantry users there is a high prevalence of both smoking and food insecurity, which may be related to one another. This study aims to evaluate the impact of a smoking cessation program carried out in food pantries on the smoking status and the food security status of food pantry users. METHODS / DESIGN Before starting the cluster randomised controlled trial, stakeholders will be engaged to adapt a behavioural group counselling program for smoking cessation to the needs of the food pantry users in a pre study. Food pantry users and workers as well as other experts, such as smoking cessation trainers, social workers, and psychologists, will be involved, using the world café technique and telephone interviews and a qualitative thematic analysis for data analysis to design the concept of the intervention program will be applied. In the second phase, the impact of the intervention on the smoking status and on food insecurity will be investigated by a cluster randomised controlled trial. A total of 416 food pantry users across 32 clusters (food pantries) in Berlin, Germany, should be recruited and randomly assigned to either the intervention group or the waiting list control group. The intervention will consist of a behavioural group counselling program for smoking cessation, specially tailored for food pantry users, as well as optional nicotine replacement therapy and the implementation of environmental smoking reduction measures in the food pantries. The primary outcomes 6 months after the treatment will be self-reported continuous smoking abstinence, validated by exhaled carbon monoxide (< 10 ppm of carbon monoxide), and increased food security level (the percentage of participants with an improved food security level). DISCUSSION This study will be the first long-term investigation into the effect of a smoking cessation program on smoking status and food insecurity. The results of this study will inform the implementation of smoking cessation programs in food pantries throughout Germany. TRIAL REGISTRATION Prospectively registered DRKS00020037 . Registered 29 April 2020.",2020,"The intervention will consist of a behavioural group counselling program for smoking cessation, specially tailored for food pantry users, as well as optional nicotine replacement therapy and the implementation of environmental smoking reduction measures in the food pantries.","['416 food pantry users across 32 clusters (food pantries) in Berlin, Germany']","['behavioural group counselling program for smoking cessation, specially tailored for food pantry users, as well as optional nicotine replacement therapy', 'smoking cessation program', 'behavioural group counselling program', 'waiting list control group']","['smoking prevalence and food security', 'self-reported continuous smoking abstinence, validated by exhaled carbon monoxide (< 10\u2009ppm of carbon monoxide), and increased food security level']","[{'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0005125', 'cui_str': 'Berlin'}, {'cui': 'C0017480', 'cui_str': 'Germany'}]","[{'cui': 'C0237547', 'cui_str': 'Group counseling'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C1278444', 'cui_str': 'Nicotine replacement therapy'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C3178753', 'cui_str': 'Food Security'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0439187', 'cui_str': 'ppm'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0554824,"The intervention will consist of a behavioural group counselling program for smoking cessation, specially tailored for food pantry users, as well as optional nicotine replacement therapy and the implementation of environmental smoking reduction measures in the food pantries.","[{'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Simmet', 'Affiliation': 'Institute of Nutritional Medicine, Department of Nutritional Psychology, University of Hohenheim, Fruwirthstr. 12, 70593, Stuttgart, Germany. Anja.Simmet@uni-hohenheim.de.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Teut', 'Affiliation': 'Institute for Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Luisenstraße 57, 10117, Berlin, Germany.'}, {'ForeName': 'Romy', 'Initials': 'R', 'LastName': 'Schleicher', 'Affiliation': 'Institute for Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Luisenstraße 57, 10117, Berlin, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Bschaden', 'Affiliation': 'Institute of Nutritional Medicine, Department of Nutritional Psychology, University of Hohenheim, Fruwirthstr. 12, 70593, Stuttgart, Germany.'}, {'ForeName': 'Nanette', 'Initials': 'N', 'LastName': 'Stroebele-Benschop', 'Affiliation': 'Institute of Nutritional Medicine, Department of Nutritional Psychology, University of Hohenheim, Fruwirthstr. 12, 70593, Stuttgart, Germany.'}]",BMC public health,['10.1186/s12889-020-09232-0'] 2165,32680480,Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.,"BACKGROUND The efficacy and safety of ambrisentan has been previously evaluated in Chinese patients with pulmonary arterial hypertension (PAH). This post-hoc analysis assessed the efficacy and safety of ambrisentan in a subgroup of connective tissue disease (CTD) patients with PAH. METHODS In this open-label, single-arm study, patients received ambrisentan 5 mg once daily for 12 weeks, followed by 12-week dose titration period (dose up to 10 mg). Efficacy endpoints included change from baseline in exercise capacity (measured by 6-min walk test [6MWT]), N-terminal pro B type natriuretic peptide (NT-proBNP) plasma levels, WHO Functional Class (FC) and Borg Dyspnoea Index (BDI) scores from baseline to weeks 12 and 24. Safety endpoints included time to clinical worsening and incidence of adverse events (AEs). RESULTS In total, 71 Chinese patients with CTD-PAH were included in this analysis. Ambrisentan treatment significantly improved exercise capacity (6MWT) from baseline (mean: 366.4 m) to week 12 (63.8 m, p < 0.001) and week 24 (73.2 m, p < 0.001). A significant reduction in NT-proBNP levels was observed from baseline (mean: 1837.5 ng/L) to week 12 (- 1156.8 ng/L, p < 0.001) and week 24 (- 1095.5 ng/L, p < 0.001). BDI scores decreased significantly at week 12 (- 0.6, p < 0.001) and week 24 (- 0.4, p = 0.002) from baseline (mean: 2.7). The WHO FC improved in 29 (40.8%) and 34 (47.9%) patients at weeks 12 and 24, respectively. Adverse events were reported in 52 (73.2%) patients. One patient (1.4%) experienced clinical worsening at week 24. CONCLUSION Ambrisentan showed significant improvement in exercise capacity and no clinical worsening in the majority of Chinese patients with CTD-PAH in the 24-week treatment period. The AEs observed in the CTD-PAH subgroup were consistent with the known safety profile of ambrisentan in the overall Chinese PAH population. TRIAL REGISTRATION ClinicalTrial.gov Identifier, https://clinicaltrials.gov/, NCT01808313 Registration date (first time): February 28, 2013.",2020,"Ambrisentan treatment significantly improved exercise capacity (6MWT) from baseline (mean: 366.4 m) to week 12 (63.8 m, p < 0.001) and week 24 (73.2 m, p < 0.001).","['Chinese patients with pulmonary arterial hypertension (PAH', '71 Chinese patients with CTD-PAH', 'Chinese patients with connective tissue disease-pulmonary arterial hypertension', 'subgroup of connective tissue disease (CTD) patients with PAH']",['ambrisentan'],"['Adverse events', 'NT-proBNP levels', 'exercise capacity (measured by 6-min walk test [6MWT]), N-terminal pro B type natriuretic peptide (NT-proBNP) plasma levels, WHO Functional Class (FC) and Borg Dyspnoea Index (BDI) scores', 'exercise capacity', 'Efficacy and safety', 'efficacy and safety', 'exercise capacity (6MWT', 'time to clinical worsening and incidence of adverse events (AEs', 'BDI scores', 'WHO FC']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2973725', 'cui_str': 'Pulmonary arterial hypertension'}, {'cui': 'C0009782', 'cui_str': 'Disorder of connective tissue'}]","[{'cui': 'C1176329', 'cui_str': 'ambrisentan'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",71.0,0.197107,"Ambrisentan treatment significantly improved exercise capacity (6MWT) from baseline (mean: 366.4 m) to week 12 (63.8 m, p < 0.001) and week 24 (73.2 m, p < 0.001).","[{'ForeName': 'Mengtao', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.'}, {'ForeName': 'Zhi-Cheng', 'Initials': 'ZC', 'LastName': 'Jing', 'Affiliation': 'Key Lab of Pulmonary Vascular Medicine & FuWai Hospital, State Key lab of Cardiovascular disease, National center for Cardiovascular disease, Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': '2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Huo', 'Affiliation': '1st Affiliated Hospital of Peking University, Beijing, China.'}, {'ForeName': 'Zaixin', 'Initials': 'Z', 'LastName': 'Yu', 'Affiliation': 'Xiangya Hospital Central-South University, Changsha, Hunan, China.'}, {'ForeName': 'Gangcheng', 'Initials': 'G', 'LastName': 'Zhang', 'Affiliation': 'Wuhan Asia Heart Hospital, Wuhan, Hubei, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Zhu', 'Affiliation': ""1st Affiliated Hospital of the Fourth Military Medical University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Jinming', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.'}, {'ForeName': 'Qiushang', 'Initials': 'Q', 'LastName': 'Ji', 'Affiliation': 'Qilu Hospital, Shandong University, Jinan, Shandong, China.'}, {'ForeName': 'Bingxiang', 'Initials': 'B', 'LastName': 'Wu', 'Affiliation': '2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Jinhua', 'Initials': 'J', 'LastName': 'Zhong', 'Affiliation': 'GlaxoSmithKline (China) R&D Company Limited, Shanghai, China.'}, {'ForeName': 'Pingping', 'Initials': 'P', 'LastName': 'Wang', 'Affiliation': 'GlaxoSmithKline (China) R&D Company Limited, Shanghai, China.'}, {'ForeName': 'Wenjing', 'Initials': 'W', 'LastName': 'Zhu', 'Affiliation': 'GlaxoSmithKline (China) R&D Company Limited, Shanghai, China.'}, {'ForeName': 'Xiaofeng', 'Initials': 'X', 'LastName': 'Zeng', 'Affiliation': 'Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China. xiaofeng.zeng@cstar.org.cn.'}]",BMC cardiovascular disorders,['10.1186/s12872-020-01591-1'] 2166,32680487,Patients' and clinicians' perspectives on a 'fast-track' pathway for patients with sciatica in primary care: qualitative findings from the SCOPiC stratified care trial.,"BACKGROUND Sciatica is common and associated with significant impacts for the individual and society. The SCOPiC randomised controlled trial (RCT) (trial registration: ISRCTN75449581 ) tested stratified primary care for sciatica by subgrouping patients into one of three groups based on prognostic and clinical indicators. Patients in one group were 'fast-tracked' for a magnetic resonance imaging (MRI) scan and spinal specialist opinion. This paper reports qualitative research exploring patients' and clinicians' perspectives on the acceptability of this 'fast-track' pathway. METHODS Semi-structured interviews were conducted with 20 patients and 20 clinicians (general practitioners, spinal specialist physiotherapists, spinal surgeons). Data were analysed thematically and findings explored using Normalisation Process Theory (NPT) and 'boundary objects' concept. RESULTS Whilst the 'fast-track' pathway achieved a degree of 'coherence' (i.e. made sense) to both patients and clinicians, particularly in relation to providing early reassurance based on MRI scan findings, it was less 'meaningful' to some clinicians for managing patients with acute symptoms, reflecting a reluctance to move away from the usual 'stepped care' approach. Both groups felt a key limitation of the pathway was that it did not shorten patient waiting times between their spinal specialist consultation and further treatments. CONCLUSION Findings contribute new knowledge about patients' and clinicians' perspectives on the role of imaging and spinal specialist opinion in the management of sciatica, and provide important insights for understanding the 'fast-track' pathway, as part of the stratified care model tested in the RCT. Future research into the early referral of patients with sciatica for investigation and specialist opinion should include strategies to support clinician behaviour change; as well as take into account the role of imaging in providing reassurance to patients with severe symptoms in cases where imaging reveals a clear explanation for the patient's pain, and where this is accompanied by a thorough explanation from a trusted clinical expert.",2020,"Both groups felt a key limitation of the pathway was that it did not shorten patient waiting times between their spinal specialist consultation and further treatments. ","['patients with sciatica in primary care', 'Semi-structured interviews were conducted with 20 patients and 20 clinicians (general practitioners, spinal specialist physiotherapists, spinal surgeons']",['magnetic resonance imaging (MRI) scan and spinal specialist opinion'],['patient waiting times'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036396', 'cui_str': 'Sciatica'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}]","[{'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0034030', 'cui_str': 'Public Opinion'}]","[{'cui': 'C0542399', 'cui_str': 'Patient waiting for'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",20.0,0.0378034,"Both groups felt a key limitation of the pathway was that it did not shorten patient waiting times between their spinal specialist consultation and further treatments. ","[{'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Saunders', 'Affiliation': 'Primary Care Centre Versus Arthritis, School of Primary, Community and Social Care, Keele University, Staffordshire, ST5 5BG, UK. b.saunders@keele.ac.uk.'}, {'ForeName': 'Kika', 'Initials': 'K', 'LastName': 'Konstantinou', 'Affiliation': 'Primary Care Centre Versus Arthritis, School of Primary, Community and Social Care, Keele University, Staffordshire, ST5 5BG, UK.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Artus', 'Affiliation': 'Primary Care Centre Versus Arthritis, School of Primary, Community and Social Care, Keele University, Staffordshire, ST5 5BG, UK.'}, {'ForeName': 'Nadine E', 'Initials': 'NE', 'LastName': 'Foster', 'Affiliation': 'Primary Care Centre Versus Arthritis, School of Primary, Community and Social Care, Keele University, Staffordshire, ST5 5BG, UK.'}, {'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'Bartlam', 'Affiliation': 'Primary Care Centre Versus Arthritis, School of Primary, Community and Social Care, Keele University, Staffordshire, ST5 5BG, UK.'}]",BMC musculoskeletal disorders,['10.1186/s12891-020-03483-z'] 2167,32680548,Whey protein supplementation reducing fasting levels of anandamide and 2-AG without weight loss in pre-menopausal women with obesity on a weight-loss diet.,"BACKGROUND Despite the importance of dairy proteins in modifying of metabolic abnormalities, no attention has been given to their effects on endocannabinoids. METHODS A total number of 60 obese women were recruited in a 2-month randomized clinical trial. Following random allocation, they were assigned to one of the two groups: control (n = 30) and intervention (n = 30). Then, all the subjects followed a hypocaloric diet of 800 kcal below estimated energy needs. The intervention group received isocaloric weight-loss diet and whey protein powders (30 g/day). Baseline and 2-month fasting anthropometric, blood glucose, serum insulin, insulin resistance, lipid profile, AEA, and 2-AG were measured. RESULTS The study groups were homogenous in terms of baseline characteristics (p > 0.05) except for MUFA intake (p = 0.021). There were no significant differences in energy and macronutrient intakes in the intervention group compared to the control group at the end of the study (p > 0.05). The results of the ANCOVA did not show significant reductions in body weight and BMI of the intervention group compared to the control group (p > 0.05); however, WC, body fat, FBS, AEA, 2-AG, total cholesterol, and triglyceride decreased and HDL-c significantly increased in the intervention group compared to the control group (p < 0.05). CONCLUSIONS In this study, the effects of simultaneous weight-loss diet and whey protein supplementation on the reduction of endocannabinoids were determined. TRIAL REGISTRATION Iranian Registry of Clinical Trials IRCT2017021410181N8 . Registered on March 2017.",2020,There were no significant differences in energy and macronutrient intakes in the intervention group compared to the control group at the end of the study (p > 0.05).,"['A total number of 60 obese women', 'pre-menopausal women with obesity on a weight-loss diet']","['simultaneous weight-loss diet and whey protein supplementation', 'Whey protein supplementation', 'isocaloric weight-loss diet and whey protein powders']","['body weight and BMI', 'energy and macronutrient intakes', 'Baseline and 2-month fasting anthropometric, blood glucose, serum insulin, insulin resistance, lipid profile, AEA, and 2-AG', 'WC, body fat, FBS, AEA, 2-AG, total cholesterol, and triglyceride decreased and HDL-c', 'MUFA intake', 'fasting levels of anandamide and 2-AG without weight loss']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0012167', 'cui_str': 'Weight reduction diet'}]","[{'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0012167', 'cui_str': 'Weight reduction diet'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032861', 'cui_str': 'Powder'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C3495427', 'cui_str': 'Fanconi-Bickel Syndrome'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0858892', 'cui_str': 'Triglycerides low'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0015687', 'cui_str': 'Monounsaturated fatty acid'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0211726', 'cui_str': 'anandamide'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]",,0.0418789,There were no significant differences in energy and macronutrient intakes in the intervention group compared to the control group at the end of the study (p > 0.05).,"[{'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Haidari', 'Affiliation': 'Department of Nutrition, Nutrition and Metabolic Research Center, Faculty of Paramedical Sciences, Ahvaz Jundishapur University of Medical Sciences, Golestan Street, Ahvaz, Iran.'}, {'ForeName': 'Vahideh', 'Initials': 'V', 'LastName': 'Aghamohammadi', 'Affiliation': 'Department of Nutrition, Nutrition and Metabolic Research Center, Faculty of Paramedical Sciences, Ahvaz Jundishapur University of Medical Sciences, Golestan Street, Ahvaz, Iran. v_agamohammadi@yahoo.com.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Mohammadshahi', 'Affiliation': 'Department of Nutrition, Nutrition and Metabolic Research Center, Faculty of Paramedical Sciences, Ahvaz Jundishapur University of Medical Sciences, Golestan Street, Ahvaz, Iran.'}, {'ForeName': 'Kambiz', 'Initials': 'K', 'LastName': 'Ahmadi-Angali', 'Affiliation': 'Department of Statistics and Epidemiology, Faculty of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Asghari-Jafarabadi', 'Affiliation': 'Department of Statistics and Epidemiology, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran.'}]",Trials,['10.1186/s13063-020-04586-7'] 2168,32680556,Factors related to dropout in integrative oncology clinical trials: interim analysis of an ongoing comparative effectiveness trial of mindfulness-based cancer recovery and Tai chi/Qigong for cancer health (The MATCH study).,"OBJECTIVE To examine the factors associated with loss to follow-up (LTFU) in an ongoing preference-based randomized waitlist controlled trial of mindfulness-based cancer recovery (MBCR) and Taichi/Qigong (TCQ) for cancer survivors (the MATCH Study). Hierarchical logistic regression was used to determine the factors associated with LTFU. Predictors included adherence to treatment, preference vs. randomized, type of intervention (MBCR vs. TCQ) and program timing (immediate {IM} vs. waitlist control {WLC} group). RESULTS Data indicated that randomization to the WLC group and, once in the intervention, low adherence were the main predictors of LTFU. Participants in the WLC group were 4 times more likely to be LTFU post-randomization [OR 3.96, 95% CI 2.08-7.56, p < 0.005] than those in the IM group. Participants showing low adherence to treatment were 6 times more likely for LTFU post-intervention [5.87 (2.57-13.400; p < 0.005] and 4 times more likely for LTFU 6 months post-intervention [OR 3.93, 95% CI 1.53-10.02, p = 0.01].",2020,"Participants showing low adherence to treatment were 6 times more likely for LTFU post-intervention [5.87 (2.57-13.400; p < 0.005] and 4 times more likely for LTFU 6 months post-intervention [OR 3.93, 95% CI 1.53-10.02, p = 0.01].",['cancer survivors'],"['mindfulness-based cancer recovery and Tai chi', 'mindfulness-based cancer recovery (MBCR) and Taichi/Qigong (TCQ', 'WLC', 'follow-up (LTFU']","['adherence to treatment, preference vs. randomized, type of intervention (MBCR vs. TCQ) and program timing (immediate {IM}\xa0vs. waitlist control {WLC}\xa0group']","[{'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0376403', 'cui_str': 'Tai-chi'}, {'cui': 'C0282077', 'cui_str': 'Qigong'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0282077', 'cui_str': 'Qigong'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0449243', 'cui_str': 'Timing'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]",,0.0464124,"Participants showing low adherence to treatment were 6 times more likely for LTFU post-intervention [5.87 (2.57-13.400; p < 0.005] and 4 times more likely for LTFU 6 months post-intervention [OR 3.93, 95% CI 1.53-10.02, p = 0.01].","[{'ForeName': 'Devesh', 'Initials': 'D', 'LastName': 'Oberoi', 'Affiliation': 'Psychosocial Resources, Tom Baker Cancer Centre, Holy Cross Site Phase I, 2202-2 St SW, Calgary, AB, T2S 3C1, Canada.'}, {'ForeName': 'Katherine-Ann L', 'Initials': 'KL', 'LastName': 'Piedalue', 'Affiliation': 'Psychosocial Resources, Tom Baker Cancer Centre, Holy Cross Site Phase I, 2202-2 St SW, Calgary, AB, T2S 3C1, Canada.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Pirbhai', 'Affiliation': 'Psychosocial Resources, Tom Baker Cancer Centre, Holy Cross Site Phase I, 2202-2 St SW, Calgary, AB, T2S 3C1, Canada.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Guirguis', 'Affiliation': 'Cancer Rehabilitation and Survivorship Program, Princess Margaret Cancer Centre, B PMB 130, 200 Elizabeth St, Toronto, ON, M5G 2C4, Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Santa Mina', 'Affiliation': 'Cancer Rehabilitation and Survivorship Program, Princess Margaret Cancer Centre, B PMB 130, 200 Elizabeth St, Toronto, ON, M5G 2C4, Canada.'}, {'ForeName': 'Linda E', 'Initials': 'LE', 'LastName': 'Carlson', 'Affiliation': 'Psychosocial Resources, Tom Baker Cancer Centre, Holy Cross Site Phase I, 2202-2 St SW, Calgary, AB, T2S 3C1, Canada. lcarlso@ucalgary.ca.'}]",BMC research notes,['10.1186/s13104-020-05172-5'] 2169,32681091,Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.,"Responses to immunotherapy are uncommon in estrogen receptor (ER)-positive breast cancer and to date, lack predictive markers. This randomized phase II study defines safety and response rate of epigenetic priming in ER-positive breast cancer patients treated with checkpoint inhibitors as primary endpoints. Secondary and exploratory endpoints included PD-L1 modulation and T-cell immune-signatures. 34 patients received vorinostat, tamoxifen and pembrolizumab with no excessive toxicity after progression on a median of five prior metastatic regimens. Objective response was 4% and clinical benefit rate (CR + PR + SD > 6 m) was 19%. T-cell exhaustion (CD8 +  PD-1 + /CTLA-4 + ) and treatment-induced depletion of regulatory T-cells (CD4 + Foxp3 + /CTLA-4 + ) was seen in tumor or blood in 5/5 patients with clinical benefit, but only in one non-responder. Tumor lymphocyte infiltration was 0.17%. Only two non-responders had PD-L1 expression >1%. This data defines a novel immune signature in PD-L1-negative ER-positive breast cancer patients who are more likely to benefit from immune-checkpoint and histone deacetylase inhibition (NCT02395627).",2020,"T-cell exhaustion (CD8 +  PD-1 + /CTLA-4 + ) and treatment-induced depletion of regulatory T-cells (CD4 + Foxp3 + /CTLA-4 + ) was seen in tumor or blood in 5/5 patients with clinical benefit, but only in one non-responder.","['34 patients received', 'ER-positive breast cancer patients treated with', 'PD-L1-negative ER-positive breast cancer patients', 'ER-positive breast cancer']","['checkpoint inhibitors', 'vorinostat, tamoxifen and pembrolizumab']","['PD-L1 modulation and T-cell immune-signatures', 'clinical benefit rate', 'PD-L1 expression', 'Objective response', 'T-cell exhaustion (CD8 +\xa0 PD-1 + /CTLA-4 + ) and treatment-induced depletion of regulatory T-cells (CD4 + Foxp3 + /CTLA-4 + ', 'Tumor lymphocyte infiltration']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2938924', 'cui_str': 'Oestrogen receptor positive breast cancer'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0205160', 'cui_str': 'Negative'}]","[{'cui': 'C1155874', 'cui_str': 'Cell Cycle Checkpoints'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0672708', 'cui_str': 'Vorinostat'}, {'cui': 'C0039286', 'cui_str': 'Tamoxifen'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}]","[{'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0333668', 'cui_str': 'Depletion'}, {'cui': 'C0039198', 'cui_str': 'Regulatory T-Lymphocytes'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0024264', 'cui_str': 'Lymphocyte'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}]",34.0,0.0718826,"T-cell exhaustion (CD8 +  PD-1 + /CTLA-4 + ) and treatment-induced depletion of regulatory T-cells (CD4 + Foxp3 + /CTLA-4 + ) was seen in tumor or blood in 5/5 patients with clinical benefit, but only in one non-responder.","[{'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Terranova-Barberio', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Nela', 'Initials': 'N', 'LastName': 'Pawlowska', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Mallika', 'Initials': 'M', 'LastName': 'Dhawan', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Moasser', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Amy J', 'Initials': 'AJ', 'LastName': 'Chien', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Michelle E', 'Initials': 'ME', 'LastName': 'Melisko', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Hope', 'Initials': 'H', 'LastName': 'Rugo', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Roshun', 'Initials': 'R', 'LastName': 'Rahimi', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Travis', 'Initials': 'T', 'LastName': 'Deal', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Adil', 'Initials': 'A', 'LastName': 'Daud', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Rosenblum', 'Affiliation': 'Department of Dermatology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Thomas', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Pamela N', 'Initials': 'PN', 'LastName': 'Munster', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco, CA, USA. pamela.munster@ucsf.edu.'}]",Nature communications,['10.1038/s41467-020-17414-y'] 2170,32681134,Stimulus modality influences session-to-session transfer of training effects in auditory and tactile streaming-based P300 brain-computer interfaces.,"Despite recent successes, patients suffering from locked-in syndrome (LIS) still struggle to communicate using vision-independent brain-computer interfaces (BCIs). In this study, we compared auditory and tactile BCIs, regarding training effects and cross-stimulus-modality transfer effects, when switching between stimulus modalities. We utilized a streaming-based P300 BCI, which was developed as a low workload approach to prevent potential BCI-inefficiency. We randomly assigned 20 healthy participants to two groups. The participants received three sessions of training either using an auditory BCI or using a tactile BCI. In an additional fourth session, BCI versions were switched to explore possible cross-stimulus-modality transfer effects. Both BCI versions could be operated successfully in the first session by the majority of the participants, with the tactile BCI being experienced as more intuitive. Significant training effects were found mostly in the auditory BCI group and strong evidence for a cross-stimulus-modality transfer occurred for the auditory training group that switched to the tactile version but not vice versa. All participants were able to control at least one BCI version, suggesting that the investigated paradigms are generally feasible and merit further research into their applicability with LIS end-users. Individual preferences regarding stimulus modality should be considered.",2020,Significant training effects were found mostly in the auditory BCI group and strong evidence for a cross-stimulus-modality transfer occurred for the auditory training group that switched to the tactile version but not vice versa.,['20 healthy participants to two groups'],"['training either using an auditory BCI or using a tactile BCI', 'auditory training']",[],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C2742590', 'cui_str': '2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one'}, {'cui': 'C0439815', 'cui_str': 'Tactile'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",[],20.0,0.0239414,Significant training effects were found mostly in the auditory BCI group and strong evidence for a cross-stimulus-modality transfer occurred for the auditory training group that switched to the tactile version but not vice versa.,"[{'ForeName': 'P', 'Initials': 'P', 'LastName': 'Ziebell', 'Affiliation': 'Institute of Psychology, University of Würzburg, Würzburg, Germany. philipp.ziebell@uni-wuerzburg.de.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Stümpfig', 'Affiliation': 'Institute of Psychology, University of Würzburg, Würzburg, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Eidel', 'Affiliation': 'Institute of Psychology, University of Würzburg, Würzburg, Germany.'}, {'ForeName': 'S C', 'Initials': 'SC', 'LastName': 'Kleih', 'Affiliation': 'Institute of Psychology, University of Würzburg, Würzburg, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Kübler', 'Affiliation': 'Institute of Psychology, University of Würzburg, Würzburg, Germany.'}, {'ForeName': 'M E', 'Initials': 'ME', 'LastName': 'Latoschik', 'Affiliation': 'Institute of Computer Science, University of Würzburg, Würzburg, Germany.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Halder', 'Affiliation': 'School of Computer Science and Electronic Engineering (CSEE), University of Essex, Colchester, UK.'}]",Scientific reports,['10.1038/s41598-020-67887-6'] 2171,32687974,Design and rationale for a randomized trial of a theory- and technology- enhanced physical activity intervention for Latinas: The Seamos Activas II study.,"INTRODUCTION Latina women report disproportionately high rates of physical inactivity and related chronic health conditions. Physical activity (PA) efforts to date have shown modest success in this at-risk population; thus, more effective interventions are necessary to help Latinas reach national PA guidelines and reduce related health disparities. This paper describes the design, rationale, and baseline findings from the Seamos Activas II intervention. METHODS/DESIGN The ongoing RCT will test the efficacy of the Seamos Saludables PA print intervention vs. a theory-and technology-enhanced version (Seamos Activas II). The purpose of the study is to increase the percentage of Latinas meeting the national PA guidelines compared to the prior trial, improve biomarkers related to disease, and extend generalizability to a broader and more representative population of Latinas (i.e. Mexican/Mexican-Americans). Intervention refinements included further targeting key constructs of Social Cognitive Theory, and incorporating interactive text message-based self-monitoring strategies. The primary outcome is change in minutes per week of MVPA measured by ActiGraph GT3X+ accelerometers at 6- and 12-months. Secondary PA outcomes assessed by the 7-Day PA Recall will be used to corroborate findings. RESULTS Participants (N = 199) are Latinas 18-65 years (mean = 43.8) of predominantly Mexican origin (89%). At baseline, objectively measured MVPA was 39.51 min/week (SD = 71.20, median = 10) and self-reported MVPA was 12.47 min/week (SD = 22.54, median = 0).Participants reported generally low self-efficacy and higher cognitive vs. behavioral processes of change. CONCLUSION Addressing interactivity and accountability through text messaging, and more rigorously targeting theoretical constructs may be key to helping Latinas achieve nationally recommended PA levels and thereby reducing health disparities.",2020,"Intervention refinements included further targeting key constructs of Social Cognitive Theory, and incorporating interactive text message-based self-monitoring strategies.","['representative population of Latinas (i.e. Mexican/Mexican-Americans', 'Latina women report disproportionately high rates of physical inactivity and related chronic health conditions', 'Participants (N\u202f=\u202f199) are Latinas 18-65\u202fyears (mean\u202f=\u202f43.8) of predominantly Mexican origin (89', 'Latinas']","['Social Cognitive Theory, and incorporating interactive text message-based self-monitoring strategies', 'theory- and technology- enhanced physical activity intervention']","['low self-efficacy and higher cognitive vs. behavioral processes of change', 'change in minutes per week of MVPA measured by ActiGraph GT3X+ accelerometers']","[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0949335', 'cui_str': 'Latinas'}, {'cui': 'C0025884', 'cui_str': 'Chicanos'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C3890554', 'cui_str': 'Physical Inactivity'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439659', 'cui_str': 'Origins'}]","[{'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C2712043', 'cui_str': 'Lacking belief in own ability'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0702093', 'cui_str': '/minute'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",,0.0266557,"Intervention refinements included further targeting key constructs of Social Cognitive Theory, and incorporating interactive text message-based self-monitoring strategies.","[{'ForeName': 'Tanya J', 'Initials': 'TJ', 'LastName': 'Benitez', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, United States of America.'}, {'ForeName': 'Shira I', 'Initials': 'SI', 'LastName': 'Dunsiger', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, United States of America.'}, {'ForeName': 'Dori J', 'Initials': 'DJ', 'LastName': 'Pekmezi', 'Affiliation': 'Department of Health Behavior, School of Public Health at University of Alabama at Birmingham, Birmingham, AL, United States of America.'}, {'ForeName': 'Britta A', 'Initials': 'BA', 'LastName': 'Larsen', 'Affiliation': 'Department of Family Medicine & Public Health, University of California, La Jolla, San Diego, CA, United States of America.'}, {'ForeName': 'Andrea S', 'Initials': 'AS', 'LastName': 'Mendoza-Vasconez', 'Affiliation': 'School of Medicine, Stanford University, Stanford, CA, United States of America.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Linke', 'Affiliation': 'Department of Family Medicine & Public Health, University of California, La Jolla, San Diego, CA, United States of America.'}, {'ForeName': 'Beth C', 'Initials': 'BC', 'LastName': 'Bock', 'Affiliation': 'Department of Psychiatry & Human Behavior, Alpert Medical School, Brown University, Providence, United States of America.'}, {'ForeName': 'Kim M', 'Initials': 'KM', 'LastName': 'Gans', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, United States of America; Department of Human Development and Family Studies, University of Connecticut, Storrs, CT, United States of America.'}, {'ForeName': 'Sheri J', 'Initials': 'SJ', 'LastName': 'Hartman', 'Affiliation': 'Department of Family Medicine & Public Health, University of California, La Jolla, San Diego, CA, United States of America.'}, {'ForeName': 'Bess H', 'Initials': 'BH', 'LastName': 'Marcus', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, United States of America. Electronic address: bess_marcus@brown.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106081'] 2172,32688045,"Effects of attention training technique on brain function in high- and low-cognitive-attentional syndrome individuals: Regional dynamics before, during, and after a single session of ATT.","OBJECTIVE Attention Training Technique (ATT) is a key therapeutic tool in metacognitive therapy. There are numerous studies on the behavioral effects of ATT, however the neural mechanisms at work in the training are yet to be uncovered. To date there have been no controlled fMRI studies of ATT. METHOD We conducted a randomized double-blind controlled study of two groups with varying levels of cognitive-attentional syndrome (CAS). Groups with high (n = 43) and low (n = 46) levels of CAS underwent a single session of ATT or a control condition (CON) in an MRI scanner. Participants underwent resting state functional MRI (rsfMRI) sessions and rumination induction sessions both pre- and post-intervention Functional connectivity analyses and inter-subject correlations analyses were computed. We also collected data on emotion and attention functioning pre- and post-intervention. RESULTS We did not observe any behavioral effects of ATT. However, direct comparison between ATT and CON sessions revealed greater inter-subject correlations in almost all hubs belonging to the studied functional networks. Moreover, subjects who received ATT showed diminished connectivity in the fronto-parietal network during ruminations and diminished connectivity of the precuneus with lateral occipital cortices and the intraparietal sulcus in abstract thinking and rsfMRI, respectively. Furthermore, some of the observed effects in functional connectivity and inter-subject correlations were specific to different levels of CAS. CONCLUSIONS Our results may support a proposed neural mechanism for ATT: disengagement of attention from CAS-type processing in either low- or high-CAS individuals. It is also possible that some neural effects of ATT are specific to individuals with different levels of CAS.",2020,"Moreover, subjects who received ATT showed diminished connectivity in the fronto-parietal network during ruminations and diminished connectivity of the precuneus with lateral occipital cortices and the intraparietal sulcus in abstract thinking and rsfMRI, respectively.","['two groups with varying levels of cognitive-attentional syndrome (CAS', 'high- and low-cognitive-attentional syndrome individuals']","['Attention Training Technique (ATT', 'attention training technique', 'resting state functional MRI (rsfMRI) sessions and rumination induction sessions']",['brain function'],"[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0556509', 'cui_str': 'Attention training'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]","[{'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",,0.0498982,"Moreover, subjects who received ATT showed diminished connectivity in the fronto-parietal network during ruminations and diminished connectivity of the precuneus with lateral occipital cortices and the intraparietal sulcus in abstract thinking and rsfMRI, respectively.","[{'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Kowalski', 'Affiliation': 'Faculty of Psychology, University of Warsaw, Stawki 5/7, 00-183, Warsaw, Poland; Institute of Psychology, Polish Academy of Sciences, Stefana Jaracza 1, 00-378, Warsaw, Poland. Electronic address: joachim.kowalski@psych.uw.edu.pl.'}, {'ForeName': 'Małgorzata', 'Initials': 'M', 'LastName': 'Wierzba', 'Affiliation': 'Laboratory of Brain Imaging, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Pasteur Street 3, 02-093, Warsaw, Poland.'}, {'ForeName': 'Marek', 'Initials': 'M', 'LastName': 'Wypych', 'Affiliation': 'Laboratory of Brain Imaging, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Pasteur Street 3, 02-093, Warsaw, Poland.'}, {'ForeName': 'Artur', 'Initials': 'A', 'LastName': 'Marchewka', 'Affiliation': 'Laboratory of Brain Imaging, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Pasteur Street 3, 02-093, Warsaw, Poland.'}, {'ForeName': 'Małgorzata', 'Initials': 'M', 'LastName': 'Dragan', 'Affiliation': 'Faculty of Psychology, University of Warsaw, Stawki 5/7, 00-183, Warsaw, Poland.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103693'] 2173,32688046,Effectiveness of a transdiagnostic group intervention to enhance emotion regulation in young Afghan refugees: A pilot randomized controlled study.,"There are several challenges to providing mental health care for refugees, including high comorbidity and structural barriers. Targeting transdiagnostic processes in a low-threshold group intervention appears particularly promising to meet these challenges. This study examined the feasibility, acceptability and effectiveness of a new transdiagnostic intervention, Skills-Training of Affect Regulation-A Culture-sensitive Approach (STARC), focusing on conveying strategies to improve emotional clarity and to regulate emotions. A parallel-group (STARC vs. waitlist) randomized-controlled study with 44 young male Afghan refugees was conducted in a routine clinical setting (NCT03162679). In intention-to-treat analyses, participants of STARC significantly improved in self-reported difficulties in emotion regulation (Δd STARC-Waitlist  = 1.22), transdiagnostic symptom severity (Δd STARC-Waitlist  = 1.69), posttraumatic stress symptoms (Δd STARC-Waitlist  = 1.19), and caregiver-reported emotional competence (Δd STARC-Waitlist  = -0.90), but not anger reactions (Δd STARC-Waitlist  = 0.50) compared to waitlist. Effects were maintained over 3 months. STARC is a feasible transdiagnostic intervention in a routine clinical setting and effective for young Afghan refugees. If replicated in large-scale studies with active control groups, it might be promising as an initial low-threshold intervention offered in a phased-based and/or stepped care approach.",2020,STARC is a feasible transdiagnostic intervention in a routine clinical setting and effective for young Afghan refugees.,"['young Afghan refugees', '44 young male Afghan refugees']","['STARC', 'transdiagnostic group intervention', 'new transdiagnostic intervention, Skills-Training of Affect Regulation-A Culture-sensitive Approach (STARC']","['self-reported difficulties in emotion regulation', 'emotion regulation', 'transdiagnostic symptom severity', 'caregiver-reported emotional competence', 'posttraumatic stress symptoms']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0034961', 'cui_str': 'Refugee'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0010453', 'cui_str': 'Culture'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}]",44.0,0.0299985,STARC is a feasible transdiagnostic intervention in a routine clinical setting and effective for young Afghan refugees.,"[{'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Koch', 'Affiliation': 'LMU Munich, Department of Psychology, Clinical Psychology and Psychotherapy, Germany; Refugio Munich, Germany. Electronic address: Theresa.koch@refugio-muenchen.de.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Ehring', 'Affiliation': 'LMU Munich, Department of Psychology, Clinical Psychology and Psychotherapy, Germany.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Liedl', 'Affiliation': 'LMU Munich, Department of Psychology, Clinical Psychology and Psychotherapy, Germany; Refugio Munich, Germany.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103689'] 2174,32688047,Power posing for paranoia: A double-blind randomised controlled experimental test using virtual reality.,"Paranoia is theorised to build upon feelings of inferior social rank. Power posing has been shown to increase feelings of power, and hence could reduce paranoia. One hundred participants with current paranoia and 50 individuals without paranoia were recruited. Using a double-blind randomised controlled experimental design, participants twice held powerful or neutral postures before entering neutral virtual reality social environments. In the paranoid sample, those who held a powerful pose did not significantly increase in feelings of power by the end of testing in comparison to controls (group difference = 0.67, C.I. = -1.12; 1.46; p = 0.098), or decrease in paranoia (group difference = -0.23, C.I. = -1.17; 0.72; p = 0.634). In the non-paranoid sample, there was a small significant increase in powerful feelings by the end of testing in the powerful group (group difference = 1.13, C.I. = 0.23; 2.02; p = 0.013), but no significant decrease in paranoia (group difference = -0.71, C.I. = -2.16; 0.74; p = 0.338). Paranoia status was not a modifier on the relationship between condition and feelings of power. We conclude that power posing results in only very small changes in self-reported feelings of power and has no subsequent effect on paranoia.",2020,"In the paranoid sample, those who held a powerful pose did not significantly increase in feelings of power by the end of testing in comparison to controls (group difference = 0.67, C.I. = -1.12; 1.46; p = 0.098), or decrease in paranoia (group difference = ","['One hundred participants with current paranoia and 50 individuals without paranoia were recruited', 'participants twice held powerful or neutral postures before entering neutral virtual reality social environments']",[],"['paranoia', 'powerful feelings', 'feelings of power']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C1456784', 'cui_str': 'Paranoid disorder'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0675390', 'cui_str': 'ARID1A protein, human'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0037414', 'cui_str': 'Social context'}]",[],"[{'cui': 'C1456784', 'cui_str': 'Paranoid disorder'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}]",100.0,0.16838,"In the paranoid sample, those who held a powerful pose did not significantly increase in feelings of power by the end of testing in comparison to controls (group difference = 0.67, C.I. = -1.12; 1.46; p = 0.098), or decrease in paranoia (group difference = ","[{'ForeName': 'Poppy', 'Initials': 'P', 'LastName': 'Brown', 'Affiliation': 'Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, UK. Electronic address: poppy.brown@psych.ox.ac.uk.'}, {'ForeName': 'Felicity', 'Initials': 'F', 'LastName': 'Waite', 'Affiliation': 'Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, UK; Oxford Health NHS Foundation Trust, UK.'}, {'ForeName': 'Aitor', 'Initials': 'A', 'LastName': 'Rovira', 'Affiliation': 'Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, UK; Oxford Health NHS Foundation Trust, UK.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Freeman', 'Affiliation': 'Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, UK; Oxford Health NHS Foundation Trust, UK.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103691'] 2175,32691207,Does antrum size matter in sleeve gastrectomy? A prospective randomized Study.,"BACKGROUND Laparoscopic sleeve gastrectomy (LSG) is a safe and effective bariatric procedure in terms of excess weight loss. Nevertheless, controversies still exist on several technical and operative aspects of LSG. The aim of this study is to evaluate variations in anthropometric features in subjects with a LSG gastric resection starting from 2 cm or 6 cm from the pylorus. Secondary aim was the evaluation of differences in morbidity, food tolerance, and GERD incidence studied with upper endoscopy (UE) and GERD Health-Related Quality-of-Life score. METHODS Patients were prospectively randomized into 2 groups: Group A (at 2 cm proximally to the pylorus) and Group B (at 6 cm proximally to the pylorus). All patients were followed-up at 3, 6, 12, and 24 months. UE was performed in all patients at 12 or 24 months. RESULTS One hundred and fifty met the inclusion criteria and were enrolled in the study. The anthropometric features (BMI, %EWL, %TWL) resulted statistically different in the first 12 months (24.2 ± 3.4 vs 27.5 ± 4.3, 63.7 ± 14.1 vs 59.6 ± 12.5 and 42.9 ± 7.4 vs 38.2 ± 6.2), in favor of group A. At 24 months the differences disappeared (25.2 ± 4.4 vs 26.2 ± 3.3, 62.8 ± 13.1 vs 61.6 ± 10.5 and 41.9 ± 7.4 vs 40.2 ± 6.2). An increased GERD was found in both groups postoperatively with a higher incidence in group A at 6-month follow-up. CONCLUSION Performing the LSG with a radical antrectomy could improve weight loss at 12-month follow-up but expose to lower food tolerance and higher transitory GERD. The differences seem to be reduced to a 24-month.",2020,"An increased GERD was found in both groups postoperatively with a higher incidence in group A at 6-month follow-up. ","['subjects with a LSG gastric resection starting from 2\xa0cm or 6\xa0cm from the pylorus', 'One hundred and fifty met the inclusion criteria and were enrolled in the study', 'Patients']",['Laparoscopic sleeve gastrectomy (LSG'],"['weight loss', 'GERD', 'morbidity, food tolerance, and GERD incidence studied with upper endoscopy (UE) and GERD Health-Related Quality-of-Life score']","[{'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}, {'cui': 'C0017118', 'cui_str': 'Gastrectomy'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0034196', 'cui_str': 'Pyloric structure of stomach'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0017168', 'cui_str': 'Gastroesophageal reflux disease'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0021150', 'cui_str': 'Incidence Studies'}, {'cui': 'C0017195', 'cui_str': 'Endoscopy of stomach'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0229578,"An increased GERD was found in both groups postoperatively with a higher incidence in group A at 6-month follow-up. ","[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Pizza', 'Affiliation': 'Department of Surgery, Hospital ""A. Rizzoli"", Aslnapoli2nord, Naples, Italy. Francesco_pizza@libero.it.'}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': ""D'Antonio"", 'Affiliation': 'Department of Surgery, Hospital ""A. Rizzoli"", Aslnapoli2nord, Naples, Italy.'}, {'ForeName': 'Francesco Saverio', 'Initials': 'FS', 'LastName': 'Lucido', 'Affiliation': 'Division of General, Mininvasive and Bariatric Surgery, University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Gambardella', 'Affiliation': 'Division of General, Mininvasive and Bariatric Surgery, University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Carbonell Asíns Juan', 'Initials': 'CAJ', 'LastName': 'Antonio', 'Affiliation': 'Bioinformatics and Biostatistics Unit, Biomedical Research Institute (INCLIVA), Valencia, Spain.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': ""Dell'Isola"", 'Affiliation': 'Department of Infectious Diseases, AORN ""Dei Colli"", Naples, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Tolone', 'Affiliation': 'Division of General, Mininvasive and Bariatric Surgery, University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}]",Surgical endoscopy,['10.1007/s00464-020-07811-1'] 2176,32691228,"The effectiveness of the intramuscular quadratus lumborum block in postoperative analgesia after cesarean section with vertical incision: a randomized, double-blinded placebo-controlled study.","PURPOSE Quadratus lumborum block (QLB) has recently been used for postoperative analgesia after abdominal surgery. Although there are several approaches to QLB, the effectiveness of intramuscular QLB (QLBi) remains controversial. The aim of the present study was to examine the effectiveness of QLBi for postoperative analgesia after cesarean section with a vertical midline incision. METHODS In this single-center, randomized, double-blinded placebo-controlled study, 36 women who were scheduled for elective cesarean section were randomly divided into a QLBi group (n = 18) and a placebo group (n = 18). In both groups, spinal anesthesia was performed with 10-11 mg hyperbaric bupivacaine and 15 µg fentanyl. After the surgery, in the QLBi group, 0.4 mL/kg of 0.25% ropivacaine was injected into the bilateral quadratus lumborum muscle under ultrasound guidance (the total volume was 0.8 mL/kg). In the placebo group, instead of ropivacaine, the subjects were injected with the same amount of normal saline. The primary outcome measure was elapsed time to first analgesic use from the QLBi block after cesarean section. RESULTS The data from all 36 patients were analyzed. There were no significant differences between the QLBi and placebo groups regarding elapsed time to first postoperative analgesic use [mean 230 (standard deviation 103) vs 194 (89) min; 95% confidence interval - 101 to 30; p = 0.27]. CONCLUSIONS QLBi with the concentration and amount of local anesthetic used in the present study was clinically slightly effective, and the effect was limited for postoperative analgesia after cesarean section.",2020,"There were no significant differences between the QLBi and placebo groups regarding elapsed time to first postoperative analgesic use [mean 230 (standard deviation 103) vs 194 (89) min; 95% confidence interval - 101 to 30; p = 0.27]. ","['postoperative analgesia after cesarean section with vertical incision', '36 women who were scheduled for elective cesarean section']","['normal saline', 'Quadratus lumborum block (QLB', 'placebo', 'intramuscular quadratus lumborum block', 'ropivacaine', 'hyperbaric bupivacaine', 'QLBi']","['elapsed time to first analgesic use from the QLBi block after cesarean section', 'elapsed time to first postoperative analgesic use']","[{'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}]","[{'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0224380', 'cui_str': 'Structure of quadratus lumborum muscle'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]",36.0,0.511965,"There were no significant differences between the QLBi and placebo groups regarding elapsed time to first postoperative analgesic use [mean 230 (standard deviation 103) vs 194 (89) min; 95% confidence interval - 101 to 30; p = 0.27]. ","[{'ForeName': 'Keisuke', 'Initials': 'K', 'LastName': 'Yoshida', 'Affiliation': 'Department of Anesthesiology, Aidu Chuo Hospital, 1-1, Tsuruga-machi, Aizuwakmatsu, Fukushima, 965-8611, Japan. kei-y7of@fmu.ac.jp.'}, {'ForeName': 'Shiori', 'Initials': 'S', 'LastName': 'Tanaka', 'Affiliation': 'Department of Anesthesiology, Aidu Chuo Hospital, 1-1, Tsuruga-machi, Aizuwakmatsu, Fukushima, 965-8611, Japan.'}, {'ForeName': 'Kazuhiro', 'Initials': 'K', 'LastName': 'Watanabe', 'Affiliation': 'Department of Anesthesiology, Aidu Chuo Hospital, 1-1, Tsuruga-machi, Aizuwakmatsu, Fukushima, 965-8611, Japan.'}, {'ForeName': 'Shinju', 'Initials': 'S', 'LastName': 'Obara', 'Affiliation': 'Department of Anesthesiology, Fukushima Medical University, 1, Hikariga-oka, Fukushima, Fukushima, 960-1297, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Murakawa', 'Affiliation': 'Department of Anesthesiology, Fukushima Medical University, 1, Hikariga-oka, Fukushima, Fukushima, 960-1297, Japan.'}]",Journal of anesthesia,['10.1007/s00540-020-02829-0'] 2177,32691232,Endoscopic single versus double flap tympanoplasty: a randomized clinical trial.,"OBJECTIVE This study aims to compare the results of endoscopic over-underlay tympanoplasty, single flap technique, with endoscopic over-underlay tympanoplasty combined with an anterior tab, double flap technique, in repair of the challenging total and subtotal tympanic membrane perforations with inadequate anterior remnant. This is to determine whether highly adequate visualization at the anterior meatal angle area offered by endoscopy can eliminate the need for anterior tab reinforcement. SUBJECTS AND METHODS A prospective randomized single-blinded study involving 104 patients with total or subtotal tympanic membrane perforations was conducted. Patients were randomized into two groups: 52 with endoscopic single flap tympanoplasty, first group, and 52 with endoscopic double flap tympanoplasty, second group, between August 2017 and February 2019. The main outcome is graft take rate. Secondary outcomes include hearing results, pain score assessment, operative time and postoperative complications. RESULTS Graft take rates were 94% and 98% for the first and second groups, respectively (P value = 0.307). Significant improvement was achieved in total air-bone gap from 21.45 ± 5.37 and 23.1 ± 4.47 preoperatively to 6.4 ± 5.46 and 6.15 ± 3.57 postoperatively for the first and second groups, respectively. Pain scores were not significantly different between the two groups. Mean operative time was significantly longer in the second group (P value = 0.010). There was no reported lateralization or anterior blunting in both groups. CONCLUSION In repair of total and subtotal tympanic membrane perforations with inadequate anterior remnant, endoscopic enrollment provides excellent visualization and good manipulation at the anterior meatal angle area with favorable results, eliminating the need for adding an anterior tab and alleviating the burden of longer operative time. CLINICAL TRIAL REGISTRY ClinicalTrials.gov (NCT03922295) ""retrospectively registered"" at 18/4/2019.",2020,Mean operative time was significantly longer in the second group (P value = 0.010).,"['104 patients with total or subtotal tympanic membrane perforations was conducted', ' second group, between August 2017 and February 2019']","['endoscopic over-underlay tympanoplasty, single flap technique, with endoscopic over-underlay tympanoplasty combined with an anterior tab, double flap technique', 'Endoscopic single versus double flap tympanoplasty', 'endoscopic single flap tympanoplasty, first group, and 52 with endoscopic double flap tympanoplasty']","['Mean operative time', 'total air-bone gap', 'lateralization or anterior blunting', 'hearing results, pain score assessment, operative time and postoperative complications', 'Graft take rates', 'graft take rate', 'Pain scores']","[{'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C0206504', 'cui_str': 'Perforation of tympanic membrane'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0444455', 'cui_str': 'Underlay'}, {'cui': 'C0041447', 'cui_str': 'Repair of middle ear'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0038925', 'cui_str': 'Flap'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0061928', 'cui_str': 'GTPase-Activating Protein'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}]",104.0,0.148788,Mean operative time was significantly longer in the second group (P value = 0.010).,"[{'ForeName': 'Noha Ahmed', 'Initials': 'NA', 'LastName': 'El-Kholy', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Mansoura University, El-Gomhoria Street, Dakahlia Governorate, Mansoura, 35516, Egypt. nohaaelkholy@gmail.com.'}, {'ForeName': 'Mohammed Abdelbadie', 'Initials': 'MA', 'LastName': 'Salem', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Mansoura University, El-Gomhoria Street, Dakahlia Governorate, Mansoura, 35516, Egypt.'}, {'ForeName': 'Abdelwahab Mohamed', 'Initials': 'AM', 'LastName': 'Rakha', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Mansoura University, El-Gomhoria Street, Dakahlia Governorate, Mansoura, 35516, Egypt.'}]",European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,['10.1007/s00405-020-06212-3'] 2178,32691260,Validation of a German version of the Caregiver Quality of Life Index-Cancer (CQOLC) in a sample of significant others of breast and gynaecologic cancer patients.,"There is no disease-specific instrument to measure the quality of life of significant others of cancer patients in Germany. In this study, we evaluated the reliability and construct validity of a German version of the Caregiver Quality of Life Index-Cancer (CQOLC) in a sample of 212 caregivers of breast and gynaecologic cancer patients. The CQOLC was administered along with the World Health Organization Quality of Life short version (WHOQOL-BREF) to caregivers of patients taking part in a randomized-controlled intervention study. Data of 212 caregivers were gained at the baseline of the study. Internal consistency was determined by Cronbach's α. Construct validity was examined by conducting a confirmatory factor analysis (CFA) and hypothesis testing. Correlations between change scores with patients' global health-related quality of life (HRQoL) were calculated for three time points to evaluate the responsiveness. The three subscales ""burden"", ""disruptiveness"", and ""financial concerns"" indicate to a good reliability of the instrument (Cronbach's α ranged between 0.754 and 0.832), while the subscale ""positive adaptation"" demonstrated low reliability (α = 0.579). A CFA based on data from the whole set of CQOLC items resulted in CFI levels < .90, and a CFA without problematic items resulted in CFI levels also < .90.The construct validity of the CQOLC could be approved by a moderate to high convergence with close variables as the global HRQoL. Mean differences between caregivers of curatively or palliatively treated patients were nonsignificant (p = 0.959) at T1. Correlations for responsiveness were low with correlation coefficients ranging from 0.030 to 0.326. These data indicate that additional research is needed to further verify the validity of the instrument. The German scale of the CQOLC might be appropriate for clinical and research use, if the wording of some items is refined and if content validity is also assessed by caregivers themselves. The assessment of cancer patients' caregiver's quality of life can contribute to a better understanding of the effects of patient-oriented interventions including also closely involved next of kin's around the cancer patients.",2020,Correlations between change scores with patients' global health-related quality of life (HRQoL) were calculated for three time points to evaluate the responsiveness.,"['cancer patients in Germany', '212 caregivers', 'breast and gynaecologic cancer patients', '212 caregivers of breast and gynaecologic cancer patients']",[],"['Caregiver Quality of Life Index-Cancer (CQOLC', 'global health-related quality of life (HRQoL', 'CFI levels']","[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0205480', 'cui_str': 'Gynecologic'}]",[],"[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0451498', 'cui_str': 'Spitzer quality of life index'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0055288', 'cui_str': 'Chemotaxis factor inhibitor'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",212.0,0.0283725,Correlations between change scores with patients' global health-related quality of life (HRQoL) were calculated for three time points to evaluate the responsiveness.,"[{'ForeName': 'Anna Tamara', 'Initials': 'AT', 'LastName': 'Ehmann', 'Affiliation': 'Institute of Occupational and Social Medicine and Health Services Research, University Hospital Tübingen, 72074, Tübingen, Wilhelmstraße 27, Germany.'}, {'ForeName': 'Cornelia', 'Initials': 'C', 'LastName': 'Mahler', 'Affiliation': 'Department of Nursing Science, University Hospital Tübingen, Hoppe-Seyler-Straße 9, 72076, Tübingen, Germany.'}, {'ForeName': 'Nadja', 'Initials': 'N', 'LastName': 'Klafke', 'Affiliation': 'Department of General Practice and Health Services Research, University Hospital Heidelberg, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany. nadja.klafke@med.uni-heidelberg.de.'}]","Psicologia, reflexao e critica : revista semestral do Departamento de Psicologia da UFRGS",['10.1186/s41155-020-00155-8'] 2179,32691499,Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.,"This study compared initiation of insulin and other AHAs with canagliflozin versus placebo for participants with type 2 diabetes and a history/high risk of cardiovascular disease in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. After 1 year fewer participants treated with canagliflozin versus placebo initiated any AHA (7% vs 16%), insulin (3% vs 9%;) or any non-insulin AHA (5% vs 12%; p<0.001 for all); overall AHA initiation rates increased over time but were consistently lower with canagliflozin compared with placebo. During the study, the likelihood of initiating insulin was 2.7 times lower for participants treated with canagliflozin compared with placebo (hazard ratio, 0.37; 95% CI: 0.31,0.43; p<0.001). The time difference between 10% of patients in the canagliflozin and placebo groups being initiated on insulin from the beginning of the trial was about two years. Time to initiation of other AHAs, including metformin, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sulphonylureas, was also delayed for canagliflozin versus placebo (p<0.001 for each). Compared with placebo, canagliflozin delayed the need for initiation of other AHAs and delayed time to insulin therapy, an outcome that is important to many people with diabetes. Trial registration: ClinicalTrials.gov identifiers NCT01032629, NCT01989754. This article is protected by copyright. All rights reserved.",2020,"Compared with placebo, canagliflozin delayed the need for initiation of other AHAs and delayed time to insulin therapy, an outcome that is important to many people with diabetes.",['participants with type 2 diabetes and a history/high risk of cardiovascular disease in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program'],"['insulin and other AHAs with canagliflozin versus placebo', 'canagliflozin', 'placebo, canagliflozin', 'canagliflozin versus placebo', 'placebo']","['overall AHA initiation rates', 'likelihood of initiating insulin']","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C2974540', 'cui_str': 'canagliflozin'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0050451', 'cui_str': 'acetohydroxamic acid'}, {'cui': 'C2974540', 'cui_str': 'canagliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0050451', 'cui_str': 'acetohydroxamic acid'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}]",,0.476696,"Compared with placebo, canagliflozin delayed the need for initiation of other AHAs and delayed time to insulin therapy, an outcome that is important to many people with diabetes.","[{'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Matthews', 'Affiliation': 'Oxford Centre for Diabetes, Endocrinology and Metabolism and Harris Manchester College, University of Oxford, Oxford, UK.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Wysham', 'Affiliation': 'University of Washington, Spokane, WA, USA.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Davies', 'Affiliation': 'Diabetes Research Centre, University of Leicester, Leicester, UK.'}, {'ForeName': 'April', 'Initials': 'A', 'LastName': 'Slee', 'Affiliation': 'Axio Research, Seattle, WA, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Alba', 'Affiliation': 'Janssen Research & Development, LLC, Raritan, NJ, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Lee', 'Affiliation': 'Janssen Research & Development, LLC, Raritan, NJ, USA.'}, {'ForeName': 'Vlado', 'Initials': 'V', 'LastName': 'Perkovic', 'Affiliation': 'UNSW Sydney, The George Institute for Global Health, Sydney, Australia.'}, {'ForeName': 'Kenneth W', 'Initials': 'KW', 'LastName': 'Mahaffey', 'Affiliation': 'Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Neal', 'Affiliation': 'UNSW Sydney, The George Institute for Global Health, Sydney, Australia.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14143'] 2180,32691513,Benefit:Risk Profile of Dapagliflozin 5 mg in the DEPICT-1 and -2 Trials in Individuals with Type 1 Diabetes and BMI ≥27 kg/m 2 .,"AIM The DEPICT-1 and -2 studies (NCT02268214, NCT02460978) evaluated the efficacy and safety of dapagliflozin in individuals with type 1 diabetes who were receiving intensive insulin therapy. This post-hoc analysis investigated the safety and efficacy of dapagliflozin in individuals with BMI ≥27 kg/m 2 . METHODS Changes in HbA1c and body weight, percent change in daily insulin dose and proportion of participants achieving HbA1c reduction ≥0.5% without severe hypoglycaemia were evaluated at Weeks 24 and 52. Changes in mean interstitial glucose, mean amplitude of glycaemic excursions, and time in target glycaemic range were evaluated at Week 24. Safety was assessed until Week 56. RESULTS Week-52 adjusted mean (SE) change from baseline for HbA1c was -0.26% (0.05) with dapagliflozin versus +0.08% (0.05) with placebo and for body weight was -2.74 kg [0.25] with dapagliflozin versus +0.81 kg [0.26] with placebo. Mean [SE] percent change in daily insulin dose was -10.5% (1.23) with dapagliflozin versus -1.4% (1.36) with placebo. Time spent in target glycaemic range increased by 2.2 hours/day versus placebo. Dapagliflozin was well tolerated, with lower proportion of participants experiencing diabetic ketoacidosis (dapagliflozin, 1.7%; placebo, 1.0%) than dapagliflozin 5 mg receiving participants in the pooled DEPICT populations. CONCLUSIONS Compared with the pooled DEPICT population, the benefit:risk profile of adjunct dapagliflozin therapy was more favourable in individuals with T1D with BMI ≥27 kg/m 2 due to the reduced risk of diabetic ketoacidosis in this population. This article is protected by copyright. All rights reserved.",2020,Week-52 adjusted mean (SE) change from baseline for HbA1c was -0.26% (0.05) with dapagliflozin versus +0.08% (0.05) with placebo and for body weight was -2.74,"['Individuals with Type 1 Diabetes and BMI ≥27 kg/m 2 ', 'individuals with BMI ≥27 kg/m 2 ', 'individuals with type 1 diabetes who were receiving intensive insulin therapy']","['dapagliflozin therapy', 'Dapagliflozin', 'dapagliflozin', 'placebo']","['Safety', 'tolerated', 'Time spent in target glycaemic range', 'Mean [SE] percent change in daily insulin dose', 'diabetic ketoacidosis', 'efficacy and safety', 'safety and efficacy', 'mean interstitial glucose, mean amplitude of glycaemic excursions, and time in target glycaemic range', 'HbA1c and body weight, percent change in daily insulin dose and proportion of participants achieving HbA1c reduction ≥0.5% without severe hypoglycaemia']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0011880', 'cui_str': 'Diabetic ketoacidosis'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1522203', 'cui_str': 'Interstitial route'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C4728082', 'cui_str': 'Severe hypoglycaemia'}]",,0.178292,Week-52 adjusted mean (SE) change from baseline for HbA1c was -0.26% (0.05) with dapagliflozin versus +0.08% (0.05) with placebo and for body weight was -2.74,"[{'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Mathieu', 'Affiliation': 'Clinical and Experimental Endocrinology, UZ Gasthuisberg, University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Paresh', 'Initials': 'P', 'LastName': 'Dandona', 'Affiliation': 'State University of New York at Buffalo, Williamsville, NY, USA.'}, {'ForeName': 'Andreas L', 'Initials': 'AL', 'LastName': 'Birkenfeld', 'Affiliation': 'Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich at the University of Tübingen, Tübingen, Germany.'}, {'ForeName': 'Troels', 'Initials': 'T', 'LastName': 'Krarup Hansen', 'Affiliation': 'Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Nayyar', 'Initials': 'N', 'LastName': 'Iqbal', 'Affiliation': 'Late-stage Development Cardiovascular, Renal and Metabolism, AstraZeneca, Gaithersburg, MD, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Late-stage Development Cardiovascular, Renal and Metabolism, AstraZeneca, Gaithersburg, MD, USA.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Repetto', 'Affiliation': 'Global Medical Affairs, AstraZeneca, Gaithersburg, MD, USA.'}, {'ForeName': 'Markus Florian', 'Initials': 'MF', 'LastName': 'Scheerer', 'Affiliation': 'Diabetes Medical Department, AstraZeneca, Wedel, Germany.'}, {'ForeName': 'Fredrik', 'Initials': 'F', 'LastName': 'Thoren', 'Affiliation': 'Late-stage Development Cardiovascular, Renal and Metabolism, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Moshe', 'Initials': 'M', 'LastName': 'Phillip', 'Affiliation': ""Schneider Children's Medical Center of Israel, Petah Tikva, Israel.""}]","Diabetes, obesity & metabolism",['10.1111/dom.14144'] 2181,32673573,"Comparison of Surgical Drain Placement With Use of Kinesiologic Tape on Postoperative Pain, Swelling, and Trismus in Impacted Mandibular Third Molar Surgery.","PURPOSE The aim of this prospective study was to compare the effects of a surgical tube drain with kinesiologic tape (KT) application on postoperative complications such as trismus, swelling, and pain after impacted third molar surgery. PATIENTS AND METHODS This single-center, randomized study included 90 patients divided into 3 groups. After impacted third molar removal, 30 patients were treated with a tube drain (drain group), 30 patients were treated with KT application (KT group), and 30 patients were treated with a routine surgical operation and no extra procedure (control group). RESULTS A total of 29 male and 61 female patients were included. Mouth opening was greatest in the drain group over a period of 7 days. Patients in the control group had more pain than those in the drain and KT groups. No statistically significant difference was found in terms of pain and swelling between the drain and KT groups over the 7-day period of the study. The tube drain was found to improve patients' quality-of-life compared with the KT and control groups. CONCLUSIONS Although the effects of a tube drain and KT in terms of pain and swelling were similar, the tube drain was more effective in reducing postoperative complications.",2020,No statistically significant difference was found in terms of pain and swelling between the drain and KT groups over the 7-day period of the study.,"['90 patients divided into 3 groups', 'A total of 29 male and 61 female patients were included']","['Surgical Drain Placement', 'Kinesiologic Tape', 'tube drain and KT', 'KT application', 'surgical tube drain with kinesiologic tape (KT) application', 'tube drain', 'routine surgical operation and no extra procedure (control group']","['Postoperative Pain, Swelling, and Trismus', ""patients' quality of life"", 'postoperative complications such as trismus, swelling, and pain', 'pain and swelling', 'postoperative complications', 'pain', 'Mouth opening']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C2607832', 'cui_str': 'Surgical drain'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0184114', 'cui_str': 'Tube drain'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0041105', 'cui_str': 'Trismus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0240379', 'cui_str': 'Open mouth'}]",90.0,0.0266718,No statistically significant difference was found in terms of pain and swelling between the drain and KT groups over the 7-day period of the study.,"[{'ForeName': 'Dilek', 'Initials': 'D', 'LastName': 'Menziletoglu', 'Affiliation': 'Assistant Professor, Faculty of Dentistry, Oral and Maxillofacial Surgery, Necmettin Erbakan University, Konya, Turkey. Electronic address: drdilekmenziletoglu@gmail.com.'}, {'ForeName': 'Arif Yigit', 'Initials': 'AY', 'LastName': 'Guler', 'Affiliation': 'Research Assistant, Faculty of Dentistry, Oral and Maxillofacial Surgery, Necmettin Erbakan University, Konya, Turkey.'}, {'ForeName': 'Funda', 'Initials': 'F', 'LastName': 'Basturk', 'Affiliation': 'Research Assistant, Faculty of Dentistry, Oral and Maxillofacial Surgery, Necmettin Erbakan University, Konya, Turkey.'}, {'ForeName': 'Bozkurt Kubilay', 'Initials': 'BK', 'LastName': 'Isik', 'Affiliation': 'Professor and Department Head, Faculty of Dentistry, Oral and Maxillofacial Surgery, Necmettin Erbakan University, Konya, Turkey.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2020.06.023'] 2182,32688143,"The effects of multidisciplinary rehabilitation on neuroimaging, biological, cognitive and motor outcomes in individuals with premanifest Huntington's disease.","BACKGROUND Huntington's disease (HD) is a chronic, progressive neurodegenerative condition for which there are currently no proven disease-modifying therapies. Lifestyle factors have been shown to impact on the age of disease onset and progression of disease features. We therefore investigated the effects of a nine-month multidisciplinary rehabilitation intervention on neuroimaging, biological and clinical disease outcomes in individuals with premanifest HD. METHODS 31 individuals with premanifest HD participated in the study. Eighteen participants underwent a nine-month multidisciplinary rehabilitation intervention comprising aerobic and resistance exercise, computerised cognitive training, dual-task training and sleep hygiene and nutritional guidance. The remaining 13 participants were allocated to a standard care control group. Neuroimaging, biological, cognitive, motor and cardiorespiratory fitness data was collected. RESULTS Participants displayed good adherence (87%) and compliance (85%) to the intervention. Maintenance of the shape of the right putamen was observed in the intervention group when compared to the control group. The intervention group displayed significant improvements in verbal learning and memory, attention, cognitive flexibility and processing speed following the intervention when compared to the control group. Performance on the mini-social cognition and emotional assessment (mini-SEA) was maintained in the intervention group, but decreased in the control group. No changes were observed in serum neurofilament light protein levels, postural stability outcomes or cardiorespiratory fitness. CONCLUSION This study adds to the accumulating body of literature to suggest that multidisciplinary rehabilitation is of clinical benefit for individuals with HD. Large randomised controlled trials are necessary to determine the extent to which benefits occur across the spectrum of the disease.",2020,"The intervention group displayed significant improvements in verbal learning and memory, attention, cognitive flexibility and processing speed following the intervention when compared to the control group.","['individuals with HD', 'individuals with premanifest HD', '31 individuals with premanifest HD participated in the study', ""individuals with premanifest Huntington's disease"", 'Eighteen participants underwent a nine-month']","['nine-month multidisciplinary rehabilitation intervention', 'multidisciplinary rehabilitation', 'multidisciplinary rehabilitation intervention comprising aerobic and resistance exercise, computerised cognitive training, dual-task training and sleep hygiene and nutritional guidance', 'standard care control group']","['serum neurofilament light protein levels, postural stability outcomes or cardiorespiratory fitness', 'mini-social cognition and emotional assessment (mini-SEA', 'good adherence', 'neuroimaging, biological, cognitive and motor outcomes', 'verbal learning and memory, attention, cognitive flexibility and processing speed']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0020179', 'cui_str': ""Huntington's chorea""}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4277672', 'cui_str': 'Good Sleep Habits'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C0670902', 'cui_str': 'LIGHT Protein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0042531', 'cui_str': 'Verbal learning'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0582591', 'cui_str': 'Processing speed'}]",18.0,0.0225136,"The intervention group displayed significant improvements in verbal learning and memory, attention, cognitive flexibility and processing speed following the intervention when compared to the control group.","[{'ForeName': 'Danielle M', 'Initials': 'DM', 'LastName': 'Bartlett', 'Affiliation': 'School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Govus', 'Affiliation': 'School of Allied Health, Human Services & Sport, Department of Dietetics, Nutrition and Sport, La Trobe University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Rankin', 'Affiliation': 'School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia; Centre for Sleep Science, School of Human Sciences, Faculty of Science, University of Western Australia, Crawley, Western Australia, Australia.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Lampit', 'Affiliation': 'Department of Psychiatry, University of Melbourne, Victoria, Australia; Department of Neurology, Charité - Universitätsmedizin Berlin, Germany.'}, {'ForeName': 'Kirk', 'Initials': 'K', 'LastName': 'Feindel', 'Affiliation': 'Centre for Microscopy, Characterisation and Analysis, University of Western Australia, Australia.'}, {'ForeName': 'Govinda', 'Initials': 'G', 'LastName': 'Poudel', 'Affiliation': 'Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.'}, {'ForeName': 'Wei-Peng', 'Initials': 'WP', 'LastName': 'Teo', 'Affiliation': 'National Institute of Education, Nanyang Technological University, Singapore.'}, {'ForeName': 'Johnny', 'Initials': 'J', 'LastName': 'Lo', 'Affiliation': 'School of Science, Edith Cowan University, Joondalup, Western Australia, Australia.'}, {'ForeName': 'Nellie', 'Initials': 'N', 'LastName': 'Georgiou-Karistianis', 'Affiliation': 'School of Psychological Sciences, The Turner Institute of Brain and Mental Health, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'Mel R', 'Initials': 'MR', 'LastName': 'Ziman', 'Affiliation': 'School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia; School of Biomedical Science, University of Western Australia, Crawley, Western Australia, Australia.'}, {'ForeName': 'Travis M', 'Initials': 'TM', 'LastName': 'Cruickshank', 'Affiliation': 'School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia; Exercise Medicine Research Institute, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; Perron Institute for Neurological and Translational Science, Perth, Western Australia, Australia. Electronic address: t.cruickshank@ecu.edu.au.'}]",Journal of the neurological sciences,['10.1016/j.jns.2020.117022'] 2183,32688208,PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery.,"BACKGROUND Enhanced recovery after surgery (ERAS) programs include multiple perioperative elements designed to achieve early recovery after surgery and a shorter length of stay (LOS) in hospital. The PROFAST trial aimed to expand the evidence base for implementing ERAS in advanced gynaecologic oncology surgery. METHODS This prospective, interventional randomised clinical trial enrolled women undergoing surgery for either suspected or diagnosed advanced ovarian cancer, at a reference hospital in gynaecologic oncology in Barcelona (Spain) and who were treated after either an ERAS protocol or conventional management (CM) protocol. All enrolled women who underwent cytoreductive surgery were included in the primary analysis. The primary outcome was reduction in LOS, and secondary outcomes were incidence and type of intraoperative and postoperative complications, rate of readmission and mortality within a 30-d follow-up period. This trial is registered at ClinicalTrials.gov, number NCT02172638. FINDINGS From June 2014 to March 2018, 110 women were recruited, of which eleven were excluded. The ERAS group comprised 50 patients, and the CM group, 49 patients. Both groups were comparable with respect to baseline characteristics and complexity of the cytoreductive surgery, with an overall medium/high Aletti surgical complexity score of 7.4. Overall compliance to the ERAS protocol was 92%. As compared with the patients in the CM group, patients in the ERAS group had a decreased median of LOS of two days (7 versus 9 days; p = 0.0099) and a decreased rate of readmission (6% versus 20%, p = 0.0334). No further significant differences were detected with respect to incidence of intraoperative or postoperative complications, severe (Clavien-Dindo grade IIIB-IV) complications, Comprehensive Complication Index, reoperation during primary stay, or mortality. INTERPRETATION Patients with advanced ovarian cancer in the ERAS program had a decreased LOS and decreased rate of readmission as compared with those in CM, with no increased morbidity or mortality. This study provides important evidence for the benefits of ERAS management even for gynaecologic surgeries of medium/high complexity and suggests that ERAS should be a standard practice for cytoreductive surgeries for peritoneal carcinomatosis.",2020,"No further significant differences were detected with respect to incidence of intraoperative or postoperative complications, severe (Clavien-Dindo grade IIIB-IV) complications, Comprehensive Complication Index, reoperation during primary stay, or mortality. ","['Patients with advanced ovarian cancer', 'enrolled women undergoing surgery for either suspected or diagnosed advanced ovarian cancer, at a reference hospital in gynaecologic oncology in Barcelona (Spain) and who were treated after either an', 'All enrolled women who underwent cytoreductive surgery were included in the primary analysis', 'From June 2014 to March 2018, 110 women were recruited, of which eleven were excluded', 'advanced gynaecologic oncology surgery', 'highcomplexity advanced ovarian cancer surgery']","['PROFAST', 'ERAS', 'ERAS protocol or conventional management (CM) protocol']","['incidence of intraoperative or postoperative complications, severe (Clavien-Dindo grade IIIB-IV) complications, Comprehensive Complication Index, reoperation during primary stay, or mortality', 'incidence and type of intraoperative and postoperative complications, rate of readmission\xa0and mortality within a 30-d\xa0follow-up period', 'rate of readmission', 'morbidity or mortality', 'median of LOS', 'reduction in LOS', 'Overall compliance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205480', 'cui_str': 'Gynecologic'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C3850079', 'cui_str': 'Cytoreductive surgery'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}]","[{'cui': 'C0381011', 'cui_str': 'ProFast'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}]",110.0,0.308005,"No further significant differences were detected with respect to incidence of intraoperative or postoperative complications, severe (Clavien-Dindo grade IIIB-IV) complications, Comprehensive Complication Index, reoperation during primary stay, or mortality. ","[{'ForeName': 'José Luis', 'Initials': 'JL', 'LastName': 'Sánchez-Iglesias', 'Affiliation': ""Gynecological Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain. Electronic address: jlsanig@yahoo.es.""}, {'ForeName': 'Melchor', 'Initials': 'M', 'LastName': 'Carbonell-Socias', 'Affiliation': ""Gynecological Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.""}, {'ForeName': 'Ma Assumpció', 'Initials': 'MA', 'LastName': 'Pérez-Benavente', 'Affiliation': ""Gynecological Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.""}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Monreal Clua', 'Affiliation': ""Gynecological Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.""}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Manrique-Muñoz', 'Affiliation': ""Unit of Anesthesiology and Resuscitation, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Manel', 'Initials': 'M', 'LastName': 'García Gorriz', 'Affiliation': ""Unit of Anesthesiology and Resuscitation, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Burgos-Peláez', 'Affiliation': ""Nutritional Support Unit, Endocrinology and Nutrition Service, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Hegoi', 'Initials': 'H', 'LastName': 'Segurola Gurrutxaga', 'Affiliation': ""Nutritional Support Unit, Endocrinology and Nutrition Service, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Mónica', 'Initials': 'M', 'LastName': 'Pamies Serrano', 'Affiliation': ""Nutritional Support Unit, Endocrinology and Nutrition Service, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Ma Del', 'Initials': 'MD', 'LastName': 'Pilar Gutiérrez-Barceló', 'Affiliation': ""Nutritional Support Unit, Endocrinology and Nutrition Service, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Serrano-Castro', 'Affiliation': ""Nursing Unit for Gynecologic Oncology and Breast Diseases, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Ma Teresa', 'Initials': 'MT', 'LastName': 'Balcells-Farré', 'Affiliation': ""Data and Innovation Department, Vall d'Hebron Hospital, Barcelona, Spain; Research Group of Healthcare System Management, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.""}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Pérez-Barragán', 'Affiliation': ""Data and Innovation Department, Vall d'Hebron Hospital, Barcelona, Spain; Research Group of Healthcare System Management, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.""}, {'ForeName': 'Axelle', 'Initials': 'A', 'LastName': 'Scaillet-Houberechts', 'Affiliation': ""Data and Innovation Department, Vall d'Hebron Hospital, Barcelona, Spain; Research Group of Healthcare System Management, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.""}, {'ForeName': 'Yolima', 'Initials': 'Y', 'LastName': 'Cossio-Gil', 'Affiliation': ""Data and Innovation Department, Vall d'Hebron Hospital, Barcelona, Spain; Research Group of Healthcare System Management, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.""}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Gil-Moreno', 'Affiliation': ""Gynecological Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Biomedical Research Group in Gynecology, Vall d'Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, CIBERONC, Barcelona, Spain. Electronic address: antonioimma@yahoo.es.""}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.06.011'] 2184,32687161,"A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naïve Adults.","BACKGROUND A previous RTS,S/AS01B vaccine challenge trial demonstrated a three-dose (0,1,7-month [M]) regimen with a fractional third dose can produce high vaccine efficacy (VE) in adults challenged three weeks post-vaccination. This study explored VE of different delayed fractional dose-regimens of adult and pediatric RTS,S/AS01-formulations. METHODS 130 subjects were randomized into 5 groups. Four received three doses of RTS,S/AS01B or RTS,S/AS01E on a 0,1,7M schedule, with the final one or two doses being fractional (1/5th dose-volume). One received 1 full (0M) and 1 fractional (7M) dose of RTS,S/AS01E. Immunized and unvaccinated control participants underwent Plasmodium falciparum-infected mosquito challenge (CHMI) 3M post-immunization, a timing chosen to potentially discriminate VE between groups. RESULTS VE of three-dose formulations ranged from 55% (95% CI: 27-72%) to 76% (95% CI: 48-89%). Groups administered equivalent formulations of RTS,S/AS01E and RTS,S/AS01B demonstrated comparable VE. The two-dose group demonstrated lower VE (29% [95% CI: 6, 46%]). All regimens were well-tolerated and immunogenic, with trends toward higher anti-CS antibody titers in participants protected against infection. CONCLUSIONS RTS,S/AS01E can provide VE comparable to an equivalent RTS,S/AS01B regimen in adults, suggesting a universal formulation may be considered. Results also suggest the two-dose regimen is inferior to the three-dose regimens evaluated.",2020,"Groups administered equivalent formulations of RTS,S/AS01E and RTS,S/AS01B demonstrated comparable VE.","['Malaria-Naïve Adults', '130 subjects']","['RTS,S/AS01E. Immunized and unvaccinated control participants underwent Plasmodium falciparum-infected mosquito challenge (CHMI) 3M post-immunization', 'RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens', 'RTS,S/AS01B or RTS,S/AS01E']",['lower VE'],"[{'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4319552', 'cui_str': '130'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032150', 'cui_str': 'Plasmodium falciparum'}, {'cui': 'C0026584', 'cui_str': 'Family Culicidae'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0020971', 'cui_str': 'Immunization'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",130.0,0.0363794,"Groups administered equivalent formulations of RTS,S/AS01E and RTS,S/AS01B demonstrated comparable VE.","[{'ForeName': 'James E', 'Initials': 'JE', 'LastName': 'Moon', 'Affiliation': 'Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Ockenhouse', 'Affiliation': 'PATH-Malaria Vaccine Initiative, Washington, DC, USA.'}, {'ForeName': 'Jason A', 'Initials': 'JA', 'LastName': 'Regules', 'Affiliation': 'Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Vekemans', 'Affiliation': ""GSK, 89 Rue de l'Institut, , Belgium.""}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Lee', 'Affiliation': 'PATH-Malaria Vaccine Initiative, Washington, DC, USA.'}, {'ForeName': 'Ilin', 'Initials': 'I', 'LastName': 'Chuang', 'Affiliation': 'Naval Medical Research Center (NMRC), Silver Spring, MD, USA.'}, {'ForeName': 'Magali', 'Initials': 'M', 'LastName': 'Traskine', 'Affiliation': ""GSK, 89 Rue de l'Institut, , Belgium.""}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Jongert', 'Affiliation': ""GSK, 89 Rue de l'Institut, , Belgium.""}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Ivinson', 'Affiliation': 'PATH-Malaria Vaccine Initiative, Washington, DC, USA.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Morelle', 'Affiliation': ""GSK, 89 Rue de l'Institut, , Belgium.""}, {'ForeName': 'Jack L', 'Initials': 'JL', 'LastName': 'Komisar', 'Affiliation': 'Naval Medical Research Center (NMRC), Silver Spring, MD, USA.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Lievens', 'Affiliation': ""GSK, 89 Rue de l'Institut, , Belgium.""}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Sedegah', 'Affiliation': 'Naval Medical Research Center (NMRC), Silver Spring, MD, USA.'}, {'ForeName': 'Lindsey S', 'Initials': 'LS', 'LastName': 'Garver', 'Affiliation': 'Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA.'}, {'ForeName': 'April K', 'Initials': 'AK', 'LastName': 'Sikaffy', 'Affiliation': 'Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA.'}, {'ForeName': 'Norman C', 'Initials': 'NC', 'LastName': 'Waters', 'Affiliation': 'Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA.'}, {'ForeName': 'William Ripley', 'Initials': 'WR', 'LastName': 'Ballou', 'Affiliation': ""GSK, 89 Rue de l'Institut, , Belgium.""}, {'ForeName': 'Opokua', 'Initials': 'O', 'LastName': 'Ofori-Anyinam', 'Affiliation': ""GSK, 89 Rue de l'Institut, , Belgium.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Journal of infectious diseases,['10.1093/infdis/jiaa421'] 2185,32687174,"Efficacy and Safety of a Naphthoquine-Azithromycin Co-Formulation for Malaria Prophylaxis in Southeast Asia: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial.","BACKGROUND A prophylactic antimalarial drug that is both effective for protection and improves compliance is in high demand. METHODS We conducted a randomized, placebo-controlled, double-blinded, phase-3 trial to evaluate the 1:1 fixed-dose combination of naphthoquine-azithromycin (NQAZ) for safety and protection against Plasmodium infections in villages along the China-Myanmar border. A total of 631 residents, 5-65 years old, were randomized into the drug group (319) and the placebo group (312) to receive NZAQ and placebo, respectively, as a single-dose monthly treatment. Follow-ups were conducted weekly to monitor for adverse events and malaria infections. RESULTS Of the 531 subjects completing the trial, there were 46 and 3 blood smear-positive Plasmodium infections in the placebo and treatment groups, respectively. For the intent-to-treat analysis, the single-dose monthly NQAZ treatment had 93.62% protective efficacy (95% confidence interval [CI]: 91.72-95.52%). For the per-protocol analysis, NQAZ treatment provided a 93.04% protective efficacy (95% CI: 90.98-95.1%). Three smear-positive cases in the NQAZ group were all due to acute falciparum malaria. In comparison, NQAZ treatment provided 100% protection against the relapsing malaria Plasmodium vivax and Plasmodium ovale. The treatment group had 5.6% of participants experiencing transient elevation of liver transaminases as compared to 2.2% in the placebo group (P > 0.05). CONCLUSIONS Monthly prophylaxis with NQAZ tablets was well tolerated and highly effective for preventing Plasmodium infections. It may prove useful for eliminating P. vivax in areas with a high prevalence of glucose-6-phosphate dehydrogenase deficiency in the population.",2020,"The treatment group had 5.6% of participants experiencing transient elevation of liver transaminases as compared to 2.2% in the placebo group (P > 0.05). ","['531 subjects completing the trial', 'villages along the China-Myanmar border', 'Malaria Prophylaxis in Southeast Asia', 'A total of 631 residents, 5-65 years old']","['Placebo', 'NQAZ', 'NQAZ tablets', 'NZAQ and placebo', 'naphthoquine-azithromycin (NQAZ', 'Naphthoquine-Azithromycin Co-Formulation', 'placebo']","['Efficacy and Safety', 'relapsing malaria Plasmodium vivax and Plasmodium ovale', 'protective efficacy', 'blood smear-positive Plasmodium infections', 'tolerated and highly effective for preventing Plasmodium infections', 'transient elevation of liver transaminases']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0006416', 'cui_str': 'Burma'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0199244', 'cui_str': 'Antimalarial prophylaxis'}, {'cui': 'C0003983', 'cui_str': 'South east Asian country'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4058704', 'cui_str': 'NAPHTHOQUINE'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C1245010', 'cui_str': 'Azithromycin Oral Tablet'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0024537', 'cui_str': 'Vivax malaria'}, {'cui': 'C0320744', 'cui_str': 'Plasmodium ovale'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0444186', 'cui_str': 'Smear test'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0040704', 'cui_str': 'Transients'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0002594', 'cui_str': 'Aminotransferase'}]",631.0,0.633984,"The treatment group had 5.6% of participants experiencing transient elevation of liver transaminases as compared to 2.2% in the placebo group (P > 0.05). ","[{'ForeName': 'Henglin', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': ""Yunnan Institute of Parasitic Diseases, Yunnan Provincial Center of Malaria Research, Pu'er, Yunnan, China.""}, {'ForeName': 'Jingyan', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Institute of Microbiology and Epidemiology, Chinese Academy of Military Medical Sciences, Beijing, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': ""Yunnan Institute of Parasitic Diseases, Yunnan Provincial Center of Malaria Research, Pu'er, Yunnan, China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Department of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning, China.'}, {'ForeName': 'Seetha', 'Initials': 'S', 'LastName': 'Lakshmi', 'Affiliation': 'Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Xingliang', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': ""Yunnan Institute of Parasitic Diseases, Yunnan Provincial Center of Malaria Research, Pu'er, Yunnan, China.""}, {'ForeName': 'Renhua', 'Initials': 'R', 'LastName': 'Nie', 'Affiliation': ""Yunnan Institute of Parasitic Diseases, Yunnan Provincial Center of Malaria Research, Pu'er, Yunnan, China.""}, {'ForeName': 'Chunfu', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': ""Yunnan Institute of Parasitic Diseases, Yunnan Provincial Center of Malaria Research, Pu'er, Yunnan, China.""}, {'ForeName': 'Hengye', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': ""Yunnan Institute of Parasitic Diseases, Yunnan Provincial Center of Malaria Research, Pu'er, Yunnan, China.""}, {'ForeName': 'Yaming', 'Initials': 'Y', 'LastName': 'Cao', 'Affiliation': 'Department of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning, China.'}, {'ForeName': 'Lynette', 'Initials': 'L', 'LastName': 'Menezes', 'Affiliation': 'Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Liwang', 'Initials': 'L', 'LastName': 'Cui', 'Affiliation': 'Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciaa1018'] 2186,32687185,A multi-institutional randomized phase III trial comparing anatomical segmentectomy and wedge resection for clinical stage IA non-small cell lung cancer in high-risk operable patients: Japan Clinical Oncology Group Study JCOG1909 (ANSWER study).,"Anatomical segmentectomy or wedge resection is recommended for high-risk operable patients with clinical stage IA non-small cell lung cancer in guidelines of the National Comprehensive Cancer Network and the Japanese Lung Cancer Society. However, there is no clear evidence comparing the sublobar resections. The less invasive and more generally performed is wedge resection but anatomical segmentectomy may have better survival benefits than wedge resection owing to its superiority in locoregional control. In April 2020, we have initiated a randomized phase III trial in Japan to confirm the superiority of anatomical segmentectomy over wedge resection in high-risk operable patients with clinical stage IA non-small cell lung cancer. We plan to enroll a total of 370 patients from 47 institutions over a period of 5 years. The primary endpoint is overall survival; the secondary endpoints are adverse events, postoperative respiratory function, relapse-free survival, proportion of local recurrence, operative time and blood loss.",2020,"In April 2020, we have initiated a randomized phase III trial in Japan to confirm the superiority of anatomical segmentectomy over wedge resection in high-risk operable patients with clinical stage IA non-small cell lung cancer.","['high-risk operable patients', 'high-risk operable patients with clinical stage IA non-small cell lung cancer', 'high-risk operable patients with clinical stage IA non-small cell lung cancer in guidelines of the National Comprehensive Cancer Network and the Japanese Lung Cancer Society', '370 patients from 47 institutions over a period of 5\xa0years']","['anatomical segmentectomy over wedge resection', 'anatomical segmentectomy and wedge resection', 'Anatomical segmentectomy or wedge resection']","['overall survival', 'survival benefits', 'adverse events, postoperative respiratory function, relapse-free survival, proportion of local recurrence, operative time and blood loss']","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0205188', 'cui_str': 'Operable'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205563', 'cui_str': 'Clinical stage finding'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C4517743', 'cui_str': '370'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0220784', 'cui_str': 'Anatomic'}, {'cui': 'C0024885', 'cui_str': 'Partial mastectomy'}, {'cui': 'C0184909', 'cui_str': 'Wedge resection - action'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]",370.0,0.203473,"In April 2020, we have initiated a randomized phase III trial in Japan to confirm the superiority of anatomical segmentectomy over wedge resection in high-risk operable patients with clinical stage IA non-small cell lung cancer.","[{'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Shimoyama', 'Affiliation': 'JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Tsutani', 'Affiliation': 'Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Masashi', 'Initials': 'M', 'LastName': 'Wakabayashi', 'Affiliation': 'JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Katayama', 'Affiliation': 'JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Haruhiko', 'Initials': 'H', 'LastName': 'Fukuda', 'Affiliation': 'JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Suzuki', 'Affiliation': 'Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Shun-Ichi', 'Initials': 'SI', 'LastName': 'Watanabe', 'Affiliation': 'Division of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Japanese journal of clinical oncology,['10.1093/jjco/hyaa107'] 2187,32682457,"S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.","BACKGROUND S-1 plus leucovorin and oxaliplatin showed promising efficacy for treatment of advanced gastric cancer in a randomised phase 2 study. We aimed to evaluate the efficacy and safety of oral TAS-118 (S-1 plus leucovorin) and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer. METHODS We did a randomised, open-label, phase 3 trial in 62 centres across Japan and South Korea. Patients aged 20 years or older, with a histologically confirmed advanced gastric cancer with negative or unknown HER2 status, with Eastern Cooperative Oncology Group performance status of 0 or 1, measurable or evaluable metastatic lesions, and no previous treatment were randomly assigned (1:1) via an interactive web response system using the minimisation method, stratified by performance status, presence of a measurable lesion, and country, to receive TAS-118 (S-1 40-60 mg and leucovorin 25 mg orally twice daily for 7 days) plus oxaliplatin (85 mg/m 2 intravenously on day 1) every 2 weeks, or S-1 (40-60 mg orally twice daily) for 21 days plus cisplatin (60 mg/m 2 intravenously on day 1 or 8) every 5 weeks. The primary endpoint was overall survival in patients who had advanced gastric cancer with measurable or evaluable metastatic lesions and who received the study drug. Safety was assessed in all patients who received the study drug. This study was registered at ClinicalTrials.gov, NCT02322593. FINDINGS Between Jan 28, 2015, and Dec 5, 2016, 711 patients were randomised to TAS-118 plus oxaliplatin (n=356) or S-1 plus cisplatin (n=355). 11 untreated patients and 19 ineligible patients were excluded from the primary analysis (TAS-118 plus oxaliplatin group n=347, S-1 plus cisplatin group n=334) following recommendation from the independent data monitoring committee. After median follow-up of 26·0 months (IQR 22·0-32·8), median overall survival was 16·0 months (95% CI 13·8-18·3) in the TAS-118 plus oxaliplatin group and 15·1 months (95% CI 13·6-16·4) in the S-1 plus cisplatin group (hazard ratio 0·83, 95% CI 0·69-0·99; p=0·039). The most common grade 3 or higher adverse events in the 352 patients in the TAS-118 plus oxaliplatin group and the 348 patients in the S-1 plus cisplatin group were anaemia (56 [16%] vs 64 [18%]), neutropenia (54 [15%] vs 88 [25%]), decreased appetite (53 [15%] vs 46 [13%]), diarrhoea (33 [9%] vs 15 [4%]), and peripheral sensory neuropathy (30 [9%] vs one [<1%]). Serious adverse events were observed in 155 (44%) of 352 patients in the TAS-118 plus oxaliplatin group and 159 (46%) of 348 patients in the S-1 plus cisplatin group. Two treatment-related deaths occurred in the TAS-118 plus oxaliplatin group (pulmonary tuberculosis and viral pneumonia). INTERPRETATION TAS-118 plus oxaliplatin showed a clinically meaningful improvement in efficacy compared with S-1 plus cisplatin, and could be considered a new first-line treatment option for advanced gastric cancer in Asian patients. FUNDING Taiho Pharmaceutical and Yakult Honsha.",2020,"Two treatment-related deaths occurred in the TAS-118 plus oxaliplatin group (pulmonary tuberculosis and viral pneumonia). ","['advanced gastric cancer in Asian patients', 'patients with advanced gastric cancer (SOLAR', 'Patients aged 20 years or older, with a histologically confirmed advanced gastric cancer with negative or unknown HER2 status, with Eastern Cooperative Oncology Group performance status of 0 or 1, measurable or evaluable metastatic lesions, and no previous treatment', 'patients with advanced gastric cancer', 'Between Jan 28, 2015, and Dec 5, 2016, 711 patients', '11 untreated patients and 19 ineligible patients were excluded from the primary analysis ', '62 centres across Japan and South Korea', 'group n=334) following recommendation from the independent data monitoring committee', 'advanced gastric cancer', 'patients who had advanced gastric cancer with measurable or evaluable metastatic lesions and who received the study drug']","['oxaliplatin', 'TAS-118 (S-1 40-60 mg and leucovorin 25 mg orally twice daily for 7 days) plus oxaliplatin', 'TAS-118 plus oxaliplatin', 'S-1', 'leucovorin and oxaliplatin', 'cisplatin', 'S-1 plus cisplatin', 'S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin', 'oral TAS-118 (S-1 plus leucovorin) and oxaliplatin versus S-1 plus cisplatin']","['Safety', 'neutropenia', 'overall survival', 'diarrhoea', 'efficacy and safety', 'anaemia', 'peripheral sensory neuropathy', 'median overall survival', 'adverse events', 'deaths', 'decreased appetite', 'Serious adverse events']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0013175', 'cui_str': 'Clinical drug trial'}]","[{'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0559483', 'cui_str': 'Pentalogy of Cantrell'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0879262', 'cui_str': 'S 1 (combination)'}, {'cui': 'C1125365', 'cui_str': 'Leucovorin 25 MG'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0151313', 'cui_str': 'Sensory neuropathy'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0232462', 'cui_str': 'Decrease in appetite'}]",11.0,0.251793,"Two treatment-related deaths occurred in the TAS-118 plus oxaliplatin group (pulmonary tuberculosis and viral pneumonia). ","[{'ForeName': 'Yoon-Koo', 'Initials': 'YK', 'LastName': 'Kang', 'Affiliation': 'Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Keisho', 'Initials': 'K', 'LastName': 'Chin', 'Affiliation': 'Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.'}, {'ForeName': 'Hyun Cheol', 'Initials': 'HC', 'LastName': 'Chung', 'Affiliation': 'Division of Medical Oncology, Institute for Cancer Research, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea.'}, {'ForeName': 'Shigenori', 'Initials': 'S', 'LastName': 'Kadowaki', 'Affiliation': 'Department of Clinical Oncology, Aichi Cancer Centre Hospital, Aichi, Japan.'}, {'ForeName': 'Sang Cheul', 'Initials': 'SC', 'LastName': 'Oh', 'Affiliation': 'Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Norisuke', 'Initials': 'N', 'LastName': 'Nakayama', 'Affiliation': 'Department of Gastroenterology, Kanagawa Cancer Centre, Kanagawa, Japan.'}, {'ForeName': 'Keun-Wook', 'Initials': 'KW', 'LastName': 'Lee', 'Affiliation': 'Division of Haematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Hara', 'Affiliation': 'Department of Gastroenterology, Saitama Cancer Centre, Saitama, Japan.'}, {'ForeName': 'Ik-Joo', 'Initials': 'IJ', 'LastName': 'Chung', 'Affiliation': 'Department of Haematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University College of Medicine, Hwasun, South Korea.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Tsuda', 'Affiliation': 'Department of Gastroenterological Oncology, Hyogo Cancer Centre, Hyogo, Japan.'}, {'ForeName': 'Se Hoon', 'Initials': 'SH', 'LastName': 'Park', 'Affiliation': 'Department of Medicine, Division of Haematology-Oncology, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Hisashi', 'Initials': 'H', 'LastName': 'Hosaka', 'Affiliation': 'Department of Gastroenterology, Gunma Prefectural Cancer Centre, Gunma, Japan.'}, {'ForeName': 'Shuichi', 'Initials': 'S', 'LastName': 'Hironaka', 'Affiliation': 'Clinical Trial Promotion Department, Chiba Cancer Centre, Chiba, Japan.'}, {'ForeName': 'Yoshinori', 'Initials': 'Y', 'LastName': 'Miyata', 'Affiliation': 'Department of Medical Oncology, Saku Central Hospital Advanced Care Centre, Nagano, Japan.'}, {'ForeName': 'Min-Hee', 'Initials': 'MH', 'LastName': 'Ryu', 'Affiliation': 'Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Hideo', 'Initials': 'H', 'LastName': 'Baba', 'Affiliation': 'Department of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan.'}, {'ForeName': 'Ichinosuke', 'Initials': 'I', 'LastName': 'Hyodo', 'Affiliation': 'Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.'}, {'ForeName': 'Yung-Jue', 'Initials': 'YJ', 'LastName': 'Bang', 'Affiliation': 'Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Narikazu', 'Initials': 'N', 'LastName': 'Boku', 'Affiliation': 'Division of Gastrointestinal Medical Oncology, National Cancer Centre Hospital, Tokyo, Japan. Electronic address: nboku@ncc.go.jp.'}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30315-6'] 2188,32682482,Urgent endoscopic retrograde cholangiopancreatography with sphincterotomy versus conservative treatment in predicted severe acute gallstone pancreatitis (APEC): a multicentre randomised controlled trial.,"BACKGROUND It remains unclear whether urgent endoscopic retrograde cholangiopancreatography (ERCP) with biliary sphincterotomy improves the outcome of patients with gallstone pancreatitis without concomitant cholangitis. We did a randomised trial to compare urgent ERCP with sphincterotomy versus conservative treatment in patients with predicted severe acute gallstone pancreatitis. METHODS In this multicentre, parallel-group, assessor-masked, randomised controlled superiority trial, patients with predicted severe (Acute Physiology and Chronic Health Evaluation II score ≥8, Imrie score ≥3, or C-reactive protein concentration >150 mg/L) gallstone pancreatitis without cholangitis were assessed for eligibility in 26 hospitals in the Netherlands. Patients were randomly assigned (1:1) by a web-based randomisation module with randomly varying block sizes to urgent ERCP with sphincterotomy (within 24 h after hospital presentation) or conservative treatment. The primary endpoint was a composite of mortality or major complications (new-onset persistent organ failure, cholangitis, bacteraemia, pneumonia, pancreatic necrosis, or pancreatic insufficiency) within 6 months of randomisation. Analysis was by intention to treat. This trial is registered with the ISRCTN registry, ISRCTN97372133. FINDINGS Between Feb 28, 2013, and March 1, 2017, 232 patients were randomly assigned to urgent ERCP with sphincterotomy (n=118) or conservative treatment (n=114). One patient from each group was excluded from the final analysis because of cholangitis (urgent ERCP group) and chronic pancreatitis (conservative treatment group) at admission. The primary endpoint occurred in 45 (38%) of 117 patients in the urgent ERCP group and in 50 (44%) of 113 patients in the conservative treatment group (risk ratio [RR] 0·87, 95% CI 0·64-1·18; p=0·37). No relevant differences in the individual components of the primary endpoint were recorded between groups, apart from the occurrence of cholangitis (two [2%] of 117 in the urgent ERCP group vs 11 [10%] of 113 in the conservative treatment group; RR 0·18, 95% CI 0·04-0·78; p=0·010). Adverse events were reported in 87 (74%) of 118 patients in the urgent ERCP group versus 91 (80%) of 114 patients in the conservative treatment group. INTERPRETATION In patients with predicted severe gallstone pancreatitis but without cholangitis, urgent ERCP with sphincterotomy did not reduce the composite endpoint of major complications or mortality, compared with conservative treatment. Our findings support a conservative strategy in patients with predicted severe acute gallstone pancreatitis with an ERCP indicated only in patients with cholangitis or persistent cholestasis. FUNDING The Netherlands Organization for Health Research and Development, Fonds NutsOhra, and the Dutch Patient Organization for Pancreatic Diseases.",2020,"No relevant differences in the individual components of the primary endpoint were recorded between groups, apart from the occurrence of cholangitis (two [2%] of 117 in the urgent ERCP group vs 11 [10%] of 113 in the conservative treatment group; RR 0·18, 95% CI 0·04-0·78; p=0·010).","['predicted severe acute gallstone pancreatitis (APEC', 'patients with predicted severe acute gallstone pancreatitis', 'patients with predicted severe (Acute Physiology and Chronic Health Evaluation II score ≥8, Imrie score ≥3, or C-reactive protein concentration >150 mg/L) gallstone pancreatitis without cholangitis were assessed for eligibility in 26 hospitals in the Netherlands', 'Between Feb 28, 2013, and March 1, 2017', '232 patients', 'patients with cholangitis or persistent cholestasis', 'patients with gallstone pancreatitis without concomitant cholangitis', 'One patient from each group was excluded from the final analysis because of cholangitis (urgent ERCP group) and chronic pancreatitis (conservative treatment group) at admission', 'patients with predicted severe acute gallstone pancreatitis with an']","['ERCP', 'Urgent endoscopic retrograde cholangiopancreatography with sphincterotomy versus conservative treatment', 'ERCP with sphincterotomy versus conservative treatment', 'endoscopic retrograde cholangiopancreatography (ERCP) with biliary sphincterotomy', 'conservative treatment', 'ERCP with sphincterotomy']","['Adverse events', 'composite endpoint of major complications or mortality', 'composite of mortality or major complications (new-onset persistent organ failure, cholangitis, bacteraemia, pneumonia, pancreatic necrosis, or pancreatic insufficiency', 'severe gallstone pancreatitis', 'occurrence of cholangitis']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0521614', 'cui_str': 'Gallstone pancreatitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4758051', 'cui_str': 'APACHE II (Acute Physiology and Chronic Health Evaluation II) score'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0439268', 'cui_str': 'mg/L'}, {'cui': 'C0008311', 'cui_str': 'Cholangitis'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0008370', 'cui_str': 'Cholestasis'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0149521', 'cui_str': 'Chronic pancreatitis'}, {'cui': 'C0459914', 'cui_str': 'Conservative therapy'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0177047', 'cui_str': 'Sphincterotomy (bladder)'}, {'cui': 'C0459914', 'cui_str': 'Conservative therapy'}, {'cui': 'C0948386', 'cui_str': 'Biliary sphincterotomy'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0349410', 'cui_str': 'Single organ dysfunction'}, {'cui': 'C0008311', 'cui_str': 'Cholangitis'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0267941', 'cui_str': 'Acute necrotizing pancreatitis'}, {'cui': 'C0030293', 'cui_str': 'Pancreatic insufficiency'}, {'cui': 'C0521614', 'cui_str': 'Gallstone pancreatitis'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}]",232.0,0.207888,"No relevant differences in the individual components of the primary endpoint were recorded between groups, apart from the occurrence of cholangitis (two [2%] of 117 in the urgent ERCP group vs 11 [10%] of 113 in the conservative treatment group; RR 0·18, 95% CI 0·04-0·78; p=0·010).","[{'ForeName': 'Nicolien J', 'Initials': 'NJ', 'LastName': 'Schepers', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands; Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, Netherlands. Electronic address: n.schepers@antoniusziekenhuis.nl.'}, {'ForeName': 'Nora D L', 'Initials': 'NDL', 'LastName': 'Hallensleben', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands; Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Marc G', 'Initials': 'MG', 'LastName': 'Besselink', 'Affiliation': 'Department of Surgery, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Marie-Paule G F', 'Initials': 'MGF', 'LastName': 'Anten', 'Affiliation': 'Department of Gastroenterology and Hepatology, Franciscus and Vlietland Hospital, Rotterdam, Netherlands.'}, {'ForeName': 'Thomas L', 'Initials': 'TL', 'LastName': 'Bollen', 'Affiliation': 'Department of Radiology, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'da Costa', 'Affiliation': 'Department of Radiology, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Foke', 'Initials': 'F', 'LastName': 'van Delft', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Sven M', 'Initials': 'SM', 'LastName': 'van Dijk', 'Affiliation': 'Department of Surgery, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Hendrik M', 'Initials': 'HM', 'LastName': 'van Dullemen', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, Netherlands.'}, {'ForeName': 'Marcel G W', 'Initials': 'MGW', 'LastName': 'Dijkgraaf', 'Affiliation': 'Department of Clinical Epidemiology, Biostatistics, and Bioinformatics, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Casper H J', 'Initials': 'CHJ', 'LastName': 'van Eijck', 'Affiliation': 'Department of Surgery, Erasmus MC University Medical Center, Rotterdam, Netherlands.'}, {'ForeName': 'G Willemien', 'Initials': 'GW', 'LastName': 'Erkelens', 'Affiliation': 'Department of Gastroenterology and Hepatology, Gelre Hospital, Apeldoorn, Netherlands.'}, {'ForeName': 'Nicole S', 'Initials': 'NS', 'LastName': 'Erler', 'Affiliation': 'Department of Biostatistics, Erasmus MC University Medical Center, Rotterdam, Netherlands.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Fockens', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Erwin J M', 'Initials': 'EJM', 'LastName': 'van Geenen', 'Affiliation': 'Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.'}, {'ForeName': 'Janneke', 'Initials': 'J', 'LastName': 'van Grinsven', 'Affiliation': 'Department of Surgery, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Robbert A', 'Initials': 'RA', 'LastName': 'Hollemans', 'Affiliation': 'Department of Surgery, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Jeanin E', 'Initials': 'JE', 'LastName': 'van Hooft', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Rene W M', 'Initials': 'RWM', 'LastName': 'van der Hulst', 'Affiliation': 'Department of Gastroenterology and Hepatology, Spaarne Hospital, Haarlem, Netherlands.'}, {'ForeName': 'Jeroen M', 'Initials': 'JM', 'LastName': 'Jansen', 'Affiliation': 'Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands.'}, {'ForeName': 'Frank J G M', 'Initials': 'FJGM', 'LastName': 'Kubben', 'Affiliation': 'Department of Gastroenterology and Hepatology, Maasstad Hospital, Rotterdam, Netherlands.'}, {'ForeName': 'Sjoerd D', 'Initials': 'SD', 'LastName': 'Kuiken', 'Affiliation': 'Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands.'}, {'ForeName': 'Robert J F', 'Initials': 'RJF', 'LastName': 'Laheij', 'Affiliation': 'Department of Gastroenterology and Hepatology, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands.'}, {'ForeName': 'Rutger', 'Initials': 'R', 'LastName': 'Quispel', 'Affiliation': 'Department of Gastroenterology and Hepatology, Reinier de Graaf Group, Delft, Netherlands.'}, {'ForeName': 'Rogier J J', 'Initials': 'RJJ', 'LastName': 'de Ridder', 'Affiliation': 'Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, Netherlands.'}, {'ForeName': 'Marno C M', 'Initials': 'MCM', 'LastName': 'Rijk', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amphia Hospital, Breda, Netherlands.'}, {'ForeName': 'Tessa E H', 'Initials': 'TEH', 'LastName': 'Römkens', 'Affiliation': 'Department of Gastroenterology and Hepatology, Jeroen Bosch Hospital, Den Bosch, Netherlands.'}, {'ForeName': 'Carola H M', 'Initials': 'CHM', 'LastName': 'Ruigrok', 'Affiliation': 'Department of Gastroenterology and Hepatology, Reinier de Graaf Group, Delft, Netherlands.'}, {'ForeName': 'Erik J', 'Initials': 'EJ', 'LastName': 'Schoon', 'Affiliation': 'Department of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, Netherlands.'}, {'ForeName': 'Matthijs P', 'Initials': 'MP', 'LastName': 'Schwartz', 'Affiliation': 'Department of Gastroenterology and Hepatology, Meander Medical Center, Amersfoort, Netherlands.'}, {'ForeName': 'Xavier J N M', 'Initials': 'XJNM', 'LastName': 'Smeets', 'Affiliation': 'Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.'}, {'ForeName': 'B W Marcel', 'Initials': 'BWM', 'LastName': 'Spanier', 'Affiliation': 'Department of Gastroenterology and Hepatology, Rijnstate Hospital, Arnhem, Netherlands.'}, {'ForeName': 'Adriaan C I T L', 'Initials': 'ACITL', 'LastName': 'Tan', 'Affiliation': 'Department of Gastroenterology and Hepatology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands.'}, {'ForeName': 'Willem J', 'Initials': 'WJ', 'LastName': 'Thijs', 'Affiliation': 'Department of Gastroenterology and Hepatology, Martini Hospital, Groningen, Netherlands.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Timmer', 'Affiliation': 'Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Niels G', 'Initials': 'NG', 'LastName': 'Venneman', 'Affiliation': 'Department of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede, Netherlands.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Verdonk', 'Affiliation': 'Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Frank P', 'Initials': 'FP', 'LastName': 'Vleggaar', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'van de Vrie', 'Affiliation': 'Department of Gastroenterology and Hepatology, Albert Schweitzer Hospital, Dordrecht, Netherlands.'}, {'ForeName': 'Ben J', 'Initials': 'BJ', 'LastName': 'Witteman', 'Affiliation': 'Department of Gastroenterology and Hepatology, Hospital Gelderse Vallei, Ede, Netherlands.'}, {'ForeName': 'Hjalmar C', 'Initials': 'HC', 'LastName': 'van Santvoort', 'Affiliation': 'Department of Surgery, St Antonius Hospital, Nieuwegein, Netherlands; Department of Surgery, University Medical Center Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Olaf J', 'Initials': 'OJ', 'LastName': 'Bakker', 'Affiliation': 'Department of Surgery, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Marco J', 'Initials': 'MJ', 'LastName': 'Bruno', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(20)30539-0'] 2189,32682483,Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial.,"BACKGROUND Atrial fibrillation and delirium are common consequences of cardiac surgery. Dexmedetomidine has unique properties as sedative agent and might reduce the risk of each complication. This study coprimarily aimed to establish whether dexmedetomidine reduces the incidence of new-onset atrial fibrillation and the incidence of delirium. METHODS A randomised, placebo-controlled trial was done at six academic hospitals in the USA. Patients who had had cardiac surgery with cardiopulmonary bypass were enrolled. Patients were randomly assigned 1:1, stratified by site, to dexmedetomidine or normal saline placebo. Randomisation was computer generated with random permuted block size 2 and 4, and allocation was concealed by a web-based system. Patients, caregivers, and evaluators were all masked to treatment. The study drug was prepared by the pharmacy or an otherwise uninvolved research associate so that investigators and clinicians were fully masked to allocation. Participants were given either dexmedetomidine infusion or saline placebo started before the surgical incision at a rate of 0·1 μg/kg per h then increased to 0·2 μg/kg per h at the end of bypass, and postoperatively increased to 0·4 μg/kg per h, which was maintained until 24 h. The coprimary outcomes were atrial fibrillation and delirium occurring between intensive care unit admission and the earlier of postoperative day 5 or hospital discharge. All analyses were intention-to-treat. The trial is registered with ClinicalTrials.gov, NCT02004613 and is closed. FINDINGS 798 patients of 3357 screened were enrolled from April 17, 2013, to Dec 6, 2018. The trial was stopped per protocol after the last designated interim analysis. Among 798 patients randomly assigned, 794 were analysed, with 400 assigned to dexmedetomidine and 398 assigned to placebo. The incidence of atrial fibrillation was 121 (30%) in 397 patients given dexmedetomidine and 134 (34%) in 395 patients given placebo, a difference that was not significant: relative risk 0·90 (97·8% CI 0·72, 1·15; p=0·34). The incidence of delirium was non-significantly increased from 12% in patients given placebo to 17% in those given dexmedetomidine: 1·48 (97·8% CI 0·99-2·23). Safety outcomes were clinically important bradycardia (requiring treatment) and hypotension, myocardial infarction, stroke, surgical site infection, pulmonary embolism, deep venous thrombosis, and death. 21 (5%) of 394 patients given dexmedetomidine and 8 (2%) of 396 patients given placebo, had a serious adverse event as determined by clinicians. 1 (<1%) of 391 patients given dexmedetomidine and 1 (<1%) of 387 patients given placebo died. INTERPRETATION Dexmedetomidine infusion, initiated at anaesthetic induction and continued for 24 h, did not decrease postoperative atrial arrhythmias or delirium in patients recovering from cardiac surgery. Dexmedetomidine should not be infused to reduce atrial fibrillation or delirium in patients having cardiac surgery. FUNDING Hospira Pharmaceuticals.",2020,The incidence of delirium was non-significantly increased from 12% in patients given placebo to 17% in those given dexmedetomidine: 1·48 (97·8% CI 0·99-2·23).,"['six academic hospitals in the USA', '798 patients of 3357 screened were enrolled from April 17, 2013, to Dec 6, 2018', '391 patients given', 'patients recovering from cardiac surgery', '394 patients given', 'patients having cardiac surgery', '798 patients randomly assigned, 794 were analysed, with 400 assigned to', 'atrial fibrillation and delirium after cardiac surgery (DECADE', 'Patients who had had cardiac surgery with cardiopulmonary bypass were enrolled']","['dexmedetomidine infusion or saline placebo', 'dexmedetomidine or normal saline placebo', 'Dexmedetomidine', 'dexmedetomidine', 'placebo']","['incidence of atrial fibrillation', 'relative risk 0·90', 'postoperative atrial arrhythmias or delirium', 'atrial fibrillation and delirium occurring between intensive care unit admission and the earlier of postoperative day 5 or hospital discharge', 'serious adverse event', 'incidence of delirium', 'atrial fibrillation or delirium', 'important bradycardia (requiring treatment) and hypotension, myocardial infarction, stroke, surgical site infection, pulmonary embolism, deep venous thrombosis, and death', 'incidence of new-onset atrial fibrillation']","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0521108', 'cui_str': 'Recovering from'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0085611', 'cui_str': 'Atrial arrhythmia'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}]",3357.0,0.797581,The incidence of delirium was non-significantly increased from 12% in patients given placebo to 17% in those given dexmedetomidine: 1·48 (97·8% CI 0·99-2·23).,"[{'ForeName': 'Alparslan', 'Initials': 'A', 'LastName': 'Turan', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA; Department of General Anesthesiology, Cleveland Clinic, Cleveland, OH, USA. Electronic address: turana@ccf.org.'}, {'ForeName': 'Andra', 'Initials': 'A', 'LastName': 'Duncan', 'Affiliation': 'Department of Cardiovascular Anesthesiology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Leung', 'Affiliation': 'Department of Radiology, Metrohealth Hospital, Cleveland, OH, USA.'}, {'ForeName': 'Nika', 'Initials': 'N', 'LastName': 'Karimi', 'Affiliation': 'Department of Anesthesiology, University of Rochester, Rochester, NY, USA.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Fang', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Guangmei', 'Initials': 'G', 'LastName': 'Mao', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hargrave', 'Affiliation': 'Department of Cardiovascular Anesthesiology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Gillinov', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Trombetta', 'Affiliation': 'Department of Cardiovascular Anesthesiology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Sabry', 'Initials': 'S', 'LastName': 'Ayad', 'Affiliation': 'Department of Regional Practice, Cleveland Clinic, Cleveland, OH, USA; Department of General Anesthesiology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Manal', 'Initials': 'M', 'LastName': 'Hassan', 'Affiliation': 'Department of Regional Practice, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Feider', 'Affiliation': 'Department of Anesthesia, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Howard-Quijano', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA, USA.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Ruetzler', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA; Department of General Anesthesiology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Daniel I', 'Initials': 'DI', 'LastName': 'Sessler', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(20)30631-0'] 2190,32682484,"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.","BACKGROUND Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in combination with daratumumab has shown substantial efficacy with tolerable safety in relapsed or refractory multiple myeloma in a phase 1 study. In this study, we aimed to compare the efficacy and safety of carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. METHODS In this randomised, multicentre, open-label, phase 3 study, 466 patients recruited from 102 sites across North America, Europe, Australia, and Asia with relapsed or refractory multiple myeloma were randomly assigned 2:1 to carfilzomib, dexamethasone, and daratumumab (KdD) or carfilzomib and dexamethasone (Kd). All patients received twice per week carfilzomib at 56 mg/m 2 (20 mg/m 2 ; days 1 and 2 during cycle 1). Daratumumab (8 mg/kg) was administered intravenously on days 1 and 2 of cycle 1 and at 16 mg/kg weekly for the remaining doses of the first two cycles, then every 2 weeks for four cycles (cycles 3-6), and every 4 weeks thereafter. Patients received 40 mg dexamethasone weekly (20 mg for patients ≥75 years old starting on the second week). The primary endpoint was progression-free survival assessed by intention to treat. Adverse events were assessed in the safety population. This trial (NCT03158688) is registered with ClinicalTrials.gov, and is active but not recruiting. FINDINGS Between June 13, 2017, and June 25, 2018, 466 patients of 569 assessed for eligibility were enrolled. After median follow-up of approximately 17 months, median progression-free survival was not reached in the KdD group versus 15·8 months in the Kd group (hazard ratio 0·63; 95% CI 0·46-0·85; p=0·0027). Median treatment duration was longer in the KdD versus the Kd group (70·1 vs 40·3 weeks). Grade 3 or higher adverse events were reported in 253 (82%) patients in the KdD group and 113 (74%) patients in the Kd group. The frequency of adverse events leading to treatment discontinuation was similar in both groups (KdD, 69 [22%]; Kd, 38 [25%]). INTERPRETATION KdD significantly prolonged progression-free survival versus Kd in patients with relapsed or refractory multiple myeloma and was associated with a favourable benefit-risk profile. FUNDING Amgen.",2020,Median treatment duration was longer in the KdD versus the Kd group (70·1 vs 40·3 weeks).,"['patients with relapsed or refractory multiple myeloma', '466 patients recruited from 102 sites across North America, Europe, Australia, and Asia with relapsed or refractory multiple myeloma', 'Between June 13, 2017, and June 25, 2018, 466 patients of 569 assessed for eligibility were enrolled', 'patients with relapsed or refractory multiple myeloma (CANDOR']","['dexamethasone', 'carfilzomib, dexamethasone, and daratumumab (KdD) or carfilzomib and dexamethasone (Kd', 'carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone', 'Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone']","['frequency of adverse events leading to treatment discontinuation', 'median progression-free survival', 'Adverse events', 'progression-free survival', 'Median treatment duration', 'efficacy and safety', 'Grade 3 or higher adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C4551538', 'cui_str': 'Plasma cell myeloma refractory'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0003980', 'cui_str': 'Asia'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C2001856', 'cui_str': 'carfilzomib'}, {'cui': 'C2346801', 'cui_str': 'daratumumab'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0205250', 'cui_str': 'High'}]",466.0,0.106024,Median treatment duration was longer in the KdD versus the Kd group (70·1 vs 40·3 weeks).,"[{'ForeName': 'Meletios', 'Initials': 'M', 'LastName': 'Dimopoulos', 'Affiliation': 'National and Kapodistrian University Athens School of Medicine, Athens, Greece.'}, {'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Quach', 'Affiliation': ""University of Melbourne, St Vincent's Hospital, Fitzroy, VIC, Australia.""}, {'ForeName': 'Maria-Victoria', 'Initials': 'MV', 'LastName': 'Mateos', 'Affiliation': 'Cancer Research Center, University Hospital Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain.'}, {'ForeName': 'Ola', 'Initials': 'O', 'LastName': 'Landgren', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Leleu', 'Affiliation': 'Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Siegel', 'Affiliation': 'John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Weisel', 'Affiliation': 'University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Amgen, Thousand Oaks, CA, USA.'}, {'ForeName': 'Zandra', 'Initials': 'Z', 'LastName': 'Klippel', 'Affiliation': 'Amgen, Thousand Oaks, CA, USA.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Zahlten-Kumeli', 'Affiliation': 'Amgen, Thousand Oaks, CA, USA.'}, {'ForeName': 'Saad Z', 'Initials': 'SZ', 'LastName': 'Usmani', 'Affiliation': 'Atrium Health, Charlotte, NC, USA. Electronic address: usmani@atriumhealth.org.'}]","Lancet (London, England)",['10.1016/S0140-6736(20)30734-0'] 2191,32689827,Long-term outcomes of laser incision and triamcinolone injection for the management of ureteroenteric anastomotic strictures.,"PURPOSE Benign ureteroenteric anastomotic stricture (UEAS) is a common postoperative complication after urinary diversion with an incidence of 3-10%. Our objective is to report long-term follow up of our technique for endoscopically managing UEAS after cystectomy. MATERIALS AND METHODS Patients with endoscopically managed benign UEAS after cystectomy were included. Intervention entailed anetegrade flexible ureteroscopy with biopsy followed by laser incision of the stricture and of periureteral and peri-ileal tissues 1 cm below and 1 cm above the stricture into fat. Triamcinolone injection was then performed, followed by balloon dilation of the incised area to 24F. Parallel double-J ureteral stents or upside down nephrostomy tubes were placed for 6 weeks. CT scans were obtained at three months and one year after surgery, and renal ultrasound at six and nine months, and then annually. RESULTS Twenty one patients, and a total of 24 UEAS were treated. Urinary diversion included ileal conduit (n=12), neobladder (n=7), and Indiana pouch (n=2). Twenty out of 24 strictures had no recurrence, including three patients who had bilateral disease, yielding an overall success rate of 83.3%. The remaining three patients with recurrence had evidence of stricture within three months. Follow-up ranged from eight to 102 months, with a median of 30 months. CONCLUSIONS Patients treated endoscopically for UEAS have been shown to have acceptable immediate success with less morbidity when compared to ureteral reimplantation. Our technique of laser incision, triamcinolone injection, balloon dilation, and temporary stent placement has a success rate of over 80% and is unique in that long-term data confirms the durability of this endoscopic procedure.",2020,"Twenty out of 24 strictures had no recurrence, including three patients who had bilateral disease, yielding an overall success rate of 83.3%.","['ureteroenteric anastomotic strictures', 'Twenty one patients, and a total of 24 UEAS', 'Patients with endoscopically managed benign UEAS after cystectomy were included', 'Urinary diversion included ileal conduit (n=12), neobladder (n=7), and Indiana pouch (n=2']","['Triamcinolone', 'laser incision, triamcinolone injection, balloon dilation, and temporary stent placement', 'laser incision and triamcinolone injection', 'Intervention entailed anetegrade flexible ureteroscopy with biopsy followed by laser incision of the stricture and of periureteral and peri-ileal tissues 1 cm below and 1 cm above the stricture into fat']","['CT scans', 'overall success rate']","[{'cui': 'C0677554', 'cui_str': 'Anastomosis - action'}, {'cui': 'C1261287', 'cui_str': 'Stenosis'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0205183', 'cui_str': 'Benign'}, {'cui': 'C0010651', 'cui_str': 'Bladder excision'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0042020', 'cui_str': 'Urinary diversion procedure'}, {'cui': 'C0348002', 'cui_str': 'Ileal Conduit'}, {'cui': 'C0021206', 'cui_str': 'Indiana'}, {'cui': 'C4319584', 'cui_str': 'Pouch'}]","[{'cui': 'C0040864', 'cui_str': 'Triamcinolone'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C4084816', 'cui_str': 'Triamcinolone Injection'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0205374', 'cui_str': 'Transitory'}, {'cui': 'C0522776', 'cui_str': 'Placement of stent'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0443220', 'cui_str': 'Flexible'}, {'cui': 'C1279395', 'cui_str': 'Ureteroscopy with biopsy'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C1261287', 'cui_str': 'Stenosis'}, {'cui': 'C0227328', 'cui_str': 'Structure of peri-ileal tissue'}, {'cui': 'C0015677', 'cui_str': 'Fat'}]","[{'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",24.0,0.0443233,"Twenty out of 24 strictures had no recurrence, including three patients who had bilateral disease, yielding an overall success rate of 83.3%.","[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Katims', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, 5925, Urology, New York, New York, United States; andrew.katims@mountsinai.org.'}, {'ForeName': 'Beth T', 'Initials': 'BT', 'LastName': 'Edelblute', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, 5925, Urology, New York, New York, United States; beth.edelblute@mountsinai.org.'}, {'ForeName': 'Andrew W', 'Initials': 'AW', 'LastName': 'Tam', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, 5925, Urology, New York, New York, United States; andrew.tam1@mountsinai.org.'}, {'ForeName': 'Anna M', 'Initials': 'AM', 'LastName': 'Zampini', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, 5925, New York, New York, United States; anna.zampini@mountsinai.org.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Mehrazin', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, 5925, Urology, New York, New York, United States; reza.mehrazin@mountsinai.org.'}, {'ForeName': 'Mantu', 'Initials': 'M', 'LastName': 'Gupta', 'Affiliation': 'Mount Sinai Health System, 5944, Urology, 425 W. 59th Street, New York, New York, United States, 10019; mantu.gupta@mountsinai.org.'}]",Journal of endourology,['10.1089/end.2020.0593'] 2192,32689839,Inspiratory Muscle Training Potentiates the Beneficial Effects of Proportional Assisted Ventilation on Exertional Dyspnea and Exercise Tolerance in COPD: A Proof-of-Concept Randomized and Controlled Trial.,"During pulmonary rehabilitation, a subset of subjects with COPD requires adjunct therapy to achieve high-intensity training. Both noninvasive ventilation (NIV) and inspiratory muscle training (IMT) are available to assist these subjects. We aimed to prime the respiratory muscles before NIV with IMT, anticipating additive effects for maximal exercise tolerance ( T lim ) and dyspnea/leg fatigue relief throughout the exercise as primary outcomes. Changes in the respiratory pattern were secondary outcomes. COPD subjects performed a total of four identical constant work rate tests on a cycle ergometer at 75% of maximum work rate, under control ventilation (SHAM, 4 cm H 2 O) or proportional assisted ventilation (PAV, individually adjusted), before and after 10 sessions of high-intensity IMT (three times/week) during 30 days. Two-way RM ANOVA with appropriate corrections were performed. Final analysis in nine subjects showed improved T lim (Δ = 111 s) and lower minute-ventilation (Δ = 4 L . min -1 ) at exhaustion, when comparing the IMT effects within the PAV modality ( p =  0.001 and p =  0.036, respectively) and improved T lim for PAV vs. SHAM (PAV main-effect, p  = 0.001; IMT main-effect, p  = 0.006; PAV vs. IMT interaction, p  = 0.034). In addition, IMT + PAV association, compared to PAV alone, resulted in lower respiratory frequency (IMT main-effect, p  = 0.009; time main-effect, p  < 0.0001; IMT vs. time interaction, p  = 0.242) and lower inspiratory time related to duty cycle (IMT main-effect, p  = 0.018; time main-effect, p  = 0.0001; IMT vs. time interaction, p  = 0.004) throughout exercise. The addition of IMT prior to a PAV-supported aerobic bout potentiates exercise tolerance and dyspnea relief and induces favourable changes in ventilatory pattern in severe COPD during high-intensity training ( Brazilian Registry of Clinical Trials , number RBR-6n3dzz).",2020,"min -1 ) at exhaustion, when comparing the IMT effects within the PAV modality ( p =  0.001 and p =  0.036, respectively) and improved T lim for PAV vs. SHAM","['COPD subjects', 'COPD']","['control ventilation (SHAM, 4\u2009cm H 2 O) or proportional assisted ventilation', 'SHAM', 'noninvasive ventilation (NIV) and inspiratory muscle training (IMT', 'Proportional Assisted Ventilation', 'Inspiratory Muscle Training', 'IMT']","['lower minute-ventilation', 'Exertional Dyspnea and Exercise Tolerance', 'maximal exercise tolerance ( T lim ) and dyspnea/leg fatigue relief', 'lower inspiratory time related to duty cycle (IMT main-effect']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}]","[{'cui': 'C0419011', 'cui_str': 'Controlled ventilation'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C3178855', 'cui_str': 'Proportional Assist Ventilation'}, {'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}, {'cui': 'C0454511', 'cui_str': 'Inspiratory muscle training'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1301655', 'cui_str': 'Minute ventilation'}, {'cui': 'C0231807', 'cui_str': 'Dyspnea on exertion'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0449205', 'cui_str': 'LIM'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0428686', 'cui_str': 'Inspiratory time'}, {'cui': 'C0454511', 'cui_str': 'Inspiratory muscle training'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",,0.0682771,"min -1 ) at exhaustion, when comparing the IMT effects within the PAV modality ( p =  0.001 and p =  0.036, respectively) and improved T lim for PAV vs. SHAM","[{'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Koch', 'Affiliation': 'Laboratory of Respiratory Pathophysiology (LAFIR), Maria Aparecida Pedrossian Universitary Hospital (HUMAP), Campo Grande, Mato Grosso do Sul, Brazil.'}, {'ForeName': 'Tiago Rodrigues de Lemos', 'Initials': 'TRL', 'LastName': 'Augusto', 'Affiliation': 'Laboratory of Respiratory Pathophysiology (LAFIR), Maria Aparecida Pedrossian Universitary Hospital (HUMAP), Campo Grande, Mato Grosso do Sul, Brazil.'}, {'ForeName': 'Alessandro Gomes', 'Initials': 'AG', 'LastName': 'Ramos', 'Affiliation': 'Laboratory of Respiratory Pathophysiology (LAFIR), Maria Aparecida Pedrossian Universitary Hospital (HUMAP), Campo Grande, Mato Grosso do Sul, Brazil.'}, {'ForeName': 'Paulo de Tarso', 'Initials': 'PT', 'LastName': 'Müller', 'Affiliation': 'Laboratory of Respiratory Pathophysiology (LAFIR), Maria Aparecida Pedrossian Universitary Hospital (HUMAP), Campo Grande, Mato Grosso do Sul, Brazil.'}]",COPD,['10.1080/15412555.2020.1789085'] 2193,32689849,Assessment of two prophylactic fluid strategies in aneurysmal subarachnoid hemorrhage: A randomized trial.,"OBJECTIVE To compare the effect of two prophylactic euvolemic fluid strategy regimens on the incidence of cerebral vasospasm and clinical outcomes in patients with aneurysmal subarachnoid hemorrhage (SAH). METHODS Ninety-six patients with a basal intravenous intake of 15 mL/kg/day of Ringer's lactate solution were included, and an additional 15 to 50 mL/kg/day Ringer's lactate (RL-group) or hydroxyethyl starch 130/0.4 solution (HES-group) was administered to maintain the targeted mean arterial pressure. The primary end point was the occurrence of cerebral vasospasm during the first 14 days. The secondary end points were case fatality, Barthel's index, and Glasgow Outcome Scores (GOS) at 30 days after SAH. RESULTS Cerebral vasospasm developed in 42 patients (43.7%), and nine of these events were severe. The vasospasm rate among the RL- and HES-based groups was 25/48 and 17/48, respectively. For the secondary endpoint, four patients (4%) died by the end of follow-up (two in each group). Unfavorable outcome cases were not different in the RL and HES groups (9 vs. 14, respectively). There was no difference between the Barthel's scores at 30 days between the two groups. CONCLUSIONS Using starches in a prophylactic treatment strategy in aneurysmal SAH in not supported by the study.The trial was registered at Clinicaltrials.gov under the number NCT02064075.",2020,"RESULTS Cerebral vasospasm developed in 42 patients (43.7%), and nine of these events were severe.","['aneurysmal subarachnoid hemorrhage', ""Ninety-six patients with a basal intravenous intake of 15 mL/kg/day of Ringer's lactate solution"", 'patients with aneurysmal subarachnoid hemorrhage (SAH']","['prophylactic euvolemic fluid strategy regimens', ""Ringer's lactate (RL-group) or hydroxyethyl starch 130/0.4 solution (HES-group) was administered to maintain the targeted mean arterial pressure""]","[""Barthel's scores"", 'cerebral vasospasm and clinical outcomes', 'vasospasm rate', 'Cerebral vasospasm', 'occurrence of cerebral vasospasm', ""case fatality, Barthel's index, and Glasgow Outcome Scores (GOS""]","[{'cui': 'C0751530', 'cui_str': 'Subarachnoid Hemorrhage, Aneurysmal'}, {'cui': 'C4319625', 'cui_str': '96'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C1532579', 'cui_str': 'mL/kg/day'}, {'cui': 'C0073385', 'cui_str': ""Lactated Ringer's Solution""}, {'cui': 'C0038525', 'cui_str': 'Subarachnoid hemorrhage'}]","[{'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0073385', 'cui_str': ""Lactated Ringer's Solution""}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3495434', 'cui_str': 'hydroxyethyl starch 130-0.4'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0265110', 'cui_str': 'Spasm of cerebral arteries'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0042396', 'cui_str': 'Vascular constriction'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}]",96.0,0.232831,"RESULTS Cerebral vasospasm developed in 42 patients (43.7%), and nine of these events were severe.","[{'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Gál', 'Affiliation': 'Department of Anesthesiology and Intensive Care, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}, {'ForeName': 'Béla', 'Initials': 'B', 'LastName': 'Fülesdi', 'Affiliation': 'Department of Anesthesiology and Intensive Care, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}, {'ForeName': 'Dávid', 'Initials': 'D', 'LastName': 'Varga', 'Affiliation': 'Department of Anesthesiology and Intensive Care, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}, {'ForeName': 'Babett', 'Initials': 'B', 'LastName': 'Fodor', 'Affiliation': 'Department of Anesthesiology and Intensive Care, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}, {'ForeName': 'Eszter', 'Initials': 'E', 'LastName': 'Varga', 'Affiliation': 'Department of Anesthesiology and Intensive Care, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}, {'ForeName': 'Péter', 'Initials': 'P', 'LastName': 'Siró', 'Affiliation': 'Department of Anesthesiology and Intensive Care, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}, {'ForeName': 'Dániel', 'Initials': 'D', 'LastName': 'Bereczki', 'Affiliation': 'Department of Neurology Semmelweis University, Budapest, Hungary.'}, {'ForeName': 'Sándor', 'Initials': 'S', 'LastName': 'Szabó', 'Affiliation': 'Department of Neurosurgery, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}, {'ForeName': 'Csilla', 'Initials': 'C', 'LastName': 'Molnár', 'Affiliation': 'Department of Anesthesiology and Intensive Care, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}]",The Journal of international medical research,['10.1177/0300060520927526'] 2194,32689975,"A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial.","BACKGROUND Currently recommended boosted protease-inhibitor (bPI) regimens may be associated with increased risk of cardiovascular or chronic kidney diseases; in addition, boosted regimens are particularly associated with drug-drug interactions. Since both cardiovascular and renal disease, and polypharmacy, are common in ageing people with HIV, there is a need for alternative efficacious regimens. bPI-based regimens are often the treatment of choice for individuals with pre-treatment or treatment-acquired resistance but it is plausible that carefully selected HIV-positive individuals with drug resistance, who are virologically suppressed on their current bPI regimen, could maintain virological efficacy when switched to bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) fixed dose combination (FDC). METHODS/DESIGN A phase IV, investigator-initiated, multicentre, open label pilot, randomised two-arm study to assess the safety and efficacy of switching from bPI regimen to B/F/TAF single tablet regimen in integrase inhibitor-naïve, virologically suppressed adults with HIV-1 infection harbouring drug resistance mutations. Eligible individuals will either continue on their bPI regimen or switch to B/F/TAF FDC. After 24 weeks, all participants in the bPI arm will be switched to B/F/TAF and followed for a further 24 weeks and all participants will be followed for 48 weeks. The primary efficacy endpoint is the proportion of participants with HIV-1 RNA < 50 copies/mL at week 24 using pure virologic response whilst the secondary efficacy endpoint is the proportion of participants with HIV-1 RNA < 50 copies/mL at Week 48. Other secondary outcome measures include between arm comparisons of drug resistance at virological failure, safety and tolerability and patient-reported outcome measures. DISCUSSION We aim to provide preliminary evidence of the efficacy of switching to B/F/TAF in patients with virological suppression on a bPI-based regimen who harbour select drug resistance mutations. TRIAL REGISTRATION ISRCTN 44453201 , registered 19 June 2019 and EudraCT 2018-004732-30.",2020,The primary efficacy endpoint is the proportion of participants with HIV-1 RNA < 50 copies/mL at week 24 using pure virologic response whilst the secondary efficacy endpoint is the proportion of participants with HIV-1 RNA < 50 copies/mL at Week 48.,"['Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study', 'patients with virological suppression on a bPI-based regimen who harbour select drug resistance mutations', 'integrase inhibitor-naïve, virologically suppressed adults with HIV-1 infection harbouring drug resistance mutations', '44453201 , registered 19 June 2019 and EudraCT 2018-004732-30', 'Eligible individuals will either continue on their bPI regimen or switch to B/F/TAF FDC']","['Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen', 'switching to B/F/TAF']","['safety and efficacy', 'drug resistance at virological failure, safety and tolerability and patient-reported outcome measures', 'proportion of participants with HIV-1 RNA']","[{'cui': 'C0376601', 'cui_str': 'Integrase strand transfer inhibitor-containing product'}, {'cui': 'C1260953', 'cui_str': 'Suppressed'}, {'cui': 'C0019704', 'cui_str': 'Human immunodeficiency virus type I'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0475311', 'cui_str': 'Harbor'}, {'cui': 'C0013203', 'cui_str': 'Drug resistance'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0033607', 'cui_str': 'Peptide hydrolase inhibitor'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C2363741', 'cui_str': 'HIV-1 infection'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C1450557', 'cui_str': 'IGFBP7 protein, human'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]","[{'cui': 'C4542162', 'cui_str': 'emtricitabine, tenofovir alafenamide and bictegravir'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C1450557', 'cui_str': 'IGFBP7 protein, human'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0013203', 'cui_str': 'Drug resistance'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C4277735', 'cui_str': 'Patient Reported Outcome Measures'}, {'cui': 'C0369499', 'cui_str': 'Human immunodeficiency virus 1 RNA'}]",,0.162955,The primary efficacy endpoint is the proportion of participants with HIV-1 RNA < 50 copies/mL at week 24 using pure virologic response whilst the secondary efficacy endpoint is the proportion of participants with HIV-1 RNA < 50 copies/mL at Week 48.,"[{'ForeName': 'Collins C', 'Initials': 'CC', 'LastName': 'Iwuji', 'Affiliation': 'Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton, BN1 9PX, UK. c.iwuji@bsms.ac.uk.'}, {'ForeName': 'Duncan', 'Initials': 'D', 'LastName': 'Churchill', 'Affiliation': 'Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Bremner', 'Affiliation': 'Department of Primary Care and Public Health, Brighton and Sussex Medical School, University of Sussex, Brighton, UK.'}, {'ForeName': 'Nicky', 'Initials': 'N', 'LastName': 'Perry', 'Affiliation': 'Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.'}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'To', 'Affiliation': 'Brighton & Sussex Clinical Trials Unit, University of Sussex, Brighton, UK.'}, {'ForeName': 'Debbie', 'Initials': 'D', 'LastName': 'Lambert', 'Affiliation': 'Brighton & Sussex Clinical Trials Unit, University of Sussex, Brighton, UK.'}, {'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Bruce', 'Affiliation': 'Brighton & Sussex Clinical Trials Unit, University of Sussex, Brighton, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Waters', 'Affiliation': 'The Mortimer Market Centre, Central and North West London NHS Foundation Trust, London, UK.'}, {'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Orkin', 'Affiliation': 'Barts Health NHS Trust, London, UK.'}, {'ForeName': 'Anna Maria', 'Initials': 'AM', 'LastName': 'Geretti', 'Affiliation': 'Institute of Infection, University of Liverpool, Liverpool, UK.'}]",BMC infectious diseases,['10.1186/s12879-020-05240-y'] 2195,32689993,"Evaluating the effect of an educational program on increasing cervical cancer screening behavior among rural women in Guilan, Iran.","BACKGROUND Cervical cancer is one of the major health problems and the third prevalent cancer in women all around the world. As a simple, inexpensive, and with no side-effects, Pap test is a reliable way to screen cervical cancer. This study aimed to investigate, the effects of educational intervention based on the Health Belief Model (HBM) on doing Pap smear tests among the rural women of the north of Iran. METHODS In a quasi-experimental study, 160 rural women were randomly divided into control and experimental groups to experience a three-session intervention. The experimental group received the usual educational programs of rural health center and educational programs based on the HBM constructs through personal consultation, asking/answering questions, and an educational pamphlet. The control group, received the usual educational programs of rural health center. The post-test data were collected 2 months after the intervention and analyzed in SPSS-18. RESULTS Before the intervention, there was no significant difference between the control and experimental groups regarding the mean score of knowledge, performance and constructs of the HBM. After the intervention, however, there was a significant difference in the mean scores of knowledge performance and all constructs of the HBM in two groups (p < 0.001). Rate of doing the Pap smear test in the experimental group increased from 18.7 to 78.7% in the intervention group. CONCLUSION These findings support the effectiveness of cervical cancer prevention programs based on the HBM. Therefore, conducting similar programs in other regions is recommended.",2020,"Before the intervention, there was no significant difference between the control and experimental groups regarding the mean score of knowledge, performance and constructs of the HBM.","['rural women of the north of Iran', '160 rural women', 'rural women in Guilan, Iran']","['educational program', 'usual educational programs of rural health center', 'Health Belief Model (HBM', 'usual educational programs of rural health center and educational programs based on the HBM constructs through personal consultation, asking/answering questions, and an educational pamphlet', 'educational intervention']","['Rate of doing the Pap smear test', 'cervical cancer screening behavior', 'mean score of knowledge, performance and constructs of the HBM', 'mean scores of knowledge performance and all constructs of the HBM']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C4319554', 'cui_str': '160'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0035960', 'cui_str': 'Rural health center'}, {'cui': 'C3714363', 'cui_str': 'Health belief model'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0012931', 'cui_str': 'Recombinant DNA'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C1172410', 'cui_str': 'ASK protein, human'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0079104', 'cui_str': 'Smear cervix'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0012931', 'cui_str': 'Recombinant DNA'}, {'cui': 'C3714363', 'cui_str': 'Health belief model'}]",160.0,0.0155,"Before the intervention, there was no significant difference between the control and experimental groups regarding the mean score of knowledge, performance and constructs of the HBM.","[{'ForeName': 'Sedighe Bab', 'Initials': 'SB', 'LastName': 'Eghbal', 'Affiliation': 'Reproductive Health Research Center, Department of Obstetrics and Gynecology, Al-Zahra Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.'}, {'ForeName': 'Mahmood', 'Initials': 'M', 'LastName': 'Karimy', 'Affiliation': 'Department of public health, faculty of health, Social Determinants of Health Research Center, Saveh University of medical sciences, Saveh, Iran.'}, {'ForeName': 'Parisa', 'Initials': 'P', 'LastName': 'Kasmaei', 'Affiliation': 'Department of Health Education and Promotion, Research Center of Health and Environment, School of Health, Guilan University of Medical Sciences, Rasht, Iran. kasmayparisa@yahoo.com.'}, {'ForeName': 'Zahra Atrkar', 'Initials': 'ZA', 'LastName': 'Roshan', 'Affiliation': 'Department of Social Medicine, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.'}, {'ForeName': 'Roghieh', 'Initials': 'R', 'LastName': 'Valipour', 'Affiliation': 'Department of public health, Mazandaran Training & Education Organization, Babol, Iran.'}, {'ForeName': 'Seyedeh Maryam', 'Initials': 'SM', 'LastName': 'Attari', 'Affiliation': 'Reproductive Health Research Center, Department of Obstetrics and Gynecology, Al-Zahra Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.'}]",BMC women's health,['10.1186/s12905-020-01020-7'] 2196,32690001,"Low-level laser therapy effectiveness in reducing initial orthodontic archwire placement pain in premolars extraction cases: a single-blind, placebo-controlled, randomized clinical trial.","BACKGROUND The objective of this randomized clinical trial was to evaluate Low-Level Laser Therapy (LLLT) effectiveness in spontaneous and chewing pain reduction following initial orthodontic archwire placement. METHODS 26 patients (mean age 20.07 ± 3.13 years) with maxillary Little's Irregularity Index (LII) of 7 mm or more that indicates first maxillary premolars extraction and no medications intake were eligible for this trial. Patients were randomly assigned with 1:1 ratio using simple randomization technique to receive either LLL or placebo treatment. Blinding was applicable for patients only. In the laser group, patients received a single LLL dose (wavelength 830 nm, energy 2 J/point) in four points (2 buccal, 2 palatal) for each maxillary anterior tooth root. Patients in the placebo group had the same laser application procedure without emitting the laser beam. Patients were asked to score spontaneous and chewing pain intensity by filling out a questionnaire with a 100-mm Visual Analogue Scale (VAS) after 1, 6, 24, 48, and 72 h of treatment application. Independent t-test was used to compare the mean pain scores between the laser and placebo groups for both spontaneous and chewing pain at each studied time point. RESULTS No dropout occurred so the results of the 26 patients were statistically analyzed. Despite some clinical differences observed between the two groups, no statistical significance was found for each studied time point (p > 0.05) for both spontaneous and chewing pain except after 72 h for chewing pain with a VAS score of (18.84 ± 13.44) mm for the laser group compared to (38.15 ± 27.06) mm for the placebo group. CONCLUSIONS LLLT, with the suggested parameters, is not effective in pain reduction following initial orthodontic archwire placement. TRIAL REGISTRATION Name of the registry: Clinicaltrials.gov Trial registration number: NCT02568436. Date of registration: 26 September 2015 'Retrospectively registered'.",2020,"Despite some clinical differences observed between the two groups, no statistical significance was found for each studied time point (p > 0.05) for both spontaneous and chewing pain except after 72 h for chewing pain with a VAS score of (18.84 ± 13.44) mm for the laser group compared to (38.15 ± 27.06) mm for the placebo group. ","['premolars extraction cases', ""26 patients (mean age 20.07\u2009±\u20093.13\u2009years) with maxillary Little's Irregularity Index (LII) of 7\u2009mm or more that indicates first maxillary premolars extraction and no medications intake were eligible for this trial""]","['Low-level laser therapy effectiveness', 'Low-Level Laser Therapy (LLLT', 'LLL or placebo treatment', 'single LLL', 'placebo']","['pain reduction', 'score spontaneous and chewing pain intensity by filling out a questionnaire with a 100-mm Visual Analogue Scale (VAS', 'mean pain scores']","[{'cui': 'C1704302', 'cui_str': 'Structure of premolar tooth'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C5191364', 'cui_str': '3.13'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0023882', 'cui_str': 'Spastic diplegia'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1261077', 'cui_str': 'Structure of lower lobe of left lung'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0037179', 'cui_str': 'Single person'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0024888', 'cui_str': 'Mastication'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",26.0,0.624408,"Despite some clinical differences observed between the two groups, no statistical significance was found for each studied time point (p > 0.05) for both spontaneous and chewing pain except after 72 h for chewing pain with a VAS score of (18.84 ± 13.44) mm for the laser group compared to (38.15 ± 27.06) mm for the placebo group. ","[{'ForeName': 'Mohammad Moaffak A', 'Initials': 'MMA', 'LastName': 'AlSayed Hasan', 'Affiliation': 'Department of Orthodontics and Dentofacial Orthopaedics, Faculty of Dental Medicine, Damascus University, Damascus, Syria. drmoaffak89@gmail.com.'}, {'ForeName': 'Kinda', 'Initials': 'K', 'LastName': 'Sultan', 'Affiliation': 'Department of Orthodontics and Dentofacial Orthopaedics, Faculty of Dental Medicine, Damascus University, Damascus, Syria.'}, {'ForeName': 'Mowaffak', 'Initials': 'M', 'LastName': 'Ajaj', 'Affiliation': 'Department of Orthodontics and Dentofacial Orthopaedics, Faculty of Dental Medicine, Damascus University, Damascus, Syria.'}, {'ForeName': 'Iva', 'Initials': 'I', 'LastName': 'Voborná', 'Affiliation': 'Department of Prosthodontics, Institute of Dentistry and Oral Sciences, Palacký University in Olomouc, Olomouc, Czech Republic.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Hamadah', 'Affiliation': 'Department of Oral Medicine, Faculty of Dental Medicine, Damascus University, Damascus, Syria.'}]",BMC oral health,['10.1186/s12903-020-01191-7'] 2197,32690008,PACE-IT study protocol: a stepped wedge cluster randomised controlled trial evaluating the implementation of telehealth visual assessment in emergency care for people living in residential aged-care facilities.,"BACKGROUND Transfer of residential aged-care facility (RACF) residents to Emergency Departments (ED) is common, risky and expensive. RACF residents who present to ED are more likely to have hospital readmissions, longer stays and face major risks related to hospital acquired complications. Aged Care Emergency services (ACE) is a nurse led, protocol- guided, telephone RACF/ED outreach model that has been shown to be effective in reducing hospitalisation and length of hospital stay for RACF residents in the Hunter New England Local Health District, New South Wales (NSW). The Partnerships in Aged-Care Emergency services using Interactive Telehealth (PACE-IT) project enhances ACE by incorporating interactive video assessment and consultation. The PACE-IT project's primary aim is to assess whether augmentation of ACE services through the addition of protocol-guided interactive Visual Telehealth Consultation (VTC) for clinical decision-making, plus telephone follow-up, reduces RACF resident transfers to ED. METHODS A stepped-wedge cluster randomised controlled trial will be conducted. The intervention will be delivered sequentially to 8 clusters; each cluster comprises one ED and two RACFs in NSW, Australia. The 16 RACFs in the study will be selected for order of implementation using a computer-generated randomisation sequence. A 2-step randomisation process will be undertaken, randomising the hospital EDs first and then randomising the RACFs aligned with each hospital. The PACE-IT intervention comprises: an initial phone call by RACFs to the ACE service in the ED; the ACE service in ED responds with a protocol-guided VTC, a management plan agreed between all participants; an automated consultation summary letter to the General Practitioner and the RACF; a post VTC 24 h follow-up phone call to the RACF. DISCUSSION If shown to be effective, the intervention has the potential to improve the clinical care and quality of life for residents. Findings will provide high level evidence that will inform sustainable change and broad translation into practice across NSW. It will show how the change has been achieved and highlight success factors for scalability and sustainability. It will inform review of processes, the development of policy and guidelines that will integrate PACE-IT into existing service models in NSW. TRIAL REGISTRATION The trial is registered with the Australian New Zealand Clinical Trials Registry (Trial ID ACTR N12619001692123 ) 02/12/2020.).",2020,"RACF residents who present to ED are more likely to have hospital readmissions, longer stays and face major risks related to hospital acquired complications.","['residential aged-care facility (RACF) residents to Emergency Departments (ED', 'people living in residential aged-care facilities', 'Aged-Care Emergency services', 'Aged Care Emergency services (ACE', 'RACF residents in the Hunter New England Local Health District, New South Wales (NSW']","['telehealth visual assessment', 'automated consultation summary letter to the General Practitioner and the RACF; a post VTC 24\u2009h follow-up phone call to the RACF']",[],"[{'cui': 'C0419193', 'cui_str': 'Care of aged'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0013961', 'cui_str': 'Emergency medical services'}, {'cui': 'C0027965', 'cui_str': 'Northeastern United States'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0043015', 'cui_str': 'Wales'}]","[{'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0419193', 'cui_str': 'Care of aged'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}]",[],,0.103282,"RACF residents who present to ED are more likely to have hospital readmissions, longer stays and face major risks related to hospital acquired complications.","[{'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Sunner', 'Affiliation': 'Hunter New England Nursing and Midwifery Research Centre, James Fletcher Campus, 72 Watt Street, Newcastle, NSW, 2300, Australia. Carla.sunner@health.nsw.gov.au.'}, {'ForeName': 'Michelle Therese', 'Initials': 'MT', 'LastName': 'Giles', 'Affiliation': 'Hunter New England Nursing and Midwifery Research Centre, James Fletcher Campus, 72 Watt Street, Newcastle, NSW, 2300, Australia.'}, {'ForeName': 'Vicki', 'Initials': 'V', 'LastName': 'Parker', 'Affiliation': 'Hunter New England Nursing and Midwifery Research Centre, James Fletcher Campus, 72 Watt Street, Newcastle, NSW, 2300, Australia.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Dilworth', 'Affiliation': 'Dementia Advisory Service Community Aged Care Services, Hunter New England Local Health District, Locked Bay 119, Wallsend, NSW, 2287, Australia.'}, {'ForeName': 'Kamana', 'Initials': 'K', 'LastName': 'Bantawa', 'Affiliation': 'Hunter New England Nursing and Midwifery Research Centre, James Fletcher Campus, 72 Watt Street, Newcastle, NSW, 2300, Australia.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Kable', 'Affiliation': 'School of Nursing and Midwifery, University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Oldmeadow', 'Affiliation': 'Hunter Medical Research Institute, Locked Bag 1000, Kookaburra Circuit, New Lambton, NSW, 2305, Australia.'}, {'ForeName': 'Maralyn', 'Initials': 'M', 'LastName': 'Foureur', 'Affiliation': 'Hunter New England Nursing and Midwifery Research Centre, James Fletcher Campus, 72 Watt Street, Newcastle, NSW, 2300, Australia.'}]",BMC health services research,['10.1186/s12913-020-05539-1'] 2198,32690032,Timing-dependent effects of transcranial direct current stimulation with mirror therapy on daily function and motor control in chronic stroke: a randomized controlled pilot study.,"BACKGROUND The timing of transcranial direct current stimulation (tDCS) with neurorehabilitation interventions may affect its modulatory effects. Motor function has been reported to be modulated by the timing of tDCS; however, whether the timing of tDCS would also affect restoration of daily function and upper extremity motor control with neurorehabilitation in stroke patients remains largely unexplored. Mirror therapy (MT) is a potentially effective neurorehabilitation approach for improving paretic arm function in stroke patients. This study aimed to determine whether the timing of tDCS with MT would influence treatment effects on daily function, motor function and motor control in individuals with chronic stroke. METHODS This study was a double-blinded randomized controlled trial. Twenty-eight individuals with chronic stroke received one of the following three interventions: (1) sequentially combined tDCS with MT (SEQ), (2) concurrently combined tDCS with MT (CON), and (3) sham tDCS with MT (SHAM). Participants received interventions for 90 min/day, 5 days/week for 4 weeks. Daily function was assessed using the Nottingham Extended Activities of Daily Living Scale. Upper extremity motor function was assessed using the Fugl-Meyer Assessment Scale. Upper extremity motor control was evaluated using movement kinematic assessments. RESULTS There were significant differences in daily function between the three groups. The SEQ group had greater improvement in daily function than the CON and SHAM groups. Kinematic analyses showed that movement time of the paretic hand significantly reduced in the SEQ group after interventions. All three groups had significant improvement in motor function from pre-intervention to post-intervention. CONCLUSION The timing of tDCS with MT may influence restoration of daily function and movement efficiency of the paretic hand in chronic stroke patients. Sequentially applying tDCS prior to MT seems to be advantageous for enhancing daily function and hand movement control, and may be considered as a potentially useful strategy in future clinical application. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02827864 . Registered on 29th June, 2016.",2020,Mirror therapy (MT) is a potentially effective neurorehabilitation approach for improving paretic arm function in stroke patients.,"['Twenty-eight individuals with chronic stroke', 'individuals with chronic stroke', 'stroke patients', 'chronic stroke', 'chronic stroke patients']","['combined tDCS with MT (SEQ), (2) concurrently combined tDCS with MT (CON), and (3) sham tDCS with MT (SHAM', 'SEQ', 'tDCS with MT', 'transcranial direct current stimulation (tDCS) with neurorehabilitation interventions', 'Mirror therapy (MT', 'CON', 'transcranial direct current stimulation with mirror therapy']","['daily function, motor function and motor control', 'Upper extremity motor function', 'daily function and motor control', 'daily function', 'movement time of the paretic', 'Nottingham Extended Activities of Daily Living Scale', 'motor function', 'Daily function']","[{'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0181868', 'cui_str': 'Mirror'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0204096', 'cui_str': 'Neurological rehabilitation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",28.0,0.17181,Mirror therapy (MT) is a potentially effective neurorehabilitation approach for improving paretic arm function in stroke patients.,"[{'ForeName': 'Wan-Wen', 'Initials': 'WW', 'LastName': 'Liao', 'Affiliation': 'Department of Occupational Therapy and Graduate Institute of Behavioral Sciences, College of Medicine, Chang Gung University, 259 Wen-hwa 1st Road, Taoyuan City, Taiwan.'}, {'ForeName': 'Wei-Chi', 'Initials': 'WC', 'LastName': 'Chiang', 'Affiliation': 'Department of Occupational Therapy, I-Shou University, Kaohsiung, Taiwan.'}, {'ForeName': 'Keh-Chung', 'Initials': 'KC', 'LastName': 'Lin', 'Affiliation': 'School of Occupational Therapy, College of Medicine, National Taiwan University, Taipei, Taiwan.'}, {'ForeName': 'Ching-Yi', 'Initials': 'CY', 'LastName': 'Wu', 'Affiliation': 'Department of Occupational Therapy and Graduate Institute of Behavioral Sciences, College of Medicine, Chang Gung University, 259 Wen-hwa 1st Road, Taoyuan City, Taiwan. cywu@mail.cgu.edu.tw.'}, {'ForeName': 'Chien-Ting', 'Initials': 'CT', 'LastName': 'Liu', 'Affiliation': 'Department of Rehabilitation, Taipei Tzu Chi Hospital, The Buddhist Tzu-Chi Medical Foundation, Taipei, Taiwan.'}, {'ForeName': 'Yu-Wei', 'Initials': 'YW', 'LastName': 'Hsieh', 'Affiliation': 'Department of Occupational Therapy and Graduate Institute of Behavioral Sciences, College of Medicine, Chang Gung University, 259 Wen-hwa 1st Road, Taoyuan City, Taiwan.'}, {'ForeName': 'Yun-Chung', 'Initials': 'YC', 'LastName': 'Lin', 'Affiliation': 'Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Chia-Ling', 'Initials': 'CL', 'LastName': 'Chen', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Linkou, Taiwan.'}]",Journal of neuroengineering and rehabilitation,['10.1186/s12984-020-00722-1'] 2199,32690147,"Association of rs670 variant of APOA-1 gene with cardiometabolic markers after consuming sesame, canola and sesame-canola oils in adults with and without type 2 diabetes mellitus.","BACKGROUND & AIMS The inter-individual variations of the metabolic markers in response to dietary interventions may be mediated by genetic factors. We examined whether the type of dietary oils can modulate the effects of -75G/A polymorphism in APOA-1 gene on cardiometabolic markers. METHODS This study was a randomized, triple-blind, cross-over clinical trial. Participants with and without type 2 diabetes were randomly assigned to replace their regular oil with sesame oil, canola oil and sesame-canola oil for 9 weeks. Genotyping was conducted using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. RESULTS Ninety-five diabetes patients and 73 healthy individuals completed the study protocol. In patients with type 2 diabetes, the A allele carriers experienced greater decrease in systolic blood pressure compared with GG homozygotes following sesame-canola oil intake. Serum levels of HDL-C and TG: HDL ratio was increased and decreased following canola oil intake in patients carrying the A allele rather than non-A allele carriers, respectively. More reductions for risk of cardiovascular diseases and mortality, except risk of stroke were found in the A allele carriers compared with GG homozygotes after intakes of canola and sesame-canola oils, but not sesame oil. There was also a significant genotype effect as well as genotype-dietary oil interactions on cardiovascular risk scores. In healthy individuals, a considerable decrease in visceral fat was accompanied by a significant increase in HDL-C levels in the A allele carriers compared with non-A allele carriers after sesame oil intake. CONCLUSION Patients with diabetes carrying the A allele might benefit from canola and sesame-canola oils intakes, and healthy A allele carriers from sesame and sesame-canola oils intakes as well. Future clinical trials are recommended to warrant current findings.",2020,"In patients with type 2 diabetes, the A allele carriers experienced greater decrease in systolic blood pressure compared with GG homozygotes following sesame-canola oil intake.","['adults with and without type 2 diabetes mellitus', 'Ninety-five diabetes patients and 73 healthy individuals', 'Participants with and without type 2 diabetes']","['replace their regular oil with sesame oil, canola oil and sesame-canola oil', 'canola and sesame-canola oils']","['HDL-C levels', 'risk of cardiovascular diseases and mortality, except risk of stroke', 'systolic blood pressure', 'visceral fat', 'cardiovascular risk scores', 'Serum levels of HDL-C and TG: HDL ratio']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C4517906', 'cui_str': '95'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0036845', 'cui_str': 'Sesame Oil'}, {'cui': 'C0054599', 'cui_str': 'canola oil'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0330502', 'cui_str': 'Brassica napus'}, {'cui': 'C1123051', 'cui_str': 'Sesame'}]","[{'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C1563740', 'cui_str': 'Abdominal Visceral Fat'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.0963584,"In patients with type 2 diabetes, the A allele carriers experienced greater decrease in systolic blood pressure compared with GG homozygotes following sesame-canola oil intake.","[{'ForeName': 'Nahid', 'Initials': 'N', 'LastName': 'Ramezani-Jolfaie', 'Affiliation': 'Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Shiva', 'Initials': 'S', 'LastName': 'Aghaei', 'Affiliation': 'Stem Cell Biology Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Ehsan Farashahi', 'Initials': 'EF', 'LastName': 'Yazd', 'Affiliation': 'Stem Cell Biology Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Moradi', 'Affiliation': 'Department of Biochemistry and Molecular Biology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Mozaffari-Khosravi', 'Affiliation': 'Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; Yazd Diabetic Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Zimorovat', 'Affiliation': 'Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Hamidreza', 'Initials': 'H', 'LastName': 'Raeisi-Dehkordi', 'Affiliation': 'Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Moghtaderi', 'Affiliation': 'Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Mojgan', 'Initials': 'M', 'LastName': 'Amiri', 'Affiliation': 'Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Seyed Ali', 'Initials': 'SA', 'LastName': 'Yasini Ardakani', 'Affiliation': 'Department of Food Science and Technology, Islamic Azad University, Yazd, Iran.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Salehi-Abargouei', 'Affiliation': 'Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Electronic address: abargouei@ssu.ac.ir.'}]",Clinical nutrition ESPEN,['10.1016/j.clnesp.2020.05.016'] 2200,32690156,Growth of cardiac infants with post-surgical chylothorax can be supported using modified fat breast milk with proactive nutrient-enrichment and advancement feeding protocols; an open-label trial.,"BACKGROUND & AIM Previously we showed that modified fat breast milk (MFBM) facilitated resolution of post-surgical chylothorax in cardiac infants, but their weight-for-age and length-for-age z-scores declined over the ≥6-week treatment duration. Our aim was to evaluate the growth of infants diagnosed with post-surgical chylothorax and fed according to one of two proactive feeding protocols using MFBM or a high medium triglyceride (MCT)-containing formula (standard of care). METHODS In this open-label trial, infants who were receiving >50% of their enteral feeds as breast milk prior to chylothorax diagnosis were randomized to receive their enteral feeds according to one of two proactive MFBM protocols: Target Fortification (n = 8), where the protein concentration of defatted breast milk was measured weekly and multi- and single-nutrient modulars were added to provide 3.5 g/kg/day of protein; or Higher Initial Concentration (n = 8), where defatted breast milk was initially fortified to an energy and nutrient level higher than that of unmodified breast milk (80kcal/100 ml; 2.2 g/100 ml protein). A third nonrandomized group of infants (n = 8) received high MCT formula (68kcal/100 ml; 2.3 g/100 ml protein). The intervention lasted for a minimum of 6-weeks after chest tube removal and continued after discharge. Weekly weight, length and head circumference (HC) measurements were completed. RESULTS At enrolment, there was no statistically significant differences in mean (±SD) weight-for-age (-1.6 ± 0.9, n = 24), length-for-age (-1.3 ± 0.8), or HC-for-age (-0.9 ± 1.0) z-scores among groups. Changes in mean weight- (-0.3 ± 0.9, n = 23), length- (0.1 ± 0.6) and HC-for-age (0.2 ± 0.6) z-scores did not differ among groups over the treatment period. There was no difference in duration or volume of chest tube drainage across groups. CONCLUSION Use of proactive MFBM feeding protocols both resolve chylothorax and support growth in infants following cardiothoracic surgery. TRIAL REGISTRATION ClinicalTrials.gov (NCT02577419).",2020,"There was no difference in duration or volume of chest tube drainage across groups. ","['infants diagnosed with post-surgical chylothorax and fed', 'infants who were receiving >50% of their enteral feeds as breast milk prior to chylothorax diagnosis', 'infants following cardiothoracic surgery']","['MFBM or a high medium triglyceride (MCT)-containing formula (standard of care', 'high MCT formula (68kcal/100\xa0ml; 2.3\xa0g/100\xa0ml protein', 'modified fat breast milk (MFBM', 'proactive MFBM protocols: Target Fortification (n\xa0=\xa08), where the protein concentration of defatted breast milk was measured weekly and multi- and single-nutrient modulars were added to provide 3.5\xa0g/kg/day of protein; or Higher Initial Concentration (n\xa0=\xa08), where defatted breast milk was initially fortified to an energy and nutrient level higher than that of unmodified breast milk (80kcal/100\xa0ml; 2.2\xa0g/100']","['duration or volume of chest tube drainage', 'mean (±SD) weight-for-age', 'Weekly weight, length and head circumference (HC) measurements', 'z-scores']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0008733', 'cui_str': 'Chylothorax'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0086225', 'cui_str': 'Enteral feeding'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C1274037', 'cui_str': 'Cardiothoracic surgery'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0026687', 'cui_str': 'Mucociliary clearance'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0427716', 'cui_str': 'Protein concentration, test strip measurement'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C1532536', 'cui_str': 'g/kg/day'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4517629', 'cui_str': '2.2'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0008034', 'cui_str': 'Chest drain'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0262499', 'cui_str': 'Head circumference'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}]",,0.0748741,"There was no difference in duration or volume of chest tube drainage across groups. ","[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'DiLauro', 'Affiliation': ""Department of Nutritional Sciences, University of Toronto, Medical Sciences Building, 5th Floor, Room 5253, 1 King's College Circle, Toronto, M5S 1A8, Canada; Labatt Family Heart Centre, The Hospital for Sick Children, 555 University Avenue, Toronto, M5G 1X8, Canada; Translational Medicine Program, The Hospital for Sick Children, 686 Bay Street, Toronto, M5G 0A4, Canada.""}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Russell', 'Affiliation': 'Labatt Family Heart Centre, The Hospital for Sick Children, 555 University Avenue, Toronto, M5G 1X8, Canada; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, M5G 1X8, Canada.'}, {'ForeName': 'Brian W', 'Initials': 'BW', 'LastName': 'McCrindle', 'Affiliation': ""Department of Nutritional Sciences, University of Toronto, Medical Sciences Building, 5th Floor, Room 5253, 1 King's College Circle, Toronto, M5S 1A8, Canada; Labatt Family Heart Centre, The Hospital for Sick Children, 555 University Avenue, Toronto, M5G 1X8, Canada; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, M5G 1X8, Canada.""}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Tomlinson', 'Affiliation': ""Department of Nutritional Sciences, University of Toronto, Medical Sciences Building, 5th Floor, Room 5253, 1 King's College Circle, Toronto, M5S 1A8, Canada; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, M5G 1X8, Canada; Department of Neonatology, The Hospital for Sick Children, 555 University Avenue, Toronto, M5G 1X8, Canada.""}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Unger', 'Affiliation': ""Department of Nutritional Sciences, University of Toronto, Medical Sciences Building, 5th Floor, Room 5253, 1 King's College Circle, Toronto, M5S 1A8, Canada; Department of Neonatology, The Hospital for Sick Children, 555 University Avenue, Toronto, M5G 1X8, Canada; Rogers Hixon Ontario Human Milk Bank, Mount Sinai Hospital, 600 University Ave, Toronto, M5G 1X5, Canada; Department of Pediatrics, Mount Sinai Hospital, 600 University Avenue, Toronto, M5G 1X5, Canada.""}, {'ForeName': 'Deborah L', 'Initials': 'DL', 'LastName': ""O'Connor"", 'Affiliation': ""Department of Nutritional Sciences, University of Toronto, Medical Sciences Building, 5th Floor, Room 5253, 1 King's College Circle, Toronto, M5S 1A8, Canada; Translational Medicine Program, The Hospital for Sick Children, 686 Bay Street, Toronto, M5G 0A4, Canada; Rogers Hixon Ontario Human Milk Bank, Mount Sinai Hospital, 600 University Ave, Toronto, M5G 1X5, Canada; Department of Pediatrics, Mount Sinai Hospital, 600 University Avenue, Toronto, M5G 1X5, Canada. Electronic address: deborah.oconnor@utoronto.ca.""}]",Clinical nutrition ESPEN,['10.1016/j.clnesp.2020.05.001'] 2201,32690164,Effect of lifestyle modification education based on health belief model in overweight/obese patients with non-alcoholic fatty liver disease: A parallel randomized controlled clinical trial.,"BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is the most common emerging liver disease worldwide. Lifestyle modification is the most emphasized method on management of this disease. METHODS In order to conduct this parallel, randomized controlled trial study, eighty-two NAFLD patients recruited and allocated to intervention group or the control. RESULTS After two months of intervention, significant improvements in all health belief model (HBM) variables and knowledge were seen within the intervention group (p < 0.001) and also the improvements were significantly superior between two groups (p < 0.001). Furthermore, prominent significant reduction for liver enzyme was observed in the intervention group compared to the controls. Similarly, ultra-sonographic findings revealed a significant improvement in the intervention group versus control. CONCLUSIONS This HBM-based lifestyle modification education could be effective not only in the HBM domains but also in the improvement of NAFLD parameters. Therefore, it could be useful to use this educational program for NAFLD patients in order to impact on their beliefs and body together. REGISTRATION Iranian Registry of Clinical Trials (IRCT2014101811763N17).",2020,"After two months of intervention, significant improvements in all health belief model (HBM) variables and knowledge were seen within the intervention group (p < 0.001) and also the improvements were significantly superior between two groups (p < 0.001).","['eighty-two NAFLD patients', 'overweight/obese patients with non-alcoholic fatty liver disease']",['lifestyle modification education'],"['health belief model (HBM) variables and knowledge', 'liver enzyme']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C3714363', 'cui_str': 'Health belief model'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme'}]",82.0,0.0906348,"After two months of intervention, significant improvements in all health belief model (HBM) variables and knowledge were seen within the intervention group (p < 0.001) and also the improvements were significantly superior between two groups (p < 0.001).","[{'ForeName': 'Mojgan', 'Initials': 'M', 'LastName': 'Nourian', 'Affiliation': 'Department of Community Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Gholamreza', 'Initials': 'G', 'LastName': 'Askari', 'Affiliation': 'Department of Community Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Parastoo', 'Initials': 'P', 'LastName': 'Golshiri', 'Affiliation': 'Department of Community Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Miraghajani', 'Affiliation': 'Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; The Early Life Research Unit, Academic Division of Child Health, Obstetrics and Gynaecology, and Nottingham Digestive Disease Centre and Biomedical Research Centre, The School of Medicine, University of Nottingham, Nottingham, NG7 2UH, UK.'}, {'ForeName': 'Saeideh', 'Initials': 'S', 'LastName': 'Shokri', 'Affiliation': 'Department of Radiology, School of Medical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Arman', 'Initials': 'A', 'LastName': 'Arab', 'Affiliation': 'Department of Community Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: arman4369@gmail.com.'}]",Clinical nutrition ESPEN,['10.1016/j.clnesp.2020.04.004'] 2202,32690185,"Creatine supplementation does not promote additional effects on inflammation and insulin resistance in older adults: A pilot randomized, double-blind, placebo-controlled trial.","BACKGROUND A chronic, low-grade inflammation is commonly present in older adults and has been associated with the onset of age-related chronic diseases. Resistance training (RT) and creatine (CR) supplementation emerged as promising strategies to reduce circulating pro-inflammatory cytokines. This study aimed to investigate the effects of CR supplementation combined with RT on markers of inflammation and insulin resistance in community-dwelling older adults. METHODS In a pilot randomized, double-blind, placebo-controlled trial, participants were allocated to one of the following groups: 1) Creatine supplementation and resistance training (CR + RT, n = 13); 2) Placebo and resistance training (PL + RT, n = 14). While engaged in a 12-week RT program, participants from CR + RT group received 5 g/day of CR monohydrate and participants from PL + RT group received the same dose of maltodextrin. At baseline and at week 12, blood samples were collected for glucose, insulin, adiponectin, leptin, interleukin 6, interleukin 10, monocyte chemo-attractant protein-1 and C-reactive protein analysis. RESULTS After 12 weeks of intervention, there were no differences between groups in any of the variables analyzed. Monocyte chemoattractant protein-1 was reduced in both groups (CR + RT: -55.66 ± 48.93 pg/mL, p < 0.01, dz = 1.13; PL + RT: -46.52 ± 55.21 pg/mL, p < 0.01, dz = 0.84). CONCLUSION Resistance training, regardless of CR supplementation, decreased MCP-1 concentration in older adults.",2020,Monocyte chemoattractant protein-1 was reduced in both groups (CR + RT: -55.66 ± 48.93 ,"['community-dwelling older adults', 'older adults']","['maltodextrin', 'CR supplementation combined with RT', 'Resistance training (RT) and creatine (CR) supplementation', 'Creatine supplementation', 'CR monohydrate', 'Creatine supplementation and resistance training (CR + RT, n = 13); 2) Placebo and resistance training', 'placebo']","['glucose, insulin, adiponectin, leptin, interleukin 6, interleukin 10, monocyte chemo-attractant protein-1 and C-reactive protein analysis', 'inflammation and insulin resistance', 'MCP-1 concentration', 'Monocyte chemoattractant protein-1']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0010286', 'cui_str': 'Creatine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0873188', 'cui_str': 'Creatine monohydrate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0026473', 'cui_str': 'Monocyte'}, {'cui': 'C0392920', 'cui_str': 'Antineoplastic chemotherapy regimen'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0128897', 'cui_str': 'Monocyte Chemoattractant Protein-1'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",14.0,0.559441,Monocyte chemoattractant protein-1 was reduced in both groups (CR + RT: -55.66 ± 48.93 ,"[{'ForeName': 'Camila L P', 'Initials': 'CLP', 'LastName': 'Oliveira', 'Affiliation': 'Human Nutrition Research Unit, Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, AB, T6G 2E1, Canada.'}, {'ForeName': 'Barbara de Moura Mello', 'Initials': 'BMM', 'LastName': 'Antunes', 'Affiliation': 'Exercise and Immunometabolism Research Group, Department of Physical Education, Sao Paulo State University, Presidente Prudente, SP, 19060-900, Brazil.'}, {'ForeName': 'Aline Corado', 'Initials': 'AC', 'LastName': 'Gomes', 'Affiliation': 'Clinical and Sports Nutrition Research Laboratory, Faculty of Nutrition, Goiás Federal University, 227 Street, Block 68, Setor Leste Universitario, Goiania, GO, 74.605-080, Brazil.'}, {'ForeName': 'Fábio Santos', 'Initials': 'FS', 'LastName': 'Lira', 'Affiliation': 'Exercise and Immunometabolism Research Group, Department of Physical Education, Sao Paulo State University, Presidente Prudente, SP, 19060-900, Brazil.'}, {'ForeName': 'Gustavo Duarte', 'Initials': 'GD', 'LastName': 'Pimentel', 'Affiliation': 'Clinical and Sports Nutrition Research Laboratory, Faculty of Nutrition, Goiás Federal University, 227 Street, Block 68, Setor Leste Universitario, Goiania, GO, 74.605-080, Brazil.'}, {'ForeName': 'Normand G', 'Initials': 'NG', 'LastName': 'Boulé', 'Affiliation': 'Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, AB, T6G 2H9, Canada.'}, {'ForeName': 'João Felipe', 'Initials': 'JF', 'LastName': 'Mota', 'Affiliation': 'Clinical and Sports Nutrition Research Laboratory, Faculty of Nutrition, Goiás Federal University, 227 Street, Block 68, Setor Leste Universitario, Goiania, GO, 74.605-080, Brazil. Electronic address: jfemota@gmail.com.'}]",Clinical nutrition ESPEN,['10.1016/j.clnesp.2020.05.024'] 2203,32690492,ALADDIN study: does assisted hatching of vitrified/warmed blastocysts improve live birth rate? Protocol for a multicentric randomised controlled trial.,"INTRODUCTION Recent data suggest a higher clinical pregnancy rate performing assisted hatching (AH) on previously cryopreserved embryos but fail to demonstrate significant effects on live birth rate. However, current evidence is based on studies with a small sample size and may hide a type II error. Moreover, poor attention has been given to the specific effect of AH on frozen/thawed blastocysts. To shed light on this topic, we developed the present protocol for a randomised trial to investigate the benefits of the laser-mediated partial removal of the zona pellucida in vitrified/warmed blastocysts. METHODS AND ANALYSIS The pArtiaL zonA pelluciDa removal by assisteD hatchINg of blastocysts (ALADDIN) study is a multicentric prospective comparative study with a parallel randomised controlled design aiming to investigate whether AH performed on warmed blastocysts before embryo transfer can improve live birth rate. Women allocated to the control group will undergo embryo transfer of blastocysts not previously subjected to AH. Two infertility units will be involved in the study. Enrolment of patients will last 18 months with quarterly monitoring and the entire study is foreseen to be closed in 36 months. Secondary outcomes include: proportion of transferred blastocysts/thawed blastocyst, morphological features of blastocysts before embryo transfer, implantation, biochemical pregnancy, clinical pregnancy (ultrasound visible gestational sac), miscarriage, multiple pregnancy, preterm birth (<37 weeks of gestation), obstetrical and neonatal complications and congenital anomaly rates. ETHICS AND DISSEMINATION This protocol received a favourable ethical opinion from the Ethical Committee of IRCCS San Raffaele Scientific Institute and the Ethical Committee Area 2 Milan. Each participant will provide written consent to participate and remain encoded during the study. The trial results will be published in peer-reviewed journals and presented at conferences. TRIAL REGISTRATION NUMBER NCT03623659; Pre-results.",2020,The pArtiaL zonA pelluciDa removal by assisteD hatchINg of blastocysts (ALADDIN) study is a multicentric prospective comparative study with a parallel randomised controlled design aiming to investigate whether AH performed on warmed blastocysts before embryo transfer can improve live birth rate.,[],['control group will undergo embryo transfer of blastocysts not previously subjected to AH'],"[' proportion of transferred blastocysts/thawed blastocyst, morphological features of blastocysts before embryo transfer, implantation, biochemical pregnancy, clinical pregnancy (ultrasound visible gestational sac), miscarriage, multiple pregnancy, preterm birth (<37 weeks of gestation), obstetrical and neonatal complications and congenital anomaly rates', 'live birth rate']",[],"[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013938', 'cui_str': 'Embryo transfer'}, {'cui': 'C1281743', 'cui_str': 'Blastocyst structure'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}]","[{'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C1281743', 'cui_str': 'Blastocyst structure'}, {'cui': 'C0543482', 'cui_str': 'morphology'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0013938', 'cui_str': 'Embryo transfer'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0404845', 'cui_str': 'Biochemical pregnancy'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0205379', 'cui_str': 'Visible'}, {'cui': 'C0553498', 'cui_str': 'Gestation Sac'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}, {'cui': 'C0032989', 'cui_str': 'Multiple pregnancy'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}]",,0.229643,The pArtiaL zonA pelluciDa removal by assisteD hatchINg of blastocysts (ALADDIN) study is a multicentric prospective comparative study with a parallel randomised controlled design aiming to investigate whether AH performed on warmed blastocysts before embryo transfer can improve live birth rate.,"[{'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Alteri', 'Affiliation': 'Obstetrics and Gynaecology Department, IRCCS San Raffaele Scientific Institute, Milan, Italy alteri.alessandra@hsr.it.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Guarneri', 'Affiliation': ""Infertility Unit, Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Corti', 'Affiliation': 'Obstetrics and Gynaecology Department, IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Liliana', 'Initials': 'L', 'LastName': 'Restelli', 'Affiliation': ""Infertility Unit, Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Reschini', 'Affiliation': ""Infertility Unit, Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Giardina', 'Affiliation': 'Obstetrics and Gynaecology Department, IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Papaleo', 'Affiliation': 'Obstetrics and Gynaecology Department, IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Edgardo', 'Initials': 'E', 'LastName': 'Somigliana', 'Affiliation': ""Infertility Unit, Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Viganò', 'Affiliation': 'Reproductive Sciences Laboratory, Obstetrics and Gynaecology Department, IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Alessio', 'Initials': 'A', 'LastName': 'Paffoni', 'Affiliation': 'Infertility Unit, ASST Lariana, Cantù, Como, Italy.'}]",BMJ open,['10.1136/bmjopen-2019-031544'] 2204,32690499,Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.,"INTRODUCTION Patients with metastatic or locally advanced, non-resectable, grade 3 poorly differentiated gastroenteropancreatic (GEP) and lung neuroendocrine carcinomas (NECs) are usually treated with in first-line platinum compounds. There is no standard second-line treatment on progression. Accurate biomarkers are needed to facilitate diagnosis and prognostic assessment of patients with NEC. METHODS AND ANALYSIS The SEcond-line therapy in NEuroendocrine CArcinomas (SENECA) study is a randomised, non-comparative, multicentre phase II trial designed to evaluate the efficacy and safety of folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) or capecitabine plus temozolomide (CAPTEM) regimens after failure of first-line chemotherapy in patients with lung NEC and GEP-NEC. Secondary aims are to correlate the serum miRNA profile and primary mutational status of MEN1, DAXX, ATRX and RB-1 with prognosis and outcome and to investigate the prognostic and predictive role of the Ki-67 score and 18-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) or 68 Ga-PET/CT. The main eligibility criteria are age ≥18 years; metastatic or locally advanced, non-resectable, grade 3 lung or GEP-NECs; progression to first-line platinum-based chemotherapy. A Bryant and Day design taking into account treatment activity and toxicity was used to estimate the sample size. All analyses will be performed separately for each treatment group in the intention-to-treat population. A total of 112 patients (56/arm) will be randomly assigned (1:1) to receive FOLFIRI every 14 days or CAPTEM every 28 days until disease progression or unacceptable toxicity or for a maximum of 6 months. Patients undergo testing for specific biomarkers in primary tumour tissue and for miRNA in blood samples. MiRNA profiling will be performed in the first 20 patients who agree to participate in the biological substudy. ETHICS AND DISSEMINATION The SENECA trial, supported by Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), was authorised by the locals Ethics Committee and the Italian Medicines Agency (AIFA). Results will be widely disseminated via peer-reviewed manuscripts, conference presentations and reports to relevant authorities.The study is currently open in Italy. TRAIL REGISTRATION NUMBER NCT03387592; Pre-results. EudraCT-2016-000767-17. PROTOCOL VERSION Clinical Study Protocol Version 1, 7 November 2016.",2020,"Secondary aims are to correlate the serum miRNA profile and primary mutational status of MEN1, DAXX, ATRX and RB-1 with prognosis and outcome and to investigate the prognostic and predictive role of the Ki-67 score and 18-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) or 68 Ga-PET/CT.","['112 patients (56/arm', 'Patients with metastatic or locally advanced, non-resectable, grade 3 poorly differentiated gastroenteropancreatic (GEP) and lung neuroendocrine carcinomas (NECs', '20 patients who agree to participate in the biological substudy', 'patients with NEC', 'The main eligibility criteria are age ≥18 years; metastatic or locally advanced, non-resectable, grade 3 lung or GEP-NECs; progression to first-line platinum-based chemotherapy', 'patients with lung NEC and GEP-NEC']","['18-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT', 'folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) or capecitabine plus temozolomide (CAPTEM', 'Cura dei Tumori (IRST', 'Istituto Scientifico Romagnolo per lo Studio e la']","['serum miRNA profile and primary mutational status of MEN1, DAXX, ATRX and RB-1 with prognosis and outcome']","[{'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0205617', 'cui_str': 'Poorly differentiated'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0206695', 'cui_str': 'Neuroendocrine carcinoma'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C3536920', 'cui_str': 'Platinum compounds'}]","[{'cui': 'C3641247', 'cui_str': 'FDG PET scan'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0046056', 'cui_str': 'Fluorodeoxyglucose F18'}, {'cui': 'C1699633', 'cui_str': 'Positron emission tomography with computed tomography'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0076080', 'cui_str': 'temozolomide'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1101610', 'cui_str': 'MicroRNA'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0025267', 'cui_str': 'Multiple endocrine neoplasia, type 1'}, {'cui': 'C0541030', 'cui_str': 'DAXX protein, human'}, {'cui': 'C1845055', 'cui_str': 'Alpha thalassemia X-linked intellectual disability syndrome'}, {'cui': 'C0033325', 'cui_str': 'Determination of prognosis'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",112.0,0.050486,"Secondary aims are to correlate the serum miRNA profile and primary mutational status of MEN1, DAXX, ATRX and RB-1 with prognosis and outcome and to investigate the prognostic and predictive role of the Ki-67 score and 18-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) or 68 Ga-PET/CT.","[{'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Bongiovanni', 'Affiliation': 'Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy alberto.bongiovanni@irst.emr.it.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Liverani', 'Affiliation': 'Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Pusceddu', 'Affiliation': 'Department of Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Lombardia, Italy.'}, {'ForeName': 'Silvana', 'Initials': 'S', 'LastName': 'Leo', 'Affiliation': 'Oncology Unit, Ospedale Vito Fazzi, Lecce, Puglia, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Di Meglio', 'Affiliation': 'Oncology Unit, Ospedale di Bolzano, Bolzano, Trentino-Alto Adige, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Tamberi', 'Affiliation': 'Oncology Unit, Ospedale degli Infermi di Faenza, Faenza, Emilia-Romagna, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Santini', 'Affiliation': 'Department of Medical Oncology, Campus Bio-Medico University, Roma, Lazio, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Gelsomino', 'Affiliation': 'Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Emilia-Romagna, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Pucci', 'Affiliation': 'Medical Oncology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Emilia-Romagna, Italy.'}, {'ForeName': 'Rossana', 'Initials': 'R', 'LastName': 'Berardi', 'Affiliation': 'Oncology Clinic, University Hospital of Ancona Umberto I G M Lancisi G Salesi, Ancona, Marche, Italy.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Lolli', 'Affiliation': 'Department of Oncology, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico Saverio de Bellis, Castellana Grotte, Puglia, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Bergamo', 'Affiliation': 'Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Veneto, Italy.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Ricci', 'Affiliation': 'Internal Medicine and Medical Oncology, Santa Chiara Hospital, Pisa, Toscana, Italy.'}, {'ForeName': 'Flavia', 'Initials': 'F', 'LastName': 'Foca', 'Affiliation': 'Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Severi', 'Affiliation': 'Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy.'}, {'ForeName': 'Toni', 'Initials': 'T', 'LastName': 'Ibrahim', 'Affiliation': 'Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2019-034393'] 2205,32690503,Behaviour change physiotherapy intervention to increase physical activity following hip and knee replacement (PEP-TALK): study protocol for a pragmatic randomised controlled trial.,"INTRODUCTION While total hip replacement (THR) and total knee replacement (TKR) successfully reduce pain associated with chronic joint pathology, this infrequently translates into increased physical activity. This is a challenge given that over 50% of individuals who undergo these operations are physically inactive and have medical comorbidities such as hypertension, heart disease, diabetes and depression. The impact of these diseases can be reduced with physical activity. This trial aims to investigate the effectiveness of a behaviour change physiotherapy intervention to increase physical activity compared with usual rehabilitation after THR or TKR. METHODS AND ANALYSIS The PEP-TALK trial is a multicentre, open-labelled, pragmatic randomised controlled trial. 260 adults who are scheduled to undergo a primary unilateral THR or TKR and are moderately inactive or inactive, with comorbidities, will be recruited across eight sites in England. They will be randomised post-surgery, prior to hospital discharge, to either six, 30 min weekly group-based exercise sessions (control), or the same six weekly, group-based, exercise sessions each preceded by a 30 min cognitive behaviour approach discussion group. Participants will be followed-up to 12 months by postal questionnaire. The primary outcome is the University of California, Los Angeles (UCLA) Physical Activity Score at 12 months. Secondary outcomes include: physical function, disability, health-related quality of life, kinesiophobia, perceived pain, self-efficacy and health resource utilisation. ETHICS AND DISSEMINATION Research ethics committee approval was granted by the NRES Committee South Central (Oxford B - 18/SC/0423). Dissemination of results will be through peer-reviewed, scientific journals and conference presentations. TRIAL REGISTRATION NUMBER ISRCTN29770908.",2020,"This trial aims to investigate the effectiveness of a behaviour change physiotherapy intervention to increase physical activity compared with usual rehabilitation after THR or TKR. ","['260 adults who are scheduled to undergo a primary unilateral THR or TKR and are moderately inactive or inactive, with comorbidities, will be recruited across eight sites in England']","['behaviour change physiotherapy intervention', 'While total hip replacement (THR) and total knee replacement (TKR', 'Behaviour change physiotherapy intervention']","['Physical Activity Score', 'University of California, Los Angeles (UCLA', 'physical activity', 'physical function, disability, health-related quality of life, kinesiophobia, perceived pain, self-efficacy and health resource utilisation']","[{'cui': 'C4517669', 'cui_str': '260'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0014282', 'cui_str': 'England'}]","[{'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C4285782', 'cui_str': 'Kinesiophobia'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0018741', 'cui_str': 'Health Resources'}]",260.0,0.138093,"This trial aims to investigate the effectiveness of a behaviour change physiotherapy intervention to increase physical activity compared with usual rehabilitation after THR or TKR. ","[{'ForeName': 'Toby O', 'Initials': 'TO', 'LastName': 'Smith', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK toby.smith@ndorms.ox.ac.uk.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Parsons', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Fordham', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Ooms', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Dutton', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Hing', 'Affiliation': ""University of London St George's Molecular and Clinical Sciences Research Institute, London, UK.""}, {'ForeName': 'Vicki S', 'Initials': 'VS', 'LastName': 'Barber', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'May Ee', 'Initials': 'ME', 'LastName': 'Png', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Lamb', 'Affiliation': 'College of Medicine and Health Sciences, University of Exeter, Exeter, Devon, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2019-035014'] 2206,32690508,"Effect of an innovative behavioural change strategy and small-quantity lipid-based nutrient supplements on stunting and obesity in children in Baja Verapaz, Guatemala: protocol for a randomised control trial.","INTRODUCTION In Latin America, a rapid increase in obesity alongside persistent malnutrition has resulted in a double burden of disease that affects the most vulnerable segments of the population. Infant and young child feeding practices are important factors that affect both sides of the growth curve. Interventions such as behavioural change strategies and home fortification using products like small-quantity lipid-based nutrient supplements (SQ-LNS) have the potential to reduce the presence of both these conditions, especially if they are implemented during the first 1000 days of life. This paper details the protocol for Sustained Programme for Improving Nutrition (SPOON), an innovative strategy to prevent stunting and reduce risk for obesity in children under 24 months old in high-poverty areas in Baja Verapaz, Guatemala. METHODS AND ANALYSIS SPOON Guatemala is a three-arm randomised control trial: treatment group 1 will receive the SPOON behavioural change strategy and SQ-LNS, treatment group 2 will receive the SPOON behavioural change strategy and micronutrient powders; the control group will receive the standard of care provided by the Ministry of Health, which includes micronutrient powders. A modified formula of SQ-LNS has been especially developed for this trial. A total of 76 communities are included in the study and 1628 households with a pregnant woman in the third trimester or a child under 4.5 months were recruited at baseline. Baseline data were collected between September and November 2018. Follow-up data will be collected 2 years after the start of the intervention. The primary outcomes of interest are related to mothers' infant feeding knowledge and practice, and indicators of children's nutritional status and growth including height, weight, weight gain rate and prevalence of stunting, overweight, obesity and anaemia. After follow-up data have been collected, differences of simple means and regression models including covariates such as child's age and sex, characteristics of the primary caregiver and household socioeconomic indicators will be estimated. Heterogeneous effects will also be estimated within subgroups of age at exposure, sex, caregiver characteristics and household socioeconomic status. ETHICS AND DISSEMINATION This study was approved by the National Health Ethics Committee of the Ministry of Health of Guatemala (resolution 10-2018). Informed consent was obtained from all mothers and caregivers prior to enrolment in the programme. Results will be submitted to a peer-reviewed medical or public health journal, and disseminated internally at the Inter-American Development Bank, with the Government and Stakeholders in Guatemala and through international conferences and seminars. TRIAL REGISTRATION NUMBER NCT03399617.",2020,"Guatemala is a three-arm randomised control trial: treatment group 1 will receive the SPOON behavioural change strategy and SQ-LNS, treatment group 2 will receive the SPOON behavioural change strategy and micronutrient powders; the control group will receive the standard of care provided by the Ministry of Health, which includes micronutrient powders.","['children under 24 months old in high-poverty areas in Baja Verapaz, Guatemala', 'A total of 76 communities are included in the study and 1628 households with a pregnant woman in the third trimester or a child under 4.5 months were recruited at baseline', 'stunting and obesity in children in Baja Verapaz, Guatemala']","['innovative behavioural change strategy and small-quantity lipid-based nutrient supplements', 'home fortification using products like small-quantity lipid-based nutrient supplements (SQ-LNS', 'SPOON behavioural change strategy and SQ-LNS, treatment group 2 will receive the SPOON behavioural change strategy and micronutrient powders; the control group will receive the standard of care provided by the Ministry of Health, which includes micronutrient powders']","[""mothers' infant feeding knowledge and practice, and indicators of children's nutritional status and growth including height, weight, weight gain rate and prevalence of stunting, overweight, obesity and anaemia""]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0032855', 'cui_str': 'Poverty Areas'}, {'cui': 'C0018367', 'cui_str': 'Guatemala'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0032981', 'cui_str': 'Third trimester pregnancy'}, {'cui': 'C3844009', 'cui_str': '4.5'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0018273', 'cui_str': 'Growth disorder'}, {'cui': 'C2362324', 'cui_str': 'Childhood obesity'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0040577', 'cui_str': 'Trace element'}, {'cui': 'C0032861', 'cui_str': 'Powder'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0018273', 'cui_str': 'Growth disorder'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}]",1628.0,0.129446,"Guatemala is a three-arm randomised control trial: treatment group 1 will receive the SPOON behavioural change strategy and SQ-LNS, treatment group 2 will receive the SPOON behavioural change strategy and micronutrient powders; the control group will receive the standard of care provided by the Ministry of Health, which includes micronutrient powders.","[{'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'González Acero', 'Affiliation': 'Social Protection and Health Division, Inter- American Development Bank, Washington, District of Columbia, USA.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Martinez', 'Affiliation': 'Office of Strategic Planning and Development Effectiveness, Inter- American Development Bank, Washington, District of Columbia, USA SMARTINEZ@iadb.org.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Pérez-Expósito', 'Affiliation': 'Social Protection and Health Division, Inter- American Development Bank, Washington, District of Columbia, USA.'}, {'ForeName': 'Solis', 'Initials': 'S', 'LastName': 'Winters', 'Affiliation': 'Office of Strategic Planning and Development Effectiveness, Inter- American Development Bank, Washington, District of Columbia, USA.'}]",BMJ open,['10.1136/bmjopen-2019-035528'] 2207,32687434,Effect of holistic relapse prevention intervention among individuals with alcohol dependence: a prospective study at a mental health care setting in India.,"Present study examined effectiveness of Integrative Body Mind Spirit (I-BMS) intervention among individuals with alcohol dependence. A 2-group single blind RCT design was used, comparing I-BMS to treatment as usual (TAU) on drinking and psychological outcomes. One hundred participants diagnosed with alcohol dependent syndrome were randomly assigned to receive 7 sessions of I-BMS or TAU. Measurements done by a registered nurse who was blinded to the experimental design used standardized questionnaire on wellbeing, readiness to change, craving, quantity and frequency of drinking before and up to 6 months after the intervention. With respect to the within group effects, the I-BMS group demonstrated significant improvement in all outcome measures with large effect size. Compared to TAU, I-BMS participants showed lesser relapse rates and quantity of drinking at 3-month follow-up, reduction in craving and drinking days at 2-month follow-up. At 6 months follow-up, participants in I-BMS group reported significant improvement in wellbeing and motivation compared to TAU. Results of binary logistic regression showed that number of previous attempts and living in urban area positively predicted participant's relapse possibility at 6-month follow-up. Results suggest that I-BMS is worthy of further efficacy testing. In conclusion, it is feasible to implement I-BMS intervention for individuals with alcohol dependence.",2020,"Compared to TAU, I-BMS participants showed lesser relapse rates and quantity of drinking at 3-month follow-up, reduction in craving and drinking days at 2-month follow-up.","['One hundred participants diagnosed with alcohol dependent syndrome', 'individuals with alcohol dependence']","['holistic relapse prevention intervention', 'BMS or TAU', 'Integrative Body Mind Spirit (I-BMS) intervention']","['relapse rates and quantity of drinking', 'wellbeing and motivation']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001973', 'cui_str': 'Alcohol dependence'}]","[{'cui': 'C0679867', 'cui_str': 'Relapse prevention'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0301611', 'cui_str': 'Distilled spirits'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0429648', 'cui_str': 'Quantity of drinking'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}]",100.0,0.024241,"Compared to TAU, I-BMS participants showed lesser relapse rates and quantity of drinking at 3-month follow-up, reduction in craving and drinking days at 2-month follow-up.","[{'ForeName': 'Sreevani', 'Initials': 'S', 'LastName': 'Rentala', 'Affiliation': 'Department of Psychiatric Nursing, Dharwad Institute of Mental health and Neuroscience, Dharwad, Karnataka, India.'}, {'ForeName': 'Siu-Man', 'Initials': 'SM', 'LastName': 'Ng', 'Affiliation': 'Department of Social Work & Social Administration, The University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Cecilia L W', 'Initials': 'CLW', 'LastName': 'Chan', 'Affiliation': 'Department of Social Work & Social Administration, The University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Prasanth', 'Initials': 'P', 'LastName': 'Bevoor', 'Affiliation': 'Department of Nursing, Dharwad Institute of Mental health and Neuroscience, Dharwad, Karnataka, India.'}, {'ForeName': 'Raghavendra Bheemappa', 'Initials': 'RB', 'LastName': 'Nayak', 'Affiliation': 'Department of Psychiatry, Dharwad Institute of Mental health and Neuroscience, Dharwad, Karnataka, India.'}, {'ForeName': 'Mahesh', 'Initials': 'M', 'LastName': 'Desai', 'Affiliation': 'Department of Psychiatry, Dharwad Institute of Mental health and Neuroscience, Dharwad, Karnataka, India.'}]",Journal of ethnicity in substance abuse,['10.1080/15332640.2020.1793867'] 2208,32687474,Effect of Adding Telephone-based Brief Coaching to a mHealth App for Promoting Physical Activity Among Veterans: Results from the Stay Strong Randomized Controlled Trial.,"BACKGROUND Though maintaining physical conditioning and a healthy weight are requirements of active military duty, many U.S. Veterans lose conditioning and rapidly gain weight after discharge from active duty service. Mobile health (mHealth) interventions using wearable devices are appealing to users and can be effective in the shorter term, but adherence to study protocols and subsequent engagement often declines over time. We developed Stay Strong, a mobile app tailored to U.S. Veterans, to promote physical activity using a wrist-worn physical activity tracker, a Bluetooth-enabled scale, and app-based dashboard. We sought to determine whether adding personalized coaching components (Stay Strong+Coaching) would improve physical activity compared to Stay Strong alone. Personalized health coaching has potential to strengthen adherence and engagement with, and outcomes from, mHealth interventions. OBJECTIVE The goal was to compare 12-month outcomes from Stay Strong alone versus Stay Strong+Coaching. METHODS Participants (n=357) were recruited from a national random sample of U.S. Veterans of recent wars and randomly assigned to Stay Strong app alone (n=179) or Stay Strong+Coaching (n=178); both programs lasted 12 months. Personalized coaching components for Stay Strong+Coaching comprised of automated in-app motivational messages (3/week), telephone-based human health coaching (up to 3 calls), and personalized weekly goal-setting. All aspects of enrollment process and program delivery were accomplished virtually for both groups, except for the telephone-based coaching. The primary outcome was change in physical activity at 12 months post-baseline, measured by average weekly Active Minutes, captured by the Fitbit Charge 2 device. Secondary outcomes included changes in step counts, weight, and patient activation. RESULTS Average age of participants was 39.8 (8.7) years and 25.2% were female. Active Minutes decreased from baseline to 12-months for both groups (P<.001) with no between-group differences at 6- (P=.82) or 12-months (P=.98). However, at 12 months, many participants in both groups did not record Active Minutes, leading to missing data in 67.0% for Stay Strong and 61.8% for Stay Strong+Coaching. Average baseline weight for participants in Stay Strong and Stay Strong+Coaching was 214 and 198lbs, respectively, with no difference at baseline (P=.54) nor at 6- (P=.28), or 12-months (P=.18) post-baseline based on administrative weights, which had lower rates of missing data. Changes in number of steps recorded and patient activation also did not differ by arm. CONCLUSIONS Adding personalized health coaching comprised of in-app automated messages, up to 3 coaching calls, plus automated weekly personalized goals did not improve levels of physical activity compared to using a smartphone app alone. Physical activity in both groups decreased over time. Sustaining long-term adherence and engagement in this mHealth intervention proved difficult; approximately two-thirds of the trial's 357 participants failed to sync their Fitbit device at 12-months and thus, were lost to follow-up. CLINICALTRIAL clinicaltrials.gov identifier: NCT02360293. INTERNATIONAL REGISTERED REPORT RR2-10.2196/12526.",2020,"All aspects of enrollment process and program delivery were accomplished virtually for both groups, except for the telephone-based coaching.","['Veterans', 'Participants (n=357) were recruited from a national random sample of U.S. Veterans of recent wars and randomly assigned to', 'Average age of participants was 39.8 (8.7) years and 25.2% were female']","['Stay Strong alone versus Stay Strong+Coaching', 'Personalized coaching components for Stay Strong+Coaching comprised of automated in-app motivational messages (3/week), telephone-based human health coaching', 'Personalized health coaching', 'personalized coaching components (Stay Strong+Coaching', 'Telephone-based Brief Coaching to a mHealth App', 'Stay Strong app alone (n=179) or Stay Strong+Coaching', 'Mobile health (mHealth) interventions']","['number of steps recorded and patient activation', 'changes in step counts, weight, and patient activation', 'change in physical activity', 'Physical activity', 'Average baseline weight', 'Physical Activity', 'physical activity', 'levels of physical activity']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0043027', 'cui_str': 'War'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517880', 'cui_str': '8.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C3853034', 'cui_str': 'Patient Activation'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0851408', 'cui_str': 'Changes in physical activity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1303013', 'cui_str': 'Baseline weight'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",357.0,0.0813274,"All aspects of enrollment process and program delivery were accomplished virtually for both groups, except for the telephone-based coaching.","[{'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Damschroder', 'Affiliation': 'Veterans Affairs (VA) Center for Clinical Management Research, Ann Arbor Healthcare System, 2215 Fuller Rd (152), Ann Arbor, US.'}, {'ForeName': 'Lorraine R', 'Initials': 'LR', 'LastName': 'Buis', 'Affiliation': 'University of Michigan, Department of Family Medicine, Ann Arbor, US.'}, {'ForeName': 'Felicia A', 'Initials': 'FA', 'LastName': 'McCant', 'Affiliation': 'Veterans Affairs (VA) Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, Durham, US.'}, {'ForeName': 'H Myra', 'Initials': 'HM', 'LastName': 'Kim', 'Affiliation': 'Veterans Affairs (VA) Center for Clinical Management Research, Ann Arbor Healthcare System, 2215 Fuller Rd (152), Ann Arbor, US.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Evans', 'Affiliation': 'Veterans Affairs (VA) Center for Clinical Management Research, Ann Arbor Healthcare System, 2215 Fuller Rd (152), Ann Arbor, US.'}, {'ForeName': 'Eugene Z', 'Initials': 'EZ', 'LastName': 'Oddone', 'Affiliation': 'Veterans Affairs (VA) Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, Durham, US.'}, {'ForeName': 'Lori A', 'Initials': 'LA', 'LastName': 'Bastian', 'Affiliation': 'Veterans Affairs (VA) Pain Research, Informatics, Multimorbidities, and Education Center, VA Connecticut, West Haven, US.'}, {'ForeName': 'Gwendolyn', 'Initials': 'G', 'LastName': 'Hooks', 'Affiliation': 'Veterans Affairs (VA) Center for Clinical Management Research, Ann Arbor Healthcare System, 2215 Fuller Rd (152), Ann Arbor, US.'}, {'ForeName': 'Reema', 'Initials': 'R', 'LastName': 'Kadri', 'Affiliation': 'University of Michigan, Department of Family Medicine, Ann Arbor, US.'}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'White-Clark', 'Affiliation': 'Veterans Affairs (VA) Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, Durham, US.'}, {'ForeName': 'Caroline R', 'Initials': 'CR', 'LastName': 'Richardson', 'Affiliation': 'University of Michigan, Department of Family Medicine, Ann Arbor, US.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Gierisch', 'Affiliation': 'Veterans Affairs (VA) Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, Durham, US.'}]",Journal of medical Internet research,['10.2196/19216'] 2209,32687478,Assessing a WeChat-based integrative family intervention (WIFI) for schizophrenia: protocol for a stepped-wedge cluster randomized trial.,"BACKGROUND Schizophrenia is a persistent and debilitating mental illness, whose prognosis depends largely on supportive care and systematic treatment. In developing countries like China, family constitute the major caregiving force for schizophrenia and are faced with many challenges, such as lack of knowledge, skills and resources. How to support family caregiving in an accessible, affordable, feasible and cost-effective way remains unresolved. The widely spread use of WeChat provides a promising and cost-effective medium for support. OBJECTIVE The current study aims to assess a WeChat WeChat-based integrative family intervention (WIFI) to support family caregiving of schizophrenia. METHODS A WIFI program will be developed that include three core components: 1) psycho-education through WeChat Official Account (WOA), 2) peer support through WeChat chat group, and 3) professional support through WeChat video chat. A rigorous stepped wedge cluster randomized trial will be used to evaluate the implementation, effectiveness, and cost of the WIFI program. The WIFI program will be implemented in 12 communities affiliated with the Changsha psychiatric hospital through the free medicine delivery process in the 686 Program. The 12 communities will be randomized to one of four fixed sequences every two months during an 8-month intervention period in four clusters of 3 communities each. Outcomes will be assessed for both family caregivers and the family member with schizophrenia. Family caregivers will be assessed for their knowledge and skills about caregiving, social support and coping, perceived stigma, caregiver burden, family functioning, positive feelings, and psychological distress. Schizophrenia individuals will be assessed for their symptoms and functioning, quality of life, recovery and rehospitalization. Cost data such as costs of the intervention, health care utilization, and costs associated with lost productivity will also be collected. In addition, we will collect process data including fidelity and quality of program implementation as well as users' attitudes will also be collected. Treatment effects will be estimated using generalized linear maximum likelihood mixed modeling (GLMM) with clusters as a random effect and time as a fixed effect. Cost-effectiveness analysis will be performed from the societal perspective using incremental cost effectiveness ratios (ICERs). Qualitative analysis will use the grounded theory approach and immersion-crystallization process. RESULTS The study was funded in August 2018, approved by IRB on Jan 15th 2019. Preliminary baseline data collection was conducted in May 2019 and completed in Sep 2019. The WIFI intervention is expected to start in May 2020. CONCLUSIONS This is the first study to test a WeChat-based mHealth intervention to support family caregiving of schizophrenia in China. The innovative study will contribute to the development of a more cost-effective and evidence-based family management model in the community for schizophrenia individuals, and potentially be integrated into national policy and adapted for use with other populations. CLINICALTRIAL Nct04393896.",2020,This is the first study to test a WeChat-based mHealth intervention to support family caregiving of schizophrenia in China.,"['Schizophrenia individuals', '12 communities affiliated with the Changsha psychiatric hospital through the free medicine delivery process in the 686 Program', 'family caregiving of schizophrenia in China']","['WeChat-based mHealth intervention', 'WeChat WeChat-based integrative family intervention (WIFI', 'WeChat-based integrative family intervention (WIFI', 'psycho-education through WeChat Official Account (WOA), 2) peer support through WeChat chat group, and 3) professional support through WeChat video chat']",[],"[{'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0020021', 'cui_str': 'Psychiatric hospital'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C5191070', 'cui_str': '686'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0124604', 'cui_str': 'Catha edulis'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0042655', 'cui_str': 'Video'}]",[],,0.0677755,This is the first study to test a WeChat-based mHealth intervention to support family caregiving of schizophrenia in China.,"[{'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': 'Department of Social Medicine and Health Management, Xiangya School of Public Health,Central South University, Upper Mayuanling Road No. 238, Changsha, CN.'}, {'ForeName': 'Tong-Xin', 'Initials': 'TX', 'LastName': 'Li', 'Affiliation': 'Department of Social Medicine and Health Management, Xiangya School of Public Health,Central South University, Upper Mayuanling Road No. 238, Changsha, CN.'}, {'ForeName': 'Shi-Jun', 'Initials': 'SJ', 'LastName': 'Xi', 'Affiliation': 'Department of Social Medicine and Health Management, Xiangya School of Public Health,Central South University, Upper Mayuanling Road No. 238, Changsha, CN.'}, {'ForeName': 'Yi-Lu', 'Initials': 'YL', 'LastName': 'Li', 'Affiliation': 'Department of Social Medicine and Health Management, Xiangya School of Public Health,Central South University, Upper Mayuanling Road No. 238, Changsha, CN.'}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Xiao', 'Affiliation': 'Department of Geriatrics, Changsha Psychiatric Hospital, Changsha, CN.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Yang', 'Affiliation': 'Department of Geriatrics, Changsha Psychiatric Hospital, Changsha, CN.'}, {'ForeName': 'Xiaoping', 'Initials': 'X', 'LastName': 'Ge', 'Affiliation': 'Department of Geriatrics, Changsha Psychiatric Hospital, Changsha, CN.'}, {'ForeName': 'Shuiyuan', 'Initials': 'S', 'LastName': 'Xiao', 'Affiliation': 'Department of Social Medicine and Health Management, Xiangya School of Public Health,Central South University, Upper Mayuanling Road No. 238, Changsha, CN.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Tebes', 'Affiliation': 'Division of Prevention and Community Research, Department of Psychiatry,Yale School of Medicine, New Haven, US.'}]",JMIR research protocols,['10.2196/18538'] 2210,32553875,Precision of Dynamic Navigation to Perform Endodontic Ultraconservative Access Cavities: A Preliminary In Vitro Analysis.,"INTRODUCTION Ultraconservative access cavities (UCACs) have been proposed to reduce crown weakening, but there is no consensus about their design and size and about their advantages and disadvantages, which are also related to how differently they are performed. The purpose of the present study was to evaluate the possible use of a novel Dynamic Navigation System (DNS) in planning and executing UCACs and its precision in vitro, compared with a manual approach (MA) without any guide. METHODS Twenty radiopaque, artificial teeth replicas were randomly divided into 2 identical groups and scanned using cone-beam computed tomography. In the first group (MA) MB1 canal orifice was reached, starting from the central part of the molar occlusal surface, using a micro endodontic bur. In the second group, DNS allowed to plan and execute a more direct, straight-line truss access. After cavity preparation, teeth were scanned again, and cone-beam computed tomography images were compared. Data were statistically analyzed with analysis of variance test. RESULTS Significant differences (P < .05) were found in the tested parameters between the 2 groups. The DNS group was significantly more precise, showing smaller mean values in the angulation (4.8°) and in the maximum distance from the ideal position (0.34 mm), when compared with MA group (mean values, 21.2° and 0.88 mm, respectively). CONCLUSIONS Hence, we may conclude that the use of DNS increased the benefits of UCACs by minimizing the potential risk of iatrogenic weakening of critical portions of the crown and reducing negative influences to shaping procedures.",2020,"The DNS group was significantly more precise, showing smaller mean values in the angulation (4.8°) and in the maximum distance from the ideal position (0.34 mm), when compared with MA group (mean values, 21.2° and 0.88 mm, respectively). ","['Twenty radiopaque, artificial teeth replicas']","['Dynamic Navigation to Perform Endodontic Ultraconservative Access Cavities', 'scanned using cone-beam computed tomography', 'novel Dynamic Navigation System (DNS']",[],"[{'cui': 'C0040454', 'cui_str': 'Artificial Teeth'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0332274', 'cui_str': 'Endodontic'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C1956110', 'cui_str': 'Cone beam CT'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C4075648', 'cui_str': 'Navigation system'}]",[],20.0,0.0265075,"The DNS group was significantly more precise, showing smaller mean values in the angulation (4.8°) and in the maximum distance from the ideal position (0.34 mm), when compared with MA group (mean values, 21.2° and 0.88 mm, respectively). ","[{'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Gambarini', 'Affiliation': 'Department of Oral and Maxillo-Facial Sciences, University of Rome, Sapienza, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Galli', 'Affiliation': 'Department of Oral and Maxillo-Facial Sciences, University of Rome, Sapienza, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Morese', 'Affiliation': 'Department of Oral and Maxillo-Facial Sciences, University of Rome, Sapienza, Italy.'}, {'ForeName': 'Luigi Vito', 'Initials': 'LV', 'LastName': 'Stefanelli', 'Affiliation': 'Department of Oral and Maxillo-Facial Sciences, University of Rome, Sapienza, Italy.'}, {'ForeName': 'Fouad', 'Initials': 'F', 'LastName': 'Abduljabbar', 'Affiliation': 'Dental Department, King Abdulaziz Medical City, Jeddaah, Saudi Arabia.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Giovarruscio', 'Affiliation': 'Department of Therapeutic Dentistry, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.'}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Di Nardo', 'Affiliation': 'Department of Oral and Maxillo-Facial Sciences, University of Rome, Sapienza, Italy. Electronic address: dario.dinardo@uniroma1.it.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Seracchiani', 'Affiliation': 'Department of Oral and Maxillo-Facial Sciences, University of Rome, Sapienza, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Testarelli', 'Affiliation': 'Department of Oral and Maxillo-Facial Sciences, University of Rome, Sapienza, Italy.'}]",Journal of endodontics,['10.1016/j.joen.2020.05.022'] 2211,30041576,Novel Smartphone-Based Measures of Cell Phone Use While Driving in a Sample of Newly Licensed Adolescent Drivers.,"BACKGROUND Motor vehicle crashes are the leading cause of adolescent death. Cell phone use while driving is a contributor to adolescent motor vehicle crash risk. Objective and directly observable measures of cell phone use while driving are needed to implement interventions aimed at reducing cell phone-related crash risk. AIMS To describe novel smartphone-based measures of cell phone use while driving in a sample of newly licensed male and female adolescent drivers. METHODS Newly licensed adolescents in Pennsylvania installed a windshield-mounted device that pairs with a smartphone application to collect data on cell phone use while driving over 2 weeks during June 2016-October 2016. Descriptive statistics, independent t tests, and Wilcoxin Mann-Whitney U test were used to characterize handheld cell phone use (""unlock"") and call time while accounting for driving exposure. RESULTS Data from 16 adolescents (50% male) resulted in 5,624 miles in 705 trips, 964 cell phone unlocks, and 146.22 minutes of call time. Participants had a mean of 23.96 unlocks/100 miles ( SD = 22.97), 1.23 unlocks/trip ( SD = 0.96), and 4.87 unlocks/hour driven ( SD = 3.93). Males had significantly more unlocks/100 miles, unlocks at speed >25 mph/100 miles, unlocks/hour driven, and unlocks at speed > 25 mph/hour driven ( p < .05). CONCLUSIONS Smartphone-based applications are an innovative means by which to collect continuous data on cell phone use while driving that can be used to better understand and intervene on this frequent behavior in newly licensed adolescent drivers.",2019,"Males had significantly more unlocks/100 miles, unlocks at speed >25 mph/100 miles, unlocks/hour driven, and unlocks at speed > 25 mph/hour driven ( p < .05). ","['newly licensed male and female adolescent drivers', '16 adolescents (50% male) resulted in 5,624 miles in 705 trips, 964 cell phone unlocks, and 146.22 minutes of call time', 'newly licensed adolescent drivers', 'Participants had a mean of 23.96 unlocks/100 miles ( SD = 22.97), 1.23 unlocks/trip ( SD = 0.96), and 4.87 unlocks/hour driven ( SD = 3.93', 'Newly licensed adolescents in Pennsylvania installed a windshield-mounted device that pairs with a smartphone application to collect data on cell phone use while driving over 2 weeks during June 2016-October 2016']",['Novel Smartphone-Based Measures of Cell Phone Use'],"['unlocks/100 miles, unlocks at speed >25 mph/100 miles, unlocks/hour driven, and unlocks', 'handheld cell phone use (""unlock"") and call time while accounting for driving exposure']","[{'cui': 'C0023636', 'cui_str': 'Licenses'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0684312', 'cui_str': 'Vehicle driver'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}, {'cui': 'C0331865', 'cui_str': 'miles'}, {'cui': 'C0077275', 'cui_str': 'Triptorelin'}, {'cui': 'C1136359', 'cui_str': 'Cellular Phone'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4517495', 'cui_str': '1.23'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0030853', 'cui_str': 'Pennsylvania'}, {'cui': 'C0181909', 'cui_str': 'Mount'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C4505320', 'cui_str': 'Mobile Phone Use'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C4505320', 'cui_str': 'Mobile Phone Use'}]","[{'cui': 'C0331865', 'cui_str': 'miles'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C4505320', 'cui_str': 'Mobile Phone Use'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}]",,0.0393649,"Males had significantly more unlocks/100 miles, unlocks at speed >25 mph/100 miles, unlocks/hour driven, and unlocks at speed > 25 mph/hour driven ( p < .05). ","[{'ForeName': 'Catherine C', 'Initials': 'CC', 'LastName': 'McDonald', 'Affiliation': '1 University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Ward', 'Affiliation': '1 University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Yanlan', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': '1 University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Douglas J', 'Initials': 'DJ', 'LastName': 'Wiebe', 'Affiliation': '1 University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'M Kit', 'Initials': 'MK', 'LastName': 'Delgado', 'Affiliation': '1 University of Pennsylvania, Philadelphia, PA, USA.'}]",Health education & behavior : the official publication of the Society for Public Health Education,['10.1177/1090198118788612'] 2212,30080982,Using EPPM to Evaluate the Effectiveness of Fear Appeal Messages Across Different Media Outlets to Increase the Intention of Breast Self-Examination Among Chinese Women.,"The current study aims to examine the influence of fear appeal messages across different media outlets on Chinese women's intention of breast self-examination using the Extended Parallel Processing Model (EPPM). A two-by-two-by-two factorial experiment is designed to examine the effect of threat and efficacy level of stimulus on different media outlets on behavioral intention. The sample includes 488 Chinese women who are between 25 and 50 years old. The results revealed that there were significant main effects of both threat and efficacy on the intention to performing breast self-examination. Moreover, the significant two-way interaction effect between threat and efficacy was detected, which indicated that Chinese women who received messages containing both high threat and high efficacy had the highest intention of breast self-examination. Besides, the results demonstrated that there was no significant difference in the effectiveness of fear appeal messages on between traditional and social media.",2019,The results revealed that there were significant main effects of both threat and efficacy on the intention to performing breast self-examination.,"['Chinese Women', '488 Chinese women who are between 25 and 50\xa0years old', ""Chinese women's intention of breast self-examination using the Extended Parallel Processing Model (EPPM""]",['Fear Appeal Messages'],"['Intention of Breast Self-Examination', 'effectiveness of fear appeal messages']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0085105', 'cui_str': 'Breast self-examination'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0015726', 'cui_str': 'Fear'}]","[{'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0085105', 'cui_str': 'Breast self-examination'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0015726', 'cui_str': 'Fear'}]",488.0,0.0183749,The results revealed that there were significant main effects of both threat and efficacy on the intention to performing breast self-examination.,"[{'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Lab for Big Data and Communication, School of Communication and Design, Sun Yat-sen University.'}, {'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'School of Journalism and Communication, Shandong University.'}]",Health communication,['10.1080/10410236.2018.1493416'] 2213,32695159,"Comparison of Dexmedetomidine, Lidocaine, and Fentanyl in Attenuation Hemodynamic Response of Laryngoscopy and Intubation in Patients Undergoing Cardiac Surgery.","Materials and Methods This clinical trial was conducted on 90 patients, aged 30-70 years, who had heart surgery. The participants were categorized into three groups. Group D received 1  µ g/kg intravenous dexmedetomidine in 10 minutes, group L received 1.5 mg/kg lidocaine (1%) 90 seconds before intubation, and group F received 2  µ g/kg fentanyl. The vital signs (HR, SBP, DBP, and MAP) were measured before intubation and 1st, 3rd, 5th, and 10th minutes after intubation. Data were analyzed with SPSS 19 software (chi-square, one-way ANOVA, or Kruskal-Wallis). Results The age ( P =0.389) and gender distributions of patients were similar in all three groups. Dexmedetomidine significantly attenuated HR in the 3 rd ( P =0.001), 5 th ( P =0.001), and 10 th ( P =0.003) minutes after intervention. It also reduced the systolic blood pressure in the 5 th ( P =0.024) and 10 th ( P =0.006) minutes. This reduction was significantly higher in the dexmedetomidine group than that in the two other groups. In addition, dexmedetomidine caused a greater reduction in MAP in the 1 st ( P =0.048), 5 th ( P =0.0001), and 10 th ( P =0.0001) minutes. Discussion . All three medications were effective in controlling HR; however, dexmedetomidine caused bradycardia in the 3 rd , 5 th , and 10 th minutes. Lidocaine resulted in an increase in MAP in the 1 st minute after intubation; whereas, dexmedetomidine reduced MAP at the 5 th and 10 th minutes after intubation. Changes in blood pressure and mean arterial pressure in the fentanyl group was lower than the two other groups. Conclusion As a result, dexmedetomidine was not suitable for hemodynamic control and led to hypotension and bradycardia; on the other hand, fentanyl was more effective than two other medications in patients undergoing cardiac surgery. This trial is registered with IRCT2017013132320N1.",2020,"Dexmedetomidine significantly attenuated HR in the 3 rd ( P =0.001), 5 th ( P =0.001), and 10 th ( P =0.003) minutes after intervention.","['90 patients, aged 30-70 years, who had heart surgery', 'patients undergoing cardiac surgery', 'Patients Undergoing Cardiac Surgery']","['Lidocaine', 'Dexmedetomidine', 'lidocaine (1%) 90 seconds before intubation, and group F received 2\u2009 µ g/kg fentanyl', 'Dexmedetomidine, Lidocaine, and Fentanyl', 'dexmedetomidine']","['hypotension and bradycardia', 'blood pressure and mean arterial pressure', 'bradycardia', 'MAP', 'vital signs (HR, SBP, DBP, and MAP', 'systolic blood pressure']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0441840', 'cui_str': 'Group F'}, {'cui': 'C1300563', 'cui_str': 'g/kg'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}]","[{'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0024779', 'cui_str': 'Maps'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",90.0,0.069062,"Dexmedetomidine significantly attenuated HR in the 3 rd ( P =0.001), 5 th ( P =0.001), and 10 th ( P =0.003) minutes after intervention.","[{'ForeName': 'Maziar', 'Initials': 'M', 'LastName': 'Mahjoubifard', 'Affiliation': 'Fellowship of Cardiac Anesthesia, Zahedan University of Medical Sciences, Zahedan, Iran.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Heidari', 'Affiliation': 'Fellowship of Cardiac Anesthesia, Zahedan University of Medical Sciences, Zahedan, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Dahmardeh', 'Affiliation': 'Fellowship of Cardiac Anesthesia, Zahedan University of Medical Sciences, Zahedan, Iran.'}, {'ForeName': 'Seyed Bashir', 'Initials': 'SB', 'LastName': 'Mirtajani', 'Affiliation': 'Mycobacteriology Research Center (MRC), National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Jahangirifard', 'Affiliation': 'Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}]",Anesthesiology research and practice,['10.1155/2020/4814037'] 2214,32695196,Dosimetric evaluation of vaginal cuff brachytherapy planning in cervical and endometrial cancer patients.,"Purpose The aim of the study was to perform a prospective analysis of dosimetric consequences of rectal enema administration before vaginal cuff brachytherapy (VCB), the dose distribution in organs at risk (OARs), and the presence of air gaps (AGs) in patients with cervical or endometrial cancer. Material and methods In total, 75 patients treated in 2019 were randomly divided into two groups including 38 patients with and 37 without an enema before VCB. All patients received post-operative high-dose-rate (HDR). Single-channel vaginal cylinders with active length of 2.75 cm were used. Prescription dose was 7 Gy at 5 mm depth from the applicator surface in all directions. Treatment plans were based on computed tomography (CT). Results Enema performed before cylinder insertion had no effect on rectosigmoid D max or D 2cm3 . Rectosigmoid median V 100 was 0.5 cm 3 (range, 0-2.7 cm 3 ). V 100 ≥ 1 cm 3 in 22 and ≥ 2 cm 3 in 6 patients, with D max up to 19.7 Gy (282%) were observed. No effect of bladder volume in the range of 27-256 cm 3 on D max or D 2cm3 was found. The median bladder V 100 was 0.1 cm 3 (range, 0-1.4 cm 3 ). There were 62 (83%) patients with AGs, with 24% at the top of the vagina and 75% on the remaining length of the vagina. Most of the AGs were small (≤ 3 mm), but in 5 (8%) cases, they were bigger than 5 mm. Conclusions VCB planning with the use of CT is essential. CT can facilitate the selection of optimal cylinder size to reduce the occurrence of large AGs. A few percent of plans require correction of dose distribution because of hot spots in OARs and the presence of AGs. Enema before cylinder insertion does not influence rectosigmoid D max and D 2cm3 . The analysis revealed no bladder volume effect on bladder doses D max and D 2cm3 .",2020,"Rectosigmoid median V 100 was 0.5 cm 3 (range, 0-2.7 cm 3 ).","['cervical and endometrial cancer patients', 'patients with cervical or endometrial cancer', '75 patients treated in 2019 were randomly divided into two groups including 38 patients with and 37 without an enema before VCB']","['vaginal cuff brachytherapy planning', 'CT', 'rectal enema administration before vaginal cuff brachytherapy (VCB']","['bladder volume', 'remaining length of the vagina', 'rectosigmoid D max or D 2cm3 ']","[{'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0007103', 'cui_str': 'Endometrial neoplasms malignant'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0014268', 'cui_str': 'Giving patient an enema'}, {'cui': 'C1550321', 'cui_str': 'Vaginal cuff'}, {'cui': 'C0006098', 'cui_str': 'Brachytherapy'}]","[{'cui': 'C1550321', 'cui_str': 'Vaginal cuff'}, {'cui': 'C0006098', 'cui_str': 'Brachytherapy'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0205052', 'cui_str': 'Rectal'}, {'cui': 'C0014268', 'cui_str': 'Giving patient an enema'}]","[{'cui': 'C0429770', 'cui_str': 'Bladder volume'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0521377', 'cui_str': 'Rectosigmoid structure'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}]",38.0,0.0517072,"Rectosigmoid median V 100 was 0.5 cm 3 (range, 0-2.7 cm 3 ).","[{'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Sikorska', 'Affiliation': 'Department of Medical Physics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.'}, {'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Zolciak-Siwinska', 'Affiliation': 'Department of Gynecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Kowalczyk', 'Affiliation': 'Department of Medical Physics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.'}, {'ForeName': 'Michał', 'Initials': 'M', 'LastName': 'Bijok', 'Affiliation': 'Department of Medical Physics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.'}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Michalski', 'Affiliation': 'Department of Clinical Trials and Biostatistics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.'}, {'ForeName': 'Ewelina', 'Initials': 'E', 'LastName': 'Gruszczynska', 'Affiliation': 'Department of Medical Physics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.'}]",Journal of contemporary brachytherapy,['10.5114/jcb.2020.96865'] 2215,32695206,"In Vitro and Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy and Safety of Nine Antiacne Medicinal Plants.","The present in vitro and randomized, double-blind, placebo-controlled trial aims to determine the efficacy and safety of nine Mediterranean antiacne medicinal plants. The antimicrobial, antisebum, and anti-inflammatory activities of the plant extracts were evaluated in cells from the immortalized human keratinocytes (HaCaT) and human monocytic cell line (THP-1) as well as in a double-blind, randomized, and placebo-controlled trial. Most of the extracts showed no significant cytotoxic effects on HaCaT cells up to 250  μ g/ml. Inula helenium (IH) and Saponaria officinalis (SO) inhibited sebum production at 90  μ g/ml and 30  μ g/ml, respectively. The inhibition effect of SO on the growth of Cutibacterium acnes was 1.2 times higher than that of chloramphenicol. IH and SO extracts significantly inhibited the lipopolysaccharide- (LPS-) induced IL-6 and TNF- α production in THP-1 cells reaching the control levels of untreated cells at a concentration of 250  μ g/ml. SO, IH, and Solanum nigrum (SN) extracts inhibited the nitric oxide (NO) production in a dose-dependent manner. Based on these results, an antiacne herbal cream (AHC) was prepared from different portions of extracts from SO, IH, and SN, and its efficacy was evaluated in a double-blind, randomized, and controlled efficacy study with 41 acne patients, ages 18-24, who were asked to apply AHC ( n  = 27) or a placebo ( n  = 14) two to three times daily for six weeks. Results obtained indicate that the AHC has unique synergistic effects that halt sebum production, combined with highly antiseptic and anti-inflammatory activity, in which 54.95% ( t  = 19.37 P < 0.001) of acne inflammatory and noninflammatory lesions disappeared after two weeks, 85.3%, after five weeks ( t  = 14.19 P < 0.001), and 91.4%, at the end of the sixth week of application ( t  = 5.7 P < 0.001). In conclusion, SO, IH, and SN as single extracts and in combination as AHC showed significant antimicrobial, antisebum, and anti-inflammatory activities in vitro and in a double-blind, randomized, and controlled antiacne efficacy. Therefore, AHC represents an interesting alternative treatment for acne.",2020,IH and SO extracts significantly inhibited the lipopolysaccharide- (LPS-) induced IL-6 and TNF- α production in THP-1 cells reaching the control levels of untreated cells at a concentration of 250  μ g/ml.,"['41 acne patients, ages 18-24, who were asked to apply AHC ( n \u2009=\u200927) or a']","['antiacne herbal cream (AHC', 'Placebo', 'Nine Antiacne Medicinal Plants', 'nine Mediterranean antiacne medicinal plants', 'Inula helenium (IH) and Saponaria officinalis (SO', 'chloramphenicol', 'placebo']","['sebum production', 'cytotoxic effects on HaCaT cells', 'efficacy and safety', 'nitric oxide (NO) production', 'acne inflammatory and noninflammatory lesions']","[{'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1172410', 'cui_str': 'ASK protein, human'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0220766', 'cui_str': 'Congenital hypoplasia of adrenal gland'}]","[{'cui': 'C0376667', 'cui_str': 'Herbals'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0220766', 'cui_str': 'Congenital hypoplasia of adrenal gland'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0032100', 'cui_str': 'Medicinal Plants'}, {'cui': 'C0063734', 'cui_str': 'Elecampane'}, {'cui': 'C0330382', 'cui_str': 'Saponaria officinalis'}, {'cui': 'C0008168', 'cui_str': 'Chloramphenicol'}]","[{'cui': 'C0036511', 'cui_str': 'Sebum'}, {'cui': 'C0304497', 'cui_str': 'Cytotoxic agent'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C1998083', 'cui_str': 'Inflammatory acne'}, {'cui': 'C0442743', 'cui_str': 'Noninflammatory'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",41.0,0.470705,IH and SO extracts significantly inhibited the lipopolysaccharide- (LPS-) induced IL-6 and TNF- α production in THP-1 cells reaching the control levels of untreated cells at a concentration of 250  μ g/ml.,"[{'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Said', 'Affiliation': 'Independent Researcher, Beleaf Pharma, P.O. Box 2205, Kfar Kana, Galilee 16930, Israel.'}, {'ForeName': 'Iyad', 'Initials': 'I', 'LastName': 'Khamaysi', 'Affiliation': 'Faculty of Medicine, Technion-ITT, Rambam Medical Center, Haifa, Israel.'}, {'ForeName': 'Abdalsalam', 'Initials': 'A', 'LastName': 'Kmail', 'Affiliation': 'Faculty of Arts and Sciences, Arab American University Jenin, P.O. Box 240, Jenin, State of Palestine.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Fulder', 'Affiliation': 'Independent Researcher, Beleaf Pharma, P.O. Box 2205, Kfar Kana, Galilee 16930, Israel.'}, {'ForeName': 'Basheer', 'Initials': 'B', 'LastName': 'AboFarekh', 'Affiliation': 'Qasemi Research Center-Al-Qasemi Academy, P.O. Box 124, Baqa El-Gharbia 30100, Israel.'}, {'ForeName': 'Riyad', 'Initials': 'R', 'LastName': 'Amin', 'Affiliation': 'Independent Researcher, Beleaf Pharma, P.O. Box 2205, Kfar Kana, Galilee 16930, Israel.'}, {'ForeName': 'Jamila', 'Initials': 'J', 'LastName': 'Daraghmeh', 'Affiliation': 'Faculty of Arts and Sciences, Arab American University Jenin, P.O. Box 240, Jenin, State of Palestine.'}, {'ForeName': 'Bashar', 'Initials': 'B', 'LastName': 'Saad', 'Affiliation': 'Faculty of Arts and Sciences, Arab American University Jenin, P.O. Box 240, Jenin, State of Palestine.'}]",Evidence-based complementary and alternative medicine : eCAM,['10.1155/2020/3231413'] 2216,32695229,Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol.,"Objectives Several beneficial effects of resveratrol have already been published. This study evaluated the effect of resveratrol on the hemorheological parameters in patients with heart failure with reduced ejection fraction. Methods In our double-blind, placebo-controlled human clinical trial, we enrolled 60 outpatients with heart failure. Patients were randomized into two groups: receiving either 100 mg resveratrol capsule daily or placebo for 3 months. Hematocrit was determined by microhematocrit centrifuge. Plasma and whole blood viscosity was evaluated by capillary viscometer. Erythrocyte aggregation was measured by both LORCA and Myrenne aggregometers. LORCA ektacytometer was used for measuring erythrocyte deformability. Exercise capacity was assessed by a 6-minute walk test. Results Resveratrol treatment did not have any significant effect on hematocrit and viscosity. The erythrocyte deformability also remained unchanged. However, significant improvement of red blood cell aggregation was observed in the resveratrol group compared to baseline after 3 months. Furthermore, positive correlation was found between the exercise capacity and the hemorheological properties (Hct, WBV, and RBC aggregation and deformability) as well. Conclusion These findings indicate that resveratrol can significantly reduce red blood cell aggregation, which may positively influence microcirculation, which may contribute to the improvement of tissue perfusion and oxygen supply in heart failure.",2020,"Results Resveratrol treatment did not have any significant effect on hematocrit and viscosity.","['60 outpatients with heart failure', 'patients with heart failure with reduced ejection fraction', 'Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol']","['100\u2009mg resveratrol capsule daily or placebo', 'placebo']","['Plasma and whole blood viscosity', 'erythrocyte deformability', 'Hemorheological Alterations', 'exercise capacity and the hemorheological properties (Hct, WBV, and RBC aggregation and deformability', 'Exercise capacity', 'hemorheological parameters', 'hematocrit and viscosity', 'Hematocrit', 'red blood cell aggregation', 'Erythrocyte aggregation']","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0073096', 'cui_str': 'resveratrol'}]","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0073096', 'cui_str': 'resveratrol'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0427691', 'cui_str': 'Whole blood viscosity measurement'}, {'cui': 'C0014774', 'cui_str': 'Erythrocyte deformability'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0332621', 'cui_str': 'Aggregation'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0042784', 'cui_str': 'Viscosity'}, {'cui': 'C0014766', 'cui_str': 'Erythrocyte Aggregation'}]",60.0,0.117976,"Results Resveratrol treatment did not have any significant effect on hematocrit and viscosity.","[{'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Gal', 'Affiliation': 'Division of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, Hungary.'}, {'ForeName': 'Dora', 'Initials': 'D', 'LastName': 'Praksch', 'Affiliation': 'Division of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, Hungary.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Kenyeres', 'Affiliation': 'Division of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, Hungary.'}, {'ForeName': 'Miklos', 'Initials': 'M', 'LastName': 'Rabai', 'Affiliation': 'Division of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, Hungary.'}, {'ForeName': 'Kalman', 'Initials': 'K', 'LastName': 'Toth', 'Affiliation': 'Division of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, Hungary.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Halmosi', 'Affiliation': 'Division of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, Hungary.'}, {'ForeName': 'Tamas', 'Initials': 'T', 'LastName': 'Habon', 'Affiliation': 'Division of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, Hungary.'}]",Cardiovascular therapeutics,['10.1155/2020/7262474'] 2217,32695435,A feasibility study of the physiotherapy management of urinary incontinence in athletic women: trial protocol for the POsITIve study.,"Background Urinary incontinence (UI) affects up to 40% of adult women within the UK, and pelvic floor muscle training can be effective as a treatment. The prevalence of UI is higher in athletic women than in their sedentary counterparts, but there is little research into reasons for this or into treatment within this population.The aim of this study is to investigate the feasibility of conducting a future randomised controlled trial of physiotherapeutic management of UI in athletic women. Methods This is a mixed methods study with three distinct but related phases.Phase 1: Semi-structured interviews with health care professionals in the community will explore current management practices of UI in women and particularly in female athletes in order to inform the control arm of a future study. It will also establish community health care professionals' understanding of pelvic health physiotherapy.Phase 2: Athletic and regularly exercising women recruited directly from gyms and sports clubs will undergo a course of physiotherapy to manage UI. This will establish study recruitment, eligibility, consent, attendance, attrition, and data completion rates. It will provide information regarding appropriate clinical venues and outcome measures to use for this patient group.Phase 3: Semi-structured interviews with purposefully selected participants from phase 2 will investigate participant satisfaction with recruitment procedures, the intervention, outcome measures and the venues. Further, we will collect data regarding the use of a smartphone 'app' for adherence and monitoring of home exercises and participants' beliefs around randomisation in a future study. We will explore the impact of UI on life and sport in more detail. Discussion This study will establish the ease and acceptability of recruiting athletic women directly from gyms and sports clubs and identify attrition rates. It will also explore the acceptability of the intervention, clinical venues and outcome measures. Data collected will be used to inform a future randomised controlled trial. Trial registration NCT03986411 (clinicaltrials.gov). Registered on 14 June 2019.",2020,Phase 1: Semi-structured interviews with health care professionals in the community will explore current management practices of UI in women and particularly in female athletes in order to inform the control arm of a future study.,"['athletic women than in their sedentary counterparts', 'Phase 2: Athletic and regularly exercising women recruited directly from gyms and sports clubs', 'athletic women', 'urinary incontinence in athletic women']","['physiotherapy management', 'Semi-structured interviews with health care professionals']",[],"[{'cui': 'C1510656', 'cui_str': 'Athletics'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0282460', 'cui_str': 'Clinical Trials, Phase II as Topic'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0149651', 'cui_str': 'Clubbing'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}]","[{'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}]",[],,0.12637,Phase 1: Semi-structured interviews with health care professionals in the community will explore current management practices of UI in women and particularly in female athletes in order to inform the control arm of a future study.,"[{'ForeName': 'K Gillian', 'Initials': 'KG', 'LastName': 'Campbell', 'Affiliation': 'Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, NG7 2HA UK.'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Batt', 'Affiliation': 'Centre for Sports Medicine, Nottingham University Hospitals, Nottingham, UK.'}, {'ForeName': 'Avril', 'Initials': 'A', 'LastName': 'Drummond', 'Affiliation': 'Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, NG7 2HA UK.'}]",Pilot and feasibility studies,['10.1186/s40814-020-00638-6'] 2218,32695500,Comparison of Repeated Fluid-Air Exchange and Passive Drainage for Removing Residual Emulsified Silicone Oil Droplets.,"Purpose To compare the efficacy of passive drainage (PD) and repeated fluid-air (FA) exchange for removing emulsified silicone oil (SO) droplets. Methods Twenty rhegmatogenous retinal detachment (RRD) patients who underwent primary pars plana vitrectomy (PPV) with SO tamponade were randomly and evenly divided into two groups for PD and FA exchange. Once the bulk of SO was removed, the first 2 mL of the washout fluid was collected, and then, another 2 mL of the washout fluid was collected after PD or FA exchange. The size and number of SO droplets in the washout fluid were measured using a Coulter counter (Multisizer 3, Beckman Coulter, Indianapolis, IN, USA). The efficiencies of FA exchange and PD for removing emulsified SO were compared. Results The number of SO droplets decreased significantly after FA exchange and PD. The decrease in the number of droplets was statistically significant for larger droplets (>4  µ m) with PD and for all droplet sizes with FA exchange. The decrease in the number of SO droplets of <4  μ m was significantly greater with FA exchange than with PD. However, at the end of the procedure, the overall number and size distribution of SO droplets were similar for both procedures. Conclusions PD and FA exchange reduced the number of residual emulsified SO droplets after SO tamponade efficiently. FA exchange may have some advantages over PD in removing small droplets.",2020,The decrease in the number of droplets was statistically significant for larger droplets (>4  µ m) with PD and for all droplet sizes with FA exchange.,"['RRD) patients who underwent primary pars plana vitrectomy (PPV) with SO tamponade', 'Twenty rhegmatogenous retinal detachment ']","['passive drainage (PD) and repeated fluid-air (FA) exchange', 'Repeated Fluid-Air Exchange and Passive Drainage']","['efficiencies of FA exchange and PD', 'number of droplets', 'number of SO droplets', 'size and number of SO droplets', 'overall number and size distribution of SO droplets']","[{'cui': 'C0271055', 'cui_str': 'Rhegmatogenous retinal detachment'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0563537', 'cui_str': 'Mechanical vitrectomy by pars plana approach'}, {'cui': 'C0037111', 'cui_str': 'Silicone oil'}, {'cui': 'C0332459', 'cui_str': 'Compression'}]","[{'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0001861', 'cui_str': 'Air'}]","[{'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0037111', 'cui_str': 'Silicone oil'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}]",20.0,0.0819036,The decrease in the number of droplets was statistically significant for larger droplets (>4  µ m) with PD and for all droplet sizes with FA exchange.,"[{'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai 200031, China.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Zong', 'Affiliation': 'Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai 200031, China.'}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Tan', 'Affiliation': 'Gongli Hospital of Shanghai Pudong New Area, Shanghai 200135, China.'}, {'ForeName': 'Chunhui', 'Initials': 'C', 'LastName': 'Jiang', 'Affiliation': 'Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai 200031, China.'}, {'ForeName': 'Gezhi', 'Initials': 'G', 'LastName': 'Xu', 'Affiliation': 'Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai 200031, China.'}]",Journal of ophthalmology,['10.1155/2020/8184607'] 2219,32695631,An analysis of the correlation between the human apolipoprotein E gene polymorphism and lipoprotein-associated phospholipase A2.,"Background Atherosclerosis is one of the most common cardiovascular and cerebrovascular diseases. This study aimed to explore the correlation between gene polymorphism of human apolipoprotein E (ApoE) and lipoprotein-associated phospholipase A2 (Lp-PLA2). Methods A total of 220 patients with atherosclerotic cardiovascular disease who were treated in our hospital from June 2016 to March 2017 were enrolled in this study and assigned as the atherosclerotic cardiovascular disease group and 193 patients who were treated contemporaneously in our hospital but had no atherosclerotic cardiovascular disease were enrolled and assigned as the control group. Gene polymorphism of ApoE was detected by PCR-fluorescent probe technique and the level of Lp-PLA2 was detected by ELISA. Results There were a total of 5 genotypes of ApoE in these two groups, which were E2/3, E3/3, E3/4, E2/4, and E4/4. E2/2 was not found in any of the patients. E3/3 made up the majority in both groups. There was no significant difference between the proportion of genotypes and frequencies of alleles in the two groups (P>0.05). There was no difference between LP-PLA2 among the different genotypes in these two groups (P>0.05). Conclusions We cannot conclude that ApoE gene polymorphism is related to atherosclerotic cardiovascular and cerebrovascular diseases. And it cannot be concluded that ApoE gene polymorphism is related to Lp-PLA2 level.",2020,"There was no difference between LP-PLA2 among the different genotypes in these two groups (P>0.05). ",['220 patients with atherosclerotic cardiovascular disease who were treated in our hospital from June 2016 to March 2017 were enrolled in this study and assigned as the atherosclerotic cardiovascular disease group and 193 patients who were treated contemporaneously in our hospital but had no atherosclerotic cardiovascular disease were enrolled and assigned as the control group'],[],"['LP-PLA2', 'proportion of genotypes and frequencies of alleles']","[{'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],"[{'cui': 'C0914069', 'cui_str': '1-alkyl-2-acetylglycerophosphocholine esterase'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0002085', 'cui_str': 'Genetic alleles'}]",220.0,0.0294344,"There was no difference between LP-PLA2 among the different genotypes in these two groups (P>0.05). ","[{'ForeName': 'Wei-Guo', 'Initials': 'WG', 'LastName': 'Yin', 'Affiliation': ""Department of Molecular Diagnosis Center, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China.""}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Zhou', 'Affiliation': ""Department of Molecular Diagnosis Center, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China.""}, {'ForeName': 'Xiao-Hong', 'Initials': 'XH', 'LastName': 'Zhou', 'Affiliation': 'Kingmed Diagnostic Center for Clinical Laboratory, Guangzhou, China.'}, {'ForeName': 'Yan-Mei', 'Initials': 'YM', 'LastName': 'Liu', 'Affiliation': ""Department of Molecular Diagnosis Center, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China.""}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': ""Department of Molecular Diagnosis Center, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China.""}, {'ForeName': 'Shu-Xia', 'Initials': 'SX', 'LastName': 'Xuan', 'Affiliation': ""Department of Molecular Diagnosis Center, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China.""}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Cheng', 'Affiliation': ""Department of Molecular Diagnosis Center, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China.""}, {'ForeName': 'Jin-Duan', 'Initials': 'JD', 'LastName': 'Lin', 'Affiliation': ""Department of Molecular Diagnosis Center, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China.""}, {'ForeName': 'Ling-Qing', 'Initials': 'LQ', 'LastName': 'Xu', 'Affiliation': ""Clinical Laboratory, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China.""}]",Cardiovascular diagnosis and therapy,['10.21037/cdt-20-43'] 2220,32695652,"Effects of the tai chi qigong programme on functional capacity, and lung function in chronic obstructive pulmonary disease patients: A ramdomised controlled trial.","Although the beneficial effect of exercise on the health of Chronic Obstructive Pulmonary Disease (COPD) patients has been widely demonstrated, that of Tai Chi Qigong (TCQ), as an alternative exercise, has been inconclusive. Therefore, this study aimed to evaluate the effects of combined center-and home-based TCQ on functional capacity and lung function in patients with mildly and moderately severe COPD. A total of 50 patients, with a mild and moderate degree of COPD, were recruited and randomly assigned to either the TCQ (n = 25) or control group (n = 25). The TCQ group completed 12-week center-and 12-week home-based training. The control group attended a meeting class once a week for 12 weeks. Outcome measures were assessed at baseline, and the 6th, 12th and 24th week. The primary outcomes were functional capacity (6-min walk test; 6MWT) and lung function. The secondary outcomes were dyspnea score and quality of life. The TCQ group demonstrated significant improvement in functional capacity at week 12 and 24 (p < 0.05) and dyspnea score and quality of life at week 6, 12 and 24 (p < 0.05) when compared to baseline. Functional capacity, forced expiratory volume in 1st second (FEV 1 ), dyspnea score, and quality of life were significantly better in the TCQ group from week 6 to week 24 when compared to the control group (p < 0.05). Combined center-and home-based TCQ training for patients with mildly and moderately severe COPD is effective in improving functional capacity, dyspnea score, and quality of life.",2020,"The TCQ group demonstrated significant improvement in functional capacity at week 12 and 24 (p < 0.05) and dyspnea score and quality of life at week 6, 12 and 24 (p < 0.05) when compared to baseline.","['patients with mildly and moderately severe COPD', '50 patients, with a mild and moderate degree of COPD', 'chronic obstructive pulmonary disease patients', 'Chronic Obstructive Pulmonary Disease (COPD) patients']","['exercise', 'combined center-and home-based TCQ', 'Combined center-and home-based TCQ training', 'TCQ', 'tai chi qigong programme', 'Tai Chi Qigong (TCQ']","['functional capacity and lung function', 'dyspnea score and quality of life', 'functional capacity, and lung function', 'functional capacity, dyspnea score, and quality of life', 'functional capacity', 'Functional capacity, forced expiratory volume in 1st second (FEV 1 ), dyspnea score, and quality of life', 'functional capacity (6-min walk test; 6MWT) and lung function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2945599', 'cui_str': 'Mild'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0730607', 'cui_str': 'Severe chronic obstructive pulmonary disease'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0376403', 'cui_str': 'Tai-chi'}, {'cui': 'C0282077', 'cui_str': 'Qigong'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0205435', 'cui_str': 'First'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}]",50.0,0.0384705,"The TCQ group demonstrated significant improvement in functional capacity at week 12 and 24 (p < 0.05) and dyspnea score and quality of life at week 6, 12 and 24 (p < 0.05) when compared to baseline.","[{'ForeName': 'Tassawan', 'Initials': 'T', 'LastName': 'Kantatong', 'Affiliation': 'Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Ratana', 'Initials': 'R', 'LastName': 'Panpanich', 'Affiliation': 'Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Athavudh', 'Initials': 'A', 'LastName': 'Deesomchok', 'Affiliation': 'Division of Pulmonary, Critical Care and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Somporn', 'Initials': 'S', 'LastName': 'Sungkarat', 'Affiliation': 'Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Penprapa', 'Initials': 'P', 'LastName': 'Siviroj', 'Affiliation': 'Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}]",Journal of traditional and complementary medicine,['10.1016/j.jtcme.2019.03.008'] 2221,32695921,The effect of pain management group on chronic pain and pain related co-morbidities and symptoms. A stepped-wedge cluster randomized controlled trial. A study protocol.,"Introduction In primary care settings, pain - management group therapy is a tool potentially cost-effective but very much underused. Methods Our purpose here is to provide useful scientific information on the effect of pain-management group participation on chronic pain and pain-related co-morbidities and symptoms, as well as practical information for primary and occupational health services to initiate pain-management group activity.This study will be carried out at primary care Occupational Health Helsinki (Helsinki city employees' occupational health services), with the Finnish Institute of Occupational Health as the research partner.This is a stepped-wedge cluster randomized controlled trial among both male and female municipal employees aged 18 to 65, all of whom had visited an occupational doctor, nurse, psychologist, or physiotherapist because of any chronic pain unrelated to malignant disease. An additional inclusion criterion is work disability risk being elevated, based on a short screening questionnaire (modified Örebro questionnaire). Each participant and each interviewer will be blinded at randomization. Three groups, 10 subjects in each, begin directly after recruitment with 6 weekly 2-h meetings and a follow-up meeting 6 months later. Three waiting-list groups begin 4 months later. Subjects complete self-administered questionnaires before and after the sixth meetings, also 6 months later. Primary outcomes are pain intensity, current work ability, pain self-efficacy, fear-avoidance beliefs, chronic pain acceptance, depressive symptoms, sleep problems, sickness absence days, and number of occupational health care contacts from OH's medical records. Results We will publish our results in a peer-reviewed scientific journals.",2020,"An additional inclusion criterion is work disability risk being elevated, based on a short screening questionnaire (modified Örebro questionnaire).","[""primary care Occupational Health Helsinki (Helsinki city employees' occupational health services"", 'male and female municipal employees aged 18 to 65, all of whom had visited an occupational doctor, nurse, psychologist, or physiotherapist because of any chronic pain unrelated to malignant disease']","['pain - management group therapy', 'pain management']","[""pain intensity, current work ability, pain self-efficacy, fear-avoidance beliefs, chronic pain acceptance, depressive symptoms, sleep problems, sickness absence days, and number of occupational health care contacts from OH's medical records"", 'chronic pain and pain related co-morbidities and symptoms']","[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0079920', 'cui_str': 'Occupational Health'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C0028801', 'cui_str': 'Occupational health service'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0521127', 'cui_str': 'Occupational'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0033908', 'cui_str': 'Psychologist'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0445356', 'cui_str': 'Unrelated'}, {'cui': 'C0205282', 'cui_str': 'Malignant'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0033971', 'cui_str': 'Group psychotherapy'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnia'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0079920', 'cui_str': 'Occupational Health'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0025102', 'cui_str': 'Medical record'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.0653411,"An additional inclusion criterion is work disability risk being elevated, based on a short screening questionnaire (modified Örebro questionnaire).","[{'ForeName': 'Marjatta', 'Initials': 'M', 'LastName': 'Reilimo', 'Affiliation': 'Occupational Health Helsinki, Helsinginkatu 24, 00101, Helsinki, Finland.'}, {'ForeName': 'Leena', 'Initials': 'L', 'LastName': 'Kaila-Kangas', 'Affiliation': 'Work Ability and Working Careers, Finnish Institute of Occupational Health, P.O Box 40, FI-00032, Helsinki, Finland.'}, {'ForeName': 'Rahman', 'Initials': 'R', 'LastName': 'Shiri', 'Affiliation': 'Work Ability and Working Careers, Finnish Institute of Occupational Health, P.O Box 40, FI-00032, Helsinki, Finland.'}, {'ForeName': 'Marjukka', 'Initials': 'M', 'LastName': 'Laurola', 'Affiliation': 'Work Ability and Working Careers, Finnish Institute of Occupational Health, P.O Box 40, FI-00032, Helsinki, Finland.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Miranda', 'Affiliation': 'Work Ability and Working Careers, Finnish Institute of Occupational Health, P.O Box 40, FI-00032, Helsinki, Finland.'}]",Contemporary clinical trials communications,['10.1016/j.conctc.2020.100603'] 2222,32695954,Effectiveness of home-based rehabilitation program in minimizing disability and secondary falls after a hip fracture: Protocol for a randomized controlled trial.,"Introduction Hip fractures are a major health problem globally and are associated with increased morbidity, mortality, and substantial economic costs. Successful operative treatment of hip fracture patients is necessary for the optimization of post-op mobility and functional recovery of the patient. Rehabilitation after surgical stabilization of a hip fracture is crucial in order to restore pre-fracture function and to avoid long-term institutionalization. In particular ongoing exercise which targets balance can prevent up to 40% of falls. Therefore, we have designed a post-discharge home-based physical rehabilitation intervention program to minimize disability and falls in this high-risk elderly population. Methods and analysis The study will be an open label, simple randomized controlled trial at a single hospital. The two arms will be equally allocated on a 1:1 ratio into intervention and control groups. The control arm will receive the usual standard postoperative rehabilitation. The intervention group will receive an extended home-based rehabilitation program twice a week continued for 3 months (12 weeks) after discharge. The Primary outcome of the study is occurrence of falls. Falls will be measured at 3, 6, 12, and 24 months by research-assistant follow-up telephone calls for both the groups. Mobility-related disability will be measured with a self-reported test at every routine follow-up for up to two years using a performance-based short battery tool. Negative binomial regression model will be used to compare number of falls in both the groups by computing incidence ratio rates. Ethics and dissemination Approval for the conduction of this study has been taken from the Ethical Review Committee (ERC) of the institution. Evidences which will be obtained from this study will facilitate to propose changes in existing guidelines and policies for treating fall and hip fracture patients.Trial registrationThis trial is registered on clinicaltrials.gov ID: NCT04108793.",2020,Successful operative treatment of hip fracture patients is necessary for the optimization of post-op mobility and functional recovery of the patient.,"['minimizing disability and secondary falls after a hip fracture', 'hip fracture patients']","['home-based rehabilitation program', 'discharge home-based physical rehabilitation intervention program', 'extended home-based rehabilitation program']","['Mobility-related disability', 'occurrence of falls']","[{'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0231448', 'cui_str': 'Extension'}]","[{'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}]",,0.099062,Successful operative treatment of hip fracture patients is necessary for the optimization of post-op mobility and functional recovery of the patient.,"[{'ForeName': 'Anum', 'Initials': 'A', 'LastName': 'Sadruddin Pidani', 'Affiliation': 'Department of Surgery, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Saniya', 'Initials': 'S', 'LastName': 'Sabzwari', 'Affiliation': 'Department of Family Medicine, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Khabir', 'Initials': 'K', 'LastName': 'Ahmad', 'Affiliation': 'Department of Surgery, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Ata', 'Initials': 'A', 'LastName': 'Mohammed', 'Affiliation': 'Department of Physiotherapy, Aga Khan University, Karachi, Pakistan.'}, {'ForeName': 'Shahryar', 'Initials': 'S', 'LastName': 'Noordin', 'Affiliation': 'Department of Surgery, Aga Khan University, Karachi, Pakistan.'}]",International journal of surgery protocols,['10.1016/j.isjp.2020.06.002'] 2223,32695957,Variation of Serum Lycopene in Response to 100% Watermelon Juice: An Exploratory Analysis of Genetic Variants in a Randomized Controlled Crossover Study.,"Background Watermelon, a rich source of lycopene, has garnered attention for cardioprotective effects including cholesterol reduction and promotion of redox balance. It is unknown whether 100% watermelon juice may represent a food-first approach to confer cardioprotective benefits of lycopene. Objectives This study examined influences of 100% watermelon juice on serum lycopene, lipids, and antioxidant capacity. Secondly, the study explored genetic influences on lycopene metabolism and bioavailability. Methods A placebo-controlled, randomized, double-blind, crossover trial with postmenopausal women ( n  = 16, mean ± SD age: 60 ± 4.1 y) assessed effects of 100% watermelon juice on mechanistic and clinical outcomes influencing vascular function. Participants maintained low-lycopene diets for a 1-wk run-in period and throughout the study. Morning and evening consumption of 100% watermelon juice provided a daily dose of 14.4 ± 0.34 mg lycopene. Study arms of 4 wk were separated by a 2-wk washout period. Saliva was collected for genetic analysis of single nucleotide polymorphisms, and fasting blood samples were taken pre- and post-study arms. Statistical analyses included mixed models, linear regression, and nonparametric tests. Results Serum lycopene exhibited a significant treatment effect ( P  = 0.002) along with notable interindividual responses; however, significant improvements in serum lipids or antioxidant capacity were not observed. Genetic variant rs6564851 in the β-carotene 15,15'-oxygenase-1 ( BCO1 ) gene was associated with changes in lycopene such that TT homozygotes exhibited a significantly greater increase (β ± SE: 13.4 ± 1.6, P  = 1.4 × 10 -06 ). Conclusions Watermelon juice supplementation did not result in improvements in serum lipids or antioxidant capacity; however, results support findings in which watermelon juice significantly, yet differentially, increased circulating lycopene. Genetics appears to explain some of the variability. Given that dose has been shown to overcome individual responsiveness to lycopene interventions, future investigations with varying doses of lycopene-rich foods would be strengthened by genotyping so as to establish personalized nutrition recommendations.This trial was registered at clinicaltrials.gov as NCT03626168.",2020,"Serum lycopene exhibited a significant treatment effect ( P  = 0.002) along with notable interindividual responses; however, significant improvements in serum lipids or antioxidant capacity were not observed.","['SD age: 60\xa0±\xa04.1 y', 'postmenopausal women ( n \xa0']","['100% watermelon juice', 'Watermelon Juice', 'lycopene', 'Serum Lycopene', 'placebo']","['serum lipids or antioxidant capacity', 'lycopene metabolism and bioavailability', 'vascular function', 'serum lycopene, lipids, and antioxidant capacity']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517756', 'cui_str': '4.1'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0874041', 'cui_str': 'Watermelon Preparation'}, {'cui': 'C1268568', 'cui_str': 'Juice'}, {'cui': 'C0065331', 'cui_str': 'lycopene'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0428462', 'cui_str': 'Measurement of serum lipid level'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0065331', 'cui_str': 'lycopene'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}]",,0.358314,"Serum lycopene exhibited a significant treatment effect ( P  = 0.002) along with notable interindividual responses; however, significant improvements in serum lipids or antioxidant capacity were not observed.","[{'ForeName': 'Kristi M', 'Initials': 'KM', 'LastName': 'Crowe-White', 'Affiliation': 'Department of Human Nutrition, University of Alabama, Tuscaloosa, AL, USA.'}, {'ForeName': 'Venkata S', 'Initials': 'VS', 'LastName': 'Voruganti', 'Affiliation': 'Department of Nutrition and Nutrition Research Institute, University of North Carolina-Chapel Hill, Kannapolis, NC, USA.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Talevi', 'Affiliation': 'Department of Nutrition and Nutrition Research Institute, University of North Carolina-Chapel Hill, Kannapolis, NC, USA.'}, {'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Dudenbostel', 'Affiliation': 'Cardiovascular Disease, Vascular Biology & Hypertension, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Vinoth A', 'Initials': 'VA', 'LastName': 'Nagabooshanam', 'Affiliation': 'Nutrition Obesity Research Center, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Julie L', 'Initials': 'JL', 'LastName': 'Locher', 'Affiliation': 'Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Amy C', 'Initials': 'AC', 'LastName': 'Ellis', 'Affiliation': 'Department of Human Nutrition, University of Alabama, Tuscaloosa, AL, USA.'}]",Current developments in nutrition,['10.1093/cdn/nzaa102'] 2224,32696014,Subcutaneous Enoxaparin Safely Facilitates Bedside Sustained Low-Efficiency Hemodialysis in Hypercoagulopathic Coronavirus Disease 2019 Patients-A Proof-of-Principle Trial.,"Objectives Renal replacement therapy in coronavirus disease 2019 patients is complicated by increased activation of the coagulation system. This may worsen the quality of hemodialysis and contribute to a shortage of dialysis machines as well as plastic disposables during the pandemic. This study describes a simple and safe protocol of anticoagulation with low-molecular-weight heparin in combination with bedside sustained low-efficiency hemodialysis in coronavirus disease 2019 patients. Design Monocentric observational cross-over trial investigating sustained low-efficiency hemodialysis with unfractionated heparin following sustained low-efficiency hemodialysis with low-molecular-weight heparin. Setting Coronavirus disease 2019-ICU in a German Tertiary Care University Hospital. Patients Three consecutive severe coronavirus disease 2019 patients receiving nine sustained low-efficiency hemodialysis therapies with unfractionated heparin followed by 18 sustained low-efficiency hemodialysis therapies with low-molecular-weight heparin. Interventions Switch from IV unfractionated heparin to subcutaneous low-molecular-weight heparin enoxaparin in therapeutic doses for patients receiving bedside sustained low-efficiency hemodialysis. Measurements and Main Results Nine renal replacement therapy sessions in patients anticoagulated with high doses of unfractionated heparin had to be discontinuated prematurely because of clotting of tubes or membrane and poor quality of hemodialysis. In the same patients, the switch to anticoagulation with therapeutic doses of the low-molecular-weight heparin enoxaparin allowed undisturbed bedside sustained low-efficiency hemodialysis for at least 12 hours. Quality of hemodialysis was excellent, no bleeding event was observed. Conclusions Systemic anticoagulation with subcutaneous enoxaparin provides an effective and safe renal replacement procedure in critically ill patients with coronavirus disease 2019 and hypercoagulability. The protocol reduces the risk of filter clotting, blood loss, and poor dialysis quality and may also prevent systemic thromboembolism.",2020,"Conclusions Systemic anticoagulation with subcutaneous enoxaparin provides an effective and safe renal replacement procedure in critically ill patients with coronavirus disease 2019 and hypercoagulability.","['2019 Patients-A Proof-of-Principle Trial', 'coronavirus disease 2019 patients', '2019 patients receiving nine sustained low-efficiency hemodialysis therapies with', 'followed by 18 sustained low-efficiency hemodialysis therapies with low-molecular-weight heparin', 'Hypercoagulopathic Coronavirus Disease', 'Patients\n\n\nThree consecutive severe coronavirus disease', 'patients receiving bedside sustained low-efficiency hemodialysis', 'patients anticoagulated with high doses of', 'Setting\n\n\nCoronavirus disease 2019-ICU in a German Tertiary Care University Hospital', 'critically ill patients with coronavirus disease 2019 and hypercoagulability']","['anticoagulation with low-molecular-weight heparin', 'subcutaneous enoxaparin', 'Subcutaneous Enoxaparin', 'heparin enoxaparin', 'unfractionated heparin']","['Quality of hemodialysis', 'bleeding event', 'systemic thromboembolism', 'risk of filter clotting, blood loss, and poor dialysis quality', 'clotting of tubes or membrane and poor quality of hemodialysis']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0556981', 'cui_str': '% proof'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0019139', 'cui_str': 'Low molecular weight heparin'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0398623', 'cui_str': 'Thrombophilia'}]","[{'cui': 'C0019139', 'cui_str': 'Low molecular weight heparin'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0206460', 'cui_str': 'Enoxaparin'}, {'cui': 'C0019134', 'cui_str': 'heparin'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0180860', 'cui_str': 'Filter'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0009074', 'cui_str': 'Clotrimazole'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}]",,0.0251721,"Conclusions Systemic anticoagulation with subcutaneous enoxaparin provides an effective and safe renal replacement procedure in critically ill patients with coronavirus disease 2019 and hypercoagulability.","[{'ForeName': 'Elke', 'Initials': 'E', 'LastName': 'Neumann-Haefelin', 'Affiliation': 'Renal Devision Department of Medicine, University Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Strasse, Freiburg, Germany.'}, {'ForeName': 'Eugen', 'Initials': 'E', 'LastName': 'Widmeier', 'Affiliation': 'Renal Devision Department of Medicine, University Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Strasse, Freiburg, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Bansbach', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, University Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Strasse, Freiburg, Germany.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Kaufmann', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, University Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Strasse, Freiburg, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Heinrich', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, University Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Strasse, Freiburg, Germany.'}, {'ForeName': 'Gerd', 'Initials': 'G', 'LastName': 'Walz', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, University Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Strasse, Freiburg, Germany.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Bürkle', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, University Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Strasse, Freiburg, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Kalbhenn', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, University Medical Center, Faculty of Medicine, University of Freiburg, Hugstetter Strasse, Freiburg, Germany.'}]",Critical care explorations,['10.1097/CCE.0000000000000155'] 2225,32696021,Preconception nutraceutical food supplementation can prevent oxidative and epigenetic DNA alterations induced by ovarian stimulation for IVF and increases pregnancy rates.,"Background It is hypothesized that oxidative and epigenetic alterations to DNA induced by ovarian stimulation for in vitro fertilization (IVF) may be associated with an increased risk of diseases and cancer in the offspring and could possibly be attenuated by preconception food supplementation. Methods In a prospective randomised open-label trial, 62 patients were randomly assigned to either 30 days of preconception treatment with the nutraceutical Fertility woman ® duo (Nutriphyt, Beernem, Belgium) (group 1), this nutraceutical complemented with selenomethionine (group 2), or folic acid only (group 3). Biochemical and epigenetic effects and pregnancy rates were assessed. Results In all 3 groups the level of DNA oxidative damage, estimated by the concentration of 8-hydroxy- 2-deoxyguanosine over creatinine in early morning urine, and the concentration of homocysteine in the blood decreased after treatment. In group 2, the degree of methylation of the cancer-associated CpG2 dinucleotide of the human Telomerase Reverse Transcriptase (hTERT) promoter region, assessed by pyrosequence in follicular cells obtained at oocyte pick-up, was 18% lower than that of group 3. The pregnancy rate, including the transfer of fresh and frozen embryos, was significantly higher in group 2 (50%) than in group 3 (6%) with the result in group 1 being intermediate (30%). Conclusion The results suggest that preconception food supplementation using a specific nutraceutical significantly reduces oxidative and epigenetic DNA changes to follicular cells of women treated by IVF, and may optimize gene expression in the oocytes, thus increasing the pregnancy rate per cycle of ovarian stimulation.",2020,"In all 3 groups the level of DNA oxidative damage, estimated by the concentration of 8-hydroxy- 2-deoxyguanosine over creatinine in early morning urine, and the concentration of homocysteine in the blood decreased after treatment.",['62 patients'],"['preconception treatment with the nutraceutical Fertility woman ® duo (Nutriphyt, Beernem, Belgium', 'selenomethionine (group 2), or folic acid']","['Biochemical and epigenetic effects and pregnancy rates', 'level of DNA oxidative damage', 'oxidative and epigenetic DNA changes to follicular cells', 'degree of methylation of the cancer-associated CpG2 dinucleotide of the human Telomerase Reverse Transcriptase (hTERT) promoter region', 'pregnancy rate, including the transfer of fresh and frozen embryos']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1518478', 'cui_str': 'Nutriceuticals'}, {'cui': 'C0015895', 'cui_str': 'Ability to conceive'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0004950', 'cui_str': 'Belgium'}, {'cui': 'C0034616', 'cui_str': 'Selenomethionine Se 75'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}]","[{'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C1655731', 'cui_str': 'Epigenetic'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rates'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439682', 'cui_str': 'Follicular'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0025723', 'cui_str': 'Methylation'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0007072', 'cui_str': 'glucarpidase'}, {'cui': 'C0012476', 'cui_str': 'Dinucleoside Phosphates'}, {'cui': 'C0754515', 'cui_str': 'TERT protein, human'}, {'cui': 'C0033413', 'cui_str': 'Genetic promotor region'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0443224', 'cui_str': 'Fresh'}, {'cui': 'C0440733', 'cui_str': 'Frozen embryo'}]",62.0,0.135308,"In all 3 groups the level of DNA oxidative damage, estimated by the concentration of 8-hydroxy- 2-deoxyguanosine over creatinine in early morning urine, and the concentration of homocysteine in the blood decreased after treatment.","[{'ForeName': 'W', 'Initials': 'W', 'LastName': 'Decleer', 'Affiliation': 'Fertility-Belgium Clinic, Weststraat, 16-18, B-9880 Aalter, Belgium.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Comhaire', 'Affiliation': 'Fertility-Belgium Clinic, Weststraat, 16-18, B-9880 Aalter, Belgium.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'De Clerck', 'Affiliation': 'Lab Protein Science, Proteomics and Epigenetic Signaling, Department of Biomedical Sciences, University Antwerp, Campus Drie Eiken, Universiteitsplein 1, B-2610 Wilrijk, Belgium.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Vanden Berghe', 'Affiliation': 'Lab Protein Science, Proteomics and Epigenetic Signaling, Department of Biomedical Sciences, University Antwerp, Campus Drie Eiken, Universiteitsplein 1, B-2610 Wilrijk, Belgium.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Devriendt', 'Affiliation': 'Pures Ltd., Kasteelhoek 12, B-8730 Beernem, Belgium.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Osmanagaoglu', 'Affiliation': 'Centre for Fertility, AZ Jan Palfijn Gent, Watersportlaan 5, B-9000 Gent, Belgium.'}]","Facts, views & vision in ObGyn",[] 2226,32696031,"Effects on clinical outcomes of adjunctive moxifloxacin versus amoxicillin plus metronidazole in periodontitis patients harboring Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, and Tannerella forsythia: exploratory analyses from a clinical trial.","OBJECTIVE Considering the etiopathogenesis of periodontitis, it is relevant to evaluate the efficacy of the adjunctive use of systemic antimicrobials based on microbial occurrence. This report explores whether patients harboring Aggregatibacter actinomycetemcomitans (Aa), Porphyromonas gingivalis (Pg), or Tannerella forsythia (Tf) at baseline could receive greater clinical benefits from adjunctive moxifloxacin (MXF) and amoxicillin plus metronidazole (AM+MT) in comparison to patients without the presence of these microorganisms before therapy for generalized periodontitis. A control group was established that received subgingival debridement (SD) alone. METHOD AND MATERIALS Thirty-six patients younger than 30 years of age were randomly allocated to one of three treatment groups: SD plus placebo, systemic MXF with SD, or AM+MT combined with SD. Subgingival samples were studied. The effects of the therapies on probing depth and clinical attachment level, including interactions with Aa, Pg, or Tf at baseline, were explored using regression models. RESULTS At 6 months, all treatment groups showed improved clinical outcomes in patients harboring Aa, Pg, or Tf at baseline compared to the patients who did not harbor these microorganisms at baseline. Indeed, in the presence of Aa, Pg, or Tf at baseline, the patients receiving antimicrobial protocols showed the most significant gains compared to the control group. Furthermore, the percentage of sites ≥ 6 mm was reduced in the test groups, compared to the control group; these periodontopathogens were not present in sites with probing depth ≥ 6 mm in the MXF group. The interactions of Aa, Pg, and Tf with the test groups significantly improved clinical parameters at 6 months (P < .001). Interestingly, the R2 value in the models that explored clinical attachment gain produced a high degree of correlation (> 0.75), indicating that a high percentage (> 75%) of the total variation in clinical attachment level gain can be explained by the independent variables. CONCLUSIONS Although all patients benefited from the treatments, patients harboring Aa, Pg, or Tf at baseline showed improved clinical benefits at 6 months, suggesting that Aa, Pg, or Tf at baseline may change the effects of systemic MXF and AM+MT in generalized periodontitis. After 6 months, Aa, Pg, and Tf were not present in sites with probing depth ≥ 6 mm in the MXF group.",2020,"Furthermore, the percentage of sites ≥ 6 mm was reduced in the test groups, compared to the control group; these periodontopathogens were not present in sites with probing depth ≥","['periodontitis patients harboring Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, and Tannerella forsythia', 'Thirty-six patients younger than 30 years of age', 'patients harboring Aggregatibacter actinomycetemcomitans (Aa), Porphyromonas gingivalis (Pg), or Tannerella forsythia ']","['moxifloxacin (MXF) and amoxicillin plus metronidazole (AM+MT', 'subgingival debridement (SD) alone', 'MXF', 'SD plus placebo, systemic MXF with SD, or AM+MT combined with SD', 'amoxicillin plus metronidazole', 'adjunctive moxifloxacin']","['clinical outcomes', 'probing depth and clinical attachment level, including interactions with Aa, Pg, or Tf']","[{'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0475311', 'cui_str': 'Harbor'}, {'cui': 'C0085488', 'cui_str': 'Aggregatibacter actinomycetemcomitans'}, {'cui': 'C0085478', 'cui_str': 'Porphyromonas gingivalis'}, {'cui': 'C0314961', 'cui_str': 'Tannerella forsythia'}, {'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0595817', 'cui_str': 'Subgingival route'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0085478', 'cui_str': 'Porphyromonas gingivalis'}, {'cui': 'C0314961', 'cui_str': 'Tannerella forsythia'}]",36.0,0.0816652,"Furthermore, the percentage of sites ≥ 6 mm was reduced in the test groups, compared to the control group; these periodontopathogens were not present in sites with probing depth ≥","[{'ForeName': 'Carlos-M', 'Initials': 'CM', 'LastName': 'Ardila', 'Affiliation': ''}, {'ForeName': 'Catalina', 'Initials': 'C', 'LastName': 'Hernández-Casas', 'Affiliation': ''}, {'ForeName': 'Jader-A', 'Initials': 'JA', 'LastName': 'Bedoya-García', 'Affiliation': ''}]","Quintessence international (Berlin, Germany : 1985)",['10.3290/j.qi.a44927'] 2227,32696033,"Subcutaneous administration of benzathine benzylpenicillin G has favourable pharmacokinetic characteristics for the prevention of rheumatic heart disease compared with intramuscular injection: a randomized, crossover, population pharmacokinetic study in healthy adult volunteers.","BACKGROUND Benzathine penicillin G has been used as monthly deep intramuscular (IM) injections since the 1950s for secondary prevention of acute rheumatic fever and rheumatic heart disease (RHD). Injection frequency and pain are major programmatic barriers for adherence, prompting calls for development of better long-acting penicillin preparations to prevent RHD. We hypothesized that subcutaneous (SC) administration of benzathine penicillin G could delay penicillin absorption when compared with IM injections. METHODS To compare the pharmacokinetic profile and tolerability of benzathine penicillin G according to different routes of administration, 15 healthy males participated in a randomized crossover study to receive benzathine penicillin G by either SC or IM routes, with a 10 week washout period before the second dose by the alternative route. Ultrasound guidance confirmed injection location. Penicillin concentrations and pain scores were measured for 6 weeks following injections. RESULTS SC administration was well tolerated with no significant differences in pain scores. Following SC injection, the principal absorption half-life (95% CI) was 20.1 (16.3-29.5) days and 89.6% (87.1%-92.0%) of the drug was directed via this pathway compared with 10.2 (8.6-12.5) days and 71.3% (64.9%-77.4%) following IM administration. Lower peak and higher trough penicillin concentrations resulted following SC injection. Simulations demonstrated that SC infusion of higher doses of benzathine penicillin G could provide therapeutic penicillin concentrations for 3 months. CONCLUSIONS SC administration of benzathine penicillin G is safe and significantly delays penicillin absorption. High-dose benzathine penicillin G via the SC route would fulfil many product characteristics required for the next generation of longer-acting penicillins for use in RHD.",2020,"RESULTS SC administration was well tolerated with no significant differences in pain scores.","['15 healthy males', 'healthy adult volunteers']","['benzathine benzylpenicillin G', 'Benzathine penicillin G', 'benzathine penicillin G']","['pain scores', 'Lower peak and higher trough penicillin concentrations', 'pharmacokinetic profile and tolerability', 'delay penicillin absorption', 'Penicillin concentrations and pain scores', 'therapeutic penicillin concentrations']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0030829', 'cui_str': 'benzathine benzylpenicillin'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0444506', 'cui_str': 'Trough'}, {'cui': 'C0030842', 'cui_str': 'Penicillin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]",15.0,0.295838,"RESULTS SC administration was well tolerated with no significant differences in pain scores.","[{'ForeName': 'Joseph H', 'Initials': 'JH', 'LastName': 'Kado', 'Affiliation': 'Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Salman', 'Affiliation': 'Faculty of Health and Medical Sciences, University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Henderson', 'Affiliation': 'Department of Radiology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Hand', 'Affiliation': 'Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia.'}, {'ForeName': 'Rosemary', 'Initials': 'R', 'LastName': 'Wyber', 'Affiliation': 'Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia.'}, {'ForeName': 'Madhu', 'Initials': 'M', 'LastName': 'Page-Sharp', 'Affiliation': 'School of Pharmacy and Biomedical Sciences, Curtin University, Bentley, Western Australia, Australia.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Batty', 'Affiliation': 'School of Pharmacy and Biomedical Sciences, Curtin University, Bentley, Western Australia, Australia.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Carapetis', 'Affiliation': 'Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia.'}, {'ForeName': 'Laurens', 'Initials': 'L', 'LastName': 'Manning', 'Affiliation': 'Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia.'}]",The Journal of antimicrobial chemotherapy,['10.1093/jac/dkaa282'] 2228,32696102,The role of ozonized oil and a combination of tobramycin/dexamethasone eye drops in the treatment of viral conjunctivitis: a randomized clinical trial.,"PURPOSE To determine whether topical tobramycin 0.3%/dexamethasone 0.1% plus ozonized oil eye drops reduces clinical signs and infectious viral titers of presumed viral conjunctivitis more than tobramycin/dexamethasone eye drops alone. METHODS Prospective, single-blind, randomized, parallel-groups trial. Eighty patients with a clinical diagnosis of presumed viral conjunctivitis were randomizedly divided into two treatment groups: a study group and a control group, 40 for each group. Patients in the study group received topical tobramycin 0.3%/dexamethasone 0.1% eye drops, plus ozonized oil eye drops, both four times daily; patients in the control group received only topical tobramycin 0.3%/dexamethasone eye drops four times daily. The treatment was for seven days in both groups. Swabs were taken from the conjunctival fornix for adenovirus PCR analysis on the day of recruitment and at seven days follow-up. Clinical signs were also recorded on the day of recruitment and at follow-up examination: the main outcomes were conjunctival injection and conjunctival chemosis, graded on a 4-point clinical scale, presence or absence of superficial punctate keratitis and subepithelial corneal infiltrates. RESULTS No statistically significant difference was reached in adenoviral infection negativization between the two groups, although the study group showed a higher number of PCR negative results at seven days follow-up. PCR real time detected adenoviral infection in 17 of 24 patients on the day of recruitment and it was positive in 4 patients on the seventh day (viral positivity reduction of 76%). In the control group PCR was positive for adenovirus in 18 of 24 patients on the day of recruitment and in 7 patients at seven days follow-up (reduction of 61%). There was statistically significant difference on conjunctival clinical signs between the study and control groups. Significant difference was also found on superficial punctate keratitis resolution between the study and the control group. In the former superficial punctate keratitis was detected in 14 eyes on the first day and in 5 eyes after seven days while in the latter superficial punctate keratitis was found in 124 eyes on the first day and in 6 eyes on the seventh day. No difference was found in subepithelial corneal infiltrates appearance between the two groups. CONCLUSIONS The use of ozonized-oil containing eye drops in combination with topical tobramycin 0.3%/dexamethasone 0.1% eye drops four times daily seems to reduce the signs of conjunctivitis, and the duration of viral infection, although it does not affect the subepithelial corneal infiltrates appearance.",2020,"No statistically significant difference was reached in adenoviral infection negativization between the two groups, although the study group showed a higher number of PCR negative results at seven days follow-up.","['viral conjunctivitis', 'Eighty patients with a clinical diagnosis of presumed viral conjunctivitis']","['topical tobramycin 0.3%/dexamethasone 0.1% eye drops, plus ozonized oil eye drops', 'topical tobramycin 0.3%/dexamethasone', 'topical tobramycin 0.3%/dexamethasone 0.1% plus ozonized oil eye drops', 'tobramycin/dexamethasone', 'ozonized oil and a combination of tobramycin/dexamethasone eye drops', 'topical tobramycin 0.3%/dexamethasone eye drops four times daily']","['conjunctival injection and conjunctival chemosis, graded on a 4-point clinical scale, presence or absence of superficial punctate keratitis and subepithelial corneal infiltrates', 'PCR real time detected adenoviral infection', 'adenoviral infection negativization', 'signs of conjunctivitis, and the duration of viral infection', 'subepithelial corneal infiltrates appearance', 'clinical signs and infectious viral titers of presumed viral conjunctivitis', 'PCR negative results', 'conjunctival clinical signs', 'superficial punctate keratitis resolution']","[{'cui': 'C0009774', 'cui_str': 'Viral conjunctivitis'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0040341', 'cui_str': 'Tobramycin'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C0015399', 'cui_str': 'Eye drops'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0304706', 'cui_str': 'Dexamethasone-containing product in ocular dose form'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0585291', 'cui_str': 'Four times daily'}]","[{'cui': 'C1761613', 'cui_str': 'Conjunctival hyperemia'}, {'cui': 'C0271298', 'cui_str': 'Chemosis of conjunctiva'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0259799', 'cui_str': 'Superficial punctate keratitis'}, {'cui': 'C0853336', 'cui_str': 'Infiltrate of cornea'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0851887', 'cui_str': 'Adenoviral infections'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0009763', 'cui_str': 'Conjunctivitis'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C2748213', 'cui_str': 'Viral titre'}, {'cui': 'C0009774', 'cui_str': 'Viral conjunctivitis'}, {'cui': 'C4704700', 'cui_str': 'Null Results'}]",80.0,0.0466561,"No statistically significant difference was reached in adenoviral infection negativization between the two groups, although the study group showed a higher number of PCR negative results at seven days follow-up.","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Cagini', 'Affiliation': 'Division of Ophthalmology, Department of Surgical and Biomedical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea Delle Fratte, 06156, Perugia, Italy. carlo.cagini@unipg.it.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Mariniello', 'Affiliation': 'Division of Ophthalmology, Department of Surgical and Biomedical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea Delle Fratte, 06156, Perugia, Italy.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Messina', 'Affiliation': 'Division of Ophthalmology, Department of Surgical and Biomedical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea Delle Fratte, 06156, Perugia, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Muzi', 'Affiliation': 'Division of Ophthalmology, Department of Surgical and Biomedical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea Delle Fratte, 06156, Perugia, Italy.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Balducci', 'Affiliation': 'Division of Ophthalmology, Department of Surgical and Biomedical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea Delle Fratte, 06156, Perugia, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Moretti', 'Affiliation': 'Microbiology Unit, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Levorato', 'Affiliation': 'Microbiology Unit, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Mencacci', 'Affiliation': 'Microbiology Unit, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy.'}]",International ophthalmology,['10.1007/s10792-020-01503-4'] 2229,32696120,Effectiveness of an Educational Video in Maternity Wards to Prevent Self-Reported Shaking and Smothering during the First Week of Age: A Cluster Randomized Controlled Trial.,"This study aimed to investigate whether watching an educational video on infant crying and the dangers of shaking and smothering within 1 week after delivery at maternity wards reduces self-reported shaking and smothering, at a 1-month health checkup. A cluster randomized controlled trial, stratified by area and hospital function, was employed in 45 obstetrics hospitals/clinics in Osaka Prefecture, Japan. In the intervention group, mothers watched an educational video on infant crying and the dangers of shaking and smothering an infant, within 1 week of age, during hospitalization at maternity wards, without blinding on group allocation. Control group received usual care. A total of 4722 (N = 2350 and 2372 for intervention and control group, respectively) mothers who delivered their babies (still birth and gestational age < 22 weeks were excluded) between October 1, 2014, and January 31 were recruited. Outcomes were self-reported shaking and smothering behaviors, knowledge on infant crying and shaking, and behaviors to cope with infant crying, assessed via a questionnaire at a 1-month health checkup. In all, 2718 (N = 1078 and 1640) responded to the questionnaire (response rate: 58.3%), and analytic sample size was 2655 (N = 1058 and 1597 for intervention and control group, respectively). Multilevel analysis was used to adjust for correlation within the cluster. Prevalence of shaking was significantly lower in the intervention group (0.19%) than in the control group (1.69%). Intention-to-treat analysis showed an 89% reduction in the reported prevalence of self-reported shaking (OR: 0.11, 95% CI: 0.02-0.53) due to watching the educational video. However, self-reported smothering behavior showed no significant reduction (OR: 0.66, 95% CI: 0.27-1.60). No side effects were reported. Watching an educational video on infant crying and the dangers of shaking and smothering within 1 week after delivery at maternity wards reduced self-reported shaking at 1 month of age. UMIN Clinical Trial Registry UMIN000015558.",2020,Prevalence of shaking was significantly lower in the intervention group (0.19%) than in the control group (1.69%).,"['45 obstetrics hospitals/clinics in Osaka Prefecture, Japan', 'Maternity Wards to Prevent Self-Reported Shaking and Smothering during the First Week of Age', 'A total of 4722 (N\u2009=\u20092350 and 2372 for intervention and control group, respectively) mothers who delivered their babies (still birth and gestational age\u2009<\u200922\xa0weeks were excluded) between October 1, 2014, and January 31 were recruited']","['mothers watched an educational video', 'usual care', 'Educational Video', 'watching an educational video', 'Watching an educational video']","['Prevalence of shaking', 'self-reported shaking and smothering behaviors, knowledge on infant crying and shaking, and behaviors to cope with infant crying, assessed via a questionnaire at a 1-month health checkup']","[{'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0040822', 'cui_str': 'Tremor'}, {'cui': 'C0277619', 'cui_str': 'Traumatic asphyxiation'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0040822', 'cui_str': 'Tremor'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0277619', 'cui_str': 'Traumatic asphyxiation'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0581876', 'cui_str': 'Crying infant'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0260860', 'cui_str': 'General medical examination'}]",4722.0,0.0869133,Prevalence of shaking was significantly lower in the intervention group (0.19%) than in the control group (1.69%).,"[{'ForeName': 'Takeo', 'Initials': 'T', 'LastName': 'Fujiwara', 'Affiliation': 'Department of Global Health Promotion, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan. fujiwara.hlth@tmd.ac.jp.'}, {'ForeName': 'Aya', 'Initials': 'A', 'LastName': 'Isumi', 'Affiliation': 'Department of Global Health Promotion, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.'}, {'ForeName': 'Makiko', 'Initials': 'M', 'LastName': 'Sampei', 'Affiliation': 'Department of Global Health Promotion, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Miyazaki', 'Affiliation': 'Department of Systems and Control Engineering, Tokyo Institute of Technology, Tokyo, Japan.'}, {'ForeName': 'Fujiko', 'Initials': 'F', 'LastName': 'Yamada', 'Affiliation': 'Department of Global Health Promotion, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.'}, {'ForeName': 'Hisashi', 'Initials': 'H', 'LastName': 'Noma', 'Affiliation': 'Department of Data Science, The Institute of Statistical Mathematics, Tokyo, Japan.'}, {'ForeName': 'Kazuhide', 'Initials': 'K', 'LastName': 'Ogita', 'Affiliation': 'Department of Obstetrics and Gynecology, Rinku General Medical Center, Osaka, Japan.'}, {'ForeName': 'Nobuaki', 'Initials': 'N', 'LastName': 'Mitsuda', 'Affiliation': 'Department of Obstetrics, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-020-01145-z'] 2230,32696128,Penile low intensity shock wave treatment for PDE5I refractory erectile dysfunction: a randomized double-blind sham-controlled clinical trial.,"PURPOSE Over the last decade, penile low-intensity extracorporeal shockwave therapy (LI-ESWT) has emerged as a promising alternative for the treatment of erectile dysfunction (ED). The aim of this trial is to assess the effect of electromagnetic LI-ESWT on the erectile function of vascular phosphodiesterase type 5 inhibitor (PDE5I) refractory ED patients. METHODS Randomized, double-blind, sham-controlled study. 76 patients with vascular PDE5I-refractory ED completed the study. 40 men were treated with LI-ESWT (1 session/week for 4 weeks, 5000 shocks/session, 0.09 mJ/mm 2 energy density) and 36 were treated with a sham probe. Baseline and post-treatment (1, 3 and 6 months) evaluations were performed using validated erectile function questionnaires (IIEF-EF, EHS, SEP2, SEP3 and GAQ1). The groups were compared using Mann-Whitney-Wilcoxon and chi-squared tests, with results considered statistically significant at p < 0.05. RESULTS At the 3-month follow-up, median change in IIEF-EF score for active and sham groups was 3.5 (IQR 0-10) and - 0.5 (IQR - 11 to 1), respectively (p < 0.05). Six months after treatment, 52.5% of patients (21/40) in the active group and 27.8% of patients (10/36) in the sham group presented an EHS > 2 (p < 0.05). At the same evaluation, 40.0% (16/40) and 13.9% (5/36) of patients had positive answers to GAQ-1, in the treated and sham groups, respectively (p < 0.05). No adverse events were observed during the study. CONCLUSION This study showed that penile electromagnetic shockwave therapy may improve erectile function, to a modest extent, on certain patients that do not respond to PDE5I; making it an alternative for vascular ED patients that reject more invasive therapies.",2020,"No adverse events were observed during the study. ","['76 patients with vascular PDE5I-refractory ED completed the study', '40 men', 'PDE5I refractory erectile dysfunction']","['Penile low intensity shock wave treatment', 'penile electromagnetic shockwave therapy', 'LI-ESWT', 'extracorporeal shockwave therapy (LI-ESWT', 'electromagnetic LI-ESWT']","['median change in IIEF-EF score', 'erectile function', 'erectile function questionnaires (IIEF-EF, EHS, SEP2, SEP3 and GAQ1', 'adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C1318700', 'cui_str': 'Phosphodiesterase 5 inhibitor'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0242350', 'cui_str': 'Impotence'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0030851', 'cui_str': 'Penile structure'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0036974', 'cui_str': 'Shock'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0013838', 'cui_str': 'Electromagnetics'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1737238', 'cui_str': 'Extracorporeal shock wave therapy'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030847', 'cui_str': 'Penile erection'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",76.0,0.420917,"No adverse events were observed during the study. ","[{'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Vinay', 'Affiliation': 'Andrology Department, Fundació Puigvert/Universidad Autònoma de Barcelona, Carrer de Cartagena, 340-350, 08025, Barcelona, Spain. jose.vinay@gmail.com.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Moreno', 'Affiliation': 'Andrology Department, Fundació Puigvert/Universidad Autònoma de Barcelona, Carrer de Cartagena, 340-350, 08025, Barcelona, Spain.'}, {'ForeName': 'Osvaldo', 'Initials': 'O', 'LastName': 'Rajmil', 'Affiliation': 'Andrology Department, Fundació Puigvert/Universidad Autònoma de Barcelona, Carrer de Cartagena, 340-350, 08025, Barcelona, Spain.'}, {'ForeName': 'Eduard', 'Initials': 'E', 'LastName': 'Ruiz-Castañe', 'Affiliation': 'Andrology Department, Fundació Puigvert/Universidad Autònoma de Barcelona, Carrer de Cartagena, 340-350, 08025, Barcelona, Spain.'}, {'ForeName': 'Josvany', 'Initials': 'J', 'LastName': 'Sanchez-Curbelo', 'Affiliation': 'Andrology Department, Fundació Puigvert/Universidad Autònoma de Barcelona, Carrer de Cartagena, 340-350, 08025, Barcelona, Spain.'}]",World journal of urology,['10.1007/s00345-020-03373-y'] 2231,32696159,Impact of Full-Incision Double-Eyelid Blepharoplasty on Tear Film Dynamics and Dry Eye Symptoms in Young Asian Females.,"BACKGROUND Dry eye symptoms as a complication of double-eyelid blepharoplasty are controversial. This article evaluates tear film dynamics and changes in dry eye symptoms after cosmetic double-eyelid blepharoplasty in young Asian female. METHODS One hundred and twenty patients underwent full-incisional double-eyelid blepharoplasty. Subjective and objective parameters were documented before surgery, at 1 week, 1 month and 3 months post-surgery, which included Ocular Surface Disease Index questionnaire (OSDI), tear meniscus height (TMH), noninvasive breakup time (NIBUT), Schirmer I test, corneal and conjunctival fluorescein staining scores, and palpebral fissure height. Dry eyes were defined based on the DEWS II criteria: OSDI ≥ 13 points and NIBUT < 10 s. Patients were divided into two groups, group A included patients with redundant skin, while group B included patients with absence of redundant skin. RESULTS The incident rate of dry eyes preoperatively, and at 1 week, 1 month and 3 months were 12.5%, 12.5%, 32.5%, and 16.67%. OSDI scores were significantly increased at 1 week (9.71 ± 10.07, P < 0.001) and 1 month (11.35 ± 12.28, P < 0.001) postoperatively. A significant increase in TMH, NIBUT and Schirmer's test I values were observed at 1 week post-surgery (P < 0.001). Patients in group A showed higher OSDI scores compared to group B at 1 week and 1 month (P = 0.051) post-surgery, and the other variables showed no difference between the groups. CONCLUSIONS Cosmetic double-eyelid blepharoplasty may temporarily affect tear film dynamics and aggravate dry eye symptoms in young females. However, these changes generally recover 3 months postoperatively. LEVEL OF EVIDENCE IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .",2020,"Patients in group A showed higher OSDI scores compared to group B at 1 week and 1 month (P = 0.051) post-surgery, and the other variables showed no difference between the groups. ","['One hundred and twenty patients underwent', 'young females', 'young Asian female', 'patients with redundant skin, while group B included patients with absence of redundant skin', 'Young Asian Females']","['IV', 'Cosmetic double-eyelid blepharoplasty', 'full-incisional double-eyelid blepharoplasty', 'cosmetic double-eyelid blepharoplasty', 'Full-Incision Double-Eyelid Blepharoplasty']","['OSDI scores', ""TMH, NIBUT and Schirmer's test"", 'Tear Film Dynamics and Dry Eye Symptoms', 'included Ocular Surface Disease Index questionnaire (OSDI), tear meniscus height (TMH), noninvasive breakup time (NIBUT), Schirmer I test, corneal and conjunctival fluorescein staining scores, and palpebral fissure height']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0581342', 'cui_str': 'Redundant skin'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332197', 'cui_str': 'Absent'}]","[{'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0015426', 'cui_str': 'Eyelid structure'}, {'cui': 'C0197213', 'cui_str': 'Repair of eyelid'}, {'cui': 'C0184898', 'cui_str': 'Incision'}]","[{'cui': 'C1557335', 'cui_str': 'Ocular surface disease'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1827565', 'cui_str': 'Tear meniscus height'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0200152', 'cui_str': ""Schirmer's test""}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0013238', 'cui_str': 'Dry Eye Disease'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1301514', 'cui_str': 'Schirmer I test'}, {'cui': 'C0060520', 'cui_str': 'Fluorescein'}, {'cui': 'C0423104', 'cui_str': 'Height of palpebral fissure'}]",120.0,0.0416135,"Patients in group A showed higher OSDI scores compared to group B at 1 week and 1 month (P = 0.051) post-surgery, and the other variables showed no difference between the groups. ","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': 'Department of Ophthalmology, Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Yixiong', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Ophthalmology, Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Siyi', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': 'Department of Ophthalmology, Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Chang', 'Initials': 'C', 'LastName': 'Cui', 'Affiliation': 'Department of Ophthalmology, Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Xuefei', 'Initials': 'X', 'LastName': 'Song', 'Affiliation': 'Department of Ophthalmology, Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Xiangyang', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Institute of Image Communication and Network Engineering, Shanghai Jiao Tong University, Shanghai, China.'}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Fu', 'Affiliation': 'Department of Ophthalmology, Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. drfuyao@126.com.'}]",Aesthetic plastic surgery,['10.1007/s00266-020-01874-0'] 2232,32696178,Effect of weight-loss diet combined with taurine supplementation on body composition and some biochemical markers in obese women: a randomized clinical trial.,"Taurine (Tau), an endogenous non-protein and sulfuric-amino acid, is involved in various biological pathways including anti-inflammatory, anti-oxidation, insulin resistance inhibition, and lipid profile improvement. According to some experimental and clinical studies, insulin resistance and excess body weight are associated with reduced serum level of Tau. Therefore, this study was aimed to evaluate Tau supplementation and a diet-induced weight-loss intervention on body composition and some biochemical indices of obese women. Participants were divided randomly into the intervention (standard weight-loss group + cap Tau 3 g/day for 8 weeks, n = 20) and control (standard weight-loss group + cap placebo for 8 weeks, n = 18) groups. To achieve weight loss, all participants received an individualized diet that included a 30% reduction in their total energy intake. Chi-square test was applied to compare categorical variables between two groups at baseline. Paired t test and independent-sample t test were also used to analyze the parametric continuous data within and between the two groups, respectively. Analysis of covariance was run for controlling the confounding variables. At the post-intervention, the mean changes of total cholesterol (p = 0.03), low-density lipoprotein cholesterol (p = 0.03), leptin (p = 0. 006), total adiponectin (p = 0.04), and high sensitivity C-reactive protein (p = 0.03) decreased significantly in Tau group compared with the control group. No significant results were found in the mean changes of high-density lipoprotein cholesterol, anthropometric measurements, glycemic indices, and liver enzymes between the two groups (p > 0.05). The findings showed that Tau supplementation along with a weight-loss diet may be more effective in improving the lipid profile and metabolic risk factors compared with a weight-loss diet alone.",2020,"At the post-intervention, the mean changes of total cholesterol (p = 0.03), low-density lipoprotein cholesterol (p = 0.03), leptin (p = 0. 006), total adiponectin (p = 0.04), and high sensitivity C-reactive protein (p = 0.03) decreased significantly in Tau group compared with the control group.",['obese women'],"['Tau supplementation and a diet-induced weight-loss intervention', 'weight-loss diet combined with taurine supplementation', 'Taurine (Tau', 'intervention (standard weight-loss group\u2009+\u2009cap Tau 3 g/day for 8\xa0weeks, n\u2009=\u200920) and control (standard weight-loss group\u2009+\u2009cap placebo']","['high sensitivity C-reactive protein', 'leptin', 'low-density lipoprotein cholesterol', 'body composition', 'total adiponectin', 'weight loss', 'mean changes of high-density lipoprotein cholesterol, anthropometric measurements, glycemic indices, and liver enzymes', 'lipid profile and metabolic risk factors', 'mean changes of total cholesterol']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0039350', 'cui_str': 'Taurine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0012167', 'cui_str': 'Weight reduction diet'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}]",,0.0281008,"At the post-intervention, the mean changes of total cholesterol (p = 0.03), low-density lipoprotein cholesterol (p = 0.03), leptin (p = 0. 006), total adiponectin (p = 0.04), and high sensitivity C-reactive protein (p = 0.03) decreased significantly in Tau group compared with the control group.","[{'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Haidari', 'Affiliation': 'Department of Nutrition, Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Asadi', 'Affiliation': 'Diabetes Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. maryamasadi136@gmail.com.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Mohammadi-Asl', 'Affiliation': 'Department of Medical Genetics, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Kambiz', 'Initials': 'K', 'LastName': 'Ahmadi-Angali', 'Affiliation': 'Faculty of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}]",Amino acids,['10.1007/s00726-020-02876-7'] 2233,32696183,Letter to the editor: Is it time to abandon episiotomy use? A randomized controlled trial (EPITRIAL).,,2020,,[],[],[],[],[],[],,0.0788517,,"[{'ForeName': 'Melania Maria', 'Initials': 'MM', 'LastName': 'Amorim', 'Affiliation': 'Instituto de Medicina Integral Prof. Fernando Figueira, Recife, Brazil. profmelania.amorim@gmail.com.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Delgado', 'Affiliation': 'Instituto de Medicina Integral Prof. Fernando Figueira, Recife, Brazil.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Katz', 'Affiliation': 'Instituto de Medicina Integral Prof. Fernando Figueira, Recife, Brazil.'}]",International urogynecology journal,['10.1007/s00192-020-04421-2'] 2234,32696185,Use of pelvic model-based simulation for sacrospinous ligament fixation education in novice learners: a single-blinded randomized controlled trial.,"INTRODUCTION AND HYPOTHESIS We hypothesize that there will be improvement in a novice learners' confidence and skill level with sacrospinous ligament fixation (SSLF) following a pelvic model-based simulation. METHODS We performed a single-blinded randomized controlled trial with obstetrics and gynecology residents who were novices at SSLF. The residents were randomly assigned to two groups. The control group received a lecture on the SSLF procedure and anatomy, whereas the intervention group received the same lecture in addition to a pelvic model-based simulation session taught by urogynecologists. The residents' knowledge of SSLF anatomy and confidence level with the procedure were measured via assessments administered before and after the educational interventions. Their technical skills were objectively assessed by one of two fellowship-trained urogynecologists who were blinded to their group allocation. RESULTS A total of 28 residents were recruited with 14 residents in each group and equal distribution of junior and senior trainees. None of the residents had previously performed the SSLF procedure. There was no difference in anatomical knowledge between the two groups. The intervention group showed a greater increase in their average confidence score compared with the control group: 4.0 ± 1.4 (95% CI 3.1-4.8) versus 2.6 ± 1.6 (95% CI 1.7-3.4) respectively, with p = 0.02. The intervention group also showed better objective scores in specific technical skills, such as instrument handling (p < 0.001), instrument movement/motion (p < 0.001), and speed (p = 0.01). CONCLUSION Our results demonstrate that inclusion of a pelvic model simulation significantly improves confidence and certain technical skills of novice trainees in performing SSLF.",2020,"The intervention group also showed better objective scores in specific technical skills, such as instrument handling (p < 0.001), instrument movement/motion (p < 0.001), and speed (p = 0.01). ","['28 residents were recruited with 14 residents in each group and equal distribution of junior and senior trainees', 'obstetrics and gynecology residents who were novices at SSLF', 'novice learners']","['pelvic model-based simulation', 'sacrospinous ligament fixation education', 'sacrospinous ligament fixation (SSLF', 'lecture on the SSLF procedure and anatomy, whereas the intervention group received the same lecture in addition to a pelvic model-based simulation session taught by urogynecologists']","['instrument movement/motion', 'average confidence score', 'anatomical knowledge', 'objective scores in specific technical skills, such as instrument handling', 'confidence and certain technical skills']","[{'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C1274104', 'cui_str': 'Obstetrics and gynecology'}, {'cui': 'C0225049', 'cui_str': 'Structure of sacrospinous ligament'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}]","[{'cui': 'C0030797', 'cui_str': 'Pelvic'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0225049', 'cui_str': 'Structure of sacrospinous ligament'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0376683', 'cui_str': 'Lectures'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0002808', 'cui_str': 'Anatomy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039401', 'cui_str': 'Education'}]","[{'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0220784', 'cui_str': 'Anatomic'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0449851', 'cui_str': 'Technique'}, {'cui': 'C0205423', 'cui_str': 'Certain'}]",28.0,0.196025,"The intervention group also showed better objective scores in specific technical skills, such as instrument handling (p < 0.001), instrument movement/motion (p < 0.001), and speed (p = 0.01). ","[{'ForeName': 'Yoko', 'Initials': 'Y', 'LastName': 'Takashima', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Harbor-UCLA Medical Center, 1000 W. Carson Street, Torrance, CA, 90509, USA. ytakashima@dhs.lacounty.gov.'}, {'ForeName': 'Stephanie J', 'Initials': 'SJ', 'LastName': 'Handler', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Harbor-UCLA Medical Center, 1000 W. Carson Street, Torrance, CA, 90509, USA.'}, {'ForeName': 'Aldene', 'Initials': 'A', 'LastName': 'Zeno', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Keck Hospital of USC, Los Angeles, CA, USA.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Miyazaki', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Del Canto', 'Affiliation': 'David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Tajnoos', 'Initials': 'T', 'LastName': 'Yazdany', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Harbor-UCLA Medical Center, 1000 W. Carson Street, Torrance, CA, 90509, USA.'}, {'ForeName': 'Tam Hoang', 'Initials': 'TH', 'LastName': 'Le', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.'}]",International urogynecology journal,['10.1007/s00192-020-04445-8'] 2235,32696210,Adhesive restoration of molars affected by molar incisor hypomineralization: a randomized clinical trial.,"OBJECTIVE This randomized clinical trial evaluated the survival of direct restorations on first permanent molars (FPMs) with molar incisor hypomineralization (MIH) and its impact on self-reported dental pain and dental anxiety. MATERIAL AND METHOD FPMs with MIH of 35 patients aged 7 to 16 years were included. The FPMs were randomized into the following two groups: total-etch (TE-37% phosphoric acid etching) and self-etch (SE-no prior etching). The FPMs were restored with universal adhesive and bulk-fill resin composites. The restoration survival was evaluated according to USPHS criteria modified by a blinded examiner. Dental anxiety (Venham picture test) and dental pain (Faces pain scale-revised) were evaluated before treatment and at 1, 6, and 12 months post-treatment. Survival rates were analyzed by the Kaplan-Meier method and the log-rank test. Nonparametric tests compared pain and anxiety in the follow-up periods. RESULTS A total of 64 FPMs were restored (TE = 33; SE = 31). Survival rates were 96.9% (TE) and 96.7% (SE) after 1 month, 90.5% (TE) and 80.6% (SE) after 6 months, and 80.8% (TE) and 62.3% (SE) after 12 months (p > 0.05). Self-reported dental pain and anxiety level decreased after treatment in both groups (p < 0.05). Self-reported pain decreased after 1 month in SE, but it occurred at 6 months in TE. CONCLUSION Both restorative protocols presented similar longevity, decreasing self-reported pain and anxiety levels. CLINICAL RELEVANCE A universal adhesive could be appropriate for restoration of MIH-affected teeth, and the survival of restorations could be higher in the total-etch technique, reducing dental pain and anxiety.",2020,Self-reported dental pain and anxiety level decreased after treatment in both groups (p < 0.05).,"['molars affected by molar incisor hypomineralization', 'FPMs with MIH of 35 patients aged 7 to 16\xa0years were included']","['molar incisor hypomineralization (MIH', 'total-etch (TE-37% phosphoric acid etching) and self-etch']","['Dental anxiety (Venham picture test) and dental pain (Faces pain scale-revised', 'Self-reported pain', 'restoration survival', 'Survival rates', 'pain and anxiety', 'Self-reported dental pain and anxiety level', 'similar longevity, decreasing self-reported pain and anxiety levels']","[{'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C2350038', 'cui_str': 'Molar incisor hypomineralization'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C2350038', 'cui_str': 'Molar incisor hypomineralization'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0031700', 'cui_str': 'Phosphoric acid'}, {'cui': 'C0036588', 'cui_str': 'Self'}]","[{'cui': 'C0085380', 'cui_str': 'Dental phobia'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0040460', 'cui_str': 'Toothache'}, {'cui': 'C0015468', 'cui_str': 'Pain in face'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0023980', 'cui_str': 'Longevity'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}]",64.0,0.0636983,Self-reported dental pain and anxiety level decreased after treatment in both groups (p < 0.05).,"[{'ForeName': 'Tatiane Zahn Cardoso', 'Initials': 'TZC', 'LastName': 'Rolim', 'Affiliation': 'Department of Stomatology, Universidade Federal do Parana Setor de Ciencias da Saude, Av. Prefeito Lothário Meissner 632, Curitiba, State of Paraná, 80210-170, Brazil.'}, {'ForeName': 'Thays Regina Ferreira', 'Initials': 'TRF', 'LastName': 'da Costa', 'Affiliation': 'Department of Stomatology, Universidade Federal do Parana Setor de Ciencias da Saude, Av. Prefeito Lothário Meissner 632, Curitiba, State of Paraná, 80210-170, Brazil.'}, {'ForeName': 'Leticia Maira', 'Initials': 'LM', 'LastName': 'Wambier', 'Affiliation': 'School of Health and Biological Sciences, Universidade Positivo, Curitiba, Brazil.'}, {'ForeName': 'Ana Claudia', 'Initials': 'AC', 'LastName': 'Chibinski', 'Affiliation': 'Department of Dentistry, State University of Ponta Grossa, Ponta Grossa, Brazil.'}, {'ForeName': 'Denise Stadler', 'Initials': 'DS', 'LastName': 'Wambier', 'Affiliation': 'Department of Dentistry, State University of Ponta Grossa, Ponta Grossa, Brazil.'}, {'ForeName': 'Luciana Reichert', 'Initials': 'LR', 'LastName': 'da Silva Assunção', 'Affiliation': 'Department of Stomatology, Universidade Federal do Parana Setor de Ciencias da Saude, Av. Prefeito Lothário Meissner 632, Curitiba, State of Paraná, 80210-170, Brazil.'}, {'ForeName': 'José Vitor Borges Nogara', 'Initials': 'JVBN', 'LastName': 'de Menezes', 'Affiliation': 'Department of Stomatology, Universidade Federal do Parana Setor de Ciencias da Saude, Av. Prefeito Lothário Meissner 632, Curitiba, State of Paraná, 80210-170, Brazil.'}, {'ForeName': 'Juliana', 'Initials': 'J', 'LastName': 'Feltrin-Souza', 'Affiliation': 'Department of Stomatology, Universidade Federal do Parana Setor de Ciencias da Saude, Av. Prefeito Lothário Meissner 632, Curitiba, State of Paraná, 80210-170, Brazil. julianafeltrin1@gmail.com.'}]",Clinical oral investigations,['10.1007/s00784-020-03459-2'] 2236,32696226,A pilot randomized-controlled trial evaluating the erector spinae plane block in thoracic and breast surgery.,"PURPOSE This pilot study evaluated the feasibility of investigating the effect of the erector spinae plane (ESP) block on the patient-centred outcomes of quality of recovery-15 (QoR-15), and brief pain inventory (BPI) in thoracic and breast surgery patients. METHODS In this randomized-controlled pilot trial, 82 patients undergoing video-assisted thoracoscopic surgery (n = 77) and mastectomy (n = 5) received either continuous ESP block with ropivacaine (ropivacaine group) or the same procedure with 0.9% saline (saline group). All patients received surgical intercostal block (thoracic surgery) or local anesthetic infiltration (breast surgery). Feasibility as the primary outcome was evaluated on recruitment (three patients per week), catheter retention (above 90% at 24 hr), and patient attrition (less than 10%). Secondary outcomes comprised of QoR-15, BPI, and opioid consumption. RESULTS Recruitment rate was 1.8 patients per week. Catheters were retained in 77 patients (94%) at 24 hr. At three months, five patients were lost to follow-up (6%). At 24 hr compared with baseline, the ropivacaine group had a smaller decline in QoR-15 score (median difference, 14; 95% confidence interval [CI], 2 to 26; P = 0.02) and a smaller increase in BPI global score (median difference, 14; 95% CI, 0 to 24; P = 0.048). There was no difference in opioid consumption (P = 0.08). CONCLUSIONS In this pilot study, the target recruitment rate was not met, but catheter retention and patient attrition rates were both satisfactory. A definitive trial with QoR-15 as the primary outcome would require 300 study participants. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry (ID12618000701224); registered 30 April 2018.",2020,"At 24 hr compared with baseline, the ropivacaine group had a smaller decline in QoR-15 score (median difference, 14; 95% confidence interval [CI], 2 to 26; P = 0.02) and a smaller increase in BPI global score (median difference, 14; 95% CI, 0 to 24; P = 0.048).","['82 patients undergoing', 'thoracic and breast surgery', '300 study participants', 'n = 77) and mastectomy (n = 5) received either', 'thoracic and breast surgery patients']","['erector spinae plane block', 'continuous ESP block with ropivacaine (ropivacaine group) or the same procedure with 0.9% saline (saline', 'video-assisted thoracoscopic surgery', 'ropivacaine', 'QoR-15', 'surgical intercostal block (thoracic surgery) or local anesthetic infiltration (breast surgery', 'erector spinae plane (ESP) block']","['QoR-15 score', 'BPI global score', 'catheter retention', 'QoR-15, BPI, and opioid consumption', 'quality of recovery-15 (QoR-15), and brief pain inventory (BPI', 'opioid consumption', 'catheter retention and patient attrition rates', 'patient attrition']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0851312', 'cui_str': 'Breast surgery'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0024881', 'cui_str': 'Mastectomy'}]","[{'cui': 'C0224301', 'cui_str': 'Structure of erector spinae muscle'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0752151', 'cui_str': 'Surgery, Thoracic, Video-Assisted'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0039986', 'cui_str': 'Thoracic surgery'}, {'cui': 'C0198813', 'cui_str': 'Local anesthesia, by infiltration'}, {'cui': 'C0851312', 'cui_str': 'Breast surgery'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}]",82.0,0.51871,"At 24 hr compared with baseline, the ropivacaine group had a smaller decline in QoR-15 score (median difference, 14; 95% confidence interval [CI], 2 to 26; P = 0.02) and a smaller increase in BPI global score (median difference, 14; 95% CI, 0 to 24; P = 0.048).","[{'ForeName': 'Yoshiaki', 'Initials': 'Y', 'LastName': 'Uda', 'Affiliation': ""Department of Anaesthesia and Acute Pain Medicine, St. Vincent's Hospital, Victoria Parade, Fitzroy, PO Box 2900, Melbourne, VIC, 3065, Australia. Yoshiaki.Uda@svha.org.au.""}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Byrne', 'Affiliation': 'Department of Anaesthesia, Waikato Hospital, Hamilton, New Zealand.'}, {'ForeName': 'Anjalee', 'Initials': 'A', 'LastName': 'Brahmbhatt', 'Affiliation': ""Department of Anaesthesia and Acute Pain Medicine, St. Vincent's Hospital, Victoria Parade, Fitzroy, PO Box 2900, Melbourne, VIC, 3065, Australia.""}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Gotmaker', 'Affiliation': ""Department of Anaesthesia and Acute Pain Medicine, St. Vincent's Hospital, Victoria Parade, Fitzroy, PO Box 2900, Melbourne, VIC, 3065, Australia.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Lim', 'Affiliation': ""Department of Pharmacy, St. Vincent's Hospital, Melbourne, VIC, Australia.""}, {'ForeName': 'Yasutaka', 'Initials': 'Y', 'LastName': 'Konishi', 'Affiliation': ""Department of Anaesthesia and Acute Pain Medicine, St. Vincent's Hospital, Victoria Parade, Fitzroy, PO Box 2900, Melbourne, VIC, 3065, Australia.""}, {'ForeName': 'Tessa Katherine', 'Initials': 'TK', 'LastName': 'Eves', 'Affiliation': 'Department of Anatomy and Neuroscience, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Paxton', 'Affiliation': ""Department of Anaesthesia and Acute Pain Medicine, St. Vincent's Hospital, Victoria Parade, Fitzroy, PO Box 2900, Melbourne, VIC, 3065, Australia.""}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Barrington', 'Affiliation': ""Department of Anaesthesia and Acute Pain Medicine, St. Vincent's Hospital, Victoria Parade, Fitzroy, PO Box 2900, Melbourne, VIC, 3065, Australia.""}]",Canadian journal of anaesthesia = Journal canadien d'anesthesie,['10.1007/s12630-020-01759-5'] 2237,32696227,Intravenous dextrose versus ondansetron for prevention of postoperative vomiting in children: a randomized non-inferiority trial.,"BACKGROUND Postoperative vomiting (POV) in children is frequent. Dextrose-containing intravenous fluids in the perioperative period have shown improvement of POV in adults. Similar studies have not been done in children. AIM The primary purpose was to study the efficacy of intraoperative intravenous dextrose for antiemetic prophylaxis in children undergoing ambulatory surgery. METHODS A non-inferiority randomized clinical trial of healthy children (three to nine years old) undergoing ambulatory dental surgery was conducted. The control group received dexamethasone (0.15 mg·kg -1 iv) and ondansetron (0.05 mg·kg -1 iv); the intervention group received dexamethasone (0.15 mg·kg -1 iv) and intravenous 5% dextrose in 0.9% normal saline according to a weight-based maintenance rate. The primary outcome was POV in the postanesthetic care unit (PACU) within two hr after surgery. Secondary outcomes included POV within 24 hr from discharge and unplanned hospital admission. A non-inferiority analysis was conducted on the primary outcome using an absolute risk difference of 7.5% as the non-inferiority margin. RESULTS Data from 290 patients were analyzed. Demographics and intraoperative anesthetic management were similar between groups. Vomiting in the PACU occurred in 7.6% and 3.5% of the dextrose and ondansetron groups, respectively, with a risk difference of 4.2% (95% confidence interval [CI], -1.0 to 9.5). Given that the upper limit of the 95% CI exceeded our non-inferiority margin, non-inferiority of dextrose compared with ondansetron was not shown. CONCLUSION These results do not support the use of intravenous dextrose as a satisfactory alternative to ondansetron to prevent POV in ambulatory pediatric dental surgery patients. TRIAL REGISTRATION www.clinicaltrials.gov (NCT01912807); registered 18 July 2013.",2020,The control group received dexamethasone (0.15 mg·kg -1 iv) and ondansetron (0.05 mg·kg -1 iv); the intervention group received dexamethasone (0.15 mg·kg -1 iv) and intravenous 5% dextrose in 0.9% normal saline according to a weight-based maintenance rate.,"['ambulatory pediatric dental surgery patients', 'children', 'healthy children (three to nine years old) undergoing ambulatory dental surgery was conducted', 'children undergoing ambulatory surgery', '290 patients were analyzed']","['dexamethasone (0.15 mg·kg -1 iv) and intravenous 5% dextrose in 0.9% normal saline', 'intraoperative intravenous dextrose', 'dexamethasone', 'ondansetron', 'dextrose', 'Dextrose-containing intravenous fluids', 'Intravenous dextrose']","['postoperative vomiting', 'Vomiting', 'Demographics and intraoperative anesthetic management', 'POV within 24 hr from discharge and unplanned hospital admission', 'POV in the postanesthetic care unit (PACU']","[{'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0204324', 'cui_str': 'Dental surgical procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0002428', 'cui_str': 'Ambulatory surgery'}, {'cui': 'C5191218', 'cui_str': '290'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C4068886', 'cui_str': '0.15'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0985452', 'cui_str': 'Glucose 50 MG/ML'}, {'cui': 'C4068881', 'cui_str': '0.9'}, {'cui': 'C0439166', 'cui_str': '% normal'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0061851', 'cui_str': 'Ondansetron'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C1289919', 'cui_str': 'Intravenous fluid'}]","[{'cui': 'C0520905', 'cui_str': 'Postoperative vomiting'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0034871', 'cui_str': 'Postoperative anesthesia care unit'}]",290.0,0.623907,The control group received dexamethasone (0.15 mg·kg -1 iv) and ondansetron (0.05 mg·kg -1 iv); the intervention group received dexamethasone (0.15 mg·kg -1 iv) and intravenous 5% dextrose in 0.9% normal saline according to a weight-based maintenance rate.,"[{'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Vasquez-Camargo', 'Affiliation': 'Department of Academic Family Medicine, University of Saskatchewan, 172-1621 Albert Street, Regina, SK, S4P 2S5, Canada. a.vasquez@usask.ca.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Gamble', 'Affiliation': 'Department of Anesthesiology, Perioperative Medicine and Pain Management, University of Saskatchewan, Saskatoon, SK, Canada.'}, {'ForeName': 'Kelly A', 'Initials': 'KA', 'LastName': 'Fedoruk', 'Affiliation': 'Department of Anesthesiology, Perioperative Medicine and Pain Management, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Hyun J June', 'Initials': 'HJJ', 'LastName': 'Lim', 'Affiliation': 'Community Health and Epidemiology Department, University of Saskatchewan, Saskatoon, SK, Canada.'}, {'ForeName': 'Prosanta K', 'Initials': 'PK', 'LastName': 'Mondal', 'Affiliation': 'Clinical Research Support Unit, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Martinez', 'Affiliation': 'College of Nursing, University of Saskatchewan, Saskatoon, SK, Canada.'}, {'ForeName': 'Grant G', 'Initials': 'GG', 'LastName': 'Miller', 'Affiliation': 'Department of Surgery, University of Saskatchewan, Saskatoon, SK, Canada.'}]",Canadian journal of anaesthesia = Journal canadien d'anesthesie,['10.1007/s12630-020-01757-7'] 2238,32696258,An analysis of the safety and efficacy of dexmedetomidine in posterior spinal fusion surgery for adolescent idiopathic scoliosis: a prospective randomized study.,"PURPOSE To evaluate whether use of dexmedetomidine, a centrally acting α2 adrenergic agonist, reduces opioid consumption in PSF. METHODS Adolescent idiopathic scoliosis patients who underwent PSF were randomized into morphine (M) and dexmedetomidine (D) group. M group received a 10 μg/kg/h IV infusion of morphine for 24 h post-surgery, while the D group received a 0.4 μg/kg/h IV infusion of dexmedetomidine. Trained nursing staffs recorded hourly vital parameters (blood pressure, pulse rate, respiratory rate, and oxygen saturation). Pain, postoperative nausea/vomiting (PONV), and sedation were rated using: the numerical rating scale (NRS), the PONV scale, and sedation status scale (SS). Preemptive analgesia with gabapentin and postoperative analgesia with ketorolac and paracetamol were used in both the groups. Any complications in the study groups were recorded. RESULTS No significant difference was noted between the groups (M vs D) with respect to NRS (3.1 ± 0.8 vs 2.7 ± 0.5) (p = 0.07) and breakthrough analgesia requirements (0.78 vs 0.45) (p = 0.17). A significant difference was noted between the groups with respect to the secondary outcome measures of time to ambulation (56.6 ± 12.7 h vs 45.2 ± 7.7 h), time to oral analgesics (84.3 ± 20 h vs 64.0 ± 15.4 h), and time to liquid intake (8.3 ± 1.3 h vs 7.2 ± 1.2 h). The M group had a higher PONV score (0.46 ± 0.3 vs 0.16 ± 0.1) (p < 0.001) and mean time to bowel opening (112.7 ± 28.4 h vs 90.1 ± 20.5 h) (p < 0.001). Additionally, the enema or suppository requirements for bowel opening were significantly more (0.59 ± 0.6 vs 0.26 ± 0.4) (p = 0.01) in the M group. CONCLUSION Dexmedetomidine provided analgesia comparable to morphine with lower PONV scores. It also reduced the opioid requirements in the PSF patients without additional complications and can therefore be incorporated in pain management protocols.",2020,The M group had a higher PONV score (0.46 ± 0.3 vs 0.16 ± 0.1) (,"['Adolescent idiopathic scoliosis patients who underwent PSF', 'adolescent idiopathic scoliosis']","['morphine (M) and dexmedetomidine (D', 'Dexmedetomidine', 'gabapentin', 'ketorolac and paracetamol', 'posterior spinal fusion surgery', 'dexmedetomidine', 'morphine']","['Pain, postoperative nausea/vomiting (PONV), and sedation', 'numerical rating scale (NRS), the PONV scale, and sedation status\xa0scale\xa0(SS', 'breakthrough analgesia requirements', 'higher PONV score', 'hourly vital parameters (blood pressure, pulse rate, respiratory rate, and oxygen saturation', 'PONV scores', 'opioid requirements', 'time to oral analgesics', 'safety and efficacy', 'time to liquid intake', 'mean time to bowel opening', 'enema or suppository requirements for bowel opening', 'time to ambulation']","[{'cui': 'C0410702', 'cui_str': 'Adolescent idiopathic scoliosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0214345', 'cui_str': 'Splicing Factor Proline-Glutamine Rich Protein'}]","[{'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0060926', 'cui_str': 'gabapentin'}, {'cui': 'C0073631', 'cui_str': 'Ketorolac'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0919636', 'cui_str': 'Spinal fusion surgery'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0520904', 'cui_str': 'Postoperative nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0444503', 'cui_str': 'Breakthrough'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0558292', 'cui_str': 'Hourly'}, {'cui': 'C0442732', 'cui_str': 'Vital'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0014268', 'cui_str': 'Giving patient an enema'}, {'cui': 'C0031246', 'cui_str': 'Pessary'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]",,0.0558677,The M group had a higher PONV score (0.46 ± 0.3 vs 0.16 ± 0.1) (,"[{'ForeName': 'Ankith', 'Initials': 'A', 'LastName': 'Naduvanahalli Vivekanandaswamy', 'Affiliation': 'Department of Orthopaedics and Spine Surgery, Ganga Medical Centre and Hospital Pvt. Ltd, #313, Mettupalayam Road, Sai Baba Colony, Coimbatore, Tamilnadu, 641001, India.'}, {'ForeName': 'Ajoy', 'Initials': 'A', 'LastName': 'Prasad Shetty', 'Affiliation': 'Department of Orthopaedics and Spine Surgery, Ganga Medical Centre and Hospital Pvt. Ltd, #313, Mettupalayam Road, Sai Baba Colony, Coimbatore, Tamilnadu, 641001, India. ajoyshetty@gmail.com.'}, {'ForeName': 'Rishi', 'Initials': 'R', 'LastName': 'Mugesh Kanna', 'Affiliation': 'Department of Orthopaedics and Spine Surgery, Ganga Medical Centre and Hospital Pvt. Ltd, #313, Mettupalayam Road, Sai Baba Colony, Coimbatore, Tamilnadu, 641001, India.'}, {'ForeName': 'Rajasekaran', 'Initials': 'R', 'LastName': 'Shanmuganathan', 'Affiliation': 'Department of Orthopaedics and Spine Surgery, Ganga Medical Centre and Hospital Pvt. Ltd, #313, Mettupalayam Road, Sai Baba Colony, Coimbatore, Tamilnadu, 641001, India.'}]","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society",['10.1007/s00586-020-06539-9'] 2239,32696304,Impact of Phone-Call and Access-Enhancing Intervention on Mammography Uptake among Primary Care Patients at an Urban Safety-Net Hospital: A Randomized Controlled Study.,"BACKGROUND Our urban safety-net hospital (SNH) has very low screening mammogram rates within its primary care clinics. Despite Commission on Cancer (CoC) accreditation, we see ~ 3 × more late-stage breast cancer diagnoses than other CoC sites across the country, and recently showed this to be strongly associated with lack of screening (Ahmadiyeh et al. in J Health Care Poor Underserved, in press, 2020). Here we study whether a two-step intervention (phone calls and assistance scheduling mammograms) increases uptake over usual care. PATIENTS AND METHODS Randomized controlled study of 890 women aged 50-65 years who were due for biennial screening mammograms and who were established within one of five primary care clinics at an urban SNH. Each patient in the intervention group was called with overdue status (up to three times, voicemail left if needed) and offered assistance scheduling mammogram appointment. Mammography uptake at 3 and 6 months was analyzed. RESULTS Intervention significantly increased uptake compared with usual care at both timepoints (18% versus 6% at 3 months; χ 2  = 27.597, p < 0.0001; 23% versus 12% at 6 months; χ 2  = 18.0, p < 0.0001), with scheduling component driving effectiveness. Of those who were successfully contacted, uptake was significantly greater among those who scheduled appointments versus those who did not (47% versus 9%, χ 2  = 95, p < 0.0001), and uptake was no different between contacted but not scheduled patients and usual care controls. CONCLUSIONS Phone call with access-enhancing intervention (facilitating mammogram appointments) increased screening mammogram uptake among primary care patients in an urban safety-net setting and may be applicable to other urban SNHs around the country.",2020,"RESULTS Intervention significantly increased uptake compared with usual care at both timepoints (18% versus 6% at 3 months; χ 2  = 27.597, p < 0.0001; 23% versus 12% at 6 months; χ 2  = 18.0, p < 0.0001), with scheduling component driving effectiveness.","['890 women aged 50-65\xa0years who were due for biennial screening mammograms and who were established within one of five primary care clinics at an urban SNH', 'Primary Care Patients at an Urban Safety-Net Hospital']","['Phone-Call and Access-Enhancing Intervention', 'Phone call with access-enhancing intervention (facilitating mammogram appointments', 'two-step intervention (phone calls and assistance scheduling mammograms']","['Mammography Uptake', 'screening mammogram uptake', 'Mammography uptake']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0203028', 'cui_str': 'Screening mammography'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C3661443', 'cui_str': 'Safety-net Hospitals'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0205539', 'cui_str': 'Scheduled - procedure status'}]","[{'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]",890.0,0.0457554,"RESULTS Intervention significantly increased uptake compared with usual care at both timepoints (18% versus 6% at 3 months; χ 2  = 27.597, p < 0.0001; 23% versus 12% at 6 months; χ 2  = 18.0, p < 0.0001), with scheduling component driving effectiveness.","[{'ForeName': 'Asha D', 'Initials': 'AD', 'LastName': 'Nanda', 'Affiliation': 'University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.'}, {'ForeName': 'Melissa P', 'Initials': 'MP', 'LastName': 'Mann', 'Affiliation': 'Truman Medical Centers, Kansas City, MO, USA.'}, {'ForeName': 'An-Lin', 'Initials': 'AL', 'LastName': 'Cheng', 'Affiliation': 'Department of Biomedical and Health Informatics, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Moormeier', 'Affiliation': 'Truman Medical Centers, Kansas City, MO, USA.'}, {'ForeName': 'Nasim', 'Initials': 'N', 'LastName': 'Ahmadiyeh', 'Affiliation': 'Truman Medical Centers, Kansas City, MO, USA. ahmadiyehn@umkc.edu.'}]",Annals of surgical oncology,['10.1245/s10434-020-08884-x'] 2240,32696349,The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome.,"BACKGROUND Women with polycystic ovary syndrome (PCOS) are characterized by increased cardiometabolic risk. The aim of the current study was to compare the impact of atorvastatin on plasma levels of cardiometabolic risk factors between men whose sisters had either PCOS or were unaffected. METHODS The study population consisted of two age-, fat-free mass index-, blood pressure- and plasma lipid-matched groups of men with elevated total and LDL cholesterol levels: 20 brothers of PCOS probands (group 1) and 20 brothers of healthy women (group 2). Both groups were then treated with atorvastatin (40 mg daily) for the following 6 months. At the beginning and at the end of the study, we assessed plasma lipid levels, glucose homeostasis markers and levels of dehydroepiandrosterone sulfate, testosterone, bioavailable testosterone, uric acid, high-sensitivity C-reactive protein (hsCRP), homocysteine, fibrinogen and 25-hydroxyvitamin D. RESULTS At the beginning of the study, both treatment arms differed in the degree of insulin resistance, calculated bioavailable testosterone, as well as in plasma levels of dehydroepiandrosterone sulfate, uric acid, hsCRP and 25-hydroxyvitamin D. Although atorvastatin reduced total and LDL cholesterol levels, this effect was stronger in group 2 than group 1. In group 2, atorvastatin exerted also a more potent impact on hsCRP, fibrinogen and homocysteine. An unfavorable impact on insulin sensitivity was observed only in group 1; while, statistically significant changes in uric acid and 25-hydroxyvitamin D levels were found only in group 2. CONCLUSION The obtained results suggest that cardiometabolic effects of atorvastatin are less pronounced in male siblings of PCOS probands than in brothers of unaffected women.",2020,"An unfavorable impact on insulin sensitivity was observed only in group 1; while, statistically significant changes in uric acid and 25-hydroxyvitamin D levels were found only in group 2. ","['male siblings of PCOS probands than in brothers of unaffected women', 'brothers of women with polycystic ovary syndrome', 'Women with polycystic ovary syndrome (PCOS', 'study population consisted of two age-, fat-free mass index-, blood pressure- and plasma lipid-matched groups of men with elevated total and LDL cholesterol levels: 20 brothers of PCOS probands (group 1) and 20 brothers of healthy women (group 2', 'men whose sisters had either PCOS or were unaffected']",['atorvastatin'],"['plasma lipid levels, glucose homeostasis markers and levels of dehydroepiandrosterone sulfate, testosterone, bioavailable testosterone, uric acid, high-sensitivity C-reactive protein (hsCRP), homocysteine, fibrinogen and 25-hydroxyvitamin D', 'total and LDL cholesterol levels', 'hsCRP, fibrinogen and homocysteine', 'uric acid and 25-hydroxyvitamin D levels', 'insulin sensitivity', 'degree of insulin resistance, calculated bioavailable testosterone, as well as in plasma levels of dehydroepiandrosterone sulfate, uric acid, hsCRP and 25-hydroxyvitamin D', 'plasma levels of cardiometabolic risk factors', 'cardiometabolic risk factors']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0037047', 'cui_str': 'Sibling'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C0702111', 'cui_str': 'Proband'}, {'cui': 'C0337527', 'cui_str': 'Brother'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C1278073', 'cui_str': 'Plasma lipid measurement'}, {'cui': 'C0024908', 'cui_str': 'Matched Groups'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0337514', 'cui_str': 'Sister'}]","[{'cui': 'C0286651', 'cui_str': 'atorvastatin'}]","[{'cui': 'C1278073', 'cui_str': 'Plasma lipid measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0057277', 'cui_str': 'Dehydroepiandrosterone sulfate'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0370051', 'cui_str': 'Bioavailable testosterone'}, {'cui': 'C0041980', 'cui_str': 'Uric Acid'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0019878', 'cui_str': 'Homocysteine'}, {'cui': 'C0016006', 'cui_str': 'Fibrinogen'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}]",,0.0637695,"An unfavorable impact on insulin sensitivity was observed only in group 1; while, statistically significant changes in uric acid and 25-hydroxyvitamin D levels were found only in group 2. ","[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Krysiak', 'Affiliation': 'Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, 40-752, Katowice, Poland. r.krysiak@interia.pl.'}, {'ForeName': 'Witold', 'Initials': 'W', 'LastName': 'Szkróbka', 'Affiliation': 'Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, 40-752, Katowice, Poland.'}, {'ForeName': 'Bogusław', 'Initials': 'B', 'LastName': 'Okopień', 'Affiliation': 'Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, 40-752, Katowice, Poland.'}]",Pharmacological reports : PR,['10.1007/s43440-020-00135-w'] 2241,32696472,Cost-Effectiveness of 2 Support Models for a Healthy School Initiative.,"BACKGROUND In school year (SY) 2014-2015, 128 schools in 24 districts and 14 states were randomly assigned to receive either onsite or online support to implement a school-based wellness program. The objective of this study was to assess the cost-effectiveness (CE) of the 2 models of implementation support: onsite and online. METHODS We adapted the ""ingredients method"" for the CE analysis. Using expenditure data, we tabulated the costs of relevant expense categories and allocated the appropriate proportion to determine the total costs of providing each type of support for 4 years (SY 2014-2015 through SY 2017-2018). We divided the average cost per school by the average change in school wellness policies and practices, using assessment data provided by the program provider, to calculate a CE ratio for schools in each group. RESULTS Findings indicate that when the program is implemented as intended, online support is, on average, approximately 1.3 times more cost-effective than onsite support at the end of 4 years. CONCLUSIONS By demonstrating the relative CE of 2 approaches to supporting the implementation of a school health program, this study provides further insight on more efficient interventions for improving overall school wellness.",2020,"RESULTS Findings indicate that when the program is implemented as intended, online support is, on average, approximately 1.3 times more cost-effective than onsite support at the end of 4 years. ","['Healthy School Initiative', 'In school year (SY) 2014-2015, 128 schools in 24 districts and 14 states']",['onsite or online support to implement a school-based wellness program'],"['cost-effectiveness (CE', 'Cost-Effectiveness']","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1301808', 'cui_str': 'State'}]","[{'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0043113', 'cui_str': 'Wellness Programs'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",,0.0227649,"RESULTS Findings indicate that when the program is implemented as intended, online support is, on average, approximately 1.3 times more cost-effective than onsite support at the end of 4 years. ","[{'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Finster', 'Affiliation': 'Senior Study Director, (matthewfinster@westat.com), Westat, Inc., 1600 Research Blvd., Rockville, MD 20850.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Feldman', 'Affiliation': 'Senior Study Director, (jillfeldman@westat.com), Westat, Inc.,1600 Research Blvd., Rockville, MD 20850.'}]",The Journal of school health,['10.1111/josh.12931'] 2242,32696559,Rationale and design of a risk-guided strategy for reducing readmissions for acute decompensated heart failure: the Risk-HF study.,"AIMS Heart failure (HF) readmission commonly arises owing to insufficient patient knowledge and failure of recognition of the early stages of recurrent fluid congestion. In previous work, we developed a score to predict short-term hospital readmission and showed that higher-risk patients benefit most from a disease management programme (DMP) that included enhancing knowledge and education by a nurse. We aim to evaluate the effectiveness of a novel, nurse-led HF DMP in selected patients at high risk of short-term hospital readmission, using ultrasound-guided diuretic management and artificial intelligence to enhance HF knowledge in an outpatient setting. METHODS AND RESULTS Risk-HF is a prospective multisite randomized controlled trial that will allocate 404 patients hospitalized with acute decompensated HF, and ≥33% risk of readmission and/or death at 30 days, into risk-guided nurse intervention (DMP-Plus group) compared with usual care. Intervention elements include (i) fluid management with a handheld ultrasound (HHU) device at point of care; (ii) post-discharge follow-up; (iii) optimal programmed drug titration; (iv) better transition of care; (v) intensive self-care education via an avatar-based 'digital health coach'; and (vi) exercise guidance through the digital coach. Usual care involves standard post-discharge hospital care. The primary outcome is reduced death and/or hospital readmissions at 30 days post-discharge, and secondary outcomes include quality of life, fluid management efficacy, and feasibility and patient engagement. Assuming that our intervention will reduce readmissions and/or deaths by 50%, with a 1:1 ratio of intervention vs. usual care, we plan to randomize 404 patients to show a difference at a statistical power of 80%, using a two-sided alpha of 0.05. We anticipate this recruitment will be achieved by screening 2020 hospitalized HF patients for eligibility. An 8 week pilot programme of our digital health coach in 21 HF patients, age > 75 years, showed overall improvements in quality of life (13 of 21), self-care (12 of 21), and HF knowledge (13 of 21). A pilot of the use of HHU by nurses showed that it was feasible and accurate. CONCLUSIONS The Risk-HF trial will evaluate the effectiveness of a risk-guided intervention to improve HF outcomes and will evaluate the efficacy of trained HF nurses delivering a fluid management protocol that is guided by lung ultrasound with an HHU at point of care.",2020,"An 8 week pilot programme of our digital health coach in 21 HF patients, age > 75 years, showed overall improvements in quality of life (13 of 21), self-care (12 of 21), and HF knowledge (13 of 21).","['404 patients hospitalized with acute decompensated HF, and ≥33% risk of readmission and/or death at 30\xa0days, into risk', '2020 hospitalized HF patients for eligibility', 'acute decompensated heart failure', '21 HF patients, age\xa0>\xa075\xa0years', 'selected patients at high risk of short-term hospital readmission, using']","['novel, nurse-led HF DMP', ""Intervention elements include (i) fluid management with a handheld ultrasound (HHU) device at point of care; (ii) post-discharge follow-up; (iii) optimal programmed drug titration; (iv) better transition of care; (v) intensive self-care education via an avatar-based 'digital health coach'; and (vi) exercise guidance through the digital coach"", 'risk-guided strategy', 'ultrasound-guided diuretic management and artificial intelligence', 'guided nurse intervention (DMP-Plus group) compared with usual care']","['reduced death and/or hospital readmissions at 30\xa0days post-discharge, and secondary outcomes include quality of life, fluid management efficacy, and feasibility and patient engagement', 'quality of life (13 of 21), self-care (12 of 21), and HF knowledge', 'readmissions and/or deaths']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C1303150', 'cui_str': 'Disease management program'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013879', 'cui_str': 'Chemical element'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0553741', 'cui_str': 'Fluid balance regulation'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0282664', 'cui_str': 'Point-of-Care'}, {'cui': 'C1320368', 'cui_str': 'Post-discharge follow-up'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C4761127', 'cui_str': 'Drug titration'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C3266241', 'cui_str': 'Transition of care'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C2317129', 'cui_str': 'Health coach'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0012798', 'cui_str': 'Diuretic'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0003916', 'cui_str': 'Computer Reasoning'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0553741', 'cui_str': 'Fluid balance regulation'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C3508152', 'cui_str': 'Patient Engagement'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",21.0,0.07804,"An 8 week pilot programme of our digital health coach in 21 HF patients, age > 75 years, showed overall improvements in quality of life (13 of 21), self-care (12 of 21), and HF knowledge (13 of 21).","[{'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Zisis', 'Affiliation': 'Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Vic., 3004, Australia.'}, {'ForeName': 'Quan', 'Initials': 'Q', 'LastName': 'Huynh', 'Affiliation': 'Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Vic., 3004, Australia.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Faculty of Medicine, University of Melbourne, Melbourne, Vic., Australia.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Neil', 'Affiliation': 'Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Vic., 3004, Australia.'}, {'ForeName': 'Melinda J', 'Initials': 'MJ', 'LastName': 'Carrington', 'Affiliation': 'Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Vic., 3004, Australia.'}, {'ForeName': 'Jocasta', 'Initials': 'J', 'LastName': 'Ball', 'Affiliation': 'Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Vic., 3004, Australia.'}, {'ForeName': 'Graeme', 'Initials': 'G', 'LastName': 'Maguire', 'Affiliation': 'Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Vic., 3004, Australia.'}, {'ForeName': 'Thomas H', 'Initials': 'TH', 'LastName': 'Marwick', 'Affiliation': 'Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Vic., 3004, Australia.'}]",ESC heart failure,['10.1002/ehf2.12897'] 2243,32696598,High-flow nasal cannula versus standard respiratory care in pediatric procedural sedation: a randomized controlled pilot trial.,"INTRODUCTION Respiratory instability is frequently observed during pediatric procedural sedation. The aim of this trial was to estimate the impact of nasal high-flow nasal cannula (HFNC) therapy on respiratory stability during sedation for upper gastrointestinal tract endoscopy in children. METHODS Prospective randomized controlled non-blinded single-center pilot trial. Children were randomly allocated to receive either HFNC (2 L/kg/min) or low-flow nasal oxygen cannula (LFNC, standard care). FiO 2 was titrated to maintain SpO 2 94%-98% in both groups. Primary outcome was the number of events of respiratory instability defined by prespecified criteria (hypoxia, hypercapnia, apnea). Secondary outcomes included type and duration of events, number of interventions to regain respiratory stability and cumulative doses of medication. RESULTS Fifty children (mean age 12.3±3.1 years) were enrolled and treated with HFNC (n=25) or LFNC (n=25). Patient and intervention characteristics were not different in the two study groups, including total oxygen flow rate. Mean (SD) number of respiratory events in the HFNC group was 2.0±1.9 events compared to 2.0±1.4 events in the LFNC group (P = 0.65, 95% CI of difference -1.0 - 1.0). There was no difference for any secondary outcome criteria, percentage of patients for any outcome criteria and no difference in the number of respiratory events or airway management maneuvers per patient between treatment groups. CONCLUSIONS HFNC did not increase respiratory stability in sedated children undergoing upper gastrointestinal tract endoscopy compared to LFNC. This article is protected by copyright. All rights reserved.",2020,"There was no difference for any secondary outcome criteria, percentage of patients for any outcome criteria and no difference in the number of respiratory events or airway management maneuvers per patient between treatment groups. ","['upper gastrointestinal tract endoscopy in children', 'sedated children undergoing upper gastrointestinal tract endoscopy', 'Fifty children (mean', 'age 12.3±3.1 years) were enrolled and treated with', 'pediatric procedural sedation']","['HFNC (2 L/kg/min) or low-flow nasal oxygen cannula (LFNC, standard care', 'High-flow nasal cannula versus standard respiratory care', 'LFNC', 'nasal high-flow nasal cannula (HFNC) therapy', 'HFNC']","['total oxygen flow rate', 'Mean (SD) number of respiratory events', 'respiratory stability', 'type and duration of events, number of interventions to regain respiratory stability and cumulative doses of medication', 'number of respiratory events or airway management maneuvers', 'number of events of respiratory instability defined by prespecified criteria (hypoxia, hypercapnia, apnea']","[{'cui': 'C0079304', 'cui_str': 'Esophagogastroduodenoscopy'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}, {'cui': 'C1637390', 'cui_str': 'mL/g'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0520453', 'cui_str': 'Cannula'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0035239', 'cui_str': 'Respiratory therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1320717', 'cui_str': 'Respiratory event'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0150126', 'cui_str': 'Airway management'}, {'cui': 'C0085633', 'cui_str': 'Mood swings'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0020440', 'cui_str': 'Hypercapnia'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}]",50.0,0.190034,"There was no difference for any secondary outcome criteria, percentage of patients for any outcome criteria and no difference in the number of respiratory events or airway management maneuvers per patient between treatment groups. ","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Klotz', 'Affiliation': 'Center for Pediatrics and Adolescent Medicine, Division of Neonatology and Pediatric Intensive Care Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Viktor', 'Initials': 'V', 'LastName': 'Seifert', 'Affiliation': 'Center for Pediatrics and Adolescent Medicine, Division of Neonatology and Pediatric Intensive Care Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Baumgartner', 'Affiliation': 'Center for Pediatrics and Adolescent Medicine, Division of Neonatology and Pediatric Intensive Care Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Teufel', 'Affiliation': 'Center for Pediatrics and Adolescent Medicine, Department of Gastroenterology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Fuchs', 'Affiliation': 'Center for Pediatrics and Adolescent Medicine, Division of Neonatology and Pediatric Intensive Care Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}]",Pediatric pulmonology,['10.1002/ppul.24975'] 2244,32696600,The detrimental effect of COVID-19 nationwide quarantine on accelerometer-assessed physical activity of heart failure patients.,"AIMS A reduction of habitual physical activity due to prolonged COVID-19 quarantine can have serious consequences for patients with cardiovascular diseases, such as heart failure. This study aimed to explore the effect of COVID-19 nationwide quarantine on accelerometer-assessed physical activity of heart failure patients. METHODS AND RESULTS We analysed the daily number of steps in 26 heart failure patients during a 6-week period that included 3 weeks immediately preceding the onset of the quarantine and the first 3 weeks of the quarantine. The daily number of steps was assessed using a wrist-worn accelerometer worn by the patients as part of an ongoing randomized controlled trial. Multilevel modelling was used to explore the effect of the quarantine on the daily step count adjusted for weather conditions. As compared with the 3 weeks before the onset of the quarantine, the step count was significantly lower during each of the first 3 weeks of the quarantine (P < 0.05). When the daily step count was averaged across the 3 weeks before and during the quarantine, the decrease amounted to 1134 (SE 189) steps per day (P < 0.001), which translated to a 16.2% decrease. CONCLUSIONS The introduction of the nationwide quarantine due to COVID-19 had a detrimental effect on the level of habitual physical activity in heart failure patients, leading to an abrupt decrease of daily step count that lasted for at least the 3-week study period. Staying active and maintaining sufficient levels of physical activity during the COVID-19 pandemic are essential despite the unfavourable circumstances of quarantine.",2020,"The introduction of the nationwide quarantine due to COVID-19 had a detrimental effect on the level of habitual physical activity in heart failure patients, leading to an abrupt decrease of daily step count that lasted for at least the 3-week study period.","['heart failure patients', 'patients with cardiovascular diseases, such as heart failure', '26 heart failure patients']",['COVID-19 nationwide quarantine'],['habitual physical activity'],"[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}]","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0034386', 'cui_str': 'Quarantine'}]","[{'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0344114,"The introduction of the nationwide quarantine due to COVID-19 had a detrimental effect on the level of habitual physical activity in heart failure patients, leading to an abrupt decrease of daily step count that lasted for at least the 3-week study period.","[{'ForeName': 'Tomas', 'Initials': 'T', 'LastName': 'Vetrovsky', 'Affiliation': 'Faculty of Physical Education and Sport, Charles University, José Martího 269/31, Prague, 162 52, Czech Republic.'}, {'ForeName': 'Tereza', 'Initials': 'T', 'LastName': 'Frybova', 'Affiliation': '2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.'}, {'ForeName': 'Iulian', 'Initials': 'I', 'LastName': 'Gant', 'Affiliation': '2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.'}, {'ForeName': 'Miroslav', 'Initials': 'M', 'LastName': 'Semerad', 'Affiliation': 'Faculty of Physical Education and Sport, Charles University, José Martího 269/31, Prague, 162 52, Czech Republic.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Cimler', 'Affiliation': 'Faculty of Science, University of Hradec Králové, Hradec Králové, Czech Republic.'}, {'ForeName': 'Vaclav', 'Initials': 'V', 'LastName': 'Bunc', 'Affiliation': 'Faculty of Physical Education and Sport, Charles University, José Martího 269/31, Prague, 162 52, Czech Republic.'}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Siranec', 'Affiliation': '2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Miklikova', 'Affiliation': 'Cardiology Department, University Hospital Brno and Medical Faculty of the Masaryk University, Brno, Czech Republic.'}, {'ForeName': 'Jiri', 'Initials': 'J', 'LastName': 'Vesely', 'Affiliation': 'Faculty of Medicine in Hradec Králové, Charles University, Prague, Czech Republic.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Griva', 'Affiliation': 'Department of Cardiology, Tomas Bata Regional Hospital in Zlin, Zlin, Czech Republic.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Precek', 'Affiliation': 'Department of Internal Medicine I-Cardiology, University Hospital Olomouc, Olomouc, Czech Republic.'}, {'ForeName': 'Radek', 'Initials': 'R', 'LastName': 'Pelouch', 'Affiliation': '1st Department of Internal Medicine-Cardioangiology, University Hospital Hradec Králové, Hradec Králové, Czech Republic.'}, {'ForeName': 'Jiri', 'Initials': 'J', 'LastName': 'Parenica', 'Affiliation': 'Cardiology Department, University Hospital Brno and Medical Faculty of the Masaryk University, Brno, Czech Republic.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Belohlavek', 'Affiliation': '2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.'}]",ESC heart failure,['10.1002/ehf2.12916'] 2245,32696603,Differential Effects of High- and Low-Arousal Positive Emotions on Help-Seeking for Depression.,"BACKGROUND The current set of pre-registered studies tested the effect of savoring a high-arousal (exciting) or low-arousal (calm) positive experience on help-seeking intentions among people with heightened depressive symptomatology. METHODS Across all three studies, participants with heightened depressive symptomatology who had not yet sought help were randomly assigned to complete a 6-minute writing task where they reflected on an exciting memory, a calm memory, or what they did today and yesterday. RESULTS Savoring an exciting memory was associated with significantly greater arousal than savoring a calm memory and the control condition (Study 1; N = 218). Both savoring conditions were associated with greater positive emotion than the control condition (Study 2; N = 193). In Study 3 (N = 1,238), savoring an exciting memory, when compared to the control condition, increased help-seeking intentions, whereas savoring a calm memory did not. CONCLUSIONS The current studies support the use of high-arousal, rather than low-arousal, positive emotions to increase help-seeking intentions among people with depression.",2020,"In Study 3 (N = 1,238), savoring an exciting memory, when compared to the control condition, increased help-seeking intentions, whereas savoring a calm memory did not. ","['participants with heightened depressive symptomatology who had not yet sought help', 'people with heightened depressive symptomatology', 'people with depression']","['High- and Low-Arousal Positive Emotions', 'savoring a high-arousal (exciting) or low-arousal (calm) positive experience']","['positive emotion', 'help-seeking intentions']","[{'cui': 'C0442803', 'cui_str': 'Heightened'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]",,0.14009,"In Study 3 (N = 1,238), savoring an exciting memory, when compared to the control condition, increased help-seeking intentions, whereas savoring a calm memory did not. ","[{'ForeName': 'Tasha', 'Initials': 'T', 'LastName': 'Straszewski', 'Affiliation': 'Claremont Graduate University, Claremont, USA.'}, {'ForeName': 'Jason T', 'Initials': 'JT', 'LastName': 'Siegel', 'Affiliation': 'Claremont Graduate University, Claremont, USA.'}]",Applied psychology. Health and well-being,['10.1111/aphw.12214'] 2246,32696695,Impact of Self-Monitoring of Blood Pressure on Processes of Hypertension Care and Long-Term Blood Pressure Control.,"Background Self-monitoring of blood pressure (SMBP) improves blood pressure (BP) outcomes at 12-months, but information is lacking on how SMBP affects hypertension care processes and longer-term BP outcomes. Methods and Results We pooled individual participant data from 4 randomized clinical trials of SMBP in the United Kingdom (combined n=2590) with varying intensities of support. Multivariable random effects regression was used to estimate the probability of antihypertensive intensification at 12 months for usual care versus SMBP. Using these data, we simulated 5-year BP control rates using a validated mathematical model. Trial participants were mostly older adults (mean age 66.6 years, SD 9.5), male (53.9%), and predominantly white (95.6%); mean baseline BP was 151.8/85.0 mm Hg. Compared with usual care, the likelihood of antihypertensive intensification increased with both SMBP with feedback to patient or provider alone (odds ratio 1.8, 95% CI 1.2-2.6) and with telemonitoring or self-management (3.3, 2.5-4.2). Over 5 years, we estimated 33.4% BP control (<140/90 mm Hg) with usual care (95% uncertainty interval 27.7%-39.4%). One year of SMBP with feedback to patient or provider alone achieved 33.9% (28.3%-40.3%) BP control and SMBP with telemonitoring or self-management 39.0% (33.1%-45.2%) over 5 years. If SMBP interventions and associated BP control processes were extended to 5 years, BP control increased to 52.4% (45.4%-59.8 %) and 72.1% (66.5%-77.6%), respectively. Conclusions One year of SMBP plus telemonitoring or self-management increases the likelihood of antihypertensive intensification and could improve BP control rates at 5 years; continuing SMBP for 5 years could further improve BP control.",2020,"Compared with usual care, the likelihood of antihypertensive intensification increased with both SMBP with feedback to patient or provider alone (odds ratio 1.8, 95% CI 1.2-2.6) and with telemonitoring or self-management (3.3, 2.5-4.2).","['Trial participants were mostly older adults (mean age 66.6\xa0years, SD 9.5), male (53.9%), and predominantly white (95.6%); mean baseline BP was 151.8/85.0\xa0mm\xa0Hg']","[' Self-monitoring of blood pressure (SMBP', 'SMBP', 'Self-Monitoring of Blood Pressure']","['5-year BP control rates', 'BP control processes', 'BP control rates', 'BP control', 'blood pressure (BP) outcomes']","[{'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517899', 'cui_str': '9.5'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]","[{'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0699419,"Compared with usual care, the likelihood of antihypertensive intensification increased with both SMBP with feedback to patient or provider alone (odds ratio 1.8, 95% CI 1.2-2.6) and with telemonitoring or self-management (3.3, 2.5-4.2).","[{'ForeName': 'Kelsey B', 'Initials': 'KB', 'LastName': 'Bryant', 'Affiliation': 'Columbia University New York NY.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Sheppard', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences University of Oxford United Kingdom.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Ruiz-Negrón', 'Affiliation': 'University of Utah Salt Lake City UT.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Kronish', 'Affiliation': 'Columbia University New York NY.'}, {'ForeName': 'Valy', 'Initials': 'V', 'LastName': 'Fontil', 'Affiliation': 'University of California at San Francisco CA.'}, {'ForeName': 'Jordan B', 'Initials': 'JB', 'LastName': 'King', 'Affiliation': 'University of Utah Salt Lake City UT.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Pletcher', 'Affiliation': 'University of California at San Francisco CA.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Bibbins-Domingo', 'Affiliation': 'University of California at San Francisco CA.'}, {'ForeName': 'Andrew E', 'Initials': 'AE', 'LastName': 'Moran', 'Affiliation': 'Columbia University New York NY.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'McManus', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences University of Oxford United Kingdom.'}, {'ForeName': 'Brandon K', 'Initials': 'BK', 'LastName': 'Bellows', 'Affiliation': 'Columbia University New York NY.'}]",Journal of the American Heart Association,['10.1161/JAHA.120.016174'] 2247,32696704,"Effects of Sugar-Sweetened, Artificially Sweetened, and Unsweetened Beverages on Cardiometabolic Risk Factors, Body Composition, and Sweet Taste Preference: A Randomized Controlled Trial.","Background A 2018 American Heart Association science advisory indicated that, pending further research, artificially sweetened beverages (ASBs) may be an appropriate initial replacement for sugar-sweetened beverages (SSBs) during transition to unsweetened beverages (USBs). Methods and Results We randomly assigned 203 adults (121 males, 82 females; 91.6% retention), who habitually consumed SSBs, to 3 groups and delivered free SSBs, ASBs, or USBs to their homes for 12 months. Outcomes included serum triglyceride to high-density lipoprotein cholesterol ratio (primary), body weight, and sweet taste preference (experimental assessment, 0%-18% sucrose solutions). Change in serum triglyceride to high-density lipoprotein cholesterol ratio was not different between groups. Although overall change in weight also was not different between groups, we found effect modification ( P =0.006) by central adiposity. Among participants in the highest tertile of baseline trunk fat but not other tertiles, weight gain was greater ( P =0.002) for the SSB (4.4±1.0 kg, estimate±SE) compared with ASB (0.5±0.9 kg) or USB (-0.2±0.9 kg) group. Both sweetness threshold (-1.0±0.2% m/v; P =0.005) and favorite concentration (-2.3±0.4% m/v; P <0.0001) decreased in the USB group; neither changed in the SSB group. In the ASB group, sweetness threshold did not change, and favorite concentration decreased (-1.1±0.5% m/v; P =0.02). Pairwise comparison between the ASB and USB groups indicated a difference in sweetness threshold ( P =0.015). Conclusions Replacing SSBs with noncaloric beverages for 12 months did not affect serum triglyceride to high-density lipoprotein cholesterol ratio. Among individuals with central adiposity, replacing SSBs with either ASBs or USBs lowered body weight. However, USBs may have the most favorable effect on sweet taste preference. Registration URL: https://www.clinicaltrials.gov; unique identifier: NCT01295671.",2020,Both sweetness threshold (-1.0±0.2% m/v; P =0.005) and favorite concentration (-2.3±0.4% m/v; P <0.0001) decreased in the USB group; neither changed in the SSB group.,"['203 adults (121 males, 82 females; 91.6% retention), who habitually consumed SSBs, to 3 groups and delivered free SSBs, ASBs, or USBs to their homes for 12\xa0months', 'individuals with central adiposity, replacing SSBs with either ASBs or USBs lowered body weight']","['Sugar-Sweetened, Artificially Sweetened, and Unsweetened Beverages']","['favorite concentration', 'serum triglyceride to high-density lipoprotein cholesterol ratio', 'weight gain', 'serum triglyceride to high-density lipoprotein cholesterol ratio (primary), body weight, and sweet taste preference (experimental assessment, 0%-18% sucrose solutions', 'Cardiometabolic Risk Factors, Body Composition, and Sweet Taste Preference']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C5197754', 'cui_str': 'Sugar-Added Beverages'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C5197916', 'cui_str': 'Artificially Sweetened Beverages'}, {'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4551560', 'cui_str': 'Central obesity'}, {'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]","[{'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0542495', 'cui_str': 'Measurement of serum triglyceride level'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0858600', 'cui_str': 'Taste sweet'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}]",203.0,0.228294,Both sweetness threshold (-1.0±0.2% m/v; P =0.005) and favorite concentration (-2.3±0.4% m/v; P <0.0001) decreased in the USB group; neither changed in the SSB group.,"[{'ForeName': 'Cara B', 'Initials': 'CB', 'LastName': 'Ebbeling', 'Affiliation': ""New Balance Foundation Obesity Prevention Center Boston Children's Hospital Boston MA.""}, {'ForeName': 'Henry A', 'Initials': 'HA', 'LastName': 'Feldman', 'Affiliation': ""Institutional Centers for Clinical and Translational Research Boston Children's Hospital Boston MA.""}, {'ForeName': 'Sarah K', 'Initials': 'SK', 'LastName': 'Steltz', 'Affiliation': ""New Balance Foundation Obesity Prevention Center Boston Children's Hospital Boston MA.""}, {'ForeName': 'Nicolle L', 'Initials': 'NL', 'LastName': 'Quinn', 'Affiliation': ""Institutional Centers for Clinical and Translational Research Boston Children's Hospital Boston MA.""}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Robinson', 'Affiliation': 'Shape Up Somerville City of Somerville MA.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Ludwig', 'Affiliation': ""New Balance Foundation Obesity Prevention Center Boston Children's Hospital Boston MA.""}]",Journal of the American Heart Association,['10.1161/JAHA.119.015668'] 2248,32696742,[Palmitic acid decreases phosphorylation of eNOS Ser1177 by activating protein phosphatase 2C (PP2C) of human umbilical vein endothelial cells].,"Objective To investigate the roles of protein phosphatase 2C (PP2C) activated by palmitic acid (PA) in the phosphorylation modulation of endothelial nitric oxide (eNOS) at the site of serine 1177 (eNOS Ser1177) in human umbilical vein endothelial cells (HUVECs). Methods HUVECs were randomly divided into control group, PA group, specific PP2C inhibitor sanguinarine (San) combined with PA group and PP2Cα specific small interference RNA (siRNA) transfection group. The protein expression of total eNOS, phosphorylated eNOS Ser1177 and PP2Cα were detected by Western blotting. The intracellular NO content was measured by DAF-FM DA. The co-localization of eNOS protein and PP2C protein was observed by co-immunoprecipitation. Results Compared with the control group, the phosphorylation levels of eNOS Ser1177 and NO content decreased significantly in the PA group. The PP2C inhibitor sanguinarine reversed PA-induced decrease of eNOS Ser1177 phosphorylation level and NO content. The phosphorylation levels of eNOS Ser1177 were enhanced dramatically after PP2Cα protein was knocked down by specific siRNA. The eNOS protein and PP2C protein co-localized in endothelial cells. Conclusion PA reduces the phosphorylation level of endothelial eNOS Ser1177 in HUVECs by activating PP2C.",2020,"Compared with the control group, the phosphorylation levels of eNOS Ser1177 and NO content decreased significantly in the PA group.",['human umbilical vein endothelial cells (HUVECs'],"['Palmitic acid', 'PA group, specific PP2C inhibitor sanguinarine (San) combined with PA group and PP2Cα specific small interference RNA (siRNA) transfection group', 'protein phosphatase 2C (PP2C) activated by palmitic acid (PA']","['phosphorylation levels of eNOS Ser1177', 'co-localization of eNOS protein and PP2C protein', 'phosphorylation levels of eNOS Ser1177 and NO content', 'protein expression of total eNOS, phosphorylated eNOS Ser1177 and PP2Cα']","[{'cui': 'C3179121', 'cui_str': 'Endothelial Cells, Human Umbilical Vein'}]","[{'cui': 'C0030234', 'cui_str': 'Palmitic acid'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0031678', 'cui_str': 'Phosphoric monoester hydrolase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0074027', 'cui_str': 'sanguinarine'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0040669', 'cui_str': 'Transfection'}, {'cui': 'C0247248', 'cui_str': 'Ptc2 Phosphatase'}]","[{'cui': 'C0031715', 'cui_str': 'Phosphorylation'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0037710', 'cui_str': 'Auditory localization'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0031678', 'cui_str': 'Phosphoric monoester hydrolase'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",,0.0170423,"Compared with the control group, the phosphorylation levels of eNOS Ser1177 and NO content decreased significantly in the PA group.","[{'ForeName': 'Jingjie', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Pathophysiology, Basic Medicine School, Guizhou Medical University, Key Laboratory of Drug Research and Pathogenesis of Common Chronic Diseases in Guizhou Province, Guizhou Medical University, Guiyang 550025, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Department of Pathophysiology, Basic Medicine School, Guizhou Medical University, Key Laboratory of Drug Research and Pathogenesis of Common Chronic Diseases in Guizhou Province, Guizhou Medical University, Guiyang 550025, China.'}, {'ForeName': 'Si', 'Initials': 'S', 'LastName': 'Qin', 'Affiliation': 'Department of Pathophysiology, Basic Medicine School, Guizhou Medical University, Key Laboratory of Drug Research and Pathogenesis of Common Chronic Diseases in Guizhou Province, Guizhou Medical University, Guiyang 550025, China.'}, {'ForeName': 'Yanbei', 'Initials': 'Y', 'LastName': 'Luo', 'Affiliation': 'Department of Pathophysiology, Basic Medicine School, Guizhou Medical University, Key Laboratory of Drug Research and Pathogenesis of Common Chronic Diseases in Guizhou Province, Guizhou Medical University, Guiyang 550025, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Yu', 'Affiliation': 'Department of Pathophysiology, Basic Medicine School, Guizhou Medical University, Key Laboratory of Drug Research and Pathogenesis of Common Chronic Diseases in Guizhou Province, Guizhou Medical University, Guiyang 550025, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Ding', 'Affiliation': 'Department of Pathophysiology, Basic Medicine School, Guizhou Medical University, Key Laboratory of Drug Research and Pathogenesis of Common Chronic Diseases in Guizhou Province, Guizhou Medical University, Guiyang 550025, China.'}, {'ForeName': 'Deqin', 'Initials': 'D', 'LastName': 'Lu', 'Affiliation': 'Department of Pathophysiology, Basic Medicine School, Guizhou Medical University, Key Laboratory of Drug Research and Pathogenesis of Common Chronic Diseases in Guizhou Province, Guizhou Medical University, Guiyang 550025, China. *Corresponding author, E-mail: dqlu91@hotmail.com.'}]",Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,[] 2249,32696820,"An intensive education program for caregivers ameliorates anxiety, depression, and quality of life in patients with drug-resistant temporal lobe epilepsy and mesial temporal sclerosis who underwent cortico-amygdalohippocampectomy.","This study aimed to investigate the effect of a caregiver intensive education program (CIEP) on anxiety, depression, and quality of life (QOL) in patients with drug-resistant temporal lobe epilepsy and mesial temporal sclerosis (TLE-MTS) who underwent cortico-amygdalohippocampectomy (CAH). Ninety patients with drug-resistant TLE-MTS who underwent CAH and their caregivers were recruited and randomly allocated to the CIEP group or control group as 1:1 ratio. Caregivers received the CIEP program or routine guidance/education (control group). Anxiety/depression and QOL in patients at month (M)0, M1, M3, and M6 were assessed by the Hospital Anxiety and Depression Scale (HADS) scale and the QOL in Epilepsy Inventory-31 (QOLIE-31), respectively. Treatment efficacy at M6 was assessed by Engel classification. The HADS-anxiety score at M3 (P=0.049) and M6 (P=0.028), HADS-anxiety score change (M6-M0) (P=0.001), percentage of anxiety patients at M6 (P=0.025), and anxiety severity at M6 (P=0.011) were all decreased in the CIEP group compared with the control group. The HADS-depression score at M6 (P=0.033) and HADS-depression score change (M6-M0) (P=0.022) were reduced, while percentage of depression patients at M6 (P=0.099) and depression severity at M6 (P=0.553) showed no difference in the CIEP group compared with the control group. The QOLIE-31 score at M6 (P=0.043) and QOLIE-31 score change (M6-M0) (P=0.010) were both elevated in the CIEP group compared with the control group. In conclusion, CIEP for caregivers contributed to the recovery of anxiety and depression as well as the improvement of QOL in patients with drug-resistant TLE-MTS who underwent CAH.",2020,The QOLIE-31 score at M6 (P=0.043) and QOLIE-31 score change (M6-M0) (P=0.010) were both elevated in the CIEP group compared with the control group.,"['patients with drug-resistant temporal lobe epilepsy and mesial temporal sclerosis who underwent cortico-amygdalohippocampectomy', 'patients with drug-resistant temporal lobe epilepsy and mesial temporal sclerosis (TLE-MTS) who underwent cortico-amygdalohippocampectomy (CAH', 'Ninety patients with drug-resistant TLE-MTS who underwent CAH and their caregivers']","['CIEP program or routine guidance/education (control group', 'caregiver intensive education program (CIEP', 'CIEP', 'intensive education program']","['QOLIE-31 score at M6', 'HADS-anxiety score change (M6-M0', 'percentage of anxiety patients at M6', 'HADS-depression score change (M6-M0', 'recovery of anxiety and depression', 'Anxiety/depression and QOL', 'HADS-depression score', 'anxiety severity at M6', 'QOLIE-31 score change (M6-M0', 'Hospital Anxiety and Depression Scale (HADS) scale and the QOL in Epilepsy Inventory-31 (QOLIE-31', 'HADS-anxiety score at M3', 'anxiety, depression, and quality of life (QOL', 'depression severity', 'anxiety, depression, and quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0014556', 'cui_str': 'Temporal lobe epilepsy'}, {'cui': 'C2062593', 'cui_str': 'Mesial temporal sclerosis'}, {'cui': 'C2921031', 'cui_str': 'Amygdalohippocampectomy'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}]","[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",90.0,0.0319824,The QOLIE-31 score at M6 (P=0.043) and QOLIE-31 score change (M6-M0) (P=0.010) were both elevated in the CIEP group compared with the control group.,"[{'ForeName': 'Yuena', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Neurosurgery, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Dongyu', 'Initials': 'D', 'LastName': 'Hou', 'Affiliation': 'Department of Orthopedics, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Xiaohua', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Department of Neurosurgery, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Qiu', 'Affiliation': 'Department of Endocrinology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Department of Neurosurgery, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Jianxia', 'Initials': 'J', 'LastName': 'Xin', 'Affiliation': 'Department of Neurosurgery, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Zhirong', 'Initials': 'Z', 'LastName': 'Yan', 'Affiliation': 'Department of Orthopedics, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Meiling', 'Initials': 'M', 'LastName': 'Sun', 'Affiliation': 'Department of Nursing, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}]",Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,['10.1590/1414-431x20209000'] 2250,32696839,Comparison of the effects of voluntary and involuntary breath stacking techniques on respiratory mechanics and lung function patterns in tracheostomized patients: a randomized crossover clinical trial.,"OBJECTIVE To compare the effects of voluntary breath stacking (VBS) and involuntary breath stacking (IBS) techniques on respiratory mechanics, lung function patterns, and inspiratory capacity in tracheostomized patients. METHODS This was a randomized crossover clinical trial involving 20 tracheostomized patients admitted to the ICU and submitted to the VBS and IBS techniques, in random order, with an interval of 5 h between each. Ten cycles of each technique were performed with an interval of 30 s between each cycle. In VBS, patients performed successive inspirations for up to 30 s through a one-way valve, whereas in IBS, successive slow insufflations were performed with a resuscitator bag until the pressure reached 40 cmH2O. Respiratory mechanics, inspiratory capacity, and the lung function pattern were evaluated before and after the interventions. RESULTS After IBS, there was an increase in static compliance (p = 0.007), which was also higher after IBS than after VBS (p = 0.03). There was no significant difference between the pre-VBS and post-VBS evaluations in terms of static compliance (p = 0.42). Inspiratory capacity was also greater after IBS than after VBS (2,420.7 ± 480.9 mL vs. 1,211.3 ± 562.8 mL; p < 0.001), as was airway pressure (38.3 ± 2.6 cmH2O vs. 25.8 ± 5.5 cmH2O; p < 0.001). There were no changes in resistance or lung function pattern after the application of either technique. CONCLUSIONS In comparison with VBS, IBS promoted greater inspiratory capacity and higher airway pressure, resulting in an increase in static compliance.",2020,"After IBS, there was an increase in static compliance (p = 0.007), which was also higher after IBS than after VBS (p = 0.03).","['tracheostomized patients', '20 tracheostomized patients admitted to the ICU and submitted to the VBS and IBS techniques, in random order, with an interval of 5 h between each']","['voluntary and involuntary breath stacking techniques', 'VBS, IBS', 'voluntary breath stacking (VBS) and involuntary breath stacking (IBS) techniques']","['resistance or lung function pattern', 'respiratory mechanics, lung function patterns, and inspiratory capacity', 'Inspiratory capacity', 'respiratory mechanics and lung function patterns', 'airway pressure', 'static compliance', 'inspiratory capacity and higher airway pressure']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C1710178', 'cui_str': 'Breath stacking'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C1272706', 'cui_str': 'Interval'}]","[{'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C1710178', 'cui_str': 'Breath stacking'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0035230', 'cui_str': 'Breathing Mechanics'}, {'cui': 'C0021610', 'cui_str': 'Inspiratory capacity'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}, {'cui': 'C0429681', 'cui_str': 'Static lung compliance'}, {'cui': 'C1320796', 'cui_str': 'High airway pressure'}]",20.0,0.0237629,"After IBS, there was an increase in static compliance (p = 0.007), which was also higher after IBS than after VBS (p = 0.03).","[{'ForeName': 'Luciano Matos', 'Initials': 'LM', 'LastName': 'Chicayban', 'Affiliation': 'Laboratório de Pesquisa em Fisioterapia Pneumofuncional e Intensiva, Institutos Superiores de Ensino do Centro Educacional Nossa Senhora Auxiliadora, Campos dos Goytacazes, RJ, Brasil.'}, {'ForeName': 'Alice Campos', 'Initials': 'AC', 'LastName': 'Hemétrio', 'Affiliation': 'Institutos Superiores de Ensino do Centro Educacional Nossa Senhora Auxiliadora, Campos dos Goytacazes, RJ, Brasil.'}, {'ForeName': 'Liz Tavares Rangel', 'Initials': 'LTR', 'LastName': 'Azevedo', 'Affiliation': 'Institutos Superiores de Ensino do Centro Educacional Nossa Senhora Auxiliadora, Campos dos Goytacazes, RJ, Brasil.'}]",Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia,['10.36416/1806-3756/e20190295'] 2251,32696886,"The effect of cognitive behavioral counseling on sexual knowledge, motivation to avoid risky sexual relationships, and sexual depression in female university students.","Introduction Misunderstanding of different aspects of sex makes individuals vulnerable to sexual dysfunction, sexually transmitted diseases, mental disorders, and illegal relationships. This study aimed to determine the effect of cognitive behavioral counseling on the sexual self-concept of female students at Kerman University of Medical Sciences. Methods This study is an intervention conducted with female students living in dormitories at Kerman and Rafsanjan Universities of Medical Sciences. The sample size was estimated at 63 students from different fields of study; 31 students from Kerman University of Medical Sciences comprised the experimental group and 32 students from Rafsanjan University of Medical Sciences comprised the control group. Cognitive behavioral group counseling sessions were held every 3 days. The instrument used for collecting pre-test and post-test data was Snell's Multidimensional Sexual Self-concept Questionnaire. Data analysis was conducted using measures of central tendency, t tests and chi-square tests. Results The two groups were homogenous in terms of demographic factors. Analysis of the results of the intervention revealed significant differences in sexual self-consciousness and motivation to avoid high risk sexual relationships, but there was no significant difference in terms of sexual depression. Discussion Cognitive behavioral group counseling can improve sexual self-concept. Therefore, this type of counseling is recommended from younger ages or at enrollment at university, to help correct development of this important part of identity.",2020,"Analysis of the results of the intervention revealed significant differences in sexual self-consciousness and motivation to avoid high risk sexual relationships, but there was no significant difference in terms of sexual depression.","['female students at Kerman University of Medical Sciences', 'female university students', 'female students living in dormitories at Kerman and Rafsanjan Universities of Medical Sciences', '63 students from different fields of study; 31 students from Kerman University of Medical Sciences comprised the experimental group and 32 students from Rafsanjan University of Medical Sciences comprised the control group']","['Discussion Cognitive behavioral group counseling', 'Cognitive behavioral group counseling sessions', 'cognitive behavioral counseling']","['sexual self-consciousness and motivation to avoid high risk sexual relationships', 'sexual depression', 'sexual knowledge, motivation to avoid risky sexual relationships, and sexual depression']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0557061', 'cui_str': 'Discussion'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0237547', 'cui_str': 'Group counseling'}, {'cui': 'C4546207', 'cui_str': 'Behavioral counseling'}]","[{'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0009791', 'cui_str': 'Consciousness related finding'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",31.0,0.0146882,"Analysis of the results of the intervention revealed significant differences in sexual self-consciousness and motivation to avoid high risk sexual relationships, but there was no significant difference in terms of sexual depression.","[{'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Hosseini', 'Affiliation': 'Midwifery Department, Razi Faculty of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Katayoun', 'Initials': 'K', 'LastName': 'Alidousti Shahraki', 'Affiliation': 'Nursing Research Center, Razi Faculty of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Mansooreh', 'Initials': 'M', 'LastName': 'Azizzadeh Forouzi', 'Affiliation': 'Nursing Research Center, Razi Faculty of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Atefeh', 'Initials': 'A', 'LastName': 'Ahmadi', 'Affiliation': 'Midwifery Department, Razi Faculty of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Tania', 'Initials': 'T', 'LastName': 'Dehesh', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Kerman University of Medical Sciences, Kerman, Iran.'}]",Trends in psychiatry and psychotherapy,['10.1590/2237-6089-2019-0052'] 2252,32696895,The effectiveness of mindfulness-based cognitive therapy for reducing rumination and improving mindfulness and self-compassion in patients with treatment-resistant depression.,"Introduction Depression is one of the most important psychiatric disorders, and the rate of recurrence is high. The heavy cost burden of depression is probably due to treatment-resistant depression. The purpose of this study was to determine the effectiveness of mindfulness-based cognitive therapy (MBCT) in patients with treatment-resistant depression (TRD). Method The present study was a quasi-experimental study conducted with twenty-four patients with treatment-resistant depression. Participants were selected by purposive sampling and randomly assigned to two groups, an experimental group and a control group. The experimental group received MBCT and antidepressants, while the control group received antidepressants only. The Hamilton and Beck Depression Inventory, Self-Compassion Scale, Thought Rumination Scale, and Mindfulness Scale were administered. The treatment program was conducted in eight sessions; with a follow-up period of one month subsequent to treatment termination. Data were analyzed using descriptive statistics (mean and standard deviation) and inferential statistics (analysis of variance for repeated measures and Bonferroni's post-hoc test). Results The results showed that MBCT significantly reduced depression and ruminative thinking in the experimental group and also improved mediators such as mindfulness and self-compassion. Patients maintained gains over the one month follow-up period (p < 0.01). Conclusion The present study provides additional evidence for the effectiveness of MBCT for TRD.",2020,The results showed that MBCT significantly reduced depression and ruminative thinking in the experimental group and also improved mediators such as mindfulness and self-compassion.,"['patients with treatment-resistant depression', 'patients with treatment-resistant depression (TRD', 'quasi-experimental study conducted with twenty-four patients with treatment-resistant depression']","['MBCT and antidepressants, while the control group received antidepressants only', 'MBCT', 'mindfulness-based cognitive therapy', 'mindfulness-based cognitive therapy (MBCT']","['rumination and improving mindfulness and self-compassion', 'Hamilton and Beck Depression Inventory, Self-Compassion Scale, Thought Rumination Scale, and Mindfulness Scale', 'depression and ruminative thinking']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2063866', 'cui_str': 'Therapy-Resistant Depression'}, {'cui': 'C2985410', 'cui_str': 'Controlled Clinical Trials, Non-Randomized'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C3715070', 'cui_str': '24'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0039869', 'cui_str': 'Thinking'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",24.0,0.0126586,The results showed that MBCT significantly reduced depression and ruminative thinking in the experimental group and also improved mediators such as mindfulness and self-compassion.,"[{'ForeName': 'Aliakbar', 'Initials': 'A', 'LastName': 'Foroughi', 'Affiliation': 'Department of Clinical Psychology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Kheirollah', 'Initials': 'K', 'LastName': 'Sadeghi', 'Affiliation': 'Department of Clinical Psychology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'AliAkbar', 'Initials': 'A', 'LastName': 'Parvizifard', 'Affiliation': 'Department of Clinical Psychology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Arash', 'Initials': 'A', 'LastName': 'Parsa Moghadam', 'Affiliation': 'Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Omran', 'Initials': 'O', 'LastName': 'Davarinejad', 'Affiliation': 'Substance Abuse Prevention Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Vahid', 'Initials': 'V', 'LastName': 'Farnia', 'Affiliation': 'Substance Abuse Prevention Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Ghazale', 'Initials': 'G', 'LastName': 'Azar', 'Affiliation': 'Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}]",Trends in psychiatry and psychotherapy,['10.1590/2237-6089-2019-0016'] 2253,32696905,Shortening of etching time of the dentin in primary teeth restorations: a randomized clinical trial.,"The aim of this study was to investigate the influence of shortening of etching time for dentin on the restoration survival after selective carious tissue removal in primary molars. This two-arm randomized clinical trial included sixty-two subjects (5-8 year-old) and 100 primary molars presenting moderate dentin carious lesions on occlusal surface. The sample was randomly assigned into groups previously to adhesive application (Adper Single Bond 2; 3M ESPE): etching time recommended by manufacturer (15 s) or reduced (7 s). Resin composite (Filtek Bulk Fill Posterior Restorative; 3M ESPE) was inserted in a single increment for all restorations. Restorations were evaluated at 1, 6, 12, and 18 months using FDI criteria. Survival estimates for restorations' longevity were evaluated with Kaplan-Meier method. Multivariate Cox regression analysis with shared frailty was used to assess the factors associated with failures (p < 0.05). The etching time did not influence the restorations' survival (HR 0.35 95%CI 0.11-1.12; p = 0.06). Mean estimated time of survival was 17.6 months (95%CI, 17.2-17.9). The survival rates at the 18-month follow-up were 75.7% and 91.4% (AFR: 16.9% and 5.7%) when primary dentin was acid etched for 15 and 7 s, respectively (log-rank p = 0.06). In conclusion, the etching time for dentin did not influence the clinical behavior of adhesives restorations. However, there was a tendency for better clinical outcome when using etching time of 7 s.",2020,The etching time did not influence the restorations' survival (HR 0.35 95%CI 0.11-1.12; p = 0.06).,"['sixty-two subjects (5-8 year-old) and 100 primary molars presenting moderate dentin carious lesions on occlusal surface', 'primary molars', 'primary teeth restorations']","['adhesive application (Adper Single Bond 2; 3M ESPE): etching time recommended by manufacturer', 'Resin composite (Filtek Bulk Fill Posterior Restorative; 3M ESPE']","['survival rates', 'Mean estimated time of survival', 'Shortening of etching time', ""restorations' survival"", 'Survival estimates']","[{'cui': 'C4517835', 'cui_str': '62'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0011429', 'cui_str': 'Dentin structure'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0447303', 'cui_str': 'Structure of occlusal surface of tooth'}, {'cui': 'C3266841', 'cui_str': 'All deciduous teeth'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}]","[{'cui': 'C0001516', 'cui_str': 'Adhesive'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0001459', 'cui_str': 'Adenosine diphosphate'}, {'cui': 'C0759863', 'cui_str': 'single bond'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0009570', 'cui_str': 'Composite Resins'}, {'cui': 'C4505780', 'cui_str': 'Filtek Bulk Fill'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}]","[{'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}]",62.0,0.127887,The etching time did not influence the restorations' survival (HR 0.35 95%CI 0.11-1.12; p = 0.06).,"[{'ForeName': 'Cleber Paradzinski', 'Initials': 'CP', 'LastName': 'Cavalheiro', 'Affiliation': 'Dental Science Graduate Program, School of Dentistry, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.'}, {'ForeName': 'Pablo Soares de', 'Initials': 'PS', 'LastName': 'Souza', 'Affiliation': 'Departament of Stomatology, School of Dentistry, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.'}, {'ForeName': 'Djessica', 'Initials': 'D', 'LastName': 'Pedrotti', 'Affiliation': 'Dental Science Graduate Program, School of Dentistry, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.'}, {'ForeName': 'Luciano', 'Initials': 'L', 'LastName': 'Casagrande', 'Affiliation': 'Post-Graduate Program in Pediatric Dentistry, School of Dentistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Thiago Machado', 'Initials': 'TM', 'LastName': 'Ardenghi', 'Affiliation': 'Department of Orthodontics and Pediatric Dentistry, School of Dentistry, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Rachel de Oliveira', 'Initials': 'RO', 'LastName': 'Rocha', 'Affiliation': 'Department of Orthodontics and Pediatric Dentistry, School of Dentistry, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Daniela Prócida', 'Initials': 'DP', 'LastName': 'Raggio', 'Affiliation': 'Department of Orthodontics and Pediatric Dentistry, School of Dentistry, Universidade de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Tathiane Larissa', 'Initials': 'TL', 'LastName': 'Lenzi', 'Affiliation': 'Post-Graduate Program in Pediatric Dentistry, School of Dentistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}]",Brazilian oral research,['10.1590/1807-3107bor-2020.vol34.0081'] 2254,32696911,Postoperative pain after root canal filling with different endodontic sealers: a randomized clinical trial.,"The aim of this randomized clinical trial was to compare the occurrence and intensity of postoperative pain and analgesic intake after root canal treatment, using different root canal sealers. Sixty single-rooted teeth diagnosed with asymptomatic necrosis and apical periodontitis were randomly assigned to 3 experimental groups (n=20), according to the root canal sealer: AH Plus, Endofill or MTA Fillapex. Endodontic treatment was performed in two sessions, and calcium hydroxide was used as the intracanal dressing. Patients were instructed to record pain intensity as none, slight, moderate and severe. Scores from 1 to 4 were attributed to each level of pain after 24 h, 48 h and 7 days. The need for analgesic intake was also recorded. Differences in the incidence of postoperative pain and the need for an analgesic were analyzed using the chi-square test. Differences in pain intensity after treatment were analyzed using the ordinal (linear) chi-square test. No significant differences were detected among the groups in terms of either incidence or intensity of postoperative pain, or need for analgesic intake, at any timepoint (p>0.05). No pain was reported after 7 days. AH Plus, Endofill and MTA Fillapex used for filling root canals resulted in the same rate of postoperative pain and need for analgesic medication.",2020,"No significant differences were detected among the groups in terms of either incidence or intensity of postoperative pain, or need for analgesic intake, at any timepoint (p>0.05).",['Sixty single-rooted teeth diagnosed with asymptomatic necrosis and apical periodontitis'],"['root canal sealer: AH Plus, Endofill or MTA Fillapex', 'Endofill and MTA Fillapex', 'calcium hydroxide', 'AH']","['postoperative pain and need for analgesic medication', 'pain intensity', 'postoperative pain', 'analgesic intake', 'incidence or intensity of postoperative pain, or need for analgesic intake', 'occurrence and intensity of postoperative pain and analgesic intake', 'pain', 'Postoperative pain']","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0027540', 'cui_str': 'Necrosis'}, {'cui': 'C0031030', 'cui_str': 'Apical periodontitis'}]","[{'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0449942', 'cui_str': 'Sealer'}, {'cui': 'C0673096', 'cui_str': 'AH Plus'}, {'cui': 'C0167863', 'cui_str': 'Endo-Fill'}, {'cui': 'C3852787', 'cui_str': 'MTA-Fillapex'}, {'cui': 'C0006701', 'cui_str': 'calcium hydroxide'}]","[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",60.0,0.139671,"No significant differences were detected among the groups in terms of either incidence or intensity of postoperative pain, or need for analgesic intake, at any timepoint (p>0.05).","[{'ForeName': 'Nadia de Souza', 'Initials': 'NS', 'LastName': 'Ferreira', 'Affiliation': 'Department of Semiology and Clinics, School of Dentistry, Universidade Federal de Pelotas, Pelotas, RS, Brazil.'}, {'ForeName': 'Elisa Korte Fortes', 'Initials': 'EKF', 'LastName': 'Gollo', 'Affiliation': 'School of Dentistry, Universidade Federal de Pelotas, Pelotas, RS, Brazil.'}, {'ForeName': 'Noeli', 'Initials': 'N', 'LastName': 'Boscato', 'Affiliation': 'Department of Restorative Dentsitry, School of Dentistry, Universidade Federal de Pelotas, Pelotas, RS, Brazil.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Arias', 'Affiliation': 'Conservative Dentistry Department, School of Dentistry, Universidad Complutense de Madrid, Madrid, Spain.'}, {'ForeName': 'Emmanuel João Nogueira Leal da', 'Initials': 'EJNLD', 'LastName': 'Silva', 'Affiliation': 'Endodontics Department, School of Dentistry, Universidade do Grande Rio, Rio de Janeiro, RJ, Brazil.'}]",Brazilian oral research,['10.1590/1807-3107bor-2020.vol34.0069'] 2255,32696964,The Evidence-Based Sexual Abuse Prevention Program: Strong With Sam.,"The present study was initiated to design and evaluate a sexual abuse prevention program for deaf and hard of hearing (DHH) children. This evidence-based prevention program is the first of its kind for DHH children. A total of 92 DHH children aged 8-12 years participated in the program ""STARK mit SAM"" (Strong with Sam, SmS), a program conducted in primary schools for DHH children in Germany. The program evaluation consisted of a pretest-posttest design. As per class, the subjects were assigned to either the experimental or the wait list control group. Participants from both groups were pretested for their knowledge about content related to the prevention of sexual abuse. The experimental group received the prevention program and both groups were posttested to examine the effects of the program. Additionally, the experimental group was tested again 6 months after the program. DHH children who participated in the SmS program showed a significant knowledge gain and a nonsignificant change in their anxiety. No significant factor affecting the children's significant knowledge gain was found. SmS is an effective sexual abuse prevention program for DHH children, which can be offered without incurring anxiety in the children.",2020,"SmS is an effective sexual abuse prevention program for DHH children, which can be offered without incurring anxiety in the children.","['DHH children who participated in the SmS program', 'DHH children', '92 DHH children aged 8-12\xa0years participated in the', 'DHH children in Germany', 'sexual abuse prevention program for deaf and hard of hearing (DHH) children']","['prevention program', 'program ""STARK mit SAM"" (Strong with Sam, SmS', 'SmS']","['knowledge gain', 'anxiety']","[{'cui': 'C0525064', 'cui_str': 'Hearing Impaired Persons'}, {'cui': 'C0018772', 'cui_str': 'Partial deafness'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0795864', 'cui_str': 'Smith-Magenis syndrome'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0282350', 'cui_str': 'Sexual abuse'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018599', 'cui_str': 'Hard'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}]","[{'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0036002', 'cui_str': 'S-Adenosylmethionine'}, {'cui': 'C0442821', 'cui_str': 'Strong'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",92.0,0.0164724,"SmS is an effective sexual abuse prevention program for DHH children, which can be offered without incurring anxiety in the children.","[{'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Urbann', 'Affiliation': 'Faculty of Human Sciences, Education and Rehabilitation of the Deaf and the Hard of Hearing, University of Cologne.'}, {'ForeName': 'Pia', 'Initials': 'P', 'LastName': 'Bienstein', 'Affiliation': 'TU Dortmund University, Faculty of Rehabilitation Sciences, Rehabilitation and Education: Intellectual Disabilities.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Kaul', 'Affiliation': 'Faculty of Human Sciences, Education and Rehabilitation of the Deaf and the Hard of Hearing, University of Cologne.'}]",Journal of deaf studies and deaf education,['10.1093/deafed/enaa019'] 2256,32688457,[The application of amodified scalp retractor in the craniotomy for intracranial aneurysms].,"Objective: To investigate the application of a modified scalp retractor in the craniotomy for intracranial aneurysms withlateral supraorbital approach. Methods: From January 1, 2019, to April 31, 2020, a total of 32 patients with anterior circulation aneurysms clipping by superior lateral orbital approach were selected from Beijing Tiantan Hospital and Peking University International Hospital. The subjects were randomly divided into the traditional scalp retractor group and the modified scalp retractor group utilizing a random number table, with 16 patients in each group. The number of intraoperative retractor adjustment, incision length, postoperative scalp necrosis rate, postoperative wound healing grade, postoperative neurosurgical satisfaction score and patients' satisfaction score for incision were compared between the two groups. Results: The number of retractor adjustment in the modified scalp retractors group was significantly less than that in the traditional scalp retractor group ((10.1±2.2) vs (14.2±3.6), P< 0.05). Incision length was also significantly shorter than that of the conventional scalp retractor group((10.1±1.0) cm vs (13.9±0.9) cm, P< 0.05). Neurosurgeons were significantly more satisfied with modified scalp retractors than the traditional scalp retractors [(8.1±0.9) vs (6.0±0.9); P< 0.05)]. There was no significant difference in postoperative scalp necrosis rate between two groups ( P> 0.05). Conclusion: The modified scalp retractor group is superior to the traditional scalp retractor group in the craniotomy for intracranial adjustment and shorter surgical time.",2020,There was no significant difference in postoperative scalp necrosis rate between two groups ( P> 0.05). ,['32 patients with anterior circulation aneurysms clipping by superior lateral orbital approach were selected from Beijing Tiantan Hospital and Peking University International Hospital'],"['conventional scalp retractor group((10.1±1.0', 'amodified scalp retractor', 'modified scalp retractor', 'traditional scalp retractor group and the modified scalp retractor group utilizing a random number table']","[""number of intraoperative retractor adjustment, incision length, postoperative scalp necrosis rate, postoperative wound healing grade, postoperative neurosurgical satisfaction score and patients' satisfaction score for incision"", 'postoperative scalp necrosis rate', 'number of retractor adjustment', 'Incision length']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0005775', 'cui_str': 'Circulation, Blood'}, {'cui': 'C0179977', 'cui_str': 'Aneurysm clip'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0699036', 'cui_str': 'Orbital'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0183031', 'cui_str': 'Scalp retractor'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0039224', 'cui_str': 'Table'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0183014', 'cui_str': 'Retractor'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0036270', 'cui_str': 'Scalp structure'}, {'cui': 'C0027540', 'cui_str': 'Necrosis'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",32.0,0.0135821,There was no significant difference in postoperative scalp necrosis rate between two groups ( P> 0.05). ,"[{'ForeName': 'X', 'Initials': 'X', 'LastName': 'Ye', 'Affiliation': 'Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.'}, {'ForeName': 'P C', 'Initials': 'PC', 'LastName': 'Ge', 'Affiliation': 'Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Ma', 'Affiliation': 'Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Duan', 'Affiliation': 'Department of Neurosurgery, Peking University International Hospital, Beijing 102206, China.'}, {'ForeName': 'C X', 'Initials': 'CX', 'LastName': 'Tan', 'Affiliation': 'Department of Neurosurgery, Peking University International Hospital, Beijing 102206, China.'}, {'ForeName': 'X L', 'Initials': 'XL', 'LastName': 'Chen', 'Affiliation': 'Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.'}, {'ForeName': 'Y L', 'Initials': 'YL', 'LastName': 'Zhao', 'Affiliation': 'Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.'}, {'ForeName': 'X J', 'Initials': 'XJ', 'LastName': 'Meng', 'Affiliation': 'Department of Operating Room, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.'}]",Zhonghua yi xue za zhi,['10.3760/cma.j.cn112137-20200529-01705'] 2257,32689594,Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy.,"BACKGROUND Non-stenotic intracranial and systemic atherosclerosis are associated with ischemic stroke. We report frequency and response to anticoagulant vs. antiplatelet prophylaxis of patients with embolic stroke of undetermined source (ESUS) who have non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis. METHODS Exploratory analysis of the international NAVIGATE ESUS randomized trial comparing rivaroxaban 15mg daily with aspirin 100mg daily in 7213 patients with recent ESUS. Among participants with results of intracranial arterial imaging with either computed tomographic angiography (CTA) or magnetic resonance angiography (MRA), the frequency and predictors of non-stenotic intracranial and systemic atherosclerosis and responses to antithrombotic therapy were assessed. RESULTS Among 4723 participants with available intracranial CTA or MRA results (65% of the trial cohort), the prevalence of intracranial atherosclerosis was 16% (n=739). Patient features independently associated with intracranial atherosclerosis included East Asian region (odds ratio 2.7, 95%CI 2.2,3.3) and cervical carotid plaque (odds ratio 2.3, 95%CI 1.9,2.7), among others. The rate of recurrent ischemic stroke averaged 4.8%/year among those with intracranial atherosclerosis vs. 5.0.%/year for those without (HR 0.95, 95%CI 0.65, 1.4). Among those with intracranial atherosclerosis, the recurrent ischemic stroke rate was higher if assigned to rivaroxaban (5.8%/year) vs. aspirin (3.7%/year), but the difference was not statistically significant (HR 1.6, 95%CI 0.78, 3.3). There was trend for the effect of antithrombotic treatments to be different according to the presence or absence of intracranial atherosclerosis (p interaction =0.09). Among participants with evidence of systemic atherosclerosis by either history or imaging (n=3820), recurrent ischemic stroke rates were similar among those assigned to rivaroxaban (5.5%/year) vs. aspirin (4.9%/year)(HR 1.1, 95%CI 0.84, 1.5). CONCLUSIONS East Asia region was the strongest factor associated with intracranial atherosclerosis. There were no statistically significant differences between rivaroxaban and aspirin prophylaxis for recurrent ischemic stroke in patients with non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis.",2020,There were no statistically significant differences between rivaroxaban and aspirin prophylaxis for recurrent ischemic stroke in patients with non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis.,"['patients with embolic stroke of undetermined source (ESUS) who have non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis', 'patients with non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis', 'participants with evidence of systemic atherosclerosis by either history or imaging (n=3820', '7213 patients with recent ESUS', '4723 participants with available intracranial CTA or MRA results (65% of the trial cohort', 'participants with results of intracranial arterial imaging with either']","['computed tomographic angiography (CTA) or magnetic resonance angiography (MRA', 'aspirin', 'anticoagulant vs. antiplatelet prophylaxis', 'rivaroxaban', 'aspirin prophylaxis']","['recurrent ischemic stroke rates', 'prevalence of intracranial atherosclerosis', 'recurrent ischemic stroke rate', 'recurrent ischemic stroke', 'intracranial atherosclerosis included East Asian region', 'rate of recurrent ischemic stroke', 'cervical carotid plaque']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3888970', 'cui_str': 'Embolic stroke of undetermined source'}, {'cui': 'C0333181', 'cui_str': 'Stenosed'}, {'cui': 'C0751007', 'cui_str': 'Intracranial Atherosclerosis'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0524466', 'cui_str': 'Intracranial'}, {'cui': 'C1536105', 'cui_str': 'CT angiography'}, {'cui': 'C0243032', 'cui_str': 'Magnetic resonance imaging (MRI) of vessels'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}]","[{'cui': 'C1536105', 'cui_str': 'CT angiography'}, {'cui': 'C0243032', 'cui_str': 'Magnetic resonance imaging (MRI) of vessels'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C0729799', 'cui_str': 'Aspirin prophylaxis'}]","[{'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0751007', 'cui_str': 'Intracranial Atherosclerosis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}]",7213.0,0.167373,There were no statistically significant differences between rivaroxaban and aspirin prophylaxis for recurrent ischemic stroke in patients with non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis.,"[{'ForeName': 'Sebastian F', 'Initials': 'SF', 'LastName': 'Ameriso', 'Affiliation': 'Institute for Neurological Research-FLENI, Buenos Aires, Argentina. Electronic address: sameriso@fleni.org.ar.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Amarenco', 'Affiliation': 'Department of Neurology, Bichat Hospital, Paris University, Paris, France.'}, {'ForeName': 'Lesly A', 'Initials': 'LA', 'LastName': 'Pearce', 'Affiliation': 'Biostatistics Consultant, Minot, ND, USA.'}, {'ForeName': 'Kanjana S', 'Initials': 'KS', 'LastName': 'Perera', 'Affiliation': 'Department of Medicine (Neurology), McMaster University/Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Ntaios', 'Affiliation': 'Department of Medicine, University of Thessaly, Larissa, Greece.'}, {'ForeName': 'Wilfried', 'Initials': 'W', 'LastName': 'Lang', 'Affiliation': 'Medical Faculty, Hospital St. John of God, Sigmund Freud Private University, Vienna, Austria.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Bereczki', 'Affiliation': 'Department of Neurology, Semmelweis University, Budapest, Hungary.'}, {'ForeName': 'Shinichiro', 'Initials': 'S', 'LastName': 'Uchiyama', 'Affiliation': 'International University of Health and Welfare, Sanno Hospital and Sanno Medical Center, Tokyo, Japan.'}, {'ForeName': 'Scott E', 'Initials': 'SE', 'LastName': 'Kasner', 'Affiliation': 'Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Byung-Woo', 'Initials': 'BW', 'LastName': 'Yoon', 'Affiliation': 'Department of Neurology, Seoul National University Hospital, Seoul, Korea.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Lavados', 'Affiliation': 'Clinica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Firstenfeld', 'Affiliation': 'Instituto Cardiologico Banfield, Buenos Aires, Argentina.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Mikulik', 'Affiliation': ""International Clinical Research Center and Neurology Department, St. Anne's University Hospital and Masaryk University, Brno, Czech Republic.""}, {'ForeName': 'Guillermo Pablo', 'Initials': 'GP', 'LastName': 'Povedano', 'Affiliation': 'Complejo Medico de la PFA Churruca Visca, Buenos Aires, Argentina.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Ferrari', 'Affiliation': 'Hospital Interzonal General de Agudos Eva Peron, Buenos Aires, Argentina.'}, {'ForeName': 'Hardi', 'Initials': 'H', 'LastName': 'Mundl', 'Affiliation': 'Bayer AG, Wuppertal, Germany.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Berkowitz', 'Affiliation': 'Pharmaceuticals Clinical Development Thrombosis, Bayer U.S. LLC, Whippany, NJ, USA.'}, {'ForeName': 'Stuart J', 'Initials': 'SJ', 'LastName': 'Connolly', 'Affiliation': 'Department of Medicine (Cardiology), McMaster University / Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Hart', 'Affiliation': 'Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada.'}]",Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association,['10.1016/j.jstrokecerebrovasdis.2020.104936'] 2258,32689601,Can robotic gait rehabilitation plus Virtual Reality affect cognitive and behavioural outcomes in patients with chronic stroke? A randomized controlled trial involving three different protocols.,"BACKGROUND The rehabilitation of cognitive and behavioral abnormalities in individuals with stroke is essential for promoting patient's recovery and autonomy. The aim of our study is to evaluate the effects of robotic neurorehabilitation using Lokomat with and without VR on cognitive functioning and psychological well-being in stroke patients, as compared to traditional therapy. METHODS Ninety stroke patients were included in this randomized controlled clinical trial. The patients were assigned to one of the three treatment groups, i.e. the Robotic Rehabilitation group undergoing robotic rehab with VR (RRG+VR), the Robotic Rehabilitation Group (RRG-VR) using robotics without VR, and the Conventional Rehabilitation group (CRG) submitted to conventional physiotherapy and cognitive treatment. RESULTS The analysis showed that either the robotic training (with and without VR) or the conventional rehabilitation led to significant improvements in the global cognitive functioning, mood, and executive functions, as well as in activities of daily living. However, only in the RRG+VR we observed a significant improvement in cognitive flexibility and shifting skills, selective attention/visual research, and quality of life, with regard to the perception of the mental and physical state. CONCLUSION Our study shows that robotic treatment, especially if associated with VR, may positively affect cognitive recovery and psychological well-being in patients with chronic stroke, thanks to the complex interation between movement and cognition.",2020,"However, only in the RRG+VR we observed a significant improvement in cognitive flexibility and shifting skills, selective attention/visual research, and quality of life, with regard to the perception of the mental and physical state. ","['stroke patients', 'Ninety stroke patients', 'individuals with stroke', 'patients with chronic stroke']","['robotic gait rehabilitation plus Virtual Reality', 'robotic training (with and without VR', 'robotic neurorehabilitation using Lokomat with and without VR', 'Robotic Rehabilitation group undergoing robotic rehab with VR (RRG+VR), the Robotic Rehabilitation Group (RRG-VR) using robotics without VR, and the Conventional Rehabilitation group (CRG) submitted to conventional physiotherapy and cognitive treatment']","['cognitive flexibility and shifting skills, selective attention/visual research, and quality of life, with regard to the perception of the mental and physical state', 'global cognitive functioning, mood, and executive functions, as well as in activities of daily living']","[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}]","[{'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0204096', 'cui_str': 'Neurological rehabilitation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0233421', 'cui_str': 'Selective inattention'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0597240', 'cui_str': 'State of matter'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}]",90.0,0.0238372,"However, only in the RRG+VR we observed a significant improvement in cognitive flexibility and shifting skills, selective attention/visual research, and quality of life, with regard to the perception of the mental and physical state. ","[{'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Manuli', 'Affiliation': 'IRCCS Centro Neurolesi ""Bonino Pulejo"", Messina, Italy. Electronic address: alfredo.manuli@irccsme.it.'}, {'ForeName': 'Maria Grazia', 'Initials': 'MG', 'LastName': 'Maggio', 'Affiliation': 'IRCCS Centro Neurolesi ""Bonino Pulejo"", Messina, Italy. Electronic address: mariagrazia.maggio@irccsme.it.'}, {'ForeName': 'Desiree', 'Initials': 'D', 'LastName': 'Latella', 'Affiliation': 'IRCCS Centro Neurolesi ""Bonino Pulejo"", Messina, Italy. Electronic address: desiree.latella@irccsme.it.'}, {'ForeName': 'Antonino', 'Initials': 'A', 'LastName': 'Cannavò', 'Affiliation': 'IRCCS Centro Neurolesi ""Bonino Pulejo"", Messina, Italy. Electronic address: an.cannavo@irccsme.it.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Balletta', 'Affiliation': 'IRCCS Centro Neurolesi ""Bonino Pulejo"", Messina, Italy. Electronic address: tina.balletta@irccsme.it.'}, {'ForeName': 'Rosaria', 'Initials': 'R', 'LastName': 'De Luca', 'Affiliation': 'IRCCS Centro Neurolesi ""Bonino Pulejo"", Messina, Italy. Electronic address: dlucaros@yahoo.it.'}, {'ForeName': 'Antonino', 'Initials': 'A', 'LastName': 'Naro', 'Affiliation': 'IRCCS Centro Neurolesi ""Bonino Pulejo"", Messina, Italy. Electronic address: antonino.naro@irccsme.it.'}, {'ForeName': 'Rocco Salvatore', 'Initials': 'RS', 'LastName': 'Calabrò', 'Affiliation': 'IRCCS Centro Neurolesi ""Bonino Pulejo"", Messina, Italy. Electronic address: salbro77@tiscali.it.'}]",Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association,['10.1016/j.jstrokecerebrovasdis.2020.104994'] 2259,32689617,Effects of joint mobilization and stretching on the range of motion for ankle joint and spatiotemporal gait variables in stroke patients.,"BACKGROUND AND PURPOSE Stroke patients have limited ranges of motion and gait disturbances due to neurological deficits and connective tissue changes. We assessed the effects of joint mobilization and active stretching on ankle joint range of motion and gait in stroke patients. METHODS In total, 45 stroke patients were evenly divided into three groups: joint mobilization, active stretching, and combination (joint mobilization and active stretching) groups. Patients in each group received the corresponding interventions in a non-simultaneous manner for 6 weeks in total (3 days per week, 15 min per day). The range of motion of the ankle joint was measured using a goniometer, and spatiotemporal gait variables were measured using G-walk. All measurements were taken immediately before and after the 6-week intervention. RESULTS The joint mobilization group exhibited significantly increased range of motion for ankle joint after the intervention (p < 0.05), while the spatiotemporal gait variables were unchanged. In the active stretching group, both the range of motion of the ankle joint in the supine position and the spatiotemporal gait variables (cadence, speed, stride length) were significantly increased (p < 0.05). In the combination group, both the range of motion of the ankle joint and spatiotemporal gait variables (cadence, speed, stride length) were significantly increased (p < 0.05). CONCLUSION Combination therapy of joint mobilization and active stretching improves the range of motion of the ankle joint and spatiotemporal gait variables in stroke patients, suggesting that ankle rehabilitation of stroke patients should include limited joint structure and muscles shortness.",2020,"The joint mobilization group exhibited significantly increased range of motion for ankle joint after the intervention (p < 0.05), while the spatiotemporal gait variables were unchanged.","['Stroke patients', 'stroke patients', '45 stroke patients']","['joint mobilization, active stretching, and combination (joint mobilization and active stretching', 'joint mobilization and active stretching', 'joint mobilization and stretching', 'active stretching']","['range of motion for ankle joint', 'spatiotemporal gait variables', 'range of motion for ankle joint and spatiotemporal gait variables', 'range of motion of the ankle joint and spatiotemporal gait variables', 'spatiotemporal gait variables (cadence, speed, stride length', 'range of motion of the ankle joint', 'range of motion of the ankle joint and spatiotemporal gait variables (cadence, speed, stride length']","[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0231588', 'cui_str': 'Physiatric mobilization of joint'}, {'cui': 'C1720873', 'cui_str': 'Static-Active Stretching'}]","[{'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0003087', 'cui_str': 'Ankle joint structure'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C1444754', 'cui_str': 'Length'}]",45.0,0.0296743,"The joint mobilization group exhibited significantly increased range of motion for ankle joint after the intervention (p < 0.05), while the spatiotemporal gait variables were unchanged.","[{'ForeName': 'Kyun-Hee', 'Initials': 'KH', 'LastName': 'Cho', 'Affiliation': 'Department of Physical Therapy, Graduate School, YongIn University, Republic of Korea.'}, {'ForeName': 'Shin-Jun', 'Initials': 'SJ', 'LastName': 'Park', 'Affiliation': 'Department of Physical Therapy, GangdDong University, 205ho, hongikgwan, 278, Daehak-gil, Gamgok-myeon, Eumseong-gun, Chungcheongbuk-do, Republic of Korea. Electronic address: 3178310@naver.com.'}]",Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association,['10.1016/j.jstrokecerebrovasdis.2020.104933'] 2260,32690050,Effectiveness of the level of personal relevance of visual autobiographical stimuli in the induction of positive emotions in young and older adults: pilot study protocol for a randomized controlled trial.,"BACKGROUND The ability to retrieve specific memories is a cognitive and emotional protective factor. Among the most effective techniques to generate autobiographical memories is the use of audio-visual stimuli, particularly images. Developing and improving techniques that facilitate the generation of such memories could be highly effective in the prevention of depressive symptoms, especially in the elderly population. The aim of the present study is to examine how the level of personal relevance of pictures as autobiographical memory cues to induce positive emotions may affect an individual's emotion regulation. METHODS The participants, 120 older adults aged 65 and over and 120 young adults aged between 18 and 35, of both sexes and without depressive symptoms, will be induced to a negative mood state by means of viewing a film clip. Following the negative mood induction, the participants will be shown positive images according to experimental group to which they were randomly assigned (high personal relevance: personal autobiographical photographs; medium personal relevance: pictures of favourite locations associated with specific positive autobiographical memories; and low personal relevance: positive images from the International Affective Picture System). We will analyse the differences in subjective (responses to questionnaires) and objectives measures (EEG signal, heart rate variability and electrodermal activity) between the groups before and after the induction of negative affect and following the recall of positive memories. DISCUSSION The use of images associated with specific positive autobiographical memories may be an effective input for inducing positive mood states, which has potentially important implications for their use as a cognitive behavioural technique to treat emotional disorders, such as depression, which are highly prevalent among older adults. TRIAL REGISTRATION ClinicalTrials.gov NCT04251104 . Registered on 30 January 2020.",2020,"The use of images associated with specific positive autobiographical memories may be an effective input for inducing positive mood states, which has potentially important implications for their use as a cognitive behavioural technique to treat emotional disorders, such as depression, which are highly prevalent among older adults. ","['120 older adults aged 65 and over and 120 young adults aged between 18 and 35, of both sexes and without depressive symptoms, will be induced to a negative mood state by means of viewing a film clip', 'older adults', 'young and older adults']",['visual autobiographical stimuli'],"['subjective (responses to questionnaires) and objectives measures (EEG signal, heart rate variability and electrodermal activity']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0175722', 'cui_str': 'Clip'}, {'cui': 'C0332239', 'cui_str': 'Young'}]","[{'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",120.0,0.0844888,"The use of images associated with specific positive autobiographical memories may be an effective input for inducing positive mood states, which has potentially important implications for their use as a cognitive behavioural technique to treat emotional disorders, such as depression, which are highly prevalent among older adults. ","[{'ForeName': 'Dolores', 'Initials': 'D', 'LastName': 'Fernández', 'Affiliation': 'Department of Psychology, University of Castilla La Mancha, 02006, Albacete, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Ros', 'Affiliation': 'Department of Psychology, University of Castilla La Mancha, 02006, Albacete, Spain. laura.ros@uclm.es.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Sánchez-Reolid', 'Affiliation': 'Computer Research Institute, University of Castilla La Mancha, 02071, Albacete, Spain.'}, {'ForeName': 'Jorge Javier', 'Initials': 'JJ', 'LastName': 'Ricarte', 'Affiliation': 'Department of Psychology, University of Castilla La Mancha, 02006, Albacete, Spain.'}, {'ForeName': 'José Miguel', 'Initials': 'JM', 'LastName': 'Latorre', 'Affiliation': 'Department of Psychology, University of Castilla La Mancha, 02006, Albacete, Spain.'}]",Trials,['10.1186/s13063-020-04596-5'] 2261,32690056,Surgery simulation teaching based on real reconstruction aid versus traditional surgical live teaching in the acquisition of an adult total hip arthroplasty surgical technique for developmental dysplasia of the hip: a randomized comparative study.,"BACKGROUND A simulation and model (SM) teaching aid using 3D printing was developed to improve a training course for total hip arthroplasty of adult developmental dysplasia of the hip (adult DDH-THA). We named this new method Surgery Simulation Teaching based on a Real Reconstruction Aid (RRA-SST). A prospective randomized comparison was performed with the traditional surgical live teaching method to evaluate the training effectiveness of RRA-SST for adult DDH-THA. METHODS Twenty-six trainees, who were already practicing but were not experienced, participated in the study. We randomly divided the trainees into two groups: Group A (n = 13) received RRA-SST and group B (n = 13) received traditional surgical live teaching. A surgery simulation test and a questionnaire were used for evaluation. Next, each group received training with the other teaching method, and then the test and questionnaire were used again for evaluation. RESULTS After the first test, the RRA-SST method was shown to produce better results than the traditional surgical live teaching method. After the second test, the results showed the training effect in both groups reached the same level, which was level as Group A RRA-SST results. Analysis of the questionnaire results showed that the training effect of RRA-SST was higher than that of traditional surgical live teaching, from multiple perspectives. CONCLUSIONS The use of RRA-SST improved participant performance according to simulation assessment. RRA-SST can be helpful for trainees who are already practicing but not experienced when developing proficiency in adult DDH-THA surgical techniques.",2020,"After the first test, the RRA-SST method was shown to produce better results than the traditional surgical live teaching method.","['total hip arthroplasty of adult developmental dysplasia of the hip (adult DDH-THA', 'Twenty-six trainees, who were already practicing but were not experienced, participated in the study', 'adult total hip arthroplasty surgical technique for developmental dysplasia of the hip']","['traditional surgical live teaching', 'RRA-SST', 'Surgery simulation teaching based on real reconstruction aid versus traditional surgical live teaching']",[],"[{'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4551649', 'cui_str': 'Congenital hip dysplasia'}, {'cui': 'C0039245', 'cui_str': 'Tacrine'}, {'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0034596', 'cui_str': 'Radioreceptor assay'}, {'cui': 'C0037659', 'cui_str': 'Somatostatin'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}]",[],26.0,0.0145606,"After the first test, the RRA-SST method was shown to produce better results than the traditional surgical live teaching method.","[{'ForeName': 'Chenggong', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Office of teaching affairs, Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Ouyang', 'Affiliation': 'Office of teaching affairs, Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Office of teaching affairs, Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Can', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': 'Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Han', 'Initials': 'H', 'LastName': 'Xiao', 'Affiliation': 'Department of Sports Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Yihe', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Yusheng', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Office of teaching affairs, Xiangya Hospital, Central South University, Changsha, Hunan, China. liyusheng@csu.edu.cn.'}, {'ForeName': 'Da', 'Initials': 'D', 'LastName': 'Zhong', 'Affiliation': 'Office of teaching affairs, Xiangya Hospital, Central South University, Changsha, Hunan, China. dr_zhongda@126.com.'}]",BMC medical education,['10.1186/s12909-020-02135-z'] 2262,32690063,"Adaptive interventions for optimizing malaria control: an implementation study protocol for a block-cluster randomized, sequential multiple assignment trial.","BACKGROUND In the past two decades, the massive scale-up of long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) has led to significant reductions in malaria mortality and morbidity. Nonetheless, the malaria burden remains high, and a dozen countries in Africa show a trend of increasing malaria incidence over the past several years. This underscores the need to improve the effectiveness of interventions by optimizing first-line intervention tools and integrating newly approved products into control programs. Because transmission settings and vector ecologies vary from place to place, malaria interventions should be adapted and readapted over time in response to evolving malaria risks. An adaptive approach based on local malaria epidemiology and vector ecology may lead to significant reductions in malaria incidence and transmission risk. METHODS/DESIGN This study will use a longitudinal block-cluster sequential multiple assignment randomized trial (SMART) design with longitudinal outcome measures for a period of 3 years to develop an adaptive intervention for malaria control in western Kenya, the first adaptive trial for malaria control. The primary outcome is clinical malaria incidence rate. This will be a two-stage trial with 36 clusters for the initial trial. At the beginning of stage 1, all clusters will be randomized with equal probability to either LLIN, piperonyl butoxide-treated LLIN (PBO Nets), or LLIN + IRS by block randomization based on their respective malaria risks. Intervention effectiveness will be evaluated with 12 months of follow-up monitoring. At the end of the 12-month follow-up, clusters will be assessed for ""response"" versus ""non-response"" to PBO Nets or LLIN + IRS based on the change in clinical malaria incidence rate and a pre-defined threshold value of cost-effectiveness set by the Ministry of Health. At the beginning of stage 2, if an intervention was effective in stage 1, then the intervention will be continued. Non-responders to stage 1 PBO Net treatment will be randomized equally to either PBO Nets + LSM (larval source management) or an intervention determined by an enhanced reinforcement learning method. Similarly, non-responders to stage 1 LLIN + IRS treatment will be randomized equally to either LLIN + IRS + LSM or PBO Nets + IRS. There will be an 18-month evaluation follow-up period for stage 2 interventions. We will monitor indoor and outdoor vector abundance using light traps. Clinical malaria will be monitored through active case surveillance. Cost-effectiveness of the interventions will be assessed using Q-learning. DISCUSSION This novel adaptive intervention strategy will optimize existing malaria vector control tools while allowing for the integration of new control products and approaches in the future to find the most cost-effective malaria control strategies in different settings. Given the urgent global need for optimization of malaria control tools, this study can have far-reaching implications for malaria control and elimination. TRIAL REGISTRATION US National Institutes of Health, study ID NCT04182126 . Registered on 26 November 2019.",2020,"Given the urgent global need for optimization of malaria control tools, this study can have far-reaching implications for malaria control and elimination. ","['malaria control in western Kenya, the first adaptive trial for malaria control']","['LLIN, piperonyl butoxide-treated LLIN (PBO Nets), or LLIN + IRS', 'LLIN + IRS + LSM or PBO Nets + IRS', 'Adaptive interventions', 'PBO Nets + LSM (larval source management) or an intervention determined by an enhanced reinforcement learning method']","['malaria mortality and morbidity', 'Intervention effectiveness', 'Cost-effectiveness', 'clinical malaria incidence rate']","[{'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0031962', 'cui_str': 'Piperonyl Butoxide'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0449416', 'cui_str': 'Source'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0035007', 'cui_str': 'Psychological Reinforcement'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C4543807', 'cui_str': 'Clinical malaria'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",,0.093538,"Given the urgent global need for optimization of malaria control tools, this study can have far-reaching implications for malaria control and elimination. ","[{'ForeName': 'Guofa', 'Initials': 'G', 'LastName': 'Zhou', 'Affiliation': 'Program in Public Health, University of California, Irvine, CA, USA.'}, {'ForeName': 'Ming-Chieh', 'Initials': 'MC', 'LastName': 'Lee', 'Affiliation': 'Program in Public Health, University of California, Irvine, CA, USA.'}, {'ForeName': 'Harrysone E', 'Initials': 'HE', 'LastName': 'Atieli', 'Affiliation': 'Department of Public Health, Maseno University, Kisumu, Kenya.'}, {'ForeName': 'John I', 'Initials': 'JI', 'LastName': 'Githure', 'Affiliation': 'Department of Public Health, Maseno University, Kisumu, Kenya.'}, {'ForeName': 'Andrew K', 'Initials': 'AK', 'LastName': 'Githeko', 'Affiliation': 'Kenya Medical Research Institute, Kisumu, Kenya.'}, {'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'Kazura', 'Affiliation': 'Center for Global Health and Diseases, Case Western Reserve University, Cleveland, OH, USA.'}, {'ForeName': 'Guiyun', 'Initials': 'G', 'LastName': 'Yan', 'Affiliation': 'Program in Public Health, University of California, Irvine, CA, USA. guiyuny@uci.edu.'}]",Trials,['10.1186/s13063-020-04573-y'] 2263,32690067,Internet-based cognitive rehabilitation for WORking Cancer survivors (i-WORC): study protocol of a randomized controlled trial.,"BACKGROUND Cognitive problems are common in non-central nervous system cancer survivors. These problems are perceived as an important contributor to decline in work performance and work ability. Various interventions for cognitive problems have been proposed, but effectiveness regarding work-related outcomes has not yet been established. Effective treatment options to alleviate the adverse influence of cognitive problems on work performance are needed for working cancer survivors. In this paper, we will describe the design of a randomized, controlled, multicenter trial that evaluates the (cost-)effectiveness of an Internet-based cognitive rehabilitation program for occupationally active cancer survivors confronted with cognitive problems. METHODS/ DESIGN A three-armed randomized controlled trial will be conducted, including two intervention groups (i.e., basic and extensive cognitive rehabilitation program) and one waitlist control group. In total, 261 cancer survivors (18-65 years) who have returned to work and who experience cognitive problems will be recruited. Patients with and without cognitive impairment as established in a neuropsychological assessment will be eligible; stratification will take place based on the presence of this cognitive impairment. The extensive intervention arm will contain a comprehensive training program (including psycho-education, fatigue management, and cognitive strategy training) with individual guidance (blended intervention). The basic intervention arm will contain a brief cognitive training program (including psycho-education and fatigue management) without individual guidance. The primary outcome will be accomplishment of an individually defined work-related treatment goal. Secondary outcomes include, among others, subjective cognitive functioning, work functioning, and quality of life. Primary and secondary outcomes will be measured at baseline (T0) and at 12 weeks (T1) and 26 weeks (T2) post-randomization. DISCUSSION About 40-50% of the cancer patients worldwide are of working age at time of diagnosis. Many of the occupationally active cancer survivors experience cognitive problems. Both from an individual and a societal perspective, it is important to sustain cancer survivors' employability. An effective treatment to alleviate the impact of cognitive decline and to improve work ability might help cancer survivors to sustain employability. TRIAL REGISTRATION ClinicalTrials.gov NCT03900806 . Registered on 03 April 2019 (current status: ongoing).",2020,The basic intervention arm will contain a brief cognitive training program (including psycho-education and fatigue management) without individual guidance.,"['occupationally active cancer survivors experience cognitive problems', 'occupationally active cancer survivors confronted with cognitive problems', 'working cancer survivors', 'Patients with and without cognitive impairment', '261 cancer survivors (18-65\u2009years) who have returned to work and who experience cognitive problems will be recruited']","['Internet-based cognitive rehabilitation', 'comprehensive training program (including psycho-education, fatigue management, and cognitive strategy training) with individual guidance (blended intervention', 'basic and extensive cognitive rehabilitation program) and one waitlist control group', 'cognitive training program (including psycho-education and fatigue management) without individual guidance', 'Internet-based cognitive rehabilitation program']","['accomplishment of an individually defined work-related treatment goal', 'others, subjective cognitive functioning, work functioning, and quality of life']","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0425105', 'cui_str': 'Returned to work'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0851283', 'cui_str': 'Management of fatigue'}, {'cui': 'C0589105', 'cui_str': 'Strategy training'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205231', 'cui_str': 'Extensive'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}]","[{'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",261.0,0.159225,The basic intervention arm will contain a brief cognitive training program (including psycho-education and fatigue management) without individual guidance.,"[{'ForeName': 'Kete M', 'Initials': 'KM', 'LastName': 'Klaver', 'Affiliation': 'Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. k.klaver@nki.nl.'}, {'ForeName': 'Saskia F A', 'Initials': 'SFA', 'LastName': 'Duijts', 'Affiliation': 'Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Chantal A V', 'Initials': 'CAV', 'LastName': 'Geusgens', 'Affiliation': 'Department of Medical Psychology, Zuyderland MC, Sittard, The Netherlands.'}, {'ForeName': 'Maureen J B', 'Initials': 'MJB', 'LastName': 'Aarts', 'Affiliation': 'Department of Medical Oncology, Maastricht University MC, Maastricht, The Netherlands.'}, {'ForeName': 'Rudolf W H M', 'Initials': 'RWHM', 'LastName': 'Ponds', 'Affiliation': 'Department of Medical Psychology/School of Mental Health and Neurosciences (MHeNS), Maastricht University MC, Maastricht, The Netherlands.'}, {'ForeName': 'Allard J', 'Initials': 'AJ', 'LastName': 'van der Beek', 'Affiliation': 'Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Sanne B', 'Initials': 'SB', 'LastName': 'Schagen', 'Affiliation': 'Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.'}]",Trials,['10.1186/s13063-020-04570-1'] 2264,32690203,An RCT to Increase Breast and Colorectal Cancer Screening.,"INTRODUCTION Adherence to breast and colorectal cancer screenings reduce mortality from these cancers, yet screening rates remain suboptimal. This 2 × 2 RCT compared 3 theory-based interventions to usual care to simultaneously increase breast and colon cancer screening in women who were nonadherent to both screenings at study entry. DESIGN RCT. SETTING/PARTICIPANTS Women (n=692) who were nonadherent to both breast and colon cancer screenings and aged 51-75 years were recruited. Enrollment, intervention delivery, and data collection were completed between 2013 and 2017, and data analyzed in 2018. INTERVENTION The randomized intervention included the following 4 groups: 3 intervention arms (personally tailored messages using a web-based intervention, phone delivery by a trained navigator, or both) compared with usual care. Women at an average risk for colon cancer were allowed to select either colonoscopy or stool test as their preferred colon cancer screening. Mammography was promoted for breast cancer screening. MAIN OUTCOME MEASURES Outcome data at 6 months included self-report and medical records for screening activity. RESULTS All intervention arms significantly increased receipt of either a mammogram or stool test compared with control (web: p<0.0249, phone: p<0.0001, web + phone: p<0.0001). When considering receipt of both mammogram and stool test, all intervention arms were significantly different from usual care (web: p<0.0249, phone: p<0.0003, web + phone: p<0.0001). In addition, women who were adherent to mammography had a 4.5 times greater odds of becoming adherent to colonoscopy. CONCLUSIONS The tailored intervention simultaneously supporting both breast and colon cancer screenings significantly improved rates of obtaining one of the screenings and increased receipt of both tests. TRIAL REGISTRATION This study is registered with the clinical trials identifier NCT03279198 at www.clinicaltrials.gov.",2020,"All intervention arms significantly increased receipt of either a mammogram or stool test compared with control (web: p<0.0249, phone:","['Women (n=692) who were nonadherent to both breast and colon cancer screenings and aged 51-75 years were recruited', 'women who were nonadherent to both screenings at study entry', 'Women at an average risk for colon cancer']","['RCT', '3 intervention arms (personally tailored messages using a web-based intervention, phone delivery by a trained navigator, or both) compared with usual care', 'Mammography', 'RCT compared 3 theory-based interventions to usual care to simultaneously increase breast and colon cancer screening']","['self-report and medical records for screening activity', 'rates of obtaining one of the screenings and increased receipt of both tests', 'receipt of either a mammogram or stool test']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0222605', 'cui_str': 'Both breasts'}, {'cui': 'C0554837', 'cui_str': 'Screening for malignant neoplasm of colon'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C3898714', 'cui_str': 'Internet Intervention'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0554837', 'cui_str': 'Screening for malignant neoplasm of colon'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0025102', 'cui_str': 'Medical record'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0201811', 'cui_str': 'Screening for occult blood in feces'}]",,0.0798623,"All intervention arms significantly increased receipt of either a mammogram or stool test compared with control (web: p<0.0249, phone:","[{'ForeName': 'Victoria L', 'Initials': 'VL', 'LastName': 'Champion', 'Affiliation': 'Department of Community and Health Systems, Indiana University School of Nursing, Indianapolis, Indiana; Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana. Electronic address: vchampio@iu.edu.'}, {'ForeName': 'Shannon M', 'Initials': 'SM', 'LastName': 'Christy', 'Affiliation': 'Department of Health Outcomes and Behavior, Division of Population Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, Florida.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Rakowski', 'Affiliation': 'Professor Emeritus, Brown University, Providence, Rhode Island.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Lairson', 'Affiliation': 'School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas.'}, {'ForeName': 'Patrick O', 'Initials': 'PO', 'LastName': 'Monahan', 'Affiliation': 'Department of Biostatistics, Indiana University School of Medicine, Richard M. Fairbanks School of Public Health, Indianapolis, Indiana.'}, {'ForeName': 'Wambui G', 'Initials': 'WG', 'LastName': 'Gathirua-Mwangi', 'Affiliation': 'Department of Community and Health Systems, Indiana University School of Nursing, Indianapolis, Indiana.'}, {'ForeName': 'Timothy E', 'Initials': 'TE', 'LastName': 'Stump', 'Affiliation': 'Department of Biostatistics, Indiana University School of Medicine, Richard M. Fairbanks School of Public Health, Indianapolis, Indiana; Department of Psychology, Purdue School of Science, Indianapolis, Indiana.'}, {'ForeName': 'Erika B', 'Initials': 'EB', 'LastName': 'Biederman', 'Affiliation': 'Department of Community and Health Systems, Indiana University School of Nursing, Indianapolis, Indiana.'}, {'ForeName': 'Carla D', 'Initials': 'CD', 'LastName': 'Kettler', 'Affiliation': 'Department of Biostatistics, Indiana University School of Medicine, Richard M. Fairbanks School of Public Health, Indianapolis, Indiana.'}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Rawl', 'Affiliation': 'Department of Science of Nursing Care, Indiana University School of Nursing, Indianapolis, Indiana.'}]",American journal of preventive medicine,['10.1016/j.amepre.2020.03.008'] 2265,32690274,Utility of Circulating Tumor Cells for Detection of Early-Stage Luminal A Breast Cancer.,"BACKGROUND Patients with early-stage luminal A breast cancer (LABC) have better prognoses. However, follow-up examinations are frequent and remain complex. The present study examined whether circulating tumor cell (CTC) detection could be used as an earlier and more reproducible indicator of disease status among patients with early-stage LABC, and given China's healthcare resource challenges, whether it could periodically replace follow-up routine imaging. METHODS A total of 135 postoperative Chinese patients with early-stage LABC were randomly assigned to a CTC group (68 patients underwent alternating assessments using CTC detection and routine re-examination) or control group (67 patients underwent only routine re-examination). The prognosis and patient-covered costs of the various assessments were calculated for the 2 groups. RESULTS No patients had normal CTCs and simultaneous abnormal imaging findings. There were no differences in overall survival, disease-free survival and total patient-covered cost of follow-up between the 2 groups (all P > 0.05). However, there was a significant difference in the average patient-covered cost (P < 0.001). Furthermore, significant intergroup differences were observed in the total and average hospitalization times (P < 0.05). CONCLUSIONS Among Chinese patients with low-risk LABC, CTC detection was highly reliable and relatively low cost. Therefore, CTC detection may be used to reduce the number of routine imaging follow-ups.",2020,"There were no differences in overall survival, disease-free survival and total patient-covered cost of follow-up between the 2 groups (all P > 0.05).","[""patients with early-stage LABC, and given China's healthcare resource challenges"", '135 postoperative Chinese patients with early-stage LABC', 'Chinese patients with low-risk LABC', 'Patients with early-stage luminal A breast cancer (LABC']","['alternating assessments using CTC detection and routine re-examination) or control group (67 patients underwent only routine re-examination', 'CTC', 'Circulating Tumor Cells']","['average patient-covered cost', 'total and average hospitalization times', 'overall survival, disease-free survival and total patient-covered cost of follow']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0699493', 'cui_str': 'Luminal'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}]","[{'cui': 'C0332270', 'cui_str': 'Alternating'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0027625', 'cui_str': 'Circulating Neoplastic Cells'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439844', 'cui_str': 'Covered'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]",135.0,0.0264389,"There were no differences in overall survival, disease-free survival and total patient-covered cost of follow-up between the 2 groups (all P > 0.05).","[{'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Breast Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.'}, {'ForeName': 'Ji', 'Initials': 'J', 'LastName': 'Qi', 'Affiliation': 'School of Epidemiology, China Medical University, Shenyang, Liaoning Province, China.'}, {'ForeName': 'Jianyi', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Breast Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China. Electronic address: sjbreast@yeah.net.'}, {'ForeName': 'Shi', 'Initials': 'S', 'LastName': 'Jia', 'Affiliation': 'Department of Breast Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.'}, {'ForeName': 'Yitong', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Breast Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Sun', 'Affiliation': 'Department of Breast Surgery, General Hospital of Benxi Iron & Steel Industry Group of Liaoning Health Industry Group, Benxi, Liaoning Province, China.'}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Kang', 'Affiliation': 'Department of Pathology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.'}, {'ForeName': 'Yushi', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'School of Clinical Medicine, China Medical University, Shenyang, Liaoning Province, China.'}, {'ForeName': 'Yanan', 'Initials': 'Y', 'LastName': 'Cao', 'Affiliation': 'School of Clinical Medicine, China Medical University, Shenyang, Liaoning Province, China.'}, {'ForeName': 'Jiaxin', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'School of Clinical Medicine, Jinzhou Medical University, Jinzhou, Liaoning Province, China.'}]",The American journal of the medical sciences,['10.1016/j.amjms.2020.01.020'] 2266,32690314,The Effect of a Cartoon and an Information Video About Intravenous Insertion on Pain and Fear in Children Aged 6 to 12 Years in the Pediatric Emergency Unit: A Randomized Controlled Trial.,"INTRODUCTION Intravenous insertion is the most common invasive procedure made for administering intravascular fluid and medicine. Peripheral venous catheterization may cause pain, fear, and stress in children. This study aimed to compare the effects of watching a cartoon and an information video about intravenous insertion on the pain and fear levels of children aged 6-12 years. METHODS The study was an experimental, randomized controlled clinical trial. It was conducted with 477 children aged 6-12 years randomized into 3 groups: the informative animated video group, the cartoon group, and the control group. Fear and pain perception were evaluated on the basis of the feedback from the child, observer nurse, and parents. The Children's Fear Scale was used to evaluate the fear level and the Wong-Baker FACES Scale was used to assess pain levels. Data were analyzed using one-way analysis of variance, the chi-square test, and the intraclass correlation coefficient test. RESULTS The children who watched the information video before the intravenous insertion procedure and those who watched a cartoon during the procedure had lower mean pain and fear scores as evaluated by the child (pain: F = 278.67, P = 0.001; fear: F = 294.88, P = 0.001), parent (pain: F = 279.53, P = 0.001; fear: F = 294.47, P = 0.001), and nurse (pain: F = 286.88, P = 0.001; fear: F = 300.81, P = 0.001) than children in the control group. DISCUSSION This study showed that watching an animation video or a cartoon was effective in lowering children's perceived level of pain and fear during an intravenous insertion intervention.",2020,This study showed that watching an animation video or a cartoon was effective in lowering children's perceived level of pain and fear during an intravenous insertion intervention.,"['children', '477 children aged 6-12 years randomized into 3 groups: the', 'Children', 'children aged 6-12 years', 'Aged 6 to 12 Years in the Pediatric Emergency Unit']","['Peripheral venous catheterization', 'informative animated video group, the cartoon group, and the control group', 'Cartoon and an Information Video About Intravenous Insertion', 'watching a cartoon and an information video about intravenous insertion']","['Pain and Fear', 'Fear and pain perception', 'pain and fear levels', 'pain levels', 'parent (pain', 'level of pain and fear', 'mean pain and fear scores']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}]","[{'cui': 'C0031127', 'cui_str': 'Catheterization, Peripheral Venous'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0007306', 'cui_str': 'Cartoons'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C1319227', 'cui_str': 'Level of fear'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",477.0,0.0806166,This study showed that watching an animation video or a cartoon was effective in lowering children's perceived level of pain and fear during an intravenous insertion intervention.,"[{'ForeName': 'Duygu Sönmez', 'Initials': 'DS', 'LastName': 'Düzkaya', 'Affiliation': ''}, {'ForeName': 'Gülçin', 'Initials': 'G', 'LastName': 'Bozkurt', 'Affiliation': ''}, {'ForeName': 'Sevim', 'Initials': 'S', 'LastName': 'Ulupınar', 'Affiliation': ''}, {'ForeName': 'Gülzade', 'Initials': 'G', 'LastName': 'Uysal', 'Affiliation': ''}, {'ForeName': 'Serpil', 'Initials': 'S', 'LastName': 'Uçar', 'Affiliation': ''}, {'ForeName': 'Metin', 'Initials': 'M', 'LastName': 'Uysalol', 'Affiliation': ''}]",Journal of emergency nursing,['10.1016/j.jen.2020.04.011'] 2267,32690330,[Effects of including mutual aid groups in the adherence of a continuing care programme of alcohol dependent patients carried out in a Primary Care setting].,"OBJECTIVES To demonstrate the effects of including mutual aid associations into a continuing care programme for patients with alcohol dependence carried out by Primary Care teams. SITE: Primary Care Teams belonging to the attendance area of the University Hospital 12 de Octubre at Madrid. PARTICIPANTS 207 participants with alcohol dependence treated in an intensive hospital outpatient-setting programme were included in a continuing care programme carried out by a Primary Care team for a four-year period. INTERVENTIONS Patients were randomised into two intervention modalities. The first group was followed up while receiving a treatment modality known as «monitoring recovery» (Group A, n = 97). The other group, in addition to the above-mentioned intervention, attended to a mutual aid association included in the Federation of Alcoholics of the Community of Madrid (FACOMA) in which the programme «Help Yourself-Help Us» was carried out (Group B, n = 112). MAIN OUTCOMES Dropout rates on the sessions designed to monitor their recovery from their alcohol dependence and other comorbid medical conditions. RESULTS Patients in Group B reached higher rates of therapeutic adherence to the programme (47.9% vs. 14.7%, p < 0.01), as well as for the comorbid medical issues when compared to Group A. CONCLUSIONS Including mutual aid associations that carried out the «Help yourself-Help Us» programme for a four-year period improves outcomes related to therapeutic adherence in patients with alcohol dependence attending Primary Care teams.",2020,» programme for a four-year period improves outcomes related to therapeutic adherence in patients with alcohol dependence attending Primary Care teams.,"['207 participants with alcohol dependence treated in an intensive hospital outpatient-setting programme were included in a continuing care programme carried out by a Primary Care team for a four-year period', 'patients with alcohol dependence attending Primary Care teams', 'patients with alcohol dependence carried out by Primary Care teams', 'Primary Care Teams belonging to the attendance area of the University Hospital 12 de Octubre at Madrid']",['SITE'],"['alcohol dependence and other comorbid medical conditions', 'therapeutic adherence']","[{'cui': 'C0001973', 'cui_str': 'Alcohol dependence'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}]","[{'cui': 'C0205145', 'cui_str': 'Site'}]","[{'cui': 'C0001973', 'cui_str': 'Alcohol dependence'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C4505265', 'cui_str': 'Therapeutic Adherence'}]",207.0,0.0135567,» programme for a four-year period improves outcomes related to therapeutic adherence in patients with alcohol dependence attending Primary Care teams.,"[{'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Rubio', 'Affiliation': 'Servicio de Psiquiatría, Hospital Universitario 12 de Octubre, Madrid, España; Instituto de Investigación 12 de Octubre (I+12), Hospital Universitario 12 de Octubre, Madrid, España; Departamento de Medicina Legal, Psiquiatría y Anatomía, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España; Red de Trastornos Adictivos (RETIS), Instituto Carlos III, Madrid, España.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Marín', 'Affiliation': 'Servicio de Psiquiatría, Hospital Universitario 12 de Octubre, Madrid, España; Instituto de Investigación 12 de Octubre (I+12), Hospital Universitario 12 de Octubre, Madrid, España; Red de Trastornos Adictivos (RETIS), Instituto Carlos III, Madrid, España. Electronic address: marta.marin@salud.madrid.org.'}, {'ForeName': 'José Ramón', 'Initials': 'JR', 'LastName': 'López-Trabada', 'Affiliation': 'Servicio de Psiquiatría, Hospital Universitario 12 de Octubre, Madrid, España; Instituto de Investigación 12 de Octubre (I+12), Hospital Universitario 12 de Octubre, Madrid, España; Red de Trastornos Adictivos (RETIS), Instituto Carlos III, Madrid, España.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Arias', 'Affiliation': 'Servicio de Psiquiatría, Hospital Universitario 12 de Octubre, Madrid, España; Instituto de Investigación 12 de Octubre (I+12), Hospital Universitario 12 de Octubre, Madrid, España; Red de Trastornos Adictivos (RETIS), Instituto Carlos III, Madrid, España.'}]",Atencion primaria,['10.1016/j.aprim.2020.04.010'] 2268,32679370,Early application of caffeine improves white matter development in very preterm infants.,"The aim of this study was to evaluate the effect of early prophylactic caffeine treatment on white matter development in very preterm infants using cerebral magnetic resonance imaging. A total of 194 preterm infants (≤32 weeks gestational age) were randomly assigned to the caffeine (n = 96) or placebo (n = 93) treatment group and administered with either caffeine or placebo within 72 h after birth. Cerebral magnetic resonance imaging, including diffuse tensor imaging examination, was performed at 34-36 weeks of corrected gestational age, and the fractional anisotropy (FA) and apparent diffusion coefficient (ADC) values were measured. In total, 160 infants were included in the final analysis, including 80 cases in the placebo group and 80 cases in the caffeine group. There were fewer instances of apnea of prematurity and shorter assisted ventilation times for infants in the caffeine group compared to the placebo group (p < 0.05). Infants in the caffeine group had significantly higher FA values in white matter, including the posterior limb of the internal capsule, the corpus callosum, the frontal, occipital, and parietal white matter, the cerebellum, and the cerebral peduncle, compared to infants in the placebo group. ADC values in the above white matter areas were significantly reduced in the caffeine group. However, there were no significant differences regarding the FA and ADC in the gray matter between the two groups. These results demonstrate that early administration of caffeine improves white matter micro-structural development in preterm infants, but with no significant effect on short-term complications related to prematurity.",2020,"Infants in the caffeine group had significantly higher FA values in white matter, including the posterior limb of the internal capsule, the corpus callosum, the frontal, occipital, and parietal white matter, the cerebellum, and the cerebral peduncle, compared to infants in the placebo group.","['very preterm infants', 'very preterm infants using cerebral magnetic resonance imaging', 'preterm infants', '194 preterm infants (≤32 weeks gestational age', '160 infants were included in the final analysis, including 80 cases in the placebo group and 80 cases in the caffeine group']","['placebo', 'caffeine', 'caffeine or placebo', 'prophylactic caffeine']","['white matter micro-structural development', 'apnea of prematurity and shorter assisted ventilation times', 'FA values', 'fractional anisotropy (FA) and apparent diffusion coefficient (ADC) values', 'FA and ADC', 'ADC values']","[{'cui': 'C3897192', 'cui_str': 'Very preterm infant'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0009653', 'cui_str': 'Condom'}]","[{'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0085672', 'cui_str': 'Microbiology procedure'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0475715', 'cui_str': 'Apnea of prematurity'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0554804', 'cui_str': 'Assisted breathing'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0085406', 'cui_str': 'Anisotropy'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}]",194.0,0.144528,"Infants in the caffeine group had significantly higher FA values in white matter, including the posterior limb of the internal capsule, the corpus callosum, the frontal, occipital, and parietal white matter, the cerebellum, and the cerebral peduncle, compared to infants in the placebo group.","[{'ForeName': 'Shasha', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Xiaoli', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Yanchao', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Brain Imaging, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Yuan', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Ruili', 'Initials': 'R', 'LastName': 'Zhang', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Xiaoan', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Brain Imaging, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Xiaoyang', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China; Center for Perinatal Medicine and Health, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg 40530, Sweden.'}, {'ForeName': 'Falin', 'Initials': 'F', 'LastName': 'Xu', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Changlian', 'Initials': 'C', 'LastName': 'Zhu', 'Affiliation': ""Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China; Center for Brain Repair and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg 40530, Sweden; Department of Women's and Children's Health, Karolinska Institutet, Stockholm 17177, Sweden. Electronic address: changlian.zhu@neuro.gu.se.""}]",Respiratory physiology & neurobiology,['10.1016/j.resp.2020.103495'] 2269,32679400,Determinants of healthcare use by homeless people with schizophrenia or bipolar disorder: results from the French Housing First Study.,"OBJECTIVES There is limited evidence available on the health-seeking behaviours of individuals in relation to determinants of healthcare use. This study aimed to analyse the determinants of healthcare use (including both hospital and outpatient services) among homeless people with severe mental health illnesses. STUDY DESIGN The study used data from a multicentre, randomised, controlled trial conducted in four large French cities (the French Housing First Study). METHODS Data were drawn from 671 homeless people enrolled in the study between August 2011 and April 2014. Mobile mental health outreach teams recruited homeless individuals with severe mental health illnesses who were living on the street or in emergency shelters, hospitals or prisons. Data collection was performed during face-to-face interviews. Healthcare service use included hospitalisations, mental health and regular emergency department (ED) visits and outpatient visits to healthcare facilities or physicians' offices over a 6-month follow-up period. The data were analysed with zero-inflated (ZI) two-part models. RESULTS In total, 61.1% of participants had at least one hospitalisation stay over the previous 6 months, with a mean of 25 (+/- 39.2) hospital days, and the majority (51%) had visited the ED (either for regular or mental health issues) during the same time period. The results confirmed the role of financial barriers (resources and health insurance) in seeking hospital care (P < 0.05). The main predictors for hospital use in the study population were a better social functioning score (odds ratio [OR]: 1.03; P < 0.001) and having schizophrenia (OR: 1.39; P < 0.01). Higher mental health scores (assessed by the Medical Outcomes Study 36-item Short Form Health Survey) (OR: 1.03, P < 0.01) and alcohol dependence (OR: 2.13; P < 0.01) were associated with not using ED healthcare services. Being 'absolutely homeless' predicted an increased use of the ED and a zero use of outpatient services. Inversely, no association with factors related to the homelessness trajectory was found in hospital ZI negative binomial models. CONCLUSION This study is important because a comprehensive understanding of the determinants of healthcare use enables healthcare systems to adapt and develop. The efficiency of medicosocial interventions targeting the homeless population with mental health illnesses must also be assessed. CLINICAL TRIAL NUMBER NCT01570712.",2020,"Healthcare service use included hospitalisations, mental health and regular emergency department (ED) visits and outpatient visits to healthcare facilities or physicians' offices over a 6-month follow-up period.","['homeless people with schizophrenia or bipolar disorder', 'Mobile mental health outreach teams recruited homeless individuals with severe mental health illnesses who were living on the street or in emergency shelters, hospitals or prisons', 'Data were drawn from 671 homeless people enrolled in the study between August 2011 and April 2014', 'four large French cities (the French Housing First Study', 'homeless people with severe mental health illnesses', 'homeless population with mental health illnesses']",['medicosocial interventions'],"['hospitalisations, mental health and regular emergency department (ED) visits and outpatient visits', 'alcohol dependence ', 'social functioning score', 'hospitalisation stay', 'financial barriers (resources and health insurance', 'Higher mental health scores']","[{'cui': 'C0237154', 'cui_str': 'Homeless'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0425242', 'cui_str': 'Homeless single person'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C3178959', 'cui_str': 'Evacuation Shelter'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0033168', 'cui_str': 'Prisons'}, {'cui': 'C0013113', 'cui_str': 'Drawings'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0001973', 'cui_str': 'Alcohol dependence'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0021682', 'cui_str': 'Health Insurance'}, {'cui': 'C0205250', 'cui_str': 'High'}]",,0.0642052,"Healthcare service use included hospitalisations, mental health and regular emergency department (ED) visits and outpatient visits to healthcare facilities or physicians' offices over a 6-month follow-up period.","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Loubière', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France; Department of Research and Innovation, Support Unit for Clinical Research and Economic Evaluation, Assistance Publique - Hôpitaux de Marseille, Marseille, 13385, France. Electronic address: sandrine.loubiere@univ-amu.fr.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Tinland', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France; Department of Psychiatry, Sainte-Marguerite University Hospital, Marseille, 13009, France.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Taylor', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Loundou', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France; Department of Research and Innovation, Support Unit for Clinical Research and Economic Evaluation, Assistance Publique - Hôpitaux de Marseille, Marseille, 13385, France.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Girard', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Boyer', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France; Department of Research and Innovation, Support Unit for Clinical Research and Economic Evaluation, Assistance Publique - Hôpitaux de Marseille, Marseille, 13385, France.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Auquier', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France; Department of Research and Innovation, Support Unit for Clinical Research and Economic Evaluation, Assistance Publique - Hôpitaux de Marseille, Marseille, 13385, France.'}]",Public health,['10.1016/j.puhe.2020.05.019'] 2270,32679403,"Commentary on Liu, K. et al. (2018). Handgrip exercise reduces peripherally-inserted central catheter-related venous thrombosis in patients with solid cancers: A randomized controlled trial.",,2020,,['patients with solid cancers'],['Handgrip exercise reduces peripherally-inserted central catheter-related venous thrombosis'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205208', 'cui_str': 'Solid'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0179740', 'cui_str': 'Peripherally inserted central catheter'}, {'cui': 'C0042487', 'cui_str': 'Venous thrombosis'}]",[],,0.162369,,"[{'ForeName': 'Cui', 'Initials': 'C', 'LastName': 'Wen', 'Affiliation': 'Department of Nursing, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, 530021 Nanning, Guangxi, China.'}, {'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Ying', 'Affiliation': 'Department of Nursing, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, 530021 Nanning, Guangxi, China. Electronic address: yanpingying0116@126.com.'}, {'ForeName': 'Jianpeng', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': 'Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, 530021 Nanning, Guangxi, China.'}]",International journal of nursing studies,['10.1016/j.ijnurstu.2020.103691'] 2271,32679405,A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311.,"PURPOSE Understanding the role of transoral surgery in oropharyngeal cancer (OPC) requires prospective, randomized multi-institutional data. Meticulous evaluation of surgeon expertise and surgical quality assurance (QA) will be critical to the validity of such trials. We describe a novel surgeon credentialing and QA process developed to support the ECOG-ACRIN Cancer Research Group E3311 (E3311) and report outcomes related to QA. PATIENTS AND METHODS E3311 was a phase II randomized clinical trial of transoral surgery followed by low- or standard-dose, risk-adjusted post-operative therapy with stage III-IVa (AJCC 7th edition) HPV-associated OPC. In order to be credentialed to accrue to this trial, surgeons were required to demonstrate active hospital credentials and technique-specific surgical expertise with ≥20 cases of transoral resection for OPC. In addition, 10 paired operative and surgical pathology reports from the preceding 24 months were reviewed by an expert panel. Ongoing QA required <10% rate of positive margins, low oropharyngeal bleeding rates, and accrual of at least one patient per 12 months. Otherwise surgeons were placed on hold and not permitted to accrue until re-credentialed using a new series of transoral resections. RESULTS 120 surgeons trained in transoral minimally invasive surgery applied for credentialing for E3311 and after peer-review, 87 (73%) were approved from 59 centers. During QA on E3311, positive final pathologic margins were reported in 19 (3.8%) patients. Grade III/IV and grade V oropharyngeal bleeding was reported in 29 (5.9%) and 1 (0.2%) of patients. CONCLUSIONS We provide proof of concept that a comprehensive credentialing process can support multicenter transoral head and neck surgical oncology trials, with low incidence of positive margins and *grade III/V oropharyngeal bleeding.",2020,"RESULTS 120 surgeons trained in transoral minimally invasive surgery applied for credentialing for E3311 and after peer-review, 87 (73%) were approved from 59 centers.","['120 surgeons trained in transoral minimally invasive surgery applied for credentialing for E3311 and after peer-review, 87 (73%) were approved from 59 centers', 'oropharyngeal cancer (OPC']","['surgeon expertise and surgical quality assurance (QA', 'transoral surgery', 'transoral surgery followed by low- or standard-dose, risk-adjusted post-operative therapy with stage III-IVa (AJCC 7th edition) HPV-associated OPC']","['positive final pathologic margins', 'positive margins, low oropharyngeal bleeding rates', 'Grade III/IV and grade V oropharyngeal bleeding']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0442366', 'cui_str': 'Transoral approach'}, {'cui': 'C0282624', 'cui_str': 'Procedures, Minimally Invasive Surgical'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0010298', 'cui_str': 'Credentialing'}, {'cui': 'C0030768', 'cui_str': 'Peer review'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0153382', 'cui_str': 'Malignant tumor of oropharynx'}]","[{'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0442366', 'cui_str': 'Transoral approach'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0268575', 'cui_str': 'Isovaleryl-CoA dehydrogenase deficiency'}, {'cui': 'C0441915', 'cui_str': 'AJCC'}, {'cui': 'C0441792', 'cui_str': 'Editions'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0153382', 'cui_str': 'Malignant tumor of oropharynx'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C1709603', 'cui_str': 'Positive Surgical Margins'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0521367', 'cui_str': 'Oropharyngeal structure'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0205617', 'cui_str': 'Poorly differentiated'}, {'cui': 'C0441800', 'cui_str': 'Grade'}]",120.0,0.0606723,"RESULTS 120 surgeons trained in transoral minimally invasive surgery applied for credentialing for E3311 and after peer-review, 87 (73%) were approved from 59 centers.","[{'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Ferris', 'Affiliation': 'UPMC Hillman Cancer Center, Pittsburgh, PA, United States. Electronic address: Ferrisrl@upmc.edu.'}, {'ForeName': 'Yael', 'Initials': 'Y', 'LastName': 'Flamand', 'Affiliation': 'Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, United States.'}, {'ForeName': 'F Christopher', 'Initials': 'FC', 'LastName': 'Holsinger', 'Affiliation': 'Stanford University, Palo Alto, CA, United States.'}, {'ForeName': 'Gregory S', 'Initials': 'GS', 'LastName': 'Weinstein', 'Affiliation': 'University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'Quon', 'Affiliation': 'Johns Hopkins University, Baltimore, MD, United States.'}, {'ForeName': 'Ranee', 'Initials': 'R', 'LastName': 'Mehra', 'Affiliation': 'University of Maryland, Baltimore, MD, United States.'}, {'ForeName': 'Joaquin J', 'Initials': 'JJ', 'LastName': 'Garcia', 'Affiliation': 'Mayo Clinic, Rochester, MN, United States.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Hinni', 'Affiliation': 'Mayo Clinic in Arizona, Phoenix, AZ, United States.'}, {'ForeName': 'Neil D', 'Initials': 'ND', 'LastName': 'Gross', 'Affiliation': 'The University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States.'}, {'ForeName': 'Erich M', 'Initials': 'EM', 'LastName': 'Sturgis', 'Affiliation': 'The University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States.'}, {'ForeName': 'Umamaheswar', 'Initials': 'U', 'LastName': 'Duvvuri', 'Affiliation': 'UPMC Hillman Cancer Center, Pittsburgh, PA, United States.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Méndez', 'Affiliation': 'University of Washington, Seattle, WA, United States.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Ridge', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, PA, United States.'}, {'ForeName': 'J Scott', 'Initials': 'JS', 'LastName': 'Magnuson', 'Affiliation': 'Florida Hospital Orlando, Celebration, FL, United States.'}, {'ForeName': 'Kerry A', 'Initials': 'KA', 'LastName': 'Higgins', 'Affiliation': 'ECOG-ACRIN Cancer Research Group, Boston, MA, United States.'}, {'ForeName': 'Mihir R', 'Initials': 'MR', 'LastName': 'Patel', 'Affiliation': 'Winship Cancer Institute at Emory University, Atlanta, GA, United States.'}, {'ForeName': 'Russel B', 'Initials': 'RB', 'LastName': 'Smith', 'Affiliation': 'University of Nebraska, Omaha, NE, United States.'}, {'ForeName': 'Daniel W', 'Initials': 'DW', 'LastName': 'Karakla', 'Affiliation': 'Sentara Norfolk General Hospital, Norfolk, VA, United States.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Kupferman', 'Affiliation': 'The University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Malone', 'Affiliation': 'UPMC Pinnacle Cancer Center, Harrisburg, PA, United States.'}, {'ForeName': 'Benjamin L', 'Initials': 'BL', 'LastName': 'Judson', 'Affiliation': 'Yale School of Medicine and Yale Cancer Center, New Haven, CT, United States.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Richmon', 'Affiliation': 'Massachusetts Eye and Ear, Harvard University, Boston, MA, United States.'}, {'ForeName': 'Jay O', 'Initials': 'JO', 'LastName': 'Boyle', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, United States.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Bayon', 'Affiliation': 'University of Iowa, Iowa City, IA, United States.'}, {'ForeName': 'Bert W', 'Initials': 'BW', 'LastName': ""O'Malley"", 'Affiliation': 'University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Enver', 'Initials': 'E', 'LastName': 'Ozer', 'Affiliation': 'The Ohio State University, Columbus, OH, United States.'}, {'ForeName': 'Giovana R', 'Initials': 'GR', 'LastName': 'Thomas', 'Affiliation': 'University of Miami Leonard Miller School of Medicine, Miami, FL, United States.'}, {'ForeName': 'Wayne M', 'Initials': 'WM', 'LastName': 'Koch', 'Affiliation': 'Johns Hopkins University, Baltimore, MD, United States.'}, {'ForeName': 'R Bryan', 'Initials': 'RB', 'LastName': 'Bell', 'Affiliation': 'Providence Cancer Institute, Portland, OR, United States.'}, {'ForeName': 'Nabil F', 'Initials': 'NF', 'LastName': 'Saba', 'Affiliation': 'Winship Cancer Institute at Emory University, Atlanta, GA, United States.'}, {'ForeName': 'Shuli', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, United States.'}, {'ForeName': 'Elin R', 'Initials': 'ER', 'LastName': 'Sigurdson', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, PA, United States.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Burtness', 'Affiliation': 'Yale School of Medicine and Yale Cancer Center, New Haven, CT, United States.'}]",Oral oncology,['10.1016/j.oraloncology.2020.104797'] 2272,32353079,"Weekly, seasonal and holiday body weight fluctuation patterns among individuals engaged in a European multi-centre behavioural weight loss maintenance intervention.","BACKGROUND Technological advances in remote monitoring offer new opportunities to quantify body weight patterns in free-living populations. This paper describes body weight fluctuation patterns in response to weekly, holiday (Christmas) and seasonal time periods in a large group of individuals engaged in a weight loss maintenance intervention. METHODS Data was collected as part The NoHoW Project which was a pan-European weight loss maintenance trial. Three eligible groups were defined for weekly, holiday and seasonal analyses, resulting in inclusion of 1,421, 1,062 and 1,242 participants, respectively. Relative weight patterns were modelled on a time series following removal of trends and grouped by gender, country, BMI and age. RESULTS Within-week fluctuations of 0.35% were observed, characterised by weekend weight gain and weekday reduction which differed between all groups. Over the Christmas period, weight increased by a mean 1.35% and was not fully compensated for in following months, with some differences between countries observed. Seasonal patterns were primarily characterised by the effect of Christmas weight gain and generally not different between groups. CONCLUSIONS This evidence may improve current understanding of regular body weight fluctuation patterns and help target future weight management interventions towards periods, and in groups, where weight gain is anticipated.",2020,"Over the Christmas period, weight increased by a mean 1.35% and was not fully compensated for in following months, with some differences between countries observed.","['Three eligible groups were defined for weekly, holiday and seasonal analyses, resulting in inclusion of 1,421, 1,062 and 1,242 participants, respectively', 'individuals engaged in a European multi-centre behavioural weight loss maintenance intervention', 'large group of individuals engaged in a weight loss maintenance intervention']",[],"['weekend weight gain and weekday reduction', 'Relative weight patterns', 'Christmas weight gain', 'weight']","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0019843', 'cui_str': 'Holidays'}, {'cui': 'C0439601', 'cui_str': 'Seasonal course'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0549177', 'cui_str': 'Large'}]",[],"[{'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}]",,0.025608,"Over the Christmas period, weight increased by a mean 1.35% and was not fully compensated for in following months, with some differences between countries observed.","[{'ForeName': 'Jake', 'Initials': 'J', 'LastName': 'Turicchi', 'Affiliation': 'Appetite Control and Energy Balance Group, School of Psychology, University of Leeds, Leeds, United Kingdom.'}, {'ForeName': 'Ruairi', 'Initials': 'R', 'LastName': ""O'Driscoll"", 'Affiliation': 'Appetite Control and Energy Balance Group, School of Psychology, University of Leeds, Leeds, United Kingdom.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Horgan', 'Affiliation': 'Biomathematics & Statistics Scotland, Aberdeen, United Kingdom.'}, {'ForeName': 'Cristiana', 'Initials': 'C', 'LastName': 'Duarte', 'Affiliation': 'Appetite Control and Energy Balance Group, School of Psychology, University of Leeds, Leeds, United Kingdom.'}, {'ForeName': 'Antonio L', 'Initials': 'AL', 'LastName': 'Palmeira', 'Affiliation': 'Faculdade de Motricidade Humana, Universidade de Lisboa, Lisbon, Portugal.'}, {'ForeName': 'Sofus C', 'Initials': 'SC', 'LastName': 'Larsen', 'Affiliation': 'Research Unit for Dietary Studies, The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region, Copenhagen, Denmark.'}, {'ForeName': 'Berit L', 'Initials': 'BL', 'LastName': 'Heitmann', 'Affiliation': 'Research Unit for Dietary Studies, The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region, Copenhagen, Denmark.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Stubbs', 'Affiliation': 'Appetite Control and Energy Balance Group, School of Psychology, University of Leeds, Leeds, United Kingdom.'}]",PloS one,['10.1371/journal.pone.0232152'] 2273,32475251,Total hip arthroplasty versus hemiarthroplasty for intracapsular hip fracture.,,2020,,['intracapsular hip fracture'],['Total hip arthroplasty versus hemiarthroplasty'],[],"[{'cui': 'C0019557', 'cui_str': 'Hip fracture'}]","[{'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0744743', 'cui_str': 'Hemi-Arthroplasty'}]",[],,0.0117921,,"[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Judge', 'Affiliation': 'Musculoskeletal Research Unit, Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Metcalfe', 'Affiliation': 'Oxford Trauma and Emergency Care, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Whitehouse', 'Affiliation': 'Biomedical Research Centre, National Institute for Health Research, University of Bristol, Bristol, UK.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Parsons', 'Affiliation': 'Statistics and Epidemiology, Warwick Medical School, University of Warwich, Warwick, UK.'}, {'ForeName': 'Matt', 'Initials': 'M', 'LastName': 'Costa', 'Affiliation': 'Oxford Trauma and Emergency Care, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}]",The bone & joint journal,['10.1302/0301-620X.102B6.BJJ-2020-0101.R1'] 2274,31708410,"Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses.","BACKGROUND Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9). OBJECTIVE Changes in PCSK9, alirocumab, and low-density lipoprotein cholesterol (LDL-C) levels were assessed after treatment with alirocumab at doses of 75 or 150 mg every 2 weeks (Q2W). METHODS Data were analyzed from 4 phase 3 trials (MONO; COMBO II; FH I; LONG TERM); all but MONO enrolled patients on statins. Three trials evaluated alirocumab 75 mg Q2W, with possible dose increase to 150 mg Q2W at week 12 based on week 8 LDL-C; LONG TERM studied alirocumab 150 mg Q2W. RESULTS Patients on background statin therapy had higher mean baseline free PCSK9 concentrations vs patients not on statin. After alirocumab administration, increased alirocumab concentrations were associated with dramatic reductions in circulating free PCSK9, resulting in significant LDL-C reductions and a corresponding increase in inactive PCSK9:alirocumab complex. Alirocumab dose increase was associated with a further lowering of PCSK9 and LDL-C. Patients with higher baseline LDL-C levels (>160 mg/dL) were more likely to have their dose increased. LDL-C reductions with alirocumab were consistent between patients with baseline PCSK9 levels above or below the median when the dose increase strategy was used. When started as alirocumab 150 mg Q2W, patients with PCSK9 levels above vs below the median had a greater LDL-C reduction. CONCLUSIONS Alirocumab-induced changes in PCSK9 and LDL-C levels were consistent with the known physiologic relationship between PCSK9, LDL receptor, and LDL-C levels, as well as statin-induced increases in PCSK9 production.",2019,LDL-C reductions with alirocumab were consistent between patients with baseline PCSK9 levels above or below the median when the dose increase strategy was used.,[],"['alirocumab', 'alirocumab 150\xa0mg Q2W', 'Alirocumab', 'alirocumab 75\xa0mg Q2W']","['alirocumab concentrations', 'PCSK9, alirocumab, and low-density lipoprotein cholesterol (LDL-C) levels', 'inactive PCSK9:alirocumab complex', 'alirocumab, PCSK9, and LDL-C levels', 'mean baseline free PCSK9 concentrations', 'PCSK9 and LDL-C levels', 'PCSK9, LDL receptor, and LDL-C levels']",[],"[{'cui': 'C3491162', 'cui_str': 'alirocumab'}, {'cui': 'C4321486', 'cui_str': '150'}]","[{'cui': 'C3491162', 'cui_str': 'alirocumab'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1174937', 'cui_str': 'PCSK9 protein, human'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C1100660', 'cui_str': 'Proprotein Convertase'}, {'cui': 'C0038601', 'cui_str': 'Subtilisins'}, {'cui': 'C0165249', 'cui_str': 'Kexin'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0034821', 'cui_str': 'LDL receptor'}]",,0.0655535,LDL-C reductions with alirocumab were consistent between patients with baseline PCSK9 levels above or below the median when the dose increase strategy was used.,"[{'ForeName': 'Jennifer G', 'Initials': 'JG', 'LastName': 'Robinson', 'Affiliation': 'University of Iowa, Iowa City, IA, USA. Electronic address: jennifer-g-robinson@uiowa.edu.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Farnier', 'Affiliation': 'Lipid Clinic, Point Médical and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France.'}, {'ForeName': 'John J P', 'Initials': 'JJP', 'LastName': 'Kastelein', 'Affiliation': 'Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.'}, {'ForeName': 'Eli M', 'Initials': 'EM', 'LastName': 'Roth', 'Affiliation': 'The Sterling Research Group, Cincinnati, OH, USA.'}, {'ForeName': 'Marja-Riitta', 'Initials': 'MR', 'LastName': 'Taskinen', 'Affiliation': 'Research Program Unit, Clinical and Molecular Metabolism, University of Helsinki, Finland.'}, {'ForeName': 'Helen M', 'Initials': 'HM', 'LastName': 'Colhoun', 'Affiliation': 'University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Aurelie', 'Initials': 'A', 'LastName': 'Brunet', 'Affiliation': 'Sanofi, Clinical Development, R&D, Montpellier, France.'}, {'ForeName': 'A Thomas', 'Initials': 'AT', 'LastName': 'DiCioccio', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Lecorps', 'Affiliation': 'Sanofi, Chilly-Mazarin, France.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Pordy', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Marie T', 'Initials': 'MT', 'LastName': 'Baccara-Dinet', 'Affiliation': 'Sanofi, Clinical Development, R&D, Montpellier, France.'}, {'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Cannon', 'Affiliation': 'Harvard Clinical Research Institute, Boston, MA, USA.'}]",Journal of clinical lipidology,['10.1016/j.jacl.2019.10.004'] 2275,31822285,Concordances and differences between a unidimensional and multidimensional assessment of frailty: a cross-sectional study.,"BACKGROUND Many instruments to identify frail older people have been developed. One of the consequences is that the prevalence rates of frailty vary widely dependent on the instrument selected. The aims of this study were 1) to examine the concordances and differences between a unidimensional and multidimensional assessment of frailty, 2) to assess to what extent the characteristics of a 'frail sample' differ depending on the selected frailty measurement because 'being frail' is used in many studies as an inclusion criterion. METHOD A cross-sectional study was conducted among 196 community-dwelling older adults (≥60 years), which were selected from the census records. Unidimensional frailty was operationalized according to the Fried Phenotype (FP) and multidimensional frailty was measured with the Comprehensive Frailty Assessment Instrument (CFAI). The concordances and differences were examined by prevalence, correlations, observed agreement and Kappa values. Differences between sample characteristics (e.g., age, physical activity, life satisfaction) were investigated with ANOVA and Kruskall-Wallis test. RESULTS The mean age was 72.74 (SD 8.04) and 48.98% was male. According to the FP 23.59% was not-frail, 56.92% pre-frail and 19.49% frail. According to the CFAI, 44.33% was no-to-low frail, 37.63% was mild frail and 18.04% was high frail. The correlation between FP and the CFAI was r = 0.46 and the observed agreement was 52.85%. The Kappa value was κ = 0.35 (quadratic κ = 0.45). In total, 11.92% of the participants were frail according to both measurements, 7.77% was solely frail according to the FP and 6.21% was solely frail according to the CFAI. The 'frail sample respondents' according to the FP had higher levels of life satisfaction and net income, but performed less physical activities in comparison to high frail people according to the CFAI. CONCLUSION The present study shows that the FP and CFAI partly measure the same 'frailty-construct', although differences were found for instance in the prevalence of frailty and the composition of the 'frail participants'. Since 'being frail' is an inclusion criterion in many studies, researchers must be aware that the choice of the frailty measurement has an impact on both the estimates of frailty prevalence and the characteristics of the selected sample.",2019,"The 'frail sample respondents' according to the FP had higher levels of life satisfaction and net income, but performed less physical activities in comparison to high frail people according to the CFAI. ","['participants were frail according to both measurements, 7.77% was solely frail according to the FP and 6.21% was solely frail according to the CFAI', 'frail older people', 'The mean age was 72.74 (SD 8.04) and 48.98% was male', '196 community-dwelling older adults (≥60\u2009years), which were selected from the census records']",[],['Fried Phenotype (FP) and multidimensional frailty'],"[{'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C1510451', 'cui_str': 'French fries'}, {'cui': 'C0031437', 'cui_str': 'Phenotype'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4517625', 'cui_str': '196'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0007663', 'cui_str': 'Census'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}]",[],"[{'cui': 'C1510451', 'cui_str': 'French fries'}, {'cui': 'C0031437', 'cui_str': 'Phenotype'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}]",196.0,0.0293039,"The 'frail sample respondents' according to the FP had higher levels of life satisfaction and net income, but performed less physical activities in comparison to high frail people according to the CFAI. ","[{'ForeName': 'Michael C J', 'Initials': 'MCJ', 'LastName': 'Van der Elst', 'Affiliation': 'Department of Public Health and Primary Care, KU Leuven, Kapucijnenvoer 33 bus 7001, B-3000, Leuven, Belgium. michael.vanderelst@kuleuven.be.'}, {'ForeName': 'Birgitte', 'Initials': 'B', 'LastName': 'Schoenmakers', 'Affiliation': 'Department of Public Health and Primary Care, KU Leuven, Kapucijnenvoer 33 bus 7001, B-3000, Leuven, Belgium.'}, {'ForeName': 'Linda P M', 'Initials': 'LPM', 'LastName': 'Op Het Veld', 'Affiliation': 'Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Ellen E', 'Initials': 'EE', 'LastName': 'De Roeck', 'Affiliation': 'Department of Clinical and Lifespan Psychology, Vrije Universiteit Brussel, Brussels, Belgium.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Van der Vorst', 'Affiliation': 'Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Gertrudis I J M', 'Initials': 'GIJM', 'LastName': 'Kempen', 'Affiliation': 'Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Nico', 'Initials': 'N', 'LastName': 'De Witte', 'Affiliation': 'Faculty of Psychology and Educational Sciences, Vrije Universiteit Brussel, Brussels, Belgium.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'De Lepeleire', 'Affiliation': 'Department of Public Health and Primary Care, KU Leuven, Kapucijnenvoer 33 bus 7001, B-3000, Leuven, Belgium.'}, {'ForeName': 'Jos M G A', 'Initials': 'JMGA', 'LastName': 'Schols', 'Affiliation': 'Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMC geriatrics,['10.1186/s12877-019-1369-7'] 2276,31823428,Astragaloside IV reverses simvastatin-induced skeletal muscle injury by activating the AMPK-PGC-1α signalling pathway.,"In this study, we investigated the effect of astragaloside IV on skeletal muscle energy metabolism disorder caused by statins and explored the possible mechanisms. High-fat diet-fed apolipoprotein E knockout (ApoE -/- ) mice performed aerobic exercise and were administered simvastatin, simvastatin + trimetazidine, or simvastatin + astragaloside IV by gavage. At the end of treatment, exercise performance was assessed by the hanging grid test, forelimb grip test, and running tolerance test. Moreover, plasma lipid and creatine kinase concentrations were measured. After sacrifice, the gastrocnemius muscle was used to assess muscle morphology, and energy metabolism was evaluated by determining the concentration of lactic acid and the storage capacity of adenosine triphosphate and glycogen. Mitochondrial function was assessed by measuring mitochondrial complex III and citrate synthase activity and membrane potential. In addition, oxidative stress was assessed by determining the level of hydrogen peroxide. Finally, using western blotting and reverse transcription polymerase chain reaction, we explored the mechanism of astragaloside IV in alleviating simvastatin-induced muscle injury. Our results demonstrated that astragaloside IV reversed simvastatin-induced muscle injury without affecting the lipid-lowering effect of simvastatin. Moreover, astragaloside IV promoted the phosphorylation of AMPK and activated PGC-1α, which upregulated the expression of NRF1 to enhance energy metabolism and inhibit skeletal muscle cell apoptosis.",2020,"Moreover, astragaloside IV promoted the phosphorylation of AMPK and activated PGC-1α, which upregulated the expression of NRF1 to enhance energy metabolism and inhibit skeletal muscle cell apoptosis.",[],"['Astragaloside IV reverses simvastatin', 'simvastatin', 'astragaloside IV', 'High-fat diet-fed apolipoprotein E knockout ', 'aerobic exercise and were administered simvastatin, simvastatin + trimetazidine, or simvastatin + astragaloside IV by gavage']","['oxidative stress', 'plasma lipid and creatine kinase concentrations', 'mitochondrial complex III and citrate synthase activity and membrane potential', 'Mitochondrial function', 'level of hydrogen peroxide', 'exercise performance']",[],"[{'cui': 'C0378018', 'cui_str': 'astragaloside IV'}, {'cui': 'C0074554', 'cui_str': 'Simvastatin'}, {'cui': 'C0521974', 'cui_str': 'High fat diet'}, {'cui': 'C0342895', 'cui_str': 'Fish-eye disease'}, {'cui': 'C0003595', 'cui_str': 'Apolipoprotein E'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0041037', 'cui_str': 'Trimetazidine'}, {'cui': 'C0041281', 'cui_str': 'Tube feeding of patient'}]","[{'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C1278073', 'cui_str': 'Plasma lipid measurement'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C1176474', 'cui_str': 'Ubiquinol-cytochrome-c reductase'}, {'cui': 'C0008855', 'cui_str': 'Citrate(si)-synthase'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0025251', 'cui_str': 'Transmembrane Potentials'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0639506,"Moreover, astragaloside IV promoted the phosphorylation of AMPK and activated PGC-1α, which upregulated the expression of NRF1 to enhance energy metabolism and inhibit skeletal muscle cell apoptosis.","[{'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Jiang', 'Affiliation': 'Department of Pharmacology of Chinese Materia Medica, School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China.'}, {'ForeName': 'Yu-Jiao', 'Initials': 'YJ', 'LastName': 'Yang', 'Affiliation': 'Department of Pharmacology of Chinese Materia Medica, School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China.'}, {'ForeName': 'Wen-Zhen', 'Initials': 'WZ', 'LastName': 'Dang', 'Affiliation': 'Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.'}, {'ForeName': 'Gui-Ze', 'Initials': 'GZ', 'LastName': 'Feng', 'Affiliation': 'Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.'}, {'ForeName': 'Xiao-Chen', 'Initials': 'XC', 'LastName': 'Yu', 'Affiliation': 'Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.'}, {'ForeName': 'Xiao-Yan', 'Initials': 'XY', 'LastName': 'Shen', 'Affiliation': 'Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.'}, {'ForeName': 'Xu-Guang', 'Initials': 'XG', 'LastName': 'Hu', 'Affiliation': 'Department of Pharmacology of Chinese Materia Medica, School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China.'}]",Phytotherapy research : PTR,['10.1002/ptr.6593'] 2277,32690738,Risk assessment and antibiotic prescribing decisions in children presenting to UK primary care with cough: a vignette study.,"OBJECTIVES The validated 'STARWAVe' (Short illness duration, Temperature, Age, Recession, Wheeze, Asthma, Vomiting) clinical prediction rule (CPR) uses seven variables to guide risk assessment and antimicrobial stewardship in children presenting with cough. We aimed to compare general practitioners' (GPs) risk assessments and prescribing decisions to those of STARWAVe and assess the influence of the CPR's clinical variables. SETTING Primary care. PARTICIPANTS 252 GPs, currently practising in the UK. DESIGN GPs were randomly assigned to view four (of a possible eight) clinical vignettes online. Each vignette depicted a child presenting with cough, who was described in terms of the seven STARWAVe variables. Systematically, we manipulated patient age (20 months vs 5 years), illness duration (3 vs 6 days), vomiting (present vs absent) and wheeze (present vs absent), holding the remaining STARWAVe variables constant. OUTCOME MEASURES Per vignette, GPs assessed risk of hospitalisation and indicated whether they would prescribe antibiotics or not. RESULTS GPs overestimated risk of hospitalisation in 9% of vignette presentations (88/1008) and underestimated it in 46% (459/1008). Despite underestimating risk, they overprescribed: 78% of prescriptions were unnecessary relative to GPs' own risk assessments (121/156), while 83% were unnecessary relative to STARWAVe risk assessments (130/156). All four of the manipulated variables influenced risk assessments, but only three influenced prescribing decisions: a shorter illness duration reduced prescribing odds (OR 0.14, 95% CI 0.08 to 0.27, p<0.001), while vomiting and wheeze increased them (OR vomit 2.17, 95% CI 1.32 to 3.57, p=0.002; OR wheeze 8.98, 95% CI 4.99 to 16.15, p<0.001). CONCLUSIONS Relative to STARWAVe, GPs underestimated risk of hospitalisation, overprescribed and appeared to misinterpret illness duration (prescribing for longer rather than shorter illnesses). It is important to ascertain discrepancies between CPRs and current clinical practice. This has implications for the integration of CPRs into the electronic health record and the provision of intelligible explanations to decision-makers.",2020,"All four of the manipulated variables influenced risk assessments, but only three influenced prescribing decisions: a shorter illness duration reduced prescribing odds (OR 0.14, 95% CI 0.08 to 0.27, p<0.001), while vomiting and wheeze increased them (OR vomit 2.17, 95% CI 1.32 to 3.57, p=0.002; OR wheeze 8.98, 95% CI 4.99 to 16.15, p<0.001). ","['children presenting with cough', '252 GPs, currently practising in the UK', 'children presenting to UK primary care with cough']",[],"['illness duration', 'vomiting', 'risk of hospitalisation']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}]",[],"[{'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",252.0,0.0689741,"All four of the manipulated variables influenced risk assessments, but only three influenced prescribing decisions: a shorter illness duration reduced prescribing odds (OR 0.14, 95% CI 0.08 to 0.27, p<0.001), while vomiting and wheeze increased them (OR vomit 2.17, 95% CI 1.32 to 3.57, p=0.002; OR wheeze 8.98, 95% CI 4.99 to 16.15, p<0.001). ","[{'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'Nurek', 'Affiliation': 'Surgery and Cancer, Imperial College London, London, UK m.nurek@imperial.ac.uk.'}, {'ForeName': 'Brendan C', 'Initials': 'BC', 'LastName': 'Delaney', 'Affiliation': 'Surgery and Cancer, Imperial College London, London, UK.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Kostopoulou', 'Affiliation': 'Surgery and Cancer, Imperial College London, London, UK.'}]",BMJ open,['10.1136/bmjopen-2019-035761'] 2278,32690739,Study protocol for the POPART study-Prophylactic Oropharyngeal surfactant for Preterm infants: A Randomised Trial.,"INTRODUCTION Many preterm infants develop respiratory distress syndrome (RDS), a condition characterised by a relative lack of surfactant. Endotracheal surfactant therapy revolutionised the care of preterm infants in the 1990s. However, supporting newborns with RDS with continuous positive airway pressure (CPAP) and reserving endotracheal surfactant for those who develop respiratory failure despite CPAP yield better results than intubating all infants for surfactant. Half of preterm infants born before 29 weeks gestation initially managed with CPAP are intubated for surfactant. Intubation is difficult to learn and associated with adverse effects. Surfactant administration into the oropharynx has been reported in preterm animals and humans and may be effective. We wished to determine whether giving oropharyngeal surfactant at birth reduces the rate of endotracheal intubation for respiratory failure in preterm infants within 120 hours of birth. METHODS AND ANALYSIS Prophylactic Oropharyngeal surfactant for Preterm infants: A Randomised Trial (POPART, Eudract No. 2016-004198-41) is an investigator-led, unblinded, multicentre, randomised, parallel group, controlled trial. Infants are eligible if born at a participating centre before 29 weeks gestational age (GA) and there is a plan to offer intensive care. Infants are excluded if they have major congenital anomalies. Infants are randomised at birth to treatment with oropharyngeal surfactant (120 mg vial <26 weeks GA stratum; 240 mg vial 26-28 +6 weeks GA stratum) in addition to CPAP or CPAP alone. The primary outcome is intubation within 120 hours of birth, for bradycardia and/or apnoea despite respiratory support in the delivery room or respiratory failure in the intensive care unit. Secondary outcomes include incidence of mechanical ventilation, endotracheal surfactant use, chronic lung disease and death before hospital discharge. ETHICS AND DISSEMINATION Approval for the study has been granted by the Research Ethics Committees at the National Maternity Hospital, Dublin, Ireland (EC31.2016) and at each participating site. The trial is being conducted at nine centres in six European countries. The study results will be submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER 2016-004198-41; Pre-results.",2020,"We wished to determine whether giving oropharyngeal surfactant at birth reduces the rate of endotracheal intubation for respiratory failure in preterm infants within 120 hours of birth. ","['Many preterm infants develop respiratory distress syndrome (RDS', 'newborns with RDS with continuous positive airway pressure (CPAP', 'Infants are eligible if born at a participating centre before 29 weeks gestational age (GA) and there is a plan to offer intensive care', 'nine centres in six European countries', 'preterm infants in the 1990s', 'Preterm infants', 'preterm infants born before 29 weeks gestation initially managed with', 'preterm infants within 120\u2009hours of birth']","['Endotracheal surfactant therapy', 'oropharyngeal surfactant', 'CPAP', 'Prophylactic Oropharyngeal surfactant', 'CPAP or CPAP alone']","['intubation within 120\u2009hours of birth, for bradycardia and/or apnoea despite respiratory support in the delivery room or respiratory failure in the intensive care unit', 'incidence of mechanical ventilation, endotracheal surfactant use, chronic lung disease and death before hospital discharge']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0035220', 'cui_str': 'Respiratory distress syndrome in the newborn'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0454713', 'cui_str': 'European country'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0005615', 'cui_str': 'Birth'}]","[{'cui': 'C1522653', 'cui_str': 'Intratracheal route'}, {'cui': 'C0034085', 'cui_str': 'Lung surfactant'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0521367', 'cui_str': 'Oropharyngeal structure'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0009653', 'cui_str': 'Condom'}]","[{'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0011212', 'cui_str': 'Delivery suite'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C1522653', 'cui_str': 'Intratracheal route'}, {'cui': 'C0034085', 'cui_str': 'Lung surfactant'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0746102', 'cui_str': 'Chronic lung disease'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}]",,0.44978,"We wished to determine whether giving oropharyngeal surfactant at birth reduces the rate of endotracheal intubation for respiratory failure in preterm infants within 120 hours of birth. ","[{'ForeName': 'Madeleine Claire', 'Initials': 'MC', 'LastName': 'Murphy', 'Affiliation': 'Department of Neonatology, National Maternity Hospital, Dublin, Ireland.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Galligan', 'Affiliation': 'UCD Clinical Research Centre, School of Medicine, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Molloy', 'Affiliation': 'UCD Clinical Research Centre, School of Medicine, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Rabia', 'Initials': 'R', 'LastName': 'Hussain', 'Affiliation': 'UCD Clinical Research Centre, School of Medicine, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Doran', 'Affiliation': 'UCD Clinical Research Centre, School of Medicine, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Colm', 'Initials': 'C', 'LastName': ""O'Donnell"", 'Affiliation': 'Department of Neonatology, National Maternity Hospital, Dublin, Ireland codonnell@nmh.ie.'}]",BMJ open,['10.1136/bmjopen-2019-035994'] 2279,32690743,Wool-derived keratin dressings versus usual care dressings for treatment of slow healing venous leg ulceration: a randomised controlled trial (Keratin4VLU).,"OBJECTIVE To determine the effect of a keratin dressing for treating slow-to-heal venous leg ulcers (VLU) on VLU healing. DESIGN Pragmatic parallel group randomised controlled trial. SETTING Community-dwelling participants. PARTICIPANTS People aged 18 or more years with VLU (either present for more than 26 weeks or ulcer area larger than 5 cm 2 or both). INTERVENTION Wool-derived keratin dressing or usual care formulary of non-medicated dressings, on a background treatment with compression. PRIMARY AND SECONDARY OUTCOME MEASURES Healing at 24 weeks based on blinded assessment of ulcer photographs. Other outcomes included time to complete healing, change in ulcer area to 24 weeks, change in health-related quality of life and incidence of adverse events. RESULTS We screened 1068 patients with VLU and randomised 143 participants (51.1% of target recruitment), 71 to the keratin dressing group and 72 to the usual care group.The mean age was 66.1 years (SD 15.9) and 53 participants (37.1%) were women. There were no significant differences between the groups on the primary outcome (risk difference -6.4%, 95% CI -22.5% to 9.7%), change in ulcer area (-1.9 cm 2 , 95% CI -16.5 to 12.8 cm 2 ), time to complete healing (HR 0.80, 95% CI 0.52 to 1.23) or the incidence of adverse events (incidence rate ratio 1.19, 95% CI 0.89 to 1.59) in the intention-to-treat analyses. However, the direction of effect on the primary outcome was reversed in a per protocol analysis specified a priori (risk difference 6.2%, 95% CI -12.4% to 24.9%). CONCLUSION The effect of adding a keratin dressing to the treatment regimen for prognostically slow-to-heal VLU remains unclear. TRIAL REGISTRATION NUMBER NCT02896725.",2020,"There were no significant differences between the groups on the primary outcome (risk difference -6.4%, 95% CI -22.5% to 9.7%), change in ulcer area (-1.9 cm 2 , 95% CI -16.5 to 12.8 cm 2 ), time to complete healing (HR 0.80, 95% CI 0.52 to 1.23) or the incidence of adverse events (incidence rate ratio 1.19, 95% CI 0.89 to 1.59) in the intention-to-treat analyses.","['slow healing venous leg ulceration', 'People aged 18 or more years with VLU (either present for more than 26 weeks or ulcer area larger than 5 cm 2 or both', 'The mean age was 66.1 years (SD 15.9) and 53 participants (37.1%) were women', 'Community-dwelling participants', '1068 patients with VLU and randomised 143 participants (51.1% of target recruitment), 71 to the keratin dressing group and 72 to the usual care group']","['Wool-derived keratin dressings versus usual care dressings', 'Wool-derived keratin dressing', 'keratin dressing']","['change in ulcer area', 'time to complete healing, change in ulcer area to 24 weeks, change in health-related quality of life and incidence of adverse events', 'incidence of adverse events', 'time to complete healing']","[{'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0042344', 'cui_str': 'Stasis ulcer'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4045975', 'cui_str': 'Community Dwelling'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517573', 'cui_str': '143'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C3876144', 'cui_str': 'Keratin dressing'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0043220', 'cui_str': 'Wool'}, {'cui': 'C3876144', 'cui_str': 'Keratin dressing'}, {'cui': 'C0013119', 'cui_str': 'Medical dressing'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",1068.0,0.218728,"There were no significant differences between the groups on the primary outcome (risk difference -6.4%, 95% CI -22.5% to 9.7%), change in ulcer area (-1.9 cm 2 , 95% CI -16.5 to 12.8 cm 2 ), time to complete healing (HR 0.80, 95% CI 0.52 to 1.23) or the incidence of adverse events (incidence rate ratio 1.19, 95% CI 0.89 to 1.59) in the intention-to-treat analyses.","[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Jull', 'Affiliation': 'School of Nursing, University of Auckland, Auckland, Auckland, New Zealand a.jull@auckland.ac.nz.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Wadham', 'Affiliation': 'National Institute for Health Innovation, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Bullen', 'Affiliation': 'National Institute for Health Innovation, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Varsha', 'Initials': 'V', 'LastName': 'Parag', 'Affiliation': 'National Institute for Health Innovation, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Weller', 'Affiliation': 'School of Nursing and Midwifery, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Waters', 'Affiliation': 'Hope Foundation for Research on Ageing, Auckland, New Zealand.'}]",BMJ open,['10.1136/bmjopen-2019-036476'] 2280,32690749,Complex Large-Bore Radial percutaneous coronary intervention: rationale of the COLOR trial study protocol.,"INTRODUCTION The radial artery has become the standard access site for percutaneous coronary intervention (PCI) in stable coronary artery disease and acute coronary syndrome, because of less access site related bleeding complications. Patients with complex coronary lesions are under-represented in randomised trials comparing radial with femoral access with regard to safety and efficacy. The femoral artery is currently the most applied access site in patients with complex coronary lesions, especially when large bore guiding catheters are required. With slender technology, transradial PCI may be increasingly applied in patients with complex coronary lesions when large bore guiding catheters are mandatory and might be a safer alternative as compared with the transfemoral approach. METHODS AND ANALYSIS A total of 388 patients undergoing complex PCI will be randomised to radial 7 French access with Terumo Glidesheath Slender (Terumo, Japan) or femoral 7 French access as comparator. The primary outcome is the incidence of the composite end point of clinically relevant access site related bleeding and/or vascular complications requiring intervention. Procedural success and major adverse cardiovascular events up to 1 month will also be compared between both groups. ETHICS AND DISSEMINATION Ethical approval for the study was granted by the local Ethics Committee at each recruiting center ('Medisch Ethische Toetsing Commissie Isala Zwolle', 'Commissie voor medische ethiek ZNA', 'Comité Medische Ethiek Ziekenhuis Oost-Limburg', 'Comité d'éthique CHU-Charleroi-ISPPC', 'Commission cantonale d'éthique de la recherche CCER-Republique et Canton de Geneve', 'Ethik Kommission de Ärztekammer Nordrhein' and 'Riverside Research Ethics Committee'). The trial outcomes will be published in peer-reviewed journals of the concerned literature. TRIAL REGISTRATION NUMBER NCT03846752.",2020,The primary outcome is the incidence of the composite end point of clinically relevant access site related bleeding and/or vascular complications requiring intervention.,"['388 patients undergoing', 'Patients with complex coronary lesions', 'patients with complex coronary lesions']","['radial 7 French access with Terumo Glidesheath Slender (Terumo, Japan) or femoral 7 French access as comparator', 'percutaneous coronary intervention (PCI', 'Complex Large-Bore Radial percutaneous coronary intervention', 'complex PCI']","['safety and efficacy', 'incidence of the composite end point of clinically relevant access site related bleeding and/or vascular complications requiring intervention', 'Procedural success and major adverse cardiovascular events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]","[{'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C2945608', 'cui_str': 'Bore'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0589360', 'cui_str': 'Site of access'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",388.0,0.369498,The primary outcome is the incidence of the composite end point of clinically relevant access site related bleeding and/or vascular complications requiring intervention.,"[{'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Meijers', 'Affiliation': 'Cardiology, Isala Hospitals, Zwolle, The Netherlands.'}, {'ForeName': 'Adel', 'Initials': 'A', 'LastName': 'Aminian', 'Affiliation': 'Cardiology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Wallonie, Belgium.'}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'Teeuwen', 'Affiliation': 'Cardiology, Catharina Hospital, Eindhoven, Noord Brabant, The Netherlands.'}, {'ForeName': 'Marleen', 'Initials': 'M', 'LastName': 'van Wely', 'Affiliation': 'Cardiology, Radboudumc, Nijmegen, Gelderland, The Netherlands.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Schmitz', 'Affiliation': 'Cardiology, Elisabeth-Krankenhaus-Essen GmbH, Essen, Nordrhein-Westfalen, Germany.'}, {'ForeName': 'Maurits T', 'Initials': 'MT', 'LastName': 'Dirksen', 'Affiliation': 'Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, Noord-Holland, The Netherlands.'}, {'ForeName': 'Rene J', 'Initials': 'RJ', 'LastName': 'van der Schaaf', 'Affiliation': 'Cardiology, OLVG, Amsterdam, Noord-Holland, The Netherlands.'}, {'ForeName': 'Juan F', 'Initials': 'JF', 'LastName': 'Iglesias', 'Affiliation': 'Cardiology, Geneva University Hospitals, Geneve, Genève, Switzerland.'}, {'ForeName': 'Pierfrancesco', 'Initials': 'P', 'LastName': 'Agostoni', 'Affiliation': 'Cardiology, ZNA, Antwerpen, Belgium.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Dens', 'Affiliation': 'Cardiology, Ziekenhuis Oost-Limburg, Genk, Limburg, Belgium.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Knaapen', 'Affiliation': 'Cardiology, Amsterdam UMC - Locatie VUMC, Amsterdam, Noord-Holland, The Netherlands.'}, {'ForeName': 'Sudhir', 'Initials': 'S', 'LastName': 'Rathore', 'Affiliation': 'Cardiology, Frimley Health NHS Foundation Trust, Frimley, Surrey, UK.'}, {'ForeName': 'Jan Paul', 'Initials': 'JP', 'LastName': 'Ottervanger', 'Affiliation': 'Cardiology, Isala Hospitals, Zwolle, The Netherlands.'}, {'ForeName': 'Jan-Henk E', 'Initials': 'JE', 'LastName': 'Dambrink', 'Affiliation': 'Cardiology, Isala Hospitals, Zwolle, The Netherlands.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Roolvink', 'Affiliation': 'Cardiology, Isala Hospitals, Zwolle, The Netherlands.'}, {'ForeName': 'A T Marcel', 'Initials': 'ATM', 'LastName': 'Gosselink', 'Affiliation': 'Cardiology, Isala Hospitals, Zwolle, The Netherlands.'}, {'ForeName': 'Renicus S', 'Initials': 'RS', 'LastName': 'Hermanides', 'Affiliation': 'Cardiology, Isala Hospitals, Zwolle, The Netherlands.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'van Royen', 'Affiliation': 'Cardiology, Radboudumc, Nijmegen, Gelderland, The Netherlands.'}, {'ForeName': 'Maarten A H', 'Initials': 'MAH', 'LastName': 'van Leeuwen', 'Affiliation': 'Cardiology, Isala Hospitals, Zwolle, The Netherlands m.a.h.van.leeuwen@isala.nl.'}]",BMJ open,['10.1136/bmjopen-2020-038042'] 2281,32690783,Internet based self-help randomized trial for motor Functional Neurological Disorder (SHIFT).,"OBJECTIVE To determine if self-rated health of patients with motor Functional Neurological Disorder can be improved by unguided internet-based self-help and education. METHODS In this non-blinded randomised controlled trial, patients were 1:1 allocated unbiased to an unguided education and self-help website in addition to usual care, or usual care only. Patients over 17 years of age with a functional motor symptom which caused distress or disability were included. The primary outcome was self-rated health on the Clinical Global Improvement (CGI) scale, at three and six months. Secondary outcomes were severity of motor symptoms, other physical and psychiatric symptoms, physical functioning, quality of life, work and social adjustment, illness beliefs and satisfaction with care. RESULTS 186 patients were randomised, with a follow-up rate of 87% at 6 months. There was no difference in improvement of self-rated health at three months (44% vs 40%, p=0.899) or six months (42% vs 43%, p=0.435). Secondary outcomes did not differ between groups with a threshold of p<0.01. Satisfaction was high, with 86% of patients recommending the website to other patients. CONCLUSION We found no significant effect of the intervention added to usual care on self-rated health or secondary outcome measures, despite high patient satisfaction with the intervention. These results suggest online education and non-guided self-help could be valuable additions to stepped care for motor FND, but are not effective treatments as interventions in their own right. CLASSIFICATION OF EVIDENCE This study provides Class III evidence that for patients with motor Functional Neurological Disorder, an online education and self-help intervention does not significantly improve self-rated health. Trial registry: NCT02589886.",2020,"There was no difference in improvement of self-rated health at three months (44% vs 40%, p=0.899) or six months (42% vs 43%, p=0.435).","['motor Functional Neurological Disorder (SHIFT', 'Patients over 17 years of age with a functional motor symptom which caused distress or disability were included', 'patients with motor Functional Neurological Disorder', '186 patients']","['unguided education and self-help website in addition to usual care, or usual care only', 'unguided internet-based self-help and education']","['self-rated health on the Clinical Global Improvement (CGI) scale', 'Satisfaction', 'severity of motor symptoms, other physical and psychiatric symptoms, physical functioning, quality of life, work and social adjustment, illness beliefs and satisfaction with care', 'improvement of self-rated health']","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0027765', 'cui_str': 'Disorder of nervous system'}, {'cui': 'C0333051', 'cui_str': 'Shift'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0233401', 'cui_str': 'Psychiatric symptom'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}]",186.0,0.125596,"There was no difference in improvement of self-rated health at three months (44% vs 40%, p=0.899) or six months (42% vs 43%, p=0.435).","[{'ForeName': 'Jeannette M', 'Initials': 'JM', 'LastName': 'Gelauff', 'Affiliation': 'University of Groningen, University Medical Center Groningen, Department of Neurology, The Netherlands.'}, {'ForeName': 'Judith G', 'Initials': 'JG', 'LastName': 'Rosmalen', 'Affiliation': 'University of Groningen, University Medical Center Groningen, Departments of Psychiatry and Internal Medicine, The Netherlands.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Carson', 'Affiliation': 'University of Edinburgh, Centre for Clinical Brain Sciences, Edinburgh, United Kingdom.'}, {'ForeName': 'Joke M', 'Initials': 'JM', 'LastName': 'Dijk', 'Affiliation': 'University of Amsterdam, Amsterdam University Medical Center, Department of Neurology, The Netherlands.'}, {'ForeName': 'Martijn', 'Initials': 'M', 'LastName': 'Ekkel', 'Affiliation': 'University of Groningen, University Medical Center Groningen, Department of Neurology, The Netherlands.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Nielsen', 'Affiliation': ""Neurosciences Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.""}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Stone', 'Affiliation': 'University of Edinburgh, Centre for Clinical Brain Sciences, Edinburgh, United Kingdom.'}, {'ForeName': 'Marina A J', 'Initials': 'MAJ', 'LastName': 'Tijssen', 'Affiliation': 'University of Groningen, University Medical Center Groningen, Department of Neurology, The Netherlands. m.a.j.de.koning-tijssen@umcg.nl.'}]",Neurology,['10.1212/WNL.0000000000010381'] 2282,32690791,Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.,"OBJECTIVE To assess over 3 years of follow-up, the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA studies in relapsing multiple sclerosis. METHODS After 2 years of double-blind, controlled treatment, patients continued OCR (600 mg infusions every 24 weeks) or switched from interferon (IFN) β-1a (44 μg 3 times weekly) to OCR when entering the OLE phase (3 years). Adjusted annualized relapse rate, time to onset of 24-week confirmed disability progression/improvement (CDP/CDI), brain MRI activity (gadolinium-enhanced and new/enlarging T2 lesions), and percentage brain volume change were analyzed. RESULTS Of patients entering the OLE phase, 88.6% completed Year 5. The cumulative proportion with 24-week CDP was lower in patients who initiated OCR earlier, vs patients initially receiving IFN β-1a (16.1% vs 21.3% at Year 5; p =0.014). Patients continuing OCR maintained, and those switching from IFN β-1a to OCR attained near complete and sustained suppression of new brain MRI lesion activity from Year 3 to 5. Over the OLE phase, patients continuing OCR exhibited less whole brain volume loss from double-blind study baseline vs those switching from IFN β-1a (-1.87% vs -2.15% at Year 5; p <0.01). Adverse events were consistent with past reports and no new safety signals emerged with prolonged treatment. CONCLUSION Compared with patients switching from IFN β-1a, earlier and continuous OCR treatment up to 5 years provided sustained benefit on clinical and MRI measures of disease progression. CLASSIFICATION OF EVIDENCE This study provides Class III evidence that earlier and continuous treatment with ocrelizumab provided sustained benefit on clinical and MRI outcomes of disease activity and progression compared with patients switching from IFN β-1a. The study is rated Class III because of the initial treatment randomization disclosure that occurred after inclusion in OLE. CLINICAL TRIAL IDENTIFIER NUMBERS NCT01247324/NCT01412333.",2020,This study provides Class III evidence that earlier and continuous treatment with ocrelizumab provided sustained benefit on clinical and MRI outcomes of disease activity and progression compared with patients switching from IFN β-1a.,[],"['OCR', 'maintaining or switching to ocrelizumab (OCR) therapy', 'interferon (IFN) β-1a', 'ocrelizumab']","['Adverse events', 'IFN β-1a', 'brain volume loss', 'new brain MRI lesion activity', 'cumulative proportion with 24-week CDP', 'Adjusted annualized relapse rate, time to onset of 24-week confirmed disability progression/improvement (CDP/CDI), brain MRI activity (gadolinium-enhanced and new/enlarging T2 lesions), and percentage brain volume change']",[],"[{'cui': 'C1882138', 'cui_str': 'ocrelizumab'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C4028269', 'cui_str': 'Nuclear magnetic resonance imaging brain'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0008188', 'cui_str': 'Chlordiazepoxide'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332162', 'cui_str': 'Onset of'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0282601', 'cui_str': 'Compact Disk Interactive'}, {'cui': 'C0016911', 'cui_str': 'Gadolinium'}, {'cui': 'C0442800', 'cui_str': 'Enlarged'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",,0.0438357,This study provides Class III evidence that earlier and continuous treatment with ocrelizumab provided sustained benefit on clinical and MRI outcomes of disease activity and progression compared with patients switching from IFN β-1a.,"[{'ForeName': 'Stephen L', 'Initials': 'SL', 'LastName': 'Hauser', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Ludwig', 'Initials': 'L', 'LastName': 'Kappos', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Douglas L', 'Initials': 'DL', 'LastName': 'Arnold', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Bar-Or', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Brochet', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Robert T', 'Initials': 'RT', 'LastName': 'Naismith', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Traboulsee', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Jerry S', 'Initials': 'JS', 'LastName': 'Wolinsky', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Shibeshih', 'Initials': 'S', 'LastName': 'Belachew', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Harold', 'Initials': 'H', 'LastName': 'Koendgen', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA harold.koendgen@roche.com.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Levesque', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Marianna', 'Initials': 'M', 'LastName': 'Manfrini', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Fabian', 'Initials': 'F', 'LastName': 'Model', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Stanislas', 'Initials': 'S', 'LastName': 'Hubeaux', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Lahar', 'Initials': 'L', 'LastName': 'Mehta', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Montalban', 'Affiliation': 'SL Hauser, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.'}]",Neurology,['10.1212/WNL.0000000000010376'] 2283,32690830,A Comparative Evaluation of Subgingivally Delivered 2% Curcumin and 0.2% Chlorhexidine Gel Adjunctive to Scaling and Root Planing in Chronic Periodontitis.,"AIM This study aimed to compare the effects of subgingival delivery of 2% curcumin gel and 0.2% chlorhexidine gel as an adjunct to scaling and root planing (SRP) on clinical and microbiological parameters in the management of patients with chronic periodontitis. MATERIALS AND METHODS In total, 25 systemically healthy individuals with age group ≥30 years diagnosed with chronic periodontitis were included in the study. The study was a double-blind split-mouth randomized control clinical trial. Two sites were selected in each patient and were randomly allocated to experimental and control sites. At baseline, measurements of site-specific periodontal parameters and collection of subgingival plaque sample were done. After full-mouth SRP, subgingival delivery of 2% curcumin gel in experimental sites and 0.2% chlorhexidine gel in control sites was done. At 1 and 3 months, subgingival plaque samples were collected again and site-specific periodontal parameters were measured. RESULTS The experimental group (2% curcumin gel) showed statistically significant improvements in periodontal [i.e., sulcus bleeding index (SBI), probing pocket depth (PPD), and relative attachment level (RAL)] and microbiologic parameters in the form of colony-forming units (CFUs) in comparison with control group (0.2% chlorhexidine gel). CONCLUSION Subgingival delivery of curcumin has shown effective anti-inflammatory and antibacterial properties. Since it is biologically accepted by the patients and its delivery in periodontal pockets can be recommended as an adjunct to SRP therapy for the treatment of patients with localized, moderate chronic periodontitis and in patients under the periodontal maintenance phase. CLINICAL SIGNIFICANCE Curcumin being a herbal agent may be excellent alternative to chlorhexidine. It is biologically accepted by the patients and can be recommended as an adjunct to SRP in the treatment of localized moderate chronic periodontitis and periodontal maintenance patients.",2020,"The experimental group (2% curcumin gel) showed statistically significant improvements in periodontal [i.e., sulcus bleeding index (SBI), probing pocket depth (PPD), and relative attachment level (RAL)] and microbiologic parameters in the form of colony-forming units (CFUs) in comparison with control group (0.2% chlorhexidine gel). ","['Chronic Periodontitis', 'patients with chronic periodontitis', '25 systemically healthy individuals with age group ≥30 years diagnosed with chronic periodontitis', 'patients with localized, moderate chronic periodontitis and in patients under the periodontal maintenance phase']","['chlorhexidine gel', 'root planing (SRP', 'chlorhexidine', 'curcumin gel and 0.2% chlorhexidine gel', 'SRP therapy', 'Subgingivally Delivered 2% Curcumin and 0.2% Chlorhexidine Gel Adjunctive to Scaling and Root Planing']","['periodontal [i.e., sulcus bleeding index (SBI), probing pocket depth (PPD), and relative attachment level (RAL)] and microbiologic parameters']","[{'cui': 'C0266929', 'cui_str': 'Chronic periodontitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C4268588', 'cui_str': 'Localized moderate chronic periodontitis'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0205390', 'cui_str': 'Phase'}]","[{'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0085287', 'cui_str': 'Root planing of tooth'}, {'cui': 'C0010467', 'cui_str': 'Curcumin'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",25.0,0.0347497,"The experimental group (2% curcumin gel) showed statistically significant improvements in periodontal [i.e., sulcus bleeding index (SBI), probing pocket depth (PPD), and relative attachment level (RAL)] and microbiologic parameters in the form of colony-forming units (CFUs) in comparison with control group (0.2% chlorhexidine gel). ","[{'ForeName': 'Mallapragada', 'Initials': 'M', 'LastName': 'Siddharth', 'Affiliation': 'Department of Periodontology, School of Dental Sciences, Sharda University, Greater Noida, Uttar Pradesh, India.'}, {'ForeName': 'Priyanka', 'Initials': 'P', 'LastName': 'Singh', 'Affiliation': 'Department of Periodontology, School of Dental Sciences, Sharda University, Greater Noida, Uttar Pradesh, India.'}, {'ForeName': 'Radhika', 'Initials': 'R', 'LastName': 'Gupta', 'Affiliation': 'Department of Periodontology, School of Dental Sciences, Sharda University, Greater Noida, Uttar Pradesh, India, Phone: +91 9818150018, e-mail: radhika_aaryan@yahoo.co.in.'}, {'ForeName': 'Abhishek', 'Initials': 'A', 'LastName': 'Sinha', 'Affiliation': 'Department of Periodontology, School of Dental Sciences, Sharda University, Greater Noida, Uttar Pradesh, India.'}, {'ForeName': 'Shanta', 'Initials': 'S', 'LastName': 'Shree', 'Affiliation': 'Department of Periodontology, School of Dental Sciences, Sharda University, Greater Noida, Uttar Pradesh, India.'}, {'ForeName': 'Komal', 'Initials': 'K', 'LastName': 'Sharma', 'Affiliation': 'Department of Periodontology, School of Dental Sciences, Sharda University, Greater Noida, Uttar Pradesh, India.'}]",The journal of contemporary dental practice,[] 2284,32690834,"Chemopreventive Synergism between Green Tea Extract and Curcumin in Patients with Potentially Malignant Oral Disorders: A Double-blind, Randomized Preliminary Study.","AIM The aim of the study was to assess the synergistic effect of green tea extract and curcumin in patients with oral potentially malignant disorders (OPMDs) and to ascertain the mechanism of action of these chemopreventive agents through assessment of suitable biomarkers. MATERIALS AND METHODS Subjects with OPMDs ( n = 60) were randomized to receive green tea extract [topical + systemic (800 mg/day)] or curcumin [topical + Systemic (950 mg/day)] or a combination therapy with 20 patients in each group for 3 months. Biomarkers (Ki67, cyclin D1, and p53) were evaluated in baseline and 12-week biopsies. RESULTS The clinical response rate observed in OPMDs was higher in the combination group ( n = 13; 65%) as compared to the curcumin ( n = 11; 55%) and the green tea extract group ( n = 7; 35%) and was statistically highly significant. Treatment medications also improved histological grades, although not statistically significant. All the study drugs were well tolerated by patients and did not raise any safety concerns. There was statistically significant ( p < 0.01) downregulation of p53, Ki67, and cyclin D1 expression at 3 months as compared to baseline in the combination group. CONCLUSION Treatment of OPMDs with curcumin and green tea extract combination demonstrated a significant clinical response supported by downregulation of molecular biomarkers in the short-term (12 weeks). The present results warrant a long-term clinical testing of green tea and curcumin combination for oral cancer prevention. CLINICAL SIGNIFICANCE Chemoprevention is a promising treatment strategy to reverse, stabilize, or arrest progression of these OPMDs. Use of natural dietary agents like green tea and curcumin, which are readily available, have low toxicity, and more importantly demonstrate a synergistic effect, is an attractive alternative in the chemoprevention of oral cancer. The assessment of biomarkers has helped us to understand the mechanism of action of these chemopreventive agents.",2020,"There was statistically significant ( p < 0.01) downregulation of p53, Ki67, and cyclin D1 expression at 3 months as compared to baseline in the combination group. ","['Subjects with OPMDs ( n = 60', 'patients with oral potentially malignant disorders (OPMDs', 'Patients with Potentially Malignant Oral Disorders']","['combination therapy', 'green tea extract [topical + systemic (800 mg/day)] or curcumin [topical + Systemic', 'green tea extract and curcumin', 'Green Tea Extract and Curcumin', 'green tea and curcumin combination', 'green tea extract combination']","['Biomarkers (Ki67, cyclin D1, and p53', 'downregulation of p53, Ki67, and cyclin D1 expression', 'histological grades', 'clinical response rate observed in OPMDs']","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0205282', 'cui_str': 'Malignant'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026636', 'cui_str': 'Disease of mouth'}]","[{'cui': 'C0009429', 'cui_str': 'Combination therapy'}, {'cui': 'C1704263', 'cui_str': 'Green Tea Extract'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0010467', 'cui_str': 'Curcumin'}, {'cui': 'C1384640', 'cui_str': 'Green tea'}]","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0174680', 'cui_str': 'bcl-1 Proto-Oncogene Proteins'}, {'cui': 'C0079419', 'cui_str': 'Genes, TP53'}, {'cui': 'C0013081', 'cui_str': 'Down-regulation'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0456201', 'cui_str': 'Histological grades'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0205282', 'cui_str': 'Malignant'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",60.0,0.0416746,"There was statistically significant ( p < 0.01) downregulation of p53, Ki67, and cyclin D1 expression at 3 months as compared to baseline in the combination group. ","[{'ForeName': 'Mellekatte C', 'Initials': 'MC', 'LastName': 'Neetha', 'Affiliation': 'Department of Oral Medicine and Radiology, College of Dental Sciences, Davangere, Karnataka, India, Phone: +91 9900207778, e-mail: neethamc@gmail.com.'}, {'ForeName': 'Mamatha G', 'Initials': 'MG', 'LastName': 'Panchaksharappa', 'Affiliation': 'Department of Oral Medicine and Radiology, College of Dental Sciences, Davangere, Karnataka, India.'}, {'ForeName': 'Shashikala', 'Initials': 'S', 'LastName': 'Pattabhiramasastry', 'Affiliation': 'Department of Pathology, SS Institute of Medical Sciences and Research Centre, Davangere, Karnataka, India.'}, {'ForeName': 'Nandish V', 'Initials': 'NV', 'LastName': 'Shivaprasad', 'Affiliation': 'Department of Pathology, SS Institute of Medical Sciences and Research Centre, Davangere, Karnataka, India.'}, {'ForeName': 'Usha G', 'Initials': 'UG', 'LastName': 'Venkatesh', 'Affiliation': 'Department of Preventive and Public Health Dentistry, Bapuji Dental College and Hospital, Davangere, Karnataka, India.'}]",The journal of contemporary dental practice,[] 2285,32690837,Effect of Probiotic Mouthrinses on Surface Microhardness of Esthetic Restorative Materials.,"AIM To assess the influence of three probiotic mouthrinses on the microhardness of three esthetic materials used for teeth restorations. MATERIALS AND METHODS Thirty specimens of each material: conventional glass ionomer cement (GIC), resin-modified glass ionomer, and resin composite were randomly assigned to three groups. Surface microhardness was measured at baseline. The specimens were immersed in probiotic mouthrinses, group I: (P2 probiotic power), group II: (Probioclean), and group III (BōKU natural). Microhardness was measured after 21 and 63 minutes of immersion which is comparable with 3 and 9 weeks of mouthrinse use every day, respectively. Measurements of microhardness were completed using Micro Vickers testing machine with a 200 g load applied for a duration of 15 seconds. RESULTS The microhardness change of the three restorative materials reveled statistically significant differences in all mouthrinse groups ( p = 0.001). BōKU natural mouthrinse decreased microhardness significantly in all restorative materials ( p < 0.05). However, Probioclean mouthrinse was associated with an increase in microhardness in all restorative materials. The effect of P2 probiotic power mouthrinse varied depending on time cycles and the restorative material. The mean difference in mouthrinse groups of resin composite was highest in BōKU natural at immersion time of 63 minutes. While no mean difference was seen in P2 probiotic power group at immersion time of 21 minutes which had no effect on the microhardness of resin composite. CONCLUSION Surface microhardness was affected by immersion in probiotic mouthrinses. The BōKU natural mouthrinse had the highest reduction, while resin composite showed the least change in surface microhardness. CLINICAL SIGNIFICANCE There is lack of studies that investigated the effect of probiotics mouthrinses on the surface properties of restorative materials. This study showed evidence that some of the tested probiotic mouthrinses in this study decreased the microhardness of the tested tooth-colored restorative materials after immersion for 21 and 63 minutes which is equivalent to 3 and 9 weeks of everyday use.",2020,BōKU natural mouthrinse decreased microhardness significantly in all restorative materials ( p < 0.05).,"['Thirty specimens of each material: conventional glass ionomer cement (GIC), resin-modified glass ionomer, and resin composite', 'Surface Microhardness of Esthetic Restorative Materials']","['P2 probiotic power mouthrinse', 'Probiotic Mouthrinses', 'Probioclean mouthrinse']","['Microhardness', 'Surface microhardness']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0017597', 'cui_str': 'Glass-ionomer dental material'}, {'cui': 'C0035191', 'cui_str': 'Resins, Plant'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0061297', 'cui_str': 'glass ionomer'}, {'cui': 'C0009570', 'cui_str': 'Composite Resins'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0182981', 'cui_str': 'Dental restorative material'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotic'}]","[{'cui': 'C0205148', 'cui_str': 'Surface'}]",,0.0230832,BōKU natural mouthrinse decreased microhardness significantly in all restorative materials ( p < 0.05).,"[{'ForeName': 'Bashaer', 'Initials': 'B', 'LastName': 'Altwaim', 'Affiliation': 'Department of Dentistry, College of Dentistry, King Saud University, Riyadh, Kingdom of Saudi Arabia.'}, {'ForeName': 'Fouad', 'Initials': 'F', 'LastName': 'Salama', 'Affiliation': 'Department of Clinical Dentistry, School of Dentistry, University of Detroit Mercy, Detroit, Michigan, USA, Phone: +1 313-494-6877, e-mail: salamafs@udmercy.edu.'}, {'ForeName': 'Shahad', 'Initials': 'S', 'LastName': 'Alogayyel', 'Affiliation': 'Department of Dentistry, College of Dentistry, King Saud University, Riyadh, Kingdom of Saudi Arabia.'}]",The journal of contemporary dental practice,[] 2286,32691120,Oral tramadol versus oral celecoxib for analgesia after mediolateral episiotomy repair in obese primigravidae: a randomized controlled trial.,"INTRODUCTION AND HYPOTHESIS A variety of pharmacological and non-pharmacological interventions have been investigated, with the goal of relieving pain after post-episiotomy repair. We aimed to compare the efficacy of tramadol versus celecoxib orally in reducing pain after mediolateral episiotomy repair in obese primigravidae undergoing spontaneous vaginal delivery. METHODS We conducted a randomized double-blinded trial in Cairo University hospital, Cairo, Egypt, from October 2018 to December 2019. We randomly assigned 200 women into two groups: group A (n = 100) received one tramadol tablet 100 mg orally whereas group B (n = 100) received one celecoxib tablet 200 mg orally. Our primary outcome was pain score using a 10-cm visual analog scale at different time intervals. Our secondary outcomes were the overall satisfaction score and drug side effects. RESULTS After mediolateral episiotomy repair, the pain scores at 1, 2, and 4 h were significantly lower in the tramadol group than in the celecoxib group (p < 0.001). However, there were no significantly differences in pain scores at 8 and 12 h between the two groups (p = 0.50 and 0.48 respectively). Women's satisfaction score was significantly higher in the tramadol group than in the celecoxib group (p < 0.001). Fewer participants in the tramadol group needed additional analgesics than in the celecoxib group; however, the difference was not significant (p = 0.17). Drug adverse effects were comparable in the two groups. CONCLUSIONS Primigravid women who received tramadol 100 mg orally after mediolateral episiotomy repair had lower pain scores and were more satisfied than women who received celecoxib 200 mg orally. Both drugs were well tolerated, with few side effects.",2020,"After mediolateral episiotomy repair, the pain scores at 1, 2, and 4 h were significantly lower in the tramadol group than in the celecoxib group (p < 0.001).","['Cairo University hospital, Cairo, Egypt, from October 2018 to December 2019', 'obese primigravidae', 'obese primigravidae undergoing spontaneous vaginal delivery']","['tramadol tablet 100\xa0mg orally whereas group B (n\u2009=\u2009100) received one celecoxib tablet 200\xa0mg orally', 'tramadol', 'celecoxib', 'Oral tramadol', 'pharmacological and non-pharmacological interventions']","['pain scores', 'overall satisfaction score and drug side effects', 'additional analgesics', 'Drug adverse effects', 'pain score using a 10-cm visual analog scale', 'pain', ""Women's satisfaction score""]","[{'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0013715', 'cui_str': 'Egypt'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0269694', 'cui_str': 'Normal delivery procedure'}]","[{'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0538927', 'cui_str': 'celecoxib'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0041755', 'cui_str': 'Adverse reaction to drug'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",200.0,0.617768,"After mediolateral episiotomy repair, the pain scores at 1, 2, and 4 h were significantly lower in the tramadol group than in the celecoxib group (p < 0.001).","[{'ForeName': 'Dina', 'Initials': 'D', 'LastName': 'Latif', 'Affiliation': 'Department of Obstetrics and Gynecology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Fatma Faisal', 'Initials': 'FF', 'LastName': 'Darweesh', 'Affiliation': 'Department of Obstetrics and Gynecology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Omneya M', 'Initials': 'OM', 'LastName': 'Osman', 'Affiliation': 'Department of Obstetrics and Gynecology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Ahmed Mohamed', 'Initials': 'AM', 'LastName': 'Abdelhakim', 'Affiliation': 'Kasr Al-Ainy, Faculty of Medicine, Cairo University, 395 Port Said Street, Bab el-kalq, Cairo, 11638, Egypt. ahmed.m.rohei@students.kasralainy.edu.eg.'}, {'ForeName': 'Hala', 'Initials': 'H', 'LastName': 'Nabil', 'Affiliation': 'Department of Obstetrics and Gynecology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Ahmed S A', 'Initials': 'ASA', 'LastName': 'Ashour', 'Affiliation': 'Department of Obstetrics and Gynecology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.'}]",International urogynecology journal,['10.1007/s00192-020-04411-4'] 2287,32691121,"Letter to the editor regarding ""Safety of one-stage bilateral total knee arthroplasty -one surgeon sequential vs. two surgeons simultaneous: a randomized controlled study"".",,2020,,[],['bilateral total knee arthroplasty -one surgeon sequential vs. two surgeons simultaneous'],[],[],"[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}]",[],,0.0740354,,"[{'ForeName': 'Tomonori', 'Initials': 'T', 'LastName': 'Shigemura', 'Affiliation': 'Department of Orthopaedic Surgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan. tshigepon@yahoo.co.jp.'}, {'ForeName': 'Yohei', 'Initials': 'Y', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Orthopaedic Surgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan.'}, {'ForeName': 'Yuichi', 'Initials': 'Y', 'LastName': 'Wada', 'Affiliation': 'Department of Orthopaedic Surgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan.'}]",International orthopaedics,['10.1007/s00264-020-04744-1'] 2288,32691141,Modified abbreviated burn severity index as a predictor of in-hospital mortality in patients with inhalation injury: development and validation using independent cohorts.,"PURPOSE The ability to accurately evaluate the severity of inhalation injury can help to optimize patient care. However, there is no accepted severity grading system, especially for inhalation injury. METHODS We screened a multicenter burn registry and included adult patients who required oxygen treatment or mechanical ventilation. After the patient data were divided into development and validation cohorts, missing values were replaced with multiple imputation. Twelve potential predictors were analyzed using multivariate logistic regression to identify prognostic variables for in-hospital mortality and scores were assigned to each predictor based on odds ratios to develop the Modified Abbreviated Burn Severity Index, mABSI. The mABSI was validated using c-statistics and calibration curves. RESULTS We randomly assigned 1377 and 919 patients to the development and validation cohorts, respectively. Age, self-inflicted injury, cutaneous burn area, and mechanical ventilation requirement were identified as independent predictors, and the mABSI (1-17 scale) was, thus, developed. The mABSI has a high discriminatory power (c-statistic = 0.94; 95% CI 0.92-0.97), and both estimated and observed in-hospital mortalities increased from 1% at score ≤ 5 to almost 100% at score ≥ 14 with linear calibration plots. CONCLUSIONS We developed and validated the mABSI which accurately predicts in-hospital mortality.",2020,"The mABSI has a high discriminatory power (c-statistic = 0.94; 95% CI 0.92-0.97), and both estimated and observed in-hospital mortalities increased from 1% at score ≤ 5 to almost 100% at score ≥ 14 with linear calibration plots. ","['patients with inhalation injury', 'multicenter burn registry and included adult patients who required oxygen treatment or mechanical ventilation']",[],"['hospital mortalities', 'Age, self-inflicted injury, cutaneous burn area, and mechanical ventilation requirement']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0745334', 'cui_str': 'Inhalation injury'}, {'cui': 'C0000912', 'cui_str': 'Accident caused by unspecified fire'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}]",[],"[{'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0036601', 'cui_str': 'Self-mutilation'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0000912', 'cui_str': 'Accident caused by unspecified fire'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}]",1377.0,0.027316,"The mABSI has a high discriminatory power (c-statistic = 0.94; 95% CI 0.92-0.97), and both estimated and observed in-hospital mortalities increased from 1% at score ≤ 5 to almost 100% at score ≥ 14 with linear calibration plots. ","[{'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Emergency and Critical Care Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan. ryo.yamamoto@gmail.com.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Shibusawa', 'Affiliation': 'Department of Emergency and Critical Care Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Aikawa', 'Affiliation': 'Department of Emergency and Critical Care Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.'}, {'ForeName': 'Junichi', 'Initials': 'J', 'LastName': 'Sasaki', 'Affiliation': 'Department of Emergency and Critical Care Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.'}]",Surgery today,['10.1007/s00595-020-02085-5'] 2289,32691205,Efficacy and patient satisfaction of single-session transoral incisionless fundoplication and laparoscopic hernia repair.,"BACKGROUND AND AIMS Transoral incisionless fundoplication (TIF) is an effective endoscopic treatment for refractory GERD with small or absent hiatal hernia (< 2 cm in length and width). The single-session laparoscopic hernia repair followed by transoral incisionless fundoplication (HH + TIF) aims to repair mechanical defects in the lower esophageal sphincter that leads to GERD in patients with hiatal hernias ≥ 2 cm. The procedure effectively treats GERD without causing added post-surgical dysphagia and gas bloating commonly associated with partial laparoscopic fundoplication. We aimed to assess patient satisfaction, symptom resolution, safety, and proton pump inhibitor use following the HH + TIF procedure. METHODS Thirty-three patients underwent single-session laparoscopic hernia repair with intraoperative TIF using the EsophyX Z device (EndoGastric Solutions, Inc.) between June 2015 and June 2018. The presence of GERD and normal esophageal motility were confirmed with pH testing and manometry prior to the procedure. Data were collected on pre- and post-procedure symptoms, patient satisfaction, PPI use, and complications. Median post-procedure follow-up with symptom surveys was 9 months (11-29 months). RESULTS Patients reported significant decreases in common GERD symptoms including heartburn, regurgitation, cough, and hoarse voice. Eighty-one percent (27/33) of patients were off daily PPIs. Ninety-four percent (31/33) of patients reported 75% or greater satisfaction with the procedure and outcomes. One patient had a superficial mucosal laceration after the procedure, likely due to vomiting, which was treated conservatively. CONCLUSIONS The majority of patients reported 75% or greater satisfaction with the procedure and had an improvement in GERD symptoms as well as decreased PPI use. There were no serious adverse events.",2020,The majority of patients reported 75% or greater satisfaction with the procedure and had an improvement in GERD symptoms as well as decreased PPI use.,"['Thirty-three patients underwent single-session laparoscopic hernia repair with intraoperative TIF using the EsophyX Z device (EndoGastric Solutions, Inc.) between June 2015 and June 2018', 'patients with hiatal hernias\xa0≥']","['partial laparoscopic fundoplication', 'Transoral incisionless fundoplication (TIF', 'single-session laparoscopic hernia repair followed by transoral incisionless fundoplication (HH\xa0+\xa0TIF', 'single-session transoral incisionless fundoplication and laparoscopic hernia repair']","['presence of GERD and normal esophageal motility', 'GERD symptoms', 'patient satisfaction, symptom resolution, safety', 'superficial mucosal laceration', 'Efficacy and patient satisfaction', 'serious adverse events', 'common GERD symptoms including heartburn, regurgitation, cough, and hoarse voice', 'patient satisfaction, PPI use, and complications']","[{'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0019328', 'cui_str': 'Hernia repair'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0442366', 'cui_str': 'Transoral approach'}, {'cui': 'C0192499', 'cui_str': 'Esophagogastric fundoplasty'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C3489393', 'cui_str': 'Hiatal hernia'}]","[{'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0521257', 'cui_str': 'Laparoscopic fundoplication'}, {'cui': 'C0442366', 'cui_str': 'Transoral approach'}, {'cui': 'C0192499', 'cui_str': 'Esophagogastric fundoplasty'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0019328', 'cui_str': 'Hernia repair'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0017168', 'cui_str': 'Gastroesophageal reflux disease'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0007608', 'cui_str': 'Motility, Cell'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C0043246', 'cui_str': 'Laceration'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0018834', 'cui_str': 'Heartburn'}, {'cui': 'C0232605', 'cui_str': 'Regurgitates after swallowing'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0019825', 'cui_str': 'Hoarse'}, {'cui': 'C0358591', 'cui_str': 'H+/K+-exchanging ATPase inhibitor'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",33.0,0.0937687,The majority of patients reported 75% or greater satisfaction with the procedure and had an improvement in GERD symptoms as well as decreased PPI use.,"[{'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Gisi', 'Affiliation': 'Department of Internal Medicine, Harbor-UCLA Medical Center, Torrance, USA. ckulaga@dhs.lacounty.gov.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Department of Internal Medicine, Harbor-UCLA Medical Center, Torrance, USA.'}, {'ForeName': 'Farhaad', 'Initials': 'F', 'LastName': 'Khan', 'Affiliation': 'Keck School of Medicine at USC, Los Angeles, USA.'}, {'ForeName': 'Sonya', 'Initials': 'S', 'LastName': 'Reicher', 'Affiliation': 'Division of Gastroenterology, David Geffen School of Medicine at UCLA, Harbor-UCLA Medical Center, Torrance, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Hou', 'Affiliation': 'Division of Gastroenterology, David Geffen School of Medicine at UCLA, Harbor-UCLA Medical Center, Torrance, USA.'}, {'ForeName': 'Clark', 'Initials': 'C', 'LastName': 'Fuller', 'Affiliation': 'Torrance Memorial Medical Center, Torrance, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Sattler', 'Affiliation': 'Torrance Memorial Medical Center, Torrance, USA.'}, {'ForeName': 'Viktor', 'Initials': 'V', 'LastName': 'Eysselein', 'Affiliation': 'Division of Gastroenterology, David Geffen School of Medicine at UCLA, Harbor-UCLA Medical Center, Torrance, USA.'}]",Surgical endoscopy,['10.1007/s00464-020-07796-x'] 2290,32691272,Student Knowledge Gain Following the Second Step Child Protection Unit: the Influence of Treatment Integrity.,"Treatment integrity is an important yet understudied component of school-based prevention programming, particularly for sensitive topics such as child sexual abuse prevention (CSA). This study examined student- and teacher-level characteristics, including components of treatment integrity, that contributed to greater knowledge gain among students participating in the Second Step Child Protection Unit (CPU). The study was conducted with 1132 students and 57 teachers from four elementary schools enrolled in a randomized controlled trial of the CPU. Students were administered assessments at pre-test, post-test, 6-month follow-up, and 12-month follow-up. Teachers were observed and rated on Content Integrity (CI; adherence to content), Process Integrity (PI; teacher enthusiasm, encouragement, behavior management), and Dose Received (DR; student behavior and interest) when delivering the lessons. Hierarchical linear growth modeling indicated that students who received the CPU made gains in the knowledge of CSA concepts and skills over a 12-month follow-up period. Girls had significantly greater CSA knowledge than boys immediately after the intervention, with gender remaining significant even when accounting for level-3 variables. Older children had better knowledge scores at post-test, but growth over time results revealed that younger students made greater gains. For students in 2nd through 4th grade, CI was more important for post-test outcomes, while for all students, CI and grade taught were important to post-test scores. Teachers of lower grades had students with a faster growth rate on correct responses to vignettes. Implications for CSA prevention programming and future research are discussed.",2020,"Older children had better knowledge scores at post-test, but growth over time results revealed that younger students made greater gains.","['Older children', '1132 students and 57 teachers from four elementary schools enrolled', 'students participating in the Second Step Child Protection Unit (CPU']",['CPU'],"['Student Knowledge Gain', 'knowledge scores', 'CSA knowledge', 'Content Integrity (CI; adherence to content), Process Integrity (PI; teacher enthusiasm, encouragement, behavior management), and Dose Received (DR; student behavior and interest']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0337542', 'cui_str': 'Stepchild'}, {'cui': 'C0439148', 'cui_str': 'Unit'}]",[],"[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0008062', 'cui_str': 'Sexual Abuse of Child'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0424090', 'cui_str': 'Level of interest'}, {'cui': 'C0150143', 'cui_str': 'Behavior management'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0543488', 'cui_str': 'Interested'}]",1132.0,0.0133982,"Older children had better knowledge scores at post-test, but growth over time results revealed that younger students made greater gains.","[{'ForeName': 'Margaret E', 'Initials': 'ME', 'LastName': 'Manges', 'Affiliation': 'Alberti Center for Bullying Abuse Prevention, The University at Buffalo, State University of New York, 428 Baldy Hall, Buffalo, NY, 14260-1000, USA. memanges@buffalo.edu.'}, {'ForeName': 'Amanda B', 'Initials': 'AB', 'LastName': 'Nickerson', 'Affiliation': 'Alberti Center for Bullying Abuse Prevention, The University at Buffalo, State University of New York, 428 Baldy Hall, Buffalo, NY, 14260-1000, USA.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-020-01146-y'] 2291,32691298,Effect of drain application on postoperative complaints after surgical removal of impacted wisdom teeth-a randomized observer-blinded split-mouth clinical trial.,"OBJECTIVES The aim of this randomized observer-blinded split-mouth-study is to objectively assess the influence of a rubber drain on postoperative swelling using 3D face scans as measurement method and additionally evaluate pain, trismus and complications after the osteotomy of lower third molars. MATERIAL AND METHODS Seventy-two patients with symmetrically impacted lower wisdom teeth were recruited. Before the operation, patients rated pain using the visual analogue scale, the interincisal distance was measured, and 3D face scans were taken with an optical scanner. Each patient underwent two procedures which were at least 30 days apart. On one side, a rubber drain was inserted randomly before closure, the contralateral control side was closed without drainage. On the third and tenth postoperative day, face scans to quantify the swelling, pain evaluation and trismus measurements were performed. Due to loss of follow-up, 32 patients were excluded which resulted in 40 out of 72 patients remaining in the study. RESULTS There was no statistical difference in using a drain on swelling and trismus on the third and tenth day (p > 0.05). Pain was slightly worse on the third day on the treatment side, but the difference was not significant (p > 0.05). We observed no differences in the number of wound infections. CONCLUSIONS The insertion of a rubber drain does not have any influence on swelling, pain or trismus and has no impact on the number of wound infections. CLINICAL RELEVANCE The use of a rubber drain cannot be recommended as no reduction of postoperative discomfort was detected.",2020,"The insertion of a rubber drain does not have any influence on swelling, pain or trismus and has no impact on the number of wound infections. ","['postoperative complaints after surgical removal of impacted wisdom teeth', 'Seventy-two patients with symmetrically impacted lower wisdom teeth were recruited', '32 patients were excluded which resulted in 40 out of 72 patients remaining in the study']","['drain application', 'rubber drain']","['rated pain using the visual analogue scale, the interincisal distance', 'Pain', 'swelling, pain or trismus', 'number of wound infections', 'swelling, pain evaluation and trismus measurements', 'pain, trismus and complications', 'swelling and trismus', 'postoperative discomfort']","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0398942', 'cui_str': 'Surgical removal of impacted third molar tooth'}, {'cui': 'C4319632', 'cui_str': '72'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0026369', 'cui_str': 'Structure of wisdom tooth'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0013103', 'cui_str': 'Drainage procedure'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0009653', 'cui_str': 'Condom'}]","[{'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0041105', 'cui_str': 'Trismus'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0043241', 'cui_str': 'Local infection of wound'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}]",72.0,0.113895,"The insertion of a rubber drain does not have any influence on swelling, pain or trismus and has no impact on the number of wound infections. ","[{'ForeName': 'Marie Sophie', 'Initials': 'MS', 'LastName': 'Katz', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University Hospital RWTH Aachen, Pauwelstraße 30, 52074, Aachen, Germany. mkatz@ukaachen.de.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Peters', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University Hospital RWTH Aachen, Pauwelstraße 30, 52074, Aachen, Germany.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Elvers', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University Hospital RWTH Aachen, Pauwelstraße 30, 52074, Aachen, Germany.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Winterhalder', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University Hospital RWTH Aachen, Pauwelstraße 30, 52074, Aachen, Germany.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Kniha', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University Hospital RWTH Aachen, Pauwelstraße 30, 52074, Aachen, Germany.'}, {'ForeName': 'Stephan Christian', 'Initials': 'SC', 'LastName': 'Möhlhenrich', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University Hospital RWTH Aachen, Pauwelstraße 30, 52074, Aachen, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Hölzle', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University Hospital RWTH Aachen, Pauwelstraße 30, 52074, Aachen, Germany.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Modabber', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University Hospital RWTH Aachen, Pauwelstraße 30, 52074, Aachen, Germany.'}]",Clinical oral investigations,['10.1007/s00784-020-03464-5'] 2292,32691431,Effectiveness of intensive cognitive behavioral therapy in adolescents and adults with anorexia nervosa.,"OBJECTIVE This study aimed to compare the effectiveness of an intensive treatment based on enhanced cognitive behavioral therapy (CBT-E) in adolescent and adult patients with anorexia nervosa. METHODS A total of 150 consecutive patients (74 adolescents and 81 adults) were admitted to a 20-week intensive CBT-E program (13 weeks of inpatient followed by 7 weeks of day-hospital treatment). All patients had responded poorly to previous outpatient treatments and were assessed at admission, end of treatment (EOT), and 20- and 60-week follow-ups. RESULTS About 70% of eligible patients began the program, and more than 85% completed it. Body mass index (BMI) in adults and BMI-for-age percentile in adolescents improved significantly from baseline to EOT, remained stable until 20-week follow-up, and slightly decreased from 20-week follow-up to 60-week follow-up, while remaining in the lower normal range. Eating disorder psychopathology, general psychopathology, and clinical impairment scores decreased significantly at EOT and showed only a slight increase from EOT to follow-ups. No difference was found between adolescent and adult patients in treatment acceptance, dropout, or any outcome measure. DISCUSSION These findings indicate that intensive CBT-E seems to be an effective treatment for severely ill adolescent and adult patients with anorexia nervosa.",2020,"No difference was found between adolescent and adult patients in treatment acceptance, dropout, or any outcome measure. ","['adults and BMI-for-age percentile in adolescents', '150 consecutive patients (74 adolescents and 81 adults', 'severely ill adolescent and adult patients with anorexia nervosa', 'adolescent and adult patients with anorexia nervosa', 'adolescents and adults with anorexia nervosa']","['intensive cognitive behavioral therapy', 'intensive treatment based on enhanced cognitive behavioral therapy (CBT-E', 'intensive CBT-E program']","['Body mass index (BMI', 'Eating disorder psychopathology, general psychopathology, and clinical impairment scores']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0231218', 'cui_str': 'Malaise'}, {'cui': 'C0003125', 'cui_str': 'Anorexia nervosa'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0013473', 'cui_str': 'Eating disorder'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",150.0,0.023763,"No difference was found between adolescent and adult patients in treatment acceptance, dropout, or any outcome measure. ","[{'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Dalle Grave', 'Affiliation': 'Department of Eating and Weight Disorders, Villa Garda Hospital, Garda (VR), Veneto, Italy.'}, {'ForeName': 'Maddalena', 'Initials': 'M', 'LastName': 'Conti', 'Affiliation': 'Department of Eating and Weight Disorders, Villa Garda Hospital, Garda (VR), Veneto, Italy.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Calugi', 'Affiliation': 'Department of Eating and Weight Disorders, Villa Garda Hospital, Garda (VR), Veneto, Italy.'}]",The International journal of eating disorders,['10.1002/eat.23337'] 2293,32691455,Co-created Internet-based Stepped Care for Individuals with Cancer and Concurrent Symptoms of Anxiety and Depression: Results from the U-CARE AdultCan Randomized Controlled Trial.,,2020,,['Individuals with Cancer and Concurrent Symptoms of Anxiety and Depression'],['Co-created Internet-based Stepped Care'],[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}]",[],,0.108249,,"[{'ForeName': 'Hauffman', 'Initials': 'H', 'LastName': 'Anna', 'Affiliation': 'Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Alfonsson', 'Initials': 'A', 'LastName': 'Sven', 'Affiliation': ""Department of Women's and Children's Health, Section of Clinical Psychology in Healthcare, Uppsala University, Uppsala, Sweden.""}, {'ForeName': 'Bill-Axelson', 'Initials': 'BA', 'LastName': 'Anna', 'Affiliation': 'Department of Surgical Sciences, Section of Urology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Bergkvist', 'Initials': 'B', 'LastName': 'Leif', 'Affiliation': 'Centre for Clinical Research, Uppsala University, Västerås, Sweden.'}, {'ForeName': 'Forslund', 'Initials': 'F', 'LastName': 'Marina', 'Affiliation': 'Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Mattsson', 'Initials': 'M', 'LastName': 'Susanne', 'Affiliation': 'Department of Public Health and Caring Sciences, Lifestyle and Rehabilitation in long-term illness, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'von Essen', 'Initials': 'VE', 'LastName': 'Louise', 'Affiliation': ""Department of Women's and Children's Health, Section of Clinical Psychology in Healthcare, Uppsala University, Uppsala, Sweden.""}, {'ForeName': 'Nygren', 'Initials': 'N', 'LastName': 'Peter', 'Affiliation': 'Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Igelström', 'Initials': 'I', 'LastName': 'Helena', 'Affiliation': 'Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Johansson', 'Initials': 'J', 'LastName': 'Birgitta', 'Affiliation': 'Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden.'}]",Psycho-oncology,['10.1002/pon.5489'] 2294,32691681,Effects of Child Sexual Abuse Prevention Education Program Using Hybrid Application (CSAPE-H) on Fifth-Grade Students in South Korea.,"The purpose of this study was to test the effects of a child sexual abuse prevention education program using a hybrid application (CSAPE-H) by examining fifth-grade students' (a) knowledge for sexual abuse prevention and (b) self-protective behaviors against sexual abuse. A quasi-experimental, pretest /posttest design was used. Sixty-eight students from two schools participated. The intervention group ( n = 48) received six sessions in CSA prevention education using the hybrid app, whereas the control group ( n = 35) was taught using a lecture in a classroom environment. Between the two groups, there were significant differences in self-protective behaviors against CSA ( t = 2.26, p = .027). In addition, educational satisfaction was significantly higher in the experimental group than the control group ( t = 2.41, p = .019). A CSAPE-H may be effective for elementary school students, especially for self-protective behaviors.",2020,"In addition, educational satisfaction was significantly higher in the experimental group than the control group ( t = 2.41, p = .019).","['Fifth-Grade Students in South Korea', 'Sixty-eight students from two schools participated', 'elementary school students']","['child sexual abuse prevention education program', 'six sessions in CSA prevention education using the hybrid app, whereas the control group ( n = 35) was taught using a lecture in a classroom environment', 'Child Sexual Abuse Prevention Education Program Using Hybrid Application (CSAPE-H']","['self-protective behaviors against CSA', 'educational satisfaction']","[{'cui': 'C0205439', 'cui_str': 'Fifth'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0450387', 'cui_str': '68'}, {'cui': 'C0036375', 'cui_str': 'School'}]","[{'cui': 'C0008062', 'cui_str': 'Sexual Abuse of Child'}, {'cui': 'C1633748', 'cui_str': 'Prevention education'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0010592', 'cui_str': 'Cyclosporine'}, {'cui': 'C0007597', 'cui_str': 'Cell hybridization'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0376683', 'cui_str': 'Lectures'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0010592', 'cui_str': 'Cyclosporine'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",68.0,0.0122056,"In addition, educational satisfaction was significantly higher in the experimental group than the control group ( t = 2.41, p = .019).","[{'ForeName': 'So Ra', 'Initials': 'SR', 'LastName': 'Kang', 'Affiliation': 'Division of Nursing, Ewha Womans University, Seoul, Korea.'}, {'ForeName': 'Shin-Jeong', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'School of Nursing, Hallym University, Chunchon, Korea.'}, {'ForeName': 'Kyung-Ah', 'Initials': 'KA', 'LastName': 'Kang', 'Affiliation': 'College of Nursing, Sahmyook University, Seoul, Korea.'}]",The Journal of school nursing : the official publication of the National Association of School Nurses,['10.1177/1059840520940377'] 2295,32691848,"The promise, and challenges, of methods to enhance the external validity of randomized trial results.","Results from randomized trials do not necessarily apply to clinical practice, particularly if the trial sample and target population differ on factors that modify treatment effects. Happich et al. illustrate recently developed methods that may account for such differences when estimating population average treatment effects. In this commentary, we connect the paper to the broader literature on assessing and enhancing generalizability of trial results, and highlight the causal assumptions required to estimate target population effects.",2020,"Results from randomized trials do not necessarily apply to clinical practice, particularly if the trial sample and target population differ on factors that modify treatment effects.",[],[],[],[],[],[],,0.132061,"Results from randomized trials do not necessarily apply to clinical practice, particularly if the trial sample and target population differ on factors that modify treatment effects.","[{'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Stuart', 'Affiliation': 'Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, USA.'}, {'ForeName': 'Catherine R', 'Initials': 'CR', 'LastName': 'Lesko', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, USA.'}]",Clinical pharmacology and therapeutics,['10.1002/cpt.1992'] 2296,32692071,Assessing the Quality of Rectal Cancer Pathology Reports in National Surgical Adjuvant Breast and Bowel Project Protocol R-04/NRG Oncology.,"BACKGROUND Accurate and comprehensive surgical pathology reports are integral to the quality of cancer care. Despite guidelines from the College of American Pathologists, variations in reporting quality continue to exist. OBJECTIVE The aim of this study was to evaluate the quality of rectal cancer pathology reports and to identify areas of deficiency and potential sources of reporting variations. DESIGN This is a retrospective analysis of prospectively obtained pathology reports. SETTING This study is based at the hospitals participating in the National Surgical Adjuvant Breast and Bowel Project Protocol R-04 study. PATIENTS Patients with rectal cancer undergoing surgical resection between July 2004 and August 2010 were included. MAIN OUTCOME MEASURES The primary outcomes measured were the adherence to the College of American Pathologists guidelines and the impact of synoptic reporting, academic status, rural/urban setting, and hospital bed size on reporting quality. RESULTS We identified 1004 surgical pathology reports for rectal cancer surgery from 383 hospitals and 755 pathologists. The overall adherence rate to the College of American Pathologists guidelines was 73.3%. Notable reporting deficiencies were found in several key pathology characteristics, including tumor histologic grade (reporting rate 77.8%), radial margin (84.6%), distance from the closest margin (47.9%), treatment effect (47.1%), and lymphovascular (73.1%)/perineural invasions (35.4%). Synoptic reporting use and urban hospital settings were associated with better adherence rates, whereas academic status and hospital bed size had no impact. Reporting variations existed not only between institutions, but also within individual hospitals and pathologists. There was a trend for improved adherence over time (2005 = 65.7% vs 2010 = 82.3%, p < 0.001), which coincided with the increased adoption of synoptic reporting by pathologists (2005 vs 2010, 9.4% vs 25.3%, p < 0.001). LIMITATIONS Data were obtained from a restricted setting (ie, hospitals participating in a randomized clinical trial). CONCLUSIONS Wide variations in the quality of pathology reporting are observed for rectal cancer. The National Accreditation Program for Rectal Cancer mandates that programs meet strict quality standards for surgical pathology reporting. Further improvement is needed in this key aspect of oncology care for patients with rectal cancer. See Video Abstract at http://links.lww.com/DCR/B238.ClinicalTrials.gov registration: NCT00058 EVALUACIÓN DE LA CALIDAD DE LOS INFORMES DE PATOLOGÍA QUIRÚRGICA EN CASOS DE CÁNCER DE RECTO DEL NSABP R-04/ ONCOLOGÍA DEL NRG: Un informe de patología quirúrgica preciso y completo es fundamental en la calidad de atención de pacientes con cáncer. A pesar de las normas establecidas por el Colegio Americano de Patología, la variabilidad en la calidad de los informes es evidente.Evaluar la calidad de los informes de patología en casos de cáncer de recto para así identificar las áreas con deficiencias y las posibles fuentes variables en los mencionados informes.Análisis retrospectivo de informes de patología quirúrgica obtenidos prospectivamente.Hospitales que participan del Protocolo del Estudio Nacional R-04 como Adyuvantes Quirúrgicos de Mama e Intestino.Todos aquellos pacientes con cáncer de recto sometidos a resección quirúrgica entre Julio 2004 y Agosto 2010.Cumplimiento de las normas del Colegio Americano de Patología, del impacto de los informes sinópticos, del estado académico, del entorno rural / urbano y el número de camas hospitalarias en en la calidad de los informes.Identificamos 1,004 informes de patología quirúrgica en casos de cirugía en cáncer de recto en 383 hospitales y 755 patólogos. La tasa general de adherencia a las directivas del Colegio Americano de Patología fue del 73.3%. Se encontraron deficiencias notables en los informes en varias características patológicas clave incluidos, el grado histológico del tumor (tasa de informe 77.8%), margenes radiales (84.6%), distancia del margen más cercano (47.9%), efecto del tratamiento (47.1%) invasión linfovascular (73.1 %) / invasion perineural (35.4%). El uso de informes sinópticos y los entornos hospitalarios urbanos se asociaron con mejores tasas de adherencia, mientras que el estado académico y el número de camas hospitalarias no tuvieron ningún impacto. Hubo variaciones en los informes no solo entre instituciones, sino también dentro de hospitales y patólogos individuales. Hubo una tendencia a una mejor adherencia a lo largo del tiempo (2005 = 65.7% v 2010 = 82.3%, p < 0.001), que coincidió con la mayor adopción de informes sinópticos por parte de los patólogos (2005 v 2010, 9.4% v 25.3%, p < 0.001)Datos obtenidos de un entorno restringido (es decir, hospitales que participan en un ensayo clínico aleatorizado).Se observaron grandes variaciones en la calidad de los informes de patología quirúrgica en casos de cáncer de recto. El Programa Nacional de Acreditación para Cáncer de Recto exige que los programas cumplan con estrictos estándares de calidad para los informes de patología quirúrgica. Se necesita una mejoría adicional en este aspecto clave de la atención oncológica para pacientes con cáncer de recto. Video Resumen en http://links.lww.com/DCR/B238.Registro de Clinical Trials.gov: NCT00058.",2020,"There was a trend for improved adherence over time (2005 = 65.7% vs 2010 = 82.3%, p < 0.001), which coincided with the increased adoption of synoptic reporting by pathologists (2005 vs 2010, 9.4% vs 25.3%, p < 0.001). ","['Hubo una tendencia a una mejor adherencia', 'Patients with rectal cancer undergoing surgical resection between July 2004 and August 2010 were included', 'patients with rectal cancer', 'QUIRÚRGICA EN', '1004 surgical pathology reports for rectal cancer surgery from 383 hospitals and 755 pathologists', 'hospitals participating in the National Surgical Adjuvant Breast and Bowel Project Protocol R-04 study', 'hospitales que participan en un ensayo clínico aleatorizado).Se observaron grandes variaciones en']","['See Video Abstract at http://links.lww.com/DCR/B238.ClinicalTrials.gov registration', 'Evaluar la calidad', 'CASOS DE CÁNCER']","['tumor histologic grade', 'adherence rates', 'el estado académico', 'patología quirúrgica en casos de cirugía', 'adherence over time', 'adoption of synoptic reporting by pathologists', 'radial margin', 'adherence to the College of American Pathologists guidelines and the impact of synoptic reporting, academic status, rural/urban setting, and hospital bed size on reporting quality', 'que coincidió con la mayor adopción', 'overall adherence rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030669', 'cui_str': 'Surgical Pathology'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C4517872', 'cui_str': '755'}, {'cui': 'C0334866', 'cui_str': 'Medical pathologist'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0000857', 'cui_str': 'Abstracting as Topic'}]","[{'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0919553', 'cui_str': 'Histologic grade'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0001593', 'cui_str': 'Adoption'}, {'cui': 'C0334866', 'cui_str': 'Medical pathologist'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0019954', 'cui_str': 'Bed Capacities, Hospital'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.0272938,"There was a trend for improved adherence over time (2005 = 65.7% vs 2010 = 82.3%, p < 0.001), which coincided with the increased adoption of synoptic reporting by pathologists (2005 vs 2010, 9.4% vs 25.3%, p < 0.001). ","[{'ForeName': 'Shonan', 'Initials': 'S', 'LastName': 'Sho', 'Affiliation': '1 Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California 2 NRG Oncology, Pittsburgh, Pennsylvania 3 The University of Pittsburgh, Pittsburgh, Pennsylvania 4 Department of Health Policy & Management, Fielding School of Public Health and the Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California 5 Glendale Memorial Hospital and Health Center, Glendale, California 6 Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Yothers', 'Affiliation': ''}, {'ForeName': 'Linda H', 'Initials': 'LH', 'LastName': 'Colangelo', 'Affiliation': ''}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Ganz', 'Affiliation': ''}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': ""O'Connell"", 'Affiliation': ''}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Beart', 'Affiliation': ''}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Hemmelgarn', 'Affiliation': ''}, {'ForeName': 'Formosa C', 'Initials': 'FC', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Clifford Y', 'Initials': 'CY', 'LastName': 'Ko', 'Affiliation': ''}, {'ForeName': 'Marcia M', 'Initials': 'MM', 'LastName': 'Russell', 'Affiliation': ''}]",Diseases of the colon and rectum,['10.1097/DCR.0000000000001578'] 2297,32691548,[Optimization of Operative Procedure in Total Laparoscopic Pancreaticoduodenectomy (with Video)].,"Objective To optimize operative procedure on intraoperative exploration, resection and reconstruction in total laparoscopic pancreaticoduodenectomy (LPD). Methods The clinical data of patients who underwent total LPD in West China Hospital (and Shangjin Hospital) of Sichuan University from Dec. 2015 to Dec. 2017 were retrospectively analyzed. The diagnosis of the patients included ampullar cancer, distal common bile duct cancer, benign and maligant tumors of pancreatic head and chronic pancreatitis of pancreatic head. The patients were divided into experimental group and control group according to weather the optimization of operative procedure was used. The position and Trocar arrangement in both groups were same. Two Chief Surgeons Model was used in experimental group, the procedure was divided into three key steps: laparoscopic exploration, resection and reconstruction, each followed anticlockwise operative process, from left to right, from shallow to deep (see the Videos 1 to 3 in Supplemental Contents, http://ykxb.scu.edu.cn/article/doi/10.12182/202007606108). As to control group, the chief operation was finished by chief surgeon and no specific operative procedure was applied. All the patients were followed up to postoperative 90 d. Results A total of 146 patients were collected, including 76 patients undergoing LPD with optimization of operative procedure and 70 patients in the control group. There was no significant difference in preoperative data between the two groups regarding to ASA scoring, age, gender, body mass index and laboratory tests ( P >0.05). Compared with the control group, the operative time in the experimental group was significantly shorter (341 min vs. 397 min, P <0.05), estimated blood loss was significantly reduced (110 mL vs. 180 mL, P <0.05). The conversive rate, transfusion rate, length of postoperative hospital stay, number of harvested lymph nodes, post pancreatectomy hemorrhage, bile leakage, pancreatic fistula (Grade B+C), reoperation, the occurrence of severe postoperative morbidity (Clavien-Dindo Ⅲ-Ⅳ), and postoperative 90 d mortality were no statistically difference. Conclusion With Two Chief Surgeons Model combined with anticlockwise operative process could optimize operative procedure in total LPD. It is safe and feasible, and could shorten the operation time and reduce intraoperative blood loss.",2020,"There was no significant difference in preoperative data between the two groups regarding to ASA scoring, age, gender, body mass index and laboratory tests ( P >0.05).","['146 patients were collected, including 76 patients undergoing LPD with optimization of operative procedure and 70 patients in the control group', 'patients who underwent total LPD in West China Hospital (and Shangjin Hospital) of Sichuan University from Dec. 2015 to Dec. 2017 were retrospectively analyzed']","['laparoscopic exploration, resection and reconstruction, each followed anticlockwise operative process', 'intraoperative exploration, resection and reconstruction in total laparoscopic pancreaticoduodenectomy (LPD', 'Total Laparoscopic Pancreaticoduodenectomy (with Video']","['conversive rate, transfusion rate, length of postoperative hospital stay, number of harvested lymph nodes, post pancreatectomy hemorrhage, bile leakage, pancreatic fistula (Grade B+C), reoperation, the occurrence of severe postoperative morbidity (Clavien-Dindo Ⅲ-Ⅳ), and postoperative 90 d mortality', 'preoperative data', 'operative time', 'estimated blood loss']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0085162', 'cui_str': 'Pancreaticoduodenectomy'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037769', 'cui_str': 'West syndrome'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C1280903', 'cui_str': 'Exploration procedure'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0085162', 'cui_str': 'Pancreaticoduodenectomy'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0024204', 'cui_str': 'Structure of lymph node'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0030279', 'cui_str': 'Pancreatectomy'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0400997', 'cui_str': 'Leakage of bile'}, {'cui': 'C0030290', 'cui_str': 'Pancreatic fistula'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C1443559', 'cui_str': 'Estimated blood loss'}]",146.0,0.0164687,"There was no significant difference in preoperative data between the two groups regarding to ASA scoring, age, gender, body mass index and laboratory tests ( P >0.05).","[{'ForeName': 'Yong-Bin', 'Initials': 'YB', 'LastName': 'Li', 'Affiliation': 'Department of Hepatobiliary Pancreas Minimally Invasive Surgery, Shangjin Hospital of West China Hospital , Sichuan University, Chengdu 611730, China.'}, {'ForeName': 'Yun-Qiang', 'Initials': 'YQ', 'LastName': 'Cai', 'Affiliation': 'Department of Hepatobiliary Pancreas Minimally Invasive Surgery, Shangjin Hospital of West China Hospital , Sichuan University, Chengdu 611730, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.'}, {'ForeName': 'Ling-Wei', 'Initials': 'LW', 'LastName': 'Meng', 'Affiliation': 'Department of Hepatobiliary Pancreas Minimally Invasive Surgery, Shangjin Hospital of West China Hospital , Sichuan University, Chengdu 611730, China.'}, {'ForeName': 'He', 'Initials': 'H', 'LastName': 'Cai', 'Affiliation': 'Department of Hepatobiliary Pancreas Minimally Invasive Surgery, Shangjin Hospital of West China Hospital , Sichuan University, Chengdu 611730, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Department of Hepatobiliary Pancreas Minimally Invasive Surgery, Shangjin Hospital of West China Hospital , Sichuan University, Chengdu 611730, China.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Peng', 'Affiliation': 'Department of Hepatobiliary Pancreas Minimally Invasive Surgery, Shangjin Hospital of West China Hospital , Sichuan University, Chengdu 611730, China.'}]",Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition,['10.12182/20200760108'] 2298,32691639,An Examination of a Novel Weight Loss Supplement on Anthropometry and Indices of Cardiovascular Disease Risk.,"PURPOSE This study examined whether adding Dichrostachys glomerata (DG; 300 mg/d) to thermogenic supplements with (DG + C) and without (DG) caffeine and other nutrients affects weight loss, changes in body composition, and/or markers of health. METHODS Sixty-eight participants (female, 54%) were grouped in a double-blind, parallel, stratified random, placebo-controlled manner to supplement their diet with a placebo, DG, or DG + C for 12 weeks while maintaining their normal diet and physical activity. Diet, physical activity, body weight, body composition, anthropometric measures, resting energy expenditure, fasting blood samples, and questionnaires were obtained at 0, 4, 8, and 12 weeks and analyzed using general linear models with repeated measures. Data are reported as mean (±SD) and change from baseline (mean, 95% confidence interval) for weeks 4, 8, and 12, respectively, with p values showing changes from baseline. RESULTS DG treatment promoted significant but minor reductions in fat mass (-0.56 [-1.02, -0.14], p  = 0.01; -0.63 [-1.23, -0.02], p  = 0.04; -0.71 [-1.47, 0.09] kg, p  = 0.08) and percent body fat (-0.46 [-0.96, -0.04], p  = 0.07; -0.63 [-1.16, -0.10], p  = 0.02; -0.78 [-1.45, 0.07] %, p  = 0.03). There was some evidence that DG + C increased resting energy expenditure, decreased hunger, increased satiety, and improved sleep quality (diminished in DG + C). No other significant effects were observed. CONCLUSIONS Ingestion of thermogenic supplements containing DG (300 mg/d) with and without caffeine and other nutrients in overweight but otherwise healthy participants who did not alter diet or physical activity promoted clinically insignificant changes in body weight and composition.",2020,"RESULTS DG treatment promoted significant but minor reductions in fat mass (-0.56 [-1.02, -0.14], p  = 0.01; -0.63","['Sixty-eight participants (female, 54']","['placebo-controlled manner to supplement their diet with a placebo, DG, or DG\u2009+\u2009C', 'Dichrostachys glomerata (DG; 300\u2009mg/d) to thermogenic supplements with (DG\u2009+\u2009C) and without (DG) caffeine']","['Diet, physical activity, body weight, body composition, anthropometric measures, resting energy expenditure, fasting blood samples, and questionnaires', 'body weight and composition', 'weight loss, changes in body composition, and/or markers of health', 'fat mass', 'percent body fat ', 'resting energy expenditure, decreased hunger, increased satiety, and improved sleep quality']","[{'cui': 'C0450387', 'cui_str': '68'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}]",68.0,0.149437,"RESULTS DG treatment promoted significant but minor reductions in fat mass (-0.56 [-1.02, -0.14], p  = 0.01; -0.63","[{'ForeName': 'Ryan J', 'Initials': 'RJ', 'LastName': 'Sowinski', 'Affiliation': 'Exercise & Sport Nutrition Lab, Human Clinical Research Facility, Department of Health & Kinesiology, Texas A&M University, College Station, TX, USA.'}, {'ForeName': 'Tyler J', 'Initials': 'TJ', 'LastName': 'Grubic', 'Affiliation': 'Exercise & Sport Nutrition Lab, Human Clinical Research Facility, Department of Health & Kinesiology, Texas A&M University, College Station, TX, USA.'}, {'ForeName': 'Ryan L', 'Initials': 'RL', 'LastName': 'Dalton', 'Affiliation': 'Exercise & Sport Nutrition Lab, Human Clinical Research Facility, Department of Health & Kinesiology, Texas A&M University, College Station, TX, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Schlaffer', 'Affiliation': 'Exercise & Sport Nutrition Lab, Human Clinical Research Facility, Department of Health & Kinesiology, Texas A&M University, College Station, TX, USA.'}, {'ForeName': 'Aimee G', 'Initials': 'AG', 'LastName': 'Reyes-Elrod', 'Affiliation': 'Exercise & Sport Nutrition Lab, Human Clinical Research Facility, Department of Health & Kinesiology, Texas A&M University, College Station, TX, USA.'}, {'ForeName': 'Victoria M', 'Initials': 'VM', 'LastName': 'Jenkins', 'Affiliation': 'Exercise & Sport Nutrition Lab, Human Clinical Research Facility, Department of Health & Kinesiology, Texas A&M University, College Station, TX, USA.'}, {'ForeName': 'Susannah', 'Initials': 'S', 'LastName': 'Williamson', 'Affiliation': 'Exercise & Sport Nutrition Lab, Human Clinical Research Facility, Department of Health & Kinesiology, Texas A&M University, College Station, TX, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Rasmussen', 'Affiliation': 'Exercise & Sport Nutrition Lab, Human Clinical Research Facility, Department of Health & Kinesiology, Texas A&M University, College Station, TX, USA.'}, {'ForeName': 'Peter S', 'Initials': 'PS', 'LastName': 'Murano', 'Affiliation': 'Department of Nutrition and Food Sciences, Texas A&M University, College Station, TX, USA.'}, {'ForeName': 'Conrad P', 'Initials': 'CP', 'LastName': 'Earnest', 'Affiliation': 'Exercise & Sport Nutrition Lab, Human Clinical Research Facility, Department of Health & Kinesiology, Texas A&M University, College Station, TX, USA.'}, {'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Kreider', 'Affiliation': 'Exercise & Sport Nutrition Lab, Human Clinical Research Facility, Department of Health & Kinesiology, Texas A&M University, College Station, TX, USA.'}]",Journal of dietary supplements,['10.1080/19390211.2020.1786207'] 2299,32692216,"Treatment of hyperlipidemic acute pancreatitis with modified Dachengqi decoction combining with conventional therapy based on ""six-hollow-organs to be unblocked"" theory.","BACKGROUND The increase of triglyceride (TG) can induce coronary heart disease, atherosclerosis, pancreatitis and other diseases and is the most common inducing factor of acute pancreatitis (AP) second only to biliary tract disease and drinking. The pathogenesis of hyperlipidemic acute pancreatitis (HLAP) is not exactly clear, but it may be related to the toxic effect of the increase of free fatty acids produced by TG decomposition on the pancreas itself, microcirculation disorder of the pancreas, and calcium overload. At present, non-surgical therapy is the main treatment for HLAP. The key to preventing recurrence is to reduce blood lipids, change the diet structure, and reduce weight. This study aimed to treat HLAP with modified Dachengqi decoction combined with conventional therapy, based on the ""six-hollow-organs to be unblocked"" theory. METHODS Forty patients with HLAP who received treatment in the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine and Puding County Hospital of Traditional Chinese Medicine from September 2016 to August 2019 were selected and divided into a control group and an intervention group, each with 20 cases, following a random number table. The control group was treated with conventional therapy while the intervention group was treated with modified Dachengqi decoction combined with conventional therapy. RESULTS After treatment, the cure rate and the total effective rate were 60% and 95% respectively in the intervention group, and 25% and 75% respectively in the control group (P<0.05). The TG, serum amylase, leukocyte count, and neutrophil ratio of the two groups decreased significantly after treatment, and there was a greater decrease in the intervention group than that in the control group, with this being significantly different between the two groups. The gastrointestinal function score, total score of the acute physiology and chronic health evaluation II (APACHE II), and the pain score of the visual analog scale (VAS) decreased markedly in the two groups after the treatment, with scores in the intervention group being significantly lower than those in the control group (P<0.05). CONCLUSIONS Modified Dachengqi decoction combined with conventional therapy has a better therapeutic effect on HLAP than conventional therapy.",2020,"After treatment, the cure rate and the total effective rate were 60% and 95% respectively in the intervention group, and 25% and 75% respectively in the control group (P<0.05).","['hyperlipidemic acute pancreatitis', 'hyperlipidemic acute pancreatitis (HLAP', 'Forty patients with HLAP who received treatment in the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine and Puding County Hospital of Traditional Chinese Medicine from September 2016 to August 2019']","['HLAP with modified Dachengqi decoction combined with conventional therapy', 'modified Dachengqi decoction combining with conventional therapy', 'triglyceride (TG', 'conventional therapy', 'Modified Dachengqi decoction combined with conventional therapy', 'modified Dachengqi decoction combined with conventional therapy']","['gastrointestinal function score, total score of the acute physiology and chronic health evaluation II (APACHE II), and the pain score of the visual analog scale (VAS', 'TG, serum amylase, leukocyte count, and neutrophil ratio', 'cure rate and the total effective rate']","[{'cui': 'C0001339', 'cui_str': 'Acute pancreatitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0030920', 'cui_str': 'Peptic ulcer'}, {'cui': 'C0020005', 'cui_str': 'County Hospitals'}]","[{'cui': 'C0001339', 'cui_str': 'Acute pancreatitis'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1311504', 'cui_str': 'dachengqi decoction'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}]","[{'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0243028', 'cui_str': 'Acute physiology and chronic health evaluation II'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0201885', 'cui_str': 'Amylase measurement, serum'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",40.0,0.0187697,"After treatment, the cure rate and the total effective rate were 60% and 95% respectively in the intervention group, and 25% and 75% respectively in the control group (P<0.05).","[{'ForeName': 'Guoxiong', 'Initials': 'G', 'LastName': 'Liu', 'Affiliation': 'Department of Orthopedics, the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China. zgliuguoxiong@163.com.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Liu', 'Affiliation': 'Department of Orthopedics, the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China.'}, {'ForeName': 'Long', 'Initials': 'L', 'LastName': 'Xiao', 'Affiliation': 'Department of Orthopedics, the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China.'}, {'ForeName': 'Qiaogui', 'Initials': 'Q', 'LastName': 'Kuang', 'Affiliation': 'College of Acupuncture and Orthopedics, Guizhou University of Traditional Chinese Medicine, Guiyang, China.'}, {'ForeName': 'Xingfeng', 'Initials': 'X', 'LastName': 'He', 'Affiliation': 'Department of Orthopedics, the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Puding County Hospital of Traditional Chinese Medicine, Anshun, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': 'Puding County Hospital of Traditional Chinese Medicine, Anshun, China.'}]",Annals of palliative medicine,['10.21037/apm-20-1106'] 2300,32692240,Effectiveness of a multidisciplinary comprehensive intervention model based on the Hospital Elderly Life Program to prevent delirium in patients with severe acute pancreatitis.,"BACKGROUND Pancreatic encephalopathy is the most serious complication of severe acute pancreatitis (SAP) and substantially increases mortality. Delirium is a common clinical manifestation of pancreatic encephalopathy. This study aimed to assess the clinical effects of an improved version of the Hospital Elderly Life Program (HELP) on preventing delirium in elderly patients with SAP. METHODS A total of 106 patients with SAP aged 70 years or older were randomly divided into an experimental group (53 cases) and a control group (53 cases). The experimental group was given 2 weeks of conventional nursing combined with the HELP regimen, while the control group was given 2 weeks of conventional nursing. Conventional nursing included disease care, geriatric syndrome care and observation of critically ill patients. The incidence of delirium, severity of delirium, self-care ability, cognitive function, length of hospital stay, and patient satisfaction were compared between the 2 groups before and after the intervention. RESULTS The incidence of delirium was 4.00% in the experimental group and 16.98% in the control group; the difference was statistically significant (P=0.033). After 2 weeks of intervention, the experimental group showed significantly better self-care ability and cognitive function, shorter hospital stay, and greater patient satisfaction than the control group (all P<0.05). CONCLUSIONS The improved HELP protocol for elderly patients with SAP can reduce the incidence and severity of delirium, improve self-care ability and cognitive function, shorten hospital stay, and increase patient satisfaction.",2020,"After 2 weeks of intervention, the experimental group showed significantly better self-care ability and cognitive function, shorter hospital stay, and greater patient satisfaction than the control group (all P<0.05). ","['patients with severe acute pancreatitis', '106 patients with SAP aged 70 years or older', 'critically ill patients', 'elderly patients with SAP']","['conventional nursing combined with the HELP regimen', 'Hospital Elderly Life Program (HELP', 'multidisciplinary comprehensive intervention model']","['better self-care ability and cognitive function, shorter hospital stay, and greater patient satisfaction', 'incidence of delirium, severity of delirium, self-care ability, cognitive function, length of hospital stay, and patient satisfaction', 'incidence of delirium', 'mortality', 'incidence and severity of delirium, improve self-care ability and cognitive function, shorten hospital stay, and increase patient satisfaction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001339', 'cui_str': 'Acute pancreatitis'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0562734', 'cui_str': 'Ability to perform personal care activity'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",106.0,0.0291091,"After 2 weeks of intervention, the experimental group showed significantly better self-care ability and cognitive function, shorter hospital stay, and greater patient satisfaction than the control group (all P<0.05). ","[{'ForeName': 'Zhixia', 'Initials': 'Z', 'LastName': 'Dong', 'Affiliation': 'Department of Gastroenterology, the Affiliated Hospital of Jiangnan University, Wuxi, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Song', 'Affiliation': 'Department of Gastroenterology, the Affiliated Hospital of Jiangnan University, Wuxi, China.'}, {'ForeName': 'Minhua', 'Initials': 'M', 'LastName': 'Ge', 'Affiliation': 'Department of Gastroenterology, the Affiliated Hospital of Jiangnan University, Wuxi, China.'}, {'ForeName': 'Chunyan', 'Initials': 'C', 'LastName': 'Lin', 'Affiliation': 'Department of Gastroenterology, the Affiliated Hospital of Jiangnan University, Wuxi, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Hepatobiliary, the Affiliated Hospital of Jiangnan University, Wuxi, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Hepatobiliary, the Affiliated Hospital of Jiangnan University, Wuxi, China.'}, {'ForeName': 'Yanmin', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Gastroenterology, the Affiliated Hospital of Jiangnan University, Wuxi, China. 396285432@qq.com.'}]",Annals of palliative medicine,['10.21037/apm-20-913'] 2301,32692244,The appropriate dose of propofol for anesthesia induction in morbidly obese patients.,"BACKGROUND To investigate the optimal dose of propofol in patients with morbid obesity when the anesthetic induction dosage is calculated based on lean body weight (LBW). METHODS Forty morbid obese patients with body mass index (BMI) ≥35 kg/m2 were randomly divided into two groups: B and M. The sequential method was used in group B to study the EC50 and 95% confidence interval (CI) that met a bispectral index (BIS) value of <50 (the initial dose was set at 2.5 mg/kg). The sequential method was used in group M to obtain the EC50 and 95% CI (the initial dose was set as 3.0 mg/kg) satisfying the mean arterial pressure (MAP) fluctuation margin of >40%. The optimal dose interval of propofol was obtained by synthetically analyzing the results of the two-sequence method. RESULTS There was no significant difference in the general condition between the two groups (P>0.05). There was no significant change in vital signs from when patients entered the operating room to when sufentanil was infused (P>0.05). The probit model of group B was Y=-5.411+2.343X, the EC50 of positive reaction with BIS <50 was 2.310 mg/kg, and 95% CI was 1.850-2.883 mg/kg. The probit model in the M group was Y=3.275 - 0.918X, the EC50 of positive reaction that reached >40% of the whole process of anesthetic induction was 3.567 mg/kg, and 95% CI was 1.233-7.165 mg/kg. CONCLUSIONS The appropriate dosage of propofol was 2.310-3.567 mg/kg when the anesthetic induction dosage for patients with morbid obesity was calculated based on LBW. With this dose, the depth of intubation is satisfactory and the hemodynamics are stable.",2020,There was no significant difference in the general condition between the two groups (P>0.05).,"['morbidly obese patients', 'patients with morbid obesity', 'Forty morbid obese patients with body mass index']","['sufentanil', 'propofol']","['general condition', 'mean arterial pressure (MAP) fluctuation margin', 'bispectral index (BIS) value', 'vital signs']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028756', 'cui_str': 'Morbid obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0231239', 'cui_str': 'Fluctuation'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C1301882', 'cui_str': 'Bispectral index'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}]",40.0,0.023511,There was no significant difference in the general condition between the two groups (P>0.05).,"[{'ForeName': 'Guiping', 'Initials': 'G', 'LastName': 'Xu', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China. xgpsyl@126.com.""}, {'ForeName': 'Nannan', 'Initials': 'N', 'LastName': 'Qiao', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.""}, {'ForeName': 'Yangyang', 'Initials': 'Y', 'LastName': 'Pan', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.""}, {'ForeName': 'Alimujiang', 'Initials': 'A', 'LastName': 'Simayi', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.""}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Chen', 'Affiliation': ""Department of Anesthesiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.""}]",Annals of palliative medicine,['10.21037/apm-20-1223'] 2302,32692245,Clinical research of percutaneous spinal nerve posteromedial ramus destruction in treatment for chronic facet arthrogenic low back pain: a randomized trial.,"BACKGROUND To investigate the clinical effect of percutaneous spinal nerve posteromedial ramus destruction in treatment for chronic facet arthrogenic low back pain. METHODS A total of 118 patients with chronic facet arthrogenic low back pain were enrolled in our hospital from October 2015 to October 2018 and randomly divided into two groups. Of these patients, 59 received conservative treatment as the control group while 59 patients were treated with percutaneous spinal nerve posteromedial ramus destruction as the observation group. Pain score (Visual Analogue Scale, VAS), functional score (Oswestry Disability Index, ODI), treatment score (Japanese Orthopaedic Association, JOA), life quality score (Short Form 36-item Health Survey, SF-36), and lumbar mobility (range of motion, ROM) were evaluated before and after treatment. The treatment effect between two groups was compared. RESULTS The VAS score and ODI score at 2, 4, and 12 weeks after treatment and last follow-up in the observation group were lower than those of the control group (P<0.05). JOA score, SF-36, and ROM were higher than those of the control group (P<0.05). CONCLUSIONS Percutaneous spinal nerve posteromedial ramus destruction has a significant effect in treatment for chronic facet arthrogenic low back pain, which can relieve pain, improve function, and enhance quality of life.",2020,"JOA score, SF-36, and ROM were higher than those of the control group (P<0.05). ","['chronic facet arthrogenic low back pain', '118 patients with chronic facet arthrogenic low back pain were enrolled in our hospital from October 2015 to October 2018 and randomly divided into two groups']","['percutaneous spinal nerve posteromedial ramus destruction as the observation group', 'percutaneous spinal nerve posteromedial ramus destruction']","['Pain score (Visual Analogue Scale, VAS), functional score (Oswestry Disability Index, ODI), treatment score (Japanese Orthopaedic Association, JOA), life quality score (Short Form 36-item Health Survey, SF-36), and lumbar mobility (range of motion, ROM', 'VAS score and ODI score', 'JOA score, SF-36, and ROM']","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0222679', 'cui_str': 'Structure of articular surface of bone'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0037941', 'cui_str': 'Spinal nerve structure'}, {'cui': 'C1261381', 'cui_str': 'Destructive procedure'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0948106', 'cui_str': 'Amniorrhexis'}]",118.0,0.0287034,"JOA score, SF-36, and ROM were higher than those of the control group (P<0.05). ","[{'ForeName': 'Shuang', 'Initials': 'S', 'LastName': 'Feng', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China.'}, {'ForeName': 'Qiujin', 'Initials': 'Q', 'LastName': 'Xiao', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China.'}, {'ForeName': 'Yinchu', 'Initials': 'Y', 'LastName': 'Shao', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Yu', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Hu', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China.'}, {'ForeName': 'Guoyun', 'Initials': 'G', 'LastName': 'Bu', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China. 517730611@qq.com.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'The 908th Hospital of Chinese PLA, Nanchang, China. 47160843@qq.com.'}]",Annals of palliative medicine,['10.21037/apm-20-1374'] 2303,32692247,Clinical study on different doses and fractionated radiotherapies for multiple brain metastases of non-EGFR mutant lung adenocarcinoma.,"BACKGROUND To study the effects and adverse reactions of different doses and fractionated radiotherapies on non-epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma patients with multiple brain metastases. METHODS In total, 80 patients eligible for inclusion were randomly divided into 4 groups. Group A included whole brain radiotherapy (WBRT) alone 300 cGy/fraction ×10 fractions, at a total dose of 3,000 cGy. Group B included WBRT alone 180 cGy/fraction ×22 fractions, at a total dose of 3,960 cGy. Group C included intracranial metastases radiotherapy alone 250 cGy/fraction ×22 fractions at a total dose of 5,500 cGy. Group D included the whole brain + intracranial metastases group (SIB group) whole brain 180 cGy/fraction ×22 fractions intracranial metastases 250 cGy/fraction ×22 fractions, at a total dose 3,960 cGy, 5,500 cGy, respectively. RESULTS The median survival time of intracranial disease-free survival (IPFS) in group A, group B, group C, and group D was 6, 9, 8, and 13 months, respectively (P=0.000). The median overall survival (OS) time was 16, 24.5, 24, and 30 months, respectively (P=0.150). There was a significant difference in IPFS between different doses and fractionated radiotherapies, but there was no difference in OS. Multivariate analysis showed that the radiotherapy dose of intracranial metastases was positively correlated with IPFS and OS. The incidence rate of adverse reaction of memory decline in 0.5, 1, and 2 years in group A, group B, group C, and group D was respectively 10.0%, 15.0%, 5.0%, and 15.0% (P=0.006); 20.0%, 45.0%, 30.0%, and 60.0% (P=0.000); 10.0%, 20.0%, 35.0%, and 65.0% (P=0.000). The incidence rates of memory decline in the groups of WBRT were significantly more increased than in the non-WBRT group. CONCLUSIONS Radiotherapy is effective for multiple brain metastases of lung adenocarcinoma, the increase of radiotherapy dose can improve IPFS and OS, and the adverse reaction of memory decline after WBRT is increased but tolerable. Therefore, WBRT and simultaneous integrated boost (SIB) radiotherapy of intracranial metastases is recommended for multiple brain metastases of non-EGFR-mutant lung adenocarcinoma.",2020,"The incidence rates of memory decline in the groups of WBRT were significantly more increased than in the non-WBRT group. ","['multiple brain metastases of non-EGFR mutant lung adenocarcinoma', '80 patients eligible for inclusion', 'lung adenocarcinoma patients with multiple brain metastases']","['whole brain radiotherapy (WBRT) alone 300 cGy/fraction ×10 fractions', 'WBRT and simultaneous integrated boost (SIB) radiotherapy', 'fractionated radiotherapies', 'whole brain + intracranial metastases group (SIB group) whole brain 180 cGy/fraction ×22 fractions intracranial metastases 250 cGy/fraction ×22 fractions', 'WBRT', 'Radiotherapy']","['median survival time of intracranial disease-free survival (IPFS', 'IPFS', 'OS', 'median overall survival (OS) time', 'incidence rate of adverse reaction of memory decline', 'incidence rates of memory decline']","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0220650', 'cui_str': 'Secondary malignant neoplasm of brain'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0152013', 'cui_str': 'Adenocarcinoma of lung'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}]","[{'cui': 'C1520143', 'cui_str': 'Whole brain radiation therapy'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0556645', 'cui_str': 'cGy'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0524466', 'cui_str': 'Intracranial'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C2348831', 'cui_str': '250'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C2919552', 'cui_str': 'Survival time'}, {'cui': 'C0524466', 'cui_str': 'Intracranial'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}]",80.0,0.0197721,"The incidence rates of memory decline in the groups of WBRT were significantly more increased than in the non-WBRT group. ","[{'ForeName': 'Hongli', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'School of Medicine and Life Science, University of Jinan-Shandong Academy of Medical Sciences, Jining Tumor Hospital, Jinan, China.'}, {'ForeName': 'Xuedong', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': 'Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.'}, {'ForeName': 'Jinzhi', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.'}, {'ForeName': 'Changsheng', 'Initials': 'C', 'LastName': 'Ma', 'Affiliation': 'Department of Radiophysics and Technology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Sun', 'Affiliation': 'Department of Radiophysics and Technology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Shao', 'Affiliation': 'Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. shaoqian2009@sina.com.'}]",Annals of palliative medicine,['10.21037/apm-20-1203'] 2304,32692284,Prediction of Minor Salivary Gland Carcinoma: A Novel Nomogram and Risk Classification System for Overall Survival and Cancer-Specific Survival.,"OBJECTIVE Minor salivary gland carcinoma (MiSGC) is rare, and the understanding of this disease is insufficient. This study aimed to identify independent risk factors and develop a nomogram for evaluating the overall survival (OS) and cancer-specific survival (CSS) of patients with MiSGC. STUDY DESIGN Retrospective cohort study. SETTING SEER database (Surveillance, Epidemiology, and End Results). SUBJECTS AND METHODS We collected data from patients diagnosed with MiSGC between 2004 and 2015 from the SEER database. According to patient registration, all patients were randomly allocated to training sets and validation sets (2:1). Then, Kaplan-Meier product limit curves and Cox proportional hazard regressions were performed to estimate the prognostic effect of variables. Nomograms based on Cox proportional hazard regressions were established to estimate 3- and 5-year OS and CSS. Finally, the nomogram was developed by the training set, and validation was performed with the concordance index, calibration curves, and decision curve analyses. RESULTS In total, 1787 MiSGC cases were registered in SEER. The concordance index for internal validation of OS and CSS prediction was 0.842 and 0.816; that of external validation was 0.871 and 0.831. The calibration plots showed good consistency between nomogram prediction and actual survival. The decision curve analysis showed substantial net benefits of the new predictive model. CONCLUSIONS We constructed nomograms and a corresponding risk classification system predicting the OS and CSS of patients with MiSGC. These tools can generate simple-to-use clinical risk grouping and determine the relationship between adjuvant therapy and active surveillance.",2020,The concordance index for internal validation of OS and CSS prediction was 0.842 and 0.816; that of external validation was 0.871 and 0.831.,"['patients with MiSGC', 'Minor Salivary Gland Carcinoma', 'We collected data from patients diagnosed with MiSGC between 2004 and 2015 from the SEER database']",[],"['concordance index for internal validation of OS and CSS prediction', 'overall survival (OS) and cancer-specific survival (CSS', 'Overall Survival and Cancer-Specific Survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036099', 'cui_str': 'Minor salivary gland structure'}, {'cui': 'C0007097', 'cui_str': 'Carcinoma'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}]",[],"[{'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205369', 'cui_str': 'Specific'}]",,0.0427726,The concordance index for internal validation of OS and CSS prediction was 0.842 and 0.816; that of external validation was 0.871 and 0.831.,"[{'ForeName': 'Ling-Feng', 'Initials': 'LF', 'LastName': 'Lan', 'Affiliation': 'Department of Otolaryngology, the 903(rd) Hospital of PLA, Hangzhou, China.'}, {'ForeName': 'Chen-Kai', 'Initials': 'CK', 'LastName': 'Gao', 'Affiliation': 'Department of Otolaryngology, the 903(rd) Hospital of PLA, Hangzhou, China.'}, {'ForeName': 'Chao-Wu', 'Initials': 'CW', 'LastName': 'Ma', 'Affiliation': 'Department of Otolaryngology, the 903(rd) Hospital of PLA, Hangzhou, China.'}]",Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery,['10.1177/0194599820938323'] 2305,32692299,Two-year Review on Mortality and Morbidity after Femoropopliteal Drug-coated Balloon Angioplasty in the Randomized EffPac Trial.,,2020,,[],['Femoropopliteal Drug-coated Balloon Angioplasty'],['Mortality and Morbidity'],[],"[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0453946', 'cui_str': 'Coat'}, {'cui': 'C0002996', 'cui_str': 'Balloon Angioplasty'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}]",,0.0892218,,"[{'ForeName': 'Ulf', 'Initials': 'U', 'LastName': 'Teichgräber', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); REGIOMED Clinics, Sonneberg, Germany (M.T.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); and Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.).'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Lehmann', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); REGIOMED Clinics, Sonneberg, Germany (M.T.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); and Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.).'}, {'ForeName': 'René', 'Initials': 'R', 'LastName': 'Aschenbach', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); REGIOMED Clinics, Sonneberg, Germany (M.T.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); and Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.).'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Thieme', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); REGIOMED Clinics, Sonneberg, Germany (M.T.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); and Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.).'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Zeller', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); REGIOMED Clinics, Sonneberg, Germany (M.T.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); and Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.).'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Beschorner', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); REGIOMED Clinics, Sonneberg, Germany (M.T.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); and Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.).'}, {'ForeName': 'Dierk', 'Initials': 'D', 'LastName': 'Scheinert', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); REGIOMED Clinics, Sonneberg, Germany (M.T.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); and Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.).'}]",Radiology,['10.1148/radiol.2020201370'] 2306,32692356,The Moderating Effects of Social Support and Stress on Physical Activity in African American Women.,"BACKGROUND African American women participate in less physical activity (PA), have higher rates of chronic disease, and report higher perceived stress relative to other race and sex demographic groups. PURPOSE Based on the stress-buffering hypothesis, this study tested the hypothesis that social support would buffer the negative effects of perceived stress on moderate-to-vigorous PA (MVPA) under high, but not low, perceived stress. METHODS Participants were 143 African American women (mean [M] age = 43.94, standard deviation [SD] = 8.62; M body mass index = 37.94, SD = 8.11) enrolled in the Families Improving Together (FIT) for Weight Loss Trial. Average daily minutes of MVPA were obtained via 7 day accelerometer estimates at baseline and 8 and 16 weeks. RESULTS A multilevel growth model demonstrated a significant three-way interaction between stress, social support, and time (B = -0.31, standard error [SE] = 0.14, p = .03). Simple slopes analyses revealed that, at baseline, among participants with high social support (+1 SD), stress was positively associated with greater MVPA (B = 0.49, SE = 0.18, p = .008), whereas among participants with low social support (-1 SD), stress was not significantly associated with MVPA (B = -0.04, SE = 0.14, p = .81). However, at 8 and 16 weeks, stress was not significantly associated with MVPA for either high or low support groups. CONCLUSIONS Findings highlight the importance of integrating constructs of stress and social support into future physical activity intervention programs for African American women and the need to evaluate changes in stress and social support longitudinally.",2020,"However, at 8 and 16 weeks, stress was not significantly associated with MVPA for either high or low support groups. ","['African American women participate in less physical activity (PA', 'African American Women', 'African American women', 'Participants were 143 African American women (mean [M] age = 43.94, standard deviation [SD] = 8.62; M body mass index = 37.94, SD = 8.11) enrolled in the Families Improving Together (FIT) for Weight Loss Trial']",['Social Support and Stress'],"['Average daily minutes of MVPA', 'Physical Activity']","[{'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4517573', 'cui_str': '143'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",143.0,0.020482,"However, at 8 and 16 weeks, stress was not significantly associated with MVPA for either high or low support groups. ","[{'ForeName': 'Asia', 'Initials': 'A', 'LastName': 'Brown', 'Affiliation': 'Department of Psychology, Barnwell College, University of South Carolina, Columbia, SC, USA.'}, {'ForeName': 'Dawn K', 'Initials': 'DK', 'LastName': 'Wilson', 'Affiliation': 'Department of Psychology, Barnwell College, University of South Carolina, Columbia, SC, USA.'}, {'ForeName': 'Allison M', 'Initials': 'AM', 'LastName': 'Sweeney', 'Affiliation': 'Department of Psychology, Barnwell College, University of South Carolina, Columbia, SC, USA.'}, {'ForeName': 'M Lee', 'Initials': 'ML', 'LastName': 'Van Horn', 'Affiliation': 'Department of Educational Psychology, University of New Mexico, Albuquerque, NM, USA.'}]",Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,['10.1093/abm/kaaa051'] 2307,32692358,A Randomized Controlled Trial of Long-Term (R)-α-Lipoic Acid Supplementation Promotes Weight Loss in Overweight or Obese Adults without Altering Baseline Elevated Plasma Triglyceride Concentrations.,"BACKGROUND α-Lipoic acid (LA) is a dietary supplement for maintaining energy balance, but well-controlled clinical trials in otherwise healthy, overweight adults using LA supplementation are lacking. OBJECTIVES The primary objective was to evaluate whether LA supplementation decreases elevated plasma triglycerides in overweight or obese adults. Secondary aims examined if LA promotes weight loss and improves oxidative stress and inflammation. METHODS Overweight adults [n = 81; 57% women; 21-60 y old; BMI (in kg/m2) ≥ 25] with elevated plasma triglycerides ≥100 mg/dL were enrolled in a 24-wk, randomized, double-blind, controlled trial, assigned to either (R)-α-lipoic acid (R-LA; 600 mg/d) or matching placebo, and advised not to change their diet or physical activity. Linear models were used to evaluate treatment effects from baseline for primary and secondary endpoints. RESULTS R-LA did not decrease triglyceride concentrations, but individuals on R-LA had a greater reduction in BMI at 24 wk than the placebo group (-0.8; P = 0.04). The effect of R-LA on BMI was correlated to changes in plasma triglycerides (r = +0.50, P = 0.004). Improvement in body weight was greater at 24 wk in R-LA subgroups than in placebo subgroups. Women and obese participants (BMI ≥ 35) showed greater weight loss (-5.0% and -4.8%, respectively; both P < 0.001) and loss of body fat (-9.4% and -8.6%, respectively; both P < 0.005). Antioxidant gene expression in mononuclear cells at 24 wk was greater in the R-LA group (Heme oxygenase 1 [HMOX1] : +22%; P = 0.02) than in placebo. Less urinary F2-isoprostanes (-25%; P = 0.005), blood leukocytes (-10.1%; P = 0.01), blood thrombocytes (-5.1%; P = 0.03), and ICAM-1 (-7.4%; P = 0.04) at 24 wk were also observed in the R-LA group than in placebo. CONCLUSIONS Long-term LA supplementation results in BMI loss, greater antioxidant enzyme synthesis, and less potential for inflammation in overweight adults. Improved cellular bioenergetics is also evident in some individuals given R-LA.This trial was registered at clinicaltrials.gov as NCT00765310.",2020,"Less urinary F2-isoprostanes (-25%; P = 0.005), blood leukocytes (-10.1%; P = 0.01), blood thrombocytes (-5.1%; P = 0.03), and ICAM-1 (-7.4%; P = 0.04) at 24 wk were also observed in the R-LA group than in placebo. ","['overweight adults', 'overweight or obese adults', 'Overweight or Obese Adults without Altering Baseline Elevated Plasma Triglyceride Concentrations', 'Overweight adults [n\xa0=\xa081; 57% women; 21-60 y old; BMI (in kg/m2)\xa0≥\xa025] with elevated plasma triglycerides ≥100']","['Long-term LA supplementation', 'α-Lipoic acid (LA', 'R-LA', 'Long-Term (R)-α-Lipoic Acid Supplementation', 'R)-α-lipoic acid (R-LA; 600\xa0mg/d) or matching placebo', 'LA supplementation', 'LA', 'placebo']","['Antioxidant gene expression in mononuclear cells', 'triglyceride concentrations', 'Weight Loss', 'oxidative stress and inflammation', 'body weight', 'Less urinary F2-isoprostanes', 'BMI', 'weight loss', 'blood leukocytes', 'blood thrombocytes', 'ICAM-1', 'loss of body fat', 'cellular bioenergetics', 'plasma triglycerides', 'BMI loss, greater antioxidant enzyme synthesis']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0583329', 'cui_str': 'Plasma triglyceride measurement'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0023791', 'cui_str': 'thioctic acid'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C1294062', 'cui_str': 'Mononuclear cell count'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0949861', 'cui_str': 'F2-Isoprostane'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0023516', 'cui_str': 'Leukocyte'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0063695', 'cui_str': 'Lymphocyte antigen CD54'}, {'cui': 'C0424630', 'cui_str': 'Loss of body fat - finding'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0005486', 'cui_str': 'Bioenergetics'}, {'cui': 'C0583329', 'cui_str': 'Plasma triglyceride measurement'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0014442', 'cui_str': 'Enzyme'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}]",,0.697621,"Less urinary F2-isoprostanes (-25%; P = 0.005), blood leukocytes (-10.1%; P = 0.01), blood thrombocytes (-5.1%; P = 0.03), and ICAM-1 (-7.4%; P = 0.04) at 24 wk were also observed in the R-LA group than in placebo. ","[{'ForeName': 'Gerd', 'Initials': 'G', 'LastName': 'Bobe', 'Affiliation': 'Linus Pauling Institute, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Alexander J', 'Initials': 'AJ', 'LastName': 'Michels', 'Affiliation': 'Linus Pauling Institute, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Wei-Jian', 'Initials': 'WJ', 'LastName': 'Zhang', 'Affiliation': 'Linus Pauling Institute, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Jonathan Q', 'Initials': 'JQ', 'LastName': 'Purnell', 'Affiliation': 'Department of Medicine, Oregon Health & Science University, Portland, OR, USA.'}, {'ForeName': 'Clive', 'Initials': 'C', 'LastName': 'Woffendin', 'Affiliation': 'Oregon Clinical and Translational Research Institute, Oregon Health & Science University, Portland, OR, USA.'}, {'ForeName': 'Cliff', 'Initials': 'C', 'LastName': 'Pereira', 'Affiliation': 'Department of Statistics, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'Vita', 'Affiliation': 'Evans Department of Medicine and the Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA.'}, {'ForeName': 'Nicholas O', 'Initials': 'NO', 'LastName': 'Thomas', 'Affiliation': 'Linus Pauling Institute, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Maret G', 'Initials': 'MG', 'LastName': 'Traber', 'Affiliation': 'Linus Pauling Institute, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Balz', 'Initials': 'B', 'LastName': 'Frei', 'Affiliation': 'Linus Pauling Institute, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Tory M', 'Initials': 'TM', 'LastName': 'Hagen', 'Affiliation': 'Linus Pauling Institute, Oregon State University, Corvallis, OR, USA.'}]",The Journal of nutrition,['10.1093/jn/nxaa203'] 2308,32692370,Association of Gender and Race With Allocation of Advanced Heart Failure Therapies.,"Importance Racial bias is associated with the allocation of advanced heart failure therapies, heart transplants, and ventricular assist devices. It is unknown whether gender and racial biases are associated with the allocation of advanced therapies among women. Objective To determine whether the intersection of patient gender and race is associated with the decision-making of clinicians during the allocation of advanced heart failure therapies. Design, Setting, and Participants In this qualitative study, 46 US clinicians attending a conference for an international heart transplant organization in April 2019 were interviewed on the allocation of advanced heart failure therapies. Participants were randomized to examine clinical vignettes that varied 1:1 by patient race (African American to white) and 20:3 by gender (women to men) to purposefully target vignettes of women patients to compare with a prior study of vignettes of men patients. Participants were interviewed about their decision-making process using the think-aloud technique and provided supplemental surveys. Interviews were analyzed using grounded theory methodology, and surveys were analyzed with Wilcoxon tests. Exposure Randomization to clinical vignettes. Main Outcomes and Measures Thematic differences in allocation of advanced therapies by patient race and gender. Results Among 46 participants (24 [52%] women, 20 [43%] racial minority), participants were randomized to the vignette of a white woman (20 participants [43%]), an African American woman (20 participants [43%]), a white man (3 participants [7%]), and an African American man (3 participants [7%]). Allocation differences centered on 5 themes. First, clinicians critiqued the appearance of the women more harshly than the men as part of their overall impressions. Second, the African American man was perceived as experiencing more severe illness than individuals from other racial and gender groups. Third, there was more concern regarding appropriateness of prior care of the African American woman compared with the white woman. Fourth, there were greater concerns about adequacy of social support for the women than for the men. Children were perceived as liabilities for women, particularly the African American woman. Family dynamics and finances were perceived to be greater concerns for the African American woman than for individuals in the other vignettes; spouses were deemed inadequate support for women. Last, participants recommended ventricular assist devices over transplantation for all racial and gender groups. Surveys revealed no statistically significant differences in allocation recommendations for African American and white women patients. Conclusions and Relevance This national study of health care professionals randomized to clinical vignettes that varied only by gender and race found evidence of gender and race bias in the decision-making process for offering advanced therapies for heart failure, particularly for African American women patients, who were judged more harshly by appearance and adequacy of social support. There was no associated between patient gender and race and final recommendations for allocation of advanced therapies. However, it is possible that bias may contribute to delayed allocation and ultimately inequity in the allocation of advanced therapies in a clinical setting.",2020,Family dynamics and finances were perceived to be greater concerns for the African American woman than for individuals in the other vignettes; spouses were deemed inadequate support for women.,"['Participants were randomized to examine clinical vignettes that varied 1:1 by patient race (African American to white) and 20:3 by gender (women to men) to purposefully target vignettes of women patients to compare with a prior study of vignettes of men patients', '46 US clinicians attending a conference for an international heart transplant organization in April 2019 were interviewed on the allocation of advanced heart failure therapies', 'African American and white women patients', 'African American woman than for individuals in the other vignettes; spouses were deemed inadequate support for women', 'African American women patients', '46 participants (24 [52%] women, 20 [43%] racial minority), participants were randomized to the vignette of a white woman (20 participants [43%]), an African American woman (20 participants [43%]), a white man (3 participants [7%]), and an African American man (3 participants [7']",[],"['severe illness', 'allocation recommendations', 'allocation of advanced therapies by patient race and gender']","[{'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0018823', 'cui_str': 'Transplantation of heart'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0162409', 'cui_str': 'Spouse'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0026192', 'cui_str': 'Minority Groups'}]",[],"[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0079399', 'cui_str': 'Gender'}]",,0.0634317,Family dynamics and finances were perceived to be greater concerns for the African American woman than for individuals in the other vignettes; spouses were deemed inadequate support for women.,"[{'ForeName': 'Khadijah', 'Initials': 'K', 'LastName': 'Breathett', 'Affiliation': 'Sarver Heart Center, Division of Cardiology, Department of Medicine, University of Arizona, Tucson.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Yee', 'Affiliation': 'Sarver Heart Center, Clinical Research Office, University of Arizona, Tucson.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Pool', 'Affiliation': 'College of Nursing, University of Arizona, Tucson.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Hebdon', 'Affiliation': 'College of Nursing, University of Utah, Salt Lake City.'}, {'ForeName': 'Janice D', 'Initials': 'JD', 'LastName': 'Crist', 'Affiliation': 'College of Nursing, University of Arizona, Tucson.'}, {'ForeName': 'Ryan H', 'Initials': 'RH', 'LastName': 'Yee', 'Affiliation': 'Sarver Heart Center, Clinical Research Office, University of Arizona, Tucson.'}, {'ForeName': 'Shannon M', 'Initials': 'SM', 'LastName': 'Knapp', 'Affiliation': 'Statistics Consulting Lab, Bio5 Institute, University of Arizona, Tucson.'}, {'ForeName': 'Sade', 'Initials': 'S', 'LastName': 'Solola', 'Affiliation': 'Department of Medicine, University of Arizona, Tucson.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Luy', 'Affiliation': 'University of Rochester, New York.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Herrera-Theut', 'Affiliation': 'University of Arizona Medical School, Tucson.'}, {'ForeName': 'Leanne', 'Initials': 'L', 'LastName': 'Zabala', 'Affiliation': 'Department of Medicine, University of California, Los Angeles.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Stone', 'Affiliation': 'Department of Psychology, University of Arizona, Tucson.'}, {'ForeName': 'Marylyn M', 'Initials': 'MM', 'LastName': 'McEwen', 'Affiliation': 'College of Nursing, University of Arizona, Tucson.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Calhoun', 'Affiliation': 'Center for Population Health Sciences, University of Arizona, Tucson.'}, {'ForeName': 'Nancy K', 'Initials': 'NK', 'LastName': 'Sweitzer', 'Affiliation': 'Sarver Heart Center, Division of Cardiology, Department of Medicine, University of Arizona, Tucson.'}]",JAMA network open,['10.1001/jamanetworkopen.2020.11044'] 2309,32692386,Effect of Levothyroxine on Left Ventricular Ejection Fraction in Patients With Subclinical Hypothyroidism and Acute Myocardial Infarction: A Randomized Clinical Trial.,"Importance Thyroid hormones play a key role in modulating myocardial contractility. Subclinical hypothyroidism in patients with acute myocardial infarction is associated with poor prognosis. Objective To evaluate the effect of levothyroxine treatment on left ventricular function in patients with acute myocardial infarction and subclinical hypothyroidism. Design, Setting, and Participants A double-blind, randomized clinical trial conducted in 6 hospitals in the United Kingdom. Patients with acute myocardial infarction including ST-segment elevation and non-ST-segment elevation were recruited between February 2015 and December 2016, with the last participant being followed up in December 2017. Interventions Levothyroxine treatment (n = 46) commencing at 25 µg titrated to aim for serum thyrotropin levels between 0.4 and 2.5 mU/L or identical placebo (n = 49), both provided in capsule form, once daily for 52 weeks. Main Outcomes and Measures The primary outcome measure was left ventricular ejection fraction at 52 weeks, assessed by magnetic resonance imaging, adjusted for age, sex, type of acute myocardial infarction, affected coronary artery territory, and baseline left ventricular ejection fraction. Secondary measures were left ventricular volumes, infarct size (assessed in a subgroup [n = 60]), adverse events, and patient-reported outcome measures of health status, health-related quality of life, and depression. Results Among the 95 participants randomized, the mean (SD) age was 63.5 (9.5) years, 72 (76.6%) were men, and 65 (69.1%) had ST-segment elevation myocardial infarction. The median serum thyrotropin level was 5.7 mU/L (interquartile range, 4.8-7.3 mU/L) and the mean (SD) free thyroxine level was 1.14 (0.16) ng/dL. The primary outcome measurements at 52 weeks were available in 85 patients (89.5%). The mean left ventricular ejection fraction at baseline and at 52 weeks was 51.3% and 53.8%, respectively, in the levothyroxine group compared with 54.0% and 56.1%, respectively, in the placebo group (adjusted difference in groups, 0.76% [95% CI, -0.93% to 2.46%]; P = .37). None of the 6 secondary outcomes showed a significant difference between the levothyroxine and placebo treatment groups. There were 15 (33.3%) and 18 (36.7%) cardiovascular adverse events in the levothyroxine and placebo groups, respectively. Conclusions and Relevance In this preliminary study involving patients with subclinical hypothyroidism and acute myocardial infarction, treatment with levothyroxine, compared with placebo, did not significantly improve left ventricular ejection fraction after 52 weeks. These findings do not support treatment of subclinical hypothyroidism in patients with acute myocardial infarction. Trial Registration isrctn.org Identifier: http://www.isrctn.com/ISRCTN52505169.",2020,"The mean left ventricular ejection fraction at baseline and at 52 weeks was 51.3% and 53.8%, respectively, in the levothyroxine group compared with 54.0% and 56.1%, respectively, in the placebo group (adjusted difference in groups, 0.76% [95% CI, -0.93% to 2.46%];","['patients with acute myocardial infarction', '95 participants randomized, the mean (SD) age was 63.5 (9.5) years, 72 (76.6%) were men, and 65 (69.1%) had ST-segment elevation myocardial infarction', '6 hospitals in the United Kingdom', 'Patients with acute myocardial infarction including ST-segment elevation and non-ST-segment elevation were recruited between February 2015 and December 2016, with the last participant being followed up in December 2017', 'patients with acute myocardial infarction and subclinical hypothyroidism', 'patients with subclinical hypothyroidism and acute myocardial infarction, treatment with', 'Patients With Subclinical Hypothyroidism and Acute Myocardial Infarction']","['Levothyroxine', 'L or identical placebo', 'levothyroxine', 'placebo']","['left ventricular volumes, infarct size (assessed in a subgroup [n\u2009=\u200960]), adverse events, and patient-reported outcome measures of health status, health-related quality of life, and depression', 'median serum thyrotropin level', 'Left Ventricular Ejection Fraction', 'left ventricular function', 'Subclinical hypothyroidism', 'serum thyrotropin levels', 'mean (SD) free thyroxine level', 'mean left ventricular ejection fraction', 'cardiovascular adverse events', 'left ventricular ejection fraction', 'left ventricular ejection fraction at 52 weeks, assessed by magnetic resonance imaging, adjusted for age, sex, type of acute myocardial infarction, affected coronary artery territory, and baseline left ventricular ejection fraction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517899', 'cui_str': '9.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C1536220', 'cui_str': 'ST Segment Elevation Myocardial Infarction'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom of Great Britain and Northern Ireland'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0520886', 'cui_str': 'ST segment elevation'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0271790', 'cui_str': 'Subclinical hypothyroidism'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0040165', 'cui_str': 'levothyroxine'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0021308', 'cui_str': 'Infarct'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4277735', 'cui_str': 'Patient Reported Outcome Measures'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0040160', 'cui_str': 'Thyrotropin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0080310', 'cui_str': 'Left ventricular function'}, {'cui': 'C0271790', 'cui_str': 'Subclinical hypothyroidism'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0202225', 'cui_str': 'T4 free measurement'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0205042', 'cui_str': 'Coronary artery structure'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",95.0,0.618371,"The mean left ventricular ejection fraction at baseline and at 52 weeks was 51.3% and 53.8%, respectively, in the levothyroxine group compared with 54.0% and 56.1%, respectively, in the placebo group (adjusted difference in groups, 0.76% [95% CI, -0.93% to 2.46%];","[{'ForeName': 'Avais', 'Initials': 'A', 'LastName': 'Jabbar', 'Affiliation': 'Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'Lorna', 'Initials': 'L', 'LastName': 'Ingoe', 'Affiliation': 'Department of Cardiology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'Shahid', 'Initials': 'S', 'LastName': 'Junejo', 'Affiliation': 'Department of Endocrinology and Cardiology, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, United Kingdom.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Carey', 'Affiliation': 'Department of Endocrinology and Cardiology, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, United Kingdom.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Addison', 'Affiliation': 'Department of Endocrinology, Gateshead Health NHS Foundation Trust, Gateshead, United Kingdom.'}, {'ForeName': 'Honey', 'Initials': 'H', 'LastName': 'Thomas', 'Affiliation': 'Department of Cardiology, Northumbria Healthcare NHS Foundation Trust, Cramlington, United Kingdom.'}, {'ForeName': 'Jehill D', 'Initials': 'JD', 'LastName': 'Parikh', 'Affiliation': 'Newcastle Magnetic Resonance Centre, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Austin', 'Affiliation': 'Department of Cardiology, South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom.'}, {'ForeName': 'Kieren G', 'Initials': 'KG', 'LastName': 'Hollingsworth', 'Affiliation': 'Newcastle Magnetic Resonance Centre, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'Deborah D', 'Initials': 'DD', 'LastName': 'Stocken', 'Affiliation': 'Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom.'}, {'ForeName': 'Simon H S', 'Initials': 'SHS', 'LastName': 'Pearce', 'Affiliation': 'Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Greenwood', 'Affiliation': 'Leeds University and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.'}, {'ForeName': 'Azfar', 'Initials': 'A', 'LastName': 'Zaman', 'Affiliation': 'Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'Salman', 'Initials': 'S', 'LastName': 'Razvi', 'Affiliation': 'Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}]",JAMA,['10.1001/jama.2020.9389'] 2310,32692425,Adolescent cannabis and tobacco use are associated with opioid use in young adulthood-12-year longitudinal study in an urban cohort.,"BACKGROUND AND AIMS Cannabis, tobacco and alcohol use are prevalent among youth in the United States and may be risk factors for opioid use. The current study aimed at investigating associations between developmental trajectories of cannabis, tobacco and alcohol use in adolescence and opioid use in young adulthood in an urban cohort over the span of 12 years. DESIGN Cohort study of adolescents originally recruited for a randomized prevention trial with yearly assessments into young adulthood. SETTING Nine urban elementary schools in Baltimore, MD in the United States. PARTICIPANTS Participants (n = 583, 86.8% African American, 54.7% male) were originally recruited as first grade students. MEASUREMENTS Cannabis, tobacco and alcohol use were assessed annually from ages 14-18 years and opioid use from ages 19-26. Socio-demographics were assessed at age 6. Intervention status was also randomly assigned at age 6. Gender, race, free/reduced-priced lunch and intervention status were included as covariates in individual and sequential growth models. FINDINGS There were significant positive associations between the cannabis use intercept at age 14 and the opioid use intercept at age 19 (beta = 1.43; P = 0.028), the tobacco use intercept at age 14 and the opioid use intercept at age 19 (beta = 0.82; P = 0.042). Specifically, more frequent use of cannabis or tobacco at age 14 was associated with more frequent use of opioids at age 19. CONCLUSIONS Cannabis and tobacco use in early adolescence may be risk factors for opioid use in young adulthood among African Americans living in urban areas.",2020,"Specifically, more frequent use of cannabis or tobacco at age 14 was associated with more frequent use of opioids at age 19. ","['young adulthood in an urban cohort over the span of 12\xa0years', 'young adulthood-12-year longitudinal study in an urban cohort', 'Nine urban elementary schools in Baltimore, MD in the United States', 'African Americans living in urban areas', 'Participants (n\xa0=\xa0583, 86.8% African American, 54.7% male) were originally recruited as first grade students', 'Cohort study of adolescents originally recruited for a randomized prevention trial with yearly assessments into young adulthood']",[],"['Socio-demographics', 'Cannabis, tobacco and alcohol use']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0700597', 'cui_str': 'Adulthood'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0004716', 'cui_str': 'Baltimore'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C5191355', 'cui_str': '583'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",[],"[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}]",,0.0279499,"Specifically, more frequent use of cannabis or tobacco at age 14 was associated with more frequent use of opioids at age 19. ","[{'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Thrul', 'Affiliation': 'Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Jill A', 'Initials': 'JA', 'LastName': 'Rabinowitz', 'Affiliation': 'Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Beth A', 'Initials': 'BA', 'LastName': 'Reboussin', 'Affiliation': 'Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC,, USA.'}, {'ForeName': 'Brion S', 'Initials': 'BS', 'LastName': 'Maher', 'Affiliation': 'Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Nicholas S', 'Initials': 'NS', 'LastName': 'Ialongo', 'Affiliation': 'Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}]","Addiction (Abingdon, England)",['10.1111/add.15183'] 2311,32687296,[The scientific rationale for the use of electroneurostimulation of the cervical sympathetic ganglia in patients with computer vision syndrome].,"A frequent reason for visiting an ophthalmologist for patients of working age is computer vision syndrome (CVS): statistics show that up to 90% of users of personal electronic computers (PCs) suffer from this disease. Therefore, the actual task of modern rehabilitation medicine and ophthalmology is the search for an effective and safe way to prevent and treat the CVS among employees of enterprises. THE PURPOSE OF THIS STUDY Was a scientific justification, an assessment of the effectiveness and safety of the use of electroneurostimulation (ENS) of the cervical sympathetic ganglia in patients with CVS. MATERIAL AND METHODS 120 patients with the syndrome observed on an outpatient basis were examined. Patients were divided into 3 groups using simple randomization method. The 1st group (the main group - MG) included 39 patients who, against the background of gymnastics of the oculomotor muscles and muscles of the shoulder girdle, used ENS on the area of the sympathetic ganglia; in the 2nd group (group of comparison - GoC) included 41 patients who strictly performed the same muscle gymnastics (after every 2 hours of work with the PC); Group 3 (control group - CG) consisted of 40 patients who took an ENS course of exposure in placebo mode. In the dynamics, the stock of relative accommodation, near heterophory, tear production, threshold electrical sensitivity of the retina, electrolability of the optic nerve, contrast sensitivity, reading speed, print speed and accuracy and the level of subjective asthenopia were evaluated. RESULTS Initially, groups of patients with CVS did not differ among themselves in any of the investigated parameters. After a course of procedures in the MG, in contrast to the other two (GoC and CG), statistically significant positive shifts were revealed in relation to the selected endpoints, reflecting the severity of asthenopia, sensorineural, accommodative and oculomotor functions of the visual analyzer, as well as ophthalmoergonomics. Of the side effects of the procedures were recorded: moderate drowsiness (in 4 patients), a feeling of heaviness of the head (in 1 patient) and an increase in blood pressure (BP) by more than 15% of the initial (in 1 patient). They disappeared on their own and did not require withdrawal of treatment. A patient who noted a single increase in blood pressure subsequently received therapy every other day. Redness of the skin of the neck in the area of application of the electrodes was found with the same frequency in MG and CG. CONCLUSION The inclusion of ENS in the rehabilitation treatment of workers professionally using a personal computer significantly increases the effectiveness of therapeutic measures, which proves the appropriateness of applying the proposed technology in CVS. The therapeutic action of complex therapy is realized through the effect of the ENS on an important reflexogenic zone - the cervical sympathetic ganglia, the activation of which ensures the normalization of the central, peripheral and autonomic functioning of the visual analyzer. Analysis of the frequency of registration of side effects in patients of the three groups allows us to conclude that the technique is safe.",2020,"The inclusion of ENS in the rehabilitation treatment of workers professionally using a personal computer significantly increases the effectiveness of therapeutic measures, which proves the appropriateness of applying the proposed technology in CVS.","['patients with computer vision syndrome', '120 patients with the syndrome observed on an outpatient basis were examined', 'patients with CVS', '39 patients who, against the background of gymnastics of the oculomotor muscles and muscles of the shoulder girdle, used ENS on the area of the sympathetic ganglia; in the 2nd group (group of comparison - GoC) included 41 patients who strictly performed the same muscle gymnastics (after every 2 hours of work with the PC']","['electroneurostimulation (ENS', 'electroneurostimulation']","['blood pressure', 'stock of relative accommodation, near heterophory, tear production, threshold electrical sensitivity of the retina, electrolability of the optic nerve, contrast sensitivity, reading speed, print speed and accuracy and the level of subjective asthenopia', 'severity of asthenopia, sensorineural, accommodative and oculomotor functions of the visual analyzer, as well as ophthalmoergonomics', 'blood pressure (BP', 'feeling of heaviness of the head', 'moderate drowsiness']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2609092', 'cui_str': 'Computer vision syndrome'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C1857276', 'cui_str': 'Trichohepatoenteric syndrome'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0018409', 'cui_str': 'Gymnastics'}, {'cui': 'C0028863', 'cui_str': 'Structure of extraocular muscle'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0427245', 'cui_str': 'Shoulder girdle structure'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0017071', 'cui_str': 'Sympathetic ganglion structure'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0585322', 'cui_str': 'Every two hours'}, {'cui': 'C0043227', 'cui_str': 'Working'}]",[],"[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0453908', 'cui_str': 'Stocking'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C0423153', 'cui_str': 'Lacrimation'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C0029130', 'cui_str': 'Optic nerve structure'}, {'cui': 'C0009928', 'cui_str': 'Contrast sensitivity'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0033161', 'cui_str': 'Printing'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0004095', 'cui_str': 'Accommodative asthenopia'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0179038', 'cui_str': 'Analyzer'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0850001', 'cui_str': 'Heaviness of head'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}]",120.0,0.0192778,"The inclusion of ENS in the rehabilitation treatment of workers professionally using a personal computer significantly increases the effectiveness of therapeutic measures, which proves the appropriateness of applying the proposed technology in CVS.","[{'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Nikiforova', 'Affiliation': 'Ural State Medical University, Ekaterinburg, Russia.'}, {'ForeName': 'B A', 'Initials': 'BA', 'LastName': 'Gusova', 'Affiliation': 'Pyatigorsk Medical and Pharmaceutical Institute - a branch of Volgograd State Medical University, Pyatigorsk, Russia.'}, {'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Korotkikh', 'Affiliation': 'Ural State Medical University, Ekaterinburg, Russia.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Fedorov', 'Affiliation': 'Ural State Medical University, Ekaterinburg, Russia.'}, {'ForeName': 'A S', 'Initials': 'AS', 'LastName': 'Kaysinova', 'Affiliation': 'Pyatigorsk Medical and Pharmaceutical Institute - a branch of Volgograd State Medical University, Pyatigorsk, Russia.'}]","Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury",['10.17116/kurort20209704117'] 2312,31419322,Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis.,"BACKGROUND It has previously been shown in an uncontrolled study that the IgE response to vaccine antigens is downregulated by co-vaccination with cellular Bordetella pertussis vaccine. METHODS In the present study, we compared in a controlled trial the humoral immune response to diphtheria toxoid (D) and tetanus toxoid (T) in relation to co-vaccinated cellular or acellular B pertussis vaccine. IgE, IgG4, and IgG to D and T were analyzed at 2, 7, and 12 months of age in sera of children vaccinated with D and T (DT, N = 68), cellular (DTPw, N = 68), 2- or 5-component acellular B pertussis vaccine (DTPa2, N = 64; DTPa5, N = 65). RESULTS One month after vaccination, D-IgE was detected in 10% sera of DTPw-vaccinated children, whereas vaccination in the absence of whole-cell pertussis resulted in 50%-60% IgE positivity. Six months after vaccination, the IgE antibody levels were found to be more persistent than the IgG antibodies. These diphtheria findings were mirrored by those for tetanus. Only minor differences between vaccine groups were found with regard to D-IgG and T-IgG. No immediate-type allergic reactions were observed. CONCLUSION Cellular (but not acellular) B pertussis vaccine downregulates IgE to co-vaccinated antigens in infants. We assume that the absence of immediate-type allergic reactions is due to the high levels of IgG antibodies competing with IgE antibodies.",2019,"One month after vaccination, D-IgE was detected in 10% sera of DTPw-vaccinated children, whereas vaccination in the absence of whole-cell pertussis resulted in 50%-60% IgE positivity.","['64', 'infants']","['diphtheria toxoid (D) and tetanus toxoid (T', '2- or 5-component acellular B\xa0pertussis vaccine (DTPa2, N\xa0', 'Cellular (but not acellular']","['IgE, IgG4, and IgG to D and T', 'IgE antibody levels', 'immediate-type allergic reactions']","[{'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0012551', 'cui_str': 'diphtheria toxoid vaccine, inactivated'}, {'cui': 'C0039620', 'cui_str': 'Tetanus vaccine'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0031237', 'cui_str': 'Pertussis Vaccine'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}]","[{'cui': 'C0020846', 'cui_str': 'Immunoglobulin E'}, {'cui': 'C0020860', 'cui_str': 'Immunoglobulin IgG4'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]",,0.0258826,"One month after vaccination, D-IgE was detected in 10% sera of DTPw-vaccinated children, whereas vaccination in the absence of whole-cell pertussis resulted in 50%-60% IgE positivity.","[{'ForeName': 'Rob C', 'Initials': 'RC', 'LastName': 'Aalberse', 'Affiliation': 'Amsterdam and Landsteiner Laboratory, Department of Immunopathology, Academic Medical Center, Sanquin Research, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Grüber', 'Affiliation': 'Department of Pediatric Pneumology and Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Margaretha', 'Initials': 'M', 'LastName': 'Ljungman', 'Affiliation': 'Health Agency of Sweden, Solna, Sweden.'}, {'ForeName': 'Suzan', 'Initials': 'S', 'LastName': 'Kakat', 'Affiliation': 'Department of Pediatric Pneumology and Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Wahn', 'Affiliation': 'Department of Pediatric Pneumology and Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Bodo', 'Initials': 'B', 'LastName': 'Niggemann', 'Affiliation': 'Department of Pediatric Pneumology and Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Lennart J', 'Initials': 'LJ', 'LastName': 'Nilsson', 'Affiliation': 'Department of Clinical and Experimental Medicine, Allergy Center, Linköping University, Linköping, Sweden.'}]",Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,['10.1111/pai.13113'] 2313,31421110,The Neurokinin-1 Receptor Antagonist Orvepitant Is a Novel Antitussive Therapy for Chronic Refractory Cough: Results From a Phase 2 Pilot Study (VOLCANO-1).,"BACKGROUND Substance P and the neurokinin-1 (NK-1) receptor are implicated in chronic refractory cough pathophysiology. We assessed the efficacy and safety of orvepitant, a brain-penetrant NK-1 antagonist, in an open-label study in CRC patients with chronic refractory cough. METHODS Thirteen patients with daytime cough frequency >3 to <250 coughs/h took orvepitant 30 mg once daily for 4 weeks. Objective cough frequency was measured over 24 h at baseline and weeks 1, 4, and 8. The primary end point was change from Baseline in daytime cough frequency at week 4. Secondary end points included cough severity visual analog scale (VAS) score, global ratings of change for cough frequency and severity, and Cough-specific Quality of Life Questionnaire score. RESULTS All patients completed the study. Mean baseline cough frequency was 71.4/h. A statistically and clinically significant improvement in objective daytime cough frequency was observed at week 4: reduction from baseline of 18.9 (26%) coughs/h (95% CI, 9.6-28.3; P < .001). This effect was apparent at week 1 (reduction from baseline of 27.0 [38%] coughs/h [95% CI, 11.4-42.7; P = .001]) and sustained after drug discontinuation at week 8 (reduction from baseline of 20.4 [29%] coughs/h [95% CI, 3.2-37.5; P = .020]). Statistically significant improvements were seen for severity VAS and quality of life. Orvepitant was safe and well-tolerated. CONCLUSIONS Orvepitant resulted in a significant and sustained improvement in objective cough frequency, severity VAS, and quality of life; appeared safe; and merits further clinical investigation. TRIAL REGISTRY EU Clinical Trials Register; No.: 2014-003947-36; URL: www.clinicaltrialsregister.eu.",2020,"This effect was apparent at week 1 (reduction from baseline of 27.0 [38%] coughs/h [95% CI, 11.4-42.7; P = .001]) and sustained after drug discontinuation at week 8 (reduction from baseline of 20.4 [29%] coughs/h [95% CI, 3.2-37.5; P = .020]).","['CRC patients with chronic refractory cough', 'Chronic Refractory Cough', 'Thirteen patients with daytime cough frequency >3 to\xa0<250 coughs/h took orvepitant 30\xa0mg once daily for 4\xa0weeks']",[],"['severity VAS and quality of life', 'objective cough frequency, severity VAS, and quality of life', 'Objective cough frequency', 'Mean baseline cough frequency', 'cough severity visual analog scale (VAS) score, global ratings of change for cough frequency and severity, and Cough-specific Quality of Life Questionnaire score', 'safe and well-tolerated', 'daytime cough frequency', 'objective daytime cough frequency']","[{'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C2983799', 'cui_str': 'orvepitant'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0439230', 'cui_str': 'week'}]",[],"[{'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}]",13.0,0.0998724,"This effect was apparent at week 1 (reduction from baseline of 27.0 [38%] coughs/h [95% CI, 11.4-42.7; P = .001]) and sustained after drug discontinuation at week 8 (reduction from baseline of 20.4 [29%] coughs/h [95% CI, 3.2-37.5; P = .020]).","[{'ForeName': 'Jaclyn', 'Initials': 'J', 'LastName': 'Smith', 'Affiliation': 'Division of Infection Immunity and Respiratory Medicine, University of Manchester, Manchester, England; Manchester University NHS Foundation Trust, Manchester, England. Electronic address: Jacky.Smith@manchester.ac.uk.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Allman', 'Affiliation': 'Artemida Pharma Ltd, Stevenage, England.'}, {'ForeName': 'Huda', 'Initials': 'H', 'LastName': 'Badri', 'Affiliation': 'Division of Infection Immunity and Respiratory Medicine, University of Manchester, Manchester, England; North Manchester General Hospital, Pennine Acute NHS Trust, Manchester, England.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Miller', 'Affiliation': 'Artemida Pharma Ltd, Stevenage, England.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Morris', 'Affiliation': 'Division of Infection Immunity and Respiratory Medicine, University of Manchester, Manchester, England; Manchester University NHS Foundation Trust, Manchester, England.'}, {'ForeName': 'Imran', 'Initials': 'I', 'LastName': 'Satia', 'Affiliation': 'Division of Infection Immunity and Respiratory Medicine, University of Manchester, Manchester, England; Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Wood', 'Affiliation': 'Idfac Ltd, Devon, England.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'K Trower', 'Affiliation': 'NeRRe Therapeutics Ltd, Stevenage, England.'}]",Chest,['10.1016/j.chest.2019.08.001'] 2314,31866800,"Gadobutrol Precedes Gd-DTPA in Abdominal Contrast-Enhanced MRA and MRI: A Prospective, Multicenter, Intraindividual Study.","Objective To qualitatively and quantitatively compare the contrast-enhanced magnetic resonance angiography (MRA) and magnetic resonance imaging (MRI) in one-stop shop of abdominal imaging with Gadobutrol and Gd-DTPA at equimolar doses of gadolinium. Materials and Methods This was a prospective designed, multiple center, intraindividual comparison study. All volunteers underwent Gadobutrol- and Gd-DTPA-enhanced MRA and MRI in one-stop shop. Qualitative analysis for large vessels and small vessels was performed by a three-point scale, while for minute small vessels, by a five-point scale. Quantitative analysis was performed for large vessels by signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR). Visceral organ enhancements on the equilibrium phase were also analyzed. Wilcoxon matched-pair signed-rank tests were used to evaluate the qualitative and quantitative results. Results 40 volunteers were enrolled. Qualitative analyses results for large vessels, small vessels, and minute small vessels of Gadobutrol and Gd-DTPA were 20.98 ± 2.11, 6.03 ± 1.03, and 3.41 ± 1.18 and 20.01 ± 2.18, 5.28 ± 1.67, and 2.61 ± 1.40, respectively. Wilcoxon signed-rank tests revealed Gadobutrol-enhanced MRA was superior to that of Gd-DTPA significantly for small vessels ( p =0.028) and minute small vessels ( p =0.007). For quantitative analysis of large vessels, no statistic difference was found. Gadobutrol-enhanced MRI had higher CNR of the liver ( p =0.003), spleen ( p =0.001), and pancreas ( p =0.001) and higher SNR of spleen ( p =0.009) than those of Gd-DTPA statistically. Conclusion Our study proved Gadobutrol was superior to Gd-DTPA in qualitative analysis of CE-MRA and quantitative analysis of visceral organ enhancement on CE-MRI in abdomen of healthy volunteers. Gadobutrol may be more suitable for abdominal one-stop examination for CE-MRA and CE-MRI.",2019,"Gadobutrol-enhanced MRI had higher CNR of the liver ( p =0.003), spleen ( p =0.001), and pancreas ( p =0.001) and higher SNR of spleen ( p =0.009) than those of Gd-DTPA statistically. ","['40 volunteers were enrolled', 'healthy volunteers']","['MRI', 'Gadobutrol- and Gd-DTPA-enhanced MRA and MRI', 'contrast-enhanced magnetic resonance angiography (MRA) and magnetic resonance imaging (MRI']","['higher SNR of spleen', 'Wilcoxon signed-rank tests revealed Gadobutrol-enhanced MRA']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0291216', 'cui_str': 'gadobutrol'}, {'cui': 'C0060933', 'cui_str': 'gadopentetic acid'}, {'cui': 'C0243032', 'cui_str': 'Magnetic resonance imaging (MRI) of vessels'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C2986823', 'cui_str': 'Signal-To-Noise Ratio'}, {'cui': 'C0037993', 'cui_str': 'Splenic structure'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0667477', 'cui_str': 'TNFRSF11A protein, human'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0443289', 'cui_str': 'Revealed'}, {'cui': 'C0291216', 'cui_str': 'gadobutrol'}, {'cui': 'C0243032', 'cui_str': 'Magnetic resonance imaging (MRI) of vessels'}]",40.0,0.0242626,"Gadobutrol-enhanced MRI had higher CNR of the liver ( p =0.003), spleen ( p =0.001), and pancreas ( p =0.001) and higher SNR of spleen ( p =0.009) than those of Gd-DTPA statistically. ","[{'ForeName': 'Xijiao', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.'}, {'ForeName': 'Zhengyan', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.'}, {'ForeName': 'Weiwei', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.'}, {'ForeName': 'Caiwei', 'Initials': 'C', 'LastName': 'Yang', 'Affiliation': 'Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.'}, {'ForeName': 'Yike', 'Initials': 'Y', 'LastName': 'Diao', 'Affiliation': 'Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Duan', 'Affiliation': 'Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Fu', 'Affiliation': 'Department of Radiology, The First Hospital of Jilin University, Changchun, Jilin Province, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Ren', 'Affiliation': 'Department of Radiology, Sichuan Cancer Hospital, Chengdu, Sichuan Province, China.'}, {'ForeName': 'Song', 'Initials': 'S', 'LastName': 'Bin', 'Affiliation': 'Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.'}]",Contrast media & molecular imaging,['10.1155/2019/9738464'] 2315,31895947,Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.,,2020,,[],[],[],[],[],[],,0.0300532,,"[{'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Strati', 'Affiliation': 'Department of Lymphoma and Myeloma.'}, {'ForeName': 'Ellen J', 'Initials': 'EJ', 'LastName': 'Schlette', 'Affiliation': 'Department of Hematopathology.'}, {'ForeName': 'Luisa M', 'Initials': 'LM', 'LastName': 'Solis Soto', 'Affiliation': 'Department of Translational Pathology, and.'}, {'ForeName': 'Daniela E', 'Initials': 'DE', 'LastName': 'Duenas', 'Affiliation': 'Department of Translational Pathology, and.'}, {'ForeName': 'Mariela', 'Initials': 'M', 'LastName': 'Sivina', 'Affiliation': 'Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX.'}, {'ForeName': 'Ekaterina', 'Initials': 'E', 'LastName': 'Kim', 'Affiliation': 'Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Keating', 'Affiliation': 'Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX.'}, {'ForeName': 'William G', 'Initials': 'WG', 'LastName': 'Wierda', 'Affiliation': 'Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Ferrajoli', 'Affiliation': 'Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX.'}, {'ForeName': 'Hagop', 'Initials': 'H', 'LastName': 'Kantarjian', 'Affiliation': 'Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX.'}, {'ForeName': 'Zeev', 'Initials': 'Z', 'LastName': 'Estrov', 'Affiliation': 'Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX.'}, {'ForeName': 'Nitin', 'Initials': 'N', 'LastName': 'Jain', 'Affiliation': 'Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX.'}, {'ForeName': 'Philip A', 'Initials': 'PA', 'LastName': 'Thompson', 'Affiliation': 'Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX.'}, {'ForeName': 'Ignacio I', 'Initials': 'II', 'LastName': 'Wistuba', 'Affiliation': 'Department of Translational Pathology, and.'}, {'ForeName': 'Jan A', 'Initials': 'JA', 'LastName': 'Burger', 'Affiliation': 'Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX.'}]",Blood,['10.1182/blood.2019003570'] 2316,31897428,Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses.,"The neonatal crystallizable fragment receptor (FcRn) functions as an intracellular protection receptor for immunoglobulin G (IgG). Recently, several clinical studies have reported the lowering of circulating monomeric IgG levels through FcRn blockade for the potential treatment of autoimmune diseases. Many autoimmune diseases, however, are derived from the effects of IgG immune complexes (ICs). We generated, characterized, and assessed the effects of SYNT001, a FcRn-blocking monoclonal antibody, in mice, nonhuman primates (NHPs), and humans. SYNT001 decreased all IgG subtypes and IgG ICs in the circulation of humans, as we show in a first-in-human phase 1, single ascending dose study. In addition, IgG IC induction of inflammatory pathways was dependent on FcRn and inhibited by SYNT001. These studies expand the role of FcRn in humans by showing that it controls not only IgG protection from catabolism but also inflammatory pathways associated with IgG ICs involved in a variety of autoimmune diseases.",2019,"We generated, characterized, and assessed the effects of SYNT001, a FcRn-blocking monoclonal antibody, in mice, nonhuman primates (NHPs), and humans.",[],[],['IgG subtypes and IgG ICs'],[],[],"[{'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0449560', 'cui_str': 'Subtype'}, {'cui': 'C0003313', 'cui_str': 'Immune complex'}]",,0.0359691,"We generated, characterized, and assessed the effects of SYNT001, a FcRn-blocking monoclonal antibody, in mice, nonhuman primates (NHPs), and humans.","[{'ForeName': 'L J', 'Initials': 'LJ', 'LastName': 'Blumberg', 'Affiliation': 'Syntimmune Inc., Boston, MA 02116, USA.'}, {'ForeName': 'J E', 'Initials': 'JE', 'LastName': 'Humphries', 'Affiliation': 'Biologics Consulting, Alexandria, VA 22314, USA.'}, {'ForeName': 'S D', 'Initials': 'SD', 'LastName': 'Jones', 'Affiliation': 'BioProcess Technology Consultants, Woburn, MA 01801, USA.'}, {'ForeName': 'L B', 'Initials': 'LB', 'LastName': 'Pearce', 'Affiliation': 'Biologics Consulting, Alexandria, VA 22314, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Holgate', 'Affiliation': 'Abzena, Babraham, Cambridge, CB22 3AT, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Hearn', 'Affiliation': 'Abzena, Babraham, Cambridge, CB22 3AT, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Cheung', 'Affiliation': 'New York Structural Biology Center, New York, NY 10027, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Mahmood', 'Affiliation': 'New York Structural Biology Center, New York, NY 10027, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Del Tito', 'Affiliation': 'Biologics Consulting, Alexandria, VA 22314, USA.'}, {'ForeName': 'J S', 'Initials': 'JS', 'LastName': 'Graydon', 'Affiliation': 'Syntimmune Inc., Boston, MA 02116, USA.'}, {'ForeName': 'L E', 'Initials': 'LE', 'LastName': 'Stolz', 'Affiliation': 'Syntimmune Inc., Boston, MA 02116, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Bitonti', 'Affiliation': 'Syntimmune Inc., Boston, MA 02116, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Purohit', 'Affiliation': 'BioProcess Technology Consultants, Woburn, MA 01801, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'de Graaf', 'Affiliation': 'Syntimmune Inc., Boston, MA 02116, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Kacena', 'Affiliation': 'BioBridges, Wellesley, MA 02481, USA.'}, {'ForeName': 'J T', 'Initials': 'JT', 'LastName': 'Andersen', 'Affiliation': 'Department of Immunology and Centre for Immune Regulation, Oslo University Hospital Rikshospitalet and University of Oslo, Oslo 0424, Norway.'}, {'ForeName': 'G J', 'Initials': 'GJ', 'LastName': 'Christianson', 'Affiliation': 'The Jackson Laboratory, Bar Harbor, ME 04609, USA.'}, {'ForeName': 'D C', 'Initials': 'DC', 'LastName': 'Roopenian', 'Affiliation': 'The Jackson Laboratory, Bar Harbor, ME 04609, USA.'}, {'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Hubbard', 'Affiliation': ""Department of Medicine, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}, {'ForeName': 'A K', 'Initials': 'AK', 'LastName': 'Gandhi', 'Affiliation': ""Department of Medicine, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Lasseter', 'Affiliation': 'Clinical Pharmacology of Miami, Miami, FL 33014, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Pyzik', 'Affiliation': ""Department of Medicine, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}, {'ForeName': 'R S', 'Initials': 'RS', 'LastName': 'Blumberg', 'Affiliation': ""Department of Medicine, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.""}]",Science advances,['10.1126/sciadv.aax9586'] 2317,32692701,Could Anise decrease the intensity of premenstrual syndrome symptoms in comparison to placebo? A double-blind randomized clinical trial.,"Background Premenstrual syndrome (PMS) has a high prevalence among women of reproductive ages but despite its high prevalence, it has no determined and absolute treatment, so far. So, the aim of the present study was to compare the effect Pimpinella Anisum (Anise) with placebo on the intensity of the symptoms of PMS. Methods The present study was a randomized double-blind controlled clinical trial. College students who were suffering from PMS and had the inclusion criteria were selected and randomly assigned into two groups of intervention (Anise) and control (placebo). Participants in the intervention group, received 110 mg capsules of Anise three times day (a total dose of 330 mg per day); the control group received similar capsules with the same dosing that contained starch. Consumption of the capsules was started 7 days before the start of the menstruation and continued until 3 days after, which was a total of 10 days during two consecutive menstruation cycles. The intensity of the symptoms of premenstrual syndrome was measured using Premenstrual Symptoms Screening Tool (PSST). To compare the intensity of the symptoms between the two study groups, generalized estimating equation statistical method was used. Results Eventually, sixty-seven 18-35 year old college students who were suffering from premenstrual syndrome were enrolled in the study. Comparing the mean score of the intensity of the syndrome between the two groups after the first and the second menstruation cycles showed a decrease in the intervention group to 13.9 (p-value<0.001; 95% CI: 16.5,-11.4) and 9.8 (p-value<0.001; 95% CI: 12.4,-7.3), respectively. Conclusion Results of the study showed that, in general, Anise was effective in decreasing the symptoms of premenstrual syndrome in comparison to placebo.",2020,"Comparing the mean score of the intensity of the syndrome between the two groups after the first and the second menstruation cycles showed a decrease in the intervention group to 13.9 (p-value<0.001; 95% CI: 16.5,-11.4) and 9.8 (p-value<0.001; 95% CI: 12.4,-7.3), respectively.","['Eventually, sixty-seven 18-35\u2006year old college students who were suffering from premenstrual syndrome were enrolled in the study', 'College students who were suffering from PMS and had the inclusion criteria']","['control group received similar capsules with the same dosing that contained starch', 'intervention (Anise) and control (placebo', 'placebo']","['mean score of the intensity of the syndrome', 'symptoms of premenstrual syndrome', 'intensity of premenstrual syndrome symptoms', 'intensity of the symptoms of premenstrual syndrome']","[{'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0033046', 'cui_str': 'Premenstrual syndrome'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0038179', 'cui_str': 'Starch'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C1857276', 'cui_str': 'Trichohepatoenteric syndrome'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0033046', 'cui_str': 'Premenstrual syndrome'}]",,0.376752,"Comparing the mean score of the intensity of the syndrome between the two groups after the first and the second menstruation cycles showed a decrease in the intervention group to 13.9 (p-value<0.001; 95% CI: 16.5,-11.4) and 9.8 (p-value<0.001; 95% CI: 12.4,-7.3), respectively.","[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Farahmand', 'Affiliation': 'Research Institute for Endocrine Sciences, Reproductive Endocrinology Research Center, Shahid Beheshti University of Medical Sciences Tehran, Iran (Islamic Republic of).'}, {'ForeName': 'Davood', 'Initials': 'D', 'LastName': 'Khalili', 'Affiliation': 'Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Fahimeh', 'Initials': 'F', 'LastName': 'Ramezani Tehrani', 'Affiliation': 'Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Gholamreza', 'Initials': 'G', 'LastName': 'Amin', 'Affiliation': 'Department of Pharmacognosy, faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Negarandeh', 'Affiliation': 'Nursing & Midwifery Care Research Center, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.'}]",Journal of complementary & integrative medicine,['10.1515/jcim-2019-0077'] 2318,32692705,Which technique is better to place a manoeuvrable vacuum extractor cup on the flexion point? Vacca versus Bird technique.,"Objectives The purpose of this study is to compare the vacuum extractor cup application technique described by Bird vs. the technique described by Vacca on a simulation model. Methods Six obstetricians participated in the study. Each obstetrician performed eight vacuum assisted deliveries using the Bird technique and eight vacuum assisted deliveries using the Vacca 5-Steps technique. Results A total of 96 vacuum assisted deliveries were performed. The mean distance from the centre of the cup to the flexion point was 1.78 ± 0.96 cm for the Bird technique and 1.05 ± 0.60 cm for the Vacca technique (p<0.001). The lateral distance (over the parietal bone) was 1.16 ± 0.69 cm for the Bird technique and 0.66 ± 0.52 cm for the Vacca technique (p<0.001). The vertical distance (towards the frontal or occipital bone) was 1.12 ± 1.02 cm for the Bird technique and 0.67 ± 0.55 cm for the Vacca technique (p=0.009). In occipito anterior positions, there were no significant differences between both techniques. Conclusions The Vacca technique was better in transverse and posterior positions.",2020,cm for the Bird technique and 1.05 ± 0.60 cm for the Vacca technique (p<0.001).,[],"['Vacca versus Bird technique', 'vacuum extractor cup application technique']","['mean distance', 'lateral distance', 'vertical distance']",[],"[{'cui': 'C0005595', 'cui_str': 'Class Aves'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1272612', 'cui_str': 'Vacuum extractor'}, {'cui': 'C0220647', 'cui_str': 'Carcinoma of unknown primary'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}]",6.0,0.0171587,cm for the Bird technique and 1.05 ± 0.60 cm for the Vacca technique (p<0.001).,"[{'ForeName': 'Marcos Javier', 'Initials': 'MJ', 'LastName': 'Cuerva', 'Affiliation': 'Department of Obstetrics, Hospital Universitario La Paz, Madrid, Spain.'}, {'ForeName': 'Jose Ángel', 'Initials': 'JÁ', 'LastName': 'Espinosa', 'Affiliation': 'Department of Affective Childbirth (UPA), Hospital San Francisco de Asís, Madrid, Spain.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Barras', 'Affiliation': 'Department of Obstetrics and Gynaecology, Hospital Universitario Infanta Cristina, Madrid, Spain.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Gonzalez-Cerron', 'Affiliation': 'Department of Obstetrics and Gynaecology, Hospital Universitario de Fuenlabrada, Madrid, Spain.'}, {'ForeName': 'Faride', 'Initials': 'F', 'LastName': 'Ojeda', 'Affiliation': 'Department of Affective Childbirth (UPA), Hospital San Francisco de Asís, Madrid, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Cortés', 'Affiliation': 'Department of Obstetrics, Hospital Universitario La Paz, Madrid, Spain.'}]",Journal of perinatal medicine,['10.1515/jpm-2020-0077'] 2319,32692747,"Polygenic risk score for obesity and the quality, quantity, and timing of workplace food purchases: A secondary analysis from the ChooseWell 365 randomized trial.","BACKGROUND The influence of genetic risk for obesity on food choice behaviors is unknown and may be in the causal pathway between genetic risk and weight gain. The aim of this study was to examine associations between genetic risk for obesity and food choice behaviors using objectively assessed workplace food purchases. METHODS AND FINDINGS This study is a secondary analysis of baseline data collected prior to the start of the ""ChooseWell 365"" health-promotion intervention randomized control trial. Participants were employees of a large hospital in Boston, MA, who enrolled in the study between September 2016 and February 2018. Cafeteria sales data, collected retrospectively for 3 months prior to enrollment, were used to track the quantity (number of items per 3 months) and timing (median time of day) of purchases, and participant surveys provided self-reported behaviors, including skipping meals and preparing meals at home. A previously validated Healthy Purchasing Score was calculated using the cafeteria traffic-light labeling system (i.e., green = healthy, yellow = less healthy, red = unhealthy) to estimate the healthfulness (quality) of employees' purchases (range, 0%-100% healthy). DNA was extracted and genotyped from blood samples. A body mass index (BMI) genome-wide polygenic score (BMIGPS) was generated by summing BMI-increasing risk alleles across the genome. Additionally, 3 polygenic risk scores (PRSs) were generated with 97 BMI variants previously identified at the genome-wide significance level (P < 5 × 10-8): (1) BMI97 (97 loci), (2) BMICNS (54 loci near genes related to central nervous system [CNS]), and (3) BMInon-CNS (43 loci not related to CNS). Multivariable linear and logistic regression tested associations of genetic risk score quartiles with workplace purchases, adjusted for age, sex, seasonality, and population structure. Associations were considered significant at P < 0.05. In 397 participants, mean age was 44.9 years, and 80.9% were female. Higher genetic risk scores were associated with higher BMI. The highest quartile of BMIGPS was associated with lower Healthy Purchasing Score (-4.8 percentage points [95% CI -8.6 to -1.0]; P = 0.02), higher quantity of food purchases (14.4 more items [95% CI -0.1 to 29.0]; P = 0.03), later time of breakfast purchases (15.0 minutes later [95% CI 1.5-28.5]; P = 0.03), and lower likelihood of preparing dinner at home (Q4 odds ratio [OR] = 0.3 [95% CI 0.1-0.9]; P = 0.03) relative to the lowest BMIGPS quartile. Compared with the lowest quartile, the highest BMICNS quartile was associated with fewer items purchased (P = 0.04), and the highest BMInon-CNS quartile was associated with purchasing breakfast at a later time (P = 0.01), skipping breakfast (P = 0.03), and not preparing breakfast (P = 0.04) or lunch (P = 0.01) at home. A limitation of this study is our data come from a relatively small sample of healthy working adults of European ancestry who volunteered to enroll in a health-promotion study, which may limit generalizability. CONCLUSIONS In this study, genetic risk for obesity was associated with the quality, quantity, and timing of objectively measured workplace food purchases. These findings suggest that genetic risk for obesity may influence eating behaviors that contribute to weight and could be targeted in personalized workplace wellness programs in the future. TRIAL REGISTRATION Clinicaltrials.gov NCT02660086.",2020,"Compared with the lowest quartile, the highest BMICNS quartile was associated with fewer items purchased (P = 0.04), and the highest BMInon-CNS quartile was associated with purchasing breakfast at a later time (P = 0.01), skipping breakfast (P = 0.03), and not preparing breakfast (P = 0.04) or lunch (P = 0.01) at home.","['healthy working adults of European ancestry who volunteered to enroll in a health-promotion study', 'Participants were employees of a large hospital in Boston, MA, who enrolled in the study between September 2016 and February 2018', '397 participants, mean age was 44.9 years, and 80.9% were female']",[],"['higher quantity of food purchases', 'skipping breakfast', 'A body mass index (BMI) genome-wide polygenic score (BMIGPS', 'highest BMInon-CNS quartile', 'Polygenic risk score for obesity and the quality, quantity, and timing of workplace food purchases', '3 polygenic risk scores (PRSs', 'Higher genetic risk scores', 'later time of breakfast purchases', 'Healthy Purchasing Score']","[{'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0018738', 'cui_str': 'Health promotion'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0006037', 'cui_str': 'Boston'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",[],"[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0560435', 'cui_str': 'Does skip'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0028654', 'cui_str': 'Clinical nurse specialist'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0449243', 'cui_str': 'Timing'}, {'cui': 'C0162579', 'cui_str': 'Work environment'}, {'cui': 'C0017296', 'cui_str': 'Gene therapy'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",,0.112173,"Compared with the lowest quartile, the highest BMICNS quartile was associated with fewer items purchased (P = 0.04), and the highest BMInon-CNS quartile was associated with purchasing breakfast at a later time (P = 0.01), skipping breakfast (P = 0.03), and not preparing breakfast (P = 0.04) or lunch (P = 0.01) at home.","[{'ForeName': 'Hassan S', 'Initials': 'HS', 'LastName': 'Dashti', 'Affiliation': 'Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Marie-France', 'Initials': 'MF', 'LastName': 'Hivert', 'Affiliation': 'Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Douglas E', 'Initials': 'DE', 'LastName': 'Levy', 'Affiliation': 'Mongan Institute Health Policy Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'McCurley', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Richa', 'Initials': 'R', 'LastName': 'Saxena', 'Affiliation': 'Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Anne N', 'Initials': 'AN', 'LastName': 'Thorndike', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.'}]",PLoS medicine,['10.1371/journal.pmed.1003219'] 2320,32692751,Effect of supplemental nutrition in pregnancy on offspring's risk of cardiovascular disease in young adulthood: Long-term follow-up of a cluster trial from India.,"BACKGROUND Undernutrition during intrauterine life and early childhood is hypothesised to increase the risk of cardiovascular disease (Developmental Origins of Health and Disease Hypothesis), but experimental evidence from humans is limited. This hypothesis has major implications for control of the cardiovascular disease epidemic in South Asia (home to a quarter of world's population), where a quarter of newborns have low birth weight. We investigated whether, in an area with prevalent undernutrition, supplemental nutrition offered to pregnant women and their offspring below the age of 6 years was associated with a lower risk of cardiovascular disease in the offspring when they were young adults. METHODS AND FINDINGS The Hyderabad Nutrition Trial was a community-based nonrandomised controlled intervention trial conducted in 29 villages near Hyderabad, India (1987-1990). Protein-calorie food supplement was offered daily to pregnant and lactating women (2.09 MJ energy and 20-25 g protein) and their offspring (1.25 MJ energy and 8-10 g protein) until the age of six years in the 15 intervention villages, but not in the 14 control villages. A total of 1,826 participants (949 from the intervention villages and 877 from the control villages, representing 70% of the cohort) at a mean age of 21.6 years (62% males) were examined between 2009 and 2012. The mean body mass index (BMI) of the participants was 20 kg/m2 and the mean systolic blood pressure was 115 mm Hg. The age, sex, socioeconomic position, and urbanisation-adjusted effects of intervention (beta coefficients and 95% confidence intervals) on outcomes were as follows: carotid intima-media thickness, 0.01 mm (-0.01 to 0.03), p = 0.36; arterial stiffness (augmentation index), -1.1% (-2.5 to 0.3), p = 0.097; systolic blood pressure, 0.5 mm Hg (-0.6 to 1.6), p = 0.36; BMI, -0.13 kg/m2 (-0.75 to 0.09), p = 0.093; low-density lipoprotein (LDL) cholesterol, 0.06 mmol/L (-0.07 to 0.2), p = 0.37; and fasting insulin (log), -0.06 mU/L (-0.19 to 0.07), p = 0.43. The limitations of this study include nonrandomised allocation of intervention and lack of data on compliance, and potential for selection bias due to incomplete follow-up. CONCLUSIONS Our results showed that in an area with prevalent undernutrition, protein-calorie food supplements offered to pregnant women and their offspring below the age of 6 years were not associated with lower levels of cardiovascular risk factors among offspring when they were young adults. Our findings, coupled with evidence from other intervention studies to date, suggest that policy makers should attach limited value to cardiovascular health benefits of maternal and child protein-calorie food supplementation programmes.",2020,"The Hyderabad Nutrition Trial was a community-based nonrandomised controlled intervention trial conducted in 29 villages near Hyderabad, India (1987-1990).","['pregnant women and their offspring below the age of 6 years was associated with a lower risk of cardiovascular disease in the offspring when they were young adults', 'young adulthood', '1,826 participants (949 from the intervention villages and 877 from the control villages, representing 70% of the cohort) at a mean age of 21.6 years (62% males) were examined between 2009 and 2012', 'pregnant and lactating women (2.09 MJ energy and 20-25 g protein) and their offspring (1.25 MJ energy and 8-10 g protein) until the age of six years in the 15 intervention villages, but not in the 14 control villages', '29 villages near Hyderabad, India (1987-1990']","['supplemental nutrition', 'Protein-calorie food supplement']","['mean systolic blood pressure', 'mean body mass index (BMI', 'cardiovascular risk factors', 'arterial stiffness (augmentation index', 'fasting insulin', 'systolic blood pressure', 'low-density lipoprotein (LDL) cholesterol']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C1720477', 'cui_str': 'When'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0700597', 'cui_str': 'Adulthood'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0456638', 'cui_str': '25G'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C4517497', 'cui_str': '1.25'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C1318182', 'cui_str': '10G'}, {'cui': 'C1720302', 'cui_str': 'Until'}, {'cui': 'C0233535', 'cui_str': 'Butting'}, {'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0456591', 'cui_str': '1987'}]","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0439259', 'cui_str': 'kcal'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}]",1826.0,0.0584498,"The Hyderabad Nutrition Trial was a community-based nonrandomised controlled intervention trial conducted in 29 villages near Hyderabad, India (1987-1990).","[{'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Kinra', 'Affiliation': 'Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Gregson', 'Affiliation': 'Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Poornima', 'Initials': 'P', 'LastName': 'Prabhakaran', 'Affiliation': 'Public Health Foundation of India, Delhi, India.'}, {'ForeName': 'Vipin', 'Initials': 'V', 'LastName': 'Gupta', 'Affiliation': 'Department of Anthropology, University of Delhi, Delhi, India.'}, {'ForeName': 'Gagandeep Kaur', 'Initials': 'GK', 'LastName': 'Walia', 'Affiliation': 'Public Health Foundation of India, Delhi, India.'}, {'ForeName': 'Santhi', 'Initials': 'S', 'LastName': 'Bhogadi', 'Affiliation': 'National Institute of Nutrition, Hyderabad, India.'}, {'ForeName': 'Ruby', 'Initials': 'R', 'LastName': 'Gupta', 'Affiliation': 'Public Health Foundation of India, Delhi, India.'}, {'ForeName': 'Aastha', 'Initials': 'A', 'LastName': 'Aggarwal', 'Affiliation': 'Public Health Foundation of India, Delhi, India.'}, {'ForeName': 'Poppy Alice Carson', 'Initials': 'PAC', 'LastName': 'Mallinson', 'Affiliation': 'Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Bharati', 'Initials': 'B', 'LastName': 'Kulkarni', 'Affiliation': 'National Institute of Nutrition, Hyderabad, India.'}, {'ForeName': 'Dorairaj', 'Initials': 'D', 'LastName': 'Prabhakaran', 'Affiliation': 'Public Health Foundation of India, Delhi, India.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Davey Smith', 'Affiliation': 'MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.'}, {'ForeName': 'K V', 'Initials': 'KV', 'LastName': 'Radha Krishna', 'Affiliation': 'National Institute of Nutrition, Hyderabad, India.'}, {'ForeName': 'Shah', 'Initials': 'S', 'LastName': 'Ebrahim', 'Affiliation': 'Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Kuper', 'Affiliation': 'Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Yoav', 'Initials': 'Y', 'LastName': 'Ben-Shlomo', 'Affiliation': 'Population Health Sciences, University of Bristol, Bristol, United Kingdom.'}]",PLoS medicine,['10.1371/journal.pmed.1003183'] 2321,32692788,"The clinical outcomes of medical therapies in chronic rhinosinusitis is independent of microbiomic outcomes: a double-blinded, randomised placebo-controlled trial.","BACKGROUND Oral and topical corticosteroids, and antibiotics form the mainstay medical treatment of chronic rhinosinusitis (CRS). Clinical outcomes vary depending on the chosen therapy, resident microbiome and disease phenotype. We conducted a double- blinded, placebo-controlled Randomised Controlled Trial (RCT) to investigate effects of medical therapy on clinical outcomes and associated microbiome shifts. METHODOLOGY Fifty eligible patients (CRS with and without polyps) were treated for 3 weeks after randomisation into 3 arms: na- mely oral prednisolone, topical budesonide irrigations and oral doxycycline; each with appropriate placebo. Clinical scoring and microbiome swabs were performed on enrolment, at treatment completion and 3-weeks post treatment completion. Microbiome analysis was performed using the llumina-MiSeq next generation sequencing platform and QIME-2 pipeline. RESULTS Significant improvement in clinical scores was observed in prednisolone and budesonide arms at treatment completion but not with antibiotic. Sub-group analysis showed more pronounced effects in patients with polyposis. Corynebacterium and Staphylococcus species predominated, with variable bacterial relative abundance among different treatments at all time-points. The only significant microbiome finding was an increase in bacterial diversity in topical budesonide group immediately after treatment, which returned to baseline 3-weeks post treatment. CONCLUSION Clinical improvement was significant with oral and topical steroid but not empirical antibiotic. Although there were some associated microbiome changes with the various treatments, we could not ascertain the consistency of these and whether they do have a clinical significance at all.",2020,"Corynebacterium and Staphylococcus species predominated, with variable bacterial relative abundance among different treatments at all time-points.","['chronic rhinosinusitis (CRS', 'Fifty eligible patients (CRS with and without polyps', 'patients with polyposis']","['topical budesonide', 'medical therapy', 'na- mely oral prednisolone, topical budesonide irrigations and oral doxycycline', 'budesonide', 'prednisolone', 'placebo']","['clinical scores', 'bacterial diversity']","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032584', 'cui_str': 'Polyp'}, {'cui': 'C0334108', 'cui_str': 'Multiple polyps'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0358513', 'cui_str': 'Prednisolone-containing product in oral dose form'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0013090', 'cui_str': 'Doxycycline'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",50.0,0.460936,"Corynebacterium and Staphylococcus species predominated, with variable bacterial relative abundance among different treatments at all time-points.","[{'ForeName': 'L M', 'Initials': 'LM', 'LastName': 'Cherian', 'Affiliation': 'Department of Surgery - Otolaryngology, Head and Neck Surgery, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Bassiouni', 'Affiliation': 'Department of Surgery - Otolaryngology, Head and Neck Surgery, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Cooksley', 'Affiliation': 'Department of Surgery - Otolaryngology, Head and Neck Surgery, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Vreugde', 'Affiliation': 'Department of Surgery - Otolaryngology, Head and Neck Surgery, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'P-J', 'Initials': 'PJ', 'LastName': 'Wormald', 'Affiliation': 'Department of Surgery - Otolaryngology, Head and Neck Surgery, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'A J', 'Initials': 'AJ', 'LastName': 'Psaltis', 'Affiliation': 'Department of Surgery - Otolaryngology, Head and Neck Surgery, University of Adelaide, Adelaide, Australia.'}]",Rhinology,['10.4193/Rhin20.055'] 2322,32692805,Effectiveness of a normative nutrition intervention in Chilean pregnant women on maternal and neonatal outcomes: the CHiMINCs study.,"BACKGROUND Some nutritional interventions have shown their efficacy in reducing gestational weight gain (GWG); however, their applicability in routine care is limited. OBJECTIVE We assessed the effectiveness of a low-intensity and high-coverage nutritional intervention on maternal and offspring outcomes; the intervention enhanced existing nutritional health care standards and practices at the primary health care level in Chile. METHODS This study was a cluster-randomized controlled trial of 12 primary health care centers (PHCCs) from Santiago, Chile. PHCCs were randomly allocated to either nutritional intervention [intervention group (IG), n = 5] or routine care [control group (CG), n = 7]. A total of 4631 pregnant women were recruited (IG, n = 2565; and CG, n = 2066). Primary outcomes were adequate GWG and glycemic control in mothers and birth weight, birth length, macrosomia, and large for gestational age in neonates. The intervention consisted of 4 key actions: training of health care professionals on nutritional recommendations, counseling of pregnant women on diet and physical activity recommendations, offering a physical activity program implemented in the participating PHCCs, and adequate referral to dietitians. Women randomly assigned to the CG received routine antenatal care. RESULTS At baseline, the mean age was 26.1 y; 45% of women were primipara and 24% were obese. No differences were found in the percentage of women achieving adequate GWG (IG: 30.3%, compared with CG: 31.3%; OR: 0.94; 95% CI: 0.81, 1.09), but women in the IG had lower GWG than those in the CG (11.3 compared with 11.9 kg; mean difference: -0.63 kg; 95% CI: -1.19, -0.08). Effects of the intervention were significantly higher in women with obesity at the begining of pregnancy (mean difference: -1.24 kg; 95% CI: -2.18, -0.30; P for interaction < 0.05). No differences were found between groups regarding maternal glycemic control or neonatal outcomes. CONCLUSIONS Our findings demonstrate that a low-intensity, high-coverage intervention delivered through the Chilean public health care system under standard operating conditions reduces GWG and has the potential for successful scale-up. This trial was registered at clinicaltrials.gov as NCT01916603.",2020,"No differences were found between groups regarding maternal glycemic control or neonatal outcomes. ","['4631 pregnant women were recruited (IG, n\xa0=\xa02565; and CG, n\xa0=\xa02066', 'mean age was 26.1 y; 45% of women were primipara and 24% were obese', '12 primary health care centers (PHCCs) from Santiago, Chile', 'Chilean pregnant women on maternal and neonatal outcomes']","['low-intensity and high-coverage nutritional intervention', 'CG received routine antenatal care', 'normative nutrition intervention', '4 key actions: training of health care professionals on nutritional recommendations, counseling of pregnant women on diet and physical activity recommendations, offering a physical activity program implemented in the participating PHCCs, and adequate referral to dietitians', 'nutritional intervention [intervention group (IG), n\xa0=\xa05] or routine care [control group (CG), n\xa0=\xa07']","['gestational weight gain (GWG', 'percentage of women achieving adequate GWG', 'maternal glycemic control or neonatal outcomes', 'adequate GWG and glycemic control in mothers and birth weight, birth length, macrosomia, and large for gestational age in neonates']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0033150', 'cui_str': 'Para 1'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008107', 'cui_str': 'Chile'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C1274040', 'cui_str': 'Result'}]","[{'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1276362', 'cui_str': 'Routine antenatal care'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0420347', 'cui_str': 'Patient referral to dietitian'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C1398625', 'cui_str': 'Maternal Weight Gain'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0419415', 'cui_str': 'Birth length'}, {'cui': 'C0158915', 'cui_str': 'Exceptionally large at birth'}, {'cui': 'C1848395', 'cui_str': 'Large for dates baby'}, {'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}]",4631.0,0.127877,"No differences were found between groups regarding maternal glycemic control or neonatal outcomes. ","[{'ForeName': 'Maria Luisa', 'Initials': 'ML', 'LastName': 'Garmendia', 'Affiliation': 'Institute of Nutrition and Food Technology (INTA), University of Chile, Santiago, Chile.'}, {'ForeName': 'Camila', 'Initials': 'C', 'LastName': 'Corvalan', 'Affiliation': 'Institute of Nutrition and Food Technology (INTA), University of Chile, Santiago, Chile.'}, {'ForeName': 'Marcela', 'Initials': 'M', 'LastName': 'Araya', 'Affiliation': 'Department of Women and Newborn Health Promotion, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Casanello', 'Affiliation': 'Department of Obstetrics and Gynecology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.'}, {'ForeName': 'Juan Pedro', 'Initials': 'JP', 'LastName': 'Kusanovic', 'Affiliation': 'Department of Obstetrics and Gynecology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Uauy', 'Affiliation': 'Institute of Nutrition and Food Technology (INTA), University of Chile, Santiago, Chile.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa185'] 2323,32682556,Norepinephrine or phenylephrine during spinal anaesthesia for Caesarean delivery: a randomised double-blind pragmatic non-inferiority study of neonatal outcome.,"BACKGROUND Norepinephrine is an effective vasopressor during spinal anaesthesia for Caesarean delivery. However, before it can be fully recommended, possible adverse effects on neonatal outcome should be excluded. We aimed to test the hypothesis that umbilical arterial cord pH is at least as good (non-inferior) when norepinephrine is used compared with phenylephrine for treatment of hypotension. METHODS We enrolled 668 subjects having elective and non-elective Caesarean delivery under spinal or combined spinal-epidural anaesthesia in this randomised, double-blind, two-arm parallel, non-inferiority clinical trial. Arterial blood pressure was maintained using norepinephrine 6 μg ml -1 or phenylephrine 100 μg ml -1 according to the practice of the anaesthetist, either prophylactically or therapeutically, as an infusion or bolus. The primary outcome was umbilical arterial pH with a chosen non-inferiority margin of 0.01 units. RESULTS Of 664 subjects (531 elective and 133 non-elective) who completed the study, umbilical arterial cord blood was analysed for 351 samples from 332 subjects in the norepinephrine group and 343 samples from 332 subjects in the phenylephrine group. Umbilical arterial pH was non-inferior in the norepinephrine group (mean, 7.289; 95% confidence interval [CI], 7.284-7.294) compared with the phenylephrine group (mean, 7.287; 95% CI, 7.281-7.292) (mean difference between groups, 0.002; 95% CI, -0.005 to 0.009; P=0.017). Subgroup analysis confirmed the non-inferiority of norepinephrine for elective cases but was inconclusive for non-elective cases. CONCLUSIONS Norepinephrine was non-inferior to phenylephrine for neonatal outcome assessed by umbilical arterial pH. These results provide high-quality evidence supporting the fetal safety of norepinephrine in obstetric anaesthesia. CLINICAL TRIAL REGISTRATION ChiCTR-IPR-15006235.",2020,"Umbilical arterial pH was non-inferior in the norepinephrine group (mean, 7.289; 95% confidence interval [CI], 7.284-7.294) compared with the phenylephrine group (mean, 7.287; 95% CI, 7.281-7.292) (mean difference between groups, 0.002; 95% CI, -0.005 to 0.009; P=0.017).","['664 subjects (531 elective and 133 non-elective) who completed the study', '332 subjects in the norepinephrine group and 343 samples from 332 subjects in the phenylephrine group', '668 subjects having elective and non', 'spinal anaesthesia for Caesarean delivery']","['phenylephrine', 'norepinephrine 6 μg ml -1 or phenylephrine', 'Norepinephrine', 'elective Caesarean delivery under spinal or combined spinal-epidural anaesthesia', 'Norepinephrine or phenylephrine', 'norepinephrine']","['umbilical arterial pH with a chosen non-inferiority margin of 0.01 units', 'Arterial blood pressure', 'umbilical arterial cord blood', 'Umbilical arterial pH']","[{'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0031469', 'cui_str': 'Phenylephrine'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}]","[{'cui': 'C0031469', 'cui_str': 'Phenylephrine'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C2744579', 'cui_str': 'ATP8A2 protein, human'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002913', 'cui_str': 'Epidural anesthesia'}]","[{'cui': 'C0041638', 'cui_str': 'Umbilical structure'}, {'cui': 'C0428199', 'cui_str': 'pH measurement, arterial'}, {'cui': 'C0237666', 'cui_str': 'Inferiority feeling'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C4517393', 'cui_str': '0.01'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C1272641', 'cui_str': 'Systemic arterial pressure'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0162371', 'cui_str': 'Cord blood'}]",668.0,0.630435,"Umbilical arterial pH was non-inferior in the norepinephrine group (mean, 7.289; 95% confidence interval [CI], 7.284-7.294) compared with the phenylephrine group (mean, 7.287; 95% CI, 7.281-7.292) (mean difference between groups, 0.002; 95% CI, -0.005 to 0.009; P=0.017).","[{'ForeName': 'Warwick D', 'Initials': 'WD', 'LastName': 'Ngan Kee', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China; Department of Anesthesiology, Sidra Medicine, Doha, Qatar. Electronic address: wngankee@gmail.com.'}, {'ForeName': 'Shara W Y', 'Initials': 'SWY', 'LastName': 'Lee', 'Affiliation': 'Department of Health Technology & Informatics, Hong Kong Polytechnic University, Kowloon, Hong Kong, China.'}, {'ForeName': 'Floria F', 'Initials': 'FF', 'LastName': 'Ng', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Lee', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China.'}]",British journal of anaesthesia,['10.1016/j.bja.2020.05.057'] 2324,32682559,Individualized PEEP to optimise respiratory mechanics during abdominal surgery: a pilot randomised controlled trial.,"BACKGROUND Higher intraoperative driving pressures (ΔP) are associated with increased postoperative pulmonary complications (PPC). We hypothesised that dynamic adjustment of PEEP throughout abdominal surgery reduces ΔP, maintains positive end-expiratory transpulmonary pressures (P tp_ee ) and increases respiratory system static compliance (C rs ) with PEEP levels that are variable between and within patients. METHODS In a prospective multicentre pilot study, adults at moderate/high risk for PPC undergoing elective abdominal surgery were randomised to one of three ventilation protocols: (1) PEEP≤2 cm H 2 O, compared with periodic recruitment manoeuvres followed by individualised PEEP to either optimise respiratory system compliance (PEEP maxCrs ) or maintain positive end-expiratory transpulmonary pressure (PEEP Ptp_ee ). The composite primary outcome included intraoperative ΔP, P tp_ee , C rs , and PEEP values (median (interquartile range) and coefficients of variation [CV PEEP ]). RESULTS Thirty-seven patients (48.6% female; age range: 47-73 yr) were assigned to control (PEEP≤2 cm H 2 O; n=13), PEEP maxCrs (n=16), or PEEP Ptp_ee (n=8) groups. The PEEP Ptp_ee intervention could not be delivered in two patients. Subjects assigned to PEEP maxCrs had lower ΔP (median8 cm H 2 O [7-10]), compared with the control group (12 cm H 2 O [10-15]; P=0.006). PEEP maxCrs was also associated with higher P tp_ee (2.0 cm H 2 O [-0.7 to 4.5] vs controls: -8.3 cm H 2 O [-13.0 to -4.0]; P≤0.001) and higher C rs (47.7 ml cm H 2 O [43.2-68.8] vs controls: 39.0 ml cm H 2 O [32.9-43.4]; P=0.009). Individualised PEEP (PEEP maxCrs and PEEP Ptp_ee combined) varied widely (median: 10 cm H 2 O [8-15]; CV PEEP =0.24 [0.14-0.35]), both between, and within, subjects throughout surgery. CONCLUSIONS This pilot study suggests that individualised PEEP management strategies applied during abdominal surgery reduce driving pressure, maintain positive P tp_ee and increase static compliance. The wide range of PEEP observed suggests that an individualised approach is required to optimise respiratory mechanics during abdominal surgery. CLINICAL TRIAL REGISTRATION NCT02671721.",2020,Subjects assigned to PEEP maxCrs had lower ΔP (median8 cm H,"['Thirty-seven patients (48.6% female; age range: 47-73 yr', 'adults at moderate/high risk for PPC undergoing elective abdominal surgery', 'abdominal surgery']","['Individualised PEEP', 'PEEP maxCrs (n=16), or PEEP Ptp_ee', 'Individualized PEEP']","['respiratory system static compliance (C rs ) with PEEP levels', 'driving pressure, maintain positive P tp_ee and increase static compliance', 'postoperative pulmonary complications (PPC', 'intraoperative ΔP, P tp_ee , C rs , and PEEP values (median (interquartile range) and coefficients of variation [CV PEEP ']","[{'cui': 'C4319569', 'cui_str': '37'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}]","[{'cui': 'C0032740', 'cui_str': 'Positive end-expiratory pressure'}]","[{'cui': 'C0035237', 'cui_str': 'Structure of respiratory system'}, {'cui': 'C0429681', 'cui_str': 'Static lung compliance'}, {'cui': 'C0032740', 'cui_str': 'Positive end-expiratory pressure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0442700', 'cui_str': 'End-expiration'}, {'cui': 'C0442377', 'cui_str': 'Transpulmonary artery approach'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}]",,0.272444,Subjects assigned to PEEP maxCrs had lower ΔP (median8 cm H,"[{'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Fernandez-Bustamante', 'Affiliation': 'Department of Anesthesiology, University of Colorado School of Medicine, Aurora, CO, USA; Webb-Waring Center, University of Colorado School of Medicine, Aurora, CO, USA. Electronic address: Ana.Fernandez-Bustamante@cuanschutz.edu.'}, {'ForeName': 'Juraj', 'Initials': 'J', 'LastName': 'Sprung', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Parker', 'Affiliation': 'Department of Medicine, Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Karsten', 'Initials': 'K', 'LastName': 'Bartels', 'Affiliation': 'Department of Anesthesiology, University of Colorado School of Medicine, Aurora, CO, USA.'}, {'ForeName': 'Toby N', 'Initials': 'TN', 'LastName': 'Weingarten', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Kosour', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'B Taylor', 'Initials': 'BT', 'LastName': 'Thompson', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Marcos F', 'Initials': 'MF', 'LastName': 'Vidal Melo', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}]",British journal of anaesthesia,['10.1016/j.bja.2020.06.030'] 2325,32682616,"Re: Marc-Oliver Grimm, Antione G. van der Heijden, Marc Colombel, et al. Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial ""NIMBUS"". Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.066.",,2020,,[],"['BCG', 'BCG Instillations']",[],[],"[{'cui': 'C0004886', 'cui_str': 'BCG vaccine'}, {'cui': 'C0184959', 'cui_str': 'Instillation'}]",[],,0.0627577,,"[{'ForeName': 'Emre', 'Initials': 'E', 'LastName': 'Karabay', 'Affiliation': 'Department of Urology, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey. Electronic address: emrekarabay@gmail.com.'}, {'ForeName': 'İlker', 'Initials': 'İ', 'LastName': 'Tınay', 'Affiliation': 'Department of Urology, Marmara University School of Medicine, Istanbul, Turkey.'}]",European urology,['10.1016/j.eururo.2020.06.060'] 2326,32682668,The Effect of a Small Priming Dose of Sufentanil on Sufentanil-Induced Cough.,"PURPOSE The aim of this study was to investigate the effect of a small priming dose of sufentanil on sufentanil-induced cough during induction of anesthesia. DESIGN Randomized controlled trial. METHODS Adult patients (N = 220) aged 18 to 65 years undergoing general anesthesia were randomized into two groups (n = 110), a total dose of sufentanil 0.4 mcg/kg was used during induction of anesthesia. Group P (intervention) received a bolus of 5 mcg of sufentanil 1 minute before a bolus of the remaining larger dose of sufentanil, whereas group C (comparison) received an equal volume of normal saline 1 minute before a bolus of the total dose of sufentanil. The incidence and severity of cough were noted for 1 minute after each injection of sufentanil or normal saline. FINDINGS The incidence of cough in group P was significantly lower than group C (6.4% vs 21.8%, P < .001). The severity of cough in group P was significantly decreased compared with group C (P < .001). In group P, three patients (2.7%, P = .247) coughed after the priming sufentanil injection. CONCLUSIONS A priming dose of 5 mcg of sufentanil 1 minute before a larger dose of sufentanil injection could effectively alleviate sufentanil-induced cough, the small priming dose of sufentanil could also elicit cough with a low incidence.",2020,The severity of cough in group P was significantly decreased compared with group C (P < .001).,['Adult patients (N\xa0=\xa0220) aged 18 to 65\xa0years undergoing general anesthesia'],"['Sufentanil', 'sufentanil', 'sufentanil injection']","['incidence of cough', 'incidence and severity of cough', 'severity of cough']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}]","[{'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C4283241', 'cui_str': 'Sufentanil Injection'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",220.0,0.349508,The severity of cough in group P was significantly decreased compared with group C (P < .001).,"[{'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Zou', 'Affiliation': ""Department of Anesthesiology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Clinical Research Center for Anesthesiology of ERAS in Hunan Province, Changsha, China.""}, {'ForeName': 'Yingzi', 'Initials': 'Y', 'LastName': 'Ling', 'Affiliation': ""Department of Anesthesiology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Clinical Research Center for Anesthesiology of ERAS in Hunan Province, Changsha, China.""}, {'ForeName': 'Lai', 'Initials': 'L', 'LastName': 'Wei', 'Affiliation': ""Department of Anesthesiology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Clinical Research Center for Anesthesiology of ERAS in Hunan Province, Changsha, China.""}, {'ForeName': 'Yixun', 'Initials': 'Y', 'LastName': 'Tang', 'Affiliation': ""Department of Anesthesiology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Clinical Research Center for Anesthesiology of ERAS in Hunan Province, Changsha, China.""}, {'ForeName': 'Gaoyin', 'Initials': 'G', 'LastName': 'Kong', 'Affiliation': ""Department of Anesthesiology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Clinical Research Center for Anesthesiology of ERAS in Hunan Province, Changsha, China. Electronic address: 1193135376@qq.com.""}, {'ForeName': 'Le', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': ""Department of Cardiovascular Disease, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.""}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.03.016'] 2327,32060665,"Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate.","Doravirine is a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of human immunodeficiency virus-1 infection, available as a single tablet in combination with other antiretroviral agents or as a fixed-dose regimen with lamivudine and tenofovir disoproxil fumarate (TDF). Alternative formulations of these drugs are being developed for individuals who have difficulty swallowing tablets. Two phase 1 trials were conducted, both in 24 healthy adults, to assess the pharmacokinetics of uncoated and coated oral granule formulations of doravirine, lamivudine, and TDF administered alone and with vanilla pudding or apple sauce. The pharmacokinetics for all uncoated granules, and of coated lamivudine and TDF granules, were similar to those of currently marketed tablets (geometric mean ratios [GMRs] 0.92-1.04). Coated doravirine granules had decreased AUC 0-∞ (11%) and C max (23%) values versus the tablet. The pharmacokinetics were similar for uncoated and coated doravirine granules administered with or without pudding (GMRs 0.96-1.10); administration with apple sauce increased doravirine AUC 0-∞ (26-29%), C max (56-59%), and C 24 (20-21%) versus administration of granules alone. Lamivudine granules administered with pudding or apple sauce decreased AUC 0-∞ and C max (14-25%) versus granules alone. Tenofovir AUC 0-∞ , C max , and C 24 increased for TDF granules administered with pudding or apple sauce versus alone (11-23%). Pharmacokinetic differences when administering doravirine, lamivudine, or TDF as uncoated or coated granules versus tablets, or when granules were administered with (versus without) pudding or apple sauce, are not considered clinically meaningful, supporting further development of these granule formulations.",2020,"Doravirine is a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of human immunodeficiency virus-1 infection, available as a single tablet in combination with other antiretroviral agents or as a fixed-dose regimen with lamivudine and tenofovir disoproxil fumarate (TDF).","['individuals who have difficulty swallowing tablets', '24 healthy adults']","['Lamivudine, and Tenofovir Disoproxil Fumarate', 'Doravirine', 'doravirine, lamivudine, and TDF administered alone and with vanilla pudding or apple sauce', 'Lamivudine granules administered with pudding or apple sauce', 'pudding or apple sauce', 'lamivudine and tenofovir disoproxil fumarate (TDF', 'doravirine, lamivudine, or TDF', 'apple sauce increased doravirine']","['Tenofovir AUC 0-∞ , C max , and C 24 increased for TDF granules', 'AUC 0-∞ and C max']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0209738', 'cui_str': 'Lamivudine'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C4045491', 'cui_str': 'DORAVIRINE'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0678424', 'cui_str': 'Vanilla'}, {'cui': 'C2347717', 'cui_str': 'Pudding'}, {'cui': 'C0003625', 'cui_str': 'Malus'}, {'cui': 'C0453357', 'cui_str': 'Sauce'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}, {'cui': 'C3871446', 'cui_str': 'lamivudine and tenofovir disoproxil'}, {'cui': 'C0016801', 'cui_str': 'Fumarates'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]","[{'cui': 'C0384228', 'cui_str': 'Tenofovir'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}]",,0.0339645,"Doravirine is a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of human immunodeficiency virus-1 infection, available as a single tablet in combination with other antiretroviral agents or as a fixed-dose regimen with lamivudine and tenofovir disoproxil fumarate (TDF).","[{'ForeName': 'Ka Lai', 'Initials': 'KL', 'LastName': 'Yee', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey, USA.'}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'DiBenedetto', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey, USA.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Fan', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey, USA.'}, {'ForeName': 'Sauzanne', 'Initials': 'S', 'LastName': 'Khalilieh', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey, USA.'}, {'ForeName': 'Ilias', 'Initials': 'I', 'LastName': 'Triantafyllou', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey, USA.'}, {'ForeName': 'Marie-Helene', 'Initials': 'MH', 'LastName': 'Vallee', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Fackler', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey, USA.'}, {'ForeName': 'S Aubrey', 'Initials': 'SA', 'LastName': 'Stoch', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey, USA.'}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Iwamoto', 'Affiliation': 'Merck & Co., Inc., Kenilworth, New Jersey, USA. marian_iwamoto@merck.com.'}]",AAPS PharmSciTech,['10.1208/s12249-020-1630-6'] 2328,29746177,Exploration of Effective Persuasive Strategies Used in Resisting Product Advertising: A Case Study of Adult Health Check-Ups.,"This research addressed adults' health check-ups through the lens of Role Transportation Theory. This theory is applied to narrative advertising that lures adults into seeking health check-ups by causing audiences to empathize with the advertisement's character. This study explored the persuasive mechanism behind narrative advertising and reinforced the Protection Motivation Theory model. We added two key perturbation variables: optimistic bias and truth avoidance. To complete the verification hypothesis, we performed two experiments. In Experiment 1, we recruited 77 respondents online for testing. We used analyses of variance to verify the effectiveness of narrative and informative advertising. Then, in Experiment 2, we recruited 228 respondents to perform offline physical experiments and conducted a path analysis through structural equation modelling. The findings showed that narrative advertising positively impacted participants' disease prevention intentions. The use of Role Transportation Theory in advertising enables the audience to be emotionally connected with the character, which enhances persuasiveness. In Experiment 2, we found that the degree of role transference can interfere with optimistic bias, improve perceived health risk, and promote behavioral intentions for health check-ups. Furthermore, truth avoidance can interfere with perceived health risks, which, in turn, reduce behavioral intentions for health check-ups.",2019,"In Experiment 2, we found that the degree of role transference can interfere with optimistic bias, improve perceived health risk, and promote behavioral intentions for health check-ups.","['Resisting Product Advertising', '228 respondents to perform offline physical experiments and conducted a path analysis through structural equation modelling']",[],"[""narrative advertising positively impacted participants' disease prevention intentions"", 'optimistic bias, improve perceived health risk']","[{'cui': 'C0001690', 'cui_str': 'Advertising as Topic'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]",[],"[{'cui': 'C1135957', 'cui_str': 'Narration'}, {'cui': 'C0001690', 'cui_str': 'Advertising as Topic'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0564470', 'cui_str': 'Optimistic'}, {'cui': 'C0005346', 'cui_str': 'Biases'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",,0.0154759,"In Experiment 2, we found that the degree of role transference can interfere with optimistic bias, improve perceived health risk, and promote behavioral intentions for health check-ups.","[{'ForeName': 'Han-Kuang', 'Initials': 'HK', 'LastName': 'Tien', 'Affiliation': 'Advertising Department, School of Continuing Education, Chinese Culture University.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Chung', 'Affiliation': 'Program of Marketing, Business College at Chinese Culture University.'}]",Health communication,['10.1080/10410236.2018.1473706'] 2329,29958013,"Clicking Health Risk Messages on Social Media: Moderated Mediation Paths Through Perceived Threat, Perceived Efficacy, and Fear Arousal.","This study drew on appraisal theory to examine how fear appeal messages and individual coping styles combined to drive users' intention to click (ITC) health risk messages on social media. A 2 × 2 × 2 mixed-design experiment was conducted, with threat and efficacy as between subject factors and message as the within subject factor. The results suggested that: (1) threat and efficacy message influenced ITC via the mediating effect of perceived threat, and perceived efficacy; (2) fear arousal was positively related to intention to click; (3) blunting style used by the participant suppressed fear arousal's ability to mobilize ITC; and (4) monitoring style had a positive main effect on ITC. Theoretical and practical implications are discussed.",2019,This study drew on appraisal theory to examine how fear appeal messages and individual coping styles combined to drive users' intention to click (ITC) health risk messages on social media.,['Social Media'],"[""individual coping styles combined to drive users' intention to click (ITC) health risk messages""]","['threat and efficacy message influenced ITC via the mediating effect of perceived threat, and perceived efficacy; (2) fear arousal', 'Moderated Mediation Paths Through Perceived Threat, Perceived Efficacy, and Fear Arousal', 'ITC']","[{'cui': 'C3179065', 'cui_str': 'Social Medium'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0680727', 'cui_str': 'Mediation'}]",,0.015058,This study drew on appraisal theory to examine how fear appeal messages and individual coping styles combined to drive users' intention to click (ITC) health risk messages on social media.,"[{'ForeName': 'Xueying', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Journalism and Mass Communication, North Carolina Agricultural and Technical State University.'}, {'ForeName': 'Shuhua', 'Initials': 'S', 'LastName': 'Zhou', 'Affiliation': 'College of Communication and Information Sciences, University of Alabama.'}]",Health communication,['10.1080/10410236.2018.1489202'] 2330,30012018,Associations Between Hand Hygiene Education and Self-Reported Hand-Washing Behaviors Among Korean Adults During MERS-CoV Outbreak.,"BACKGROUND Hand washing is an effective way to prevent transmission of infectious diseases. Education and promotional materials about hand washing may change individuals' awareness toward hand washing. Infectious disease outbreak may also affect individuals' awareness. AIMS Our study aimed to examine associations between hand-washing education and self-reported hand-washing behaviors among Korean adults during the year of the Middle East respiratory syndrome (MERS) outbreak. METHODS Data from the 2015 Community Health Survey were used for this study. The total study population comprised 222,599 individuals who were older than 20 years of age. A multiple linear regression model was used to investigate associations between hand hygiene education and self-reported hand-washing behaviors. Subgroup analyses stratified by age, sex, income, and MERS outbreak regions were also performed. RESULTS Individuals who received hand-washing education or saw promotional materials related to hand washing had significantly higher scores for self-reported use of soap or sanitizer (β = 0.177, P < .0001) and self-reported frequency of hand washing (β = 0.481, P < .0001) than those who did not have such experiences. The effect of hand-washing education on self-reported behavior change was greater among older adults, women, and lower income earners. The effect of hand hygiene education on self-reported use of soap or sanitizer was similar regardless of whether the participants lived in MERS regions. CONCLUSION Our findings emphasize the importance of education or promotions encouraging hand washing, especially for older adults, women, and lower income earners. In addition, MERS outbreak itself affected individuals' awareness of hand-washing behaviors. Well-organized campaigns that consider these factors are needed to prevent infectious diseases.",2019,"RESULTS Individuals who received hand-washing education or saw promotional materials related to hand washing had significantly higher scores for self-reported use of soap or sanitizer (β = 0.177, P < .0001) and self-reported frequency of hand washing (β = 0.481, P < .0001) than those who did not have such experiences.","['older adults, women, and lower income earners', 'Korean Adults', 'participants lived in MERS regions', '222,599 individuals who were older than 20 years of age', 'Korean adults during the year of the Middle East respiratory syndrome (MERS) outbreak.\nMETHODS\n\n\nData from the 2015 Community Health Survey']","['hand hygiene education', 'hand-washing education and self-reported hand-washing behaviors', 'hand-washing education']",[],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C3694279', 'cui_str': 'Middle East respiratory syndrome'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0012652', 'cui_str': 'Disease outbreak'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]","[{'cui': 'C4544100', 'cui_str': 'Education about hand hygiene'}, {'cui': 'C3697311', 'cui_str': 'Hand washing education'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",[],,0.0197308,"RESULTS Individuals who received hand-washing education or saw promotional materials related to hand washing had significantly higher scores for self-reported use of soap or sanitizer (β = 0.177, P < .0001) and self-reported frequency of hand washing (β = 0.481, P < .0001) than those who did not have such experiences.","[{'ForeName': 'Jieun', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': '1 Yonsei University, Seoul, Republic of Korea.'}, {'ForeName': 'Eun-Cheol', 'Initials': 'EC', 'LastName': 'Park', 'Affiliation': '1 Yonsei University, Seoul, Republic of Korea.'}, {'ForeName': 'Sang Ah', 'Initials': 'SA', 'LastName': 'Lee', 'Affiliation': '1 Yonsei University, Seoul, Republic of Korea.'}, {'ForeName': 'Sang Gyu', 'Initials': 'SG', 'LastName': 'Lee', 'Affiliation': '1 Yonsei University, Seoul, Republic of Korea.'}]",Health education & behavior : the official publication of the Society for Public Health Education,['10.1177/1090198118783829'] 2331,32695261,Promoting Alzheimer's Risk-Reduction through Community-Based Lifestyle Education and Exercise in Rural America: A Pilot Intervention.,"Introduction Rural Americans (RA) have poorer vascular health and physical activity levels than their urban counterparts; all are dementia risk factors. Dementia risk reduction among rural individuals requires a tailored approach. The purpose of this project was to examine preliminary efficacy of a community-based physical exercise and/or dementia risk factor-reduction curriculum among rural adults 50 and older. Methods Seventy-five rural dwelling adults 50 and older were randomized to one of three groups: 1) 10 weeks of Alzheimer's disease risk-reduction education (ED), 2) risk-reduction education and supervised exercise (EDEX) or 3) control group (CON). Outcomes included baseline to 10-week follow-up difference in dementia knowledge (primary outcome) and physical activity, muscular endurance, healthy lifestyle engagement, and anthropometrics (secondary outcomes). Results Sixty-nine adults successfully completed the 10-week study. Dementia knowledge increased in a Treatment Arm-dependent manner (χ 2 = 6.95 (2), p = 0.03), being ED and EDEX superior to CON. Engagement in healthy lifestyle behaviors did not change statistically. However, participation specifically in physical activity increased over time (χ 2 = 11.47 (2), p = 0.003) with EDEX reporting the greatest increases. No significant change in average daily steps was observed for any group. Conclusion The results suggested dementia risk-reduction education, both with and without structured exercise, leads to improvements in dementia knowledge. When coupled with regular, supervised exercise, this education intervention also helped participants increase engagement in physical activity over 10 weeks. Tailored interventions that combine Alzheimer's disease education and regular, supervised exercise may help reduce dementia risk in rural communities.",2020,"However, participation specifically in physical activity increased over time (χ 2 = 11.47 (2), p = 0.003) with EDEX reporting the greatest increases.","['rural adults 50 and older', 'Results\n\n\nSixty-nine adults successfully completed the 10-week study', 'Methods\n\n\nSeventy-five rural dwelling adults 50 and older', 'Rural America', 'Introduction\n\n\nRural Americans (RA', 'rural communities']","['community-based physical exercise and/or dementia risk factor-reduction curriculum', ""Alzheimer's disease risk-reduction education (ED), 2) risk-reduction education and supervised exercise (EDEX) or 3) control group (CON""]","['Dementia knowledge', 'dementia knowledge', 'physical activity', 'dementia knowledge (primary outcome) and physical activity, muscular endurance, healthy lifestyle engagement, and anthropometrics (secondary outcomes', 'vascular health and physical activity levels', 'average daily steps', 'Dementia risk reduction', 'healthy lifestyle behaviors']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0450388', 'cui_str': '69'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319621', 'cui_str': '75'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002454', 'cui_str': 'America'}, {'cui': 'C0086944', 'cui_str': 'Rural Communities'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C4277664', 'cui_str': 'Healthy Lifestyles'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",75.0,0.0536369,"However, participation specifically in physical activity increased over time (χ 2 = 11.47 (2), p = 0.003) with EDEX reporting the greatest increases.","[{'ForeName': 'Erin M', 'Initials': 'EM', 'LastName': 'Blocker', 'Affiliation': 'University of Kansas, Department of Health, Sport and Exercise Science, Lawrence, KS.'}, {'ForeName': 'Andrew C', 'Initials': 'AC', 'LastName': 'Fry', 'Affiliation': 'University of Kansas, Department of Health, Sport and Exercise Science, Lawrence, KS.'}, {'ForeName': 'Paul E', 'Initials': 'PE', 'LastName': 'Luebbers', 'Affiliation': 'Emporia State University, Department of Health, Physical Education, & Recreation, Emporia, KS.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Burns', 'Affiliation': ""University of Kansas, Alzheimer's Disease Center, Fairway, KS.""}, {'ForeName': 'Jaime', 'Initials': 'J', 'LastName': 'Perales-Puchalt', 'Affiliation': ""University of Kansas, Alzheimer's Disease Center, Fairway, KS.""}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Hansen', 'Affiliation': 'University of Kansas, Department of Educational Psychology, Lawrence, KS.'}, {'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Vidoni', 'Affiliation': ""University of Kansas, Alzheimer's Disease Center, Fairway, KS.""}]",Kansas journal of medicine,[] 2332,32695314,Effect of supraneural transforaminal epidural steroid injection combined with caudal epidural steroid injection with catheter in chronic radicular pain management: Double blinded randomized controlled trial.,"Background: Epidural steroid injection (ESI) has been used in managing chronic radicular pain. Regarding various techniques of ESI, the synergistic effect of caudal ESI (CESI) on transforaminal ESI (TFESI) in chronic lumbosacral radicular pain in prospective randomized controlled trial has not been determined. Methods :  A total of 54 eligible patients with lumbosacral radicular pain were randomly allocated to undergo TFESI plus CESI (TC group) or TFESI alone (T group).  The effective response to treatment was predefined by at least a 50% reduced verbal numerical rating scale (VNRS) from baseline between group comparison and the functional outcomes as measured by improved Oswestry Disability Index by least 15 points from baseline. All participants were evaluated using a single blinded outcome assessor before the  procedure and at 1, 3 and 6 months after the procedure. P <0.05 was considered as statistically significant. Results :  Average VNRS reduced significantly from baseline after receiving procedure at 1, 3 and 6 months in both groups (P-value <0.05). However, the TC group showed significant pain relief compared with the T group in spondylolisthesis and failed back surgery syndrome at 1 month. No statistical difference was observed between group comparisons of functional outcomes. Conclusions : A treatment combining TFESI and CESI showed significant pain relief over TFESI alone in spondylolithesis and failed back surgery syndrome at 1 month. No effect was found concerning functional evaluation. Registration: Thai Clinical Trials Registry ID TCTR20171101002 01/11/2017.",2020,A treatment combining TFESI and CESI showed significant pain relief over TFESI alone in spondylolithesis and failed back surgery syndrome at 1 month.,"['chronic radicular pain management', 'chronic lumbosacral radicular pain', '54 eligible patients with lumbosacral radicular pain']","['Epidural steroid injection (ESI', 'TC', 'TFESI and CESI', 'caudal ESI (CESI', 'TFESI plus CESI (TC group) or TFESI alone (T group', 'supraneural transforaminal epidural steroid injection combined with caudal epidural steroid injection with catheter', 'transforaminal ESI (TFESI']","['Average VNRS', 'Oswestry Disability Index', 'pain relief', 'verbal numerical rating scale (VNRS']","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0278147', 'cui_str': 'Radicular pain'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0450206', 'cui_str': 'Lumbosacral'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0196394', 'cui_str': 'Epidural steroid injection'}, {'cui': 'C0142580', 'cui_str': 'PI3 protein, human'}, {'cui': 'C0205097', 'cui_str': 'Caudal'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0036669', 'cui_str': 'Group T'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0394837', 'cui_str': 'Local anesthetic sacral epidural block'}, {'cui': 'C1261311', 'cui_str': 'Injection of steroid'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}]","[{'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",54.0,0.143353,A treatment combining TFESI and CESI showed significant pain relief over TFESI alone in spondylolithesis and failed back surgery syndrome at 1 month.,"[{'ForeName': 'Sithapan', 'Initials': 'S', 'LastName': 'Munjupong', 'Affiliation': 'Department of Anaesthesiology, Phramongkutklao Hospital and College of Medicine, Bangkok, Bangkok, 10400, Thailand.'}, {'ForeName': 'Wipoo', 'Initials': 'W', 'LastName': 'Kumnerddee', 'Affiliation': 'Department of Rehabilitation Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Bangkok, 10400, Thailand.'}]",F1000Research,['10.12688/f1000research.23188.1'] 2333,32695433,Safety and feasibility of a Dalcroze eurhythmics and a simple home exercise program among older adults with mild cognitive impairment (MCI) or mild dementia: the MOVE for your MIND pilot trial.,"Background Falls represent a major health problem for older adults with cognitive impairment, and the effects of exercise for fall reduction are understudied in this population. This pilot randomized controlled trial evaluated the feasibility, safety, and exploratory effectiveness of a Dalcroze eurhythmics program and a home exercise program designed for fall prevention in older adults with mild cognitive impairment (MCI) or early dementia. Methods For this three-arm, single-blind, 12-month randomized controlled pilot trial, we recruited community-dwelling women and men age 65 years and older with MCI or early dementia through participating memory clinics in Zurich, Switzerland. Participants were randomly assigned to a Dalcroze eurhythmics group program, a simple home exercise program (SHEP), or a non-exercise control group. All participants received 800 IU of vitamin D 3 per day. The main objective of the study was to test the feasibility of recruitment and safety of the interventions. Additional outcomes included fall rate, gait performance, and cognitive function. Results Over 12 months, 221 older adults were contacted and 159 (72%) were screened via telephone. Following screening, 12% (19/159) met the inclusion criteria and were willing to participate. One participant withdrew at the end of the baseline visit and 18 were randomized to Dalcroze eurhythmics ( n = 7), SHEP ( n = 5), or control ( n = 6). Adherence was similarly low in the Dalcroze eurhythmics group (56%) and in the SHEP group (62%; p = 0.82). Regarding safety and pilot clinical endpoints, there were no differences between groups. Conclusion The MOVE for your MIND pilot study showed that recruitment of older adults with MCI or early dementia for long-term exercise interventions is challenging. While there were no safety concerns, adherence to both exercise programs was low. Trial registration ClinicalTrials.gov, NCT02279316. Registered on 31 October 2014.",2020,Adherence was similarly low in the Dalcroze eurhythmics group (56%) and in the SHEP group (62%; ,"['recruited community-dwelling women and men age 65\u2009years and older with MCI or early dementia through participating memory clinics in Zurich, Switzerland', 'older adults with MCI or early dementia', 'older adults with mild cognitive impairment (MCI) or mild dementia', 'older adults with mild cognitive impairment (MCI) or early dementia', '221 older adults were contacted and 159 (72%) were screened via telephone', 'older adults with cognitive impairment']","['Dalcroze eurhythmics', 'Dalcroze eurhythmics group program, a simple home exercise program (SHEP), or a non-exercise control group', 'Dalcroze eurhythmics and a simple home exercise program', 'Dalcroze eurhythmics program and a home exercise program', 'vitamin D', 'SHEP']","['fall rate, gait performance, and cognitive function', 'Adherence']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C3494623', 'cui_str': 'Mild dementia'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}]","[{'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",221.0,0.166892,Adherence was similarly low in the Dalcroze eurhythmics group (56%) and in the SHEP group (62%; ,"[{'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Fischbacher', 'Affiliation': 'Department of Geriatrics, University Hospital Zurich, Rämistrasse 100, 8091 Zürich, Switzerland.'}, {'ForeName': 'Patricia Orializ', 'Initials': 'PO', 'LastName': 'Chocano-Bedoya', 'Affiliation': 'Department of Geriatrics, University Hospital Zurich, Rämistrasse 100, 8091 Zürich, Switzerland.'}, {'ForeName': 'Ursina', 'Initials': 'U', 'LastName': 'Meyer', 'Affiliation': 'Department of Geriatrics, University Hospital Zurich, Rämistrasse 100, 8091 Zürich, Switzerland.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Bopp', 'Affiliation': 'University Clinic for Acute Geriatric Care, Waid City Hospital, Tièchestrasse 99, 8037 Zürich, Switzerland.'}, {'ForeName': 'Michèle', 'Initials': 'M', 'LastName': 'Mattle', 'Affiliation': 'Department of Geriatrics, University Hospital Zurich, Rämistrasse 100, 8091 Zürich, Switzerland.'}, {'ForeName': 'Reto Werner', 'Initials': 'RW', 'LastName': 'Kressig', 'Affiliation': 'Felix Platter-Hospital, University Center for Medicine of Aging, Burgfelderstrasse 101, Postfach, 4002 Basel, Switzerland.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Egli', 'Affiliation': 'Department of Geriatrics, University Hospital Zurich, Rämistrasse 100, 8091 Zürich, Switzerland.'}, {'ForeName': 'Heike Annette', 'Initials': 'HA', 'LastName': 'Bischoff-Ferrari', 'Affiliation': 'Department of Geriatrics, University Hospital Zurich, Rämistrasse 100, 8091 Zürich, Switzerland.'}]",Pilot and feasibility studies,['10.1186/s40814-020-00645-7'] 2334,32695434,"Feasibility of a cluster randomized controlled trial on the effectiveness of peer-led health education interventions to increase uptake of retinal examination for diabetic retinopathy in Kirinyaga, Kenya: a pilot trial.","Background People living with diabetes can reduce their risk of vision loss from diabetic retinopathy by attending screening, which enables early detection and timely treatment. The aim of this pilot trial was to assess the feasibility of a full-scale cluster randomized controlled trial of an intervention to increase uptake of retinal examination in this population, as delivered within existing community-based diabetes support groups (DSGs). Methods All 16 DSGs in Kirinyaga county were invited to participate in the study. The first two groups recruited took part in the pilot trial. DSG members who met the eligibility criteria were recruited before the groups that were randomized to the two arms. In the intervention group, two peer educators were trained to deliver monthly DSG-based eye health education and individual telephone reminders to attend screening. The control group continued with usual DSG practice which is monthly meetings without eye health education. The recruitment team and outcome assessors were masked to the allocation. We documented the study processes to ascertain the feasibility, acceptability, and potential effectiveness of the intervention. Feasibility was assessed in terms of clarity of study procedures, recruitment and retention rates, level of acceptability, and rates of uptake of eye examination. We set the target feasibility criteria for continuation to the main study to be recruitment of 50 participants in the trial, 80% monthly follow-up rates for individuals, and no attrition of clusters. Results Of the 122 DSG members who were assessed for eligibility, 104 were recruited and followed up: 51 (intervention) and 53 (control) arm. The study procedures were well understood and easy to apply. We learnt the DSG meeting days were the best opportunities for recruitment. The study had a high acceptance rate (100% for clusters, 95% for participants) and high follow-up and retention rate (100% of those recruited). All clusters and participants were analysed. We observed that the rate of incidence of eye exam was about 6 times higher in the intervention arm as compared to the control arm. No adverse unexpected events were reported in either arm. Conclusions The study is feasible and acceptable in the study population. The results support the development of a full-scale cluster RCT, as the success criteria for the pilot were met. Trial registration Pan African Clinical Trials Registry PACTR201707002430195 Registered on 25 July 2017.",2020,"No adverse unexpected events were reported in either arm. ","['Methods\n\n\nAll 16 DSGs in Kirinyaga county were invited to participate in the study', '122 DSG members who were assessed for eligibility, 104 were recruited and followed up: 51 (intervention) and 53 (control) arm', 'diabetic retinopathy in Kirinyaga, Kenya', 'DSG members who met the eligibility criteria', '50 participants in the trial, 80% monthly follow-up rates for individuals, and no attrition of clusters']","['peer-led health education interventions', 'usual DSG practice which is monthly meetings without eye health education', 'peer educators were trained to deliver monthly DSG-based eye health education and individual telephone reminders to attend screening']","['acceptance rate', 'clarity of study procedures, recruitment and retention rates, level of acceptability, and rates of uptake of eye examination', 'rate of incidence of eye exam', 'retention rate']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0036606', 'cui_str': 'Support Groups'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0284559', 'cui_str': 'gusperimus'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0011884', 'cui_str': 'Retinopathy due to diabetes mellitus'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}]","[{'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0284559', 'cui_str': 'gusperimus'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0486588', 'cui_str': 'Clarity (property)'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0200149', 'cui_str': 'Ophthalmic examination and evaluation'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",104.0,0.124047,"No adverse unexpected events were reported in either arm. ","[{'ForeName': 'Nyawira', 'Initials': 'N', 'LastName': 'Mwangi', 'Affiliation': 'Kenya Medical Training College, Nairobi, Kenya.'}, {'ForeName': 'Covadonga', 'Initials': 'C', 'LastName': 'Bascaran', 'Affiliation': 'London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': ""Ng'ang'a"", 'Affiliation': 'Kerugoya County Referral Hospital, Kerugoya, Kenya.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Ramke', 'Affiliation': 'London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Mathew', 'Initials': 'M', 'LastName': 'Kipturgo', 'Affiliation': 'Kenya Medical Training College, Nairobi, Kenya.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Gichuhi', 'Affiliation': 'University of Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Kim', 'Affiliation': 'London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Macleod', 'Affiliation': 'London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Consuela', 'Initials': 'C', 'LastName': 'Moorman', 'Affiliation': 'Oxford Universities NHS Trust, Oxford, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Muraguri', 'Affiliation': 'Kerugoya County Referral Hospital, Kerugoya, Kenya.'}, {'ForeName': 'Esbon', 'Initials': 'E', 'LastName': 'Gakuo', 'Affiliation': 'Kerugoya County Referral Hospital, Kerugoya, Kenya.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Muthami', 'Affiliation': 'Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Allen', 'Initials': 'A', 'LastName': 'Foster', 'Affiliation': 'London School of Hygiene and Tropical Medicine, London, UK.'}]",Pilot and feasibility studies,['10.1186/s40814-020-00644-8'] 2335,32695692,"A Randomized Study to Evaluate the Efficacy Fractional CO 2 Laser, Microneedling and Platelet Rich Plasma in Post-Acne Scarring.","Background Acne scarring commonly seen in young adults causes marked psychological distress. Commonly used procedural treatments for post-acne scarring have limited efficacy. This prospective, randomized study was undertaken to evaluate the efficacy and adverse effects offractional CO2 laser, microneedling, and platelet-rich plasma (PRP) in post-acne scarring. Materials and Methods Sixty clinically diagnosed cases of post-acne scarring of both sexes were enrolled and divided into three groups of 20 patients each. The severity of scarring was graded as per the qualitative and quantitative grading system proposed by Goodman and Baron. Group A, B, and C patients were treated with fractional CO2 laser, microneedling, and PRP,respectively, at monthly intervals for foursessions. Improve men tin quantitative and qualitative grades of scars and adverse effects were noted at each session and 1 month after the final sitting. Statistical analysis was done using Student 't' test for quantitative values and Chi square test for qualitative values. Results At the end of foursessions, based on mean percentage of improvement in quantitative grade, the efficacy of fractional CO2 laser is significantly greater than that of PRP ( P = 0.00), while CO2 laser and microneedling did not show significant difference ( P = 0.106). Based on qualitative scores, fractional CO2 laser group showed statistically higher therapeutic efficacy compared to microneedling and PRP ( P = 0.00).No significant adverse effects were encountered in any groups. Conclusion Fractional CO 2 laser resurfacing is more efficacious than microneedling and PRP. Unsatisfactory results were obtained with PRP as monotherapy in post-acne scarring.",2020,"Based on qualitative scores, fractional CO2 laser group showed statistically higher therapeutic efficacy compared to microneedling and PRP ( P = 0.00).No significant adverse effects were encountered in any groups. ","['post-acne scarring', 'Post-Acne Scarring', 'Sixty clinically diagnosed cases of post-acne scarring of both sexes were enrolled and divided into three groups of 20 patients each', 'young adults']","['PRP', 'fractional CO2 laser, microneedling, and PRP']","['efficacy of fractional CO2 laser', 'severity of scarring', 'efficacy and adverse effects offractional CO2 laser, microneedling, and platelet-rich plasma (PRP', 'men tin quantitative and qualitative grades of scars and adverse effects', 'therapeutic efficacy', 'psychological distress']","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0392251', 'cui_str': 'Carbon dioxide laser device'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0392251', 'cui_str': 'Carbon dioxide laser device'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0040238', 'cui_str': 'Tin'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0205556', 'cui_str': 'Qualitative'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}]",60.0,0.0237435,"Based on qualitative scores, fractional CO2 laser group showed statistically higher therapeutic efficacy compared to microneedling and PRP ( P = 0.00).No significant adverse effects were encountered in any groups. ","[{'ForeName': 'T', 'Initials': 'T', 'LastName': 'Pooja', 'Affiliation': ""Department of Dermatology, Maharajah's Institute of Medical Sciences, Nellimarla, Vizianagaram, Andhra Pradesh, India.""}, {'ForeName': 'K V T', 'Initials': 'KVT', 'LastName': 'Gopal', 'Affiliation': ""Department of Dermatology, Maharajah's Institute of Medical Sciences, Nellimarla, Vizianagaram, Andhra Pradesh, India.""}, {'ForeName': 'T Narayana', 'Initials': 'TN', 'LastName': 'Rao', 'Affiliation': ""Department of Dermatology, Maharajah's Institute of Medical Sciences, Nellimarla, Vizianagaram, Andhra Pradesh, India.""}, {'ForeName': 'B Gayatri', 'Initials': 'BG', 'LastName': 'Devi', 'Affiliation': ""Department of Dermatology, Maharajah's Institute of Medical Sciences, Nellimarla, Vizianagaram, Andhra Pradesh, India.""}, {'ForeName': 'S Ashwin', 'Initials': 'SA', 'LastName': 'Kumar', 'Affiliation': ""Department of Dermatology, Maharajah's Institute of Medical Sciences, Nellimarla, Vizianagaram, Andhra Pradesh, India.""}]",Indian dermatology online journal,['10.4103/idoj.IDOJ_370_19'] 2336,32695728,"Investigation of Efficacy of Short-Acting Methylphenidate (Ritalin) and Long-Acting (Matoride) on Symptoms of Attention Deficit Hyperactivity Disorder in Children Aged 6-18 Years: A Single-Blind, Randomized Clinical Trial.","Background This study aimed to evaluate the efficacy and safety of long-acting versus short-acting methylphenidate on the symptoms of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6-18 years. Materials and Methods This single-blind, randomized clinical trial was conducted on 150 children and adolescents aged 6-18 years with ADHD based on the Diagnostic and Statistical Manual of Mental Disorder-5 criteria. The patients were randomly assigned to two groups (Matoride or Ritalin). In the first group, Ritalin was prescribed 2/3 times a day, and in the second group, Matoride was prescribed once a day for 3 weeks. The Conner's questionnaire was completed by the parents of the participants for evaluation of the performance and symptoms of ADHD in both groups at the beginning and 3 weeks after treatment. In addition, the incidence of any drug complications at the end of 3-week treatment period was evaluated. Results There were no statistically significant differences between the two groups before the intervention ( P > 0.05) in the dimensions of attention deficit, emotional reaction, behavioral disorder, learning disorder, and impulsivity. At the postinterventional periods, behavioral disorder of the Ritalin group was statistically significantly lower than that of the Matoride group ( P = 0.001). This treatment did not have a statistically significant effect on the total score of Conners ( P = 0.255). Complications were seen in 58 cases (77.3%) of Matoride group and 49 ones (67.1%) of the Ritalin group. Weight loss in the Ritalin group was higher than that of the Matoride group ( P = 0.019). Compared to the Ritalin group, anxiety was higher in the Matoride group ( P = 0.022). Conclusion Given the similar effect of Matoride and Ritalin and no significant difference in drug complications, it seems that Matoride (slow release) can be used as an alternative to Ritalin (short acting).",2020,"Compared to the Ritalin group, anxiety was higher in the Matoride group ( P = 0.022). ","['Aged 6-18 Years', 'Children', 'children and adolescents aged 6-18 years', '150 children and adolescents aged 6-18 years with ADHD based on the Diagnostic and Statistical Manual of Mental Disorder-5 criteria']","['Short-Acting Methylphenidate (Ritalin) and Long-Acting (Matoride', 'long-acting versus short-acting methylphenidate']","['Weight loss', 'anxiety', 'drug complications', 'behavioral disorder', 'efficacy and safety', 'Complications', 'total score of Conners', 'incidence of any drug complications', 'dimensions of attention deficit, emotional reaction, behavioral disorder, learning disorder, and impulsivity']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1136324', 'cui_str': 'Diagnostic and Statistical Manual of Mental Disorders'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0025810', 'cui_str': 'Methylphenidate'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0004930', 'cui_str': 'Behaviour disorder'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0041671', 'cui_str': 'Attention Deficit Disorder'}, {'cui': 'C0221736', 'cui_str': 'Reaction emotional'}, {'cui': 'C0023186', 'cui_str': 'Learning disorder'}, {'cui': 'C0021125', 'cui_str': 'Impulsive behaviour'}]",150.0,0.066061,"Compared to the Ritalin group, anxiety was higher in the Matoride group ( P = 0.022). ","[{'ForeName': 'Mojgan', 'Initials': 'M', 'LastName': 'Karahmadi', 'Affiliation': 'Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Sahar', 'Initials': 'S', 'LastName': 'Saadatmand', 'Affiliation': 'Department of Psychiatry, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Mohammad Javad', 'Initials': 'MJ', 'LastName': 'Tarahi', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Health, Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",Advanced biomedical research,['10.4103/abr.abr_9_20'] 2337,32695815,Effectiveness of Gelatin-Thrombin Matrix Sealants (Floseal®) on Postoperative Spinal Epidural Hematoma during Single-Level Lumbar Decompression Using Biportal Endoscopic Spine Surgery: Clinical and Magnetic Resonance Image Study.,"Background Symptomatic postoperative spinal epidural hematoma (PSEH) is a devastating complication that could develop after lumbar decompression surgery. PSEH can also develop after biportal endoscopic spine surgery (BESS), one of the recently introduced minimally invasive spine surgery techniques. Gelatin-thrombin matrix sealant (GTMS) is commonly used to prevent PSEH. This study aimed at analyzing the clinical and radiological effects of GTMS use during BESS. Methods A total of 206 patients with spinal stenosis who underwent decompression by BESS through a posterior interlaminar approach from October 2015 to September 2018 were enrolled in this study. Postoperative magnetic resonance imaging (MRI) was performed in all patients for evaluation of PSEH. Patients in whom GTMS was not used during surgery were assigned to Group A, and those in whom GTMS was used were classified as Group B. In the clinical evaluation, the visual analog scale (VAS) of the leg and back, Oswestry Disability Index (ODI), and modified MacNab criteria were used. The incidence rate and degree of dural compression of PSEH on postoperative MRI were measured. Results The average age of the patients was 68.1 ± 11.2 (42-89) years. The overall incidence rate of PSEH was 20.9% (43/206). The incidence rates in Groups A and B were 26.4% and 13.6%, respectively, showing a significant difference ( p = 0.023). The VAS-leg and ODI improvement was significantly different depending on the intraoperative use of GTMS. However, there was no statistically significant difference between the two groups in terms of the VAS-back improvement. Groups A and B showed ""good"" and ""excellent"" rates according to the modified MacNab criteria in 79.4% and 87.6% of patients, respectively, showing statistically significant difference ( p = 0.049). In Group A, two patients underwent revision surgery due to PSEH, while none in Group B had such event. Conclusion Intraoperative use of GTMS during BESS may be related to reduction in the occurrence rate of PSEH. Specifically, patients with GTMS appliance showed marked decrease in the occurrence of PSEH and had better clinical outcomes.",2020,"Groups A and B showed ""good"" and ""excellent"" rates according to the modified MacNab criteria in 79.4% and 87.6% of patients, respectively, showing statistically significant difference ( p = 0.049).","['Postoperative Spinal Epidural Hematoma during Single-Level Lumbar Decompression Using Biportal Endoscopic Spine Surgery', '206 patients with spinal stenosis who underwent decompression by BESS through a posterior interlaminar approach from October 2015 to September 2018 were enrolled in this study', 'The average age of the patients was 68.1 ± 11.2 (42-89) years']","['GTMS', 'Gelatin-thrombin matrix sealant (GTMS', 'PSEH', '\n\n\nSymptomatic postoperative spinal epidural hematoma (PSEH', 'Gelatin-Thrombin Matrix Sealants (Floseal®', 'Postoperative magnetic resonance imaging (MRI']","['VAS-back improvement', 'incidence rates', 'visual analog scale (VAS) of the leg and back, Oswestry Disability Index (ODI), and modified MacNab criteria', 'incidence rate and degree of dural compression of PSEH on postoperative MRI', 'overall incidence rate of PSEH', 'VAS-leg and ODI improvement', 'occurrence of PSEH', 'good"" and ""excellent"" rates']","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0877172', 'cui_str': 'Spinal epidural hematoma'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0011117', 'cui_str': 'Decompression'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0920347', 'cui_str': 'Procedure on spinal cord'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037944', 'cui_str': 'Spinal stenosis'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517531', 'cui_str': '11.2'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0017237', 'cui_str': 'Gelatin'}, {'cui': 'C0040018', 'cui_str': 'Thrombin'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0729415', 'cui_str': 'Sealant'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0877172', 'cui_str': 'Spinal epidural hematoma'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0877172', 'cui_str': 'Spinal epidural hematoma'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1961136', 'cui_str': 'Excellent'}]",206.0,0.0317699,"Groups A and B showed ""good"" and ""excellent"" rates according to the modified MacNab criteria in 79.4% and 87.6% of patients, respectively, showing statistically significant difference ( p = 0.049).","[{'ForeName': 'Ju-Eun', 'Initials': 'JE', 'LastName': 'Kim', 'Affiliation': 'Department of Orthopedic Surgery, Himnaera Hospital, Busan, Republic of Korea.'}, {'ForeName': 'Hyun-Seung', 'Initials': 'HS', 'LastName': 'Yoo', 'Affiliation': 'Department of Orthopedic Surgery, Daegu Fatima Hospital, Daegu, Republic of Korea.'}, {'ForeName': 'Dae-Jung', 'Initials': 'DJ', 'LastName': 'Choi', 'Affiliation': 'Department of Orthopedic Surgery, Himnaera Hospital, Busan, Republic of Korea.'}, {'ForeName': 'Eugene J', 'Initials': 'EJ', 'LastName': 'Park', 'Affiliation': 'Department of Orthopedic Surgery, Kyungpook National University hospital, Daegu, Republic of Korea.'}, {'ForeName': 'Jin-Ho', 'Initials': 'JH', 'LastName': 'Hwang', 'Affiliation': 'Department of Orthopedic Surgery, Himnaera Hospital, Busan, Republic of Korea.'}, {'ForeName': 'Jeong-Duk', 'Initials': 'JD', 'LastName': 'Suh', 'Affiliation': 'Department of Orthopedic Surgery, Daegu Fatima Hospital, Daegu, Republic of Korea.'}, {'ForeName': 'Jun-Hyug', 'Initials': 'JH', 'LastName': 'Yoo', 'Affiliation': 'Department of Orthopedic Surgery, Daegu Fatima Hospital, Daegu, Republic of Korea.'}]",BioMed research international,['10.1155/2020/4801641'] 2338,32695905,The effects of sunlight exposure therapy on the improvement of depression and quality of life in post-stroke patients: A RCT study.,"Previous studies have suggested that nearly 30% of the stroke victims present with signs of depression within the first 5 years of illness. Since post-stroke depression significantly affects the patient both physically and psychologically, the emotional disturbances impede the progress and effectiveness of rehabilitation. To utilize sunlight therapy in post-stroke patients in order to improve the depression and daily activity function. This study was a single-blind design randomized controlled intervention with sunlight exposure design. The population were stroke patients with tendency to depression. Exposed to sunlight for at least 30 min per day, at least 14 days of exposure duration of 4 weeks. A total of 46 patients were 23 patients in the experimental group and the control group. The research tools include: depression status (Taiwanese depression scale, TDS), physical activity function (Barthel Index), and cognitive status (MMSE). The CONSORT guideline was used in this study. After the data was analyzed with the generalized estimating equation (GEE), significant improvement was noted among the experimental ground in 2 nd post-test depression score, daily function in the first and second post-test Barthel Index score. There was no significant improvement in cognitive function. This study confirms that sunlight therapy improves the mental health of post-stroke patients with depressed mood. It also enhances daily activity and facilitates the recovery to a health state.",2020,There was no significant improvement in cognitive function.,"['stroke patients with tendency to depression', '46 patients were 23 patients in the experimental group and the control group', 'post-stroke patients', 'post-stroke patients with depressed mood']","['sunlight exposure therapy', 'sunlight therapy']","['cognitive function', 'mental health', 'depression and daily activity function', 'depression status (Taiwanese depression scale, TDS), physical activity function (Barthel Index), and cognitive status (MMSE', 'depression and quality of life']","[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0618884', 'cui_str': 'IS 23'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0344315', 'cui_str': 'Depressed mood'}]","[{'cui': 'C0497062', 'cui_str': '[X]Exposure to sunlight'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0038817', 'cui_str': 'Sunlight'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C1556096', 'cui_str': 'Taiwanese'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0172161', 'cui_str': 'tyramine-deoxysorbitol'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",46.0,0.0331667,There was no significant improvement in cognitive function.,"[{'ForeName': 'Su-Jen', 'Initials': 'SJ', 'LastName': 'Wang', 'Affiliation': 'School of Nursing, National Taipei University of Nursing and Health Sciences, Department of Nursing, Taipei Veterans General Hospital, 7F., No. 70, Ln. 88, Zhongpu 1st St., Taoyuan Dist., Taoyuan City 33055, Taiwan, ROC.'}, {'ForeName': 'Miao-Yen', 'Initials': 'MY', 'LastName': 'Chen', 'Affiliation': 'School of Nursing, National Taipei University of Nursing and Health Sciences, No. 365, Ming-te Road, Peitou District, Taipei, Taiwan, ROC.'}]",Heliyon,['10.1016/j.heliyon.2020.e04379'] 2339,32694366,"Effect of Functional Impact Training on Body Composition, Bone Mineral Density, and Strength in Breast Cancer Survivors.","PURPOSE The purpose of this study was to examine the effects of 24 weeks of functional impact training (FIT) that consisted of resistance and high impact exercises in comparison to yin yoga on body composition, bone mineral density (BMD), blood biomarkers for bone metabolism, and strength in breast cancer survivors (BCS). METHODS Forty-four BCS (60.3±8.3 years) were randomly assigned to the FIT or yin yoga group. Body composition and BMD were measured via dual energy X-ray absorptiometry. Blood biomarkers for bone metabolism were analyzed via enzyme-linked immunosorbent assays. Upper and lower body strength were assessed using a one-repetition maximum chest press and isokinetic knee extension/flexion using the Biodex System 3, respectively. Participants completed 45-minute FIT or yin yoga sessions twice weekly for 24 weeks. Changes in dependent variables over time were analyzed using repeated measures analysis of variance. Significance was accepted at p≤0.05. RESULTS There were no group by time effects for body composition, BMD or blood biomarkers. Main effects were observed for left femoral neck (0.883±0.138 g/cm to 0.870±0.131 g/cm) and left forearm (0.465±0.078 g/cm to 0.457±0.069 g/cm) BMD. The FIT group improved upper body strength (73.2±18.1 kg to 83.2±22.3 kg) while the yin yoga group did not (59.8±14.8 kg to 59.3±15.6 kg). Main time effects were observed for peak isokinetic knee extension and flexion at all speeds with an average improvement of 13.2% and 16.2%, respectively. CONCLUSION Both FIT and yin yoga may be beneficial exercise modes for improving lower body strength, although only FIT improved upper body strength. Additional research is needed to examine the effectiveness of FIT programs of longer duration and/or higher intensity on body composition and BMD in BCS.",2020,"Main time effects were observed for peak isokinetic knee extension and flexion at all speeds with an average improvement of 13.2% and 16.2%, respectively. ","['Breast Cancer Survivors', 'breast cancer survivors (BCS', 'Forty-four BCS (60.3±8.3 years']","['FIT and yin yoga', 'yin yoga', 'Functional Impact Training', 'FIT or yin yoga sessions', 'FIT or yin yoga group', 'functional impact training (FIT']","['body composition, bone mineral density (BMD), blood biomarkers for bone metabolism, and strength', 'Body Composition, Bone Mineral Density, and Strength', 'peak isokinetic knee extension and flexion', 'left femoral neck', 'left forearm', 'upper body strength', 'Blood biomarkers for bone metabolism', 'Body composition and BMD', 'body composition, BMD or blood biomarkers', 'Upper and lower body strength']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0015815', 'cui_str': 'Structure of neck of femur'}, {'cui': 'C0016536', 'cui_str': 'Forearm structure'}, {'cui': 'C1268087', 'cui_str': 'Upper body structure'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C1268088', 'cui_str': 'Lower body structure'}]",44.0,0.0418724,"Main time effects were observed for peak isokinetic knee extension and flexion at all speeds with an average improvement of 13.2% and 16.2%, respectively. ","[{'ForeName': 'Ashley L', 'Initials': 'AL', 'LastName': 'Artese', 'Affiliation': 'Department of Health and Human Performance, Roanoke College, Salem, VA.'}, {'ForeName': 'Rachael L', 'Initials': 'RL', 'LastName': 'Hunt', 'Affiliation': 'Department of Nutrition, Food and Exercise Sciences, College of Human Sciences, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Ormsbee', 'Affiliation': 'Department of Nutrition, Food and Exercise Sciences, College of Human Sciences, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Jeong-Su', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': 'Department of Nutrition, Food and Exercise Sciences, College of Human Sciences, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Bahram H', 'Initials': 'BH', 'LastName': 'Arjmandi', 'Affiliation': 'Department of Nutrition, Food and Exercise Sciences, College of Human Sciences, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Lynn B', 'Initials': 'LB', 'LastName': 'Panton', 'Affiliation': 'Department of Nutrition, Food and Exercise Sciences, College of Human Sciences, Florida State University, Tallahassee, FL.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002438'] 2340,32697018,Food supplements and diet as treatment options in irritable bowel syndrome.,"Irritable bowel syndrome (IBS) is a chronic functional bowel disorder affecting 5.7% of the general population. Most patients relate their symptoms of IBS to foods they consume with diet being the most frequently reported factor impacting their life. However, although some foods may trigger symptoms, others may provide symptom relief. Indeed, several foods and diets have been investigated for their effectiveness in relieving IBS symptoms. In this issue of Neurogastroenterology and Motility, a double-blind randomized placebo-controlled trial in 160 patients with IBS demonstrated Aloe vera not to be effective in improving IBS symptoms. The aim of this review is to discuss the evidence on the effect of food supplements and diets in the management of IBS. Specifically, this review examines the evidence for aloe vera, peppermint oil, probiotics, fiber and prebiotics, healthy eating, the low FODMAP diet, and the gluten-free diet.",2020,Most patients relate their symptoms of IBS to foods they consume with diet being the most frequently reported factor impacting their life.,"['irritable bowel syndrome', '160 patients with IBS demonstrated Aloe vera not to be effective in improving IBS symptoms']","['food supplements and diets', 'Food supplements and diet', 'placebo']",['Irritable bowel syndrome (IBS'],"[{'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0718405', 'cui_str': 'Aloe vera'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}]",160.0,0.0704266,Most patients relate their symptoms of IBS to foods they consume with diet being the most frequently reported factor impacting their life.,"[{'ForeName': 'Eirini', 'Initials': 'E', 'LastName': 'Dimidi', 'Affiliation': ""Department of Nutritional Sciences, King's College London, London, UK.""}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Whelan', 'Affiliation': ""Department of Nutritional Sciences, King's College London, London, UK.""}]",Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,['10.1111/nmo.13951'] 2341,32697031,Outcomes of brief and enhanced cognitive-behavioural therapy for adults with non-underweight eating disorders: A non-randomized comparison.,"OBJECTIVE Cognitive-behavioural therapy (CBT) is an efficacious and effective treatment for eating disorders, and is particularly valuable in the treatment of non-underweight cases (e.g., bulimia nervosa; binge eating-disorders). However, its recommended length for such cases (up to 20 sessions) makes it a relatively costly therapy. It has been suggested that a 10-session version (CBT-T) can also be effective, but there has been no direct comparison between the two forms (10 vs. 20 sessions). METHOD This study reports the outcomes of brief and standard-length CBT for non-underweight eating disorders, comparing two cohorts of patients from the same clinic (N = 55 and 138, respectively). RESULTS The two therapies had very similar results in terms of eating pathology, remission rate, and improved quality of life. Each showed substantial change by the mid-point of therapy and up to 6-month follow-up. CONCLUSION It appears that brief CBT (CBT-T) is as effective as existing 20-session CBT, and is less demanding of time and resource. The findings need to be replicated in a randomized control trial before this conclusion can be made definitive.",2020,"The two therapies had very similar results in terms of eating pathology, remission rate, and improved quality of life.","['non-underweight eating disorders, comparing two cohorts of patients from the same clinic (N =\u200955 and 138, respectively', 'adults with non-underweight eating disorders']","['brief and enhanced cognitive-behavioural therapy', 'CBT (CBT-T', 'standard-length CBT', 'Cognitive-behavioural therapy (CBT']","['eating pathology, remission rate, and improved quality of life']","[{'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1444754', 'cui_str': 'Length'}]","[{'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.0213776,"The two therapies had very similar results in terms of eating pathology, remission rate, and improved quality of life.","[{'ForeName': 'Madeleine', 'Initials': 'M', 'LastName': 'Tatham', 'Affiliation': 'Norfolk Community Eating Disorders Service, Norwich, UK.'}, {'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Hewitt', 'Affiliation': 'Norfolk Community Eating Disorders Service, Norwich, UK.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Waller', 'Affiliation': 'Department of Psychology, University of Sheffield, Sheffield, UK.'}]",European eating disorders review : the journal of the Eating Disorders Association,['10.1002/erv.2765'] 2342,32693116,Topical therapy with rhubarb navel plasters in patients with chronic constipation: Results from a prospective randomized multicenter study.,"ETHNOPHARMACOLOGICAL RELEVANCE Constipation is a functional gastrointestinal disorder and one of the most prevalent conditions encountered in primary care settings. Rhubarb navel dressings have been used for more than 2,000 years in Chinese medicine to treat constipation. However, the effect of topical rhubarb administration has still not been well recognized and this strategy is not yet established as an evidence-based approach. AIM OF THE STUDY In this study, we performed a prospective multicentric randomized controlled trial to evaluate the efficacy and safety of rhubarb navel plasters for patients with chronic constipation. MATERIALS AND METHODS A total of 374 patients from six teaching hospitals were prospectively included between 09/2016 and 10/2017 in the study based on Rome III criteria. All participants were randomly assigned (1:1) into verum/placebo group and given either Rheum officinale rhubarb powder or a placebo flour stick on the navel for 6 h/day/8 days. Primary outcome measures were the Cleveland Constipation Score (CCS) for the feces condition and Bristol Stool Scale (BSS) for stool consistency and 24 h defecation frequency. RESULTS The groups demonstrated no statistical differences in demographic data, clinical diagnoses and concomitant medication at baseline. In patients treated with the verum CCS was 5.61 (day 8, 95% CI 5.15-6.07) compared to 8.62 (95% CI 8.07-9.18) in placebo-treated controls (P < 0.001). The mean change of CCS at the end of treatment (day 8 versus [vs] day 0) was 6.04 in verum-treated vs 2.73 in placebo-treated controls (P < 0.001). Also 24 h defecation frequency (BSS) showed superior results (day 5: 0.84 vs 0.62, 95% CI 0.67-0.80, P < 0.001; day 6: 0.82 vs 0.60, 95% CI 0.64-0.78, P < 0.01 and day 8: 0.82 vs 0.60, 95% CI 0.64-0.78, P < 0.01) and better BSS type classification during treatment than controls (P < 0.05). No significant differences in adverse events between both groups became obvious. CONCLUSION Rhubarb navel plaster administration over an 8-day-treatment period resulted in significantly improved bowel function as demonstrated by the CCS, 24 h defecating frequency and BSS. Our results suggest that rhubarb navel plasters represent a feasible, safe and efficient application route for the treatment of patients suffering from chronic constipation.",2020,"Also 24 h defecation frequency (BSS) showed superior results (day 5: 0.84 vs 0.62, 95% CI 0.67-0.80, P < 0.001; day 6: 0.82 vs 0.60, 95% CI 0.64-0.78, P < 0.01 and day 8: 0.82 vs 0.60, 95% CI 0.64-0.78, P < 0.01) and better BSS type classification during treatment than controls (P < 0.05).","['patients with chronic constipation', 'patients suffering from chronic constipation', '374 patients from six teaching hospitals were prospectively included between 09/2016 and 10/2017 in the study based on Rome III criteria']","['verum/placebo group and given either Rheum officinale rhubarb powder or a placebo flour stick', 'Rhubarb navel dressings', 'Topical therapy', 'rhubarb navel plasters', 'verum CCS']","['demographic data, clinical diagnoses and concomitant medication', 'bowel function', 'BSS type classification', 'efficacy and safety', 'adverse events', 'defecation frequency (BSS', 'Cleveland Constipation Score (CCS) for the feces condition and Bristol Stool Scale (BSS) for stool consistency and 24\u202fh defecation frequency', 'mean change of CCS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0401149', 'cui_str': 'Chronic constipation'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0035831', 'cui_str': 'Rome'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0035509', 'cui_str': 'Rhubarb'}, {'cui': 'C1815861', 'cui_str': 'Rhubarb powder'}, {'cui': 'C0016260', 'cui_str': 'Flour'}, {'cui': 'C1706582', 'cui_str': 'Stick'}, {'cui': 'C0041638', 'cui_str': 'Umbilical structure'}, {'cui': 'C0013119', 'cui_str': 'Medical dressing'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0460977', 'cui_str': 'Plasters'}, {'cui': 'C0454845', 'cui_str': 'Cleveland'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0457570', 'cui_str': 'Scale type'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0454845', 'cui_str': 'Cleveland'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0426740', 'cui_str': 'Consistency of stool'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",374.0,0.207116,"Also 24 h defecation frequency (BSS) showed superior results (day 5: 0.84 vs 0.62, 95% CI 0.67-0.80, P < 0.001; day 6: 0.82 vs 0.60, 95% CI 0.64-0.78, P < 0.01 and day 8: 0.82 vs 0.60, 95% CI 0.64-0.78, P < 0.01) and better BSS type classification during treatment than controls (P < 0.05).","[{'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Wei', 'Affiliation': 'The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address: weilin22@126.com.'}, {'ForeName': 'Yueming', 'Initials': 'Y', 'LastName': 'Luo', 'Affiliation': 'The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address: 314851488@qq.com.'}, {'ForeName': 'Xiaopei', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address: xingyunxing021@163.com.'}, {'ForeName': 'Yangchen', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address: morning924@126.com.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Gasser', 'Affiliation': 'University of Wuerzburg, Wuerzburg, Germany. Electronic address: gasser_m@t-online.de.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Tang', 'Affiliation': 'The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address: tangtang56love@126.com.'}, {'ForeName': 'Wen-Wei', 'Initials': 'WW', 'LastName': 'Ouyang', 'Affiliation': 'The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address: yudexin1984@163.com.'}, {'ForeName': 'Hengqiu', 'Initials': 'H', 'LastName': 'Wei', 'Affiliation': 'The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address: 1131968978@qq.com.'}, {'ForeName': 'Shengzhen', 'Initials': 'S', 'LastName': 'Lu', 'Affiliation': 'Jiangxi Integrated Traditional Chinese and Western Medicine Hospital, Nanchang, China. Electronic address: 982121880@qq.com.'}, {'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Yang', 'Affiliation': 'The First Affiliated Hospital of Nanchang University, Nanchang, China. Electronic address: 64243156@qq.com.'}, {'ForeName': 'Ana Maria', 'Initials': 'AM', 'LastName': 'Waaga-Gasser', 'Affiliation': ""Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: awaaga@bwh.harvard.edu.""}, {'ForeName': 'Chong', 'Initials': 'C', 'LastName': 'Deng', 'Affiliation': 'Guangzhou University of Traditional Chinese Medicine, Guangzhou, China. Electronic address: gzdtcm@163.com.'}, {'ForeName': 'Meizhen', 'Initials': 'M', 'LastName': 'Lin', 'Affiliation': 'The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address: lmzmay@163.com.'}]",Journal of ethnopharmacology,['10.1016/j.jep.2020.113096'] 2343,32693177,Enhancing employer coverage of smoking cessation treatment: A randomized trial of the partners in helping you quit program.,"The workplace is a key channel for delivering tobacco cessation treatment to a population. Employers can provide workplace-based programs and/or financial incentives such as health insurance benefits that cover the cost of treatment accessed outside the workplace. Little is known about the effect of combining these strategies. We tested the benefit of adding a workplace cessation program, Partners in Helping You Quit (PiHQ), to comprehensive health insurance coverage of smoking cessation medications by Partners HealthCare, a large Boston-based healthcare delivery system. PiHQ offers biweekly telephone-based behavioral support, additional automated calls, and medication care coordination for 3 months then monthly telephone monitoring for 9 months. In a pragmatic randomized trial, employees who smoked were informed about the insurance benefit, then randomly assigned (2:1) to PiHQ or to active referral to a free 3-month phone-based community program, Massachusetts Quitline (QL). Outcomes were assessed at 3, 6, and 12 months. During 2015-2018, 106 smokers (n = 73 PiHQ, n = 33 QL) enrolled (64% female; 75% white, 21% black; mean age 46 years, mean cigarettes/day = 13). More PiHQ than QL participants made a quit attempt by 3 months (82 vs. 61%, p < .02) and achieved the primary outcome, verified past 7-day cigarette abstinence at 6 months (31 vs. 12%, odds ratio 3.34, 95%CI, 1.05-10.60). Among participants using behavioral support, PiHQ participants completed more scheduled calls and rated counseling helpfulness higher than did QL participants. These results suggest that employers can enhance the impact of providing comprehensive health insurance coverage of smoking cessation medication by adding a phone-based worksite cessation program.",2020,"More PiHQ than QL participants made a quit attempt by 3 months (82 vs. 61%, p < .02) and achieved the primary outcome, verified past 7-day cigarette abstinence at 6 months (31 vs. 12%, odds ratio 3.34, 95%CI, 1.05-10.60).","['During 2015-2018, 106 smokers (n\u202f=\u202f73 PiHQ, n\u202f=\u202f33 QL) enrolled (64% female; 75% white, 21% black; mean age 46\u202fyears, mean cigarettes/day\u202f=\u202f13']","['PiHQ or to active referral to a free 3-month phone-based community program, Massachusetts Quitline (QL', 'workplace cessation program, Partners in Helping You Quit (PiHQ']","['scheduled calls and rated counseling helpfulness', '7-day cigarette abstinence']","[{'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0024874', 'cui_str': 'Massachusetts'}, {'cui': 'C0162579', 'cui_str': 'Work environment'}]","[{'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}]",,0.052749,"More PiHQ than QL participants made a quit attempt by 3 months (82 vs. 61%, p < .02) and achieved the primary outcome, verified past 7-day cigarette abstinence at 6 months (31 vs. 12%, odds ratio 3.34, 95%CI, 1.05-10.60).","[{'ForeName': 'Nancy A', 'Initials': 'NA', 'LastName': 'Rigotti', 'Affiliation': 'Tobacco Research and Treatment Center, Division of General Internal Medicine, Mongan Institute, Massachusetts General Hospital, Boston, MA, United States of America; Department of Medicine, Harvard Medical School, Boston, MA, United States of America. Electronic address: Rigotti.Nancy@mgh.harvard.edu.'}, {'ForeName': 'Jennifer H K', 'Initials': 'JHK', 'LastName': 'Kelley', 'Affiliation': 'Tobacco Research and Treatment Center, Division of General Internal Medicine, Mongan Institute, Massachusetts General Hospital, Boston, MA, United States of America.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Regan', 'Affiliation': 'Tobacco Research and Treatment Center, Division of General Internal Medicine, Mongan Institute, Massachusetts General Hospital, Boston, MA, United States of America; Department of Medicine, Harvard Medical School, Boston, MA, United States of America.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Inman', 'Affiliation': 'Tobacco Research and Treatment Center, Division of General Internal Medicine, Mongan Institute, Massachusetts General Hospital, Boston, MA, United States of America.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Kalkhoran', 'Affiliation': 'Tobacco Research and Treatment Center, Division of General Internal Medicine, Mongan Institute, Massachusetts General Hospital, Boston, MA, United States of America; Department of Medicine, Harvard Medical School, Boston, MA, United States of America.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Flaster', 'Affiliation': ""Department of Medicine, Harvard Medical School, Boston, MA, United States of America; Population Health, Partners HealthCare System, Inc., Boston, MA, United States of America; Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, United States of America.""}, {'ForeName': 'Sreekanth K', 'Initials': 'SK', 'LastName': 'Chaguturu', 'Affiliation': 'Department of Medicine, Harvard Medical School, Boston, MA, United States of America; Population Health, Partners HealthCare System, Inc., Boston, MA, United States of America.'}]",Preventive medicine,['10.1016/j.ypmed.2020.106216'] 2344,32693185,"Efficacy and Safety of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial.","BACKGROUND & AIMS Treatments are needed for gastroparesis; antagonists of tachykinin receptor 1 (TACR1, also called NK1R) can reduce symptoms of nausea and vomiting. We investigated the safety and efficacy of tradipitant, an antagonist of NK1R, in patients with idiopathic or diabetic gastroparesis. METHODS We performed a double-blind trial of 152 adults with gastroparesis at 47 sites in the United States from November 2016 through December 2018. Participants were randomly assigned to groups given oral tradipitant (85 mg, n=77) or placebo (n=75) twice daily for 4 weeks. Symptoms were assessed by a daily symptom dairy, gastroparesis cardinal symptom index scores, and other patient-reported questionnaires. The primary outcome from the intent to treat analysis was change from baseline to week 4 in average nausea severity, measured by the gastroparesis core symptom daily diary. RESULTS Patients receiving tradipitant had a significant decrease in nausea score (reduction of 1.2) at week 4 compared with placebo (reduction of 0.7) (P=.0099), and a significant increase in of nausea-free days at week 4 (28.8% increase on tradipitant vs 15.0% on placebo; P=.0160). Patients with nausea and vomiting at baseline (n=101) had an even greater decrease in nausea in when given tradipitant (reduction of 1.4) compared with those given placebo (reduction of 0.4) (P<.0001), as well as an increase in nausea-free days at week 4 (32.3% improvement on tradipitant vs 7.6% on placebo; P=.0003). Average nausea score was 1 or less at week 4 in 32.9% of patients given tradipitant compared with 11.8% of patients given placebo (P=.0013). A greater than 1-point improvement in gastroparesis cardinal symptom index score was observed in 46.6% of patients given tradipitant compared with 23.5% of patients given placebo (P=.0053). CONCLUSIONS Tradipitant resulted in statistically and clinically meaningful improvements in nausea and reduced vomiting, compared with placebo, in patients with idiopathic or diabetic gastroparesis.",2020,"RESULTS Patients receiving tradipitant had a significant decrease in nausea score (reduction of 1.2) at week 4 compared with placebo (reduction of 0.7) (P=.0099), and a significant increase in of nausea-free days at week 4 (28.8% increase on tradipitant vs 15.0% on placebo; P=.0160).","['patients with idiopathic or diabetic gastroparesis', 'Patients with Diabetic and Idiopathic Gastroparesis', '152 adults with gastroparesis at 47 sites in the United States from November 2016 through December 2018']","['oral tradipitant', 'Tradipitant', 'Placebo', 'placebo']","['Efficacy and Safety', 'nausea-free days', 'gastroparesis cardinal symptom index score', 'daily symptom dairy, gastroparesis cardinal symptom index scores', 'Average nausea score', 'nausea and vomiting', 'nausea and reduced vomiting', 'average nausea severity, measured by the gastroparesis core symptom daily diary', 'safety and efficacy', 'nausea', 'nausea score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0267176', 'cui_str': 'Gastroparesis with diabetes mellitus'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0859972', 'cui_str': 'Idiopathic gastroparesis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0152020', 'cui_str': 'Gastroparesis syndrome'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C1301808', 'cui_str': 'State'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0152020', 'cui_str': 'Gastroparesis syndrome'}, {'cui': 'C0326926', 'cui_str': 'Cardinalis cardinalis'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}]",152.0,0.491972,"RESULTS Patients receiving tradipitant had a significant decrease in nausea score (reduction of 1.2) at week 4 compared with placebo (reduction of 0.7) (P=.0099), and a significant increase in of nausea-free days at week 4 (28.8% increase on tradipitant vs 15.0% on placebo; P=.0160).","[{'ForeName': 'Jesse L', 'Initials': 'JL', 'LastName': 'Carlin', 'Affiliation': 'Lead Clinical Scientist, Vanda Pharmaceuticals, Inc., Washington, DC. Electronic address: Jesse.Carlin@vandapharma.com.'}, {'ForeName': 'V Rose', 'Initials': 'VR', 'LastName': 'Lieberman', 'Affiliation': 'Clinical Study Member, Vanda Pharmaceuticals, Inc., Washington, DC.'}, {'ForeName': 'Arya', 'Initials': 'A', 'LastName': 'Dahal', 'Affiliation': 'Clinical Study Member, Vanda Pharmaceuticals, Inc., Washington, DC.'}, {'ForeName': 'Madison S', 'Initials': 'MS', 'LastName': 'Keefe', 'Affiliation': 'Clinical Study Member, Vanda Pharmaceuticals, Inc., Washington, DC.'}, {'ForeName': 'Changfu', 'Initials': 'C', 'LastName': 'Xiao', 'Affiliation': 'Head of Biometrics, Vanda Pharmaceuticals, Inc., Washington, DC.'}, {'ForeName': 'Gunther', 'Initials': 'G', 'LastName': 'Birznieks', 'Affiliation': 'Research and Development Committee Member, Vanda Pharmaceuticals, Inc., Washington, DC.'}, {'ForeName': 'Thomas L', 'Initials': 'TL', 'LastName': 'Abell', 'Affiliation': 'Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, University of Louisville, Louisville, KY.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Lembo', 'Affiliation': 'Division of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Parkman', 'Affiliation': 'Department of Medicine, Temple University School of Medicine, Philadelphia, PA.'}, {'ForeName': 'Mihael H', 'Initials': 'MH', 'LastName': 'Polymeropoulos', 'Affiliation': 'Research and Development Committee Member, Vanda Pharmaceuticals, Inc., Washington, DC.'}]",Gastroenterology,['10.1053/j.gastro.2020.07.029'] 2345,32693197,"Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.","Vitamin K antagonists are the only approved oral anticoagulants for long-term prophylaxis against valve thrombosis and thromboembolism in patients with a mechanical heart valve. Despite the proven efficacy and safety of anticoagulation with the oral direct factor Xa inhibitor apixaban compared with warfarin in high-risk populations including subjects with atrial fibrillation or with venous thromboembolism, it remains unknown whether patients with a mechanical heart valve can be safely managed with apixaban. The On-X Aortic Heart Valve and On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft may have lower rates of valve thrombosis and thromboembolism than conventional bileaflet and tilting disc valves due its unique pyrolytic carbon composition and flared inlet design. DESIGN: PROACT Xa is a randomized, multicenter, open-label, active-controlled trial comparing apixaban with warfarin in patients with an On-X Aortic Heart Valve or On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft. The study will randomize approximately 1,000 patients from approximately 60 sites in North America who underwent aortic valve replacement at least 3 months prior. Patients will be randomized 1:1 to receiving apixaban 5 mg twice daily or warfarin with a target international normalized ratio of 2.0-3.0. The last randomized participant will be followed for at least 2 years. The primary efficacy outcome is the composite of valve thrombosis and valve-related thromboembolism, and the primary safety outcome is major bleeding. Assuming the primary outcome occurs in warfarin-anticoagulated patients at a rate of 1.75%/patient-year, the study has more than 90% power to assess noninferiority of apixaban treatment with an absolute noninferiority margin of 1.75%/patient-year. A second co-primary analysis is to compare the hazard rate for the apixaban arm to twice the objective performance criterion for thromboembolism and valve thrombosis, that is, 3.4%/patient-year. SUMMARY: PROACT Xa will determine whether patients with an On-X Aortic Heart Valve can be anticoagulated with apixaban as an alternative to warfarin.",2020,"The primary efficacy outcome is the composite of valve thrombosis and valve-related thromboembolism, and the primary safety outcome is major bleeding.","['patients with an On-X Aortic Heart Valve or On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft', 'subjects with atrial fibrillation or with venous thromboembolism', '1,000 patients from approximately 60 sites in North America who underwent aortic valve replacement at least 3\u202fmonths prior', 'patients with a mechanical heart valve', 'patients with a mechanical On-X Aortic Heart Valve']","['PROACT Xa', 'apixaban 5\u202fmg twice daily or warfarin', 'apixaban versus warfarin', 'apixaban', 'warfarin', 'Vitamin K antagonists', 'apixaban with warfarin']","['efficacy and safety', 'composite of valve thrombosis and valve-related thromboembolism, and the primary safety outcome is major bleeding', 'hazard rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003483', 'cui_str': 'Aortic'}, {'cui': 'C0018825', 'cui_str': 'Cardiac valve prosthesis'}, {'cui': 'C0205385', 'cui_str': 'Ascending'}, {'cui': 'C0175649', 'cui_str': 'Prosthesis'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0018829', 'cui_str': 'Prosthetic heart'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}]","[{'cui': 'C3530472', 'cui_str': 'apixaban 5 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C1096489', 'cui_str': 'Vitamin K antagonist'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",,0.0697264,"The primary efficacy outcome is the composite of valve thrombosis and valve-related thromboembolism, and the primary safety outcome is major bleeding.","[{'ForeName': 'Oliver K', 'Initials': 'OK', 'LastName': 'Jawitz', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC; Department of Surgery, Duke University Medical Center, Durham, NC. Electronic address: oliver.jawitz@duke.edu.'}, {'ForeName': 'Tracy Y', 'Initials': 'TY', 'LastName': 'Wang', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Renato D', 'Initials': 'RD', 'LastName': 'Lopes', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Alma', 'Initials': 'A', 'LastName': 'Chavez', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Brittanny', 'Initials': 'B', 'LastName': 'Boyer', 'Affiliation': 'CryoLife, Inc., Kennesaw, GA.'}, {'ForeName': 'Hwasoon', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Kevin J', 'Initials': 'KJ', 'LastName': 'Anstrom', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Richard C', 'Initials': 'RC', 'LastName': 'Becker', 'Affiliation': 'Division of Cardiovascular Health and Diseases, University of Cincinnati Heart, Lung & Vascular Institute, Cincinnati, OH.'}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Blackstone', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Ruel', 'Affiliation': 'Division of Cardiac Surgery, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Vinod H', 'Initials': 'VH', 'LastName': 'Thourani', 'Affiliation': 'Piedmont Heart Institute, Atlanta, GA.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Puskas', 'Affiliation': ""Department of Cardiovascular Surgery, Mount Sinai St. Luke's, New York, NY.""}, {'ForeName': 'Marc W', 'Initials': 'MW', 'LastName': 'Gerdisch', 'Affiliation': 'Department of Cardiothoracic Surgery, Franciscan Hospital, Indianapolis, IN.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Johnston', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Capps', 'Affiliation': 'CryoLife, Inc., Kennesaw, GA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Alexander', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Lars G', 'Initials': 'LG', 'LastName': 'Svensson', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH.'}]",American heart journal,['10.1016/j.ahj.2020.06.014'] 2346,32693833,Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study.,"BACKGROUND Chronic wounds are a fundamental issue for patients with epidermolysis bullosa (EB). Herein, we assess the natural history of wound closure in patients with EB who were randomly assigned to the vehicle-control arm of the multicenter, randomized, double-blind, phase 3 ESSENCE (NCT02384460) trial. METHODS ESSENCE was designed to assess the efficacy and safety of a topical cream formulation of 6% allantoin (SD-101 6%) vs vehicle (SD-101 0%) in patients ≥1 month old who had a diagnosis of EB (simplex, recessive dystrophic, or intermediate junctional) and a target wound 10-50 cm 2 present for ≥21 days. Time to complete target wound closure and the proportion of patients with target wound closure over time were analyzed overall and by parameters including patient age and baseline body surface area index (BSAi) of total wound burden (< 5% and ≥ 5%). Changes in BSAi of lesional skin, pain, and itching were also assessed. RESULTS The vehicle-control arm included 87 patients. Mean (standard deviation [SD]) time to target wound closure within 3 months was 53.6 (28.6) days, with a range of 14 to 142 days. The proportion of patients with target wound closure increased over time from 7.1% at day 14 to 53.6% at month 3. Mean (SD) changes from baseline in BSAi of total wound burden and BSAi of lesional skin at month 3 were -2.3% (6.3) and -5.0% (13.5) of total body coverage, respectively. Reductions in pain and itching were observed at day 7 and maintained for 3 months. Faster healing times and a greater proportion of patients with wound closure were observed in patients aged 1 month to < 2 years; those with wounds < 30 days old, and in those with BSAi of total body wound burden < 5%. CONCLUSIONS Treatment response observed in the vehicle-control arm of the ESSENCE study was unexpectedly high and may have been due to unforeseen benefits of vehicle or enhanced wound care provided by the clinical trial staff. These observations will help inform the study design of future trials in patients with EB. TRIAL REGISTRATION ClinicalTrials.gov , NCT02384460 ; Date of registration: February 13, 2015; First participant enrollment: March 11, 2015.",2020,"Faster healing times and a greater proportion of patients with wound closure were observed in patients aged 1 month to < 2 years; those with wounds < 30 days old, and in those with BSAi of total body wound burden < 5%. ","['patients with epidermolysis bullosa (EB', 'patients ≥1\u2009month old who had a diagnosis of EB (simplex, recessive dystrophic, or intermediate junctional) and a target wound 10-50\u2009cm 2 present for ≥21\u2009days', 'patients with EB', '87 patients']",['topical cream formulation of 6% allantoin (SD-101 6%) vs vehicle (SD-101 0'],"['pain and itching', 'proportion of patients with wound closure', 'patient age and baseline body surface area index (BSAi) of total wound burden', 'natural history of wound closure', 'Mean (standard deviation [SD]) time to target wound closure', 'BSAi of lesional skin, pain, and itching', 'efficacy and safety', 'proportion of patients with target wound closure', 'Mean (SD) changes from baseline in BSAi of total wound burden and BSAi of lesional skin', 'Faster healing times']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0014527', 'cui_str': 'Epidermolysis bullosa'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0228492', 'cui_str': 'Structure of posterior semilunar lobule'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0205144', 'cui_str': 'Junctional'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0991551', 'cui_str': 'Cutaneous cream'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0002083', 'cui_str': 'Allantoin'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0450015', 'cui_str': 'Method of wound closure'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005902', 'cui_str': 'Body surface area'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0175860', 'cui_str': 'Natural History'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}]",,0.297534,"Faster healing times and a greater proportion of patients with wound closure were observed in patients aged 1 month to < 2 years; those with wounds < 30 days old, and in those with BSAi of total body wound burden < 5%. ","[{'ForeName': 'Dedee F', 'Initials': 'DF', 'LastName': 'Murrell', 'Affiliation': 'University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Amy S', 'Initials': 'AS', 'LastName': 'Paller', 'Affiliation': 'Departments of Dermatology and Pediatric Dermatology, Northwestern University Feinberg School of Medicine, 676 N. St. Clair, Suite 1600, Chicago, IL, 60611-2997, USA. apaller@northwestern.edu.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Bodemer', 'Affiliation': 'EB Expert Centre (MAGEC), Department of Dermatology, Necker-Enfants Malades Hospital, Paris Centre University, Paris, France.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Browning', 'Affiliation': 'Texas Dermatology & Laser Specialists, San Antonio, TX, USA.'}, {'ForeName': 'Milos', 'Initials': 'M', 'LastName': 'Nikolic', 'Affiliation': 'Clinical Center of Serbia, Department of Dermatology, University of Belgrade, Belgrade, Serbia.'}, {'ForeName': 'Jay A', 'Initials': 'JA', 'LastName': 'Barth', 'Affiliation': 'Amicus Therapeutics, Inc., Cranbury, NJ, USA.'}, {'ForeName': 'Hjalmar', 'Initials': 'H', 'LastName': 'Lagast', 'Affiliation': 'Amicus Therapeutics, Inc., Cranbury, NJ, USA.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Krusinska', 'Affiliation': 'Amicus Therapeutics, Inc., Cranbury, NJ, USA.'}, {'ForeName': 'Allen', 'Initials': 'A', 'LastName': 'Reha', 'Affiliation': 'Amicus Therapeutics, Inc., Cranbury, NJ, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Orphanet journal of rare diseases,['10.1186/s13023-020-01435-3'] 2347,32693842,Better Outcomes for Older people with Spinal Trouble (BOOST) trial: statistical analysis plan for a randomised controlled trial of a combined physical and psychological intervention for older adults with neurogenic claudication.,"BACKGROUND Neurogenic claudication is a common spinal condition affecting older adults that has a major effect on mobility and implicitly independence. The effectiveness of conservative interventions in this population is not known. We describe the statistical analysis plan for the Better Outcomes for Older people with Spinal trouble (BOOST) randomised controlled trial. METHODS/DESIGN BOOST is a pragmatic, multicentre, parallel, two-arm, randomised controlled trial. Participants are community-dwelling adults, 65 years or older, with neurogenic claudication, registered prospectively, and randomised 2:1 (intervention to control) to the combined physical and psychological BOOST group physiotherapy programme or best practice advice. The primary outcome is the Oswestry Disability Index at 12 months. Secondary outcomes include the Short Physical Performance Battery, Swiss Spinal Stenosis Scale, 6 Minute Walk Test, Fear Avoidance Beliefs Questionnaire, and Tilburg Frailty Indicator. Outcomes are measured at 6 and 12 months by researchers blinded to treatment allocation. The primary statistical analysis is by intention to treat. Further study design details are published in the BOOST protocol. DISCUSSION The planned statistical analyses for the BOOST trial aim to reduce the risk of outcome reporting bias from prior data knowledge. Any changes or deviations from this statistical analysis plan will be described and justified in the final study report. TRIAL REGISTRATION This study has been registered in the International Standard Randomised Controlled Trial Number registry, reference number ISRCTN12698674 . Registered on 10 November 2015.",2020,"Secondary outcomes include the Short Physical Performance Battery, Swiss Spinal Stenosis Scale, 6 Minute Walk Test, Fear Avoidance Beliefs Questionnaire, and Tilburg Frailty Indicator.","['Older people with Spinal trouble (BOOST', 'older adults', 'older adults with neurogenic claudication', 'Older people with Spinal Trouble (BOOST', 'Participants are community-dwelling adults, 65\u2009years or older, with neurogenic claudication']","['combined physical and psychological intervention', 'combined physical and psychological BOOST group physiotherapy programme or best practice advice', 'conservative interventions']","['Oswestry Disability Index', 'Short Physical Performance Battery, Swiss Spinal Stenosis Scale, 6\u2009Minute Walk Test, Fear Avoidance Beliefs Questionnaire, and Tilburg Frailty Indicator']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0580173', 'cui_str': 'Neurogenic claudication'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4704938', 'cui_str': 'Group Physiotherapy'}, {'cui': 'C3179154', 'cui_str': 'Best Practices'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}]","[{'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C4075461', 'cui_str': 'Short Physical Performance Battery'}, {'cui': 'C0241315', 'cui_str': 'Swiss'}, {'cui': 'C0037944', 'cui_str': 'Spinal stenosis'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0430515', 'cui_str': '6-minute walk test'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}]",,0.266594,"Secondary outcomes include the Short Physical Performance Battery, Swiss Spinal Stenosis Scale, 6 Minute Walk Test, Fear Avoidance Beliefs Questionnaire, and Tilburg Frailty Indicator.","[{'ForeName': 'Ioana R', 'Initials': 'IR', 'LastName': 'Marian', 'Affiliation': 'Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Old Road, Oxford, OX3 7LD, UK. ioana.marian@csm.ox.ac.uk.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Williamson', 'Affiliation': 'Centre for Rehabilitation Research, Nuffield Department of Rheumatology, Orthopaedics and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Garrett', 'Affiliation': 'Centre for Rehabilitation Research, Nuffield Department of Rheumatology, Orthopaedics and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Lamb', 'Affiliation': 'Centre for Rehabilitation Research, Nuffield Department of Rheumatology, Orthopaedics and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Susan J', 'Initials': 'SJ', 'LastName': 'Dutton', 'Affiliation': 'Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Old Road, Oxford, OX3 7LD, UK.'}]",Trials,['10.1186/s13063-020-04590-x'] 2348,32693852,Targeted adaptation in infants following live exposure to an accented talker.,"Infants struggle to understand familiar words spoken in unfamiliar accents. Here, we examine whether accent exposure facilitates accent-specific adaptation. Two types of pre-exposure were examined: video-based (i.e., listening to pre-recorded stories; Experiment 1) and live interaction (reading books with an experimenter; Experiments 2 and 3). After video-based exposure, Canadian English-learning 15- to 18-month-olds failed to recognize familiar words spoken in an unfamiliar accent. However, after face-to-face interaction with a Mandarin-accented talker, infants showed enhanced recognition for words produced in Mandarin English compared to Australian English. Infants with live exposure to an Australian talker were not similarly facilitated, perhaps due to the lower vocabulary scores of the infants assigned to the Australian exposure condition. Thus, live exposure can facilitate accent adaptation, but this ability is fragile in young infants and is likely influenced by vocabulary size and the specific mapping between the speaker and the listener's phonological system.",2020,"Infants with live exposure to an Australian talker were not similarly facilitated, perhaps due to the lower vocabulary scores of the infants assigned to the Australian exposure condition.",['Infants with live exposure to an Australian talker'],[],[],"[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}]",[],[],,0.0208127,"Infants with live exposure to an Australian talker were not similarly facilitated, perhaps due to the lower vocabulary scores of the infants assigned to the Australian exposure condition.","[{'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Paquette-Smith', 'Affiliation': 'Department of Psychology, University of California Los Angeles, 502 Portola Plaza, Los Angeles, CA, 90095, USA.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Cooper', 'Affiliation': 'Department of Psychology, University of Toronto, 3359 Mississauga Rd., Mississauga, ON, L5L 1C6, CANADA.'}, {'ForeName': 'Elizabeth K', 'Initials': 'EK', 'LastName': 'Johnson', 'Affiliation': 'Department of Psychology, University of Toronto, 3359 Mississauga Rd., Mississauga, ON, L5L 1C6, CANADA.'}]",Journal of child language,['10.1017/S030500092000029X'] 2349,32693855,"Effect of maternal nutritional education and counselling on children's stunting prevalence in urban informal settlements in Nairobi, Kenya.","OBJECTIVE To determine whether the prevalence of stunting differed between an intervention group and a control group and to identify factors associated with the children's linear growth. DESIGN This was a follow-up study of mother-child pairs who participated in a 2012-2015 cluster randomised controlled trial. Linear mixed effects models were performed to model the children's linear growth and identify the determinants of child linear growth. SETTING The study was conducted in two slums in Nairobi. The intervention group received monthly nutrition education and counselling (NEC) during pregnancy and infancy period. PARTICIPANTS A birth cohort of 1004 was followed up every 3 months after delivery to the 13th month. However, as a result of dropouts, a total of 438 mother-child pairs participated during the 55-month follow-up. The loss to follow-up baseline characteristics did not differ from those included for analysis. RESULTS Length-for-age z-scores decreased from birth to the 13th month, mean -1·42 (sd 2·04), with the control group (33·5 %) reporting a significantly higher prevalence of stunting than the intervention group (28·6 %). Conversely, the scores increased in the 55th month, mean -0·89 (sd 1·04), with significantly more males (16·5 %) stunted in the control group than in the intervention group (8·3 %). Being in the control group, being a male child, often vomiting/regurgitating food, mother's stature of <154 cm and early weaning were negatively associated with children's linear growth. CONCLUSIONS Home-based maternal NEC reduced stunting among under five years; however, the long-term benefits of this intervention on children's health need to be elucidated.",2020,"Conversely, the scores increased in the 55th month, mean -0·89","[""children's stunting prevalence in urban informal settlements in Nairobi, Kenya"", 'mother-child pairs who participated in a 2012-2015 cluster randomised controlled trial', 'The study was conducted in two slums in Nairobi']","['monthly nutrition education and counselling (NEC', 'maternal nutritional education and counselling']","['prevalence of stunting', 'Length-for-age z-scores']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0018273', 'cui_str': 'Growth disorder'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0027345', 'cui_str': 'Nairobi sheep virus disease'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0037345', 'cui_str': 'Slums'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0204934', 'cui_str': 'Nutrition education'}]","[{'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0018273', 'cui_str': 'Growth disorder'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}]",,0.0299816,"Conversely, the scores increased in the 55th month, mean -0·89","[{'ForeName': 'C K', 'Initials': 'CK', 'LastName': 'Nyamasege', 'Affiliation': 'Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki305-8575, Japan.'}, {'ForeName': 'E W', 'Initials': 'EW', 'LastName': 'Kimani-Murage', 'Affiliation': 'African Population and Health Research Center (APHRC), Nairobi, Kenya.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Wanjohi', 'Affiliation': 'African Population and Health Research Center (APHRC), Nairobi, Kenya.'}, {'ForeName': 'Dwm', 'Initials': 'D', 'LastName': 'Kaindi', 'Affiliation': 'Department of Food Science, Nutrition and Technology, University of Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Wagatsuma', 'Affiliation': 'Department of Clinical Trial and Clinical Epidemiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki305-8575, Japan.'}]",Public health nutrition,['10.1017/S1368980020001962'] 2350,32694032,Adductor Canal Block Combined With iPACK (Interspace Between the Popliteal Artery and the Capsule of the Posterior Knee) Block vs Periarticular Injection for Analgesia After Total Knee Arthroplasty: A Randomized Noninferiority Trial.,"BACKGROUND The combination of adductor canal block (ACB) and infiltration between the popliteal artery and the posterior capsule of the knee (iPACK) block may provide sufficient motor-sparing anterior and posterior knee analgesia after total knee arthroplasty. This study aimed to determine if ACB with iPACK block was noninferior to ACB with periarticular injection (PAI) when combined with postoperative multimodal analgesia regimen. METHODS Seventy-six patients were randomized to receive either ACB + iPACK block and continuous ACB (CACB) (ACB + iPACK group) or PAI and CACB (ACB + PAI group). Noninferiority was concluded for the primary outcome if the adjusted mean between-group difference in pain on movement at 12 postoperative hours was within 1.3 points on a visual analog pain scale. Pain scores, morphine consumption, functional performance, and adverse events were the secondary outcome measures assessed for superiority. RESULTS Adjusted mean differences, (ACB + iPACK) - (ACB + PAI), in anterior and posterior knee pain scores on movement at 12 postoperative hours were -0.66 (-1.86, 0.54) and -0.19 (-1.36, 0.99), respectively. The upper limit of 95% confident interval was lower than the prespecified noninferiority limit. The mean visual analog scale pain scores were low and no clinically significant differences between groups. However, morphine requirement at 48 postoperative hours was significantly higher (P < .05) and showed greater reduced quadriceps strength at 0 and 45 degrees on postoperative day 0 (P = .006 and .04, respectively) in the ACB + iPACK group. CONCLUSIONS ACB with iPACK block provides a noninferior analgesia compared with PAI when combined with CACB. However, patients who received ACB + iPACK block may require higher amounts of opioids and have worse immediate functional performance. LEVEL OF EVIDENCE Therapeutic level I.",2020,"However, morphine requirement at 48 postoperative hours was significantly higher (P < .05) and showed greater reduced quadriceps strength at 0 and 45 degrees on postoperative day 0","['After Total Knee Arthroplasty', 'Seventy-six patients']","['Block vs Periarticular Injection for Analgesia', 'adductor canal block (ACB', 'ACB\xa0+ iPACK block and continuous ACB (CACB', 'ACB with periarticular injection (PAI', 'morphine']","['ACB\xa0+ iPACK)\xa0- (ACB\xa0+ PAI), in anterior and posterior knee pain scores', 'quadriceps strength', 'mean visual analog scale pain scores', 'visual analog pain scale', 'Pain scores, morphine consumption, functional performance, and adverse events', 'pain on movement', 'Adductor Canal Block']","[{'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C4319622', 'cui_str': '76'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0595695', 'cui_str': 'Periarticular route'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0225273', 'cui_str': 'Structure of adductor canal'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]","[{'cui': 'C0225273', 'cui_str': 'Structure of adductor canal'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0595695', 'cui_str': 'Periarticular route'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0231749', 'cui_str': 'Knee pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2732809', 'cui_str': 'Visual analog scale pain score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0026649', 'cui_str': 'Movement'}]",76.0,0.385277,"However, morphine requirement at 48 postoperative hours was significantly higher (P < .05) and showed greater reduced quadriceps strength at 0 and 45 degrees on postoperative day 0","[{'ForeName': 'Wannida', 'Initials': 'W', 'LastName': 'Kertkiatkachorn', 'Affiliation': 'Department of Anesthesiology, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Wirinaree', 'Initials': 'W', 'LastName': 'Kampitak', 'Affiliation': 'Department of Anesthesiology, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Aree', 'Initials': 'A', 'LastName': 'Tanavalee', 'Affiliation': 'Department of Orthopedics, King Chulalongkorn Memorial Hospital and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Srihatach', 'Initials': 'S', 'LastName': 'Ngarmukos', 'Affiliation': 'Department of Orthopedics, King Chulalongkorn Memorial Hospital and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}]",The Journal of arthroplasty,['10.1016/j.arth.2020.06.086'] 2351,32694058,Mid-Term Outcomes After Treatment for Antibody-Mediated Rejection by De Novo Donor-Specific HLA Antibody in Renal Transplant Recipients: Does Early Treatment Lead to Better Outcomes?,"BACKGROUND De novo donor-specific HLA antibody (DSA) and antibody-mediated rejection (ABMR) are strongly associated with late allograft loss in renal transplant recipients. However, the impact of therapeutic intervention with the current treatment options for ABMR remains unclear. This study aimed to elucidate the efficacy of treatment for ABMR. METHODS Sixty-seven patients who had de novo DSAs underwent diagnostic biopsy for ABMR, and these patients were classified into 3 groups: ABMR-free group (n = 40), clinical ABMR group (n = 15), and subclinical ABMR group (n = 12). The ABMR-positive groups were treated mainly with double-filtration plasmapheresis followed by rituximab and corticosteroid pulse. The patient characteristics and graft outcomes were compared between groups. RESULTS The clinical and subclinical ABMR groups were younger and had a higher number and mean fluorescence intensity (MFI) of de novo DSAs than the ABMR-free group. The graft survival in the clinical ABMR group was significantly lower than that in the ABMR-free group, but the subclinical ABMR group had a surprisingly good graft survival rate compared to the ABMR-free group (43.3% vs 100% vs 94.2% 5 years after diagnostic biopsy in the clinical ABMR, subclinical ABMR, and ABMR-free groups, respectively, P < .001). CONCLUSIONS Our findings indicated that early therapeutic intervention for patients with de novo DSAs may improve graft survival.",2020,"The graft survival in the clinical ABMR group was significantly lower than that in the ABMR-free group, but the subclinical ABMR group had a surprisingly good graft survival rate compared to the ABMR-free group (43.3% vs 100% vs 94.2% 5 years after diagnostic biopsy in the clinical ABMR, subclinical ABMR, and ABMR-free groups, respectively, P < .001). ","['Sixty-seven patients who had de novo DSAs underwent diagnostic biopsy for ABMR, and these patients were classified into 3 groups: ABMR-free group (n\xa0= 40), clinical ABMR group (n\xa0= 15), and subclinical ABMR group (n\xa0= 12', 'Renal Transplant Recipients', 'renal transplant recipients']",['rituximab and corticosteroid pulse'],"['graft survival', 'mean fluorescence intensity (MFI) of de novo DSAs', 'graft survival rate']","[{'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C1608421', 'cui_str': 'Antibody-mediated rejection'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205211', 'cui_str': 'Subclinical'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}]","[{'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}]","[{'cui': 'C0018131', 'cui_str': 'Graft Survival'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0016315', 'cui_str': 'Fluorescence'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]",67.0,0.0202951,"The graft survival in the clinical ABMR group was significantly lower than that in the ABMR-free group, but the subclinical ABMR group had a surprisingly good graft survival rate compared to the ABMR-free group (43.3% vs 100% vs 94.2% 5 years after diagnostic biopsy in the clinical ABMR, subclinical ABMR, and ABMR-free groups, respectively, P < .001). ","[{'ForeName': 'Manabu', 'Initials': 'M', 'LastName': 'Okada', 'Affiliation': 'Department of Transplant and Endocrine Surgery, Kidney Disease Center, Nagoya Daini Red Cross Hospital, Nagoya, Japan. Electronic address: ubanam@nagoya2.jrc.or.jp.'}, {'ForeName': 'Toshihide', 'Initials': 'T', 'LastName': 'Tomosugi', 'Affiliation': 'Department of Transplant and Endocrine Surgery, Kidney Disease Center, Nagoya Daini Red Cross Hospital, Nagoya, Japan.'}, {'ForeName': 'Kenta', 'Initials': 'K', 'LastName': 'Futamura', 'Affiliation': 'Department of Transplant and Endocrine Surgery, Kidney Disease Center, Nagoya Daini Red Cross Hospital, Nagoya, Japan.'}, {'ForeName': 'Takahisa', 'Initials': 'T', 'LastName': 'Hiramitsu', 'Affiliation': 'Department of Transplant and Endocrine Surgery, Kidney Disease Center, Nagoya Daini Red Cross Hospital, Nagoya, Japan.'}, {'ForeName': 'Norihiko', 'Initials': 'N', 'LastName': 'Goto', 'Affiliation': 'Department of Transplant and Endocrine Surgery, Kidney Disease Center, Nagoya Daini Red Cross Hospital, Nagoya, Japan.'}, {'ForeName': 'Shunji', 'Initials': 'S', 'LastName': 'Narumi', 'Affiliation': 'Department of Transplant and Endocrine Surgery, Kidney Disease Center, Nagoya Daini Red Cross Hospital, Nagoya, Japan.'}, {'ForeName': 'Asami', 'Initials': 'A', 'LastName': 'Takeda', 'Affiliation': 'Department of Nephrology, Kidney Disease Center, Nagoya Daini Red Cross Hospital, Nagoya, Japan.'}, {'ForeName': 'Yoshihiko', 'Initials': 'Y', 'LastName': 'Watarai', 'Affiliation': 'Department of Transplant and Endocrine Surgery, Kidney Disease Center, Nagoya Daini Red Cross Hospital, Nagoya, Japan.'}]",Transplantation proceedings,['10.1016/j.transproceed.2020.06.022'] 2352,32694076,Symptom assessment after nasal irrigation with xylitol in the postoperative period of endonasal endoscopic surgery.,"INTRODUCTION Chronic rhinosinusitis is an inflammatory condition of the nasal cavity and the paranasal sinuses that requires multifactorial treatment. Xylitol can be employed with nasal irrigation and can provide better control of the disease. OBJECTIVE To evaluate the association between the effects of nasal lavage with saline solution compared to nasal lavage with a xylitol solution. METHODS Fifty-two patients, divided into two groups (n = 26 in the ""Xylitol"" group and n = 26 in the ""Saline solution"" group) answered questionnaires validated in Portuguese (NOSE and SNOT-22) about their nasal symptoms and general symptoms, before and after endonasal endoscopic surgery and after a period of 30 days of nasal irrigation. RESULTS The ""Xylitol"" group showed significant improvement in pain relief and nasal symptom reduction after surgery and nasal irrigation with xylitol solution (p < 0.001). The ""Saline solution"" group also showed symptom improvement, but on a smaller scale. CONCLUSION This study suggests that the xylitol solution can be useful in the postoperative period after endonasal endoscopic surgery, because it leads to a greater reduction in nasal symptoms.",2020,"RESULTS The ""Xylitol"" group showed significant improvement in pain relief and nasal symptom reduction after surgery and nasal irrigation with xylitol solution (p < 0.001).","['Fifty-two patients, divided into two groups (n\u202f=\u202f26 in the']","['xylitol', 'xylitol solution', 'endonasal endoscopic surgery', 'nasal lavage with saline solution', 'Xylitol', 'Xylitol"" group and n\u202f=\u202f26 in the ""Saline solution"" group) answered questionnaires validated in Portuguese (NOSE and SNOT-22']",['pain relief and nasal symptom reduction'],"[{'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0043369', 'cui_str': 'Xylitol'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0225425', 'cui_str': 'Internal nose structure'}, {'cui': 'C0282493', 'cui_str': 'Endoscopy with surgical procedure'}, {'cui': 'C2350442', 'cui_str': 'Nasal irrigation'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0032730', 'cui_str': 'Portuguese'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C5197690', 'cui_str': 'SNOT-22'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0231918', 'cui_str': 'Nose symptoms'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",52.0,0.025318,"RESULTS The ""Xylitol"" group showed significant improvement in pain relief and nasal symptom reduction after surgery and nasal irrigation with xylitol solution (p < 0.001).","[{'ForeName': 'Caroline Feliz Fonseca Sepeda da', 'Initials': 'CFFSD', 'LastName': 'Silva', 'Affiliation': 'Instituto Paranaense de Otorrinolaringologia (IPO), Curitiba, PR, Brazil.'}, {'ForeName': 'Flávia Emilly Rodrigues da', 'Initials': 'FERD', 'LastName': 'Silva', 'Affiliation': 'Pontifícia Universidade Católica do Paraná (PUC-PR), Curitiba, PR, Brazil.'}, {'ForeName': 'Henrique Furlan', 'Initials': 'HF', 'LastName': 'Pauna', 'Affiliation': 'Instituto Paranaense de Otorrinolaringologia (IPO), Curitiba, PR, Brazil; Universidade de São Paulo (FMRP-USP), Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, SP, Brazil. Electronic address: h_pauna@hotmail.com.'}, {'ForeName': 'Johann Gustavo Guilhermo Melcherts', 'Initials': 'JGGM', 'LastName': 'Hurtado', 'Affiliation': 'Instituto Paranaense de Otorrinolaringologia (IPO), Curitiba, PR, Brazil; Universidade Federal do Paraná, Hospital de Clínicas, Curitiba, PR, Brazil.'}, {'ForeName': 'Marco Cesar', 'Initials': 'MC', 'LastName': 'Santos', 'Affiliation': 'Instituto Paranaense de Otorrinolaringologia (IPO), Curitiba, PR, Brazil.'}]",Brazilian journal of otorhinolaryngology,['10.1016/j.bjorl.2020.05.023'] 2353,32694162,Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.,"BACKGROUND AND OBJECTIVES Ferric citrate is an oral medication approved for treatment of iron deficiency anemia in patients with CKD not requiring dialysis. The relative efficacy of ferric citrate versus ferrous sulfate in treating iron deficiency in patients with CKD is unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS We randomized 60 adults with moderate to severe CKD (eGFR 15-45 ml/min per 1.73 m 2 ) and iron deficiency (transferrin saturation [TSAT] ≤30% and ferritin ≤300 ng/ml) to ferric citrate (2 g three times a day with meals, n =30) or ferrous sulfate (325 mg three times a day, n =30) for 12 weeks. Primary outcomes were change in TSAT and ferritin from baseline to 12 weeks. Secondary outcomes were change in hemoglobin, fibroblast growth factor 23 (FGF23), and hepcidin. RESULTS Baseline characteristics were well balanced between study arms. There was a greater increase in TSAT (between-group difference in mean change, 8%; 95% confidence interval [95% CI], 1 to 15; P =0.02) and ferritin (between-group difference in mean change, 37 ng/ml; 95% CI, 10 to 64; P =0.009) from baseline to 12 weeks in participants randomized to ferric citrate as compared with ferrous sulfate. Similarly, as compared with ferrous sulfate, treatment with ferric citrate resulted in a greater increase in hepcidin from baseline to 12 weeks (between-group difference, 69 pg/ml; 95% CI, 8 to 130). There were no between-group differences in mean change for hemoglobin (0.3 g/dl; 95% CI, -0.2 to 0.8), intact FGF23 (-29 pg/ml; 95% CI, -59 to 0.1), or C-terminal FGF23 (61 RU/ml; 95% CI, -181 to 58). The incidence of adverse events did not differ between treatment arms. CONCLUSIONS As compared with ferrous sulfate, treatment with ferric citrate for 12 weeks resulted in a greater mean increase in TSAT and ferritin concentrations in individuals with moderate to severe CKD and iron deficiency. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With Moderate to Severe Chronic Kidney Disease (CKD) With Iron Deficiency, NCT02888171.",2020,"There was a greater increase in TSAT (between-group difference in mean change, 8%; 95% confidence interval [95% CI], 1 to 15; P =0.02) and ferritin (between-group difference in mean change, 37 ng/ml; 95% CI, 10 to 64; P =0.009) from baseline to 12 weeks in participants randomized to ferric citrate as compared with ferrous sulfate.","['60 adults with moderate to severe CKD (eGFR 15-45 ml/min per 1.73 m 2 ) and iron deficiency (transferrin saturation [TSAT] ≤30% and ferritin ≤300 ng/ml) to', 'individuals with moderate to severe CKD and iron deficiency', 'patients with CKD not requiring dialysis', 'Individuals With Moderate to Severe Chronic Kidney Disease (CKD', 'patients with CKD', 'Patients with Iron Deficiency and CKD']","['Ferric Citrate versus Ferrous Sulfate', 'ferric citrate', 'ferrous sulfate', 'Ferric Citrate vs Ferrous Sulfate', 'ferric citrate (2 g three times a day with meals, n =30) or ferrous sulfate', 'ferric citrate versus ferrous sulfate']","['mean change for hemoglobin', 'TSAT', 'change in TSAT and ferritin', 'TSAT and ferritin concentrations', 'ferritin', 'hepcidin', 'change in hemoglobin, fibroblast growth factor 23 (FGF23), and hepcidin', 'intact FGF23', 'incidence of adverse events']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0439445', 'cui_str': 'mL/min'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation'}, {'cui': 'C0015879', 'cui_str': 'Ferritin'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}]","[{'cui': 'C0060231', 'cui_str': 'ferric citrate'}, {'cui': 'C0060282', 'cui_str': 'ferrous sulfate'}, {'cui': 'C0556984', 'cui_str': 'Three times daily'}, {'cui': 'C4553624', 'cui_str': 'With meals'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0015879', 'cui_str': 'Ferritin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C0962301', 'cui_str': 'Fibroblast growth factor 23'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C3272931', 'cui_str': 'Fibroblast growth factor 23'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",60.0,0.220652,"There was a greater increase in TSAT (between-group difference in mean change, 8%; 95% confidence interval [95% CI], 1 to 15; P =0.02) and ferritin (between-group difference in mean change, 37 ng/ml; 95% CI, 10 to 64; P =0.009) from baseline to 12 weeks in participants randomized to ferric citrate as compared with ferrous sulfate.","[{'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Womack', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Fabian', 'Initials': 'F', 'LastName': 'Berru', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Bhupesh', 'Initials': 'B', 'LastName': 'Panwar', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Orlando M', 'Initials': 'OM', 'LastName': 'Gutiérrez', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama ogutierrez@uabmc.edu.'}]",Clinical journal of the American Society of Nephrology : CJASN,['10.2215/CJN.15291219'] 2354,32694375,Exercise Performance Is Impaired during the Mid-Luteal Phase of the Menstrual Cycle.,"PURPOSE Test the hypothesis that aerobic exercise performance is impaired in the mid-luteal (ML) compared to the mid-follicular (MF) phase of the menstrual cycle. METHODS Twelve recreationally active eumenorrheic women (25±6 y) completed exercise sessions during the MF and ML phases. Each session consisted of an 8 km cycling time trial that was preceded by 10 min of cycling performed at a constant power below and above gas exchange threshold. Heart rate, ventilation, oxygen uptake were continuously measured. Ratings of perceived exertion (RPE) and ratings of fatigue were assessed during the time trial using visual analog scales. Total mood disturbance was calculated from the Profile of Mood States Questionnaire administered before and 20 min post-exercise RESULTS: Salivary progesterone concentration was 578±515 pg/ml higher in ML compared to MF phase (P<0.01), while estradiol concentration did not differ between phases (167±55 vs. 206±120 pg/ml, P=0.31). Total mood disturbance prior to exercise was greater during the ML compared with the MF phase (P<0.01) but this difference was abolished post-exercise (P=0.14). Mean power output was lower during the ML phase (115±29 vs. 125±28 W, P<0.01) which led to a slower time trial in the ML phase (18.3±2.0 min) compared to the MF phase (17.8±1.7 min, P=0.03). Ratings of fatigue were greater during the ML phase from 2-8 km (P≤0.01), while no differences in RPE were observed. Heart rate (P=0.85), minute ventilation (P=0.53), and oxygen uptake (P=0.32) did not differ between phases during the time trial. CONCLUSION Aerobic exercise performance is worse in the ML phase compared to the MF phase in recreationally active women which was accompanied by a more negative mood state pre-exercise and increased ratings of fatigue.",2020,Total mood disturbance prior to exercise was greater during the ML compared with the MF phase (P<0.01) but this difference was abolished post-exercise (P=0.14).,['Twelve recreationally active eumenorrheic women (25±6 y) completed'],['exercise sessions'],"['Heart rate, ventilation, oxygen uptake', 'Exercise Performance', 'Ratings of perceived exertion (RPE) and ratings of fatigue', 'Salivary progesterone concentration', 'Total mood disturbance', 'Ratings of fatigue', 'Heart rate', 'Total mood disturbance prior to exercise', 'estradiol concentration', 'minute ventilation (P=0.53), and oxygen uptake', 'ratings of fatigue', 'Mean power output', 'RPE']","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0033308', 'cui_str': 'Progesterone'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C2939186', 'cui_str': 'Disturbance in mood'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C1301655', 'cui_str': 'Minute ventilation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0445194', 'cui_str': 'Power output'}]",,0.080312,Total mood disturbance prior to exercise was greater during the ML compared with the MF phase (P<0.01) but this difference was abolished post-exercise (P=0.14).,"[{'ForeName': 'Jessica A', 'Initials': 'JA', 'LastName': 'Freemas', 'Affiliation': 'H.H. Morris Human Performance Laboratories, Dept. of Kinesiology, School of Public Health, Indiana University, Bloomington, IN.'}, {'ForeName': 'Marissa N', 'Initials': 'MN', 'LastName': 'Baranauskas', 'Affiliation': 'H.H. Morris Human Performance Laboratories, Dept. of Kinesiology, School of Public Health, Indiana University, Bloomington, IN.'}, {'ForeName': 'Keren', 'Initials': 'K', 'LastName': 'Constantini', 'Affiliation': 'School of Public Health, Sackler Faculty of Medicine and Sylvan Adams Sports Institute, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Naama', 'Initials': 'N', 'LastName': 'Constantini', 'Affiliation': 'Shaare Zedek Medical center affiliated to the Hebrew University, Jerusalem, Israel.'}, {'ForeName': 'Joel T', 'Initials': 'JT', 'LastName': 'Greenshields', 'Affiliation': 'H.H. Morris Human Performance Laboratories, Dept. of Kinesiology, School of Public Health, Indiana University, Bloomington, IN.'}, {'ForeName': 'Timothy D', 'Initials': 'TD', 'LastName': 'Mickleborough', 'Affiliation': 'H.H. Morris Human Performance Laboratories, Dept. of Kinesiology, School of Public Health, Indiana University, Bloomington, IN.'}, {'ForeName': 'John S', 'Initials': 'JS', 'LastName': 'Raglin', 'Affiliation': 'H.H. Morris Human Performance Laboratories, Dept. of Kinesiology, School of Public Health, Indiana University, Bloomington, IN.'}, {'ForeName': 'Zachary J', 'Initials': 'ZJ', 'LastName': 'Schlader', 'Affiliation': 'H.H. Morris Human Performance Laboratories, Dept. of Kinesiology, School of Public Health, Indiana University, Bloomington, IN.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002464'] 2355,32694376,Ventilatory Responsiveness during Exercise and Performance Impairment in Acute Hypoxia.,"INTRODUCTION An adequate increase in minute ventilation to defend arterial oxyhemoglobin saturation (SpO2) during hypoxic exercise is commonly viewed as an important factor contributing to large inter-individual variations in the degree of exercise performance impairment in hypoxia. While the hypoxic ventilatory response (HVR) could provide insight into the underpinnings of such impairments, it is typically measured at rest under isocapnic conditions. Thus, we aimed to determine whether 1) HVR at rest and during exercise are similar, and 2) exercise HVR is related to the degree of impairment in cycling time trial performance from normoxia to acute hypoxia ([INCREMENT]TT). METHODS Sixteen endurance-trained men (V[Combining Dot Above]O2peak: 62.5±5.8 ml·kg·min) performed two poikilocapnic HVR tests: one during seated rest (HVRREST) and another during submaximal cycling (HVREX). On two separate visits, subjects (n=12) performed a 10km cycling time trial (TT) while breathing either room air (FiO2 = 0.21) or a hypoxic gas mixture (FiO2 = 0.16), in a randomized order. RESULTS HVREX was significantly (p<0.001) greater than HVRREST (1.52±0.47 and 0.22±0.13 l·min·%SpO2, respectively), and these measures were not correlated (r=-0.16, p=0.57). [INCREMENT]TT was not correlated with HVRREST (p=0.70) or HVREX (p=0.54), but differences in ventilation and end tidal CO2 between hypoxic and normoxic TTs and the ventilatory equivalent for CO2 during normoxic TT explained ~85% of the variance in performance impairment in acute hypoxia (p < 0.01). CONCLUSION We conclude that 1) HVR is not an appropriate measure to predict the exercise ventilatory response or performance impairments in acute hypoxia; and 2) an adequate and metabolically-matched increase in exercise ventilation, but not the gain in the ventilatory response to hypoxia, is essential for mitigating hypoxia-induced impairments in endurance cycling performance.",2020,"RESULTS HVREX was significantly (p<0.001) greater than HVRREST","['Sixteen endurance-trained men (V[Combining', 'Acute Hypoxia']","['HVRREST', '10km cycling time trial (TT) while breathing either room air (FiO2 = 0.21) or a hypoxic gas mixture', 'poikilocapnic HVR tests: one during seated rest (HVRREST) and another during submaximal cycling (HVREX']","['ventilation and end tidal CO2 between hypoxic and normoxic TTs and the ventilatory equivalent for CO2', 'Ventilatory Responsiveness']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}]","[{'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0277814', 'cui_str': 'Sitting position'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0428167', 'cui_str': 'Fraction of inspired oxygen'}, {'cui': 'C4517437', 'cui_str': '0.21'}, {'cui': 'C0068879', 'cui_str': 'nitrox'}]","[{'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C3267130', 'cui_str': 'End-tidal CO2'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}]",16.0,0.0277928,"RESULTS HVREX was significantly (p<0.001) greater than HVRREST","[{'ForeName': 'Keren', 'Initials': 'K', 'LastName': 'Constantini', 'Affiliation': 'Department of Kinesiology, Indiana University, Bloomington, IN.'}, {'ForeName': 'Anna C', 'Initials': 'AC', 'LastName': 'Bouillet', 'Affiliation': 'Department of Kinesiology, Indiana University, Bloomington, IN.'}, {'ForeName': 'Chad C', 'Initials': 'CC', 'LastName': 'Wiggins', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Bruce J', 'Initials': 'BJ', 'LastName': 'Martin', 'Affiliation': 'Indiana University School of Medicine, Bloomington, IN.'}, {'ForeName': 'Robert F', 'Initials': 'RF', 'LastName': 'Chapman', 'Affiliation': 'Department of Kinesiology, Indiana University, Bloomington, IN.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002466'] 2356,32694412,"Advanced HIV disease in the botswana combination prevention project: prevalence, risk factors, and outcomes.","OBJECTIVE(S) To determine the proportion of individuals linking to HIV-care with advanced HIV-disease (CD4 ≤200 cells/μL) in the Botswana Combination Prevention Project, describe the characteristics of these individuals, and examine treatment outcomes. DESIGN A sub-analysis of a cluster-randomized HIV-prevention trial. HIV status was assessed in 16-64-year-olds through home and mobile testing. All HIV-positive persons not on antiretroviral-therapy (ART) were referred to local Ministry of Health and Wellness clinics for treatment. METHODS Analysis was restricted to the 15 intervention clusters. The proportion of individuals with advanced HIV disease was determined; associations between advanced HIV disease and sex and age explored; and rates of viral suppression determined at 1-year. Mortality and retention in care were compared between CD4 strata (CD4 ≤200 cells/μL vs. > 200 cells/μL). RESULTS Overall, 17.2% (430/2,499; 95% confidence interval [CI] 15.7-18.8%) of study participants had advanced HIV disease (CD4 ≤200 cells/μL) at time of clinic linkage. Men were significantly more likely to present with CD4 ≤200 cells/μL than women (23.7% versus 13.4%, adjusted odds ratio [aOR] 1.9, 95% CI 1.5-2.3). The risk of advanced HIV disease increased with increasing age (aOR 2.2, 95% CI 1.4-3.2 > 35 years versus < 25 years). Patients with CD4 ≤200 cells/μL had significantly higher rates of attrition from care during follow-up (hazards ratio 1.47, 95% CI 1.1-2.1). CONCLUSIONS Advanced HIV disease due to late presentation to or disengagement from ART care remains common in the Treat All era in Botswana, calling for innovative testing, linkage, and treatment strategies to engage and retain harder-to-reach populations in care.",2020,"The risk of advanced HIV disease increased with increasing age (aOR 2.2, 95% CI 1.4-3.2 > 35 years versus < 25 years).","['individuals linking to HIV-care with advanced HIV-disease (CD4 ≤200\u200acells/μL', 'All HIV-positive persons not on antiretroviral-therapy (ART) were referred to local Ministry of Health and Wellness clinics for treatment']",[],"['Mortality and retention in care', 'rates of attrition from care', 'viral suppression', 'advanced HIV disease', 'HIV status', 'proportion of individuals with advanced HIV disease', 'risk of advanced HIV disease']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0019693', 'cui_str': 'Human immunodeficiency virus infection'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0019699', 'cui_str': 'HIV positive'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",[],"[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C4704685', 'cui_str': 'Care Retention'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0019693', 'cui_str': 'Human immunodeficiency virus infection'}, {'cui': 'C0458074', 'cui_str': 'HIV status'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",,0.286856,"The risk of advanced HIV disease increased with increasing age (aOR 2.2, 95% CI 1.4-3.2 > 35 years versus < 25 years).","[{'ForeName': 'Refeletswe', 'Initials': 'R', 'LastName': 'Lebelonyane', 'Affiliation': 'Botswana Ministry of Health and Wellness, Gaborone, Botswana.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Mills', 'Affiliation': 'Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Chipo', 'Initials': 'C', 'LastName': 'Mogorosi', 'Affiliation': 'Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Faith', 'Initials': 'F', 'LastName': 'Ussery', 'Affiliation': 'Centers for Disease Control and Prevention, Division of Global HIV/AIDS and TB, Atlanta, GA, USA.'}, {'ForeName': 'Tafireyi', 'Initials': 'T', 'LastName': 'Marukutira', 'Affiliation': 'Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'Theu', 'Affiliation': 'Botswana Ministry of Health and Wellness, Gaborone, Botswana.'}, {'ForeName': 'Max', 'Initials': 'M', 'LastName': 'Kapanda', 'Affiliation': 'Botswana Ministry of Health and Wellness, Gaborone, Botswana.'}, {'ForeName': 'Stembile', 'Initials': 'S', 'LastName': 'Matambo', 'Affiliation': 'Centers for Disease Control and Prevention, Gaborone, Botswana.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Block', 'Affiliation': 'Northrop Grumman, Atlanta, GA, USA.'}, {'ForeName': 'Elliot', 'Initials': 'E', 'LastName': 'Raizes', 'Affiliation': 'Centers for Disease Control and Prevention, Division of Global HIV/AIDS and TB, Atlanta, GA, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Makhema', 'Affiliation': 'Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.'}, {'ForeName': 'Shahin', 'Initials': 'S', 'LastName': 'Lockman', 'Affiliation': 'Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Bachanas', 'Affiliation': 'Centers for Disease Control and Prevention, Division of Global HIV/AIDS and TB, Atlanta, GA, USA.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Moore', 'Affiliation': 'Centers for Disease Control and Prevention, Division of Global HIV/AIDS and TB, Atlanta, GA, USA.'}, {'ForeName': 'Joseph N', 'Initials': 'JN', 'LastName': 'Jarvis', 'Affiliation': 'Centers for Disease Control and Prevention, Gaborone, Botswana.'}]","AIDS (London, England)",['10.1097/QAD.0000000000002627'] 2357,32694454,Comprehensive Cardiac Rehabilitation Effectiveness in a Middle-Income Setting: A RANDOMIZED CONTROLLED TRIAL.,"PURPOSE The impact of comprehensive cardiac rehabilitation (CCR) in Latin America is not well known. Herein, the pre-specified tertiary outcomes of a cardiac rehabilitation (CR) trial are reported: disease-related knowledge, depressive symptoms, and heart-health behaviors (exercise, diet, and smoking). METHODS This was a single-blinded, single-center (Brazil) randomized trial with three parallel arms: CCR (exercise + education) versus exercise-only CR versus wait-list control. Eligible patients were randomized in blocks of four with 1:1:1 concealed allocation. The CR program was 6 mo long. Participants randomized to exercise-only CR received 36 exercise classes; the CCR group also received 24 educational sessions, including a workbook. All outcomes were assessed at pre-test and 6-mo later (blinded). Analysis of covariance was performed by intention-to-treat (ITT) and per-protocol (PP). RESULTS A total of 115 (89%) patients were randomized; 93 (81%) were retained. There were significant improvements in knowledge with CCR (ITT [51.2 ± 11.9 pre and 60.8 ± 13.2 post] and PP; P < .01), with significantly greater knowledge with CCR versus control (ITT mean difference [MD] = 9.5, 95% CI, 2.3-16.8) and CCR vs exercise-only CR at post-test (ITT MD = 6.8, 95% CI, 0.3-14.0). There were also significant improvements in self-reported exercise with CCR (ITT [13.7 ± 15.8 pre and 32.1 ± 2 5.7 post] and PP; P < .001), with significantly greater exercise with CCR versus control at post-test (ITT MD = 7.6, 95% CI, 3.8-11.4). Also, there were significant improvements in diet with CCR (PP: 3.4 ± 7.5 pre and 8.0 ± 7.0 post; P < .05). CONCLUSIONS In this first-ever randomized trial of CR for coronary artery disease in Latin America, the benefits of CCR have been supported.",2020,"There were also significant improvements in self-reported exercise with CCR (ITT [13.7 ± 15.8 pre and 32.1 ± 2 5.7 post] and PP; P < .001), with significantly greater exercise with CCR versus control at post-test (ITT MD = 7.6, 95% CI, 3.8-11.4).","['Middle-Income Setting', 'A total of 115 (89%) patients were randomized; 93 (81%) were retained', 'Eligible patients']","['comprehensive cardiac rehabilitation (CCR', 'exercise-only CR received 36 exercise classes; the CCR group also received 24 educational sessions', 'CR', 'CCR (exercise + education) versus exercise-only CR versus wait-list control']","['self-reported exercise with CCR', 'knowledge with CCR']","[{'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0333118', 'cui_str': 'Retained'}]","[{'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0454306', 'cui_str': 'Exercise class'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",115.0,0.282397,"There were also significant improvements in self-reported exercise with CCR (ITT [13.7 ± 15.8 pre and 32.1 ± 2 5.7 post] and PP; P < .001), with significantly greater exercise with CCR versus control at post-test (ITT MD = 7.6, 95% CI, 3.8-11.4).","[{'ForeName': 'Gabriela Lima de Melo', 'Initials': 'GLM', 'LastName': 'Ghisi', 'Affiliation': 'Cardiovascular Prevention and Rehabilitation Program, Toronto Rehabilitation Institute, University Health Network, University of Toronto, Ontario, Canada (Drs Ghisi, Oh, and Dr Grace); Physical Therapy Department, Federal University of Minas Gerais, Minas Gerais, Brazil (Drs Chaves and Britto); School of Kinesiology and Health Science, York University, Toronto, Ontario, Canada (Drs Chaves and Grace); and University Hospital, Division of Cardiology and Cardiovascular Surgery, Federal University of Minas Gerais, Minas Gerais, Brazil (Dr Ribeiro).'}, {'ForeName': 'Gabriela S S', 'Initials': 'GSS', 'LastName': 'Chaves', 'Affiliation': ''}, {'ForeName': 'Antonio L', 'Initials': 'AL', 'LastName': 'Ribeiro', 'Affiliation': ''}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Oh', 'Affiliation': ''}, {'ForeName': 'Raquel R', 'Initials': 'RR', 'LastName': 'Britto', 'Affiliation': ''}, {'ForeName': 'Sherry L', 'Initials': 'SL', 'LastName': 'Grace', 'Affiliation': ''}]",Journal of cardiopulmonary rehabilitation and prevention,['10.1097/HCR.0000000000000512'] 2358,32690516,HIV and other STIs self-testing to reduce risk compensation among men who have sex with men who use oral pre-exposure prophylaxis in China: protocol for a randomised waitlist-controlled trial.,"INTRODUCTION Pre-exposure prophylaxis (PrEP) reduces the risk of HIV infection among men who have sex with men by up to 99%. However, in real-world settings, PrEP users may exhibit risk compensation after uptake of PrEP, including more condomless anal intercourse (CAI) and increased sexually transmitted infection (STI) acquisition. HIV self-testing (HIVST) decreases CAI among men who have sex with men (MSM) by providing awareness of the HIV status of oneself and one's sexual partners. Here, we describe the rationale and design of a randomised waitlist-controlled trial to examine the impact of HIVST on risk compensation among PrEP users. METHODS AND ANALYSIS The study is a two-arm randomised waitlist-controlled trial with 1000 HIV-negative MSM in four major cities in China who will be taking oral PrEP (involving tenofovir disoproxil fumarate/emtricitabine) either daily (n=500) or in an event-driven regimen (n=500). The participants will be randomised (1:1) to either the immediate HIVST intervention arm (HIVST plus standard facility-based counselling and testing from 0 to 12 months) or the waitlist arm (standard facility-based counselling and testing from 0 to 6 months, then crossover to receive the HIVST intervention in months 7-12). Participants will provide blood samples to assess the incidence of syphilis and herpes simplex virus type 2 (HSV-2) during a follow-up. The primary outcomes will be the occurrence of CAI, number of sexual partners and incidence of syphilis and HSV-2 during a follow-up. The secondary outcomes will be the HIV and STI testing frequency and STI treatment adherence during a follow-up. The planned start and end dates for the study is 26 December 2018 and 31 December 2020. ETHICS AND DISSEMINATION The Medical Science Research Ethics Committee of The First Affiliated Hospital of China Medical University has approved the study (IRB(2018)273). TRIAL REGISTRATION NUMBER ChiCTR1800020374.",2020,HIV self-testing (HIVST) decreases CAI among men who have sex with men (MSM) by providing awareness of the HIV status of oneself and one's sexual partners.,"['1000 HIV-negative MSM in four major cities in China who will be taking oral PrEP (involving', 'either daily (n=500) or in an event-driven regimen (n=500', '26 December 2018 and 31 December 2020', ""men who have sex with men (MSM) by providing awareness of the HIV status of oneself and one's sexual partners"", 'men who have sex with men by up to 99', 'men who have sex with men who use oral pre-exposure prophylaxis in China']","['HIVST', 'HIV and other STIs self-testing', 'immediate HIVST intervention arm (HIVST plus standard facility-based counselling and testing from 0 to 12 months) or the waitlist arm (standard facility-based counselling and testing from 0 to 6 months, then crossover to receive the HIVST intervention', 'HIV self-testing (HIVST', 'Pre-exposure prophylaxis (PrEP', 'tenofovir disoproxil fumarate/emtricitabine']","['risk of HIV infection', 'condomless anal intercourse (CAI) and increased sexually transmitted infection (STI) acquisition', 'HIV and STI testing frequency and STI treatment adherence', 'risk compensation', 'occurrence of CAI, number of sexual partners and incidence of syphilis and HSV-2 during a follow-up']","[{'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0481430', 'cui_str': 'HIV negative'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3850098', 'cui_str': 'Pre-Exposure Prophylaxis (PrEP)'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0458074', 'cui_str': 'HIV status'}, {'cui': 'C0036911', 'cui_str': 'Sexual partners'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C1527415', 'cui_str': 'Oral route'}]","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0036916', 'cui_str': 'Sexually transmitted infectious disease'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C3850098', 'cui_str': 'Pre-Exposure Prophylaxis (PrEP)'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019693', 'cui_str': 'Human immunodeficiency virus infection'}, {'cui': 'C0556628', 'cui_str': 'Anal penetration'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0036916', 'cui_str': 'Sexually transmitted infectious disease'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C4505265', 'cui_str': 'Therapeutic Adherence'}, {'cui': 'C0152057', 'cui_str': 'Compensation'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0556463', 'cui_str': 'Number of sexual partners'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039128', 'cui_str': 'Syphilis'}, {'cui': 'C0228492', 'cui_str': 'Structure of posterior semilunar lobule'}, {'cui': 'C0449572', 'cui_str': 'Virus type'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]",1000.0,0.118556,HIV self-testing (HIVST) decreases CAI among men who have sex with men (MSM) by providing awareness of the HIV status of oneself and one's sexual partners.,"[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Xiaojie', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.'}, {'ForeName': 'Yaokai', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': ""Department of Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, China.""}, {'ForeName': 'Yonghui', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Hongyi', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Zhu', 'Initials': 'Z', 'LastName': 'Mei', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Yueru', 'Initials': 'Y', 'LastName': 'Jia', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'ZhenXing', 'Initials': 'Z', 'LastName': 'Chu', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Qing-Hai', 'Initials': 'QH', 'LastName': 'Hu', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Xiaoqing', 'Initials': 'X', 'LastName': 'He', 'Affiliation': 'Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Lukun', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': ""Department of Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, China.""}, {'ForeName': 'Zhili', 'Initials': 'Z', 'LastName': 'Hu', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Rantong', 'Initials': 'R', 'LastName': 'Bao', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Shangcao', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Haibo', 'Initials': 'H', 'LastName': 'Ding', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Yongjun', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Wenqing', 'Initials': 'W', 'LastName': 'Geng', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'Weiming', 'Initials': 'W', 'LastName': 'Tang', 'Affiliation': 'University of North Carolina at Chapel Hill Project-China, Guangzhou, China.'}, {'ForeName': 'Junjie', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China xjjcmu@163.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2019-036231'] 2359,32690519,Person-centred care by a combined digital platform and structured telephone support for people with chronic obstructive pulmonary disease and/or chronic heart failure: study protocol for the PROTECT randomised controlled trial.,"BACKGROUND A core feature of chronic obstructive pulmonary disorder (COPD) and chronic heart failure (CHF) is that symptoms may change rapidly because of illness progression. Thus, these chronic conditions are associated with high rehospitalisation rates. Person-centred care (PCC) has been shown to have several benefits for patients with COPD or CHF (or both disorders) but it has not yet been investigated through e-health services. AIM The project aims to evaluate the effects of PCC by a combined digital platform and structured telephone support for people with COPD and/or CHF. METHODS AND ANALYSIS A randomised controlled trial with open, parallel groups which employs a participatory design process will be used. This project will also include process and health economic evaluation of the intervention. ETHICS AND DISSEMINATION Ethical approval has been secured from the Regional Ethical Review Board in Gothenburg, Sweden (Dnr 063-17 and T063-18). Results will be presented at conferences and to healthcare professionals, participants and patient organisations. Findings will also be submitted for publication in peer-reviewed journals. TRIAL REGISTRATION NUMBER NCT03183817.",2020,"Person-centred care (PCC) has been shown to have several benefits for patients with COPD or CHF (or both disorders) but it has not yet been investigated through e-health services. ","['patients with COPD or CHF (or both disorders', 'people with COPD and/or CHF', 'people with chronic obstructive pulmonary disease and/or chronic heart failure']","['Person-centred care (PCC', 'PCC', 'Person-centred care by a combined digital platform and structured telephone support']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0024115', 'cui_str': 'Disorder of lung'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0183683', 'cui_str': 'Support'}]",[],,0.307293,"Person-centred care (PCC) has been shown to have several benefits for patients with COPD or CHF (or both disorders) but it has not yet been investigated through e-health services. ","[{'ForeName': 'Lilas', 'Initials': 'L', 'LastName': 'Ali', 'Affiliation': 'Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden lilas.ali@gu.se.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Wallström', 'Affiliation': 'Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Emmelie', 'Initials': 'E', 'LastName': 'Barenfeld', 'Affiliation': 'Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Fors', 'Affiliation': 'Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Fredholm', 'Affiliation': 'Patient representative, The Swedish Heart & Lung Foundation, Stockholm, Sweden.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Gyllensten', 'Affiliation': 'Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Karl', 'Initials': 'K', 'LastName': 'Swedberg', 'Affiliation': 'Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Inger', 'Initials': 'I', 'LastName': 'Ekman', 'Affiliation': 'Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}]",BMJ open,['10.1136/bmjopen-2019-036356'] 2360,32690521,"Foot orthoses for people with rheumatoid arthritis, involving quantitative and qualitative outcomes: protocol for a randomised controlled trial.","INTRODUCTION Rheumatoid arthritis (RA) involves changes to foot structure and function, and there is an association between RA and foot pain. This pain affects those patient's physical activity and experience of daily living. While there is clinical evidence for the value of foot orthoses (FO) on foot pain, there is a wide range of FO available and there is little evidence on the relative benefits of one orthoses type over another, especially in terms of their impact on physical activity and associated well-being. The aim of this study is to compare physical activity, general and foot health and foot health experiences in people with RA when wearing three different types of FO. METHODS AND ANALYSIS A randomised controlled trial with three arms will compare the effects of (1) custom FO made using a direct adaptation technique, (2) custom FO made through a digital design and production process and (3) prefabricated orthoses. The primary outcome is physical activity measured using a GENEActiv bracelet. Secondary outcomes will be pain, function and disability and associated foot and general health evaluated using existing questionnaires. Semistructured interviews will identify patients' experiences of the orthoses and living with RA. ETHICS AND DISSEMINATION The study has been approved by the Portal de Ética de la Investigación Biomédica de Andalucía ethical committee (SPAR-001). The results will be disseminated regardless of the magnitude or direction of effect. TRIAL REGISTRATION NUMBER NCT03170947; Pre-results.",2020,"A randomised controlled trial with three arms will compare the effects of (1) custom FO made using a direct adaptation technique, (2) custom FO made through a digital design and production process and (3) prefabricated orthoses.","['people with RA', 'people with rheumatoid arthritis']","['custom FO made using a direct adaptation technique, (2) custom FO made through a digital design and production process and (3) prefabricated orthoses', 'Foot orthoses']","['pain, function and disability and associated foot and general health evaluated using existing questionnaires', 'physical activity', 'physical activity, general and foot health and foot health experiences']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}]","[{'cui': 'C0162343', 'cui_str': 'Customs'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C1522240', 'cui_str': 'Process'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]",3.0,0.232378,"A randomised controlled trial with three arms will compare the effects of (1) custom FO made using a direct adaptation technique, (2) custom FO made through a digital design and production process and (3) prefabricated orthoses.","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Ramos-Petersen', 'Affiliation': 'Podiatry, Universidad Catolica San Antonio de Murcia - Campus de los Jeronimos, Murcia, Spain.'}, {'ForeName': 'Christoper J', 'Initials': 'CJ', 'LastName': 'Nester', 'Affiliation': 'University of Salford Faculty of Health and Society, Salford, UK.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Gijon-Nogueron', 'Affiliation': 'Nursing and Podiatry, Universidad de Malaga Facultad de Ciencias de la Salud, Malaga, Andalucía, Spain gagijon@uma.es.'}, {'ForeName': 'Ana Belen', 'Initials': 'AB', 'LastName': 'Ortega-Avila', 'Affiliation': 'Nursing and Podiatry, Universidad de Malaga Facultad de Ciencias de la Salud, Malaga, Andalucía, Spain.'}]",BMJ open,['10.1136/bmjopen-2019-036433'] 2361,32690523,Study protocol for a 9-month randomised controlled trial assessing the effects of almonds versus carbohydrate-rich snack foods on weight loss and weight maintenance.,"INTRODUCTION Epidemiological studies indicate an inverse association between nut consumption and body mass index (BMI). However, clinical trials evaluating the effects of nut consumption compared with a nut-free diet on adiposity have reported mixed findings with some studies reporting greater weight loss and others reporting no weight change. This paper describes the rationale and detailed protocol for a randomised controlled trial assessing whether the inclusion of almonds or carbohydrate-rich snacks in an otherwise nut-free energy-restricted diet will promote weight loss during 3 months of energy restriction and limit weight regain during 6 months of weight maintenance. METHODS AND ANALYSIS One hundred and thirty-four adults aged 25-65 years with a BMI of 27.5-34.9 kg/m 2 will be recruited and randomly allocated to either the almond-enriched diet (AED) (15% energy from almonds) or a nut-free control diet (NFD) (15% energy from carbohydrate-rich snack foods). Study snack foods will be provided. Weight loss will be achieved through a 30% energy restriction over 3 months, and weight maintenance will be encouraged for 6 months by increasing overall energy intake by ~120-180 kcal/day (~500-750kJ/day) as required. Food will be self-selected, based on recommendations from the study dietitian. Body composition, resting energy expenditure, total daily energy expenditure (via doubly labelled water), physical activity, appetite regulation, cardiometabolic health, gut microbiome, liver health, inflammatory factors, eating behaviours, mood and personality, functional mobility and pain, quality of life and sleep patterns will be measured throughout the 9-month trial. The effects of intervention on the outcome measures over time will be analysed using random effects mixed models, with treatment (AED or NFD) and time (baseline, 3 months and 9 months) being the between and within factors, respectively in the analysis. ETHICS AND DISSEMINATION Ethics approval was obtained from the University of South Australia Human Research Ethics Committee (201436). Results from this trial will be disseminated through publication in peer-reviewed journals, national and international presentations. TRIAL REGISTRATION NUMBER Australian New Zealand Clinical Trials Registry (ACTRN12618001861246).",2020,"Body composition, resting energy expenditure, total daily energy expenditure (via doubly labelled water), physical activity, appetite regulation, cardiometabolic health, gut microbiome, liver health, inflammatory factors, eating behaviours, mood and personality, functional mobility and pain, quality of life and sleep patterns will be measured throughout the 9-month trial.",['One hundred and thirty-four adults aged 25-65 years with a BMI of 27.5-34.9\u2009kg/m 2'],"['almond-enriched diet (AED) (15% energy from almonds) or a nut-free control diet (NFD) (15% energy from carbohydrate-rich snack foods', 'carbohydrate-rich snacks', 'carbohydrate-rich snack foods']","['weight loss', 'weight loss and weight maintenance', 'Body composition, resting energy expenditure, total daily energy expenditure (via doubly labelled water), physical activity, appetite regulation, cardiometabolic health, gut microbiome, liver health, inflammatory factors, eating behaviours, mood and personality, functional mobility and pain, quality of life and sleep patterns', 'Weight loss']","[{'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517674', 'cui_str': '27.5'}]","[{'cui': 'C0440286', 'cui_str': 'Almond'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0028723', 'cui_str': 'Nut'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0743195', 'cui_str': 'Dietary control'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0453863', 'cui_str': 'Snack food'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0003622', 'cui_str': 'Appetite control'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0015745', 'cui_str': 'Eating Behavior'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0003944', 'cui_str': 'As If Personality'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0474396', 'cui_str': 'Sleep behavior finding'}]",134.0,0.152979,"Body composition, resting energy expenditure, total daily energy expenditure (via doubly labelled water), physical activity, appetite regulation, cardiometabolic health, gut microbiome, liver health, inflammatory factors, eating behaviours, mood and personality, functional mobility and pain, quality of life and sleep patterns will be measured throughout the 9-month trial.","[{'ForeName': 'Sharayah', 'Initials': 'S', 'LastName': 'Carter', 'Affiliation': 'Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Alison M', 'Initials': 'AM', 'LastName': 'Hill', 'Affiliation': 'Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Yandell', 'Affiliation': 'Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Buckley', 'Affiliation': 'Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Sze-Yen', 'Initials': 'SY', 'LastName': 'Tan', 'Affiliation': 'Institute for Physical Activity and Nutrition (IPAN), Deakin University, Burwood, Victoria, Australia.'}, {'ForeName': 'Geraint B', 'Initials': 'GB', 'LastName': 'Rogers', 'Affiliation': 'Microbiome Research, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia.'}, {'ForeName': 'Jessie', 'Initials': 'J', 'LastName': 'Childs', 'Affiliation': 'Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Matheson', 'Affiliation': 'Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Lamb', 'Affiliation': 'Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Ward', 'Affiliation': 'Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Tasha R', 'Initials': 'TR', 'LastName': 'Stanton', 'Affiliation': 'Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Fraysse', 'Affiliation': 'Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Andrew P', 'Initials': 'AP', 'LastName': 'Hills', 'Affiliation': 'School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Tasmania, Australia.'}, {'ForeName': 'Alison M', 'Initials': 'AM', 'LastName': 'Coates', 'Affiliation': 'Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia alison.coates@unisa.edu.au.'}]",BMJ open,['10.1136/bmjopen-2019-036542'] 2362,32690536,Study protocol for a randomised controlled trial evaluating the effects of the orexin receptor antagonist suvorexant on sleep architecture and delirium in the intensive care unit.,"INTRODUCTION Insomnia frequently occurs in patients admitted to an intensive care unit (ICU). Sleep-promoting agents may reduce rapid eye movement sleep and have deliriogenic effects. Suvorexant (Belsomra) is an orexin receptor antagonist with Food and Drug Administration (FDA) approval for the treatment of adult insomnia, which improves sleep onset and maintenance as well as subjective measures of quality of sleep. This trial will evaluate the efficacy of postoperative oral suvorexant treatment on night-time wakefulness after persistent sleep onset as well as the incidence and duration of delirium among adult cardiac surgical patients. METHODS AND ANALYSIS In this single-centre, randomised, double-blind, placebo-controlled trial, we will enrol 120 patients, aged 60 years or older, undergoing elective cardiac surgery with planned postoperative admission to the ICU. Participants will be randomised to receive oral suvorexant (20 mg) or placebo one time a day starting the night after extubation. The primary outcome will be wakefulness after persistent sleep onset. The secondary outcome will be total sleep time. Exploratory outcomes will include time to sleep onset, incidence of postoperative in-hospital delirium, number of delirium-free days and subjective sleep quality. ETHICS AND DISSEMINATION Ethics approval was obtained through the 'Committee on Clinical Investigations' at Beth Israel Deaconess Medical Center (protocol number 2019P000759). The findings will be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER This trial has been registered at clinicaltrials.gov on 17 September 2019 (NCT04092894).",2020,"This trial will evaluate the efficacy of postoperative oral suvorexant treatment on night-time wakefulness after persistent sleep onset as well as the incidence and duration of delirium among adult cardiac surgical patients. ","['adult cardiac surgical patients', '120 patients, aged 60 years or older, undergoing elective cardiac surgery with planned postoperative admission to the ICU', 'patients admitted to an intensive care unit (ICU']","['oral suvorexant', 'orexin receptor antagonist suvorexant', 'postoperative oral suvorexant treatment', 'placebo']","['total sleep time', 'wakefulness after persistent sleep onset', 'night-time wakefulness', 'sleep architecture and delirium', 'time to sleep onset, incidence of postoperative in-hospital delirium, number of delirium-free days and subjective sleep quality']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3179535', 'cui_str': 'suvorexant'}, {'cui': 'C4019081', 'cui_str': 'Orexin Receptor Blockers'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0043012', 'cui_str': 'Wakefulness'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0003737', 'cui_str': 'Architecture'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}]",,0.584136,"This trial will evaluate the efficacy of postoperative oral suvorexant treatment on night-time wakefulness after persistent sleep onset as well as the incidence and duration of delirium among adult cardiac surgical patients. ","[{'ForeName': 'Omid', 'Initials': 'O', 'LastName': 'Azimaraghi', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Maximilian', 'Initials': 'M', 'LastName': 'Hammer', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Santer', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Platzbecker', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Friederike C', 'Initials': 'FC', 'LastName': 'Althoff', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Patrocinio', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Stephanie D', 'Initials': 'SD', 'LastName': 'Grabitz', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Karuna', 'Initials': 'K', 'LastName': 'Wongtangman', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Rumyantsev', 'Affiliation': 'Pharmacy, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Xinling', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Maximilian S', 'Initials': 'MS', 'LastName': 'Schaefer', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Patrick M', 'Initials': 'PM', 'LastName': 'Fuller', 'Affiliation': 'Department of Neurology, Program in Neuroscience and Division of Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Balachundhar', 'Initials': 'B', 'LastName': 'Subramaniam', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Eikermann', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA meikerma@bidmc.harvard.edu.'}]",BMJ open,['10.1136/bmjopen-2020-038474'] 2363,32697104,RCT of a Comprehensive Outpatient Treatment for Children with Autism Spectrum Disorder.,"OBJECTIVE This study tested the efficacy of an intensive outpatient psychosocial treatment for children with autism spectrum disorder (ASD) without intellectual disability (ID). METHOD Eighty-eight children (ages 7-12 years) were randomly assigned to the treatment or control (waitlist) condition. The 18-week cognitive-behavioral treatment (two 90-min sessions per week) included small-group instruction and therapeutic activities targeting social/social-communication skills, face-emotion recognition, nonliteral language skills, and interest expansion. A behavioral system was used to increase skills development and reduce ASD symptoms. Efficacy was tested immediately following treatment (posttest), with maintenance assessed 4-6 weeks later (follow-up). Measures included parent ratings of the children's social/social-communication skills, ASD symptoms, broad social skills, and behavior symptoms, child tests of social-cognitive skills (emotion recognition and nonliteral language), and behavioral observations. RESULTS Significant effects favoring the treatment group were found at posttest on the primary measures of ASD symptoms (Social Responsiveness Scale, Second Edition; Constantino & Gruber, 2012) and social/social-communication skills (Adapted Skillstreaming Checklist; Lopata, Thomeer, Volker, Nida & Lee, 2008), and secondary measures of nonliteral language skills, broad social skills, and behavior symptoms (measures of emotion-recognition skills and social behaviors during structured game sessions were non-significant). The significant treatment effects found at posttest were all maintained at follow-up. CONCLUSIONS The outpatient treatment improved several core areas of functioning for children with ASD without ID. Additional elements may be needed to expand the efficacy of the treatment so that the observed skills/symptom improvements generalize to social interactions during gameplay.",2020,"RESULTS Significant effects favoring the treatment group were found at posttest on the primary measures of ASD symptoms (Social Responsiveness Scale, Second Edition; Constantino & Gruber, 2012) and social/social-communication skills (Adapted Skillstreaming Checklist; Lopata, Thomeer, Volker, Nida & Lee, 2008), and secondary measures of nonliteral language skills, broad social skills, and behavior symptoms (measures of emotion-recognition skills and social behaviors during structured game sessions were non-significant).","['Children with Autism Spectrum Disorder', 'children with autism spectrum disorder (ASD) without intellectual disability (ID', 'Eighty-eight children (ages 7-12\xa0years']","['RCT', 'intensive outpatient psychosocial treatment', '18-week cognitive-behavioral treatment (two 90-min sessions per week) included small-group instruction and therapeutic activities targeting social/social-communication skills, face-emotion recognition, nonliteral language skills, and interest expansion']","[""parent ratings of the children's social/social-communication skills, ASD symptoms, broad social skills, and behavior symptoms, child tests of social-cognitive skills (emotion recognition and nonliteral language), and behavioral observations"", 'ASD symptoms (Social Responsiveness Scale, Second Edition; Constantino & Gruber, 2012) and social/social-communication skills (Adapted Skillstreaming Checklist; Lopata, Thomeer, Volker, Nida & Lee, 2008), and secondary measures of nonliteral language skills, broad social skills, and behavior symptoms (measures of emotion-recognition skills and social behaviors', 'Efficacy', 'skills development and reduce ASD symptoms']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C3714756', 'cui_str': 'Intellectual disability'}, {'cui': 'C4517898', 'cui_str': '88'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0150375', 'cui_str': 'Group education'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0870313', 'cui_str': 'Communication skills'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0543488', 'cui_str': 'Interested'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0870313', 'cui_str': 'Communication skills'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0679005', 'cui_str': 'Social Abilities'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0558039', 'cui_str': 'Observation of behavior'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0441795', 'cui_str': 'Second edition'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0068218', 'cui_str': 'N-nitrosoiminodiacetic acid'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0037397', 'cui_str': 'Social behavior'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",88.0,0.0134071,"RESULTS Significant effects favoring the treatment group were found at posttest on the primary measures of ASD symptoms (Social Responsiveness Scale, Second Edition; Constantino & Gruber, 2012) and social/social-communication skills (Adapted Skillstreaming Checklist; Lopata, Thomeer, Volker, Nida & Lee, 2008), and secondary measures of nonliteral language skills, broad social skills, and behavior symptoms (measures of emotion-recognition skills and social behaviors during structured game sessions were non-significant).","[{'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Lopata', 'Affiliation': 'Institute for Autism Research, Canisius College.'}, {'ForeName': 'Marcus L', 'Initials': 'ML', 'LastName': 'Thomeer', 'Affiliation': 'Institute for Autism Research, Canisius College.'}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Rodgers', 'Affiliation': 'Institute for Autism Research, Canisius College.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Donnelly', 'Affiliation': 'Institute for Autism Research, Canisius College.'}, {'ForeName': 'Adam J', 'Initials': 'AJ', 'LastName': 'Booth', 'Affiliation': 'Institute for Autism Research, Canisius College.'}]","Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53",['10.1080/15374416.2020.1790380'] 2364,32697145,Re: Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 mL): 6-Month Results from the WATER II Trial.,,2020,,['Benign Prostatic Hyperplasia in Large Prostates (80-150 mL'],[],[],"[{'cui': 'C0005001', 'cui_str': 'Hypertrophy, Benign Prostatic'}, {'cui': 'C0426732', 'cui_str': 'Large prostate'}, {'cui': 'C4321486', 'cui_str': '150'}]",[],[],,0.0279485,,"[{'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Kaplan', 'Affiliation': ''}]",The Journal of urology,['10.1097/JU.0000000000001205'] 2365,32697197,Mechanisms of action of a web-based intervention with health professional support to increase nebulizer adherence in adults with Cystic Fibrosis: a qualitative interview study.,"BACKGROUND Adherence to nebulizer treatments in adults with cystic fibrosis is often low. A new complex intervention to help adults with cystic fibrosis increase adherence to nebulizer treatments was tested in a pilot randomized controlled trial in two UK cystic fibrosis centers. Patients used a nebulizer with electronic monitoring capabilities that transferred data automatically to a digital platform (CFHealthHub) to monitor adherence over time, and a tailored website to display graphs of adherence data and educational and problem solving information about adherence. A trained interventionist helped patients to identify ways to increase their adherence. OBJECTIVE To explore the mechanisms of action of this complex intervention. METHODS A qualitative interview study undertaken concurrently with a pilot randomized controlled trial. 25 semi-structured interviews were conducted with three interventionists at two time points, 14 patients in the intervention arm of the trial, and five members of the multidisciplinary teams offering wider care to patients. A framework approach was used for analysis. RESULTS The intervention was informed by a theoretical framework of behavior change. There was evidence of the expected behavior change mechanisms of action. There was also evidence of Vassilev's mechanisms of action associated with effective telehealth interventions for self-management support: relationships, visibility, and fit. Patients described how building a relationship with the interventionist through face-to-face visits with someone who cared about them and their progress helped them to consider ways of increasing adherence to medication. Rather than seeing the visibility of adherence data to clinicians as problematic, patients found this motivating, particularly if they received praise about progress made. The intervention was tailored to individuals but there were challenges in how the intervention fitted into some patients' busy lives when delivered through a desktop computer. CONCLUSIONS Mechanisms associated with effective telehealth interventions for self-management operated within this new intervention. The intervention was modified to strengthen mechanisms of action based on these findings, for example delivery through an app accessed via mobile phones, and then tested in a randomized controlled trial in 19 UK cystic fibrosis centers. CLINICALTRIAL Registration: ISRCTN 13076797.",2020,"There was also evidence of Vassilev's mechanisms of action associated with effective telehealth interventions for self-management support: relationships, visibility, and fit.","['adults with cystic fibrosis', '25 semi-structured interviews', '19 UK cystic fibrosis centers', 'two UK cystic fibrosis centers', 'adults with Cystic Fibrosis']","['complex intervention', 'health professional support']",['nebulizer adherence'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0010674', 'cui_str': 'Cystic fibrosis'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0183683', 'cui_str': 'Support'}]","[{'cui': 'C0027524', 'cui_str': 'Nebulizer'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",2.0,0.0567727,"There was also evidence of Vassilev's mechanisms of action associated with effective telehealth interventions for self-management support: relationships, visibility, and fit.","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Drabble', 'Affiliation': 'School of Health and Related Research, University of Sheffield, ScHARR, University of SheffieldRegent Court, 30 Regent St, Sheffield, GB.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': ""O'Cathain"", 'Affiliation': 'School of Health and Related Research, University of Sheffield, ScHARR, University of SheffieldRegent Court, 30 Regent St, Sheffield, GB.'}, {'ForeName': 'Alexander J', 'Initials': 'AJ', 'LastName': 'Scott', 'Affiliation': 'School of Health and Related Research, University of Sheffield, ScHARR, University of SheffieldRegent Court, 30 Regent St, Sheffield, GB.'}, {'ForeName': 'Madelynne A', 'Initials': 'MA', 'LastName': 'Arden', 'Affiliation': 'Centre for Behavioural Science and Applied Psychology, Sheffield Hallam University, Sheffield, GB.'}, {'ForeName': 'Samuel M', 'Initials': 'SM', 'LastName': 'Keating', 'Affiliation': 'School of Health and Related Research, University of Sheffield, ScHARR, University of SheffieldRegent Court, 30 Regent St, Sheffield, GB.'}, {'ForeName': 'Marlene', 'Initials': 'M', 'LastName': 'Hutchings', 'Affiliation': 'Sheffield Adult CF Centre, Sheffield Teaching Hospitals, Sheffield, GB.'}, {'ForeName': 'Chin', 'Initials': 'C', 'LastName': 'Maguire', 'Affiliation': 'School of Health and Related Research, University of Sheffield, ScHARR, University of SheffieldRegent Court, 30 Regent St, Sheffield, GB.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Wildman', 'Affiliation': 'Sheffield Adult CF Centre, Sheffield Teaching Hospitals, Sheffield, GB.'}]",Journal of medical Internet research,['10.2196/16782'] 2366,32697288,Dialectical Behavior Therapy for Posttraumatic Stress Disorder (DBT-PTSD) Compared With Cognitive Processing Therapy (CPT) in Complex Presentations of PTSD in Women Survivors of Childhood Abuse: A Randomized Clinical Trial.,"Importance Childhood abuse significantly increases the risk of developing posttraumatic stress disorder (PTSD), often accompanied by symptoms of borderline personality disorder (BPD) and other co-occurring mental disorders. Despite the high prevalence, systematic evaluations of evidence-based treatments for PTSD after childhood abuse are sparse. Objective To compare the efficacy of dialectical behavior therapy for PTSD (DBT-PTSD), a new, specifically designed, phase-based treatment program, against that of cognitive processing therapy (CPT), one of the best empirically supported treatments for PTSD. Design, Setting, and Participants From January 2014 to October 2016, women who sought treatment were included in a multicenter randomized clinical trial with blinded outcome assessments at 3 German university outpatient clinics. The participants were prospectively observed for 15 months. Women with childhood abuse-associated PTSD who additionally met 3 or more DSM-5 criteria for BPD, including affective instability, were included. Data analysis took place from October 2018 to December 2019. Interventions Participants received equal dosages and frequencies of DBT-PTSD or CPT, up to 45 individual sessions within 1 year and 3 additional sessions during the following 3 months. Main Outcomes and Measures The predefined primary outcome was the course of the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score from randomization to month 15. Intent-to-treat analyses based on dimensional CAPS-5 scores were complemented by categorical outcome measures assessing symptomatic remission, reliable improvement, and reliable recovery. Results Of 955 consecutive individuals assessed for eligibility, 193 were randomized (DBT-PTSD, 98; CPT, 95; mean [SD] age, 36.3 [11.1] years) and included in the intent-to-treat analyses. Analysis revealed significantly improved CAPS-5 scores in both groups (effect sizes: DBT-PTSD: d, 1.35; CPT: d, 0.98) and a small but statistically significant superiority of DBT-PTSD (group difference: 4.82 [95% CI, 0.67-8.96]; P = .02; d, 0.33). Compared with the CPT group, participants in the DBT-PTSD group were less likely to drop out early (37 [39.0%] vs 25 [25.5%]; P = .046) and had higher rates of symptomatic remission (35 [40.7%] vs 52 [58.4%]; P = .02), reliable improvement (53 [55.8%] vs 73 [74.5%]; P = .006), and reliable recovery (34 [38.6%] vs 52 [57.1%]; P = .01). Conclusions and Relevance These findings support the efficacy of DBT-PTSD and CPT in the treatment of women with childhood abuse-associated complex PTSD. Results pertaining to the primary outcomes favored DBT-PTSD. The study shows that even severe childhood abuse-associated PTSD with emotion dysregulation can be treated efficaciously. Trial Registration German Clinical Trials Register: DRKS00005578.",2020,"Analysis revealed significantly improved CAPS-5 scores in both groups (effect sizes: DBT-PTSD: d, 1.35; CPT: d, 0.98) and a small but statistically significant superiority of DBT-PTSD (group difference: 4.82 [95% CI, 0.67-8.96]; P = .02; d, 0.33).","['women with childhood abuse-associated complex PTSD', 'Posttraumatic Stress Disorder (DBT-PTSD', 'From January 2014 to October 2016, women who sought treatment were included in a multicenter randomized clinical trial with blinded outcome assessments at 3 German university outpatient clinics', '955 consecutive individuals assessed for eligibility, 193 were randomized (DBT-PTSD, 98', 'Women Survivors of Childhood Abuse', 'Women with childhood abuse-associated PTSD who additionally met 3 or more DSM-5 criteria for BPD, including affective instability, were included']","['DBT-PTSD and CPT', 'CPT', 'Dialectical Behavior Therapy', 'DBT-PTSD or CPT', 'cognitive processing therapy (CPT', 'dialectical behavior therapy', 'Cognitive Processing Therapy (CPT']","['CAPS-5 scores', 'DBT-PTSD', 'symptomatic remission, reliable improvement, and reliable recovery', 'rates of symptomatic remission', 'course of the Clinician-Administered PTSD Scale for DSM-5', 'dimensional CAPS-5 scores', 'reliable recovery']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0562381', 'cui_str': 'Victim of abuse'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C2733207', 'cui_str': 'Complex posttraumatic stress disorder'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C3472347', 'cui_str': 'Digital breast tomosynthesis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0085565', 'cui_str': 'Outcome Assessment (Health Care)'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0006012', 'cui_str': 'Borderline personality disorder'}, {'cui': 'C0085633', 'cui_str': 'Mood swings'}]","[{'cui': 'C3472347', 'cui_str': 'Digital breast tomosynthesis'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1321145', 'cui_str': 'Dialectical behavior therapy'}]","[{'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3472347', 'cui_str': 'Digital breast tomosynthesis'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0750729', 'cui_str': 'Courses'}]",193.0,0.0786922,"Analysis revealed significantly improved CAPS-5 scores in both groups (effect sizes: DBT-PTSD: d, 1.35; CPT: d, 0.98) and a small but statistically significant superiority of DBT-PTSD (group difference: 4.82 [95% CI, 0.67-8.96]; P = .02; d, 0.33).","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Bohus', 'Affiliation': 'Institute of Psychiatric and Psychosomatic Psychotherapy, Central Institute of Mental Health Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Nikolaus', 'Initials': 'N', 'LastName': 'Kleindienst', 'Affiliation': 'Institute of Psychiatric and Psychosomatic Psychotherapy, Central Institute of Mental Health Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Hahn', 'Affiliation': 'Institute of Psychiatric and Psychosomatic Psychotherapy, Central Institute of Mental Health Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Meike', 'Initials': 'M', 'LastName': 'Müller-Engelmann', 'Affiliation': 'Institute of Psychology, Goethe University Frankfurt am Main, Frankfurt, Germany.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Ludäscher', 'Affiliation': 'Institute of Psychiatric and Psychosomatic Psychotherapy, Central Institute of Mental Health Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Regina', 'Initials': 'R', 'LastName': 'Steil', 'Affiliation': 'Institute of Psychology, Goethe University Frankfurt am Main, Frankfurt, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Fydrich', 'Affiliation': 'Department of Psychology, Faculty of Life Sciences, Humboldt University, Berlin, Germany.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Kuehner', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Central Institute of Mental Health Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Resick', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Stiglmayr', 'Affiliation': 'AWP Berlin, Berlin, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Schmahl', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Central Institute of Mental Health Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Kathlen', 'Initials': 'K', 'LastName': 'Priebe', 'Affiliation': 'Institute of Psychiatric and Psychosomatic Psychotherapy, Central Institute of Mental Health Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}]",JAMA psychiatry,['10.1001/jamapsychiatry.2020.2148'] 2367,32697335,A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.,"BACKGROUND In a randomized study, glasdegib (a hedgehog inhibitor) plus low-dose cytarabine (LDAC) significantly prolonged survival in comparison with LDAC in patients with acute myeloid leukemia (AML). A quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) approach was used to evaluate comparative quality-adjusted survival. METHODS Overall survival was partitioned into the following: time with any treatment-emergent grade 3 or higher adverse events (TOX); time without symptoms of disease progression or toxicity (TWiST); and time after treatment discontinuation due to insufficient clinical response, relapse, or death time after progression (REL). Q-TWiST was calculated by multiplying the restricted mean time in each state by respective utilities and then summing up the utility-adjusted time. RESULTS At 20 months of follow-up, the survival probabilities for the glasdegib-LDAC arm and the LDAC arm were 28.2% and 7.9%, respectively. Glasdegib-LDAC patients (n = 78), in comparison with LDAC patients (n = 38), had significantly longer mean TWiST (+3.4 months; 95% confidence interval [CI], 1.8-5.2 months) and TOX (+0.8 months; 95% CI, 0.1-1.6 months) and longer but nonsignificant REL (+0.3 months; 95% CI, -1.9 to 2.3 months). Q-TWiST was 4.0 months (95% CI, 2.1-5.8 months) longer with glasdegib plus LDAC, and this translated into a 75% relative improvement in quality-adjusted survival with respect to LDAC. Results were robust to the length of follow-up (6-24 months) and remained significant when all adverse events, regardless of grade, were included. CONCLUSIONS These results suggest that most of the survival benefit from glasdegib plus LDAC versus LDAC alone is TWiST, and this represents added time in relatively ""good"" health. These results support the clinical value of glasdegib plus LDAC as initial therapy for AML in patients for whom intensive chemotherapy is not an option.",2020,"Results were robust to the length of follow-up (6-24 months) and remained significant when all adverse events, regardless of grade, were included. ","['acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy', 'patients with acute myeloid leukemia (AML']","['cytarabine', 'glasdegib (a hedgehog inhibitor) plus low-dose cytarabine (LDAC', 'LDAC', 'glasdegib plus low-dose cytarabine']","['comparative quality-adjusted survival', 'survival probabilities', 'adverse events (TOX); time without symptoms of disease progression or toxicity (TWiST); and time after treatment discontinuation due to insufficient clinical response, relapse, or death time after progression (REL', 'TOX', 'quality-adjusted survival', 'longer mean TWiST']","[{'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0010711', 'cui_str': 'Cytarabine'}, {'cui': 'C4519273', 'cui_str': 'glasdegib'}, {'cui': 'C0018866', 'cui_str': 'Erinaceidae'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C1301931', 'cui_str': 'Time of death'}, {'cui': 'C0040541', 'cui_str': 'Toxicology'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.107607,"Results were robust to the length of follow-up (6-24 months) and remained significant when all adverse events, regardless of grade, were included. ","[{'ForeName': 'Caitlyn T', 'Initials': 'CT', 'LastName': 'Solem', 'Affiliation': 'Pharmerit - an OPEN Health Company, Bethesda.'}, {'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'Bell', 'Affiliation': 'Pfizer, Inc, New York, New York.'}, {'ForeName': 'Youngmin', 'Initials': 'Y', 'LastName': 'Kwon', 'Affiliation': 'Pharmerit - an OPEN Health Company, Bethesda.'}, {'ForeName': 'Joseph C', 'Initials': 'JC', 'LastName': 'Cappelleri', 'Affiliation': 'Pfizer, Inc, New York, New York.'}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Johnson', 'Affiliation': 'Pharmerit - an OPEN Health Company, Bethesda.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Bhattacharyya', 'Affiliation': 'Pfizer, Inc, New York, New York.'}, {'ForeName': 'Caroline J', 'Initials': 'CJ', 'LastName': 'Hoang', 'Affiliation': 'Pfizer, Inc, New York, New York.'}, {'ForeName': 'Jorge E', 'Initials': 'JE', 'LastName': 'Cortes', 'Affiliation': 'Pharmerit - an OPEN Health Company, Bethesda.'}]",Cancer,['10.1002/cncr.33072'] 2368,32697444,"Human Amniotic Membrane to treat macular holes that failed to close, Sulfur Hexafluoride endotamponade versus air endotamponade: a prospective comparative study.","PURPOSE To determinate the efficacy of the human amniotic membrane plugs with sulfur hexafluoride versus human amniotic membrane plug with air as endotamponade to treat macular holes that failed to close after vitrectomy plus internal limiting membrane peeling. We focused on multimodal imaging to evaluate pre-operative features and post-operative changes. MATERIALS AND METHODS Prospective interventional comparative study. Twenty eyes of 20 patients affected by macular hole that failed to close were divided into 2 groups: 10 eyes received an amniotic membrane plug with 20% sulfur hexafluoride tamponade and 10 eyes received an amniotic membrane plug with air tamponade. All eyes were studied using multimodal advanced diagnostic tools such as spectral domain optical coherence tomography, optical coherence tomography angiography, microperimetry and adaptive optics to investigate the post-operative results. RESULTS In both groups all macular holes were found successfully closed after 12-months. Mean pre-operative BCVA was 20/400 in the SF6-group and 20/250 in Air-group. Final mean BCVA was 20/63 in both groups. The superficial capillary plexus, studied using optical coherence tomography angiography, showed a statistically significant difference between the treated and the fellow eyes. Adaptive Optics images revealed the presence of a photoreceptor cell mosaic in the area of the amniotic membrane plug. CONCLUSION The human amniotic membrane combined with air endotamponade demonstrated its effectiveness to seal macular holes that failed to close after vitrectomy plus internal limiting membrane peeling. Advanced multimodal diagnostic imaging helped us to better understand the modifications associated with the use of the amniotic membrane in these cases.",2020,"The superficial capillary plexus, studied using optical coherence tomography angiography, showed a statistically significant difference between the treated and the fellow eyes.",['Twenty eyes of 20 patients affected by macular hole that failed to close were divided into 2 groups: 10 eyes received an'],"['amniotic membrane plug with 20% sulfur hexafluoride tamponade and 10 eyes received an amniotic membrane plug with air tamponade', 'sulfur hexafluoride versus human amniotic membrane plug with air as endotamponade', 'Sulfur Hexafluoride endotamponade versus air endotamponade']","['Mean pre-operative BCVA', 'Final mean BCVA']","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0522476', 'cui_str': 'Patient affected'}, {'cui': 'C0024441', 'cui_str': 'Macular hole'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0002630', 'cui_str': 'Structure of amnion'}, {'cui': 'C0182324', 'cui_str': 'Plug'}, {'cui': 'C0038779', 'cui_str': 'Sulfur Hexafluoride'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C2936394', 'cui_str': 'Endotamponade'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}]",20.0,0.0285286,"The superficial capillary plexus, studied using optical coherence tomography angiography, showed a statistically significant difference between the treated and the fellow eyes.","[{'ForeName': 'Tomaso', 'Initials': 'T', 'LastName': 'Caporossi', 'Affiliation': ""1Department of NEUROFARBA, Ophthalmology, University of Florence, Careggi, Florence, Italy 2Department of Ophthalmology, Catholic University of Sacred Hearth-Foundation 'Policlinico Universitario A. Gemelli'-IRCCS, Rome, Italy.""}, {'ForeName': 'Ruggero', 'Initials': 'R', 'LastName': 'Tartaro', 'Affiliation': ''}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Finocchio', 'Affiliation': ''}, {'ForeName': 'Bianca', 'Initials': 'B', 'LastName': 'Pacini', 'Affiliation': ''}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'De Angelis', 'Affiliation': ''}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Bacherini', 'Affiliation': ''}, {'ForeName': 'Stanislao', 'Initials': 'S', 'LastName': 'Rizzo', 'Affiliation': ''}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000002913'] 2369,32105001,Impacts of phototherapy on DNA damage and total oxidant/ antioxidant status in jaundiced newborns.,"Bulut Ö, Dürüyen S. Impacts of phototherapy on DNA damage and total oxidant/antioxidant status in jaundiced newborns. Turk J Pediatr 2019; 61: 697-703. Jaundice is common in newborn babies, and pathologic hyperbilirubinemia is frequently treated with phototherapy. Although it is considered to be safe, the side effects of phototherapy in newborns are still a matter of debate. In this study, the impacts of two types of phototherapy, conventional fluorescence and intensive light-emitting diodes (LED), on DNA damage and total oxidant/ antioxidant status in jaundiced newborns were assessed. The study group included 40 newborns (gestation age ≥ 37 weeks) on days 2-8 after birth. Newborns were divided into two groups on the basis of need for phototherapy: 20 newborns were exposed to conventional phototherapy (Group I); and 20 infants were exposed to intensive phototherapy (Group II). Blood samples were taken from all infants at admission and after phototherapy to determine plasma 8-hydroxy-2-deoxy-guanosine (8-OH-dG; a marker of DNA damage), total oxidant status (TOS), and total antioxidant capacity (TAC). The oxidative stress index (OSI) was also calculated. Demographic information was recorded, and DNA damage, TOS, and TAC were compared. There were no differences in demographic information between the two groups. There were no significant differences in DNA damage, TOS, TAC, and OSI between Groups I and II before phototherapy (p > 0.05) and no significant differences in DNA damage, TOS, TAC, and OSI between the two groups after phototherapy (p > 0.05). However, the TAC decreased significantly in both groups after phototherapy (p < 0.01). These findings suggest that conventional and intensive phototherapies do not affect DNA damage and oxidative stress, supporting the safety of its use as the preferred treatment for jaundiced newborns.",2019,"There were no significant differences in DNA damage, TOS, TAC, and OSI between Groups I and II before phototherapy (p > 0.05) and no significant differences in DNA damage, TOS, TAC, and OSI between the two groups after phototherapy (p > 0.05).","['Newborns', '40 newborns (gestation age ≥ 37 weeks) on days 2-8 after birth', 'jaundiced newborns']","['phototherapy, conventional fluorescence and intensive light-emitting diodes (LED', 'phototherapy', 'conventional phototherapy', 'intensive phototherapy']","['DNA damage and total oxidant/antioxidant status', 'DNA damage, TOS, TAC, and OSI', 'DNA damage and total oxidant/ antioxidant status', 'total oxidant status (TOS), and total antioxidant capacity (TAC', 'demographic information', 'oxidative stress index (OSI', 'DNA damage and oxidative stress', 'DNA damage, TOS, and TAC', 'TAC']","[{'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005615', 'cui_str': 'Birth'}]","[{'cui': 'C0031765', 'cui_str': 'Light therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0016315', 'cui_str': 'Fluorescence'}, {'cui': 'C0023693', 'cui_str': 'Light'}]","[{'cui': 'C0012860', 'cui_str': 'DNA damage'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0085403', 'cui_str': 'Oxidizing Agents'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}]",20.0,0.0312448,"There were no significant differences in DNA damage, TOS, TAC, and OSI between Groups I and II before phototherapy (p > 0.05) and no significant differences in DNA damage, TOS, TAC, and OSI between the two groups after phototherapy (p > 0.05).","[{'ForeName': 'Özgül', 'Initials': 'Ö', 'LastName': 'Bulut', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, İstanbul Medeniyet University Göztepe Training and Research Hospital, İstanbul, Turkey.'}, {'ForeName': 'Saadettin', 'Initials': 'S', 'LastName': 'Dürüyen', 'Affiliation': 'Department of Biochemistry, İstanbul Medeniyet University Göztepe Training and Research Hospital, İstanbul, Turkey.'}]",The Turkish journal of pediatrics,['10.24953/turkjped.2019.05.008'] 2370,30537550,"Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.","The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly haploidentical (haplo)-HSCT, in pediatric patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in the tyrosine kinase inhibitor (TKI) era is unclear. This study aimed to identify prognostic factors and explore the role of haplo-HSCT in the treatment of Ph+ ALL in the TKI era. We analyzed clinical data of Ph+ ALL patients aged 1 to 18 years who received imatinib added to intensive chemotherapy at the start of induction therapy. Among the 68 patients who completed at least 2 consolidation cycles, 44 underwent transplantation (transplant arm) and 24 received continuous TKI with chemotherapy (nontransplant arm). At the 3-year follow-up the cumulative incidence of relapse (CIR), event-free survival (EFS), and overall survival (OS) were 23.5%, 73.4%, and 80.3%, respectively. Multivariate analysis showed that hematologic response (whether complete remission [CR] was achieved) at the induction end, BCR-ABL levels (whether major molecular response [MMR] was achieved) at 3 months, and transplantation were independent affecting factors for CIR, EFS, and OS. In the risk stratification analysis based on the first 2 prognostic factors mentioned above, no significant difference existed between the transplant and nontransplant arms for the probabilities of 3-year OS, EFS, and CIR in the standard-risk group (no poor prognostic factors). Meanwhile, OS, EFS, and CIR rates were significantly better in the transplant arm in the high-risk group (≥1 poor prognostic factor). Among the 44 patients in the transplant arm, 37 underwent haplo-HSCT. Achieving CR at the induction end, MMR at 3 months, and haplo-transplant were also independent favorable factors of CIR, EFS, and OS in the nontransplant and haplo-HSCT arms. Haplo-HSCT showed a significant survival advantage in the high-risk group only. Hematologic response at the induction end and BCR-ABL levels at 3 months are likely to be useful for identifying pediatric Ph+ ALL patients at a high risk of relapse in the TKI era. Children with Ph+ ALL in first CR may benefit from allo-HSCT, particularly those at high risk. Haplo-HSCT could achieve good long-term survival for pediatric Ph+ ALL. Thus, haplo-HSCT can be an alternative approach for high-risk Ph+ ALL patients.",2019,"Meanwhile, OS, EFS, and CIR rates were significantly better in the transplant arm in the high-risk group (≥1 poor prognostic factor).","['pediatric patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in the tyrosine kinase inhibitor', '68 patients who completed at least 2 consolidation cycles, 44 underwent transplantation (transplant arm) and 24 received continuous TKI with chemotherapy (nontransplant arm', 'Ph+ ALL patients aged 1 to 18 years who received imatinib added to intensive chemotherapy at the start of induction therapy', 'High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era', '44 patients in the transplant arm, 37 underwent haplo-HSCT']","['Haplo-HSCT', 'allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly haploidentical (haplo)-HSCT', 'Allogeneic Hematopoietic Stem Cell Transplantation', 'haplo-HSCT']","['cumulative incidence of relapse (CIR), event-free survival (EFS), and overall survival (OS', 'CIR, EFS, and OS', 'survival advantage', 'Meanwhile, OS, EFS, and CIR rates', 'probabilities of 3-year OS, EFS, and CIR', 'BCR-ABL levels', 'hematologic response', 'Hematologic response']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0856536', 'cui_str': 'Philadelphia chromosome positive'}, {'cui': 'C0450407', 'cui_str': 'ph+'}, {'cui': 'C0023449', 'cui_str': 'Acute lymphoid leukemia'}, {'cui': 'C1268567', 'cui_str': 'Protein-tyrosine kinase inhibitor'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0521530', 'cui_str': 'Lung consolidation'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1709527', 'cui_str': 'Philadelphia chromosome-positive acute lymphoblastic leukemia'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0935989', 'cui_str': 'imatinib'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C1521863', 'cui_str': 'estrogen receptor alpha, human'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}]","[{'cui': 'C0018591', 'cui_str': 'Haplotypes'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0105421', 'cui_str': 'BCR protein, human'}, {'cui': 'C0000744', 'cui_str': 'Abetalipoproteinemia'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0018943', 'cui_str': 'Hematology'}]",68.0,0.0411342,"Meanwhile, OS, EFS, and CIR rates were significantly better in the transplant arm in the high-risk group (≥1 poor prognostic factor).","[{'ForeName': 'Yu-Juan', 'Initials': 'YJ', 'LastName': 'Xue', 'Affiliation': ""Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing, China.""}, {'ForeName': 'Yi-Fei', 'Initials': 'YF', 'LastName': 'Cheng', 'Affiliation': ""Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China.""}, {'ForeName': 'Ai-Dong', 'Initials': 'AD', 'LastName': 'Lu', 'Affiliation': ""Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing, China.""}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China.""}, {'ForeName': 'Ying-Xi', 'Initials': 'YX', 'LastName': 'Zuo', 'Affiliation': ""Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing, China.""}, {'ForeName': 'Chen-Hua', 'Initials': 'CH', 'LastName': 'Yan', 'Affiliation': ""Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': ""Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing, China.""}, {'ForeName': 'Yu-Qian', 'Initials': 'YQ', 'LastName': 'Sun', 'Affiliation': ""Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China.""}, {'ForeName': 'Pan', 'Initials': 'P', 'LastName': 'Suo', 'Affiliation': ""Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China.""}, {'ForeName': 'Yu-Hong', 'Initials': 'YH', 'LastName': 'Chen', 'Affiliation': ""Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China.""}, {'ForeName': 'Huan', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': ""Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China.""}, {'ForeName': 'Yue-Ping', 'Initials': 'YP', 'LastName': 'Jia', 'Affiliation': ""Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing, China.""}, {'ForeName': 'Kai-Yan', 'Initials': 'KY', 'LastName': 'Liu', 'Affiliation': ""Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Han', 'Affiliation': ""Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China.""}, {'ForeName': 'Lan-Ping', 'Initials': 'LP', 'LastName': 'Xu', 'Affiliation': ""Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China.""}, {'ForeName': 'Le-Ping', 'Initials': 'LP', 'LastName': 'Zhang', 'Affiliation': ""Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing, China. Electronic address: zhangleping@pkuph.edu.cn.""}, {'ForeName': 'Xiao-Jun', 'Initials': 'XJ', 'LastName': 'Huang', 'Affiliation': ""Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China. Electronic address: xjhrm@medmail.com.cn.""}]",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,['10.1016/j.bbmt.2018.12.007'] 2371,32695974,Residual SYNTAX Score and One-Year Outcome in Elderly Patients With Acute Coronary Syndrome.,"Background The residual burden of coronary artery disease after percutaneous coronary intervention (PCI) has been associated with worse ischemic outcome. However, data are conflicting in elderly patients. The aim of our study was to verify the incremental value of the residual Syn ergy Between Percutaneous Coronary Intervention With Tax us and Cardiac Surgery (SYNTAX) score (rSS) over clinical variables and baseline SYNTAX score (bSS) in predicting 1-year mortality or cardiovascular events. Methods A post hoc analysis of data collected in the Elderly-ACS 2 multicenter randomized trial was performed. We included 630 patients aged > 75 years with multivessel coronary disease undergoing PCI for acute coronary syndrome (ACS). The primary outcome was a composite of death, recurrent myocardial infarction, and stroke at 1-year follow up. Change in c-statistic and standardized net benefit were used to evaluate the incremental value of the rSS. Results Event rates were significantly higher in patients with incomplete revascularization (rSS > 8). When the rSS was included in a core Cox regression model containing age, previous myocardial infarction, and ACS type, the hazard ratio for patients with score values > 8 was 2.47 (95% confidence interval, 1.51-4.06). However, the core model with rSS did not increase the c-statistic compared with the core model with the bSS (from 0.69 to 0.70) and gave little incremental value in the standardized net benefit. Conclusions In elderly patients with ACS with multivessel disease undergoing PCI, incomplete revascularization was associated with worse outcome at 1-year follow-up. However, there was no clear incremental value of the rSS in the prediction of 1-year adverse outcome compared with a model including clinical variables and bSS.",2020,"Results Event rates were significantly higher in patients with incomplete revascularization (rSS > 8).","['630 patients aged > 75 years with multivessel coronary disease undergoing PCI for acute coronary syndrome (ACS', 'elderly patients with ACS with multivessel disease undergoing PCI, incomplete revascularization', 'Elderly Patients With Acute Coronary Syndrome', 'elderly patients']","['percutaneous coronary intervention (PCI', 'Percutaneous Coronary Intervention With', 'Cardiac Surgery']","['residual burden of coronary artery disease', 'SYNTAX) score (rSS) over clinical variables and baseline SYNTAX score (bSS', 'c-statistic', '1-year mortality or cardiovascular events', 'composite of death, recurrent myocardial infarction, and stroke at 1-year follow up']","[{'cui': 'C4708165', 'cui_str': '630'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0010068', 'cui_str': 'Coronary Heart Disease'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}]","[{'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}]","[{'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005129', 'cui_str': 'Bernard Soulier syndrome'}, {'cui': 'C0600673', 'cui_str': 'Statistics'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]",630.0,0.107541,"Results Event rates were significantly higher in patients with incomplete revascularization (rSS > 8).","[{'ForeName': 'Nuccia', 'Initials': 'N', 'LastName': 'Morici', 'Affiliation': 'Unità di Cure Intensive Cardiologiche and De Gasperis Cardio-Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.'}, {'ForeName': 'Gianfranco', 'Initials': 'G', 'LastName': 'Alicandro', 'Affiliation': 'Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy.'}, {'ForeName': 'Luca A', 'Initials': 'LA', 'LastName': 'Ferri', 'Affiliation': 'Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Piatti', 'Affiliation': 'Division of Cardiology, Ospedale Manzoni, Lecco, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Grosseto', 'Affiliation': 'Division of Cardiology, Ospedale Infermi, Rimini, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Sganzerla', 'Affiliation': 'Division of Cardiology, ASST Bergamo ovest-ospedale di Treviglio, Treviglio, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Tortorella', 'Affiliation': 'Division of Cardiology, IRCCS Arcispedale S. Maria Nuova, Reggio Emilia, Italy.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Ferrario', 'Affiliation': 'Division of Cardiology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Crimi', 'Affiliation': 'Interventional Cardiology Unit, Cardio Thoraco Vascular Department (DICATOV), IRCCS Policlinico San Martino, Genova, Italy.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Bossi', 'Affiliation': 'Interventional Cardiology Division and De Gasperis Cardio-Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Tondi', 'Affiliation': 'Division of Cardiology, Ospedale Baggiovara, Modena, Italy.'}, {'ForeName': 'Anna Sonia', 'Initials': 'AS', 'LastName': 'Petronio', 'Affiliation': 'Cardiothoracic and Vascular Department, Cardiac Catheterization Laboratory, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Mariani', 'Affiliation': 'Division of Cardiology, Ospedale Civile, Legnano, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Toso', 'Affiliation': 'Division of Cardiology, Ospedale S. Stefano, Prato, Italy.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'Ravera', 'Affiliation': ""Division of Cardiology, Ospedale Ruggi D' Aragona, Salerno, Italy.""}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Corrada', 'Affiliation': 'Cardiovascular Department, Humanitas Research Hospital, Rozzano, Italy.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Cao', 'Affiliation': 'Cardiovascular Department, Humanitas Research Hospital, Rozzano, Italy.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Di Ascenzo', 'Affiliation': 'Division of Cardiology - Azienda ULSS ""Veneto Orientale,"" San Donà di Piave, Venezia, Italy.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'La Vecchia', 'Affiliation': 'Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'De Servi', 'Affiliation': 'University of Pavia, Italy, Milan, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Savonitto', 'Affiliation': 'Division of Cardiology, Ospedale Manzoni, Lecco, Italy.'}]",CJC open,['10.1016/j.cjco.2020.03.005'] 2372,32695977,"Effects of CPAP on Blood Pressure and Sympathetic Activity in Patients With Diabetes Mellitus, Chronic Kidney Disease, and Resistant Hypertension.","Background Patients with obstructive sleep apnea (OSA) have increased sympathetic activity and frequently also have resistant hypertension (HTN). Treatment of OSA with continuous positive airway pressure (CPAP) decreases awake and sleep blood pressure (BP) and sympathetic activity. This study was designed to assess the effect of treatment of OSA with CPAP on sympathetic activity and BP in patients with diabetes mellitus (DM), chronic kidney disease (CKD), and resistant HTN. Methods This was a randomized, double-blind, sham-controlled trial. Patients with DM, CKD, and resistant HTN were randomized to treatment with a therapeutic or subtherapeutic CPAP for 6 weeks. They underwent 24-hour ambulatory BP monitoring and assessment of muscle sympathetic nerve activity before and after 6 weeks on treatment. Results Treatment with therapeutic CPAP caused significant decreases in awake systolic and diastolic BP from 144 to 136 mm Hg ( P = 0.004) and from 79 to 74 mm Hg ( P = 0.004) and in sleep BP from 135 to 119 mm Hg ( P = 0.045) and from 75 to 65 mm Hg ( P =  0.015) compared with treatment with subtherapeutic CPAP. In contrast, treatment with therapeutic CPAP did not decrease sympathetic activity as assessed from muscle sympathetic nerve activity. Conclusions Decrease in BP by treatment with CPAP in patients with DM, CKD, and OSA indicates the contribution of OSA to severity of HTN in this clinical scenario. Decrease in BP in the absence of changes in sympathetic activity is suggestive that other mechanisms induced by OSA play a larger role in the maintenance of HTN in these patients.",2020,"Results Treatment with therapeutic CPAP caused significant decreases in awake systolic and diastolic BP from 144 to 136 mm Hg ( P = 0.004) and from 79 to 74 mm Hg ( P = 0.004) and in sleep BP from 135 to 119 mm Hg ( P = 0.045) and from 75 to 65 mm Hg ( P =  0.015) compared with treatment with subtherapeutic CPAP.","['\n\n\nPatients with obstructive sleep apnea (OSA', 'Patients with DM, CKD, and resistant HTN', 'patients with diabetes mellitus (DM), chronic kidney disease (CKD), and resistant HTN', 'Patients With Diabetes Mellitus, Chronic Kidney Disease, and Resistant Hypertension']","['OSA with continuous positive airway pressure (CPAP', 'CPAP', 'OSA with CPAP', 'therapeutic or subtherapeutic CPAP']","['sympathetic activity', 'awake systolic and diastolic BP', 'sympathetic activity and BP', 'Blood Pressure and Sympathetic Activity', 'sleep BP', 'BP', 'sleep blood pressure (BP) and sympathetic activity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0745130', 'cui_str': 'Resistant hypertensive disorder'}]","[{'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0234422', 'cui_str': 'Awake'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}]",,0.0474073,"Results Treatment with therapeutic CPAP caused significant decreases in awake systolic and diastolic BP from 144 to 136 mm Hg ( P = 0.004) and from 79 to 74 mm Hg ( P = 0.004) and in sleep BP from 135 to 119 mm Hg ( P = 0.045) and from 75 to 65 mm Hg ( P =  0.015) compared with treatment with subtherapeutic CPAP.","[{'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Ruzicka', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Knoll', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Frans H H', 'Initials': 'FHH', 'LastName': 'Leenen', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Leech', 'Affiliation': 'Division of Respirology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Shawn D', 'Initials': 'SD', 'LastName': 'Aaron', 'Affiliation': 'Division of Respirology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Swapnil', 'Initials': 'S', 'LastName': 'Hiremath', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.'}]",CJC open,['10.1016/j.cjco.2020.03.010'] 2373,32695998,Impact of Fiber-Based Enteral Nutrition on the Gut Microbiome of ICU Patients Receiving Broad-Spectrum Antibiotics: A Randomized Pilot Trial.,"Objectives Dietary fiber increases the abundance of bacteria that metabolize fiber into short-chain fatty acids and confers resistance against gut colonization with multidrug-resistant bacteria. This pilot trial estimated the effect of fiber on gut short-chain fatty acid-producing bacteria in the ICU. Design Randomized, controlled, open label trial. Setting Medical ICU. Patients Twenty ICU adults receiving broad-spectrum IV antibiotics for sepsis. Intervention 1:1 randomization to enteral nutrition with mixed soy- and oat-derived fiber (14.3 g fiber/L) versus calorie- and micronutrient-identical enteral nutrition with 0 g/L fiber. Measurements Rectal swabs and whole stools were collected at baseline and on study Days 3, 7, 14, and 30. The primary outcome was within-individual change in the cumulative relative abundance of short-chain fatty acid-producing taxa from baseline to Day 3 based on 16S sequencing of rectal swabs. The secondary outcome was Day 3 cumulative short-chain fatty acid levels based on mass spectrometry of whole stools. Analyses were all intent to treat. Main Results By Day 3, the fiber group received a median of 32.1 g fiber cumulatively (interquartile range, 17.6-54.6) versus 0 g fiber (interquartile range, 0-4.0) in the no fiber group. The median within-individual change in short-chain fatty acid producer relative abundance from baseline to Day 3 was +61% (interquartile range -51 to +1,688) in the fiber group versus -46% (interquartile range, -78 to +13) in the no fiber group ( p = 0.28). Whole stool short-chain fatty acid levels on Day 3 were a median of 707 μg short-chain fatty acids/g stool (interquartile range, 190-7,265) in the fiber group versus 118 μg short-chain fatty acids/g stool (interquartile range, 22-1,195) in the no fiber group ( p = 0.16). Conclusions Enteral fiber was associated with nonsignificant trends toward increased relative abundance of short-chain fatty acid-producing bacteria and increased short-chain fatty acid levels among ICU patients receiving broad-spectrum IV antibiotics. Larger studies should be undertaken and our results can be used for effect size estimates.",2020,"The median within-individual change in short-chain fatty acid producer relative abundance from baseline to Day 3 was +61% (interquartile range -51 to +1,688) in the fiber group versus -46% (interquartile range, -78 to +13) in the no fiber group (","['Patients\n\n\nTwenty ICU adults receiving broad-spectrum IV antibiotics for sepsis', 'ICU Patients Receiving Broad-Spectrum Antibiotics']","['enteral nutrition with mixed soy- and oat-derived fiber (14.3\u2009g fiber/L) versus calorie- and micronutrient-identical enteral nutrition with 0\u2009g/L fiber', 'Fiber-Based Enteral Nutrition', 'fiber on gut short-chain fatty acid-producing bacteria']","['relative abundance of short-chain fatty acid-producing bacteria and increased short-chain fatty acid levels', 'Measurements\n\n\nRectal swabs and whole stools', 'Day 3 cumulative short-chain fatty acid levels based on mass spectrometry of whole stools', 'cumulative relative abundance of short-chain fatty acid-producing taxa from baseline to Day 3 based on 16S sequencing of rectal swabs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}]","[{'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0037733', 'cui_str': 'Soya bean'}, {'cui': 'C0028753', 'cui_str': 'Oats'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0040577', 'cui_str': 'Trace element'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0015691', 'cui_str': 'Short chain fatty acid'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}]","[{'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0015691', 'cui_str': 'Short chain fatty acid'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0444215', 'cui_str': 'Rectal swab'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0037813', 'cui_str': 'Mass spectrometry measurement'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0162801', 'cui_str': 'Analysis, Sequence'}]",20.0,0.138437,"The median within-individual change in short-chain fatty acid producer relative abundance from baseline to Day 3 was +61% (interquartile range -51 to +1,688) in the fiber group versus -46% (interquartile range, -78 to +13) in the no fiber group (","[{'ForeName': 'Daniel E', 'Initials': 'DE', 'LastName': 'Freedberg', 'Affiliation': 'Division of Digestive and Liver Diseases, NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, NY.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Messina', 'Affiliation': 'Department of Food and Nutrition, NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, NY.'}, {'ForeName': 'Elissa', 'Initials': 'E', 'LastName': 'Lynch', 'Affiliation': 'Division of Digestive and Liver Diseases, NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, NY.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Tess', 'Affiliation': 'Department of Food and Nutrition, NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, NY.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Miracle', 'Affiliation': 'Department of Food and Nutrition, NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, NY.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Chong', 'Affiliation': 'Division of Pulmonary, Allergy, and Critical Care Medicine, NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, NY.'}, {'ForeName': 'Romina', 'Initials': 'R', 'LastName': 'Wahab', 'Affiliation': 'Division of Pulmonary, Allergy, and Critical Care Medicine, NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, NY.'}, {'ForeName': 'Julian A', 'Initials': 'JA', 'LastName': 'Abrams', 'Affiliation': 'Division of Digestive and Liver Diseases, NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, NY.'}, {'ForeName': 'Harris H', 'Initials': 'HH', 'LastName': 'Wang', 'Affiliation': 'Department of Systems and Synthetic Biology, NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, NY.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Munck', 'Affiliation': 'Department of Systems and Synthetic Biology, NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, NY.'}]",Critical care explorations,['10.1097/CCE.0000000000000135'] 2374,32698151,The role of IL-1 in the regulation of copeptin in patients with metabolic syndrome.,"Arginine vasopressin (AVP) was suggested to contribute to cardiovascular risk and type 2 diabetes in patients with metabolic syndrome. The proinflammatory cytokine interleukin-(IL)-1 is able to induce AVP secretion and plays a causal role in cardiovascular mortality and type 2 diabetes. We investigated in two studies whether copeptin levels - the surrogate marker for AVP - are regulated by IL-1-mediated chronic inflammation in patients with metabolic syndrome. Study A was a prospective, interventional, single-arm study (2014-2016). Study B was a randomized, placebo-controlled, double-blind study (2016-2017). n=73 (Study A) and n=66 (Study B) adult patients with metabolic syndrome were treated with 100 mg anakinra or placebo (only in study B) twice daily for 1 day (study A), and 28 days (study B). Fasting blood samples were drawn at day 1, 7, and 28 of treatment for measurement of serum copeptin. Patients with chronic low-grade inflammation (C-reactive protein levels ≥2 mg/l) and BMI >35 kg/m2 had higher baseline copeptin levels (7.7 [IQR 4.9-11.9] vs. 5.8 [IQR 3.9-9.3] pmol/l, pinflamm=0.009; 7.8 [IQR 5.4-11.7] vs. 4.9 [IQR 3.7-9.8] pmol/l, pBMI=0.008). Copeptin levels did not change neither in the anakinra nor in the placebo group and remained stable throughout the treatment (p=0.44). Subgroup analyses did not reveal effect modifications. Therefore, we conclude that although IL-1-mediated inflammation is associated with increased circulating copeptin levels, antagonizing IL-1 does not significantly alter copeptin levels in patients with metabolic syndrome.",2020,Copeptin levels did not change neither in the anakinra nor in the placebo group and remained stable throughout the treatment (p=0.44).,"['patients with metabolic syndrome', 'n=73 (Study A) and', 'Patients with chronic low-grade inflammation (C-reactive protein levels ≥2', 'n=66 (Study B) adult patients with metabolic syndrome']","['Arginine vasopressin (AVP', '100 mg anakinra or placebo', 'placebo']","['Copeptin levels', 'Fasting blood samples', 'baseline copeptin levels', 'copeptin levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C1962916', 'cui_str': 'Low grade (lymphoma)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0003779', 'cui_str': 'Argipressin'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0245109', 'cui_str': 'anakinra'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0056279', 'cui_str': 'copeptins'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",,0.131798,Copeptin levels did not change neither in the anakinra nor in the placebo group and remained stable throughout the treatment (p=0.44).,"[{'ForeName': 'Milica', 'Initials': 'M', 'LastName': 'Popovic', 'Affiliation': 'M Popovic, Endocrinology, Diabetology and Metabolism, Universitatsspital Basel, Basel, Switzerland.'}, {'ForeName': 'Fahim', 'Initials': 'F', 'LastName': 'Ebrahimi', 'Affiliation': 'F Ebrahimi, Endocrinology, Diabetology, and Metabolism, Universitätsspital Basel, Basel, Switzerland.'}, {'ForeName': 'Sandrine Andrea', 'Initials': 'SA', 'LastName': 'Urwyler', 'Affiliation': 'S Urwyler, Endocrinology, Diabetology, and Metabolism, Universitätsspital Basel, Basel, Switzerland.'}, {'ForeName': 'Marc Yves', 'Initials': 'MY', 'LastName': 'Donath', 'Affiliation': 'M Donath, Endocrinology, Diabetology and Metabolism, Universitatsspital Basel, Basel, Switzerland.'}, {'ForeName': 'Mirjam', 'Initials': 'M', 'LastName': 'Christ-Crain', 'Affiliation': 'M Christ-Crain, Endocrinology, Diabetology and Metabolism, Universitatsspital Basel, Basel, Switzerland.'}]",Endocrine connections,['10.1530/EC-20-0197'] 2375,32698159,"Effect of conjugated estrogens and bazedoxifene on glucose, energy and lipid metabolism in obese postmenopausal women.","OBJECTIVE Combining conjugated estrogens (CE) with the selective estrogen receptor modulator bazedoxifene (BZA) is a novel orally-administered menopausal therapy. We investigated the effect of CE/BZA on insulin sensitivity, energy metabolism, and serum metabolome in postmenopausal women with obesity. DESIGN Randomized, double-blind, crossover pilot trial with washout was conducted at Pennington Biomedical Research Center. Eight postmenopausal women (age 50-60 y, BMI 30-40 kg/m2) were randomized to 8 weeks CE/BZA or placebo. Primary outcome was insulin sensitivity (hyperinsulinemic-euglycemic clamp). Secondary outcomes included body composition (DXA); resting metabolic rate (RMR); substrate oxidation (indirect calorimetry); ectopic lipids (1H-MRS); fat cell size, adipose and skeletal muscle gene expression (biopsies); serum inflammatory markers; and serum metabolome (LC/MS). RESULTS CE/BZA treatment produced no detectable effect on insulin sensitivity, body composition, ectopic fat, fat cell size, or substrate oxidation, but resulted in a non-significant increase in RMR (basal: p=0.06; high-dose clamp: p=0.08) compared to placebo. CE/BZA increased serum high-density lipoprotein (HDL)-cholesterol. CE/BZA also increased serum diacylglycerol (DAG) and triacylglycerol (TAG) species containing long-chain saturated, mono- and polyunsaturated fatty acids (FAs), and decreased long-chain acylcarnitines, possibly reflecting increased hepatic de novo FA synthesis and esterification into TAGs for export into very low-density lipoproteins, as well as decreased FA oxidation, respectively (p<0.05). CE/BZA increased serum phosphatidylcholines, phosphatidylethanolamines, ceramides, and sphingomyelins, possibly reflecting the increase in serum lipoproteins (p<0.05). CONCLUSIONS A short treatment of obese postmenopausal women with CE/BZA does not alter insulin action or ectopic fat but increases serum markers of hepatic de novo lipogenesis and TAG production.",2020,"RESULTS CE/BZA treatment produced no detectable effect on insulin sensitivity, body composition, ectopic fat, fat cell size, or substrate oxidation, but resulted in a non-significant increase in RMR (basal: p=0.06; high-dose clamp: p=0.08) compared to placebo.","['obese postmenopausal women', 'postmenopausal women with obesity', 'Eight postmenopausal women (age 50-60 y, BMI 30-40 kg/m2', 'obese postmenopausal women with']","['CE/BZA or placebo', 'conjugated estrogens (CE) with the selective estrogen receptor modulator bazedoxifene (BZA', 'CE/BZA', 'conjugated estrogens and bazedoxifene', 'placebo']","['serum phosphatidylcholines, phosphatidylethanolamines, ceramides, and sphingomyelins, possibly reflecting the increase in serum lipoproteins (p<0.05', 'RMR', 'glucose, energy and lipid metabolism', 'body composition (DXA); resting metabolic rate (RMR); substrate oxidation (indirect calorimetry); ectopic lipids (1H-MRS); fat cell size, adipose and skeletal muscle gene expression (biopsies); serum inflammatory markers; and serum metabolome (LC/MS', 'insulin sensitivity (hyperinsulinemic-euglycemic clamp', 'insulin sensitivity, body composition, ectopic fat, fat cell size, or substrate oxidation', 'serum high-density lipoprotein (HDL)-cholesterol', 'insulin sensitivity, energy metabolism, and serum metabolome', 'serum diacylglycerol (DAG) and triacylglycerol']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}]","[{'cui': 'C0014938', 'cui_str': 'Estrogens, Conjugated (USP)'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0732611', 'cui_str': 'Selective estrogen receptor modulator'}, {'cui': 'C2346970', 'cui_str': 'bazedoxifene'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1959616', 'cui_str': 'Lecithin'}, {'cui': 'C0031618', 'cui_str': 'Phosphatidylethanolamines'}, {'cui': 'C0007745', 'cui_str': 'Ceramides'}, {'cui': 'C0037906', 'cui_str': 'Sphingomyelin'}, {'cui': 'C2362652', 'cui_str': 'Possible diagnosis'}, {'cui': 'C0558058', 'cui_str': 'Reflecting'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0023820', 'cui_str': 'Lipoprotein'}, {'cui': 'C4082350', 'cui_str': 'Resting Metabolic Rate'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0006781', 'cui_str': 'Indirect calorimetry'}, {'cui': 'C0340464', 'cui_str': 'Ectopic beats'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C3850002', 'cui_str': '1H-MRS'}, {'cui': 'C0206131', 'cui_str': 'Adipocyte'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C2350399', 'cui_str': 'Metabolome'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0079318', 'cui_str': 'Euglycaemic Clamp'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0012262', 'cui_str': 'Diacylglycerols'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}]",,0.199062,"RESULTS CE/BZA treatment produced no detectable effect on insulin sensitivity, body composition, ectopic fat, fat cell size, or substrate oxidation, but resulted in a non-significant increase in RMR (basal: p=0.06; high-dose clamp: p=0.08) compared to placebo.","[{'ForeName': 'Kara L', 'Initials': 'KL', 'LastName': 'Marlatt', 'Affiliation': 'K Marlatt, Clinical Science, Pennington Biomedical Research Center, Baton Rouge, United States.'}, {'ForeName': 'Dragana', 'Initials': 'D', 'LastName': 'Lovre', 'Affiliation': 'D Lovre, Endocrinology, Tulane University Health Sciences Center, New Orleans, United States.'}, {'ForeName': 'Robbie A', 'Initials': 'RA', 'LastName': 'Beyl', 'Affiliation': 'R Beyl, Biostatistics, Pennington Biomedical Research Center, Baton Rouge, United States.'}, {'ForeName': 'Chandra R', 'Initials': 'CR', 'LastName': 'Tate', 'Affiliation': 'C Tate, Endocrinology, Tulane University Health Sciences Center, New Orleans, United States.'}, {'ForeName': 'Evelyn K', 'Initials': 'EK', 'LastName': 'Hayes', 'Affiliation': 'E Hayes, Baton Rouge General Hospital, Baton Rouge General, Baton Rouge, United States.'}, {'ForeName': 'Charles F', 'Initials': 'CF', 'LastName': 'Burant', 'Affiliation': 'C Burant, Molecular and Integrative Physiology, University of Michigan, Ann Arbor, United States.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Ravussin', 'Affiliation': 'E Ravussin, Clinical Science, Pennington Biomedical Research Center, Baton Rouge, United States.'}, {'ForeName': 'Franck', 'Initials': 'F', 'LastName': 'Mauvais-Jarvis', 'Affiliation': 'F Mauvais-Jarvis, Endocrinology, Tulane University Health Sciences Center, New Orleans, United States.'}]",European journal of endocrinology,['10.1530/EJE-20-0619'] 2376,32698233,Narrow-Band Imaging versus Lugol chromoendoscopy for esophageal squamous cell cancer screening in normal endoscopic practice: randomized controlled trial.,"OBJECTIVE Narrow-Band Imaging (NBI) is as sensitive as Lugol chromoendoscopy to detect oesophageal squamous cell carcinoma (SCC) but its specificity, which appears higher than than that of Lugol chromoendoscopy in expert centres, remains to be established in current practice. This study aimed to prove the superiority of NBI specificity over Lugol chromoendoscopy in the detection of oesophageal SCC and high-grade dysplasia (HGD) in current practice (including tertiary care centres, local hospitals, and private clinics). TRIAL DESIGN Prospective randomised multicentre trial including consecutive patients with previous or current SCC of the upper aerodigestive tract addressed for gastroscopy. Patients included were randomly allocated to either the Lugol or NBI group. In the Lugol group, examination with white light and Lugol chromoendoscopy were successively performed. In the NBI group, NBI exam was performed after white light endoscopy. We compared the diagnostic characteristics of NBI and Lugol chromoendoscopy in a per-patient analysis. RESULTS 334 patients with previous history of SCC were included and analysed in intention-to-tret from 15 French institutions between March 2011 and December 2015. In a per-patient analysis, sensitivity, specificity, positive and negative likelihood values were respectively 100%, 66.0%, 21.2%, and 100% for Lugol chromoendoscopy vs. 100%, 79.9%, 37.5%, and 100% for NBI. NBI specificity was greater than Lugol chromoendoscopy (p=0.0023). CONCLUSIONS As previously demonstrated in expert centres, NBI is more specific than Lugol in current gastroenterology practice for the detection of early SCC but combined approaches with both NBI and lugol could improve the detection of squamous neoplasia.",2020,"NBI specificity was greater than Lugol chromoendoscopy (p=0.0023). ","['consecutive patients with previous or current SCC of the upper aerodigestive tract addressed for gastroscopy', '334 patients with previous history of SCC', 'esophageal squamous cell cancer screening in normal endoscopic practice', 'oesophageal SCC and high-grade dysplasia (HGD) in current practice (including tertiary care centres, local hospitals, and private clinics']","['Lugol chromoendoscopy', 'Narrow-Band Imaging versus Lugol chromoendoscopy', 'Lugol or NBI', 'Narrow-Band Imaging (NBI']","['sensitivity, specificity, positive and negative likelihood values', 'NBI specificity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0007137', 'cui_str': 'Squamous cell carcinoma'}, {'cui': 'C1267213', 'cui_str': 'Upper aerodigestive tract structure'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0017195', 'cui_str': 'Endoscopy of stomach'}, {'cui': 'C4517729', 'cui_str': '334'}, {'cui': 'C4040853', 'cui_str': 'History of squamous cell carcinoma'}, {'cui': 'C0279626', 'cui_str': 'Squamous cell carcinoma of esophagus'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0334044', 'cui_str': 'Dysplasia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0033175', 'cui_str': 'Private Room'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}]","[{'cui': 'C0065234', 'cui_str': ""Lugol's solution""}, {'cui': 'C0332463', 'cui_str': 'Narrowed structure'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C3494253', 'cui_str': 'Narrowband Imaging'}]","[{'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C3494253', 'cui_str': 'Narrowband Imaging'}]",334.0,0.0821646,"NBI specificity was greater than Lugol chromoendoscopy (p=0.0023). ","[{'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Gruner', 'Affiliation': 'Pavillon L Edouard Herriot Hospital, gastroenterology and endoscopy, Lyon, France.'}, {'ForeName': 'Angélique', 'Initials': 'A', 'LastName': 'Denis', 'Affiliation': 'Hospices Civils de Lyon, Pôle IMER- Department of medical evaluation, Lyon cedex 03, France.'}, {'ForeName': 'Claude', 'Initials': 'C', 'LastName': 'Masliah', 'Affiliation': ""Clinique mutualiste de l'estuaire, Gastroenterology, Saint-Nazaire, France.""}, {'ForeName': 'Morgane', 'Initials': 'M', 'LastName': 'Amil', 'Affiliation': 'Centre Hospitalier Departemental Les Oudairies, Gastroenterology, La Roche-sur-Yon, France.'}, {'ForeName': 'Elodie', 'Initials': 'E', 'LastName': 'Metivier', 'Affiliation': ""Centre Hospitalier Universitaire d\\'Angers, service d'hépato-gastro-entérologie, Angers, France.""}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Luet', 'Affiliation': 'CHU ANGERS, Department of hepatology, ANGERS, France.'}, {'ForeName': 'Medhi', 'Initials': 'M', 'LastName': 'Kaassis', 'Affiliation': 'Centre Hospitalier de Cholet, Gastroenterology, Cholet, France.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Coron', 'Affiliation': ""Centre hospitalier universitaire Hotel Dieu, Nantes, Institut des Maladies de l'Appareil Digestif, IMAD, Nantes, France.""}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Le Rhun', 'Affiliation': 'IMAD, Hôtel Dieu, CHU de Nantes, Hépato-Gastroentérologie, Nantes, France.'}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Lecleire', 'Affiliation': 'CHu de Rouen, Gastroenterologie, Rouen, France.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Antonietti', 'Affiliation': 'CHu de Rouen, Gastroenterologie, Rouen, France.'}, {'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'Legoux', 'Affiliation': 'ORLEANS REGIONAL HOSPITAL, Hepato-Gastroenterology and Digestive Oncology, Orleans, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Lefrou', 'Affiliation': 'ORLEANS REGIONAL HOSPITAL, Hepato-Gastroenterology and Digestive Oncology, Orleans, France.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Renkes', 'Affiliation': 'Hôpital Clinique Claude-Bernard, Gastroenterology, Metz, France.'}, {'ForeName': 'Anne-Laure', 'Initials': 'AL', 'LastName': 'Tarrerias', 'Affiliation': 'Hopital Foch, Gastroenterology, Suresnes, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Balian', 'Affiliation': 'Hopital Foch, Gastroenterology, Suresnes, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Rey', 'Affiliation': ""Hopital d'Instruction des Armees Legouest, Gastroenterology, Metz, France.""}, {'ForeName': 'Bénédicte', 'Initials': 'B', 'LastName': 'Prost', 'Affiliation': 'hopital saint Joseph Saint Luc, Gastroenterology, Lyon, France.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Cellier', 'Affiliation': 'George Pompidou European Hospital, Gastroenterology and Digestive Endoscopy, Paris, France.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Rahmi', 'Affiliation': 'Georges Pompidou European Hospital, Gastroenterology and Digestive Endoscopy, Paris, France.'}, {'ForeName': 'Elia', 'Initials': 'E', 'LastName': 'Samaha', 'Affiliation': 'Hôpital Européen Georges Pompidou, Hépatogastroentérologie, paris, France.'}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Fratte', 'Affiliation': 'Centre Hospitalier Belfort-Montbéliard - Site de Belfort, Gastroenterology, Belfort, France.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Guerrier', 'Affiliation': 'Hopital E.Herriot, Service de Gastroentérologie, Lyon, France.'}, {'ForeName': 'Verena', 'Initials': 'V', 'LastName': 'Landel', 'Affiliation': ""Hospices Civils de Lyon, Direction de la Recherche Clinique et de l'Innovation, Lyon, France.""}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Touzet', 'Affiliation': 'Hospices Civils de Lyon, DIM - Department of medical evaluation, Lyon cedex 03, France.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Ponchon', 'Affiliation': 'Edouard Herriot, hepatogastroenterology, LYON, France.'}, {'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Pioche', 'Affiliation': 'Edouard Herriot Hospital, Gastroenterology, Lyon, France.'}]",Endoscopy,['10.1055/a-1224-6822'] 2377,32698260,Effects of leucine-enriched essential amino acid supplementation on muscular fatigue and inflammatory cytokines in wheelchair basketball players.,"PURPOSE This study aimed to investigate the effects of leucine-enriched essential amino acid (LEAA) supplementation on muscle fatigue and the level of inflammatory cytokines in wheelchair basketball players after a basketball game and interval training. METHODS Of the ten recruited wheelchair basketball players (aged 34.5±8.9 years; lean body mass of 34.3±10.0 kg) who had spinal cord injury (SCI) and had undergone amputation, nine participated in the final test. These nine athletes received LEAA supplements (3 times 4.0 g/day) or placebo treatment in a double-blind, randomized, crossover study. We measured variables related to muscular fatigue and inflammatory response before the intense exercise and 4 days after recovery. RESULTS The significant effect of LEAA supplementation was inhibition of circulating IL-6 levels in the LEAA-treated group compared with the placebo group (P < .05). However, no changes were observed in the TNF-α and creatinine kinase levels. Moreover, analysis of variance analysis showed no significant difference in the relative values of muscle soreness. However, the effect size analysis with Cohen's d reported a significant improvement in the relative values of whole body and back muscle soreness. CONCLUSION Our results revealed that LEAA supplementation before and after intense exercise could help reduce muscle soreness and IL-6 levels in wheelchair basketball players.",2020,Our results revealed that LEAA supplementation before and after intense exercise could help reduce muscle soreness and IL-6 levels in wheelchair basketball players.,"['wheelchair basketball players', 'wheelchair basketball players after a basketball game and interval training', 'Of the ten recruited wheelchair basketball players (aged 34.5±8.9 years; lean body mass of 34.3±10.0 kg) who had spinal cord injury (SCI) and had undergone amputation, nine participated in the final test']","['LEAA supplements', 'leucine-enriched essential amino acid supplementation', 'LEAA', 'leucine-enriched essential amino acid (LEAA) supplementation', 'placebo']","['muscular fatigue and inflammatory cytokines', 'muscle soreness and IL-6 levels', 'muscle fatigue and the level of inflammatory cytokines', 'relative values of muscle soreness', 'relative values of whole body and back muscle soreness', 'circulating IL-6 levels', 'TNF-α and creatinine kinase levels', 'muscular fatigue and inflammatory response']","[{'cui': 'C0043143', 'cui_str': 'Wheelchair'}, {'cui': 'C0004818', 'cui_str': 'Basketball'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0023401', 'cui_str': 'Leucine'}, {'cui': 'C0002525', 'cui_str': 'Essential amino acid'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0556083', 'cui_str': 'Essential amino acid supplementation'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0242979', 'cui_str': 'Muscle fatigue'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205345', 'cui_str': 'Relative'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0224334', 'cui_str': 'Skeletal muscle structure of back'}, {'cui': 'C0234233', 'cui_str': 'Soreness'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0031727', 'cui_str': 'Kinase'}]",10.0,0.524042,Our results revealed that LEAA supplementation before and after intense exercise could help reduce muscle soreness and IL-6 levels in wheelchair basketball players.,"[{'ForeName': 'Young Hwan', 'Initials': 'YH', 'LastName': 'An', 'Affiliation': ''}, {'ForeName': 'Jisu', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Hee-Jae', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Kiwon', 'Initials': 'K', 'LastName': 'Lim', 'Affiliation': ''}]",Journal of exercise nutrition & biochemistry,['10.20463/pan.2020.0013'] 2378,32698326,Psychometric and Structural Validity of the Pittsburgh Sleep Quality Index among Filipino Domestic Workers.,"Objectives : Evaluate the psychometric properties and structural validity of the Filipino version of the Pittsburgh Sleep Quality Index (PSQI) among Filipino domestic workers (FDWs). Methods : In Study 1, 131 FDWs completed PSQI and other scales, along with 10-day actigraphic assessment with accompanying electronic daily sleep dairy. A subsample of 61 participants completed follow-up assessment after 10 days. In Study 2, 1363 FDWs were recruited and randomized into two halves. Exploratory factor analysis (EFA) and Confirmatory factor analysis (CFA) were used in the two halves, respectively. Results : In Study 1, the Cronbach's alpha of the PSQI was 0.63 at baseline and 0.67 at follow-up. Test-retest reliability for the PSQI global score based on intraclass correlation was 0.63. Convergent validity was supported by the significant associations between the PSQI global score, PSQI components scores, sleep patterns from the daily sleep diary, and measures of depression, anxiety, and rumination. Small correlations between the PSQI global score and measures of daytime sleepiness, social support, and self-reported height, supported discriminant validity. In Study 2, EFA yielded two PSQI factors with acceptable factor loadings. CFA established that this two-factor model, comprised of perceived sleep quality and sleep efficiency, evidenced better model fit than alternative models tested. The Cronbach's alpha of two factors was 0.70 and 0.81, respectively. Conclusions : The PSQI demonstrated good internal consistency of two factors, and good convergent, and divergent validity. Results can be referenced in future studies to measure and screen sleep dysfunction among clinical and non-clinical populations in the Philippines.",2020,"Convergent validity was supported by the significant associations between the PSQI global score, PSQI components scores, sleep patterns from the daily sleep diary, and measures of depression, anxiety, and rumination.","['1363 FDWs', 'Filipino domestic workers (FDWs', 'Filipino Domestic Workers']",['Filipino version of the Pittsburgh Sleep Quality Index (PSQI'],"['Exploratory factor analysis (EFA) and Confirmatory factor analysis (CFA', 'sleep quality and sleep efficiency', 'PSQI global score, PSQI components scores, sleep patterns from the daily sleep diary, and measures of depression, anxiety, and rumination', 'PSQI global score and measures of daytime sleepiness, social support, and self-reported height', 'Psychometric and Structural Validity of the Pittsburgh Sleep Quality Index']","[{'cui': 'C1556093', 'cui_str': 'Filipinos'}, {'cui': 'C0003063', 'cui_str': 'Domestic Animals'}, {'cui': 'C1306056', 'cui_str': 'Worker'}]","[{'cui': 'C1556093', 'cui_str': 'Filipinos'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}]","[{'cui': 'C0085801', 'cui_str': 'Factor Analysis'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0474396', 'cui_str': 'Sleep behavior finding'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0541854', 'cui_str': 'Daytime sleepiness'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0033920', 'cui_str': 'Psychometric testing'}, {'cui': 'C0042283', 'cui_str': 'Validity (Epidemiology)'}]",1363.0,0.0399617,"Convergent validity was supported by the significant associations between the PSQI global score, PSQI components scores, sleep patterns from the daily sleep diary, and measures of depression, anxiety, and rumination.","[{'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Xiong', 'Affiliation': 'Division of Medical Psychology and Behavioral Sciences, Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou 510632, China.'}, {'ForeName': 'Adam P', 'Initials': 'AP', 'LastName': 'Spira', 'Affiliation': 'Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Johns Hopkins Center on Aging and Health, Baltimore, MD 21205, USA.'}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Hall', 'Affiliation': 'Global and Community Mental Health Research Group, Department of Psychology, The University of Macau, Macau (SAR) 999078, China.'}]",International journal of environmental research and public health,['10.3390/ijerph17145219'] 2379,32698329,Effect of a Cognitive Training Program on the Platelet APP Ratio in Patients with Alzheimer's Disease.,"In patients with Alzheimer's disease (AD), synaptic plasticity seems to be involved in cognitive improvement induced by cognitive training. The platelet amyloid precursor protein (APP) ratio (APPr), i.e., the ratio between two APP isoforms, may be a useful peripheral biomarker to investigate synaptic plasticity pathways. This study evaluates the changes in neuropsychological/cognitive performance and APPr induced by cognitive training in AD patients participating in the ""My Mind Project"". Neuropsychological/cognitive variables and APPr were evaluated in the trained group ( n = 28) before a two-month experimental protocol, immediately after its termination at follow-up 1 (FU1), after 6 months at follow-up 2 (FU2), and after 24 months at follow-up 3 (FU3). The control group ( n = 31) received general psychoeducational training for two months. Some memory and attention parameters were significantly improved in trained vs. control patients at FU1 and FU2 compared to baseline (Δ values). At FU3, APPr and Mini Mental State Examination (MMSE) scores decreased in trained patients. Δ APPr correlated significantly with the Δ scores of (i) MMSE at FU1, (ii) the prose memory test at FU2, and (iii) Instrumental Activities of Daily Living (IADL), the semantic word fluency test, Clinical Dementia Rating (CDR), and the attentive matrices test at FU3. Our data demonstrate that the platelet APPr correlates with key clinical variables, thereby proving that it may be a reliable biomarker of brain function in AD patients.",2020,Some memory and attention parameters were significantly improved in trained vs. control patients at FU1 and FU2 compared to baseline (Δ values).,"[""Patients with Alzheimer's Disease"", ""patients with Alzheimer's disease (AD"", 'AD patients', 'AD patients participating in the ""My Mind Project']","['cognitive training', 'general psychoeducational training', 'Cognitive Training Program']","['Some memory and attention parameters', 'Neuropsychological/cognitive variables and APPr', 'Instrumental Activities of Daily Living (IADL), the semantic word fluency test, Clinical Dementia Rating (CDR', 'prose memory test at FU2, and (iii', 'Platelet APP Ratio', 'platelet amyloid precursor protein (APP) ratio (APPr', 'At FU3, APPr and Mini Mental State Examination', 'MMSE) scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0150641', 'cui_str': 'Instrumental activities of daily living'}, {'cui': 'C0036612', 'cui_str': 'Semantics'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0451074', 'cui_str': 'Clinical dementia rating scale'}, {'cui': 'C0021024', 'cui_str': 'Immunoglobulin, hypervariable region'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0085151', 'cui_str': 'Amyloid beta Precursor Protein'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0170945,Some memory and attention parameters were significantly improved in trained vs. control patients at FU1 and FU2 compared to baseline (Δ values).,"[{'ForeName': 'Tiziana', 'Initials': 'T', 'LastName': 'Casoli', 'Affiliation': 'Center for Neurobiology of Aging, IRCCS INRCA, 60121 Ancona, Italy.'}, {'ForeName': 'Cinzia', 'Initials': 'C', 'LastName': 'Giuli', 'Affiliation': 'Geriatrics Operative Unit, IRCCS INRCA, 63023 Fermo, Italy.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Balietti', 'Affiliation': 'Center for Neurobiology of Aging, IRCCS INRCA, 60121 Ancona, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Fabbietti', 'Affiliation': 'Unit of Geriatric Pharmacoepidemiology, IRCCS INRCA, 87100 Cosenza, Italy.'}, {'ForeName': 'Fiorenzo', 'Initials': 'F', 'LastName': 'Conti', 'Affiliation': 'Center for Neurobiology of Aging, IRCCS INRCA, 60121 Ancona, Italy.'}]",International journal of molecular sciences,['10.3390/ijms21145110'] 2380,32698410,"Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II Trial.","This study is an investigator-initiated randomized phase II trial focusing on the treatment of advanced biliary tract cancer with either oxaliplatin 50 mg/m 2 and gemcitabine 1000 mg/m 2 on day 1 in a two-week cycle with capecitabine 650 mg/m 2 twice-daily continuously or cisplatin 25 mg/m 2 and gemcitabine 1000 mg/m 2 on day 1 and day 8 in a three-week cycle. One-hundred patients were included. Forty-seven patients received oxaliplatin, gemcitabine, and capecitabine with a median progression-free survival (mPFS) of 5.7 months (95% CI 3.0-7.8) and a median overall survival (mOS) of 8.7 months (95% CI 6.5-11.2). Forty-nine patients received cisplatin and gemcitabine with a mPFS of 7.3 months (95% CI 6.0-8.7) and a mOS of 12.0 months (95% CI 8.3-16.7). This trial confirms a mOS of 12 months with cisplatin and gemcitabine, as found in earlier trials. With a superior tumor control rate of 79% vs. 60% ( p = 0.045), a difference in the mPFS of 1.6 months (HR = 0.721, p = 0.1), and a difference in the mOS of 3.3 months (HR = 0.731, p = 0.1), cisplatin and gemcitabine should still be considered the standard first-line treatment for advanced biliary tract cancer.",2020,"With a superior tumor control rate of 79% vs. 60% ( p = 0.045), a difference in the mPFS of 1.6 months (HR = 0.721, p = 0.1), and a difference in the mOS of 3.3 months (HR = 0.731, p = 0.1), cisplatin and gemcitabine should still be considered the standard first-line treatment for advanced biliary tract cancer.","['One-hundred patients were included', 'Patients with Advanced Biliary Tract Cancer with Either', 'advanced biliary tract cancer', 'advanced biliary tract cancer with either']","['Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine', 'oxaliplatin 50 mg/m 2 and gemcitabine', 'capecitabine 650 mg/m 2 twice-daily continuously or cisplatin 25 mg/m 2 and gemcitabine', 'oxaliplatin, gemcitabine, and capecitabine', 'cisplatin and gemcitabine']",['median overall survival'],"[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0750952', 'cui_str': 'Malignant tumor of biliary tract'}]","[{'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C4081032', 'cui_str': 'oxaliplatin 50 MG'}, {'cui': 'C3844101', 'cui_str': '650'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",100.0,0.0374273,"With a superior tumor control rate of 79% vs. 60% ( p = 0.045), a difference in the mPFS of 1.6 months (HR = 0.721, p = 0.1), and a difference in the mOS of 3.3 months (HR = 0.731, p = 0.1), cisplatin and gemcitabine should still be considered the standard first-line treatment for advanced biliary tract cancer.","[{'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Markussen', 'Affiliation': 'Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte, 2730 Herlev, Denmark.'}, {'ForeName': 'Lars Henrik', 'Initials': 'LH', 'LastName': 'Jensen', 'Affiliation': 'Department of Oncology, Vejle University Hospital, 7100 Vejle, Denmark.'}, {'ForeName': 'Laura Vittrup', 'Initials': 'LV', 'LastName': 'Diness', 'Affiliation': 'Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte, 2730 Herlev, Denmark.'}, {'ForeName': 'Finn Ole', 'Initials': 'FO', 'LastName': 'Larsen', 'Affiliation': 'Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte, 2730 Herlev, Denmark.'}]",Cancers,['10.3390/cancers12071975'] 2381,32698457,"Effects of Pistachio Consumption in a Behavioral Weight Loss Intervention on Weight Change, Cardiometabolic Factors, and Dietary Intake.","Epidemiological studies have linked regular nut consumption with lower body mass index and reduced likelihood of weight gain in adulthood. Nuts can displace other foods in the diet, and thus, promote a healthier dietary pattern. The purpose of this study was to examine the effect of pistachio nut consumption in overweight/obese adults. This randomized controlled study enrolled non-diabetic overweight/obese adults ( n = 100) assigned to a 4-month behavioral weight loss intervention only group (controls) or also prescribed 1.5 oz/day (42 g/day) of pistachios (pistachio group). Outcomes were change in body weight, cardiometabolic factors, and dietary intake. Percent weight change was similar in the two groups (-5.1 [0.5] (mean [SE])% in the control group and -4.9 [0.6]% in the pistachio group, and body mass index (BMI) and waist circumference were reduced in both groups (time effect p ≤ 0.05). The pistachio group (but not the control group) exhibited a significant reduction in both systolic and diastolic blood pressure (time effect p = 0.01). Plasma alpha-carotene, beta-carotene, and lutein concentrations increased significantly in the pistachio group (time effect p < 0.05). Pistachio consumption was associated with increased dietary fiber intake and decreased consumption of sweets. Regular consumption of pistachios was associated with a comparable degree of weight loss, and similar reductions in BMI and waist circumference, in overweight/obese men and women compared to controls, and favorable changes in the diet, in the context of a behavioral weight loss intervention.",2020,"Plasma alpha-carotene, beta-carotene, and lutein concentrations increased significantly in the pistachio group (time effect p < 0.05).","['enrolled non-diabetic overweight/obese adults ( n = 100) assigned to a', 'overweight/obese adults']","['4-month behavioral weight loss intervention only group (controls) or also prescribed 1.5 oz/day (42 g/day) of pistachios (pistachio group', 'pistachio nut consumption', 'Pistachio Consumption']","['BMI and waist circumference', 'body weight, cardiometabolic factors, and dietary intake', 'systolic and diastolic blood pressure', 'dietary fiber intake and decreased consumption of sweets', 'weight loss', 'Plasma alpha-carotene, beta-carotene, and lutein concentrations', 'Weight Change, Cardiometabolic Factors, and Dietary Intake', 'body mass index (BMI) and waist circumference', 'Percent weight change']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0560718', 'cui_str': 'oz/day'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}, {'cui': 'C0459819', 'cui_str': 'Pistachio nut'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0474451', 'cui_str': 'Dietary fiber intake'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0085077', 'cui_str': 'Acute febrile neutrophilic dermatosis'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0051336', 'cui_str': 'Alpha-carotene'}, {'cui': 'C0053396', 'cui_str': 'Beta Carotene'}, {'cui': 'C0043328', 'cui_str': 'Lutein'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0439165', 'cui_str': 'Percent'}]",,0.0181975,"Plasma alpha-carotene, beta-carotene, and lutein concentrations increased significantly in the pistachio group (time effect p < 0.05).","[{'ForeName': 'Cheryl L', 'Initials': 'CL', 'LastName': 'Rock', 'Affiliation': 'Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0901, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Zunshine', 'Affiliation': 'Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0901, USA.'}, {'ForeName': 'Huong Thien', 'Initials': 'HT', 'LastName': 'Nguyen', 'Affiliation': 'Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0901, USA.'}, {'ForeName': 'Annemarie O', 'Initials': 'AO', 'LastName': 'Perez', 'Affiliation': 'Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0901, USA.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Zoumas', 'Affiliation': 'Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0901, USA.'}, {'ForeName': 'Bilge', 'Initials': 'B', 'LastName': 'Pakiz', 'Affiliation': 'Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0901, USA.'}, {'ForeName': 'Martha M', 'Initials': 'MM', 'LastName': 'White', 'Affiliation': 'Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0901, USA.'}]",Nutrients,['10.3390/nu12072155'] 2382,32698532,A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18-50 Years of Age.,"Inactivated influenza vaccines efficacy is variable and often poor. We conducted a phase 1 trial (NCT02188810), to assess the safety and immunogenicity of a novel nanoparticle Toll-like receptor 7/8 agonist adjuvant (Papaya Mosaic Virus) at different dose levels combined with trivalent influenza vaccine in healthy persons 18-50 years of age. Hemagglutination-inhibition assays, antibody to Influenza A virus nucleoprotein and peripheral blood mononuclear cells for measurement of interferon-gamma ELISPOT response to influenza antigens, Granzyme B and IFNγ:IL-10 ratio were measured. The most common adverse events were transient mild to severe injection site pain and no safety signals were observed. A dose-related adjuvant effect was observed. Geometric mean hemagglutination-inhibition titers increased at day 28 in most groups and waned over time, but fold-antibody responses were poor in all groups. Cell mediated immunity results were consistent with humoral responses. The Papaya Mosaic Virus adjuvant in doses of 30 to 240 µg combined with reduced influenza antigen content was safe with no signals up to 3 years after vaccination. A dose-related adjuvant effect was observed and immunogenicity results suggest that efficacy study should be conducted in influenza antigen-naïve participants.",2020,"Geometric mean hemagglutination-inhibition titers increased at day 28 in most groups and waned over time, but fold-antibody responses were poor in all groups.","['healthy persons 18-50 years of age', 'Healthy Adults 18-50 Years of Age']","['novel nanoparticle Toll-like receptor 7/8 agonist adjuvant (Papaya Mosaic Virus) at different dose levels combined with trivalent influenza vaccine', 'Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine']","['Geometric mean hemagglutination-inhibition titers', 'safety and immunogenicity', 'Safety and Reactogenicity', 'severe injection site pain and no safety signals', 'Granzyme B and IFNγ:IL-10 ratio']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C1450054', 'cui_str': 'Nanoparticles'}, {'cui': 'C1321919', 'cui_str': 'TLR4 protein, human'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C1000301', 'cui_str': 'Papaya mosaic virus'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0021403', 'cui_str': 'Influenza virus vaccine'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0032092', 'cui_str': 'Plant virus'}, {'cui': 'C0439601', 'cui_str': 'Seasonal course'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0018904', 'cui_str': 'Hemagglutination inhibition assay'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0151828', 'cui_str': 'Injection site pain'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0061878', 'cui_str': 'Granzyme B'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.0384984,"Geometric mean hemagglutination-inhibition titers increased at day 28 in most groups and waned over time, but fold-antibody responses were poor in all groups.","[{'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Langley', 'Affiliation': 'Canadian Center for Vaccinology (Dalhousie University, IWK Health Centre, Nova Scotia Health Authority), 5850 University Avenue, Halifax, NS B3K 6R8, Canada.'}, {'ForeName': 'Elodie', 'Initials': 'E', 'LastName': 'Pastural', 'Affiliation': 'Pan-Provincial Vaccine Enterprise (PREVENT), 120 Veterinary Road, Saskatoon, SK S7N 5E3, Canada.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Halperin', 'Affiliation': 'Canadian Center for Vaccinology (Dalhousie University, IWK Health Centre, Nova Scotia Health Authority), 5850 University Avenue, Halifax, NS B3K 6R8, Canada.'}, {'ForeName': 'Shelly', 'Initials': 'S', 'LastName': 'McNeil', 'Affiliation': 'Canadian Center for Vaccinology (Dalhousie University, IWK Health Centre, Nova Scotia Health Authority), 5850 University Avenue, Halifax, NS B3K 6R8, Canada.'}, {'ForeName': 'May', 'Initials': 'M', 'LastName': 'ElSherif', 'Affiliation': 'Canadian Center for Vaccinology (Dalhousie University, IWK Health Centre, Nova Scotia Health Authority), 5850 University Avenue, Halifax, NS B3K 6R8, Canada.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'MacKinnon-Cameron', 'Affiliation': 'Canadian Center for Vaccinology (Dalhousie University, IWK Health Centre, Nova Scotia Health Authority), 5850 University Avenue, Halifax, NS B3K 6R8, Canada.'}, {'ForeName': 'Lingyun', 'Initials': 'L', 'LastName': 'Ye', 'Affiliation': 'Canadian Center for Vaccinology (Dalhousie University, IWK Health Centre, Nova Scotia Health Authority), 5850 University Avenue, Halifax, NS B3K 6R8, Canada.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Grange', 'Affiliation': ""Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (C.R.H.U.M.), 900 rue St-Denis, Tour Viger, Montreal, QC H2X 0A9, Canada.""}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Thibodeau', 'Affiliation': ""Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (C.R.H.U.M.), 900 rue St-Denis, Tour Viger, Montreal, QC H2X 0A9, Canada.""}, {'ForeName': 'Jean-François', 'Initials': 'JF', 'LastName': 'Cailhier', 'Affiliation': ""Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (C.R.H.U.M.), 900 rue St-Denis, Tour Viger, Montreal, QC H2X 0A9, Canada.""}, {'ForeName': 'Rejean', 'Initials': 'R', 'LastName': 'Lapointe', 'Affiliation': ""Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (C.R.H.U.M.), 900 rue St-Denis, Tour Viger, Montreal, QC H2X 0A9, Canada.""}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'McElhaney', 'Affiliation': 'Northern Ontario School of Medicine, 41 Ramsey Lake Health Centre, Thunder Bay, ON P3E 5J1, Canada.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Martin', 'Affiliation': 'Pan-Provincial Vaccine Enterprise (PREVENT), 120 Veterinary Road, Saskatoon, SK S7N 5E3, Canada.'}, {'ForeName': 'Marilène', 'Initials': 'M', 'LastName': 'Bolduc', 'Affiliation': 'Department of Microbiology, Infectiology and Immunology, Laval University, 1050, avenue de la Médecine, bureau 4633, QC G1V 0A6, Canada.'}, {'ForeName': 'Marie-Eve', 'Initials': 'ME', 'LastName': 'Laliberté-Gagné', 'Affiliation': 'Department of Microbiology, Infectiology and Immunology, Laval University, 1050, avenue de la Médecine, bureau 4633, QC G1V 0A6, Canada.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Leclerc', 'Affiliation': 'Department of Microbiology, Infectiology and Immunology, Laval University, 1050, avenue de la Médecine, bureau 4633, QC G1V 0A6, Canada.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Savard', 'Affiliation': 'Department of Molecular Biology, Medical Biology and Pathology, Laval University, 2705 boulevard Laurier P-09835, QC PQ G1V 4G2, Canada.'}]",Vaccines,['10.3390/vaccines8030393'] 2383,32698540,The Effect of Dynamic Food Labels with Real-Time Feedback on Diet Quality: Results from a Randomized Controlled Trial.,"The rising prevalence of non-communicable diseases has brought attention to the importance of consuming a healthy diet. One strategy to improve diet quality is through front-of-pack (FOP) nutrition labels. Taking advantage of an online grocery store, we allowed consumers to choose the FOP labels they preferred, and combined this information with real-time feedback on the overall nutritional quality of the shopping basket. We hypothesized that these dynamic food labels with real-time feedback (DFLF) would improve nutritional quality of food purchases. This trial followed a two-arm (no-label control and DFLF) crossover design with 125 participants exposed to each condition once in random order via an online grocery store. A first difference regression model allowed for estimating the unbiased effect of the DFLF on diet quality, measured by the weighted average Nutri-Score (ranging 1 to 5) per serving (primary) and changes in select nutrients and calories. The mean weighted Nutri-Score was 0.4 (12.6%) higher in the DFLF arm (CI: [0.2, 0.6]) relative to the control. The DFLF also decreased the amount of sugar per serving by 0.9 g (CI: [-1.7, -0.0]) and total sugar per shop by 169.5 g (CI: [-284.5, -54.5]). The DFLF features significantly improved nutrition quality relative to no labelling, as measured by average Nutri-Score values. These results shed light on the considerable potential of the online shopping environment to improve diet quality through customization and real time feedback.",2020,"The DFLF features significantly improved nutrition quality relative to no labelling, as measured by average Nutri-Score values.",['125 participants exposed to each condition once in random order via an online grocery store'],"['Dynamic Food Labels with Real-Time Feedback', 'dynamic food labels with real-time feedback (DFLF']","['mean weighted Nutri-Score', 'Diet Quality', 'nutritional quality of food purchases', 'nutrition quality', 'diet quality']","[{'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0557778', 'cui_str': 'Supermarket'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0016475', 'cui_str': 'Food Labelling'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C3489446', 'cui_str': 'Nutritive Quality'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}]",125.0,0.0394557,"The DFLF features significantly improved nutrition quality relative to no labelling, as measured by average Nutri-Score values.","[{'ForeName': 'Soye', 'Initials': 'S', 'LastName': 'Shin', 'Affiliation': 'Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore 169857, Singapore.'}, {'ForeName': 'Rob M', 'Initials': 'RM', 'LastName': 'van Dam', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore, Singapore 117549, Singapore.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Finkelstein', 'Affiliation': 'Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore 169857, Singapore.'}]",Nutrients,['10.3390/nu12072158'] 2384,32698557,Stability of Recombinant Human Platelet-Derived Growth Factor-BB- Regenerated Periodontal Defects: Sixty-Month Clinical and Radiographic Observations.,"INTRODUCTION The availability of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) plus β-tricalcium phosphate (β-TCP) for periodontal therapeutic use resulted from a large-scale, prospective, masked, randomized clinical trial. This pivotal trial indicated that this combination can safely and effectively be used to treat advanced periodontal osseous defects. Previous reports demonstrated significant gain in clinical attachment level, linear bone gain, and percentage bone fill after 6 months. Subsequent evaluation of selected cases 24 months after treatment indicated the clinical gains were maintainable. Furthermore, there appeared to be substantial increase in linear bone gain and percentage bone fill. Radiographically, there was increased radiopacity and bone trabeculation, suggesting bone maturation. CASE SERIES This report presents representative cases from the rhPDGF-BB plus β-TCP pivotal clinical trial after 60 months. Maximal regenerative results were achieved after 12 months and maintained ≥5 years. Sites treated with rhPDGF-BB plus β-TCP were generally healthy, with no evidence of ankylosis, root resorption, or abnormal tissue reaction. However, a limited number of cases deteriorated, suggesting that smoking and poor self/supportive care compliance can adversely affect periodontal regenerative results. CONCLUSIONS The use of rhPDGF-BB plus β-TCP was safe and effective in the treatment of periodontal osseous defects. The regenerated results are maintainable ≥5 years, with adverse events attributable to the treatment.",2011,The use of rhPDGF-BB plus β-TCP was safe and effective in the treatment of periodontal osseous defects.,[],"['Recombinant Human Platelet-Derived Growth Factor-BB- Regenerated Periodontal Defects', 'rhPDGF-BB plus β-TCP', 'recombinant human platelet-derived growth factor-BB (rhPDGF-BB) plus β-tricalcium phosphate (β-TCP']","['clinical attachment level, linear bone gain, and percentage bone fill', 'ankylosis, root resorption, or abnormal tissue reaction', 'clinical gains', 'linear bone gain and percentage bone fill', 'radiopacity and bone trabeculation, suggesting bone maturation']",[],"[{'cui': 'C0379135', 'cui_str': 'Becaplermin'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0108136', 'cui_str': 'tricalcium phosphate'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0003090', 'cui_str': 'Ankylosis'}, {'cui': 'C0035851', 'cui_str': 'Root Resorption'}, {'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}]",,0.0236986,The use of rhPDGF-BB plus β-TCP was safe and effective in the treatment of periodontal osseous defects.,"[{'ForeName': 'Richard T', 'Initials': 'RT', 'LastName': 'Kao', 'Affiliation': 'Private practice, Cupertino, CA.'}, {'ForeName': 'Samuel E', 'Initials': 'SE', 'LastName': 'Lynch', 'Affiliation': 'BioMimetic Therapeutics, Franklin, TN.'}]",Clinical advances in periodontics,['10.1902/cap.2011.110038'] 2385,32698618,Comparison of corneal biomechanical changes after LASIK and F-SMILE with CorVis ST.,"PURPOSE To evaluate changes in corneal biomechanics after LASIK and F-SMILE. SETTING Elite Eye Center, Tanta, Egypt. DESIGN Prospective, randomized, unmasked, interventional comparative case series. PATIENTS AND METHODS A total of 60 eyes were equally divided into two groups; group A: received LASIK and group B: received F-SMILE. Pentacam and CorVis ST parameters were compared before and 6 months after procedures. P  ⩽ 0.05 was used for significance of results. RESULTS bIOP decreased by 0.762 ± 1.211 mmHg in group A ( p  = 0.092), and by 2.52 ± 1.389 mmHg in group B ( p  < 0.001) and the difference between groups became significant ( p  = 0.001). A1 increased significantly in group A only ( p  = 0.036); while A2 decreased insignificantly in both groups. DAR increased significantly in both groups ( p  < 0.001, p  = 0.022), but the difference between groups remained insignificant ( p  = 0.461). IR increased significantly in group A only ( p  < 0.001) and the difference between groups became significant ( p  = 0.026). ARTH decreased in both groups ( p  = 0.245, p  = 0.695) and the difference remained insignificant ( p  = 0.928). SP-A1 decreased in group A by 8.89 ± 1.38 mmHg/mm ( p  = 0.637), and by 32.6 ± 4.39 mmHg/mm in group B ( p  < 0.001) and the postoperative difference between groups was significant ( p  = 0.013). CBI increased significantly in group A ( p  < 0.001), but insignificantly in group B ( p  = 0.098) and postoperative difference between groups was highly significant ( p  < 0.001). A significant correlation was found between change in CCT and corresponding changes in DAR, IR, and ARTH after surgery in both groups. CONCLUSION The significant differences between groups postoperatively as regards bIOP ( p  = 0.001), IR ( p  = 0.026), SP-A1 ( p  = 0.013), and CBI ( p  < 0.001) indicate stiffer corneas after F-SMILE and suggest less influence on corneal biomechanics than LASIK.",2020,"The significant differences between groups postoperatively as regards bIOP ( p  = 0.001), IR ( p  = 0.026), SP-A1 ( p  = 0.013), and CBI ( p  < 0.001) indicate stiffer corneas after F-SMILE and suggest less influence on corneal biomechanics than LASIK.","['Elite Eye Center, Tanta, Egypt', 'A total of 60 eyes']","['LASIK and F-SMILE with CorVis ST', 'LASIK and group B: received F-SMILE']","['CBI', 'corneal biomechanics', 'SP-A1', 'DAR, IR, and ARTH', 'Pentacam and CorVis ST parameters', 'ARTH', 'DAR', 'bIOP', 'IR']","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0013715', 'cui_str': 'Egypt'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0752094', 'cui_str': 'Laser assisted in situ keratomileusis'}, {'cui': 'C0037363', 'cui_str': 'Smiling'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}]","[{'cui': 'C0259095', 'cui_str': '9a-chloromethyl-1,2,9,9a-tetrahydrocyclopropa(c)benz(e)indol-4-one'}, {'cui': 'C0022595', 'cui_str': 'Darier disease'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",60.0,0.0254855,"The significant differences between groups postoperatively as regards bIOP ( p  = 0.001), IR ( p  = 0.026), SP-A1 ( p  = 0.013), and CBI ( p  < 0.001) indicate stiffer corneas after F-SMILE and suggest less influence on corneal biomechanics than LASIK.","[{'ForeName': 'Eman A', 'Initials': 'EA', 'LastName': 'Abd El-Fattah', 'Affiliation': 'Department of Ophthalmology, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Alaa A', 'Initials': 'AA', 'LastName': 'El Dorghamy', 'Affiliation': 'Department of Ophthalmology, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Ghoneim', 'Affiliation': 'Department of Ophthalmology, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Hisham A', 'Initials': 'HA', 'LastName': 'Saad', 'Affiliation': 'Department of Ophthalmology, Faculty of Medicine, Tanta University, Tanta, Egypt.'}]",European journal of ophthalmology,['10.1177/1120672120945664'] 2386,32698620,You won't regret it (or love it) as much as you think: impact biases for everyday health behavior outcomes.,"When predicting the future, people tend to overestimate the intensity of their emotions, a phenomenon known as the impact bias. Design: In two studies, we examined the impact bias for health outcomes. In Study 1, participants were randomized to think about a negative health outcome in the future or one in the past. In Study 2, participants came to the laboratory and were asked to predict and report their emotions surrounding an actual health outcome (consuming an unhealthy food). Results: In both studies, an impact bias emerged. In Study 1, participants thinking about an outcome in the future estimated more negative emotion than those thinking about an outcome in the past. In Study 2, when facing an actual health outcome, participants anticipated more negative and positive emotion than they experienced. Impact biases were also associated with behavioral motivation - desire to change the outcome (Study 1) and increased preventive intentions (Study 2). Additional analyses revealed that regret was a particularly important emotion. Conclusion: Although research has highlighted an impact bias for severe health outcomes like disease, these studies provide evidence of an impact bias for health outcomes generally. They also suggest that the bias may have implications for behavior intentions.",2020,"In Study 1, participants thinking about an outcome in the future estimated more negative emotion than those thinking about an outcome in the past.",['participants came to the laboratory and were asked to predict and report their emotions surrounding an actual health outcome (consuming an unhealthy food'],[],"['negative emotion', 'negative and positive emotion', 'behavioral motivation - desire', 'preventive intentions']","[{'cui': 'C0205115', 'cui_str': 'Afferent'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C1172410', 'cui_str': 'ASK protein, human'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1282914', 'cui_str': 'Circumscribed'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0016452', 'cui_str': 'Foods'}]",[],"[{'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]",2.0,0.0661434,"In Study 1, participants thinking about an outcome in the future estimated more negative emotion than those thinking about an outcome in the past.","[{'ForeName': 'Amanda J', 'Initials': 'AJ', 'LastName': 'Dillard', 'Affiliation': 'Department of Psychology, Grand Valley State University, Allendale, MI, USA.'}, {'ForeName': 'Kristy K', 'Initials': 'KK', 'LastName': 'Dean', 'Affiliation': 'Department of Psychology, Grand Valley State University, Allendale, MI, USA.'}, {'ForeName': 'HanaLi', 'Initials': 'H', 'LastName': 'Gilbert', 'Affiliation': 'Department of Psychology, Grand Valley State University, Allendale, MI, USA.'}, {'ForeName': 'Isaac M', 'Initials': 'IM', 'LastName': 'Lipkus', 'Affiliation': 'School of Nursing, Duke University, Durham, NC, USA.'}]",Psychology & health,['10.1080/08870446.2020.1795171'] 2387,32698622,Nostalgic Emotional Valence and Its Effects on Help-Seeking in Depression. An Application of the Theory of Planned Behavior.,"In times of distress, people show a tendency to remember the 'good old days,' a bittersweet emotion called Nostalgia. This study advances the role of nostalgic emotions to influence help-seeking intentions in depression. Depression is a critical public health concern, which can be mitigated by seeking professional psychological help. Several communication researchers have studied this area to improve help-seeking intentions through message design and evaluation. This study investigates the use of nostalgic valence: positive, negative, and coactive to influence help-seeking behavioral intentions. Using the theory of planned behavior (TPB) as a guiding framework, the study examined the effects of nostalgic valence on emotions, attitude, perceived behavioral control, and subjective norms to seek help. The study recruited 366 participants, experiencing mild to severe levels of depression, from Amazon Mechanical Turk. Participants were randomly assigned to one of the three video conditions: positive, negative, or coactive nostalgia. The study resulted in two distinct findings. First, we found that positive, negative, and coactive nostalgic messages lead to different levels of emotional responses. Specifically, the coactive nostalgic condition resulted in the least positive emotional response. Second, these different levels of emotional responses are correlated with perceived behavioral control, and descriptive norms that mediated the effects of nostalgia on help-seeking intentions. The main contribution of our study is to inform health communicators about the complexity of persuading people with depression to seek help via nostalgic emotional appeals. Theoretical implications of the study in context with emotion infusion are discussed, and practical implications for interventions to design depression-related help seeking campaigns are provided.",2020,"First, we found that positive, negative, and coactive nostalgic messages lead to different levels of emotional responses.","['366 participants, experiencing mild to severe levels of depression, from Amazon Mechanical Turk']",[],"['Nostalgic Emotional Valence', 'least positive emotional response']","[{'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1319226', 'cui_str': 'Level of depression'}, {'cui': 'C0325969', 'cui_str': 'Genus Amazona'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0337911', 'cui_str': 'Turks'}]",[],"[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",366.0,0.024318,"First, we found that positive, negative, and coactive nostalgic messages lead to different levels of emotional responses.","[{'ForeName': 'Syed Ali', 'Initials': 'SA', 'LastName': 'Hussain', 'Affiliation': 'Walter Cronkite School of Journalism and Mass Communication, Arizona State University.'}, {'ForeName': 'Saleem', 'Initials': 'S', 'LastName': 'Alhabash', 'Affiliation': 'Department of Advertising and Public Relations, Michigan State University.'}]",Health communication,['10.1080/10410236.2020.1794549'] 2388,32698634,"Effect of oral administration of Triphala, a polyphenol-rich prebiotic, on scalp sebum in patients with scalp seborrhea A Randomized Clinical Trial.","Background: Although there are various therapeutic options to control oily skin, they have potential side effects and limitations especially in long-term use. Pre/probiotics may have beneficial effects in atopic dermatitis' acne, dandruff, and seborrhea, demonstrated by some clinical trials. This trial conducted to determine whether herbal prebiotic Triphala is effective in reducing scalp sebum secretion in patients with scalp seborrhea. Methods: In this 8week patient and outcome assessor-blinded, placebo-controlled trial participants with scalp seborrhea aged 14-50 years were randomized to Triphala or placebo groups. 1 g of Triphala (standardized as 91.82 ± 0.5 mg gallic acid) or placebo (wheat flour) were administered BID. Scalp sebum levels were detected objectively using Sebumeter® sm 815, and treatment satisfaction was measured using a score between 0 and 100. [Registration no. IRCT2014070218332N1]. Results: Eighty patients completed the study (40 in Triphala group and 40 in placebo group). Participants in the Triphala group experienced 25.34 scores (95% CI, 0.39-50.29: P  = 0.047) more improvement in scalp sebum levels compared with the placebo group. The mean percentage of patients' satisfaction was 37.91 (24.88) in the Triphala group and 17.89 (25.80) in the placebo group ( P  = 0.001). Conclusion: Herbal prebiotic Triphala significantly reduced scalp sebum scores compared to placebo.",2020,"Participants in the Triphala group experienced 25.34 scores (95% CI, 0.39-50.29: P  = 0.047) more improvement in scalp sebum levels compared with the placebo group.","['patients with scalp seborrhea', 'Eighty patients completed the study (40 in Triphala group and 40 in placebo group', 'controlled trial participants with scalp seborrhea aged 14-50 years']","['herbal prebiotic Triphala', 'Triphala (standardized as 91.82\u2009±\u20090.5\u2009mg gallic acid) or placebo (wheat flour', 'Triphala, a polyphenol-rich prebiotic', 'Herbal prebiotic Triphala', 'Triphala or placebo', 'placebo']","['scalp sebum secretion', 'scalp sebum scores', 'Scalp sebum levels', 'scalp sebum levels', ""mean percentage of patients' satisfaction""]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0221244', 'cui_str': 'Seborrheic dermatitis of scalp'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1958185', 'cui_str': 'triphala'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0376667', 'cui_str': 'Herbals'}, {'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C1958185', 'cui_str': 'triphala'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0016979', 'cui_str': 'Gallic acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0458980', 'cui_str': 'Wheat flour'}, {'cui': 'C0071649', 'cui_str': 'Polyphenol'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}]","[{'cui': 'C0036270', 'cui_str': 'Scalp structure'}, {'cui': 'C0232436', 'cui_str': 'Sebaceous gland activity'}, {'cui': 'C0036511', 'cui_str': 'Sebum'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",,0.680131,"Participants in the Triphala group experienced 25.34 scores (95% CI, 0.39-50.29: P  = 0.047) more improvement in scalp sebum levels compared with the placebo group.","[{'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Zareie', 'Affiliation': 'Department of Persian Medicine, The School of Persian Medicine, Shahid Sadoughi University of Medical Sciences, Ardakan, Yazd, Iran.'}, {'ForeName': 'Parvin', 'Initials': 'P', 'LastName': 'Mansouri', 'Affiliation': 'Department of Dermatology, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hamed', 'Initials': 'H', 'LastName': 'Hosseini', 'Affiliation': 'Department of Epidemiology, Center for Research and Training in Skin Diseases and Leprosy (CRTSDL), Tehran University of Medical Sciences (TUMS), Tehran, Iran.'}, {'ForeName': 'Omid', 'Initials': 'O', 'LastName': 'Sadeghpour', 'Affiliation': 'School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Laila', 'Initials': 'L', 'LastName': 'Shirbeigi', 'Affiliation': 'Department of Persian medicine, School of Persian medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Someyeh', 'Initials': 'S', 'LastName': 'Hejazi', 'Affiliation': 'Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Emtiazy', 'Affiliation': 'Department of Persian Medicine, The School of Persian Medicine, Shahid Sadoughi University of Medical Sciences, Ardakan, Yazd, Iran.'}]",The Journal of dermatological treatment,['10.1080/09546634.2020.1800568'] 2389,32698681,Efficacy of laparoscopic gastric bypass vs laparoscopic sleeve gastrectomy in treating obesity combined with type-2 diabetes.,"OBJECTIVE This prospective study compared the efficacy and safety of laparoscopic gastric bypass and laparoscopic sleeve gastrectomy in treating overweight and obese patients with BMI>28 kg/m 2 and type-2 diabetes. METHODS Patients were randomized into a gastric bypass group (n=77) or a gastrectomy group (n=80). The surgery time, intraoperative blood loss, recovery time, and hospitalization time were collected. BMI, waistline, hipline, C-peptide level, insulin resistance index (HOMA-IR), and their blood and lipid profile, were also measured. RESULTS Surgery time and blood loss were significantly higher in the gastrectomy group, when compared to the gastric bypass group ( P <0.05). In both groups, the levels of BMI, waist circumference and hip circumference (but not their ratio) gradually and significantly decreased after surgery compared with baseline ( P <0.05), and no significant difference was found between these two groups. The C-peptide level, HOMA-IR, fasting blood glucose, 2-hour postprandial blood glucose and glycosylated hemoglobin gradually and significantly decreased after surgery compared with the values before treatment ( P <0.05). The levels of total cholesterol, triglyceride, LDL, and monocyte chemoattractant protein-1 were also lower after surgery in both groups, while HDL and glucagon-like peptide-1 were significantly higher after surgery compared with the values before treatment ( P <0.05). However, no significant difference was found between these two groups of patients. CONCLUSION Both laparoscopic gastric bypass and laparoscopic sleeve gastrectomy improved the BMI and diabetic conditions of overweight/obese diabetics, while laparoscopic sleeve gastrectomy had a shorter surgical time and less blood loss.",2020,"Both laparoscopic gastric bypass and laparoscopic sleeve gastrectomy improved the BMI and diabetic conditions of overweight/obese diabetics, while laparoscopic sleeve gastrectomy had a shorter surgical time and less blood loss.","['treating overweight and obese patients with BMI>28 kg/m 2 and type-2 diabetes', 'overweight/obese diabetics', 'Patients were randomized into a gastric bypass group (n=77) or a gastrectomy group (n=80']","['laparoscopic gastric bypass and laparoscopic sleeve gastrectomy', 'laparoscopic gastric bypass vs laparoscopic sleeve gastrectomy', 'laparoscopic sleeve gastrectomy']","['levels of total cholesterol, triglyceride, LDL, and monocyte chemoattractant protein-1', 'C-peptide level, HOMA-IR, fasting blood glucose, 2-hour postprandial blood glucose and glycosylated hemoglobin', 'levels of BMI, waist circumference and hip circumference', 'surgery time, intraoperative blood loss, recovery time, and hospitalization time', 'BMI, waistline, hipline, C-peptide level, insulin resistance index (HOMA-IR), and their blood and lipid profile', 'efficacy and safety', 'Surgery time and blood loss', 'BMI and diabetic conditions', 'surgical time and less blood loss', 'HDL and glucagon-like peptide-1']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0017125', 'cui_str': 'Bypass of stomach'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0017118', 'cui_str': 'Gastrectomy'}]","[{'cui': 'C4039248', 'cui_str': 'Laparoscopic bypass of stomach'}, {'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0128897', 'cui_str': 'Monocyte Chemoattractant Protein-1'}, {'cui': 'C0202100', 'cui_str': 'Insulin C-peptide measurement'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C1292425', 'cui_str': '2 hours'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0562350', 'cui_str': 'Hip circumference'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}]",,0.0129514,"Both laparoscopic gastric bypass and laparoscopic sleeve gastrectomy improved the BMI and diabetic conditions of overweight/obese diabetics, while laparoscopic sleeve gastrectomy had a shorter surgical time and less blood loss.","[{'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': ""Department of gastrointestinal surgery, The affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang; Lianyungang Clinical College of Nanjing Medical University, The First People's Hospital of Lianyungang , 222000, JiangSu, China.""}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': ""Department of gastrointestinal surgery, The affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang; Lianyungang Clinical College of Nanjing Medical University, The First People's Hospital of Lianyungang , 222000, JiangSu, China.""}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': ""Department of gastrointestinal surgery, The affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang; Lianyungang Clinical College of Nanjing Medical University, The First People's Hospital of Lianyungang , 222000, JiangSu, China.""}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'Department of Gastrointestinal Surgery, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Kangda College, Nanjing Medical University.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Yin', 'Affiliation': ""Department of Endocrinology, The affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang; Lianyungang Clinical College of Nanjing Medical University, The First People's Hospital of Lianyungang , 222000, Jiangsu, China.""}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Hui', 'Affiliation': ""Department of Endocrinology, The affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang; Lianyungang Clinical College of Nanjing Medical University, The First People's Hospital of Lianyungang , 222000, Jiangsu, China.""}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Ma', 'Affiliation': ""Department of Endocrinology, The affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang; Lianyungang Clinical College of Nanjing Medical University, The First People's Hospital of Lianyungang , 222000, Jiangsu, China.""}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Yang', 'Affiliation': ""Department of Endocrinology, The affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang; Lianyungang Clinical College of Nanjing Medical University, The First People's Hospital of Lianyungang , 222000, Jiangsu, China.""}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Zheng', 'Affiliation': ""Department of Endocrinology, The affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang; Lianyungang Clinical College of Nanjing Medical University, The First People's Hospital of Lianyungang , 222000, Jiangsu, China.""}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': ""Department of Endocrinology, The affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang; Lianyungang Clinical College of Nanjing Medical University, The First People's Hospital of Lianyungang , 222000, Jiangsu, China.""}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Xu', 'Affiliation': ""Department of Endocrinology, The affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang; Lianyungang Clinical College of Nanjing Medical University, The First People's Hospital of Lianyungang , 222000, Jiangsu, China.""}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': ""Department of Endocrinology, The affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang; Lianyungang Clinical College of Nanjing Medical University, The First People's Hospital of Lianyungang , 222000, Jiangsu, China.""}]",British journal of biomedical science,[] 2390,32698694,Tailoring Health-promoting Programs for Patients with Chronic Kidney Disease: Randomized Controlled Trial.,"Research on dietary and lifestyle modifications to decrease cardiovascular risk and slow disease progression has been limited to patients in the later stages of chronic kidney disease (CKD). Studies on the effectiveness of stage-of-change-tailored interventions on lifestyle modifications for individuals with early stage CKD are limited. Using random assignment, 60 patients with early stage CKD who received up to six tailored intervention visits over 30 months were compared to 60 usual care patients on physical indicators, lifestyle behaviors, and quality of life. Tailored interventions were consistent with the trans-theoretical Model of Change. Waist circumference, nutrition, and stress management improved over time in the intervention group. There was no difference or change in quality of life. To promote a healthier lifestyle, findings suggest that clinicians working with patients with CKD should consider patients' readiness to change their behaviors as well as implementation strategies tailored for different processes of change.",2020,There was no difference or change in quality of life.,"['patients in the later stages of chronic kidney disease (CKD', '60 patients with early stage CKD who received', 'individuals with early stage CKD', 'Patients with Chronic Kidney Disease']","['Tailoring Health-promoting Programs', 'up to six tailored intervention visits']","['Waist circumference, nutrition, and stress management', 'quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",60.0,0.0266218,There was no difference or change in quality of life.,"[{'ForeName': 'Hsiu-Lan', 'Initials': 'HL', 'LastName': 'Teng', 'Affiliation': 'Department of Nursing, Foo-Yin University, Kaohsiung City, Taiwan.'}, {'ForeName': 'Miaofen', 'Initials': 'M', 'LastName': 'Yen', 'Affiliation': 'Department of Nursing, College of Medicine, National Cheng Kung University, Tainan City, Taiwan.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Fetzer', 'Affiliation': 'Department of Nursing, College of Health and Human Services, University of New Hampshire, Durham, NH, USA.'}, {'ForeName': 'Shih-Yuan', 'Initials': 'SY', 'LastName': 'Hung', 'Affiliation': 'Research Institute of Clinical Medicine, School of Medicine, National Cheng Kung University/Renal Division, National Cheng Kung University Hospital, Tainan City, Taiwan.'}, {'ForeName': 'Junne-Ming', 'Initials': 'JM', 'LastName': 'Sung', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, E-DA Hospital / Department of Health Management, I-Shou University, Kaohsiung City, Taiwan.'}]",Western journal of nursing research,['10.1177/0193945920942487'] 2391,32692121,The Effects of Shared Decision Making on Different Renal Replacement Therapy Decisions in Patients With Chronic Kidney Disease.,"BACKGROUND The prevalence and incidence of end-stage renal disease (ESRD) in Taiwan are the highest of any country in the world. The different renal replacement therapies that are adopted by patients with ESRD significantly affect their social roles and daily life. However, because of the complexities of different renal replacement therapies, patients may be unsure of which to choose. PURPOSE The aim of this study was to explore the effectiveness of a shared decision-making (SDM) program regarding different renal replacement therapies for patients with chronic kidney disease. METHODS A quasi-experimental design was conducted at two similar regional hospitals in Miaoli County, Taiwan. One hospital hosted the intervention group, and the other hospital hosted the control group. The 31 participants in the intervention group took part in a SDM program. The 36 control group participants took part in the pre-ESRD care program. Data collection included demographic and disease characteristics, decisional conflict scale, and decision self-efficacy scale. Results were analyzed using independent t test, Fisher's exact test, generalized estimating equation, and paired t tests. RESULTS The study results revealed that the intervention group experienced a significant increase in decision self-efficacy and a significant decrease in decisional conflict at 1 month after receiving the SDM intervention in comparison to before and immediately after receiving the intervention. Moreover, the intervention group had higher decision self-efficacy and lower decisional conflict than the control group. CONCLUSIONS/IMPLICATIONS FOR PRACTICE The SDM program may be an effective intervention for complex decision-making processes, such as the process involved in making renal replacement treatment decisions. The SDM program group intervention improved decisional conflict and decision self-efficacy. Thus, to improve patients' decision-making processes, the application of an SDM program focused on the personal values and opinions of patients with ESRD will be necessary. Physicians and case managers of patients with ESRD should act in complementary and cooperative roles in SDM programs.",2020,"Moreover, the intervention group had higher decision self-efficacy and lower decisional conflict than the control group. ","['A quasi-experimental design was conducted at two similar regional hospitals in Miaoli County, Taiwan', 'Patients With Chronic Kidney Disease', 'Physicians and case managers of patients with ESRD', '31 participants in the intervention group took part in a SDM program', 'patients with chronic kidney disease']","['SDM intervention', 'shared decision-making (SDM) program']","['higher decision self-efficacy and lower decisional conflict', 'social roles and daily life', 'decisional conflict and decision self-efficacy', 'decision self-efficacy', 'demographic and disease characteristics, decisional conflict scale, and decision self-efficacy scale', 'decisional conflict']","[{'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0687694', 'cui_str': 'Case manager'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3179495', 'cui_str': 'Decision Making, Shared'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0231394', 'cui_str': 'Decisional conflict'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.0143736,"Moreover, the intervention group had higher decision self-efficacy and lower decisional conflict than the control group. ","[{'ForeName': 'Ya-Fang', 'Initials': 'YF', 'LastName': 'Ho', 'Affiliation': '1PhD, RN, Assistant Professor, School of Nursing & Graduate Institute of Nursing, China Medical University, Taiwan, ROC 2PhD, RN, Associate Professor, Institute of Clinical Nursing, School of Nursing, National Yang-Ming University, Taiwan, ROC 3MD, Chair Professor, China Medical University Hospital, Taiwan, ROC 4PhD, RN, Professor, School and Graduate Institute of Nursing, College of Medicine, National Taiwan University, and Director, Nursing Department, National Taiwan University Hospital, Taiwan, ROC 5PhD, Professor, Institute of Hospital and Health Care Administration, Community Medicine Research Center, Preventive Medicine Research Center, National Yang-Ming University, Taiwan, ROC 6PhD, RN, Professor, Institute of Community Health Care, National Yang-Ming University, Taiwan, ROC.'}, {'ForeName': 'Yu-Chi', 'Initials': 'YC', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Chiu-Chin', 'Initials': 'CC', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Wen-Yu', 'Initials': 'WY', 'LastName': 'Hu', 'Affiliation': ''}, {'ForeName': 'Kuan-Chia', 'Initials': 'KC', 'LastName': 'Lin', 'Affiliation': ''}, {'ForeName': 'I-Chuan', 'Initials': 'IC', 'LastName': 'Li', 'Affiliation': ''}]",The journal of nursing research : JNR,['10.1097/jnr.0000000000000386'] 2392,32692124,Cognitive Remediation for Outpatients With Recurrent Mood Disorders: A Feasibility Study.,"Current first-line treatments for mood disorders often improve mood symptoms but do little to reduce cognitive and functional impairment. This 10-week, uncontrolled, feasibility study evaluated a cognitive remediation (CR) intervention for individuals with recurrent mood disorders. Adults with recurrent major depressive disorder or bipolar disorder, who had recently been treated and discharged from specialized mental health services, were eligible for inclusion. Twenty patients completed the CR intervention, which involved weekly individual sessions with a therapist, as well as the practice of computerized CR exercises between sessions. The study assessed the acceptability of the assessment and treatment as well as outcomes in terms of mood symptoms, general functioning, and cognitive functioning. Patients reported that they were generally satisfied with the CR intervention and were close to reaching the recommended amount of practice between therapist-led sessions. The retention rate from baseline to posttreatment was 87%. When within-group effects were examined, large effect sizes over time (>0.9) were seen for 2 cognitive variables that measured executive function: Category Switching-Total Words and Total Switching Score. Findings from the current feasibility study will inform the development of a large randomized controlled trial of an adapted version of the CR intervention for mood disorders assessed in this preliminary study, with the goal of translating the intervention into clinical practice.",2020,"When within-group effects were examined, large effect sizes over time (>0.9) were seen for 2 cognitive variables that measured executive function: Category Switching-Total Words and Total Switching Score.","['individuals with recurrent mood disorders', 'Twenty patients completed the', 'Outpatients', 'Adults with recurrent major depressive disorder or bipolar disorder, who had recently been treated and discharged from specialized mental health services, were eligible for inclusion', 'With Recurrent Mood Disorders']","['cognitive remediation (CR) intervention', 'CR intervention']","['executive function: Category Switching-Total Words and Total Switching Score', 'retention rate', 'Cognitive Remediation', 'mood symptoms, general functioning, and cognitive functioning']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0525045', 'cui_str': 'Mood disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0154409', 'cui_str': 'Recurrent major depressive episodes'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0025355', 'cui_str': 'Mental health service'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}]","[{'cui': 'C4277695', 'cui_str': 'Cognitive Remediation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C4277695', 'cui_str': 'Cognitive Remediation'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}]",,0.0344902,"When within-group effects were examined, large effect sizes over time (>0.9) were seen for 2 cognitive variables that measured executive function: Category Switching-Total Words and Total Switching Score.","[{'ForeName': 'Katie M', 'Initials': 'KM', 'LastName': 'Douglas', 'Affiliation': ""DOUGLAS, JORDAN, INDER, CROWE: Department of Psychological Medicine, University of Otago, Christchurch, New Zealand MULDER, BEAGLEHOLE, PORTER: Department of Psychological Medicine, University of Otago, and Specialist Mental Health Services, Canterbury District Health Board, Christchurch, New Zealand LACEY: Department of Psychological Medicine, University of Otago, Christchurch, New Zealand, and West Coast District Health Board, Greymouth, New Zealand BOWIE: Department of Psychology, Queen's University, Kingston, ON, Canada.""}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Jordan', 'Affiliation': ''}, {'ForeName': 'Maree L', 'Initials': 'ML', 'LastName': 'Inder', 'Affiliation': ''}, {'ForeName': 'Marie T', 'Initials': 'MT', 'LastName': 'Crowe', 'Affiliation': ''}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Mulder', 'Affiliation': ''}, {'ForeName': 'Cameron', 'Initials': 'C', 'LastName': 'Lacey', 'Affiliation': ''}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Beaglehole', 'Affiliation': ''}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Bowie', 'Affiliation': ''}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Porter', 'Affiliation': ''}]",Journal of psychiatric practice,['10.1097/PRA.0000000000000487'] 2393,32693198,Short term effects of the REAL media e-learning media literacy substance prevention curriculum: An RCT of adolescents disseminated through a community organization.,"BACKGROUND The primary aim of this study was to evaluate the short-term effects of testing an e-learning program to reduce adolescent substance use and abuse. Early initiation of substance use is linked to a variety of negative outcomes, thus effective intervention programs are needed. One approach is to use media literacy to capitalize on adolescents' immersion with media in a variety of forms. We developed, implemented, and tested an engaging substance use prevention program by collaborating with a youth-oriented community partner (4-H). METHODS 639 middle adolescents from nine U.S. states participated in an RCT of REAL media. Participants completed a series of online surveys and were randomized to use an online substance prevention program (REAL media) or serve as control (delayed program use). Self-report surveys were administered at three points in time. This short-term evaluation uses data from the pretest (Time 1) and short-term posttest three-month surveys, which measured demographics, self-efficacy to counterargue, and injunctive and descriptive substance use norms. RESULTS Participants who completed the REAL media program reported increased self-efficacy to counterargue and decreased positive injunctive norms compared to control participants who did not complete the program. No significant differences were observed for descriptive norms. CONCLUSIONS We found support for the REAL media program in changing key predictors of youth substance use demonstrating (1) the efficacy of media literacy interventions targeting adolescents and (2) that e-learning substance use prevention efforts can be adapted for and implemented through community organizations.",2020,"RESULTS Participants who completed the REAL media program reported increased self-efficacy to counterargue and decreased positive injunctive norms compared to control participants who did not complete the program.",['639 middle adolescents from nine U.S. states participated in an RCT of REAL media'],"['e-learning program', 'engaging substance use prevention program by collaborating with a youth-oriented community partner (4-H', 'REAL media e-learning media literacy substance prevention curriculum', 'online substance prevention program (REAL media) or serve as control (delayed program use']",['self-efficacy to counterargue and decreased positive injunctive norms'],"[{'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}]","[{'cui': 'C0086858', 'cui_str': 'Programmed Learning'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0150358', 'cui_str': 'Substance use prevention'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}]",639.0,0.0245006,"RESULTS Participants who completed the REAL media program reported increased self-efficacy to counterargue and decreased positive injunctive norms compared to control participants who did not complete the program.","[{'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Greene', 'Affiliation': 'Department of Communication, Rutgers, the State University of New Jersey, 4 Huntington St., New Brunswick, NJ, 08901, USA. Electronic address: klgreene@rutgers.edu.'}, {'ForeName': 'Anne E', 'Initials': 'AE', 'LastName': 'Ray', 'Affiliation': 'Department of Health, Behavior & Society, University of Kentucky, 343 Bowman Hall, Lexington, KY, 40536, USA.'}, {'ForeName': 'Hye Jeong', 'Initials': 'HJ', 'LastName': 'Choi', 'Affiliation': 'Department of Health Sciences, University of Missouri, 501 Clark Hall, Columbia, MO, 65211, USA.'}, {'ForeName': 'Shannon D', 'Initials': 'SD', 'LastName': 'Glenn', 'Affiliation': 'Department of Communication, Rutgers, the State University of New Jersey, 4 Huntington St., New Brunswick, NJ, 08901, USA; REAL Prevention, LLC, 130 Pearl Brook Drive, Clifton, NJ, 07013, USA.'}, {'ForeName': 'Rachel E', 'Initials': 'RE', 'LastName': 'Lyons', 'Affiliation': 'Department of 4-H Youth Development, Rutgers, the State University of New Jersey, 88 Lipman Drive, New Brunswick, NJ, 08901, USA.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Hecht', 'Affiliation': 'REAL Prevention, LLC, 130 Pearl Brook Drive, Clifton, NJ, 07013, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108170'] 2394,32693214,Biomarkers of type 2 airway inflammation as predictors of loss of asthma control during step-down therapy for well-controlled disease: The Long Acting Beta Agonist Step-down Study (LASST).,"BACKGROUND Biomarkers that can predict loss of asthma control among patients being considered for step-down therapy in well-controlled disease are lacking. OBJECTIVE To evaluate if baseline biomarkers of type 2 airway inflammation and/or serial measurement of fractional exhaled nitric oxide (FeNO) predict loss of asthma control as therapy is stepped down. METHODS In sub-analyses of a multi-center randomized, double-blind, parallel 3-arm trial comparing strategies for step-down therapy in well-controlled asthma (LASST), we assessed whether baseline atopy as determined by serum aeroallergen allergy screening test (Phadiatop), baseline serum eosinophil peroxidase (EpX), or baseline or serial FeNO measurements during follow-up, predicted the time to loss of asthma control among participants. Loss of asthma control was defined in the study protocol. We analyzed these associations in adjusted models including all participants, after testing for interactions with assignment to each of the three treatment groups (continuation of stable dose of combination ICS-LABA, step-down of inhaled corticosteroid (ICS), or discontinuation of long acting bronchodilator (LABA)). RESULTS Four hundred and forty-seven of the 553 LASST participants who were randomized to one of 3 treatment arms and had at least one biomarker measurement were included in this analysis. At baseline, higher levels of FeNO were significantly associated with greater levels of multi-allergen IgE levels (P<0.001), but not with serum EpX (p=0.742). Among all participants as a group, elevations in baseline biomarkers were not predictive of higher risk of treatment failure. In addition, FeNO levels measured serially at 6-week intervals, demonstrated that compared to participants with low levels (<25 ppb), those with intermediate (25-50 ppb) and high (>50 ppb) levels did not have significantly increased likelihood of subsequent treatment failure (hazard ratios (95% confidence interval) 1.03 (0.59, 1.78) and 1.29 (0.65, 2.54), respectively. There were no significant interactions of treatment group and baseline biomarkers. CONCLUSIONS In patients with well-controlled asthma, neither baseline levels of type 2 airway inflammatory biomarkers nor serial measures of FeNO are strong predictors of treatment failure.",2020,"In patients with well-controlled asthma, neither baseline levels of type 2 airway inflammatory biomarkers nor serial measures of FeNO are strong predictors of treatment failure.",['Four hundred and forty-seven of the 553 LASST participants who were randomized to one of 3 treatment arms and had at least one biomarker measurement were included in this analysis'],"['combination ICS-LABA, step-down of inhaled corticosteroid (ICS), or discontinuation of long acting bronchodilator (LABA']","['levels of FeNO', 'likelihood of subsequent treatment failure', 'FeNO levels', 'levels of multi-allergen IgE levels', 'serum aeroallergen allergy screening test (Phadiatop), baseline serum eosinophil peroxidase (EpX), or baseline or serial FeNO measurements', 'Loss of asthma control']","[{'cui': 'C4517777', 'cui_str': '440'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0006280', 'cui_str': 'Bronchodilator agent'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4523905', 'cui_str': 'Fractional exhaled nitric oxide'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0002092', 'cui_str': 'Allergen'}, {'cui': 'C0020846', 'cui_str': 'Immunoglobulin E'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0001697', 'cui_str': 'Aeroallergen'}, {'cui': 'C1273434', 'cui_str': 'Allergy screening test'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil'}, {'cui': 'C0027021', 'cui_str': 'Peroxidase'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",553.0,0.395791,"In patients with well-controlled asthma, neither baseline levels of type 2 airway inflammatory biomarkers nor serial measures of FeNO are strong predictors of treatment failure.","[{'ForeName': 'Sonali', 'Initials': 'S', 'LastName': 'Bose', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY; Johns Hopkins School of Medicine, Baltimore, MD.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Bime', 'Affiliation': 'University of Arizona College of Medicine, Tucson, AZ.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Henderson', 'Affiliation': 'Johns Hopkins School of Medicine, Baltimore, MD.'}, {'ForeName': 'Kathryn V', 'Initials': 'KV', 'LastName': 'Blake', 'Affiliation': ""Nemours Children's Health System, Jacksonville, FL.""}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Castro', 'Affiliation': 'Washington University School of Medicine, St Louis, MO.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'DiMango', 'Affiliation': 'Columbia University College of Physicians and Surgeons, New York, NY.'}, {'ForeName': 'Nicola A', 'Initials': 'NA', 'LastName': 'Hanania', 'Affiliation': 'Baylor College of Medicine, Houston, TX.'}, {'ForeName': 'Janet T', 'Initials': 'JT', 'LastName': 'Holbrook', 'Affiliation': 'Johns Hopkins School of Medicine, Baltimore, MD.'}, {'ForeName': 'Charles G', 'Initials': 'CG', 'LastName': 'Irvin', 'Affiliation': 'University of Vermont, Burlington, VT.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Kraft', 'Affiliation': 'University of Arizona College of Medicine, Tucson, AZ.'}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Peters', 'Affiliation': 'Wake Forest University School of Medicine, Winston-Salem, NC.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Reibman', 'Affiliation': 'New York University School of Medicine, New York, NY.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Sugar', 'Affiliation': 'Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.'}, {'ForeName': 'Kaharu', 'Initials': 'K', 'LastName': 'Sumino', 'Affiliation': 'Washington University School of Medicine, St Louis, MO.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Wise', 'Affiliation': 'Johns Hopkins School of Medicine, Baltimore, MD.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Rogers', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: linda.rogers@mssm.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2020.06.067'] 2395,32693310,The influence of type of feedback during tablet-based delivery of intensive treatment for childhood apraxia of speech.,"PURPOSE One of the key principles of motor learning supports using knowledge of results feedback (KR, i.e., whether a response was correct / incorrect only) during high intensity motor practice, rather than knowledge of performance (KP, i.e., whether and how a response was correct/incorrect). In the future, mobile technology equipped with automatic speech recognition (ASR) could provide KR feedback, enabling this practice to move outside the clinic, supplementing speech pathology sessions and reducing burden on already stretched speech-language pathology resources. Here, we employ a randomized controlled trial design to test the impact of KR vs KP feedback on children's response to the Nuffield Dyspraxia Programme 3, delivered through an android tablet. At the time of testing, ASR was not feasible and so correctness of responses was decided by the treating clinician. METHOD Fourteen children with CAS, aged 4-10 years, participated in a parallel group design, matched for age and severity of CAS. Both groups attended a university clinic for 1-hr therapy sessions 4 days a week for 3 weeks. One group received high frequency feedback comprised of both KR and KP, in the style of traditional, face-to-face intensive intervention on all days. The other group received high frequency KR + KP feedback on 1 day per week and high frequency KR feedback on the other 3 days per week, simulating the service delivery model of one clinic session per week supported by tablet-based home practice. RESULTS Both groups had significantly improved speech outcomes at 4-months post-treatment. Post-hoc comparisons suggested that only the KP group showed a significant change from pre- to immediately post-treatment but the group difference had dissipated by 1-month post-treatment. Heterogeneity in response to intervention within the groups suggests that other factors, not measured here, may be having a substantive influence on response to intervention and feedback type. CONCLUSION Mobile technology has the potential to increase motivation and engagement with therapy and to mitigate barriers associated with distance and access to speech pathology services. Further research is needed to explore the influence of type and frequency of feedback on motor learning, optimal timing for transitioning from KP to KR feedback, and how these parameters interact with task, child and context-related factors.",2020,Post-hoc comparisons suggested that only the KP group showed a significant change from pre- to immediately post-treatment but the group difference had dissipated by 1-month post-treatment.,"['childhood apraxia of speech', 'Fourteen children with CAS, aged 4-10 years, participated in a parallel group design, matched for age and severity of CAS']","['KR vs KP feedback', 'mobile technology equipped with automatic speech recognition (ASR', 'high frequency KR + KP feedback', 'high frequency feedback comprised of both KR and KP']",['speech outcomes'],"[{'cui': 'C0750927', 'cui_str': 'Developmental verbal dyspraxia'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]","[{'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}]","[{'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",14.0,0.0201653,Post-hoc comparisons suggested that only the KP group showed a significant change from pre- to immediately post-treatment but the group difference had dissipated by 1-month post-treatment.,"[{'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'McKechnie', 'Affiliation': 'Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW, Australia; Faculty of Health, University of Canberra, Bruce, ACT, Australia. Electronic address: Jacqui.McKechnie@canberra.edu.au.'}, {'ForeName': 'Beena', 'Initials': 'B', 'LastName': 'Ahmed', 'Affiliation': 'Texas A&M University at Qatar, Doha, Qatar; Faculty of Engineering, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Gutierrez-Osuna', 'Affiliation': 'Texas A & M University, College Station, TX, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Murray', 'Affiliation': 'Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW, Australia.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'McCabe', 'Affiliation': 'Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW, Australia.'}, {'ForeName': 'Kirrie J', 'Initials': 'KJ', 'LastName': 'Ballard', 'Affiliation': 'Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW, Australia.'}]",Journal of communication disorders,['10.1016/j.jcomdis.2020.106026'] 2396,32693322,"Effects of messaging on public support for drug consumption rooms in scotland, UK.","BACKGROUND There is evidence to suggest that medically supervised drug consumption rooms (DCRs) may form part of responses to reduce drug-related harm. Although DCRs have been established globally, they are perceived by some to be a controversial approach in the UK, and Government has repeatedly rejected proposals to establish one in Glasgow, Scotland. As public support is an important component of policy development and enactment, we sought to investigate the effects of different types of message framing on public support for DCR. METHODS We undertook a cross-sectional online study with a randomised design, conducted with a nationally representative sample. Participants were randomised to one of six message conditions comprising combinations of four components. All conditions included i) a basic description of a DCR, and conditions included combinations of ii) factual information; iii) pre-emptive refutation of common public concerns about DCR; and/or iv) a sympathetic narrative describing a mother whose son died from a heroin overdose. After reading each message, participants completed a bespoke measure assessing support for DCR. Data were analysed using ANCOVA. RESULTS Complete data were obtained from 1591 participants (50.3% Female; mean age 44.9 ± 16.1 years). Compared to reading a basic description of DCR alone, there was greater support for DCR in participants receiving the refutation (p < .001); sympathetic + factual (p < .05); and sympathetic + factual + refutation (p < .001) message conditions. Presenting factual or sympathetic messages alone were not associated with increased support. CONCLUSION Our findings suggest that public support for DCRs is not improved through communication of factual statements outlining potential benefits of the intervention alone. Advocates seeking to foster public support, and thus influence policy making, should also consider communication campaigns that address common concerns that the public might have about DCRs, and present the intervention in relation to potential benefits that they hold for people indirectly affected by drug-related harm.",2020,"Compared to reading a basic description of DCR alone, there was greater support for DCR in participants receiving the refutation (p < .001);",['1591 participants (50.3% Female; mean age 44.9\xa0±\xa016.1 years'],[],[],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4319689', 'cui_str': '16.1'}, {'cui': 'C0439234', 'cui_str': 'year'}]",[],[],1591.0,0.119354,"Compared to reading a basic description of DCR alone, there was greater support for DCR in participants receiving the refutation (p < .001);","[{'ForeName': 'H R', 'Initials': 'HR', 'LastName': 'Sumnall', 'Affiliation': 'Public Health Institute, Liverpool John Moores University, Liverpool, UK. Electronic address: h.sumnall@ljmu.ac.uk.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Atkinson', 'Affiliation': 'Public Health Institute, Liverpool John Moores University, Liverpool, UK.'}, {'ForeName': 'K M A', 'Initials': 'KMA', 'LastName': 'Trayner', 'Affiliation': 'School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK; Health Protection Scotland, Glasgow, UK.'}, {'ForeName': 'S H', 'Initials': 'SH', 'LastName': 'Gage', 'Affiliation': 'Psychological Sciences, University of Liverpool, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'McAuley', 'Affiliation': 'Public Health Institute, Liverpool John Moores University, Liverpool, UK; Health Protection Scotland, Glasgow, UK.'}]",The International journal on drug policy,['10.1016/j.drugpo.2020.102855'] 2397,32693427,Capsaicin Supplementation during High-intensity Continuous Exercise: A Double-blind Study.,"To investigate the effect of acute capsaicin (CAP) supplementation on time to exhaustion, physiological responses and energy systems contribution during continuous high-intensity exercise session in runners. Fifteen recreationally-trained runners completed two randomized, double-blind continuous high-intensity exercises at the speed eliciting 90% V̇O 2peak (90% s V̇O 2peak ), 45 minutes after consuming capsaicin or an isocaloric placebo. Time to exhaustion, blood lactate concentration, oxygen consumption during and 20-min post-exercise, energy systems contribution, time to reach V̇O 2peak , heart rate and the rate of perceived exertion (RPE) were evaluated. There was no significant difference between conditions for time to reach V̇O 2peak (CAP:391.71±221.8 vs. PLA:298.20±174.5 sec, ES:0.58, p=0.872), peak lactate (CAP:7.98±2.11 vs. PLA:8.58±2.15 µmol, ES:-0.28, p=0.257), time to exhaustion (CAP:654.28±195.44 vs. PLA:709.20±208.44 sec, ES:-0.28, p=0.462, end-of-exercise heart rate (CAP:177.6±14.9 vs. PLA:177.5±17.9 bpm, ES:-0.10, p=0.979) and end-of-exercise RPE (CAP: 19±0.8 vs. PLA: 18±2.4, ES: 0.89, p=0.623). In conclusion, acute CAP supplementation did not increase time to exhaustion during high-intensity continuous exercise nor alter physiological responses in runners.",2020,"There was no significant difference between conditions for time to reach V̇O 2peak (CAP:391.71±221.8 vs. PLA:298.20±174.5 sec, ES:0.58, p=0.872), peak lactate (CAP:7.98±2.11 vs. PLA:8.58±2.15 µmol, ES:-0.28, p=0.257), time to exhaustion (CAP:654.28±195.44 vs. PLA:709.20±208.44 sec, ES:-0.28, p=0.462, end-of-exercise heart rate (CAP:177.6±14.9 vs. PLA:177.5±17.9 bpm, ES:-0.10, p=0.979) and end-of-exercise RPE (CAP:","['runners', 'High-intensity Continuous Exercise', 'Fifteen recreationally-trained runners']","['exercise RPE (CAP', 'acute capsaicin (CAP) supplementation', 'PLA', 'capsaicin or an isocaloric placebo', 'double-blind continuous high-intensity exercises at the speed eliciting 90% V̇O 2peak', 'Capsaicin Supplementation']","['time to reach V̇O 2peak', 'time to exhaustion', 'peak lactate', 'exercise heart rate', 'Time to exhaustion, blood lactate concentration, oxygen consumption during and 20-min post-exercise, energy systems contribution, time to reach V̇O 2peak , heart rate and the rate of perceived exertion (RPE']","[{'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0035322', 'cui_str': 'Structure of retinal pigment epithelium'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0006931', 'cui_str': 'Capsaicin'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0456170', 'cui_str': 'Left atrial pressure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0449265', 'cui_str': 'Elicited by'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0035322', 'cui_str': 'Structure of retinal pigment epithelium'}]",,0.50741,"There was no significant difference between conditions for time to reach V̇O 2peak (CAP:391.71±221.8 vs. PLA:298.20±174.5 sec, ES:0.58, p=0.872), peak lactate (CAP:7.98±2.11 vs. PLA:8.58±2.15 µmol, ES:-0.28, p=0.257), time to exhaustion (CAP:654.28±195.44 vs. PLA:709.20±208.44 sec, ES:-0.28, p=0.462, end-of-exercise heart rate (CAP:177.6±14.9 vs. PLA:177.5±17.9 bpm, ES:-0.10, p=0.979) and end-of-exercise RPE (CAP:","[{'ForeName': 'Camila S', 'Initials': 'CS', 'LastName': 'Padilha', 'Affiliation': 'Laboratory of Exercise Biochemistry. Department of Physical Education. Universidade Estadual de Londrina, Paraná, Brazil.'}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Billaut', 'Affiliation': 'Département de Kinésiologie, Université Laval, Quebec, Canada.'}, {'ForeName': 'Caique', 'Initials': 'C', 'LastName': 'Figueiredo', 'Affiliation': 'Exercise and Immunometabolism Research Group. Post-Graduation Program in Physiotherapy. Department of Physical Education. State University of São Paulo (UNESP). School of T-echnology and Sciences. Presidente Prudente, São Paulo, Brazil.'}, {'ForeName': 'Valéria Leme Gonçalves', 'Initials': 'VLG', 'LastName': 'Panissa', 'Affiliation': 'Physical Education, University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Fabrício Eduardo', 'Initials': 'FE', 'LastName': 'Rossi', 'Affiliation': 'Department of Physical Education, Unversidade Federal do Piaui, Teresina, Brazil.'}, {'ForeName': 'Fabio S', 'Initials': 'FS', 'LastName': 'Lira', 'Affiliation': 'Exercise and Immunometabolism Research Group. Post-Graduation Program in Moviment Sicences. Department of Physical Education. State University of São Paulo (UNESP). School of Technology and Sciences. Presidente Prudente, São Paulo, Brazil.'}]",International journal of sports medicine,['10.1055/a-1088-5388'] 2398,32694184,Restarting CPAP Therapy for Sleep Apnea After a Previous Failure.,"BACKGROUND About one third of patients fail their first CPAP trial due to several factors. Despite its clinical importance, data on the success of CPAP re-initiation are scarce. METHODS Of the 6,231 patients referred to our sleep unit for sleep apnea, we included 224 subjects referred for re-initiation of CPAP therapy (re-CPAP). The control group consisted of 228 CPAP-naïve subjects referred for CPAP initiation. Data on subject characteristics, sleep study, and CPAP outcome were collected. RESULTS The re-CPAP group had more severe apnea than the control group. After at least 1 y of CPAP therapy, 52% of the re-CPAP group stayed on therapy; this was significantly lower than the 67% adherence for the control group ( P = .001). No gender difference was observed in the control group ( P = .12), whereas women in the re-CPAP group remained on therapy significantly less than men ( P = .002). CONCLUSIONS The percentage of subjects who stayed on CPAP therapy after 1 y was significantly reduced when CPAP was re-initiated compared to the control group. CPAP acceptance after re-initiation was higher among men than women. Further studies are necessary to explain this gender difference.",2020,"No gender difference was observed in the control group ( P = .12), whereas women in the re-CPAP group remained on therapy significantly less than men ( P = .002). ","['224 subjects referred for re-initiation of CPAP therapy (re-CPAP', '6,231 patients referred to our sleep unit for sleep apnea', 'men than women']","['228 CPAP-naïve subjects referred for CPAP initiation', 'Restarting CPAP Therapy']","['CPAP acceptance', 'severe apnea', 'Sleep Apnea']","[{'cui': 'C4319560', 'cui_str': '224'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0037315', 'cui_str': 'Sleep apnea'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0037315', 'cui_str': 'Sleep apnea'}]",224.0,0.0300057,"No gender difference was observed in the control group ( P = .12), whereas women in the re-CPAP group remained on therapy significantly less than men ( P = .002). ","[{'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Avellan-Hietanen', 'Affiliation': 'Sleep Unit, Heart and Lung Centre, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. heidi.avellan-hietanen@hus.fi.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Maasilta', 'Affiliation': 'Sleep Unit, Heart and Lung Centre, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Adel', 'Initials': 'A', 'LastName': 'Bachour', 'Affiliation': 'Sleep Unit, Heart and Lung Centre, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.'}]",Respiratory care,['10.4187/respcare.07766'] 2399,32694214,"Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.","OBJECTIVE To examine the mechanisms responsible for improved glycemia with combined sodium-glucose cotransporter 2 inhibitor (SGLT2i) plus dipeptidyl peptidase 4 inhibitor therapy in type 2 diabetes. RESEARCH DESIGN AND METHODS Fifty-six patients (HbA 1c 8.9 ± 0.2% [74 ± 2 mmol/mol]) were randomized to dapagliflozin (DAPA) 10 mg, DAPA/saxagliptin (SAXA) 10/5 mg, or placebo (PCB) for 16 weeks. Basal endogenous glucose production (EGP) (3- 3 H-glucose), urinary glucose excretion, glucose/lipid oxidation, HbA 1c , and substrate/hormone levels were determined before treatment (Pre-Tx) and after treatment (Post-Tx). RESULTS At week 16, HbA 1c decrease was greater ( P < 0.05) in DAPA/SAXA (-2.0 ± 0.3%) vs. DAPA (-1.4 ± 0.2%) and greater than PCB (0.2 ± 0.2%). Day 1 of drug administration, EGP (∼2.40 mg/kg.min) decreased by -0.44 ± 0.09 mg/kg.min in PCB ( P < 0.05) but only by -0.21 ± 0.02 mg/kg.min in DAPA and DAPA/SAXA ( P < 0.05 vs. PCB). At week 16, EGP increased to 2.67 ± 0.09 mg/kg.min (DAPA) and 2.61 ± 0.08 mg/kg.min (DAPA/SAXA), despite reductions in fasting plasma glucose by 47 and 77 mg/dL, respectively, and no changes in PCB. Baseline plasma free fatty acids rose by 40 µmol/L with DAPA but declined by -110 with PCB and -90 µmol/L with DAPA/SAXA ( P < 0.05, Pre-Tx vs. Post-Tx). In DAPA, carbohydrate oxidation rates decreased from 1.1 ± 0.1 to 0.7 ± 0.1 mg/kg.min, whereas lipid oxidation rates increased from 0.6 ± 0.1 to 0.8 ± 0.1 mg/kg.min ( P < 0.01). In DAPA/SAXA, the shift in carbohydrate (1.1 ± 0.1 to 0.9 ± 0.1 mg/kg.min) and lipid (0.6 ± 0.1 to 0.7 ± 0.1 mg/kg.min) oxidation was attenuated ( P < 0.05). CONCLUSIONS The addition of SAXA to DAPA resulted in superior glycemic control compared with DAPA monotherapy partly because of increased glucose utilization and oxidation. Although the decrease in insulin/glucagon ratio was prevented by SAXA, EGP paradoxical elevation persisted, indicating that other factors mediate EGP changes in response to SGLT2i-induced glucosuria.",2020,"At week 16, HbA 1c decrease was greater ( P < 0.05) in DAPA/SAXA (-2.0 ± 0.3%) vs. DAPA (-1.4 ± 0.2%) and greater than PCB (0.2 ± 0.2%).","['Fifty-six patients (HbA 1c 8.9 ± 0.2% [74 ± 2 mmol/mol', 'Patients With Type 2 Diabetes Treated With']","['Dapagliflozin Plus Saxagliptin', 'combined sodium-glucose cotransporter 2 inhibitor (SGLT2i) plus dipeptidyl peptidase 4 inhibitor therapy', 'dapagliflozin (DAPA) 10 mg, DAPA/saxagliptin (SAXA) 10/5 mg, or placebo (PCB', 'EGP']","['glucose utilization and oxidation', 'insulin/glucagon ratio', 'carbohydrate oxidation rates', 'Clinical Parameters, Fuel Oxidation, and Glucose Kinetics', 'Basal endogenous glucose production (EGP) (3- 3 H-glucose), urinary glucose excretion, glucose/lipid oxidation, HbA 1c , and substrate/hormone levels', 'lipid oxidation rates', 'Baseline plasma free fatty acids', 'fasting plasma glucose']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1611934', 'cui_str': 'saxagliptin'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0017739', 'cui_str': 'Glucose-Sodium Transport System'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C1827106', 'cui_str': 'Dipeptidyl peptidase IV inhibitor'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C3709918', 'cui_str': 'dapagliflozin 10 MG'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0032447', 'cui_str': 'Polychlorinated biphenyl'}, {'cui': 'C0903677', 'cui_str': 'TACSTD1 protein, human'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0017687', 'cui_str': 'Glucagon'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0556991', 'cui_str': 'Fuel'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C0041119', 'cui_str': 'Tritium'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C1287355', 'cui_str': 'Hormone level - finding'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0015688', 'cui_str': 'Unesterified fatty acid'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}]",,0.0320243,"At week 16, HbA 1c decrease was greater ( P < 0.05) in DAPA/SAXA (-2.0 ± 0.3%) vs. DAPA (-1.4 ± 0.2%) and greater than PCB (0.2 ± 0.2%).","[{'ForeName': 'Yuejuan', 'Initials': 'Y', 'LastName': 'Qin', 'Affiliation': 'Texas Diabetes Institute-University Health System and UT Health San Antonio, San Antonio, TX.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Adams', 'Affiliation': 'Texas Diabetes Institute-University Health System and UT Health San Antonio, San Antonio, TX.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Solis-Herrera', 'Affiliation': 'Texas Diabetes Institute-University Health System and UT Health San Antonio, San Antonio, TX.'}, {'ForeName': 'Curtis', 'Initials': 'C', 'LastName': 'Triplitt', 'Affiliation': 'Texas Diabetes Institute-University Health System and UT Health San Antonio, San Antonio, TX.'}, {'ForeName': 'Ralph', 'Initials': 'R', 'LastName': 'DeFronzo', 'Affiliation': 'Texas Diabetes Institute-University Health System and UT Health San Antonio, San Antonio, TX.'}, {'ForeName': 'Eugenio', 'Initials': 'E', 'LastName': 'Cersosimo', 'Affiliation': 'Texas Diabetes Institute-University Health System and UT Health San Antonio, San Antonio, TX cersosimo@uthscsa.edu.'}]",Diabetes care,['10.2337/dc19-1993'] 2400,32694215,"Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.","OBJECTIVE The principle of replacing prandial insulin lispro with a once-weekly glucagon-like peptide 1 receptor agonist (GLP-1RA) for type 2 diabetes inadequately controlled on a multiple daily insulin injections regimen was tested with albiglutide. RESEARCH DESIGN AND METHODS In this treat-to-target study, basal plus prandial insulin was optimized over 4 weeks before participants were randomized (1:1) to albiglutide plus optimized basal insulin glargine and lispro (dose reduced by 50% at randomization; subsequently, lispro injections were fully discontinued 4 weeks later) ( n = 402) or to continued optimized lispro plus optimized glargine ( n = 412). RESULTS Mean ± SD HbA 1c at baseline, 7.8 ± 0.6% (61 ± 7 mmol/mol) in the albiglutide + glargine group and 7.7 ± 0.6% (60 ± 7 mmol/mol) in the lispro + glargine group, was reduced at week 26 to 6.7% ± 0.8% (49 ± 8 mmol/mol) and 6.6 ± 0.8% (48 ± 8 mmol/mol), respectively (least squares [LS] difference 0.06% [95% CI -0.05 to 0.17]; noninferiority P < 0.0001). In the albiglutide + glargine group, 218 participants (54%) replaced all prandial insulin without reintroducing lispro up to week 26. Total daily prandial insulin dose was similar at baseline but was lower by 62 units/day (95% CI -65.9 to -57.8; P < 0.0001) at week 26 in the albiglutide + glargine group, and the total number of weekly injections was also reduced from 29 to 13 per week. Less severe/documented symptomatic hypoglycemia (57.2% vs. 75.0%) occurred in the albiglutide + glargine group with meaningful weight differences (LS mean ± SE -2.0 ± 0.2 vs. +2.4 ± 0.2 kg; P < 0.0001) vs. lispro + glargine. Gastrointestinal adverse events were higher with albiglutide + glargine (26% vs. 13%). CONCLUSIONS A once-weekly GLP-1RA was able to substitute for prandial insulin in 54% of people, substantially reducing the number of prandial insulin injections; glycemic control improved, with the added benefits of weight loss and less hypoglycemia in the GLP-1RA arm. Replacing prandial insulin with a weekly GLP-1RA can simplify basal plus prandial insulin treatments and achieve better outcomes in type 2 diabetes.",2020,"Gastrointestinal adverse events were higher with albiglutide + glargine (26% vs. 13%). ","['type 2 diabetes', 'Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy']","['lispro + glargine', 'lispro plus optimized glargine', 'albiglutide + glargine', 'albiglutide plus optimized basal insulin glargine and lispro', 'prandial insulin lispro with a once-weekly glucagon-like peptide 1 receptor agonist (GLP-1RA', 'Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide']","['number of prandial insulin injections; glycemic control', 'Total daily prandial insulin dose', 'weight loss and less hypoglycemia', 'total number of weekly injections', 'symptomatic hypoglycemia', 'Gastrointestinal adverse events', 'Mean ± SD HbA 1c']","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0293359', 'cui_str': 'Insulin Lispro'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2607479', 'cui_str': 'albiglutide'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0558293', 'cui_str': 'Once a week'}, {'cui': 'C1562104', 'cui_str': 'Glucagon-like peptide 1 receptor agonist-containing product'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0199782', 'cui_str': 'Administration of insulin'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}]",,0.146788,"Gastrointestinal adverse events were higher with albiglutide + glargine (26% vs. 13%). ","[{'ForeName': 'Julio', 'Initials': 'J', 'LastName': 'Rosenstock', 'Affiliation': 'Dallas Diabetes Research Center at Medical City, Dallas, TX juliorosenstock@dallasdiabetes.com.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Nino', 'Affiliation': 'Research and Development Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Collegeville, PA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Soffer', 'Affiliation': 'Research and Development Future Pipelines Discovery, GlaxoSmithKline, Collegeville, PA.'}, {'ForeName': 'Lois', 'Initials': 'L', 'LastName': 'Erskine', 'Affiliation': 'Clinical Development, GlaxoSmithKline, King of Prussia, PA.'}, {'ForeName': 'Andre', 'Initials': 'A', 'LastName': 'Acusta', 'Affiliation': 'Clinical Statistics, GlaxoSmithKline, Collegeville, PA.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Dole', 'Affiliation': 'Research and Development Future Pipelines Discovery, GlaxoSmithKline, Collegeville, PA.'}, {'ForeName': 'Molly C', 'Initials': 'MC', 'LastName': 'Carr', 'Affiliation': 'Research and Development Future Pipelines Discovery, GlaxoSmithKline, Collegeville, PA.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Mallory', 'Affiliation': 'Clinical Development, GlaxoSmithKline, King of Prussia, PA.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Home', 'Affiliation': 'Newcastle University, Newcastle upon Tyne, U.K.'}]",Diabetes care,['10.2337/dc19-2316'] 2401,32694216,Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.,"BACKGROUND Traditionally, clinical trials evaluating effects of a new therapy with creatinine-based renal end points use doubling of serum creatinine (equivalent to a 57% eGFR reduction), requiring large sample sizes. METHODS To assess whether eGFR declines <57% could detect canagliflozin's effects on renal outcomes, we conducted a post hoc study comparing effects of canagliflozin versus placebo on composite renal outcomes using sustained 57%, 50%, 40%, or 30% eGFR reductions in conjunction with ESKD and renal death. Because canagliflozin causes an acute reversible hemodynamic decline in eGFR, we made estimates using all eGFR values as well as estimates that excluded early measures of eGFR influenced by the acute hemodynamic effect. RESULTS Among the 10,142 participants, 93 (0.9%), 161 (1.6%), 352 (3.5%), and 800 (7.9%) participants recorded renal outcomes on the basis of 57%, 50%, 40%, or 30% eGFR reduction, respectively, during a mean follow-up of 188 weeks. Compared with a 57% eGFR reduction (risk ratio [RR], 0.51; 95% confidence interval [95% CI], 0.34 to 0.77), the effect sizes were progressively attenuated when using 50% (RR, 0.61; 95% CI, 0.45 to 0.83), 40% (RR, 0.70; 95% CI, 0.57 to 0.86), or 30% (RR, 0.81; 95% CI, 0.71 to 0.93) eGFR reductions. In analyses that controlled for the acute hemodynamic fall in eGFR, effect sizes were comparable, regardless of whether a 57%, 50%, 40%, or 30% eGFR reduction was used. Estimated sample sizes for studies on the basis of lesser eGFR reductions were much reduced by controlling for this early hemodynamic effect. CONCLUSIONS Declines in eGFR <57% may provide robust estimates of canagliflozin's effects on renal outcomes if the analysis controls for the drug's acute hemodynamic effect. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER CANagliflozin cardioVascular Assessment Study (CANVAS), NCT01032629 and CANVAS-R, NCT01989754.",2020,"Compared with a 57% eGFR reduction (risk ratio [RR], 0.51; 95% confidence interval [95% CI], 0.34 to 0.77), the effect sizes were progressively attenuated when using 50% (RR, 0.61; 95% CI, 0.45 to 0.83), 40% (RR, 0.70; 95% CI, 0.57 to 0.86), or 30% (RR, 0.81; 95% CI, 0.71 to 0.93) eGFR reductions.",[],"['canagliflozin versus placebo', 'Canagliflozin']","['renal death', 'renal outcomes', 'effect sizes', 'composite renal outcomes']",[],"[{'cui': 'C2974540', 'cui_str': 'canagliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0205199', 'cui_str': 'Composite'}]",10142.0,0.280517,"Compared with a 57% eGFR reduction (risk ratio [RR], 0.51; 95% confidence interval [95% CI], 0.34 to 0.77), the effect sizes were progressively attenuated when using 50% (RR, 0.61; 95% CI, 0.45 to 0.83), 40% (RR, 0.70; 95% CI, 0.57 to 0.86), or 30% (RR, 0.81; 95% CI, 0.71 to 0.93) eGFR reductions.","[{'ForeName': 'Megumi', 'Initials': 'M', 'LastName': 'Oshima', 'Affiliation': 'Department of Renal and Metabolic, The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Neal', 'Affiliation': 'Department of Renal and Metabolic, The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Tadashi', 'Initials': 'T', 'LastName': 'Toyama', 'Affiliation': 'Department of Nephrology and Laboratory Medicine, Kanazawa University, Kanazawa, Japan.'}, {'ForeName': 'Toshiaki', 'Initials': 'T', 'LastName': 'Ohkuma', 'Affiliation': 'Department of Renal and Metabolic, The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Renal and Metabolic, The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Dick', 'Initials': 'D', 'LastName': 'de Zeeuw', 'Affiliation': 'Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Hiddo J L', 'Initials': 'HJL', 'LastName': 'Heerspink', 'Affiliation': 'Department of Renal and Metabolic, The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Kenneth W', 'Initials': 'KW', 'LastName': 'Mahaffey', 'Affiliation': 'Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Fulcher', 'Affiliation': 'Royal North Shore Hospital, Sydney, New South Wales, Australia.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Canovatchel', 'Affiliation': 'Janssen Global Services, LLC, Raritan, New Jersey.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Matthews', 'Affiliation': 'Harris Manchester College, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Vlado', 'Initials': 'V', 'LastName': 'Perkovic', 'Affiliation': 'Department of Renal and Metabolic, The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia vlado.perkovic@unsw.edu.au.'}]",Journal of the American Society of Nephrology : JASN,['10.1681/ASN.2019121312'] 2402,32694328,The Impact of Unguided Trauma Simulation Practice on Novice Performance: A Randomized Controlled Trial.,"INTRODUCTION The purpose of this investigation was to determine the impact of simulator practice on task completion time, radiation use, success rate, and overall quality in a simulation of placing a distal locking screw. METHODS This was a prospective, randomized control trial with one-to-one randomization and parallel group design. Twenty-eight volunteer novice trainees (medical and premedical students) participated. Using the TraumaVision Virtual Reality Simulator (Swemac, Sweden), subjects performed locking screw placement using the ""perfect circle"" technique. All subjects underwent a pretest and posttest on the simulator. The simulator group completed three additional simulator training sessions. The primary outcome variables were simulator-collected task completion time, success rate, radiation exposure time, and overall score. RESULTS No notable difference existed between groups for pretest completion time, radiation use, success rate, or overall score. No notable difference in posttest radiation use or overall procedure score was found between groups. A significant difference existed in posttest total completion time (trained = 251.2 ± 103.4; control = 497.3 ± 223.1; P = 0.001) and success rate (64.3% versus 100%; P = 0.041) between groups. In addition, a significant difference existed in variance between groups for completion time (P = 0.029). CONCLUSIONS These findings suggest that independent simulator practice leads to improved speed and success rates; however, radiation use and overall score do not improve in the same manner. The design of simulator-based curriculum must be tailored to specific educational objectives and ultimately validated in the clinical setting.",2020,"No notable difference existed between groups for pretest completion time, radiation use, success rate, or overall score.","['Twenty-eight volunteer novice trainees (medical and premedical students) participated', 'Novice Performance']","['additional simulator training sessions', 'locking screw placement', 'Unguided Trauma Simulation Practice']","['posttest total completion time', 'posttest radiation use or overall procedure score', 'task completion time, radiation use, success rate, and overall quality', 'simulator-collected task completion time, success rate, radiation exposure time, and overall score', 'pretest completion time, radiation use, success rate, or overall score', 'success rate']","[{'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0038498', 'cui_str': 'Premedical Student'}]","[{'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0441273', 'cui_str': 'Locking screw'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0015333', 'cui_str': 'Exposure to radiation'}]",28.0,0.168417,"No notable difference existed between groups for pretest completion time, radiation use, success rate, or overall score.","[{'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Wang', 'Affiliation': 'From the Department of Orthopaedic Surgery, Mount Sinai Icahn School of Medicine, New York, NY (Dr. Wang), the Department of Orthopaedic Surgery, University of Wisconsin School of Medicine, Madison, WI (Dr. Bernardoni and Dr. Cotter), the Department of Orthopaedic Surgery, Midwest Orthopaedics, Rush University Medical Center, Chicago, IL (Dr. Levine), and the Department of Orthopaedic Surgery, University of Colorado School of Medicine, Denver, CO (Dr. Frank).'}, {'ForeName': 'Eamon D', 'Initials': 'ED', 'LastName': 'Bernardoni', 'Affiliation': ''}, {'ForeName': 'Eric J', 'Initials': 'EJ', 'LastName': 'Cotter', 'Affiliation': ''}, {'ForeName': 'Brett R', 'Initials': 'BR', 'LastName': 'Levine', 'Affiliation': ''}, {'ForeName': 'Rachel M', 'Initials': 'RM', 'LastName': 'Frank', 'Affiliation': ''}]",The Journal of the American Academy of Orthopaedic Surgeons,['10.5435/JAAOS-D-19-00225'] 2403,32694337,Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials.,"AIMS There is conflicting evidence on whether in treated hypertensive patients the risk of renal outcomes is associated with visit-to-visit SBP variability. Furthermore, limited evidence is available on how important is SBP variability for prediction of renal outcomes compared with on-treatment mean SBP. We addressed these issues in 28 790 participants of the Ongoing Treatment Alone and in combination with Ramipril Global End point Trial and Telmisartan Randomized Assessment Study in ace iNtolerant Subjects with Cardiovascular Disease trials. METHODS AND RESULTS SBP variability was expressed as the coefficient of variation of the mean with which it showed no relationship. SBP variability and mean values were obtained from five visits during the first 2 years of treatment after the end of the titration phase. Incidence of several renal outcomes (end-stage renal disease, doubling of serum creatinine, new microalbuminuria, new macroalbuminuria and their composite) was calculated from the third year of treatment onward. Patients were divided in quintiles of SBP-coefficient of variation (SBP-CV) or mean SBP, which exhibited superimposable mean blood pressure and SBP-CV values, respectively. A progressive increase of SBP-CV was not accompanied by a parallel increase in a widely adjusted (baseline and on-treatment confounders) risk of most renal outcomes (end-stage renal disease, new macroalbuminuria, new microalbuminuria and their composite) in the subsequent on-treatment years. In contrast, the adjusted risk of most renal outcomes increased progressively from the lowest to the highest quintile of on-treatment mean SBP. Progression from lowest to highest mean on-treatment SBP, but not SBP-CV, was also associated with a less frequent return to normoalbuminuria in patients with initial micro or macroalbuminuria. Renal outcome prediction was slightly improved by the combined use of SBP-CV and mean SBP quintiles. CONCLUSION Visit-to-visit SBP variability had no major predictive value for the risk of renal outcomes, which, in contrast, was sensitively predicted by mean on-treatment SBP. A further slight increase in prediction of renal outcomes was seen by combining on-treatment mean SBP and variability.",2020,"Incidence of several renal outcomes (end-stage renal disease, doubling of serum creatinine, new microalbuminuria, new macroalbuminuria and their composite) was calculated from the third year of treatment onward.",['28\u200a790 participants of the Ongoing Treatment Alone and in combination with Ramipril Global End point Trial and Telmisartan Randomized Assessment Study in ace iNtolerant Subjects with Cardiovascular Disease trials'],[],"['SBP variability and mean values', 'adjusted risk of most renal outcomes', 'prediction of renal outcomes', 'SBP-CV', 'SBP-CV and mean SBP quintiles', 'Incidence of several renal outcomes (end-stage renal disease, doubling of serum creatinine, new microalbuminuria, new macroalbuminuria and their composite', 'Visit-to-visit blood pressure variability and renal outcomes', 'SBP-coefficient of variation (SBP-CV) or mean SBP']","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0072973', 'cui_str': 'Ramipril'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0248719', 'cui_str': 'telmisartan'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0050385', 'cui_str': 'AC protocol'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}]",[],"[{'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0730345', 'cui_str': 'Microalbuminuria'}, {'cui': 'C1654921', 'cui_str': 'Macroalbuminuria'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]",,0.0179591,"Incidence of several renal outcomes (end-stage renal disease, doubling of serum creatinine, new microalbuminuria, new macroalbuminuria and their composite) was calculated from the third year of treatment onward.","[{'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Mancia', 'Affiliation': 'University of Milano-Bicocca, Milan.'}, {'ForeName': 'Helmut', 'Initials': 'H', 'LastName': 'Schumacher', 'Affiliation': 'Statistical Consultant, Ingelheim.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Böhm', 'Affiliation': 'Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, Saarland University, Saarbrücken.'}, {'ForeName': 'Johannes F E', 'Initials': 'JFE', 'LastName': 'Mann', 'Affiliation': 'KfH Kidney Center and Friedrich Alexander University, Erlangen, Germany.'}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Redon', 'Affiliation': 'Incliva Research Institute, University of Valencia and CIBEROBn, Carlos III Institute, Madrid, Spain.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Facchetti', 'Affiliation': 'Dipartimento di Medicina e Chirurgia, Università Milano-Bicocca, Milan, Italy.'}, {'ForeName': 'Roland E', 'Initials': 'RE', 'LastName': 'Schmieder', 'Affiliation': 'Department of Nephrology and Hypertension, University Hospital Erlangen, Erlangen, Germany.'}, {'ForeName': 'Eva M', 'Initials': 'EM', 'LastName': 'Lonn', 'Affiliation': 'Population Health Research Institute, Hamilton Health Science, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Koon K', 'Initials': 'KK', 'LastName': 'Teo', 'Affiliation': 'Population Health Research Institute, Hamilton Health Science, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Salim', 'Initials': 'S', 'LastName': 'Yusuf', 'Affiliation': 'Population Health Research Institute, Hamilton Health Science, McMaster University, Hamilton, Ontario, Canada.'}]",Journal of hypertension,['10.1097/HJH.0000000000002567'] 2404,32692952,Posterior Rotational and Translational Stability in Acromioclavicular Ligament Complex Reconstruction: A Comparative Biomechanical Analysis in Cadaveric Specimens.,"BACKGROUND Persistent posterior instability of the acromioclavicular (AC) joint is a reported complication after isolated coracoclavicular (CC) reconstruction. Thus, multiple techniques have been proposed attempting to restore biomechanics of the AC ligament complex (ACLC). PURPOSE/HYPOTHESIS The purpose was to evaluate the posterior translational and rotational stability of an ACLC reconstruction with a dermal allograft (ACLC patch) as compared with 3 suture brace constructs. It was hypothesized that the ACLC patch would better restore AC joint posterior stability. STUDY DESIGN Controlled laboratory study. METHODS A total of 28 cadaveric shoulders (mean ± SD age, 57.6 ± 8.3 years) were randomly assigned to 1 of 4 surgical techniques: ACLC patch, oblique brace, anterior brace, and x-frame brace. The force and torque to achieve 10 mm of posterior translation and 20° of posterior rotation of the AC joint were recorded in the following conditions: intact, transected ACLC, ACLC patch/brace repair, ACLC patch/brace repair with dissected CC ligaments, and ACLC patch/brace repair with CC ligament repair. RESULTS For posterior translation, transection of the ACLC reduced resistance to 16.7% of the native. With the native CC ligaments intact, the ACLC patch (59.1%), oblique brace (54.1%), and anterior brace (60.7%) provided significantly greater stability than the x-frame brace (33.2%; P < .001, P = .008, P < .001, respectively). ACLC patch, oblique brace, and anterior brace continued to have significantly higher posterior translational resistance than the x-frame (35.1%; P < .001, P = .003, P < .001) after transection and subsequent CC ligament repair. For posterior rotation, transection of the ACLC decreased the resistance to 5.4% of the intact state. With the CC ligaments intact, the ACLC patch (77.1%) better restored posterior rotational stability than the oblique (35.3%), anterior (48.5%), and x-frame (23.0%) brace repairs ( P < .001, P = .002, P < .001). CC ligament transection and subsequent repair demonstrated the ACLC patch (41.0%) to have improved stability when compared with the oblique (16.0%), anterior (14.0%), and x-frame (12.7%) repairs ( P = .006, P = .003, P = .002). CONCLUSION ACLC reconstruction with a dermal allograft better restored native posterior rotational stability than other brace constructs, with translational stability similar to the oblique and anterior brace technique at the time of surgery. CLINICAL RELEVANCE Horizontal stability of the AC joint is primarily controlled by the ACLC. Inability to restore AC joint biomechanics can result in persistent posterior instability and lead to functional impairment.",2020,"With the CC ligaments intact, the ACLC patch (77.1%) better restored posterior rotational stability than the oblique (35.3%), anterior (48.5%), and x-frame (23.0%) brace repairs ( P < .001, P = .002, P < .001).","['Cadaveric Specimens', 'Acromioclavicular Ligament Complex Reconstruction', '28 cadaveric shoulders (mean ± SD age, 57.6 ± 8.3 years']","['ACLC reconstruction with a dermal allograft (ACLC patch', '4 surgical techniques: ACLC patch, oblique brace, anterior brace, and x-frame brace', 'ACLC patch', 'intact, transected ACLC, ACLC patch/brace repair, ACLC patch/brace repair with dissected CC ligaments, and ACLC patch/brace repair with CC ligament repair']","['posterior translational and rotational stability', 'restore AC joint posterior stability', 'anterior brace', 'oblique brace', 'posterior rotational stability', 'posterior translational resistance']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0225039', 'cui_str': 'Structure of acromioclavicular ligament'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0023685', 'cui_str': 'Structure of ligament'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0040739', 'cui_str': 'Allogeneic transplantation'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205315', 'cui_str': 'Oblique'}, {'cui': 'C0006086', 'cui_str': 'Brace'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0080089', 'cui_str': 'Reading Frames'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0205239', 'cui_str': 'Dissecting'}, {'cui': 'C0225040', 'cui_str': 'Coracoclavicular ligament structure'}]","[{'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0445237', 'cui_str': 'Rotational'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0001208', 'cui_str': 'Acromioclavicular joint structure'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0006086', 'cui_str': 'Brace'}, {'cui': 'C0205315', 'cui_str': 'Oblique'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}]",28.0,0.0329299,"With the CC ligaments intact, the ACLC patch (77.1%) better restored posterior rotational stability than the oblique (35.3%), anterior (48.5%), and x-frame (23.0%) brace repairs ( P < .001, P = .002, P < .001).","[{'ForeName': 'Daichi', 'Initials': 'D', 'LastName': 'Morikawa', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Joel B', 'Initials': 'JB', 'LastName': 'Huleatt', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Lukas N', 'Initials': 'LN', 'LastName': 'Muench', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Cameron', 'Initials': 'C', 'LastName': 'Kia', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Daniel P', 'Initials': 'DP', 'LastName': 'Berthold', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Mark P', 'Initials': 'MP', 'LastName': 'Cote', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Elifho', 'Initials': 'E', 'LastName': 'Obopilwe', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Kelolli', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Bastian', 'Initials': 'B', 'LastName': 'Scheiderer', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Augustus D', 'Initials': 'AD', 'LastName': 'Mazzocca', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}]",The American journal of sports medicine,['10.1177/0363546520939882'] 2405,32692990,Liposomal Bupivacaine Local Infiltration for Buccal Mucosal Graft Harvest Site Pain Control: A Single-blinded Randomized Controlled Trial.,"OBJECTIVE To assess efficacy and safety of liposomal bupivacaine (LB) infiltration of the buccal mucosal graft (BMG) harvest site in alleviating pain by evaluating the postoperative narcotic usage, pain score and morbidities. METHODS Single-blinded randomized controlled trial of 43 adult patients for BMG substitution urethroplasty between January 2015 to June 2017 (Clinicaltrials.gov: NCT03720223). A computer-generated allocation scheme randomized patients to control group (n=22) no further local anesthetic infiltration aside from that of used in the hydro-dissection for BMG harvest, and to intervention group with additional infiltration of LB to BMG harvest site (n=21). We assessed postoperative cumulative narcotic use on post-op day-1 and 2, (24hr and 48hr total intravenous (IV) morphine equivalents in milligrams). A self-reported 10-point numeric rating scale survey was administered to assess post-procedural oral pain, oral conditions and morbidity on days 1 to 3, and at 1-month follow-up. Fisher's-exact test and independent T-test were performed to assess differences between treatment groups. Linear-regression was used to determine adjusted effect estimates of intervention. RESULTS Compared to controls, a significantly lower narcotic use was noticed among the LB treatment group on post-op day-1 (IV-Morphine equivalent mean difference 8.58mg; 95%CI 1.59, 15.56, p=0.017), while no significant difference was noticed on post-op day-2. There was no significant difference between treatment groups with regards to post-procedural oral pain score or oral morbidities. CONCLUSIONS Our study showed that LB infiltration of the BMG harvest site is safe and associated with lower 24hr narcotic use only at post-op day-1.",2020,"Compared to controls, a significantly lower narcotic use was noticed among the LB treatment group on post-op day-1","['43 adult patients for BMG substitution urethroplasty between January 2015 to June 2017', 'Buccal Mucosal Graft Harvest Site Pain Control']","['liposomal bupivacaine (LB', 'Liposomal Bupivacaine']","['narcotic use', 'postoperative cumulative narcotic', 'post-procedural oral pain score or oral morbidities']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0450135', 'cui_str': 'Mucosal graft'}, {'cui': 'C0161922', 'cui_str': 'Repair of urethra'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]","[{'cui': 'C0023828', 'cui_str': 'Liposomes'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]","[{'cui': 'C0027415', 'cui_str': 'Narcotic'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0221776', 'cui_str': 'Painful mouth'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}]",43.0,0.0844186,"Compared to controls, a significantly lower narcotic use was noticed among the LB treatment group on post-op day-1","[{'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Chua', 'Affiliation': 'Department of Urology, Eastern Virginia Medical School, Norfolk, Virginia, USA; Devine-Jordan Center for Reconstructive Surgery and Pelvic Health, Urology of Virginia, Virginia Beach, VA, USA.'}, {'ForeName': 'Jack M', 'Initials': 'JM', 'LastName': 'Zuckerman', 'Affiliation': 'Department of Urology, Eastern Virginia Medical School, Norfolk, Virginia, USA; Devine-Jordan Center for Reconstructive Surgery and Pelvic Health, Urology of Virginia, Virginia Beach, VA, USA; Department of Urology, Naval Medical Center, Portsmouth, VA, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Strehlow', 'Affiliation': 'Department of Urology, Eastern Virginia Medical School, Norfolk, Virginia, USA; Devine-Jordan Center for Reconstructive Surgery and Pelvic Health, Urology of Virginia, Virginia Beach, VA, USA; Spartanburg Medical Center, Spartanburg, South Carolina, USA.'}, {'ForeName': 'Ramón', 'Initials': 'R', 'LastName': 'Virasoro', 'Affiliation': 'Department of Urology, Eastern Virginia Medical School, Norfolk, Virginia, USA; Devine-Jordan Center for Reconstructive Surgery and Pelvic Health, Urology of Virginia, Virginia Beach, VA, USA.'}, {'ForeName': 'Jessica M', 'Initials': 'JM', 'LastName': 'DeLong', 'Affiliation': 'Department of Urology, Eastern Virginia Medical School, Norfolk, Virginia, USA; Devine-Jordan Center for Reconstructive Surgery and Pelvic Health, Urology of Virginia, Virginia Beach, VA, USA.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Tonkin', 'Affiliation': 'Department of Urology, Eastern Virginia Medical School, Norfolk, Virginia, USA; Devine-Jordan Center for Reconstructive Surgery and Pelvic Health, Urology of Virginia, Virginia Beach, VA, USA.'}, {'ForeName': 'Kurt A', 'Initials': 'KA', 'LastName': 'McCammon', 'Affiliation': 'Department of Urology, Eastern Virginia Medical School, Norfolk, Virginia, USA; Devine-Jordan Center for Reconstructive Surgery and Pelvic Health, Urology of Virginia, Virginia Beach, VA, USA. Electronic address: mccammKa@evms.edu.'}]",Urology,['10.1016/j.urology.2020.06.067'] 2406,32693009,Physical exercise interventions have no effect on serum BDNF concentration in older adults living in long-term nursing homes.,"Physical exercise protects against age-related cognitive decline. Brain-derived neurotrophic factor (BDNF) may mediate some of the cognitive benefits of physical exercise, but the effect of physical exercise on serum BDNF is unclear. Indeed, differential findings have been reported depending on the characteristics of the participants and the intensity, duration, and type of exercise. The aim of this study was to determine whether three different physical exercise interventions alter serum BDNF levels in older adults living in long-term nursing homes (LTNHs) and whether changes in physical, cognitive, and dual-task performance are related to changes in serum BDNF. LTNH study participants (n = 126) were randomly assigned to multicomponent or dual-task training or a walking program and serum BDNF levels were analyzed by ELISA. We also assessed physical, cognitive, and dual-task parameters. Neither the multicomponent, dual-task, nor walking exercise programs caused changes in serum BDNF concentration in older adults living in LTNHs. Changes in BDNF during the interventions were not significantly associated with modifications in physical, cognitive or dual-task performance parameters. Our results provide new evidence clarifying the relationship between physical and cognitive exercise and BDNF.",2020,"Neither the multicomponent, dual-task, nor walking exercise programs caused changes in serum BDNF concentration in older adults living in LTNHs.","['older adults living in long-term nursing homes (LTNHs', 'older adults living in LTNHs', 'LTNH study participants (n\u202f=\u202f126', 'older adults living in long-term nursing homes']","['physical exercise interventions', 'multicomponent or dual-task training or a walking program and serum BDNF levels were analyzed by ELISA', 'Physical exercise', 'multicomponent, dual-task, nor walking exercise programs', 'Physical exercise interventions']","['physical, cognitive, and dual-task parameters', 'physical, cognitive or dual-task performance parameters', 'serum BDNF levels', 'serum BDNF concentration']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0470256', 'cui_str': '126'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",126.0,0.0209679,"Neither the multicomponent, dual-task, nor walking exercise programs caused changes in serum BDNF concentration in older adults living in LTNHs.","[{'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Rezola-Pardo', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: chloe.rezola@ehu.eus.'}, {'ForeName': 'Gotzone', 'Initials': 'G', 'LastName': 'Hervás', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: gotzone.hervas@ehu.eus.'}, {'ForeName': 'Haritz', 'Initials': 'H', 'LastName': 'Arrieta', 'Affiliation': 'Department of Nursing II, Faculty of Medicine and Nursery, University of the Basque Country (UPV/EHU), Paseo Dr. J. Beguiristain, 105, Donostia/San Sebastian 20014, Gipuzkoa, Spain; Onkologikoa Foundation, Paseo Doctor Beguiristain, 121, Donostia/San Sebastián 20014, Gipuzkoa, Spain. Electronic address: haritz.arrieta@ehu.eus.'}, {'ForeName': 'Alejanda Hernández-De', 'Initials': 'AH', 'LastName': 'Diego', 'Affiliation': 'Zorroaga Foundation, Alto Zorroaga, 1, Donostia/San Sebastian 20014, Gipuzkoa, Spain. Electronic address: s.hernandez@zorroaga.eus.'}, {'ForeName': 'Fatima', 'Initials': 'F', 'LastName': 'Ruiz-Litago', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: fatima.ruiz@ehu.eus.'}, {'ForeName': 'Susana Maria', 'Initials': 'SM', 'LastName': 'Gil', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: susana.gil@ehu.eus.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Rodriguez-Larrad', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: ana.rodriguez@ehu.eus.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Irazusta', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: jon.irazusta@ehu.eus.'}]",Experimental gerontology,['10.1016/j.exger.2020.111024'] 2407,32693097,"Improving Management of the Genitourinary Syndrome of Menopause: Evaluation of a Health-system Based, Cluster-Randomized Intervention.","BACKGROUND Genitourinary symptoms are common in postmenopausal women and adversely impact quality of life. National surveys and data collected from our health care system demonstrate that postmenopausal women with the genitourinary syndrome of menopause often fail to receive appropriate diagnosis or treatment. OBJECTIVE To promote greater detection and treatment of the genitourinary syndrome of menopause, we created and tested a clinician-focused, health system intervention that included clinician education sessions and a suite of evidence-based electronic health record tools. STUDY DESIGN Using a cluster randomized design, we allocated primary care (16) and gynecology (6) clinics to intervention or control. From September-November 2014, we provided training about the diagnosis and treatment of genitourinary syndrome of menopause in face-to-face presentations at each intervention clinic and in an online video. We developed clinical decision support tools in the electronic health record that contained an evidence-based, point-of-care knowledge resource, a standardized order set and a checklist of patient education materials for the patient's after visit summary. The tools aimed to facilitate accurate diagnostic coding and prescribing (SmartSet, SmartRx) along with relevant patient information (SmartText). Clinicians who only performed visits at control clinics received no training or notification about the tools. Our primary outcome was vulvovaginal diagnoses made at well visits for women aged 55 and older from 11/15/14 through 11/15/15. We also assessed urinary diagnoses, vaginal estrogen prescriptions and use of the electronic tools. There was departmental support for the intervention but no prioritization within the health care system to incentivize change. RESULTS In the one-year period, 386 clinicians performed 14,921 well visits for women aged 55 and older. Among the 190 clinicians who performed well visits in the intervention clinics, 109 (57.4%) completed either in-person or online educational training. The proportion of visits that included a vulvovaginal (7.2% vs 5.8%; OR=1.27, 95% CI [0.65, 2.51]) or urinary diagnosis (2.5% vs. 3.1%; OR=0.79, 95% CI [0.55, 1.13]) or vaginal estrogen prescription (4.5% vs 3.7%; OR=1.24, 95% CI [0.63, 2.46]) did not differ between study arms. There was a significant interaction for primary care and gynecology, which revealed more vulvovaginal diagnoses by gynecology but not primary care intervention clinics (OR=1.63, 95% CI [1.15, 2.31]), but there was no significant interaction for prescriptions. Clinicians in the intervention clinics were more likely to use decision support tools compared to those in control clinics--SmartSet (22.2% vs.1.5%) OR=18.8, 95% CI [5.5, 63.8] and SmartText for patient information (38.0% vs. 24.4%) OR=1.91, 95% CI [1.10, 3.34]. A per protocol analysis showed similar findings. CONCLUSION Overall, the intervention did not lead to more diagnoses or prescription therapy for postmenopausal genitourinary symptoms but did result in greater distribution of patient information. Gynecology clinicians were more likely to address genitourinary symptoms generally and were more likely to make a vulvovaginal diagnosis after the intervention. Further efforts for improving care should consider ongoing clinician education beginning with enhanced menopause curricula in residency training. Additional interventions to consider include greater access for postmenopausal women to gynecologic care, addressing treatment barriers and development of national performance metrics.",2020,Clinicians in the intervention clinics were more likely to use decision support tools compared to those in control clinics--SmartSet (22.2% vs.1.5%),"['postmenopausal women with the genitourinary syndrome of menopause often fail to receive appropriate diagnosis or treatment', '386 clinicians performed 14,921 well visits for women aged 55 and older', 'women aged 55 and older from 11/15/14 through 11/15/15', 'postmenopausal women', 'postmenopausal women to gynecologic care', '190 clinicians who performed well visits in the intervention clinics, 109 (57.4%) completed either in-person or']","['gynecology (6) clinics to intervention or control', 'online educational training']","['vaginal estrogen prescription', 'proportion of visits that included a vulvovaginal', 'urinary diagnosis', 'postmenopausal genitourinary symptoms', 'vulvovaginal diagnoses', 'vulvovaginal diagnosis', 'vulvovaginal diagnoses made at well visits']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C5192371', 'cui_str': 'Genitourinary syndrome of menopause'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C1704447', 'cui_str': 'Patient visit for'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205480', 'cui_str': 'Gynecologic'}, {'cui': 'C4517622', 'cui_str': '190'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C3839674', 'cui_str': 'Gynecology clinic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0426317', 'cui_str': 'Genitourinary symptoms'}]",,0.0627479,Clinicians in the intervention clinics were more likely to use decision support tools compared to those in control clinics--SmartSet (22.2% vs.1.5%),"[{'ForeName': 'Kimberly K', 'Initials': 'KK', 'LastName': 'Vesco', 'Affiliation': 'Kaiser Permanente Center for Health Research, 3800 N. Interstate Ave., Portland, OR, 97227, USA; Department of Obstetrics and Gynecology, Kaiser Permanente Northwest, 500 N.E. Multnomah St., #100, Portland, OR 97232, USA. Electronic address: kimberly.k.vesco@kpchr.org.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Leo', 'Affiliation': 'Kaiser Permanente Center for Health Research, 3800 N. Interstate Ave., Portland, OR, 97227, USA.'}, {'ForeName': 'Joanna E', 'Initials': 'JE', 'LastName': 'Bulkey', 'Affiliation': 'Kaiser Permanente Center for Health Research, 3800 N. Interstate Ave., Portland, OR, 97227, USA.'}, {'ForeName': 'Kate R', 'Initials': 'KR', 'LastName': 'Beadle', 'Affiliation': 'Department of Obstetrics and Gynecology, Kaiser Permanente Northwest, 500 N.E. Multnomah St., #100, Portland, OR 97232, USA.'}, {'ForeName': 'Ashley B', 'Initials': 'AB', 'LastName': 'Stoneburner', 'Affiliation': 'Kaiser Permanente Center for Health Research, 3800 N. Interstate Ave., Portland, OR, 97227, USA.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Francisco', 'Affiliation': 'Kaiser Permanente Center for Health Research, 3800 N. Interstate Ave., Portland, OR, 97227, USA.'}, {'ForeName': 'Amanda L', 'Initials': 'AL', 'LastName': 'Clark', 'Affiliation': 'Kaiser Permanente Center for Health Research, 3800 N. Interstate Ave., Portland, OR, 97227, USA; Department of Obstetrics and Gynecology, Kaiser Permanente Northwest, 500 N.E. Multnomah St., #100, Portland, OR 97232, USA.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.07.029'] 2408,32693104,Early antibiotic therapy and adverse outcomes in preterm infants: Time for a trial!,,2020,,['preterm infants'],[],[],"[{'cui': 'C0021294', 'cui_str': 'Premature infant'}]",[],[],,0.0647176,,"[{'ForeName': 'Joseph B', 'Initials': 'JB', 'LastName': 'Cantey', 'Affiliation': 'Department of Pediatrics, Divisions of Neonatology and Pediatric Infectious Diseases, University of Texas Health San Antonio, San Antonio, TX. Electronic address: cantey@uthscsa.edu.'}]",The Journal of pediatrics,['10.1016/j.jpeds.2020.07.046'] 2409,32693563,"Effects of in-play cooling during simulated tennis match play in the heat on performance, physiological, and perceptual measures.","BACKGROUND This crossover study's objective was to investigate whether a cooling intervention during simulated tennis match play in the heat could affect players' performance, physiology, perception of effort, and well-being. METHODS Eight competitive male tennis players performed two testing sessions of 45-minute simulated tennis match play on a hard court at 31.8 ± 2.1°C and 48.5 ± 9.6% relative humidity. During change-of-end breaks, the cooling interventions (COL) consisted of cold water ingestion (ad libitum) and an electric fan facing the players at a distance of 1 m combined with an ice-filled damp towel around the neck and on the thighs or no cooling (CON) were applied. Measures of performance, heart rate, blood lactate concentration, tympanic and local skin temperature, sweat loss, perceived exertion, and thermal sensation as well as ratings of recovery were recorded in both sessions. RESULTS Paired-samples t-tests showed no significant differences (p > 0.05) in any of the measures between COL and CON. Effect size (ES) calculations indicated moderate evidencethat COL was beneficial to local skin temperature (ES = -0.95) and thermal sensation (ES = -0.77). At the individual level, a positive response to COL was found in some players for heart rate, local skin temperature, thermal sensation, and ratings of recovery. CONCLUSIONS A likely inability of COL to improve players' performance or reduce thermal strain during tennis match play in hot humid conditions was found at the group level. However, some players may be more likely to benefit from COL. Therefore, the use of COL should be individualized.",2020,"RESULTS Paired-samples t-tests showed no significant differences (p > 0.05) in any of the measures between COL and CON.",['Eight competitive male tennis players'],"['cooling interventions (COL) consisted of cold water ingestion (ad libitum) and an electric fan facing the players at a distance of 1 m combined with an ice-filled damp towel around the neck and on the thighs or no cooling (CON', 'cooling intervention', 'play cooling']","['heart rate, local skin temperature, thermal sensation, and ratings of recovery', 'performance, heart rate, blood lactate concentration, tympanic and local skin temperature, sweat loss, perceived exertion, and thermal sensation as well as ratings of recovery', 'heat on performance, physiological, and perceptual measures']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0039515', 'cui_str': 'Tennis'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C4708833', 'cui_str': 'Cold water'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0441039', 'cui_str': 'Fan'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0020746', 'cui_str': 'Ice'}, {'cui': 'C0205381', 'cui_str': 'Wet'}, {'cui': 'C0336616', 'cui_str': 'Towel'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0032214', 'cui_str': 'Play'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0037294', 'cui_str': 'Temperature of skin'}, {'cui': 'C0039478', 'cui_str': 'Thermal sensation, function'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0038984', 'cui_str': 'Sweat'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",8.0,0.0250116,"RESULTS Paired-samples t-tests showed no significant differences (p > 0.05) in any of the measures between COL and CON.","[{'ForeName': 'Thimo', 'Initials': 'T', 'LastName': 'Wiewelhove', 'Affiliation': 'Faculty of Sport Science, Ruhr University, Bochum, Germany - thimo.wiewelhove@rub.de.'}, {'ForeName': 'Fabian', 'Initials': 'F', 'LastName': 'Conradt', 'Affiliation': 'Faculty of Sport Science, Ruhr University, Bochum, Germany.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Rawlins', 'Affiliation': 'Tennis Australia, Brisbane, Australia.'}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Deacon', 'Affiliation': 'Tennis Australia, Brisbane, Australia.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Meyer', 'Affiliation': 'Institute of Sports and Preventive Medicine, Saarland University, Saarbrücken, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kellmann', 'Affiliation': 'Faculty of Sport Science, Ruhr University, Bochum, Germany.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Pfeiffer', 'Affiliation': 'Johannes-Gutenberg University, Mainz, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Ferrauti', 'Affiliation': 'Faculty of Sport Science, Ruhr University, Bochum, Germany.'}]",The Journal of sports medicine and physical fitness,['10.23736/S0022-4707.20.11243-X'] 2410,32693615,A Prospective Randomized Trial of N-butyl-cyanoacrylate + Metacryloxysulfolane Adhesive versus Suture Alone for Grafting in Rhinoplasty: 9 year Follow-up.,"OBJECTIVE Use of cyanoacrylate glue in facial plastic surgery is still controversial due to the absence of long-term follow up showing the results. Aim of our study is comparing the long-term outcomes of N-butyl-cyanoacrylate + Metacryloxysulfolane versus traditional sutures in rhinoplasty. METHODS Prospective comparative study. One hundred forty-two patients affected by ptotic nasal tip were included and randomized in two groups. In group A, the surgeon fixed the graft by using the glue and suture and in group B by using the traditional suture only. The following data were collected and compared by statistical analysis: nasolabial angle before and after surgery, dimensions of the graft, duration time (in minutes) for graft application during the surgery, number of sutures applied to fix the graft, presence of post-surgery negative outcomes. RESULTS All patients statistically improved their nasolabial angle after surgery (ANOVA: P < .0001) without statistically significant differences between the two groups both at short and long follow-up (χ: P = 1 and P = .9 respectively). A statistically significant difference in graft fixation time ( P < .00001) and number of sutures (t: P < .00001) used was observed between the two groups. No statistically significant difference was observed in prevalence of infection after surgery. CONCLUSION N-butyl-cyanoacrylate + Metacryloxysulfolane could be a valid tool to reduce the necessary number of sutures and to reduce the time required for graft fixation graft fixation with consistent results in long-term follow-up.",2020,A statistically significant difference in graft fixation time ( P < .00001) and number of sutures (t: P < .00001) used was observed between the two groups.,"['One hundred forty-two patients affected by ptotic nasal tip', 'facial plastic surgery']","['N-butyl-cyanoacrylate + Metacryloxysulfolane', 'cyanoacrylate glue', 'N-butyl-cyanoacrylate + Metacryloxysulfolane Adhesive versus Suture Alone']","['nasolabial angle', 'number of sutures', 'prevalence of infection', 'time required for graft fixation graft fixation', 'graft fixation time']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0522476', 'cui_str': 'Patient affected'}, {'cui': 'C0225409', 'cui_str': 'Structure of apex of nose'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0038911', 'cui_str': 'Plastic surgery - specialty'}]","[{'cui': 'C0014035', 'cui_str': 'Enbucrilate'}, {'cui': 'C0010507', 'cui_str': 'Cyanoacrylate'}, {'cui': 'C0017780', 'cui_str': 'Glue'}, {'cui': 'C0001516', 'cui_str': 'Adhesive'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}]","[{'cui': 'C0429143', 'cui_str': 'Nasolabial angle'}, {'cui': 'C0457280', 'cui_str': 'Number of sutures'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}]",142.0,0.0413664,A statistically significant difference in graft fixation time ( P < .00001) and number of sutures (t: P < .00001) used was observed between the two groups.,"[{'ForeName': 'Martino', 'Initials': 'M', 'LastName': 'Carmine', 'Affiliation': 'University Hospital of Salerno, Italy.'}, {'ForeName': 'Salzano', 'Initials': 'S', 'LastName': 'Francesco', 'Affiliation': 'University Hospital of Salerno, Italy.'}, {'ForeName': 'Martino', 'Initials': 'M', 'LastName': 'Diletta', 'Affiliation': 'The nose clinic, rhinosurgery unit c/o check-up day-surgery Salerno, Italy.'}, {'ForeName': 'Ralli', 'Initials': 'R', 'LastName': 'Massimo', 'Affiliation': 'Organ of Sense Department, La Sapienza University of Rome, Italy.'}, {'ForeName': 'De Vincentiis', 'Initials': 'V', 'LastName': 'Marco', 'Affiliation': 'Organ of Sense Department, La Sapienza University of Rome, Italy.'}, {'ForeName': 'Maranzano', 'Initials': 'M', 'LastName': 'Massimo', 'Affiliation': 'Department of Oral Maxillo-Facial and Facial Plastic Surgery, University of Manchester, Manchester, UK.'}, {'ForeName': 'Greco', 'Initials': 'G', 'LastName': 'Antonio', 'Affiliation': 'Organ of Sense Department, La Sapienza University of Rome, Italy.'}, {'ForeName': 'Salzano', 'Initials': 'S', 'LastName': 'Giovanni', 'Affiliation': 'Head and Neck Department, Neurosciences, Reproductive and Odontostomatological Science, University Federico II, Naples, Italy.'}, {'ForeName': 'Di Stadio', 'Initials': 'DS', 'LastName': 'Arianna', 'Affiliation': 'Otolaryngology Department, University of Perugia, Perugia, Italy.'}]","The Annals of otology, rhinology, and laryngology",['10.1177/0003489420943910'] 2411,32693653,Topical anaesthesia as an adjuvant to local anaesthetic injection in open trigger digit release: a randomized controlled trial.,"We conducted a randomized controlled trial to compare pain scores and patient satisfaction between topical anaesthetic cream (5% lidocaine-prilocaine cream) versus placebo cream, applied approximately 90 minutes before local anaesthetic injection for open trigger digit release. One hundred participants were enrolled and randomly allocated into the two groups between May 2019 and February 2020. The visual analogue pain scores and satisfaction scores were measured. Most participants were female with Quinnell Grade 2-3 trigger digits. The pain scores during needle injection, local anaesthetic infiltration, the overall pain and satisfaction scores had no statistically significant differences between groups. There was no correlation between duration of topical anaesthetic drug application and pain scores. Subgroup analysis did not show significant differences in pain scores between genders. No complications were found during the study period. The topical anaesthetic drug was ineffective to use on the palmar skin during open trigger digit release surgery. Level of evidence: II.",2020,"The pain scores during needle injection, local anaesthetic infiltration, the overall pain and satisfaction scores had no statistically significant differences between groups.","['One hundred participants were enrolled and randomly allocated into the two groups between May 2019 and February 2020', 'Most participants were female with Quinnell Grade 2-3 trigger digits']","['topical anaesthetic cream (5% lidocaine-prilocaine cream', 'placebo cream', 'Topical anaesthesia']","['duration of topical anaesthetic drug application and pain scores', 'pain scores', 'pain scores and patient satisfaction', 'visual analogue pain scores and satisfaction scores', 'local anaesthetic infiltration, the overall pain and satisfaction scores']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0475270', 'cui_str': 'G2 grade'}, {'cui': 'C0158328', 'cui_str': 'Trigger finger'}]","[{'cui': 'C0040464', 'cui_str': 'Topical anesthetic'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0617623', 'cui_str': 'Lidocaine- and prilocaine-containing product'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0472473', 'cui_str': 'Topical local anesthetic'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0040464', 'cui_str': 'Topical anesthetic'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0198813', 'cui_str': 'Local anesthesia, by infiltration'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",100.0,0.254486,"The pain scores during needle injection, local anaesthetic infiltration, the overall pain and satisfaction scores had no statistically significant differences between groups.","[{'ForeName': 'Panai', 'Initials': 'P', 'LastName': 'Laohaprasitiporn', 'Affiliation': 'Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Yuwarat', 'Initials': 'Y', 'LastName': 'Monteerarat', 'Affiliation': 'Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Roongsak', 'Initials': 'R', 'LastName': 'Limthongthang', 'Affiliation': 'Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Torpon', 'Initials': 'T', 'LastName': 'Vathana', 'Affiliation': 'Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Vajara', 'Initials': 'V', 'LastName': 'Wilairatana', 'Affiliation': 'Department of Orthopaedic Surgery, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.'}]","The Journal of hand surgery, European volume",['10.1177/1753193420939494'] 2412,32693660,Efficacy of a 3-year course of sublingual immunotherapy for mite-induced allergic rhinitis with a 3-year follow-up.,"Aim: To evaluate the long-term efficacy of sublingual immunotherapy (SLIT) in treating mite-sensitized allergic rhinitis (AR). Materials & methods:  150 AR children were randomly divided into SLIT and pharmacotherapy (PT) groups, receiving a 3-year course of SLIT along with PT or PT only. Results: The symptom and medication scores at the 3- and 6-year follow-up were significantly lower compared with the baseline levels in both groups, while the values were significantly lower in SLIT group than in PT group. No significant differences were observed between 3- and 6-year follow-up in SLIT group. Conclusion: 3-year SLIT along with PT appeared more effective compared with PT only for mite-induced AR in children, and the treatment was effective for at least 3 consecutive years even after SLIT ceased.",2020,"The symptom and medication scores at the 3- and 6-year follow-up were significantly lower compared with the baseline levels in both groups, while the values were significantly lower in SLIT group than in PT group.","['150\xa0AR children', 'treating mite-sensitized allergic rhinitis (AR', 'mite-induced allergic rhinitis with a 3-year follow-up']","['sublingual immunotherapy', 'sublingual immunotherapy (SLIT', 'SLIT', 'SLIT and pharmacotherapy (PT)\xa0groups, receiving a 3-year course of SLIT along with PT or PT only']",['symptom and medication scores'],"[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0026231', 'cui_str': 'Mite'}, {'cui': 'C2607914', 'cui_str': 'Allergic rhinitis'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C3658366', 'cui_str': 'Sublingual Immunotherapy'}, {'cui': 'C0184904', 'cui_str': 'Slitting'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0750729', 'cui_str': 'Courses'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0113851,"The symptom and medication scores at the 3- and 6-year follow-up were significantly lower compared with the baseline levels in both groups, while the values were significantly lower in SLIT group than in PT group.","[{'ForeName': 'Wen-Bo', 'Initials': 'WB', 'LastName': 'Chen', 'Affiliation': ""Department of Otorhinolaryngology, Children's Hospital of Nanjing Medical University, 72 Guangzhou Road, Nanjing 210008, China.""}, {'ForeName': 'Xiao-Fei', 'Initials': 'XF', 'LastName': 'Shen', 'Affiliation': ""Department of Otorhinolaryngology, Children's Hospital of Nanjing Medical University, 72 Guangzhou Road, Nanjing 210008, China.""}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': ""Department of Otorhinolaryngology, Children's Hospital of Nanjing Medical University, 72 Guangzhou Road, Nanjing 210008, China.""}, {'ForeName': 'Wen-Cheng', 'Initials': 'WC', 'LastName': 'Zhou', 'Affiliation': 'Department of Otorhinolaryngology, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Cheng', 'Affiliation': 'Department of Otorhinolaryngology, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China.'}]",Immunotherapy,['10.2217/imt-2020-0006'] 2413,32693858,Assessment of an adolescent-girl-focused nutritional educational intervention within a girls' empowerment programme: a cluster randomised evaluation in Zambia.,"OBJECTIVE Adolescent girls are at risk for both macro- and micronutrient deficiencies affecting growth, maternal and child health. This study assessed the impact of an adolescent-girl-tailored nutritional education curriculum on nutritional outcomes, including knowledge, dietary behaviour, anthropometry and anaemia. DESIGN A cluster-randomised evaluation was conducted with two study arms: girls in mentor-led weekly girls' groups receiving sexual and reproductive health and life-skills training assigned to an age-appropriate nutritional curriculum and control girls in the weekly girls' groups without the nutritional education. The primary analysis was intent-to-treat (ITT) generalised least squares regression. Secondary analysis using two-stage, instrumental-variables estimation was also conducted. SETTING The intervention and evaluation were conducted in urban and rural areas across four of ten provinces in Zambia. PARTICIPANTS In total, 2660 girl adolescents aged 10-19 years were interviewed in 2013 (baseline) and annually through 2017. RESULTS ITT results indicate that exposure to the nutritional educational programme did not meaningfully change outcomes for adolescents or their children. Intervention adolescents were no more likely to correctly identify healthy foods (P = 0·51) or proper infant-feeding practices (P = 0·92); were no less likely to be stunted (P = 0·30) or underweight (P = 0·87) and no less likely to be anaemic (P = 0·38). Outcomes for children of intervention participants were not improved, including being breastfed (P = 0·42), stunted (P = 0·21), wasted (P = 0·77) or anaemic (P = 0·51). CONCLUSIONS Even a high-quality nutritional educational intervention tailored to adolescents within an empowerment programme does not assure improved nutritional outcomes; adolescent preferences, resource control and household dynamics require consideration in the context of nutritional educational programmes.",2020,Intervention adolescents were no more likely to correctly identify healthy foods (P = 0·51) or proper infant-feeding practices (P = 0·92); were no less likely to be stunted (P = 0·30) or underweight (P = 0·87) and no less likely to be anaemic (P = 0·38).,"['2660 girl adolescents aged 10-19 years were interviewed in 2013 (baseline) and annually through 2017', 'Adolescent girls', 'urban and rural areas across four of ten provinces in Zambia']","['adolescent-girl-tailored nutritional education curriculum', ""mentor-led weekly girls' groups receiving sexual and reproductive health and life-skills training assigned to an age-appropriate nutritional curriculum and control girls in the weekly girls' groups without the nutritional education"", 'nutritional educational intervention']","['knowledge, dietary behaviour, anthropometry and anaemia']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0043445', 'cui_str': 'Zambia'}]","[{'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0204934', 'cui_str': 'Nutrition education'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C0025369', 'cui_str': 'Mentors'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0242667', 'cui_str': 'Reproductive Health'}, {'cui': 'C0556562', 'cui_str': 'Life skills training'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}]",2660.0,0.0505079,Intervention adolescents were no more likely to correctly identify healthy foods (P = 0·51) or proper infant-feeding practices (P = 0·92); were no less likely to be stunted (P = 0·30) or underweight (P = 0·87) and no less likely to be anaemic (P = 0·38).,"[{'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'Hewett', 'Affiliation': 'Population Council, Washington, DC, USA.'}, {'ForeName': 'Amanda L', 'Initials': 'AL', 'LastName': 'Willig', 'Affiliation': 'Deptarment of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Digitale', 'Affiliation': 'Population Council, New York, NY, USA.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Soler-Hampejsek', 'Affiliation': 'Population Council, New York, NY, USA.'}, {'ForeName': 'Jere R', 'Initials': 'JR', 'LastName': 'Behrman', 'Affiliation': 'Department of Economics, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Austrian', 'Affiliation': 'Population Council, Nairobi, Kenya.'}]",Public health nutrition,['10.1017/S1368980020001263'] 2414,32693930,"Reply to Emre Karabay and İlker Tınay's Letter to the Editor re: Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial ""NIMBUS"". Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.066.",,2020,,[],['BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations'],[],[],"[{'cui': 'C0004886', 'cui_str': 'BCG vaccine'}, {'cui': 'C0184959', 'cui_str': 'Instillation'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]",[],,0.0614359,,"[{'ForeName': 'Marc-Oliver', 'Initials': 'MO', 'LastName': 'Grimm', 'Affiliation': 'Department of Urology, University Hospital of Jena, Jena, Germany. Electronic address: marc-oliver.grimm@med.uni-jena.de.'}, {'ForeName': 'Christien', 'Initials': 'C', 'LastName': 'Caris', 'Affiliation': 'EAU Research Foundation, Arnhem, The Netherlands.'}, {'ForeName': 'Wim P J', 'Initials': 'WPJ', 'LastName': 'Witjes', 'Affiliation': 'EAU Research Foundation, Arnhem, The Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European urology,['10.1016/j.eururo.2020.07.004'] 2415,32693993,Instability in Preference for Place of Death Among Patients With Symptoms of Advanced Heart Failure.,"OBJECTIVES Patient preference for place of death is an important component of advance care planning (ACP). If patients' preference for place of death changes over time, this questions the value of their documented preference. We aimed to assess the extent and correlates of change in preference for place of death over time among patients with symptoms of advanced heart failure. DESIGN We conducted a secondary analysis of data from a randomized controlled trial of a formal ACP program vs usual care. SETTING AND PARTICIPANTS We interviewed 282 patients aged 21 years old and above with heart failure and New York Heart Association Classification III and IV symptoms in Singapore. Analytic sample included 200 patients interviewed at least twice. METHODS We assessed factors associated with patients' preference for place of death (home/institution/no preference) and change in their preference for place of death from previous time point (change toward home death/toward an institutional death/toward no preference/no change). These included patient demographics, quality of life (Kansas City Cardiomyopathy Questionnaire), and prognostic understanding. RESULTS In our study, 66% of patients with heart failure changed their preference for place of death at least once during the study period with no consistent pattern of change. Correct prognostic understanding at the time of survey reduced the relative risk of change in preference for place of death to home (relative risk ratio 0.49, 95% confidence interval 0.32, 0.76), whereas a higher quality of life score was associated with a lower relative risk of patients changing their preferred place of death to an institution (relative risk ratio 0.99, 95% confidence interval 0.97, 1.00) relative to no change in preference. CONCLUSIONS AND IMPLICATIONS We provide evidence of instability in patients with heart failure preference for place of death, which suggests that ACP documents should be regularly re-evaluated.",2020,"Correct prognostic understanding at the time of survey reduced the relative risk of change in preference for place of death to home (relative risk ratio 0.49, 95% confidence interval 0.32, 0.76), whereas a higher quality of life score was associated with a lower relative risk of patients changing their preferred place of death to an institution (relative risk ratio 0.99, 95% confidence interval 0.97, 1.00) relative to no change in preference. ","['patients with symptoms of advanced heart failure', '282 patients aged 21\xa0years old and above with heart failure and New York Heart Association Classification III and IV symptoms in Singapore', 'patients with heart failure preference for place of death', 'Patients With Symptoms of Advanced Heart Failure', '200 patients interviewed at least twice']",['formal ACP program vs usual care'],"['quality of life score', 'patient demographics, quality of life (Kansas City Cardiomyopathy Questionnaire), and prognostic understanding']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C4517681', 'cui_str': '282'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1275491', 'cui_str': 'New York Heart Association Classification'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0037173', 'cui_str': 'Singapore'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0421611', 'cui_str': 'Place of death'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C1720725', 'cui_str': 'Twice'}]","[{'cui': 'C0600371', 'cui_str': 'Advance care planning'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0878544', 'cui_str': 'Cardiomyopathy'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}]",282.0,0.150174,"Correct prognostic understanding at the time of survey reduced the relative risk of change in preference for place of death to home (relative risk ratio 0.49, 95% confidence interval 0.32, 0.76), whereas a higher quality of life score was associated with a lower relative risk of patients changing their preferred place of death to an institution (relative risk ratio 0.99, 95% confidence interval 0.97, 1.00) relative to no change in preference. ","[{'ForeName': 'Chetna', 'Initials': 'C', 'LastName': 'Malhotra', 'Affiliation': 'Lien Center for Palliative Care, Duke-NUS Medical School, Singapore. Electronic address: chetna.malhotra@duke-nus.edu.sg.'}, {'ForeName': 'Filipinas G', 'Initials': 'FG', 'LastName': 'Bundoc', 'Affiliation': 'Lien Center for Palliative Care, Duke-NUS Medical School, Singapore.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Sim', 'Affiliation': 'National Heart Center Singapore, Singapore.'}, {'ForeName': 'Fazlur Rehman', 'Initials': 'FR', 'LastName': 'Jaufeerally', 'Affiliation': 'Singapore General Hospital, Singapore.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Finkelstein', 'Affiliation': 'Lien Center for Palliative Care, Duke-NUS Medical School, Singapore.'}]",Journal of the American Medical Directors Association,['10.1016/j.jamda.2020.05.030'] 2416,32694001,Effects of Home-Based Physical Exercise on Days at Home and Cost-Effectiveness in Pre-Frail and Frail Persons: Randomized Controlled Trial.,"OBJECTIVES Frailty increases the risks of hospitalization, institutionalization, and death. Our objective was to study the effects of home-based physical exercise on the number of days spent at home among pre-frail and frail persons, versus usual care. In addition, utilization and costs of health care and social services, cost-effectiveness, and health-related quality-of-life (HRQoL) were explored. DESIGN Randomized controlled trial, with year-long supervised exercise for 60 minutes twice a week versus usual care. Follow-up for 24 months after randomization. SETTING AND PARTICIPANTS A sample of 299 home-dwelling persons in South Karelia, Finland. Main inclusion criteria: ≥65 years, meeting at least 1 of the frailty phenotype criteria, Mini-Mental State Examination score ≥17. METHODS Primary outcome, days spent at home over 24 months, was calculated deducting days in inpatient care, in nursing homes, and days after death. HRQoL was assessed (15D questionnaire) at baseline and at 3, 6, and 12 months. Utilization data were retrieved from medical records. RESULTS The participants' mean age was 82.5 (SD 6.3), 75% were women, 61% were pre-frail and 39% frail. After 24 months, there was no difference between groups in days spent at home [incidence rate ratio 1.03; 95% confidence interval (CI) 0.98-1.09]. After 12 months, the costs per person-year were 1.60-fold in the exercise group (95% CI 1.23-1.98), and after 24 months, 1.23-fold (95% CI 0.95-1.50) versus usual care. Over 12 months, the exercise group gained 0.04 quality-adjusted life-years and maintained the baseline 15D level, while the score in the usual care group deteriorated (P for group <.001, time 0.002, interaction 0.004). CONCLUSIONS AND IMPLICATIONS Physical exercise did not increase the number of days spent at home. Exercise prevented deterioration of HRQoL, and in the frail subgroup, all intervention costs were compensated with decreased utilization of other health care and social services over 24 months.",2020,"Exercise prevented deterioration of HRQoL, and in the frail subgroup, all intervention costs were compensated with decreased utilization of other health care and social services over 24 months.","['A sample of 299 home-dwelling persons in South Karelia, Finland', ""participants' mean age was 82.5 (SD 6.3), 75% were women, 61% were pre-frail and 39% frail"", 'Pre-Frail and Frail Persons', 'Main inclusion criteria: ≥65\xa0years, meeting at least 1 of the frailty phenotype criteria, Mini-Mental State Examination score ≥17']","['home-based physical exercise', 'Home-Based Physical Exercise']","['costs per person-year', 'utilization of other health care and social services', 'days spent at home over 24\xa0months, was calculated deducting days in inpatient care, in nursing homes, and days after death', 'HRQoL', 'risks of hospitalization, institutionalization, and death', 'utilization and costs of health care and social services, cost-effectiveness, and health-related quality-of-life (HRQoL', 'number of days spent', 'deterioration of HRQoL']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0016132', 'cui_str': 'Finland'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517887', 'cui_str': '82.5'}, {'cui': 'C4319697', 'cui_str': '6.3'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0031437', 'cui_str': 'Phenotype'}, {'cui': 'C2960235', 'cui_str': 'Mini-mental state examination score'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0037441', 'cui_str': 'Social Service'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0021629', 'cui_str': 'Institutionalization'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}]",299.0,0.150555,"Exercise prevented deterioration of HRQoL, and in the frail subgroup, all intervention costs were compensated with decreased utilization of other health care and social services over 24 months.","[{'ForeName': 'Sara A', 'Initials': 'SA', 'LastName': 'Suikkanen', 'Affiliation': 'Rehabilitation, South Karelia Social and Health Care District, Lappeenranta, Finland; Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland. Electronic address: sara.suikkanen@eksote.fi.'}, {'ForeName': 'Paula K', 'Initials': 'PK', 'LastName': 'Soukkio', 'Affiliation': 'Rehabilitation, South Karelia Social and Health Care District, Lappeenranta, Finland; Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.'}, {'ForeName': 'Eeva M', 'Initials': 'EM', 'LastName': 'Aartolahti', 'Affiliation': 'Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.'}, {'ForeName': 'Hannu', 'Initials': 'H', 'LastName': 'Kautiainen', 'Affiliation': 'Unit of Primary Health Care, University of Helsinki, Department of General Practice, and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Sanna M', 'Initials': 'SM', 'LastName': 'Kääriä', 'Affiliation': 'Raatimiehet Oy, Lappeenranta, Finland.'}, {'ForeName': 'Markku T', 'Initials': 'MT', 'LastName': 'Hupli', 'Affiliation': 'Rehabilitation, South Karelia Social and Health Care District, Lappeenranta, Finland.'}, {'ForeName': 'Sarianna', 'Initials': 'S', 'LastName': 'Sipilä', 'Affiliation': 'Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland; Faculty of Sport and Health Sciences, Gerontology Research Center, University of Jyväskylä, Jyväskylä, Finland.'}, {'ForeName': 'Kaisu H', 'Initials': 'KH', 'LastName': 'Pitkälä', 'Affiliation': 'Unit of Primary Health Care, University of Helsinki, Department of General Practice, and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Katriina T', 'Initials': 'KT', 'LastName': 'Kukkonen-Harjula', 'Affiliation': 'Rehabilitation, South Karelia Social and Health Care District, Lappeenranta, Finland.'}]",Journal of the American Medical Directors Association,['10.1016/j.jamda.2020.06.005'] 2417,32694002,Science-based communication to decrease disparities in adult pneumococcal vaccination rates.,"OBJECTIVES The objective of our study was to determine the effects of science-based communications on the attitude toward pneumococcal vaccination and understand how nonwhite racial and ethnic populations respond to these messages. DESIGN Our team tested several science-based communications using a nationally representative survey, and validated them in a local community pharmacy as a field experiment. SETTING/PARTICIPANTS The nationally representative sample phase was a survey of 3276 participants, conducted by YouGov, a leading online survey firm. The field experiment was conducted at a community pharmacy in the northeastern United States and included 86 participants. OUTCOME MEASURES In the national survey, participants were assigned to treatment groups or a control group to determine the effects of messaging strategies on influencing favorable views of pneumococcal vaccination. In the field experiment, participants were assigned to treatment or control groups to determine if the messaging strategies affected intent to ask a medical professional about the vaccine. RESULTS The nationally representative sample survey identified that messaging that focused on community and family duty had statistically significant treatment effects toward increasing individuals' perception of personal importance to have the vaccine in both the nonwhite (increase of 12.2% points relative to control) and white respondents (increase of 8.7% points relative to control). These results were validated through a field experiment, which showed that a combination message, emphasizing duty, increased the individual's intent to vaccinate by 25% points in a diverse ethnic population as compared with the control. CONCLUSIONS Messaging focused on appeals to community and family duty produced statistically significant increases in favorable attitudes toward pneumococcal vaccines and behavioral intent to seek medical advice about the vaccine in white and nonwhite populations across both the nationally representative survey and the field experiment. Medical professionals should highlight the duty to family and community when communicating with patients, as it may motivate vaccination in all populations.",2020,"CONCLUSIONS Messaging focused on appeals to community and family duty produced statistically significant increases in favorable attitudes toward pneumococcal vaccines and behavioral intent to seek medical advice about the vaccine in white and nonwhite populations across both the nationally representative survey and the field experiment.","['The nationally representative sample phase was a survey of 3276 participants, conducted by YouGov, a leading online survey firm', 'community pharmacy in the northeastern United States and included 86 participants']",[],[],"[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0205233', 'cui_str': 'Firm'}, {'cui': 'C0009478', 'cui_str': 'Community Pharmacies'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0332257', 'cui_str': 'Including'}]",[],[],3276.0,0.0262256,"CONCLUSIONS Messaging focused on appeals to community and family duty produced statistically significant increases in favorable attitudes toward pneumococcal vaccines and behavioral intent to seek medical advice about the vaccine in white and nonwhite populations across both the nationally representative survey and the field experiment.","[{'ForeName': 'Brian S', 'Initials': 'BS', 'LastName': 'Krueger', 'Affiliation': ''}, {'ForeName': 'Marc L', 'Initials': 'ML', 'LastName': 'Hutchison', 'Affiliation': ''}, {'ForeName': 'Emily C', 'Initials': 'EC', 'LastName': 'Bodo', 'Affiliation': ''}, {'ForeName': 'Kelly K', 'Initials': 'KK', 'LastName': 'Orr', 'Affiliation': ''}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'DeAngelis', 'Affiliation': ''}, {'ForeName': 'Aisling R', 'Initials': 'AR', 'LastName': 'Caffrey', 'Affiliation': ''}, {'ForeName': 'Kerry L', 'Initials': 'KL', 'LastName': 'LaPlante', 'Affiliation': ''}]",Journal of the American Pharmacists Association : JAPhA,['10.1016/j.japh.2020.05.020'] 2418,32694245,Psychopathological Networks in Cognitive-Behavioral Treatments for Binge-Eating Disorder.,"INTRODUCTION Network approaches to psychopathology posit that mental disorders emerge from interrelated symptoms, and thus connectivity among symptoms are assumed to negatively predict the treatment response and decrease with efficacious treatment. OBJECTIVE This study uniquely sought to elucidate the network structure, its change, and its predictive value in cognitive-behavioral therapy (CBT) for binge-eating disorder (BED). METHODS In a multicenter randomized trial of face-to-face and Internet-based guided self-help CBT, 178 individuals with full syndrome and subsyndromal BED, eating disorder and general psychopathology, and body mass index (BMI) were subjected to Gaussian Graphical Network and Exploratory Graph Analyses before and after treatment and at 6-month follow-up. RESULTS At pretreatment, 3 network communities of: eating disorder psychopathology; general psychopathology; and restraint and BMI were identified, with the latter community included in the first thereafter. Eating disorder-related impairment and self-esteem were the most central symptoms, while BMI and binge eating had the lowest centrality. Network connectivity significantly increased from pre- to posttreatment, with the greatest increases in strength centrality found in binge eating and shape concern, but it did not predict remission from binge eating. CONCLUSIONS With decreasing symptom severity, CBT resulted in a greater integration and connectivity of the psychopathology network in BED, suggesting an increased patient understanding of relations between binge eating and other symptoms. Network connectivity was not a negative prognostic indicator of treatment outcome. These results indicate a need for further research on the predictive value of network variables in the explanation of therapeutic change for patients with BED.",2020,"Network connectivity significantly increased from pre- to posttreatment, with the greatest increases in strength centrality found in binge eating and shape concern, but it did not predict remission from binge eating. ","['patients with BED', '178 individuals with full syndrome and subsyndromal BED, eating disorder and general psychopathology, and body mass index (BMI', 'binge-eating disorder (BED', 'Binge-Eating Disorder']","['cognitive-behavioral therapy (CBT', 'face-to-face and Internet-based guided self-help CBT']","['strength centrality', 'symptom severity', 'Eating disorder-related impairment and self-esteem', 'Network connectivity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0596170', 'cui_str': 'Binge eating disorder'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0013473', 'cui_str': 'Eating disorder'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C2733435', 'cui_str': 'Guided self-help cognitive behavioral therapy'}]","[{'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0013473', 'cui_str': 'Eating disorder'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}]",178.0,0.0301089,"Network connectivity significantly increased from pre- to posttreatment, with the greatest increases in strength centrality found in binge eating and shape concern, but it did not predict remission from binge eating. ","[{'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Hilbert', 'Affiliation': 'Integrated Research and Treatment Center AdiposityDiseases, Behavioral Medicine Research Unit, Department of Psychosomatic Medicine and Psychotherapy, University of Leipzig Medical Center, Leipzig, Germany, Anja.Hilbert@medizin.uni-leipzig.de.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Herpertz', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, LWL University, Bochum, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Zipfel', 'Affiliation': 'Psychosomatic Medicine and Psychotherapy, Medical University Hospital Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Brunna', 'Initials': 'B', 'LastName': 'Tuschen-Caffier', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Hans-Christoph', 'Initials': 'HC', 'LastName': 'Friederich', 'Affiliation': 'Department of General Internal Medicine and Psychosomatics, Medical University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Mayr', 'Affiliation': 'Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'de Zwaan', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany.'}]",Psychotherapy and psychosomatics,['10.1159/000509458'] 2419,32694286,Influence of Second Generation Oral Contraceptive Use on Adaptations to Resistance Training in Young Untrained Women.,"Dalgaard, LB, Jørgensen, EB, Oxfeldt, M, Dalgaard, EB, Johansen, FT, Karlsson, M, Ringgaard, S, and Hansen, M. Influence of second generation oral contraceptive use on adaptations to resistance training in young untrained women. J Strength Cond Res XX(X): 000-000, 2020-The study purpose was to determine effects of using second generation oral contraceptives (OC) on muscle adaptations to resistance training in young untrained women. Twenty users and 18 nonusers of OC completed a 10-week supervised progressive resistance training program. Before and after the intervention, muscle cross-sectional area (mCSA) of the quadriceps was measured using magnetic resonance imaging and muscle fiber CSA (fCSA) was determined by immunohistochemistry. In addition, body composition (DXA, fat mass/fat-free mass), maximal isometric muscle strength (dynamometry), 5 repetition maximum (5RM) leg press strength, counter movement jump (CMJ) height, and average power using a modified Wingate test were determined. Serum hormone analysis ensured OC compliance and 4-day food records documented dietary intake. After the training period, quadriceps mCSA (OC: 11.0 ± 6.0% vs. non-OC: 9.2 ± 5.0%, p = 0.001), type II fCSA (OC: 19.9 ± 7.9% vs. non-OC: 16.6 ± 7.2%, p = 0.05), muscle strength (knee extension, knee flexion and 5RM, p < 0.001), and functional power (CMJ, AP, p < 0.001) were significantly increased with no significant difference between the groups. However, a tendency toward a greater increase in fat-free mass (FFM) in the OC group was observed (OC: 3.7 ± 3.8% vs. non-OC: 2.7 ± 3.5%, p = 0.08). Collectively, use of second generation OCs in young untrained women did not significantly improve adaptations to 10 weeks of resistance training compared with nonusers. The trend toward greater gains in FFM in the OC group warrant future studies.",2020,"However, a tendency toward a greater increase in fat-free mass (FFM) in the OC group was observed (OC: 3.7 ± 3.8% vs. non-OC: 2.7 ± 3.5%, p = 0.08).","['Twenty users and 18 nonusers of OC completed a 10-week', 'Young Untrained Women', 'young untrained women']","['J Strength Cond Res XX(X', 'supervised progressive resistance training program', 'second generation oral contraceptives (OC']","['muscle strength (knee extension, knee flexion and 5RM', 'body composition (DXA, fat mass/fat-free mass), maximal isometric muscle strength (dynamometry), 5 repetition maximum (5RM) leg press strength, counter movement jump (CMJ) height, and average power using a modified Wingate test', 'fat-free mass (FFM', 'Dalgaard, LB, Jørgensen, EB, Oxfeldt, M, Dalgaard, EB, Johansen, FT, Karlsson, M, Ringgaard, S, and Hansen, M. Influence of second generation oral contraceptive use on adaptations to resistance training']","[{'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}]","[{'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0677601', 'cui_str': 'Counter'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0023343', 'cui_str': 'Leprosy'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]",,0.0140267,"However, a tendency toward a greater increase in fat-free mass (FFM) in the OC group was observed (OC: 3.7 ± 3.8% vs. non-OC: 2.7 ± 3.5%, p = 0.08).","[{'ForeName': 'Line B', 'Initials': 'LB', 'LastName': 'Dalgaard', 'Affiliation': '1Department of Public Health, Aarhus University, Aarhus C, Denmark; 2Department of Clinical Medicine, Diagnostic Center, Silkeborg Regional Hospital, Silkeborg, Denmark; 3Institute of Sports Medicine Copenhagen, Bispebjerg Hospital, Copenhagen, Denmark; and 4The MR Research Center, Aarhus University, Aarhus N, Denmark.'}, {'ForeName': 'Emil B', 'Initials': 'EB', 'LastName': 'Jørgensen', 'Affiliation': ''}, {'ForeName': 'Mikkel', 'Initials': 'M', 'LastName': 'Oxfeldt', 'Affiliation': ''}, {'ForeName': 'Emil B', 'Initials': 'EB', 'LastName': 'Dalgaard', 'Affiliation': ''}, {'ForeName': 'Frank T', 'Initials': 'FT', 'LastName': 'Johansen', 'Affiliation': ''}, {'ForeName': 'Mads', 'Initials': 'M', 'LastName': 'Karlsson', 'Affiliation': ''}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Ringgaard', 'Affiliation': ''}, {'ForeName': 'Mette', 'Initials': 'M', 'LastName': 'Hansen', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003735'] 2420,32694287,Improved Ankle Mobility After a 4-Week Training Program Affects Landing Mechanics: A Randomized Controlled Trial.,"Howe, LP, Bampouras, TM, North, JS, and Waldron, M. Improved ankle mobility after a 4-week training program affects landing mechanics: a randomized controlled trial. J Strength Cond Res XX(X): 000-000, 2020-This study examined the effects of a 4-week ankle mobility intervention on landing mechanics. Twenty subjects with restricted ankle dorsiflexion range of motion (DF ROM) were allocated to either a strength training only (n = 9) or a strength training and ankle mobility program (n = 11). Subjects performed a weight-bearing lunge test and bilateral drop-landings before and after the intervention. Normalized peak vertical ground reaction force (vGRF), time to peak vGRF, and loading rate were calculated, alongside sagittal-plane initial contact angles, peak angles, and sagittal-plane joint displacement for the ankle, knee, and hip. Frontal-plane projection angles were also calculated. After the intervention, only the strength and mobility group improved ankle DF ROM (mean difference = 4.1°, effect size [ES] = 1.00, p = 0.002). A one-way analysis of covariance found group effects for ankle joint angle at initial contact (p = 0.045), ankle (p < 0.001) and hip joint angle at peak flexion (p = 0.041), and sagittal-plane ankle (p < 0.001) and hip joint displacement (p = 0.024) during bilateral drop-landings. Post hoc analysis revealed that the strength and mobility group landed with greater ankle plantarflexion at initial contact (mean difference = 1.4 ± 2.0°, ES = 0.46) and ankle dorsiflexion at peak flexion (mean difference = 6.3 ± 2.9°, ES = 0.74) after the intervention, resulting in a greater ankle joint displacement (mean difference = 7.7 ± 4.0°, ES = 1.00). However, the strength training only group landed with increased peak hip flexion (mean difference = 14.4 ± 11.0°, ES = 0.70) and hip joint displacement (mean difference = 8.0 ± 6.6°, ES = 0.44) during post-testing. The findings suggest that changes in landing strategies following the performance of a strength training program are specific to whether restrictions in ankle mobility are considered as part of the intervention.",2020,"A one-way analysis of covariance found group effects for ankle joint angle at initial contact (p = 0.045), ankle (p < 0.001) and hip joint angle at peak flexion (p = 0.041), and sagittal-plane ankle (p < 0.001) and hip joint displacement (p = 0.024) during bilateral drop-landings.","['Twenty subjects with restricted ankle dorsiflexion range of motion (DF ROM', ' 000-000']","['strength training', 'J Strength Cond Res XX(X', '4-week ankle mobility intervention', 'strength training and ankle mobility program']","['Normalized peak vertical ground reaction force (vGRF), time to peak vGRF, and loading rate were calculated, alongside sagittal-plane initial contact angles, peak angles, and sagittal-plane joint displacement for the ankle, knee, and hip', 'hip joint angle at peak flexion', 'landing mechanics', 'ankle DF ROM', 'sagittal-plane ankle', 'hip joint displacement', 'peak hip flexion', 'ankle dorsiflexion at peak flexion', 'ankle plantarflexion at initial contact', 'Howe, LP, Bampouras, TM, North, JS, and Waldron, M. Improved ankle mobility', 'ankle joint displacement', 'Ankle Mobility']","[{'cui': 'C0231770', 'cui_str': 'Dorsiflexion of foot'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0935598', 'cui_str': 'Sagittal plane'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0019558', 'cui_str': 'Hip joint structure'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0557668', 'cui_str': 'Landing'}, {'cui': 'C0376706', 'cui_str': 'Mechanics'}, {'cui': 'C0231770', 'cui_str': 'Dorsiflexion of foot'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0003087', 'cui_str': 'Ankle joint structure'}]",20.0,0.042808,"A one-way analysis of covariance found group effects for ankle joint angle at initial contact (p = 0.045), ankle (p < 0.001) and hip joint angle at peak flexion (p = 0.041), and sagittal-plane ankle (p < 0.001) and hip joint displacement (p = 0.024) during bilateral drop-landings.","[{'ForeName': 'Louis P', 'Initials': 'LP', 'LastName': 'Howe', 'Affiliation': ""1Faculty of Arts and Sciences, Edge Hill University, Ormskirk, United Kingdom; 2Medical and Sport Sciences, University of Cumbria, Lancaster, United Kingdom; 3Lancaster Medical School, Lancaster University, Lancaster, United Kingdom; 4Faculty of Sport, Health and Applied Science, St Mary's University, Twickenham, London, United Kingdom; 5College of Engineering, Swansea University, Swansea, United Kingdom; and 6School of Science and Technology, University of New England, Armidale, New South Wales, Australia.""}, {'ForeName': 'Theodoros M', 'Initials': 'TM', 'LastName': 'Bampouras', 'Affiliation': ''}, {'ForeName': 'Jamie S', 'Initials': 'JS', 'LastName': 'North', 'Affiliation': ''}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Waldron', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003717'] 2421,32694318,"Mechanisms of Mindfulness Meditation, Cognitive Therapy, and Mindfulness-based Cognitive Therapy for Chronic Low Back Pain.","OBJECTIVES This study evaluated theoretically derived mechanisms and common therapeutic factors to test their role in accounting for pain-related outcome change during group-delivered cognitive therapy (CT), mindfulness meditation (MM) and mindfulness-based cognitive therapy (MBCT) for chronic low back pain. METHODS A secondary analysis of a pilot randomized controlled trial was used to explore the primary mechanisms of pre- to post-treatment changes in pain control beliefs, mindful observing, and pain catastrophizing, and the secondary common factor mechanisms of therapeutic alliance, group cohesion, and amount of at-home skills practice during treatment. The primary outcome was pain interference; pain intensity was a secondary outcome. RESULTS Large effect size changes in the three primary mechanisms and the outcome variables were found across the conditions. Across all three treatment conditions, change in pain control beliefs and pain catastrophizing were significantly associated with improved pain interference, but not pain intensity. Therapeutic alliance was significantly associated with pain intensity improvement and change in the therapy-specific mechanisms across the three conditions. Mindful observing, group cohesion, and amount of at-home practice were not significantly associated with changes in the outcomes. DISCUSSION CT, MM and MBCT for CLBP were all associated with significant changes in the primary mechanisms to a similar degree. Change in perceived pain control and pain catastrophizing emerged as a potential ""meta-mechanisms"" that might be a shared pathway that contributes to improved pain-related outcomes across treatments. Further, strong working alliance may represent a critical therapeutic process that both promotes and interacts with therapeutic techniques to influence outcome.",2020,"Across all three treatment conditions, change in pain control beliefs and pain catastrophizing were significantly associated with improved pain interference, but not pain intensity.",['Chronic Low Back Pain'],"['cognitive therapy (CT), mindfulness meditation (MM) and mindfulness-based cognitive therapy (MBCT', 'Mindfulness Meditation, Cognitive Therapy, and Mindfulness-based Cognitive Therapy']","['pain control beliefs, mindful observing, and pain catastrophizing', 'pain intensity', 'pain interference; pain intensity', 'pain control beliefs and pain catastrophizing', 'pain interference']","[{'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}]",3.0,0.0798335,"Across all three treatment conditions, change in pain control beliefs and pain catastrophizing were significantly associated with improved pain interference, but not pain intensity.","[{'ForeName': 'Melissa A', 'Initials': 'MA', 'LastName': 'Day', 'Affiliation': 'School of Psychology, University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'L Charles', 'Initials': 'LC', 'LastName': 'Ward', 'Affiliation': 'School of Psychology, University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'Beverly E', 'Initials': 'BE', 'LastName': 'Thorn', 'Affiliation': 'Department of Psychology, University of Alabama, Tuscaloosa, AL, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Burns', 'Affiliation': 'Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA.'}, {'ForeName': 'Dawn M', 'Initials': 'DM', 'LastName': 'Ehde', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Amanda J', 'Initials': 'AJ', 'LastName': 'Barnier', 'Affiliation': 'Department of Cognitive Science, Macquarie University, Sydney, NSW, Australia.'}, {'ForeName': 'Jason B', 'Initials': 'JB', 'LastName': 'Mattingley', 'Affiliation': 'School of Psychology, University of Queensland, Brisbane, QLD, Australia.'}, {'ForeName': 'Mark P', 'Initials': 'MP', 'LastName': 'Jensen', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA.'}]",The Clinical journal of pain,['10.1097/AJP.0000000000000862'] 2422,32699126,Barriers and facilitators to uptake and retention of inner-city ethnically diverse women in a postnatal weight management intervention: a mixed-methods process evaluation within a feasibility trial in England.,"OBJECTIVES To understand the barriers and facilitators to uptake and retention of postnatal women randomised to a commercial group weight management intervention using the COM-B (capability, opportunity, motivation and behaviour) behaviour change model. DESIGN Concurrent mixed-methods (qualitative dominant) process evaluation nested within a feasibility randomised controlled trial, comprising questionnaires and interviews at 6 and 12 months postbirth. SETTING One National Health Service maternity unit in an inner city area in the south of England. PARTICIPANTS 98 postnatal women with body mass indices>25 kg/m 2 (overweight/obese) at pregnancy commencement. INTERVENTION Twelve-week Slimming World (SW) commercial group weight management programme, commencing anytime from 8 to 16 weeks postnatally. PRIMARY AND SECONDARY OUTCOME MEASURES Data regarding uptake and retention from questionnaires and interviews conducted 6 and 12 months postbirth analysed thematically and mapped to the COM-B model. RESULTS Barriers to SW uptake mostly concerned opportunity issues (eg, lack of time or childcare support) though some women also lacked motivation, not feeling that weight reduction was a priority, and a few cited capability issues such as lacking confidence. Weight loss aspirations were also a key factor explaining retention, as were social opportunity issues, particularly in relation to factors such as the extent of group identity and relationship with the group consultant; and physical opportunity such as perceived support from and fit with family lifestyle. In addition, barriers relating to beliefs and expectations about the SW programme were identified, including concerns regarding compatibility with breastfeeding and importance of exercise. Women's understanding of the SW approach, and capability to implement into their lifestyles, appeared related to level of attendance (dose-response effect). CONCLUSIONS Uptake and retention in commercial weight management programmes may be enhanced by applying behaviour change techniques to address the barriers impacting on women's perceived capability, motivation and opportunity to participate. TRIAL REGISTRATION NUMBER ISRCTN39186148.",2020,"Weight loss aspirations were also a key factor explaining retention, as were social opportunity issues, particularly in relation to factors such as the extent of group identity and relationship with the group consultant; and physical opportunity such as perceived support from and fit with family lifestyle.","['One National Health Service maternity unit in an inner city area in the south of England', '98 postnatal women with body mass indices>25 kg/m 2 (overweight/obese) at pregnancy commencement']","['postnatal weight management intervention', 'commercial group weight management intervention']","['COM-B (capability, opportunity, motivation and behaviour) behaviour change model']","[{'cui': 'C0027462', 'cui_str': 'National Health Services'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0557849', 'cui_str': 'Inner city'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0443281', 'cui_str': 'Postnatal'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0443281', 'cui_str': 'Postnatal'}, {'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0009490', 'cui_str': 'Comoros islands'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]",98.0,0.0765417,"Weight loss aspirations were also a key factor explaining retention, as were social opportunity issues, particularly in relation to factors such as the extent of group identity and relationship with the group consultant; and physical opportunity such as perceived support from and fit with family lifestyle.","[{'ForeName': 'Cath', 'Initials': 'C', 'LastName': 'Taylor', 'Affiliation': 'School of Health Sciences, University of Surrey, Guildford, UK cath.taylor@surrey.ac.uk.'}, {'ForeName': 'Vanita', 'Initials': 'V', 'LastName': 'Bhavnani', 'Affiliation': 'National Childbirth Trust, London, UK.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Zasada', 'Affiliation': 'School of Health Sciences, University of Surrey, Guildford, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Ussher', 'Affiliation': ""Population Health Research Institute, St George's University of London, London, UK.""}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Bick', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, West Midlands, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2019-034747'] 2423,32699128,Early Parenting Intervention - Biobehavioral Outcomes in infants with Neurodevelopmental Disabilities (EPI-BOND): study protocol for an Italian multicentre randomised controlled trial.,"INTRODUCTION Neurodevelopmental disability (ND) represents an adverse condition for infants' socio-emotional and behavioural development as well as for caregiving (eg, parental sensitivity) and mother-infant interaction. Adverse exposures are associated with altered neuroendocrine hormones concentrations (eg, oxytocin and cortisol) and epigenetic regulation (eg, methylation of stress-related genes), which in turn may contribute to less-than-optimal mother-infant interaction. Parental sensitivity is a protective factor for childrens' development and early parental interventions (eg, video-feedback intervention) can promote parental caregiving and better developmental outcomes in children. The present multi-centric and longitudinal randomised controlled trial aims to assess if and to which extent early VFI could benefit both infants and mothers in terms of behavioural outcomes as well as neuroendocrine and epigenetic regulation. METHODS AND ANALYSIS Dyads will be randomly assigned to the video-feedback Intervention Group or Control Group ('dummy' intervention: telephone calls). Infants with ND aged 3 to 18 months will be recruited from three major child neuropsychiatric units in northern Italy. A multi-layer approach to intervention effects will include videotapes of mother-infant interaction, maternal reports as well as saliva samples for hormones concentrations and target-gene methylation analysis (eg, BDNF , NR3C1 , OXTR and SCL6A4 ) that will be obtained at each of the four assessment sessions: T 0 , baseline; T 1 , post-intervention; T 2 , short-term follow-up (3 month); T 3 , long-term follow-up (6 month). Primary effectiveness measures will be infant socio-emotional behaviour and maternal sensitivity. Neuroendocrine hormones concentrations and DNA methylation status of target genes will be secondary outcomes. Feasibility, moderation and confounding variables will be measured and controlled between the two groups. ETHICS AND DISSEMINATION Ethics approval has been obtained in all three participating units. Results of the main trial and each of the secondary endpoints will be submitted for publication in peer-reviewed journals and international conferences. TRIAL REGISTRATION NUMBER NCT03853564; Pre-results.",2020,"Parental sensitivity is a protective factor for childrens' development and early parental interventions (eg, video-feedback intervention) can promote parental caregiving and better developmental outcomes in children.","['children', 'Infants with ND aged 3 to 18 months will be recruited from three major child neuropsychiatric units in northern Italy', 'infants with Neurodevelopmental Disabilities (EPI-BOND']","[""video-feedback Intervention Group or Control Group ('dummy' intervention: telephone calls""]",['infant socio-emotional behaviour and maternal sensitivity'],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}]","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]",,0.22658,"Parental sensitivity is a protective factor for childrens' development and early parental interventions (eg, video-feedback intervention) can promote parental caregiving and better developmental outcomes in children.","[{'ForeName': 'Rosario', 'Initials': 'R', 'LastName': 'Montirosso', 'Affiliation': '0-3 Center for the at-Risk Infant, Scientific Institute IRCCS E. Medea, Bosisio Parini, Lecco, Italy rosario.montirosso@lanostrafamiglia.it.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Rosa', 'Affiliation': '0-3 Center for the at-Risk Infant, Scientific Institute IRCCS E. Medea, Bosisio Parini, Lecco, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Giorda', 'Affiliation': 'Biology Lab, Scientific Institute IRCCS E. Medea, Bosisio Parini, Lecco, Italy.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Fazzi', 'Affiliation': 'Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Orcesi', 'Affiliation': 'Child Neurology and Psychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Cavallini', 'Affiliation': 'Neuropsychiatry and Neurorehabilitation Unit, Scientific Institute IRCCS E. Medea, Bosisio Parini, Lecco, Italy.'}, {'ForeName': 'Livio', 'Initials': 'L', 'LastName': 'Provenzi', 'Affiliation': 'Child Neurology and Psychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2019-035249'] 2424,32699167,Artificial intelligence mobile health platform for early detection of COVID-19 in quarantine subjects using a wearable biosensor: protocol for a randomised controlled trial.,"INTRODUCTION There is an outbreak of COVID-19 worldwide. As there is no effective therapy or vaccine yet, rigorous implementation of traditional public health measures such as isolation and quarantine remains the most effective tool to control the outbreak. When an asymptomatic individual with COVID-19 exposure is being quarantined, it is necessary to perform temperature and symptom surveillance. As such surveillance is intermittent in nature and highly dependent on self-discipline, it has limited effectiveness. Advances in biosensor technologies made it possible to continuously monitor physiological parameters using wearable biosensors with a variety of form factors. OBJECTIVE To explore the potential of using wearable biosensors to continuously monitor multidimensional physiological parameters for early detection of COVID-19 clinical progression. METHOD This randomised controlled open-labelled trial will involve 200-1000 asymptomatic subjects with close COVID-19 contact under mandatory quarantine at designated facilities in Hong Kong. Subjects will be randomised to receive a remote monitoring strategy (intervention group) or standard strategy (control group) in a 1:1 ratio during the 14 day-quarantine period. In addition to fever and symptom surveillance in the control group, subjects in the intervention group will wear wearable biosensors on their arms to continuously monitor skin temperature, respiratory rate, blood pressure, pulse rate, blood oxygen saturation and daily activities. These physiological parameters will be transferred in real time to a smartphone application called Biovitals Sentinel. These data will then be processed using a cloud-based multivariate physiology analytics engine called Biovitals to detect subtle physiological changes. The results will be displayed on a web-based dashboard for clinicians' review. The primary outcome is the time to diagnosis of COVID-19. ETHICS AND DISSEMINATION Ethical approval has been obtained from institutional review boards at the study sites. Results will be published in peer-reviewed journals.",2020,Subjects will be randomised to receive a remote monitoring strategy (intervention group) or standard strategy (control group) in a 1:1 ratio during the 14 day-quarantine period.,"['200-1000 asymptomatic subjects with close COVID-19 contact under mandatory quarantine at designated facilities in Hong Kong', 'quarantine subjects']","['Artificial intelligence mobile health platform', 'remote monitoring strategy (intervention group) or standard strategy (control group']","['skin temperature, respiratory rate, blood pressure, pulse rate, blood oxygen saturation and daily activities', 'time to diagnosis of COVID-19', 'fever and symptom surveillance']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0034386', 'cui_str': 'Quarantine'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}]","[{'cui': 'C0003916', 'cui_str': 'Computer Reasoning'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0037294', 'cui_str': 'Temperature of skin'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}, {'cui': 'C0428174', 'cui_str': 'Hemoglobin saturation with oxygen'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}]",1000.0,0.0878264,Subjects will be randomised to receive a remote monitoring strategy (intervention group) or standard strategy (control group) in a 1:1 ratio during the 14 day-quarantine period.,"[{'ForeName': 'Chun Ka', 'Initials': 'CK', 'LastName': 'Wong', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Deborah Tip Yin', 'Initials': 'DTY', 'LastName': 'Ho', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Anthony Raymond', 'Initials': 'AR', 'LastName': 'Tam', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Mi', 'Initials': 'M', 'LastName': 'Zhou', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Yuk Ming', 'Initials': 'YM', 'LastName': 'Lau', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Milky Oi Yan', 'Initials': 'MOY', 'LastName': 'Tang', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Raymond Cheuk Fung', 'Initials': 'RCF', 'LastName': 'Tong', 'Affiliation': 'Harmony Medical Inc, Hong Kong, Hong Kong.'}, {'ForeName': 'Kuldeep Singh', 'Initials': 'KS', 'LastName': 'Rajput', 'Affiliation': 'Biofourmis, Singapore.'}, {'ForeName': 'Gengbo', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Research and Development, Biofourmis, Singapore.'}, {'ForeName': 'Soon Chee', 'Initials': 'SC', 'LastName': 'Chan', 'Affiliation': 'Research and Development, Biofourmis, Singapore.'}, {'ForeName': 'Chung Wah', 'Initials': 'CW', 'LastName': 'Siu', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong cwdsiu@hku.hk.'}, {'ForeName': 'Ivan Fan Ngai', 'Initials': 'IFN', 'LastName': 'Hung', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}]",BMJ open,['10.1136/bmjopen-2020-038555'] 2425,32699168,"Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI).","INTRODUCTION Obstructive sleep apnoea (OSA) and type 2 diabetes mellitus (T2DM) often occur concurrently, and untreated OSA may potentially amplify the high risk of cardiovascular disease in T2DM. Compliance with continuous positive airway pressure (CPAP), the conventional treatment for OSA, can be poor and considering weight loss is the most effective treatment for OSA. This trial examines whether the glucagon-like peptide-1 receptor agonist liraglutide, a glucose-lowering therapy associated with significant weight loss used in T2DM, can improve the severity and symptoms of OSA. METHODS AND ANALYSIS This is an outpatient, single-centred, open-labelled, prospective, phase IV randomised controlled trial in a two-by-two factorial design. One hundred and thirty-two patients with newly diagnosed OSA (apnoea-hypopnoea index (AHI) ≥15 events/hour), and existing obesity and T2DM (glycated haemoglobin (HbA 1c ) ≥47 mmol/mol), will be recruited from diabetes and sleep medicine outpatient clinics in primary and secondary care settings across Liverpool. Patients will be allocated equally, using computer-generated random, permuted blocks of unequal sizes, to each of the four treatment arms for 26 weeks: (i) liraglutide (1.8 mg once per day) alone, (ii) liraglutide 1.8 mg once per day with CPAP, (iii) CPAP alone (conventional care) or (iv) no treatment (control). The primary outcome measure is change in OSA severity, determined by AHI. Secondary outcome measures include effects on glycaemic control (glycated haemoglobin (HbA1c)), body weight and quality of life measures. Exploratory measures include measures of physical activity, MRI-derived measures of regional body composition including fat mass (abdominal subcutaneous, visceral, neck and liver fat) and skeletal muscle mass (cross-sectional analysis of thigh), indices of cardiac function (using transthoracic echocardiography) and endothelial function. ETHICAL APPROVAL The study has been approved by the North West Liverpool Central Research Ethics Committee (14/NW/1019) and it is being conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. TRIAL REGISTRATION NUMBERS ISRCTN16250774. EUDRACT No. 2014-000988-41. UTN U1111-1139-0677.",2020,"Secondary outcome measures include effects on glycaemic control (glycated haemoglobin (HbA1c)), body weight and quality of life measures.","['One hundred and thirty-two patients with newly diagnosed OSA (apnoea-hypopnoea index (AHI) ≥15 events/hour), and existing obesity and T2DM (glycated haemoglobin (HbA 1c ) ≥47\u2009mmol/mol), will be recruited from diabetes and sleep medicine outpatient clinics in primary and secondary care settings across Liverpool', 'patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE']","['UTN', 'liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP', 'liraglutide 1.8\u2009mg once per day with CPAP, (iii) CPAP alone (conventional care) or (iv) no treatment (control', 'liraglutide', 'glucagon-like peptide-1 receptor agonist liraglutide', 'continuous positive airway pressure (CPAP']","['apnea-hypnoea index (AHI', 'glycaemic control (glycated haemoglobin (HbA1c)), body weight and quality of life measures', 'physical activity, MRI-derived measures of regional body composition including fat mass (abdominal subcutaneous, visceral, neck and liver fat) and skeletal muscle mass (cross-sectional analysis of thigh), indices of cardiac function (using transthoracic echocardiography) and endothelial function', 'change in OSA severity, determined by AHI']","[{'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}, {'cui': 'C4304028', 'cui_str': 'Sleep medicine specialist'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C3494402', 'cui_str': 'Secondary Care'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C1456408', 'cui_str': 'liraglutide'}, {'cui': 'C1562104', 'cui_str': 'Glucagon-like peptide 1 receptor agonist-containing product'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0013516', 'cui_str': 'Echocardiography'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}]",132.0,0.0452433,"Secondary outcome measures include effects on glycaemic control (glycated haemoglobin (HbA1c)), body weight and quality of life measures.","[{'ForeName': 'Victoria S', 'Initials': 'VS', 'LastName': 'Sprung', 'Affiliation': 'Research Institute for Sport & Exercise Sciences, Liverpool John Moores University, Liverpool, UK v.s.sprung@ljmu.ac.uk.'}, {'ForeName': 'Graham J', 'Initials': 'GJ', 'LastName': 'Kemp', 'Affiliation': 'Department of Musculoskeletal & Ageing Science, University of Liverpool, Liverpool, Merseyside, UK.'}, {'ForeName': 'John Ph', 'Initials': 'JP', 'LastName': 'Wilding', 'Affiliation': 'Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Adams', 'Affiliation': 'Liverpool Magnetic Resonance Imaging Centre (LiMRIC), University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Kieran', 'Initials': 'K', 'LastName': 'Murphy', 'Affiliation': 'Liverpool Magnetic Resonance Imaging Centre (LiMRIC), University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Malcolm', 'Initials': 'M', 'LastName': 'Burgess', 'Affiliation': 'Department of Cardiology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Emegbo', 'Affiliation': 'Liverpool Sleep & Ventilation Unit, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Thomas', 'Affiliation': 'Liverpool Sleep & Ventilation Unit, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK.'}, {'ForeName': 'Alexander J', 'Initials': 'AJ', 'LastName': 'Needham', 'Affiliation': 'Liverpool Clinical Trials Unit, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Weimken', 'Affiliation': 'Center for Sleep & Circadian Neurobiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Schwab', 'Affiliation': 'Center for Sleep & Circadian Neurobiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Ari', 'Initials': 'A', 'LastName': 'Manuel', 'Affiliation': 'Liverpool Sleep & Ventilation Unit, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK.'}, {'ForeName': 'Sonya E', 'Initials': 'SE', 'LastName': 'Craig', 'Affiliation': 'Liverpool Sleep & Ventilation Unit, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Cuthbertson', 'Affiliation': 'Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool, UK.'}]",BMJ open,['10.1136/bmjopen-2020-038856'] 2426,32699546,Urinary tract infections in the elderly: a review of disease characteristics and current treatment options.,"Urinary tract infections (UTIs) are common in the elderly, and cover a range of conditions from asymptomatic bacteriuria to urosepsis. Risk factors for developing symptomatic UTIs include immunosenescence, exposure to nosocomial pathogens, multiple comorbidities, and a history of UTIs. European guidelines on urological infections recommend antimicrobial treatment only for symptomatic UTIs. Non-antimicrobial options to treat and prevent UTIs include among others cranberry products, OM-89 Escherichia coli bacterial lysate vaccine, and estrogen therapy in postmenopausal women, although evidence for their efficacy is weak. Another non-antimicrobial option to control and prevent UTIs is a medical device (Utipro Plus ® ) containing xyloglucan, gelatin, propolis, and extracts of Hibiscus sabdariffa . The device acts in the intestine as a mechanical barrier to protect against invasion by uropathogenic E. coli strains. A randomized controlled trial of Utipro Plus ® in patients with uncomplicated UTIs provided good-quality evidence of its efficacy compared with placebo. In an observational study of Utipro Plus ® in patients with recurrent UTIs, more than 80% women reported a return to their pre-UTI clinical status and about 30% transitioned from symptomatic UTIs to asymptomatic bacteriuria. New treatment strategies that offer a safe and effective non-antimicrobial means of managing UTIs could have an important role in the elderly.",2020,A randomized controlled trial of Utipro Plus ® in patients with uncomplicated UTIs provided good-quality evidence of its efficacy compared with placebo.,"['postmenopausal women', 'patients with recurrent UTIs, more than 80% women reported a return to their pre-UTI clinical status and about 30% transitioned from symptomatic UTIs to asymptomatic bacteriuria', 'Urinary tract infections in the elderly', 'patients with uncomplicated UTIs']","['placebo', 'Utipro Plus ®']",['Urinary tract infections (UTIs'],"[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0262655', 'cui_str': 'Recurrent urinary tract infection'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0449440', 'cui_str': 'Clinical status'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0262380', 'cui_str': 'Asymptomatic bacteriuria'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0443334', 'cui_str': 'Uncomplicated'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4506389', 'cui_str': 'Utipro'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}]",,0.0324642,A randomized controlled trial of Utipro Plus ® in patients with uncomplicated UTIs provided good-quality evidence of its efficacy compared with placebo.,"[{'ForeName': 'Leocadio', 'Initials': 'L', 'LastName': 'Rodriguez-Mañas', 'Affiliation': 'Servicio de Geriatría, Hospital Universitario de Getafe, Madrid, Spain.'}]",Drugs in context,['10.7573/dic.2020-4-13'] 2427,32699561,Long-time follow up of physical activity level among older adults with rheumatoid arthritis.,"Background Physical activity and exercise are acknowledged as important parts in the management of rheumatoid arthritis (RA). However, long-term maintenance of exercise is known to be difficult. The aim of this study was to evaluate change in physical activity and physical fitness after four years in older adults with RA who had previously participated in exercise with person-centred guidance compared to controls. Method A follow-up study was performed where older adults (> 65 years) who had participated in a randomized controlled trial where they were allocated to either exercise with person-centred guidance or home-based, light-intensity exercise (controls) were invited to one visit and assessed with performance-based test, blood-sampling and self-reported questionnaires. Forty-seven out of 70 older adults accepted participation, 24 from the exercise group and 23 from the control group. Comparisons of the result with baseline values were performed and explanatory factors for increase of physical activity were examined with logistic regression. Results The result show that there was no significant difference in weekly hours of physical activity when groups where compared. However, participants in the exercise group rated significantly increased weekly hours of physical activity after four years ( p  = 0.004) when compared to baseline. Higher levels of fatigue, BMI and physical activity, at baseline were negatively associated with increased physical activity after four years. There was no significant difference in change of physical fitness between the groups. Within group analysis showed that the control group reported increased pain ( p  = 0.035), fatigue ( p  = 0.023) increased number of tender joints ( p  = 0.028) higher disease activity ( p  = 0.007) and worsening of global health ( p  = 0.004) when compared to baseline while the exercise group remained at the same level as at baseline. Conclusion These results indicate that introducing moderate- to high intensity exercise with person-centred guidance might favor increased physical activity after four years in older adults with RA. Previous partaking in moderate- to high intensity exercise might also be protective against increased disease activity, pain and fatigue over time.",2020,"Within group analysis showed that the control group reported increased pain ( p  = 0.035), fatigue ( p  = 0.023) increased number of tender joints ( p  = 0.028) higher disease activity ( p  = 0.007) and worsening of global health ( p  = 0.004) when compared to baseline while the exercise group remained at the same level as at baseline. ","['older adults with RA', 'older adults (>\u200965\u2009years) who had participated', 'older adults with rheumatoid arthritis', 'Forty-seven out of 70 older adults accepted participation, 24 from the exercise group and 23 from the control group', 'older adults with RA who had previously participated in exercise with person-centred guidance compared to controls']","['exercise with person-centred guidance or home-based, light-intensity exercise (controls) were invited to one visit and assessed with performance-based test, blood-sampling and self-reported questionnaires', '\n\n\nPhysical activity and exercise']","['disease activity', 'physical activity and physical fitness', 'weekly hours of physical activity', 'fatigue', 'worsening of global health', 'Higher levels of fatigue, BMI and physical activity', 'disease activity, pain and fatigue', 'physical activity', 'pain', 'number of tender joints', 'change of physical fitness']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0005834', 'cui_str': 'Collection of blood specimen for laboratory'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C2586108', 'cui_str': 'Level of fatigue'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0240094', 'cui_str': 'Tenderness of joint'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",70.0,0.0227157,"Within group analysis showed that the control group reported increased pain ( p  = 0.035), fatigue ( p  = 0.023) increased number of tender joints ( p  = 0.028) higher disease activity ( p  = 0.007) and worsening of global health ( p  = 0.004) when compared to baseline while the exercise group remained at the same level as at baseline. ","[{'ForeName': 'Elvira', 'Initials': 'E', 'LastName': 'Lange', 'Affiliation': 'Department of Health and Rehabilitation, Unit of Physiotherapy, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Box 455, 405 30 Göteborg, Sweden.'}, {'ForeName': 'Inger', 'Initials': 'I', 'LastName': 'Gjertsson', 'Affiliation': 'University of Gothenburg Center for Person-centred Care, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Kaisa', 'Initials': 'K', 'LastName': 'Mannerkorpi', 'Affiliation': 'Department of Health and Rehabilitation, Unit of Physiotherapy, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Box 455, 405 30 Göteborg, Sweden.'}]",European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity,['10.1186/s11556-020-00242-w'] 2428,32699595,Prophylaxis and treatment of acute and chronic postoperative inguinal pain (CPIP)-association of pain with compression neuropathy.,"Can open inguinal hernia repair (OIHR) and tailored neurectomy (TN) be effective for prophylaxis of chronic postoperative inguinal hernia repair (CPIP) (I) and treatment of CPIP (II)? Patients with symptomatic primary inguinal hernia (I group 1) and secondary hernia with CPIP (II, groups 2-5) were investigated for postoperative complications and nerve damage. About, 98% of patients with OIHR with TN reported preoperative pain (I group 1, n  = 388, recurrence rate 1%). There were 73 cases (II) of CPIP after laparoscopic inguinal hernia repair (LIHR) (group 2, n  = 22), OIHR (group 3, n  = 37), LIHR followed by OIHR/LIHR (group 4, n  = 5) and OIHR followed by LIHR/OIHR (group 5, n  = 9). The results were as follows: preoperative pain: 33-100%, recurrence rate 0-11% (II, groups 2-5), nerve damage 92-100% and persistent CPIP: n  = 1 after trocar perforation of inguinal nerve elsewhere. OIHR is effective to avoid CPIP with compression neuropathy. This is the largest series of histological nerve damage in CPIP.",2020,Can open inguinal hernia repair (OIHR) and tailored neurectomy (TN) be effective for prophylaxis of chronic postoperative inguinal hernia repair (CPIP) (I) and treatment of CPIP (II)?,"['Patients with symptomatic primary inguinal hernia (I group 1) and secondary hernia with CPIP (II, groups 2-5', 'acute and chronic postoperative inguinal pain (CPIP)-association of pain with compression neuropathy', '0-11% (II, groups 2-5), nerve damage 92-100% and persistent CPIP: n \xa0=\xa01 after trocar perforation of inguinal nerve elsewhere']","['OIHR followed by LIHR/OIHR', 'OIHR', 'LIHR followed by OIHR/LIHR', 'inguinal hernia repair (OIHR) and tailored neurectomy (TN', 'laparoscopic inguinal hernia repair (LIHR']","['postoperative complications and nerve damage', 'recurrence rate', 'preoperative pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0019294', 'cui_str': 'Inguinal hernia'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0021446', 'cui_str': 'Repair of inguinal hernia'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0239783', 'cui_str': 'Inguinal pain'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0393814', 'cui_str': 'Hereditary liability to pressure palsies'}, {'cui': 'C0161479', 'cui_str': 'Nerve injury'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0041158', 'cui_str': 'Trocar'}, {'cui': 'C0549099', 'cui_str': 'Perforation'}, {'cui': 'C0018246', 'cui_str': 'Inguinal'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}]","[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0021446', 'cui_str': 'Repair of inguinal hernia'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0196652', 'cui_str': 'Nerve excision'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}]","[{'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0161479', 'cui_str': 'Nerve injury'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",388.0,0.0356841,Can open inguinal hernia repair (OIHR) and tailored neurectomy (TN) be effective for prophylaxis of chronic postoperative inguinal hernia repair (CPIP) (I) and treatment of CPIP (II)?,"[{'ForeName': 'René Gordon', 'Initials': 'RG', 'LastName': 'Holzheimer', 'Affiliation': 'Surgeon/Sportsmedicine - Chirurgische Tagesklinik Sauerlach/München - Ludwig-Maximilians-Universität München Germany - Sant Anna Klinik Meran Italy.'}, {'ForeName': 'Nikolai', 'Initials': 'N', 'LastName': 'Gaschütz', 'Affiliation': 'General Practitioner D-97500 Ebelsbach.'}]",Journal of surgical case reports,['10.1093/jscr/rjaa143'] 2429,32699621,Effects of early high-dose erythropoietin on acute kidney injury following cardiac arrest: exploratory post hoc analyses from an open-label randomized trial.,"Background Acute kidney injury (AKI) is frequent in patients resuscitated from cardiac arrest (CA) and may worsen outcome. Experimental data suggest a renoprotective effect by treating these patients with a high dose of erythropoietin (Epo) analogues. We aimed to evaluate the efficacy of epoetin alpha treatment on renal outcome after CA. Methods We did a post hoc analysis of the Epo-ACR-02 trial, which randomized patients with a persistent coma after a witnessed out-of-hospital CA. Only patients admitted in one intensive care unit were analysed. In the intervention group, patients received five intravenous injections of Epo spaced 12 h apart during the first 48 h, started as soon as possible after resuscitation. In the control group, patients received standard care without Epo. The main endpoint was the proportion of patients with persistent AKI defined by Kidney Disease: Improving Global Outcomes criteria at Day 2. Secondary endpoints included the occurrence of AKI through Day 7, estimated glomerular filtration rate (eGFR) at Day 28, haematological indices and adverse events. Results A total of 162 patients were included in the primary analysis (74 in the Epo group, 88 in the control group). Baseline characteristics were similar in the two groups. At Day 2, 52.8% of the patients (38/72) in the intervention group had an AKI, as compared with 54.4% of the patients (46/83) in the control group (P = 0.74). There was no significant difference between the two groups regarding the proportion of patients with AKI through Day 7. Among patients with persistent AKI at Day 2, 33% (4/12) in the intervention group had an eGFR <75 mL/min/1.73 m 2 compared with 25% (3/12) in the control group at Day 28 (P = 0.99). We found no significant differences in haematological indices or adverse events. Conclusion After CA, early administration of Epo did not confer any renal protective effect as compared with standard therapy.",2020,"At Day 2, 52.8% of the patients (38/72) in the intervention group had an AKI, as compared with 54.4% of the patients (46/83) in the control group (P = 0.74).","['A total of 162 patients were included in the primary analysis (74 in the Epo group, 88 in the control group', 'patients resuscitated from cardiac arrest (CA', 'Only patients admitted in one intensive care unit were analysed', 'patients with a persistent coma after a witnessed out-of-hospital CA', 'patients with a high dose of erythropoietin (Epo) analogues', 'acute kidney injury following cardiac arrest']","['epoetin alpha treatment', 'early high-dose erythropoietin', 'standard care without Epo']","['renal protective effect', 'occurrence of AKI through Day 7, estimated glomerular filtration rate (eGFR) at Day 28, haematological indices and adverse events', 'proportion of patients with persistent AKI', 'haematological indices or adverse events']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C5191360', 'cui_str': '162'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0014822', 'cui_str': 'erythropoietin'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2587207', 'cui_str': 'For resuscitation'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0009421', 'cui_str': 'Coma'}, {'cui': 'C2936490', 'cui_str': 'Out-of-Hospital Heart Arrest'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0014822', 'cui_str': 'erythropoietin'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}]",162.0,0.121765,"At Day 2, 52.8% of the patients (38/72) in the intervention group had an AKI, as compared with 54.4% of the patients (46/83) in the control group (P = 0.74).","[{'ForeName': 'Lucie', 'Initials': 'L', 'LastName': 'Guillemet', 'Affiliation': 'Medical Intensive Care Unit, Cochin Hospital (AP-HP), Paris, France.'}, {'ForeName': 'Matthieu', 'Initials': 'M', 'LastName': 'Jamme', 'Affiliation': 'Medical Intensive Care Unit, Cochin Hospital (AP-HP), Paris, France.'}, {'ForeName': 'Wulfran', 'Initials': 'W', 'LastName': 'Bougouin', 'Affiliation': 'Medical Intensive Care Unit, Cochin Hospital (AP-HP), Paris, France.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Geri', 'Affiliation': 'Medical Intensive Care Unit, Cochin Hospital (AP-HP), Paris, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Deye', 'Affiliation': 'Medical Intensive Care Unit, Lariboisière Hospital (AP-HP) and INSERM U942, Paris, France.'}, {'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Vivien', 'Affiliation': 'Paris Descartes University, Paris, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Varenne', 'Affiliation': 'Paris Descartes University, Paris, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Pène', 'Affiliation': 'Medical Intensive Care Unit, Cochin Hospital (AP-HP), Paris, France.'}, {'ForeName': 'Jean-Paul', 'Initials': 'JP', 'LastName': 'Mira', 'Affiliation': 'Medical Intensive Care Unit, Cochin Hospital (AP-HP), Paris, France.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Barat', 'Affiliation': 'Clinical Trial Unit, Central Pharmacy, AP-HP, Paris, France.'}, {'ForeName': 'Jean-Marc', 'Initials': 'JM', 'LastName': 'Treluyer', 'Affiliation': 'Paris Descartes University, Paris, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Hermine', 'Affiliation': 'Paris Descartes University, Paris, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Carli', 'Affiliation': 'Paris Descartes University, Paris, France.'}, {'ForeName': 'Joël', 'Initials': 'J', 'LastName': 'Coste', 'Affiliation': 'Paris Descartes University, Paris, France.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Cariou', 'Affiliation': 'Medical Intensive Care Unit, Cochin Hospital (AP-HP), Paris, France.'}]",Clinical kidney journal,['10.1093/ckj/sfz068'] 2430,32699739,The Effects of Obligatory and Preferential Frames on Delay Discounting.,"Human decision making is partly determined by the verbal stimuli involved in a choice. Verbal stimuli that may be particularly relevant to human decision making are the words should and like , whereby should is presumably associated with what one ought to choose, and like is presumably associated with what one prefers to choose. The current study examined the potential effects of should and like on decisions in a monetary delay-discounting task. Eighty-three participants were recruited from Amazon's Mechanical Turk and were randomly assigned to a sequence of 2 conditions- should and like -in a repeated-measures experimental design. Based on condition assignment, the questions ""Which should you choose?"" and ""Which would you like to choose?"" appeared above each monetary option and its respective delay. Overall, participants demonstrated significantly lower levels of discounting in the should condition when compared to the like condition. However, this effect was much less consistent for participants exposed to the should condition prior to the like condition. The results of the current investigation indicate that the use of the words should and like constitutes separate classes of verbal stimuli that we refer to as obligatory and preferential frames. The effect of obligatory and preferential frames on delay discounting may be relevant to the prediction and control of decision making in social contexts.",2020,The effect of obligatory and preferential frames on delay discounting may be relevant to the prediction and control of decision making in social contexts.,"[""Eighty-three participants were recruited from Amazon's Mechanical Turk""]",['sequence of 2 conditions- should and'],['Delay Discounting'],"[{'cui': 'C4517888', 'cui_str': '83'}, {'cui': 'C0325969', 'cui_str': 'Genus Amazona'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0337911', 'cui_str': 'Turks'}]","[{'cui': 'C0004793', 'cui_str': 'Base sequence'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]",[],83.0,0.0172793,The effect of obligatory and preferential frames on delay discounting may be relevant to the prediction and control of decision making in social contexts.,"[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Barcelos Nomicos', 'Affiliation': 'Department of Psychology/296, University of Nevada, Reno, 1664 N. Virginia Street, Reno, NV 89557 USA.'}, {'ForeName': 'Kenneth W', 'Initials': 'KW', 'LastName': 'Jacobs', 'Affiliation': 'Department of Psychology/296, University of Nevada, Reno, 1664 N. Virginia Street, Reno, NV 89557 USA.'}, {'ForeName': 'Matthew L', 'Initials': 'ML', 'LastName': 'Locey', 'Affiliation': 'Department of Psychology/296, University of Nevada, Reno, 1664 N. Virginia Street, Reno, NV 89557 USA.'}]",The Analysis of verbal behavior,['10.1007/s40616-020-00127-0'] 2431,32694367,An Untargeted Urine Metabolomics Approach for Autologous Blood Transfusion Detection.,"PURPOSE Autologous blood transfusion is performance enhancing and prohibited in sport but remains difficult to detect. This study explored the hypothesis that an untargeted urine metabolomics analysis can reveal one or more novel metabolites with high sensitivity and specificity for detection of autologous blood transfusion. METHODS In a randomized, double-blinded, placebo-controlled, cross-over design, exercise-trained males (n=12) donated 900 ml blood or were sham phlebotomized. After four weeks, RBCs or saline were reinfused. Urine samples were collected before phlebotomy and 2 h, 1, 2, 3, 5 and 10 days after reinfusion and analyzed by UPLC-QTOF-MS. Models of unique metabolites reflecting autologous blood transfusion were attained by partial least squares discriminant analysis. RESULTS The strongest model was obtained 2 h after reinfusion with a misclassification error of 6.3% and 98.8% specificity. However, combining only a few of the strongest metabolites selected by this model provided a sensitivity of 100% at days 1 and 2 and 66% at day 3 with 100% specificity. Metabolite identification revealed the presence of secondary di-2-ethylhexyl phtalate metabolites and putatively identified the presence of (iso)caproic acid glucuronide as the strongest candidate biomarker. CONCLUSION Untargeted urine metabolomics revealed several plasticizers as the strongest metabolic pattern for detection of autologous blood transfusion for up to 3 days. Importantly, no other metabolites in urine appear of value for anti-doping purposes.",2020,The strongest model was obtained 2 h after reinfusion with a misclassification error of 6.3% and 98.8% specificity.,[],"['RBCs or saline', 'placebo-controlled, cross-over design, exercise-trained males (n=12) donated 900 ml blood or were sham phlebotomized']",[],[],"[{'cui': 'C0014792', 'cui_str': 'erythrocytes'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0242817', 'cui_str': 'Crossover Design'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4517900', 'cui_str': '900'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]",[],,0.125286,The strongest model was obtained 2 h after reinfusion with a misclassification error of 6.3% and 98.8% specificity.,"[{'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Bejder', 'Affiliation': 'Department of Nutrition, Exercise and Sports (NEXS), University of Copenhagen, Denmark.'}, {'ForeName': 'Gözde', 'Initials': 'G', 'LastName': 'Gürdeniz', 'Affiliation': 'Department of Nutrition, Exercise and Sports (NEXS), University of Copenhagen, Denmark.'}, {'ForeName': 'Cătălina', 'Initials': 'C', 'LastName': 'Cuparencu', 'Affiliation': 'Department of Nutrition, Exercise and Sports (NEXS), University of Copenhagen, Denmark.'}, {'ForeName': 'Frederikke', 'Initials': 'F', 'LastName': 'Hall', 'Affiliation': 'Department of Nutrition, Exercise and Sports (NEXS), University of Copenhagen, Denmark.'}, {'ForeName': 'Mikkel', 'Initials': 'M', 'LastName': 'Gybel-Brask', 'Affiliation': 'Section for Transfusion Medicine, Capital Region Blood Bank, Rigshospitalet, Department of Clinical Medicine, University of Copenhagen, Denmark.'}, {'ForeName': 'Andreas Breenfeldt', 'Initials': 'AB', 'LastName': 'Andersen', 'Affiliation': 'Department of Nutrition, Exercise and Sports (NEXS), University of Copenhagen, Denmark.'}, {'ForeName': 'Lars Ove', 'Initials': 'LO', 'LastName': 'Dragsted', 'Affiliation': 'Department of Nutrition, Exercise and Sports (NEXS), University of Copenhagen, Denmark.'}, {'ForeName': 'Niels H', 'Initials': 'NH', 'LastName': 'Secher', 'Affiliation': 'Department of Anesthesiology, Rigshospitalet, University of Copenhagen, Denmark.'}, {'ForeName': 'Pär I', 'Initials': 'PI', 'LastName': 'Johansson', 'Affiliation': 'Section for Transfusion Medicine, Capital Region Blood Bank, Rigshospitalet, Department of Clinical Medicine, University of Copenhagen, Denmark.'}, {'ForeName': 'Nikolai Baastrup', 'Initials': 'NB', 'LastName': 'Nordsborg', 'Affiliation': 'Department of Nutrition, Exercise and Sports (NEXS), University of Copenhagen, Denmark.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002442'] 2432,32694372,Blood Flow Restriction Improves Executive Function following Walking.,"PURPOSE Blood flow restriction (BFR) walking is recognized as a beneficial strategy for increasing skeletal muscle mass and strength. No study has examined the effect of BFR exercise on cognitive functions, including executive function (EF). In this study, we examined the effect of BFR walking on EF. METHODS We performed two studies, at rest and exercise, with BFR or non-BFR (NBFR) in a crossover design. Sitting rest was performed for 15 min (study 1, n = 8). Exercise was programed at five sets of 2-min walking at 5 km/h with 1-min rest intervals (study 2, n = 16). The BFR condition was achieved using 200 mmHg pressure cuffs placed around the proximal region of the thighs. The NBFR condition involved no pressure cuffs. EF was assessed using the color-word Stroop task before and after each condition. RESULTS In study 1, there were no significant effects on EF parameters for both BFR and NBFR conditions, suggesting that BFR alone does not improve EF. In study 2, incongruent reaction time shortened after BFR walking compared to that before walking (P = 0.001). Furthermore, the reverse-Stroop interference score decreased after BFR walking compared to that before walking (P < 0.001). CONCLUSION These findings suggest that, even with a mild exercise, BFR walking improves EF independently of the effect of BFR alone or walking alone.",2020,"In study 2, incongruent reaction time shortened after BFR walking compared to that before walking (P = 0.001).",[],"['BFR exercise', 'BFR or non-BFR (NBFR', 'Blood Flow Restriction', 'BFR walking']","['EF parameters', 'EF', 'incongruent reaction time shortened after BFR walking', 'reverse-Stroop interference score', 'cognitive functions, including executive function (EF']",[],"[{'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1321310', 'cui_str': 'Incongruous'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0332257', 'cui_str': 'Including'}]",,0.0346689,"In study 2, incongruent reaction time shortened after BFR walking compared to that before walking (P = 0.001).","[{'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Sugimoto', 'Affiliation': 'Faculty of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.'}, {'ForeName': 'Tadashi', 'Initials': 'T', 'LastName': 'Suga', 'Affiliation': 'Faculty of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.'}, {'ForeName': 'Keigo', 'Initials': 'K', 'LastName': 'Tomoo', 'Affiliation': 'Faculty of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.'}, {'ForeName': 'Kento', 'Initials': 'K', 'LastName': 'Dora', 'Affiliation': 'Faculty of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.'}, {'ForeName': 'Ernest', 'Initials': 'E', 'LastName': 'Mok', 'Affiliation': 'Faculty of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.'}, {'ForeName': 'Hayato', 'Initials': 'H', 'LastName': 'Tsukamoto', 'Affiliation': 'Faculty of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.'}, {'ForeName': 'Shingo', 'Initials': 'S', 'LastName': 'Takada', 'Affiliation': 'Faculty of Lifelong Sport, Department of Sports Education, Hokusho University, Ebetsu, Hokkaido, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Hashimoto', 'Affiliation': 'Faculty of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.'}, {'ForeName': 'Tadao', 'Initials': 'T', 'LastName': 'Isaka', 'Affiliation': 'Faculty of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002446'] 2433,32694373,Accelerated Muscle Recovery in Baseball Pitchers Using Phase Change Material Cooling.,"PURPOSE The purpose of this study was to document recovery following a pitching performance and determine if prolonged post-game phase change material (PCM) cooling of the shoulder and forearm accelerates recovery. METHODS Strength, soreness and serum creatine kinase (CK) activity were assessed prior to, and on the two days following pitching performances in 16 college pitchers. Pitchers were randomized to receive either post-game PCM cooling packs on the shoulder and forearm, or no cooling (control). PCM packs were applied inside compression shirts and delivered cooling at a constant temperature of 15°C for 3 hours. Strength was assessed for shoulder internal rotation (IR), external rotation (ER), empty can test (EC) and grip. RESULTS Total pitch count was 60±16 for 23 PCM cooling games and 62±17 for 24 control games (P=.679). On the days following pitching IR strength (P=.006) and grip strength (P=.036) were higher in the PCM cooling group versus control. One day after pitching IR strength was 95±14% of baseline with PCM cooling versus 83±13% for control (P=.008, effect size d 0.91) and 107±9% versus 95±10% for grip strength (P=.022, effect size d 1.29). There was a trend for greater ER strength with PCM cooling (P=.091, effect size d 0.51). The EC strength was not impaired after pitching (P=.147) and was therefore unaffected by PCM cooling (P=.168). Elevations in soreness and CK were not different between treatments (Treatment by Time CK P=.139, shoulder soreness P=.885, forearm soreness P=.206). CONCLUSION This is one of the first studies to document impairments in muscle function on the days following baseball pitching, and the first study showing a novel cryotherapy intervention that accelerates recovery of muscle function in baseball pitchers following a game.",2020,"Elevations in soreness and CK were not different between treatments (Treatment by Time CK P=.139, shoulder soreness P=.885, forearm soreness P=.206). ",['16 college pitchers'],"['novel cryotherapy intervention', 'post-game PCM cooling packs on the shoulder and forearm, or no cooling (control']","['soreness and serum creatine kinase (CK) activity', 'shoulder internal rotation (IR), external rotation (ER), empty can test (EC) and grip', 'greater ER strength', 'Elevations in soreness and CK', 'EC strength', 'grip strength', 'Total pitch count']","[{'cui': 'C0557806', 'cui_str': 'College'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C4551716', 'cui_str': 'Cryotherapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0184967', 'cui_str': 'Insertion of pack'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0016536', 'cui_str': 'Forearm structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0234233', 'cui_str': 'Soreness'}, {'cui': 'C0858112', 'cui_str': 'Serum creatine'}, {'cui': 'C0031727', 'cui_str': 'Kinase'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0231459', 'cui_str': 'Internal rotation'}, {'cui': 'C0231462', 'cui_str': 'External rotation'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0220843', 'cui_str': 'Grasp'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0175681', 'cui_str': 'Pitch'}, {'cui': 'C0439157', 'cui_str': 'counts'}]",,0.0397356,"Elevations in soreness and CK were not different between treatments (Treatment by Time CK P=.139, shoulder soreness P=.885, forearm soreness P=.206). ","[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Mullaney', 'Affiliation': 'Nicholas Institute of Sports Medicine & Athletic Trauma, Lenox Hill Hospital, New York, NY.'}, {'ForeName': 'Malachy P', 'Initials': 'MP', 'LastName': 'McHugh', 'Affiliation': 'Nicholas Institute of Sports Medicine & Athletic Trauma, Lenox Hill Hospital, New York, NY.'}, {'ForeName': 'Susan Y', 'Initials': 'SY', 'LastName': 'Kwiecien', 'Affiliation': 'Nicholas Institute of Sports Medicine & Athletic Trauma, Lenox Hill Hospital, New York, NY.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Ioviero', 'Affiliation': 'Kean University, Union, NJ.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Fink', 'Affiliation': 'Mullaney & Associates Physical Therapy, Matawan, NJ.'}, {'ForeName': 'Glyn', 'Initials': 'G', 'LastName': 'Howatson', 'Affiliation': 'Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle upon Tyne, United Kingdom.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002447'] 2434,32694374,Muscle Glycogen Utilization during Exercise following Ingestion of Alcohol.,"PURPOSE Ingested ethanol (EtOH) is metabolized gastrically and hepatically, which may influence resting and exercise metabolism. Previous exercise studies have provided EtOH intravenously rather than orally, altering the metabolic effects of EtOH. No studies to date have investigated the effects of EtOH ingestion on systemic and peripheral (e.g. skeletal muscle) exercise metabolism. METHODS Eight men (Mean ± SD, Age: 24 ± 5 y; Body Mass: 76.7 ± 5.6 kg; Height: 1.80 ± 0.04 m; V[Combining Dot Above]O2peak: 4.1 ± 0.2 L.min) performed two bouts of fasted cycling exercise at 55% V[Combining Dot Above]O2peak for 2-h, with (EtOH) and without (Control) prior ingestion of EtOH 1-h and immediately before exercise (total dose: 0.1 g·kg lean body mass·h; 30.2 ± 1.1 g 40% ABV Vodka; fed in 2 equal boluses) in a randomized order, separated by 7-10 days. RESULTS Muscle glycogen use during exercise was not different between conditions (EtOH: 229 [156, 302] vs CONTROL: 258 [185, 331] mmol·kg dm; p = 0.67; means with normalized 95% confident intervals). Mean plasma glucose concentrations during exercise were similar (Control: 5.26 [5.17, 5.34] vs EtOH: 5.26 [5.18, 5.34] mmol·L; p = 0.04). EtOH ingestion resulted in similar plasma non-esterified fatty acid (NEFA) concentrations compared to rest (Control: 0.43 [0.31,0.55] vs EtOH: 0.30 [0.21,0.40] mmol·L) and during exercise. Plasma lactate concentration was higher during the first 30-min of rest following EtOH consumption (mean concentration: Control: 0.83 [0.77, 0.90] vs EtOH 1.00 [0.93, 1.07] mmol·L) but the response during exercise was similar between conditions. CONCLUSIONS Muscle glycogen utilization was similar during exercise with or without prior ethanol ingestion, reflected in similar total whole-body carbohydrate oxidation rates observed.",2020,"Mean plasma glucose concentrations during exercise were similar (Control: 5.26 [5.17, 5.34] vs EtOH: 5.26 [5.18, 5.34]","['Eight men (Mean ± SD, Age: 24 ± 5 y; Body Mass: 76.7 ± 5.6 kg; Height: 1.80 ± 0.04 m']","['Dot Above]O2peak for 2-h, with (EtOH) and without (Control) prior ingestion of EtOH 1-h and immediately before exercise', 'ethanol (EtOH', 'V[Combining', 'fasted cycling exercise']","['Mean plasma glucose concentrations', 'similar plasma non-esterified fatty acid (NEFA) concentrations', 'Plasma lactate concentration', 'similar total whole-body carbohydrate oxidation rates']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C4517794', 'cui_str': '5.6'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C4517407', 'cui_str': '0.04'}]","[{'cui': 'C1720485', 'cui_str': 'Corneal epithelial dots'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0587107', 'cui_str': 'During exercise'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0700308', 'cui_str': 'Protium'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0585043', 'cui_str': 'Before exercise'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2584434', 'cui_str': 'Plasma glucose concentration'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0369212', 'cui_str': 'Esterified fatty acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}]",,0.0813671,"Mean plasma glucose concentrations during exercise were similar (Control: 5.26 [5.17, 5.34] vs EtOH: 5.26 [5.18, 5.34]","[{'ForeName': 'Harry A', 'Initials': 'HA', 'LastName': 'Smith', 'Affiliation': 'Department for Health, University of Bath, United Kingdom.'}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Hengist', 'Affiliation': 'Department for Health, University of Bath, United Kingdom.'}, {'ForeName': 'Drusus Johnson', 'Initials': 'DJ', 'LastName': 'Bonson', 'Affiliation': 'Department for Health, University of Bath, United Kingdom.'}, {'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Walhin', 'Affiliation': 'Department for Health, University of Bath, United Kingdom.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Jones', 'Affiliation': 'School of Life Sciences, Queens Medical Centre, University of Nottingham, United Kingdom.'}, {'ForeName': 'Kostas', 'Initials': 'K', 'LastName': 'Tsintzas', 'Affiliation': 'School of Life Sciences, Queens Medical Centre, University of Nottingham, United Kingdom.'}, {'ForeName': 'Gregg H', 'Initials': 'GH', 'LastName': 'Afman', 'Affiliation': 'Department of Kinesiology, Westmont College, CA.'}, {'ForeName': 'Javier T', 'Initials': 'JT', 'LastName': 'Gonzalez', 'Affiliation': 'Department for Health, University of Bath, United Kingdom.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Betts', 'Affiliation': 'Department for Health, University of Bath, United Kingdom.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002458'] 2435,32694457,"Effects of Predischarge Patient Education Combined With Postdischarge Follow-Ups on Self-Care, Readmission, Sleep, and Depression in Patients With Heart Failure.","BACKGROUND Patients with heart failure rarely engage in adequate self-care. Greater emphasis on self-care discharge readiness is needed. PURPOSE This study examined the effects of a predischarge educational program combined with 1 year of postdischarge follow-up on self-care behaviors, readmission, sleep quality, and depression in patients with heart failure. METHODS A longitudinal, nonequivalent two-group pretest-posttest design was used. The intervention group received tailored education and follow-ups, whereas the control group received routine predischarge heart-failure education from direct care nurses only. Measurements included the self-care maintenance and self-care management subscales of the Self-Care of Heart Failure Index, Pittsburg Sleep Quality Index, Patient Health Questionnaire-9, and readmission rate. Data obtained at baseline and at 1, 3, 6, and 12 months postdischarge were analyzed using linear mixed models with both intention-to-treat and per-protocol approaches. The propensity score was used to adjust for the confounding effects of the New York Heart Association functional class and left ventricular ejection fraction. RESULTS Of the 62 patients with heart failure (28 in the intervention group and 34 in the control group) who were sampled at baseline, 47 (n = 25 vs. n = 22) provided data over the entire course of this 1-year study (76% retention rate). The per-protocol analysis did not find significant differences for any variables. However, the intention-to-treat analysis showed that the intervention group significantly improved in self-care maintenance at 6 months and self-care management at 12 months after hospital discharge, with fewer, albeit not significantly fewer, first and subsequent hospital readmissions than the control group. CONCLUSIONS/IMPLICATIONS FOR PRACTICE The effect of this intervention was not found to be substantial, indicating a need to design more efficacious and powerful interventions. Hospitalized patients must receive patient education before discharge to foster their self-care knowledge and skills regarding self-care at home. Strategies are needed to help nurses provide patient education in a time-efficient manner.",2020,The per-protocol analysis did not find significant differences for any variables.,"['Hospitalized patients', 'Patients with heart failure rarely engage in adequate self-care', 'patients with heart failure', '62 patients with heart failure ', 'Patients With Heart Failure']","['tailored education and follow-ups, whereas the control group received routine predischarge heart-failure education from direct care nurses only', 'Predischarge Patient Education Combined With Postdischarge Follow-Ups', 'predischarge educational program']","['self-care maintenance', 'self-care behaviors, readmission, sleep quality, and depression', 'hospital readmissions', 'self-care maintenance and self-care management subscales of the Self-Care of Heart Failure Index, Pittsburg Sleep Quality Index, Patient Health Questionnaire-9, and readmission rate', 'Self-Care, Readmission, Sleep, and Depression']","[{'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0522498', 'cui_str': 'Rare'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C1828111', 'cui_str': 'Heart failure education'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0030688', 'cui_str': 'Patient education'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0474417', 'cui_str': 'Self-care behavior'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}]",62.0,0.0320725,The per-protocol analysis did not find significant differences for any variables.,"[{'ForeName': 'Hsing-Mei', 'Initials': 'HM', 'LastName': 'Chen', 'Affiliation': 'PhD, RN, Associate Professor, Department of Nursing, College of Medicine, National Cheng Kung University, Taiwan, ROC.'}, {'ForeName': 'Shan-Tair', 'Initials': 'ST', 'LastName': 'Wang', 'Affiliation': 'PhD, Deputy Superintendent, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi City, Taiwan.'}, {'ForeName': 'Shyh-Jong', 'Initials': 'SJ', 'LastName': 'Wu', 'Affiliation': 'PhD, Associate Professor, Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University, Taiwan, ROC.'}, {'ForeName': 'Chee-Siong', 'Initials': 'CS', 'LastName': 'Lee', 'Affiliation': 'MD, Lecturer, Division of Cardiology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Taiwan, ROC.'}, {'ForeName': 'Susan J', 'Initials': 'SJ', 'LastName': 'Fetzer', 'Affiliation': 'PhD, RN, CNL, CCRN, Professor, Department of Nursing, University of New Hampshire, USA.'}, {'ForeName': 'Liang-Miin', 'Initials': 'LM', 'LastName': 'Tsai', 'Affiliation': ''}]",The journal of nursing research : JNR,['10.1097/JNR.0000000000000395'] 2436,32694482,Cryobiopsy With Radial UltraSound Guidance (CYRUS): A Pilot Randomized Controlled Study.,"BACKGROUND Major airway bleeding is the most feared complication of transbronchial cryobiopsy (TBC). Radial endobronchial ultrasound (REBUS) has been used to assess the peripheral lung, primarily to identify pulmonary nodules, and also peripheral blood vessels. Using REBUS-guided TBC to avoid peripheral vasculature might reduce bleeding risk. This prospective randomized double-blind pilot trial was designed to investigate the feasibility of study procedures and inform the power calculation and clinical significance of a future large randomized trial. METHODS Consecutive TBCs were randomized to be performed with or without REBUS guidance in the same patient. A nonblinded operator obtained each biopsy while a blinded second operator managed the bleeding after each biopsy and determined when hemostasis had been obtained. Feasibility of study procedures and the ability to recruit patients were of primary interest. Time to hemostasis after each biopsy was also examined. RESULTS Forty TBCs were performed in 10 patients (4 biopsies per patient) over an enrollment period of 6 months. The time to control bleeding between biopsies was not statistically different between intervention and control arms [-14.3 (-120.1 to 92.0) s, P=0.7878]. Mean bleeding time was 139.4±59.895 seconds (REBUS 132.25± 89.305 s, non-REBUS 146.55±82.043 s). A trend towards the decreased grade of bleeding and less need for additional interventions was observed with REBUS use, but this difference did not reach statistical significance in this pilot investigation. CONCLUSION Our findings suggest that REBUS-guided TBC is feasible. We did not observe any statistically significant difference in time to hemostasis or bleeding grade in this pilot study.",2020,"Mean bleeding time was 139.4±59.895 seconds (REBUS 132.25± 89.305 s, non-REBUS 146.55±82.043 s).",['Consecutive TBCs'],"['Radial endobronchial ultrasound (REBUS', 'Cryobiopsy With Radial UltraSound Guidance (CYRUS']","['bleeding risk', 'Mean bleeding time', 'time to hemostasis or bleeding grade', 'time to control bleeding between biopsies', 'grade of bleeding']",[],"[{'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C3160856', 'cui_str': 'Endobronchial ultrasound'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure'}]","[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005729', 'cui_str': 'Bleeding time'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}]",40.0,0.0809112,"Mean bleeding time was 139.4±59.895 seconds (REBUS 132.25± 89.305 s, non-REBUS 146.55±82.043 s).","[{'ForeName': 'Jasleen K', 'Initials': 'JK', 'LastName': 'Pannu', 'Affiliation': 'Division of Allergy, Pulmonary and Critical Care Medicine.'}, {'ForeName': 'Lance J', 'Initials': 'LJ', 'LastName': 'Roller', 'Affiliation': 'Division of Allergy, Pulmonary and Critical Care Medicine.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Lentz', 'Affiliation': 'Division of Allergy, Pulmonary and Critical Care Medicine.'}, {'ForeName': 'Otis B', 'Initials': 'OB', 'LastName': 'Rickman', 'Affiliation': 'Division of Allergy, Pulmonary and Critical Care Medicine.'}, {'ForeName': 'Matthew C', 'Initials': 'MC', 'LastName': 'Aboudara', 'Affiliation': ""Department of Pulmonary Critical Care Medicine, St. Luke's Health System, University of Missouri at Kansas City, Kansas City, MO.""}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Department of Biostatistics, Vanderbilt University Medical Center.'}, {'ForeName': 'Fabien', 'Initials': 'F', 'LastName': 'Maldonado', 'Affiliation': 'Division of Allergy, Pulmonary and Critical Care Medicine.'}]",Journal of bronchology & interventional pulmonology,['10.1097/LBR.0000000000000699'] 2437,32694494,Facet Arthropathy Following Disc Replacement Versus Rehabilitation: A Prospective Study with Eight-Year Follow-Up.,"STUDY DESIGN A prospective study of patients originally randomized to total disc replacement (TDR) or multidisciplinary rehabilitation. OBJECTIVE To assess the long-term development of facet arthropathy (FA) after TDR versus non-operative treatment, and to analyze the association between FA and clinical outcome. SUMMARY OF BACKGROUND DATA FA may appear or increase following TDR, but the natural course of FA is unclear, and no previous study has evaluated the long-term development of FA following TDR compared to non-operative treatment. METHODS The study included 126 patients with chronic low back pain and degenerative changes in the lumbar intervertebral discs. The patients underwent pre-treatment and eight-year follow-up magnetic resonance imaging (MRI) and eight-year follow-up computed tomography (CT) of the lumbar spine. The primary outcome measure was FA development (yes/no) on MRI at index level L4/L5 or L5/S1, defined as increased FA grade value from pre-treatment to follow-up according to Weishaupt's grading system. Secondary outcomes included the association between FA (on MRI and CT) and Oswestry Disability Index (ODI) or back pain as well as reoperations. RESULTS Increased index level FA grade was more frequent after TDR versus non-operative treatment (36%, 25/69 versus 2%, 1/57 of patients, p < 0.001), but was not related to change in ODI or back pain. At follow-up, index level FA grades were higher after TDR versus non-operative treatment (odds ratio 4.0 MRI and 5.9 CT), but were not related to ODI ≤ 22. Four patients (6%) treated with TDR and no patients treated non-operatively were operated for lateral recess stenosis with posterior decompression at the index level during follow-up. CONCLUSIONS Index level FA development was more likely after TDR compared to non-operative treatment but was not associated with the eight-year clinical outcome. Index level FA may have contributed to reoperations in the TDR group. LEVEL OF EVIDENCE 2.",2020,"At follow-up, index level FA grades were higher after TDR versus non-operative treatment (odds ratio 4.0 MRI and 5.9 CT), but were not related to ODI ≤ 22.",['126 patients with chronic low back pain and degenerative changes in the lumbar intervertebral discs'],"['TDR', 'Disc Replacement Versus Rehabilitation', 'pre-treatment and eight-year follow-up magnetic resonance imaging (MRI) and eight-year follow-up computed tomography (CT) of the lumbar spine', 'total disc replacement (TDR) or multidisciplinary rehabilitation']","['Index level FA development', 'index level FA grades', 'Facet Arthropathy', 'association between FA (on MRI and CT) and Oswestry Disability Index (ODI) or back pain as well as reoperations', 'FA development (yes/no) on MRI at index level L4/L5 or L5/S1, defined as increased FA grade value', 'index level FA grade', 'ODI or back pain']","[{'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0011164', 'cui_str': 'Degeneration'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0021815', 'cui_str': 'Structure of intervertebral disc'}]","[{'cui': 'C2144940', 'cui_str': 'Total Disk Replacement'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0024091', 'cui_str': 'Bone structure of lumbar vertebra'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}]","[{'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0222679', 'cui_str': 'Structure of articular surface of bone'}, {'cui': 'C0022408', 'cui_str': 'Arthropathy'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C1298907', 'cui_str': 'Yes'}, {'cui': 'C1298908', 'cui_str': 'No'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0441799', 'cui_str': 'Grading values'}]",126.0,0.0217514,"At follow-up, index level FA grades were higher after TDR versus non-operative treatment (odds ratio 4.0 MRI and 5.9 CT), but were not related to ODI ≤ 22.","[{'ForeName': 'Håvard', 'Initials': 'H', 'LastName': 'Furunes', 'Affiliation': 'Innlandet Hospital Gjøvik, Department of Surgery, Innlandet Hospital Gjøvik, Gjøvik, Norway.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Berg', 'Affiliation': 'Department of Radiology, Nordland Hospital, Bodø, Norway.'}, {'ForeName': 'Ansgar', 'Initials': 'A', 'LastName': 'Espeland', 'Affiliation': 'Department of Radiology, Haukeland University Hospital, Bergen, Norway.'}, {'ForeName': 'Hanne', 'Initials': 'H', 'LastName': 'Thoresen', 'Affiliation': 'Department of Radiology, Nordland Hospital, Bodø, Norway.'}, {'ForeName': 'Gesche', 'Initials': 'G', 'LastName': 'Neckelmann', 'Affiliation': 'Department of Radiology, Haukeland University Hospital, Bergen, Norway.'}, {'ForeName': 'Helga Maria', 'Initials': 'HM', 'LastName': 'Brøgger', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Milada Cvancarova', 'Initials': 'MC', 'LastName': 'Småstuen', 'Affiliation': 'Oslo University Hospital Ullevål, Research- and Communication Unit for Musculoskeletal Health (FORMI), Oslo, Norway.'}, {'ForeName': 'Jens Ivar', 'Initials': 'JI', 'LastName': 'Brox', 'Affiliation': 'University of Oslo, Oslo, Norway.'}, {'ForeName': 'Kjersti', 'Initials': 'K', 'LastName': 'Storheim', 'Affiliation': 'Oslo University Hospital Ullevål, Research- and Communication Unit for Musculoskeletal Health (FORMI), Oslo, Norway.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Hellum', 'Affiliation': 'Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.'}]",Spine,['10.1097/BRS.0000000000003600'] 2438,32694619,Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.,"The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been defined. This randomized, open-label, phase III, multicenter trial randomized patients with 1st-3rd relapse of multiple myeloma (MM) to a transplant arm (n = 139) consisting of 3 Rd (lenalidomide 25 mg, day 1-21; dexamethasone 40 mg, day 1, 8, 15, and 22; 4-week cycles) reinduction cycles, sHDCT (melphalan 200 mg/m 2 ), ASCT, and lenalidomide maintenance (10 mg/day) or to a control arm (n = 138) of continuous Rd. Median PFS was 20.7 months in the transplant and 18.8 months in the control arm (HR 0.87; 95% CI 0.65-1.16; p = 0.34). Median OS was not reached in the transplant and 62.7 months in the control arm (HR 0.81; 95% CI 0.52-1.28; p = 0.37). Forty-one patients (29%) did not receive the assigned sHDCT/ASCT mainly due to early disease progression, adverse events, and withdrawal of consent. Multivariate landmark analyses from the time of sHDCT showed superior PFS and OS (p = 0.0087/0.0057) in patients who received sHDCT/ASCT. Incorporation of sHDCT/ASCT into relapse treatment with Rd was feasible in 71% of patients and did not significantly prolong PFS and OS on ITT analysis while patients who received sHDCT/ASCT may have benefitted.",2020,Multivariate landmark analyses from the time of sHDCT showed superior PFS and OS (p = 0.0087/0.0057) in patients who received sHDCT/ASCT.,"['relapsed multiple myeloma', 'multicenter trial randomized patients with 1st-3rd relapse of multiple myeloma (MM) to a transplant arm (n\u2009=\u2009139) consisting of', 'relapsed and/or refractory multiple myeloma (RRMM']","['3 Rd (lenalidomide 25\u2009mg, day 1-21; dexamethasone', 'Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone', 'sHDCT/ASCT', 'sHDCT (melphalan 200\u2009mg/m 2 ), ASCT, and lenalidomide maintenance', 'salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT']","['superior PFS and OS', 'Median PFS', 'Median OS', 'early disease progression, adverse events, and withdrawal of consent']","[{'cui': 'C2349261', 'cui_str': 'Relapse multiple myeloma'}, {'cui': 'C0206012', 'cui_str': 'Multicentre Trials'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205435', 'cui_str': 'First'}, {'cui': 'C0205437', 'cui_str': 'Third'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C5191072', 'cui_str': '139'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C4551538', 'cui_str': 'Plasma cell myeloma refractory'}]","[{'cui': 'C1724165', 'cui_str': 'lenalidomide 25 MG'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0085405', 'cui_str': 'Salvage therapy'}, {'cui': 'C0040736', 'cui_str': 'Autogenous transplantation'}, {'cui': 'C1144149', 'cui_str': 'lenalidomide'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1831743', 'cui_str': 'Transplantation of autologous hematopoietic stem cell'}, {'cui': 'C0025241', 'cui_str': 'Melphalan'}, {'cui': 'C4319558', 'cui_str': '200'}]","[{'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C2711213', 'cui_str': 'Consented'}]",,0.0568923,Multivariate landmark analyses from the time of sHDCT showed superior PFS and OS (p = 0.0087/0.0057) in patients who received sHDCT/ASCT.,"[{'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Goldschmidt', 'Affiliation': 'Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany. hartmut.goldschmidt@med.uni-heidelberg.de.'}, {'ForeName': 'Marc-Andrea', 'Initials': 'MA', 'LastName': 'Baertsch', 'Affiliation': 'Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Schlenzka', 'Affiliation': 'Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Becker', 'Affiliation': 'Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Habermehl', 'Affiliation': 'Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Hielscher', 'Affiliation': 'Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.'}, {'ForeName': 'Marc-Steffen', 'Initials': 'MS', 'LastName': 'Raab', 'Affiliation': 'Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Hillengass', 'Affiliation': 'Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Sauer', 'Affiliation': 'Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Müller-Tidow', 'Affiliation': 'Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Luntz', 'Affiliation': 'Coordination Centre for Clinical Trials (KKS), University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Jauch', 'Affiliation': 'Institute for Human Genetics, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Hose', 'Affiliation': 'Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Seckinger', 'Affiliation': 'Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Brossart', 'Affiliation': 'Department of Oncology, Hematology, Immuno-Oncology and Rheumatology, Med. Klinik und Poliklinik III, University Hospital Bonn, Bonn, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Goerner', 'Affiliation': 'Department of Hematology, Oncology and Palliative Care, Community Hospital Bielefeld, Bielefeld, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Klein', 'Affiliation': 'Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Schmidt-Hieber', 'Affiliation': 'Clinic for Hematology and Stem Cell Transplantation, Helios-Hospital Berlin Buch, Berlin, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Reimer', 'Affiliation': 'Department of Hematology, Oncology and Stem Cell Transplantation, Evangelisches Krankenhaus Essen-Werden gGmbH, Essen, Germany.'}, {'ForeName': 'Ullrich', 'Initials': 'U', 'LastName': 'Graeven', 'Affiliation': 'Department of Hematology, Oncology and Gastroenterology, Kliniken Maria Hilf GmbH, Mönchengladbach, Germany.'}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Fenk', 'Affiliation': 'Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Duesseldorf, Germany.'}, {'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Haenel', 'Affiliation': 'Department of Hematology, Oncology and Stem Cell Transplantation, Klinikum Chemnitz GmbH, Chemnitz, Germany.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Martin', 'Affiliation': 'Department of Hematology and Oncology, Goethe University, Frankfurt, Germany.'}, {'ForeName': 'Hans W', 'Initials': 'HW', 'LastName': 'Lindemann', 'Affiliation': 'Department of Hematology and Oncology, Kath. Krankenhaus Hagen gem. GmbH, Hagen, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Scheid', 'Affiliation': 'Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Nogai', 'Affiliation': 'Internal Medicine III, Charité Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Salwender', 'Affiliation': 'Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Noppeney', 'Affiliation': 'Department of Hematology, University Hospital Essen, Essen, Germany.'}, {'ForeName': 'Britta', 'Initials': 'B', 'LastName': 'Besemer', 'Affiliation': 'Department of Hematology, Oncology and Immunology, University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Weisel', 'Affiliation': 'Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Leukemia,['10.1038/s41375-020-0948-0'] 2439,32695003,Remifentanil for Carboprost-Induced Adverse Reactions During Cesarean Delivery Under Combined Spinal-Epidural Anesthesia.,"Purpose Carboprost may induce adverse reactions when used to treat postpartum hemorrhage. We aimed to explore the effects of intravenous infusion of low-dose remifentanil to prevent such reactions. Methods We enrolled parturient patients scheduled for elective cesarean section. Anesthesiologist administered combined spinal epidurals at the L3/4 interspace, with 0.5% hyperbaric bupivacaine subarachnoid space injections (1.5-2.5 ml). We randomly divided parturient patients, administered carboprost during surgery, into the remifentanil group (group R) and the control group (group C). Patients in group R received an intravenous target-controlled infusion of remifentanil (target effect-site concentration, 1.5 ng/ml) simultaneously with a carboprost tromethamine injection (250 µg). Patients in group C received a normal saline infusion with carboprost. We recorded and analyzed the incidence of carboprost-related adverse reactions (vomiting, nausea, chest congestion, flushing, hypertension, tachycardia, cough, and shivering), and assessed patient comfort using a numerical rating scale ([NRS], on which 0 was very uncomfortable and 10 was very comfortable). Results After applying inclusion and exclusion criteria, we conducted statistical analysis of the data from 70 women. The incidence of vomiting was significantly lower in group R than in group C (14.3 vs. 51.4%, p < 0.01); and the incidence of nausea, chest congestion, facial flushing, and hypertension were significantly lower in group R than in group C (all p < 0.01). Furthermore, the patients' comfort scores were significantly higher in group R than in group C (8.0 ± 1.8 vs. 3.6 ± 2.1, p < 0.01). Conclusion Our results demonstrate that an intravenous low-dose remifentanil infusion can effectively prevent carboprost-related adverse reactions during cesarean delivery under combined spinal and epidural anesthesia. Clinical Trial Registration We pre-registered this study at http://www.chictr.org.cn/showproj.aspx?proj=27707 (ChiCTR1800016292).",2020,"The incidence of vomiting was significantly lower in group R than in group C (14.3 vs. 51.4%, p < 0.01); and the incidence of nausea, chest congestion, facial flushing, and hypertension were significantly lower in group R than in group C (all p < 0.01).",['enrolled parturient patients scheduled for elective cesarean section'],"['Remifentanil', 'intravenous\xa0target-controlled infusion of remifentanil', 'Cesarean Delivery Under Combined Spinal-Epidural Anesthesia', 'normal saline infusion with carboprost', 'intravenous infusion of low-dose remifentanil', 'Anesthesiologist administered combined spinal epidurals at the L3/4 interspace, with 0.5% hyperbaric bupivacaine subarachnoid space injections', 'remifentanil', 'carboprost tromethamine injection']","['incidence of nausea, chest congestion, facial flushing, and hypertension', 'incidence of carboprost-related adverse reactions (vomiting, nausea, chest congestion, flushing, hypertension, tachycardia, cough, and shivering), and assessed patient comfort using a numerical rating scale ([NRS', 'incidence of vomiting', 'adverse reactions', ""patients' comfort scores"", 'Adverse Reactions']","[{'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}]","[{'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002913', 'cui_str': 'Epidural anesthesia'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0007047', 'cui_str': 'Carboprost'}, {'cui': 'C0021440', 'cui_str': 'Intravenous infusion'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0228134', 'cui_str': 'Structure of epidural space of spine'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0038527', 'cui_str': 'Subarachnoid space structure'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0054721', 'cui_str': 'Carboprost tromethamine'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0242073', 'cui_str': 'Pulmonary congestion'}, {'cui': 'C0016382', 'cui_str': 'Flushing'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0007047', 'cui_str': 'Carboprost'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0036973', 'cui_str': 'Shivering or rigors'}, {'cui': 'C4277744', 'cui_str': 'Patient Comfort'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.137653,"The incidence of vomiting was significantly lower in group R than in group C (14.3 vs. 51.4%, p < 0.01); and the incidence of nausea, chest congestion, facial flushing, and hypertension were significantly lower in group R than in group C (all p < 0.01).","[{'ForeName': 'Chang-Na', 'Initials': 'CN', 'LastName': 'Wei', 'Affiliation': 'Department of Anesthesia, Jiaxing University Affiliated Women and Children Hospital, Jiaxing, China.'}, {'ForeName': 'Xiang-Yang', 'Initials': 'XY', 'LastName': 'Chang', 'Affiliation': 'Department of Anesthesia, Jiaxing University Affiliated Women and Children Hospital, Jiaxing, China.'}, {'ForeName': 'Jin-Hua', 'Initials': 'JH', 'LastName': 'Dong', 'Affiliation': 'Department of Obstetrics, Jiaxing University Affiliated Women and Children Hospital, Jiaxing, China.'}, {'ForeName': 'Qing-He', 'Initials': 'QH', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesia, Affiliated Hospital of Jiaxing University, Jiaxing, China.'}]",Frontiers in pharmacology,['10.3389/fphar.2020.00980'] 2440,32695044,Effects of a Four-Day Mindfulness Intervention on Teachers' Stress and Affect: A Pilot Study in Eastern China.,"Stress is becoming increasingly prevalent among teacher groups, and this is problematic for education. Mindfulness training (MT) is a well-supported way to help various populations cope with and reduce stress. In this study, a 4-day intensive MT program that aimed to increase teachers' emotional health was developed and implemented into the existing post-service education for teachers in eastern China. A total of 161 teachers voluntarily enrolled in the course and were assigned to either the mindfulness group or the waitlist group. Participants completed measures of mindfulness, positive affect, negative affect, and perceived stress before and after the program. The results showed that MT had statistically significant positive effects on mindfulness, negative affect, and stress. The present findings indicate that a 4-day intensive MT program is a promising way to decrease teachers' stress and improve their emotional health. The practical meaning of the short-term intensive MT program for teachers is discussed. It is easier for teachers to enroll such a short-term training program, as it may have higher acceptance and feasibility than an 8-week training program in some areas. Clinical Trial Registration: www.ClinicalTrials.gov, identifier ChiCTR2000029653.",2020,"The results showed that MT had statistically significant positive effects on mindfulness, negative affect, and stress.","['teachers in eastern China', ""Teachers' Stress and Affect"", '161 teachers voluntarily enrolled in the course', 'Eastern China']","['Mindfulness training (MT', 'Four-Day Mindfulness Intervention']","['mindfulness, negative affect, and stress', ""teachers' stress and improve their emotional health"", ""teachers' emotional health""]","[{'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0750729', 'cui_str': 'Courses'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]",161.0,0.0184668,"The results showed that MT had statistically significant positive effects on mindfulness, negative affect, and stress.","[{'ForeName': 'Xiaolan', 'Initials': 'X', 'LastName': 'Song', 'Affiliation': 'Laboratory of Mindfulness, Department of Psychology, College of Teacher Education, Zhejiang Normal University, Jinhua, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Zheng', 'Affiliation': 'Laboratory of Mindfulness, Department of Psychology, College of Teacher Education, Zhejiang Normal University, Jinhua, China.'}, {'ForeName': 'Huiwen', 'Initials': 'H', 'LastName': 'Zhao', 'Affiliation': 'Laboratory of Mindfulness, Department of Psychology, College of Teacher Education, Zhejiang Normal University, Jinhua, China.'}, {'ForeName': 'Tianqi', 'Initials': 'T', 'LastName': 'Yang', 'Affiliation': 'Laboratory of Mindfulness, Department of Psychology, College of Teacher Education, Zhejiang Normal University, Jinhua, China.'}, {'ForeName': 'Xingcheng', 'Initials': 'X', 'LastName': 'Ge', 'Affiliation': 'Laboratory of Mindfulness, Department of Psychology, College of Teacher Education, Zhejiang Normal University, Jinhua, China.'}, {'ForeName': 'Hongmei', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Laboratory of Mindfulness, Department of Psychology, College of Teacher Education, Zhejiang Normal University, Jinhua, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Lou', 'Affiliation': 'MindUp Mindfulness Center, Hangzhou, China.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.01298'] 2441,32695047,A Randomized Field Experiment Using Self-Reflection on School Behavior to Help Students in Secondary School Reach Their Performance Potential.,"Recent policy reports documented that a growing group of students in secondary education could perform better given their expected performance. Studies showed that school performance is related to a range of social-emotional factors, including self-awareness, self-management, social awareness, and responsible decision making. However, experimental studies in schools on the relation between these factors and school performance are scarce, and results are mixed. This study used a randomized field experiment to examine whether self-reflection on school behavior of underperforming secondary school students affected their school performance [grade point average (GPA)], school engagement, and self-concept. The sample comprised 337 ninth-grade students ( M = 15.74 years old; SD = 0.58) from 18 secondary schools in Netherlands. The intervention was designed in co-creation with teachers, to be as close to school practice as possible. Underperformance was measured using achievement test scores from both primary and secondary school, supplemented with teacher and parental assessments. Different model specifications were estimated to perform the analyses and test for robustness of findings. The results showed that, for treatment compliance, students with higher school motivation were approximately 29% more likely to comply. Students who reported higher levels of self-concept of school tasks were 17% less likely to comply. No significant effects of the treatment were observed on students' GPA, school motivation, hours spent on homework, or self-concept of school tasks. The treatment showed a negative effect on self-concept of leadership skills.",2020,"No significant effects of the treatment were observed on students' GPA, school motivation, hours spent on homework, or self-concept of school tasks.","['337 ninth-grade students ( M = 15.74 years old; SD = 0.58) from 18 secondary schools in Netherlands', 'school behavior of underperforming secondary school students']","['Self-Reflection', 'self-reflection']","['school performance [grade point average (GPA)], school engagement, and self-concept', 'school motivation', 'levels of self-concept of school tasks', ""students' GPA, school motivation, hours spent on homework, or self-concept of school tasks""]","[{'cui': 'C0205443', 'cui_str': 'Ninth'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4517463', 'cui_str': '0.58'}, {'cui': 'C0036530', 'cui_str': 'Secondary school'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}]","[{'cui': 'C0036373', 'cui_str': 'Academic Test Performance'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0036594', 'cui_str': 'Self Concept'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0589414', 'cui_str': 'Homework'}]",,0.0120501,"No significant effects of the treatment were observed on students' GPA, school motivation, hours spent on homework, or self-concept of school tasks.","[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Feron', 'Affiliation': 'Organisation of Economic Co-operation and Development (OECD), Centre for Educational Research and Innovation, Paris, France.'}, {'ForeName': 'Trudie', 'Initials': 'T', 'LastName': 'Schils', 'Affiliation': 'Department of Macro, International and Labour Economics, School of Business and Economics, Maastricht University, Maastricht, Netherlands.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.01356'] 2442,32698021,Impaired Baseline Renal Function May not Influence Outcomes and Survival after LVAD Implantation.,"BACKGROUND We investigated changes in estimated glomerular filtration rate (eGFR) post LVAD implant and the impact on long term outcomes. METHODS A retrospective analysis was conducted for 255 LVAD. They were divided into two groups based on pre-implant eGFR (< 60, > 60 ml/min/1.73 m 2 ) and into 6 grades (Grade1:> 90 ml/min/1.73 m 2 normal, 2: 60-89 mild dysfunction, 3: 45- 59 moderate, 4: 30- 44 moderate to severe, 5 :15- 29 severe, 6: < 15 kidney failure). Changes in eGFR and the impact on long term outcome and survival were analysed. RESULTS One-month post-implant eGFR of the total cohort increased from a baseline of 75.19 ± 34.35 to 118.97 ± 67.62 ml/min/1.73 m 2 (p < 0.001). eGRF 4 years post implant was higher than baseline but not significantly (p=0.48). Patients with a preimplant eGFR >60 followed the same pattern as the entire cohort. Preimplant eGFR< 60 group had a significant increase at 1 month (p< 0.001), eGFR remained significantly higher than baseline 4 years post-implant (p=0.032), there was a sustained transition to improved distribution of renal function grade post-LVAD. Post-LVAD survival at 1, 3, and 5 years for baseline eGFR > 60 was 76 %, 54%, 48% and for eGFR < 60 was 71%, 60%, 48%, respectively (p = 0.92). CONCLUSIONS Patients with low preimplant eGFR derive benefit from LVAD therapy, with eGFR remaining elevated above preimplant levels. Pre-implant renal dysfunction did not impact negatively on long term morbidity and mortality.",2020,"Preimplant eGFR< 60 group had a significant increase at 1 month (p< 0.001), eGFR remained significantly higher than baseline 4 years post-implant (p=0.032), there was a sustained transition to improved distribution of renal function grade post-LVAD.","['Patients with a preimplant eGFR >60 followed the same pattern as the entire cohort', ' 60, > 60 ml/min/1.73 m 2 ) and into 6 grades (Grade1:> 90 ml/min/1.73 m 2 normal, 2: 60-89 mild dysfunction, 3: 45- 59 moderate, 4: 30- 44 moderate to severe, 5 :15- 29 severe, 6: < 15 kidney failure']",['pre-implant eGFR'],"['eGFR', 'Impaired Baseline Renal Function', 'long term morbidity and mortality', 'Post-LVAD survival', 'implant renal dysfunction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0439751', 'cui_str': 'Entire'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0439083', 'cui_str': '>90'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0035078', 'cui_str': 'Renal insufficiency'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}]","[{'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0181598', 'cui_str': 'Left ventricular assist device'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C1565489', 'cui_str': 'Renal impairment'}]",,0.0926761,"Preimplant eGFR< 60 group had a significant increase at 1 month (p< 0.001), eGFR remained significantly higher than baseline 4 years post-implant (p=0.032), there was a sustained transition to improved distribution of renal function grade post-LVAD.","[{'ForeName': 'Hassiba', 'Initials': 'H', 'LastName': 'Smail', 'Affiliation': 'Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom. Electronic address: h.smail@rbht.nhs.uk.'}, {'ForeName': 'Hesham Ahmed', 'Initials': 'HA', 'LastName': 'Hassan', 'Affiliation': 'Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Bowles', 'Affiliation': 'Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Stock', 'Affiliation': 'Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom.'}, {'ForeName': 'Giovani', 'Initials': 'G', 'LastName': 'Benedetti', 'Affiliation': 'Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom.'}, {'ForeName': 'Prashant', 'Initials': 'P', 'LastName': 'Mohite', 'Affiliation': 'Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom.'}, {'ForeName': 'Binu', 'Initials': 'B', 'LastName': 'Raj', 'Affiliation': 'Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom.'}, {'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'Robinson', 'Affiliation': 'Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom.'}, {'ForeName': 'André R', 'Initials': 'AR', 'LastName': 'Simon', 'Affiliation': 'Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom.'}]",The Annals of thoracic surgery,['10.1016/j.athoracsur.2020.05.127'] 2443,32698033,The Role of Topical Antibiotic Prophylaxis in Oculofacial Plastic Surgery: A Randomized Controlled Study.,"PURPOSE The utility of topical antibiotic prophylaxis for routine oculofacial plastic surgery is not well-established. Given concerns such as contact dermatitis, antibiotic resistance, and healthcare costs, in conjunction with a low baseline rate of surgical site infections, the investigators sought to determine the frequency of infection with and without the use of topical antibiotic prophylaxis. DESIGN Randomized, controlled, unmasked clinical trial. PARTICIPANTS Adult patients undergoing routine periocular surgery without prior history of periocular surgical site infection, need for perioperative oral or parenteral antibiotics, or allergy to all study medications. METHODS Participants were randomized pre-operatively to receive either antibiotic or placebo (mineral oil/petrolatum-based) ointment after surgery. Outcomes were measured at the first post-operative visit. The two-tailed Fisher's exact test was used to compare outcomes between groups. MAIN OUTCOME MEASURES The primary outcome was the incidence of surgical site infections. The secondary outcomes included stratification of infections by patient risk characteristics, incidence of allergic contact dermatitis, and incidence of wound complications. RESULTS Four hundred and one participants were enrolled and randomized, and 13 participants did not proceed with surgery or were lost to follow-up. High-risk features for infection were identified in 24% of the placebo group and 21% of the antibiotic group. Surgical site infections were more common in the placebo group (2.7% vs. 0.0%; p=0.025). The rate of contact dermatitis was similar (0.5% vs. 0.5%; p=1.00), as was the rate of wound dehiscence (2.7% vs. 3.6%; p=0.77). Among the placebo group, the incidence of infections in the low- and high-risk participants was 2.9% and 2.2%, respectively. Infections were treated with oral or topical antibiotics and resolved without complication, except in one case that required two subsequent surgeries to address the sequelae. CONCLUSION After routine oculofacial plastic surgery, patients treated with a topical antibiotic ointment had a lower risk of surgical site infection compared with patients treated with a non-antibiotic ointment.",2020,Surgical site infections were more common in the placebo group (2.7% vs. 0.0%; p=0.025).,"['Adult patients undergoing routine periocular surgery without prior history of periocular surgical site infection, need for perioperative oral or parenteral antibiotics, or allergy to all study medications', 'Participants', 'Four hundred and one participants were enrolled and randomized, and 13 participants did not proceed with surgery or were lost to follow-up', 'Oculofacial Plastic Surgery']","['topical antibiotic ointment', 'oral or topical antibiotics', 'antibiotic or placebo (mineral oil/petrolatum-based) ointment', 'Topical Antibiotic Prophylaxis', 'topical antibiotic prophylaxis', 'placebo']","['High-risk features for infection', 'rate of contact dermatitis', 'incidence of infections', 'stratification of infections by patient risk characteristics, incidence of allergic contact dermatitis, and incidence of wound complications', 'Surgical site infections', 'rate of wound dehiscence', 'risk of surgical site infection', 'incidence of surgical site infections']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0030547', 'cui_str': 'Parenteral nutrition'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0002111', 'cui_str': 'Allergy - specialty'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C1302313', 'cui_str': 'Lost to follow-up'}, {'cui': 'C0038911', 'cui_str': 'Plastic surgery - specialty'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0028912', 'cui_str': 'Ointment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1875504', 'cui_str': 'Mineral Oil / Petrolatum'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0282638', 'cui_str': 'Antibiotic prophylaxis'}]","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0011616', 'cui_str': 'Contact dermatitis'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0162820', 'cui_str': 'Allergic contact dermatitis'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0259768', 'cui_str': 'Wound dehiscence'}]",401.0,0.379817,Surgical site infections were more common in the placebo group (2.7% vs. 0.0%; p=0.025).,"[{'ForeName': 'Davin C', 'Initials': 'DC', 'LastName': 'Ashraf', 'Affiliation': 'Department of Ophthalmology, University of California San Francisco, San Francisco, CA. Electronic address: davin.ashraf@ucsf.edu.'}, {'ForeName': 'Oluwatobi O', 'Initials': 'OO', 'LastName': 'Idowu', 'Affiliation': 'Department of Ophthalmology, University of California San Francisco, San Francisco, CA.'}, {'ForeName': 'Qinyun', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': 'Department of Ophthalmology, University of California San Francisco, San Francisco, CA.'}, {'ForeName': 'Tak', 'Initials': 'T', 'LastName': 'YeEun', 'Affiliation': 'Department of Ophthalmology, University of California San Francisco, San Francisco, CA.'}, {'ForeName': 'Thomas S', 'Initials': 'TS', 'LastName': 'Copperman', 'Affiliation': 'Department of Ophthalmology, University of California San Francisco, San Francisco, CA.'}, {'ForeName': 'Sombat', 'Initials': 'S', 'LastName': 'Tanaboonyawat', 'Affiliation': 'Department of Ophthalmology, University of California San Francisco, San Francisco, CA; Department of Ophthalmology, Phramongkutklao College of Medicine, Royal Thai Army, Thailand.'}, {'ForeName': 'Benjamin F', 'Initials': 'BF', 'LastName': 'Arnold', 'Affiliation': 'Department of Ophthalmology, University of California San Francisco, San Francisco, CA; Francis I. Proctor Foundation, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Catherine E', 'Initials': 'CE', 'LastName': 'Oldenburg', 'Affiliation': 'Department of Ophthalmology, University of California San Francisco, San Francisco, CA; Francis I. Proctor Foundation, University of California, San Francisco, CA, USA.'}, {'ForeName': 'M Reza', 'Initials': 'MR', 'LastName': 'Vagefi', 'Affiliation': 'Department of Ophthalmology, University of California San Francisco, San Francisco, CA.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Kersten', 'Affiliation': 'Department of Ophthalmology, University of California San Francisco, San Francisco, CA.'}]",Ophthalmology,['10.1016/j.ophtha.2020.07.032'] 2444,32698121,"The Effects of a High-Protein Diet on Markers of Muscle Damage Following Exercise in Active Older Adults: A Randomized, Controlled Trial.","PURPOSE This study examined whether a higher protein diet following strenuous exercise can alter markers of muscle damage and inflammation in older adults. METHODS Using a double-blind, independent group design, 10 males and eight females (age 57 ± 4 years; mass 72.3 ± 5.6 kg; height 1.7 ± 6.5 m) were supplied with a higher protein (2.50 g·kg-1·day-1) or moderate protein (1.25 g·kg-1·day-1) diet for 48 hr after 140 squats with 25% of their body mass. Maximal isometric voluntary contractions, muscle soreness, creatine kinase, Brief Assessment of Mood Adapted, and inflammatory markers were measured preexercise, and 24 hr and 48 hr postexercise. RESULTS The maximal isometric voluntary contractions decreased postexercise (p = .001, ηp2=.421), but did not differ between groups (p = .822, ηp2=.012). Muscle soreness peaked at 24 hr post in moderate protein (44 ± 30 mm) and 48 hr post in higher protein (70 ± 46 mm; p = .005; ηp2=.282); however, no group differences were found (p = .585; ηp2=.083). Monocytes and lymphocytes significantly decreased postexercise, and eosinophils increased 24 hr postexercise (p < 0.05), but neutrophils, creatine kinase, interleukin-6, C-reactive protein, monocyte chemotactic protein-1, and Brief Assessment of Mood Adapted were unchanged by exercise or the intervention (p > .05). CONCLUSION In conclusion, 2.50 g·kg-1·day-1 of protein is not more effective than 1.25 g·kg-1·day-1 for attenuating indirect markers of muscle damage and inflammation following strenuous exercise in older adults.",2020,"The maximal isometric voluntary contractions decreased postexercise (p = .001, ηp2=.421), but did not differ between groups (p = .822, ηp2=.012).","['Active Older Adults', 'older adults', '10 males and eight females (age 57 ± 4\xa0years; mass 72.3 ± 5.6\xa0kg; height 1.7 ± 6.5\xa0m) were supplied with a higher protein (2.50\xa0g·kg-1·day-1) or moderate protein (1.25\xa0g·kg-1·day-1) diet for 48\xa0hr after 140 squats with 25% of their body mass']","['High-Protein Diet', 'strenuous exercise']","['Muscle soreness', 'postexercise, and eosinophils increased 24\xa0hr postexercise', 'neutrophils, creatine kinase, interleukin-6, C-reactive protein, monocyte chemotactic protein-1, and Brief Assessment of Mood Adapted', 'maximal isometric voluntary contractions decreased postexercise', 'Maximal isometric voluntary contractions, muscle soreness, creatine kinase, Brief Assessment of Mood Adapted, and inflammatory markers']","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C4517794', 'cui_str': '5.6'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C4517512', 'cui_str': '1.7'}, {'cui': 'C3844007', 'cui_str': '6.5'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C4517497', 'cui_str': '1.25'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}]","[{'cui': 'C0425403', 'cui_str': 'Increased protein diet'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0014457', 'cui_str': 'Eosinophilia'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0128897', 'cui_str': 'Monocyte Chemoattractant Protein-1'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C2237119', 'cui_str': 'Assessment of mood'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",10.0,0.156618,"The maximal isometric voluntary contractions decreased postexercise (p = .001, ηp2=.421), but did not differ between groups (p = .822, ηp2=.012).","[{'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Clifford', 'Affiliation': 'Newcastle University.'}, {'ForeName': 'Eleanor J', 'Initials': 'EJ', 'LastName': 'Hayes', 'Affiliation': 'Newcastle University.'}, {'ForeName': 'Jadine H', 'Initials': 'JH', 'LastName': 'Scragg', 'Affiliation': 'Newcastle University.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Taylor', 'Affiliation': 'Newcastle University.'}, {'ForeName': 'Kieran', 'Initials': 'K', 'LastName': 'Smith', 'Affiliation': 'Newcastle University.'}, {'ForeName': 'Kelly A', 'Initials': 'KA', 'LastName': 'Bowden Davies', 'Affiliation': 'Newcastle University.'}, {'ForeName': 'Emma J', 'Initials': 'EJ', 'LastName': 'Stevenson', 'Affiliation': 'Newcastle University.'}]",International journal of sport nutrition and exercise metabolism,['10.1123/ijsnem.2020-0113'] 2445,32698123,Presleep α-Lactalbumin Consumption Does Not Improve Sleep Quality or Time-Trial Performance in Cyclists.,"We tested the hypothesis that presleep consumption of α-lactalbumin (LA), a fraction of whey with a high abundance of tryptophan, would improve indices of sleep quality and time-trial (TT) performance in cyclists relative to an isonitrogenous collagen peptide (CP) supplement lacking tryptophan. Using randomized, double-blind, crossover designs, cyclists consumed either 40 g of LA or CP 2 hr prior to sleep. In Study 1, six elite male endurance track cyclists (age 23 ± 6 years, V˙O2peak 70.2 ± 4.4 ml·kg-1·min-1) consumed a supplement for three consecutive evenings before each 4-km TT on a velodrome track, whereas in Study 2, six well-trained cyclists (one female; age 24 ± 5 years, V˙O2peak 66.9 ± 8.3 ml·kg-1·min-1) consumed a supplement the evening before each 4-km TT on a stationary cycle ergometer. Indices of sleep quality were assessed with wrist-based actigraphy. There were no differences between the CP and LA supplements in terms of total time in bed, total sleep time, or sleep efficiency in Study 1 (LA: 568 ± 71 min, 503 ± 67 min, 88.3% ± 3.4%; CP: 546 ± 30 min, 479 ± 35 min, 87.8% ± 3.1%; p = .41, p = .32, p = .74, respectively) or Study 2 (LA: 519 ± 90 min, 450 ± 78 min, 87.2% ± 7.6%; CP: 536 ± 62 min, 467 ± 57 min, 87.3% ± 6.4%; p = .43, p = .44, p = .97, respectively). Similarly, time to complete the 4-km TT was unaffected by supplementation in Study 1 (LA: 274.9 ± 7.6 s; CP: 275.5 ± 7.2 s; p = .62) and Study 2 (LA: 344.3 ± 22.3 s; CP: 343.3 ± 23.0 s; p = .50). Thus, relative to CP, consuming LA 2 hr prior to sleep over 1-3 days did not improve actigraphy-based indices of sleep quality or 4-km TT performance in cyclists.",2020,"There were no differences between the CP and LA supplements in terms of total time in bed, total sleep time, or sleep efficiency in Study 1 (LA: 568 ± 71 min, 503 ± 67 min, 88.3% ± 3.4%; CP: 546 ± 30 min, 479 ± 35 min, 87.8% ± 3.1%; p = .41, p = .32, p = .74, respectively) or Study 2 (LA: 519 ± 90 min, 450 ± 78 min, 87.2% ± 7.6%; CP: 536 ± 62 min, 467 ± 57 min, 87.3% ± 6.4%; p = .43, p = .44, p = .97, respectively).","['Cyclists', 'six elite male endurance track cyclists (age 23 ± 6\xa0years, V˙O2peak 70.2 ± 4.4\xa0ml·kg-1·min-1) consumed a supplement for three consecutive evenings before each 4-km TT on a velodrome track, whereas in Study 2, six well-trained cyclists (one female; age 24 ± 5\xa0years']","['V˙O2peak 66.9 ± 8.3\xa0ml·kg-1·min-1) consumed a supplement the evening before each 4-km TT on a stationary cycle ergometer', 'isonitrogenous collagen peptide (CP) supplement lacking tryptophan', 'α-lactalbumin (LA', 'LA or CP']","['total time in bed, total sleep time, or sleep efficiency', 'Sleep Quality', 'Indices of sleep quality', 'time to complete the 4-km TT', 'actigraphy-based indices of sleep quality or 4-km TT performance', 'sleep quality and time-trial (TT) performance']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517761', 'cui_str': '4.4'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0587117', 'cui_str': 'Evening'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0562987', 'cui_str': 'Cycle track'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0587117', 'cui_str': 'Evening'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439835', 'cui_str': 'Stationary'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0041249', 'cui_str': 'Tryptophan'}, {'cui': 'C0022912', 'cui_str': 'Lactalbumin'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]",,0.103252,"There were no differences between the CP and LA supplements in terms of total time in bed, total sleep time, or sleep efficiency in Study 1 (LA: 568 ± 71 min, 503 ± 67 min, 88.3% ± 3.4%; CP: 546 ± 30 min, 479 ± 35 min, 87.8% ± 3.1%; p = .41, p = .32, p = .74, respectively) or Study 2 (LA: 519 ± 90 min, 450 ± 78 min, 87.2% ± 7.6%; CP: 536 ± 62 min, 467 ± 57 min, 87.3% ± 6.4%; p = .43, p = .44, p = .97, respectively).","[{'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'MacInnis', 'Affiliation': 'McMaster University.'}, {'ForeName': 'Christine E', 'Initials': 'CE', 'LastName': 'Dziedzic', 'Affiliation': 'Canadian Sport Institute Ontario.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Wood', 'Affiliation': 'Canadian Sport Institute Ontario.'}, {'ForeName': 'Sara Y', 'Initials': 'SY', 'LastName': 'Oikawa', 'Affiliation': 'McMaster University.'}, {'ForeName': 'Stuart M', 'Initials': 'SM', 'LastName': 'Phillips', 'Affiliation': 'McMaster University.'}]",International journal of sport nutrition and exercise metabolism,['10.1123/ijsnem.2020-0009'] 2446,32699909,"Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle-invasive bladder cancer: results from JCOG0209, a randomized phase III study.","BACKGROUND Although neoadjuvant chemotherapy provides survival benefits in muscle-invasive bladder cancer, the impact of neoadjuvant chemotherapy on health-related quality of life has not been investigated by a randomized trial. The purpose of this study is to compare health-related quality of life in patients with muscle-invasive bladder cancer who received neoadjuvant chemotherapy followed by radical cystectomy or radical cystectomy alone based on patient-reported outcome data. METHODS Patients were randomized to receive two cycles of neoadjuvant methotrexate, doxorubicin, vinblastine, and cisplatin followed by radical cystectomy or radical cystectomy alone. Health-related quality of life was measured using the Functional Assessment of Cancer Therapy-Bladder (version 4) questionnaire before the protocol treatments, after neoadjuvant chemotherapy, after radical cystectomy and 1 year after registration. RESULTS A total of 99 patients were analysed. No statistically significant differences in postoperative health-related quality of life were found between the arms. In the neoadjuvant chemotherapy arm, the scores after neoadjuvant chemotherapy were significantly lower than the baseline scores in physical well-being, functional well-being, Functional Assessment of Cancer Therapy-General total, weight loss, diarrhoea, appetite, body appearance, embarrassment by ostomy appliance and total Functional Assessment of Cancer Therapy-Bladder. However, there was no difference in scores for these domains, except for embarrassment by ostomy appliance, between the two arms after radical cystectomy and 1 year after registration. CONCLUSIONS Although health-related quality of life declined during neoadjuvant chemotherapy, no negative effect of neoadjuvant chemotherapy on health-related quality of life was apparent after radical cystectomy. These data support the view that neoadjuvant chemotherapy can be considered as a standard of care for patients with muscle-invasive bladder cancer regarding health-related quality of life.",2020,"In the neoadjuvant chemotherapy arm, the scores after neoadjuvant chemotherapy were significantly lower than the baseline scores in physical well-being, functional well-being, Functional Assessment of Cancer Therapy-General total, weight loss, diarrhoea, appetite, body appearance, embarrassment by ostomy appliance and total Functional Assessment of Cancer Therapy-Bladder.","['patients with muscle-invasive bladder cancer who received', 'muscle-invasive bladder cancer', 'Patients', 'patients with muscle-invasive bladder cancer', 'A total of 99 patients were analysed']","['neoadjuvant methotrexate, doxorubicin, vinblastine, and cisplatin followed by radical cystectomy or radical cystectomy alone', 'neoadjuvant chemotherapy', 'neoadjuvant chemotherapy followed by radical cystectomy or radical cystectomy alone']","['health-related quality of life', 'Functional Assessment of Cancer Therapy-Bladder (version 4) questionnaire', 'physical well-being, functional well-being, Functional Assessment of Cancer Therapy-General total, weight loss, diarrhoea, appetite, body appearance, embarrassment by ostomy appliance and total Functional Assessment of Cancer Therapy-Bladder', 'postoperative health-related quality of life', 'Health-related quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1827293', 'cui_str': 'Carcinoma of urinary bladder, invasive'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0042670', 'cui_str': 'Vinblastine'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0194401', 'cui_str': 'Complete cystectomy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0005682', 'cui_str': 'Urinary bladder structure'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0679112', 'cui_str': 'Embarrassment'}, {'cui': 'C0182096', 'cui_str': 'Ostomy appliance'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]",99.0,0.136211,"In the neoadjuvant chemotherapy arm, the scores after neoadjuvant chemotherapy were significantly lower than the baseline scores in physical well-being, functional well-being, Functional Assessment of Cancer Therapy-General total, weight loss, diarrhoea, appetite, body appearance, embarrassment by ostomy appliance and total Functional Assessment of Cancer Therapy-Bladder.","[{'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Kitamura', 'Affiliation': 'Department of Urology, Faculty of Medicine, University of Toyama, Toyama Toyama, Japan.'}, {'ForeName': 'Shiro', 'Initials': 'S', 'LastName': 'Hinotsu', 'Affiliation': 'Department of Biostatistics, Sapporo Medical University, SapporoHokkaido, Japan.'}, {'ForeName': 'Taiji', 'Initials': 'T', 'LastName': 'Tsukamoto', 'Affiliation': 'Department of Urology, Sapporo Medical University School of Medicine, Sapporo Hokkaido, Japan.'}, {'ForeName': 'Taro', 'Initials': 'T', 'LastName': 'Shibata', 'Affiliation': 'Japan Clinical Oncology Group Data Center, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Junki', 'Initials': 'J', 'LastName': 'Mizusawa', 'Affiliation': 'Japan Clinical Oncology Group Data Center, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Kobayashi', 'Affiliation': 'Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.'}, {'ForeName': 'Makito', 'Initials': 'M', 'LastName': 'Miyake', 'Affiliation': 'Department of Urology, Nara Medical University, Kashihara, Nara, Japan.'}, {'ForeName': 'Naotaka', 'Initials': 'N', 'LastName': 'Nishiyama', 'Affiliation': 'Department of Urology, Faculty of Medicine, University of Toyama, Toyama Toyama, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Kojima', 'Affiliation': 'Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Nishiyama', 'Affiliation': 'Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Japanese journal of clinical oncology,['10.1093/jjco/hyaa123'] 2447,32699911,The effect of a split portion of flaxseed on 24-h blood glucose response.,"PURPOSE Flaxseed can be effective at lowering and stabilising blood glucose responses. The aim of this study was to determine whether flaxseed could lower blood glucose response more effectively when consumed as a single portion of 30 g, or a split portion consumed three times per day (10 g flaxseed per portion). METHODS The study was a randomised, repeated measures, cross-over design. Fifteen healthy participants consumed either (1) three flaxseed muffins containing a total of 30 g of flaxseed once in the morning, (2) three flaxseed muffins consumed at three different timepoints across the day (10 g flaxseed per muffin) or (3) three control muffins consumed at three different timepoints across the day (0 g flaxseed). The 24-h blood glucose response was measured using a continuous glucose monitor. RESULTS The results of this study demonstrated that flaxseed muffins given three times a day were effective at lowering and maintaining blood glucose levels over 24 h, compared to the control muffins and that both flaxseed treatments resulting in a lower blood glucose iAUC during the night. CONCLUSION The results of this study indicated that adding flaxseed to a daily diet produced a lower glucose profile over 24 h in a free-living context compared to the control muffins.",2020,The results of this study indicated that adding flaxseed to a daily diet produced a lower glucose profile over 24 h in a free-living context compared to the control muffins.,['Fifteen healthy participants'],[],"['blood glucose iAUC', '24-h blood glucose response', 'blood glucose response', 'effective at lowering and maintaining blood glucose levels']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]",[],"[{'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}]",15.0,0.0400749,The results of this study indicated that adding flaxseed to a daily diet produced a lower glucose profile over 24 h in a free-living context compared to the control muffins.,"[{'ForeName': 'Awatif', 'Initials': 'A', 'LastName': 'Almehmadi', 'Affiliation': 'Department of Sport, Health Sciences and Social Work, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, OX3 0BP, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Lightowler', 'Affiliation': 'Department of Sport, Health Sciences and Social Work, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, OX3 0BP, UK.'}, {'ForeName': 'Magali', 'Initials': 'M', 'LastName': 'Chohan', 'Affiliation': ""Department of Health and Exercise Science, Faculty of Sport, Health and Applied Science, St Mary's University, Twickenham, TW1 4SX, UK.""}, {'ForeName': 'Miriam E', 'Initials': 'ME', 'LastName': 'Clegg', 'Affiliation': 'Department of Food and Nutritional Sciences, School of Chemistry, Food and Pharmacy, University of Reading, Reading, RG6 6AP, UK. m.e.clegg@reading.ac.uk.'}]",European journal of nutrition,['10.1007/s00394-020-02333-x'] 2448,32699918,The effect of melatonin on reduction in the need for sedative agents and duration of mechanical ventilation in traumatic intracranial hemorrhage patients: a randomized controlled trial.,"PURPOSE This study aimed to determine the effect of exogenous melatonin on the number of sedative drugs and the duration of mechanical ventilation in traumatic intracranial hemorrhage patients in ICU. METHODS This double-blind randomized clinical trial study was conducted in the ICU wards of Golestan Hospital, Ahvaz, Iran, from September 2017 to March 2018. In this study, 52 patients with intracerebral hemorrhage were selected by convenient sampling (26 patients in each group) and were randomly assigned to two groups of melatonin and control. Sedation and pain management package was applied to both groups. OUTCOMES Amount of the sedative and opioid drug; mechanical ventilation time; ICU staying time; Glasgow Coma Score; hemodynamic parameters. RESULTS There was no significant difference between them in terms of demographic characteristics. Cumulative doses of morphine and mechanical ventilation time were significant in two groups. (P < 0.05) The mean length of ICU staying was not significant. Glasgow Coma Score on the 6th day was significant in two groups (P < 0.05). Diastolic blood pressure was significant between groups (P < 0.001). CONCLUSION This study presented that morphine consumption and mechanical ventilation time were significantly lower in the melatonin group than in the control. Also, rise in GCS in the melatonin group was faster in the melatonin group than in the control. The use of melatonin can be recommended for patients with ICH in the ICU for better outcomes.",2020,Glasgow Coma Score on the 6th day was significant in two groups (P < 0.05).,"['traumatic intracranial hemorrhage patients', 'ICU wards of Golestan Hospital, Ahvaz, Iran, from September 2017 to March 2018', 'patients with ICH in the ICU for better outcomes', 'traumatic intracranial hemorrhage patients in ICU', '52 patients with intracerebral hemorrhage were selected by convenient sampling (26 patients in each group']","['morphine', 'melatonin', 'exogenous melatonin', 'melatonin and control']","['sedative and opioid drug; mechanical ventilation time; ICU staying time; Glasgow Coma Score; hemodynamic parameters', 'Diastolic blood pressure', 'mechanical ventilation time', 'morphine consumption and mechanical ventilation time', 'Glasgow Coma Score', 'mean length of ICU staying', 'rise in GCS']","[{'cui': 'C0273058', 'cui_str': 'Intracranial hemorrhage following injury'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0019191', 'cui_str': 'Infectious Canine Hepatitis'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C2937358', 'cui_str': 'Cerebral hemorrhage'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0020592', 'cui_str': 'HYPNOTICS AND SEDATIVES'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C1271007', 'cui_str': 'Glasgow coma score'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C1522376', 'cui_str': 'GCLC protein, human'}]",52.0,0.0797376,Glasgow Coma Score on the 6th day was significant in two groups (P < 0.05).,"[{'ForeName': 'Farhad', 'Initials': 'F', 'LastName': 'Soltani', 'Affiliation': 'Department of Anesthesia, Ahvaz Anesthesiology and Pain Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Salari', 'Affiliation': 'Department of Anesthesia, Ahvaz Anesthesiology and Pain Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Javaherforooshzadeh', 'Affiliation': 'Department of Anesthesia, Ahvaz Anesthesiology and Pain Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. f_javaherforoosh@yahoo.com.'}, {'ForeName': 'Nozar', 'Initials': 'N', 'LastName': 'Nassajjian', 'Affiliation': 'Department of Anesthesia, Ahvaz Anesthesiology and Pain Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Farahmand', 'Initials': 'F', 'LastName': 'Kalantari', 'Affiliation': 'Department of Anesthesia, Ahvaz Anesthesiology and Pain Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}]",European journal of trauma and emergency surgery : official publication of the European Trauma Society,['10.1007/s00068-020-01449-3'] 2449,32699919,ACL reconstruction using a quadruple semitendinosus graft with cortical fixations gives suitable isokinetic and clinical outcomes after 2 years.,"PURPOSE The objective of this single-center randomized single-blinded trial was to assess the hypothesis that anterior cruciate ligament reconstruction (ACLR) using a four-strand semitendinosus (ST) graft with adjustable femoral and tibial cortical fixation produced good outcomes compared to an ST/gracilis (ST/G) graft with femoral pin transfixation and tibial bioscrew fixation. Follow-up was 2 years. METHODS Patients older than 16 years who underwent primary isolated ACLR included for 1 year until August 2017 were eligible. The primary outcome measures were the subjective International Knee Documentation Committee (IKDC) score, isokinetic muscle strength recovery, and return to work within 2 years. The study was approved by the ethics committee. RESULTS Of 66 eligible patients, 60 completed the study and were included, 33 in the 4ST group and 27 in the ST/G group. Mean age was 30.5 ± 8.9 years in the 4ST group and 30.3 ± 8.5 in the ST/G group (n.s.). No significant between-group differences were found for mean postoperative subjective IKDC (4ST group, 80.2 ± 12.5; ST/G group, 83.6 ± 13.6; n.s.), side-to-side percentage deficits in isokinetic hamstring strength (at 60°/s: ST group, 17% ± 16%; ST/G group, 14% ± 11%; n.s.) or quadriceps strength (at 60°/s: ST group, 14% ± 12%; ST/G group, 19% ± 17%; n.s.), return to work, pain during physical activities, side-to-side differential laxity, balance, loss of flexion/extension, or surgical complications. CONCLUSION This trial demonstrates that functional outcomes after 4ST for ACLR with cortical fixations could be as good, although not better, than those obtained using ST/G. The 4ST technique spares the gracilis tendon, which thus preserves the medial sided muscle and thereby could improve function and limit donor-side morbidity. LEVEL OF EVIDENCE Level I.",2020,"No significant between-group differences were found for mean postoperative subjective IKDC (4ST group, 80.2 ± 12.5; ST/G group, 83.6 ± 13.6; n.s.), side-to-side percentage deficits in isokinetic hamstring strength (at 60°/s","[' 60 completed the study and were included, 33 in the 4ST group and 27 in the ST/G group', 'Mean age was 30.5\u2009±\u20098.9\xa0years in the 4ST group and 30.3\u2009±\u20098.5 in the ST/G group (n.s', 'Patients older than 16\xa0years who underwent primary isolated ACLR included for 1\xa0year until August 2017 were eligible', '66 eligible patients']","['anterior cruciate ligament reconstruction (ACLR) using a four-strand semitendinosus (ST) graft with adjustable femoral and tibial cortical fixation', 'ST/gracilis (ST/G) graft with femoral pin transfixation and tibial bioscrew fixation', 'ACL reconstruction']","['subjective International Knee Documentation Committee (IKDC) score, isokinetic muscle strength recovery, and return to work within 2\xa0years', 'quadriceps strength', 'mean postoperative subjective IKDC', 'return to work, pain during physical activities, side-to-side differential laxity, balance, loss of flexion/extension, or surgical complications', 'isokinetic hamstring strength']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0224453', 'cui_str': 'Semitendinosus muscle structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517877', 'cui_str': '8.5'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}]","[{'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C0224453', 'cui_str': 'Semitendinosus muscle structure'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0021885', 'cui_str': 'Bone nailing'}, {'cui': 'C0162596', 'cui_str': 'Cardiolipin antibody'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0175636', 'cui_str': 'Documentation procedure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0425105', 'cui_str': 'Returned to work'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0443199', 'cui_str': 'Differential'}, {'cui': 'C0332536', 'cui_str': 'Laxity'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0444509', 'cui_str': 'Flexion/extension'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0584895', 'cui_str': 'Posterior muscle of thigh structure'}]",66.0,0.0333182,"No significant between-group differences were found for mean postoperative subjective IKDC (4ST group, 80.2 ± 12.5; ST/G group, 83.6 ± 13.6; n.s.), side-to-side percentage deficits in isokinetic hamstring strength (at 60°/s","[{'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Roger', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, Hôpital de La Croix Rousse, Hospices Civils de Lyon, 103 Grande Rue de la Croix Rousse, 69004, Lyon, France. julien.roger@chu-lyon.fr.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Bertani', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France. antoine.bertani@chu-lyon.fr.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Vigouroux', 'Affiliation': ""Division of Orthopaedic Surgery, Department of Surgery, Hôpital d'Instruction des Armées Bégin, Service de Santé des Armées, Saint-Mandé, France.""}, {'ForeName': 'Franck', 'Initials': 'F', 'LastName': 'Mottier', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, Centre Hospitalier Pierre Oudot, Bourgoin-Jallieu, France.'}, {'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Gaillard', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, Hôpital de La Croix Rousse, Hospices Civils de Lyon, 103 Grande Rue de la Croix Rousse, 69004, Lyon, France.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Have', 'Affiliation': 'Department of Physical and Medical Rehabilitation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Rongièras', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.'}]","Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA",['10.1007/s00167-020-06121-2'] 2450,32700009,Comparison of Rapid Absorbable Sutures with Nonabsorbable Sutures in Closing Transcolumellar Incision in Septorhinoplasty: Short-term Outcomes.,"BACKGROUND Following open rhinoplasty, a postoperative scar at the columellar incision line is a common morbidity. The aim of this study is to compare absorbable and nonabsorbable suture materials which had been used for closing the transcolumellar incision, in the aspect of risk of postoperative infection, wound healing, postoperative columellar scar and patient satisfaction. METHOD A prospective, randomized, single-blind study was conducted between May 2017 and February 2018. Sixty-four rhinoplasty patients were randomly assigned to absorbable (n = 32) or nonabsorbable (n = 32) groups. The columellar incision was closed with 7 full-thickness skin sutures. Either nonabsorbable 6/0 polypropylene (Group 1) or absorbable 6/0 polyglytone 6211 (Group 2) sutures were placed at the columellar incisions. Polypropylene sutures were removed at the 7th postoperative day. A Mann-Whitney U test and Monte Carlo were used for statistical comparison. Photographs of the patients at the postoperative third month (Fig. 2) were evaluated and scored in terms of scarring, pigmentation, notching, level differences in the incision area by two different otorhinolaryngologists who did not know the randomization. Suture removing discomfort was assessed with visual analogue scale scores. A satisfaction survey was filled out by all the patients completing their third month after the operation. RESULTS According to the results of both otorhinolaryngologists, there was no significant difference between the two groups in terms of pigmentation, level difference, notching, overall appearance and total score (p = 0.920, p = 0.498, respectively). The mean score on the Wong-Baker scale was 3.19 ± 1.67 in group 1. In the Satisfaction Survey, the average score of the group 1 was 6.90 ± 3.24, while the mean score of the group 2 was 7.062 ± 2.77. There was no statistically significant difference between the two groups (p = 0.715). CONCLUSIONS Suturing inverted V transcolumellar incisions with rapid resorbable sutures caused significantly less discomfort but no difference in scarring compared to nonresorbable sutures as evaluated by patients and observers. LEVEL OF EVIDENCE III This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .",2020,"According to the results of both otorhinolaryngologists, there was no significant difference between the two groups in terms of pigmentation, level difference, notching, overall appearance and total score (p = 0.920, p = 0.498, respectively).","['Sixty-four rhinoplasty patients', 'May 2017 and February 2018']","['absorbable and nonabsorbable suture materials', 'Polypropylene sutures', 'Rapid Absorbable Sutures with Nonabsorbable Sutures', 'absorbable (n\u2009=\u200932) or nonabsorbable', 'nonabsorbable 6/0 polypropylene (Group 1) or absorbable 6/0 polyglytone 6211 (Group 2) sutures were placed at the columellar incisions']","['Suture removing discomfort', 'scarring', 'discomfort', 'pigmentation, level difference, notching, overall appearance and total score', 'visual analogue scale scores', 'mean score on the Wong-Baker scale']","[{'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0035467', 'cui_str': 'Rhinoplasty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0461628', 'cui_str': 'Non-absorbable suture'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0491217', 'cui_str': 'Polypropylene suture'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0461643', 'cui_str': 'Absorbable suture'}, {'cui': 'C0032582', 'cui_str': 'Polypropylene'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C1702173', 'cui_str': 'polyglytone 6211'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0184898', 'cui_str': 'Incision'}]","[{'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C1883720', 'cui_str': 'Removes'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0031911', 'cui_str': 'Pigmentation'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0238749', 'cui_str': 'Baker, general'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",64.0,0.0358099,"According to the results of both otorhinolaryngologists, there was no significant difference between the two groups in terms of pigmentation, level difference, notching, overall appearance and total score (p = 0.920, p = 0.498, respectively).","[{'ForeName': 'Ozan', 'Initials': 'O', 'LastName': 'Erol', 'Affiliation': 'Department of Otorhinolaryngology, Elmadag Hulusi Alatas State Hospital, Ankara, Turkey. ozzy.erol@gmail.com.'}, {'ForeName': 'Fuat', 'Initials': 'F', 'LastName': 'Buyuklu', 'Affiliation': 'Department of Otorhinolaryngology, Baskent University Hospital, Ankara, Turkey.'}, {'ForeName': 'Alper', 'Initials': 'A', 'LastName': 'Koycu', 'Affiliation': 'Department of Otorhinolaryngology, Baskent University Hospital, Ankara, Turkey.'}, {'ForeName': 'Sabuhi', 'Initials': 'S', 'LastName': 'Jafarov', 'Affiliation': 'Department of Otorhinolaryngology, Baskent University Hospital, Ankara, Turkey.'}, {'ForeName': 'Goknil', 'Initials': 'G', 'LastName': 'Gultekin', 'Affiliation': 'Department of Otorhinolaryngology, Baskent University Hospital, Ankara, Turkey.'}, {'ForeName': 'Selim S', 'Initials': 'SS', 'LastName': 'Erbek', 'Affiliation': 'Department of Otorhinolaryngology, Baskent University Hospital, Ankara, Turkey.'}]",Aesthetic plastic surgery,['10.1007/s00266-020-01864-2'] 2451,32700217,"A Telehealth-supported, Integrated care with CHWs, and MEdication-access (TIME) Program for Diabetes Improves HbA1c: a Randomized Clinical Trial.","BACKGROUND Many individuals with diabetes live in low- or middle-income settings. Glycemic control is challenging, particularly in resource-limited areas that face numerous healthcare barriers. OBJECTIVE To compare HbA1c outcomes for individuals randomized to TIME, a Telehealth-supported, Integrated care with CHWs (Community Health Workers), and MEdication-access program (intervention) versus usual care (wait-list control). DESIGN Randomized clinical trial. PARTICIPANTS Low-income Latino(a) adults with type 2 diabetes. INTERVENTIONS TIME consisted of (1) CHW-participant telehealth communication via mobile health (mHealth) for 12 months, (2) CHW-led monthly group visits for 6 months, and (3) weekly CHW-physician diabetes training and support via telehealth (video conferencing). MAIN MEASURES Investigators compared TIME versus control participant baseline to month 6 changes of HbA1c (primary outcome), blood pressure, body mass index (BMI), weight, and adherence to seven American Diabetes Association (ADA) standards of care. CHW assistance in identifying barriers to healthcare in the intervention group were measured at the end of mHealth communication (12 months). KEY RESULTS A total of 89 individuals participated. TIME individuals compared to control participants had significant HbA1c decreases (9.02 to 7.59% (- 1.43%) vs. 8.71 to 8.26% (- 0.45%), respectively, p = 0.002), blood pressure changes (systolic: - 6.89 mmHg vs. 0.03 mmHg, p = 0.023; diastolic: - 3.36 mmHg vs. 0.2 mmHg, respectively, p = 0.046), and ADA guideline adherence (p < 0.001) from baseline to month 6. At month 6, more TIME than control participants achieved > 0.50% HbA1c reductions (88.57% vs. 43.75%, p < 0.001). BMI and weight changes were not significant between groups. Many (54.6%) TIME participants experienced > 1 barrier to care, of whom 91.7% had medication issues. CHWs identified the majority (87.5%) of barriers. CONCLUSIONS TIME participants resulted in improved outcomes including HbA1c. CHWs are uniquely positioned to identify barriers to care particularly related to medications that may have gone unrecognized otherwise. Larger trials are needed to determine the scalability and sustainability of the intervention. CLINICAL TRIAL NCT03394456, accessed at https://clinicaltrials.gov/ct2/show/NCT03394456.",2020,"TIME individuals compared to control participants had significant HbA1c decreases (9.02 to 7.59% (- 1.43%) vs. 8.71 to 8.26% (- 0.45%), respectively, p = 0.002), blood pressure changes (systolic: - 6.89 mmHg vs. 0.03 mmHg, p = 0.023; diastolic: - 3.36 mmHg vs. 0.2 mmHg, respectively, p = 0.046), and ADA guideline adherence (p < 0.001) from baseline to month 6.","['Diabetes Improves HbA1c', 'individuals with diabetes live in low- or middle-income settings', 'Low-income Latino(a) adults with type 2 diabetes', '89 individuals participated']","['Integrated care with CHWs, and MEdication-access (TIME', 'MEdication-access program (intervention) versus usual care (wait-list control', 'TIME consisted of (1) CHW-participant telehealth communication via mobile health (mHealth) for 12\xa0months, (2) CHW-led monthly group visits for 6\xa0months, and (3) weekly CHW-physician diabetes training and support via telehealth (video conferencing']","['blood pressure, body mass index (BMI), weight, and adherence to seven American Diabetes Association (ADA) standards of care', 'blood pressure changes', 'BMI and weight changes', 'outcomes including HbA1c', 'ADA guideline adherence']","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1704447', 'cui_str': 'Patient visit for'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C1268766', 'cui_str': 'Blood pressure alteration'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0525059', 'cui_str': 'Guideline Adherence'}]",89.0,0.135301,"TIME individuals compared to control participants had significant HbA1c decreases (9.02 to 7.59% (- 1.43%) vs. 8.71 to 8.26% (- 0.45%), respectively, p = 0.002), blood pressure changes (systolic: - 6.89 mmHg vs. 0.03 mmHg, p = 0.023; diastolic: - 3.36 mmHg vs. 0.2 mmHg, respectively, p = 0.046), and ADA guideline adherence (p < 0.001) from baseline to month 6.","[{'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Vaughan', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine , Baylor College of Medicine, Houston, TX, USA. elizabeth.vaughan@bcm.edu.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Hyman', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine , Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Aanand D', 'Initials': 'AD', 'LastName': 'Naik', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine , Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Samson', 'Affiliation': 'Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, USA.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Razjouyan', 'Affiliation': 'Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E DeBakey VA Medical Center, Houston, TX, USA.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Foreyt', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine , Baylor College of Medicine, Houston, TX, USA.'}]",Journal of general internal medicine,['10.1007/s11606-020-06017-4'] 2452,32700220,Peer Support for Self-Management of Chronic Pain: the Evaluation of a Peer Coach-Led Intervention to Improve Pain Symptoms (ECLIPSE) Trial.,"BACKGROUND Pain self-management is an effective, evidence-based treatment for chronic pain. Peer support, in which patients serve as coaches for other patients, has been effective in other chronic conditions and is a potentially promising approach to implementing pain self-management programs using fewer clinical resources. OBJECTIVE To test a peer coach-delivered pain self-management program for chronic pain. DESIGN Randomized controlled trial. PARTICIPANTS Veterans with chronic musculoskeletal pain. INTERVENTION Intervention patients were assigned a trained peer coach for 6 months. Coaches, who were volunteers, were asked to contact their assigned patients, either by phone or in person, twice per month. Coaches and patients were given an intervention manual to guide sessions. The control group was offered a 2-hour pain self-management class. MAIN MEASURES The primary outcome was total pain, assessed by the Brief Pain Inventory (BPI). Secondary outcomes were anxiety, depression, pain catastrophizing, self-efficacy, social support, patient activation, health-related quality of life, and healthcare utilization. Outcomes were measured at baseline, 6 months, and 9 months. KEY RESULTS Two hundred fifteen patients enrolled (120 intervention, 95 control). Adherence to intervention protocol was low, with only 13% of patients reporting having at least the recommended 12 peer coach meetings over the 6-month intervention. BPI total decreased from baseline to 6 months and baseline to 9 months in both groups. At 9 months, this change was statistically significant (intervention, - 0.40, p = 0.018; control, - 0.47, p = 0.006). There was not a statistically significant difference between groups on BPI at either time point. No secondary outcomes improved significantly in either group after adjusting for multiple comparisons. CONCLUSIONS Patients randomized to peer support did not differ from control patients on primary and secondary outcomes. Other peer support models that do not rely on volunteers might be more effective. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02380690.",2020,"At 9 months, this change was statistically significant (intervention, - 0.40, p = 0.018; control, - 0.47, p = 0.006).","['Two hundred fifteen patients enrolled (120 intervention, 95 control', 'Veterans with chronic musculoskeletal pain', 'Chronic Pain']","['peer coach-delivered pain self-management program', 'Peer Coach-Led Intervention']","['BPI', 'total pain, assessed by the Brief Pain Inventory (BPI', 'BPI total', 'anxiety, depression, pain catastrophizing, self-efficacy, social support, patient activation, health-related quality of life, and healthcare utilization']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0746683', 'cui_str': 'Chronic musculoskeletal pain'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}]","[{'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C3853034', 'cui_str': 'Patient Activation'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",215.0,0.133219,"At 9 months, this change was statistically significant (intervention, - 0.40, p = 0.018; control, - 0.47, p = 0.006).","[{'ForeName': 'Marianne S', 'Initials': 'MS', 'LastName': 'Matthias', 'Affiliation': 'VA HSR&D Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, USA. mmatthia@iupui.edu.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Bair', 'Affiliation': 'VA HSR&D Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Ofner', 'Affiliation': 'Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Heisler', 'Affiliation': 'Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Kukla', 'Affiliation': 'VA HSR&D Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, USA.'}, {'ForeName': 'Alan B', 'Initials': 'AB', 'LastName': 'McGuire', 'Affiliation': 'VA HSR&D Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, USA.'}, {'ForeName': 'Jasma', 'Initials': 'J', 'LastName': 'Adams', 'Affiliation': 'VA HSR&D Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, USA.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Kempf', 'Affiliation': 'VA HSR&D Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, USA.'}, {'ForeName': 'Emilee', 'Initials': 'E', 'LastName': 'Pierce', 'Affiliation': 'VA HSR&D Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, USA.'}, {'ForeName': 'Tetla', 'Initials': 'T', 'LastName': 'Menen', 'Affiliation': 'VA HSR&D Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'McCalley', 'Affiliation': 'VA HSR&D Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, USA.'}, {'ForeName': 'Nicole L', 'Initials': 'NL', 'LastName': 'Johnson', 'Affiliation': 'VA HSR&D Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, USA.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Daggy', 'Affiliation': 'Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA.'}]",Journal of general internal medicine,['10.1007/s11606-020-06007-6'] 2453,32700236,"Application of transoral endoscopic parathyroidectomy via vestibular approach, endoscopic parathyroidectomy via areola approach for parathyroid adenoma.","BACKGROUND Transoral endoscopic parathyroidectomy via vestibular approach (TOEPVA) and total endoscopic parathyroidectomy via areola approach (EPA) are commonly used endoscopic parathyroidectomy approaches. This study compares effectiveness of these approaches with conventional open parathyroidectomy (COP) in relation to safety, associated trauma, and feasibility in the treatment of parathyroid adenoma (PTA). METHODS We examined patients who had undergone TOEPVA (n = 15), EPA (n = 14), and COP (n = 30). All patients had a pathological diagnosis of PTA. We analyzed operative time, intraoperative blood loss, postoperative visual analog scale (VAS) score, postoperative drainage volume, hospital stay and complications such as changes in parathyroid hormone (PTH) and serum calcium before and after surgery. RESULTS Clinical variables across the three experimental groups were similar except for patient age. TOEPVA and EPA groups had a higher proportion of young patients than COP group. Operation time for endoscopic group was longer than that of open group, and the longest operation time was recorded in TOEPVA group (P = 0.000). Postoperative VAS score: postoperative pain in patients in the endoscopic group was less than that of patients in the open group on the first day (P = 0.001). Postoperative pain in patients of the endoscopic group was significant on the second day (P = 0.044). Pain experienced by patients in the three groups was the same on the third day after surgery (P = 0.312). Postoperative drainage volume in the endoscopic group was more than that in the open group (P = 0.000). There were no significant differences between intraoperative blood loss (P = 0.089), complications (P = 0.407) and hospital stay (P = 0.389) in TOEPVA, EPA and COP groups. PTH and serum calcium levels in the three experimental groups were considerably lower after surgery (P < 0.05). Tumor recurrence was not recorded in the three groups during a follow-up period of between 3 and 36 months. CONCLUSIONS TOEPVA and EPA are safe treatment options for PTA. The therapeutic effects of TOEPVA and EPA were similar to those of COP in the treatment of PTA.",2020,Pain experienced by patients in the three groups was the same on the third day after surgery (P = 0.312).,"['parathyroid adenoma', 'patients who had undergone TOEPVA (n\u2009=\u200915), EPA (n\u2009=\u200914), and COP (n\u2009=\u200930', 'All patients had a pathological diagnosis of PTA']","['transoral endoscopic parathyroidectomy via vestibular approach, endoscopic parathyroidectomy via areola approach', 'Transoral endoscopic parathyroidectomy via vestibular approach (TOEPVA) and total endoscopic parathyroidectomy via areola approach (EPA', 'conventional open parathyroidectomy (COP', 'TOEPVA and EPA', 'TOEPVA']","['Postoperative VAS score: postoperative pain', 'Tumor recurrence', 'longest operation time', 'operative time, intraoperative blood loss, postoperative visual analog scale (VAS) score, postoperative drainage volume, hospital stay and complications such as changes in parathyroid hormone (PTH) and serum calcium', 'Pain', 'Postoperative drainage volume', 'complications', 'hospital stay', 'intraoperative blood loss', 'Operation time', 'Postoperative pain', 'PTH and serum calcium levels']","[{'cui': 'C0262587', 'cui_str': 'Parathyroid adenoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442366', 'cui_str': 'Transoral approach'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0079989', 'cui_str': 'Parathyroidectomy'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0222608', 'cui_str': 'Areola structure'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0442366', 'cui_str': 'Transoral approach'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0079989', 'cui_str': 'Parathyroidectomy'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0222608', 'cui_str': 'Areola structure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0175566', 'cui_str': 'Open'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0521158', 'cui_str': 'Recurrent tumor'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0020063', 'cui_str': 'PTH protein, human'}, {'cui': 'C0728876', 'cui_str': 'Serum calcium measurement'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.0239519,Pain experienced by patients in the three groups was the same on the third day after surgery (P = 0.312).,"[{'ForeName': 'Qingquan', 'Initials': 'Q', 'LastName': 'Zhao', 'Affiliation': 'Department of Thyroid Surgery, The Second Affiliated Hospital of Fujian Medical University, Donghai Road, Quanzhou, 362000, Fujian, China.'}, {'ForeName': 'Wenrui', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': ""Department of Thyroid Surgery, Dezhou People's Hospital, Dong Fang Hong West Road, Dezhou, 253000, Shandong, China.""}, {'ForeName': 'Xing', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': 'Department of Thyroid Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Jiefang Road, Hangzhou, 310009, Zhejiang, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Thyroid Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Jiefang Road, Hangzhou, 310009, Zhejiang, China. surgwy@zju.edu.cn.'}]",European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,['10.1007/s00405-020-06231-0'] 2454,32700359,Effect of misoprostol with and without letrozole on induction of abortion for women with first-trimester missed abortion.,"OBJECTIVE To determine whether addition of letrozole to a misoprostol-based abortion regimen can increase the rate of complete abortion. METHODS The randomized, placebo-controlled, double-blind trial enrolled women with missed abortion in the first trimester of pregnancy attending Sadooghi Hospital, Isfahan, Iran, from 2016 to 2018. The women were randomly assigned to the study group, which received 10 mg of letrozole daily for 3 days, followed by two doses of 800 µg of vaginal misoprostol at a 4-hour interval, or the control group, which received a placebo, followed by the same dose of misoprostol. Sonography was performed to check the abortion status. RESULTS In total, 120 women completed the study: 60 in the misoprostol plus letrozole group, and 60 in the misoprostol only group. Complete abortion was documented for 93 (77.5%) women: 48 (80.0%) in the misoprostol plus letrozole group and 45 (75.0%) in the misoprostol only group (P=0.80). The mean duration of induction in the misoprostol plus letrozole and misoprostol only groups was 7.35 ± 3.54 hours and 8.2 ± 3.84 hours, respectively (P=0.21). CONCLUSION Administration of misoprostol alone was found to be as effective as the administration of misoprostol plus letrozole for first-trimester missed abortion.",2020,Complete abortion was documented for 93 (77.5%) women: 48 (80.0%) in the misoprostol plus letrozole group and 45 (75.0%) in the misoprostol only group (P=0.80).,"['women with first-trimester missed abortion', 'enrolled women with missed abortion in the first trimester of pregnancy attending Sadooghi Hospital, Isfahan, Iran, from 2016 to 2018', '120 women completed the study: 60 in the']","['misoprostol-based abortion regimen', 'misoprostol with and without letrozole', 'misoprostol', 'letrozole', 'misoprostol plus letrozole', 'vaginal misoprostol', 'placebo']","['Complete abortion', 'mean duration of induction', 'induction of abortion', 'rate of complete abortion']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032979', 'cui_str': 'First trimester pregnancy'}, {'cui': 'C0000814', 'cui_str': 'Missed miscarriage'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0085174', 'cui_str': 'Misoprostol'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0233105', 'cui_str': 'Abortion complete'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}]",120.0,0.443939,Complete abortion was documented for 93 (77.5%) women: 48 (80.0%) in the misoprostol plus letrozole group and 45 (75.0%) in the misoprostol only group (P=0.80).,"[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Allameh', 'Affiliation': 'Department of Obstetrics & Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Goharian', 'Affiliation': 'Department of Obstetrics & Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Eslamian', 'Affiliation': 'Department of Surgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,['10.1002/ijgo.13326'] 2455,32700409,The impact of pharmacist/physician care on quality of life in heart failure patients: the PHARM-CHF randomized controlled trial.,"AIMS Patients with heart failure (HF) have impaired quality of life (QoL). The randomized controlled trial PHARM-CHF investigated whether an interdisciplinary intervention consisting of regular contacts with the community pharmacy and weekly dosing aids improves medication adherence in patients with HF. It is unknown how an intervention involving frequent structured pharmacy visits affects QoL. Our aim was to explore adherence to the intervention and effects on QoL. METHODS AND RESULTS Among 237 patients, n = 110 were randomized to pharmacy care and n = 127 to usual care. The pharmacy care group received a medication review followed by (bi-)weekly dose dispensing and counselling. The median follow-up was 2.0 years [inter-quartile range (IQR) 1.2-2.7]. Median interval between pharmacy visits was 8.4 days (IQR 8.0-10.3) and the visits lasted in median 14 min (IQR 10-15). Median adherence to the intervention was 96% (IQR 84-100). QoL at 365 days was predefined as a main secondary and at 730 days as another secondary endpoint in PHARM-CHF. QoL was measured by the Minnesota Living with Heart Failure Questionnaire; and for 111 patients (n = 47 in the pharmacy care group and n = 64 in the usual care group), data were available at baseline, and after 365 and 730 days (mean age 74 years; 41% female). Improvement in QoL was numerically higher in the pharmacy care group after 365 days and was significantly better after 730 days (difference in total scores -7.7 points [-14.5 to -1.0]; P = 0.026) compared to the usual care group. In all subgroups examined, this treatment effect was preserved. Improvements in the physical and emotional dimensions were numerically higher in the pharmacy care group after 365 days and were significantly better after 730 days: -4.0 points [-6.9 to -1.2]; P = 0.006, and -1.9 points [-3.7 to -0.1]; P = 0.039, respectively. CONCLUSIONS A pharmacy-based interdisciplinary intervention was well received by the patients and suggests clinically important improvements in QoL.",2020,Improvements in the physical and emotional dimensions were numerically higher in the pharmacy care group after 365 days and were significantly better after 730 days: -4.0 points [,"['patients with HF', '111 patients (n\xa0=\xa047 in the pharmacy care group and n\xa0=\xa064 in the usual care group), data were available at baseline, and after 365 and 730\xa0days (mean age 74\xa0years; 41% female', 'Patients with heart failure (HF', 'heart failure patients', '237 patients, n\xa0=\xa0110 were randomized to pharmacy care and n\xa0=\xa0127 to usual care']",['pharmacist/physician care'],"['quality of life', 'Improvement in QoL', 'quality of life (QoL', 'QoL', 'physical and emotional dimensions', 'Median interval between pharmacy visits', 'Median adherence', 'medication adherence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0031321', 'cui_str': 'Pharmacy service'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517536', 'cui_str': '110'}]","[{'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0031831', 'cui_str': 'Physician'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0031321', 'cui_str': 'Pharmacy service'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}]",110.0,0.0898566,Improvements in the physical and emotional dimensions were numerically higher in the pharmacy care group after 365 days and were significantly better after 730 days: -4.0 points [,"[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Schulz', 'Affiliation': 'Department of Medicine, ABDA - Federal Union of German Associations of Pharmacists, Berlin, Germany.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Griese-Mammen', 'Affiliation': 'Department of Medicine, ABDA - Federal Union of German Associations of Pharmacists, Berlin, Germany.'}, {'ForeName': 'Pia M', 'Initials': 'PM', 'LastName': 'Schumacher', 'Affiliation': 'Department of Medicine, ABDA - Federal Union of German Associations of Pharmacists, Berlin, Germany.'}, {'ForeName': 'Stefan D', 'Initials': 'SD', 'LastName': 'Anker', 'Affiliation': 'Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Friedrich', 'Initials': 'F', 'LastName': 'Koehler', 'Affiliation': 'Centre for Cardiovascular Telemedicine, Department of Cardiology and Angiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Ruckes', 'Affiliation': 'Interdisciplinary Centre for Clinical Trials, University Medical Centre Mainz, Mainz, Germany.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Rettig-Ewen', 'Affiliation': 'Schwemlinger Gemeinschaftspraxis, Merzig, Germany.'}, {'ForeName': 'Rolf', 'Initials': 'R', 'LastName': 'Wachter', 'Affiliation': 'Department of Cardiology, University Hospital, Leipzig University, Leipzig, Germany.'}, {'ForeName': 'Dietmar', 'Initials': 'D', 'LastName': 'Trenk', 'Affiliation': 'Department of Clinical Pharmacology, University Heart Centre Freiburg-Bad Krozingen, Bad Krozingen, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Böhm', 'Affiliation': 'Department of Internal Medicine III - Cardiology, Angiology and Intensive Care Medicine, University Hospital of Saarland, Saarland University, Homburg/Saar, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Laufs', 'Affiliation': 'Department of Cardiology, University Hospital, Leipzig University, Leipzig, Germany.'}]",ESC heart failure,['10.1002/ehf2.12904'] 2456,32700415,Intermittent pneumatic compression versus additional prophylaxis with enoxaparin for prevention of venous thromboembolism after laparoscopic surgery for gastric and colorectal malignancies: multicentre randomized clinical trial.,"BACKGROUND The role of antithrombotic chemoprophylaxis in prevention of venous thromboembolism (VTE) in laparoscopic surgery for gastric and colorectal malignancies is unknown. This study compared the addition of enoxaparin following intermittent pneumatic compression (IPC) with IPC alone in patients undergoing laparoscopic surgery for gastrointestinal malignancy. METHODS In this multicentre RCT, eligible patients were older than 40 years and had a WHO performance status of 0 or 1. Exclusion criteria were prescription of antiplatelet or anticoagulant drugs and history of VTE. Patients were allocated to IPC or to ICP with enoxaparin in a 1 : 1 ratio. Stratification factors included sex, location of cancer, age 61 years and over, and institution. Enoxaparin was administered on days 1-7 after surgery. Primary outcome was VTE, evaluated by multidetector CT on day 7. RESULTS Of 448 patients randomized, 208 in the IPC group and 182 in the IPC with enoxaparin group were evaluated. VTE occurred in ten patients (4·8 per cent) in the IPC group and six (3·3 per cent) in the IPC with enoxaparin group (P = 0·453). Proximal deep vein thrombosis and/or pulmonary embolism occurred in seven patients (3·4 per cent) in the IPC group and one patient (0·5 per cent) in the IPC with enoxaparin group (P = 0·050). All VTE events were asymptomatic and non-fatal. Bleeding occurred in 11 of 202 patients in the IPC with enoxaparin group, and one patient needed a transfusion. All bleeding events were managed by discontinuation of the drug. CONCLUSION IPC with enoxaparin after laparoscopic surgery for gastric and colorectal malignancies did not reduce the rate of VTE. Registration number: UMIN000011667 ( https://www.umin.ac.jp/).",2020,Proximal deep vein thrombosis and/or pulmonary embolism occurred in seven patients (3·4 per cent) in the IPC group and one patient (,"['448 patients randomized, 208 in the IPC group and 182 in the IPC with', 'patients undergoing laparoscopic surgery for gastrointestinal malignancy', 'venous thromboembolism after laparoscopic surgery for gastric and colorectal malignancies', 'eligible patients were older than 40\u2009years and had a WHO performance status of 0 or 1']","['IPC', 'ICP with enoxaparin', 'Enoxaparin', 'antithrombotic chemoprophylaxis', 'intermittent pneumatic compression (IPC) with IPC alone', 'Intermittent pneumatic compression versus additional prophylaxis with enoxaparin', 'enoxaparin', 'laparoscopic surgery']","['Proximal deep vein thrombosis and/or pulmonary embolism', 'All bleeding events', 'VTE', 'Bleeding', 'VTE, evaluated by multidetector CT on day 7', 'rate of VTE']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0449438', 'cui_str': 'Status'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0206460', 'cui_str': 'Enoxaparin'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}]","[{'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C3179130', 'cui_str': 'Multidetector-Row Computed Tomography'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",448.0,0.16477,Proximal deep vein thrombosis and/or pulmonary embolism occurred in seven patients (3·4 per cent) in the IPC group and one patient (,"[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Kamachi', 'Affiliation': 'Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Homma', 'Affiliation': 'Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Kawamura', 'Affiliation': 'Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Yoshida', 'Affiliation': 'Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Ohno', 'Affiliation': 'Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Ichikawa', 'Affiliation': 'Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Yokota', 'Affiliation': 'Department of Surgery, Sunagawa City Medical Centre, Sunagawa, Japan.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Funakoshi', 'Affiliation': 'Department of Surgery, Asahikawa-Kosei General Hospital, Asahikawa, Japan.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Maeda', 'Affiliation': 'Department of Gastrointestinal Surgery, National Hospital Organization Hokkaido Cancer Centre, Hokkaido.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Takahashi', 'Affiliation': 'Surgical Centre, Hokkaido, Japan.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Amano', 'Affiliation': 'Clinical Research and Medical Innovation Centre, Hokkaido University Hospital, Hokkaido, Japan.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Taketomi', 'Affiliation': 'Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.'}]",BJS open,['10.1002/bjs5.50323'] 2457,32700421,Efficacy and safety of ertugliflozin in older patients with type 2 diabetes mellitus: A pooled analysis of phase III studies.,"AIMS To assess the efficacy and safety of ertugliflozin in older patients with type 2 diabetes (T2DM). MATERIALS AND METHODS This is a post hoc analysis of patients with T2DM aged <65 and ≥65 years who participated in randomized, double-blind phase III studies of ertugliflozin. Efficacy was evaluated in a pooled analysis of three placebo-controlled studies (ertugliflozin monotherapy and add-on therapy). Safety was evaluated in a pooled analysis of seven placebo- and active-controlled studies (including those used for efficacy). Least-squares (LS) mean change from baseline was calculated for glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight (BW) and systolic blood pressure (SBP). Safety evaluation included overall and prespecified adverse events (AEs). RESULTS In participants aged <65 years, the placebo-adjusted mean changes from baseline in HbA1c, BW and SBP with ertugliflozin 5 mg and 15 mg at Week 26 were: -0.9% and -1.0%; -1.9 kg and -1.8 kg; and -3.7 mmHg and -3.6 mmHg, respectively; in participants aged ≥65 years they were: -0.6% and -0.8%; -1.9 kg and -2.2 kg; and -2.7 mmHg and -3.4 mmHg, respectively. The incidences of AEs, serious AEs, discontinuations and deaths in participants aged <65 years and ≥65 years were generally similar across the treatment groups. In patients aged ≥65 years, the incidences of volume depletion AEs and genital mycotic infection were higher with ertugliflozin than with non-ertugliflozin. CONCLUSIONS Ertugliflozin improved glycaemic control, BW and SBP in younger and older individuals with T2DM and was generally well tolerated in both groups. This article is protected by copyright. All rights reserved.",2020,"In patients aged ≥65 years, the incidences of volume depletion AEs and genital mycotic infection were higher with ertugliflozin than with non-ertugliflozin. ","['younger and older individuals with T2DM', 'older patients with type 2 diabetes mellitus', 'patients with T2DM aged <65 and ≥65\u2009years who participated', 'participants aged <65\u2009years, the placebo-adjusted mean changes from baseline in HbA1c, BW and SBP with ertugliflozin 5 mg and 15 mg at Week 26 were: -0.9% and -1.0%; -1.9 kg and -1.8 kg; and -3.7\u2009mmHg and -3.6\u2009mmHg, respectively; in participants aged ≥65\u2009years they were', 'older patients with type 2 diabetes (T2DM']","['ertugliflozin', 'placebo-controlled studies (ertugliflozin monotherapy', 'Ertugliflozin']","['glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight (BW) and systolic blood pressure (SBP', 'volume depletion AEs and genital mycotic infection', 'overall and prespecified adverse events (AEs', 'Efficacy and safety', 'efficacy and safety', 'Efficacy', 'glycaemic control, BW and SBP', 'incidences of AEs, serious AEs, discontinuations and deaths']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C4535679', 'cui_str': 'ertugliflozin 5 MG'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4068881', 'cui_str': '0.9'}, {'cui': 'C4517517', 'cui_str': '1.9'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C4517696', 'cui_str': '3.7'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C4517694', 'cui_str': '3.6'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C4079805', 'cui_str': 'ertugliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0546884', 'cui_str': 'Hypovolemia'}, {'cui': 'C0017420', 'cui_str': 'Reproductive System'}, {'cui': 'C0026946', 'cui_str': 'Mycosis'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",,0.175419,"In patients aged ≥65 years, the incidences of volume depletion AEs and genital mycotic infection were higher with ertugliflozin than with non-ertugliflozin. ","[{'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Pratley', 'Affiliation': 'AdventHealth Translational Research Institute for Metabolism and Diabetes, Orlando, FL, USA.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Dagogo-Jack', 'Affiliation': 'University of Tennessee Health Science Center, Memphis, TN, USA.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Charbonnel', 'Affiliation': 'University of Nantes, Nantes, France.'}, {'ForeName': 'Shrita', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Hickman', 'Affiliation': 'Pfizer Inc., Groton, CT, USA.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Tarasenko', 'Affiliation': 'Pfizer Inc., New York, NY, USA.'}, {'ForeName': 'Annpey', 'Initials': 'A', 'LastName': 'Pong', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Misoo C', 'Initials': 'MC', 'LastName': 'Ellison', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Huyck', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Ira', 'Initials': 'I', 'LastName': 'Gantz', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Steven G', 'Initials': 'SG', 'LastName': 'Terra', 'Affiliation': 'Pfizer Inc., Andover, MA, USA.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14150'] 2458,32701012,"Novel Cross-Linked Ocular Bandage Gel Improves Reepithelialization After Photorefractive Keratectomy: A Randomized, Masked Prospective Study.","Purpose: To compare, in a masked manner, a novel cross-linked hyaluronic acid ocular bandage gel (OBG) versus standard-of-care bandage contact lens (BCL) plus artificial tears with respect to safety and effectiveness in healing epithelial defects created for photorefractive keratectomy (PRK). Methods: This was a randomized, reading center-masked, exploratory study. Forty-five patients (myopic without significant anisometropia) scheduled for bilateral PRK (9-mm epithelial defect) were randomized post-PRK to treatment with OBG 8 times daily for 3 days, followed by 4 times daily for 11 days (Group 1); OBG 4 times daily for 14 days (Group 2); or BCL and artificial tears (Control). A masked reading center used image analysis of digital slit lamp photos of the fluorescein-stained cornea to evaluate defect size during the 14-day postoperative follow-up period. Effectiveness endpoints were (1) time to complete closure of the corneal defect and (2) proportion of patients with complete healing on day 3 postoperatively, whose defect remained closed. Safety assessments included findings for adverse events and vision, Standard Patient Evaluation of Eye Dryness (SPEED ™ ) Questionnaire, slit lamp, intraocular pressure, and fundus examinations. Results: The proportion of patients with complete healing at 3 days was 73.3%, 86.7%, and 66.7% of patients in Groups 1, 2, and Control, respectively. On day 2, the mean wound size was 6%-26% smaller in Groups 1 and 2 compared with Control. No safety concern arose. SPEED scores were not significantly different across groups. Conclusion: OBG offers a well-tolerated and effective therapy for quickly reepithelializing the cornea following trauma, disease, or surgery.",2020,"On day 2, the mean wound size was 6%-26% smaller in Groups 1 and 2 compared with Control.","['Forty-five patients (myopic without significant anisometropia) scheduled for bilateral PRK (9-mm epithelial defect', 'After Photorefractive Keratectomy']","['OBG', 'hyaluronic acid ocular bandage gel (OBG) versus standard-of-care bandage contact lens (BCL) plus artificial tears', 'Novel Cross-Linked Ocular Bandage Gel Improves Reepithelialization']","['proportion of patients with complete healing', 'Effectiveness endpoints were (1) time to complete closure of the corneal defect and (2) proportion of patients with complete healing', 'SPEED scores', 'adverse events and vision, Standard Patient Evaluation of Eye Dryness (SPEED ™ ) Questionnaire, slit lamp, intraocular pressure, and fundus examinations', 'mean wound size']","[{'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027092', 'cui_str': 'Myopia'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0003081', 'cui_str': 'Anisometropia'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0022772', 'cui_str': ""Democratic people's republic of Korea""}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0395416', 'cui_str': 'Refractive keratoplasty by laser surgery'}]","[{'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0004726', 'cui_str': 'Bandage'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2608262', 'cui_str': 'Artificial Tears'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0332220', 'cui_str': 'Cross-linking'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0948085', 'cui_str': 'Corneal defect'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0314719', 'cui_str': 'Dry eyes'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0183355', 'cui_str': 'Slit lamp biomicroscope'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0016823', 'cui_str': 'Structure of fundus of eye'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0456389', 'cui_str': 'Size'}]",45.0,0.061894,"On day 2, the mean wound size was 6%-26% smaller in Groups 1 and 2 compared with Control.","[{'ForeName': 'Darcy', 'Initials': 'D', 'LastName': 'Wolsey', 'Affiliation': 'The Eye Institute of Utah, Salt Lake City, Utah, USA.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Slade', 'Affiliation': 'Slade & Baker Vision Center, Houston, Texas, USA.'}, {'ForeName': 'Barbara M', 'Initials': 'BM', 'LastName': 'Wirostko', 'Affiliation': 'EyeGate Pharmaceuticals, Inc., Salt Lake City, Utah, USA.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Brandano', 'Affiliation': 'EyeGate Pharmaceuticals, Inc., Waltham, Massachusetts, USA.'}, {'ForeName': 'Brenda K', 'Initials': 'BK', 'LastName': 'Mann', 'Affiliation': 'EyeGate Pharmaceuticals, Inc., Salt Lake City, Utah, USA.'}, {'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Durrie', 'Affiliation': 'Durrie Vision, Overland Park, Kansas, USA.'}, {'ForeName': 'Vance', 'Initials': 'V', 'LastName': 'Thompson', 'Affiliation': 'Vance Thompson Vision, Sioux Falls, South Dakota, USA.'}]",Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics,['10.1089/jop.2019.0156'] 2459,32701013,Novel serum peptide model revealed by MALDI-TOF-MS and its diagnostic value in early bladder cancer.,"BACKGROUND Bladder cancer is the ninth most common cancer worldwide and has high morbidity and mortality. We aimed to search for potential serum peptide biomarkers and establish a diagnostic model for early bladder cancer. METHODS A total of 67 bladder cancer patients and 64 healthy volunteers were randomly divided into a training set and testing set 1. There were 30 hematuria patients used as testing set 2. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry based on weak cation exchange magnetic beads was used to obtain and analyze the serum peptide profiles between bladder cancer patients and healthy volunteers in the training set. Serum peptide diagnostic model through a k-nearest neighbor algorithm, was established and validated, and significantly differentially expressed protein biomarkers were ultimately identified. RESULTS We constructed a diagnostic model containing five peptides (m/z 1954.9, m/z 2081.0, m/z 3938.3, m/z 3946.5, and m/z 4268.8). In the training set, the area under the curve (AUC) value of the five-peptide model was 0.923, and the sensitivity and specificity was 93.75% and 96.77%, respectively. In testing set 1, the sensitivity and specificity was 91.43% and 90.91%, respectively, and the specificity of testing set 2 was 73.33%. For early-stage bladder cancer, the sensitivity and specificity was 92.31% and 93.75%, respectively; the sensitivity of early low-grade bladder cancer was 90.00%; and the AUC value was 0.944. CONCLUSION The five-peptide diagnostic model established in this study had high sensitivity and specificity, especially in the diagnosis of early bladder cancer, and could differentiate between healthy volunteers and hematuria patients.",2020,"The five-peptide diagnostic model established in this study had high sensitivity and specificity, especially in the diagnosis of early bladder cancer, and could differentiate between healthy volunteers and hematuria patients.","['early bladder cancer', 'bladder cancer patients and healthy volunteers', 'healthy volunteers and hematuria patients', '67 bladder cancer patients and 64 healthy volunteers', '30 hematuria patients']",['Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry'],"['sensitivity and specificity', 'Serum peptide diagnostic model', 'sensitivity of early low-grade bladder cancer']","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0005684', 'cui_str': 'Malignant tumor of urinary bladder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0018965', 'cui_str': 'Blood in urine'}]","[{'cui': 'C1518101', 'cui_str': 'Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry'}]","[{'cui': 'C0036668', 'cui_str': 'Sensitivity and Specificity'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C1962916', 'cui_str': 'Low grade (lymphoma)'}, {'cui': 'C0005684', 'cui_str': 'Malignant tumor of urinary bladder'}]",67.0,0.0223575,"The five-peptide diagnostic model established in this study had high sensitivity and specificity, especially in the diagnosis of early bladder cancer, and could differentiate between healthy volunteers and hematuria patients.","[{'ForeName': 'Dapeng', 'Initials': 'D', 'LastName': 'Ding', 'Affiliation': 'Department of Clinical Laboratory, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.'}, {'ForeName': 'Mingying', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': 'Department of Clinical Laboratory, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.'}, {'ForeName': 'Xiaoguang', 'Initials': 'X', 'LastName': 'Xiao', 'Affiliation': 'Department of Clinical Laboratory, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.'}, {'ForeName': 'Penglong', 'Initials': 'P', 'LastName': 'Cao', 'Affiliation': 'Department of Clinical Laboratory, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.'}, {'ForeName': 'Shijun', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Department of Clinical Laboratory, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.'}]",The International journal of biological markers,['10.1177/1724600820935473'] 2460,32701116,Effect of febuxostat on renal function in patients from South China with CKD3 diabetic nephropathy.,"OBJECTIVE To investigate the efficacy and safety of febuxostat on renal function in CKD stage 3 diabetic nephropathy patients. METHODS Patients in our hospital with chronic kidney disease (CKD) stage 3 diabetic nephropathy (DN) complicated by high serum uric acid (360 µmol/L) were recruited. Patients were then divided into treatment group and control group according to the random number table method. All the patients received low purine diet, renin-angiotensin-aldosterone system (RAAS) inhibitors, and adequate routine hypoglycemic treatment. Febuxostat was employed only in the treatment group. The levels of blood uric acid (sUA), serum creatinine (Scr), cystatin C (cys-c), eGFR, 24-hour urine protein quantification, albuminuria, and creatinine ratio (ACR) were evaluated in all patients before and after treatment at 4, 8, 12, and 24 week. RESULTS No difference was found before treatment between the two groups. After treatment at 4, 8, 12, and 24 week, the levels of sUA, SCr, cys-c, and eGFR between the two groups were significant different (P<0.05). There was no difference in 24-hour urine protein quantification, albuminuria, and creatinine ratio between two groups before treatment, and significant differences were observed after treatment. Fifty percent of patients from the treatment group achieved the treatment goal with 20 mg febuxostat at 4 weeks. Tubular markers were also decreased with the treatment. CONCLUSIONS Febuxostat can reduce uric acid and improve renal function effectively in patients with CKD stage 3 diabetic nephropathy, while being well tolerated. However, the conclusion is still uncertain due to the short term of the study.",2020,"There was no difference in 24-hour urine protein quantification, albuminuria, and creatinine ratio between two groups before treatment, and significant differences were observed after treatment.","['patients with CKD stage 3 diabetic nephropathy', 'Patients in our hospital with chronic kidney disease (CKD) stage 3 diabetic nephropathy (DN) complicated by high serum uric acid (360 µmol/L) were recruited', 'patients from South China with CKD3 diabetic nephropathy', 'CKD stage 3 diabetic nephropathy patients']","['Febuxostat', 'low purine diet, renin-angiotensin-aldosterone system (RAAS) inhibitors', 'febuxostat']","['renal function', '24-hour urine protein quantification, albuminuria, and creatinine ratio', 'levels of blood uric acid (sUA), serum creatinine (Scr), cystatin C (cys-c), eGFR, 24-hour urine protein quantification, albuminuria, and creatinine ratio (ACR', 'levels of sUA, SCr, cys-c, and eGFR', 'Tubular markers', 'efficacy and safety', 'renal function effectively']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2316787', 'cui_str': 'Chronic kidney disease stage 3'}, {'cui': 'C0011881', 'cui_str': 'Kidney disorder due to diabetes mellitus'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C0455272', 'cui_str': 'Serum urate measurement'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0249529', 'cui_str': 'febuxostat'}, {'cui': 'C0452275', 'cui_str': 'Purine restricted diet'}, {'cui': 'C0086907', 'cui_str': 'Renin-Angiotensin-Aldosterone System'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C1254855', 'cui_str': 'Protein urine 24 hour'}, {'cui': 'C0001925', 'cui_str': 'Albuminuria'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0373739', 'cui_str': 'Blood uric acid'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0071744', 'cui_str': 'Cystatin C'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0332208', 'cui_str': 'Tubular'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0139044,"There was no difference in 24-hour urine protein quantification, albuminuria, and creatinine ratio between two groups before treatment, and significant differences were observed after treatment.","[{'ForeName': 'Huang', 'Initials': 'H', 'LastName': 'Wen', 'Affiliation': 'Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Department of Nephrology, Wenzhou, China.'}, {'ForeName': 'Zhu', 'Initials': 'Z', 'LastName': 'Yongling', 'Affiliation': ""Wenzhou City Second People's Hospital, Hematological Department, Wenzhou City, China.""}, {'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Shuying', 'Affiliation': 'Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Department of Nephrology, Wenzhou, China.'}, {'ForeName': 'Wang', 'Initials': 'W', 'LastName': 'Jiali', 'Affiliation': 'Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Department of Nephrology, Wenzhou, China.'}, {'ForeName': 'Zhao', 'Initials': 'Z', 'LastName': 'Yanling', 'Affiliation': 'Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Department of Nephrology, Wenzhou, China.'}]",Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia,['10.1590/2175-8239-JBN-2019-0091'] 2461,32701129,Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.,"Importance The role of locoregional radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma (mNPC) is unclear. Objective To investigate the efficacy and safety of locoregional radiotherapy in de novo mNPC. Design, Setting, and Participants Patients with biopsy-proven mNPC, who demonstrated complete or partial response (RECIST v1.1) following 3 cycles of cisplatin and fluorouracil chemotherapy, were enrolled. Eligible patients were randomly assigned (1:1) to receive either chemotherapy plus radiotherapy or chemotherapy alone. Overall, 126 of 173 patients screened were eligible to the study, and randomized to chemotherapy plus radiotherapy (n = 63) or chemotherapy alone (n = 63). Median (IQR) follow-up duration was 26.7 (17.2-33.5) months. Interventions The chemotherapy regimens were fluorouracil continuous intravenous infusion at 5 g/m2 over 120 hours and 100 mg/m2 intravenous cisplatin on day 1, administered every 3 weeks for 6 cycles. Patients assigned to the chemotherapy plus radiotherapy group received intensity-modulated radiotherapy (IMRT) after chemotherapy. Main Outcomes and Measures The primary end point of the study was overall survival (OS). The secondary end point was progression-free survival (PFS) and safety. Results Overall, 126 patients were enrolled (105 men [83.3%] and 21 women [16.7%]; median [IQR] age, 46 [39-52] years). The 24-month OS was 76.4% (95% CI, 64.4%-88.4%) in the chemotherapy plus radiotherapy group, compared with 54.5% (95% CI, 41.0%-68.0%) in the chemotherapy-alone group. The study met its primary end point of improved OS (stratified hazard ratio [HR], 0.42; 95% CI, 0.23-0.77; P = .004) in favor of chemotherapy plus radiotherapy. Progression-free survival was also improved in the chemotherapy plus radiotherapy group compared with the chemotherapy-alone group (stratified HR, 0.36; 95% CI, 0.23-0.57). No significant differences in acute hematological or gastrointestinal toxic effects were observed between the treatment arms. The frequency of acute grade 3 or higher dermatitis, mucositis, and xerostomia was 8.1%, 33.9%, and 6.5%, respectively, in the chemotherapy plus radiotherapy group. The frequency of late severe grade 3 or higher hearing loss and trismus was 5.2% and 3.4%, respectively, in the chemotherapy plus radiotherapy group. Conclusions and Relevance In this randomized clinical trial, radiotherapy added to chemotherapy significantly improved OS in chemotherapy-sensitive patients with mNPC. Trial Registration ClinicalTrials.gov Identifier: NCT02111460.",2020,"The 24-month OS was 76.4% (95% CI, 64.4%-88.4%) in the chemotherapy plus radiotherapy group, compared with 54.5% (95% CI, 41.0%-68.0%) in the chemotherapy-alone group.","['De Novo Metastatic Nasopharyngeal Carcinoma', '126 patients were enrolled (105 men [83.3%] and 21 women [16.7%]; median [IQR] age, 46 [39-52] years', 'Participants\n\n\nPatients with biopsy-proven mNPC, who demonstrated complete or partial response (RECIST v1.1) following 3 cycles of', 'chemotherapy-sensitive patients with mNPC', '126 of 173 patients screened were eligible to the study, and randomized to', 'patients with de novo metastatic nasopharyngeal carcinoma (mNPC', 'Eligible patients']","['locoregional radiotherapy', 'chemotherapy plus radiotherapy', 'chemotherapy plus radiotherapy or chemotherapy alone', 'radiotherapy', 'Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone', 'cisplatin', 'cisplatin and fluorouracil chemotherapy', 'chemotherapy alone', 'intensity-modulated radiotherapy (IMRT) after chemotherapy', 'chemotherapy']","['progression-free survival (PFS) and safety', 'Efficacy and Safety', '24-month OS', 'OS', 'frequency of acute grade 3 or higher dermatitis, mucositis, and xerostomia', 'Median (IQR) follow-up duration', 'frequency of late severe grade 3 or higher hearing loss and trismus', 'overall survival (OS', 'Progression-free survival', 'acute hematological or gastrointestinal toxic effects']","[{'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C2931822', 'cui_str': 'Nasopharyngeal carcinoma'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517590', 'cui_str': '16.7'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C1709926', 'cui_str': 'RECIST'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0011603', 'cui_str': 'Dermatitis'}, {'cui': 'C0333355', 'cui_str': 'Inflammatory disease of mucous membrane'}, {'cui': 'C0043352', 'cui_str': 'Xerostomia'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0041105', 'cui_str': 'Trismus'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}]",126.0,0.264303,"The 24-month OS was 76.4% (95% CI, 64.4%-88.4%) in the chemotherapy plus radiotherapy group, compared with 54.5% (95% CI, 41.0%-68.0%) in the chemotherapy-alone group.","[{'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'You', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'You-Ping', 'Initials': 'YP', 'LastName': 'Liu', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Pei-Yu', 'Initials': 'PY', 'LastName': 'Huang', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Xiong', 'Initials': 'X', 'LastName': 'Zou', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Sun', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Yu-Xiang', 'Initials': 'YX', 'LastName': 'He', 'Affiliation': 'Department of Radiation Oncology, Xiangya Hospital of Central South University, Changsha, China.'}, {'ForeName': 'Yi-Shan', 'Initials': 'YS', 'LastName': 'Wu', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Guo-Ping', 'Initials': 'GP', 'LastName': 'Shen', 'Affiliation': 'Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.'}, {'ForeName': 'Hong-Dan', 'Initials': 'HD', 'LastName': 'Zhang', 'Affiliation': ""Department of Radiation Oncology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Science, Guangzhou 510080, China.""}, {'ForeName': 'Chong-Yang', 'Initials': 'CY', 'LastName': 'Duan', 'Affiliation': 'Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, 510515, China.'}, {'ForeName': 'Sze Huey', 'Initials': 'SH', 'LastName': 'Tan', 'Affiliation': 'Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore.'}, {'ForeName': 'Jing-Yu', 'Initials': 'JY', 'LastName': 'Cao', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Ji-Bin', 'Initials': 'JB', 'LastName': 'Li', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine.'}, {'ForeName': 'Yu-Long', 'Initials': 'YL', 'LastName': 'Xie', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Yi-Nuan', 'Initials': 'YN', 'LastName': 'Zhang', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Zhi-Qiang', 'Initials': 'ZQ', 'LastName': 'Wang', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Yang', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Lin', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Rou', 'Initials': 'R', 'LastName': 'Jiang', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Meng-Xia', 'Initials': 'MX', 'LastName': 'Zhang', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Yi-Jun', 'Initials': 'YJ', 'LastName': 'Hua', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Lin-Quan', 'Initials': 'LQ', 'LastName': 'Tang', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Ai-Hua', 'Initials': 'AH', 'LastName': 'Zhuang', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine.'}, {'ForeName': 'Qiu-Yan', 'Initials': 'QY', 'LastName': 'Chen', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Guo', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Hao-Yuan', 'Initials': 'HY', 'LastName': 'Mo', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.'}, {'ForeName': 'Hai-Qiang', 'Initials': 'HQ', 'LastName': 'Mai', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Ling', 'Affiliation': 'Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Liu', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine.'}, {'ForeName': 'Melvin Lee Kiang', 'Initials': 'MLK', 'LastName': 'Chua', 'Affiliation': 'Division of Radiation Oncology and Medical Sciences, National Cancer Centre Singapore, 169610, Singapore.'}, {'ForeName': 'Ming-Yuan', 'Initials': 'MY', 'LastName': 'Chen', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}]",JAMA oncology,['10.1001/jamaoncol.2020.1808'] 2462,32697476,The Effect of Sunflower Seed and Almond Oil on Preterm Infant Skin: A Randomized Controlled Trial.,"OBJECTIVE To investigate the effect of sunflower seed oil (SSO) and almond oil (AO) on stratum corneum hydration and Neonatal Skin Condition Scores (NSCSs) of preterm infants. METHODS This randomized controlled trial recruited 90 preterm infants whose gestational ages were between 32 and 37 weeks in the neonatal ICU. Infants were randomly assigned to three groups (SSO, AO, or control). The oils were applied to the whole body of each infant except for the head and face by a nurse researcher four times a day (4 mL/kg) for 5 days. MAIN OUTCOME MEASURES Skin condition of the infants as evaluated with the NSCS; hydration as measured by a skin moisture meter before and after application. MAIN RESULTS When average stratum corneum hydration was compared, infants in the SSO and AO groups had better hydration than infants in the control group. The NSCS scores in the control group were significantly higher than in the intervention groups, but there was no difference between the SSO and AO groups. CONCLUSIONS Neither SSO nor AO has harmful effects on the skin, and their use may improve stratum corneum hydration. These oils can be used by nurses to hydrate the skin of preterm infants. Further studies are needed to evaluate the efficacy of natural oils on infant skin.",2020,"The NSCS scores in the control group were significantly higher than in the intervention groups, but there was no difference between the SSO and AO groups. ","['90 preterm infants whose gestational ages were between 32 and 37 weeks in the neonatal ICU', 'preterm infants', 'Preterm Infant Skin']","['Sunflower Seed and Almond Oil', 'sunflower seed oil (SSO) and almond oil (AO']","['skin moisture meter', 'stratum corneum hydration and Neonatal Skin Condition Scores (NSCSs', 'NSCS scores']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}]","[{'cui': 'C0947381', 'cui_str': 'Helianthus annuus'}, {'cui': 'C0036563', 'cui_str': 'Plant seeds'}, {'cui': 'C0102271', 'cui_str': 'almond oil'}, {'cui': 'C0028908', 'cui_str': 'Oil'}]","[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0441074', 'cui_str': 'Meters'}, {'cui': 'C0221921', 'cui_str': 'Stratum corneum structure'}, {'cui': 'C1321013', 'cui_str': 'Hydration status'}, {'cui': 'C1274236', 'cui_str': 'Neonatal dermatosis'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",90.0,0.037843,"The NSCS scores in the control group were significantly higher than in the intervention groups, but there was no difference between the SSO and AO groups. ","[{'ForeName': 'Seda', 'Initials': 'S', 'LastName': 'Caglar', 'Affiliation': 'Seda Caglar, PhD, RN, is Associate Professor, Pediatric Nursing Department, Florence Nightingale Faculty of Nursing, İstanbul University-Cerrahpaşa, İstanbul, Turkey. Gizem Kerimoglu Yildiz, PhD, RN, is Assistant Professor, Hatay School of Health, Hatay Mustafa Kemal University. Ilkay Bakoglu, RN, is Clinical Nurse, and Ozgul Salihoglu, MD, is Associate Professor, Neonatal Intensive Care Unit, Bakirköy Dr. Sadi Konuk Training and Research Hospital, İstanbul. The authors have disclosed no financial relationships related to this article. Submitted August 8, 2019; accepted in revised form October 2, 2019.'}, {'ForeName': 'Gizem Kerimoglu', 'Initials': 'GK', 'LastName': 'Yildiz', 'Affiliation': ''}, {'ForeName': 'Ilkay', 'Initials': 'I', 'LastName': 'Bakoglu', 'Affiliation': ''}, {'ForeName': 'Ozgul', 'Initials': 'O', 'LastName': 'Salihoglu', 'Affiliation': ''}]",Advances in skin & wound care,['10.1097/01.ASW.0000672500.18525.2e'] 2463,32697482,Potential for Lung Recruitment and Ventilation-Perfusion Mismatch in Patients With the Acute Respiratory Distress Syndrome From Coronavirus Disease 2019.,"OBJECTIVES Severe cases of coronavirus disease 2019 develop the acute respiratory distress syndrome, requiring admission to the ICU. This study aimed to describe specific pathophysiological characteristics of acute respiratory distress syndrome from coronavirus disease 2019. DESIGN Prospective crossover physiologic study. SETTING ICU of a university-affiliated hospital from northern Italy dedicated to care of patients with confirmed diagnosis of coronavirus disease 2019. PATIENTS Ten intubated patients with acute respiratory distress syndrome and confirmed diagnosis of coronavirus disease 2019. INTERVENTIONS We performed a two-step positive end-expiratory pressure trial with change of 10 cm H2O in random order. MEASUREMENTS AND MAIN RESULTS At each positive end-expiratory pressure level, we assessed arterial blood gases, respiratory mechanics, ventilation inhomogeneity, and potential for lung recruitment by electrical impedance tomography. Potential for lung recruitment was assessed by the recently described recruitment to inflation ratio. In a subgroup of seven paralyzed patients, we also measured ventilation-perfusion mismatch at lower positive end-expiratory pressure by electrical impedance tomography. At higher positive end-expiratory pressure, respiratory mechanics did not change significantly: compliance remained relatively high with low driving pressure. Oxygenation and ventilation inhomogeneity improved but arterial CO2 increased despite unchanged respiratory rate and tidal volume. The recruitment to inflation ratio presented median value higher than previously reported in acute respiratory distress syndrome patients but with large variability (median, 0.79 [0.53-1.08]; range, 0.16-1.40). The FIO2 needed to obtain viable oxygenation at lower positive end-expiratory pressure was significantly correlated with the recruitment to inflation ratio (r = 0.603; p = 0.05). The ventilation-perfusion mismatch was elevated (median, 34% [32-45%] of lung units) and, in six out of seven patients, ventilated nonperfused units represented a much larger proportion than perfused nonventilated ones. CONCLUSIONS In patients with acute respiratory distress syndrome from coronavirus disease 2019, potential for lung recruitment presents large variability, while elevated dead space fraction may be a specific pathophysiological trait. These findings may guide selection of personalized mechanical ventilation settings.",2020,"At higher positive end-expiratory pressure, respiratory mechanics did not change significantly: compliance remained relatively high with low driving pressure.","['acute respiratory distress syndrome from coronavirus disease 2019', 'Patients With the Acute Respiratory Distress Syndrome From Coronavirus Disease 2019', 'patients with acute respiratory distress syndrome', 'ICU of a university-affiliated hospital from northern Italy dedicated to care of patients with confirmed diagnosis of coronavirus disease 2019', 'Severe cases of coronavirus disease 2019 develop the acute respiratory distress syndrome, requiring admission to the ICU', 'Ten intubated patients with acute respiratory distress syndrome and confirmed diagnosis of coronavirus disease 2019']",['Lung Recruitment and Ventilation-Perfusion Mismatch'],"['respiratory rate and tidal volume', 'ventilation-perfusion mismatch', 'arterial blood gases, respiratory mechanics, ventilation inhomogeneity, and potential for lung recruitment by electrical impedance tomography']","[{'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C2721740', 'cui_str': 'Ventilation perfusion mismatch'}]","[{'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C2721740', 'cui_str': 'Ventilation perfusion mismatch'}, {'cui': 'C0150411', 'cui_str': 'Analysis of arterial blood gases and pH'}, {'cui': 'C0035230', 'cui_str': 'Breathing Mechanics'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0162537', 'cui_str': 'Impedance'}, {'cui': 'C0040395', 'cui_str': 'Diagnostic tomography'}]",10.0,0.127794,"At higher positive end-expiratory pressure, respiratory mechanics did not change significantly: compliance remained relatively high with low driving pressure.","[{'ForeName': 'Tommaso', 'Initials': 'T', 'LastName': 'Mauri', 'Affiliation': ""1Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. 2Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.""}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Spinelli', 'Affiliation': ''}, {'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Scotti', 'Affiliation': ''}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Colussi', 'Affiliation': ''}, {'ForeName': 'Maria Cristina', 'Initials': 'MC', 'LastName': 'Basile', 'Affiliation': ''}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Crotti', 'Affiliation': ''}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Tubiolo', 'Affiliation': ''}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Tagliabue', 'Affiliation': ''}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Zanella', 'Affiliation': ''}, {'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Grasselli', 'Affiliation': ''}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Pesenti', 'Affiliation': ''}]",Critical care medicine,['10.1097/CCM.0000000000004386'] 2464,32697484,Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy.,"OBJECTIVES To assess the effects of recombinant human soluble thrombomodulin treatment on 28-day all-cause mortality in subgroups categorized by baseline coagulation biomarker levels (prothrombin fragment 1.2, thrombin-antithrombin complex, D-dimer) in patients with sepsis-associated coagulopathy in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial (SCARLET) (NCT01598831). DESIGN Post hoc, subgroup analysis of a randomized, double-blind, placebo-controlled, multinational, multicenter phase 3 study. SETTING ICUs at 159 sites in 26 countries. PATIENTS Eight-hundred adults with sepsis-associated coagulopathy defined as international normalized ratio greater than 1.40 and platelet count between 30 × 10/L and 150 × 10/L or greater than 30% decrease within 24 hours with concomitant cardiovascular and/or respiratory failure. INTERVENTIONS Patients randomized and treated with recombinant human soluble thrombomodulin (0.06 mg/kg/d; n = 395) or equivalent placebo (n = 405) for 6 days. MEASUREMENTS AND MAIN RESULTS Recombinant human soluble thrombomodulin did not significantly reduce 28-day all-cause mortality in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial: absolute risk reduction was 2.55% (p = 0.32) in patients with sepsis-associated coagulopathy. In this post hoc analysis, mortality steadily increased with increasing baseline prothrombin fragment 1.2 and thrombin-antithrombin complex levels in the placebo group; for those values exceeding the upper limit of normal, the mortality increases in the recombinant human soluble thrombomodulin group were lower or negligible with increasing baseline prothrombin fragment 1.2 and thrombin-antithrombin complex. Consequently, absolute risk reductions were greater in subgroups with higher baseline prothrombin fragment 1.2 or thrombin-antithrombin complex. Absolute risk reductions were also greater in subgroups with baseline coagulation biomarker levels at or above median of the entire study population, ranging from 4.2% (95% CI, -5.0% to 13.4%) to 5.5% (95% CI, -4.0% to 14.9%). CONCLUSIONS Compared with patients receiving placebo, patients treated with recombinant human soluble thrombomodulin having higher baseline thrombin generation biomarker levels had lower mortality. Further research regarding the predictive role of coagulation biomarkers for recombinant human soluble thrombomodulin treatment response in sepsis-associated coagulopathy is warranted to evaluate clinical relevance.",2020,Recombinant human soluble thrombomodulin did not significantly reduce 28-day all-cause mortality in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial: absolute risk reduction was 2.55% (p = 0.32) in patients with sepsis-associated coagulopathy.,"['patients with sepsis-associated coagulopathy in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial (SCARLET) (NCT01598831', 'Patients With Sepsis-Associated Coagulopathy', 'ICUs at 159 sites in 26 countries', 'Eight-hundred adults with sepsis-associated coagulopathy defined as international normalized ratio greater than 1.40 and platelet count between 30 × 10/L and 150 × 10/L or greater than 30% decrease within 24 hours with concomitant cardiovascular and/or respiratory failure']","['equivalent placebo', 'Recombinant Human Soluble Thrombomodulin', 'recombinant human soluble thrombomodulin', 'recombinant human soluble thrombomodulin treatment', 'Recombinant human soluble thrombomodulin', 'placebo']","['Baseline Coagulation Biomarker Levels and Mortality Outcome', 'Absolute risk reductions', 'absolute risk reductions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0005779', 'cui_str': 'Blood coagulation disorder'}, {'cui': 'C0145779', 'cui_str': 'Thrombomodulin'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0525032', 'cui_str': 'International normalized ratio'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}]","[{'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0145779', 'cui_str': 'Thrombomodulin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C3179139', 'cui_str': 'Absolute Risk Reduction'}]",800.0,0.39019,Recombinant human soluble thrombomodulin did not significantly reduce 28-day all-cause mortality in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial: absolute risk reduction was 2.55% (p = 0.32) in patients with sepsis-associated coagulopathy.,"[{'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Levi', 'Affiliation': '1Department of Medicine and Cardiometabolic Programme - NIHR UCLH/UCL BRC, University College London Hospitals NHS Trust, London, United Kingdom. 2Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. 3Asahi Kasei Pharma America Corporation, Waltham, MA. 4Loyola University Medical Center, Maywood, IL.'}, {'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'Vincent', 'Affiliation': ''}, {'ForeName': 'Kosuke', 'Initials': 'K', 'LastName': 'Tanaka', 'Affiliation': ''}, {'ForeName': 'Amanda H', 'Initials': 'AH', 'LastName': 'Radford', 'Affiliation': ''}, {'ForeName': 'Toshihiko', 'Initials': 'T', 'LastName': 'Kayanoki', 'Affiliation': ''}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Fineberg', 'Affiliation': ''}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Hoppensteadt', 'Affiliation': ''}, {'ForeName': 'Jawed', 'Initials': 'J', 'LastName': 'Fareed', 'Affiliation': ''}]",Critical care medicine,['10.1097/CCM.0000000000004426'] 2465,31292301,Changes in plasma lipids predict pravastatin efficacy in secondary prevention.,"BACKGROUNDStatins have pleiotropic effects on lipid metabolism. The relationship between these effects and future cardiovascular events is unknown. We characterized the changes in lipids upon pravastatin treatment and defined the relationship with risk reduction for future cardiovascular events.METHODSPlasma lipids (n = 342) were measured in baseline and 1-year follow-up samples from a Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study subcohort (n = 4991). The associations of changes in lipids with treatment and cardiovascular outcomes were investigated using linear and Cox regression. The effect of treatment on future cardiovascular outcomes was examined by the relative risk reduction (RRR).RESULTSPravastatin treatment was associated with changes in 206 lipids. Species containing arachidonic acid were positively associated while phosphatidylinositol species were negatively associated with pravastatin treatment. The RRR from pravastatin treatment for cardiovascular events decreased from 23.5% to 16.6% after adjustment for clinical risk factors and change in LDL-cholesterol (LDL-C) and to 3.0% after further adjustment for the change in the lipid ratio PI(36:2)/PC(38:4). Change in PI(36:2)/PC(38:4) mediated 58% of the treatment effect. Stratification of patients into quartiles of change in PI(36:2)/PC(38:4) indicated no benefit of pravastatin in the fourth quartile.CONCLUSIONThe change in PI(36:2)/PC(38:4) predicted benefit from pravastatin, independent of change in LDL-C, demonstrating its potential as a biomarker for monitoring the clinical benefit of statin treatment in secondary prevention.TRIAL REGISTRATIONAustralian New Zealand Clinical Trials Registry identifier ACTRN12616000535471.FUNDINGBristol-Myers Squibb; NHMRC grants 211086, 358395, and 1029754; NHMRC program grant 1149987; NHMRC fellowship 108026; and the Operational Infrastructure Support Program of the Victorian government of Australia.",2019,The RRR from pravastatin treatment for cardiovascular events decreased from 23.5% to 16.6% after adjustment for clinical risk factors and change in LDL-cholesterol (LDL-C) and to 3.0% after further adjustment for the change in the lipid ratio PI(36:2)/PC(38:4).,['in Ischaemic Disease (LIPID) study subcohort (n = 4991'],"['Pravastatin', 'pravastatin']","['LDL-cholesterol (LDL-C', 'cardiovascular events', 'phosphatidylinositol species', 'relative risk reduction']","[{'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0085542', 'cui_str': 'Pravastatin'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0085542', 'cui_str': 'Pravastatin'}]","[{'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0031621', 'cui_str': 'Phosphatidylinositols'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",342.0,0.0268361,The RRR from pravastatin treatment for cardiovascular events decreased from 23.5% to 16.6% after adjustment for clinical risk factors and change in LDL-cholesterol (LDL-C) and to 3.0% after further adjustment for the change in the lipid ratio PI(36:2)/PC(38:4).,"[{'ForeName': 'Kaushala S', 'Initials': 'KS', 'LastName': 'Jayawardana', 'Affiliation': 'Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Piyushkumar A', 'Initials': 'PA', 'LastName': 'Mundra', 'Affiliation': 'Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Corey', 'Initials': 'C', 'LastName': 'Giles', 'Affiliation': 'Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Christopher K', 'Initials': 'CK', 'LastName': 'Barlow', 'Affiliation': 'Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Nestel', 'Affiliation': 'Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Elizabeth H', 'Initials': 'EH', 'LastName': 'Barnes', 'Affiliation': 'National Health and Medical Research Council of Australia (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'Kirby', 'Affiliation': 'National Health and Medical Research Council of Australia (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Thompson', 'Affiliation': 'Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Sullivan', 'Affiliation': 'Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.'}, {'ForeName': 'Zahir H', 'Initials': 'ZH', 'LastName': 'Alshehry', 'Affiliation': 'Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Natalie A', 'Initials': 'NA', 'LastName': 'Mellett', 'Affiliation': 'Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Huynh', 'Affiliation': 'Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Malcolm J', 'Initials': 'MJ', 'LastName': 'McConville', 'Affiliation': 'Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, Australia.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Zoungas', 'Affiliation': 'The George Institute for Global Health, Sydney, New South Wales, Australia.'}, {'ForeName': 'Graham S', 'Initials': 'GS', 'LastName': 'Hillis', 'Affiliation': 'The George Institute for Global Health, Sydney, New South Wales, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Chalmers', 'Affiliation': 'The George Institute for Global Health, Sydney, New South Wales, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Woodward', 'Affiliation': 'The George Institute for Global Health, Sydney, New South Wales, Australia.'}, {'ForeName': 'Ian C', 'Initials': 'IC', 'LastName': 'Marschner', 'Affiliation': 'National Health and Medical Research Council of Australia (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Wong', 'Affiliation': 'Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Bronwyn A', 'Initials': 'BA', 'LastName': 'Kingwell', 'Affiliation': 'Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Simes', 'Affiliation': 'National Health and Medical Research Council of Australia (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Tonkin', 'Affiliation': 'Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Meikle', 'Affiliation': 'Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JCI insight,['10.1172/jci.insight.128438'] 2466,31342199,Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1.,"A mechanistic model of the immune response was evaluated for its ability to predict anti-drug antibody (ADA) and their impact on pharmacokinetics (PK) and pharmacodynamics (PD) for a biotherapeutic in a phase 1 clinical trial. Observed ADA incidence ranged from 33 to 67% after single doses and 27-50% after multiple doses. The model captured the single dose incidence well; however, there was overprediction after multiple dosing. The model was updated to include a T-regulatory (Treg) cell mediated tolerance, which reduced the overprediction (relative decrease in predicted incidence rate of 21.5-59.3% across multidose panels) without compromising the single dose predictions (relative decrease in predicted incidence rate of 0.6-13%). The Treg-adjusted model predicted no ADA impact on PK or PD, consistent with the observed data. A prospective phase 2 trial was simulated, including co-medication effects in the form of corticosteroid-induced immunosuppression. Predicted ADA incidences were 0-10%, depending on co-medication dosage. This work demonstrates the utility in applying an integrated, iterative modeling approach to predict ADA during different stages of clinical development.",2019,A mechanistic model of the immune response was evaluated for its ability to predict anti-drug antibody (ADA) and their impact on pharmacokinetics (PK) and pharmacodynamics (PD) for a biotherapeutic in a phase 1 clinical trial.,[],['corticosteroid-induced immunosuppression'],"['pharmacokinetics (PK) and pharmacodynamics (PD', 'Observed ADA incidence', 'Predicted ADA incidences']",[],"[{'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0021079', 'cui_str': 'Immunosuppressive therapy'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",,0.0197327,A mechanistic model of the immune response was evaluated for its ability to predict anti-drug antibody (ADA) and their impact on pharmacokinetics (PK) and pharmacodynamics (PD) for a biotherapeutic in a phase 1 clinical trial.,"[{'ForeName': 'Lora', 'Initials': 'L', 'LastName': 'Hamuro', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb, Princeton, New Jersey, 08543, USA.'}, {'ForeName': 'Giridhar S', 'Initials': 'GS', 'LastName': 'Tirucherai', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb, Princeton, New Jersey, 08543, USA.'}, {'ForeName': 'Sean M', 'Initials': 'SM', 'LastName': 'Crawford', 'Affiliation': 'Bioanalytical Sciences, Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey, 08543, USA.'}, {'ForeName': 'Akbar', 'Initials': 'A', 'LastName': 'Nayeem', 'Affiliation': 'Molecular Structure and Design, Bristol-Myers Squibb, Princeton, New Jersey, 08543, USA.'}, {'ForeName': 'Renuka C', 'Initials': 'RC', 'LastName': 'Pillutla', 'Affiliation': 'Bioanalytical Sciences, Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey, 08543, USA.'}, {'ForeName': 'Binodh S', 'Initials': 'BS', 'LastName': 'DeSilva', 'Affiliation': 'Analytical Strategy and Operations, Product Development, Bristol-Myers Squibb, Princeton, New Jersey, 08543, USA.'}, {'ForeName': 'Tarek A', 'Initials': 'TA', 'LastName': 'Leil', 'Affiliation': 'Quantitative Clinical Pharmacology, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey, 08543, USA.'}, {'ForeName': 'Craig J', 'Initials': 'CJ', 'LastName': 'Thalhauser', 'Affiliation': 'Quantitative Clinical Pharmacology, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey, 08543, USA. craig.thalhauser@bms.com.'}]",The AAPS journal,['10.1208/s12248-019-0361-7'] 2467,32701199,"A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib vs. Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.","LESSONS LEARNED The results from the liposarcoma cohort of SARC024 confirm previously published data and do not support the routine use of regorafenib in this patient population. Continued exploration of novel therapies, including combination approaches, is warranted for a patient population in whom limited treatment options exist. BACKGROUND Regorafenib is a multi-targeted kinase inhibitor with a kinase profile overlapping, but distinct from pazopanib, an agent approved for recurrent/metastatic non-gastrointestinal tumors (GIST), non-adipocytic soft tissue sarcoma. We conducted a randomized, phase II study of regorafenib versus placebo in refractory liposarcoma patients. METHODS Patients with advanced/metastatic, treatment-refractory liposarcoma were randomized 1:1 to receive regorafenib 160 mg or placebo once daily (3 weeks on, 1 week off). Patients with well-differentiated liposarcoma only were excluded. Crossover for placebo was allowed upon progression. The primary endpoint was progression-free survival (PFS), according to RECIST version 1.1. RESULTS Forty-eight subjects with liposarcoma (34 dedifferentiated, 12 myxoid/round cell, 2 pleomorphic) were enrolled. Median PFS was 1.87 (95% confidence interval [CI]: 0.92-3.67) months for regorafenib versus 2.07 (95% CI: 1.64-3.44) months for placebo; stratified hazard ratio [HR] 0.85 (95% CI: 0.46, 1.58), p value = .62. No responses were seen on regorafenib. One PR was observed on placebo. Median overall survival was 6.46 (95% CI: 4.16-23.48) months for regorafenib and 4.89 (95% CI: 3.02-9.77) months for placebo, stratified HR 0.66 (95% CI: 0.31-1.40), p value = .28). Treatment-related adverse events were similar to the known safety profile of regorafenib. CONCLUSION Regorafenib did not appear to improve PFS in treatment-refractory liposarcoma. No new significant safety signals were observed.",2020,Median PFS was 1.87 (95% confidence interval [CI]: 0.92-3.67) months for regorafenib versus 2.07 (95% CI: 1.64-3.44) months for placebo; stratified hazard ratio [HR] 0.85,"['Advanced/Metastatic, Treatment-Refractory Liposarcoma', 'Patients with well-differentiated liposarcoma only were excluded', 'Patients with advanced/metastatic, treatment-refractory liposarcoma', 'Forty-eight subjects with liposarcoma (34 dedifferentiated, 12 myxoid/round cell, 2 pleomorphic) were enrolled', 'refractory liposarcoma patients']","['Regorafenib vs. Placebo', 'Placebo', 'regorafenib 160 mg or placebo', 'Regorafenib', 'regorafenib versus placebo', 'placebo']","['Median overall survival', 'Median PFS', 'PFS', 'progression-free survival (PFS), according to RECIST version 1.1']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0023827', 'cui_str': 'Liposarcoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205615', 'cui_str': 'Well differentiated'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0205295', 'cui_str': 'Myxoid'}, {'cui': 'C0332490', 'cui_str': 'Round shape'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}]","[{'cui': 'C2980094', 'cui_str': 'regorafenib'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4319554', 'cui_str': '160'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1709926', 'cui_str': 'RECIST'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C4517491', 'cui_str': '1.1'}]",48.0,0.650568,Median PFS was 1.87 (95% confidence interval [CI]: 0.92-3.67) months for regorafenib versus 2.07 (95% CI: 1.64-3.44) months for placebo; stratified hazard ratio [HR] 0.85,"[{'ForeName': 'Richard F', 'Initials': 'RF', 'LastName': 'Riedel', 'Affiliation': 'Duke Cancer Institute, Duke University Medical Center, Durham, NC.'}, {'ForeName': 'Karla V', 'Initials': 'KV', 'LastName': 'Ballman', 'Affiliation': 'Weill Cornell Medicine, New York, NY.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Attia', 'Affiliation': 'Mayo Clinic, Jacksonville, FL.'}, {'ForeName': 'Elizabeth T', 'Initials': 'ET', 'LastName': 'Loggers', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Kristen N', 'Initials': 'KN', 'LastName': 'Ganjoo', 'Affiliation': 'Stanford Cancer Institute, Stanford University, Stanford, CA.'}, {'ForeName': 'Michael B', 'Initials': 'MB', 'LastName': 'Livingston', 'Affiliation': 'Levine Cancer Institute, Atrium Health, Charlotte, NC.'}, {'ForeName': 'Warren', 'Initials': 'W', 'LastName': 'Chow', 'Affiliation': 'City of Hope Cancer Center, Duarte, CA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Wright', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Ward', 'Affiliation': 'Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Rushing', 'Affiliation': 'Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN.'}, {'ForeName': 'Scott H', 'Initials': 'SH', 'LastName': 'Okuno', 'Affiliation': 'Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Damon R', 'Initials': 'DR', 'LastName': 'Reed', 'Affiliation': 'H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Liebner', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Vicki L', 'Initials': 'VL', 'LastName': 'Keedy', 'Affiliation': 'Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Leo', 'Initials': 'L', 'LastName': 'Mascarenhas', 'Affiliation': ""Children's Hospital of Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA.""}, {'ForeName': 'Lara E', 'Initials': 'LE', 'LastName': 'Davis', 'Affiliation': 'Knight Cancer Institute, Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Ryan', 'Affiliation': 'Knight Cancer Institute, Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Denise K', 'Initials': 'DK', 'LastName': 'Reinke', 'Affiliation': 'Sarcoma Alliance for Research through Collaboration (SARC), Ann Arbor, MI.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Maki', 'Affiliation': 'Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA.'}]",The oncologist,['10.1634/theoncologist.2020-0679'] 2468,32701201,Age-related macular degeneration in a randomized trial of selenium and vitamin E in men: the Select Eye Endpoints (SEE) study (SWOG S0000B).,,2020,,['men'],['selenium and vitamin E'],[],"[{'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}]",[],,0.0755668,,"[{'ForeName': 'William G', 'Initials': 'WG', 'LastName': 'Christen', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Amy K', 'Initials': 'AK', 'LastName': 'Darke', 'Affiliation': 'Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Gaziano', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Glynn', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Phyllis J', 'Initials': 'PJ', 'LastName': 'Goodman', 'Affiliation': 'Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'Lori M', 'Initials': 'LM', 'LastName': 'Minasian', 'Affiliation': 'Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Thompson', 'Affiliation': 'Department of Urology, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, TX, USA.'}]",Acta ophthalmologica,['10.1111/aos.14538'] 2469,32701239,[Inverse ratio ventilation combined with PEEP in infants undergoing thoracoscopic surgery with one lung ventilation for lung cystadenomas: a randomized control trial of 63 cases].,"OBJECTIVE To investigate the effect of inverse ratio ventilation (IRV) combined with positive end-expiratory pressure (PEEP) in infants undergoing thoracoscopic surgery with single lung ventilation (OLV) for lung cystadenomas. METHODS A total of 66 infants undergoing thoracoscopic surgery with OLV for lung cystadenomas in our hospital from February, 2018 to February, 2019 were randomized into conventional ventilation groups (group N, n =33) and inverse ventilation group (group R, n =33). Hemodynamics and respiratory parameters of the infants were recorded and arterial blood gas analysis was performed at 15 min after two lung ventilation (TLV) (T 1 ), OLV30 min (T 2 ), OLV60 min (T 3 ), and 15 min after recovery of TLV (T 4 ). Bronchoalveolar lavage fluid was collected before and after surgery to detect the expression level of advanced glycation end product receptor (RAGE). RESULTS Sixty-three infants were finally included in this study. At T 2 and T 3 , Cdyn, PaO 2 and OI in group R were significantly higher ( P < 0.05) and Ppeak, PaCO 2 and PA-aO 2 were significantly lower than those in group N ( P < 0.05). There was no significant difference in HR or MAP between the two groups at T 2 and T 3 ( P > 0.05). The level of RAGE significantly increased after the surgery in both groups ( P < 0.05), and was significantly lower in R group than in N group ( P < 0.05). CONCLUSIONS In infants undergoing thoracoscopic surgery with OLV for pulmonary cystadenoma, appropriate IRV combined with PEEP does not affect hemodynamic stability and can increases pulmonary compliance, reduce the peak pressure, and improve oxygenation to provide pulmonary protection.",2020,There was no significant difference in HR or MAP between the two groups at T 2 and T 3 ( P > 0.05).,"['infants undergoing', '66 infants undergoing thoracoscopic surgery with OLV for lung cystadenomas in our hospital from February, 2018 to February, 2019 were randomized into', 'infants undergoing thoracoscopic surgery with OLV for pulmonary cystadenoma', 'infants undergoing thoracoscopic surgery with one lung ventilation for lung cystadenomas', 'Sixty-three infants were finally included in this study']","['inverse ratio ventilation (IRV) combined with positive end-expiratory pressure (PEEP', 'thoracoscopic surgery with single lung ventilation (OLV', 'Inverse ratio ventilation combined with PEEP', 'conventional ventilation', 'inverse ventilation group']","['HR or MAP', 'hemodynamic stability', 'level of RAGE', 'Bronchoalveolar lavage fluid', 'Hemodynamics and respiratory parameters', 'Ppeak, PaCO 2 and PA-aO 2']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0751551', 'cui_str': 'Thoracoscopic Surgical Procedures'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0010633', 'cui_str': 'Cystadenoma'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0559312', 'cui_str': 'One lung ventilation'}, {'cui': 'C4319614', 'cui_str': '63'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0439850', 'cui_str': 'Inverse'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0032740', 'cui_str': 'Positive end-expiratory pressure'}, {'cui': 'C0751551', 'cui_str': 'Thoracoscopic Surgical Procedures'}, {'cui': 'C0559312', 'cui_str': 'One lung ventilation'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0024779', 'cui_str': 'Maps'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0034634', 'cui_str': 'Rage'}, {'cui': 'C0006279', 'cui_str': 'Bronchoalveolar lavage fluid sample'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",66.0,0.035269,There was no significant difference in HR or MAP between the two groups at T 2 and T 3 ( P > 0.05).,"[{'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}, {'ForeName': 'Weijian', 'Initials': 'W', 'LastName': 'Huang', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}, {'ForeName': 'Mudan', 'Initials': 'M', 'LastName': 'He', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}, {'ForeName': 'Lingli', 'Initials': 'L', 'LastName': 'Peng', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}, {'ForeName': 'Mingyang', 'Initials': 'M', 'LastName': 'Cai', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Yuan', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}, {'ForeName': 'Zurong', 'Initials': 'Z', 'LastName': 'Hu', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}, {'ForeName': 'Kunwei', 'Initials': 'K', 'LastName': 'Li', 'Affiliation': ""Department of Anesthesiology, Guangdong Women and Children's Hospital, Guangzhou 511400, China.""}]",Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,[] 2470,32701242,[Dexmedetomidine combined with protective lung ventilation strategy provides lung protection in patients undergoing radical resection of esophageal cancer with one-lung ventilation].,"OBJECTIVE To investigate the effect of dexmedetomidine combined with pulmonary protective ventilation against lung injury in patients undergoing surgeries for esophageal cancer with one-lung ventilation (OLV). METHODS Forty patients with undergoing surgery for esophageal cancer with OLV were randomly divided into pulmonary protective ventilation strategy group (F group) and dexmedetomidine combined with protective ventilation strategy group (DF group; n =20). In F group, lung protective ventilation strategy during anesthesia was adopte, and in DF group, the patients received intravenous infusion of dexmedetomidine hydrochloride (0.3 μg · kg -1 ·h -1 ) during the surgery starting at 10 min before anesthesia induction in addition to protective ventilation strategy. Brachial artery blood was sampled before ventilation (T 0 ), at 30 and 90 min after the start of OLV (T 1 and T 2 , respectively) and at the end of the surgery (T 3 ) for analysis of superoxide dismutase (SOD), malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), arterial oxygenation pressure (PaO 2 ), oxygenation index (OI) and lung compliance (CL). RESULTS At the time points of T 1 , T 2 and T 3 , SOD level was significantly higher and IL-6 level was significantly lower in the DF group than in F group ( P < 0.05). The patients in DF group showed significantly higher PaO 2 , OI and CL index than those in F group at all the 3 time points. CONCLUSIONS Dexmedetomidine combined with pulmonary protective ventilation strategy can reduce perioperative lung injury in patients undergoing surgery for esophageal cancer with OLV by suppressing inflammation and oxidative stress to improve lung function and reduce adverse effects of the surgery.",2020,"At the time points of T 1 , T 2 and T 3 , SOD level was significantly higher and IL-6 level was significantly lower in the DF group than in F group ( P < 0.05).","['patients undergoing surgeries for esophageal cancer with one-lung ventilation (OLV', 'patients undergoing radical resection of esophageal cancer with one-lung ventilation', 'patients undergoing surgery for esophageal cancer with OLV', 'Forty patients with undergoing surgery for esophageal cancer with OLV']","['Dexmedetomidine combined with protective lung ventilation strategy', 'dexmedetomidine hydrochloride', 'dexmedetomidine combined with pulmonary protective ventilation', 'Dexmedetomidine combined with pulmonary protective ventilation strategy', 'pulmonary protective ventilation strategy group (F group) and dexmedetomidine combined with protective ventilation strategy']","['SOD level', 'superoxide dismutase (SOD), malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), arterial oxygenation pressure (PaO 2 ), oxygenation index (OI) and lung compliance (CL', 'Brachial artery blood', 'lung protective ventilation strategy', 'PaO 2 , OI and CL index', 'IL-6 level']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0014859', 'cui_str': 'Neoplasm of esophagus'}, {'cui': 'C0559312', 'cui_str': 'One lung ventilation'}, {'cui': 'C0302912', 'cui_str': 'Radical'}, {'cui': 'C0015252', 'cui_str': 'Removal'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0554804', 'cui_str': 'Assisted breathing'}, {'cui': 'C0752310', 'cui_str': 'Dexmedetomidine hydrochloride'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441840', 'cui_str': 'Group F'}]","[{'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output'}, {'cui': 'C1278185', 'cui_str': 'Oxygenation index measurement'}, {'cui': 'C0024112', 'cui_str': 'Lung compliance'}, {'cui': 'C0006087', 'cui_str': 'Structure of brachial artery'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",40.0,0.0490837,"At the time points of T 1 , T 2 and T 3 , SOD level was significantly higher and IL-6 level was significantly lower in the DF group than in F group ( P < 0.05).","[{'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Gong', 'Affiliation': 'Department of Anesthesiology, Nanning 530021, China.'}, {'ForeName': 'Xiaomao', 'Initials': 'X', 'LastName': 'Long', 'Affiliation': ""Department Cardiothoracic Surgery, People's Hospital of Guangxi Autonomous Region, Nanning 530021, China.""}, {'ForeName': 'Huijun', 'Initials': 'H', 'LastName': 'Wei', 'Affiliation': 'Department of Anesthesiology, Nanning 530021, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Tang', 'Affiliation': 'Department of Anesthesiology, Nanning 530021, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Nanning 530021, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Ma', 'Affiliation': 'Department of Anesthesiology, Nanning 530021, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': ""People's Hospital of Guangxi Autonomous Region, Nanning 530021, China.""}]",Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,[] 2471,32627316,"Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome.","AIM To report an analysis of ~1 year of setmelanotide treatment for obesity and hunger, as well as metabolic and cardiac outcomes, in individuals with Bardet-Biedl syndrome (BBS). MATERIALS AND METHODS Individuals aged 12 years and older with BBS received once-daily setmelanotide. The dose was titrated every 2 weeks to establish the individual therapeutic dose (≤3 mg); treatment continued for an additional 10 weeks. Participants who lost 5 kg or more (or ≥5% of body weight if <100 kg at baseline) continued into the 52-week extension phase. The primary outcome was mean percent change from baseline in body weight at 3 months. Hunger scores and safety were secondary outcomes. RESULTS From February 2017 and February 2018, 10 individuals were screened; eight completed the 3-month treatment phase and seven completed the extension phase. Mean percent change in body weight from baseline to 3 months was -5.5% (90% CI, -9.3% to -1.6%; n = 8); change from baseline was -11.3% (90% CI, -15.5% to -7.0%; n = 8) at 6 months and -16.3% (90% CI, -19.9% to -12.8%; n = 7) at 12 months. All participants reported at least one treatment-emergent adverse event (AE), most commonly injection-site reaction. No AEs led to study withdrawal or death. Most, morning, and average hunger scores were reduced across time points. CONCLUSIONS Setmelanotide reduced body weight and hunger in individuals with BBS and had a safety profile consistent with previous reports. Setmelanotide may be a treatment option in individuals with BBS-associated obesity and hyperphagia.",2020,"Mean percent change in body weight from baseline to 3 months was -5.5% (90% CI, -9.3% to -1.6%; n = 8); change from baseline was -11.3% (90% CI, -15.5% to -7.0%; n = 8) at 6 months and -16.3% (90% CI, -19.9% to -12.8%; n = 7) at 12 months.","['Individuals aged 12\u2009years and older with BBS received once', 'Participants who lost 5 kg or more (or ≥5% of body weight if <100\u2009kg at baseline) continued into the 52-week extension phase', 'Bardet-Biedl syndrome', 'individuals with Bardet-Biedl syndrome (BBS', 'individuals with BBS-associated obesity and hyperphagia', 'From February 2017 and February 2018, 10 individuals were screened; eight completed the 3-month treatment phase and seven completed the extension phase', 'individuals with BBS']","['setmelanotide treatment', 'setmelanotide, a melanocortin-4 receptor agonist', 'daily setmelanotide', 'Setmelanotide']","['body weight', 'Hunger scores and safety', 'mean percent change from baseline in body weight', 'study withdrawal or death', 'average hunger scores', 'body weight and hunger']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0752166', 'cui_str': 'Bardet-Biedl syndrome'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0020505', 'cui_str': 'Overeating'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205453', 'cui_str': '7'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0527721', 'cui_str': 'MC4R protein, human'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",10.0,0.255532,"Mean percent change in body weight from baseline to 3 months was -5.5% (90% CI, -9.3% to -1.6%; n = 8); change from baseline was -11.3% (90% CI, -15.5% to -7.0%; n = 8) at 6 months and -16.3% (90% CI, -19.9% to -12.8%; n = 7) at 12 months.","[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Haws', 'Affiliation': 'Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.'}, {'ForeName': 'Sheila', 'Initials': 'S', 'LastName': 'Brady', 'Affiliation': 'Section on Growth and Obesity, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Davis', 'Affiliation': 'Section on Growth and Obesity, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Fletty', 'Affiliation': 'Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.'}, {'ForeName': 'Guojun', 'Initials': 'G', 'LastName': 'Yuan', 'Affiliation': 'Rhythm Pharmaceuticals, Boston, Massachusetts, USA.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Gordon', 'Affiliation': 'Rhythm Pharmaceuticals, Boston, Massachusetts, USA.'}, {'ForeName': 'Murray', 'Initials': 'M', 'LastName': 'Stewart', 'Affiliation': 'Rhythm Pharmaceuticals, Boston, Massachusetts, USA.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Yanovski', 'Affiliation': 'Section on Growth and Obesity, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14133'] 2472,32697485,Personalized Positive End-Expiratory Pressure in Acute Respiratory Distress Syndrome: Comparison Between Optimal Distribution of Regional Ventilation and Positive Transpulmonary Pressure.,"OBJECTIVES Different techniques exist to select personalized positive end-expiratory pressure in patients affected by the acute respiratory distress syndrome. The positive end-expiratory transpulmonary pressure strategy aims to counteract dorsal lung collapse, whereas electrical impedance tomography could guide positive end-expiratory pressure selection based on optimal homogeneity of ventilation distribution. We compared the physiologic effects of positive end-expiratory pressure guided by electrical impedance tomography versus transpulmonary pressure in patients affected by acute respiratory distress syndrome. DESIGN Cross-over prospective physiologic study. SETTING Two academic ICUs. PATIENTS Twenty ICU patients affected by acute respiratory distress syndrome undergoing mechanical ventilation. INTERVENTION Patients monitored by an esophageal catheter and a 32-electrode electrical impedance tomography monitor underwent two positive end-expiratory pressure titration trials by randomized cross-over design to find the level of positive end-expiratory pressure associated with: 1) positive end-expiratory transpulmonary pressure (PEEPPL) and 2) proportion of poorly or nonventilated lung units (Silent Spaces) less than or equal to 15% (PEEPEIT). Each positive end-expiratory pressure level was maintained for 20 minutes, and afterward, lung mechanics, gas exchange, and electrical impedance tomography data were collected. MEASUREMENTS AND MAIN RESULTS PEEPEIT and PEEPPL differed in all patients, and there was no correlation between the levels identified by the two methods (Rs = 0.25; p = 0.29). PEEPEIT determined a more homogeneous distribution of ventilation with a lower percentage of dependent Silent Spaces (p = 0.02), whereas PEEPPL was characterized by lower airway-but not transpulmonary-driving pressure (p = 0.04). PEEPEIT was significantly higher than PEEPPL in subjects with extrapulmonary acute respiratory distress syndrome (p = 0.006), whereas the opposite was true for pulmonary acute respiratory distress syndrome (p = 0.03). CONCLUSIONS Personalized positive end-expiratory pressure levels selected by electrical impedance tomography- and transpulmonary pressure-based methods are not correlated at the individual patient level. PEEPPL is associated with lower dynamic stress, whereas PEEPEIT may help to optimize lung recruitment and homogeneity of ventilation. The underlying etiology of acute respiratory distress syndrome could deeply influence results from each method.",2020,"PEEPEIT determined a more homogeneous distribution of ventilation with a lower percentage of dependent Silent Spaces (p = 0.02), whereas PEEPPL was characterized by lower airway-but not transpulmonary-driving pressure (p = 0.04).","['Twenty ICU patients affected by acute respiratory distress syndrome undergoing mechanical ventilation', 'patients affected by the acute respiratory distress syndrome', 'patients affected by acute respiratory distress syndrome', 'Acute Respiratory Distress Syndrome', 'Two academic ICUs']","['PEEPPL', 'Personalized Positive End-Expiratory Pressure', 'positive end-expiratory pressure guided by electrical impedance tomography versus transpulmonary pressure', 'Patients monitored by an esophageal catheter and a 32-electrode electrical impedance tomography monitor underwent two positive end-expiratory pressure titration trials by randomized cross-over design to find the level of positive end-expiratory pressure associated with: 1) positive end-expiratory transpulmonary pressure (PEEPPL) and 2) proportion of poorly or nonventilated lung units (Silent Spaces) less than or equal to 15% (PEEPEIT', 'Regional Ventilation and Positive Transpulmonary Pressure']",['pulmonary acute respiratory distress syndrome'],"[{'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0522476', 'cui_str': 'Patient affected'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}]","[{'cui': 'C0032740', 'cui_str': 'Positive end-expiratory pressure'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0162537', 'cui_str': 'Impedance'}, {'cui': 'C0040395', 'cui_str': 'Diagnostic tomography'}, {'cui': 'C0442377', 'cui_str': 'Transpulmonary artery approach'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0013812', 'cui_str': 'Electrode'}, {'cui': 'C0162621', 'cui_str': 'Titration method'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0242817', 'cui_str': 'Crossover Design'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0442700', 'cui_str': 'End-expiration'}, {'cui': 'C0205169', 'cui_str': 'Bad'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0443304', 'cui_str': 'Silent'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0439090', 'cui_str': '<='}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}]","[{'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}]",20.0,0.161415,"PEEPEIT determined a more homogeneous distribution of ventilation with a lower percentage of dependent Silent Spaces (p = 0.02), whereas PEEPPL was characterized by lower airway-but not transpulmonary-driving pressure (p = 0.04).","[{'ForeName': 'Gaetano', 'Initials': 'G', 'LastName': 'Scaramuzzo', 'Affiliation': ""1Department of Morphology, Surgery and Experimental Medicine, Azienda Ospedaliera-Universitaria Arcispedale Sant'Anna, University of Ferrara, Ferrara, Italy. 2Department of Anesthesiology and Intensive Care Medicine, Rostock University Medical Center, Rostock, Germany. 3Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. 4Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.""}, {'ForeName': 'Savino', 'Initials': 'S', 'LastName': 'Spadaro', 'Affiliation': ''}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Dalla Corte', 'Affiliation': ''}, {'ForeName': 'Andreas D', 'Initials': 'AD', 'LastName': 'Waldmann', 'Affiliation': ''}, {'ForeName': 'Stephan H', 'Initials': 'SH', 'LastName': 'Böhm', 'Affiliation': ''}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Ragazzi', 'Affiliation': ''}, {'ForeName': 'Elisabetta', 'Initials': 'E', 'LastName': 'Marangoni', 'Affiliation': ''}, {'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Grasselli', 'Affiliation': ''}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Pesenti', 'Affiliation': ''}, {'ForeName': 'Carlo Alberto', 'Initials': 'CA', 'LastName': 'Volta', 'Affiliation': ''}, {'ForeName': 'Tommaso', 'Initials': 'T', 'LastName': 'Mauri', 'Affiliation': ''}]",Critical care medicine,['10.1097/CCM.0000000000004439'] 2473,32697510,Effects of Different Doses of Remote Ischemic Preconditioning on Kidney Damage Among Patients Undergoing Cardiac Surgery: A Single-Center Mechanistic Randomized Controlled Trial.,"OBJECTIVES We have previously shown that remote ischemic preconditioning reduces acute kidney injury (acute kidney injury) in high-risk patients undergoing cardiopulmonary bypass and that the protective effect is confined to patients who exhibit an increased urinary tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein 7 in response to remote ischemic preconditioning. The purpose of this study was to determine the optimal intensity of remote ischemic preconditioning to induce required [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] changes and further explore mechanisms of remote ischemic preconditioning. DESIGN Observational and randomized controlled, double-blind clinical trial. SETTING University Hospital of Muenster, Germany. PATIENTS High-risk patients undergoing cardiac surgery as defined by the Cleveland Clinic Foundation Score. INTERVENTIONS In the interventional part, patients were randomized to receive either one of four different remote ischemic preconditioning doses (3 × 5 min, 3 × 7 min, 3 × 10 min remote ischemic preconditioning, or 3 × 5 min remote ischemic preconditioning + 2 × 10 min remote ischemic preconditioning in nonresponders) or sham-remote ischemic preconditioning (control). MEASUREMENTS AND MAIN RESULTS The primary endpoint of the interventional part was change in urinary [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] between pre- and postintervention. To examine secondary objectives including acute kidney injury incidence, we included an observational cohort. A total of 180 patients were included in the trial (n = 80 observational and n = 100 randomized controlled part [20 patients/group]). The mean age was 69.3 years (10.5 yr), 119 were men (66.1%). Absolute changes in [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] were significantly higher in all remote ischemic preconditioning groups when compared with controls (p < 0.01). Although we did not observe a dose-response relationship on absolute changes in [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] across the four different remote ischemic preconditioning groups, in the 15 patients failing to respond to the lowest dose, nine (60%) responded to a subsequent treatment at a higher intensity. Compared with controls, fewer patients receiving remote ischemic preconditioning developed acute kidney injury within 72 hours after surgery as defined by both Kidney Disease: Improving Global Outcomes criteria (30/80 [37.5%] vs 61/100 [61.0%]; p = 0.003). CONCLUSIONS All doses of remote ischemic preconditioning significantly increased [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] and significantly decreased acute kidney injury compared with controls. High-dose remote ischemic preconditioning could stimulate [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] increases in patients refractory to low-dose remote ischemic preconditioning.",2020,"Compared with controls, fewer patients receiving remote ischemic preconditioning developed acute kidney injury within 72 hours after surgery as defined by both Kidney Disease: Improving Global Outcomes criteria (30/80 [37.5%] vs 61/100 [61.0%]; p = 0.003). ","['University Hospital of Muenster, Germany', 'High-risk patients undergoing cardiac surgery as defined by the Cleveland Clinic Foundation Score', 'A total of 180 patients were included in the trial (n = 80 observational and n = 100 randomized controlled part [20 patients/group', 'The mean age was 69.3 years (10.5 yr), 119 were men (66.1', 'Patients', 'Undergoing Cardiac Surgery', 'high-risk patients undergoing', 'acute kidney injury incidence']","['cardiopulmonary bypass', 'metalloproteinases-2]*[insulin-like growth factor-binding protein 7', 'remote ischemic preconditioning doses (3\u2009×\u20095\u2009min, 3\u2009×\u20097\u2009min, 3\u2009×\u200910\u2009min remote ischemic preconditioning, or 3\u2009×\u20095\u2009min remote ischemic preconditioning + 2\u2009×\u200910\u2009min remote ischemic preconditioning in nonresponders) or sham-remote ischemic preconditioning (control', 'Remote Ischemic Preconditioning']","['acute kidney injury', 'Kidney Damage', 'urinary [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] between pre- and postintervention']","[{'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0454845', 'cui_str': 'Cleveland'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0016617', 'cui_str': 'Foundations'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1518527', 'cui_str': 'Observational Study'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517521', 'cui_str': '10.5'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]","[{'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0018284', 'cui_str': 'Growth factor'}, {'cui': 'C0242210', 'cui_str': 'Binding protein'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0376466', 'cui_str': 'Ischemic Pre-Conditioning'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0018284', 'cui_str': 'Growth factor'}, {'cui': 'C0242210', 'cui_str': 'Binding protein'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]",180.0,0.22112,"Compared with controls, fewer patients receiving remote ischemic preconditioning developed acute kidney injury within 72 hours after surgery as defined by both Kidney Disease: Improving Global Outcomes criteria (30/80 [37.5%] vs 61/100 [61.0%]; p = 0.003). ","[{'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Meersch', 'Affiliation': '1Department of Anaesthesiology, Intensive Care Medicine and Pain Medicine, University Hospital Münster, Münster, Germany. 2Department of Medicine, Division D, Nephrology, University Hospital Münster, Münster, Germany. 3Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA. 4Department of Cardiac Surgery, University of Münster, Münster, Germany. 5Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.'}, {'ForeName': 'Mira', 'Initials': 'M', 'LastName': 'Küllmar', 'Affiliation': ''}, {'ForeName': 'Hermann', 'Initials': 'H', 'LastName': 'Pavenstädt', 'Affiliation': ''}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Rossaint', 'Affiliation': ''}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Kellum', 'Affiliation': ''}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Martens', 'Affiliation': ''}, {'ForeName': 'Pia', 'Initials': 'P', 'LastName': 'Klausmeyer', 'Affiliation': ''}, {'ForeName': 'Elisa A', 'Initials': 'EA', 'LastName': 'Schmidt', 'Affiliation': ''}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Kerschke', 'Affiliation': ''}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Zarbock', 'Affiliation': ''}]",Critical care medicine,['10.1097/CCM.0000000000004415'] 2474,32697556,Validation of a More Reliable Method of Eye Drop Self-Administration.,"SIGNIFICANCE We propose an alternative method for eye drop self-administration. Similar IOP reductions were found with this method compared with clinician instillation. The alternative method of self-administration potentially benefits patients who have trouble successfully instilling drops. PURPOSE The purpose of this study was to validate the efficacy of an alternative method of drop instillation. METHODS This study is a randomized controlled crossover clinical trial. Thirty participants were recruited. A drop of 0.5% timolol maleate was instilled into subject's eye on two separate visits. On one visit, eye drop instillation was by a trained clinician, and on the other, self-instillation using an alternative method was used. The order was randomly chosen. Intraocular pressure was measured before drop instillation and 2 hours after drop instillation. The investigator was masked during measurement, and an observer recorded the IOP measurements. RESULTS Mean ± SD IOP measurement before 0.5% timolol maleate instillation measured 13.89 ± 2.29 mmHg. An average reduction 3.75 ± 2.36 mmHg was found with clinician administration, and an average reduction of 3.32 ± 2.31 mmHg was recorded with the new method. No significance was found in IOP reduction between two groups P < .45. Percent reduction was 25.17 ± 16.21% and 24.38 ± 16.31% in clinician instillation and alternative instillation method group, respectively. No significant difference was found. This percentage reduction was similar to previously reported studies. No reported cases of eye infection or irritation were found in any case, within a 3-month follow-up period. CONCLUSIONS We have proposed a more reliable method for instillation that provides a larger area for instillation and lessen the risk of contamination and patient's fear for eye drops. Similar efficacy was found compared with that of having a clinician directly administer the drop. This alternative method could potentially benefit patients who require topical eye drop therapy and result in increased compliance.",2020,"No reported cases of eye infection or irritation were found in any case, within a 3-month follow-up period. ",['Thirty participants were recruited'],['timolol maleate'],"['eye infection or irritation', 'IOP reductions', 'Intraocular pressure', 'IOP reduction', 'Mean ± SD IOP measurement']","[{'cui': 'C3816446', 'cui_str': '30'}]","[{'cui': 'C0087093', 'cui_str': 'Timolol maleate'}]","[{'cui': 'C0015403', 'cui_str': 'Eye infection'}, {'cui': 'C0441723', 'cui_str': 'Irritation'}, {'cui': 'C0578862', 'cui_str': 'Intraocular pressure finding'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",30.0,0.0265121,"No reported cases of eye infection or irritation were found in any case, within a 3-month follow-up period. ","[{'ForeName': 'Thomas F', 'Initials': 'TF', 'LastName': 'Freddo', 'Affiliation': '1Massachusetts College of Pharmacy and Health Sciences University, Boston, Massachusetts 2School of Optometry and Vision Science, University of Waterloo, Waterloo, Ontario, Canada *derek.ho@uwaterloo.ca.'}, {'ForeName': 'Derek Y', 'Initials': 'DY', 'LastName': 'Ho', 'Affiliation': ''}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Steenbakkers', 'Affiliation': ''}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Furtado', 'Affiliation': ''}]",Optometry and vision science : official publication of the American Academy of Optometry,['10.1097/OPX.0000000000001535'] 2475,32697559,Randomized Clinical Trial of Near Visual Performance with Digital Devices Using Spherical and Toric Contact Lenses.,"SIGNIFICANCE Visual demands today incorporate a significant amount of time using digital devices. Results of this randomized crossover study of spherical and toric contact lenses demonstrated that participants were able to read smaller print size more comfortably and preferred toric contact lenses when using digital devices. PURPOSE The purpose of this study was to assess how toric contact lens correction affects subjective and objective outcomes of astigmatic patients using real-world digital devices. METHODS Adult participants, aged between 20 and 38 years with -0.75 to -1.50 D of astigmatism were enrolled in this double-masked randomized crossover 10-day study of Alcon Dailies Aqua Comfort Plus Sphere and Toric (Alcon, Geneva, Switzerland) contact lenses. Electronic high- and low-contrast near logMAR visual acuity and contrast sensitivity were tested. Reading performance was assessed using custom iPad applications; one used a reading sentences test, whereas the other analyzed zoom, contrast, and distance with website-based articles. Participants completed the Near Activity Visual Questionnaire and stated their preferred contact lens correction. RESULTS Thirty seven participants were screened, 35 participants were enrolled, and 34 participants completed the study. Toric lens correction improved near high- and low-contrast visual acuity by 0.5 to 1 full line (P < .0001) and allowed participants to read one line smaller text on the iPad (P = .01). Participants increased the zoom 11% (P = .004) and the contrast 4% (P = .006) more with spherical lenses while reading articles. Participants held the iPad at approximately the same distance, about 33 cm (P = .63). Eighty five percent of participants preferred the toric correction (P < .0001). Participants reported improved satisfaction with toric lens correction (P = .0002) and noticed the most benefit with tasks such as reading small print and labels/instructions. CONCLUSIONS This study used digital devices to demonstrate realistic benefits of toric contact lens designs for astigmatic patients.",2020,"Results of this randomized crossover study of spherical and toric contact lenses demonstrated that participants were able to read smaller print size more comfortably and preferred toric contact lenses when using digital devices. ","['Adult participants, aged between 20 and 38 years with -0.75 to -1.50', 'astigmatic patients', 'Thirty seven participants were screened, 35 participants were enrolled, and 34 participants completed the study']","['spherical and toric contact lenses', 'Alcon Dailies Aqua Comfort Plus Sphere and Toric (Alcon, Geneva, Switzerland) contact lenses', 'Digital Devices', 'toric contact lens correction']","['Toric lens correction improved near high- and low-contrast visual acuity', 'Electronic high- and low-contrast near logMAR visual acuity and contrast sensitivity', 'satisfaction with toric lens correction', 'Reading performance', 'toric correction', 'Near Activity Visual Questionnaire and stated their preferred contact lens correction']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4068882', 'cui_str': '0.75'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319569', 'cui_str': '37'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0332501', 'cui_str': 'Spherical shape'}, {'cui': 'C0009836', 'cui_str': 'Contact lenses'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0023317', 'cui_str': 'Lens clear'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0009928', 'cui_str': 'Contrast sensitivity'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0009836', 'cui_str': 'Contact lenses'}]",35.0,0.226215,"Results of this randomized crossover study of spherical and toric contact lenses demonstrated that participants were able to read smaller print size more comfortably and preferred toric contact lenses when using digital devices. ","[{'ForeName': 'Anna-Kaye M', 'Initials': 'AM', 'LastName': 'Logan', 'Affiliation': '1University of Houston College of Optometry, Houston, Texas 2Ophthalmic Research Group, Aston University, Birmingham, United Kingdom *Richdale@UH.edu.'}, {'ForeName': 'Ananya', 'Initials': 'A', 'LastName': 'Datta', 'Affiliation': ''}, {'ForeName': 'Kelsea', 'Initials': 'K', 'LastName': 'Skidmore', 'Affiliation': ''}, {'ForeName': 'Erin S', 'Initials': 'ES', 'LastName': 'Tomiyama', 'Affiliation': ''}, {'ForeName': 'Chuan', 'Initials': 'C', 'LastName': 'Hu', 'Affiliation': ''}, {'ForeName': 'Moriah A', 'Initials': 'MA', 'LastName': 'Chandler', 'Affiliation': ''}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Procopio', 'Affiliation': ''}, {'ForeName': 'Minal', 'Initials': 'M', 'LastName': 'Bhadane', 'Affiliation': ''}, {'ForeName': 'Julia S', 'Initials': 'JS', 'LastName': 'Benoit', 'Affiliation': ''}, {'ForeName': 'Eric R', 'Initials': 'ER', 'LastName': 'Ritchey', 'Affiliation': ''}, {'ForeName': 'James S', 'Initials': 'JS', 'LastName': 'Wolffsohn', 'Affiliation': ''}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Richdale', 'Affiliation': ''}]",Optometry and vision science : official publication of the American Academy of Optometry,['10.1097/OPX.0000000000001540'] 2476,32697560,"The Effect of a Photochromic Contact Lens on Visual Function Indoors: A Randomized, Controlled Trial.","SIGNIFICANCE Photochromic soft contact lenses contain light-sensitive additives that allow them to darken when exposed to ultraviolet or violet light. One question, however, is whether the lenses influence vision indoors (minimally activated). In this study, we found that the minimally activated lenses improved many aspects of visual function under bright light. PURPOSE Photochromic contact lenses were designed to darken when exposed to outdoor sunlight. The filtering that results improves visual function under bright light conditions. Not all bright light exposures occur outdoors. In this study, we tested whether a photochromic contact lens improved visual function under conditions where the lens was minimally activated (i.e., no more than it normally would be in an indoor environment). METHODS A subject-masked contralateral design was used comparing a photochromic contact lens randomized to one eye against a nonphotochromic contact in the other eye of the same subject. Sixty subjects (mean = 34.90 ± 11.24 years) were tested. The primary endpoints consisted of four visual function outcomes: photostress recovery, glare disability, glare discomfort, and chromatic contrast. Photostress recovery was quantified by measuring the time needed to recover visual acquisition of a grating target after 5 seconds of an intense xenon white flash exposure; glare disability was evaluated as the energy in a surrounding xenon white annulus necessary to veil a central grating target; and glare discomfort was assessed using bioimaging of the squint response. Chromatic contrast was measured as thresholds for a green-yellow (580 nm) grating target superposed on a blue (460 nm) background. RESULTS The minimally activated photochromic contact demonstrated improved visual performance compared with the nonphotochromic control across all visual functions tested (P < .01). CONCLUSIONS Even under conditions of exiguous activation (e.g., as would be expected indoors or while driving at night), a photochromic contact will improve many of the more deleterious aspects of bright light.",2020,"The minimally activated photochromic contact demonstrated improved visual performance compared with the nonphotochromic control across all visual functions tested (P < .01). ",['Sixty subjects (mean = 34.90 ± 11.24 years) were tested'],"['photochromic contact lens', 'Photochromic Contact Lens']","['visual performance', 'four visual function outcomes: photostress recovery, glare disability, glare discomfort, and chromatic contrast', 'Photostress recovery', 'Visual Function Indoors', 'glare discomfort', 'visual function']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C1444754', 'cui_str': 'Length'}]","[{'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1321306', 'cui_str': 'Glare disability'}, {'cui': 'C0278215', 'cui_str': 'Glare'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}]",,0.0395735,"The minimally activated photochromic contact demonstrated improved visual performance compared with the nonphotochromic control across all visual functions tested (P < .01). ","[{'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Renzi-Hammond', 'Affiliation': '1Human Biofactors Laboratory, Institute of Gerontology, Department of Health Promotion and Behavior, College of Public Health, University of Georgia, Athens, Georgia 2Johnson & Johnson Vision Care, Inc., Jacksonville, Florida 3Georgia Center for Sight, Athens, Georgia 4Vision Sciences Laboratory, Behavioral Brain Sciences Program, Department of Psychology, University of Georgia, Athens, Georgia *bhammond@uga.edu.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Buch', 'Affiliation': ''}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Hacker', 'Affiliation': ''}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Cannon', 'Affiliation': ''}, {'ForeName': 'Billy R', 'Initials': 'BR', 'LastName': 'Hammond', 'Affiliation': ''}]",Optometry and vision science : official publication of the American Academy of Optometry,['10.1097/OPX.0000000000001537'] 2477,32697858,Topical application of autophagy activating peptide improved skin barrier function and reduced acne symptoms in acne-prone skin.,"BACKGROUND Recent studies about the important roles of autophagy signaling in sebaceous lipogenesis and epidermal differentiation suggest potential benefits of autophagy activation in acne. OBJECTIVE To investigate the effects of an autophagy activator on acne-prone skin. METHODS Autophagy signaling in human immortalized SZ95 sebocytes, normal human epidermal keratinocytes and 3D reconstituted skin was examined. Effects of an autophagy-activating peptide on sebaceous lipogenesis was measured by fluorescence microscopic analysis. The clinical efficacy in acne-prone skin was evaluated through an eight week, double-blind, randomized, vehicle-controlled study. Changes in skin surface lipid compositions were further analyzed. RESULTS In cultured sebocytes and keratinocytes, the investigated autophagy-activating peptide increased LC3-II expression, indicating a stimulation of autophagy signaling. Testosterone and linoleic acid treatment induced lipogenesis in cultured sebocytes and further inhibited by the autophagy activator peptide treatment. Increased expression of differentiation marker proteins in cultured keratinocytes was also observed by autophagy activating peptide. In clinical study, reduction of closed comedones and the amount of skin surface lipids as well as of trans-epidermal water loss (TEWL) was observed in acne-prone skin after autophagy activating peptide application. In addition, reduction of squalene and increase of cholesterol were observed after an 8-week of application. CONCLUSIONS Topical application of an autophagy activator down-regulated sebaceous lipogenesis and improved the skin barrier function. Considering the important roles of sebum and skin barrier function in acne pathogenesis, autophagy activation might represent a new therapeutic option in early forms of acne.",2020,"In cultured sebocytes and keratinocytes, the investigated autophagy-activating peptide increased LC3-II expression, indicating a stimulation of autophagy signaling.",['acne-prone skin'],"['autophagy-activating peptide', 'autophagy activator', 'Testosterone and linoleic acid']","['reduction of squalene and increase of cholesterol', 'Increased expression of differentiation marker proteins', 'skin barrier function', 'sebaceous lipogenesis']","[{'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0033422', 'cui_str': 'Prone body position'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}]","[{'cui': 'C0004391', 'cui_str': 'Autophagocytosis'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0023749', 'cui_str': 'Linoleic acid'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0038071', 'cui_str': 'Squalene'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0007589', 'cui_str': 'Differentiation, Cell'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0596843', 'cui_str': 'Adipogenesis'}]",,0.0186451,"In cultured sebocytes and keratinocytes, the investigated autophagy-activating peptide increased LC3-II expression, indicating a stimulation of autophagy signaling.","[{'ForeName': 'Yoonjin', 'Initials': 'Y', 'LastName': 'Lee', 'Affiliation': 'College of Life Science and Biotechnology, Korea University, Seoul, South Korea, 02841.'}, {'ForeName': 'Kayoung', 'Initials': 'K', 'LastName': 'Shin', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, Seoul, South Korea, 34036.'}, {'ForeName': 'Kyong-Oh', 'Initials': 'KO', 'LastName': 'Shin', 'Affiliation': 'Department of Food Science and Nutrition, Hallym University, Chuncheon, South Korea, 24252.'}, {'ForeName': 'Seokjeong', 'Initials': 'S', 'LastName': 'Yoon', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, Seoul, South Korea, 34036.'}, {'ForeName': 'Juyeon', 'Initials': 'J', 'LastName': 'Jung', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, Seoul, South Korea, 34036.'}, {'ForeName': 'Eojin', 'Initials': 'E', 'LastName': 'Hwang', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, Seoul, South Korea, 34036.'}, {'ForeName': 'Hwa-Jee', 'Initials': 'HJ', 'LastName': 'Chung', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, Seoul, South Korea, 34036.'}, {'ForeName': 'Amir M', 'Initials': 'AM', 'LastName': 'Hossini', 'Affiliation': 'Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany, 06847.'}, {'ForeName': 'Christos C', 'Initials': 'CC', 'LastName': 'Zouboulis', 'Affiliation': 'Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany, 06847.'}, {'ForeName': 'Min Jeong', 'Initials': 'MJ', 'LastName': 'Baek', 'Affiliation': 'Dermapro Skin Research Center, DERMAPRO Ltd, Seoul, South Korea, 06684.'}, {'ForeName': 'JiHwoon', 'Initials': 'J', 'LastName': 'Baek', 'Affiliation': 'Dermapro Skin Research Center, DERMAPRO Ltd, Seoul, South Korea, 06684.'}, {'ForeName': 'Young', 'Initials': 'Y', 'LastName': 'Min Chi', 'Affiliation': 'College of Life Science and Biotechnology, Korea University, Seoul, South Korea, 02841.'}, {'ForeName': 'Sangeun', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Department of Dermatology, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea, 06273).'}, {'ForeName': 'Sekyoo', 'Initials': 'S', 'LastName': 'Jeong', 'Affiliation': 'Research Division, Incospharm Corp. Daejeon, Seoul, South Korea, 34036.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13636'] 2478,32697879,"Bihemispheric tDCS for upper-limb hemiparesis in acute stroke: a randomized, double-blind, sham-controlled trial.","BACKGROUND AND PURPOSE Neuromodulation is a promising approach to increase motor recovery in stroke. However, so far, there is a scarcity of evidence documenting the clinical potential of tDCS administered in the acute phase of stroke. The present study aims to examine the clinical effects of a treatment involving the application of tDCS in the acute stage post-stroke. METHODS This is a randomized, double-blind, sham-controlled trial. A cohort of 32 stroke patients with severe motor impairment underwent a 5-days treatment with real or sham bi-hemispheric tDCS over the motor cortex. During the treatment, tDCS was applied twice per day (2 daily applications each of 15 min), starting 48-72 hours after stroke onset. RESULTS We found statistically significant improvements after both real and sham tDCS treatments in primary (Hand Grip Strength, Motricity Index) and secondary (NIHSS, Barthel Index) outcomes. Patients receiving real tDCS showed a larger improvement of upper-limb muscle strength at the end of treatment phase; this advantage was not present any longer after 6 months. CONCLUSIONS tDCS may be used to accelerate the rate of upper-limb motor recovery during the spontaneous recovery period.",2020,"We found statistically significant improvements after both real and sham tDCS treatments in primary (Hand Grip Strength, Motricity Index) and secondary (NIHSS, Barthel Index) outcomes.","['acute stroke', '32 stroke patients with severe motor impairment underwent a']","['real tDCS', 'tDCS', 'Bihemispheric tDCS', '5-days treatment with real or sham bi-hemispheric tDCS']","['upper-limb muscle strength', 'rate of upper-limb motor recovery', 'primary (Hand Grip Strength, Motricity Index) and secondary (NIHSS, Barthel Index) outcomes']","[{'cui': 'C0751956', 'cui_str': 'Acute stroke'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0205139', 'cui_str': 'Hemispheric'}]","[{'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1293900', 'cui_str': 'Hand grip'}, {'cui': 'C0451322', 'cui_str': 'Motricity index'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1697238', 'cui_str': 'NIH stroke scale'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.629061,"We found statistically significant improvements after both real and sham tDCS treatments in primary (Hand Grip Strength, Motricity Index) and secondary (NIHSS, Barthel Index) outcomes.","[{'ForeName': 'N', 'Initials': 'N', 'LastName': 'Bolognini', 'Affiliation': 'Department of Psychology & Milan Center for Neuroscience (NeuroMi), University of Milano-Bicocca, Milan, Italy.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Russo', 'Affiliation': 'Department of Psychology & Milan Center for Neuroscience (NeuroMi), University of Milano-Bicocca, Milan, Italy.'}, {'ForeName': 'M I', 'Initials': 'MI', 'LastName': 'Cairnero Souza', 'Affiliation': 'Department of Psychology & Milan Center for Neuroscience (NeuroMi), University of Milano-Bicocca, Milan, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Nicotra', 'Affiliation': 'Department of Psychology & Milan Center for Neuroscience (NeuroMi), University of Milano-Bicocca, Milan, Italy.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Olgiati', 'Affiliation': 'Department of Psychology & Milan Center for Neuroscience (NeuroMi), University of Milano-Bicocca, Milan, Italy.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Spandri', 'Affiliation': 'Department of Psychology & Milan Center for Neuroscience (NeuroMi), University of Milano-Bicocca, Milan, Italy.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Agostoni', 'Affiliation': ""Department of Neurosciences, Neurology and Stroke Unit, Niguarda Ca' Granda Hospital, Milan, Italy.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Salmaggi', 'Affiliation': 'Neurology - Stroke Unit, A. Manzoni Hospital, ASST Lecco, Lecco, Italy.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Vallar', 'Affiliation': 'Department of Psychology & Milan Center for Neuroscience (NeuroMi), University of Milano-Bicocca, Milan, Italy.'}]",European journal of neurology,['10.1111/ene.14451'] 2479,32697889,Improving self-management in adolescents with sickle cell disease.,"BACKGROUND Sickle cell disease (SCD) is associated with significant medical challenges that often worsen in adolescence when caregivers are beginning to transfer responsibility for disease management. Behavioral activation (BA) is an important precedent to improvements in self-management and ultimately health outcomes; however, few interventions targeting BA have been developed for the SCD population. The goal of the present study was to evaluate a technology-enhanced self-management intervention for adolescents and young adults (AYA) with SCD targeting BA domains (ie, disease knowledge, self-efficacy, motivation, and self-management skills). DESIGN/METHODS Participants were randomized to one of two study arms. SCThrive participants (N = 26) completed six weekly group sessions, an in-person booster session, and used a companion app (iManage) to record symptoms, progress on goals, and connect with other group members. Each SCHealthEd participant (N = 27) received six weekly phone calls on SCD-related and general health education topics. All AYA completed questionnaires assessing BA at baseline and posttreatment. RESULTS Separate mixed ANOVA analyses to assess for the effects of group (SCThrive/SCHealthEd), time (baseline/posttreatment), and group × time interaction indicated that there was a clinically meaningful improvement (8-point change) in self-efficacy, with a medium effect size, P = .09, η 2  = .06, and there was statistically significant improvement in one self-management skill (tracking health), P = .001, d = .71, among SCThrive participants. CONCLUSIONS The results support the potential for a self-management intervention to improve self-efficacy in AYA with SCD. Health care providers are encouraged to target BA skills to support self-management of AYA with SCD.",2020,Each SCHealthEd participant (N = 27) received six weekly phone calls on SCD-related and general health education topics.,"['adolescents and young adults (AYA', 'Participants', 'adolescents with sickle cell disease', 'Sickle cell disease (SCD']","['six weekly phone calls on SCD-related and general health education topics', 'technology-enhanced self-management intervention']","['Behavioral activation (BA', 'one self-management skill (tracking health', 'self-efficacy']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0002895', 'cui_str': 'Sickling disorder due to hemoglobin S'}]","[{'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0002895', 'cui_str': 'Sickling disorder due to hemoglobin S'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C1522168', 'cui_str': 'Topical route'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",,0.045265,Each SCHealthEd participant (N = 27) received six weekly phone calls on SCD-related and general health education topics.,"[{'ForeName': 'Lori E', 'Initials': 'LE', 'LastName': 'Crosby', 'Affiliation': ""Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Hood', 'Affiliation': 'Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, UK.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Kidwell', 'Affiliation': ""Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Cara', 'Initials': 'C', 'LastName': 'Nwankwo', 'Affiliation': ""Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Peugh', 'Affiliation': ""Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Strong', 'Affiliation': ""Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Quinn', 'Affiliation': 'Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}, {'ForeName': 'Maria T', 'Initials': 'MT', 'LastName': 'Britto', 'Affiliation': 'Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}]",Pediatric blood & cancer,['10.1002/pbc.28492'] 2480,32697909,Improved Fast Randomized Iteration Approach to Full Configuration Interaction.,"We present three modifications to our recently introduced fast randomized iteration method for full configuration interaction (FCI-FRI) and investigate their effects on the method's performance for Ne, H 2 O, and N 2 . The initiator approximation, originally developed for full configuration interaction quantum Monte Carlo, significantly reduces statistical error in FCI-FRI when few samples are used in compression operations, enabling its application to larger chemical systems. The semi-stochastic extension, which involves exactly preserving a fixed subset of elements in each compression, improves statistical efficiency in some cases but reduces it in others. We also developed a new approach to sampling excitations that yields consistent improvements in statistical efficiency and reductions in computational cost. We discuss possible strategies based on our findings for improving the performance of stochastic quantum chemistry methods more generally.",2020,"The initiator approximation, originally developed for full configuration interaction quantum Monte Carlo, significantly reduces statistical error in FCI-FRI when few samples are used in compression operations, enabling its application to larger chemical systems.",[],[],[],[],[],[],,0.0381083,"The initiator approximation, originally developed for full configuration interaction quantum Monte Carlo, significantly reduces statistical error in FCI-FRI when few samples are used in compression operations, enabling its application to larger chemical systems.","[{'ForeName': 'Samuel M', 'Initials': 'SM', 'LastName': 'Greene', 'Affiliation': ''}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Webber', 'Affiliation': ''}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Weare', 'Affiliation': ''}, {'ForeName': 'Timothy C', 'Initials': 'TC', 'LastName': 'Berkelbach', 'Affiliation': ''}]",Journal of chemical theory and computation,['10.1021/acs.jctc.0c00437'] 2481,31454264,Metabolic Profile of Supragingival Plaque Exposed to Arginine and Fluoride.,"Caries lesions develop when acid production from bacterial metabolism of dietary carbohydrates outweighs the various mechanisms that promote pH homeostasis, including bacterial alkali production. Therapies that provide arginine as a substrate for alkali production in supragingival oral biofilms have strong anticaries potential. The objective of this study was to investigate the metabolic profile of site-specific supragingival plaque in response to the use of arginine (Arg: 1.5% arginine, fluoride-free) or fluoride (F: 1,100 ppm F/NaF) toothpastes. Eighty-three adults of different caries status were recruited and assigned to treatment with Arg or F for 12 wk. Caries lesions were diagnosed using International Caries Detection and Assessment System II, and plaque samples were collected from caries-free and carious tooth surfaces. Taxonomic profiles were obtained by HOMINGS (Human Oral Microbe Identification using Next Generation Sequencing), and plaque metabolism was assessed by the levels of arginine catabolism via the arginine deiminase pathway (ADS), acidogenicity, and global metabolomics. Principal component analysis (PCA), partial least squares-discriminant analysis, analysis of variance, and random forest tests were used to distinguish metabolic profiles. Of the 509 active lesions diagnosed at baseline, 70 (14%) were inactive after 12 wk. Generalized linear model showed that enamel lesions were significantly more likely to become inactive compared to dentin lesions ( P < 0.0001), but no difference was found when treatment with Arg was compared to F ( P = 0.46). Arg significantly increased plaque ADS activity ( P = 0.031) and plaque pH values after incubation with glucose ( P = 0.001). F reduced plaque lactate production from endogenous sources ( P = 0.02). PCA revealed differences between the metabolic profiles of plaque treated with Arg or F. Arg significantly affected the concentrations of 16 metabolites, including phenethylamine, agmatine, and glucosamine-6-phosphate ( P < 0.05), while F affected the concentrations of 9 metabolites, including phenethylamine, N -methyl-glutamate, and agmatine ( P < 0.05). The anticaries mechanisms of action of arginine and fluoride are distinct. Arginine metabolism promotes biofilm pH homeostasis, whereas fluoride is thought to enhance resistance of tooth minerals to low pH and reduce acid production by supragingival oral biofilms.",2019,Arg significantly increased plaque ADS activity ( P = 0.031) and plaque pH values after incubation with glucose ( P = 0.001).,['Eighty-three adults of different caries status'],"['arginine (Arg: 1.5% arginine, fluoride-free) or fluoride (F: 1,100 ppm F/NaF) toothpastes', 'Arginine and Fluoride']","['concentrations of 16 metabolites, including phenethylamine, agmatine, and glucosamine-6-phosphate', 'enamel lesions', 'plaque pH values', 'plaque lactate production', 'concentrations of 9 metabolites, including phenethylamine, N -methyl-glutamate, and agmatine', 'plaque ADS activity']","[{'cui': 'C4517888', 'cui_str': '83'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0449438', 'cui_str': 'Status'}]","[{'cui': 'C0003765', 'cui_str': 'Arginine'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0016327', 'cui_str': 'Fluoride'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0439187', 'cui_str': 'ppm'}, {'cui': 'C0037508', 'cui_str': 'Sodium Fluoride'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0031399', 'cui_str': 'Phenylethylamines'}, {'cui': 'C0001814', 'cui_str': '1-Amino-4-guanidinobutane'}, {'cui': 'C0061393', 'cui_str': 'glucosamine 6-phosphate'}, {'cui': 'C0011350', 'cui_str': 'Enamel structure'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0017789', 'cui_str': 'Glutamates'}, {'cui': 'C0052332', 'cui_str': 'Arginine deiminase'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",,0.0437561,Arg significantly increased plaque ADS activity ( P = 0.031) and plaque pH values after incubation with glucose ( P = 0.001).,"[{'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Nascimento', 'Affiliation': 'Department of Restorative Dental Sciences, Division of Operative Dentistry, College of Dentistry, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'A J', 'Initials': 'AJ', 'LastName': 'Alvarez', 'Affiliation': 'College of Dentistry, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Department of Oral Biology, College of Dentistry, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Browngardt', 'Affiliation': 'Department of Oral Biology, College of Dentistry, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Jenkins', 'Affiliation': 'Dental Clinical Research Unit, College of Dentistry, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'M C', 'Initials': 'MC', 'LastName': 'Sinhoreti', 'Affiliation': 'Dental Materials Division, Department of Restorative Dentistry, Piracicaba Dental School, State University of Campinas, Piracicaba, SP, Brazil.'}, {'ForeName': 'A P D', 'Initials': 'APD', 'LastName': 'Ribeiro', 'Affiliation': 'Department of Restorative Dental Sciences, Division of Operative Dentistry, College of Dentistry, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'D A', 'Initials': 'DA', 'LastName': 'Dilbone', 'Affiliation': 'Department of Restorative Dental Sciences, Division of Operative Dentistry, College of Dentistry, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'V P', 'Initials': 'VP', 'LastName': 'Richards', 'Affiliation': 'Department of Biological Sciences, College of Science, Clemson University, Clemson, SC, USA.'}, {'ForeName': 'T J', 'Initials': 'TJ', 'LastName': 'Garrett', 'Affiliation': 'Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'R A', 'Initials': 'RA', 'LastName': 'Burne', 'Affiliation': 'Department of Oral Biology, College of Dentistry, University of Florida, Gainesville, FL, USA.'}]",Journal of dental research,['10.1177/0022034519869906'] 2482,31814516,Gratitude increases third-party punishment.,"Third-party punishment occurs when a perpetrator of a transgression is punished by another person who was not directly affected by the transgression (i.e. a third-party). Given gratitude's demonstrated ability to enhance both cooperation and the value people place on future-rewards, its capacity to increase third-party punishment - a phenomenon theorised to increase future cooperative behaviour - was investigated. In two experiments, participants were randomly assigned to experience one of three emotional states (i.e. gratitude, happiness, or neutrality) prior to making decisions about how much of a previous financial endowment they would spend to punish a person who transgressed against another at differing degrees within the context of a dictator game. As expected, punishment expenditures decreased for all participants as a dictator's decision became fairer. Of primary interest, however, participants who felt grateful, as compared to those who felt neutral or happy, engaged in significantly more third-party punishment across dictator splits that were not altruistic in nature.",2020,"Of primary interest, however, participants who felt grateful, as compared to those who felt neutral or happy, engaged in significantly more third-party punishment across dictator splits that were not altruistic in nature.",[],['financial endowment they would spend to punish a person who transgressed against another at differing degrees within the context of a dictator game'],"['punishment expenditures', 'Gratitude increases third-party punishment']",[],"[{'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0014265', 'cui_str': 'Endowments'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0521124', 'cui_str': 'Against'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0332285', 'cui_str': 'In'}]","[{'cui': 'C0006912', 'cui_str': 'Death Penalty'}, {'cui': 'C0015316', 'cui_str': 'Expenditures'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",,0.0235318,"Of primary interest, however, participants who felt grateful, as compared to those who felt neutral or happy, engaged in significantly more third-party punishment across dictator splits that were not altruistic in nature.","[{'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Vayness', 'Affiliation': 'Department of Psychology, Northeastern University, Boston, MA, USA.'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Duong', 'Affiliation': 'Department of Psychology, Northeastern University, Boston, MA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'DeSteno', 'Affiliation': 'Department of Psychology, Northeastern University, Boston, MA, USA.'}]",Cognition & emotion,['10.1080/02699931.2019.1700100'] 2483,32033718,Steroid hormones and hormone antagonists regulate the neural marker neurotrimin in uterine leiomyoma.,"OBJECTIVE To characterize the role of steroid hormone and antihormone exposure on neurotrimin (NTM) expression in human leiomyoma and myometrial tissue and cells. DESIGN Laboratory study of placebo and ulipristal acetate (UPA)-treated patient tissue. In vitro assessment of immortalized myometrial and leiomyoma cell lines after hormone and antihormone exposure. SETTING Academic research center. PATIENT(S) Not applicable. INTERVENTIONS(S) Exposure of leiomyoma cell lines to 17β-E 2 , medroxyprogesterone acetate (MPA), UPA, and fulvestrant. MAIN OUTCOME MEASURE(S) Messenger RNA expression quantified with the use of RNASeq analysis and quantitative real-time polymerase chain reaction (qRT-PCR). Protein levels quantified by means of Western blot analysis. Immunohistochemistry (IHC) on placebo- and UPA-treated patient uterine tissue specimens. RESULT(S) Expression of NTM in human uterine leiomyoma specimens according to RNASeq was increased compared with myometrium (5.22 ± 0.57-fold), which was confirmed with the use of qRT-PCR (1.95 ± 0.05). Furthermore, NTM protein was elevated in leiomyoma tissue compared with matched myometrium (2.799 ± 0.575). IHC revealed increased staining intensity in leiomyoma surgical specimens compared with matched myometrium of placebo patients. Western blot analysis in immortalized leiomyoma cell lines demonstrated an up-regulation of NTM protein expression (2.4 ± 0.04). Treatment of leiomyoma cell lines with 17β-E 2 yielded a 1.98 ± 0.11-fold increase in NTM protein expression; however, treatment with fulvestrant showed no significant change compared with control. Leiomyoma cell lines demonstrated a 1.91 ± 0.97-fold increase in NTM protein expression after progesterone treatment. RNASeq analysis demonstrated a reduced expression in patient leiomyoma after UPA treatment (0.75 ± 0.14). Treatment of leiomyoma cells with UPA demonstrated a reduced total NTM protein amount (0.54 ± 0.31) in patients, which was confirmed with the use of IHC (UPA10 147.2 ± 9.40, UPA20 182.8 ± 8.98). In vitro studies with UPA treatment revealed a concentration-dependent effect that supported these findings. CONCLUSION(S) NTM, a neural cell adhesion molecule, is increased in leiomyoma compared with myometrium in patient tissue and in vitro models after estrogen and progesterone treatment. Down-regulation of expression occurs after UPA treatment, but not after fulvestrant exposure. CLINICAL TRIAL REGISTRATION NUMBER NCT00290251.",2020,"Treatment of leiomyoma cells with UPA demonstrated a reduced total NTM protein amount (0.54 ± 0.31) in patients, which was confirmed with the use of IHC (UPA10 147.2 ± 9.40, UPA20 182.8 ± 8.98).","['uterine leiomyoma', 'Academic research center']","['medroxyprogesterone acetate (MPA), UPA, and fulvestrant', 'Steroid hormones and hormone antagonists', 'steroid hormone and antihormone exposure', 'IHC', 'placebo and ulipristal acetate (UPA)-treated patient tissue', 'UPA', 'placebo']","['Messenger RNA expression', 'staining intensity', 'Immunohistochemistry (IHC', 'total NTM protein', 'NTM protein expression']","[{'cui': 'C0042133', 'cui_str': 'Leiomyoma'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0065864', 'cui_str': 'Medroxyprogesterone acetate'}, {'cui': 'C2723461', 'cui_str': 'Ulipristal acetate'}, {'cui': 'C0935916', 'cui_str': 'fulvestrant'}, {'cui': 'C0301818', 'cui_str': 'Steroid hormone'}, {'cui': 'C0019927', 'cui_str': 'Hormone receptor antagonist-containing product'}, {'cui': 'C0522259', 'cui_str': 'Antihormone'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0021044', 'cui_str': 'Immunohistochemistry'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}]","[{'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0038128', 'cui_str': 'Stain'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0021044', 'cui_str': 'Immunohistochemistry'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0295342', 'cui_str': 'neurotrimin'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}]",,0.119122,"Treatment of leiomyoma cells with UPA demonstrated a reduced total NTM protein amount (0.54 ± 0.31) in patients, which was confirmed with the use of IHC (UPA10 147.2 ± 9.40, UPA20 182.8 ± 8.98).","[{'ForeName': 'Toral P', 'Initials': 'TP', 'LastName': 'Parikh', 'Affiliation': 'Uniformed Services University of the Health Sciences, Bethesda, Maryland; Program in Reproductive Endocrinology and Gynecology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Minnie', 'Initials': 'M', 'LastName': 'Malik', 'Affiliation': 'Uniformed Services University of the Health Sciences, Bethesda, Maryland.'}, {'ForeName': 'Joy', 'Initials': 'J', 'LastName': 'Britten', 'Affiliation': 'Uniformed Services University of the Health Sciences, Bethesda, Maryland.'}, {'ForeName': 'Jasmine M', 'Initials': 'JM', 'LastName': 'Aly', 'Affiliation': 'Uniformed Services University of the Health Sciences, Bethesda, Maryland.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Pilgrim', 'Affiliation': 'Uniformed Services University of the Health Sciences, Bethesda, Maryland; Program in Reproductive Endocrinology and Gynecology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'William H', 'Initials': 'WH', 'LastName': 'Catherino', 'Affiliation': 'Uniformed Services University of the Health Sciences, Bethesda, Maryland; Program in Reproductive Endocrinology and Gynecology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. Electronic address: william.catherino@usuhs.edu.'}]",Fertility and sterility,['10.1016/j.fertnstert.2019.08.090'] 2484,32700432,A randomized controlled pilot study comparing the efficacy of Pulsed Radiofrequency combined with Exercise versus Exercise in pain relief and functional improvement for chronic knee osteoarthritis.,"OBJECTIVES To compare the long-term efficacy between pulsed radiofrequency (PRF) combined with passive stretching (PRF-PS) exercise and PS exercise alone in reducing pain and improving quadriceps muscle strength and knee function. METHODS Sixty-two participants were randomly assigned with 1:1 allocation to PRF-PS exercise group or PS exercise group. Level of pain, muscle strength and knee function were assessed from baseline to 1st, 3rd and 6th months after treatment using VAS, peak torque (PT) and WOMAC, respectively. RESULTS There were no significant differences at baseline between two groups. Compared to exercise, participants achieved superior efficacy of PRF-PS exercise in pain relief, improvement of muscle strength and knee function. Moreover, the efficacy improvement at all variable could maintain a longer time in the PRF-PS exercise group. The reduction in VAS pain intensity was superior for PRF-PS versus PS with overall estimation (adjusted mean difference: -1.85cm; 95% CI: -2.25, -1.45 cm; P=0.000). The increase in PT score was superior for PRF-PS versus PS with overall estimation (adjusted mean difference for PT 60°/s and PT 180°/s, respectively: 15.53 N. m; 95% CI: 7.07, 23.98 N. m; P=0.000, 12.62 N. m; 95% CI: 0.96, 24.28 N. m; P=0.000). The reduction in WOMAC score was superior for PRF-PS versus PS with overall estimation (adjusted mean difference: -16.43; 95% CI: -22.22, -10.64; P=0.000). DISCUSSION The pain relief and knee function improvement might be associated with restoration of muscle strength after PRF-PS exercise through overcoming the inhibition from muscle.",2020,"Compared to exercise, participants achieved superior efficacy of PRF-PS exercise in pain relief, improvement of muscle strength and knee function.","['chronic knee osteoarthritis', 'Sixty-two participants']","['pulsed radiofrequency (PRF) combined with passive stretching (PRF-PS) exercise and PS exercise alone', 'PRF-PS exercise', 'PRF-PS exercise group or PS exercise group', 'Pulsed Radiofrequency combined with Exercise versus Exercise']","['WOMAC score', 'pain relief and functional improvement', 'pain and improving quadriceps muscle strength and knee function', 'PT score', 'pain relief, improvement of muscle strength and knee function', 'Level of pain, muscle strength and knee function', 'pain relief and knee function', 'VAS, peak torque (PT) and WOMAC, respectively', 'VAS pain intensity', 'efficacy improvement']","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C4517835', 'cui_str': '62'}]","[{'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1720871', 'cui_str': 'Static-Passive Stretching'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",62.0,0.137443,"Compared to exercise, participants achieved superior efficacy of PRF-PS exercise in pain relief, improvement of muscle strength and knee function.","[{'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Han', 'Affiliation': 'Department of Pain Management, Huadong Hospital affiliated to Fudan University, Shanghai, 200040, China.'}, {'ForeName': 'Yantao', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': 'Department of Pain Management, Huadong Hospital affiliated to Fudan University, Shanghai, 200040, China.'}, {'ForeName': 'Peiyu', 'Initials': 'P', 'LastName': 'Jia', 'Affiliation': 'Department of Pain Management, Huadong Hospital affiliated to Fudan University, Shanghai, 200040, China.'}, {'ForeName': 'Xiaolei', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Pain Management, Huadong Hospital affiliated to Fudan University, Shanghai, 200040, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': 'Department of Pain Management, Huadong Hospital affiliated to Fudan University, Shanghai, 200040, China.'}, {'ForeName': 'Yongjun', 'Initials': 'Y', 'LastName': 'Zheng', 'Affiliation': 'Department of Pain Management, Huadong Hospital affiliated to Fudan University, Shanghai, 200040, China.'}]",Pain practice : the official journal of World Institute of Pain,['10.1111/papr.12942'] 2485,32700461,Consistent improvement with eculizumab across muscle groups in myasthenia gravis.,"OBJECTIVE To assess whether eculizumab, a terminal complement inhibitor, improves patient- and physician-reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale, respectively) in patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis across four domains, representing ocular, bulbar, respiratory, and limb/gross motor muscle groups. METHODS Patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis were randomized 1:1 to receive either placebo or eculizumab during the REGAIN study (NCT01997229). Patients who completed REGAIN were eligible to continue into the open-label extension trial (NCT02301624) for up to 4 years. The four domain scores of each of the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale recorded throughout REGAIN and through 130 weeks of the open-label extension were analyzed. RESULTS Of the 125 patients who participated in REGAIN, 117 enrolled in the open-label extension; 61 had received placebo and 56 had received eculizumab during REGAIN. Patients experienced rapid improvements in total scores and all four domain scores of both the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale with eculizumab treatment. These improvements were sustained through 130 weeks of the open-label extension. INTERPRETATION Eculizumab treatment elicits rapid and sustained improvements in muscle strength across ocular, bulbar, respiratory, and limb/gross motor muscle groups and in associated daily activities in patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.",2020,Patients experienced rapid improvements in total scores and all four domain scores of both the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale with eculizumab treatment.,"['Patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis', 'patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis across four domains, representing ocular, bulbar, respiratory, and limb/gross motor muscle groups', 'myasthenia gravis', 'patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis', '125 patients who participated in REGAIN, 117 enrolled in the open-label extension; 61 had received']","['eculizumab', 'placebo or eculizumab', 'placebo']","['total scores', 'myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0236516', 'cui_str': 'Acetylcholine receptor antibody'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0472367', 'cui_str': 'Generalized myasthenia'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0026896', 'cui_str': 'Myasthenia gravis'}, {'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0231448', 'cui_str': 'Extension'}]","[{'cui': 'C1541483', 'cui_str': 'eculizumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026896', 'cui_str': 'Myasthenia gravis'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.0560943,Patients experienced rapid improvements in total scores and all four domain scores of both the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale with eculizumab treatment.,"[{'ForeName': 'Renato', 'Initials': 'R', 'LastName': 'Mantegazza', 'Affiliation': 'Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.'}, {'ForeName': 'Fanny L', 'Initials': 'FL', 'LastName': ""O'Brien"", 'Affiliation': 'Alexion Pharmaceuticals, Boston, MA.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Yountz', 'Affiliation': 'Alexion Pharmaceuticals, Boston, MA.'}, {'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Howard', 'Affiliation': 'Department of Neurology, University of North Carolina, Chapel Hill, NC.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Annals of clinical and translational neurology,['10.1002/acn3.51121'] 2486,32700489,[Experimental study of individualized 3D printing-guided template combined with thoracolumbar pedicle screw placement for the treatment of ankylosing spondylitis].,"OBJECTIVE To evaluate accuracy and safety of individualized 3D printing guided template for thoracolumbar pedicle screw placement in patients with ankylosing spondylitis. METHODS From January 2016 to September 2019, thoracolumbar spine three-dimensional CT data of 8 patients with ankylosing spondylitis were included, Mimics 17.0 and ideaMaker computer software were applied to design thoracolumbar pedicle screw guided template of patients with AS, physical model of all patients (T 10 -L 2 )were printed by 3D printer, 2 parts in each patient, and divided into guide-plate-assisted screw group (experimental group) and free-hand nail group (control group). Thoracolumbar pedicle screws of both groups were placed by the same spinal surgeon. The accuracy of pedicle screw placement between two groups were evaluated according to results of postoperative CT, the accuracy of the fixation of thoracolumbar pedicle screw was divided into 4 grades, grade 0 and 1 screws were acceptable nails, grade 2 and 3 screws were unacceptable nails. The diameter and length of pedicle screws, the distance between entry point and posterior median line designed by preoperative 3D printing were compared with actual use in operation. RESULTS Twenty three blocks of thoracolumbar 3D printing screw of ankylosing spondylitis guided templates were designed and printed in guide-plate-assisted screw group, 46 screws were inserted and 44 screws were accepted. The time of implanting a screw into thoracolumbar pedicle was (4.20±1.15) min, the frequency of X-ray was (5.00±1.25) times and the average adjustment times of screw and Kirschner needle during screw placement was (1.76±1.32) times. In the control group, 46 nails were placed by traditional surgical method and 30 screws were accepted. The time of implanting a screw into thoracolumbar pedicle was (14.67±2.23) min, the frequency of X-ray fluoroscopy was (14.46±2.21) times and the average times of Kirschner needle adjustment was (4.76±3.39) times. The success rates between experimental group and control group were 95.65%(44 / 46) and 56.22%(30 / 46) respectively, and had statistical difference (χ 2 =13.538, P <0.05). There was no significant difference in diameter, length of pedicle screws and the distance of posterior median line between virtual designed by 3D printing before operation and actual situation in opertaion ( P >0.05). The operation time of inserting a single screw, the times of X-ray fluoroscopy, and the average times of adjustment screw and Kirschner needle in experimental group were significant less than those in control group( P <0.01). CONCLUSION The personalized guide template assisted the thoracolumbar fixation designed by 3D printing could significantly improve safety, accuracy and efficiency of surgery, especially suitable for thoracolumbar vertebral bodies requiring posterior pedicle screw fixation for fracture or dislocation with AS.",2020,"There was no significant difference in diameter, length of pedicle screws and the distance of posterior median line between virtual designed by 3D printing before operation and actual situation in opertaion ( P >0.05).","['patients with ankylosing spondylitis', 'From January 2016 to September 2019, thoracolumbar spine three-dimensional CT data of 8 patients with ankylosing spondylitis', 'ankylosing spondylitis', 'Twenty']","['thoracolumbar pedicle screw placement', 'individualized 3D printing guided template', 'thoracolumbar', 'thoracolumbar pedicle screw guided template', 'individualized 3D printing-guided template combined with thoracolumbar pedicle screw placement', 'guide-plate-assisted screw group (experimental group) and free-hand nail group (control group']","['time of implanting a screw into thoracolumbar pedicle', 'Thoracolumbar pedicle screws', 'accuracy of pedicle screw placement', 'diameter, length of pedicle screws and the distance of posterior median line between virtual designed by 3D printing before operation and actual situation in opertaion', 'safety, accuracy and efficiency of surgery', 'success rates', 'operation time of inserting a single screw', 'average times of adjustment screw and Kirschner needle', 'diameter and length of pedicle screws, the distance between entry point and posterior median line designed by preoperative 3D printing']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038013', 'cui_str': 'Ankylosing spondylitis'}, {'cui': 'C0450219', 'cui_str': 'Thoracolumbar'}, {'cui': 'C0037949', 'cui_str': 'Structure of vertebral column'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional'}]","[{'cui': 'C0450219', 'cui_str': 'Thoracolumbar'}, {'cui': 'C1961768', 'cui_str': 'Pedicle Screws'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0033161', 'cui_str': 'Printing'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C4317132', 'cui_str': 'Template'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0027342', 'cui_str': 'Nail plate structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C0450219', 'cui_str': 'Thoracolumbar'}, {'cui': 'C0456605', 'cui_str': 'Pedicle'}, {'cui': 'C1961768', 'cui_str': 'Pedicle Screws'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0033161', 'cui_str': 'Printing'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C3849992', 'cui_str': 'Three-Dimensional Printing'}]",8.0,0.0132114,"There was no significant difference in diameter, length of pedicle screws and the distance of posterior median line between virtual designed by 3D printing before operation and actual situation in opertaion ( P >0.05).","[{'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Orthopaedics, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233000, Anhui, China.'}, {'ForeName': 'Guo-Qi', 'Initials': 'GQ', 'LastName': 'Niu', 'Affiliation': 'Department of Orthopaedics, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233000, Anhui, China.'}, {'ForeName': 'Wei-Li', 'Initials': 'WL', 'LastName': 'Jiang', 'Affiliation': 'Department of Orthopaedics, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233000, Anhui, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Department of Orthopaedics, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233000, Anhui, China.'}, {'ForeName': 'Lu-Tan', 'Initials': 'LT', 'LastName': 'Liu', 'Affiliation': 'Department of Orthopaedics, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233000, Anhui, China.'}, {'ForeName': 'Qian-Kun', 'Initials': 'QK', 'LastName': 'Zhou', 'Affiliation': 'Department of Orthopaedics, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233000, Anhui, China.'}, {'ForeName': 'Jia-Wei', 'Initials': 'JW', 'LastName': 'Cheng', 'Affiliation': 'Department of Orthopaedics, the Second Affiliated Hospital of Bengbu Medical College, Bengbu 233000, Anhui, China.'}]",Zhongguo gu shang = China journal of orthopaedics and traumatology,['10.12200/j.issn.1003-0034.2020.07.011'] 2487,32700492,[Back arm flexion and extension combined with manipulation for the treatment of patient with adhesive scapulohumeral periarthritis].,"OBJECTIVE To observe clinical efficacy of back arm flexion and extension combined with manipulation in treating adhesive scapulohumeral periarthritis. METHODS From March 2016 to April 2018, 53 patients with adhesive scapulohumeral periarthritis were treated with back arm flexion and extension combined with manipulation, the main symptoms were shoulder pain and limited activity. There were 22 males and 31 females aged from 45 to 71 years old with an average of (51.63±5.79) years;the courses of disease ranged from 3 to 24 months with an average of (8.62±3.73) months. Manipulation treatment was carried out once a week, and back arm flexion and extension were performed for 3 times a day with15 movements each time, totally 4 weeks for a single course. Visual analogue scale (VAS) and Constant-Murley shoulder function score were observed and compared before treatment and one week, one and three months after treatment. RESULTS All patients were followed up from 3 to 12 months, with an average of (5.91±3.55) months. VAS score before treatment was 4.02±1.46, and was improved to 3.15±1.54, 1.98±1.37, 1.12±0.86 respectively at one week, one and three months after treatment. Constant-Murley score before treatment was 42.70 ±5.72, and improved to 54.25 ±6.34, 67.45 ±6.84, 82.40 ±6.63 at one week, one and three months after treatment respectively;19 patients got excellent result, 22 good, 9 fair and 3 poor. CONCLUSION Back arm flexion combined with manipulation for the treatment of adhesive scapulohumeral periarthritis could effectively relieve pain, improve shoulder function, which is a simple effective treatment strategy.",2020,"CONCLUSION Back arm flexion combined with manipulation for the treatment of adhesive scapulohumeral periarthritis could effectively relieve pain, improve shoulder function, which is a simple effective treatment strategy.","['22 males and 31 females aged from 45 to 71 years old with an average of (51.63±5.79) years;the courses of disease ranged from 3 to 24 months with an average of (8.62±3.73) months', 'patient with adhesive scapulohumeral periarthritis', 'From March 2016 to April 2018, 53 patients with adhesive scapulohumeral periarthritis']","['back arm flexion and extension combined with manipulation', 'Back arm flexion and extension combined with manipulation']","['Constant-Murley score', 'Visual analogue scale (VAS) and Constant-Murley shoulder function score', 'VAS score']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001516', 'cui_str': 'Adhesive'}, {'cui': 'C0031037', 'cui_str': 'Periarthritis'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}]","[{'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",53.0,0.0277231,"CONCLUSION Back arm flexion combined with manipulation for the treatment of adhesive scapulohumeral periarthritis could effectively relieve pain, improve shoulder function, which is a simple effective treatment strategy.","[{'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Zhang', 'Affiliation': 'Wenzhou TCM Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Wenzhou 325000, Zhejiang, China.'}, {'ForeName': 'Hong-Sheng', 'Initials': 'HS', 'LastName': 'Zhan', 'Affiliation': 'Wenzhou TCM Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Wenzhou 325000, Zhejiang, China.'}, {'ForeName': 'Qing-Lai', 'Initials': 'QL', 'LastName': 'Wang', 'Affiliation': 'Wenzhou TCM Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Wenzhou 325000, Zhejiang, China.'}, {'ForeName': 'Hui-Ming', 'Initials': 'HM', 'LastName': 'Wu', 'Affiliation': 'Wenzhou TCM Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Wenzhou 325000, Zhejiang, China.'}, {'ForeName': 'Jiang-Tao', 'Initials': 'JT', 'LastName': 'Zhou', 'Affiliation': 'Wenzhou TCM Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Wenzhou 325000, Zhejiang, China.'}]",Zhongguo gu shang = China journal of orthopaedics and traumatology,['10.12200/j.issn.1003-0034.2020.07.014'] 2488,32700515,Efficacy of a Stannous-containing Dentifrice for Protecting Against Combined Erosive and Abrasive Tooth Wear In Situ.,"PURPOSE The in-situ efficacy of an experimental stannous (Sn)-containing sodium fluoride (NaF) dentifrice against erosion and erosive tooth wear was compared with a conventional NaF dentifrice. MATERIALS AND METHODS This was a randomised, controlled, double-blind, parallel-group clinical trial. Mandibular appliances containing four enamel specimens (2 per side [L/R] of the appliance) were worn by 60 generally healthy adult subjects. Subjects were randomised to treatment based on age and gender. Treatments included a Sn-containing NaF or conventional NaF dentifrice. Conditions of erosion (dentifrice slurry treatment) and erosion/tooth wear (dentifrice slurry plus brushing) were compared. Dentifrices were used twice per day for 30 s of lingual brushing, followed by 90 s of slurry exposure. In addition, the two specimens on the left side of the mouth were brushed for 5 s each, using a power toothbrush. All specimens were exposed to four daily erosive challenges with commercial orange juice (pH 3.6). Tooth wear was measured as enamel loss using non-contact profilometry on day 10. RESULTS At the day 10 visit, the adjusted mean (SE) enamel loss for specimens receiving slurry (erosion) treatment was 4.7 µm (0.61) [Sn-containing NaF] and 8.73 µm (1.12) [NaF control], with results demonstrating a statistically significant benefit for the Sn-containing dentifrice (46.2% benefit; p = 0.009). For specimens exposed to erosion/tooth wear conditions, enamel loss = 6.68 µm (1.29) (Sn-containing NaF) and 10.99 µm (1.29) (NaF group), with results statistically significant (p = 0.048; 39.2% better, favouring the Sn-containing dentifrice). When data were combined, enamel loss (SE) for all specimens subjected to erosion + erosion/tooth wear was 5.61 µm (0.77) (Sn-containing NaF]) and 9.9 µm (1.3) (NaF group). The difference again was statistically significant, favouring the Sn-containing group (p = 0.022; 43.4% better). CONCLUSIONS The Sn-containing dentifrice demonstrated significantly better protection than did NaF under erosive and erosive/tooth wear conditions.",2020,The Sn-containing dentifrice demonstrated significantly better protection than did NaF under erosive and erosive/tooth wear conditions.,['Mandibular appliances containing four enamel specimens (2 per side [L/R] of the appliance) were worn by 60 generally healthy adult subjects'],"['experimental stannous (Sn)-containing sodium fluoride (NaF) dentifrice', 'Dentifrices', 'Stannous-\ufeffcontaining Dentifrice', 'conventional NaF dentifrice', 'Sn-containing NaF or conventional NaF dentifrice']",['enamel loss'],"[{'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C1542418', 'cui_str': 'Appliance'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0011350', 'cui_str': 'Enamel structure'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0037508', 'cui_str': 'Sodium Fluoride'}, {'cui': 'C0011427', 'cui_str': 'Dentifrice'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0011350', 'cui_str': 'Enamel structure'}]",60.0,0.0809518,The Sn-containing dentifrice demonstrated significantly better protection than did NaF under erosive and erosive/tooth wear conditions.,"[{'ForeName': 'Xinyi', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': ''}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'He', 'Affiliation': ''}, {'ForeName': 'Yanyan', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': ''}, {'ForeName': 'Haijing', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': ''}]",Oral health & preventive dentistry,['10.3290/j.ohpd.a44926'] 2489,32700919,Indigenously adapted cognitive-behavioral therapy for excessive smartphone use (IACBT-ESU): A randomized controlled trial.,"This study aims to assess whether 12 sessions of indigenously adapted cognitive-behavioral therapy for excessive smartphone use (IACBT-ESU) would reduce excessive smartphone use. A single-blind randomized controlled trial was conducted in students (12 to 19 years of age) to examine the potential beneficial effects of IACBT-ESU ( n = 62) compared with brief educational data alone ( n = 62). Symptoms of depression, anxiety, stress, and peer relations were also compared between the two groups. The IACBT-ESU group demonstrated significant reductions in excessive smartphone use, with reduced symptoms of depression, anxiety, stress, hyperactivity, and emotional difficulties at both trial end and at 3-month follow-up ( p < .01) compared with control participants. IACBT-ESU was associated with reduced excessive smartphone use and improved psychological well-being, with beneficial findings maintained 3 months after the trial's end. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"The IACBT-ESU group demonstrated significant reductions in excessive smartphone use, with reduced symptoms of depression, anxiety, stress, hyperactivity, and emotional difficulties at both trial end and at 3-month follow-up ( p < .01) compared with control participants.",['students (12 to 19 years of age'],"['brief educational data alone', 'IACBT-ESU', 'Indigenously adapted cognitive-behavioral therapy', '12 sessions of indigenously adapted cognitive-behavioral therapy for excessive smartphone use (IACBT-ESU']","['Symptoms of depression, anxiety, stress, and peer relations', 'symptoms of depression, anxiety, stress, hyperactivity, and emotional difficulties', 'excessive smartphone use']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0442802', 'cui_str': 'Excessive'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0424295', 'cui_str': 'Hyperactive behavior'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0442802', 'cui_str': 'Excessive'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",,0.0621227,"The IACBT-ESU group demonstrated significant reductions in excessive smartphone use, with reduced symptoms of depression, anxiety, stress, hyperactivity, and emotional difficulties at both trial end and at 3-month follow-up ( p < .01) compared with control participants.","[{'ForeName': 'Muhammad Tahir', 'Initials': 'MT', 'LastName': 'Khalily', 'Affiliation': 'Department of Psychology, International Islamic University Islamabad.'}, {'ForeName': 'Mujeeb Masud', 'Initials': 'MM', 'LastName': 'Bhatti', 'Affiliation': 'Department of Psychology, International Islamic University Islamabad.'}, {'ForeName': 'Irshad', 'Initials': 'I', 'LastName': 'Ahmad', 'Affiliation': 'Department of Psychology, International Islamic University Islamabad.'}, {'ForeName': 'Tamkeen', 'Initials': 'T', 'LastName': 'Saleem', 'Affiliation': 'Department of Psychology, International Islamic University Islamabad.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Hallahan', 'Affiliation': 'Department of Psychiatry, National University of Ireland.'}, {'ForeName': 'Syeda Ayat-E-Zainab', 'Initials': 'SA', 'LastName': 'Ali', 'Affiliation': 'Department of Psychology, International Islamic University Islamabad.'}, {'ForeName': 'Ahmad Ali', 'Initials': 'AA', 'LastName': 'Khan', 'Affiliation': 'Department of Psychology, International Islamic University Islamabad.'}, {'ForeName': 'Basharat', 'Initials': 'B', 'LastName': 'Hussain', 'Affiliation': 'Department of Psychology, International Islamic University Islamabad.'}]",Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors,['10.1037/adb0000677'] 2490,32698766,Outcome impact of individualized fluid management during spine surgery: a before-after prospective comparison study.,"BACKGROUND Individualized fluid management (IFM) has been shown to be useful to improve the postoperative outcome of patients undergoing major abdominal surgery. A limited number of clinical studies have been done in orthopaedic patients and have yielded conflicting results. We designed the present study to investigate the clinical impact of IFM in patients undergoing major spine surgery. METHODS This is a before-after study done in 300 patients undergoing posterior spine arthrodesis. Postoperative outcomes were compared between control group implementing standard fluid management (n = 150) and IFM group (n = 150) guided by fluid protocol based on continuous stroke volume monitoring and optimization. The primary outcome measure was the proportion of patients who developed one or more complications within 30 days following surgery. RESULTS During surgery, patients received on average the same volume of crystalloids (7.4 vs 7.2 ml/kg/h) and colloids (1.6 vs 1.6 ml/kg/h) before and after the implementation of IFM. During 30 days following surgery, the proportion of patients who developed one or more complications was lower in the IFM group (32 vs 48%, p < 0.01). This difference was mainly explained by a significant decrease in post-operative nausea and vomiting (from 38 to 19%, p < 0.01), urinary tract infections (from 9 to 1%, p < 0.01) and surgical site infections (from 5 to 1%, p < 0.05). Median hospital length of stay was not affected by the implementation of IFM. CONCLUSION In patients undergoing major spine surgery, the implementation of IFM was associated with a significant decrease in postoperative morbidity. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02470221 . Prospectively registered on June 12, 2015.",2020,"During 30 days following surgery, the proportion of patients who developed one or more complications was lower in the IFM group (32 vs 48%, p < 0.01).","['patients undergoing major abdominal surgery', '300 patients undergoing posterior spine arthrodesis', 'spine surgery', 'patients undergoing major spine surgery']","['IFM', 'individualized fluid management', 'Individualized fluid management (IFM']","['urinary tract infections', 'Median hospital length of stay', 'post-operative nausea and vomiting', 'postoperative morbidity', 'proportion of patients who developed one or more complications', 'surgical site infections']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0037949', 'cui_str': 'Structure of vertebral column'}, {'cui': 'C0003881', 'cui_str': 'Arthrodesis'}, {'cui': 'C0920347', 'cui_str': 'Procedure on spinal cord'}]","[{'cui': 'C0553741', 'cui_str': 'Fluid balance regulation'}]","[{'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}]",300.0,0.151746,"During 30 days following surgery, the proportion of patients who developed one or more complications was lower in the IFM group (32 vs 48%, p < 0.01).","[{'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Che', 'Affiliation': 'Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, 100730, China.'}, {'ForeName': 'Xiu H', 'Initials': 'XH', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, 100730, China.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, 100730, China.'}, {'ForeName': 'Yue L', 'Initials': 'YL', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, 100730, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, 100730, China. pumchxuli@163.com.'}, {'ForeName': 'Yu G', 'Initials': 'YG', 'LastName': 'Huang', 'Affiliation': 'Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, 100730, China.'}]",BMC anesthesiology,['10.1186/s12871-020-01092-w'] 2491,32698790,AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.,"BACKGROUND Immune checkpoint inhibitors (ICIs) reported remarkable achievements in several solid tumours. However, in metastatic colorectal cancer (mCRC) promising results are limited to patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-high) tumours due to their immune-enriched microenvironment. Combining cytotoxic agents and bevacizumab in mCRC with proficient mismatch repair/microsatellite stability (pMMR/MSS) could make ICIs efficacious by increasing the exposure of neoantigens, especially with highly active chemotherapy regimens, inducing immunogenic cell death, increasing the tumoral infiltration of CD8+ T-cells and reducing tumour-associated myeloid-derived suppressor cells. VEGF-blockade also plays an immunomodulatory role by inhibiting the expansion of T regulatory lymphocytes. Consistently with this rationale, a phase Ib study combined the anti-PDL-1 atezolizumab with FOLFOX/bevacizumab as first-line treatment of mCRC, irrespective of microsatellite status, and reported interesting activity and efficacy results, without safety concerns. Phase III trials led to identify FOLFOXIRI plus bevacizumab as an upfront therapeutic option in selected mCRC patients. Drawing from these considerations, the combination of atezolizumab with an intensified upfront treatment (FOLFOXIRI) and bevacizumab could be worthy of investigation. METHODS AtezoTRIBE is a prospective, open label, phase II, comparative trial in which initially unresectable and previously untreated mCRC patients, irrespective of microsatellite status, are randomized in a 1:2 ratio to receive up to 8 cycles of FOLFOXIRI/bevacizumab alone or in combination with atezolizumab, followed by maintenance with bevacizumab plus 5-fluoruracil/leucovorin with or without atezolizumab according to treatment arm until disease progression. The primary endpoint is PFS. Assuming a median PFS of 12 months for standard arm, 201 patients should be randomized in a 1:2 ratio to detect a hazard ratio of 0.66 in favour of the experimental arm. A safety run-in phase including the first 6 patients enrolled in the FOLFOXIRI/bevacizumab/atezolizumab arm was planned, and no unexpected adverse events or severe toxicities were highlighted by the Safety Monitoring Committee. DISCUSSION The AtezoTRIBE study aims at assessing whether the addition of atezolizumab to an intensified chemotherapy plus bevacizumab might be an efficacious upfront strategy for the treatment of mCRC, irrespective of the microsatellite status. TRIAL REGISTRATION AtezoTRIBE is registered at Clinicaltrials.gov ( NCT03721653 ), October 26th, 2018 and at EUDRACT (2017-000977-35), Februray 28th, 2017.",2020,"Combining cytotoxic agents and bevacizumab in mCRC with proficient mismatch repair/microsatellite stability (pMMR/MSS) could make ICIs efficacious by increasing the exposure of neoantigens, especially with highly active chemotherapy regimens, inducing immunogenic cell death, increasing the tumoral infiltration of CD8+ T-cells and reducing tumour-associated myeloid-derived suppressor cells.","['metastatic colorectal cancer (mCRC', 'selected mCRC patients', 'patients with unresectable metastatic colorectal cancer', 'initially unresectable and previously untreated mCRC patients, irrespective of microsatellite status']","['FOLFOXIRI/bevacizumab alone or in combination with atezolizumab', 'FOLFOX/bevacizumab', 'bevacizumab plus 5-fluoruracil/leucovorin with or without atezolizumab', 'FOLFOXIRI/bevacizumab/atezolizumab', 'atezolizumab', 'FOLFOXIRI plus bevacizumab', 'bevacizumab']","['PFS', 'adverse events or severe toxicities']","[{'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C1519302', 'cui_str': 'Short Tandem Repeats'}, {'cui': 'C0449438', 'cui_str': 'Status'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C4055433', 'cui_str': 'atezolizumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0040539', 'cui_str': 'TO'}]",6.0,0.0553497,"Combining cytotoxic agents and bevacizumab in mCRC with proficient mismatch repair/microsatellite stability (pMMR/MSS) could make ICIs efficacious by increasing the exposure of neoantigens, especially with highly active chemotherapy regimens, inducing immunogenic cell death, increasing the tumoral infiltration of CD8+ T-cells and reducing tumour-associated myeloid-derived suppressor cells.","[{'ForeName': 'Carlotta', 'Initials': 'C', 'LastName': 'Antoniotti', 'Affiliation': 'Department of Oncology, University Hospital of Pisa, Pisa, Italy.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Borelli', 'Affiliation': 'Department of Oncology, University Hospital of Pisa, Pisa, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Rossini', 'Affiliation': 'Department of Oncology, University Hospital of Pisa, Pisa, Italy.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Pietrantonio', 'Affiliation': 'Oncology and Hemato-Oncology Department, University of Milan, Milano, Italy.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Morano', 'Affiliation': 'Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Salvatore', 'Affiliation': 'Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Lonardi', 'Affiliation': 'Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto - IRCCS, Padova, Italy.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Marmorino', 'Affiliation': 'Department of Oncology, University Hospital of Pisa, Pisa, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Tamberi', 'Affiliation': 'Medical Oncology, Ospedale degli Infermi, Faenza, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Corallo', 'Affiliation': 'Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.'}, {'ForeName': 'Giampaolo', 'Initials': 'G', 'LastName': 'Tortora', 'Affiliation': 'Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Bergamo', 'Affiliation': 'Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto - IRCCS, Padova, Italy.'}, {'ForeName': 'Di Stefano', 'Initials': 'DS', 'LastName': 'Brunella', 'Affiliation': 'Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Boccaccino', 'Affiliation': 'Department of Oncology, University Hospital of Pisa, Pisa, Italy.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Grassi', 'Affiliation': 'Medical Oncology, Ospedale degli Infermi, Faenza, Italy.'}, {'ForeName': 'Patrizia', 'Initials': 'P', 'LastName': 'Racca', 'Affiliation': 'SSD ColoRectal Cancer Unit, Department of Oncology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.'}, {'ForeName': 'Emiliano', 'Initials': 'E', 'LastName': 'Tamburini', 'Affiliation': 'Department of Oncology and Palliative Care, Cardinale G. Panico, Tricase City Hospital, Tricase, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Aprile', 'Affiliation': 'Department of Oncology, San Bortolo General Hospital, ULSS8 Berica, East District, Vicenza, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Moretto', 'Affiliation': 'Department of Oncology, University Hospital of Pisa, Pisa, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Boni', 'Affiliation': 'Clinical Trials Coordinating Center, Toscano Cancer Institute, University Hospital Careggi, Firenze, Italy.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Falcone', 'Affiliation': 'Department of Oncology, University Hospital of Pisa, Pisa, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Cremolini', 'Affiliation': 'Department of Oncology, University Hospital of Pisa, Pisa, Italy. chiaracremolini@gmail.com.'}]",BMC cancer,['10.1186/s12885-020-07169-6'] 2492,32698812,Protocol: examining the effectiveness of an adaptive implementation intervention to improve uptake of the VA suicide risk identification strategy: a sequential multiple assignment randomized trial.,"BACKGROUND In 2018, the Veterans Health Administration (VHA) mandated implementation of a national suicide risk identification strategy (Risk ID). The goal of Risk ID is to improve the detection and management of suicide risk by standardizing suicide risk screening and evaluation enterprise-wide. In order to ensure continuous quality improvement (QI), ongoing evaluation and targeted interventions to improve implementation of Risk ID are needed. Moreover, given that facilities will vary with respect to implementation needs and barriers, the dose and type of intervention needed may vary across facilities. Thus, the objective of this study is to examine the effectiveness of an adaptive implementation strategy to improve the uptake of suicide risk screening and evaluation in VHA ambulatory care settings. In addition, this study will examine specific factors that may impact the uptake of suicide risk screening and evaluation and the adoption of different implementation strategies. This protocol describes the stepped implementation approach and proposed evaluation plan. METHODS Using a sequential multiple assignment randomized trial (SMART) design, two evidence-based implementation strategies will be evaluated: (1) audit and feedback (A&F); (2) A&F plus external facilitation (A&F + EF). Implementation outcomes of interest include uptake of secondary suicide risk screening and uptake of comprehensive suicide risk evaluation (stages 2 and 3 of Risk ID). Secondary outcomes include rates of other clinical outcomes (i.e., safety planning) and organizational factors that may impact Risk ID implementation (i.e., leadership climate and leadership support). DISCUSSION This national QI study will use a SMART design to evaluate whether an adaptive implementation strategy is effective in improving uptake of a mandated VHA-wide suicide risk screening and evaluation initiative. If this study finds that the proposed stepped implementation strategy is effective at increasing uptake and maintaining performance improvements, this approach may be used as an overarching QI strategy for other national suicide prevention programs. TRIAL REGISTRATION ClinicalTrials.gov NCT04243330 . Registered 28 January 2020.",2020,"If this study finds that the proposed stepped implementation strategy is effective at increasing uptake and maintaining performance improvements, this approach may be used as an overarching QI strategy for other national suicide prevention programs. ",[],"['adaptive implementation intervention', 'feedback (A&F); (2) A&F plus external facilitation (A&F + EF']","['rates of other clinical outcomes (i.e., safety planning) and organizational factors that may impact Risk ID implementation (i.e., leadership climate and leadership support']",[],"[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0037415', 'cui_str': 'Social Facilitation'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning'}, {'cui': 'C0029246', 'cui_str': 'Organizations'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0150323', 'cui_str': 'Risk identification'}, {'cui': 'C0023181', 'cui_str': 'Leadership'}, {'cui': 'C0008946', 'cui_str': 'Climate'}, {'cui': 'C0183683', 'cui_str': 'Support'}]",,0.112886,"If this study finds that the proposed stepped implementation strategy is effective at increasing uptake and maintaining performance improvements, this approach may be used as an overarching QI strategy for other national suicide prevention programs. ","[{'ForeName': 'Nazanin H', 'Initials': 'NH', 'LastName': 'Bahraini', 'Affiliation': 'VA Rocky Mountain Mental Illness Research, Education and Clinical Center (MIRECC), Rocky Mountain Regional VA Medical Center, 1700 N Wheeling St, Aurora, CO, 80045, USA. nazanin.bahraini@va.gov.'}, {'ForeName': 'Bridget B', 'Initials': 'BB', 'LastName': 'Matarazzo', 'Affiliation': 'VA Rocky Mountain Mental Illness Research, Education and Clinical Center (MIRECC), Rocky Mountain Regional VA Medical Center, 1700 N Wheeling St, Aurora, CO, 80045, USA.'}, {'ForeName': 'Catherine N', 'Initials': 'CN', 'LastName': 'Barry', 'Affiliation': 'VA Program Evaluation and Resource Center (PERC), Palo Alto, CA, USA.'}, {'ForeName': 'Edward P', 'Initials': 'EP', 'LastName': 'Post', 'Affiliation': 'Ann Arbor VA Health Care System, Ann Arbor, MI, USA.'}, {'ForeName': 'Jeri E', 'Initials': 'JE', 'LastName': 'Forster', 'Affiliation': 'VA Rocky Mountain Mental Illness Research, Education and Clinical Center (MIRECC), Rocky Mountain Regional VA Medical Center, 1700 N Wheeling St, Aurora, CO, 80045, USA.'}, {'ForeName': 'Katherine M', 'Initials': 'KM', 'LastName': 'Dollar', 'Affiliation': 'VA Center for Integrated Healthcare, Syracuse, NY, USA.'}, {'ForeName': 'Steven K', 'Initials': 'SK', 'LastName': 'Dobscha', 'Affiliation': 'VA Center to Improve Veteran Involvement in Care, Portland VA Health Care System, Portland, OR, USA.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Brenner', 'Affiliation': 'VA Rocky Mountain Mental Illness Research, Education and Clinical Center (MIRECC), Rocky Mountain Regional VA Medical Center, 1700 N Wheeling St, Aurora, CO, 80045, USA.'}]",Implementation science : IS,['10.1186/s13012-020-01019-6'] 2493,32698830,Vestibular prognosis in idiopathic sudden sensorineural hearing loss with vestibular dysfunction treated with oral or intratympanic glucocorticoids: a protocol for randomized controlled trial.,"BACKGROUND Idiopathic sudden sensorineural hearing loss (ISSNHL) is a rapid-onset sensorineural hearing impairment with unclear etiology and unsatisfying treatment effects. Vestibular dysfunction has been considered as a poor indicator in the clinical manifestations and prognosis of ISSNHL, which occurred in approximately 28-57% cases. Glucocorticoids, administered through oral or intratympanic way, are currently regularly and standardly applied for ISSNHL to improve the hearing outcome. However, the vestibular prognosis of ISSNHL after routine treatments remains seldom explored. This study aims to compare the effectiveness of oral and intratympanic glucocorticoids in ISSNHL with vestibular dysfunction in terms of the pattern and trajectory of possible process of vestibular function recovery. METHODS/DESIGN A randomized, outcome-assessor- and analyst-blinded, controlled, clinical trial (RCT) will be carried out. Seventy-two patients with ISSNHL complaining of vestibular dysfunction appearing as vertigo or imbalance will be recruited and randomized into either oral or intratympanic glucocorticoid therapy group with a 1:1 allocation ratio. The primary outcomes will be vestibular function outcomes assessed by sensory organization test, caloric test, video head impulse test, cervical vestibular evoked myogenic potential, and ocular vestibular evoked myogenic potential; the secondary outcomes include self-reported vestibular dysfunction symptoms; dizziness-related handicap, visual analogue scale for vertigo and tinnitus; and pure tone audiometry. Assessments of primary outcomes will be performed at baseline and at 4 and 8 weeks post-randomization, while assessments of secondary outcomes will be performed at baseline and 1, 2, 4, and 8 weeks post-randomization. DISCUSSION Previous intervention studies of ISSNHL included only hearing outcomes, with little attention paid on the prognosis of vestibular dysfunction. This trial will be the first RCT study focusing on the progress and prognosis of vestibular dysfunction in ISSNHL. The efficacy of two commonly used therapies of glucocorticoids will be compared in both auditory and vestibular function fields, rather than in the hearing outcome alone. TRIAL REGISTRATION ClinicalTrials.gov NCT03974867 . Registered on 23 July 2019.",2020,"The efficacy of two commonly used therapies of glucocorticoids will be compared in both auditory and vestibular function fields, rather than in the hearing outcome alone. ",['Seventy-two patients with ISSNHL complaining of vestibular dysfunction appearing as vertigo or imbalance'],"['oral or intratympanic glucocorticoids', 'oral and intratympanic glucocorticoids', 'Glucocorticoids', 'glucocorticoids', 'oral or intratympanic glucocorticoid therapy']","['vestibular function outcomes assessed by sensory organization test, caloric test, video head impulse test, cervical vestibular evoked myogenic potential, and ocular vestibular evoked myogenic potential; the secondary outcomes include self-reported vestibular dysfunction symptoms; dizziness-related handicap, visual analogue scale for vertigo and tinnitus; and pure tone audiometry']","[{'cui': 'C4319632', 'cui_str': '72'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C4275242', 'cui_str': 'Sudden sensorineural hearing loss'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0042571', 'cui_str': 'Vertigo'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1517566', 'cui_str': 'Intratympanic route'}, {'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}, {'cui': 'C0744425', 'cui_str': 'Glucocorticoid therapy'}]","[{'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C4720873', 'cui_str': 'Sensory organization test'}, {'cui': 'C0006778', 'cui_str': 'Caloric vestibular test'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C3658201', 'cui_str': 'Head impulse test'}, {'cui': 'C2936455', 'cui_str': 'Cervical Vestibular Evoked Myogenic Potentials'}, {'cui': 'C2936454', 'cui_str': 'Ocular Vestibular Evoked Myogenic Potentials'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0231172', 'cui_str': 'Handicap'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0042571', 'cui_str': 'Vertigo'}, {'cui': 'C0040264', 'cui_str': 'Tinnitus'}, {'cui': 'C0004292', 'cui_str': 'Pure tone audiometry'}]",72.0,0.111893,"The efficacy of two commonly used therapies of glucocorticoids will be compared in both auditory and vestibular function fields, rather than in the hearing outcome alone. ","[{'ForeName': 'Weiming', 'Initials': 'W', 'LastName': 'Hao', 'Affiliation': ""ENT Institute and Otorhinolaryngology Department of Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, 83 Fenyang Road, Shanghai, 200031, People's Republic of China.""}, {'ForeName': 'Liping', 'Initials': 'L', 'LastName': 'Zhao', 'Affiliation': ""ENT Institute and Otorhinolaryngology Department of Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, 83 Fenyang Road, Shanghai, 200031, People's Republic of China.""}, {'ForeName': 'Huiqian', 'Initials': 'H', 'LastName': 'Yu', 'Affiliation': ""ENT Institute and Otorhinolaryngology Department of Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, 83 Fenyang Road, Shanghai, 200031, People's Republic of China. yhq925@163.com.""}, {'ForeName': 'Huawei', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': ""ENT Institute and Otorhinolaryngology Department of Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, 83 Fenyang Road, Shanghai, 200031, People's Republic of China. huaweili2000@163.com.""}]",Trials,['10.1186/s13063-020-04579-6'] 2494,32698855,Closed drainage versus non-drainage for single-level lumbar discectomy: a prospective randomized controlled study.,"BACKGROUND Postoperative epidural haematoma and wound infection can cause devastating neurological damage in spinal surgery. Closed drainage is a common method to prevent epidural haematoma, infection and related neurological impairment after lumbar decompression; however, it is not clear whether drainage can reduce postoperative complications and improve clinical efficacy. This randomized study aims to explore the role of closed drainage in reducing postoperative complications and improving the clinical efficacy of single-level lumbar discectomy. METHODS A total of 420 patients with single-level lumbar disc herniation were finally included in this study (169 females and 251 males, age 50.0 ± 6.4 years). A total of 214 patients were randomly assigned to the closed drainage group, and 206 patients were assigned to the non-drainage group. The incidence of postoperative fever, symptomatic epidural haematoma, wound infection and the need for revision surgery were compared between the two groups by the chi-square test or Fisher's exact test. The visual analogue scale (VAS) and oswestry disability index (ODI) were used to evaluate the improvement of pain relief and the recovery of lumbar function. The VAS and ODI scores were compared between the two groups using t tests. RESULTS The complications of the two groups were compared and analysed. There was only a statistically significant difference in the postoperative fever rate (p = 0.022), as the non-drainage group had a higher fever rate, but there were no significant differences in the rates of symptomatic epidural haematoma, wound infection or revision operation (p > 0.05). After concrete analysis, for the rate of fever less than 38.5 degrees, there was a statistically significant difference (p = 0.027), but there was no significant difference when the fever was greater than 38.5 degrees (p > 0.05). When comparing the VAS scores of the operation area on the first day after the operation, the pain relief in the closed drainage group was significantly better than that in the non-drainage group, with scores of 5.1 ± 0.8 and 6.0 ± 0.7, respectively (p < 0.001). However, there was no significant difference between the two groups in the other VAS scores of operation areas, the VAS scores of the lower extremity, or the ODI scores (p > 0.05). CONCLUSIONS For single-level lumbar discectomy, closed drainage is beneficial for reducing postoperative low-grade fever and relieving pain in the operation area in the very early postoperative stage. However, drainage does not have a significant impact on reducing the incidence of postoperative complications or improving clinical efficacy. TRIAL REGISTRATION Current Controlled Trials ChiCTR1800016005 , May/06/2018, retrospectively registered.",2020,"However, there was no significant difference between the two groups in the other VAS scores of operation areas, the VAS scores of the lower extremity, or the ODI scores (p > 0.05). ","['214 patients were randomly assigned to the closed drainage group, and 206 patients were assigned to the non-drainage group', 'spinal surgery', '420 patients with single-level lumbar disc herniation were finally included in this study (169 females and 251 males, age 50.0\u2009±\u20096.4\u2009years']","['Closed drainage versus non-drainage', 'closed drainage']","['postoperative low-grade fever and relieving pain', 'pain relief', 'visual analogue scale (VAS) and oswestry disability index (ODI', 'rate of fever less', 'VAS scores of operation areas, the VAS scores of the lower extremity, or the ODI scores', 'rates of symptomatic epidural haematoma, wound infection or revision operation', 'pain relief and the recovery of lumbar function', 'postoperative complications', 'postoperative fever rate', 'VAS and ODI scores', 'fever rate', 'fever', 'postoperative fever, symptomatic epidural haematoma, wound infection and the need for revision surgery', 'VAS scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C4517774', 'cui_str': '420'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0281899', 'cui_str': 'Prolapsed lumbar intervertebral disc'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0761050', 'cui_str': '(GVGVP)251'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517822', 'cui_str': '6.4'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0239574', 'cui_str': 'Low grade pyrexia'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C2960603', 'cui_str': 'Oswestry disability index score'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0238154', 'cui_str': 'Epidural hemorrhage'}, {'cui': 'C0043241', 'cui_str': 'Local infection of wound'}, {'cui': 'C0439616', 'cui_str': 'Revisions'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0424786', 'cui_str': 'Postoperative fever'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}]",420.0,0.0745268,"However, there was no significant difference between the two groups in the other VAS scores of operation areas, the VAS scores of the lower extremity, or the ODI scores (p > 0.05). ","[{'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Guo', 'Affiliation': ""Department of Spine Surgery, Xi'an Jiaotong University College of Medicine, Honghui Hospital, Xi'an, Shaanxi, China.""}, {'ForeName': 'Biao', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': ""Department of Spine Surgery, Xi'an Jiaotong University College of Medicine, Honghui Hospital, Xi'an, Shaanxi, China.""}, {'ForeName': 'Zhaohua', 'Initials': 'Z', 'LastName': 'Ji', 'Affiliation': ""Department of epidemiology, Shaanxi Provincial Key Laboratory of Free Radical Biology and Medicine, The Ministry of Education Key Laboratory of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Air Force Medical University, Xi'an, Shaanxi, China.""}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': ""Department of Intensive Care Unit, Xi'an Jiaotong University College of Medicine, Honghui Hospital, Xi'an, Shaanxi, China.""}, {'ForeName': 'Yuting', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ""Department of Computed Tomography, Xi'an Jiaotong University College of Medicine, Honghui Hospital, Xi'an, Shaanxi, China.""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Yuan', 'Affiliation': ""Department of Spine Surgery, Xi'an Jiaotong University College of Medicine, Honghui Hospital, Xi'an, Shaanxi, China.""}, {'ForeName': 'Dingjun', 'Initials': 'D', 'LastName': 'Hao', 'Affiliation': ""Department of Spine Surgery, Xi'an Jiaotong University College of Medicine, Honghui Hospital, Xi'an, Shaanxi, China. dingjunhaowb@163.com.""}]",BMC musculoskeletal disorders,['10.1186/s12891-020-03504-x'] 2495,32698860,Automated vs. conventional ventilation in the ICU: a randomized controlled crossover trial comparing blood oxygen saturation during daily nursing procedures (I-NURSING).,"BACKGROUND Hypoxia is common during daily nursing procedures (DNPs) routinely performed on mechanically ventilated patients. The impact of automated ventilation on the incidence and severity of blood oxygen desaturation during DNPs remains unknown. METHODS A prospective randomized controlled crossover trial was carried out in a French intensive care unit to compare blood oxygen pulse saturation (SpO 2 ) during DNPs performed on patients mechanically ventilated in automated and conventional ventilation modes (AV and CV, respectively). All patients with FiO 2  ≤ 60% and without prone positioning or neuromuscular blocking agents were included. Patients underwent two DNPs on the same day using AV (INTELLiVENT-ASV®) and CV (volume control, biphasic positive airway pressure, or pressure support ventilation) in a randomized order. The primary outcome was the percentage of time spent with SpO 2 in the acceptable range of 90-95% during the DNP. RESULTS Of the 265 included patients, 93% had been admitted for a medical pathology, the majority for acute respiratory failure (52%). There was no difference between the two periods in terms of DNP duration, sedation requirements, or ventilation parameters, but patients had more spontaneous breaths and lower peak airway pressures during the AV period (p <  0.001). The percentage of time spent with SpO 2 in the acceptable range during DNPs was longer in the AV period than in the CV period (48 ± 37 vs. 43 ± 37, percentage of DNP period; p = 0.03). After adjustment, AV was associated with a higher number of DNPs carried out with SpO 2 in the acceptable range (odds ratio, 1.82; 95% CI, 1.28 to 2.6; p = 0.001) and a lower incidence of blood oxygen desaturation ≤ 85% (adjusted odds ratio, 0.50; 95% CI, 0.30 to 0.85; p = 0.01). CONCLUSION AV appears to reduce the incidence and severity of blood oxygen desaturation during daily nursing procedures (DNPs) in comparison to CV. TRIAL REGISTRATION This study was registered in clinical-trial.gov ( NCT03176329 ) in June 2017.",2020,"There was no difference between the two periods in terms of DNP duration, sedation requirements, or ventilation parameters, but patients had more spontaneous breaths and lower peak airway pressures during the AV period (p <  0.001).","['All patients with FiO 2 \u2009≤\u200960% and without prone positioning or neuromuscular blocking agents were included', 'Of the 265 included patients', 'patients mechanically ventilated in automated and conventional ventilation modes (AV and CV, respectively', 'mechanically ventilated patients']","['conventional ventilation', 'CV (volume control, biphasic positive airway pressure, or pressure support ventilation', 'automated ventilation', 'blood oxygen saturation']","['DNP duration, sedation requirements, or ventilation parameters', 'acute respiratory failure', 'spontaneous breaths and lower peak airway pressures', 'percentage of time spent with SpO 2', 'percentage of time spent with SpO 2 in the acceptable range', 'blood oxygen desaturation', 'blood oxygen pulse saturation (SpO 2 ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033422', 'cui_str': 'Prone body position'}, {'cui': 'C0150305', 'cui_str': 'Positioning - therapy'}, {'cui': 'C0027866', 'cui_str': 'Neuromuscular blocking agent'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0042491', 'cui_str': 'Ventilation'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C1299448', 'cui_str': 'Patient ventilated'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0449972', 'cui_str': 'Volume control'}, {'cui': 'C1611149', 'cui_str': 'Bilevel positive airway pressure'}, {'cui': 'C0419008', 'cui_str': 'Pressure support'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0428174', 'cui_str': 'Hemoglobin saturation with oxygen'}]","[{'cui': 'C0045511', 'cui_str': '2,4-dinitrophenol'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0264490', 'cui_str': 'Acute respiratory failure'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0225386', 'cui_str': 'Breath'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}]",,0.163451,"There was no difference between the two periods in terms of DNP duration, sedation requirements, or ventilation parameters, but patients had more spontaneous breaths and lower peak airway pressures during the AV period (p <  0.001).","[{'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Chelly', 'Affiliation': 'Intensive Care Unit, Groupe Hospitalier Sud Ile de France, 270 avenue Marc Jacquet, 77000, Melun, France. jonathanchelly1@gmail.com.'}, {'ForeName': 'Sandie', 'Initials': 'S', 'LastName': 'Mazerand', 'Affiliation': 'Intensive Care Unit, Groupe Hospitalier Sud Ile de France, 270 avenue Marc Jacquet, 77000, Melun, France.'}, {'ForeName': 'Sebastien', 'Initials': 'S', 'LastName': 'Jochmans', 'Affiliation': 'Intensive Care Unit, Groupe Hospitalier Sud Ile de France, 270 avenue Marc Jacquet, 77000, Melun, France.'}, {'ForeName': 'Claire-Marie', 'Initials': 'CM', 'LastName': 'Weyer', 'Affiliation': 'Intensive Care Unit, Groupe Hospitalier Sud Ile de France, 270 avenue Marc Jacquet, 77000, Melun, France.'}, {'ForeName': 'Franck', 'Initials': 'F', 'LastName': 'Pourcine', 'Affiliation': 'Intensive Care Unit, Groupe Hospitalier Sud Ile de France, 270 avenue Marc Jacquet, 77000, Melun, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Ellrodt', 'Affiliation': 'Intensive Care Unit, Groupe Hospitalier Sud Ile de France, 270 avenue Marc Jacquet, 77000, Melun, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Thieulot-Rolin', 'Affiliation': 'Intensive Care Unit, Groupe Hospitalier Sud Ile de France, 270 avenue Marc Jacquet, 77000, Melun, France.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Serbource-Goguel', 'Affiliation': 'Intensive Care Unit, Groupe Hospitalier Sud Ile de France, 270 avenue Marc Jacquet, 77000, Melun, France.'}, {'ForeName': 'Oumar', 'Initials': 'O', 'LastName': 'Sy', 'Affiliation': 'Intensive Care Unit, Groupe Hospitalier Sud Ile de France, 270 avenue Marc Jacquet, 77000, Melun, France.'}, {'ForeName': 'Ly Van Phach', 'Initials': 'LVP', 'LastName': 'Vong', 'Affiliation': 'Intensive Care Unit, Groupe Hospitalier Sud Ile de France, 270 avenue Marc Jacquet, 77000, Melun, France.'}, {'ForeName': 'Mehran', 'Initials': 'M', 'LastName': 'Monchi', 'Affiliation': 'Intensive Care Unit, Groupe Hospitalier Sud Ile de France, 270 avenue Marc Jacquet, 77000, Melun, France.'}]","Critical care (London, England)",['10.1186/s13054-020-03155-3'] 2496,32698903,Effects of beta-conglycinin intake on circulating FGF21 levels and brown adipose tissue activity in Japanese young men: a single intake study and a randomized controlled trial.,"BACKGROUND Human brown adipose tissue (BAT) activity has beneficial effects on body composition and glucose metabolism. A previous study reported that beta-conglycinin intake induced postprandial fibroblast growth factor 21 (FGF21) secretion, thereby promoting adipose tissue thermogenesis in mice. Since it has not been evaluated whether beta-conglycinin intake is associated with induced FGF21 secretion and BAT thermogenesis in humans, the current study examined the effects of beta-conglycinin intake on circulating FGF21 level and BAT activity. METHODS Twenty-two healthy young male subjects participated. This study consisted of 2 interventional studies. In one of them, the effects of single beta-conglycinin intake at thermoneutral temperature on circulating FGF21 levels were examined (n = 7). The other study was a single-blinded randomized crossover trial of 2 weeks (n = 14). The subjects were exposed to mild cold conditions using a climatic chamber, and BAT activity was analyzed using thermography. Serum FGF21 level was determined by ELISA in these studies. RESULTS In the single intake study, serum FGF21 level was the highest before beta-conglycinin intake and gradually and significantly decreased throughout the 2-h experimental period (P < 0.05). The randomized crossover trial showed that 2-week beta-conglycinin intake did not affect serum FGF21 level and BAT activity, whereas changes (Δ) in baseline levels of serum FGF21 were positively correlated with Δ BAT activity (P < 0.05). In addition, analysis of each group revealed that there was significant correlation between the Δ serum FGF21 level and Δ BAT activity in the beta-conglycinin group (P < 0.05), but not in the placebo group. CONCLUSIONS This study reveals that although serum FGF21 levels are not increased by a single or short-term intake of beta-conglycinin, the Δ basal FGF21 level is associated with Δ BAT activity. These results suggest that human FGF21 responsiveness is different from that of rodents and support the importance of FGF21 in human BAT thermogenesis. TRIAL REGISTRATION This study is registered with University Hospital Medical Information Network in Japan (number 000038723,  https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043942 ).",2020,"FGF21 level and Δ BAT activity in the beta-conglycinin group (P < 0.05), but not in the placebo group. ","['Twenty-two healthy young male subjects participated', 'Japanese young men']","['2-week beta-conglycinin', 'beta-conglycinin intake', 'placebo']","['BAT activity', 'serum FGF21 level', 'serum FGF21 levels', 'serum FGF21 level and BAT activity', 'Serum FGF21 level', 'baseline levels of serum FGF21', 'circulating FGF21 levels and brown adipose tissue activity', 'FGF21 level and Δ BAT activity', 'circulating FGF21 levels', 'postprandial fibroblast growth factor 21 (FGF21) secretion']","[{'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0053405', 'cui_str': 'beta-conglycinin protein, Glycine max'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0006298', 'cui_str': 'Brown fat'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0972232', 'cui_str': 'fibroblast growth factor 21'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0036536', 'cui_str': 'secretion'}]",22.0,0.0355452,"FGF21 level and Δ BAT activity in the beta-conglycinin group (P < 0.05), but not in the placebo group. ","[{'ForeName': 'Hirokazu', 'Initials': 'H', 'LastName': 'Taniguchi', 'Affiliation': 'Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, 1-5 Hangi-cho, Shimogamo, Sakyo-ku, Kyoto, 606-8522, Japan. hirokazu-t@kpu.ac.jp.'}, {'ForeName': 'Keigo', 'Initials': 'K', 'LastName': 'Shimizu', 'Affiliation': 'Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, 1-5 Hangi-cho, Shimogamo, Sakyo-ku, Kyoto, 606-8522, Japan.'}, {'ForeName': 'Sayori', 'Initials': 'S', 'LastName': 'Wada', 'Affiliation': 'Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, 1-5 Hangi-cho, Shimogamo, Sakyo-ku, Kyoto, 606-8522, Japan.'}, {'ForeName': 'Shinsuke', 'Initials': 'S', 'LastName': 'Nirengi', 'Affiliation': 'Clinical Research Institute, Division of Preventive Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, 612-8555, Japan.'}, {'ForeName': 'Haruki', 'Initials': 'H', 'LastName': 'Kataoka', 'Affiliation': 'Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, 1-5 Hangi-cho, Shimogamo, Sakyo-ku, Kyoto, 606-8522, Japan.'}, {'ForeName': 'Akane', 'Initials': 'A', 'LastName': 'Higashi', 'Affiliation': 'Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, 1-5 Hangi-cho, Shimogamo, Sakyo-ku, Kyoto, 606-8522, Japan.'}]",Journal of physiological anthropology,['10.1186/s40101-020-00226-w'] 2497,32698912,12-weeks of Calanus finmarchicus oil intake improves omega-3-index in healthy older subjects engaging in an exercise program.,"The omega-3 polyunsaturated fatty acids (n-3 PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) play an important role in human health. As the intake of EPA and DHA from the diet is often inadequate, supplementation of those fatty acids is recommended. A novel source of n-3 PUFAs is the oil from Calanus finmarchicus (CO) which contains fatty acids mainly bound in wax esters. To date, no data is available on the effects of long-term intake of this marine oil on n-3 PUFA blood levels. Therefore, the aim of this study was to evaluate the effect of CO on the n-3 PUFA blood levels using the omega-3-index (O3I). The data originate from a larger randomized controlled trial. For this analysis samples from 72 participants (59.2 ± 6.2 years, BMI was 27.7 ± 5.28 kg/m2) were analyzed. Of those, 36 performed 2x/week exercise and received 2g of CO, which provided 124 mg stearidonic acid (SDA), 109 mg EPA, and 87 mg DHA daily (EXCO group), while the other group performed exercise only (EX group) and served as a control for this analysis. The O3I increased from 6.07 ± 1.29% at baseline to 7.37 ± 1.10% after 12 weeks within the EXCO group (p<0.001), while there were no significant changes in the EX group (6.01 ± 1.26% to 6.15 ± 1.32%, p=0.238). These data provide first evidence that wax ester-bound n-3 PUFAs from CO can significantly increase the omega-3-index despite relatively low EPA+DHA amounts. Further, the effects of exercise could be excluded.",2020,"The O3I increased from 6.07 ± 1.29% at baseline to 7.37 ± 1.10% after 12 weeks within the EXCO group (p<0.001), while there were no significant changes in the EX group (6.01 ± 1.26% to 6.15 ± 1.32%, p=0.238).","['human health', '72 participants (59.2 ± 6.2 years, BMI was 27.7 ± 5.28 kg/m2) were analyzed', 'healthy older subjects engaging in an exercise program']","['n-3 PUFAs', 'CO, which provided 124 mg stearidonic acid (SDA), 109 mg EPA, and 87 mg DHA daily (EXCO group), while the other group performed exercise only (EX group) and served as a control for this analysis', 'CO', 'Calanus finmarchicus oil intake', 'omega-3 polyunsaturated fatty acids (n-3 PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA', 'EXCO']",['n-3 PUFA blood levels'],"[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C4517820', 'cui_str': '6.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0075197', 'cui_str': 'stearidonic acid'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0556200', 'cui_str': 'Oil intake'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}]","[{'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0342047,"The O3I increased from 6.07 ± 1.29% at baseline to 7.37 ± 1.10% after 12 weeks within the EXCO group (p<0.001), while there were no significant changes in the EX group (6.01 ± 1.26% to 6.15 ± 1.32%, p=0.238).","[{'ForeName': 'Paulina', 'Initials': 'P', 'LastName': 'Wasserfurth', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany; wasserfurth@nutrition.uni-hannover.de; nebl@nutrition.uni-hannover.de; hahn@nutrition.uni-hannover.de; schuchardt@nutrition.uni-hannover.de.'}, {'ForeName': 'Josefine', 'Initials': 'J', 'LastName': 'Nebl', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany; wasserfurth@nutrition.uni-hannover.de; nebl@nutrition.uni-hannover.de; hahn@nutrition.uni-hannover.de; schuchardt@nutrition.uni-hannover.de.'}, {'ForeName': 'Tim Konstantin', 'Initials': 'TK', 'LastName': 'Boßlau', 'Affiliation': 'Department of Exercise Physiology and Sports Therapy, Institute of Sports Science, Justus-Liebig-University Giessen, Giessen, Germany; tim.k.bosslau@med.uni-giessen.de; karsten.krueger@sport.uni-giessen.de.'}, {'ForeName': 'Karsten', 'Initials': 'K', 'LastName': 'Krüger', 'Affiliation': 'Department of Exercise Physiology and Sports Therapy, Institute of Sports Science, Justus-Liebig-University Giessen, Giessen, Germany; tim.k.bosslau@med.uni-giessen.de; karsten.krueger@sport.uni-giessen.de.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Hahn', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany; wasserfurth@nutrition.uni-hannover.de; nebl@nutrition.uni-hannover.de; hahn@nutrition.uni-hannover.de; schuchardt@nutrition.uni-hannover.de.'}, {'ForeName': 'Jan Philipp', 'Initials': 'JP', 'LastName': 'Schuchardt', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany; wasserfurth@nutrition.uni-hannover.de; nebl@nutrition.uni-hannover.de; hahn@nutrition.uni-hannover.de; schuchardt@nutrition.uni-hannover.de.'}]",The British journal of nutrition,['10.1017/S0007114520002809'] 2498,32698957,"The effect of synbiotic on glycemic profile and sex hormones in overweight and obese breast cancer survivors following a weight-loss diet: A randomized, triple-blind, controlled trial.","BACKGROUND The investigation was designed to assess the effects of synbiotic supplementation on glycemic profile, insulin-like growth factor-1 (IGF-1) and sex hormones in overweight and obese postmenopausal breast cancer survivors (BCSs) who had hormone-receptor-positive breast cancer. METHODS This randomized, triple-blind, placebo-controlled trial was conducted on 76 overweight and obese BCSs aged 57.43 (5.82) years. All participants were given a specified low calorie diet and were randomly assigned into two groups to intake 10 9  CFU/day of synbiotic supplement (n = 38) or placebo (n = 38) for 8 weeks. Body composition, physical activity, glycemic profile, IGF-1, estradiol, testosterone and dehydroepiandrosterone sulfate (DHEA-S) were measured at baseline and after 8 weeks. RESULTS A significant reduction in serum insulin (median change (Q1, Q3) from baseline of -1.05 (-2.36, 0.32) μIU/mL; P = 0.006) and insulin resistance (HOMA-IR) (mean change (SD) from baseline of -4.0 (0.9); P = 0.007) were seen over the 8 weeks in the synbiotic group. However, no significant changes were observed in serum insulin, fasting plasma glucose, HbA1c, HOMA-IR, IGF-1, estradiol, testosterone, DHEA-S and sex hormone binding globulin between-groups at the end of the intervention. CONCLUSIONS Overall, as the 8-week synbiotic consumption compared with placebo had insignificant-reducing effects on glycemic profile, IGF-1 and sex hormones among overweight and obese postmenopausal BCSs, synbiotics may exert considerable beneficial consequences, which need to be further assessed in future clinical trials. TRIAL REGISTRATION IRCT, IRCT2015090223861N1. Registered 02 February 2017, http://www.irct.ir: IRCT2015090223861N1.",2020,"However, no significant changes were observed in serum insulin, fasting plasma glucose, HbA1c, HOMA-IR, IGF-1, estradiol, testosterone, DHEA-S and sex hormone binding globulin between-groups at the end of the intervention. ","['overweight and obese breast cancer survivors following a weight-loss diet', '76 overweight and obese BCSs aged 57.43 (5.82)\xa0years', 'overweight and obese postmenopausal breast cancer survivors (BCSs) who had hormone-receptor-positive breast cancer']","['μIU', 'specified low calorie diet', 'synbiotic supplementation', 'intake 10 9 \xa0CFU/day of synbiotic supplement', 'synbiotic', 'placebo']","['serum insulin (median change (Q1, Q3', 'glycemic profile, insulin-like growth factor-1 (IGF-1) and sex hormones', 'Body composition, physical activity, glycemic profile, IGF-1, estradiol, testosterone and dehydroepiandrosterone sulfate (DHEA-S', 'serum insulin, fasting plasma glucose, HbA1c, HOMA-IR, IGF-1, estradiol, testosterone, DHEA-S and sex hormone binding globulin', 'glycemic profile, IGF-1 and sex hormones', 'insulin resistance (HOMA-IR', 'glycemic profile and sex hormones']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0012167', 'cui_str': 'Weight reduction diet'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C2930544', 'cui_str': 'Calorie restricted diet'}, {'cui': 'C2936470', 'cui_str': 'Synbiotics'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0553561', 'cui_str': 'colony-forming unit'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0021665', 'cui_str': 'Somatomedin C'}, {'cui': 'C0036884', 'cui_str': 'Sex hormone'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0057277', 'cui_str': 'Dehydroepiandrosterone sulfate'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0036883', 'cui_str': 'Sex steroid binding globulin'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}]",76.0,0.356573,"However, no significant changes were observed in serum insulin, fasting plasma glucose, HbA1c, HOMA-IR, IGF-1, estradiol, testosterone, DHEA-S and sex hormone binding globulin between-groups at the end of the intervention. ","[{'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Raji Lahiji', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Safa', 'Initials': 'S', 'LastName': 'Najafi', 'Affiliation': 'Breast Disease Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Janani', 'Affiliation': 'Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Bahareh', 'Initials': 'B', 'LastName': 'Yazdani', 'Affiliation': 'Department of Microbiology, School of Biology Sciences, Islamic Azad University, Tehran, Iran.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Razmpoosh', 'Affiliation': 'Quality of Life Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran; Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Mitra', 'Initials': 'M', 'LastName': 'Zarrati', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. Electronic address: Zarrati_ms@yahoo.com.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.05.043'] 2499,32700955,A randomized controlled trial of central executive training (CET) versus inhibitory control training (ICT) for ADHD.,"OBJECTIVE Executive function deficits are well-established in ADHD. Unfortunately, replicated evidence indicates that executive function training for ADHD has been largely unsuccessful. We hypothesized that this may reflect insufficient targeting, such that extant protocols do not sufficiently and specifically target the neurocognitive systems associated with phenotypic ADHD behaviors/impairments. METHOD Children with ADHD ages 8-12 (M = 10.41, SD = 1.46; 12 girls; 74% Caucasian/Non-Hispanic) were randomized with allocation concealment to either central executive training (CET; n = 25) or newly developed inhibitory control training (ICT; n = 29). Detailed data analytic plans were preregistered. RESULTS Both treatments were feasible/acceptable based on training duration, child-reported ease of use, and parent-reported high satisfaction. CET was superior to ICT for improving its primary intervention targets: phonological and visuospatial working memory (d = 0.70-0.84). CET was also superior to ICT for improving go/no-go (d = 0.84) but not stop-signal inhibition. Mechanisms of change analyses indicated that CET-related working memory improvements produced significant reductions in the primary clinical endpoints (objectively assessed hyperactivity) during working memory and inhibition testing (indirect effects: β ≥ -.11; 95% CIs exclude 0.0). CET was also superior to ICT on 3 of 4 secondary clinical endpoints (blinded teacher-rated ADHD symptoms; d = 0.46-0.70 vs. 0.16-0.42) and 2 of 4 feasibility/acceptability clinical endpoints (parent-reported ADHD symptoms; d = 0.96-1.42 vs. 0.45-0.65). CET-related gains were maintained at 2-4 month follow-up; ICT-related gains were maintained for attention problems but not hyperactivity/impulsivity per parent report. CONCLUSIONS Results support the use of CET for treating executive function deficits and targeting ADHD behavioral symptoms in children with ADHD. Findings for ICT were mixed at best and indicate the need for continued development/study. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"CET-related gains were maintained at 2-4 month follow-up; ICT-related gains were maintained for attention problems but not hyperactivity/impulsivity per parent report. ","['children with ADHD', 'Children with ADHD ages 8-12 (M = 10.41, SD = 1.46; 12 girls; 74% Caucasian/Non-Hispanic']","['central executive training (CET; n = 25) or newly developed inhibitory control training (ICT', 'central executive training (CET) versus inhibitory control training (ICT', 'ICT', 'CET']",[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C5191363', 'cui_str': '1.46'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}]","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],,0.087537,"CET-related gains were maintained at 2-4 month follow-up; ICT-related gains were maintained for attention problems but not hyperactivity/impulsivity per parent report. ","[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Kofler', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Erica L', 'Initials': 'EL', 'LastName': 'Wells', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Leah J', 'Initials': 'LJ', 'LastName': 'Singh', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Elia F', 'Initials': 'EF', 'LastName': 'Soto', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Lauren N', 'Initials': 'LN', 'LastName': 'Irwin', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Nicole B', 'Initials': 'NB', 'LastName': 'Groves', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Elizabeth S M', 'Initials': 'ESM', 'LastName': 'Chan', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Caroline E', 'Initials': 'CE', 'LastName': 'Miller', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Kijana P', 'Initials': 'KP', 'LastName': 'Richmond', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Schatschneider', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Lonigan', 'Affiliation': 'Department of Psychology.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000550'] 2500,32700956,Applying experimental therapeutics to examine cognitive and chronological vulnerabilities as mediators of acute outcomes in cognitive-behavioral therapy and light therapy for winter depression.,"OBJECTIVE We applied the experimental therapeutics approach to test whether acute treatment outcomes for winter seasonal affective disorder (SAD) are mediated by a cognitive mechanism in cognitive-behavioral therapy (CBT-SAD) versus a chronobiologic mechanism in light therapy (LT). METHOD Currently depressed adults with major depression, recurrent with seasonal pattern (N = 177; 83.6% female, 92.1% non-Hispanic White, M age = 45.6) were randomized to 6 weeks of LT or group CBT-SAD. SAD symptoms were assessed weekly on the Structured Clinical Interview for the Hamilton Rating Scale for Depression-SAD Version. At pre-, mid-, and posttreatment, participants completed measures of general depressogenic cognitions (Dysfunctional Attitudes Scale; DAS); SAD-specific negative cognitions (Seasonal Beliefs Questionnaire; SBQ); chronotype (Morningness-Eveningness Questionnaire; MEQ); and depressive symptoms (Beck Depression Inventory-Second Edition). RESULTS Parallel-process growth models showed evidence for hypothesized mechanisms. For SAD-specific negative cognitions (SBQ), both symptom measures showed (1) an effect of treatment group on the slope of the mediator, with CBT-SAD demonstrating greater decreases, and (2) an effect of the slope of the mediator on the slope of the outcome. These effects held for the SBQ but not the broader measure of depressogenic cognitions (DAS). For the chronotype measure (MEQ), treatment assignment affected change, whereby LT was associated with reduced ""eveningness,"" but this was unrelated to change in symptoms. CONCLUSIONS CBT-SAD promoted decreases in SAD-specific negative cognitions, and these changes were related to decreases in symptoms. Consistent with the theory that LT corrects misaligned circadian rhythms, LT reduced eveningness, but this did not correspond to symptom improvement. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"For the chronotype measure (MEQ), treatment assignment affected change, whereby LT was associated with reduced ""eveningness,"" but this was unrelated to change in symptoms. ","['winter depression', 'Currently depressed adults with major depression, recurrent with seasonal pattern (N = 177; 83.6% female, 92.1% non-Hispanic White, M age = 45.6', 'winter seasonal affective disorder (SAD']","['cognitive-behavioral therapy (CBT-SAD', 'cognitive-behavioral therapy and light therapy', 'CBT-SAD', 'LT or group CBT-SAD']","['general depressogenic cognitions (Dysfunctional Attitudes Scale; DAS); SAD-specific negative cognitions (Seasonal Beliefs Questionnaire; SBQ); chronotype (Morningness-Eveningness Questionnaire; MEQ); and depressive symptoms (Beck Depression Inventory-Second Edition', 'depressogenic cognitions (DAS', 'SAD symptoms', 'SAD-specific negative cognitions', 'Structured Clinical Interview for the Hamilton Rating Scale for Depression-SAD Version', 'For SAD-specific negative cognitions (SBQ']","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0439601', 'cui_str': 'Seasonal course'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0085159', 'cui_str': 'Seasonal affective disorder'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0085159', 'cui_str': 'Seasonal affective disorder'}, {'cui': 'C0031765', 'cui_str': 'Light therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0051767', 'cui_str': 'amsonic acid'}, {'cui': 'C0085159', 'cui_str': 'Seasonal affective disorder'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0439601', 'cui_str': 'Seasonal course'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439152', 'cui_str': 'mEq'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0441795', 'cui_str': 'Second edition'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0199182', 'cui_str': 'History taking'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C2607870', 'cui_str': 'Version'}]",,0.0343493,"For the chronotype measure (MEQ), treatment assignment affected change, whereby LT was associated with reduced ""eveningness,"" but this was unrelated to change in symptoms. ","[{'ForeName': 'Kelly J', 'Initials': 'KJ', 'LastName': 'Rohan', 'Affiliation': 'Department of Psychological Science.'}, {'ForeName': 'Keith B', 'Initials': 'KB', 'LastName': 'Burt', 'Affiliation': 'Department of Psychological Science.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Camuso', 'Affiliation': 'Department of Psychological Science.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Perez', 'Affiliation': 'Department of Psychological Science.'}, {'ForeName': 'Jonah', 'Initials': 'J', 'LastName': 'Meyerhoff', 'Affiliation': 'Department of Psychological Science.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000499'] 2501,32694343,"Effect of aerobic and resistance exercise training on inflammation, endothelial function and ambulatory blood pressure in middle-aged hypertensive patients.","OBJECTIVE The current randomized controlled trial tested the hypothesis that both aerobic training and dynamic resistance training will improve inflammation, endothelial function and 24-h ambulatory blood pressure (ABP) in middle-aged adults with hypertension, but aerobic training would be more effective. METHODS Forty-two hypertensive patients on at least one antihypertensive medication (19 men/23 women; 30-59 years of age) were randomly assigned to 12 weeks of supervised aerobic training (n = 15), resistance training (n = 15) or a nonexercise control (n = 12) group. Inflammation, endothelial function, 24-h ABP and related measures were evaluated at pre and postintervention. RESULTS We found that aerobic training and resistance training were well tolerated. Both aerobic training and resistance training reduced daytime systolic ABP (-7.2 ± 7.9 and -4.4 ± 5.8 mmHg; P < 0.05) and 24-h systolic ABP (-5.6 ± 6.2 and -3.2 ± 6.4 mmHg; P < 0.05). aerobic training and resistance training both improved brachial artery flow-mediated dilation by 1.7 ± 2.8 and 1.4 ± 2.6%, respectively (7.59 ± 3.36 vs. 9.26 ± 2.93 and 7.24 ± 3.18 vs. 8.58 ± 2.37; pre vs. post P < 0.05). However, only aerobic training decreased markers of inflammation (C-reactive protein, monocyte chemoattractant protein-1, vascular cell adhesion molecule-1 and lectin-like oxidized LDL receptor-1) and endothelin-1 and increased nitrite and nitrate levels (P < 0.05). CONCLUSION Healthcare providers should continue to emphasize aerobic training for hypertension management given the established role of nitric oxide, endothelin-1 and chronic low-level inflammation in the pathogenesis of cardiovascular disease. However, our study demonstrates that resistance training should also be encouraged for middle-aged hypertensive patients. Our results also suggest that even if patients are on antihypertensive medications, regular aerobic training and resistance training are beneficial for blood pressure control and cardiovascular disease risk reduction.",2020,"However, only aerobic training decreased markers of inflammation (C-reactive protein, monocyte chemoattractant protein-1, vascular cell adhesion molecule-1 and lectin-like oxidized LDL receptor-1) and endothelin-1 and increased nitrite and nitrate levels (P < 0.05). ","['middle-aged adults with hypertension', 'Forty-two hypertensive patients on at least one antihypertensive medication (19 men/23 women; 30-59 years of age', 'middle-aged hypertensive patients']","['aerobic training and dynamic resistance training', 'resistance training', 'supervised aerobic training (n\u200a=\u200a15), resistance training (n\u200a=\u200a15) or a nonexercise control', 'aerobic training and resistance training', 'aerobic and resistance exercise training']","['brachial artery flow-mediated dilation', 'tolerated', 'Inflammation, endothelial function, 24-h ABP and related measures', 'inflammation, endothelial function and 24-h ambulatory blood pressure (ABP', '24-h systolic ABP', 'daytime systolic ABP', 'inflammation, endothelial function and ambulatory blood pressure', 'markers of inflammation (C-reactive protein, monocyte chemoattractant protein-1, vascular cell adhesion molecule-1 and lectin-like oxidized LDL receptor-1) and endothelin-1 and increased nitrite and nitrate levels']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}]","[{'cui': 'C0006087', 'cui_str': 'Structure of brachial artery'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0855316', 'cui_str': 'Blood pressure ambulatory'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0128897', 'cui_str': 'Monocyte Chemoattractant Protein-1'}, {'cui': 'C0078056', 'cui_str': 'Lymphocyte antigen CD106'}, {'cui': 'C0023206', 'cui_str': 'Lectin'}, {'cui': 'C0034821', 'cui_str': 'LDL receptor'}, {'cui': 'C0079281', 'cui_str': 'Endothelin Type 1'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0028137', 'cui_str': 'Nitrite salt'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",42.0,0.0213078,"However, only aerobic training decreased markers of inflammation (C-reactive protein, monocyte chemoattractant protein-1, vascular cell adhesion molecule-1 and lectin-like oxidized LDL receptor-1) and endothelin-1 and increased nitrite and nitrate levels (P < 0.05). ","[{'ForeName': 'Francesco P', 'Initials': 'FP', 'LastName': 'Boeno', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre.'}, {'ForeName': 'Thiago R', 'Initials': 'TR', 'LastName': 'Ramis', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre.'}, {'ForeName': 'Samuel V', 'Initials': 'SV', 'LastName': 'Munhoz', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre.'}, {'ForeName': 'Juliano B', 'Initials': 'JB', 'LastName': 'Farinha', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre.'}, {'ForeName': 'Cesar E J', 'Initials': 'CEJ', 'LastName': 'Moritz', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Leal-Menezes', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre.'}, {'ForeName': 'Jerri L', 'Initials': 'JL', 'LastName': 'Ribeiro', 'Affiliation': 'Centro Universitário Metodista - IPA, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'ForeName': 'Demetra D', 'Initials': 'DD', 'LastName': 'Christou', 'Affiliation': 'Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, Florida, USA.'}, {'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Reischak-Oliveira', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre.'}]",Journal of hypertension,['10.1097/HJH.0000000000002581'] 2502,32698959,Acute and chronic improvement in postprandial glucose metabolism by a diet resembling the traditional Mediterranean dietary pattern: Can SCFAs play a role?,"BACKGROUND & AIMS Postprandial metabolic abnormalities are considered important and independent risk factors for cardiovascular diseases. However, the effects of the Mediterranean diet on postprandial metabolism and the mechanism underpinning the effects on clinical variables have not been exhaustively explored. Therefore, the aims of the present study were to evaluate the acute and medium-term effects (8 weeks) on postprandial glucose and lipid metabolism of a diet resembling a typical Mediterranean diet (Med-D) compared to a western-type diet (Control-D), and the mechanisms underlying those effects. METHODS Twenty-nine overweight/obese individuals of both genders, aged 20-60 years, were enrolled and randomly assigned to two isoenergetic dietary interventions: 1) a Med-D (n = 16), and 2) a Control-D (n = 13). Adherence to the dietary interventions was assessed by a 7-day food record. A meal test resembling the assigned diet was performed at baseline and after 8 weeks of intervention. Blood samples at fasting and over 4-h after the meal were collected to assess metabolic parameters and short chain fatty acid (SCFA) levels. Fecal samples were also collected to evaluate the microbiota composition. RESULTS Glucose and insulin responses were significantly reduced at baseline after the Med test meal compared to the Control meal (p < 0.05) and this effect was strengthened after 8 weeks of intervention with the Mediterranean diet (p < 0.05); together with an improvement in OGIS. At the end of the intervention, postprandial plasma butyric acid incremental area under the curve (IAUC) was significantly increased in the Med-D group (p = 0.019) and correlated inversely with plasma insulin IAUC and directly with oral glucose insulin sensitivity (OGIS) (r: -0.411, p = 0.046 and r: 0.397, p = 0.050 respectively). These metabolic changes were accompanied by significant changes in gut microbiota, such as an increase in the relative abundance of Intestinimonas butyriciproducens and Akkermansia muciniphila (p < 0.05) in the Med-D compared to Control-D group. CONCLUSIONS Our study provides strong evidence that a diet resembling the traditional Med-D improves postprandial glucose metabolism and insulin sensitivity. Furthermore, the study highlights a possible involvement of gut microbiota metabolites - such as butyric acid, and of dietary fiber as a precursor - in improving glucose metabolism and insulin sensitivity.",2020,"RESULTS Glucose and insulin responses were significantly reduced at baseline after the Med test meal compared to the Control meal (p < 0.05) and this effect was strengthened after 8 weeks of intervention with the Mediterranean diet (p < 0.05); together with an improvement in OGIS.","['Twenty-nine overweight/obese individuals of both genders, aged 20-60 years']","['Mediterranean diet', 'diet resembling a typical Mediterranean diet (Med-D) compared to a western-type diet (Control-D']","['postprandial glucose metabolism', 'metabolic parameters and short chain fatty acid (SCFA) levels', 'postprandial plasma butyric acid incremental area under the curve (IAUC', 'relative abundance of Intestinimonas butyriciproducens and Akkermansia muciniphila', 'postprandial glucose metabolism and insulin sensitivity', 'plasma insulin IAUC and directly with oral glucose insulin sensitivity (OGIS', 'postprandial metabolism', 'Glucose and insulin responses', 'postprandial glucose and lipid metabolism']","[{'cui': 'C0450351', 'cui_str': '29'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1138412', 'cui_str': 'Mediterranean Diet'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0015691', 'cui_str': 'Short chain fatty acid'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0006523', 'cui_str': 'Butanoic Acids'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C1490590', 'cui_str': 'Akkermansia muciniphila'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}]",,0.019173,"RESULTS Glucose and insulin responses were significantly reduced at baseline after the Med test meal compared to the Control meal (p < 0.05) and this effect was strengthened after 8 weeks of intervention with the Mediterranean diet (p < 0.05); together with an improvement in OGIS.","[{'ForeName': 'Marilena', 'Initials': 'M', 'LastName': 'Vitale', 'Affiliation': 'Dept. of Clinical Medicine and Surgery, ""Federico II"" University of Naples, Italy.'}, {'ForeName': 'Rosalba', 'Initials': 'R', 'LastName': 'Giacco', 'Affiliation': 'CNR-Institute of Food Sciences, Avellino, Italy.'}, {'ForeName': 'Manolo', 'Initials': 'M', 'LastName': 'Laiola', 'Affiliation': 'Dept. of Agricultural Sciences, ""Federico II"" University of Naples, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Della Pepa', 'Affiliation': 'Dept. of Clinical Medicine and Surgery, ""Federico II"" University of Naples, Italy.'}, {'ForeName': 'Delia', 'Initials': 'D', 'LastName': 'Luongo', 'Affiliation': 'CNR-Institute of Biostructures and Bioimaging, Naples, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Mangione', 'Affiliation': 'Dept. of Clinical Medicine and Surgery, ""Federico II"" University of Naples, Italy.'}, {'ForeName': 'Dominic', 'Initials': 'D', 'LastName': 'Salamone', 'Affiliation': 'Dept. of Clinical Medicine and Surgery, ""Federico II"" University of Naples, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Vitaglione', 'Affiliation': 'Dept. of Agricultural Sciences, ""Federico II"" University of Naples, Italy; Task Force on Microbiome Studies, University of Naples ""Federico II"", Naples, Italy.'}, {'ForeName': 'Danilo', 'Initials': 'D', 'LastName': 'Ercolini', 'Affiliation': 'Dept. of Agricultural Sciences, ""Federico II"" University of Naples, Italy; Task Force on Microbiome Studies, University of Naples ""Federico II"", Naples, Italy.'}, {'ForeName': 'Angela Albarosa', 'Initials': 'AA', 'LastName': 'Rivellese', 'Affiliation': 'Dept. of Clinical Medicine and Surgery, ""Federico II"" University of Naples, Italy; Task Force on Microbiome Studies, University of Naples ""Federico II"", Naples, Italy. Electronic address: rivelles@unina.it.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.05.025'] 2503,32698986,A pilot randomised controlled trial of dressing and securement methods to prevent arterial catheter failure in intensive care.,"BACKGROUND Critically ill patients in an intensive care setting often require arterial catheters for blood pressure monitoring and arterial blood collection. Arterial catheter failure, which manifests in both mechanical and infective forms, remains common. Dressing and securement inadequacies may impact this failure; however, the best method for dressing and securing arterial catheters is yet to be determined. OBJECTIVES The objective of this study was to establish the feasibility of a definitive randomised controlled trial comparing methods for dressing and securing arterial catheters and to prevent device failure in an adult intensive care setting. METHODS A pilot, parallel-group, randomised controlled trial was conducted between April 2017 and June 2018. Patients receiving treatment in two adult intensive care units (Queensland, Australia) were eligible for inclusion and were allocated to receive either (i) an integrated securement dressing or (ii) a simple polyurethane dressing (with gauze/foam), applied to their newly inserted arterial catheters. MAIN OUTCOME MEASURES Primary outcomes were (i) feasibility (defined by pre-established criteria: patient eligibility, consent, protocol adherence, retention, and staff acceptability) and (ii) all-cause arterial catheter failure (a composite of local and bloodstream infection, occlusion, dislodgement, infiltration/extravasation, arterial inflammation, thrombosis, and/or inaccurate trace). Secondary outcomes included: failure type, dwell time, dressing adhesion, adverse event profiles, and staff acceptability. RESULTS In total, 109 patients were studied (n = 53 integrated securement dressing; n = 56 simple polyurethane). The feasibility criterion was met by most patients (including rates of consent [86%], protocol adherence [93%], and retention [100%]); however, the criteria for patient eligibility were not met (73%). All-cause device failure did not differ significantly between the integrated securement device group (n = 12/53, 23%) and the simple polyurethane group (n = 6/56, 11%) (hazard ratio = 2.39, 95% confidence interval = 0.89-6.37, p = 0.083). CONCLUSIONS Findings indicate a larger study is feasible, with minor alterations to recruitment methods required. Arterial catheter failure remains unacceptably common; further research to determine optimal dressing/securement practices is urgently needed.",2020,"All-cause device failure did not differ significantly between the integrated securement device group (n = 12/53, 23%) and the simple polyurethane group (n = 6/56, 11%) (hazard ratio = 2.39, 95% confidence interval = 0.89-6.37,","['Critically ill patients in an intensive care setting often require arterial catheters for blood pressure monitoring and arterial blood collection', 'Patients receiving treatment in two adult intensive care units (Queensland, Australia) were eligible for inclusion', 'April 2017 and June 2018', '109 patients were studied (n\xa0=\xa053 integrated securement dressing; n\xa0=\xa056 simple polyurethane', 'intensive care']","['dressing and securement methods', 'integrated securement dressing or (ii) a simple polyurethane dressing (with gauze/foam), applied to their newly inserted arterial catheters', 'dressing and securing arterial catheters']","['All-cause device failure', 'failure type, dwell time, dressing adhesion, adverse event profiles, and staff acceptability', 'arterial catheter failure', 'i) feasibility (defined by pre-established criteria: patient eligibility, consent, protocol adherence, retention, and staff acceptability)\xa0and (ii) all-cause arterial catheter failure (a composite of local and bloodstream infection, occlusion, dislodgement, infiltration/extravasation, arterial inflammation, thrombosis, and/or inaccurate trace']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0581447', 'cui_str': 'Arterial catheter'}, {'cui': 'C0026426', 'cui_str': 'Blood pressure monitoring'}, {'cui': 'C0229665', 'cui_str': 'Arterial blood'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0587445', 'cui_str': 'Adult intensive care unit'}, {'cui': 'C0034391', 'cui_str': 'Queensland'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0013119', 'cui_str': 'Medical dressing'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0032616', 'cui_str': 'Polyisocyanate'}]","[{'cui': 'C0013119', 'cui_str': 'Medical dressing'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0032616', 'cui_str': 'Polyisocyanate'}, {'cui': 'C0590323', 'cui_str': 'Gauzes'}, {'cui': 'C0991510', 'cui_str': 'Foam'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0581447', 'cui_str': 'Arterial catheter'}]","[{'cui': 'C0086138', 'cui_str': 'Equipment malfunction'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0429659', 'cui_str': 'Dwell time'}, {'cui': 'C0013119', 'cui_str': 'Medical dressing'}, {'cui': 'C0001511', 'cui_str': 'Adhesion'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0581447', 'cui_str': 'Arterial catheter'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C2316160', 'cui_str': 'Infection of bloodstream'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0015376', 'cui_str': 'Extravasation'}, {'cui': 'C0003860', 'cui_str': 'Arteritis'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0443236', 'cui_str': 'Inaccurate'}, {'cui': 'C0442822', 'cui_str': 'Trace'}]",109.0,0.28401,"All-cause device failure did not differ significantly between the integrated securement device group (n = 12/53, 23%) and the simple polyurethane group (n = 6/56, 11%) (hazard ratio = 2.39, 95% confidence interval = 0.89-6.37,","[{'ForeName': 'Emily N', 'Initials': 'EN', 'LastName': 'Larsen', 'Affiliation': ""Alliance for Vascular Access Teaching and Research Group, Menzies Health Institute Queensland, Brisbane, Queensland, Australia; School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia; The Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. Electronic address: e.larsen@griffith.edu.au.""}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Corley', 'Affiliation': 'Alliance for Vascular Access Teaching and Research Group, Menzies Health Institute Queensland, Brisbane, Queensland, Australia; School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia; The Prince Charles Hospital, Brisbane, Queensland, Australia. Electronic address: amanda.corley@health.qld.gov.au.'}, {'ForeName': 'Marion', 'Initials': 'M', 'LastName': 'Mitchell', 'Affiliation': 'Alliance for Vascular Access Teaching and Research Group, Menzies Health Institute Queensland, Brisbane, Queensland, Australia; School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia; The Princess Alexandra Hospital, Brisbane, Queensland, Australia. Electronic address: marion.mitchell@griffith.edu.au.'}, {'ForeName': 'India', 'Initials': 'I', 'LastName': 'Lye', 'Affiliation': 'Alliance for Vascular Access Teaching and Research Group, Menzies Health Institute Queensland, Brisbane, Queensland, Australia; School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia; The Prince Charles Hospital, Brisbane, Queensland, Australia. Electronic address: india.lye@health.qld.gov.au.'}, {'ForeName': 'Madeleine', 'Initials': 'M', 'LastName': 'Powell', 'Affiliation': 'The Prince Charles Hospital, Brisbane, Queensland, Australia. Electronic address: madeleine.powell@health.qld.gov.au.'}, {'ForeName': 'Sheena', 'Initials': 'S', 'LastName': 'Tom', 'Affiliation': 'The Prince Charles Hospital, Brisbane, Queensland, Australia. Electronic address: sheena.tom@health.qld.gov.au.'}, {'ForeName': 'Gabor', 'Initials': 'G', 'LastName': 'Mihala', 'Affiliation': 'Alliance for Vascular Access Teaching and Research Group, Menzies Health Institute Queensland, Brisbane, Queensland, Australia; School of Medicine, Griffith University, Queensland, Australia; Centre for Applied Health Economics, Menzies Health Institute, Queensland, Australia. Electronic address: g.mihala@griffith.edu.au.'}, {'ForeName': 'Amanda J', 'Initials': 'AJ', 'LastName': 'Ullman', 'Affiliation': ""Alliance for Vascular Access Teaching and Research Group, Menzies Health Institute Queensland, Brisbane, Queensland, Australia; School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia; The Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia; Queensland Children's Hospital, Brisbane, Queensland, Australia. Electronic address: a.ullman@griffith.edu.au.""}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Gibson', 'Affiliation': ""Alliance for Vascular Access Teaching and Research Group, Menzies Health Institute Queensland, Brisbane, Queensland, Australia; Queensland Children's Hospital, Brisbane, Queensland, Australia. Electronic address: victoria.gibson@health.qld.gov.au.""}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Marsh', 'Affiliation': ""Alliance for Vascular Access Teaching and Research Group, Menzies Health Institute Queensland, Brisbane, Queensland, Australia; The Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. Electronic address: nicole.marsh@health.qld.gov.au.""}, {'ForeName': 'Tricia M', 'Initials': 'TM', 'LastName': 'Kleidon', 'Affiliation': ""Alliance for Vascular Access Teaching and Research Group, Menzies Health Institute Queensland, Brisbane, Queensland, Australia; School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia; Queensland Children's Hospital, Brisbane, Queensland, Australia. Electronic address: tricia.kleidon@health.qld.gov.au.""}, {'ForeName': 'Ivan L', 'Initials': 'IL', 'LastName': 'Rapchuk', 'Affiliation': 'The Prince Charles Hospital, Brisbane, Queensland, Australia; The University of Queensland, Brisbane, Queensland, Australia. Electronic address: ivan.rapchuk@health.qld.gov.au.'}, {'ForeName': 'Claire M', 'Initials': 'CM', 'LastName': 'Rickard', 'Affiliation': ""Alliance for Vascular Access Teaching and Research Group, Menzies Health Institute Queensland, Brisbane, Queensland, Australia; School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia; The Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia; The Princess Alexandra Hospital, Brisbane, Queensland, Australia. Electronic address: c.rickard@griffith.edu.au.""}]",Australian critical care : official journal of the Confederation of Australian Critical Care Nurses,['10.1016/j.aucc.2020.05.004'] 2504,32699034,"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial.","OBJECTIVES This ongoing Phase-2, randomised, placebo-controlled, double-blind study evaluated the efficacy, safety and pharmacokinetics of intravenous belimumab in childhood-onset systemic lupus erythematosus (cSLE). METHODS Patients (5 to 17 years) were randomised to belimumab 10 mg/kg intravenous or placebo every 4 weeks, plus standard SLE therapy. Primary endpoint: SLE Responder Index (SRI4) response rate (Week 52). Key major secondary endpoints: proportion of patients achieving the Paediatric Rheumatology International Trials Organisation/American College of Rheumatology (PRINTO/ACR) response using 50 and '30 alternative' definitions (Week 52), and sustained response (Weeks 44 to 52) by SRI4 and Parent Global Assessment of well-being (Parent-global). Safety and pharmacokinetics were assessed. Study not powered for statistical testing. RESULTS Ninety-three patients were randomised (belimumab, n=53; placebo, n=40). At Week 52, there were numerically more SRI4 responders with belimumab versus placebo (52.8% vs 43.6%; OR 1.49 (95% CI 0.64 to 3.46)). PRINTO/ACR 30 alternative (52.8% vs 27.5%; OR 2.92 (95% CI 1.19 to 7.17)) and PRINTO/ACR 50 (60.4% vs 35.0%; OR 2.74 (95% CI 1.15 to 6.54)) responses were more frequent with belimumab than placebo, as were sustained responses for SRI4 (belimumab, 43.4%; placebo, 41.0%; OR 1.08 (95% CI 0.46 to 2.52)) and Parent-global (belimumab, 59.1%; placebo, 33.3%; OR 3.49 (95% CI 1.23 to 9.91)). Serious adverse events were reported in 17.0% of belimumab patients and 35.0% of placebo patients; one death occurred (placebo). Week-52, geometric mean (95% CI) belimumab trough concentration was 56.2 (45.2 to 69.8) µg/mL. CONCLUSION The belimumab intravenous pharmacokinetics and benefit-risk profile in cSLE are consistent with adult belimumab studies and the 10 mg/kg every 4 weeks dose is appropriate. TRIAL REGISTRATION NUMBER NCT01649765.",2020,"ACR 30 alternative (52.8% vs 27.5%; OR 2.92 (95% CI 1.19 to 7.17)) and PRINTO/ACR 50 (60.4% vs 35.0%; OR 2.74 (95% CI 1.15 to 6.54)) responses were more frequent with belimumab than placebo, as were sustained responses for SRI4 (belimumab, 43.4%; placebo, 41.0%; OR 1.08 (95% CI 0.46 to 2.52)) and Parent-global (belimumab, 59.1%; placebo, 33.3%; OR 3.49 (95% CI 1.23 to 9.91)).","['childhood-onset systemic lupus erythematosus (cSLE', 'Ninety-three patients were randomised (belimumab, n=53', 'Patients (5 to 17 years', 'children with systemic lupus erythematosus']","['placebo', 'belimumab 10 mg/kg intravenous or placebo every 4 weeks, plus standard SLE therapy', 'intravenous belimumab']","['efficacy, safety and pharmacokinetics', 'death', 'Safety and pharmacokinetics', 'Safety and efficacy', 'SRI4 responders', ""patients achieving the Paediatric Rheumatology International Trials Organisation/American College of Rheumatology (PRINTO/ACR) response using 50 and '30 alternative' definitions (Week 52), and sustained response (Weeks 44 to 52) by SRI4 and Parent Global Assessment of well-being (Parent-global"", 'SLE Responder Index (SRI4) response rate (Week 52', 'Serious adverse events']","[{'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0024141', 'cui_str': 'Systemic lupus erythematosus'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1723401', 'cui_str': 'belimumab'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1723401', 'cui_str': 'belimumab'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C1275555', 'cui_str': 'Every four weeks'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0024141', 'cui_str': 'Systemic lupus erythematosus'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1621271', 'cui_str': 'Pediatric rheumatology'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0035452', 'cui_str': 'Rheumatology'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0024141', 'cui_str': 'Systemic lupus erythematosus'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",93.0,0.776003,"ACR 30 alternative (52.8% vs 27.5%; OR 2.92 (95% CI 1.19 to 7.17)) and PRINTO/ACR 50 (60.4% vs 35.0%; OR 2.74 (95% CI 1.15 to 6.54)) responses were more frequent with belimumab than placebo, as were sustained responses for SRI4 (belimumab, 43.4%; placebo, 41.0%; OR 1.08 (95% CI 0.46 to 2.52)) and Parent-global (belimumab, 59.1%; placebo, 33.3%; OR 3.49 (95% CI 1.23 to 9.91)).","[{'ForeName': 'Hermine I', 'Initials': 'HI', 'LastName': 'Brunner', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, Division of Rheumatology, University of Cincinnati, Cincinnati, Ohio, USA Hermine.brunner@cchmc.org.""}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Abud-Mendoza', 'Affiliation': 'Hospital Central ""Dr Ignacio Morones Prieto"", Unidad Regional de Reumatologia y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.'}, {'ForeName': 'Diego O', 'Initials': 'DO', 'LastName': 'Viola', 'Affiliation': 'Reumatologia, Instituto CAICI, Rosario, Argentina.'}, {'ForeName': 'Inmaculada', 'Initials': 'I', 'LastName': 'Calvo Penades', 'Affiliation': 'Pediatric Rheumatology Unit, Hospital Universitario y Politecnico la Fe, Valencia, Spain.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Levy', 'Affiliation': 'Rheumatology, Hospital for Sick Children and Univeristy of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Anton', 'Affiliation': 'Division of Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Julia E', 'Initials': 'JE', 'LastName': 'Calderon', 'Affiliation': 'El Derby, Instituto de Ginecologia y Reproduccion, Lima, Peru.'}, {'ForeName': 'Vyacheslav G', 'Initials': 'VG', 'LastName': 'Chasnyk', 'Affiliation': 'Department of Hospital Pediatrics, Saint Petersburg State Pediatric Medical University, Saint Petersburg, Russian Federation.'}, {'ForeName': 'Manuel A', 'Initials': 'MA', 'LastName': 'Ferrandiz', 'Affiliation': 'Reumatologia, Instituto Nacional de Salud del Niño, Lima, Peru.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Keltsev', 'Affiliation': 'Pediatric Department, Togliatti City Clinical Hospital №5, Togliatti, Russian Federation.'}, {'ForeName': 'Maria E', 'Initials': 'ME', 'LastName': 'Paz Gastanaga', 'Affiliation': 'Servicio de Reumatologia, Clinica Anglo Americana, Lima, Peru.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Shishov', 'Affiliation': ""Phoenix Children's Hospital, Phoenix, Arizona, USA.""}, {'ForeName': 'Alina Lucica', 'Initials': 'AL', 'LastName': 'Boteanu', 'Affiliation': 'Pediatric Rheumatology Unit, University Hospital Ramón y Cajal, Madrid, Spain.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Henrickson', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, Division of Rheumatology, University of Cincinnati, Cincinnati, Ohio, USA.""}, {'ForeName': 'Damon', 'Initials': 'D', 'LastName': 'Bass', 'Affiliation': 'GSK, Collegevile, Pennsylvania, USA.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Clark', 'Affiliation': 'GSK, Stevenage, UK.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Hammer', 'Affiliation': 'GSK, Collegevile, Pennsylvania, USA.'}, {'ForeName': 'Beulah N', 'Initials': 'BN', 'LastName': 'Ji', 'Affiliation': 'GSK, Stevenage, UK.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Nino', 'Affiliation': 'GSK, Collegevile, Pennsylvania, USA.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Roth', 'Affiliation': 'GSK, Collegevile, Pennsylvania, USA.'}, {'ForeName': 'Herbert', 'Initials': 'H', 'LastName': 'Struemper', 'Affiliation': 'GSK, Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'Mei-Lun', 'Initials': 'ML', 'LastName': 'Wang', 'Affiliation': 'GSK, Collegevile, Pennsylvania, USA.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Martini', 'Affiliation': 'Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Università degli Studi di Genova, Genova, Liguria, Italy.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Lovell', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, Division of Rheumatology, University of Cincinnati, Cincinnati, Ohio, USA.""}, {'ForeName': 'Nicolino', 'Initials': 'N', 'LastName': 'Ruperto', 'Affiliation': 'Clinica Pediatrica e Reumatologia, PRINTO, IRCCS Istituto Giannina Gaslini, Genoa, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Annals of the rheumatic diseases,['10.1136/annrheumdis-2020-217101'] 2505,32699049,A randomised controlled trial comparing femtosecond laser-assisted cataract surgery versus conventional phacoemulsification surgery: 12-month results.,"AIMS To report 12-month outcomes of randomised controlled trial comparing conventional phacoemulsification surgery (CPS) with femtosecond laser-assisted cataract surgery (FLACS). METHODS This was a single-centre, prospective single-masked randomised case-controlled trial. Four hundred patients were randomised to CPS or FLACS with the LenSx platform (Alcon Laboratories Inc.). Visual acuity, refraction, central corneal thickness, endothelial cell loss (ECL), adverse events and quality of life outcomes, using EuroQOL 5-dimensions (EQ-5D-3 L) and cataract surgery patient-reported outcome measures (PROMs) questionnaires (Cat-PROM5), were recorded. RESULTS Two hundred and thirty four patients (58.5%) attended 12-month follow-up (116 FLACS, 118 CPS). Mean LogMAR unaided distance visual acuity) (±SD) was 0.12 (0.18) with FLACS and 0.13 (0.19) with CPS (p=0.68; 95% Confidence Interval [CI]-0.06,0.04). Mean spherical equivalent (SE) refraction was -0.1±0.6 diopters (D) with FLACS and -0.2±0.6 D with CPS (p=0.44; 95% CI -0.09, 0.21). Mean corrected distance visual acuity (±SD) was -0.01 (0.1) with FLACS and 0(0.1) with CPS (p=0.45; 95% CI -0.04,0.02). Two patients per group underwent YAG laser capsulotomy for posterior capsular opacification (p=1). Mean ECL (per mm 2 ±SD) was 301±320 with FLACS and 228±303 with CPS (p=0.07; 95% CI -7.26, 153.26). Mean Cat-PROM scores (±SD) were -5.5 (2.6) with FLACS and -5.8 (2.5) with CPS (p=0.3; 95% CI 0.31,1.01). EQ5-3DL mean index score (±SD) was 0.92 (0.13) with FLACS and 0.89 (0.14) with CPS (p=0.1; 95% CI -0.1, 0.01). Vector analysis comparing manual limbal relaxing incisions (LRIs) and intrastromal femtosecond laser-assisted astigmatic keratotomies (iFAKs) showed a greater correction index (p=0.02; 95% CI 0.06 to 0.60) and smaller difference vector (p=0.046; 95% CI -0.54, -0.01) with iFAK. CONCLUSIONS There were no differences in vision, refraction, adverse postoperative events or PROMs between FLACS and CPS groups at 12 months. iFAKs may provide more effective astigmatic correction compared to LRIs, 12 months postoperatively.",2020,"There were no differences in vision, refraction, adverse postoperative events or PROMs between FLACS and CPS groups at 12 months.","['Four hundred patients', 'Two hundred and thirty four patients (58.5%) attended 12-month follow-up (116 FLACS, 118 CPS']","['CPS or FLACS', 'CPS', 'manual limbal relaxing incisions (LRIs) and intrastromal femtosecond laser-assisted astigmatic keratotomies (iFAKs', 'YAG laser capsulotomy', 'femtosecond laser-assisted cataract surgery (FLACS', 'femtosecond laser-assisted cataract surgery', 'conventional phacoemulsification surgery', 'conventional phacoemulsification surgery (CPS']","['Visual acuity, refraction, central corneal thickness, endothelial cell loss (ECL), adverse events and quality of life outcomes, using EuroQOL 5-dimensions', 'correction index', 'vision, refraction, adverse postoperative events or PROMs', 'Mean LogMAR unaided distance visual acuity) (±SD', 'outcome measures (PROMs) questionnaires (Cat-PROM5', 'Mean spherical equivalent (SE) refraction', 'EQ5-3DL mean index score (±SD', 'Mean corrected distance visual acuity (±SD', 'Mean Cat-PROM scores (±SD', 'Mean ECL']","[{'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C4517541', 'cui_str': '116'}, {'cui': 'C1531960', 'cui_str': 'Femtosecond pulsed laser device'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1531960', 'cui_str': 'Femtosecond pulsed laser device'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0443251', 'cui_str': 'Limbal'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0730588', 'cui_str': 'Astigmatic keratotomy'}, {'cui': 'C0587723', 'cui_str': 'YAG - laser'}]","[{'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0429585', 'cui_str': 'Refraction measurement - finding'}, {'cui': 'C1720164', 'cui_str': 'Central corneal thickness'}, {'cui': 'C0225336', 'cui_str': 'Endothelial cell'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C4277735', 'cui_str': 'Patient Reported Outcome Measures'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439846', 'cui_str': 'Unaided'}, {'cui': 'C0429537', 'cui_str': 'Distance visual acuity'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0007366', 'cui_str': 'Catalan language'}, {'cui': 'C0332501', 'cui_str': 'Spherical shape'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0015944', 'cui_str': 'Premature rupture of membranes'}]",400.0,0.312384,"There were no differences in vision, refraction, adverse postoperative events or PROMs between FLACS and CPS groups at 12 months.","[{'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Stanojcic', 'Affiliation': ""Department of Ophthalmology, St.Thomas' Hospital, London, UK nstanojcic@doctors.org.uk.""}, {'ForeName': 'Harry William', 'Initials': 'HW', 'LastName': 'Roberts', 'Affiliation': ""Department of Ophthalmology, St.Thomas' Hospital, London, UK.""}, {'ForeName': 'Vijay K', 'Initials': 'VK', 'LastName': 'Wagh', 'Affiliation': ""Department of Ophthalmology, St.Thomas' Hospital, London, UK.""}, {'ForeName': 'Ji-Peng Olivia', 'Initials': 'JO', 'LastName': 'Li', 'Affiliation': ""King's College, London, UK.""}, {'ForeName': 'Khayam', 'Initials': 'K', 'LastName': 'Naderi', 'Affiliation': ""Department of Ophthalmology, St.Thomas' Hospital, London, UK.""}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': ""O'Brart"", 'Affiliation': ""Department of Ophthalmology, St.Thomas' Hospital, London, UK.""}]",The British journal of ophthalmology,['10.1136/bjophthalmol-2020-316311'] 2506,32699176,"Effects of food supplementation on cognitive function, cerebral blood flow, and nutritional status in young children at risk of undernutrition: randomized controlled trial.","OBJECTIVE To assess the effects of food supplementation on improving working memory and additional measures including cerebral blood flow in children at risk of undernutrition. DESIGN Randomized controlled trial. SETTING 10 villages in Guinea-Bissau. PARTICIPANTS 1059 children aged 15 months to 7 years; children younger than 4 were the primary population. INTERVENTIONS Supervised isocaloric servings (≈1300 kJ, five mornings each week, 23 weeks) of a new food supplement (NEWSUP, high in plant polyphenols and omega 3 fatty acids, within a wide variety and high fortification of micronutrients, and a high protein content), or a fortified blended food (FBF) used in nutrition programs, or a control meal (traditional rice breakfast). MAIN OUTCOME MEASUREMENTS The primary outcome was working memory, a core executive function predicting long term academic achievement. Additional outcomes were hemoglobin concentration, growth, body composition, and index of cerebral blood flow (CBF i ). In addition to an intention-to-treat analysis, a predefined per protocol analysis was conducted in children who consumed at least 75% of the supplement (820/925, 89%). The primary outcome was assessed by a multivariable Poisson model; other outcomes were assessed by multivariable linear mixed models. RESULTS Among children younger than 4, randomization to NEWSUP increased working memory compared with the control meal (rate ratio 1.20, 95% confidence interval 1.02 to 1.41, P=0.03), with a larger effect in the per protocol population (1.25, 1.06 to 1.47, P=0.009). NEWSUP also increased hemoglobin concentration among children with anemia (adjusted mean difference 0.65 g/dL, 95% confidence interval 0.23 to 1.07, P=0.003) compared with the control meal, decreased body mass index z score gain (-0.23, -0.43 to -0.02, P=0.03), and increased lean tissue accretion (2.98 cm 2 , 0.04 to 5.92, P=0.046) with less fat (-5.82 cm 2 , -11.28 to -0.36, P=0.04) compared with FBF. Additionally, NEWSUP increased CBF i compared with the control meal and FBF in both age groups combined (1.14 mm 2 /s×10 -8 , 0.10 to 2.23, P=0.04 for both comparisons). Among children aged 4 and older, NEWSUP had no significant effect on working memory or anemia, but increased lean tissue compared with FBF (4.31 cm 2 , 0.34 to 8.28, P=0.03). CONCLUSIONS Childhood undernutrition is associated with long term impairment in cognition. Contrary to current understanding, supplementary feeding for 23 weeks could improve executive function, brain health, and nutritional status in vulnerable young children living in low income countries. Further research is needed to optimize nutritional prescriptions for regenerative improvements in cognitive function, and to test effectiveness in other vulnerable groups. TRIAL REGISTRATION ClinicalTrials.gov NCT03017209.",2020,"Among children aged 4 and older, NEWSUP had no significant effect on working memory or anemia, but increased lean tissue compared with FBF (4.31 cm 2 , 0.34 to 8.28, P=0.03). ","['10 villages in Guinea-Bissau', 'young children at risk of undernutrition', 'children at risk of undernutrition', '1059 children aged 15 months to 7 years; children younger than 4 were the primary population']","['NEWSUP', 'food supplementation', 'Supervised isocaloric servings', 'new food supplement (NEWSUP, high in plant polyphenols and omega 3 fatty acids, within a wide variety and high fortification of micronutrients, and a high protein content), or a fortified blended food (FBF) used in nutrition programs, or a control meal (traditional rice breakfast']","['working memory, a core executive function predicting long term academic achievement', 'hemoglobin concentration', 'lean tissue accretion', 'working memory', 'hemoglobin concentration, growth, body composition, and index of cerebral blood flow (CBF i ', 'cerebral blood flow', 'body mass index z score gain', 'CBF', 'executive function, brain health, and nutritional status', 'lean tissue', 'cognitive function, cerebral blood flow, and nutritional status', 'working memory or anemia']","[{'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0018387', 'cui_str': 'Guinea-Bissau'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C0425119', 'cui_str': 'Child at risk'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0032098', 'cui_str': 'Kingdom Viridiplantae'}, {'cui': 'C0071649', 'cui_str': 'Polyphenol'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0040577', 'cui_str': 'Trace element'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0453850', 'cui_str': 'Liquidized food'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0035567', 'cui_str': 'Rice'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}]","[{'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0013658', 'cui_str': 'Educational achievement'}, {'cui': 'C1318517', 'cui_str': 'Hemoglobin concentration, dipstick - finding'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0333038', 'cui_str': 'Accretion'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}]",1059.0,0.234524,"Among children aged 4 and older, NEWSUP had no significant effect on working memory or anemia, but increased lean tissue compared with FBF (4.31 cm 2 , 0.34 to 8.28, P=0.03). ","[{'ForeName': 'Susan B', 'Initials': 'SB', 'LastName': 'Roberts', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA susan.roberts@tufts.edu.'}, {'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Franceschini', 'Affiliation': 'Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA.'}, {'ForeName': 'Rachel E', 'Initials': 'RE', 'LastName': 'Silver', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Salima F', 'Initials': 'SF', 'LastName': 'Taylor', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Augusto Braima', 'Initials': 'AB', 'LastName': 'de Sa', 'Affiliation': 'International Partnership for Human Development, Leesburg, VA, USA and Bissau, Guinea Bissau.'}, {'ForeName': 'Raimundo', 'Initials': 'R', 'LastName': 'Có', 'Affiliation': 'International Partnership for Human Development, Leesburg, VA, USA and Bissau, Guinea Bissau.'}, {'ForeName': 'Aliu', 'Initials': 'A', 'LastName': 'Sonco', 'Affiliation': 'International Partnership for Human Development, Leesburg, VA, USA and Bissau, Guinea Bissau.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Krauss', 'Affiliation': 'Peeled Snacks, Cumberland, RI, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Taetzsch', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Webb', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Sai Krupa', 'Initials': 'SK', 'LastName': 'Das', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'C-Y', 'Initials': 'CY', 'LastName': 'Chen', 'Affiliation': 'Biofortis, Mérieux NutriSciences, Addison, IL, USA.'}, {'ForeName': 'Beatrice L', 'Initials': 'BL', 'LastName': 'Rogers', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Saltzman', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Pei-Yi', 'Initials': 'PY', 'LastName': 'Lin', 'Affiliation': 'Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Schlossman', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Pruzensky', 'Affiliation': 'International Partnership for Human Development, Leesburg, VA, USA and Bissau, Guinea Bissau.'}, {'ForeName': 'Carlito', 'Initials': 'C', 'LastName': 'Balé', 'Affiliation': 'International Partnership for Human Development, Leesburg, VA, USA and Bissau, Guinea Bissau.'}, {'ForeName': 'Kenneth Kwan Ho', 'Initials': 'KKH', 'LastName': 'Chui', 'Affiliation': 'Department of Public Health and Community Medicine, Tufts School of Medicine, Boston, MA, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Muentener', 'Affiliation': 'Department of Psychology, Tufts University, Medford, MA, USA.'}]",BMJ (Clinical research ed.),['10.1136/bmj.m2397'] 2507,32699180,Dietary sodium restriction decreases urinary NGAL in older adults with moderately elevated systolic blood pressure free from chronic kidney disease.,"Increased aortic stiffness may contribute to kidney damage by transferring excessive flow pulsatility to susceptible renal microvasculature, leading to constriction or vessel loss. We previously demonstrated that 5 weeks of dietary sodium restriction (DSR) reduces large-elastic artery stiffness as well as blood pressure in healthy middle-aged/older adults with moderately elevated systolic blood pressure (SBP) who are free from chronic kidney disease (CKD). We hypothesized that DSR in this cohort would also reduce urinary concentrations of renal tubular injury biomarkers, which predict incident CKD in the general population. We performed a post hoc analysis using stored 24 hours urine samples collected in 13 participants as part of a randomized, double-blind, crossover clinical trial of DSR (low sodium (LS) target: 50 mmol/day; normal sodium (NS) target: 150 mmol/day). Participants were 61±2 (mean±SEM) years (8 M/5 F) with a baseline blood pressure of 139±2/82±2 mm Hg and an estimated glomerular filtration rate of 79±3 mL/min/1.73 m 2 Twenty-four hour urinary sodium excretion was reduced from 149±7 to 66±8 mmol/day during week 5. Despite having preserved kidney function, participants had a 31% reduction in urinary neutrophil gelatinase-associated lipocalin concentrations with just 5 weeks of DSR (LS: 2.8±0.6 vs NS: 4.2±0.8 ng/mL, p<0.05). Results were similar when normalized to urinary creatinine (urinary creatinine did not change between conditions). Concentrations of another kidney tubular injury biomarker, kidney injury molecule-1, were below the detectable limit in all but one sample. In conclusion, DSR reduces an established clinical biomarker of kidney tubular damage in adults with moderately elevated SBP who are free from prevalent kidney disease.",2020,"Despite having preserved kidney function, participants had a 31% reduction in urinary neutrophil gelatinase-associated lipocalin concentrations with just 5 weeks of DSR (LS: 2.8±0.6 vs NS: 4.2±0.8 ng/mL, p<0.05).","['adults with moderately elevated SBP who are free from prevalent kidney disease', '13 participants', 'healthy middle-aged/older adults with moderately elevated systolic blood pressure (SBP) who are free from chronic kidney disease (CKD', 'Participants were 61±2 (mean±SEM) years (8 M/5 F) with a baseline blood pressure of 139±2/82±2 mm Hg and an estimated glomerular filtration rate of', 'older adults with moderately elevated systolic blood pressure free from chronic kidney disease']","['dietary sodium restriction (DSR', 'DSR (low sodium (LS) target: 50 mmol/day; normal sodium', 'Dietary sodium restriction']","['urinary neutrophil gelatinase-associated lipocalin concentrations', 'blood pressure', 'urinary sodium excretion', 'Concentrations of another kidney tubular injury biomarker, kidney injury molecule-1', 'urinary creatinine (urinary creatinine']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0026062', 'cui_str': 'Middle-age'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}]","[{'cui': 'C0037570', 'cui_str': 'Dietary Sodium'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0012169', 'cui_str': 'Low sodium diet'}, {'cui': 'C0439433', 'cui_str': 'mmol/24h'}, {'cui': 'C0860872', 'cui_str': 'Sodium normal'}]","[{'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0206528', 'cui_str': 'Gelatinase'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1956074', 'cui_str': 'Lipocalin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0332208', 'cui_str': 'Tubular'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1313407', 'cui_str': 'HAVCR1 protein, human'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}]",13.0,0.0829219,"Despite having preserved kidney function, participants had a 31% reduction in urinary neutrophil gelatinase-associated lipocalin concentrations with just 5 weeks of DSR (LS: 2.8±0.6 vs NS: 4.2±0.8 ng/mL, p<0.05).","[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Chonchol', 'Affiliation': 'Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Douglas R', 'Initials': 'DR', 'LastName': 'Seals', 'Affiliation': 'Department of Integrative Physiology, University of Colorado Boulder, Boulder, Colorado, USA.'}, {'ForeName': 'Kristen L', 'Initials': 'KL', 'LastName': 'Nowak', 'Affiliation': 'Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA Kristen.Nowak@cuanschutz.edu.'}]",Journal of investigative medicine : the official publication of the American Federation for Clinical Research,['10.1136/jim-2020-001343'] 2508,32699231,LSD-induced increases in social adaptation to opinions similar to one's own are associated with stimulation of serotonin receptors.,"Adapting one's attitudes and behaviors to group norms is essential for successful social interaction and, thus, participation in society. Yet, despite its importance for societal and individual functioning, the underlying neuropharmacology is poorly understood. We therefore investigated its neurochemical and neural correlates in a pharmacological functional magnetic resonance imaging study. Lysergic acid diethylamide (LSD) has been shown to alter social processing and therefore provides the unique opportunity to investigate the role of the 5-HT 2A receptor in social influence processing. Twenty-four healthy human volunteers received either (1) placebo + placebo, (2) placebo + LSD (100 µg), or (3) the 5-HT 2A receptor antagonist ketanserin (40 mg) + LSD (100 µg) at three different occasions in a double-blind, randomized, counterbalanced, cross-over design. LSD increases social adaptation but only if the opinions of others are similar to the individual's own. These increases were associated with increased activity in the medial prefrontal cortex while participants received social feedback. Furthermore, pretreatment with the 5-HT 2A antagonist ketanserin fully blocked LSD-induced changes during feedback processing, indicating a key role of the 5-HT 2A system in social feedback processing. Our results highlight the crucial role of the 5-HT-system in social influence and, thus, provide important insight into the neuropharmacological basis of social cognition and behavior.",2020,"Furthermore, pretreatment with the 5-HT 2A antagonist ketanserin fully blocked LSD-induced changes during feedback processing, indicating a key role of the 5-HT 2A system in social feedback processing.",['Twenty-four healthy human volunteers'],"['LSD', '5-HT 2A receptor antagonist ketanserin (40\xa0mg)\u2009+\u2009LSD', 'placebo\u2009+\u2009placebo, (2) placebo\u2009+\u2009LSD', '5-HT 2A antagonist ketanserin', 'Lysergic acid diethylamide (LSD']",['social adaptation'],"[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0020155', 'cui_str': 'Human Volunteers'}]","[{'cui': 'C0024334', 'cui_str': 'Lysergic acid diethylamide'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C4543207', 'cui_str': 'Receptor antagonist'}, {'cui': 'C0022616', 'cui_str': 'Ketanserin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}]","[{'cui': 'C0037395', 'cui_str': 'Social adjustment'}]",24.0,0.0406971,"Furthermore, pretreatment with the 5-HT 2A antagonist ketanserin fully blocked LSD-induced changes during feedback processing, indicating a key role of the 5-HT 2A system in social feedback processing.","[{'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Duerler', 'Affiliation': 'Neuropsychopharmacology and Brain Imaging, Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital for Psychiatry Zurich, Lenggstrasse 31, 8032, Zürich, Switzerland. patricia.duerler@bli.uzh.ch.'}, {'ForeName': 'Leonhard', 'Initials': 'L', 'LastName': 'Schilbach', 'Affiliation': 'Independent Max Planck Research Group for Social Neuroscience, Max Planck Institute of Psychiatry, Kraepelinstr. 2-10, 80804, Munich, Germany.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Stämpfli', 'Affiliation': 'Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital for Psychiatry Zurich, Lenggstr. 31, 8032, Zurich, Switzerland.'}, {'ForeName': 'Franz X', 'Initials': 'FX', 'LastName': 'Vollenweider', 'Affiliation': 'Neuropsychopharmacology and Brain Imaging, Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital for Psychiatry Zurich, Lenggstrasse 31, 8032, Zürich, Switzerland.'}, {'ForeName': 'Katrin H', 'Initials': 'KH', 'LastName': 'Preller', 'Affiliation': 'Neuropsychopharmacology and Brain Imaging, Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital for Psychiatry Zurich, Lenggstrasse 31, 8032, Zürich, Switzerland.'}]",Scientific reports,['10.1038/s41598-020-68899-y'] 2509,32699287,"Hydrogen-rich water reduces inflammatory responses and prevents apoptosis of peripheral blood cells in healthy adults: a randomized, double-blind, controlled trial.","The evidence for the beneficial effects of drinking hydrogen-water (HW) is rare. We aimed to investigate the effects of HW consumption on oxidative stress and immune functions in healthy adults using systemic approaches of biochemical, cellular, and molecular nutrition. In a randomized, double-blind, placebo-controlled study, healthy adults (20-59 y) consumed either 1.5 L/d of HW (n = 20) or plain water (PW, n = 18) for 4 weeks. The changes from baseline to the 4th week in serum biological antioxidant potential (BAP), derivatives of reactive oxygen, and 8-Oxo-2'-deoxyguanosine did not differ between groups; however, in those aged ≥ 30 y, BAP increased greater in the HW group than the PW group. Apoptosis of peripheral blood mononuclear cells (PBMCs) was significantly less in the HW group. Flow cytometry analysis of CD4 + , CD8 + , CD20 + , CD14 + and CD11b + cells showed that the frequency of CD14 + cells decreased in the HW group. RNA-sequencing analysis of PBMCs demonstrated that the transcriptomes of the HW group were clearly distinguished from those of the PW group. Most notably, transcriptional networks of inflammatory responses and NF-κB signaling were significantly down-regulated in the HW group. These finding suggest HW increases antioxidant capacity thereby reducing inflammatory responses in healthy adults.",2020,"Most notably, transcriptional networks of inflammatory responses and NF-κB signaling were significantly down-regulated in the HW group.","['healthy adults', 'healthy adults (20-59 y) consumed either 1.5 L/d of HW (n\u2009=\u200920) or']","['drinking hydrogen-water (HW', 'Hydrogen-rich water', 'plain water', 'HW consumption', 'placebo']","['transcriptional networks of inflammatory responses and NF-κB signaling', 'Apoptosis of peripheral blood mononuclear cells (PBMCs', 'oxidative stress and immune functions', 'frequency of CD14 + cells', 'BAP', ""serum biological antioxidant potential (BAP), derivatives of reactive oxygen, and 8-Oxo-2'-deoxyguanosine"", 'Flow cytometry analysis of CD4 + , CD8 + , CD20 + , CD14 + and CD11b + cells']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0475219', 'cui_str': 'L/day'}, {'cui': 'C0020275', 'cui_str': 'Hydrogen'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}]","[{'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0020275', 'cui_str': 'Hydrogen'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0013123', 'cui_str': 'Water intake'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1720950', 'cui_str': 'Gene Networks'}, {'cui': 'C0162638', 'cui_str': 'Apoptosis'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C1817756', 'cui_str': 'Immunologic function'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0947286', 'cui_str': 'Cell positive for CD14 antigen'}, {'cui': 'C4049351', 'cui_str': 'Biological antioxidant potential'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0243072', 'cui_str': 'derivatives'}, {'cui': 'C0205332', 'cui_str': 'Reactive'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0050078', 'cui_str': '8-hydroxy-deoxyguanosine'}, {'cui': 'C0016263', 'cui_str': 'Flow cytometry'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C3888518', 'cui_str': 'CD20 antigen positive'}, {'cui': 'C0108768', 'cui_str': 'Lymphocyte antigen CD14'}, {'cui': 'C1136310', 'cui_str': 'Lymphocyte antigen CD11b'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}]",,0.289546,"Most notably, transcriptional networks of inflammatory responses and NF-κB signaling were significantly down-regulated in the HW group.","[{'ForeName': 'Minju', 'Initials': 'M', 'LastName': 'Sim', 'Affiliation': 'Department of Food and Nutrition, Seoul National University, Seoul, 08826, Republic of Korea.'}, {'ForeName': 'Chong-Su', 'Initials': 'CS', 'LastName': 'Kim', 'Affiliation': 'Department of Food and Nutrition, Seoul National University, Seoul, 08826, Republic of Korea.'}, {'ForeName': 'Woo-Jeong', 'Initials': 'WJ', 'LastName': 'Shon', 'Affiliation': 'Department of Food and Nutrition, Seoul National University, Seoul, 08826, Republic of Korea.'}, {'ForeName': 'Young-Kwan', 'Initials': 'YK', 'LastName': 'Lee', 'Affiliation': 'Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.'}, {'ForeName': 'Eun Young', 'Initials': 'EY', 'LastName': 'Choi', 'Affiliation': 'Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.'}, {'ForeName': 'Dong-Mi', 'Initials': 'DM', 'LastName': 'Shin', 'Affiliation': 'Department of Food and Nutrition, Seoul National University, Seoul, 08826, Republic of Korea. shindm@snu.ac.kr.'}]",Scientific reports,['10.1038/s41598-020-68930-2'] 2510,32699471,Impact of Monthly A1C Values Obtained at Home on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.,"The purpose of this randomized controlled clinical trial was to determine whether an A1C value obtained at home by participants followed by a phone discussion of the result with a clinician would lead to 1 ) a more rapid and significant decrease in A1C, 2 ) more effective advancement of diabetes treatment, and 3 ) improvement in diabetes self-care behaviors. The study included 307 participants with type 2 diabetes, most of whom were of Latino origin. All study participants experienced a statistically significant reduction in mean A1C (control subjects -0.3%, P = 0.04; intervention subjects -0.5%, P = 0.0002), but there was a statistically significant difference in the number of people who achieved a reduction of ≥0.5% by 6 months, favoring the intervention (33.6 vs. 46.7%, P = 0.05).",2020,"All study participants experienced a statistically significant reduction in mean A1C (control subjects -0.3%, P = 0.04; intervention subjects -0.5%, P = 0.0002), but there was a statistically significant difference in the number of people who achieved a reduction of ≥0.5% by 6 months, favoring the intervention (33.6 vs. 46.7%, P = 0.05).","['307 participants with type 2 diabetes, most of whom were of Latino origin', 'Patients With Type 2 Diabetes']",[],"['A1C, 2 ) more effective advancement of diabetes treatment, and 3 ) improvement in diabetes self-care behaviors', 'mean A1C']","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",[],"[{'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0441478', 'cui_str': 'Surgical advancement - action'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0474417', 'cui_str': 'Self-care behavior'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",307.0,0.0282233,"All study participants experienced a statistically significant reduction in mean A1C (control subjects -0.3%, P = 0.04; intervention subjects -0.5%, P = 0.0002), but there was a statistically significant difference in the number of people who achieved a reduction of ≥0.5% by 6 months, favoring the intervention (33.6 vs. 46.7%, P = 0.05).","[{'ForeName': 'Andreina', 'Initials': 'A', 'LastName': 'Millan-Ferro', 'Affiliation': 'Latino Diabetes Initiative, Joslin Diabetes Center, Boston, MA.'}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Garcia-Dolagaray', 'Affiliation': 'Tufts University School of Medicine, Boston, MA.'}, {'ForeName': 'Shiva', 'Initials': 'S', 'LastName': 'Gautam', 'Affiliation': 'Center for Health Equity, Quality Research, University of Florida College of Medicine, Jacksonville, FL.'}, {'ForeName': 'A Enrique', 'Initials': 'AE', 'LastName': 'Caballero', 'Affiliation': ""Brigham and Women's Hospital, Harvard Medical School, Boston, MA.""}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Mitri', 'Affiliation': 'Latino Diabetes Initiative, Joslin Diabetes Center, Boston, MA.'}]",Clinical diabetes : a publication of the American Diabetes Association,['10.2337/cd19-0086'] 2511,32699643,Tranexamic acid and rosuvastatin in patients at risk of cardiovascular events after noncardiac surgery: a pilot of the POISE-3 randomized controlled trial.,"Background Surgical bleeding is associated with postoperative cardiovascular complications. The efficacy and safety of tranexamic acid (TXA) in noncardiac surgery are still uncertain. Statins may prevent perioperative cardiovascular complications. We conducted a pilot to assess the feasibility of a perioperative trial of TXA and rosuvastatin. Methods Using a factorial design, we randomized patients at cardiovascular risk undergoing noncardiac surgery to intravenous TXA (1 g at the start and end of surgery) or placebo, and oral rosuvastatin (40 mg before and 20 mg daily for 30 days after surgery) or placebo. Feasibility outcomes included recruitment rates, follow-up, and compliance to interventions. Clinical outcomes were secondarily explored. Results After 3 months, we changed the design to a partial factorial due to the difficult recruitment of statin-naive patients. Over 6 months, 100 patients were randomized in the TXA trial (49 TXA, 51 placebo), 34 in the rosuvastatin trial (18 rosuvastatin, 16 placebo). Ninety-two percent (95% CI 80-98) of TXA and 86% (95% CI 74-94) of TXA-placebo patients received the 2 study doses. Thirty-three percent (95% CI 13-59) of rosuvastatin patients and 37% (95% CI 15-65) of rosuvastatin-placebo patients discontinued the study drug. A major cardiovascular complication occurred at 30 days in 1 TXA and 6 TXA-placebo patients, and 1 rosuvastatin and no rosuvastatin-placebo patients. Conclusions Our pilot study supports the feasibility of a perioperative TXA trial in noncardiac surgery. Feasibility of a perioperative rosuvastatin trial is uncertain because of a high prevalence of statin use in the target population and concerns about compliance. Trial registration ClinicalTrials.govNCT02546648.",2020,"A major cardiovascular complication occurred at 30 days in 1 TXA and 6 TXA-placebo patients, and 1 rosuvastatin and no rosuvastatin-placebo patients. ","['noncardiac surgery', 'patients at cardiovascular risk undergoing noncardiac surgery to intravenous TXA (1\u2009g at the start and end of surgery) or', '100 patients', 'patients at risk of cardiovascular events after noncardiac surgery']","['placebo, and oral rosuvastatin', 'rosuvastatin', 'tranexamic acid (TXA', 'TXA', 'perioperative rosuvastatin', 'TXA and rosuvastatin', 'rosuvastatin trial (18 rosuvastatin, 16 placebo', 'TXA-placebo', 'rosuvastatin-placebo', 'Tranexamic acid and rosuvastatin', 'placebo']","['perioperative cardiovascular complications', 'recruitment rates, follow-up, and compliance to interventions', 'cardiovascular complication']","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0161816', 'cui_str': 'Cardiac complication'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",100.0,0.689961,"A major cardiovascular complication occurred at 30 days in 1 TXA and 6 TXA-placebo patients, and 1 rosuvastatin and no rosuvastatin-placebo patients. ","[{'ForeName': 'Maura', 'Initials': 'M', 'LastName': 'Marcucci', 'Affiliation': 'Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON Canada.'}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Duceppe', 'Affiliation': 'Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON Canada.'}, {'ForeName': 'Yannick', 'Initials': 'Y', 'LastName': 'Le Manach', 'Affiliation': 'Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON Canada.'}, {'ForeName': 'Clive', 'Initials': 'C', 'LastName': 'Kearon', 'Affiliation': 'Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON Canada.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Eikelboom', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, ON Canada.'}, {'ForeName': 'Kayla', 'Initials': 'K', 'LastName': 'Pohl', 'Affiliation': 'Population Health Research Institute, Hamilton, ON Canada.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Vincent', 'Affiliation': 'Population Health Research Institute, Hamilton, ON Canada.'}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Darvish-Kazem', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, ON Canada.'}, {'ForeName': 'Sadeesh K', 'Initials': 'SK', 'LastName': 'Srinathan', 'Affiliation': 'Department of Surgery, University of Manitoba, Winnipeg, MB Canada.'}, {'ForeName': 'John D D', 'Initials': 'JDD', 'LastName': 'Neary', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, ON Canada.'}, {'ForeName': 'Joel L', 'Initials': 'JL', 'LastName': 'Parlow', 'Affiliation': ""Department of Anesthesiology and Perioperative Medicine, Kingston General Hospital and Queen's University, Kingston, ON Canada.""}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Kurz', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH USA.'}, {'ForeName': 'Peter L', 'Initials': 'PL', 'LastName': 'Gross', 'Affiliation': 'Department of Medicine, University of Montreal, Montreal, QC Canada.'}, {'ForeName': 'Marko', 'Initials': 'M', 'LastName': 'Mrkobrada', 'Affiliation': 'Department of Medicine, University of Western Ontario, London, ON Canada.'}, {'ForeName': 'Kumar', 'Initials': 'K', 'LastName': 'Balasubramanian', 'Affiliation': 'Population Health Research Institute, Hamilton, ON Canada.'}, {'ForeName': 'Daniel I', 'Initials': 'DI', 'LastName': 'Sessler', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH USA.'}, {'ForeName': 'P J', 'Initials': 'PJ', 'LastName': 'Devereaux', 'Affiliation': 'Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON Canada.'}]",Pilot and feasibility studies,['10.1186/s40814-020-00643-9'] 2512,32699760,Effect of Instrument Navigation on C-arm Radiation and Time during Spinal Procedures: A Clinical Evaluation.,"Introduction As minimally invasive spine surgery gains popularity, a focused effort must be made to reduce intraoperative radiation exposure to levels as low as reasonably achievable. Here, we demonstrate the clinical efficacy of a novel technology to aid in instrument navigation that aims to reduce intraoperative radiation exposure, number of fluoroscopic images, and time required to perform the most radiation intensive portions of a multitude of spinal procedures. Methods An internally randomized controlled study was performed over a 1-month period in order to clinically evaluate the effect of the C-arm assisted instrument tracking system, TrackX, on surgeon workflow, time, and radiation emitted. Three surgeons performed multiple spinal procedures on a total of 10 study patients and an additional 3 control patients. The surgeries encompassed minimally invasive spinal techniques and spanned extreme lateral interbody fusion, oblique lumbar interbody fusion, transforaminal lumbar interbody fusion along with percutaneous iliac screw placement, hardware removal, and kyphoplasty. The tasks studied included skin marking, first dilator insertion, localization for hardware placement and hardware removal. Results Overall radiation reduction was 83% ( P < .0001). Overall reduction in x-rays taken was 78% ( P < .0001). Overall time reduction was 81% ( P = .0003). Statistical significance held for each surgeon studied and for nearly every procedure type. In these 10 study procedures, over 2 hours of overall operating room time was saved, all while requiring negligible set up time and no system calibration or supplementary x-rays to be taken. There were no adverse outcomes for any study patient, and there was no case where TrackX was not able to successfully complete a given portion of a procedure. Conclusions TrackX instrument navigation is a clinically efficacious and accurate instrument tracking modality. This is the first instrument navigational technology that reduces radiation exposure and images required to complete a procedure while decreasing operative time. TrackX thus allows increased surgical efficiency while increasing operative efficiency and improving intraoperative safety. Level of Evidence 2.",2020,This is the first instrument navigational technology that reduces radiation exposure and images required to complete a procedure while decreasing operative time.,['Spinal Procedures'],['TrackX'],"['Overall radiation reduction', 'Overall time reduction', 'surgical efficiency']","[{'cui': 'C0025664', 'cui_str': 'methods'}]",[],"[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}]",10.0,0.0351895,This is the first instrument navigational technology that reduces radiation exposure and images required to complete a procedure while decreasing operative time.,"[{'ForeName': 'Timothy Y', 'Initials': 'TY', 'LastName': 'Wang', 'Affiliation': 'Duke University Medical Center, Department of Neurological Surgery, Durham, North Carolina.'}, {'ForeName': 'Farah', 'Initials': 'F', 'LastName': 'Hamouda', 'Affiliation': 'TrackX Technology, LLC, Chapel Hill, North Carolina.'}, {'ForeName': 'Vikram A', 'Initials': 'VA', 'LastName': 'Mehta', 'Affiliation': 'Duke University Medical Center, Department of Neurological Surgery, Durham, North Carolina.'}, {'ForeName': 'Eric W', 'Initials': 'EW', 'LastName': 'Sankey', 'Affiliation': 'Duke University Medical Center, Department of Neurological Surgery, Durham, North Carolina.'}, {'ForeName': 'Chester', 'Initials': 'C', 'LastName': 'Yarbrough', 'Affiliation': 'Duke University Medical Center, Department of Neurological Surgery, Durham, North Carolina.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Lark', 'Affiliation': 'Duke University Medical Center, Department of Neurological Surgery, Durham, North Carolina.'}, {'ForeName': 'Muhammad M', 'Initials': 'MM', 'LastName': 'Abd-El-Barr', 'Affiliation': 'Duke University Medical Center, Department of Neurological Surgery, Durham, North Carolina.'}]",International journal of spine surgery,['10.14444/7049'] 2513,32699784,Incidence of New-Onset Diabetes and PostTransplant Metabolic Syndrome after Liver Transplantation - A Prospective Study from South India.,"Background and Aims Liver transplantation has become an effective therapy for patients with end-stage liver disease. The risk of new-onset diabetes after transplantation (NODAT) and posttransplant metabolic syndrome (PTMS) is high among patients after liver transplantation. These are thought to be associated with increased risks of graft rejection, infection, cardiovascular disease, and death. Our study aimed to document the incidence of NODAT and PTMS and analyze pre and posttransplant predictive factors for their development in patients undergoing a liver transplant. Methods This was a prospective comparative study on 51 patients who underwent live donor liver transplantation. They were evaluated at baseline, 3 and 6 months after transplantation with fasting glucose, lipids, serum insulin levels, C-peptide, and HbA1C. They were followed up at 5 years to document any cardiovascular events or rejection. Results The incidence of preoperative diabetes mellitus (DM) in the study group was 25/51 (49%). The incidence of NODAT was 38.5% (10/26 patients) and PTMS 29% (10/35), respectively. Age (47.7 ± 5.4 vs 41.5 ± 12.7 years), HOMA2 - IR (2.3 ± 1.8 vs 2.1 ± 1.6), serum insulin (16.1 ± 12.0 vs 17.9 ± 14.5), and C-peptide (4.6 ± 0.5 vs 4.8 ± 0.7) were similar at baseline in the NODAT group compared to those who did not develop it. Mean tacrolimus levels were higher in PTMS group (6.8 ± 2.9 vs 5.0. ± 2.0 P value = 0.042). By the end of 5 years, 7 patients expired; 6 due to rejection and one due to cardiovascular disease. Moreover, 2 of these patients had preexisting DM and 2 had NODAT. Conclusions None of the baseline metabolic factors in patients undergoing liver transplant were predictive of the development of NODAT or PTMS. Mean tacrolimus levels were significantly higher in the PTMS group. A 5-year follow-up showed no excess risk of cardiovascular events or rejection in those with preexisting DM or in those who developed NODAT.",2020,Mean tacrolimus levels were significantly higher in the PTMS group.,"['patients undergoing liver transplant', 'New-Onset Diabetes and PostTransplant Metabolic Syndrome after Liver Transplantation - A Prospective Study from South India', '51 patients who underwent live donor liver transplantation', 'Age (47.7 ± 5.4 vs 41.5 ± 12.7 years), HOMA2 - IR (2.3 ± 1.8 vs 2.1 ± 1.6), serum insulin (16.1 ± 12.0 vs 17.9 ± 14.5), and C-peptide (4.6 ± 0.5 vs 4.8 ± 0.7) were similar at baseline in the NODAT group compared to those who did not develop it', 'patients after liver transplantation', 'patients with end-stage liver disease', 'patients undergoing a liver transplant']",['PTMS'],"['incidence of preoperative diabetes mellitus (DM', 'fasting glucose, lipids, serum insulin levels, C-peptide, and HbA1C', 'Mean tacrolimus levels', 'risks of graft rejection, infection, cardiovascular disease, and death', 'incidence of NODAT', 'cardiovascular events or rejection']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023911', 'cui_str': 'Transplantation of liver'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0033522', 'cui_str': 'Prospective Studies'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0348050', 'cui_str': 'Live donor'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517792', 'cui_str': '5.4'}, {'cui': 'C4517546', 'cui_str': '12.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C4068876', 'cui_str': '2.1'}, {'cui': 'C4517508', 'cui_str': '1.6'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C4319689', 'cui_str': '16.1'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}, {'cui': 'C4517764', 'cui_str': '4.6'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C4517765', 'cui_str': '4.8'}, {'cui': 'C4517474', 'cui_str': '0.7'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0745744', 'cui_str': 'End stage liver disease'}]","[{'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0519826', 'cui_str': 'Tacrolimus measurement'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0018129', 'cui_str': 'Graft rejection'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0035015', 'cui_str': 'Rejection (Psychology)'}]",51.0,0.0332132,Mean tacrolimus levels were significantly higher in the PTMS group.,"[{'ForeName': 'Tittu', 'Initials': 'T', 'LastName': 'Oommen', 'Affiliation': 'Department of Endocrinology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.'}, {'ForeName': 'Chankramath S', 'Initials': 'CS', 'LastName': 'Arun', 'Affiliation': 'Department of Endocrinology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.'}, {'ForeName': 'Harish', 'Initials': 'H', 'LastName': 'Kumar', 'Affiliation': 'Department of Endocrinology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.'}, {'ForeName': 'Vasantha', 'Initials': 'V', 'LastName': 'Nair', 'Affiliation': 'Department of Endocrinology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.'}, {'ForeName': 'R V', 'Initials': 'RV', 'LastName': 'Jayakumar', 'Affiliation': 'Consultant Endocrinologist, Aster Medcity, Kochi, Kerala, India.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Sudhindran', 'Affiliation': 'Department of Gastro-Intestinal Surgery, Amrita Institute of Medical Sciences, Kochi, Kerala, India.'}, {'ForeName': 'V P', 'Initials': 'VP', 'LastName': 'Praveen', 'Affiliation': 'Department of Endocrinology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.'}, {'ForeName': 'Nisha B', 'Initials': 'NB', 'LastName': 'Nithya Abraham', 'Affiliation': 'Department of Endocrinology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.'}, {'ForeName': 'Usha', 'Initials': 'U', 'LastName': 'Menon', 'Affiliation': 'Department of Endocrinology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.'}]",Indian journal of endocrinology and metabolism,['10.4103/ijem.IJEM_602_19'] 2514,32699904,Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.,"OBJECTIVES This report provides data for the extent of B cell depletion and recovery, efficacy, safety and immunogenicity of Sandoz rituximab (SDZ-RTX; GP2013; Rixathon®) compared with reference rituximab (Ref-RTX) up to week 52 of the ASSIST-RA study. METHODS Patients were randomized to SDZ-RTX or Ref-RTX in combination with methotrexate according to the RTX label. The primary endpoint was analysed at week 24. Responders (28-joint DAS [DAS28] decrease from baseline >1.2) at week 24 with residual disease activity (DAS28 ≥2.6) were eligible for a second treatment course between week 24 and 52. Endpoints after week 24 included change from baseline in peripheral B cells, DAS28, ACR 20% response rate (ACR20), Clinical and Simplified Disease Activity Indexes (CDAI, SDAI) and HAQ disability index (HAQ-DI). Safety and immunogenicity were assessed by the incidence of adverse events and antidrug antibodies. RESULTS Primary and secondary endpoints up to week 24 were met. Overall, 260/312 randomized patients completed treatment up to week 52. SDZ-RTX resulted in B cell concentrations over time similar to Ref-RTX. The efficacy of SDZ-RTX was similar to Ref-RTX up to week 52, as measured by DAS28, ACR20/50/70, CDAI, SDAI and HAQ-DI. Safety of SDZ-RTX was similar to Ref-RTX regarding frequency, type and severity of adverse events, which were consistent with the known Ref-RTX safety profile. The incidence of antidrug antibodies was low and transient similarly across treatment groups. CONCLUSION SDZ-RTX demonstrated similar B cell concentrations over time, efficacy, safety and immunogenicity to Ref-RTX over 52 weeks of the ASSIST-RA study.",2020,"Safety of SDZ-RTX was similar to Ref-RTX regarding frequency, type and severity of adverse events, which were consistent with the known Ref-RTX safety profile.","['active rheumatoid arthritis', 'Patients']","['SDZ-RTX or Ref-RTX in combination with methotrexate', 'reference rituximab (Ref-RTX', 'SDZ-RTX', 'Sandoz rituximab (SDZ-RTX; GP2013; Rixathon®', 'Sandoz biosimilar rituximab']","['incidence of antidrug antibodies', 'Safety and immunogenicity', 'adverse events and antidrug antibodies', 'B cell concentrations', 'efficacy, safety and immunogenicity', 'Efficacy and safety', 'peripheral B cells, DAS28, ACR 20% response rate (ACR20), Clinical and Simplified Disease Activity Indexes (CDAI, SDAI) and HAQ disability index (HAQ-DI']","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C4046044', 'cui_str': 'GP2013'}, {'cui': 'C4045974', 'cui_str': 'Biosimilars'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0004561', 'cui_str': 'B lymphocyte'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0102923', 'cui_str': 'ametantrone'}, {'cui': 'C0231170', 'cui_str': 'Disability'}]",,0.132052,"Safety of SDZ-RTX was similar to Ref-RTX regarding frequency, type and severity of adverse events, which were consistent with the known Ref-RTX safety profile.","[{'ForeName': 'Josef S', 'Initials': 'JS', 'LastName': 'Smolen', 'Affiliation': 'Department of Rheumatology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Stanley B', 'Initials': 'SB', 'LastName': 'Cohen', 'Affiliation': 'Department of Rheumatology, Metroplex Clinical Research Center, Dallas, TX, USA.'}, {'ForeName': 'Hans-Peter', 'Initials': 'HP', 'LastName': 'Tony', 'Affiliation': 'Department of Internal Medicine, Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, Germany.'}, {'ForeName': 'Morton', 'Initials': 'M', 'LastName': 'Scheinberg', 'Affiliation': 'Rheumatology Section, Orthopedic Department, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Kivitz', 'Affiliation': 'Altoona Center for Clinical Research, Altoona Arthritis and Osteoporosis Center, Duncansville, PA, USA.'}, {'ForeName': 'Andra', 'Initials': 'A', 'LastName': 'Balanescu', 'Affiliation': 'Sf. Maria Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Gomez-Reino', 'Affiliation': 'Fundacion IDIS, Hospital Clinico Universitario, Santiago, Spain.'}, {'ForeName': 'Liyi', 'Initials': 'L', 'LastName': 'Cen', 'Affiliation': 'Biostatistics Biosimilars Analytics, Novartis Pharmaceuticals Corp,\xa0East Hanover, NJ, USA.'}, {'ForeName': 'Johann', 'Initials': 'J', 'LastName': 'Poetzl', 'Affiliation': 'Biosimilar Clinical Development, Hexal AG, Holzkirchen, Germany.'}, {'ForeName': 'Tamas', 'Initials': 'T', 'LastName': 'Shisha', 'Affiliation': 'Translational Medicine, Novartis Institute of Biomedical Research, Basel, Switzerland.'}, {'ForeName': 'Dmitrij', 'Initials': 'D', 'LastName': 'Kollins', 'Affiliation': 'Biosimilar Clinical Development, Hexal AG, Holzkirchen, Germany.'}]","Rheumatology (Oxford, England)",['10.1093/rheumatology/keaa234'] 2515,32699906,"Effects of MOPP Gear on SAM Medical Junctional Tourniquet Application: A Prospective, Randomized Control Trial.","INTRODUCTION Hemorrhage is the leading cause of preventable death on the battlefield, and hemostasis is particularly challenging to achieve at junctional sites such as the axillary or inguinal regions. Mission-oriented protective posture (MOPP) gear, as worn most recently in Syria to guard against chemical weapons, can make the performance of technical skills more challenging still. The objective of this study was to evaluate how wearing MOPP gear affects the application time of the SAM Medical Junctional Tourniquet (SJT) by U.S. Army combat medics. MATERIALS AND METHODS We conducted a prospective, randomized control trial evaluating time for SJT application between participants wearing MOPP versus those not wearing MOPP. Secondary outcomes included SJT application success rate and participant appraisal of SJT application difficulty assessed with five-point Likert items, between groups. Participants placed SJTs on robotic simulation mannequins with a penetrating inguinal injury. RESULTS In April 2019, we enrolled 49 combat medics. Most participants were male (77.5%), had a median age of 25 (interquartile range 23-28), and in the grade of E4 or less (63.3%). Mean SJT application times in seconds were higher among those wearing MOPP versus those who were not (223.1 versus 167.2; 95% confidence interval for difference in means 5.293, 106.374; P = 0.03). Participants wearing MOPP had a less successful application rate overall, but this difference was not statistically significant (64.3% versus 81.0%, P = 0.34). Compared to participants not wearing MOPP, those wearing MOPP agreed that SJT application was difficult (4 versus 3, P = 0.03), what they were wearing affected SJT application (4 versus 2, P = 0.01), and it was difficult to use their hands during SJT application (4 versus 1, P < 0.001). CONCLUSIONS Wearing military MOPP gear significantly prolongs the amount of time required for combat medics to apply an SJT on a simulated casualty with a penetrating inguinal injury. This study highlights the importance of incorporating MOPP gear into medical training scenarios to improve skills competency while wearing these protective garments.",2020,"Participants wearing MOPP had a less successful application rate overall, but this difference was not statistically significant (64.3% versus 81.0%, P = 0.34).","['SAM Medical Junctional Tourniquet Application', 'participants wearing MOPP versus those not wearing MOPP', 'Most participants were male (77.5%), had a median age of 25 (interquartile range 23-28), and in the grade of E4 or less (63.3']","['SAM Medical Junctional Tourniquet (SJT', 'MOPP Gear', 'Mission-oriented protective posture (MOPP']","['SJT application success rate and participant appraisal of SJT application difficulty assessed with five-point Likert items', 'Mean SJT application times', 'successful application rate overall']","[{'cui': 'C0036002', 'cui_str': 'S-Adenosylmethionine'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0205144', 'cui_str': 'Junctional'}, {'cui': 'C0204731', 'cui_str': 'Application of tourniquet'}, {'cui': 'C0026219', 'cui_str': 'Missions'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0441800', 'cui_str': 'Grade'}]","[{'cui': 'C0036002', 'cui_str': 'S-Adenosylmethionine'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0205144', 'cui_str': 'Junctional'}, {'cui': 'C0040519', 'cui_str': 'Tourniquet'}, {'cui': 'C0026219', 'cui_str': 'Missions'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}]","[{'cui': 'C0036002', 'cui_str': 'S-Adenosylmethionine'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0205144', 'cui_str': 'Junctional'}, {'cui': 'C0204731', 'cui_str': 'Application of tourniquet'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.084364,"Participants wearing MOPP had a less successful application rate overall, but this difference was not statistically significant (64.3% versus 81.0%, P = 0.34).","[{'ForeName': 'Eric M', 'Initials': 'EM', 'LastName': 'Wagner', 'Affiliation': 'Madigan Army Medical Center, 9040A Jackson Ave, Joint Base Lewis-McChord, Tacoma, WA 98431.'}, {'ForeName': 'Jason F', 'Initials': 'JF', 'LastName': 'Naylor', 'Affiliation': 'Madigan Army Medical Center, 9040A Jackson Ave, Joint Base Lewis-McChord, Tacoma, WA 98431.'}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Ahern', 'Affiliation': 'Madigan Army Medical Center, 9040A Jackson Ave, Joint Base Lewis-McChord, Tacoma, WA 98431.'}, {'ForeName': 'Brett C', 'Initials': 'BC', 'LastName': 'Gendron', 'Affiliation': 'Brooke Army Medical Center, 3551 Roger Brooke Dr, Joint Base San Antonio-Fort Sam Houston, TX 78234.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'April', 'Affiliation': 'Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814.'}, {'ForeName': 'Steven G', 'Initials': 'SG', 'LastName': 'Schauer', 'Affiliation': 'Brooke Army Medical Center, 3551 Roger Brooke Dr, Joint Base San Antonio-Fort Sam Houston, TX 78234.'}]",Military medicine,['10.1093/milmed/usaa138'] 2516,32700060,The Effect of Multimodal Emotional Expression on Responses to a Digital Human during a Self-Disclosure Conversation: a Computational Analysis of User Language.,"Digital humans show promise for use in healthcare as virtual therapists to deliver psychotherapy or companions for social support. For digital humans to be effective and engaging in these roles, it is important they can build close relationships with people. Emotional expressiveness can improve social closeness in human relationships, especially for females. However, it is unknown whether multimodal emotional expression improves relationships with digital humans. Participants were 185 adults aged 18 years or older with English fluency. Participants were block-randomized by gender to complete the Relationship Closeness Induction Task with one of six versions of a digital human. The digital humans varied in modality richness (face, no face) and emotional expression (emotional voice, neutral voice; emotional face, neutral face). Participants' language was analysed for emotional content using Linguistic Inquiry and Word Count software. A series of three-way ANOVA and ANCOVA were conducted to evaluate the effect of digital human face type, voice type, and participant gender on emotional content in participant language. A digital human with no face was associated with more first-person singular pronoun use than a neutral face and an emotional face digital human. A digital human with no face and a neutral voice received more general negative emotion language than a digital human with no face and an emotional voice. Findings suggest the presence of a face and emotion in the voice may improve emotional responses to digital humans. Results provide evidence for aspects of the theoretical framework of embodied agent-patient communication.",2020,A digital human with no face and a neutral voice received more general negative emotion language than a digital human with no face and an emotional voice.,['Participants were 185 adults aged 18\xa0years or older with English fluency'],['Multimodal Emotional Expression'],"['emotional expression (emotional voice, neutral voice; emotional face, neutral face', 'general negative emotion language', 'emotional responses']","[{'cui': 'C4517617', 'cui_str': '185'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0376245', 'cui_str': 'English language'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0023008', 'cui_str': 'Language'}]",185.0,0.0394297,A digital human with no face and a neutral voice received more general negative emotion language than a digital human with no face and an emotional voice.,"[{'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Loveys', 'Affiliation': 'Department of Psychological Medicine, The University of Auckland, Auckland, New Zealand. k.loveys@auckland.ac.nz.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Sagar', 'Affiliation': 'Soul Machines Ltd, Auckland, New Zealand.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Broadbent', 'Affiliation': 'Department of Psychological Medicine, The University of Auckland, Auckland, New Zealand.'}]",Journal of medical systems,['10.1007/s10916-020-01624-4'] 2517,32700098,"Suspension training vs. traditional resistance training: effects on muscle mass, strength and functional performance in older adults.","PURPOSE We compared the effects of suspension training (ST) with traditional resistance training (TRT) on muscle mass, strength and functional performance in older adults. METHODS Forty-two untrained older adults were randomized in TRT, ST (both performed 3 sets of whole body exercises to muscle failure) or control group (CON). Muscle thickness (MT) of biceps brachii (MT BB ) and vastus lateralis (MT VL ), maximal dynamic strength test (1RM) for biceps curl (1RM BC ) and leg extension exercises (1RM LE ), and functional performance tests (chair stand [CS], timed up and go [TUG] and maximal gait speed [MGS]) were performed before and after 12 weeks of training. RESULTS MT BB increased significantly and similarly for all training groups (TRT 23.35%; ST 21.56%). MT VL increased significantly and similarly for all training groups (TRT 13.03%; ST 14.07%). 1RM BC increased significantly and similarly for all training groups (TRT 16.06%; ST 14.33%). 1RM LE increased significantly and similarly for all training groups (TRT 14.89%; ST 18.06%). MGS increased significantly and similarly for all groups (TRT 6.26%; ST 5.99%; CON 2.87%). CS decreased significantly and similarly for all training groups (TRT - 20.80%; ST - 15.73%). TUG decreased significantly and similarly for all training groups (TRT - 8.66%; ST - 9.16%). CONCLUSION Suspension training (ST) promotes similar muscle mass, strength and functional performance improvements compared to TRT in older adults.",2020,1RM BC increased significantly and similarly for all training groups (TRT 16.06%; ST 14.33%).,"['Forty-two untrained older adults', 'older adults']","['Suspension training vs. traditional resistance training', 'suspension training (ST) with traditional resistance training (TRT', 'TRT, ST (both performed 3 sets of whole body exercises to muscle failure) or control group (CON', 'Suspension training (ST']","['MGS', 'TUG', '1RM BC', 'CS', 'MT BB', 'Muscle thickness (MT) of biceps brachii (MT BB ) and vastus lateralis (MT VL ), maximal dynamic strength test (1RM) for biceps curl (1RM BC ) and leg extension exercises (1RM LE ), and functional performance tests (chair stand [CS], timed up and go [TUG] and maximal gait speed [MGS', '1RM LE', 'muscle mass, strength and functional performance', 'MT VL']","[{'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0007985', 'cui_str': 'Chemical suspension'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0559499', 'cui_str': 'Biceps brachii muscle structure'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0010474', 'cui_str': ""Curling's ulcers""}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}]",42.0,0.0105798,1RM BC increased significantly and similarly for all training groups (TRT 16.06%; ST 14.33%).,"[{'ForeName': 'Samuel Domingos', 'Initials': 'SD', 'LastName': 'Soligon', 'Affiliation': 'MUSCULAB, Laboratory of Neuromuscular Adaptations to Resistance Training, Department of Physical Education, Federal University of São Carlos, UFSCar, Rod. Washington Luiz, km 235-SP 310, São Carlos, SP, 13565-905, Brazil.'}, {'ForeName': 'Deivid Gomes', 'Initials': 'DG', 'LastName': 'da Silva', 'Affiliation': 'MUSCULAB, Laboratory of Neuromuscular Adaptations to Resistance Training, Department of Physical Education, Federal University of São Carlos, UFSCar, Rod. Washington Luiz, km 235-SP 310, São Carlos, SP, 13565-905, Brazil.'}, {'ForeName': 'João Guilherme Almeida', 'Initials': 'JGA', 'LastName': 'Bergamasco', 'Affiliation': 'MUSCULAB, Laboratory of Neuromuscular Adaptations to Resistance Training, Department of Physical Education, Federal University of São Carlos, UFSCar, Rod. Washington Luiz, km 235-SP 310, São Carlos, SP, 13565-905, Brazil.'}, {'ForeName': 'Vitor', 'Initials': 'V', 'LastName': 'Angleri', 'Affiliation': 'MUSCULAB, Laboratory of Neuromuscular Adaptations to Resistance Training, Department of Physical Education, Federal University of São Carlos, UFSCar, Rod. Washington Luiz, km 235-SP 310, São Carlos, SP, 13565-905, Brazil.'}, {'ForeName': 'Ricardo Alessandro Medalha', 'Initials': 'RAM', 'LastName': 'Júnior', 'Affiliation': 'MUSCULAB, Laboratory of Neuromuscular Adaptations to Resistance Training, Department of Physical Education, Federal University of São Carlos, UFSCar, Rod. Washington Luiz, km 235-SP 310, São Carlos, SP, 13565-905, Brazil.'}, {'ForeName': 'Nathalia Fernanda', 'Initials': 'NF', 'LastName': 'Dias', 'Affiliation': 'MUSCULAB, Laboratory of Neuromuscular Adaptations to Resistance Training, Department of Physical Education, Federal University of São Carlos, UFSCar, Rod. Washington Luiz, km 235-SP 310, São Carlos, SP, 13565-905, Brazil.'}, {'ForeName': 'Sanmy Rocha', 'Initials': 'SR', 'LastName': 'Nóbrega', 'Affiliation': 'MUSCULAB, Laboratory of Neuromuscular Adaptations to Resistance Training, Department of Physical Education, Federal University of São Carlos, UFSCar, Rod. Washington Luiz, km 235-SP 310, São Carlos, SP, 13565-905, Brazil.'}, {'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'de Castro Cesar', 'Affiliation': 'Department of Medicine, Federal University of São Carlos, UFSCar, Rod. Washington Luiz, km 235-SP 310, São Carlos, SP, 13565-905, Brazil.'}, {'ForeName': 'Cleiton Augusto', 'Initials': 'CA', 'LastName': 'Libardi', 'Affiliation': 'MUSCULAB, Laboratory of Neuromuscular Adaptations to Resistance Training, Department of Physical Education, Federal University of São Carlos, UFSCar, Rod. Washington Luiz, km 235-SP 310, São Carlos, SP, 13565-905, Brazil. c.libardi@ufscar.br.'}]",European journal of applied physiology,['10.1007/s00421-020-04446-x'] 2518,32700114,The effectiveness and cost-effectiveness of an integrated osteoporosis care programme for postmenopausal women in Flanders: study protocol of a quasi-experimental controlled design.,"Osteoporosis causes high individual and societal burden, due to limited attention to fracture prevention. Integrated care for chronic conditions has shown to facilitate management of these conditions, improving clinical outcomes alongside quality of life and cost-effectiveness. This manuscript describes an integrated osteoporosis care programme that will be implemented in primary care. OBJECTIVE To provide a comprehensive description of a quasi-experimental study design in which a newly developed integrated osteoporosis care (IOC) programme for the management of postmenopausal osteoporosis (PO) in primary care (PC) is implemented and will be compared with care as usual (CAU). METHODS A literature research was performed and expert meetings have been taking place, which has led to the development of a complex PC intervention based on framework for integrated people-centred health services (IPCHS). RESULTS This manuscript describes the developmental process of the preclinical phase of a quasi-experimental real-world design and the interventions as a result of this process that will be implemented during the clinical phase, along with the evaluation that will take place alongside the clinical phase: An integrative approach for the management of PO in primary care was developed and will be implemented in greater region of Ghent (GRG), Belgium. The approach consists of a complex intervention targeting patients and PC stakeholders in osteoporosis care (e.g. general practitioners (GPs), physiotherapists, nurses, pharmacists). A comparison will be made with CAU using medication possession ratios (MPR) of included patients as primary outcome. These data will be obtained from the national health database. Secondary outcomes are physician outcomes, patient-reported outcome measures (PROMs), and patient-reported experience measures (PREMs). A cost-effectiveness evaluation will be performed if the programme appears to be effective in terms of MPR. TRIAL REGISTRATION ClinicalTrials.gov : NCT03970902.",2020,"Integrated care for chronic conditions has shown to facilitate management of these conditions, improving clinical outcomes alongside quality of life and cost-effectiveness.","['patients and PC stakeholders in osteoporosis care (e.g. general practitioners (GPs), physiotherapists, nurses, pharmacists', 'postmenopausal osteoporosis (PO) in primary care (PC', 'postmenopausal women in Flanders']","['complex intervention targeting', 'integrated osteoporosis care programme', 'integrated osteoporosis care (IOC) programme']","['effectiveness and cost-effectiveness', 'physician outcomes, patient-reported outcome measures (PROMs), and patient-reported experience measures (PREMs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0029458', 'cui_str': 'Postmenopausal osteoporosis'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1875156', 'cui_str': 'Flanders'}]","[{'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C4277735', 'cui_str': 'Patient Reported Outcome Measures'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",,0.0446341,"Integrated care for chronic conditions has shown to facilitate management of these conditions, improving clinical outcomes alongside quality of life and cost-effectiveness.","[{'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Verdonck', 'Affiliation': 'Department of Public Health and Primary Care, Ghent University, Ghent, Belgium. caroline.verdonck@ugent.be.'}, {'ForeName': 'Lieven', 'Initials': 'L', 'LastName': 'Annemans', 'Affiliation': 'Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Goemaere', 'Affiliation': 'Department of Endocrinology and Rheumatology, Unit Osteoporosis and Metabolic Bone Disease, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Lapauw', 'Affiliation': 'Department of Endocrinology and Rheumatology, Unit Osteoporosis and Metabolic Bone Disease, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Geert', 'Initials': 'G', 'LastName': 'Goderis', 'Affiliation': 'Academic Centre for General practice, Department of Public Health and Primary Care, KU Leuven - University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Elie', 'Initials': 'E', 'LastName': 'Balligand', 'Affiliation': ', Beringen, Belgium.'}, {'ForeName': 'Marie-Paule', 'Initials': 'MP', 'LastName': 'Doom', 'Affiliation': ', Beringen, Belgium.'}, {'ForeName': 'Stany', 'Initials': 'S', 'LastName': 'Perkisas', 'Affiliation': 'University Centre Geriatrics, University Hospital Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Liesbeth', 'Initials': 'L', 'LastName': 'Borgermans', 'Affiliation': 'Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.'}]",Archives of osteoporosis,['10.1007/s11657-020-00776-7'] 2519,32700151,Impact of haptic feedback on applied intracorporeal forces using a novel surgical robotic system-a randomized cross-over study with novices in an experimental setup.,"BACKGROUND Most currently used surgical robots have no force feedback; the next generation displays forces visually. A novel single-port robotic surgical system called FLEXMIN has been developed. Through an outer diameter of 38 mm, two instruments are teleoperated from a surgeon's control console including true haptic force feedback. One additional channel incorporates a telescope, another is free for special instrument functions. METHODS This randomized cross-over study analyzed the effect of haptic feedback on the application of intracorporeal forces. In a standardized experiment setup, the subjects had to draw circles with the surgical robot as gently as possible. The applied forces, the required time spans, and predefined error rates were measured. RESULTS Without haptic feedback, the maximum forces (median/IQR) were 6.43 N/2.96 N. With haptic feedback, the maximum forces were lower (3.57 N/1.94 N, p < 0.001). Also, the arithmetic means of the force progression (p < 0.001) and their standard deviations (p < 0.001) were lower. Not significant were the shorter durations and lower error rates. No sequence effect of force or duration was detected. No characteristic learning or fatigue curve was observed. CONCLUSIONS In the experiment setup, the true haptic force feedback can reduce the applied intracorporeal robotic force to one-half when considering the aspects maximum, means, and standard deviation. Other test tasks are needed to validate the influence of force feedback on surgical efficiency and safety.",2020,"With haptic feedback, the maximum forces were lower (3.57 N/1.94 N, p < 0.001).",[],['haptic feedback'],"['characteristic learning or fatigue curve', 'shorter durations and lower error rates']",[],"[{'cui': 'C0015744', 'cui_str': 'Feedback'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0439593', 'cui_str': 'Short duration'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",,0.0216932,"With haptic feedback, the maximum forces were lower (3.57 N/1.94 N, p < 0.001).","[{'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Miller', 'Affiliation': 'Clinic of General, Visceral and Transplant Surgery, Working Group Surgical Technology and Training, Tübingen University Hospital, Waldhörnlestrasse 22, 72072, Tübingen, Germany.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Braun', 'Affiliation': 'Clinic for Orthopaedics, Tübingen University Hospital, Waldhörnlestrasse 22, 72072, Tübingen, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Bilz', 'Affiliation': 'Department of Electromechanical Design, Darmstadt Technical University, Merckstrasse 25, 64283, Darmstadt, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Matich', 'Affiliation': 'Department of Electromechanical Design, Darmstadt Technical University, Merckstrasse 25, 64283, Darmstadt, Germany.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Neupert', 'Affiliation': 'Department of Electromechanical Design, Darmstadt Technical University, Merckstrasse 25, 64283, Darmstadt, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Kunert', 'Affiliation': 'Clinic of General, Visceral and Transplant Surgery, Working Group Surgical Technology and Training, Tübingen University Hospital, Waldhörnlestrasse 22, 72072, Tübingen, Germany. wolfgang.kunert@uni-tuebingen.de.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Kirschniak', 'Affiliation': 'Clinic of General, Visceral and Transplant Surgery, Working Group Surgical Technology and Training, Tübingen University Hospital, Waldhörnlestrasse 22, 72072, Tübingen, Germany.'}]",Surgical endoscopy,['10.1007/s00464-020-07818-8'] 2520,32700186,The effects of intervening with physical activity in the early years (ages 3-5) on health-related quality of life: a secondary analysis of the Activity Begins in Childhood (ABC) trial.,"PURPOSE Limited research has measured the effect of physical activity (PA) interventions on health-related quality of life (HRQoL) among pre-school-aged children. This study evaluates the effect of the Activity Begins in Childhood (ABC) cluster-randomized controlled trial designed to increase PA in the ages 3-5 years on HRQoL. METHODS This was a cluster-randomized controlled trial where the intervention group included PA education delivered to daycare providers only, or daycare providers and parents. In the current study, the two PA intervention groups were combined. The comparator group received standard daycare curriculum (COM). A total of 215 children were included (PA n = 161, COM n = 54). Parents completed the proxy Pediatric Quality of Life Inventory Generic Core Scale (PedsQL™ 4.0) to measure HRQoL at baseline and the end of the 6-month trial. HRQoL scores were analyzed as physical, psychosocial, and total domains. Baseline and 6-months measurements were compared for PA and COM groups, and mean changes in scores (95% confidence intervals) were measured using absolute values. RESULTS No between-group differences were observed for the physical (p = 0.17), psychosocial (p = 0.95) or total scores (p = 0.20). Paired comparisons showed that only the PA group improved psychosocial- (PA mean difference = 2.18 (0.20, 4.15), p = 0.03; COM mean difference = 2.05 (- 1.03, 5.13), p = 0.19) and total-HRQoL scores (PA mean difference = 2.83 (1.83, 3.84), p < 0.001; COM mean difference = 0.19 (- 1.78, 2.16), p = 0.84) after 6 months. CONCLUSION Although the within-PA group analysis showed an improvement in psychosocial and total HRQoL scores from baseline, no between-group differences were observed in the HRQoL over time among children aged 3-5 years.",2020,"No between-group differences were observed for the physical (p = 0.17), psychosocial (p = 0.95) or total scores (p = 0.20).","['pre-school-aged children', '215 children were included (PA n\u2009=\u2009161, COM n\u2009=\u200954']","['standard daycare curriculum (COM', 'physical activity (PA) interventions']","['health-related quality of life (HRQoL', 'proxy Pediatric Quality of Life Inventory Generic Core Scale', 'psychosocial and total HRQoL scores', 'health-related quality of life', 'HRQoL scores', 'total scores', 'psychosocial', 'total-HRQoL scores']","[{'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4709308', 'cui_str': '215'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009490', 'cui_str': 'Comoros islands'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0008070', 'cui_str': 'Child day care center'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C0009490', 'cui_str': 'Comoros islands'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0600420', 'cui_str': 'Proxy'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",215.0,0.166496,"No between-group differences were observed for the physical (p = 0.17), psychosocial (p = 0.95) or total scores (p = 0.20).","[{'ForeName': 'Taniya S', 'Initials': 'TS', 'LastName': 'Nagpal', 'Affiliation': 'School of Human Kinetics, Faculty of Health Sciences, The University of Ottawa, Lees Campus, E 250F, 200 Lees Ave., Ottawa, ON, K1N 6N5, Canada.'}, {'ForeName': 'Gary S', 'Initials': 'GS', 'LastName': 'Goldfield', 'Affiliation': ""Healthy Active Living & Obesity (HALO) Research Group, Children's Hospital of Eastern Ontario (CHEO) Research Institute, Ottawa, Canada.""}, {'ForeName': 'Danilo F', 'Initials': 'DF', 'LastName': 'da Silva', 'Affiliation': 'School of Human Kinetics, Faculty of Health Sciences, The University of Ottawa, Lees Campus, E 250F, 200 Lees Ave., Ottawa, ON, K1N 6N5, Canada.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Souza', 'Affiliation': 'School of Human Kinetics, Faculty of Health Sciences, The University of Ottawa, Lees Campus, E 250F, 200 Lees Ave., Ottawa, ON, K1N 6N5, Canada.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Burhunduli', 'Affiliation': 'Department of Biomedical Science, Faculty of Science, The University of Ottawa, Ottawa, Canada.'}, {'ForeName': 'Rebecca H', 'Initials': 'RH', 'LastName': 'Liu', 'Affiliation': ""Institute for Health System Solutions & Virtual Care, Women's College Hospital, Toronto, ON, Canada.""}, {'ForeName': 'Patti-Jean', 'Initials': 'PJ', 'LastName': 'Naylor', 'Affiliation': 'School of Exercise Science, University of Victoria, Victoria, Canada.'}, {'ForeName': 'Kristi B', 'Initials': 'KB', 'LastName': 'Adamo', 'Affiliation': 'School of Human Kinetics, Faculty of Health Sciences, The University of Ottawa, Lees Campus, E 250F, 200 Lees Ave., Ottawa, ON, K1N 6N5, Canada. kristi.adamo@uottawa.ca.'}]","Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation",['10.1007/s11136-020-02587-2'] 2521,32700188,"Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.","INTRODUCTION International guidelines recommend treatment with a sodium-glucose cotransporter-2 (SGLT-2) inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist for treatment intensification in type 2 diabetes mellitus (T2DM) patients with progression on metformin. In the randomised, controlled, Peptide Innovation for Early Diabetes Treatment (PIONEER) 2 trial, the SGLT-2 inhibitor empagliflozin was compared with the GLP-1 receptor agonist oral semaglutide, in addition to metformin. The aim of the current study was to assess the long-term cost-effectiveness of empagliflozin 25 mg versus oral semaglutide 14 mg, in addition to metformin, for T2DM patients in the UK. METHODS Analyses were conducted from the UK healthcare payer perspective, using the IQVIA Core Diabetes model, with a time horizon of 50 years. Patients received either empagliflozin or oral semaglutide, in addition to metformin, until Hba1c threshold of 7.5% (58 mmol/mol) was exceeded, following which treatment intensification with insulin glargine in addition to empagliflozin or oral semaglutide plus metformin was assumed. Baseline cohort characteristics and 52-week treatment effects were derived from the PIONEER 2 trial. Treatment effects of empagliflozin and GLP-1 receptor agonists on hospitalisation for heart failure (hHF) were based on the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) real-world study. Utilities, treatment costs and costs of diabetes-related complications were obtained from published sources. RESULTS Direct costs for empagliflozin plus metformin were considerably lower than those for oral semaglutide plus metformin (by more than GBP 6000). Compared with oral semaglutide plus metformin, empagliflozin plus metformin was a cost-effective treatment for T2DM patients in all scenarios tested. Probabilistic sensitivity analysis showed cost-effectiveness in > 95% of the iterations using a threshold of 20,000 GBP/QALY. CONCLUSION Empagliflozin 25 mg is a cost-effective treatment option versus oral semaglutide 14 mg, when used in addition to metformin, for the treatment of T2DM patients in the UK.",2020,"Probabilistic sensitivity analysis showed cost-effectiveness in > 95% of the iterations using a threshold of 20,000 GBP/QALY. ","['type 2 diabetes mellitus (T2DM) patients with progression on', 'T2DM patients in the UK', 'Early Diabetes Treatment (PIONEER', 'Analyses were conducted from the UK healthcare payer perspective, using the IQVIA Core Diabetes model, with a time horizon of 50\xa0years', 'Type 2 Diabetes in the UK']","['oral semaglutide plus metformin, empagliflozin plus metformin', 'Metformin', 'empagliflozin', 'SGLT-2 inhibitor empagliflozin', 'Empagliflozin Versus Oral Semaglutide', 'metformin', 'insulin glargine in addition to empagliflozin or oral semaglutide plus metformin', 'empagliflozin and GLP-1 receptor agonists', 'Empagliflozin', 'oral semaglutide plus metformin', 'empagliflozin plus metformin', 'sodium-glucose cotransporter-2\xa0(SGLT-2) inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist', 'empagliflozin or oral semaglutide, in addition to metformin']","['cost-effectiveness', 'hospitalisation for heart failure (hHF', 'Utilities, treatment costs and costs of diabetes-related complications']","[{'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C2348942', 'cui_str': 'Healthcare payer'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3885068', 'cui_str': 'semaglutide'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C0017739', 'cui_str': 'Glucose-Sodium Transport System'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C1562104', 'cui_str': 'Glucagon-like peptide 1 receptor agonist-containing product'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C2987634', 'cui_str': 'Receptor agonist'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0087112', 'cui_str': 'Treatment Costs'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0342257', 'cui_str': 'Diabetic complication'}]",,0.0229317,"Probabilistic sensitivity analysis showed cost-effectiveness in > 95% of the iterations using a threshold of 20,000 GBP/QALY. ","[{'ForeName': 'Mafalda', 'Initials': 'M', 'LastName': 'Ramos', 'Affiliation': 'Global HEOR/Real World Solutions, IQVIA, 2740-266, Porto Salvo, Portugal.'}, {'ForeName': 'Michael H', 'Initials': 'MH', 'LastName': 'Cummings', 'Affiliation': 'Academic Department of Diabetes and Endocrinology, Queen Alexandra Hospital, Portsmouth, PO6 3LY, Hampshire, UK.'}, {'ForeName': 'Anastasia', 'Initials': 'A', 'LastName': 'Ustyugova', 'Affiliation': 'Boehringer Ingelheim International GmbH, 55216, Ingelheim Am Rhein, Germany.'}, {'ForeName': 'Syed I', 'Initials': 'SI', 'LastName': 'Raza', 'Affiliation': 'Boehringer Ingelheim Ltd., Bracknell, RG12 8YS, Berkshire, UK.'}, {'ForeName': 'Shamika U', 'Initials': 'SU', 'LastName': 'de Silva', 'Affiliation': 'Boehringer Ingelheim Ltd., Bracknell, RG12 8YS, Berkshire, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Lamotte', 'Affiliation': 'Global HEOR/Real World Solutions, IQVIA, 1930, Zaventem, Belgium. Mark.lamotte@iqvia.com.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00883-1'] 2522,32700191,"Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design.","BACKGROUND Felbinac trometamol, an anti-inflammatory and analgesic drug, has been used to treat immediate postoperative pain. OBJECTIVE The aim of this study was to evaluate the safety, tolerability, and pharmacokinetics of single or multiple intravenous infusions of felbinac trometamol in healthy Chinese volunteers. METHODS A total of 56 healthy subjects were enrolled in a single-ascending dose study (11.78-377.00 mg), meanwhile 36 subjects were enrolled in a multiple-ascending dose study (47.13-188.50 mg). Safety endpoints included treatment-emergent adverse events, vital signs, electrocardiograms, and laboratory parameters. Pharmacokinetic endpoints included exposure of subjects to felblinac and metabolites of the drug in plasma, urine, and feces. RESULTS Felblinac time to maximum plasma concentration was obtained at 0.5 h, corresponding to the end of the infusion. Maximum plasma concentration and area under the curve increased in a dose-dependent manner for felblinac and its metabolite, showing linear pharmacokinetic characteristics at single and multiple doses. After intravenous infusions of multiple doses three times (30 min each time) per day, the accumulation ratio of felblinac and its metabolite based on the area under the curve had a range of 1.34-1.45 and 1.60-1.87, respectively, across cohorts. After administration of the fourth dose, the plasma concentration of both felblinac and its metabolites was maintained at a steady state. Felbinac trometamol was well tolerated. Neither treatment-emergent adverse event frequency nor severity increased with increasing felbinac trometamol dose. CONCLUSIONS Felbinac trometamol was well tolerated in our study. Based on the dose range in this study, 94.25 mg is the recommended target dose for a phase II study. CLINICAL TRIAL REGISTRATION CTR20170496 and CTR20180896. The dates of registration are 2017-06-19 and 2018-07-02 ( https://www.chinadrugtrials.org.cn/ ).",2020,"Maximum plasma concentration and area under the curve increased in a dose-dependent manner for felblinac and its metabolite, showing linear pharmacokinetic characteristics at single and multiple doses.","['56 healthy subjects were enrolled in a single-ascending dose study (11.78-377.00\xa0mg), meanwhile 36 subjects were enrolled in a multiple-ascending dose study (47.13-188.50\xa0mg', 'healthy Chinese volunteers', 'Healthy Chinese Volunteers']","['Felbinac trometamol', 'Placebo', 'Intravenous Felbinac Trometamol', 'felbinac trometamol']","['tolerated', 'treatment-emergent adverse events, vital signs, electrocardiograms, and laboratory parameters', 'safety, tolerability, and pharmacokinetics', 'Maximum plasma concentration and area under the curve', 'Felblinac time to maximum plasma concentration', 'exposure of subjects to felblinac and metabolites of the drug in plasma, urine, and feces', 'plasma concentration of both felblinac and its metabolites', 'accumulation ratio of felblinac and its metabolite', 'Pharmacokinetics, Safety, and Tolerability']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205385', 'cui_str': 'Ascending'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0877860', 'cui_str': 'Felbinac'}, {'cui': 'C0041175', 'cui_str': 'Tromethamine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",56.0,0.0956679,"Maximum plasma concentration and area under the curve increased in a dose-dependent manner for felblinac and its metabolite, showing linear pharmacokinetic characteristics at single and multiple doses.","[{'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.'}, {'ForeName': 'Cuiyun', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.'}, {'ForeName': 'Jixuan', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': 'Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.'}, {'ForeName': 'Xiaoxue', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.'}, {'ForeName': 'Xiaojiao', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.'}, {'ForeName': 'Xuedong', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': 'Shijiazhuang Yiling Pharmaceutical Co., Ltd, Shijiazhuang, 050035, Hebei, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Shijiazhuang Yiling Pharmaceutical Co., Ltd, Shijiazhuang, 050035, Hebei, China.'}, {'ForeName': 'Yanhua', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, 130021, Jilin, China. dingyanhua2003@126.com.'}]",CNS drugs,['10.1007/s40263-020-00739-z'] 2523,32700212,Right-sided versus left-sided percutaneous transhepatic biliary drainage in the management of malignant biliary obstruction: a randomized controlled study.,"AIM To compare the technical difficulty, safety, radiation exposure and success rates between right-sided and left-sided percutaneous transhepatic biliary drainage (RPTBD and LPTBD) in patients with malignant biliary obstruction (MBO). MATERIALS AND METHODS Fifty patients (28 males, 22 females; mean age 51.78 years) with MBO were randomized to undergo either RPTBD or LPTBD during the study period between June 2016 and May 2018. The procedure time, fluoroscopy time, radiation doses to the operators and patients, technical success, clinical success, complications and effect on quality of life were evaluated and compared between the two groups. RESULTS Twenty-five patients were included in each group. The technical success was 100% in both groups. There was no significant difference between RPTBD and LPTBD groups in terms of major complications [4% and 12%, respectively; p = 0.297] and minor complications [40% and 32%, respectively; p = 0.597]. Further, the average procedure time (37.80 ± 13.07 min vs 41.04 ± 14.94 min), fluoroscopy time (5.88 ± 4.2 min vs 5.97 ± 3.8 min), radiation doses to the operator (136.84 ± 106.67 μSv vs 130.40 ± 106.46 μSv) and to the patient (8.23 ± 5.80 Gycm 2 vs 11.74 ± 11.28 Gycm 2 ) were not significantly different between the groups. Clinical success was achieved in 21 patients (84%) of RPTBD group and 17 patients (68%) of LPTBD group with no significant difference (p = 0.416) between them. CONCLUSION There was no significant difference between RPTBD and LPTBD with reference to the technique, safety, radiation dose, success rates and impact on quality of life suggesting no laterality advantage for biliary drainage in cases of MBO.",2020,"There was no significant difference between RPTBD and LPTBD with reference to the technique, safety, radiation dose, success rates and impact on quality of life suggesting no laterality advantage for biliary drainage in cases of MBO.","['Twenty-five patients were included in each group', 'malignant biliary obstruction', 'Fifty patients (28 males, 22 females; mean age 51.78\xa0years) with MBO', 'patients with malignant biliary obstruction (MBO']","['Right-sided versus left-sided percutaneous transhepatic biliary drainage', 'right-sided and left-sided percutaneous transhepatic biliary drainage (RPTBD and LPTBD', 'RPTBD or LPTBD']","['procedure time, fluoroscopy time, radiation doses to the operators and patients, technical success, clinical success, complications and effect on quality of life', 'Clinical success', 'technique, safety, radiation dose, success rates and impact on quality of life', 'fluoroscopy time', 'technical success', 'technical difficulty, safety, radiation exposure and success rates', 'average procedure time', 'minor complications']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3898473', 'cui_str': 'Malignant biliary obstruction'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C1504490', 'cui_str': 'Percutaneous transhepatic cholangiodrainage'}]","[{'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0449851', 'cui_str': 'Technique'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0015333', 'cui_str': 'Exposure to radiation'}, {'cui': 'C0026193', 'cui_str': 'Minor'}]",25.0,0.0580947,"There was no significant difference between RPTBD and LPTBD with reference to the technique, safety, radiation dose, success rates and impact on quality of life suggesting no laterality advantage for biliary drainage in cases of MBO.","[{'ForeName': 'Rajendra', 'Initials': 'R', 'LastName': 'Kumar Behera', 'Affiliation': 'Department of Radiodiagnosis, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Deep', 'Initials': 'D', 'LastName': 'Narayan Srivastava', 'Affiliation': 'Department of Radiodiagnosis, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Pratik', 'Initials': 'P', 'LastName': 'Kumar', 'Affiliation': 'Department of Medical Physics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Sujoy', 'Initials': 'S', 'LastName': 'Pal', 'Affiliation': 'Department of Gastrointestinal Surgery, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Nihar', 'Initials': 'N', 'LastName': 'Ranjan', 'Affiliation': 'Department of Gastrointestinal Surgery, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Pramod', 'Initials': 'P', 'LastName': 'Garg', 'Affiliation': 'Department of Gastroenterology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Peush', 'Initials': 'P', 'LastName': 'Sahni', 'Affiliation': 'Department of Gastrointestinal Surgery, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.'}, {'ForeName': 'Kumble', 'Initials': 'K', 'LastName': 'Seetharama Madhusudhan', 'Affiliation': 'Department of Radiodiagnosis, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India. drmadhuks@gmail.com.'}]",Abdominal radiology (New York),['10.1007/s00261-020-02651-y'] 2524,32700215,Mobile-Enhanced Peer Support for African Americans with Type 2 Diabetes: a Randomized Controlled Trial.,"BACKGROUND Peer support has been shown to improve diabetes self-management and control, but no standard exists to link peer support interventions to clinical care. OBJECTIVE To compare a community-based diabetes self-management education (DSME) plus mobile health (mHealth)-enhanced peer support intervention to community-based diabetes self-management education (DSME) alone for African American adults with poorly controlled type 2 diabetes. DESIGN A randomized controlled trial. PARTICIPANTS African American adults, age > 19 years, receiving care within a safety-net healthcare system in Jefferson County, Alabama, with a diagnosis of type 2 diabetes and a hemoglobin A1c (A1C) ≥ 7.5%. INTERVENTIONS Participants in the intervention group received community-based diabetes self-management education (DSME) plus 6 months of mHealth-enhanced peer support, including 12 weekly phone calls, then 3 monthly calls from community health workers, who used a novel web application to communicate with participants' healthcare teams. In the control group, participants received community-based DSME alone. MAIN MEASURES The primary outcome was A1C; secondary outcomes included diabetes distress, depressive symptoms, self-efficacy or confidence in their ability to manage diabetes, and social support. We used mixed models repeated measures analyses to assess for between-arm differences and baseline to follow-up changes. KEY RESULTS Of 120 participants randomized, 97 completed the study. Participants in intervention and control groups experienced clinically meaningful reduction in A1C, 10.1 (SD 1.7) to 9.6 (SD 1.9) and 9.8 (SD 1.7) to 9.1 (SD 1.9) respectively, p = 0.004. Participants in the intervention group experienced a significantly larger reduction in diabetes distress compared to the control, 2.7 (SD 1.2) to 2.1 (1.0) versus 2.6 (SD 1.1) to 2.3 (SD 1.0) p = 0.041. CONCLUSIONS Community-based DSME with and without peer support led to improved glycemic control. Peer support linked to clinical care led to a larger reduction in diabetes distress, which has important implications for the overall wellbeing of adults with type 2 diabetes.",2020,"Participants in the intervention group experienced a significantly larger reduction in diabetes distress compared to the control, 2.7 (SD 1.2) to 2.1 (1.0) versus 2.6 (SD 1.1) to 2.3 (SD 1.0) p = 0.041. ","['African Americans with Type 2 Diabetes', 'Of 120 participants randomized, 97 completed the study', '19\xa0years, receiving care within a safety-net healthcare system in Jefferson County, Alabama, with a diagnosis of type 2 diabetes and a hemoglobin A1c (A1C) ≥\u20097.5', 'adults with type 2 diabetes', 'African American adults with poorly controlled type 2 diabetes', 'African American adults, age\xa0']","[""community-based diabetes self-management education (DSME) plus 6\xa0months of mHealth-enhanced peer support, including 12 weekly phone calls, then 3 monthly calls from community health workers, who used a novel web application to communicate with participants' healthcare teams"", 'Mobile-Enhanced Peer Support', 'community-based diabetes self-management education (DSME) plus mobile health (mHealth)-enhanced peer support intervention to community-based diabetes self-management education (DSME) alone', 'community-based DSME alone']","['glycemic control', 'diabetes distress, depressive symptoms, self-efficacy or confidence in their ability to manage diabetes, and social support', 'diabetes distress']","[{'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0018696', 'cui_str': 'Healthcare Systems'}, {'cui': 'C0001895', 'cui_str': 'Alabama'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1319140', 'cui_str': 'Diabetes self-management behavior'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0205196', 'cui_str': 'Communicating'}, {'cui': 'C0086390', 'cui_str': 'Health Care Team'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0037438', 'cui_str': 'Social support'}]",120.0,0.0921981,"Participants in the intervention group experienced a significantly larger reduction in diabetes distress compared to the control, 2.7 (SD 1.2) to 2.1 (1.0) versus 2.6 (SD 1.1) to 2.3 (SD 1.0) p = 0.041. ","[{'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Presley', 'Affiliation': 'Division of Preventive Medicine, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. capresley@uabmc.edu.'}, {'ForeName': 'April', 'Initials': 'A', 'LastName': 'Agne', 'Affiliation': 'Division of Preventive Medicine, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Shelton', 'Affiliation': 'Cooper Green Mercy Health Services, Birmingham, AL, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Oster', 'Affiliation': 'Division of Preventive Medicine, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Cherrington', 'Affiliation': 'Division of Preventive Medicine, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.'}]",Journal of general internal medicine,['10.1007/s11606-020-06011-w'] 2525,32697479,Financial Toxicity After Acute Respiratory Distress Syndrome: A National Qualitative Cohort Study.,"OBJECTIVES The financial burdens and subsequent related distress of medical care, referred to as financial toxicity, may limit access to beneficial treatments. However, financial toxicity after acute care is less described-and may be an important but underexplored mechanism preventing full recovery after critical illnesses such as acute respiratory distress syndrome. We sought to identify the mechanisms by which financial toxicity manifested in patients with acute respiratory distress syndrome, protective factors against such toxicity, and the consequences of financial toxicity to survivors' lives following acute respiratory distress syndrome. DESIGN We conducted semistructured interviews following patients' hospitalization and during recovery as an ancillary study to a multicenter randomized clinical trial in acute respiratory distress syndrome. Patients were 9-16 months post randomization at the time of interview. SETTING AND PARTICIPANTS The Reevaluation Of Systemic Early Neuromuscular Blockade trial examined the use of early neuromuscular blockade in mechanically ventilated patients with moderate/severe acute respiratory distress syndrome. We recruited consecutive surviving patients who were English speaking, consented to follow-up, and were randomized between December 11, 2017, and May 4, 2018 (n = 79) from 29 U.S. sites. MEASUREMENTS AND MAIN RESULTS We asked about patients' perceptions of financial burden(s) that they associated with their acute respiratory distress syndrome hospitalization. Forty-six of 79 eligible acute respiratory distress syndrome survivors (58%) participated (from 22 sites); their median age was 56 (interquartile range 47-62). Thirty-one of 46 reported at least one acute respiratory distress syndrome-related financial impact. Financial toxicity manifested via medical bills, changes in insurance coverage, and loss of employment income. Respondents reported not working prior to acute respiratory distress syndrome, using Medicaid or Medicare, or, conversely, generous work benefits as factors which may have limited financial burdens. Patients reported multiple consequences of acute respiratory distress syndrome-related financial toxicity, including harms to their mental and physical health, increased reliance on others, and specific material hardships. CONCLUSIONS Financial toxicity related to critical illness is common and may limit patients' emotional, physical, and social recovery after acute respiratory distress syndrome hospitalization for at least a year.",2020,"Patients reported multiple consequences of acute respiratory distress syndrome-related financial toxicity, including harms to their mental and physical health, increased reliance on others, and specific material hardships. ","['patients with acute respiratory distress syndrome', 'acute respiratory distress syndrome', 'consecutive surviving patients who were English speaking, consented to follow-up, and were randomized between December 11, 2017, and May 4, 2018 (n = 79) from 29 U.S. sites', 'Forty-six of 79 eligible acute respiratory distress syndrome survivors (58%) participated (from 22 sites); their median age was 56 (interquartile range 47-62', 'mechanically ventilated patients with moderate/severe acute respiratory distress syndrome', 'Thirty-one of 46 reported at least one acute respiratory distress syndrome-related financial impact', 'After Acute Respiratory Distress Syndrome']",[],"['Financial toxicity manifested via medical bills, changes in insurance coverage, and loss of employment income', 'acute respiratory distress syndrome hospitalization', 'financial toxicity', 'Financial Toxicity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0234856', 'cui_str': 'Speaking'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C1299448', 'cui_str': 'Patient ventilated'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}]",[],"[{'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0205319', 'cui_str': 'Manifest'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0004895', 'cui_str': 'Beak'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0376629', 'cui_str': 'Insurance Status'}, {'cui': 'C0425083', 'cui_str': 'Loss of job'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",,0.13736,"Patients reported multiple consequences of acute respiratory distress syndrome-related financial toxicity, including harms to their mental and physical health, increased reliance on others, and specific material hardships. ","[{'ForeName': 'Katrina E', 'Initials': 'KE', 'LastName': 'Hauschildt', 'Affiliation': '1Department of Sociology, College of Literature, Science, and Arts, University of Michigan, Ann Arbor, MI. 2Institute for Social Research, University of Michigan, Ann Arbor, MI. 3Veterans Affairs Center for Clinical Management Research, HSR&D Center of Innovation, Ann Arbor, MI. 4Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA. 5Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO. 6NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, Glasgow, United Kingdom. 7University of Glasgow, School of Medicine, Dentistry and Nursing, Glasgow, United Kingdom. 8Department of Internal Medicine, Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Seigworth', 'Affiliation': ''}, {'ForeName': 'Lee A', 'Initials': 'LA', 'LastName': 'Kamphuis', 'Affiliation': ''}, {'ForeName': 'Catherine L', 'Initials': 'CL', 'LastName': 'Hough', 'Affiliation': ''}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Moss', 'Affiliation': ''}, {'ForeName': 'Joanne M', 'Initials': 'JM', 'LastName': 'McPeake', 'Affiliation': ''}, {'ForeName': 'Theodore J', 'Initials': 'TJ', 'LastName': 'Iwashyna', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Critical care medicine,['10.1097/CCM.0000000000004378'] 2526,32697618,Methyldopa versus labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial.,"OBJECTIVE to assess the maternal and fetal outcome in women with mild to moderate chronic hypertension on antihypertensive drug (methyldopa or labetalol) therapy compared to no medication. METHODS This multicenter randomized clinical study was conducted at Menoufia University hospital, Shibin El-kom Teaching hospital at Menoufia governorate, Egypt.486 pregnant women with mild to moderate chronic hypertension were randomized into three groups; methyldopa group (n = 164), labetalol group (n = 160), and control or no medication group (n = 162) who were followed from the beginning of pregnancy till the end of puerperium to record maternal and fetal outcome. RESULTS There was a highly significant difference between treatment groups (methyldopa and labetalol) and control group regarding the development of maternal severe hypertension, development of preeclampsia, renal impairment, presence of ECG changes, placental abruption, and repeated admission to hospital for blood pressure control (p < 0.001) with higher occurrence in the control (no treatment) group. Neonates in the labetalol group were more prone for the development of small for gestational age (SGA), neonatal hypotension, neonatal hyperbilirubinemia, and admission to NICU than their counterparts in the methyldopa and control groups (p < 0.001). The rate of prematurity was significantly higher in the control group than the treatment groups (p < 0.05). CONCLUSION Treatment of mild to moderate chronic hypertension during pregnancy is beneficial in decreasing both maternal and fetal morbidity. The use of labetalol was associated with higher rates of SGA, neonatal hypotension, and neonatal hyperbilirubinemia compared to methyldopa or no medication.",2020,"The rate of prematurity was significantly higher in the control group than the treatment groups (p < 0.05). ","['women with mild to moderate chronic hypertension on antihypertensive drug (methyldopa or labetalol) therapy compared to no medication', 'Menoufia University hospital, Shibin El-kom Teaching hospital at Menoufia governorate, Egypt.486 pregnant women with mild to moderate chronic hypertension', 'mild and moderate chronic hypertension during pregnancy']","['Methyldopa', 'labetalol or no medication', 'methyldopa', 'labetalol group (n\xa0=\xa0160), and control or no medication group', 'labetalol']","['development of small for gestational age (SGA), neonatal hypotension, neonatal hyperbilirubinemia, and admission to NICU', 'maternal severe hypertension, development of preeclampsia, renal impairment, presence of ECG changes, placental abruption, and repeated admission to hospital for blood pressure control', 'rates of SGA, neonatal hypotension, and neonatal hyperbilirubinemia', 'rate of prematurity']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0025741', 'cui_str': 'Methyldopa'}, {'cui': 'C0022860', 'cui_str': 'Labetalol'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0574690', 'cui_str': 'Komi language'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0025741', 'cui_str': 'Methyldopa'}, {'cui': 'C0022860', 'cui_str': 'Labetalol'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0235991', 'cui_str': 'Small for gestational age'}, {'cui': 'C0455995', 'cui_str': 'Neonatal hypotension'}, {'cui': 'C0857007', 'cui_str': 'Neonatal hyperbilirubinemia'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C1565489', 'cui_str': 'Renal impairment'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0855329', 'cui_str': 'Electrocardiogram change'}, {'cui': 'C0000832', 'cui_str': 'Placental abruption'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}]",,0.0339825,"The rate of prematurity was significantly higher in the control group than the treatment groups (p < 0.05). ","[{'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Rezk', 'Affiliation': 'Department of Obstetrics and Gynecology, Menoufia University , Shibin Al Kawm, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Emarh', 'Affiliation': 'Department of Obstetrics and Gynecology, Menoufia University , Shibin Al Kawm, Egypt.'}, {'ForeName': 'Alaa', 'Initials': 'A', 'LastName': 'Masood', 'Affiliation': 'Department of Obstetrics and Gynecology, Menoufia University , Shibin Al Kawm, Egypt.'}, {'ForeName': 'Ragab', 'Initials': 'R', 'LastName': 'Dawood', 'Affiliation': 'Department of Obstetrics and Gynecology, Menoufia University , Shibin Al Kawm, Egypt.'}, {'ForeName': 'Elsayed', 'Initials': 'E', 'LastName': 'El-Shamy', 'Affiliation': 'Department of Obstetrics and Gynecology, Menoufia University , Shibin Al Kawm, Egypt.'}, {'ForeName': 'Awni', 'Initials': 'A', 'LastName': 'Gamal', 'Affiliation': 'Department of Cardiology, Menoufia University , Shibin Al Kawm, Egypt.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Badr', 'Affiliation': 'Department of Pediatrics, Menoufia University , Shibin Al Kawm, Egypt.'}]",Hypertension in pregnancy,['10.1080/10641955.2020.1791902'] 2527,32697659,Response to Peng and Zhong: Editorial Comment on: Toward Respiratory-Gated Retrograde Intrarenal Surgery: A Prospective Controlled Randomized Study by Kourmpetis et al. (From: J Endourol 2018;32(9):812-817; DOI: 10.1089/end.2018.0231).,,2020,,[],"['Peng and Zhong: Editorial Comment', 'Respiratory-Gated Retrograde Intrarenal Surgery']",[],[],"[{'cui': 'C0282411', 'cui_str': 'Editorial Comment'}, {'cui': 'C0237633', 'cui_str': 'Sensory Filtering'}, {'cui': 'C0439784', 'cui_str': 'Retrograde direction'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",[],,0.0144958,,"[{'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Sofer', 'Affiliation': 'Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}]",Journal of endourology,['10.1089/end.2020.29094.mso'] 2528,32697707,Antidepressant effects of ketamine and ECT: A pilot comparison.,"BACKGROUND To compare the antidepressant effects and cognitive adverse effects of intravenous ketamine infusion and Electro-convulsive therapy (ECT) in persons with severe depressive episodes. METHODS This assessor-blinded randomized control trial included 25 patients (either sex; 18-65 years) meeting ICD-10 criteria for severe depression (bipolar or unipolar). Patients received either ECT (n = 13) or intravenous infusions of ketamine hydrochloride (0.5 mg/kg over 45 min; n = 12) for six alternate day sessions over a period of two weeks. Severity of depression was assessed at baseline and on every alternate day of intervention using the Hamilton Depression Rating Scale (HDRS) and self-reported Beck Depression Inventory (BDI). RESULTS Baseline socio-demographic and clinical variables including HDRS (ECT: 25.15±6.58; Ketamine: 23.33±4.05, p = 0.418) and BDI (ECT: 37.07±6.58; Ketamine: 33.33±9.29; p = 0.254) were comparable. Repeated-measures analysis of variance revealed that ECT patients showed significantly greater reduction in HDRS (group*time interaction effect; F = 4.79; p<0.001) and BDI scores (group*time interaction effect; F = 3.83; p<0.01). ECT patients had higher response rate than ketamine patients [HDRS: ECT- 13/13(100%) vs ketamine- 8/12 (66.70%); p = 0.04]. This was true for remission as well [ECT- 12/13(92.30%) vs ketamine- 6/12(50%), p = 0.030; both HDRS and BDI]. Performance on Digit Symbol Substitution Test (as part of the Battery for ECT-Related Cognitive Deficits scale) significantly improved in ketamine patients (p = 0.02) while that in ECT patients worsened non significantly (p = 0.30). LIMITATIONS Relatively small sample size; higher proportion of dropouts in the Ketamine arm. CONCLUSION This study favoured ECT over ketamine for a better efficacy over six treatment sessions in severe depression. The results need to be replicated in larger studies. TRIAL REGISTRATION CTRI/2019/09/021184.",2020,"Performance on Digit Symbol Substitution Test (as part of the Battery for ECT-Related Cognitive Deficits scale) significantly improved in ketamine patients (p = 0.02) while that in ECT patients worsened non significantly (p = 0.30). ","['25 patients (either sex; 18-65 years) meeting ICD-10 criteria for severe depression (bipolar or unipolar', 'persons with severe depressive episodes', 'severe depression']","['ECT', 'ketamine', 'Ketamine', 'ketamine infusion and Electro-convulsive therapy (ECT', 'ketamine and ECT', 'ketamine hydrochloride']","['Severity of depression', 'Hamilton Depression Rating Scale (HDRS) and self-reported Beck Depression Inventory (BDI', 'HDRS', 'Cognitive Deficits scale', 'Performance on Digit Symbol Substitution Test', 'response rate', 'BDI scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C1137110', 'cui_str': 'ICD-10'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0588008', 'cui_str': 'Severe depression'}, {'cui': 'C0443156', 'cui_str': 'Bipolar'}, {'cui': 'C0443340', 'cui_str': 'Unipolar'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0349217', 'cui_str': 'Depressive episode, unspecified'}]","[{'cui': 'C0009953', 'cui_str': 'Convulsive therapy'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0700541', 'cui_str': 'Ketamine hydrochloride'}]","[{'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0009241', 'cui_str': 'Cognitive disorder'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C2960571', 'cui_str': 'Beck depression inventory score'}]",25.0,0.172461,"Performance on Digit Symbol Substitution Test (as part of the Battery for ECT-Related Cognitive Deficits scale) significantly improved in ketamine patients (p = 0.02) while that in ECT patients worsened non significantly (p = 0.30). ","[{'ForeName': 'Ravi K', 'Initials': 'RK', 'LastName': 'Sharma', 'Affiliation': 'Department of Psychiatry, Trivanta Medical and Neuro-psychiatry Hospital and Research Center, Udaipur, Rajasthan 313001, India. Electronic address: drravisharma1984@gmail.com.'}, {'ForeName': 'Gajanan', 'Initials': 'G', 'LastName': 'Kulkarni', 'Affiliation': 'Department of Psychiatry, Magna Centers for Obesity, Diabetes and Endocrinology, Bangalore, Karnataka 560076, India. Electronic address: gajanan.kulkarni.97@gmail.com.'}, {'ForeName': 'Channaveerachari Naveen', 'Initials': 'CN', 'LastName': 'Kumar', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 60029, India. Electronic address: cnkumar1974@gmail.com.'}, {'ForeName': 'Shyam Sundar', 'Initials': 'SS', 'LastName': 'Arumugham', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 60029, India. Electronic address: a.shyamsundar@gmail.com.'}, {'ForeName': 'Venkataramaiah', 'Initials': 'V', 'LastName': 'Sudhir', 'Affiliation': 'Department of Neuro-anaesthesia, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India. Electronic address: vsudhir77@gmail.com.'}, {'ForeName': 'Urvakhsh M', 'Initials': 'UM', 'LastName': 'Mehta', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 60029, India. Electronic address: urvakhsh@gmail.com.'}, {'ForeName': 'Sayantanava', 'Initials': 'S', 'LastName': 'Mitra', 'Affiliation': 'Queensland Health and Faculty of Medicine, University of Queensland Rural Medical\xa0School, Rockhampton, Queensland 4700, Australia. Electronic address: sayantanava@gmail.com.'}, {'ForeName': 'Milind Vijay', 'Initials': 'MV', 'LastName': 'Thanki', 'Affiliation': 'Hertfordshire Partnership University, NHS Foundation Trust, Hatfeild, Hertfordshire, AL108YE England United Kingdom. Electronic address: milind_thanki@yahoo.com.'}, {'ForeName': 'Jagadisha', 'Initials': 'J', 'LastName': 'Thirthalli', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 60029, India. Electronic address: jagatth@yahoo.com.'}]",Journal of affective disorders,['10.1016/j.jad.2020.07.066'] 2529,32697847,Improving the Delivery of Chronic Opioid Therapy among People Living with HIV: A Cluster Randomized Clinical Trial.,"BACKGROUND Chronic pain is prevalent among people living with HIV (PLWH); managing pain with chronic opioid therapy (COT) is common. HIV providers often diverge from prescribing guidelines. METHODS This two-arm, unblinded cluster-randomized clinical trial assessed whether the Targeting Effective Analgesia in Clinics for HIV (TEACH) intervention improves guideline-concordant care compared to usual care for PLWH on COT. The trial was implemented from 2015-2018 with 12-month follow-up at safety-net hospital-based HIV clinics in Boston and Atlanta. We enrolled 41 providers and their 187 patients on COT. Prescribers were randomized 1:1 to either a 12-month intervention consisting of a nurse care manager with an interactive electronic registry, opioid education, academic detailing and access to addiction specialists or a control condition consisting of usual care. Two primary outcomes were assessed through electronic medical records: ≥2 urine drug tests and any early COT refills by 12 months. Other outcomes included possible adverse consequences. RESULTS At 12-months, the TEACH intervention arm had higher odds of ≥2 urine drug tests than the usual care arm (71% vs. 20%, adjusted odds ratio [AOR]: 13.38; 95% confidence interval [CI]: 5.85-30.60; p<0.0001). We did not detect a statistically significant difference in early refills (22% vs. 30%; AOR: 0.55; 95% CI: 0.26-1.15; p=0.11), pain severity (6.30 vs. 5.76; adjusted mean difference 0.10; 95% CI: -1.56-1.75; p=0.91), or HIV viral load suppression (86.9% vs. 82.1%; AOR: 1.21; 95% CI: 0.47-3.09; p=0.69). CONCLUSIONS TEACH is a promising intervention to improve adherence to COT guidelines without evident adverse consequences.",2020,"At 12-months, the TEACH intervention arm had higher odds of ≥2 urine drug tests than the usual care arm (71% vs. 20%, adjusted odds ratio [AOR]: 13.38; 95% confidence interval [CI]: 5.85-30.60; p<0.0001).","['2015-2018 with 12-month follow-up at safety-net hospital-based HIV clinics in Boston and Atlanta', 'People Living with HIV', 'people living with HIV (PLWH', 'We enrolled 41 providers and their 187 patients on COT']","['chronic opioid therapy (COT', 'Chronic Opioid Therapy', 'nurse care manager with an interactive electronic registry, opioid education, academic detailing and access to addiction specialists or a control condition consisting of usual care']","['electronic medical records: ≥2 urine drug tests and any early COT refills', 'higher odds of ≥2 urine drug tests', 'HIV viral load suppression', 'pain severity', 'early refills']","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C3661443', 'cui_str': 'Safety-net Hospitals'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0006037', 'cui_str': 'Boston'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0687694', 'cui_str': 'Case manager'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0085281', 'cui_str': 'Addiction'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}]","[{'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0013175', 'cui_str': 'Clinical drug trial'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1168369', 'cui_str': 'HIV viral load'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",41.0,0.24101,"At 12-months, the TEACH intervention arm had higher odds of ≥2 urine drug tests than the usual care arm (71% vs. 20%, adjusted odds ratio [AOR]: 13.38; 95% confidence interval [CI]: 5.85-30.60; p<0.0001).","[{'ForeName': 'Jeffrey H', 'Initials': 'JH', 'LastName': 'Samet', 'Affiliation': 'Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA.'}, {'ForeName': 'Judith I', 'Initials': 'JI', 'LastName': 'Tsui', 'Affiliation': 'Department of Medicine, University of Washington, Seattle, WA.'}, {'ForeName': 'Debbie M', 'Initials': 'DM', 'LastName': 'Cheng', 'Affiliation': 'Clinical Addiction Research and Education (CARE) Unit, Department of Medicine, Boston University School of Medicine, Boston, MA.'}, {'ForeName': 'Jane M', 'Initials': 'JM', 'LastName': 'Liebschutz', 'Affiliation': 'Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.'}, {'ForeName': 'Marlene C', 'Initials': 'MC', 'LastName': 'Lira', 'Affiliation': 'Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA.'}, {'ForeName': 'Alexander Y', 'Initials': 'AY', 'LastName': 'Walley', 'Affiliation': 'Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA.'}, {'ForeName': 'Jonathan A', 'Initials': 'JA', 'LastName': 'Colasanti', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Leah S', 'Initials': 'LS', 'LastName': 'Forman', 'Affiliation': 'Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, MA.'}, {'ForeName': 'Christin', 'Initials': 'C', 'LastName': 'Root', 'Affiliation': 'Department of Global Health, Emory University Rollins School of Public Health, Atlanta, GA.'}, {'ForeName': 'Christopher W', 'Initials': 'CW', 'LastName': 'Shanahan', 'Affiliation': 'Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA.'}, {'ForeName': 'Margaret M', 'Initials': 'MM', 'LastName': 'Sullivan', 'Affiliation': 'Clinical Addiction Research and Education (CARE) Unit, Department of Medicine, Boston University School of Medicine, Boston, MA.'}, {'ForeName': 'Carly L', 'Initials': 'CL', 'LastName': 'Bridden', 'Affiliation': 'Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Abrams', 'Affiliation': 'Department of Global Health, Emory University Rollins School of Public Health, Atlanta, GA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Harris', 'Affiliation': 'Department of Global Health, Emory University Rollins School of Public Health, Atlanta, GA.'}, {'ForeName': 'Kishna', 'Initials': 'K', 'LastName': 'Outlaw', 'Affiliation': 'Department of Global Health, Emory University Rollins School of Public Health, Atlanta, GA.'}, {'ForeName': 'Wendy S', 'Initials': 'WS', 'LastName': 'Armstrong', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Del Rio', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciaa1025'] 2530,32697957,"Effects of long-term concurrent training to failure or not in muscle power output, muscle quality and cardiometabolic risk factors in older men: A secondary analysis of a randomized clinical trial.","This study investigated the effects of concurrent training performed either with repetitions to failure or not to failure in muscle power, muscle quality (MQ), peak oxygen uptake (VO 2peak ), and visceral fat in older men. This is an ancillary analysis of a randomized controlled trial. 36 older men (mean age ± SD; 67.1 ± 5.1 years) were randomized into three groups: one performing repetitions to failure (RFG, n = 13), another performing repetitions not to failure and 50% of the repetitions of the RFG (NFG, n = 12), and third performing repetitions not to failure with equal training volume of the RFG (ENFG, n = 11). The training was performed twice a week for 20 weeks at intensities ranging from 65 to 80% of maximal strength. In each session, the individuals started with strengthening exercises and then performed aerobic exercise (i.e., walking) on a treadmill. The primary endpoint was change from baseline to post-20 wk of absolute and relative muscle power output during squat and countermovement jump, ultrasound measurements for MQ using quadriceps echo intensity, and visceral fat thickness, as well as their VO 2peak through a maximal incremental test on a treadmill. All training groups improved similarly and significantly jump height (ranging from 9 to 16%) and all their muscle power outcomes (mean change ranging from 2 to 7%) (P < .001). In addition, all groups significantly decreased visceral fat thickness (ranging from -11 to -21%) (P < .001), and significantly increased VO 2peak (ranging from 4 to 8%) (P < .01), with no differences between groups. No changes were observed in the MQ outcomes. Concurrent training performed using repetitions to failure or not to failure promoted similar gains in the muscle power output, aerobic capacity, and visceral fat in healthy older men.",2020,All training groups improved similarly and significantly jump height (ranging from 9 to 16%) and all their muscle power outcomes (mean change ranging from 2 to 7%) (P < .001).,"['36 older men (mean age\u202f±\u202fSD; 67.1\u202f±\u202f5.1\u202fyears', 'healthy older men', 'older men']","['another performing repetitions not to failure and 50% of the repetitions of the RFG (NFG, n\u202f=\u202f12), and third performing repetitions not to failure with equal training volume of the RFG (ENFG, n', 'strengthening exercises and then performed aerobic exercise (i.e., walking) on a treadmill']","['VO 2peak', 'visceral fat thickness', 'MQ outcomes', 'muscle power output, muscle quality and cardiometabolic risk factors', 'change from baseline to post-20\u202fwk of absolute and relative muscle power output during squat and countermovement jump, ultrasound measurements for MQ using quadriceps echo intensity, and visceral fat thickness, as well as their VO 2peak through a maximal incremental test on a treadmill', 'jump height', 'muscle power, muscle quality (MQ), peak oxygen uptake (VO 2peak ), and visceral fat']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0452260', 'cui_str': 'Muscular strength development exercise'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}]","[{'cui': 'C1563740', 'cui_str': 'Abdominal Visceral Fat'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0427052', 'cui_str': 'Finding of power of skeletal muscle'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0013520', 'cui_str': 'Doppler Echocardiography'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0332273', 'cui_str': 'Through'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}]",36.0,0.0273081,All training groups improved similarly and significantly jump height (ranging from 9 to 16%) and all their muscle power outcomes (mean change ranging from 2 to 7%) (P < .001).,"[{'ForeName': 'Juliana L', 'Initials': 'JL', 'LastName': 'Teodoro', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Mikel', 'Initials': 'M', 'LastName': 'Izquierdo', 'Affiliation': 'Navarrabiomed, Complejo Hospitalario de Navarra (CHN)-Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.'}, {'ForeName': 'Larissa X N', 'Initials': 'LXN', 'LastName': 'da Silva', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Bruno M', 'Initials': 'BM', 'LastName': 'Baroni', 'Affiliation': 'Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Grazioli', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Lopez', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Carolina G', 'Initials': 'CG', 'LastName': 'Fritsch', 'Affiliation': 'Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Régis', 'Initials': 'R', 'LastName': 'Radaelli', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Mikel L', 'Initials': 'ML', 'LastName': 'Saez de Asteasu', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Navarrabiomed, Complejo Hospitalario de Navarra (CHN)-Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.'}, {'ForeName': 'Martim', 'Initials': 'M', 'LastName': 'Bottaro', 'Affiliation': 'College of Physical Education, University of Brasilia, Brasília, DF, Brazil.'}, {'ForeName': 'Juliano', 'Initials': 'J', 'LastName': 'Farinha', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Ronei S', 'Initials': 'RS', 'LastName': 'Pinto', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Eduardo L', 'Initials': 'EL', 'LastName': 'Cadore', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. Electronic address: edcadore@yahoo.com.br.'}]",Experimental gerontology,['10.1016/j.exger.2020.111023'] 2531,32251400,Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.,"PD-1 plus CTLA-4 blockade is highly effective in advanced-stage, mismatch repair (MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We postulated a higher efficacy of neoadjuvant immunotherapy in early-stage colon cancers. In the exploratory NICHE study (ClinicalTrials.gov: NCT03026140), patients with dMMR or pMMR tumors received a single dose of ipilimumab and two doses of nivolumab before surgery, the pMMR group with or without celecoxib. The primary objective was safety and feasibility; 40 patients with 21 dMMR and 20 pMMR tumors were treated, and 3 patients received nivolumab monotherapy in the safety run-in. Treatment was well tolerated and all patients underwent radical resections without delays, meeting the primary endpoint. Of the patients who received ipilimumab + nivolumab (20 dMMR and 15 pMMR tumors), 35 were evaluable for efficacy and translational endpoints. Pathological response was observed in 20/20 (100%; 95% exact confidence interval (CI): 86-100%) dMMR tumors, with 19 major pathological responses (MPRs, ≤10% residual viable tumor) and 12 pathological complete responses. In pMMR tumors, 4/15 (27%; 95% exact CI: 8-55%) showed pathological responses, with 3 MPRs and 1 partial response. CD8 + PD-1 + T cell infiltration was predictive of response in pMMR tumors. These data indicate that neoadjuvant immunotherapy may have the potential to become the standard of care for a defined group of colon cancer patients when validated in larger studies with at least 3 years of disease-free survival data.",2020,CD8 + PD-1 + T cell infiltration was predictive of response in pMMR tumors.,"['early-stage colon cancers', '40 patients with 21 dMMR and 20 pMMR tumors', 'patients with dMMR or pMMR tumors']","['ipilimumab and two doses of nivolumab before surgery, the pMMR group with or without celecoxib', 'Neoadjuvant immunotherapy', 'CD8 + PD-1 + T cell infiltration', 'ipilimumab\u2009+\u2009nivolumab', 'nivolumab monotherapy', 'neoadjuvant immunotherapy', 'PD-1 plus CTLA-4 blockade']","['safety and feasibility', 'Pathological response', 'pathological responses']","[{'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}]","[{'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0538927', 'cui_str': 'celecoxib'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0111208', 'cui_str': 'Cytotoxic T-Lymphocyte Antigen 4'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}]",40.0,0.120671,CD8 + PD-1 + T cell infiltration was predictive of response in pMMR tumors.,"[{'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Chalabi', 'Affiliation': 'Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. m.chalabi@nki.nl.'}, {'ForeName': 'Lorenzo F', 'Initials': 'LF', 'LastName': 'Fanchi', 'Affiliation': 'Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Krijn K', 'Initials': 'KK', 'LastName': 'Dijkstra', 'Affiliation': 'Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'José G', 'Initials': 'JG', 'LastName': 'Van den Berg', 'Affiliation': 'Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Arend G', 'Initials': 'AG', 'LastName': 'Aalbers', 'Affiliation': 'Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Karolina', 'Initials': 'K', 'LastName': 'Sikorska', 'Affiliation': 'Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Lopez-Yurda', 'Affiliation': 'Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Cecile', 'Initials': 'C', 'LastName': 'Grootscholten', 'Affiliation': 'Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Geerard L', 'Initials': 'GL', 'LastName': 'Beets', 'Affiliation': 'Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Petur', 'Initials': 'P', 'LastName': 'Snaebjornsson', 'Affiliation': 'Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Maas', 'Affiliation': 'Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Marjolijn', 'Initials': 'M', 'LastName': 'Mertz', 'Affiliation': 'Bioimaging Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Vivien', 'Initials': 'V', 'LastName': 'Veninga', 'Affiliation': 'Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Gergana', 'Initials': 'G', 'LastName': 'Bounova', 'Affiliation': 'Oncode Institute, Utrecht, the Netherlands.'}, {'ForeName': 'Annegien', 'Initials': 'A', 'LastName': 'Broeks', 'Affiliation': 'Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Regina G', 'Initials': 'RG', 'LastName': 'Beets-Tan', 'Affiliation': 'GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'de Wijkerslooth', 'Affiliation': 'Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Anja U', 'Initials': 'AU', 'LastName': 'van Lent', 'Affiliation': 'Gastroenterology & Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.'}, {'ForeName': 'Hendrik A', 'Initials': 'HA', 'LastName': 'Marsman', 'Affiliation': 'Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.'}, {'ForeName': 'Elvira', 'Initials': 'E', 'LastName': 'Nuijten', 'Affiliation': 'Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Niels F', 'Initials': 'NF', 'LastName': 'Kok', 'Affiliation': 'Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Kuiper', 'Affiliation': 'Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Wieke H', 'Initials': 'WH', 'LastName': 'Verbeek', 'Affiliation': 'Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Marleen', 'Initials': 'M', 'LastName': 'Kok', 'Affiliation': 'Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Monique E', 'Initials': 'ME', 'LastName': 'Van Leerdam', 'Affiliation': 'Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Ton N', 'Initials': 'TN', 'LastName': 'Schumacher', 'Affiliation': 'Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Emile E', 'Initials': 'EE', 'LastName': 'Voest', 'Affiliation': 'Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. e.voest@nki.nl.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Haanen', 'Affiliation': 'Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.'}]",Nature medicine,['10.1038/s41591-020-0805-8'] 2532,31158470,African Americans With Advanced Heart Failure Are More Likely to Die in a Health Care Facility Than at Home or in Hospice: An Analysis From the PAL-HF Trial.,,2019,,['African Americans With Advanced Heart Failure'],[],[],"[{'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}]",[],[],,0.0539443,,"[{'ForeName': 'Haider J', 'Initials': 'HJ', 'LastName': 'Warraich', 'Affiliation': 'Department of Medicine, Duke University Medical Center, Durham, NC. Electronic address: haider.warraich@duke.edu.'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': ""O'Connor"", 'Affiliation': 'Inova Heart and Vascular Institute, Falls Church, VA.'}, {'ForeName': 'Hongqiu', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Bradi B', 'Initials': 'BB', 'LastName': 'Granger', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC; Duke University School of Nursing, Durham, NC.'}, {'ForeName': 'Kimberly S', 'Initials': 'KS', 'LastName': 'Johnson', 'Affiliation': 'Department of Medicine, Duke University Medical Center, Durham, NC; Center for the Study of Aging and Human Development, Duke University, Durham, NC.'}, {'ForeName': 'Daniel B', 'Initials': 'DB', 'LastName': 'Mark', 'Affiliation': 'Department of Medicine, Duke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Kevin J', 'Initials': 'KJ', 'LastName': 'Anstrom', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Chetan B', 'Initials': 'CB', 'LastName': 'Patel', 'Affiliation': 'Department of Medicine, Duke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Karen E', 'Initials': 'KE', 'LastName': 'Steinhauser', 'Affiliation': 'Department of Medicine, Duke University Medical Center, Durham, NC; Center for the Study of Aging and Human Development, Duke University, Durham, NC; Center for Health Services Research in Primary Care, Veterans Affairs Medical Center, Durham, NC.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Tulsky', 'Affiliation': 'Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.'}, {'ForeName': 'Donald H', 'Initials': 'DH', 'LastName': 'Taylor', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC; Duke University School of Nursing, Durham, NC; Sanford School of Public Policy, Duke University, Durham, NC; Margolis Center for Health Policy, Duke University, Durham, NC.'}, {'ForeName': 'Joseph G', 'Initials': 'JG', 'LastName': 'Rogers', 'Affiliation': 'Department of Medicine, Duke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Mentz', 'Affiliation': 'Department of Medicine, Duke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC.'}]",Journal of cardiac failure,['10.1016/j.cardfail.2019.05.013'] 2533,31265187,Predictors for Excellent Versus Partial Response to Prolonged Exposure Therapy: Who Needs Additional Sessions?,"In practice, the duration of psychotherapy is determined by the patient's response to treatment. Identifying predictors for treatment responses is of great clinical utility to guide clinicians in their treatment planning. Demographic characteristics, trauma history, comorbidity, and early reduction of posttraumatic stress disorder (PTSD) symptoms were examined as predictors of excellent versus partial response to prolonged exposure therapy (PE) for PTSD. Participants were 96 female assault survivors with chronic PTSD who received at least eight PE sessions with or without cognitive restructuring. Participants were classified as excellent responders (n = 27) or partial responders (n = 69) based on whether they achieved at least 70% improvement in self-reported PTSD severity on the PTSD Symptom Scale-Self-Report at the end of Session 8. Excellent responders terminated therapy after Session 9, and partial responders were offered up to three additional sessions. Logistic regression was conducted to investigate predictors of response to PE. Results showed that prior interpersonal violence and comorbid alcohol use disorder were associated with partial response. Comorbid depressive disorder and early PTSD symptom reduction were associated with excellent response. Being treated by a cognitive behavioral therapy expert predicted higher excellent response for patients with a history of prior interpersonal violence. The model accounted for 56.6% of the variance in treatment response and correctly predicted responder status for 83.3% of the sample. These findings contribute to the field's understanding of factors that predict or moderate response to PE and have implications for treatment planning.",2019,Being treated by a cognitive behavioral therapy expert predicted higher excellent response for patients with a history of prior interpersonal violence.,"['Participants were 96 female assault survivors with chronic PTSD who received at least eight PE sessions with or without cognitive restructuring', 'patients with a history of prior interpersonal violence']","['Prolonged Exposure Therapy', 'cognitive behavioral therapy expert']","['Comorbid depressive disorder and early PTSD symptom reduction', 'interpersonal violence and comorbid alcohol use disorder', 'Demographic characteristics, trauma history, comorbidity, and early reduction of posttraumatic stress disorder (PTSD) symptoms', 'self-reported PTSD severity on the PTSD Symptom Scale-Self-Report']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0730525', 'cui_str': 'Chronic post-traumatic stress disorder'}, {'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C0150173', 'cui_str': 'Cognitive restructuring'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0042693', 'cui_str': 'Violence'}]","[{'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0011581', 'cui_str': 'Depressive disorder'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",96.0,0.00993199,Being treated by a cognitive behavioral therapy expert predicted higher excellent response for patients with a history of prior interpersonal violence.,"[{'ForeName': 'Yinyin', 'Initials': 'Y', 'LastName': 'Zang', 'Affiliation': 'Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Yi-Jen', 'Initials': 'YJ', 'LastName': 'Su', 'Affiliation': 'Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Carmen P', 'Initials': 'CP', 'LastName': 'McLean', 'Affiliation': 'Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Edna B', 'Initials': 'EB', 'LastName': 'Foa', 'Affiliation': 'Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}]",Journal of traumatic stress,['10.1002/jts.22412'] 2534,31356704,Patterns of Treatment Disengagement and Personality Traits Associated With Posttraumatic Stress Disorder in Recent-Era U.S. Veterans Receiving Cognitive Processing Therapy.,"Low treatment engagement is a barrier to implementation of empirically supported treatments for posttraumatic stress disorder (PTSD) among veterans. Understanding personality traits that predict dropout may help focus attempts to improve engagement. The current study included 90 veterans who served in recent conflicts in Iraq and/or Afghanistan and participated in a trial of cognitive processing therapy for PTSD. Goals were to characterize (a) personality correlates of PTSD, (b) patterns of engagement (i.e., attendance and homework completion), and (c) personality correlates of reduced engagement. Higher levels of PTSD symptoms were associated with a range of characteristics, including affective lability, r = .44 p < .001; anxiety, r = .38, p < .001; identity problems, r = .57, p < .001; intimacy problems, r = .34, p = .001; low affiliation, r = .33, p = .002; oppositionality, r = .36, p = .001; restricted expression, r = .35, p = .001; and suspiciousness, r = .50, p < .001. Notably, veterans with worse PTSD symptoms endorsed more cognitive dysregulation, r = .40, p < .001; and less insecure attachment, r = .14, p = .190, than expected. Only 52.2% of veterans completed the 12-session course of treatment and 31.0% of participants completed fewer than six sessions. Personality traits did not predict attendance or homework completion. Disengagement continues to be a significant issue in trauma-focused treatment for veterans with PTSD. Understanding veteran-level factors, such as personality traits, may be useful considerations for future research seeking to understand and improve engagement.",2019,"Higher levels of PTSD symptoms were associated with a range of characteristics, including affective lability, r = .44","['posttraumatic stress disorder (PTSD) among veterans', 'veterans with PTSD', '90 veterans who served in recent conflicts in Iraq and/or Afghanistan and participated in a trial of']",['cognitive processing therapy for PTSD'],"['Personality Traits', 'Higher levels of PTSD symptoms', 'characterize (a) personality correlates of PTSD, (b) patterns of engagement (i.e., attendance and homework completion), and (c) personality correlates of reduced engagement']","[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0009671', 'cui_str': 'Conflict'}, {'cui': 'C0022066', 'cui_str': 'Iraq'}, {'cui': 'C0001732', 'cui_str': 'Afghanistan'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}]","[{'cui': 'C0233849', 'cui_str': 'Character trait finding'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C0003944', 'cui_str': 'As If Personality'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0589414', 'cui_str': 'Homework'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",90.0,0.0213389,"Higher levels of PTSD symptoms were associated with a range of characteristics, including affective lability, r = .44","[{'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Lamkin', 'Affiliation': 'Veterans Affairs (VA), Health Services Research and Development Service, Houston Center of Excellence, Michael E. DeBakey VA Medical Center, Houston, Texas, USA.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Hundt', 'Affiliation': 'Veterans Affairs (VA), Health Services Research and Development Service, Houston Center of Excellence, Michael E. DeBakey VA Medical Center, Houston, Texas, USA.'}, {'ForeName': 'Eileen P', 'Initials': 'EP', 'LastName': 'Ahearn', 'Affiliation': 'Department of Psychiatry, University of Wisconsin Hospitals and Clinics, Madison, Wisconsin, USA.'}, {'ForeName': 'Melinda', 'Initials': 'M', 'LastName': 'Stanley', 'Affiliation': 'Veterans Affairs (VA), Health Services Research and Development Service, Houston Center of Excellence, Michael E. DeBakey VA Medical Center, Houston, Texas, USA.'}, {'ForeName': 'Tracey L', 'Initials': 'TL', 'LastName': 'Smith', 'Affiliation': 'Veterans Affairs (VA), Health Services Research and Development Service, Houston Center of Excellence, Michael E. DeBakey VA Medical Center, Houston, Texas, USA.'}]",Journal of traumatic stress,['10.1002/jts.22428'] 2535,32700585,"Severe, transient pulmonary ventilation-perfusion mismatch in the lung after porcine high velocity projectile behind armor blunt trauma.","BACKGROUND Behind armor blunt trauma (BABT) is a non-penetrating injury caused by the rapid deformation of body armor, by a projectile, which may in extreme circumstances cause death. Although there is not a high incidence of high energy BABT, the understanding of the mechanisms is still low, in relation to what is needed for safety threshold levels. BABT is also useful as a model for blunt thoracic trauma, with a compressive speed between traffic accidents and blast caused by explosives. High velocity projectile BABT causes severe hypoxia. The mechanisms are not fully known. We investigated the acute pulmonary consequences in the individual lungs, and the effects of alveolar recruitment. METHODS 12 swine (mean weight 62.5 kg) were randomized to groups BABT by 7.62 × 51 mm NATO-type bullets (mean velocity 803 m/s) to a military grade ceramic plate armor (n = 7) or control (n = 5). Modified double lumen tracheal tubes provided respiratory dynamics in the lungs separately/intermittently for two hours, with alveolar recruitment after one hour. RESULTS Venous admixture increased 5 min after BABT (p < .05) and correlated with increased cardiac output. Static compliance decreased 5 minutes after BABT (p < .05) and further by recruitment (p < .005). Physiological dead space decreased 5 minutes after BABT (p < .01) and further by recruitment (p < .01), while not in the contralateral lung. V'A/Q' decreased 5 minutes after BABT (p < .05), also shown in phase III volumetric capnography (p < .05). Most effects regressed after one hour. CONCLUSIONS High velocity projectile BABT caused hypoxia by a severe and transient decrease in V'A/Q' to <1 and increased venous admixture in the exposed lung. Alveolar recruitment was hemodynamically and respiratory tolerable and increased V'A/Q'. Body armor development should aim at ameliorating severe pulmonary consequences from high projectile velocities which also needs to include further understanding of how primary and secondary effects are distributed between the lungs.",2020,"RESULTS Venous admixture increased 5 min after BABT (p < .05) and correlated with increased cardiac output.","['12 swine ', 'mean weight 62.5\u2009kg']","['military grade ceramic plate armor (n\u2009=\u20097) or control', 'BABT']","['cardiac output', 'Venous admixture increased 5\u2009min after BABT', ""Alveolar recruitment was hemodynamically and respiratory tolerable and increased V'A/Q"", 'Physiological dead space', ""V'A/Q"", 'Static compliance']","[{'cui': 'C0039005', 'cui_str': 'Suidae'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C4517836', 'cui_str': '62.5'}]","[{'cui': 'C0026126', 'cui_str': 'Military personnel'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0007742', 'cui_str': 'Ceramic'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0043253', 'cui_str': 'Blunt injury'}]","[{'cui': 'C0007165', 'cui_str': 'Cardiac output'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0043253', 'cui_str': 'Blunt injury'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0231936', 'cui_str': 'Normal ventilation-perfusion ratio'}, {'cui': 'C0231975', 'cui_str': 'Physiological dead space'}, {'cui': 'C0429681', 'cui_str': 'Static lung compliance'}]",,0.039932,"RESULTS Venous admixture increased 5 min after BABT (p < .05) and correlated with increased cardiac output.","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Rocksén', 'Affiliation': 'Department of Neuroscience, section of Experimental Traumatology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Ulf P', 'Initials': 'UP', 'LastName': 'Arborelius', 'Affiliation': 'Department of Neuroscience, section of Experimental Traumatology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Gustavsson', 'Affiliation': 'Department of Neuroscience, section of Experimental Traumatology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Mattias', 'Initials': 'M', 'LastName': 'Günther', 'Affiliation': 'Department of Clinical Science and Education, Section of Anesthesiology and Intensive Care, Karolinska Institutet, Stockholm, Sweden.'}]",Experimental lung research,['10.1080/01902148.2020.1797246'] 2536,32700655,Incidence of silent venous thromboembolism after total hip arthroplasty: A comparison of rivaroxaban and enoxaparin.,"PROPOSE Total hip arthroplasty (THA) is associated with a significant risk of venous thromboembolism (VTE). Different thromboprophylaxis strategies have been used to prevent VTE. The primary aim of this study was to report the incidence of VTE and compare the efficacy and safety of rivaroxaban to enoxaparin. The secondary outcome was to report the incidence of silent deep venous thrombosis (DVT) using computed tomography venography. METHODS One hundred sixty patients who underwent THA were enrolled in a prospective study. Patients were randomized into two groups as follows: those who received rivaroxaban 10 mg oral daily (group RXE) and those who received enoxaparin 40 IU/day subcutaneously for 14 days (group ENO). RESULTS Both groups were matched for age, sex, comorbidities, special habits and preoperative laboratory investigations. The overall incidence of DVT was 5% ( n = 8), which included four patients clinically diagnosed as having DVT and four with silent DVT. All the DVT cases occurred in veins below the knee and in the group RXE; none of the cases occurred in group ENO ( p = 0.04). The incidence of DVT was significantly higher in patients with high body mass indexes ( p < 0.001), older age ( p = 0.024) and medical comorbidities ( p = 0.14). No mortality, pulmonary embolism, stroke, wound infection or major bleeding occurred in either group. CONCLUSIONS Among the patients who underwent hip arthroplasty, rivaroxaban prophylaxis was found to be associated with lower efficacy and similar safety outcomes as compared with enoxaparin anticoagulants.",2020,"The incidence of DVT was significantly higher in patients with high body mass indexes ( p < 0.001), older age ( p = 0.024) and medical comorbidities ( p = 0.14).","['One hundred sixty patients who underwent THA were enrolled in a prospective study', 'total hip arthroplasty']","['rivaroxaban', 'enoxaparin', 'rivaroxaban prophylaxis', 'rivaroxaban and enoxaparin']","['overall incidence of DVT', 'No mortality, pulmonary embolism, stroke, wound infection or major bleeding', 'incidence of silent deep venous thrombosis (DVT', 'Incidence of silent venous thromboembolism', 'efficacy and safety', 'medical comorbidities', 'incidence of DVT']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0033522', 'cui_str': 'Prospective Studies'}]","[{'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C0206460', 'cui_str': 'Enoxaparin'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0043241', 'cui_str': 'Local infection of wound'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0443304', 'cui_str': 'Silent'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}]",160.0,0.0228021,"The incidence of DVT was significantly higher in patients with high body mass indexes ( p < 0.001), older age ( p = 0.024) and medical comorbidities ( p = 0.14).","[{'ForeName': 'Wael A', 'Initials': 'WA', 'LastName': 'Rahman', 'Affiliation': 'Department of Orthopedics, Faculty of Medicine, Mansoura University, Mansoura, Egypt.'}, {'ForeName': 'Gamal H', 'Initials': 'GH', 'LastName': 'Habsa', 'Affiliation': 'Department of Orthopedics, Faculty of Medicine, Mansoura University, Mansoura, Egypt.'}, {'ForeName': 'Omar A', 'Initials': 'OA', 'LastName': 'Al-Mohrej', 'Affiliation': 'Department of orthopedics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.'}, {'ForeName': 'Mohammed', 'Initials': 'M', 'LastName': 'Hammad', 'Affiliation': 'Department of Orthopedics, Faculty of Medicine, Mansoura University, Mansoura, Egypt.'}, {'ForeName': 'Naser M', 'Initials': 'NM', 'LastName': 'Selim', 'Affiliation': 'Department of Orthopedics, Faculty of Medicine, Mansoura University, Mansoura, Egypt.'}, {'ForeName': 'Akram', 'Initials': 'A', 'LastName': 'Hammad', 'Affiliation': 'Department of Orthopedics, Faculty of Medicine, Mansoura University, Mansoura, Egypt.'}]",Journal of orthopaedic surgery (Hong Kong),['10.1177/2309499020938865'] 2537,32700772,GLP-1 receptor agonists for Parkinson's disease.,"BACKGROUND Parkinson's disease (PD) is a progressive disorder characterised by both motor and non-motor problems. Glucagon-like peptide-1 (GLP-1) receptor agonists, licensed for treatment of type 2 diabetes, work by stimulating GLP-1 receptors in the pancreas, which triggers the release of insulin. GLP-1 receptors have been found in the brain. Insulin signalling in the brain plays a key role in neuronal metabolism and repair and in synaptic efficacy, but insulin signalling is desensitised in the brain of people with PD. Researchers are exploring the neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders such as PD. OBJECTIVES To evaluate the effectiveness and safety of GLP-1 receptor agonists for Parkinson's disease. SEARCH METHODS We searched the Cochrane Movement Disorders Group trials register; the Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library; and Ovid MEDLINE and Embase. We also searched clinical trials registries, and we handsearched conference abstracts. The most recent search was run on 25 June 2020. SELECTION CRITERIA We included randomised controlled trials (RCTs) of adults with PD that compared GLP-1 receptor agonists with conventional PD treatment, placebo, or no treatment. DATA COLLECTION AND ANALYSIS Two review authors independently assessed studies for inclusion, extracted data, and assessed risk of bias. We rated the quality of evidence using GRADE. We resolved discrepancies between the two data extractors by consultation with a third review author. MAIN RESULTS Through our searches, we retrieved 99 unique records, of which two met our inclusion criteria. One double-blind study of exenatide versus placebo randomised 62 participants, who self-administered exenatide or placebo for 48 weeks and were followed up at 60 weeks after a 12-week washout. One single-blind study of exenatide versus no additional treatment randomised 45 participants; participants in the intervention group self-administered exenatide for 12 months, and all participants were followed up at 14 months and 24 months following absence of exenatide for 2 months and 12 months, respectively. These trials had low risk of bias, except risk of performance bias was high for Aviles-Olmos 2013. Exenatide versus placebo Primary outcomes We found low-certainty evidence suggesting that exenatide improves motor impairment as assessed by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III in the off-medication state (mean difference (MD) -3.10, 95% confidence interval (CI) -6.11 to -0.09). The difference in scores was slightly greater when scores were adjusted for baseline severity of the condition (as reported by study authors) (MD -3.5, 95% CI -6.7 to -0.3), exceeding the minimum clinically important difference (MCID). We found low-certainty evidence suggesting that exenatide has little or no effect on health-related quality of life (HRQoL) as assessed by the Parkinson's Disease Questionnaire (PDQ)-39 Summary Index (SI) (MD -1.80, 95% CI -6.95 to 3.35), the EuroQol scale measuring health status in five dimensions (EQ5D) (MD 0.07, 95% CI -0.03 to 0.16), or the EQ5D visual analogue scale (VAS) (MD 5.00, 95% CI -3.42 to 13.42). Eight serious adverse events (SAEs) were recorded, but all were considered unrelated to the intervention. Low-certainty evidence suggests that exenatide has little or no effect on weight loss (risk ratio (RR) 1.25, 95% CI 0.89 to 1.76). Exenatide versus no treatment Primary outcomes at 14 months We found very low-certainty evidence suggesting that exenatide improves motor impairment as assessed by MDS-UPDRS Part III off medication (MD -4.50, 95% CI -8.64 to -0.36), exceeding the MCID. We are uncertain whether exenatide improves HRQoL as assessed by the PDQ-39 SI (MD 3.50, 95% CI -2.75 to 9.75; very low-quality evidence). We found very low-certainty evidence suggesting that exenatide has little or no effect on the number of SAEs (RR 1.60, 95% 0.40 to 6.32). We found very low-certainty evidence suggesting that exenatide may lead to weight loss (MD -2.40 kg, 95% CI -4.56 to -0.24). Primary outcomes at 24 months We found evidence as reported by study authors to suggest that exenatide improves motor impairment as measured by MDS-UPDRS Part III off medication (MD 5.6 points, 95% CI 2.2 to 9.0). Exenatide may not improve HRQoL as assessed by the PDQ-39 SI (P = 0.682) and may not result in weight loss (MD 0.1 kg, 95% CI 3.0 to 2.8). AUTHORS' CONCLUSIONS Low- or very low-certainty evidence suggests that exenatide may improve motor impairment for people with PD. The difference in motor impairment observed between groups may persist for some time following cessation of exenatide. This raises the possibility that exenatide may have a disease-modifying effect. SAEs were unlikely to be related to treatment. The effectiveness of exenatide for improving HRQoL, non-motor outcomes, ADLs, and psychological outcomes is unclear. Ongoing studies are assessing other GLP-1 receptor agonists.",2020,"Exenatide may not improve HRQoL as assessed by the PDQ-39 SI (P = 0.682) and may not result in weight loss (MD 0.1 kg, 95% CI 3.0 to 2.8). ","[""Parkinson's disease"", 'adults with PD that compared', 'randomised 62 participants, who self-administered', 'people with PD', '45 participants']","['exenatide', 'Glucagon-like peptide-1', 'Exenatide', 'exenatide or placebo', 'GLP-1 receptor agonists', 'GLP-1 receptor agonists with conventional PD treatment, placebo, or no treatment', 'placebo']","['motor impairment', 'health-related quality of life (HRQoL', 'HRQoL', 'weight loss', ""Parkinson's Disease Questionnaire (PDQ)-39 Summary Index (SI"", ""Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS"", 'Eight serious adverse events (SAEs', 'EuroQol scale measuring health status', 'number of SAEs', 'MDS-UPDRS Part III off medication', 'EQ5D visual analogue scale (VAS']","[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0167117', 'cui_str': 'exenatide'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1562104', 'cui_str': 'Glucagon-like peptide 1 receptor agonist-containing product'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0026650', 'cui_str': 'Movement disorder'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",,0.369049,"Exenatide may not improve HRQoL as assessed by the PDQ-39 SI (P = 0.682) and may not result in weight loss (MD 0.1 kg, 95% CI 3.0 to 2.8). ","[{'ForeName': 'Caroline A', 'Initials': 'CA', 'LastName': 'Mulvaney', 'Affiliation': 'Lancaster Medical School, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Gonçalo S', 'Initials': 'GS', 'LastName': 'Duarte', 'Affiliation': 'Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa, Lisboa, Portugal.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Handley', 'Affiliation': 'Lancaster Medical School, Lancaster University, Lancaster, UK.'}, {'ForeName': 'David Jw', 'Initials': 'DJ', 'LastName': 'Evans', 'Affiliation': 'Lancaster Medical School, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Suresh', 'Initials': 'S', 'LastName': 'Menon', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Canada.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Wyse', 'Affiliation': ""The Cure Parkinson's Trust, London, UK.""}, {'ForeName': 'Hedley Ca', 'Initials': 'HC', 'LastName': 'Emsley', 'Affiliation': 'Lancaster Medical School, Lancaster University, Lancaster, UK.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD012990.pub2'] 2538,32700828,Hippocampal circuits underlie improvements in self-reported anxiety following mindfulness training.,"INTRODUCTION Mindfulness meditation has successfully been applied to cultivate skills in self-regulation of emotion, as it employs the unbiased present moment awareness of experience. This heightened attention to and awareness of sensory experience has been postulated to create an optimal therapeutic exposure condition and thereby improve extinction learning. We recently demonstrated increased connectivity in hippocampal circuits during the contextual retrieval of extinction memory following mindfulness training. METHODS Here, we examine the role of structural changes in hippocampal subfields following mindfulness training in a randomized controlled longitudinal study using a two-day fear-conditioning and extinction protocol. RESULTS We demonstrate an association between mindfulness training-related increases in subiculum and decreased hippocampal connectivity to lateral occipital regions during contextual retrieval of extinguished fear. Further, we demonstrate an association between decreased connectivity and decreases in self-reported anxiety following mindfulness training. CONCLUSIONS The results highlight the role of the subiculum in gating interactions with contextual stimuli during memory retrieval and, also, the mechanisms through which mindfulness training may foster resilience.",2020,We demonstrate an association between mindfulness training-related increases in subiculum and decreased hippocampal connectivity to lateral occipital regions during contextual retrieval of extinguished fear.,[],['mindfulness training'],[],[],"[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",[],,0.0119425,We demonstrate an association between mindfulness training-related increases in subiculum and decreased hippocampal connectivity to lateral occipital regions during contextual retrieval of extinguished fear.,"[{'ForeName': 'Gunes', 'Initials': 'G', 'LastName': 'Sevinc', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Greenberg', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Britta K', 'Initials': 'BK', 'LastName': 'Hölzel', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Gard', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Calahan', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Brunsch', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Javeria A', 'Initials': 'JA', 'LastName': 'Hashmi', 'Affiliation': 'Department of Anesthesia, Pain Management & Perioperative Medicine, Dalhousie University, Halifax, NS, Canada.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Vangel', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Scott P', 'Initials': 'SP', 'LastName': 'Orr', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Mohammed R', 'Initials': 'MR', 'LastName': 'Milad', 'Affiliation': 'Psychiatry Department, New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Sara W', 'Initials': 'SW', 'LastName': 'Lazar', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}]",Brain and behavior,['10.1002/brb3.1766'] 2539,32700883,Effect of interferon-α-2b and interleukin-2 combined with chemotherapy in metastatic melanoma.,"BACKGROUND To explore the efficacy and safety of interferon-α-2b and interleukin-2 combined with chemotherapy in treating patients with metastatic melanoma. METHODS The patients with metastatic melanoma in control group (n=52) were treated with conventional DDAVC chemotherapy regimen, while those in combination group (n=52) received biotherapy with interferon-α-2b and interleukin-2 in addition to the chemotherapy in control group. At the end of the treatments, the serum immune function indicators, short-term efficacy and incidence of adverse reactions were compared between the two groups of patients, and patient's survival was followed up and recorded. RESULTS At 1 week after treatment, it was found that the overall response rate in combination group was substantially higher than that in control group (P=0.027). Besides, according to the serologic test results at 1 week after the chemotherapy, T lymphocyte subset activity was enhanced in patients in combination group compared with that before chemotherapy, with no statistically significant difference (P>0.05), but it was notably weakened in control group in comparison with that before chemotherapy (P<0.05). Finally, it was discovered through the log-rank test that the overall survival (OS) rate in combination group was remarkably superior to that in control group (P=0.029), but there was no statistically significant difference in the progression-free survival (PFS) rate between the two groups (P=0.076). CONCLUSIONS Compared with chemotherapy alone, interferon-α-2b and interleukin-2 combined with chemotherapy can raise the clinical short-term efficacy and long-term OS rate in the patients with metastatic melanoma and alleviate their toxic side reactions, with higher safety.",2020,"At the end of the treatments, the serum immune function indicators, short-term efficacy and incidence of adverse reactions were compared between the two groups of patients, and patient's survival was followed up and recorded. ","['metastatic melanoma', 'patients with metastatic melanoma', 'patients with metastatic melanoma in control group (n=52']","['interferon-α-2b and interleukin-2 combined with chemotherapy', 'conventional DDAVC chemotherapy regimen', 'biotherapy with interferon-α-2b and interleukin-2 in addition to the chemotherapy in control group']","['serum immune function indicators, short-term efficacy and incidence of adverse reactions', 'progression-free survival (PFS) rate', 'overall response rate', 'T lymphocyte subset activity', 'overall survival (OS) rate']","[{'cui': 'C0278883', 'cui_str': 'Metastatic melanoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0021735', 'cui_str': 'Interferon Alfa-2b'}, {'cui': 'C0021756', 'cui_str': 'Interleukin-2'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0392920', 'cui_str': 'Antineoplastic chemotherapy regimen'}, {'cui': 'C0005527', 'cui_str': 'Biotherapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0020960', 'cui_str': 'Antiserum'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0080202', 'cui_str': 'T-Cell Subsets'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",52.0,0.0897825,"At the end of the treatments, the serum immune function indicators, short-term efficacy and incidence of adverse reactions were compared between the two groups of patients, and patient's survival was followed up and recorded. ","[{'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Su', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, China.'}, {'ForeName': 'Fen', 'Initials': 'F', 'LastName': 'Shi', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, China.'}, {'ForeName': 'Weiqiang', 'Initials': 'W', 'LastName': 'Liang', 'Affiliation': 'Department of Plastic and Reconstructive Surgery, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, China - mam3p3@163.com.'}]",Panminerva medica,['10.23736/S0031-0808.20.03912-9'] 2540,32700954,A multiple baseline study of a brief alcohol reduction and family engagement intervention for fathers in Kenya.,"OBJECTIVE To evaluate a lay provider-delivered, brief intervention to reduce problem drinking and related family consequences among men in Kenya. The 5-session intervention combines behavioral activation (BA) and motivational interviewing (MI). It integrates family-related material explicitly and addresses central cultural factors through gender transformative strategies. METHOD A nonconcurrent multiple-baseline design was used. We initiated treatment with 9 men ages 30 to 48 who were fathers and screened positive for problem drinking; the median Alcohol Use Identification Test score was 17 (harmful range). Participants were randomized to staggered start dates. We measured the primary outcome of weekly alcohol consumption 4 weeks before treatment, during treatment, and 4 weeks posttreatment using the Timeline Followback measure. Secondary outcomes were assessed using a pre-post assessment (1-month) of men's depression symptoms, drinking- and family-related problem behavior, involvement with child, time with family, family functioning, relationship quality (child and partner), and harsh treatment of child and partner. Men, partners, and children (ages 8-17) reported on family outcomes. RESULTS Eight men completed treatment. Mixed-effects hurdle model analysis showed that alcohol use, both number of days drinking and amount consumed, significantly decreased during and after treatment. Odds of not drinking were 5.1 times higher posttreatment (95% CI [3.3, 7.9]). When men did drink posttreatment, they drank 50% less (95% CI [0.39, 0.65]). Wilcoxon signed-ranks test demonstrated pre-post improvements in depression symptoms and family related outcomes. CONCLUSION Results provide preliminary evidence that a BA-MI intervention developed for lay providers may reduce alcohol use and improve family outcomes among men in Kenya. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"When men did drink posttreatment, they drank 50% less (95% CI [0.39, 0.65]).","['Eight men completed treatment', '9 men ages 30 to 48 who were fathers and screened positive for problem drinking; the median Alcohol Use Identification Test score was 17 (harmful range', 'Men, partners, and children (ages 8-17) reported on family outcomes', 'men in Kenya', 'fathers in Kenya']","['alcohol reduction and family engagement intervention', 'BA-MI intervention', '5-session intervention combines behavioral activation (BA) and motivational interviewing (MI']","[""pre-post assessment (1-month) of men's depression symptoms, drinking- and family-related problem behavior, involvement with child, time with family, family functioning, relationship quality (child and partner), and harsh treatment of child and partner"", 'depression symptoms and family related outcomes']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0015671', 'cui_str': 'Father'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0020792', 'cui_str': 'Identification - mental defense mechanism'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}]","[{'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0500725,"When men did drink posttreatment, they drank 50% less (95% CI [0.39, 0.65]).","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Giusto', 'Affiliation': 'Department of Psychology and Neuroscience.'}, {'ForeName': 'Eric P', 'Initials': 'EP', 'LastName': 'Green', 'Affiliation': 'Duke Global Health Institute.'}, {'ForeName': 'Ryan A', 'Initials': 'RA', 'LastName': 'Simmons', 'Affiliation': 'Department of Biostatistics and Bioinformatics.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Ayuku', 'Affiliation': 'Department of Behavioural Sciences.'}, {'ForeName': 'Puja', 'Initials': 'P', 'LastName': 'Patel', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Eve S', 'Initials': 'ES', 'LastName': 'Puffer', 'Affiliation': 'Department of Psychology and Neuroscience.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000559'] 2541,32458495,Locomotion replacement exercise cannot counteract cartilage biomarker response to 5 days of immobilization in healthy adults.,"Biomarkers of cartilage metabolism are sensitive to changes in the biological and mechanical environment and can indicate early changes in cartilage homeostasis. The purpose of this study was to determine if a daily locomotion replacement program can serve as a countermeasure for changes in cartilage biomarker serum concentration caused by immobilization. Ten healthy male subjects (mean ± 1 standard deviation; age: 29.4 ± 5.9 years; body mass: 77.7 ± 4.1 kg) participated in the crossover 5-day bed rest study with three interventions: control (CON), standing (STA), and locomotion replacement training (LRT). Serum samples were taken before, during, and after bed rest. Biomarker concentrations were measured using commercial enzyme-linked immunosorbent assays. Cartilage oligomeric matrix protein (COMP) levels after 24 hours of bed rest decreased independently of the intervention (-16.8% to -9.8%) and continued to decrease until 72 hours of bed rest (minimum, -23.2% to -20.6%). LRT and STA did not affect COMP during bed rests (P = .056) but there was a strong tendency for a slower decrease with LRT (-9.4%) and STA (-11.7%) compared with CON (-16.8%). MMP-3 levels decreased within the first 24 hours of bed rest (CON: -22.3%; STA: -14.7%; LRT: -17%) without intervention effect. Both COMP and MMP-3 levels recovered to baseline levels during the 6-day recovery period. MMP-1, MMP-9, and TNF-α levels were not affected by immobilization or intervention. COMP and MMP-3 are mechano-sensitive cartilage biomarkers affected by immobilization, and simple interventions such as standing upright or LRT during bed rest cannot prevent these changes. Clinical significance: simple locomotion interventions cannot prevent cartilage biomarker change during bed rest.",2020,"Cartilage oligomeric matrix protein (COMP) levels after 24 hours of bed rest decreased independently of the intervention (-16.8% to -9.8%) and continued to decrease until 72 hours of bed rest (minimum, -23.2% to -20.6%).","['Ten healthy male subjects (mean\u2009±\u20091 standard deviation; age: 29.4\u2009±\u20095.9 years; body mass: 77.7\u2009±\u20094.1\u2009kg) participated in the crossover 5-day bed rest study with three', 'healthy adults']","['interventions: control (CON), standing (STA), and locomotion replacement training (LRT', 'daily locomotion replacement program', 'locomotion interventions', 'Locomotion replacement exercise', 'LRT and STA']","['MMP-1, MMP-9, and TNF-α levels', 'LRT', 'cartilage biomarker response', 'COMP and MMP-3 levels', 'Biomarker concentrations', 'MMP-3 levels', 'Cartilage oligomeric matrix protein (COMP) levels']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C4517756', 'cui_str': '4.1'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0004910', 'cui_str': 'Bedrest'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0023946', 'cui_str': 'Locomotor Activity'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C2001899', 'cui_str': 'MMP1 protein, human'}, {'cui': 'C0165519', 'cui_str': 'Gelatinase B'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023946', 'cui_str': 'Locomotor Activity'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0007301', 'cui_str': 'Cartilage tissue'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0601900', 'cui_str': 'COMP (Cartilage Oligomeric Matrix Protein)'}, {'cui': 'C0164371', 'cui_str': 'Stromelysin 1'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",10.0,0.0232491,"Cartilage oligomeric matrix protein (COMP) levels after 24 hours of bed rest decreased independently of the intervention (-16.8% to -9.8%) and continued to decrease until 72 hours of bed rest (minimum, -23.2% to -20.6%).","[{'ForeName': 'Anna-Maria', 'Initials': 'AM', 'LastName': 'Liphardt', 'Affiliation': 'Department of Internal Medicine 3-Rheumatology and Immunology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.'}, {'ForeName': 'Annegret', 'Initials': 'A', 'LastName': 'Mündermann', 'Affiliation': 'Department of Orthopaedics and Traumatology, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Heer', 'Affiliation': 'Department of Nutrition and Food Science-Nutrition Physiology, University of Bonn, Bonn, Germany.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Achtzehn', 'Affiliation': 'Institute of Cardiology and Sports Medicine, German Sport University Cologne (DSHS Köln), Köln, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Niehoff', 'Affiliation': 'Institute of Biomechanics and Orthopaedics, German Sport University Cologne (DSHS Köln), Köln, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Mester', 'Affiliation': 'The German Research Centre of Elite Sport Cologne (Momentum), German Sport University Cologne (DSHS Köln), Köln, Germany.'}]",Journal of orthopaedic research : official publication of the Orthopaedic Research Society,['10.1002/jor.24753'] 2542,32585742,"10-kHz Spinal Cord Stimulation for Chronic Postsurgical Pain: Results From a 12-Month Prospective, Multicenter Study.","BACKGROUND Chronic postsurgical pain (CPSP) can be caused by peripheral nerve injury (PNI) resulting from surgical procedures and has a significant neuropathic component. This prospective, single-arm study was conducted to document the effectiveness of 10-kHz spinal cord stimulation (10-kHz SCS) as a treatment for patients with CPSP. METHODS Subjects with CPSP who were refractory to conventional medical interventions and reported pain scores of ≥5 cm on a 10-cm VAS underwent trial stimulations lasting up to 14 days. Epidural leads were implanted at locations appropriate for the primary area of pain, and trials resulting in ≥40% pain relief were considered successful. Subjects with successful trials underwent implantation with a permanent 10-kHz SCS system and were followed for 12 months after implantation. RESULTS Of the 34 subjects who underwent trial stimulation, 1 was withdrawn early and 29 (87.9%) had a successful trial and received a permanent implant. After 12 months of treatment, the mean VAS score decreased by 6.5 cm, the response rate was 88.0% (22/25), and 18 subjects (62.1%) were remitters with VAS scores sustained at ≤3.0 cm. Scores for all components of the short-form McGill Pain Questionnaire 2 were significantly reduced, including affective descriptors of pain. Pain catastrophizing and vigilance, patient function, physical and mental well-being, and sleep quality all improved over the course of the study. No neurologic deficits reported in the study. CONCLUSIONS 10-kHz SCS is effective and tolerated in patients with CPSP, and further study of its clinical application in this population is warranted.",2020,"Scores for all components of the short-form McGill Pain Questionnaire 2 were significantly reduced, including affective descriptors of pain.","['Subjects with CPSP who were refractory to conventional medical interventions and reported pain scores of ≥5\xa0cm on a 10-cm VAS underwent trial stimulations lasting up to 14\xa0days', 'Subjects with successful trials underwent', 'patients with CPSP', '34 subjects who underwent trial stimulation, 1 was withdrawn early and 29 (87.9%) had a successful trial and received a permanent implant', 'Chronic Postsurgical Pain']","['implantation with a permanent 10-kHz SCS system', '10-kHz Spinal Cord Stimulation', '10-kHz spinal cord stimulation (10-kHz SCS', '10-kHz SCS']","['Pain catastrophizing and vigilance, patient function, physical and mental well-being, and sleep quality', 'affective descriptors of pain', 'effective and tolerated', 'mean VAS score', 'neurologic deficits', 'response rate', 'McGill Pain Questionnaire']","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0021102', 'cui_str': 'Implant'}]","[{'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0556965', 'cui_str': 'kHz'}, {'cui': 'C0394477', 'cui_str': 'Neurostimulation of spinal cord tissue'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0043012', 'cui_str': 'Wakefulness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0282354', 'cui_str': 'Descriptor'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0521654', 'cui_str': 'Motor dysfunction'}, {'cui': 'C0024985', 'cui_str': 'McGill pain chart questionnaire'}]",34.0,0.0971671,"Scores for all components of the short-form McGill Pain Questionnaire 2 were significantly reduced, including affective descriptors of pain.","[{'ForeName': 'Mayank', 'Initials': 'M', 'LastName': 'Gupta', 'Affiliation': 'Kansas Pain Management, Overland Park, Kansas, U.S.A.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Scowcroft', 'Affiliation': ""KC Pain Centers, Lee's Summit, Missouri, U.S.A.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Kloster', 'Affiliation': 'Menorah Medical Center, Overland Park, Kansas, U.S.A.'}, {'ForeName': 'Maged', 'Initials': 'M', 'LastName': 'Guirguis', 'Affiliation': 'Ochsner Health System, New Orleans, Louisiana, U.S.A.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Carlson', 'Affiliation': 'AZ Pain Specialists, Scottsdale, Arizona, U.S.A.'}, {'ForeName': 'Tory', 'Initials': 'T', 'LastName': 'McJunkin', 'Affiliation': 'AZ Pain Specialists, Scottsdale, Arizona, U.S.A.'}, {'ForeName': 'Gassan', 'Initials': 'G', 'LastName': 'Chaiban', 'Affiliation': 'Ochsner Health System, New Orleans, Louisiana, U.S.A.'}, {'ForeName': 'Atef', 'Initials': 'A', 'LastName': 'Israel', 'Affiliation': 'Menorah Medical Center, Overland Park, Kansas, U.S.A.'}, {'ForeName': 'Jeyakumar', 'Initials': 'J', 'LastName': 'Subbaroyan', 'Affiliation': 'Nevro Corp, Redwood City, California, U.S.A.'}]",Pain practice : the official journal of World Institute of Pain,['10.1111/papr.12929'] 2543,30114980,The acceptance and commitment therapy model in occupational rehabilitation of musculoskeletal and common mental disorders: a qualitative focus group study.,"Aims: The aim of this study was to examine whether and how intended processes of behavioural change were reflected in participants' experiences after an inpatient occupational rehabilitation programme. The programme was transdiagnostic, lasted 3½ weeks and was based on the acceptance and commitment therapy model. Methods: Twenty-two participants (17 women and 5 men) took part in five qualitative focus group interviews after the programme. Analysis was data-driven, categorising participants' experiences using an initial explorative phenomenological approach. The emerging data-driven categories were re-contextualised within the theoretical framework of the therapy model. Results: The participants referred to experiences within all three intended domains of the model (openness, awareness, and engagement). Our results indicate that the transdiagnostic approach may have facilitated openness, while the attainment of flexible self-awareness was less evident. Participants expressed engagement and behavioural changes linked to personal values, but did not mention actions leading to imminent return to work. Conclusions: The results imply that for implementation in occupational rehabilitation, further development of this model is needed specifically regarding processes related to self-awareness and committed action towards work. These findings are relevant for the interpretation of results from randomised clinical trials on acceptance and commitment therapy in occupational rehabilitation.Implications for rehabilitationAcceptance and commitment therapy seems to be a feasible component in an occupational rehabilitation programme for persons with different diagnoses.A transdiagnostic approach mixing musculoskeletal pain disorders and common mental disorders in the same rehabilitation programme seems to facilitate the process of openness and acceptance.There is a need to further develop and operationalise some of the processes in Acceptance and commitment therapy to accommodate the approach to the occupational rehabilitation context.",2019,"Participants expressed engagement and behavioural changes linked to personal values, but did not mention actions leading to imminent return to work.","['Methods: Twenty-two participants (17 women and 5 men', ""participants' experiences after an inpatient occupational rehabilitation programme"", 'occupational rehabilitation of musculoskeletal and common mental disorders', 'persons with different diagnoses']",[],[],"[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0521127', 'cui_str': 'Occupational'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]",[],[],22.0,0.0301897,"Participants expressed engagement and behavioural changes linked to personal values, but did not mention actions leading to imminent return to work.","[{'ForeName': 'Sigmund Ø', 'Initials': 'SØ', 'LastName': 'Gismervik', 'Affiliation': 'Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Marius S', 'Initials': 'MS', 'LastName': 'Fimland', 'Affiliation': 'Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Egil A', 'Initials': 'EA', 'LastName': 'Fors', 'Affiliation': 'Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Roar', 'Initials': 'R', 'LastName': 'Johnsen', 'Affiliation': 'Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Marit B', 'Initials': 'MB', 'LastName': 'Rise', 'Affiliation': 'Department of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.'}]",Disability and rehabilitation,['10.1080/09638288.2018.1490824'] 2544,30137250,"Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction.","BACKGROUND AIDS Clinical Trial Group 5199 compared neurological and neuropsychological test performance of human immunodeficiency virus type 1 (HIV-1)-infected participants in resource-limited settings treated with 3 World Health Organization-recommended antiretroviral (ART) regimens. We investigated the impact of tuberculosis (TB) on neurological and neuropsychological outcomes. METHODS Standardized neurological and neuropsychological examinations were administered every 24 weeks. Generalized estimating equation models assessed the association between TB and neurological/neuropsychological performance. RESULTS Characteristics of the 860 participants at baseline were as follows: 53% female, 49% African; median age, 34 years; CD4 count, 173 cells/μL; and plasma HIV-1 RNA, 5.0 log copies/mL. At baseline, there were 36 cases of pulmonary, 9 cases of extrapulmonary, and 1 case of central nervous system (CNS) TB. Over the 192 weeks of follow-up, there were 55 observations of pulmonary TB in 52 persons, 26 observations of extrapulmonary TB in 25 persons, and 3 observations of CNS TB in 2 persons. Prevalence of TB decreased with ART initiation and follow-up. Those with TB coinfection had significantly poorer performance on grooved pegboard (P < .001) and fingertapping nondominant hand (P < .01). TB was associated with diffuse CNS disease (P < .05). Furthermore, those with TB had 9.27 times (P < .001) higher odds of reporting decreased quality of life, and had 8.02 times (P = .0005) higher odds of loss of productivity. CONCLUSIONS TB coinfection was associated with poorer neuropsychological functioning, particularly the fine motor skills, and had a substantial impact on functional ability and quality of life. CLINICAL TRIALS REGISTRATION NCT00096824.",2019,Those with TB coinfection had significantly poorer performance on grooved pegboard (P < .001) and fingertapping nondominant hand (P < .01).,"['860 participants at baseline were as follows: 53% female, 49% African; median age, 34 years; CD4 count, 173 cells/μL; and plasma HIV-1 RNA, 5.0 log copies/mL', 'human immunodeficiency virus type 1 (HIV-1)-infected participants in resource-limited settings treated with 3 World Health Organization-recommended antiretroviral (ART) regimens', 'Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings']",[],"['Prevalence of TB', 'quality of life', 'Neurological Dysfunction', 'central nervous system (CNS) TB', 'functional ability and quality of life']","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0027567', 'cui_str': 'African race'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Cell Counts'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0019704', 'cui_str': 'Human immunodeficiency virus type I'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0599685', 'cui_str': 'Antiretroviral-containing product'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0041296', 'cui_str': 'Tuberculosis'}, {'cui': 'C0275524', 'cui_str': 'Mixed infectious disease'}]",[],"[{'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0041296', 'cui_str': 'Tuberculosis'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}]",,0.404807,Those with TB coinfection had significantly poorer performance on grooved pegboard (P < .001) and fingertapping nondominant hand (P < .01).,"[{'ForeName': 'Kevin R', 'Initials': 'KR', 'LastName': 'Robertson', 'Affiliation': 'AIDS Neurological Center, Neurology, University of North Carolina, Chapel Hill.'}, {'ForeName': 'Bibilola', 'Initials': 'B', 'LastName': 'Oladeji', 'Affiliation': 'University of Ibadan, Nigeria.'}, {'ForeName': 'Hongyu', 'Initials': 'H', 'LastName': 'Jiang', 'Affiliation': 'Harvard T.H. Chan School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Johnstone', 'Initials': 'J', 'LastName': 'Kumwenda', 'Affiliation': 'Queen Elizabeth, Blantyre, Malawi.'}, {'ForeName': 'Khuanchai', 'Initials': 'K', 'LastName': 'Supparatpinyo', 'Affiliation': 'Chiang Mai University, Thailand.'}, {'ForeName': 'Thomas B', 'Initials': 'TB', 'LastName': 'Campbell', 'Affiliation': 'University of Colorado Health Sciences Center, Denver.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Hakim', 'Affiliation': 'University of Zimbabwe, Harare, Zimbabwe.'}, {'ForeName': 'Srikanth', 'Initials': 'S', 'LastName': 'Tripathy', 'Affiliation': 'National AIDS Research Institute, Pune, India.'}, {'ForeName': 'Mina C', 'Initials': 'MC', 'LastName': 'Hosseinipour', 'Affiliation': 'Lilongwe, Malawi.'}, {'ForeName': 'Christina M', 'Initials': 'CM', 'LastName': 'Marra', 'Affiliation': 'University of Washington, Seattle.'}, {'ForeName': 'Nagalingeswaran', 'Initials': 'N', 'LastName': 'Kumarasamy', 'Affiliation': 'Gaitonde Centre for AIDS Research and Education, Chennai, India.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Evans', 'Affiliation': 'Harvard T.H. Chan School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Alyssa', 'Initials': 'A', 'LastName': 'Vecchio', 'Affiliation': 'Vita-Salute San Raffaele University, Milan, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'La Rosa', 'Affiliation': 'Asociacion Civil Impacta Salud y Educacion,Lima, Peru.'}, {'ForeName': 'Breno', 'Initials': 'B', 'LastName': 'Santos', 'Affiliation': 'Hospital Conceicao, Porto Alegre Porto Alegre.'}, {'ForeName': 'Marcus T', 'Initials': 'MT', 'LastName': 'Silva', 'Affiliation': 'Fiocruz, Rio De Janeiro, Brazil.'}, {'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Montano', 'Affiliation': 'Asociacion Civil Impacta Salud y Educacion,Lima, Peru.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Kanyama', 'Affiliation': 'Lilongwe, Malawi.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Firnhaber', 'Affiliation': 'Johannesburg, South Africa.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Price', 'Affiliation': 'University of California San Francisco.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Marcus', 'Affiliation': 'AIDS Neurological Center, Neurology, University of North Carolina, Chapel Hill.'}, {'ForeName': 'Baida', 'Initials': 'B', 'LastName': 'Berzins', 'Affiliation': 'Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Reena', 'Initials': 'R', 'LastName': 'Masih', 'Affiliation': 'Social Scientific Systems, Silver Springs, Maryland.'}, {'ForeName': 'Umesh', 'Initials': 'U', 'LastName': 'Lalloo', 'Affiliation': 'Durban, South Africa.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Sanne', 'Affiliation': 'Johannesburg, South Africa.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Yosief', 'Affiliation': 'AIDS Neurological Center, Neurology, University of North Carolina, Chapel Hill.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Walawander', 'Affiliation': 'Frontier Science & Technology Research Foundation, Buffalo, New York.'}, {'ForeName': 'Aspara', 'Initials': 'A', 'LastName': 'Nair', 'Affiliation': 'Frontier Science & Technology Research Foundation, Buffalo, New York.'}, {'ForeName': 'Ned', 'Initials': 'N', 'LastName': 'Sacktor', 'Affiliation': 'Johns Hopkins University, Baltimore.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Hall', 'Affiliation': 'AIDS Neurological Center, Neurology, University of North Carolina, Chapel Hill.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciy718'] 2545,30329030,Maternal Measles Antibodies and Their Influence on All-cause Mortality Following Measles Vaccination: An Alternative to Measure Very Low Maternal Antibody Levels.,It was previously shown by hemagglutination inhibition that measles vaccination in the presence of maternal measles antibodies was associated with reduced all-cause mortality. We confirmed this serological association using a multiplexed immunoassay as a sensitive alternative and estimated a threshold concentration (28.7 mIU/mL) that correlates with lower all-cause mortality (P = .02).,2019,It was previously shown by hemagglutination inhibition that measles vaccination in the presence of maternal measles antibodies was associated with reduced all-cause mortality.,['Measles Vaccination'],[],[],"[{'cui': 'C0042196', 'cui_str': 'Vaccination'}]",[],[],,0.0218649,It was previously shown by hemagglutination inhibition that measles vaccination in the presence of maternal measles antibodies was associated with reduced all-cause mortality.,"[{'ForeName': 'Gaby', 'Initials': 'G', 'LastName': 'Smits', 'Affiliation': 'Centre for Immunology of Infectious Diseases and Vaccines, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Stabell Benn', 'Affiliation': 'Research Center for Vitamins and Vaccines, Bandim Health Project, Statens Serum Institut, Copenhagen.'}, {'ForeName': 'Hilton', 'Initials': 'H', 'LastName': 'Whittle', 'Affiliation': 'Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, United Kingdom.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'van Binnendijk', 'Affiliation': 'Centre for Immunology of Infectious Diseases and Vaccines, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Aaby', 'Affiliation': 'Projécto de Saúde Bandim, INDEPTH Network, Bissau, Guinea-Bissau.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'van der Klis', 'Affiliation': 'Centre for Immunology of Infectious Diseases and Vaccines, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciy900'] 2546,30374040,Evaluation of the Omron HEM-907 automated blood pressure device: comparison with office and ambulatory blood pressure readings.,"Blood pressure (BP) measured in the clinic is subject to the white coat effect and does not always indicate the 'usual' BP. Ambulatory BP is the current gold standard, but remains inconvenient for routine use. Interest in automated BP, where the healthcare professional is absent from the examination room during BP measurement, is growing, as this reduces the white coat effect and yields BP values that are close to ambulatory readings. The aim of this study was to investigate how well automated office BP (AOBP), measured using the Omron HEM-907 device, compares with observed office BP (OOBP, healthcare professional remains in the examination room) and awake ambulatory BP (AABP) measurements. OOBP, AOBP and AABP were measured in 108 participants, with OOBP and AOBP measurements repeated 1 week later, following a standardised protocol. Average BP readings for visit one were 134 ± 18/77 ± 11 for OOBP, 131 ± 16/75 ± 11 for AOBP, and 133 ± 15/82 ± 12 for AABP. On both visits, automated readings were significantly lower than observed readings for both systolic and diastolic BP (P < 0.001 for both). Automated readings were also significantly lower than ambulatory readings, with a mean difference in systolic/diastolic BP of - 2 ± 11/- 7 ± 10 (P < 0.001 for both), with high correlations between the two modalities (r = 0.75 and r = 0.64, for systolic and diastolic BP, respectively, P < 0.001 for both). AOBP measured by the Omron HEM-907 is not associated with a white coat effect, unlike observed readings, and provides reproducible results and good correlations with ambulatory readings. Automated BP measured using the Omron HEM-907 is, therefore, a useful alternative to observed office readings.",2019,"On both visits, automated readings were significantly lower than observed readings for both systolic and diastolic BP (P < 0.001 for both).",[],[],"['AOBP', 'systolic and diastolic BP', 'Blood pressure (BP', 'systolic/diastolic BP', 'automated office BP (AOBP', 'Average BP readings', 'awake ambulatory BP (AABP) measurements', 'OOBP, AOBP and AABP']",[],[],"[{'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C4301973', 'cui_str': 'Average blood pressure'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0234422', 'cui_str': 'Awake'}, {'cui': 'C0855316', 'cui_str': 'Blood pressure ambulatory'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",,0.0362904,"On both visits, automated readings were significantly lower than observed readings for both systolic and diastolic BP (P < 0.001 for both).","[{'ForeName': 'Lauren', 'Initials': 'L', 'LastName': ""D'Sa"", 'Affiliation': ""Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Box 98, Cambridge, CB2 0QQ, UK.""}, {'ForeName': 'Nipuna', 'Initials': 'N', 'LastName': 'Senaratne', 'Affiliation': ""Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Box 98, Cambridge, CB2 0QQ, UK.""}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Woodcock-Smith', 'Affiliation': ""Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Box 98, Cambridge, CB2 0QQ, UK.""}, {'ForeName': 'Karen M', 'Initials': 'KM', 'LastName': 'Miles', 'Affiliation': ""Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Box 98, Cambridge, CB2 0QQ, UK.""}, {'ForeName': 'Ian B', 'Initials': 'IB', 'LastName': 'Wilkinson', 'Affiliation': ""Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Box 98, Cambridge, CB2 0QQ, UK.""}, {'ForeName': 'Carmel M', 'Initials': 'CM', 'LastName': 'McEniery', 'Affiliation': ""Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Box 98, Cambridge, CB2 0QQ, UK. cmm41@cam.ac.uk.""}]",Hypertension research : official journal of the Japanese Society of Hypertension,['10.1038/s41440-018-0120-7'] 2547,30663168,Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.,This study evaluated 12-week retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus (HCV) infection who did not achieve sustained virologic response after previous treatment with a sofosbuvir- and velpatasvir-containing regimen. All 31 patients maintained a sustained virologic response 12 weeks after the last sofosbuvir/velpatasvir/voxilaprevir dose.,2019,All 31 patients maintained a sustained virologic response 12 weeks after the last sofosbuvir/velpatasvir/voxilaprevir dose.,"['patients with HCV', 'patients with chronic hepatitis C virus (HCV) infection who did not achieve sustained virologic response after previous treatment with a sofosbuvir- and velpatasvir-containing regimen']","['Sofosbuvir/Velpatasvir/Voxilaprevir', 'sofosbuvir/velpatasvir/voxilaprevir']",['sustained virologic response'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0079500', 'cui_str': 'Hepacivirus'}, {'cui': 'C0524910', 'cui_str': 'Chronic hepatitis C'}, {'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4271578', 'cui_str': 'sofosbuvir and velpatasvir'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]","[{'cui': 'C4518997', 'cui_str': 'sofosbuvir, velpatasvir and voxilaprevir'}]","[{'cui': 'C4050171', 'cui_str': 'Sustained Viral Suppression'}]",31.0,0.0144499,All 31 patients maintained a sustained virologic response 12 weeks after the last sofosbuvir/velpatasvir/voxilaprevir dose.,"[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Ruane', 'Affiliation': 'Ruane Medical and Liver Health Institute, Los Angeles, California.'}, {'ForeName': 'Simone I', 'Initials': 'SI', 'LastName': 'Strasser', 'Affiliation': 'AW Morrow Gastroenterology and Liver Centre, Sydney, NSW, Australia.'}, {'ForeName': 'Edward J', 'Initials': 'EJ', 'LastName': 'Gane', 'Affiliation': 'University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Robert H', 'Initials': 'RH', 'LastName': 'Hyland', 'Affiliation': 'Gilead Sciences Inc., Foster City, California.'}, {'ForeName': 'Jiang', 'Initials': 'J', 'LastName': 'Shao', 'Affiliation': 'Gilead Sciences Inc., Foster City, California.'}, {'ForeName': 'Hadas', 'Initials': 'H', 'LastName': 'Dvory-Sobol', 'Affiliation': 'Gilead Sciences Inc., Foster City, California.'}, {'ForeName': 'Tram', 'Initials': 'T', 'LastName': 'Tran', 'Affiliation': 'Gilead Sciences Inc., Foster City, California.'}, {'ForeName': 'Luisa M', 'Initials': 'LM', 'LastName': 'Stamm', 'Affiliation': 'Gilead Sciences Inc., Foster City, California.'}, {'ForeName': 'Diana M', 'Initials': 'DM', 'LastName': 'Brainard', 'Affiliation': 'Gilead Sciences Inc., Foster City, California.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Nyberg', 'Affiliation': 'Kaiser Permanente, San Diego, California.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Shafran', 'Affiliation': 'University of Alberta, Edmonton, AB, Canada.'}]",Journal of viral hepatitis,['10.1111/jvh.13067'] 2548,30729666,Serum semaphorin 7A is associated with the risk of acute atherothrombotic stroke.,"Semaphorin 7A (Sema7A), a neural guidance cue, was recently identified to regulate atherosclerosis in mice. However, the clinical relevance of Sema7A with atherosclerotic diseases remains unknown. The aim of this study was to investigate the association between serum Sema7A and the risk of acute atherothrombotic stroke (AAS). We measured serum concentrations of Sema7A in 105 newly onset AAS cases and 105 age- and sex-matched controls, showing that median Sema7A level in AAS cases was over three times of that in controls (5.86 vs 1.66 ng/mL). Adjusted for hypertension, body mass index, fasting blood glucose, total cholesterol, triglyceride, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, current smoking and alcohol consumption, multivariate logistic regression showed that higher Sema7A was independently associated with the odds of AAS (OR = 6.40, 95% CI: 2.88-14.25). Each 1-standard deviation increase in Sema7A was associated with a threefold higher odds of AAS (OR = 3.42, 95% CI: 1.84-6.35). Importantly, adding Sema7A to a multivariate logistic model containing conventional cardiovascular risk factors improved the area under receiver operating characteristic curves from 0.831 to 0.891 for the association with AAS. In conclusion, elevated serum Sema7A is independently associated with the risk of AAS, suggesting that it may play a potential role in AAS.",2019,"Importantly, adding Sema7A to a multivariate logistic model containing conventional cardiovascular risk factors improved the area under receiver operating characteristic curves from 0.831 to 0.891 for the association with AAS.",[],[],"['serum concentrations of Sema7A', 'hypertension, body mass index, fasting blood glucose, total cholesterol, triglyceride, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, current smoking and alcohol consumption']",[],[],"[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1136340', 'cui_str': 'Semaphorin'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}]",105.0,0.0335702,"Importantly, adding Sema7A to a multivariate logistic model containing conventional cardiovascular risk factors improved the area under receiver operating characteristic curves from 0.831 to 0.891 for the association with AAS.","[{'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'You', 'Affiliation': 'Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, China.'}, {'ForeName': 'Zhengbao', 'Initials': 'Z', 'LastName': 'Zhu', 'Affiliation': 'Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.'}, {'ForeName': 'Xiaowei', 'Initials': 'X', 'LastName': 'Zheng', 'Affiliation': 'Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.'}, {'ForeName': 'Nimei', 'Initials': 'N', 'LastName': 'Zeng', 'Affiliation': 'Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.'}, {'ForeName': 'Shuhong', 'Initials': 'S', 'LastName': 'Hu', 'Affiliation': 'Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, China.'}, {'ForeName': 'Yifei', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, China.'}, {'ForeName': 'Lijie', 'Initials': 'L', 'LastName': 'Ren', 'Affiliation': 'Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, China.'}, {'ForeName': 'Qiongyu', 'Initials': 'Q', 'LastName': 'Lu', 'Affiliation': 'Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, China.'}, {'ForeName': 'Chaojun', 'Initials': 'C', 'LastName': 'Tang', 'Affiliation': 'Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, China.'}, {'ForeName': 'Changgeng', 'Initials': 'C', 'LastName': 'Ruan', 'Affiliation': 'Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, China.'}, {'ForeName': 'Yonghong', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhu', 'Affiliation': 'Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, China.'}]",Journal of cellular and molecular medicine,['10.1111/jcmm.14186'] 2549,30856111,Comorbidity in Dementia Diseases and Associated Health Care Resources Utilization and Cost.,"BACKGROUND People with dementia (PwD) suffer from coexisting medical conditions, creating complex clinical challenges and increasing the risk of poor outcomes, which could be associated with high healthcare cost. OBJECTIVE To describe the prevalence of comorbidity in PwD and to analyze the association between comorbidity in dementia diseases and healthcare costs from a payer's perspective. METHODS This cross-sectional analysis was based on n = 362 PwD of the DelpHi-MV trial (Dementia: Life-and person-centered help in Mecklenburg-Western Pomerania). Comorbidity was assessed using the Charlson comorbidity index (CCI) and was categorized into low, high, and very high comorbidity. Healthcare resource utilization and unit costs were used to calculate costs. Multivariable regression models were applied to analyze the association between comorbidity and costs. RESULTS Comorbidity was highly prevalent in the sample. 47% of PwD had a very high, 37% a high, and 16% a low comorbidity in addition to dementia. The most prevalent co-existing comorbidity were diabetes mellitus (42%), peripheral vascular disease (28%) and cerebrovascular disease (25%). Total costs significantly increased by 528€ (SE = 214, CI95 = 109-947, p = 0.014) with each further comorbidity, especially due to higher cost for medication and medical aids. Compared with a low comorbidity, a very high comorbidity was significantly associated with 818€ (SE = 168, CI95 = 489-1147, p < 0.001) higher medication costs and 336€ (SE = 161, CI95 = 20-652, p = 0.037) higher cost for medical aids. There were no significant association between a higher comorbidity and cost for formal care services. CONCLUSIONS Comorbidity in PwD represents a substantial financial burden on healthcare payers and is a challenge for patients, healthcare providers, and the health systems. Innovative approaches are needed to achieve a patient-oriented management of treatment and care in comorbid PwD to reduce long-term costs.",2019,"Total costs significantly increased by 528€ (SE = 214, CI95 = 109-947, p = 0.014) with each further comorbidity, especially due to higher cost for medication and medical aids.","['n\u200a=\u200a362 PwD of the DelpHi-MV trial (Dementia: Life-and person-centered help in Mecklenburg-Western Pomerania', 'People with dementia (PwD']",[],"['peripheral vascular disease', 'medication costs', 'Total costs', 'cerebrovascular disease', 'Charlson comorbidity index (CCI']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}]",[],"[{'cui': 'C0085096', 'cui_str': 'Peripheral vascular disease'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0007820', 'cui_str': 'Cerebrovascular disease'}, {'cui': 'C4546361', 'cui_str': 'Charlson Comorbidity Index'}]",,0.0155118,"Total costs significantly increased by 528€ (SE = 214, CI95 = 109-947, p = 0.014) with each further comorbidity, especially due to higher cost for medication and medical aids.","[{'ForeName': 'Anika', 'Initials': 'A', 'LastName': 'Kaczynski', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE) site Rostock/Greifswald, Greifswald, Germany.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Michalowsky', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE) site Rostock/Greifswald, Greifswald, Germany.'}, {'ForeName': 'Tilly', 'Initials': 'T', 'LastName': 'Eichler', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE) site Rostock/Greifswald, Greifswald, Germany.'}, {'ForeName': 'Jochen René', 'Initials': 'JR', 'LastName': 'Thyrian', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE) site Rostock/Greifswald, Greifswald, Germany.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Wucherer', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE) site Rostock/Greifswald, Greifswald, Germany.'}, {'ForeName': 'Ina', 'Initials': 'I', 'LastName': 'Zwingmann', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE) site Rostock/Greifswald, Greifswald, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Hoffmann', 'Affiliation': 'German Center for Neurodegenerative Diseases (DZNE) site Rostock/Greifswald, Greifswald, Germany.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-180896'] 2550,31515083,Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.,"BACKGROUND There is no standardized assessment of symptomatic events in metastatic colorectal cancer (mCRC) despite disease symptoms that affect treatment decisions. Data from 3 first-line panitumumab in mCRC trials were retrospectively analyzed to assess whether early tumor shrinkage (ETS) and depth of response (DpR) were associated with time to occurrence of tumor-related symptoms. PATIENTS AND METHODS Patients with RAS wild-type mCRC from PRIME, PEAK, and Study 314 were included. ETS was defined as a reduction of ≥ 30% in the sum of the longest diameters of lesions at 8 weeks. DpR was calculated as maximum percentage change in tumor size from baseline to nadir. The proportion of patients who developed symptoms (including a composite symptomatic endpoint) during study treatment was calculated. This study was registered at ClinicalTrials.gov as PRIME (NCT00364013), PEAK (NCT00819780), and Study 314 (NCT00508404). RESULTS Overall, data of 659 patients were analyzed. Onset of symptoms was delayed in patients with ETS ≥ 30% versus ETS < 30% and in patients with greater DpR. In patients with symptoms at baseline who experienced ETS ≥ 30%, overall survival was similar to that seen for patients without symptoms at baseline. CONCLUSION Both ETS and DpR were associated with delayed onset of symptoms in RAS wild-type mCRC patients. Treatments with high cytoreductive potential may delay symptom development.",2019,Onset of symptoms was delayed in patients with ETS ≥ 30% versus ETS < 30% and in patients with greater DpR.,"['Patients with RAS wild-type mCRC from PRIME, PEAK, and Study 314 were included', 'RAS Wild-Type Metastatic Colorectal Cancer', 'metastatic colorectal cancer (mCRC', '659 patients were analyzed']",[],"['early tumor shrinkage (ETS) and depth of response (DpR', 'overall survival', 'Onset of symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0445392', 'cui_str': 'Wild'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0071973', 'cui_str': 'PRIME protocol'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}]",[],"[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0332513', 'cui_str': 'Shrinkage'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0332162', 'cui_str': 'Onset of'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",659.0,0.218892,Onset of symptoms was delayed in patients with ETS ≥ 30% versus ETS < 30% and in patients with greater DpR.,"[{'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Taieb', 'Affiliation': 'Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France. Electronic address: julien.taieb@aphp.fr.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Geissler', 'Affiliation': 'Klinikum Esslingen, Cancer Center Esslingen, Esslingen am Neckar, Germany.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Rivera', 'Affiliation': 'Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.'}, {'ForeName': 'Meinolf', 'Initials': 'M', 'LastName': 'Karthaus', 'Affiliation': 'Department of Hematology and Oncology, Klinikum München, Klinikum Neuperlach, Munich, Germany.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Wilson', 'Affiliation': ""Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Fotios', 'Initials': 'F', 'LastName': 'Loupakis', 'Affiliation': 'Veneto Institute of Oncology, Padova, Italy.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Price', 'Affiliation': 'Queen Elizabeth Hospital/University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Tracy', 'Affiliation': 'Biostatistics, Amgen Ltd, Uxbridge, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Burdon', 'Affiliation': 'European Medical, Amgen (Europe) GmbH, Rotkreuz, Switzerland.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Peeters', 'Affiliation': 'Department of Oncology, Antwerp University Hospital, Edegem, Belgium.'}]",Clinical colorectal cancer,['10.1016/j.clcc.2019.07.009'] 2551,30339635,Acute Lung Injury in Critically Ill Patients: Actin-Scavenger Gelsolin Signals Prolonged Respiratory Failure.,"BACKGROUND Gelsolin is an actin-scavenger controlling the tissue damage from actin in the blood. Gelsolin levels in circulation drops when tissue damage and corresponding actin release is pronounced due to catabolic conditions. The purpose of this study was to determine if low plasma gelsolin independently predicts a reduced chance of weaning from ventilator-demanding respiratory failure in critically ill patients within 28 days from admission. RESULTS This cohort study included 746 critically ill patients with ventilator-demanding respiratory failure from the randomized clinical trial, ""Procalcitonin And Survival Study (PASS)."" Primary end point was successful weaning from mechanical ventilation within 28 days. We used multivariable Cox regression adjusted for age, sepsis, PaO2/FiO2 ratio and other known and suspected predictors of persistent respiratory failure. Follow-up was complete.For medical patients, baseline-gelsolin below the 25th percentile independently predicted a 40% lower chance of successful weaning within 28 days (HR 0.60, 95% CI 0.46-0.79, P = 0.0002); among surgical patients this end point was not predicted. Low gelsolin levels predicted chance of being ""alive and out of intensive care at day 14"" for both medical and surgical patients (HR 0.69, 95% CI 0.54-0.89, P = 0.004). Gelsolin levels did not predict 28 day mortality for surgical or medical patients. CONCLUSIONS Low levels of serum gelsolin independently predict a decreased chance of successful weaning from ventilator within 28 days among medical intensive care patients. This finding has implications for identifying patients who need individualized intervention early in intensive care course to prevent unfavorable lung prognosis in acute respiratory failure. TRIAL REGISTRATION This is a substudy to the PASS, Clinicaltrials.gov ID: NCT00271752, first registered January 1, 2006.",2019,"CONCLUSIONS Low levels of serum gelsolin independently predict a decreased chance of successful weaning from ventilator within 28 days among medical intensive care patients.","['critically ill patients within 28 days from admission', 'Critically Ill Patients', 'medical intensive care patients', '746 critically ill patients with ventilator-demanding respiratory failure from the randomized clinical trial, ""Procalcitonin And Survival Study (PASS']",[],"['successful weaning from mechanical ventilation', 'Gelsolin levels']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0087153', 'cui_str': 'Ventilator'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}, {'cui': 'C0206034', 'cui_str': 'Trials, Randomized Clinical'}, {'cui': 'C0072027', 'cui_str': 'Procalcitonin'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],"[{'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0043084', 'cui_str': 'Weaning'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0061187', 'cui_str': 'Gelsolin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",746.0,0.220985,"CONCLUSIONS Low levels of serum gelsolin independently predict a decreased chance of successful weaning from ventilator within 28 days among medical intensive care patients.","[{'ForeName': 'Freja Stæhr', 'Initials': 'FS', 'LastName': 'Holm', 'Affiliation': 'Department of Internal Medicine, Herlev and Gentofte University Hospital, Hellerup, Denmark.'}, {'ForeName': 'Pradeesh', 'Initials': 'P', 'LastName': 'Sivapalan', 'Affiliation': 'Department of Internal Medicine, Herlev and Gentofte University Hospital, Hellerup, Denmark.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Seersholm', 'Affiliation': 'Department of Internal Medicine, Herlev and Gentofte University Hospital, Hellerup, Denmark.'}, {'ForeName': 'Theis Skovsgaard', 'Initials': 'TS', 'LastName': 'Itenov', 'Affiliation': 'Department of Infectious Diseases, University of Copenhagen, CHIP/PERSIMUNE, Rigshospitalet, Finsencentret, Copenhagen, Denmark.'}, {'ForeName': 'Per Hjort', 'Initials': 'PH', 'LastName': 'Christensen', 'Affiliation': 'Agilent Technologies Denmark Aps, Glostrup, Denmark.'}, {'ForeName': 'Jens-Ulrik Stæhr', 'Initials': 'JS', 'LastName': 'Jensen', 'Affiliation': 'Department of Internal Medicine, Herlev and Gentofte University Hospital, Hellerup, Denmark.'}]","Shock (Augusta, Ga.)",['10.1097/SHK.0000000000001279'] 2552,31556787,Effects of selective serotonin reuptake inhibitors on DNA damage in patients with depression.,"BACKGROUND The relationship between depression and increased oxidative stress is well known. DNA damage by oxidation factors is an important cause of the aging process in psychiatric disorders. AIMS Owing to the scarcity of human studies and high inconsistencies in studies of the effects of antidepressants on DNA damage, the current study was undertaken to investigate the effects of depression and its treatment on DNA damage. METHODS In a 15-week open-label study of citalopram ( n  = 25) and sertraline ( n  = 20), levels of DNA damage were measured by comet assay, proinflammatory (Interlukin-6 (IL-6)) and oxidative DNA damage (8-hydroxy-2'-deoxyguanosine (8-OHdG)) markers by ELISA, and gene expression of base excision repair enzymes (8-oxoguanine glycosylase (OGG1) and poly (ADP)-ribose polymerase-1 (PARP1)) by quantitative real-time polymerase chain reaction in healthy control patients ( n  = 14), with depression at the baseline and the same patients after week 15. RESULTS DNA damage, 8-OHdG, IL-6 and expression of PARP1 were elevated in patients with depression compared with the healthy controls ( p  < 0.001). Selective serotonin reuptake inhibitor (SSRI) therapy could significantly reduce the depression score ( p  < 0.01), DNA damage ( p  < 0.001), as well as 8-OHdG and IL-6 ( p  < 0.0001). Nevertheless, the expression of PARP1 and OGG1 showed no significant changes after treatment. CONCLUSIONS This is the first study on the effect of SSRIs on the DNA damage and some of the repair enzymes in depression. Based on the results, depression can cause increased DNA damage. This damage is followed by activation of compensatory mechanisms whereby the expression of DNA damage repair enzymes is elevated. Finally, the treatment of psychiatric disorder by antidepressants can lower the level of oxidative DNA damage.",2019,"RESULTS DNA damage, 8-OHdG, IL-6 and expression of PARP1 were elevated in patients with depression compared with the healthy controls ( p  < 0.001).","['patients with depression', 'healthy control patients ( n \u2009=\u200914), with depression at the baseline and the same patients after week 15']","['citalopram', 'Selective serotonin reuptake inhibitor (SSRI) therapy', 'sertraline', 'SSRIs', 'selective serotonin reuptake inhibitors']","['DNA damage, 8-OHdG, IL-6 and expression of PARP1', ""comet assay, proinflammatory (Interlukin-6 (IL-6)) and oxidative DNA damage (8-hydroxy-2'-deoxyguanosine (8-OHdG"", '8-OHdG and IL-6', 'markers by ELISA, and gene expression of base excision repair enzymes (8-oxoguanine glycosylase (OGG1) and poly (ADP)-ribose polymerase-1 (PARP1)) by quantitative real-time polymerase chain reaction', 'expression of PARP1 and OGG1', 'levels of DNA damage', 'depression score', 'DNA damage']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0008845', 'cui_str': 'Citalopram'}, {'cui': 'C0360105', 'cui_str': 'Selective serotonin re-uptake inhibitor'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0074393', 'cui_str': 'Sertraline'}]","[{'cui': 'C0012860', 'cui_str': 'DNA damage'}, {'cui': 'C0050078', 'cui_str': '8-hydroxy-deoxyguanosine'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C1567710', 'cui_str': 'PARP1 protein, human'}, {'cui': 'C0751980', 'cui_str': 'Gel Electrophoresis, Single-Cell'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C1158530', 'cui_str': 'Base Excision Repair'}, {'cui': 'C0014442', 'cui_str': 'Enzyme'}, {'cui': 'C0167195', 'cui_str': '8-oxoguanine'}, {'cui': 'C0035549', 'cui_str': 'Ribose'}, {'cui': 'C1709846', 'cui_str': 'Real-Time PCR'}, {'cui': 'C1313359', 'cui_str': 'oxoguanine glycosylase 1, human'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0501313,"RESULTS DNA damage, 8-OHdG, IL-6 and expression of PARP1 were elevated in patients with depression compared with the healthy controls ( p  < 0.001).","[{'ForeName': 'Mahnaz', 'Initials': 'M', 'LastName': 'Ahmadimanesh', 'Affiliation': 'Department of Pharmacodynamics and Toxicology, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Abbaszadegan', 'Affiliation': 'Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Dorsa', 'Initials': 'D', 'LastName': 'Morshedi Rad', 'Affiliation': 'Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Seyed Adel', 'Initials': 'SA', 'LastName': 'Moallem', 'Affiliation': 'Department of Pharmacodynamics and Toxicology, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Amir Hooshang', 'Initials': 'AH', 'LastName': 'Mohammadpour', 'Affiliation': 'Department of Clinical Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mohammad Hossein', 'Initials': 'MH', 'LastName': 'Ghahremani', 'Affiliation': 'Department of Toxicology-Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Farhad', 'Initials': 'F', 'LastName': 'Farid Hosseini', 'Affiliation': 'Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Behdani', 'Affiliation': 'Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Akhondpour Manteghi', 'Affiliation': 'Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Jowsey', 'Affiliation': 'National Institute for Health Research (NIHR), Health Protection Research Unit for Chemical and Radiation Threats and Hazards, Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Shabani Behbahani', 'Affiliation': 'Department of Pharmacodynamics and Toxicology, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Seyed Mohammad Hassan', 'Initials': 'SMH', 'LastName': 'Moallem', 'Affiliation': 'School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Etemad', 'Affiliation': 'Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881119874461'] 2553,31606265,Effects of Interleukin 17A Inhibition on Myocardial Deformation and Vascular Function in Psoriasis.,"BACKGROUND Interleukin (IL)-17A activity is implicated in psoriasis. We investigated the effects of IL-17A inhibition on vascular and left ventricular (LV) function in patients with psoriasis. METHODS A total of 150 patients with psoriasis received either an anti-IL-17A agent (secukinumab, n = 50), cyclosporine (n = 50), or methotrexate treatment (n = 50). At baseline and after 4 and 12 months of treatment, we measured (1) LV global longitudinal strain (GLS), GLS rate (GLSR), GLSR at early diastole, LV twisting, and untwisting; (2) coronary flow reserve (CFR); (3) pulse wave velocity (PWV); and (4) malondialdehyde and protein carbonyl as markers of oxidative stress. RESULTS Compared with cyclosporine and methotrexate, anti-IL-17A treatment resulted in a greater increase in GLS at 4 and 12 months after treatment (10% and 14% with anti-IL-17A vs 2% and 2% with cyclosporine vs 4% and 4% with methotrexate, respectively), GLSR, GLSR at early diastole (45% and 41% vs 5% and 4% vs 7% and 9%, respectively), and LV twisting (32% and 28% vs 6% and 8% vs 7% and 6%, respectively) (P < 0.05). Anti-IL-17A treatment resulted in greater improvement of CFR and PWV than cyclosporine or methotrexate (P < 0.05). PWV increased after cyclosporine treatment (+11% at 4 and +14% and 12 months) (P < 0.05). Markers of oxidative stress were reduced only after anti-IL-17A treatment (P < 0.05). Changes of myocardial deformation markers and CFR after anti-IL-17A treatment correlated with a concomitant reduction of oxidative stress. CONCLUSIONS In psoriasis, inhibition of IL-17A results in a greater improvement of vascular and myocardial function compared with cyclosporine or methotrexate treatment, indicating a beneficial effect on overall cardiovascular function.",2020,Anti-IL-17A treatment resulted in greater improvement of CFR and PWV than cyclosporine or methotrexate (P < 0.05).,"['150 patients with psoriasis', 'patients with psoriasis', 'Psoriasis']","['cyclosporine and methotrexate, anti-IL-17A', 'anti-IL-17A agent (secukinumab, n\xa0= 50), cyclosporine', 'Interleukin 17A Inhibition', 'IL-17A inhibition', 'methotrexate treatment', 'cyclosporine or methotrexate', 'cyclosporine']","['myocardial deformation markers and CFR', 'LV twisting', 'PWV', 'CFR and PWV', 'GLSR, GLSR at early diastole', 'Myocardial Deformation and Vascular Function', 'vascular and myocardial function', 'overall cardiovascular function', 'LV global longitudinal strain (GLS), GLS rate (GLSR), GLSR at early diastole, LV twisting, and untwisting; (2) coronary flow reserve (CFR); (3) pulse wave velocity (PWV); and (4) malondialdehyde and protein carbonyl as markers of oxidative stress', 'GLS', 'vascular and left ventricular (LV) function', 'Markers of oxidative stress']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}]","[{'cui': 'C0010592', 'cui_str': 'Cyclosporine'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C1701790', 'cui_str': 'IL17A protein, human'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C3179547', 'cui_str': 'secukinumab'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C0017767', 'cui_str': 'Glucosinolate'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0007227', 'cui_str': 'Cardiovascular function'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}]",150.0,0.0966276,Anti-IL-17A treatment resulted in greater improvement of CFR and PWV than cyclosporine or methotrexate (P < 0.05).,"[{'ForeName': 'George', 'Initials': 'G', 'LastName': 'Makavos', 'Affiliation': 'Second Department of Cardiology, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece.'}, {'ForeName': 'Ignatios', 'Initials': 'I', 'LastName': 'Ikonomidis', 'Affiliation': 'Second Department of Cardiology, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece. Electronic address: ignoik@gmail.com.'}, {'ForeName': 'Ioanna', 'Initials': 'I', 'LastName': 'Andreadou', 'Affiliation': 'Department of Pharmaceutical Chemistry, National and Kapodistrian University of Athens School of Pharmacy, Athens, Greece.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Varoudi', 'Affiliation': 'Second Department of Cardiology, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece.'}, {'ForeName': 'Irini', 'Initials': 'I', 'LastName': 'Kapniari', 'Affiliation': 'Second Department of Dermatology and Venereology, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece.'}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Loukeri', 'Affiliation': 'Department of Pharmaceutical Chemistry, National and Kapodistrian University of Athens School of Pharmacy, Athens, Greece.'}, {'ForeName': 'Kostas', 'Initials': 'K', 'LastName': 'Theodoropoulos', 'Affiliation': 'Second Department of Dermatology and Venereology, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Pavlidis', 'Affiliation': 'Second Department of Cardiology, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Triantafyllidi', 'Affiliation': 'Second Department of Cardiology, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Thymis', 'Affiliation': 'Second Department of Cardiology, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Parissis', 'Affiliation': 'Second Department of Cardiology, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Tsoumani', 'Affiliation': 'Department of Pharmaceutical Chemistry, National and Kapodistrian University of Athens School of Pharmacy, Athens, Greece.'}, {'ForeName': 'Pinelopi', 'Initials': 'P', 'LastName': 'Rafouli-Stergiou', 'Affiliation': 'Second Department of Cardiology, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece.'}, {'ForeName': 'Pelagia', 'Initials': 'P', 'LastName': 'Katsimbri', 'Affiliation': 'Rheumatology and Clinical Immunology Unit, Fourth Department of Internal Medicine, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece.'}, {'ForeName': 'Evangelia', 'Initials': 'E', 'LastName': 'Papadavid', 'Affiliation': 'Second Department of Dermatology and Venereology, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece.'}]",The Canadian journal of cardiology,['10.1016/j.cjca.2019.06.021'] 2554,31880804,Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.,"Acute myeloid leukemia (AML) is a highly heterogeneous disease both in terms of genetic background and response to chemotherapy. Although molecular aberrations are routinely used to stratify AML patients into prognostic subgroups when receiving standard chemotherapy, the predictive value of the genetic background and co-occurring mutations remains to be assessed when using newly approved antileukemic drugs. In the present study, we retrospectively addressed the question of the predictive value of molecular events on the benefit of the addition of gemtuzumab ozogamicin (GO) to standard front-line chemotherapy. Using the more recent European LeukemiaNet (ELN) 2017 risk classification, we confirmed that the benefit of GO was restricted to the favorable (hazard ratio [HR], 0.54, 95% confidence interval [CI], 0.30-0.98) and intermediate (HR, 0.57; 95% CI, 0.33-1.00) risk categories, whereas it did not influence the outcome of patients within the adverse risk subgroup (HR, 0.93; 95% CI, 0.61-1.43). Interestingly, the benefit of GO was significant for patients with activating signaling mutations (HR, 0.43; 95% CI, 0.28-0.65), which correlated with higher CD33 expression levels. These results suggest that molecular aberrations could be critical for future differentially tailored treatments based on integrated genetic profiles that are able to predict the benefit of GO on outcome.",2020,"Interestingly, the benefit of GO was significant for patients with activating signaling mutations (HR, 0.43; 95% CI, 0.28-0.65), which correlated with higher CD33 expression levels.","['Acute myeloid leukemia (AML', 'acute myeloid leukemia']","['gemtuzumab ozogamicin (GO) to standard front-line chemotherapy', 'gemtuzumab ozogamicin']","['CD33 expression levels', 'benefit of GO']","[{'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}]","[{'cui': 'C0876099', 'cui_str': 'Mylotarg'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0054952', 'cui_str': 'Lymphocyte antigen CD33'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0876099', 'cui_str': 'Mylotarg'}]",,0.0990933,"Interestingly, the benefit of GO was significant for patients with activating signaling mutations (HR, 0.43; 95% CI, 0.28-0.65), which correlated with higher CD33 expression levels.","[{'ForeName': 'Elise', 'Initials': 'E', 'LastName': 'Fournier', 'Affiliation': 'Laboratory of Hematology, Centre Hospitalo-Universitaire de Lille, INSERM Unité Mixte de Recherche en Santé (UMR-S) 1172, Lille University, Lille, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Duployez', 'Affiliation': 'Laboratory of Hematology, Centre Hospitalo-Universitaire de Lille, INSERM Unité Mixte de Recherche en Santé (UMR-S) 1172, Lille University, Lille, France.'}, {'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Ducourneau', 'Affiliation': 'Laboratory of Hematology, Centre Hospitalo-Universitaire de Lille, INSERM Unité Mixte de Recherche en Santé (UMR-S) 1172, Lille University, Lille, France.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Raffoux', 'Affiliation': 'Department of Hematology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Institut de Recherche Saint-Louis, Université de Paris, Paris, France.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Turlure', 'Affiliation': 'Department of Hematology, Centre Hospitalo-Universitaire de Limoges, Limoges University, Limoges, France.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Caillot', 'Affiliation': 'Department of Hematology, Centre Hospitalo-Universitaire de Dijon, Dijon, France.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Thomas', 'Affiliation': 'Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Marceau-Renaut', 'Affiliation': 'Laboratory of Hematology, Centre Hospitalo-Universitaire de Lille, INSERM Unité Mixte de Recherche en Santé (UMR-S) 1172, Lille University, Lille, France.'}, {'ForeName': 'Sylvain', 'Initials': 'S', 'LastName': 'Chantepie', 'Affiliation': 'Department of Hematology, Centre Hospitalo-Universitaire de Caen, Caen, France.'}, {'ForeName': 'Jean-Valère', 'Initials': 'JV', 'LastName': 'Malfuson', 'Affiliation': ""Department of Hematology, Hôpital d'Instruction des Armées Percy, Clamart, France.""}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Lemasle', 'Affiliation': 'Henri-Becquerel Cancer Center, Rouen, France.'}, {'ForeName': 'Meyling', 'Initials': 'M', 'LastName': 'Cheok', 'Affiliation': 'Laboratory of Hematology, Centre Hospitalo-Universitaire de Lille, INSERM Unité Mixte de Recherche en Santé (UMR-S) 1172, Lille University, Lille, France.'}, {'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Celli-Lebras', 'Affiliation': 'Department of Hematology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Institut de Recherche Saint-Louis, Université de Paris, Paris, France.'}, {'ForeName': 'Estelle', 'Initials': 'E', 'LastName': 'Guerin', 'Affiliation': 'Laboratory of Hematology, Centre Hospitalo-Universitaire de Limoges, INSERM UMR-S 7276, Limoges University, Limoges, France.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Terré', 'Affiliation': 'Department of Medical Genetics, Centre Hospitalier de Versailles, Le Chesnay, France.'}, {'ForeName': 'Juliette', 'Initials': 'J', 'LastName': 'Lambert', 'Affiliation': 'Department of Hematology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Institut de Recherche Saint-Louis, Université de Paris, Paris, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Pautas', 'Affiliation': 'Department of Hematology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France; and.'}, {'ForeName': 'Hervé', 'Initials': 'H', 'LastName': 'Dombret', 'Affiliation': 'Department of Hematology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Institut de Recherche Saint-Louis, Université de Paris, Paris, France.'}, {'ForeName': 'Sylvie', 'Initials': 'S', 'LastName': 'Castaigne', 'Affiliation': 'Department of Hematology, Centre Hospitalier de Versailles, Le Chesnay, France.'}, {'ForeName': 'Claude', 'Initials': 'C', 'LastName': 'Preudhomme', 'Affiliation': 'Laboratory of Hematology, Centre Hospitalo-Universitaire de Lille, INSERM Unité Mixte de Recherche en Santé (UMR-S) 1172, Lille University, Lille, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Boissel', 'Affiliation': 'Department of Hematology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Institut de Recherche Saint-Louis, Université de Paris, Paris, France.'}]",Blood,['10.1182/blood.2019003471'] 2555,32057125,Sleep Deprivation Affects Tau Phosphorylation in Human Cerebrospinal Fluid.,"Tau hyperphosphorylation is an early step in tau-mediated neurodegeneration and is associated with intracellular aggregation of tau as neurofibrillary tangles, neuronal and synaptic loss, and eventual cognitive dysfunction in Alzheimer disease. Sleep loss increases the cerebrospinal fluid concentration of amyloid-β and tau. Using mass spectrometry, we measured tau and phosphorylated tau concentrations in serial samples of cerebrospinal fluid collected from participants who were sleep-deprived, treated with sodium oxybate, or allowed to sleep normally. We found that sleep loss affected phosphorylated tau differently depending on the modified site. These findings suggest a mechanism for sleep loss to increase risk of Alzheimer disease. ANN NEUROL 2020;87:700-709.",2020,Sleep loss increases the cerebrospinal fluid concentration of amyloid-β and tau.,['Human Cerebrospinal Fluid'],"['sodium oxybate', 'Tau hyperphosphorylation']",[],"[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}]","[{'cui': 'C0037537', 'cui_str': 'Sodium Oxybate'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}]",[],,0.0858229,Sleep loss increases the cerebrospinal fluid concentration of amyloid-β and tau.,"[{'ForeName': 'Nicolas R', 'Initials': 'NR', 'LastName': 'Barthélemy', 'Affiliation': 'Department of Neurology, Washington University School of Medicine, St Louis, MO.'}, {'ForeName': 'Haiyan', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Department of Neurology, Washington University School of Medicine, St Louis, MO.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Lu', 'Affiliation': 'Department of Neurology, Washington University School of Medicine, St Louis, MO.'}, {'ForeName': 'Paul T', 'Initials': 'PT', 'LastName': 'Kotzbauer', 'Affiliation': 'Department of Neurology, Washington University School of Medicine, St Louis, MO.'}, {'ForeName': 'Randall J', 'Initials': 'RJ', 'LastName': 'Bateman', 'Affiliation': 'Department of Neurology, Washington University School of Medicine, St Louis, MO.'}, {'ForeName': 'Brendan P', 'Initials': 'BP', 'LastName': 'Lucey', 'Affiliation': 'Department of Neurology, Washington University School of Medicine, St Louis, MO.'}]",Annals of neurology,['10.1002/ana.25702'] 2556,30379749,"Incidence, Patient Characteristics, Mode of Drug Delivery, and Outcomes of Septic Shock Patients Treated With Vasopressors in the Arise Trial.","INTRODUCTION To describe the utilization of vasopressors (VP) in patients enrolled in the Australasian Resuscitation In Sepsis Evaluation (ARISE) trial, and to explore the association between time to VP and 90-day mortality. METHODS The primary exposure variable was VP use after arrival in the emergency department (ED). Vasoactive agents considered as VP included: norepinephrine, epinephrine, metaraminol, or vasopressin. Time-to-event analysis, multivariable logistic regression, and propensity-matched treatment effects modeling were used to assess the association between time to VP and 90-day mortality. RESULTS In total 1,102 of 1,588 patients (69%) in ARISE received VP at any point. The median [interquartile range (IQR)] time from ED presentation to commencing VP was 4.4 [2.7, 7.1] h, and 38% did so prior to central venous access. The median [IQR] volume of intravenous (i.v.) fluid administered prior to commencing VP was 3.1 [2.3, 4.3] L. Increasing age and volume of i.v. fluid therapy were associated with a lower likelihood of commencing VP early (within 4 h of ED presentation), while greater illness severity was associated with a higher likelihood, P < 0.001, respectively. In those who subsequently died within 90 days, the sub-hazard ratio (95% confidence interval) for commencing VP was 1.4 (1.20, 1.68), P < 0.001, adjusted for age, acute physiology and chronic health evaluation II score, study group, inclusion criteria, plasma lactate, i.v. fluid prior to VP, study institution, and site of infection. DISCUSSION 50% of the ARISE cohort commenced VP within 4.4 h of ED presentation, and many did so prior to central venous access. Earlier initiation of VP was associated with greater crude and adjusted 90-day mortality.",2019,"fluid therapy were associated with a lower likelihood of commencing VP early (within 4 h of ED presentation), while greater illness severity was associated with a higher likelihood, P < 0.001, respectively.",['patients enrolled in the Australasian Resuscitation'],[],"['Incidence, Patient Characteristics, Mode of Drug Delivery, and Outcomes', 'median [IQR] volume', 'median [interquartile range (IQR)] time from ED presentation to commencing VP', 'illness severity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035273', 'cui_str': 'Resuscitation'}]",[],"[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}, {'cui': 'C0042397', 'cui_str': 'Vasoconstrictor agent'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",1588.0,0.0477168,"fluid therapy were associated with a lower likelihood of commencing VP early (within 4 h of ED presentation), while greater illness severity was associated with a higher likelihood, P < 0.001, respectively.","[{'ForeName': 'Andrew A', 'Initials': 'AA', 'LastName': 'Udy', 'Affiliation': 'Department of Intensive Care and Hyperbaric Medicine, The Alfred, Melbourne, Victoria 3004, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Finnis', 'Affiliation': 'Intensive Care Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.'}, {'ForeName': 'Daryl', 'Initials': 'D', 'LastName': 'Jones', 'Affiliation': 'Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Delaney', 'Affiliation': 'Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Macdonald', 'Affiliation': 'Centre for Clinical Research in Emergency Medicine, Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia.'}, {'ForeName': 'Rinaldo', 'Initials': 'R', 'LastName': 'Bellomo', 'Affiliation': 'Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Peake', 'Affiliation': 'Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Shock (Augusta, Ga.)",['10.1097/SHK.0000000000001281'] 2557,30239421,Late Peaks of HMGB1 and Sepsis Outcome: Evidence For Synergy With Chronic Inflammatory Disorders.,"High mobility group box 1 (HMGB1) is released from macrophages as a late biomarker of sepsis. Conditions associated with pre-existing macrophage activation may modify HMGB1 expression. This study aimed to assess the impact of HMGB1 kinetics on 28-day mortality. In a sub-study of a previous randomized clinical trial among patients with systemic inflammatory response syndrome and gram-negative infections, patients were classified in early and late HMGB1 peak groups. Serial measurements of HMGB1, ferritin and interferon-gamma (IFNγ) were performed in all available sera. Two hundred ten patients were included; 118 (46.5%) had at least one inflammatory disease (diabetes, chronic obstructive pulmonary disease, chronic heart failure, or chronic renal disease). Mortality after 28 days was higher among patients with a late peak of HMGB1 (OR 2.640; P = 0.026). Co-existence of late peak and inflammatory disease synergistically impacted mortality (odds ratio of logistic regression analysis 3.17; P: 0.027). Late peak was concomitantly associated with higher values of ferritin (P = 0.035), and IFNγ (P = 0.002) among patients with hyperferritinemia. It is concluded that late HMGB1 peak was associated with worse prognosis, especially in patients with underlying chronic inflammatory conditions.",2019,Mortality after 28 days was higher among patients with a late peak of HMGB1 (OR 2.640; P = 0.026).,"['patients with underlying chronic inflammatory conditions', 'patients with systemic inflammatory response syndrome and gram-negative infections, patients were classified in early and late HMGB1 peak groups', 'Two hundred ten patients were included; 118 (46.5%) had at least one inflammatory disease (diabetes, chronic obstructive pulmonary disease, chronic heart failure, or chronic renal disease']",['High mobility group box 1 (HMGB1'],"['HMGB1, ferritin and interferon-gamma (IFNγ', '28-day mortality', 'IFNγ', 'Mortality', 'Late peak']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0242966', 'cui_str': 'Systemic inflammatory response syndrome'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0019796', 'cui_str': 'HMG-1 Protein'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C1290884', 'cui_str': 'Inflammatory disorder'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}]","[{'cui': 'C0019796', 'cui_str': 'HMG-1 Protein'}]","[{'cui': 'C0019796', 'cui_str': 'HMG-1 Protein'}, {'cui': 'C0015879', 'cui_str': 'Ferritin'}, {'cui': 'C0021745', 'cui_str': 'Interferon Type II'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0444505', 'cui_str': 'Peak'}]",210.0,0.0996019,Mortality after 28 days was higher among patients with a late peak of HMGB1 (OR 2.640; P = 0.026).,"[{'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Karakike', 'Affiliation': '4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.'}, {'ForeName': 'Maria-Evangelia', 'Initials': 'ME', 'LastName': 'Adami', 'Affiliation': '4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.'}, {'ForeName': 'Malvina', 'Initials': 'M', 'LastName': 'Lada', 'Affiliation': '2nd Department of Internal Medicine, Sismanogleion General Hospital, Athens, Greece.'}, {'ForeName': 'Theologia', 'Initials': 'T', 'LastName': 'Gkavogianni', 'Affiliation': '4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.'}, {'ForeName': 'Ioannis M', 'Initials': 'IM', 'LastName': 'Koutelidakis', 'Affiliation': '2nd Department of Surgery, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Bauer', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Center for Sepsis Control and Care, Jena University Hospital, Germany.'}, {'ForeName': 'Evangelos J', 'Initials': 'EJ', 'LastName': 'Giamarellos-Bourboulis', 'Affiliation': '4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.'}, {'ForeName': 'Iraklis', 'Initials': 'I', 'LastName': 'Tsangaris', 'Affiliation': '2nd Department of Critical Care Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.'}]","Shock (Augusta, Ga.)",['10.1097/SHK.0000000000001265'] 2558,32702259,Re: Home-Based 'Exergaming' Was Safe and Significantly Improved 6-Min Walking Distance in Patients with Prostate Cancer: A Single-Blinded Randomised Controlled Trial.,,2020,,['Patients with Prostate Cancer'],[],['6-Min Walking Distance'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}]",[],"[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0012751', 'cui_str': 'Distance'}]",,0.10883,,"[{'ForeName': 'Tomas L', 'Initials': 'TL', 'LastName': 'Griebling', 'Affiliation': ''}]",The Journal of urology,['10.1097/JU.0000000000001207.03'] 2559,32702276,"EFFECTS OF ELASTIC TAPE ON THORACOABDOMINAL MECHANICS, DYSPNEA, EXERCISE CAPACITY AND PHYSICAL ACTIVITY LEVEL IN NON-OBESE MALE SUBJECTS WITH COPD.","Subjects with severe and very severe chronic obstructive pulmonary disease(COPD) present thoracoabdominal asynchrony(TAA) that reduces ventilatory efficiency and exercise capacity. However, no therapeutic intervention has focused on reducing TAA. The purpose of this study was to evaluate the effects of elastic tape(ET) on thoracoabdominal mechanics, dyspnea symptoms, exercise capacity, and physical activity level in non-obese male subjects with severe to very severe COPD. Methods: This crossover, randomized trial included non-obese males with severe to very severe COPD. ET was placed on the chest wall and abdomen to reduce TAA. Subjects were evaluated at 3 hospital visits, each seven days apart. At visit 1, thoracoabdominal kinematic and pulmonary ventilation were evaluated simultaneously by optoelectronic plethysmography and electrical impedance tomography, both at rest and during isoload exercise testing. At visit 2, a cardiopulmonary exercise test(CPET,10W/min) was performed until exhaustion. Between the visits, subjects used physical activity monitor(PAM) for 7 days (at least 5 days of measurement; 10h/day). At visit 3, all the tests were repeated in the opposite order of the previous randomization. Results: During the isoload exercise, subjects with ET presented lower tidal and minute volumes(p=0.01) and reduced TAA(p=0.02) and dyspnea(p=0.04). During the CPET, subjects with ET presented an increase in VO 2 peak(l/min and ml/kg/min;p=0.01), test duration(p=0.009) and maximal load(p=0.03). Moderate and vigorous physical activity(MVPA), which was assessed by the PAM, was also increased in subjects with ET(p=0.01). ET reduced TAA and dyspnea and increased exercise capacity and the duration of MVPA in non-obese male subjects with severe to very severe COPD.",2020,"During the isoload exercise, subjects with ET presented lower tidal and minute volumes(p=0.01) and reduced TAA(p=0.02) and dyspnea(p=0.04).","['non-obese male subjects with severe to very severe COPD', 'non-obese males with severe to very severe COPD', 'Subjects with severe and very severe chronic obstructive pulmonary disease(COPD']","['elastic tape(ET', 'thoracoabdominal asynchrony(TAA', 'thoracoabdominal kinematic and pulmonary ventilation were evaluated simultaneously by optoelectronic plethysmography and electrical impedance tomography, both at rest and during isoload exercise testing']","['Moderate and vigorous physical activity(MVPA', 'TAA and dyspnea and increased exercise capacity and the duration of MVPA', 'thoracoabdominal mechanics, dyspnea symptoms, exercise capacity, and physical activity level']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C3641272', 'cui_str': 'Very severe'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0600260', 'cui_str': 'Obstructive airways disorder'}]","[{'cui': 'C0221839', 'cui_str': 'Orthodontic band, elastic'}, {'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0444467', 'cui_str': 'Thoracoabdominal'}, {'cui': 'C0600169', 'cui_str': 'Kinematics'}, {'cui': 'C0035213', 'cui_str': 'Ventilation, Pulmonary'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0032221', 'cui_str': 'Plethysmography'}, {'cui': 'C0162537', 'cui_str': 'Impedance'}, {'cui': 'C0040395', 'cui_str': 'Diagnostic tomography'}, {'cui': 'C0443144', 'cui_str': 'At rest'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0444467', 'cui_str': 'Thoracoabdominal'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0376706', 'cui_str': 'Mechanics'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0363452,"During the isoload exercise, subjects with ET presented lower tidal and minute volumes(p=0.01) and reduced TAA(p=0.02) and dyspnea(p=0.04).","[{'ForeName': 'Thiago', 'Initials': 'T', 'LastName': 'Fernandes Pinto', 'Affiliation': 'University of São Paulo.'}, {'ForeName': 'Rafaella', 'Initials': 'R', 'LastName': 'Fagundes Xavier', 'Affiliation': 'University of São Paulo.'}, {'ForeName': 'Adriana Claudia', 'Initials': 'AC', 'LastName': 'Lunardi', 'Affiliation': 'Department of Physical Therapy, School of Medicine, University of Sao Paulo, Brazil.'}, {'ForeName': 'Cibele C B', 'Initials': 'CCB', 'LastName': 'Marques da Silva', 'Affiliation': 'Department of Physical Therapy, School of Medicine, University of Sao Paulo, Brazil.'}, {'ForeName': 'Henrique Takachi', 'Initials': 'HT', 'LastName': 'Moriya', 'Affiliation': 'Telecommunication and Control Engineering, University of Sao Paulo, Brazil.'}, {'ForeName': 'Renato', 'Initials': 'R', 'LastName': 'Lima Vitorasso', 'Affiliation': 'University of São Paulo.'}, {'ForeName': 'Vinicius', 'Initials': 'V', 'LastName': 'Torsani', 'Affiliation': 'University of São Paulo.'}, {'ForeName': 'Marcelo B P', 'Initials': 'MBP', 'LastName': 'Amato', 'Affiliation': 'University of São Paulo.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Stelmach', 'Affiliation': 'Pulmonary Division, Heart Institue (InCor), School of Medicine, University of Sao Paulo, Brazil.'}, {'ForeName': 'João Marcos', 'Initials': 'JM', 'LastName': 'Salge', 'Affiliation': 'University of São Paulo.'}, {'ForeName': 'Regina Maria Carvalho', 'Initials': 'RMC', 'LastName': 'Pinto', 'Affiliation': 'Pulmonary Division, Heart Institute (InCor), University of Sao Paulo, Brazil.'}, {'ForeName': 'Celso R F', 'Initials': 'CRF', 'LastName': 'Carvalho', 'Affiliation': 'School of Medicine, University of São Paulo.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00690.2019'] 2560,32702299,"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.","BACKGROUND This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study. METHODS This randomised, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine was done in a single centre in Wuhan, China. Healthy adults aged 18 years or older, who were HIV-negative and previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-free, were eligible to participate and were randomly assigned to receive the vaccine at a dose of 1 × 10 11 viral particles per mL or 5 × 10 10 viral particles per mL, or placebo. Investigators allocated participants at a ratio of 2:1:1 to receive a single injection intramuscularly in the arm. The randomisation list (block size 4) was generated by an independent statistician. Participants, investigators, and staff undertaking laboratory analyses were masked to group allocation. The primary endpoints for immunogenicity were the geometric mean titres (GMTs) of specific ELISA antibody responses to the receptor binding domain (RBD) and neutralising antibody responses at day 28. The primary endpoint for safety evaluation was the incidence of adverse reactions within 14 days. All recruited participants who received at least one dose were included in the primary and safety analyses. This study is registered with ClinicalTrials.gov, NCT04341389. FINDINGS 603 volunteers were recruited and screened for eligibility between April 11 and 16, 2020. 508 eligible participants (50% male; mean age 39·7 years, SD 12·5) consented to participate in the trial and were randomly assigned to receive the vaccine (1 × 10 11 viral particles n=253; 5 × 10 10 viral particles n=129) or placebo (n=126). In the 1 × 10 11 and 5 × 10 10 viral particles dose groups, the RBD-specific ELISA antibodies peaked at 656·5 (95% CI 575·2-749·2) and 571·0 (467·6-697·3), with seroconversion rates at 96% (95% CI 93-98) and 97% (92-99), respectively, at day 28. Both doses of the vaccine induced significant neutralising antibody responses to live SARS-CoV-2, with GMTs of 19·5 (95% CI 16·8-22·7) and 18·3 (14·4-23·3) in participants receiving 1 × 10 11 and 5 × 10 10 viral particles, respectively. Specific interferon γ enzyme-linked immunospot assay responses post vaccination were observed in 227 (90%, 95% CI 85-93) of 253 and 113 (88%, 81-92) of 129 participants in the 1 × 10 11 and 5 × 10 10 viral particles dose groups, respectively. Solicited adverse reactions were reported by 183 (72%) of 253 and 96 (74%) of 129 participants in the 1 × 10 11 and 5 × 10 10 viral particles dose groups, respectively. Severe adverse reactions were reported by 24 (9%) participants in the 1 × 10 11 viral particles dose group and one (1%) participant in the 5 × 10 10 viral particles dose group. No serious adverse reactions were documented. INTERPRETATION The Ad5-vectored COVID-19 vaccine at 5 × 10 10 viral particles is safe, and induced significant immune responses in the majority of recipients after a single immunisation. FUNDING National Key R&D Programme of China, National Science and Technology Major Project, and CanSino Biologics.",2020,"Both doses of the vaccine induced significant neutralising antibody responses to live SARS-CoV-2, with GMTs of 19·5 (95% CI 16·8-22·7) and 18·3 (14·4-23·3) in participants receiving 1 × 10 11 and 5 × 10 10 viral particles, respectively.","['single centre in Wuhan, China', 'healthy adults aged 18 years or older', '508 eligible participants (50% male; mean age 39·7 years, SD 12·5) consented to participate in the trial', 'Healthy adults aged 18 years or older, who were HIV-negative and previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-free, were eligible to participate', '603 volunteers were recruited and screened for eligibility between April 11 and 16, 2020', 'All recruited participants who received at least one dose were included in the primary and safety analyses']","['recombinant adenovirus type-5-vectored', 'vaccine at a dose of 1\u2008×\u200810 11 viral particles per mL or 5\u2008×\u200810 10 viral particles per mL, or placebo', 'Ad5-vectored COVID-19 vaccine', 'vaccine', 'COVID-19 vaccine', 'placebo']","['serious adverse reactions', 'Specific interferon γ enzyme-linked immunospot assay responses post vaccination', 'Severe adverse reactions', 'seroconversion rates', 'incidence of adverse reactions', 'geometric mean titres (GMTs) of specific ELISA antibody responses to the receptor binding domain (RBD) and neutralising antibody responses', 'Solicited adverse reactions', 'Immunogenicity and safety', 'RBD-specific ELISA antibodies']","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0481430', 'cui_str': 'HIV negative'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0001483', 'cui_str': 'Adenoviridae'}, {'cui': 'C0457499', 'cui_str': 'Type 5'}, {'cui': 'C0012656', 'cui_str': 'Infectious Disease Vectors'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0042760', 'cui_str': 'Virion'}, {'cui': 'C0439526', 'cui_str': '/mL'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}]","[{'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0920508', 'cui_str': 'Enzyme linked immunospot assay'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0003261', 'cui_str': 'Antibody Production'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0332297', 'cui_str': 'Bounded by'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0475463', 'cui_str': 'Neutralizing antibody'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1522002', 'cui_str': 'RRM Motif'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}]",508.0,0.652323,"Both doses of the vaccine induced significant neutralising antibody responses to live SARS-CoV-2, with GMTs of 19·5 (95% CI 16·8-22·7) and 18·3 (14·4-23·3) in participants receiving 1 × 10 11 and 5 × 10 10 viral particles, respectively.","[{'ForeName': 'Feng-Cai', 'Initials': 'FC', 'LastName': 'Zhu', 'Affiliation': 'NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China. Electronic address: jszfc@vip.sina.com.'}, {'ForeName': 'Xu-Hua', 'Initials': 'XH', 'LastName': 'Guan', 'Affiliation': 'Hubei Provincial Center for Diseases Control and Prevention, Wuhan, China.'}, {'ForeName': 'Yu-Hua', 'Initials': 'YH', 'LastName': 'Li', 'Affiliation': 'National Institute for Food and Drug Control, Dongcheng, Beijing, China.'}, {'ForeName': 'Jian-Ying', 'Initials': 'JY', 'LastName': 'Huang', 'Affiliation': 'Clinical Trial Center, Zhongnan Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Jiang', 'Affiliation': 'Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China.'}, {'ForeName': 'Li-Hua', 'Initials': 'LH', 'LastName': 'Hou', 'Affiliation': 'Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.'}, {'ForeName': 'Jing-Xin', 'Initials': 'JX', 'LastName': 'Li', 'Affiliation': 'NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.'}, {'ForeName': 'Bei-Fang', 'Initials': 'BF', 'LastName': 'Yang', 'Affiliation': 'Hubei Provincial Center for Diseases Control and Prevention, Wuhan, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'National Institute for Food and Drug Control, Dongcheng, Beijing, China.'}, {'ForeName': 'Wen-Juan', 'Initials': 'WJ', 'LastName': 'Wang', 'Affiliation': 'NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.'}, {'ForeName': 'Shi-Po', 'Initials': 'SP', 'LastName': 'Wu', 'Affiliation': 'Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.'}, {'ForeName': 'Zhao', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Hubei Provincial Center for Diseases Control and Prevention, Wuhan, China.'}, {'ForeName': 'Xiao-Hong', 'Initials': 'XH', 'LastName': 'Wu', 'Affiliation': 'National Institute for Food and Drug Control, Dongcheng, Beijing, China.'}, {'ForeName': 'Jun-Jie', 'Initials': 'JJ', 'LastName': 'Xu', 'Affiliation': 'Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.'}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.'}, {'ForeName': 'Si-Yue', 'Initials': 'SY', 'LastName': 'Jia', 'Affiliation': 'NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.'}, {'ForeName': 'Bu-Sen', 'Initials': 'BS', 'LastName': 'Wang', 'Affiliation': 'Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China.'}, {'ForeName': 'Jing-Jing', 'Initials': 'JJ', 'LastName': 'Liu', 'Affiliation': 'National Institute for Food and Drug Control, Dongcheng, Beijing, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.'}, {'ForeName': 'Xiao-Ai', 'Initials': 'XA', 'LastName': 'Qian', 'Affiliation': 'Hubei Provincial Center for Diseases Control and Prevention, Wuhan, China.'}, {'ForeName': 'Qiong', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Hubei Provincial Center for Diseases Control and Prevention, Wuhan, China.'}, {'ForeName': 'Hong-Xing', 'Initials': 'HX', 'LastName': 'Pan', 'Affiliation': 'NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.'}, {'ForeName': 'Hu-Dachuan', 'Initials': 'HD', 'LastName': 'Jiang', 'Affiliation': 'NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Deng', 'Affiliation': 'Hubei Provincial Center for Diseases Control and Prevention, Wuhan, China.'}, {'ForeName': 'Jin-Bo', 'Initials': 'JB', 'LastName': 'Gou', 'Affiliation': 'CanSino Biologics, Tianjin, China.'}, {'ForeName': 'Xue-Wen', 'Initials': 'XW', 'LastName': 'Wang', 'Affiliation': 'Shanghai Canming Medical Technology, Shanghai, China.'}, {'ForeName': 'Xing-Huan', 'Initials': 'XH', 'LastName': 'Wang', 'Affiliation': 'Clinical Trial Center, Zhongnan Hospital of Wuhan University, Wuhan, China. Electronic address: wangxinghuan@whu.edu.cn.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': 'Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China. Electronic address: cw0226@foxmail.com.'}]","Lancet (London, England)",['10.1016/S0140-6736(20)31605-6'] 2561,30877053,Hoarding Symptoms in Children and Adolescents With Obsessive-Compulsive Disorder: Clinical Features and Response to Cognitive-Behavioral Therapy.,"OBJECTIVE Although adult hoarding disorder is relatively common and often debilitating, few studies have examined the phenomenology of pediatric hoarding. We examined the clinical phenomenology and response to cognitive-behavioral therapy (CBT) treatment in youths with a diagnosis of obsessive-compulsive disorder (OCD) with and without hoarding symptoms. Age was tested as a moderator across analyses, given prior findings that the impact of hoarding symptoms may not become apparent until adolescence. METHOD Youths (N = 215; aged 7-17 years) with OCD pursuing evaluation and/or treatment at a university-based specialty clinic participated in the current study. Presence of hoarding symptoms was assessed as part of a larger battery. Data from a subset of youths (n = 134) who received CBT were included in treatment response analyses. RESULTS Youths with hoarding symptoms did not differ from those without hoarding symptoms with respect to overall OCD symptom severity and impairment. Youths with hoarding met criteria for more concurrent diagnoses, including greater rates of internalizing and both internalizing/externalizing, but not externalizing-only, disorders. Youths with and without hoarding symptoms did not significantly differ in rate of response to CBT. Age did not moderate any of these relationships, suggesting that the presence of hoarding symptoms was not associated with greater impairments across the clinical presentation of OCD or its response to treatment by age. CONCLUSION We found no evidence that hoarding is associated with greater OCD severity or poorer treatment response in affected youth. Theoretical and clinical implications of these findings, including future directions for research on testing developmental models of hoarding across the lifespan, are discussed.",2019,"RESULTS Youths with hoarding symptoms did not differ from those without hoarding symptoms with respect to overall OCD symptom severity and impairment.","['Children and Adolescents With Obsessive-Compulsive Disorder', 'Youths (N\xa0= 215; aged 7-17 years) with OCD pursuing evaluation and/or treatment at a university-based specialty clinic participated in the current study', 'youths with a diagnosis of obsessive-compulsive disorder (OCD) with and without hoarding symptoms', 'Data from a subset of youths (n\xa0= 134) who received']","['CBT', 'cognitive-behavioral therapy (CBT']","['OCD severity', 'overall OCD symptom severity and impairment', 'rate of response to CBT']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C4709308', 'cui_str': '215'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0037778', 'cui_str': 'Medical specialty'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0424337', 'cui_str': 'Hoarding'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4517565', 'cui_str': '134'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]",215.0,0.0266047,"RESULTS Youths with hoarding symptoms did not differ from those without hoarding symptoms with respect to overall OCD symptom severity and impairment.","[{'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Rozenman', 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA; University of Denver, CO. Electronic address: mrozenman@mednet.ucla.edu.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'McGuire', 'Affiliation': 'Johns Hopkins University, Baltimore, MD.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Ricketts', 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA.'}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Peris', 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': ""O'Neill"", 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA.'}, {'ForeName': 'R Lindsey', 'Initials': 'RL', 'LastName': 'Bergman', 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA.'}, {'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Chang', 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Piacentini', 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA.'}]",Journal of the American Academy of Child and Adolescent Psychiatry,['10.1016/j.jaac.2019.01.017'] 2562,32702298,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.","BACKGROUND The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2. METHODS We did a phase 1/2, single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control. Healthy adults aged 18-55 years with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 at a dose of 5 × 10 10 viral particles or MenACWY as a single intramuscular injection. A protocol amendment in two of the five sites allowed prophylactic paracetamol to be administered before vaccination. Ten participants assigned to a non-randomised, unblinded ChAdOx1 nCoV-19 prime-boost group received a two-dose schedule, with the booster vaccine administered 28 days after the first dose. Humoral responses at baseline and following vaccination were assessed using a standardised total IgG ELISA against trimeric SARS-CoV-2 spike protein, a muliplexed immunoassay, three live SARS-CoV-2 neutralisation assays (a 50% plaque reduction neutralisation assay [PRNT 50 ]; a microneutralisation assay [MNA 50 , MNA 80 , and MNA 90 ]; and Marburg VN), and a pseudovirus neutralisation assay. Cellular responses were assessed using an ex-vivo interferon-γ enzyme-linked immunospot assay. The co-primary outcomes are to assess efficacy, as measured by cases of symptomatic virologically confirmed COVID-19, and safety, as measured by the occurrence of serious adverse events. Analyses were done by group allocation in participants who received the vaccine. Safety was assessed over 28 days after vaccination. Here, we report the preliminary findings on safety, reactogenicity, and cellular and humoral immune responses. The study is ongoing, and was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606. FINDINGS Between April 23 and May 21, 2020, 1077 participants were enrolled and assigned to receive either ChAdOx1 nCoV-19 (n=543) or MenACWY (n=534), ten of whom were enrolled in the non-randomised ChAdOx1 nCoV-19 prime-boost group. Local and systemic reactions were more common in the ChAdOx1 nCoV-19 group and many were reduced by use of prophylactic paracetamol, including pain, feeling feverish, chills, muscle ache, headache, and malaise (all p<0·05). There were no serious adverse events related to ChAdOx1 nCoV-19. In the ChAdOx1 nCoV-19 group, spike-specific T-cell responses peaked on day 14 (median 856 spot-forming cells per million peripheral blood mononuclear cells, IQR 493-1802; n=43). Anti-spike IgG responses rose by day 28 (median 157 ELISA units [EU], 96-317; n=127), and were boosted following a second dose (639 EU, 360-792; n=10). Neutralising antibody responses against SARS-CoV-2 were detected in 32 (91%) of 35 participants after a single dose when measured in MNA 80 and in 35 (100%) participants when measured in PRNT 50 . After a booster dose, all participants had neutralising activity (nine of nine in MNA 80 at day 42 and ten of ten in Marburg VN on day 56). Neutralising antibody responses correlated strongly with antibody levels measured by ELISA (R 2 =0·67 by Marburg VN; p<0·001). INTERPRETATION ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses. These results, together with the induction of both humoral and cellular immune responses, support large-scale evaluation of this candidate vaccine in an ongoing phase 3 programme. FUNDING UK Research and Innovation, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research (NIHR), NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and the German Center for Infection Research (DZIF), Partner site Gießen-Marburg-Langen.",2020,Neutralising antibody responses against SARS-CoV-2 were detected in 32 (91%) of 35 participants after a single dose when measured in MNA 80 and in 35 (100%) participants when measured in PRNT 50 .,"['n=543) or MenACWY (n=534), ten of whom were enrolled in the non-randomised', 'Between April 23 and May 21, 2020, 1077 participants were enrolled and assigned to receive either', 'Healthy adults aged 18-55 years with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms']","['ChAdOx1 nCoV-19 at a dose of 5', 'ChAdOx1 nCoV-19 vaccine against SARS-CoV-2', 'vaccine', 'ChAdOx1 nCoV-19 prime-boost group', 'chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine (MenACWY', 'ChAdOx1 nCoV-19']","['pain, feeling feverish, chills, muscle ache, headache, and malaise (all p<0·05', 'Safety', 'Safety and immunogenicity', 'spike-specific T-cell responses', 'Neutralising antibody responses', 'antibody responses', 'safety, reactogenicity, and cellular and humoral immune responses', 'Humoral responses', 'safety, reactogenicity, and immunogenicity', 'Local and systemic reactions', 'Neutralising antibody responses against SARS-CoV-2', 'neutralising activity', 'symptomatic virologically confirmed COVID-19, and safety, as measured by the occurrence of serious adverse events']","[{'cui': 'C2003457', 'cui_str': 'MenACWY'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332122', 'cui_str': 'No history of'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0071973', 'cui_str': 'PRIME protocol'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008111', 'cui_str': 'Pan troglodytes'}, {'cui': 'C0001483', 'cui_str': 'Adenoviridae'}, {'cui': 'C0012656', 'cui_str': 'Infectious Disease Vectors'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1660580', 'cui_str': 'Meningococcal conjugate vaccine'}, {'cui': 'C2003457', 'cui_str': 'MenACWY'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0687681', 'cui_str': 'Feeling feverish'}, {'cui': 'C0085593', 'cui_str': 'Chill'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0231218', 'cui_str': 'Malaise'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0475463', 'cui_str': 'Neutralizing antibody'}, {'cui': 'C0003261', 'cui_str': 'Antibody Production'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0020967', 'cui_str': 'Humoral Immunity'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",1077.0,0.295654,Neutralising antibody responses against SARS-CoV-2 were detected in 32 (91%) of 35 participants after a single dose when measured in MNA 80 and in 35 (100%) participants when measured in PRNT 50 .,"[{'ForeName': 'Pedro M', 'Initials': 'PM', 'LastName': 'Folegatti', 'Affiliation': 'The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Katie J', 'Initials': 'KJ', 'LastName': 'Ewer', 'Affiliation': 'The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Parvinder K', 'Initials': 'PK', 'LastName': 'Aley', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Angus', 'Affiliation': 'Nuffield Department of Medicine, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Becker', 'Affiliation': 'Institute of Virology, Philipps University of Marburg, Marburg, Germany.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Belij-Rammerstorfer', 'Affiliation': 'The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Duncan', 'Initials': 'D', 'LastName': 'Bellamy', 'Affiliation': 'The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Sagida', 'Initials': 'S', 'LastName': 'Bibi', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Mustapha', 'Initials': 'M', 'LastName': 'Bittaye', 'Affiliation': 'The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Clutterbuck', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Dold', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Saul N', 'Initials': 'SN', 'LastName': 'Faust', 'Affiliation': 'NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Finn', 'Affiliation': 'School of Population Health Sciences, University of Bristol, Bristol, UK.'}, {'ForeName': 'Amy L', 'Initials': 'AL', 'LastName': 'Flaxman', 'Affiliation': 'The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Bassam', 'Initials': 'B', 'LastName': 'Hallis', 'Affiliation': 'National Infection Service, Public Health England, Salisbury, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Heath', 'Affiliation': ""Vaccine Institute, St George's University, London, UK.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Jenkin', 'Affiliation': 'The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Rajeka', 'Initials': 'R', 'LastName': 'Lazarus', 'Affiliation': 'Department of Microbiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Makinson', 'Affiliation': 'The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Angela M', 'Initials': 'AM', 'LastName': 'Minassian', 'Affiliation': 'The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Katrina M', 'Initials': 'KM', 'LastName': 'Pollock', 'Affiliation': 'NIHR Imperial Clinical Research Facility, Imperial College London, London, UK.'}, {'ForeName': 'Maheshi', 'Initials': 'M', 'LastName': 'Ramasamy', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Robinson', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Snape', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Tarrant', 'Affiliation': 'Clinical Biomanufacturing Facility, University of Oxford, Oxford, UK.'}, {'ForeName': 'Merryn', 'Initials': 'M', 'LastName': 'Voysey', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Green', 'Affiliation': 'Clinical Biomanufacturing Facility, University of Oxford, Oxford, UK.'}, {'ForeName': 'Alexander D', 'Initials': 'AD', 'LastName': 'Douglas', 'Affiliation': 'The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Adrian V S', 'Initials': 'AVS', 'LastName': 'Hill', 'Affiliation': 'The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Lambe', 'Affiliation': 'The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Sarah C', 'Initials': 'SC', 'LastName': 'Gilbert', 'Affiliation': 'The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Pollard', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: andrew.pollard@paediatrics.ox.ac.uk.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(20)31604-4'] 2563,32702309,"Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.","BACKGROUND Outcomes for children and adults with advanced soft tissue sarcoma are poor with traditional therapy. We investigated whether the addition of pazopanib to preoperative chemoradiotherapy would improve pathological near complete response rate compared with chemoradiotherapy alone. METHODS In this joint Children's Oncology Group and NRG Oncology multicentre, randomised, open-label, phase 2 trial, we enrolled eligible adults (aged ≥18 years) and children (aged between 2 and <18 years) from 57 hospitals in the USA and Canada with unresected, newly diagnosed trunk or extremity chemotherapy-sensitive soft tissue sarcoma, which were larger than 5 cm in diameter and of intermediate or high grade. Eligible patients had Lansky (if aged ≤16 years) or Karnofsky (if aged >16 years) performance status score of at least 70. Patients received ifosfamide (2·5 g/m 2 per dose intravenously on days 1-3 with mesna) and doxorubicin (37·5 mg/m 2 per dose intravenously on days 1-2) with 45 Gy preoperative radiotherapy, followed by surgical resection at week 13. Patients were randomly assigned (1:1) using a web-based system, in an unmasked manner, to receive oral pazopanib (if patients <18 years 350 mg/m 2 once daily; if patients ≥18 years 600 mg once daily) or not (control group), with pazopanib not given immediately before or after surgery at week 13. The study projected 100 randomly assigned patients were needed to show an improvement in the number of participants with a 90% or higher pathological response at week 13 from 40% to 60%. Analysis was done per protocol. This study has completed accrual and is registered with ClinicalTrials.gov, NCT02180867. FINDINGS Between July 7, 2014, and Oct 1, 2018, 81 eligible patients were enrolled and randomly assigned to the pazopanib group (n=42) or the control group (n=39). At the planned second interim analysis with 42 evaluable patients and a median follow-up of 0·8 years (IQR 0·3-1·6) in the pazopanib group and 1 year (0·3-1·6) in the control group, the number of patients with a 90% pathological response or higher was 14 (58%) of 24 patients in the pazopanib group and four (22%) of 18 patients in the control group, with a between-group difference in the number of 90% or higher pathological response of 36·1% (83·8% CI 16·5-55·8). On the basis of an interim analysis significance level of 0·081 (overall one-sided significance level of 0·20, power of 0·80, and O'Brien-Fleming-type cumulative error spending function), the 83·8% CI for response difference was between 16·5% and 55·8% and thus excluded 0. The improvement in pathological response rate with the addition of pazopanib crossed the predetermined boundary and enrolment was stopped. The most common grade 3-4 adverse events were leukopenia (16 [43%] of 37 patients), neutropenia (15 [41%]), and febrile neutropenia (15 [41%]) in the pazopanib group, and neutropenia (three [9%] of 35 patients) and febrile neutropenia (three [9%]) in the control group. 22 (59%) of 37 patients in the pazopanib group had a pazopanib-related serious adverse event. Paediatric and adult patients had a similar number of grade 3 and 4 toxicity. There were seven deaths (three in the pazopanib group and four in the control group), none of which were treatment related. INTERPRETATION In this presumed first prospective trial of soft tissue sarcoma spanning nearly the entire age spectrum, adding pazopanib to neoadjuvant chemoradiotherapy improved the rate of pathological near complete response, suggesting that this is a highly active and feasible combination in children and adults with advanced soft tissue sarcoma. The comparison of survival outcomes requires longer follow-up. FUNDING National Institutes of Health, St Baldrick's Foundation, Seattle Children's Foundation.",2020,"The most common grade 3-4 adverse events were leukopenia (16 [43%] of 37 patients), neutropenia (15 [41%]), and febrile neutropenia (15 [41%]) in the pazopanib group, and neutropenia (three [9%] of 35 patients) and febrile neutropenia (three [9%]) in the control group.","['Between July 7, 2014, and Oct 1, 2018, 81 eligible patients', 'Eligible patients had Lansky (if aged ≤16 years) or Karnofsky (if aged >16 years) performance status score of at least 70', 'children and adults with advanced soft tissue sarcoma', 'enrolled eligible adults (aged ≥18 years) and children (aged between 2 and <18 years) from 57 hospitals in the USA and Canada with unresected, newly diagnosed trunk or extremity chemotherapy-sensitive soft tissue sarcoma, which were larger than 5 cm in diameter and of intermediate or high grade', 'group (n=42) or the control group (n=39', 'children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving']","['pazopanib', 'pazopanib to neoadjuvant chemoradiotherapy', 'doxorubicin (37·5 mg/m 2 per dose intravenously on days 1-2) with 45 Gy preoperative radiotherapy', 'ifosfamide', 'pazopanib to preoperative chemoradiotherapy', 'oral pazopanib', 'preoperative chemoradiotherapy with or without pazopanib (ARST1321']","['pazopanib-related serious adverse event', 'febrile neutropenia', 'neutropenia', 'grade 3 and 4 toxicity', 'Pathological response', 'pathological response rate', 'pathological response', 'leukopenia']","[{'cui': 'C1442824', 'cui_str': 'POU2F1 protein, human'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0206065', 'cui_str': 'Karnofsky performance status'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1261473', 'cui_str': 'Sarcoma'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0441800', 'cui_str': 'Grade'}]","[{'cui': 'C1831796', 'cui_str': 'pazopanib'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0020823', 'cui_str': 'Ifosfamide'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C1831796', 'cui_str': 'pazopanib'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0746883', 'cui_str': 'Febrile neutropenia'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}]",100.0,0.19607,"The most common grade 3-4 adverse events were leukopenia (16 [43%] of 37 patients), neutropenia (15 [41%]), and febrile neutropenia (15 [41%]) in the pazopanib group, and neutropenia (three [9%] of 35 patients) and febrile neutropenia (three [9%]) in the control group.","[{'ForeName': 'Aaron R', 'Initials': 'AR', 'LastName': 'Weiss', 'Affiliation': 'Department of Pediatrics, Maine Medical Center, Portland, ME, USA. Electronic address: weissa2@mmc.org.'}, {'ForeName': 'Yen-Lin', 'Initials': 'YL', 'LastName': 'Chen', 'Affiliation': 'Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Scharschmidt', 'Affiliation': ""Department of Orthopaedics, James Cancer Hospital and Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Yueh-Yun', 'Initials': 'YY', 'LastName': 'Chi', 'Affiliation': 'Department of Pediatrics and Preventative Medicine, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Tian', 'Affiliation': 'Department of Biostatistics, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Jennifer O', 'Initials': 'JO', 'LastName': 'Black', 'Affiliation': ""Department of Pathology, Children's Hospital Colorado, Aurora, CO, USA.""}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Davis', 'Affiliation': 'Department of Pathology, Oregon Health & Science University, Portland, OR, USA.'}, {'ForeName': 'Julie C', 'Initials': 'JC', 'LastName': 'Fanburg-Smith', 'Affiliation': ""Department of Pathology, Penn State Children's Hospital, Hershey, PA, USA.""}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Zambrano', 'Affiliation': 'Department of Pathology, Rocky Mountain Hospital for Children, Presbyterian St Luke Medical Centre, Denver, CO, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Anderson', 'Affiliation': 'Department of Biostatistics and Research Decision Sciences, Merck and Co, North Wales, PA, USA.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Arens', 'Affiliation': ""Department of Clinical Trials, Connecticut Children's Medical Center, Hartford, CT, USA.""}, {'ForeName': 'Odion', 'Initials': 'O', 'LastName': 'Binitie', 'Affiliation': 'Department of Sarcoma, Moffitt Cancer Center, Tampa, FL, USA.'}, {'ForeName': 'Edwin', 'Initials': 'E', 'LastName': 'Choy', 'Affiliation': 'Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Justin W', 'Initials': 'JW', 'LastName': 'Davis', 'Affiliation': ""Children's Oncology Group, Monrovia, CA, USA.""}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Hayes-Jordan', 'Affiliation': 'Department of Surgery, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.'}, {'ForeName': 'Simon C', 'Initials': 'SC', 'LastName': 'Kao', 'Affiliation': 'Department of Radiology, University of Iowa Carver College of Medicine, Iowa City, IA, USA.'}, {'ForeName': 'Mark L', 'Initials': 'ML', 'LastName': 'Kayton', 'Affiliation': ""Department of Surgery, Palm Beach Children's Hospital, St Mary's Medical Center, Florida Atlantic University, West Palm Beach, FL, USA.""}, {'ForeName': 'Sandy', 'Initials': 'S', 'LastName': 'Kessel', 'Affiliation': 'Imaging and Radiation Oncology Core Rhode Island, Lincoln, RI, USA.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Lim', 'Affiliation': 'Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'William H', 'Initials': 'WH', 'LastName': 'Meyer', 'Affiliation': 'Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Million', 'Affiliation': 'Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, CA, USA.'}, {'ForeName': 'Scott H', 'Initials': 'SH', 'LastName': 'Okuno', 'Affiliation': 'Department of Oncology, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Ostrenga', 'Affiliation': 'Department of Pharmacy, University of Mississippi Medical Center, Jackson, MS, USA.'}, {'ForeName': 'Marguerite T', 'Initials': 'MT', 'LastName': 'Parisi', 'Affiliation': ""Department of Radiology and Pediatrics, University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, USA.""}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Pryma', 'Affiliation': 'Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'R Lor', 'Initials': 'RL', 'LastName': 'Randall', 'Affiliation': 'Department of Orthopaedic Surgery, University of California Davis, Sacramento, CA, USA.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Rosen', 'Affiliation': 'Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Schlapkohl', 'Affiliation': 'Department of Pediatrics, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.'}, {'ForeName': 'Barry L', 'Initials': 'BL', 'LastName': 'Shulkin', 'Affiliation': ""Department of Diagnostic Imaging, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Ethan A', 'Initials': 'EA', 'LastName': 'Smith', 'Affiliation': ""Department of Radiology and Medical Imaging, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Joel I', 'Initials': 'JI', 'LastName': 'Sorger', 'Affiliation': ""Department of Orthopaedic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Terezakis', 'Affiliation': 'Department of Radiation Oncology, University of Minnesota, Masonic Cancer Center, Minneapolis, MN, USA.'}, {'ForeName': 'Douglas S', 'Initials': 'DS', 'LastName': 'Hawkins', 'Affiliation': ""Department of Pediatrics, University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, USA.""}, {'ForeName': 'Sheri L', 'Initials': 'SL', 'LastName': 'Spunt', 'Affiliation': 'Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA.'}, {'ForeName': 'Dian', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA.'}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30325-9'] 2564,32702315,"Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.","BACKGROUND Peanut allergy is the leading cause of food-related anaphylaxis. Current management options can negatively affect food allergy-related quality of life. We aimed to investigate the efficacy of an investigational oral biologic drug (AR101). METHODS The AR101 Trial in Europe Measuring Oral Immunotherapy Success in peanut-allergic children (ARTEMIS) trial was a multicentre, double-blind, randomised, placebo-controlled phase 3 trial done at 18 hospitals in Ireland, France, Germany, Italy, Spain, Sweden, and the UK. Children and adolescents with peanut allergy, aged 4-17 years, who developed dose-limiting symptoms to 300 mg or less peanut protein (equivalent to approximately one peanut kernel) during a double-blind placebo-controlled food challenge test at study entry were enrolled. Participants were randomly assigned (3:1) to receive daily doses of either AR101 oral immunotherapy (AR101 group) or a taste-masked placebo (placebo group). All participants, investigators, and care providers were masked to treatment allocation until the study was completed. Doses were increased every 2 weeks over 6 months until a dose of 300 mg was reached and maintained for 3 months. The primary endpoint was the proportion of participants in the intention-to-treat or safety population (defined as those participants who had been randomly assigned and had received at least one dose of the assigned drug) who could consume a single dose of 1000 mg (cumulative dose 2043 mg) peanut protein without developing dose-limiting allergic symptoms at an exit double-blind placebo-controlled food challenge after 9 months of treatment. Additional endpoints included safety (ie, the frequency and severity of adverse events) and changes in food allergy-related quality of life, assessed by use of age-appropriate Food Allergy Quality of Life Questionnaires (FAQLQs) and the Food Allergy Independent Measure (FAIM). The study is registered with ClinicalTrials.gov, NCT03201003, and is completed. FINDINGS Between June 12, 2017, and Feb 15, 2018, 227 patients were screened, of whom 175 were randomly assigned to the AR101 group (n=132) and the placebo group (n=43). All primary and secondary endpoints were met. 77 (58%) of 132 participants in the AR101 group tolerated 1000 mg peanut protein at the exit food challenge versus one (2%) of 43 participants in the placebo group (AR101-placebo treatment difference 56·0% [95% CI 44·1-65·2], p<0·0001). Adverse events were reported by almost all participants. The maximum severity of adverse events reported was mild or moderate for most participants who received AR101 (mild, 66 [50%] of 132 participants; moderate, 63 [48%]; and severe, one [1%]) or placebo (mild, 24 [56%] of 43 participants; moderate, 18 [42%]; severe, none). Participants aged 8-12 years in the AR101 group reported improvements that exceeded the minimum clinically important difference between the two groups across all FAQLQ domains. Additionally, participants in the AR101 group and their caregivers reported improvements that exceeded the minimum clinically important difference in FAIM domains related to the perceived likelihood and outcomes of a severe allergic reaction. INTERPRETATION AR101 oral immunotherapy treatment led to rapid desensitisation to peanut protein, with a predictable safety profile that improved with treatment, and an associated improvement in self-reported and caregiver-reported food allergy-related quality of life. These patient-oriented outcomes provide invaluable data to help physicians, patients, and caregivers make informed, shared decisions on the management of peanut allergy. FUNDING Aimmune Therapeutics.",2020,Participants aged 8-12 years in the AR101 group reported improvements that exceeded the minimum clinically important difference between the two groups across all FAQLQ domains.,"['European children with a peanut allergy (ARTEMIS', 'peanut-allergic children', 'Between June 12, 2017, and Feb 15, 2018, 227 patients were screened, of whom 175 were randomly assigned to the AR101 group (n=132) and the', 'Children and adolescents with peanut allergy, aged 4-17 years, who developed dose-limiting symptoms to 300 mg or less peanut protein (equivalent to approximately one peanut kernel) during a double-blind placebo-controlled food challenge test at study entry were enrolled', '18 hospitals in Ireland, France, Germany, Italy, Spain, Sweden, and the UK']","['AR101 oral immunotherapy (AR101 group) or a taste-masked placebo (placebo', 'investigational oral biologic drug (AR101', 'could consume a single dose of 1000 mg (cumulative dose 2043 mg) peanut protein without developing dose-limiting allergic symptoms at an exit double-blind placebo', 'oral immunotherapy with AR101', 'placebo']","['maximum severity of adverse events', 'proportion of participants in the intention-to-treat or safety population', 'Adverse events', 'safety (ie, the frequency and severity of adverse events) and changes in food allergy-related quality of life, assessed by use of age-appropriate Food Allergy Quality of Life Questionnaires', 'Efficacy and safety', 'severe allergic reaction', 'FAIM domains', 'FAQLQs) and the Food Allergy Independent Measure (FAIM']","[{'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0559470', 'cui_str': 'Allergy to peanut'}, {'cui': 'C0030736', 'cui_str': 'Arachis hypogaea'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022067', 'cui_str': 'Republic of Ireland'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0039336', 'cui_str': 'Finding of sense of taste'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4553887', 'cui_str': 'Biologics'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0030736', 'cui_str': 'Arachis hypogaea'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0337094', 'cui_str': 'Exit'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0016470', 'cui_str': 'Allergy to food'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]",227.0,0.78594,Participants aged 8-12 years in the AR101 group reported improvements that exceeded the minimum clinically important difference between the two groups across all FAQLQ domains.,"[{'ForeName': ""Jonathan O'B"", 'Initials': 'JO', 'LastName': 'Hourihane', 'Affiliation': 'Paediatrics and Child Health, Royal College of Surgeons in Ireland, Dublin, Ireland; Paediatrics and Child Health, INFANT Centre and HRB Clinical Research Facility, University College Cork, Cork, Ireland.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Beyer', 'Affiliation': 'Department of Pediatric Pneumology, Immunology and Intensive Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Allyah', 'Initials': 'A', 'LastName': 'Abbas', 'Affiliation': 'Aimmune Therapeutics, London, UK.'}, {'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Fernández-Rivas', 'Affiliation': 'Hospital Clínico San Carlos, UCM, IDISSC, ARADyAL, Madrid, Spain.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Turner', 'Affiliation': 'Imperial College, London, London, UK.'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Blumchen', 'Affiliation': 'Department of Children and Adolescent Medicine, Division of Allergology, Pneumology and Cystic Fibrosis, Goethe University Frankfurt, Frankfurt, Germany.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Nilsson', 'Affiliation': ""Clinical Science and Education, Karolinska Institutet, Sachs' Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden.""}, {'ForeName': 'Maria D', 'Initials': 'MD', 'LastName': 'Ibáñez', 'Affiliation': 'H. Infantil Universitario Niño Jesús, ARADyAL-RETICs Instituto de Salud Carlos III, IIS-P, FibHNJ, Madrid, Spain.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Deschildre', 'Affiliation': 'Université de Lille, CHU Lille, Pediatric Pulmonology and Allergy Unit, Hôpital Jeanne de Flandre, Lille, France.'}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Muraro', 'Affiliation': 'Food Allergy Referral Centre Veneto Region, Department of Woman and Child Health, Padua University Hospital, Padua, Italy.'}, {'ForeName': 'Vibha', 'Initials': 'V', 'LastName': 'Sharma', 'Affiliation': ""Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust and Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.""}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Erlewyn-Lajeunesse', 'Affiliation': 'University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'José Manuel', 'Initials': 'JM', 'LastName': 'Zubeldia', 'Affiliation': 'Hospital GU Gregorio Marañón, and Biomedical Research Network on Rare Diseases, Madrid, Spain.'}, {'ForeName': 'Frederic', 'Initials': 'F', 'LastName': 'De Blay', 'Affiliation': 'University Hospital Strasbourg, Strasbourg, France.'}, {'ForeName': 'Christine D', 'Initials': 'CD', 'LastName': 'Sauvage', 'Affiliation': 'Hôpital Saint-Vincent, Saint Antoine, Lille, France.'}, {'ForeName': 'Aideen', 'Initials': 'A', 'LastName': 'Byrne', 'Affiliation': ""National Children's Research Centre, Dublin, Ireland.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Chapman', 'Affiliation': 'James Paget University Hospitals NHS Foundation Trust, Great Yarmouth, UK.'}, {'ForeName': 'Franck', 'Initials': 'F', 'LastName': 'Boralevi', 'Affiliation': 'CIC 1401, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'DunnGalvin', 'Affiliation': 'Paediatrics and Child Health, Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Pediatrics and Pediatric Infectious Diseases, Sechenov University, Moscow, Russia.'}, {'ForeName': 'Charmaine', 'Initials': 'C', 'LastName': ""O'Neill"", 'Affiliation': 'Aimmune Therapeutics, London, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Norval', 'Affiliation': 'Aimmune Therapeutics, London, UK.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Vereda', 'Affiliation': 'Aimmune Therapeutics, London, UK.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Skeel', 'Affiliation': 'Aimmune Therapeutics, London, UK.'}, {'ForeName': 'Daniel C', 'Initials': 'DC', 'LastName': 'Adelman', 'Affiliation': 'Aimmune Therapeutics, Brisbane, CA, USA; Department of Medicine, University of California San Francisco, San Francisco, CA, USA. Electronic address: dadelman@aimmune.com.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'du Toit', 'Affiliation': ""Evelina London, Children's Allergy Service, Guy's and St Thomas' Hospital, London, UK; Department of Women and Children's Health (Paediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.""}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(20)30234-0'] 2565,32702335,"Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial.","BACKGROUND Studies have suggested that fluoxetine could improve neurological recovery after stroke. The Efficacy oF Fluoxetine-a randomisEd Controlled Trial in Stroke (EFFECTS) trial aimed to assess whether administration of oral fluoxetine for 6 months after acute stroke improves functional outcome. METHODS EFFECTS was an investigator-led, multicentre, randomised, placebo-controlled, double-blind, parallel group trial that enrolled patients aged 18 years or older between 2 and 15 days after stroke onset in 35 stroke and rehabilitation centres in Sweden. Eligible patients had a clinical diagnosis of ischaemic or intracerebral haemorrhage, brain imaging that was consistent with intracerebral haemorrhage or ischaemic stroke, and had at least one persisting focal neurological deficit. A web-based randomisation system that incorporated a minimisation algorithm was used to randomly assign (1:1) participants to receive oral fluoxetine 20 mg once daily or matching placebo capsules for 6 months. Patients, care providers, investigators, and outcomes assessors were masked to the allocation. The primary outcome was functional status, measured with the modified Rankin Scale (mRS) at 6 months, analysed in all patients with available mRS data at the 6-month follow-up; we did an ordinal analysis adjusted for the minimisation variables used in the randomisation. This trial is registered with EudraCT, 2011-006130-16; ISRCTN, 13020412; and ClinicalTrials.gov, NCT02683213. FINDINGS Between Oct 20, 2014, and June 28, 2019, 1500 patients were enrolled, of whom 750 were randomly assigned to fluoxetine and 750 were randomly assigned to placebo. At 6 months, mRS data were available for 737 (98%) patients in the fluoxetine group and 742 (99%) patients in the placebo group. There was no effect of fluoxetine on the primary outcome-distribution across mRS score categories-compared with placebo (adjusted common odds ratio 0·94 [95% CI 0·78 to 1·13]; p=0·42). The proportion of patients with a new diagnosis of depression was lower with fluoxetine than with placebo (54 [7%] patients vs 81 [11%] patients; difference -3·60% [-6·49 to -0·71]; p=0·015), but fluoxetine was associated with more bone fractures (28 [4%] vs 11 [2%]; difference 2·27% [0·66 to 3·87]; p=0·0058) and hyponatraemia (11 [1%] vs one [<1%]; difference 1·33% [0·43 to 2·23]; p=0·0038) at 6 months. INTERPRETATION Functional outcome after acute stroke did not improve with oral fluoxetine 20 mg once daily for 6 months. Fluoxetine reduced the occurrence of depression but increased the risk of bone fractures and hyponatraemia. Our results do not support the use of fluoxetine after acute stroke. FUNDING The Swedish Research Council, the Swedish Heart-Lung Foundation, the Swedish Brain Foundation, the Swedish Society of Medicine, King Gustav V and Queen Victoria's Foundation of Freemasons, and the Swedish Stroke Association (STROKE-Riksförbundet).",2020,There was no effect of fluoxetine on the primary outcome-distribution across mRS score categories-compared with placebo (adjusted common odds ratio 0·94 [95% CI 0·78 to 1·13]; p=0·42).,"['enrolled patients aged 18 years or older between 2 and 15 days after stroke onset in 35 stroke and rehabilitation centres in Sweden', 'Eligible patients had a clinical diagnosis of ischaemic or intracerebral haemorrhage, brain imaging that was consistent with intracerebral haemorrhage or ischaemic stroke, and had at least one persisting focal neurological deficit', '1500 patients were enrolled, of whom 750 were randomly assigned to', 'Between Oct 20, 2014, and June 28, 2019']","['oral fluoxetine', 'fluoxetine', 'oral fluoxetine 20 mg once daily or matching placebo', 'Fluoxetine', 'placebo']","['occurrence of depression', 'functional outcome', 'bone fractures', 'risk of bone fractures and hyponatraemia', 'Safety and efficacy', 'proportion of patients with a new diagnosis of depression', 'functional status, measured with the modified Rankin Scale (mRS', 'neurological recovery']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C2937358', 'cui_str': 'Cerebral hemorrhage'}, {'cui': 'C0203860', 'cui_str': 'Imaging of brain'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0521654', 'cui_str': 'Motor dysfunction'}, {'cui': 'C4517582', 'cui_str': '1500'}, {'cui': 'C4517868', 'cui_str': '750'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0029279', 'cui_str': 'Ornithine carbamoyltransferase'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0016365', 'cui_str': 'Fluoxetine'}, {'cui': 'C0986112', 'cui_str': 'Fluoxetine 20 MG'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0020625', 'cui_str': 'Hyponatremia'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2585997', 'cui_str': 'New diagnosis'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}]",1500.0,0.629145,There was no effect of fluoxetine on the primary outcome-distribution across mRS score categories-compared with placebo (adjusted common odds ratio 0·94 [95% CI 0·78 to 1·13]; p=0·42).,"[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Neurology,['10.1016/S1474-4422(20)30219-2'] 2566,32702334,"Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial.","BACKGROUND Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population. METHODS AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2-15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. FINDINGS Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76-1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months. INTERPRETATION Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke. FUNDING National Health and Medical Research Council of Australia.",2020,"Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures.","['43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten', 'ethnically diverse population', 'Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2-15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more', '1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706', 'after acute stroke (AFFINITY', 'Between Jan 11, 2013, and June 30, 2019']","['FluoxetINe', 'fluoxetine', 'fluoxetine 20 mg capsules or matching placebo', 'Oral fluoxetine', 'placebo']","['functional outcome', 'distribution of mRS categories', 'bone fractures', 'falls', 'Safety and efficacy', 'epileptic seizures', 'risk of falls, bone fractures, and epileptic seizures', 'mRS data']","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0587502', 'cui_str': 'Stroke unit'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0042658', 'cui_str': 'Vietnam'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis'}, {'cui': 'C0751956', 'cui_str': 'Acute stroke'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0553692', 'cui_str': 'Haemorrhagic stroke'}, {'cui': 'C0521654', 'cui_str': 'Motor dysfunction'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0016365', 'cui_str': 'Fluoxetine'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0016365', 'cui_str': 'Fluoxetine'}, {'cui': 'C0986112', 'cui_str': 'Fluoxetine 20 MG'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",1280.0,0.655404,"Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures.","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Neurology,['10.1016/S1474-4422(20)30207-6'] 2567,32702360,Comparison of long-term rotational stability of three commonly implanted intraocular lenses.,"PURPOSE To compare rotational stability and its influencing factors in 3 different widely used hydrophobic acrylic intraocular lenses (IOL) from end of surgery (EoS) to 4 to 7 months (6m) in over 380 eyes. DESIGN Prospective interventional comparative clinical study METHODS: Setting: Department of Ophthalmology, Medical University of Vienna PATIENT POPULATION: 381 eyes of 199 patients with age-related cataract received an IOL Acrysof SN60WF, Tecnis ZCB00 or Envista MX60 in a consecutive order. INTERVENTION Implantation of an Acrysof, Tecnis or Envista IOL randomized to the 0±10, 45±10, 90±10 or 135±10 degree axis in one or both eyes. Baseline measurement was performed with patients supine still on the operating table. Postoperative follow-ups were conducted after 1hour, 1 week, 1month and 6m. MAIN OUTCOME MEASURES Difference of absolute rotation from EoS to 6m. RESULTS Absolute rotations from EoS to 6m were 1.65 ± 2.1, 2.65 ± 4.1and 3.18 ± 5.8 degrees for the Acrysof, Tecnis and Envista group. Rotational stability was statistically significantly superior in the Acrysof compared to the Envista group (p=0.014), but not compared to the Tecnis group (p=0.10). No significant difference was found between the Tecnis and the Envista groups (p=0.761). Maximum values of 15.8, 38.6 and 44.9 degrees were observed for the Acrysof, Tecnis and Envista group. CONCLUSION The Acrysof IOL showed the least amount of absolute rotation compared to the Tecnis and Envista IOLs. Outliers possibly requiring secondary intervention were observed in all groups. The amount of rotation was greatest during the first postoperative hour.",2020,"Rotational stability was statistically significantly superior in the Acrysof compared to the Envista group (p=0.014), but not compared to the Tecnis group (p=0.10).",['Medical University of Vienna PATIENT POPULATION: 381 eyes of 199 patients with age-related cataract received an'],"['hydrophobic acrylic intraocular lenses (IOL', 'IOL Acrysof SN60WF, Tecnis ZCB00 or Envista MX60']",['Rotational stability'],"[{'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C4708787', 'cui_str': '381'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}]","[{'cui': 'C0598629', 'cui_str': 'Hydrophobicity'}, {'cui': 'C0440181', 'cui_str': 'Acrylic dental material'}, {'cui': 'C0023311', 'cui_str': 'Insertion of intraocular lens'}]","[{'cui': 'C0445237', 'cui_str': 'Rotational'}, {'cui': 'C0205360', 'cui_str': 'Stable'}]",199.0,0.0268413,"Rotational stability was statistically significantly superior in the Acrysof compared to the Envista group (p=0.014), but not compared to the Tecnis group (p=0.10).","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Schartmüller', 'Affiliation': 'Medical University of Vienna, Department of Ophthalmology, Waehringer Guertel 18-20, Vienna, Austria.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Schwarzenbacher', 'Affiliation': 'Medical University of Vienna, Department of Ophthalmology, Waehringer Guertel 18-20, Vienna, Austria.'}, {'ForeName': 'Elias Laurin', 'Initials': 'EL', 'LastName': 'Meyer', 'Affiliation': 'Section for Medical Statistics, Center for Medical Statistics,Informatics and Intelligent Systems, Medical University of Vienna,Spitalgasse 23 Vienna, Austria.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Schriefl', 'Affiliation': 'Medical University of Vienna, Department of Ophthalmology, Waehringer Guertel 18-20, Vienna, Austria.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Leydolt', 'Affiliation': 'Medical University of Vienna, Department of Ophthalmology, Waehringer Guertel 18-20, Vienna, Austria.'}, {'ForeName': 'Rupert', 'Initials': 'R', 'LastName': 'Menapace', 'Affiliation': 'Medical University of Vienna, Department of Ophthalmology, Waehringer Guertel 18-20, Vienna, Austria. Electronic address: rupert.menapace@meduniwien.ac.at.'}]",American journal of ophthalmology,['10.1016/j.ajo.2020.07.019'] 2568,32702848,The effect of dexmedetomidine and remifentanil on the postoperative sore throat after thyroidectomy.,"BACKGROUND Postoperative sore throat (POST) is an important concern in surgical patients undergoing endotracheal intubation. Its prevalence after thyroidectomy is up to 80%. The current study aimed to assess the effect of dexmedetomidine and remifentanil on postoperative sore throat. METHODS Seventy-four patients who underwent thyroidectomy were randomized to receive either dexmedetomidine (group D) or remifentanil (group R). At anesthesia induction, group D received dexmedetomidine 1 μg/kg over 10 minutes, followed by continuous dexmedetomidine infusion at 0.3 to 0.6 μg/kg/hour during surgery. Group R received remifentanil of 3 to 4 ng/ml during induction, followed by 1.5 to 2.5 ng/ml remifentanil infusion during surgery. POST at rest and swallowing was assessed during the first 24 hours in serial time periods (0-1, 1-6, and 6-24 hours). Hoarseness and postoperative pain score were also assessed. RESULTS POST incidence at rest (0-1, 1-6, and 6-24 hours) and swallowing (1-6 and 6-24 hours) was lower in group D than in group R. POST severity was significantly lower in group D than in group R during each time period. The incidence of postoperative hoarseness was also lower in group D than in group R at 1 to 6 and 6 to 24 hours. The postoperative pain score was lower in group D than in group R during each time period. CONCLUSION Intraoperative dexmedetomidine infusion reduced the incidence and severity of POST for 24 hours after thyroidectomy.",2020,The incidence of postoperative hoarseness was also lower in group D than in group R at 1 to 6 and 6 to 24 hours.,"['surgical patients undergoing endotracheal intubation', 'Seventy-four patients who underwent thyroidectomy', 'postoperative sore throat after thyroidectomy']","['dexmedetomidine and remifentanil', 'remifentanil', 'Postoperative sore throat (POST', 'dexmedetomidine']","['postoperative pain score', 'incidence and severity of POST', 'incidence of postoperative hoarseness', 'swallowing', 'Hoarseness and postoperative pain score', 'postoperative sore throat']","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C4517867', 'cui_str': '74'}, {'cui': 'C0040145', 'cui_str': 'Thyroidectomy'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0031350', 'cui_str': 'Pharyngitis'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0031350', 'cui_str': 'Pharyngitis'}]","[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0031350', 'cui_str': 'Pharyngitis'}, {'cui': 'C0019825', 'cui_str': 'Hoarse'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}]",74.0,0.0827207,The incidence of postoperative hoarseness was also lower in group D than in group R at 1 to 6 and 6 to 24 hours.,"[{'ForeName': 'Hyuckgoo', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Yeungnam University College of Medicine, Daegu, Republic of Korea.'}, {'ForeName': 'Hyojin', 'Initials': 'H', 'LastName': 'Kwon', 'Affiliation': ''}, {'ForeName': 'Sungmin', 'Initials': 'S', 'LastName': 'Jeon', 'Affiliation': ''}, {'ForeName': 'Eun Kyung', 'Initials': 'EK', 'LastName': 'Choi', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021060'] 2569,32702849,Effects of Fusu mixture (Wen-Shen-Qian-Yang Method) on sepsis-induced acute respiratory distress syndrome.,"INTRODUCTION Sepsis is the most common etiology of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Capillary leakage caused by lung endothelial injury is the central cause of ARDS. The results of research in modern medicine in reducing endothelial damage and restoring endothelial functions are limited. In the previous clinical observations, we found that the Fusu mixture not only improves the clinical symptoms but also reduces the leakage of pulmonary capillaries. Therefore, the purpose of this study is to determine the clinical efficacy of the Fusu mixture combined with Western medicine in the treatment of ARDS caused by sepsis and to explore the mechanism of traditional Chinese medicine. METHODS This is a prospective, single-center, randomized, single-blind, and controlled clinical study involving 620 eligible patients. The patients will be randomly divided into 2 groups: the Western medicine treatment group and the combination of Chinese and Western medicine treatment group. After 14 days of intervention, the clinical efficacy and safety of the Fusu mixture on sepsis-induced ARDS patients will be observed. The primary outcome will be measured as 28-day mortality. The secondary outcome indices include inflammatory markers (CRP, PCT, IL-6, TNF - α), APACHE II score, SOFA score, days without a ventilator, blood gas analysis (Lac, PaO2 / FiO2), intensive care unit hospital stay time, intensive care unit mortality. Simultaneously, the analysis of the exploratory results will be carried out to analyze the possible mechanism of Fusu mixture in the treatment of sepsis-induced ARDS by the high-throughput sequencing and bioinformatics. DISCUSSION The purpose of this study is to evaluate the clinical efficacy of Fusu mixture in the treatment of sepsis-induced ARDS and explore its possible mechanism of action. If successful, it will provide evidence-based adjuvant therapy for the clinical treatment of ARDS.",2020,"The secondary outcome indices include inflammatory markers (CRP, PCT, IL-6, TNF - α), APACHE II score, SOFA score, days without a ventilator, blood gas analysis (Lac, PaO2 / FiO2), intensive care unit hospital stay time, intensive care unit mortality.","['sepsis-induced acute respiratory distress syndrome', '620 eligible patients']","['Fusu mixture combined with Western medicine', 'Fusu mixture', 'Western medicine treatment group and the combination of Chinese and Western medicine treatment group', 'Fusu mixture (Wen-Shen-Qian-Yang Method']","['clinical efficacy and safety', 'clinical symptoms', 'inflammatory markers (CRP, PCT, IL-6, TNF - α), APACHE II score, SOFA score, days without a ventilator, blood gas analysis (Lac, PaO2\u200a/ FiO2), intensive care unit hospital stay time, intensive care unit mortality', '28-day mortality', 'leakage of pulmonary capillaries', 'endothelial damage and restoring endothelial functions']","[{'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'C4708788', 'cui_str': '620'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0014511', 'cui_str': 'Epidermoid cyst'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0032452', 'cui_str': 'Polychlorotriphenyl Compounds'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0489438', 'cui_str': 'APACHE II score'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0087153', 'cui_str': 'Ventilator'}, {'cui': 'C0005800', 'cui_str': 'Blood gas analysis'}, {'cui': 'C0202155', 'cui_str': 'Oxygen measurement, partial pressure, arterial'}, {'cui': 'C0428167', 'cui_str': 'Fraction of inspired oxygen'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0015376', 'cui_str': 'Extravasation'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0006901', 'cui_str': 'Structure of capillary blood vessel (organ)'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",620.0,0.0535987,"The secondary outcome indices include inflammatory markers (CRP, PCT, IL-6, TNF - α), APACHE II score, SOFA score, days without a ventilator, blood gas analysis (Lac, PaO2 / FiO2), intensive care unit hospital stay time, intensive care unit mortality.","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'aDepartment of Critical Care Medicine bDepartment of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.'}, {'ForeName': 'Kunlan', 'Initials': 'K', 'LastName': 'Long', 'Affiliation': ''}, {'ForeName': 'Chunxia', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Xuemei', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Hongjing', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Peiyang', 'Initials': 'P', 'LastName': 'Gao', 'Affiliation': ''}, {'ForeName': 'Song', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021066'] 2570,32702867,A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections: Study protocol for antiretroviral therapy timing in AIDS patients with toxoplasma encephalitis.,"BACKGROUND Toxoplasma encephalitis (TE) is one of the main opportunistic infections in acquired immunodeficiency syndrome (AIDS) patients, and represents a social burden due to its high prevalence and morbidity. Concomitant antiretroviral therapy (ART), together with effective anti- toxoplasma combination therapy, is an effective strategy to treat AIDS-associated TE (AIDS/TE) patients. However, the timing for the initiation of ART after diagnosis of TE remains controversial. We therefore designed the present study to determine the optimal timing for ART initiation in AIDS/TE patients. METHODS/DESIGN This trial is a 17-center, randomized, prospective clinical study with 2 parallel arms. A total of 200 participants will be randomized at a 1:1 ratio into the 2 arms: the early ART initiation (≤14 days after TE diagnosis) arm and the deferred ART (>14 days after TE diagnosis) arm. The primary outcome will be the difference of mortality between the 2 arms at 48 weeks. The secondary outcomes will be the differences between the 2 arms in the changes of CD4+ counts from baseline to week 48, the rate of virologic suppression (HIV ribonucleic acid <50 copies/mL) from baseline to week 48, the incidence of TE-associated immune reconstitution inflammatory syndrome during the study period, and the incidence of adverse effects during the study period. DISCUSSION This present trial aims to evaluate the optimal timing for ART initiation in AIDS/TE patients, and will provide strong evidence for AIDS/TE treatment should it be successful. TRIAL REGISTRATION This trial was registered as one of the 12 trials under the name of a general project at the chictr.gov (http://www.chictr.org.cn/showproj.aspx?proj=35362) on February 1, 2019, and the registration number of the general project is ChiCTR1900021195.",2020,"The secondary outcomes will be the differences between the 2 arms in the changes of CD4+ counts from baseline to week 48, the rate of virologic suppression (HIV ribonucleic acid <50 copies/mL) from baseline to week 48, the incidence of TE-associated immune reconstitution inflammatory syndrome during the study period, and the incidence of adverse effects during the study period. ","['difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections', 'AIDS patients with toxoplasma encephalitis', '200 participants', 'acquired immunodeficiency syndrome (AIDS) patients', '12 trials under the name of a general project at the chictr.gov (http://www.chictr.org.cn/showproj.aspx?proj=35362) on February 1, 2019, and the registration number of the general project is ChiCTR1900021195']",['Concomitant antiretroviral therapy (ART'],"['incidence of TE-associated immune reconstitution inflammatory syndrome', 'rate of virologic suppression (HIV ribonucleic acid', 'changes of CD4+ counts', 'mortality', 'adverse effects']","[{'cui': 'C0332218', 'cui_str': 'Difficult'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0021051', 'cui_str': 'Immunodeficiency disorder'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0029118', 'cui_str': 'Opportunistic infectious disease'}, {'cui': 'C0001175', 'cui_str': 'AIDS'}, {'cui': 'C0085315', 'cui_str': 'Meningoencephalitis due to acquired toxoplasmosis'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C0237753', 'cui_str': 'Number'}]","[{'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0085315', 'cui_str': 'Meningoencephalitis due to acquired toxoplasmosis'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1619738', 'cui_str': 'Immune reconstitution inflammatory syndrome'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Cell Counts'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",200.0,0.23435,"The secondary outcomes will be the differences between the 2 arms in the changes of CD4+ counts from baseline to week 48, the rate of virologic suppression (HIV ribonucleic acid <50 copies/mL) from baseline to week 48, the incidence of TE-associated immune reconstitution inflammatory syndrome during the study period, and the incidence of adverse effects during the study period. ","[{'ForeName': 'Yan-Ming', 'Initials': 'YM', 'LastName': 'Zeng', 'Affiliation': 'Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.'}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Xiao-Qing', 'Initials': 'XQ', 'LastName': 'He', 'Affiliation': ''}, {'ForeName': 'Yin-Qiu', 'Initials': 'YQ', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Yuan', 'Affiliation': ''}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Bai', 'Affiliation': ''}, {'ForeName': 'Yan-Qiu', 'Initials': 'YQ', 'LastName': 'Lu', 'Affiliation': ''}, {'ForeName': 'Huan', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Yao-Kai', 'Initials': 'YK', 'LastName': 'Chen', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021141'] 2571,32702876,The effect of early dual antiplatelet timing on the microvascular resistance and ventricular function in primary percutaneous coronary intervention.,"Although dual antiplatelet therapy (DAPT) has been shown to improve index of microcirculatory resistance (IMR), the importance of the early DAPT administration on IMR and left ventricular function has not been clearly defined. In this study, we aimed to assess whether early DAPT administration affect IMR, epicardial flow, and left ventricular function in ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI).This was a prospective non-randomized study on STEMI receiving primary PCI in a tertiary hospital. All subjects received loading dose DAPT (Aspirin + Clopidogrel) before primary PCI. Patients were then divided into 2 groups, the first group consists of patients receiving DAPT time ≤2 hours and the second group consists of those with DAPT time >2 hours. The primary endpoint of this study was IMR, a microvasculature function index measured quantitatively by pressure-/temperature-tipped guidewire after balloon dilatation. The secondary endpoint was the mean difference of global longitudinal strain (GLS) change at 6 months follow-up, TIMI flow before, and after PCI between the 2 groups.There were 40 subjects qualified for the study, 20 subjects in each group. There was no significant difference in IMR (50.90 [34.66] vs 58.06 [45.56], P = .579) between the 2 groups. Early administration of DAPT improved ventricular function at 6 months, reflected by statistically significant greater improvement in terms of ΔGLS (-3.48 [2.61] vs -1.23 [2.87], P = .013) and Δejection fraction (10.65% [8.74] vs -0.75% [12.83], P = .002) in the DAPT time ≤2 hours group compared with DAPT time >2 hours group. TIMI flow before PCI (P = .653) and TIMI flow after PCI (P = .205) were similar in the 2 groups.Early DAPT administration ≤2 hours may improve left ventricular function, but not IMR and TIMI flow.",2020,TIMI flow before PCI (P = .653) and TIMI flow after PCI (P = .205) were similar in the 2 groups.,"['primary percutaneous coronary intervention', 'ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI).This was a prospective non-randomized study on STEMI receiving primary PCI in a tertiary hospital', '40 subjects qualified for the study, 20 subjects in each group']","['DAPT time ≤2\u200ahours and the second group consists of those with DAPT time >2\u200ahours', 'dual antiplatelet therapy (DAPT', 'DAPT', 'loading dose DAPT (Aspirin + Clopidogrel']","['mean difference of global longitudinal strain (GLS) change at 6 months follow-up, TIMI flow', 'IMR', 'TIMI flow after PCI', 'microvascular resistance and ventricular function', 'ventricular function', 'left ventricular function', 'IMR and TIMI flow', 'IMR, epicardial flow, and left ventricular function', 'Δejection fraction', 'IMR, a microvasculature function index measured quantitatively by pressure-/temperature-tipped guidewire after balloon dilatation', 'TIMI flow before PCI']","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C1536220', 'cui_str': 'ST Segment Elevation Myocardial Infarction'}, {'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C1292425', 'cui_str': '2 hours'}, {'cui': 'C3714444', 'cui_str': 'Loading dose'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C0080309', 'cui_str': 'Ventricular Function'}, {'cui': 'C0080310', 'cui_str': 'Left ventricular function'}, {'cui': 'C0442016', 'cui_str': 'Epicardial'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0243079', 'cui_str': 'microvasculature'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0339897', 'cui_str': 'Transjugular intrahepatic portosystemic shunt'}, {'cui': 'C0181089', 'cui_str': 'Guide wire'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0002940', 'cui_str': 'Aneurysm'}]",40.0,0.0357008,TIMI flow before PCI (P = .653) and TIMI flow after PCI (P = .205) were similar in the 2 groups.,"[{'ForeName': 'Doni', 'Initials': 'D', 'LastName': 'Firman', 'Affiliation': 'aDepartment of Cardiology and Vascular Medicine, Faculty of Medicine, National Cardiovascular Center Harapan Kita bFaculty of Medicine, Universitas Indonesia cFaculty of Medicine, Universitas YARSI, Jakarta dFaculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia.'}, {'ForeName': 'Imammurahman', 'Initials': 'I', 'LastName': 'Taslim', 'Affiliation': ''}, {'ForeName': 'Surya Buana', 'Initials': 'SB', 'LastName': 'Wangi', 'Affiliation': ''}, {'ForeName': 'Emir', 'Initials': 'E', 'LastName': 'Yonas', 'Affiliation': ''}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Pranata', 'Affiliation': ''}, {'ForeName': 'Amir Aziz', 'Initials': 'AA', 'LastName': 'Alkatiri', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021177'] 2572,32702912,A randomized interventional parallel study to evaluate the effect of pelvic floor muscle training with stabilization exercises of high and low intensity in women with stress urinary incontinence: The PELSTAB study.,"INTRODUCTION The effect of different intensities of pelvic floor muscle training (PFMT) assessed by 2D/3D ultrasound (USG) have not been sufficiently monitored in the literature. The objective of the study will be to evaluate the effect of this intervention by assessing the change in incontinence episode frequency, hiatal area (HA) and hiatal diameter by 2D/3D USG and quality of life over 12 weeks of treatment. METHODS Using a randomized interventional parallel study, patients will be assigned to groups A and B using simple software randomization according to odd and even patient sequence numbers. The following methods will be used for evaluation: change in incontinence episode frequency, power and endurance of pelvic floor muscles assessed by perineometer (in cmH2O), HA (in cm) during contraction, Valsalva manoeuvre assessed by 3D USG, hiatal diameter assessed by 2D USG, the Incontinence Quality of Life scale (I-QoL) and the Patient Global Impression of Improvement score (PGI-I). INTERVENTIONS Group A, high-intensity PFMT 5 times a week for 30 minutes per day. Group B, low-intensity PFMT twice a week for 15 minutes per day. The duration of the intervention will be 12 weeks. DISCUSSION The study protocol presents the starting points, design, and methods of the PELSTAB Study. We expect that, after 12 weeks of high-intensity PFMT, women with stress urinary incontinence will have significantly less incontinence episode frequency, better reduction of HA during contraction and Valsalva manoeuvre, higher power and endurance of pelvic floor muscles and better quality of life compared to the group with low-intensity PFMT. REGISTRATION This study was registered in the ClinicalTrials.govNCT04340323.",2020,"The following methods will be used for evaluation: change in incontinence episode frequency, power and endurance of pelvic floor muscles assessed by perineometer (in cmH2O), HA (in cm) during contraction, Valsalva manoeuvre assessed by 3D USG, hiatal diameter assessed by 2D USG, the Incontinence Quality of Life scale (I-QoL) and",['women with stress urinary incontinence'],"['pelvic floor muscle training with stabilization exercises', 'pelvic floor muscle training (PFMT) assessed by 2D/3D ultrasound (USG']","['incontinence episode frequency, power and endurance of pelvic floor muscles assessed by perineometer (in cmH2O), HA (in\u200acm) during contraction, Valsalva manoeuvre assessed by 3D USG, hiatal diameter assessed by 2D USG, the Incontinence Quality of Life scale (I-QoL', 'incontinence episode frequency, better reduction of HA during contraction and Valsalva manoeuvre, higher power and endurance of pelvic floor muscles and better quality of life', 'incontinence episode frequency, hiatal area (HA) and hiatal diameter by 2D/3D USG and quality of life']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}]","[{'cui': 'C4087139', 'cui_str': 'Pelvic floor muscle training'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}]","[{'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0449622', 'cui_str': 'Muscle assessed'}, {'cui': 'C0491718', 'cui_str': 'Perineometer'}, {'cui': 'C0439476', 'cui_str': 'cmH2O'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0042293', 'cui_str': 'Valsalva maneuver'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.0823383,"The following methods will be used for evaluation: change in incontinence episode frequency, power and endurance of pelvic floor muscles assessed by perineometer (in cmH2O), HA (in cm) during contraction, Valsalva manoeuvre assessed by 3D USG, hiatal diameter assessed by 2D USG, the Incontinence Quality of Life scale (I-QoL) and","[{'ForeName': 'Magdaléna', 'Initials': 'M', 'LastName': 'Hagovská', 'Affiliation': 'aDepartment of Physiatry, Balneology, and Medical Rehabilitation, Institution - Faculty of Medicine, PJ Safarik University bUrogynecology and Physiotherapy in Gynecology and Urology, Institution - Clinic Centrum s.r.o. cDepartment of Gynecology and Obstetrics, Faculty of Medicine , Institution -PJ Safarik University, Kosice dDepartment of Urology, Institution - Jessenius Faculty of Medicine, Martin, Comenius University Bratislava, Slovakia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Urdzík', 'Affiliation': ''}, {'ForeName': 'Ján', 'Initials': 'J', 'LastName': 'Švihra', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021264'] 2573,32702919,Effect of early activity combined with early nutrition on acquired weakness in ICU patients.,"INTRODUCTION Intensive care unit-acquired weakness (ICU-AW) occurs in 25% to 100% of critically ill patients, and is associated with prolonged mechanical ventilation, extended ICU stay, and total hospital stay, increased hospital costs, higher risk of death, impaired physical function, and decreased quality of life. However, there are not any current guidelines that mention management of ICU-AW. The present study will evaluate the effects of a combination of early nutrition and early exercise compared to those of either early exercise alone or the standard care for patients in ICUs. METHODS This is a 3-arm, parallel, randomized controlled trial including an estimated 147 critically ill patients aged ≥18 years recruited from the ICUs of 2 hospitals in Heilongjiang, China. Patients will be prospectively randomized 1:1:1 to receive early mobilization, early nutrition combined with early mobilization, or standard care (minimal exercises, experience-based initiation and enrollment of nutrition support). Outcomes are assessed at ICU discharge after baseline. The primary outcome is occurrence of ICU-AW according to the Medical Research Council scale at the end of treatment. Muscle strength, organ failure, functional independence, self-care ability, time of ICU stay, duration of mechanical ventilation, and ICU mortality are secondary outcome measures. DISCUSSION This trial has the potential to identify a novel strategy for preventing or managing ICU-AW. The findings may increase the clinical knowledge about nutrition and mobilization interventions for people with ICU-AW, and contribute to the formation of practice guidelines for managing this condition. TRIAL REGISTRATION NUMBER ChiCTR2000033482.",2020,"Muscle strength, organ failure, functional independence, self-care ability, time of ICU stay, duration of mechanical ventilation, and ICU mortality are secondary outcome measures. ","['ICU patients', 'patients in ICUs', '147 critically ill patients aged ≥18 years recruited from the ICUs of 2 hospitals in Heilongjiang, China']","['early nutrition and early exercise', 'early mobilization, early nutrition combined with early mobilization, or standard care (minimal exercises, experience-based initiation and enrollment of nutrition support', 'early activity combined with early nutrition', 'early exercise alone']","['prolonged mechanical ventilation, extended ICU stay, and total hospital stay, increased hospital costs, higher risk of death, impaired physical function, and decreased quality of life', 'Muscle strength, organ failure, functional independence, self-care ability, time of ICU stay, duration of mechanical ventilation, and ICU mortality', 'occurrence of ICU-AW according to the Medical Research Council scale']","[{'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0013459', 'cui_str': 'Early Mobilization'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0242739', 'cui_str': 'Nutritional support'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]","[{'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0206174', 'cui_str': 'Cost, Hospital'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0349410', 'cui_str': 'Single organ dysfunction'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0562734', 'cui_str': 'Ability to perform personal care activity'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C4087120', 'cui_str': 'Intensive care unit acquired weakness'}, {'cui': 'C0079816', 'cui_str': 'Research, Medical'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",147.0,0.141729,"Muscle strength, organ failure, functional independence, self-care ability, time of ICU stay, duration of mechanical ventilation, and ICU mortality are secondary outcome measures. ","[{'ForeName': 'Wendie', 'Initials': 'W', 'LastName': 'Zhou', 'Affiliation': 'aThe Second Affiliated Hospital of Harbin Medical University bSchool of Nursing, Harbin Medical University cDepartment of Rehabilitation, the Second Affiliated Hospital of Harbin Medical University, Harbin city dNursing Department, the First Affiliated Hospital of Jiamusi University, Jiamusi city, China.'}, {'ForeName': 'Baisheng', 'Initials': 'B', 'LastName': 'Shi', 'Affiliation': ''}, {'ForeName': 'Yuying', 'Initials': 'Y', 'LastName': 'Fan', 'Affiliation': ''}, {'ForeName': 'Jinsong', 'Initials': 'J', 'LastName': 'Zhu', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021282'] 2574,32702925,To use indwelling drainage or not in dual-plane breast augmentation mammoplasty patients: A comparative study.,"To explore the necessity of indwelling drainage in dual-plane breast augmentation mammoplasty patients.Female patients (123 in total) were selected from June 2015 to June 2018 in the Department of Plastic Surgery at Peking Union Medical College Hospital and were randomly divided into 2 different groups: the with drainage group (WD group, 57 patients) and the without drainage group (WOD group, 66 patients). In the 2 groups, the operation time, postoperative stay, and hospitalization expenses were recorded. The BREAST-Q Version 2.0 Augmentation Module Pre- and Postoperative Scales (Chinese Version) were used to evaluate psychosocial well-being, sexual well-being, physical well-being, and satisfaction with breasts preoperatively and postoperatively (1 year after operation).Before the operation, no significant differences were found in psychosocial well-being, sexual well-being, physical well-being, or satisfaction with breasts between these 2 groups. In the WOD group, postoperative stay and hospitalization expenses were remarkably decreased, but the operation time was similar, compared with the WD group. Compared with before the operation, both groups had significantly increased scores in psychosocial well-being, sexual well-being, and satisfaction with breasts after the operation. However, no significant differences were found between the 2 groups. No complications were found in any of the patients.Although the operation time was not significantly decreased, patients without drainage could save much more time and money and simultaneously reach similar postoperative effects in psychosocial well-being, sexual well-being, physical well-being, and satisfaction with breasts. Therefore, drainage may not be necessary in patients who undergo dual-plane breast augmentation mammoplasty.",2020,"Compared with before the operation, both groups had significantly increased scores in psychosocial well-being, sexual well-being, and satisfaction with breasts after the operation.","['Female patients (123 in total) were selected from June 2015 to June 2018 in the Department of Plastic Surgery at Peking Union Medical College Hospital', 'patients who undergo dual-plane breast augmentation mammoplasty', 'dual-plane breast augmentation mammoplasty patients']",[],"['operation time, postoperative stay, and hospitalization expenses', 'scores in psychosocial well-being, sexual well-being, and satisfaction with breasts', 'psychosocial well-being, sexual well-being, physical well-being, and satisfaction', 'postoperative stay and hospitalization expenses', 'psychosocial well-being, sexual well-being, physical well-being, or satisfaction with breasts', 'operation time']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0038911', 'cui_str': 'Plastic surgery - specialty'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0191925', 'cui_str': 'Augmentation mammoplasty'}, {'cui': 'C0085076', 'cui_str': 'Mammoplasty'}]",[],"[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",,0.0119244,"Compared with before the operation, both groups had significantly increased scores in psychosocial well-being, sexual well-being, and satisfaction with breasts after the operation.","[{'ForeName': 'Yiding', 'Initials': 'Y', 'LastName': 'Xiao', 'Affiliation': 'aDepartment of Plastic Surgery, Peking Union Medical College Hospital, Beijing bDepartment of Orthopaedics, Qingdao Huangdao District Hospital of Traditional Chinese Medicine, Qingdao, Shandong cDepartment of Information Engineering, Chaoshan Polytechnic College, Puning, Guangdong, China.'}, {'ForeName': 'Jianqiang', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': ''}, {'ForeName': 'Mingzi', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Wenchao', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Qin', 'Affiliation': ''}, {'ForeName': 'Ang', 'Initials': 'A', 'LastName': 'Zeng', 'Affiliation': ''}, {'ForeName': 'Xiaojun', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Zhifei', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Zhu', 'Affiliation': ''}, {'ForeName': 'Nanze', 'Initials': 'N', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Loubin', 'Initials': 'L', 'LastName': 'Si', 'Affiliation': ''}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Long', 'Affiliation': ''}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021305'] 2575,32703038,Multiple functions of policosanol in elderly patients with dyslipidemia.,"OBJECTIVE To determine the multiple functions of policosanol in elderly dyslipidemia patients. Methodology: There were 294 elderly dyslipidemia patients enrolled into this clinical study. They were randomly divided into four groups, as follows: 20 mg policosanol (group A, n = 64); 10 mg policosanol (group B, n = 72); 20 mg atorvastatin (group C, n = 91); and 10 mg policosanol + 20 mg atorvastatin (group D, n = 62). Plasma platelet count, platelet aggregation rate, circulating endothelial cell (CEC) count, high sensitivity C-reactive protein (hs-CRP), and carotid intima-media thickness (IMT) were measured before the study (week 0) and at weeks 12, 24, and 52. RESULTS In group A, the platelet aggregation rate caused by adenosine diphosphate (ADP) after treatment was significantly decreased compared with before treatment (48.79% ± 20.29% vs. 40.37% ± 23.56%), but the arachidonic acid (AA)-induced platelet aggregation rates were similar. The platelet aggregation rates induced by AA and ADP in groups B, C, and D did not change significantly. CEC counts and hs-CRP and homocysteine levels in all groups after treatment were significantly lower compared with before treatment, but carotid IMTs were similar. CONCLUSION Policosanol regulates blood lipid levels and improves endothelial cell function, and it could delay the progress of atherosclerosis. Trial registration number: ChiCTR-RRC-17013396 (retrospectively registered).",2020,"In group A, the platelet aggregation rate caused by adenosine diphosphate (ADP) after treatment was significantly decreased compared with before treatment (48.79% ± 20.29% vs. 40.37% ± 23.56%), but the arachidonic acid (AA)-induced platelet aggregation rates were similar.","['elderly patients with dyslipidemia', '294 elderly dyslipidemia patients enrolled into this clinical study', 'elderly dyslipidemia patients']","['atorvastatin', 'policosanol', 'Policosanol', 'policosanol\u2009+\u200920\u2009mg atorvastatin']","['arachidonic acid (AA)-induced platelet aggregation rates', 'Plasma platelet count, platelet aggregation rate, circulating endothelial cell (CEC) count, high sensitivity C-reactive protein (hs-CRP), and carotid intima-media thickness (IMT', 'platelet aggregation rates', 'endothelial cell function', 'CEC counts and hs-CRP and homocysteine levels', 'carotid IMTs', 'platelet aggregation rate caused by adenosine diphosphate (ADP']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0286651', 'cui_str': 'atorvastatin'}, {'cui': 'C0215278', 'cui_str': 'policosanol'}]","[{'cui': 'C0003695', 'cui_str': 'Arachidonic acid'}, {'cui': 'C1268819', 'cui_str': 'Induced platelet aggregation'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0032176', 'cui_str': 'Platelet aggregation'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0429518', 'cui_str': 'Endothelial cell density'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0162864', 'cui_str': 'Tunica intima'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0334121', 'cui_str': 'Inflammatory myofibroblastic tumor'}, {'cui': 'C0225336', 'cui_str': 'Endothelial cell'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0318601', 'cui_str': 'Canine enteric calicivirus'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C2242817', 'cui_str': 'Homocysteine measurement'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0001459', 'cui_str': 'Adenosine diphosphate'}]",294.0,0.0213996,"In group A, the platelet aggregation rate caused by adenosine diphosphate (ADP) after treatment was significantly decreased compared with before treatment (48.79% ± 20.29% vs. 40.37% ± 23.56%), but the arachidonic acid (AA)-induced platelet aggregation rates were similar.","[{'ForeName': 'Chunlin', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Second Department of Internal Medicine, 316 Hospital of PLA, Beijing, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'First Department of Cardiovascular Diseases, South Building, Chinese PLA General Hospital, Beijing, China.'}, {'ForeName': 'Quanjin', 'Initials': 'Q', 'LastName': 'Si', 'Affiliation': 'First Department of Cardiovascular Diseases, South Building, Chinese PLA General Hospital, Beijing, China.'}, {'ForeName': 'Kailiang', 'Initials': 'K', 'LastName': 'Li', 'Affiliation': 'First Department of Cardiovascular Diseases, South Building, Chinese PLA General Hospital, Beijing, China.'}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Xu', 'Affiliation': 'First Department of Cardiovascular Diseases, South Building, Chinese PLA General Hospital, Beijing, China.'}]",The Journal of international medical research,['10.1177/0300060520936082'] 2576,32703548,A restrictive versus liberal transfusion strategy to prevent myocardial injury in patients undergoing surgery for fractured neck of femur: a feasibility randomised trial (RESULT-NOF).,"BACKGROUND The optimum transfusion strategy in patients with fractured neck of femur is uncertain, particularly if there is coexisting cardiovascular disease. METHODS We conducted a prospective, single-centre, randomised feasibility trial of two transfusion strategies. We randomly assigned patients undergoing surgery for fractured neck of femur to a restrictive (haemoglobin, 70-90 g L -1 ) or liberal (haemoglobin, 90-110 g L -1 ) transfusion strategy throughout their hospitalisation. Feasibility outcomes included: enrolment rate, protocol compliance, difference in haemoglobin, and blood exposure. The primary clinical outcome was myocardial injury using troponin estimations. Secondary outcomes included major adverse cardiac events, postoperative complications, duration of hospitalisation, mortality, and quality of life. RESULTS We enrolled 200 (22%) of 907 eligible patients, and 62 (31%) showed decreased haemoglobin (to 90 g L -1 or less) and were thus exposed to the intervention. The overall protocol compliance was 81% in the liberal group and 64% in the restrictive group. Haemoglobin concentrations were similar preoperatively and at postoperative day 1 but lower in the restrictive group on day 2 (mean difference [MD], 7.0 g L -1 ; 95% confidence interval [CI], 1.6-12.4). Lowest haemoglobin within 30 days/before discharge was lower in the restrictive group (MD, 5.3 g L -1 ; 95% CI, 1.7-9.0). Overall, 58% of patients in the restrictive group received no transfusion compared with 4% in the liberal group (difference in proportion, 54.5%; 95% CI, 36.8-72.2). The proportion with the primary clinical outcome was 14/26 (54%, liberal) vs 24/34 (71%, restrictive), and the difference in proportion was -16.7% (95% CI, -41.3 to 7.8; P=0.18). CONCLUSION A clinical trial of two transfusion strategies in hip fracture with a clinically relevant cardiac outcome is feasible. CLINICAL TRIAL REGISTRATION NCT03407573.",2020,"Lowest haemoglobin within 30 days/before discharge was lower in the restrictive group (MD,","['We enrolled 200 (22%) of 907 eligible patients, and 62 (31%) showed decreased haemoglobin (to 90 g', 'patients with fractured neck of femur', 'patients undergoing surgery for fractured neck of femur']","['surgery for fractured neck of femur to a restrictive (haemoglobin, 70-90 g L -1 ) or liberal (haemoglobin, 90-110 g L -1 ) transfusion strategy throughout their hospitalisation']","['major adverse cardiac events, postoperative complications, duration of hospitalisation, mortality, and quality of life', 'Haemoglobin concentrations', 'myocardial injury using troponin estimations', 'overall protocol compliance', 'enrolment rate, protocol compliance, difference in haemoglobin, and blood exposure']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0015806', 'cui_str': 'Fracture of neck of femur'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0015806', 'cui_str': 'Fracture of neck of femur'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1318517', 'cui_str': 'Hemoglobin concentration, dipstick - finding'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0041199', 'cui_str': 'Troponin'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0525058', 'cui_str': 'Protocol Compliance'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}]",907.0,0.200366,"Lowest haemoglobin within 30 days/before discharge was lower in the restrictive group (MD,","[{'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Gillies', 'Affiliation': 'Department of Anaesthesia, Critical Care and Pain Medicine, Royal Infirmary Edinburgh, Edinburgh, UK; Edinburgh Critical Care Research Group, University of Edinburgh, Edinburgh, UK. Electronic address: Michael.Gillies@ed.ac.uk.'}, {'ForeName': 'Sadia', 'Initials': 'S', 'LastName': 'Ghaffar', 'Affiliation': 'Department of Anaesthesia, Critical Care and Pain Medicine, Royal Infirmary Edinburgh, Edinburgh, UK; Edinburgh Critical Care Research Group, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Iain K', 'Initials': 'IK', 'LastName': 'Moppett', 'Affiliation': ""Anaesthesia and Critical Care Section, Division of Clinical Neuroscience, Queen's Medical Centre, University of Nottingham, Nottingham, UK.""}, {'ForeName': 'Annemarie B', 'Initials': 'AB', 'LastName': 'Docherty', 'Affiliation': 'Department of Anaesthesia, Critical Care and Pain Medicine, Royal Infirmary Edinburgh, Edinburgh, UK; Edinburgh Critical Care Research Group, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Clarke', 'Affiliation': 'Edinburgh Critical Care Research Group, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Rea', 'Affiliation': 'Edinburgh Critical Care Research Group, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Stephen', 'Affiliation': 'Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Catriona', 'Initials': 'C', 'LastName': 'Keerie', 'Affiliation': 'Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Ray', 'Affiliation': 'Department of Anaesthesia, Critical Care and Pain Medicine, Royal Infirmary Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Timothy O', 'Initials': 'TO', 'LastName': 'White', 'Affiliation': 'Department of Trauma and Orthopaedics, Royal Infirmary Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Alasdair M J', 'Initials': 'AMJ', 'LastName': 'MacLullich', 'Affiliation': 'Geriatric Medicine, University of Edinburgh, Royal Infirmary Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Nicholas M', 'Initials': 'NM', 'LastName': 'Mills', 'Affiliation': 'BHF Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Megan R', 'Initials': 'MR', 'LastName': 'Rowley', 'Affiliation': 'Scottish National Blood Transfusion Service, Royal Infirmary Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Krishna', 'Initials': 'K', 'LastName': 'Murthy', 'Affiliation': 'Department of Emergency Medicine, Royal Infirmary Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Rupert M', 'Initials': 'RM', 'LastName': 'Pearse', 'Affiliation': 'William Harvey Research Institute, Queen Mary University of London, London, UK.'}, {'ForeName': 'Simon J', 'Initials': 'SJ', 'LastName': 'Stanworth', 'Affiliation': 'Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Radcliffe Department of Medicine, University of Oxford, Oxford BRC Haematology Theme, Oxford, UK; Transfusion Medicine, NHS Blood and Transplant, Oxford, UK.'}, {'ForeName': 'Timothy S', 'Initials': 'TS', 'LastName': 'Walsh', 'Affiliation': 'Department of Anaesthesia, Critical Care and Pain Medicine, Royal Infirmary Edinburgh, Edinburgh, UK; Edinburgh Critical Care Research Group, University of Edinburgh, Edinburgh, UK.'}]",British journal of anaesthesia,['10.1016/j.bja.2020.06.048'] 2577,32703583,Percutaneous coronary intervention with an initial bolus of low-dose heparin in biomarker negative patients.,"OBJECTIVES The safety and efficacy of an initial intravenous bolus of low-dose heparin (40 IU/kg) was evaluated in biomarker negative patients undergoing percutaneous coronary intervention (PCI). BACKGROUND A bolus of 70-100 IU/kg of heparin is currently recommended for patients undergoing PCI. However, the ideal dose of heparin has not been evaluated in a randomized trial. The higher dose of 100 IU/kg may increase the risk of bleeding. An initial bolus of low-dose heparin may be advantageous to avoid supratherapeutic activating clotting times (ACT) while still allowing for the administration of additional heparin if the ACT is subtherapeutic. METHODS From January 2008 to February 2020, 904 patients undergoing elective transfemoral PCI received an initial bolus of 40 IU/kg of heparin. Patients who underwent transradial PCI were not included. Patients were routinely pretreated with dual antiplatelet therapy. The primary end point was the composite of cardiac death, myocardial infarction (MI), urgent target vessel revascularization (TVR) for ischemia, or major bleeding within 30 days after PCI. RESULTS The initial mean activating clotting time was 235.4 ± 26.6 s. The clinical event rates were low: the primary end point occurred in 5.3%, cardiac death in 1.0%, MI in 3.1%, urgent TVR in 0.7% and major bleeding in 1.9%. Stent thrombosis was uncommon (0.2%). No patients developed profound thrombocytopenia. Three patients (0.3%) had acute limb ischemia that required revascularization. CONCLUSION An initial strategy of low-dose heparin is associated with low ischemic and bleeding complications in biomarker negative patients who undergo transfemoral PCI.",2020,No patients developed profound thrombocytopenia.,"['biomarker negative patients who undergo transfemoral PCI', 'biomarker negative patients', 'patients undergoing PCI', 'biomarker negative patients undergoing percutaneous coronary intervention (PCI', 'From January 2008 to February 2020, 904 patients undergoing elective transfemoral PCI received an']","['low-dose heparin', 'Percutaneous coronary intervention with an initial bolus of low-dose heparin', 'initial bolus of 40\xa0IU/kg of heparin', 'heparin', 'transradial PCI', 'dual antiplatelet therapy']","['cardiac death', 'Stent thrombosis', 'composite of cardiac death, myocardial infarction (MI), urgent target vessel revascularization (TVR) for ischemia, or major bleeding within 30\xa0days after PCI', 'acute limb ischemia', 'safety and efficacy', 'risk of bleeding', 'major bleeding', 'initial mean activating clotting time', 'profound thrombocytopenia']","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}]","[{'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0439463', 'cui_str': 'IU/kg'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}]","[{'cui': 'C0376297', 'cui_str': 'Cardiac death'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0449618', 'cui_str': 'Target vessel'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C4049535', 'cui_str': 'Acute limb ischaemia'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0427611', 'cui_str': 'Coagulation time, activated'}, {'cui': 'C0439808', 'cui_str': 'Profound'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}]",904.0,0.18958,No patients developed profound thrombocytopenia.,"[{'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Lee', 'Affiliation': 'UCLA Medical Center, Los Angeles, CA, United States of America. Electronic address: mslee@mednet.ucla.edu.'}, {'ForeName': 'Seung-Woon', 'Initials': 'SW', 'LastName': 'Rha', 'Affiliation': 'Korea University Guro Hospital, Seoul, South Korea.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Shlofmitz', 'Affiliation': 'St. Francis Hospital, Roslyn, NY, United States of America.'}]",Cardiovascular revascularization medicine : including molecular interventions,['10.1016/j.carrev.2020.07.015'] 2578,32703593,Titanium-Nitride-Oxide-Coated Versus Everolimus-Eluting Stents in Acute Coronary Syndrome: The Randomized TIDES-ACS Trial.,"OBJECTIVES This study sought to compare next-generation cobalt-chromium-based titanium-nitride-oxide (TiNO)-coated stents with a platinum-chromium-based biodegradable polymer everolimus-eluting stent (EES) in patients with acute coronary syndrome (ACS). BACKGROUND Previous generation TiNO-coated stents showed acceptable performance in patients with ACS. METHODS In a multicenter, randomized trial, we randomly assigned 1,491 ACS patients (2:1) to receive either a TiNO-coated stent (n = 989) or EES (n = 502). The primary endpoint was the rate of a composite of cardiac death, myocardial infarction (MI), or ischemia-driven target lesion revascularization at 12-month follow-up. The co-primary endpoint was a composite of cardiac death, MI, or major bleeding at 18 months. RESULTS A primary endpoint event occurred in 6.3% of patients in the TiNO-coated stent group versus in 7.0% in the EES group (hazard ratio: 0.93; 95% confidence interval: 0.71 to 1.22; p = 0.66 for superiority; p < 0.001 for noninferiority). A co-primary endpoint event occurred in 3.7% of the patients in the TiNO group and in 7.8% in the EES group (hazard ratio: 0.64; 95% confidence interval: 0.51 to 0.80; p = 0.001). TiNO-coated stents were associated with lower rates of cardiac death (0.6% vs. 2.6%; p = 0.002) and MI (2.2% vs. 5.0%; p = 0.007) at 18 months of follow-up. Rates of target lesion revascularization were not significantly different at 18 months (5.8% vs. 4.4%; p = 0.27). CONCLUSIONS In patients with ACS, cobalt-chromium-based TiNO-coated stents were noninferior to platinum-chromium-based biodegradable polymer EES for major cardiac events at 12 months, and were superior for the co-primary endpoint of cardiac death, MI, and bleeding at 18 months. (Comparison of Titanium-Nitride-Oxide-Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome [TIDES-ACS]; NCT02049229).",2020,"Rates of target lesion revascularization were not significantly different at 18 months (5.8% vs. 4.4%; p = 0.27). ","['Acute Coronary Syndrome', '1,491 ACS patients (2:1) to receive either a', 'patients with ACS', 'patients with acute coronary syndrome (ACS']","['next-generation cobalt-chromium-based titanium-nitride-oxide (TiNO)-coated stents with a platinum-chromium-based biodegradable polymer everolimus-eluting stent (EES', 'Coated Versus\xa0Everolimus-Eluting Stents', 'Stent (Synergy™', 'TiNO-coated stent (n\xa0=\xa0989) or EES', 'platinum-chromium-based biodegradable polymer EES', 'Titanium-Nitride-Oxide-Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting', 'Titanium-Nitride-Oxide']","['Rates of target lesion revascularization', 'cardiac death, MI, and bleeding', 'rates of cardiac death', 'rate of a composite of cardiac death, myocardial infarction (MI), or ischemia-driven target lesion revascularization', 'composite of cardiac death, MI, or major bleeding at 18\xa0months']","[{'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0009148', 'cui_str': 'Cobalt'}, {'cui': 'C0008574', 'cui_str': 'Chromium'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0969380', 'cui_str': 'titanium-nitride-oxide'}, {'cui': 'C0453946', 'cui_str': 'Coat'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0032521', 'cui_str': 'Polymer'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0591911', 'cui_str': 'Optimax'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0014742', 'cui_str': 'Erythema multiforme'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0376297', 'cui_str': 'Cardiac death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",1491.0,0.109829,"Rates of target lesion revascularization were not significantly different at 18 months (5.8% vs. 4.4%; p = 0.27). ","[{'ForeName': 'Pim A L', 'Initials': 'PAL', 'LastName': 'Tonino', 'Affiliation': 'Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands. Electronic address: pim.tonino@cze.nl.'}, {'ForeName': 'Nico H J', 'Initials': 'NHJ', 'LastName': 'Pijls', 'Affiliation': 'Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands; Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Collet', 'Affiliation': 'Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.'}, {'ForeName': 'Wail', 'Initials': 'W', 'LastName': 'Nammas', 'Affiliation': 'Heart Center, Satakunta Central Hospital, Pori, Finland.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Van der Heyden', 'Affiliation': 'Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'Hannu', 'Initials': 'H', 'LastName': 'Romppanen', 'Affiliation': 'Department of Cardiology, Kuopio University Hospital, Kuopio, Finland.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Kervinen', 'Affiliation': 'Clinical Research Center, Oulu University Hospital, Oulu, Finland.'}, {'ForeName': 'Juhani K E', 'Initials': 'JKE', 'LastName': 'Airaksinen', 'Affiliation': 'Department of Cardiology, Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Jussi', 'Initials': 'J', 'LastName': 'Sia', 'Affiliation': 'Department of Cardiology, Kokkola Central Hospital, Kokkola, Finland.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Lalmand', 'Affiliation': 'Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Frambach', 'Affiliation': 'Department of Cardiology, INCCI Luxembourg Hospital, Luxembourg City, Luxembourg.'}, {'ForeName': 'Antonio Serra', 'Initials': 'AS', 'LastName': 'Penaranda', 'Affiliation': 'Department of Cardiology, Hospital Sant Pau, Barcelona, Spain.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'De Bruyne', 'Affiliation': 'Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Department of Cardiology, Lausanne University Center Hospital, Lausanne, Switzerland. Electronic address: bernard.de.bruyne@olvz-aalst.be.'}, {'ForeName': 'Pasi P', 'Initials': 'PP', 'LastName': 'Karjalainen', 'Affiliation': 'Heart Center, Satakunta Central Hospital, Pori, Finland; Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2020.04.021'] 2579,32703613,Effects of a Single Myofascial Induction Session on Neural Mechanosensitivity in Breast Cancer Survivors: A Secondary Analysis of a Crossover Study.,"OBJECTIVES The purpose of this study was to investigate the short-term effects of myofascial induction on mechanosensitivity of upper limb nerves. METHODS In this secondary analysis of a randomized, single-blind, placebo-controlled crossover study, 21 breast cancer survivors with stage I-IIIA cancer were randomly allocated to an experimental group (30 minutes of myofascial induction session) or placebo control group (unplugged pulsed 30 minutes of shortwave therapy), with a 4-week washout period between sessions that occurred in a physical therapy laboratory in the Health Science Faculty (University of Granada, Spain). Range of motion (universal goniometry), structural differentiation, symptoms (yes/no), and pressure pain thresholds (electronic algometry) were assessed during neurodynamic tests and attitude toward massage scale as covariate. RESULTS An analysis of covariance revealed significant time × group interactions for range of motion in affected upper limb nerves (median, P < .001; radial, P = .036; ulnar, P = .002), but not for nonaffected upper limb nerves (median, P = .083; radial, P = .072; ulnar, P = .796). A χ 2 or Fisher exact test, as appropriate, also revealed a significant difference (P = .044) in sensitivity for the affected upper limb ulnar nerve in the experimental group, whereas the rest of the assessed nerves (affected and nonaffected upper limb nerves) showed no significant changes in either the experimental or control groups (P > .05). An analysis of covariance revealed no significant interactions on pressure pain thresholds over the nerves for affected (all P > .05) and nonaffected (all P > .05) upper limb nerves. CONCLUSION A single myofascial induction session may partially improve mechanosensitivity of median, radial, and ulnar nerves and yield positive effects on symptom mechanosensitivity, especially regarding the ulnar nerve in breast cancer survivors.",2020,"An analysis of covariance revealed no significant interactions on pressure pain thresholds over the nerves for affected (all P > .05) and nonaffected (all P > .05) upper limb nerves. ","['Breast Cancer Survivors', '21 breast cancer survivors with stage I-IIIA cancer']","['placebo control group (unplugged pulsed 30 minutes of shortwave therapy', 'myofascial induction', 'Single Myofascial Induction Session', 'placebo']","['pressure pain thresholds', 'Range of motion (universal goniometry), structural differentiation, symptoms (yes/no), and pressure pain thresholds (electronic algometry', 'Neural Mechanosensitivity', 'mechanosensitivity of median, radial, and ulnar nerves']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0037000', 'cui_str': 'Short Wave Therapy'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0037179', 'cui_str': 'Single person'}]","[{'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0175671', 'cui_str': 'Universal'}, {'cui': 'C0007589', 'cui_str': 'Differentiation, Cell'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1298907', 'cui_str': 'Yes'}, {'cui': 'C1298908', 'cui_str': 'No'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0041602', 'cui_str': 'Structure of ulnar nerve'}]",21.0,0.0523857,"An analysis of covariance revealed no significant interactions on pressure pain thresholds over the nerves for affected (all P > .05) and nonaffected (all P > .05) upper limb nerves. ","[{'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Castro-Martín', 'Affiliation': 'Department of Physical Therapy, University of Granada, Granada, Spain; Instituto Mixto Universitario Deporte y Salud, Granada, Spain.'}, {'ForeName': 'Noelia', 'Initials': 'N', 'LastName': 'Galiano-Castillo', 'Affiliation': 'Department of Physical Therapy, University of Granada, Granada, Spain; Instituto Mixto Universitario Deporte y Salud, Granada, Spain; Instituto Biosanitario Granada, Granada, Spain. Electronic address: noeliagaliano@ugr.es.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Ortiz-Comino', 'Affiliation': 'Department of Physical Therapy, University of Granada, Granada, Spain.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Cantarero-Villanueva', 'Affiliation': 'Department of Physical Therapy, University of Granada, Granada, Spain; Instituto Mixto Universitario Deporte y Salud, Granada, Spain; Instituto Biosanitario Granada, Granada, Spain.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Lozano-Lozano', 'Affiliation': 'Department of Physical Therapy, University of Granada, Granada, Spain; Instituto Mixto Universitario Deporte y Salud, Granada, Spain; Instituto Biosanitario Granada, Granada, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Arroyo-Morales', 'Affiliation': 'Department of Physical Therapy, University of Granada, Granada, Spain; Instituto Mixto Universitario Deporte y Salud, Granada, Spain; Instituto Biosanitario Granada, Granada, Spain.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Fernández-Lao', 'Affiliation': 'Department of Physical Therapy, University of Granada, Granada, Spain; Instituto Mixto Universitario Deporte y Salud, Granada, Spain; Instituto Biosanitario Granada, Granada, Spain.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2019.03.016'] 2580,32703614,Effect of Pelvic Floor and Hip Muscle Strengthening in the Treatment of Stress Urinary Incontinence: A Randomized Clinical Trial.,"OBJECTIVE To investigate the effectiveness of strengthening the hip muscles in addition to strengthening the pelvic floor muscles (PFM) in the treatment of stress urinary incontinence. METHODS This study used a prospective, assessor-blind, randomized clinical trial with parallel groups. We randomly allocated 47 individuals with stress urinary incontinence to 2 groups: 1 performing only pelvic floor strengthening exercises (PF, n = 21) and the other performing pelvic floor strengthening exercises plus exercises for the gluteus maximus and medius and hip adductor muscles (PFH, n = 22). Four individuals did not complete the study. Frequency of urine leakage was the primary outcome (3-day voiding diary and a follow-up voiding diary). Secondary outcomes were pelvic floor muscle strength (Ortiz scale, PERFECT scheme [Oxford Scale], and perineometry) and quality of life (QoL; International Consultation on Incontinence Questionnaire-Short Form and King's Health Questionnaire), which were evaluated by a blinded assessor before and after 20 sessions over 10 weeks. RESULTS Regarding the daily frequency of urine loss evaluated by the follow-up voiding diary, an effect of group was observed (P < .001), with the PFH group showing a significant decrease in daily loss frequency, although no significant differences were found in the comparison between groups for the 3-day voiding diary, QoL, or functional assessment of the PFM. CONCLUSION Strengthening the PFM together with the hip synergic muscles showed better results for frequency of daily urine loss throughout the sessions, although there was no accompanying superiority in improvement of strength, perineometry, or QoL over the group that performed only PFM-strengthening exercises.",2020,"Strengthening the PFM together with the hip synergic muscles showed better results for frequency of daily urine loss throughout the sessions, although there was no accompanying superiority in improvement of strength, perineometry, or QoL over the group that performed only PFM-strengthening exercises.","['Stress Urinary Incontinence', '47 individuals with stress urinary incontinence to 2 groups', 'stress urinary incontinence']","['Pelvic Floor and Hip Muscle Strengthening', 'PFH', '1 performing only pelvic floor strengthening exercises (PF, n\u202f=\u202f21) and the other performing pelvic floor strengthening exercises plus exercises']","['Frequency of urine leakage', 'strength, perineometry, or QoL', 'daily loss frequency', 'frequency of daily urine loss', '3-day voiding diary, QoL, or functional assessment of the PFM', ""pelvic floor muscle strength (Ortiz scale, PERFECT scheme [Oxford Scale], and perineometry) and quality of life (QoL; International Consultation on Incontinence Questionnaire-Short Form and King's Health Questionnaire""]","[{'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0224415', 'cui_str': 'Skeletal muscle structure of hip'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0452260', 'cui_str': 'Muscular strength development exercise'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0152245', 'cui_str': 'Extravasation of urine'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0042034', 'cui_str': 'Micturition'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C2711460', 'cui_str': 'International consultation on incontinence questionnaire'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",47.0,0.0646245,"Strengthening the PFM together with the hip synergic muscles showed better results for frequency of daily urine loss throughout the sessions, although there was no accompanying superiority in improvement of strength, perineometry, or QoL over the group that performed only PFM-strengthening exercises.","[{'ForeName': 'Simone A A', 'Initials': 'SAA', 'LastName': 'Marques', 'Affiliation': 'Department of Physical Therapy, Speech and Occupational Therapy, School of Medicine, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Simone R B da', 'Initials': 'SRBD', 'LastName': 'Silveira', 'Affiliation': 'Department of Obstetrics and Gynecology, Urogynecology Section, University Hospital, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Anice C', 'Initials': 'AC', 'LastName': 'Pássaro', 'Affiliation': 'Department of Physical Therapy, Speech and Occupational Therapy, School of Medicine, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Jorge M', 'Initials': 'JM', 'LastName': 'Haddad', 'Affiliation': 'Department of Obstetrics and Gynecology, Urogynecology Section, Clinical Hospital, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Edmund C', 'Initials': 'EC', 'LastName': 'Baracat', 'Affiliation': 'Department of Obstetrics and Gynecology, Urogynecology Section, University Hospital, University of São Paulo, São Paulo, Brazil; Department of Obstetrics and Gynecology, Urogynecology Section, Clinical Hospital, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Elizabeth A G', 'Initials': 'EAG', 'LastName': 'Ferreira', 'Affiliation': 'Department of Physical Therapy, Speech and Occupational Therapy, School of Medicine, University of São Paulo, São Paulo, Brazil. Electronic address: elferreira@usp.br.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2019.01.007'] 2581,32703623,The use of the reds noninvasive lung fluid monitoring system to assess readiness for discharge in patients hospitalized with acute heart failure: A pilot study.,"BACKGROUND Inadequate decongestion is common in hospitalized heart failure (HF) patients and may contribute to readmissions. Our purpose was to use remote dielectric sensing (ReDS) technology to measure lung congestion at discharge in patients admitted with acute HF and to see if a device-targeted intervention could reduce HF readmission rates. METHODS We conducted a prospective pilot study of patients admitted with acute decompensated HF randomized to receive standard therapy or ReDS-guided therapy to determine the timing of hospital discharge based on the amount of lung congestion present after diuresis. ReDS measurement was performed for all patients once they were deemed ready for discharge. Patients in the treatment arm with residual lung congestion defined by ReDS ≥39% had HF consultation and further diuresis. RESULTS Of 108 HF patients (50% male, age 73.6 ± 12.6 years, BMI 29.3 ± 4.3 kg/m 2 , EF 38.5 ± 15.1%, BNP 1138 ± 987 pg/mL), 32% demonstrated residual lung congestion at the time of proposed hospital discharge. ReDS guided therapy triggered additional diuresis in 30% (18/60) of the patients in the treatment arm (average weight loss 5.6 pounds, p = 0.02). 30-day HF readmission rates were similar in the treatment and the control arms (1.7% vs 4.2%; p = 0.44). Patients discharged as planned with residual lung congestion with ReDS ≥39% had higher 30-day readmission rate compared to patients who were adequately decongested at discharge with ReDS <39% (11.8% vs. 1.4%, p = 0.03). CONCLUSION In our single-center cohort, ReDS testing demonstrated that 32% of HF patients deemed ready for discharge have clinically significant residual lung congestion which was associated with a higher risk of readmission. ReDS-guided management was associated with significant decongestion but not a reduction in HF readmissions in this sample.",2020,"Patients discharged as planned with residual lung congestion with ReDS ≥39% had higher 30-day readmission rate compared to patients who were adequately decongested at discharge with ReDS <39% (11.8% vs. 1.4%, p = 0.03). ","['108 HF patients (50% male', 'patients admitted with acute HF', 'patients hospitalized with acute heart failure', 'hospitalized heart failure (HF) patients', 'patients admitted with acute decompensated HF randomized to receive', 'age 73.6\u202f±\u202f12.6 years, BMI 29.3\u202f±\u202f4.3\u202fkg/m 2 , EF 38.5\u202f±\u202f15.1%, BNP 1138\u202f±\u202f987 pg/mL']","['remote dielectric sensing (ReDS) technology', 'reds noninvasive lung fluid monitoring system', 'standard therapy or ReDS-guided therapy']","['HF consultation and further diuresis', 'HF readmissions', '30-day HF readmission rates', 'residual lung congestion', '30-day readmission rate']","[{'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0264714', 'cui_str': 'Acute heart failure'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517545', 'cui_str': '12.6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517759', 'cui_str': '4.3'}, {'cui': 'C0054015', 'cui_str': 'Nesiritide'}, {'cui': 'C0439297', 'cui_str': 'ng/L'}]","[{'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0332575', 'cui_str': 'Red color'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0012797', 'cui_str': 'Diuresis'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0242073', 'cui_str': 'Pulmonary congestion'}, {'cui': 'C0030700', 'cui_str': 'Thirty Day Readmission'}]",108.0,0.0711084,"Patients discharged as planned with residual lung congestion with ReDS ≥39% had higher 30-day readmission rate compared to patients who were adequately decongested at discharge with ReDS <39% (11.8% vs. 1.4%, p = 0.03). ","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Bensimhon', 'Affiliation': 'Department of Cardiology, Cone Health, Greensboro, NC, United States.'}, {'ForeName': 'Sukaina Ali', 'Initials': 'SA', 'LastName': 'Alali', 'Affiliation': 'Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, United States. Electronic address: sukainaalali@gmail.com.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Curran', 'Affiliation': 'Department of Cardiology, Cone Health, Greensboro, NC, United States.'}, {'ForeName': 'Elad', 'Initials': 'E', 'LastName': 'Gelbart', 'Affiliation': 'Sensible Medical Innovations Ltd. Netanya, Israel.'}, {'ForeName': 'Daphne Wooda Vivian', 'Initials': 'DWV', 'LastName': 'Garman', 'Affiliation': 'Department of Cardiology, Cone Health, Greensboro, NC, United States.'}, {'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Taylor', 'Affiliation': 'Department of Cardiology, Cone Health, Greensboro, NC, United States.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Chase', 'Affiliation': 'Department of Cardiology, Cone Health, Greensboro, NC, United States.'}, {'ForeName': 'W Frank', 'Initials': 'WF', 'LastName': 'Peacock', 'Affiliation': 'Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, United States.'}]",Heart & lung : the journal of critical care,['10.1016/j.hrtlng.2020.07.003'] 2582,32703627,Effectiveness of a Back School and Postural Education Program on the improvement of literacy about postures and low back pain in adolescents: A 1-year follow-up study.,"BACKGROUND Some health problems can be associated with the school environment and lifestyles, so it is necessary to carry out intervention actions that promote health and problem prevention. This study evaluates the effects of a Back School and Postural Education on improving short-term and long-term ergonomic knowledge of postures adopted at school and home, as well as reducing low back pain (LBP) in adolescents. METHODS The sample comprises 98 students, aged 10-16 years (11.61 ± 1.28 years), with 63 (64.3%) girls. The measuring instruments included a theoretical and a practical test, a low back pain (LBP) questionnaire and a scale. The tests and the scale have been applied 1 week before the intervention, 1 week following the Back School and Postural Education Program, and a 1 year later. The questionnaire was applied 1 week before of intervention and after 1 year. The intervention included three sessions of a theoretical and practical nature, each lasting 45 min, with intervals of 1 week. RESULTS The values of the theoretical test before the intervention, 1 week, and 1 year after the intervention were, respectively, 8.67 ± 2.64, 11.37 ± 1.93, and 11.11 ± 1.92 (p ≤ 0.001), and the practical test were 6.42 ± 2.47, 12.48 ± 2.25, and 12.83 ± 1.78 (p ≤ 0.001). The presence of LBP fell by 42.9%-25.5% after the 1-year period. CONCLUSIONS Our data show an improvement of ergonomic knowledge of postures adopted at school and home as a result of the education program and a decrease of self-reported LBP.",2020,Our data show an improvement of ergonomic knowledge of postures adopted at school and home as a result of the education program and a decrease of self-reported LBP.,"['The sample comprises 98 students, aged 10-16 years (11.61\xa0±\xa01.28 years), with 63 (64.3%) girls', 'adolescents']","['Back School and Postural Education', 'Back School and Postural Education Program']","['LBP fell', 'low back pain (LBP', 'literacy about postures and low back pain', 'low back pain (LBP) questionnaire and a scale']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}]","[{'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",98.0,0.0199644,Our data show an improvement of ergonomic knowledge of postures adopted at school and home as a result of the education program and a decrease of self-reported LBP.,"[{'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Minghelli', 'Affiliation': 'School of Health Jean Piaget Algarve, Piaget Institute, Research in Education and Community Intervention (RECI), Portugal. Electronic address: beatriz.minghelli@silves.ipiaget.pt.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Nunes', 'Affiliation': 'National School of Public Health, NOVA University of Lisbon, Lisbon, Portugal.'}, {'ForeName': 'Raul', 'Initials': 'R', 'LastName': 'Oliveira', 'Affiliation': 'CIPER, Human Kinetics Faculty, University of Lisbon, UL, Lisbon, Portugal.'}]",Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association,['10.1016/j.jos.2020.05.014'] 2583,32703634,A Randomised Controlled Trial Assessing the Effects of Peri-operative Fenofibrate Administration on Abdominal Aortic Aneurysm Pathology: Outcomes From the FAME Trial.,"OBJECTIVE Experimental studies suggest that fenofibrate prevents abdominal aortic aneurysm (AAA) development by lowering aortic osteopontin (OPN) concentration and reducing the number of macrophages infiltrating the aortic wall. The current study examined the effects of a short course of fenofibrate on AAA pathology in people with large AAAs awaiting aortic repair. METHODS This randomised double blind parallel trial included male and female participants aged ≥ 60 years who had an asymptomatic AAA measuring ≥ 50 mm and were scheduled to undergo open AAA repair. Participants were allocated to fenofibrate (145 mg/day) or matching placebo for at least two weeks before elective AAA repair. Blood samples were collected at recruitment and immediately prior to surgery. AAA biopsies were obtained during aortic surgery. The primary outcomes were (1) AAA OPN concentration; (2) serum OPN concentration; and (3) number of AAA macrophages. Exploratory outcomes included circulating and aortic concentrations of other proteins previously associated with AAA. Outcomes assessed at a single time point were compared using logistic regression. Longitudinal outcomes were compared using linear mixed effects models. RESULTS Forty-three participants were randomised. After three withdrawals, 40 were followed until the time of surgery (21 allocated fenofibrate and 19 allocated placebo). As expected, serum triglycerides reduced significantly from recruitment to the time of surgery in participants allocated fenofibrate. No differences in any of the primary and exploratory outcomes were observed between groups. CONCLUSION A short course of 145 mg of fenofibrate/day did not lower concentrations of OPN or aortic macrophage density in people with large AAAs.",2020,A short course of 145 mg of fenofibrate/day did not lower concentrations of OPN or aortic macrophage density in people with large AAAs.,"['Forty-three participants were randomised', 'people with large AAAs', 'male and female participants aged ≥ 60 years who had an asymptomatic AAA measuring ≥ 50\xa0mm and were scheduled to undergo open AAA repair', 'people with large AAAs awaiting aortic repair', 'Abdominal Aortic Aneurysm Pathology']","['fenofibrate and 19 allocated placebo', 'fenofibrate', 'Peri-operative Fenofibrate Administration', 'matching placebo']","['serum triglycerides', 'Blood samples', 'AAA OPN concentration; (2) serum OPN concentration; and (3) number of AAA macrophages', 'concentrations of OPN or aortic macrophage density', 'circulating and aortic concentrations of other proteins previously associated with AAA']","[{'cui': 'C0450368', 'cui_str': '43'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0271742', 'cui_str': 'Glucocorticoid deficiency with achalasia'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0162871', 'cui_str': 'Abdominal aortic aneurysm'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0450400', 'cui_str': '50mm'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0741152', 'cui_str': 'Repair of aneurysm of abdominal aorta'}, {'cui': 'C0003483', 'cui_str': 'Aortic'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}]","[{'cui': 'C0033228', 'cui_str': 'Fenofibrate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]","[{'cui': 'C0542495', 'cui_str': 'Measurement of serum triglyceride level'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0162871', 'cui_str': 'Abdominal aortic aneurysm'}, {'cui': 'C0069676', 'cui_str': 'Osteopontin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0024432', 'cui_str': 'Macrophage'}, {'cui': 'C0003483', 'cui_str': 'Aortic'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}]",43.0,0.5654,A short course of 145 mg of fenofibrate/day did not lower concentrations of OPN or aortic macrophage density in people with large AAAs.,"[{'ForeName': 'Joseph V', 'Initials': 'JV', 'LastName': 'Moxon', 'Affiliation': 'The Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia; Centre for Molecular Therapeutics, The Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia.'}, {'ForeName': 'Sophie E', 'Initials': 'SE', 'LastName': 'Rowbotham', 'Affiliation': ""The University of Queensland, UQ Centre for Clinical Research, Herston, Queensland, Australia; Department of Vascular Surgery, The Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.""}, {'ForeName': 'Jenna L', 'Initials': 'JL', 'LastName': 'Pinchbeck', 'Affiliation': 'The Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.'}, {'ForeName': 'Sharon M', 'Initials': 'SM', 'LastName': 'Lazzaroni', 'Affiliation': 'The Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.'}, {'ForeName': 'Susan K', 'Initials': 'SK', 'LastName': 'Morton', 'Affiliation': 'The Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.'}, {'ForeName': 'Corey S', 'Initials': 'CS', 'LastName': 'Moran', 'Affiliation': 'The Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Quigley', 'Affiliation': 'Mater Medical Centre, Pimlico, Queensland, Australia.'}, {'ForeName': 'Jason S', 'Initials': 'JS', 'LastName': 'Jenkins', 'Affiliation': ""Department of Vascular Surgery, The Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.""}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Reid', 'Affiliation': 'School of Public Health, Curtin University, Perth, Western Australia, Australia; School of Public Health and Preventative Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Doug', 'Initials': 'D', 'LastName': 'Cavaye', 'Affiliation': ""St Vincent's Private Hospital Northside, Chermside, Queensland, Australia.""}, {'ForeName': 'Rene', 'Initials': 'R', 'LastName': 'Jaeggi', 'Affiliation': 'The Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Golledge', 'Affiliation': 'The Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia; Centre for Molecular Therapeutics, The Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia; Department of Vascular and Endovascular Surgery, Townsville University Hospital, Townsville, Queensland, Australia. Electronic address: jonathan.golledge@jcu.edu.au.'}]",European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery,['10.1016/j.ejvs.2020.06.006'] 2584,32703974,"Functional high-intensity exercise is more effective in acutely increasing working memory than aerobic walking: an exploratory randomized, controlled trial.","Aerobic and resistance exercise acutely increase cognitive performance (CP). High-intensity functional training (HIFT) combines the characteristics of both regimes but its effect on CP is unclear. Thirty-five healthy individuals (26.7 ± 3.6 years, 18 females) were randomly allocated to three groups. The first (HIFT) performed a functional whole-body workout at maximal effort and in circuit format, while a second walked at 60% of the heart rate reserve (WALK). The third group remained physically inactive reading a book (CON). Before and after the 15-min intervention period, CP was assessed with the Stroop Test, Trail Making Test and Digit Span Test. Repeated-measures ANOVAs and post-hoc 95% confidence intervals (95% CI) were used to detect time/group differences. A significant group*time interaction was found for the backwards condition of the Digit Span Test (p = 0.04) and according to the 95% CI, HIFT was superior to WALK and CON. Analysis of the sum score of the Digit Span Test and the incongruent condition of the Stroop Test, furthermore, revealed main effects for time (p < 0.05) with HIFT being the only intervention improving CP. No differences were found for the Trail Making Test (p > 0.05). In conclusion, HIFT represents an appropriate method to acutely improve working memory, potentially being superior to moderate aerobic-type exercise.",2020,No differences were found for the Trail Making Test (p > 0.05).,"['Thirty-five healthy individuals (26.7\u2009±\u20093.6\xa0years, 18 females']","['Aerobic and resistance exercise', 'HIFT', 'Functional high-intensity exercise', 'High-intensity functional training (HIFT']","['cognitive performance (CP', 'Stroop Test, Trail Making Test and Digit Span Test', 'physically inactive reading a book (CON']","[{'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4517694', 'cui_str': '3.6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]","[{'cui': 'C2718024', 'cui_str': 'Stroop Task'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0006002', 'cui_str': 'Book'}]",35.0,0.0307978,No differences were found for the Trail Making Test (p > 0.05).,"[{'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Wilke', 'Affiliation': 'Department of Sports Medicine, Goethe University Frankfurt am Main, Ginnheimer Landstraße 39, 60487, Frankfurt am Main, Germany. wilke@sport.uni-frankfurt.de.'}]",Scientific reports,['10.1038/s41598-020-69139-z'] 2585,32694638,Circulatory and prostatic tissue lipidomic profiles shifts after high-dose atorvastatin use in men with prostate cancer.,"Prostate cancer patients using cholesterol-lowering statins have 30% lower risk of prostate cancer death compared to non-users. The effect is attributed to the inhibition of the mevalonate pathway in prostate cancer cells. Moreover, statin use causes lipoprotein metabolism changes in the serum. Statin effect on serum or intraprostatic lipidome profiles in prostate cancer patients has not been explored. We studied changes in the serum metabolomic and prostatic tissue lipidome after high-dose 80 mg atorvastatin intervention to expose biological mechanisms causing the observed survival benefit. Our randomized, double-blind, placebo-controlled clinical trial consisted of 103 Finnish men with prostate cancer. We observed clear difference in post-intervention serum lipoprotein lipid profiles between the study arms (median classification error 11.7%). The atorvastatin effect on intraprostatic lipid profile was not as clear (median classification error 44.7%), although slightly differing lipid profiles by treatment arm was observed, which became more pronounced in men who used atorvastatin above the median of 27 days (statin group median classification error 27.2%). Atorvastatin lowers lipids important for adaptation for hypoxic microenvironment in the prostate suggesting that prostate cancer cell survival benefit associated with statin use might be mediated by both, local and systemic, lipidomic/metabolomic profile changes.",2020,We observed clear difference in post-intervention serum lipoprotein lipid profiles between the study arms (median classification error 11.7%).,"['Prostate cancer patients using', 'men with prostate cancer', 'prostate cancer patients', '103 Finnish men with prostate cancer']","['atorvastatin', 'atorvastatin intervention', 'Atorvastatin', 'cholesterol-lowering statins', 'placebo']","['post-intervention serum lipoprotein lipid profiles', 'intraprostatic lipid profile', 'prostate cancer death', 'serum metabolomic and prostatic tissue lipidome', 'serum or intraprostatic lipidome profiles']","[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0016134', 'cui_str': 'Finnish language'}]","[{'cui': 'C0286651', 'cui_str': 'atorvastatin'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0023820', 'cui_str': 'Lipoprotein'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C1512969', 'cui_str': 'Intraprostatic route'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1328813', 'cui_str': 'Metabolomics'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C4727084', 'cui_str': 'Lipidome'}]",103.0,0.131476,We observed clear difference in post-intervention serum lipoprotein lipid profiles between the study arms (median classification error 11.7%).,"[{'ForeName': 'Paavo', 'Initials': 'P', 'LastName': 'Raittinen', 'Affiliation': 'Department of Mathematics and Systems Analysis, Aalto University School of Science, Helsinki, Finland. paavo.raittinen@aalto.fi.'}, {'ForeName': 'Kati', 'Initials': 'K', 'LastName': 'Niemistö', 'Affiliation': 'Tampere University, Tampere, Finland.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Pennanen', 'Affiliation': 'School of Pharmacy, University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Heimo', 'Initials': 'H', 'LastName': 'Syvälä', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Seppo', 'Initials': 'S', 'LastName': 'Auriola', 'Affiliation': 'School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Jarno', 'Initials': 'J', 'LastName': 'Riikonen', 'Affiliation': 'Tays Cancer Center, Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Terho', 'Initials': 'T', 'LastName': 'Lehtimäki', 'Affiliation': 'Department of Clinical Chemistry, Faculty of Medicine and Health Technology, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, Tampere University, Tampere, Finland.'}, {'ForeName': 'Pauliina', 'Initials': 'P', 'LastName': 'Ilmonen', 'Affiliation': 'Department of Mathematics and Systems Analysis, Aalto University School of Science, Helsinki, Finland.'}, {'ForeName': 'Teemu', 'Initials': 'T', 'LastName': 'Murtola', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland.'}]",Scientific reports,['10.1038/s41598-020-68868-5'] 2586,32694705,The closed eye harbours a unique microbiome in dry eye disease.,"Dry eye affects millions of individuals. In experimental models, dry eye disease is associated with T helper cell 17-mediated inflammation of the ocular surface that may cause persistent damage to the corneal epithelium. However, the initiating and perpetuating factors associated with chronic inflammation of the ocular surface remain unclear. The ocular microbiota alters ocular surface inflammation and may influence dry eye disease development and progression. Here, we collected serial samples of tears on awakening from sleep, closed eye tears, during a randomized clinical trial of a non-pharmaceutical dry eye therapy and used 16S rRNA metabarcoding to characterize the microbiome. We show the closed dry eye microbiome is distinct from the healthy closed eye microbiome, and that the microbiome remains distinct despite daily saline eye wash upon awakening. The ocular microbiome was described only recently, and this report implicates a distinct microbiome in ocular disease development. Our findings suggest an interplay between microbial commensals and inflammation on the ocular surface. This information may inform future studies of the pathophysiological mechanisms of dry eye disease.",2020,"In experimental models, dry eye disease is associated with T helper cell 17-mediated inflammation of the ocular surface that may cause persistent damage to the corneal epithelium.",[],[],[],[],[],[],,0.0277235,"In experimental models, dry eye disease is associated with T helper cell 17-mediated inflammation of the ocular surface that may cause persistent damage to the corneal epithelium.","[{'ForeName': 'Kent A', 'Initials': 'KA', 'LastName': 'Willis', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, USA.'}, {'ForeName': 'Cameron K', 'Initials': 'CK', 'LastName': 'Postnikoff', 'Affiliation': 'School of Optometry, University of Alabama At Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'Freeman', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, College of Medicine, University of Alabama At Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Rezonzew', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, College of Medicine, University of Alabama At Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Nichols', 'Affiliation': 'School of Optometry, University of Alabama At Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Gaggar', 'Affiliation': 'Program in Protease and Matrix Biology, Department of Pediatrics, College of Medicine, Women and Infants Center, University of Alabama At Birmingham, 176F Suite 9380, 619 South 19th Street, Birmingham, AL, 35249-7335, USA.'}, {'ForeName': 'Charitharth V', 'Initials': 'CV', 'LastName': 'Lal', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, College of Medicine, University of Alabama At Birmingham, Birmingham, AL, USA. clal@peds.uab.edu.'}]",Scientific reports,['10.1038/s41598-020-68952-w'] 2587,32694748,A tele-health intervention to increase physical fitness in people with spinal cord injury and cardiometabolic disease or risk factors: a pilot randomized controlled trial.,"STUDY DESIGN Clinical trial. OBJECTIVES We used a single-blind parallel-group design to test the feasibility and preliminary efficacy of a telehealth-based physical activity counseling intervention to increase physical fitness in people with SCI. SETTING Seattle, Washington, United States. METHODS We recruited under-active, manual wheelchair-using adults at least 1-year post-SCI who had at least two cardiometabolic risk factors/diseases. Participants underwent baseline tests of peak cardiorespiratory fitness; lipids, glucose and insulin; muscle and fat mass; self-reported physical activity, depression, pain and other factors. Participants were assigned 1:1 to treatment vs. usual care (UC) control conditions via concealed computerized randomization. Treatment was delivered via telephone and adapted from the 16-session Diabetes Prevention Program. All baseline tests were repeated at 6 months. Prespecified feasibility goals were to recruit at least nine participants/quarter and retain 85% with complete fitness testing at 6 months. Prespecified efficacy goals were to demonstrate at least a medium treatment effect size (0.50) on fitness, self-reported physical activity, and other outcomes. RESULTS Seven participants were randomized to treatment, 8 to UC over 15 months. Maximum recruitment was only 5.4 participants/quarter. Thirteen (87%) of participants were retained. The effects of treatment on fitness and most cardiometabolic risk factors did not meet expectations, whereas the effects on self-reported physical activity, depression, and pain did meet expectations. CONCLUSIONS The study did not meet key efficacy and feasibility objectives, yet there were some promising effects on self-report measures and lessons to be learned for designing future trials.",2020,"The effects of treatment on fitness and most cardiometabolic risk factors did not meet expectations, whereas the effects on self-reported physical activity, depression, and pain did meet expectations. ","['We recruited under-active, manual wheelchair-using adults at least 1-year post-SCI who had at least two cardiometabolic risk factors/diseases', 'Seattle, Washington, United States', 'people with spinal cord injury and cardiometabolic disease or risk factors', 'people with SCI']","['usual care (UC) control conditions via concealed computerized randomization', 'telehealth-based physical activity counseling intervention', 'health intervention']","['physical fitness', 'fitness, self-reported physical activity, and other outcomes', 'peak cardiorespiratory fitness; lipids, glucose and insulin; muscle and fat mass; self-reported physical activity, depression, pain and other factors']","[{'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0184423', 'cui_str': 'Manual wheelchair'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0043038', 'cui_str': 'Washington'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0443189', 'cui_str': 'Concealed'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",7.0,0.120234,"The effects of treatment on fitness and most cardiometabolic risk factors did not meet expectations, whereas the effects on self-reported physical activity, depression, and pain did meet expectations. ","[{'ForeName': 'Charles H', 'Initials': 'CH', 'LastName': 'Bombardier', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA. chb@uw.edu.'}, {'ForeName': 'Joshua R', 'Initials': 'JR', 'LastName': 'Dyer', 'Affiliation': 'Peacehealth Medical Group, Vancouver, WA, USA.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Burns', 'Affiliation': 'The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Deborah A', 'Initials': 'DA', 'LastName': 'Crane', 'Affiliation': 'Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Melissa M', 'Initials': 'MM', 'LastName': 'Takahashi', 'Affiliation': 'Department of Ophthalmology, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Barber', 'Affiliation': 'Department of Neurosurgery, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Mark S', 'Initials': 'MS', 'LastName': 'Nash', 'Affiliation': 'Departments of Neurological Surgery, Physical Medicine & Rehabilitation and Physical Therapy, University of Miami Miller School of Medicine, Miami, FL, USA.'}]",Spinal cord,['10.1038/s41393-020-0523-6'] 2588,32694901,"Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors.","Objective Fluzoparib (SHR3162) is a novel, potent poly(ADP-ribose) polymerases (PARP)1, 2 inhibitor that showed anti-tumor activity in xenograft models. We conducted a phase I, first-in-human, dose-escalation and expansion (D-Esc and D-Ex) trial in patients with advanced solid cancer. Methods This was a 3+3 phase I D-Esc trial with a 3-level D-Ex at 5 hospitals in China. Eligible patients for D-Esc had advanced solid tumors refractory to standard therapies, and D-Ex enrolled patients with ovarian cancer (OC). Fluzoparib was administered orally once or twice daily (bid) at 11 dose levels from 10 to 400 mg/d. Endpoints included dose-finding, safety, pharmacokinetics, and antitumor activity. Results Seventy-nine patients were enrolled from March, 2015 to January, 2018 [OC (47, 59.5%); breast cancer (BC) (16, 20.3%); colorectal cancer (8, 10.1%), other tumors (8, 10.1%)]; 48 patients were treated in the D-Esc arm and 31 in the D-Ex arm. The maximum tolerated dose (MTD) was 150 mg bid, with a half-life of 9.14 h. Grade 3/4 adverse events included anemia (7.6%) and neutropenia (5.1%). The objective response rate (ORR) was 30% (3/10) in patients with platinum-sensitive OC and 7.7% (1/13) in patients with BC. Among patients treated with fluzoparib ≥120 mg/d, median progression-free survival (mPFS) was 7.2 [95% confidence interval (95% CI), 1.8-9.3] months in OC, 9.3 (95% CI, 7.2-9.3) months in platinum-sensitive OC, and 3.5 (range, 2.0-28.0) months in BC. In patients with germline BC susceptibility gene mutation (g BRCA Mut ) (11/43 OC; 2/16 BC), mPFS was 8.9 months for OC (range, 1.0-23.2; 95% CI, 1.0-16.8) and 14 and 28 months for BC (those two patients both also had somatic BRCA Mut ). Conclusions The MTD of fluzoparib was 150 mg bid in advanced solid malignancies. Fluzoparib demonstrated single-agent antitumor activity in BC and OC, particularly in BRCA Mut and platinum-sensitive OC.",2020,The objective response rate (ORR) was 30% (3/10) in patients with platinum-sensitive OC and 7.7% (1/13) in patients with BC.,"['patients with advanced solid cancer', 'Results\n\n\nSeventy-nine patients were enrolled from March, 2015 to January, 2018 [OC (47, 59.5%); breast cancer (BC) (16, 20.3%); colorectal cancer (8, 10.1%), other tumors (8, 10.1%)]; 48 patients were treated in the D-Esc arm and 31 in the D-Ex arm', 'Eligible patients for D-Esc had advanced solid tumors refractory to standard therapies, and D-Ex enrolled patients with ovarian cancer (OC', 'patients with advanced solid tumors']","['Fluzoparib (SHR3162', 'Fluzoparib', 'fluzoparib', 'PARP inhibitor, fluzoparib (SHR3162']","['objective response rate (ORR', 'neutropenia', 'dose-finding, safety, pharmacokinetics, and antitumor activity', 'anemia', 'maximum tolerated dose (MTD', 'median progression-free survival (mPFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205208', 'cui_str': 'Solid'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0032403', 'cui_str': 'Poly-Adenosine Diphosphate-Ribose'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0752079', 'cui_str': 'Maximal Tolerated Dose'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",79.0,0.0341463,The objective response rate (ORR) was 30% (3/10) in patients with platinum-sensitive OC and 7.7% (1/13) in patients with BC.,"[{'ForeName': 'Huiping', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.'}, {'ForeName': 'Rongrui', 'Initials': 'R', 'LastName': 'Liu', 'Affiliation': 'Department of Gastrointestinal Oncology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Shao', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.'}, {'ForeName': 'Ran', 'Initials': 'R', 'LastName': 'Ran', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.'}, {'ForeName': 'Guohong', 'Initials': 'G', 'LastName': 'Song', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.'}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Department of Gynecological Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.'}, {'ForeName': 'Yehui', 'Initials': 'Y', 'LastName': 'Shi', 'Affiliation': 'Department of Gynecological Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.'}, {'ForeName': 'Jihong', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Department of Gynecologic Oncology, Sun Yat-sen University Cancer Centre, Guangzhou 510060, China.'}, {'ForeName': 'Wenjing', 'Initials': 'W', 'LastName': 'Hu', 'Affiliation': 'The Comprehensive Cancer Center of Drum Tower Hospital, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.'}, {'ForeName': 'Fu', 'Initials': 'F', 'LastName': 'Chen', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.'}, {'ForeName': 'Xiaoran', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.'}, {'ForeName': 'Gairong', 'Initials': 'G', 'LastName': 'Zhang', 'Affiliation': 'Department of Gastrointestinal Oncology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China.'}, {'ForeName': 'Chuanhua', 'Initials': 'C', 'LastName': 'Zhao', 'Affiliation': 'Department of Gastrointestinal Oncology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China.'}, {'ForeName': 'Ru', 'Initials': 'R', 'LastName': 'Jia', 'Affiliation': 'Department of Gastrointestinal Oncology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China.'}, {'ForeName': 'Quanren', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': 'Department of Clinical Medicine-Oncology, Jiangsu Hengrui Medicine Co., Ltd., Shanghai 201203, China.'}, {'ForeName': 'Hope S', 'Initials': 'HS', 'LastName': 'Rugo', 'Affiliation': 'Department of Medicine, University of California San Francisco Comprehensive Cancer Center, San Francisco 94127, USA.'}, {'ForeName': 'Yifan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.'}, {'ForeName': 'Guangze', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Department of Clinical Medicine-Oncology, Jiangsu Hengrui Medicine Co., Ltd., Shanghai 201203, China.'}, {'ForeName': 'Jianming', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Department of Gastrointestinal Oncology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China.'}]",Chinese journal of cancer research = Chung-kuo yen cheng yen chiu,['10.21147/j.issn.1000-9604.2020.03.08'] 2589,32694916,Effectiveness of a Multidisciplinary Approach Intervention to Improve Blood Pressure Control Among Elderly Hypertensive Patients in Rural Thailand: A Quasi-Experimental Study.,"Purpose Uncontrolled blood pressure among Thai elderly hypertensive patients is a significant public health issue in primary health care facilities under the Universal Health Coverage Scheme in Thailand. This study examines the effectiveness of a multidisciplinary approach intervention to improve blood pressure control among elderly persons in rural Thailand. Patients and Methods This was quasi-experimental study conducted on 200 elderly persons who receive care for hypertension at primary health care facility in rural areas of Thailand. Participants were assigned to either the intervention or control groups. The intervention group was subjected to a multidisciplinary approach intervention program. This program included community-based care for hypertension, family-supportive care for hypertension, antihypertension medication adherence education program, the use of a reminder electronic pill box, and monthly pill counts and blood pressure measurements. The intervention continued for three months. The control group received care for hypertension at the hypertension clinic of the health center. Three measurements were taken at baseline, one month, and three months after the intervention. Data analysis included descriptive statistics and independent sample t -tests. Repeated-measure analysis of variance (ANOVA) and analysis of covariance (ANCOVA) were used to compare the differences between the two groups. Results At one month and three months after the intervention, the multidisciplinary approach intervention controlled blood pressure more effectively compared with the control group. Furthermore, the intervention group had lower systolic and diastolic blood pressure compared with the control group (P-value < 0.001). Conclusion These results suggest that the multidisciplinary approach intervention can be effective in controlling blood pressure in elderly hypertensive patients. Future studies should investigate a cost-effective means of integrating multidisciplinary approach interventions in routine hypertension care for elderly hypertensive patients.",2020,"At one month and three months after the intervention, the multidisciplinary approach intervention controlled blood pressure more effectively compared with the control group.","['Elderly Hypertensive Patients in Rural Thailand', '200 elderly persons who receive care for hypertension at primary health care facility in rural areas of Thailand', 'elderly persons in rural Thailand', 'elderly hypertensive patients', 'Thai elderly hypertensive patients']","['multidisciplinary approach intervention program', 'Multidisciplinary Approach Intervention', 'multidisciplinary approach intervention']","['lower systolic and diastolic blood pressure', 'blood pressure control', 'blood pressure', 'Blood Pressure Control']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039725', 'cui_str': 'Thailand'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0039724', 'cui_str': 'Thai language'}]","[{'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",200.0,0.0148934,"At one month and three months after the intervention, the multidisciplinary approach intervention controlled blood pressure more effectively compared with the control group.","[{'ForeName': 'Nanthakan Sungsuman', 'Initials': 'NS', 'LastName': 'Woodham', 'Affiliation': 'College of Public Health Sciences, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Surasak', 'Initials': 'S', 'LastName': 'Taneepanichskul', 'Affiliation': 'College of Public Health Sciences, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Ratana', 'Initials': 'R', 'LastName': 'Somrongthong', 'Affiliation': 'College of Public Health Sciences, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Apaporn', 'Initials': 'A', 'LastName': 'Kitsanapun', 'Affiliation': 'Sirindhorn College of Public Health Suphanburi, Suphan Buri, Thailand.'}, {'ForeName': 'Benjapan', 'Initials': 'B', 'LastName': 'Sompakdee', 'Affiliation': 'Buengkan District Health Office, Bueng Kan, Thailand.'}]",Journal of multidisciplinary healthcare,['10.2147/JMDH.S254286'] 2590,32702759,"Computer based patient education is non-inferior to nurse counselling prior to colonoscopy, a multicenter randomized controlled trial.","BACKGROUND Optimal patient education prior to colonoscopy improves adherence to instructions for bowel preparation and leads to cleaner colons. We developed computer based education (CBE) supported by video and 3D animations. We hypothesized that CBE replaces nurse counselling without losing quality of bowel preparation during colonoscopy. METHODS We conducted a prospective, multicenter, endoscopist blinded, non-inferiority randomized controlled trial. The primary outcome was adequate bowel preparation, evaluated using the Boston Bowel Preparation Scale (BBPS). Secondary outcome measures were sickness absence due to outpatient clinic visit, patient anxiety / satisfaction scores and information re-call. We included patients in four endoscopy units (rural, urban, and tertiary). RESULTS We screened 1035 eligible patients and randomized 845. After evaluation, 684 were included in the intention-to-treat (ITT) group. Subsequently, 497 patients were included in per-protocol (PP) analysis, 217 in nurse counselling and 280 in the CBE group. Baseline characteristics were similarly distributed among groups. In PP analysis, adequate bowel cleansing was achieved in 93.2 % (261/280) of CBE patients, which was non-inferior to nurse counselled patients (94%, 204/217), with a difference of -0.8% [95% CI [- 5.1; 3.5]%. Non-inferiority was confirmed in the ITT population. Sickness absence was significantly more frequent in nurse counselled patients (28.0% vs 4.8%). In CBE patients, 21.5% needed additional information, resulting in 3.0% extra outpatient visits. CONCLUSION CBE is non-inferior to nurse counselling in terms of bowel preparation during colonoscopy, with lower patient sickness leave. CBE may serve as an efficient educational tool informing patients before colonoscopy in routine clinical practice.",2020,"In PP analysis, adequate bowel cleansing was achieved in 93.2 % (261/280) of CBE patients, which was non-inferior to nurse counselled patients (94%, 204/217), with a difference of -0.8% [95% CI [- 5.1; 3.5]%. Non-inferiority was confirmed in the ITT population.","['1035 eligible patients and randomized 845', 'patients in four endoscopy units (rural, urban, and tertiary', '497 patients were included in per-protocol (PP) analysis, 217 in nurse counselling and 280 in the CBE group']","['CBE', 'Computer based patient education']","['adequate bowel cleansing', 'sickness absence due to outpatient clinic visit, patient anxiety / satisfaction scores and information re-call', 'adequate bowel preparation, evaluated using the Boston Bowel Preparation Scale (BBPS', 'Sickness absence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C4517646', 'cui_str': '217'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0150375', 'cui_str': 'Group education'}]","[{'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0030688', 'cui_str': 'Patient education'}]","[{'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0455052', 'cui_str': 'Preparation of bowel for procedure'}, {'cui': 'C4302285', 'cui_str': 'BBPS - Boston bowel preparation scale'}]",1035.0,0.368664,"In PP analysis, adequate bowel cleansing was achieved in 93.2 % (261/280) of CBE patients, which was non-inferior to nurse counselled patients (94%, 204/217), with a difference of -0.8% [95% CI [- 5.1; 3.5]%. Non-inferiority was confirmed in the ITT population.","[{'ForeName': 'Govert', 'Initials': 'G', 'LastName': 'Veldhuijzen', 'Affiliation': 'Radboudumc, Gastroenterology and hepatology, Nijmegen, Netherlands.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Klemt-Kropp', 'Affiliation': 'North West Hospital Group, Gastroenterology and Hepatology, Alkmaar, Netherlands.'}, {'ForeName': 'Jochim', 'Initials': 'J', 'LastName': 'Terhaar Sive Droste', 'Affiliation': 'Jeroen Bosch Hospital, Gastroenterology and Hepatology, Den Bosch, Netherlands.'}, {'ForeName': 'Bas', 'Initials': 'B', 'LastName': 'van Balkom', 'Affiliation': 'Ziekenhuis Bernhoven, Gastroenterology and Hepatology, Uden, Netherlands.'}, {'ForeName': 'Aura', 'Initials': 'A', 'LastName': 'van Esch', 'Affiliation': 'Radboudumc, Gastroenterology and hepatology, Nijmegen, Netherlands.'}, {'ForeName': 'Joost', 'Initials': 'J', 'LastName': 'Drenth', 'Affiliation': 'Radboudumc, Gastroenterology and hepatology, Nijmegen, Netherlands.'}]",Endoscopy,['10.1055/a-1225-8708'] 2591,32702760,The Effects of Delayed Cord Clamping on 12-Month Brain Myelin Content and Neurodevelopment: A Randomized Controlled Trial.,"OBJECTIVE This study aimed to determine if delayed cord clamping (DCC) affected brain myelin water volume fraction (VFm) and neurodevelopment in term infants. STUDY DESIGN This was a single-blinded randomized controlled trial of healthy pregnant women with term singleton fetuses randomized at birth to either immediate cord clamping (ICC) (≤ 20 seconds) or DCC (≥ 5 minutes). Follow-up at 12 months of age consisted of blood work for serum iron indices and lead levels, a nonsedated magnetic resonance imaging (MRI), followed within the week by neurodevelopmental testing. RESULTS At birth, 73 women were randomized into one of two groups: ICC (the usual practice) or DCC (the intervention). At 12 months, among 58 active participants, 41 (80%) had usable MRIs. There were no differences between the two groups on maternal or infant demographic variables. At 12 months, infants who had DCC had increased white matter brain growth in regions localized within the right and left internal capsules, the right parietal, occipital, and prefrontal cortex. Gender exerted no difference on any variables. Developmental testing (Mullen Scales of Early Learning, nonverbal, and verbal composite scores) was not significantly different between the two groups. CONCLUSION At 12 months of age, infants who received DCC had greater myelin content in important brain regions involved in motor function, visual/spatial, and sensory processing. A placental transfusion at birth appeared to increase myelin content in the early developing brain. KEY POINTS · DCC resulted in higher hematocrits in newborn period.. · DCC appears to increase myelin at 12 months.. · Gender did not influence study outcomes..",2020,"At 12 months of age, infants who received DCC had greater myelin content in important brain regions involved in motor function, visual/spatial, and sensory processing.","['term infants', '73 women', 'healthy pregnant women with term singleton fetuses randomized at birth to either']","['delayed cord clamping (DCC', 'Delayed Cord Clamping', 'ICC (the usual practice) or DCC', 'immediate cord clamping (ICC) (≤\u200920\u2009seconds) or DCC', 'DCC']","['white matter brain growth', 'usable MRIs', 'motor function, visual/spatial, and sensory processing', '12-Month Brain Myelin Content and Neurodevelopment', 'Developmental testing (Mullen Scales of Early Learning, nonverbal, and verbal composite scores']","[{'cui': 'C0456128', 'cui_str': 'Term infant'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0015965', 'cui_str': 'Fetuses'}, {'cui': 'C1744681', 'cui_str': 'Congenital'}]","[{'cui': 'C3489532', 'cui_str': 'Cone-Rod Dystrophy 2'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0175721', 'cui_str': 'Clamp'}, {'cui': 'C0205436', 'cui_str': 'Second'}]","[{'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0026969', 'cui_str': 'Myelin'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0458003', 'cui_str': 'Developmental'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",73.0,0.204555,"At 12 months of age, infants who received DCC had greater myelin content in important brain regions involved in motor function, visual/spatial, and sensory processing.","[{'ForeName': 'Judith S', 'Initials': 'JS', 'LastName': 'Mercer', 'Affiliation': 'College of Nursing, University of Rhode Island, Kingston, Rhode Island.'}, {'ForeName': 'Debra A', 'Initials': 'DA', 'LastName': 'Erickson-Owens', 'Affiliation': 'College of Nursing, University of Rhode Island, Kingston, Rhode Island.'}, {'ForeName': 'Sean C L', 'Initials': 'SCL', 'LastName': 'Deoni', 'Affiliation': 'Advanced Baby Imaging Lab, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island.'}, {'ForeName': 'Douglas C', 'Initials': 'DC', 'LastName': 'Dean Iii', 'Affiliation': 'Department of Pediatrics, University of Wisconsin, Madison, Wisconsin.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Tucker', 'Affiliation': 'Department of Pediatrics, Women and Infants Hospital of Rhode Island, Providence, Rhode Island.'}, {'ForeName': 'Ashley B', 'Initials': 'AB', 'LastName': 'Parker', 'Affiliation': 'Department of Pediatrics, Women and Infants Hospital of Rhode Island, Providence, Rhode Island.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Joelson', 'Affiliation': 'Advanced Baby Imaging Lab, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island.'}, {'ForeName': 'Emily N', 'Initials': 'EN', 'LastName': 'Mercer', 'Affiliation': 'Advanced Baby Imaging Lab, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Collins', 'Affiliation': 'Department of Pediatrics, Women and Infants Hospital of Rhode Island, Providence, Rhode Island.'}, {'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Padbury', 'Affiliation': 'Department of Pediatrics, Women and Infants Hospital of Rhode Island, Providence, Rhode Island.'}]",American journal of perinatology,['10.1055/s-0040-1714258'] 2592,32702778,Dental Decision Simulation (DDSim): Development of a virtual training environment.,"PURPOSE Case-based simulations are powerful training tools that can enhance learning and drive behavior change. This is an overview of the design/development of Dental Decision Simulation (DDSim), a web-based simulation of an electronic dental record (EDR). The purpose was to use DDSim to train dentists to make evidence-based treatment planning decisions consistent with current evidence. This simulated EDR provides case-based information in support of a set of defined evidence-based learning objectives. METHODS The development of this complex simulation model required coordinated efforts to create several components: identify behavior changes, case authoring mechanism, create virtual patient visits, require users to make treatment plan decisions related to learning objectives, and a feedback mechanism to help users recognize departures from those learning objectives. This simulation was evaluated in a 2-arm, clinic-randomized, controlled pilot study examining the extent to which DDSim changed dentists' planned treatment to conform to evidence-based treatment guidelines relative to change in dentists not exposed to DDSim. Outcomes were measured by comparing preintervention and postintervention patient EDR treatment data. RESULTS Changes in behavior over time did not favor intervention or control clinics. CONCLUSION DDSim provides a standardized learning platform that cannot be achieved through the use of live patients. Both live patients and case-based simulations can be used to transfer knowledge and skill development. DDSim offers the advantage of providing a platform for developing treatment planning skills in a low-risk environment. However, further research examining behavior change is needed.",2020,"This is an overview of the design/development of Dental Decision Simulation (DDSim), a web-based simulation of an electronic dental record (EDR).",[],"['Dental Decision Simulation', 'DDSim']",[],[],"[{'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}]",[],,0.049374,"This is an overview of the design/development of Dental Decision Simulation (DDSim), a web-based simulation of an electronic dental record (EDR).","[{'ForeName': 'Kimberly S', 'Initials': 'KS', 'LastName': 'Johnson', 'Affiliation': 'HealthPartners Institute, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Schmidt', 'Affiliation': 'HealthPartners Dental Group, Minneapolis, Minnesota, USA.'}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Bader', 'Affiliation': 'Department of Operative Dentistry, University of North Carolina School of Dentistry, Chapel Hill, North Carolina, USA.'}, {'ForeName': 'Heiko', 'Initials': 'H', 'LastName': 'Spallek', 'Affiliation': 'Dean, University of Sydney School of Dentistry, Sydney, Australia.'}, {'ForeName': 'D Brad', 'Initials': 'DB', 'LastName': 'Rindal', 'Affiliation': 'HealthPartners Institute, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Chris J', 'Initials': 'CJ', 'LastName': 'Enstad', 'Affiliation': 'HealthPartners Institute, Minneapolis, Minnesota, USA.'}, {'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Fricton', 'Affiliation': 'HealthPartners Institute, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Stephen E', 'Initials': 'SE', 'LastName': 'Asche', 'Affiliation': 'HealthPartners Institute, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Sheryl M', 'Initials': 'SM', 'LastName': 'Kane', 'Affiliation': 'HealthPartners Institute, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Vijay', 'Initials': 'V', 'LastName': 'Thirumalai', 'Affiliation': 'HealthPartners Institute, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Olga V', 'Initials': 'OV', 'LastName': 'Godlevsky', 'Affiliation': 'HealthPartners Institute, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Neil J', 'Initials': 'NJ', 'LastName': 'Johnson', 'Affiliation': 'HealthPartners Institute, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Acharya', 'Affiliation': 'Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.'}, {'ForeName': 'William A', 'Initials': 'WA', 'LastName': 'Rush', 'Affiliation': 'HealthPartners Institute, Minneapolis, Minnesota, USA.'}]",Journal of dental education,['10.1002/jdd.12303'] 2593,32702783,Aspirin (single dose) for perineal pain in the early postpartum period.,"BACKGROUND Perineal trauma, due to spontaneous tears, surgical incision (episiotomy), or in association with operative vaginal birth, is common after vaginal birth, and is often associated with postpartum perineal pain. Birth over an intact perineum may also lead to perineal pain. There are adverse health consequences associated with perineal pain for the women and their babies in the short- and long-term, and the pain may interfere with newborn care and the establishment of breastfeeding. Aspirin has been used in the management of postpartum perineal pain, and its effectiveness and safety should be assessed. This is an update of the review, last published in 2017. OBJECTIVES To determine the effects of a single dose of aspirin (acetylsalicylic acid), including at different doses, in the relief of acute postpartum perineal pain. SEARCH METHODS For this update, we searched the Cochrane Pregnancy and Childbirth's Trials Register (4 October 2019), ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (4 October 2019) and screened reference lists of retrieved studies. SELECTION CRITERIA Randomised controlled trials (RCTs), assessing single dose aspirin compared with placebo, no treatment, a different dose of aspirin, or single dose paracetamol or acetaminophen, for women with perineal pain in the early postpartum period. We planned to include cluster-RCTs, but none were identified. We excluded quasi-RCTs and cross-over studies. DATA COLLECTION AND ANALYSIS Two review authors independently assessed study eligibility, extracted data and assessed the risk of bias of the included RCTs. Data were checked for accuracy. The certainty of the evidence for the main comparison (aspirin versus placebo) was assessed using the GRADE approach. MAIN RESULTS We included 17 RCTs, 16 of which randomised 1132 women to aspirin or placebo; one RCT did not report numbers of women. Two RCTs (of 16) did not contribute data to meta-analyses. All women had perineal pain post-episiotomy, and were not breastfeeding. Studies were published between 1967 and 1997, and the risk of bias was often unclear, due to poor reporting. We included four comparisons: aspirin versus placebo (15 RCTs); 300 mg versus 600 mg aspirin (1 RCT); 600 mg versus 1200 mg aspirin (2 RCTs); and 300 mg versus 1200 mg aspirin (1 RCT). Aspirin versus placebo Aspirin may result in more women reporting adequate pain relief four to eight hours after administration compared with placebo (risk ratio (RR) 2.03, 95% confidence interval (CI) 1.69 to 2.42; 13 RCTs, 1001 women; low-certainty evidence). It is uncertain whether aspirin compared with placebo has an effect on the need for additional pain relief (RR 0.25, 95% CI 0.17 to 0.37; 10 RCTs, 744 women; very low-certainty evidence), or maternal adverse effects (RR 1.08, 95% CI 0.57 to 2.06; 14 RCTs, 1067 women; very low-certainty evidence), four to eight hours after administration. Analyses based on dose did not reveal any clear subgroup differences. 300 mg versus 600 mg aspirin It is uncertain whether over four hours after administration, 300 mg compared with 600 mg aspirin has an effect on adequate pain relief (RR 0.82, 95% CI 0.36 to 1.86; 1 RCT, 81 women) or the need for additional pain relief (RR 0.68, 95% CI 0.12 to 3.88; 1 RCT, 81 women). There were no maternal adverse effects in either aspirin group. 600 mg versus 1200 mg aspirin It is uncertain whether over four to eight hours after administration, 600 mg compared with 1200 mg aspirin has an effect on adequate pain relief (RR 0.85, 95% CI 0.52 to 1.39; 2 RCTs, 121 women), the need for additional pain relief (RR 1.32, 95% CI 0.30 to 5.68; 2 RCTs, 121 women), or maternal adverse effects (RR 3.00, 95% CI 0.13 to 69.52; 2 RCTs, 121 women). 300 mg versus 1200 mg aspirin It is uncertain whether over four hours after administration, 300 mg compared with 1200 mg aspirin has an effect on adequate pain relief (RR 0.62, 95% CI 0.29 to 1.32; 1 RCT, 80 women) or need for additional pain relief (RR 2.00, 95% CI 0.19 to 21.18; 1 RCT, 80 women). There were no maternal adverse effects in either aspirin group. None of the included RCTs reported on neonatal adverse effects. No RCTs reported on secondary review outcomes of: prolonged hospitalisation due to perineal pain; re-hospitalisation due to perineal pain; fully breastfeeding at discharge; mixed feeding at discharge; fully breastfeeding at six weeks; mixed feeding at six weeks; perineal pain at six weeks; maternal views; or maternal postpartum depression. AUTHORS' CONCLUSIONS Single dose aspirin may increase adequate pain relief in women with perineal pain post-episiotomy compared with placebo. It is uncertain whether aspirin has an effect on the need for additional analgesia, or on maternal adverse effects, compared with placebo. We downgraded the certainty of the evidence because of study limitations (risk of bias), imprecision, and publication bias. Aspirin may be considered for use in non-breastfeeding women with post-episiotomy perineal pain. Included RCTs excluded breastfeeding women, so there was no evidence to assess the effects of aspirin on neonatal adverse effects or breastfeeding. Future RCTs should be designed to ensure low risk of bias, and address gaps in the evidence, such as the secondary outcomes established for this review. Current research has focused on women with post-episiotomy pain; future RCTs could be extended to include women with perineal pain associated with spontaneous tears or operative birth.",2020,"It is uncertain whether aspirin compared with placebo has an effect on the need for additional pain relief (RR 0.25, 95% CI 0.17 to 0.37; 10 RCTs, 744 women; very low-certainty evidence), or maternal adverse effects (RR 1.08, 95% CI 0.57 to 2.06; 14 RCTs, 1067 women; very low-certainty evidence), four to eight hours after administration.","['non-breastfeeding women with post-episiotomy perineal pain', 'women with perineal pain in the early postpartum period', '17 RCTs, 16 of which randomised 1132 women to', 'women with post-episiotomy pain', 'women with perineal pain post-episiotomy']","['aspirin or placebo', 'aspirin versus placebo', 'RCT', 'placebo Aspirin', 'aspirin, or single dose paracetamol or acetaminophen', 'Aspirin', 'aspirin', 'aspirin (acetylsalicylic acid', 'placebo']","['maternal adverse effects', 'prolonged hospitalisation due to perineal pain; re-hospitalisation due to perineal pain; fully breastfeeding at discharge; mixed feeding at discharge; fully breastfeeding at six weeks; mixed feeding at six weeks; perineal pain at six weeks; maternal views; or maternal postpartum depression', 'pain relief', 'neonatal adverse effects', 'additional pain relief', 'adequate pain relief', 'perineal pain']","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0014586', 'cui_str': 'Episiotomy'}, {'cui': 'C0235641', 'cui_str': 'Pain in female perineum'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0406846', 'cui_str': 'Post-episiotomy pain'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0235641', 'cui_str': 'Pain in female perineum'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C3871203', 'cui_str': 'At discharge'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0549411', 'cui_str': 'Neonatal adverse effect'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}]",,0.696765,"It is uncertain whether aspirin compared with placebo has an effect on the need for additional pain relief (RR 0.25, 95% CI 0.17 to 0.37; 10 RCTs, 744 women; very low-certainty evidence), or maternal adverse effects (RR 1.08, 95% CI 0.57 to 2.06; 14 RCTs, 1067 women; very low-certainty evidence), four to eight hours after administration.","[{'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Shepherd', 'Affiliation': 'Robinson Research Institute, Discipline of Obstetrics and Gynaecology, Adelaide Medical School, The University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Rosalie M', 'Initials': 'RM', 'LastName': 'Grivell', 'Affiliation': 'Department of Obstetrics and Gynaecology, Flinders University and Flinders Medical Centre, Bedford Park, Australia.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD012129.pub3'] 2594,32702837,Effects of Sihogayonggolmoryeo-tang (Saikokaryukotsuboreito or Chai-Hu-Jia-Long-Gu-Mu-Li-Tang) for insomnia disorder with prehypertension or stage 1 hypertension: A study protocol for a randomized controlled trial.,"BACKGROUND Insomnia and hypertension are diseases with a high prevalence and a known association with each other. Sihogayonggolmoryeo-tang (SYM) is an herbal medicine traditionally used for the treatment of insomnia disorder concurrent with hypertension. However, no scientific clinical evidence exists supporting the effects of SYM on these disorders. This study aims to explore the feasibility, effectiveness, and safety of SYM for the treatment of insomnia disorder with concurrent prehypertension or stage 1 hypertension. METHODS A prospective, randomized, wait-list controlled, parallel, pilot clinical trial has been designed for a study to be conducted in Daejeon, Republic of Korea. Thirty insomnia disorder patients with prehypertension or stage 1 hypertension will be randomly assigned to a SYM or wait-list group at a 1:1 ratio. The SYM group will be administered SYM granules twice a day for 4 weeks and followed-up for 2 weeks while the wait-list group will not receive SYM granules. All participants in both groups will be given brochures with instructions for maintaining sleep hygiene and lifestyle modifications to reduce hypertension. Data will be collected at baseline and at 2, 4, and 6 weeks after allocation. The primary outcome is the Insomnia Severity Index score at 4 weeks post-treatment. The secondary outcomes will consist of the Pittsburgh Sleep Quality Index, sleep diary, systolic and diastolic blood pressure, brachial-ankle pulse wave velocity, ankle-brachial index, atherosclerosis biomarkers, the Hospital Anxiety and Depression Scale, the 5-level EuroQol-5 dimensions, and the Patient Global Impression of Change. Adverse events and laboratory test results will be monitored to assess the safety. Data will be recorded in electronic case report forms and analyzed using SPSS Statistics, Version 24.0. DISCUSSION This is the first clinical trial to explore the effectiveness and safety of SYM for the treatment of insomnia disorder concurrent with prehypertension or stage 1 hypertension. The results of this study can form the foundation for a future multicenter, large-scale, confirmatory clinical trial. TRIAL REGISTRATION Clinical Research Information Service, KCT0005001 (registered on May 8, 2020).",2020,Thirty insomnia disorder patients with prehypertension or stage 1 hypertension will be randomly assigned to a SYM or wait-list group at a 1:1 ratio.,"['insomnia disorder with concurrent prehypertension or stage 1 hypertension', 'insomnia disorder concurrent with prehypertension or stage 1 hypertension', 'Thirty insomnia disorder patients with prehypertension or stage 1 hypertension', 'insomnia disorder with prehypertension or stage 1 hypertension', 'Daejeon, Republic of Korea', 'insomnia disorder concurrent with hypertension']","['SYM', 'Sihogayonggolmoryeo-tang (Saikokaryukotsuboreito or Chai-Hu-Jia-Long-Gu-Mu-Li-Tang', 'Sihogayonggolmoryeo-tang (SYM']","['Insomnia Severity Index score', 'Pittsburgh Sleep Quality Index, sleep diary, systolic and diastolic blood pressure, brachial-ankle pulse wave velocity, ankle-brachial index, atherosclerosis biomarkers, the Hospital Anxiety and Depression Scale, the 5-level EuroQol-5 dimensions, and the Patient Global Impression of Change']","[{'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C1696708', 'cui_str': 'Prehypertension'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}]","[{'cui': 'C0381095', 'cui_str': 'saiko-ka-ryukotsu-borei-to'}, {'cui': 'C0164665', 'cui_str': 'Bupleurum root extract'}, {'cui': 'C3495559', 'cui_str': 'Juvenile chronic arthritis'}, {'cui': 'C0205166', 'cui_str': 'Long'}]","[{'cui': 'C4706228', 'cui_str': 'ISI (Insomnia Severity Index) score'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0232154', 'cui_str': 'Ankle pulse'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C1328319', 'cui_str': 'Ankle brachial pressure index'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0456951', 'cui_str': 'Level 5'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",,0.153707,Thirty insomnia disorder patients with prehypertension or stage 1 hypertension will be randomly assigned to a SYM or wait-list group at a 1:1 ratio.,"[{'ForeName': 'Boram', 'Initials': 'B', 'LastName': 'Lee', 'Affiliation': 'aClinical Medicine Division, Korea Institute of Oriental Medicine, Yuseong-gu, Daejeon bDepartment of Oriental Neuropsychiatry, Daejeon Korean Medicine Hospital of Daejeon University, Seo-gu, Daejeon, Republic of Korea.'}, {'ForeName': 'Yeong-Eun', 'Initials': 'YE', 'LastName': 'Jeong', 'Affiliation': ''}, {'ForeName': 'Hyo-Ju', 'Initials': 'HJ', 'LastName': 'Park', 'Affiliation': ''}, {'ForeName': 'Young-Eun', 'Initials': 'YE', 'LastName': 'Choi', 'Affiliation': ''}, {'ForeName': 'Hoseok', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Bo-Young', 'Initials': 'BY', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Changsop', 'Initials': 'C', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'In Chul', 'Initials': 'IC', 'LastName': 'Jung', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000020980'] 2595,32703182,Perineal wound closure using gluteal turnover flap or primary closure after abdominoperineal resection for rectal cancer: study protocol of a randomised controlled multicentre trial (BIOPEX-2 study).,"BACKGROUND Abdominoperineal resection (APR) for rectal cancer is associated with high morbidity of the perineal wound, and controversy exists about the optimal closure technique. Primary perineal wound closure is still the standard of care in the Netherlands. Biological mesh closure did not improve wound healing in our previous randomised controlled trial (BIOPEX-study). It is suggested, based on meta-analysis of cohort studies, that filling of the perineal defect with well-vascularised tissue improves perineal wound healing. A gluteal turnover flap seems to be a promising method for this purpose, and with the advantage of not having a donor site scar. The aim of this study is to investigate whether a gluteal turnover flap improves the uncomplicated perineal wound healing after APR for rectal cancer. METHODS Patients with primary or recurrent rectal cancer who are planned for APR will be considered eligible in this multicentre randomised controlled trial. Exclusion criteria are total exenteration, sacral resection above S4/S5, intersphincteric APR, biological mesh closure of the pelvic floor, collagen disorders, and severe systemic diseases. A total of 160 patients will be randomised between gluteal turnover flap (experimental arm) and primary closure (control arm). The total follow-up duration is 12 months, and outcome assessors and patients will be blinded for type of perineal wound closure. The primary outcome is the percentage of uncomplicated perineal wound healing on day 30, defined as a Southampton wound score of less than two. Secondary outcomes include time to perineal wound closure, incidence of perineal hernia, the number, duration and nature of the complications, re-interventions, quality of life and urogenital function. DISCUSSION The uncomplicated perineal wound healing rate is expected to increase from 65 to 85% by using the gluteal turnover flap. With proven effectiveness, a quick implementation of this relatively simple surgical technique is expected to take place. TRIAL REGISTRATION The trial was retrospectively registered at Clinicaltrials.gov NCT04004650 on July 2, 2019.",2020,Biological mesh closure did not improve wound healing in our previous randomised controlled trial (BIOPEX-study).,"['Patients with primary or recurrent rectal cancer who are planned for', 'rectal cancer', '160 patients']","['Perineal wound closure using gluteal turnover flap or primary closure after abdominoperineal resection', 'Abdominoperineal resection (APR', 'Biological mesh closure', 'gluteal turnover flap (experimental arm) and primary closure (control arm', 'gluteal turnover flap', 'APR']","['uncomplicated perineal wound healing rate', 'time to perineal wound closure, incidence of perineal hernia, the number, duration and nature of the complications, re-interventions, quality of life and urogenital function', 'wound healing', 'percentage of uncomplicated perineal wound healing on day 30, defined as a Southampton wound score of less']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0278554', 'cui_str': 'Rectal cancer recurrent'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}, {'cui': 'C4319554', 'cui_str': '160'}]","[{'cui': 'C0031066', 'cui_str': 'Perineal'}, {'cui': 'C0450015', 'cui_str': 'Method of wound closure'}, {'cui': 'C0031227', 'cui_str': 'Employee Turnover'}, {'cui': 'C0038925', 'cui_str': 'Flap'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C2004459', 'cui_str': 'Abdominoperineal resection'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0181805', 'cui_str': 'Mesh'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0443334', 'cui_str': 'Uncomplicated'}, {'cui': 'C0031066', 'cui_str': 'Perineal'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0450015', 'cui_str': 'Method of wound closure'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0019305', 'cui_str': 'Perineal hernia'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0349590', 'cui_str': 'Nature'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0579062', 'cui_str': 'Urogenital function'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",160.0,0.151325,Biological mesh closure did not improve wound healing in our previous randomised controlled trial (BIOPEX-study).,"[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Sharabiany', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands. s.sharabiany@amsterdamumc.nl.'}, {'ForeName': 'Robin D', 'Initials': 'RD', 'LastName': 'Blok', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Oren', 'Initials': 'O', 'LastName': 'Lapid', 'Affiliation': 'Department of Plastic Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Roel', 'Initials': 'R', 'LastName': 'Hompes', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Wilhelmus A', 'Initials': 'WA', 'LastName': 'Bemelman', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Victor P', 'Initials': 'VP', 'LastName': 'Alberts', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Bas', 'Initials': 'B', 'LastName': 'Lamme', 'Affiliation': 'Department of Surgery, Albert Schweitzer Hospital, Dordrecht, the Netherlands.'}, {'ForeName': 'Jan H', 'Initials': 'JH', 'LastName': 'Wijsman', 'Affiliation': 'Department of Surgery, Amphia Hospital, Breda, The Netherlands.'}, {'ForeName': 'Jurriaan B', 'Initials': 'JB', 'LastName': 'Tuynman', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, Free University, Amsterdam, The Netherlands.'}, {'ForeName': 'Arend G J', 'Initials': 'AGJ', 'LastName': 'Aalbers', 'Affiliation': 'Department of Surgery, Antoni van Leeuwenhoek Hospital-Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Geerard L', 'Initials': 'GL', 'LastName': 'Beets', 'Affiliation': 'Department of Surgery, Antoni van Leeuwenhoek Hospital-Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Hans F J', 'Initials': 'HFJ', 'LastName': 'Fabry', 'Affiliation': 'Department of Surgery, Bravis Hospital, Roosendaal, The Netherlands.'}, {'ForeName': 'Ivan M', 'Initials': 'IM', 'LastName': 'Cherepanin', 'Affiliation': 'Department of Surgery, Bravis Hospital, Roosendaal, The Netherlands.'}, {'ForeName': 'Fatih', 'Initials': 'F', 'LastName': 'Polat', 'Affiliation': 'Department of Surgery, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.'}, {'ForeName': 'Jacobus W A', 'Initials': 'JWA', 'LastName': 'Burger', 'Affiliation': 'Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands.'}, {'ForeName': 'Harm J T', 'Initials': 'HJT', 'LastName': 'Rutten', 'Affiliation': 'Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands.'}, {'ForeName': 'Robert J I', 'Initials': 'RJI', 'LastName': 'Bosker', 'Affiliation': 'Department of Surgery, Deventer Hospital, Deventer, The Netherlands.'}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'Talsma', 'Affiliation': 'Department of Surgery, Deventer Hospital, Deventer, The Netherlands.'}, {'ForeName': 'Joost', 'Initials': 'J', 'LastName': 'Rothbarth', 'Affiliation': 'Department of Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands.'}, {'ForeName': 'Cees', 'Initials': 'C', 'LastName': 'Verhoef', 'Affiliation': 'Department of Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands.'}, {'ForeName': 'Anthony W H', 'Initials': 'AWH', 'LastName': 'van de Ven', 'Affiliation': 'Department of Surgery, Flevo Hospital, Almere, The Netherlands.'}, {'ForeName': 'Jarmila D W', 'Initials': 'JDW', 'LastName': 'van der Bilt', 'Affiliation': 'Department of Surgery, Flevo Hospital, Almere, The Netherlands.'}, {'ForeName': 'Eelco J R', 'Initials': 'EJR', 'LastName': 'de Graaf', 'Affiliation': 'Department of Surgery, IJsselland Hospital, Capelle aan den Ijssel, The Netherlands.'}, {'ForeName': 'Pascal G', 'Initials': 'PG', 'LastName': 'Doornebosch', 'Affiliation': 'Department of Surgery, IJsselland Hospital, Capelle aan den Ijssel, The Netherlands.'}, {'ForeName': 'Jeroen W A', 'Initials': 'JWA', 'LastName': 'Leijtens', 'Affiliation': 'Department of Surgery, Laurentius Hospital, Roermond, The Netherlands.'}, {'ForeName': 'Jeroen', 'Initials': 'J', 'LastName': 'Heemskerk', 'Affiliation': 'Department of Surgery, Laurentius Hospital, Roermond, The Netherlands.'}, {'ForeName': 'Baljit', 'Initials': 'B', 'LastName': 'Singh', 'Affiliation': 'Department of Surgery, Leicester Hospital, Leicester, UK.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Chaudhri', 'Affiliation': 'Department of Surgery, Leicester Hospital, Leicester, UK.'}, {'ForeName': 'Michael F', 'Initials': 'MF', 'LastName': 'Gerhards', 'Affiliation': 'Department of Surgery, OLVG Hospital, Amsterdam, The Netherlands.'}, {'ForeName': 'Tom M', 'Initials': 'TM', 'LastName': 'Karsten', 'Affiliation': 'Department of Surgery, OLVG Hospital, Amsterdam, The Netherlands.'}, {'ForeName': 'Johannes H W', 'Initials': 'JHW', 'LastName': 'de Wilt', 'Affiliation': 'Department of Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands.'}, {'ForeName': 'Andre J A', 'Initials': 'AJA', 'LastName': 'Bremers', 'Affiliation': 'Department of Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands.'}, {'ForeName': 'Ronald J C L M', 'Initials': 'RJCLM', 'LastName': 'Vuylsteke', 'Affiliation': 'Department of Surgery, Spaarne Gasthuis, Haarlem, The Netherlands.'}, {'ForeName': 'Gijsbert', 'Initials': 'G', 'LastName': 'Heuff', 'Affiliation': 'Department of Surgery, Spaarne Gasthuis, Haarlem, The Netherlands.'}, {'ForeName': 'Anna A W', 'Initials': 'AAW', 'LastName': 'van Geloven', 'Affiliation': 'Department of Surgery, Tergooi Hospital, Hilversum, The Netherlands.'}, {'ForeName': 'Pieter J', 'Initials': 'PJ', 'LastName': 'Tanis', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Gijsbert D', 'Initials': 'GD', 'LastName': 'Musters', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.'}]",BMC surgery,['10.1186/s12893-020-00823-7'] 2596,32703188,Scent dog identification of samples from COVID-19 patients - a pilot study.,"BACKGROUND As the COVID-19 pandemic continues to spread, early, ideally real-time, identification of SARS-CoV-2 infected individuals is pivotal in interrupting infection chains. Volatile organic compounds produced during respiratory infections can cause specific scent imprints, which can be detected by trained dogs with a high rate of precision. METHODS Eight detection dogs were trained for 1 week to detect saliva or tracheobronchial secretions of SARS-CoV-2 infected patients in a randomised, double-blinded and controlled study. RESULTS The dogs were able to discriminate between samples of infected (positive) and non-infected (negative) individuals with average diagnostic sensitivity of 82.63% (95% confidence interval [CI]: 82.02-83.24%) and specificity of 96.35% (95% CI: 96.31-96.39%). During the presentation of 1012 randomised samples, the dogs achieved an overall average detection rate of 94% (±3.4%) with 157 correct indications of positive, 792 correct rejections of negative, 33 incorrect indications of negative or incorrect rejections of 30 positive sample presentations. CONCLUSIONS These preliminary findings indicate that trained detection dogs can identify respiratory secretion samples from hospitalised and clinically diseased SARS-CoV-2 infected individuals by discriminating between samples from SARS-CoV-2 infected patients and negative controls. This data may form the basis for the reliable screening method of SARS-CoV-2 infected people.",2020,These preliminary findings indicate that trained detection dogs can identify respiratory secretion samples from hospitalised and clinically diseased SARS-CoV-2 infected individuals by discriminating between samples from SARS-CoV-2 infected patients and negative controls.,['Eight detection dogs'],[],['overall average detection rate'],"[{'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0012984', 'cui_str': 'Canis lupus familiaris'}]",[],"[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}]",,0.105029,These preliminary findings indicate that trained detection dogs can identify respiratory secretion samples from hospitalised and clinically diseased SARS-CoV-2 infected individuals by discriminating between samples from SARS-CoV-2 infected patients and negative controls.,"[{'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Jendrny', 'Affiliation': 'Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Hannover, Germany.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Schulz', 'Affiliation': 'Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.'}, {'ForeName': 'Friederike', 'Initials': 'F', 'LastName': 'Twele', 'Affiliation': 'Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Hannover, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Meller', 'Affiliation': 'Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Hannover, Germany.'}, {'ForeName': 'Maren', 'Initials': 'M', 'LastName': 'von Köckritz-Blickwede', 'Affiliation': 'Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.'}, {'ForeName': 'Albertus Dominicus Marcellinus Erasmus', 'Initials': 'ADME', 'LastName': 'Osterhaus', 'Affiliation': 'Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.'}, {'ForeName': 'Janek', 'Initials': 'J', 'LastName': 'Ebbers', 'Affiliation': ', Hörstel, Germany.'}, {'ForeName': 'Veronika', 'Initials': 'V', 'LastName': 'Pilchová', 'Affiliation': 'Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.'}, {'ForeName': 'Isabell', 'Initials': 'I', 'LastName': 'Pink', 'Affiliation': 'Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Welte', 'Affiliation': 'Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Michael Peter', 'Initials': 'MP', 'LastName': 'Manns', 'Affiliation': 'Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Anahita', 'Initials': 'A', 'LastName': 'Fathi', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Christiane', 'Initials': 'C', 'LastName': 'Ernst', 'Affiliation': 'Central Institute of Medical Service, German Armed Forces, Koblenz, Germany.'}, {'ForeName': 'Marylyn Martina', 'Initials': 'MM', 'LastName': 'Addo', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Schalke', 'Affiliation': 'Bundeswehr School of Dog handling, German Armed Forces, Ulmen, Germany.'}, {'ForeName': 'Holger Andreas', 'Initials': 'HA', 'LastName': 'Volk', 'Affiliation': 'Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Hannover, Germany. holger.volk@tiho-hannover.de.'}]",BMC infectious diseases,['10.1186/s12879-020-05281-3'] 2597,32703191,A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).,"BACKGROUND Although surgery is the definitive curative treatment for biliary tract cancer (BTC), outcomes after surgery alone have not been satisfactory. Adjuvant therapy with S-1 may improve survival in patients with BTC. This study examined the safety and efficacy of 1 year adjuvant S-1 therapy for BTC in a multi-institutional trial. METHODS The inclusion criteria were as follows: histologically proven BTC, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, R0 or R1 surgery performed, cancer classified as Stage IB to III. Within 10 weeks post-surgery, a 42-day cycle of treatment with S-1 (80 mg/m 2 /day orally twice daily on days 1-28 of each cycle) was initiated and continued up to 1 year post surgery. The primary endpoint was adjuvant therapy completion rate. The secondary endpoints were toxicities, disease-free survival (DFS), and overall survival (OS). RESULTS Forty-six patients met the inclusion criteria of whom 19 had extrahepatic cholangiocarcinoma, 10 had gallbladder carcinoma, 9 had ampullary carcinoma, and 8 had intrahepatic cholangiocarcinoma. Overall, 25 patients completed adjuvant chemotherapy, with a 54.3% completion rate while the completion rate without recurrence during the 1 year administration was 62.5%. Seven patients (15%) experienced adverse events (grade 3/4). The median number of courses administered was 7.5. Thirteen patients needed dose reduction or temporary therapy withdrawal. OS and DFS rates at 1/2 years were 91.2/80.0% and 84.3/77.2%, respectively. Among patients who were administered more than 3 courses of S-1, only one patient discontinued because of adverse events. CONCLUSIONS One-year administration of adjuvant S-1 therapy for resected BTC was feasible and may be a promising treatment for those with resected BTC. Now, a randomized trial to determine the optimal duration of S-1 is ongoing. TRIAL REGISTRATION UMIN-CTR, UMIN000009029. Registered 5 October 2012-Retrospectively registered, https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009347.",2020,"Overall, 25 patients completed adjuvant chemotherapy, with a 54.3% completion rate while the completion rate without recurrence during the 1 year administration was 62.5%.","['Forty-six patients met the inclusion criteria of whom 19 had extrahepatic cholangiocarcinoma, 10 had gallbladder carcinoma, 9 had ampullary carcinoma, and 8 had intrahepatic cholangiocarcinoma', 'patients with BTC', 'The inclusion criteria were as follows: histologically proven BTC, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, R0 or R1 surgery performed, cancer classified as Stage IB to III', 'Thirteen patients needed dose reduction or temporary therapy withdrawal']","['adjuvant S-1 therapy', '1\u2009year adjuvant S-1 therapy']","['toxicities, disease-free survival (DFS), and overall survival (OS', 'completion rate without recurrence', 'OS and DFS rates', 'survival', 'adjuvant therapy completion rate', 'safety and efficacy', 'adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C3805278', 'cui_str': 'Extrahepatic Cholangiocarcinoma'}, {'cui': 'C0235782', 'cui_str': 'Carcinoma of gallbladder'}, {'cui': 'C0262401', 'cui_str': 'Carcinoma of ampulla of Vater'}, {'cui': 'C0345905', 'cui_str': 'Intrahepatic bile duct carcinoma'}, {'cui': 'C0750952', 'cui_str': 'Malignant tumor of biliary tract'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0456597', 'cui_str': 'Stage 1B'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0205374', 'cui_str': 'Transitory'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}]","[{'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0879262', 'cui_str': 'S 1 (combination)'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.540534,"Overall, 25 patients completed adjuvant chemotherapy, with a 54.3% completion rate while the completion rate without recurrence during the 1 year administration was 62.5%.","[{'ForeName': 'Osamu', 'Initials': 'O', 'LastName': 'Itano', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan. laplivertiger@gmail.com.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Takemura', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Norihiro', 'Initials': 'N', 'LastName': 'Kishida', 'Affiliation': 'Department of Surgery, Japanese Red Cross Ashikaga Hospital, Tochigi, Japan.'}, {'ForeName': 'Eiji', 'Initials': 'E', 'LastName': 'Tamagawa', 'Affiliation': 'Department of Surgery, Machida Keisen Hospital, Tokyo, Japan.'}, {'ForeName': 'Hiroharu', 'Initials': 'H', 'LastName': 'Shinozaki', 'Affiliation': 'Department of Surgery, Saiseikai Utsunomiya Hospital, Tochigi, Japan.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Ikeda', 'Affiliation': 'Department of Surgery, Sano Kousei General Hospital, Tochigi, Japan.'}, {'ForeName': 'Hidejiro', 'Initials': 'H', 'LastName': 'Urakami', 'Affiliation': 'Department of Surgery, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.'}, {'ForeName': 'Shigenori', 'Initials': 'S', 'LastName': 'Ei', 'Affiliation': 'Department of Surgery, Eiju General Hospital, Tokyo, Japan.'}, {'ForeName': 'Shigeo', 'Initials': 'S', 'LastName': 'Hayatsu', 'Affiliation': 'Department of Surgery, National Hospital Organization Saitama National Hospital, Saitama, Japan.'}, {'ForeName': 'Keiichi', 'Initials': 'K', 'LastName': 'Suzuki', 'Affiliation': 'Department of Surgery, National Hospital Organization Tochigi Medical Center, Tochigi, Japan.'}, {'ForeName': 'Tadayuki', 'Initials': 'T', 'LastName': 'Sakuragawa', 'Affiliation': 'Department of Surgery, Tama Kyuryo Hospital, Tokyo, Japan.'}, {'ForeName': 'Masatsugu', 'Initials': 'M', 'LastName': 'Ishii', 'Affiliation': 'Department of Surgery, Fussa Hospital, Tokyo, Japan.'}, {'ForeName': 'Masaya', 'Initials': 'M', 'LastName': 'Shito', 'Affiliation': 'Department of Surgery, Kawasaki Municipal Kawasaki Hospital, Kanagawa, Japan.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Aiura', 'Affiliation': 'Department of Surgery, Kawasaki Municipal Kawasaki Hospital, Kanagawa, Japan.'}, {'ForeName': 'Hiroto', 'Initials': 'H', 'LastName': 'Fujisaki', 'Affiliation': 'Department of Surgery, Hiratsuka City Hospital, Kanagawa, Japan.'}, {'ForeName': 'Kiminori', 'Initials': 'K', 'LastName': 'Takano', 'Affiliation': 'Department of Surgery, Hiratsuka City Hospital, Kanagawa, Japan.'}, {'ForeName': 'Junichi', 'Initials': 'J', 'LastName': 'Matsui', 'Affiliation': 'Department of Surgery, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan.'}, {'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Minagawa', 'Affiliation': 'Department of Surgery, Saitama City Hospital, Saitama, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Shinoda', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Minoru', 'Initials': 'M', 'LastName': 'Kitago', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Yuta', 'Initials': 'Y', 'LastName': 'Abe', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Yagi', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Go', 'Initials': 'G', 'LastName': 'Oshima', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Shutaro', 'Initials': 'S', 'LastName': 'Hori', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Kitagawa', 'Affiliation': 'Department of Surgery, Keio University School of Medicine, Tokyo, Japan.'}]",BMC cancer,['10.1186/s12885-020-07185-6'] 2598,32703194,Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease - a randomised placebo-controlled trial.,"BACKGROUND Patients suffering from fibrotic interstitial lung diseases (fILD) have a poor prognosis and a high symptom burden. Palliative treatment includes relief of symptoms such as breathlessness. There is no evidence-based treatment for chronic breathlessness but opioids are often used despite concerns due to the hypothetical risk of respiratory depression. This study investigated the effect of oral morphine drops in patients with fILD on chronic breathlessness and safety. METHODS In a double-blinded placebo-controlled study, 36 patients with fILD were randomised to either four daily doses of 5 mg of oral morphine drops or placebo for 1 week. Endpoints and safety parameters were obtained at baseline, at follow-up after 1 h and 1 week. RESULTS The primary endpoint, the visual analogue score (VAS) of dyspnea was reduced by 1.1 ± 0.33 cm in the morphine group at follow-up compared to baseline (P < 0.01), whereas the reduction was 0.35 ± 0.47 cm in the placebo group. However, the difference between the two groups was not statistically significant (p = 0.2). Oral morphine drops did not affect respiratory frequency, pulse rate, blood pressure, peripheral saturation or the 6-min walk test. More patients treated with morphine reported constipation, nausea and confusion. CONCLUSION Oral administration of morphine drops, 20 mg a day, in patients with fILD did not significantly reduce dyspnea VAS score during 1 week compared to placebo. Oral morphine did not induce respiratory depression, but was related to an increased risk of constipation, nausea and confusion. TRIAL REGISTRATION The trial is registered in clinicaltrials.gov (Identifier: NCT02622022 ). Registered 4 December 2015.",2020,"Oral morphine drops did not affect respiratory frequency, pulse rate, blood pressure, peripheral saturation or the 6-min walk test.","['Patients suffering from fibrotic interstitial lung diseases (fILD', '36 patients with fILD', 'patients with fILD on chronic breathlessness and safety', 'patients with fibrotic interstitial lung disease - a randomised']","['oral morphine drops or placebo', 'morphine', 'oral morphine', 'Oral morphine', 'placebo']","['dyspnea VAS score', 'constipation, nausea and confusion', 'risk of constipation, nausea and confusion', 'respiratory depression', 'relief of symptoms such as breathlessness', 'respiratory frequency, pulse rate, blood pressure, peripheral saturation or the 6-min walk test', 'visual analogue score (VAS) of dyspnea']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206062', 'cui_str': 'Interstitial lung disease'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]","[{'cui': 'C0360457', 'cui_str': 'Morphine-containing product in oral dose form'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]","[{'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0009676', 'cui_str': 'Confusional state'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0235063', 'cui_str': 'Decreased respiratory function'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}]",36.0,0.451365,"Oral morphine drops did not affect respiratory frequency, pulse rate, blood pressure, peripheral saturation or the 6-min walk test.","[{'ForeName': 'Sissel', 'Initials': 'S', 'LastName': 'Kronborg-White', 'Affiliation': 'Department of Respiratory Diseases and Allergy, Aarhus University Hospital, 8200, Aarhus N, Denmark. siskro@rm.dk.'}, {'ForeName': 'Charlotte Uggerhøj', 'Initials': 'CU', 'LastName': 'Andersen', 'Affiliation': 'Department of Pharmacology, Aarhus University Hospital, 8200, Aarhus N, Denmark.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Kohberg', 'Affiliation': 'Department of Oncology, Odense University Hospital, Odense, 5000, Denmark.'}, {'ForeName': 'Ole', 'Initials': 'O', 'LastName': 'Hilberg', 'Affiliation': 'Department of Internal Medicine, Lillebaelt Hospital, 7100, Vejle, Denmark.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Bendstrup', 'Affiliation': 'Department of Respiratory Diseases and Allergy, Aarhus University Hospital, 8200, Aarhus N, Denmark.'}]",Respiratory research,['10.1186/s12931-020-01452-7'] 2599,32705121,Efficacy of a Stress Management Intervention for Mothers of Children with Cancer.,"OBJECTIVE Mothers of children with cancer confront life stress that can impact their psychological and physical health and, in turn, the health of the family. Recommendations advocate preemptive stress-management interventions; however, few studies have investigated their efficacy. Here, we report results of a parallel randomized pilot trial examining health benefits of a stress management intervention designed to teach coping skills. METHODS One hundred twenty mothers (age 36 ± 8 years) of children newly diagnosed with cancer were randomized to a 12-session stress management intervention (n = 60) or usual care (n = 60). Sessions took place in the inpatient or outpatient setting of a children's hospital. Primary outcome variables included psychological function and physical health assessed preintervention and postintervention and at 6-month follow-up (∼12 months postdiagnosis). RESULTS Enrollment, retention, and satisfaction data supported feasibility and acceptability. Latent change score models showed the intervention reduced perceived stress (d = -0.37, p = 0.03), anxiety symptoms (ds = -0.38 and -0.56, ps < .03) and, a nonsignificant effect for depressive symptoms (d = -0.29, p = .11) across the 6 months following diagnosis. Intervention participants also endorsed fewer depressive symptoms than controls ∼12 months after diagnosis. The intervention improved stress management skills, which associated with the psychological benefits of participation. There were no intervention-related changes in perceived health or markers of inflammation. CONCLUSION Intervention-related improvements in stress management skills may result in better psychological health in the face of caring for a child with cancer. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02022449.",2020,"Latent change score models showed the intervention reduced perceived stress (d = -0.37, p = 0.03), anxiety symptoms (ds = -0.38 and -0.56, ps < .03) and, a nonsignificant effect for depressive symptoms (d = -0.29, p = .11) across the 6 months following diagnosis.","['Mothers of Children with Cancer', 'Mothers of children with cancer confront life stress', 'One hundred twenty mothers (age 36\u2009±\u20098\u2009years) of children newly diagnosed with cancer']","['12-session stress management intervention (n\u2009=\u200960) or usual care', 'stress management intervention designed to teach coping skills', 'Stress Management Intervention']","['stress management skills', 'anxiety symptoms', 'perceived health or markers of inflammation', 'psychological benefits of participation', 'retention, and satisfaction data supported feasibility and acceptability', 'psychological function and physical health assessed preintervention and postintervention and at 6-month follow-up (∼12\u2009months postdiagnosis', 'depressive symptoms']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0038443', 'cui_str': 'Psychological Stress'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0086059', 'cui_str': 'Coping Skills'}]","[{'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0233398', 'cui_str': 'Psychological function'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",120.0,0.0683488,"Latent change score models showed the intervention reduced perceived stress (d = -0.37, p = 0.03), anxiety symptoms (ds = -0.38 and -0.56, ps < .03) and, a nonsignificant effect for depressive symptoms (d = -0.29, p = .11) across the 6 months following diagnosis.","[{'ForeName': 'Anna L', 'Initials': 'AL', 'LastName': 'Marsland', 'Affiliation': 'University of Pittsburgh.'}, {'ForeName': 'Catherine P', 'Initials': 'CP', 'LastName': 'Walsh', 'Affiliation': 'University of Pittsburgh.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Cleary', 'Affiliation': 'University of Michigan.'}, {'ForeName': 'Alina D', 'Initials': 'AD', 'LastName': 'Vaisleib', 'Affiliation': 'Chatham University.'}, {'ForeName': 'Chelsea', 'Initials': 'C', 'LastName': 'Farrell', 'Affiliation': 'University of Pittsburgh.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Woods', 'Affiliation': 'University of Pittsburgh.'}, {'ForeName': 'Jean M', 'Initials': 'JM', 'LastName': 'Tersak', 'Affiliation': 'University of Pittsburgh.'}, {'ForeName': 'Aidan', 'Initials': 'A', 'LastName': 'Wright', 'Affiliation': 'University of Pittsburgh.'}, {'ForeName': 'Linda J', 'Initials': 'LJ', 'LastName': 'Ewing', 'Affiliation': 'University of Pittsburgh.'}]",Journal of pediatric psychology,['10.1093/jpepsy/jsaa058'] 2600,32705205,Protective effect of bromfenac sodium on femtosecond laser‑assisted cataract surgery via modulating cyclooxygenase‑2 expression.,"Cataract is a blinding‑caused disease and affects millions of individuals worldwide. Although conventional phacoemulsification (CPCS) has been widely used for treatment of cataract, the incidence of cataract‑caused blindness still increased year by year. Recently, femtosecond laser technology has been expanded to variety of clinical applications, including cataract surgery. The present study evaluated the curative effect of bromfenac sodium (BS) after femtosecond laser‑assisted cataract surgery (FLACS) and analyzed the mechanism of action. A total of 90 patients were randomly divided into five groups: Group I, conventional phacoemulsification treatment (CPCS) + dexamethasone (DEX)/tobramycin (TOB); group II, CPCS + bromfenac sodium (BS); group III, Femtosecond laser‑assisted cataract surgery (FLACS) + DEX/TOB; group IV, FLACS + BS; and group V, FLACS + pranoprofen. Aqueous humor was collected from these patients post‑surgery. For in vitro studies, SRA01/04 cells were irradiated using UV, followed by the collection of culture media and cell lysate. Prostaglandin E2 (PGE2) levels, an indicator of inflammation, were measured using ELISA both in vivo and in vitro. In addition, cyclooxygenase (COX) and cleaved caspase‑1 p20 expression levels were analyzed using western blotting. The findings suggested that BS was more effective and safer compared with glucocorticoids (GCs) after cataract surgery. BS can protect against post‑operative inflammation by inhibiting PGE2 production. Under in vitro conditions BS prevented the SRA01/04 cells from undergoing apoptosis after UV treatment and also suppressed PGE2 release from UV‑irradiated SRA01/04 cells by modulating COX‑2 expression. Furthermore, BS may have an inhibitory effect on the inflammatory form of cell death. Overall, these results indicated that BS could replace existing GCs as a reliable drug for a perioperative period of cataract surgery. It was also identified that the inhibitory effect of BS on PGE2 production was mediated via the regulation of COX‑2.",2020,Under in vitro conditions BS prevented the SRA01/04 cells from undergoing apoptosis after UV treatment and also suppressed PGE2 release from UV‑irradiated SRA01/04 cells by modulating COX‑2 expression.,['A total of 90\xa0patients'],"['bromfenac sodium', 'conventional phacoemulsification treatment (CPCS) + dexamethasone (DEX)/tobramycin (TOB); group\xa0II, CPCS + bromfenac sodium (BS); group\xa0III, Femtosecond laser‑assisted cataract surgery (FLACS)\xa0+ DEX/TOB; group\xa0IV, FLACS + BS; and group\xa0V, FLACS\xa0+ pranoprofen', 'glucocorticoids (GCs', 'bromfenac sodium (BS', 'femtosecond laser technology', 'conventional phacoemulsification (CPCS', 'femtosecond laser‑assisted cataract surgery (FLACS', 'cyclooxygenase (COX']","['Prostaglandin\xa0E2 (PGE2) levels, an indicator of inflammation']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0107211', 'cui_str': 'Bromfenac sodium'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C1276848', 'cui_str': 'Dexamethasone- and tobramycin-containing product'}, {'cui': 'C0441855', 'cui_str': 'Group V'}, {'cui': 'C0072652', 'cui_str': 'pranoprofen'}, {'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}, {'cui': 'C1531960', 'cui_str': 'Femtosecond pulsed laser device'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0033551', 'cui_str': 'Prostaglandin synthase'}]","[{'cui': 'C0012472', 'cui_str': 'Dinoprostone'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",,0.0145938,Under in vitro conditions BS prevented the SRA01/04 cells from undergoing apoptosis after UV treatment and also suppressed PGE2 release from UV‑irradiated SRA01/04 cells by modulating COX‑2 expression.,"[{'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Lu', 'Affiliation': 'Department of Ophthalmology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning 110059, P.R. China.'}, {'ForeName': 'Jiangyue', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'Department of Ophthalmology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning 110059, P.R. China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Ophthalmology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning 110059, P.R. China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Qin', 'Affiliation': 'Department of Ophthalmology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning 110059, P.R. China.'}, {'ForeName': 'Jingsong', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Ophthalmology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning 110059, P.R. China.'}]",Molecular medicine reports,['10.3892/mmr.2020.11311'] 2601,32705319,"Effects of morphine on peri-articular infiltration analgesia in total knee arthroplasty: a prospective, double-blind, randomized controlled trial.","PURPOSE Peri-articular infiltration analgesia (PIA) is a widely used method to control post-operative pain in total knee arthroplasty (TKA) patients. However, there are limited data that support the use of morphine in PIA. This study aims to evaluate the efficacy of peri-articular morphine infiltration for pain management in TKA patients. METHODS Based on a double-blind, randomized approach, patients were allocated to the morphine or control group. Patients in the morphine group received a peri-articular infiltration of an analgesic cocktail consisting of ropivacaine, epinephrine, and morphine. Morphine was omitted from the cocktail in the control group. Primary outcomes were post-operative consumption of morphine hydrochloride used for rescue analgesia and post-operative pain as assessed by visual analog scale (VAS) score. Secondary outcomes were functional recovery as assessed by a range of knee motion, quadriceps strength, and daily ambulation distance. The duration of hospital stay was also recorded. Tertiary outcomes included the occurrence of post-operative adverse effects and the consumption of antiemetics. RESULTS Patients in the morphine group had significantly lower post-operative morphine consumption in the first 24 h and total morphine consumption. There was no significant difference between the two groups in post-operative VAS pain scores at rest or during motion. There was no significant difference between the two groups in the post-operative knee range of motion, quadriceps strength, daily ambulation distance, or duration of post-operative hospital stay. The two groups were similar in the incidence of adverse effects and the consumption of antiemetics. CONCLUSION Adding morphine into the analgesic cocktail of PIA could reduce postoperative morphine consumption in TKA patients, but does not improve early pain relief or accelerate functional recovery or provide clinical benefits for TKA patients. In addition, the complications and safety of peri-articular morphine infiltration need to be further investigated in larger sample studies.",2020,"There was no significant difference between the two groups in the post-operative knee range of motion, quadriceps strength, daily ambulation distance, or duration of post-operative hospital stay.","['total knee arthroplasty', 'TKA patients', 'pain management in TKA patients', 'total knee arthroplasty (TKA) patients']","['ropivacaine, epinephrine, and morphine', 'morphine', 'peri-articular morphine infiltration', 'Morphine', 'Peri-articular infiltration analgesia (PIA']","['occurrence of post-operative adverse effects and the consumption of antiemetics', 'adverse effects and the consumption of antiemetics', 'post-operative morphine consumption', 'post-operative consumption of morphine hydrochloride used for rescue analgesia and post-operative pain as assessed by visual analog scale (VAS) score', 'functional recovery as assessed by a range of knee motion, quadriceps strength, and daily ambulation distance', 'post-operative knee range of motion, quadriceps strength, daily ambulation distance, or duration of post-operative hospital stay', 'post-operative VAS pain scores', 'duration of hospital stay']","[{'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]","[{'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]","[{'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0003297', 'cui_str': 'Antiemetic agent'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0770901', 'cui_str': 'Morphine hydrochloride'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0599766', 'cui_str': 'Recovery of Function'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0576094', 'cui_str': 'Knee joint - range of movement'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C2732809', 'cui_str': 'Visual analog scale pain score'}]",,0.223407,"There was no significant difference between the two groups in the post-operative knee range of motion, quadriceps strength, daily ambulation distance, or duration of post-operative hospital stay.","[{'ForeName': 'Qiuru', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': ""Department of Orthopaedics Surgery, West China Hospital, Sichuan University, 37# Wainan Guoxue Road, Chengdu, 610041, People's Republic of China.""}, {'ForeName': 'Jikui', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': ""State Key Laboratory of Oral Diseases, West China School Stomatology, Sichuan University, No. 14, Third Section South Renmin Road, Chengdu, 610041, People's Republic of China.""}, {'ForeName': 'Yunlian', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': ""Department of General Surgery, Yongchuan Hospital of Traditional Chinese Medicine, 2# Yingbin Road, Yongchuan, Chongqing, 402160, People's Republic of China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zeng', 'Affiliation': ""Department of Anesthesiology, West China Hospital, Sichuan University, 37# Wainan Guoxue Road, Chengdu, 610041, People's Republic of China.""}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': ""Department of Anesthesiology, West China Hospital, Sichuan University, 37# Wainan Guoxue Road, Chengdu, 610041, People's Republic of China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': ""Department of Anesthesiology, West China Hospital, Sichuan University, 37# Wainan Guoxue Road, Chengdu, 610041, People's Republic of China. hxyangjing@qq.com.""}, {'ForeName': 'Pengde', 'Initials': 'P', 'LastName': 'Kang', 'Affiliation': ""Department of Orthopaedics Surgery, West China Hospital, Sichuan University, 37# Wainan Guoxue Road, Chengdu, 610041, People's Republic of China. kangpengd@163.com.""}]",International orthopaedics,['10.1007/s00264-020-04700-z'] 2602,32705393,Inspiratory muscle training improves cerebrovascular and postural control responses during orthostatic stress in older women.,"PURPOSE We aimed to investigate the effect of inspiratory muscle training (IMT) on, hemodynamic, cerebrovascular and postural balance responses during orthostatic stress, in older women. METHODS Fourteen elderly women were assigned to perform IMT at 50% of maximal inspiratory pressure (MIP) (IMT group, n = 8) or placebo training at 5% MIP (Sham group, n = 6), in a counter-balanced order, using an inspiratory threshold device for 4 weeks. During the protocol, MIP was tested weekly once. In a second visit, blood pressure, heart rate, stroke volume, cardiac output, middle cerebral artery blood flow velocity (MCAv), and ventilation parameters were recorded continuously at rest and during orthostatic stress testing, which was conducted on a force plate to measure center-of-pressure (COP) oscillations (postural balance) and the electromyographic activity of the right medial gastrocnemius and tibialis anterior. RESULTS IMT increased MIP from second to 4th week. The drops in MCAv, stroke volume, and cardiac output, as well as COP displacements during initial orthostasis decreased post-IMT. CONCLUSION IMT improves the interplay of the respiratory pump, hemodynamic, cerebrovascular and postural balance responses during orthostatic stress in older women.",2020,"IMT improves the interplay of the respiratory pump, hemodynamic, cerebrovascular and postural balance responses during orthostatic stress in older women.","['older women', 'Fourteen elderly women']","['IMT at 50% of maximal inspiratory pressure (MIP) (IMT group, n\u2009=\u20098) or placebo training at 5% MIP (Sham group, n\u2009=\u20096), in a counter-balanced order, using an inspiratory threshold device for 4\xa0weeks', 'Inspiratory muscle training', 'inspiratory muscle training (IMT', 'IMT']","['MCAv, stroke volume, and cardiac output, as well as COP displacements', 'cerebrovascular and postural control responses', 'hemodynamic, cerebrovascular and postural balance responses', 'force plate to measure center-of-pressure (COP) oscillations (postural balance) and the electromyographic activity of the right medial gastrocnemius and tibialis anterior', 'blood pressure, heart rate, stroke volume, cardiac output, middle cerebral artery blood flow velocity (MCAv), and ventilation parameters']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0524338', 'cui_str': 'Elderly woman'}]","[{'cui': 'C0454511', 'cui_str': 'Inspiratory muscle training'}, {'cui': 'C4083126', 'cui_str': 'Maximum Inspiratory Pressure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0677601', 'cui_str': 'Counter'}, {'cui': 'C0205415', 'cui_str': 'Balanced'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0149566', 'cui_str': 'Structure of middle cerebral artery'}, {'cui': 'C0005798', 'cui_str': 'Blood Flow Velocity'}, {'cui': 'C0038455', 'cui_str': 'Stroke volume'}, {'cui': 'C0007165', 'cui_str': 'Cardiac output'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C4760618', 'cui_str': 'Posture Control'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C1256755', 'cui_str': 'Postural balance'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0242691', 'cui_str': 'Gastrocnemius muscle structure'}, {'cui': 'C0242690', 'cui_str': 'Tibialis anterior muscle structure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",14.0,0.052373,"IMT improves the interplay of the respiratory pump, hemodynamic, cerebrovascular and postural balance responses during orthostatic stress in older women.","[{'ForeName': 'Gabriel Dias', 'Initials': 'GD', 'LastName': 'Rodrigues', 'Affiliation': 'Department of Physiology and Pharmacology, Fluminense Federal University, Rua Professor Hernani Pires de Melo, 101, São Domingos, Niteroi, RJ, CEP 24210-130, Brazil.'}, {'ForeName': 'Jonas Lírio', 'Initials': 'JL', 'LastName': 'Gurgel', 'Affiliation': 'Department of Physical Education and Sports, Fluminense Federal University, Niteroi, Brazil.'}, {'ForeName': 'Iuri Dos Santos', 'Initials': 'IDS', 'LastName': 'Galdino', 'Affiliation': 'Department of Physiology and Pharmacology, Fluminense Federal University, Rua Professor Hernani Pires de Melo, 101, São Domingos, Niteroi, RJ, CEP 24210-130, Brazil.'}, {'ForeName': 'Antonio Claudio Lucas', 'Initials': 'ACL', 'LastName': 'da Nóbrega', 'Affiliation': 'Department of Physiology and Pharmacology, Fluminense Federal University, Rua Professor Hernani Pires de Melo, 101, São Domingos, Niteroi, RJ, CEP 24210-130, Brazil.'}, {'ForeName': 'Pedro Paulo da Silva', 'Initials': 'PPDS', 'LastName': 'Soares', 'Affiliation': 'Department of Physiology and Pharmacology, Fluminense Federal University, Rua Professor Hernani Pires de Melo, 101, São Domingos, Niteroi, RJ, CEP 24210-130, Brazil. ppssoares@id.uff.br.'}]",European journal of applied physiology,['10.1007/s00421-020-04441-2'] 2603,32705417,High-dose rocuronium-induced paralysis of the adductor pollicis muscle facilitates detection of the timing for tracheal intubation in elderly patients: a randomized double-blind study.,"PURPOSE To prevent coughing related to tracheal intubation and the resultant exposure of intubating staff to the patients' expiratory aerosols, the timing of tracheal intubation needs to be precisely predicted. The aim of this study was to evaluate the hypothesis that the timing for safe tracheal intubation in elderly patients can be determined by acceleromyographically monitoring paralysis of the adductor pollicis muscle when high-dose rocuronium, given to block the respiratory muscles, is administered. METHODS Forty elderly (65-92 years) patients were enrolled in this study and randomly assigned to two groups, to receive rocuronium 0.6 mg/kg or 1 mg/kg. After induction of anesthesia and observing acceleromyographic train-of-four (TOF) responses of the adductor pollicis muscle to ulnar nerve stimulation, the patients randomly received either dose of rocuronium. The onset times from rocuronium administration to TOF counts of 0 were measured. Soon thereafter, a single anesthesiologist who was blinded to the allocated dose of rocuronium performed laryngoscopy and tracheal intubation, and assessed intubating conditions. Data were analyzed by the unpaired t-test and Chi-squared test. RESULTS The averaged [SD] onset time of neuromuscular blockade was significantly shorter with 1 mg/kg than 0.6 mg/kg rocuronium (104.3 [30.1] s vs. 186.8 [37.5] s, p < 0.001). Patients who received 0.6 mg/kg rocuronium variously showed either poor (n = 9) or good (n = 11) intubating conditions. However, all patients who received 1 mg/kg rocuronium had excellent intubating conditions. CONCLUSIONS If 1 mg/kg rocuronium is administered, a TOF count of 0 acceleromyographically observed at the adductor pollicis muscle can reveal the adequate timing for tracheal intubation.",2020,The averaged [SD] onset time of neuromuscular blockade was significantly shorter with 1 mg/kg than 0.6 mg/kg rocuronium (104.3 [30.1] s vs. 186.8,"['Forty elderly (65-92\xa0years', 'elderly patients']","['rocuronium', 'anesthesia and observing acceleromyographic train-of-four (TOF', 'rocuronium 0.6\xa0mg/kg or 1\xa0mg/kg', 'rocuronium performed laryngoscopy and tracheal intubation, and assessed intubating conditions']","['averaged [SD] onset time of neuromuscular blockade', 'excellent intubating conditions']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0209337', 'cui_str': 'Rocuronium'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C4068883', 'cui_str': '0.6'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0023072', 'cui_str': 'Laryngoscopy'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0449244', 'cui_str': 'Time of onset'}, {'cui': 'C0234119', 'cui_str': 'Neuromuscular blockade'}, {'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]",40.0,0.550908,The averaged [SD] onset time of neuromuscular blockade was significantly shorter with 1 mg/kg than 0.6 mg/kg rocuronium (104.3 [30.1] s vs. 186.8,"[{'ForeName': 'Shunichi', 'Initials': 'S', 'LastName': 'Takagi', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan.'}, {'ForeName': 'Nami', 'Initials': 'N', 'LastName': 'Sugaya', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan.'}, {'ForeName': 'Naoto', 'Initials': 'N', 'LastName': 'Kiuchi', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan.'}, {'ForeName': 'Aya', 'Initials': 'A', 'LastName': 'Iwasa', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan.'}, {'ForeName': 'Masumi', 'Initials': 'M', 'LastName': 'Itagaki', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan.'}, {'ForeName': 'Aya', 'Initials': 'A', 'LastName': 'Seki', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan.'}, {'ForeName': 'Junko', 'Initials': 'J', 'LastName': 'Suzuki', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Suzuki', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan. suzuki.takahiro@nihon-u.ac.jp.'}]",Journal of anesthesia,['10.1007/s00540-020-02831-6'] 2604,32705460,Parent Management Training Oregon Model and Family-Based Services as Usual for Behavioral Problems in Youth: A National Randomized Controlled Trial in Denmark.,"This randomized control trial used intent-to-treat analyses to compare parent management training-Oregon model (PMTO) (N = 64) to family-based services as usual (SAU) (N = 62) in 3.5-13-year-old children and their families in Denmark. Outcomes were parent report of child internalizing and externalizing problems, parenting efficacy, parenting stress, parent sense of coherence, parent-report of life satisfaction, and parental depressive symptoms. Outcomes were measured at pretreatment, post-treatment, and 18-20 months post-treatment. Results demonstrated that both PMTO and family-based SAU resulted in significant improvements in child externalizing and internalizing problems, parenting efficacy, as well as parent-reported stress and depressive symptoms, life satisfaction, and aspects of sense of cohesion. Effect sizes at post-treatment and follow-up were in the small to moderate range, consistent with prior PMTO evaluations. However, there were no significant differences between PMTO and family-based SAU. Further research on the process and content of family-based SAU is needed to determine how this approach overlaps with and is distinct from PMTO.",2020,"Results demonstrated that both PMTO and family-based SAU resulted in significant improvements in child externalizing and internalizing problems, parenting efficacy, as well as parent-reported stress and depressive symptoms, life satisfaction, and aspects of sense of cohesion.","['Youth', 'N\u2009=\u200964) to family-based services as usual (SAU) (N\u2009=\u200962) in 3.5-13-year-old children and their families in Denmark']",['parent management training-Oregon model (PMTO'],"['child internalizing and externalizing problems, parenting efficacy, parenting stress, parent sense of coherence, parent-report of life satisfaction, and parental depressive symptoms', 'child externalizing and internalizing problems, parenting efficacy, as well as parent-reported stress and depressive symptoms, life satisfaction, and aspects of sense of cohesion']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0029195', 'cui_str': 'Oregon'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C3178983', 'cui_str': 'Salutogenesis'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}]",,0.0611722,"Results demonstrated that both PMTO and family-based SAU resulted in significant improvements in child externalizing and internalizing problems, parenting efficacy, as well as parent-reported stress and depressive symptoms, life satisfaction, and aspects of sense of cohesion.","[{'ForeName': 'Christoffer', 'Initials': 'C', 'LastName': 'Scavenius', 'Affiliation': 'VIVE - The Danish Center for Social Science Research, Copenhagen, Denmark.'}, {'ForeName': 'Anil', 'Initials': 'A', 'LastName': 'Chacko', 'Affiliation': 'New York University, New York, NY, USA. anil.chacko@nyu.edu.'}, {'ForeName': 'M R', 'Initials': 'MR', 'LastName': 'Lindberg', 'Affiliation': 'Aalborg University, Aalborg, Denmark.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Granski', 'Affiliation': 'New York University, New York, NY, USA.'}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Vardanian', 'Affiliation': 'New York University, New York, NY, USA.'}, {'ForeName': 'Maiken', 'Initials': 'M', 'LastName': 'Pontoppidan', 'Affiliation': 'VIVE - The Danish Center for Social Science Research, Copenhagen, Denmark.'}, {'ForeName': 'Helle', 'Initials': 'H', 'LastName': 'Hansen', 'Affiliation': 'VIVE - The Danish Center for Social Science Research, Copenhagen, Denmark.'}, {'ForeName': 'Misja', 'Initials': 'M', 'LastName': 'Eiberg', 'Affiliation': 'VIVE - The Danish Center for Social Science Research, Copenhagen, Denmark.'}]",Child psychiatry and human development,['10.1007/s10578-020-01028-y'] 2605,32705473,12-Month Evaluation of an EHR-Supported Staff Role Change for Provision of Tobacco Cessation Care in 8 Primary Care Safety-Net Clinics.,"SIGNIFICANCE Guidelines urge primary care practices to routinely provide tobacco cessation care (i.e., assess tobacco use, provide brief cessation advice, and refer to cessation support). This study evaluates the impact of a systems-based strategy to provide tobacco cessation care in eight primary care clinics serving low-income patients. METHODS A non-randomized stepped wedge study design was used to implement an intervention consisting of (1) changes to the electronic health record (EHR) referral functionality and (2) expansion of staff roles to provide brief advice to quit; assess readiness to quit; offer a referral to tobacco cessation counseling; and sign the referral order. Outcomes assessed from the EHR include performance of tobacco cessation care tasks, referral contact, and enrollment rates for the quitline (QL) and in-house Freedom from Smoking (FFS) program. Generalized estimating equations (GEE) methods were used to compute odds ratios contrasting the pre-implementation vs. 1-, 3-, 6-, and 12-month post-implementation periods. RESULTS Of the 176,061 visits, 26.1% were by identified tobacco users. All indicators significantly increased at each time period evaluated post-implementation. In comparison with the pre-intervention period, assessing smoking status (26.6% vs. 55.7%; OR = 3.7, CI = 3.6-3.9), providing advice (44.8% vs. 88.7%; OR = 7.8, CI = 6.6-9.1), assessing readiness to quit (15.8% vs. 55.0%; OR = 6.2, CI = 5.4-7.0), and acceptance of a referral to tobacco cessation counseling (0.5% vs. 30.9%; OR = 81.0, CI = 11.4-575.8) remained significantly higher 12 months post-intervention. For the QL and FFS, respectively, there were 1223 and 532 referrals; 324 (31.1%) and 103 (24.7%) were contacted; 241 (74.4%) and 72 (69.6%) enrolled; and 195 (80.9%) and 14 (19.4%) received at least one counseling session. CONCLUSIONS This system change intervention that includes an EHR-supported role expansion substantially increased the provision of tobacco cessation care and improvements were sustained beyond 1 year. This approach has the potential to greatly increase the number of individuals referred for tobacco cessation counseling.",2020,This system change intervention that includes an EHR-supported role expansion substantially increased the provision of tobacco cessation care and improvements were sustained beyond 1 year.,['eight primary care clinics serving low-income patients'],"['systems-based strategy to provide tobacco cessation care', 'EHR-Supported Staff Role Change for Provision of Tobacco Cessation Care', 'electronic health record (EHR) referral functionality and (2) expansion of staff roles to provide brief advice to quit; assess readiness to quit']","['assessing readiness to quit', 'acceptance of a referral to tobacco cessation counseling', 'smoking status', 'EHR include performance of tobacco cessation care tasks, referral contact, and enrollment rates for the quitline (QL) and in-house Freedom from Smoking (FFS) program']","[{'cui': 'C1552443', 'cui_str': 'Primary care clinic'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0600549', 'cui_str': 'Tobacco Cessation'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0237102', 'cui_str': 'Role change'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}]","[{'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C0600549', 'cui_str': 'Tobacco Cessation'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]",,0.075455,This system change intervention that includes an EHR-supported role expansion substantially increased the provision of tobacco cessation care and improvements were sustained beyond 1 year.,"[{'ForeName': 'Susan A', 'Initials': 'SA', 'LastName': 'Flocke', 'Affiliation': 'Department of Family Medicine, Oregon Health & Science University, Portland, OR, USA. flocke@ohsu.edu.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Seeholzer', 'Affiliation': 'Center for Health Care Research and Policy, The MetroHealth System, Cleveland, OH, USA.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Lewis', 'Affiliation': 'Center for Health Care Research and Policy, The MetroHealth System, Cleveland, OH, USA.'}, {'ForeName': 'India J', 'Initials': 'IJ', 'LastName': 'Gill', 'Affiliation': 'Center for Community Health Integration, Case Western Reserve University, Cleveland, OH, USA.'}, {'ForeName': 'Jeanmarie C', 'Initials': 'JC', 'LastName': 'Rose', 'Affiliation': 'Center for Community Health Integration, Case Western Reserve University, Cleveland, OH, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Albert', 'Affiliation': 'Center for Community Health Integration, Case Western Reserve University, Cleveland, OH, USA.'}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Love', 'Affiliation': 'Center for Health Care Research and Policy, The MetroHealth System, Cleveland, OH, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kaelber', 'Affiliation': 'Center for Health Care Research and Policy, The MetroHealth System, Cleveland, OH, USA.'}]",Journal of general internal medicine,['10.1007/s11606-020-06030-7'] 2606,32705528,The utility of proinflammatory markers in patients with obstructive sleep apnea.,"PURPOSE To evaluate the association of recently diagnosed obstructive sleep apnea (OSA) with TNF-α and IL-6 and to measure the effect of short-term continuous positive airway pressure (CPAP) therapy on these markers. METHODS A prospective, open-label, controlled trial was conducted among patients referred for diagnostic polysomnography (PSG). After PSG, patients were divided into 3 groups: OSA intervention group (N = 21), OSA control untreated group (N = 19), and non-OSA control group (N = 24). IL-6 and TNF-α levels were measured at baseline and 1 month after intervention. Repeated measures (RM) ANOVA and ANCOVA were used to compare the three groups regarding changes in TNF-α and IL-6 levels by analyzing between-subject and within-subject effects as a function of time and adjusting for significant covariates. RESULTS At baseline, IL-6 (p = 0.05) and TNF-α (p = 0.04) were significantly higher in the OSA patients than in the non-OSA controls. There was no effect of time either on the TNF-α (p = 0.069) or IL-6 (p = 0.717) after 1 month of CPAP. No interaction effect between group and time was found for either TNF-α (p = 0.240) or IL-6 (p = 0.552) after 1 month of CPAP. There was neither a group effect nor an interaction effect between group and time for either IL-6 or TNF α after adjusting for age, BMI, neck circumference, and AHI. CONCLUSION This study showed increases in proinflammatory state as illustrated by plasma TNF-α and IL-6 levels among recently diagnosed OSA patients, but there were no changes in these inflammatory markers following 1-month CPAP therapy.",2020,"There was neither a group effect nor an interaction effect between group and time for either IL-6 or TNF α after adjusting for age, BMI, neck circumference, and AHI. ","['patients with obstructive sleep apnea', 'patients referred for diagnostic polysomnography (PSG']","['TNF-α', 'OSA intervention', 'IL-6', 'OSA control untreated group (N\u2009=\u200919), and non-OSA control', 'short-term continuous positive airway pressure (CPAP) therapy']","['TNF-α and IL-6 levels', 'proinflammatory state', 'TNF-α', 'plasma TNF-α and IL-6 levels', 'and TNF-α levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0162701', 'cui_str': 'Polysomnography'}]","[{'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205304', 'cui_str': 'Non-obstructive'}, {'cui': 'C0037315', 'cui_str': 'Sleep apnea'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}]",,0.0130855,"There was neither a group effect nor an interaction effect between group and time for either IL-6 or TNF α after adjusting for age, BMI, neck circumference, and AHI. ","[{'ForeName': 'Siraj Omar', 'Initials': 'SO', 'LastName': 'Wali', 'Affiliation': 'Sleep Medicine and Research Center, Sleep Medicine Research Group, Internal Medicine Department, Faculty of Medicine, College of Medicine, King Abdulaziz University Hospital, King Abdulaziz University, POBOX 21589, Jeddah, 80215, Saudi Arabia. sowali@kau.edu.sa.'}, {'ForeName': 'Jamil', 'Initials': 'J', 'LastName': 'Al-Mughales', 'Affiliation': 'Diagnostic Immunology Division, Department of Clinical Laboratory Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.'}, {'ForeName': 'Faris', 'Initials': 'F', 'LastName': 'Alhejaili', 'Affiliation': 'Sleep Medicine and Research Center, Sleep Medicine Research Group, Internal Medicine Department, Faculty of Medicine, College of Medicine, King Abdulaziz University Hospital, King Abdulaziz University, POBOX 21589, Jeddah, 80215, Saudi Arabia.'}, {'ForeName': 'Md Dilshad', 'Initials': 'MD', 'LastName': 'Manzar', 'Affiliation': 'Department of Nursing, College of Applied Medical Sciences, Majmaah University, Majmaah, Saudi Arabia.'}, {'ForeName': 'Fahad', 'Initials': 'F', 'LastName': 'Alsallum', 'Affiliation': 'Medical Student, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.'}, {'ForeName': 'Hashim', 'Initials': 'H', 'LastName': 'Almojaddidi', 'Affiliation': 'Medical Student, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Gozal', 'Affiliation': 'Department of Child Health and the Child Health Research Institute, The University of Missouri School of Medicine, Columbia, MO, USA.'}]",Sleep & breathing = Schlaf & Atmung,['10.1007/s11325-020-02149-3'] 2607,32705612,Implementation of Prehabilitation for Major Abdominal Surgery and Head and Neck Surgery: a Simplified Seven-Day Protocol.,"PURPOSE The aim of this prospective trial was to assess the compliance of a prehabilitation protocol on post-operative outcome after major abdominal and head and neck surgery. METHODS A single-arm, prospective 7-day intervention trial was approved by our local IRB for patients undergoing major abdominal and head-and-neck (H&N) surgery from 8/2018 to 3/2019. This was a 7-day intervention trial at the time of pre-admission testing to assess compliance for pulmonary, nutritional, and physical activity prior to surgery. RESULTS Seventy-six patients were enrolled in this compliance with IS use that was 85%, with a median of 2200 cc (range 1500-2500cc), pre-operative nutritional drink (89.5%), and chlorhexidine gluconate use was 92%. Ambulation/step compliance was only 32 patients (44%), with median steps of 7500 (range 400-15,000). Compared with the non-prehabilitation patients, we found significant improvement in immediate post-operative mobility (OR 0.73, 95% CI 0.46-0.97, p = 0.04), and improvement in prevention of pulmonary morbidity (OR 0.82, 95% CI 0.23-1.18, p = 0.07) was observed in the prehabilitation group. No significant difference in overall infectious complications (18% vs 27%), surgical site infections (14% vs 22%), length of stay (median 6 days vs 6), or readmissions (18% vs 22%). CONCLUSIONS A simple 7-day prehabilitation protocol at the time of pre-admission testing is feasible with a high degree of compliance regardless of a patient's disease type, education, or socioeconomic background.",2020,"No significant difference in overall infectious complications (18% vs 27%), surgical site infections (14% vs 22%), length of stay (median 6 days vs 6), or readmissions (18% vs 22%). ","['patients undergoing major abdominal and head-and-neck (H&N) surgery from 8/2018 to 3/2019', 'Seventy-six patients were enrolled in this compliance with']",['chlorhexidine gluconate'],"['pre-operative nutritional drink', 'Ambulation/step compliance', 'overall infectious complications', 'length of stay', 'prevention of pulmonary morbidity', 'immediate post-operative mobility', 'surgical site infections']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0460004', 'cui_str': 'Structure of head and/or neck'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C4319622', 'cui_str': '76'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}]","[{'cui': 'C0055361', 'cui_str': 'Chlorhexidine gluconate'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}]",76.0,0.103679,"No significant difference in overall infectious complications (18% vs 27%), surgical site infections (14% vs 22%), length of stay (median 6 days vs 6), or readmissions (18% vs 22%). ","[{'ForeName': 'Jaclyn', 'Initials': 'J', 'LastName': 'Moore', 'Affiliation': 'Norton Cancer Institute, Louisville, KY, 40202, USA.'}, {'ForeName': 'Charles R', 'Initials': 'CR', 'LastName': 'Scoggins', 'Affiliation': 'Department of Surgery, Division of Surgical Oncology, University of Louisville, 315 E. Broadway-#311, Louisville, KY, 40202, USA.'}, {'ForeName': 'Prejesh', 'Initials': 'P', 'LastName': 'Philips', 'Affiliation': 'Department of Surgery, Division of Surgical Oncology, University of Louisville, 315 E. Broadway-#311, Louisville, KY, 40202, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Egger', 'Affiliation': 'Department of Surgery, Division of Surgical Oncology, University of Louisville, 315 E. Broadway-#311, Louisville, KY, 40202, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Tennant', 'Affiliation': 'Department of Otolaryngology, University of Louisville, Louisville, KY, 40202, USA.'}, {'ForeName': 'Jerod', 'Initials': 'J', 'LastName': 'Little', 'Affiliation': 'Department of Otolaryngology, University of Louisville, Louisville, KY, 40202, USA.'}, {'ForeName': 'Robert C G', 'Initials': 'RCG', 'LastName': 'Martin', 'Affiliation': 'Department of Surgery, Division of Surgical Oncology, University of Louisville, 315 E. Broadway-#311, Louisville, KY, 40202, USA. Robert.Martin@louisville.edu.'}]",Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,['10.1007/s11605-020-04740-1'] 2608,32705703,Internet-based cognitive behavioral therapy for anxiety in an outpatient specialized care setting: A qualitative study of the patients' experience of the therapy.,"Knowledge about user experiences of internet-based cognitive behavioral therapy (iCBT) has mostly been drawn from non-clinical groups or with iCBT offered via self-referral. The present study therefore focused on patients who had undergone iCBT with minimal support while actively awaiting outpatient psychological treatment in the form of face-to-face CBT. To seek out barriers to adherence the study also included patients who had withdrawn from the iCBT treatment before completion. The study was performed in an outpatient clinic for anxiety disorders where twelve participants with a primary diagnosis of either social anxiety disorder or panic disorder were recruited from an ongoing randomized control trial for semi-structured interviews. Statements from the interviews showed that the iCBT treatment was unfavorably compared to the usual face-to-face treatment at the clinic. Despite this, a majority of the interview participants still expressed to have experienced various benefits from the treatment. Some participants did however, experience difficulties putting the materials to practical use. Furthermore, a large majority of the participants expressed a need for additional support, with a strong tendency for non-completers specifically expressing a need for face-to-face contact with a clinician. Implications for future research and implementation of iCBT in clinical practice are discussed.",2020,Statements from the interviews showed that the iCBT treatment was unfavorably compared to the usual face-to-face treatment at the clinic.,"['patients who had undergone iCBT with minimal support while actively awaiting outpatient psychological treatment in the form of face-to-face CBT', 'patients who had withdrawn from the iCBT treatment before completion', 'outpatient clinic for anxiety disorders where twelve participants with a primary diagnosis of either social anxiety disorder or panic disorder']","['Internet-based cognitive behavioral therapy', 'internet-based cognitive behavioral therapy (iCBT', 'iCBT']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0332137', 'cui_str': 'Principal diagnosis'}, {'cui': 'C0031572', 'cui_str': 'Social phobia'}, {'cui': 'C0030319', 'cui_str': 'Panic disorder'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]",[],12.0,0.0128324,Statements from the interviews showed that the iCBT treatment was unfavorably compared to the usual face-to-face treatment at the clinic.,"[{'ForeName': 'Martin Kent', 'Initials': 'MK', 'LastName': 'Pedersen', 'Affiliation': 'Psychological Private Practice, Copenhagen, Denmark.'}, {'ForeName': 'Rozhiar', 'Initials': 'R', 'LastName': 'Mohammadi', 'Affiliation': 'Department of Psychotherapy, Psychiatric Center Amager, Copenhagen, Denmark.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Mathiasen', 'Affiliation': 'Department of Depression and Anxiety, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Mette', 'Initials': 'M', 'LastName': 'Elmose', 'Affiliation': 'Department of Psychology, University of Southern Denmark, Odense, Denmark.'}]",Scandinavian journal of psychology,['10.1111/sjop.12665'] 2609,32705710,Comparison of peritoneal dialysis catheter insertion techniques by nephrologists: Surgical vs blind methods.,"BACKGROUND The aim of the present study was to perform a comparative analysis of peritoneal dialysis catheter (PDC) insertion between blind and surgical methods by nephrologists. PATIENTS AND METHODS The present study enrolled 249 peritoneal dialysis patients who received first-time PDC insertion. All PDC insertions were performed using either the blind or surgical method. In our hospital during the study period, two of three nephrologists performed the blind method routinely in all eligible patients (blind group), and one of three nephrologists performed the surgical method in all eligible patients (surgical group). Catheter outcomes, including infectious or mechanical complications, functional parameters, and catheter survival, were evaluated. RESULTS The numbers of patients underwent surgical or blind methods were 105 and 144, respectively. The use of systemic analgesics in the surgical group was higher than that in the blind group. The operation time was longer in the blind group than in the surgical group. The D0 level and peritoneal Kt/V were similar between the two groups. There was no significant difference in infectious and mechanical complications between the two groups. The catheter survival and intervention-free survival were similar between the two groups (P = .995 for catheter survival and P = .723 for intervention-free survival). CONCLUSION Our study shows that catheter outcomes are similar between blind and surgical insertion techniques performed by nephrologists. These findings reveal that patients without previous major abdominal surgery would be suitable to receive any one of the two methods according to the operator-friendly technique.",2020,The catheter survival and intervention-free survival were similar between the two groups (P = .995 for catheter survival and P = ,"['249 peritoneal dialysis patients who received first-time PDC insertion', 'patients without previous major abdominal surgery']","['peritoneal dialysis catheter insertion techniques', 'peritoneal dialysis catheter (PDC) insertion']","['infectious or mechanical complications, functional parameters, and catheter survival', 'infectious and mechanical complications', 'catheter survival and intervention-free survival', 'D0 level and peritoneal', 'operation time']","[{'cui': 'C0031139', 'cui_str': 'Peritoneal dialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0179783', 'cui_str': 'Peritoneal dialysis catheter'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}]","[{'cui': 'C0179783', 'cui_str': 'Peritoneal dialysis catheter'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0031153', 'cui_str': 'Peritoneum (serous membrane) structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",249.0,0.0632112,The catheter survival and intervention-free survival were similar between the two groups (P = .995 for catheter survival and P = ,"[{'ForeName': 'Seok Hui', 'Initials': 'SH', 'LastName': 'Kang', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Republic of Korea.'}, {'ForeName': 'Jong Won', 'Initials': 'JW', 'LastName': 'Park', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Republic of Korea.'}, {'ForeName': 'Kyu Hyang', 'Initials': 'KH', 'LastName': 'Cho', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Republic of Korea.'}, {'ForeName': 'Jun Young', 'Initials': 'JY', 'LastName': 'Do', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Republic of Korea.'}]",Seminars in dialysis,['10.1111/sdi.12904'] 2610,32705801,Propofol for migraine in the emergency department: A pilot randomised controlled trial.,"OBJECTIVE To test the administration of intravenous (i.v.) propofol at a procedural sedation dose compared to standard therapy for initial management of migraine in the ED. METHODS This was an open label, randomised controlled pilot trial. Eligible patients were adults with a diagnosis of migraine and planned for treatment with i.v. medications. Patients were randomised to propofol or standard therapy groups. The primary outcome variable was time to discharge (TTD) defined as time from intervention to discharge from the ED. Secondary outcomes were safety of propofol administration and change in pain scores. A reduction of pain by ≥50% or discharge from the ED was defined as favourable. All analyses were performed on an intention-to-treat basis. RESULTS Data from 29 patients were analysed, with 15 patients in the propofol group and 14 patients in the standard therapy group. TTD was significantly lower in the propofol group with median of 290 (interquartile range 162-500) min compared to 554.5 (interquartile range 534-639) min in the standard therapy group (P = 0.021). The hazard ratio for the defined favourable outcome of reduction of pain scores or discharge from the ED was 1.54 (95% CI 0.69-3.41). CONCLUSIONS Initial management of migraine with i.v. propofol at procedural sedation doses significantly reduced TTD compared to standard therapy. We did not detect any significant safety concerns although the study was not adequately powered to detect safety of the intervention and requires validation.",2020,We did not detect any significant safety concerns although the study was not adequately powered to detect safety of the intervention and requires validation.,"['29 patients were analysed, with 15 patients in the propofol group and 14 patients in the standard therapy group', 'Eligible patients were adults with a diagnosis of migraine and planned for treatment with i.v']","['Propofol', 'intravenous (i.v.) propofol', 'propofol']","['time to discharge (TTD) defined as time from intervention to discharge from the ED', 'TTD', 'pain scores or discharge', 'safety of propofol administration and change in pain scores', 'pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",29.0,0.13792,We did not detect any significant safety concerns although the study was not adequately powered to detect safety of the intervention and requires validation.,"[{'ForeName': 'Biswadev', 'Initials': 'B', 'LastName': 'Mitra', 'Affiliation': 'Emergency and Trauma Centre, The Alfred Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Roman', 'Affiliation': 'Emergency and Trauma Centre, The Alfred Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Mercier', 'Affiliation': 'CHU de Québec-Université Laval Research Center, Population Health and Optimal Health Practices Axis, Université Laval, Quebec, Quebec, Canada.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Moloney', 'Affiliation': 'Department of Anaesthesiology and Perioperative Medicine, The Alfred Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Yip', 'Affiliation': 'Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Keshav', 'Initials': 'K', 'LastName': 'Khullar', 'Affiliation': 'Emergency and Trauma Centre, The Alfred Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Kieran', 'Initials': 'K', 'LastName': 'Walsh', 'Affiliation': 'Emergency and Trauma Centre, The Alfred Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'De Villiers', 'Initials': 'V', 'LastName': 'Smit', 'Affiliation': 'Emergency and Trauma Centre, The Alfred Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Cameron', 'Affiliation': 'Emergency and Trauma Centre, The Alfred Hospital, Melbourne, Victoria, Australia.'}]",Emergency medicine Australasia : EMA,['10.1111/1742-6723.13542'] 2611,32705811,Be Healthy in Pregnancy: Exploring factors that impact pregnant women's nutrition and exercise behaviours.,"Excess gestational weight gain is associated with short- and long-term pregnancy complications. Although a healthy diet and physical activity during pregnancy are recommended and shown to reduce the risk of complications and improve outcomes, adherence to these recommendations is low. The aims of this study were to explore women's view of nutrition and physical activity during pregnancy and to describe barriers and facilitators experienced in implementing physical activity and nutrition recommendations. In a substudy of the Be Healthy in Pregnancy randomized trial, 20 semistructured focus groups were conducted with 66 women randomized to the control group when they were between 16 and 24 weeks gestation. Focus groups were recorded, transcribed verbatim, coded and thematically analysed. The results indicate that women felt motivated to be healthy for their baby, but competing priorities may take precedence. Participants described limited knowledge and access to information on safe physical activity in pregnancy and lacked the skills needed to operationalize both physical activity and dietary recommendations. Women's behaviours regarding diet and physical activity in pregnancy were highly influenced by their own and their peers' beliefs and values regarding how weight gain impacted their health during pregnancy. Pregnancy symptoms beyond women's control such as fatigue and nausea made physical activity and healthy eating more challenging. Counselling from care providers about nutrition and physical activity was perceived as minimal and ineffective. Future interventions should address improving counselling strategies and address individual's beliefs around nutrition and activity in pregnancy.",2020,Women's behaviours regarding diet and physical activity in pregnancy were highly influenced by their own and their peers' beliefs and values regarding how weight gain impacted their health during pregnancy.,"['Be Healthy in Pregnancy', ""pregnant women's nutrition and exercise behaviours"", '66 women randomized to the control group when they were between 16 and 24 weeks gestation']",[],['Excess gestational weight gain'],"[{'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0439230', 'cui_str': 'week'}]",[],"[{'cui': 'C1398625', 'cui_str': 'Maternal Weight Gain'}]",66.0,0.051411,Women's behaviours regarding diet and physical activity in pregnancy were highly influenced by their own and their peers' beliefs and values regarding how weight gain impacted their health during pregnancy.,"[{'ForeName': 'Lindsay N', 'Initials': 'LN', 'LastName': 'Grenier', 'Affiliation': 'McMaster Midwifery Research Center, Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Stephanie A', 'Initials': 'SA', 'LastName': 'Atkinson', 'Affiliation': 'Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Michelle F', 'Initials': 'MF', 'LastName': 'Mottola', 'Affiliation': 'R. Samuel McLaughlin Foundation-Exercise and Pregnancy Lab, School of Kinesiology, The University of Western Ontario, London, Ontario, Canada.'}, {'ForeName': 'Olive', 'Initials': 'O', 'LastName': 'Wahoush', 'Affiliation': 'Global Health, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Lehana', 'Initials': 'L', 'LastName': 'Thabane', 'Affiliation': 'Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Xie', 'Affiliation': 'Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Vickers-Manzin', 'Affiliation': 'Public Health Services-Healthy Families, Healthy & Safe Communities, Hamilton, Ontario, Canada.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Moore', 'Affiliation': 'Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Eileen K', 'Initials': 'EK', 'LastName': 'Hutton', 'Affiliation': 'McMaster Midwifery Research Center, Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Murray-Davis', 'Affiliation': 'McMaster Midwifery Research Center, Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada.'}]",Maternal & child nutrition,['10.1111/mcn.13068'] 2612,32705817,Is autism driven by epilepsy in infants with Tuberous Sclerosis Complex?,"OBJECTIVE To evaluate the relationship between age at seizure onset and neurodevelopmental outcome at age 24 months in infants with TSC, as well as the effect on neurodevelopmental outcome of early versus conventional treatment of epileptic seizures with vigabatrin (80-150 mg/kg/day). METHODS Infants with TSC, aged ≤4 months and without previous seizures were enrolled in a prospective study and closely followed with monthly video EEG and serial standardized neurodevelopmental testing (Bayley Scales of Infant Development and Autism Diagnostic Observation Schedule). RESULTS Eighty infants were enrolled. At the age of 24 months testing identified risk of Autism Spectrum Disorder (ASD) in 24/80 children (30.0%), and developmental delay (DD) in 26/80 (32.5%). Children with epilepsy (51/80; 63.8%) had a higher risk of ASD (P = 0.02) and DD (P = 0.001). Overall, no child presented with moderate or severe DD at 24 months (developmental quotient < 55). In 20% of children abnormal developmental trajectories were detected before the onset of seizures. Furthermore, 21% of all children with risk of ASD at 24 months had not developed seizures at that timepoint. There was no significant difference between early and conventional treatment with respect to rate of risk of ASD (P = 0.8) or DD (P = 0.9) at 24 months. INTERPRETATION This study confirms a relationship between epilepsy and risk of ASD/DD. However, in this combined randomized/open label study, early treatment with vigabatrin did not alter the risk of ASD or DD at age 2 years.",2020,Children with epilepsy (51/80; 63.8%) had a higher risk of ASD (P = 0.02) and DD (P = 0.001).,"['80-150\xa0mg/kg/day', '24/80 children (30.0%), and developmental delay (DD) in 26/80 (32.5', 'Infants with TSC, aged ≤4\xa0months and without previous seizures were enrolled in a prospective study and closely followed with monthly video EEG and serial standardized neurodevelopmental testing (Bayley Scales of Infant Development and Autism Diagnostic Observation Schedule', 'Eighty infants were enrolled']",['vigabatrin'],"['moderate or severe DD', 'higher risk of ASD', 'seizures', 'risk of ASD or DD', 'risk of Autism Spectrum Disorder (ASD', 'rate of risk of ASD']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C3665414', 'cui_str': 'mg/kg/day'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0424605', 'cui_str': 'Developmental delay'}, {'cui': 'C4517710', 'cui_str': '32.5'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0041341', 'cui_str': 'Tuberous sclerosis syndrome'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0033522', 'cui_str': 'Prospective Studies'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0430801', 'cui_str': 'Video EEG'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0451021', 'cui_str': 'Bayley scale of infant development'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C3816958', 'cui_str': '80'}]","[{'cui': 'C0048044', 'cui_str': 'Vigabatrin'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0424605', 'cui_str': 'Developmental delay'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",80.0,0.0825755,Children with epilepsy (51/80; 63.8%) had a higher risk of ASD (P = 0.02) and DD (P = 0.001).,"[{'ForeName': 'Romina', 'Initials': 'R', 'LastName': 'Moavero', 'Affiliation': 'Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University, Via Montpellier 1, Rome, 00133, Italy.'}, {'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Kotulska', 'Affiliation': ""Department of Neurology and Epileptology, The Children's Memorial Health Institute, Al. Dzieci Polskich 20, Warsaw, 04-730, Poland.""}, {'ForeName': 'Lieven', 'Initials': 'L', 'LastName': 'Lagae', 'Affiliation': 'Department of Development and Regeneration-Section Pediatric Neurology, University Hospitals KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Arianna', 'Initials': 'A', 'LastName': 'Benvenuto', 'Affiliation': 'Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University, Via Montpellier 1, Rome, 00133, Italy.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Emberti Gialloreti', 'Affiliation': 'Department of Biomedicine and Prevention, Tor Vergata University of Rome, Via Montpellier 1, Rome, 00133, Italy.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Weschke', 'Affiliation': 'Department of Child Neurology, Charité University Medicine Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Riney', 'Affiliation': ""Neuroscience Unit, Queensland Children's Hospital, 501 Stanley Street, South Brisbane, QLD, 4101, Australia.""}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Feucht', 'Affiliation': 'Department of Pediatrics, Medical University Vienna, Vienna, Austria.'}, {'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Krsek', 'Affiliation': 'Department of Paediatric Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic.'}, {'ForeName': 'Rima', 'Initials': 'R', 'LastName': 'Nabbout', 'Affiliation': 'Department of Pediatric Neurology, Reference Centre for Rare Epilepsies, Necker- Enfants Malades Hospital, University Paris Descartes, Imagine Institute, Paris, France.'}, {'ForeName': 'Anna C', 'Initials': 'AC', 'LastName': 'Jansen', 'Affiliation': 'Pediatric Neurology Unit-UZ Brussel, Brussels, Belgium.'}, {'ForeName': 'Konrad', 'Initials': 'K', 'LastName': 'Wojdan', 'Affiliation': 'Warsaw University of Technology, Institute of Heat Engineering, Warsaw, Poland.'}, {'ForeName': 'Julita', 'Initials': 'J', 'LastName': 'Borkowska', 'Affiliation': ""Department of Neurology and Epileptology, The Children's Memorial Health Institute, Al. Dzieci Polskich 20, Warsaw, 04-730, Poland.""}, {'ForeName': 'Krzysztof', 'Initials': 'K', 'LastName': 'Sadowski', 'Affiliation': ""Department of Neurology and Epileptology, The Children's Memorial Health Institute, Al. Dzieci Polskich 20, Warsaw, 04-730, Poland.""}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Hertzberg', 'Affiliation': 'Diagnose und Behandlungszentrum für Kinder und Jugendliche, Vivantes Klinikum Neuköln, Berlin, Germany.'}, {'ForeName': 'Monique M', 'Initials': 'MM', 'LastName': 'Van Schooneveld', 'Affiliation': 'Department of Child Neurology, Brain Center University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Samueli', 'Affiliation': 'Department of Pediatrics, Medical University Vienna, Vienna, Austria.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Maulisovà', 'Affiliation': 'Department of Paediatric Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic.'}, {'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Aronica', 'Affiliation': 'Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Meibergdreef 9, Amsterdam, The Netherlands.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Kwiatkowski', 'Affiliation': ""Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.""}, {'ForeName': 'Floor E', 'Initials': 'FE', 'LastName': 'Jansen', 'Affiliation': 'Department of Child Neurology, Brain Center University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Sergiusz', 'Initials': 'S', 'LastName': 'Jozwiak', 'Affiliation': ""Department of Neurology and Epileptology, The Children's Memorial Health Institute, Al. Dzieci Polskich 20, Warsaw, 04-730, Poland.""}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Curatolo', 'Affiliation': 'Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University, Via Montpellier 1, Rome, 00133, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Annals of clinical and translational neurology,['10.1002/acn3.51128'] 2613,32705821,Vitamin D supplementation and serum neurofilament light chain in interferon-beta-1b-treated MS patients.,"OBJECTIVES Serum neurofilament light chain (sNfL) is a promising biomarker of MS activity, progression, and treatment response. The aim of the present study was to address whether sNfL concentrations are affected by supplementation of vitamin D and correlate with disease activity in interferon-beta-1b (IFNb-1b)-treated Finnish MS. MATERIALS AND METHODS Serum samples were available of 32 participants of the Finnish vitamin D randomized controlled trial (17 vitamin D/15 placebo). Serum 25 hydroxyvitamin D was measured using radioimmunoassay and sNfL using single-molecule array (Simoa). Correlation of sNfL with brain magnetic resonance imaging (MRI) activity, burden of disease (BOD, mm 3 ), and disability was assessed at the study baseline and at 52 weeks. RESULTS Serum NfL concentrations were similar in the patients randomized to high-dose vitamin D and placebo at the study baseline and at month 12 follow-up (p-value). Concentrations of sNfL were higher in patients with Gadolinium-enhancing lesions in brain MRI: median (95% CI) sNfL was 14.84 (9.9-42.5) pg/ml and 11.39 (8.9-13.2) pg/ml in patients without Gd + lesions (p = .0144) and correlated with enhancing lesion volume (Pearson r = .36, p = .037) at the study baseline but not at week 52. Serum NfL did not correlate with the MRI BOD or disability measured by expanded disability status scale and 25-foot walk test. CONCLUSION In this small cohort of clinically stable IFN-treated Finnish MS patients, sNfL levels were similarly low in patients supplemented with high-dose vitamin D or placebo. Subclinical disease activity in MRI was associated with higher sNfL levels.",2020,"Serum NfL did not correlate with the MRI BOD or disability measured by expanded disability status scale and 25-foot walk test. ","['interferon-beta-1b-treated MS patients', '32 participants of the Finnish vitamin D randomized controlled trial (17']","['vitamin D/15 placebo', 'Vitamin D supplementation', 'vitamin D or placebo', 'Serum neurofilament light chain (sNfL', 'vitamin D and placebo']","['enhancing lesion volume', 'sNfL levels', 'Serum 25 hydroxyvitamin D', 'MRI BOD or disability measured by expanded disability status scale and 25-foot walk test', 'Concentrations of sNfL', 'Subclinical disease activity', 'brain magnetic resonance imaging (MRI) activity, burden of disease (BOD, mm 3 ), and disability']","[{'cui': 'C0244713', 'cui_str': 'interferon beta-1b'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0016134', 'cui_str': 'Finnish language'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0042890', 'cui_str': 'Vitamin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0337112', 'cui_str': 'Chain'}]","[{'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C1562562', 'cui_str': 'Light chain level'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0028580', 'cui_str': 'Nuclear Magnetic Resonance'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0205211', 'cui_str': 'Subclinical'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]",,0.335645,"Serum NfL did not correlate with the MRI BOD or disability measured by expanded disability status scale and 25-foot walk test. ","[{'ForeName': 'Katariina', 'Initials': 'K', 'LastName': 'Hänninen', 'Affiliation': 'Turku University Hospital Neurocenter, Turku University Hospital, University of Turku, Turku, Finland.'}, {'ForeName': 'Olli', 'Initials': 'O', 'LastName': 'Jääskeläinen', 'Affiliation': 'Institute of Clinical Medicine-Neurology, University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Sanna-Kaisa', 'Initials': 'SK', 'LastName': 'Herukka', 'Affiliation': 'Institute of Clinical Medicine-Neurology, University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Merja', 'Initials': 'M', 'LastName': 'Soilu-Hänninen', 'Affiliation': 'Turku University Hospital Neurocenter, Turku University Hospital, University of Turku, Turku, Finland.'}]",Brain and behavior,['10.1002/brb3.1772'] 2614,32705829,[Effect of Tongdu Tiaoshen needling in treatment of chronic insomnia by regulating the hypothalamic-pituitary-adrenal axis].,"OBJECTIVE To investigate the clinical effect of Tongdu Tiaoshen needling in the treatment of chronic insomnia and its mechanism based on the hypothalamic-pituitary-adrenal (HPA) axis. METHODS A total of 60 patients with chronic insomnia were randomly divided into treatment group and control group, with 30 patients in each group. In addition to the health education on sleep, the patients in the treatment group were given Tongdu Tiaoshen needling, i．e., electroacupuncture at Baihui (GV20), Shenting (GV24), Yintang (EX-HN3), bilateral Shenmen (HT7), and bilateral Sanyinjiao (SP6), and those in the control group were given superficial acupuncture at Shousanli (LI10), Futu (ST32), and Feiyang (BL58) at both sides, once every other day and three times a week for 4 consecutive weeks. Before and after treatment, the Pittsburgh Sleep Quality Index (PSQI) was used to assess the quality and efficiency of sleep, and ELISA was used to measure the serum levels of corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), and corticosterone (CORT). RESULTS After treatment, the treatment group had significant reductions in the total PSQI score and the score of each component of PSQI ( P <0.01), and the control group had significant reductions in the total PSQI score ( P <0.01) and the scores of all components except sleep duration ( P <0.05); compared with the control group, the treatment group had significantly lower total PSQI score and the score of each component ( P <0.01). After treatment, the treatment group had significant reductions in the serum levels of CRH, ACTH and CORT ( P <0.05，P <0.01), and compared with the control group, the treatment group had significant reductions in the serum levels of CRH, ACTH and CORT ( P <0.01， P <0.05). CONCLUSION Tongdu Tiaoshen needling has a good clinical effect in the treatment of chronic insomnia and can significantly improve the sleep condition of patients with chronic insomnia, possibly by reducing the hormones associated with the HPA axis.",2020,"After treatment, the treatment group had significant reductions in the serum levels of CRH, ACTH and CORT ( P <0.05，P","['patients with chronic insomnia', '60 patients with chronic insomnia']","['Tongdu Tiaoshen needling, i．e., electroacupuncture at Baihui (GV20), Shenting (GV24), Yintang (EX-HN3), bilateral Shenmen (HT7), and bilateral Sanyinjiao (SP6), and those in the control group were given superficial acupuncture at Shousanli (LI10), Futu (ST32), and Feiyang (BL58', 'Tongdu Tiaoshen needling']","['sleep duration', 'chronic insomnia', 'Pittsburgh Sleep Quality Index (PSQI', 'serum levels of corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), and corticosterone (CORT', 'quality and efficiency of sleep, and ELISA', 'serum levels of CRH, ACTH and CORT', 'total PSQI score and the score of each component of PSQI', 'total PSQI score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751249', 'cui_str': 'Chronic insomnia'}]","[{'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0450834', 'cui_str': 'Yintang'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0450652', 'cui_str': 'BL58'}]","[{'cui': 'C0424574', 'cui_str': 'Duration of sleep'}, {'cui': 'C0751249', 'cui_str': 'Chronic insomnia'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0010132', 'cui_str': 'Corticotropin-Releasing Hormone'}, {'cui': 'C0001655', 'cui_str': 'Corticotropin'}, {'cui': 'C0010124', 'cui_str': 'Corticosterone'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4545801', 'cui_str': 'Pittsburgh Sleep Quality Index score'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0449432', 'cui_str': 'Component'}]",60.0,0.0165864,"After treatment, the treatment group had significant reductions in the serum levels of CRH, ACTH and CORT ( P <0.05，P","[{'ForeName': 'Han-Qing', 'Initials': 'HQ', 'LastName': 'Xi', 'Affiliation': 'Department of Acupuncture and Rehabilitation, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.'}, {'ForeName': 'Wen-Zhong', 'Initials': 'WZ', 'LastName': 'Wu', 'Affiliation': 'Department of Acupuncture and Rehabilitation, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.'}, {'ForeName': 'Cheng-Yong', 'Initials': 'CY', 'LastName': 'Liu', 'Affiliation': 'Department of Acupuncture and Rehabilitation, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.'}, {'ForeName': 'Xiao-Qiu', 'Initials': 'XQ', 'LastName': 'Wang', 'Affiliation': 'Department of Acupuncture and Rehabilitation, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.'}, {'ForeName': 'Ya-Nan', 'Initials': 'YN', 'LastName': 'Zhao', 'Affiliation': 'Department of Acupuncture and Rehabilitation, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.'}, {'ForeName': 'Shi-Yu', 'Initials': 'SY', 'LastName': 'Zheng', 'Affiliation': 'Department of Acupuncture and Rehabilitation, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.'}, {'ForeName': 'Jia-Huan', 'Initials': 'JH', 'LastName': 'Li', 'Affiliation': 'Department of Acupuncture and Rehabilitation, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.'}]",Zhen ci yan jiu = Acupuncture research,['10.13702/j.1000-0607.190791'] 2615,32705831,[Effect of hysteretic acupuncture on joint function and related cytokines in articular fluid in patients with knee osteoarthritis].,"OBJECTIVE To observe the difference of therapeutic effect between hysteretic acupuncture and Celecoxib capsules for knee osteoarthritis(KOA), and to investigate their effects on levels of interleukin 6(IL-6) and tumor necrosis factor α(TNF-α) in articular fluid. METHODS Seventy-two patients with KOA were randomly divided into hysteretic acupuncture and me-dication groups, with 36 cases in each group. The patients of the hysteretic acupuncture group received hysteretic acupuncture stimulation at Dubi (ST35), Neixiyan (EX-LE4), Zusanli (ST36), Yanglingquan (GB34), Yinlingquan (SP9), Xuehai (SP10), Liangqiu (ST34) and Heding (EX-LE2) as the main acupoints for 30 min once daily. The patients of the medication group received oral administration of Celecoxib capsules(200 mg) once daily. Both of the two groups were treated with 14 days as a course of treatment, with a 2-day rest between each course of treatment, and the treatments were conducted for 2 courses. The visual analogue scale(VAS) score of pain, Lequesne index score, IL-6 and TNF-α level in joint fluid and the change of traditional Chinese medicine(TCM) syndrome score were observed before and after treatment. RESULTS Compared with pre-treatment, the VAS score, Lequesne index score, IL-6 and TNF-α level, and total TCM syndrome score decreased significantly after treatment in both of the two groups ( P <0.05). Hysteretic acupuncture was more effective in reducing VAS score, Lequesne index score, IL-6 and TNF-α level than Celecoxib capsules ( P <0.05), and there was no significant difference in total TCM syndrome score and total effective rate between the two groups( P >0.05). No adverse events occurred in both groups during the treatment. CONCLUSION Hysteretic acupuncture can effectively relieve pain symptoms and improve joint function in KOA patients. Its effect is comparable to that of oral administration of Celecoxib capsules.",2020,"Compared with pre-treatment, the VAS score, Lequesne index score, IL-6 and TNF-α level, and total TCM syndrome score decreased significantly after treatment in both of the two groups ( P <0.05).","['Seventy-two patients with KOA', 'patients with knee osteoarthritis', 'knee osteoarthritis(KOA', 'KOA patients']","['Celecoxib capsules(200 mg) once daily', 'hysteretic acupuncture stimulation at Dubi (ST35), Neixiyan (EX-LE4), Zusanli (ST36), Yanglingquan (GB34), Yinlingquan (SP9), Xuehai (SP10), Liangqiu (ST34) and Heding (EX-LE2', 'hysteretic acupuncture and Celecoxib', 'hysteretic acupuncture', 'Hysteretic acupuncture', 'Celecoxib', 'hysteretic acupuncture and me-dication']","['VAS score, Lequesne index score, IL-6 and TNF-α level', 'joint function and related cytokines', 'joint function', 'total TCM syndrome score and total effective rate', 'VAS score, Lequesne index score, IL-6 and TNF-α level, and total TCM syndrome score', 'pain symptoms', 'adverse events', 'visual analogue scale(VAS) score of pain, Lequesne index score, IL-6 and TNF-α level in joint fluid and the change of traditional Chinese medicine(TCM) syndrome score']","[{'cui': 'C4319632', 'cui_str': '72'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}]","[{'cui': 'C0538927', 'cui_str': 'celecoxib'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0451257', 'cui_str': 'Lequesne index'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0542330', 'cui_str': 'Joint mobilization'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0444497', 'cui_str': 'In joint'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",72.0,0.0576997,"Compared with pre-treatment, the VAS score, Lequesne index score, IL-6 and TNF-α level, and total TCM syndrome score decreased significantly after treatment in both of the two groups ( P <0.05).","[{'ForeName': 'Guo-Xiang', 'Initials': 'GX', 'LastName': 'Wang', 'Affiliation': 'Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China.'}, {'ForeName': 'Kai-Feng', 'Initials': 'KF', 'LastName': 'Deng', 'Affiliation': 'Graduate School of Guangxi University of Chinese Medicine, Nanning 530001.'}, {'ForeName': 'Zi-Long', 'Initials': 'ZL', 'LastName': 'Liao', 'Affiliation': 'Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China.'}, {'ForeName': 'Ri-Lan', 'Initials': 'RL', 'LastName': 'Chen', 'Affiliation': 'Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China.'}]",Zhen ci yan jiu = Acupuncture research,['10.13702/j.1000-0607.200054'] 2616,32705832,[Comparision of therapertic effect of different acupuncture methods for knee osteoarthritis].,"OBJECTIVE To compare the clinical efficacy of acupuncture, electroacupuncture (EA) and moxibustion in the treatment of knee osteoarthritis (KOA). METHODS A total of eight-four patients with KOA were randomly and equally divided into acupuncture group, EA group and moxibustion group. Neixiyan (EX-LE40), Dubi (ST35), Heding (EX-LE2), Liangqiu (ST34), Xuehai (SP10), Zusanli (ST36) and Ashi-point on the affected side of the body were punctured with filiform needles or EA (2 Hz/100 Hz) for 30 min. In the moxibustion group, moxibustion was applied to the surrounding area of the affected joint for 60 min. The treatment was conducted once every other day for 4 weeks. The pain degree was assessed by using numerical rating scale (NRS) and the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) scale (0－240 points) was used to evaluate the severity of KOA. The ""Minimal Clinically Important Improvement (MCII)"" was used to assess the therapeutic effect after the treatment. RESULTS After the treatment, the scores of NRS, and the pain, stiffness, motor function and total scores of WOMAC were significantly decreased in the three groups compared with their own pre-treatment ( P <0.05), and were obviously lower in the EA and moxibustion groups than in the acupuncture group ( P <0.05), and those of the moxibustion group was notably lower than those of the acupuncture group ( P <0.05). Of the 28 cases in the acupuncture, EA and moxibustion groups, 11, 17 and 22 were effective, with the effective rate being 39.29%, 60.71% and 78.57%, respectively. The comprehensive therapeutic effect of the moxibustion group was significantly superior to that of the acupuncture and EA groups ( P <0.05). CONCLUSION All the three different kinds of acupuncture and moxibustion methods have positively regulatory effect on KOA, and moxibustion is the best for reducing the joint pain and stiffness, and improving the motor function.",2020,"The comprehensive therapeutic effect of the moxibustion group was significantly superior to that of the acupuncture and EA groups ( P <0.05). ","['knee osteoarthritis', 'knee osteoarthritis (KOA', 'A total of eight-four patients with KOA']","['acupuncture', 'acupuncture, electroacupuncture (EA) and moxibustion', 'acupuncture and moxibustion', 'acupuncture methods', 'moxibustion', 'acupuncture, EA and moxibustion', 'acupuncture group, EA group and moxibustion group']","['pain degree', 'comprehensive therapeutic effect', 'Neixiyan (EX-LE40), Dubi (ST35), Heding (EX-LE2), Liangqiu (ST34), Xuehai (SP10), Zusanli (ST36) and Ashi-point', 'effective rate', 'scores of NRS, and the pain, stiffness, motor function and total scores of WOMAC', 'numerical rating scale (NRS) and the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) scale']","[{'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0026652', 'cui_str': 'Moxibustion'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",12.0,0.0291857,"The comprehensive therapeutic effect of the moxibustion group was significantly superior to that of the acupuncture and EA groups ( P <0.05). ","[{'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'School of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050091, China.'}, {'ForeName': 'Ye-Juan', 'Initials': 'YJ', 'LastName': 'Jia', 'Affiliation': 'School of Acupuncture-moxibustion and Tuina, Hebei University of Chinese Medicine, Shijiazhuang 050091, China.'}, {'ForeName': 'Jiu-Heng', 'Initials': 'JH', 'LastName': 'LÜ', 'Affiliation': 'School of Acupuncture-moxibustion and Tuina, Hebei University of Chinese Medicine, Shijiazhuang 050091, China.'}, {'ForeName': 'Jing-Xuan', 'Initials': 'JX', 'LastName': 'Liu', 'Affiliation': 'School of Acupuncture-moxibustion and Tuina, Hebei University of Chinese Medicine, Shijiazhuang 050091, China.'}, {'ForeName': 'Zi-di', 'Initials': 'ZD', 'LastName': 'Zhang', 'Affiliation': 'School of Acupuncture-moxibustion and Tuina, Hebei University of Chinese Medicine, Shijiazhuang 050091, China.'}, {'ForeName': 'Rui-Qing', 'Initials': 'RQ', 'LastName': 'Wang', 'Affiliation': 'School of Acupuncture-moxibustion and Tuina, Hebei University of Chinese Medicine, Shijiazhuang 050091, China.'}, {'ForeName': 'Chun-Sheng', 'Initials': 'CS', 'LastName': 'Jia', 'Affiliation': 'School of Acupuncture-moxibustion and Tuina, Hebei University of Chinese Medicine, Shijiazhuang 050091, China.'}]",Zhen ci yan jiu = Acupuncture research,['10.13702/j.1000-0607.191015'] 2617,32705833,[Ginger-partitioned moxibustion in the prevention of nausea and vomiting induced by chemotherapy in lung cancer：a randomized controlled trial].,"OBJECTIVE To observe the effect of ginger-partitioned moxibustion intervention on gastrointestinal reaction, the quality of life, the counts of blood platelet (PLT) and white blood cells (WBC) after chemotherapy in lung cancer patients. METHODS The lung cancer patients treated with chemotherapy were randomized into observation group (30 cases) and control group (30 cases). In the control group, the intravenous injection with Tropisetron(5 mg) was given 1 h before chemotherapy. In the observation group, in addition to the same treatment as the control group, 2 hours after chemotherapy, ginger-partitioned moxibustion was applied to bilateral Zusanli (ST36), bilateral Neiguan (PC6) and bilateral Tianshu (ST25) for 20 min each time. The treatments were conducted once daily for 3 days. Separately, 2 days before chemotherapy, 24 h and 7 days after chemotherapy, the gastrointestinal reaction score and the score of the quality of life, the PLT and WBC counts were observed in the two groups. RESULTS The effective rate of the gastrointestinal reaction degree in the observation group were higher than those in the control group 24 h and 7 days after chemotherapy ( P <0.05). Twenty-four hours after chemotherapy, the score of the quality of life, the PLT and WBC counts were lower as compared with those before the treatment in both groups respectively( P <0.05). Seven days after chemotherapy, the score of the quality of life, the PLT and WBC counts in the observation group were higher than those in the control group ( P <0.05). CONCLUSION The ginger-partitioned moxibustion achieves the definite clinical effect of the prevention of nausea and vomiting induced by chemotherapy in lung cancer. This therapy is simple in operation, high in safety, absent in obvious adverse reactions and high in patient's compliance.",2020,"Twenty-four hours after chemotherapy, the score of the quality of life, the PLT and WBC counts were lower as compared with those before the treatment in both groups respectively( P <0.05).","['lung cancer patients', 'lung cancer patients treated with', 'lung cancer']","['chemotherapy, ginger-partitioned moxibustion was applied to bilateral Zusanli (ST36), bilateral Neiguan (PC6) and bilateral Tianshu (ST25', 'ginger-partitioned moxibustion intervention', 'ginger-partitioned moxibustion', 'chemotherapy', 'Ginger-partitioned moxibustion']","['gastrointestinal reaction, the quality of life, the counts of blood platelet (PLT) and white blood cells (WBC', 'nausea and vomiting', 'effective rate of the gastrointestinal reaction degree', 'score of the quality of life, the PLT and WBC counts', 'gastrointestinal reaction score and the score of the quality of life, the PLT and WBC counts']","[{'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0162751', 'cui_str': 'Ginger'}, {'cui': 'C0026652', 'cui_str': 'Moxibustion'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0450522', 'cui_str': 'ST25'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0330694,"Twenty-four hours after chemotherapy, the score of the quality of life, the PLT and WBC counts were lower as compared with those before the treatment in both groups respectively( P <0.05).","[{'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Huzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Huzhou 313000, Zhejiang Province, China.'}, {'ForeName': 'Ya-Ling', 'Initials': 'YL', 'LastName': 'Wang', 'Affiliation': 'Huzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Huzhou 313000, Zhejiang Province, China.'}, {'ForeName': 'Rui-Yang', 'Initials': 'RY', 'LastName': 'Fu', 'Affiliation': 'Huzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Huzhou 313000, Zhejiang Province, China.'}, {'ForeName': 'Jin-Xia', 'Initials': 'JX', 'LastName': 'Li', 'Affiliation': 'Huzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Huzhou 313000, Zhejiang Province, China.'}, {'ForeName': 'Xiao-Qing', 'Initials': 'XQ', 'LastName': 'Guo', 'Affiliation': 'Huzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Huzhou 313000, Zhejiang Province, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Xu', 'Affiliation': 'Huzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Huzhou 313000, Zhejiang Province, China.'}, {'ForeName': 'Shou-Han', 'Initials': 'SH', 'LastName': 'Feng', 'Affiliation': 'Huzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Huzhou 313000, Zhejiang Province, China.'}, {'ForeName': 'Xin-Jun', 'Initials': 'XJ', 'LastName': 'Guan', 'Affiliation': 'Huzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Huzhou 313000, Zhejiang Province, China.'}]",Zhen ci yan jiu = Acupuncture research,['10.13702/j.1000-0607.190568'] 2618,32705834,[Clinical observation on electroacupuncture combined with moxibustion for treatment of urinary incontinence after stroke due to deficiency of kidney- yang ].,"OBJECTIVE To observe the clinical effect of electroacupuncture combined with moxibustion in the treatment of urinary incontinence after stroke due to deficiency of kidney- yang . METHODS Sixty patients with urinary incontinence after stroke due to kidney- yang deficiency were randomly divided into a control group and an observation group，with 30 cases in each group. The patients in the control group were given oral administration of Jingui Shenqi pills and Suoquan capsules. On the basis of the treatment in the control group, the patients in the observation group were given electroacupuncture treatment at the Foot Motor sensory Area on the head, Shenshu(BL23) and Huiyang(BL35), together with moxibustion at Guanyuan(CV4) and Qihai(CV6) once daily. The treatment was conducted 6 times per week and for 2 successive weeks. The average number of daily urinary incontinence and night urinary incontinence, maximum bladder volume, residual bladder urine volume, degree of urinary incontinence and clinical symptoms score of the two groups before and after treatment were observed. And the clinical efficacy of the two groups were compared. RESULTS After the treatment, compared with those before the treatment, the average numbers of daily and night urinary incontinence of the two groups were significantly reduced ( P <0.01), the maximum bladder volume was significantly increased ( P <0.05), and the residual urine volume of the bladder was significantly reduced ( P <0.05). The number of cases with urinary incontinence degree Ⅰ and Ⅱ increased ( P <0.05), and the score of clinical symptoms of urinary incontinence was significantly reduced ( P <0.05). After the treatment, compared with the control group, the number of daily and night urinary incontinence in the observation group decreased ( P <0.05), the maximum bladder volume increased ( P <0.05), the residual bladder urine volume decreased ( P <0.05), and the number of cases with urinary incontinence degree Ⅰ and Ⅱ increased ( P <0.05), the clinical symptom score of urinary incontinence was significantly reduced ( P <0.05). The total effective rates of the control group and the observation group were 73.3% (22/30) and 93.3% (28/30) respectively, and the effective rate of the observation group was higher than that of the control group ( P <0.05). CONCLUSION The combination of electroacupuncture, moxibustion and traditional Chinese medicine is effective in treating urinary incontinence after stroke due to deficiency of kidney- yang .",2020,"After the treatment, compared with the control group, the number of daily and night urinary incontinence in the observation group decreased ( P <0.05), the maximum bladder volume increased ( P <0.05), the residual bladder urine volume decreased ( P <0.05), and the number of cases with urinary incontinence degree Ⅰ and Ⅱ increased ( P <0.05), the clinical symptom score of urinary incontinence was significantly reduced ( P <0.05).","['Sixty patients with urinary incontinence after stroke due to kidney- yang deficiency', 'urinary incontinence after stroke due to deficiency of kidney- yang ']","['electroacupuncture combined with moxibustion', 'electroacupuncture treatment at the Foot Motor sensory Area on the head, Shenshu(BL23) and Huiyang(BL35), together with moxibustion at Guanyuan(CV4) and Qihai(CV6', 'oral administration of Jingui Shenqi pills and Suoquan capsules', 'electroacupuncture, moxibustion and traditional Chinese medicine']","['total effective rates', 'score of clinical symptoms of urinary incontinence', 'number of daily and night urinary incontinence', 'residual bladder urine volume', 'clinical symptom score of urinary incontinence', 'residual urine volume of the bladder', 'maximum bladder volume', 'number of cases with urinary incontinence degree Ⅰ and Ⅱ', 'average numbers of daily and night urinary incontinence', 'effective rate', 'average number of daily urinary incontinence and night urinary incontinence, maximum bladder volume, residual bladder urine volume, degree of urinary incontinence and clinical symptoms score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0085258', 'cui_str': 'Yang deficiency'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}]","[{'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0026652', 'cui_str': 'Moxibustion'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0001563', 'cui_str': 'Medication administration: oral'}, {'cui': 'C1721493', 'cui_str': 'jingui shenqi'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0005682', 'cui_str': 'Urinary bladder structure'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0429774', 'cui_str': 'Residual urine volume'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0429770', 'cui_str': 'Bladder volume'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4759318', 'cui_str': 'Daily urinary incontinence'}]",60.0,0.0179437,"After the treatment, compared with the control group, the number of daily and night urinary incontinence in the observation group decreased ( P <0.05), the maximum bladder volume increased ( P <0.05), the residual bladder urine volume decreased ( P <0.05), and the number of cases with urinary incontinence degree Ⅰ and Ⅱ increased ( P <0.05), the clinical symptom score of urinary incontinence was significantly reduced ( P <0.05).","[{'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Jiang', 'Affiliation': 'Taikang Yanyuan Rehibilitation Hospital of Beijing, Beijing 102200, China.'}, {'ForeName': 'Li-Na', 'Initials': 'LN', 'LastName': 'Lu', 'Affiliation': 'Taikang Yanyuan Rehibilitation Hospital of Beijing, Beijing 102200, China.'}]",Zhen ci yan jiu = Acupuncture research,['10.13702/j.1000-0607.200300'] 2619,32705835,[Effect of elongated-needle by Hui-puncture method on piriformis syndrome].,"OBJECTIVE To observe the clinical effect of elongated needle by Hui-puncture method in the treatment of piriformis syndrome. METHODS A total of 100 piriformis syndrome patients were randomly divided into routine acupuncture group ( n ＝50) and elongated needle by Hui-puncture method (Hui-puncture) group ( n ＝50). For patients of the routine acupuncture group, Huantiao (GB30), Juliao (GB29), Zhibian (BL54), Weizhong (BL40), Yanglingquan (GB34), Juegu (GB39) and Ashi-point on the affected side of the body were punctured with filiform needles for 30 min. And for those of the Hui-puncture group, elongated needles were respectively inserted into GB30 and Ashi-point. The treatment was conducted once every other day for 10 times. The visual analog scale (VAS) pain score and the severity scores of symptoms (hip pain, lower limb pain, walking ability, straight leg elevation test, piriformis muscle tension test, piriformis muscle tenderness, 0-15 points) were measured before and after the treatment. The therapeutic effect was assessed by Criteria for Diagnosis and Assessment of Therapeutic Effect of Syndromes or Illnesses of Traditional Chinese Medicine (1994). RESULTS After the treatment, the scores of symptoms and VAS scores of both routine acupuncture and Hui-puncture groups were significantly decreased in comparison with their own pre-treatment ( P <0.05), and the scores of the two indexes of the Hui-puncture group were evidently lower than those of the routine acupuncture group ( P <0.05). Of the two 50 cases in the routine acupuncture and Hui-puncture groups, 39 and 47 were effective, with the effective rate being 78.00% and 94.00%, respectively. The comprehensive therapeutic effect of the Hui-puncture group was significantly superior to that of the routine acupuncture group ( P <0.05). CONCLUSION Elongated-needle by Hui-puncture method has significant effect in treating piriformis syndrome patients and is worthy of promotion.",2020,"The comprehensive therapeutic effect of the Hui-puncture group was significantly superior to that of the routine acupuncture group ( P <0.05). ","['100 piriformis syndrome patients', 'piriformis syndrome', 'piriformis syndrome patients']","['routine acupuncture group ( n ＝50) and elongated needle by Hui-puncture method (Hui-puncture', 'elongated-needle by Hui-puncture method', 'elongated needle by Hui-puncture method', 'Hui-puncture', 'Elongated-needle by Hui-puncture method', 'routine acupuncture']","['visual analog scale (VAS) pain score and the severity scores of symptoms (hip pain, lower limb pain, walking ability, straight leg elevation test, piriformis muscle tension test, piriformis muscle tenderness, 0-15 points', 'scores of symptoms and VAS scores', 'comprehensive therapeutic effect', 'effective rate', 'Huantiao (GB30), Juliao (GB29), Zhibian (BL54), Weizhong (BL40), Yanglingquan (GB34), Juegu (GB39) and Ashi-point on the affected side of the body']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0458224', 'cui_str': 'Piriformis syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0019559', 'cui_str': 'Hip pain'}, {'cui': 'C0023222', 'cui_str': 'Pain in lower limb'}, {'cui': 'C0559964', 'cui_str': 'Ability to walk'}, {'cui': 'C0019421', 'cui_str': 'Heterosexuality'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0224429', 'cui_str': 'Structure of piriformis muscle'}, {'cui': 'C0233494', 'cui_str': 'Tension'}, {'cui': 'C0234233', 'cui_str': 'Soreness'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0450634', 'cui_str': 'BL40 - popliteal crease'}, {'cui': 'C0392760', 'cui_str': 'Affecting'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}]",100.0,0.0179744,"The comprehensive therapeutic effect of the Hui-puncture group was significantly superior to that of the routine acupuncture group ( P <0.05). ","[{'ForeName': 'Shi-Sheng', 'Initials': 'SS', 'LastName': 'Li', 'Affiliation': ""Department of Acupuntrue, Massage and Traditional Medical Traumatology and Orthopedic, The Sixth People's Hospital, Shanghai 200233, China.""}, {'ForeName': 'Yao-Chi', 'Initials': 'YC', 'LastName': 'Wu', 'Affiliation': ""Department of Acupuntrue, Massage and Traditional Medical Traumatology and Orthopedic, The Sixth People's Hospital, Shanghai 200233, China.""}]",Zhen ci yan jiu = Acupuncture research,['10.13702/j.1000-0607.190672'] 2620,32705913,Mobile Technology Care Coordination of Long-Term Services and Support: Cluster Randomized Clinical Trial.,"The purpose of the study was to assess whether the effects of a mobile predictive intervention used by Service Coordinators (SCs) reduce hospital utilization in a Medicaid Long-Term Services and Supports (LTSS) population in Baltimore city during a 5-month intervention. SC participants ( n = 11) were recruited to treatment or control groups. LTSS clients ( n = 420) followed their SC randomization assignment. Utilization data were obtained from the Maryland Chesapeake Regional Information System for our Patients (CRISP) Health Information Exchange (HIE) system and linked to service coordination records. Study groups were similar in age, gender, race, and years receiving LTSS. SCs' satisfaction with use of the mobile tool was surveyed. SC perceptions were neutral (mean scores ranged from 2.3 to 3.3 on a 5-point scale). No significant differences between groups were observed for all utilization metrics. The mobile technology software system used in this study did not improve health care utilization for a LTSS population needing ongoing clinical and social services coordinated care.",2020,The mobile technology software system used in this study did not improve health care utilization for a LTSS population needing ongoing clinical and social services coordinated care.,"['SC participants ( n = 11) were recruited to treatment or control groups', 'a Medicaid Long-Term Services and Supports (LTSS) population in Baltimore city during a 5-month intervention']","['LTSS', 'mobile predictive intervention used by Service Coordinators (SCs']",[],"[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0025071', 'cui_str': 'Medicaid coverage'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0004716', 'cui_str': 'Baltimore'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1273517', 'cui_str': 'Used by'}]",[],11.0,0.0427744,The mobile technology software system used in this study did not improve health care utilization for a LTSS population needing ongoing clinical and social services coordinated care.,"[{'ForeName': 'Charlene C', 'Initials': 'CC', 'LastName': 'Quinn', 'Affiliation': 'University of Maryland School of Medicine, Baltimore, USA.'}, {'ForeName': 'Kasey L', 'Initials': 'KL', 'LastName': 'Knopp', 'Affiliation': 'University of Maryland School of Medicine, Baltimore, USA.'}, {'ForeName': 'Carol A', 'Initials': 'CA', 'LastName': 'Marsiglia', 'Affiliation': 'The Coordinating Center, Columbia, MD, USA.'}, {'ForeName': 'R Colby', 'Initials': 'RC', 'LastName': 'Bearch', 'Affiliation': 'The Coordinating Center, Columbia, MD, USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'LeFever', 'Affiliation': 'The Coordinating Center, Columbia, MD, USA.'}, {'ForeName': 'Erik A', 'Initials': 'EA', 'LastName': 'Barr', 'Affiliation': 'University of Maryland School of Nursing, Baltimore, USA.'}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Liang', 'Affiliation': 'University of Maryland School of Medicine, Baltimore, USA.'}, {'ForeName': 'Ann L', 'Initials': 'AL', 'LastName': 'Gruber-Baldini', 'Affiliation': 'University of Maryland School of Medicine, Baltimore, USA.'}]",Journal of applied gerontology : the official journal of the Southern Gerontological Society,['10.1177/0733464820944043'] 2621,32705925,Curcumin Improves Delayed Onset Muscle Soreness and Postexercise Lactate Accumulation.,"The efficacy of curcumin supplementation is traditionally limited due to its poor bioavailability. Despite this, curcumin has previously been shown to improve biomarkers of muscle damage. The addition of a novel drug delivery system that improves bioavailability could improve exercise recovery. The purpose of this randomized double-blind placebo-controlled study was to assess the effect of curcumin (combined with LipiSperse) when consumed as a drink on exercise recovery in recreationally trained healthy males aged 18-35 yrs. The study included 28 young healthy males with strength training experience. The participants undertook lower limb resistance exercise to exhaustion. Fourteen participants received curcumin dispersed in water pre and postexercise and 14 received a matched placebo drink. Pain (visual analogue scale), thigh circumference (TC), lactate, creatine kinase, lactate dehydrogenase, high sensitivity C-reactive protein, myoglobin, interleukin-6, interleukin-10, and tumor necrosis factor-alpha were assessed pre, postexercise and 1, 2, 3, 24, 48, and 72 h postexercise. There was less appearance of postexercise capillary lactate in the curcumin group compared to placebo (7.4 vs 8.8 mmol/L). The placebo group rated overall muscle pain as higher compared to the curcumin group at 48- and 72-h postexercise. TC was reduced in the curcumin group compared to the placebo group at 24- and 48-h postexercise. The results suggest curcumin may facilitate a quicker return to exercise training and/or allow a higher training intensity than a placebo by reducing postexercise pain, modulating inflammatory pathways and reducing lactate accumulation in an exercising population.",2020,TC was reduced in the curcumin group compared to the placebo group at 24- and 48-h postexercise.,"['Fourteen participants received', '28 young healthy males with strength training experience', 'recreationally trained healthy males aged 18-35\u2009yrs']","['curcumin dispersed in water pre and postexercise and 14 received a matched placebo drink', 'curcumin (combined with LipiSperse', 'curcumin supplementation', 'placebo']","['overall muscle pain', 'appearance of postexercise capillary lactate', 'postexercise pain, modulating inflammatory pathways and reducing lactate accumulation', 'Delayed Onset Muscle Soreness and Postexercise Lactate Accumulation', 'Pain (visual analogue scale), thigh circumference (TC), lactate, creatine kinase, lactate dehydrogenase, high sensitivity C-reactive protein, myoglobin, interleukin-6, interleukin-10, and tumor necrosis factor', 'TC']","[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0010467', 'cui_str': 'Curcumin'}, {'cui': 'C0332624', 'cui_str': 'Dispersion'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0006901', 'cui_str': 'Structure of capillary blood vessel (organ)'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0202113', 'cui_str': 'Lactate dehydrogenase measurement'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0027078', 'cui_str': 'Myoglobin'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}]",28.0,0.356971,TC was reduced in the curcumin group compared to the placebo group at 24- and 48-h postexercise.,"[{'ForeName': 'Alistair R', 'Initials': 'AR', 'LastName': 'Mallard', 'Affiliation': 'RDC Clinical, Brisbane, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Briskey', 'Affiliation': 'RDC Clinical, Brisbane, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Richards BExSSc', 'Affiliation': 'RDC Clinical, Brisbane, Australia.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Rao', 'Affiliation': 'RDC Clinical, Brisbane, Australia.'}]",Journal of dietary supplements,['10.1080/19390211.2020.1796885'] 2622,32705941,Use of chest X-ray in the assessment of community acquired pneumonia in primary care - an intervention study.,"OBJECTIVES The aim of this study was to explore if consequent use of chest X-ray (CXR), when the physician is not sure of the diagnosis of pneumonia after clinical examination and CRP-testing, favors a more restrictive prescribing of antibiotics. DESIGN This was an intervention study conducted between September 2015 and December 2017. SETTING Two intervention primary health care centers (PHCCs) and three control PHCCs in the southeast of Sweden. INTERVENTION All patients were referred for CXR when the physician´s suspicion of pneumonia was 'unsure', or 'quite sure' after CRP-testing. Control units managed patients according to their usual routine after clinical examination and CRP-testing. SUBJECTS A total of 104 patients were included in the intervention group and 81 patients in the control group. The inclusion criteria of the study were clinically suspected pneumonia in patients ≥18 years, with respiratory symptoms for more than 24 h. Main outcome measure: Antibiotic prescribing rate. RESULTS In the intervention group, 85% were referred for CXR and 69% were prescribed antibiotics, as compared to 26% and 77% in the control group. The difference in antibiotic prescribing rate was not statistically significant, unadjusted OR 0.68 [0.35-1.3] and adjusted OR 1.1 [CI 0.43-3.0]. A total of 24% of patients with negative CXR were prescribed antibiotics. CONCLUSION This study could not prove that use of CXR when the physician was not sure of the diagnosis of pneumonia results in lowered antibiotic prescribing rate in primary care. In cases of negative findings on CXR the physicians do not seem to rely on the outcome when it comes to antibiotic prescribing. Key Points Routine use of chest X-ray when the clinical diagnosis of pneumonia is uncertain has not been proven to result in lowered antibiotic prescribing rate. Physicians do not fully rely on chest X-ray outcome and to some extent prescribe antibiotics even if negative, when community-acquired pneumonia is suspected. Chest X-ray is already used in one out of four cases in routine primary care of pneumonia patients in Sweden.",2020,"The difference in antibiotic prescribing rate was not statistically significant, unadjusted OR 0.68 [0.35-1.3] and adjusted OR 1.1 [CI 0.43-3.0].","['pneumonia patients in Sweden', 'Two intervention primary health care centers (PHCCs) and three control PHCCs in the southeast of Sweden', 'patients ≥18 years, with respiratory symptoms for more than 24\u2009h. Main outcome measure: Antibiotic prescribing rate', 'September 2015 and December 2017', 'Control units managed patients according to their usual routine after clinical examination and CRP-testing', '104 patients were included in the intervention group and 81 patients in the control group']","['chest X-ray', 'chest X-ray (CXR']",['antibiotic prescribing rate'],"[{'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0037090', 'cui_str': 'Respiratory symptom'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C3873701', 'cui_str': 'Control unit'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0039985', 'cui_str': 'Plain chest X-ray'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}]",104.0,0.026647,"The difference in antibiotic prescribing rate was not statistically significant, unadjusted OR 0.68 [0.35-1.3] and adjusted OR 1.1 [CI 0.43-3.0].","[{'ForeName': 'Moberg', 'Initials': 'M', 'LastName': 'Anna B', 'Affiliation': 'Kärna Primary Healthcare Centre, Linköping, Sweden.'}, {'ForeName': 'Kling', 'Initials': 'K', 'LastName': 'Moa', 'Affiliation': 'Kungsgatan Primary Healthcare Centre, Linköping, Sweden.'}, {'ForeName': 'Paues', 'Initials': 'P', 'LastName': 'Jakob', 'Affiliation': 'Department of Health, Medicine and Caring Sciences and Department of Radiological Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Fransson', 'Initials': 'F', 'LastName': 'Sven Göran', 'Affiliation': 'Department of Health, Medicine and Caring Sciences, General Practice, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Falk', 'Initials': 'F', 'LastName': 'Magnus', 'Affiliation': 'Kärna Primary Healthcare Centre, Linköping, Sweden.'}]",Scandinavian journal of primary health care,['10.1080/02813432.2020.1794404'] 2623,32706100,"A study on the effect of intraoperative continuous positive airway pressure (CPAP) on the postoperative pulmonary function in overweight patients undergoing lower limb, lower abdominal or vaginal surgeries under spinal anesthesia.","INTRODUCTION Spinal anaesthesia, supine position and higher BMI are risk factors for pulmonary atelectasis. NIV, PEEP and CPAP are employed in ICU's to treat atelectasis postoperatively. However, we wanted to investigate whether CPAP was protective against atelectasis when used intraoperatively, in high risk patients. MATERIAL AND METHODS This study was a randomized controlled trial. Overweight patients, who were to undergo surgeries under spinal anesthesia were included in the study. After informed consent, 126 patients underwent preoperative pulmonary function tests (PFT: FEV1, FVC, PEFR). Following the onset of spinal anaesthesia patients were randomised into group E (n = 63, received CPAP) and control group, group C ( n =63, received nil intervention). Postoperative PFT was done at 20 minutes, 1 hour, 2 hours and 3 hours after surgery. Patients were followed up till discharge for pulmonary complications. RESULTS We observed significant reduction in pulmonary function (FEV1, FVC and PEFR) postoperatively compared to base-line. CPAP group had better pulmonary function when compared to control group, the difference being significant 20 minu-tes after the surgery(p < 0.05). No postoperative pulmonary complication was reported among the 126 patients studied. CONCLUSION Intraoperative use of CPAP in overweight patients undergoing surgeries under spinal anaesthesia could be beneficial in improving pulmonary function in the immediate post-operative period.",2020,"We observed significant reduction in pulmonary function (FEV1, FVC and PEFR) postoperatively compared to base-line.","['overweight patients undergoing surgeries under spinal anaesthesia', '126 patients underwent', 'Overweight patients, who were to undergo surgeries under spinal anesthesia were included in the study', 'spinal anaesthesia patients', 'overweight patients undergoing lower limb, lower abdominal or vaginal surgeries under spinal anesthesia', '126 patients studied']","['preoperative pulmonary function tests (PFT: FEV1, FVC, PEFR', 'CPAP', 'intraoperative continuous positive airway pressure (CPAP', 'nil intervention']","['pulmonary function (FEV1, FVC and PEFR', 'pulmonary function', 'postoperative pulmonary complication']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0195117', 'cui_str': 'Operation on vagina'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C3714541', 'cui_str': 'Forced vital capacity'}, {'cui': 'C0030735', 'cui_str': 'Peak expiratory flow rate'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0442734', 'cui_str': 'Nil'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C3714541', 'cui_str': 'Forced vital capacity'}, {'cui': 'C0030735', 'cui_str': 'Peak expiratory flow rate'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",126.0,0.0720106,"We observed significant reduction in pulmonary function (FEV1, FVC and PEFR) postoperatively compared to base-line.","[{'ForeName': 'Mamatha', 'Initials': 'M', 'LastName': 'Munaf', 'Affiliation': 'Department of Cardiac Anesthesia, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Trivandrum, Thiruvananthapuram, India. mamathamunaf@gmail.com.'}, {'ForeName': 'Chitra', 'Initials': 'C', 'LastName': 'Rajeswari', 'Affiliation': 'Department of Anaesthesiology and Critical Care, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.'}, {'ForeName': 'Manju', 'Initials': 'M', 'LastName': 'Rajaram', 'Affiliation': 'Department of Pulmonary Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.'}, {'ForeName': 'Hemavathi', 'Initials': 'H', 'LastName': 'Balachander', 'Affiliation': 'Department of Anaesthesiology and Critical Care, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.'}]",Advances in respiratory medicine,['10.5603/ARM.2020.0105'] 2624,32706122,Cost-effectiveness of botulinum neurotoxin A versus surgery for drooling: a randomized clinical trial.,"AIM This study compared the cost-effectiveness of botulinum neurotoxin A (BoNT-A) injections with two-duct ligation of the submandibular glands as treatment for severe drooling after one treatment cycle. METHOD The study was part of a larger, partly single-blinded, randomized clinical trial (trialregister.nl identifier NTR3537). Data were collected between 2012 and 2017. Evaluation was at 32 weeks after one treatment cycle. Fifty-seven patients with cerebral palsy or other neurological, non-progressive disorders and severe drooling classified as having a drooling frequency ≥3 or a drooling severity ≥2, in whom conservative treatment was deemed ineffective, were randomized to treatment by BoNT-A or two-duct ligation. An incremental cost-effectiveness ratio (ICER) was calculated using the success rates as the measure of benefit. Treatment success was defined as a decrease ≥50% from baseline to 32 weeks in the subjective visual analogue scale for the severity of drooling or the objective drooling quotient. RESULTS Fifty-three patients were analysed (22 females, 31 males; mean age 11y, range 8-22y). Average costs for one treatment cycle, which included one BoNT-A injection, were €1929 (standard error 62) for BoNT-A and €3155 (standard error 99) for two-duct ligation. Treatment success was in favour of two-duct ligation (63% vs 27%; number needed to treat 3). The ICER was €34 per 1% gain in treatment success in favour of two-duct ligation versus BoNT-A. INTERPRETATION The additional cost of two-duct ligation is to some extent offset by a larger treatment success rate compared with BoNT-A. WHAT THIS PAPER ADDS Botulinum neurotoxin A (BoNT-A) is less expensive per percentage of success than two-duct ligation. The additional cost of two-duct ligation over BoNT-A is offset by greater treatment success.",2020,Treatment success was in favour of two-duct ligation (63% vs 27%; number needed to treat 3).,"['severe drooling after one treatment cycle', 'Fifty-seven patients with cerebral palsy or other neurological, non-progressive disorders and severe drooling classified as having a drooling frequency ≥3 or a drooling severity ≥2, in whom conservative treatment was deemed ineffective', 'Fifty-three patients were analysed (22 females, 31 males; mean age 11y, range 8-22y', 'drooling']","['Botulinum neurotoxin', 'botulinum neurotoxin A (BoNT-A) injections with two-duct ligation of the submandibular glands', 'botulinum neurotoxin A versus surgery']","['Cost-effectiveness', 'Average costs', 'ICER', 'subjective visual analogue scale for the severity of drooling or the objective drooling quotient', 'incremental cost-effectiveness ratio (ICER']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4517815', 'cui_str': '57'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C3839460', 'cui_str': 'Non-progressive'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0013132', 'cui_str': 'Dribbling from mouth'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0459914', 'cui_str': 'Conservative therapy'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]","[{'cui': 'C1295507', 'cui_str': 'Bontoxilysin'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0687028', 'cui_str': 'Duct (organ) structure'}, {'cui': 'C0023690', 'cui_str': 'Ligation'}, {'cui': 'C0038556', 'cui_str': 'Submandibular salivary apparatus'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0013132', 'cui_str': 'Dribbling from mouth'}, {'cui': 'C0018017', 'cui_str': 'Goal'}]",53.0,0.0603741,Treatment success was in favour of two-duct ligation (63% vs 27%; number needed to treat 3).,"[{'ForeName': 'Stijn', 'Initials': 'S', 'LastName': 'Bekkers', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Kim J', 'Initials': 'KJ', 'LastName': 'van Ulsen', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Eddy', 'Initials': 'E', 'LastName': 'M M Adang', 'Affiliation': 'Department for Health Evidence Rehabilitation, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Arthur', 'Initials': 'A', 'LastName': 'R T Scheffer', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'J A van den Hoogen', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.'}]",Developmental medicine and child neurology,['10.1111/dmcn.14636'] 2625,32706124,Exposure-based cognitive behavior therapy for anxiety related to asthma: A feasibility study with multivariate baseline design.,"In the presence of asthma, the risk of having an anxiety disorder is increased twofold. The few trials conducted on cognitive behavior therapy (CBT) for anxiety and asthma have mainly targeted panic disorder, and with mixed results. Experimental laboratory research indicates that increased anxiety may lead to hypervigilance toward asthma. Hence, fear and avoidance associated with increased anxiety due to asthma may be an important treatment target. A treatment that learn participants to differentiate between anxiety and asthma through gradual exposure to situations that risk triggering anxiety for asthma may be a possible avenue. As a first step to investigate this issue further, we developed a 10-week exposure-based CBT protocol for anxiety related to asthma and tested it in six participants using multivariate baseline design with repeated assessments throughout treatment. All participants reported satisfaction with treatment, as well as subjective overall improvement after treatment. Visual analysis, using graphs over each individual's trajectory, as well as potential efficacy on group level analyzing standardized mean change, indicated improvements in important outcomes. We conclude that exposure-based CBT is feasible and may improve anxiety related to asthma. Further investigation under randomized controlled trial conditions is warranted.",2020,"All participants reported satisfaction with treatment, as well as subjective overall improvement after treatment.",['anxiety related to asthma'],"['10-week exposure-based CBT protocol', 'Exposure-based cognitive behavior therapy', 'cognitive behavior therapy (CBT']",[],"[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]",[],6.0,0.0303651,"All participants reported satisfaction with treatment, as well as subjective overall improvement after treatment.","[{'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Bonnert', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Andersson', 'Affiliation': 'Department of Clinical Neuroscience, Division of Psychology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Serlachius', 'Affiliation': 'Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Ida-Kaisa', 'Initials': 'IK', 'LastName': 'Manninen', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Sten-Erik', 'Initials': 'SE', 'LastName': 'Bergström', 'Affiliation': ""Pediatric Allergy and Pulmonology Unit at Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.""}, {'ForeName': 'Catarina', 'Initials': 'C', 'LastName': 'Almqvist', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}]",Scandinavian journal of psychology,['10.1111/sjop.12674'] 2626,32706159,The effect of okra (Abelmoschus esculentus) on lipid profiles and glycemic indices in Type 2 diabetic adults: Randomized double blinded trials.,"The aim of the present study was to investigate the effect of okra consumption on serum levels of lipid profiles and glycemic indices in Type 2 diabetic (T2D) patients. The present study was a randomized, double-blinded clinical trial, carried out in Kerman, Iran. Sixty T2D patients were randomized into intervention and control groups and received 10 g okra powder blended in 150 g conventional yogurt or conventional yogurt alone, along with dinner and lunch, for 8 weeks. Glycemic markers and lipid profile were assessed, as well as anthropometric measures, at the beginning and end of study. The findings showed that 8 weeks okra consumption resulted in a significant decrease in fasting plasma glucose (-15.61 ± 19.44 vs. -3.40 ± 24.78; p = .02), homeostatic model of assessment for insulin resistance (-1.17 ± 1.61 vs. -0.14 ± 1.64; p = .01), quantitative insulin sensitivity check index (0.01 ± 0.007 vs. 0.00 ± 0.01; p = .004), triacylglycerol (-22.30 ± 32.46 vs. -3.86 ± 30.57; p = .001), total cholesterol (-10.23 ± 10.36 vs. -2.03 ± 13.94; p = .004), low-density lipoprotein cholesterol (LDL-C; -8.15 ± 10.01 vs. -2.31 ± 9.37; p = .02), and LDL-C/high-density lipoprotein cholesterol (HDL-C) ratio (-0.28 ± 0.37 vs. -0.08 ± 0.24; p = .01). No significant difference was observed between groups in HDL-C, glycated hemoglobin, fasting insulin levels, and anthropometric measures. The present study suggests that okra consumption can elicit improvements in lipid profile, as well as glycemic markers, among T2D patients.",2020,"No significant difference was observed between groups in HDL-C, glycated hemoglobin, fasting insulin levels, and anthropometric measures.","['Kerman, Iran', 'T2D patients', 'Sixty T2D patients', 'Type 2 diabetic adults', 'Type 2 diabetic (T2D) patients']","['10 g okra powder blended in 150\u2009g conventional yogurt or conventional yogurt alone', 'okra (Abelmoschus esculentus', 'okra consumption']","['quantitative insulin sensitivity check index', 'HDL-C, glycated hemoglobin, fasting insulin levels, and anthropometric measures', 'total cholesterol', 'low-density lipoprotein cholesterol', 'triacylglycerol', 'homeostatic model of assessment for insulin resistance', 'LDL-C/high-density lipoprotein cholesterol (HDL-C) ratio', 'serum levels of lipid profiles and glycemic indices', 'lipid profiles and glycemic indices', 'fasting plasma glucose', 'Glycemic markers and lipid profile']","[{'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C1318182', 'cui_str': '10G'}, {'cui': 'C1116542', 'cui_str': 'Abelmoschus esculentus'}, {'cui': 'C0032861', 'cui_str': 'Powder'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0043419', 'cui_str': 'Yogurt'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C1283174', 'cui_str': 'Checking - action'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",60.0,0.343498,"No significant difference was observed between groups in HDL-C, glycated hemoglobin, fasting insulin levels, and anthropometric measures.","[{'ForeName': 'Arezoo', 'Initials': 'A', 'LastName': 'Moradi', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Science, Isfahan, Iran.'}, {'ForeName': 'Moahammad-Javad', 'Initials': 'MJ', 'LastName': 'Tarrahi', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Science, Isfahan, Iran.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Ghasempour', 'Affiliation': 'Department of Nutrition, Lorestan University of Medical Science, Khorramabad, Iran.'}, {'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Shafiepour', 'Affiliation': 'Department of Internal medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.'}, {'ForeName': 'Cain C T', 'Initials': 'CCT', 'LastName': 'Clark', 'Affiliation': 'Faculty Research Centre for Sport, Exercise and Life Sciences, Coventry University, Coventry, UK.'}, {'ForeName': 'Sayyed-Morteza', 'Initials': 'SM', 'LastName': 'Safavi', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Science, Isfahan, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.6782'] 2627,32706168,Two-Year Follow-Up of the Efficacy of the PREP Training on Iranian Newlyweds.,"The aim of the present study was to replicate the efficacy of the Prevention and Relationship Education Program (PREP) training on marital satisfaction and dyadic adjustment among a group of Iranian newlyweds. One hundred and sixty heterosexual couples (N = 320 participants) were randomly assigned to an experimental or a wait list control group. Data from one hundred and forty-eight couples were analyzed. Participants completed the ENRICH Marital Satisfaction Scale (The Family Journal, 1, 1993, 196-207) and Dyadic Adjustment Scale (The Journal of Sex Research, 39, 1976, 190-196) at pretest, posttest, 1-year follow-up, and 2-year follow-up. Results indicated that mean marital satisfaction and dyadic adjustment scores between the experimental and control groups were significantly different at posttest. Therefore, PREP training improved marital satisfaction and dyadic adjustment of couples at posttest. The data suggests that PREP training program can be introduced as an effective relationship education program for Iranian newlyweds.",2020,Results indicated that mean marital satisfaction and dyadic adjustment scores between the experimental and control groups were significantly different at posttest.,"['Data from one hundred and forty-eight couples were analyzed', 'marital satisfaction and dyadic adjustment among a group of Iranian newlyweds', 'One hundred and sixty heterosexual couples (N\xa0=\xa0320 participants']","['Prevention and Relationship Education Program (PREP) training', 'PREP training', 'PREP Training']","['mean marital satisfaction and dyadic adjustment scores', 'ENRICH Marital Satisfaction Scale', 'marital satisfaction and dyadic adjustment']","[{'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0024841', 'cui_str': 'Marriage'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0425381', 'cui_str': 'Newly wed'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0019421', 'cui_str': 'Heterosexuality'}, {'cui': 'C4517711', 'cui_str': '320'}]","[{'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0024841', 'cui_str': 'Marriage'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",160.0,0.0179955,Results indicated that mean marital satisfaction and dyadic adjustment scores between the experimental and control groups were significantly different at posttest.,"[{'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Fallahchai', 'Affiliation': 'University of Hormozgan, Bandar Abbas, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Fallahi', 'Affiliation': 'University of Hormozgan, Bandar Abbas, Iran.'}, {'ForeName': 'Manijeh', 'Initials': 'M', 'LastName': 'Badiee', 'Affiliation': 'California State University, San Bernardino, CA, USA.'}]",Journal of marital and family therapy,['10.1111/jmft.12444'] 2628,32706184,"The use of collagen porcine dermal matrix and connective tissue graft with modified coronally advanced tunnel technique in the treatment of multiple adjacent type I gingival recessions: A randomized, controlled clinical trial.","OBJECTIVE To assess the clinical efficacy and esthetic outcome of porcine-derived dermal collagen matrix in comparison with connective tissue graft in the treatment of multiple adjacent gingival recessions (MAGR), 6 and 12 months after the surgery. MATERIALS AND METHODS Twenty patients with bilateral type I MAGR were treated randomly with porcine-derived dermal collagen matrix (test site) or connective tissue graft (control site) in combination with a modified coronally advanced tunnel technique. The primary objectives were to evaluate the mean and complete root coverage. The secondary objectives were to assess keratinized tissue width, gingival thickness gain, and root coverage esthetic score. RESULTS Six and 12 months postoperatively, both groups achieved significant improvements in all clinical parameters compared to baseline, with no statistically significant differences between the groups. Mean root coverage change (Δ12m - 6 m) was statistically significant between the groups in favor of connective tissue graft, and twice as many patients exhibited a complete coverage of all recessions in the control group than the test group. CONCLUSION The porcine-derived dermal collagen matrix combined with a modified coronally advanced tunnel technique resulted in satisfactory clinical and esthetic outcomes, which were similar to connective tissue graft. CLINICAL SIGNIFICANCE Porcine-derived dermal collagen matrix (XDM) may be proposed as a substitute for connective tissue graft in multiple adjacent recession treatment due to successful root coverage, a significant increase of gingival thickness, and high esthetic outcomes. The clinical benefits for the use of XDM could be: (a) second surgical wound avoidance, (b) patient discomfort decrease, and (c) lower complications' rate.",2020,"Mean root coverage change (Δ12m - 6 m) was statistically significant between the groups in favor of connective tissue graft, and twice as many patients exhibited a complete coverage of all recessions in the control group than the test group. ","['multiple adjacent type I gingival recessions', 'multiple adjacent gingival recessions (MAGR), 6 and 12\u2009months after the surgery', 'Twenty patients with bilateral type I MAGR']","['porcine-derived dermal collagen matrix (test site) or connective tissue graft (control site) in combination with a modified coronally advanced tunnel technique', 'porcine-derived dermal collagen matrix', 'collagen porcine dermal matrix and connective tissue graft with modified coronally advanced tunnel technique', 'Porcine-derived dermal collagen matrix (XDM']","['mean and complete root coverage', 'keratinized tissue width, gingival thickness gain, and root coverage esthetic score', 'satisfactory clinical and esthetic outcomes', 'Mean root coverage change']","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205117', 'cui_str': 'Juxta-posed'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0017572', 'cui_str': 'Gingival recession'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}]","[{'cui': 'C0039005', 'cui_str': 'Suidae'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0009780', 'cui_str': 'Connective tissue'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0337138', 'cui_str': 'Tunnel'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C3486131', 'cui_str': 'Pork collagen preparation'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0487742', 'cui_str': 'Width'}, {'cui': 'C0017562', 'cui_str': 'Gingival structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",20.0,0.0471807,"Mean root coverage change (Δ12m - 6 m) was statistically significant between the groups in favor of connective tissue graft, and twice as many patients exhibited a complete coverage of all recessions in the control group than the test group. ","[{'ForeName': 'Dragana L', 'Initials': 'DL', 'LastName': 'Rakasevic', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.'}, {'ForeName': 'Iva Z', 'Initials': 'IZ', 'LastName': 'Milinkovic', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.'}, {'ForeName': 'Sasa M', 'Initials': 'SM', 'LastName': 'Jankovic', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.'}, {'ForeName': 'Ivan A', 'Initials': 'IA', 'LastName': 'Soldatovic', 'Affiliation': 'Institute for Biostatistics, University of Belgrade, Belgrade, Serbia.'}, {'ForeName': 'Zoran M', 'Initials': 'ZM', 'LastName': 'Aleksic', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.'}, {'ForeName': 'Natasa S', 'Initials': 'NS', 'LastName': 'Nikolic-Jakoba', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.'}]",Journal of esthetic and restorative dentistry : official publication of the American Academy of Esthetic Dentistry ... [et al.],['10.1111/jerd.12624'] 2629,32706198,Computerized cognitive rehabilitation for treatment of cognitive impairment in multiple sclerosis: an explorative study.,"In this explorative study, forty-seven patients with relapsing-remitting multiple sclerosis were randomized to a custom 6-week cognitive rehabilitation intervention (n = 23) using the BrainHQ TM web-based platform and to a control group condition (n = 24). Cognitive rehabilitation intervention consisted of two 40-minute sessions per week. All patients were tested with the Brief International Cognitive Assessment for Multiple Sclerosis battery, the Stroop Color-Word Test, and the trail making test, while the Beck Depression Inventory - Fast Screen questionnaire was used as a measure of mood and the cognitive reserve index as a measure of cognitive reserve. We used the reliable change index, to calculate clinically meaningful changes of performance, and to discriminate between responders and non-responders of this intervention. Statistically significant improvement of the group receiving treatment was observed mainly on measures of verbal and non-verbal episodic memory and, to a lesser extent, on reading speed, selective attention/response inhibition, and visual attention. Verbal memory and visual attention improvements remained significant after considering the corrected for multiple comparisons level of significance. According to reliable change index scores, 12/23 (52.2%) of patients in the intervention group presented meaningful improvement in at least one measure (Greek Verbal Learning Test: 26%, Brief Visuospatial Memory Test-Revised: 17.4%, Stroop-Words test: 13%). This explorative study provides evidence that, at least in the short term, cognitive rehabilitation may improve the cognitive performance of multiple sclerosis patients.",2020,"Statistically significant improvement of the group receiving treatment was observed mainly on measures of verbal and non-verbal episodic memory and, to a lesser extent, on reading speed, selective attention/response inhibition, and visual attention.","['multiple sclerosis patients', 'forty-seven patients with relapsing-remitting multiple sclerosis', 'multiple sclerosis']","['BrainHQ TM web-based platform and to a control group condition', 'Computerized cognitive rehabilitation', 'custom 6-week cognitive rehabilitation intervention', 'Cognitive rehabilitation intervention']","['cognitive performance', 'reading speed, selective attention/response inhibition, and visual attention', 'meaningful improvement', 'Verbal memory and visual attention improvements', 'measures of verbal and non-verbal episodic memory']","[{'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0751967', 'cui_str': 'Relapsing remitting multiple sclerosis'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C0162343', 'cui_str': 'Customs'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0233421', 'cui_str': 'Selective inattention'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0589102', 'cui_str': 'Visual attention'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}]",47.0,0.0170816,"Statistically significant improvement of the group receiving treatment was observed mainly on measures of verbal and non-verbal episodic memory and, to a lesser extent, on reading speed, selective attention/response inhibition, and visual attention.","[{'ForeName': 'Irini', 'Initials': 'I', 'LastName': 'Vilou', 'Affiliation': 'Lab of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece.'}, {'ForeName': 'Christos', 'Initials': 'C', 'LastName': 'Bakirtzis', 'Affiliation': 'The Multiple Sclerosis Center, 2nd Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, 54621, Greece.'}, {'ForeName': 'Artemios', 'Initials': 'A', 'LastName': 'Artemiadis', 'Affiliation': 'Medical School, University of Cyprus, Nicosia, 1678, Cyprus.'}, {'ForeName': 'Panagiotis', 'Initials': 'P', 'LastName': 'Ioannidis', 'Affiliation': 'The Multiple Sclerosis Center, 2nd Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, 54621, Greece.'}, {'ForeName': 'Malamati', 'Initials': 'M', 'LastName': 'Papadimitriou', 'Affiliation': 'Department of Neurology, Inselspital, University Hospital, Bern, 3010, Switzerland.'}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Konstantinopoulou', 'Affiliation': 'Lab of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece.'}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Aretouli', 'Affiliation': 'Lab of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece.'}, {'ForeName': 'Lambros', 'Initials': 'L', 'LastName': 'Messinis', 'Affiliation': 'Neuropsychology Section, Departments of Neurology and Psychiatry, University Hospital of Patras and University of Patras Medical School, Patras, 26504, Greece.'}, {'ForeName': 'Grigorios', 'Initials': 'G', 'LastName': 'Nasios', 'Affiliation': 'Department of Speech and Language Therapy, School of Health Sciences, University of Ioannina, Ioannina, 45100, Greece.'}, {'ForeName': 'Efthimios', 'Initials': 'E', 'LastName': 'Dardiotis', 'Affiliation': 'Department of Neurology, University of Thessaly, University Hospital of Larissa, Larissa, 41334, Greece.'}, {'ForeName': 'MaryHelen', 'Initials': 'M', 'LastName': 'Kosmidis', 'Affiliation': 'Lab of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece.'}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Grigoriadis', 'Affiliation': 'The Multiple Sclerosis Center, 2nd Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, 54621, Greece.'}]",Journal of integrative neuroscience,['10.31083/j.jin.2020.02.35'] 2630,32706261,"Acute mitochondrial antioxidant intake improves endothelial function, antioxidant enzyme activity, and exercise tolerance in peripheral artery disease patients.","Peripheral artery disease (PAD) is a manifestation of atherosclerosis in the leg arteries, which causes claudication. This may be in part due to vascular mitochondrial dysfunction and excessive reactive oxygen species (ROS) production. A mitochondrial-targeted antioxidant (MitoQ) has been shown to improve vascular mitochondrial function which, in turn, led to improved vascular function in older adults and animal models. However, the roles of vascular mitochondria in vascular function including endothelial function and arterial stiffness in patients with PAD are unknown, therefore, by utilizing acute MitoQ intake, this study examined the roles of vascular mitochondria in endothelial function, arterial stiffness, exercise tolerance, and skeletal muscle function in patients with PAD. 11 patients with PAD received either MitoQ or placebo in a randomized crossover design. At each visit, blood samples, brachial and popliteal artery flow-mediated dilation (FMD), peripheral and central pulse-wave velocity (PWV), blood pressure (BP), maximal walking capacity, time to claudication (COT), and oxygen utility capacity were measured pre-and-post MitoQ and placebo. There were significant group by time interactions (p<0.05) for brachial and popliteal FMD which both increased (Δ2.6% and Δ3.3%, respectively), and increases superoxide dismutase (Δ0.03 U/mL), maximal walking time (Δ73.8 s), maximal walking distance (Δ49.3 m) and COT (Δ44.2 s). There were no changes in resting heart rate, BP, malondialdehyde, total antioxidant capacity, PWV, or oxygen utility capacity (p>0.05). MitoQ intake may be an effective strategy for targeting the vascular mitochondrial environment, which may be useful for restoring endothelial function, leg pain, and walking time in patients with PAD.",2020,"There were no changes in resting heart rate, BP, malondialdehyde, total antioxidant capacity, PWV, or oxygen utility capacity (p>0.05).","['peripheral artery disease patients', '11 patients with PAD received either', 'patients with PAD']","['Acute mitochondrial antioxidant intake', 'mitochondrial-targeted antioxidant (MitoQ', 'MitoQ or placebo']","['maximal walking time (Δ73.8 s), maximal walking distance', 'superoxide dismutase', 'Peripheral artery disease (PAD', 'time interactions (p<0.05) for brachial and popliteal FMD', 'resting heart rate, BP, malondialdehyde, total antioxidant capacity, PWV, or oxygen utility capacity (p>0.05', 'blood samples, brachial and popliteal artery flow-mediated dilation (FMD), peripheral and central pulse-wave velocity (PWV), blood pressure (BP), maximal walking capacity, time to claudication (COT), and oxygen utility capacity', 'endothelial function, antioxidant enzyme activity, and exercise tolerance']","[{'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0442037', 'cui_str': 'Popliteal'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C1821417', 'cui_str': 'Resting heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0032649', 'cui_str': 'Structure of popliteal artery'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0021775', 'cui_str': 'Intermittent claudication'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0243102', 'cui_str': 'enzyme activity'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}]",11.0,0.183995,"There were no changes in resting heart rate, BP, malondialdehyde, total antioxidant capacity, PWV, or oxygen utility capacity (p>0.05).","[{'ForeName': 'Song-Young', 'Initials': 'SY', 'LastName': 'Park', 'Affiliation': 'School of Health & Kinesiology, University of Nebraska at Omaha, United States.'}, {'ForeName': 'Elizabeth J', 'Initials': 'EJ', 'LastName': 'Pekas', 'Affiliation': 'School of Health & Kinesiology, University of Nebraska at Omaha, United States.'}, {'ForeName': 'Ronald J', 'Initials': 'RJ', 'LastName': 'Headid', 'Affiliation': 'School of Health & Kinesiology, University of Nebraska at Omaha, United States.'}, {'ForeName': 'Won-Mok', 'Initials': 'WM', 'LastName': 'Son', 'Affiliation': 'School of Health and Kinesiology, University of Nebraska at Omaha, United States.'}, {'ForeName': 'TeSean K', 'Initials': 'TK', 'LastName': 'Wooden', 'Affiliation': 'School of Health & Kinesiology, University of Nebraska at Omaha, United States.'}, {'ForeName': 'Jiwon', 'Initials': 'J', 'LastName': 'Song', 'Affiliation': 'Health and Exercise Science, University of Oklahoma, United States.'}, {'ForeName': 'Gwenael', 'Initials': 'G', 'LastName': 'Layec', 'Affiliation': 'Kinesiology, University of Massachusetts Amherst, United States.'}, {'ForeName': 'Saantosh', 'Initials': 'S', 'LastName': 'Yadav', 'Affiliation': 'Cellular and Integrative Physiology, University of Nebraska Medical Center, United States.'}, {'ForeName': 'Paras K', 'Initials': 'PK', 'LastName': 'Mishra', 'Affiliation': 'Cellular and Integrative Physiology, University of Nebraska Medical Center, United States.'}, {'ForeName': 'Iraklis I', 'Initials': 'II', 'LastName': 'Pipinos', 'Affiliation': 'Surgery, University of Nebraska Medical Center, United States.'}]",American journal of physiology. Heart and circulatory physiology,['10.1152/ajpheart.00235.2020'] 2631,32706285,Effectiveness of Bath Wipes After Hematopoietic Cell Transplantation: A Randomized Trial.,"Objective: Bacteremia is a leading cause of morbidity and mortality in children undergoing hematopoietic cell transplantation (HCT). Infections of vancomycin-resistant enterococci (VRE) and multidrug resistant (MDR) gram-negative rods (GNRs) are common in this population. Our objective was to assess whether experimental bath wipes containing silver were more effective than standard bath wipes containing soap at reducing skin colonization by VRE and MDR GNRs, and nonmucosal barrier injury bacteremia. Study Design: Patients undergoing autologous or allogeneic HCT in a tertiary referral center were randomized to receive experimental or standard bath wipes for 60 days post-HCT. Skin swabs were collected at baseline, discharge, and day +60 post-HCT. The rate of VRE colonization was chosen as the marker for efficacy. Results: Experimental bath wipes were well tolerated. Before the study, the rate of colonization with VRE in HCT recipients was 25%. In an interim analysis of 127 children, one (2%) patient in the experimental arm and two (3%) in the standard arm were colonized with VRE. Two (3%) patients had nonmucosal barrier injury bacteremia in the standard arm, with none in the experimental arm. MDR GNRs were not isolated. The trial was halted because the interim analyses indicated equivalent efficacy of the two methods. Conclusions: Skin cleansing with silver-containing or standard bath wipes resulted in very low and equivalent rates of bacteremia and colonization with VRE and MDR GNRs in children post-HCT. Future studies in other high-risk populations are needed to confirm these results.",2020,"Our objective was to assess whether experimental bath wipes containing silver were more effective than standard bath wipes containing soap at reducing skin colonization by VRE and MDR GNRs, and nonmucosal barrier injury bacteremia. ","['After Hematopoietic Cell Transplantation', 'children undergoing hematopoietic cell transplantation (HCT', 'Patients undergoing autologous or allogeneic HCT in a tertiary referral center']","['Bath Wipes', 'vancomycin-resistant enterococci (VRE) and multidrug resistant (MDR) gram-negative rods (GNRs', 'Skin cleansing with silver-containing or standard bath wipes', 'experimental or standard bath wipes for 60 days post-HCT']","['rate of colonization with VRE', 'nonmucosal barrier injury bacteremia', 'rate of VRE colonization', 'tolerated']","[{'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}]","[{'cui': 'C1265175', 'cui_str': 'Vancomycin resistant enterococcus'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0314752', 'cui_str': 'Gram-negative bacillus'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0037125', 'cui_str': 'silver'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}]","[{'cui': 'C1265175', 'cui_str': 'Vancomycin resistant enterococcus'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}]",127.0,0.12009,"Our objective was to assess whether experimental bath wipes containing silver were more effective than standard bath wipes containing soap at reducing skin colonization by VRE and MDR GNRs, and nonmucosal barrier injury bacteremia. ","[{'ForeName': 'Margie', 'Initials': 'M', 'LastName': 'Kjellin', 'Affiliation': ""St. Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Amr', 'Initials': 'A', 'LastName': 'Qudeimat', 'Affiliation': ""St. Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Browne', 'Affiliation': ""St. Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Dinesh', 'Initials': 'D', 'LastName': 'Keerthi', 'Affiliation': ""St. Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Anusha', 'Initials': 'A', 'LastName': 'Sunkara', 'Affiliation': ""St. Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Guolian', 'Initials': 'G', 'LastName': 'Kang', 'Affiliation': ""St. Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Winfield', 'Affiliation': ""St. Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Mary Anne', 'Initials': 'MA', 'LastName': 'Giannini', 'Affiliation': ""St. Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Maron', 'Affiliation': ""St. Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Randall', 'Initials': 'R', 'LastName': 'Hayden', 'Affiliation': ""St. Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Wing', 'Initials': 'W', 'LastName': 'Leung', 'Affiliation': ""St. Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Brandon', 'Initials': 'B', 'LastName': 'Triplett', 'Affiliation': ""St. Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Ashok', 'Initials': 'A', 'LastName': 'Srinivasan', 'Affiliation': ""St. Jude Children's Research Hospital, Memphis, TN, USA.""}]",Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses,['10.1177/1043454220944061'] 2632,32706428,Efficacy of testosterone replacement therapy on pain in hypogonadal men with chronic pain syndrome: A subanalysis of a prospective randomised controlled study in Japan (EARTH study).,"The present study investigated the efficacy of 6 months of testosterone replacement therapy (TRT) on chronic pain syndrome in late-onset hypogonadal (LOH) men. Sixty hypogonadal patients with chronic pain syndrome (31 patients in TRT group and 29 controls) were extracted from a previous randomised controlled study in Japan. Chronic pain was evaluated based on bodily pain (BP) subscale of Short-form (36) Health Survey (SF-36), and patients with a score of 50.0 or less were defined as suffering from chronic pain. SF-36 scores, Aging Male Symptoms (AMS) scale, international prostatic symptoms score (IPSS) and prostate-specific antigen (PSA) levels at baseline and a 6-month visit for the two groups were collected and compared. There were no statistically significant differences in baseline backgrounds between the two groups. Six-month TRT could contribute to significant improvements in BP, mental health of SF-36 and sleep disturbance (AMS question 4). Though the PSA level in the TRT group also significantly elevated at 6 months, the increase was not clinically significant. No significant improvements were evident in any characteristics in the controls. In conclusion, 6-month TRT can improve pain and some aspects of quality of life in LOH men with chronic pain.",2020,"Six-month TRT could contribute to significant improvements in BP, mental health of SF-36 and sleep disturbance (AMS question 4).","['LOH men with chronic pain', 'Sixty hypogonadal patients with chronic pain syndrome (31 patients in TRT group and 29 controls', 'late-onset hypogonadal (LOH) men', 'hypogonadal men with chronic pain syndrome']","['testosterone replacement therapy (TRT', 'testosterone replacement therapy', 'TRT']","['quality of life', 'bodily pain (BP) subscale of Short-form (36) Health Survey (SF-36', 'PSA level', 'Chronic pain', 'BP, mental health of SF-36 and sleep disturbance', 'pain', 'chronic pain syndrome', 'SF-36 scores, Aging Male Symptoms (AMS) scale, international prostatic symptoms score (IPSS) and prostate-specific antigen (PSA) levels']","[{'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1298685', 'cui_str': 'Chronic pain syndrome'}, {'cui': 'C4510497', 'cui_str': 'Testosterone replacement therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C4510497', 'cui_str': 'Testosterone replacement therapy'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C1298685', 'cui_str': 'Chronic pain syndrome'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}]",60.0,0.0864117,"Six-month TRT could contribute to significant improvements in BP, mental health of SF-36 and sleep disturbance (AMS question 4).","[{'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Kato', 'Affiliation': 'Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.'}, {'ForeName': 'Kazuyoshi', 'Initials': 'K', 'LastName': 'Shigehara', 'Affiliation': 'Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.'}, {'ForeName': 'Shohei', 'Initials': 'S', 'LastName': 'Kawaguchi', 'Affiliation': 'Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.'}, {'ForeName': 'Kouji', 'Initials': 'K', 'LastName': 'Izumi', 'Affiliation': 'Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.'}, {'ForeName': 'Yoshifumi', 'Initials': 'Y', 'LastName': 'Kadono', 'Affiliation': 'Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Mizokami', 'Affiliation': 'Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.'}]",Andrologia,['10.1111/and.13768'] 2633,32706442,Effects of eccentric training at long muscle length on architectural and functional characteristics of the hamstrings.,"Hamstring strain injuries during sprinting or stretching frequently occur at long muscle length. Yet, previous research has mainly focused on studying the effectiveness of eccentric hamstring strengthening at shorter muscle length on hamstring performance, morphology, and hamstring strain injury risk factors. Here we evaluated the effects of six weeks eccentric hamstring training at long muscle length on functional and architectural characteristics of the hamstrings. Healthy and injury-free participants (n=40; age 23.7±2.5 years) were randomly assigned to control or intervention group. Training intervention consisted of 12 sessions with two eccentric hamstring exercises in a lengthened position. Outcome measures included isokinetic and isometric knee flexion peak torque, Nordic hamstring exercise peak torque, voluntary activation level, and countermovement jump performance. Ultrasonography was used to determine muscle thickness, pennation angle and fascicle length of biceps femoris long head (BFlh). A significant time × group interaction effect was observed for all measured parameters except countermovement jump performance and muscle thickness. The training intervention resulted in increased concentric and eccentric knee flexion peak torque at 60°/s (d=0.55-0.62, p=0.02 and 0.03) and concentric peak torque at 180°/s (d=0.99, p=0.001), increased isometric knee flexion peak torque (d=0.73, p=0.008) and Nordic hamstring exercise peak torque (d=1.19, p<0.001), increased voluntary activation level (d=1.29, p<0.001), decreased pennation angle (d=1.31, p<0.001) and increased fascicle length (d=1.12, p<0.001) of BFlh. These results provide evidence that short-term eccentric hamstring strengthening at long muscle length can have significant favourable effects on various architectural and functional characteristics of the hamstrings.",2020,"The training intervention resulted in increased concentric and eccentric knee flexion peak torque at 60°/s (d=0.55-0.62, p=0.02 and 0.03) and concentric peak torque at 180°/s",['Healthy and injury-free participants (n=40; age 23.7±2.5 years'],"['eccentric training', 'eccentric hamstring training', 'eccentric hamstring exercises', 'Ultrasonography']","['fascicle length', 'isokinetic and isometric knee flexion peak torque, Nordic hamstring exercise peak torque, voluntary activation level, and countermovement jump performance', 'muscle thickness, pennation angle and fascicle length of biceps femoris long head (BFlh', 'decreased pennation angle', 'concentric peak torque', 'isometric knee flexion peak torque', 'Nordic hamstring exercise peak torque', 'countermovement jump performance and muscle thickness', 'Hamstring strain injuries', 'voluntary activation level', 'concentric and eccentric knee flexion peak torque']","[{'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0584895', 'cui_str': 'Posterior muscle of thigh structure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}]","[{'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0224449', 'cui_str': 'Biceps femoris muscle structure'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0439744', 'cui_str': 'Concentric'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}]",,0.034489,"The training intervention resulted in increased concentric and eccentric knee flexion peak torque at 60°/s (d=0.55-0.62, p=0.02 and 0.03) and concentric peak torque at 180°/s","[{'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Marušič', 'Affiliation': 'University of Primorska, Faculty of Health Sciences, Izola, Slovenia.'}, {'ForeName': 'Rok', 'Initials': 'R', 'LastName': 'Vatovec', 'Affiliation': 'University of Primorska, Faculty of Health Sciences, Izola, Slovenia.'}, {'ForeName': 'Goran', 'Initials': 'G', 'LastName': 'Marković', 'Affiliation': 'University of Zagreb, Faculty of Kinesiology, Zagreb, Croatia.'}, {'ForeName': 'Nejc', 'Initials': 'N', 'LastName': 'Šarabon', 'Affiliation': 'University of Primorska, Faculty of Health Sciences, Izola, Slovenia.'}]",Scandinavian journal of medicine & science in sports,['10.1111/sms.13770'] 2634,32706502,"Repetitive transcranial magnetic stimulation treatment in severe, enduring anorexia nervosa: An open longer-term follow-up.","OBJECTIVE This study assessed longer-term outcomes from a randomised controlled feasibility trial of 20 sessions of real versus sham high-frequency repetitive transcranial magnetic stimulation (rTMS) to the left dorsolateral prefrontal cortex in adults with severe, enduring anorexia nervosa (SE-AN). METHODS Thirty participants who completed the original study protocol were invited to take part in an open follow-up (18-months post-randomisation), assessing body mass index (BMI), eating disorder (ED) symptoms and other psychopathology. RESULTS Twenty-four participants (12 each originally allocated to real/sham) completed the 18-month follow-up. Ten of 12 participants who originally received sham treatment had real rTMS at some stage during the follow-up. A medium between-group effect size was seen for BMI change from baseline to 18-months, favouring those originally allocated to real rTMS. In this group at 18-months, five participants were weight recovered (BMI ≥18.5 kg/m 2 ), compared with one participant in the original sham group. Both groups showed further improvement in ED symptoms during the follow-up. Effects on mood were largely maintained at follow-up, with catch-up effects in the original sham group. CONCLUSIONS Findings suggest that rTMS treatment effects on mood are durable and that BMI and ED symptom improvements need time to emerge. Large-scale trials are needed. Highlights At 18-months post-randomisation, mood improvements seen in the real rTMS group at 4-months post-randomisation remained broadly stable. In relation to body mass index (BMI) change, whilst there were further improvements in both groups up to the 18-month follow-up, change in the original real rTMS group was larger. Participants in both the real rTMS and sham rTMS groups showed further improvements in eating disorder symptoms and associated psychosocial impairment during the follow-up with small between-group differences at 18-months.",2020,Participants in both the real rTMS and sham rTMS groups showed further improvements in eating disorder symptoms and associated psychosocial impairment during the follow-up with small between-group differences at 18-months.,"['severe, enduring anorexia nervosa', 'adults with severe, enduring anorexia nervosa (SE-AN', 'Thirty participants who completed the original study protocol', 'Ten of 12 participants who originally received sham treatment had real rTMS at some stage during the follow-up']","['rTMS and sham rTMS', 'Repetitive transcranial magnetic stimulation treatment', 'rTMS', '20 sessions of real versus sham high-frequency repetitive transcranial magnetic stimulation (rTMS']","['BMI change', 'body mass index (BMI), eating disorder (ED) symptoms and other psychopathology', 'psychosocial impairment', 'eating disorder symptoms', 'ED symptoms']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0003125', 'cui_str': 'Anorexia nervosa'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C2599718', 'cui_str': 'Clinical Trial Protocols'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}]","[{'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0013473', 'cui_str': 'Eating disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0855228', 'cui_str': 'Eating disorder symptom'}]",5.0,0.0317723,Participants in both the real rTMS and sham rTMS groups showed further improvements in eating disorder symptoms and associated psychosocial impairment during the follow-up with small between-group differences at 18-months.,"[{'ForeName': 'Bethan', 'Initials': 'B', 'LastName': 'Dalton', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Yael D', 'Initials': 'YD', 'LastName': 'Lewis', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Savani', 'Initials': 'S', 'LastName': 'Bartholdy', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Kekic', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'McClelland', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Iain C', 'Initials': 'IC', 'LastName': 'Campbell', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Schmidt', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}]",European eating disorders review : the journal of the Eating Disorders Association,['10.1002/erv.2766'] 2635,32706534,Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease.,"BACKGROUND Vitamin D metabolites support innate immune responses to Mycobacterium tuberculosis . Data from phase 3, randomized, controlled trials of vitamin D supplementation to prevent tuberculosis infection are lacking. METHODS We randomly assigned children who had negative results for M. tuberculosis infection according to the QuantiFERON-TB Gold In-Tube assay (QFT) to receive a weekly oral dose of either 14,000 IU of vitamin D 3 or placebo for 3 years. The primary outcome was a positive QFT result at the 3-year follow-up, expressed as a proportion of children. Secondary outcomes included the serum 25-hydroxyvitamin D (25[OH]D) level at the end of the trial and the incidence of tuberculosis disease, acute respiratory infection, and adverse events. RESULTS A total of 8851 children underwent randomization: 4418 were assigned to the vitamin D group, and 4433 to the placebo group; 95.6% of children had a baseline serum 25(OH)D level of less than 20 ng per milliliter. Among children with a valid QFT result at the end of the trial, the percentage with a positive result was 3.6% (147 of 4074 children) in the vitamin D group and 3.3% (134 of 4043) in the placebo group (adjusted risk ratio, 1.10; 95% confidence interval [CI], 0.87 to 1.38; P = 0.42). The mean 25(OH)D level at the end of the trial was 31.0 ng per milliliter in the vitamin D group and 10.7 ng per milliliter in the placebo group (mean between-group difference, 20.3 ng per milliliter; 95% CI, 19.9 to 20.6). Tuberculosis disease was diagnosed in 21 children in the vitamin D group and in 25 children in the placebo group (adjusted risk ratio, 0.87; 95% CI, 0.49 to 1.55). A total of 29 children in the vitamin D group and 34 in the placebo group were hospitalized for treatment of acute respiratory infection (adjusted risk ratio, 0.86; 95% CI, 0.52 to 1.40). The incidence of adverse events did not differ significantly between the two groups. CONCLUSIONS Vitamin D supplementation did not result in a lower risk of tuberculosis infection, tuberculosis disease, or acute respiratory infection than placebo among vitamin D-deficient schoolchildren in Mongolia. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT02276755.).",2020,"The incidence of adverse events did not differ significantly between the two groups. ","['8851 children underwent randomization: 4418', 'We randomly assigned children who had negative results for M. tuberculosis infection according to the QuantiFERON-TB Gold In-Tube assay (QFT', '29 children in the']","['Vitamin D metabolites', 'vitamin D 3 or placebo', 'Vitamin D supplementation', 'Vitamin D Supplements', 'vitamin D', 'vitamin D supplementation', 'placebo']","['Tuberculosis disease', 'lower risk of tuberculosis infection, tuberculosis disease, or acute respiratory infection', 'positive QFT result at the 3-year follow-up, expressed as a proportion of children', 'acute respiratory infection', 'serum 25-hydroxyvitamin D (25[OH]D) level at the end of the trial and the incidence of tuberculosis disease, acute respiratory infection, and adverse events', 'incidence of adverse events', 'mean 25(OH)D level']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C4704700', 'cui_str': 'Null Results'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0026926', 'cui_str': 'Mycobacterium tuberculosis'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0018026', 'cui_str': 'Gold'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0420176', 'cui_str': 'Vitamin D supplement therapy'}]","[{'cui': 'C0041296', 'cui_str': 'Tuberculosis'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0238990', 'cui_str': 'Acute lower respiratory tract infection'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",8851.0,0.752656,"The incidence of adverse events did not differ significantly between the two groups. ","[{'ForeName': 'Davaasambuu', 'Initials': 'D', 'LastName': 'Ganmaa', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Buyanjargal', 'Initials': 'B', 'LastName': 'Uyanga', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Garmaa', 'Initials': 'G', 'LastName': 'Gantsetseg', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Baigali', 'Initials': 'B', 'LastName': 'Delgerekh', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Davaasambuu', 'Initials': 'D', 'LastName': 'Enkhmaa', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Dorjnamjil', 'Initials': 'D', 'LastName': 'Khulan', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Saranjav', 'Initials': 'S', 'LastName': 'Ariunzaya', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Erdenebaatar', 'Initials': 'E', 'LastName': 'Sumiya', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Batbileg', 'Initials': 'B', 'LastName': 'Bolortuya', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Jutmaan', 'Initials': 'J', 'LastName': 'Yanjmaa', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Tserenkhuu', 'Initials': 'T', 'LastName': 'Enkhtsetseg', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Ankhbat', 'Initials': 'A', 'LastName': 'Munkhzaya', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Murneren', 'Initials': 'M', 'LastName': 'Tunsag', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Polyna', 'Initials': 'P', 'LastName': 'Khudyakov', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Seddon', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Ben J', 'Initials': 'BJ', 'LastName': 'Marais', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Ochirbat', 'Initials': 'O', 'LastName': 'Batbayar', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Ganbaatar', 'Initials': 'G', 'LastName': 'Erdenetuya', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Bazarsaikhan', 'Initials': 'B', 'LastName': 'Amarsaikhan', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Spiegelman', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Jadambaa', 'Initials': 'J', 'LastName': 'Tsolmon', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Adrian R', 'Initials': 'AR', 'LastName': 'Martineau', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}]",The New England journal of medicine,['10.1056/NEJMoa1915176'] 2636,32706546,Randomization versus Real-World Evidence.,,2020,,[],[],[],[],[],[],,0.0783911,,"[{'ForeName': 'Ajeet', 'Initials': 'A', 'LastName': 'Gajra', 'Affiliation': 'Cardinal Health Specialty Solutions, Dublin, OH ajeet.gajra@cardinalhealth.com.'}, {'ForeName': 'Marjorie E', 'Initials': 'ME', 'LastName': 'Zettler', 'Affiliation': 'Cardinal Health Specialty Solutions, Dublin, OH ajeet.gajra@cardinalhealth.com.'}, {'ForeName': 'Bruce A', 'Initials': 'BA', 'LastName': 'Feinberg', 'Affiliation': 'Cardinal Health Specialty Solutions, Dublin, OH ajeet.gajra@cardinalhealth.com.'}]",The New England journal of medicine,['10.1056/NEJMc2020020'] 2637,32706547,Randomization versus Real-World Evidence.,,2020,,[],[],[],[],[],[],,0.0783911,,"[{'ForeName': 'Lukas', 'Initials': 'L', 'LastName': 'Aguirre Dávila', 'Affiliation': 'Paul-Ehrlich-Institut, Langen, Germany aguirredavila.lukas@gmx.de.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Koch', 'Affiliation': 'Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Lasch', 'Affiliation': 'Hannover Medical School, Hannover, Germany.'}]",The New England journal of medicine,['10.1056/NEJMc2020020'] 2638,32706548,Randomization versus Real-World Evidence.,,2020,,[],[],[],[],[],[],,0.0783911,,"[{'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Dal-Ré', 'Affiliation': ', Madrid, Spain rafael.dalre@quironsalud.es.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Mentz', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Frits R', 'Initials': 'FR', 'LastName': 'Rosendaal', 'Affiliation': 'Leiden University Medical Center, Leiden, the Netherlands.'}]",The New England journal of medicine,['10.1056/NEJMc2020020'] 2639,32706549,Randomization versus Real-World Evidence.,,2020,,[],[],[],[],[],[],,0.0783911,,"[{'ForeName': 'Almut G', 'Initials': 'AG', 'LastName': 'Winterstein', 'Affiliation': 'University of Florida, Gainesville, FL almut@ufl.edu.'}, {'ForeName': 'Cynthia J', 'Initials': 'CJ', 'LastName': 'Girman', 'Affiliation': 'CERobs Consulting, Chapel Hill, NC.'}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Pottegård', 'Affiliation': 'Syddansk Universitet, Odense, Denmark.'}]",The New England journal of medicine,['10.1056/NEJMc2020020'] 2640,32706550,Randomization versus Real-World Evidence.,,2020,,[],[],[],[],[],[],,0.0783911,,"[{'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Shrier', 'Affiliation': 'McGill University, Montreal, QC, Canada ian.shrier@mcgill.ca.'}, {'ForeName': 'Steven D', 'Initials': 'SD', 'LastName': 'Stovitz', 'Affiliation': 'University of Minnesota, Minneapolis, MN.'}]",The New England journal of medicine,['10.1056/NEJMc2020020'] 2641,32706551,Randomization versus Real-World Evidence.,,2020,,[],[],[],[],[],[],,0.0783911,,"[{'ForeName': 'Laura B', 'Initials': 'LB', 'LastName': 'Balzer', 'Affiliation': 'University of Massachusetts-Amherst, Amherst, MA lbalzer@umass.edu.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Dominici', 'Affiliation': 'Harvard T.H. Chan School of Public Health, Boston, MA.'}]",The New England journal of medicine,['10.1056/NEJMc2020020'] 2642,32701372,Re: Effect of Multimodal Prehabilitation vs Postoperative Rehabilitation on 30-Day Postoperative Complications for Frail Patients Undergoing Resection of Colorectal Cancer: A Randomized Clinical Trial.,,2020,,['Frail Patients Undergoing Resection of Colorectal Cancer'],['Multimodal Prehabilitation vs Postoperative Rehabilitation'],['30-Day Postoperative Complications'],"[{'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}]","[{'cui': 'C5192101', 'cui_str': 'Prehabilitation'}, {'cui': 'C0877071', 'cui_str': 'Postoperative rehabilitation'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}]",,0.10665,,"[{'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Resnick', 'Affiliation': ''}]",The Journal of urology,['10.1097/JU.0000000000001215.02'] 2643,32701392,Ubiquitin Proteasome System Activity is Suppressed by Curcumin following Exercise-Induced Muscle Damage in Human Skeletal Muscle.,"PURPOSE Curcumin is a polyphenolic compound that is suggested to dysregulate the ubiquitin-proteasome system (UPS). This study investigated the effects of curcumin supplementation on markers of UPS activity in response to muscle damage. METHODS Twenty-three recreationally active male and females between the ages of 18-30 were randomized into a curcumin (CUR) or placebo (PLA) group. Both groups ingested 2 g of their respective supplement and 20 mg of piperine for 11 consecutive days. Following 8 consecutive days of supplementation, participants performed a 45-minute eccentrically-biased treadmill protocol at 60% VO2max. Muscle biopsies and delayed onset muscle soreness (DOMS) assessments were performed 30 minutes prior and 3, 24, 48, and 72 hours following exercise. Skeletal muscle ubiquitin, MAFbx/Atrogin-1, ubiquitin specific peptidase 19 (USP19), and chymotrypsin-like protease concentrations were measured using ELISA. A 3-way repeated measures ANOVA with pairwise comparisons was conducted with significance set at p ≤ 0.05. RESULTS Compared to baseline, DOMS for both groups was significantly increased (p < 0.05) at all time points except 72 hours following exercise. No significant differences were found for USP19 between groups. Ubiquitin (p=.016) and MAFbx/Atrogin-1 (p=.006) were significantly lower for CUR compared to PLA. Additionally, MAFbx/Atrogin-1 was significantly greater for females (p=.013) compared to males. In males, curcumin resulted in significant reductions (p = .049) in chymotrypsin-like protease (p = .049). CONCLUSION While elevations in UPS activity were not observed in response to muscle damage, curcumin supplementation in humans does appear to dysregulate basal UPS activity in the presence of exercise-induced muscle damage.",2020,"Compared to baseline, DOMS for both groups was significantly increased (p < 0.05) at all time points except 72 hours following exercise.",['Twenty-three recreationally active male and females between the ages of 18-30'],"['45-minute eccentrically-biased treadmill protocol at 60% VO2max', 'curcumin supplementation', 'respective supplement and 20\u2009mg of piperine', 'curcumin (CUR) or placebo (PLA']","['MAFbx/Atrogin-1', 'Muscle biopsies and delayed onset muscle soreness (DOMS) assessments', 'Skeletal muscle ubiquitin, MAFbx/Atrogin-1, ubiquitin specific peptidase 19 (USP19), and chymotrypsin-like protease concentrations']","[{'cui': 'C0450348', 'cui_str': '23'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C1442463', 'cui_str': 'Forty-five minutes'}, {'cui': 'C0005346', 'cui_str': 'Biases'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0010467', 'cui_str': 'Curcumin'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0071112', 'cui_str': 'piperine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0185283', 'cui_str': 'Biopsy of muscle'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0041538', 'cui_str': 'Ubiquitin'}, {'cui': 'C0669472', 'cui_str': 'Ubiquitin-Specific Peptidases'}, {'cui': 'C0055673', 'cui_str': 'Chymase'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",,0.0565822,"Compared to baseline, DOMS for both groups was significantly increased (p < 0.05) at all time points except 72 hours following exercise.","[{'ForeName': 'Thomas D', 'Initials': 'TD', 'LastName': 'Cardaci', 'Affiliation': 'Department of Health, Human Performance, & Recreation, Exercise & Biochemical Nutrition Laboratory, Baylor University, Waco, Texas, USA.'}, {'ForeName': 'Steven B', 'Initials': 'SB', 'LastName': 'Machek', 'Affiliation': 'Department of Health, Human Performance, & Recreation, Exercise & Biochemical Nutrition Laboratory, Baylor University, Waco, Texas, USA.'}, {'ForeName': 'Dylan T', 'Initials': 'DT', 'LastName': 'Wilburn', 'Affiliation': 'Department of Health, Human Performance, & Recreation, Exercise & Biochemical Nutrition Laboratory, Baylor University, Waco, Texas, USA.'}, {'ForeName': 'Paul S', 'Initials': 'PS', 'LastName': 'Hwang', 'Affiliation': 'Department of Health, Human Performance, & Recreation, Exercise & Biochemical Nutrition Laboratory, Baylor University, Waco, Texas, USA.'}, {'ForeName': 'Darryn S', 'Initials': 'DS', 'LastName': 'Willoughby', 'Affiliation': 'Department of Health, Human Performance, & Recreation, Exercise & Biochemical Nutrition Laboratory, Baylor University, Waco, Texas, USA.'}]",Journal of the American College of Nutrition,['10.1080/07315724.2020.1783721'] 2644,32701419,A Randomized and Controlled Acceptability Trial of an Internet-based Therapy among Inpatients with Co-occurring Substance Use and Other Psychiatric Disorders.,"OBJECTIVES Technology-assisted treatment (TAT) holds promise for innovative assessment, prevention, and treatment of substance use disorders (SUD). The widespread access to TAT makes it a potentially cost-effective and inventive option available for delivery in multiple settings. This study assessed acceptability of the web-based Therapeutic Education System (TES) in hospitalized dual diagnosis patients with SUDs and other psychiatric disorders. Methods: Eligible participants were nonpsychotic, voluntary patients with self-reported drug or alcohol use in the 30 days prior to admission. They were randomly assigned to treatment as usual (TAU, n  = 47) or TAU + TES ( n  = 48). Acceptability of this Internet-based intervention was assessed by observed utilization and self-report. Results: The TAU + TES group (# analyzed = 41) completed a mean total of 5.5 ( SEM  = 0.8) modules with about one module per day while hospitalized and rated TES highly on several constructs of acceptability, including novelty, usefulness and ease of understanding. Conclusions: These findings support further exploration of TAT for treatment expansion in a high acuity, dual diagnosis population and indicate the value of future research on efficacy. ClinicalTrials.gov Identifier: NCT02674477.",2020,This study assessed acceptability of the web-based Therapeutic Education System (TES) in hospitalized dual diagnosis patients with SUDs and other psychiatric disorders. ,"['hospitalized dual diagnosis patients with SUDs and other psychiatric disorders', 'Inpatients with Co-occurring Substance Use and Other Psychiatric Disorders', 'Eligible participants were nonpsychotic, voluntary patients with self-reported drug or alcohol use in the 30 days prior to admission']","['Internet-based Therapy', 'TAT', 'web-based Therapeutic Education System (TES', 'usual (TAU, n \u2009=\u200947) or TAU\u2009+\u2009TES', 'Technology-assisted treatment (TAT']","['acceptability, including novelty, usefulness and ease of understanding']","[{'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0206308', 'cui_str': 'Dual Diagnosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0580276', 'cui_str': 'Informal patient'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}]",,0.0530963,This study assessed acceptability of the web-based Therapeutic Education System (TES) in hospitalized dual diagnosis patients with SUDs and other psychiatric disorders. ,"[{'ForeName': 'Alexis S', 'Initials': 'AS', 'LastName': 'Hammond', 'Affiliation': 'Behavioral Pharmacology Research Unit, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Denis G', 'Initials': 'DG', 'LastName': 'Antoine', 'Affiliation': 'Behavioral Pharmacology Research Unit, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Maxine L', 'Initials': 'ML', 'LastName': 'Stitzer', 'Affiliation': 'Behavioral Pharmacology Research Unit, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Eric C', 'Initials': 'EC', 'LastName': 'Strain', 'Affiliation': 'Behavioral Pharmacology Research Unit, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}]",Journal of dual diagnosis,['10.1080/15504263.2020.1794094'] 2645,32701478,Feasibility and Preliminary Effects of Implementing Acceptance and Commitment Therapy for Inpatients With Psychotic-Spectrum Disorders in a Clinical Psychiatric Intensive Care Setting.,"The aim of this study was to adapt Acceptance and Commitment Therapy for Inpatients (ACT-IN) for implementation in a typical hospital setting to prepare for a larger clinical trial. The sample consisted of 26 inpatients diagnosed with psychotic-spectrum disorders. Using an open trial design, patients received individual and group ACT-IN sessions during their stay. We assessed the feasibility/acceptability of ACT-IN and preliminary changes on patient outcomes at baseline, discharge, and 4-month follow-up. We successfully recruited and retained participants as planned. Patients reported satisfaction with treatment, and routine hospital staff showed adoption and fidelity to the intervention. Relative to baseline, patients demonstrated significant improvements in symptoms and functioning across the 4-month follow-up. The current study shows that ACT-IN may be feasible and acceptable for inpatients with psychotic disorders in a psychiatric intensive care setting and should be tested in a future effectiveness-implementation trial.",2020,"Relative to baseline, patients demonstrated significant improvements in symptoms and functioning across the 4-month follow-up.","['26 inpatients diagnosed with psychotic-spectrum disorders', 'inpatients with psychotic disorders in a psychiatric intensive care setting', 'Inpatients With Psychotic-Spectrum Disorders in a Clinical Psychiatric Intensive Care Setting']",['Implementing Acceptance and Commitment Therapy'],['symptoms and functioning'],"[{'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]","[{'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",26.0,0.105218,"Relative to baseline, patients demonstrated significant improvements in symptoms and functioning across the 4-month follow-up.","[{'ForeName': 'Brandon A', 'Initials': 'BA', 'LastName': 'Gaudiano', 'Affiliation': 'Alpert Medical School of Brown University.'}, {'ForeName': 'Stacy', 'Initials': 'S', 'LastName': 'Ellenberg', 'Affiliation': 'Binghamton University, Binghamton, NY, USA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Ostrove', 'Affiliation': 'Butler Hospital, Providence, RI, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Johnson', 'Affiliation': 'Michigan State University, Flint, MI, USA.'}, {'ForeName': 'Kim T', 'Initials': 'KT', 'LastName': 'Mueser', 'Affiliation': 'Boston University, Boston, MA, USA.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Furman', 'Affiliation': 'Alpert Medical School of Brown University.'}, {'ForeName': 'Ivan W', 'Initials': 'IW', 'LastName': 'Miller', 'Affiliation': 'Alpert Medical School of Brown University.'}]",Journal of cognitive psychotherapy,['10.1891/0889-8391.34.1.80'] 2646,32701480,A randomized trial of the effect of peer education on the sexual quality of life in patients with myocardial infarction.,"Background One of the factors associated with readmission is inappropriate sexual activity after myocardial infarction (MI). This study aimed to assess the effect of peer education on the sexual quality of life (SQOL) in patients with MI. Methods In this randomized controlled clinical trial, 70 patients with MI meeting the inclusion criteria were assigned to experimental or control groups using block randomization. Peer education for the intervention group was provided on the third day after MI. Education sessions lasted from 90 to 120 minutes. Data were collected using demographic, sexual quality of life-female (SQOL-F), and sexual quality of life-male (SQOL-M) questionnaires during the fourth week after MI. Results There was no significant difference between the two groups before the intervention in terms of demographic and SQOL. The mean of SQOL in the peer education group was significantly higher than the control group at the 4-week follow-up. Conclusions According to the results, using peer education is recommended for the sexual health care professionals.",2020,The mean of SQOL in the peer education group was significantly higher than the control group at the 4-week follow-up.,"['70 patients with MI meeting the inclusion criteria', 'patients with myocardial infarction', 'patients with MI']",['peer education'],"['Peer education', 'sexual quality of life', 'mean of SQOL', 'demographic and SQOL', 'demographic, sexual quality of life-female (SQOL-F), and sexual quality of life-male (SQOL-M) questionnaires', 'sexual quality of life (SQOL']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",70.0,0.0423129,The mean of SQOL in the peer education group was significantly higher than the control group at the 4-week follow-up.,"[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Abbasi', 'Affiliation': 'Department of Nursing, School of Nursing and Midwifery, Shahroud University of Medical Sciences, 7th Sq., Shahroud, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Ebrahimi', 'Affiliation': 'Randomized Controlled Trial Research Center, Shahroud University of Medical Sciences, Shahroud, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Bagheri', 'Affiliation': 'Department of Nursing, School of Nursing and Midwifery, Shahroud University of Medical Sciences, 7th Sq., Shahroud, Iran.'}, {'ForeName': 'Mohammad Hasan', 'Initials': 'MH', 'LastName': 'Basirinezhad', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Seyedmohammad', 'Initials': 'S', 'LastName': 'Mirhosseini', 'Affiliation': 'Student Research Committee, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Mohammadpourhodki', 'Affiliation': 'Department of Nursing, School of Nursing and Midwifery, Shahroud University of Medical Sciences, 7th Sq., Shahroud, Iran.'}]",Journal of complementary & integrative medicine,['10.1515/jcim-2019-0204'] 2647,32701508,Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.,"Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity among people living with HIV with a more aggressive course than in the general population. In a recent randomized placebo-controlled trial, we demonstrated that the growth hormone-releasing hormone analogue tesamorelin reduced liver fat and prevented fibrosis progression in HIV-associated NAFLD over one year. As such, tesamorelin is the first strategy that has shown to be effective against NAFLD among the HIV population. The current study leveraged paired liver biopsy specimens from this trial to identify hepatic gene pathways that are differentially modulated by tesamorelin versus placebo. Using Gene Set Enrichment Analysis (GSEA), we found that tesamorelin increased hepatic expression of hallmark gene sets involved in oxidative phosphorylation and decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division. Tesamorelin also reciprocally up- and downregulated curated gene sets associated with favorable and poor hepatocellular carcinoma prognosis, respectively. Notably, among tesamorelin-treated participants, these changes in hepatic expression correlated with improved fibrosis-related gene score. Our findings inform our knowledge of the biology of growth hormone action on the liver and provide a mechanistic basis for the observed clinical effects of tesamorelin on the liver.",2020,"Using Gene Set Enrichment Analysis (GSEA), we found that tesamorelin increased hepatic expression of hallmark gene sets involved in oxidative phosphorylation and decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division.","['HIV-associated NAFLD', 'people living with HIV with a more aggressive course than in the general population']","['growth hormone-releasing hormone analogue tesamorelin', 'tesamorelin', 'Nonalcoholic fatty liver disease (NAFLD', 'placebo']","['hepatic transcriptomic signatures', 'hepatic expression', 'liver fat and prevented fibrosis progression']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0037668', 'cui_str': 'Somatotropin releasing factor'}, {'cui': 'C1876200', 'cui_str': 'tesamorelin'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}]",,0.0417018,"Using Gene Set Enrichment Analysis (GSEA), we found that tesamorelin increased hepatic expression of hallmark gene sets involved in oxidative phosphorylation and decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division.","[{'ForeName': 'Lindsay T', 'Initials': 'LT', 'LastName': 'Fourman', 'Affiliation': 'Medicine, Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, United States of America.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Billingsley', 'Affiliation': 'Harvard Chan Bioinformatics Core, Harvard School of Pulic Health, Boston, United States of America.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Agyapong', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, United States of America.'}, {'ForeName': 'Shannan J', 'Initials': 'SJ', 'LastName': 'Ho Sui', 'Affiliation': 'Harvard Chan Bioinformatics Core, Harvard School of Public Health, Boston, United States of America.'}, {'ForeName': 'Meghan N', 'Initials': 'MN', 'LastName': 'Feldpausch', 'Affiliation': 'Medicine, Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, United States of America.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Purdy', 'Affiliation': 'National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States of America.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Zheng', 'Affiliation': 'Medicine, Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, United States of America.'}, {'ForeName': 'Chelsea S', 'Initials': 'CS', 'LastName': 'Pan', 'Affiliation': 'Medicine, Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, United States of America.'}, {'ForeName': 'Kathleen E', 'Initials': 'KE', 'LastName': 'Corey', 'Affiliation': 'Liver Center and GI Division, Massachusetts General Hospital and Harvard Medical School, Boston, United States of America.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Torriani', 'Affiliation': 'Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, United States of America.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Kleiner', 'Affiliation': 'Laboratory of Pathology, National Cancer Institute, Bethesda, United States of America.'}, {'ForeName': 'Colleen M', 'Initials': 'CM', 'LastName': 'Hadigan', 'Affiliation': 'National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States of America.'}, {'ForeName': 'Takara L', 'Initials': 'TL', 'LastName': 'Stanley', 'Affiliation': 'Medicine, Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, United States of America.'}, {'ForeName': 'Raymond T', 'Initials': 'RT', 'LastName': 'Chung', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, United States of America.'}, {'ForeName': 'Steven K', 'Initials': 'SK', 'LastName': 'Grinspoon', 'Affiliation': 'Medicine, Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, United States of America.'}]",JCI insight,['10.1172/jci.insight.140134'] 2648,32701512,Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.,"Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival, but up to 30% of patients exhibit recurrence. Using a genome-wide association study of patients entered on MA.27, a phase III randomized trial of anastrozole vs exemestane, we identified a SNP in CUB And Sushi Multiple Domains 1 (CSMD1) associated with breast cancer free interval, with the variant allele associated with fewer distant recurrences. Mechanistically, CSMD1 regulates CYP19 expression in a SNP-, and drug-dependent fashion and this regulation is different among three AIs, anastrozole, exemestane, and letrozole. Overexpression of CSMD1 sensitized AI-resistant cells to anastrozole but not to the other two AIs. The SNP in CSMD1 that was associated with increased CSMD1 and CYP19 expression levels increased anastrozole sensitivity, but not letrozole or exemestane sensitivity. Anastrozole degrades estrogen receptor α (ERα), especially in the presence of estradiol (E2). ER positive breast cancer organoids and AI- or fulvestrant-resistant breast cancer cells were more sensitive to anastrozole plus E2 than to AI alone. Our findings suggest that the CSMD1 SNP might help to predict AI response and anastrozole plus E2 serves as a potential new therapeutic strategy for patients with AI- or fulvestrant-resistant breast cancers.",2020,ER positive breast cancer organoids and AI- or fulvestrant-resistant breast cancer cells were more sensitive to anastrozole plus E2 than to AI alone.,"['postmenopausal breast cancer', 'patients with AI- or fulvestrant-resistant breast cancers']","['CSMD1 SNP', 'anastrozole', 'anastrozole, exemestane, and letrozole', 'anastrozole vs exemestane', 'Anastrozole', 'aromatase inhibitors']","['Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival', 'CSMD1 and CYP19 expression levels increased anastrozole sensitivity']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0935916', 'cui_str': 'fulvestrant'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}]","[{'cui': 'C0010435', 'cui_str': 'Cuba'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0752046', 'cui_str': 'Single Nucleotide Polymorphism'}, {'cui': 'C0290883', 'cui_str': 'anastrozole'}, {'cui': 'C0851344', 'cui_str': 'exemestane'}, {'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0593802', 'cui_str': 'Aromatase inhibitor'}]","[{'cui': 'C0593802', 'cui_str': 'Aromatase inhibitor'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0010435', 'cui_str': 'Cuba'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0003805', 'cui_str': 'Androstenedione Aromatase'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0290883', 'cui_str': 'anastrozole'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]",,0.0242212,ER positive breast cancer organoids and AI- or fulvestrant-resistant breast cancer cells were more sensitive to anastrozole plus E2 than to AI alone.,"[{'ForeName': 'Junmei', 'Initials': 'J', 'LastName': 'Cairns', 'Affiliation': 'Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, United States of America.'}, {'ForeName': 'James N', 'Initials': 'JN', 'LastName': 'Ingle', 'Affiliation': 'Division of Medical Oncology, Mayo Clinic, Rochester, United States of America.'}, {'ForeName': 'Tanda T M', 'Initials': 'TTM', 'LastName': 'Dudenkov', 'Affiliation': 'Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, United States of America.'}, {'ForeName': 'Krishna R', 'Initials': 'KR', 'LastName': 'Kalari', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, United States of America.'}, {'ForeName': 'Erin E', 'Initials': 'EE', 'LastName': 'Carlson', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, United States of America.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Na', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, United States of America.'}, {'ForeName': 'Aman U', 'Initials': 'AU', 'LastName': 'Buzdar', 'Affiliation': 'MD Anderson Cancer Center, University of Texas, Houston, United States of America.'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Robson', 'Affiliation': 'Breast Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, United States of America.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Ellis', 'Affiliation': 'Department of Medicine, Baylor College of Medicine, Houston, United States of America.'}, {'ForeName': 'Paul E', 'Initials': 'PE', 'LastName': 'Goss', 'Affiliation': 'MGH Cancer Center, Massachusetts General Hospital, Boston, United States of America.'}, {'ForeName': 'Lois E', 'Initials': 'LE', 'LastName': 'Shepherd', 'Affiliation': ""NCIC Clinical Trials Group, Queen's University, Kingston, Canada.""}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Goodnature', 'Affiliation': 'Mayo Clinic Breast Cancer Specialized Program of Research, Mayo Clinic, Rochester, United States of America.'}, {'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Goetz', 'Affiliation': 'Division of Medical Oncology, Mayo Clinic, Rochester, United States of America.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Weinshilboum', 'Affiliation': 'Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, United States of America.'}, {'ForeName': 'Hu', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, United States of America.'}, {'ForeName': 'Mehrab', 'Initials': 'M', 'LastName': 'Ghanat Bari', 'Affiliation': 'Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, United States of America.'}, {'ForeName': 'Liewei', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, United States of America.'}]",JCI insight,['10.1172/jci.insight.137571'] 2649,32701542,Reflection Versus Rebreathing for Administration of Sevoflurane During Minor Gynecological Surgery.,"BACKGROUND Contemporary anesthetic circle systems, when used at low fresh gas flows (FGF) to allow rebreathing of anesthetic, lack the ability for rapid dose titration. The small-scale anesthetic reflection device Anaesthetic Conserving Device (50mL Version; AnaConDa-S) permits administration of volatile anesthetics with high-flow ventilators. We compared washin, washout, and sevoflurane consumption using AnaConDa-S versus a circle system with low and minimal FGF. METHODS Forty patients undergoing breast surgery were randomized to receive 0.5 minimal alveolar concentration (MAC) sevoflurane with AnaConDa-S (21 patients, reflection group) or with a circle system (low flow: FGF = 0.2 minute ventilation [V'E], 9 patients; or minimal flow: 0.1 V'E, 10 patients). In the reflection group, syringe pump boluses were given for priming and washin; to simulate an open system, the FGF of the anesthesia ventilator was set to 18 L·min with the soda lime removed. In the other groups, the FGF was increased for washin (1 V'E for 8 minutes) and washout (3 V'E). For all patients, tidal volume was 7 mL·kg and the respiratory rate adjusted to ensure normoventilation. Analgesia was attained with remifentanil 0.3 µg·kg·min. Sevoflurane consumption was compared between the reflection group and the low- and minimal-flow groups, respectively, using a post hoc test (Fisher Least Significant Difference). To compare washin and washout (half-life), the low- and minimal-flow groups were combined. RESULTS Sevoflurane consumption was reduced in the reflection group (9.4 ± 2.0 vs 15.0 ± 3.5 [low flow, P < .001] vs 11.6 ± 2.3 mL·MAC h [minimal flow, P = .02]); washin (33 ± 15 vs 49 ± 12 seconds, P = .001) and washout (28 ± 15 vs 55 ± 19 seconds, P < .001) times were also significantly shorter. CONCLUSIONS In this clinical setting with short procedures, low anesthetic requirements, and low tidal volumes, AnaConDa-S decreased anesthetic consumption, washin, and washout times compared to a circle system.",2020,"washin (33 ± 15 vs 49 ± 12 seconds, P = .001) and washout (28 ± 15 vs 55 ± 19 seconds, P < .001)",['Forty patients undergoing breast surgery'],"['sevoflurane consumption using AnaConDa-S versus a circle system with low and minimal FGF', 'remifentanil 0.3 µg·kg·min', 'Anaesthetic Conserving Device (50mL Version; AnaConDa-S', ""0.5 minimal alveolar concentration (MAC) sevoflurane with AnaConDa-S (21 patients, reflection group) or with a circle system (low flow: FGF = 0.2 minute ventilation [V'E], 9 patients; or minimal flow: 0.1 V'E"", 'Sevoflurane']","['Sevoflurane consumption', 'low anesthetic requirements, and low tidal volumes, AnaConDa-S decreased anesthetic consumption, washin, and washout times', 'Analgesia', 'FGF']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0851312', 'cui_str': 'Breast surgery'}]","[{'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0206302', 'cui_str': 'Eunectes murinus'}, {'cui': 'C1531632', 'cui_str': 'Circle system'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0428716', 'cui_str': 'Fresh gas flow'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C4068885', 'cui_str': '0.3'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C1301655', 'cui_str': 'Minute ventilation'}, {'cui': 'C4517420', 'cui_str': '0.1'}]","[{'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C0206302', 'cui_str': 'Eunectes murinus'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0428716', 'cui_str': 'Fresh gas flow'}]",40.0,0.0534774,"washin (33 ± 15 vs 49 ± 12 seconds, P = .001) and washout (28 ± 15 vs 55 ± 19 seconds, P < .001)","[{'ForeName': 'Azzeddine', 'Initials': 'A', 'LastName': 'Kermad', 'Affiliation': 'From the Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, Saarland University Hospital Medical Center, Homburg/Saar, Germany.'}, {'ForeName': 'Madeleine', 'Initials': 'M', 'LastName': 'Appenzeller', 'Affiliation': 'From the Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, Saarland University Hospital Medical Center, Homburg/Saar, Germany.'}, {'ForeName': 'Emanuela', 'Initials': 'E', 'LastName': 'Morinello', 'Affiliation': 'From the Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, Saarland University Hospital Medical Center, Homburg/Saar, Germany.'}, {'ForeName': 'Sven Oliver', 'Initials': 'SO', 'LastName': 'Schneider', 'Affiliation': 'From the Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, Saarland University Hospital Medical Center, Homburg/Saar, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Kleinschmidt', 'Affiliation': 'From the Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, Saarland University Hospital Medical Center, Homburg/Saar, Germany.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': ""O'Gara"", 'Affiliation': 'Department of Anesthesiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Volk', 'Affiliation': 'From the Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, Saarland University Hospital Medical Center, Homburg/Saar, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Meiser', 'Affiliation': 'From the Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, Saarland University Hospital Medical Center, Homburg/Saar, Germany.'}]",Anesthesia and analgesia,['10.1213/ANE.0000000000005074'] 2650,32701564,Cardiac baroreflex function and vascular reactivity recovery after aerobic exercise in patients with early cirrhosis.,"OBJECTIVE To investigate the effects of aerobic exercise on the cardiac baroreflex function and vascular reactivity in patients with cirrhosis. METHODS Thirteen patients with cirrhosis were submitted to exercise and control intervention. At baseline and at 30 and 60 min following intervention, we evaluated cardiac baroreflex sensitivity (cBRS) and the baroreflex effectiveness index (BEI) using sequence technique. Vascular reactivity was assessed inducing reactive hyperemia before and 60 min after intervention. RESULTS At baseline, there was no difference (P interaction = 0.848) between exercise (from 3.0 ± 0.34 to 14.60 ± 1.06 ml/100ml/min) and control sessions (from 2.38 ± 0.10 to 13.73 ± 1.05 ml/100ml/min) regarding the increase in forearm blood flow during reactive hyperemia. However, this response was higher postexercise (from 3.38 ± 0.31 to 16.58 ± 1.58 ml/100ml/min) than postcontrol intervention (from 2.04 ± 0.23 to 11.98 ± 1.16 ml/100ml/min, P interaction < 0.001). BEI increased at 30- and 60-min postexercise (from 32 ± 7 to 42 ± 7 and 46 ± 7%), but not after control intervention (from 33 ± 6 to 31 ± 5 and 33 ± 7%, P interaction = 0.014). In contrast, cBRS decreased at 30-min postexercise (from 10.3 ± 1.9 to 8.2 ± 1.4 and 10.3 ± 2.1 ms/mmHg) and increased postcontrol intervention (from 7.9 ± 0.9 to 10.5 ± 1.5 and 10.3 ± 1.3 ms/mmHg, P interaction = 0.012). CONCLUSION The results suggest that a single bout of aerobic exercise improved cardiac baroreflex function and increased vascular reactivity in patients with early-stage cirrhosis.",2020,"At baseline, there was no difference (P interaction = 0.848) between exercise (from 3.0 ± 0.34 to 14.60 ± 1.06 ml/100ml/min) and control sessions (from 2.38 ± 0.10 to 13.73 ± 1.05 ml/100ml/min) regarding the increase in forearm blood flow during reactive hyperemia.","['patients with cirrhosis', 'Thirteen patients with cirrhosis', 'patients with early-stage cirrhosis', 'patients with early cirrhosis']","['exercise and control intervention', 'aerobic exercise']","['BEI', 'cBRS', 'Vascular reactivity', 'Cardiac baroreflex function and vascular reactivity recovery', 'cardiac baroreflex function and vascular reactivity', 'cardiac baroreflex sensitivity (cBRS) and the baroreflex effectiveness index (BEI', 'postcontrol intervention', 'forearm blood flow', 'vascular reactivity', 'reactive hyperemia', 'cardiac baroreflex function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C1299579', 'cui_str': 'Early cirrhosis'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}]","[{'cui': 'C0206162', 'cui_str': 'Baroreceptor reflex'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0016536', 'cui_str': 'Forearm structure'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0178824', 'cui_str': 'Reactive Hyperemia'}]",13.0,0.060632,"At baseline, there was no difference (P interaction = 0.848) between exercise (from 3.0 ± 0.34 to 14.60 ± 1.06 ml/100ml/min) and control sessions (from 2.38 ± 0.10 to 13.73 ± 1.05 ml/100ml/min) regarding the increase in forearm blood flow during reactive hyperemia.","[{'ForeName': 'Pedro Augusto de C', 'Initials': 'PAC', 'LastName': 'Mira', 'Affiliation': 'Cardiovascular Research Unit and Exercise Physiology, University Hospital and Faculty of Physical Education and Sports, Federal University of Juiz de Fora, Juiz de Fora, MG.'}, {'ForeName': 'Diane M N', 'Initials': 'DMN', 'LastName': 'Henrique', 'Affiliation': 'Faculty of Medicine.'}, {'ForeName': 'Renato Q', 'Initials': 'RQ', 'LastName': 'Loschi', 'Affiliation': 'Cardiovascular Research Unit and Exercise Physiology, University Hospital and Faculty of Physical Education and Sports, Federal University of Juiz de Fora, Juiz de Fora, MG.'}, {'ForeName': 'Maria F A', 'Initials': 'MFA', 'LastName': 'Falci', 'Affiliation': 'Cardiovascular Research Unit and Exercise Physiology, University Hospital and Faculty of Physical Education and Sports, Federal University of Juiz de Fora, Juiz de Fora, MG.'}, {'ForeName': 'Rosa V D', 'Initials': 'RVD', 'LastName': 'Guerrero', 'Affiliation': 'Cardiovascular Research Unit and Exercise Physiology, University Hospital and Faculty of Physical Education and Sports, Federal University of Juiz de Fora, Juiz de Fora, MG.'}, {'ForeName': 'Thompson B', 'Initials': 'TB', 'LastName': 'Machado Júnior', 'Affiliation': 'Hepatology Unit of Gastroenterology Department of University Hospital, Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil.'}, {'ForeName': 'Kátia V B D', 'Initials': 'KVBD', 'LastName': 'Barbosa', 'Affiliation': 'Hepatology Unit of Gastroenterology Department of University Hospital, Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil.'}, {'ForeName': 'Tarsila C da R', 'Initials': 'TCDR', 'LastName': 'Ribeiro', 'Affiliation': 'Hepatology Unit of Gastroenterology Department of University Hospital, Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil.'}, {'ForeName': 'Fábio H de L', 'Initials': 'FHL', 'LastName': 'Pace', 'Affiliation': 'Hepatology Unit of Gastroenterology Department of University Hospital, Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil.'}, {'ForeName': 'Daniel G', 'Initials': 'DG', 'LastName': 'Martinez', 'Affiliation': 'Cardiovascular Research Unit and Exercise Physiology, University Hospital and Faculty of Physical Education and Sports, Federal University of Juiz de Fora, Juiz de Fora, MG.'}, {'ForeName': 'Mateus C', 'Initials': 'MC', 'LastName': 'Laterza', 'Affiliation': 'Cardiovascular Research Unit and Exercise Physiology, University Hospital and Faculty of Physical Education and Sports, Federal University of Juiz de Fora, Juiz de Fora, MG.'}]",Blood pressure monitoring,['10.1097/MBP.0000000000000474'] 2651,32701597,Pharmacologic and psychological interventions for depression treatment in patients with kidney disease.,"PURPOSE OF REVIEW It remains controversial whether existing therapies, including pharmacologic and psychological interventions, are effective for treatment of depression in patients with chronic kidney disease (CKD) and end-stage kidney disease. RECENT FINDINGS Most studies of depression treatment were underpowered or uncontrolled. The CKD Antidepressant Sertraline Trial showed no benefit of a serotonin-selective reuptake inhibitor (SSRI), sertraline, over double-blind matched placebo for the treatment of depressive symptoms in patients with nondialysis CKD. A Trial of Sertraline vs. Cognitive Behavioral Therapy (CBT) for End-stage Renal Disease Patients with Depression showed improvement in depressive symptoms from baseline in both groups and a marginal benefit of sertraline over CBT that was of unclear clinical significance, given the lack of an active control group. SSRIs are associated with poor tolerability in clinical trials and serious adverse outcomes in large retrospective studies. SUMMARY Although the data do not support unlimited use of SSRIs in patients with CKD or end-stage kidney disease, it is reasonable to initiate a cautious trial of sertraline while closely monitoring for depressive symptom improvement and adverse effects. CBT is a low-risk, possibly effective intervention to treat major depressive disorder in patients with kidney disease who have access to such treatments.",2020,"The CKD Antidepressant Sertraline Trial showed no benefit of a serotonin-selective reuptake inhibitor (SSRI), sertraline, over double-blind matched placebo for the treatment of depressive symptoms in patients with nondialysis CKD.","['patients with kidney disease', 'patients with nondialysis CKD', 'patients with CKD or end-stage kidney disease', 'patients with kidney disease who have access to such treatments', 'patients with chronic kidney disease (CKD) and end-stage kidney disease']","['serotonin-selective reuptake inhibitor (SSRI), sertraline', 'CBT', 'Pharmacologic and psychological interventions', 'Sertraline vs. Cognitive Behavioral Therapy (CBT', 'placebo']",['depressive symptoms'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",,0.0565791,"The CKD Antidepressant Sertraline Trial showed no benefit of a serotonin-selective reuptake inhibitor (SSRI), sertraline, over double-blind matched placebo for the treatment of depressive symptoms in patients with nondialysis CKD.","[{'ForeName': 'L Parker', 'Initials': 'LP', 'LastName': 'Gregg', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center.'}, {'ForeName': 'S Susan', 'Initials': 'SS', 'LastName': 'Hedayati', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center.'}]",Current opinion in nephrology and hypertension,['10.1097/MNH.0000000000000629'] 2652,32701637,"Effects of high frequency neuronavigated repetitive transcranial magnetic stimulation in fibromyalgia syndrome: A double-blinded, randomized controlled study.","OBJECTIVE The primary aim of the study was to investigate the effect of 10 Hz repetitive transcranial magnetic stimulation (rTMS) to the left dorsolateral prefrontal cortex (DLPFC) on pain in fibromyalgia. Secondary aims were to determine its effects on stiffness, fatigue, quality of life, depression/anxiety and cognitive functions. DESIGN Twenty participants were randomized into 2 groups. Group A received 10 Hz rTMS to left DLPFC and Group B received sham stimulation. Visual analogue scale (VAS)-pain, VAS-stiffness, fibromyalgia impact questionnaire (FIQ), and fatigue severity scale (FSS) were assessed at the baseline, 2nd and 6th weeks, while hospital anxiety depression scale (HADS) and Addenbrooke's cognitive examination (ACE-R) were assessed at the baseline and 6th-week. RESULTS There was no significant difference in VAS-pain and FSS within and between groups over time (p>0.05). In group A, significant improvement was found in VAS-stiffness and FIQ at the 2nd week in comparison to the baseline (p<0.05). However, no significant difference was detected in comparison to group B. There was no significant change in HADS scores between and within groups. All cognitive measures were similar in terms of differences from baseline between the groups (p>0.05). CONCLUSION High frequency rTMS to the left DLPFC did not show any significant beneficial effect on pain, stiffness, fatigue, quality of life, mood and cognitive state over sham stimulation.",2020,"High frequency rTMS to the left DLPFC did not show any significant beneficial effect on pain, stiffness, fatigue, quality of life, mood and cognitive state over sham stimulation.","['Twenty participants were randomized into 2 groups', 'pain in fibromyalgia', 'fibromyalgia syndrome']","['10 Hz repetitive transcranial magnetic stimulation (rTMS', '10 Hz rTMS to left DLPFC and Group B received sham stimulation', 'high frequency neuronavigated repetitive transcranial magnetic stimulation']","['Visual analogue scale (VAS)-pain, VAS-stiffness, fibromyalgia impact questionnaire (FIQ), and fatigue severity scale (FSS', 'stiffness, fatigue, quality of life, depression/anxiety and cognitive functions', 'HADS scores', 'VAS-pain and FSS', 'pain, stiffness, fatigue, quality of life, mood and cognitive state', ""hospital anxiety depression scale (HADS) and Addenbrooke's cognitive examination (ACE-R"", 'VAS-stiffness and FIQ']","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0451107', 'cui_str': 'Depression anxiety scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0050385', 'cui_str': 'AC protocol'}]",20.0,0.0960521,"High frequency rTMS to the left DLPFC did not show any significant beneficial effect on pain, stiffness, fatigue, quality of life, mood and cognitive state over sham stimulation.","[{'ForeName': 'İbrahim', 'Initials': 'İ', 'LastName': 'Bİlİr', 'Affiliation': 'Katip Çelebi University, Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Izmir, TURKEY.'}, {'ForeName': 'Ayhan', 'Initials': 'A', 'LastName': 'AŞkin', 'Affiliation': 'Katip Çelebi University, Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Izmir, TURKEY.'}, {'ForeName': 'İlker', 'Initials': 'İ', 'LastName': 'ŞengÜl', 'Affiliation': 'Katip Çelebi University, Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Izmir, TURKEY.'}, {'ForeName': 'Aliye', 'Initials': 'A', 'LastName': 'Tosun', 'Affiliation': 'Katip Çelebi University, Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Izmir, TURKEY.'}]",American journal of physical medicine & rehabilitation,['10.1097/PHM.0000000000001536'] 2653,32701652,Intradural artery dilation during experimentally induced migraine attacks.,"The middle meningeal artery is a proposed surrogate marker for activation of trigeminal nociceptors during migraine. Previous studies focused on the extracranial part of the artery, hence vasoreactivity in the intradural arteries during migraine is unknown.Thirty-four patients with migraine without aura were given sildenafil on one day and calcitonin gene-related peptide on another in double-blind crossover fashion. Patients were scanned with 3.0 tesla MR angiography before drug administration and again 6 hours later during induced attacks of migraine. We measured circumference of the intradural segment of the middle meningeal artery before and during induced migraine attacks. The middle cerebral and superficial temporal arteries were also examined.Fourteen patients had attacks during the second scan after both study drugs and 11 had a migraine after either one or the other, resulting in a total of 39 attacks included in the final analysis. Mean circumference of the intradural middle meningeal artery at baseline was 3.18 mm with an increase of 0.11 mm during attacks (p=0.005), corresponding to a relative dilation of 3.6% [95% CI: 1.4 to 5.7 %]. Middle cerebral artery dilated by 9.4 % [95% CI: 7.1 to 11.7 %] and superficial temporal artery by 2.3 % [95% CI: 0.2 to 4.4 %].Our study shows that the intradural middle meningeal artery and the middle cerebral artery are dilated during migraine induced by calcitonin gene-related peptide as well as sildenafil. We propose that intradural vasculature is affected by migraine-driven activation of trigeminal afferents during migraine attacks.",2020,Middle cerebral artery dilated by 9.4 % [95% CI: 7.1 to 11.7 %] and superficial temporal artery by 2.3 % [95% CI: 0.2 to 4.4 %].Our,"['Thirty-four patients with migraine without aura', 'Fourteen patients had attacks during the second scan after both study drugs and 11 had a migraine after either one or the other, resulting in a total of 39 attacks included in the final analysis']","['calcitonin gene-related peptide', 'sildenafil']","['Mean circumference of the intradural middle meningeal artery', 'superficial temporal artery', 'Middle cerebral artery dilated']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0338480', 'cui_str': 'Migraine without aura'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0013175', 'cui_str': 'Clinical drug trial'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0006669', 'cui_str': 'Calcitonin gene-related peptide'}, {'cui': 'C0529793', 'cui_str': 'sildenafil'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0226147', 'cui_str': 'Structure of middle meningeal artery'}, {'cui': 'C0226130', 'cui_str': 'Structure of superficial temporal artery'}, {'cui': 'C0149566', 'cui_str': 'Structure of middle cerebral artery'}, {'cui': 'C0700124', 'cui_str': 'Ectatic'}]",,0.0474213,Middle cerebral artery dilated by 9.4 % [95% CI: 7.1 to 11.7 %] and superficial temporal artery by 2.3 % [95% CI: 0.2 to 4.4 %].Our,"[{'ForeName': 'Casper Emil', 'Initials': 'CE', 'LastName': 'Christensen', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.'}, {'ForeName': 'Samaira', 'Initials': 'S', 'LastName': 'Younis', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Lindberg', 'Affiliation': 'Functional Imaging Unit, Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'de Koning', 'Affiliation': 'Division of Image Processing, Department of Radiology, Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Tolnai', 'Affiliation': 'Department of Radiology, Rigshospitalet Glostrup, Denmark.'}, {'ForeName': 'Olaf Bjarne', 'Initials': 'OB', 'LastName': 'Paulson', 'Affiliation': 'Neurobiology Research Unit, Department of Neurology, Rigshospitalet Blegdamsvej, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.'}, {'ForeName': 'Henrik Bo', 'Initials': 'HB', 'LastName': 'Wiberg Larsson', 'Affiliation': 'Functional Imaging Unit, Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.'}, {'ForeName': 'Faisal Mohammad', 'Initials': 'FM', 'LastName': 'Amin', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.'}, {'ForeName': 'Messoud', 'Initials': 'M', 'LastName': 'Ashina', 'Affiliation': 'Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.'}]",Pain,['10.1097/j.pain.0000000000002008'] 2654,32701665,Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.,"OBJECTIVE The Menopause Strategies: Finding Lasting Answers for Symptoms and Health network conducted three randomized clinical trials (RCTs) testing six interventions treating vasomotor symptoms (VMS), and also collected menopause-related quality of life (QOL) measures. A fourth RCT assessed an intervention for insomnia symptoms among women with VMS. We describe these seven interventions' effects on menopause-related QOL relative to control in women with VMS. METHODS We pooled individual-level data from 1,005 peri- and postmenopausal women with 14 or more VMS/week across the four RCTs. Interventions included escitalopram 10 to 20 mg/d; yoga/aerobic exercise; 1.8 g/d omega-3-fatty acids; oral 17-beta-estradiol 0.5 mg/d; venlafaxine XR 75 mg/d; and cognitive behavioral therapy for insomnia (CBT-I). Outcomes measures were the Menopause-specific Quality of Life scale and its subscales. RESULTS Significant improvements in total Menopause-specific Quality of Life from baseline were observed with estradiol, escitalopram, CBT-I, and yoga, with mean decreases of 0.3 to 0.5 points relative to control. The largest improvement in the vasomotor subscale was observed with estradiol (-1.2 points), with more modest but significant effects seen with escitalopram, yoga, and CBT-I. Significant improvements in the psychosocial subscale were observed for escitalopram, venlafaxine, and CBT-I. For the physical subscale, the greatest improvement was observed for CBT-I and exercise, whereas for the sexual subscale, the greatest improvement was observed for CBT-I, with yoga and estradiol demonstrating smaller effects. CONCLUSIONS These results suggest that for menopause-related QOL, women have a variety of treatment strategies to choose from and can select an approach based on most bothersome symptoms and individual preferences.",2020,"RESULTS Significant improvements in total Menopause-specific Quality of Life from baseline were observed with estradiol, escitalopram, CBT-I, and yoga, with mean decreases of 0.3 to 0.5 points relative to control.","['1,005 peri- and postmenopausal women with 14 or more VMS/week across the four RCTs', 'women with VMS']","['escitalopram 10 to 20\u200amg/d; yoga/aerobic exercise; 1.8\u200ag/d omega-3-fatty acids; oral 17-beta-estradiol 0.5\u200amg/d; venlafaxine XR 75\u200amg/d; and cognitive behavioral therapy', 'venlafaxine', 'pharmacologic and nonpharmacologic interventions']","['vasomotor subscale', 'Menopause-specific Quality of Life scale and its subscales', 'menopause-related quality of life', 'insomnia symptoms', 'total Menopause-specific Quality of Life', 'psychosocial subscale']","[{'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C1099456', 'cui_str': 'Escitalopram'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0078569', 'cui_str': 'venlafaxine'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",,0.0397297,"RESULTS Significant improvements in total Menopause-specific Quality of Life from baseline were observed with estradiol, escitalopram, CBT-I, and yoga, with mean decreases of 0.3 to 0.5 points relative to control.","[{'ForeName': 'Susan J', 'Initials': 'SJ', 'LastName': 'Diem', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN.'}, {'ForeName': 'Andrea Z', 'Initials': 'AZ', 'LastName': 'LaCroix', 'Affiliation': 'Department of Family Medicine and Public Health, University of California - San Diego, La Jolla, CA.'}, {'ForeName': 'Susan D', 'Initials': 'SD', 'LastName': 'Reed', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Washington, Seattle, WA.'}, {'ForeName': 'Joseph C', 'Initials': 'JC', 'LastName': 'Larson', 'Affiliation': 'Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Katherine M', 'Initials': 'KM', 'LastName': 'Newton', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute, Seattle, WA.'}, {'ForeName': 'Kristine E', 'Initials': 'KE', 'LastName': 'Ensrud', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN.'}, {'ForeName': 'Nancy F', 'Initials': 'NF', 'LastName': 'Woods', 'Affiliation': 'School of Nursing, University of Washington, Seattle, WA.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Guthrie', 'Affiliation': 'Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.'}]","Menopause (New York, N.Y.)",['10.1097/GME.0000000000001597'] 2655,32701682,Mechanical Evaluation of 2.7- Versus 3.5-mm Plating Constructs for Midshaft Clavicle Fractures.,"OBJECTIVES This study compares the mechanical performance of 2.7- and 3.5-mm plating constructs for the treatment of midshaft clavicle fractures. METHODS Twenty-four synthetic clavicles were randomly divided into four treatment groups-Synthes 2.7-mm cold-worked calcaneal reconstruction plate with 6 (CRP6) or 8 bicortical screws (CRP8); Synthes 3.5-mm LCP reconstruction plate (RP; and Synthes 3.5-mm LCP precontoured superior-anterior clavicle plate (PCRP). All clavicles were plated, a wedge-shaped inferior cortical defect was created, and testing was performed using a cantilever bending model to determine bending stiffness and yield point for each construct. RESULTS Bending stiffness for the 3.5-mm PCRP construct was markedly higher when compared with the other three constructs, whereas the 3.5-mm RP construct was markedly stiffer than both of the 2.7-mm CR constructs. The yield point for the 3.5-mm PCRP construct was greater than the other three constructs; however, the yield point for the 2.7-mm CRP with six screws and with eight screws was higher than the 3.5-mm RP construct. The amount of displacement required to reach the yield point was highest for the 2.7-mm CRP with six screws. and this was markedly higher than the values for the other three constructs. DISCUSSION The 3.5-mm plates demonstrated increased bending stiffness compared with the 2.7-mm plates. Despite the lower resistance to bending forces, the cold-worked 2.7-mm plate exhibited a markedly higher yield point and required markedly more superior to inferior displacement to initiate plastic deformation when compared with the 3.5-mm LCP RP. LEVEL OF EVIDENCE Level IV.",2020,"RESULTS Bending stiffness for the 3.5-mm PCRP construct was markedly higher when compared with the other three constructs, whereas the 3.5-mm RP construct was markedly stiffer than both of the 2.7-mm CR constructs.","['Twenty-four synthetic clavicles', 'Midshaft Clavicle Fractures']",['Synthes 2.7-mm cold-worked calcaneal reconstruction plate with 6 (CRP6) or 8 bicortical screws (CRP8); Synthes 3.5-mm LCP reconstruction plate (RP; and Synthes 3.5-mm LCP precontoured superior-anterior clavicle plate (PCRP'],['bending stiffness'],"[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0008913', 'cui_str': 'Bone structure of clavicle'}, {'cui': 'C0159658', 'cui_str': 'Fracture of clavicle'}]","[{'cui': 'C4517635', 'cui_str': '2.7'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0006655', 'cui_str': 'Bone structure of calcaneum'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C0023234', 'cui_str': 'Coxa plana'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0008913', 'cui_str': 'Bone structure of clavicle'}]","[{'cui': 'C0011119', 'cui_str': 'Bends'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}]",24.0,0.0172024,"RESULTS Bending stiffness for the 3.5-mm PCRP construct was markedly higher when compared with the other three constructs, whereas the 3.5-mm RP construct was markedly stiffer than both of the 2.7-mm CR constructs.","[{'ForeName': 'Mohammad M', 'Initials': 'MM', 'LastName': 'Alzahrani', 'Affiliation': 'From the Department of Orthopaedics (Dr. Alzahrani), College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia, the Rocky Mountain Orthopaedic Associates (Dr. Cota), Grand Junction, CO, the Department of Orthopedic Surgery (Dr. Alkhelaifi), ASPETAR, Orthopaedic and Sports Medicine Hospital, Doha, Qatar, and the Division of Orthopaedic Surgery (Dr. Harvey), McGill University Health Center, Montreal, Quebec, Canada.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Cota', 'Affiliation': ''}, {'ForeName': 'Khalid', 'Initials': 'K', 'LastName': 'Alkhelaifi', 'Affiliation': ''}, {'ForeName': 'Edward J', 'Initials': 'EJ', 'LastName': 'Harvey', 'Affiliation': ''}]",The Journal of the American Academy of Orthopaedic Surgeons,['10.5435/JAAOS-D-19-00495'] 2656,32701739,"""Effect of Tracheal Intubation Mode on Cuff Pressure During Retractor Splay and Dysphonia Recovery after for Anterior Cervical Spine Surgery: A Randomized Clinical Trial"" by Huang et al.",,2020,,['Anterior Cervical Spine Surgery'],['Tracheal Intubation Mode'],['Cuff Pressure'],"[{'cui': 'C0442011', 'cui_str': 'Anterior cervical spine approach'}, {'cui': 'C0920347', 'cui_str': 'Procedure on spinal cord'}]","[{'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}]","[{'cui': 'C0441107', 'cui_str': 'Device cuff'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}]",,0.0696395,,"[{'ForeName': 'Vishal', 'Initials': 'V', 'LastName': 'Kumar', 'Affiliation': 'Department of Orthopaedics, PGIMER, Sector 12, Chandigarh, India.'}, {'ForeName': 'Amit Kumar', 'Initials': 'AK', 'LastName': 'Salaria', 'Affiliation': ''}, {'ForeName': 'Aditya', 'Initials': 'A', 'LastName': 'Aggarwal', 'Affiliation': ''}]",Spine,['10.1097/BRS.0000000000003578'] 2657,32701744,"Letter to Editor-Postoperative Single Shot Epidural Fentanyl and Bupivacaine for Postoperative Analgesia After Lumbar Decompression: A Prospective, Double-Blind Randomized Study.",,2020,,[],['Bupivacaine'],['Postoperative Analgesia'],[],"[{'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]","[{'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}]",,0.257894,,"[{'ForeName': 'Vishal', 'Initials': 'V', 'LastName': 'Kumar', 'Affiliation': 'Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Avinash', 'Initials': 'A', 'LastName': 'Kumar', 'Affiliation': ''}, {'ForeName': 'Amit Kumar', 'Initials': 'AK', 'LastName': 'Salaria', 'Affiliation': ''}]",Spine,['10.1097/BRS.0000000000003584'] 2658,32701767,Should Overnight Orthokeratology Patients Wear Their Lenses During Their Afternoon Nap?,"PURPOSE The purpose of this study was to evaluate changes in visual acuity, corneal curvature, elevation, pachymetry, and objective quality of vision of experienced orthokeratology patients using their contact lenses during a simulated 30-min afternoon nap. METHOD Twelve patients aged 30.8±8.3 years were recruited for the study, with a history of overnight orthokeratology of 27.4±23.0 months. Patients were instructed to close their eyes for 30 min while wearing their contact lenses or without lenses. Anterior corneal curvature, elevation, and corneal pachymetry were assessed with the Pentacam Scheimpflug System at 17 predefined corneal locations, and the HD Analyzer (Terrassa, Spain) was used to measure objective quality of vision. Measurements were conducted before eye closure (baseline), immediately after eye opening/lens removal (M1), and 30 min later (M2). RESULTS No statistically significant differences were found in anterior corneal curvature and elevation between baseline values and M1 or M2, with and without contact lenses. Corneal swelling at M1 was greater without contact lenses (change in central corneal thickness of 2.3%±3.1%, P=0.001) than with contact lenses (1.7%±1.3%, P<0.001). Recovery at M2 was slower when lenses were worn. A statistically significant improvement in objective quality of vision and visual acuity was found only when patients napped with their lenses. CONCLUSIONS Even if no significant changes were found in corneal curvature and elevation, patients of overnight orthokeratology may benefit from using their contact lenses during their afternoon nap in terms of objective quality of vision and visual acuity.",2020,"No statistically significant differences were found in anterior corneal curvature and elevation between baseline values and M1 or M2, with and without contact lenses.","['Twelve patients aged 30.8±8.3 years were recruited for the study, with a history of overnight orthokeratology of 27.4±23.0 months']","['Overnight Orthokeratology Patients Wear Their Lenses', 'close their eyes for 30 min while wearing their contact lenses or without lenses']","['objective quality of vision and visual acuity', 'objective quality of vision', 'Anterior corneal curvature, elevation, and corneal pachymetry', 'corneal curvature and elevation', 'visual acuity, corneal curvature, elevation, pachymetry, and objective quality of vision', 'Corneal swelling at M1', 'anterior corneal curvature and elevation between baseline values and M1 or M2, with and without contact lenses']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0439583', 'cui_str': 'Overnight'}, {'cui': 'C1533088', 'cui_str': 'Orthokeratology'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0439583', 'cui_str': 'Overnight'}, {'cui': 'C1533088', 'cui_str': 'Orthokeratology'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023317', 'cui_str': 'Lens clear'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0009836', 'cui_str': 'Contact lenses'}, {'cui': 'C0332288', 'cui_str': 'Without'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0412514', 'cui_str': 'Corneal pachymetry'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0009836', 'cui_str': 'Contact lenses'}]",12.0,0.0552198,"No statistically significant differences were found in anterior corneal curvature and elevation between baseline values and M1 or M2, with and without contact lenses.","[{'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Pérez-Corral', 'Affiliation': 'Department of Optics and Optometry (J.P.-C., G.C.), Universitat Politècnica de Catalunya, School of Optics and Optometry, Terrassa, Spain; Department of Optics, Pharmacology, and Anatomy (D.P.P.), University of Alicante, Alicante, Spain; and Department of Contact Lenses (Y.A., M.G.), Institut Català de Retina, Barcelona, Spain.'}, {'ForeName': 'Genis', 'Initials': 'G', 'LastName': 'Cardona', 'Affiliation': ''}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Piñero', 'Affiliation': ''}, {'ForeName': 'Yolanda', 'Initials': 'Y', 'LastName': 'Aradilla', 'Affiliation': ''}, {'ForeName': 'Mireia', 'Initials': 'M', 'LastName': 'García', 'Affiliation': ''}]",Eye & contact lens,['10.1097/ICL.0000000000000732'] 2659,32701768,"The Early Effects of Alcohol Consumption on Functional Visual Acuity, Tear Functions, and the Ocular Surface.","PURPOSE We investigated the early effects of alcohol intake on tear functions and ocular surface health in this prospective controlled study. METHODS Forty-four eyes of 22 subjects (17 males, 5 females; mean age: 35.3 years) who drank 200 mL of 25% Japanese vodka and 44 eyes of age- and sex-matched 22 control subjects who drank water were investigated. Subjects were requested to refrain from alcohol consumption from the previous day and food ingestion 6 hr before the study. Each subject consumed exactly the same order prepared dinner and same quantity of alcohol over the same time frame. Subjects underwent breath alcohol level, tear evaporation and blink rate, tear lipid layer interferometry, tear film break-up time (BUT), fluorescein and Rose Bengal stainings, Schirmer test, and visual analog scale (VAS) evaluation of dry eye symptoms before, as well as 2 and 12 hr after alcohol intake. RESULTS The mean breath alcohol level was significantly higher in the alcohol group compared to the water group at 2 and 12 hr (P<0.001). The mean tear evaporation increased significantly from 2.5×10 to 8.8×10 gr/cm/sec 12 hr after alcohol intake (P<0.001). The mean BUT shortened significantly from 15.0±5.0 to 5.0±2.5 sec 12 hr after alcohol intake. Lipid layer interferometry showed signs of tear film thinning 12 hr after alcohol intake in all subjects of the alcohol intake group, which was not observed in the water group. The mean blink rates increased significantly from 10.6±1.5 blinks/min to 13.5±0.9 blinks/min and 15.1±1.2 blinks/min at 2 and 12 hr, respectively, in the alcohol group (P<0.001). The Schirmer test values decreased significantly 12 hr after alcohol intake (P<0.001). The mean VAS score for dryness increased from baseline significantly in the alcohol group at 12 hr (P<0.001). No significant time-wise changes in tear functions were observed in the water group. CONCLUSION The tear film and ocular surface epithelia showed early and distinctive quantitative and qualitative changes associated with visual disturbances after alcohol intake.",2020,The tear film and ocular surface epithelia showed early and distinctive quantitative and qualitative changes associated with visual disturbances after alcohol intake.,"['Forty-four eyes of 22 subjects (17 males, 5 females; mean age: 35.3 years) who drank 200 mL of 25% Japanese vodka and 44 eyes of age- and sex-matched 22 control subjects who drank water were investigated']","['alcohol intake', 'Alcohol Consumption', 'Lipid layer interferometry']","['mean blink rates', 'mean tear evaporation', 'Schirmer test values', 'BUT), fluorescein and Rose Bengal stainings, Schirmer test, and visual analog scale (VAS) evaluation of dry eye symptoms', 'time-wise changes in tear functions', 'Functional Visual Acuity, Tear Functions, and the Ocular Surface', 'mean BUT', 'breath alcohol level, tear evaporation and blink rate, tear lipid layer interferometry, tear film break-up time', 'mean VAS score for dryness', 'mean breath alcohol level']","[{'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0452263', 'cui_str': 'Vodka'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}]","[{'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0021730', 'cui_str': 'Interferometry'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005757', 'cui_str': 'Blinking'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0200152', 'cui_str': ""Schirmer's test""}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0016314', 'cui_str': 'Fluoresceins'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0444826', 'cui_str': 'Bengal'}, {'cui': 'C0487602', 'cui_str': 'Staining method'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0013238', 'cui_str': 'Dry Eye Disease'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0202306', 'cui_str': 'Ethanol measurement, breath'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0021730', 'cui_str': 'Interferometry'}, {'cui': 'C0429495', 'cui_str': 'Tear film break-up time'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0129406,The tear film and ocular surface epithelia showed early and distinctive quantitative and qualitative changes associated with visual disturbances after alcohol intake.,"[{'ForeName': 'Cem', 'Initials': 'C', 'LastName': 'Simsek', 'Affiliation': 'Department of Ophthalmology (C.S., T.K., M.D., T.W., K.N., K.T.), Keio University School of Medicine, Tokyo, Japan; Ajisai Eye Clinic (M.T.), Musashinoshi, Chiba, Japan; Eye Clinic (Y.T.), Kawasaki Municipal Ida Hospital, Kawasaki, Japan; Department of Ophthalmology (O.I.), Tokyo Dental College, Chiba, Japan; Minamiaoyama Eye Clinic (I.T.), Tokyo, Japan; and Department of Ophthalmology (C.S.), Mugla Sitki Kocman University School of Medicine, Mugla, Turkey.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Kojima', 'Affiliation': ''}, {'ForeName': 'Murat', 'Initials': 'M', 'LastName': 'Dogru', 'Affiliation': ''}, {'ForeName': 'Mari', 'Initials': 'M', 'LastName': 'Tanaka', 'Affiliation': ''}, {'ForeName': 'Yoji', 'Initials': 'Y', 'LastName': 'Takano', 'Affiliation': ''}, {'ForeName': 'Tais', 'Initials': 'T', 'LastName': 'Wakamatsu', 'Affiliation': ''}, {'ForeName': 'Osama', 'Initials': 'O', 'LastName': 'Ibrahim', 'Affiliation': ''}, {'ForeName': 'Ikuko', 'Initials': 'I', 'LastName': 'Toda', 'Affiliation': ''}, {'ForeName': 'Kazuno', 'Initials': 'K', 'LastName': 'Negishi', 'Affiliation': ''}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Tsubota', 'Affiliation': ''}]",Eye & contact lens,['10.1097/ICL.0000000000000725'] 2660,32701780,Feasibility and Acceptability of a Self-Management Program for Patients With Rheumatoid Arthritis.,"BACKGROUND Joint activity and protection are key components in the management of rheumatoid arthritis (RA). Despite a shift from care in health settings to empowering patients to play an active role in the day-to-day management of their own chronic conditions, there is little evidence on RA self-management, especially for Chinese patients. PURPOSE This pilot study sought to determine the feasibility and acceptability of a self-management program for patients with RA in Taiwan. METHODS Participants were recruited at a medical center in northern Taiwan. The intervention group participated in a 6-week self-management program; the control group received standard rheumatology care. Both groups underwent baseline assessments before the intervention and at 12 weeks. RESULTS A total of 32 participants were recruited: 15 in the intervention group and 17 in the control group. Patients in the intervention group found the self-management protocol beneficial to their joint protection and activity behaviors and reported higher motivation to perform RA self-management. The posttest score for joint protection and activity self-management behavior were significantly greater for the intervention group than for the control group (p = .02). CONCLUSIONS Participants in the intervention group were highly satisfied with home visits (which included peer story-telling and goal setting) and telephone calls to support their daily home-based joint protection and self-management activities (which included self-monitoring and self-evaluation). To mitigate the fear of scammers, researchers should begin by building a trust relationship with participants.",2020,Patients in the intervention group found the self-management protocol beneficial to their joint protection and activity behaviors and reported higher motivation to perform RA self-management.,"['Participants were recruited at a medical center in northern Taiwan', 'A total of 32 participants were recruited: 15 in the intervention group and 17 in the control group', 'patients with RA in Taiwan', 'Chinese patients', 'Patients With Rheumatoid Arthritis']","['Self-Management Program', 'self-management program', '6-week self-management program; the control group received standard rheumatology care']","['feasibility and acceptability', 'posttest score for joint protection and activity self-management behavior', 'self-management protocol beneficial to their joint protection and activity behaviors', 'Feasibility and Acceptability', 'highly satisfied with home visits']","[{'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}]","[{'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0035452', 'cui_str': 'Rheumatology'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}]",32.0,0.0308169,Patients in the intervention group found the self-management protocol beneficial to their joint protection and activity behaviors and reported higher motivation to perform RA self-management.,"[{'ForeName': 'Jung-Hua', 'Initials': 'JH', 'LastName': 'Shao', 'Affiliation': 'Jung-Hua Shao, PhD, RN, Assistant Professor, School of Nursing, College of Medicine, Chang Gung University, Guishan District, Taoyuan City, Taiwan; and Assistant Research Fellow, Chang Gung Memorial Hospital, Linkou, Taiwan. Kuang-Hui Yu, PhD, Associate Professor, Chang Gung Memorial Hospital, Linkou, Taiwan. Su-Hui Chen, PhD, RN, Professor, School of Nursing, Chang Gung University of Science and Technology, Guishan District, Taoyuan City, Taiwan; and Research Fellow, Chang Gung Memorial Hospital, Linkou, Taiwan.'}, {'ForeName': 'Kuang-Hui', 'Initials': 'KH', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Su-Hui', 'Initials': 'SH', 'LastName': 'Chen', 'Affiliation': ''}]",Orthopedic nursing,['10.1097/NOR.0000000000000676'] 2661,32701823,Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-Existing NRTI Resistance.,"BACKGROUND Study 4030 was a phase 3, randomized, double-blinded study of 565 HIV-1 RNA suppressed participants switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+F/TAF. NRTI, NNRTI, and PI resistance (-R) was allowed, but INSTI-R was excluded. Here, we describe the detailed resistance analysis. METHODS Historical plasma HIV-1 RNA genotypes and baseline proviral DNA genotypes were analyzed. Documented or investigator-suspected NRTI-R was grouped for stratification into three categories of level of resistance. Viral blips were assessed through Week 48. Virologic failures had genotypic and phenotypic resistance analyses at Week 48, confirmed failure, or last visit, if HIV-1 RNA did not resuppress to <50 copies/mL while on study drug. RESULTS In total, 83% (470/565) of participants had baseline genotypic data available with NRTI-R detected in 24% (138/565), including 5% (30/565) with K65R/E/N or ≥3 thymidine analog mutations (TAMs) and 19% (108/565) with other NRTI-R mutations. M184V/I was present in 14% (81/565). Pre-existing INSTI-R mutations were found in 4% (20/565) of participants. Primary NNRTI-R and PI-R mutations were present in 21% (118/565) and 7% (38/565) of participants. High rates of viral suppression were maintained in all groups through Week 48; blips were observed in only 15 participants (2.7%). Three participants met criteria for resistance analysis (all in DTG+F/TAF arm); none developed treatment-emergent resistance to study drugs. CONCLUSIONS Participants with baseline NRTI resistance, much of which was previously undocumented, maintained suppression 48 weeks after switching to B/F/TAF or DTG+F/TAF triple therapy. Blips and virologic failure were uncommon using either regimen, with no treatment-emergent resistance.",2020,High rates of viral suppression were maintained in all groups through Week 48; blips were observed in only 15 participants (2.7%).,"['Three participants met criteria for resistance analysis (all in DTG+F/TAF arm); none developed treatment-emergent resistance to study drugs', '565 HIV-1 RNA suppressed participants switching to']","['bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+F/TAF', 'Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF']","['NRTI, NNRTI, and PI resistance (-R', 'High rates of viral suppression', 'Primary NNRTI-R and PI-R mutations', 'Viral blips', 'Blips and virologic failure']","[{'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1450557', 'cui_str': 'IGFBP7 protein, human'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0013175', 'cui_str': 'Clinical drug trial'}, {'cui': 'C0369499', 'cui_str': 'Human immunodeficiency virus 1 RNA'}, {'cui': 'C1260953', 'cui_str': 'Suppressed'}]","[{'cui': 'C4542162', 'cui_str': 'emtricitabine, tenofovir alafenamide and bictegravir'}, {'cui': 'C3253985', 'cui_str': 'dolutegravir'}, {'cui': 'C1450557', 'cui_str': 'IGFBP7 protein, human'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C1699206', 'cui_str': 'Virologic failure'}]",565.0,0.237309,High rates of viral suppression were maintained in all groups through Week 48; blips were observed in only 15 participants (2.7%).,"[{'ForeName': 'Rima K', 'Initials': 'RK', 'LastName': 'Acosta', 'Affiliation': 'Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94044.'}, {'ForeName': 'Madeleine', 'Initials': 'M', 'LastName': 'Willkom', 'Affiliation': 'Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94044.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Andreatta', 'Affiliation': 'Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94044.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94044.'}, {'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Martin', 'Affiliation': 'Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94044.'}, {'ForeName': 'Aiyappa', 'Initials': 'A', 'LastName': 'Parvangada', 'Affiliation': 'Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94044.'}, {'ForeName': 'Hal', 'Initials': 'H', 'LastName': 'Martin', 'Affiliation': 'Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94044.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Collins', 'Affiliation': 'Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94044.'}, {'ForeName': 'Kirsten L', 'Initials': 'KL', 'LastName': 'White', 'Affiliation': 'Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94044.'}]",Journal of acquired immune deficiency syndromes (1999),['10.1097/QAI.0000000000002454'] 2662,32701826,Body Composition Changes in Response to Moderate or High-Intensity Exercise Among Older Adults with or without HIV Infection.,"BACKGROUND People with HIV (PWH) are at increased risk for adiposity and sarcopenia, despite effective antiretroviral therapy. Our objective was to compare the effects of prescribed exercise on body composition in older PWH and uninfected controls. SETTING Academic medical center METHODS:: Sedentary PWH (n=27) and uninfected controls (n=28) aged 50-75 completed 24 weeks of cardiovascular and resistance exercise. Participants completed 12 weeks of moderate-intensity exercise then were randomized to moderate- or high-intensity exercise for 12 additional weeks. Total lean (LEAN) and fat mass (FAT) and visceral adipose tissue area (VAT) were measured using DXA at baseline and 24 weeks; baseline and intervention differences were compared by HIV serostatus using multivariable regression analyses adjusted for baseline values, age, and exercise adherence. RESULTS At baseline, PWH had significantly lower FAT (P=0.003), but no significant differences in LEAN or VAT compared to controls (P>0.20). Changes over 24 weeks were not significantly different by HIV serostatus, though controls tended to gain more LEAN (0.8 kg [0, 1.6; P=0.04] than PWH (0.6 kg [-0.2, 1.4; P=0.12]) and lose less FAT and VAT (controls (-0.9 [-1.8, 0.0] kg; -10.3 [-19.6, 1.0] cm; both P = 0.03 vs PWH -2.0 [-2.9, -1.1] kg; -17.7 [-27.1, -8.2] cm; both P< 0.001). Exercise intensity differences were not apparent for LEAN, FAT, or VAT. CONCLUSION Exercise reduced total and visceral fat in older PWH and controls. Minimal gains in lean mass suggest that greater emphasis on resistance exercise may be needed to more effectively increase muscle in PWH.",2020,"At baseline, PWH had significantly lower FAT (P=0.003), but no significant differences in LEAN or VAT compared to controls (P>0.20).","['Participants completed 12 weeks of moderate-intensity exercise', 'People with HIV (PWH', 'Academic medical center METHODS:: Sedentary PWH (n=27) and uninfected controls (n=28) aged 50-75 completed 24 weeks of', 'Older Adults with or without HIV Infection', 'older PWH and uninfected controls']","['moderate- or high-intensity exercise', 'Exercise', 'cardiovascular and resistance exercise']","['Total lean (LEAN) and fat mass (FAT) and visceral adipose tissue area (VAT', 'LEAN or VAT', 'FAT and VAT', 'FAT', 'total and visceral fat']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0019693', 'cui_str': 'Human immunodeficiency virus infection'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C1563740', 'cui_str': 'Abdominal Visceral Fat'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0042427', 'cui_str': 'Vatican City'}]",,0.152703,"At baseline, PWH had significantly lower FAT (P=0.003), but no significant differences in LEAN or VAT compared to controls (P>0.20).","[{'ForeName': 'Catherine M', 'Initials': 'CM', 'LastName': 'Jankowski', 'Affiliation': 'University of Colorado College of Nursing.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Mawhinney', 'Affiliation': 'University of Colorado Anschutz Medical Campus, School of Public Health, Department of Biostatistics.'}, {'ForeName': 'Melissa P', 'Initials': 'MP', 'LastName': 'Wilson', 'Affiliation': 'University of Colorado Anschutz Medical Campus, School of Public Health, Department of Biostatistics.'}, {'ForeName': 'Thomas B', 'Initials': 'TB', 'LastName': 'Campbell', 'Affiliation': 'University of Colorado Anschutz Medical Campus, Department of Medicine, Division of Infectious Diseases.'}, {'ForeName': 'Wendy M', 'Initials': 'WM', 'LastName': 'Kohrt', 'Affiliation': 'University of Colorado Anschutz Medical Campus, Department of Medicine, Division of Geriatric Medicine.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Schwartz', 'Affiliation': 'University of Colorado Anschutz Medical Campus, Department of Medicine, Division of Geriatric Medicine.'}, {'ForeName': 'Todd T', 'Initials': 'TT', 'LastName': 'Brown', 'Affiliation': 'Johns Hopkins University, Department of Medicine, Division of Endocrinology, Diabetes, & Metabolism.'}, {'ForeName': 'Kristine M', 'Initials': 'KM', 'LastName': 'Erlandson', 'Affiliation': 'University of Colorado Anschutz Medical Campus, Department of Medicine, Division of Infectious Diseases.'}]",Journal of acquired immune deficiency syndromes (1999),['10.1097/QAI.0000000000002443'] 2663,32701836,"Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial.","Propranolol is a nonselective beta-adrenergic receptor antagonist. A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 2b trial enrolled participants aged 18 to 65 years with temporomandibular disorder myalgia to evaluate efficacy and safety of propranolol compared with placebo in reducing facial pain. Participants were randomized 1:1 to either extended-release propranolol hydrochloride (60 mg, BID) or placebo. The primary endpoint was change in facial pain index (FPI = facial pain intensity multiplied by facial pain duration, divided by 100). Efficacy was analyzed as a mean change in FPI from randomization to week 9 and as the proportion of participants with ≥30% or ≥50% reductions in FPI at week 9. Regression models tested for treatment-group differences adjusting for study site, sex, race, and FPI at randomization. Of 299 participants screened, 200 were randomized; 199 had at least one postrandomization FPI measurement and were included in intention-to-treat analysis. At week 9, model-adjusted reductions in mean FPI did not differ significantly between treatment groups (-1.8, 95% CL: -6.2, 2.6; P = 0.41). However, the proportion with a ≥30% reduction in FPI was significantly greater for propranolol (69.0%) than placebo (52.6%), and the associated number-needed-to-treat was 6.1 (P = 0.03). Propranolol was likewise efficacious for a ≥50% reduction in FPI (number-needed-to-treat = 6.1, P = 0.03). Adverse event rates were similar between treatment groups, except for more frequent fatigue, dizziness, and sleep disorder in the propranolol group. Propranolol was not different from placebo in reducing mean FPI but was efficacious in achieving ≥30% and ≥50% FPI reductions after 9 weeks of treatment among temporomandibular disorder participants.",2020,"Adverse event rates were similar between treatment groups, except for more frequent fatigue, dizziness, and sleep disorder in the propranolol group.","['temporomandibular disorder pain', '299 participants screened, 200 were randomized; 199 had at least one postrandomization FPI measurement and were included in intention-to-treat analysis', 'participants aged 18 to 65 years with temporomandibular disorder myalgia', 'temporomandibular disorder participants']","['Propranolol', 'extended-release propranolol hydrochloride', 'propranolol', 'placebo']","['frequent fatigue, dizziness, and sleep disorder', 'FPI', 'facial pain index (FPI = facial pain intensity multiplied by facial pain duration, divided by 100', 'Efficacy and safety', 'Adverse event rates', 'Efficacy', 'mean change in FPI', 'mean FPI', 'facial pain']","[{'cui': 'C0039494', 'cui_str': 'Temporomandibular joint disorder'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}]","[{'cui': 'C0033497', 'cui_str': 'Propranolol'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0282321', 'cui_str': 'Propranolol hydrochloride'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0851578', 'cui_str': 'Sleep disorder'}, {'cui': 'C0015468', 'cui_str': 'Pain in face'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C1719797', 'cui_str': 'Multiply'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",200.0,0.579533,"Adverse event rates were similar between treatment groups, except for more frequent fatigue, dizziness, and sleep disorder in the propranolol group.","[{'ForeName': 'Inna E', 'Initials': 'IE', 'LastName': 'Tchivileva', 'Affiliation': 'Center for Pain Research and Innovation, Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}, {'ForeName': 'Holly', 'Initials': 'H', 'LastName': 'Hadgraft', 'Affiliation': 'Rho Inc, Durham, NC, United States.'}, {'ForeName': 'Pei Feng', 'Initials': 'PF', 'LastName': 'Lim', 'Affiliation': 'Center for Pain Research and Innovation, Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}, {'ForeName': 'Massimiliano', 'Initials': 'M', 'LastName': 'Di Giosia', 'Affiliation': 'Center for Pain Research and Innovation, Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}, {'ForeName': 'Margarete', 'Initials': 'M', 'LastName': 'Ribeiro-Dasilva', 'Affiliation': 'Department of Community Dentistry & Behavioral Science, University of Florida, Gainesville, FL, United States.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Campbell', 'Affiliation': 'Departments of Oral and Maxillofacial Surgery and.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Willis', 'Affiliation': 'Rho Inc, Durham, NC, United States.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'James', 'Affiliation': 'Rho Inc, Durham, NC, United States.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Herman-Giddens', 'Affiliation': 'Rho Inc, Durham, NC, United States.'}, {'ForeName': 'Roger B', 'Initials': 'RB', 'LastName': 'Fillingim', 'Affiliation': 'Department of Community Dentistry & Behavioral Science, University of Florida, Gainesville, FL, United States.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Ohrbach', 'Affiliation': 'Oral Diagnostic Sciences, University at Buffalo, State University of New York, Buffalo, NY, United States.'}, {'ForeName': 'Samuel J', 'Initials': 'SJ', 'LastName': 'Arbes', 'Affiliation': 'Rho Inc, Durham, NC, United States.'}, {'ForeName': 'Gary D', 'Initials': 'GD', 'LastName': 'Slade', 'Affiliation': 'Center for Pain Research and Innovation, Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}]",Pain,['10.1097/j.pain.0000000000001882'] 2664,32701843,Enhanced mindfulness-based stress reduction in episodic migraine: a randomized clinical trial with magnetic resonance imaging outcomes.,"We aimed to evaluate the efficacy of an enhanced mindfulness-based stress reduction (MBSR+) vs stress management for headache (SMH). We performed a randomized, assessor-blind, clinical trial of 98 adults with episodic migraine recruited at a single academic center comparing MBSR+ (n = 50) with SMH (n = 48). MBSR+ and SMH were delivered weekly by group for 8 weeks, then biweekly for another 8 weeks. The primary clinical outcome was reduction in headache days from baseline to 20 weeks. Magnetic resonance imaging (MRI) outcomes included activity of left dorsolateral prefrontal cortex (DLPFC) and cognitive task network during cognitive challenge, resting state connectivity of right dorsal anterior insula to DLPFC and cognitive task network, and gray matter volume of DLPFC, dorsal anterior insula, and anterior midcingulate. Secondary outcomes were headache-related disability, pain severity, response to treatment, migraine days, and MRI whole-brain analyses. Reduction in headache days from baseline to 20 weeks was greater for MBSR+ (7.8 [95% CI, 6.9-8.8] to 4.6 [95% CI, 3.7-5.6]) than for SMH (7.7 [95% CI 6.7-8.7] to 6.0 [95% CI, 4.9-7.0]) (P = 0.04). Fifty-two percent of the MBSR+ group showed a response to treatment (50% reduction in headache days) compared with 23% in the SMH group (P = 0.004). Reduction in headache-related disability was greater for MBSR+ (59.6 [95% CI, 57.9-61.3] to 54.6 [95% CI, 52.9-56.4]) than SMH (59.6 [95% CI, 57.7-61.5] to 57.5 [95% CI, 55.5-59.4]) (P = 0.02). There were no differences in clinical outcomes at 52 weeks or MRI outcomes at 20 weeks, although changes related to cognitive networks with MBSR+ were observed. Enhanced mindfulness-based stress reduction is an effective treatment option for episodic migraine.",2020,"There were no differences in clinical outcomes at 52 weeks or MRI outcomes at 20 weeks, although changes related to cognitive networks with MBSR+ were observed.","['headache (SMH', '98 adults with episodic migraine recruited at a single academic center comparing MBSR+ (n = 50) with SMH (n = 48', 'episodic migraine']","['Magnetic resonance imaging (MRI', 'enhanced mindfulness-based stress reduction (MBSR', 'MBSR+ and SMH', 'SMH', 'MBSR']","['headache days', 'reduction in headache days', 'headache-related disability', 'headache-related disability, pain severity, response to treatment, migraine days, and MRI whole-brain analyses', 'MBSR', 'activity of left dorsolateral prefrontal cortex (DLPFC) and cognitive task network during cognitive challenge, resting state connectivity of right dorsal anterior insula to DLPFC and cognitive task network, and gray matter volume of DLPFC, dorsal anterior insula, and anterior midcingulate']","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4760993', 'cui_str': 'Episodic migraine'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0018681', 'cui_str': 'Headache'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0521982', 'cui_str': 'Response to treatment'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0028580', 'cui_str': 'Nuclear Magnetic Resonance'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0228259', 'cui_str': 'Anterior insula'}, {'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}]",98.0,0.12879,"There were no differences in clinical outcomes at 52 weeks or MRI outcomes at 20 weeks, although changes related to cognitive networks with MBSR+ were observed.","[{'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Seminowicz', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Shana A B', 'Initials': 'SAB', 'LastName': 'Burrowes', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Kearson', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Samuel R', 'Initials': 'SR', 'LastName': 'Krimmel', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Luma', 'Initials': 'L', 'LastName': 'Samawi', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Furman', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Keaser', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Neda F', 'Initials': 'NF', 'LastName': 'Gould', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States.'}, {'ForeName': 'Trish', 'Initials': 'T', 'LastName': 'Magyari', 'Affiliation': 'Private Mindfulness-based Psychotherapy Practice, Baltimore, MD, United States.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'White', 'Affiliation': 'Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Goloubeva', 'Affiliation': 'University of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Madhav', 'Initials': 'M', 'LastName': 'Goyal', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.'}, {'ForeName': 'B Lee', 'Initials': 'BL', 'LastName': 'Peterlin', 'Affiliation': 'Neuroscience Institute, Penn Medicine Lancaster General Health, Lancaster, PA, United States.'}, {'ForeName': 'Jennifer A', 'Initials': 'JA', 'LastName': 'Haythornthwaite', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States.'}]",Pain,['10.1097/j.pain.0000000000001860'] 2665,32701846,Placebo hypoalgesia: racial differences.,"No large-cohort studies that examine potential racial effects on placebo hypoalgesic effects exist. To fill this void, we studied placebo effects in healthy and chronic pain participants self-identified as either African American/black (AA/black) or white. We enrolled 372 study participants, 186 with a diagnosis of temporomandibular disorder (TMD) and 186 race-, sex-, and age-matched healthy participants to participate in a placebo experiment. Using a well-established paradigm of classical conditioning with verbal suggestions, each individual pain sensitivity was measured to calibrate the temperatures for high- and low-pain stimuli in the conditioning protocol. These 2 temperatures were then paired with a red and green screen, respectively, and participants were told that the analgesic intervention would activate during the green screens to reduce pain. Participants then rated the painfulness of each stimulus on a visual analog scale ranging from 0 to 100. Racial influences were tested on conditioning strength, reinforced expectations, and placebo hypoalgesia. We found that white participants reported greater conditioning effects, reinforced relief expectations, and placebo effects when compared with their AA/black counterparts. Racial effects on placebo were observed in TMD, although negligible, short-lasting, and mediated by conditioning strength. Secondary analyses on the effect of experimenter-participant race and sex concordance indicated that same experimenter-participant race induced greater placebo hypoalgesia in TMDs while different sex induced greater placebo hypoalgesia in healthy participants. This is the first and largest study to analyze racial effects on placebo hypoalgesia and has implications for both clinical research and treatment outcomes.",2020,Secondary analyses on the effect of experimenter-participant race and sex concordance indicated that same experimenter-participant race induced greater placebo hypoalgesia in TMDs while different sex induced greater placebo hypoalgesia in healthy participants.,"['healthy and chronic pain participants self-identified as either African American/black (AA/black) or white', 'We enrolled 372 study participants, 186 with a diagnosis of temporomandibular disorder (TMD) and 186 race-, sex-, and age-matched healthy participants to participate in a placebo experiment', 'healthy participants']","['Placebo', 'placebo']",[],"[{'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039494', 'cui_str': 'Temporomandibular joint disorder'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],372.0,0.217704,Secondary analyses on the effect of experimenter-participant race and sex concordance indicated that same experimenter-participant race induced greater placebo hypoalgesia in TMDs while different sex induced greater placebo hypoalgesia in healthy participants.,"[{'ForeName': 'Chika', 'Initials': 'C', 'LastName': 'Okusogu', 'Affiliation': 'Department of Pain and Translational Symptom Science, School of Nursing, University of Maryland, Baltimore, MD, United States.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Pain and Translational Symptom Science, School of Nursing, University of Maryland, Baltimore, MD, United States.'}, {'ForeName': 'Titilola', 'Initials': 'T', 'LastName': 'Akintola', 'Affiliation': 'Department of Pain and Translational Symptom Science, School of Nursing, University of Maryland, Baltimore, MD, United States.'}, {'ForeName': 'Nathaniel R', 'Initials': 'NR', 'LastName': 'Haycock', 'Affiliation': 'Department of Pain and Translational Symptom Science, School of Nursing, University of Maryland, Baltimore, MD, United States.'}, {'ForeName': 'Nandini', 'Initials': 'N', 'LastName': 'Raghuraman', 'Affiliation': 'Department of Pain and Translational Symptom Science, School of Nursing, University of Maryland, Baltimore, MD, United States.'}, {'ForeName': 'Joel D', 'Initials': 'JD', 'LastName': 'Greenspan', 'Affiliation': 'Center to Advance Chronic Pain Research, University of Maryland, Baltimore, MD, United States.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Phillips', 'Affiliation': 'Department of Neural and Pain Sciences and Brotman Facial Pain Clinic, School of Dentistry, Baltimore, MD, United States.'}, {'ForeName': 'Susan G', 'Initials': 'SG', 'LastName': 'Dorsey', 'Affiliation': 'Department of Pain and Translational Symptom Science, School of Nursing, University of Maryland, Baltimore, MD, United States.'}, {'ForeName': 'Claudia M', 'Initials': 'CM', 'LastName': 'Campbell', 'Affiliation': 'Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine, Baltimore, MD, United States.'}, {'ForeName': 'Luana', 'Initials': 'L', 'LastName': 'Colloca', 'Affiliation': 'Department of Pain and Translational Symptom Science, School of Nursing, University of Maryland, Baltimore, MD, United States.'}]",Pain,['10.1097/j.pain.0000000000001876'] 2666,32701847,Attention to breath sensations does not engage endogenous opioids to reduce pain.,"The endogenous opioidergic system is critically involved in the cognitive modulation of pain. Slow-breathing-based techniques are widely used nonpharmacological approaches to reduce pain. Yet, the active mechanisms of actions supporting these practices are poorly characterized. Growing evidence suggest that mindfulness-meditation, a slow-breathing technique practiced by nonreactively attending to breathing sensations, engages multiple unique neural mechanisms that bypass opioidergically mediated descending pathways to reduce pain. However, it is unknown whether endogenous opioids contribute to pain reductions produced by slow breathing. The present double-blind, placebo-controlled crossover study examined behavioral pain responses during mindfulness-meditation (n = 19), sham-mindfulness meditation (n = 20), and slow-paced breathing (n = 20) in response to noxious heat (49°C) and intravenous administration (0.15 mg/kg bolus + 0.1 mg/kg/hour maintenance infusion) of the opioid antagonist, naloxone, and placebo saline. Mindfulness significantly reduced pain unpleasantness ratings across both infusion sessions when compared to rest, but not pain intensity. Slow-paced breathing significantly reduced pain intensity and unpleasantness ratings during naloxone but not saline infusion. Pain reductions produced by mindfulness-meditation and slow-paced breathing were insensitive to naloxone when compared to saline administration. By contrast, sham-mindfulness meditation produced pain unpleasantness reductions during saline infusion but this effect was reversed by opioidergic antagonism. Sham-mindfulness did not lower pain intensity ratings. Self-reported ""focusing on the breath"" was identified as the operational feature particularly unique to the mindfulness-meditation and slow paced-breathing, but not sham-mindfulness meditation. Across all individuals, attending to the breath was associated with naloxone insensitive pain-relief. These findings provide evidence that slow breathing combined with attention to breath reduces pain independent of endogenous opioids.",2020,Slow-paced breathing significantly reduced pain intensity and unpleasantness ratings during naloxone but not saline infusion.,[],"['Slow-paced breathing', 'mindfulness-meditation (n = 19), sham-mindfulness meditation (n = 20), and slow-paced breathing (n = 20) in response to noxious heat (49°C) and intravenous administration (0.15 mg/kg bolus + 0.1 mg/kg/hour maintenance infusion) of the opioid antagonist, naloxone, and placebo saline', 'naloxone', 'placebo']","['Pain reductions', 'pain intensity ratings', 'pain unpleasantness ratings', 'pain unpleasantness reductions', 'pain intensity and unpleasantness ratings', 'behavioral pain responses']",[],"[{'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0021440', 'cui_str': 'Intravenous infusion'}, {'cui': 'C4068886', 'cui_str': '0.15'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0027410', 'cui_str': 'Opioid receptor antagonist'}, {'cui': 'C0027358', 'cui_str': 'Naloxone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0424543', 'cui_str': 'Response to pain'}]",,0.112843,Slow-paced breathing significantly reduced pain intensity and unpleasantness ratings during naloxone but not saline infusion.,"[{'ForeName': 'Rebecca E', 'Initials': 'RE', 'LastName': 'Wells', 'Affiliation': 'Departments of Neurology and.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Collier', 'Affiliation': 'Neurobiology and Anatomy.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Posey', 'Affiliation': 'Neurobiology and Anatomy.'}, {'ForeName': 'Afrayem', 'Initials': 'A', 'LastName': 'Morgan', 'Affiliation': 'Psychiatry, Wake Forest School of Medicine, Winston-Salem, NC, United States.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Auman', 'Affiliation': 'Neurobiology and Anatomy.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Strittmatter', 'Affiliation': 'School of Pharmacy, Wake Forest School of Medicine, Winston-Salem, NC, United States.'}, {'ForeName': 'Rossana', 'Initials': 'R', 'LastName': 'Magalhaes', 'Affiliation': 'Neurobiology and Anatomy.'}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'Adler-Neal', 'Affiliation': 'Neurobiology and Anatomy.'}, {'ForeName': 'John G', 'Initials': 'JG', 'LastName': 'McHaffie', 'Affiliation': 'Neurobiology and Anatomy.'}, {'ForeName': 'Fadel', 'Initials': 'F', 'LastName': 'Zeidan', 'Affiliation': 'Department of Anesthesiology, University of California San Diego, San Diego, CA, United States.'}]",Pain,['10.1097/j.pain.0000000000001865'] 2667,32701865,Use of the Fundamentals of Arthroscopic Surgical Training Workstation for Immediate Objective Feedback During Training Improves Hand-Tied Surgical Knot Proficiency: A Randomized Controlled Study.,"INTRODUCTION In a prior study, we validated the FAST workstation as an objective evaluator of hand-tied surgical knots. The goal of this study was to determine whether guided practice with the FAST workstation could lead to objective improvement in hand-tied surgical knot performance. METHODS Sixty participants were randomized into 1 of 2 groups: a control group, with access to only the knot-tying station, and a test group, with access to the knot-tying station plus the knot testing station. The study was divided into 3 phases: prepractice, practice, and postpractice. Using the FAST workstation, participants hand-tied 5 knots, 15 knots, and 5 knots using 0 Vicryl suture in the prepractice, practice, and postpractice phases, respectively. Knots for each participant from the prepractice and postpractice phases were collected, tested, and compared. RESULTS Within the control group, the average number of prepractice knot successes was 2.63, and the average number of postpractice knot successes was 3.40, which resulted in an improvement of average knot successes of 0.77 (P < 0.01). Within the test group, the average number of prepractice knot successes was 2.40, and the average number of postpractice knot successes was 4.10, which resulted in an improvement of average knot successes of 1.70 (P < 0.01). The difference in average improvement of knot-tying successes (0.93 knots) between the 2 groups was statistically significant (P < 0.01). DISCUSSION A knot-tying trainer that provides objective feedback on knot performance may better improve hand-tied surgical knot proficiency compared with one without objective feedback.",2020,"The difference in average improvement of knot-tying successes (0.93 knots) between the 2 groups was statistically significant (P < 0.01). ",['Sixty participants'],"['FAST workstation', 'Arthroscopic Surgical Training Workstation', 'control group, with access to only the knot-tying station, and a test group, with access to the knot-tying station plus the knot testing station', 'knot-tying trainer']","['average number of prepractice knot successes', 'average knot successes', 'average improvement of knot-tying successes', 'average number of postpractice knot successes']",[],"[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C1736830', 'cui_str': 'Workstation'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0560032', 'cui_str': 'knot'}, {'cui': 'C0453920', 'cui_str': 'Tie'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0453962', 'cui_str': 'Trainers'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0560032', 'cui_str': 'knot'}, {'cui': 'C0453920', 'cui_str': 'Tie'}]",60.0,0.0219455,"The difference in average improvement of knot-tying successes (0.93 knots) between the 2 groups was statistically significant (P < 0.01). ","[{'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Schneider', 'Affiliation': 'From the Department of Orthopaedic Surgery and Rehabilitation (A.M.S., W.D., D.W., D.A.E.), Loyola University Medical Center, Maywood, IL; and Department of Orthopaedic Surgery (R.A.P.), University of California Los Angeles, Los Angeles, CA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Davis', 'Affiliation': ''}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Walsh', 'Affiliation': ''}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Pedowitz', 'Affiliation': ''}, {'ForeName': 'Douglas A', 'Initials': 'DA', 'LastName': 'Evans', 'Affiliation': ''}]",Simulation in healthcare : journal of the Society for Simulation in Healthcare,['10.1097/SIH.0000000000000494'] 2668,32701871,Energy Requirements of Male Academy Soccer Players from the English Premier League.,"PURPOSE To inform the energy requirements of highly trained adolescent soccer players, total energy expenditure (TEE) was quantified in academy soccer players from the English Premier League (EPL). METHODS Twenty-four male adolescent soccer players from an EPL academy (n=8 U12/13; n=8 U15; n=8 U18) were assessed for baseline maturity (maturity offset), body composition (DXA) and resting metabolic rate (RMR; indirect calorimetry). Subsequently, TEE, energy intake (EI) and physical loading patterns were assessed over a 14-day in-season period using doubly labelled water, the remote food photographic method and global positioning system technology, respectively. RESULTS Under-18 players presented with greater RMR (2236±93 kcal⋅day) and TEE (3586±487 kcal⋅day; range: 2542-5172 kcal⋅day) than both U15 (2023±162 and 3029±262 kcal⋅day, respectively; TEE range: 2738-3726 kcal⋅day) and U12/13 players (1892±211 and 2859±265 kcal⋅day, respectively; TEE range: 2275-3903 kcal⋅day) (all P<0.01), though no difference in TEE was apparent between the U12/13 and U15 age-groups. Fat-free mass was significantly different between all comparisons in a hierarchal manner (U18: 57.2±6.1 kg > U15: 42.9±5.8 kg > U12/13: 31.1±3.5 kg; all P<0.01). Within age-groups, no differences were apparent between EI and TEE (U12/13: -29±277 kcal⋅day, P=0.78; U15: -134±327 kcal⋅day, P=0.28; U18: -243±724 kcal⋅day, P=0.37), whilst U18 players (3180±279 kcal⋅day) reported higher EI than both U15 (2821±338 kcal⋅day; P=0.05) and U12/13 players (2659±187 kcal⋅day; P<0.01). CONCLUSION The TEE of male academy soccer players progressively increase as players progress through the academy age-groups. In some individuals (evident in all age-groups), TEE was greater than that previously observed in adult EPL soccer players.",2020,"In some individuals (evident in all age-groups), TEE was greater than that previously observed in adult EPL soccer players.","['Twenty-four male adolescent soccer players from an EPL academy (n=8 U12/13; n=8 U15; n=8 U18', 'academy soccer players from the English Premier League (EPL', 'male academy soccer players', 'highly trained adolescent soccer players', 'Male Academy Soccer Players from the English Premier League']",[],"['baseline maturity (maturity offset), body composition (DXA) and resting metabolic rate (RMR; indirect calorimetry', 'Fat-free mass', 'TEE, energy intake (EI) and physical loading patterns', 'total energy expenditure (TEE']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0001589', 'cui_str': 'Adolescents, Male'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0000876', 'cui_str': 'Academies'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]",[],"[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205286', 'cui_str': 'Mature'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C4082350', 'cui_str': 'Resting Metabolic Rate'}, {'cui': 'C0006781', 'cui_str': 'Indirect calorimetry'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass'}, {'cui': 'C0429629', 'cui_str': 'Total energy expenditure'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}]",24.0,0.0180906,"In some individuals (evident in all age-groups), TEE was greater than that previously observed in adult EPL soccer players.","[{'ForeName': 'Marcus P', 'Initials': 'MP', 'LastName': 'Hannon', 'Affiliation': 'Research Institute for Sport and Exercise Sciences (RISES), Liverpool John Moores University, Liverpool, England, United Kingdom.'}, {'ForeName': 'Lloyd J F', 'Initials': 'LJF', 'LastName': 'Parker', 'Affiliation': 'Research Institute for Sport and Exercise Sciences (RISES), Liverpool John Moores University, Liverpool, England, United Kingdom.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Carney', 'Affiliation': 'Research Institute for Sport and Exercise Sciences (RISES), Liverpool John Moores University, Liverpool, England, United Kingdom.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'McKeown', 'Affiliation': 'Everton Football Club, Liverpool, England, United Kingdom.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Speakman', 'Affiliation': 'School of Biological Sciences, University of Aberdeen, Aberdeen, Scotland, United Kingdom.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Hambly', 'Affiliation': 'School of Biological Sciences, University of Aberdeen, Aberdeen, Scotland, United Kingdom.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Drust', 'Affiliation': 'Research Institute for Sport and Exercise Sciences (RISES), Liverpool John Moores University, Liverpool, England, United Kingdom.'}, {'ForeName': 'Viswanath B', 'Initials': 'VB', 'LastName': 'Unnithan', 'Affiliation': 'Research Institute of Clinical Exercise and Health Science, School of Health and Life Sciences, University of the West of Scotland, Hamilton, Scotland, United Kingdom.'}, {'ForeName': 'Graeme L', 'Initials': 'GL', 'LastName': 'Close', 'Affiliation': 'Research Institute for Sport and Exercise Sciences (RISES), Liverpool John Moores University, Liverpool, England, United Kingdom.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Morton', 'Affiliation': 'Research Institute for Sport and Exercise Sciences (RISES), Liverpool John Moores University, Liverpool, England, United Kingdom.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002443'] 2669,32701874,Supplementary Energy Increases Bone Formation during Arduous Military Training.,"PURPOSE To investigate the effect of supplementary energy on bone formation and resorption during arduous military training in energy deficit. METHODS Thirty male soldiers completed an 8-week military combat course (mean ± SD, age 25 ± 3 years, height 1.78 ± 0.05 m, body mass 80.9 ± 7.7 kg). Participants received either the habitual diet (control group, n = 15) or an additional 5.1 MJ·d to eliminate the energy deficit (supplemented group, n = 15). Circulating markers of bone formation and resorption, and reproductive, thyroid, and metabolic status, were measured at baseline, and week 6 and 8 of training. RESULTS Bone ALP decreased in controls (-4.4 ± 1.9 μg·L) and increased in the supplemented group (16.0 ± 6.6 μg·L), between baseline and week 8 (P < 0.001). P1NP increased between baseline and week 6 for both groups (5.6 ± 8.1 μg·L, P = 0.005). βCTX decreased between baseline and week 8 for both groups (-0.16 ± 0.20 μg·L, P < 0.001). Prolactin increased from baseline to week 8 for the supplemented group (148 ± 151 IU·L, P = 0.041). The increase in adiponectin from baseline to week 8 was higher in controls (4.3 ± 1.8 mg·L, P < 0.001) than the supplemented group (1.4 ± 1.0 mg·L, P < 0.001). IGF binding protein-3 was lower at week 8 than baseline for controls (-461 ± 395 ng·mL, P < 0.001). CONCLUSION The increase in bone ALP, a marker of bone formation, with supplementation supports a role of energy in osteoblastic activity; the implications for skeletal adaptation and stress fracture risk is unclear. The mechanism is likely through protecting markers of metabolic, but not reproductive or thyroid, function.",2020,"IGF binding protein-3 was lower at week 8 than baseline for controls (-461 ± 395 ng·mL, P < 0.001). ","['Thirty male soldiers completed an 8-week military combat course (mean ± SD, age 25 ± 3 years, height 1.78 ± 0.05 m, body mass 80.9 ± 7.7 kg']","['habitual diet (control group, n = 15) or an additional 5.1 MJ·d to eliminate the energy deficit', 'supplementary energy']","['P1NP', 'IGF binding protein-3', 'adiponectin', 'Circulating markers of bone formation and resorption, and reproductive, thyroid, and metabolic status', 'bone formation and resorption', 'Prolactin', 'βCTX', 'bone ALP', 'Bone ALP']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0524647', 'cui_str': 'Soldiers'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0026126', 'cui_str': 'Military personnel'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C4517411', 'cui_str': '0.05'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C4517860', 'cui_str': '7.7'}]","[{'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0072053', 'cui_str': 'Procollagen peptide, type 1 N-terminal'}, {'cui': 'C0123707', 'cui_str': 'Insulin-like growth factor binding protein 3'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0029433', 'cui_str': 'Bone formation'}, {'cui': 'C0035150', 'cui_str': 'Reproduction'}, {'cui': 'C0040132', 'cui_str': 'Thyroid structure'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0033371', 'cui_str': 'Prolactin'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}]",30.0,0.0353909,"IGF binding protein-3 was lower at week 8 than baseline for controls (-461 ± 395 ng·mL, P < 0.001). ","[{'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': ""O'Leary"", 'Affiliation': 'Army Health and Performance Research, Army Headquarters, Andover, United Kingdom.'}, {'ForeName': 'Neil P', 'Initials': 'NP', 'LastName': 'Walsh', 'Affiliation': 'Research Institute for Sport and Exercise Science, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Casey', 'Affiliation': 'Army Health and Performance Research, Army Headquarters, Andover, United Kingdom.'}, {'ForeName': 'Rachel M', 'Initials': 'RM', 'LastName': 'Izard', 'Affiliation': 'Department of Occupational Medicine, HQ Army Recruiting and Initial Training Command, Upavon, United Kingdom.'}, {'ForeName': 'Jonathan Cy', 'Initials': 'JC', 'LastName': 'Tang', 'Affiliation': 'Norwich Medical School, University of East Anglia, Norwich, United Kingdom.'}, {'ForeName': 'William D', 'Initials': 'WD', 'LastName': 'Fraser', 'Affiliation': 'Norwich Medical School, University of East Anglia, Norwich, United Kingdom.'}, {'ForeName': 'Julie P', 'Initials': 'JP', 'LastName': 'Greeves', 'Affiliation': 'Army Health and Performance Research, Army Headquarters, Andover, United Kingdom.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002473'] 2670,32701900,"The Effects of Nicotine on Cortical Excitability After Exercise: A Double-Blind Randomized, Placebo-controlled, Crossover Study.","PURPOSE The use of smokeless tobacco/nicotine products is common among athletes, but clear evidence for their positive or negative effect on sports performance is lacking. Nicotine is a psychoactive substance involved in numerous neuronal processes including cortical excitability. The aim of this study was to evaluate its effect on cortical excitability associated with aerobic exercise in nicotine-naive healthy volunteers. METHODS Ten nicotine-naive healthy volunteers were recruited for this double-blind, randomized, crossover study to compare the effect of snus (8 mg nicotine), an oral, smokeless tobacco product, to placebo on cortical excitability before and after aerobic exercise. Transcranial magnetic stimulation (TMS) was used to measure changes in corticomotor excitability (motor-evoked potentials, MEPs) and electromyography of leg muscles during maximal voluntary contractions (MVC) to assess changes in muscle contractions. Before and after aerobic exercise and with or without nicotine treatment, MEPs and MVCs were measured. RESULTS Analysis of TMS data showed lower motor cortex activation (lower MEP amplitude) after snus administration compared with placebo, whereas electromyography data showed no difference in muscle contraction between snus and placebo treatment. CONCLUSIONS These findings suggest a general reduction in cortical excitability, without no relevant effect on physical performance.",2020,"RESULTS Analysis of TMS data showed lower motor cortex activation (lower MEP amplitude) after snus administration compared with placebo, whereas electromyography data showed no difference in muscle contraction between snus and placebo treatment. ","['nicotine-naive healthy volunteers', 'Ten nicotine-naive healthy volunteers']","['Placebo', 'aerobic exercise and with or without nicotine', 'oral, smokeless tobacco product, to placebo', 'placebo', 'snus (8 mg nicotine', 'Transcranial magnetic stimulation (TMS', 'smokeless tobacco/nicotine products', 'Nicotine', 'aerobic exercise']","['muscle contraction', 'Cortical Excitability', 'motor cortex activation', 'cortical excitability', 'corticomotor excitability (motor-evoked potentials, MEPs) and electromyography of leg muscles', 'physical performance']","[{'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0040338', 'cui_str': 'Smokeless Tobacco'}, {'cui': 'C4288198', 'cui_str': 'Snus'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}]","[{'cui': 'C0026820', 'cui_str': 'Muscle contraction'}, {'cui': 'C4277734', 'cui_str': 'Cortical Excitability'}, {'cui': 'C0026607', 'cui_str': 'Motor cortex'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C0282617', 'cui_str': 'Motor Evoked Potentials'}, {'cui': 'C0054871', 'cui_str': 'Cathepsin L'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0224456', 'cui_str': 'Skeletal muscle structure of lower leg'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",,0.62248,"RESULTS Analysis of TMS data showed lower motor cortex activation (lower MEP amplitude) after snus administration compared with placebo, whereas electromyography data showed no difference in muscle contraction between snus and placebo treatment. ","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Zandonai', 'Affiliation': 'From the Department of Pharmacology, Pediatrics and Organic Chemistry, Miguel Hernández University, Elche.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Pizzolato', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Tam', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Bruseghini', 'Affiliation': 'Department of Molecular and Translational Medicine, University of Brescia, Brescia.'}, {'ForeName': 'Cristiano', 'Initials': 'C', 'LastName': 'Chiamulera', 'Affiliation': 'Neuropsychopharmacology Laboratory, Department of Diagnostic and Public Health, University of Verona, Verona, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Cesari', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona.'}]",Journal of clinical psychopharmacology,['10.1097/JCP.0000000000001246'] 2671,32701901,Lurasidone Efficacy in Mixed Depressive States: A Comparison of Standard Rating Scales to the Koukopoulos Mixed Depression Rating Scale.,"INTRODUCTION A new mood rating scale for mixed states of depression along with manic-like excitatory symptoms, the Koukopoulos Mixed Depression Rating Scale (KMDRS), was assessed in a post hoc analysis of a randomized clinical trial of lurasidone versus placebo in major depressive disorder (MDD) with mixed features. METHODS The KMDRS was compared with the Montgomery Asberg Depression Rating Scale (MADRS) and the Young Mania Rating Scale (YMRS). Item weighting was performed and compared with an original KMDRS validation data set. Weighting was used to provide imputed KMDRS scores in the lurasidone study, based on observed MADRS and YMRS scores. RESULTS Standardized effect sizes were larger for MADRS (0.61) and YMRS (0.79) than for KMDRS (0.44, Cohen d). CONCLUSIONS This analysis did not find that the KMDRS produced a larger effect size than the MADRS in Diagnostic and Statistical Manual for Mental Disorder-5 (DSM-5) defined MDD with mixed features. The lower utility of KMDRS may be due to the imputed nature of this analysis, or also to the DSM-5 defined patient population, which may reflect mixed hypomania rather than mixed depression.",2020,This analysis did not find that the KMDRS produced a larger effect size than the MADRS in Diagnostic and Statistical Manual for Mental Disorder-5 (DSM-5) defined MDD with mixed features.,"['Mixed Depressive States', 'major depressive disorder (MDD) with mixed features']","['lurasidone versus placebo', 'KMDRS']","['Koukopoulos Mixed Depression Rating Scale (KMDRS', 'Montgomery Asberg Depression Rating Scale (MADRS) and the Young Mania Rating Scale (YMRS', 'Koukopoulos Mixed Depression Rating Scale']","[{'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]","[{'cui': 'C2003424', 'cui_str': 'lurasidone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]","[{'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4087288', 'cui_str': 'Young mania rating scale'}]",,0.0448118,This analysis did not find that the KMDRS produced a larger effect size than the MADRS in Diagnostic and Statistical Manual for Mental Disorder-5 (DSM-5) defined MDD with mixed features.,"[{'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Vöhringer', 'Affiliation': 'From the Department of Psychiatry, Tufts University School of Medicine, Boston, MA.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Sani', 'Affiliation': 'From the Department of Psychiatry, Tufts University School of Medicine, Boston, MA.'}, {'ForeName': 'Sergio A', 'Initials': 'SA', 'LastName': 'Barroilhet', 'Affiliation': 'From the Department of Psychiatry, Tufts University School of Medicine, Boston, MA.'}, {'ForeName': 'Yongcai', 'Initials': 'Y', 'LastName': 'Mao', 'Affiliation': 'Sunovion Pharmaceuticals, Marlborough.'}, {'ForeName': 'S Nassir', 'Initials': 'SN', 'LastName': 'Ghaemi', 'Affiliation': 'From the Department of Psychiatry, Tufts University School of Medicine, Boston, MA.'}]",Journal of clinical psychopharmacology,['10.1097/JCP.0000000000001261'] 2672,32701903,Is Sitagliptin Effective for Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients? A Double-blind Placebo-controlled Clinical Trial.,"PURPOSE/BACKGROUND The mortality rate of patients with schizophrenia due to metabolic disturbances is high. Our aim is to survey the effects of sitagliptin on metabolic disturbances associated with olanzapine in patients with schizophrenia. METHODS/PROCEDURES In this 12-week double-blind placebo-controlled clinical trial, 71 patients taking olanzapine (10 to 30 mg) for at least 1 month were randomly allocated to enter 1 of the 2 treatment groups (olanzapine plus placebo or olanzapine plus sitagliptin). Sitagliptin was added to patients 'current medications with the dose of 100 mg/d. Physical examinations and measurement of anthropometric (body mass index and waist circumference) and laboratory parameters (fasting blood sugar, glycated hemoglobin, total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglyceride) were measured at baseline, week 4, and week 12. The patients were assessed for any side effects of the medications in each visit. FINDINGS/RESULTS Sixty-one patients (30 in the sitagliptin and 31 in the placebo group) completed the trial. The anthropometric measurements at the end of the study did not differ between the 2 groups. glycated hemoglobin and total cholesterol were significantly lower in the sitagliptin group after 12 weeks. Other metabolic profile revealed either no change or minimal magnitude changes. No major side effect was reported. IMPLICATIONS/CONCLUSIONS Metabolic disturbances associated with olanzapine treatment in patients with schizophrenia can be modulated by sitagliptin.",2020,glycated hemoglobin and total cholesterol were significantly lower in the sitagliptin group after 12 weeks.,"['patients with schizophrenia', '71 patients taking', 'Sixty-one patients (30 in the sitagliptin and 31 in the placebo group) completed the trial', '10 to 30 mg) for at least 1 month']","['olanzapine', 'Placebo', 'Olanzapine', 'olanzapine plus placebo or olanzapine plus sitagliptin', 'Sitagliptin', 'sitagliptin', 'placebo']","['glycated hemoglobin and total cholesterol', 'Physical examinations and measurement of anthropometric (body mass index and waist circumference) and laboratory parameters (fasting blood sugar, glycated hemoglobin, total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglyceride']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C4517832', 'cui_str': '61'}, {'cui': 'C1565750', 'cui_str': 'sitagliptin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1565750', 'cui_str': 'sitagliptin'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}]",71.0,0.0833552,glycated hemoglobin and total cholesterol were significantly lower in the sitagliptin group after 12 weeks.,"[{'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Moghimi Sarani', 'Affiliation': 'From the Substance Abuse and Mental Health Research Center, Department of Psychiatry.'}, {'ForeName': 'Elahe', 'Initials': 'E', 'LastName': 'Memari', 'Affiliation': 'Research Center for Psychiatry and Behavioral Sciences, Department of Psychiatry, Shiraz University of Medical Sciences, School of Medicine, Shiraz.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Anushiravani', 'Affiliation': 'Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Arash', 'Initials': 'A', 'LastName': 'Mowla', 'Affiliation': 'Research Center for Psychiatry and Behavioral Sciences, Department of Psychiatry, Shiraz University of Medical Sciences, School of Medicine, Shiraz.'}]",Journal of clinical psychopharmacology,['10.1097/JCP.0000000000001259'] 2673,32701926,"Efficacy of methylprednisolone on pain, trismus and quality of life following surgical removal of mandibular third molars: a double-blind, split-mouth, randomised controlled trial.","BACKGROUND The objective of the present study was to compare the efficacy of different doses of methylprednisolone on postoperative sequelae and quality of life (QoL) following surgical removal of mandibular third molars (SRM3). MATERIAL AND METHODS Fifty-two patients (16 men and 36 women, mean age 25.9 years, range: 18-39) with bilateral impacted mandibular third molars were randomly allocated into intraoperative muscular injection of either 20mg, 30mg, 40mg methylprednisolone or saline injection. Baseline measurements were obtained preoperatively and compared with assessment after one day, three days, seven days and one month. Pain and trismus were estimated by visual analog scale score and interincisal mouth opening, respectively. Subjective assessment of QoL included Oral Health Impact Profile (OHIP-14). Descriptive and generalized estimating equation analyses were made and expressed as mean values with a 95% confidence interval. RESULTS Methylprednisolone revealed no significant differences in pain, trismus and QoL compared with placebo. Higher prevalence of postoperative pain and worsening in QoL were observed with increased age (P=0.00). Smoking and increased time of surgery decreased mouth opening in the early healing phase (P=0.00). CONCLUSIONS The present study revealed no significant improvement of methylprednisolone on postoperative sequelae and QoL following SRM3 compared with placebo.",2020,"Smoking and increased time of surgery decreased mouth opening in the early healing phase (P=0.00). ","['surgical removal of mandibular third molars (SRM3', 'surgical removal of mandibular third molars', 'Fifty-two patients (16 men and 36 women, mean age 25.9 years, range: 18-39) with bilateral impacted mandibular third molars']","['methylprednisolone', 'intraoperative muscular injection of either 20mg, 30mg, 40mg methylprednisolone or saline injection', 'Methylprednisolone', 'placebo']","['pain, trismus and quality of life', 'pain, trismus and QoL', 'time of surgery decreased mouth opening', 'postoperative sequelae and quality of life (QoL', 'postoperative sequelae and QoL', 'postoperative pain and worsening in QoL', 'visual analog scale score and interincisal mouth opening', 'Pain and trismus', 'Subjective assessment of QoL included Oral Health Impact Profile (OHIP-14']","[{'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026369', 'cui_str': 'Structure of wisdom tooth'}, {'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}]","[{'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0041105', 'cui_str': 'Trismus'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1290672', 'cui_str': 'Limited ability to open mouth'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0243088', 'cui_str': 'sequels'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0240379', 'cui_str': 'Open mouth'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0281588', 'cui_str': 'Assessment of quality of life'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}]",,0.610954,"Smoking and increased time of surgery decreased mouth opening in the early healing phase (P=0.00). ","[{'ForeName': 'M-K', 'Initials': 'MK', 'LastName': 'Larsen', 'Affiliation': 'Department of Oral and Maxillofacial Surgery Aalborg University Hospital 18-22 Hobrovej, DK-9000 Aalborg, Denmark marie.kjaergaard@rn.dk.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Kofod', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Duch', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Starch-Jensen', 'Affiliation': ''}]","Medicina oral, patologia oral y cirugia bucal",['10.4317/medoral.24094'] 2674,32701928,"Volume and effectiveness assessment of articain 4% versus mepivacaine 2% used in third molar surgery: randomized, double-blind, split-mouth controlled clinical trial.","BACKGROUND The different indications for extraction of the lower third molars, require resources to manage pain and discomfort, such as, for example, adequate anesthetic techniques, and the type of anesthetic used can influence the management of pain in tooth extractions. Few studies in the literature compare the anesthetics 4% articaine hydrochloride and 2% mepivacaine hydrochloride showing evidence that both allow for successful pain management. This study sought to compare the volume, efficacy and safety of these two anesthetic drugs, both associated with epinephrine at a ratio of 1:100,000, used in the extraction of lower third molars. MATERIAL AND METHODS A controlled, clinical, split-mouth compared these both local anesthetics in a sample of 20 patients requiring bilateral extraction of teeth. Pain was the main parameter to be assessed by means of the visual analogue scale (VAS) applied during and immediately after the surgery. Hemodynamic parameters, adverse events, presence of paresthesia and satisfaction of patients and surgeon were also analysed. RESULTS Pain management was more effective with mepivacaine up to two hours after surgery (p=0.014), whereas the surgeon was more satisfied with the use of articaine during divulsion and suture (p<0.05). However no statistically significant differences were found between both anesthetics regarding pain perception. CONCLUSIONS It was observed that both anesthetics are efficient and safe in the management of pain for extraction of third molars, in which less amount of mepivacaine is needed. The satisfaction of patients and surgeon was the same for both anesthetics, with articaine being highlighted during divulsion and suture.",2020,"It was observed that both anesthetics are efficient and safe in the management of pain for extraction of third molars, in which less amount of mepivacaine is needed.",['20 patients requiring bilateral extraction of teeth'],"['mepivacaine hydrochloride', 'local anesthetics', 'articaine', 'articaine hydrochloride', 'epinephrine', 'mepivacaine']","['visual analogue scale (VAS', 'Pain', 'Hemodynamic parameters, adverse events, presence of paresthesia and satisfaction of patients and surgeon', 'volume, efficacy and safety', 'pain perception']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0040440', 'cui_str': 'Tooth extraction'}]","[{'cui': 'C0700542', 'cui_str': 'Mepivacaine hydrochloride'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C1608295', 'cui_str': 'Articaine'}, {'cui': 'C0007300', 'cui_str': 'Articaine hydrochloride'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0025384', 'cui_str': 'Mepivacaine'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}]",20.0,0.145288,"It was observed that both anesthetics are efficient and safe in the management of pain for extraction of third molars, in which less amount of mepivacaine is needed.","[{'ForeName': 'P-C', 'Initials': 'PC', 'LastName': 'Almeida', 'Affiliation': 'Cale Francisco José Longo Avenue, 777 Jardim São Dimas, São José dos Campos SP, Brazil, 12245 -000 paulacarolinasj@yahoo.com.br.'}, {'ForeName': 'F-V', 'Initials': 'FV', 'LastName': 'Raldi', 'Affiliation': ''}, {'ForeName': 'F-R', 'Initials': 'FR', 'LastName': 'Sato', 'Affiliation': ''}, {'ForeName': 'R-D', 'Initials': 'RD', 'LastName': 'Nascimento', 'Affiliation': ''}, {'ForeName': 'M-B', 'Initials': 'MB', 'LastName': 'Moraes', 'Affiliation': ''}]","Medicina oral, patologia oral y cirugia bucal",['10.4317/medoral.23780'] 2675,32701929,Leukocyte- and platelet-rich fibrin does not provide any additional benefit for tooth extraction in head and neck cancer patients post-radiotherapy: a randomized clinical trial.,"BACKGROUND One of the most important complications of radiotherapy (RT) for head and neck cancer (HNC) is osteoradionecrosis (ORN) of the jaws, arising mainly from tooth extractions. Thus, the present study aimed to evaluate the efficacy of leukocyte- and platelet-rich fibrin (L-PRF) in preventing ORN following tooth extraction in post-irradiated HNC patients, as well as other postoperative complications. MATERIAL AND METHODS 23 patients previously submitted to conventionally fractionated 3D-conformational RT for HNC underwent atraumatic tooth extractions with perioperative antibiotic therapy. Besides, they were randomly assigned to receive L-PRF clots to fill and cover the extraction sockets (n=11, Test Group) or not (n=12, Control Group). A visual analog scale was used to quantify postoperative pain on the 3rd and 7th days. For ORN diagnosis, patients were clinically assessed for up to 180 days. Other postoperative complications (edema, alveolitis, suture dehiscence, continuous bleeding, and oroantral communication) were also evaluated within this period. RESULTS No case of ORN or another surgical complication was observed and there were no differences in the postoperative pain scores between the groups on the 3rd and 7th days. CONCLUSIONS L-PRF did not seem to provide any additional benefits than those achieved by the combination of the surgical and drug protocols used for tooth extractions in the post-irradiated HNC patients.",2020,"No case of ORN or another surgical complication was observed and there were no differences in the postoperative pain scores between the groups on the 3rd and 7th days. ","['head and neck cancer patients post', '23 patients previously submitted to conventionally fractionated 3D-conformational RT for HNC underwent atraumatic tooth extractions with perioperative antibiotic therapy']","['radiotherapy', 'radiotherapy (RT', 'leukocyte- and platelet-rich fibrin (L-PRF', 'L-PRF clots to fill and cover the extraction sockets', 'Leukocyte- and platelet-rich fibrin']","['ORN or another surgical complication', 'postoperative complications (edema, alveolitis, suture dehiscence, continuous bleeding, and oroantral communication', 'postoperative pain scores']","[{'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0040440', 'cui_str': 'Tooth extraction'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C4505052', 'cui_str': 'Leukocyte- and Platelet-Rich Fibrin'}, {'cui': 'C0009074', 'cui_str': 'Clotrimazole'}, {'cui': 'C0439844', 'cui_str': 'Covered'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0224517', 'cui_str': 'Gomphosis structure'}]","[{'cui': 'C0029461', 'cui_str': 'Osteoradionecrosis'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0549493', 'cui_str': 'Alveolitis'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0149663', 'cui_str': 'Dehiscence'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0029293', 'cui_str': 'Oroantral fistula'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",23.0,0.0349457,"No case of ORN or another surgical complication was observed and there were no differences in the postoperative pain scores between the groups on the 3rd and 7th days. ","[{'ForeName': 'L-F', 'Initials': 'LF', 'LastName': 'Palma', 'Affiliation': 'Rua da Moóca, 2518 cj13. 03104-002 São Paulo, SP, Brazil leandro_chambrone@hotmail.com.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Marcucci', 'Affiliation': ''}, {'ForeName': 'C-M', 'Initials': 'CM', 'LastName': 'Remondes', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Chambrone', 'Affiliation': ''}]","Medicina oral, patologia oral y cirugia bucal",['10.4317/medoral.23804'] 2676,32701954,Effectiveness and cost-effectiveness of the GoActive intervention to increase physical activity among UK adolescents: A cluster randomised controlled trial.,"BACKGROUND Less than 20% of adolescents globally meet recommended levels of physical activity, and not meeting these recommended levels is associated with social disadvantage and rising disease risk. The determinants of physical activity in adolescents are multilevel and poorly understood, but the school's social environment likely plays an important role. We conducted a cluster randomised controlled trial to assess the effectiveness of a school-based programme (GoActive) to increase moderate-to-vigorous physical activity (MVPA) among adolescents. METHODS AND FINDINGS Non-fee-paying, co-educational schools including Year 9 students in the UK counties of Cambridgeshire and Essex were eligible for inclusion. Within participating schools (n = 16), all Year 9 students were eligible and invited to participate. Participants were 2,862 13- to 14-year-olds (84% of eligible students). After baseline assessment, schools were computer-randomised, stratified by school-level pupil premium funding (below/above county-specific median) and county (control: 8 schools, 1,319 participants, mean [SD] participants per school n = 165 [62]; intervention: 8 schools, 1,543 participants, n = 193 [43]). Measurement staff were blinded to allocation. The iteratively developed, feasibility-tested 12-week intervention, aligned with self-determination theory, trained older adolescent mentors and in-class peer-leaders to encourage classes to conduct 2 new weekly activities. Students and classes gained points and rewards for engaging in any activity in or out of school. The primary outcome was average daily minutes of accelerometer-assessed MVPA at 10-month follow-up; a mixed-methods process evaluation evaluated implementation. Of 2,862 recruited participants (52.1% male), 2,167 (76%) attended 10-month follow-up measurements; we analysed the primary outcome for 1,874 participants (65.5%). At 10 months, there was a mean (SD) decrease in MVPA of 8.3 (19.3) minutes in the control group and 10.4 (22.7) minutes in the intervention group (baseline-adjusted difference [95% confidence interval] -1.91 minutes [-5.53 to 1.70], p = 0.316). The programme cost £13 per student compared with control; it was not cost-effective. Overall, 62.9% of students and 87.3% of mentors reported that GoActive was fun. Teachers and mentors commented that their roles in programme delivery were unclear. Implementation fidelity was low. The main methodological limitation of this study was the relatively affluent and ethnically homogeneous sample. CONCLUSIONS In this study, we observed that a rigorously developed school-based intervention was no more effective than standard school practice at preventing declines in adolescent physical activity. Interdisciplinary research is required to understand educational-setting-specific implementation challenges. School leaders and authorities should be realistic about expectations of the effect of school-based physical activity promotion strategies implemented at scale. TRIAL REGISTRATION ISRCTN Registry ISRCTN31583496.",2020,The programme cost £13 per student compared with control; it was not cost-effective.,"['1,319 participants, mean [SD] participants per school n = 165 [62]; intervention: 8 schools, 1,543 participants, n = 193 [43', 'Non-fee-paying, co-educational schools including Year 9 students in the UK counties of Cambridgeshire and Essex were eligible for inclusion', 'Of 2,862 recruited participants (52.1% male), 2,167 (76%) attended 10-month follow-up measurements; we analysed the primary outcome for 1,874 participants (65.5', 'Within participating schools (n = 16), all Year 9 students were eligible and invited to participate', 'UK adolescents', 'Participants were 2,862 13- to 14-year-olds (84% of eligible students', 'adolescents']","['school-based programme (GoActive', 'GoActive intervention']","['average daily minutes of accelerometer-assessed MVPA', 'physical activity', 'Effectiveness and cost-effectiveness', 'moderate-to-vigorous physical activity (MVPA', 'mean (SD) decrease in MVPA']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015751', 'cui_str': 'Fees'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0454843', 'cui_str': 'Cambridgeshire'}, {'cui': 'C0454853', 'cui_str': 'Essex'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}]",2862.0,0.114617,The programme cost £13 per student compared with control; it was not cost-effective.,"[{'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Corder', 'Affiliation': 'UKCRC Centre for Diet and Activity Research, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Sharp', 'Affiliation': 'UKCRC Centre for Diet and Activity Research, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Stephanie T', 'Initials': 'ST', 'LastName': 'Jong', 'Affiliation': 'UKCRC Centre for Diet and Activity Research, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Campbell', 'Initials': 'C', 'LastName': 'Foubister', 'Affiliation': 'UKCRC Centre for Diet and Activity Research, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Helen Elizabeth', 'Initials': 'HE', 'LastName': 'Brown', 'Affiliation': 'UKCRC Centre for Diet and Activity Research, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Emma K', 'Initials': 'EK', 'LastName': 'Wells', 'Affiliation': 'UKCRC Centre for Diet and Activity Research, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Sofie M', 'Initials': 'SM', 'LastName': 'Armitage', 'Affiliation': 'UKCRC Centre for Diet and Activity Research, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Caroline H D', 'Initials': 'CHD', 'LastName': 'Croxson', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Vignoles', 'Affiliation': 'Faculty of Education, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Paul O', 'Initials': 'PO', 'LastName': 'Wilkinson', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom.'}, {'ForeName': 'Edward C F', 'Initials': 'ECF', 'LastName': 'Wilson', 'Affiliation': 'Health Economics Group, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.'}, {'ForeName': 'Esther M F', 'Initials': 'EMF', 'LastName': 'van Sluijs', 'Affiliation': 'UKCRC Centre for Diet and Activity Research, University of Cambridge, Cambridge, United Kingdom.'}]",PLoS medicine,['10.1371/journal.pmed.1003210'] 2677,32701984,Acupuncture in persons with an increased stress level-Results from a randomized-controlled pilot trial.,"BACKGROUND In today's Western societies a high percentage of people experience increased or chronic stress. Acupuncture could serve as treatment for persons affected adversely by the increased stress. METHODS The AkuRest study was a two-centre randomized controlled pilot study in adult persons with increased stress levels. Participants were randomly allocated to one of three groups: verum acupuncture treatment, sham acupuncture, and a waiting control group. The feasibility of the study was assessed. In addition, effects on stress level (measured by the Perceived Stress Questionnaire (PSQ-20)) and other variables were assessed at the end of treatment and a 3-month follow-up. RESULTS Altogether, N = 70 persons were included in the study. At the end of the treatment 15.7% were lost to follow-up. The adherence to the protocol was good: 82.9% of the participants completed 100% of their treatment. The stress level of the participants was high at baseline (mean PSQ-20 score 75.5, SD = 8.2). Effect sizes (ES) at T1 showed that verum and sham acupuncture were superior to the waiting condition in reducing stress (ES (verum) = -1.39, 95%-CI = [-2.11; -0.67]: ES (sham) = -1.12, CI = [-1.78;-0.44]). At follow-up, effect sizes were in favour of the verum group (as compared to sham). However, confidence intervals and t-tests showed that these differences were not significant. CONCLUSION The pilot study demonstrated the feasibility of the acupuncture RCT in persons with increased stress levels. Estimated parameters can be used to design a larger RCT to prove the-here indicated-efficacy of verum acupuncture to decrease stress. TRIAL REGISTRATION NUMBER ISRCTN15259166.",2020,Effect sizes (ES) at T1 showed that verum and sham acupuncture were superior to the waiting condition in reducing stress (ES (verum) =,"['persons with increased stress levels', 'persons with an increased stress level', 'Altogether, N = 70 persons were included in the study', 'adult persons with increased stress levels']","['acupuncture RCT', 'verum and sham acupuncture', 'Acupuncture', 'verum acupuncture', 'verum acupuncture treatment, sham acupuncture, and a waiting control group']","['Perceived Stress Questionnaire (PSQ-20', 'stress level']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0394664', 'cui_str': 'Acupuncture'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}]",70.0,0.0786007,Effect sizes (ES) at T1 showed that verum and sham acupuncture were superior to the waiting condition in reducing stress (ES (verum) =,"[{'ForeName': 'Beate', 'Initials': 'B', 'LastName': 'Wild', 'Affiliation': 'Department of General Internal Medicine and Psychosomatics, Medical University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Brenner', 'Affiliation': 'Department of General Internal Medicine and Psychosomatics, Medical University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Joos', 'Affiliation': 'Institute for General Practice and Interprofessional Care, Medical University Hospital Tübingen, Tübingen, Germany.'}, {'ForeName': 'Yvonne', 'Initials': 'Y', 'LastName': 'Samstag', 'Affiliation': 'Institute of Immunology, Section Molecular Immunology, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Buckert', 'Affiliation': 'Department of General Internal Medicine and Psychosomatics, Medical University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Valentini', 'Affiliation': 'Institute for General Practice and Interprofessional Care, Medical University Hospital Tübingen, Tübingen, Germany.'}]",PloS one,['10.1371/journal.pone.0236004'] 2678,32702079,Assessment of Shared Decision-making for Stroke Prevention in Patients With Atrial Fibrillation: A Randomized Clinical Trial.,"Importance Shared decision-making (SDM) about anticoagulant treatment in patients with atrial fibrillation (AF) is widely recommended but its effectiveness is unclear. Objective To assess the extent to which the use of an SDM tool affects the quality of SDM and anticoagulant treatment decisions in at-risk patients with AF. Design, Setting, and Participants This encounter-randomized trial recruited patients with nonvalvular AF who were considering starting or reviewing anticoagulant treatment and their clinicians at academic, community, and safety-net medical centers between January 30, 2017 and June 27, 2019. Encounters were randomized to either the standard care arm or care that included the use of an SDM tool (intervention arm). Data were analyzed from August 1 to November 30, 2019. Interventions Standard care or care using the Anticoagulation Choice Shared Decision Making tool (which presents individualized risk estimates and compares anticoagulant treatment options across issues of importance to patients) during the clinical encounter. Main Outcomes and Measures Quality of SDM (which included quality of communication, patient knowledge about AF and anticoagulant treatment, accuracy of patient estimates of their own stroke risk [within 30% of their estimate], decisional conflict, and satisfaction), decisions made during the encounter, duration of the encounter, and clinician involvement of patients in the SDM process. Results The clinical trial enrolled 922 patients (559 men [60.6%]; mean [SD] age, 71 [11] years) and 244 clinicians. A total of 463 patients were randomized to the intervention arm and 459 patients to the standard care arm. Participants in both arms reported high communication quality, high knowledge, and low decisional conflict, demonstrated low accuracy in their risk perception, and would similarly recommend the approach used in their encounter. Clinicians were significantly more satisfied after intervention encounters (400 of 453 encounters [88.3%] vs 277 of 448 encounters [61.8%]; adjusted relative risk, 1.49; 95% CI, 1.42-1.53). A total of 747 of 873 patients (85.6%) chose to start or continue receiving an anticoagulant medication. Patient involvement in decision-making (as assessed through video recordings of the encounters using the Observing Patient Involvement in Decision Making 12-item scale) scores were significantly higher in the intervention arm (mean [SD] score, 33.0 [10.8] points vs 29.1 [13.1] points, respectively; adjusted mean difference, 4.2 points; 95% CI, 2.8-5.6 points). No significant between-arm difference was found in encounter duration (mean [SD] duration, 32 [16] minutes in the intervention arm vs 31 [17] minutes in the standard care arm; adjusted mean between-arm difference, 1.1; 95% CI, -0.3 to 2.5 minutes). Conclusion and Relevance The use of an SDM encounter tool improved several measures of SDM quality and clinician satisfaction, with no significant effect on treatment decisions or encounter duration. These results help to calibrate expectations about the value of implementing SDM tools in the care of patients with AF. Trial Registration ClinicalTrials.gov Identifier: NCT02905032.",2020,"The use of an SDM encounter tool improved several measures of SDM quality and clinician satisfaction, with no significant effect on treatment decisions or encounter duration.","['Patients With Atrial Fibrillation', 'mean [SD] age, 71 [11] years) and 244 clinicians', 'patients with atrial fibrillation (AF', '922 patients (559 men [60.6', 'A total of 747 of 873 patients (85.6%) chose to start or continue receiving an anticoagulant medication', 'patients with AF', '463 patients were randomized to the intervention arm and 459 patients to the standard care arm', 'patients with nonvalvular AF who were considering starting or reviewing anticoagulant treatment and their clinicians at academic, community, and safety-net medical centers between January 30, 2017 and June 27, 2019']",['standard care arm or care that included the use of an SDM tool (intervention arm'],"['Decision Making 12-item scale) scores', 'encounter duration', 'SDM quality and clinician satisfaction', 'Measures\n\n\nQuality of SDM (which included quality of communication, patient knowledge about AF and anticoagulant treatment, accuracy of patient estimates of their own stroke risk [within 30% of their estimate], decisional conflict, and satisfaction), decisions made during the encounter, duration of the encounter, and clinician involvement of patients in the SDM process']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517660', 'cui_str': '244'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C3179495', 'cui_str': 'Decision Making, Shared'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C1277291', 'cui_str': 'Stroke risk'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C0231394', 'cui_str': 'Decisional conflict'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0347984', 'cui_str': 'During'}, {'cui': 'C1522240', 'cui_str': 'Process'}]",922.0,0.0691682,"The use of an SDM encounter tool improved several measures of SDM quality and clinician satisfaction, with no significant effect on treatment decisions or encounter duration.","[{'ForeName': 'Marleen', 'Initials': 'M', 'LastName': 'Kunneman', 'Affiliation': 'Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Megan E', 'Initials': 'ME', 'LastName': 'Branda', 'Affiliation': 'Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Ian G', 'Initials': 'IG', 'LastName': 'Hargraves', 'Affiliation': 'Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Angela L', 'Initials': 'AL', 'LastName': 'Sivly', 'Affiliation': 'Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Alexander T', 'Initials': 'AT', 'LastName': 'Lee', 'Affiliation': 'Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Haeshik', 'Initials': 'H', 'LastName': 'Gorr', 'Affiliation': 'Division of General Internal Medicine, Hennepin Health, Minneapolis, Minnesota.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Burnett', 'Affiliation': 'Thrombosis Clinic and Anticoagulation Services, Park Nicollet Health Services, St Louis Park, Minnesota.'}, {'ForeName': 'Takeki', 'Initials': 'T', 'LastName': 'Suzuki', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Mississippi Medical Center, Jackson.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Jackson', 'Affiliation': 'Department of Internal Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Hess', 'Affiliation': 'Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Linzer', 'Affiliation': 'Division of General Internal Medicine, Hennepin Health, Minneapolis, Minnesota.'}, {'ForeName': 'Sarah R', 'Initials': 'SR', 'LastName': 'Brand-McCarthy', 'Affiliation': 'Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Juan P', 'Initials': 'JP', 'LastName': 'Brito', 'Affiliation': 'Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Noseworthy', 'Affiliation': 'Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Victor M', 'Initials': 'VM', 'LastName': 'Montori', 'Affiliation': 'Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA internal medicine,['10.1001/jamainternmed.2020.2908'] 2679,32702101,Nonsteroidal Anti-inflammatory Drugs vs Cognitive Behavioral Therapy for Arthritis Pain: A Randomized Withdrawal Trial.,"Importance Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for knee osteoarthritis. However, they are associated with uncertain long-term clinical benefit and significant toxic effects. Objective To evaluate whether discontinuing NSAIDs and engaging in a telephone-based cognitive behavioral therapy (CBT) program is noninferior to continuing NSAIDs for patients with knee osteoarthritis. Design, Setting, and Participants The Stopping NSAIDs for Arthritis Pain multicenter randomized withdrawal trial was conducted for 364 patients taking NSAIDs for knee osteoarthritis pain on most days of the week for at least 3 months between September 1, 2013, and September 30, 2018. Analysis was performed on an intent-to-treat basis. Interventions Participants discontinued their current NSAID and took 15 mg per day of meloxicam daily during a 2-week run-in period. Those who remained eligible were randomized in a 1:1 ratio to receive meloxicam or placebo for 4 weeks (blinded phase 1). Participants receiving meloxicam then continued this medication for 10 weeks, while those receiving placebo participated in a 10-week CBT program (unblinded phase 2). Main Outcomes and Measures The primary outcome measure was the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at 4 weeks with the noninferiority margin set at 1. Secondary outcomes included the area under the curve of the pain score after 4 weeks as well as the WOMAC pain score, area under the curve of the pain score, WOMAC disability score, and global impression of change after treatment at 14 weeks. Results A total of 180 participants (161 men; mean [SD] age, 58. 2 [11.8] years) were randomized to receive placebo followed by CBT, and a total of 184 participants (154 men; mean [SD] age, 58.5 [10.0] years) were randomized to receive meloxicam. After adjustment for baseline pain and study site, the estimated mean difference in WOMAC pain score between the placebo and meloxicam groups after 4 weeks was 1.4 (95% CI, 0.8-2.0; noninferiority test P = .92). At week 14, the adjusted mean difference in WOMAC pain score between the placebo (followed by CBT) and meloxicam groups was 0.8 (95% CI, 0.2-1.4; noninferiority P = .28). There was no statistically significant difference in the global impression of change (mean difference in scores, -0.2; 95% CI, -0.4 to 0.1; P = .15) or lower extremity disability (mean difference in scores, 0.9; 95% CI, -1.4 to 3.2; P = .45) between the 2 groups after 14 weeks. Conclusions and Relevance Among patients with knee osteoarthritis, placebo and CBT (after placebo) are inferior to meloxicam. However, the WOMAC pain score differences between the 2 groups were small, and there were no statistically significant differences in participants' global impression of change or function after 14 weeks. Trial Registration ClinicalTrials.gov Identifier: NCT01799213.",2020,"There was no statistically significant difference in the global impression of change (mean difference in scores, -0.2; 95% CI, -0.4 to 0.1; P = .15) or lower extremity disability (mean difference in scores, 0.9; 95% CI, -1.4 to 3.2; P = .45) between the 2 groups after 14 weeks. ","['Arthritis Pain', '184 participants (154 men; mean [SD] age, 58.5 [10.0] years', '180 participants (161 men; mean [SD] age, 58', '364 patients taking NSAIDs for knee osteoarthritis pain on most days of the week for at least 3 months between September 1, 2013, and September 30, 2018', 'patients with knee osteoarthritis']","['discontinuing NSAIDs and engaging in a telephone-based cognitive behavioral therapy (CBT) program', 'meloxicam', 'placebo followed by CBT', 'Nonsteroidal Anti-inflammatory Drugs vs Cognitive Behavioral Therapy', 'Nonsteroidal anti-inflammatory drugs (NSAIDs', 'placebo and CBT (after placebo', 'meloxicam or placebo', 'placebo']","['Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score', 'area under the curve of the pain score after 4 weeks as well as the WOMAC pain score, area under the curve of the pain score, WOMAC disability score, and global impression of change', 'extremity disability', 'global impression of change', 'WOMAC pain score differences', 'WOMAC pain score']","[{'cui': 'C0003864', 'cui_str': 'Arthritis'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4517616', 'cui_str': '184'}, {'cui': 'C5191279', 'cui_str': '154'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0585023', 'cui_str': 'Days of the week'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0083381', 'cui_str': 'meloxicam'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C3472647', 'cui_str': 'Western Ontario and McMaster Universities osteoarthritis index'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}]",180.0,0.518584,"There was no statistically significant difference in the global impression of change (mean difference in scores, -0.2; 95% CI, -0.4 to 0.1; P = .15) or lower extremity disability (mean difference in scores, 0.9; 95% CI, -1.4 to 3.2; P = .45) between the 2 groups after 14 weeks. ","[{'ForeName': 'Liana', 'Initials': 'L', 'LastName': 'Fraenkel', 'Affiliation': 'Veterans Affairs Connecticut Healthcare System, West Haven.'}, {'ForeName': 'Eugenia', 'Initials': 'E', 'LastName': 'Buta', 'Affiliation': 'Veterans Affairs Connecticut Healthcare System, West Haven.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Suter', 'Affiliation': 'Veterans Affairs Connecticut Healthcare System, West Haven.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Dubreuil', 'Affiliation': 'Veterans Affairs Boston Healthcare System, Boston, Massachusetts.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Levy', 'Affiliation': 'North Florida/South Georgia Veterans Health System, Gainesville, Florida.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Najem', 'Affiliation': 'Providence Veterans Affairs Medical Center, Providence, Rhode Island.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Brennan', 'Affiliation': 'Veterans Affairs Connecticut Healthcare System, West Haven.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Corn', 'Affiliation': 'Veterans Affairs Connecticut Healthcare System, West Haven.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Kerns', 'Affiliation': 'Yale University School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Goulet', 'Affiliation': 'Veterans Affairs Connecticut Healthcare System, West Haven.'}]",JAMA internal medicine,['10.1001/jamainternmed.2020.2821'] 2680,32702169,Randomised clinical trial: Significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea.,"BACKGROUND In primary bile acid diarrhoea, feedback by farnesoid X receptor (FXR) and fibroblast growth hormone 19 (FGF19) on hepatic bile acid production is impaired. AIMS To evaluate the safety, mechanisms and efficacy of negative feedback by FXR activation with tropifexor, a non-bile acid FXR agonist, in patients with primary bile acid diarrhoea. METHODS In this double-blind, multicentre, randomised, cross-over study, patients received tropifexor 60 µg or placebo once daily for 14 days in each of two treatment periods. Primary objectives included tropifexor safety and tolerability, and on stool frequency and form. Other assessments included pharmacokinetic and pharmacodynamic measures, biochemical markers and gastrointestinal transit. RESULTS Twenty patients (tropifexor 60 µg/placebo [N = 10]; placebo/tropifexor 60 µg [N = 10]) were enrolled. Adverse event rates were lower with tropifexor vs placebo (52.9% vs 73.7%). No patient had pruritus during tropifexor intake. There were no significant differences in stool frequency, stool form or loperamide use between treatments. Tropifexor increased FGF19 and decreased 7α-hydroxy-4-cholesten-3-one (C4) levels for up to 8 h. Plasma tropifexor concentrations peaked at 5 hours post-dose on days 1 and 12. At day 12, tropifexor caused reduction in peak total bile acid concentration (33%, P = 0.032) and exposure (36%, P = 0.005). Moreover, tropifexor showed a significant increase in ascending colon half-emptying time (P = 0.036). CONCLUSIONS Tropifexor 60 µg once daily had acceptable safety and tolerability. Changes in FGF19 and C4 showed effective target engagement; however, higher doses may be required to observe stool frequency changes. Slowing of ascending colon emptying suggests therapeutic potential of tropifexor in patients with primary bile acid diarrhoea. ClinicalTrials.gov number: NCT02713243.",2020,Tropifexor increased FGF19 and decreased 7α-hydroxy-4-cholesten-3-one (C4) levels for up to 8 h. Plasma tropifexor concentrations peaked at 5 hours post-dose on days 1 and 12.,"['60\xa0µg [N\xa0=\xa010]) were enrolled', 'patients with primary bile acid diarrhoea', 'Twenty patients (tropifexor 60\xa0µg']","['placebo/tropifexor', 'placebo', 'tropifexor 60\xa0µg or placebo', 'farnesoid X receptor agonist tropifexor', 'tropifexor vs placebo']","['stool frequency, stool form or loperamide use', 'tropifexor safety and tolerability, and on stool frequency and form', 'acceptable safety and tolerability', 'Plasma tropifexor concentrations', 'peak total bile acid concentration', 'Tropifexor increased FGF19 and decreased 7α-hydroxy-4-cholesten-3-one (C4) levels', 'Adverse event rates', 'pharmacokinetic and pharmacodynamic measures, biochemical markers and gastrointestinal transit', 'ascending colon half-emptying time']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C4524087', 'cui_str': 'Bile acid diarrhea'}, {'cui': 'C4726919', 'cui_str': 'tropifexor'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4726919', 'cui_str': 'tropifexor'}, {'cui': 'C4521707', 'cui_str': 'Farnesoid X receptor agonist'}]","[{'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0023992', 'cui_str': 'Loperamide'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C4726919', 'cui_str': 'tropifexor'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0201914', 'cui_str': 'Total bile acids measurement'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0055520', 'cui_str': 'cholest-4-en-3-one'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Markers'}, {'cui': 'C0017191', 'cui_str': 'Gastrointestinal transit study'}, {'cui': 'C0227375', 'cui_str': 'Ascending colon structure'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",,0.357184,Tropifexor increased FGF19 and decreased 7α-hydroxy-4-cholesten-3-one (C4) levels for up to 8 h. Plasma tropifexor concentrations peaked at 5 hours post-dose on days 1 and 12.,"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Camilleri', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Sara Linker', 'Initials': 'SL', 'LastName': 'Nord', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Duane', 'Initials': 'D', 'LastName': 'Burton', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Ibironke', 'Initials': 'I', 'LastName': 'Oduyebo', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Yiming', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Novartis Institutes for Biomedical Research, Cambridge, MA, USA.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Koeun', 'Initials': 'K', 'LastName': 'Im', 'Affiliation': 'Novartis Institutes for Biomedical Research, Cambridge, MA, USA.'}, {'ForeName': 'Prafulla', 'Initials': 'P', 'LastName': 'Bhad', 'Affiliation': 'Novartis Institutes for Biomedical Research, Cambridge, MA, USA.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Badman', 'Affiliation': 'Novartis Institutes for Biomedical Research, Cambridge, MA, USA.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Sanders', 'Affiliation': 'The Academic Unit of Gastroenterology, Royal Hallamshire Hospital, Sheffield, UK.'}, {'ForeName': 'Julian R F', 'Initials': 'JRF', 'LastName': 'Walters', 'Affiliation': 'Division of Digestive Diseases, Imperial College London, London, UK.'}]",Alimentary pharmacology & therapeutics,['10.1111/apt.15967'] 2681,32702212,Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis.,"OBJECTIVE Evaluate changes in health-related quality of life (HRQOL) and disability in children with systemic juvenile idiopathic arthritis (sJIA) or polyarticular juvenile idiopathic arthritis (pJIA) treated with tocilizumab. METHODS Secondary analyses of two double-blind, placebo-controlled trials of intravenous tocilizumab in children with active sJIA or pJIA were conducted. Patient-reported outcomes of disability (Childhood Health Assessment Questionnaire [CHAQ]), HRQOL (Child Health Questionnaire-Parent Form-50 [CHQ-P50]; health concepts, physical summary score [CHQ-P50-PhS]; psychosocial summary score [CHQ-P50-PsS]), pain, and well-being (100-mm visual analog scale [VAS]) were measured at weeks 0 and 12 (sJIA), 16 and 40 (pJIA), and 104. RESULTS 112 sJIA and 188 pJIA patients entered the trials. At week 16, pJIA patients' mean ± SD CHAQ decreased from 1.39 ± 0.74 at baseline to 0.67 ± 0.65 (P < 0.001). At week 12, sJIA patients' mean CHQ-P50-PhS improved more with tocilizumab than placebo (7.3 ± 10.2 vs 2.4 ± 10.6; P < 0.05). Almost all mean CHQ-P50 health concept scores, CHQ-P50-PsS, and CHQ-P50-PhS improved (P ≤ 0.002) by week 104 for patients with sJIA. pJIA and sJIA patients showed significant (P < 0.001) reductions in disability (mean CHAQ scores: -1.09 ± 0.71; -1.17 ± 0.80), improvements in well-being (-43.76 ± 26.61; -51.53 ± 23.57), and decreases in pain (-41.56 ± 31.06; -51.26 ± 26.79); 92.9%/96.8% of tocilizumab-treated pJIA/sJIA patients reported no more than minimal pain (VAS ≤35 mm) at week 104. CONCLUSION Tocilizumab treatment was associated with significantly reduced disability and pain and improved HRQOL in sJIA and pJIA patients.",2020,Tocilizumab treatment was associated with significantly reduced disability and pain and improved HRQOL in sJIA and pJIA patients.,"['children with systemic juvenile idiopathic arthritis (sJIA) or polyarticular juvenile idiopathic arthritis (pJIA) treated with', '112 sJIA and 188 pJIA', 'Patients With Juvenile Idiopathic Arthritis', 'children with active sJIA or pJIA were conducted']","['intravenous tocilizumab', 'Tocilizumab', 'tocilizumab', 'placebo']","['mean ± SD CHAQ', 'health-related quality of life (HRQOL) and disability', 'disability', 'mean CHQ-P50-PhS', 'pain', 'Functional Ability and Health-Related Quality of Life', 'disability and pain and improved HRQOL', 'mean CHQ-P50 health concept scores, CHQ-P50-PsS, and CHQ-P50-PhS', 'disability (Childhood Health Assessment Questionnaire [CHAQ]), HRQOL (Child Health Questionnaire-Parent Form-50 [CHQ-P50]; health concepts, physical summary score [CHQ-P50-PhS]; psychosocial summary score [CHQ-P50-PsS]), pain, and well-being (100-mm visual analog scale [VAS', 'minimal pain']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1384600', 'cui_str': 'Systemic onset juvenile chronic arthritis'}, {'cui': 'C4521004', 'cui_str': 'Polyarticular juvenile idiopathic arthritis'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3495559', 'cui_str': 'Juvenile chronic arthritis'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C1609165', 'cui_str': 'tocilizumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2732494', 'cui_str': 'Childhood health assessment questionnaire'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0055461', 'cui_str': 'chloroxine'}, {'cui': 'C0219874', 'cui_str': 'p50(csk)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0008078', 'cui_str': 'Child health care'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}]",,0.307086,Tocilizumab treatment was associated with significantly reduced disability and pain and improved HRQOL in sJIA and pJIA patients.,"[{'ForeName': 'Hermine I', 'Initials': 'HI', 'LastName': 'Brunner', 'Affiliation': ""Division of Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States.""}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': ""Division of Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States.""}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Bovis', 'Affiliation': 'Department of Health Sciences, University of Genoa, Genoa, Italy.'}, {'ForeName': 'Fabrizio', 'Initials': 'F', 'LastName': 'De Benedetti', 'Affiliation': 'Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.'}, {'ForeName': 'Graciela', 'Initials': 'G', 'LastName': 'Espada', 'Affiliation': 'Rheumatology Section, Hospital de Ninos Ricardo Gutierrez, Buenos Aires, Argentina.'}, {'ForeName': 'Rik', 'Initials': 'R', 'LastName': 'Joos', 'Affiliation': 'Pediatric Rheumatology, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Akikusa', 'Affiliation': ""Pediatric Rheumatology, Royal Children's Hospital, Melbourne, Australia.""}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Chaitow', 'Affiliation': ""Department of Rheumatology, The Children's Hospital Westmead, Sydney, Australia.""}, {'ForeName': 'Alina Lucica', 'Initials': 'AL', 'LastName': 'Boteanu', 'Affiliation': 'Pediatric Rheumatology Unit, University Hospital Ramón y Cajal, Madrid, Spain.'}, {'ForeName': 'Yukiko', 'Initials': 'Y', 'LastName': 'Kimura', 'Affiliation': ""Division of Pediatric Rheumatology, Joseph M. Sanzari Children's Hospital, Hackensack Meridian School of Medicine, Hackensack, NJ, USA.""}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Rietschel', 'Affiliation': ""Rheumatology for Children and Adolescents, Clementine Children's Hospital, Frankfurt on Main, Germany.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Siri', 'Affiliation': 'Department of Rheumatology, Instituto CAICI, Rosario, Argentina.'}, {'ForeName': 'Elzbieta', 'Initials': 'E', 'LastName': 'Smolewska', 'Affiliation': 'Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Lodz, Poland.'}, {'ForeName': 'Heinrike', 'Initials': 'H', 'LastName': 'Schmeling', 'Affiliation': ""Department of Pediatrics, Alberta Children's Hospital and Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.""}, {'ForeName': 'Diane E', 'Initials': 'DE', 'LastName': 'Brown', 'Affiliation': ""Pediatric Rheumatology, Children's Hospital of Los Angeles, and Clinical Pediatrics, University of Southern California, Los Angeles, California, United States.""}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Martini', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal-Child Sciences, University of Genoa, Genoa, Italy.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Lovell', 'Affiliation': ""Division of Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States.""}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Huang', 'Affiliation': ""Division of Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States.""}, {'ForeName': 'Nicolino', 'Initials': 'N', 'LastName': 'Ruperto', 'Affiliation': 'Pediatric and Rheumatology Clinic, PRINTO, IRCCS Istituto Giannina Gaslini, Genoa, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Arthritis care & research,['10.1002/acr.24384'] 2682,32702216,A Neurofeedback Protocol for Executive Function to Reduce Depression and Rumination: A Controlled Study.,"Objective Rumination is a maladaptive emotional-regulation strategy that is strongly associated with depression. Impaired executive function can lead to difficulties in disengaging from rumination, thus exacerbating depression. In this study, we inspect an electroencephalograph neurofeedback protocol that enhance the target peak alpha frequency (PAF) activation in the prefrontal region. We examine the protocol's effects on depression and rumination. Methods We randomly assigned 30 dysphoric participants into either the neurofeedback training group or the control group. We then evaluated their depression, rumination, and executive function at pre- and posttraining so as to examine the effects of the neurofeedback. Results The results show that this neurofeedback protocol can specifically enhance participants' target PAF. The participants' executive function performances significantly improved after undergoing 20 neurofeedback sessions. Compared with those in the control group, those in the neurofeedback group had significantly fewer depressive symptoms and significantly reduced rumination. Moreover, as target PAF and executive function improved, depression and rumination both declined. Conclusion Our data are in line with those of previous studies that indicated a relationship between upper-band alpha activity and executive function. This PAF neurofeedback can effectively enhance participants' executive function, which can reduce rumination and ameliorate depression. This neurofeedback training is based on basic cognitive neuroscience, so it sheds light on depression's pathological factors and etiology.",2020,"Compared with those in the control group, those in the neurofeedback group had significantly fewer depressive symptoms and significantly reduced rumination.",[],['neurofeedback training group or the control group'],"['target PAF and executive function improved, depression and rumination both declined', 'rumination', 'depression and rumination', 'peak alpha frequency (PAF) activation', 'depression, rumination, and executive function', 'executive function performances', 'Depression and Rumination', 'depressive symptoms']",[],"[{'cui': 'C2713543', 'cui_str': 'Electroencephalographic biofeedback'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",30.0,0.043171,"Compared with those in the control group, those in the neurofeedback group had significantly fewer depressive symptoms and significantly reduced rumination.","[{'ForeName': 'Sheng-Hsiang', 'Initials': 'SH', 'LastName': 'Yu', 'Affiliation': 'Department of Psychology, Fo Guang University, Jiaosi, Yilan County, Taiwan.'}, {'ForeName': 'Chao-Yuan', 'Initials': 'CY', 'LastName': 'Tseng', 'Affiliation': 'Department of Psychology, Fo Guang University, Jiaosi, Yilan County, Taiwan.'}, {'ForeName': 'Wei-Lun', 'Initials': 'WL', 'LastName': 'Lin', 'Affiliation': 'Department of Psychology, Fo Guang University, Jiaosi, Yilan County, Taiwan.'}]",Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology,['10.9758/cpn.2020.18.3.375'] 2683,31212376,The entrepreneurship of survival among urban adults experiencing homelessness and mental illness.,"AIMS Using an entrepreneurship lens, this study examined the narratives of urban adults experiencing homelessness and living with mental illness, to explore strategies used for day-to-day survival. METHODS Semi-structured qualitative interviews were conducted with 14 females, 30 males, and one individual identifying as ""other,"" living in a mid-sized Canadian city. The average age was 39 years. Data were transcribed verbatim and analyzed using thematic analysis informed by grounded theory. FINDINGS Participants described creative and intentional strategies for managing life on the street without permanent shelter, including recognition of opportunities, mobilization of their own or acquired resources, and use of social connections and communication skills, and strategies that demonstrated entrepreneurial processes. CONCLUSIONS Findings suggest that participants used survival entrepreneurship strategies and processes to navigate daily life while experiencing homelessness. Recognition and validation of the propensity for enterprise and self-sufficiency are central for both individual recovery and ending homelessness within similar populations.",2019,Recognition and validation of the propensity for enterprise and self-sufficiency are central for both individual recovery and ending homelessness within similar populations.,"['urban adults experiencing homelessness and living with mental illness', 'urban adults experiencing homelessness and mental illness', 'Semi-structured qualitative interviews were conducted with 14 females, 30 males, and one individual identifying as ""other,"" living in a mid-sized Canadian city']",['entrepreneurship lens'],['entrepreneurship of survival'],"[{'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0237154', 'cui_str': 'Homeless'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0205556', 'cui_str': 'Qualitative'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0008848', 'cui_str': 'Cities'}]","[{'cui': 'C0085116', 'cui_str': 'Entrepreneurship'}, {'cui': 'C1444754', 'cui_str': 'Length'}]","[{'cui': 'C0085116', 'cui_str': 'Entrepreneurship'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.0489831,Recognition and validation of the propensity for enterprise and self-sufficiency are central for both individual recovery and ending homelessness within similar populations.,"[{'ForeName': 'Corinne A', 'Initials': 'CA', 'LastName': 'Isaak', 'Affiliation': 'Department of Psychiatry, University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Reynolds', 'Affiliation': 'Department of Psychology, University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Jitender', 'Initials': 'J', 'LastName': 'Sareen', 'Affiliation': 'Department of Psychiatry, University of Manitoba, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Jino', 'Initials': 'J', 'LastName': 'Distasio', 'Affiliation': 'Institute of Urban Studies, University of Winnipeg, Winnipeg, Manitoba, Canada.'}]",Journal of community psychology,['10.1002/jcop.22204'] 2684,31389278,Relationship between the Daily Rhythm of Distal Skin Temperature and Brown Adipose Tissue 18 F-FDG Uptake in Young Sedentary Adults.,"The present study examines whether the daily rhythm of distal skin temperature (DST) is associated with brown adipose tissue (BAT) metabolism as determined by 18 F-fluorodeoxyglucose ( 18 F-FDG) uptake in young adults. Using a wireless thermometer (iButton) worn on the nondominant wrist, DST was measured in 77 subjects (26% male; age 22 ± 2 years; body mass index 25.2 ± 4.8 kg/m 2 ) for 7 consecutive days. The temperatures to which they were habitually exposed over the day were also recorded. The interday stability of DST was calculated from the collected data, along with the intraday variability and relative amplitude; the mean temperature of the 5 and 10 consecutive hours with the maximum and minimum DST values, respectively; and when these hours occurred. Following exposure to cold, BAT volume and mean and peak standardized 18 F-FDG uptake (SUV mean and SUV peak ) were determined for each subject via static 18 F-FDG positron emission tomography/computed tomography scanning. Relative amplitude and the time at which the 10 consecutive hours of minimum DST values occurred were positively associated with BAT volume, SUV mean , and SUV peak ( p ≤ 0.02), whereas the mean DST of that period was inversely associated with the latter BAT variables ( p ≤ 0.01). The interday stability and intraday variability of the DST were also associated (directly and inversely, respectively) with BAT SUV peak ( p ≤ 0.02 for both). All of these associations disappeared, however, when the analyses were adjusted for the ambient temperature to which the subjects were habitually exposed. Thus, the relationship between the daily rhythm of DST and BAT activity estimated by 18 F-FDG uptake is masked by environmental and likely behavioral factors. Of note is that those participants exposed to the lowest ambient temperature showed 3 to 5 times more BAT volume and activity compared with subjects who were exposed to a warmer ambient temperature.",2019,"Following exposure to cold, BAT volume and mean and peak standardized 18 F-FDG uptake (SUV mean and SUV peak ) were determined for each subject via static 18 F-FDG positron emission tomography/computed tomography scanning.","['Young Sedentary Adults', 'young adults', '77 subjects (26% male; age 22 ± 2 years; body mass index 25.2 ± 4.8 kg/m 2 ) for 7 consecutive days']",['distal skin temperature (DST'],"['BAT SUV peak', 'BAT volume and mean and peak standardized 18 F-FDG uptake (SUV mean and SUV peak ', 'interday stability of DST', 'latter BAT variables', 'BAT volume and activity', 'interday stability and intraday variability of the DST', 'BAT volume, SUV mean , and SUV peak']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517765', 'cui_str': '4.8'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0037294', 'cui_str': 'Temperature of skin'}]","[{'cui': 'C0006298', 'cui_str': 'Brown fat'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0046056', 'cui_str': 'Fluorodeoxyglucose F18'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0037294', 'cui_str': 'Temperature of skin'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",77.0,0.0340463,"Following exposure to cold, BAT volume and mean and peak standardized 18 F-FDG uptake (SUV mean and SUV peak ) were determined for each subject via static 18 F-FDG positron emission tomography/computed tomography scanning.","[{'ForeName': 'Francisco M', 'Initials': 'FM', 'LastName': 'Acosta', 'Affiliation': 'PROFITH ""PROmoting FITness and Health through physical activity"" research group, Department of Physical and Sports Education, Sport and Health University Research Institute (iMUDS), Faculty of Sports Science, University of Granada, Granada, Spain.'}, {'ForeName': 'Borja', 'Initials': 'B', 'LastName': 'Martinez-Tellez', 'Affiliation': 'PROFITH ""PROmoting FITness and Health through physical activity"" research group, Department of Physical and Sports Education, Sport and Health University Research Institute (iMUDS), Faculty of Sports Science, University of Granada, Granada, Spain.'}, {'ForeName': 'Denis P', 'Initials': 'DP', 'LastName': 'Blondin', 'Affiliation': 'Faculty of Medicine and Health Sciences, Department of Pharmacology-Physiology, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Québec, Canada.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Haman', 'Affiliation': 'Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Patrick C N', 'Initials': 'PCN', 'LastName': 'Rensen', 'Affiliation': 'Department of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Jose M', 'Initials': 'JM', 'LastName': 'Llamas-Elvira', 'Affiliation': 'Servicio de Medicina Nuclear, Hospital Universitario Virgen de las Nieves, Granada, Spain; Instituto de Investigación Biosanitaria (ibs. GRANADA), Servicio de Medicina Nuclear, Granada, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Martinez-Nicolas', 'Affiliation': 'Chronobiology Lab, Department of Physiology, College of Biology, University of Murcia, Mare Nostrum Campus, IUIE, IMIB-Arrixaca, Murcia, Spain.'}, {'ForeName': 'Jonatan R', 'Initials': 'JR', 'LastName': 'Ruiz', 'Affiliation': 'PROFITH ""PROmoting FITness and Health through physical activity"" research group, Department of Physical and Sports Education, Sport and Health University Research Institute (iMUDS), Faculty of Sports Science, University of Granada, Granada, Spain.'}]",Journal of biological rhythms,['10.1177/0748730419865400'] 2685,32708396,Effects of Exercise Combined with a Healthy Diet or Calanus finmarchicus Oil Supplementation on Body Composition and Metabolic Markers-A Pilot Study.,"Aging is accompanied by a progressive decline in muscle mass and an increase in fat mass, which are detrimental changes associated with the development of health conditions such as type-2 diabetes mellitus or chronic low-grade inflammation. Although both exercise as well as nutritional interventions are known to be beneficial in counteracting those age-related changes, data to which extent untrained elderly people may benefit is still sparse. Therefore, a randomized, controlled, 12-week interventional trial was conducted in which 134 healthy untrained participants (96 women and 38 men, age 59.4 ± 5.6 years, body mass index (BMI) 28.4 ± 5.8 kg/m 2 ) were allocated to one of four study groups: (1) control group with no intervention (CON); (2) 2×/week aerobic and resistance training only (EX); (3) exercise routine combined with dietary counseling in accordance with the guidelines of the German Nutrition Society (EXDC); (4) exercise routine combined with intake of 2 g/day oil from Calanus finmarchicus (EXCO). Body composition (bioelectrical impedance analysis), as well as markers of glucose metabolism and blood lipids, were analyzed at the beginning and the end of the study. The highest decreases in body fat were observed within the EXCO group (-1.70 ± 2.45 kg, p < 0.001), and the EXDC (-1.41 ± 2.13 kg, p = 0.008) group. Markers of glucose metabolism and blood lipids remained unchanged in all groups. Taken together results of this pilot study suggest that a combination of moderate exercise and intake of oil from Calanus finmarchicus or a healthy diet may promote fat loss in elderly untrained overweight participants.",2020,Markers of glucose metabolism and blood lipids remained unchanged in all groups.,"['elderly untrained overweight participants', '134 healthy untrained participants (96 women and 38 men, age 59.4 ± 5.6 years, body mass index (BMI) 28.4 ± 5.8 kg/m 2 ']","['Exercise Combined with a Healthy Diet or Calanus finmarchicus Oil Supplementation', 'control group with no intervention (CON); (2) 2×/week aerobic and resistance training only (EX); (3) exercise routine combined with dietary counseling in accordance with the guidelines of the German Nutrition Society (EXDC); (4) exercise routine combined with intake of 2 g/day oil from Calanus finmarchicus (EXCO']","['Markers of glucose metabolism and blood lipids', 'Body composition (bioelectrical impedance analysis), as well as markers of glucose metabolism and blood lipids', 'body fat', 'Body Composition and Metabolic Markers']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517794', 'cui_str': '5.6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517796', 'cui_str': '5.8'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}]","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0162536', 'cui_str': 'Biolectric Impedance'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C1513159', 'cui_str': 'Metabolic marker'}]",134.0,0.0438269,Markers of glucose metabolism and blood lipids remained unchanged in all groups.,"[{'ForeName': 'Paulina', 'Initials': 'P', 'LastName': 'Wasserfurth', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany.'}, {'ForeName': 'Josefine', 'Initials': 'J', 'LastName': 'Nebl', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany.'}, {'ForeName': 'Jan Philipp', 'Initials': 'JP', 'LastName': 'Schuchardt', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany.'}, {'ForeName': 'Mattea', 'Initials': 'M', 'LastName': 'Müller', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany.'}, {'ForeName': 'Tim Konstantin', 'Initials': 'TK', 'LastName': 'Boßlau', 'Affiliation': 'Department of Exercise Physiology and Sports Therapy, Institute of Sports Science, Justus-Liebig-University Giessen, 35394 Giessen, Germany.'}, {'ForeName': 'Karsten', 'Initials': 'K', 'LastName': 'Krüger', 'Affiliation': 'Department of Exercise Physiology and Sports Therapy, Institute of Sports Science, Justus-Liebig-University Giessen, 35394 Giessen, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Hahn', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany.'}]",Nutrients,['10.3390/nu12072139'] 2686,32708428,Randomised Controlled Trial: Partial Hydrolysation of Casein Protein in Milk Decreases Gastrointestinal Symptoms in Subjects with Functional Gastrointestinal Disorders.,"Unspecific gastrointestinal symptoms associated with milk consumption are common. In addition to lactose, also other components of milk may be involved. We studied whether the partial hydrolysation of milk proteins would affect gastrointestinal symptoms in subjects with functional gastrointestinal disorders. In a randomised, placebo-controlled crossover intervention, subjects ( n = 41) were given ordinary or hydrolysed high-protein, lactose-free milkshakes (500 mL, 50 g protein) to be consumed daily for ten days. After a washout period of ten days, the other product was consumed for another ten days. Gastrointestinal symptoms were recorded daily during the study periods, and a validated irritable bowel syndrome-symptom severity scale (IBS-SSS) questionnaire was completed at the beginning of the study and at the end of both study periods. Blood and urine samples were analysed for markers of inflammation, intestinal permeability and immune activation. Both the IBS-SSS score ( p = 0.001) and total symptom score reported daily ( p = 0.002) were significantly reduced when participants consumed the hydrolysed product. Less bloating was reported during both study periods when compared with the baseline ( p < 0.01 for both groups). Flatulence ( p = 0.01) and heartburn ( p = 0.03) decreased when consuming the hydrolysed product but not when drinking the control product. No significant differences in the levels of inflammatory markers (tumor necrosis factor alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid binding protein 2, FABP2) or immune activation (1-methylhistamine) were detected between the treatment periods. The results suggest that the partial hydrolysation of milk proteins (mainly casein) reduces subjective symptoms to some extent in subjects with functional gastrointestinal disorders. The mechanism remains to be resolved.",2020,"No significant differences in the levels of inflammatory markers (tumor necrosis factor alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid binding protein 2, FABP2) or immune activation (1-methylhistamine) were detected between the treatment periods.","['subjects ( n = 41', 'Subjects with Functional Gastrointestinal Disorders', 'subjects with functional gastrointestinal disorders']","['ordinary or hydrolysed high-protein, lactose-free milkshakes', 'milk proteins (mainly casein', 'partial hydrolysation of milk proteins', 'Partial Hydrolysation of Casein Protein', 'placebo']","['total symptom score', 'IBS-SSS score', 'subjective symptoms', 'levels of inflammatory markers (tumor necrosis factor alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid binding protein 2, FABP2) or immune activation (1-methylhistamine', 'Flatulence', 'irritable bowel syndrome-symptom severity scale (IBS-SSS) questionnaire', 'Less bloating', 'gastrointestinal symptoms', 'heartburn', 'Gastrointestinal symptoms']","[{'cui': 'C0559031', 'cui_str': 'Functional disorder of gastrointestinal tract'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0022949', 'cui_str': 'Lactose'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0026138', 'cui_str': 'Milk protein'}, {'cui': 'C0007332', 'cui_str': 'Caseins'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0037052', 'cui_str': 'Sick sinus syndrome'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0031164', 'cui_str': 'Permeability'}, {'cui': 'C1173118', 'cui_str': 'FABP2 protein, human'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0076065', 'cui_str': 'tele-methylhistamine'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0018834', 'cui_str': 'Heartburn'}]",41.0,0.0657328,"No significant differences in the levels of inflammatory markers (tumor necrosis factor alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid binding protein 2, FABP2) or immune activation (1-methylhistamine) were detected between the treatment periods.","[{'ForeName': 'Reijo', 'Initials': 'R', 'LastName': 'Laatikainen', 'Affiliation': 'Booston Oy Ltd., Viikinkaari 6, FI-00790 Helsinki, Finland.'}, {'ForeName': 'Hanne', 'Initials': 'H', 'LastName': 'Salmenkari', 'Affiliation': 'Pharmacology, Medical Faculty, University of Helsinki, P.O. Box 63, FI-00014 Helsinki, Finland.'}, {'ForeName': 'Timo', 'Initials': 'T', 'LastName': 'Sibakov', 'Affiliation': 'Valio Ltd., R&D, P.O. Box 30, FI-00039 Valio, Finland.'}, {'ForeName': 'Heikki', 'Initials': 'H', 'LastName': 'Vapaatalo', 'Affiliation': 'Pharmacology, Medical Faculty, University of Helsinki, P.O. Box 63, FI-00014 Helsinki, Finland.'}, {'ForeName': 'Anu', 'Initials': 'A', 'LastName': 'Turpeinen', 'Affiliation': 'Valio Ltd., R&D, P.O. Box 30, FI-00039 Valio, Finland.'}]",Nutrients,['10.3390/nu12072140'] 2687,32708446,Effects on Gastroesophageal Reflux of Donkey Milk-Derived Human Milk Fortifier Versus Standard Fortifier in Preterm Newborns: Additional Data from the FortiLat Study.,"BACKGROUND Feeding intolerance is a frequent diagnosis in very preterm infants. As seen in the FortiLat trial, human milk fortification with the new donkey milk-derived human milk fortifier (DF) seems to improve feeding tolerance in these infants. The aim of this study was to evaluate the effects of using the DF compared with bovine milk-derived fortifier (BF) on gastroesophageal reflux (GER) in very low birth weight (VLBW) infants. METHODS Over a total of 156 preterm infants were enrolled into the FortiLat trial (GA <32 weeks and birth weight <1500 g) and randomized into the BF arm or DF arm, and we selected all infants with clinical signs of GER and cardiorespiratory (CR) symptoms. All the infants underwent CR and multichannel intraluminal impedance and pH (MII/pH) monitoring associated with gastric ultrasound to evaluate GER and gastric emptying time. RESULTS 10 infants were enrolled, and 5 were in the DF arm. At MII/pH, infants enrolled into the DF arm showed a lower GER frequency than BF arm infants ( p = 0.036). Half gastric emptying time was similar in DF and BF arm infants ( p = 0.744). CONCLUSION The use of donkey-derived human milk fortifier reduced the GER frequency and consequently should be recommended in infants with feeding intolerance.",2020,"Half gastric emptying time was similar in DF and BF arm infants ( p = 0.744). ","['very preterm infants', 'infants with feeding intolerance', 'very low birth weight (VLBW) infants', '156 preterm infants were enrolled into the FortiLat trial (GA', 'Preterm Newborns', '10 infants were enrolled, and 5 were in the DF arm']","['bovine milk-derived fortifier (BF', 'Donkey Milk-Derived Human Milk Fortifier Versus Standard Fortifier']","['feeding tolerance', 'gastroesophageal reflux (GER', 'GER frequency', 'lower GER frequency', 'Half gastric emptying time']","[{'cui': 'C3897192', 'cui_str': 'Very preterm infant'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1820738', 'cui_str': 'Feeding intolerance'}, {'cui': 'C0282666', 'cui_str': 'Very Low Birth Weight'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0026140', 'cui_str': 'Breast milk'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0007452', 'cui_str': 'Cattle'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0324145', 'cui_str': 'Equus asinus'}, {'cui': 'C3853188', 'cui_str': 'Human milk fortifier'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0017168', 'cui_str': 'Gastroesophageal reflux disease'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",156.0,0.0357146,"Half gastric emptying time was similar in DF and BF arm infants ( p = 0.744). ","[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Cresi', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Maggiora', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Pirra', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Tonetto', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Carlotta', 'Initials': 'C', 'LastName': 'Rubino', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Cavallarin', 'Affiliation': 'Institute of Sciences of Food Production, Italian National Research Council, 10126 Turin, Italy.'}, {'ForeName': 'Marzia', 'Initials': 'M', 'LastName': 'Giribaldi', 'Affiliation': 'Research Centre for Engineering and Agro-Food Processing, Council for Agricultural Research and Economics (CREA), 10100 Turin, Italy.'}, {'ForeName': 'Guido E', 'Initials': 'GE', 'LastName': 'Moro', 'Affiliation': 'Italian Association of Human Milk Banks, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Peila', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Coscia', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}]",Nutrients,['10.3390/nu12072142'] 2688,32708456,Long-Term Follow-Up of Targeted Biopsy Yield (LOFTY Study) in Ulcerative Colitis Surveillance Colonoscopy.,"We previously performed a randomized controlled trial (RCT) comparing targeted and random biopsy in neoplasia detection in patients with ulcerative colitis (UC), which showed the short-term effectiveness of targeted biopsy with one-time colonoscopy. In this retrospective cohort study, we investigated the long-term effectiveness of targeted biopsy in tertiary care hospitals, using the follow-up data from patients with UC for ≥ 8 years who had enrolled in the initial RCT. The primary outcome was death from colorectal cancer (CRC). Secondary outcomes were advanced neoplasia (CRC or high-grade dysplasia) and colectomy due to neoplasia after the RCT. We compared these outcomes between target and random groups. Data on 195 of the 221 patients (88.2%) enrolled in the previous RCT were collected from 28 institutions between 2008 and 2019. No patients died of CRC in either group, with a median 8.8-year follow-up demonstrating a robustness for targeted biopsy in terms of CRC death prevention. Advanced neoplasia was detected in four and three patients in the target and random groups, respectively. Colectomy was required due to neoplasia in three patients in each group. The chance of developing CRC in patients with a negative colonoscopy was low, and the targeted biopsy appeared effective in this population. Conversely, patients found with low-grade dysplasia at initial RCT have 10-fold higher risk of progression to high-grade dysplasia and/or CRC. Ten extracolonic malignancies were observed during the follow-up, resulting in four deaths. Panchromoendoscopy was used only in 4.6% and targeted biopsy was only performed in 59.1% of colonoscopies. We recommend targeted biopsy rather than > 33 random biopsies in real-world settings under adequate observation by specialists.",2020,"The chance of developing CRC in patients with a negative colonoscopy was low, and the targeted biopsy appeared effective in this population.","['patients with ulcerative colitis (UC', 'patients with UC for ≥ 8 years who had enrolled in the initial RCT', 'Ulcerative Colitis Surveillance Colonoscopy', 'Data on 195 of the 221 patients (88.2%) enrolled in the previous RCT were collected from 28 institutions between 2008 and 2019']","['random biopsy', 'Panchromoendoscopy']","['Advanced neoplasia', 'advanced neoplasia (CRC or high-grade dysplasia) and colectomy due to neoplasia after the RCT', 'died of CRC', 'death from colorectal cancer (CRC']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}]","[{'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}]","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0334044', 'cui_str': 'Dysplasia'}, {'cui': 'C0009274', 'cui_str': 'Excision of colon'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",28.0,0.0353662,"The chance of developing CRC in patients with a negative colonoscopy was low, and the targeted biopsy appeared effective in this population.","[{'ForeName': 'Keisuke', 'Initials': 'K', 'LastName': 'Hata', 'Affiliation': 'Department of Surgical Oncology, The University Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.'}, {'ForeName': 'Soichiro', 'Initials': 'S', 'LastName': 'Ishihara', 'Affiliation': 'Department of Surgical Oncology, The University Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.'}, {'ForeName': 'Yoichi', 'Initials': 'Y', 'LastName': 'Ajioka', 'Affiliation': 'Division of Molecular and Diagnostic Pathology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata 951-8510, Japan.'}, {'ForeName': 'Keiichi', 'Initials': 'K', 'LastName': 'Mitsuyama', 'Affiliation': 'Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Watanabe', 'Affiliation': 'Center for Inflammatory Bowel Disease, Division of Internal Medicine, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Hanai', 'Affiliation': 'Center for Gastroenterology & IBD Research Hamamatsu South Hospital, 26 Shirowa-cho, Minami-ku, Hamamatsu 430-0846, Japan.'}, {'ForeName': 'Reiko', 'Initials': 'R', 'LastName': 'Kunisaki', 'Affiliation': 'Inflammatory Bowel Disease Center, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama 232-0024, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Nakase', 'Affiliation': 'Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo 060-8543 Japan.'}, {'ForeName': 'Keiji', 'Initials': 'K', 'LastName': 'Matsuda', 'Affiliation': 'Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-Ku, Tokyo 117-0033, Japan.'}, {'ForeName': 'Ryuichi', 'Initials': 'R', 'LastName': 'Iwakiri', 'Affiliation': 'Faculty of Medicine, Saga University, 5-1-1, Nabeshima, Saga 849-8501, Japan.'}, {'ForeName': 'Nobuyuki', 'Initials': 'N', 'LastName': 'Hida', 'Affiliation': 'Center for Inflammatory Bowel Disease, Division of Internal Medicine, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Tanaka', 'Affiliation': 'Department of Endoscopy, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.'}, {'ForeName': 'Yoshiaki', 'Initials': 'Y', 'LastName': 'Takeuchi', 'Affiliation': 'Department of Medicine, Division of Gastroenterology, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan.'}, {'ForeName': 'Masaru', 'Initials': 'M', 'LastName': 'Shinozaki', 'Affiliation': 'Department of Surgery, the Institute of Medical Science, the University of Tokyo, Tokyo 108-8639, Japan.'}, {'ForeName': 'Noriyuki', 'Initials': 'N', 'LastName': 'Ogata', 'Affiliation': 'Digestive Disease Center, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-chuo, Tsuzuki Yokohama 224-8503, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Moriichi', 'Affiliation': 'Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan.'}, {'ForeName': 'Fumihito', 'Initials': 'F', 'LastName': 'Hirai', 'Affiliation': 'Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, 7-45-1 Nakanuma, Jonan-ku, Fukuoka 814-0180, Japan.'}, {'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Sugihara', 'Affiliation': 'Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.'}, {'ForeName': 'Tadakazu', 'Initials': 'T', 'LastName': 'Hisamatsu', 'Affiliation': 'Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan.'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Suzuki', 'Affiliation': 'Inflammatory Bowel Disease Center, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba 285-8741, Japan.'}, {'ForeName': 'Mamoru', 'Initials': 'M', 'LastName': 'Watanabe', 'Affiliation': 'Department of Gastroenterology and Hepatology, Advanced Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.'}, {'ForeName': 'Toshifumi', 'Initials': 'T', 'LastName': 'Hibi', 'Affiliation': 'Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, 5-9-1 Shirokanedai, Minato-ku, Tokyo 108-8642, Japan.'}]",Journal of clinical medicine,['10.3390/jcm9072286'] 2689,32708511,Lactobacillus paracasei KW3110 Suppresses Inflammatory Stress-Induced Premature Cellular Senescence of Human Retinal Pigment Epithelium Cells and Reduces Ocular Disorders in Healthy Humans.,"Lactobacillus paracasei KW3110 (KW3110) has anti-inflammatory effects and mitigates retinal pigment epithelium (RPE) cell damage caused by blue-light exposure. We investigated whether KW3110 suppresses chronic inflammatory stress-induced RPE cell damage by modulating immune cell activity and whether it improves ocular disorders in healthy humans. First, we showed that KW3110 treatment of mouse macrophages (J774A.1) produced significantly higher levels of interleukin-10 as compared with other lactic acid bacterium strains (all p < 0.01). Transferring supernatant from KW3110- and E. coli 0111:B4 strain and adenosine 5'-triphosphate (LPS/ATP)-stimulated J774A.1 cells to human retinal pigment epithelium (ARPE-19) cells suppressed senescence-associated phenotypes, including proliferation arrest, abnormal appearance, cell cycle arrest, and upregulation of cytokines, and also suppressed expression of tight junction molecule claudin-1. A randomized, double-blind, placebo-controlled parallel-group study of healthy subjects ( n = 88; 35 to below 50 years) ingesting placebo or KW3110-containing supplements for 8 weeks showed that changes in critical flicker frequency, an indicator of eye fatigue, from the week-0 value were significantly larger in the KW3110 group at weeks 4 ( p = 0.040) and 8 ( p = 0.036). These results suggest that KW3110 protects ARPE-19 cells against premature senescence and aberrant expression of tight junction molecules caused by chronic inflammatory stress, and may improve chronic eye disorders including eye fatigue.",2020,Lactobacillus paracasei KW3110 (KW3110) has anti-inflammatory effects and mitigates retinal pigment epithelium (RPE) cell damage caused by blue-light exposure.,"['Healthy Humans', 'healthy humans', 'healthy subjects ( n = 88; 35 to below 50 years) ingesting']","['placebo or KW3110-containing supplements', 'Lactobacillus paracasei KW3110 (KW3110', 'KW3110', 'Lactobacillus paracasei KW3110', 'placebo']","['critical flicker frequency, an indicator of eye fatigue']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C1080735', 'cui_str': 'Lactobacillus paracasei'}]","[{'cui': 'C0085635', 'cui_str': 'Photopsia'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0004095', 'cui_str': 'Accommodative asthenopia'}]",,0.0862613,Lactobacillus paracasei KW3110 (KW3110) has anti-inflammatory effects and mitigates retinal pigment epithelium (RPE) cell damage caused by blue-light exposure.,"[{'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Yamazaki', 'Affiliation': 'KIRIN Central Research Institute, Kirin Holdings Co., Ltd., Kanagawa 236-0004, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Suzuki', 'Affiliation': 'KIRIN Central Research Institute, Kirin Holdings Co., Ltd., Kanagawa 236-0004, Japan.'}, {'ForeName': 'Sayuri', 'Initials': 'S', 'LastName': 'Yamada', 'Affiliation': 'KIRIN Central Research Institute, Kirin Holdings Co., Ltd., Kanagawa 236-0004, Japan.'}, {'ForeName': 'Konomi', 'Initials': 'K', 'LastName': 'Ohshio', 'Affiliation': 'KIRIN Central Research Institute, Kirin Holdings Co., Ltd., Kanagawa 236-0004, Japan.'}, {'ForeName': 'Miho', 'Initials': 'M', 'LastName': 'Sugamata', 'Affiliation': 'KIRIN Central Research Institute, Kirin Holdings Co., Ltd., Kanagawa 236-0004, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Yamada', 'Affiliation': 'Ario Nishi-Arai Eye Clinic, Tokyo 123-0843, Japan.'}, {'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Morita', 'Affiliation': 'KIRIN Central Research Institute, Kirin Holdings Co., Ltd., Kanagawa 236-0004, Japan.'}]",International journal of molecular sciences,['10.3390/ijms21145091'] 2690,32708517,Concurrent Validity of Digital Vascular Auscultation for the Assessment of Blood Flow Obliteration on the Radial Artery in Healthy Subjects.,"This study aimed to determine the validity of digital vascular auscultation for the assessment of changes in the radial pulse in healthy subjects, using Doppler sonography as a validated test referent. Sixty-one non-symptomatic subjects (mean age of 52.5 ± 16.1 years) were assigned and evaluated under one of the following conditions: In condition 1, blood flow of the radial artery was not modified; for condition 2, blood flow of the radial artery was modified using a pressure sleeve around the humerus. The radial pulse was then measured three times with each diagnostic tool by three different blinded evaluators. Both instruments demonstrated a high association between the identification of blood flow modifications or not and the assigned condition ( p < 0.001). A strong concordance between the two devices when detecting the ""changes"" or ""no changes"" in blood flow was demonstrated ( k = 0.936, p < 0.001). Stethoscope sensitivity was 95%, and specificity was 99%. In conclusion, digital vascular auscultation seems to be a valid technique to examine blood flow changes of the radial artery in non-symptomatic subjects, and it could be useful for physical therapists when combined with provocative tests for the screening of possible thoracic outlet syndrome in patients.",2020,"A strong concordance between the two devices when detecting the ""changes"" or ""no changes"" in blood flow was demonstrated ( k = 0.936, p < 0.001).","['Sixty-one non-symptomatic subjects (mean age of 52.5 ± 16.1 years', 'healthy subjects', 'Healthy Subjects']","['digital vascular auscultation', 'Digital Vascular Auscultation']","['changes"" or ""no changes"" in blood flow', 'Stethoscope sensitivity', 'Blood Flow Obliteration', 'radial pulse']","[{'cui': 'C4517832', 'cui_str': '61'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517802', 'cui_str': '52.5'}, {'cui': 'C4319689', 'cui_str': '16.1'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0004339', 'cui_str': 'Auscultation'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0442739', 'cui_str': 'No status change'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0183559', 'cui_str': 'Stethoscope'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0332465', 'cui_str': 'Obliteration'}, {'cui': 'C0232142', 'cui_str': 'Radial pulse'}]",,0.0586544,"A strong concordance between the two devices when detecting the ""changes"" or ""no changes"" in blood flow was demonstrated ( k = 0.936, p < 0.001).","[{'ForeName': 'María-Dolores', 'Initials': 'MD', 'LastName': 'Cortés-Vega', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}, {'ForeName': 'María Jesús', 'Initials': 'MJ', 'LastName': 'Casuso-Holgado', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}, {'ForeName': 'Ángel', 'Initials': 'Á', 'LastName': 'Oliva-Pascual-Vaca', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}, {'ForeName': 'María-Isabel', 'Initials': 'MI', 'LastName': 'García-Bernal', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'González-García', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}, {'ForeName': 'Cleofás', 'Initials': 'C', 'LastName': 'Rodríguez-Blanco', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}]","Diagnostics (Basel, Switzerland)",['10.3390/diagnostics10070494'] 2691,32708555,"Caffeine Supplementation for 4 Days Does Not Induce Tolerance to the Ergogenic Effects Promoted by Acute Intake on Physiological, Metabolic, and Performance Parameters of Cyclists: A Randomized, Double-Blind, Crossover, Placebo-Controlled Study.","The present study investigated whether the caffeine supplementation for four days would induce tolerance to the ergogenic effects promoted by acute intake on physiological, metabolic, and performance parameters of cyclists. A double-blind placebo-controlled cross-over design was employed, involving four experimental trials; placebo (4-day)-placebo (acute)/PP, placebo (4-day)-caffeine (acute)/PC, caffeine (4-day)-caffeine (acute)/CC and caffeine (4-day)-placebo (acute)/CP. Fourteen male recreationally-trained cyclists ingested capsules containing either placebo or caffeine (6 mg∙kg -1 ) for 4 days. On day 5 (acute), capsules containing placebo or caffeine (6 mg∙kg -1 ) were ingested 60 min before completing a 16 km time-trial (TT). CC and PC showed improvements in time (3.54%, ES = 0.72; 2.53%, ES = 0.51) and in output power (2.85%, ES = 0.25; 2.53%, ES = 0.20) ( p < 0.05) compared to CP and PP conditions, respectively. These effects were accompanied by increased heart rate (2.63%, ES = 0.47; 1.99%, ES = 0.34), minute volume (13.11%, ES = 0.61; 16.32%, ES = 0.75), expired O 2 fraction (3.29%, ES = 0.96; 2.87, ES = 0.72), lactate blood concentration (immediately after, 29.51% ES = 0.78; 28.21% ES = 0.73 recovery (10 min), 36.01% ES = 0.84; 31.22% ES = 0.81), and reduction in expired CO 2 fraction (7.64%, ES = 0.64; 7.75%, ES = 0.56). In conclusion, these results indicate that caffeine, when ingested by cyclists in a dose of 6 mg∙kg -1 for 4 days, does not induce tolerance to the ergogenic effects promoted by acute intake on physiological, metabolic, and performance parameters.",2020,"CC and PC showed improvements in time (3.54%, ES = 0.72; 2.53%, ES = 0.51) and in output power (2.85%, ES = 0.25; 2.53%, ES = 0.20) ( p < 0.05) compared to CP and PP conditions, respectively.",['Fourteen male recreationally-trained cyclists ingested capsules containing either'],"['Placebo', 'Caffeine Supplementation', 'placebo or caffeine', 'caffeine supplementation', 'caffeine', 'placebo (4-day)-placebo (acute)/PP, placebo (4-day)-caffeine (acute)/PC, caffeine (4-day)-caffeine (acute)/CC and caffeine (4-day)-placebo', 'placebo']","['acute intake on physiological, metabolic, and performance parameters', 'lactate blood concentration', 'output power', 'heart rate', 'minute volume']","[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0332256', 'cui_str': 'Containing'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0427728', 'cui_str': 'Blood concentration, dipstick - finding'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0428679', 'cui_str': 'Minute volume'}]",,0.335508,"CC and PC showed improvements in time (3.54%, ES = 0.72; 2.53%, ES = 0.51) and in output power (2.85%, ES = 0.25; 2.53%, ES = 0.20) ( p < 0.05) compared to CP and PP conditions, respectively.","[{'ForeName': 'Anderson Pontes', 'Initials': 'AP', 'LastName': 'Morales', 'Affiliation': 'Laboratory Research and Innovation in Sports Sciences, Federal University of Rio de Janeiro (UFRJ), Macaé, RJ 27930-560, Brazil.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Sampaio-Jorge', 'Affiliation': 'Laboratory Research and Innovation in Sports Sciences, Federal University of Rio de Janeiro (UFRJ), Macaé, RJ 27930-560, Brazil.'}, {'ForeName': 'Thiago', 'Initials': 'T', 'LastName': 'Barth', 'Affiliation': 'Postgraduate Program in Bioactive Products and Biosciences, Federal University of Rio de Janeiro (UFRJ), Macaé, RJ 27930-560, Brazil.'}, {'ForeName': 'Anna Paola Trindade Rocha', 'Initials': 'APTR', 'LastName': 'Pierucci', 'Affiliation': 'Postgraduate Program in Nutrition, Josué de Castro Nutrition Institute, Federal University of Rio de Janeiro (UFRJ), Macaé, RJ 21941-590, Brazil.'}, {'ForeName': 'Beatriz Gonçalves', 'Initials': 'BG', 'LastName': 'Ribeiro', 'Affiliation': 'Laboratory Research and Innovation in Sports Sciences, Federal University of Rio de Janeiro (UFRJ), Macaé, RJ 27930-560, Brazil.'}]",Nutrients,['10.3390/nu12072101'] 2692,32708600,Impact of Exercises and Chair Massage on Musculoskeletal Pain of Young Musicians.,"Due to the occurrence among musicians of musculoskeletal problems associated with playing a musical instrument, it is necessary to use prophylaxis. The aim of the study was to compare the effectiveness of two physioprophylaxis methods: chair massage and an original set of exercises. The study lasted four weeks and consisted of eight 15-min meetings (chair massage/exercises). The study was conducted on 44 music students assigned to three groups (chair massage/exercise program/control group). The algometric measurements and questionnaire were conducted. Health problems associated with playing an instrument was reported by 86.4% of the participants. The largest changes in pain threshold concerned the trigger points of the muscles with the highest pain sensitivity, i.e., upper part of trapezius ones, and reached 25-34% in relation to the initial values. For the trigger points of the levator scapulae and lower part of trapezius, the increase in the pain threshold was between 20 and 28%. Raising the pain threshold was observed both after each session and meeting by meeting, and these differences were most visible in the massage group. This effect was particularly visible from the fourth treatment. Chair massage and exercise should be used regularly, and significant results can be obtained after two weeks.",2020,"For the trigger points of the levator scapulae and lower part of trapezius, the increase in the pain threshold was between 20 and 28%.","['44 music students assigned to three groups ', 'Musculoskeletal Pain of Young Musicians']","['Exercises and Chair Massage', 'physioprophylaxis methods: chair massage', 'Chair massage and exercise', 'chair massage/exercise program/control group']",['pain threshold'],"[{'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0026858', 'cui_str': 'Musculoskeletal pain'}, {'cui': 'C0332239', 'cui_str': 'Young'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0162703', 'cui_str': 'Pain threshold'}]",44.0,0.0195533,"For the trigger points of the levator scapulae and lower part of trapezius, the increase in the pain threshold was between 20 and 28%.","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Cygańska', 'Affiliation': 'Faculty of Rehabilitation, Józef Piłsudski University of Physical Education in Warsaw, Poland, Marymoncka 34, 00-968 Warsaw, Poland.'}, {'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Truszczyńska-Baszak', 'Affiliation': 'Faculty of Rehabilitation, Józef Piłsudski University of Physical Education in Warsaw, Poland, Marymoncka 34, 00-968 Warsaw, Poland.'}, {'ForeName': 'Paweł', 'Initials': 'P', 'LastName': 'Tomaszewski', 'Affiliation': 'Faculty of Physical Education, Józef Piłsudski University of Physical Education in Warsaw, Poland, Marymoncka 34, 00-968 Warsaw, Poland.'}]",International journal of environmental research and public health,['10.3390/ijerph17145128'] 2693,32708637,Virtual Reality Aggression Prevention Therapy (VRAPT) versus Waiting List Control for Forensic Psychiatric Inpatients: A Multicenter Randomized Controlled Trial.,"Many forensic psychiatric inpatients have difficulties regulating aggressive behavior. Evidence of effective aggression treatments is limited. We designed and investigated the effectiveness of a transdiagnostic application of a virtual reality aggression prevention training (VRAPT). In this randomized controlled trial at four Dutch forensic psychiatric centers, 128 inpatients with aggressive behavior were randomly assigned to VRAPT ( N = 64) or waiting list control group ( N = 64). VRAPT consisted of 16 one-hour individual treatment sessions twice a week. Assessments were done at baseline, post-treatment and at 3-month follow-up. Primary outcome measures were aggressive behavior observed by staff and self-reported aggressive behavior. Analysis was by intention to treat. This trial was registered in the Dutch Trial Register (NTR, TC = 6340). Participants were included between 1 March 2017, and 31 December 2018. Compared to waiting list, VRAPT did not significantly decrease in self-reported or observed aggressive behavior (primary outcomes). Hostility, anger control, and non-planning impulsiveness improved significantly in the VRAPT group compared to the control group at post-treatment. Improvements were not maintained at 3-month follow-up. Results suggest that VRAPT does not decrease aggressive behavior in forensic inpatients. However, there are indications that VRAPT temporarily influences anger control skills, impulsivity and hostility.",2020,"Hostility, anger control, and non-planning impulsiveness improved significantly in the VRAPT group compared to the control group at post-treatment.","['forensic inpatients', 'Participants were included between 1 March 2017, and 31 December 2018', 'Forensic Psychiatric Inpatients', 'four Dutch forensic psychiatric centers, 128 inpatients with aggressive behavior']","['virtual reality aggression prevention training (VRAPT', 'waiting list control', 'Virtual Reality Aggression Prevention Therapy (VRAPT', 'VRAPT']","['anger control skills, impulsivity and hostility', 'Hostility, anger control, and non-planning impulsiveness', 'aggressive behavior', 'aggressive behavior observed by staff and self-reported aggressive behavior']","[{'cui': 'C0016557', 'cui_str': 'Medicine, Forensic'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0748064', 'cui_str': 'Psychiatric in-patient'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0002957', 'cui_str': 'Feeling angry'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021125', 'cui_str': 'Impulsive behaviour'}, {'cui': 'C0020039', 'cui_str': 'Hostile behavior'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning'}, {'cui': 'C0564567', 'cui_str': 'Impulsive character'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}]",128.0,0.149137,"Hostility, anger control, and non-planning impulsiveness improved significantly in the VRAPT group compared to the control group at post-treatment.","[{'ForeName': 'Stéphanie', 'Initials': 'S', 'LastName': 'Klein Tuente', 'Affiliation': 'Department of Psychiatry, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Bogaerts', 'Affiliation': 'Department of Developmental Psychology, Tilburg University, Prof Cobbenhagenlaan 225, P.O. Box 90153, 5000 LE Tilburg, The Netherlands.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Bulten', 'Affiliation': 'Division Diagnostics Research and Education, Forensic Psychiatric Hospital Pompefoundation, Weg door Jonkerbos 55, 6532 CN Nijmegen, The Netherlands.'}, {'ForeName': 'Marije', 'Initials': 'M', 'LastName': 'Keulen-de Vos', 'Affiliation': 'Forensic Psychiatric Center (FPC) de Rooyse Wissel, P.O. Box 433, 5800AK Venray, The Netherlands.'}, {'ForeName': 'Maarten', 'Initials': 'M', 'LastName': 'Vos', 'Affiliation': 'Department of Psychiatry, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Hein', 'Initials': 'H', 'LastName': 'Bokern', 'Affiliation': 'Forensic Psychiatric Center (FPC) Dr. S. van Mesdag, Helperlinie 2, 9722 AZ Groningen, The Netherlands.'}, {'ForeName': 'Sarah van', 'Initials': 'SV', 'LastName': 'IJzendoorn', 'Affiliation': 'Fivoor, Fivoor Science & Treatment Innovation, Kijvelandsekade 1, 3172 AB Poortugaal, The Netherlands.'}, {'ForeName': 'Chris N W', 'Initials': 'CNW', 'LastName': 'Geraets', 'Affiliation': 'Department of Psychiatry, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'Veling', 'Affiliation': 'Department of Psychiatry, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.'}]",Journal of clinical medicine,['10.3390/jcm9072258'] 2694,32708657,Changes in Circulating Extracellular Vesicles in Patients with ST-Elevation Myocardial Infarction and Potential Effects of Remote Ischemic Conditioning-A Randomized Controlled Trial.,"(1) Background: Extracellular vesicles (EVs) have been recognized as a cellular communication tool with cardioprotective properties; however, it is unknown whether cardioprotection by remote ischemic conditioning (RIC) involves EVs. (2) Methods: We randomized patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) to additionally receive a protocol of RIC or a sham-intervention. Blood was taken before and immediately, 24 h, four days and one month after PCI. Additionally, we investigated EVs from healthy volunteers undergoing RIC. EVs were characterized by a high-sensitive flow cytometer (Beckman Coulter Cytoflex S, Krefeld, Germany). (3) Results: We analyzed 32 patients (16 RIC, 16 control) and five healthy volunteers. We investigated platelet-, endothelial-, leukocyte-, monocyte- and granulocyte-derived EVs and their pro-thrombotic sub-populations expressing superficial phosphatidylserine (PS + ). We did not observe a significant effect of RIC on the numbers of circulating EVs, although granulocyte-derived EVs were significantly higher in the RIC group. In line, RIC had not impact on EVs in healthy volunteers. Additionally, we observed changes of PS + /PEV, EEVs and PS + /CD15 + EVs irrespective of RIC with time following STEMI. 4) Conclusion: We provide further insights into the course of different circulating EVs during the acute and sub-acute phases of STEMI. With respect to the investigated EV populations, RIC seems to have no effect, with only minor differences found for granulocyte EVs.",2020,"With respect to the investigated EV populations, RIC seems to have no effect, with only minor differences found for granulocyte EVs.","['patients with ST-elevation myocardial infarction (STEMI) undergoing primary', 'healthy volunteers', 'Patients with ST-Elevation Myocardial Infarction', '32 patients (16 RIC, 16 control) and five healthy volunteers', 'healthy volunteers undergoing RIC']","['platelet-, endothelial-, leukocyte-, monocyte- and granulocyte-derived EVs and their pro-thrombotic sub-populations expressing superficial phosphatidylserine (PS + ', 'percutaneous coronary intervention (PCI) to additionally receive a protocol of RIC or a sham-intervention']","['PS + /PEV, EEVs and PS + /CD15 + EVs irrespective of RIC', 'numbers of circulating EVs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1303258', 'cui_str': 'Acute ST segment elevation myocardial infarction'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0026473', 'cui_str': 'Monocyte'}, {'cui': 'C0018183', 'cui_str': 'Granulocyte'}, {'cui': 'C0560135', 'cui_str': 'eV'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0031623', 'cui_str': 'Phosphatidylserine'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0560135', 'cui_str': 'eV'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}]",32.0,0.0477398,"With respect to the investigated EV populations, RIC seems to have no effect, with only minor differences found for granulocyte EVs.","[{'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Haller', 'Affiliation': '3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, 1160 Vienna, Austria.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Jäger', 'Affiliation': '3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, 1160 Vienna, Austria.'}, {'ForeName': 'Edita', 'Initials': 'E', 'LastName': 'Piackova', 'Affiliation': '3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, 1160 Vienna, Austria.'}, {'ForeName': 'Larissa', 'Initials': 'L', 'LastName': 'Sztulman', 'Affiliation': '3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, 1160 Vienna, Austria.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Wegberger', 'Affiliation': '3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, 1160 Vienna, Austria.'}, {'ForeName': 'Johann', 'Initials': 'J', 'LastName': 'Wojta', 'Affiliation': 'Ludwig Boltzmann Institute for Cardiovascular Research, 1160 Vienna, Austria.'}, {'ForeName': 'Mariann', 'Initials': 'M', 'LastName': 'Gyöngyösi', 'Affiliation': 'Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.'}, {'ForeName': 'Attila', 'Initials': 'A', 'LastName': 'Kiss', 'Affiliation': 'Ludwig Boltzmann Institute for Cardiovascular Research, 1160 Vienna, Austria.'}, {'ForeName': 'Bruno K', 'Initials': 'BK', 'LastName': 'Podesser', 'Affiliation': 'Ludwig Boltzmann Institute for Cardiovascular Research, 1160 Vienna, Austria.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Spittler', 'Affiliation': 'Core Facility, Medical University of Vienna, 1090 Vienna, Austria.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Huber', 'Affiliation': '3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, 1160 Vienna, Austria.'}]",Biomedicines,['10.3390/biomedicines8070218'] 2695,32708699,A Randomized Controlled Trial of Thermo-Sensitive Sol-Gel Anti-Adhesion Agent after Gynecologic Surgery.,"Postoperative abdominal adhesions can lead to several adverse consequences such as pelvic pain, bowel obstruction, and infertility. We aimed to explore the anti-adhesion efficacy and safety of a thermo-sensitive sol-gel agent in patients who receive abdominopelvic surgery for benign gynecologic disease. This study was a randomized, controlled, single-blind clinical trial of women undergoing benign gynecologic surgery between January 2017 and December 2017. The patients were randomly assigned to three groups with a 1:1:1 ratio: experimental group (received the thermo-sensitive sol-gel agent), control group (untreated), and comparator group (received 4% icodextrin). Patients were followed for 4 weeks postoperatively, and efficacy was evaluated by performing the visceral slide test to identify adhesion formation. In total, 183 patients were enrolled in the study, and 178 (97.3%) completed the trial. The incidence rate of abdominal adhesion formation was significantly lower in the experimental group than in the control group (7.9% vs. 21.1%, p = 0.040); however, it was similar between the experimental and comparator groups (7.9% vs. 13.8%. p = 0.299). At 4 weeks, no differences in adhesion-related symptoms were observed between the experimental and control groups. Adverse events were mostly mild and did not differ significantly among the three groups ( p = 0.375). In conclusion, use of a thermo-sensitive sol-gel agent was safe and effective to prevent abdominal adhesions after benign gynecologic surgeries.",2020,Adverse events were mostly mild and did not differ significantly among the three groups ( p = 0.375).,"['patients who receive abdominopelvic surgery for benign gynecologic disease', 'after Gynecologic Surgery', '183 patients were enrolled in the study, and 178 (97.3%) completed the trial', 'women undergoing benign gynecologic surgery between January 2017 and December 2017']","['thermo-sensitive sol-gel agent', 'Thermo-Sensitive Sol-Gel Anti-Adhesion Agent', 'thermo-sensitive sol-gel agent), control group (untreated), and comparator group (received 4% icodextrin']","['adhesion-related symptoms', 'abdominal adhesions', 'Adverse events', 'incidence rate of abdominal adhesion formation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205183', 'cui_str': 'Benign'}, {'cui': 'C0017411', 'cui_str': 'Disorder of female genital organs'}, {'cui': 'C0038902', 'cui_str': 'Operation on female genital organs'}, {'cui': 'C4517615', 'cui_str': '183'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0205208', 'cui_str': 'Solid'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0001511', 'cui_str': 'Adhesion'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0538727', 'cui_str': 'icodextrin'}]","[{'cui': 'C0001511', 'cui_str': 'Adhesion'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0549357', 'cui_str': 'Abdominal adhesions'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}]",183.0,0.0586886,Adverse events were mostly mild and did not differ significantly among the three groups ( p = 0.375).,"[{'ForeName': 'Young Im', 'Initials': 'YI', 'LastName': 'Kim', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul 03080, Korea.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Lee', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Korea.'}, {'ForeName': 'Se Ik', 'Initials': 'SI', 'LastName': 'Kim', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Korea.'}, {'ForeName': 'Aeran', 'Initials': 'A', 'LastName': 'Seol', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Korea.'}, {'ForeName': 'Eun Ji', 'Initials': 'EJ', 'LastName': 'Lee', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Korea.'}, {'ForeName': 'Hee Seung', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Korea.'}, {'ForeName': 'Yong Sang', 'Initials': 'YS', 'LastName': 'Song', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Korea.'}]",Journal of clinical medicine,['10.3390/jcm9072261'] 2696,32708705,Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy.,"The metabolic requirements of metastatic non-small cell lung (mNSCLC) tumors from patients receiving first-line platinum-doublet chemotherapy are hypothesized to imprint a blood signature suitable for survival prediction. Pre-treatment samples prospectively collected at baseline from a randomized phase III trial were assayed using nuclear magnetic resonance (NMR) spectroscopy ( n = 341) and ultra-high performance liquid chromatography - mass spectrometry (UPLC-MS) ( n = 297). Distributions of time to event outcomes were estimated by Kaplan-Meier analysis, and baseline characteristics adjusted Cox regression modeling was used to correlate markers' levels to time to event outcomes. Sixteen polar metabolites were significantly correlated with overall survival (OS) by univariate analysis ( p < 0.025). Formate, 2-hydroxybutyrate, glycine and myo -inositol were selected for a multivariate model. The median OS was 6.6 months in the high-risk group compared to 11.4 months in the low risk group HR (Hazard Ratio) = 1.99, 95% C.I. (Confidence Interval) 1.45-2.68; p < 0.0001). Modeling of lipids by class (sphingolipids, acylcarnitines and lysophosphatidylcholines) revealed a median OS = 5.7 months vs. 11. 9 months for the high vs. low risk group. (HR: 2.23, 95% C.I. 1.55-3.20; p < 0.0001). These results demonstrate that metabolic profiles from pre-treatment samples may be useful to stratify clinical outcomes for mNSCLC patients receiving chemotherapy. Genomic and longitudinal measurements pre- and post-treatment may yield addition information to personalize treatment decisions further.",2020,Sixteen polar metabolites were significantly correlated with overall survival (OS) by univariate analysis ( p < 0.025).,"['Metastatic Non-Small Cell Lung Cancer', 'metastatic non-small cell lung (mNSCLC) tumors from patients receiving first-line platinum-doublet chemotherapy', 'mNSCLC patients receiving chemotherapy']","['nuclear magnetic resonance (NMR) spectroscopy ( n = 341) and ultra-high performance liquid chromatography - mass spectrometry (UPLC-MS', 'First-Line Platinum-Doublet Chemotherapy']","['median OS', 'overall survival (OS']","[{'cui': 'C0278987', 'cui_str': 'Metastatic non-small cell lung cancer'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0445128', 'cui_str': 'Non-small cell'}, {'cui': 'C0024121', 'cui_str': 'Neoplasm of lung'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0877853', 'cui_str': 'Spectroscopy, NMR'}, {'cui': 'C0008562', 'cui_str': 'High pressure liquid chromatography'}, {'cui': 'C0037813', 'cui_str': 'Mass spectrometry measurement'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.0689696,Sixteen polar metabolites were significantly correlated with overall survival (OS) by univariate analysis ( p < 0.025).,"[{'ForeName': 'Desirée', 'Initials': 'D', 'LastName': 'Hao', 'Affiliation': 'Department of Medical Oncology, Tom Baker Cancer Centre and Cummings School of Medicine, University of Calgary, 1331-29th Street N.W., Calgary, AB T2N 4N2, Canada.'}, {'ForeName': 'Arjun', 'Initials': 'A', 'LastName': 'Sengupta', 'Affiliation': 'Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA 19104, USA.'}, {'ForeName': 'Keyue', 'Initials': 'K', 'LastName': 'Ding', 'Affiliation': ""Canadian Cancer Trials Group, Queen's University, 10 Stuart Street, Kingston, ON K7L 3N6, Canada.""}, {'ForeName': 'E R', 'Initials': 'ER', 'LastName': 'Ubeydullah', 'Affiliation': 'Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA 19104, USA.'}, {'ForeName': 'Saikumari', 'Initials': 'S', 'LastName': 'Krishnaiah', 'Affiliation': 'Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA 19104, USA.'}, {'ForeName': 'Natasha B', 'Initials': 'NB', 'LastName': 'Leighl', 'Affiliation': 'University Health Network, Princess Margaret Cancer Centre, 700 University Avenue, Toronto, ON M5G 1Z5, Canada.'}, {'ForeName': 'Frances A', 'Initials': 'FA', 'LastName': 'Shepherd', 'Affiliation': 'University Health Network, Princess Margaret Cancer Centre, 700 University Avenue, Toronto, ON M5G 1Z5, Canada.'}, {'ForeName': 'Lesley', 'Initials': 'L', 'LastName': 'Seymour', 'Affiliation': ""Canadian Cancer Trials Group, Queen's University, 10 Stuart Street, Kingston, ON K7L 3N6, Canada.""}, {'ForeName': 'Aalim', 'Initials': 'A', 'LastName': 'Weljie', 'Affiliation': 'Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA 19104, USA.'}]",Cancers,['10.3390/cancers12071926'] 2697,32708741,Locally Applied Slow-Release of Minocycline Microspheres in the Treatment of Peri-Implant Mucositis: An Experimental In Vivo Study.,"BACKGROUND The objective of this is preclinical investigation was to evaluate the differential drug sustainability and pharmacodynamic properties of two local minocycline microsphere carriers: chitosan-coated alginate (CA) and poly(meth)acrylate-glycerin (PG). METHODS Four dental implants were placed unilaterally in the edentulous mandible of six beagle dogs. Each implant was randomly assigned to receive one of the following four treatments: (i) CA (CA-based minocycline), (ii) placebo (CA substrate without minocycline), (iii) PG (PG-based minocycline) and (iv) control (mechanical debridement only). After inducing peri-implant mucositis, the randomly assigned treatments were administered into the gingival sulcus twice at a 4-week interval using a plastic-tipped syringe. Drug sustainability and pharmacodynamic (clinical, radiographical and cell marker intensity) evaluations were performed after each administration. RESULTS The CA microspheres remained longer around the healing abutment compared to the PG microspheres at both administrations and a longer bacteriostatic effect was observed from CA (7.0 ± 5.7 days) compared to PG (1.2 ± 2.6 days). The efficacy of the applied therapies based on clinical, radiographical and histological analyses were comparable across all treatment groups. CONCLUSIONS CA microspheres showed longer carrier and bacteriostatic effect sustainability when compared to PG microspheres, however, longer drug sustainability did not lead to improved treatment outcomes.",2020,The CA microspheres remained longer around the healing abutment compared to the PG microspheres at both administrations and a longer bacteriostatic effect was observed from CA (7.0 ± 5.7 days) compared to PG (1.2 ± 2.6 days).,"['Peri-Implant Mucositis', 'Four dental implants were placed unilaterally in the edentulous mandible of six beagle dogs']","['Minocycline Microspheres', 'CA microspheres', 'CA (CA-based minocycline), (ii) placebo (CA substrate without minocycline), (iii) PG (PG-based minocycline) and (iv) control (mechanical debridement only', 'minocycline microsphere carriers: chitosan-coated alginate (CA) and poly(meth)acrylate-glycerin (PG']","['longer carrier and bacteriostatic effect sustainability', 'bacteriostatic effect', 'Drug sustainability and pharmacodynamic (clinical, radiographical and cell marker intensity) evaluations', 'CA microspheres']","[{'cui': 'C3698407', 'cui_str': 'Peri-implant mucositis'}, {'cui': 'C0011370', 'cui_str': 'Dental implantation'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C3853359', 'cui_str': 'Edentulous mandible'}, {'cui': 'C0324306', 'cui_str': 'Beagle'}, {'cui': 'C0012984', 'cui_str': 'Canis lupus familiaris'}]","[{'cui': 'C0026187', 'cui_str': 'Minocycline'}, {'cui': 'C0026032', 'cui_str': 'Microbeads'}, {'cui': 'C0453946', 'cui_str': 'Coat'}, {'cui': 'C0002040', 'cui_str': 'Alginates'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0597265', 'cui_str': 'polyacrylate'}, {'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}, {'cui': 'C0162969', 'cui_str': 'Chitosan'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1611701', 'cui_str': 'Cell marker'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0453946', 'cui_str': 'Coat'}, {'cui': 'C0002040', 'cui_str': 'Alginates'}, {'cui': 'C0026032', 'cui_str': 'Microbeads'}]",,0.0567987,The CA microspheres remained longer around the healing abutment compared to the PG microspheres at both administrations and a longer bacteriostatic effect was observed from CA (7.0 ± 5.7 days) compared to PG (1.2 ± 2.6 days).,"[{'ForeName': 'Sung-Wook', 'Initials': 'SW', 'LastName': 'Yoon', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul 03772, Korea.'}, {'ForeName': 'Myong-Ji', 'Initials': 'MJ', 'LastName': 'Kim', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul 03772, Korea.'}, {'ForeName': 'Kyeong-Won', 'Initials': 'KW', 'LastName': 'Paeng', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul 03772, Korea.'}, {'ForeName': 'Kyeong Ae', 'Initials': 'KA', 'LastName': 'Yu', 'Affiliation': 'College of Pharmacy, Chungbuk National University, Cheongju 28165, Korea.'}, {'ForeName': 'Chong-Kil', 'Initials': 'CK', 'LastName': 'Lee', 'Affiliation': 'College of Pharmacy, Chungbuk National University, Cheongju 28165, Korea.'}, {'ForeName': 'Young Woo', 'Initials': 'YW', 'LastName': 'Song', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul 03772, Korea.'}, {'ForeName': 'Jae-Kook', 'Initials': 'JK', 'LastName': 'Cha', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul 03772, Korea.'}, {'ForeName': 'Mariano', 'Initials': 'M', 'LastName': 'Sanz', 'Affiliation': 'Section of Graduate Periodontology, Faculty of Odontology, Complutense University of Madrid, 28040 Madrid, Spain.'}, {'ForeName': 'Ui-Won', 'Initials': 'UW', 'LastName': 'Jung', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul 03772, Korea.'}]",Pharmaceutics,['10.3390/pharmaceutics12070668'] 2698,32708743,Effect of a Nutritional Intervention on the Intestinal Microbiota of Vertically HIV-Infected Children: The Pediabiota Study.,"AIMS The gut microbiota exerts a critical influence in the immune system. The gut microbiota of human virus immunodeficiency (HIV)-infected children remains barely explored. We aimed to characterize the fecal microbiota in vertically HIV-infected children and to explore the effects of its modulation with a symbiotic nutritional intervention. METHODS a pilot, double blind, randomized placebo-controlled study including HIV-infected children who were randomized to receive a nutritional supplementation including prebiotics and probiotics or placebo for four weeks. HIV-uninfected siblings were recruited as controls. The V3-V4 region of the 16S rRNA gene was sequenced in fecal samples. RESULTS 22 HIV-infected children on antiretroviral therapy (ART) and with viral load (VL) <50/mL completed the follow-up period. Mean age was 11.4 ± 3.4 years, eight (32%) were male. Their microbiota showed reduced alpha diversity compared to controls and distinct beta diversity at the genus level (Adonis p = 0.042). Patients showed decreased abundance of commensals Faecalibacterium and an increase in Prevotella, Akkermansia and Escherichia. The nutritional intervention shaped the microbiota towards the control group, without a clear directionality. CONCLUSIONS Vertical HIV infection is characterized by changes in gut microbiota structure, distinct at the compositional level from the findings reported in adults. A short nutritional intervention attenuated bacterial dysbiosis, without clear changes at the community level. SUMMARY In a group of 24 vertically HIV-infected children, in comparison to 11 uninfected controls, intestinal dysbiosis was observed despite effective ART. Although not fully effective to restore the microbiota, a short intervention with pre/probiotics attenuated bacterial dysbiosis.",2020,Their microbiota showed reduced alpha diversity compared to controls and distinct beta diversity at the genus level,"['HIV-infected children', 'Vertically HIV-Infected Children', '22 HIV-infected children on antiretroviral therapy (ART) and with viral load (VL) <50/mL completed the follow-up period', 'vertically HIV-infected children', 'HIV-uninfected siblings', 'Mean age was 11.4 ± 3.4 years, eight (32%) were male']","['nutritional supplementation including prebiotics and probiotics or placebo', 'Nutritional Intervention', 'symbiotic nutritional intervention', 'placebo']","['abundance of commensals Faecalibacterium and an increase in Prevotella, Akkermansia and Escherichia', 'fecal microbiota', 'alpha diversity']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0037047', 'cui_str': 'Sibling'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517533', 'cui_str': '11.4'}, {'cui': 'C4517692', 'cui_str': '3.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}]","[{'cui': 'C0542329', 'cui_str': 'Commensal parasite'}, {'cui': 'C1229075', 'cui_str': 'Faecalibacterium'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0242946', 'cui_str': 'Prevotella'}, {'cui': 'C1490589', 'cui_str': 'Akkermansia'}, {'cui': 'C0014833', 'cui_str': 'Escherichia'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}]",,0.0511436,Their microbiota showed reduced alpha diversity compared to controls and distinct beta diversity at the genus level,"[{'ForeName': 'Talía', 'Initials': 'T', 'LastName': 'Sainz', 'Affiliation': 'Servicio de Pediatría, Hospital Universitario La Paz and IdiPAZ, 28046 Madrid, Spain.'}, {'ForeName': 'María José', 'Initials': 'MJ', 'LastName': 'Gosalbes', 'Affiliation': 'Área Genómica y Salud, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), 46010 Valencia, Spain.'}, {'ForeName': 'Alba', 'Initials': 'A', 'LastName': 'Talavera', 'Affiliation': 'Bioinformatics Unit, Hospital Universitario Ramón y Cajal and IRYCIS, 28034 Madrid, Spain.'}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Jimenez-Hernandez', 'Affiliation': 'Área Genómica y Salud, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), 46010 Valencia, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Prieto', 'Affiliation': 'Red de Investigación CoRISpe integrada en la Red en Infectología Pediátrica (RITIP), 28046 Madrid, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Escosa', 'Affiliation': 'Servicio de Pediatría, Hospital Universitario La Paz and IdiPAZ, 28046 Madrid, Spain.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Guillén', 'Affiliation': 'Red de Investigación CoRISpe integrada en la Red en Infectología Pediátrica (RITIP), 28046 Madrid, Spain.'}, {'ForeName': 'José Tomás', 'Initials': 'JT', 'LastName': 'Ramos', 'Affiliation': 'Red de Investigación CoRISpe integrada en la Red en Infectología Pediátrica (RITIP), 28046 Madrid, Spain.'}, {'ForeName': 'María Ángeles', 'Initials': 'MÁ', 'LastName': 'Muñoz-Fernández', 'Affiliation': 'Laboratorio InmunoBiología Molecular, Sección Inmunología, Hospital General Universitario Gregorio Marañón and Spanish HIV HGM BioBank, Madrid Spain, Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28007 Madrid, Spain.'}, {'ForeName': 'Andrés', 'Initials': 'A', 'LastName': 'Moya', 'Affiliation': 'Área Genómica y Salud, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), 46010 Valencia, Spain.'}, {'ForeName': 'Maria Luisa', 'Initials': 'ML', 'LastName': 'Navarro', 'Affiliation': 'Red de Investigación CoRISpe integrada en la Red en Infectología Pediátrica (RITIP), 28046 Madrid, Spain.'}, {'ForeName': 'María José', 'Initials': 'MJ', 'LastName': 'Mellado', 'Affiliation': 'Servicio de Pediatría, Hospital Universitario La Paz and IdiPAZ, 28046 Madrid, Spain.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Serrano-Villar', 'Affiliation': 'Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal and IRYCIS, 28034 Madrid, Spain.'}]",Nutrients,['10.3390/nu12072112'] 2699,32708831,Effect of a Single Nutritional Intervention Previous to a Critical Period of Fat Gain in University Students with Overweight and Obesity: A Randomized Controlled Trial.,"BACKGROUND the present study aimed to investigate the effects of a single nutritional preventive session previous to a critical period linked to fat gain in university students with overweightness and obesity, emulating a nutritional session of a public health system. METHODS In this single-blind randomized controlled trial, 23 students met all the criteria to be included (20.91 ± 2.52-year-old; 52.2% women) who were divided into two groups: intervention group (IG) and control group (CG). Fat mass (FM) by dual-energy X-ray absorptiometry (DXA), physical activity by accelerometry, feeding evaluation through three questionnaires, and a set of healthy lifestyle recommendations were evaluated before and after the national holidays (NH). RESULTS Our findings showed that FM increased significantly in the CG, but not in the IG (CG = 428.1 g; IG = 321.9 g; Δ = 106.2 g; p = 0.654 [95% CI = -379.57, 591.92]). However, no differences were found during the NH between them (Hedges' g effect size = 0.19; p = 0.654). In addition, no statistical differences were observed between groups in feeding evaluations, the set of recommendations performed, and physical activity. CONCLUSION a single preventive session before a critical period, using a similar counselling approach as used in the public health system, might not be enough to promote changes in eating and physical activity patterns and preventing fat gain in overweight/obese university students. Long-term interventions are a must.",2020,"In addition, no statistical differences were observed between groups in feeding evaluations, the set of recommendations performed, and physical activity. ","['university students with overweightness and obesity, emulating a nutritional session of a public health system', 'University Students with Overweight and Obesity', 'overweight/obese university students', '23 students met all the criteria to be included (20.91 ± 2.52-year-old; 52.2% women']","['Single Nutritional Intervention', 'single nutritional preventive session', 'intervention group (IG) and control group (CG']","['FM', 'Fat mass (FM']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517632', 'cui_str': '2.52'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4517801', 'cui_str': '52.2'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}]",23.0,0.0394414,"In addition, no statistical differences were observed between groups in feeding evaluations, the set of recommendations performed, and physical activity. ","[{'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Hernández-Jaña', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Huber-Pérez', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Ximena', 'Initials': 'X', 'LastName': 'Palma-Leal', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Guerrero-Ibacache', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Campos-Nuñez', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Juan Pablo', 'Initials': 'JP', 'LastName': 'Zavala-Crichton', 'Affiliation': 'Faculty of Education and Social Sciences, Universidad Andres Bello, 2531015 Viña del Mar, Chile.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Jorquera-Aguilera', 'Affiliation': 'School of Nutrition and Dietetics, Faculty of Science, Universidad Mayor, 8580000 Santiago, Chile.'}, {'ForeName': 'Kabir P', 'Initials': 'KP', 'LastName': 'Sadarangani', 'Affiliation': 'Department of Kinesiology, Universidad Autónoma de Chile, 7500912 Santiago, Chile.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Rodríguez-Rodríguez', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Cristi-Montero', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}]",International journal of environmental research and public health,['10.3390/ijerph17145149'] 2700,32708859,Exploring the Effect of Esomeprazole on Gastric and Duodenal Fluid Volumes and Absorption of Ritonavir.,"Proton-pump inhibitors (PPIs), frequently prescribed to lower gastric acid secretion, often exert an effect on the absorption of co-medicated drug products. A previous study showed decreased plasma levels of the lipophilic drug ritonavir after co-administration with the PPI Nexium (40 mg esomeprazole), even though duodenal concentrations were not affected. The present study explored if a PPI-induced decrease in gastrointestinal (GI) fluid volume might contribute to the reduced absorption of ritonavir. In an exploratory cross-over study, five volunteers were given a Norvir tablet (100 mg ritonavir) orally, once without PPI pre-treatment and once after a three-day pre-treatment with the PPI esomeprazole. Blood samples were collected for eight hours to assess ritonavir absorption and magnetic resonance imaging (MRI) was used to determine the gastric and duodenal fluid volumes during the first three hours after administration of the tablet. The results confirmed that PPI intake reduced ritonavir plasma concentrations by 40%. The gastric residual volume and gastric fluid volume decreased by 41% and 44% respectively, while the duodenal fluid volume was reduced by 33%. These data suggest that the PPI esomeprazole lowers the available fluid volume for dissolution, which may limit the amount of ritonavir that can be absorbed. Although additional factors may play a role, the effect of PPI intake on the GI fluid volume should be considered when simulating the absorption of poorly soluble drugs like ritonavir in real-life conditions.",2020,"The gastric residual volume and gastric fluid volume decreased by 41% and 44% respectively, while the duodenal fluid volume was reduced by 33%.",[],"['Norvir tablet (100 mg ritonavir', 'PPI esomeprazole', 'esomeprazole', 'Proton-pump inhibitors (PPIs', 'Esomeprazole', 'ritonavir absorption and magnetic resonance imaging (MRI']","['duodenal concentrations', 'Gastric and Duodenal Fluid Volumes and Absorption of Ritonavir', 'duodenal fluid volume', 'plasma levels', 'gastric residual volume and gastric fluid volume', 'ritonavir plasma concentrations']",[],"[{'cui': 'C0678152', 'cui_str': 'Norvir'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0358591', 'cui_str': 'H+/K+-exchanging ATPase inhibitor'}, {'cui': 'C0937846', 'cui_str': 'Esomeprazole'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0013303', 'cui_str': 'Duodenal'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0227306', 'cui_str': 'Duodenal juice'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C3665864', 'cui_str': 'Gastric residual assessment'}, {'cui': 'C0449971', 'cui_str': 'Volume of fluid used'}]",5.0,0.0522133,"The gastric residual volume and gastric fluid volume decreased by 41% and 44% respectively, while the duodenal fluid volume was reduced by 33%.","[{'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'de Waal', 'Affiliation': 'Drug Delivery and Disposition, KU Leuven, Gasthuisberg O&N II, Herestraat 49-Box 921, 3000 Leuven, Belgium.'}, {'ForeName': 'Jari', 'Initials': 'J', 'LastName': 'Rubbens', 'Affiliation': 'Drug Delivery and Disposition, KU Leuven, Gasthuisberg O&N II, Herestraat 49-Box 921, 3000 Leuven, Belgium.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Grimm', 'Affiliation': 'Center of Drug Absorption and Transport, Institute of Pharmacy, University of Greifswald, 17489 Greifswald, Germany.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Vandecaveye', 'Affiliation': 'Radiology Department, University Hospitals Leuven, 3000 Leuven, Belgium.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Tack', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders, TARGID, KU Leuven, 3000 Leuven, Belgium.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Weitschies', 'Affiliation': 'Center of Drug Absorption and Transport, Institute of Pharmacy, University of Greifswald, 17489 Greifswald, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Brouwers', 'Affiliation': 'Drug Delivery and Disposition, KU Leuven, Gasthuisberg O&N II, Herestraat 49-Box 921, 3000 Leuven, Belgium.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Augustijns', 'Affiliation': 'Drug Delivery and Disposition, KU Leuven, Gasthuisberg O&N II, Herestraat 49-Box 921, 3000 Leuven, Belgium.'}]",Pharmaceutics,['10.3390/pharmaceutics12070670'] 2701,32708860,We Don't Talk about It: Cancer Pain and American Indian Survivors.,"Pain is a common symptom among cancer survivors, yet is rarely talked about by American Indians. Understanding the reasons for reduced communication by American Indian cancer survivors is important for healthcare providers, family members, and others providing treatment and support for cancer symptoms. Thirteen focus groups with Southwest American Indian adult cancer survivors were audiotaped and transcribed as part of a randomized intervention to remove barriers to cancer symptom management. Constant comparative methods were employed in the data analysis, topic categories were grouped for comparison, and final assessment followed Grounded Theory methods. Findings were categorized into two major groupings: communication with family members and communication with health care providers. Within these two groupings, three themes emerged to describe cancer pain experiences and communication barriers: (1) We don't talk about it, (2) Respect for healthcare providers; and (3) Culturally prohibitive topics on death and pain experiences. Not talking about their cancer diagnosis and cancer-related pain leaves many American Indian cancer survivors without much-needed social support, contributing to reduced treatment compliance and access to healthcare. Findings have implications for educational interventions and quality of life improvement for American Indian and other underrepresented communities.",2020,"Not talking about their cancer diagnosis and cancer-related pain leaves many American Indian cancer survivors without much-needed social support, contributing to reduced treatment compliance and access to healthcare.","['Thirteen focus groups with Southwest American Indian adult cancer survivors', 'American Indian and other underrepresented communities', 'American Indian cancer survivors']",[],['death and pain experiences'],"[{'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0016400', 'cui_str': 'Focus Groups'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0009462', 'cui_str': 'Community'}]",[],"[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]",,0.0190248,"Not talking about their cancer diagnosis and cancer-related pain leaves many American Indian cancer survivors without much-needed social support, contributing to reduced treatment compliance and access to healthcare.","[{'ForeName': 'Felicia Schanche', 'Initials': 'FS', 'LastName': 'Hodge', 'Affiliation': 'School of Nursing, University of California, 700 Tiverton Avenue, Room 5-934A Factor Building, Los Angeles, CA 90095-1702, USA.'}, {'ForeName': 'Tracy Line', 'Initials': 'TL', 'LastName': 'Itty', 'Affiliation': 'School of Nursing, University of California, 700 Tiverton Avenue, Room 5-934A Factor Building, Los Angeles, CA 90095-1702, USA.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Samuel-Nakamura', 'Affiliation': 'School of Nursing, University of California, 700 Tiverton Avenue, Room 5-934A Factor Building, Los Angeles, CA 90095-1702, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Cadogan', 'Affiliation': 'School of Nursing, University of California, 700 Tiverton Avenue, Room 5-934A Factor Building, Los Angeles, CA 90095-1702, USA.'}]",Cancers,['10.3390/cancers12071932'] 2702,32708864,Effects of a Multidisciplinary Residential Nutritional Rehabilitation Program in Head and Neck Cancer Survivors-Results from the NUTRI-HAB Randomized Controlled Trial.,"Head and neck cancer survivors frequently experience nutritional challenges, and proper rehabilitation should be offered. The trial objective was to test the effect of a multidisciplinary residential nutritional rehabilitation programme addressing physical, psychological, and social aspects of eating problems after treatment. In a randomized controlled trial, 71 head and neck cancer survivors recruited through a nationwide survey were randomized to the program or a wait-list control group. Inclusion was based on self-reported interest in participation. The primary outcome was change in body weight. Secondary outcomes included physical function, quality of life, and symptoms of anxiety and depression. Differences between groups at the 3-month follow-up were tested. No significant differences were seen in body weight change, but there were overall trends towards greater improvements in physical function (hand grip strength: p = 0.042; maximal mouth opening: p = 0.072) and quality of life (""Role functioning"": p = 0.041; ""Speech problems"": p = 0.040; ""Pain"": p = 0.048) in the intervention group. To conclude, a multidisciplinary residential nutritional rehabilitation program had no effect on body weight in head and neck cancer survivors with self-reported interest in participation, but it may have effect on physical function and quality of life. Further research on relevant outcomes, inclusion criteria, and the program's effect in different subgroups is needed.",2020,"No significant differences were seen in body weight change, but there were overall trends towards greater improvements in physical function (hand grip strength: p = 0.042; maximal mouth opening: p = 0.072) and quality of life (""Role functioning"": p = 0.041; ""Speech problems"": ","['Head and Neck Cancer Survivors', 'head and neck cancer survivors', '71 head and neck cancer survivors recruited through a nationwide survey', 'Head and neck cancer survivors']","['Multidisciplinary Residential Nutritional Rehabilitation Program', 'multidisciplinary residential nutritional rehabilitation programme', 'wait-list control group', 'multidisciplinary residential nutritional rehabilitation program']","['quality of life', 'physical function', 'physical function, quality of life, and symptoms of anxiety and depression', 'body weight', 'change in body weight', 'physical function and quality of life', 'body weight change']","[{'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]","[{'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}]",71.0,0.117048,"No significant differences were seen in body weight change, but there were overall trends towards greater improvements in physical function (hand grip strength: p = 0.042; maximal mouth opening: p = 0.072) and quality of life (""Role functioning"": p = 0.041; ""Speech problems"": ","[{'ForeName': 'Marianne Boll', 'Initials': 'MB', 'LastName': 'Kristensen', 'Affiliation': 'Department of Nursing and Nutrition, University College Copenhagen, Sigurdsgade 26, 2200 Copenhagen N, Denmark.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Wessel', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery & Audiology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark.'}, {'ForeName': 'Anne Marie', 'Initials': 'AM', 'LastName': 'Beck', 'Affiliation': 'Department of Nursing and Nutrition, University College Copenhagen, Sigurdsgade 26, 2200 Copenhagen N, Denmark.'}, {'ForeName': 'Karin B', 'Initials': 'KB', 'LastName': 'Dieperink', 'Affiliation': 'Research Unit of Oncology, Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark.'}, {'ForeName': 'Tina Broby', 'Initials': 'TB', 'LastName': 'Mikkelsen', 'Affiliation': 'REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care, Odense University Hospital, and Department of Clinical Research, University of Southern Denmark, Vestergade 17, 5800 Nyborg, Denmark.'}, {'ForeName': 'Jens-Jakob Kjer', 'Initials': 'JK', 'LastName': 'Møller', 'Affiliation': 'REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care, Odense University Hospital, and Department of Clinical Research, University of Southern Denmark, Vestergade 17, 5800 Nyborg, Denmark.'}, {'ForeName': 'Ann-Dorthe', 'Initials': 'AD', 'LastName': 'Zwisler', 'Affiliation': 'REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care, Odense University Hospital, and Department of Clinical Research, University of Southern Denmark, Vestergade 17, 5800 Nyborg, Denmark.'}]",Nutrients,['10.3390/nu12072117'] 2703,32708893,Timing of Nutrient Ingestion after Mild to Moderate Cycling Exercise Does Not Affect Gastric Emptying Rate in Humans.,"This study examined the effect of carbohydrate drink ingestion timing on gastrointestinal tract blood flow and motility after mild cycling exercise. Eight healthy participants were randomly assigned to ingest a liquid solution with 75 g glucose at either 5 min (PE-5) or 30 min (PE-30) after a single bout of leg cycling exercise according to target heart rate (approximately 120 beats/min). As the control trial (Con), participants ingested the same liquid solution without exercise. Celiac artery blood flow (BF), superior mesenteric artery BF, and gastric emptying rate were assessed by ultrasonography before and for 60 min after ingesting the glucose solution. Blood lactate, glucose, and plasma insulin were also measured at baseline and for 60 min after ingesting the glucose solution. Celiac artery BF significantly decreased from resting baseline immediately after exercise in both the PE-5 and PE-30 trials, and then returned to resting baseline just before the ingestion of glucose solution in the PE-30 trial. After ingesting the glucose solution, changes in celiac artery BF, superior mesenteric artery BF, % gastric emptying rate, blood lactate, blood glucose, and plasma insulin were not significantly different among the three trials. The timing of nutrient ingestion after mild exercise does not seem to impact the subsequent gastrointestinal motility, blood flow, and glycemic responses.",2020,"Celiac artery BF significantly decreased from resting baseline immediately after exercise in both the PE-5 and PE-30 trials, and then returned to resting baseline just before the ingestion of glucose solution in the PE-30 trial.","['Eight healthy participants', 'Humans', 'after mild cycling exercise']","['carbohydrate drink ingestion', 'liquid solution with 75 g glucose at either 5 min (PE-5) or 30 min (PE-30) after a single bout of leg cycling exercise']","['Gastric Emptying Rate', 'Celiac artery blood flow (BF), superior mesenteric artery BF, and gastric emptying rate', 'celiac artery BF, superior mesenteric artery BF, % gastric emptying rate, blood lactate, blood glucose, and plasma insulin', 'gastrointestinal motility, blood flow, and glycemic responses', 'Celiac artery BF', 'gastrointestinal tract blood flow and motility', 'Blood lactate, glucose, and plasma insulin']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0007569', 'cui_str': 'Structure of celiac artery'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0162861', 'cui_str': 'Superior mesenteric artery structure'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0017184', 'cui_str': 'Gastrointestinal Motility'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0007608', 'cui_str': 'Motility, Cell'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}]",8.0,0.0331816,"Celiac artery BF significantly decreased from resting baseline immediately after exercise in both the PE-5 and PE-30 trials, and then returned to resting baseline just before the ingestion of glucose solution in the PE-30 trial.","[{'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Kashima', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}, {'ForeName': 'Saori', 'Initials': 'S', 'LastName': 'Kamimura', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}, {'ForeName': 'Ayumi', 'Initials': 'A', 'LastName': 'Honma', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}, {'ForeName': 'Masako Yamaoka', 'Initials': 'MY', 'LastName': 'Endo', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Miura', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}, {'ForeName': 'Toshio', 'Initials': 'T', 'LastName': 'Kobayashi', 'Affiliation': 'Department of Health Promotion and Development, Graduate School of Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8551, Japan.'}, {'ForeName': 'Yoshiyuki', 'Initials': 'Y', 'LastName': 'Fukuba', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}]",Nutrients,['10.3390/nu12072118'] 2704,32708894,"Effects of Ibuprofen Intake in Muscle Damage, Body Temperature and Muscle Power in Paralympic Powerlifting Athletes.","The aim of this study is to evaluate the effect of ingesting ibuprofen on post-workout recovery of muscle damage, body temperature and muscle power indicators in Paralympic powerlifting athletes. The study was carried out with eight Paralympic powerlifting athletes (aged 27.0 ± 5.3 years and 79.9 ± 25.5 kg of body mass) competing at the national level, with a minimum training experience of 12 months, who all submitted to two experimental conditions: Ibuprofen (2 × 00 mg) and control. The maximal isometric force of the upper limbs and rate of force development, thermography, and serum biochemical analyzes of creatine kinase, lactate dehydrogenase, aspartate aminotransferase and alanine aminotransferase were measured before, after, 24 h after and 48 h after the intervention. Maximal isometric force only decreased in the placebo condition, which increased back to baseline levels, while no substantial decline in baseline force was seen in the ibuprofen condition, although no effect for exercise condition was detected. After the exercise, the rate of force development decreased significantly for both conditions and did not exceed baseline levels again after 48 h. Muscle temperature decreased significantly at 48-h post-exercise in the placebo condition, when compared with the previous day of measurement; and deltoid muscle temperature at 48-h post-exercise was higher with the ibuprofen condition. Although the results indicate some positive effects of ibuprofen use, they do not enable a clear statement regarding its positive effects on muscle function and muscle damage. Ibuprofen seems to have caused a delay in the anti-inflammatory response following exercise.",2020,"Maximal isometric force only decreased in the placebo condition, which increased back to baseline levels, while no substantial decline in baseline force was seen in the ibuprofen condition, although no effect for exercise condition was detected.","['Paralympic powerlifting athletes', 'eight Paralympic powerlifting athletes (aged 27.0 ± 5.3 years and 79.9 ± 25.5 kg of body mass) competing at the national level, with a minimum training experience of 12 months, who all submitted to two experimental conditions', 'Paralympic Powerlifting Athletes']","['ingesting ibuprofen', 'Ibuprofen (2 × 00 mg) and control', 'ibuprofen', 'Ibuprofen']","['deltoid muscle temperature', 'Muscle temperature', 'Muscle Damage, Body Temperature and Muscle Power', 'Maximal isometric force', 'rate of force development', 'maximal isometric force of the upper limbs and rate of force development, thermography, and serum biochemical analyzes of creatine kinase, lactate dehydrogenase, aspartate aminotransferase and alanine aminotransferase']","[{'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C4708663', 'cui_str': '5.3'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517663', 'cui_str': '25.5'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0224234', 'cui_str': 'Structure of deltoid muscle'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage NOS'}, {'cui': 'C0427052', 'cui_str': 'Finding of power of skeletal muscle'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0039810', 'cui_str': 'Thermography'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0202113', 'cui_str': 'Lactate dehydrogenase measurement'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}]",,0.0728658,"Maximal isometric force only decreased in the placebo condition, which increased back to baseline levels, while no substantial decline in baseline force was seen in the ibuprofen condition, although no effect for exercise condition was detected.","[{'ForeName': 'Guacira S', 'Initials': 'GS', 'LastName': 'Fraga', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe (UFS), São Cristovão, Sergipe 49100-000, Brazil.'}, {'ForeName': 'Felipe J', 'Initials': 'FJ', 'LastName': 'Aidar', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe (UFS), São Cristovão, Sergipe 49100-000, Brazil.'}, {'ForeName': 'Dihogo G', 'Initials': 'DG', 'LastName': 'Matos', 'Affiliation': 'Group of Studies and Research of Performance, Sport, Health and Paralympic Sports (GEPEPS), Federal University of Sergipe (UFS), São Cristovão, Sergipe 49100-000, Brazil.'}, {'ForeName': 'Anderson C', 'Initials': 'AC', 'LastName': 'Marçal', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe (UFS), São Cristovão, Sergipe 49100-000, Brazil.'}, {'ForeName': 'Jymmys L', 'Initials': 'JL', 'LastName': 'Santos', 'Affiliation': 'Northeast Network in Biotechnology (RENORBIO), Federal University of Sergipe, Sergipe 49100-000, Brazil.'}, {'ForeName': 'Raphael F', 'Initials': 'RF', 'LastName': 'Souza', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe (UFS), São Cristovão, Sergipe 49100-000, Brazil.'}, {'ForeName': 'André L', 'Initials': 'AL', 'LastName': 'Carneiro', 'Affiliation': 'Department of Physical Education, State University of Montes Claros, Minas Gerais 30000-000, Brazil.'}, {'ForeName': 'Alan B', 'Initials': 'AB', 'LastName': 'Vasconcelos', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe (UFS), São Cristovão, Sergipe 49100-000, Brazil.'}, {'ForeName': 'Marzo E', 'Initials': 'ME', 'LastName': 'Da Silva-Grigoletto', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe (UFS), São Cristovão, Sergipe 49100-000, Brazil.'}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'van den Tillaar', 'Affiliation': 'Department of Sport Sciences and Physical Education, Nord University, 7600 Levanger, Norway.'}, {'ForeName': 'Breno T', 'Initials': 'BT', 'LastName': 'Cabral', 'Affiliation': 'Department of Physical Education, Federal University of Rio Grande do Norte, Natal 59072970, Brazil.'}, {'ForeName': 'Victor M', 'Initials': 'VM', 'LastName': 'Reis', 'Affiliation': 'Research Center in Sports Sciences, Health Sciences and Human Development (CIDESD), University of Trás-os-Montes and Alto Douro, 5000-412 Vila Real, Portugal.'}]",International journal of environmental research and public health,['10.3390/ijerph17145157'] 2705,32708898,Sex Differences in Maintaining the Requested Handgrip Force Enhanced by Auditory or Visual Feedback.,"Thus far, the differences in effect of auditory or visual feedback in motor learning have presented results derived from mixed groups and sex differences have not been considered. However, perception and processing of auditory stimuli and performance of visual motor tasks appear to be sex-related. The purpose of this study was to investigate the learning of the simple motor task of maintaining a requested handgrip force in separate male and female groups. A total of 31 volunteers (15 males, 16 females) were randomly assigned to one of four experimental groups with defined sex and training conditions (audio or visual feedback). Participants performed training sessions over a period of six days, for which auditory or visual feedback was provided, and the effectiveness of both types of signals was compared. The evident learning effect was found in all groups, and the main effect of sex was significant among visual groups in favor of the males ( p < 0.05). On the other hand, the main effect of feedback conditions was found to be significant among females, beneficially in the case of auditory displays ( p < 0.05). The results lead to the conclusion that an equal number of males and females in mixed experimental groups may be supportive to obtain reliable results. Moreover, in motor-learning studies conducted on females only, a design including auditory feedback would be more suitable.",2020,"The evident learning effect was found in all groups, and the main effect of sex was significant among visual groups in favor of the males ( p < 0.05).","['31 volunteers (15 males, 16 females', 'separate male and female groups']",['defined sex and training conditions (audio or visual feedback'],"['evident learning effect', 'perception and processing of auditory stimuli and performance of visual motor tasks']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C2936181', 'cui_str': 'Visual Feedback'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0178490', 'cui_str': 'Auditory stimulus'}, {'cui': 'C0234621', 'cui_str': 'Visual'}]",31.0,0.0238798,"The evident learning effect was found in all groups, and the main effect of sex was significant among visual groups in favor of the males ( p < 0.05).","[{'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Tarnas', 'Affiliation': 'Department of Physical Education and Lifelong Sports, Poznan University of Physical Education, Królowej Jadwigi 27/39, 61-871 Poznań, Poland.'}, {'ForeName': 'Rafał', 'Initials': 'R', 'LastName': 'Stemplewski', 'Affiliation': 'Department of Physical Activity Sciences and Health Promotion, Poznan University of Physical Education, Królowej Jadwigi 27/39, 61-871 Poznań, Poland.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Krutki', 'Affiliation': 'Department of Neurobiology, Poznan University of Physical Education, Królowej Jadwigi 27/39, 61-871 Poznań, Poland.'}]",International journal of environmental research and public health,['10.3390/ijerph17145158'] 2706,32708906,The Contrasting Effects of an Action Video Game on Visuo-Spatial Processing and Proactive Cognitive Control.,"First person shooter or action video games represent one of the most popular genres within the gaming industry. Studies reveal that action gaming experience leads to enhancements of visuo-spatial processing. In contrast, some correlational evidence reveals that experience with action video games may be associated with reduced proactive cognitive control. The two primary goals of the current study were to test the causal nature of the effect of action gaming on proactive cognitive control and to examine whether an increase in visuo-spatial processing and a decrease in proactive cognitive control arise from the same amount of experience playing an action video game. Participants completed tasks measuring visuo-spatial processing and cognitive control before and after 10 practice sessions involving one of three video games or were assigned to a no gaming experience control group. The data revealed the typical increase in visuo-spatial processing and a decrease in proactive, but not reactive, cognitive control following action game training. The sizes of these two training effects were similar in magnitude, but interpretation of the effects was constrained by baseline differences between the four groups of subjects. The possibility of a causal effect of action gaming on proactive cognitive control is interesting within the context of correlational evidence linking greater action gaming experience to reduced cognitive control, poor decision making, and increased impulsivity.",2020,Participants completed tasks measuring visuo-spatial processing and cognitive control before and after 10 practice sessions involving one of three video games or were assigned to a no gaming experience control group.,[],"['tasks measuring visuo-spatial processing and cognitive control before and after 10 practice sessions involving one of three video games or were assigned to a no gaming experience control group', 'action gaming', 'Action Video Game']","['visuo-spatial processing', 'proactive cognitive control', 'Visuo-Spatial Processing and Proactive Cognitive Control']",[],"[{'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C3850026', 'cui_str': 'Auditory Spatial Processing'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0042649', 'cui_str': 'Video Games'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0441472', 'cui_str': 'Action'}]","[{'cui': 'C3850026', 'cui_str': 'Auditory Spatial Processing'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",,0.0152109,Participants completed tasks measuring visuo-spatial processing and cognitive control before and after 10 practice sessions involving one of three video games or were assigned to a no gaming experience control group.,"[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'West', 'Affiliation': 'Department of Psychology and Neuroscience, DePauw University, Greencastle, IN 46135, USA.'}, {'ForeName': 'Edward L', 'Initials': 'EL', 'LastName': 'Swing', 'Affiliation': ""Phoenix Children's Hospital, Phoenix, AZ 85016, USA.""}, {'ForeName': 'Craig A', 'Initials': 'CA', 'LastName': 'Anderson', 'Affiliation': 'Department of Psychology, Iowa State University, Ames, IA 50010, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Prot', 'Affiliation': 'School of Psychological, Social, and Behavioral Sciences, Coventry University, Coventry CV1 5FB, UK.'}]",International journal of environmental research and public health,['10.3390/ijerph17145160'] 2707,32708930,The Effects of Loaded Plyometric Exercise during Warm-Up on Subsequent Sprint Performance in Collegiate Track Athletes: A Randomized Trial.,"Prior evidence demonstrates the efficacy by which plyometric activities during warm-up conditions augment the subsequent performance in power-centric exercise. We investigated the acute effects of loaded jump squats incorporated into a standard sprinters' warm-up protocol on subsequent sprint performance in collegiate track athletes. Sprint times of 22 male and female collegiate track athletes were measured in 10-m intervals during a 30-m sprint trial following a standard sprinters' warm-up routine with or without plyometric exercise. Subjects were tested on two separate occasions, once with loaded jump squats as the experimental treatment (two sets of eight jumps, load = 13% bodyweight) (PLYO) and once with time-equated rest as the control treatment (CON). Treatments were implemented following a standard sprinters' warm-up routine familiar to the subjects. A dependent T-test was used for comparison of sprint interval times between conditions with a significant effect indicated by a p -value < 0.05. Sprint time did not differ between CON vs. PLYO at the 10 m (PLYO = 1.90 ± 0.12 s vs. CON = 1.90 ± 0.11 s, p = 0.66), 20 m (PLYO = 3.16 ± 0.21 s vs. CON = 3.15 ± 0.19 s, p = 0.53), and 30 m (PLYO = 4.32 ± 0.32 s vs. CON = 4.31 ± 0.28 s, p = 0.61) intervals. There was no interaction between treatment and sex, sex-specific ranking (above vs. below sex-specific mean), or sprint event (short vs. short-long vs. long) for 10 m, 20 m, or 30-m interval sprint times. At least within the limits of the current investigation, no evidence was provided to suggest that jump squats loaded at 13% bodyweight are an effective means to acutely potentiate sprint performance in collegiate track athletes. However, a further examination of responders indicates that the present loaded jump squat protocol may preferentially potentiate sprint performance in faster male athletes.",2020,"Sprint time did not differ between CON vs. PLYO at the 10 m (PLYO = 1.90 ± 0.12 s vs. CON = 1.90 ± 0.11 s, p = 0.66), 20 m (PLYO = 3.16 ± 0.21 s vs. CON = 3.15 ± 0.19 s, p = 0.53), and 30 m (PLYO = 4.32 ± 0.32 s vs. CON = 4.31 ± 0.28 s, p = 0.61) intervals.","['22 male and female collegiate track athletes', 'Collegiate Track Athletes', 'faster male athletes', 'collegiate track athletes']","[""standard sprinters' warm-up routine with or without plyometric exercise"", 'Loaded Plyometric Exercise']","['sprint performance', 'Sprint time']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2350169', 'cui_str': 'Warming-Up Exercise'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C3178799', 'cui_str': 'Plyometric Drill'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}]",22.0,0.0364633,"Sprint time did not differ between CON vs. PLYO at the 10 m (PLYO = 1.90 ± 0.12 s vs. CON = 1.90 ± 0.11 s, p = 0.66), 20 m (PLYO = 3.16 ± 0.21 s vs. CON = 3.15 ± 0.19 s, p = 0.53), and 30 m (PLYO = 4.32 ± 0.32 s vs. CON = 4.31 ± 0.28 s, p = 0.61) intervals.","[{'ForeName': 'Kalin A', 'Initials': 'KA', 'LastName': 'Tomlinson', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Hansen', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Helzer', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Zakkoyya H', 'Initials': 'ZH', 'LastName': 'Lewis', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Whitney D', 'Initials': 'WD', 'LastName': 'Leyva', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Meghan', 'Initials': 'M', 'LastName': 'McCauley', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Pritchard', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Silvestri', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Quila', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Yi', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Jo', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}]","Sports (Basel, Switzerland)",['10.3390/sports8070101'] 2708,32708938,"Effectiveness of 6-Week Nordic Walking Training on Functional Performance, Gait Quality, and Quality of Life in Parkinson's Disease.","Background and objectives: Motor rehabilitation improves physical mobility and quality of life in Parkinson's disease (PD). As specialized rehabilitation is expensive and resource-consuming, there is a need for simpler, cost-effective methods. The purpose of the study was to determine whether Nordic Walking (NW) training may support the management of motor disability in PD. Materials and Methods: Forty patients (median age 64.0 years, range 50-75 years) with idiopathic PD, Hoehn and Yahr stages II-III, were randomly assigned to NW or standard rehabilitation (SR) programs, comprising twelve rehabilitation sessions conducted bi-weekly throughout the 6-week study period. Results: Median Unified Parkinson's Disease Rating Scale part III scores were significantly reduced with NW, by 8.5, and with SR, by 6.0 points (both p < 0.001), with significantly greater improvement with NW than with SR ( p = 0.047). Gait quality and balance control, measured using the Dynamic Gait Index, improved with NW by a median of 8.0 and with SR by 5.5 points (both p < 0.001), with slightly greater improvement with NW, compared to the SR group ( p = 0.064). Quality of life, assessed using the Parkinson's Disease Questionnaire (PDQ-39), improved with NW by a median of 15 and with SR by 12 points, p = 0.001 and p = 0.008, respectively. Conclusions: The 6-week Nordic Walking program improves functional performance, quality of gait, and quality of life in patients with PD and has comparable effectiveness to standard rehabilitation.",2020,"Gait quality and balance control, measured using the Dynamic Gait Index, improved with NW by a median of 8.0 and with SR by 5.5 points (both p < 0.001), with slightly greater improvement with NW, compared to the SR group ( p = 0.064).","['patients with PD', ""Parkinson's Disease"", ""Parkinson's disease (PD"", 'Forty patients (median age 64.0 years, range 50-75 years) with idiopathic PD, Hoehn and Yahr stages II-III']","['Nordic Walking program', 'Motor rehabilitation', 'NW or standard rehabilitation (SR) programs', '6-Week Nordic Walking Training', 'Nordic Walking (NW) training']","[""Quality of life, assessed using the Parkinson's Disease Questionnaire (PDQ-39"", ""Unified Parkinson's Disease Rating Scale part III scores"", 'Functional Performance, Gait Quality, and Quality of Life', 'Dynamic Gait Index', 'physical mobility and quality of life', 'Gait quality and balance control', 'functional performance, quality of gait, and quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C2919794', 'cui_str': 'Dynamic gait index'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",,0.0206053,"Gait quality and balance control, measured using the Dynamic Gait Index, improved with NW by a median of 8.0 and with SR by 5.5 points (both p < 0.001), with slightly greater improvement with NW, compared to the SR group ( p = 0.064).","[{'ForeName': 'Justyna', 'Initials': 'J', 'LastName': 'Szefler-Derela', 'Affiliation': 'Department of Physiotherapy, School of Health Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.'}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Arkuszewski', 'Affiliation': 'Institute for Innovative Medicine, 15-082 Białystok, Poland.'}, {'ForeName': 'Andrzej', 'Initials': 'A', 'LastName': 'Knapik', 'Affiliation': 'Department of Adapted Physical Activity and Sport, School of Health Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.'}, {'ForeName': 'Dagmara', 'Initials': 'D', 'LastName': 'Wasiuk-Zowada', 'Affiliation': 'Department of Physiotherapy, School of Health Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.'}, {'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Gorzkowska', 'Affiliation': 'Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.'}, {'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Krzystanek', 'Affiliation': 'Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.'}]","Medicina (Kaunas, Lithuania)",['10.3390/medicina56070356'] 2709,32708973,Efficacy of a High-Iron Dietary Intervention in Women with Celiac Disease and Iron Deficiency without Anemia: A Clinical Trial.,"BACKGROUND AND AIM Iron deficiency without anemia (IDWA) is a common finding in celiac disease (CD) and can also persist in case of good compliance and clinical response to a strict gluten-free diet (GFD). This scenario usually presents in CD women of child-bearing age in whom the imbalance between menstrual iron loss and inadequate iron intake from their diet plays the major role. A recommended approach to this condition is yet to be established. This study aimed to compare, in this subset of patients, the efficacy of a dietary approach consisting of an iron-rich diet against the traditional pharmacological oral-replacement therapy. MATERIAL AND METHODS Between February and December 2016, consecutive CD female patients of child-bearing age as referred to our outpatient center with evidence of IDWA (ferritin <15 ng/mL or 15-20 ng/L with transferrin saturation <15%) were enrolled. After the completion of a 7-day weighed food intake recording to assess the usual iron dietary intake, the patients were randomized in two arms to receive a 12-week iron-rich diet (iron intake >20 mg/die) versus oral iron supplementation with ferrous sulfate (FS) (105 mg/day). Blood tests and dietary assessments were repeated at the end of treatment. The degree of compliance and tolerability to the treatments were assessed every month by means of specific questionnaires and symptoms evaluation. RESULTS A total of 22 women were enrolled and divided in the diet group ( n = 10, age 37 ± 8 years) and in the FS group ( n = 12, age 38 ± 10 years). The food intake records demonstrated an inadequate daily intake of iron in all the enrolled subjects. At the end of the treatments, ferritin levels were higher in the FS group (8.5 (5) versus 34 (30.8), p = 0.002). Compliance and tolerability were similar in both treatment groups (89% versus 87%, p = ns). CONCLUSIONS These findings did not support any equivalent efficacy of an iron-rich diet compared to a FS supplementation in non-anemic iron-deficient women affected by CD. However, the diet appeared a well-tolerated approach, and adequate dietary instructions could effectively increase the daily iron consumption, suggesting a role in the long-term management of IDWA, especially in patients who do not tolerate pharmacological supplementation.",2020,"Compliance and tolerability were similar in both treatment groups (89% versus 87%, p = ns). ","['Between February and December 2016, consecutive CD female patients of child-bearing age as referred to our outpatient center with evidence of IDWA (ferritin <15 ng/mL or 15-20 ng/L with transferrin saturation <15%) were enrolled', 'Women with Celiac Disease and Iron Deficiency without Anemia', 'A total of 22 women were enrolled and divided in the diet group ( n = 10, age 37 ± 8 years) and in the FS group ( n = 12, age 38 ± 10 years']","['12-week iron-rich diet (iron intake >20 mg/die) versus oral iron supplementation with ferrous sulfate (FS', 'High-Iron Dietary Intervention', 'dietary approach consisting of an iron-rich diet against the traditional pharmacological oral-replacement therapy', 'FS supplementation']","['Compliance and tolerability', 'daily iron consumption', 'degree of compliance and tolerability', 'Blood tests and dietary assessments', 'ferritin levels']","[{'cui': 'C0007570', 'cui_str': 'Celiac disease'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0340950', 'cui_str': 'Iron deficiency without anemia'}, {'cui': 'C0015879', 'cui_str': 'Ferritin'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0439297', 'cui_str': 'ng/L'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0060282', 'cui_str': 'ferrous sulfate'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0518043', 'cui_str': 'Iron intake'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3537005', 'cui_str': 'Iron supplement therapy'}, {'cui': 'C0060282', 'cui_str': 'ferrous sulfate'}, {'cui': 'C0860976', 'cui_str': 'Iron increased'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0279033', 'cui_str': 'Replacement therapy'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0373607', 'cui_str': 'Ferritin measurement'}]",22.0,0.0323893,"Compliance and tolerability were similar in both treatment groups (89% versus 87%, p = ns). ","[{'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Scricciolo', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Elli', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}, {'ForeName': 'Luisa', 'Initials': 'L', 'LastName': 'Doneda', 'Affiliation': 'Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy.'}, {'ForeName': 'Karla A', 'Initials': 'KA', 'LastName': 'Bascunan', 'Affiliation': 'Department of Nutrition, School of Medicine, University of Chile, 8380453 Santiago, Chile.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Branchi', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Ferretti', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Vecchi', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}, {'ForeName': 'Leda', 'Initials': 'L', 'LastName': 'Roncoroni', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}]",Nutrients,['10.3390/nu12072122'] 2710,32708991,"Effect of High versus Low Dairy Consumption on the Gut Microbiome: Results of a Randomized, Cross-Over Study.","The influence of dairy on the gut microbiome has not been studied extensively. We performed a randomized cross-over study to analyze the effect of high dairy intake on the gut microbiome. Subjects were randomly assigned to a high-dairy diet (HDD) (5-6 dairy portions per day) and a low-dairy diet (LDD) (≤1 dairy portion per day) for 6 weeks with a washout period of 4 weeks in between both diets. The gut microbiome was assessed using 16S rRNA gene sequencing. Compositionality and functionality of the gut microbiome was assessed using Quantitative Insights Into Microbial Ecology (QIIME) and Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt). Stool consistency was evaluated using the Bristol stool chart. In total, 46 healthy overweight subjects (BMI range 25-30 kg/m 2 ) completed both intervention periods. During the HDD, there was a significantly higher abundance of the genera Streptococcus , Leuconostoc , and Lactococcus , and the species Streptococcus thermophilus , Erysipelatoclostridium ramosum and Leuconostoc mesenteroides ( p FDR < 0.10). Furthermore, during the HDD, there was a significantly lower abundance of the genera Faecalibacterium and Bilophila , and the species Faecalibacterium prausnitzii , Clostridium aldenense , Acetivibrio ethanolgignens , Bilophila wadsworthia and Lactococcus lactis ( p FDR < 0.10). There were eight subjects who became constipated during the HDD and these subjects all had a lower abundance of F. prausnitzii . This is the first cross-over study in which the effect of an HDD compared to an LDD on the gut microbiome has been studied. An HDD led to a significantly different composition of the gut microbiome, with a particularly lower abundance of F. prausnitzii and a higher abundance of S. thermophilus . Constipation was observed in several subjects during the HDD. Predicted metabolic pathways were not significantly altered due to an HDD.",2020,"An HDD led to a significantly different composition of the gut microbiome, with a particularly lower abundance of F. prausnitzii and a higher abundance of S. thermophilus .","['46 healthy overweight subjects (BMI range 25-30 kg/m 2 ) completed both intervention periods', 'Gut Microbiome']","['High versus Low Dairy Consumption', 'high-dairy diet (HDD) (5-6 dairy portions per day) and a low-dairy diet (LDD']","['abundance of the genera Streptococcus , Leuconostoc , and Lactococcus , and the species Streptococcus thermophilus , Erysipelatoclostridium ramosum and Leuconostoc mesenteroides', 'Stool consistency', 'Predicted metabolic pathways', 'Constipation']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0442749', 'cui_str': '6/5'}, {'cui': 'C0449719', 'cui_str': 'Part'}, {'cui': 'C0439505', 'cui_str': '/day'}]","[{'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0023411', 'cui_str': 'Leuconostoc'}, {'cui': 'C0085549', 'cui_str': 'Lactococcus'}, {'cui': 'C0318180', 'cui_str': 'Streptococcus salivarius subsp. thermophilus'}, {'cui': 'C0315111', 'cui_str': 'Clostridium ramosum'}, {'cui': 'C0317708', 'cui_str': 'Leuconostoc mesenteroides'}, {'cui': 'C0426740', 'cui_str': 'Consistency of stool'}, {'cui': 'C1291081', 'cui_str': 'Metabolic pathway'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}]",46.0,0.0185083,"An HDD led to a significantly different composition of the gut microbiome, with a particularly lower abundance of F. prausnitzii and a higher abundance of S. thermophilus .","[{'ForeName': 'J Casper', 'Initials': 'JC', 'LastName': 'Swarte', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Coby', 'Initials': 'C', 'LastName': 'Eelderink', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Rianne M', 'Initials': 'RM', 'LastName': 'Douwes', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'M Yusof', 'Initials': 'MY', 'LastName': 'Said', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Shixian', 'Initials': 'S', 'LastName': 'Hu', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Post', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Westerhuis', 'Affiliation': 'Dialyses Center Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Stephan J L', 'Initials': 'SJL', 'LastName': 'Bakker', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Hermie J M', 'Initials': 'HJM', 'LastName': 'Harmsen', 'Affiliation': 'Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}]",Nutrients,['10.3390/nu12072129'] 2711,32709005,Importance of Self-Efficacy in Eating Behavior and Physical Activity Change of Overweight and Non-Overweight Adolescent Girls Participating in Healthy Me: A Lifestyle Intervention with Mobile Technology.,"Very little is known about how multicomponent interventions directed to entire populations work in selected groups of adolescents. The aim was to evaluate the effectiveness of the Healthy Me one-year program on changes in healthy eating and physical activity among overweight and non-overweight female students. Randomization involved the allocation of full, partial or null intervention. The randomized field trial was implemented in 48 secondary schools (clusters) all over Poland among 1198 15-year-old girls. In this study, a sample of N = 1111 girls who participated in each evaluation study was analyzed. Using multimedia technologies, efforts were made to improve health behaviors and increase self-efficacy. The main outcome was a health behavior index (HBI), built on the basis of six nutritional indicators and one related to physical activity. HBI was analyzed before and immediately after intervention and at three months' follow-up, and the HBI change was modeled. Statistical analysis included nonparametric tests and generalized linear models with two-way interactions. Comparing the first and third surveys, in the overweight girls, the HBI index improved by 0.348 (SD = 3.17), while in the non-overweight girls it had worsened. After adjusting for other factors, a significant interaction between body weight status and level of self-efficacy as predictors of HBI changes was confirmed. The program turned out to be more beneficial for overweight girls.",2020,"Comparing the first and third surveys, in the overweight girls, the HBI index improved by 0.348 (SD = 3.17), while in the non-overweight girls it had worsened.","['sample of N = 1111 girls who participated in each evaluation study was analyzed', 'Overweight and Non-Overweight Adolescent Girls Participating in Healthy Me', 'healthy eating and physical activity among overweight and non-overweight female students', '48 secondary schools (clusters) all over Poland among 1198 15-year-old girls']",['Healthy Me one-year program'],"['health behavior index (HBI), built on the basis of six nutritional indicators and one related to physical activity', 'HBI index', 'body weight status and level of self-efficacy', 'HBI', 'health behaviors and increase self-efficacy']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0015196', 'cui_str': 'Evaluation Studies'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0036530', 'cui_str': 'Secondary school'}, {'cui': 'C0032356', 'cui_str': 'Poland'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",1111.0,0.0178854,"Comparing the first and third surveys, in the overweight girls, the HBI index improved by 0.348 (SD = 3.17), while in the non-overweight girls it had worsened.","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Dzielska', 'Affiliation': 'Department of Child and Adolescent Health, Institute of Mother and Child, 17a Kasprzaka St., 01-211 Warsaw, Poland.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Mazur', 'Affiliation': 'Department of Child and Adolescent Health, Institute of Mother and Child, 17a Kasprzaka St., 01-211 Warsaw, Poland.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Nałęcz', 'Affiliation': 'Department of Child and Adolescent Health, Institute of Mother and Child, 17a Kasprzaka St., 01-211 Warsaw, Poland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Oblacińska', 'Affiliation': 'Department of Child and Adolescent Health, Institute of Mother and Child, 17a Kasprzaka St., 01-211 Warsaw, Poland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Fijałkowska', 'Affiliation': 'Department of Cardiology, Institute of Mother and Child, 17a Kasprzaka St., 01-211 Warsaw, Poland.'}]",Nutrients,['10.3390/nu12072128'] 2712,32709051,The Effect of Dietary Inorganic Nitrate Supplementation on Cardiac Function during Submaximal Exercise in Men with Heart Failure with Reduced Ejection Fraction (HFrEF): A Pilot Study.,"Heart failure with reduced ejection fraction (HFrEF) is a common end point for patients with coronary artery disease and it is characterized by exercise intolerance due, in part, to a reduction in cardiac output. Nitric oxide (NO) plays a vital role in cardiac function and patients with HFrEF have been identified as having reduced vascular NO. This pilot study aimed to investigate if nitrate supplementation could improve cardiac measures during acute, submaximal exercise. Five male participants (61 ± 3 years) with HFrEF (EF 32 ± 2.2%) completed this pilot study. All participants supplemented with inorganic nitrate (beetroot juice) or a nitrate-depleted placebo for ~13 days prior to testing. Participants completed a three-stage submaximal exercise protocol on a recumbent cycle ergometer with simultaneous echocardiography for calculation of cardiac output (Q), stroke volume (SV), and total peripheral resistance (TPR). Heart rate and blood pressure were measured at rest and during each stage. Both plasma nitrate (mean = ~1028%, p = 0.004) and nitrite (mean = ~109%, p = 0.01) increased following supplementation. There were no differences between interventions at rest, but the percent change in SV and Q from rest to stage two and stage three of exercise was higher following nitrate supplementation (all p > 0.05, ES > 0.8). Both interventions showed decreases in TPR during exercise, but the percent reduction TPR in stages two and three was greater following nitrate supplementation ( p = 0.09, ES = 0.98 and p = 0.14, ES = 0.82, respectively). There were clinically relevant increases in cardiac function during exercise following supplementation with nitrate. The findings from this pilot study warrant further investigation in larger clinical trials.",2020,"Both plasma nitrate (mean = ~1028%, p = 0.004) and nitrite (mean = ~109%, p = 0.01) increased following supplementation.","['Five male participants (61 ± 3 years) with HFrEF (EF 32 ± 2.2%) completed this pilot study', 'Men with Heart Failure with Reduced Ejection Fraction (HFrEF', 'patients with coronary artery disease']","['Nitric oxide (NO', 'Dietary Inorganic Nitrate Supplementation', 'nitrate supplementation', 'inorganic nitrate (beetroot juice) or a nitrate-depleted placebo', 'submaximal exercise protocol on a recumbent cycle ergometer with simultaneous echocardiography', 'reduced ejection fraction (HFrEF']","['percent reduction TPR', 'Heart rate and blood pressure', 'Cardiac Function', 'TPR during exercise', 'cardiac measures', 'cardiac function', 'cardiac output (Q), stroke volume (SV), and total peripheral resistance (TPR', 'plasma nitrate']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0031928', 'cui_str': 'Pilot Study'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}]","[{'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C1095905', 'cui_str': 'Beets preparation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0444334', 'cui_str': 'Recumbent body position'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0013516', 'cui_str': 'Echocardiography'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1258192', 'cui_str': 'Systemic vascular resistance'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0587107', 'cui_str': 'During exercise'}, {'cui': 'C0588131', 'cui_str': 'Cardiac measure'}, {'cui': 'C0007165', 'cui_str': 'Cardiac output'}, {'cui': 'C0038455', 'cui_str': 'Stroke volume'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}]",5.0,0.203872,"Both plasma nitrate (mean = ~1028%, p = 0.004) and nitrite (mean = ~109%, p = 0.01) increased following supplementation.","[{'ForeName': 'Mary N', 'Initials': 'MN', 'LastName': 'Woessner', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 3011, Australia.'}, {'ForeName': 'Itamar', 'Initials': 'I', 'LastName': 'Levinger', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 3011, Australia.'}, {'ForeName': 'Jason D', 'Initials': 'JD', 'LastName': 'Allen', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 3011, Australia.'}, {'ForeName': 'Luke C', 'Initials': 'LC', 'LastName': 'McIlvenna', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 3011, Australia.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Neil', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 3011, Australia.'}]",Nutrients,['10.3390/nu12072132'] 2713,32709172,Bilateral Ultrasound-Guided Erector Spinae Plane Block Versus Transversus Abdominis Plane Block on Postoperative Analgesia after Total Abdominal Hysterectomy.,"BACKGROUND Transversus abdominis plane (TAP) blocks provide postoperative pain relief after various abdominal surgeries. Recently, erector spinae plane (ESP) block has obtained vast attention due to its simplicity and usage in truncal procedures. OBJECTIVES This study aims to compare the ultrasound-guided bilateral ESP block versus bilateral TAP block on postoperative analgesia after open total abdominal hysterectomy. STUDY DESIGN A prospective, double-blinded, randomized, controlled, clinical trial. SETTING Zagazig University Hospitals. METHODS After ending of surgical procedure and before reversing of the muscle relaxant, 48 women were randomly allocated into 2 equal groups: erector spinae (ES) group received bilateral ultrasound-guided ESP block with 20 mL of bupivacaine 0.375% plus 5 ug/mL adrenaline (1:200000) in each side at the level of T9, and transversus abdominis (TA) group received bilateral ultrasound-guided TAP block with the same volume of bupivacaine plus adrenaline. RESULTS Visual Analog Scale scores at 30 minutes, 2, 4, 6, 8, 12, 16, 20, and 24 hours were statistically significantly lower in the ES group compared with the TA group. The time for requirement of first morphine was highly statistically significantly prolonged in the ES group (14.81 ± 3.52 hours) compared with the TA group (10.58 ± 2.35 hours). The total amount of morphine consumption in 24 hours postoperatively was statistically significantly decreased in the ES group; P = 0.01. Incidence of postoperative nausea and vomiting was higher but statistically insignificant in the TA group than the ES group. There were statistically significant numbers of unsatisfied patients (4) in the TA group compared with the ES group (no patient). LIMITATIONS Sensorial evaluation of patients was not performed because both blocks had been done under general anesthesia but did not affect outcome. Therefore we recommend further studies comparing between both blocks. CONCLUSIONS Bilateral ultrasound-guided ESP block provides more potent and longer postoperative analgesia with less morphine consumption than TAP block after open total abdominal hysterectomy. KEY WORDS Abdominal hysterectomy, transversus abdominis plane block, erector spinae plane block, postoperative analgesia.",2020,The total amount of morphine consumption in 24 hours postoperatively was statistically significantly decreased in the ES group; P = 0.01.,"['Zagazig University Hospitals', 'Postoperative Analgesia after Total Abdominal Hysterectomy', '48 women']","['Bilateral Ultrasound-Guided Erector Spinae Plane Block Versus Transversus Abdominis Plane Block', 'Abdominal hysterectomy, transversus abdominis plane block, erector spinae plane block, postoperative analgesia', 'Transversus abdominis plane (TAP) blocks', 'bupivacaine plus adrenaline', 'ultrasound-guided bilateral ESP block versus bilateral TAP block', 'erector spinae (ES) group received bilateral ultrasound-guided ESP block with 20 mL of bupivacaine 0.375% plus 5 ug/mL adrenaline (1:200000) in each side at the level of T9, and transversus abdominis (TA) group received bilateral ultrasound-guided TAP block']","['Incidence of postoperative nausea and vomiting', 'total amount of morphine consumption', 'time for requirement of first morphine', 'postoperative analgesia', 'Visual Analog Scale scores']","[{'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0404079', 'cui_str': 'Total abdominal hysterectomy'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0224301', 'cui_str': 'Structure of erector spinae muscle'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0404077', 'cui_str': 'Abdominal hysterectomy'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517455', 'cui_str': '0.375'}, {'cui': 'C0439268', 'cui_str': 'mg/L'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",48.0,0.14806,The total amount of morphine consumption in 24 hours postoperatively was statistically significantly decreased in the ES group; P = 0.01.,"[{'ForeName': 'Alshaimaa Abdel Fattah', 'Initials': 'AAF', 'LastName': 'Kamel', 'Affiliation': 'Anaesthesia and Surgical Intensive Care Department, Faculty of Medicine, Zagazig University, Alsharkia, Egypt.'}, {'ForeName': 'Olfat Abdelmoniem Ibrahem', 'Initials': 'OAI', 'LastName': 'Amin', 'Affiliation': 'Anaesthesia and Surgical Intensive Care Department, Faculty of Medicine, Zagazig University, Alsharkia, Egypt.'}, {'ForeName': 'Mohamed Abdel Moniem', 'Initials': 'MAM', 'LastName': 'Ibrahem', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Zagazig University, Alsharkia, Egypt.'}]",Pain physician,[] 2714,32709173,Contrast Medium Volume Needed to Reach Anterior Epidural Space via the Kambin Triangle or Subpedicular Approach for Transforaminal Epidural Injection.,"BACKGROUND Transforaminal (TF) lumbar injection is a commonly used minimally invasive intervention for management of chronic low back pain. TF injection can be performed using various approaches to inject the drug to the anterior epidural space (AES). OBJECTIVES To identify the volumes of contrast medium needed to reach the AES and other landmarks in the Kambin triangle (KB) and subpedicular (SP) approach of TF injection in patients with lumbosacral radicular pain. STUDY DESIGN Randomized controlled trial. SETTING Pain clinic and operating room of a tertiary care hospital. METHODS Seventy-five eligible patients were randomized to receive TF epidural injection either by SP (SP group; n = 38) or the KB (KB group; n = 37) approach under fluoroscopic guidance. After confirming the appropriate needle position, contrast medium was injected at 0.5 mL increments up to 2 mL under intermittent fluoroscopy. Contrast medium volumes needed to reach specific landmarks, that is, AES, medial to superior pedicle, medial to inferior pedicle, medial aspect of both the superior, and neural spread, were recorded. Following this, 4 mL of the drug (0.5% lidocaine 1 mL + methylprednisolone 80 mg + 1 mL normal saline solution) was injected. Patients were evaluated for Visual Analog Scale (VAS) and modified Oswestry Disability Questionnaire (MODQ) scores after epidural injections at 2 weeks, 1 month, and 2 months. RESULTS Average volume of contrast medium needed to reach AES was 1.10 ± 0.46 mL in the KB approach and 1.10 ± 0.38 mL in the SP approach. Contrast medium volume needed to reach other landmarks showed comparable results in both groups. AES was seen in 27.02% (10/37) patients in the KB group and 23.6% (9/38) patients in the SP group with 0.5 mL of contrast medium. This increased to 56.76% (21/37) and 77.7% (28/38) with 1 mL of contrast medium (P = 0.03, chi-square test). No anterior spread was seen even after 2 mL of contrast medium in 4 patients in the KB group and 2 patients in the SP group. Neural spread was seen in 100% of patients in the KB group after 0.5 mL of contrast medium, but in 34 (89.4%) patients in the SP group (P = 0.03, chi-square test). We did not note any contralateral spread. Short-term effectiveness in pain relief in terms of VAS for back pain and functional improvement in terms of MODQ score over time showed similar results in both groups. Intravascular needle puncture and needle paresthesia was comparable in both groups. LIMITATIONS Small follow-up duration is one the limitations of this study. Future studies will be needed to assess any long-term differences in outcome between approach methods. Also, use of intermittent fluoroscopy might have limited detection of intravascular injections of the contrast medium in comparison to the continuous fluoroscopy. CONCLUSIONS To conclude, our study revealed that average volume of contrast medium needed to reach AES and other landmarks were comparable with both approaches of TF injection. KEY WORDS Transforaminal injection, subpedicular approach, Kambin triangle approach, contrast medium spread, anterior epidural spread.",2020,No anterior spread was seen even after 2 mL of contrast medium in 4 patients in the KB group and 2 patients in the SP group.,"['patients with lumbosacral radicular pain', 'Seventy-five eligible patients', 'Pain clinic and operating room of a tertiary care hospital']","['KB (KB group; n = 37) approach under fluoroscopic guidance', 'TF injection', 'Transforaminal (TF) lumbar injection', 'TF epidural injection either by SP', 'lidocaine 1 mL + methylprednisolone 80 mg + 1 mL normal saline solution']","['pain relief', 'Neural spread', 'Visual Analog Scale (VAS) and modified Oswestry Disability Questionnaire (MODQ) scores', 'MODQ score', 'Intravascular needle puncture and needle paresthesia', 'AES']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0450206', 'cui_str': 'Lumbosacral'}, {'cui': 'C0278147', 'cui_str': 'Radicular pain'}, {'cui': 'C4319621', 'cui_str': '75'}, {'cui': 'C0242936', 'cui_str': 'Pain clinic'}, {'cui': 'C0337954', 'cui_str': 'Tertiary care hospital'}]","[{'cui': 'C0205119', 'cui_str': 'Triangular'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0560563', 'cui_str': 'Fluoroscopic guidance'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0021486', 'cui_str': 'Injections, Peridural'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0332261', 'cui_str': 'Spreading'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0442123', 'cui_str': 'Intravascular'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0014537', 'cui_str': 'Structure of epidural space'}]",75.0,0.0565945,No anterior spread was seen even after 2 mL of contrast medium in 4 patients in the KB group and 2 patients in the SP group.,"[{'ForeName': 'Babita', 'Initials': 'B', 'LastName': 'Ghai', 'Affiliation': 'Department of Anaesthesia, Post Graduate Institute of Medical Education and Research, Chandigarh.'}, {'ForeName': 'Amit Kumar', 'Initials': 'AK', 'LastName': 'Gupta', 'Affiliation': 'Departments of Orthopaedic Surgery, Anesthesia, and Intensive Care, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Jeetinder Kaur', 'Initials': 'JK', 'LastName': 'Makkar', 'Affiliation': 'Department of Anesthesia and Intensive care, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Sarvdeep Singh', 'Initials': 'SS', 'LastName': 'Dhatt', 'Affiliation': 'Department of Orthopedics, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}]",Pain physician,[] 2715,32709189,"Re: Comparisons of Monopolar Lesion Volumes with Hypertonic Saline Solution in Radiofrequency Ablation: A Randomized, Double-Blind, Ex Vivo Study.",,2020,,['Radiofrequency Ablation'],['Hypertonic Saline Solution'],[],"[{'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}]","[{'cui': 'C0036085', 'cui_str': 'sodium chloride, hypertonic'}]",[],,0.71595,,"[{'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Provenzano', 'Affiliation': 'Pain Diagnostics and Interventional Care, Sewickley, Pennsylvania.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Cosman', 'Affiliation': 'Cambridge Interventional, Burlington, MA.'}, {'ForeName': 'Jared', 'Initials': 'J', 'LastName': 'Wilsey', 'Affiliation': 'Smith-Nephew, Memphis, TN.'}]",Pain physician,[] 2716,32709230,Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China: a multicentre RCT study protocol.,"BACKGROUND Pre-exposure prophylaxis (PrEP) is an effective biomedical strategy to prevent transmission of HIV infection, although medication adherence remains a challenge. We present the protocol for a multicentre randomised controlled trial to measure the effectiveness of a real-time monitoring and just-in-time intervention on medication adherence among PrEP users in China. METHODS Study participants will include 1000 men who have sex with men (MSM) from four cites in China (Shenyang, Beijing, Chongqing and Shenzhen) attending a tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) PrEP project as part of a real-world, prospective multicentre cohort study (CROPrEP). Participants will be randomised into the intervention and control arms in a 1:1 ratio. Participants in the intervention arm will be provided with remote real-time monitoring equipment that triggers twice just-in-time SMS (Short Messaging Service) medication reminders to PrEP users every half an hour when a scheduled dosage is missed, and followed with just-in-time SMS medication reminders to clinicians half an hour when there is no supplement after the second just-in-time SMS reminder to PrEP users. Clinicians will initiate individualised telephone intervention as soon as possible upon receipt of the just-in-time SMS missed dose alert. Those in the control arm will only receive generic weekly SMS reminders. The study will last 6 months. Participants will be seen at follow-up visits at three and 6 months. Trial outcomes to be measured include self-reported adherence assessed via questionnaire and pill counts, as well as drug concentration test results. DISCUSSION Medication adherence is critical to achieve optimal benefits from PrEP. This study will be the first individualised behaviour intervention using real-time technology to increase adherence among MSM PrEP users globally. If found effective, a real-time monitoring and just-in-time intervention system may be utilized for improving adherence and thus effectiveness of global PrEP application. TRIAL REGISTRATION This study registered at ClinicalTrials.gov ( ChiCTR1900025604 ) on September 2, 2019.",2020,"Participants in the intervention arm will be provided with remote real-time monitoring equipment that triggers twice just-in-time SMS (Short Messaging Service) medication reminders to PrEP users every half an hour when a scheduled dosage is missed, and followed with just-in-time","['Study participants will include 1000 men who have sex with men (MSM) from four cites in China (Shenyang, Beijing, Chongqing and Shenzhen) attending a', 'men who have sex with men in China', 'PrEP users in China']","['remote real-time monitoring equipment that triggers twice just-in-time SMS (Short Messaging Service) medication reminders to PrEP', 'Real-time monitoring and just-in-time intervention', 'Pre-exposure prophylaxis (PrEP', 'tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) PrEP project', 'real-time monitoring and just-in-time intervention']","['self-reported adherence assessed via questionnaire and pill counts, as well as drug concentration test results', 'medication adherence']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C3850098', 'cui_str': 'Pre-Exposure Prophylaxis (PrEP)'}]","[{'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}, {'cui': 'C0032930', 'cui_str': 'Precipitating Factors'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C3850098', 'cui_str': 'Pre-Exposure Prophylaxis (PrEP)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C0206682', 'cui_str': 'Follicular thyroid carcinoma'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0456984', 'cui_str': 'Test finding'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}]",1000.0,0.0827213,"Participants in the intervention arm will be provided with remote real-time monitoring equipment that triggers twice just-in-time SMS (Short Messaging Service) medication reminders to PrEP users every half an hour when a scheduled dosage is missed, and followed with just-in-time","[{'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Jin', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Hongyi', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Zhenxing', 'Initials': 'Z', 'LastName': 'Chu', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Qinghai', 'Initials': 'Q', 'LastName': 'Hu', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Lv', 'Affiliation': 'Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.'}, {'ForeName': 'Xiaojie', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.'}, {'ForeName': 'Yaokai', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Chongqing Public Health Medical Center, Chongqing, 400036, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': ""Shenzhen Third People's Hospital, Shenzhen, 518000, Guangdong, China.""}, {'ForeName': 'Xiaoqing', 'Initials': 'X', 'LastName': 'He', 'Affiliation': 'Chongqing Public Health Medical Center, Chongqing, 400036, China.'}, {'ForeName': 'Lukun', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': ""Shenzhen Third People's Hospital, Shenzhen, 518000, Guangdong, China.""}, {'ForeName': 'Zhili', 'Initials': 'Z', 'LastName': 'Hu', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Rantong', 'Initials': 'R', 'LastName': 'Bao', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Shangcao', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Haibo', 'Initials': 'H', 'LastName': 'Ding', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Wenqing', 'Initials': 'W', 'LastName': 'Geng', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Yongjun', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Shang', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China. hongshang100@hotmail.com.'}, {'ForeName': 'Junjie', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China. xjjcmu@163.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMC public health,['10.1186/s12889-020-08709-2'] 2717,32709274,Vitiligo: Targeted Therapies Add Color to Disease Pathophysiology.,"There is excitement in the air for patients with vitiligo. For the first time in decades, we have early case studies showing that targeted therapies can repigment vitiliginous skin, and well-powered clinical trials are underway. However, at the time of this writing, there is no Food and Drug Administration-approved drug for vitiligo. In a randomized clinical trial by Khemis et al. report negative results on a randomized clinical trial testing the combination of apremilast, a phosphodiesterase 4 inhibitor, and narrowband-ultraviolet B versus placebo and narrowband-ultraviolet B in patients with nonsegmental vitiligo. The results of this trial are a reminder that clinical management of vitiligo is challenging at best, even when combining anti-inflammatory and/or immunomodulating agents with repigmenting agents. However, these negative trials are critical in improving our understanding of this complex and disfiguring disease.",2020,"report negative results on a randomized clinical trial testing the combination of apremilast, a phosphodiesterase 4 inhibitor, and narrowband-ultraviolet B versus placebo and narrowband-ultraviolet B in patients with nonsegmental vitiligo.","['Vitiligo', 'patients with vitiligo', 'patients with nonsegmental vitiligo']","['phosphodiesterase 4 inhibitor, and narrowband-ultraviolet B versus placebo and narrowband-ultraviolet B']",[],"[{'cui': 'C0042900', 'cui_str': 'Vitiligo'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C2936609', 'cui_str': 'Phosphodiesterase 4 inhibitor'}, {'cui': 'C1532472', 'cui_str': 'Ultra-violet'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.131962,"report negative results on a randomized clinical trial testing the combination of apremilast, a phosphodiesterase 4 inhibitor, and narrowband-ultraviolet B versus placebo and narrowband-ultraviolet B in patients with nonsegmental vitiligo.","[{'ForeName': 'Khaled', 'Initials': 'K', 'LastName': 'Ezzedine', 'Affiliation': 'Department of Dermatology, Henri Mondor University Hospital, Créteil, France; EpidermE, Université Paris-Est Créteil, UPEC, Créteil, France. Electronic address: khaled.ezzedine@aphp.fr.'}, {'ForeName': 'Terrence M', 'Initials': 'TM', 'LastName': 'Vance', 'Affiliation': 'Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.'}, {'ForeName': 'Iltefat H', 'Initials': 'IH', 'LastName': 'Hamzavi', 'Affiliation': 'Department of Dermatology, Henry Ford Hospital, Detroit, Michigan, USA.'}, {'ForeName': 'Abrar A', 'Initials': 'AA', 'LastName': 'Qureshi', 'Affiliation': 'Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.'}]",The Journal of investigative dermatology,['10.1016/j.jid.2020.01.033'] 2718,32709430,"Yoga in Burn: Role of pranayama breathing exercise on pulmonary function, respiratory muscle activity and exercise tolerance in full-thickness circumferential burns of the chest.","BACKGROUND Circumferential burn of chest (CBC) is a significant type of burn and considers as a major cause of restrictive lung disease (RLD). Patient who has CBC with RLD leads to respiratory symptoms such as breathing difficulty, airway obstruction, reduced exercise capacity and altered pulmonary functions. However, studies examining the role of pranayama breathing exercise on pulmonary function, respiratory muscle activity and exercise tolerance in full thickness circumferential burn of chest are lacking. OBJECTIVE To find the short term effects of pranayama breathing exercise on pulmonary function, respiratory muscle activity and exercise tolerance in full thickness circumferential burns of chest. METHODS Through simple random sampling method thirty subjects (N = 30) with RLD following CBC were allocated to pranayama breathing exercise group (PBE-G; n = 15) and conventional breathing exercise group (CBE-G; n = 15). They received pranayama breathing exercise and conventional breathing exercise for 4 weeks respectively. All the subjects received chest mobility exercise as common treatment. Primary (Numeric Pain Rating Scale - NPRS, forced expiratory volume (FEV1), forced vital capacity (FVC) and maximum voluntary ventilation (MVV) and secondary (Electromyogram of sternocleidomastoid, scalene, external intercostal and diaphragm muscle, 6 min walk test & Global Rating of Change - GRC) outcome measures were measured at baseline, after four weeks and after three months follow up. RESULTS Baseline demographic and clinical variables show homogenous distribution between the groups (p > 0.05). Four weeks following different breathing exercises, PBE-G group shows more significant changes in pain intensity, pulmonary function, respiratory muscle activity, exercise tolerance and global rating of change than CBE-G group (p ≤ 0.05) at four weeks and three months follow up. CONCLUSION Both groups showed improvement over time. However, differences between the groups were noticed small. Still physiotherapy management, which included pranayama breathing exercises with chest mobilization program, had an effective strategy in the treatment of restrictive lung disease following circumferential burn of chest.",2020,"Four weeks following different breathing exercises, PBE-G group shows more significant changes in pain intensity, pulmonary function, respiratory muscle activity, exercise tolerance and global rating of change than CBE-G group (p ≤ 0.05) at four weeks and three months follow up. ","['full-thickness circumferential burns of the chest', 'thirty subjects (N = 30) with RLD following CBC', 'Yoga in Burn', 'full thickness circumferential burns of chest']","['pranayama breathing exercise and conventional breathing exercise', 'conventional breathing exercise', 'pranayama breathing exercises with chest mobilization program', 'pranayama breathing exercise', 'chest mobility exercise']","['Primary (Numeric Pain Rating Scale - NPRS, forced expiratory volume (FEV1), forced vital capacity (FVC) and maximum voluntary ventilation (MVV) and secondary (Electromyogram of sternocleidomastoid, scalene, external intercostal and diaphragm muscle, 6 min walk test & Global Rating of Change - GRC) outcome measures', 'pulmonary function, respiratory muscle activity and exercise tolerance', 'pain intensity, pulmonary function, respiratory muscle activity, exercise tolerance and global rating of change']","[{'cui': 'C0439809', 'cui_str': 'Full thickness'}, {'cui': 'C0205113', 'cui_str': 'Circumferential'}, {'cui': 'C0000912', 'cui_str': 'Accident caused by unspecified fire'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0085581', 'cui_str': 'Restrictive lung disease'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0740396', 'cui_str': 'Chest burning'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}, {'cui': 'C0024967', 'cui_str': 'Maximum voluntary ventilation'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0224153', 'cui_str': 'Structure of sternocleidomastoid muscle'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0011980', 'cui_str': 'Diaphragm structure'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0018226', 'cui_str': 'Greece'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0021724', 'cui_str': 'Structure of intercostal muscle'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",30.0,0.0228202,"Four weeks following different breathing exercises, PBE-G group shows more significant changes in pain intensity, pulmonary function, respiratory muscle activity, exercise tolerance and global rating of change than CBE-G group (p ≤ 0.05) at four weeks and three months follow up. ","[{'ForeName': 'Gopal', 'Initials': 'G', 'LastName': 'Nambi', 'Affiliation': 'Department of Physical Therapy and Health Rehabilitation, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia. Electronic address: physio_gopal@rediffmail.com.'}, {'ForeName': 'Walid Kamal', 'Initials': 'WK', 'LastName': 'Abdelbasset', 'Affiliation': 'Department of Physical Therapy and Health Rehabilitation, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia; Department of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt.'}, {'ForeName': 'Ahmed A', 'Initials': 'AA', 'LastName': 'Elshehawy', 'Affiliation': 'Department of Physical Therapy for Cardiovascular/Respiratory Disorder and Geriatrics, Faculty of Physical Therapy, Cairo University, Giza, Egypt; Department of Physical Therapy, Faculty of Applied Medical Sciences, Tabuk University, Tabuk, Saudi Arabia.'}, {'ForeName': 'Heba H', 'Initials': 'HH', 'LastName': 'Altrawy', 'Affiliation': 'Department of Chest Diseases, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.'}, {'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Abodonya', 'Affiliation': 'Anesthesia and Intensive Care Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt; College of Medicine, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.'}, {'ForeName': 'Ayman K', 'Initials': 'AK', 'LastName': 'Saleh', 'Affiliation': 'College of Medicine, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia; Orthopedic Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.'}, {'ForeName': 'Ramadan S', 'Initials': 'RS', 'LastName': 'Hussein', 'Affiliation': 'College of Medicine, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.'}]",Burns : journal of the International Society for Burn Injuries,['10.1016/j.burns.2020.06.033'] 2719,32709507,The Effects of Inhalation Aromatherapy Using Lavender Essential Oil on Postoperative Pain of Inguinal Hernia: A Randomized Controlled Trial.,"PURPOSE One of the main problems after inguinal hernia surgery is postoperative pain. The purpose of this study was to examine the effects of aromatherapy with lavender oil inhalation on postoperative pain after inguinal hernia surgery. DESIGN A randomized controlled design was used. METHODS Ninety participants were selected and assigned to two groups: the intervention group (n = 45) and the control group (n = 45). The patients in the intervention group inhaled four drops of 2% lavender essential oil with oxygen for 20 minutes. The patients in the control group inhaled only oxygen. Postoperative pain was measured 0 minutes after being transferred to the surgery ward, and then 2 hours, 6 hours, and 24 hours after surgery using the visual analog scale. FINDINGS In comparison to the control group, levels of pain severity in the intervention group were significantly lower in four stages of measurements (P < .001). Also, in all stages, measurements showed significant statistical differences within the groups (P < .001). CONCLUSIONS Aromatherapy with lavender essential oil helped decrease postoperative pain after inguinal hernia surgery.",2020,"In comparison to the control group, levels of pain severity in the intervention group were significantly lower in four stages of measurements (P < .001).","['after inguinal hernia surgery', 'Ninety participants']","['aromatherapy with lavender oil inhalation', 'inguinal hernia surgery', 'Inhalation Aromatherapy Using Lavender Essential Oil', 'Aromatherapy with lavender essential oil', 'intervention group inhaled four drops of 2% lavender essential oil with oxygen', 'control group inhaled only oxygen']","['postoperative pain', 'Postoperative Pain of Inguinal Hernia', 'Postoperative pain', 'levels of pain severity']","[{'cui': 'C0019294', 'cui_str': 'Inguinal hernia'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C3816959', 'cui_str': '90'}]","[{'cui': 'C0376547', 'cui_str': 'Aromatherapy'}, {'cui': 'C0064694', 'cui_str': 'lavender oil'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0019294', 'cui_str': 'Inguinal hernia'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0524903', 'cui_str': 'Lavender'}, {'cui': 'C0028910', 'cui_str': 'Volatile oil'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0019294', 'cui_str': 'Inguinal hernia'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",90.0,0.0607485,"In comparison to the control group, levels of pain severity in the intervention group were significantly lower in four stages of measurements (P < .001).","[{'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Bagheri', 'Affiliation': 'Department of Nursing, School of Nursing and Midwifery, Shahroud University of Medical Sciences, Shahroud, Iran.'}, {'ForeName': 'Tahereh', 'Initials': 'T', 'LastName': 'Salmani', 'Affiliation': 'Operating Room, Imam Hossein Center for Education, Research and Treatment, Shahroud University of Medical Sciences, Shahroud, Iran.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Nourian', 'Affiliation': 'Clinical Research Development Unit, Imam Hossein Hospital, Shahroud University of Medical Sciences, Shahroud, Iran.'}, {'ForeName': 'Seyed Mohammad', 'Initials': 'SM', 'LastName': 'Mirrezaie', 'Affiliation': 'Center for Health Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Shahroud, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Abbasi', 'Affiliation': 'Department of Nursing, School of Nursing and Midwifery, Shahroud University of Medical Sciences, Shahroud, Iran.'}, {'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Mardani', 'Affiliation': 'Nursing Care Research Center, School of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran. Electronic address: mardani.a@iums.ac.ir.'}, {'ForeName': 'Zeljko', 'Initials': 'Z', 'LastName': 'Vlaisavljevic', 'Affiliation': 'Clinical Center of Serbia, Clinic for Gastroenterology and Hepatology Belgarade, Serbia.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.03.003'] 2720,32709513,Three-Dimensional Spinal Position With and Without Manual Distraction Load Increases Spinal Height.,"OBJECTIVE The purpose of this study was to investigate if spinal height increases using 3-dimensional (3-D) spinal position with and without manual distraction load and to assess the correlation between spine height changes and degrees of trunk rotation. METHODS Fifty-six participants were randomly placed in one of two groups: (1) 3-D spinal position with manual distraction load, and (2) without manual distraction load. Spinal height was measured before and after the interventions using a stadiometer. For the statistical analysis, we used a 2 (Loading status: pre- versus post-intervention height) X 2 (3-D spinal position: with versus without manual distraction load) repeated measures Analysis of Variance (ANOVA) was used to identify significant interaction and main effects. Paired t-tests were used to calculate differences in spinal height changes between the two interventions. Pearson correlation coefficient was used to measure correlations between changes in spinal heights and degrees of trunk rotation. RESULTS Mean spinal height increase with 3-D spinal position with and without manual distraction load was 6.30 mm (±6.22) and 5.69 mm (±4.13), respectively. No significant interaction effect was present between loading status and 3-D spinal position but a significant main effect in loading status was. Paired t-tests revealed significant differences in spinal heights between pre-and post-3-D spinal position with and without manual distraction load. No significant correlation was measured between trunk rotation and spinal height changes. CONCLUSION 3-D spinal position with or without distraction load increased spinal height. This suggests that 3-D spinal positioning without manual distraction could be used in home settings to help maintain intervertebral disc (IVD) health.",2020,No significant interaction effect was present between loading status and 3-D spinal position but a significant main effect in loading status was.,['Fifty-six participants'],"['3-D spinal position with manual distraction load, and (2) without manual distraction load', '3-dimensional (3-D) spinal position with and without manual distraction load']","['Mean spinal height increase with 3-D spinal position', 'trunk rotation and spinal height changes', 'spinal heights and degrees of trunk rotation', 'spinal height changes', 'spinal heights', 'spinal height', 'Spinal height']",[],"[{'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0150189', 'cui_str': 'Distraction training'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0557899', 'cui_str': 'Height increased'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",56.0,0.0215252,No significant interaction effect was present between loading status and 3-D spinal position but a significant main effect in loading status was.,"[{'ForeName': 'Sohal S', 'Initials': 'SS', 'LastName': 'Hallur', 'Affiliation': 'Center for Rehabilitation Research, School of Health Professions, Texas Tech University Health Sciences Center, Lubbock, TX.'}, {'ForeName': 'Jean-Michel', 'Initials': 'JM', 'LastName': 'Brismée', 'Affiliation': 'Center for Rehabilitation Research, School of Health Professions, Texas Tech University Health Sciences Center, Lubbock, TX. Electronic address: jm.brismee@ttuhsc.edu.'}, {'ForeName': 'Phillip S', 'Initials': 'PS', 'LastName': 'Sizer', 'Affiliation': 'Center for Rehabilitation Research, School of Health Professions, Texas Tech University Health Sciences Center, Lubbock, TX.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Dierick', 'Affiliation': ""Centre National de R é education Fonctionnelle et de R éadaptation-Rehazenter, Laboratoire d'Analyse du Mouvement et de la Posture (LAMP), Luxembourg, Grand Duchy of Luxembourg.""}, {'ForeName': 'Birendra M', 'Initials': 'BM', 'LastName': 'Dewan', 'Affiliation': 'Center for Rehabilitation Research, School of Health Professions, Texas Tech University Health Sciences Center, Lubbock, TX.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Thiry', 'Affiliation': 'Forme & Fonctionnement Humain Laboratory, Physical Therapy Department, CERISIC, Haute Ecole Louvain en Hainaut & Université Catholique de Louvain, Faculty of Motor Sciences, Louvain-la-Neuve, Belgium.'}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Sobczak', 'Affiliation': ""Research Unit in Clinical and Functional Anatomy, Départment d'anatomie, Université du Québec à Trois-Rivières, Canada.""}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2019.04.007'] 2721,32709514,The Effects of Thrust Joint Manipulation on the Resting and Contraction Thickness of Transversus Abdominis in Patients With Low Back Pain: A Randomized Control Trial.,"OBJECTIVE To investigate the immediate changes in resting and contracted thickness of the transversus abdominis (TrA) muscle after application of thrust joint manipulation (TJM) vs sham manipulation in participants with low back pain. METHODS A pretest-posttest randomized controlled trial design was performed. Consecutive subjects satisfying eligibility criteria completed patient-report outcome baseline measures, pretreatment rehabilitative ultrasound imaging (RUSI) measurements, followed by the randomly assigned intervention then, post-treatment RUSI measurements, and post-treatment & final patient-reported outcome measures. To compare the outcomes of TJM and sham manipulation on the TrA muscle thickness, a 2-by-2 analysis of variance (treatment [TJM and sham manipulation]) by time (pretreatment and post-treatment) was completed for both the TrA muscle thickness at rest and muscle thickness during contraction. Descriptive statistics including independent-sample t tests for continuous variables and χ 2 tests for categorical variables were used to analyze differences in patient-reported outcome measures between groups. RESULTS Sixty-seven eligible participants agreed to participate. No significant interactions were identified for either muscle thickness at rest or contraction. CONCLUSION This study did not support the hypothesis that manipulation would result in greater changes in TrA thickness at rest or during contraction in participants with low back pain. Based on prior research that identified subgroups of participants likely to respond to manipulation, future research should include participants more likely to respond favorably to TJM. This study was a priori registered with clinicaltrails.gov (NCT02558855).",2020,"No significant interactions were identified for either muscle thickness at rest or contraction. ","['participants with low back pain', 'Patients With Low Back Pain', 'Sixty-seven eligible participants agreed to participate']","['TJM and sham manipulation', 'transversus abdominis (TrA) muscle after application of thrust joint manipulation (TJM) vs sham manipulation', 'Thrust Joint Manipulation']",['TrA thickness'],"[{'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517852', 'cui_str': '67'}]","[{'cui': 'C0556783', 'cui_str': 'Manipulation of joint - non-surgical'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C1280412', 'cui_str': 'Thick'}]",67.0,0.123283,"No significant interactions were identified for either muscle thickness at rest or contraction. ","[{'ForeName': 'Kelly K', 'Initials': 'KK', 'LastName': 'Fosberg', 'Affiliation': 'Nova Southeastern University, Fort Lauderdale, FL; DeRosa Physical Therapy, Flagstaff, AZ. Electronic address: fosbergk@summitctr.net.'}, {'ForeName': 'Emilio', 'Initials': 'E', 'LastName': 'Puentedura', 'Affiliation': 'School of Allied Health Sciences Department, University of Las Vegas Nevada, Las Vegas, NV.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Schmitz', 'Affiliation': 'DeRosa Physical Therapy, Flagstaff, AZ.'}, {'ForeName': 'Tarang K', 'Initials': 'TK', 'LastName': 'Jain', 'Affiliation': 'Department of Physical Therapy, Northern Arizona University, Flagstaff, AZ.'}, {'ForeName': 'Joshua A', 'Initials': 'JA', 'LastName': 'Cleland', 'Affiliation': 'Franklin Pierce University, Manchester, NH.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2019.04.006'] 2722,32709516,Efficacy of Kinesio Taping and Postural Correction Exercises on Levator Scapula Electromyographic Activities in Mechanical Cervical Dysfunction: A Randomized Blinded Clinical Trial.,"OBJECTIVE Mechanical neck dysfunction (MND) is a major health burden. Although postural correction exercises (PCEs) are commonly used for its treatment, efficacy of Kinesio Taping (KT) has received considerable attention. This study was conducted to determine the effect of KT and PCEs on levator scapula (LS) electromyography. METHODS Ninety-one patients with MND were randomly assigned into 1 of 3 groups that received 4 weeks' treatment: group A, KT; group B, PCE; and group C, both interventions. Neck pain, LS root mean square (RMS), and median frequency (MDF) were measured pretreatment and post-treatment with the Numerical Pain Rating Scale and surface electromyography, respectively, by an assessor blinded to the patients' allocation. RESULTS Multivariate analysis of variance indicates a statistically significant group-by-time interaction (P = .000). Pain intensity was significantly reduced in group C more than in group B (P = .001). Mean values of RMS were significantly reduced in group C compared to both group A (P = .001) and group B (P = .022), whereas MDF was significantly increased in group C compared to either group A (P = .00) or group B (P = .026), and in group B compared to group A (P = 0.26). A paired t test revealed that there was a significant decrease in pain and RMS, and a significant increase in MDF in all groups (P < .01). CONCLUSION Application of both KT and PCE combined can significantly reduce neck pain and normalize LS activities in patients with MND more than the application of either intervention.",2020,"Mean values of RMS were significantly reduced in group C compared to both group A (P = .001) and group B (P = .022), whereas MDF was significantly increased in group C compared to either group A (P = .00) or group B (P = .026), and in group B compared to group A (P = 0.26).","['patients with MND', 'Mechanical Cervical Dysfunction', 'Ninety-one patients with MND']","['KT and PCEs', 'KT and PCE', 'Kinesio Taping and Postural Correction Exercises', 'Kinesio Taping (KT', 'postural correction exercises (PCEs', 'PCE']","['levator scapula (LS) electromyography', 'Pain intensity', 'Mean values of RMS', 'Neck pain, LS root mean square (RMS), and median frequency (MDF', 'MDF', 'Numerical Pain Rating Scale and surface electromyography', 'Levator Scapula Electromyographic Activities', 'neck pain and normalize LS activities', 'pain and RMS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C3816959', 'cui_str': '90'}]","[{'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0246101', 'cui_str': 'PCV regimen'}]","[{'cui': 'C0036277', 'cui_str': 'Bone structure of scapula'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0430815', 'cui_str': 'Surface EMG'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",91.0,0.0936901,"Mean values of RMS were significantly reduced in group C compared to both group A (P = .001) and group B (P = .022), whereas MDF was significantly increased in group C compared to either group A (P = .00) or group B (P = .026), and in group B compared to group A (P = 0.26).","[{'ForeName': 'Aliaa M', 'Initials': 'AM', 'LastName': 'Elabd', 'Affiliation': 'Basic Sciences Department, Faculty of Physical Therapy, Pharos University in Alexandria, Egypt. Electronic address: Aliaelabd88@gmail.com.'}, {'ForeName': 'Abeer R', 'Initials': 'AR', 'LastName': 'Ibrahim', 'Affiliation': 'Basic Sciences Department, Faculty of Physical Therapy, Cairo University, Egypt; Physiotherapy Department, College of Applied Medical Sciences, Umm Al-Qura University, Saudi Arabia.'}, {'ForeName': 'Haytham M', 'Initials': 'HM', 'LastName': 'Elhafez', 'Affiliation': 'Basic Sciences Department, Faculty of Physical Therapy, Cairo University, Egypt; Dean, Faculty of physical therapy, Suez University, Egypt.'}, {'ForeName': 'Hussien A', 'Initials': 'HA', 'LastName': 'Hussien', 'Affiliation': 'Department of Orthopedics, Ahmed Maher Teaching Hospital, Egypt.'}, {'ForeName': 'Omar M', 'Initials': 'OM', 'LastName': 'Elabd', 'Affiliation': 'Department of Musculoskeletal Disorders and Their Surgery, Faculty of Physical Therapy, Delta University for Science and Technology, Egypt.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2019.05.010'] 2723,32709586,Zataria multiflora induced bronchodilatoion comparable to theophylline syrup in asthmatic patients.,"OBJECTIVE The bronchodilatory effect of hydro-ethanolic extract of Z. multiflora was examined in asthmatic patients. DESIGN Pulmonary function tests (PFTs) were measured before and 15, 30, 60, 90, 120, 150, and 180 min after administration of the extract (20 mg/kg) in 18 asthmatics and after theophylline syrup (6 mg/kg) in 12 patients. MAIN OUTCOME MEASURES The extract of Z. multiflora significantly increased all PFT values, 30 to 180 min post-administration similar to the effect of theophylline (all, p<0.001). Increased PFT values due to the extract were significantly declined 180 min but the effects of theophylline were declined 150 min after administration (p<0.05 to p<0.001). Values of PFTs at baseline, 30 and 180 min after drugs administration were not singnificantly different between the extract and theophylline. CONCLUSIONS Z. multiflora showed a bronchodilatory effect in asthmatic patients comparable to theophylline effect but with a longer duration of action.",2020,"The extract of Z. multiflora significantly increased all PFT values, 30 to 180 min post-administration similar to the effect of theophylline (all, p<0.001).",['asthmatic patients'],"['theophylline', 'hydro-ethanolic extract', 'theophylline syrup']","['PFT values', 'Values of PFTs']","[{'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0039771', 'cui_str': 'Theophylline'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C1248150', 'cui_str': 'Theophylline Oral Solution'}]","[{'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.0439761,"The extract of Z. multiflora significantly increased all PFT values, 30 to 180 min post-administration similar to the effect of theophylline (all, p<0.001).","[{'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Boskabady', 'Affiliation': 'Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Azam', 'Initials': 'A', 'LastName': 'Alavinezhad', 'Affiliation': 'Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mohammad Hossein', 'Initials': 'MH', 'LastName': 'Boskabady', 'Affiliation': 'Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: boskabadymh@mums.ac.ir.'}]","Explore (New York, N.Y.)",['10.1016/j.explore.2020.07.002'] 2724,32709590,An individualised self-management exercise and education program did not prevent recurrence of low back pain but may reduce care seeking: a randomised trial.,"QUESTION What is the effect of a McKenzie-based self-management exercise and education program on the risk of recurrence of low back pain (LBP) and on the impact of LBP? DESIGN Randomised controlled trial with concealed allocation, blinded assessors and intention-to-treat analysis. PARTICIPANTS 262 adults recently recovered from an episode of LBP. INTERVENTION The experimental group received a McKenzie-based self-management exercise and education program delivered over two individual sessions of 30 to 45 minutes with a physiotherapist, approximately 2 weeks apart. The control group received a single advice session over the phone. OUTCOME MEASURES The primary outcome was time to first recurrence of an episode of activity-limiting LBP. Secondary outcomes included time to recurrence of any LBP, time to a recurrence causing care seeking and a composite measure of pain and function ('impact of LBP'). Participants were followed-up monthly for ≥ 12 months. RESULTS The estimated effect of the experimental intervention on the risk of recurrence of an episode of: activity-limiting LBP was HR 1.11 (95% CI 0.80 to 1.54), any LBP was HR 0.95 (95% CI 0.72 to 1.26), and LBP for which care was sought was HR 0.69 (95% CI 0.46 to 1.04). The quarterly estimates of the experimental intervention's effect on impact of LBP and their 95% CIs were all within 4 points above or below 0 (no effect) on this scale from 8 to 50. CONCLUSION This study's best estimate is that a McKenzie-based self-management exercise and education program does not produce a worthwhile reduction in the risk of an activity-limiting episode of LBP; however, modestly reduced or moderately increased risk cannot be ruled out. It may markedly reduce the risk of an episode of LBP resulting in care seeking, but does not have any worthwhile effect on the impact of LBP over 12 months. TRIAL REGISTRATION ACTRN12616000926437.",2020,"It may markedly reduce the risk of an episode of LBP resulting in care seeking, but does not have any worthwhile effect on the impact of LBP over 12 months. ",['262 adults recently recovered from an episode of LBP'],"['single advice session', 'McKenzie-based self-management exercise and education program', 'individualised self-management exercise and education program']","[""time to recurrence of any LBP, time to a recurrence causing care seeking and a composite measure of pain and function ('impact of LBP"", 'time to first recurrence of an episode of activity-limiting LBP', 'risk of recurrence of an episode of: activity-limiting LBP', 'LBP']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0521108', 'cui_str': 'Recovering from'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",262.0,0.199324,"It may markedly reduce the risk of an episode of LBP resulting in care seeking, but does not have any worthwhile effect on the impact of LBP over 12 months. ","[{'ForeName': 'Tarcisio F', 'Initials': 'TF', 'LastName': 'de Campos', 'Affiliation': 'Department of Health Professions, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia. Electronic address: tarcisio.de-campos@hdr.mq.edu.au.'}, {'ForeName': 'Natasha C', 'Initials': 'NC', 'LastName': 'Pocovi', 'Affiliation': 'Department of Health Professions, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.'}, {'ForeName': 'Chris G', 'Initials': 'CG', 'LastName': 'Maher', 'Affiliation': 'Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.'}, {'ForeName': 'Helen A', 'Initials': 'HA', 'LastName': 'Clare', 'Affiliation': 'Helen Clare Physiotherapy, Sydney, Australia.'}, {'ForeName': 'Tatiane M', 'Initials': 'TM', 'LastName': 'da Silva', 'Affiliation': 'Master and Doctoral Programs in Physical Therapy, Universidade Cidade de Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Hancock', 'Affiliation': 'Department of Health Professions, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.'}]",Journal of physiotherapy,['10.1016/j.jphys.2020.06.006'] 2725,32709643,Is a definitive trial of prehospital continuous positive airway pressure versus standard oxygen therapy for acute respiratory failure indicated? The ACUTE pilot randomised controlled trial.,"OBJECTIVES To determine the feasibility of a large-scale definitive multicentre trial of prehospital continuous positive airway pressure (CPAP) in acute respiratory failure. DESIGN A single-centre, open-label, individual patient randomised, controlled, external pilot trial. SETTING A single UK Ambulance Service, between August 2017 and July 2018. PARTICIPANTS Adults with respiratory distress and peripheral oxygen saturations below British Thoracic Society target levels despite controlled oxygen treatment. INTERVENTIONS Patients were randomised to prehospital CPAP (O-Two system) versus standard oxygen therapy in a 1:1 ratio using simple randomisation. PRIMARY AND SECONDARY OUTCOME MEASURES Feasibility outcomes comprised recruitment rate, adherence to allocated treatment, retention and data completeness. The primary clinical outcome was 30-day mortality. RESULTS 77 patients were enrolled (target 120), including 7 cases with a diagnosis where CPAP could be ineffective or harmful. CPAP was fully delivered in 74% (target 75%). There were no major protocol violations. Full data were available for all key outcomes (targets ≥90%). Overall 30-day mortality was 27.3%. Of these deceased patients, 14/21 (68%) either did not have a respiratory condition or had ceiling of treatment decisions implemented excluding hospital non-invasive ventilation and critical care. CONCLUSIONS Recruitment rate was below target and feasibility was not demonstrated. Limited compliance with CPAP, and difficulty in identifying patients who could benefit from CPAP, indicate that prehospital CPAP is unlikely to materially reduce mortality. A definitive effectiveness trial of CPAP is therefore not recommended. TRIAL REGISTRATION NUMBER ISRCTN12048261; Post-results.",2020,There were no major protocol violations.,"['77 patients were enrolled (target 120), including 7 cases with a diagnosis where CPAP could be ineffective or harmful', 'Adults with respiratory distress and peripheral oxygen saturations below British Thoracic Society target levels despite controlled oxygen treatment', 'A single UK Ambulance Service, between August 2017 and July 2018', 'Of these deceased patients, 14/21 (68%) either did not have a respiratory condition or had ceiling of treatment decisions implemented excluding hospital non-invasive ventilation and critical care']","['prehospital CPAP (O-Two system) versus standard oxygen therapy', 'CPAP', 'prehospital continuous positive airway pressure versus standard oxygen therapy', 'prehospital continuous positive airway pressure (CPAP']","['30-day mortality', 'recruitment rate, adherence to allocated treatment, retention and data completeness', 'CPAP', 'Overall 30-day mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0476273', 'cui_str': 'Respiratory distress'}, {'cui': 'C2317096', 'cui_str': 'Peripheral oxygen saturation'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0002422', 'cui_str': 'Ambulance'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}, {'cui': 'C0010337', 'cui_str': 'Care of intensive care unit patient'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0439812', 'cui_str': 'Completeness'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",77.0,0.313875,There were no major protocol violations.,"[{'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Fuller', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK g.fuller@sheffield.ac.uk.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Keating', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Goodacre', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Herbert', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Perkins', 'Affiliation': 'Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Rosser', 'Affiliation': 'West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill, West Midlands, UK.'}, {'ForeName': 'Imogen', 'Initials': 'I', 'LastName': 'Gunson', 'Affiliation': 'West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill, West Midlands, UK.'}, {'ForeName': 'Josh', 'Initials': 'J', 'LastName': 'Miller', 'Affiliation': 'West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill, West Midlands, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Ward', 'Affiliation': 'West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill, West Midlands, UK.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Bradburn', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Praveen', 'Initials': 'P', 'LastName': 'Thokala', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Harris', 'Affiliation': 'School of Medicine and Dentistry, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK.'}, {'ForeName': 'Maggie', 'Initials': 'M', 'LastName': 'Marsh', 'Affiliation': 'Sheffield Emergency Care Forum, Sheffield, UK.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Scott', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Cooper', 'Affiliation': 'Clinical Trials Research Unit, University of Sheffield, Sheffield, UK.'}]",BMJ open,['10.1136/bmjopen-2019-035915'] 2726,32709645,Infant formula composition and educational performance: a protocol to extend follow-up for a set of randomised controlled trials using linked administrative education records.,"INTRODUCTION The effect of infant nutrition on long-term cognition is important for parents and policy makers. However, most clinical trials typically have short follow-up periods, when measures of cognition are poorly predictive of later function. The few trials with longer-term follow-up have high levels of attrition, which can lead to selection bias, and in turn to erroneous interpretation of long-term harms and benefits of infant nutrition. We address the need for unbiased, long-term follow-up, by linking measures of educational performance from administrative education records. Educational performance is a meaningful marker of cognitive function in children and it is strongly correlated with IQ. We aim to evaluate educational performance for children who, as infants, were part of a series of trials that randomised participants to either nutritionally modified infant formula or standard formula. Most trialists anticipated positive effects of these interventions on later cognitive function. METHODS AND ANALYSIS Using data from 1923 participants of seven randomised infant formula trials linked to the English National Pupil Database (NPD), this study will provide new insights into the effect of nutrient intake in infancy on school achievement. Our primary outcome will be the mean differences in z-scores between intervention and control groups for a compulsory Mathematics exam sat at age 16. Secondary outcomes will be z-scores for a compulsory English exam at age 16 and z-scores for compulsory Mathematics and English exams at age 11. We will also evaluate intervention effects on the likelihood of receiving special educational needs (SEN) support. All analyses will be performed separately by trial. ETHICS AND DISSEMINATION Research ethics approval, and approval from the Health Research Authority Confidentiality Advisory Group, has been obtained for this study. The results of this study will be disseminated to scientific, practitioner, and lay audiences, submitted for publication in peer-reviewed journals, and will contribute towards a PhD dissertation.",2020,Our primary outcome will be the mean differences in z-scores between intervention and control groups for a compulsory Mathematics exam sat at age 16.,"['1923 participants of seven randomised infant formula trials linked to the English National Pupil Database (NPD', 'children who, as infants']",['nutritionally modified infant formula or standard formula'],"['z-scores for a compulsory English exam at age 16 and z-scores for compulsory Mathematics and English exams at age 11', 'z-scores', 'educational performance']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0150589', 'cui_str': 'Infant formula'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0034121', 'cui_str': 'Pupil structure'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0150589', 'cui_str': 'Infant formula'}, {'cui': 'C3853255', 'cui_str': 'Standard formula'}]","[{'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0582103', 'cui_str': 'Medical assessment'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0024934', 'cui_str': 'Mathematics'}, {'cui': 'C0036373', 'cui_str': 'Academic Test Performance'}]",1923.0,0.167281,Our primary outcome will be the mean differences in z-scores between intervention and control groups for a compulsory Mathematics exam sat at age 16.,"[{'ForeName': 'Maximiliane', 'Initials': 'M', 'LastName': 'Verfürden', 'Affiliation': 'Great Ormond Street Institute of Child Health, University College London, London, UK m.verfuerden@ucl.ac.uk.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Harron', 'Affiliation': 'Great Ormond Street Institute of Child Health, University College London, London, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Jerrim', 'Affiliation': 'Institute of Education, University College London, London, UK.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Fewtrell', 'Affiliation': 'Great Ormond Street Institute of Child Health, University College London, London, UK.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Gilbert', 'Affiliation': 'Great Ormond Street Institute of Child Health, University College London, London, UK.'}]",BMJ open,['10.1136/bmjopen-2019-035968'] 2727,32709656,"Efficacy, cost-utility and physiological effects of Acceptance and Commitment Therapy (ACT) and Behavioural Activation Treatment for Depression (BATD) in patients with chronic low back pain and depression: study protocol of a randomised, controlled trial including mobile-technology-based ecological momentary assessment (IMPACT study).","INTRODUCTION The IMPACT study focuses on chronic low back pain (CLBP) and depression symptoms, a prevalent and complex problem that represents a challenge for health professionals. Acceptance and Commitment Therapy (ACT) and Brief Behavioural Activation Treatment for Depression (BATD) are effective treatments for patients with persistent pain and depression, respectively. The objectives of this 12 month, multicentre, randomised, controlled trial (RCT) are (i) to examine the efficacy and cost-utility of adding a group-based form of ACT or BATD to treatment-as-usual (TAU) for patients with CLBP and moderate to severe levels of depressive symptoms; (ii) identify pre-post differences in levels of some physiological variables and (iii) analyse the role of polymorphisms in the FKBP5 gene, psychological process measures and physiological variables as mediators or moderators of long-term clinical changes. METHODS AND ANALYSIS Participants will be 225 patients with CLBP and moderate to severe depression symptoms recruited at Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat, Spain) and Hospital del Mar (Barcelona, Spain), randomly allocated to one of the three study arms: TAU vs TAU+ACT versus TAU+BATD. A comprehensive assessment to collect clinical variables and costs will be conducted pretreatment, post-treatment and at 12 months follow-up, being pain interference the primary outcome measure. The following physiological variables will be considered at pretreatment and post-treatment assessments in 50% of the sample: immune-inflammatory markers, hair cortisol and cortisone, serum cortisol, corticosteroid-binding globulin and vitamin D. Polymorphisms in the FKBP5 gene (rs3800373, rs9296158, rs1360780, rs9470080 and rs4713916) will be analysed at baseline assessment. Moreover, we will include mobile-technology-based ecological momentary assessment, through the Pain Monitor app, to track ongoing clinical status during ACT and BATD treatments. Linear mixed-effects models using restricted maximum likelihood, and a full economic evaluation applying bootstrapping techniques, acceptability curves and sensitivity analyses will be computed. ETHICS AND DISSEMINATION This study has been approved by the Ethics Committee of the Fundació Sant Joan de Déu and Hospital del Mar. The results will be actively disseminated through peer-reviewed journals, conference presentations, social media and various community engagement activities. TRIAL REGISTRATION NUMBER NCT04140838.",2020,"Acceptance and Commitment Therapy (ACT) and Brief Behavioural Activation Treatment for Depression (BATD) are effective treatments for patients with persistent pain and depression, respectively.","['patients with chronic low back pain and depression', 'patients with CLBP and moderate to severe levels of depressive symptoms', 'patients with persistent pain and depression, respectively', 'Participants will be 225 patients with CLBP and moderate to severe depression symptoms recruited at Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat, Spain) and Hospital del Mar (Barcelona, Spain']","['Acceptance and Commitment Therapy (ACT) and Brief Behavioural Activation Treatment', 'Acceptance and Commitment Therapy (ACT) and Behavioural Activation Treatment', 'ACT or BATD to treatment-as-usual (TAU', 'TAU vs TAU+ACT\u2009versus TAU+BATD']","['chronic low back pain (CLBP) and depression symptoms', 'immune-inflammatory markers, hair cortisol and cortisone, serum cortisol, corticosteroid-binding globulin and vitamin D. Polymorphisms', 'efficacy and cost-utility', 'Efficacy, cost-utility and physiological effects']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4517652', 'cui_str': '225'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008628', 'cui_str': 'Chromosomal deletion'}, {'cui': 'C0024782', 'cui_str': 'Marathi language'}]","[{'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}, {'cui': 'C0029917', 'cui_str': 'Outpatient Commitment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0010137', 'cui_str': 'Cortisone'}, {'cui': 'C0236396', 'cui_str': 'Serum cortisol measurement'}, {'cui': 'C0040643', 'cui_str': 'Corticotropin binding globulin'}, {'cui': 'C0042890', 'cui_str': 'Vitamin'}, {'cui': 'C0032529', 'cui_str': 'Genetic polymorphism'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",225.0,0.185291,"Acceptance and Commitment Therapy (ACT) and Brief Behavioural Activation Treatment for Depression (BATD) are effective treatments for patients with persistent pain and depression, respectively.","[{'ForeName': 'Juan P', 'Initials': 'JP', 'LastName': 'Sanabria-Mazo', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Carlos G', 'Initials': 'CG', 'LastName': 'Forero', 'Affiliation': 'Department of Medicine, International University of Catalunya, Barcelona, Spain.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Cristobal-Narváez', 'Affiliation': 'Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Suso-Ribera', 'Affiliation': 'Department of Basic and Clinical Psychology and Psychobiology, Universitat Jaume I, Castelló de la Plana, Spain.'}, {'ForeName': 'Azucena', 'Initials': 'A', 'LastName': 'García-Palacios', 'Affiliation': 'Department of Basic and Clinical Psychology and Psychobiology, Universitat Jaume I, Castelló de la Plana, Spain.'}, {'ForeName': 'Ariadna', 'Initials': 'A', 'LastName': 'Colomer-Carbonell', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Adrián', 'Initials': 'A', 'LastName': 'Pérez-Aranda', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Andrés-Rodríguez', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Lance M', 'Initials': 'LM', 'LastName': 'McCracken', 'Affiliation': 'Psychology Department, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': ""D'Amico"", 'Affiliation': 'Personal Social Services Research Unit, London School of Economics and Political Science, London, UK.'}, {'ForeName': 'Pere', 'Initials': 'P', 'LastName': 'Estivill-Rodríguez', 'Affiliation': 'Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain.'}, {'ForeName': 'Bernat', 'Initials': 'B', 'LastName': 'Carreras-Marcos', 'Affiliation': 'Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Montes-Pérez', 'Affiliation': 'Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Comps-Vicente', 'Affiliation': 'Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain.'}, {'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Esteve', 'Affiliation': 'Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERobn), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Mar', 'Initials': 'M', 'LastName': 'Grasa', 'Affiliation': 'Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERobn), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Araceli', 'Initials': 'A', 'LastName': 'Rosa', 'Affiliation': 'Network Centre for Biomedical Research in Mental Health (CIBERSAM), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Antonio I', 'Initials': 'AI', 'LastName': 'Cuesta-Vargas', 'Affiliation': 'Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Maes', 'Affiliation': 'Department of Psychiatry, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Borràs', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Edo', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Sanz', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Feliu-Soler', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Juan R', 'Initials': 'JR', 'LastName': 'Castaño-Asins', 'Affiliation': 'Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain.'}, {'ForeName': 'Juan V', 'Initials': 'JV', 'LastName': 'Luciano', 'Affiliation': 'Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain jvluciano@pssjd.org.'}]",BMJ open,['10.1136/bmjopen-2020-038107'] 2728,32709657,Bridging the gap between physical and mental illness in community pharmacy ( PharMIbridge ): protocol for an Australian cluster randomised controlled trial.,"INTRODUCTION There is a significant life expectancy gap attributable to physical comorbidities for people living with severe and persistent mental illness (SPMI) compared with the general population. Medications are a major treatment for SPMI management and physical illnesses, hence pharmacists are well positioned to support mental healthcare and comorbidities. The randomised controlled trial (RCT) aim is to evaluate effectiveness of an individualised, pharmacist led, support service for people experiencing SPMI focusing on medication adherence and physical comorbidity management, compared with standard care (a medication-management service; MedsCheck). METHODS AND ANALYSIS: PharMIbridge is a cluster RCT, whereby community pharmacies in four Australian regions will be randomised (1:1 ratio), to either Intervention Group (IG) or Comparator Group (CG). All IG and CG pharmacy staff will receive Blended-Mental Health First Aid training. Additionally, IG pharmacists will receive further training on medication adherence, goal setting, motivational interviewing, managing physical health concerns and complex issues relating to psychotropic medication. CG pharmacists will not receive additional training, and will provide standard care (MedsCheck). The primary outcome will be change in participants medication adherence for psychotropic medication over 6-months. Using mixed-effects logistic regression model and a cluster size of 48 pharmacies, a total of 190 participants will need to be recruited to each arm to find a statistically significant difference in medication adherence. Secondary outcomes will be changes in factors associated with cardiometabolic risk and quality of life, emphasising physical and psychological well-being; medication-related problems; adherence to other prescribed medication; pharmacists knowledge, confidence and ability to support people experiencing SPMI; and effects on healthcare utilisation. A within RCT-based economic evaluation comparing the intervention with standard care will be undertaken. ETHICS AND DISSEMINATION The protocol and pharmacist training programme received Griffith University Human Research Ethics Committee approval (HREC/2019/473 and HREC/2019/493 respectively). Results will be published in peer-reviewed journals and available at the Sixth Community Pharmacy Agreement website (http://6cpa.com.au/about-6cpa/). TRIAL REGISTRATION NUMBER ANZCTR12620000577910.",2020,"The randomised controlled trial (RCT) aim is to evaluate effectiveness of an individualised, pharmacist led, support service for people experiencing SPMI focusing on medication adherence and physical comorbidity management, compared with standard care (a medication-management service; MedsCheck).","['people living with severe and persistent mental illness (SPMI', '48 pharmacies, a total of 190 participants']",['Blended-Mental Health First Aid training'],"['cardiometabolic risk and quality of life, emphasising physical and psychological well-being; medication-related problems; adherence to other prescribed medication; pharmacists knowledge, confidence and ability to support people experiencing SPMI; and effects on healthcare utilisation', 'participants medication adherence for psychotropic medication', 'medication adherence']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0870281', 'cui_str': 'Chronic mental disorder'}, {'cui': 'C0031321', 'cui_str': 'Pharmacy service'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517622', 'cui_str': '190'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1276379', 'cui_str': 'First aid education'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0424578', 'cui_str': 'Well in self'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0870281', 'cui_str': 'Chronic mental disorder'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0033978', 'cui_str': 'Psychotherapeutic agent'}]",190.0,0.139524,"The randomised controlled trial (RCT) aim is to evaluate effectiveness of an individualised, pharmacist led, support service for people experiencing SPMI focusing on medication adherence and physical comorbidity management, compared with standard care (a medication-management service; MedsCheck).","[{'ForeName': 'Amanda J', 'Initials': 'AJ', 'LastName': 'Wheeler', 'Affiliation': 'Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia a.wheeler@griffith.edu.au.'}, {'ForeName': 'Claire L', 'Initials': 'CL', 'LastName': ""O'Reilly"", 'Affiliation': 'Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Sarira', 'Initials': 'S', 'LastName': 'El-Den', 'Affiliation': 'Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Byrnes', 'Affiliation': 'Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Ware', 'Affiliation': 'Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia.'}, {'ForeName': 'Sara S', 'Initials': 'SS', 'LastName': 'McMillan', 'Affiliation': 'Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia.'}]",BMJ open,['10.1136/bmjopen-2020-039983'] 2729,32700926,Countering emotional behaviors in the treatment of borderline personality disorder.,"The purpose of the current study was to investigate the unique effects of a commonly used skill incorporated into treatment packages for borderline personality disorder (BPD), countering emotion-driven behavioral urges. Individuals with BPD ( N = 8) participated in a single-case experimental design, specifically a multiple baseline, in which they were randomly assigned to complete a baseline assessment-only phase of 2 or 4 weeks. Participants then received four sessions of the countering emotional behaviors module from the unified protocol, followed by a 4-week follow-up phase. Throughout the duration of the study, daily data capture was used to assess real-time changes in the frequency of emotionally avoidant behaviors in response to emotional experiences. Symptoms of BPD, depression, and anxiety were also assessed. By follow-up, the majority of patients demonstrated a meaningful reduction (per single-case experimental design guidelines for evaluating improvements) in their use of avoidant behaviors. There was also preliminary evidence that encouraging participants to act counter to avoidant urges is associated with decreases in BPD, depression, and anxiety symptoms, as well as negative affectivity. The countering emotional behaviors skill from the unified protocol indeed engages its putative target of emotionally avoidant behavioral coping, indicating it is an active ingredient in multicomponent treatment packages for BPD, with implications for downstream clinical endpoints such as BPD and depressive and anxiety symptoms. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"There was also preliminary evidence that encouraging participants to act counter to avoidant urges is associated with decreases in BPD, depression, and anxiety symptoms, as well as negative affectivity.","['borderline personality disorder', 'Individuals with BPD ( N = 8) participated', 'borderline personality disorder (BPD']",[],"['Countering emotional behaviors', 'Symptoms of BPD, depression, and anxiety', 'BPD, depression, and anxiety symptoms']","[{'cui': 'C0006012', 'cui_str': 'Borderline personality disorder'}, {'cui': 'C0027361', 'cui_str': 'Person'}]",[],"[{'cui': 'C0677601', 'cui_str': 'Counter'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0006012', 'cui_str': 'Borderline personality disorder'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}]",,0.0317915,"There was also preliminary evidence that encouraging participants to act counter to avoidant urges is associated with decreases in BPD, depression, and anxiety symptoms, as well as negative affectivity.","[{'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Sauer-Zavala', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Clair', 'Initials': 'C', 'LastName': 'Cassiello-Robbins', 'Affiliation': 'Department of Psychological and Brain Sciences.'}, {'ForeName': 'Brittany K', 'Initials': 'BK', 'LastName': 'Woods', 'Affiliation': 'Department of Psychological and Brain Sciences.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Curreri', 'Affiliation': 'Department of Psychological and Brain Sciences.'}, {'ForeName': 'Juilanne', 'Initials': 'J', 'LastName': 'Wilner Tirpak', 'Affiliation': 'Department of Psychological and Brain Sciences.'}, {'ForeName': 'Madeleine', 'Initials': 'M', 'LastName': 'Rassaby', 'Affiliation': 'Department of Psychological and Brain Sciences.'}]",Personality disorders,['10.1037/per0000379'] 2730,32700944,Prosocial skills causally mediate the relation between effective classroom management and academic competence: An application of direction dependence analysis.,"Direction dependence analysis (DDA) is a recently developed method that addresses the need for more sophisticated tools to evaluate causal mechanisms of developmental processes and interventions. The present study applied DDA to evaluate the hypothesized mediators of a classroom behavior management training program on student academic competence. The study involved a group randomized controlled trial with 105 teachers and 1,818 students (K-3rd grade) in a large urban school district in the United States. Analyses revealed only student prosocial skill development causally mediated the intervention's effects on student academic competence. The findings support the importance of explicit instruction and coaching of student social skills as part of classroom behavior management programs and confirm the causal link between prosocial skills and academic success. The findings are discussed with regard to implications for future applications of DDA in developmental research. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,Analyses revealed only student prosocial skill development causally mediated the intervention's effects on student academic competence.,"['student academic competence', '105 teachers and 1,818 students (K-3rd grade) in a large urban school district in the United States']",['classroom behavior management training program'],['student academic competence'],"[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0205437', 'cui_str': 'Third'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C1301808', 'cui_str': 'State'}]","[{'cui': 'C0150143', 'cui_str': 'Behavior management'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0086035', 'cui_str': 'Competence'}]",105.0,0.0164057,Analyses revealed only student prosocial skill development causally mediated the intervention's effects on student academic competence.,"[{'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Wiedermann', 'Affiliation': 'Missouri Prevention Science Institute and Department of Educational, School, and Counseling Psychology.'}, {'ForeName': 'Wendy M', 'Initials': 'WM', 'LastName': 'Reinke', 'Affiliation': 'Missouri Prevention Science Institute and Department of Educational, School, and Counseling Psychology.'}, {'ForeName': 'Keith C', 'Initials': 'KC', 'LastName': 'Herman', 'Affiliation': 'Missouri Prevention Science Institute and Department of Educational, School, and Counseling Psychology.'}]",Developmental psychology,['10.1037/dev0001087'] 2731,32700952,Community-based randomized controlled trial of psychological first aid with crime victims.,"OBJECTIVE The first randomized controlled trial of psychological first aid (PFA) was conducted, using crime victims as participants. For study Aim 1, investigators tested whether paraprofessional victim advocates could be trained to deliver PFA to crime victims. For study Aim 2, investigators tested the effect of PFA delivery on victims' psychiatric (i.e., symptoms of PTSD, somatization, depression, anxiety, and substance use) and adaptive functioning outcomes. METHOD Two law enforcement agencies served as study sites. A dynamic wait-listed design included a phase when advocates at both sites delivered usual services (US) to victims, a phase when one site was randomly selected to deliver PFA while the other delivered US, and a phase when both sites delivered PFA. Across all phases, 172 crime victims (mean age = 36.4 years; 81% female) were recruited, and a battery assessed their psychiatric symptoms and adaptive functioning at baseline and 1, 2, and 4 months postbaseline. RESULTS From the US to PFA phases, advocates' PFA adherence (i.e., their delivery of PFA components) increased significantly. PFA did not outperform US with regard to improvement on victims' individual psychiatric and adaptive functioning outcomes. However, on a composite global functioning outcome created for this trial, PFA yielded significantly greater improvement relative to US. CONCLUSION Paraprofessional victim advocates have the capacity to deliver PFA. Conclusions regarding the effectiveness of PFA for crime victims vary depending on the nature of the scored outcome variable (individual vs. global), highlighting the importance of careful outcome measurement considerations in future research on PFA. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,PFA did not outperform US with regard to improvement on victims' individual psychiatric and adaptive functioning outcomes.,"['Two law enforcement agencies served as study sites', '172 crime victims (mean age = 36.4 years; 81% female']","['psychological first aid (PFA', 'PFA']","[""victims' psychiatric (i.e., symptoms of PTSD, somatization, depression, anxiety, and substance use) and adaptive functioning outcomes"", ""victims' individual psychiatric and adaptive functioning outcomes"", ""advocates' PFA adherence""]","[{'cui': 'C0162469', 'cui_str': 'Law Enforcement'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C4517601', 'cui_str': '172'}, {'cui': 'C0302823', 'cui_str': 'Victim of crime'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0016143', 'cui_str': 'First aid'}]","[{'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0016143', 'cui_str': 'First aid'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",,0.047885,PFA did not outperform US with regard to improvement on victims' individual psychiatric and adaptive functioning outcomes.,"[{'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'McCart', 'Affiliation': 'Oregon Social Learning Center.'}, {'ForeName': 'Jason E', 'Initials': 'JE', 'LastName': 'Chapman', 'Affiliation': 'Oregon Social Learning Center.'}, {'ForeName': 'Kristyn', 'Initials': 'K', 'LastName': 'Zajac', 'Affiliation': 'Department of Medicine.'}, {'ForeName': 'Alyssa A', 'Initials': 'AA', 'LastName': 'Rheingold', 'Affiliation': 'National Crime Victims Research and Treatment Center.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000588'] 2732,32700953,Direct and indirect effects of a couple-focused preventive intervention on children's outcomes: A randomized controlled trial with African American families.,"OBJECTIVE This study examined the effects of the Protecting Strong African American Families (ProSAAF) prevention program on children's outcomes more than 2 years after enrollment, including direct effects of the intervention and indirect effects through couple functioning and parent-child relations. METHOD Three hundred forty-six African American couples with an early adolescent child participated; all families lived in rural, low-income communities in the southern United States. Families were randomly assigned to ProSAAF or control conditions and completed four waves of data collection. Couples reported couple functioning at baseline (Wave 1) and at 9-month follow-up (Wave 2), and parent-child relations at 17-month follow-up (Wave 3). Children reported their conduct problems, affiliation with deviant peers, substance use, sexual onset, depressive symptoms, and self-control at 25-month follow-up (Wave 4). RESULTS Path analyses indicated significant indirect effects of ProSAAF on children's outcomes through improvements in couple functioning and better parent-child relations. There were no significant direct effects of the intervention on children's outcomes or significant indirect effects through couple functioning alone. CONCLUSIONS This couple-focused prevention program has positive indirect effects on several child outcomes through the intervening processes of promoting improvements in couple functioning and better parent-child relations. These findings provide cautious optimism regarding the possible benefits of couple-focused programming on participants' children while suggesting ways in which future couple-focused interventions could yield stronger effects on these youth. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"RESULTS Path analyses indicated significant indirect effects of ProSAAF on children's outcomes through improvements in couple functioning and better parent-child relations.","['Three hundred forty-six African American couples with an early adolescent child participated; all families lived in rural, low-income communities in the southern United States', 'African American families', ""participants' children"", ""children's outcomes""]","['ProSAAF', 'couple-focused preventive intervention', 'Protecting Strong African American Families (ProSAAF) prevention program']",['couple functioning and better parent-child relations'],"[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0557130', 'cui_str': 'Lives with family'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C1274040', 'cui_str': 'Result'}]","[{'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0030542', 'cui_str': 'Parent-Child Relationship'}]",,0.0600898,"RESULTS Path analyses indicated significant indirect effects of ProSAAF on children's outcomes through improvements in couple functioning and better parent-child relations.","[{'ForeName': 'Justin A', 'Initials': 'JA', 'LastName': 'Lavner', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Allen W', 'Initials': 'AW', 'LastName': 'Barton', 'Affiliation': 'Department of Human Development and Family Studies.'}, {'ForeName': 'Steven R H', 'Initials': 'SRH', 'LastName': 'Beach', 'Affiliation': 'Department of Psychology and Center for Family Research.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000589'] 2733,32703680,"Effects of parental education on screen time, sleep disturbances, and psychosocial adaptation among Asian preschoolers: A randomized controlled study.","PURPOSE A recent increase in screen time during early childhood has adversely affected the sleep and psychosocial health of children; however, limited information is available regarding effective interventions to reduce the screen time among them. This study aimed to investigate the effect of a parental educational program on screen use, sleep quality, and psychosocial adaptation among preschoolers. DESIGN AND METHODS A clustered randomized controlled study with a parallel-group design was conducted. Preschoolers with a screen time of ≥2 h/day and their parents were recruited. In total, 14 kindergartens containing 129 parent-child dyads were randomly allocated to either the experimental group (receiving parental education, N = 63 dyads) or the control group (daily activities, N = 66 dyads). Data were collected before and after the intervention. A screen time questionnaire, the Children's Sleep Habits Questionnaire, and the Pediatric Symptom checklist-17 were provided to the participants. A linear mixed-model analysis was performed to examine the efficacy of the intervention. RESULTS After the intervention, the screen time of children in the experimental group was significantly reduced (effect size: 0.83, p < .001), and they presented improved sleep quality (effect size: 0.57, p = .01) and attention score (effect size: 0.77, p = .02) for psychosocial adaptation. CONCLUSIONS Parental education is an effective intervention for reducing screen time and improving sleep quality and attention among preschoolers. PRACTICE IMPLICATIONS Healthcare professionals should consider implementing parental educational programs to reduce screen time, and thus improve the sleep quality and psychosocial health of preschoolers.",2020,"After the intervention, the screen time of children in the experimental group was significantly reduced (effect size: 0.83, p < .001), and they presented improved sleep quality (effect size: 0.57, p = .01) and attention score (effect size: 0.77, p = .02) for psychosocial adaptation. ","['preschoolers', 'In total, 14 kindergartens containing 129 parent-child dyads', 'Asian preschoolers', 'Preschoolers with a screen time of ≥2\xa0h/day and their parents were recruited']","['experimental group (receiving parental education, N\xa0=\xa063 dyads) or the control group (daily activities, N\xa0=\xa066 dyads', 'parental education', 'parental educational program']","['screen time, sleep disturbances, and psychosocial adaptation', ""Children's Sleep Habits Questionnaire"", 'screen time of children', 'screen use, sleep quality, and psychosocial adaptation', 'attention score', 'sleep quality']","[{'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C4704787', 'cui_str': 'Screen Time'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C4704787', 'cui_str': 'Screen Time'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C2133558', 'cui_str': 'Sleep Habits'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0308923,"After the intervention, the screen time of children in the experimental group was significantly reduced (effect size: 0.83, p < .001), and they presented improved sleep quality (effect size: 0.57, p = .01) and attention score (effect size: 0.77, p = .02) for psychosocial adaptation. ","[{'ForeName': 'Yen-Miao', 'Initials': 'YM', 'LastName': 'Lin', 'Affiliation': 'School of Nursing, College of Nursing, Taipei Medical University, Taiwan. Electronic address: marianne01011414@gmail.com.'}, {'ForeName': 'Shu-Yu', 'Initials': 'SY', 'LastName': 'Kuo', 'Affiliation': 'School of Nursing, College of Nursing, Taipei Medical University, Taiwan. Electronic address: sykuo@tmu.edu.tw.'}, {'ForeName': 'Yu-Kai', 'Initials': 'YK', 'LastName': 'Chang', 'Affiliation': 'Department of Physical Education and Institute for Research Excellence in Learning Science, National Taiwan Normal University, Republic of China (Taiwan). Electronic address: yukaichangnew@gmail.com.'}, {'ForeName': 'Pi-Chu', 'Initials': 'PC', 'LastName': 'Lin', 'Affiliation': 'Master Program in Long-Term Care, College of Nursing, Taipei Medical University, Taiwan. Electronic address: pclin@tmu.edu.tw.'}, {'ForeName': 'Yen-Kuang', 'Initials': 'YK', 'LastName': 'Lin', 'Affiliation': 'Biostatistics Center, Taipei Medical University, Taiwan. Electronic address: robbinlin@tmu.edu.tw.'}, {'ForeName': 'Pi-Hsia', 'Initials': 'PH', 'LastName': 'Lee', 'Affiliation': 'School of Nursing, College of Nursing, Taipei Medical University, Taiwan. Electronic address: pihsia@tmu.edu.tw.'}, {'ForeName': 'Pu-Hung', 'Initials': 'PH', 'LastName': 'Lin', 'Affiliation': 'Department of Nursing, Taipei Municipal Wan Fang Hospital, Taiwan. Electronic address: 88235@w.tmu.edu.tw.'}, {'ForeName': 'Su-Ru', 'Initials': 'SR', 'LastName': 'Chen', 'Affiliation': 'Post-Baccalaureate Program in Nursing, College of Nursing, Taipei Medical University, Taiwan. Electronic address: suru@tmu.edu.tw.'}]",Journal of pediatric nursing,['10.1016/j.pedn.2020.07.003'] 2734,32703720,The efficacy of different vitamin D supplementation delivery methods on serum 25(OH)D: A randomised double-blind placebo trial.,"BACKGROUND The use of vitamin D supplementation has increased due to greater recognition of widespread deficiency. AIMS There has been little research on the effectiveness of different delivery methods and therefore the aim of was to test the efficacy of different delivery methods on serum 25(OH)D. METHODS Using a randomised repeated measures double-blind placebo design (registered under ClinicalTrials.gov Identifier no. NCT03463642), changes in serum 25(OH)D over a 4-week period using a capillary spot method were monitored. 62 female participants blindly chose a number related to a supplementation delivery method: pill placebo, pill, oral liquid, oral liquid placebo, Skin oil application (SOA) placebo, SOA plus vitamin D 3 suspension, or SOA plus vitamin D 3 suspension with essential oil enhancer; active vitamin D supplements contained 100,000IU. Participants took their allocated supplements over a 24-hr period with serum 25(OH)D retested 4 weeks later. Liquid chromatography-tandem mass spectrometry method was applied to dried blood spot samples by an independent laboratory. RESULTS ANCOVA reported a significant difference between the groups (F 1,6  = 146.68; p < 0.001, eta 2  = 0.51). Separate analysis within the delivery methods (pill, SOA, oral liquid) indicated significant differences between the active and placebo supplementation groups (p < 0.01). Post hoc analysis of absolute changes indicated vit D pill and SOA + vit D + essential oil had significant increases (p < 0.05) in serum 25(OH)D compared to all other interventions with no significant difference between them. CONCLUSIONS In human participants vitamin D oral pill has the greatest effect on serum 25(OH)D levels. Skin oil application delivery of vitamin D using a penetrator enhancer has also been shown to be an effective method of delivery.",2020,"vit D + essential oil had significant increases (p < 0.05) in serum 25(OH)D compared to all other interventions with no significant difference between them. ",['62 female participants blindly chose a number related to a supplementation delivery method'],"['vit D\xa0+\xa0essential oil', 'pill placebo, pill, oral liquid, oral liquid placebo, Skin oil application (SOA) placebo, SOA plus vitamin D 3 suspension, or SOA plus vitamin D 3 suspension with essential oil enhancer; active vitamin D supplements', 'vitamin D', 'vitamin D supplementation', 'placebo']","['vit D pill and SOA\xa0', 'serum 25(OH)D', 'serum 25(OH)D levels']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0028910', 'cui_str': 'Volatile oil'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1273619', 'cui_str': 'Oral Liquid Product'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0007985', 'cui_str': 'Chemical suspension'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0420176', 'cui_str': 'Vitamin D supplement therapy'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}]","[{'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",62.0,0.543137,"vit D + essential oil had significant increases (p < 0.05) in serum 25(OH)D compared to all other interventions with no significant difference between them. ","[{'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Wyon', 'Affiliation': 'Sport and Physical Activity Research Centre, Institute of Sport and Health Sciences, University of Wolverhampton, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Wolman', 'Affiliation': 'Department of Rheumatology and Sport and Exercise Medicine, Royal National Orthopaedic Hospital, Stanmore, UK.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Martin', 'Affiliation': ""Worcester Biomedical Science Research Group, Institute of Science and the Environment, St. John's Campus, University of Worcester, Henwick Grove, Worcester, WR2 6AJ, UK. Electronic address: m.wyon@wlv.ac.uk.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Galloway', 'Affiliation': 'Sport and Physical Activity Research Centre, Institute of Sport and Health Sciences, University of Wolverhampton, UK.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.05.040'] 2735,32703721,Effects of Ketogenic metabolic therapy on patients with breast cancer: A randomized controlled clinical trial.,"BACKGROUND Ketogenic metabolic therapy (KMT) using ketogenic diets (KD) is emerging as viable alternative or complementary strategy for managing cancer; however, few clinical trials have been reported. The present study aimed to evaluate the effects of a KD in patients with locally advanced and metastatic breast cancer receiving chemotherapy. METHODS A total of 80 patients undergoing treatment with chemotherapy were randomly assigned to KD or control group for 12 weeks. Concurrent with the admission, midway point, and at 12 weeks, fasting blood samples were collected for evaluation of insulin, IGF-1, CEA, CA15-3, ESR, CRP, IL-10, and TNF-α. Sonography for patients with locally advanced disease and CT or MRI scans for patients with metastatic disease were done on admission and at 12 weeks. At the completion of the chemotherapy, patients with locally advanced disease underwent surgery and stage was recalculated. Also patients with metastases were evaluated for response rate. RESULTS TNF-α decreased significantly after 12 weeks of treatment (MD: 0.64 [CI 95%: -3.7, 5] P < 0.001), while IL-10 increased (MD: 0.95 [CI 95%: -1,3] P < 0.001) in the intervention compared to the control group. Patients in the KD group had lower adjusted serum insulin compared to the control group (MD:-1.1 [CI 95%: -3,1] p < 0.002). KD lead to a reduction in tumor size in the KD compared to the control (27 vs 6 mm, P = 0.01). Stage decreased significantly in patients with locally advanced disease in the KD group after 12 weeks (P < 0.01). No significant differences in response rate were observed in patients with metastatic disease. CONCLUSIONS KMT in breast cancer patients might exert beneficial effects through decreasing TNF-α and insulin and increasing IL-10. KD may result in a better response through reductions in tumor size and downstaging in patients with locally advanced disease; however, more studies are needed to elucidate the potential beneficial effects of KD in patients with metastases. TRIAL REGISTRATION This trial has been registered on Iranian Registry of Clinical Trials (IRCT) under the identification code: IRCT20171105037259N2. https://www.irct.ir/trial/30755.",2020,Stage decreased significantly in patients with locally advanced disease in the KD group after 12 weeks (P < 0.01).,"['80 patients undergoing treatment with', 'patients with locally advanced disease underwent surgery and stage was recalculated', 'patients with locally advanced disease', 'patients with metastases', 'breast cancer patients', 'patients with metastatic disease', 'patients with locally advanced and metastatic breast cancer receiving chemotherapy', 'patients with breast cancer']","['chemotherapy', 'KD', 'Ketogenic metabolic therapy (KMT) using ketogenic diets (KD', 'Ketogenic metabolic therapy']","['insulin, IGF-1, CEA, CA15-3, ESR, CRP, IL-10, and TNF-α. Sonography', 'TNF-α', 'fasting blood samples', 'lower adjusted serum insulin', 'tumor size', 'response rate', 'IL-10']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0730490', 'cui_str': 'Stage 1S'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0259972', 'cui_str': 'Ketogenic diet'}, {'cui': 'C0587059', 'cui_str': 'Metabolic therapy'}]","[{'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0021665', 'cui_str': 'Somatomedin C'}, {'cui': 'C0007082', 'cui_str': 'Carcinoembryonic antigen'}, {'cui': 'C0006611', 'cui_str': 'Cancer antigen 15-3'}, {'cui': 'C0013845', 'cui_str': 'Electron spin resonance measurement'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0475440', 'cui_str': 'Tumor size'}]",80.0,0.11375,Stage decreased significantly in patients with locally advanced disease in the KD group after 12 weeks (P < 0.01).,"[{'ForeName': 'Adeleh', 'Initials': 'A', 'LastName': 'Khodabakhshi', 'Affiliation': 'Department of Nutrition, School of Public Health, Kerman University of Medical Sciences, Kerman, Iran; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad Esmaeil', 'Initials': 'ME', 'LastName': 'Akbari', 'Affiliation': 'Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hamid Reza', 'Initials': 'HR', 'LastName': 'Mirzaei', 'Affiliation': 'Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Thomas N', 'Initials': 'TN', 'LastName': 'Seyfried', 'Affiliation': 'Department of Biology, Boston College, Chestnut Hill, MA, United States.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Kalamian', 'Affiliation': 'Dietary Therapies LLLC, Hamilton, MT, United States.'}, {'ForeName': 'Sayed Hossein', 'Initials': 'SH', 'LastName': 'Davoodi', 'Affiliation': 'Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Cellular and Molecular Nutrition, Faculty of Nutrition Science and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: khodabakhshiadeleh@yahoo.com.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.06.028'] 2736,32703746,The effects of switching from 10 to 5-dose vials of MR vaccine on vaccination coverage and wastage: A mixed-method study in Zambia.,"INTRODUCTION Vaccines procured for low-income countries are often packaged in multi-dose vials to reduce program costs. To avoid wastage, health workers may refrain from opening a vial if few children attend an immunization session, possibly leading to lower coverage. Lowering the number of doses in a vial may increase coverage and reduce wastage. METHODS We used a mixed methods approach to measure the effects of switching from conventional 10-dose measles containing vaccine (MCV) vials to 5-dose MCV vials on coverage and open vial wastage in 14 districts purposely selected from two provinces in Zambia. The districts were paired based on the number of health facilities and the average size of the health facility catchment population. One district from each pair was randomly allocated to receive 5-dose vials while the other continued with the conventional vials. We applied propensity score matched difference-in-difference analysis to estimate intervention effects on coverage using pre-intervention household survey and post-intervention household survey after 11 months of the intervention. The intervention effects on wastage rates were estimated from multivariate analysis of the administrative data. Key informant interviews were conducted to better understand health workers' behavior and preferences at baseline, midline and endline, and analyzed using thematic analysis techniques. RESULTS MCV coverage rates increased across both arms for both doses. A five percentage-point intervention effect was detected for MCV1 and 3.5 percentage-point effect for MCV2. The MCV wastage rate was 47% lower in facilities using 5-dose vials (16.2%) versus 10-dose vials (30.5%). Healthcare workers reported being more willing to open a 5-dose vial than a 10-dose vial for one child, as they were less concerned about wastage. DISCUSSION Switching 10-dose MCV vials to 5-dose vials improved coverage, decreased wastage, and improved willingness to open a vial. These findings can contribute to strategies for reducing missed opportunities for vaccination.",2020,The MCV wastage rate was 47% lower in facilities using 5-dose vials (16.2%) versus 10-dose vials (30.5%).,"['14 districts purposely selected from two provinces in Zambia', 'Zambia']",['MR vaccine'],"['wastage rates', 'vaccination coverage and wastage', 'MCV wastage rate', 'MCV coverage rates', 'coverage and reduce wastage']","[{'cui': 'C0043445', 'cui_str': 'Zambia'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C4505148', 'cui_str': 'Vaccination Coverage'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",,0.0316677,The MCV wastage rate was 47% lower in facilities using 5-dose vials (16.2%) versus 10-dose vials (30.5%).,"[{'ForeName': 'Kirstin', 'Initials': 'K', 'LastName': 'Krudwig', 'Affiliation': 'John Snow, Inc, United States.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Knittel', 'Affiliation': 'John Snow, Inc, United States.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Karim', 'Affiliation': 'John Snow, Inc, United States.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Kanagat', 'Affiliation': 'John Snow, Inc, United States.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Prosser', 'Affiliation': 'John Snow, Inc, United States. Electronic address: wendy_prosser@jsi.com.'}, {'ForeName': 'Guissimon', 'Initials': 'G', 'LastName': 'Phiri', 'Affiliation': 'Ministry of Health, Zambia, Immunization Program, Zambia.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Mwansa', 'Affiliation': 'Ministry of Health, Zambia, Immunization Program, Zambia.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Steinglass', 'Affiliation': 'John Snow, Inc, United States.'}]",Vaccine,['10.1016/j.vaccine.2020.07.012'] 2737,32703758,"The Effect of Music Therapy, Hand Massage, and Kaleidoscope Usage on Postoperative Nausea and Vomiting, Pain, Fear, and Stress in Children: A Randomized Controlled Trial.","PURPOSE The objective of this study was to investigate the effects of music therapy, hand massage, and kaleidoscope usage on nausea and vomiting, pain, fear, and stress in 7-year-old to 11-year-old children after circumcision. DESIGN This study was a prospective and randomized controlled trial. METHODS The study was conducted at the pediatric surgery unit in a hospital in Turkey. The children were assigned to four groups through randomization performed using a computer program: group 1 was the control group with children who received no intervention; group 2 received hand massage; group 3 were distracted using kaleidoscope; and group 4 received music therapy. FINDINGS There was a significant difference between the postoperative pain scores of the children in the intervention and control groups after the intervention (P < .05). This difference was found to be caused by the music therapy and kaleidoscope methods. There was a significant difference between the intervention and control groups' postoperative fear and anxiety levels in favor of the kaleidoscope group after the intervention (P < .05). But, no significant difference was found between the groups for the children's postoperative vomiting and nausea levels after the intervention (P > .05). CONCLUSIONS Distraction with music therapy and kaleidoscope is recommended for use in the postoperative period in children with circumcision to reduce the severity of their pain, fear, and anxiety.",2020,"But, no significant difference was found between the groups for the children's postoperative vomiting and nausea levels after the intervention (P > .05). ","['7-year-old to 11-year-old children after circumcision', 'pediatric surgery unit in a hospital in Turkey', 'Children']","['music therapy, hand massage, and kaleidoscope usage', 'Music Therapy, Hand Massage, and Kaleidoscope Usage', 'Distraction with music therapy and kaleidoscope', 'control group with children who received no intervention; group 2 received hand massage; group 3 were distracted using kaleidoscope; and group 4 received music therapy']","['postoperative pain scores', 'Postoperative Nausea and Vomiting, Pain, Fear, and Stress', 'postoperative fear and anxiety levels', ""children's postoperative vomiting and nausea levels"", 'nausea and vomiting, pain, fear, and stress']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0008819', 'cui_str': 'Circumcision'}, {'cui': 'C0279077', 'cui_str': 'Pediatric surgery'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041400', 'cui_str': 'Turkey - country'}]","[{'cui': 'C0026868', 'cui_str': 'Music therapy'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C0150189', 'cui_str': 'Distraction training'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0441876', 'cui_str': 'Group 4'}]","[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0520905', 'cui_str': 'Postoperative vomiting'}, {'cui': 'C3839628', 'cui_str': 'Level of nausea'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}]",,0.0445665,"But, no significant difference was found between the groups for the children's postoperative vomiting and nausea levels after the intervention (P > .05). ","[{'ForeName': 'Muhammet', 'Initials': 'M', 'LastName': 'Bulut', 'Affiliation': 'Department of Pediatrics, Giresun University, Giresun Woman and Child Education and Research Hospital, Giresun, Turkey.'}, {'ForeName': 'Dilek', 'Initials': 'D', 'LastName': 'Küçük Alemdar', 'Affiliation': 'Faculty of Health Sciences, Department of Pediatrics Nursing, Ordu University, Ordu, Turkey. Electronic address: dilekkucuk@atauni.edu.tr.'}, {'ForeName': 'Azime', 'Initials': 'A', 'LastName': 'Bulut', 'Affiliation': 'Department of Anesthesia and Reanimation, Giresun University, Giresun Education and Research Hospital, Giresun, Turkey.'}, {'ForeName': 'Gül', 'Initials': 'G', 'LastName': 'Şalcı', 'Affiliation': 'Department of Pediatrics, Giresun University, Giresun Woman and Child Education and Research Hospital, Giresun, Turkey; Department of Pediatrics Surgery, Giresun University, Giresun Woman and Child Education and Research Hospital, Giresun, Turkey.'}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2020.03.013'] 2738,32703776,The Effect of Pain Conditioning on Experimentally Evoked Cough: Evidence of Impaired Endogenous Inhibitory Control Mechanisms in Refractory Chronic Cough.,"The pathophysiology of refractory chronic cough (RCC) is unclear. We hypothesised that endogenous inhibitory control mechanisms, such as those activated by noxiousstimuli inducing pain (conditioned pain modulation (CPM)), may be capable of inhibiting coughing and urge to cough evoked by inhaled capsaicin. Furthermore, these mechanisms may be impaired in patients with RCC.The objective was to investigate the effects of pain on cough and urge to cough (UTC) in healthy volunteers (HV) and RCC. HV and RCC patients underwent a randomised, controlled, 4-way cross-over study comparing the effect of 4 interventions on capsaicin evoked coughing and UTC. The interventions comprised immersing a hand in i) noxious cold-water, ii) warm water, iii) warm water but instructed to voluntarily supress coughing and iv) no intervention. The co-primary outcomes were numbers of evoked coughs and UTC scores.Twenty HV (mean age 50.1(±SD14.2), M:F 10:10) and 20 RCC (age 60.1(±7.9), M:F 9:11) participated. Overall, noxious cold water reduced capsaicin evoked UTC scores and cough numbers compared with warm water (1.6 (95% C.I. 1.3-2.0) versus 2.2 (1.8-2.6) p<0.001; 4.8 coughs (3.7-6.2) versus 7.9 coughs (6.7-9.5) p<0.001, respectively). HV and RCC demonstrated similar reductions in the UTC during noxious cold-water immersion, but noxious cold water and voluntary suppression interventions were less effective in RCC than HV in reducing capsaicin evoked cough (p=0.041).Endogenous inhibitory control mechanisms, specifically those activated by pain, can reduce both coughing and the UTC. Impairment of endogenous inhibitory control mechanisms may contribute to excessive coughing in RCC.",2020,"HV and RCC demonstrated similar reductions in the UTC during noxious cold-water immersion, but noxious cold water and voluntary suppression interventions were less effective in RCC than HV in reducing capsaicin evoked cough (p=0.041).Endogenous inhibitory control mechanisms, specifically those activated by pain, can reduce both coughing and the UTC.","['HV and RCC patients', 'healthy volunteers (HV) and RCC', 'Refractory Chronic Cough']","['immersing a hand in i) noxious cold-water, ii) warm water, iii) warm water but instructed to voluntarily supress coughing and iv) no intervention', 'Pain Conditioning', 'capsaicin evoked coughing and UTC']","['Overall, noxious cold water reduced capsaicin evoked UTC scores and cough numbers', 'numbers of evoked coughs and UTC scores']","[{'cui': 'C0007134', 'cui_str': 'Renal cell carcinoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4552486', 'cui_str': 'Refractory chronic cough'}]","[{'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C4708833', 'cui_str': 'Cold water'}, {'cui': 'C0184348', 'cui_str': 'Warmer'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0006931', 'cui_str': 'Capsaicin'}, {'cui': 'C1444748', 'cui_str': 'Evoked'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C4708833', 'cui_str': 'Cold water'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0006931', 'cui_str': 'Capsaicin'}, {'cui': 'C1444748', 'cui_str': 'Evoked'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",,0.0227186,"HV and RCC demonstrated similar reductions in the UTC during noxious cold-water immersion, but noxious cold water and voluntary suppression interventions were less effective in RCC than HV in reducing capsaicin evoked cough (p=0.041).Endogenous inhibitory control mechanisms, specifically those activated by pain, can reduce both coughing and the UTC.","[{'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Hilton', 'Affiliation': 'Division of Infection, Immunity and Respiratory Medicine, and Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Imran', 'Initials': 'I', 'LastName': 'Satia', 'Affiliation': 'Division of Infection, Immunity and Respiratory Medicine, and Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Kimberley', 'Initials': 'K', 'LastName': 'Holt', 'Affiliation': 'Division of Infection, Immunity and Respiratory Medicine, and Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Ashley A', 'Initials': 'AA', 'LastName': 'Woodcock', 'Affiliation': 'Division of Infection, Immunity and Respiratory Medicine, and Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Belcher', 'Affiliation': 'Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Jaclyn A', 'Initials': 'JA', 'LastName': 'Smith', 'Affiliation': 'Division of Infection, Immunity and Respiratory Medicine, and Manchester Academic Health Science Centre, University of Manchester, Manchester, UK jacky.smith@manchester.ac.uk.'}]",The European respiratory journal,['10.1183/13993003.01387-2020'] 2739,32703779,Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial.,"BACKGROUND A randomised controlled trial in Japan showed that inhaled N-acetylcysteine monotherapy stabilised serial decline in forced vital capacity (FVC) in some patients with early idiopathic pulmonary fibrosis (IPF). However, the efficacy and tolerability of combination therapy with an antifibrotic agent and inhaled N-acetylcysteine are unknown. METHODS This 48-week, randomised, open-label, multicentre phase 3 trial compared the efficacy and tolerability of combination therapy with pirfenidone plus inhaled N-acetylcysteine 352.4 mg twice daily with the results for pirfenidone alone in patients with IPF. The primary endpoint was annual rate of decline in FVC. Exploratory efficacy measurements included serial change in carbon monoxide diffusing capacity (DLco), and 6-minute walk distance (6MWD), progression-free survival (PFS), incidence of acute exacerbation, and tolerability. RESULTS A total of 81 patients were randomly assigned in a 1:1 ratio to receive pirfenidone plus inhaled N-acetylcysteine (n=41) or pirfenidone (n=40). The 48-week rate of change in FVC was -300 mL and -123 mL, respectively (difference, -178 mL; 95% CI, -324 to -31; p=0.018). Serial change in DLco, 6MWD, PFS, and incidence of acute exacerbation did not significantly differ between the two groups. The incidence of adverse events (n=19 [55.9%] for pirfenidone plus N-acetylcysteine; n=18 [50%] for pirfenidone alone) was similar between groups. CONCLUSIONS Combination treatment with inhaled N-acetylcysteine and pirfenidone is likely to result in worse outcomes for IPF.",2020,"Serial change in DLco, 6MWD, PFS, and incidence of acute exacerbation did not significantly differ between the two groups.","['patients with IPF', 'idiopathic pulmonary fibrosis', 'patients with early idiopathic pulmonary fibrosis (IPF', 'A total of 81 patients']","['antifibrotic agent and inhaled N-acetylcysteine', 'pirfenidone plus inhaled N-acetylcysteine (n=41) or pirfenidone', 'pirfenidone plus N-acetylcysteine', 'pirfenidone plus inhaled N-acetylcysteine', 'pirfenidone alone', 'Pirfenidone plus inhaled N-acetylcysteine']","['serial change in carbon monoxide diffusing capacity (DLco), and 6-minute walk distance (6MWD), progression-free survival (PFS), incidence of acute exacerbation, and tolerability', 'forced vital capacity (FVC', '48-week rate of change in FVC', 'annual rate of decline in FVC', 'Serial change in DLco, 6MWD, PFS, and incidence of acute exacerbation', 'efficacy and tolerability', 'incidence of adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1800706', 'cui_str': 'Idiopathic pulmonary fibrosis'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C0298067', 'cui_str': 'pirfenidone'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0199525', 'cui_str': 'Carbon monoxide diffusing capacity measurement'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",81.0,0.272843,"Serial change in DLco, 6MWD, PFS, and incidence of acute exacerbation did not significantly differ between the two groups.","[{'ForeName': 'Susumu', 'Initials': 'S', 'LastName': 'Sakamoto', 'Affiliation': 'Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo, Japan susumu1029@gmail.com.'}, {'ForeName': 'Kensuke', 'Initials': 'K', 'LastName': 'Kataoka', 'Affiliation': 'Tosei General Hospital, Department of Respiratory Medicine and Allergy, Seto, Japan.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Kondo', 'Affiliation': 'Tosei General Hospital, Department of Respiratory Medicine and Allergy, Seto, Japan.'}, {'ForeName': 'Motoyasu', 'Initials': 'M', 'LastName': 'Kato', 'Affiliation': 'Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Masaki', 'Initials': 'M', 'LastName': 'Okamoto', 'Affiliation': 'Department of Internal Medicine, Division of Respirology, Neurology, and Rheumatology, Kurume University School of Medicine, Fukuoka, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Mukae', 'Affiliation': 'Second Department of Internal Medicine, Nagasaki University, Graduate School of Biomedical Sciences, Fukuoka, Japan.'}, {'ForeName': 'Masashi', 'Initials': 'M', 'LastName': 'Bando', 'Affiliation': 'Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Tochigi, Japan.'}, {'ForeName': 'Takafumi', 'Initials': 'T', 'LastName': 'Suda', 'Affiliation': 'Internal Medicine 2, Hamamatsu University School of Medicine, Hamamatsu, Japan.'}, {'ForeName': 'Kazuhiro', 'Initials': 'K', 'LastName': 'Yatera', 'Affiliation': 'Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Fukuoka, Japan.'}, {'ForeName': 'Yoshinori', 'Initials': 'Y', 'LastName': 'Tanino', 'Affiliation': 'Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan.'}, {'ForeName': 'Tomoo', 'Initials': 'T', 'LastName': 'Kishaba', 'Affiliation': 'Department of Respiratory Medicine, Okinawa Chubu Hospital, Okinawa, Japan.'}, {'ForeName': 'Noboru', 'Initials': 'N', 'LastName': 'Hattori', 'Affiliation': 'Department of Molecular and Internal Medicine, Hiroshima University, Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.'}, {'ForeName': 'Yoshio', 'Initials': 'Y', 'LastName': 'Taguchi', 'Affiliation': 'Department of Respiratory Medicine, Tenri Yorozu Hospital, Nara, Japan.'}, {'ForeName': 'Takefumi', 'Initials': 'T', 'LastName': 'Saito', 'Affiliation': 'Department of Respiratory Medicine, Ibarakihigashi National Hospital, Ibaragi, Japan.'}, {'ForeName': 'Yasuhiko', 'Initials': 'Y', 'LastName': 'Nishioka', 'Affiliation': 'Department of Respiratory Medicine and Rheumatology, Tokushima University Graduate School of Medical Sciences, Tokushima, Japan.'}, {'ForeName': 'Kazuyoshi', 'Initials': 'K', 'LastName': 'Kuwano', 'Affiliation': 'Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kazuma', 'Initials': 'K', 'LastName': 'Kishi', 'Affiliation': 'Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo, Japan.'}, {'ForeName': 'Naohiko', 'Initials': 'N', 'LastName': 'Inase', 'Affiliation': 'Department of Respiratory Medicine, Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Tokyo, Japan.'}, {'ForeName': 'Shinichi', 'Initials': 'S', 'LastName': 'Sasaki', 'Affiliation': 'Department of Respiratory Medicine, Juntendo University Urayasu Hospital, Chiba, Japan.'}, {'ForeName': 'Hajime', 'Initials': 'H', 'LastName': 'Takizawa', 'Affiliation': 'Department of Respiratory Medicine, Kyorin University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Johkoh', 'Affiliation': 'Department of Radiology, Kansai Rosai Hospital, Hyogo, Japan.'}, {'ForeName': 'Fumikazu', 'Initials': 'F', 'LastName': 'Sakai', 'Affiliation': 'Department of Diagnostic Radiology, Saitama Medical University International Medical Center, Saitama, Japan.'}, {'ForeName': 'Sakae', 'Initials': 'S', 'LastName': 'Homma', 'Affiliation': 'Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The European respiratory journal,['10.1183/13993003.00348-2020'] 2740,32703808,"When possible, report a Fisher-exact P value and display its underlying null randomization distribution.","In randomized experiments, Fisher-exact P values are available and should be used to help evaluate results rather than the more commonly reported asymptotic P values. One reason is that using the latter can effectively alter the question being addressed by including irrelevant distributional assumptions. The Fisherian statistical framework, proposed in 1925, calculates a P value in a randomized experiment by using the actual randomization procedure that led to the observed data. Here, we illustrate this Fisherian framework in a crossover randomized experiment. First, we consider the first period of the experiment and analyze its data as a completely randomized experiment, ignoring the second period; then, we consider both periods. For each analysis, we focus on 10 outcomes that illustrate important differences between the asymptotic and Fisher tests for the null hypothesis of no ozone effect. For some outcomes, the traditional P value based on the approximating asymptotic Student's t distribution substantially subceeded the minimum attainable Fisher-exact P value. For the other outcomes, the Fisher-exact null randomization distribution substantially differed from the bell-shaped one assumed by the asymptotic t test. Our conclusions: When researchers choose to report P values in randomized experiments, 1) Fisher-exact P values should be used, especially in studies with small sample sizes, and 2) the shape of the actual null randomization distribution should be examined for the recondite scientific insights it may reveal.",2020,"For some outcomes, the traditional P value based on the approximating asymptotic Student's t distribution substantially subceeded the minimum attainable Fisher-exact P value.",[],[],[],[],[],[],,0.0315853,"For some outcomes, the traditional P value based on the approximating asymptotic Student's t distribution substantially subceeded the minimum attainable Fisher-exact P value.","[{'ForeName': 'M-A C', 'Initials': 'MC', 'LastName': 'Bind', 'Affiliation': 'Department of Statistics, Faculty of Arts and Sciences, Harvard University, Cambridge, MA 02138; ma.bind@mail.harvard.edu.'}, {'ForeName': 'D B', 'Initials': 'DB', 'LastName': 'Rubin', 'Affiliation': 'Yau Center for Mathematical Sciences, Tsinghua University, Beijing 100084, China.'}]",Proceedings of the National Academy of Sciences of the United States of America,['10.1073/pnas.1915454117'] 2741,32703925,Comparison of Clinical Outcomes of Different Rates of Infusion in Caudal Epidural Steroid Injection: A Randomized Controlled Trial.,"Study Design Prospective randomized controlled equivalence trial. Purpose To compare the clinical outcomes between patients with lumbosacral radiculopathy that received caudal epidural steroid injection (CESI) at injection rates of 40 mL/min (fast rate) and 20 mL/min (slow rate) and to identify the complications associated with these different CESI rates. Overview of Literature CESI is widely used for chronic low back pain with lumbar radiculopathy. However, the influence of CESI rates on clinical outcomes has not been well studied. Methods Ninety patients were randomized into two CESI groups. Two patients did not complete the study. Eighty-eight were included in the final analysis: 44 patients were in the fast infusion group, and 44 patients were in the slow infusion group. Intragroup and intergroup comparisons were conducted with regard to the Visual Analog Scale (VAS), Roland 5-point pain scale, standing tolerance test, walking tolerance test, and patient satisfaction scale at pre-injection, 2 weeks, 6 weeks, and 12 weeks post-injection. Complications associated with the different rates were recorded. Results Both groups demonstrated clinical improvement in all parameters, except for VAS, after injection. There were no statistically significant differences in any outcomes at each time point between the two groups. One patient in the fast rate group and no patients in the slow rate group experienced nausea and vomiting after injection (p =0.320). Eight patents in the fast rate group and two patients in the slow rate group experienced pain at the injection site (p =0.044). Conclusions Although there were no significant differences between injection rates in the short-term clinical improvement outcomes, the fast injection rate group experienced more pain at the injection site, suggesting that the use of the slow injection rate may be considered.",2020,"Although there were no significant differences between injection rates in the short-term clinical improvement outcomes, the fast injection rate group experienced more pain at the injection site, suggesting that the use of the slow injection rate may be considered.","['Methods\n\n\nNinety patients', 'chronic low back pain with lumbar radiculopathy', 'Eighty-eight were included in the final analysis: 44 patients were in the fast infusion group, and 44 patients were in the slow infusion group', 'patients with lumbosacral radiculopathy that received']","['Caudal Epidural Steroid Injection', 'caudal epidural steroid injection (CESI']","['injection rates', 'nausea and vomiting', 'Visual Analog Scale (VAS), Roland 5-point pain scale, standing tolerance test, walking tolerance test, and patient satisfaction scale', 'pain']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C1263855', 'cui_str': 'Lumbar radiculopathy'}, {'cui': 'C4517898', 'cui_str': '88'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0154738', 'cui_str': 'Lumbosacral radiculopathy'}]","[{'cui': 'C0394837', 'cui_str': 'Local anesthetic sacral epidural block'}, {'cui': 'C1261311', 'cui_str': 'Injection of steroid'}]","[{'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0589035', 'cui_str': 'Standing tolerance'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0201777', 'cui_str': 'Tolerance test'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",90.0,0.135557,"Although there were no significant differences between injection rates in the short-term clinical improvement outcomes, the fast injection rate group experienced more pain at the injection site, suggesting that the use of the slow injection rate may be considered.","[{'ForeName': 'Satit', 'Initials': 'S', 'LastName': 'Thiengwittayaporn', 'Affiliation': 'Department of Orthopaedics, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.'}, {'ForeName': 'Punsang', 'Initials': 'P', 'LastName': 'Koompong', 'Affiliation': 'Department of Orthopaedics, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.'}, {'ForeName': 'Supat', 'Initials': 'S', 'LastName': 'Khamrailert', 'Affiliation': 'Department of Orthopaedics, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.'}, {'ForeName': 'Pumibal', 'Initials': 'P', 'LastName': 'Wetpiriyakul', 'Affiliation': 'Department of Orthopaedics, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.'}]",Asian spine journal,['10.31616/asj.2019.0380'] 2742,32704254,Comparison of mean pain score using topical and oral metronidazole in post milligan morgan hemorrhoidectomy patient; A randomized controlled trial.,"Background and Objectives Milligan Morgan Hemorrhoidectomy is one of the most commonly performed surgeries. Post-operative pain is the major cause of morbidity in post hemorrhoidectomy patients. Metronidazole has an established role in relieving post hemorrhoidectomy pain. The objective was to evaluate the pain score by using topical and oral metronidazole in post Milligan Morgan hemorrhoidectomy patients. Methods A prospective randomized controlled trail was done in surgical departments of Akbar Niazi Teaching Hospital, Islamabad. A total of 166 consecutive patients with 3 rd and 4 th degree hemorrhoids were presenting in surgical OPD and who underwent Milligan Morgan hemorrhoidectomy between July 2018 and December 2018 were included in the study. Patients allocated in two groups, Group-A received topical metronidazole 10% post hemorrhoidectomy for seven days and Group-B were given oral metronidazole 400mg for 07 days. Analgesics were given on patient's requirement. Patients post hemorrhoidectomy pain was recorded by using VSA scale at baseline (1 st day) and on 7 th post-operative day. Data analysis was done by using SPSS 21. Pain calculated by compared in terms of mean, standard deviation between groups and independent sample T test was used. Association between demographic details like gender and ages of the patients with pain scale on 7 th day was measured and chi-square distribution was used. Results Total 166 patients were included in this study. The mean ages of the patients were 44.07±10.62 years with minimum 20 and maximum 60 years. Out of 166 patients, female were 55 (33.1%) and male were 111 (66.9%). Results showed significantly lower pain in patients using topical metronidazole as compared to oral metronidazole ( p=0.001 ). Association of pain with respect to ages was insignificant ( p=0.202 ) whereas between genders inside the groups showed significant difference ( p=0.028 ). Conclusion These results showed that topical metronidazole significantly reduces pain in post hemorrhoidectomy patients as compared to oral metronidazole overall and even when data stratified among age, gender and type of hemorrhoids.",2020,Results showed significantly lower pain in patients using topical metronidazole as compared to oral metronidazole ( p=0.001 ).,"['post hemorrhoidectomy patients', 'mean ages of the patients were 44.07±10.62 years with minimum 20 and maximum 60 years', '166 patients were included in this study', 'post Milligan Morgan hemorrhoidectomy patients', '166 consecutive patients with 3 rd and 4 th degree hemorrhoids were presenting in surgical OPD and who underwent Milligan Morgan hemorrhoidectomy between July 2018 and December 2018 were included in the study', 'surgical departments of Akbar Niazi Teaching Hospital, Islamabad', '166 patients, female were 55 (33.1%) and male were 111 (66.9', 'post milligan morgan hemorrhoidectomy patient']","['topical and oral metronidazole', 'topical metronidazole', 'Metronidazole', 'topical metronidazole 10% post hemorrhoidectomy', 'metronidazole']","['Association of pain', 'hemorrhoidectomy pain', 'pain', 'lower pain', 'Pain calculated', 'mean pain score', 'pain score', 'pain scale']","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0019108', 'cui_str': 'Hemorrhoidectomy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C5191361', 'cui_str': '166'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0582521', 'cui_str': 'Morgan'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0019112', 'cui_str': 'Hemorrhoids'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0587503', 'cui_str': 'Surgical department'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C2003373', 'cui_str': 'AM 111'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0360345', 'cui_str': 'Metronidazole-containing product in oral dose form'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0019108', 'cui_str': 'Hemorrhoidectomy'}]","[{'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0019108', 'cui_str': 'Hemorrhoidectomy'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}]",166.0,0.0692413,Results showed significantly lower pain in patients using topical metronidazole as compared to oral metronidazole ( p=0.001 ).,"[{'ForeName': 'Syed Tatheer', 'Initials': 'ST', 'LastName': 'Abbas', 'Affiliation': 'Syed Tatheer Abbas, FCPS. Department of Surgery, Akbar Niazi Teaching Hospital, Islamabad, Pakistan.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Raza', 'Affiliation': 'Ahmad Raza, MRCS, FCPS. Department of Surgery, Akbar Niazi Teaching Hospital, Islamabad, Pakistan.'}, {'ForeName': 'Ihtasham', 'Initials': 'I', 'LastName': 'Muhammad Ch', 'Affiliation': 'Ihtasham Muhammad Ch, FCPS. Associate Professor Department of Surgery, Al-Nafees Medical College, Islamabad, Pakistan.'}, {'ForeName': 'Tahira', 'Initials': 'T', 'LastName': 'Hameed', 'Affiliation': 'Tahira Hameed, MBBS, MRCS. Registrar, Department of Surgery, Akbar Niazi Teaching Hospital, Islamabad, Pakistan.'}, {'ForeName': 'Nausheen', 'Initials': 'N', 'LastName': 'Hasham', 'Affiliation': 'Nausheen Hasham, MBBS. Registrar, Department of Surgery, Akbar Niazi Teaching Hospital, Islamabad, Pakistan.'}, {'ForeName': 'Naveed', 'Initials': 'N', 'LastName': 'Arshad', 'Affiliation': 'Naveed Arshad M.Phil. Assistant Professor, Rehabilitation Department, Islamabad Medical and Dental College, Islamabad, Pakistan.'}]",Pakistan journal of medical sciences,['10.12669/pjms.36.5.1796'] 2743,32701140,Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.,"Importance Pathologic complete response (pCR) is a known prognostic biomarker for long-term outcomes. The I-SPY2 trial evaluated if the strength of this clinical association persists in the context of a phase 2 neoadjuvant platform trial. Objective To evaluate the association of pCR with event-free survival (EFS) and pCR with distant recurrence-free survival (DRFS) in subpopulations of women with high-risk operable breast cancer treated with standard therapy or one of several novel agents. Design, Setting, and Participants Multicenter platform trial of women with operable clinical stage 2 or 3 breast cancer with no prior surgery or systemic therapy for breast cancer; primary tumors were 2.5 cm or larger. Women with tumors that were ERBB2 negative/hormone receptor (HR) positive with low 70-gene assay score were excluded. Participants were adaptively randomized to one of several different investigational regimens or control therapy within molecular subtypes from March 2010 through 2016. The analysis included participants with follow-up data available as of February 26, 2019. Interventions Standard-of-care neoadjuvant therapy consisting of taxane treatment with or without (as control) one of several investigational agents or combinations followed by doxorubicin and cyclophosphamide. Main Outcomes and Measures Pathologic complete response and 3-year EFS and DRFS. Results Of the 950 participants (median [range] age, 49 [23-77] years), 330 (34.7%) achieved pCR. Three-year EFS and DRFS for patients who achieved pCR were both 95%. Hazard ratios for pCR vs non-pCR were 0.19 for EFS (95% CI, 0.12-0.31) and 0.21 for DRFS (95% CI, 0.13-0.34) and were similar across molecular subtypes, varying from 0.14 to 0.18 for EFS and 0.10 to 0.20 for DRFS. Conclusions and Relevance The 3-year outcomes from the I-SPY2 trial show that, regardless of subtype and/or treatment regimen, including 9 novel therapeutic combinations, achieving pCR after neoadjuvant therapy implies approximately an 80% reduction in recurrence rate. The goal of the I-SPY2 trial is to rapidly identify investigational therapies that may improve pCR when validated in a phase 3 confirmatory trial. Whether pCR is a validated surrogate in the sense that a therapy that improves pCR rate can be assumed to also improve long-term outcome requires further study. Trial Registration ClinicalTrials.gov Identifier: NCT01042379.",2020,"Hazard ratios for pCR vs non-pCR were 0.19 for EFS (95% CI, 0.12-0.31) and 0.21 for DRFS (95% CI, 0.13-0.34) and were similar across molecular subtypes, varying from 0.14 to 0.18 for EFS and 0.10 to 0.20 for DRFS. ","['participants with follow-up data available as of February 26, 2019', 'Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer', 'women with operable clinical stage 2 or 3 breast cancer with no prior surgery or systemic therapy for breast cancer; primary tumors were 2.5 cm or larger', 'subpopulations of women with high-risk operable breast cancer treated with standard therapy or one of several novel agents', '950 participants (median [range] age, 49 [23-77] years), 330 (34.7%) achieved pCR']","['taxane', 'pCR', 'doxorubicin and cyclophosphamide', 'control therapy']","['Hazard ratios', 'ERBB2 negative/hormone receptor (HR) positive with low 70-gene assay score', 'pCR with event-free survival (EFS) and pCR with distant recurrence-free survival (DRFS', 'pCR rate', 'Measures\n\n\nPathologic complete response and 3-year EFS and DRFS', 'recurrence rate']","[{'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205188', 'cui_str': 'Operable'}, {'cui': 'C0205563', 'cui_str': 'Clinical stage finding'}, {'cui': 'C0455610', 'cui_str': 'H/O: surgery'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C1257890', 'cui_str': 'Group'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C4708800', 'cui_str': '950'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517719', 'cui_str': '330'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}]","[{'cui': 'C0215136', 'cui_str': 'taxane'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0443203', 'cui_str': 'Distant'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",,0.184284,"Hazard ratios for pCR vs non-pCR were 0.19 for EFS (95% CI, 0.12-0.31) and 0.21 for DRFS (95% CI, 0.13-0.34) and were similar across molecular subtypes, varying from 0.14 to 0.18 for EFS and 0.10 to 0.20 for DRFS. ","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Yee', 'Affiliation': 'Masonic Cancer Center, University of Minnesota, Minneapolis.'}, {'ForeName': 'Angela M', 'Initials': 'AM', 'LastName': 'DeMichele', 'Affiliation': 'Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Yau', 'Affiliation': 'Department of Surgery, University of California, San Francisco.'}, {'ForeName': 'Claudine', 'Initials': 'C', 'LastName': 'Isaacs', 'Affiliation': 'Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'W Fraser', 'Initials': 'WF', 'LastName': 'Symmans', 'Affiliation': 'Department of Pathology, University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Kathy S', 'Initials': 'KS', 'LastName': 'Albain', 'Affiliation': 'Loyola University Chicago Stritch School of Medicine, Chicago, Illinois.'}, {'ForeName': 'Yunn-Yi', 'Initials': 'YY', 'LastName': 'Chen', 'Affiliation': 'Department of Pathology, University of California, San Francisco.'}, {'ForeName': 'Gregor', 'Initials': 'G', 'LastName': 'Krings', 'Affiliation': 'Department of Pathology, University of California, San Francisco.'}, {'ForeName': 'Shi', 'Initials': 'S', 'LastName': 'Wei', 'Affiliation': 'Department of Pathology, University of Alabama Birmingham.'}, {'ForeName': 'Shuko', 'Initials': 'S', 'LastName': 'Harada', 'Affiliation': 'Department of Pathology, University of Alabama Birmingham.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Datnow', 'Affiliation': 'Department of Pathology, University of California, San Diego.'}, {'ForeName': 'Oluwole', 'Initials': 'O', 'LastName': 'Fadare', 'Affiliation': 'Department of Pathology, University of California, San Diego.'}, {'ForeName': 'Molly', 'Initials': 'M', 'LastName': 'Klein', 'Affiliation': 'Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Pambuccian', 'Affiliation': 'Department of Pathology, Loyola University Chicago Stritch School of Medicine, Chicago, Illinois.'}, {'ForeName': 'Beiyun', 'Initials': 'B', 'LastName': 'Chen', 'Affiliation': 'Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota.'}, {'ForeName': 'Kathi', 'Initials': 'K', 'LastName': 'Adamson', 'Affiliation': 'Department of Pathology, Swedish Cancer Institute, Seattle, Washington.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Sams', 'Affiliation': 'Department of Pathology, University of Colorado, Denver.'}, {'ForeName': 'Paulette', 'Initials': 'P', 'LastName': 'Mhawech-Fauceglia', 'Affiliation': 'Keck School of Medicine, University of Southern California, Los Angeles.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Magliocco', 'Affiliation': 'Department of Pathology, Moffitt Cancer Center, Tampa, Florida.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Feldman', 'Affiliation': 'Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia.'}, {'ForeName': 'Mara', 'Initials': 'M', 'LastName': 'Rendi', 'Affiliation': 'Department of Anatomic Pathology, University of Washington, Seattle.'}, {'ForeName': 'Husain', 'Initials': 'H', 'LastName': 'Sattar', 'Affiliation': 'Department of Pathology, University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Zeck', 'Affiliation': 'Department of Pathology, Georgetown University, Washington, DC.'}, {'ForeName': 'Idris T', 'Initials': 'IT', 'LastName': 'Ocal', 'Affiliation': 'Laboratory Medicine and Pathology, Mayo Clinic Scottsdale, Scottsdale, Arizona.'}, {'ForeName': 'Ossama', 'Initials': 'O', 'LastName': 'Tawfik', 'Affiliation': 'Department of Pathology and Laboratory Medicine, University of Kansas, Lawrence.'}, {'ForeName': 'Lauren Grasso', 'Initials': 'LG', 'LastName': 'LeBeau', 'Affiliation': 'Department of Pathology, University of Arizona, Tucson.'}, {'ForeName': 'Sunati', 'Initials': 'S', 'LastName': 'Sahoo', 'Affiliation': 'Department of Pathology, University of Texas Southwestern, Dallas.'}, {'ForeName': 'Tuyethoa', 'Initials': 'T', 'LastName': 'Vinh', 'Affiliation': 'Inova Pathology Institute, Inova Health System, Falls Church, Virginia.'}, {'ForeName': 'A Jo', 'Initials': 'AJ', 'LastName': 'Chien', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco.'}, {'ForeName': 'Andres', 'Initials': 'A', 'LastName': 'Forero-Torres', 'Affiliation': 'Division of Hematology and Oncology, University of Alabama Birmingham.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Stringer-Reasor', 'Affiliation': 'Division of Hematology and Oncology, University of Alabama Birmingham.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Wallace', 'Affiliation': 'Department of Surgery, University of California, San Diego.'}, {'ForeName': 'Lajos', 'Initials': 'L', 'LastName': 'Pusztai', 'Affiliation': 'Medical Oncology, Yale Cancer Center, New Haven, Connecticut.'}, {'ForeName': 'Judy C', 'Initials': 'JC', 'LastName': 'Boughey', 'Affiliation': 'Department of Surgery, Mayo Clinic Rochester, Rochester, Minnesota.'}, {'ForeName': 'Erin D', 'Initials': 'ED', 'LastName': 'Ellis', 'Affiliation': 'Medical Oncology, Swedish Cancer Institute, Seattle, Washington.'}, {'ForeName': 'Anthony D', 'Initials': 'AD', 'LastName': 'Elias', 'Affiliation': 'Department of Medicine, University of Colorado, Denver.'}, {'ForeName': 'Janice', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': 'Medical Oncology, Keck School of Medicine, University of Southern California, Los Angeles.'}, {'ForeName': 'Julie E', 'Initials': 'JE', 'LastName': 'Lang', 'Affiliation': 'Surgery, Keck School of Medicine, University of Southern California, Los Angeles.'}, {'ForeName': 'Hyo S', 'Initials': 'HS', 'LastName': 'Han', 'Affiliation': 'Medical Oncology, Moffitt Cancer Center, Tampa, Florida.'}, {'ForeName': 'Amy S', 'Initials': 'AS', 'LastName': 'Clark', 'Affiliation': 'Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Nanda', 'Affiliation': 'Hematology and Oncology, University of Chicago Medical Center, Chicago, Illinois.'}, {'ForeName': 'Donald W', 'Initials': 'DW', 'LastName': 'Northfelt', 'Affiliation': 'Medical Oncology, Mayo Clinic Scottsdale, Scottsdale, Arizona.'}, {'ForeName': 'Qamar J', 'Initials': 'QJ', 'LastName': 'Khan', 'Affiliation': 'Medical Oncology, University of Kansas Medical Center, Lawrence.'}, {'ForeName': 'Rebecca K', 'Initials': 'RK', 'LastName': 'Viscusi', 'Affiliation': 'Hematology/Oncology, University of Arizona, Tucson.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Euhus', 'Affiliation': 'Department of Surgery, Johns Hopkins Medicine, Baltimore, Maryland.'}, {'ForeName': 'Kirsten K', 'Initials': 'KK', 'LastName': 'Edmiston', 'Affiliation': 'Inova Schar Cancer Institute, Fairfax, Virginia.'}, {'ForeName': 'Stephen Y', 'Initials': 'SY', 'LastName': 'Chui', 'Affiliation': 'Genentech, South San Francisco, California.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Kemmer', 'Affiliation': 'Knight Cancer Institute, Oregon Health & Science University, Portland.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Park', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco.'}, {'ForeName': 'Minetta C', 'Initials': 'MC', 'LastName': 'Liu', 'Affiliation': 'Department of Oncology, Mayo Clinic Rochester, Rochester, Minnesota.'}, {'ForeName': 'Olufunmilayo', 'Initials': 'O', 'LastName': 'Olopade', 'Affiliation': 'Hematology and Oncology, University of Chicago Medical Center, Chicago, Illinois.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Leyland-Jones', 'Affiliation': 'Avera Cancer Institute, Sioux Falls, South Dakota.'}, {'ForeName': 'Debasish', 'Initials': 'D', 'LastName': 'Tripathy', 'Affiliation': 'Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Stacy L', 'Initials': 'SL', 'LastName': 'Moulder', 'Affiliation': 'Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Hope S', 'Initials': 'HS', 'LastName': 'Rugo', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Schwab', 'Affiliation': 'Medical Oncology, University of California, San Diego.'}, {'ForeName': 'Shelly', 'Initials': 'S', 'LastName': 'Lo', 'Affiliation': 'Medical Oncology, Loyola University Chicago Stritch School of Medicine, Chicago, Illinois.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Helsten', 'Affiliation': 'Medical Oncology, University of California, San Diego.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Beckwith', 'Affiliation': 'Masonic Cancer Center, University of Minnesota, Minneapolis.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Haugen', 'Affiliation': 'National Breast Cancer Coalition, Washington, DC.'}, {'ForeName': 'Nola M', 'Initials': 'NM', 'LastName': 'Hylton', 'Affiliation': 'Department of Radiology and Biomedical Imaging, University of California, San Francisco.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': ""Van't Veer"", 'Affiliation': 'Department of Laboratory Medicine, University of California, San Francisco.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Perlmutter', 'Affiliation': 'Gemini Group, Ann Arbor, Michigan.'}, {'ForeName': 'Michelle E', 'Initials': 'ME', 'LastName': 'Melisko', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Wilson', 'Affiliation': 'Quantum Leap Healthcare Collaborative, San Francisco, California.'}, {'ForeName': 'Garry', 'Initials': 'G', 'LastName': 'Peterson', 'Affiliation': 'Department of Surgery, University of California, San Francisco.'}, {'ForeName': 'Adam L', 'Initials': 'AL', 'LastName': 'Asare', 'Affiliation': 'Quantum Leap Healthcare Collaborative, San Francisco, California.'}, {'ForeName': 'Meredith B', 'Initials': 'MB', 'LastName': 'Buxton', 'Affiliation': 'Berry Consultants, LLC, Austin, Texas.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Paoloni', 'Affiliation': 'Berry Consultants, LLC, Austin, Texas.'}, {'ForeName': 'Julia L', 'Initials': 'JL', 'LastName': 'Clennell', 'Affiliation': 'Berry Consultants, LLC, Austin, Texas.'}, {'ForeName': 'Gillian L', 'Initials': 'GL', 'LastName': 'Hirst', 'Affiliation': 'Department of Surgery, University of California, San Francisco.'}, {'ForeName': 'Ruby', 'Initials': 'R', 'LastName': 'Singhrao', 'Affiliation': 'Department of Surgery, University of California, San Francisco.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Steeg', 'Affiliation': 'Department of Surgery, University of California, San Francisco.'}, {'ForeName': 'Jeffrey B', 'Initials': 'JB', 'LastName': 'Matthews', 'Affiliation': 'Department of Surgery, University of California, San Francisco.'}, {'ForeName': 'Smita M', 'Initials': 'SM', 'LastName': 'Asare', 'Affiliation': 'Quantum Leap Healthcare Collaborative, San Francisco, California.'}, {'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Sanil', 'Affiliation': 'Berry Consultants, LLC, Austin, Texas.'}, {'ForeName': 'Scott M', 'Initials': 'SM', 'LastName': 'Berry', 'Affiliation': 'Berry Consultants, LLC, Austin, Texas.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Esserman', 'Affiliation': 'Department of Surgery, University of California, San Francisco.'}, {'ForeName': 'Donald A', 'Initials': 'DA', 'LastName': 'Berry', 'Affiliation': 'Berry Consultants, LLC, Austin, Texas.'}]",JAMA oncology,['10.1001/jamaoncol.2020.2535'] 2744,32701144,Comparison of Three Devices for 24-hour Ambulatory Blood Pressure Monitoring in a Nonclinical Environment Through a Randomized Trial.,"BACKGROUND The U.S. Preventive Services Task Force recommends the use of 24-hour ambulatory blood pressure monitoring (ABPM) as part of screening and diagnosis of hypertension. The optimal ABPM device for population-based surveys is unknown. OBJECTIVE Among three ABPM devices, we compared the proportion of valid BP readings, mean awake and asleep BP readings, differences between awake ABPM readings and initial standardized BP readings, and sleep experience. RESULTS The proportions of valid blood pressure readings were not different among the three devices ( p > 0.45). Mean awake and asleep systolic BP were significantly higher for STO device (WA vs. STO vs. SL: 126.65 mmHg, 138.09 mmHg, 127.44 mmHg; 114.34 mmHg, 120.34 mmHg, 113.13 mmHg; p <0.0001 for both). The difference between the initial average standardized mercury systolic BP readings and the ABPM mean awake systolic BP was larger for STO device (WA vs. STO. vs. SL: -5.26 mmHg, -16.24 mmHg, -5.36 mmHg; p <0.0001); diastolic BP mean differences were ~ -6 mmHg for all three devices ( p =0.6). Approximately 55% of participants reported that the devices interfered with sleep; however, there were no sleep differences across the devices (p >0.4 for all). CONCLUSION Most of the participants met the threshold of 70% valid readings over 24 hours. Sleep disturbance was common but did not interfere with completion of measurement in most of the participants.",2020,The proportions of valid blood pressure readings were not different among the three devices ( p > 0.45).,[],"['24-hour ambulatory blood pressure monitoring (ABPM', 'SL']","['proportions of valid blood pressure readings', 'proportion of valid BP readings, mean awake and asleep BP readings, differences between awake ABPM readings and initial standardized BP readings, and sleep experience', 'Mean awake and asleep systolic BP', 'initial average standardized mercury systolic BP readings and the ABPM mean awake systolic BP', 'Sleep disturbance', 'diastolic BP mean differences']",[],"[{'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0242876', 'cui_str': 'Ambulatory Blood Pressure Monitoring'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0234422', 'cui_str': 'Awake'}, {'cui': 'C0424522', 'cui_str': 'Asleep'}, {'cui': 'C0242876', 'cui_str': 'Ambulatory Blood Pressure Monitoring'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0025424', 'cui_str': 'Mercury'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}]",,0.0996408,The proportions of valid blood pressure readings were not different among the three devices ( p > 0.45).,"[{'ForeName': 'Tatiana', 'Initials': 'T', 'LastName': 'Nwankwo', 'Affiliation': 'Division of Health and Nutrition Examination Surveys, National Center for Health Statistics, CDC.'}, {'ForeName': 'Sallyann M', 'Initials': 'SM', 'LastName': 'Coleman King', 'Affiliation': 'Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC.'}, {'ForeName': 'Yechiam', 'Initials': 'Y', 'LastName': 'Ostchega', 'Affiliation': 'Division of Health and Nutrition Examination Surveys, National Center for Health Statistics, CDC.'}, {'ForeName': 'Guangyu', 'Initials': 'G', 'LastName': 'Zhang', 'Affiliation': 'Division of Research and Methodology, National Center for Health Statistics, CDC.'}, {'ForeName': 'Fleetwood', 'Initials': 'F', 'LastName': 'Loustalot', 'Affiliation': 'Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC.'}, {'ForeName': 'Cathleen', 'Initials': 'C', 'LastName': 'Gillespie', 'Affiliation': 'Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC.'}, {'ForeName': 'Tiffany E', 'Initials': 'TE', 'LastName': 'Chang', 'Affiliation': 'Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC.'}, {'ForeName': 'Elin B', 'Initials': 'EB', 'LastName': 'Begley', 'Affiliation': 'Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC.'}, {'ForeName': 'Mary G', 'Initials': 'MG', 'LastName': 'George', 'Affiliation': 'Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC.'}, {'ForeName': 'Daichi', 'Initials': 'D', 'LastName': 'Shimbo', 'Affiliation': 'Department of Medicine, Center for Behavioral Cardiovascular Health, Columbia University, Medical Center, New York, N.Y.'}, {'ForeName': 'Joseph E', 'Initials': 'JE', 'LastName': 'Schwartz', 'Affiliation': 'Applied Behavioral Medicine Research Institute, Stony Brook University, Stony Brook, N.Y.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Muntner', 'Affiliation': 'Department of Epidemiology, University of Alabama at Birmingham, Birmingham Alabama.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Kronish', 'Affiliation': 'Department of Medicine, Center for Behavioral Cardiovascular Health, Columbia University, Medical Center, New York, N.Y.'}, {'ForeName': 'Yuling', 'Initials': 'Y', 'LastName': 'Hong', 'Affiliation': 'Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Merritt', 'Affiliation': 'Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC.'}]",American journal of hypertension,['10.1093/ajh/hpaa117'] 2745,32701172,The effect of orally administered glycerol on anterior chamber depth during cataract surgery in eyes with narrow anterior chambers.,"PURPOSE Cataract surgery on eyes with shallow anterior chambers may be demanding. Glycerol intake prior to surgery has been a well-known method in an effort to increase anterior chamber depth. It is used since it is thought that glycerol as an osmotic agent causes the vitreous body to shrink, pulling back the iris and thereby deepening the anterior chamber - making the surgery easier. Our controlled clinical trial tests this hypothesis and investigates the effect of glycerol on anterior chamber depth (ACD), intraocular pressure (IOP), corneal thickness (CCT), pupil diameter change after viscodilation (PD), operating time and perioperative complications. METHODS We performed a controlled clinical trial. All patients underwent cataract surgery on both eyes with at least 7 days apart. Preoperatively the patient was given glycerol orally when the right eye was operated - when the left eye was operated, nothing was given. In this way, each patient was serving as its own control. Measurements of ACD, IOP and CCT were performed before and after glycerol intake, pupillary diameter was measured before and after viscoelastics during the operation, and operating time and surgical complications were noted. RESULTS The study included 22 patients with bilateral cataract and anterior chambers depth <2.5 mm. Glycerol caused the anterior chamber to increase by 0.022 mm (p < 0.05), and IOP was lowered by 5.1 mmHg compared to the control group (p < 0.05). However, exposure to glycerol showed no effect on CCT, pupillary dilation of viscoelastics, operating time or surgical complications. CONCLUSION Glycerol increases anterior chamber depth and lowers intraocular pressure significantly. These changes had no significant impact on operating time nor on the complication rate, suggesting that these changes are too subtle to have a clinical impact on the cataract procedure.",2020,"Glycerol caused the anterior chamber to increase by 0.022 mm (p < 0.05), and IOP was lowered by 5.1 mmHg compared to the control group (p < 0.05).","['eyes with shallow anterior chambers', '22 patients with bilateral cataract and anterior chambers depth <2.5\xa0mm', 'eyes with narrow anterior chambers']","['glycerol', 'cataract surgery', 'Glycerol']","['pupillary diameter', 'anterior chamber depth', 'Measurements of ACD, IOP and CCT', 'anterior chamber depth and lowers intraocular pressure', 'IOP', 'operating time and surgical complications', 'anterior chamber depth (ACD), intraocular pressure (IOP), corneal thickness (CCT), pupil diameter change after viscodilation (PD), operating time and perioperative complications', 'complication rate', 'CCT, pupillary dilation of viscoelastics, operating time or surgical complications']","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0423276', 'cui_str': 'Shallow anterior chamber of eye'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521707', 'cui_str': 'Bilateral cataracts'}, {'cui': 'C0429492', 'cui_str': 'Depth of anterior chamber'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0332463', 'cui_str': 'Narrowed structure'}, {'cui': 'C0003151', 'cui_str': 'Anterior chamber of eye structure'}]","[{'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}]","[{'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0429492', 'cui_str': 'Depth of anterior chamber'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0002873', 'cui_str': 'Anemia of chronic disease'}, {'cui': 'C0578862', 'cui_str': 'Intraocular pressure finding'}, {'cui': 'C4049005', 'cui_str': 'Cataract, total congenital with posterior sutural opacities in Heterozygotes'}, {'cui': 'C0028841', 'cui_str': 'Hypotony of eye'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0429493', 'cui_str': 'Corneal thickness'}, {'cui': 'C0034121', 'cui_str': 'Pupil structure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C4545429', 'cui_str': 'Perioperative complication'}, {'cui': 'C0026961', 'cui_str': 'Dilated pupil'}]",22.0,0.0321974,"Glycerol caused the anterior chamber to increase by 0.022 mm (p < 0.05), and IOP was lowered by 5.1 mmHg compared to the control group (p < 0.05).","[{'ForeName': 'Kristoffer', 'Initials': 'K', 'LastName': 'Nissen', 'Affiliation': 'Department of Ophthalmology, University Hospital of Copenhagen, Rigshospitalet, Glostrup, Denmark.'}, {'ForeName': 'Jesper Skovlund', 'Initials': 'JS', 'LastName': 'Jørgensen', 'Affiliation': 'Department of Ophthalmology, University Hospital of Copenhagen, Rigshospitalet, Glostrup, Denmark.'}, {'ForeName': 'Jens Christian', 'Initials': 'JC', 'LastName': 'Nørregaard', 'Affiliation': 'Private Practice, Frederiksberg, Denmark.'}, {'ForeName': 'Allan', 'Initials': 'A', 'LastName': 'Storr-Paulsen', 'Affiliation': 'Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Daniella', 'Initials': 'D', 'LastName': 'Bach-Holm', 'Affiliation': 'Department of Ophthalmology, University Hospital of Copenhagen, Rigshospitalet, Glostrup, Denmark.'}]",Acta ophthalmologica,['10.1111/aos.14543'] 2746,32701188,"Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.","BACKGROUND Tegoprazan is a novel potassium-competitive acid blocker for the treatment of acid-related disorders. AIMS To assess whether tegoprazan is non-inferior to lansoprazole in terms of efficacy and safety in patients with gastric ulcers. METHODS In this phase 3, double-blind, active control, multicentre study, 306 gastric ulcer patients were randomised to one of three treatment groups: tegoprazan 50 mg, tegoprazan 100 mg and lansoprazole 30 mg once daily for 4 or 8 weeks.The primary endpoint was the cumulative percentages of patients with healed ulcers confirmed by endoscopy up to 8 weeks from treatment initiation. Symptoms and safety were assessed. RESULTS In the full analysis set, the cumulative healing rates at week 8 were 94.8% (91/96) for the tegoprazan 50 mg, 95.0% (94/99) for the tegoprazan 100 mg and 95.7% (89/93) for the lansoprazole 30 mg groups. At week 4, the respective healing rates were 90.6% (87/96), 91.9% (91/99), and 89.2% (83/93). In per protocol analysis, 4-week healing rates were 95.4% (84/88), 94.6% (88/93) and 92.9% (79/85) for tegoprazan 50 mg, tegoprazan 100 mg and lansoprazole 30 mg, respectively. Both doses of tegoprazan were non-inferior to lansoprazole in ulcer healing at 4 and 8 weeks. The incidence of drug-related treatment-emergent adverse events did not differ among groups. The increase in serum gastrin concentration was not higher in tegoprazan-treated patients than in lansoprazole-treated patients. CONCLUSIONS Tegoprazan 50 or 100 mg were not inferior to lansoprazole 30 mg once daily in the treatment of gastric ulcers.",2020,Both doses of tegoprazan were non-inferior to lansoprazole in ulcer healing at 4 and 8 weeks.,"['306 gastric ulcer patients', 'patients with gastric ulcers', 'gastric ulcer']","['tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole', 'lansoprazole', 'Tegoprazan', 'tegoprazan', 'tegoprazan 50\xa0mg, tegoprazan 100\xa0mg and lansoprazole']","['ulcer healing', 'cumulative healing rates', 'cumulative percentages of patients with healed ulcers', 'respective healing rates', 'Symptoms and safety', 'efficacy and safety', '4-week healing rates', 'incidence of drug-related treatment-emergent adverse events', 'serum gastrin concentration']","[{'cui': 'C0038358', 'cui_str': 'Gastric ulcer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4726822', 'cui_str': 'tegoprazan'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0032821', 'cui_str': 'Potassium'}, {'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0050940', 'cui_str': 'lansoprazole'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C0333293', 'cui_str': 'Healing ulcer'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0428386', 'cui_str': 'Serum gastrin measurement'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",306.0,0.118333,Both doses of tegoprazan were non-inferior to lansoprazole in ulcer healing at 4 and 8 weeks.,"[{'ForeName': 'Yu Kyung', 'Initials': 'YK', 'LastName': 'Cho', 'Affiliation': 'Seoul, Korea.'}, {'ForeName': 'Myung-Gyu', 'Initials': 'MG', 'LastName': 'Choi', 'Affiliation': 'Seoul, Korea.'}, {'ForeName': 'Suck Chei', 'Initials': 'SC', 'LastName': 'Choi', 'Affiliation': 'Iksan, Korea.'}, {'ForeName': 'Kee Myung', 'Initials': 'KM', 'LastName': 'Lee', 'Affiliation': 'Suwon, Korea.'}, {'ForeName': 'Tae Oh', 'Initials': 'TO', 'LastName': 'Kim', 'Affiliation': 'Busan, Korea.'}, {'ForeName': 'Soo-Heon', 'Initials': 'SH', 'LastName': 'Park', 'Affiliation': 'Seoul, Korea.'}, {'ForeName': 'Jeong Seop', 'Initials': 'JS', 'LastName': 'Moon', 'Affiliation': 'Seoul, Korea.'}, {'ForeName': 'Yun Jeong', 'Initials': 'YJ', 'LastName': 'Lim', 'Affiliation': 'Goyang, Korea.'}, {'ForeName': 'Dae Hwan', 'Initials': 'DH', 'LastName': 'Kang', 'Affiliation': 'Yangsan, Korea.'}, {'ForeName': 'Gab Jin', 'Initials': 'GJ', 'LastName': 'Cheon', 'Affiliation': 'Gangneung, Korea.'}, {'ForeName': 'Gwang Ho', 'Initials': 'GH', 'LastName': 'Baik', 'Affiliation': 'Chuncheon, Korea.'}, {'ForeName': 'Kyoung Oh', 'Initials': 'KO', 'LastName': 'Kim', 'Affiliation': 'Incheon, Korea.'}, {'ForeName': 'Kwang Bum', 'Initials': 'KB', 'LastName': 'Cho', 'Affiliation': 'Daegu, Korea.'}, {'ForeName': 'Jin Seok', 'Initials': 'JS', 'LastName': 'Jang', 'Affiliation': 'Busan, Korea.'}, {'ForeName': 'Jong-Jae', 'Initials': 'JJ', 'LastName': 'Park', 'Affiliation': 'Seoul, Korea.'}, {'ForeName': 'Byoung Kwan', 'Initials': 'BK', 'LastName': 'Son', 'Affiliation': 'Seoul, Korea.'}, {'ForeName': 'Hye-Kyung', 'Initials': 'HK', 'LastName': 'Jung', 'Affiliation': 'Seoul, Korea.'}, {'ForeName': 'Byung-Wook', 'Initials': 'BW', 'LastName': 'Kim', 'Affiliation': 'Incheon, Korea.'}, {'ForeName': 'Sung Kuk', 'Initials': 'SK', 'LastName': 'Kim', 'Affiliation': 'Daegu, Korea.'}, {'ForeName': 'Soo Teik', 'Initials': 'ST', 'LastName': 'Lee', 'Affiliation': 'Jeonju, Korea.'}, {'ForeName': 'Jae Myung', 'Initials': 'JM', 'LastName': 'Cha', 'Affiliation': 'Seoul, Korea.'}, {'ForeName': 'Ah Rong', 'Initials': 'AR', 'LastName': 'Kim', 'Affiliation': 'Seoul, Korea.'}, {'ForeName': 'Eun Ji', 'Initials': 'EJ', 'LastName': 'Kim', 'Affiliation': 'Seoul, Korea.'}, {'ForeName': 'Hyun Wook', 'Initials': 'HW', 'LastName': 'Park', 'Affiliation': 'Seoul, Korea.'}, {'ForeName': 'Geun Seog', 'Initials': 'GS', 'LastName': 'Song', 'Affiliation': 'Seoul, Korea.'}]",Alimentary pharmacology & therapeutics,['10.1111/apt.15865'] 2747,32703266,Evaluation of antenatal risk factors for postpartum depression: a secondary cohort analysis of the cluster-randomised GeliS trial.,"BACKGROUND Maternal weight variables are important predictors of postpartum depression (PPD). While preliminary evidence points to an association between pre-pregnancy obesity and PPD, the role of excessive gestational weight gain (GWG) on PPD is less studied. In this secondary cohort analysis of the German 'healthy living in pregnancy' (GeliS) trial, we aimed to investigate associations between weight-related variables and PPD and to assess the influence of GWG on the risk for PPD. METHODS We included women with normal weight, overweight, and obesity (BMI 18.5-40.0 kg/m 2 ). Symptoms of PPD were assessed 6-8 weeks postpartum using the Edinburgh Postnatal Depression Scale. Pre-pregnancy BMI was self-reported. During the course of pregnancy, weight was measured at gynaecological practices within regular check-ups. GWG was defined as the difference between the last measured weight before delivery and the first measured weight at the time of recruitment (≤ 12 th week of gestation). Excessive GWG was classified according to the Institute of Medicine. Multiple logistic regression analyses were used to estimate the odds of PPD in relation to pre-pregnancy BMI, GWG, and excessive GWG adjusting for important confounders. RESULTS Of the total 1583 participants, 45.6% (n = 722) showed excessive GWG and 7.9% (n = 138) experienced PPD. Pre-pregnancy BMI (per 5-unit increase; OR = 1.23, 95% CI 1.08-1.41, p = 0.002) and pre-pregnancy overweight or obesity were significantly positively associated with the odds of developing PPD, particularly among women with an antenatal history of anxiety or depressive symptoms (overweight: OR = 1.93, 95% CI = 1.15-3.22, p = 0.01; obesity: OR = 2.11, 95% CI = 1.13-3.96, p = 0.02). Sociodemographic or lifestyle factors did not additively influence the odds of having PPD. In fully adjusted models, there was no significant evidence that GWG or the occurrence of excessive GWG increased the odds of experiencing PPD (excessive vs. non-excessive: OR = 3.48, 95% CI 0.35-34.94; GWG per 1 kg increase: OR = 1.16, 95% CI 0.94-1.44). CONCLUSION Pre-pregnancy overweight or obesity is associated with PPD independent of concurrent risk factors. History of anxiety or depressive symptoms suggests a stress-induced link between pre-pregnancy weight and PPD. TRIAL REGISTRATION NCT01958307 , ClinicalTrials.gov, retrospectively registered on 9 October 2013.",2020,"RESULTS Of the total 1583 participants, 45.6% (n = 722) showed excessive GWG and 7.9% (n = 138) experienced PPD","['postpartum depression', 'women with normal weight, overweight, and obesity (BMI 18.5-40.0\u2009kg/m 2 ', ""German 'healthy living in pregnancy' (GeliS) trial""]",[],"[' Pre-pregnancy BMI', 'antenatal history of anxiety or depressive symptoms', 'excessive GWG', 'PPD', 'Edinburgh Postnatal Depression Scale. Pre', 'Symptoms of PPD', 'pregnancy BMI', 'pre-pregnancy overweight or obesity']","[{'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517611', 'cui_str': '18.5'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],"[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C2828394', 'cui_str': 'Antenatal'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0442802', 'cui_str': 'Excessive'}, {'cui': 'C1398625', 'cui_str': 'Maternal Weight Gain'}, {'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0451144', 'cui_str': 'Edinburgh postnatal depression scale'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]",1583.0,0.137812,"RESULTS Of the total 1583 participants, 45.6% (n = 722) showed excessive GWG and 7.9% (n = 138) experienced PPD","[{'ForeName': 'Hamimatunnisa', 'Initials': 'H', 'LastName': 'Johar', 'Affiliation': 'Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Hoffmann', 'Affiliation': 'Institute of Nutritional Medicine, Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Georg-Brauchle-Ring 62, 80992, Munich, Germany.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Günther', 'Affiliation': 'Institute of Nutritional Medicine, Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Georg-Brauchle-Ring 62, 80992, Munich, Germany.'}, {'ForeName': 'Seryan', 'Initials': 'S', 'LastName': 'Atasoy', 'Affiliation': 'Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany.'}, {'ForeName': 'Lynne', 'Initials': 'L', 'LastName': 'Stecher', 'Affiliation': 'Institute of Nutritional Medicine, Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Georg-Brauchle-Ring 62, 80992, Munich, Germany.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Spies', 'Affiliation': 'Institute of Nutritional Medicine, Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Georg-Brauchle-Ring 62, 80992, Munich, Germany.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Hauner', 'Affiliation': 'Institute of Nutritional Medicine, Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Georg-Brauchle-Ring 62, 80992, Munich, Germany. hans.hauner@tum.de.'}, {'ForeName': 'Karl-Heinz', 'Initials': 'KH', 'LastName': 'Ladwig', 'Affiliation': 'Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany. Karl-Heinz.Ladwig@tum.de.'}]",BMC medicine,['10.1186/s12916-020-01679-7'] 2748,32703270,The effect of blue dishware versus white dishware on food intake and eating challenges among residents living with dementia: a crossover trial.,"OBJECTIVE Residents living with dementia (RLWD) often experience changes in their visual perception, which could reduce food intake. Inadequate food intake is known to cause malnutrition, which increases the risk of hospitalization, morbidity, and mortality. This study evaluated the effectiveness of using blue dishware compared to white dishware to improve food intake and mitigate eating challenges among 18 RLWD (mean age 84.6 ± 7.9 years, 72.2% female). RESULTS A within-within person crossover design determined differences in food intake and eating challenges between blue and white dishware conditions. Five participants responded to the blue dishware and increased their average food intake by ≥ 10%. Responders were not different from non-responders in terms of demographic or health characteristics. The proportion of eating challenges experienced was not significantly different between the blue and white dishware conditions. Percent food intake was significantly greater at lunch (83.5 ± 19.0%) compared to dinner (75.8 ± 22.1%; p < 0.0001), regardless of dishware condition. However, there were no significant differences for food intake between the dishware conditions, even after matching food choices. Promoting food intake and reducing eating challenges in RLWD likely needs multi-component interventions targeting meal quality, meal access, and mealtime experience. Trial registration ClincialTrials.gov Identifier: NCT04298788. Retrospectively registered: 6 March 2020, https://clinicaltrials.gov/ct2/show/NCT04298788?term=NCT04298788&draw=2&rank=1 .",2020,"Percent food intake was significantly greater at lunch (83.5 ± 19.0%) compared to dinner (75.8 ± 22.1%; p < 0.0001), regardless of dishware condition.","['18 RLWD (mean age 84.6\u2009±\u20097.9\xa0years, 72.2% female', 'Residents living with dementia (RLWD', 'residents living with dementia']",['blue dishware versus white dishware'],"['Percent food intake', 'food intake and eating challenges', 'proportion of eating challenges', 'food intake', 'food intake and mitigate eating challenges', 'risk of hospitalization, morbidity, and mortality', 'average food intake']","[{'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C1260957', 'cui_str': 'Blue color'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",5.0,0.0765427,"Percent food intake was significantly greater at lunch (83.5 ± 19.0%) compared to dinner (75.8 ± 22.1%; p < 0.0001), regardless of dishware condition.","[{'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Donnelly', 'Affiliation': 'University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Wei', 'Affiliation': 'University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Morrison-Koechl', 'Affiliation': 'University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Keller', 'Affiliation': 'University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada. hkeller@uwaterloo.ca.'}]",BMC research notes,['10.1186/s13104-020-05195-y'] 2749,32703288,Randomized control trial testing the effectiveness of implemented depression prevention in high-risk adolescents.,"BACKGROUND Adolescent depression is a global mental health concern. Identification and effective prevention in an early stage are necessary. The present randomized, controlled trial aimed to examine the effectiveness of Cognitive Behavioral Therapy (CBT)-based depression prevention in adolescents with elevated depressive symptoms. This prevention approach is implemented in school communities, which allows to examine effects under real-life circumstances. METHODS A total of 5222 adolescents were screened for elevated depressive symptoms in the second grade of secondary schools; 130 adolescents aged between 12 and 16 years old (M = 13.59; SD = 0.68; 63.8% girls) were randomly assigned to the experimental (OVK 2.0) or control condition (psycho-education). Self- and parent-reported depressive symptoms were assessed at pretest and post intervention, as well as 6- and 12-months follow-up. Clinical assessment of depression was assessed at pretest and 6-months follow-up. RESULTS Intent-to-treat analyses revealed that the decrease in adolescent-rated depressive symptoms was significantly larger in the intervention condition than in the control condition. There was no significant difference in decrease of parent-rated depressive symptoms between both conditions. CONCLUSIONS Based on the findings, we recommend the implementation of screening and prevention in schools, according the basics of this study design. Since this is a new step forward, we discuss the clinical impact and challenges, as well possibilities for future research. TRIAL REGISTRATION The study is registered in the Dutch Trial Register for RCT's ( NTR5725 ). Date registered: 11 March 2016.",2020,"RESULTS Intent-to-treat analyses revealed that the decrease in adolescent-rated depressive symptoms was significantly larger in the intervention condition than in the control condition.","['5222 adolescents were screened for elevated depressive symptoms in the second grade of secondary schools; 130 adolescents aged between 12 and 16\u2009years old (M\u2009=\u200913.59; SD\u2009=\u20090.68; 63.8% girls', 'adolescents with elevated depressive symptoms', 'high-risk adolescents']","['Cognitive Behavioral Therapy (CBT)-based depression prevention', 'experimental (OVK 2.0) or control condition (psycho-education']","['decrease of parent-rated depressive symptoms', 'adolescent-rated depressive symptoms', 'Self- and parent-reported depressive symptoms']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0036530', 'cui_str': 'Secondary school'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4517473', 'cui_str': '0.68'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}]","[{'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0684224', 'cui_str': 'Report'}]",5222.0,0.154615,"RESULTS Intent-to-treat analyses revealed that the decrease in adolescent-rated depressive symptoms was significantly larger in the intervention condition than in the control condition.","[{'ForeName': 'Karlijn W J', 'Initials': 'KWJ', 'LastName': 'de Jonge-Heesen', 'Affiliation': 'GGZ Oost Brabant, P.O. Box 3, 5427 ZG, Boekel, The Netherlands. kwj.heesen@ggzoostbrabant.nl.'}, {'ForeName': 'Sanne P A', 'Initials': 'SPA', 'LastName': 'Rasing', 'Affiliation': 'GGZ Oost Brabant, P.O. Box 3, 5427 ZG, Boekel, The Netherlands.'}, {'ForeName': 'Ad A', 'Initials': 'AA', 'LastName': 'Vermulst', 'Affiliation': 'GGZ Oost Brabant, P.O. Box 3, 5427 ZG, Boekel, The Netherlands.'}, {'ForeName': 'Ron H J', 'Initials': 'RHJ', 'LastName': 'Scholte', 'Affiliation': 'Praktikon, P.O. Box 6909, 6503 GK, Nijmegen, The Netherlands.'}, {'ForeName': 'Kim M', 'Initials': 'KM', 'LastName': 'van Ettekoven', 'Affiliation': 'GGZ Oost Brabant, P.O. Box 3, 5427 ZG, Boekel, The Netherlands.'}, {'ForeName': 'Rutger C M E', 'Initials': 'RCME', 'LastName': 'Engels', 'Affiliation': 'Erasmus School of Social and Behavioural Sciences, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.'}, {'ForeName': 'Daan H M', 'Initials': 'DHM', 'LastName': 'Creemers', 'Affiliation': 'GGZ Oost Brabant, P.O. Box 3, 5427 ZG, Boekel, The Netherlands.'}]",BMC medicine,['10.1186/s12916-020-01656-0'] 2750,32703293,Communities for Healthy Living (CHL) A Community-based Intervention to Prevent Obesity in Low-Income Preschool Children: Process Evaluation Protocol.,"BACKGROUND Process evaluation can illuminate barriers and facilitators to intervention implementation as well as the drivers of intervention outcomes. However, few obesity intervention studies have documented process evaluation methods and results. Community-based participatory research (CBPR) requires that process evaluation methods be developed to (a) prioritize community members' power to adapt the program to local needs over strict adherence to intervention protocols, (b) share process evaluation data with implementers to maximize benefit to participants, and (c) ensure partner organizations are not overburdened. Co-designed with low-income parents using CBPR, Communities for Healthy Living (CHL) is a family-centered intervention implemented within Head Start to prevent childhood obesity and promote family well-being. We are currently undertaking a randomized controlled trial to test the effectiveness of CHL in 23 Head Start centers in the greater Boston area. In this protocol paper, we outline an embedded process evaluation designed to monitor intervention adherence and adaptation, support ongoing quality improvement, and examine contextual factors that may moderate intervention implementation and/or effectiveness. METHODS This mixed methods process evaluation was developed using the Pérez et al. framework for evaluating adaptive interventions and is reported following guidelines outlined by Grant et al. Trained research assistants will conduct structured observations of intervention sessions. Intervention facilitators and recipients, along with Head Start staff, will complete surveys and semi-structured interviews. De-identified data for all eligible children and families will be extracted from Head Start administrative records. Qualitative data will be analyzed thematically. Quantitative and qualitative data will be integrated using triangulation methods to assess intervention adherence, monitor adaptations, and identify moderators of intervention implementation and effectiveness. DISCUSSION A diverse set of quantitative and qualitative data sources are employed to fully characterize CHL implementation. Simultaneously, CHL's process evaluation will provide a case study on strategies to address the challenges of process evaluation for CBPR interventions. Results from this process evaluation will help to explain variation in intervention implementation and outcomes across Head Start programs, support CHL sustainability and future scale-up, and provide guidance for future complex interventions developed using CBPR. TRIAL REGISTRATION ClinicalTrials.gov, NCT03334669 . Registered on October 10, 2017.",2020,We are currently undertaking a randomized controlled trial to test the effectiveness of CHL in 23 Head Start centers in the greater Boston area.,"['Healthy Living (CHL', '23 Head Start centers in the greater Boston area', 'Low-Income Preschool Children', 'Communities for Healthy Living (CHL']","['Community-based participatory research (CBPR', 'Community-based Intervention', 'CHL']",[],"[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0006037', 'cui_str': 'Boston'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0008100', 'cui_str': 'Preschool child'}]","[{'cui': 'C2350575', 'cui_str': 'Community-Based Participatory Research'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.062973,We are currently undertaking a randomized controlled trial to test the effectiveness of CHL in 23 Head Start centers in the greater Boston area.,"[{'ForeName': 'Jacob P', 'Initials': 'JP', 'LastName': 'Beckerman-Hsu', 'Affiliation': 'Department of Nutrition, Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, MA, 02115, USA.'}, {'ForeName': 'Alyssa', 'Initials': 'A', 'LastName': 'Aftosmes-Tobio', 'Affiliation': 'Boston College School of Social Work, McGuinn Hall Room 115, 140 Commonwealth Ave, Chestnut Hill, MA, 02467, USA.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Gavarkovs', 'Affiliation': 'Institute of Health Policy, Management and Evaluation & Wilson Centre, Faculty of Medicine, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Kitos', 'Affiliation': 'Massachusetts Department of Public Health, Boston, MA, 02115, USA.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Figueroa', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, 244 Garden Ave, Ithaca, NY, 14853, USA.'}, {'ForeName': 'Z Begum', 'Initials': 'ZB', 'LastName': 'Kalyoncu', 'Affiliation': 'Nutrition and Dietetics Department, Atilim University, Kizilcasar Mahallesi, Incek Golbasi, 06830, Ankara, Turkey.'}, {'ForeName': 'Kindra', 'Initials': 'K', 'LastName': 'Lansburg', 'Affiliation': 'Action for Boston Community Development, 178 Tremont Street, Boston, MA, 02111, USA.'}, {'ForeName': 'Xinting', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': ""Departments of Medicine, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.""}, {'ForeName': 'Crystal', 'Initials': 'C', 'LastName': 'Kazik', 'Affiliation': 'Community Action Agency of Somerville, 66 Union Square, Somerville, MA, 02143, USA.'}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'Vigilante', 'Affiliation': 'Community Action Agency of Somerville, 66 Union Square, Somerville, MA, 02143, USA.'}, {'ForeName': 'Jessie', 'Initials': 'J', 'LastName': 'Leonard', 'Affiliation': 'Community Action Agency of Somerville, 66 Union Square, Somerville, MA, 02143, USA.'}, {'ForeName': 'Merieka', 'Initials': 'M', 'LastName': 'Torrico', 'Affiliation': 'Action for Boston Community Development, 178 Tremont Street, Boston, MA, 02111, USA.'}, {'ForeName': 'Janine M', 'Initials': 'JM', 'LastName': 'Jurkowski', 'Affiliation': 'Department of Health Policy, Management & Behavior, University at Albany School of Public Health, 1 University Place, Rensselaer, NY, 12144, USA.'}, {'ForeName': 'Kirsten K', 'Initials': 'KK', 'LastName': 'Davison', 'Affiliation': 'Boston College School of Social Work, McGuinn Hall Room 115, 140 Commonwealth Ave, Chestnut Hill, MA, 02467, USA. kirsten.davison@bc.edu.'}]",Trials,['10.1186/s13063-020-04571-0'] 2751,32703307,Randomized control trial of advanced cancer patients at a private hospital in Kenya and the impact of dignity therapy on quality of life.,"BACKGROUND Palliative care is a modality of treatment that addresses physical, psychological and spiritual symptoms. Dignity therapy, a form of psychotherapy, was developed by Professor Harvey Chochinov, MD in 2005.The aim of the study was to assess the effect of one session of dignity therapy on quality of life in advanced cancer patients. METHODS This was a randomized control trial of 144 patients (72 in each arm) randomized into group 1 (intervention arm) and group 2 (control arm). Baseline ESAS scores were determined in both arms following which group 1 received Dignity therapy while Group 2 received usual care only. Data collected was presented as printed (Legacy) documents to group 1 participants. These documents were a summary of previous discussions held. Post intervention ESAS scores were obtained in both groups after 6 weeks. Analysis was based on the intention to treat principle and descriptive statistics computed. The main outcome was symptom distress scores on the ESAS (summated out of 100 and symptom specific scores out of 10). The student T-test was used to test for difference in ESAS scores at follow up and graphs were computed for common cancers and comorbidities. RESULTS Of the 144 (72 patients in each arm) patients randomized, 70%were female while 30% were male with a mean age of 50 years. At 6 weeks, 11 patients were lost to follow up, seven died and 126 completed the study. The commonly encountered cancers were gastrointestinal cancers (43%, p = 0.29), breast cancer (27.27% p = 0.71) and gynaecologic cancers (23% p = 0.35). Majority of the patients i.e. 64.3% had no comorbidities. The primary analysis results showed higher scores for the DT group (change in mean = 1.57) compared to the UC group (change in mean = - 0.74) yielding a non-statistically significant difference in change scores of 1.44 (p = 0.670; 95% CI - 5.20 to 8.06). After adjusting for baseline scores, the mean (summated) symptom distress score was not significant (GLM p = 0.78). Dignity therapy group showed a trend towards statistical improvement in anxiety (p = 0.059). The largest effects seen were in improvement of appetite, lower anxiety and improved wellbeing (Cohen effect size 0.3, 0.5 and 0.31 respectively). CONCLUSION Dignity therapy showed no statistical improvement in overall quality of life. Symptom improvement was seen in anxiety and this was a trend towards statistical significance (p = 0.059). TRIAL REGISTRATION Trial registration number PACTR201604001447244 retrospectively registered with Pan African Clinical trials on 28th January 2016.",2020,"The largest effects seen were in improvement of appetite, lower anxiety and improved wellbeing (Cohen effect size 0.3, 0.5 and 0.31 respectively). ","['Of the 144 (72 patients in each arm', '11 patients were lost to follow up, seven died and 126 completed the study', 'advanced cancer patients', '144 patients (72 in each arm', 'advanced cancer patients at a private hospital in Kenya', '70%were female while 30% were male with a mean age of 50\u2009years']","['Dignity therapy', 'dignity therapy']","['quality of life', 'breast cancer', 'Baseline ESAS scores', 'mean (summated) symptom distress score', 'anxiety', 'appetite, lower anxiety and improved wellbeing', 'gynaecologic cancers', 'overall quality of life', 'ESAS scores', 'symptom distress scores', 'gastrointestinal cancers']","[{'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C1302313', 'cui_str': 'Lost to follow-up'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0033173', 'cui_str': 'Private hospital'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C4704841', 'cui_str': 'Dignity'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0205480', 'cui_str': 'Gynecologic'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C3472649', 'cui_str': 'Edmonton symptom assessment system'}, {'cui': 'C0685938', 'cui_str': 'Malignant neoplasm of gastrointestinal tract'}]",144.0,0.182917,"The largest effects seen were in improvement of appetite, lower anxiety and improved wellbeing (Cohen effect size 0.3, 0.5 and 0.31 respectively). ","[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Weru', 'Affiliation': 'Palliative care, AKUHN, Nairobi, Kenya. john.weru@aku.edu.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Gatehi', 'Affiliation': 'MMED INT. Med, Nairobi, Kenya.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Musibi', 'Affiliation': 'Oncology, Kenyatta National Hospital, Nairobi, Kenya.'}]",BMC palliative care,['10.1186/s12904-020-00614-0'] 2752,32703316,"Efficacy of brief dynamic interpersonal therapy in patients with major depressive disorder: a prospective, multicenter randomized controlled trial protocol.","BACKGROUND In China, psychodynamic psychotherapies are widely used as a treatment for depression. However, very few efficacy studies of psychodynamic therapies have been conducted with the Chinese population. This paper describes a study protocol of a multicenter randomized controlled trial of dynamic interpersonal psychotherapy (DIT), a brief manualized depression-focused intervention, in Chinese adults with major depressive disorder (MDD). METHODS Recruitment is planned in five hospitals. Two hundred forty patients with MDD will be randomly allocated on a 1:1:1 basis to either medication plus DIT, medication plus an active control psychotherapy, or medication alone. Patients will be assessed at baseline and at weeks 2, 4, 8, 12, and 16 during the acute treatment phase and 1, 3, 6, and 12 months posttreatment. The primary outcome is change from baseline in the 17-item Hamilton Depression Rating Scale, administered by independent raters who are blind to treatment allocation. The Hamilton Anxiety Rating Scale, Patient Health Questionnaire-9, Generalized Anxiety Disorder 7-item scale, response, remission and relapse rates, self-assessment of overall efficacy and satisfaction of patients, and side effect profiles are secondary measures. DISCUSSION This will be the first multicentered RCT in China to assess the efficacy of a brief psychodynamic intervention for MDD. The study has the potential to inform clinical treatment guidelines for the treatment of depression in China. TRIAL REGISTRATION ChiCTR, ChiCTR1800016970 . Registered on July 5, 2018.",2020,"This paper describes a study protocol of a multicenter randomized controlled trial of dynamic interpersonal psychotherapy (DIT), a brief manualized depression-focused intervention, in Chinese adults with major depressive disorder (MDD). ","['Recruitment is planned in five hospitals', 'Chinese adults with major depressive disorder (MDD', 'patients with major depressive disorder', 'Two hundred forty patients with MDD']","['dynamic interpersonal psychotherapy (DIT', 'medication plus DIT, medication plus an active control psychotherapy, or medication alone', 'brief dynamic interpersonal therapy']","['Hamilton Anxiety Rating Scale, Patient Health Questionnaire-9, Generalized Anxiety Disorder 7-item scale, response, remission and relapse rates, self-assessment of overall efficacy and satisfaction of patients, and side effect profiles are secondary measures', '17-item Hamilton Depression Rating Scale']","[{'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319558', 'cui_str': '200'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0871787', 'cui_str': 'Interpersonal psychotherapy'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0036591', 'cui_str': 'Self Assessment'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}]",240.0,0.10072,"This paper describes a study protocol of a multicenter randomized controlled trial of dynamic interpersonal psychotherapy (DIT), a brief manualized depression-focused intervention, in Chinese adults with major depressive disorder (MDD). ","[{'ForeName': 'Lanlan', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiaotong University Medical School, Shanghai, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': 'Beijing Anding Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Wenhui', 'Initials': 'W', 'LastName': 'Jiang', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiaotong University Medical School, Shanghai, China.'}, {'ForeName': 'Jianfeng', 'Initials': 'J', 'LastName': 'Luo', 'Affiliation': 'Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Tong', 'Affiliation': 'Wuhan Mental Health Center, Wuhan, Hubei Province, China.'}, {'ForeName': 'Xiaosi', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Anhui Mental Health Center, Hefei, Anhui Province, China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Fang', 'Affiliation': 'Shanghai Hongkou District Mental Health Center, Shanghai, China.'}, {'ForeName': 'Hongyan', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiaotong University Medical School, Shanghai, China.'}, {'ForeName': 'Wenqing', 'Initials': 'W', 'LastName': 'Zhao', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiaotong University Medical School, Shanghai, China.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Koszycki', 'Affiliation': 'University of Ottawa and Insitut du Savoir Montfort, Ottawa, Ontario, Canada. dkoszyck@uottawa.ca.'}, {'ForeName': 'Jianyin', 'Initials': 'J', 'LastName': 'Qiu', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiaotong University Medical School, Shanghai, China. jianyin_qiu@163.com.'}]",Trials,['10.1186/s13063-020-04569-8'] 2753,32703371,Evolving techniques and technologies in colorectal endoscopic submucosal dissection: changing treatment paradigms and takeaways from a recent randomized trial.,,2020,,['colorectal endoscopic submucosal dissection'],[],[],"[{'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C1700929', 'cui_str': 'Endoscopic Submucosal Dissection'}]",[],[],,0.0319829,,"[{'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'McCarty', 'Affiliation': ""Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, US.""}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Aihara', 'Affiliation': ""Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, US.""}]",Gastrointestinal endoscopy,['10.1016/j.gie.2020.03.3862'] 2754,32703380,Propofol sedation with a target-controlled infusion pump in elderly patients undergoing ERCP: Is this the right way to go?,,2020,,['elderly patients undergoing ERCP'],['Propofol sedation'],[],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}]","[{'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}]",[],,0.0163177,,"[{'ForeName': 'Rajen', 'Initials': 'R', 'LastName': 'Daftary', 'Affiliation': 'Baldota Institute of Digestive Sciences, Gleneagles Global Hospital, Mumbai, India.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Maydeo', 'Affiliation': 'Baldota Institute of Digestive Sciences, Gleneagles Global Hospital, Mumbai, India.'}]",Gastrointestinal endoscopy,['10.1016/j.gie.2020.03.3843'] 2755,32703392,Re: Prajna et al.: Cross-Linking-Assisted Infection Reduction (CLAIR): A randomized clinical trial evaluating the effect of adjuvant cross-linking on outcomes in fungal keratitis (Ophthalmology. 2020;127:159-166).,,2020,,['fungal\xa0keratitis (Ophthalmology'],"['adjuvant cross-linking', ' Cross-Linking-Assisted Infection Reduction (CLAIR']",[],"[{'cui': 'C1262117', 'cui_str': 'Fungal keratitis'}, {'cui': 'C0029087', 'cui_str': 'Ophthalmology'}]","[{'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0332220', 'cui_str': 'Cross-linking'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",[],,0.130982,,"[{'ForeName': 'Darren Shu Jeng', 'Initials': 'DSJ', 'LastName': 'Ting', 'Affiliation': ""Academic Ophthalmology, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, UK; Department of Ophthalmology, Queen's Medical Centre, Nottingham, UK. Electronic address: ting.darren@gmail.com.""}, {'ForeName': 'Christin', 'Initials': 'C', 'LastName': 'Henein', 'Affiliation': 'Newcastle University, Newcastle upon Tyne, UK; National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.'}, {'ForeName': 'Dalia G', 'Initials': 'DG', 'LastName': 'Said', 'Affiliation': ""Academic Ophthalmology, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, UK; Department of Ophthalmology, Queen's Medical Centre, Nottingham, UK.""}, {'ForeName': 'Harminder S', 'Initials': 'HS', 'LastName': 'Dua', 'Affiliation': ""Academic Ophthalmology, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, UK; Department of Ophthalmology, Queen's Medical Centre, Nottingham, UK.""}]",Ophthalmology,['10.1016/j.ophtha.2020.02.032'] 2756,32703511,Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT.,"BACKGROUND The SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) randomized 2,521 patients with moderate heart failure (HF) to amiodarone, placebo drug, or implantable cardioverter-defibrillator (ICD) therapy. Original trial follow-up ended October 31, 2003. Over a median 45.5-month follow-up, amiodarone, compared with placebo, did not affect survival, whereas randomization to an ICD significantly decreased all-cause mortality by 23%. OBJECTIVES This study sought to describe the extended treatment group survival of the SCD-HeFT cohort. METHODS Mortality outcomes for the 1,855 patients alive at the end of the SCD-HeFT trial were collected between 2010 and 2011. These data were combined with the 666 deaths from the original study to compare long-term outcomes overall and for key pre-specified subgroups. RESULTS Median (25th to 75th percentiles) follow-up was 11.0 (10.0 to 12.2) years. On the basis of intention-to-treat analysis, the ICD group had overall survival benefit versus placebo drug (hazard ratio [HR]: 0.87; 95% confidence interval [CI]: 0.76 to 0.98; p = 0.028). When treatment benefit was examined as a function of time from randomization, attenuation of the ICD benefit was observed after 6 years (p value for the interaction = 0.0015). Subgroup analysis revealed long-term ICD benefit varied according to HF etiology and New York Heart Association (NYHA) functional class: ischemic HF HR: 0.81; 95% CI: 0.69 to 0.95; p = 0.009; nonischemic HF HR: 0.97; 95% CI: 0.79 to 1.20; p = 0.802; NYHA functional class II HR: 0.76; 95% CI: 0.65 to 0.90; p = 0.001; NYHA functional class III HR: 1.06; 95% CI: 0.86 to 1.31; p = 0.575. CONCLUSIONS Follow-up of SCD-HeFT patients to 11 years demonstrated heterogenous treatment-related patterns of long-term survival with ICD benefit most evident at 11 years for ischemic HF patients and for those with NYHA functional class II symptoms at trial enrollment. (SCD-HeFT 10 Year Follow-up [SCD-HeFT10 Yr]; NCT01058837).",2020,"Over a median 45.5-month follow-up, amiodarone, compared with placebo, did not affect survival, whereas randomization to an ICD significantly decreased all-cause mortality by 23%. ","['2,521 patients with moderate heart failure (HF) to', '1,855 patients alive at the end of the SCD-HeFT trial were collected between 2010 and 2011']","['Implantable Cardioverter-Defibrillator Therapy', 'placebo', 'amiodarone, placebo drug, or implantable cardioverter-defibrillator (ICD) therapy', 'amiodarone']","['ICD benefit', 'survival', 'overall survival benefit']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C2584946', 'cui_str': 'Alive'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0002895', 'cui_str': 'Sickling disorder due to hemoglobin S'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0162589', 'cui_str': 'Implantable defibrillator'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0002598', 'cui_str': 'Amiodarone'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0162589', 'cui_str': 'Implantable defibrillator'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",2521.0,0.201532,"Over a median 45.5-month follow-up, amiodarone, compared with placebo, did not affect survival, whereas randomization to an ICD significantly decreased all-cause mortality by 23%. ","[{'ForeName': 'Jeanne E', 'Initials': 'JE', 'LastName': 'Poole', 'Affiliation': 'Department of Medicine, Division of Cardiology, University of Washington, Seattle, Washington. Electronic address: jpoole@u.washington.edu.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Olshansky', 'Affiliation': 'Department of Medicine, Division of Cardiology, University of Iowa, Iowa City, Iowa.'}, {'ForeName': 'Daniel B', 'Initials': 'DB', 'LastName': 'Mark', 'Affiliation': 'Department of Medicine, Division of Cardiology, Duke University, Durham, North Carolina.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Anderson', 'Affiliation': 'Seattle Institute for Cardiac Research, Seattle, Washington.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Johnson', 'Affiliation': 'Seattle Institute for Cardiac Research, Seattle, Washington.'}, {'ForeName': 'Anne S', 'Initials': 'AS', 'LastName': 'Hellkamp', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Davidson-Ray', 'Affiliation': 'Department of Medicine, Division of Cardiology, Duke University, Durham, North Carolina.'}, {'ForeName': 'Daniel P', 'Initials': 'DP', 'LastName': 'Fishbein', 'Affiliation': 'Department of Medicine, Division of Cardiology, University of Washington, Seattle, Washington.'}, {'ForeName': 'Robin E', 'Initials': 'RE', 'LastName': 'Boineau', 'Affiliation': 'National Center for Complementary and Integrative Health, National institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Kevin J', 'Initials': 'KJ', 'LastName': 'Anstrom', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.'}, {'ForeName': 'Per G', 'Initials': 'PG', 'LastName': 'Reinhall', 'Affiliation': 'Department of Mechanical Engineering, University of Washington, Seattle, Washington.'}, {'ForeName': 'Douglas L', 'Initials': 'DL', 'LastName': 'Packer', 'Affiliation': 'Department of Cardiology, Division of Cardiac Electrophysiology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Kerry L', 'Initials': 'KL', 'LastName': 'Lee', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.'}, {'ForeName': 'Gust H', 'Initials': 'GH', 'LastName': 'Bardy', 'Affiliation': 'Department of Medicine, Division of Cardiology, Seattle Institute for Cardiac Research, Seattle, Washington.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2020.05.061'] 2757,32709890,Impact of an active lifestyle on heart rate variability and oxidative stress markers in offspring of hypertensives.,"Familial history of hypertension is associated with autonomic dysfunction and increase in blood pressure (BP). However, an active lifestyle has been found to improve a number of health outcomes and reduce all-cause mortality. The aim of the present study was to investigate the effects of an active lifestyle on hemodynamics, heart rate variability (HRV) and oxidative stress markers in offspring of hypertensive parents. One hundred twenty-seven subjects were assigned into four groups: sedentary offspring of normotensives (S-ON) or hypertensives (S-OH); and physically active offspring of normotensives (A-ON) or hypertensives (A-OH). Diastolic BP and heart rate were reduced in the physically active groups when compared to S-OH group. A-ON and A-OH groups presented increased values of RR total variance when compared to the sedentary ones (A-ON: 4,912 ± 538 vs. S-ON: 2,354 ± 159; A-OH: 3,112 ± 236 vs. S-OH: 2,232 ± 241 ms 2 ). Cardiac sympato-vagal balance (LF/HF), systemic hydrogen peroxide and superoxide anion were markedly increased in S-OH group when compared to all other studied groups. Additionally, important correlations were observed between LF/HF with diastolic BP (r = 0.30) and hydrogen peroxide (r = 0.41). Thus, our findings seem to confirm an early autonomic dysfunction in offspring of hypertensive parents, which was associated with a systemic increase in reactive oxygen species and blood pressure. However, our most important finding lies in the attenuation of such disorders in offspring of physically active hypertensives, thus emphasizing the importance of a physically active lifestyle in the prevention of early disorders that may be associated with onset of hypertension.",2020,"A-ON and A-OH groups presented increased values of RR total variance when compared to the sedentary ones (A-ON: 4,912 ± 538 vs. S-ON: 2,354 ± 159; A-OH: 3,112 ± 236 vs. S-OH: 2,232 ± ","['offspring of hypertensives', 'One hundred twenty-seven subjects', 'offspring of hypertensive parents']","['active lifestyle', 'sedentary offspring of normotensives (S-ON) or hypertensives (S-OH); and physically active offspring of normotensives (A-ON) or hypertensives (A-OH']","['LF/HF with diastolic BP', 'heart rate variability and oxidative stress markers', 'hydrogen peroxide', 'blood pressure (BP', 'values of RR total variance', 'reactive oxygen species and blood pressure', 'hemodynamics, heart rate variability (HRV) and oxidative stress markers', 'Diastolic BP and heart rate', 'Cardiac sympato-vagal balance (LF/HF), systemic hydrogen peroxide and superoxide anion']","[{'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0030551', 'cui_str': 'Parent'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0556453', 'cui_str': 'Physically active'}]","[{'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0162772', 'cui_str': 'Oxygen Species, Reactive'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0038836', 'cui_str': 'Superoxide'}]",127.0,0.0258121,"A-ON and A-OH groups presented increased values of RR total variance when compared to the sedentary ones (A-ON: 4,912 ± 538 vs. S-ON: 2,354 ± 159; A-OH: 3,112 ± 236 vs. S-OH: 2,232 ± ","[{'ForeName': 'F A', 'Initials': 'FA', 'LastName': 'Santa-Rosa', 'Affiliation': 'Laboratory of Translational Physiology, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.'}, {'ForeName': 'G L', 'Initials': 'GL', 'LastName': 'Shimojo', 'Affiliation': 'Laboratory of Translational Physiology, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.'}, {'ForeName': 'D S', 'Initials': 'DS', 'LastName': 'Dias', 'Affiliation': 'Laboratory of Translational Physiology, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Viana', 'Affiliation': 'Laboratory of Translational Physiology, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.'}, {'ForeName': 'F C', 'Initials': 'FC', 'LastName': 'Lanza', 'Affiliation': 'Laboratory of Translational Physiology, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.'}, {'ForeName': 'M C', 'Initials': 'MC', 'LastName': 'Irigoyen', 'Affiliation': 'Heart Institute (InCor), Medical School, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'De Angelis', 'Affiliation': 'Laboratory of Translational Physiology, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil. prof.kangelis@yahoo.com.br.'}]",Scientific reports,['10.1038/s41598-020-69104-w'] 2758,32709912,Exercise as a protective mechanism against the negative effects of oxidative stress in first-episode psychosis: a biomarker-led study.,"First-episode psychosis (FEP) is a psychiatric disorder, characterised by positive and negative symptoms, usually emerging during adolescence and early adulthood. FEP represents an early intervention opportunity for intervention in psychosis. Redox disturbance and subsequent oxidative stress have been linked to the pathophysiology of FEP. Exercise training can perturb oxidative stress and rebalance the antioxidant system and thus represents an intervention with the potential to interact with a mechanism of disease. The aim of this study was to assess the effect of exercise on markers of redox status in FEP. Twenty-two young men were recruited from Birmingham Early Intervention services and randomised to either a 12-week exercise programme or treatment as usual (control). Measures of blood and brain glutathione (GSH), markers of oxidative damage, inflammation, neuronal health, symptomology and habitual physical activity were assessed. Exercise training was protective against changes related to continued psychosis. Symptomatically, those in the exercise group showed reductions in positive and general psychopathology, and stable negative symptoms (compared to increased negative symptoms in the control group). Peripheral GSH was increased by 5.6% in the exercise group, compared to a significant decrease (24.4%) (p = 0.04) in the control group. Exercise attenuated negative changes in markers of neuronal function (brain-derived neurotrophic factor), lipid damage (thiobarbituric acid-reactive substances) and total antioxidant capacity. C-reactive protein and tumour necrosis factor-α also decreased in the exercise group, although protein and DNA oxidation were unchanged. Moderate-intensity exercise training has the ability to elicit changes in markers of oxidative stress and antioxidant concentration, with subsequent improvements in symptoms of psychosis.",2020,"C-reactive protein and tumour necrosis factor-α also decreased in the exercise group, although protein and DNA oxidation were unchanged.","['Twenty-two young men', 'first-episode psychosis']","['Exercise training', 'Moderate-intensity exercise training', 'FEP', 'exercise programme or treatment as usual (control']","['Peripheral GSH', 'protein and DNA oxidation', 'blood and brain glutathione (GSH), markers of oxidative damage, inflammation, neuronal health, symptomology and habitual physical activity', 'positive and general psychopathology, and stable negative symptoms', 'C-reactive protein and tumour necrosis factor-α', 'neuronal function (brain-derived neurotrophic factor), lipid damage (thiobarbituric acid-reactive substances) and total antioxidant capacity']","[{'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439615', 'cui_str': 'First episode'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0439615', 'cui_str': 'First episode'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0907533', 'cui_str': 'NOS1 protein, human'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C1456820', 'cui_str': 'Tumor necrosis factor alpha'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0162781', 'cui_str': 'TBARs'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}]",22.0,0.0277852,"C-reactive protein and tumour necrosis factor-α also decreased in the exercise group, although protein and DNA oxidation were unchanged.","[{'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Fisher', 'Affiliation': 'School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Edgbaston, B15 2TT, UK.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Wood', 'Affiliation': 'Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, Melbourne, VIC, 3052, Australia.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Elsworthy', 'Affiliation': 'School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Edgbaston, B15 2TT, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Upthegrove', 'Affiliation': 'Institute for Mental Health, University of Birmingham, Edgbaston, B15 2TT, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Aldred', 'Affiliation': 'School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Edgbaston, B15 2TT, UK. s.aldred.1@bham.ac.uk.'}]",Translational psychiatry,['10.1038/s41398-020-00927-x'] 2759,32710147,A phase Ι study to evaluate the application of photocyanine using pharmacokinetic and pharmacodynamic analysis in patients with malignancy.,"PURPOSE Photodynamic therapy (PDT) schedules are based on sensitiser dose, light dose, and drug-light interval. The aim of the phase Ι study was to choose optimal dose and drug-light interval for PDT with photocyanine using pharmacokinetics (PK) and pharmacodynamics (PD). METHODS Twenty-eight cancer patients were enrolled. In trial A, 12 patients received one of four ascending doses of photocyanine intravenously 24 h prior to 180-270 J/cm 2 illumination. 0.2 mg/kg dose was infused to ten patients 12-48 h prior to 120 J/cm 2 illumination in trial B. In trial C, 0.1 mg/kg dose was infused to six patients 6 or 12 h prior to 180-270 J/cm 2 illumination. Serum concentrations of photocyanine were measured, and simulations were performed to assess the effect of drug exposure in tissue on responses. RESULTS Analysis of photocyanine levels of patients indicated that the two-compartment model best fit the data. Simulations showed that the rates of the drug entering tissues and leaving tissues were equal at 8-12 h after injection. Patients experienced pain which was related to photocyanine serum levels, especially with serum levels above 2500 ng/ml. Fewer non-responders were observed at serum levels higher than 1000 ng/ml for illumination at least 12 h after administration. CONCLUSION It is the first report of human trials of photocyanine, and the results suggested that patients receive 180 J/cm 2 illumination about 20-30 min at serum concentrations of photocyanine between 1000 and 2500 ng/ml at least 10 h after administration.",2020,"Fewer non-responders were observed at serum levels higher than 1000 ng/ml for illumination at least 12 h after administration. ","['Twenty-eight cancer patients were enrolled', '12 patients', 'patients with malignancy']","['photocyanine', 'Photodynamic therapy (PDT', 'photocyanine using pharmacokinetics (PK) and pharmacodynamics (PD']","['rates of the drug entering tissues and leaving tissues', 'Serum concentrations of photocyanine']","[{'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",28.0,0.0857011,"Fewer non-responders were observed at serum levels higher than 1000 ng/ml for illumination at least 12 h after administration. ","[{'ForeName': 'Su', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': ""State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.""}, {'ForeName': 'Bingtian', 'Initials': 'B', 'LastName': 'Bi', 'Affiliation': ""State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.""}, {'ForeName': 'Guangyu', 'Initials': 'G', 'LastName': 'Luo', 'Affiliation': ""State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhan', 'Affiliation': ""State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.""}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Zhang', 'Affiliation': ""State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.""}, {'ForeName': 'Jibin', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ""State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.""}, {'ForeName': 'Naisheng', 'Initials': 'N', 'LastName': 'Chen', 'Affiliation': ""College of Chemistry, Fuzhou University, Fuzhou, 350108, People's Republic of China.""}, {'ForeName': 'Jinling', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': ""College of Chemistry, Fuzhou University, Fuzhou, 350108, People's Republic of China.""}, {'ForeName': 'Jinping', 'Initials': 'J', 'LastName': 'Xue', 'Affiliation': ""College of Chemistry, Fuzhou University, Fuzhou, 350108, People's Republic of China. xuejinping66@fzu.edu.cn.""}, {'ForeName': 'Guoliang', 'Initials': 'G', 'LastName': 'Xu', 'Affiliation': ""State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. xugl@sysucc.org.cn.""}]",Cancer chemotherapy and pharmacology,['10.1007/s00280-020-04096-y'] 2760,32710165,Change in Dynamic Hyperinflation After Bronchoscopic Lung Volume Reduction in Patients with Emphysema.,"BACKGROUND AND PURPOSE In patients with severe emphysema, dynamic hyperinflation is superimposed on top of already existing static hyperinflation. Static hyperinflation reduces significantly after bronchoscopic lung volume reduction (BLVR). In this study, we investigated the effect of BLVR compared to standard of care (SoC) on dynamic hyperinflation. METHODS Dynamic hyperinflation was induced by a manually paced tachypnea test (MPT) and was defined by change in inspiratory capacity (IC) measured before and after MPT. Static and dynamic hyperinflation measurements were performed both at baseline and 6 months after BLVR with endobronchial valves or coils (treatment group) or SoC (control group). RESULTS Eighteen patients underwent BLVR (78% female, 57 (43-67) years, FEV 1 25(18-37) %predicted, residual volume 231 (182-376) %predicted). Thirteen patients received SoC (100% female, 59 (44-74) years, FEV 1 25 (19-37) %predicted, residual volume 225 (152-279) %predicted. The 6 months median change in dynamic hyperinflation in the treatment group was: + 225 ml (range - 113 to + 803) (p < 0.01) vs 0 ml (- 1067 to + 500) in the control group (p = 0.422). An increase in dynamic hyperinflation was significantly associated with a decrease in residual volume (r = - 0.439, p < 0.01). CONCLUSION Bronchoscopic lung volume reduction increases the ability for dynamic hyperinflation in patients with severe emphysema. We propose this is a consequence of improved static hyperinflation.",2020,"An increase in dynamic hyperinflation was significantly associated with a decrease in residual volume (r = - 0.439, p < 0.01). ","['patients with severe emphysema', 'Patients with Emphysema']","['endobronchial valves or coils (treatment group) or SoC (control group', 'Bronchoscopic lung volume reduction', 'BLVR', 'standard of care (SoC', 'Static hyperinflation']","['Dynamic Hyperinflation', 'inspiratory capacity (IC', 'residual volume', 'dynamic hyperinflation', 'Static and dynamic hyperinflation measurements']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0013990', 'cui_str': 'Emphysema'}]","[{'cui': 'C3880733', 'cui_str': 'Endobronchial valve'}, {'cui': 'C0419518', 'cui_str': 'Contraceptive coil'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3697654', 'cui_str': 'Bronchoscopic lung volume reduction'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0020449', 'cui_str': 'Hyperdistention'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0020449', 'cui_str': 'Hyperdistention'}, {'cui': 'C0021610', 'cui_str': 'Inspiratory capacity'}, {'cui': 'C0035190', 'cui_str': 'Residual respiratory volume'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",18.0,0.0337627,"An increase in dynamic hyperinflation was significantly associated with a decrease in residual volume (r = - 0.439, p < 0.01). ","[{'ForeName': 'Marlies', 'Initials': 'M', 'LastName': 'van Dijk', 'Affiliation': 'Department of Pulmonary Diseases, University Medical Center Groningen, Research Institute for Asthma and COPD Groningen, University of Groningen, Groningen, The Netherlands. m.van.dijk05@umcg.nl.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Klooster', 'Affiliation': 'Department of Pulmonary Diseases, University Medical Center Groningen, Research Institute for Asthma and COPD Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Jorine E', 'Initials': 'JE', 'LastName': 'Hartman', 'Affiliation': 'Department of Pulmonary Diseases, University Medical Center Groningen, Research Institute for Asthma and COPD Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Nick H T', 'Initials': 'NHT', 'LastName': 'Ten Hacken', 'Affiliation': 'Department of Pulmonary Diseases, University Medical Center Groningen, Research Institute for Asthma and COPD Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Dirk-Jan', 'Initials': 'DJ', 'LastName': 'Slebos', 'Affiliation': 'Department of Pulmonary Diseases, University Medical Center Groningen, Research Institute for Asthma and COPD Groningen, University of Groningen, Groningen, The Netherlands.'}]",Lung,['10.1007/s00408-020-00382-x'] 2761,32710396,Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.,"BACKGROUND Alemtuzumab efficacy versus subcutaneous interferon-β-1a (SC IFNB-1a) was demonstrated over 2 years in patients with relapsing-remitting multiple sclerosis, with continued efficacy over 7 additional years. Alemtuzumab is included as a recommended treatment for patients with highly active disease (HAD) by the American Academy of Neurology Practice Guidelines, and the label indication in Europe was recently restricted to the treatment of HAD patients. There is currently no consensus definition for HAD, and alemtuzumab efficacy across various HAD definitions has not been explored previously. OBJECTIVES In this post hoc analysis, we assess the efficacy and safety of alemtuzumab in Comparison of Alemtuzumab and Rebif ® Efficacy in Multiple Sclerosis (CARE-MS) trial patients who met criteria for at least one of four separate definitions of HAD (one primary and three alternatives). Over 2 years, alemtuzumab-treated HAD patients were compared with SC IFNB-1a-treated HAD patients, with additional 7-year follow-up in patients from the alemtuzumab arm. METHODS Patients in the CARE-MS studies received either alemtuzumab (baseline: 5 days; 12 months later: 3 days) or SC IFNB-1a (3 times weekly). Alemtuzumab-treated patients who enrolled in the extensions could receive additional courses ≥ 12 months apart. Four definitions of HAD were applied to assess alemtuzumab efficacy: the pre-specified primary definition (two or more relapses in the year prior to baseline and at least one gadolinium [Gd]-enhancing lesion at baseline) and three alternative definitions that focused on relapse, magnetic resonance imaging (MRI), or prior treatment response criteria. Efficacy outcomes were annualized relapse rate, change in Expanded Disability Status Scale score, 6-month confirmed disability worsening, 6-month confirmed disability improvement, MRI disease activity, and brain volume change. Adverse events were summarized for HAD patients meeting the primary definition. RESULTS In the pooled CARE-MS population, 208 alemtuzumab-treated patients met the primary HAD definition. Annualized relapse rate was 0.27 in years 0-2 and 0.16 in years 3-9. Over 9 years, 62% of patients were free of 6-month confirmed disability worsening, 50% had 6-month confirmed disability improvement, and median cumulative change in brain volume was - 2.15%. During year 9, 62% had no evidence of disease activity, and 69% were free of MRI disease activity. Similar efficacy outcomes were observed using an alternative relapse-driven HAD definition. For patients meeting alternative HAD definitions focused on either higher MRI lesion counts or disease activity while on prior therapy, reduced efficacy for some endpoints was seen. Safety was consistent with the overall CARE-MS population through year 9. CONCLUSIONS Over 9 years, alemtuzumab efficacy was maintained in CARE-MS HAD patients based on four HAD definitions. These results support intervention with alemtuzumab in patients with early indicators of HAD, including frequent relapse without high MRI activity. No safety signals were observed over 9 years that were unique to the HAD populations. CLINICALTRIALS. GOV IDENTIFIERS NCT00530348; NCT00548405; NCT00930553; NCT02255656.",2020,Annualized relapse rate was 0.27 in years 0-2 and 0.16 in years 3-9.,"['patients with relapsing-remitting multiple sclerosis', 'Multiple Sclerosis (CARE-MS) trial patients who met criteria for at least one of four separate definitions of HAD', 'Patients in the CARE-MS studies received either', 'Patients with Highly Active Disease', 'treated patients who enrolled in the extensions could receive additional courses ≥', 'patients with highly active disease (HAD) by the American Academy of Neurology Practice Guidelines']","['subcutaneous interferon-β-1a (SC IFNB-1a', 'Alemtuzumab', 'alemtuzumab', 'alemtuzumab (baseline: 5\xa0days; 12\xa0months later: 3\xa0days) or SC IFNB-1a']","['annualized relapse rate, change in Expanded Disability Status Scale score, 6-month confirmed disability worsening, 6-month confirmed disability improvement, MRI disease activity, and brain volume change', 'Efficacy and Safety', 'alternative relapse-driven HAD definition', 'disease activity', 'Adverse events', 'free of MRI disease activity', 'MRI lesion counts or disease activity', 'efficacy and safety', 'alemtuzumab efficacy', 'Annualized relapse rate', 'disability improvement, and median cumulative change in brain volume']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751967', 'cui_str': 'Relapsing remitting multiple sclerosis'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0000876', 'cui_str': 'Academies'}, {'cui': 'C0027855', 'cui_str': 'Neurology'}, {'cui': 'C0162793', 'cui_str': 'Practice Guidelines as Topic'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0383429', 'cui_str': 'alemtuzumab'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205087', 'cui_str': 'Late'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0383429', 'cui_str': 'alemtuzumab'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",,0.0685088,Annualized relapse rate was 0.27 in years 0-2 and 0.16 in years 3-9.,"[{'ForeName': 'Tjalf', 'Initials': 'T', 'LastName': 'Ziemssen', 'Affiliation': 'Center of Clinical Neuroscience, University Clinic Carl Gustav Carus, Fetscherstr. 74, 01307, Dresden, Germany. Tjalf.Ziemssen@uniklinikum-dresden.de.'}, {'ForeName': 'Ann D', 'Initials': 'AD', 'LastName': 'Bass', 'Affiliation': 'Neurology Center of San Antonio, San Antonio, TX, USA.'}, {'ForeName': 'Regina', 'Initials': 'R', 'LastName': 'Berkovich', 'Affiliation': 'Regina Berkovich, MD, PhD, Inc., West Hollywood, CA, USA.'}, {'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Comi', 'Affiliation': 'Ospedale San Raffaele, Milan, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Eichau', 'Affiliation': 'Hospital Universitario Virgen Macarena, Seville, Spain.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Hobart', 'Affiliation': 'Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK.'}, {'ForeName': 'Samuel F', 'Initials': 'SF', 'LastName': 'Hunter', 'Affiliation': 'Advanced Neurosciences Institute, Franklin, TN, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'LaGanke', 'Affiliation': 'North Central Neurology Associates, Cullman, AL, USA.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Limmroth', 'Affiliation': 'Klinik für Neurologie und Palliativmedizin, Cologne, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Pelletier', 'Affiliation': 'Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Pozzilli', 'Affiliation': 'Department of Human Neuroscience, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Schippling', 'Affiliation': 'Neuroimmunology and Multiple Sclerosis Research, University Hospital Zürich and University of Zürich, Zürich, Switzerland.'}, {'ForeName': 'Livia', 'Initials': 'L', 'LastName': 'Sousa', 'Affiliation': 'Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Traboulsee', 'Affiliation': 'University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Bernard M J', 'Initials': 'BMJ', 'LastName': 'Uitdehaag', 'Affiliation': 'Amsterdam University Medical Centers, Amsterdam, The Netherlands.'}, {'ForeName': 'Bart', 'Initials': 'B', 'LastName': 'Van Wijmeersch', 'Affiliation': 'Rehabilitation and MS-Centre Overpelt, BIOMED, Hasselt University, Hasselt, Belgium.'}, {'ForeName': 'Zia', 'Initials': 'Z', 'LastName': 'Choudhry', 'Affiliation': 'Sanofi, Cambridge, MA, USA.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Daizadeh', 'Affiliation': 'Sanofi, Cambridge, MA, USA.'}, {'ForeName': 'Barry A', 'Initials': 'BA', 'LastName': 'Singer', 'Affiliation': 'MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",CNS drugs,['10.1007/s40263-020-00749-x'] 2762,32710457,Randomized controlled trial of genotype-guided warfarin anticoagulation in Chinese elderly patients with nonvalvular atrial fibrillation.,"WHAT IS KNOWN AND OBJECTIVE Warfarin is an oral anticoagulant which has been widely used to treat and prevent thromboembolic events. Managing warfarin therapy requires careful monitoring and dose titration. This randomized controlled study was designed to assess the effect of genotype-guided warfarin anticoagulation in Chinese elderly patients with nonvalvular atrial fibrillation. METHODS 507 adults were randomized to receive initial dosing as determined by an algorithm containing genetic (VKORC1 and CYP2C9) plus clinical information or only clinical information. The primary endpoint was the time in therapeutic range (TTR) over 90 days. Secondary end points included haemorrhagic events, thrombotic events and mortality. RESULTS The TTR was significantly different between genetic group and control group. The average TTR was (70.80 ± 24.39) % in the genotype-guided group as compared with (53.44 ± 26.73) % in the control group. This represents a difference of 17.36% (95% CI, 11.82 to 22.89, P < .001). The cumulative incidence of total haemorrhagic events, minor haemorrhagic events, gastrointestinal bleeding and intracerebral bleeding events was not significantly different between two groups (P > .05). Follow-up showed that the cumulative incidence of ischaemic stroke events occurred in the genetic group was significantly lower than that in the control group (2.39% vs 6.82%), and the genetic group had a significant lower risk than control group in cumulative incidence of ischaemic stroke events [HR 0.22, (95% CI 0.065 to 0.77), P < .05]. WHAT IS NEW AND CONCLUSION Genotype-guided dosing could improve the average TTR, and follow-up result showed that genotype-guided therapy resulted in a significantly lower risk of ischaemic stroke events. Further research is required to focus on the clinical benefit of genotype-guided dosing.",2020,"The cumulative incidence of total haemorrhagic events, minor haemorrhagic events, gastrointestinal bleeding and intracerebral bleeding events was not significantly different between two groups (P > .05).","['Chinese elderly patients with nonvalvular atrial fibrillation', '507 adults']","['algorithm containing genetic (VKORC1 and CYP2C9) plus clinical information or only clinical information', 'genotype-guided warfarin anticoagulation']","['TTR', 'haemorrhagic events, thrombotic events and mortality', 'average TTR', 'time in therapeutic range (TTR', 'cumulative incidence of total haemorrhagic events, minor haemorrhagic events, gastrointestinal bleeding and intracerebral bleeding events', 'ischaemic stroke events', 'cumulative incidence of ischaemic stroke events']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0450381', 'cui_str': '507'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0017296', 'cui_str': 'Gene therapy'}, {'cui': 'C0608437', 'cui_str': 'CYP2C9 protein, human'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}]","[{'cui': 'C0460097', 'cui_str': 'Within therapeutic range'}, {'cui': 'C0333275', 'cui_str': 'Hemorrhagic'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0026193', 'cui_str': 'Minor'}, {'cui': 'C0017181', 'cui_str': 'Gastrointestinal hemorrhage'}, {'cui': 'C0442111', 'cui_str': 'Intracerebral'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}]",507.0,0.0767278,"The cumulative incidence of total haemorrhagic events, minor haemorrhagic events, gastrointestinal bleeding and intracerebral bleeding events was not significantly different between two groups (P > .05).","[{'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': 'Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu, China.'}]",Journal of clinical pharmacy and therapeutics,['10.1111/jcpt.13218'] 2763,32710485,Friend or foe? Postdivorce hostility among recently divorced individuals.,"High levels of hostility often occur during and postdivorce and may significantly affect the quality of life, parent-child relationships, and social functioning of divorcees. Moreover, hostility may predict aggressive and violent behavior. This study sought to (a) compare average general hostility levels of a large sample of Danish divorcees to the norms of the general adult Danish population, (b) compare general hostility levels between male and female divorcees, and (c) investigate the explanatory value of various sociodemographic and divorce-related factors on postdivorce general hostility and whether these factors differ across gender. Cross-sectional baseline data (N = 1,856) from a larger randomized controlled trial study was used in this study. Normative data from a general sample of Danish adults (N = 2,040) was used for comparisons of hostility levels between our study sample and the Danish background population. This study found that male and female divorcees did not report significantly different hostility levels. However, participants reported significantly higher hostility levels postdivorce than the comparative Danish norm sample. Significant predictors of postdivorce hostility were lower age, lower educational level, infidelity as a reason for divorce, higher degree of postdivorce conflict, worse communication with the former spouse, the former spouse as the initiator of the divorce, and new partner status with neither divorcees having a new partner, or only the former spouse having a new partner. The predictive strength of the factors did not differ across gender. The findings may be especially relevant for interventions targeting problematic outcomes postdivorce (e.g., preventing aggressive behavior).",2020,The predictive strength of the factors did not differ across gender.,"['Normative data from a general sample of Danish adults (N\u2009=\u20092,040']",[],"['hostility levels', 'Postdivorce hostility', 'quality of life, parent-child relationships, and social functioning of divorcees', 'postdivorce hostility', 'hostility levels postdivorce']","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0010969', 'cui_str': 'Danish language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]",[],"[{'cui': 'C0020039', 'cui_str': 'Hostile behavior'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030542', 'cui_str': 'Parent-Child Relationship'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}]",,0.0567494,The predictive strength of the factors did not differ across gender.,"[{'ForeName': 'Simone G', 'Initials': 'SG', 'LastName': 'Kjeld', 'Affiliation': 'Department of Public Health, University of Copenhagen, København K, Denmark.'}, {'ForeName': 'Jenna M', 'Initials': 'JM', 'LastName': 'Strizzi', 'Affiliation': 'Department of Public Health, University of Copenhagen, København K, Denmark.'}, {'ForeName': 'Camilla S', 'Initials': 'CS', 'LastName': 'Øverup', 'Affiliation': 'Department of Public Health, University of Copenhagen, København K, Denmark.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Cipric', 'Affiliation': 'Department of Public Health, University of Copenhagen, København K, Denmark.'}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Sander', 'Affiliation': 'Department of Public Health, University of Copenhagen, København K, Denmark.'}, {'ForeName': 'Gert M', 'Initials': 'GM', 'LastName': 'Hald', 'Affiliation': 'Department of Public Health, University of Copenhagen, København K, Denmark.'}]",Aggressive behavior,['10.1002/ab.21918'] 2764,32710493,"Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials.","OBJECTIVE Psoriatic arthritis (PsA) requires long-term treatment, yet safety concerns and monitoring requirements make maintenance a challenge. This analysis of pooled Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) 1, 2, and 3 data describes 3-year apremilast safety and tolerability in PsA. METHODS Patients with active PsA were randomized (1:1:1) to placebo, apremilast 30 mg twice daily, or apremilast 20 mg twice daily. Placebo patients were re-randomized to apremilast 30 mg twice daily or 20 mg twice daily at week 16 (early escape) or 24. Double-blind treatment continued to week 52; patients could continue apremilast during an open-label, long-term treatment phase. RESULTS In total, 1493 patients received at least one dose of study medication and were included in the safety population (placebo: n = 495; apremilast 30 mg: n = 497; apremilast 20 mg: n = 501). Among patients receiving apremilast, 53.2% (767/1441) completed 3 years of treatment. Greater rates of adverse events (AEs) were reported with apremilast (61.1%; exposure-adjusted incidence rate [EAIR]/100 patient-years, 265.1) versus placebo (47.5%; EAIR/100 patient-years, 200.7) in the placebo-controlled period. During weeks 0 to ≤52, the most common AEs occurring in apremilast-exposed patients were diarrhea (13.9%; EAIR/100 patient-years, 18.6), nausea (12.3%; EAIR/100 patient-years, 16.0), headache (9.4%; EAIR/100 patient-years, 12.1), upper respiratory tract infection (9.1%; EAIR/100 patient-years, 11.5), and nasopharyngitis (6.2%; EAIR/100 patient-years, 7.7). Most AEs were mild/moderate with apremilast exposure ≤156 weeks. Rates of depression remained low (EAIR/100 patient-years, 1.8). Major adverse cardiac events (EAIR/100 patient-years, 0.5), malignancies (EAIR/100 patient-years, 0.9), and serious opportunistic infections (EAIR/100 patient-years, 0.0) were infrequent over the 3-year exposure period. Discontinuation rates due to AEs were low (<7.5%) across all apremilast-exposure periods. Incidences of clinically meaningful abnormalities in postbaseline laboratory values was low; most values returned to baseline levels with continued treatment and without intervention. CONCLUSION Apremilast demonstrated a favorable safety profile and was well tolerated up to 156 weeks.",2020,"Among patients receiving apremilast, 53.2% (767/1441) completed 3 years of treatment.","['Patients with active PsA', '1493 patients received at least one dose of study medication and were included in the safety population ', 'Psoriatic Arthritis', 'patients receiving apremilast, 53.2% (767/1441) completed 3 years of treatment']","['Apremilast Versus Placebo', 'Placebo', 'placebo, apremilast 30 mg twice daily, or apremilast 20 mg twice daily', 'placebo']","['headache', 'diarrhea', 'Rates of depression', 'serious opportunistic infections', 'upper respiratory tract infection', 'nasopharyngitis', 'Greater rates of adverse events (AEs', 'nausea', 'Major adverse cardiac events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0003872', 'cui_str': 'Psoriatic arthritis'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1678805', 'cui_str': 'apremilast'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C1678805', 'cui_str': 'apremilast'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3819585', 'cui_str': 'apremilast 30 MG [Otezla]'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C3819586', 'cui_str': 'apremilast 20 MG [Otezla]'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0029118', 'cui_str': 'Opportunistic infectious disease'}, {'cui': 'C0041912', 'cui_str': 'Upper respiratory infection'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",1493.0,0.225162,"Among patients receiving apremilast, 53.2% (767/1441) completed 3 years of treatment.","[{'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Mease', 'Affiliation': 'Swedish Medical Center/Providence St. Joseph Health, Seattle, Washington and University of Washington School of Medicine, Seattle.'}, {'ForeName': 'Dafna D', 'Initials': 'DD', 'LastName': 'Gladman', 'Affiliation': 'Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada.'}, {'ForeName': 'Juan J', 'Initials': 'JJ', 'LastName': 'Gomez-Reino', 'Affiliation': 'Fundación Dominguez, Hospital Clínico Universitario, Santiago, Spain.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Hall', 'Affiliation': 'Monash University, Cabrini Health, Melbourne, Australia.'}, {'ForeName': 'Arthur', 'Initials': 'A', 'LastName': 'Kavanaugh', 'Affiliation': 'University of California San Diego School of Medicine, La Jolla.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Lespessailles', 'Affiliation': 'Regional Hospital, University of Orléans, Orléans, France.'}, {'ForeName': 'Georg', 'Initials': 'G', 'LastName': 'Schett', 'Affiliation': 'Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany und Universitätsklinikum Erlangen, Erlangen, Germany.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Paris', 'Affiliation': 'Amgen Inc, Thousand Oaks, California.'}, {'ForeName': 'Nikolay', 'Initials': 'N', 'LastName': 'Delev', 'Affiliation': 'Celgene Corporation, Summit, New Jersey.'}, {'ForeName': 'Lichen', 'Initials': 'L', 'LastName': 'Teng', 'Affiliation': 'Amgen Inc, Thousand Oaks, California.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Wollenhaupt', 'Affiliation': 'Jürgen Wollenhaupt: Schön Klinik Hamburg Eilbek, Hamburg, Germany.'}]",ACR open rheumatology,['10.1002/acr2.11156'] 2765,32710628,"Dropout, response, and abstinence outcomes of a national text-messaging smoking cessation intervention for teens, SmokeFreeTeen.","Although text-messaging interventions are effective for smoking cessation, few target teens in the USA and little is known about their effectiveness. The purpose of this manuscript is to examine correlates of dropout, response to smoking status prompts, and abstinence rates among subscribers of SmokeFreeTeen, a free, publicly available text-messaging smoking cessation intervention sponsored by the National Cancer Institute's SmokeFree.Gov initiative, on quit day through 1 month follow-up. In a sample of teens (N = 2,685), aged 13-19, we examined demographics, smoking frequency, cigarettes smoked per day, prequit intervention time (i.e., maximum of 14 days of prequit day preparation), and number of quit attempts as correlates of response and abstinence rates among program initiators (i.e., participants who reached quit day but dropped out on or before intervention end) and completers (i.e., participants who reached quit day and completed the intervention). We also conducted Cox regression analysis of time from quit day to dropout by daily and nondaily smoking status. Two-thirds (n = 1,733, 64.54%) dropped out before the intervention ended, with dropout rates peaking on quit day (n = 289, 13.10%). Response rate to smoking status prompts remained below 30% throughout the intervention. At intervention end and 1 month follow-up, abstinence was 2.63% and 2.55% among program initiators, whereas abstinence was 6.09% and 6.01% among program completers. Dropout, response, and abstinence rates did not consistently differ by subscriber characteristics. Prequit time was associated with decreased likelihood of dropping out (adjusted hazards ratio: 0.94, confidence interval [CI]: 0.93-0.95), responding to smoking status prompts (adjusted odds ratio [aOR]: 0.94, CI: 0.92-0.96), and being abstinent (aOR: 0.96, CI: 0.93-0.99) on quit day. Two or more quit attempts were associated with increased response (aOR: 1.61, CI: 1.16-2.23) and abstinence (aOR: 1.91, CI: 1.25-2.92) rates on Day 7. In a first assessment of SmokeFreeTeen outcomes, we document high dropouts and low response and abstinence rates. SmokeFreeTeen produced abstinence rates lower than comparable text-messaging interventions targeting teens and young adults. Improving SmokeFreeTeen's reach, engagement, and effectiveness is needed.",2020,"Two or more quit attempts were associated with increased response (aOR: 1.61, CI: 1.16-2.23) and abstinence (aOR: 1.91, CI: 1.25-2.92) rates on Day 7.","['In a sample of teens (N = 2,685), aged 13-19, we examined demographics, smoking frequency, cigarettes smoked per day, prequit intervention time (i.e., maximum of 14 days of prequit day preparation), and number of quit attempts as correlates of response and abstinence rates among program initiators (i.e., participants who reached quit day but dropped out on or before intervention end) and completers (i.e., participants who reached quit day and completed the intervention']",['national text-messaging smoking cessation intervention'],"['Dropout, response, and abstinence rates', 'Dropout, response, and abstinence outcomes', 'abstinence rates', 'high dropouts and low response and abstinence rates']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C1444748', 'cui_str': 'Evoked'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0233535', 'cui_str': 'Butting'}, {'cui': 'C0439787', 'cui_str': 'Out'}, {'cui': 'C0444930', 'cui_str': 'End'}]","[{'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C1692317', 'cui_str': 'Smoking cessation assistance'}]","[{'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",2685.0,0.0453291,"Two or more quit attempts were associated with increased response (aOR: 1.61, CI: 1.16-2.23) and abstinence (aOR: 1.91, CI: 1.25-2.92) rates on Day 7.","[{'ForeName': 'Charmaine', 'Initials': 'C', 'LastName': 'Chan', 'Affiliation': 'Intramural Research Program, National Institute on Minority Health and Health Disparities, Bethesda, MD, USA.'}, {'ForeName': 'Kristyn', 'Initials': 'K', 'LastName': 'Kamke', 'Affiliation': 'Intramural Research Program, National Institute on Minority Health and Health Disparities, Bethesda, MD, USA.'}, {'ForeName': 'Freda', 'Initials': 'F', 'LastName': 'Assuah', 'Affiliation': 'ICF International Rockville, MD, USA.'}, {'ForeName': 'Sherine', 'Initials': 'S', 'LastName': 'El-Toukhy', 'Affiliation': 'Intramural Research Program, National Institute on Minority Health and Health Disparities, Bethesda, MD, USA.'}]",Translational behavioral medicine,['10.1093/tbm/ibaa069'] 2766,32710658,Hospital Elder Life Program in Long-Term Care (HELP-LTC): A Cluster Randomized Controlled Trial.,"BACKGROUND/OBJECTIVES The Hospital Elder Life Program (HELP) has been shown to prevent delirium in hospitalized older adults. The objective of this study was to test the efficacy of HELP adapted to long-term care (HELP-LTC). DESIGN Cluster randomized controlled trial. SETTING A 514-bed academic urban nursing home. PARTICIPANTS A total of 219 long-term nursing home residents who developed an acute illness or change in condition were randomly assigned to HELP-LTC (n = 105) or usual care (n = 114) by unit. INTERVENTION HELP-LTC is a multicomponent intervention targeting delirium risk factors of cognitive impairment, immobility, dehydration, and malnutrition. Two certified nursing assistants (CNAs) delivered HELP-LTC components twice daily 7 days per week. In addition, recommendations were given to primary providers to reduce medications associated with delirium. MEASUREMENTS Delirium (primary outcome) and delirium severity were ascertained each weekday by a research assistant blinded to group assignment, using the Confusion Assessment Method (CAM) and CAM severity score (CAM-S), respectively. Cognitive function was determined using the Cognitive Performance Scale (CPS). Hospitalization was ascertained by chart review. RESULTS Participants were 81.7 years of age on average and 65.3% female. At baseline, usual care group participants had better cognitive function than intervention group participants (CPS = 1.33 vs 2.25; P = .004). Delirium symptoms declined over the course of the episode (mean CAM-S = 3.63 at start vs 3.27 at end). Overall, 33.8% of the total sample experienced incident delirium. After adjusting for baseline cognitive function, no significant differences were found in delirium or delirium severity between intervention and usual care groups. Hospitalization was not significantly different between groups. CONCLUSION An intervention targeting delirium risk in long-term nursing home residents did not prevent delirium or reduce delirium symptoms. Baseline differences in cognitive function between groups, greater than expected improvements in both groups, quality-enhancing practices such as consistent assignments delivered to both groups, and adaptations of the intervention may have biased results toward null.",2020,"After adjusting for baseline cognitive function, no significant differences were found in delirium or delirium severity between intervention and usual care groups.","['A total of 219 long-term nursing home residents who developed an acute illness or change in condition', 'Participants were 81.7\u2009years of age on average and 65.3% female', 'hospitalized older adults', 'n = 105) or usual care (n = 114) by unit', 'A 514-bed academic urban nursing home']","['LTC', 'Hospital Elder Life Program in Long-Term Care (HELP-LTC', 'HELP-LTC']","['Confusion Assessment Method (CAM) and CAM severity score (CAM-S', 'Hospitalization', 'Delirium symptoms', 'Delirium (primary outcome) and delirium severity', 'cognitive function', 'Cognitive function', 'Cognitive Performance Scale (CPS', 'delirium or delirium severity', 'incident delirium']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517648', 'cui_str': '219'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}]","[{'cui': 'C4521843', 'cui_str': 'US Military Commissioned Officer O5'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]","[{'cui': 'C0009676', 'cui_str': 'Confusional state'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",219.0,0.256808,"After adjusting for baseline cognitive function, no significant differences were found in delirium or delirium severity between intervention and usual care groups.","[{'ForeName': 'Kenneth S', 'Initials': 'KS', 'LastName': 'Boockvar', 'Affiliation': 'The New Jewish Home, New York, New York, USA.'}, {'ForeName': 'Kimberly M', 'Initials': 'KM', 'LastName': 'Judon', 'Affiliation': 'James J. Peters VA Medical Center, Bronx, New York, USA.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'Eimicke', 'Affiliation': 'Research Division, Hebrew Home at Riverdale, Bronx, New York, USA.'}, {'ForeName': 'Jeanne A', 'Initials': 'JA', 'LastName': 'Teresi', 'Affiliation': 'Research Division, Hebrew Home at Riverdale, Bronx, New York, USA.'}, {'ForeName': 'Sharon K', 'Initials': 'SK', 'LastName': 'Inouye', 'Affiliation': 'Aging Brain Center, Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA.'}]",Journal of the American Geriatrics Society,['10.1111/jgs.16695'] 2767,32710677,"Rationale, design, and baseline characteristics of the Salt Substitute in India Study (SSiIS): the protocol for a double-blinded, randomized-controlled trial.","Reduced-sodium, added-potassium salt substitutes have favorable effects on blood pressure, but have not been tested in India. The Salt Substitute in India Study (SSiIS) is a double-blinded, randomized-controlled trial designed to investigate the effects of reduced-sodium, added-potassium salt substitution to replace usual cooking salt use and blood pressure (BP) among hypertensive patients in rural India. The primary objective is to assess effects on systolic blood pressure at 3 months. The secondary objectives are to determine effects on diastolic blood pressure, urinary sodium, and potassium levels, and to determine acceptability of the intervention. Eligible individuals received usual salt (100% sodium chloride) or salt substitute (70% sodium chloride and 30% potassium chloride) to replace all salt required for cooking and seasoning in the household. A total of 502 participants aged ≥18 years with a history of hypertension were successfully recruited and randomized in a 1:1 ratio to intervention or control, between November 2019 and January 2020. Mean blood pressure at baseline was 133.5/83.6 mm Hg and 96% were using one or more blood pressure-lowering medications. The overall mean average 24-hour urinary sodium excretion was 2825 (SD, 1166) mg/L, which corresponds to a urinary salt excretion of 10.4 g/d. Baseline findings suggest sodium intake in this population significantly exceeds World Health Organization recommendations. The SSiIS trial has successfully recruited participants and is well placed to determine whether salt substitution is an effective means of lowering blood pressure for rural Indian patients with hypertension.",2020,Mean blood pressure at baseline was 133.5/83.6 mm ,"['rural Indian patients with hypertension', '502 participants aged ≥18\xa0years with a history of hypertension were successfully recruited and randomized in a 1:1 ratio to intervention or control, between November 2019 and January 2020', 'hypertensive patients in rural India']","['reduced-sodium, added-potassium salt substitution', 'usual salt (100% sodium chloride) or salt substitute (70% sodium chloride and 30% potassium chloride) to replace all salt required for cooking and seasoning in the household']","['blood pressure', 'blood pressure-lowering medications', 'diastolic blood pressure, urinary sodium, and potassium levels', 'blood pressure (BP', 'systolic blood pressure', 'Mean blood pressure', 'overall mean average 24-hour urinary sodium excretion']","[{'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0455527', 'cui_str': 'H/O: hypertension'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0021201', 'cui_str': 'India'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0032821', 'cui_str': 'Potassium'}, {'cui': 'C0036140', 'cui_str': 'Salts'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0037494', 'cui_str': 'Sodium Chloride'}, {'cui': 'C0032825', 'cui_str': 'Potassium Chloride'}, {'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C0335326', 'cui_str': 'Cookery'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}, {'cui': 'C0020052', 'cui_str': 'Households'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0202194', 'cui_str': 'Potassium measurement'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}]",502.0,0.448347,Mean blood pressure at baseline was 133.5/83.6 mm ,"[{'ForeName': 'Sudhir Raj', 'Initials': 'SR', 'LastName': 'Thout', 'Affiliation': 'The George Institute for Global Health India, Punjagutta, Hyderabad, India.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Maoyi', 'Initials': 'M', 'LastName': 'Tian', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Mark D', 'Initials': 'MD', 'LastName': 'Huffman', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Arnott', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Praveen', 'Initials': 'P', 'LastName': 'Devarsetty', 'Affiliation': 'The George Institute for Global Health India, Punjagutta, Hyderabad, India.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Johnson', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Pettigrew', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Neal', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Jason H Y', 'Initials': 'JHY', 'LastName': 'Wu', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Sydney, Australia.'}]","Journal of clinical hypertension (Greenwich, Conn.)",['10.1111/jch.13947'] 2768,32615171,Unique skin abnormality in patients with peanut allergy but no atopic dermatitis.,"BACKGROUND The nonlesional skin of children with atopic dermatitis (AD) with peanut allergy (PA) is associated with increased transepidermal water loss; low urocanic acid (UCA) and pyrrolidone carboxylic acid (PCA), both of which are filaggrin breakdown products; and a reduced ratio of esterified ω-hydroxy fatty acid sphingosine ceramides (EOS-CERs) to nonhydroxy fatty acid sphingosine ceramides (NS-CERs) in the skin. The skin barrier of subjects with PA without AD (AD - PA + ) has not been studied. OBJECTIVE Our aim was to explore whether AD - PA + is associated with skin barrier abnormalities. METHODS A total of 33 participants were enrolled, including 13 AD - PA + , 9 AD + PA + , and 11 nonatopic (NA) participants. RESULTS The PCA content in the stratum corneum of AD - PA + subjects was significantly reduced versus that in NA subjects (median level, 67 vs 97 μg/mg protein [P = .028]). The ratio between cis- and trans-UCA decreased significantly from being highest in the NA group (1.62) to lowest in AD + PA + group (0.07 [P < .001 vs in the NA group; P = .006 vs in the AD - PA + group]), with the AD - PA + group having an intermediate cis/trans-UCA ratio (1.17 [P = .024 vs in the NA group]). The TEWL in AD - PA + subjects did not differ from that in the group with NA skin. Interestingly, AD - PA + subjects had an increased EOS/NS-CER ratio versus that in the group of subjects with NA skin (1.9 vs 1.3 [P = .008]), whereas the AD + PA + group had a decreased proportion of EOS-CERs (0.8 [P = .001] vs in the AD - PA + group). CONCLUSION Our data demonstrate that irrespective of AD, PA is associated with decreased skin cis-UCA and PCA content. An increase in skin EOS-CER/NS-CER ratio separates the AD - PA + group from the AD + PA + and NA groups.",2020,An increase in skin EOS-CER/NS-CER ratio separates the AD - PA + group from the AD + PA + and NA groups.,"['patients with peanut allergy but no atopic dermatitis', '33 participants were enrolled, including 13 AD - PA + , 9 AD + PA + , and 11 nonatopic (NA) participants', 'children with atopic dermatitis (AD) with peanut allergy (PA']",[],"['skin EOS-CER/NS-CER ratio separates', 'EOS/NS-CER ratio', 'proportion of EOS-CERs', 'ratio between cis- and trans-UCA']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0559470', 'cui_str': 'Allergy to peanut'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",[],"[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0200638', 'cui_str': 'Eosinophil count'}, {'cui': 'C0237504', 'cui_str': 'CER'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0007099', 'cui_str': 'Carcinoma in situ'}, {'cui': 'C0042054', 'cui_str': 'Urocanic acid'}]",33.0,0.0250653,An increase in skin EOS-CER/NS-CER ratio separates the AD - PA + group from the AD + PA + and NA groups.,"[{'ForeName': 'Evgeny', 'Initials': 'E', 'LastName': 'Berdyshev', 'Affiliation': 'Department of Medicine, National Jewish Health, Denver, Colo.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Goleva', 'Affiliation': 'Department of Pediatrics, National Jewish Health, Denver, Colo.'}, {'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Bronova', 'Affiliation': 'Department of Medicine, National Jewish Health, Denver, Colo.'}, {'ForeName': 'Anna-Sofia', 'Initials': 'AS', 'LastName': 'Bronoff', 'Affiliation': 'Department of Pediatrics, National Jewish Health, Denver, Colo.'}, {'ForeName': 'Bryce C', 'Initials': 'BC', 'LastName': 'Hoffman', 'Affiliation': 'Department of Pediatrics, National Jewish Health, Denver, Colo.'}, {'ForeName': 'Marco A', 'Initials': 'MA', 'LastName': 'Ramirez-Gama', 'Affiliation': 'Department of Pediatrics, National Jewish Health, Denver, Colo.'}, {'ForeName': 'Shannon L', 'Initials': 'SL', 'LastName': 'Garcia', 'Affiliation': 'Department of Pediatrics, National Jewish Health, Denver, Colo.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Crumrine', 'Affiliation': 'Department of Dermatology, VA Medical Center/University of California San Francisco, San Francisco, Calif.'}, {'ForeName': 'Peter M', 'Initials': 'PM', 'LastName': 'Elias', 'Affiliation': 'Department of Dermatology, VA Medical Center/University of California San Francisco, San Francisco, Calif.'}, {'ForeName': 'Christine B', 'Initials': 'CB', 'LastName': 'Cho', 'Affiliation': 'Department of Pediatrics, National Jewish Health, Denver, Colo; Department of Pediatrics, University of Colorado, Denver, Colo.'}, {'ForeName': 'Donald Y M', 'Initials': 'DYM', 'LastName': 'Leung', 'Affiliation': 'Department of Pediatrics, National Jewish Health, Denver, Colo; Department of Pediatrics, University of Colorado, Denver, Colo. Electronic address: Leungd@njhealth.org.'}]",The Journal of allergy and clinical immunology,['10.1016/j.jaci.2020.06.015'] 2769,32706658,Scheduled Telephone Support for Internet Cognitive Behavioral Therapy for Depression in Patients at Risk for Dropout: Pragmatic Randomized Controlled Trial.,"BACKGROUND Therapist-supported, internet-delivered cognitive behavioral therapy (iCBT) is efficient in the treatment of depression. However, the optimal mode and intensity of therapist support remain to be identified. Scheduled telephone support (STS) may improve adherence and outcomes but, as it is time- and resource-consuming, should be reserved for patients for whom the usual support may be insufficient. OBJECTIVE This paper aims to reveal whether add-on STS for patients at risk of dropping out improves treatment adherence and symptoms in iCBT for depression. METHODS Among patients participating in an ongoing large observational routine clinical practice study of iCBT for depression delivered nationwide by Helsinki University Hospital (HUS-iCBT), those demonstrating a ≥14-day delay in initiation of treatment received invitations to this subsidiary STS study. A total of 100 consenting patients were randomly allocated to either HUS-iCBT as usual (control group, n=50) or HUS-iCBT plus add-on STS (intervention group, n=50). Proportions of those reaching midtreatment and treatment end point served as the primary outcome; secondary outcomes were change in Beck Depression Inventory (BDI)-measured depressive symptoms and time spent in treatment. RESULTS Add-on STS raised the proportion of patients reaching midtreatment compared with HUS-iCBT as usual (29/50, 58% vs 18/50, 36%; P=.045) and treatment end point (12/50, 24% vs 3/50, 6%; P=.02). Change in BDI score also favored add-on STS (3.63 points vs 1.1 points; P=.049), whereas duration of treatment did not differ. CONCLUSIONS Add-on STS enhances adherence and symptom improvement of patients at risk of dropping out of iCBT for depression in routine clinical practice. TRIAL REGISTRATION International Standard Randomised Controlled Trial Number (ISRCTN) 55123131; http://www.isrctn.com/ISRCTN55123131.",2020,"Change in BDI score also favored add-on STS (3.63 points vs 1.1 points; P=.049), whereas duration of treatment did not differ. ","['patients participating in an ongoing large observational routine clinical practice study of iCBT for depression delivered nationwide by Helsinki University Hospital (HUS-iCBT', '100 consenting patients']","['Scheduled Telephone Support for Internet Cognitive Behavioral Therapy', 'HUS-iCBT as usual (control group, n=50) or HUS-iCBT plus add-on STS (intervention', 'Scheduled telephone support (STS', 'Therapist-supported, internet-delivered cognitive behavioral therapy (iCBT']","['Change in BDI score', 'change in Beck Depression Inventory (BDI)-measured depressive symptoms and time spent in treatment']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C1518527', 'cui_str': 'Observational Study'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0019061', 'cui_str': 'Hemolytic uremic syndrome'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C2711213', 'cui_str': 'Consented'}]","[{'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0019061', 'cui_str': 'Hemolytic uremic syndrome'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2960571', 'cui_str': 'Beck depression inventory score'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",100.0,0.220979,"Change in BDI score also favored add-on STS (3.63 points vs 1.1 points; P=.049), whereas duration of treatment did not differ. ","[{'ForeName': 'Satu', 'Initials': 'S', 'LastName': 'Pihlaja', 'Affiliation': 'Department of Psychiatry, University of Helsinki and Helsinki University Hospital, Hospital District of Helsinki and Uusimaa, Helsinki, Finland.'}, {'ForeName': 'Jari', 'Initials': 'J', 'LastName': 'Lahti', 'Affiliation': 'Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Jari Olavi', 'Initials': 'JO', 'LastName': 'Lipsanen', 'Affiliation': 'Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Ville', 'Initials': 'V', 'LastName': 'Ritola', 'Affiliation': 'Department of Psychiatry, University of Helsinki and Helsinki University Hospital, Hospital District of Helsinki and Uusimaa, Helsinki, Finland.'}, {'ForeName': 'Eero-Matti', 'Initials': 'EM', 'LastName': 'Gummerus', 'Affiliation': 'Department of Psychiatry, University of Helsinki and Helsinki University Hospital, Hospital District of Helsinki and Uusimaa, Helsinki, Finland.'}, {'ForeName': 'Jan-Henry', 'Initials': 'JH', 'LastName': 'Stenberg', 'Affiliation': 'Department of Psychiatry, University of Helsinki and Helsinki University Hospital, Hospital District of Helsinki and Uusimaa, Helsinki, Finland.'}, {'ForeName': 'Grigori', 'Initials': 'G', 'LastName': 'Joffe', 'Affiliation': 'Department of Psychiatry, University of Helsinki and Helsinki University Hospital, Hospital District of Helsinki and Uusimaa, Helsinki, Finland.'}]",Journal of medical Internet research,['10.2196/15732'] 2770,32706659,Predictors of Self-Determined Module Choice in a Web-Based Computer-Tailored Diet and Physical Activity Intervention: Secondary Analysis of Data From a Randomized Controlled Trial.,"BACKGROUND Tailoring an online intervention to participant preferences (eg, by giving participants a choice which modules to follow) may increase engagement in the intervention, motivation for behavioral change, and possibly intervention effects. So far, little is known about what characteristics predict these module choices. Filling this knowledge gap is useful for optimizing program engagement. OBJECTIVE We investigated participant choice for a dietary and/or physical activity (PA) promotion module in our web-based computer-tailored intervention based on self-determination theory (SDT) and motivational interviewing (MI). Furthermore, we investigated which demographic characteristics, current behavior, psychosocial constructs and constructs from SDT and MI, and program-related variables such as advice on which module to follow were associated with these choices. METHODS Observational data were used from the randomized controlled trial MyLifestyleCoach of participants who were randomized into the intervention condition, completed the baseline questionnaire, and made a module choice in the opening session of the intervention. Here, they received advice on their own dietary and PA behavior. At the session's end, they chose which lifestyle modules they would like to follow (both, diet, PA, or no module). Measurements included demographic information; self-reported diet and PA; and several psychosocial, SDT, and MI constructs. In total, data from 619 Dutch adults (59.6% women; mean age was 51.9 [SD 13.5] years) were analyzed. A stepwise multinomial logistic regression analysis was conducted to investigate which characteristics are related to module choice; the diet module served as reference category as almost everyone was advised to follow this module. RESULTS Of this sample, 54.8% (339/619) chose to do both the diet and PA module, 25.4% (157/619) chose to follow the diet module, 17.8% (110/619) preferred to follow no module, and 2.1% (13/619) chose to do the PA module only. Furthermore, it was found that older people, those who consumed more fruit, and those who scored lower on importance to change their current diet were more likely to choose no module compared to the diet module. People who had more motivation to change their current PA and those who received strong advice compared with slight advice to follow the diet module were more likely to choose both modules compared with the diet module only. CONCLUSIONS The results show that more than half of the sample was interested in following both the diet and PA module in this online lifestyle intervention. Several characteristics were found to be related to module choice. A future challenge is to examine how this knowledge can be used to improve future interventions, such as tailoring (messages or content) on specific groups or examining where and how MI could be used to motivate people to make a certain module choice. TRIAL REGISTRATION Netherlands Trial Register NL7333; https://www.trialregister.nl/trial/7333.",2020,"Furthermore, it was found that older people, those who consumed more fruit, and those who scored lower on importance to change their current diet were more likely to choose no module compared to the diet module.","['619 Dutch adults (59.6% women; mean age was 51.9 [SD 13.5] years) were analyzed', 'People who had more motivation to change their current PA and those who received']","['Self-Determined Module Choice in a Web-Based Computer-Tailored Diet and Physical Activity Intervention', 'dietary and/or physical activity (PA) promotion module', 'strong advice', 'self-determination theory (SDT) and motivational interviewing (MI']","['demographic information; self-reported diet and PA; and several psychosocial, SDT, and MI constructs']","[{'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517559', 'cui_str': '13.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0036595', 'cui_str': 'Self Determination'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0036595', 'cui_str': 'Self Determination'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0012931', 'cui_str': 'Recombinant DNA'}]",619.0,0.0446689,"Furthermore, it was found that older people, those who consumed more fruit, and those who scored lower on importance to change their current diet were more likely to choose no module compared to the diet module.","[{'ForeName': 'Juul M J', 'Initials': 'JMJ', 'LastName': 'Coumans', 'Affiliation': 'Department of Health Psychology, Faculty of Psychology, Open University of the Netherlands, Heerlen, Netherlands.'}, {'ForeName': 'Catherine A W', 'Initials': 'CAW', 'LastName': 'Bolman', 'Affiliation': 'Department of Health Psychology, Faculty of Psychology, Open University of the Netherlands, Heerlen, Netherlands.'}, {'ForeName': 'Anke', 'Initials': 'A', 'LastName': 'Oenema', 'Affiliation': 'Department of Health Promotion, Caphri, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Lilian', 'Initials': 'L', 'LastName': 'Lechner', 'Affiliation': 'Department of Health Psychology, Faculty of Psychology, Open University of the Netherlands, Heerlen, Netherlands.'}]",Journal of medical Internet research,['10.2196/15024'] 2771,32706660,Combination of 3-Dimensional Virtual Reality and Hands-On Aromatherapy in Improving Institutionalized Older Adults' Psychological Health: Quasi-Experimental Study.,"BACKGROUND In Taiwan, which has one of the most rapidly aging populations in the world, it is becoming increasingly critical to promote successful aging strategies that are effective, easily usable, and acceptable to institutionalized older adults. Although many practitioners and professionals have explored aromatherapy and identified its psychological benefits, the effectiveness of combining 3-dimensional (3D) virtual reality and hands-on aromatherapy remains unknown. OBJECTIVE A quasi-experimental trial was designed to evaluate the effectiveness of this combination in lowering perceived stress and promoting happiness, sleep quality, meditation experience, and life satisfaction among institutionalized older adults in Taiwan. METHODS A total of 60 institutionalized elderly participants either received the combined intervention or were in a control group. Weekly 2-hour sessions were implemented over 9 weeks. The outcome variables were happiness, perceived stress, sleep quality, meditation experience, and life satisfaction, which were assessed at baseline and after the intervention. RESULTS Generalized estimating equation (GEE) analyses indicated that the experimental group showed significant post-intervention improvements in terms of scores for happiness, perceived stress, sleep quality, meditation experience, and life satisfaction (n=48; all P<.001). Another GEE analysis showed that the significant improvements in the 5 outcome variables persisted in participants aged 80 years and older (n=35; all P<.001). CONCLUSIONS This is the first trial to explore the effectiveness of a combination of 3D virtual reality and hands-on aromatherapy in improving older adults' psychological health. The results are promising for the promotion of psychological health in institutionalized older adults. TRIAL REGISTRATION ClinicalTrials.gov NCT04324216; https://clinicaltrials.gov/ct2/show/NCT04324216.",2020,"RESULTS Generalized estimating equation (GEE) analyses indicated that the experimental group showed significant post-intervention improvements in terms of scores for happiness, perceived stress, sleep quality, meditation experience, and life satisfaction (n=48; all P<.001).","['institutionalized older adults in Taiwan', '60 institutionalized elderly participants', ""older adults' psychological health"", 'participants aged 80 years and older (n=35; all P<.001', 'institutionalized older adults', ""Institutionalized Older Adults' Psychological Health""]","['3-Dimensional Virtual Reality and Hands', 'Aromatherapy', '3D virtual reality and hands-on aromatherapy', 'combined intervention']","['scores for happiness, perceived stress, sleep quality, meditation experience, and life satisfaction', 'lowering perceived stress and promoting happiness, sleep quality, meditation experience, and life satisfaction', 'happiness, perceived stress, sleep quality, meditation experience, and life satisfaction']","[{'cui': 'C0562359', 'cui_str': 'Institutionalized'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0376547', 'cui_str': 'Aromatherapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}]",60.0,0.0374316,"RESULTS Generalized estimating equation (GEE) analyses indicated that the experimental group showed significant post-intervention improvements in terms of scores for happiness, perceived stress, sleep quality, meditation experience, and life satisfaction (n=48; all P<.001).","[{'ForeName': 'Vivian Ya-Wen', 'Initials': 'VY', 'LastName': 'Cheng', 'Affiliation': 'PureAroma Healing Academy, Taipei, Taiwan.'}, {'ForeName': 'Chiu-Mieh', 'Initials': 'CM', 'LastName': 'Huang', 'Affiliation': 'Institute of Clinical Nursing, School of Nursing, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Jung-Yu', 'Initials': 'JY', 'LastName': 'Liao', 'Affiliation': 'Institute of Population Health sciences, National Health Research Institutes, Miaoli, Taiwan.'}, {'ForeName': 'Hsiao-Pei', 'Initials': 'HP', 'LastName': 'Hsu', 'Affiliation': 'Institute of Clinical Nursing, School of Nursing, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Shih-Wen', 'Initials': 'SW', 'LastName': 'Wang', 'Affiliation': 'Department of Health Promotion and Health Education, College of Education, National Taiwan Normal University, Taipei, Taiwan.'}, {'ForeName': 'Su-Fei', 'Initials': 'SF', 'LastName': 'Huang', 'Affiliation': 'Department of Senior Citizen Service, Mackay Junior College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Jong-Long', 'Initials': 'JL', 'LastName': 'Guo', 'Affiliation': 'Department of Health Promotion and Health Education, College of Education, National Taiwan Normal University, Taipei, Taiwan.'}]",Journal of medical Internet research,['10.2196/17096'] 2772,32699645,Internet-based cognitive behavior therapy for problem gambling in routine care: protocol for a non-randomized pilot and feasibility trial.,"Background Problem gambling and gambling disorder are major public health concerns worldwide, and awareness of associated negative consequences is rising. In parallel, treatment demand has increased, and Internet interventions offer a promising alternative for providing evidence-based treatment at scale to a low cost. Method We developed a novel Internet-delivered cognitive behavioral treatment for gambling, based on qualitative interviews with treatment-seeking gamblers, behavioral research on gambling behavior, and the pathway model for problem gambling. This research protocol describes a non-randomized pilot and feasibility trial conducted in routine addiction care with adult treatment-seeking patients (max N = 25) with problem gambling. The primary aim is to ensure acceptability and safety, measured by satisfaction, credibility, working alliance, and possible negative effects. Secondary aims are feasibility of study procedures in terms of recruitment and measurement procedures as well as potential effectiveness measured weekly by gambling symptoms as primary outcome and gambling behavior, quality of life, symptoms of depression and anxiety, alcohol, and drug use as secondary outcomes. Potential mediators measured weekly are loss of control, verbal rules, and well-being. Discussion This study is innovative in several respects, regarding both treatment development and implementation. The results of the study will guide a future randomized controlled trial, as well as the development of the intervention and intervention implementation within ordinary addiction care. Trial registration Clinical trials.gov, NCT ID: NCT03946098. Registered 10 May 2019.",2020,"In parallel, treatment demand has increased, and Internet interventions offer a promising alternative for providing evidence-based treatment at scale to a low cost. ",['routine addiction care with adult treatment-seeking patients (max N = 25) with problem gambling'],"['Internet-based cognitive behavior therapy', 'novel Internet-delivered cognitive behavioral treatment']","['gambling behavior, quality of life, symptoms of depression and anxiety, alcohol, and drug use as secondary outcomes', 'acceptability and safety']","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0085281', 'cui_str': 'Addiction'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0016995', 'cui_str': 'Gambling'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}]","[{'cui': 'C0016995', 'cui_str': 'Gambling'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0449889', 'cui_str': 'Drug used'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.114787,"In parallel, treatment demand has increased, and Internet interventions offer a promising alternative for providing evidence-based treatment at scale to a low cost. ","[{'ForeName': 'Olof', 'Initials': 'O', 'LastName': 'Molander', 'Affiliation': 'Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Lindner', 'Affiliation': 'Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Ramnerö', 'Affiliation': 'Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Bjureberg', 'Affiliation': 'Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Carlbring', 'Affiliation': 'Department of Psychology, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Anne H', 'Initials': 'AH', 'LastName': 'Berman', 'Affiliation': 'Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.'}]",Pilot and feasibility studies,['10.1186/s40814-020-00647-5'] 2773,32699648,"The impact of patient involvement in research: a case study of the planning, conduct and dissemination of a clinical, controlled trial.","Background The interest in patient and public involvement (PPI) in health research is increasing. However, the experience and knowledge of PPI throughout the entire research process and especially in the analysis are limited. We explored ways to embrace the perspectives of patients in a research process, and the impact and challenges our collaboration has had on patients, researchers, and the research outcomes. Methods This is an explorative single case study of a Danish, clinical, controlled intervention trial and a nested intervention fidelity study included herein. Five patient representatives with metastatic melanoma were part of designing, undertaking and disseminating the trial where the effect of using patient-reported outcome (PRO)-measures as a dialogue tool in the patient-physician consultation was tested. In the fidelity study, audio-recorded consultations were analyzed after training in the Verona Coding Definitions of Emotional Sequences (VR-CoDES). Results were jointly disseminated at an international scientific conference. The outcomes, impact, and challenges were explored through a workshop. Results In the design phase, we selected PRO-measures and validated the dialogue tool. The information sheet was adjusted according to the patients' suggestions. The analysis of the fidelity study showed that patients and researchers had a high consensus on the coding of emotional cues and concerns. The patients contributed with a new vocabulary and perspective on the dialogue, and they validated the results. PPI caused considerations related to emotional (sadness/sorrow and existential thoughts), administrative (e.g. arranging meetings, balancing work and small talk) and intellectual (e.g. avoiding information harm, continuing activities despite the death of patients) investments. A limitation of the study was the lack of use of a solid evaluation tool to determine the impact of PPI. Conclusion PPI throughout the process and co-creation in the analysis was feasible and beneficial. The case is unique in the degree of workable details, sustainability, and transparency. Moreover, the co-creation provides ideas of ways to operationalize PPI. An evaluation workshop revealed considerations about emotional, administrative and intellectual investments - best described as tacit, yet important 'work'. This knowledge and experience can be applied to other studies where patients are partners in the research. Trial registration ClinicalTrials.gov ID: NCT03163433, registration date: 8th May 2017.",2020,The analysis of the fidelity study showed that patients and researchers had a high consensus on the coding of emotional cues and concerns.,['Five patient representatives with metastatic melanoma'],[],[],"[{'cui': 'C0030701', 'cui_str': 'Patient Representatives'}, {'cui': 'C0278883', 'cui_str': 'Metastatic melanoma'}]",[],[],,0.0318783,The analysis of the fidelity study showed that patients and researchers had a high consensus on the coding of emotional cues and concerns.,"[{'ForeName': 'Pernille Christiansen', 'Initials': 'PC', 'LastName': 'Skovlund', 'Affiliation': 'Experimental Clinical Oncology, Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark.'}, {'ForeName': 'Berit Kjærside', 'Initials': 'BK', 'LastName': 'Nielsen', 'Affiliation': 'The Research Centre for Patient Involvement, Aarhus University & the Central Region, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark.'}, {'ForeName': 'Henriette Vind', 'Initials': 'HV', 'LastName': 'Thaysen', 'Affiliation': 'The Research Centre for Patient Involvement, Aarhus University & the Central Region, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Schmidt', 'Affiliation': 'Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark.'}, {'ForeName': 'Arnstein', 'Initials': 'A', 'LastName': 'Finset', 'Affiliation': 'Department of Behavioural Sciences in Medicine, Institute of Basic Medical Sciences, University of Oslo, Domus Medica, Gaustad, Sognsvannsveien 9, 0372 Oslo, Norway.'}, {'ForeName': 'Kristian Ahm', 'Initials': 'KA', 'LastName': 'Hansen', 'Affiliation': 'Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Lomborg', 'Affiliation': 'The Research Centre for Patient Involvement, Aarhus University & the Central Region, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark.'}]",Research involvement and engagement,['10.1186/s40900-020-00214-5'] 2774,32699685,Differences Between Esophageal and Tracheal Intubation Ultrasound View Proficiency: An Educational Study of Novice Prehospital Providers.,"Objectives Airway ultrasound is now possible in the prehospital setting due to advances in ultrasound equipment portability. We questioned how well prehospital providers without prior experience could determine both esophageal and tracheal placement of an endotracheal tube in cadavers after a brief training course in ultrasound.  Methods This educational prospective study at the Simulation Center in Mayo Clinic Jacksonville Florida enrolled 50 prehospital providers. Demographic and practice background information was obtained through surveys. Each participant performed a baseline ultrasound to determine endotracheal tube placement in a cadaver that was randomly assigned to an esophageal or tracheal intubation. Participants then repeated the randomized testing after a 15-minute tutorial. Before and after overall accuracy as well as proportions of correct identification of esophageal and tracheal intubations were determined and compared using standard binomial proportion and McNemar's tests. Results  None of the participants had prior experience of performing airway ultrasound. Baseline group scores were 60% (CI 45%-74%) for overall accuracy (n=50), 55% (CI 32%-76%) for correct identification of an esophageal intubation, and 64% (CI 44%-81%) for correct tracheal detection. Baseline scores were not significantly different from standard binomial distributions. Post-test scores were 82% (CI 69%-91%) for overall accuracy, 96% (CI 80%-100%) for esophageal intubation detection, and 66.7% (CI 45%-84%) for tracheal intubation detection, with corresponding binomial p-values of <0.001, <0.001, and 0.15. P-values for McNemar's paired test for combined overall accuracy, correct esophageal detection, and correct tracheal detection were 0.04, 0.02, and 0.62, respectively. Conclusions Prehospital participants without prior ultrasound experience demonstrated significant gains in airway ultrasound proficiency after a limited introductory course. Post-training score increases were largely due to a notable increase in correct esophageal intubation detection rates. Learners did not make significant progress in correctly identifying a tracheal intubation. Airway ultrasound educational design may benefit from added emphasis on the potentially more difficult to recognize tracheal intubation view.",2020,"Post-test scores were 82% (CI 69%-91%) for overall accuracy, 96% (CI 80%-100%) for esophageal intubation detection, and 66.7% (CI 45%-84%) for tracheal intubation detection, with corresponding binomial p-values of <0.001, <0.001, and 0.15. ",['Mayo Clinic Jacksonville Florida enrolled 50 prehospital providers'],"['Tracheal Intubation Ultrasound', 'baseline ultrasound to determine endotracheal tube placement']","['Baseline scores', 'airway ultrasound proficiency', 'overall accuracy, correct esophageal detection, and correct tracheal detection', 'tracheal intubation detection', 'esophageal intubation detection', 'correct esophageal intubation detection rates']","[{'cui': 'C0454788', 'cui_str': 'Mayo'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0016253', 'cui_str': 'Florida'}]","[{'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0336630', 'cui_str': 'Endotracheal tube'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C2945595', 'cui_str': 'Tracheal'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C0192301', 'cui_str': 'Insertion of catheter into esophagus, permanent tube type'}]",50.0,0.0919936,"Post-test scores were 82% (CI 69%-91%) for overall accuracy, 96% (CI 80%-100%) for esophageal intubation detection, and 66.7% (CI 45%-84%) for tracheal intubation detection, with corresponding binomial p-values of <0.001, <0.001, and 0.15. ","[{'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Kaminski', 'Affiliation': 'Emergency Medicine, Mayo Clinic, Jacksonville, USA.'}, {'ForeName': 'Nkechi O', 'Initials': 'NO', 'LastName': 'Dike', 'Affiliation': 'Emergency Medicine/Clinical Anatomy, University of Cape Coast, Cape Coast, GHA.'}, {'ForeName': 'Kerry', 'Initials': 'K', 'LastName': 'Bachista', 'Affiliation': 'Emergency Medicine, Baptist Medical Center, Jacksonville, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Boniface', 'Affiliation': 'Emergency Medicine, Mayo Clinc, Jacksonville, USA.'}, {'ForeName': 'Conrad', 'Initials': 'C', 'LastName': 'Dove', 'Affiliation': 'Neurosurgery, Mayo Clinic, Rochester, USA.'}, {'ForeName': 'Leslie V', 'Initials': 'LV', 'LastName': 'Simon', 'Affiliation': 'Emergency Medicine/Medical Simulation, Mayo Clinic, Jacksonville, USA.'}]",Cureus,['10.7759/cureus.8686'] 2775,32699736,Comparing Error Correction to Errorless Learning: A Randomized Clinical Trial.,"Errorless learning and error correction procedures are commonly used when teaching tact relations to individuals diagnosed with autism spectrum disorder (ASD). Research has demonstrated the effectiveness of both procedures, as well as compared them. The majority of these studies have been completed through the use of single-subject experimental designs. Evaluating both procedures using a group design may contribute to the literature and help disseminate research related to the behavioral science of language to a larger audience. The purpose of the present study was to compare an errorless learning procedure to an error correction procedure to teach tact relations to 28 individuals diagnosed with ASD through a randomized clinical trial. Several variables were assessed, including the number of stimulus sets with which participants reached the mastery criterion, responding during pre- and postprobes, responding during teaching, efficiency, and the presence of aberrant behavior. The results indicated that both procedures were effective, efficient, and unlikely to evoke aberrant behavior, despite participants in the error correction condition engaging in significantly more independent correct responses and independent incorrect responses.",2020,"The results indicated that both procedures were effective, efficient, and unlikely to evoke aberrant behavior, despite participants in the error correction condition engaging in significantly more independent correct responses and independent incorrect responses.","['individuals diagnosed with autism spectrum disorder (ASD', '28 individuals diagnosed with ASD']","['errorless learning procedure to an error correction procedure', 'Errorless learning and error correction procedures', 'Error Correction to Errorless Learning']","['mastery criterion, responding during pre- and postprobes, responding during teaching, efficiency, and the presence of aberrant behavior']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0443127', 'cui_str': 'Aberrant'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",28.0,0.0533693,"The results indicated that both procedures were effective, efficient, and unlikely to evoke aberrant behavior, despite participants in the error correction condition engaging in significantly more independent correct responses and independent incorrect responses.","[{'ForeName': 'Justin B', 'Initials': 'JB', 'LastName': 'Leaf', 'Affiliation': 'Autism Partnership Foundation, 200 Marina Drive, Seal Beach, CA 90808 USA.'}, {'ForeName': 'Joseph H', 'Initials': 'JH', 'LastName': 'Cihon', 'Affiliation': 'Autism Partnership Foundation, 200 Marina Drive, Seal Beach, CA 90808 USA.'}, {'ForeName': 'Julia L', 'Initials': 'JL', 'LastName': 'Ferguson', 'Affiliation': 'Autism Partnership Foundation, 200 Marina Drive, Seal Beach, CA 90808 USA.'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Milne', 'Affiliation': 'Autism Partnership Foundation, 200 Marina Drive, Seal Beach, CA 90808 USA.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Leaf', 'Affiliation': 'Autism Partnership Foundation, 200 Marina Drive, Seal Beach, CA 90808 USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'McEachin', 'Affiliation': 'Autism Partnership Foundation, 200 Marina Drive, Seal Beach, CA 90808 USA.'}]",The Analysis of verbal behavior,['10.1007/s40616-019-00124-y'] 2776,32702363,Predictors of Response for Elagolix with Add-back Therapy in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids.,"BACKGROUND Uterine fibroids are one of the most common neoplasms found among women globally with a prevalence of approximately 11 million women in the United States alone. The morbidity of this common disease is significant as it is the leading cause of hysterectomy and causes significant functional impairment for women of reproductive age. Factors, including age, body mass index (BMI), race, ethnicity, menstrual blood loss (MBL), fibroid location, and uterine and fibroid volume, influence the incidence of fibroids and severity of symptoms. Elagolix is an oral GnRH receptor antagonist that competitively inhibits pituitary GnRH receptor activity and suppresses release of gonadotropins from the pituitary gland, resulting in dose-dependent suppression of ovarian sex hormones, follicular growth, and ovulation. In Elaris UF-1 and UF-2, two replicate multicenter, double-blind, randomized, placebo-controlled, phase 3 studies, treatment of premenopausal women treated with elagolix with hormonal add-back therapy demonstrated reduction in heavy menstrual bleeding associated with uterine fibroids. OBJECTIVE The aim of this analysis is to evaluate the safety and efficacy of elagolix (300mg BID) with add-back therapy (1 mg estradiol/0.5mg norethindrone acetate [E2/NETA]) in reducing heavy menstrual bleeding associated with uterine fibroids in various subgroups of women over 6-months of treatment. METHODS Data were pooled from Elaris UF-1 and UF-2 which evaluated premenopausal women (18-51 years) with heavy menstrual bleeding [>80mL menstrual blood loss (MBL)/cycle; alkaline hematin methodology] and ultrasound-confirmed uterine fibroid diagnosis. Subgroups analyzed include age, BMI, race, ethnicity, baseline MBL, fibroid location, and uterine and primary fibroid volume (largest fibroid identified by ultrasound). The primary endpoint was the proportion of women with <80mL MBL during Final Month and ≥50% MBL reduction from Baseline to Final Month. Secondary and other efficacy endpoints included mean change in MBL from Baseline to Final Month, amenorrhea, symptom severity and health related quality of life (HRQOL). Adverse events as well as other safety endpoints were monitored. RESULTS The overall pooled Elaris UF-1 and UF-2 population was typical of women with fibroids with a mean age of 42.4 [standard deviation (SD), 5.4] years, a mean BMI of 33.6 (SD, 7.3) kg/m 2 , and with 67.6% Black or African American. A wide range of baseline uterine and fibroid volumes, and MBL were also represented in the overall pooled study population. In all subgroups, the proportion of responders to the primary endpoint, mean change in MBL, proportion of women who achieved amenorrhea, reduction in symptom severity, and improvement in HRQOL were clinically meaningfully greater for women who received elagolix+E2/NETA compared to placebo, and consistent with the overall pooled study population for the primary endpoint (72.2% vs 9.3%), mean change in MBL (-172.5 mL vs -0.8 mL), amenorrhea (50.4% vs 4.5%), symptom severity (-37.1 vs -9.2), and HRQOL score (39.9 vs 8.9). Adverse events by subgroup were consistent with the overall pooled study population. CONCLUSIONS Elagolix with hormonal add-back therapy was effective in reducing heavy menstrual bleeding associated with uterine fibroids independent of age, BMI, race, ethnicity, baseline MBL, fibroid location, and uterine and primary fibroid volume.",2020,"A wide range of baseline uterine and fibroid volumes, and MBL were also represented in the overall pooled study population.","['heavy menstrual bleeding associated with uterine fibroids in various subgroups of women over 6-months of treatment', 'women with fibroids with a mean age of 42.4 [standard deviation (SD), 5.4] years, a mean BMI of 33.6 (SD, 7.3) kg/m 2 , and with 67.6% Black or African American', 'women globally with a prevalence of approximately 11 million women in the United States alone', 'premenopausal women treated with', 'Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids', 'Data were pooled from Elaris UF-1 and UF-2 which evaluated premenopausal women (18-51 years) with heavy menstrual bleeding [>80mL menstrual blood loss (MBL)/cycle; alkaline hematin methodology] and ultrasound-confirmed uterine fibroid diagnosis']","['Elagolix with Add-back Therapy', 'elagolix+E2/NETA', 'add-back therapy (1 mg estradiol/0.5mg norethindrone acetate [E2/NETA', 'Elagolix with hormonal add-back therapy', 'elagolix with hormonal add-back therapy', 'elagolix', 'placebo']","['Adverse events', 'heavy menstrual bleeding', 'mean change in MBL, proportion of women who achieved amenorrhea, reduction in symptom severity, and improvement in HRQOL', 'HRQOL score', 'mean change in MBL from Baseline to Final Month, amenorrhea, symptom severity and health related quality of life (HRQOL', 'amenorrhea', 'symptom severity', 'age, body mass index (BMI), race, ethnicity, menstrual blood loss (MBL), fibroid location, and uterine and fibroid volume, influence the incidence of fibroids and severity of symptoms', 'safety and efficacy', 'proportion of women with <80mL MBL', 'mean change in MBL ']","[{'cui': 'C0025323', 'cui_str': 'Menorrhagia'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0042133', 'cui_str': 'Leiomyoma'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0023267', 'cui_str': 'Leiomyofibroma'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C4517792', 'cui_str': '5.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C1881839', 'cui_str': '1000000'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0337051', 'cui_str': 'Pool'}, {'cui': 'C0694689', 'cui_str': 'Menstrual blood'}, {'cui': 'C0018927', 'cui_str': 'hematin'}, {'cui': 'C0969625', 'cui_str': 'methodology'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C2714632', 'cui_str': 'elagolix'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0068980', 'cui_str': 'Norethindrone acetate'}, {'cui': 'C0458083', 'cui_str': 'Hormonal'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0025323', 'cui_str': 'Menorrhagia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0694689', 'cui_str': 'Menstrual blood'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0002453', 'cui_str': 'Amenorrhea'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}, {'cui': 'C0023267', 'cui_str': 'Leiomyofibroma'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.366254,"A wide range of baseline uterine and fibroid volumes, and MBL were also represented in the overall pooled study population.","[{'ForeName': 'Ayman', 'Initials': 'A', 'LastName': 'Al-Hendy', 'Affiliation': 'The University of Illinois College of Medicine, Chicago, IL. Electronic address: aalhendy@UIC.EDU.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Bradley', 'Affiliation': 'Cleveland Clinic, Cleveland, OH.'}, {'ForeName': 'Charlotte D', 'Initials': 'CD', 'LastName': 'Owens', 'Affiliation': 'AbbVie Inc, North Chicago, IL.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'AbbVie Inc, North Chicago, IL.'}, {'ForeName': 'Kurt T', 'Initials': 'KT', 'LastName': 'Barnhart', 'Affiliation': 'University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Eve', 'Initials': 'E', 'LastName': 'Feinberg', 'Affiliation': 'Northwestern University, Chicago, IL.'}, {'ForeName': 'William D', 'Initials': 'WD', 'LastName': 'Schlaff', 'Affiliation': 'Thomas Jefferson University, Philadelphia, PA.'}, {'ForeName': 'Elizabeth E', 'Initials': 'EE', 'LastName': 'Puscheck', 'Affiliation': 'Wayne State University, Detroit, MI.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Wang', 'Affiliation': 'AbbVie Inc, North Chicago, IL.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Gillispie', 'Affiliation': 'Ochsner Baptist Hospital, New Orleans, LA.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Hurtado', 'Affiliation': 'University of Texas Health Center, Houston, TX.'}, {'ForeName': 'Ozgul', 'Initials': 'O', 'LastName': 'Muneyyirci-Delale', 'Affiliation': 'SUNY Downstate Health Science University, Brooklyn, NY.'}, {'ForeName': 'David F', 'Initials': 'DF', 'LastName': 'Archer', 'Affiliation': 'Eastern Virginia Medical School, Norfolk, VA.'}, {'ForeName': 'Bruce R', 'Initials': 'BR', 'LastName': 'Carr', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Simon', 'Affiliation': 'George Washington University, IntimMedicine Specialists, Washington, D.C.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Stewart', 'Affiliation': 'Mayo Clinic and Mayo Clinic Alix School of Medicine, Rochester, MN.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.07.032'] 2777,32702468,Predicting Post One-year Durability of Glucose-lowering Monotherapies in Patients with Newly-diagnosed Type 2 Diabetes Mellitus - A MASTERMIND Precision Medicine Approach (UKPDS NN ).,"AIMS Predicting likely durability of glucose-lowering therapies for people with type 2 diabetes (T2D) could help inform individualised therapeutic choices. METHODS We used data from UKPDS patients with newly-diagnosed T2D randomised to first-line glucose-lowering monotherapy with chlorpropamide-glibenclamide-basal insulin or metformin. In 2,339 participants who achieved one-year HbA 1c values <7.5% (<59 mmol/mol)-we assessed relationships between one-year characteristics and time to monotherapy-failure (HbA 1c ≥7.5% or requiring second-line therapy). Model validation was performed using bootstrap sampling. RESULTS Follow-up was median (IQR) 11.0 (8.0-14.0) years. Monotherapy-failure occurred in 72%-82%-75% and 79% for those randomised to chlorpropamide-glibenclamide-basal insulin or metformin respectively-after median 4.5 (3.0-6.6)-3.7 (2.6-5.6)-4.2 (2.7-6.5) and 3.8 (2.6- 5.2) years. Time-to-monotherapy-failure was predicted primarily by HbA 1c and BMI values-with other risk factors varying by type of monotherapy-with predictions to within ±2.5 years for 55%-60%-56% and 57% of the chlorpropamide-glibenclamide-basal insulin and metformin monotherapy cohorts respectively. CONCLUSIONS Post one-year glycaemic durability can be predicted robustly in individuals with newly-diagnosed T2D who achieve HbA 1c values <7.5% one year after commencing traditional monotherapies. Such information could be used to help guide glycaemic management for individual patients.",2020,Monotherapy-failure occurred in 72%-82%-75% and 79% for those randomised to chlorpropamide-glibenclamide-basal insulin or metformin respectively-after median 4.5 (3.0-6.6)-3.7 (2.6-5.6)-4.2 (2.7-6.5) and 3.8 (2.6- 5.2) years.,"['2,339 participants who achieved one-year HbA 1c values <7.5% (<59 mmol/mol)-we assessed relationships between one-year characteristics and time to monotherapy-failure (HbA 1c ≥7.5% or requiring second-line therapy', 'people with type 2 diabetes ', 'Patients with Newly-diagnosed Type 2 Diabetes Mellitus', 'UKPDS patients with newly-diagnosed T2D randomised to first']","['chlorpropamide-glibenclamide-basal insulin or metformin', 'line glucose-lowering monotherapy with chlorpropamide-glibenclamide-basal insulin or metformin', 'glucose-lowering therapies', 'Glucose-lowering Monotherapies']","['Monotherapy-failure', 'Time-to-monotherapy-failure']","[{'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C1710038', 'cui_str': 'Second line treatment'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C0008287', 'cui_str': 'Chlorpropamide'}, {'cui': 'C0017628', 'cui_str': 'Glyburide'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",2339.0,0.0533422,Monotherapy-failure occurred in 72%-82%-75% and 79% for those randomised to chlorpropamide-glibenclamide-basal insulin or metformin respectively-after median 4.5 (3.0-6.6)-3.7 (2.6-5.6)-4.2 (2.7-6.5) and 3.8 (2.6- 5.2) years.,"[{'ForeName': 'Olorunsola F', 'Initials': 'OF', 'LastName': 'Agbaje', 'Affiliation': 'Diabetes Trials Unit-University of Oxford-Oxford-U.K. Electronic address: olorunsola.agbaje@dtu.ox.ac.uk.'}, {'ForeName': 'Ruth L', 'Initials': 'RL', 'LastName': 'Coleman', 'Affiliation': 'Diabetes Trials Unit-University of Oxford-Oxford-U.K.'}, {'ForeName': 'Andrew T', 'Initials': 'AT', 'LastName': 'Hattersley', 'Affiliation': 'Institute of Biomedical & Clinical Science-University of Exeter Medical School-Exeter-U.K.'}, {'ForeName': 'Angus G', 'Initials': 'AG', 'LastName': 'Jones', 'Affiliation': 'Institute of Biomedical & Clinical Science-University of Exeter Medical School-Exeter-U.K.'}, {'ForeName': 'Ewan R', 'Initials': 'ER', 'LastName': 'Pearson', 'Affiliation': 'Medical Research Institute-University of Dundee-Dundee-U.K.'}, {'ForeName': 'Beverley M', 'Initials': 'BM', 'LastName': 'Shields', 'Affiliation': 'Institute of Biomedical & Clinical Science-University of Exeter Medical School-Exeter-U.K.'}, {'ForeName': 'Rury R', 'Initials': 'RR', 'LastName': 'Holman', 'Affiliation': 'Diabetes Trials Unit-University of Oxford-Oxford-U.K.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes research and clinical practice,['10.1016/j.diabres.2020.108333'] 2778,32702522,Impact of couple conflict and mediation on how romantic partners are seen: An fMRI study.,"Previous studies on romantic love have reported increased neural activity in the brain's reward circuitry such as the striatum. To date, the extent to which this activity is modulated by couple conflict in general and mediated couple conflict in particular, is unknown. The present study seeks to fill this gap by randomly assigning 36 romantic heterosexual couples to a mediated or non-mediated conflict discussion. Before and after the conflict discussion, self-reports and functional neuroimaging data in response to a picture of the romantic partner versus an unknown person were acquired. Self-reports indicate that mediation increases conflict resolution, satisfaction about the contents and process of the discussion and decreases levels of remaining disagreement. Pre-conflict neuroimaging results replicate previous studies on romantic love, showing activations in the striatum, insula, anterior and posterior cingulate gyrus, orbitofrontal cortex, hippocampus, temporal and occipital poles and amygdala when viewing the romantic partner versus an unknown person. The general effect of conflict on neural activations in response to the romantic partner across both conditions consisted of deactivations in the striatum, insula, thalamus, precuneus and ventral tegmental area. Small volume correction analyses revealed that participants in the mediated condition trended towards having greater activation in the nucleus accumbens than participants in the non-mediated condition when looking at the romantic partner versus the unknown after the conflict discussion. Parametric modulation analyses also revealed greater activity in the nucleus accumbens when viewing the romantic partner versus the unknown for participants who felt more satisfied after the conflict resolution. Our results illustrate that mediation improves conflict resolution and is associated with increased activity in the nucleus accumbens, a key region in the brain's reward circuitry.",2020,Parametric modulation analyses also revealed greater activity in the nucleus accumbens when viewing the romantic partner versus the unknown for participants who felt more satisfied after the conflict resolution.,['36 romantic heterosexual couples to a mediated or non-mediated conflict discussion'],[],"['neural activity', 'conflict resolution']","[{'cui': 'C0019421', 'cui_str': 'Heterosexuality'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0009671', 'cui_str': 'Conflict'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}]",[],"[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0150526', 'cui_str': 'Conflict Resolution'}]",36.0,0.0299096,Parametric modulation analyses also revealed greater activity in the nucleus accumbens when viewing the romantic partner versus the unknown for participants who felt more satisfied after the conflict resolution.,"[{'ForeName': 'Halima', 'Initials': 'H', 'LastName': 'Rafi', 'Affiliation': 'Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland; Department of Psychology, University of Geneva, Geneva, Switzerland. Electronic address: Halima.Rafi@unige.ch.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Bogacz', 'Affiliation': 'Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland; Computer Vision and Multimedia Laboratory, University of Geneva, Battelle Campus, Carouge, Switzerland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Sander', 'Affiliation': 'Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland; Laboratory for the Study of Emotion Elicitation and Expression, Department of Psychology, University of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Klimecki', 'Affiliation': 'Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland; Laboratory for the Study of Emotion Elicitation and Expression, Department of Psychology, University of Geneva, Geneva, Switzerland; Laboratory for Behavioral Neurology and Imaging of Cognition, Department of Neuroscience, Medical School, University of Geneva, Geneva, Switzerland. Electronic address: Olga.Klimecki@unige.ch.'}]",Cortex; a journal devoted to the study of the nervous system and behavior,['10.1016/j.cortex.2020.04.036'] 2779,32702651,Evaluation of the efficiency of the web-based epilepsy education program (WEEP) for youth with epilepsy and parents: A randomized controlled trial.,"BACKGROUND When youth with epilepsy and their parents have insufficient information about the disease, they are known to have more problems with disease management, and they show poor compliance. Providing accurate, reliable, and accessible information with no time and space limitations is extremely important for individuals with epilepsy as well as for their caregivers. AIM In this study, we aimed to evaluate the content, quality, usability, and efficacy of our web-based epilepsy education program (WEEP) that we developed for youth with epilepsy and their parents. METHODS The sample of this randomized controlled trail was composed of youth with epilepsy who were between the ages of 9 and 18 years and their parents who had applied to the Pediatric Neurology Unit of a tertiary healthcare hospital in Turkey between November 2017 and April 2018. This study was conducted in two stages: (1) the preparation phase, during which we developed a WEEP for epilepsy, and tested its content, quality, and usability; and (2) the implementation phase, during which we evaluated the efficacy of the website by assessing users' knowledge of epilepsy, seizure self-efficacy, attitudes, and e-health literacy. Before the implementation phase, data collection tools were used to test the prior knowledge of epilepsy of the participants and control groups. Next, the youth and their parents were asked to use the WEEP for 12 weeks, while a control group was not provided with additional education tools. Written consent was obtained from the participants prior to the study in addition to obtaining approval from the ethics committee and permission from the institution where the research was conducted. The data were finally analyzed using SAS 9.4 software. RESULTS During the preparation phase, the website was developed and tested for content, quality, and usability. The WEEP was graded 72.7 ± 3.4 points by experts, 92.4 ± 1.63 by youth with epilepsy, and 92.31 ± 1.94 by the parents. During the implementation phase, the efficacy of the web site was evaluated through the assessment of participants' scores. We found that the mean knowledge, seizure self-efficacy, attitude, and e-health literacy scores of youth with epilepsy in the experimental group had significantly increased after the WEEP (p < 0.05). An increase in the scores of knowledge, anxiety, self-management, and e-health literacy scale was also found among the parents in the intervention group (p < 0.05). CONCLUSION The content, quality, and usability of the WEEP were adequate and effective in improving knowledge, self-efficacy, attitudes, and e-health literacy of youth with epilepsy as well as those of their parents.",2020,"An increase in the scores of knowledge, anxiety, self-management, and e-health literacy scale was also found among the parents in the intervention group (p < 0.05). ","['youth with epilepsy who were between the ages of 9 and 18\u202fyears and their parents who had applied to the Pediatric Neurology Unit of a tertiary healthcare hospital in Turkey between November 2017 and April 2018', 'youth with epilepsy and parents', 'youth with epilepsy and their parents']",['web-based epilepsy education program (WEEP'],"['content, quality, and usability of the WEEP were adequate and effective in improving knowledge, self-efficacy, attitudes, and e-health literacy of youth with epilepsy', 'content, quality, usability, and efficacy', ""efficacy of the website by assessing users' knowledge of epilepsy, seizure self-efficacy, attitudes, and e-health literacy"", 'scores of knowledge, anxiety, self-management, and e-health literacy scale', 'mean knowledge, seizure self-efficacy, attitude, and e-health literacy scores of youth with epilepsy']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0279167', 'cui_str': 'Pediatric neurology'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0030551', 'cui_str': 'Parent'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}]","[{'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.0299077,"An increase in the scores of knowledge, anxiety, self-management, and e-health literacy scale was also found among the parents in the intervention group (p < 0.05). ","[{'ForeName': 'Şerife', 'Initials': 'Ş', 'LastName': 'Tutar Güven', 'Affiliation': 'Department of Pediatric Nursing, Faculty of Health Sciences, Süleyman Demirel University, Isparta, Turkey. Electronic address: serifeguven@sdu.edu.tr.'}, {'ForeName': 'Ayşegül', 'Initials': 'A', 'LastName': 'İşler Dalgiç', 'Affiliation': 'Department of Pediatric Nursing, Faculty of Nursing, Akdeniz University, Antalya, Turkey. Electronic address: aisler@akdeniz.edu.tr.'}, {'ForeName': 'Özgür', 'Initials': 'Ö', 'LastName': 'Duman', 'Affiliation': 'Department of Pediatric Neurology, Faculty of Medicine, Akdeniz University, Antalya, Turkey. Electronic address: oduman@akdeniz.edu.tr.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2020.107142'] 2780,32702660,"The Effect of Foam Rolling Versus IASTM on Knee Range of Motion, Fascial Displacement, and Patient Satisfaction.","CONTEXT Soft tissue restrictions have been linked to poor flexibility and decreased range of motion (ROM). To decrease the soft tissue restrictions and ultimately increase ROM/flexibility, myofascial release techniques, such as foam rolling (FR) and instrument-assisted soft tissue mobilization (IASTM), have been used. However, the benefit regarding which technique is more beneficial remains unknown. OBJECTIVE To examine the effects of myofascial release techniques (FR vs the instrumented portion of IASTM) on knee joint ROM, rectus femoris (RF) and biceps femoris (BF) fascial displacement, and patient satisfaction. DESIGN Randomized controlled clinical trial. SETTING Mid-Atlantic University. PARTICIPANTS Twenty moderately active participants (age 21.1 [2.0] y) with variable levels of soft tissue restriction in the quadriceps and hamstrings started and completed the study. Participants were randomly assigned to 2 groups, FR or IASTM. INTERVENTIONS All participants completed the same warm-up prior to the intervention. The FR group followed the proper FR protocol for gluteals/iliotibial band, quadriceps, and hamstrings/adductors, and the participants were monitored while the protocol was completed. The IASTM group received treatment on the gluteals/iliotibial band followed by the quadriceps, adductors, and hamstrings. Participants in both groups attended intervention sessions twice per week for 3 weeks. Prior to the start, knee ROM measurements were taken, along with fascial displacement measured via ultrasound. Upon completion of the study, posttest measurements were completed. A patient satisfaction survey was also administered at this time. MAIN OUTCOME MEASURES Pretest to posttest knee ROM measurements, RF and BF fascial displacement, and patient satisfaction. RESULTS Both groups improved pretest to posttest for knee-extension ROM, with a slight trend toward increased knee-extension ROM for the FR group. Both groups improved pretest to posttest for BF and RF fascial displacement, in favor of the IASTM group for BF fascial displacement. Both groups were equally satisfied. CONCLUSIONS As both groups improved pretest to posttest, either treatment could be used.",2020,"Both groups improved pretest to posttest for knee-extension ROM, with a slight trend toward increased knee-extension ROM for the FR group.","['Mid-Atlantic University', 'Twenty moderately active participants (age 21.1 [2.0]\xa0y) with variable levels of soft tissue restriction in the quadriceps and hamstrings started and completed the study']","['FR or IASTM', 'Foam Rolling Versus IASTM', 'myofascial release techniques (FR vs the instrumented portion of IASTM']","['ROM/flexibility, myofascial release techniques, such as foam rolling (FR) and instrument-assisted soft tissue mobilization (IASTM', 'knee-extension ROM', 'Knee Range of Motion, Fascial Displacement, and Patient Satisfaction', 'soft tissue restrictions', 'posttest knee ROM measurements, RF and BF fascial displacement, and patient satisfaction', 'knee joint ROM, rectus femoris (RF) and biceps femoris (BF) fascial displacement, and patient satisfaction', 'range of motion (ROM']","[{'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0225317', 'cui_str': 'Soft tissue'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0584895', 'cui_str': 'Posterior muscle of thigh structure'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0991510', 'cui_str': 'Foam'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0686940', 'cui_str': 'Soft tissue mobilization'}, {'cui': 'C0695600', 'cui_str': 'Myofascial release'}, {'cui': 'C0449719', 'cui_str': 'Part'}]","[{'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0695600', 'cui_str': 'Myofascial release'}, {'cui': 'C0991510', 'cui_str': 'Foam'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0686940', 'cui_str': 'Soft tissue mobilization'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0576094', 'cui_str': 'Knee joint - range of movement'}, {'cui': 'C0015641', 'cui_str': 'Fascial'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0225317', 'cui_str': 'Soft tissue'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0224449', 'cui_str': 'Biceps femoris muscle structure'}, {'cui': 'C0022745', 'cui_str': 'Knee joint structure'}, {'cui': 'C0584894', 'cui_str': 'Rectus femoris muscle structure'}]",20.0,0.0595306,"Both groups improved pretest to posttest for knee-extension ROM, with a slight trend toward increased knee-extension ROM for the FR group.","[{'ForeName': 'Michelle A', 'Initials': 'MA', 'LastName': 'Sandrey', 'Affiliation': ''}, {'ForeName': 'Cody', 'Initials': 'C', 'LastName': 'Lancellotti', 'Affiliation': ''}, {'ForeName': 'Cory', 'Initials': 'C', 'LastName': 'Hester', 'Affiliation': ''}]",Journal of sport rehabilitation,['10.1123/jsr.2018-0494'] 2781,32703042,Intralesional immunotherapy for the treatment of anogenital warts in pediatric population.,"Background: The prevalence of anogenital warts is increasing in adults as well as in pediatric population. The treatment of anogenital warts is challenging, particularly in children as most conventional modalities are painful and associated with high recurrence rates. Objectives : To evaluate the efficacy and safety of intralesional immunotherapy for the treatment of anogenital warts in pediatric patients. Methods : Forty child presenting with multiple anogenital warts were randomly assigned into 3 groups. The first group (15 patients) received intralesional MMR vaccine, the second group (15 patients) received intralesional Candida antigen and the third group (10 patients) received intralesional saline as a control. Each modality was injected into the largest wart at 2-week intervals until complete clearance or for a maximum of 5 sessions. Results: Highly significant difference was found between the therapeutic response of anogenital warts to both MMR vaccine and Candida antigen compared to intralesional saline (P = 0.005). No significant difference was observed between MMR vaccine and Candida antigen groups (P= 0.885). Side effects were mild and no recurrence was detected in the 6 month follow-up period. Conclusions: Intralesional immunotherapy is a promising effective and well-tolerated treatment modality for multiple anogenital warts in children.",2020,No significant difference was observed between MMR vaccine and Candida antigen groups (P= 0.885).,"['multiple anogenital warts in children', 'anogenital warts in pediatric patients', 'Forty child presenting with multiple anogenital warts', 'anogenital warts in pediatric population']","['intralesional immunotherapy', 'intralesional MMR vaccine', 'intralesional Candida antigen', 'intralesional saline', 'Intralesional immunotherapy']","['efficacy and safety', 'mild and no recurrence', 'therapeutic response of anogenital warts to both MMR vaccine and Candida antigen']","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0009663', 'cui_str': 'Genital warts'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C1512955', 'cui_str': 'Intralesional route'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}, {'cui': 'C0065828', 'cui_str': 'Measles, mumps and rubella vaccine'}, {'cui': 'C0006836', 'cui_str': 'Candida'}, {'cui': 'C0003320', 'cui_str': 'Antigen'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0521982', 'cui_str': 'Response to treatment'}, {'cui': 'C0009663', 'cui_str': 'Genital warts'}, {'cui': 'C0065828', 'cui_str': 'Measles, mumps and rubella vaccine'}, {'cui': 'C0006836', 'cui_str': 'Candida'}, {'cui': 'C0003320', 'cui_str': 'Antigen'}]",40.0,0.0242088,No significant difference was observed between MMR vaccine and Candida antigen groups (P= 0.885).,"[{'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Nofal', 'Affiliation': 'Dermatology, Venereology and Andrology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.'}, {'ForeName': 'Rania', 'Initials': 'R', 'LastName': 'Alakad', 'Affiliation': 'Dermatology, Venereology and Andrology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.'}]",The Journal of dermatological treatment,['10.1080/09546634.2020.1800573'] 2782,32703092,A comparison of online and in-person counseling outcomes using solution-focused brief therapy for college students with anxiety.,"OBJECTIVE This study compared online, synchronous video counseling to in-person counseling using solution-focused brief therapy for college students with mild to moderate anxiety. Participants: Participants were 49 undergraduate students who were seeking counseling for mild to moderate anxiety. The study was conducted from November, 2017 to December 2018. Methods: In a randomized, non-inferiority design, undergraduate participants were randomly assigned to online, synchronous video counseling or in-person treatment for anxiety using solution-focused brief therapy (SFBT). Participants completed the Beck's Anxiety Inventory (BAI) and College Counseling Assessment of Psychological Symptoms (CCAPS) to assess outcomes. Results: The results showed significant changes in scores on the BAI and the CCAPS Generalized Anxiety and Social Anxiety subscales for participants in both study conditions, and no significant differences in effectiveness of the two delivery methods. Conclusions: The findings provide support for the treatment of college students with anxiety with SFBT through online, synchronous video counseling. Limitations related to sample size and diversity are discussed.",2020,"The results showed significant changes in scores on the BAI and the CCAPS Generalized Anxiety and Social Anxiety subscales for participants in both study conditions, and no significant differences in effectiveness of the two delivery methods. ","['college students with anxiety', '49 undergraduate students who were seeking counseling for mild to moderate anxiety', 'Participants: Participants', 'college students with anxiety with SFBT through online, synchronous video counseling', 'November, 2017 to December 2018', 'undergraduate participants', 'college students with mild to moderate anxiety']","['synchronous video counseling or in-person treatment for anxiety using solution-focused brief therapy (SFBT', 'solution-focused brief therapy', 'synchronous video counseling to in-person counseling using solution-focused brief therapy']","['BAI and the CCAPS Generalized Anxiety and Social Anxiety subscales', ""Beck's Anxiety Inventory (BAI) and College Counseling Assessment of Psychological Symptoms (CCAPS""]","[{'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0439580', 'cui_str': 'Synchronous'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0439580', 'cui_str': 'Synchronous'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C1276047', 'cui_str': 'Brief solution focused psychotherapy'}, {'cui': 'C0474145', 'cui_str': 'Person counseled'}]","[{'cui': 'C0064251', 'cui_str': 'katacalcin'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}]",49.0,0.062823,"The results showed significant changes in scores on the BAI and the CCAPS Generalized Anxiety and Social Anxiety subscales for participants in both study conditions, and no significant differences in effectiveness of the two delivery methods. ","[{'ForeName': 'Jocelyn K', 'Initials': 'JK', 'LastName': 'Novella', 'Affiliation': 'Counselor Education, Fairfield University, Fairfield, CT, USA.'}, {'ForeName': 'Kok-Mun', 'Initials': 'KM', 'LastName': 'Ng', 'Affiliation': 'Counseling, Oregon State University, Corvallis, OR, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Samuolis', 'Affiliation': 'Psychology, Sacred Heart University, Fairfield, CT, USA.'}]",Journal of American college health : J of ACH,['10.1080/07448481.2020.1786101'] 2783,32703096,Electroencephalographic Investigation of the Effect of Skill Level and Social Inhibition on Simulated Handgun Shooting.,"We examined effects of Social Inhibition (SI), and Skill Level (SL) on simulated handgun shooting performance. Electroencephalogram (EEG) was also recorded in order to measure task-related changes in cortical activity. Participants consisted of Novice (NSL) and Experienced (ESL) shooters who were randomly assigned to shoot while in the presence of an audience (Hi SI) or alone (Low SI). The results revealed that NSL were less accurate than ESL in all conditions as was predicted. Shooting accuracy was predicted by alpha and beta amplitude, indicating different roles for attention and anxiety. Prefrontal alpha amplitude was significantly influenced by SL and SI, with a finding that ES showed RH deactivation while NS showed LH deactivation. Findings are discussed in terms of theories of motor control and SI.",2020,"We examined effects of Social Inhibition (SI), and Skill Level (SL) on simulated handgun shooting performance.",['Participants consisted of Novice (NSL) and Experienced (ESL) shooters who'],"['Social Inhibition (SI), and Skill Level (SL', 'Skill Level and Social Inhibition', 'audience (Hi SI) or alone (Low SI']","['Prefrontal alpha amplitude', 'Electroencephalogram (EEG', 'Shooting accuracy', 'RH deactivation']","[{'cui': 'C0332529', 'cui_str': 'Consistency'}]","[{'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205251', 'cui_str': 'Low'}]","[{'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}]",,0.029301,"We examined effects of Social Inhibition (SI), and Skill Level (SL) on simulated handgun shooting performance.","[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Shelley-Tremblay', 'Affiliation': 'Department of Psychology, University of South Alabama, Mobile, AL, USA .'}, {'ForeName': 'Pamela R', 'Initials': 'PR', 'LastName': 'Jones', 'Affiliation': 'Department of Psychology, University of South Alabama, Mobile, AL, USA .'}, {'ForeName': 'Claire E', 'Initials': 'CE', 'LastName': 'Demming', 'Affiliation': 'Department of Psychology, University of South Alabama, Mobile, AL, USA .'}, {'ForeName': 'Elise', 'Initials': 'E', 'LastName': 'Labbe-Coldsmith', 'Affiliation': 'Department of Psychology, University of South Alabama, Mobile, AL, USA .'}]",Journal of motor behavior,['10.1080/00222895.2020.1796569'] 2784,32703098,Algorithm-Based Practice Schedule and Task Similarity Enhance Motor Learning in Older Adults.,"According to the challenge point framework, task difficulty has to be appropriate to learner skill level. The pure blocked or random practice controls the task difficulty during practice monotonically. Therefore, the purpose of this study was to investigate the effect of algorithm-based practice schedule and task similarity on motor learning in older adults. For this purpose, 60 older adults were randomly assigned into six groups of blocked-similar, algorithm-similar, random-similar, blocked-dissimilar, algorithm-dissimilar, and random-dissimilar. Sequential motor tasks were used for learning. Participants practiced absolute timing goals in similar (1350, 1500, 1650 ms) or dissimilar (1050, 1500, 1950 ms) conditions according to their practice schedule. Twenty-four hours after the acquisition phase, retention, and transfer tests were performed. Algorithm-practice was a hybrid practice schedule (blocked, serial, and random practice in forward/backward switching) that switching the schedules was according to error trial number ( n  ≤ 33%) in each block based on error range of absolute timing goals (± 5%). The results showed that the blocked-practice outperforms the other groups during the acquisition phase, whereas the algorithm-practice outperforms the other groups in retention and transfer in both similar and dissimilar conditions. These findings were discussed according to the challenge point framework.",2020,"The results showed that the blocked-practice outperforms the other groups during the acquisition phase, whereas the algorithm-practice outperforms the other groups in retention and transfer in both similar and dissimilar conditions.","['Older Adults', 'older adults', '60 older adults']","['blocked-similar, algorithm-similar, random-similar, blocked-dissimilar, algorithm-dissimilar, and random-dissimilar', 'algorithm-based practice schedule and task similarity', 'Algorithm-Based Practice Schedule and Task Similarity Enhance Motor Learning']",[],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0443202', 'cui_str': 'Dissimilar'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0013621', 'cui_str': 'Education'}]",[],60.0,0.017458,"The results showed that the blocked-practice outperforms the other groups during the acquisition phase, whereas the algorithm-practice outperforms the other groups in retention and transfer in both similar and dissimilar conditions.","[{'ForeName': 'Meysam', 'Initials': 'M', 'LastName': 'Beik', 'Affiliation': 'Department of Motor Behavior, Ferdowsi University of Mashhad, Mashhad, Iran.'}, {'ForeName': 'Hamidreza', 'Initials': 'H', 'LastName': 'Taheri', 'Affiliation': 'Department of Motor Behavior, Ferdowsi University of Mashhad, Mashhad, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Saberi Kakhki', 'Affiliation': 'Department of Motor Behavior, Ferdowsi University of Mashhad, Mashhad, Iran.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Ghoshuni', 'Affiliation': 'Department of Biomedical Engineering, Mashhad Branch, Islamic Azad University, Mashhad, Iran.'}]",Journal of motor behavior,['10.1080/00222895.2020.1797620'] 2785,32703124,Relative efficiencies of alternative preference-based designs for randomised trials.,"Recent work has shown that outcomes in clinical trials can be affected by which treatment the trial participants would select if they were allowed to do so, and if they do or do not actually receive that treatment. These influences are known as selection and preference effects, respectively. Unfortunately, they cannot be evaluated in conventional, parallel group trials because patient preferences remain unknown. However, several alternative designs have been proposed, to measure and take account of patient preferences. In this paper, we discuss three preference-based designs (the two-stage, fully randomised, and partially randomised designs). In conventional trials, only the treatment effect is estimable, while the preference-based designs have the potential to estimate some or all of the selection and preference effects. The relative efficiency of these designs is affected by several factors, including the proportion of participants who are undecided about treatments, or who are unable or unwilling to state a preference; the relative preference rate between the treatments being compared, among patients who do have a preference; and the ratio of patients randomised to each treatment. We also discuss the advantages and disadvantages of these designs under different scenarios.",2020,"The relative efficiency of these designs is affected by several factors, including the proportion of participants who are undecided about treatments, or who are unable or unwilling to state a preference; the relative preference rate between the treatments being compared, among patients who do have a preference; and the ratio of patients randomised to each treatment.",[],[],[],[],[],[],,0.123362,"The relative efficiency of these designs is affected by several factors, including the proportion of participants who are undecided about treatments, or who are unable or unwilling to state a preference; the relative preference rate between the treatments being compared, among patients who do have a preference; and the ratio of patients randomised to each treatment.","[{'ForeName': 'S D', 'Initials': 'SD', 'LastName': 'Walter', 'Affiliation': 'Department of Health Research Methodology, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bian', 'Affiliation': 'Department of Mathematics & Statistics, McMaster University, Hamilton, ON, Canada.'}]",Statistical methods in medical research,['10.1177/0962280220941874'] 2786,32703244,Treatment fidelity in the Tinnitus Retraining Therapy Trial.,"BACKGROUND Treatment fidelity, defined as ensuring that the recipient receives the intended intervention, is a critical component for accurate estimation of treatment efficacy. Ensuring fidelity and protocol adherence in behavioral trials requires careful planning during the design phase and implementation during the trial. The Tinnitus Retraining Therapy Trial (TRTT) randomized individuals with severe tinnitus to tinnitus retraining therapy (TRT, comprised of tinnitus-specific educational counseling (TC) and sound therapy (ST) using conventional sound generators (SGs)); Partial TRT (TC and placebo SGs); or standard of care (SOC), using a patient-centered care approach. Study audiologists administered both types of counseling in the TRTT, creating a challenge for managing protocol adherence. METHODS We developed methods to enhance treatment fidelity including training, competency assessment, scripts, visual aids, and fidelity monitoring. Protocol monitors identified critical topics and content to be addressed for each type of counseling session, prepared corresponding scripts, and developed training aids and treatment-specific checklists covering those topics. Study audiologists' competency assessment required submission and review by the protocol monitors of an audiotape of one TC and one SOC counseling session. Treatment-specific aids included scripts, a 3-D model of the ear, handouts, and for TC, an illustrated flip-chart with talking points that followed the scripted content. During the trial, audiologists completed treatment-specific checklists during each counseling session, indicating topics covered/discussed and submitted audiotapes of counseling sessions. Protocol monitors reviewed audiotapes using corresponding treatment-specific checklists. Results for individual checklist items were tabulated and proportions calculated. RESULTS Twenty-five audiologists were certified for TC and/or SOC counseling and 24 completed at least one counseling session. Adherence to each of 33 critical items on the TC checklist as assessed by the protocol monitor ranged from 70 to 100% across 37 counseling sessions (median 97%), with no difference between adherence for TRT (median, 97%) and partial TRT (median, 100%). Adherence to each of 44 critical items on the SOC checklist across 30 SOC counseling sessions ranged from 42 to 100% (median, 87.5%). CONCLUSION The TRTT used multiple methods to address treatment fidelity. The close adherence to each treatment type was critical for evaluating the efficacy of the study interventions in this randomized trial. TRIAL REGISTRATION clinicaltrials.gov NCT01177137 . Registered on 5 August 2010.",2020,"Adherence to each of 33 critical items on the TC checklist as assessed by the protocol monitor ranged from 70 to 100% across 37 counseling sessions (median 97%), with no difference between adherence for TRT (median, 97%) and partial TRT (median, 100%).",[],"['audiotape of one TC and one SOC counseling session', 'tinnitus retraining therapy (TRT, comprised of tinnitus-specific educational counseling (TC) and sound therapy (ST) using conventional sound generators (SGs)); Partial TRT (TC and placebo SGs); or standard of care (SOC']",['TC checklist'],[],"[{'cui': 'C0004295', 'cui_str': 'Audiotapes'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0040264', 'cui_str': 'Tinnitus'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0037709', 'cui_str': 'Sonic Radiation'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0237638', 'cui_str': 'Generator'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0265227', 'cui_str': 'Schinzel-Giedion syndrome'}]","[{'cui': 'C1707357', 'cui_str': 'Checklist'}]",25.0,0.0548366,"Adherence to each of 33 critical items on the TC checklist as assessed by the protocol monitor ranged from 70 to 100% across 37 counseling sessions (median 97%), with no difference between adherence for TRT (median, 97%) and partial TRT (median, 100%).","[{'ForeName': 'Roberta W', 'Initials': 'RW', 'LastName': 'Scherer', 'Affiliation': 'Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. rschere1@jhu.edu.'}, {'ForeName': 'Sue Ann', 'Initials': 'SA', 'LastName': 'Erdman', 'Affiliation': 'Audiologic Rehabilitation Consulting Services, Jensen Beach, FL, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Gold', 'Affiliation': 'Tinnitus and Hyperacusis Center of Maryland, Department of Otolaryngology, University of Maryland Medical Center, Baltimore, MD, USA.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Formby', 'Affiliation': 'Department of Communicative Disorders, University of Alabama, Tuscaloosa, AL, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Trials,['10.1186/s13063-020-04530-9'] 2787,32703245,"Community Tele-pal: A community-developed, culturally based palliative care tele-consult randomized controlled trial for African American and White Rural southern elders with a life-limiting illness.","BACKGROUND Patients living in rural areas experience a variety of unmet needs that result in healthcare disparities. The triple threat of rural geography, racial inequities, and older age hinders access to high-quality palliative care (PC) for a significant proportion of Americans. Rural patients with life-limiting illness are at risk of not receiving appropriate palliative care due to a limited specialty workforce, long distances to treatment centers, and limited PC clinical expertise. Although culture strongly influences people's response to diagnosis, illness, and treatment preferences, culturally based care models are not currently available for most seriously ill rural patients and their family caregivers. The purpose of this randomized clinical trial (RCT) is to compare a culturally based tele-consult program (that was developed by and for the rural southern African American (AA) and White (W) population) to usual hospital care to determine the impact on symptom burden (primary outcome) and patient and care partner quality of life (QOL), care partner burden, and resource use post-discharge (secondary outcomes) in hospitalized AA and White older adults with a life-limiting illness. METHODS Community Tele-pal is a three-site RCT that will test the efficacy of a community-developed, culturally based PC tele-consult program for hospitalized rural AA and W older adults with life-limiting illnesses (n = 352) and a care partner. Half of the participants (n = 176) and a care partner (n = 176) will be randomized to receive the culturally based palliative care consult. The other half of the patient participants (n = 176) and care partners (n = 176) will receive usual hospital care appropriate to their illness. DISCUSSION This is the first community-developed, culturally based PC tele-consult program for rural southern AA and W populations. If effective, the tele-consult palliative program and methods will serve as a model for future culturally based PC programs that can reduce patients' symptoms and care partner burden. TRIAL REGISTRATION ClinicalTrials.gov NCT03767517 . Registered on 27 December 2018.",2020,"METHODS Community Tele-pal is a three-site RCT that will test the efficacy of a community-developed, culturally based PC tele-consult program for hospitalized rural AA and W older adults with life-limiting illnesses (n = 352) and a care partner.","['Rural patients with life-limiting illness', 'rural southern African American (AA) and White (W) population', 'Community Tele-pal', 'hospitalized AA and White older adults with a life-limiting illness', 'Half of the participants (n\u2009=\u2009176) and a care partner (n\u2009=\u2009176', 'patient participants (n\u2009=\u2009176) and care partners (n\u2009=\u2009176) will receive usual hospital care appropriate to their illness', 'for hospitalized rural AA and W older adults with life-limiting illnesses (n\u2009=\u2009352) and a care partner', 'African American and White Rural southern elders with a life-limiting illness']","['culturally based palliative care consult', 'community-developed, culturally based PC tele-consult program']","['patient and care partner quality of life (QOL), care partner burden, and resource use post-discharge']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1515258', 'cui_str': 'Telephone number (property)'}, {'cui': 'C0030360', 'cui_str': 'Papillon-Lefèvre syndrome'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0331055', 'cui_str': 'Genus Sambucus'}]","[{'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1515258', 'cui_str': 'Telephone number (property)'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]",,0.11513,"METHODS Community Tele-pal is a three-site RCT that will test the efficacy of a community-developed, culturally based PC tele-consult program for hospitalized rural AA and W older adults with life-limiting illnesses (n = 352) and a care partner.","[{'ForeName': 'Kristen Allen', 'Initials': 'KA', 'LastName': 'Watts', 'Affiliation': 'School of Medicine, Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, USA.'}, {'ForeName': 'Shena', 'Initials': 'S', 'LastName': 'Gazaway', 'Affiliation': 'College of Nursing, Augusta University, Augusta, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Malone', 'Affiliation': 'School of Medicine, Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, USA.'}, {'ForeName': 'Ronit', 'Initials': 'R', 'LastName': 'Elk', 'Affiliation': 'School of Medicine, Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, USA.'}, {'ForeName': 'Rodney', 'Initials': 'R', 'LastName': 'Tucker', 'Affiliation': 'School of Medicine, Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'McCammon', 'Affiliation': 'Center for Palliative and Supportive Care, University of Alabama at Birmingham, Birmingham, USA.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Goldhagen', 'Affiliation': 'Russell Medical Center, Alexander City, USA.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Graham', 'Affiliation': 'Forrest General Hospital, Hattiesburg, USA.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Tassin', 'Affiliation': 'Highland Community Hospital, Picayune, USA.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Hauser', 'Affiliation': 'Department of Medical Education at Northwestern University, Chicago, USA.'}, {'ForeName': 'Sidney', 'Initials': 'S', 'LastName': 'Rhoades', 'Affiliation': 'Aiken Regional Medical Center, Aiken, USA.'}, {'ForeName': 'Marjorie', 'Initials': 'M', 'LastName': 'Kagawa-Singer', 'Affiliation': 'Fielding School of Public Health, Department of Community Health Sciences, University of California Los Angeles, Los Angeles, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Wallace', 'Affiliation': 'Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'McElligott', 'Affiliation': 'College of Medicine, The Medical University of South Carolina, Charleston, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Kennedy', 'Affiliation': 'School of Medicine, Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, USA.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Bakitas', 'Affiliation': 'School of Nursing, University of Alabama at Birmingham, Birmingham, USA. mbakitas@uab.edu.'}]",Trials,['10.1186/s13063-020-04567-w'] 2788,32700364,Interventions commonly available during pandemics for heavy menstrual bleeding: an overview of Cochrane Reviews.,"BACKGROUND Within the context of heavy menstrual bleeding, pandemics impact upon women's assessment and treatment by healthcare providers. OBJECTIVES To summarise the evidence from Cochrane Reviews evaluating interventions for heavy menstrual bleeding that are commonly available during pandemics. METHODS We sought published Cochrane Reviews, evaluating interventions that can continue during pandemics for women with heavy menstrual bleeding with no known underlying cause. We identified Cochrane Reviews by searching the Cochrane Database of Systematic Reviews in June 2020. The primary outcome was menstrual bleeding. Secondary outcomes included quality of life, patient satisfaction, side effects, and serious adverse events. We undertook the selection of systematic reviews, data extraction, and quality assessment in duplicate. We resolved any disagreements by discussion. We assessed review quality using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) 2 tool, and the certainty of the evidence for each outcome using GRADE methods. MAIN RESULTS We included four Cochrane Reviews, with 11 comparisons, data from 44 randomised controlled trials (RCTs), and 3196 women. We assessed all the reviews to be high quality. Non-steroidal anti-inflammatory drugs (NSAIDs) NSAIDs may be more effective in reducing heavy menstrual bleeding than placebo (mean difference (MD) -124 mL per cycle, 95% confidence interval (CI) -186 to -62 mL per cycle; 1 RCT, 11 women; low-certainty evidence). Mefenamic acid may be similar to naproxen (MD 21 mL per cycle, 95% CI -6 to 48 mL per cycle; 2 RCTs, 61 women; low-certainty evidence), and NSAIDs may be similar to combined hormonal contraceptives for heavy menstrual bleeding (MD 25 mL per cycle, 95% CI -22 to 73 mL per cycle; 1 RCT, 26 women; low-certainty evidence). NSAIDs may be be less effective in reducing menstrual bleeding than antifibrinolytics (relative risk (RR) 0.70, 95% CI 0.58 to 0.85; 2 RCTs, 161 women; low-certainty evidence). We are uncertain whether NSAIDs reduce menstrual blood loss more than short-cycle progestogens (RR 0.80, 95% CI 0.49 to 1.32; 1 RCT 32 women; very low-certainty evidence). Antifibrinolytics Antifibrinolytics appear to be more effective in reducing heavy menstrual bleeding than placebo (MD -53 mL per cycle, 95% CI -63 to -44 mL per cycle; 4 RCTs, 565 women; moderate-certainty evidence). Antifibrinolytics may be similar to placebo on the incidence of side effects (RR 1.05, 95% CI 0.93 to 1.18; 1 RCT, 297 women; low-certainty evidence), and they are probably similar on the incidence of serious adverse events (thrombotic events; RR 0.10, 95% CI 0.00 to 2.46; 2 RCT, 468 women; moderate-certainty evidence). Antifibrinolytics may be more effective in reducing heavy menstrual bleeding than short-cycle progestogen (MD -111 mL per cycle, 95% CI -178 mL to -44 mL per cycle; 1 RCT, 46 women; low-certainty evidence). We are uncertain whether antifibrinolytics are similar to short-cycle progestogens on quality of life (RR 1.67, 95% CI 0.76 to 3.64; 1 RCT, 44 women; very low-certainty evidence), patient satisfaction (RR 0.91, 95% CI 0.59 to 1.39; 1 RCT, 42 women; very low-certainty evidence), or side effects (RR 0.85, 95% CI 0.65 to 1.12; 3 RCTs, 211 women; very low-certainty evidence). We are uncertain whether antifibrinolytics are more effective in reducing heavy menstrual bleeding when compared with long-cycle progestogen (MD -9 points per cycle, 95% CI -30 to 12 points per cycle; 2 RCTs, 184 women; low-certainty evidence). Antifibrinolytics may increase self-reported improvement in menstrual bleeding when compared with long-cycle medroxyprogesterone acetate (RR 1.32, 95% CI 1.08 to 1.61; 1 RCT, 94 women; low-certainty evidence). Antifibrinolytics may be similar to long-cycle progestogens on quality of life (MD 5, 95% CI -2.49 to 12.49; 1 RCT, 90 women; low-certainty evidence). We are uncertain whether antifibrinolytics are similar to long-cycle progestogens on side effects (RR 0.58, 95% CI 0.33 to 1.00; 2 RCTs, 184 women; very low-certainty evidence). There were no trials comparing antifibrinolytics to combined hormonal contraceptives. Combined hormonal contraceptives Combined hormonal contraceptives appear to be more effective for heavy menstrual bleeding than placebo or no treatment (RR 13.25, 95% CI 2.94 to 59.64; 2 RCTs, 363 women; moderate-certainty evidence). Combined hormonal contraceptives are probably similar to placebo on the incidence of side effects (RR 1.53, 95% CI 0.90 to 2.60; 2 RCTs, 411 women; moderate-certainty evidence). Progestogens There were no trials comparing progestogens to placebo. Limitations in the evidence included risk of bias in the primary RCTs, inconsistency between the primary RCTs, and imprecision in effect estimates. AUTHORS' CONCLUSIONS There is moderate-certainty evidence that antifibrinolytics and combined hormonal contraceptives reduce heavy menstrual bleeding compared with placebo. There is low-certainty evidence that NSAIDs reduce heavy menstrual bleeding compared with placebo. There is low-certainty evidence that antifibrinolytics are more effective in reducing heavy menstrual bleeding when compared with NSAIDs and short-cycle progestogens, but we are unable to draw conclusions about the effects of antifibrinolytics compared to long-cycle progestogens, on low-certainty evidence.",2020,"Combined hormonal contraceptives are probably similar to placebo on the incidence of side effects (RR 1.53, 95% CI 0.90 to 2.60; 2 RCTs, 411 women; moderate-certainty evidence).","['heavy menstrual bleeding', 'women with heavy menstrual bleeding with no known underlying cause', '3196 women']","['Progestogens', 'Mefenamic acid', 'medroxyprogesterone acetate', 'placebo']","['quality of life', 'quality of life, patient satisfaction, side effects, and serious adverse events', 'heavy menstrual bleeding', 'menstrual blood loss', 'menstrual bleeding', 'patient satisfaction', 'side effects']","[{'cui': 'C0025323', 'cui_str': 'Menorrhagia'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205309', 'cui_str': 'Known'}]","[{'cui': 'C0033306', 'cui_str': 'Progestational hormone'}, {'cui': 'C0025152', 'cui_str': 'mefenamic acid'}, {'cui': 'C0065864', 'cui_str': 'Medroxyprogesterone acetate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0025323', 'cui_str': 'Menorrhagia'}, {'cui': 'C0694689', 'cui_str': 'Menstrual blood'}, {'cui': 'C0025344', 'cui_str': 'Menstruation'}]",4.0,0.562988,"Combined hormonal contraceptives are probably similar to placebo on the incidence of side effects (RR 1.53, 95% CI 0.90 to 2.60; 2 RCTs, 411 women; moderate-certainty evidence).","[{'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Bofill Rodriguez', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Lethaby', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Farquhar', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'James Mn', 'Initials': 'JM', 'LastName': 'Duffy', 'Affiliation': ""King's Fertility, Fetal Medicine Research Institute, London, UK.""}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD013651.pub2'] 2789,32700389,Do physician incentives increase patient medication adherence?,"OBJECTIVE To test the effectiveness of physician incentives for increasing patient medication adherence in three drug classes: diabetes medication, antihypertensives, and statins. DATA SOURCES Pharmacy and medical claims from a large Medicare Advantage Prescription Drug Plan from January 2011 to December 2012. STUDY DESIGN We conducted a randomized experiment (911 primary care practices and 8,935 nonadherent patients) to test the effect of paying physicians for increasing patient medication adherence in three drug classes: diabetes medication, antihypertensives, and statins. We measured patients' medication adherence for 18 (6) months before (after) the intervention. DATA COLLECTION/EXTRACTION METHODS We obtained data directly from the health insurer. PRINCIPAL FINDINGS We found no evidence that physician incentives increased adherence in any drug class. Our results rule out increases in the proportion of days covered by medication larger than 4.2 percentage points. CONCLUSIONS Physician incentives of $50 per patient per drug class are not effective for increasing patient medication adherence among the drug classes and primary care practices studied. Such incentives may be more likely to improve measures under physicians' direct control rather than those that predominantly reflect patient behaviors. Additional research is warranted to disentangle whether physician effort is not responsive to these types of incentives, or medication adherence is not responsive to physician effort. Our results suggest that significant changes in the incentive amount or program design may be necessary to produce responses from physicians or patients.",2020,"CONCLUSIONS Physician incentives of $50 per patient per drug class are not effective for increasing patient medication adherence among the drug classes and primary care practices studied.","['911 primary care practices and 8,935 nonadherent patients']","['paying physicians for increasing patient medication adherence in three drug classes: diabetes medication, antihypertensives, and statins']",['patient medication adherence'],"[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}]",,0.0217103,"CONCLUSIONS Physician incentives of $50 per patient per drug class are not effective for increasing patient medication adherence among the drug classes and primary care practices studied.","[{'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Kong', 'Affiliation': 'Harvard Medical School, Boston, MA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Beshears', 'Affiliation': 'Negotiation, Organizations & Markets Unit, Harvard Business School, Boston, MA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Laibson', 'Affiliation': 'Harvard Department of Economics, Cambridge, MA.'}, {'ForeName': 'Brigitte', 'Initials': 'B', 'LastName': 'Madrian', 'Affiliation': 'National Bureau of Economic Research, Cambridge, MA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Volpp', 'Affiliation': 'Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Loewenstein', 'Affiliation': 'Department of Social and Decision Sciences, Carnegie Mellon University Dietrich College of Humanities and Social Sciences, Pittsburgh, PA.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Kolstad', 'Affiliation': 'National Bureau of Economic Research, Cambridge, MA.'}, {'ForeName': 'James J', 'Initials': 'JJ', 'LastName': 'Choi', 'Affiliation': 'National Bureau of Economic Research, Cambridge, MA.'}]",Health services research,['10.1111/1475-6773.13322'] 2790,32700393,The effects of ertugliflozin on β-cell function: Pooled analysis from four phase 3 randomized controlled studies.,"AIMS To identify potential predictors and mediators of changes in β-cell function in response to ertugliflozin treatment in people with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS Data from patients with T2DM randomized to ertugliflozin (5 or 15 mg; observations from both doses were pooled) or placebo in four phase 3 clinical studies (clinicaltrials.gov: NCT01958671, NCT02226003, NCT02036515, NCT02099110) were pooled and analyzed. Change from baseline in β-cell function at Week 26 was assessed and its potential predictors and mediators were analyzed by linear and multiple regression analyses. RESULTS Compared with placebo, ertugliflozin improved β-cell function when assessed by the mean percent change from baseline (95% CI) in homeostatic model assessment (HOMA)-%β (ertugliflozin: 14.7% [12.3, 17.1]; placebo: -0.4% [-3.4, 2.5]) but not when assessed by change in the C-peptide index following a mixed meal tolerance test. Change in HOMA-%β correlated with change from baseline in HbA1c, treatment with ertugliflozin, and weakly with change from baseline in body weight. In the ertugliflozin group, change in HOMA-%β correlated with baseline fasting plasma glucose (FPG; r=0.235; P<0.001), baseline HbA1c (r=0.138; P<0.001), baseline HOMA of insulin resistance (HOMA-IR; r=0.162; P<0.01), and baseline HOMA-%β (r=-0.321, P<0.001) in linear regression analyses. Multiple regression analyses yielded similar results. CONCLUSION In people with T2DM, ertugliflozin treatment improves fasting β-cell function but no effect on postprandial β-cell function was observed in this analysis. Improvement in HOMA-%β was predicted by high baseline FPG, HbA1C, HOMA-IR, and low baseline HOMA-%β, and mediated by ertugliflozin treatment, and improved HbA1c and body weight. This article is protected by copyright. All rights reserved.",2020,"Improvement in HOMA-%β was predicted by high baseline FPG, HbA1C, HOMA-IR, and low baseline HOMA-%β, and mediated by ertugliflozin treatment, and improved HbA1c and body weight.","['Data from patients with T2DM randomized to', 'people with type 2 diabetes mellitus (T2DM']","['ertugliflozin', 'ertugliflozin treatment', 'placebo, ertugliflozin', 'placebo']","['homeostatic model assessment', 'fasting β-cell function', 'Change in HOMA-%β', 'β-cell function', 'change in HOMA-%β correlated with baseline fasting plasma glucose', 'high baseline FPG, HbA1C, HOMA-IR, and low baseline HOMA-%β, and mediated by ertugliflozin treatment, and improved HbA1c and body weight', 'postprandial β-cell function', 'baseline HOMA of insulin resistance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}]","[{'cui': 'C4079805', 'cui_str': 'ertugliflozin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0007613', 'cui_str': 'Physiology, Cell'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C4079805', 'cui_str': 'ertugliflozin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}]",,0.125365,"Improvement in HOMA-%β was predicted by high baseline FPG, HbA1C, HOMA-IR, and low baseline HOMA-%β, and mediated by ertugliflozin treatment, and improved HbA1c and body weight.","[{'ForeName': 'Silvina', 'Initials': 'S', 'LastName': 'Gallo', 'Affiliation': 'Pfizer Pharma GmbH, Berlin, Germany.'}, {'ForeName': 'Annaswamy', 'Initials': 'A', 'LastName': 'Raji', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Roberto A', 'Initials': 'RA', 'LastName': 'Calle', 'Affiliation': 'Pfizer Inc., Cambridge, MA, USA.'}, {'ForeName': 'Annpey', 'Initials': 'A', 'LastName': 'Pong', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Meyer', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14149'] 2791,32700396,Effect of cilostazol on carotid plaque volume measured by 3D ultrasound in patients with type 2 diabetes: FANCY study.,"AIMS We conducted a prospective randomized study to evaluate cilostazol, a phosphodiesterase III inhibitor, and compare it with aspirin for the prevention of the progression of atherosclerosis in patients with type 2 diabetes (T2D). MATERIALS AND METHODS Fifty patients with T2D and carotid atherosclerotic plaques were randomly assigned to either 200 mg/day cilostazol (CTZ) or 100 mg/day aspirin (ASA) groups for 6 months. The primary end point was change in plaque volume measured by carotid 3D ultrasound. The secondary end points were changes in carotid intima-media thickness (IMT) and endothelial functions assessed by laser Doppler. RESULTS Twenty-four patients in the CTZ group and 23 in the ASA group were included in the final analysis. The mean age of male (n = 20) and female (n = 16) patients was 62.2 and 59.1 years, respectively. The total plaque volume was slightly decreased in the CTZ group (from 183.8 ± 52.5 to 181.5 ± 54.0 mm 3 , P = 0.567), but significantly increased in the ASA group (from 112.9 ± 21.2 to 128.5 ± 23.3 mm 3 , P = 0.043). A significant regression in the maximum IMT was observed only in the CTZ group (right: from 2.19 ± 0.17 to 1.96 ± 0.12 mm; left: from 2.02 ± 0.20 to 1.72 ± 0.19 mm). The CTZ group exhibited an increase in HDL-cholesterol and a decrease in triglycerides and liver enzymes. CONCLUSIONS Cilostazol treatment for 6 months significantly attenuated the progression of carotid plaque compared with aspirin in patients with T2D (NCT03248401). This article is protected by copyright. All rights reserved.",2020,"The total plaque volume was slightly decreased in the CTZ group (from 183.8 ± 52.5 to 181.5 ± 54.0 mm 3 , P = 0.567), but significantly increased in the ASA group (from 112.9 ± 21.2 to 128.5 ± 23.3 mm 3 , P = 0.043).","['mean age of male (n\xa0=\xa020) and female (n\xa0=\xa016) patients was 62.2 and 59.1\u2009years, respectively', 'Fifty patients with T2D and carotid atherosclerotic plaques', 'patients with type 2 diabetes', 'patients with type 2 diabetes (T2D']","['cilostazol', 'aspirin', '200 mg/day cilostazol (CTZ) or 100 mg/day aspirin (ASA', 'CTZ', 'cilostazol, a phosphodiesterase III inhibitor']","['total plaque volume', 'plaque volume', 'maximum IMT', 'HDL-cholesterol', 'carotid plaque volume', 'progression of carotid plaque', 'triglycerides and liver enzymes', 'carotid intima-media thickness (IMT) and endothelial functions assessed by laser Doppler']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C2936350', 'cui_str': 'Atherosclerotic Plaques'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C0055729', 'cui_str': 'cilostazol'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0292144', 'cui_str': 'Phosphodiesterase III'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0162864', 'cui_str': 'Tunica intima'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol in high density lipoprotein subfraction 2'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0430489', 'cui_str': 'Laser doppler'}]",50.0,0.059515,"The total plaque volume was slightly decreased in the CTZ group (from 183.8 ± 52.5 to 181.5 ± 54.0 mm 3 , P = 0.567), but significantly increased in the ASA group (from 112.9 ± 21.2 to 128.5 ± 23.3 mm 3 , P = 0.043).","[{'ForeName': 'Dong-Hwa', 'Initials': 'DH', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, South Korea.'}, {'ForeName': 'Eun Ju', 'Initials': 'EJ', 'LastName': 'Chun', 'Affiliation': 'Department of Radiology, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, South Korea.'}, {'ForeName': 'Ji Hye', 'Initials': 'JH', 'LastName': 'Moon', 'Affiliation': 'Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, South Korea.'}, {'ForeName': 'Han Mi', 'Initials': 'HM', 'LastName': 'Yun', 'Affiliation': 'Physiologic Diagnostic Laboratory, Vascular Laboratory, Seoul National University Bundang Hospital, South Korea.'}, {'ForeName': 'Soo', 'Initials': 'S', 'LastName': 'Lim', 'Affiliation': 'Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, South Korea.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14147'] 2792,32702664,Effect of an Exergaming-Based Dance Training Paradigm on Autonomic Nervous System Modulation in Healthy Older Adults: A Randomized Controlled Trial.,"The purpose of this study was to determine if an exergaming-based dance training protocol can improve heart rate variability (HRV) in healthy older adults. A total of 20 healthy older adults (≥65 years old) were randomly assigned to two groups. The intervention group received an exergaming-based dance aerobic training for 6 weeks, while the control group received a 1-hr education on conventional physical exercises. Data obtained from HRV analysis pre- (Week 0) and postintervention (Week 7) consisted of high-frequency power, low- and high-frequency ratio, and root mean square of differences and percentage of adjacent RR intervals with a difference of duration greater than 50 ms values. HRV was assessed during rest and during a 6-min walk test. In addition, the YMCA submaximal cycle ergometer test was used to acquire estimated maximal O2 consumption pre- and postintervention. After the training, the intervention group showed significant improvement in HRV high-frequency power, root mean square of differences, and percentage of adjacent RR intervals with a difference of duration greater than 50 ms values in both rest and 6-min walk test conditions compared with the control group. Similarly, the intervention group showed higher maximal O2 consumption compared with the control group after the training. Our results support the effectiveness of an exergaming-based dance aerobic training on improving cardiac autonomic control in aging.",2020,"After the training, the intervention group showed significant improvement in HRV high-frequency power, root mean square of differences, and percentage of adjacent RR intervals with a difference of duration greater than 50 ms values in both rest and 6-min walk test conditions compared with the control group.","['20 healthy older adults (≥65 years old', 'healthy older adults', 'Healthy Older Adults']","['exergaming-based dance aerobic training', 'exergaming-based dance training protocol', 'exergaming-based dance aerobic training for 6 weeks, while the control group received a 1-hr education on conventional physical exercises', 'Exergaming-Based Dance Training Paradigm']","['HRV high-frequency power, root mean square of differences, and percentage of adjacent RR intervals', 'maximal O2 consumption', 'HRV', 'cardiac autonomic control', 'heart rate variability (HRV']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0010963', 'cui_str': 'Dance'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0205117', 'cui_str': 'Juxta-posed'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",20.0,0.0577257,"After the training, the intervention group showed significant improvement in HRV high-frequency power, root mean square of differences, and percentage of adjacent RR intervals with a difference of duration greater than 50 ms values in both rest and 6-min walk test conditions compared with the control group.","[{'ForeName': 'Gonzalo', 'Initials': 'G', 'LastName': 'Varas-Diaz', 'Affiliation': ''}, {'ForeName': 'Savitha', 'Initials': 'S', 'LastName': 'Subramaniam', 'Affiliation': ''}, {'ForeName': 'Larissa', 'Initials': 'L', 'LastName': 'Delgado', 'Affiliation': ''}, {'ForeName': 'Shane A', 'Initials': 'SA', 'LastName': 'Phillips', 'Affiliation': ''}, {'ForeName': 'Tanvi', 'Initials': 'T', 'LastName': 'Bhatt', 'Affiliation': ''}]",Journal of aging and physical activity,['10.1123/japa.2019-0452'] 2793,32702697,Comparison of Middle and Lower Calyceal Access for Renal Pelvis Stone in Percutaneous Nephrolithotomy: A Prospective Randomized Study.,"OBJECTIVE The aim of the study was to evaluate the possible effects of calyceal choice for renal puncture under sonographic guidance on the outcomes of percutaneous nephrolithotomy (PNL). MATERIALS AND METHODS A total of 70 patients for whom ultrasound-guided PNL was planned for 20-30-mm single renal pelvic stones were prospectively allocated to group 1 (n:35) with middle calyx entry or group 2 (n:35) with lower calyx entry. Procedure-related parameters such as duration of operation, stone-free rates, complication rates, and radiation exposure time were analyzed in detail. RESULTS The mean age of the patients was 45.67 ± 1.50 years and the mean stone size was 316.4 ± 17.95 mm2. There was no significant difference regarding the age, BMI, stone burden, and the grade of hydronephrosis between the groups. Skin to collecting system distance was significantly shorter in the middle calyx entrance (p = 0.021). Total duration of the procedure was again significantly shorter in group 1 cases (74.69 ± 2.94 min) than in group 2 (84.29 ± 4.25 min) (p = 0.003). Regarding the success rates, the postoperative stone-free rate was higher in group 1 (91.4% in group 1, 80.0% in group 2, p = 0.305). Last, there was no statistically significant difference in hemoglobin reduction rates, blood transfusion requirements, and complication rates between the 2 groups. CONCLUSION Getting access to the renal pelvis through the middle calyx during ultrasonic guided PNL procedure is more advantageous to lower the calyceal approach by reducing both the duration of the PNL procedure with significantly higher stone-free and comparable complication rates.",2020,Total duration of the procedure was again significantly shorter in group 1 cases (74.69 ± 2.94 min) than in group 2 (84.29 ± 4.25 min) (p = 0.003).,"['70 patients for whom ultrasound-guided PNL was planned for 20-30-mm single renal pelvic stones', 'Renal Pelvis Stone in Percutaneous Nephrolithotomy', 'The mean age of the patients was 45.67 ± 1.50 years and the mean stone size was 316.4 ± 17.95 mm2']","['percutaneous nephrolithotomy (PNL', 'renal puncture under sonographic guidance', 'Middle and Lower Calyceal Access', 'middle calyx entry or group 2 (n:35) with lower calyx entry']","['age, BMI, stone burden, and the grade of hydronephrosis', 'hemoglobin reduction rates, blood transfusion requirements, and complication rates', 'postoperative stone-free rate', 'Total duration of the procedure', 'duration of operation, stone-free rates, complication rates, and radiation exposure time']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0162428', 'cui_str': 'Removal of calculus of renal pelvis through percutaneous nephrostomy'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0450396', 'cui_str': '30mm'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0227666', 'cui_str': 'Renal pelvis structure'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0449454', 'cui_str': 'Stone size'}, {'cui': 'C0456786', 'cui_str': 'sq. mm'}]","[{'cui': 'C0162428', 'cui_str': 'Removal of calculus of renal pelvis through percutaneous nephrostomy'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0022651', 'cui_str': 'Renal calyx'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}]","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0020295', 'cui_str': 'Hydronephrosis'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0015333', 'cui_str': 'Exposure to radiation'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",70.0,0.0280723,Total duration of the procedure was again significantly shorter in group 1 cases (74.69 ± 2.94 min) than in group 2 (84.29 ± 4.25 min) (p = 0.003).,"[{'ForeName': 'Bilal', 'Initials': 'B', 'LastName': 'Eryildirim', 'Affiliation': 'Health Sciences University, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Urology Clinic, Istanbul, Turkey, bilaleryildirim@yahoo.com.'}, {'ForeName': 'Kemal', 'Initials': 'K', 'LastName': 'Sarica', 'Affiliation': 'Biruni University, Medical School, Urology Clinic, Istanbul, Turkey.'}, {'ForeName': 'Fatih', 'Initials': 'F', 'LastName': 'Ustun', 'Affiliation': 'Health Sciences University, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Urology Clinic, Istanbul, Turkey.'}, {'ForeName': 'Ahmet Halil', 'Initials': 'AH', 'LastName': 'Sevinc', 'Affiliation': 'Health Sciences University, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Urology Clinic, Istanbul, Turkey.'}, {'ForeName': 'Berkan', 'Initials': 'B', 'LastName': 'Simsek', 'Affiliation': 'Health Sciences University, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Urology Clinic, Istanbul, Turkey.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Sahan', 'Affiliation': 'Health Sciences University, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Urology Clinic, Istanbul, Turkey.'}, {'ForeName': 'Cengiz', 'Initials': 'C', 'LastName': 'Canakci', 'Affiliation': 'Health Sciences University, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Urology Clinic, Istanbul, Turkey.'}, {'ForeName': 'Fatih', 'Initials': 'F', 'LastName': 'Tarhan', 'Affiliation': 'Health Sciences University, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Urology Clinic, Istanbul, Turkey.'}]",Urologia internationalis,['10.1159/000509330'] 2794,32702699,Brain Imaging Signs and Health-Related Quality of Life after Acute Ischemic Stroke: Analysis of ENCHANTED Alteplase Dose Arm.,"BACKGROUND AND PURPOSE The influence of specific brain lesions on health-related quality of life (HRQoL) after acute ischemic stroke (AIS) is uncertain. We aimed to identify imaging predictors of poor HRQoL in alteplase-treated participants of the alteplase dose arm of the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED). METHODS ENCHANTED was an international trial of low- versus standard-dose intravenous alteplase in AIS patients, with functional outcome (modified Rankin scale [mRS]) and HRQoL on the 5-dimension European Quality of Life Scale (EQ-5D) assessed at 90 days post-randomization. Brain images were analyzed centrally by trained assessors. Multivariable logistic regression was undertaken in the study population randomly divided (2:1) into training (development) and validation (performance) groups, with age (per 10-year increase), ethnicity, baseline National Institutes of Health Stroke Scale (NIHSS) score, diabetes mellitus, premorbid function (mRS score 0 or 1), and proxy respondent, forced into all models. Data are presented with odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS Eight prediction models were developed and validated in 2,526 AIS patients (median age 67.5 years; 38.4% female; 61.7% Asian) with complete brain imaging and 90-day EQ-5D utility score data. The best performance model included acute ischemic changes in the right (OR 1.69, 95% CI: 1.24-2.29) and deep (OR 1.50, 95% CI: 1.03-2.19) middle cerebral artery (MCA) regions. Several background features of brain frailty - atrophy, white matter change, and old infarcts - were significantly associated with adverse physical but not emotional HRQoL domains. CONCLUSIONS In thrombolysed AIS patients, right-sided and deep ischemia within the MCA territory predict poor overall HRQoL, whilst features of old cerebral ischemia are associated with reduced physical HRQoL.",2020,"The best performance model included acute ischemic changes in the right (OR 1.69, 95% CI: 1.24-2.29) and deep (OR 1.50, 95% CI: 1.03-2.19) middle cerebral artery (MCA) regions.","['2,526 AIS patients (median age 67.5 years; 38.4% female; 61.7% Asian) with', 'after Acute Ischemic Stroke']",['low- versus standard-dose intravenous alteplase'],"['health-related quality of life (HRQoL', 'right-sided and deep ischemia', 'Health Stroke Scale (NIHSS', 'score, diabetes mellitus', 'functional outcome (modified Rankin scale [mRS]) and HRQoL on the 5-dimension European Quality of Life Scale (EQ-5D', 'physical HRQoL', 'complete brain imaging and 90-day EQ-5D utility score data', 'acute ischemic changes', 'Brain Imaging Signs and Health-Related Quality of Life', 'premorbid function (mRS score 0 or 1), and proxy respondent']","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0032143', 'cui_str': 'alteplase'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1697238', 'cui_str': 'NIH stroke scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0203860', 'cui_str': 'Imaging of brain'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}, {'cui': 'C0600420', 'cui_str': 'Proxy'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}]",2526.0,0.097416,"The best performance model included acute ischemic changes in the right (OR 1.69, 95% CI: 1.24-2.29) and deep (OR 1.50, 95% CI: 1.03-2.19) middle cerebral artery (MCA) regions.","[{'ForeName': 'Xiaoying', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Candice', 'Initials': 'C', 'LastName': 'Delcourt', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Lingli', 'Initials': 'L', 'LastName': 'Sun', 'Affiliation': 'The George Institute China at Peking University Health Science Centre, Beijing, China.'}, {'ForeName': 'Zien', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Sohei', 'Initials': 'S', 'LastName': 'Yoshimura', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Shoujiang', 'Initials': 'S', 'LastName': 'You', 'Affiliation': 'Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China.'}, {'ForeName': 'Alejandra', 'Initials': 'A', 'LastName': 'Malavera', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Takako', 'Initials': 'T', 'LastName': 'Torii-Yoshimura', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Carcel', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Hisatomi', 'Initials': 'H', 'LastName': 'Arima', 'Affiliation': 'Department of Preventive Medicine and Public Health, Fukuoka University, Fukuoka, Japan.'}, {'ForeName': 'Maree L', 'Initials': 'ML', 'LastName': 'Hackett', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Thompson', 'Initials': 'T', 'LastName': 'Robinson', 'Affiliation': 'Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.'}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Song', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Richard I', 'Initials': 'RI', 'LastName': 'Lindley', 'Affiliation': 'Westmead Applied Research Centre, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Chalmers', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Craig S', 'Initials': 'CS', 'LastName': 'Anderson', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Camperdown, New South Wales, Australia, canderson@georgeinstitute.org.au.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Cerebrovascular diseases (Basel, Switzerland)",['10.1159/000509226'] 2795,32702706,"Fitness, Strength and Body Composition during Weight Loss in Women with Clinically Severe Obesity: A Randomised Clinical Trial.","INTRODUCTION To determine whether combined exercise training with an energy-restricted diet leads to improved physical fitness and body composition when compared to energy restriction alone in free-living premenopausal women with clinically severe obesity. METHODS Sixty premenopausal women (BMI of 40.4 ± 6.7) were randomised to energy restriction only (ER) or to exercise plus energy restriction (EXER) for 12 months. Body composition and fitness were measured at baseline, 3, 6 and 12 months. RESULTS VO2 peak improved more for EXER compared to ER at 3 (mean difference ± SEM 2.5 ± 0.9 mL ∙ kg-1 ∙ min-1, p = 0.006) and 6 (3.1 ± 1.2 mL ∙ kg-1 ∙ min-1, p = 0.007) but not 12 months (2.3 ± 1.6 mL ∙ kg-1 ∙ min-1, p = 0.15). Muscle strength improved more for EXER compared to ER at all time points. No differences between groups for lean mass were observed at 12 months. CONCLUSION Combining exercise training with an energy-restricted diet did not lead to greater aerobic power, total body mass, fat mass or limit lean body mass loss at 12 months when compared to energy restriction alone for premenopausal women with clinically severe obesity in free-living situations. Future research should aim to determine an effective lifestyle approach which can be applied in the community setting for this high-risk group.",2020,"Combining exercise training with an energy-restricted diet did not lead to greater aerobic power, total body mass, fat mass or limit lean body mass loss at 12 months when compared to energy restriction alone for premenopausal women with clinically severe obesity in free-living situations.","['premenopausal women with clinically severe obesity in free-living situations', 'free-living premenopausal women with clinically severe obesity', 'Sixty premenopausal women (BMI of 40.4 ± 6.7', 'Women with Clinically Severe Obesity']","['EXER', 'energy restriction only (ER) or to exercise plus energy restriction (EXER', 'energy restriction alone', 'Combining exercise training with an energy-restricted diet', 'mL', 'combined exercise training']","['Fitness, Strength and Body Composition during Weight Loss', 'Muscle strength', 'lean mass', 'VO2 peak', 'aerobic power, total body mass, fat mass or limit lean body mass loss', 'physical fitness and body composition', 'Body composition and fitness']","[{'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0028756', 'cui_str': 'Morbid obesity'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0667627', 'cui_str': 'bis(kojato)oxovanadium(IV)'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}]",60.0,0.0944376,"Combining exercise training with an energy-restricted diet did not lead to greater aerobic power, total body mass, fat mass or limit lean body mass loss at 12 months when compared to energy restriction alone for premenopausal women with clinically severe obesity in free-living situations.","[{'ForeName': 'Clint T', 'Initials': 'CT', 'LastName': 'Miller', 'Affiliation': 'School of Exercise and Nutrition Sciences, Deakin University, Geelong, Victoria, Australia, c.miller@deakin.edu.au.'}, {'ForeName': 'Steve F', 'Initials': 'SF', 'LastName': 'Fraser', 'Affiliation': 'School of Exercise and Nutrition Sciences, Deakin University, Geelong, Victoria, Australia.'}, {'ForeName': 'Steve E', 'Initials': 'SE', 'LastName': 'Selig', 'Affiliation': 'School of Exercise and Nutrition Sciences, Deakin University, Geelong, Victoria, Australia.'}, {'ForeName': 'Toni', 'Initials': 'T', 'LastName': 'Rice', 'Affiliation': 'Clinical Obesity Research Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Mariee', 'Initials': 'M', 'LastName': 'Grima', 'Affiliation': 'Clinical Obesity Research Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'van den Hoek', 'Affiliation': 'Institute for Physical Activity and Nutrition, Deakin University, Geelong, Victoria, Australia.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Ika Sari', 'Affiliation': 'Human Neurotransmitters and Clinical Obesity Research Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Gavin W', 'Initials': 'GW', 'LastName': 'Lambert', 'Affiliation': 'Human Neurotransmitters and Clinical Obesity Research Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Dixon', 'Affiliation': 'Clinical Obesity Research Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}]",Obesity facts,['10.1159/000506643'] 2796,32702878,"Low-level light therapy using a helmet-type device for the treatment of androgenetic alopecia: A 16-week, multicenter, randomized, double-blind, sham device-controlled trial.","INTRODUCTION Androgenetic alopecia is the most common form of hair loss in both sexes. In recent studies, low-level light therapy (LLLT) has been established as an effective treatment for alopecia. The purpose of this study was to evaluate the safety and efficacy of LLLT using a new helmet-type device for the treatment of androgenetic alopecia. METHOD A randomized, sham device-controlled, double-blind clinical trial was conducted at 2 institutions. Sixty participants diagnosed with androgenetic alopecia aged from 19 to 65 years were recruited. LLLT was performed through a helmet-type device that emitted light with a mean output power of 2.36 mW/cm at a wavelength of 655 nm. Participants were divided into 2 groups, which respectively used the experimental device and a sham device. After tattooing at the central point of the vertex, phototrichograms at that point were obtained at 0, 8, and 16 weeks. The primary endpoint of the study was the difference in the rate of change of hair density between the test group and the control group. RESULTS Comparing the results at baseline and week 16, the experimental group showed an increase in hair density of 41.90 hairs/cm and an increase in hair thickness of 7.50 μm, whereas the control group showed an increase of 0.72 hairs/cm and a decrease of 15.03 μm, respectively (P < .001). No adverse events or side effects occurred. CONCLUSION LLLT showed a significant effect on increasing hair density in patients with androgenetic alopecia. LLLT could be a safe and effective treatment for androgenetic alopecia in both sexes.",2020,"No adverse events or side effects occurred. ","['Sixty participants diagnosed with androgenetic alopecia aged from 19 to 65 years were recruited', 'patients with androgenetic alopecia', 'androgenetic alopecia']","['LLLT', 'Low-level light therapy using a helmet-type device', 'low-level light therapy (LLLT']","['hair thickness', 'safety and efficacy', 'rate of change of hair density', 'hair density']","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0162311', 'cui_str': 'Alopecia hereditaria'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0031765', 'cui_str': 'Light therapy'}, {'cui': 'C4019433', 'cui_str': 'Photobiomodulation Therapy'}, {'cui': 'C0018884', 'cui_str': 'Helmet'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0178587', 'cui_str': 'Density'}]",60.0,0.270093,"No adverse events or side effects occurred. ","[{'ForeName': 'Jung Soo', 'Initials': 'JS', 'LastName': 'Yoon', 'Affiliation': 'aDepartment of Plastic and Reconstructive Surgery, DongGuk University Ilsan Medical Center, Goyang, South Korea bDepartment of Plastic and Reconstructive Surgery, Hanyang University Medical Center, Hanyang University College of Medicine, Seoul cDepartment of Plastic and Reconstructive Surgery, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.'}, {'ForeName': 'Won Young', 'Initials': 'WY', 'LastName': 'Ku', 'Affiliation': ''}, {'ForeName': 'Jang Hyun', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'Hee Chang', 'Initials': 'HC', 'LastName': 'Ahn', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021181'] 2797,32702879,Effects of concurrent aerobic and resistance exercise in frail and pre-frail older adults: A randomized trial of supervised versus home-based programs.,"BACKGROUND This study aimed to investigate the effects of supervised and home-based exercise programs on older people with frailty or pre-frailty. METHODS A total of 146 community-dwelling participants aged 65 and older who were prefrail or frail were randomly allocated into supervised exercise (N = 74) and home exercise (N = 72) groups. The 3-month supervised exercise training consisted of 3 exercise sessions per week, was performed at a hospital and supervised by a physical therapist. Home exercise participants took instructions on exercise and illustrated exercise handouts. The baseline and 3-month follow-up measurements included body composition, strength of selected upper and lower limb muscle groups, grip and leg press strengths, and five physical performance tests. Mixed-model repeated-measures analysis was applied to determine whether two groups differ in terms of changes before and after the intervention and to compare within-group improvements. RESULTS After 3 months of supervised or home-based exercise, the average number of frailty criteria met and fat percentage decreased significantly. Strength of knee extensors, knee flexors and leg press improved significantly in supervised exercise group. In home-based exercise group, the strength of all muscle groups tested improved significantly, except for leg press strength. Walking speed improved in both groups, and timed-up-and-go and timed chair rise tests improved significantly only in supervised exercise group. CONCLUSIONS Three-month supervised or home-based exercise improved walking speed and strength of the limb muscles. Supervised group showed more improvements in the physical performance tests compared with home-based exercise group.",2020,"Walking speed improved in both groups, and timed-up-and-go and timed chair rise tests improved significantly only in supervised exercise group. ","['A total of 146 community-dwelling participants aged 65 and older who were prefrail or frail', 'frail and pre-frail older adults', 'older people with frailty or pre-frailty']","['concurrent aerobic and resistance exercise', 'supervised exercise (N\u200a=\u200a74) and home exercise', 'Home exercise participants took instructions on exercise and illustrated exercise handouts', 'supervised and home-based exercise programs', 'supervised exercise training consisted of 3 exercise sessions per week, was performed at a hospital and supervised by a physical therapist']","['Walking speed', 'walking speed and strength of the limb muscles', 'physical performance tests', 'leg press strength', 'Strength of knee extensors, knee flexors and leg press', 'body composition, strength of selected upper and lower limb muscle groups, grip and leg press strengths, and five physical performance tests']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0079379', 'cui_str': 'Frail Older Adults'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}]","[{'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}]","[{'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0220843', 'cui_str': 'Grasp'}]",146.0,0.0319741,"Walking speed improved in both groups, and timed-up-and-go and timed chair rise tests improved significantly only in supervised exercise group. ","[{'ForeName': 'Nai-Hsin', 'Initials': 'NH', 'LastName': 'Meng', 'Affiliation': 'aDepartment of Physical Medicine and Rehabilitation, China Medical University Hospital bSchool of Medicine, College of Medicine, China Medical University cDepartment of Medical Research dDepartment of Family Medicine, China Medical University Hospital eDepartment of Public Health, College of Public Health, China Medical University fDepartment of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan.'}, {'ForeName': 'Chia-Ing', 'Initials': 'CI', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Chiu-Shong', 'Initials': 'CS', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Chih-Hsueh', 'Initials': 'CH', 'LastName': 'Lin', 'Affiliation': ''}, {'ForeName': 'Chin-Kai', 'Initials': 'CK', 'LastName': 'Chang', 'Affiliation': ''}, {'ForeName': 'Heng-Wei', 'Initials': 'HW', 'LastName': 'Chang', 'Affiliation': ''}, {'ForeName': 'Chuan-Wei', 'Initials': 'CW', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Tsai-Chung', 'Initials': 'TC', 'LastName': 'Li', 'Affiliation': ''}, {'ForeName': 'Cheng-Chieh', 'Initials': 'CC', 'LastName': 'Lin', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021187'] 2798,32702891,Efficacy and safety of epidural steroid injection following discectomy for patients with lumbar disc herniation: A protocol.,"BACKGROUND Concerns exist regarding the analgesia effect and safety of epidural steroid injection (ESI) after discectomy. There is an urgent need of studies that efficiently control for confounding, conduct comprehensive and consecutive observation of potential risks of ESI, and investigate its clinical applicability. We thus further designed a randomized controlled study to assess the efficacy of ESI on postoperative pain and complications in patients undergoing unilateral lumbar microdiscectomy. METHODS This prospective, blinded randomized controlled trial was conducted at our single hospital. This study was approved by the Committee at the No.2 People's Hospital of Yibin. All procedures were performed by a single surgeon and informed consent was obtained from each patient. Ninty eligible patients diagnosed at our institution with herniated lumbar disc during a period from June 2020 to July 2021 will be assessed. Group 1 was a mixture of 1 mL of 0.5% bupivacaine and 10 mg of triamcinolone acetonide in 1 mL. Group 2 was a mixture of 1 mL of 0.5% bupivacaine and 1 mL of normal saline. The primary outcome measure was the amount of morphine consumption from a patient-controlled analgesia pump at 12, 24, and 48 hours after surgery. The following secondary outcomes were also assessed: postoperative pain score, back pain score, functional disability, and adverse effect. CONCLUSIONS We hypothesized that the ESI was associated with lower pain score, morphine consumption, and hospital stay, with no significant difference in complications for ESI application after lumbar discectomy in lumbar disc herniation when compared with placebo. TRIAL REGISTRATION This study protocol was registered in Research Registry (researchregistry5683).",2020,"We hypothesized that the ESI was associated with lower pain score, morphine consumption, and hospital stay, with no significant difference in complications for ESI application after lumbar discectomy in lumbar disc herniation when compared with placebo. ","['Ninty eligible patients diagnosed at our institution with herniated lumbar disc during a period from June 2020 to July 2021 will be assessed', 'patients undergoing unilateral lumbar microdiscectomy', 'patients with lumbar disc herniation', ""No.2 People's Hospital of Yibin""]","['bupivacaine and 1 mL of normal saline', 'bupivacaine', 'ESI', 'epidural steroid injection (ESI', 'epidural steroid injection', 'triamcinolone acetonide']","['Efficacy and safety', 'postoperative pain and complications', 'lower pain score, morphine consumption, and hospital stay', 'postoperative pain score, back pain score, functional disability, and adverse effect', 'amount of morphine consumption']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0347984', 'cui_str': 'During'}, {'cui': 'C0042950', 'cui_str': 'Volition'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0457629', 'cui_str': 'Lumbar microdiscectomy'}, {'cui': 'C0281899', 'cui_str': 'Prolapsed lumbar intervertebral disc'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0196394', 'cui_str': 'Epidural steroid injection'}, {'cui': 'C0040866', 'cui_str': 'Triamcinolone acetonide'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",,0.324268,"We hypothesized that the ESI was associated with lower pain score, morphine consumption, and hospital stay, with no significant difference in complications for ESI application after lumbar discectomy in lumbar disc herniation when compared with placebo. ","[{'ForeName': 'Jianping', 'Initials': 'J', 'LastName': 'Cai', 'Affiliation': ""Department of Orthopedics II, The No.2 People's Hospital of Yibin, Sichuan Province, China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Jiang', 'Affiliation': ''}, {'ForeName': 'Beiming', 'Initials': 'B', 'LastName': 'Qiu', 'Affiliation': ''}, {'ForeName': 'Yuguang', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021220'] 2799,32702911,A randomized controlled trial to evaluate the effectiveness and safety of electro acupuncture and transcranial direct current stimulation with computerized cognitive rehabilitation in patients with vascular cognitive impairment.,"BACKGROUND Vascular cognitive impairment (VCI) refers to all cognitive disorders caused by cerebrovascular disorders. For the treatment, many types of pharmacologic and nonpharmacologic treatments are used but their underlying mechanisms and effects are unclear. Regarding nonpharmacologic treatment, electroacupuncture (EA), transcranial direct current stimulation (tDCS), and computerized cognitive rehabilitation treatment (CCRT) are effective. Here, we report the protocol for a randomized controlled trial of the effect and safety of combination therapy of EA or tDCS and CCRT in patients with VCI. METHODS This study will be a prospective, outcome assessor-blinded, parallel-arm, randomized controlled clinical trial. Participants with cognitive impairment caused by stroke after 3 months of onset (n = 45) will be randomly assigned to a CCRT, combination therapy with EA and computerized cognitive rehabilitation treatment, or combination therapy with tDCS and computerized cognitive rehabilitation treatment group. All groups will receive treatment 3 times per week for 8 weeks, giving a total of 24 treatments. The CCRT group will perform a training task like shopping, calculating, and others and involving computerized cognitive assessment and brain training system (RehaCom) for 30 minutes. The combination therapy with EA and computerized cognitive rehabilitation treatment group will receive EA using 8 acupuncture points - baekhoe, sinjeong, both sides of pungji, 4 sites of sishencong - and will be applied using an EA stimulator and receive CCRT for 30 minutes at the same time. The combination therapy with tDCS and computerized cognitive rehabilitation treatment group will receive tDCS treatment and receive CCRT for 30 minutes at the same time. The primary outcome will be evaluated using the Lowenstein occupational therapy cognitive assessment, while other scales assessing walking ability, activities of daily living, and quality of life are considered secondary outcome measures. Outcomes will be evaluated before intervention, at the end of intervention 8 weeks after the first intervention, and 4 weeks after completion of the intervention program. DISCUSSION This study aims to examine the effect and safety of combination therapy with EA or tDCS and CCRT in patients with VCI. This study can be useful in developing new treatment technologies using collaborative research with combined traditional Korean and conventional medicines. TRIAL REGISTRATION This trial has been registered with cris.nih.go.kr (registration number, KCT 0003644 Registered 01 April 2019, http://cris.nih.go.kr).",2020,"The CCRT group will perform a training task like shopping, calculating, and others and involving computerized cognitive assessment and brain training system (RehaCom) for 30 minutes.","['Participants with cognitive impairment caused by stroke after 3 months of onset (n\u200a=\u200a45', 'patients with vascular cognitive impairment', 'patients with VCI']","['electro acupuncture and transcranial direct current stimulation with computerized cognitive rehabilitation', 'CCRT, combination therapy with EA and computerized cognitive rehabilitation treatment, or combination therapy with tDCS and computerized cognitive rehabilitation treatment group', 'tDCS and computerized cognitive rehabilitation treatment', 'training task like shopping, calculating, and others and involving computerized cognitive assessment and brain training system (RehaCom', 'tDCS treatment and receive CCRT', 'EA and computerized cognitive rehabilitation treatment', 'electroacupuncture (EA), transcranial direct current stimulation (tDCS), and computerized cognitive rehabilitation treatment (CCRT', 'EA or tDCS and CCRT', 'CCRT']","['Lowenstein occupational therapy cognitive assessment, while other scales assessing walking ability, activities of daily living, and quality of life']","[{'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3805043', 'cui_str': 'Vascular cognitive impairment'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}, {'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0150768', 'cui_str': 'Shopping'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C1318464', 'cui_str': 'Occupational therapy'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0559964', 'cui_str': 'Ability to walk'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.0792879,"The CCRT group will perform a training task like shopping, calculating, and others and involving computerized cognitive assessment and brain training system (RehaCom) for 30 minutes.","[{'ForeName': 'Hyeng Kyu', 'Initials': 'HK', 'LastName': 'Park', 'Affiliation': 'aDepartment of Physical and Rehabilitation Medicine, Chonnam National University Medical School and Hospital, Gwangju City bDepartment of Acupuncture and Moxibustion Medicine, College of Korean Medicine, Dongshin University, Naju City, Republic of Korea.'}, {'ForeName': 'Min Keun', 'Initials': 'MK', 'LastName': 'Song', 'Affiliation': ''}, {'ForeName': 'Jae Hong', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Jae Young', 'Initials': 'JY', 'LastName': 'Han', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021263'] 2800,32703200,Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.,"BACKGROUND First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side effects. AXEPT, an Asian phase III study, showed that modified CAPIRI+BEV [capecitabine (CAP: 1600 mg/m 2 ), irinotecan (IRI: 200 mg/m 2 ), and BEV (7.5 mg/m 2 )] was non-inferior to FOLFIRI+BEV as a second-line therapy for mCRC patients and was associated with a lower incidence of hematologic toxicities. Thus, a reduced dose of the CAP and IRI regimen in combination with oxaliplatin (OX) and BEV (CAPOXIRI+BEV) may be more feasible than FOLFOXIRI+BEV, without compromising efficacy. METHODS QUATTRO-II is an open-label, multicenter, randomized phase II study. In Step 1, the recommended doses of OX and IRI will be investigated as a safety lead-in. In Step 2, patients will be randomized to the recommended dose of either CAPOXIRI+BEV or FOLFOXIRI+BEV. Induction triplet chemotherapy plus BEV treatments will be administered for up to 4 months followed by fluoropyrimidine plus BEV maintenance. The primary endpoint is progression-free survival (PFS). The similarity in PFS between the two arms will be evaluated by observing whether the point estimate of hazard ratio (HR) for PFS falls between 0.80 and 1.25. Ensuring a 70% probability that the observed HR will be ""0.8 < HR < 1.25"" under the assumption of the true HR of 1.0, and 100 patients will be evaluated during the 3-year study period. Secondary endpoints include overall survival, overall response rate, safety, and patient reported outcome (PRO) (FACT/GOG-Ntx4). DISCUSSION Considering the lower incidence of hematologic toxicities with modified CAPIRI+BEV than with FOLFIRI+BEV, CAPOXIRI+BEV may be a promising treatment option if sufficient efficacy and lower hematologic toxicities are indicated in this study. Additionally, a lower incidence of peripheral sensory neuropathy (PSN) reported following CAPEOX treatment compared to that after FOLFOX in ACHIEVE, an adjuvant phase III trial, suggest that CAPOXIRI+BEV can mitigate OX-induced PSN. TRIAL REGISTRATION Clinicaltrials.gov NCT04097444 . Registered September 20, 2019, https://clinicaltrials.gov/ct2/show/study/NCT04097444 / Japan Registry of Clinical Trials jRCTs041190072. Registered October 9, 2019.",2020,"Additionally, a lower incidence of peripheral sensory neuropathy (PSN) reported following CAPEOX treatment compared to that after FOLFOX in ACHIEVE, an adjuvant phase III trial, suggest that CAPOXIRI+BEV can mitigate OX-induced PSN. ","['patients with metastatic colorectal cancer (mCRC', 'patients with metastatic colorectal cancer']","['CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab', 'oxaliplatin (OX) and BEV (CAPOXIRI+BEV', 'modified CAPIRI+BEV [capecitabine (CAP', 'CAPOXIRI+BEV or FOLFOXIRI+BEV', 'irinotecan', 'FOLFOXIRI plus bevacizumab (BEV']","['hematologic toxicities', 'overall survival, overall response rate, safety, and patient reported outcome (PRO', 'hazard ratio (HR) for PFS falls', 'peripheral sensory neuropathy (PSN', 'progression-free survival (PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}]","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}]","[{'cui': 'C0018943', 'cui_str': 'Hematology'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0151313', 'cui_str': 'Sensory neuropathy'}]",,0.0966627,"Additionally, a lower incidence of peripheral sensory neuropathy (PSN) reported following CAPEOX treatment compared to that after FOLFOX in ACHIEVE, an adjuvant phase III trial, suggest that CAPOXIRI+BEV can mitigate OX-induced PSN. ","[{'ForeName': 'Masaaki', 'Initials': 'M', 'LastName': 'Miyo', 'Affiliation': 'Department of Surgery, National Hospital Organization Osaka National Hospital, 2-1-14, Hoenzaka, Chuo-ku, Osaka, 540-0006, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Kato', 'Affiliation': 'Department of Surgery, National Hospital Organization Osaka National Hospital, 2-1-14, Hoenzaka, Chuo-ku, Osaka, 540-0006, Japan. ken-kato@momo.so-net.ne.jp.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Yoshino', 'Affiliation': 'Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa City, Japan.'}, {'ForeName': 'Takeharu', 'Initials': 'T', 'LastName': 'Yamanaka', 'Affiliation': 'Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Bando', 'Affiliation': 'Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'Hironaga', 'Initials': 'H', 'LastName': 'Satake', 'Affiliation': 'Cancer Treatment Center, Kansai Medical University Hospital, Hirakata City, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Yamazaki', 'Affiliation': 'Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.'}, {'ForeName': 'Hiroya', 'Initials': 'H', 'LastName': 'Taniguchi', 'Affiliation': 'Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa City, Japan.'}, {'ForeName': 'Eiji', 'Initials': 'E', 'LastName': 'Oki', 'Affiliation': 'Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.'}, {'ForeName': 'Masahito', 'Initials': 'M', 'LastName': 'Kotaka', 'Affiliation': 'Gastrointestinal cancer center, Sano Hospital, Kobe, Japan.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Oba', 'Affiliation': 'Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Yoshinori', 'Initials': 'Y', 'LastName': 'Miyata', 'Affiliation': 'Saku Central Hospital Advanced Care Center, Saku City, Japan.'}, {'ForeName': 'Kei', 'Initials': 'K', 'LastName': 'Muro', 'Affiliation': 'Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'Yoshito', 'Initials': 'Y', 'LastName': 'Komatsu', 'Affiliation': 'Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo, Japan.'}, {'ForeName': 'Hideo', 'Initials': 'H', 'LastName': 'Baba', 'Affiliation': 'Department of Gastroenterological Surgery Graduate School of Medical Sciences Kumamoto University, Kumamoto, Japan.'}, {'ForeName': 'Akihito', 'Initials': 'A', 'LastName': 'Tsuji', 'Affiliation': 'Department of Medical Oncology, Kagawa University Hospital, Kagawa, Japan.'}]",BMC cancer,['10.1186/s12885-020-07186-5'] 2801,32703201,"Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study.","BACKGROUND Two antifibrotic drugs, nintedanib and pirfenidone, are available for treatment of idiopathic pulmonary fibrosis (IPF). Although efficacy and adverse events have been well studied, little is known about patient experiences with these drugs. We aimed to systematically and quantitatively evaluate patient expectations, experiences, and satisfaction with nintedanib and pirfenidone. Furthermore, we assessed which factors were associated with overall patient satisfaction with medication. METHODS Outpatients with IPF prospectively completed the Patient Experiences and Satisfaction with Medication (PESaM) questionnaire before start, and after three and 6 months of antifibrotic treatment, as part of a randomized eHealth trial (NCT03420235). The PESaM questionnaire consists of an expectation module, a validated generic module evaluating patient experiences and satisfaction concerning the effectiveness, side-effects, and ease of use of a medication, and a disease-specific module about IPF. Satisfaction was scored on a scale from - 5 (very dissatisfied) to + 5 (very satisfied). RESULTS In total, 90 patients were included, of whom 43% used nintedanib and 57% pirfenidone. After 6 months, the mean overall score for satisfaction with medication was 2.1 (SD 1.9). No differences were found in experiences and satisfaction with medication, and the number and severity of side-effects between nintedanib and pirfenidone. Perceived effectiveness of medication was rated as significantly more important than side-effects and ease of use (p = 0.001). Expectations of patients regarding effectiveness were higher than experiences after 6 months. Self-reported experience with effectiveness was the main factor associated with overall medication satisfaction. CONCLUSIONS Patient experiences and satisfaction with antifibrotic treatment were fairly positive, and similar for nintedanib and pirfenidone. Systematic evaluation of patient expectations, experiences, and satisfaction with medication could enhance shared-decision making and guide drug treatment decisions in the future. TRIAL REGISTRATION NCT03420235 .",2020,"No differences were found in experiences and satisfaction with medication, and the number and severity of side-effects between nintedanib and pirfenidone.","['90 patients were included, of whom 43% used nintedanib and 57% pirfenidone', 'idiopathic pulmonary fibrosis (IPF', 'idiopathic pulmonary fibrosis', 'Outpatients with IPF prospectively completed the Patient Experiences and Satisfaction with Medication (PESaM) questionnaire before start, and after three and 6 months of antifibrotic treatment']",['nintedanib and pirfenidone'],"['Satisfaction', 'number and severity of side-effects', 'mean overall score for satisfaction with medication']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C2930789', 'cui_str': 'nintedanib'}, {'cui': 'C0298067', 'cui_str': 'pirfenidone'}, {'cui': 'C1800706', 'cui_str': 'Idiopathic pulmonary fibrosis'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C2930789', 'cui_str': 'nintedanib'}, {'cui': 'C0298067', 'cui_str': 'pirfenidone'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",90.0,0.0265175,"No differences were found in experiences and satisfaction with medication, and the number and severity of side-effects between nintedanib and pirfenidone.","[{'ForeName': 'C C', 'Initials': 'CC', 'LastName': 'Moor', 'Affiliation': 'Department of Respiratory Medicine, Erasmus Medical Center, Dr. Molewaterplein 40, 3015, GD, Rotterdam, the Netherlands.'}, {'ForeName': 'R L M', 'Initials': 'RLM', 'LastName': 'Mostard', 'Affiliation': 'Department of Respiratory Medicine, Zuyderland Medical, Heerlen, the Netherlands.'}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Grutters', 'Affiliation': 'Interstitial Lung Diseases Centre of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Bresser', 'Affiliation': 'Department of Respiratory Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.'}, {'ForeName': 'J G J V', 'Initials': 'JGJV', 'LastName': 'Aerts', 'Affiliation': 'Department of Respiratory Medicine, Erasmus Medical Center, Dr. Molewaterplein 40, 3015, GD, Rotterdam, the Netherlands.'}, {'ForeName': 'C D', 'Initials': 'CD', 'LastName': 'Dirksen', 'Affiliation': 'Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'ForeName': 'M L', 'Initials': 'ML', 'LastName': 'Kimman', 'Affiliation': 'Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Wijsenbeek', 'Affiliation': 'Department of Respiratory Medicine, Erasmus Medical Center, Dr. Molewaterplein 40, 3015, GD, Rotterdam, the Netherlands. m.wijsenbeek-lourens@erasmusmc.nl.'}]",Respiratory research,['10.1186/s12931-020-01458-1'] 2802,32703205,Improving shared decision-making in vascular surgery by implementing decision support tools: study protocol for the stepped-wedge cluster-randomised OVIDIUS trial.,"BACKGROUND Shared decision-making improves the quality of patient care. Unfortunately, shared decision-making is not yet common practice among vascular surgeons. Thus, decision support tools were developed to assist vascular surgeons and their patients in using shared decision-making. This trial aims to evaluate the effectiveness and implementation of decision support tools to improve shared decision-making during vascular surgical consultations in which a treatment decision is to be made. METHODS The study design is a multicentre stepped-wedge cluster-randomised trial. Eligible patients are adult patients, visiting the outpatient clinic of a participating medical centre for whom several treatment options are feasible and who face a primary treatment decision for their abdominal aortic aneurysm, carotid artery disease, intermittent claudication, or varicose veins. Patients and vascular surgeons in the intervention group receive decision support tools that may help them adopt shared decision-making when making the final treatment decision. These decision support tools are decision aids, consultation cards, decision cards, and a practical training. Decision aids are informative websites that help patients become more aware of the pros and cons of the treatment options and their preferences regarding the treatment choice. Consultation cards with text or decision cards with images are used by vascular surgeons during consultation to determine which aspect of a treatment is most important to their patient. In the training vascular surgeons can practice shared decision-making with a patient actor, guided by a medical psychologist. This trial aims to include 502 vascular surgical patients to achieve a clinically relevant improvement in shared decision-making of 10 out of 100 points, using the 5-item OPTION instrument to score the audio-recordings of consultations. DISCUSSION In the OVIDIUS trial the available decision support tools for vascular surgical patients are implemented in clinical practice. We will evaluate whether these tools actually improve shared decision-making in the consultation room. The stepped-wedge cluster-randomised study design will ensure that at the end of the study all participating centres have implemented at least some of the decision support tools and thereby a certain level of shared decision-making. TRIAL REGISTRATION Netherlands Trial Registry, NTR6487 . Registered 7 June 2017. URL: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=6487.",2020,"This trial aims to evaluate the effectiveness and implementation of decision support tools to improve shared decision-making during vascular surgical consultations in which a treatment decision is to be made. ","['Eligible patients are adult patients, visiting the outpatient clinic of a participating medical centre for whom several treatment options are feasible and who face a primary treatment decision for their abdominal aortic aneurysm, carotid artery disease, intermittent claudication, or varicose veins', '502 vascular surgical patients', 'vascular surgical patients']",['URL'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C1708063', 'cui_str': 'First line treatment'}, {'cui': 'C0162871', 'cui_str': 'Abdominal aortic aneurysm'}, {'cui': 'C0007273', 'cui_str': 'Disorder of carotid artery'}, {'cui': 'C0021775', 'cui_str': 'Intermittent claudication'}, {'cui': 'C0042345', 'cui_str': 'Phlebectasia'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]","[{'cui': 'C3541384', 'cui_str': 'URL'}]",[],,0.123521,"This trial aims to evaluate the effectiveness and implementation of decision support tools to improve shared decision-making during vascular surgical consultations in which a treatment decision is to be made. ","[{'ForeName': 'S M L', 'Initials': 'SML', 'LastName': 'de Mik', 'Affiliation': 'Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'F E', 'Initials': 'FE', 'LastName': 'Stubenrouch', 'Affiliation': 'Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'D A', 'Initials': 'DA', 'LastName': 'Legemate', 'Affiliation': 'Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Balm', 'Affiliation': 'Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.'}, {'ForeName': 'D T', 'Initials': 'DT', 'LastName': 'Ubbink', 'Affiliation': 'Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands. d.ubbink@amsterdamumc.nl.'}]",BMC medical informatics and decision making,['10.1186/s12911-020-01186-y'] 2803,32703216,"Acute supplementation with an amino acid mixture suppressed the exercise-induced cortisol response in recreationally active healthy volunteers: a randomized, double-blinded, placebo-controlled crossover study.","BACKGROUND Few studies have demonstrated the suppressive effects of amino acids (AAs) on the level of cortisol during exercise in humans. We hypothesized that an AA mixture containing arginine, which promotes lipid metabolism, valine, which effectively decreases the level of glucocorticoid, and serine, a substrate in the production of phosphatidylserine that is reported to blunt increases in cortisol, would suppress the exercise-induced cortisol response by combining the positive effects of the AAs synergistically. METHODS A randomized, double-blinded, placebo-controlled crossover trial was conducted. Twenty healthy recreationally active males ingested either an AA mixture containing 1.8 g of arginine, 1.1 g of valine, and 0.1 g of serine or a placebo. Thirty minutes after ingestion, subjects performed an exercise trial on a cycle ergometer for 80 min at 50% maximal oxygen consumption. Plasma cortisol and other blood parameters immediately before and after the exercise were evaluated. RESULTS Plasma cortisol concentrations after exercise were significantly higher than those before exercise in the placebo condition (9.51 ± 0.85 vs 14.39 ± 2.15, p < 0.05), while there was no significant difference in the AA condition (9.71 ± 0.93 vs 9.99 ± 1.23, p = 0.846). In addition, the increase in plasma cortisol before and after exercise was significantly lower in the AA condition than in the placebo condition (0.28 [- 2.75, 3.31] vs 4.87 [0.89, 8.86], p < 0.05). For the level of adrenocorticotropin, there was a significant difference between before and after exercise only in the placebo condition (24.21 ± 2.91 vs 53.17 ± 6.97, p < 0.01) but not in the AA condition (27.33 ± 3.60 vs 46.92 ± 10.41, p = 0.057). Blood glucose, plasma lactate, plasma ammonia, serum creatine phosphokinase, serum total ketone body, and serum free fatty acid were also significantly changed by the exercise load in both conditions, but no significant differences were observed between the two conditions. CONCLUSIONS The present study demonstrated that the AA mixture suppressed the cortisol response during exercise without affecting exercise-related biological parameters such as glucose or lipid metabolism. TRIAL REGISTRATION UMIN Clinical Trials Registry, UMIN000023587 . Registered 19 August 2016.",2020,"For the level of adrenocorticotropin, there was a significant difference between before and after exercise only in the placebo condition (24.21 ± 2.91 vs 53.17 ± 6.97, p < 0.01) but not in the AA condition (27.33 ± 3.60 vs 46.92 ± 10.41, p = 0.057).","['recreationally active healthy volunteers', 'Twenty healthy recreationally active males ingested either an', 'humans']","['AA mixture containing 1.8\u2009g of arginine, 1.1\u2009g of valine, and 0.1\u2009g of serine or a placebo', 'amino acid mixture', 'placebo']","['Plasma cortisol concentrations', 'Blood glucose, plasma lactate, plasma ammonia, serum creatine phosphokinase, serum total ketone body, and serum free fatty acid', 'cortisol response', 'Plasma cortisol and other blood parameters', 'plasma cortisol']","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C0003765', 'cui_str': 'Arginine'}, {'cui': 'C4517491', 'cui_str': '1.1'}, {'cui': 'C0042285', 'cui_str': 'Valine'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C0036720', 'cui_str': 'Serine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}]","[{'cui': 'C1281899', 'cui_str': 'Plasma cortisol measurement'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C1278131', 'cui_str': 'Plasma ammonia measurement'}, {'cui': 'C0750860', 'cui_str': 'Serum creatine phosphokinase'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0022631', 'cui_str': 'Ketone body'}, {'cui': 'C0015688', 'cui_str': 'Unesterified fatty acid'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",20.0,0.344236,"For the level of adrenocorticotropin, there was a significant difference between before and after exercise only in the placebo condition (24.21 ± 2.91 vs 53.17 ± 6.97, p < 0.01) but not in the AA condition (27.33 ± 3.60 vs 46.92 ± 10.41, p = 0.057).","[{'ForeName': 'Yuichi', 'Initials': 'Y', 'LastName': 'Tsuda', 'Affiliation': 'R&D Division, Meiji Co., Ltd., 1-29-1 Nanakuni, Hachiouji, Tokyo, 192-0919, Japan. yuuichi.tsuda@meiji.com.'}, {'ForeName': 'Rika', 'Initials': 'R', 'LastName': 'Murakami', 'Affiliation': 'R&D Division, Meiji Co., Ltd., 1-29-1 Nanakuni, Hachiouji, Tokyo, 192-0919, Japan.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Yamaguchi', 'Affiliation': 'R&D Division, Meiji Co., Ltd., 1-29-1 Nanakuni, Hachiouji, Tokyo, 192-0919, Japan.'}, {'ForeName': 'Taiichiro', 'Initials': 'T', 'LastName': 'Seki', 'Affiliation': 'College of Bioresource Sciences, Nihon University, 1866 Kameino, Fujisawa, Kanagawa, 252-0880, Japan.'}]",Journal of the International Society of Sports Nutrition,['10.1186/s12970-020-00369-2'] 2804,32706719,A Novel Educational Control Group Mobile App for Meditation Interventions: Single-Group Feasibility Trial.,"BACKGROUND Smartphone ownership is becoming ubiquitous among US adults, making the delivery of health interventions via a mobile app (ie, mobile health [mHealth]) attractive to many researchers and clinicians. Meditation interventions have become popular and have been delivered to study participants via mobile apps to improve a range of health outcomes in both healthy adults and those with chronic diseases. However, these meditation mHealth interventions have been limited by a lack of high-quality control groups. More specifically, these studies have lacked consistency in their use of active, time-matched, and attention-matched control groups. OBJECTIVE The purpose of this study is to beta test a novel health education podcast control condition delivered via a smartphone app that would be a strong comparator to be used in future studies of app-based meditation interventions. METHODS Patients with myeloproliferative neoplasm (MPN) cancer were recruited nationally. Upon enrollment, participants were informed to download the investigator-developed health education podcast app onto their mobile phone and listen to ~60 min/week of cancer-related educational podcasts for 12 weeks. The benchmarks for feasibility included ≥70% of participants completing ≥70% of the prescribed 60 min/week of podcasts, ≥70% of participants reporting that they were satisfied with the intervention, and ≥70% of participants reporting that they enjoyed the health education podcasts. RESULTS A total of 96 patients with MPN were enrolled in the study; however, 19 never began the intervention. Of the 77 patients who participated in the intervention, 39 completed the entire study (ie, sustained participation through the follow-up period). Participation averaged 103.2 (SD 29.5) min/week. For 83.3% (10/12) of the weeks, at least 70% of participants completed at least 70% of their total prescribed use. Almost half of participants reported that they enjoyed the health education podcasts (19/39, 48.7%) and were satisfied with the intervention (17/39, 43.6%). There were no significant changes in cancer-related outcomes from baseline to postintervention. CONCLUSIONS A 12-week, health education podcast mobile app was demanded but not accepted in a sample of patients with cancer. Using the mobile app was not associated with significant changes in cancer-related symptoms. Based on findings from this study, a health education podcast mobile app may be a feasible option as a time- and attention-matched control group for efficacy trials with more extensive formative research for the content of the podcasts and its acceptability by the specific population. TRIAL REGISTRATION ClinicalTrials.gov NCT03907774; https://clinicaltrials.gov/ct2/show/NCT03907774.",2020,"There were no significant changes in cancer-related outcomes from baseline to postintervention. ","['77 patients who participated in the intervention, 39 completed the entire study (ie, sustained participation through the follow-up period', 'healthy adults and those with chronic diseases', 'patients with cancer', 'Patients with myeloproliferative neoplasm (MPN) cancer were recruited nationally', '96 patients with MPN were enrolled in the study; however, 19 never began the intervention']","['Educational Control Group Mobile App for Meditation Interventions', 'Meditation interventions']","['health education podcasts', 'cancer-related symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439751', 'cui_str': 'Entire'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0027022', 'cui_str': 'Myeloproliferative disorder'}, {'cui': 'C0439659', 'cui_str': 'Origins'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C2718063', 'cui_str': 'Podcasts'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",96.0,0.183313,"There were no significant changes in cancer-related outcomes from baseline to postintervention. ","[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Huberty', 'Affiliation': 'College of Health Solutions, Arizona State University, Phoenix, AZ, United States.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Eckert', 'Affiliation': 'Mays Cancer Center, University of Texas Health San Antonio MD Anderson, San Antonio, TX, United States.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Puzia', 'Affiliation': 'Behavioral Research and Analytics, LLC, Salt Lake City, UT, United States.'}, {'ForeName': 'Breanne', 'Initials': 'B', 'LastName': 'Laird', 'Affiliation': 'College of Health Solutions, Arizona State University, Phoenix, AZ, United States.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Larkey', 'Affiliation': 'Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, United States.'}, {'ForeName': 'Ruben', 'Initials': 'R', 'LastName': 'Mesa', 'Affiliation': 'Mays Cancer Center, University of Texas Health San Antonio MD Anderson, San Antonio, TX, United States.'}]",JMIR formative research,['10.2196/19364'] 2805,32706720,An Internet-Based Cognitive Behavioral Program for Adolescents With Anxiety: Pilot Randomized Controlled Trial.,"BACKGROUND Internet-based cognitive behavioral therapy (ICBT) is a treatment approach recently developed and studied to provide frontline treatment to adolescents with anxiety disorders. OBJECTIVE This study aimed to pilot procedures and obtain data on methodological processes and intervention satisfaction to determine the feasibility of a definitive randomized controlled trial (RCT) to test the effectiveness of a self-managed ICBT program, Breathe (Being Real, Easing Anxiety: Tools Helping Electronically), for adolescents with anxiety concerns. METHODS This study employed a two-arm, multisite, pilot RCT. Adolescents aged 13 to 17 years with a self-identified anxiety concern were recruited online from health care settings and school-based mental health care services across Canada between April 2014 and May 2016. We compared 8 weeks of ICBT with ad hoc telephone and email support (Breathe experimental group) to access to a static webpage listing anxiety resources (control group). The primary outcome was the change in self-reported anxiety from baseline to 8 weeks (posttreatment), which was used to determine the sample size for a definitive RCT. Secondary outcomes were recruitment and retention rates, a minimal clinically important difference (MCID) for the primary outcome, intervention acceptability and satisfaction, use of cointerventions, and health care resource use, including a cost-consequence analysis. RESULTS Of the 588 adolescents screened, 94 were eligible and enrolled in the study (49 adolescents were allocated to Breathe and 45 were allocated to the control group). Analysis was based on 74% (70/94) of adolescents who completed baseline measures and progressed through the study. Enrolled adolescents were, on average, 15.3 years old (SD 1.2) and female (63/70, 90%). Retention rates at 8 weeks were 28% (13/46; Breathe group) and 58% (24/43; control group). Overall, 39% (14/36) of adolescents provided feedback on completion of the Breathe program. Adolescents' scores on a satisfaction survey indicated a moderate level of satisfaction. All but one adolescent indicated that Breathe was easy to use and they understood all the material presented. The most frequent barrier identified for program completion was difficulty in completing exposure activities. The power analysis indicated that 177 adolescents per group would be needed to detect a medium effect size (d=0.3) between groups in a definitive trial. Data for calculating an MCID or conducting a cost-consequence analysis were insufficient due to a low response rate at 8 weeks. CONCLUSIONS Adolescents were moderately satisfied with Breathe. However, program adjustments will be needed to address attrition and reduce perceived barriers to completing key aspects of the program. A definitive RCT to evaluate the effectiveness of the program is feasible if protocol adjustments are made to improve recruitment and retention to ensure timely study completion and increase the completeness of the data at each outcome measurement time point. TRIAL REGISTRATION ClinicalTrials.gov NCT02059226; http://clinicaltrials.gov/ct2/show/NCT02059226.",2020,Retention rates at 8 weeks were 28% (13/46; Breathe group) and 58% (24/43; control group).,"['adolescents with anxiety concerns', '94 were eligible and enrolled in the study (49 adolescents', 'Adolescents aged 13 to 17 years with a self-identified anxiety concern were recruited online from health care settings and school-based mental health care services across Canada between April 2014 and May 2016', 'Adolescents With Anxiety', 'Enrolled adolescents were, on average, 15.3 years old (SD 1.2) and female (63/70, 90', '588 adolescents screened', 'adolescents with anxiety disorders', ' Easing Anxiety', '177 adolescents per group']","['ICBT with ad hoc telephone and email support (Breathe experimental group) to access to a static webpage listing anxiety resources (control group', 'Internet-Based Cognitive Behavioral Program', 'self-managed ICBT program, Breathe (Being Real', 'Internet-based cognitive behavioral therapy (ICBT']","['moderate level of satisfaction', 'Retention rates', 'recruitment and retention rates, a minimal clinically important difference (MCID) for the primary outcome, intervention acceptability and satisfaction, use of cointerventions, and health care resource use, including a cost-consequence analysis', 'change in self-reported anxiety']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184643', 'cui_str': 'Mental health care'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C4517578', 'cui_str': '15.3'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4068880', 'cui_str': '1.2'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C4277733', 'cui_str': 'Minimal Clinically Important Difference'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0686907', 'cui_str': 'Consequence of'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",49.0,0.139181,Retention rates at 8 weeks were 28% (13/46; Breathe group) and 58% (24/43; control group).,"[{'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': ""O'Connor"", 'Affiliation': 'Glenrose Rehabilitation Hospital, Edmonton, AB, Canada.'}, {'ForeName': 'Alexa', 'Initials': 'A', 'LastName': 'Bagnell', 'Affiliation': 'IWK Health Centre, Halifax, NS, Canada.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'McGrath', 'Affiliation': 'IWK Health Centre, Halifax, NS, Canada.'}, {'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Wozney', 'Affiliation': 'IWK Health Centre, Halifax, NS, Canada.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Radomski', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Rhonda J', 'Initials': 'RJ', 'LastName': 'Rosychuk', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Curtis', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Jabbour', 'Affiliation': 'Department of Neurosurgery, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Eleanor', 'Initials': 'E', 'LastName': 'Fitzpatrick', 'Affiliation': 'IWK Health Centre, Halifax, NS, Canada.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Johnson', 'Affiliation': 'University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Arto', 'Initials': 'A', 'LastName': 'Ohinmaa', 'Affiliation': 'School of Public Health, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Joyce', 'Affiliation': 'University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Newton', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.'}]",JMIR mental health,['10.2196/13356'] 2806,32706731,Validation of a Mobile Version of the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form: An Observational Randomized Crossover Trial.,"BACKGROUND The American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES) questionnaire is an effective tool for evaluating shoulder joint function. The development and usage of a mobile version of the ASES questionnaire has the potential to save time, money, and effort. OBJECTIVE The aim of this study is to assess the equivalence between the paper and mobile versions of the ASES questionnaire and their acceptability among patients. METHODS The paper and mobile versions of the ASES questionnaire were used to evaluate the shoulder joint function of 50 patients with shoulder pain. This study included patients from the shoulder clinic of Sun Yat-sen Memorial Hospital. The intraclass correlation coefficient (ICC) and Bland-Altman method were used to evaluate the agreement (reliability) of the scores obtained by the two methods (paper versus mobile). RESULTS Of the 50 patients recruited from March 2018 to May 2019, 46 (92%) completed the study. There was a high agreement between the paper and mobile versions of the ASES questionnaire (ICC=0.979, 95% CI 0.943-0.987; P<.001). The mean difference between the scores of the mobile and paper versions was 1.0, and only 1/46 (2%) had a difference greater than the minimal clinically important difference of 12 points. About 75% of patients preferred the mobile version to the paper version. CONCLUSIONS Our study shows that the mobile version of the ASES questionnaire is comparable to the paper version, and has a higher patient preference. This could prove to be a useful tool for epidemiological studies and patient follow-up over longer periods of time.",2020,"There was a high agreement between the paper and mobile versions of the ASES questionnaire (ICC=0.979, 95% CI 0.943-0.987; P<.001).","['American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form', '50 patients recruited from March 2018 to May 2019, 46 (92%) completed the study', '50 patients with shoulder pain', 'patients', 'patients from the shoulder clinic of Sun Yat-sen Memorial Hospital']",['Elbow Surgeons Standardized Shoulder Assessment Form (ASES) questionnaire'],[],"[{'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0038817', 'cui_str': 'Sunlight'}, {'cui': 'C0036644', 'cui_str': 'Senegal'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",[],50.0,0.0611349,"There was a high agreement between the paper and mobile versions of the ASES questionnaire (ICC=0.979, 95% CI 0.943-0.987; P<.001).","[{'ForeName': 'Jingyi', 'Initials': 'J', 'LastName': 'Hou', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Qingyue', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Menglei', 'Initials': 'M', 'LastName': 'Yu', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Fangqi', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yiyong', 'Initials': 'Y', 'LastName': 'Tang', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Long', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yamuhanmode', 'Initials': 'Y', 'LastName': 'Alike', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yuanhao', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Maslah Idiris', 'Initials': 'MI', 'LastName': 'Ali', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Congda', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Weiping', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Yang', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}]",JMIR mHealth and uHealth,['10.2196/16758'] 2807,32706734,Acceptability of an Embodied Conversational Agent for Type 2 Diabetes Self-Management Education and Support via a Smartphone App: Mixed Methods Study.,"BACKGROUND Embodied conversational agents (ECAs) are increasingly used in health care apps; however, their acceptability in type 2 diabetes (T2D) self-management apps has not yet been investigated. OBJECTIVE This study aimed to evaluate the acceptability of the ECA (Laura) used to deliver diabetes self-management education and support in the My Diabetes Coach (MDC) app. METHODS A sequential mixed methods design was applied. Adults with T2D allocated to the intervention arm of the MDC trial used the MDC app over a period of 12 months. At 6 months, they completed questions assessing their interaction with, and attitudes toward, the ECA. In-depth qualitative interviews were conducted with a subsample of the participants from the intervention arm to explore their experiences of using the ECA. The interview questions included the participants' perceptions of Laura, including their initial impression of her (and how this changed over time), her personality, and human character. The quantitative and qualitative data were interpreted using integrated synthesis. RESULTS Of the 93 intervention participants, 44 (47%) were women; the mean (SD) age of the participants was 55 (SD 10) years and the baseline glycated hemoglobin A1c level was 7.3% (SD 1.5%). Overall, 66 of the 93 participants (71%) provided survey responses. Of these, most described Laura as being helpful (57/66, 86%), friendly (57/66, 86%), competent (56/66, 85%), trustworthy (48/66, 73%), and likable (40/66, 61%). Some described Laura as not real (18/66, 27%), boring (26/66, 39%), and annoying (20/66, 30%). Participants reported that interacting with Laura made them feel more motivated (29/66, 44%), comfortable (24/66, 36%), confident (14/66, 21%), happy (11/66, 17%), and hopeful (8/66, 12%). Furthermore, 20% (13/66) of the participants were frustrated by their interaction with Laura, and 17% (11/66) of the participants reported that interacting with Laura made them feel guilty. A total of 4 themes emerged from the qualitative data (N=19): (1) perceived role: a friendly coach rather than a health professional; (2) perceived support: emotional and motivational support; (3) embodiment preference acceptability of a human-like character; and (4) room for improvement: need for greater congruence between Laura's words and actions. CONCLUSIONS These findings suggest that an ECA is an acceptable means to deliver T2D self-management education and support. A human-like character providing ongoing, friendly, nonjudgmental, emotional, and motivational support is well received. Nevertheless, the ECA can be improved by increasing congruence between its verbal and nonverbal communication and accommodating user preferences. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry CTRN12614001229662; https://tinyurl.com/yxshn6pd.",2020,"This study aimed to evaluate the acceptability of the ECA (Laura) used to deliver diabetes self-management education and support in the My Diabetes Coach (MDC) app. ","['Adults with T2D', ""participants' perceptions of Laura, including their initial impression of her (and how this changed over time), her personality, and human character""]","['Embodied Conversational Agent', 'Embodied conversational agents (ECAs', 'ECA (Laura', ""friendly coach rather than a health professional; (2) perceived support: emotional and motivational support; (3) embodiment preference acceptability of a human-like character; and (4) room for improvement: need for greater congruence between Laura's words and actions"", 'ECA']","['survey responses', 'baseline glycated hemoglobin A1c level']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0003944', 'cui_str': 'As If Personality'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0007952', 'cui_str': 'Character'}]","[{'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0007952', 'cui_str': 'Character'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0441472', 'cui_str': 'Action'}]","[{'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0474680', 'cui_str': 'Hemoglobin A1c measurement'}]",93.0,0.0433844,"This study aimed to evaluate the acceptability of the ECA (Laura) used to deliver diabetes self-management education and support in the My Diabetes Coach (MDC) app. ","[{'ForeName': 'Shaira', 'Initials': 'S', 'LastName': 'Baptista', 'Affiliation': 'The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Wadley', 'Affiliation': 'The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Bird', 'Affiliation': 'The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Oldenburg', 'Affiliation': 'The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Speight', 'Affiliation': 'The University of Melbourne, Melbourne, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ""see Authors' Contributions, .""}]",JMIR mHealth and uHealth,['10.2196/17038'] 2808,32706738,User Engagement Among Diverse Adults in a 12-Month Text Message-Delivered Diabetes Support Intervention: Results from a Randomized Controlled Trial.,"BACKGROUND Text message-delivered interventions are a feasible and scalable approach for improving chronic disease self-care and reducing health disparities; however, information on long-term user engagement with these interventions is limited. OBJECTIVE The aim of this study is to examine user engagement in a 12-month text message-delivered intervention supporting diabetes self-care, called REACH (Rapid Education/Encouragement And Communications for Health), among racially and socioeconomically diverse patients with type 2 diabetes (T2D). We explored time trends in engagement, associations between patient characteristics and engagement, and whether the addition of a human component or allowing patients to change their text frequency affected engagement. Qualitative data informed patients' subjective experience of their engagement. METHODS We recruited patients with T2D for a randomized trial evaluating mobile phone support relative to enhanced treatment as usual. This analysis was limited to participants assigned to the intervention. Participants completed a survey and hemoglobin A1c (HbA1c) test and received REACH text messages, including self-care promotion texts, interactive texts asking about medication adherence, and adherence feedback texts. For the first 6 months, texts were sent daily, and half of the participants also received monthly phone coaching. After 6 months, coaching stopped, and participants had the option to receive fewer texts for the subsequent 6 months. We defined engagement via responses to the interactive texts and responses to a follow-up interview. We used regression models to analyze associations with response rate and thematic and structural analysis to understand participants' reasons for responding to the texts and their preferred text frequency. RESULTS The participants were, on average, aged 55.8 (SD 9.8) years, 55.2% (137/248) female, and 52.0% (129/248) non-White; 40.7% (101/248) had ≤ a high school education, and 40.7% (101/248) had an annual household income 0.10). However, there was the suggestion of a greater decrease in sedentary activity in the LI group compared to the HW group (β = -3.56, p = 0.09). CONCLUSIONS In this randomized trial among high-risk Hispanic women, both groups benefitted from participation in a postpartum intervention.",2020,"Compared to baseline levels, both groups had significant increases in moderate-to-vigorous PA at 6 months and one year postpartum (i.e., LI: mean change =","['Hispanic women who screened positive for gestational diabetes mellitus', 'at-risk hispanic women', 'high-risk Hispanic women', 'Western Massachusetts from 2013-17', 'Hispanic women']","['Lifestyle Intervention (LI, n = 100) or to a comparison Health and Wellness (HW, n = 104) group during late pregnancy', 'lifestyle intervention', 'culturally modified, motivationally targeted, individually-tailored intervention']","['moderate-to-vigorous PA', 'Pregnancy Physical Activity Questionnaire (PPAQ) and the Self-Efficacy for Physical Activity Questionnaire', 'vigorous PA', 'PA intensity and type over time', 'sedentary activity', 'postpartum physical activity', 'postpartum physical activity (PA) and PA self-efficacy']","[{'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0085207', 'cui_str': 'Gestational diabetes mellitus'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}]",,0.0849279,"Compared to baseline levels, both groups had significant increases in moderate-to-vigorous PA at 6 months and one year postpartum (i.e., LI: mean change =","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Burkart', 'Affiliation': 'Department of Kinesiology, School of Public Health & Health Sciences, University of Massachusetts, Amherst, Massachusetts, United States of America.'}, {'ForeName': 'Bess H', 'Initials': 'BH', 'LastName': 'Marcus', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island, United States of America.'}, {'ForeName': 'Penelope', 'Initials': 'P', 'LastName': 'Pekow', 'Affiliation': 'Department of Biostatistics and Epidemiology, School of Public Health & Health Sciences, University of Massachusetts Amherst, Amherst, Massachusetts, United States of America.'}, {'ForeName': 'Milagros C', 'Initials': 'MC', 'LastName': 'Rosal', 'Affiliation': 'Division of Preventive and Behavioral Medicine, Department of Population & Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.'}, {'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.""}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Braun', 'Affiliation': 'Department of Health and Exercise Science, College of Health and Human Sciences, Colorado State University, Fort Collins, Colorado, United States of America.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Chasan-Taber', 'Affiliation': 'Department of Biostatistics and Epidemiology, School of Public Health & Health Sciences, University of Massachusetts Amherst, Amherst, Massachusetts, United States of America.'}]",PloS one,['10.1371/journal.pone.0236408'] 2812,32706852,Mixed-Methods Randomized Evaluation of FAMS: A Mobile Phone-Delivered Intervention to Improve Family/Friend Involvement in Adults' Type 2 Diabetes Self-Care.,"BACKGROUND Family and friends have both helpful and harmful effects on adults' diabetes self-management. Family-focused Add-on to Motivate Self-care (FAMS) is a mobile phone-delivered intervention designed to improve family/friend involvement, self-efficacy, and self-care via monthly phone coaching, texts tailored to goals, and the option to invite a support person to receive texts. PURPOSE We sought to evaluate how FAMS was received by a diverse group of adults with Type 2 diabetes and if FAMS improved diabetes-specific family/friend involvement (increased helpful and reduced harmful), diabetes self-efficacy, and self-care (diet and physical activity). We also assessed if improvements in family/friend involvement mediated improvements in self-efficacy and self-care. METHODS Participants were prospectively assigned to enhanced treatment as usual (control), an individualized text messaging intervention alone, or the individualized text messaging intervention plus FAMS for 6 months. Participants completed surveys at baseline, 3 and 6 months, and postintervention interviews. Between-group and multiple mediator analyses followed intention-to-treat principles. RESULTS Retention, engagement, and fidelity were high. FAMS was well received and helped participants realize the value of involving family/friends in their care. Relative to control, FAMS participants had improved family/friend involvement, self-efficacy, and diet (but not physical activity) at 3 and 6 months (all ps < .05). Improvements in family/friend involvement mediated effects on self-efficacy and diet for FAMS participants but not for the individualized intervention group. CONCLUSIONS The promise of effectively engaging patients' family and friends lies in sustained long-term behavior change. This work represents a first step toward this goal by demonstrating how content targeting helpful and harmful family/friend involvement can drive short-term effects. TRIAL REGISTRATION NUMBER NCT02481596.",2020,"Improvements in family/friend involvement mediated effects on self-efficacy and diet for FAMS participants but not for the individualized intervention group. ","['Participants', ""Adults' Type 2 Diabetes Self-Care""]","['FAMS', 'enhanced treatment as usual (control), an individualized text messaging intervention alone, or the individualized text messaging intervention plus FAMS', 'Mobile Phone-Delivered Intervention']","['self-efficacy and self-care', 'family/friend involvement, self-efficacy, and diet', 'Retention, engagement, and fidelity', 'diabetes-specific family/friend involvement (increased helpful and reduced harmful), diabetes self-efficacy, and self-care (diet and physical activity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}]","[{'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0079382', 'cui_str': 'Friend'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0296122,"Improvements in family/friend involvement mediated effects on self-efficacy and diet for FAMS participants but not for the individualized intervention group. ","[{'ForeName': 'Lindsay S', 'Initials': 'LS', 'LastName': 'Mayberry', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN 37203, USA.'}, {'ForeName': 'Cynthia A', 'Initials': 'CA', 'LastName': 'Berg', 'Affiliation': 'Department of Psychology, University of Utah, Salt Lake City, UT, USA.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Greevy', 'Affiliation': 'Vanderbilt Center for Diabetes Translation Research, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Lyndsay A', 'Initials': 'LA', 'LastName': 'Nelson', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN 37203, USA.'}, {'ForeName': 'Erin M', 'Initials': 'EM', 'LastName': 'Bergner', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN 37203, USA.'}, {'ForeName': 'Kenneth A', 'Initials': 'KA', 'LastName': 'Wallston', 'Affiliation': 'Vanderbilt Center for Diabetes Translation Research, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Kryseana J', 'Initials': 'KJ', 'LastName': 'Harper', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN 37203, USA.'}, {'ForeName': 'Tom A', 'Initials': 'TA', 'LastName': 'Elasy', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN 37203, USA.'}]",Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,['10.1093/abm/kaaa041'] 2813,32706883,IL-6 Response to Psychosocial Stress Predicts 12-month Changes in Cardiometabolic Biomarkers in Perimenopausal Women.,"OBJECTIVE Cardiometabolic diseases are the number one cause of mortality, accounting for over one third of all deaths in the US. Cardiometabolic risk further increases with psychosocial stress exposure and during menopausal transition in women. Because disease risk and stress burden are associated with aberrant immune signaling, we hypothesized that responses of interleukin-6 (IL-6) to psychosocial stress may predict longitudinal cardiometabolic outcomes in perimenopausal women. METHODS We conducted post hoc analyses in 151 perimenopausal or early postmenopausal women participants in a previously completed study. At study onset, participants underwent the Trier Social Stress Test (TSST), and plasma IL-6 was measured repeatedly before and during the one hour post-TSST. Subsequently, participants were randomly assigned to either hormonal treatment (HT) or placebo and followed for 12 months to determine longitudinal changes in cardiometabolic biomarkers. RESULTS Greater IL-6 reactivity to stress, measured with baseline-adjusted area-under-the-curve (AUCadj), predicted 12-month decrease in flow-mediated dilatation of the brachial artery (p=0.0005), a measure of endothelial-dependent vascular function, but not in endothelial-independent function measured with nitroglycerin-mediated dilatation (p=0.17). Greater baseline IL-6 levels predicted 12-month increase in insulin resistance based on the HOMA-IR score (p=0.0045) and in the number of criteria met for metabolic syndrome (p=0.0008). These predictions were not moderated by HT. CONCLUSIONS Greater baseline IL-6 levels as well as its reactivity to stress may predict worsening in distinct cardiometabolic biomarkers as women transition to menopause. IL-6 reactivity predicts decline in endothelial-dependent vascular function, whereas baseline IL-6 presages accumulation of metabolic risk.",2020,Greater baseline IL-6 levels predicted 12-month increase in insulin resistance based on the HOMA-IR score (p=0.0045) and in the number of criteria met for metabolic syndrome (p=0.0008).,"['perimenopausal women', 'Perimenopausal Women', '151 perimenopausal or early postmenopausal women participants in a previously completed study', 'women']","['hormonal treatment (HT) or placebo', 'IL-6']","['IL-6 reactivity to stress', 'flow-mediated dilatation of the brachial artery', 'Trier Social Stress Test (TSST), and plasma IL-6', 'HOMA-IR score', 'Greater baseline IL-6 levels', 'endothelial-dependent vascular function']","[{'cui': 'C3839366', 'cui_str': 'Perimenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0458083', 'cui_str': 'Hormonal'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}]","[{'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0002940', 'cui_str': 'Aneurysm'}, {'cui': 'C0006087', 'cui_str': 'Structure of brachial artery'}, {'cui': 'C0065404', 'cui_str': 'lysyl-5-fluorotryptophyl-lysine'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}]",,0.148833,Greater baseline IL-6 levels predicted 12-month increase in insulin resistance based on the HOMA-IR score (p=0.0045) and in the number of criteria met for metabolic syndrome (p=0.0008).,"[{'ForeName': 'Anthony S', 'Initials': 'AS', 'LastName': 'Zannas', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Gordon', 'Affiliation': 'Department of Psychology, University of Regina, Regina, Saskatchewan, Canada.'}, {'ForeName': 'Alan L', 'Initials': 'AL', 'LastName': 'Hinderliter', 'Affiliation': 'Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}, {'ForeName': 'Susan S', 'Initials': 'SS', 'LastName': 'Girdler', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Rubinow', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgaa476'] 2814,32706933,Effects of a Community-Based Multicomponent Positive Psychology Intervention on Mental Health of Rural Adults in Ghana.,"BACKGROUND There is growing evidence that positive psychology interventions (PPIs) enhance positive mental health and lead to a decrease in symptoms of psychopathology. This study examines the effectiveness of a 10-week multicomponent PPI (the Inspired Life Program; ILP) in promoting positive mental health and reducing symptoms of depression and negative affect in a sample of rural poor adults in Ghana. METHODS Using a quasi-randomized controlled trial design, participants from four rural poor communities were randomly allocated to intervention (n = 40) or control (n = 42) conditions. The intervention group participated in the 10-week ILP. Both groups completed a battery of mental health measures, including the Mental Health Continuum-Short Form, at pre-intervention, immediately after the intervention, and at 3 months follow-up. Hierarchical linear modeling was applied to evaluate whether the intervention was effective. RESULTS There was a greater improvement in positive mental health, with a marked reduction in symptoms of depression in the intervention group compared to the control group, immediately and 3 months after the intervention. There were also larger increases in the proportion of flourishers in the intervention group compared to the control group, immediately and three months after the intervention. CONCLUSIONS The observed effects of the ILP intervention program suggest that group-based PPIs can promote positive mental health and buffer against psychopathology among people living in rural poor communities in sub-Saharan Africa.",2020,"Both groups completed a battery of mental health measures, including the Mental Health Continuum-Short Form, at pre-intervention, immediately after the intervention, and at 3 months follow-up.","['rural poor adults in Ghana', 'participants from four rural poor communities', 'people living in rural poor communities in sub-Saharan Africa', 'Mental Health of Rural Adults in Ghana']","['multicomponent PPI (the Inspired Life Program; ILP', 'positive psychology interventions (PPIs', 'Community-Based Multicomponent Positive Psychology Intervention']","['symptoms of depression', 'proportion of flourishers', 'positive mental health']","[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0017516', 'cui_str': 'Ghana'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0001738', 'cui_str': 'Sub-Saharan Africa'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]","[{'cui': 'C0358591', 'cui_str': 'H+/K+-exchanging ATPase inhibitor'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1510628', 'cui_str': 'Positive Psychology'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]",4.0,0.0677002,"Both groups completed a battery of mental health measures, including the Mental Health Continuum-Short Form, at pre-intervention, immediately after the intervention, and at 3 months follow-up.","[{'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Appiah', 'Affiliation': 'Africa Unit for Transdisciplinary Health Research, North-West University, Potchefstroom, South Africa.'}, {'ForeName': 'Angelina', 'Initials': 'A', 'LastName': 'Wilson-Fadiji', 'Affiliation': 'Africa Unit for Transdisciplinary Health Research, North-West University, Potchefstroom, South Africa.'}, {'ForeName': 'Lusilda', 'Initials': 'L', 'LastName': 'Schutte', 'Affiliation': 'Africa Unit for Transdisciplinary Health Research, North-West University, Potchefstroom, South Africa.'}, {'ForeName': 'Marié P', 'Initials': 'MP', 'LastName': 'Wissing', 'Affiliation': 'Africa Unit for Transdisciplinary Health Research, North-West University, Potchefstroom, South Africa.'}]",Applied psychology. Health and well-being,['10.1111/aphw.12212'] 2815,32704023,"Soluble Klotho, a biomarker and therapeutic strategy to reduce bronchopulmonary dysplasia and pulmonary hypertension in preterm infants.","Preterm infants with bronchopulmonary dysplasia (BPD) and pulmonary hypertension (PH) have accelerated lung aging and poor long-term outcomes. Klotho is an antiaging protein that modulates oxidative stress, angiogenesis and fibrosis. Here we test the hypothesis that decreased cord Klotho levels in preterm infants predict increased BPD-PH risk and early Klotho supplementation prevents BPD-like phenotype and PH in rodents exposed to neonatal hyperoxia. In experiment 1, Klotho levels were measured in cord blood of preterm infants who were enrolled in a longitudinal cohort study. In experiment 2, using an experimental BPD-PH model, rat pups exposed to room air or hyperoxia (85% O 2 ) were randomly assigned to receive every other day injections of recombinant Klotho or placebo. The effect of Klotho on lung structure, PH and cardiac function was assessed. As compared to controls, preterm infants with BPD or BPD-PH had decreased cord Klotho levels. Early Klotho supplementation in neonatal hyperoxia-exposed rodents preserved lung alveolar and vascular structure, attenuated PH, reduced pulmonary vascular remodeling and improved cardiac function. Together, these findings have important implications as they suggest that perinatal Klotho deficiency contributes to BPD-PH risk and strategies that preserve Klotho levels, may improve long-term cardiopulmonary outcomes in preterm infants.",2020,"As compared to controls, preterm infants with BPD or BPD-PH had decreased cord Klotho levels.","['Preterm infants with bronchopulmonary dysplasia (BPD) and pulmonary hypertension (PH', 'rat pups exposed to room air or hyperoxia (85% O 2 ', 'preterm infants']","['Klotho', 'recombinant Klotho or placebo']","['bronchopulmonary dysplasia and pulmonary hypertension', 'lung structure, PH and cardiac function', 'cord Klotho levels', 'Klotho levels', 'neonatal hyperoxia-exposed rodents preserved lung alveolar and vascular structure, attenuated PH, reduced pulmonary vascular remodeling and improved cardiac function']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary dysplasia of newborn'}, {'cui': 'C0020542', 'cui_str': 'Pulmonary hypertension'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0242706', 'cui_str': 'Hyperoxia'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}]","[{'cui': 'C1144173', 'cui_str': 'KL protein, human'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0006287', 'cui_str': 'Bronchopulmonary dysplasia of newborn'}, {'cui': 'C0020542', 'cui_str': 'Pulmonary hypertension'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C3489532', 'cui_str': 'Cone-Rod Dystrophy 2'}, {'cui': 'C1144173', 'cui_str': 'KL protein, human'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0242706', 'cui_str': 'Hyperoxia'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0035804', 'cui_str': 'Order Rodentia'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C3850148', 'cui_str': 'Vascular Remodeling'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",,0.0610072,"As compared to controls, preterm infants with BPD or BPD-PH had decreased cord Klotho levels.","[{'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Batlahally', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Franklin', 'Affiliation': ""Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.""}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Damianos', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Pingping', 'Initials': 'P', 'LastName': 'Chen', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Mayank', 'Initials': 'M', 'LastName': 'Sharma', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Duara', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Divya', 'Initials': 'D', 'LastName': 'Keerthy', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Zambrano', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Lina A', 'Initials': 'LA', 'LastName': 'Shehadeh', 'Affiliation': 'The Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Eliana C', 'Initials': 'EC', 'LastName': 'Martinez', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Marissa J', 'Initials': 'MJ', 'LastName': 'DeFreitas', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Shathiyah', 'Initials': 'S', 'LastName': 'Kulandavelu', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Carolyn L', 'Initials': 'CL', 'LastName': 'Abitbol', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Freundlich', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Rosemeire M', 'Initials': 'RM', 'LastName': 'Kanashiro-Takeuchi', 'Affiliation': 'The Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Augusto', 'Initials': 'A', 'LastName': 'Schmidt', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Merline', 'Initials': 'M', 'LastName': 'Benny', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Shu', 'Initials': 'S', 'LastName': 'Wu', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Karen K', 'Initials': 'KK', 'LastName': 'Mestan', 'Affiliation': ""Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.""}, {'ForeName': 'Karen C', 'Initials': 'KC', 'LastName': 'Young', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA. Kyoung3@med.miami.edu.'}]",Scientific reports,['10.1038/s41598-020-69296-1'] 2816,32704082,Green-banana biomass consumption by diabetic patients improves plasma low-density lipoprotein particle functionality.,"The aim of this study was to investigate the effects of 6-months consumption of green-banana biomass on the LDL particle functionality in subjects with type 2 diabetes. Subjects (n = 39, mean age 65 years old) of both sexes with diabetes (HbA1c ≥ 6·5%) were randomized to receive nutritional support plus green-banana biomass (40 g) (n = 21) or diet alone (n = 18) for 6-months. Non-linear optical responses of LDL solutions from these participants were studied by Z-scan technique. UV-visible spectrophotometer was used to measure the absorbance of the LDL samples. Small Angle X-ray Scattering and Dynamic Light Scattering experiments were used to look for any structural changes in LDL samples and to determine their size distribution. The Lipoprint test was used to determine the LDL sub-fractions in terms of distribution and size. Consumption of green-banana biomass, reduced total- (p = 0.010), non-HDL-cholesterol (p = 0.043), glucose (p = 0.028) and HbA1c (p = 0.0007), and also improved the protection of the LDL particle against oxidation, by the increase in carotenoids content in the particles (p = 0.007). This higher protection against modifications may decrease the risk of developing cardiovascular disease. These benefits of the green-banana biomass encourage the use of resistant starches with potential clinical applications in individuals with pre-diabetes and diabetes.",2020,Small Angle X-ray Scattering and Dynamic Light Scattering experiments were used to look for any structural changes in LDL samples and to determine their size distribution.,"['individuals with pre-diabetes and diabetes', 'subjects with type 2 diabetes', 'Subjects (n\u2009=\u200939, mean age 65\xa0years old) of both sexes with diabetes (HbA1c\u2009≥\u20096·5']","['6-months consumption of green-banana biomass', 'nutritional support plus green-banana biomass (40\xa0g) (n\u2009=\u200921) or diet alone']","['LDL particle functionality', 'Consumption of green-banana biomass, reduced total- ', 'plasma low-density lipoprotein particle functionality', 'non-HDL-cholesterol', 'carotenoids content', 'protection of the LDL particle against oxidation']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0332583', 'cui_str': 'Green color'}, {'cui': 'C0004722', 'cui_str': 'Banana'}, {'cui': 'C0005535', 'cui_str': 'Biomass'}, {'cui': 'C0242739', 'cui_str': 'Nutritional support'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0332583', 'cui_str': 'Green color'}, {'cui': 'C0004722', 'cui_str': 'Banana'}, {'cui': 'C0005535', 'cui_str': 'Biomass'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0729627', 'cui_str': 'Non-HDL cholesterol'}, {'cui': 'C0007271', 'cui_str': 'Carotinoid'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}]",,0.0222308,Small Angle X-ray Scattering and Dynamic Light Scattering experiments were used to look for any structural changes in LDL samples and to determine their size distribution.,"[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Lotfollahi', 'Affiliation': 'Complex Fluids Group, Instituto de Física, Universidade de São Paulo, Rua Do Matão, 1371, Butantã, São Paulo, SP, CEP: 05508-090, Brazil.'}, {'ForeName': 'Ana Paula de Queiroz', 'Initials': 'APQ', 'LastName': 'Mello', 'Affiliation': 'University Center São Camilo, São Paulo, Brazil.'}, {'ForeName': 'Edna S', 'Initials': 'ES', 'LastName': 'Costa', 'Affiliation': 'Federal University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Cristiano L P', 'Initials': 'CLP', 'LastName': 'Oliveira', 'Affiliation': 'Complex Fluids Group, Instituto de Física, Universidade de São Paulo, Rua Do Matão, 1371, Butantã, São Paulo, SP, CEP: 05508-090, Brazil.'}, {'ForeName': 'Nagila R T', 'Initials': 'NRT', 'LastName': 'Damasceno', 'Affiliation': 'Faculty of Public Health, University of São Paulo (USP), São Paulo, Brazil.'}, {'ForeName': 'Maria Cristina', 'Initials': 'MC', 'LastName': 'Izar', 'Affiliation': 'Federal University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Antonio Martins Figueiredo', 'Initials': 'AMF', 'LastName': 'Neto', 'Affiliation': 'Complex Fluids Group, Instituto de Física, Universidade de São Paulo, Rua Do Matão, 1371, Butantã, São Paulo, SP, CEP: 05508-090, Brazil. afigueiredo@if.usp.br.'}]",Scientific reports,['10.1038/s41598-020-69288-1'] 2817,32704155,Effects of movement representation techniques on motor learning of thumb-opposition tasks.,"The present work is the first study that assess long run change after motor learning. The study's main objective was to evaluate the short to medium-term impact of motor imagery (MI) and action observation (AO) on motor learning of a sequence of thumb-opposition tasks of increasing complexity. We randomly assigned 45 participants to an AO, MI, or placebo observation (PO) group. A sequence of 12 thumb-opposition tasks was taught for 3 consecutive days (4 per day). The primary outcome was accuracy. The secondary outcomes were required time and perfect positioning. The outcomes were assessed immediately after the intervention and at 1 week, 1 month and 4 months postintervention. Regarding the primary outcome, AO group had significantly higher accuracy than the MI or PO group until at least 4 months (p < 0.01, d > 0.80). However, in the bimanual positions, AO was not superior to MI at 1 week postintervention. Regarding secondary outcomes, AO group required less time than the MI group to remember and perform the left-hand and both-hand gestures, with a large effect size (p < 0.01, d > 0.80). In terms of percentage of perfect positions, AO group achieved significantly better results than the MI group until at least 4 months after the intervention in the unimanual gestures (p < 0.01, d > 0.80) and up to 1 month postintervention in the bimanual gestures (p = 0.012, d = 1.29). AO training resulted in greater and longer term motor learning than MI and placebo intervention. If the goal is to learn some motor skills for whatever reason (e.g., following surgery or immobilization.), AO training should be considered clinically.",2020,"In terms of percentage of perfect positions, AO group achieved significantly better results than the MI group until at least 4 months after the intervention in the unimanual gestures (p < 0.01, d > 0.80) and up to 1 month postintervention in the bimanual gestures (p = 0.012, d = 1.29).",[],"['AO, MI, or placebo observation (PO', 'AO training', 'movement representation techniques', 'motor imagery (MI) and action observation (AO']","['required time and perfect positioning', 'longer term motor learning', 'motor learning of thumb-opposition tasks']",[],"[{'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0150305', 'cui_str': 'Positioning - therapy'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0427082', 'cui_str': 'Opposition of thumb'}]",45.0,0.0563366,"In terms of percentage of perfect positions, AO group achieved significantly better results than the MI group until at least 4 months after the intervention in the unimanual gestures (p < 0.01, d > 0.80) and up to 1 month postintervention in the bimanual gestures (p = 0.012, d = 1.29).","[{'ForeName': 'Ferran', 'Initials': 'F', 'LastName': 'Cuenca-Martínez', 'Affiliation': 'Departmento de Fisioterapia, Centro Superior de Estudios Universitarios CSEU La Salle, Universidad Autónoma de Madrid, Madrid, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Suso-Martí', 'Affiliation': 'Motion in Brains Research Group, Institute of Neuroscience and Sciences of the Movement (INCIMOV), Centro Superior de Estudios Universitarios CSEU La Salle, Universidad Autónoma de Madrid, Madrid, Spain.'}, {'ForeName': 'Jose Vicente', 'Initials': 'JV', 'LastName': 'León-Hernández', 'Affiliation': 'Departmento de Fisioterapia, Centro Superior de Estudios Universitarios CSEU La Salle, Universidad Autónoma de Madrid, Madrid, Spain.'}, {'ForeName': 'Roy', 'Initials': 'R', 'LastName': 'La Touche', 'Affiliation': 'Departmento de Fisioterapia, Centro Superior de Estudios Universitarios CSEU La Salle, Universidad Autónoma de Madrid, Madrid, Spain. roylatouche@yahoo.es.'}]",Scientific reports,['10.1038/s41598-020-67905-7'] 2818,32704387,Effect of Pulmonary Rehabilitation in Patients with Asthma COPD Overlap Syndrome: A Randomized Control Trial.,"Objectives We sought to evaluate the effectiveness of six weeks pulmonary rehabilitation (PR) in patients with asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS). Methods We enrolled 28 patients with ACOS. Fourteen patients were randomly allocated to the PR group, which comprised of supervised endurance training, supervised resistance training, breathing exercises, self management, and education. The other 14 patients were allocated to the control group, who were asked to continue their usual routine strategies for six weeks. All patients were assessed at baseline and after six weeks using the six minute walk test (6MWT), St George Respiratory Questionnaire (SGRQ), pulmonary function test (PFT), and Bode index (BI). Results We saw a significant improvement in 6MWT ( p = 0.001), SGRQ ( p = 0.007), and BI ( p < 0.001) in the PR group after six weeks compared to the control group. There was no significant difference between the groups for PFT ( p = 0.182) after six weeks. Conclusions Use of a short-term PR program in ACOS patients results in favorable changes in functional capacity, health-related quality of life, and BI. However, short-term PR was not sufficient to register changes in pulmonary function in these patients.",2020,"We saw a significant improvement in 6MWT ( p = 0.001), SGRQ ( p = 0.007), and BI ( p < 0.001) in the PR group after six weeks compared to the control group.","['28 patients with ACOS', 'Fourteen patients', '14 patients', 'patients with asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS', 'Patients with Asthma COPD Overlap Syndrome']","['six weeks pulmonary rehabilitation (PR', 'supervised endurance training, supervised resistance training, breathing exercises, self management, and education', 'Pulmonary Rehabilitation']","['functional capacity, health-related quality of life, and BI', 'SGRQ', 'pulmonary function', 'six minute walk test (6MWT), St George Respiratory Questionnaire (SGRQ), pulmonary function test (PFT), and Bode index (BI', '6MWT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4038730', 'cui_str': 'Asthma-chronic obstructive pulmonary disease overlap syndrome'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0877430', 'cui_str': 'Asthma chronic'}, {'cui': 'C0600260', 'cui_str': 'Obstructive airways disorder'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0410000', 'cui_str': 'Overlap syndrome'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}, {'cui': 'C4704697', 'cui_str': 'Endurance Training'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0006155', 'cui_str': 'Physiotherapeutic breathing exercise'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}]",28.0,0.0309214,"We saw a significant improvement in 6MWT ( p = 0.001), SGRQ ( p = 0.007), and BI ( p < 0.001) in the PR group after six weeks compared to the control group.","[{'ForeName': 'Munazza', 'Initials': 'M', 'LastName': 'Orooj', 'Affiliation': 'Centre for Physiotherapy and Rehabilitation Sciences, Jamia Millia Islamia (A Central University), New Delhi, India.'}, {'ForeName': 'Jamal Ali', 'Initials': 'JA', 'LastName': 'Moiz', 'Affiliation': 'Centre for Physiotherapy and Rehabilitation Sciences, Jamia Millia Islamia (A Central University), New Delhi, India.'}, {'ForeName': 'Aqsa', 'Initials': 'A', 'LastName': 'Mujaddadi', 'Affiliation': 'Centre for Physiotherapy and Rehabilitation Sciences, Jamia Millia Islamia (A Central University), New Delhi, India.'}, {'ForeName': 'Mir Shad', 'Initials': 'MS', 'LastName': 'Ali', 'Affiliation': 'Department of Pulmonary Rehabilitation, Metro Centre for Respiratory Diseases, Metro Hospital and Multispeciality Institute, Uttar Pradesh, India.'}, {'ForeName': 'Deepak', 'Initials': 'D', 'LastName': 'Talwar', 'Affiliation': 'Department of Pulmonary Rehabilitation, Metro Centre for Respiratory Diseases, Metro Hospital and Multispeciality Institute, Uttar Pradesh, India.'}]",Oman medical journal,['10.5001/omj.2020.54'] 2819,32704431,Endoscopic dacryocystorhinostomy using mucosal flaps for bilateral overlapping.,"BACKGROUND Recently, the use of posterior mucus flap has been introduced as a new technique for DCR, which has had a great success, as well as bone overlapping and minimal postoperative obstruction. Considering the need for these flaps to have a very good success, the purpose of this study was to examine the DCR endoscopic method using mucosal flaps for double-sided overlapping (as a new flap). METHODS In this clinical trial study, 60 patients undergoing DCR endoscopy referring to Amin and Al-Zahra hospitals during 1396 to 1398 entered the study. Patients were divided into two groups, which included endoscopic DCR by using mucosal flaps for double-sided and non-flip overlapping. The success rate of surgery, postoperative pain and its complications were studied in two groups. RESULTS Among the complications observed after surgery, hematoma (6.7 in each group), bleeding (3.3% in each group) and nasal secretion (10% in the intervention group and 6.7% in the control group) were observed. No tear and obstruction of tear ducts were seen in the two groups. There was no significant difference between the two groups based on the complications of postoperative pain and the success rate of surgery (P>0.05). CONCLUSION Using the double-sided overlapping flap method, the results of the same operation were similar to using the non-flap method. Therefore, the use of both endoscopic DCR techniques with two-way overlapping flap and without using it were two effective methods with limited complications.",2020,"There was no significant difference between the two groups based on the complications of postoperative pain and the success rate of surgery (P>0.05). ",['60 patients undergoing DCR endoscopy referring to Amin and Al-Zahra hospitals during 1396 to 1398 entered the study'],"['Endoscopic dacryocystorhinostomy', 'endoscopic DCR by using mucosal flaps for double-sided and non-flip overlapping']","['No tear and obstruction of tear ducts', 'hematoma', 'complications of postoperative pain', 'bleeding', 'nasal secretion', 'success rate of surgery, postoperative pain and its complications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010931', 'cui_str': 'Dacryocystorhinostomy'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0395256', 'cui_str': 'Intranasal dacryocystorhinostomy'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0010931', 'cui_str': 'Dacryocystorhinostomy'}, {'cui': 'C0729268', 'cui_str': 'Mucosal flap'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0540654', 'cui_str': 'Casper Protein'}]","[{'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0027437', 'cui_str': 'Nasolacrimal duct structure'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",60.0,0.0376306,"There was no significant difference between the two groups based on the complications of postoperative pain and the success rate of surgery (P>0.05). ","[{'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Rezaeian', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.'}, {'ForeName': 'Mojtaba', 'Initials': 'M', 'LastName': 'Abtahi-Forooshani', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.'}, {'ForeName': 'Mohammad-Ali', 'Initials': 'MA', 'LastName': 'Ghanbari', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.'}]",American journal of clinical and experimental immunology,[] 2820,32704498,Comparison Between Sodium Acetate and Sodium Chloride in Parenteral Nutrition for Very Preterm Infants on the Acid-Base Status and Neonatal Outcomes.,"Purpose To compare between sodium acetate (SA) and sodium chloride (SC) in parenteral nutrition (PN) with associated metabolic acidosis and neonatal morbidities in preterm infants. Methods Preterm infants below 33 weeks gestational age, and with a birth weight under 1,301 g were enrolled and further stratified into two groups: i) <1,000 g, or ii) ≥1,000 g in birth weight. The subjects were randomized to receive PN containing SA or SC within the first day of life. The results of routine blood investigations for the first 6 days of PN were collated, and the neonatal outcomes were recorded upon discharge or demise. Results Fifty-two infants entered the study, with 26 in each group: 29 infants had extremely low birth weight (ELBW). There were no significant differences in birth weight, gestation, sex, exposure to chorioamnionitis and antenatal steroids, surfactant doses and duration of mechanical ventilation between groups. The SA group had significantly higher mean pH and base excess (BE) from days 4 to 6 than the SC (mean pH, 7.36 vs. 7.34; mean BE -1.6 vs. -3.5 [ p <0.01]), with a two-fold increase in the mean BE among ELBW infants. Significantly fewer on SA required additional bicarbonate (n=4 vs. 13, p =0.01). The rate of bronchopulmonary dysplasia (BPD) was approximately four-fold lower in SA than SC (n=3 vs. 11, p <0.01). No significant differences were observed in necrotizing enterocolitis, patent ductus arteriosus, retinopathy of prematurity, cholestatic jaundice, and mortality between groups. Conclusion The use of SA in PN was associated with reduced metabolic acidosis and fewer BPD.",2020,"There were no significant differences in birth weight, gestation, sex, exposure to chorioamnionitis and antenatal steroids, surfactant doses and duration of mechanical ventilation between groups.","['Very Preterm Infants', 'Methods\n\n\nPreterm infants below 33 weeks gestational age, and with a birth weight under 1,301 g were enrolled and further stratified into two groups: i) <1,000 g, or ii) ≥1,000 g in birth weight', 'Results\n\n\nFifty-two infants entered the study, with 26 in each group: 29 infants had extremely low birth weight (ELBW', 'preterm infants']","['Sodium Acetate and Sodium Chloride', 'bicarbonate', 'PN containing SA or SC', 'sodium acetate (SA) and sodium chloride (SC', 'parenteral nutrition (PN']","['mean BE', 'mean pH and base excess (BE', 'metabolic acidosis and fewer BPD', 'birth weight, gestation, sex, exposure to chorioamnionitis and antenatal steroids, surfactant doses and duration of mechanical ventilation', 'rate of bronchopulmonary dysplasia (BPD', 'necrotizing enterocolitis, patent ductus arteriosus, retinopathy of prematurity, cholestatic jaundice, and mortality']","[{'cui': 'C3897192', 'cui_str': 'Very preterm infant'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0456065', 'cui_str': 'Extremely low birth weight infant'}]","[{'cui': 'C0142785', 'cui_str': 'Sodium Acetate'}, {'cui': 'C0037494', 'cui_str': 'Sodium Chloride'}, {'cui': 'C0005367', 'cui_str': 'Bicarbonate'}, {'cui': 'C0030547', 'cui_str': 'Parenteral nutrition'}, {'cui': 'C0332256', 'cui_str': 'Containing'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0201985', 'cui_str': 'Delta base, blood'}, {'cui': 'C0220981', 'cui_str': 'Metabolic acidosis'}, {'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C0006012', 'cui_str': 'Borderline personality disorder'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0008495', 'cui_str': 'Chorioamnionitis'}, {'cui': 'C2828394', 'cui_str': 'Antenatal'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0034085', 'cui_str': 'Lung surfactant'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary dysplasia of newborn'}, {'cui': 'C0014356', 'cui_str': 'Enterocolitis'}, {'cui': 'C0013274', 'cui_str': 'Patent ductus arteriosus'}, {'cui': 'C0035344', 'cui_str': 'Retinopathy of prematurity'}, {'cui': 'C0022354', 'cui_str': 'Obstructive hyperbilirubinemia'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",,0.0851814,"There were no significant differences in birth weight, gestation, sex, exposure to chorioamnionitis and antenatal steroids, surfactant doses and duration of mechanical ventilation between groups.","[{'ForeName': 'Adli', 'Initials': 'A', 'LastName': 'Ali', 'Affiliation': 'Department of Paediatrics, Faculty of Medicine, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Ee-Yan', 'Initials': 'EY', 'LastName': 'Ong', 'Affiliation': 'Department of Pharmacy, University Kebangsaan Malaysia Medical Center, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Birinder Kaur', 'Initials': 'BK', 'LastName': 'Sadu Singh', 'Affiliation': 'Department of Pharmacy, University Kebangsaan Malaysia Medical Center, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Fook-Choe', 'Initials': 'FC', 'LastName': 'Cheah', 'Affiliation': 'Department of Paediatrics, Faculty of Medicine, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia.'}]","Pediatric gastroenterology, hepatology & nutrition",['10.5223/pghn.2020.23.4.377'] 2821,32704500,Can a Synbiotic Supplementation Contribute to Decreasing Anti-Tissue Transglutaminase Levels in Children with Potential Celiac Disease?,"Purpose Synbiotics can alleviate some intestinal pathologies or prevent trigger mechanisms for some diseases such as celiac disease (CD). If patients with high levels of anti-tissue transglutaminase (anti-tTG) immunoglobulin A (IgA) antibodies have normal duodenal histology, they are followed as potential CD patients. The aim of this study was to investigate the effect of synbiotic use on the blood levels of anti-tTG antibodies in children. Methods Eighty-two patients with high anti-tTG levels were included in this study. Patients were randomly divided into two groups. The synbiotic group was treated with a daily dose of a synbiotic including multi-strain probiotics for 20 days. The control group was not administered any medication. Anti-tTG values at baseline and repeat measurements and the percentage change in anti-tTG levels between groups were compared. Results The anti-tTG level at baseline was 36 U/mL (interquartile range [IQR], 26.4-68 U/mL) in the synbiotic group, and it decreased significantly to 13 U/mL (IQR, 6.5-27.5 U/mL) after 20 days ( p <0.05). The anti-tTG level at baseline was 46 U/mL (IQR, 31-89 U/mL) in the control group, which also decreased significantly to 23 U/mL (IQR, 7-41 U/mL) after 20 days ( p <0.05). Anti-tTG levels exhibited 73% and 56% decreases in the synbiotic and control groups, respectively ( p <0.05). Conclusion It may be speculated that a synbiotic supplementation can contribute to decreasing anti-tTG levels in children with potential CD.",2020,"The anti-tTG level at baseline was 46 U/mL (IQR, 31-89 U/mL) in the control group, which also decreased significantly to 23 U/mL (IQR, 7-41 U/mL) after 20 days ( p <0.05).","['children', 'Methods\n\n\nEighty-two patients with high anti-tTG levels', 'patients with high levels of anti-tissue transglutaminase (anti-tTG) immunoglobulin A (IgA) antibodies have normal duodenal histology, they are followed as potential CD patients', 'Children with Potential Celiac Disease', 'children with potential CD']","['synbiotic including multi-strain probiotics', 'synbiotic supplementation', 'Synbiotic Supplementation', 'synbiotic']","['anti-tTG level', 'Anti-tTG levels', 'blood levels of anti-tTG antibodies', 'anti-tTG levels']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1277274', 'cui_str': 'Anti-tissue transglutaminase level'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0529334', 'cui_str': 'transglutaminase 2'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0013303', 'cui_str': 'Duodenal'}, {'cui': 'C0019638', 'cui_str': 'Histology'}, {'cui': 'C0007570', 'cui_str': 'Celiac disease'}]","[{'cui': 'C2936470', 'cui_str': 'Synbiotics'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C1277274', 'cui_str': 'Anti-tissue transglutaminase level'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0529334', 'cui_str': 'transglutaminase 2'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}]",82.0,0.0232137,"The anti-tTG level at baseline was 46 U/mL (IQR, 31-89 U/mL) in the control group, which also decreased significantly to 23 U/mL (IQR, 7-41 U/mL) after 20 days ( p <0.05).","[{'ForeName': 'Kaan', 'Initials': 'K', 'LastName': 'Demiroren', 'Affiliation': 'Department of Pediatric Gastroenterology, University of Health Sciences, Yuksek Ihtisas Teaching Hospital, Bursa, Turkey.'}]","Pediatric gastroenterology, hepatology & nutrition",['10.5223/pghn.2020.23.4.397'] 2822,32704499,"Effect of Supplementation of Zinc, Glutamine, Fiber, and Prebiotics in Presumed Healthy Indonesian Children Aged 1-3 Years.","Purpose Impaired intestinal mucosal integrity may affect the gastrointestinal function, especially in relation to nutrition, absorption, and barrier function. The purpose of this study was to measure the prevalence of impaired intestinal mucosal integrity in presumed healthy children aged 1-3 years and assess the effects of zinc, glutamine, fiber, and prebiotic supplementation in them. Methods A cross-sectional study was conducted in 200 children aged 1-3 years in Pasar Minggu, South Jakarta, Indonesia. A randomized double-blind parallel group method clinical trial was then performed to assess the effects of zinc, glutamine, fiber, and prebiotic supplementation. Results Elevated calprotectin was found in 91/200 subjects (45.5%) at the onset of the study. After 10 months, 144 subjects completed the study: 72 subjects received the trial formula, whereas the other 72 received the standard formula. A transitory decrease in fecal calprotectin (FC) was observed after 6 months in the subgroup with normal FC levels, who were fed the test formula ( p =0.012). Conclusion The prevalence of impaired intestinal mucosal integrity in this group of Indonesian children aged 1-3 years was high. Supplementation with zinc, glutamine, fiber, and prebiotics during 6 months reduced FC only in those who had low levels at baseline but not in those with impaired integrity.",2020,"A transitory decrease in fecal calprotectin (FC) was observed after 6 months in the subgroup with normal FC levels, who were fed the test formula ( p =0.012). ","['200 children aged 1-3 years in Pasar Minggu, South Jakarta, Indonesia', '144 subjects completed the study: 72 subjects received the trial formula, whereas the other 72 received the standard formula', 'Healthy Indonesian Children Aged 1-3 Years', 'presumed healthy children aged 1-3 years']","['zinc, glutamine, fiber, and prebiotic supplementation', 'Supplementation of Zinc, Glutamine, Fiber, and Prebiotics']","['fecal calprotectin (FC', 'Elevated calprotectin', 'prevalence of impaired intestinal mucosal integrity']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0021247', 'cui_str': 'Indonesia'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C3853255', 'cui_str': 'Standard formula'}, {'cui': 'C0021248', 'cui_str': 'Indonesian language'}, {'cui': 'C0686744', 'cui_str': 'Well child'}]","[{'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0017797', 'cui_str': 'Glutamine'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C1964053', 'cui_str': 'Faecal calprotectin'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0950624', 'cui_str': 'Calprotectin'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C0205266', 'cui_str': 'Intact'}]",200.0,0.28196,"A transitory decrease in fecal calprotectin (FC) was observed after 6 months in the subgroup with normal FC levels, who were fed the test formula ( p =0.012). ","[{'ForeName': 'Muzal', 'Initials': 'M', 'LastName': 'Kadim', 'Affiliation': 'Department of Child Health, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.'}, {'ForeName': 'Badriul', 'Initials': 'B', 'LastName': 'Hegar', 'Affiliation': 'Department of Child Health, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.'}, {'ForeName': 'Saptawati', 'Initials': 'S', 'LastName': 'Bardosono', 'Affiliation': 'Department of Nutrition, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.'}, {'ForeName': 'Ina S', 'Initials': 'IS', 'LastName': 'Timan', 'Affiliation': 'Department of Clinical Phatology Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.'}, {'ForeName': 'Hartono', 'Initials': 'H', 'LastName': 'Gunardi', 'Affiliation': 'Department of Child Health, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.'}, {'ForeName': 'Dwi', 'Initials': 'D', 'LastName': 'Prasetyo', 'Affiliation': 'Department of Child Health, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia.'}, {'ForeName': 'Agus', 'Initials': 'A', 'LastName': 'Firmansyah', 'Affiliation': 'Department of Child Health, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.'}, {'ForeName': 'Yvan', 'Initials': 'Y', 'LastName': 'Vandenplas', 'Affiliation': 'KidZ Health Castle, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.'}]","Pediatric gastroenterology, hepatology & nutrition",['10.5223/pghn.2020.23.4.388'] 2823,32704514,Effective Antimicrobial StewaRdship StrategIES (ARIES): Cluster Randomized Trial of Computerized Decision Support System and Prospective Review and Feedback.,"Background Prospective review and feedback (PRF) of antibiotic prescriptions and compulsory computerized decision support system (CDSS) are 2 strategies of antimicrobial stewardship. There are limited studies investigating their combined effects. We hypothesized that the use of on-demand (voluntary) CDSS would achieve similar patient outcomes compared with automatically triggered (compulsory) CDSS whenever broad-spectrum antibiotics are ordered. Methods A parallel-group, 1:1 block cluster randomized crossover study was conducted in 32 medical and surgical wards from March to August 2017. CDSS use for piperacillin-tazobactam or carbapenem in the intervention clusters was at the demand of the doctor, while in the control clusters CDSS use was compulsory. PRF was continued for both arms. The primary outcome was 30-day mortality. Results Six hundred forty-one and 616 patients were randomized to voluntary and compulsory CDSS, respectively. There were no differences in 30-day mortality (hazard ratio [HR], 0.87; 95% CI, 0.67-1.12), re-infection and re-admission rates, antibiotic duration, length of stay, or hospitalization cost. The proportion of patients receiving PRF recommendations was not significantly lower in the voluntary CDSS arm (62 [10%] vs 81 [13%]; P = .05). Appropriate indication of antibiotics was high in both arms (351/448 [78%] vs 330/433 [74%]; P = .18). However, in geriatric medicine patients where antibiotic appropriateness was <50%, prescription via compulsory CDSS resulted in a shorter length of stay and lower hospitalization cost. Conclusions Voluntary broad-spectrum antibiotics with PRF via CDSS did not result in differing clinical outcomes, antibiotic duration, or length of stay. However, in the setting of low antibiotic appropriateness, compulsory CDSS may be beneficial.",2020,"There were no differences in 30-day mortality (hazard ratio [HR], 0.87; 95% CI, 0.67-1.12), re-infection and re-admission rates, antibiotic duration, length of stay, or hospitalization cost.","['32 medical and surgical wards from March to August 2017', 'Six hundred forty-one and 616 patients']","['piperacillin-tazobactam or carbapenem', 'Effective Antimicrobial StewaRdship StrategIES (ARIES', 'feedback (PRF) of antibiotic prescriptions and compulsory computerized decision support system (CDSS']","['antibiotic appropriateness', 'clinical outcomes, antibiotic duration, or length of stay', 'PRF', 'shorter length of stay and lower hospitalization cost', '30-day mortality', 'proportion of patients receiving PRF recommendations', 're-infection and re-admission rates, antibiotic duration, length of stay, or hospitalization cost']","[{'cui': 'C1948041', 'cui_str': 'Surgical and medical procedures'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0250480', 'cui_str': 'Piperacillin and tazobactam'}, {'cui': 'C0006968', 'cui_str': 'Carbapenem'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C4505099', 'cui_str': 'Antimicrobial Stewardship'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0870393', 'cui_str': 'Decision support tool'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]",,0.123873,"There were no differences in 30-day mortality (hazard ratio [HR], 0.87; 95% CI, 0.67-1.12), re-infection and re-admission rates, antibiotic duration, length of stay, or hospitalization cost.","[{'ForeName': 'Shi Thong', 'Initials': 'ST', 'LastName': 'Heng', 'Affiliation': 'Department of Pharmacy, Tan Tock Seng Hospital, Singapore.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Wong', 'Affiliation': 'Office of Clinical Epidemiology, Analytics, and kNowledge (OCEAN), Tan Tock Seng Hospital, Singapore.'}, {'ForeName': 'Barnaby', 'Initials': 'B', 'LastName': 'Young', 'Affiliation': 'Department of Infectious Diseases, National Centre for Infectious Disease, Singapore.'}, {'ForeName': 'Hui Lin', 'Initials': 'HL', 'LastName': 'Tay', 'Affiliation': 'Department of Pharmacy, Tan Tock Seng Hospital, Singapore.'}, {'ForeName': 'Sock Hoon', 'Initials': 'SH', 'LastName': 'Tan', 'Affiliation': 'Department of Pharmacy, Tan Tock Seng Hospital, Singapore.'}, {'ForeName': 'Min Yi', 'Initials': 'MY', 'LastName': 'Yap', 'Affiliation': 'Department of Pharmacy, Tan Tock Seng Hospital, Singapore.'}, {'ForeName': 'Christine B', 'Initials': 'CB', 'LastName': 'Teng', 'Affiliation': 'Department of Pharmacy, Tan Tock Seng Hospital, Singapore.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Ang', 'Affiliation': 'Department of Infectious Diseases, National Centre for Infectious Disease, Singapore.'}, {'ForeName': 'Tau Hong', 'Initials': 'TH', 'LastName': 'Lee', 'Affiliation': 'Department of Infectious Diseases, National Centre for Infectious Disease, Singapore.'}, {'ForeName': 'Hui Ling', 'Initials': 'HL', 'LastName': 'Tan', 'Affiliation': 'Department of Anaesthesiology, Intensive Care and Pain Medicine, Tan Tock Seng Hospital, Singapore.'}, {'ForeName': 'Thomas W', 'Initials': 'TW', 'LastName': 'Lew', 'Affiliation': 'Department of Anaesthesiology, Intensive Care and Pain Medicine, Tan Tock Seng Hospital, Singapore.'}, {'ForeName': 'David Chien', 'Initials': 'DC', 'LastName': 'Lye', 'Affiliation': 'Department of Infectious Diseases, National Centre for Infectious Disease, Singapore.'}, {'ForeName': 'Tat Ming', 'Initials': 'TM', 'LastName': 'Ng', 'Affiliation': 'Department of Pharmacy, Tan Tock Seng Hospital, Singapore.'}]",Open forum infectious diseases,['10.1093/ofid/ofaa254'] 2824,32704534,Otitis Media Module in the Pediatric Preclerkship Educational Exercises (PRECEDE) Curriculum.,"Introduction The Johns Hopkins Pediatrics Clerkship developed the PRECEDE (preclerkship educational exercises) curriculum with the primary goal of offering students formative instruction in essential pediatric clinical skills to prepare them for their clerkship. PRECEDE sessions occur at the beginning of each basic clerkship for new clinical clerkship students. The otitis media module is one in a series of modules presented in the curriculum and consists of a lecture and four short skills-development stations, each with a faculty facilitator. Methods This 2-hour module began with a 1-hour didactic overview of otitis media. Medical students were divided into three groups. One group learned about writing prescriptions via two otitis media clinical vignettes. Another group explored visualization and diagnosis of otitis media via video. The last student group was subdivided and learned proper techniques for positioning and restraining pediatric patients during otoscopic exams and the psychomotor skills for performing otoscopic examinations, including pneumatic otoscopy. Student groups rotated through all four activity stations. Students were guided through discussion to develop interpretation, diagnostic, and treatment skills for acute otitis media. Results Between 2010 and 2012, 254 third- and fourth-year medical students participated in this module. When asked to evaluate overall quality, 86% of learners rated the module as excellent, and 14% rated it as good. Discussion By establishing these important skills, students may be better equipped to develop appropriate otitis media assessments, diagnoses, and care plans for patients and to use otitis media as a platform for broad education in other essential pediatric skills.",2020,"When asked to evaluate overall quality, 86% of learners rated the module as excellent, and 14% rated it as good. ","['Results\n\n\nBetween 2010 and 2012', 'Medical students', ' 254 third- and fourth-year medical students participated in this module']","['learned proper techniques for positioning and restraining pediatric patients during otoscopic exams and the psychomotor skills for performing otoscopic examinations, including pneumatic otoscopy']",['overall quality'],"[{'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0205438', 'cui_str': 'Fourth'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542953', 'cui_str': 'Module'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0150305', 'cui_str': 'Positioning - therapy'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0582103', 'cui_str': 'Medical assessment'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0444678', 'cui_str': 'Pneumatic otoscopy'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0332306', 'cui_str': 'Quality'}]",,0.0197339,"When asked to evaluate overall quality, 86% of learners rated the module as excellent, and 14% rated it as good. ","[{'ForeName': 'Stacy', 'Initials': 'S', 'LastName': 'Cooper', 'Affiliation': 'Assistant Professor, Department of Oncology, Johns Hopkins University School of Medicine; Assistant Professor, Department of Pediatrics, Johns Hopkins University School of Medicine.'}, {'ForeName': 'W Christopher', 'Initials': 'WC', 'LastName': 'Golden', 'Affiliation': 'Assistant Professor, Department of Pediatrics, Johns Hopkins University School of Medicine.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Barone', 'Affiliation': 'Associate Professor, Department of Pediatrics, Johns Hopkins University School of Medicine.'}, {'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Balighian', 'Affiliation': 'Assistant Professor, Department of Pediatrics, Johns Hopkins University School of Medicine.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Dudas', 'Affiliation': 'Associate Professor, Department of Pediatrics, Johns Hopkins University School of Medicine.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Frosch', 'Affiliation': 'Associate Professor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Jeffers', 'Affiliation': 'Assistant Professor, Department of Pediatrics, Johns Hopkins University School of Medicine.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Cooke', 'Affiliation': 'Associate Professor, Department of Pediatrics, Johns Hopkins University School of Medicine.'}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Widger', 'Affiliation': 'Clinical Associate, Department of Pediatrics, Johns Hopkins University School of Medicine.'}, {'ForeName': 'Rosalyn W', 'Initials': 'RW', 'LastName': 'Stewart', 'Affiliation': 'Associate Professor, Department of Medicine, Johns Hopkins University School of Medicine; Associate Professor, Department of Pediatrics, Johns Hopkins University School of Medicine.'}]",MedEdPORTAL : the journal of teaching and learning resources,['10.15766/mep_2374-8265.10920'] 2825,32704540,"Pharmacology, Pharmacotherapy, and Pharmacopolicy Through an Evidence-Based Medicine: A Novel Approach for First-Year Medical Students.","Introduction As evidenced by student performance on various assessments, pharmacotherapy remains a comparative weakness in undergraduate medical education, with several institutions developing novel strategies for students to apply these principles in a practical setting. Medical curricula have recently prioritized group-learning modalities and evidence-based medicine education. However, these principles have yet to impact pharmacology education. We developed and implemented an evidence-based, group-learning exercise for first-year medical students focusing on pharmacology through the practical lens of pharmacotherapy and pharmacopolicy. Methods First-year medical students in different groups were assigned a particular medication and, during an in-class session, were encouraged to meet with other representatives assigned the same drug to interpret the provided package insert and any online information. Students then reconvened with their groups to engage in collaborative teaching about each assigned drug before completing a group quiz using online resources. Facilitators reviewed the group quiz and allowed time for student questions. Results For 180 participants, the average group-quiz score was 86%, ranging from 68% to 100%. Student-reported satisfaction with the activity in meeting its preset objectives averaged 3.7 on a 5-point scale, with 5 being most positive. Discussion Overall, this activity effectively integrates principles of pharmacotherapy and pharmacopolicy into a group-based, evidence-based exercise. Limitations of the activity include the number of possible example drugs and the amount of material covered in a given time frame. However, the activity lends itself to the role of an introductory session in a longer curriculum centered on clinical-applied pharmacology and evidence-based practice.",2020,"Student-reported satisfaction with the activity in meeting its preset objectives averaged 3.7 on a 5-point scale, with 5 being most positive. ",['First-Year Medical Students'],['Medicine'],['quiz score'],"[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}]",180.0,0.0295536,"Student-reported satisfaction with the activity in meeting its preset objectives averaged 3.7 on a 5-point scale, with 5 being most positive. ","[{'ForeName': 'Alexander M', 'Initials': 'AM', 'LastName': 'Mozeika', 'Affiliation': 'Fourth-Year Medical Student, Department of Education, Rutgers New Jersey Medical School.'}, {'ForeName': 'Rijul', 'Initials': 'R', 'LastName': 'Asri', 'Affiliation': 'Medical Student, Department of Education, Rutgers New Jersey Medical School.'}, {'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Theis', 'Affiliation': 'Adjunct Assistant Professor, Department of Biochemistry & Molecular Biology, Rutgers New Jersey Medical School.'}, {'ForeName': 'Carolyn K', 'Initials': 'CK', 'LastName': 'Suzuki', 'Affiliation': 'Associate Professor, Department of Biochemistry & Molecular Biology, Rutgers New Jersey Medical School.'}]",MedEdPORTAL : the journal of teaching and learning resources,['10.15766/mep_2374-8265.10934'] 2826,32704547,Sweet taste does not modulate pain perception in adult humans.,"Background : It is commonly observed that humans who are in pain or discomfort seek solace in the form of sweet foods and drinks. Sugar is routinely used to comfort neonates undergoing painful procedures, and animal studies have shown that sucrose increases the time to withdrawal from painful stimuli. However, there are no published studies examining the effects of sweet substances on heat pain thresholds and percept in adult humans. Methods : Healthy adult volunteers (n=27, aged 18-48 years) were recruited to a controlled, double-blind, randomised, cross-over study to characterise the effect of tasting solutions of equivalent sweetness (10% sucrose and 0.016% sucralose) on warm detection and heat pain thresholds and the percept ratings of painfully hot stimuli. The effect of anticipation of a sweet taste on heat pain threshold was also assessed. Results : Tasting either sucrose or sucralose had no significant effect on the percept of an individually titrated hot stimulus (54.5±4.2 and 54.9±3.2 vs 53.2±3.5 for water, 0-100 visual analogue scale), on the warm detection or heat pain threshold (43.3±0.8, 43.2±0.8 vs 43.0±0.8°C). Anticipation of a sweet substance similarly did not affect heat pain thresholds. Conclusions : Sucrose and sucralose solutions had no analgesic effect when assessed using heat detection thresholds and percept ratings of painfully hot stimuli despite being perceived as sweeter and more pleasant than water. These findings are in contrast to results reported from previous animal studies in which thermal analgesia from sweet solutions is robust. Given the ubiquitous availability of sugar rich drinks in the modern environment, the lack of observable effect may be due to an insufficient hedonic value of the test solutions when compared to the experience of a laboratory rodent. Alternatively, sweet tastes may have a specific effect on pain tolerance rather than the threshold and acute percept measures assayed in this study.",2020,Conclusions : Sucrose and sucralose solutions had no analgesic effect when assessed using heat detection thresholds and percept ratings of painfully hot stimuli despite being perceived as sweeter and more pleasant than water.,"['Healthy adult volunteers (n=27, aged 18-48 years', 'adult humans']","['Sweet taste', 'sucrose or sucralose', 'tasting solutions of equivalent sweetness (10% sucrose and 0.016% sucralose) on warm detection and heat pain thresholds and the percept ratings of painfully hot stimuli', 'sweet substances']","['warm detection or heat pain threshold', 'percept of an individually titrated hot stimulus', 'pain perception', 'pain tolerance', 'heat pain threshold', 'heat pain thresholds']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0858600', 'cui_str': 'Taste sweet'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}, {'cui': 'C0077046', 'cui_str': 'sucralose'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0184348', 'cui_str': 'Warmer'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0444519', 'cui_str': 'Hot'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0085077', 'cui_str': 'Acute febrile neutrophilic dermatosis'}, {'cui': 'C0439861', 'cui_str': 'Substance'}]","[{'cui': 'C0184348', 'cui_str': 'Warmer'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0444519', 'cui_str': 'Hot'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}]",,0.175084,Conclusions : Sucrose and sucralose solutions had no analgesic effect when assessed using heat detection thresholds and percept ratings of painfully hot stimuli despite being perceived as sweeter and more pleasant than water.,"[{'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Mooney', 'Affiliation': 'School of Physiology, Pharmacology & Neuroscience, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.'}, {'ForeName': 'Alexander J', 'Initials': 'AJ', 'LastName': 'Davies', 'Affiliation': 'Nuffield Department of Clinical Neuroscience, University of Oxford, Level 6 West Wing, John Radcliffe Hospital, Oxford, OX3 9DU, UK.'}, {'ForeName': 'Anthony E', 'Initials': 'AE', 'LastName': 'Pickering', 'Affiliation': 'School of Physiology, Pharmacology & Neuroscience, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.'}]",Wellcome open research,['10.12688/wellcomeopenres.15726.1'] 2827,32704555,Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients.,"Aims The GLP1 agonist lixisenatide is glucagonostatic and reduces post-prandial blood glucose (PPBG) in type 2 diabetes. This study investigates its impact in type 1 diabetes (T1D). Methods In a blinded, crossover trial, 25 patients with T1D were randomised to 4 weeks adjunctive treatment with lixisenatide (L) or placebo (P), with a 4-week washout period. The primary outcome was percentage of 3 hours PPBG in target (4-10 mmol/L) assessed by CGM before and after treatment. Participants also underwent post-treatment standardised mixed meal test (MMT, n = 25) and hyperinsulinaemic hypoglycaemic clamp (n = 15). Results PPBG CGM readings in target were similar between L vs P (Mean % ± SE, breakfast 45.4 ± 6.0 vs 44.3 ± 6.0, P  = .48, lunch 45.5 ± 5.8 vs 50.6 ± 5.3, P  = .27 and dinner 43.0 ± 6.7 vs 47.7 ± 5.6, P  = .30). HbA1C was similar between L vs P (64.7 ± 1.6 vs 64.1 ± 1.6 mmol/mol, P  = .30). Prandial insulin fell after lixisenatide (dose change -0.7 ± 0.6 vs +2.4 ± 0.7 units/d, P  = .004), but basal insulin dose was similar between groups. The post-MMT glucose area under the curve (AUC) was lower with L than P (392.0 ± 167.7 vs 628.1 ± 132.5 mmol/L × min, P  < .001), as was the corresponding glucagon AUC (140.0 ± 110.0 vs 304.2 ± 148.2 nmol/L × min, P  < .001). Glucagon and counter-regulatory hormone values at a blood glucose of 2.4 mmol/L during the hypoglycaemic clamp were similar between L and P. Conclusion In T1D, PPBG values were not altered by adjunctive lixisenatide although prandial insulin dose fell. Glucose and glucagon level during an MMT were significantly lower after lixisenatide, without affecting counter-regulatory response during hypoglycaemia.",2020,"Glucose and glucagon level during an MMT were significantly lower after lixisenatide, without affecting counter-regulatory response during hypoglycaemia.","['type 1 diabetes', 'type 1 diabetes patients', 'type 1 diabetes (T1D', '25 patients with T1D']","['lixisenatide', 'lixisenatide (L) or placebo (P', 'post-treatment standardised mixed meal test (MMT, n\xa0=\xa025) and hyperinsulinaemic hypoglycaemic clamp', 'Lixisenatide']","['post-MMT glucose area under the curve (AUC', 'Glucagon and counter-regulatory hormone values', 'Glucose and glucagon level', 'HbA1C', 'PPBG CGM readings', 'Prandial insulin fell', 'basal insulin dose', 'percentage of 3\xa0hours PPBG', 'corresponding glucagon AUC (140.0\xa0±']","[{'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C2973895', 'cui_str': 'Lixisenatide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0046370', 'cui_str': '2-methylcyclopentadienyl manganese tricarbonyl'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic agent'}, {'cui': 'C0175721', 'cui_str': 'Clamp'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0046370', 'cui_str': '2-methylcyclopentadienyl manganese tricarbonyl'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0017687', 'cui_str': 'Glucagon'}, {'cui': 'C0677601', 'cui_str': 'Counter'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0337437', 'cui_str': 'Glucagon measurement'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0428569', 'cui_str': 'Post-prandial blood glucose measurement'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0439227', 'cui_str': 'hour'}]",25.0,0.146287,"Glucose and glucagon level during an MMT were significantly lower after lixisenatide, without affecting counter-regulatory response during hypoglycaemia.","[{'ForeName': 'Chitrabhanu', 'Initials': 'C', 'LastName': 'Ballav', 'Affiliation': 'Oxford Centre for Diabetes Endocrinology and Metabolism University of Oxford Churchill Hospital Oxford UK.'}, {'ForeName': 'Archana', 'Initials': 'A', 'LastName': 'Dhere', 'Affiliation': 'Oxford Centre for Diabetes Endocrinology and Metabolism University of Oxford Churchill Hospital Oxford UK.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Kennedy', 'Affiliation': 'Diabetes Trials Unit University of Oxford Oxford UK.'}, {'ForeName': 'Olorunsola F', 'Initials': 'OF', 'LastName': 'Agbaje', 'Affiliation': 'Diabetes Trials Unit University of Oxford Oxford UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'White', 'Affiliation': 'Oxford Centre for Diabetes Endocrinology and Metabolism University of Oxford Churchill Hospital Oxford UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Franklin', 'Affiliation': 'Oxford Centre for Diabetes Endocrinology and Metabolism University of Oxford Churchill Hospital Oxford UK.'}, {'ForeName': 'Bolette', 'Initials': 'B', 'LastName': 'Hartmann', 'Affiliation': 'NNF Center for Basic Metabolic Research and Department of Biomedical Sciences University of Copenhagen Copenhagen Denmark.'}, {'ForeName': 'Jens J', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'NNF Center for Basic Metabolic Research and Department of Biomedical Sciences University of Copenhagen Copenhagen Denmark.'}, {'ForeName': 'Rury R', 'Initials': 'RR', 'LastName': 'Holman', 'Affiliation': 'Diabetes Trials Unit University of Oxford Oxford UK.'}, {'ForeName': 'Katharine R', 'Initials': 'KR', 'LastName': 'Owen', 'Affiliation': 'Oxford Centre for Diabetes Endocrinology and Metabolism University of Oxford Churchill Hospital Oxford UK.'}]","Endocrinology, diabetes & metabolism",['10.1002/edm2.130'] 2828,32704564,A quantitative measure of treatment response in recent-onset type 1 diabetes.,"Introduction This paper develops a methodology and defines a measure that can be used to separate subjects that received an experimental therapy into those that benefitted from those that did not in recent-onset type 1 diabetes. Benefit means a slowing (or arresting) the decline in beta-cell function over time. The measure can be applied to comparing treatment arms from a clinical trial or to response at the individual level. Methods An analysis of covariance model was fitted to the 12-month area under the curve C-peptide following a 2-hour mixed meal tolerance test from 492 individuals enrolled on five TrialNet studies of recent-onset type 1 diabetes. Significant predictors in the model were age and C-peptide at study entry. The observed minus the model-based expected C-peptide value (quantitative response, QR) is defined to reflect the effect of the therapy. Results A comparison of the primary hypothesis test for each study included and a t test of the QR value by treatment group were comparable. The results were also confirmed for a new TrialNet study, independent of the set of studies used to derive the model. With our proposed analytical method and using QR as the end-point, we conducted simulation studies, to estimate statistical power in detecting a biomarker that expresses differential treatment effect. The QR in its continuous form provided the greatest statistical power when compared to several ways of defining responder/non-responder using various QR thresholds. Conclusions This paper illustrates the use of the QR, as a measure of the magnitude of treatment effect at the aggregate and subject-level. We show that the QR distribution by treatment group provides a better sense of the treatment effect than simply giving the mean estimates. Using the QR in its continuous form is shown to have higher statistical power in comparison with dichotomized categorization.",2020,Using the QR in its continuous form is shown to have higher statistical power in comparison with dichotomized categorization.,['492 individuals enrolled on five TrialNet studies of recent-onset type 1 diabetes'],[],[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}]",[],[],492.0,0.0175856,Using the QR in its continuous form is shown to have higher statistical power in comparison with dichotomized categorization.,"[{'ForeName': 'Brian N', 'Initials': 'BN', 'LastName': 'Bundy', 'Affiliation': 'Health Informatics Institute University of South Florida Tampa FL USA.'}, {'ForeName': 'Jeffrey P', 'Initials': 'JP', 'LastName': 'Krischer', 'Affiliation': 'Health Informatics Institute University of South Florida Tampa FL USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Endocrinology, diabetes & metabolism",['10.1002/edm2.143'] 2829,32704565,Infusion of N-acetyl cysteine during hypoglycaemia in humans does not preserve the counterregulatory response to subsequent hypoglycaemia.,"Aim Administration of N-acetyl cysteine (NAC) during hypoglycaemia will preserve the counterregulatory response to subsequent hypoglycaemia in healthy humans. Methods This was a randomized double-blind cross over study where humans were given either a 60-minute infusion of NAC (150 mg/kg) followed by a 4-hour infusion of NAC (50 mg/kg) or saline starting 30 minutes before the initiation of a 2-hour hypoglycaemic (HG) clamp at 8 am. After rest at euglycaemia for ~2 hours, subjects were exposed to a 2nd HG clamp at 2 pm and discharged home in euglycaemia. They returned the following day for a 3rd HG clamp at 8 am. Results Twenty-two subjects were enrolled. Eighteen subjects completed the entire protocol. The epinephrine response during clamp 3 (171 ± 247 pg/mL) following clamp 1 NAC infusion was lower than the response during the clamp 1 NAC infusion (538 ± 392 pg/mL) (clamp 3 to clamp 1 NAC: P  = .0013). The symptom response during clamp 3 (7 ± 5) following clamp 1 NAC infusion was lower than the response during the clamp 1 NAC infusion (16 ± 10) (clamp 3 to clamp 1 NAC: P  = .0003). Nine subjects experienced rash, pruritus or nausea during NAC infusion. Conclusion We found no difference in the hormone and symptom response to experimental hypoglycaemia measured in subjects who were administered NAC as opposed to saline the day before. This observation suggests that further development of NAC as a therapy for impaired awareness of hypoglycaemia in patients with diabetes may be unwarranted.",2020,We found no difference in the hormone and symptom response to experimental hypoglycaemia measured in subjects who were administered NAC as opposed to saline the day before.,"['patients with diabetes', 'healthy humans', 'Results\n\n\nTwenty-two subjects were enrolled', '247', 'Eighteen subjects completed the entire protocol']","['NAC', 'N-acetyl cysteine', 'N-acetyl cysteine (NAC']","['rash, pruritus or nausea', 'symptom response']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439751', 'cui_str': 'Entire'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}]","[{'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",22.0,0.210795,We found no difference in the hormone and symptom response to experimental hypoglycaemia measured in subjects who were administered NAC as opposed to saline the day before.,"[{'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Moheet', 'Affiliation': 'Division of Diabetes, Endocrinology and Metabolism Department of Medicine University of Minnesota Minneapolis MN USA.'}, {'ForeName': 'Anjali', 'Initials': 'A', 'LastName': 'Kumar', 'Affiliation': 'Division of Diabetes, Endocrinology and Metabolism Department of Medicine University of Minnesota Minneapolis MN USA.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Division of Biostatistics School of Public Health University of Minnesota Minneapolis MN USA.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Eberly', 'Affiliation': 'Division of Biostatistics School of Public Health University of Minnesota Minneapolis MN USA.'}, {'ForeName': 'Lisa D', 'Initials': 'LD', 'LastName': 'Coles', 'Affiliation': 'Department of Experimental and Clinical Pharmacology College of Pharmacy University of Minnesota Minneapolis MN USA.'}, {'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Seaquist', 'Affiliation': 'Division of Diabetes, Endocrinology and Metabolism Department of Medicine University of Minnesota Minneapolis MN USA.'}]","Endocrinology, diabetes & metabolism",['10.1002/edm2.144'] 2830,32704573,Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial.,"Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C-C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods We recruited patients from nine medical institutions in Japan for this randomized, open-label, parallel two-arm pilot trial. Inclusion criteria were diagnosis of type 2 diabetes, age 30-75 years, dipstick proteinuria of ≥1+ or urinary albumin-to-creatinine ratio (UACR) of ≥30 mg/g and estimated glomerular filtration rate of ≥30 mL/min/1.73 m 2 . Patients were randomly assigned (1:2) using a minimization algorithm to either continuing usual care or concomitant administration of 30 mg PG per day for 12 months. The primary outcome was the change in UACR from baseline to 12 months. We also collected safety information for all patients who received at least one dose of PG. Results We enrolled 29 patients, 10 were assigned to continue usual care and 19 to receive PG. Changes in UACR by PG in addition to the usual care were 25.0% (95% CI -20.4%, 96.5%, P  = .33). No severe adverse events or renal events were observed during the study. Conclusion Although the treatment with PG was generally well tolerated, the dosage of 30 mg/d for 12 months did not reduce albuminuria when used in addition to usual care in patients with type 2 diabetes and nephropathy. Efficacy of PG should be verified in future definitive trials.",2020,"No severe adverse events or renal events were observed during the study. ","['Inclusion criteria were diagnosis of type 2 diabetes, age 30-75\xa0years, dipstick proteinuria of ≥1+ or urinary albumin-to-creatinine ratio (UACR) of ≥30\xa0mg/g and estimated glomerular filtration rate of ≥30\xa0mL', 'patients with type 2 diabetes and nephropathy', 'all patients who received at least one dose of PG', 'recruited patients from nine medical institutions in Japan']","['PG', 'propagermanium (PG', 'minimization algorithm to either continuing usual care or concomitant administration of 30\xa0mg PG', 'continue usual care and 19 to receive PG', 'Propagermanium administration']","['change in UACR', 'severe adverse events or renal events']","[{'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0441090', 'cui_str': 'Dipstick'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1300563', 'cui_str': 'g/kg'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0081913', 'cui_str': 'proxigermanium'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C0081913', 'cui_str': 'proxigermanium'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",29.0,0.103775,"No severe adverse events or renal events were observed during the study. ","[{'ForeName': 'Akinori', 'Initials': 'A', 'LastName': 'Hara', 'Affiliation': 'Division of Nephrology Kanazawa University Hospital Kanazawa Japan.'}, {'ForeName': 'Miho', 'Initials': 'M', 'LastName': 'Shimizu', 'Affiliation': 'Division of Nephrology Kanazawa University Hospital Kanazawa Japan.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Hamaguchi', 'Affiliation': 'Department of Internal Medicine Japanese Red Cross Kanazawa Hospital Kanazawa Japan.'}, {'ForeName': 'Hirokazu', 'Initials': 'H', 'LastName': 'Kakuda', 'Affiliation': 'Kakuda clinic Kahoku Japan.'}, {'ForeName': 'Kenzo', 'Initials': 'K', 'LastName': 'Ikeda', 'Affiliation': 'Izumigaoka Medical Clinic Takaoka Japan.'}, {'ForeName': 'Toshiya', 'Initials': 'T', 'LastName': 'Okumura', 'Affiliation': 'Department of Internal Medicine Tonami General Hospital Tonami Japan.'}, {'ForeName': 'Kiyoki', 'Initials': 'K', 'LastName': 'Kitagawa', 'Affiliation': 'Division of Internal Medicine National Hospital Organization Kanazawa Medical Center Kanazawa Japan.'}, {'ForeName': 'Yoshitaka', 'Initials': 'Y', 'LastName': 'Koshino', 'Affiliation': 'Department of Internal Medicine Mizuho hospital Kahoku Japan.'}, {'ForeName': 'Motoo', 'Initials': 'M', 'LastName': 'Kobayashi', 'Affiliation': 'Department of Internal Medicine Municipal Tsuruga Hospital Tsuruga Japan.'}, {'ForeName': 'Kazuya', 'Initials': 'K', 'LastName': 'Takasawa', 'Affiliation': 'Department of Nephrology Public Central Hospital of Matto Ishikawa Hakusan Japan.'}, {'ForeName': 'Yukimasa', 'Initials': 'Y', 'LastName': 'Hisada', 'Affiliation': 'Department of Internal Medicine Japanese Red Cross Kanazawa Hospital Kanazawa Japan.'}, {'ForeName': 'Tadashi', 'Initials': 'T', 'LastName': 'Toyama', 'Affiliation': 'Division of Nephrology Kanazawa University Hospital Kanazawa Japan.'}, {'ForeName': 'Yasunori', 'Initials': 'Y', 'LastName': 'Iwata', 'Affiliation': 'Division of Nephrology Kanazawa University Hospital Kanazawa Japan.'}, {'ForeName': 'Norihiko', 'Initials': 'N', 'LastName': 'Sakai', 'Affiliation': 'Division of Nephrology Kanazawa University Hospital Kanazawa Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Wada', 'Affiliation': 'Division of Nephrology Kanazawa University Hospital Kanazawa Japan.'}]","Endocrinology, diabetes & metabolism",['10.1002/edm2.159'] 2831,32707226,Cardiovascular changes during peanut-induced allergic reactions in human subjects.,"BACKGROUND Food allergy is the commonest cause of anaphylaxis. Changes in posture during acute reactions can trigger fatal outcomes, but the impact of allergic reactions on the cardiovascular system in non-fatal reactions remains poorly understood. OBJECTIVE To systematically evaluate changes in cardiovascular function during acute allergic reactions to peanut. METHODS Participants underwent double-blind placebo-controlled food challenge to peanut as part of a clinical trial. Changes in hemodynamic parameters (heart rate, stroke volume, blood pressure, peripheral blood flow) and electrocardiogram during food challenges were assessed using continuous monitoring. ClinicalTrials.gov Identifier: NCT02665793 RESULTS: 57 adults (median age 24 (IQR 20-29) years, 53% female) participated; 22 (39%) had anaphylaxis. Acute reactions were associated with significant changes in stroke volume (mean decrease 4.2%, 95%CI 0.8 to 7.6; p=0.03), heart rate (mean increase 11.6%, 95%CI 8.4 to 14.8; p<0.0001) and peripheral blood flow (mean increase 19.7%, 95%CI 10.8 to 28.6; p<0.0001), irrespective of reaction severity. These changes were reproduced at subsequent repeat peanut challenge in 26 participants, and could be reversed with administration of intravenous fluids which resulted in faster resolution of abdominal symptoms. CONCLUSIONS In this first detailed human study of cardiovascular changes during food-allergic reactions, we found evidence for significant fluid redistribution, independent of reaction severity. This provides a sound rationale for optimizing venous return during significant allergic reactions to food. Finally, these data provide a new paradigm for understanding severity in anaphylaxis, where poor outcomes occur due to a failure in compensatory mechanisms.",2020,"mean increase 11.6%, 95%CI 8.4 to 14.8; p<0.0001) and peripheral blood flow (mean increase 19.7%, 95%CI 10.8 to 28.6; p<0.0001), irrespective of reaction severity.","['57 adults (median age 24 (IQR 20-29) years, 53% female) participated; 22 (39%) had anaphylaxis', 'Participants underwent double-blind', 'human subjects']",['placebo'],"['heart rate ', 'Acute reactions', 'hemodynamic parameters (heart rate, stroke volume, blood pressure, peripheral blood flow) and electrocardiogram during food challenges', 'stroke volume', 'cardiovascular function', 'Cardiovascular changes', 'peripheral blood flow']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0002792', 'cui_str': 'Anaphylaxis'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0080105', 'cui_str': 'Human Subjects'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0038455', 'cui_str': 'Stroke volume'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0425710', 'cui_str': 'Peripheral blood flow'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0007227', 'cui_str': 'Cardiovascular function'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",57.0,0.414272,"mean increase 11.6%, 95%CI 8.4 to 14.8; p<0.0001) and peripheral blood flow (mean increase 19.7%, 95%CI 10.8 to 28.6; p<0.0001), irrespective of reaction severity.","[{'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Ruiz-Garcia', 'Affiliation': 'Section of Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Bartra', 'Affiliation': 'Section of Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, UK; Hospital Clínic Barcelona, Barcelona, Spain.'}, {'ForeName': 'Olaya', 'Initials': 'O', 'LastName': 'Alvarez', 'Affiliation': 'Section of Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Ashna', 'Initials': 'A', 'LastName': 'Lakhani', 'Affiliation': 'Section of Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Shalinee', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'Section of Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Alistair', 'Initials': 'A', 'LastName': 'Tang', 'Affiliation': 'Section of Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Sim', 'Affiliation': 'Section of Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Mohamed H', 'Initials': 'MH', 'LastName': 'Shamji', 'Affiliation': 'Section of Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Skypala', 'Affiliation': 'Section of Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK.'}, {'ForeName': 'E N Clare', 'Initials': 'ENC', 'LastName': 'Mills', 'Affiliation': 'Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, University of Manchester, Manchester, UK.'}, {'ForeName': 'Alexander R', 'Initials': 'AR', 'LastName': 'Lyon', 'Affiliation': 'Myocardial Function, National Heart & Lung Institute, Imperial College London, and Cardiology Department, Royal Brompton & Harefield Hospitals NHS Foundation Trust, London, UK.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Hayward', 'Affiliation': 'Myocardial Function, National Heart & Lung Institute, Imperial College London, and Cardiology Department, Royal Brompton & Harefield Hospitals NHS Foundation Trust, London, UK; Barts Health NHS Trust, London, UK.'}, {'ForeName': 'Stephen R', 'Initials': 'SR', 'LastName': 'Durham', 'Affiliation': 'Section of Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Turner', 'Affiliation': 'Section of Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, UK. Electronic address: p.turner@imperial.ac.uk.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Boyle', 'Affiliation': 'Section of Inflammation, Repair and Development, National Heart & Lung Institute, Imperial College London, London, UK.'}]",The Journal of allergy and clinical immunology,['10.1016/j.jaci.2020.06.033'] 2832,32707238,Five-year follow-up of early intervention peanut oral immunotherapy.,,2020,,[],[],[],[],[],[],,0.0198285,,"[{'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Herlihy', 'Affiliation': 'The University of North Carolina at Chapel Hill. Chapel Hill, NC. Electronic address: lekoch@email.unc.edu.'}, {'ForeName': 'Edwin H', 'Initials': 'EH', 'LastName': 'Kim', 'Affiliation': 'The University of North Carolina at Chapel Hill. Chapel Hill, NC.'}, {'ForeName': 'A Wesley', 'Initials': 'AW', 'LastName': 'Burks', 'Affiliation': 'The University of North Carolina at Chapel Hill. Chapel Hill, NC.'}, {'ForeName': 'Holly', 'Initials': 'H', 'LastName': 'Barber', 'Affiliation': 'The University of North Carolina at Chapel Hill. Chapel Hill, NC.'}, {'ForeName': 'Quindelyn', 'Initials': 'Q', 'LastName': 'Cook', 'Affiliation': 'Boston University School of Medicine. Boston, MA.'}, {'ForeName': 'Luanna', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Rochester Regional Health. Rochester, NY.'}, {'ForeName': 'Deanna', 'Initials': 'D', 'LastName': 'Hamilton', 'Affiliation': 'The University of North Carolina at Chapel Hill. Chapel Hill, NC.'}, {'ForeName': 'Brian P', 'Initials': 'BP', 'LastName': 'Vickery', 'Affiliation': 'Emory University, Atlanta, GA.'}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2020.07.009'] 2833,32707246,Integrating Co-located Behavioral Healthcare into a Dermatology Clinic: A Prospective Randomized-Control Treatment Pilot Study in Patients with Alopecia Areata.,,2020,,['Patients with Alopecia Areata'],['Integrating Co-located Behavioral Healthcare'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002170', 'cui_str': 'Alopecia'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}]",[],,0.0112644,,"[{'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Gorbatenko-Roth', 'Affiliation': 'University of Wisconsin-Stout, Department of Psychology, Menomonie, WI; University of Minnesota, Department of Dermatology, Minneapolis, MN. Electronic address: gorbatenkok@uwstout.edu.'}, {'ForeName': 'James S', 'Initials': 'JS', 'LastName': 'Hodges', 'Affiliation': 'Division of Biostatistics, University of Minnesota, Minneapolis, MN.'}, {'ForeName': 'Dayna', 'Initials': 'D', 'LastName': 'Lifson', 'Affiliation': 'M Health Fairview, Minneapolis, MN.'}, {'ForeName': 'Maribeth', 'Initials': 'M', 'LastName': 'Golm', 'Affiliation': 'University of Minnesota, Department of Dermatology, Minneapolis, MN.'}, {'ForeName': 'Dory', 'Initials': 'D', 'LastName': 'Kranz', 'Affiliation': 'Formerly of the National Alopecia Areata Foundation, San Rafael, CA.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Windenburg', 'Affiliation': 'University of Minnesota, Department of Dermatology, Minneapolis, MN.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Hordinsky', 'Affiliation': 'University of Minnesota, Department of Dermatology, Minneapolis, MN.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.07.070'] 2834,32707289,Effect of an abdominal hypopressive technique programme on pelvic floor muscle tone and urinary incontinence in women: a randomised crossover trial.,"OBJECTIVES To test the effect of a structured abdominal hypopressive technique (AHT) programme on pelvic floor muscle (PFM) tone and urinary incontinence (UI) in women. DESIGN Crossover trial with random assignment of women to one of two groups: Group 1 (AHT followed by rest) and Group 2 (rest followed by AHT). SETTING Two cultural centres in Madrid, Spain. PARTICIPANTS Women aged 20-65 years. INTERVENTIONS Two months of supervised AHT exercises compared with 2 months of rest. MAIN OUTCOME MEASURES Variation in PFM tone and score on the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)]. RESULTS Forty-two women were randomised to two groups (both n=21). No sequence or period effect was noted. The mean difference in PFM tone after the 2-month AHT programme was 59g/cm² [95% confidence interval (CI) 37 to 82]; the between-group difference was 83g/cm² (95% CI 50 to 116; P<0.001). After 2 months, the between-group difference in the ICIQ-SF score was 3.3 points (P<0.001). The majority of participants reported improved body image and sense of well-being. CONCLUSIONS A structured 2-month AHT programme for women showed short-term benefits in PFM tone and UI. In addition, study participants reported improved body image and sense of well-being, and programme satisfaction, as demonstrated by questionnaire at the end of the intervention period. Further research is needed to test the long-term effects and effectiveness of AHT compared with other PFM exercises. ClinicalTrials.gov Identifier NCT0221241.",2020,"After 2 months, the between-group difference in the ICIQ-SF score was 3.3 points (P<0.001).","['women', 'women to one of two groups', 'Forty-two women', 'Two cultural centres in Madrid, Spain', 'Women aged 20-65 years']","['Group 1 (AHT followed by rest) and Group 2 (rest followed by AHT', 'structured abdominal hypopressive technique (AHT) programme', 'supervised AHT exercises', 'AHT', 'abdominal hypopressive technique programme']","['pelvic floor muscle tone and urinary incontinence', 'ICIQ-SF score', 'PFM tone', 'pelvic floor muscle (PFM) tone and urinary incontinence (UI', 'body image and sense of well-being, and programme satisfaction', 'Variation in PFM tone and score on the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF', 'body image and sense of well-being']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026841', 'cui_str': 'Muscle Tension'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C0424578', 'cui_str': 'Well in self'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C2711460', 'cui_str': 'International consultation on incontinence questionnaire'}]",42.0,0.187985,"After 2 months, the between-group difference in the ICIQ-SF score was 3.3 points (P<0.001).","[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Soriano', 'Affiliation': 'Universidad Camilo José Cela, Madrid, Spain.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'González-Millán', 'Affiliation': 'Universidad Camilo José Cela, Madrid, Spain.'}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Álvarez Sáez', 'Affiliation': 'Maio Medical Centre, Vigo, Spain.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Curbelo', 'Affiliation': 'Universidad Camilo José Cela, Madrid, Spain; Instituto de Salud Musculoesquelética, Madrid, Spain.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Carmona', 'Affiliation': 'Universidad Camilo José Cela, Madrid, Spain; Instituto de Salud Musculoesquelética, Madrid, Spain. Electronic address: loreto.carmona@inmusc.eu.'}]",Physiotherapy,['10.1016/j.physio.2020.02.004'] 2835,32707294,Effects of stress on 6- and 7-year-old children's emotional memory differs by gender.,"Understanding effects of emotional valence and stress on children's memory is important for educational and legal contexts. This study disentangled the effects of emotional content of to-be-remembered information (i.e., items differing in emotional valence and arousal), stress exposure, and associated cortisol secretion on children's memory. We also examined whether girls' memory is more affected by stress induction. A total of 143 6- and 7-year-old children were randomly allocated to the Trier Social Stress Test for Children (n = 103) or a control condition (n = 40). At 25 min after stressor onset, children incidentally encoded 75 objects varying in emotional valence (crossed with arousal) together with neutral scene backgrounds. We found that response bias corrected memory was worse for low-arousing negative items than for neutral and positive items, with the latter two categories not being different from each other. Whereas boys' memory was largely unaffected by stress, girls in the stress condition showed worse memory for negative items, especially the low-arousing ones, than girls in the control condition. Girls, compared with boys, reported higher subjective stress increases following stress exposure and had higher cortisol stress responses. Whereas a higher cortisol stress response was associated with better emotional memory in girls in the stress condition, boys' memory was not associated with their cortisol secretion. Taken together, our study suggests that 6- and 7-year-old children, more so girls, show memory suppression for negative information. Girls' memory for negative information, compared with that of boys, is also more strongly modulated by stress experience and the associated cortisol response.",2020,A total of 143 6- and 7-year-old children were randomly allocated to the Trier Social Stress Test for Children (n = 103) or a control condition (n = 40).,"[""6- and 7-year-old children's emotional memory differs by gender"", 'A total of 143 6- and 7-year-old children', ""children's memory""]",['Trier Social Stress Test for Children (n\xa0=\xa0103) or a control condition'],"['cortisol response', 'cortisol stress responses', 'cortisol stress response']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517573', 'cui_str': '143'}]","[{'cui': 'C0065404', 'cui_str': 'lysyl-5-fluorotryptophyl-lysine'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]",143.0,0.0372713,A total of 143 6- and 7-year-old children were randomly allocated to the Trier Social Stress Test for Children (n = 103) or a control condition (n = 40).,"[{'ForeName': 'Laurel', 'Initials': 'L', 'LastName': 'Raffington', 'Affiliation': 'Center for Lifespan Psychology, Max Planck Institute for Human Development, 14195 Berlin, Germany; Department of Psychology, University of Texas at Austin, Austin, TX 78712, USA.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Falck', 'Affiliation': 'Center for Lifespan Psychology, Max Planck Institute for Human Development, 14195 Berlin, Germany.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Heim', 'Affiliation': 'Institute of Medical Psychology, Charité - Universitäts medizin Berlin, 10117 Berlin, Germany; Department of Biobehavioral Health, Pennsylvania State University, University Park, PA 16802, USA.'}, {'ForeName': 'Mara', 'Initials': 'M', 'LastName': 'Mather', 'Affiliation': 'Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA 90089, USA.'}, {'ForeName': 'Yee Lee', 'Initials': 'YL', 'LastName': 'Shing', 'Affiliation': 'Center for Lifespan Psychology, Max Planck Institute for Human Development, 14195 Berlin, Germany; Institute of Psychology, Goethe-Universität Frankfurt, 60323 Frankfurt am Main, Germany. Electronic address: shing@psych.uni-frankfurt.de.'}]",Journal of experimental child psychology,['10.1016/j.jecp.2020.104924'] 2836,32707325,"Eclipse Stemless Shoulder Prosthesis versus Univers II Shoulder Prosthesis: A Multicenter, Prospective Randomized Controlled Trial.","BACKGROUND Total shoulder arthroplasty is an accepted treatment for glenohumeral osteoarthritis. The Arthrex Eclipse shoulder prosthesis is a stemless, canal-sparing, humeral prosthesis with bone ingrowth capacity on the trunnion as well as through the fenestrated hollow screw that provides both diaphyseal and metaphyseal load sharing and fixation. METHODS 16 sites in the United States enrolled 327 patients (237 Eclipse, 90 Univers II) between 2013-2019. All patients had glenohumeral arthritis refractory to non-surgical care. Exclusion criteria were strict to avoid confounding factors such as severe patient co-morbidities, arthritis not consistent with osteoarthritis, and medical or prior surgical treatments that may affect outcomes. Patients were randomized to Eclipse or Univers II using block randomization. RESULTS 149 Eclipse and 76 Univers II patients reached 2-year follow-up [139 (93.3%) Eclipse and 68 (89.5%) Univers II had complete data]. The success rate using the composite clinical success (CCS) score was 95% for Eclipse vs. 89.7% for Univers II group. No patient exhibited radiographic evidence of substantial humeral radiolucency, humeral migration, or subsidence at any point. There were 7 (3.2%) reoperations in the Eclipse and 3 (3.8%) in the Univers II group. CONCLUSION The Arthrex Eclipse shoulder prosthesis is a safe and effective humeral implant for patients with glenohumeral arthritis at two-year follow-up with no differences in outcomes when compared to the Univers II. LEVEL OF EVIDENCE Level II; Randomized Controlled Trial; Treatment Study.",2020,"The Arthrex Eclipse shoulder prosthesis is a safe and effective humeral implant for patients with glenohumeral arthritis at two-year follow-up with no differences in outcomes when compared to the Univers II. ","['16 sites in the United States enrolled 327 patients (237 Eclipse, 90 Univers II) between 2013-2019', 'glenohumeral osteoarthritis', 'All patients had glenohumeral arthritis refractory to non-surgical care']",['Eclipse Stemless Shoulder Prosthesis versus Univers II Shoulder Prosthesis'],['success rate using the composite clinical success (CCS) score'],"[{'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0003864', 'cui_str': 'Arthritis'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]","[{'cui': 'C1961833', 'cui_str': 'Artificial Shoulder Joint'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",327.0,0.112073,"The Arthrex Eclipse shoulder prosthesis is a safe and effective humeral implant for patients with glenohumeral arthritis at two-year follow-up with no differences in outcomes when compared to the Univers II. ","[{'ForeName': 'Anthony A', 'Initials': 'AA', 'LastName': 'Romeo', 'Affiliation': 'Rothman Orthopaedic Institute - New York, Department of Orthopaedic Surgery, New York, NY 10003, USA.'}, {'ForeName': 'Brandon J', 'Initials': 'BJ', 'LastName': 'Erickson', 'Affiliation': 'Rothman Orthopaedic Institute - New York, Department of Orthopaedic Surgery, New York, NY 10003, USA. Electronic address: brandon.j.erickson@gmail.com.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Costouros', 'Affiliation': 'Stanford University, Department of Orthopaedic Surgery, Stanford, CA 94305, USA.'}, {'ForeName': 'Nathan', 'Initials': 'N', 'LastName': 'Long', 'Affiliation': 'Bone and Joint Center, Columbus, OH 43215, USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Klassen', 'Affiliation': 'Essentia Health Duluth, Duluth, MN 55805, USA.'}, {'ForeName': 'Arash', 'Initials': 'A', 'LastName': 'Araghi', 'Affiliation': 'Banner Research, Sun City, AZ 85351, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Brown', 'Affiliation': 'Banner Research, Sun City, AZ 85351, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Setter', 'Affiliation': 'The Research Foundation of SUNY, Syracuse NY 13210, USA.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Port', 'Affiliation': 'Altoona Regional Health System, Altona, PA 16601, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Tyndall', 'Affiliation': 'Altoona Regional Health System, Altona, PA 16601, USA.'}, {'ForeName': 'Nikhil N', 'Initials': 'NN', 'LastName': 'Verma', 'Affiliation': 'Rush University Medical Center, Department of Orthopaedic Surgery, Chicago, IL 60612, USA.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Sears', 'Affiliation': 'Rose Medical Center, Denver, CO 80220, USA.'}, {'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Brandon', 'Affiliation': 'Peninsula Regional Medical Center, Salisbury, MD 21801, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Smith', 'Affiliation': 'Ellis and Badenhausen Orthopedics, Louisville, KY 40223, USA.'}, {'ForeName': 'Earl', 'Initials': 'E', 'LastName': 'McFadden', 'Affiliation': 'Palmetto Health Orthopedics, Columbia, SC 29203, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Patterson', 'Affiliation': 'Excelsior Orthopedics, Buffalo, NY 14215, USA.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Stein', 'Affiliation': 'Union Memorial Hospital, Baltimore, MD 21218, USA.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Cohen', 'Affiliation': 'Adena Regional Medical Center, Chillicothe, OH 45600, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Abboud', 'Affiliation': 'Rothman Orthopaedic Institute, Department of Orthopaedic Surgery, Philadelphia, PA 19148, USA.'}]",Journal of shoulder and elbow surgery,['10.1016/j.jse.2020.07.004'] 2837,32707332,An invited commentary: The efficacy of transversus abdominis plane block with or without dexmedetomidine for postoperative analgesia in renal transplantation. A randomized controlled trial.,,2020,,['renal transplantation'],['transversus abdominis plane block with or without dexmedetomidine'],[],"[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}]","[{'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}]",[],,0.168804,,"[{'ForeName': 'Yuhang', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, Guizhou, 563000, China.'}, {'ForeName': 'Taowu', 'Initials': 'T', 'LastName': 'Gong', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, Guizhou, 563000, China. Electronic address: chenmingaini1232@sina.com.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2020.07.008'] 2838,32707342,"Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis.","BACKGROUND & AIMS Serum alkaline phosphatase (ALP) and the enhanced liver fibrosis (ELF) score are used as endpoints in trials of patients with primary sclerosing cholangitis (PSC). We aimed to quantify inter- and intra-individual variation in levels of ALP and the ELF score over time, and evaluated their association with fibrosis progression. METHODS We analyzed data from 234 patients with large-duct PSC enrolled in a 2-year, phase 2b placebo-controlled trial of simtuzumab. Participants were assessed by laboratory tests every 4 weeks, and liver biopsies collected at time of screening, week 48, and week 96. RESULTS Serum levels of ALP and ELF scores did not differ significantly between simtuzumab and placebo groups, so the data were pooled. Median per-patient variations in ALP between clinic visits were approximately 12% over 12 weeks, 20% over 48 weeks, and 20% over 96 weeks. Reductions, unrelated to study intervention, of more than 40% in ALP were observed in 10.9% of patients with baseline activity greater than 2-fold the upper limit of normal (ULN) and 12.5% of patients with more than 3-fold the ULN at 1 year. At 2 years, reductions of more than 40% in ALP were observed in 15.8% of patients with baseline activity greater than 2-fold the ULN and 17.9% of patients with more than 3-fold the ULN. Among the 209 patients with Ishak fibrosis stage 0-4 at baseline, serum levels of ALP did not associate with development of cirrhosis or with a 2-point increase in fibrosis stage at 2 years. The median per-patient variation in ELF scores between clinic visits was approximately 3% over 12 weeks, 4% over 48 weeks, and 4% over 96 weeks. Increased ELF scores at baseline and at weeks 12, 24 and 48, each associated with development of cirrhosis at 2 years (odds ratio >2.75; P<.01 for all timepoints). ELF scores at baseline and weeks 12, 24 and 48, also associated with a 2-point increase in fibrosis stage at 2 years (odds ratios all greater than 2; P<.01 for all timepoints). CONCLUSIONS In an analysis of data from patients with large-duct PSC enrolled in a prospective trial, we found large variations in serum levels of ALP, within and among patients. Serum levels of ALP did not associate with disease progression over a 2-year period. Variations in ELF score were smaller, and scores determined at multiple timepoints associated with fibrosis progression and development of cirrhosis.",2020,"RESULTS Serum levels of ALP and ELF scores did not differ significantly between simtuzumab and placebo groups, so the data were pooled.","['Patients With Primary Sclerosing Cholangitis', 'patients with large-duct PSC', '209 patients with Ishak fibrosis stage 0-4 at baseline', '234 patients with large-duct PSC enrolled in a 2-year, phase 2b', 'patients with primary sclerosing cholangitis (PSC']","['simtuzumab', 'placebo']","['ELF scores', 'fibrosis stage', 'ALP', 'ELF score', 'upper limit of normal (ULN', 'Increased ELF scores', 'Serum levels of ALP', 'fibrosis progression and development of cirrhosis', 'serum levels of ALP', 'Serum levels of ALP and ELF scores', 'median per-patient variation in ELF scores between clinic visits']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0566602', 'cui_str': 'Primary sclerosing cholangitis'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0687028', 'cui_str': 'Duct (organ) structure'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0441763', 'cui_str': 'Stage 0'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205390', 'cui_str': 'Phase'}]","[{'cui': 'C4054022', 'cui_str': 'simtuzumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0239946', 'cui_str': 'Hepatic fibrosis'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0008952', 'cui_str': 'Clinic Visits'}]",234.0,0.0822935,"RESULTS Serum levels of ALP and ELF scores did not differ significantly between simtuzumab and placebo groups, so the data were pooled.","[{'ForeName': 'Palak J', 'Initials': 'PJ', 'LastName': 'Trivedi', 'Affiliation': 'National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK; University Hospitals Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Applied Health Research, University of Birmingham, UK.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Muir', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC, USA.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Levy', 'Affiliation': 'University of Miami, Miami, FL, USA.'}, {'ForeName': 'Christopher L', 'Initials': 'CL', 'LastName': 'Bowlus', 'Affiliation': 'University of California Davis, Davis, CA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Manns', 'Affiliation': 'Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Xiaomin', 'Initials': 'X', 'LastName': 'Lu', 'Affiliation': 'Gilead Sciences, Inc., Foster City, CA, USA.'}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'Crans', 'Affiliation': 'Gilead Sciences, Inc., Foster City, CA, USA.'}, {'ForeName': 'Chuhan', 'Initials': 'C', 'LastName': 'Chung', 'Affiliation': 'Gilead Sciences, Inc., Foster City, CA, USA.'}, {'ForeName': 'G Mani', 'Initials': 'GM', 'LastName': 'Subramanian', 'Affiliation': 'Gilead Sciences, Inc., Foster City, CA, USA.'}, {'ForeName': 'Robert P', 'Initials': 'RP', 'LastName': 'Myers', 'Affiliation': 'Gilead Sciences, Inc., Foster City, CA, USA.'}, {'ForeName': 'Zachary', 'Initials': 'Z', 'LastName': 'Goodman', 'Affiliation': 'Inova Fairfax Hospital, Falls Church, VA, USA.'}, {'ForeName': 'Naga', 'Initials': 'N', 'LastName': 'Chalasani', 'Affiliation': 'Indiana University School of Medicine, Indianapolis, IN, USA.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Vierling', 'Affiliation': 'Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Indra Neil', 'Initials': 'IN', 'LastName': 'Guha', 'Affiliation': 'NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Gideon M', 'Initials': 'GM', 'LastName': 'Hirschfield', 'Affiliation': 'Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, ON, Canada. Electronic address: gideon.hirschfield@uhn.ca.'}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2020.07.032'] 2839,32707403,"Changes to stance limb peak, cumulative, and regional plantar foot forces among normal walking and three mobility aids in healthy older adults.","BACKGROUND Mobility aids are commonly prescribed to offload an injured lower extremity. Device selection may impact stance foot loading patterns and foot health in clinical populations at risk of foot ulceration. RESEARCH QUESTIONS Two questions motivated this study: How does device selection influence peak plantar and regional (rearfoot, mid foot and forefoot) foot forces on the stance foot? Does device selection influence peak, cumulative, and regional plantar forces within a 200 m walking trial? METHODS Twenty-one older adults walked 200 m at self-selected pace in four randomized conditions for this prospective crossover study. Participants used a walker, crutches, wheeled knee walker (WKW), and no assistive device (control condition). Plantar forces were measured using a wireless in-shoe system (Loadsol, Novel Inc., St. Paul, MN). Repeated measures analyses of variance were used to determine differences in peak and cumulative total and regional forces among walking conditions. Paired sample t-tests compared forces during first and last 30 s epochs of each condition to determine device influence over time. RESULTS The WKW reduced peak net forces by 0.29 and 0.35 bodyweight (BW) when compared to the walker or control condition with similar trends in all foot regions. Crutch use had similar peak forces as control. There were no differences in the number of steps taken within devices comparing first and last epochs. Crutches had a 0.04 and 0.07 BW increase in peak net and forefoot forces during the last epoch. Walker use had 66.44 BW lower cumulative forefoot forces in the last epoch. SIGNIFICANCE Crutches had similar stance foot loading as normal walking while a walker lowered forefoot forces at the expense of increased steps. A WKW may be the best choice to 'protect' tissues in the stance foot from exposure to peak and cumulative forces in the forefoot region.",2020,The WKW reduced peak net forces by 0.29 and 0.35 bodyweight (BW) when compared to the walker or control condition with similar trends in all foot regions.,"['healthy older adults', 'Twenty-one older adults walked 200 m at self-selected pace']",['normal walking and three mobility aids'],"['device selection influence peak, cumulative, and regional plantar forces', 'peak net forces', 'Plantar forces', 'peak net and forefoot forces', 'stance limb peak, cumulative, and regional plantar foot forces', 'peak and cumulative total and regional forces among walking conditions', 'cumulative forefoot forces']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0287990', 'cui_str': 'Furin'}]","[{'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C3495449', 'cui_str': 'Mobility aid'}]","[{'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0031222', 'cui_str': 'Personnel Selection'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C1510667', 'cui_str': 'Forefoot region of foot'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]",21.0,0.0456241,The WKW reduced peak net forces by 0.29 and 0.35 bodyweight (BW) when compared to the walker or control condition with similar trends in all foot regions.,"[{'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Kingston', 'Affiliation': 'College of Medicine, University of Saskatchewan, 107 Wiggins Rd, Saskatoon, SK, S7N 5E5, Canada. Electronic address: david.kingston@usask.ca.'}, {'ForeName': 'A Gary', 'Initials': 'AG', 'LastName': 'Linassi', 'Affiliation': 'College of Medicine, University of Saskatchewan, 107 Wiggins Rd, Saskatoon, SK, S7N 5E5, Canada; School of Rehabilitation Science, University of Saskatchewan, Suite 3400, 3rd Floor, 104 Clinic Pl, Saskatoon, SK, S7N 2Z4, Canada. Electronic address: anl931@mail.usask.ca.'}, {'ForeName': 'Audrey R', 'Initials': 'AR', 'LastName': 'Zucker-Levin', 'Affiliation': 'School of Rehabilitation Science, University of Saskatchewan, Suite 3400, 3rd Floor, 104 Clinic Pl, Saskatoon, SK, S7N 2Z4, Canada. Electronic address: audrey.zuckerlevin@usask.ca.'}]",Gait & posture,['10.1016/j.gaitpost.2020.07.015'] 2840,32707605,Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta.,"Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis. PEG-interferon alpha-2a (PEG-IFNα-2a) is the only effective treatment but its long-term clinical impact is unclear. The aim of this study was to investigate the long-term outcome after 48 weeks of pegylated interferon alfa-2a therapy.We performed a retrospective follow-up study of the Hep-Net-International-Delta-Hepatitis-Intervention-Study 1 (HIDIT-I trial). Patients had received 48 weeks of treatment with either PEG-IFNα-2a plus adefovir dipivoxil (ADV) (Group I), PEG-IFNα-2a alone (Group II), or adefovir dipivoxil alone (Group III). Liver-related complications were defined as liver-related death, liver transplantation, liver cancer and hepatic decompensation defined as development of Child Pugh scores B or C or an increase in Model for Endstage Liver Disease (MELD) scores of five or more points in relation to baseline values. Patients were considered for further analysis when they were re-treated with PEG-IFNα-2a. Follow-up data (at least 1 visit beyond post-treatment week 24) were available for 60 patients [Group I, (n=19), Group II (n=20), Group III (n=21)]. Mean time of follow-up was 8.9 (1.6 - 13.4) years. 19 patients were re-treated with IFN-based therapy: 42% (n=8) in PEG-IFNα-2a arms and 58% (n=11) in the adefovir only arm. Clinical complications on long-term follow-up occurred in 17 patients and were associated with non-response to therapy and baseline cirrhosis. The annual event free survival rate in patients with cirrhosis vs non-cirrhotic patients at year 5 and 10 was 70% vs. 91% and 35% vs. 76%.Long-term follow-up of a large randomized clinical trial suggests that off-treatment HDV RNA response to PEG-IFNα-2a treatment leads to improved clinical long-term outcome.",2020,"Liver-related complications were defined as liver-related death, liver transplantation, liver cancer and hepatic decompensation defined as development of Child Pugh scores B or C or an increase in Model for Endstage Liver Disease (MELD) scores of five or more points in relation to baseline values.","['19 patients were re-treated with', 'chronic hepatitis delta', 'patients with cirrhosis vs non-cirrhotic patients', '17 patients']","['PEG-interferon alpha-2a (PEG-IFNα-2a', 'Hep-Net-International-Delta-Hepatitis-Intervention', 'IFN-based therapy', 'PEG-IFNα-2a', 'pegylated interferon alfa-2a therapy', 'PEG-IFNα-2a plus adefovir dipivoxil (ADV) (Group I), PEG-IFNα-2a alone (Group II), or adefovir dipivoxil alone']","['survival rate', 'Clinical complications', 'liver-related death, liver transplantation, liver cancer and hepatic decompensation', 'Mean time']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0019189', 'cui_str': 'Chronic hepatitis'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}, {'cui': 'C0439687', 'cui_str': 'Non-cirrhotic'}]","[{'cui': 'C0032478', 'cui_str': 'Polyethylene Glycol 400'}, {'cui': 'C0021734', 'cui_str': 'Interferon Alfa-2a'}, {'cui': 'C0162569', 'cui_str': 'Homozygous porphyria cutanea tarda'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0011226', 'cui_str': 'Viral hepatitis D'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0540694', 'cui_str': 'adefovir dipivoxil'}, {'cui': 'C0441843', 'cui_str': 'Group I'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0023911', 'cui_str': 'Transplantation of liver'}, {'cui': 'C0345904', 'cui_str': 'Malignant neoplasm of liver'}, {'cui': 'C1394798', 'cui_str': 'Hepatic decompensation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",19.0,0.0815091,"Liver-related complications were defined as liver-related death, liver transplantation, liver cancer and hepatic decompensation defined as development of Child Pugh scores B or C or an increase in Model for Endstage Liver Disease (MELD) scores of five or more points in relation to baseline values.","[{'ForeName': 'Anika', 'Initials': 'A', 'LastName': 'Wranke', 'Affiliation': 'Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany.'}, {'ForeName': 'Svenja', 'Initials': 'S', 'LastName': 'Hardtke', 'Affiliation': 'Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Heidrich', 'Affiliation': 'Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Dalekos', 'Affiliation': 'Department of Medicine and Research Laboratory of Internal Medicine, University Hospital of Larissa, 41110, Larissa, Greece.'}, {'ForeName': 'Kendal', 'Initials': 'K', 'LastName': 'Yalcin', 'Affiliation': 'Dicle University Medical Faculty, Diyarbakir, Turkey.'}, {'ForeName': 'Fehmi', 'Initials': 'F', 'LastName': 'Tabak', 'Affiliation': 'Department of Infectious Diseases, Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Selim', 'Initials': 'S', 'LastName': 'Gurel', 'Affiliation': 'Uludag University Medical School, Bursa, Turkey.'}, {'ForeName': 'Yilmaz', 'Initials': 'Y', 'LastName': 'Cakaloglu', 'Affiliation': 'Memorial Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ulus S', 'Initials': 'US', 'LastName': 'Akarca', 'Affiliation': 'Ege University Medical Faculty, Izmir, Turkey.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Lammert', 'Affiliation': 'Department of Medicine II, Saarland University Medical Center, Saarland University, 66421, Homburg, Germany.'}, {'ForeName': 'Dieter', 'Initials': 'D', 'LastName': 'Häussinger', 'Affiliation': 'Department of Gastroenterology, Hepatology and Infectious Diseases, Heinrich Heine University, Düsseldorf, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Müller', 'Affiliation': 'Charite University, Berlin, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Wöbse', 'Affiliation': 'Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Manns', 'Affiliation': 'Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany.'}, {'ForeName': 'Ramazan', 'Initials': 'R', 'LastName': 'Idilman', 'Affiliation': 'Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Cornberg', 'Affiliation': 'Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany.'}, {'ForeName': 'Heiner', 'Initials': 'H', 'LastName': 'Wedemeyer', 'Affiliation': 'German Center for Infection Research (DZIF), Partner Site HepNet Study-House, Hannover, Germany.'}, {'ForeName': 'Cihan', 'Initials': 'C', 'LastName': 'Yurdaydin', 'Affiliation': 'Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey.'}]",Journal of viral hepatitis,['10.1111/jvh.13366'] 2841,32707771,Co-Administration of Iron and a Bioavailable Curcumin Supplement Increases Serum BDNF Levels in Healthy Adults.,"Brain-derived neurotrophic factor (BDNF) is key for the maintenance of normal neuronal function and energy homeostasis and has been suggested to improve cognitive function, including learning and memory. Iron and the antioxidant curcumin have been shown to influence BDNF homeostasis. This 6-week, double blind, randomized, placebo-controlled study examined the effects of oral iron supplementation at low (18 mg) and high (65 mg) ferrous (FS) iron dosages, compared to a combination of these iron doses with a bioavailable formulated form of curcumin (HydroCurc TM ; 500 mg) on BDNF levels in a healthy adult cohort of 155 male (26.42 years ± 0.55) and female (25.82 years ± 0.54) participants. Participants were randomly allocated to five different treatment groups: both iron and curcumin placebo (FS0+Plac), low dose iron and curcumin placebo (FS18+Plac), low dose iron and curcumin (FS18+Curc), high dose iron and curcumin placebo (FS65+Plac) and high dose iron and curcumin (FS65+Curc). Results showed a significant increase in BDNF over time (26%) in the FS18+Curc group ( p = 0.024), and at end-point between FS18+Curc and FS18+Plac groups (35%, p = 0.042), demonstrating for the first time that the combination with curcumin, rather than iron supplementation alone, results in increased serum BDNF. The addition of curcumin to iron supplementation may therefore provide a novel approach to further enhance the benefits associated with increased BDNF levels.",2020,"Results showed a significant increase in BDNF over time (26%) in the FS18+Curc group ( p = 0.024), and at end-point between FS18+Curc and FS18+Plac groups (35%, p = 0.042), demonstrating for the first time that the combination with curcumin, rather than iron supplementation alone, results in increased serum BDNF.","['Healthy Adults', 'healthy adult cohort of 155 male (26.42 years ± 0.55) and female (25.82 years ± 0.54) participants']","['iron and curcumin placebo (FS0+Plac), low dose iron and curcumin placebo (FS18+Plac), low dose iron and curcumin (FS18+Curc), high dose iron and curcumin placebo (FS65+Plac) and high dose iron and curcumin (FS65+Curc', 'Brain-derived neurotrophic factor (BDNF', 'FS18+Curc', 'oral iron supplementation at low (18 mg) and high (65 mg) ferrous (FS) iron dosages, compared to a combination of these iron doses with a bioavailable formulated form of curcumin (HydroCurc TM ', 'Co-Administration of Iron and a Bioavailable Curcumin Supplement Increases', 'placebo']","['BDNF over time', 'serum BDNF', 'BDNF levels', 'Serum BDNF Levels']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517462', 'cui_str': '0.55'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0010467', 'cui_str': 'Curcumin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3537005', 'cui_str': 'Iron supplement therapy'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0935763', 'cui_str': 'Bioavailable'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]","[{'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.187068,"Results showed a significant increase in BDNF over time (26%) in the FS18+Curc group ( p = 0.024), and at end-point between FS18+Curc and FS18+Plac groups (35%, p = 0.042), demonstrating for the first time that the combination with curcumin, rather than iron supplementation alone, results in increased serum BDNF.","[{'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Tiekou Lorinczova', 'Affiliation': 'School of Life Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK.'}, {'ForeName': 'Owen', 'Initials': 'O', 'LastName': 'Fitzsimons', 'Affiliation': 'School of Life Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK.'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Mursaleen', 'Affiliation': 'School of Life Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK.'}, {'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'Renshaw', 'Affiliation': 'Centre for Sport, Exercise and Life Sciences, Faculty of Health and Life Sciences, Coventry University, Priory St, Coventry CV1 5FB, UK.'}, {'ForeName': 'Gulshanara', 'Initials': 'G', 'LastName': 'Begum', 'Affiliation': 'School of Life Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK.'}, {'ForeName': 'Mohammed Gulrez', 'Initials': 'MG', 'LastName': 'Zariwala', 'Affiliation': 'School of Life Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK.'}]","Antioxidants (Basel, Switzerland)",['10.3390/antiox9080645'] 2842,32707877,Trajectories of Short Physical Performance Battery Are Strongly Associated with Future Major Mobility Disability: Results from the LIFE Study.,"Short Physical Performance Battery (SPPB) assessment is a widely used measure of lower extremity function, strength, and balance. In the Lifestyles Interventions and Independence for Elders (LIFE) Study, baseline SPPB and changes throughout the trial were strongly associated with major mobility disability (MMD). This study further investigated this association by identifying trajectories of SPPB and evaluating the predictive validity of SPPB trajectories for future MMD. Participants ( n = 1635) aged 70-89 years were randomized to a physical activity or health education intervention and assessed every 6 months for MMD. We used group-based trajectory models (GBTMs) to identify trajectories of a binary outcome for a decrease from baseline SPPB of ≥1. Multinomial logistic regression explored baseline factors associated with group membership. Survival analyses evaluated the association between trajectories with MMD. The GBTM identified a 3-group model which included a ""No Decline"" group (46.0%), ""Late Decline"" group (27.7%), and an ""Early Decline"" group (26.3%). Adjusting for all other baseline characteristics, group assignment during the previous follow-up visit was strongly associated with MMD at the subsequent period. Comparisons between groups showed a 2-to-3-fold increase in MMD comparing the ""Late"" to ""No"" decline group and a 4-to-5-fold increase in MMD comparing the ""Early"" to ""No"" decline group. Group membership and impact on MMD was not different between intervention arms. Group-based trajectories of SPPB scores identified distinct subgroups in LIFE Study participants. Using these group assignments in outcome models were highly associated with MMD. GBTMs have potential to identify and improve prediction of aging-related decline to better design and identify patients for interventions.",2020,Group membership and impact on MMD was not different between intervention arms.,['Participants ( n = 1635) aged 70-89 years'],"['physical activity or health education intervention and assessed every 6 months for MMD', 'Short Physical Performance Battery (SPPB) assessment']","['MMD', 'major mobility disability (MMD']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0585339', 'cui_str': 'Every six months'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C4075461', 'cui_str': 'Short Physical Performance Battery'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0231170', 'cui_str': 'Disability'}]",1635.0,0.024193,Group membership and impact on MMD was not different between intervention arms.,"[{'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Brown', 'Affiliation': 'Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL 32610, USA.'}, {'ForeName': 'Wei-Hsuan', 'Initials': 'WH', 'LastName': 'Lo-Ciganic', 'Affiliation': 'Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL 32610, USA.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Shao', 'Affiliation': 'Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL 32610, USA.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Pahor', 'Affiliation': 'Institute on Aging, Department of Aging and Geriatric Research, University of Florida College of Medicine, Gainesville, FL 32610, USA.'}, {'ForeName': 'Todd M', 'Initials': 'TM', 'LastName': 'Manini', 'Affiliation': 'Institute on Aging, Department of Aging and Geriatric Research, University of Florida College of Medicine, Gainesville, FL 32610, USA.'}]",Journal of clinical medicine,['10.3390/jcm9082332'] 2843,32707905,Noodles Made from High Amylose Wheat Flour Attenuate Postprandial Glycaemia in Healthy Adults.,"Previous research has not considered the effect of high amylose wheat noodles on postprandial glycaemia. The aim of the study is to investigate the effect of consumption of high amylose noodles on postprandial glycaemia over 2-h periods by monitoring changes in blood glucose concentration and calculating the total area under the blood glucose concentration curve. Twelve healthy young adults were recruited to a repeated measure randomised, single-blinded crossover trial to compare the effect of consuming noodles (180 g) containing 15%, 20% and 45% amylose on postprandial glycaemia. Fasting blood glucose concentrations were taken via finger-prick blood samples. Postprandial blood glucose concentrations were taken at 15, 30, 45, 60, 90 and 120 min. Subjects consuming high amylose noodles made with flour containing 45% amylose had significantly lower blood glucose concentration at 15, 30 and 45 min (5.5 ± 0.11, 6.1 ± 0.11 and 5.6 ± 0.11 mmol/L; p = 0.01) compared to subjects consuming low amylose noodles with 15% amylose (5.8 ± 0.12, 6.6 ± 0.12 and 5.9 ± 0.12 mmol/L). The total area under the blood glucose concentration curve after consumption of high amylose noodles with 45% amylose was 640.4 ± 9.49 mmol/L/min, 3.4% lower than consumption of low amylose noodles with 15% amylose (662.9 ± 9.49 mmol/L/min), p = 0.021. Noodles made from high amylose wheat flour attenuate postprandial glycaemia in healthy young adults, as characterised by the significantly lower blood glucose concentration and a 3.4% reduction in glycaemic response.",2020,"Subjects consuming high amylose noodles made with flour containing 45% amylose had significantly lower blood glucose concentration at 15, 30 and 45 min (5.5 ± 0.11, 6.1 ± 0.11 and 5.6 ± 0.11 mmol/L; p = 0.01) compared to subjects consuming low amylose noodles with 15% amylose (5.8 ± 0.12, 6.6 ± 0.12 and 5.9 ± 0.12 mmol/L).","['Twelve healthy young adults', 'Healthy Adults', 'healthy young adults']",['High Amylose Wheat Flour'],"['Postprandial blood glucose concentrations', 'blood glucose concentration and calculating the total area under the blood glucose concentration curve', 'glycaemic response', 'postprandial glycaemia', 'Fasting blood glucose concentrations', 'blood glucose concentration', 'Postprandial Glycaemia', 'total area under the blood glucose concentration curve']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0002732', 'cui_str': 'Amylose'}, {'cui': 'C0458980', 'cui_str': 'Wheat flour'}]","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C2585282', 'cui_str': 'Blood glucose concentration'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",12.0,0.0154981,"Subjects consuming high amylose noodles made with flour containing 45% amylose had significantly lower blood glucose concentration at 15, 30 and 45 min (5.5 ± 0.11, 6.1 ± 0.11 and 5.6 ± 0.11 mmol/L; p = 0.01) compared to subjects consuming low amylose noodles with 15% amylose (5.8 ± 0.12, 6.6 ± 0.12 and 5.9 ± 0.12 mmol/L).","[{'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Ang', 'Affiliation': 'School Public Health, Curtin University, Perth 6845, Western Australia, Australia.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Bourgy', 'Affiliation': 'School Public Health, Curtin University, Perth 6845, Western Australia, Australia.'}, {'ForeName': 'Haelee', 'Initials': 'H', 'LastName': 'Fenton', 'Affiliation': 'School Public Health, Curtin University, Perth 6845, Western Australia, Australia.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Regina', 'Affiliation': 'Commonwealth Scientific and Industrial Research Organisation, Agriculture and Food, Canberra 2601, ACT, Australia.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Newberry', 'Affiliation': 'Commonwealth Scientific and Industrial Research Organisation, Agriculture and Food, Canberra 2601, ACT, Australia.'}, {'ForeName': 'Dean', 'Initials': 'D', 'LastName': 'Diepeveen', 'Affiliation': 'Department of Primary Industries and Regional Development, South Perth 6151, Western Australia; Australia.'}, {'ForeName': 'Domenico', 'Initials': 'D', 'LastName': 'Lafiandra', 'Affiliation': 'Department Agricultural and Forestry Sciences, University of Tuscia, 01100 Viterbo, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Grafenauer', 'Affiliation': 'Grains and Legumes Nutrition Council, North Ryde 2113, Australia.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Hunt', 'Affiliation': 'School Public Health, Curtin University, Perth 6845, Western Australia, Australia.'}, {'ForeName': 'Vicky', 'Initials': 'V', 'LastName': 'Solah', 'Affiliation': 'School Public Health, Curtin University, Perth 6845, Western Australia, Australia.'}]",Nutrients,['10.3390/nu12082171'] 2844,32708292,The Impact of Novel Anticoagulants on the Upper Gastrointestinal Tract Mucosa.,"Background and objectives: Although treatment with novel oral non-vitamin K antagonist 3anticoagulants (NOACs) is associated with an overall decrease in hemorrhagic complications compared to warfarin, the incidence of gastrointestinal bleeding remains contradictory. Materials and Methods: After the exclusion of patients with pre-existing pathological lesions in the upper gastrointestinal tract (GIT) on esophageal-gastroduodenoscopy (EGD) at entry, a cohort of 80 patients (mean age of 74.8 ± 2.0 years) was randomly divided into four equivalent groups, treated with dabigatran, rivaroxaban, apixaban, or warfarin. Patients were prospectively followed up for three months of treatment, with a focus on anamnestic and endoscopic signs of bleeding. In addition, bleeding risk factors were evaluated. Results: In none of the patients treated with warfarin or NOACs was any serious or clinically significant bleeding recorded within the follow-up period. The incidence of clinical bleeding and endoscopically detected bleeding in the upper GT after three months of treatment was not statistically different among groups (χ 2 = 2.8458; p = 0.41608). The presence of Helicobacter pylori (HP) was a risk factor for upper GIT bleeding ( p < 0.05), while the use of proton pump inhibitors (PPIs) was a protective factor ( p = 0.206; Spearman's correlation coefficient = 0.205). We did not record any post-biopsy continued bleeding. Conclusions: No significant GIT bleeding was found in any of the treatment groups, so we consider it beneficial to perform routine EGD before the initiation of any anticoagulant therapy in patients with an increased risk of upper GIT bleeding. Detection and eradication of HP as well as preventive PPI treatment may mitigate the occurrence of endoscopic bleeding. Endoscopic biopsy during the NOAC treatment is safe.",2020,"The presence of Helicobacter pylori (HP) was a risk factor for upper GIT bleeding ( p < 0.05), while the use of proton pump inhibitors (PPIs) was a protective factor ( p = 0.206; Spearman's correlation coefficient = 0.205).","['patients with pre-existing pathological lesions in the upper gastrointestinal tract (GIT) on esophageal-gastroduodenoscopy (EGD) at entry, a cohort of 80 patients (mean age of 74.8 ± 2.0 years']","['novel oral non-vitamin K antagonist 3anticoagulants (NOACs', 'dabigatran, rivaroxaban, apixaban, or warfarin', 'warfarin or NOACs', 'Novel Anticoagulants', 'Endoscopic biopsy']","['bleeding risk factors', 'GIT bleeding', 'hemorrhagic complications', 'presence of Helicobacter pylori (HP', 'risk of upper GIT bleeding', 'anamnestic and endoscopic signs of bleeding', 'incidence of clinical bleeding and endoscopically detected bleeding']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C3203348', 'cui_str': 'Upper gastrointestinal tract structure'}, {'cui': 'C0192657', 'cui_str': 'Gastroduodenoscopy'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1096489', 'cui_str': 'Vitamin K antagonist'}, {'cui': 'C0642228', 'cui_str': 'N(4)-oleylcytosine arabinoside'}, {'cui': 'C2348066', 'cui_str': 'dabigatran'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}, {'cui': 'C0184980', 'cui_str': 'Endoscopic biopsy'}]","[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0333275', 'cui_str': 'Hemorrhagic'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0442726', 'cui_str': 'Detected'}]",80.0,0.0200152,"The presence of Helicobacter pylori (HP) was a risk factor for upper GIT bleeding ( p < 0.05), while the use of proton pump inhibitors (PPIs) was a protective factor ( p = 0.206; Spearman's correlation coefficient = 0.205).","[{'ForeName': 'Lubomir', 'Initials': 'L', 'LastName': 'Mihalkanin', 'Affiliation': 'Gastroenterology Department, Gastro-LM, 080 01 Presov, Slovakia.'}, {'ForeName': 'Branislav', 'Initials': 'B', 'LastName': 'Stancak', 'Affiliation': 'Cardiology Department, East Slovakia Institute for Cardiovascular Diseases, 040 11 Kosice, Slovakia.'}]","Medicina (Kaunas, Lithuania)",['10.3390/medicina56070363'] 2845,32708368,Effect of Sechium edule var. nigrum spinosum (Chayote) on Telomerase Levels and Antioxidant Capacity in Older Adults with Metabolic Syndrome.,"Patients with metabolic syndrome (MetS) have a redox imbalance, due to a decay in antioxidant capacity. Oxidative stress (OxS) is considered an important modulator of telomere shortening and telomerase activity. One of the fruits that has been associated with an antioxidant effect is Sechium edule and although its properties are well established, there is only one exploratory study evaluating its effectiveness in patients with MetS. The present investigation is a much more robust and controlled study, including a placebo group. Hence, we determined the effect of consumption of the dried fruit powder (500 mg, three times per day) for three months. We measured effects on telomerase levels, antioxidant capacity, and markers for OxS. The study was performed in a sample of 75 older adults: placebo group ( n = 30) and experimental group ( n = 45) with the diagnosis of MetS according to the National Adult Treatment Panel of the National Cholesterol Program III (NCEP/ATP III) criteria. All markers were measured before and after three months of treatment. There was a statistically significant decrease in lipoperoxides and protein carbonylation with an increased superoxide dismutase (SOD), as well as sustained levels of telomerase in patients who consumed Sechium edule . Our findings suggest that consumption of this fruit has a hypoglycemic, hypotensive, and antioxidant effect, without altering telomerase levels, which could suggest better protection against telomere shortening.",2020,"There was a statistically significant decrease in lipoperoxides and protein carbonylation with an increased superoxide dismutase (SOD), as well as sustained levels of telomerase in patients who consumed Sechium edule .","['75 older adults', 'Patients with metabolic syndrome (MetS', 'patients with MetS', 'Older Adults with Metabolic Syndrome', 'group ( n = 30) and experimental group ( n = 45) with the diagnosis of MetS according to the National Adult Treatment Panel of the National Cholesterol Program III']","['placebo', 'dried fruit powder', 'Sechium edule var', 'nigrum spinosum (Chayote']","['lipoperoxides and protein carbonylation', 'Oxidative stress (OxS', 'telomerase levels, antioxidant capacity, and markers for OxS', 'superoxide dismutase (SOD', 'Telomerase Levels and Antioxidant Capacity']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0453296', 'cui_str': 'Dried fruit'}, {'cui': 'C0032861', 'cui_str': 'Powder'}]","[{'cui': 'C0023776', 'cui_str': 'Fatty Acid Hydroperoxides'}, {'cui': 'C1563721', 'cui_str': 'Carbonylation, Protein'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0087071', 'cui_str': 'Telomerase Reverse Transcriptase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}]",75.0,0.0375362,"There was a statistically significant decrease in lipoperoxides and protein carbonylation with an increased superoxide dismutase (SOD), as well as sustained levels of telomerase in patients who consumed Sechium edule .","[{'ForeName': 'Graciela', 'Initials': 'G', 'LastName': 'Gavia-García', 'Affiliation': 'Research Unit on Gerontology, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.'}, {'ForeName': 'Juana', 'Initials': 'J', 'LastName': 'Rosado-Pérez', 'Affiliation': 'Research Unit on Gerontology, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.'}, {'ForeName': 'Itzen', 'Initials': 'I', 'LastName': 'Aguiñiga-Sánchez', 'Affiliation': 'Hematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.'}, {'ForeName': 'Edelmiro', 'Initials': 'E', 'LastName': 'Santiago-Osorio', 'Affiliation': 'Hematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.'}, {'ForeName': 'Víctor Manuel', 'Initials': 'VM', 'LastName': 'Mendoza-Núñez', 'Affiliation': 'Research Unit on Gerontology, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.'}]","Antioxidants (Basel, Switzerland)",['10.3390/antiox9070634'] 2846,31919692,Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis.,"OBJECTIVE To evaluate the impact of hormone replacement therapy (HRT) on the incidence and mortality of lung cancer among female participants in the prostate, lung, colorectal, and ovary (PLCO) trial. METHODS All women participating in the PLCO trial with complete information about HRT exposure were included in the current analysis. All study population were aged 55-74 years without prior history of lung cancer at the time of study enrollment. Multivariate Cox regression analysis was used to evaluate the impact of HRT exposure on lung cancer incidence and mortality. For both end points, the model was adjusted for: age, body mass index, study arm, race, cigarette smoking and family history of lung cancer. RESULTS A total of 77,911 female participants were included in the current analysis, including 27,663 participants who never used HRT before inclusion into the PLCO trial and 50,248 participants who used some form of HRT before inclusion into the PLCO trial. Prior exposure to HRT seems to be protective against the development of lung cancer in a multivariate analysis (hazard ratio for ever exposure versus never exposure 0.876; 95% CI 0.783-0.981; P = 0.022). Similarly, prior exposure to HRT seems also to be protective against death from lung cancer in a multivariate analysis (hazard ratio for ever exposure versus never exposure 0.814; 0.709-0.934; P = 0.003). Further multivariate Cox regression analysis showed that current HRT usage at the time of PLCO trial entry (and not former HRT usage) seemed to be protective against lung cancer development (hazard ratio for current versus never users 0.842; 0.743-0.954; P = 0.007) and lung cancer-specific mortality (hazard ratio for current versus never users 0.800; 0.686-0.932; P = 0.004). CONCLUSION HRT use at the time of PLCO trial entry seems to be associated with lower probability of lung cancer development and death. Further studies are needed to elucidate the biological mechanisms behind this observation.",2020,Prior exposure to HRT seems to be protective against the development of lung cancer in a multivariate analysis (hazard ratio for ever exposure versus never exposure 0.876; 95% CI 0.783-0.981; P = 0.022).,"['All women participating in the PLCO trial with complete information about HRT exposure were included in the current analysis', 'female participants in the prostate, lung, colorectal, and ovary (PLCO) trial', '77,911 female participants were included in the current analysis, including 27,663 participants who never used HRT before inclusion into the PLCO trial and 50,248 participants who used some form of HRT before inclusion into the PLCO trial', 'All study population were aged 55-74\xa0years without prior history of lung cancer at the time of study enrollment', 'women participating in the PLCO trial']",['hormone replacement therapy (HRT'],"['lung cancer incidence and mortality', 'lung cancer-specific mortality', 'Lung cancer incidence and mortality', 'probability of lung cancer development and death', 'incidence and mortality of lung cancer']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C0029939', 'cui_str': 'Ovarian structure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0282402', 'cui_str': 'Hormone replacement therapy'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}]","[{'cui': 'C0282402', 'cui_str': 'Hormone replacement therapy'}]","[{'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",77911.0,0.13475,Prior exposure to HRT seems to be protective against the development of lung cancer in a multivariate analysis (hazard ratio for ever exposure versus never exposure 0.876; 95% CI 0.783-0.981; P = 0.022).,"[{'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Abdel-Rahman', 'Affiliation': 'Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, T6G 1Z2, Canada. omar.abdelsalam@ahs.ca.'}]",International journal of clinical oncology,['10.1007/s10147-020-01615-y'] 2847,32710888,Effects of Ramadan intermittent fasting on inflammatory and biochemical biomarkers in males with obesity.,"BACKGROUND To determine the effects of Ramadan intermittent fasting (RIF) on inflammatory (C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α)) and biochemical markers of liver-renal function (aspartate aminotransferase (AST), alanine amino transferase (ALT), bilirubin, lactate dehydrogenase (LDH), urea and creatinine) in males with obesity. MATERIALS AND METHODS Twenty-eight males with obesity were randomly allocated to an experimental group (EG, n=14) or a control group (CG, n=14). The EG group completed their fasting rituals for the entire month of Ramadan (30 days) whereas the CG group continued with their normal daily habits. Blood samples were collected 24 hours before the start of Ramadan (T0), on the 15th day of Ramadan (T1), the day after the end of Ramadan (T2), and 21 days after the end of Ramadan (T3). Resting plasma volume variation between pre and post-RIF (ΔPV) was calculated. RESULTS Decreases were noted for interleukin-6 (p = 0.02, d = 1.4) and tumor necrosis factor-alpha (p = 0.01, d = 0.7), with no changes for C-reactive protein (p = 0.3; d=0.1) in the EG compared to CG group. There were no changes (P>0.05) in ΔPV recorded after RIF for either EG (-0.035±0.02%) and CG (0.055±0.06%). CONCLUSION This study demonstrates that RIF improves systemic inflammation biomarkers in males with obesity. Moreover, RIF did not negatively affect biomarkers of liver and renal function.",2020,"RESULTS Decreases were noted for interleukin-6 (p = 0.02, d = 1.4) and tumor necrosis factor-alpha (p = 0.01, d = 0.7), with no changes for C-reactive protein (p = 0.3; d=0.1) in the EG compared to CG group.","['males with obesity', 'Twenty-eight males with obesity']","['Ramadan intermittent fasting', 'Ramadan intermittent fasting (RIF', 'RIF']","['systemic inflammation biomarkers', 'inflammatory (C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α)) and biochemical markers of liver-renal function (aspartate aminotransferase (AST), alanine amino transferase (ALT), bilirubin, lactate dehydrogenase (LDH), urea and creatinine', 'Blood samples', 'biomarkers of liver and renal function', 'inflammatory and biochemical biomarkers', 'tumor necrosis factor-alpha']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C4283787', 'cui_str': '28'}]","[{'cui': 'C4704881', 'cui_str': 'Intermittent Fasting'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Markers'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0057041', 'cui_str': 'D-amino-acid transaminase'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin'}, {'cui': 'C0202113', 'cui_str': 'Lactate dehydrogenase measurement'}, {'cui': 'C0041942', 'cui_str': 'Urea'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}]",28.0,0.0245917,"RESULTS Decreases were noted for interleukin-6 (p = 0.02, d = 1.4) and tumor necrosis factor-alpha (p = 0.01, d = 0.7), with no changes for C-reactive protein (p = 0.3; d=0.1) in the EG compared to CG group.","[{'ForeName': 'Hassane', 'Initials': 'H', 'LastName': 'Zouhal', 'Affiliation': 'Univ Rennes, M2S (Laboratoire Mouvement, Sport, Santé) - EA 1274, F-35000 Rennes, France.. Electronic address: hassane.zouhal@univ-rennes2.fr.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Bagheri', 'Affiliation': 'Department of Exercise Physiology, University of Isfahan, Isfahan, Iran.'}, {'ForeName': 'Damoon', 'Initials': 'D', 'LastName': 'Ashtary-Larky', 'Affiliation': 'Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Alexei', 'Initials': 'A', 'LastName': 'Wong', 'Affiliation': 'Department of Health and Human Performance, Marymount University, Arlington, USA.'}, {'ForeName': 'Raoua', 'Initials': 'R', 'LastName': 'Triki', 'Affiliation': 'ISSEP Ksar Said, University of Manouba, Tunis, Tunisia.'}, {'ForeName': 'Anthony C', 'Initials': 'AC', 'LastName': 'Hackney', 'Affiliation': 'Department of Exercise & Sport Science, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'Ismail', 'Initials': 'I', 'LastName': 'Laher', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Therapeutics, The University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Abderraouf Ben', 'Initials': 'AB', 'LastName': 'Abderrahman', 'Affiliation': 'ISSEP Ksar Said, University of Manouba, Tunis, Tunisia.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113090'] 2848,32711031,Developing and Evaluating ASTHMAXcel Adventures: A Novel Gamified Mobile App for Pediatric Patients with Asthma.,"BACKGROUND The ASTHMAXcel mobile application has been linked to favorable outcomes among adult asthma patients. OBJECTIVE We assessed the impact of ASTHMAXcel Adventures, a gamified, guideline-based, pediatric version on asthma control, knowledge, healthcare utilization, and patient satisfaction. METHODS Pediatric asthma patients received the ASTHMAXcel Adventures mobile intervention on-site only at baseline (Visit 1), 4 months (Visit 2) and 6 months (Visit 3). The Asthma Control Test (ACT), Asthma Illness Representation Scale-Self Administered (AIRS-SR), Pediatric Asthma Impact Survey (PAIS), and Client Satisfaction Questionnaire (CSQ-8) were used to assess asthma control, knowledge, and patient satisfaction. Patients reported the number of asthma-related emergency department (ED) visits, hospitalizations, and oral prednisone use. RESULTS 39 patients completed the study. The proportion of controlled asthma increased from Visit 1 to Visits 2 and 3 (30.8% vs. 53.9%, p=0.04; 30.8% vs. 59.0%, p=0.02), and largely seen in males. Mean AIRS-SR scores increased from baseline pre to post-intervention, with sustained improvements at Visits 2 and 3 (3.55 vs. 3.76, p=0.0006; 3.55 vs. 3.80, p=0.001; 3.55 vs. 3.99, p=0.0001). PAIS scores improved from baseline to Visits 2 and 3 (43.33 vs 34.08, p=0.0006; 43.33 vs. 31.74, p=0.0001). ED visits and prednisone use significantly decreased from baseline to Visits 2 and 3 (ED: 0.46 vs 0.13, p=0.03; 0.46 vs. 0.02, p=0.02; Prednisone: 0.49 vs 0.13, p=0.02; 0.49 vs. 0.03, p=0.003. Satisfaction was high with mean CSQ ∼30 (out of 32) at all visits. CONCLUSION ASTHMAXcel Adventures improved asthma control, knowledge, and quality of life, and reduced ED visits and prednisone use with high satisfaction scores.",2020,"Mean AIRS-SR scores increased from baseline pre to post-intervention, with sustained improvements at Visits 2 and 3 (3.55 vs. 3.76, p=0.0006; 3.55 vs. 3.80, p=0.001; 3.55 vs. 3.99, p=0.0001).","['adult asthma patients', 'Pediatric asthma patients', '39 patients completed the study', 'Pediatric Patients with Asthma']","['Prednisone', 'ASTHMAXcel Adventures mobile intervention']","['number of asthma-related emergency department (ED) visits, hospitalizations, and oral prednisone use', 'asthma control, knowledge, and patient satisfaction', 'asthma control, knowledge, healthcare utilization, and patient satisfaction', 'proportion of controlled asthma', 'Asthma Control Test (ACT), Asthma Illness Representation Scale-Self Administered (AIRS-SR), Pediatric Asthma Impact Survey (PAIS), and Client Satisfaction Questionnaire (CSQ-8', 'Mean AIRS-SR scores', 'PAIS scores', 'asthma control, knowledge, and quality of life, and reduced ED visits', 'Satisfaction']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C4048375', 'cui_str': 'Asthma control test'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",39.0,0.059259,"Mean AIRS-SR scores increased from baseline pre to post-intervention, with sustained improvements at Visits 2 and 3 (3.55 vs. 3.76, p=0.0006; 3.55 vs. 3.80, p=0.001; 3.55 vs. 3.99, p=0.0001).","[{'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Hsia', 'Affiliation': 'Division of Allergy/Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Anjani K', 'Initials': 'AK', 'LastName': 'Singh', 'Affiliation': 'Division of Allergy/Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Obumneme', 'Initials': 'O', 'LastName': 'Njeze', 'Affiliation': 'Division of Allergy/Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Emine', 'Initials': 'E', 'LastName': 'Cosar', 'Affiliation': 'Division of Allergy/Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Wenzhu B', 'Initials': 'WB', 'LastName': 'Mowrey', 'Affiliation': 'Division of Biostatistics, Department of Epidemiology and Population Health, Albert Einstein College of Medicine. Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Feldman', 'Affiliation': ""Department of Pediatrics, Division of Academic General Pediatrics, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY; Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY.""}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Reznik', 'Affiliation': ""Department of Pediatrics, Division of Academic General Pediatrics, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY.""}, {'ForeName': 'Sunit P', 'Initials': 'SP', 'LastName': 'Jariwala', 'Affiliation': 'Division of Allergy/Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY. Electronic address: sjariwal@montefiore.org.'}]","Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology",['10.1016/j.anai.2020.07.018'] 2849,32711121,A Population-based Mortality Follow-Back Survey Evaluating Good Death for Cancer and Non-cancer Patients: A Randomized Feasibility Study.,"CONTEXT Evaluation of end-of-life care is a key element in quality improvement, and population-based mortality follow-back designs have been used in several countries. This design was adapted to evaluate a Good Death in Japan. OBJECTIVES This study aimed to explain the scientific background and rationale for assessing the feasibility of a mortality follow-back survey using a randomized design. DESIGN We utilized a cross-sectional, questionnaire survey to assess feasibility using response rate, sample representativeness, effect on response rate with two methods, and survey acceptability. SETTING/PARTICIPANTS The subjects were 4,812 bereaved family members of patients who died from the major five causes of death: cancer, heart disease, cerebrovascular disease, pneumonia, or kidney failure, using mortality data. RESULTS Overall, 682 (14.2%) questionnaires could not be delivered, and 2,294 (55.5%) family members agreed to participate in the survey. There was little difference in the distribution of characteristics between the study subjects and the full population, and sample representativeness was acceptable. Sending the questionnaire with a pen achieved a higher response rate than without (weighted: 48.2% vs. 40.8%; p<0.001). In follow-up contact, there was no difference in response rate between resending the questionnaire and a reminder letter alone (weighted: 32.9% vs. 32.4%; p=0.803). In total, 84.8% (weighted) of the participants agreed with improving quality of care through this kind of survey. CONCLUSIONS This study demonstrated the feasibility of conducting a population-based mortality follow-back survey using a randomized design. An attached pen with the questionnaire was effective in improving the response rate.",2020,"In follow-up contact, there was no difference in response rate between resending the questionnaire and a reminder letter alone (weighted: 32.9% vs. 32.4%; p=0.803).","['Cancer and Non-cancer Patients', 'subjects were 4,812 bereaved family members of patients who died from the major five causes of death: cancer, heart disease, cerebrovascular disease, pneumonia, or kidney failure, using mortality data']",[],['response rate'],"[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086282', 'cui_str': 'Person in the family'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0007465', 'cui_str': 'Cause of death'}, {'cui': 'C0018799', 'cui_str': 'Heart disease'}, {'cui': 'C0007820', 'cui_str': 'Cerebrovascular disease'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0035078', 'cui_str': 'Renal insufficiency'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",[],[],4812.0,0.0916359,"In follow-up contact, there was no difference in response rate between resending the questionnaire and a reminder letter alone (weighted: 32.9% vs. 32.4%; p=0.803).","[{'ForeName': 'Yoko', 'Initials': 'Y', 'LastName': 'Nakazawa', 'Affiliation': 'Division of Medical Support and Partnership, Center for Cancer Control and Information Services, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. Electronic address: ynakazaw@ncc.go.jp.'}, {'ForeName': 'Emi', 'Initials': 'E', 'LastName': 'Takeuchi', 'Affiliation': 'Division of Medical Support and Partnership, Center for Cancer Control and Information Services, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.'}, {'ForeName': 'Mitsunori', 'Initials': 'M', 'LastName': 'Miyashita', 'Affiliation': 'Department of Palliative Nursing, Health Sciences, Tohoku University Graduate School of Medicine, 2-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.'}, {'ForeName': 'Kazuki', 'Initials': 'K', 'LastName': 'Sato', 'Affiliation': 'Department of Nursing, Nagoya University Graduate School of Medicine, 1-1-20, Daikominami, Nagoya Higashi-ku, Aichi 461-8673, Japan.'}, {'ForeName': 'Asao', 'Initials': 'A', 'LastName': 'Ogawa', 'Affiliation': 'Division of Psycho-Oncology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.'}, {'ForeName': 'Hiroya', 'Initials': 'H', 'LastName': 'Kinoshita', 'Affiliation': 'Department of Palliative Care, Tokatu Hospital, 102-1, Naka, Nagareyama, Chiba, 270-0153, Japan.'}, {'ForeName': 'Yoshiyuki', 'Initials': 'Y', 'LastName': 'Kizawa', 'Affiliation': 'Division of Palliative Medicine, Kobe University Hospital, Kobe University School of Medicine, 7-5-2, Kusunokicho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.'}, {'ForeName': 'Tatsuya', 'Initials': 'T', 'LastName': 'Morita', 'Affiliation': 'Department of Palliative and Supportive Care, Palliative Care Team, and Seirei Hospice, Seirei Mikatahara General Hospital, 3453, Mikatahara-cho, Hamamatsu, Shizuoka, 433-8558, Japan.'}, {'ForeName': 'Masashi', 'Initials': 'M', 'LastName': 'Kato', 'Affiliation': 'Division of Medical Support and Partnership, Center for Cancer Control and Information Services, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2020.07.013'] 2850,32711393,Long-Term Effects of Three Water-Based Training Programs on Resting Blood Pressure in Older Women.,"The aim of the study was to compare the effects of three water-based training on blood pressure (BP) in older women. A total of 57 participants were randomized into the following groups: (a) aerobic training (AT), (b) concurrent training in which resistance training progresses to the use of resistive equipment (CTRE), and (c) concurrent training in which resistance training progresses to multiple sets (CTMS). The participants trained twice a week for 16 weeks. Systolic BP decreased from pretraining to after 8 weeks of training and, subsequently, to after 16 weeks of training (AT: -6.53 mmHg, CTRE: -10.45 mmHg, and CTMS: -10.73 mmHg). Diastolic BP decreased from pretraining to after 8 and 16 weeks of training (AT: -6.23 mmHg, CTRE: -4.61 mmHg, and CTMS: -6.19 mmHg). Furthermore, 16% of the AT participants, 23% of the CTRE participants, and 28.5% of the CTMS participants were no longer classified as hypertensive. Water-based aerobic and concurrent training are efficient nonpharmacological measures to reduce BP in older women.",2020,"Diastolic BP decreased from pretraining to after 8 and 16 weeks of training (AT: -6.23 mmHg, CTRE:","['older women', 'Older Women', '57 participants']","['Water-based aerobic and concurrent training', 'CTRE', 'Three Water-Based Training Programs', 'three water-based training', 'aerobic training (AT), (b)\xa0concurrent training in which resistance training progresses to the use of resistive equipment (CTRE), and (c)\xa0concurrent training in which resistance training progresses to multiple sets (CTMS']","['Resting Blood Pressure', 'blood pressure (BP', 'Systolic BP', 'Diastolic BP']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0661732', 'cui_str': 'cyclohexane-1,2,4-tris(methylenesulfonate)'}]","[{'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}]",57.0,0.0251606,"Diastolic BP decreased from pretraining to after 8 and 16 weeks of training (AT: -6.23 mmHg, CTRE:","[{'ForeName': 'Thaís', 'Initials': 'T', 'LastName': 'Reichert', 'Affiliation': ''}, {'ForeName': 'Rochelle Rocha', 'Initials': 'RR', 'LastName': 'Costa', 'Affiliation': ''}, {'ForeName': 'Bruna Machado', 'Initials': 'BM', 'LastName': 'Barroso', 'Affiliation': ''}, {'ForeName': 'Vitória de Mello Bones', 'Initials': 'VMB', 'LastName': 'da Rocha', 'Affiliation': ''}, {'ForeName': 'Henrique Bianchi', 'Initials': 'HB', 'LastName': 'Oliveira', 'Affiliation': ''}, {'ForeName': 'Cláudia Gomes', 'Initials': 'CG', 'LastName': 'Bracht', 'Affiliation': ''}, {'ForeName': 'Anemarí Girardon', 'Initials': 'AG', 'LastName': 'de Azevedo', 'Affiliation': ''}, {'ForeName': 'Luiz Fernando Martins', 'Initials': 'LFM', 'LastName': 'Kruel', 'Affiliation': ''}]",Journal of aging and physical activity,['10.1123/japa.2019-0236'] 2851,32711396,Effects of Peer Encouragement on Efficacy Perceptions and Physical Performance in Children.,"Social interactions are theorized to inform relation-inferred self-efficacy (RISE), which, in turn, may influence self-efficacy and behavior. This study investigated the effects of peer encouragement on RISE, task self-efficacy, and physical performance. Children (N = 84) were assigned to dyads and randomized to provide peer encouragement to one another or not (control group). Participants completed two endurance handgrip trials, separated by a cognitively demanding task intended to induce mental fatigue and increase the salience of the peer encouragement manipulation. Participants in the experimental group exchanged words of encouragement prior to the second endurance trial, whereas those in the control group did not. The peer encouragement group reported higher RISE and showed increased performance across trials compared with controls. Providing peer encouragement prior to a challenging physical task was associated with more positive RISE perceptions and improved physical performance.",2020,The peer encouragement group reported higher RISE and showed increased performance across trials compared with controls.,"['Children', 'Children (N = 84']","['provide peer encouragement to one another or not (control group', 'endurance handgrip trials, separated by a cognitively demanding task intended to induce mental fatigue and increase the salience of the peer encouragement manipulation', 'Peer Encouragement']","['Efficacy Perceptions and Physical Performance', 'RISE, task self-efficacy, and physical performance', 'physical performance']","[{'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0015676', 'cui_str': 'Mental fatigue'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",84.0,0.030486,The peer encouragement group reported higher RISE and showed increased performance across trials compared with controls.,"[{'ForeName': 'Kira L', 'Initials': 'KL', 'LastName': 'Innes', 'Affiliation': 'McMaster University.'}, {'ForeName': 'Jeffrey D', 'Initials': 'JD', 'LastName': 'Graham', 'Affiliation': 'McMaster University.'}, {'ForeName': 'Steven R', 'Initials': 'SR', 'LastName': 'Bray', 'Affiliation': 'McMaster University.'}]",Journal of sport & exercise psychology,['10.1123/jsep.2019-0280'] 2852,32709710,Long-Term Functional Patency and Cost-Effectiveness of Arteriovenous Fistula Creation under Regional Anesthesia: a Randomized Controlled Trial.,"BACKGROUND Regional anesthesia improves short-term blood flow through arteriovenous fistulas (AVFs). We previously demonstrated that, compared with local anesthesia, regional anesthesia improves primary AVF patency at 3 months. METHODS To study the effects of regional versus local anesthesia on longer-term AVF patency, we performed an observer-blinded randomized controlled trial at three university hospitals in Glasgow, United Kingdom. We randomly assigned 126 patients undergoing primary radiocephalic or brachiocephalic AVF creation to receive regional anesthesia (brachial plexus block; 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine) or local anesthesia (0.5% L-bupivacaine and 1% lidocaine). This report includes findings on primary, functional, and secondary patency at 12 months; reinterventions; and additional access procedures (primary outcome measures were previously reported). We analyzed data by intention to treat, and also performed cost-effectiveness analyses. RESULTS At 12 months, we found higher primary patency among patients receiving regional versus local anesthesia (50 of 63 [79%] versus 37 of 63 [59%] patients; odds ratio [OR], 2.7; 95% confidence interval [95% CI], 1.6 to 3.8; P =0.02) as well as higher functional patency (43 of 63 [68%] versus 31 of 63 [49%] patients; OR, 2.1; 95% CI, 1.5 to 2.7; P =0.008). In 12 months, 21 revisional procedures, 53 new AVFs, and 50 temporary dialysis catheters were required. Regional anesthesia resulted in net savings of £195.10 (US$237.36) per patient at 1 year, and an incremental cost-effectiveness ratio of approximately £12,900 (US$15,694.20) per quality-adjusted life years over a 5-year time horizon. Results were robust after extensive sensitivity and scenario analyses. CONCLUSIONS Compared with local anesthesia, regional anesthesia significantly improved both primary and functional AVF patency at 1 year and is cost-effective. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER Local Anaesthesia versus Regional Block for Arteriovenous Fistulae, NCT01706354.",2020,"Regional anesthesia resulted in net savings of £195.10 (US$237.36) per patient at 1 year, and an incremental cost-effectiveness ratio of approximately £12,900 (US$15,694.20) per quality-adjusted life years over a 5-year time horizon.","['126 patients undergoing', 'three university hospitals in Glasgow, United Kingdom']","['primary radiocephalic or brachiocephalic', 'regional versus local anesthesia', 'regional anesthesia (brachial plexus block; 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine', 'Arteriovenous Fistula Creation under Regional Anesthesia', 'local anesthesia, regional anesthesia', 'local anesthesia (0.5% L-bupivacaine and 1% lidocaine']","['functional patency', 'primary patency', 'primary AVF patency', 'incremental cost-effectiveness ratio', 'net savings', 'cost-effective', 'functional AVF patency']","[{'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom of Great Britain and Northern Ireland'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0002911', 'cui_str': 'Regional anesthesia'}, {'cui': 'C0394697', 'cui_str': 'Injection of anesthetic agent into brachial plexus'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0398221', 'cui_str': 'Arteriovenous fistulization'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0449215', 'cui_str': 'aVF'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0036245', 'cui_str': 'Savings'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",126.0,0.356984,"Regional anesthesia resulted in net savings of £195.10 (US$237.36) per patient at 1 year, and an incremental cost-effectiveness ratio of approximately £12,900 (US$15,694.20) per quality-adjusted life years over a 5-year time horizon.","[{'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Aitken', 'Affiliation': 'Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, United Kingdom emmaaitken@nhs.net.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Kearns', 'Affiliation': 'Department of Anaesthesia, Critical Care and Pain Medicine, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Lucian', 'Initials': 'L', 'LastName': 'Gaianu', 'Affiliation': 'Scottish Health Technologies Group, Healthcare Improvement Scotland, Edinburgh, United Kingdom.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Jackson', 'Affiliation': 'Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, United Kingdom.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Steven', 'Affiliation': 'Department of Anaesthesia, Golden Jubilee National Hospital, Clydebank, United Kingdom.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Kinsella', 'Affiliation': 'Department of Anaesthesia, Critical Care and Pain Medicine, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Clancy', 'Affiliation': 'Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, United Kingdom.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Macfarlane', 'Affiliation': 'Department of Anaesthesia, Critical Care and Pain Medicine, University of Glasgow, Glasgow, United Kingdom.'}]",Journal of the American Society of Nephrology : JASN,['10.1681/ASN.2019111209'] 2853,32709757,Quality of life in patients with uveitis: data from the ULISSE study (Uveitis: cLInical and medico-economic evaluation of a Standardised Strategy for the Etiological diagnosis).,"AIMS To assess vision-related (VR-QOL) and health-related quality of life (HR-QOL) in a large series of patients with de novo uveitis at baseline and 6-month follow-up. METHODS Non-inferiority, prospective, multicentre, cluster randomised controlled trial registered under the Unique Identifier: NCT01162070. VR-QOL and HR-QOL were assessed by the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) and the Medical Outcomes Study 36-item Short Form Survey (SF-36). RESULTS At inclusion, 466 patients completed the VFQ-25. The mean composite score was 80.0 (±16.7). In multivariate analysis, higher age, female sex and insidious onset were significantly associated with lower QOL. At 6 months, 138 patients completed the VFQ-25, with a significantly higher mean composite score of 82.6 (±16.7). SF-36 mental component was 42.9 (±11.3) and physical component was 47.2 (±8.5) at inclusion (n=425). HR-QOL improvement at 6 months was not clinically significant. CONCLUSION QOL seems relatively well preserved in this cohort; only VR-QOL improved significantly at 6 months, especially in patients with low initial visual acuity.",2020,"At 6 months, 138 patients completed the VFQ-25, with a significantly higher mean composite score of 82.6 (±16.7).","['patients with de novo uveitis at baseline and 6-month follow-up', 'patients with low initial visual acuity', 'patients with uveitis', '466 patients completed the VFQ-25']",[],"['VR-QOL and HR-QOL', 'mean composite score', 'vision-related (VR-QOL) and health-related quality of life (HR-QOL', 'SF-36 mental component', 'VR-QOL', 'Quality of life', '25-item National Eye Institute Visual Function Questionnaire (VFQ-25) and the Medical Outcomes Study 36-item Short Form Survey (SF-36', 'HR-QOL improvement']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042164', 'cui_str': 'Uveitis'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]",[],"[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C1955969', 'cui_str': 'National Eye Institute'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0543472', 'cui_str': 'Outcome Studies'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]",466.0,0.0929083,"At 6 months, 138 patients completed the VFQ-25, with a significantly higher mean composite score of 82.6 (±16.7).","[{'ForeName': 'Pierre-Jean', 'Initials': 'PJ', 'LastName': 'Bertrand', 'Affiliation': 'Internal Medicine, Hospices Civils De Lyon, Lyon, France pascal.seve@chu-lyon.fr.'}, {'ForeName': 'Yvan', 'Initials': 'Y', 'LastName': 'Jamilloux', 'Affiliation': 'Internal Medicine, Hopital De La Croix-Rousse,Lyon, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Kodjikian', 'Affiliation': 'Ophthalmology, Croix Rousse University Hospital, Hospices Civils De Lyon, Lyon, France.'}, {'ForeName': 'Marie-Helene', 'Initials': 'MH', 'LastName': 'Errera', 'Affiliation': 'Department of Ophthalmology, Quinze-Vingts Hospital, Paris, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Perard', 'Affiliation': 'Internal Medicine, Edouart Herriot University Hospital, Hospices Civils De Lyon, Lyon, France.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Pugnet', 'Affiliation': 'Department of Internal Medicine, Purpan University Hospital, Toulouse, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Tieulie', 'Affiliation': 'Deparment of Rheumatology, Archet Hospital, Nice, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Andre', 'Affiliation': 'Médecine Interne, Hopital Gabriel Montpied, Clermont-Ferrand,France.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Bielefeld', 'Affiliation': 'Médecine Interne, Centre Hospitalier Universitaire De Dijon, Dijon, France.'}, {'ForeName': 'Alain M', 'Initials': 'AM', 'LastName': 'Bron', 'Affiliation': 'Ophthalmology, University Hospital, Dijon, France.'}, {'ForeName': 'Evelyne', 'Initials': 'E', 'LastName': 'Decullier', 'Affiliation': 'Pole IMER Lyon, Hospices Civils de Lyon, Lyon, France.'}, {'ForeName': 'Sylvie', 'Initials': 'S', 'LastName': 'Bin', 'Affiliation': 'Pole IMER Lyon, Hospices Civils de Lyon, Lyon, France.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Seve', 'Affiliation': 'Internal Medicine, Hospices Civils De Lyon, Lyon, France.'}]",The British journal of ophthalmology,['10.1136/bjophthalmol-2020-315862'] 2854,32709779,Evaluation of skills transfer in short-term phacoemulsification surgery training program by International Council of Ophthalmology -Ophthalmology Surgical Competency Assessment Rubrics (ICO-OSCAR) and assessment of efficacy of ICO-OSCAR for objective evaluation of skills transfer.,"Purpose To evaluate skills transfer in short-term phacoemulsification surgery training program by International Council of Ophthalmology -Ophthalmology Surgical Competency Assessment Rubrics (ICO-OSCAR) and assessment of efficacy of ICO-OSCAR for objective evaluation of skills transfer. Methods Prospective analysis of total 1300 phacoemulsification surgeries performed by 52 phacoemulsification trainees divided into three groups based on the previous cataract surgical experience. The pretraining and posttraining average mean scores, independent completion rates (ICR), and complication rates among the groups were calculated and statistically analyzed. Results Mean age of trainees (N = 52) was found to be 30.98 ± 2.44 years. Mean pretraining scores in the three groups were 42.8 ± 0.2, 46.6 ± 0.2, and 50.1 ± 0.1, respectively, and posttraining mean scores of the groups were 88.4 ± 0.2, 92.3 ± 0.2, and 94.3 ± 0.2, respectively, out of 100. Pretraining independent completion rates (%) were 22.1 ± 2.5, 52.1 ± 2.5, and 62 ± 3.7, respectively, and posttraining independent completion rates (%) were 74.8 ± 3, 79.7 ± 3, and 90.6 ± 3.5, respectively. Learning curves of all groups were noted to be steep. Rate of complications was within acceptable range, overall complication rate being 12.30% (160 out of 1300 cases). OSCAR scores correlate significantly (P = 0.0004) with ICR. Conclusion Steep learning curve for phacoemulsification can be made easy by the use of standardized rubrics, proper techniques, expert guidance, and adequate surgical volume. The previous SICS experience provides smoother learning curve. ICO-OSCAR is indicator of proficiency and provides constructive feedback and objective evaluation immediately after surgery as well as at the end of training. Short-term (1 Month) training program is an effective, efficient, and safe approach to progressively master phacoemulsification skills for trainees with SICS experience.",2020,"Rate of complications was within acceptable range, overall complication rate being 12.30% (160 out of 1300 cases).","['total 1300 phacoemulsification surgeries performed by 52 phacoemulsification trainees divided into three groups based on the previous cataract surgical experience', 'short-term phacoemulsification surgery training program by International Council of Ophthalmology', 'Mean age of trainees (N = 52) was found to be 30.98 ± 2.44 years', 'trainees with SICS experience']",['ICO-OSCAR'],"['completion rates (ICR), and complication rates', 'overall complication rate', 'OSCAR scores', 'Learning curves', 'Rate of complications', 'Mean pretraining scores', 'Ophthalmology Surgical Competency Assessment Rubrics (ICO-OSCAR']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0029087', 'cui_str': 'Ophthalmology'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0329207', 'cui_str': 'Astronotus ocellatus'}]","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0329207', 'cui_str': 'Astronotus ocellatus'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0029087', 'cui_str': 'Ophthalmology'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",1300.0,0.0188267,"Rate of complications was within acceptable range, overall complication rate being 12.30% (160 out of 1300 cases).","[{'ForeName': 'Khurshed M', 'Initials': 'KM', 'LastName': 'Bharucha', 'Affiliation': ""PBMA's H V Desai Eye Hospital, Hadapsar, Pune, Maharashtra, India.""}, {'ForeName': 'Vivek G', 'Initials': 'VG', 'LastName': 'Adwe', 'Affiliation': ""PBMA's H V Desai Eye Hospital, Hadapsar, Pune, Maharashtra, India.""}, {'ForeName': 'Atul M', 'Initials': 'AM', 'LastName': 'Hegade', 'Affiliation': ""PBMA's H V Desai Eye Hospital, Hadapsar, Pune, Maharashtra, India.""}, {'ForeName': 'Rahul D', 'Initials': 'RD', 'LastName': 'Deshpande', 'Affiliation': ""PBMA's H V Desai Eye Hospital, Hadapsar, Pune, Maharashtra, India.""}, {'ForeName': 'Madan D', 'Initials': 'MD', 'LastName': 'Deshpande', 'Affiliation': ""PBMA's H V Desai Eye Hospital, Hadapsar, Pune, Maharashtra, India.""}, {'ForeName': 'V K S', 'Initials': 'VKS', 'LastName': 'Kalyani', 'Affiliation': ""PBMA's H V Desai Eye Hospital, Hadapsar, Pune, Maharashtra, India.""}]",Indian journal of ophthalmology,['10.4103/ijo.IJO_2058_19'] 2855,32709786,Short-term outcome of botulinum neurotoxin A injection with or without sodium hyaluronate in the treatment of infantile esotropia-a prospective interventional study.,"Purpose To compare the short-term outcome of botulinum neurotoxin A (BoNT-A) with or without sodium hyaluronate in the treatment of infantile esotropia (IE). Methods In this tertiary care hospital-based prospective, interventional, non-randomized study on infants with IE below one year of age, 25 cases were enrolled in the sodium hyaluronate (SH) group to receive 2.5 U BoNT-A injection combined with SH in each medial rectus muscle (MR). Thirty patients were enrolled in the control group to receive 2.5 U BoNT-A injection with normal saline in each MR. The change in mean primary ocular deviation (POD) and complications were assessed at 2 weeks, 1 month, 3 months, and 6 months post injection. Mann-Whitney U test was used for non-parametric unpaired data. Chi-square test and Fisher's exact test were used to test for the strength of the association between the two categorical variables. Results Satisfactory ocular alignment was achieved in 76% in SH group and 73% in the control group (P value = 0.80). While the change in mean POD was comparable (29.2 prism diopters [PD] vs 29.3 PD; P value = 0.65), the complication rates were significantly lesser in SH (16% vs 33.3%; P value = 0.14). Conclusion BoNT-A combined with SH is equally effective with lesser complications as compared to botulinum toxin alone in the treatment of IE.",2020,"Results Satisfactory ocular alignment was achieved in 76% in SH group and 73% in the control group (P value = 0.80).","['Thirty patients were enrolled in the control group to', 'infants with IE below one year of age, 25 cases were enrolled in the', 'infantile esotropia (IE']","['botulinum neurotoxin', 'A injection with or without sodium hyaluronate', 'SH', 'botulinum toxin', 'sodium hyaluronate (SH) group to receive 2.5 U BoNT-A injection combined with SH', 'receive 2.5 U BoNT-A injection with normal saline', 'botulinum neurotoxin A (BoNT-A) with or without sodium hyaluronate']","['complication rates', 'mean primary ocular deviation (POD) and complications', 'Satisfactory ocular alignment', 'mean POD', 'SH']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0231330', 'cui_str': 'Infancy'}, {'cui': 'C0014877', 'cui_str': 'Esotropia'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0868928', 'cui_str': 'Case'}]","[{'cui': 'C1295507', 'cui_str': 'Bontoxilysin'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0087000', 'cui_str': 'Hyaluronate sodium'}, {'cui': 'C0006055', 'cui_str': 'botulinum toxin'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}]","[{'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1112602', 'cui_str': 'Ocular deviation'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0729280', 'cui_str': 'Ocular muscle balance'}, {'cui': 'C0087000', 'cui_str': 'Hyaluronate sodium'}]",30.0,0.0204661,"Results Satisfactory ocular alignment was achieved in 76% in SH group and 73% in the control group (P value = 0.80).","[{'ForeName': 'Nitika', 'Initials': 'N', 'LastName': 'Pandey', 'Affiliation': ""Department of Ophthalmology, King George's Medical University, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Siddharth', 'Initials': 'S', 'LastName': 'Agrawal', 'Affiliation': ""Department of Ophthalmology, King George's Medical University, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Rajat M', 'Initials': 'RM', 'LastName': 'Srivastava', 'Affiliation': ""Department of Ophthalmology, King George's Medical University, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Vinita', 'Initials': 'V', 'LastName': 'Singh', 'Affiliation': ""Department of Ophthalmology, King George's Medical University, Lucknow, Uttar Pradesh, India.""}]",Indian journal of ophthalmology,['10.4103/ijo.IJO_1552_19'] 2856,32709851,"Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study.",,2020,,['pediatric patients with relapsed/refractory acute lymphoblastic leukemia'],['Blinatumomab'],[],"[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0023449', 'cui_str': 'Acute lymphoid leukemia'}]","[{'cui': 'C3853839', 'cui_str': 'blinatumomab'}]",[],,0.0367656,,"[{'ForeName': 'Franco', 'Initials': 'F', 'LastName': 'Locatelli', 'Affiliation': ""Department of Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Sapienza, University of Rome, Rome, Italy.""}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Zugmaier', 'Affiliation': 'Amgen Research (Munich) GmbH, Munich, Germany. gerhardz@amgen.com.'}, {'ForeName': 'Noemi', 'Initials': 'N', 'LastName': 'Mergen', 'Affiliation': 'Amgen Research (Munich) GmbH, Munich, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Bader', 'Affiliation': 'Department for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany.'}, {'ForeName': 'Sima', 'Initials': 'S', 'LastName': 'Jeha', 'Affiliation': ""St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Paul-Gerhardt', 'Initials': 'PG', 'LastName': 'Schlegel', 'Affiliation': ""University Children's Hospital Wuerzburg, Wuerzburg, Germany.""}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Bourquin', 'Affiliation': ""Department of Pediatric Oncology, Children's Research Centre, University Children's Hospital Zurich, Zurich, Switzerland.""}, {'ForeName': 'Rupert', 'Initials': 'R', 'LastName': 'Handgretinger', 'Affiliation': ""Department of Hematology/Oncology, University Children's Hospital Tuebingen, Tuebingen, Germany.""}, {'ForeName': 'Benoit', 'Initials': 'B', 'LastName': 'Brethon', 'Affiliation': 'Pediatric Hematology and Immunology Department, Robert Debre Hospital, APHP, Paris, France.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Rossig', 'Affiliation': ""Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.""}, {'ForeName': 'Christiane', 'Initials': 'C', 'LastName': 'Chen-Santel', 'Affiliation': 'Department of Pediatrics, Division of Oncology and Hematology, Charité Universitätsmedizin Berlin, Berlin, Germany.'}]",Blood cancer journal,['10.1038/s41408-020-00342-x'] 2857,32710192,Vedolizumab Dose Escalation Improves Therapeutic Response in a Subset of Patients with Ulcerative Colitis.,"BACKGROUND The Gemini trial failed to detect a significant difference in response rate for patients with ulcerative colitis (UC) randomized to standard (every 8 week) vedolizumab dosing vs escalated (every 4 week) dosing. Subsequent real-world data imply the Gemini trial design may have obscured a benefit of escalated dosing. AIMS We investigated outcomes after vedolizumab dose escalation for patients with UC. We also explored potential clinical predictors of dose escalation requirement. METHODS In this retrospective study, we included patients with UC who received vedolizumab between 1/2017-1/2019. We compared rates of clinical response (decrease in partial Mayo score by ≥ 2) and remission (partial Mayo < 2) for standard vs escalated dosing. RESULTS Among the 90 patients reviewed, 52 achieved and maintained remission on standard dosing. The average time to remission with standard dosing was 33.3 ± 6.6 weeks. After an average of 56.3 ± 7.4 weeks standard dosing, 24 patients (22 ""partial responders"" and 2 ""non-responders"") were dose-escalated. Of the 22 ""partial responders"" dose-escalated, 10 (45%) achieved remission, 10 (45%) achieved further improvement. Neither ""non-responder"" demonstrated further clinical benefit. Prior anti-tumor necrosis factor (anti-TNF) biologic exposure predicted dose escalation requirement (p = 0.008). Patients requiring dose escalation had more severe disease at baseline as measured by both full Mayo (p = 0.009) and partial Mayo scores (p = 0.01). CONCLUSIONS We show dose escalation benefited patients with UC who exhibit a ""partial response"" to standard dosing. Early vedolizumab dose escalation should be considered in both patients with severe disease and those with prior anti-TNF experience.",2020,"Patients requiring dose escalation had more severe disease at baseline as measured by both full Mayo (p = 0.009) and partial Mayo scores (p = 0.01). ","['patients with UC who received vedolizumab between 1/2017-1/2019', '90 patients reviewed, 52 achieved and maintained remission on standard dosing', 'patients with severe disease and those with prior anti-TNF experience', 'Patients with Ulcerative Colitis', 'patients with ulcerative colitis (UC', 'patients with UC']","['vedolizumab', 'Vedolizumab Dose Escalation']","['partial Mayo scores', 'rates of clinical response', 'severe disease', 'response rate', 'average time to remission']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C2742797', 'cui_str': 'vedolizumab'}, {'cui': 'C0451610', 'cui_str': 'Patient review'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]","[{'cui': 'C2742797', 'cui_str': 'vedolizumab'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]","[{'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0454788', 'cui_str': 'Mayo'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}]",90.0,0.0418782,"Patients requiring dose escalation had more severe disease at baseline as measured by both full Mayo (p = 0.009) and partial Mayo scores (p = 0.01). ","[{'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Perry', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, University of Kentucky College of Medicine, 800 Rose Street, MN649, Lexington, KY, 40536, USA. clpe234@uky.edu.'}, {'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Fischer', 'Affiliation': 'Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, USA.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Elmoursi', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, University of Kentucky College of Medicine, 800 Rose Street, MN649, Lexington, KY, 40536, USA.'}, {'ForeName': 'Cody', 'Initials': 'C', 'LastName': 'Kern', 'Affiliation': 'Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, USA.'}, {'ForeName': 'Alden', 'Initials': 'A', 'LastName': 'Currier', 'Affiliation': 'Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, USA.'}, {'ForeName': 'Praneeth', 'Initials': 'P', 'LastName': 'Kudaravalli', 'Affiliation': 'Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, USA.'}, {'ForeName': 'Olalekan', 'Initials': 'O', 'LastName': 'Akanbi', 'Affiliation': 'Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, USA.'}, {'ForeName': 'Nishant', 'Initials': 'N', 'LastName': 'Tripathi', 'Affiliation': 'Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, USA.'}, {'ForeName': 'Pradeep', 'Initials': 'P', 'LastName': 'Yarra', 'Affiliation': 'Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, USA.'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Su', 'Affiliation': 'Dr. Bing Zhang Department of Statistics, University of Kentucky College of Arts and Sciences, Lexington, KY, USA.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Flomenhoft', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, University of Kentucky College of Medicine, 800 Rose Street, MN649, Lexington, KY, 40536, USA.'}, {'ForeName': 'Arnold', 'Initials': 'A', 'LastName': 'Stromberg', 'Affiliation': 'Dr. Bing Zhang Department of Statistics, University of Kentucky College of Arts and Sciences, Lexington, KY, USA.'}, {'ForeName': 'Terrence A', 'Initials': 'TA', 'LastName': 'Barrett', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, University of Kentucky College of Medicine, 800 Rose Street, MN649, Lexington, KY, 40536, USA.'}]",Digestive diseases and sciences,['10.1007/s10620-020-06486-x'] 2858,32710204,PKPD Modeling and Dosing Considerations in Advanced Ovarian Cancer Patients Treated with Cisplatin-Based Intraoperative Intraperitoneal Chemotherapy.,"Intraperitoneal chemoperfusion (IPEC) of cisplatin is a popular treatment for advanced ovarian cancer, typically under hyperthermia (HIPEC). The use of cisplatin under (H)IPEC is off-label, and the role of hyperthermia is unknown. The aim of this study was to characterize the pharmacokinetic/pharmacodynamic (PKPD) properties of cisplatin under (H)IPEC and to predict the optimal treatment regimen. Using a randomized design, data on intact cisplatin perfusate and plasma concentrations, leukocyte counts-a hematotoxicity marker-and serum creatinine-a nephrotoxicity marker-were collected from 50 patients treated with a combination of cytoreductive surgery (CRS) and either normothermic or hyperthermic IPEC of cisplatin dosed at 75, 100, and 120 mg/m 2 . The non-linear mixed effects modeling technique was used to construct the PKPD models. The PK of intact cisplatin was characterized by a two-compartment model. A semi-physiological myelosuppression model for the leukopenia was modified to account for the CRS-induced leukocytosis and the residual myelosuppression effect of neoadjuvant chemotherapy. The incidence and severity of nephrotoxicity were described by a discrete-time Markov model. Hyperthermia increased the absorption rate of cisplatin by 16.3% but did not show a clinically relevant impact on the investigated toxicities compared with normothermia. Leukopenia was not severe, but nephrotoxicity can become severe or life-threatening and was affected by the dose and IPEC duration. The model predicted that nephrotoxicity is minimal at a cisplatin dose of 75 mg/m 2 with an IPEC duration of 1-2 h and an 1-h duration is favored for doses between 100 and 120 mg/m 2 . Graphical abstract.",2020,Hyperthermia increased the absorption rate of cisplatin by 16.3% but did not show a clinically relevant impact on the investigated toxicities compared with normothermia.,"['advanced ovarian cancer, typically under hyperthermia (HIPEC', '50 patients treated with a combination of cytoreductive surgery (CRS) and either', 'Advanced Ovarian Cancer Patients Treated with']","['Intraperitoneal chemoperfusion (IPEC) of cisplatin', 'cisplatin under (H)IPEC', 'normothermic or hyperthermic IPEC of cisplatin', 'Cisplatin-Based Intraoperative Intraperitoneal Chemotherapy']","['incidence and severity of nephrotoxicity', 'toxicities', 'Leukopenia', 'plasma concentrations, leukocyte counts-a hematotoxicity marker-and serum creatinine-a nephrotoxicity marker', 'absorption rate of cisplatin']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C1868801', 'cui_str': 'Hyperthermic Intraperitoneal Chemotherapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C3850079', 'cui_str': 'Cytoreductive surgery'}]","[{'cui': 'C0442120', 'cui_str': 'Intraperitoneal'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0445103', 'cui_str': 'Normothermia'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0595916', 'cui_str': 'Toxic nephropathy'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0920103', 'cui_str': 'Haematotoxicity'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}]",,0.0393438,Hyperthermia increased the absorption rate of cisplatin by 16.3% but did not show a clinically relevant impact on the investigated toxicities compared with normothermia.,"[{'ForeName': 'Feifan', 'Initials': 'F', 'LastName': 'Xie', 'Affiliation': 'Division of Biopharmaceutics and Pharmacokinetics, Xiangya School of Pharmaceutical Sciences, Central South University, Tongzipo Road 172, Changsha, 410013, China. feifan.xie@csu.edu.cn.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Van Bocxlaer', 'Affiliation': 'Laboratory of Medical Biochemistry and Clinical Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium.'}, {'ForeName': 'Pieter', 'Initials': 'P', 'LastName': 'Colin', 'Affiliation': 'Laboratory of Medical Biochemistry and Clinical Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Carlier', 'Affiliation': 'Department of GI Surgery, Ghent University Hospital, 9000, Ghent, Belgium.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Van Kerschaver', 'Affiliation': 'Department of Surgery, St. Lucas Andreas Hospital, 9000, Ghent, Belgium.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Weerts', 'Affiliation': 'Department of Surgery, CHC, Liège, Belgium.'}, {'ForeName': 'Hannelore', 'Initials': 'H', 'LastName': 'Denys', 'Affiliation': 'Cancer Research Institute Ghent (CRIG), 9000, Ghent, Belgium.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Tummers', 'Affiliation': 'Department of Gynecology, Ghent University Hospital, 9000, Ghent, Belgium.'}, {'ForeName': 'Wouter', 'Initials': 'W', 'LastName': 'Willaert', 'Affiliation': 'Department of GI Surgery, Ghent University Hospital, 9000, Ghent, Belgium.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'Ceelen', 'Affiliation': 'Department of GI Surgery, Ghent University Hospital, 9000, Ghent, Belgium.'}, {'ForeName': 'An', 'Initials': 'A', 'LastName': 'Vermeulen', 'Affiliation': 'Laboratory of Medical Biochemistry and Clinical Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium.'}]",The AAPS journal,['10.1208/s12248-020-00489-2'] 2859,32710219,Correction to: Osseous ingrowth in allogeneic bone blocks applied for vertical bone augmentation: a preclinical randomized controlled study.,"In the article by Möst et al., entitled ""Osseous ingrowth in allogeneic bone blocks applied for vertical bone augmentation: a preclinical randomized controlled study.",2020,"In the article by Möst et al., entitled ""Osseous ingrowth in allogeneic bone blocks applied for vertical bone augmentation: a preclinical randomized controlled study.",['vertical bone augmentation'],[],[],"[{'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}]",[],[],,0.0260633,"In the article by Möst et al., entitled ""Osseous ingrowth in allogeneic bone blocks applied for vertical bone augmentation: a preclinical randomized controlled study.","[{'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Moest', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University of Erlangen-Nürnberg, Glueckstraße 11, 91054, Erlangen, Germany. tobias.moest@uk-erlangen.de.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Frabschka', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University of Erlangen-Nürnberg, Glueckstraße 11, 91054, Erlangen, Germany.'}, {'ForeName': 'Marco Rainer', 'Initials': 'MR', 'LastName': 'Kesting', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University of Erlangen-Nürnberg, Glueckstraße 11, 91054, Erlangen, Germany.'}, {'ForeName': 'Christian Martin', 'Initials': 'CM', 'LastName': 'Schmitt', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University of Erlangen-Nürnberg, Glueckstraße 11, 91054, Erlangen, Germany.'}, {'ForeName': 'Gesche', 'Initials': 'G', 'LastName': 'Frohwitter', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University of Erlangen-Nürnberg, Glueckstraße 11, 91054, Erlangen, Germany.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Lutz', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University of Erlangen-Nürnberg, Glueckstraße 11, 91054, Erlangen, Germany.'}, {'ForeName': 'Karl Andreas', 'Initials': 'KA', 'LastName': 'Schlegel', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University of Erlangen-Nürnberg, Glueckstraße 11, 91054, Erlangen, Germany.'}]",Clinical oral investigations,['10.1007/s00784-020-03466-3'] 2860,32710304,Early surfactant replacement guided by lung ultrasound in preterm newborns with RDS: the ULTRASURF randomised controlled trial.,"This study aimed to investigate whether using lung ultrasound (LUS) scores in premature newborns with respiratory distress syndrome (RDS) allows for earlier surfactant therapy (within the first 3 h of life) than using FiO 2 criteria. This was a randomised, non-blinded clinical trial conducted in a neonatal intensive care unit. The inclusion criteria were newborns with a gestational age of ≤ 32 weeks and RDS. Patients meeting the inclusion criteria were randomly assigned to two groups: the ultrasound group, administered surfactant based on LUS score and/or FiO 2 threshold, and the control group, guided by FiO 2 only. Fifty-six patients were included. The ultrasound group received surfactant earlier (1 h of life vs. 6 h, p < 0.001), with lower FiO 2 (25% vs. 30%, p = 0.016) and lower CO 2 (48 vs. 54, p = 0.011). After surfactant treatment, newborns in the ultrasound group presented a greater SpO 2 (p = 0.001) and SpO 2 /FiO 2 ratio (p = 0.012).Conclusions: LUS score allowed an earlier surfactant therapy, reduced oxygen exposure early in life and a better oxygenation after the treatment. This early surfactant replacement may lead to reduced oxygen exposure. What is Known: • Lung ultrasound scores predict the need for surfactant therapy in premature newborns. What is New: • This study shows that using lung ultrasound scores improves the timeliness of surfactant replacement compared with using FiO 2 alone.",2020,"The ultrasound group received surfactant earlier (1 h of life vs. 6 h, p < 0.001), with lower FiO 2 (25% vs. 30%, p = 0.016) and lower CO 2 (48 vs. 54, p = 0.011).","['premature newborns', 'preterm newborns with RDS', 'Patients meeting the inclusion criteria', 'newborns with a gestational age of ≤ 32 weeks and RDS', 'premature newborns with respiratory distress syndrome (RDS', 'Fifty-six patients were included']","['surfactant replacement guided by lung ultrasound', 'surfactant therapy', 'lung ultrasound (LUS) scores', 'ultrasound group, administered surfactant based on LUS score and/or FiO 2 threshold, and the control group, guided by FiO 2 only']",['oxygen exposure early in life and a better oxygenation'],"[{'cui': 'C0233315', 'cui_str': 'Premature birth of newborn'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0035220', 'cui_str': 'Respiratory distress syndrome in the newborn'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0034085', 'cui_str': 'Lung surfactant'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C4286019', 'cui_str': 'Lung ultrasound'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}]",56.0,0.110221,"The ultrasound group received surfactant earlier (1 h of life vs. 6 h, p < 0.001), with lower FiO 2 (25% vs. 30%, p = 0.016) and lower CO 2 (48 vs. 54, p = 0.011).","[{'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Rodriguez-Fanjul', 'Affiliation': 'Neonatal Intensive Care Unit, Paediatrics Department, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. javier.rodriguez.fanjul@gmail.com.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Jordan', 'Affiliation': 'Paediatric Intensive Care Unit, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Balaguer', 'Affiliation': 'Paediatric Intensive Care Unit, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Batista-Muñoz', 'Affiliation': 'Neonatal Intensive Care Unit, Paediatrics Department, Hospital Joan XXIII, Tarragona, Spain.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ramon', 'Affiliation': 'Neonatal Intensive Care Unit, Paediatrics Department, Hospital Joan XXIII, Tarragona, Spain.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Bobillo-Perez', 'Affiliation': 'Paediatric Intensive Care Unit, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.'}]",European journal of pediatrics,['10.1007/s00431-020-03744-y'] 2861,32710498,Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.,"PURPOSE We explored the potential overall survival (OS) benefit of bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine, and prednisone (BEACOPP) over doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (ABVD) in a pooled analysis of four randomized trials. PATIENTS AND METHODS Primary objective was to evaluate the OS impact of BEACOPP using individual patient data. Secondary objectives were progression-free survival (PFS), secondary cancers, and use of autologous stem cell transplantation (ASCT). RESULTS About 1227 patients were included. The 7-year OS was 84.3% (95% CI 80.8-87.2) for ABVD vs 87.7% (95% CI 84.5-90.2) for BEACOPP. Two follow-up periods were identified based on survival curves and hazard ratio (HR) over time. For the first 18 months, there was no difference. For the second period of ≥18 months, ABVD patients had a higher death risk (HR ABVD vs BEACOPP  = 1.59; 95% CI 1.09-2.33). A Cox model stratified by trial and evaluating the effect of treatment and International Prognostic Index (IPI) score as fixed effects showed that both were statistically significant (treatment, P = .0185; IPI score, P = .0107). The 7-year PFS was 71.1% (95% CI 67.1-74.6) for ABVD vs 81.1% (95% CI 77.5-84.2) for BEACOPP (P < .001). After ABVD, 25 secondary cancers (4.0%) were reported with no myelodysplasia (MDS)/acute myeloid leukemia (AML) compared to 36 (6.5%) after BEACOPP, which included 13 patients with MDS/AML. Following ABVD, 86 patients (13.8%) received ASCT vs 39 (6.4%) for BEACOPP. CONCLUSIONS This analysis showed a slight improvement in OS for BEACOPP and confirmed a PFS benefit. Frontline use of BEACOPP instead of ABVD increased secondary leukemia incidence but halved the requirement for ASCT.",2020,The 7-year OS was 84.3% (95% CI 80.8-87.2) for ABVD vs 87.7% (95% CI 84.5-90.2) for BEACOPP.,"['1227 patients were included', 'advanced Hodgkin lymphoma']","['bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine, and prednisone (BEACOPP) over doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (ABVD', 'BEACOPP', 'ASCT']","['secondary leukemia incidence', 'survival and toxicities of ABVD', 'death risk (HR ABVD', 'International Prognostic Index (IPI) score', 'progression-free survival (PFS), secondary cancers, and use of autologous stem cell transplantation (ASCT', 'survival curves and hazard ratio (HR', '7-year PFS', '7-year OS', 'no myelodysplasia (MDS)/acute myeloid leukemia (AML']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0019829', 'cui_str': 'Hodgkin lymphoma'}]","[{'cui': 'C0005740', 'cui_str': 'Bleomycin'}, {'cui': 'C0015133', 'cui_str': 'Etoposide'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0033223', 'cui_str': 'Procarbazine'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0042670', 'cui_str': 'Vinblastine'}, {'cui': 'C0010927', 'cui_str': 'Dacarbazine'}, {'cui': 'C0050380', 'cui_str': 'ABVD-I protocol'}, {'cui': 'C1831743', 'cui_str': 'Transplantation of autologous hematopoietic stem cell'}]","[{'cui': 'C0856053', 'cui_str': 'Leukemia secondary'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0050380', 'cui_str': 'ABVD-I protocol'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1512894', 'cui_str': 'International Prognostic Index'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C1831743', 'cui_str': 'Transplantation of autologous hematopoietic stem cell'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0026985', 'cui_str': 'Myelodysplasia'}, {'cui': 'C0023470', 'cui_str': 'Myeloid leukemia'}, {'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}]",13.0,0.38091,The 7-year OS was 84.3% (95% CI 80.8-87.2) for ABVD vs 87.7% (95% CI 84.5-90.2) for BEACOPP.,"[{'ForeName': 'Marc P E', 'Initials': 'MPE', 'LastName': 'André', 'Affiliation': 'Hematology Department, CHU UCL Namur, Yvoir, Belgium.'}, {'ForeName': 'Patrice', 'Initials': 'P', 'LastName': 'Carde', 'Affiliation': 'Institut Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Simonetta', 'Initials': 'S', 'LastName': 'Viviani', 'Affiliation': 'Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Bellei', 'Affiliation': ""Fondazione Italiana Limfomi, Dipartimento di Scienze Medische e Chirurgiche Materno-Infantili e dell'Adulto, University of Modena, e Reggio Emilia, Modena, Italy.""}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Fortpied', 'Affiliation': 'European Organisation for Research and Treatment of Cancer, Brussels, Belgium.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hutchings', 'Affiliation': 'Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Alessandro M', 'Initials': 'AM', 'LastName': 'Gianni', 'Affiliation': 'Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Brice', 'Affiliation': 'APHP Hopital Saint-louis, Hemato-oncologie, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Casasnovas', 'Affiliation': 'Hematology department and INSERM1231, Hôpital F. Mitterand, Dijon, France.'}, {'ForeName': 'Paolo G', 'Initials': 'PG', 'LastName': 'Gobbi', 'Affiliation': 'Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo and Università degli Studi di Pavia, Pavia, Italy.'}, {'ForeName': 'Pier Luigi', 'Initials': 'PL', 'LastName': 'Zinzani', 'Affiliation': 'Institute of Hematology ""Seràgnoli"", University of Bologna, Bologna, Italy.'}, {'ForeName': 'Jehan', 'Initials': 'J', 'LastName': 'Dupuis', 'Affiliation': 'Unité Hémopathies Lymphoïdes, AP-HP Hôpital Henri Mondor, Créteil, France.'}, {'ForeName': 'Emilio', 'Initials': 'E', 'LastName': 'Iannitto', 'Affiliation': 'Department of Oncology, Haematology Unit, AOU Policlinico P. Giaccone, Palermo, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Rambaldi', 'Affiliation': 'Department of Oncology-Hematology, Università degli Studi di Milano e Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Josette', 'Initials': 'J', 'LastName': 'Brière', 'Affiliation': 'APHP Hopital Saint-louis, Hemato-oncologie, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.'}, {'ForeName': 'Laurianne', 'Initials': 'L', 'LastName': 'Clément-Filliatre', 'Affiliation': 'Department of Hematology, CHU Nancy, Nancy, France.'}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Heczko', 'Affiliation': 'Department of Hematology, Besancon Hospital, Besancon, France.'}, {'ForeName': 'Pinuccia', 'Initials': 'P', 'LastName': 'Valagussa', 'Affiliation': 'Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Douxfils', 'Affiliation': 'Department of Pharmacy, Namur Thrombosis and Hemostasis Centre (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Depaus', 'Affiliation': 'Hematology Department, CHU UCL Namur, Yvoir, Belgium.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Federico', 'Affiliation': 'Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance, University of Modena and Reggio Emilia, Centro Oncologico Modenese, Modena, Italy.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Mounier', 'Affiliation': 'Department of Onco-Haematology, Archet Hospital, Nice, France.'}]",Cancer medicine,['10.1002/cam4.3298'] 2862,32710584,"The use of acellular porcine dermis, hyaluronic acid and polynucleotides in the treatment of cutaneous ulcers: Single blind randomised clinical trial.","Reconstruction of chronic ulcers is often hampered by lack of local tissues and poor general conditions. Conservative approaches with debridement and advanced medications, such as polyurethane foam, stand as mainstays. However, the healing process is often slow, thus increasing the risk for infection or other complications. In such cases, porcine dermis (PD) and polynucleotides-added hyaluronic acid (PAHA) were previously reported to accelerate healing. The aim of the study was to compare the efficacy of PD, PAHA and polyurethane foam in chronic ulcers. Thirty patients were randomly divided into 3 groups: group 1 was treated with advanced medications, group 2 with PD, group 3 with PAHA. Standardised photographs and biopsies were taken before treatment and at 30-day follow-up. Photographs were processed to calculate the wound area. Specimens were stained with Haematoxylin/Eosin, Masson trichrome, and immunohistochemically for CD34, alpha-Smooth Muscle Actin (α-SMA), Collagen types I and III, Ki67. The re-epithelialized area was larger in patients treated with PD and PAHA compared with those treated with polyurethane foam (P < .05 and P < .01, respectively). Specimens from patients treated with PD and PAHA showed a higher number of myofibroblasts (α-SMA+, P < .01), neo-angiogenesis (CD34+, P < .01), proliferating dermal cells (Ki67+, P < .01), proliferating keratinocytes (Ki67+, P < .01) and collagen type 1 deposition (P < .05). No difference was found between PD and PAHA. PD and PAHA proved to be more effective than polyurethane foam in the treatment of chronic ulcers. These approaches are a versatile and reliable option to address such cases.",2020,"The re-epithelialized area was larger in patients treated with PD and PAHA compared with those treated with polyurethane foam (P < .05 and P < .01, respectively).","['cutaneous ulcers', 'chronic ulcers', 'Thirty patients']","['acellular porcine dermis, hyaluronic acid and polynucleotides', 'PD, PAHA and polyurethane foam', 'advanced medications, group 2 with PD, group 3 with PAHA', 'polyurethane foam', 'PD and PAHA']","['number of myofibroblasts (α-SMA', 'collagen type 1 deposition', 'proliferating keratinocytes', 'proliferating dermal cells', 'PD and PAHA', 'neo-angiogenesis (CD34']","[{'cui': 'C0037299', 'cui_str': 'Skin ulcer'}, {'cui': 'C0333297', 'cui_str': 'Chronic ulcer'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0039005', 'cui_str': 'Suidae'}, {'cui': 'C0011646', 'cui_str': 'Dermis structure'}, {'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0032550', 'cui_str': 'Polynucleotide'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0071696', 'cui_str': 'polyurethane foam'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0225360', 'cui_str': 'Myofibroblast'}, {'cui': 'C0026847', 'cui_str': 'Spinal muscular atrophy'}, {'cui': 'C0041455', 'cui_str': 'Collagen Type I'}, {'cui': 'C0333562', 'cui_str': 'Deposition'}, {'cui': 'C0022567', 'cui_str': 'Keratinocyte'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0039005', 'cui_str': 'Suidae'}, {'cui': 'C0011646', 'cui_str': 'Dermis structure'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0054953', 'cui_str': 'Lymphocyte antigen CD34'}]",30.0,0.0203695,"The re-epithelialized area was larger in patients treated with PD and PAHA compared with those treated with polyurethane foam (P < .05 and P < .01, respectively).","[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Segreto', 'Affiliation': 'Department of Plastic, Reconstructive and Aesthetic Surgery, ""Campus Bio-Medico di Roma"" University, Rome, Italy.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Carotti', 'Affiliation': 'Laboratory of Microscopical and Ultrastructural Anatomy, ""Campus Bio-Medico di Roma"" University, Rome, Italy.'}, {'ForeName': 'Giovanni Francesco', 'Initials': 'GF', 'LastName': 'Marangi', 'Affiliation': 'Department of Plastic, Reconstructive and Aesthetic Surgery, ""Campus Bio-Medico di Roma"" University, Rome, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Francesconi', 'Affiliation': 'Laboratory of Microscopical and Ultrastructural Anatomy, ""Campus Bio-Medico di Roma"" University, Rome, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Scaramuzzino', 'Affiliation': 'Department of General and Emergency Surgery, ""Federico II"" University, Naples, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Gratteri', 'Affiliation': 'Department of Plastic, Reconstructive and Aesthetic Surgery, ""Campus Bio-Medico di Roma"" University, Rome, Italy.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Caldaria', 'Affiliation': 'Department of Plastic, Reconstructive and Aesthetic Surgery, ""Campus Bio-Medico di Roma"" University, Rome, Italy.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Morini', 'Affiliation': 'Laboratory of Microscopical and Ultrastructural Anatomy, ""Campus Bio-Medico di Roma"" University, Rome, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Persichetti', 'Affiliation': 'Department of Plastic, Reconstructive and Aesthetic Surgery, ""Campus Bio-Medico di Roma"" University, Rome, Italy.'}]",International wound journal,['10.1111/iwj.13454'] 2863,32710585,An herbal cream reduces erythema of sensitive skin.,"BACKGROUND Sensitive skin manifests itself as a syndrome defined by the occurrence of unpleasant sensations such as stinging, burning, and pruritus. Though not life-threatening, it can negatively impact the quality of people's lives because of symptoms and clinical signs. Although some skin care products can alleviate symptoms of sensitive skin, a product that can improve multiple abnormalities of sensitive skin are largely unavailable. AIMS To assess the efficacy of a newly developed herbal cream in reducing erythema. METHODS A randomized double-blind and self-controlled trial was carried out on a total of 35 volunteers. The test cream (A) was applied topically to one side of the face twice-daily, while the control cream (B) was applied to the other side of the face. Parameters were evaluated prior to, 14, and 28 days after topical applications. Primary endpoints included changes in erythema area, erythema index (EI), and a* value. Transepidermal water loss rates (TEWL), stratum corneum (SC) hydration, and lactic acid sting test (LAST) score, as well as the L* value, served as secondary endpoints. RESULT Treatments with either cream A or B markedly reduced erythema area, EI, and a* value. Significant reductions in both TEWL and L* value were also observed following topical applications of either cream A or B. Moreover, cream A decreased LAST score. Finally, the satisfaction rate of cream A was higher than that of cream B. CONCLUSION The new herbal cream improves cutaneous biophysical properties in subjects with sensitive skin, especially in reducing erythema.",2020,"Treatments with either cream A or B markedly reduced erythema area, EI, and a* value.","['35 volunteers', 'subjects with sensitive skin']",['herbal cream'],"['erythema area, EI, and a* value', 'satisfaction rate of cream A', 'LAST score', 'changes in erythema area, erythema index (EI), and a* value', 'cutaneous biophysical properties', 'erythema of sensitive skin', 'Transepidermal water loss rates (TEWL), stratum corneum (SC) hydration, and lactic acid sting test (LAST) score, as well as the L* value, served as secondary endpoints']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C4228089', 'cui_str': 'Sensitive skin'}]","[{'cui': 'C0376667', 'cui_str': 'Herbals'}, {'cui': 'C0700385', 'cui_str': 'Cream'}]","[{'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0064582', 'cui_str': 'lactic acid'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0005553', 'cui_str': 'Biophysics'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C4228089', 'cui_str': 'Sensitive skin'}, {'cui': 'C0232421', 'cui_str': 'Transepidermal water loss rate'}, {'cui': 'C0221921', 'cui_str': 'Stratum corneum structure'}, {'cui': 'C1321013', 'cui_str': 'Hydration status'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}]",35.0,0.0221458,"Treatments with either cream A or B markedly reduced erythema area, EI, and a* value.","[{'ForeName': 'Yuanjin', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, China.'}, {'ForeName': 'Yumei', 'Initials': 'Y', 'LastName': 'Jin', 'Affiliation': 'Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, China.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Humbert', 'Affiliation': 'Research Center on the Integument (CERT) Besancon, Ornans, France.'}, {'ForeName': 'Xiaoqing', 'Initials': 'X', 'LastName': 'Fan', 'Affiliation': 'Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, China.'}, {'ForeName': 'Yusi', 'Initials': 'Y', 'LastName': 'Cha', 'Affiliation': 'Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, China.'}, {'ForeName': 'Yanni', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Department of Dermatology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'He', 'Affiliation': 'Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, China.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13610'] 2864,32710606,The Perceived Opportunity to Avoid Pain Paradoxically Increases Pain-Related Fear Through Increased Threat Appraisals.,"BACKGROUND Although pain-related avoidance is mainly intended to reduce the accompanying anticipatory fear, avoidance behavior may paradoxically increase fear when a previous avoidance response is no longer available, suggesting that there is a bidirectional relationship between pain-related fear and avoidance. PURPOSE We hypothesized that avoidance can serve as a source of information that fuels irrational pain-related threat appraisals, which, in turn, increases pain-related fear. METHODS Participants (N = 66) were exposed to a painful heat stimulus and randomly assigned to the avoidance or control group. They were instructed to avoid the full heat intensity by pressing a stop button in the presence of a stop cue. Only avoidance group participants received a stop cue and were allowed to press the stop button, while control group participants received the same instructions but never had the opportunity to avoid the full heat intensity. In reality and unknown to participants, the intensity and duration of the heat stimulus was independent of the avoidance response. In the subsequent test phase, the avoidance response was unavailable for both groups. We measured pain-related fear, threat appraisals/harmfulness, and pain intensity. RESULTS In line with our expectations, pain-related fear levels were higher when the avoidance response was no longer available compared to those when the avoidance response was available. Increased threat appraisals mediated the relationship between avoidance behavior and increased pain-related fear. CONCLUSIONS The perceived opportunity to avoid increased pain-related fear through threat appraisals, suggesting a more complicated relationship between pain-related fear, threat appraisals, and avoidance behavior than the unidirectional relationships proposed in the fear-avoidance model. Clinical implications are discussed.",2020,"In line with our expectations, pain-related fear levels were higher when the avoidance response was no longer available compared to those when the avoidance response was available.",['Participants (N = 66'],"['stop cue and were allowed to press the stop button, while control group participants received the same instructions but never had the opportunity to avoid the full heat intensity', 'painful heat stimulus and randomly assigned to the avoidance or control group']","['pain-related fear, threat appraisals/harmfulness, and pain intensity', 'pain-related fear levels', 'avoidance response', 'pain-related fear']",[],"[{'cui': 'C0450446', 'cui_str': 'Stops'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0453985', 'cui_str': 'Button'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C1319227', 'cui_str': 'Level of fear'}]",66.0,0.0328777,"In line with our expectations, pain-related fear levels were higher when the avoidance response was no longer available compared to those when the avoidance response was available.","[{'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'van Vliet', 'Affiliation': 'Research Group Health Psychology, Faculty of Psychology and Educational Sciences, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Meulders', 'Affiliation': 'Research Group Health Psychology, Faculty of Psychology and Educational Sciences, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Linda M G', 'Initials': 'LMG', 'LastName': 'Vancleef', 'Affiliation': 'Experimental Health Psychology, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Johan W S', 'Initials': 'JWS', 'LastName': 'Vlaeyen', 'Affiliation': 'Research Group Health Psychology, Faculty of Psychology and Educational Sciences, KU Leuven, Leuven, Belgium.'}]",Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,['10.1093/abm/kaaa045'] 2865,32704266,Comparison of efficacy of Tranexamic Acid Mesotherapy versus 0.9% normal Saline for Melasma; A split face study in a Tertiary Care Hospital of Karachi.,"Objectives To compare the efficacy of tranexamic acid mesotherapy versus 0.9% normal saline for melasma by split-face study. Methods It was a non-randomized clinical trial performed at the Dermatology ward of JPMC from September 2018 to June 2019 after getting approval from the Ethical Committee. A total of sixty patients were recruited in the study, who had symmetrical melasma on their faces. Both halves of the face were treated by Injection Tranexamic Acid (TA) with a dose of 4mg/ml and Normal Saline (NS) two weekly for twelve weeks. Hemi Modified Melasma Area and Severity Scoring (H-mMASI) was calculated at the start and end of the study. Analyses were done by SPSS version 23. P < 0.05 was taken as significant. Results Mean of H-mMASI score was compared on both sides at the end of study, which showed significant reduction in mean score from 3.19 ±2.57 to 1.52 ± 1.2 (P < 0.05) on A side as compared to decline in scores on NS side from 3.46 ± 2.7 to 3.45 ± 2.6 (P > 0.05). Erythema, swelling, and burning were documented as temporary side effects on both sides. Conclusion Tranexamic Acid (TA) mesotherapy can be considered as the most cost-effective, safe and directly observed therapy for melasma which showed significant improvement when old prior therapies have failed.",2020,"Mean of H-mMASI score was compared on both sides at the end of study, which showed significant reduction in mean score from 3.19 ±2.57 to 1.52 ± 1.2 (P < 0.05) on A side as compared to decline in scores on NS side from 3.46 ± 2.7 to 3.45 ± 2.6 (P > 0.05).","['Melasma; A split face study in a Tertiary Care Hospital of Karachi', 'from September 2018 to June 2019 after getting approval from the Ethical Committee', 'melasma by split-face study', 'A total of sixty patients were recruited in the study, who had symmetrical melasma on their faces']","['Injection Tranexamic Acid (TA', 'Tranexamic Acid (TA) mesotherapy', 'tranexamic acid mesotherapy', 'Tranexamic Acid Mesotherapy', 'JPMC']","['Mean of H-mMASI score', 'Erythema, swelling, and burning', 'Hemi Modified Melasma Area and Severity Scoring (H-mMASI']","[{'cui': 'C0025218', 'cui_str': 'Chloasma'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0337954', 'cui_str': 'Tertiary care hospital'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0026531', 'cui_str': 'Morality'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332516', 'cui_str': 'Symmetrical'}]","[{'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C2242515', 'cui_str': 'Mesotherapy'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1285521', 'cui_str': 'Hemi'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0025218', 'cui_str': 'Chloasma'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0000912', 'cui_str': 'Accident caused by unspecified fire'}]",60.0,0.110519,"Mean of H-mMASI score was compared on both sides at the end of study, which showed significant reduction in mean score from 3.19 ±2.57 to 1.52 ± 1.2 (P < 0.05) on A side as compared to decline in scores on NS side from 3.46 ± 2.7 to 3.45 ± 2.6 (P > 0.05).","[{'ForeName': 'Sana', 'Initials': 'S', 'LastName': 'Kaleem', 'Affiliation': 'Dr. Sana Kaleem, MBBS, FCPS II Trainee., Department of Dermatology, Jinnah Postgraduate Medical Centre, Karachi, Pakistan.'}, {'ForeName': 'Rabia', 'Initials': 'R', 'LastName': 'Ghafoor', 'Affiliation': 'Dr. Rabia Ghafoor, MBBS, FCPS. Assistant Professor, Department of Dermatology, Jinnah Postgraduate Medical Centre, Karachi, Pakistan.'}, {'ForeName': 'Sidra', 'Initials': 'S', 'LastName': 'Khan', 'Affiliation': 'Dr. Sidra Khan, MBBS, FCPS II Trainee., Department of Dermatology, Jinnah Postgraduate Medical Centre, Karachi, Pakistan.'}]",Pakistan journal of medical sciences,['10.12669/pjms.36.5.2379'] 2866,32704272,"Effects of fragility fracture integrated rehabilitation management on mobility, activity of daily living and cognitive functioning in elderly with hip fracture.","Objective To determine the effectiveness of Fragility Fracture Integrated Rehabilitation Management (FIRM) on mobility, activity of daily living and cognitive functioning in elderly with hip fracture. Methods A randomized control trial was conducted at Seoul National University Bundang Hospital, South Korea from August 2017 to January 2018. Patients of both genders with the age 65-95 years, diagnosed cases of hip fracture specifically fractures neck of femur, intertrochanteric, subtrochantric, patients who got bipolar hemiarthroplasty, total hip replacement arthroplasty, reduction and internal fixation were included in this study. A total of n=39 sample was collected through non probability convenience sampling technique and randomly divided into Fragility Integrated Rehabilitation Management (FIRM) group (n=20) and Conventional Physical therapy (CPT) group (n=19). The data was collected through KOVAL for walking ability, modified barthal index (MBI) for behaviors related to activities of daily living (ADLS) and mini mental status examination (MMSE) for cognitive functions at baseline on 2 nd postoperative day and after 10 th FIRM session on 15 th postoperative day. Results The mean age of study participants was 82.07±6.00 years. The post intervention comparison did not show any significant difference ( p >0.05) in walking ability, overall ADLs and cognitive functioning. But FIRM group showed significant improvement in stair climbing {0(5) ver. 2(7.5), p =0.049} and ambulation or walker use {8(5) ver. 2(4), p =0.037}, as compared to CPT group. Conclusion Both groups improved in indoor mobility with walker and crutches as well as activities of daily living. But FIRM showed more improving ambulation with walker and stair climbing. While cognitive functioning was observed only in FIRM group.",2020,"The post intervention comparison did not show any significant difference ( p >0.05) in walking ability, overall ADLs and cognitive functioning.","['Patients of both genders with the age 65-95 years, diagnosed cases of hip fracture specifically fractures neck of femur, intertrochanteric, subtrochantric, patients who got bipolar hemiarthroplasty, total hip replacement arthroplasty, reduction and internal fixation were included in this study', 'Seoul National University Bundang Hospital, South Korea from August 2017 to January 2018', 'elderly with hip fracture', 'A total of n=39 sample was collected through non probability convenience sampling technique and randomly divided into']","['Fragility Fracture Integrated Rehabilitation Management (FIRM', 'Fragility Integrated Rehabilitation Management (FIRM) group (n=20) and Conventional Physical therapy (CPT', 'fragility fracture integrated rehabilitation management']","['ambulation with walker and stair climbing', 'cognitive functioning', 'mobility, activity of daily living and cognitive functioning', 'walking ability, modified barthal index (MBI) for behaviors related to activities of daily living (ADLS) and mini mental status examination (MMSE) for cognitive functions', 'walking ability, overall ADLs and cognitive functioning', 'indoor mobility with walker and crutches as well as activities of daily living']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0015806', 'cui_str': 'Fracture of neck of femur'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0443156', 'cui_str': 'Bipolar'}, {'cui': 'C0744743', 'cui_str': 'Hemi-Arthroplasty'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0003893', 'cui_str': 'Arthroplasty'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C3850150', 'cui_str': 'Seoul'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0332849', 'cui_str': 'Divide'}]","[{'cui': 'C4760971', 'cui_str': 'Fragility fracture'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0302113', 'cui_str': 'Fragility'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}]","[{'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0043016', 'cui_str': 'Walker'}, {'cui': 'C1290942', 'cui_str': 'Climbing stairs'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0559964', 'cui_str': 'Ability to walk'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0010397', 'cui_str': 'Crutches'}]",,0.0246572,"The post intervention comparison did not show any significant difference ( p >0.05) in walking ability, overall ADLs and cognitive functioning.","[{'ForeName': 'Anam', 'Initials': 'A', 'LastName': 'Aftab', 'Affiliation': 'Dr. Anam Aftab, PhD., Riphah College of rehabilitation Sciences, Riphah International University, Islamabad, Pakistan.'}, {'ForeName': 'Waqar Ahmed', 'Initials': 'WA', 'LastName': 'Awan', 'Affiliation': 'Dr. Waqar Ahmad Awan, PhD., Riphah College of rehabilitation Sciences, Riphah International University, Islamabad, Pakistan.'}, {'ForeName': 'Shaista', 'Initials': 'S', 'LastName': 'Habibullah', 'Affiliation': 'Dr. Shaista Habibullah, PhD. National Institute of Rehabilitation Medicine, Islamabad Pakistan.'}, {'ForeName': 'Jae Young', 'Initials': 'JY', 'LastName': 'Lim', 'Affiliation': 'Dr. Jae Young Lim, PhD. Seoul National University, Bundang Hospital, South Korea.'}]",Pakistan journal of medical sciences,['10.12669/pjms.36.5.2412'] 2867,32704294,Clinical effect of decitabine in the treatment of myelodysplastic syndrome and influencing factors.,"Objective To analyze the effect of decitabine combined with conventional chemotherapy on myelodysplastic syndrome (MDS) and its influencing factors. Methods Eighty patients with MDS who were admitted to our hospital were selected by this study between February 2017 and February 2018. The selected patients were divided into a traditional group (CAG/DA scheme) and the combined group (DAC combined with CAG/DA scheme) according to the random number table method, 40 each. The clinical treatment effects of the two groups were compared, and the influencing factors of the effect were analyzed. Results After four courses of treatment, the difference in the total effective rate between the two groups were statistically significant (P<0.05); the difference in the incidence of adverse reactions and in the overall survival (OS) rate between the two groups were not statistically significant (P>0.05). However, the progression free survival (PFS) rate of the combined group was significantly higher compared with the traditional group (P<0.05); the Hb level, WHO stage and and karyotype of the patients before treatment had significant influence on the treatment effect (P<0.05). Conclusion DAC in combination with conventional chemotherapy has good effect in the treatment of MDS, and it will not increase adverse reactions. In addition to treatment scheme, the influencing factors of the effect of treatment for MDS also include Hb, WHO stage and karyotype.",2020,"After four courses of treatment, the difference in the total effective rate between the two groups were statistically significant (P<0.05); the difference in the incidence of adverse reactions and in the overall survival (OS) rate between the two groups were not statistically significant (P>0.05).",['Eighty patients with MDS who were admitted to our hospital were selected by this study between February 2017 and February 2018'],"['decitabine', 'decitabine combined with conventional chemotherapy', 'conventional chemotherapy', 'traditional group (CAG/DA scheme) and the combined group (DAC combined with CAG/DA scheme']","['total effective rate', 'progression free survival (PFS) rate', 'incidence of adverse reactions', 'myelodysplastic syndrome (MDS', 'adverse reactions', 'overall survival (OS) rate']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2347761', 'cui_str': 'Childhood myelodysplastic syndrome'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0049065', 'cui_str': 'decitabine'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C2347761', 'cui_str': 'Childhood myelodysplastic syndrome'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",80.0,0.0290989,"After four courses of treatment, the difference in the total effective rate between the two groups were statistically significant (P<0.05); the difference in the incidence of adverse reactions and in the overall survival (OS) rate between the two groups were not statistically significant (P>0.05).","[{'ForeName': 'Tangxia', 'Initials': 'T', 'LastName': 'Liu', 'Affiliation': ""Tangxia Liu, Hematology Department, Binzhou People's Hospital, Shandong, 256610, China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""Jing Wang, Mental Health Center, Binzhou People's Hospital, Shandong, 256610, China.""}, {'ForeName': 'Chunmei', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': ""Chunmei Li, Digestive Endoscopy Center, Binzhou People's Hospital, Shandong, 256610, China.""}, {'ForeName': 'Lingzhi', 'Initials': 'L', 'LastName': 'Jia', 'Affiliation': 'Lingzhi Jia, Hematology Department, Binzhou Medical University Hospital, Shandong, 256603, China.'}]",Pakistan journal of medical sciences,['10.12669/pjms.36.5.2289'] 2868,32704386,"Erratum: Author Correction: Antibody responses to the RTS,S/AS01 E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique.",[This corrects the article DOI: 10.1038/s41541-020-0192-7.].,2020,[This corrects the article DOI: 10.1038/s41541-020-0192-7.].,['Erratum'],[],[],[],[],[],,0.0161305,[This corrects the article DOI: 10.1038/s41541-020-0192-7.].,"[{'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Sánchez', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Vidal', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.'}, {'ForeName': 'Chenjerai', 'Initials': 'C', 'LastName': 'Jairoce', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Aguilar', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.'}, {'ForeName': 'Itziar', 'Initials': 'I', 'LastName': 'Ubillos', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.'}, {'ForeName': 'Inocencia', 'Initials': 'I', 'LastName': 'Cuamba', 'Affiliation': 'Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.'}, {'ForeName': 'Augusto J', 'Initials': 'AJ', 'LastName': 'Nhabomba', 'Affiliation': 'Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.'}, {'ForeName': 'Nana Aba', 'Initials': 'NA', 'LastName': 'Williams', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.'}, {'ForeName': 'Núria', 'Initials': 'N', 'LastName': 'Díez-Padrisa', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cavanagh', 'Affiliation': ""Institute of Immunology & Infection Research and Centre for Immunity, Infection & Evolution, Ashworth Laboratories, School of Biological Sciences, University of Edinburgh, King's Buildings, Edinburgh, UK.""}, {'ForeName': 'Evelina', 'Initials': 'E', 'LastName': 'Angov', 'Affiliation': 'U.S. Military Malaria Vaccine Program, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD USA.'}, {'ForeName': 'Ross L', 'Initials': 'RL', 'LastName': 'Coppel', 'Affiliation': 'Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, VIC Australia.'}, {'ForeName': 'Deepak', 'Initials': 'D', 'LastName': 'Gaur', 'Affiliation': 'Malaria Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.'}, {'ForeName': 'James G', 'Initials': 'JG', 'LastName': 'Beeson', 'Affiliation': 'Burnet Institute, Melbourne, VIC Australia.'}, {'ForeName': 'Sheetij', 'Initials': 'S', 'LastName': 'Dutta', 'Affiliation': 'U.S. Military Malaria Vaccine Program, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD USA.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Aide', 'Affiliation': 'Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.'}, {'ForeName': 'Joseph J', 'Initials': 'JJ', 'LastName': 'Campo', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.'}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Moncunill', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.'}, {'ForeName': 'Carlota', 'Initials': 'C', 'LastName': 'Dobaño', 'Affiliation': 'ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.'}]",NPJ vaccines,['10.1038/s41541-020-00213-3'] 2869,30919515,Mechanical-ventilatory responses to peak and ventilation-matched upper- versus lower-body exercise in normal subjects.,"NEW FINDINGS What is the central question of this study? To what extent are the mechanical-ventilatory responses to upper-body exercise influenced by task-specific locomotor mechanics? What is the main finding and its importance? When compared with lower-body exercise performed at similar ventilations, upper-body exercise was characterized by tidal volume constraint, dynamic lung hyperinflation and an increased propensity towards neuromechanical uncoupling of the respiratory system. Importantly, these responses were independent of respiratory dysfunction and flow limitation. Thus, the mechanical ventilatory responses to upper-body exercise are attributable, in part, to task-specific locomotor mechanics (i.e. non-respiratory loading of the thorax). ABSTRACT The aim of this study was to determine the extent to which the mechanical ventilatory responses to upper-body exercise are influenced by task-specific locomotor mechanics. Eight healthy men (mean ± SD: age, 24 ± 5 years; mass, 74 ± 11 kg; and stature, 1.79 ± 0.07 m) completed two maximal exercise tests, on separate days, comprising 4 min stepwise increments of 15 W during upper-body exercise (arm-cranking) or 30 W during lower-body exercise (leg-cycling). The tests were repeated at work rates calculated to elicit 20, 40, 60, 80 and 100% of the peak ventilation achieved during arm-cranking ( V ̇ E , UBE ). Exercise measures included pulmonary ventilation and gas exchange, oesophageal pressure-derived indices of respiratory mechanics, operating lung volumes and expiratory flow limitation. Subjects exhibited normal resting pulmonary function. Arm-crank exercise elicited significantly lower peak values for work rate, O 2 uptake, CO 2 output, minute ventilation and tidal volume (p < 0.05). At matched ventilations, arm-crank exercise restricted tidal volume expansion relative to leg-cycling exercise at 60% V ̇ E , UBE (1.74 ± 0.61 versus 2.27 ± 0.68 l, p < 0.001), 80% V ̇ E , UBE (2.07 ± 0.70 versus 2.52 ± 0.67 l, p < 0.001) and 100% V ̇ E , UBE (1.97 ± 0.85 versus 2.55 ± 0.72 l, p = 0.002). Despite minimal evidence of expiratory flow limitation, expiratory reserve volume was significantly higher during arm-cranking versus leg-cycling exercise at 100% V ̇ E , UBE (39 ± 8 versus 29 ± 8% of vital capacity, p = 0.002). At any given ventilation, arm-cranking elicited greater inspiratory effort (oesophageal pressure) relative to thoracic displacement (tidal volume). Arm-cranking exercise is sufficient to provoke respiratory mechanical derangements (restricted tidal volume expansion, dynamic hyperinflation and neuromechanical uncoupling) in subjects with normal pulmonary function and expiratory flow reserve. These responses are likely to be attributable to task-specific locomotor mechanics (i.e. non-respiratory loading of the thorax).",2019,"Arm-crank exercise elicited significantly lower peak values for work rate, O 2 uptake, CO 2 output, minute ventilation and tidal volume (p < 0.05).","['Eight healthy men (mean\xa0±\xa0SD: age, 24\xa0±\xa05\xa0years; mass, 74\xa0±\xa011\xa0kg; and stature, 1.79\xa0±\xa00.07\xa0m) completed two', 'subjects with normal pulmonary function and expiratory flow reserve', 'normal subjects']","['maximal exercise tests, on separate days, comprising 4\xa0min stepwise increments of 15 W during upper-body exercise (arm-cranking) or 30 W during lower-body exercise (leg-cycling', 'Mechanical-ventilatory responses to peak and ventilation-matched upper- versus lower-body exercise']","['inspiratory effort (oesophageal pressure) relative to thoracic displacement (tidal volume', 'expiratory flow limitation, expiratory reserve volume', 'peak values for work rate, O 2 uptake, CO 2 output, minute ventilation and tidal volume', 'pulmonary ventilation and gas exchange, oesophageal pressure-derived indices of respiratory mechanics, operating lung volumes and expiratory flow limitation']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C4518239', 'cui_str': '0.07'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C1268087', 'cui_str': 'Upper body structure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C1268088', 'cui_str': 'Lower body structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1282910', 'cui_str': 'Upper'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0232531', 'cui_str': 'Esophageal pressure'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0015326', 'cui_str': 'Expiratory reserve volume'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}, {'cui': 'C1301655', 'cui_str': 'Minute ventilation'}, {'cui': 'C0035213', 'cui_str': 'Ventilation, Pulmonary'}, {'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0035230', 'cui_str': 'Breathing Mechanics'}, {'cui': 'C0231953', 'cui_str': 'Lung volume'}]",8.0,0.0219932,"Arm-crank exercise elicited significantly lower peak values for work rate, O 2 uptake, CO 2 output, minute ventilation and tidal volume (p < 0.05).","[{'ForeName': 'Nicholas B', 'Initials': 'NB', 'LastName': 'Tiller', 'Affiliation': 'Academy of Sport and Physical Activity, Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK.'}, {'ForeName': 'Ian G', 'Initials': 'IG', 'LastName': 'Campbell', 'Affiliation': 'Centre for Human Performance, Exercise and Rehabilitation, College of Health and Life Sciences, Brunel University London, Uxbridge, UK.'}, {'ForeName': 'Lee M', 'Initials': 'LM', 'LastName': 'Romer', 'Affiliation': 'Centre for Human Performance, Exercise and Rehabilitation, College of Health and Life Sciences, Brunel University London, Uxbridge, UK.'}]",Experimental physiology,['10.1113/EP087648'] 2870,31197361,Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas.,"BACKGROUND AND AIMS The long-term safety and efficacy of allogeneic bone marrow-derived mesenchymal stromal cell [bmMSC] therapy in perianal Crohn's disease [CD] fistulas is unknown. We aimed to provide a 4-year clinical evaluation of allogeneic bmMSC treatment of perianal CD fistulas. METHODS A double-blind dose-finding study for local bmMSC therapy in 21 patients with refractory perianal fistulising Crohn's disease was performed at the Leiden University Medical Center in 2012-2014. All patients treated with bmMSCs [1 x 107 bmMSCs cohort 1, n = 5; 3 × 107 bmMSCs cohort 2, n = 5; 9 × 107 bmMSCs cohort 3, n = 5] were invited for a 4-year evaluation. Clinical events were registered, fistula closure was evaluated, and anti-human leukocyte antigen [HLA] antibodies were assessed. Patients were also asked to undergo a pelvic magnetic resonance imaging [MRI] and rectoscopy. RESULTS Thirteen out of 15 patients [87%] treated with bmMSCs were available for long-term follow-up. Two non-MSC related malignancies were observed. No serious adverse events thought to be related to bmMSC therapy were found. In cohort 2 [n = 4], all fistulas were closed 4 years after bmMSC therapy. In cohort 1 [n = 4] 63%, and in cohort 3 [n = 5] 43%, of the fistulas were closed, respectively. In none of the patients anti-HLA antibodies could be detected 24 weeks and 4 years after therapy. Pelvic MRI showed significantly smaller fistula tracts after 4 years. CONCLUSIONS Allogeneic bmMSC therapy for CD-associated perianal fistulas is also in the long-term a safe therapy. In bmMSC-treated patients, fistulas with closure at Week 24 were still closed after 4 years.",2020,No serious adverse events thought to be related to bmMSC therapy were found.,"['1 x 107 bmMSCs cohort 1, n = 5; 3 × 107 bmMSCs cohort 2, n = 5; 9 × 107 bmMSCs cohort 3, n = 5] were invited for a 4-year evaluation', ""Crohn's Disease Perianal Fistulas"", ""perianal Crohn's disease [CD"", ""21 patients with refractory perianal fistulising Crohn's disease was performed at the Leiden University Medical Center in 2012-2014""]","['local bmMSC therapy', 'pelvic magnetic resonance imaging [MRI] and rectoscopy', 'Allogeneic bmMSC therapy', 'allogeneic bone marrow-derived mesenchymal stromal cell [bmMSC] therapy', 'allogeneic bmMSC', 'bmMSCs', 'Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy']",['smaller fistula tracts'],"[{'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0341395', 'cui_str': ""Perianal Crohn's disease""}, {'cui': 'C0016169', 'cui_str': 'Fistula'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0442158', 'cui_str': 'Perianal'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}]","[{'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0030797', 'cui_str': 'Pelvic'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0005953', 'cui_str': 'Bone marrow structure'}, {'cui': 'C3178844', 'cui_str': 'Mesenchymal Stromal Cells'}]","[{'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0016169', 'cui_str': 'Fistula'}]",5.0,0.046215,No serious adverse events thought to be related to bmMSC therapy were found.,"[{'ForeName': 'Marieke C', 'Initials': 'MC', 'LastName': 'Barnhoorn', 'Affiliation': 'Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Martin N J M', 'Initials': 'MNJM', 'LastName': 'Wasser', 'Affiliation': 'Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Helene', 'Initials': 'H', 'LastName': 'Roelofs', 'Affiliation': 'Department of Immunohematology and Blood Transfusion, University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'P W Jeroen', 'Initials': 'PWJ', 'LastName': 'Maljaars', 'Affiliation': 'Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Ilse', 'Initials': 'I', 'LastName': 'Molendijk', 'Affiliation': 'Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Bert A', 'Initials': 'BA', 'LastName': 'Bonsing', 'Affiliation': 'Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Liesbeth E M', 'Initials': 'LEM', 'LastName': 'Oosten', 'Affiliation': 'Department of Immunohematology and Blood Transfusion, University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Dijkstra', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'C Janneke', 'Initials': 'CJ', 'LastName': 'van der Woude', 'Affiliation': 'Deparment of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands.'}, {'ForeName': 'Dave L', 'Initials': 'DL', 'LastName': 'Roelen', 'Affiliation': 'Department of Immunohematology and Blood Transfusion, University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Jaap-Jan', 'Initials': 'JJ', 'LastName': 'Zwaginga', 'Affiliation': 'Department of Immunohematology and Blood Transfusion, University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Hein W', 'Initials': 'HW', 'LastName': 'Verspaget', 'Affiliation': 'Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Willem E', 'Initials': 'WE', 'LastName': 'Fibbe', 'Affiliation': 'Department of Immunohematology and Blood Transfusion, University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Daniel W', 'Initials': 'DW', 'LastName': 'Hommes', 'Affiliation': 'Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Koen C M J', 'Initials': 'KCMJ', 'LastName': 'Peeters', 'Affiliation': 'Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Andrea E', 'Initials': 'AE', 'LastName': 'van der Meulen-de Jong', 'Affiliation': 'Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.'}]",Journal of Crohn's & colitis,['10.1093/ecco-jcc/jjz116'] 2871,31686093,"Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer's Disease.","The engineered fusion protein NPT088 targets amyloid in vitro and in animal models of Alzheimer's disease. Previous studies showed that NPT088 treatment reduced β-amyloid plaque and tau aggregate loads in mouse disease models. Here, we present the results from an initial clinical study of NPT088 in patients with mild to moderate Alzheimer's disease. Patients were treated with 4 dose levels of NPT088 for 6 months to evaluate its safety and tolerability. Exploratory measurements included measurement of change in β-amyloid plaque and tau burden utilizing Positron Emission Tomography imaging as well as measures of Alzheimer's disease symptoms. At endpoint NPT088 was generally safe and well-tolerated with the most prominent finding being infusion reactions in a minority of patients. No effect of NPT088 on brain plaques, tau aggregates or Alzheimer's disease symptoms was observed.",2019,"No effect of NPT088 on brain plaques, tau aggregates or Alzheimer's disease symptoms was observed.","[""Alzheimer's disease symptoms"", ""patients with mild to moderate Alzheimer's disease"", ""Alzheimer's Disease""]","['Placebo', 'NPT088']","['safe and well-tolerated', 'safety and tolerability', ""brain plaques, tau aggregates or Alzheimer's disease symptoms"", 'β-amyloid plaque and tau aggregate loads']","[{'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C0205418', 'cui_str': 'Aggregate'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0333463', 'cui_str': 'Senile plaque'}]",,0.149159,"No effect of NPT088 on brain plaques, tau aggregates or Alzheimer's disease symptoms was observed.","[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Michelson', 'Affiliation': 'Richard Fisher, 125 Cambridgepark Dr. Ste 301, Cambridge MA 02140, USA, Tel: 1-857-998-1664, Email: rfisher@proclarabio.com, FAX: 1-857-320-4020.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Grundman', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Magnuson', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Fisher', 'Affiliation': ''}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Levenson', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Aisen', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Marek', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gray', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Hefti', 'Affiliation': ''}]",The journal of prevention of Alzheimer's disease,['10.14283/jpad.2019.37'] 2872,32706667,"An Internet-Based Psychological Intervention With a Serious Game to Improve Vitality, Psychological and Physical Condition, and Immune Function in Healthy Male Adults: Randomized Controlled Trial.","BACKGROUND Recently, internet-based cognitive behavioral therapy (ICBT) and serious gaming interventions have been suggested to enhance accessibility to interventions and engagement in psychological interventions that aim to promote health outcomes. Few studies, however, have investigated their effectiveness in the context of simulated real-life challenges. OBJECTIVE We aimed to examine the effectivity of a guided ICBT combined with a serious gaming intervention in improving self-reported psychophysiological and immunological health endpoints in response to psychophysiological and immune-related challenges. METHODS Sixty-nine healthy men were randomly assigned to the intervention condition, receiving ICBT combined with serious gaming for 6 weeks, or the control condition, receiving no intervention. Self-reported vitality was the primary endpoint. Other self-reported psychophysiological and immunological endpoints were assessed following various challenges, including a bacillus Calmette-Guérin vaccination evoking pro-inflammatory responses, 1 and 4 weeks after the intervention period. RESULTS Although the intervention did not affect vitality-associated parameters, self-reported sleep problems (P=.027) and bodily sensations (P=.042) were lower directly after the intervention compared with controls. Furthermore, wellbeing (P=.024) was higher in the intervention group after the psychophysiological challenges. Although no significant group differences were found for the psychophysiological and immunological endpoints, the data provided preliminary support for increased immunoglobulin antibody responses at the follow-up time points (P<.05). Differential chemokine endpoints between conditions were observed at the end of the test day. CONCLUSIONS The present study provides some support for improving health endpoints with an innovative ICBT intervention. Future research should replicate and further extend the present findings by consistently including challenges and a wide range of immune parameters into the study design. TRIAL REGISTRATION Nederlands Trial Register NTR5610; https://www.trialregister.nl/trial/5466.",2020,"Although the intervention did not affect vitality-associated parameters, self-reported sleep problems (P=.027) and bodily sensations (P=.042) were lower directly after the intervention compared with controls.","['Sixty-nine healthy men', 'Healthy Male Adults']","['ICBT combined with serious gaming for 6 weeks, or the control condition, receiving no intervention', 'guided ICBT combined with a serious gaming intervention', 'internet-based cognitive behavioral therapy (ICBT', 'Internet-Based Psychological Intervention With a Serious Game']","['vitality-associated parameters, self-reported sleep problems', 'immunoglobulin antibody responses', 'bodily sensations']","[{'cui': 'C0450388', 'cui_str': '69'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0686751', 'cui_str': 'Well male adult'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}]","[{'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnia'}, {'cui': 'C0021027', 'cui_str': 'Immunoglobulin'}, {'cui': 'C0003261', 'cui_str': 'Antibody Production'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}]",69.0,0.0729687,"Although the intervention did not affect vitality-associated parameters, self-reported sleep problems (P=.027) and bodily sensations (P=.042) were lower directly after the intervention compared with controls.","[{'ForeName': 'Lemmy', 'Initials': 'L', 'LastName': 'Schakel', 'Affiliation': 'Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, Leiden, Netherlands.'}, {'ForeName': 'Dieuwke S', 'Initials': 'DS', 'LastName': 'Veldhuijzen', 'Affiliation': 'Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, Leiden, Netherlands.'}, {'ForeName': 'Henriët', 'Initials': 'H', 'LastName': 'van Middendorp', 'Affiliation': 'Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, Leiden, Netherlands.'}, {'ForeName': 'Corine', 'Initials': 'C', 'LastName': 'Prins', 'Affiliation': 'Department of Infectious Diseases, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Anne M H F', 'Initials': 'AMHF', 'LastName': 'Drittij', 'Affiliation': 'Department of Infectious Diseases, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Vrieling', 'Affiliation': 'Department of Infectious Diseases, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Leo G', 'Initials': 'LG', 'LastName': 'Visser', 'Affiliation': 'Department of Infectious Diseases, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Tom H M', 'Initials': 'THM', 'LastName': 'Ottenhoff', 'Affiliation': 'Department of Infectious Diseases, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Simone A', 'Initials': 'SA', 'LastName': 'Joosten', 'Affiliation': 'Department of Infectious Diseases, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Andrea W M', 'Initials': 'AWM', 'LastName': 'Evers', 'Affiliation': 'Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, Leiden, Netherlands.'}]",Journal of medical Internet research,['10.2196/14861'] 2873,32706674,Novel Stepped Care Approach to Provide Education and Exercise Therapy for Patellofemoral Pain: Feasibility Study.,"BACKGROUND Patellofemoral pain (PFP) impairs joint- and health-related quality of life and may be associated with knee osteoarthritis. We developed a novel, 2-phase, stepped-care approach for PFP, combining (1) self-directed web-based education and exercise therapy with (2) physiotherapist-supported education and exercise therapy. Physiotherapy sessions can be provided using 2 different modalities: face-to-face and telerehabilitation. OBJECTIVE This study aims to (1) determine the feasibility of our stepped-care approach, (2) explore patient-reported outcomes following self-directed web-based education and exercise therapy in people with PFP (phase 1), and (3) estimate the differences in treatment effects between face-to-face and telerehabilitation to support further education and exercise therapy (phase 2) in those who had not completely recovered following self-directed care. METHODS Phase 1 involved 6 weeks of self-directed web-based education and exercise therapy. Phase 2 involved random allocation to a further 12 weeks of physiotherapist-led (up to 8 sessions) education and exercise therapy delivered face-to-face or via telerehabilitation to participants who did not rate themselves as completely recovered following phase 1. Feasibility indicators of process, adherence, and participant retention were collected as primary outcomes alongside patient-reported outcomes on Global Rating of Change and knee pain, disability, knee-related quality of life, pain catastrophism, kinesiophobia, and knee self-efficacy. All participants were assessed at baseline, 6 weeks, and 18 weeks. RESULTS A total of 71 participants were screened to identify 35 participants with PFP to enter the study. Overall, 100% (35/35) and 88% (31/35) of the participants were followed up with at 6 and 18 weeks, respectively. In phase 1 of the study, participants accessed the My Knee Cap website for an average of 6 (7.5) days and performed the exercises for an average of 2.5 (3.6) times per week. A total of 20% (7/35) of the participants reported that they had completely recovered at 6 weeks. Furthermore, 93% (26/28) of the participants who were followed up and had not completely recovered at 6 weeks agreed to be enrolled in phase 2. No statistically significant differences were found between the face-to-face and telerehabilitation groups for any outcome. The novel stepped-care approach was associated with marked improvement or complete recovery in 40% (14/35) of the participants following phase 1 and 71% (25/35) of the participants following phase 2. CONCLUSIONS Self-directed web-based education and exercise therapy for people with PFP is feasible, as noted by the high rate of participant retention and home exercise adherence achieved in this study. Furthermore, 20% (7/35) of people reported complete recovery at 6 weeks. Both face-to-face and telerehabilitation physiotherapy should be considered for those continuing to seek care, as there is no difference in outcomes between these delivery modes. Determining the efficacy of the stepped-care model may help guide more efficient health care for PFP.",2020,No statistically significant differences were found between the face-to-face and telerehabilitation groups for any outcome.,"['people with PFP (phase 1', '71 participants were screened to identify 35 participants with PFP to enter the study']","['Physiotherapy sessions', 'physiotherapist-led (up to 8 sessions) education and exercise therapy delivered face-to-face or via telerehabilitation', 'Novel Stepped Care Approach to Provide Education and Exercise Therapy', 'self-directed web-based education and exercise therapy', 'Self-directed web-based education and exercise therapy', 'PFP, combining (1) self-directed web-based education and exercise therapy with (2) physiotherapist-supported education and exercise therapy']","['Global Rating of Change and knee pain, disability, knee-related quality of life, pain catastrophism, kinesiophobia, and knee self-efficacy', 'Feasibility indicators of process, adherence, and participant retention', 'My Knee Cap website']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439559', 'cui_str': 'Phase 1'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C4042802', 'cui_str': 'Remote Rehabilitation'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0183683', 'cui_str': 'Support'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0231749', 'cui_str': 'Knee pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4285782', 'cui_str': 'Kinesiophobia'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0030647', 'cui_str': 'Bone structure of patella'}]",71.0,0.133706,No statistically significant differences were found between the face-to-face and telerehabilitation groups for any outcome.,"[{'ForeName': 'Danilo', 'Initials': 'D', 'LastName': 'De Oliveira Silva', 'Affiliation': 'La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Australia.'}, {'ForeName': 'Marcella F', 'Initials': 'MF', 'LastName': 'Pazzinatto', 'Affiliation': 'La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Australia.'}, {'ForeName': 'Kay M', 'Initials': 'KM', 'LastName': 'Crossley', 'Affiliation': 'La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Australia.'}, {'ForeName': 'Fabio M', 'Initials': 'FM', 'LastName': 'Azevedo', 'Affiliation': 'Laboratory of Biomechanics and Motor Control, Sao Paulo State University, Presidente Prudente, Brazil.'}, {'ForeName': 'Christian J', 'Initials': 'CJ', 'LastName': 'Barton', 'Affiliation': 'La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Australia.'}]",Journal of medical Internet research,['10.2196/18584'] 2874,32706681,Recruiting and Retaining Youth and Young Adults in the Policy and Communication Evaluation (PACE) Vermont Study: Randomized Controlled Trial of Participant Compensation.,"BACKGROUND The standard approach for evaluating the effects of population-level substance use prevention efforts on youth and young adult perceptions and behaviors has been to compare outcomes across states using national surveillance data. Novel surveillance methods that follow individuals over shorter time intervals and capture awareness of substance use prevention policy and communication efforts may provide a stronger basis for their evaluation than annual cross-sectional studies. OBJECTIVE This study aimed to identify a combination of strategies to recruit a sample of youth and young adults sufficiently representative of the Vermont population and determine how best to retain a web-based panel of youth and young adults over a 6-month period. METHODS Eligible participants were Vermont residents aged 12 to 25 years who were willing to complete three 10 to 15-minute web-based surveys over a 6-month period. Recruitment was conducted via the following three main mechanisms: (1) web-based recruitment (paid and unpaid), (2) community-based recruitment through partners, and (3) participant referrals via a personalized link. Upon completion of the baseline survey, participants were randomly assigned to one of the following three retention incentive conditions: (1) guaranteed incentive (US $10), (2) lottery incentive (US $50 weekly lottery drawing), and (3) preferred method (guaranteed or lottery). Analyses examined cost per survey start by recruitment source, distribution of demographic characteristics across incentive conditions, and retention by study condition at 3-month and 6-month follow-ups. RESULTS Over a 10-week period in 2019, we recruited 480 eligible youth (aged 12-17 years) and 1037 eligible young adults (aged 18-25 years) to the Policy and Communication Evaluation (PACE) Vermont Study. Facebook and Instagram advertising produced the greatest number of survey starts (n=2013), followed by posts to a state-wide web-based neighborhood forum (n=822) and Google advertisements (n=749). Retention was 78.11% (1185/1517) at 3 months and 72.18% (1095/1517) at 6 months. Retention was equivalent across all incentive study conditions at both waves, despite a strong stated preference among study participants for the guaranteed payment at baseline. Youth had greater retention than young adults at both waves (wave 2: 395/480, 82.3% vs 790/1037, 76.18%; wave 3: 366/480, 76.3% vs 729/1037, 70.30%). Substance use prevalence in this cohort was similar to national and state-level surveillance estimates for young adults, but was lower than state-level surveillance estimates for youth. Most participants retained at wave 3 provided positive qualitative feedback on their experience. CONCLUSIONS Our study supports the feasibility of recruiting a web-based cohort of youth and young adults with representation across an entire state to evaluate substance use prevention efforts. Findings suggest that a guaranteed payment immediately upon survey completion coupled with a bonus for completing all survey waves and weekly survey reminders may facilitate retention in a cohort of youth and young adults.",2020,Retention was 78.11% (1185/1517) at 3 months and 72.18% (1095/1517) at 6 months.,"['Eligible participants were Vermont residents aged 12 to 25 years who were willing to complete three 10 to 15-minute web-based surveys over a 6-month period', '480 eligible youth (aged 12-17 years) and 1037 eligible young adults (aged 18-25 years) to the Policy and Communication Evaluation (PACE) Vermont Study']","['retention incentive conditions: (1) guaranteed incentive (US $10), (2) lottery incentive (US $50 weekly lottery drawing), and (3) preferred method (guaranteed or lottery']",['Retention'],"[{'cui': 'C0042537', 'cui_str': 'Vermont'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0600109', 'cui_str': 'Willing'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1442447', 'cui_str': 'Fifteen minutes'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C4319609', 'cui_str': '480'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0450335', 'cui_str': '18/25'}, {'cui': 'C0242456', 'cui_str': 'Policy'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0013113', 'cui_str': 'Drawings'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}]",,0.157918,Retention was 78.11% (1185/1517) at 3 months and 72.18% (1095/1517) at 6 months.,"[{'ForeName': 'Andrea C', 'Initials': 'AC', 'LastName': 'Villanti', 'Affiliation': 'Department of Psychiatry, Vermont Center on Behavior and Health, University of Vermont Larner College of Medicine, Burlington, VT, United States.'}, {'ForeName': 'Christie P', 'Initials': 'CP', 'LastName': 'Vallencourt', 'Affiliation': 'Health Promotion & Disease Prevention, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Julia C', 'Initials': 'JC', 'LastName': 'West', 'Affiliation': 'Department of Psychiatry, Vermont Center on Behavior and Health, University of Vermont Larner College of Medicine, Burlington, VT, United States.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Peasley-Miklus', 'Affiliation': 'Department of Psychiatry, Vermont Center on Behavior and Health, University of Vermont Larner College of Medicine, Burlington, VT, United States.'}, {'ForeName': 'S Elisha', 'Initials': 'SE', 'LastName': 'LePine', 'Affiliation': 'Department of Psychiatry, Vermont Center on Behavior and Health, University of Vermont Larner College of Medicine, Burlington, VT, United States.'}, {'ForeName': 'Caitlin', 'Initials': 'C', 'LastName': 'McCluskey', 'Affiliation': 'Department of Psychiatry, Vermont Center on Behavior and Health, University of Vermont Larner College of Medicine, Burlington, VT, United States.'}, {'ForeName': 'Elias', 'Initials': 'E', 'LastName': 'Klemperer', 'Affiliation': 'Department of Psychiatry, Vermont Center on Behavior and Health, University of Vermont Larner College of Medicine, Burlington, VT, United States.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Priest', 'Affiliation': 'Biomedical Statistics Research Core, University of Vermont, Burlington, VT, United States.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Logan', 'Affiliation': 'Hark Inc, Burlington, VT, United States.'}, {'ForeName': 'Bill', 'Initials': 'B', 'LastName': 'Patton', 'Affiliation': 'Hark Inc, Burlington, VT, United States.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Erickson', 'Affiliation': 'Communication, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hicks', 'Affiliation': 'Health Surveillance, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Horton', 'Affiliation': 'Communication, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Shayla', 'Initials': 'S', 'LastName': 'Livingston', 'Affiliation': 'Public Health Policy, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Roemhildt', 'Affiliation': 'Health Surveillance, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Singer', 'Affiliation': 'Health Promotion & Disease Prevention, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Trutor', 'Affiliation': 'Alcohol & Drug Abuse Programs, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Rhonda', 'Initials': 'R', 'LastName': 'Williams', 'Affiliation': 'Health Promotion & Disease Prevention, Vermont Department of Health, Burlington, VT, United States.'}]",Journal of medical Internet research,['10.2196/18446'] 2875,32706692,Internet-Based Self-Management Support After High-Altitude Climate Treatment for Severe Asthma: Randomized Controlled Trial.,"BACKGROUND In patients with severe asthma, high-altitude climate treatment has been shown to improve asthma control. However, asthma symptoms and limitations may increase after finishing inpatient rehabilitation programs and returning to sea level. OBJECTIVE We assessed the effectiveness of a patient-tailored, internet-based, self-management strategy in addition to usual care after finishing high-altitude climate treatment. METHODS We performed a randomized controlled trial with a 1-year follow-up in patients from a high-altitude asthma center in Davos, Switzerland. At the end of a 12-week multidisciplinary rehabilitation program, 62 adults with asthma were randomized to receive either internet-based self-management support in addition to usual care (n=33) or usual care only after discharge (n=29). The endpoints were changes in asthma-related quality of life according to the Asthma Quality of Life Questionnaire (AQLQ) (a higher score is better) and asthma control according to the Asthma Control Questionnaire (ACQ) (a lower score is better), with a minimally important difference of 0.5 points for both. RESULTS Asthma-related quality of life and asthma control declined over time in the usual care strategy group, whereas there was a slower decline in the internet-based strategy group. For both endpoints, mixed-model analysis showed a significant positive effect in favor of internet-based self-management during follow-up (mean AQLQ score difference 0.39, 95% CI 0.092-0.69; P=.01 and ACQ score difference -0.50, 95% CI -0.86 to -0.15; P=.006), which was prominent among patients with uncontrolled asthma at discharge (AQLQ score difference 0.59, 95% CI 0.19-0.99; P=.003 and ACQ score difference -0.73, 95% CI -1.18 to -0.28; P=.002). CONCLUSIONS Internet-based self-management support was associated with a smaller decline in quality of life and asthma control as compared with usual care, especially in patients with lower asthma control, after completion of high-altitude climate treatment. Internet-based self-management support in adults with severe asthma seems feasible and effective to maintain quality of life and asthma control. TRIAL REGISTRATION The trial is registered in the Netherlands Trial Register (NTR1995).",2020,"Internet-based self-management support in adults with severe asthma seems feasible and effective to maintain quality of life and asthma control. ","['patients from a high-altitude asthma center in Davos, Switzerland', 'Severe Asthma', 'adults with severe asthma', '62 adults with asthma', 'patients with severe asthma']","['internet-based self-management support in addition to usual care (n=33) or usual care only after discharge', 'Internet-Based Self-Management Support', 'Internet-based self-management support']","['quality of life and asthma control', 'Asthma-related quality of life and asthma control', 'changes in asthma-related quality of life according to the Asthma Quality of Life Questionnaire (AQLQ) (a higher score is better) and asthma control according to the Asthma Control Questionnaire (ACQ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0238617', 'cui_str': 'High altitude'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}, {'cui': 'C0581126', 'cui_str': 'Severe asthma'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C2919686', 'cui_str': 'Asthma control questionnaire'}]",62.0,0.119011,"Internet-based self-management support in adults with severe asthma seems feasible and effective to maintain quality of life and asthma control. ","[{'ForeName': 'Thijs', 'Initials': 'T', 'LastName': 'Beerthuizen', 'Affiliation': 'Department of Biomedical Data Sciences, Section Medical Decision Making, Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Lucia H', 'Initials': 'LH', 'LastName': 'Rijssenbeek-Nouwens', 'Affiliation': 'Dutch Asthma Centre Davos, Davos, Switzerland.'}, {'ForeName': 'Sophia M', 'Initials': 'SM', 'LastName': 'van Koppen', 'Affiliation': 'Department of Biomedical Data Sciences, Section Medical Decision Making, Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Rishi J', 'Initials': 'RJ', 'LastName': 'Khusial', 'Affiliation': 'Department of Biomedical Data Sciences, Section Medical Decision Making, Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Jiska B', 'Initials': 'JB', 'LastName': 'Snoeck-Stroband', 'Affiliation': 'Department of Biomedical Data Sciences, Section Medical Decision Making, Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Jacob K', 'Initials': 'JK', 'LastName': 'Sont', 'Affiliation': 'Department of Biomedical Data Sciences, Section Medical Decision Making, Leiden University Medical Center, Leiden, Netherlands.'}]",Journal of medical Internet research,['10.2196/13145'] 2876,32706698,A Dietary Mobile App for Patients Undergoing Hemodialysis: Prospective Pilot Study to Improve Dietary Intakes.,"BACKGROUND Mobile technology has an impact on the health care sector, also within dietetics. Mobile health (mHealth) apps may be used for dietary assessment and self-monitoring, allowing for real-time reporting of food intakes. Changing eating behaviors is quite challenging, and patients undergoing hemodialysis, particularly, struggle to meet the target intakes set by dietary guidelines. Usage of mobile apps that are developed in a person-centered approach and in line with recommendations may support both patients and health care practitioners. OBJECTIVE This study is a pilot that aims at estimating the potential efficacy of a dietary intervention using a theory-based, person-centered smartphone app. Results will be used to improve both the app and a planned large-scale trial intended to assess app efficacy thoroughly. METHODS A prospective pilot study was performed at the hemodialysis unit of Al Qassimi Hospital (The Emirate of Sharjah). All patients that fulfilled the study inclusion criteria were considered eligible to be enrolled in the pilot study. Upon successful installation of the app, users met with a dietitian once a week. Outcomes were measured at baseline (T0) and 2 weeks post app usage (T1). This pilot is reported as per guidelines for nonrandomized pilot and feasibility studies and in line with the CONSORT 2010 checklist for reporting pilot or feasibility trials. RESULTS A total of 23 patients completed the pilot intervention. Mean energy intakes increased from 24.4 kcal/kg/day (SD 8.0) to 29.1 kcal/kg/day (SD 7.8) with a medium effect size (d=0.6, 95% CI 0.0-1.2). Mean protein intakes increased from 0.9 g/kg/day (SD 0.3) to 1.3 g/kg/day (SD 0.5) with a large effect size (d=1.0, 95% CI 0.4-1.6); mean intake of high biological value (%HBV) proteins also increased from 58.6% (SD 10.1) to 70.1% (SD 10.7) with a large effect size (d=1.1, 95% CI 0.5-1.7). Dietary intakes of minerals did not change, apart from sodium which decreased from a mean intake of 2218.8 mg/day (SD 631.6) to 1895.3 mg/day (SD 581.0) with a medium effect size (d=0.5, 95% CI 0.1-1.1). Mean serum phosphorus, potassium, and albumin levels did not change relevantly. Mean serum iron increased from 7.9 mg/dL (SD 2.8) to 11.5 mg/dL (SD 7.9) postintervention with a medium effect size (d=0.6, 95% CI 0.0-1.2). CONCLUSIONS This pilot study showed that the KELA.AE app has the potential to improve dietary intakes. Processes related to procedure, resources, tools, and app improvement for a future trial were assessed. A more extended intervention using a randomized controlled trial is required to estimate parameters concerning app efficacy accurately.",2020,"Mean protein intakes increased from 0.9 g/kg/day (SD 0.3) to 1.3 g/kg/day (SD 0.5) with a large effect size (d=1.0, 95% CI 0.4-1.6); mean intake of high biological value (%HBV) proteins also increased from 58.6% (SD 10.1) to 70.1% (SD 10.7) with a large effect size (d=1.1, 95% CI 0.5-1.7).","['All patients that fulfilled the study inclusion criteria were considered eligible to be enrolled in the pilot study', 'Patients Undergoing Hemodialysis', 'hemodialysis unit of Al Qassimi Hospital', '23 patients completed the pilot intervention']","['KELA.AE', 'dietary intervention']","['Mean protein intakes', 'Mean serum iron', 'mean intake of high biological value', 'Mean serum phosphorus, potassium, and albumin levels', 'Mean energy intakes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0031928', 'cui_str': 'Pilot Study'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0019005', 'cui_str': 'Hemodialysis machine'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0086153', 'cui_str': 'Diet Modification'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C1318312', 'cui_str': 'Serum iron measurement'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0032821', 'cui_str': 'Potassium'}, {'cui': 'C0201838', 'cui_str': 'Albumin measurement'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}]",23.0,0.105351,"Mean protein intakes increased from 0.9 g/kg/day (SD 0.3) to 1.3 g/kg/day (SD 0.5) with a large effect size (d=1.0, 95% CI 0.4-1.6); mean intake of high biological value (%HBV) proteins also increased from 58.6% (SD 10.1) to 70.1% (SD 10.7) with a large effect size (d=1.1, 95% CI 0.5-1.7).","[{'ForeName': 'Cosette', 'Initials': 'C', 'LastName': 'Fakih El Khoury', 'Affiliation': 'Department of Health Services Research, Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Rik', 'Initials': 'R', 'LastName': 'Crutzen', 'Affiliation': 'Department of Health Promotion, Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Jos M G A', 'Initials': 'JMGA', 'LastName': 'Schols', 'Affiliation': 'Department of Health Services Research, Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Ruud J G', 'Initials': 'RJG', 'LastName': 'Halfens', 'Affiliation': 'Department of Health Services Research, Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Mirey', 'Initials': 'M', 'LastName': 'Karavetian', 'Affiliation': 'Department of Health Sciences, Zayed University, Dubai, United Arab Emirates.'}]",Journal of medical Internet research,['10.2196/17817'] 2877,32706704,Features of a Patient Portal for Blood Test Results and Patient Health Engagement: Web-Based Pre-Post Experiment.,"BACKGROUND The use of patient portals for presenting health-related patient data, such as blood test results, is becoming increasingly important in health practices. Patient portals have the potential to enhance patient health engagement, but content might be misinterpreted. OBJECTIVE This study aimed to discover whether the way of presenting blood test outcomes in an electronic patient portal is associated with patient health engagement and whether this varies across different blood test outcomes. METHODS A 2x3 between-subjects experiment was conducted among members of the Nivel Dutch Health Care Consumer Panel. All participants read a scenario in which they were asked to imagine themselves receiving blood test results. These results differed in terms of the presented blood values (ie, normal vs partially abnormal vs all abnormal) as well as in terms of whether the results were accompanied with explanatory text and visualization. Patient health engagement was measured both before (T0) and after (T1) participants were exposed to their fictive blood test results. RESULTS A total 487 of 900 invited members responded (response rate 54%), of whom 50.3% (245/487) were female. The average age of the participants was 52.82 years (SD 15.41 years). Patient health engagement saw either a significant decrease or a nonsignificant difference in the experimental groups after viewing the blood test results. The mean difference was smaller in the groups that received blood test results with additional text and visualization (mean T0 5.33, SE 0.08; mean T1 5.14, SE 0.09; mean difference 0.19, SE 0.08, P=.02) compared with groups that received blood test results without explanatory text and visualization (mean T0 5.19, SE 0.08; mean T1 4.55, SE 0.09; mean difference 0.64, SE 0.08, P<.001). Adding text and visualization, in particular, reduced the decline in patient health engagement in participants who received normal results or mixed results (ie, combination of normal and abnormal results). CONCLUSIONS Adding text and visualization features can attenuate the decrease in patient health engagement in participants who receive outcomes of a blood test via a patient portal, particularly when blood test results are (partly) normal. This suggests that explanatory text and visualization can be reassuring. Future research is warranted to determine whether these results can be generalized to a patient population who receive their actual blood test results.",2020,"Adding text and visualization, in particular, reduced the decline in patient health engagement in participants who received normal results or mixed results (ie, combination of normal and abnormal results). ","['participants who received normal results or mixed results (ie, combination of normal and abnormal results', 'The average age of the participants was 52.82 years (SD 15.41 years', 'A total 487 of 900 invited members responded (response rate 54%), of whom 50.3% (245/487) were female', 'A 2x3 between-subjects experiment was conducted among members of the Nivel Dutch Health Care Consumer Panel']",[],"['blood values', 'Patient health engagement', 'patient health engagement']","[{'cui': 'C0459422', 'cui_str': 'Normal result'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0459424', 'cui_str': 'Abnormal result'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0665509', 'cui_str': 'OF 900'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0441833', 'cui_str': 'Groups'}]",[],"[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}]",900.0,0.0704985,"Adding text and visualization, in particular, reduced the decline in patient health engagement in participants who received normal results or mixed results (ie, combination of normal and abnormal results). ","[{'ForeName': 'Bas', 'Initials': 'B', 'LastName': 'Struikman', 'Affiliation': 'Nivel (Netherlands Institute for Health Services Research), Utrecht, Netherlands.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Bol', 'Affiliation': 'Department of Communication and Cognition, Tilburg School of Humanities and Digital Sciences, Tilburg University, Tilburg, Netherlands.'}, {'ForeName': 'Annelijn', 'Initials': 'A', 'LastName': 'Goedhart', 'Affiliation': 'Saltro, Diagnostics Center for Health Care, Utrecht, Netherlands.'}, {'ForeName': 'Julia C M', 'Initials': 'JCM', 'LastName': 'van Weert', 'Affiliation': 'Department of Communication Science, Amsterdam School of Communication Research, University of Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Talboom-Kamp', 'Affiliation': 'Saltro, Diagnostics Center for Health Care, Utrecht, Netherlands.'}, {'ForeName': 'Sanne', 'Initials': 'S', 'LastName': 'van Delft', 'Affiliation': 'Saltro, Diagnostics Center for Health Care, Utrecht, Netherlands.'}, {'ForeName': 'Anne E M', 'Initials': 'AEM', 'LastName': 'Brabers', 'Affiliation': 'Nivel (Netherlands Institute for Health Services Research), Utrecht, Netherlands.'}, {'ForeName': 'Liset', 'Initials': 'L', 'LastName': 'van Dijk', 'Affiliation': 'Nivel (Netherlands Institute for Health Services Research), Utrecht, Netherlands.'}]",Journal of medical Internet research,['10.2196/15798'] 2878,32242018,GPR56/ADGRG1 is associated with response to antidepressant treatment.,"It remains unclear why many patients with depression do not respond to antidepressant treatment. In three cohorts of individuals with depression and treated with serotonin-norepinephrine reuptake inhibitor (N = 424) we show that responders, but not non-responders, display an increase of GPR56 mRNA in the blood. In a small group of subjects we also show that GPR56 is downregulated in the PFC of individuals with depression that died by suicide. In mice, we show that chronic stress-induced Gpr56 downregulation in the blood and prefrontal cortex (PFC), which is accompanied by depression-like behavior, and can be reversed by antidepressant treatment. Gpr56 knockdown in mouse PFC is associated with depressive-like behaviors, executive dysfunction and poor response to antidepressant treatment. GPR56 peptide agonists have antidepressant-like effects and upregulated AKT/GSK3/EIF4 pathways. Our findings uncover a potential role of GPR56 in antidepressant response.",2020,In a small group of subjects we also show that GPR56 is downregulated in the PFC of individuals with depression that died by suicide.,[],"['GPR56/ADGRG1', 'serotonin-norepinephrine reuptake inhibitor']",[],[],"[{'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C1319313', 'cui_str': 'Norepinephrine reuptake inhibitor-containing product'}]",[],,0.0152942,In a small group of subjects we also show that GPR56 is downregulated in the PFC of individuals with depression that died by suicide.,"[{'ForeName': 'Raoul', 'Initials': 'R', 'LastName': 'Belzeaux', 'Affiliation': 'Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Gorgievski', 'Affiliation': 'CNRS (Integrative Neuroscience and Cognition Center, UMR 8002), Paris, France.'}, {'ForeName': 'Laura M', 'Initials': 'LM', 'LastName': 'Fiori', 'Affiliation': 'Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Juan Pablo', 'Initials': 'JP', 'LastName': 'Lopez', 'Affiliation': 'Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Grenier', 'Affiliation': 'INSERM UMR-S 1124 ERL 3649, Université Paris Descartes, Paris, France.'}, {'ForeName': 'Rixing', 'Initials': 'R', 'LastName': 'Lin', 'Affiliation': 'Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Corina', 'Initials': 'C', 'LastName': 'Nagy', 'Affiliation': 'Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'El Chérif', 'Initials': 'EC', 'LastName': 'Ibrahim', 'Affiliation': 'Aix-Marseille Univ, AP-HM, CNRS, INT, Inst Neurosci Timone, Hôpital Sainte Marguerite, Pôle de psychiatrie, Marseille, France.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Gascon', 'Affiliation': 'Aix-Marseille Univ, AP-HM, CNRS, INT, Inst Neurosci Timone, Hôpital Sainte Marguerite, Pôle de psychiatrie, Marseille, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Courtet', 'Affiliation': 'Fondation FondaMental, Créteil, France.'}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Richard-Devantoy', 'Affiliation': 'Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'Berlim', 'Affiliation': 'Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Chachamovich', 'Affiliation': 'Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Jean-François', 'Initials': 'JF', 'LastName': 'Théroux', 'Affiliation': 'Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Sylvie', 'Initials': 'S', 'LastName': 'Dumas', 'Affiliation': 'Oramacell, 75006, Paris, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Giros', 'Affiliation': 'Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Rotzinger', 'Affiliation': 'Centre for Mental Health, Department of Psychiatry, University Health Network, Krembil Research Institute, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Claudio N', 'Initials': 'CN', 'LastName': 'Soares', 'Affiliation': ""St Michael's Hospital, Li Ka Shing Knowledge Institute, Centre for Depression and Suicide Studies, Toronto, ON, Canada.""}, {'ForeName': 'Jane A', 'Initials': 'JA', 'LastName': 'Foster', 'Affiliation': 'Centre for Mental Health, Department of Psychiatry, University Health Network, Krembil Research Institute, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Naguib', 'Initials': 'N', 'LastName': 'Mechawar', 'Affiliation': 'Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Gregory G', 'Initials': 'GG', 'LastName': 'Tall', 'Affiliation': 'Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Eleni T', 'Initials': 'ET', 'LastName': 'Tzavara', 'Affiliation': 'Fondation FondaMental, Créteil, France.'}, {'ForeName': 'Sidney H', 'Initials': 'SH', 'LastName': 'Kennedy', 'Affiliation': 'Centre for Mental Health, Department of Psychiatry, University Health Network, Krembil Research Institute, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Gustavo', 'Initials': 'G', 'LastName': 'Turecki', 'Affiliation': 'Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada. gustavo.turecki@mcgill.ca.'}]",Nature communications,['10.1038/s41467-020-15423-5'] 2879,30514653,"Salivary Pubertal Hormones, Sleep Disturbance, and an Evening Circadian Preference in Adolescents: Risk Across Health Domains.","PURPOSE Puberty influences biological and psychological development during adolescence. This includes a shift toward an evening circadian preference, which is characterized by greater physical and mental activity at night compared to the morning. This study examines how pubertal hormones are related to risk across key health domains among adolescents with an evening circadian preference. METHODS Participants were adolescents with an evening circadian preference (n = 165, 96 female and 69 male, mean age = 14.8) from an NICHD-funded study. Hormones included testosterone, dehydroepiandrosterone (DHEA), and estradiol (females only). Sleep measures included weeknight total sleep time and weeknight bedtime. Circadian preference was assessed with the Children's Morningness-Eveningness Preferences Scale. Health domains included emotional, cognitive, behavioral, social, and physical health. RESULTS For female adolescents, estradiol was related to higher risk in the emotional domain. Among female adolescents with later bedtimes, higher estradiol was associated with higher behavioral domain risk (specifically alcohol and substance use). For male adolescents with a more extreme evening circadian preference, higher DHEA and testosterone were associated with higher behavioral domain risk, specifically greater alcohol and substance use or sensation seeking (DHEA only). Among female adolescents with a more extreme evening circadian preference, higher DHEA was associated with greater physical health risk. CONCLUSIONS Pubertal hormones may be associated with heightened risk across select health domains. Specifically, higher levels of hormones may contribute to increased risk for alcohol and substance use as well as sensation seeking in the context of an evening circadian preference.",2019,"Among female adolescents with later bedtimes, higher estradiol was associated with higher behavioral domain risk (specifically alcohol and substance use).","['Participants were adolescents with an evening circadian preference (n\u202f=\u202f165, 96 female and 69 male, mean age\u202f=\u202f14.8) from an NICHD-funded study', 'Adolescents', 'adolescents with an evening circadian preference', 'male adolescents', 'female adolescents', 'female adolescents with later bedtimes']",[],"['emotional, cognitive, behavioral, social, and physical health', 'weeknight total sleep time and weeknight bedtime', 'Salivary Pubertal Hormones, Sleep Disturbance, and an Evening Circadian Preference', 'testosterone, dehydroepiandrosterone (DHEA), and estradiol (females only', 'Circadian preference']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0587117', 'cui_str': 'Evening'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1513896', 'cui_str': 'National Institute of Child Health and Human Development'}, {'cui': 'C0016820', 'cui_str': 'Funds'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001589', 'cui_str': 'Adolescents, Male'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0521112', 'cui_str': 'Bedtime'}]",[],"[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0521112', 'cui_str': 'Bedtime'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C1627769', 'cui_str': 'Pubertal'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0587117', 'cui_str': 'Evening'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0011185', 'cui_str': 'prasterone'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",,0.0205277,"Among female adolescents with later bedtimes, higher estradiol was associated with higher behavioral domain risk (specifically alcohol and substance use).","[{'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Dolsen', 'Affiliation': 'Department of Psychology, University of California, Berkeley, Berkeley, California.'}, {'ForeName': 'Julianna', 'Initials': 'J', 'LastName': 'Deardorff', 'Affiliation': 'School of Public Health, University of California, Berkeley, Berkeley, California.'}, {'ForeName': 'Allison G', 'Initials': 'AG', 'LastName': 'Harvey', 'Affiliation': 'Department of Psychology, University of California, Berkeley, Berkeley, California. Electronic address: aharvey@berkeley.edu.'}]",The Journal of adolescent health : official publication of the Society for Adolescent Medicine,['10.1016/j.jadohealth.2018.10.003'] 2880,30660722,Sagittal plane walking biomechanics in individuals with knee osteoarthritis after quadriceps strengthening.,"OBJECTIVE To compare sagittal walking gait biomechanics between participants with knee osteoarthritis (KOA) who increased quadriceps strength following a lower-extremity strengthening intervention (responders) and those who did not increase strength following the same strengthening protocol (non-responders) both at baseline and following the lower extremity strengthening protocol. DESIGN Fifty-three participants with radiographic KOA (47% female, 62.3 ± 7.1 years, BMI = 28.5 ± 3.9 kg/m 2 ) were enrolled in 10 sessions of lower extremity strengthening over a 28-day period. Maximum isometric quadriceps strength and walking gait biomechanics were collected on the involved limb at baseline and 4-weeks following the strengthening intervention. Responders were classified as individuals who increased quadriceps strength greater than the upper limit of the 95% confidence interval (CI) for the minimal detectable change (MDC) in quadriceps strength (29 Nm) determined in a previous study. 2 × 2 functional analyses of variance were used to evaluate the effects of group (responders and non-responders) and time (baseline and 4-weeks) on time-normalized waveforms for knee flexion angle (KFA), vertical ground reaction force (vGRF), and internal knee extension moment (KEM). RESULTS A significant group x time interaction for KFA demonstrated greater KFA in the first half of stance at baseline and greater knee extension in the second half of stance at 4-weeks in responders compared to non-responders. There was no significant group x time interaction for vGRF or internal KEM. CONCLUSIONS Quadriceps strengthening may be used to stimulate small changes in KFA in individuals with KOA.",2019,Maximum isometric quadriceps strength and walking gait biomechanics were collected on the involved limb at baseline and 4-weeks following the strengthening intervention.,"['Fifty-three participants with radiographic KOA (47% female, 62.3\xa0±\xa07.1 years, BMI\xa0=\xa028.5\xa0±\xa03.9\xa0kg/m 2 ', 'participants with knee osteoarthritis (KOA) who increased quadriceps strength following a lower-extremity strengthening intervention (responders) and those who did not increase strength following the same strengthening protocol (non-responders) both at baseline and following the lower extremity strengthening protocol', 'individuals with KOA', 'individuals with knee osteoarthritis after quadriceps strengthening']","['KFA', 'Sagittal plane walking biomechanics']","['sagittal walking gait biomechanics', 'knee extension', 'time-normalized waveforms for knee flexion angle (KFA), vertical ground reaction force (vGRF), and internal knee extension moment (KEM', 'Maximum isometric quadriceps strength and walking gait biomechanics']","[{'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517678', 'cui_str': '28.5'}, {'cui': 'C4517698', 'cui_str': '3.9'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0935598', 'cui_str': 'Sagittal plane'}]","[{'cui': 'C0205129', 'cui_str': 'Sagittal'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0450448', 'cui_str': 'Waveforms'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]",53.0,0.0298898,Maximum isometric quadriceps strength and walking gait biomechanics were collected on the involved limb at baseline and 4-weeks following the strengthening intervention.,"[{'ForeName': 'H C', 'Initials': 'HC', 'LastName': 'Davis', 'Affiliation': 'University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: davishc@live.unc.edu.'}, {'ForeName': 'B A', 'Initials': 'BA', 'LastName': 'Luc-Harkey', 'Affiliation': ""Brigham and Women's Hospital, Boston, MA, USA. Electronic address: bharkey@bwh.harvard.edu.""}, {'ForeName': 'M K', 'Initials': 'MK', 'LastName': 'Seeley', 'Affiliation': 'Brigham Young University, Provo, UT, USA. Electronic address: matthewkseeley@gmail.com.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Troy Blackburn', 'Affiliation': 'University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: troyb@email.unc.edu.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Pietrosimone', 'Affiliation': 'University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: brian@unc.edu.'}]",Osteoarthritis and cartilage,['10.1016/j.joca.2018.12.026'] 2881,30878374,Cyclosporine A prevents ischemia-reperfusion-induced lymphopenia after out-of-hospital cardiac arrest: A predefined sub-study of the CYRUS trial.,,2019,,['after out-of-hospital cardiac arrest'],['Cyclosporine'],['ischemia-reperfusion-induced lymphopenia'],"[{'cui': 'C2936490', 'cui_str': 'Out-of-Hospital Heart Arrest'}]","[{'cui': 'C0010592', 'cui_str': 'Cyclosporine'}]","[{'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0035124', 'cui_str': 'Reperfusion'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0024312', 'cui_str': 'Lymphocytopenia'}]",,0.0256116,,"[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Cour', 'Affiliation': 'Hospices Civils de Lyon, Hôpital Edouard Herriot, Service\u2009de Réanimation Médicale, F-69437, Lyon, France; Université de\u2009Lyon, Université Claude Bernard Lyon 1, Faculté de médecine Lyon-Est, F-69373, Lyon, France; INSERM, U1060 CarMeN, F-69373, Lyon, France. Electronic address: martin.cour@chu-lyon.fr.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Jahandiez', 'Affiliation': 'Hospices\u2009Civils de Lyon, Hôpital Edouard Herriot, Service de Réanimation\u2009Médicale, F-69437, Lyon, France; INSERM, U1060\u2009\u2009CarMeN, F-69373, Lyon, France. Electronic address: vjahandiez@gmail.com.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Bochaton', 'Affiliation': 'Université de Lyon, Université Claude Bernard Lyon 1, Faculté de\u2009médecine Lyon-Est, F-69373, Lyon, France; INSERM, U1060\u2009 \u2009CarMeN, F-69373, Lyon, France. Electronic address: thomas.bochaton@chu-lyon.fr.'}, {'ForeName': 'Fabienne', 'Initials': 'F', 'LastName': 'Venet', 'Affiliation': ""Université\u2009de Lyon, Université Claude Bernard Lyon 1, Faculté de médecine Lyon-Est, F-69373, Lyon, France; Hospices Civils\u2009de Lyon, Hôpital Edouard Herriot, Laboratoire d'Immunologie Clinique, F-69437, Lyon, France. Electronic address: fabienne.venet@chu-lyon.fr.""}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Ovize', 'Affiliation': 'Université de Lyon, Université Claude Bernard\u2009Lyon 1, Faculté de médecine Lyon-Est, F-69373, Lyon, France; INSERM, U1060\u2009 CarMeN, F-69373, Lyon, France. Electronic address: michel.ovize@chu-lyon.fr.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Monneret', 'Affiliation': ""Université de Lyon, Université Claude Bernard Lyon 1, Faculté de médecine Lyon-Est, F-69373, Lyon, France; Hospices\u2009Civils de Lyon, Hôpital Edouard\u2009Herriot, Laboratoire d'Immunologie Clinique, F-69437, Lyon, France. Electronic address: guillaume.monneret@chu-lyon.fr.""}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Argaud', 'Affiliation': 'Hospices Civils\u2009de Lyon, Hôpital Edouard\u2009Herriot, Service de Réanimation Médicale, F-69437, Lyon, France; Université de\u2009Lyon, Université Claude Bernard Lyon 1, Faculté\u2009de médecine Lyon-Est, F-69373, Lyon, France; INSERM, U1060 \u2009CarMeN, F-69373, Lyon, France. Electronic address: laurent.argaud@chu-lyon.fr.'}]",Resuscitation,['10.1016/j.resuscitation.2019.02.048'] 2882,32706708,Evaluation of a Web-Based Self-Management Program for Patients With Cardiovascular Disease: Explorative Randomized Controlled Trial.,"BACKGROUND Web-based self-management programs have the potential to support patients with cardiovascular disease (CVD) in their self-management (eg, by focusing on behavior change and improving physical activity). The intervention mapping framework was used to develop a web-based program called Vascular View. The Vascular View program contained 6 modules (coping with CVD, setting boundaries, lifestyle, healthy nutrition, being physically active, interaction with health professionals) aiming to increase self-management behavior by tailoring to the perceived problems and (support) needs of patients after CVD. OBJECTIVE The aim was to test the effectiveness of Vascular View before embarking on a full-scale randomized clinical trial (RCT) by evaluating the potential effectiveness and effect sizes of the Vascular View program and identifying outcome measures most likely to capture the potential benefits. METHODS An explorative RCT was performed. Both control and intervention groups received care as usual and, in addition, the intervention group received 12 months of access to a web-based self-management program. Assessment occurred at baseline, 6 months, and 12 months. Outcome measures included general patient-reported outcome measurements: Illness Perception Questionnaire (IPQ), Rand-36, Patient Activation Measure, and patient self-efficacy. Module-specific patient-reported outcome measurements were Beliefs about Medicines Questionnaire, International Physical Activity Questionnaire, Dutch Healthy Diet Index, Fagerström Test for Nicotine Dependence (FTND), Alcohol Use Disorders Identification Test, and Perceived Efficacy in Patient-Physician Interaction. Linear mixed models for repeated measures using intention-to-treat and per-protocol analysis were applied to study differences between the patients in the intervention and control groups. Floor and ceiling effects were explored to give insight into the outcome measures most likely to capture the potential benefits. RESULTS A total of 105 patients in the control group and 103 patients in the intervention group participated in the study. A positive direction of change between baseline and 12 months was shown for most outcome measurements in favor of the intervention group, of which 2 out of 10 outcomes showed a significant effect: attribution of cause of the disease to risk factors and immunity factors (IPQ) and dependency of nicotine (FTND). Floor and ceiling effects were seen in the IPQ, Rand-36, and the self-efficacy questionnaire. CONCLUSIONS No conclusion for the efficacy of the Vascular View program or selection of outcome measurements can be taken yet. A process evaluation will be conducted to gain thorough insight into the working elements of the program, patient needs in eHealth, and the use of the program by patients. This can determine for whom web-based self-management programs will work and help to adapt the program. TRIAL REGISTRATION Dutch Trial Register NTR5412; https://www.trialregister.nl/trial/5303. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.2196/resprot.6352.",2020,"A positive direction of change between baseline and 12 months was shown for most outcome measurements in favor of the intervention group, of which 2 out of 10 outcomes showed a significant effect: attribution of cause of the disease to risk factors and immunity factors (IPQ) and dependency of nicotine (FTND).","['Patients With Cardiovascular Disease', '105 patients in the control group and 103 patients in the intervention group participated in the study', 'patients with cardiovascular disease (CVD']","['Web-Based Self-Management Program', 'care as usual and, in addition, the intervention group received 12 months of access to a web-based self-management program', 'NTR5412']","['self-efficacy questionnaire', 'Beliefs about Medicines Questionnaire, International Physical Activity Questionnaire, Dutch Healthy Diet Index, Fagerström Test for Nicotine Dependence (FTND), Alcohol Use Disorders Identification Test, and Perceived Efficacy in Patient-Physician Interaction', 'significant effect: attribution of cause of the disease to risk factors and immunity factors (IPQ) and dependency of nicotine (FTND', 'general patient-reported outcome measurements: Illness Perception Questionnaire (IPQ), Rand-36, Patient Activation Measure, and patient self-efficacy']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0444454', 'cui_str': 'Access'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0028043', 'cui_str': 'Nicotine dependence'}, {'cui': 'C0011546', 'cui_str': 'Dependency, Psychology'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0031830', 'cui_str': 'Physician Patient Relations'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0020964', 'cui_str': 'Immune status'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C4075707', 'cui_str': 'Patient Activation Measure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",105.0,0.0846981,"A positive direction of change between baseline and 12 months was shown for most outcome measurements in favor of the intervention group, of which 2 out of 10 outcomes showed a significant effect: attribution of cause of the disease to risk factors and immunity factors (IPQ) and dependency of nicotine (FTND).","[{'ForeName': 'Marscha M', 'Initials': 'MM', 'LastName': 'Engelen', 'Affiliation': 'IQ Healthcare, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'van Dulmen', 'Affiliation': 'Department of Primary and Community Care, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.'}, {'ForeName': 'Saskia', 'Initials': 'S', 'LastName': 'Puijk-Hekman', 'Affiliation': 'IQ Healthcare, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.'}, {'ForeName': 'Hester', 'Initials': 'H', 'LastName': 'Vermeulen', 'Affiliation': 'IQ Healthcare, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.'}, {'ForeName': 'Maria Wg', 'Initials': 'MW', 'LastName': 'Nijhuis-van der Sanden', 'Affiliation': 'IQ Healthcare, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.'}, {'ForeName': 'Sebastian Jh', 'Initials': 'SJ', 'LastName': 'Bredie', 'Affiliation': 'Department of Internal Medicine, Radboud university medical center, Nijmegen, Netherlands.'}, {'ForeName': 'Betsie Gi', 'Initials': 'BG', 'LastName': 'van Gaal', 'Affiliation': 'IQ Healthcare, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.'}]",Journal of medical Internet research,['10.2196/17422'] 2883,32706716,Efficacy of a Smartphone App Intervention for Reducing Caregiver Stress: Randomized Controlled Trial.,"BACKGROUND Caregivers play a pivotal role in maintaining an economically viable health care system, yet they are characterized by low levels of psychological well-being and consistently report unmet needs for psychological support. Mobile app-based (mobile health [mHealth]) interventions present a novel approach to both reducing stress and improving well-being. OBJECTIVE This study aims to evaluate the effectiveness of a self-guided mobile app-based psychological intervention for people providing care to family or friends with a physical or mental disability. METHODS In a randomized, single-blind, controlled trial, 183 caregivers recruited through the web were randomly allocated to either an intervention (n=73) or active control (n=110) condition. The intervention app contained treatment modules combining daily self-monitoring with third-wave (mindfulness-based) cognitive-behavioral therapies, whereas the active control app contained only self-monitoring features. Both programs were completed over a 5-week period. It was hypothesized that intervention app exposure would be associated with decreases in depression, anxiety, and stress, and increases in well-being, self-esteem, optimism, primary and secondary control, and social support. Outcomes were assessed at baseline, postintervention, and 3-4 months postintervention. App quality was also assessed. RESULTS In total, 25% (18/73) of the intervention participants were lost to follow-up at 3 months, and 30.9% (34/110) of the participants from the wait-list control group dropped out before the postintervention survey. The intervention group experienced reductions in stress (b=-2.07; P=.04) and depressive symptoms (b=-1.36; P=.05) from baseline to postintervention. These changes were further enhanced from postintervention to follow-up, with the intervention group continuing to report lower levels of depression (b=-1.82; P=.03) and higher levels of emotional well-being (b=6.13; P<.001), optimism (b=0.78; P=.007), self-esteem (b=-0.84; P=.005), support from family (b=2.15; P=.001), support from significant others (b=2.66; P<.001), and subjective well-being (b=4.82; P<.001). On average, participants completed 2.5 (SD 1.05) out of 5 treatment modules. The overall quality of the app was also rated highly, with a mean score of 3.94 out of a maximum score of 5 (SD 0.58). CONCLUSIONS This study demonstrates that mHealth psychological interventions are an effective treatment option for caregivers experiencing high levels of stress. Recommendations for improving mHealth interventions for caregivers include offering flexibility and customization in the treatment design. TRIAL REGISTRATION Australian New Zealand Clinical Trial Registry ACTRN12616000996460; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371170.",2020,The intervention group experienced reductions in stress (b=-2.07; P=.04) and depressive symptoms (b=-1.36; P=.05) from baseline to postintervention.,"['183 caregivers recruited through the web were randomly allocated to either an intervention (n=73) or active control (n=110) condition', 'people providing care to family or friends with a physical or mental disability', 'caregivers experiencing high levels of stress']","['self-guided mobile app-based psychological intervention', 'mHealth psychological interventions', 'Smartphone App Intervention', 'Mobile app-based (mobile health [mHealth]) interventions', 'intervention app contained treatment modules combining daily self-monitoring with third-wave (mindfulness-based) cognitive-behavioral therapies, whereas the active control app contained only self-monitoring features']","['levels of depression', 'overall quality', 'depression, anxiety, and stress, and increases in well-being, self-esteem, optimism, primary and secondary control, and social support', 'self-esteem', 'reductions in stress', 'depressive symptoms']","[{'cui': 'C4517615', 'cui_str': '183'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0079382', 'cui_str': 'Friend'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1306341', 'cui_str': 'Mental handicap'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]","[{'cui': 'C1319226', 'cui_str': 'Level of depression'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0237428', 'cui_str': 'Positive attitude'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",183.0,0.198433,The intervention group experienced reductions in stress (b=-2.07; P=.04) and depressive symptoms (b=-1.36; P=.05) from baseline to postintervention.,"[{'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Fuller-Tyszkiewicz', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Richardson', 'Affiliation': 'Nous Group, Melbourne, Australia.'}, {'ForeName': 'Keriann', 'Initials': 'K', 'LastName': 'Little', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Teague', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Hartley-Clark', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Capic', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Khor', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Cummins', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Craig A', 'Initials': 'CA', 'LastName': 'Olsson', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Delyse', 'Initials': 'D', 'LastName': 'Hutchinson', 'Affiliation': 'Deakin University, Geelong, Australia.'}]",JMIR mental health,['10.2196/17541'] 2884,32707476,Sales to apparently alcohol-intoxicated customers and online responsible vendor training in recreational cannabis stores in a randomized trial.,"BACKGROUND In some U.S. states, laws prohibit sales of recreational marijuana to intoxicated customers to prevent associated harms. In alcohol markets, training in responsible sales practices is one intervention to help reduce such sales to intoxicated customers. Similar training may be beneficial in the recreational cannabis market. METHODS An online responsible marijuana vendor (RMV) training was developed. Among its five modules, learning elements taught store personnel to recognize signs of alcohol impairment and intoxication, refuse sales, and understand the risks of driving under the influence of cannabis. A sample of n = 150 recreational cannabis stores in Colorado, Oregon, and Washington State, USA were enrolled in a randomized controlled trial, half of which were randomly assigned to use the RMV training. Stores were posttested using a pseudo-customer protocol in which confederate buyers feigned obvious signs of alcohol intoxication. RESULTS Deterrence of sales to intoxicated customers does not seem to exist, regardless of whether the states' laws prohibit it. Only 16 of 146 stores (11.0%; 4 Oregon stores were eliminated that were not in business) refused sales. There was no difference in refusal rates between intervention (11.6% [3.9%]) and control stores (7.6% [3.1%], F = 0.71, p = 0.401 [1-tailed]) or between stores that used the RMV training (6.3% [4.0%]) or not (12.0% [5.7%], F = 0.91, p = 0.343 [2-tailed]). In 11 visits, store personnel commented on the buyers' behavior, or expressed concern/suspicion about buyers, but sold to them anyway. CONCLUSIONS Training in responsible sales practices alone did not appear to reduce sales to apparently alcohol-intoxicated customers. Legal deterrence from making these sales may be insufficient or nonexistent for store management to support adherence to this responsible sales practice. Regulatory and policy actions may be needed to increase perceived risk with such sales (i.e., clear policy and swift, severe, and certain penalties) to achieve training's benefits.",2020,"There was no difference in refusal rates between intervention (11.6% [3.9%]) and control stores (7.6% [3.1%], F = 0.71, p = 0.401","['A sample of n\xa0=\xa0150 recreational cannabis stores in Colorado, Oregon, and Washington State, USA']","['RMV training', 'alcohol-intoxicated customers and online responsible vendor training']","['control stores', 'refusal rates']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C1698986', 'cui_str': 'Storage'}, {'cui': 'C0009399', 'cui_str': 'Colorado'}, {'cui': 'C0029195', 'cui_str': 'Oregon'}, {'cui': 'C0043038', 'cui_str': 'Washington'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C1273518', 'cui_str': 'Responsible to'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0042462', 'cui_str': 'Vendors'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1698986', 'cui_str': 'Storage'}, {'cui': 'C0040809', 'cui_str': 'Refusal of treatment by patient'}]",150.0,0.027768,"There was no difference in refusal rates between intervention (11.6% [3.9%]) and control stores (7.6% [3.1%], F = 0.71, p = 0.401","[{'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Buller', 'Affiliation': 'Klein Buendel, Inc., 1667 Cole Boulevard, Suite 225, Golden, CO 80401, USA. Electronic address: dbuller@kleinbuendel.com.'}, {'ForeName': 'W Gill', 'Initials': 'WG', 'LastName': 'Woodall', 'Affiliation': 'Klein Buendel, Inc., 1667 Cole Boulevard, Suite 225, Golden, CO 80401, USA. Electronic address: gwoodall@kleinbuendel.com.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Saltz', 'Affiliation': 'Prevention Research Center, 2150 Shattuck, Avenue, Suite 601, Berkeley, CA 94704, USA. Electronic address: saltz@prc.org.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Grayson', 'Affiliation': 'Klein Buendel, Inc., 1667 Cole Boulevard, Suite 225, Golden, CO 80401, USA. Electronic address: agrayson@kleinbuendel.com.'}, {'ForeName': 'Sierra', 'Initials': 'S', 'LastName': 'Svendsen', 'Affiliation': 'Klein Buendel, Inc., 1667 Cole Boulevard, Suite 225, Golden, CO 80401, USA. Electronic address: ssvendsen@kleinbuendel.com.'}, {'ForeName': 'Gary R', 'Initials': 'GR', 'LastName': 'Cutter', 'Affiliation': 'Department of Biostatistics, School of Public Health, University of Alabama, 403b Ryals Public Health Building 1665 University Boulevard, Birmingham, AL 35294, USA. Electronic address: cutterg@uab.edu.'}]",The International journal on drug policy,['10.1016/j.drugpo.2020.102860'] 2885,32707561,Both Caffeine and Placebo Improve Vertical Jump Performance Compared With a Nonsupplemented Control Condition.,"PURPOSE To compare the acute effects of caffeine and placebo ingestion with a control condition (ie, no supplementation) on vertical jump performance. METHODS The sample for this study consisted of 26 recreationally trained men. Following the familiarization visit, the subjects were randomized in a double-blind manner to 3 main conditions: placebo, caffeine, and control. Caffeine was administered in the form of a gelatin capsule in the dose of 6 mg·kg body weight-1. Placebo was also administered in the form of a gelatin capsule containing 6 mg·kg-1 of dextrose. Vertical jump performance was assessed using a countermovement jump performed on a force platform. Analyzed outcomes were vertical jump height and maximal power output. RESULTS For vertical jump height, significant differences were observed between placebo and control conditions (g = 0.13; 95% confidence interval [CI], 0.03-0.24; +2.5%), caffeine and control conditions (g = 0.31; 95% CI, 0.17-0.50; +6.6%), and caffeine and placebo conditions (g = 0.19; 95% CI, 0.06-0.34; +4.0%). For maximal power output, no significant main effect of condition (P = .638) was found. CONCLUSIONS Ingesting a placebo or caffeine may enhance countermovement jump performance compared with the control condition, with the effects of caffeine versus control appearing to be greater than the effects of placebo versus control. In addition, caffeine was ergogenic for countermovement jump height compared with placebo. Even though caffeine and placebo ingestion improved vertical jump height, no significant effects of condition were found on maximal power output generated during takeoff.",2020,"Even though caffeine and placebo ingestion improved vertical jump height, no significant effects of condition were found on maximal power output generated during takeoff.",['26 recreationally trained men'],"['Placebo', 'placebo or caffeine', 'gelatin capsule containing 6\xa0mg·kg-1 of dextrose', 'Caffeine and Placebo', 'caffeine and placebo', 'caffeine', 'Caffeine', 'caffeine and placebo ingestion with a control condition (ie,\xa0no supplementation', 'placebo, caffeine, and control', 'placebo']","['vertical jump performance', 'Vertical jump performance', 'Vertical Jump Performance', 'vertical jump height', 'vertical jump height and maximal power output', 'countermovement jump performance']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0017237', 'cui_str': 'Gelatin'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0445194', 'cui_str': 'Power output'}]",26.0,0.378174,"Even though caffeine and placebo ingestion improved vertical jump height, no significant effects of condition were found on maximal power output generated during takeoff.","[{'ForeName': 'Jozo', 'Initials': 'J', 'LastName': 'Grgic', 'Affiliation': ''}, {'ForeName': 'Sandro', 'Initials': 'S', 'LastName': 'Venier', 'Affiliation': ''}, {'ForeName': 'Pavle', 'Initials': 'P', 'LastName': 'Mikulic', 'Affiliation': ''}]",International journal of sports physiology and performance,['10.1123/ijspp.2019-1028'] 2886,32707579,Resistance Exercise Modulates Kynurenine Pathway in Pancreatic Cancer Patients.,"The aim of this study was to investigate the impact of Supervised and Home-based resistance exercise on the Kynurenine pathway in patients with pancreatic cancer who underwent surgery and chemotherapy. In the SUPPORT study, adult pancreatic cancer patients were randomized to intervention programs of 6-month (1) a Supervised moderate-to-high-intensity progressive resistance training or (2) unsupervised Home-based resistance training, or (3) to a standard care patient Control group. Serum levels of kynurenine, tryptophan and IL-6 were assessed for 32 participants before, after 3 months and after 6 months of exercise intervention. Group differences were investigated using analysis-of-covariance. Patients in the Supervised training group showed decreased levels of serum kynurenine and kynurenine/tryptophan ratio (p = 0.07; p = 0.01 respectively) as well as increased Tryptophan levels (p = 0.05) in comparison to Home-based and Control group over time. The Home-based exercise group had significant increased kynurenine and kynurenine/tryptophan ratio levels. IL-6 levels decreased over the first three months for both intervention groups as well as the Control group (Supervised: p < 0.01, Home-based: p < 0.010, Control group: p < 0.01). Supervised resistance exercise might positively regulate the Kynurenine pathway and downregulate the kynurenine/tryptophan (indicative of IDO/TDO enzyme) levels, hence modulating the immune system.",2020,Patients in the Supervised training group showed decreased levels of serum kynurenine and kynurenine/tryptophan ratio (p = 0.07; p = 0.01 respectively) as well as increased Tryptophan levels (p = 0.05) in comparison to Home-based and Control group over time.,"['Pancreatic Cancer Patients', 'patients with pancreatic cancer who underwent surgery and chemotherapy', 'adult pancreatic cancer patients']","['intervention programs of 6-month (1) a Supervised moderate-to-high-intensity progressive resistance training or (2) unsupervised Home-based resistance training, or (3) to a standard care patient Control group', 'Resistance Exercise', 'Supervised and Home-based resistance exercise']","['IL-6 levels', 'levels of serum kynurenine and kynurenine/tryptophan ratio', 'Serum levels of kynurenine, tryptophan and IL-6', 'kynurenine and kynurenine/tryptophan ratio levels', 'Tryptophan levels']","[{'cui': 'C0235974', 'cui_str': 'Carcinoma of pancreas'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C2931037', 'cui_str': 'Pancreatic cancer, adult'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0022818', 'cui_str': 'Kynurenine'}, {'cui': 'C0041249', 'cui_str': 'Tryptophan'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",32.0,0.0182223,Patients in the Supervised training group showed decreased levels of serum kynurenine and kynurenine/tryptophan ratio (p = 0.07; p = 0.01 respectively) as well as increased Tryptophan levels (p = 0.05) in comparison to Home-based and Control group over time.,"[{'ForeName': 'Anasua', 'Initials': 'A', 'LastName': 'Pal', 'Affiliation': 'Division of Physical Activity, Prevention and Cancer, Deutsches Krebsforschungszentrum, Heidelberg, Germany.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Zimmer', 'Affiliation': 'Institute of Cardiovascular Research and Sports Medicine; Department of Molecular and Cellular Sport Medicine, German Sport University Cologne, Cologne, Germany.'}, {'ForeName': 'Dorothea', 'Initials': 'D', 'LastName': 'Clauss', 'Affiliation': 'Division of Physical Activity, Prevention and Cancer, Deutsches Krebsforschungszentrum, Heidelberg, Germany.'}, {'ForeName': 'Martina E', 'Initials': 'ME', 'LastName': 'Schmidt', 'Affiliation': 'Division of Physical Activity, Prevention and Cancer, Deutsches Krebsforschungszentrum, Heidelberg, Germany.'}, {'ForeName': 'Cornelia M', 'Initials': 'CM', 'LastName': 'Ulrich', 'Affiliation': 'Huntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, United States.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Wiskemann', 'Affiliation': 'Medical Oncology, Heidelberg Cancer Center, Heidelberg, Germany.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Steindorf', 'Affiliation': 'Division of Physical Activity, Prevention and Cancer, Deutsches Krebsforschungszentrum, Heidelberg, Germany.'}]",International journal of sports medicine,['10.1055/a-1186-1009'] 2887,32707593,"Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2) Inhibitor.","BACKGROUND Tofogliflozin is a highly selective sodium-glucose co-transporter 2 (SGLT2) inhibitor. A mass balance study with combinations of microdoses revealed that tofogliflozin has high oral bioavailability (97.5%) and that tofogliflozin in circulation is eliminated primarily by metabolic pathways, with the liver playing a prominent role in elimination. OBJECTIVES This study aimed to evaluate the effect of moderate hepatic impairment on the pharmacokinetics of tofogliflozin and on the pharmacodynamics (urinary glucose excretion [UGE]). METHODS In an open-label, parallel-group study, 17 subjects (9 with moderate hepatic impairment [Child-Pugh Class B, score 7-9] and 8 healthy) received a single oral dose of 40 mg tofogliflozin. Plasma and urine concentrations of tofogliflozin were determined. Accumulated UGE, adverse events, and physiological and laboratory test data were monitored. RESULTS Geometric mean ratio (GMR; geometric mean value for subjects with moderate hepatic impairment / geometric mean value for healthy subjects) of C max was 1.47 and GMR of AUC inf was 1.70. Moderate hepatic impairment had only a little effect on t max and CL R but it prolonged MRT. The levels of cumulative UGE were similar between the 2 groups. No clinically significant adverse events, laboratory test values, or physiological test values were observed in any subject. CONCLUSIONS Moderate hepatic impairment increased C max and AUC inf of tofogliflozin by 47% and 70%, respectively. This increase in tofogliflozin exposure did not increase UGE in hepatically impaired subjects. A single oral dose of 40 mg tofogliflozin was well tolerated, supporting dose adjustment is unnecessary even in moderately hepatically impaired subjects.",2020,"No clinically significant adverse events, laboratory test values, or physiological test values were observed in any subject. ","['17 subjects (9 with moderate hepatic impairment [Child-Pugh Class B, score 7-9] and 8 healthy']","['tofogliflozin', 'Tofogliflozin', 'single oral dose of 40 mg tofogliflozin', 'Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2) Inhibitor']","['adverse events, laboratory test values, or physiological test values', 'C max and AUC inf of tofogliflozin', 'Moderate hepatic impairment', 'oral bioavailability', 'levels of cumulative UGE', 'Geometric mean ratio (GMR; geometric mean value', 'tofogliflozin exposure', 'Plasma and urine concentrations of tofogliflozin', 'Accumulated UGE, adverse events, and physiological and laboratory test data']","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0948807', 'cui_str': 'Hepatic impairment'}, {'cui': 'C4050412', 'cui_str': 'Child-Pugh score'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0598849', 'cui_str': 'Co-Transporters'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0022885', 'cui_str': 'Laboratory procedure'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0948807', 'cui_str': 'Hepatic impairment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",17.0,0.0295616,"No clinically significant adverse events, laboratory test values, or physiological test values were observed in any subject. ","[{'ForeName': 'Haruki', 'Initials': 'H', 'LastName': 'Yamada', 'Affiliation': 'Social Insurance Chuo General Hospital, Tokyo, Japan.'}, {'ForeName': 'Hiromasa', 'Initials': 'H', 'LastName': 'Ohira', 'Affiliation': 'Fukushima Medical University Hospital, Fukushima, Japan.'}, {'ForeName': 'Fumiaki', 'Initials': 'F', 'LastName': 'Ikegami', 'Affiliation': 'Clinical Research Hospital Tokyo, Tokyo, Japan.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Nakamura', 'Affiliation': 'Clinical Research Hospital Tokyo, Tokyo, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Takahashi', 'Affiliation': 'Fukushima Medical University Hospital, Fukushima, Japan.'}, {'ForeName': 'Kazumichi', 'Initials': 'K', 'LastName': 'Abe', 'Affiliation': 'Fukushima Medical University Hospital, Fukushima, Japan.'}, {'ForeName': 'Akihiro', 'Initials': 'A', 'LastName': 'Inano', 'Affiliation': 'Fukushima Medical University Hospital, Fukushima, Japan.'}, {'ForeName': 'Sumire', 'Initials': 'S', 'LastName': 'Shimada', 'Affiliation': 'Clinical Pharmacology Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Kumiko', 'Initials': 'K', 'LastName': 'Miyata', 'Affiliation': 'Clinical Pharmacology Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Tomohisa', 'Initials': 'T', 'LastName': 'Saito', 'Affiliation': 'Clinical Pharmacology Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Ohba', 'Affiliation': 'Clinical Pharmacology Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Kimio', 'Initials': 'K', 'LastName': 'Terao', 'Affiliation': 'Clinical Pharmacology Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Akihiro', 'Initials': 'A', 'LastName': 'Ohnishi', 'Affiliation': 'The Jikei University School of Medicine, Tokyo, Japan.'}]",Drug research,['10.1055/a-1202-0818'] 2888,32703246,Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: statistical analysis plan for a randomised controlled trial (UPGRADE trial).,"BACKGROUND Approximately 8-15% of patients undergoing bariatric surgery develop symptomatic gallstone disease within 24 months after surgery. Ursodeoxycholic acid (UDCA) seems to effectively prevent the formation of gallstones detectable by ultrasound after bariatric surgery. The aim of the UPGRADE trial is to provide evidence on the prophylactic use of UDCA in preventing symptomatic gallstone disease postoperatively. METHODS The UPGRADE trial is designed as a randomised, placebo-controlled, double-blind multicentre trial in patients with morbid obesity undergoing Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG). Patients are randomly assigned to either UDCA 900 mg daily for 6 months or placebo treatment. This paper details the statistical analysis plan (SAP) of this trial and was submitted before outcome data were available. RESULTS The primary endpoint of this trial is symptomatic gallstone disease within 24 months after bariatric surgery, defined as admission or hospital visit for symptomatic gallstone disease. Secondary outcomes consist of the development of gallstones/sludge on ultrasound at 24 months in the gallstone-negative group at baseline, presence of gallstones/sludge on ultrasound at 24 months, number of cholecystectomies, side effects of UDCA, therapy compliance, quality of life, costs and revenues. Analyses will be completed according to this pre-specified SAP. The main analysis will be performed as a standard ITT analysis using the chi-squared test. DISCUSSION The UPGRADE trial will show if prophylactic use of UDCA reduces the incidence of symptomatic gallstone disease after bariatric surgery. Unforeseen deviations from the SAP at the time of analysis will be motivated and discussed. TRIAL REGISTRATION The Netherlands Trial Register NL5954 . Registered on 21 November 2016.",2020,Ursodeoxycholic acid (UDCA) seems to effectively prevent the formation of gallstones detectable by ultrasound after bariatric surgery.,"['patients undergoing bariatric surgery develop symptomatic gallstone disease within 24\u2009months after surgery', 'symptomatic gallstone disease after bariatric surgery', 'patients with morbid obesity undergoing Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG']","['Ursodeoxycholic acid', 'UDCA 900\u2009mg daily for 6 months or placebo', 'Ursodeoxycholic acid (UDCA', 'UDCA', 'placebo']","['admission or hospital visit for symptomatic gallstone disease', 'symptomatic gallstone disease', 'development of gallstones/sludge on ultrasound at 24\u2009months in the gallstone-negative group at baseline, presence of gallstones/sludge on ultrasound at 24\u2009months, number of cholecystectomies, side effects of UDCA, therapy compliance, quality of life, costs and revenues']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1456587', 'cui_str': 'Metabolic surgery'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0008350', 'cui_str': 'Biliary calculus'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0028756', 'cui_str': 'Morbid obesity'}, {'cui': 'C0399839', 'cui_str': 'Bypass gastrojejunostomy'}, {'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}]","[{'cui': 'C0042105', 'cui_str': 'ursodeoxycholic acid'}, {'cui': 'C4517900', 'cui_str': '900'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1704447', 'cui_str': 'Patient visit for'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0008350', 'cui_str': 'Biliary calculus'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0282346', 'cui_str': 'Sludge'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0008320', 'cui_str': 'Cholecystectomy'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0042105', 'cui_str': 'ursodeoxycholic acid'}, {'cui': 'C1321605', 'cui_str': 'Compliance behavior'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",,0.41657,Ursodeoxycholic acid (UDCA) seems to effectively prevent the formation of gallstones detectable by ultrasound after bariatric surgery.,"[{'ForeName': 'Sylke', 'Initials': 'S', 'LastName': 'Haal', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. s.haal@amsterdamumc.nl.'}, {'ForeName': 'Maimoena S S', 'Initials': 'MSS', 'LastName': 'Guman', 'Affiliation': 'Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, the Netherlands.'}, {'ForeName': 'L Maurits', 'Initials': 'LM', 'LastName': 'de Brauw', 'Affiliation': 'Department of Surgery, Spaarne Gasthuis, Hoofddorp, the Netherlands.'}, {'ForeName': 'Ruben N', 'Initials': 'RN', 'LastName': 'van Veen', 'Affiliation': 'Department of Surgery, OLVG, Amsterdam, the Netherlands.'}, {'ForeName': 'Ruben', 'Initials': 'R', 'LastName': 'Schouten', 'Affiliation': 'Department of Surgery, Flevoziekenhuis, Almere, the Netherlands.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Fockens', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Victor E A', 'Initials': 'VEA', 'LastName': 'Gerdes', 'Affiliation': 'Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, the Netherlands.'}, {'ForeName': 'Marcel G W', 'Initials': 'MGW', 'LastName': 'Dijkgraaf', 'Affiliation': 'Department of Epidemiology and Data Science, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Rogier P', 'Initials': 'RP', 'LastName': 'Voermans', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}]",Trials,['10.1186/s13063-020-04605-7'] 2889,32703257,The effect of knowledge brokering on nurses' empathy with patients receiving cardiac care: a study protocol.,"BACKGROUND Hospitalization could be an unpleasant experience for patients with cardiovascular disease leading to some negative emotional reactions. These emotions can be managed by nursing empathy. There are different methods for improving empathy, but some evidence indicates a dramatic drop in nurses' empathy. In this study, we aim to provide a protocol for investigating the effect of knowledge brokering on nurses' empathy with patients receiving cardiac care. METHODS This study protocol is developed based on SPIRIT checklist with an experimental design. The study population are nurses working in cardiac wards of three educational hospitals in western Iran, Khorramabad. The quota sampling method is used. The sample size is 100 individuals. The samples will be assigned to two intervention and comparison groups using stratified random allocation method. Permuted block randomization is used in each stratum. To prevent contamination between participants; firstly, the measurements of the comparison group is done. Knowledge brokering intervention is performed in 7 stages based on Dobbins' knowledge translation framework 2009. Monica's Empathy Construct Self-Rating Scale is used for measuring empathy. Statistical analyses are performed using SPSS (SPPS Inc. Chicago, Il, version 21). P value below 0.05 is considered as statistically significant. DISCUSSION To our knowledge, there is no similar study using an experimental design to examine the efficacy of a knowledge brokering method to improve humanistic knowledge. It helps nurses to improve their empathy in caring relationships.",2020,"To our knowledge, there is no similar study using an experimental design to examine the efficacy of a knowledge brokering method to improve humanistic knowledge.","['cardiac wards of three educational hospitals in western Iran, Khorramabad', ""nurses' empathy with patients receiving cardiac care"", 'patients with cardiovascular disease leading to some negative emotional reactions']",['knowledge brokering'],"[""Monica's Empathy Construct Self-Rating Scale""]","[{'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150158', 'cui_str': 'Cardiac care'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0221736', 'cui_str': 'Reaction emotional'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}]","[{'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0012931', 'cui_str': 'Recombinant DNA'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.0349054,"To our knowledge, there is no similar study using an experimental design to examine the efficacy of a knowledge brokering method to improve humanistic knowledge.","[{'ForeName': 'Atefeh', 'Initials': 'A', 'LastName': 'Galehdarifard', 'Affiliation': 'Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran.'}, {'ForeName': 'Moloud', 'Initials': 'M', 'LastName': 'Radfar', 'Affiliation': 'Faculty of Nursing and Midwifery, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Gholami', 'Affiliation': 'Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.'}, {'ForeName': 'Mojgan', 'Initials': 'M', 'LastName': 'Khademi', 'Affiliation': 'Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran. khademi.m@lums.ac.ir.'}, {'ForeName': 'Farzad', 'Initials': 'F', 'LastName': 'Ebrahimzadeh', 'Affiliation': 'Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.'}, {'ForeName': 'Mohammad-Hasan', 'Initials': 'MH', 'LastName': 'Imani-Nasab', 'Affiliation': 'Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.'}]",BMC health services research,['10.1186/s12913-020-05377-1'] 2890,32707917,Extending the Overnight Fast: Sex Differences in Acute Metabolic Responses to Breakfast.,"Fasting for over 24 h is associated with worsening glucose tolerance, but the effect of extending the overnight fast period (a form of time-restricted feeding) on acute metabolic responses and insulin sensitivity is unclear. The aim of this pilot study was to determine the acute impact of an increased fasting period on postprandial glycaemia, insulinemia, and acute insulin sensitivity responses to a standard meal. Twenty-four lean, young, healthy adults (12 males, 12 females) consumed a standard breakfast after an overnight fast of 12, 14, and 16 h. Each fast duration was repeated on three separate occasions (3 × 3) in random order. Postprandial glucose and insulin responses were measured at regular intervals over 2 h and quantified as incremental area under the curve (iAUC). Insulin sensitivity was determined by homeostatic modelling assessment (HOMA). After 2 h, ad libitum food intake at a buffet meal was recorded. In females, but not males, insulin sensitivity improved (HOMA%S +35%, p = 0.016, marginally significant) with longer fast duration (16 h vs. 12 h), but paradoxically, postprandial glycaemia was higher (glucose iAUC +37%, p = 0.002). Overall, males showed no differences in glucose or insulin homeostasis. Both sexes consumed more energy (+28%) at the subsequent meal (16 h vs. 12 h). Delaying the first meal of the day by 4 h by extending the fasting period may have adverse metabolic effects in young, healthy, adult females, but not males.",2020,"In females, but not males, insulin sensitivity improved (HOMA%S +35%, p = 0.016, marginally significant) with longer fast duration (16 h vs. 12 h), but paradoxically, postprandial glycaemia was higher (glucose iAUC +37%, p = 0.002).","['Twenty-four lean, young, healthy adults (12 males, 12 females']",[],"['adverse metabolic effects', 'postprandial glycaemia, insulinemia, and acute insulin sensitivity responses', 'postprandial glycaemia', 'glucose or insulin homeostasis', 'Postprandial glucose and insulin responses', 'insulin sensitivity', 'Insulin sensitivity']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",[],"[{'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}]",,0.0341348,"In females, but not males, insulin sensitivity improved (HOMA%S +35%, p = 0.016, marginally significant) with longer fast duration (16 h vs. 12 h), but paradoxically, postprandial glycaemia was higher (glucose iAUC +37%, p = 0.002).","[{'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'S Atkinson', 'Affiliation': 'Charles Perkins Centre and School of Life and Environmental Sciences, The University of Sydney, Sydney 2006, Australia.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'A Heruc', 'Affiliation': 'Charles Perkins Centre and School of Life and Environmental Sciences, The University of Sydney, Sydney 2006, Australia.'}, {'ForeName': 'Verena', 'Initials': 'V', 'LastName': 'M H Tan', 'Affiliation': 'Charles Perkins Centre and School of Life and Environmental Sciences, The University of Sydney, Sydney 2006, Australia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Petocz', 'Affiliation': 'Department of Mathematics and Statistics, Macquarie University, Sydney 2109, Australia.'}, {'ForeName': 'Jennie', 'Initials': 'J', 'LastName': 'C Brand-Miller', 'Affiliation': 'Charles Perkins Centre and School of Life and Environmental Sciences, The University of Sydney, Sydney 2006, Australia.'}]",Nutrients,['10.3390/nu12082173'] 2891,32708055,The Effect of Inquiry-Based Stress Reduction on Teacher Burnout: A Controlled Trial.,"Burnout is a well-known phenomenon with significant social, biological and economic costs. In particular, teacher burnout is associated with unfavorable mental health outcomes and economic costs due to reduced hours and teacher turnover. This study investigated the effect of an Inquiry-Based Stress Reduction (IBSR) cognitive-reframing program on teacher burnout using a quasi-experimental design. Fifty-three teachers participated in a prospective intervention with a passive control group. The intervention group completed a 12-week IBSR program with 4.5 h of weekly engagement. Relative to control, teachers in the intervention group showed greater improvements in emotional exhaustion (18.8 ± 5.2 to 15.9 ± 5.7 vs. 16.0 ± 4.8 to 17.4 ± 4.8; p = 0.01) and personal accomplishment (21.8 ± 5.0 to 24.6 ± 4.3 vs. 21.9 ± 4.5 to 22.8 ± 4.3; p = 0.04). Significant correlations were found between change in emotional exhaustion and negative affect (positive correlation; r = 0.32; p = 0.034) and between personal accomplishment and perceived stress (negative correlation; r = -0.451; p = 0.002). This study demonstrates the potential of IBSR to improve teacher well-being. Future randomized studies are needed to evaluate the causality of IBSR in reducing burnout among teachers and other high-stress workplaces.",2020,"Relative to control, teachers in the intervention group showed greater improvements in emotional exhaustion (18.8 ± 5.2 to 15.9 ± 5.7 vs. 16.0 ± 4.8 to 17.4 ± 4.8; p = 0.01) and personal accomplishment (21.8 ± 5.0 to 24.6 ± 4.3 vs. 21.9 ± 4.5 to 22.8 ± 4.3; p = 0.04).",['Fifty-three teachers participated in a prospective intervention with a passive control group'],"['Inquiry-Based Stress Reduction (IBSR) cognitive-reframing program', 'IBSR program with 4.5 h of weekly engagement', 'Inquiry-Based Stress Reduction']","['personal accomplishment', 'emotional exhaustion', 'personal accomplishment and perceived stress']","[{'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C3844009', 'cui_str': '4.5'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]",53.0,0.0193901,"Relative to control, teachers in the intervention group showed greater improvements in emotional exhaustion (18.8 ± 5.2 to 15.9 ± 5.7 vs. 16.0 ± 4.8 to 17.4 ± 4.8; p = 0.01) and personal accomplishment (21.8 ± 5.0 to 24.6 ± 4.3 vs. 21.9 ± 4.5 to 22.8 ± 4.3; p = 0.04).","[{'ForeName': 'Lia', 'Initials': 'L', 'LastName': 'Schnaider-Levi', 'Affiliation': 'Department of Health Promotion, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel.'}, {'ForeName': 'Ariel B', 'Initials': 'AB', 'LastName': 'Ganz', 'Affiliation': 'Department of Genetics, Stanford University, Stanford, CA 94305, USA.'}, {'ForeName': 'Keren', 'Initials': 'K', 'LastName': 'Zafrani', 'Affiliation': ""Begin High School, John Kennedy Street 8, Rosh Ha'Ayin 4852028, Israel.""}, {'ForeName': 'Zehavit', 'Initials': 'Z', 'LastName': 'Goldman', 'Affiliation': ""Begin High School, John Kennedy Street 8, Rosh Ha'Ayin 4852028, Israel.""}, {'ForeName': 'Inbal', 'Initials': 'I', 'LastName': 'Mitnik', 'Affiliation': ""Begin High School, John Kennedy Street 8, Rosh Ha'Ayin 4852028, Israel.""}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Rolnik', 'Affiliation': 'Department of Genetics, Stanford University, Stanford, CA 94305, USA.'}, {'ForeName': 'Shahar', 'Initials': 'S', 'LastName': 'Lev-Ari', 'Affiliation': 'Department of Health Promotion, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel.'}]",Brain sciences,['10.3390/brainsci10070468'] 2892,32708119,Neurophysiological Correlates of a Single Session of Prefrontal tDCS in Patients with Prolonged Disorders of Consciousness: A Pilot Double-Blind Randomized Controlled Study.,"Background. Transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex (lDLPFC) was reported to promote the recovery of signs of consciousness in some patients in a minimally conscious state (MCS), but its electrophysiological effects on brain activity remain poorly understood. Objective. We aimed to assess behavioral (using the Coma Recovery Scale-Revised; CRS-R) and neurophysiological effects (using high density electroencephalography; hdEEG) of lDLPFC-tDCS in patients with prolonged disorders of consciousness (DOC). Methods. In a double-blind, sham-controlled, crossover design, one active and one sham tDCS (2 mA, 20 min) were delivered in a randomized order. Directly before and after tDCS, 10 min of hdEEG were recorded and the CRS-R was administered. Results. Thirteen patients with severe brain injury were enrolled in the study. We found higher relative power at the group level after the active tDCS session in the alpha band in central regions and in the theta band over the frontal and posterior regions (uncorrected results). Higher weighted symbolic mutual information (wSMI) connectivity was found between left and right parietal regions, and higher fronto-parietal weighted phase lag index (wPLI) connectivity was found, both in the alpha band (uncorrected results). At the group level, no significant treatment effect was observed. Three patients showed behavioral improvement after the active session and one patient improved after the sham. Conclusion. We provide preliminary indications that neurophysiological changes can be observed after a single session of tDCS in patients with prolonged DOC, although they are not necessarily paralleled with significant behavioral improvements.",2020,We found higher relative power at the group level after the active tDCS session in the alpha band in central regions and in the theta band over the frontal and posterior regions (uncorrected results).,"['patients with prolonged disorders of consciousness (DOC', 'Patients with Prolonged Disorders of Consciousness', 'Thirteen patients with severe brain injury']","['Transcranial direct current stimulation (tDCS', 'lDLPFC-tDCS', 'Prefrontal tDCS']","['higher fronto-parietal weighted phase lag index (wPLI) connectivity', 'Higher weighted symbolic mutual information (wSMI) connectivity', 'behavioral improvement']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009792', 'cui_str': 'Consciousness Disorders'}, {'cui': 'C0011710', 'cui_str': 'desoxycorticosterone'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0442030', 'cui_str': 'Parietal'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0948775', 'cui_str': 'High weight'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",13.0,0.240879,We found higher relative power at the group level after the active tDCS session in the alpha band in central regions and in the theta band over the frontal and posterior regions (uncorrected results).,"[{'ForeName': 'Manon', 'Initials': 'M', 'LastName': 'Carrière', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Sepehr', 'Initials': 'S', 'LastName': 'Mortaheb', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'Raimondo', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Jitka', 'Initials': 'J', 'LastName': 'Annen', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Barra', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'Binda Fossati', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Chatelle', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Hermann', 'Affiliation': 'Institut du Cerveau et de la Moelle épinière, ICM, PICNIC Lab, F-75013 Paris, France.'}, {'ForeName': 'Géraldine', 'Initials': 'G', 'LastName': 'Martens', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Di Perri', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Laureys', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Aurore', 'Initials': 'A', 'LastName': 'Thibaut', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}]",Brain sciences,['10.3390/brainsci10070469'] 2893,31819995,"Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.","OBJECTIVE Data from two double-blind, randomized, Phase III studies were analysed to investigate the ability of Routine Assessment of Patient Index Data 3, DAS28 (CRP), modified (M)-DAS28 (CRP) and Simplified or Clinical Disease Activity Indices to predict structural damage progression in RA. METHODS This post hoc analysis included data from the 2-year Abatacept vs adaliMumab comParison in bioLogic-naïvE RA subjects with background MTX (AMPLE) trial in biologic-naïve patients with active RA (<5 years) and an inadequate response to MTX, and the 12-month treatment period of the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) trial in MTX-naïve patients with early RA (⩽2 years) and poor prognostic indicators. Adjusted logistic regression analysis assessed the relationship between baseline disease activity and structural damage progression (defined as change from baseline greater than the smallest detectable change) at 12 and 24 months in AMPLE and 6 and 12 months in AVERT. Areas under the receiver operating characteristic curves for the impact of baseline disease activity on structural damage progression were calculated. RESULTS Adjusted logistic regression analyses included all randomized and treated patients in AMPLE (N = 646) and those who received abatacept plus MTX or MTX monotherapy in AVERT (N = 235). Baseline Routine Assessment of Patient Index Data 3, DAS28 (CRP) and M-DAS28 (CRP) scores significantly predicted structural progression at months 12 and 24 in AMPLE (P < 0.05) and months 6 and 12 in AVERT (P < 0.01), and were stronger predictors than Simplified or Clinical Disease Activity Indices. CONCLUSION In this post hoc analysis of two patient populations with RA, Routine Assessment of Patient Index Data 3, DAS28 (CRP) and M-DAS28 (CRP) were good at predicting structural damage. TRIAL REGISTRATION ClinicalTrials.gov, http://clinicaltrials.gov: NCT00929864 (AMPLE); NCT01142726 (AVERT).",2020,"Baseline Routine Assessment of Patient Index Data 3, DAS28 (CRP) and M-DAS28 (CRP) scores significantly predicted structural progression at months 12 and 24 in AMPLE (P < 0.05) and months 6 and 12 in AVERT (P < 0.01), and were stronger predictors than Simplified or Clinical Disease Activity Indices. ",['comParison in bioLogic-naïvE RA subjects with background MTX (AMPLE) trial in biologic-naïve patients with active RA (<5 years'],"['adaliMumab', 'abatacept plus MTX or MTX monotherapy']","['Patient Index Data 3, DAS28 (CRP) and M-DAS28 (CRP) scores', 'Patient Index Data 3, DAS28 (CRP) and M-DAS28 (CRP', 'Disease activity measures', 'ability of Routine Assessment of Patient Index Data 3, DAS28 (CRP), modified (M)-DAS28 (CRP) and Simplified or Clinical Disease Activity Indices', 'baseline disease activity and structural damage progression']","[{'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C1122087', 'cui_str': 'adalimumab'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1122087', 'cui_str': 'adalimumab'}, {'cui': 'C1619966', 'cui_str': 'abatacept'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}]",646.0,0.149377,"Baseline Routine Assessment of Patient Index Data 3, DAS28 (CRP) and M-DAS28 (CRP) scores significantly predicted structural progression at months 12 and 24 in AMPLE (P < 0.05) and months 6 and 12 in AVERT (P < 0.01), and were stronger predictors than Simplified or Clinical Disease Activity Indices. ","[{'ForeName': 'Edward C', 'Initials': 'EC', 'LastName': 'Keystone', 'Affiliation': 'Department of Rheumatology, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Harris A', 'Initials': 'HA', 'LastName': 'Ahmad', 'Affiliation': 'Rheumatology, Bristol-Myers Squibb, Princeton, NJ.'}, {'ForeName': 'Yusuf', 'Initials': 'Y', 'LastName': 'Yazici', 'Affiliation': 'Department of Internal Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY.'}, {'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'Bergman', 'Affiliation': 'Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA.'}]","Rheumatology (Oxford, England)",['10.1093/rheumatology/kez455'] 2894,32710741,"Impact of habituated dietary protein intake on fasting and postprandial whole-body protein turnover and splanchnic amino acid metabolism in elderly men: a randomized, controlled, crossover trial.","BACKGROUND Efficacy of protein absorption and subsequent amino acid utilization may be reduced in the elderly. Higher protein intakes have been suggested to counteract this. OBJECTIVES We aimed to elucidate how habituated amounts of protein intake affect the fasted state of, and the stimulatory effect of a protein-rich meal on, protein absorption, whole-body protein turnover, and splanchnic amino acid metabolism. METHODS Twelve men (65-70 y) were included in a double-blinded crossover intervention study, consisting of a 20-d habituation period to a protein intake at the RDA or a high amount [1.1 g · kg lean body mass (LBM)-1 · d-1 or >2.1 g · kg LBM-1 · d-1, respectively], each followed by an experimental trial with a primed, constant infusion of D8-phenylalanine and D2-tyrosine. Arterial and hepatic venous blood samples were obtained after an overnight fast and repeatedly 4 h after a standardized meal including intrinsically labeled whey protein concentrate and calcium-caseinate proteins. Blood was analyzed for amino acid concentrations and phenylalanine and tyrosine tracer enrichments from which whole-body and splanchnic amino acid and protein kinetics were calculated. RESULTS High (compared with the recommended amount of) protein intake resulted in a higher fasting whole-body protein turnover with a resultant mean ± SEM 0.03 ± 0.01 μmol · kg LBM-1 · min-1 lower net balance (P < 0.05), which was not rescued by the intake of a protein-dense meal. The mean ± SEM plasma protein fractional synthesis rate was 0.13 ± 0.06%/h lower (P < 0.05) after habituation to high protein. Furthermore, higher fasting and postprandial amino acid removal were observed after habituation to high protein, yielding higher urea excretion and increased phenylalanine oxidation rates (P < 0.01). CONCLUSIONS Three weeks of habituation to high protein intake (>2.1 g protein · kg LBM-1 · d-1) led to a significantly higher net protein loss in the fasted state. This was not compensated for in the 4-h postprandial period after intake of a meal high in protein.This trial was registered at clinicaltrials.gov as NCT02587156.",2020,The mean ± SEM plasma protein fractional synthesis rate was 0.13 ± 0.06%/h lower (P < 0.05) after habituation to high protein.,"['elderly men', 'Twelve men (65-70 y']","['habituated dietary protein intake', 'D8-phenylalanine and D2-tyrosine', 'protein-rich meal']","['net protein loss', 'fasting and postprandial whole-body protein turnover and splanchnic amino acid metabolism', 'Arterial and hepatic venous blood samples', 'phenylalanine oxidation rates', 'higher fasting and postprandial amino acid removal', 'mean ± SEM plasma protein fractional synthesis rate']","[{'cui': 'C0524337', 'cui_str': 'Elderly man'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0425424', 'cui_str': 'Dietary protein intake'}, {'cui': 'C0031453', 'cui_str': 'Phenylalanine'}, {'cui': 'C0041485', 'cui_str': 'Tyrosine'}, {'cui': 'C0444661', 'cui_str': 'Protein-rich meal'}]","[{'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0031227', 'cui_str': 'Employee Turnover'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0444255', 'cui_str': 'Venous blood specimen'}, {'cui': 'C0031453', 'cui_str': 'Phenylalanine'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0262878', 'cui_str': 'Scanning electron microscope'}, {'cui': 'C0032120', 'cui_str': 'Plasma protein'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}]",,0.0590021,The mean ± SEM plasma protein fractional synthesis rate was 0.13 ± 0.06%/h lower (P < 0.05) after habituation to high protein.,"[{'ForeName': 'Grith', 'Initials': 'G', 'LastName': 'Højfeldt', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M81, Bispebjerg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Bülow', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M81, Bispebjerg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Agergaard', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M81, Bispebjerg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Asmar', 'Affiliation': 'Department of Clinical Physiology and Nuclear Medicine, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Schjerling', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M81, Bispebjerg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Lene', 'Initials': 'L', 'LastName': 'Simonsen', 'Affiliation': 'Department of Clinical Physiology and Nuclear Medicine, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Bülow', 'Affiliation': 'Department of Clinical Physiology and Nuclear Medicine, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Gerrit', 'Initials': 'G', 'LastName': 'van Hall', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Holm', 'Affiliation': 'Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M81, Bispebjerg Hospital, Copenhagen, Denmark.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa201'] 2895,32710787,Blood 15N:13C Enrichment Ratios Are Proportional to the Ingested Quantity of Protein with the Dual-Tracer Approach for Determining Amino Acid Bioavailability in Humans.,"BACKGROUND Assessment of amino acid bioavailability is of key importance for the evaluation of protein quality; however, measuring ileal digestibility of dietary proteins in humans is challenging. Therefore, a less-invasive dual stable isotope tracer approach was developed. OBJECTIVE We aimed to test the assumption that the 15N:13C enrichment ratio in the blood increases proportionally to the quantity ingested by applying different quantities of 15N test protein. METHODS In a crossover design, 10 healthy adults were given a semi-liquid mixed meal containing 25 g (low protein) or 50 g (high protein) of 15N-labeled milk protein concentrate simultaneous with 0.4 g of highly 13C-enriched spirulina. The meal was distributed over multiple small portions, frequently provided every 20 min during a period of 160 min. For several amino acids, the blood 15N- related to 13C-isotopic enrichment ratio was determined at t = 0, 30, 60, 90, 120, 180, 240, 300, and 360 min and differences between the 2 meals were compared using paired analyses. RESULTS No differences in 13C AUC for each of the measured amino acids in serum was observed when ingesting a low- or high-protein meal, whereas 15N AUC of amino acids was ∼2 times larger on the high-protein meal (P < 0.001). Doubling the intake of 15N-labeled amino acids increased the 15N:13C ratio by a factor of 2.04 ± 0.445 for lysine and a factor between 1.8 and 2.2 for other analyzed amino acids, with only phenylalanine (2.26), methionine (2.48), and tryptophan (3.02) outside this range. CONCLUSIONS The amino acid 15N:13C enrichment ratio in the peripheral circulation increased proportionally to the quantity of 15N-labeled milk protein ingested, especially for lysine, in healthy adults. However, when using 15N-labeled protein, correction for, e.g., α-carbon 15N atom transamination is advised for determination of bioavailability of individual amino acids. This trial was registered at www.clinicaltrials.gov as NCT02966704.",2020,"The amino acid 15N:13C enrichment ratio in the peripheral circulation increased proportionally to the quantity of 15N-labeled milk protein ingested, especially for lysine, in healthy adults.","['10 healthy adults', 'healthy adults']",['semi-liquid mixed meal containing 25 g (low protein) or 50 g (high protein) of 15N-labeled milk protein concentrate simultaneous with 0.4 g of highly 13C-enriched spirulina'],"['13C AUC', '13C-isotopic enrichment ratio', '15N:13C ratio', 'amino acids in serum', 'Blood 15N:13C']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0456638', 'cui_str': '25G'}, {'cui': 'C0242972', 'cui_str': 'Low protein diet'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0026138', 'cui_str': 'Milk protein'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C4517457', 'cui_str': '0.4'}, {'cui': 'C0075026', 'cui_str': 'Spirulina'}]","[{'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005767', 'cui_str': 'Blood'}]",10.0,0.0251836,"The amino acid 15N:13C enrichment ratio in the peripheral circulation increased proportionally to the quantity of 15N-labeled milk protein ingested, especially for lysine, in healthy adults.","[{'ForeName': 'Nikkie', 'Initials': 'N', 'LastName': 'van der Wielen', 'Affiliation': 'Division of Human Nutrition, Wageningen University and Research, Wageningen, Netherlands.'}, {'ForeName': 'Nadezda V', 'Initials': 'NV', 'LastName': 'Khodorova', 'Affiliation': 'UMR Physiologie de la nutrition et du comportement alimentaire, AgroParisTech, National Research Institute for Agriculture, Food and Environment, Université Paris-Saclay, Paris, France.'}, {'ForeName': 'Walter J J', 'Initials': 'WJJ', 'LastName': 'Gerrits', 'Affiliation': 'Animal Nutrition Group, Wageningen University and Research, Wageningen, Netherlands.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Gaudichon', 'Affiliation': 'UMR Physiologie de la nutrition et du comportement alimentaire, AgroParisTech, National Research Institute for Agriculture, Food and Environment, Université Paris-Saclay, Paris, France.'}, {'ForeName': 'Juliane', 'Initials': 'J', 'LastName': 'Calvez', 'Affiliation': 'UMR Physiologie de la nutrition et du comportement alimentaire, AgroParisTech, National Research Institute for Agriculture, Food and Environment, Université Paris-Saclay, Paris, France.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Tomé', 'Affiliation': 'UMR Physiologie de la nutrition et du comportement alimentaire, AgroParisTech, National Research Institute for Agriculture, Food and Environment, Université Paris-Saclay, Paris, France.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Mensink', 'Affiliation': 'Division of Human Nutrition, Wageningen University and Research, Wageningen, Netherlands.'}]",The Journal of nutrition,['10.1093/jn/nxaa205'] 2896,32710862,Effect of a quality improvement package for intrapartum and immediate newborn care on fresh stillbirth and neonatal mortality among preterm and low-birthweight babies in Kenya and Uganda: a cluster-randomised facility-based trial.,"BACKGROUND Although gains in newborn survival have been achieved in many low-income and middle-income countries, reductions in stillbirth and neonatal mortality have been slow. Prematurity complications are a major driver of stillbirth and neonatal mortality. We aimed to assess the effect of a quality improvement package for intrapartum and immediate newborn care on stillbirth and preterm neonatal survival in Kenya and Uganda, where evidence-based practices are often underutilised. METHODS This unblinded cluster-randomised controlled trial was done in western Kenya and eastern Uganda at facilities that provide 24-h maternity care with at least 200 births per year. The study assessed outcomes of low-birthweight and preterm babies. Eligible facilities were pair-matched and randomly assigned (1:1) into either the intervention group or the control group. All facilities received maternity register data strengthening and a modified WHO Safe Childbirth Checklist; facilities in the intervention group additionally received provider mentoring using PRONTO simulation and team training as well as quality improvement collaboratives. Liveborn or fresh stillborn babies who weighed between 1000 g and 2500 g, or less than 3000 g with a recorded gestational age of less than 37 weeks, were included in the analysis. We abstracted data from maternity registers for maternal and birth outcomes. Follow-up was done by phone or in person to identify the status of the infant at 28 days. The primary outcome was fresh stillbirth and 28-day neonatal mortality. This trial is registered with ClinicalTrials.gov, NCT03112018. FINDINGS Between Oct 1, 2016, and April 30, 2019, 20 facilities were randomly assigned to either the intervention group (n=10) or the control group (n=10). Among 5343 eligible babies in these facilities, we assessed outcomes of 2938 newborn and fresh stillborn babies (1447 in the intervention and 1491 in the control group). 347 (23%) of 1491 infants in the control group were stillborn or died in the neonatal period compared with 221 (15%) of 1447 infants in the intervention group at 28 days (odds ratio 0·66, 95% CI 0·54-0·81). No harm or adverse effects were found. INTERPRETATION Fresh stillbirth and neonatal mortality among low-birthweight and preterm babies can be decreased using a package of interventions that reinforces evidence-based practices and invests in health system strengthening. FUNDING Bill & Melinda Gates Foundation.",2020,"347 (23%) of 1491 infants in the control group were stillborn or died in the neonatal period compared with 221 (15%) of 1447 infants in the intervention group at 28 days (odds ratio 0·66, 95% CI 0·54-0·81).","['Liveborn or fresh stillborn babies who weighed between 1000 g and 2500 g, or less than 3000 g with a recorded gestational age of less than 37 weeks, were included in the analysis', 'Between Oct 1, 2016, and April 30, 2019', 'western Kenya and eastern Uganda at facilities that provide 24-h maternity care with at least 200 births per year', ' 20 facilities', '5343 eligible babies in these facilities, we assessed outcomes of 2938 newborn and fresh stillborn babies (1447 in the intervention and 1491 in the control group', 'preterm and low-birthweight babies in Kenya and Uganda']","['provider mentoring using PRONTO simulation and team training', 'quality improvement package for intrapartum and immediate newborn care']","['fresh stillbirth and 28-day neonatal mortality', 'low-birthweight and preterm babies', 'fresh stillbirth and neonatal mortality', 'stillborn or died', 'harm or adverse effects', 'stillbirth and preterm neonatal survival']","[{'cui': 'C0443224', 'cui_str': 'Fresh'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C4319601', 'cui_str': '2500'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0470279', 'cui_str': '3000'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1442824', 'cui_str': 'POU2F1 protein, human'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0041573', 'cui_str': 'Uganda'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0439508', 'cui_str': '/year'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}]","[{'cui': 'C1260720', 'cui_str': 'Pronto'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C2936612', 'cui_str': 'Quality Improvement'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C0456337', 'cui_str': 'Intrapartum'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0204792', 'cui_str': 'Routine care of newborn'}]","[{'cui': 'C0405334', 'cui_str': 'Fresh stillbirth'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0027616', 'cui_str': 'Neonatal Mortality'}, {'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infants'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.207075,"347 (23%) of 1491 infants in the control group were stillborn or died in the neonatal period compared with 221 (15%) of 1447 infants in the intervention group at 28 days (odds ratio 0·66, 95% CI 0·54-0·81).","[{'ForeName': 'Dilys', 'Initials': 'D', 'LastName': 'Walker', 'Affiliation': 'Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA. Electronic address: dilys.walker@ucsf.edu.'}, {'ForeName': 'Phelgona', 'Initials': 'P', 'LastName': 'Otieno', 'Affiliation': 'Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Butrick', 'Affiliation': 'Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Gertrude', 'Initials': 'G', 'LastName': 'Namazzi', 'Affiliation': 'Maternal, Newborn and Child Health Centre of Excellence, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Achola', 'Affiliation': 'Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Rikita', 'Initials': 'R', 'LastName': 'Merai', 'Affiliation': 'Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Otare', 'Affiliation': 'Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Mubiri', 'Affiliation': 'Maternal, Newborn and Child Health Centre of Excellence, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda.'}, {'ForeName': 'Rakesh', 'Initials': 'R', 'LastName': 'Ghosh', 'Affiliation': 'Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Santos', 'Affiliation': 'Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Miller', 'Affiliation': 'Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Nancy L', 'Initials': 'NL', 'LastName': 'Sloan', 'Affiliation': 'Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Waiswa', 'Affiliation': 'Maternal, Newborn and Child Health Centre of Excellence, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda; Global Health Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Global health,['10.1016/S2214-109X(20)30232-1'] 2897,32706953,Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.,"BACKGROUND Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited. METHODS We conducted a multicenter, randomized, open-label, three-group, controlled trial involving hospitalized patients with suspected or confirmed Covid-19 who were receiving either no supplemental oxygen or a maximum of 4 liters per minute of supplemental oxygen. Patients were randomly assigned in a 1:1:1 ratio to receive standard care, standard care plus hydroxychloroquine at a dose of 400 mg twice daily, or standard care plus hydroxychloroquine at a dose of 400 mg twice daily plus azithromycin at a dose of 500 mg once daily for 7 days. The primary outcome was clinical status at 15 days as assessed with the use of a seven-level ordinal scale (with levels ranging from one to seven and higher scores indicating a worse condition) in the modified intention-to-treat population (patients with a confirmed diagnosis of Covid-19). Safety was also assessed. RESULTS A total of 667 patients underwent randomization; 504 patients had confirmed Covid-19 and were included in the modified intention-to-treat analysis. As compared with standard care, the proportional odds of having a higher score on the seven-point ordinal scale at 15 days was not affected by either hydroxychloroquine alone (odds ratio, 1.21; 95% confidence interval [CI], 0.69 to 2.11; P = 1.00) or hydroxychloroquine plus azithromycin (odds ratio, 0.99; 95% CI, 0.57 to 1.73; P = 1.00). Prolongation of the corrected QT interval and elevation of liver-enzyme levels were more frequent in patients receiving hydroxychloroquine, alone or with azithromycin, than in those who were not receiving either agent. CONCLUSIONS Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care. (Funded by the Coalition Covid-19 Brazil and EMS Pharma; ClinicalTrials.gov number, NCT04322123.).",2020,"Prolongation of the corrected QT interval and elevation of liver-enzyme levels were more frequent in patients receiving hydroxychloroquine, alone or with azithromycin, than in those who were not receiving either agent. ","['hospitalized patients with suspected or confirmed Covid-19 who were receiving either no supplemental oxygen or a maximum of 4 liters per minute of supplemental oxygen', 'Mild-to-Moderate Covid-19', 'patients with coronavirus disease 2019 (Covid-19', 'patients hospitalized with mild-to-moderate Covid-19', '667 patients underwent randomization; 504 patients had confirmed Covid-19 and were included in the modified intention-to-treat analysis']","['Hydroxychloroquine and azithromycin', 'hydroxychloroquine', 'hydroxychloroquine plus azithromycin', 'Hydroxychloroquine with or without Azithromycin', 'azithromycin', 'standard care, standard care plus hydroxychloroquine at a dose of 400 mg twice daily, or standard care plus hydroxychloroquine']","['safety and efficacy', 'Safety', 'Prolongation of the corrected QT interval and elevation of liver-enzyme levels', 'clinical status at 15 days as assessed with the use of a seven-level ordinal scale']","[{'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0439393', 'cui_str': 'L/min'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C4517851', 'cui_str': '667'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}]","[{'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0429028', 'cui_str': 'QT interval feature'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0428321', 'cui_str': 'Measurement of liver enzyme'}, {'cui': 'C0449440', 'cui_str': 'Clinical status'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439080', 'cui_str': 'Ordinal number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",667.0,0.251782,"Prolongation of the corrected QT interval and elevation of liver-enzyme levels were more frequent in patients receiving hydroxychloroquine, alone or with azithromycin, than in those who were not receiving either agent. ","[{'ForeName': 'Alexandre B', 'Initials': 'AB', 'LastName': 'Cavalcanti', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Fernando G', 'Initials': 'FG', 'LastName': 'Zampieri', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Regis G', 'Initials': 'RG', 'LastName': 'Rosa', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Luciano C P', 'Initials': 'LCP', 'LastName': 'Azevedo', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Viviane C', 'Initials': 'VC', 'LastName': 'Veiga', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Avezum', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Lucas P', 'Initials': 'LP', 'LastName': 'Damiani', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Aline', 'Initials': 'A', 'LastName': 'Marcadenti', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Letícia', 'Initials': 'L', 'LastName': 'Kawano-Dourado', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Thiago', 'Initials': 'T', 'LastName': 'Lisboa', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Debora L M', 'Initials': 'DLM', 'LastName': 'Junqueira', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Pedro G M', 'Initials': 'PGM', 'LastName': 'de Barros E Silva', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Tramujas', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Erlon O', 'Initials': 'EO', 'LastName': 'Abreu-Silva', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Ligia N', 'Initials': 'LN', 'LastName': 'Laranjeira', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Aline T', 'Initials': 'AT', 'LastName': 'Soares', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Leandro S', 'Initials': 'LS', 'LastName': 'Echenique', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Adriano J', 'Initials': 'AJ', 'LastName': 'Pereira', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Flávio G R', 'Initials': 'FGR', 'LastName': 'Freitas', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Otávio C E', 'Initials': 'OCE', 'LastName': 'Gebara', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Vicente C S', 'Initials': 'VCS', 'LastName': 'Dantas', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Remo H M', 'Initials': 'RHM', 'LastName': 'Furtado', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Eveline P', 'Initials': 'EP', 'LastName': 'Milan', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Nicole A', 'Initials': 'NA', 'LastName': 'Golin', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Fábio F', 'Initials': 'FF', 'LastName': 'Cardoso', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Israel S', 'Initials': 'IS', 'LastName': 'Maia', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Conrado R', 'Initials': 'CR', 'LastName': 'Hoffmann Filho', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Adrian P M', 'Initials': 'APM', 'LastName': 'Kormann', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Roberto B', 'Initials': 'RB', 'LastName': 'Amazonas', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Monalisa F', 'Initials': 'MF', 'LastName': 'Bocchi de Oliveira', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Ary', 'Initials': 'A', 'LastName': 'Serpa-Neto', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Maicon', 'Initials': 'M', 'LastName': 'Falavigna', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Renato D', 'Initials': 'RD', 'LastName': 'Lopes', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Flávia R', 'Initials': 'FR', 'LastName': 'Machado', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': 'Otavio', 'Initials': 'O', 'LastName': 'Berwanger', 'Affiliation': 'From HCor Research Institute (A.B.C., F.G.Z., L.P.D., A.M., L.K.-D., T.L., D.L.M.J., P.G.M.B.S., L.T., E.O.A.-S., L.N.L., I.S.M.), Brazilian Research in Intensive Care Network (A.B.C., F.G.Z., R.G.R., L.C.P.A., V.C.V., T.L., F.G.R.F., A.S.-N., F.R.M.), Hospital Sírio Libanês Research and Education Institute (L.C.P.A.), BP-A Beneficência Portuguesa de São Paulo (V.C.V.), International Research Center, Hospital Alemão Oswaldo Cruz (A.A.), Brazilian Clinical Research Institute (P.G.M.B.S., R.D.L.), Hospital São Camilo (A.T.S.), Hospital Moriah (L.S.E.), Academic Research Organization of Hospital Israelita Albert Einstein (R.H.M.F., O.B.), Hospital Israelita Albert Einstein (L.S.E., A.J.P., A.S.-N.), Hospital Sepaco (F.G.R.F.), and Hospital Santa Paula (O.C.E.G.), São Paulo, Hospital Moinhos de Vento, Porto Alegre (R.G.R., M.F.), Hospital Naval Marcílio Dias, Rio de Janeiro (V.C.S.D.), Hospital Giselda Trigueiro, Natal (E.P.M.), Instituto Tacchini de Pesquisa em Saúde, Hospital Tacchini, Bento Gonçalves (N.A.G.), Hospital Bruno Born, Lajeado (F.F.C.), Hospital Baia Sul, Florianópolis (I.S.M.), Hospital Regional Hans Dieter Schmidt, Joinville (C.R.H.F.); Angiocor Blumenau, Blumenau (A.P.M.K.), and EMS Pharma, Hortolândia (R.B.A., M.F.B.O.) - all in Brazil; and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa2019014'] 2898,32706996,Changes in the Health-Related Quality of Life and Weight Status of Children with Overweight or Obesity Aged 7 to 13 Years after Participating in a 10-Week Lifestyle Intervention.,"Background: The aim of the study was to assess changes in the health-related quality of life (HRQOL) and weight status of children with overweight and obesity after participating in a 10-week family-based combined lifestyle group intervention in their community. Methods: In total, 340 children with overweight or obesity aged between 7 and 13 years, as well as one of their primary caregivers, took part in this intervention, in a real-world setting. The intervention comprised 20 group sessions for a 10-week period, and focused on improving knowledge, attitudes, social support, and self-efficacy in regard to healthy lifestyles. The Pediatric Quality of Life Inventory 4.0 (PedsQL) and Impact of Weight on Quality of Life-Kids (IWQOL-KIDS) questionnaires were used to determine generic and weight-specific HRQOL. Changes in HRQOL and BMI (standard deviation [SDS] of BMI, objectively measured) were tested using a Wilcoxon signed-rank test, Mann-Whitney U test, and paired t -test. Results: Generic quality of life ( Z  = -3.58, r  = -0.25), weight-specific quality of life ( Z  = -4.83, r  = -0.34), and SDS-BMI ( d  = 0.21) were all significantly improved after participating in the 10-week intervention. The mean attendance rate was 73.74%. Conclusion: This study demonstrated that participation in the intervention LEFF for children with overweight and obesity was associated with improved generic and weight-specific HRQOL and SDS-BMI.",2020,"Results: Generic quality of life ( Z  = -3.58, r  = -0.25), weight-specific quality of life ( Z  = -4.83, r  = -0.34), and SDS-BMI ( d  = 0.21) were all significantly improved after participating in the 10-week intervention.","['Children with Overweight or Obesity Aged 7 to 13 Years after Participating in a 10-Week Lifestyle Intervention', 'children with overweight and obesity after participating in a 10-week family-based combined lifestyle group intervention in their community', '340 children with overweight or obesity aged between 7 and 13 years, as well as one of their primary caregivers, took part in this intervention, in a real-world setting', 'children with overweight and obesity']",[],"['Pediatric Quality of Life Inventory 4.0 (PedsQL) and Impact of Weight on Quality of Life-Kids (IWQOL-KIDS) questionnaires', 'mean attendance rate', 'HRQOL and BMI (standard deviation [SDS] of BMI, objectively measured', 'SDS-BMI', 'Health-Related Quality of Life and Weight Status', 'health-related quality of life (HRQOL) and weight status', 'weight-specific quality of life', 'Generic quality of life']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C4517730', 'cui_str': '340'}, {'cui': 'C1319883', 'cui_str': 'Primary caregiver'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0449719', 'cui_str': 'Part'}]",[],"[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0037506', 'cui_str': 'Sodium lauryl sulfate'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}]",340.0,0.0233863,"Results: Generic quality of life ( Z  = -3.58, r  = -0.25), weight-specific quality of life ( Z  = -4.83, r  = -0.34), and SDS-BMI ( d  = 0.21) were all significantly improved after participating in the 10-week intervention.","[{'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'van den Eynde', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Roxanna', 'Initials': 'R', 'LastName': 'Camfferman', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Linda R', 'Initials': 'LR', 'LastName': 'Putten', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Carry M', 'Initials': 'CM', 'LastName': 'Renders', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Jacob C', 'Initials': 'JC', 'LastName': 'Seidell', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Jutka', 'Initials': 'J', 'LastName': 'Halberstadt', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Institute, Amsterdam, the Netherlands.'}]",Childhood obesity (Print),['10.1089/chi.2020.0070'] 2899,32707001,Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study.,"MicroRNA (miRNA) inhibition is a promising therapeutic strategy in several disease indications. MRG-110 is a locked nucleic acid-based antisense oligonucleotide that targets miR-92a-3p and experimentally was shown to have documented therapeutic effects on cardiovascular disease and wound healing. To gain first insights into the activity of anti-miR-92a in humans, we investigated miR-92a-3p expression in several blood compartments and assessed the effect of MRG-110 on target derepression. Healthy adults were randomly assigned (5:2) to receive a single intravenous dose of MRG-110 or placebo in one of seven sequential ascending intravenous dose cohorts ranging from 0.01 to 1.5 mg/kg body weight. MiR-92a-3p whole blood levels were time and dose dependently decreased with half-maximal inhibition of 0.27 and 0.31 mg/kg at 24 and 72 h after dosing, respectively. In the high-dose groups, >95% inhibition was detected at 24-72 h postinfusion and significant inhibition was observed for 2 weeks. Similar inhibitory effects were detected in isolated CD31 + cells, and miR-92a-3p expression was also inhibited in extracellular vesicles in the high-dose group. Target derepression was measured in whole blood and showed that ITGA5 and CD93 were increased at a dose of 1.5 mg/kg. Single-cell RNA sequencing of peripheral blood cells revealed a cell type-specific derepression of miR-92a targets. Together this study demonstrates that systemic infusion of anti-miR-92a efficiently inhibits miR-92a in the peripheral blood compartment and derepresses miR-92a targets in humans.",2020,"MiR-92a-3p whole blood levels were time and dose dependently decreased with half-maximal inhibition of 0.27 and 0.31 mg/kg at 24 and 72 h after dosing, respectively.",['Healthy adults'],"['MRG-110', 'MRG-110 or placebo']","['MiR-92a-3p whole blood levels', 'Target derepression', 'ITGA5 and CD93', 'isolated CD31 + cells, and miR-92a-3p expression']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1101610', 'cui_str': 'MicroRNA'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1531430', 'cui_str': 'ITGA5 protein, human'}, {'cui': 'C0368875', 'cui_str': 'Lymphocyte antigen CD93'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0081939', 'cui_str': 'Lymphocyte antigen CD31'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}]",,0.0799216,"MiR-92a-3p whole blood levels were time and dose dependently decreased with half-maximal inhibition of 0.27 and 0.31 mg/kg at 24 and 72 h after dosing, respectively.","[{'ForeName': 'Wesley Tyler', 'Initials': 'WT', 'LastName': 'Abplanalp', 'Affiliation': 'Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Frankfurt, Germany.'}, {'ForeName': 'Ariane', 'Initials': 'A', 'LastName': 'Fischer', 'Affiliation': 'Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Frankfurt, Germany.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'John', 'Affiliation': 'Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Frankfurt, Germany.'}, {'ForeName': 'Andreas M', 'Initials': 'AM', 'LastName': 'Zeiher', 'Affiliation': 'German Center for Cardiovascular Research (DZHK), Frankfurt, Germany.'}, {'ForeName': 'Willy', 'Initials': 'W', 'LastName': 'Gosgnach', 'Affiliation': 'CentEX Biotechnology, Institut de Recherche SERVIER, Paris, France.'}, {'ForeName': 'Helene', 'Initials': 'H', 'LastName': 'Darville', 'Affiliation': 'CentEX Biotechnology, Institut de Recherche SERVIER, Paris, France.'}, {'ForeName': 'Rusty', 'Initials': 'R', 'LastName': 'Montgomery', 'Affiliation': 'miRagen Therapeutics, Inc., Boulder, Colorado, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Pestano', 'Affiliation': 'miRagen Therapeutics, Inc., Boulder, Colorado, USA.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Allée', 'Affiliation': 'Center for Therapeutic Innovation Cardiovascular and Metabolic Disease, Institut de Recherches Internationales SERVIER, Paris, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Paty', 'Affiliation': 'Center for Therapeutic Innovation Cardiovascular and Metabolic Disease, Institut de Recherches Internationales SERVIER, Paris, France.'}, {'ForeName': 'Francoise', 'Initials': 'F', 'LastName': 'Fougerousse', 'Affiliation': 'Center for Therapeutic Innovation Cardiovascular and Metabolic Disease, Institut de Recherches Internationales SERVIER, Paris, France.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Dimmeler', 'Affiliation': 'Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Frankfurt, Germany.'}]",Nucleic acid therapeutics,['10.1089/nat.2020.0871'] 2900,32707101,The family check-up 4 health: Study protocol of a randomized type II hybrid effectiveness-implementation trial in integrated primary care (the healthy communities 4 healthy students study).,"BACKGROUND Parenting interventions like the Family Check-Up have demonstrated effects on child physical and behavioral health outcomes. However, access to these programs is limited, particularly for populations experiencing health disparities. Primary care settings have become recognized as a potential delivery system in which these programs may be implemented at scale. The purpose of this trial is to test the effectiveness of the Family Check-Up 4 Health (FCU4Health) program, an adaptation of the FCU for primary care, and assess program implementation in an integrated primary care setting. METHODS We will conduct a hybrid type 2 effectiveness-implementation trial in partnership with a primary care clinic in a low-income, majority Latino community. Families with 2- to 5-year-old children will be eligible to participate. Families will be randomized to receive the intervention (n = 130) or services as usual (n = 70) and will be assessed annually over three years. Outcomes are informed by the RE-AIM framework (i.e., reach, effectiveness, adoption, implementation, and maintenance). Effectiveness outcomes include child health behaviors (e.g., Dietary Screener Questionnaire), behavioral health (e.g., Strengths and Difficulties Questionnaire), and parenting (e.g., Proactive Parenting). Early stage implementation outcomes are also included (e.g., cost, acceptability, appropriateness, and feasibility). Effectiveness outcomes will be assessed via intent-to-treat (ITT) analyses. Implementation outcomes will be primarily descriptive with comparisons to prior trials of FCU4Health and the original FCU. PROJECTED OUTCOMES This trial will provide evidence related to the potential of integrated primary care settings to deliver evidence-based preventive interventions with a dual focus on behavioral and physical health.",2020,"The purpose of this trial is to test the effectiveness of the Family Check-Up 4 Health (FCU4Health) program, an adaptation of the FCU for primary care, and assess program implementation in an integrated primary care setting. ","['partnership with a primary care clinic in a low-income, majority Latino community', 'Families with 2- to 5-year-old children', 'integrated primary care (the healthy communities 4 healthy students study']",['Family Check-Up 4 Health (FCU4Health) program'],"['RE-AIM framework (i.e., reach, effectiveness, adoption, implementation, and maintenance', 'cost, acceptability, appropriateness, and feasibility', 'child health behaviors (e.g., Dietary Screener Questionnaire), behavioral health (e.g., Strengths and Difficulties Questionnaire), and parenting (e.g., Proactive Parenting']","[{'cui': 'C1552443', 'cui_str': 'Primary care clinic'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0420160', 'cui_str': 'History and physical examination, school'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C2744535', 'cui_str': 'CD69 protein, human'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0001593', 'cui_str': 'Adoption'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0008078', 'cui_str': 'Child health care'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0870196', 'cui_str': 'Behavioral health'}, {'cui': 'C3472494', 'cui_str': 'Strengths and difficulties questionnaire'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}]",,0.0514529,"The purpose of this trial is to test the effectiveness of the Family Check-Up 4 Health (FCU4Health) program, an adaptation of the FCU for primary care, and assess program implementation in an integrated primary care setting. ","[{'ForeName': 'Cady', 'Initials': 'C', 'LastName': 'Berkel', 'Affiliation': ""REACH Institute, Arizona State University, Tempe, AZ, USA; Phoenix Children's Hospital, Phoenix, AZ, USA. Electronic address: Cady.Berkel@asu.edu.""}, {'ForeName': 'Justin D', 'Initials': 'JD', 'LastName': 'Smith', 'Affiliation': 'Center for Prevention Implementation Methodology (Ce-PIM), Department of Psychiatry and Behavioral Sciences, Department of Preventive Medicine, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Meg M', 'Initials': 'MM', 'LastName': 'Bruening', 'Affiliation': 'Department of Nutrition, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Jordan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Fu', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Mauricio', 'Affiliation': 'REACH Institute, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Kevin J', 'Initials': 'KJ', 'LastName': 'Grimm', 'Affiliation': 'Department of Psychology, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Winslow', 'Affiliation': 'REACH Institute, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Ray', 'Affiliation': 'Bayless Integrated Healthcare, Phoenix, AZ, USA.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Bourne', 'Affiliation': 'Southwest Maricopa Regional Council, First Things First, Peoria, AZ, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Dishion', 'Affiliation': 'REACH Institute, Arizona State University, Tempe, AZ, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106088'] 2901,32707159,Obesity blunts cephalic-phase microvascular responses to food.,"Neurally mediated anticipatory responses, also named cephalic-phase responses, and microcirculatory regulation are two important mechanisms to maintain metabolic homeostasis. Altered cephalic-phase responses in obesity and its metabolic consequences have been proposed. There is, however, a lack of studies focusing on in vivo assessment of the microcirculation during this phase in patients with obesity. In this randomized controlled trial, we selected patients with obesity and healthy subjects after clinical and laboratory assessments. Those with obesity were randomized into two groups: experimental (cephalic-phase microvascular response stimulation - CP group, n=13) and controls (n=14). Healthy subjects (n=17) were also included to form a CP control group. Skin microvascular assessment was used as a model of systemic microcirculation. Resting functional capillary density (FCD) and peak FCD during post-occlusive reactive hyperemia (PORH) were measured by dorsal finger videocapillaroscopy and expressed mainly capillary recruitment capacity. Resting red blood cell velocity (RBCV), peak RBCV during PORH (RBCV max ), and time taken to reach RBCV max (TRBCV max ) were assessed by dynamic nailfold videocapillaroscopy and expressed the microhemodynamics. Patients with obesity (with or without stimulus) failed to show an increase on FCD during PORH post-stimulus (p=0.221 and p=0.307, respectively) depicting lack of capillary recruitment. In contrast, healthy subjects presented an increase in this microvascular outcome (p=0.004). Changes in all variables of microhemodynamics occurred in both CP groups (healthy and those with obesity). During CP, we originally demonstrated an absence of capillary recruitment in subjects with obesity. These findings might contribute to the literature of microvascular impairment and metabolic conditions.",2020,"Patients with obesity (with or without stimulus) failed to show an increase on FCD during PORH post-stimulus (p=0.221 and p=0.307, respectively) depicting lack of capillary recruitment.","['healthy subjects', 'Patients with obesity (with or without stimulus', 'group, n=13) and controls (n=14', 'patients with obesity', 'Healthy subjects (n=17) were also included to form a CP control group', 'subjects with obesity', 'patients with obesity and healthy subjects after clinical and laboratory assessments']",['experimental (cephalic-phase microvascular response stimulation - CP'],"['Resting red blood cell velocity (RBCV), peak RBCV during PORH (RBCV max ), and time taken to reach RBCV max (TRBCV max ', 'microvascular outcome', 'Skin microvascular assessment', 'FCD during PORH post-stimulus', 'Resting functional capillary density (FCD) and peak FCD during post-occlusive reactive hyperemia (PORH']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0205096', 'cui_str': 'Cephalic'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1562113', 'cui_str': 'Fleck corneal dystrophy'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0006901', 'cui_str': 'Structure of capillary blood vessel (organ)'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C1947917', 'cui_str': 'Occluded'}, {'cui': 'C0178824', 'cui_str': 'Reactive Hyperemia'}]",17.0,0.0160267,"Patients with obesity (with or without stimulus) failed to show an increase on FCD during PORH post-stimulus (p=0.221 and p=0.307, respectively) depicting lack of capillary recruitment.","[{'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Buss', 'Affiliation': 'Department of Nutrition Federal University of Health Sciences of Porto Alegre (UFCSPA), RS, Brazil; Graduate Program in Health Sciences, UFCSPA, RS, Brazil. Electronic address: carolinebuss@ufcspa.edu.br.'}, {'ForeName': 'Priscila A', 'Initials': 'PA', 'LastName': 'Maranhão', 'Affiliation': 'Clinical and Experimental Research Laboratory on Vascular Biology (BioVasc) Biomedical Center, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Maria das Graças C', 'Initials': 'MDGC', 'LastName': 'de Souza', 'Affiliation': 'Clinical and Experimental Research Laboratory on Vascular Biology (BioVasc) Biomedical Center, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Eliete', 'Initials': 'E', 'LastName': 'Bouskela', 'Affiliation': 'Clinical and Experimental Research Laboratory on Vascular Biology (BioVasc) Biomedical Center, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Luiz Guilherme', 'Initials': 'LG', 'LastName': 'Kraemer-Aguiar', 'Affiliation': 'Clinical and Experimental Research Laboratory on Vascular Biology (BioVasc) Biomedical Center, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Department of Internal Medicine Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113087'] 2902,32706635,Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.,"PURPOSE To evaluate the efficacy and safety of pegvorhyaluronidase alfa (PEGPH20) plus nab-paclitaxel/gemcitabine (AG) in patients with hyaluronan-high metastatic pancreatic ductal adenocarcinoma (PDA). PATIENTS AND METHODS HALO 109-301 was a phase III, randomized, double-blind, placebo-controlled study. Patients ≥ 18 years of age with untreated, metastatic, hyaluronan-high PDA were randomly assigned 2:1 to PEGPH20 plus AG or placebo plus AG. Treatment was administered intravenously in 4-week cycles (3 weeks on, 1 week off) until progression or intolerable adverse events: PEGPH20 3.0 µg/kg twice per week for cycle 1 and once per week thereafter; nab-paclitaxel 125 mg/m 2 once per week; and gemcitabine 1,000 mg/m 2 once per week. The primary end point was overall survival (OS); secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety. Response was independently assessed per RECIST v1.1. RESULTS At data cutoff, 494 patients were randomly assigned, with 492 (327 for PEGPH20 and 165 for placebo) included in intention-to-treat analyses. Baseline characteristics were balanced for PEGPH20 plus AG versus placebo plus AG. There were 330 deaths, with a median OS of 11.2 months for PEGPH20 plus AG versus 11.5 months for placebo plus AG (hazard ratio [HR], 1.00; 95% CI, 0.80 to 1.27; P = .97); median PFS was 7.1 months versus 7.1 months (HR, 0.97 [95% CI, 0.75 to 1.26]); ORR was 47% versus 36% (ORR ratio, 1.29 [95% CI, 1.03 to 1.63]). Grade ≥ 3 adverse events with a ≥ 2% higher rate with PEGPH20 plus AG than with placebo plus AG included fatigue (16.0% v 9.6%), muscle spasms (6.5% v 0.6%), and hyponatremia (8.0% v 3.8%). CONCLUSION The addition of PEGPH20 to AG increased the ORR but did not improve OS or PFS. The safety profile of PEGPH20 plus AG was consistent with that found in previous studies. These results do not support additional development of PEGPH20 in metastatic PDA.",2020,"Grade ≥ 3 adverse events with a ≥ 2% higher rate with PEGPH20 plus AG than with placebo plus AG included fatigue (16.0% v 9.6%), muscle spasms (6.5% v 0.6%), and hyponatremia (8.0% v 3.8%). ","['HALO 109-301 was a phase III', 'Patients', 'Patients ≥ 18 years of age with untreated, metastatic, hyaluronan-high PDA', 'patients with hyaluronan-high metastatic pancreatic ductal adenocarcinoma (PDA', '494 patients were randomly assigned, with 492 (327 for PEGPH20 and 165 for']","['pegvorhyaluronidase alfa (PEGPH20) plus nab-paclitaxel/gemcitabine (AG', 'Pegvorhyaluronidase Alfa', 'PEGPH20 plus AG or placebo plus AG', 'PEGPH20 plus AG', 'gemcitabine', 'Nab-Paclitaxel Plus Gemcitabine', 'placebo']","['overall survival (OS); secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety', 'fatigue', 'ORR', 'efficacy and safety', 'Grade ≥ 3 adverse events', 'hyponatremia', 'muscle spasms', 'median PFS']","[{'cui': 'C0181278', 'cui_str': 'Halo brace'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1335302', 'cui_str': 'Ductal adenocarcinoma of pancreas'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C2826358', 'cui_str': 'PEGPH20'}, {'cui': 'C4319555', 'cui_str': '165'}]","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C2826358', 'cui_str': 'PEGPH20'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0020625', 'cui_str': 'Hyponatremia'}, {'cui': 'C0037763', 'cui_str': 'Spasm'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",494.0,0.605717,"Grade ≥ 3 adverse events with a ≥ 2% higher rate with PEGPH20 plus AG than with placebo plus AG included fatigue (16.0% v 9.6%), muscle spasms (6.5% v 0.6%), and hyponatremia (8.0% v 3.8%). ","[{'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Van Cutsem', 'Affiliation': 'Digestive Oncology, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Margaret A', 'Initials': 'MA', 'LastName': 'Tempero', 'Affiliation': 'Division of Hematology and Oncology, Department of Medicine, UCSF Medical Center, San Francisco, CA.'}, {'ForeName': 'Darren', 'Initials': 'D', 'LastName': 'Sigal', 'Affiliation': 'Division of Hematology/Oncology, Scripps Clinic and Scripps MD Anderson Cancer Center, La Jolla, CA.'}, {'ForeName': 'Do-Youn', 'Initials': 'DY', 'LastName': 'Oh', 'Affiliation': 'Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Fazio', 'Affiliation': 'Division of Gastrointestinal Medical Oncology & Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Macarulla', 'Affiliation': ""Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.""}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Hitre', 'Affiliation': 'Department of Medical Oncology and Clinical Pharmacology ""B,"" National Institute of Oncology, Budapest, Hungary.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Hammel', 'Affiliation': 'Hôpital Beaujon (AP-HP), Clichy, and Université de Paris, Paris, France.'}, {'ForeName': 'Andrew E', 'Initials': 'AE', 'LastName': 'Hendifar', 'Affiliation': 'Department of Gastrointestinal Malignancies, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.'}, {'ForeName': 'Susan E', 'Initials': 'SE', 'LastName': 'Bates', 'Affiliation': 'Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY.'}, {'ForeName': 'Chung-Pin', 'Initials': 'CP', 'LastName': 'Li', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Sunil R', 'Initials': 'SR', 'LastName': 'Hingorani', 'Affiliation': 'Fred Hutchinson Cancer Research Center and Division of Medical Oncology, University of Washington, Seattle, WA.'}, {'ForeName': 'Christelle', 'Initials': 'C', 'LastName': 'de la Fouchardiere', 'Affiliation': 'Department of Medical Oncology, Centre Léon Bérard, Lyon, France.'}, {'ForeName': 'Anup', 'Initials': 'A', 'LastName': 'Kasi', 'Affiliation': 'University of Kansas Medical Center, Kansas City, KS.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Heinemann', 'Affiliation': 'Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Maraveyas', 'Affiliation': 'Joint Centre for Cancer Studies, Hull York Medical School, Castle Hill Hospital, Cottingham, United Kingdom.'}, {'ForeName': 'Nathan', 'Initials': 'N', 'LastName': 'Bahary', 'Affiliation': 'Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Layos', 'Affiliation': 'Medical Oncology Service, Catalan Institute of Oncology (ICO), Hospital Germans Trias i Pujol, Badalona, Barcelona, Catalonia, Spain.'}, {'ForeName': 'Vaibhav', 'Initials': 'V', 'LastName': 'Sahai', 'Affiliation': 'Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zheng', 'Affiliation': 'The Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Lacy', 'Affiliation': 'Department of Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Joon Oh', 'Initials': 'JO', 'LastName': 'Park', 'Affiliation': 'Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Fabienne', 'Initials': 'F', 'LastName': 'Portales', 'Affiliation': 'Institut du Cancer de Montpellier, Montpellier, France.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Oberstein', 'Affiliation': 'Perlmutter Cancer Center, NYU Langone Health, New York, NY.'}, {'ForeName': 'Wilson', 'Initials': 'W', 'LastName': 'Wu', 'Affiliation': 'Halozyme Therapeutics, Inc, San Diego, CA.'}, {'ForeName': 'Dimitrios', 'Initials': 'D', 'LastName': 'Chondros', 'Affiliation': 'Halozyme Therapeutics, Inc, San Diego, CA.'}, {'ForeName': 'Andrea J', 'Initials': 'AJ', 'LastName': 'Bullock', 'Affiliation': 'Division of Medical Oncology, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.20.00590'] 2903,32706638,First Randomized Trial Supporting the Use of Proton Over Photon Chemoradiotherapy in Esophageal Cancer.,,2020,,['Esophageal Cancer'],['Proton Over Photon Chemoradiotherapy'],[],"[{'cui': 'C0014859', 'cui_str': 'Neoplasm of esophagus'}]","[{'cui': 'C0033727', 'cui_str': 'Proton'}, {'cui': 'C0086805', 'cui_str': 'Photon'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}]",[],,0.0869142,,"[{'ForeName': 'Charles B', 'Initials': 'CB', 'LastName': 'Simone', 'Affiliation': 'Department of Radiation Oncology, New York Proton Center and Memorial Sloan Kettering Cancer Center, New York, NY.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.20.01405'] 2904,32706639,"Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.","PURPOSE Radical prostatectomy (RP) alone is often inadequate in curing men with clinically localized, high-risk prostate cancer (PC). We hypothesized that chemohormonal therapy (CHT) with androgen-deprivation therapy plus docetaxel before RP would improve biochemical progression-free survival (BPFS) over RP alone. PATIENTS AND METHODS Men with clinically localized, high-risk PC were assigned to RP alone or neoadjuvant CHT with androgen deprivation plus docetaxel (75 mg/m 2 body surface area every 3 weeks for 6 cycles) and RP. The primary end point was 3-year BPFS. Biochemical failure was defined as a serum prostate-specific antigen level > 0.2 ng/mL that increased on 2 consecutive occasions that were at least 3 months apart. Secondary end points included 5-year BPFS, overall BPFS, local recurrence, metastasis-free survival (MFS), PC-specific mortality, and overall survival (OS). RESULTS In total, 788 men were randomly assigned. Median follow-up time was 6.1 years. The overall rates of grade 3 and 4 adverse events during chemotherapy were 26% and 19%, respectively. No difference was seen in 3-year BPFS between neoadjuvant CHT plus RP and RP alone (0.89 v 0.84, respectively; 95% CI for the difference, -0.01 to 0.11; P = .11). Neoadjuvant CHT was associated with improved overall BPFS (hazard ratio [HR], 0.69; 95% CI, 0.48 to 0.99), improved MFS (HR, 0.70; 95% CI, 0.51 to 0.95), and improved OS (HR, 0.61; 95% CI, 0.40 to 0.94) compared with RP alone. CONCLUSION The primary study end point, 3-year BPFS, was not met. Although some improvement was seen in secondary end points, any potential benefit must be weighed against toxicity. Our data do not support the routine use of neoadjuvant CHT and RP in patients with clinically localized, high-risk PC at this time.",2020,"No difference was seen in 3-year BPFS between neoadjuvant CHT plus RP and RP alone (0.89 v 0.84, respectively; 95% CI for the difference, -0.01 to 0.11; P = .11).","['Cancer and Leukemia Group B 90203 (Alliance', '788 men were randomly assigned', 'curing men with clinically localized, high-risk prostate cancer (PC', 'Men with clinically localized, high-risk PC']","['Neoadjuvant CHT', 'RP alone or neoadjuvant CHT with androgen deprivation plus docetaxel', 'chemohormonal therapy (CHT) with androgen-deprivation therapy plus docetaxel', 'Radical prostatectomy (RP) alone', 'Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy']","['overall rates of grade 3 and 4 adverse events', 'MFS', 'overall BPFS', '3-year BPFS', 'Biochemical failure', '5-year BPFS, overall BPFS, local recurrence, metastasis-free survival (MFS), PC-specific mortality, and overall survival (OS', 'biochemical progression-free survival (BPFS']","[{'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0023418', 'cui_str': 'Leukemia'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0392752', 'cui_str': 'Localized'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}]","[{'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}, {'cui': 'C0002844', 'cui_str': 'Androgen'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0024796', 'cui_str': ""Marfan's syndrome""}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",788.0,0.220039,"No difference was seen in 3-year BPFS between neoadjuvant CHT plus RP and RP alone (0.89 v 0.84, respectively; 95% CI for the difference, -0.01 to 0.11; P = .11).","[{'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Eastham', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Heller', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Halabi', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Duke University, Durham, NC.'}, {'ForeName': 'J Paul', 'Initials': 'JP', 'LastName': 'Monk', 'Affiliation': 'The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital, Columbus, OH.'}, {'ForeName': 'Himisha', 'Initials': 'H', 'LastName': 'Beltran', 'Affiliation': 'Dana-Farber/Partners CancerCare, Boston, MA.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Gleave', 'Affiliation': 'University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Evans', 'Affiliation': 'University of California, Davis, Sacramento, CA.'}, {'ForeName': 'Steven K', 'Initials': 'SK', 'LastName': 'Clinton', 'Affiliation': 'The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital, Columbus, OH.'}, {'ForeName': 'Russell Z', 'Initials': 'RZ', 'LastName': 'Szmulewitz', 'Affiliation': 'University of Chicago Comprehensive Cancer Center, Chicago, IL.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Coleman', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Hillman', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Colleen R', 'Initials': 'CR', 'LastName': 'Watt', 'Affiliation': 'Alliance Protocol Operations Office, University of Chicago, Chicago, IL.'}, {'ForeName': 'Saby', 'Initials': 'S', 'LastName': 'George', 'Affiliation': 'Roswell Park Comprehensive Cancer Center, Buffalo, NY.'}, {'ForeName': 'Martin G', 'Initials': 'MG', 'LastName': 'Sanda', 'Affiliation': 'Emory University, Atlanta, GA.'}, {'ForeName': 'Olwen M', 'Initials': 'OM', 'LastName': 'Hahn', 'Affiliation': 'Alliance Protocol Operations Office, University of Chicago, Chicago, IL.'}, {'ForeName': 'Mary-Ellen', 'Initials': 'ME', 'LastName': 'Taplin', 'Affiliation': 'Dana-Farber/Partners CancerCare, Boston, MA.'}, {'ForeName': 'J Kellogg', 'Initials': 'JK', 'LastName': 'Parsons', 'Affiliation': 'University of California, San Diego, San Diego, CA.'}, {'ForeName': 'James L', 'Initials': 'JL', 'LastName': 'Mohler', 'Affiliation': 'Roswell Park Comprehensive Cancer Center, Buffalo, NY.'}, {'ForeName': 'Eric J', 'Initials': 'EJ', 'LastName': 'Small', 'Affiliation': 'University of California, San Francisco, Medical Center-Mount Zion, San Francisco, CA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Morris', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.20.00315'] 2905,32706640,"Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.","PURPOSE NRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate a survival benefit of adjuvant chemoradiotherapy over radiotherapy. This post hoc study sought to determine the prognostic and predictive impact of the WHO-defined molecular subgroups and corresponding molecular alterations within NRG Oncology/RTOG 9802. METHODS IDH1/2 mutations were determined by immunohistochemistry and/or deep sequencing. A custom Ion AmpliSeq panel was used for mutation analysis. 1p/19q codeletion and MGMT promoter methylation were determined by copy-number arrays and/or Illumina 450K array, respectively. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Hazard ratios (HRs) were calculated using the Cox proportional hazard model and tested using the log-rank test. Multivariable analyses (MVAs) were performed incorporating treatment and common prognostic factors as covariates. RESULTS Of the eligible patients successfully profiled for the WHO-defined molecular groups (n = 106/251), 26 (24%) were IDH- wild type, 43 (41%) were IDH- mutant/non-codeleted, and 37(35%) were IDH- mutant/codeleted. MVAs demonstrated that WHO subgroup was a significant predictor of PFS after adjustment for clinical variables and treatment. Notably, treatment with postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine) was associated with longer PFS (HR, 0.32; P = .003; HR, 0.13; P < .001) and OS (HR, 0.38; P = .013; HR, 0.21; P = .029) in the IDH- mutant/non-codeleted and IDH- mutant/codeleted subgroups, respectively. In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH- wild-type subgroup. CONCLUSION This study is the first to report the predictive value of the WHO-defined diagnostic classification in a set of uniformly treated patients with LGG in a clinical trial. Importantly, this post hoc analysis supports the notion that patients with IDH -mutant high-risk LGG regardless of codeletion status receive benefit from the addition of PCV.",2020,"In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH- wild-type subgroup. ","['patients with WHO low-grade glioma (LGG, grade II', 'NRG Oncology/RTOG 9802', 'High-Risk Low-Grade Glioma']","['NRG', 'Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine', 'postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine', 'adjuvant chemoradiotherapy over radiotherapy']","['PFS', 'PFS or OS', 'Progression-free survival (PFS) and overall survival (OS', 'Hazard ratios (HRs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1997217', 'cui_str': 'Low grade glioma'}, {'cui': 'C1629836', 'cui_str': 'Lactobacillus rhamnosus GG'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]","[{'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0033223', 'cui_str': 'Procarbazine'}, {'cui': 'C0023972', 'cui_str': 'Lomustine'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}, {'cui': 'C3178761', 'cui_str': 'Adjuvant Chemoradiotherapy'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439227', 'cui_str': 'hour'}]",,0.0972708,"In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH- wild-type subgroup. ","[{'ForeName': 'Erica H', 'Initials': 'EH', 'LastName': 'Bell', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Peixin', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'NRG Oncology Statistics and Data Management Center, Philadelphia, PA.'}, {'ForeName': 'Edward G', 'Initials': 'EG', 'LastName': 'Shaw', 'Affiliation': 'Wake Forest School of Medicine, Winston-Salem, NC.'}, {'ForeName': 'Jan C', 'Initials': 'JC', 'LastName': 'Buckner', 'Affiliation': 'Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Geoffrey R', 'Initials': 'GR', 'LastName': 'Barger', 'Affiliation': 'Wayne State University, Detroit, MI.'}, {'ForeName': 'Dennis E', 'Initials': 'DE', 'LastName': 'Bullard', 'Affiliation': 'Triangle Neurosurgery, Raleigh, NC.'}, {'ForeName': 'Minesh P', 'Initials': 'MP', 'LastName': 'Mehta', 'Affiliation': 'Baptist Hospital of Miami, Miami, FL.'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Gilbert', 'Affiliation': 'National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Brown', 'Affiliation': 'Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Keith J', 'Initials': 'KJ', 'LastName': 'Stelzer', 'Affiliation': 'Mid-Columbia Medical Center, The Dalles, OR.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'McElroy', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Fleming', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Cynthia D', 'Initials': 'CD', 'LastName': 'Timmers', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Aline P', 'Initials': 'AP', 'LastName': 'Becker', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Andrea L', 'Initials': 'AL', 'LastName': 'Salavaggione', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Ziyan', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Aldape', 'Affiliation': 'Princess Margaret Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'David G', 'Initials': 'DG', 'LastName': 'Brachman', 'Affiliation': 'Arizona Oncology Services Foundation, Phoenix, AZ.'}, {'ForeName': 'Stanley Z', 'Initials': 'SZ', 'LastName': 'Gertler', 'Affiliation': 'The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada.'}, {'ForeName': 'Albert D', 'Initials': 'AD', 'LastName': 'Murtha', 'Affiliation': 'Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Schultz', 'Affiliation': 'Froedtert and the Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Johnson', 'Affiliation': 'Wichita NCORP, Wichita, KS.'}, {'ForeName': 'Nadia N', 'Initials': 'NN', 'LastName': 'Laack', 'Affiliation': 'Rochester Methodist Hospital, Rochester, MN.'}, {'ForeName': 'Grant K', 'Initials': 'GK', 'LastName': 'Hunter', 'Affiliation': 'Intermountain Medical Center, Murray, UT.'}, {'ForeName': 'Ian R', 'Initials': 'IR', 'LastName': 'Crocker', 'Affiliation': 'Emory University, Atlanta, GA.'}, {'ForeName': 'Minhee', 'Initials': 'M', 'LastName': 'Won', 'Affiliation': 'NRG Oncology Statistics and Data Management Center, Philadelphia, PA.'}, {'ForeName': 'Arnab', 'Initials': 'A', 'LastName': 'Chakravarti', 'Affiliation': 'The Ohio State University, Columbus, OH.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.02983'] 2906,32706652,Changes in Patient-Reported Outcome Measures With a Technology-Supported Behavioral Lifestyle Intervention Among Patients With Type 2 Diabetes: Pilot Randomized Controlled Clinical Trial.,"BACKGROUND In the United States, more than one-third of the adult population is obese, and approximately 25.2% of those aged ≥65 years have type 2 diabetes (T2D), which is the seventh leading cause of death. It is important to measure patient-reported outcomes and monitor progress or challenges over time when managing T2D to understand patients' perception of health and quantify the impact of disease processes or intervention effects. The evaluation of patient-reported outcome measures (PROMs) is especially important among patients with multiple chronic conditions in which clinical measures do not provide a complete picture of health. OBJECTIVE This study examined the feasibility of collecting Patient-Reported Outcome Measurement Information System (PROMIS) measures, and preliminarily evaluated changes in PROMIS scores and compared the scores with standard scores of the general US population. The parent study is a pilot randomized controlled clinical trial testing three different modes (mobile health [mHealth], paper diary, and control) of self-monitoring in a behavioral lifestyle intervention among overweight or obese patients with T2D. METHODS Patients with comorbid overweight or obesity and a diagnosis of T2D for at least 6 months were recruited from a diabetes education program. Participants were randomized to the following three groups: mHealth, paper diary, and control (standard of care) groups. Paper diary and mHealth experimental groups received additional behavioral lifestyle intervention education sessions, as well as tools to self-monitor weight, physical activity, diet, and blood glucose. All participants completed PROMIS-57 and PROMIS-Global Health (GH) version 1.0 questionnaires during visits at baseline, 3 months, and 6 months. The PROMIS-57 includes the following seven domains: anxiety, depression, fatigue, pain interference, physical function, satisfaction with participation in social roles, and sleep disturbance. The PROMIS-GH is composed of the following two domains: global mental health and global physical health. RESULTS A total of 26 patients (mHealth, 11; paper diary, 9; control, 6) were included in our analysis. The study sample was predominantly African American (68%) and female (57%), with a mean age of 54.7 years and a mean BMI of 37.5 kg/m 2 . All patients completed the PROMIS-57 and PROMIS-GH questionnaires, and we compared the mean scores of the three groups to investigate potential differences. No relevant differences were noted across the groups. However, positive trends were noted in both intervention (mHealth and paper diary) groups in the middle (month 3) and end (month 6) of the study. CONCLUSIONS Our pilot study provides evidence for the feasibility of using PROMIS questionnaires to record important components of T2D-related symptoms among overweight or obese individuals. The results from our study support the use of PROMIS questionnaires to provide clinicians and researchers with a benchmark for assessing the overall need for symptom management and determining the success or challenges of an intervention. TRIAL REGISTRATION ClinicalTrials.gov NCT02858648; https://clinicaltrials.gov/ct2/show/NCT02858648.",2020,No relevant differences were noted across the groups.,"['overweight or obese patients with T2D.\nMETHODS\n\n\nPatients with comorbid overweight or obesity and a diagnosis of T2D for at least 6 months were recruited from a diabetes education program', 'The study sample was predominantly African American (68%) and female (57%), with a mean age of 54.7 years and a mean BMI of 37.5 kg/m 2 ', 'overweight or obese individuals', '26 patients (mHealth, 11; paper diary, 9; control, 6) were included in our analysis', 'Patients With Type']","['additional behavioral lifestyle intervention education sessions', 'Technology-Supported Behavioral Lifestyle Intervention', 'modes (mobile health [mHealth], paper diary, and control) of self-monitoring in a behavioral lifestyle intervention']","['anxiety, depression, fatigue, pain interference, physical function, satisfaction with participation in social roles, and sleep disturbance']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517742', 'cui_str': '37.5'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}]",6.0,0.0698373,No relevant differences were noted across the groups.,"[{'ForeName': 'Rozmin', 'Initials': 'R', 'LastName': 'Jiwani', 'Affiliation': 'University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Berndt', 'Affiliation': 'University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.'}, {'ForeName': 'Padmavathy', 'Initials': 'P', 'LastName': 'Ramaswamy', 'Affiliation': 'Cizik School of Nursing, The University of Texas Health Science Center at Houston, Houston, TX, United States.'}, {'ForeName': 'Nitha', 'Initials': 'N', 'LastName': 'Mathew Joseph', 'Affiliation': 'Cizik School of Nursing, The University of Texas Health Science Center at Houston, Houston, TX, United States.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Du', 'Affiliation': 'University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.'}, {'ForeName': 'Jisook', 'Initials': 'J', 'LastName': 'Ko', 'Affiliation': 'University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Espinoza', 'Affiliation': 'University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.'}]",JMIR diabetes,['10.2196/19268'] 2907,32702252,Safety Assessment of HEA-Enriched Cordyceps cicadae Mycelium: A Randomized Clinical Trial.,"Objective: Cordyceps cicadae , a medicinal fungus, is assessed as having many functions: anti-cancer, anti-fatigue, anti-aging, immune-boosting, renal and liver protection. Since the industrial production of C. cicadae mycelium consistently manufactures bioactive compounds superior to wild fruiting bodies, there is a need to confirm the toxicity of liquid fermented C. cicadae mycelium. Studies showed the toxicity evaluation of C. cicadae mycelium in animal models, but safety reports in clinical studies are scarce. As such, a safety assessment of oral N6-(2-hydroxyethyl) adenosine (HEA-enriched) C. cicadae mycelium in humans is provided here. Method: After 49 participants ingested granules of 1.05 g of freeze-dried C. cicadae mycelium once a day for 3 months, their blood samples were collected at the beginning and end of the experiment for analysis. Results: There were no significant differences between the initial and final measurements in renal and liver function. Also, there was no influence on blood electrolytes as well as blood lipid levels. In clinical observation, there were also no side effects or adverse feelings mentioned by participants. Conclusion: These results suggested that HEA-enriched C. cicadae mycelium produced by liquid fermentation is safe and can be developed as a functional health food.",2020,There were no significant differences between the initial and final measurements in renal and liver function.,[],"['HEA-Enriched Cordyceps cicadae Mycelium', 'oral N6-(2-hydroxyethyl) adenosine (HEA-enriched']","['toxicity evaluation', 'blood electrolytes', 'renal and liver function', 'blood lipid levels']",[],"[{'cui': 'C0449204', 'cui_str': 'HEA'}, {'cui': 'C1011843', 'cui_str': 'Cordyceps'}, {'cui': 'C0949695', 'cui_str': 'Mycelium'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0001443', 'cui_str': 'Adenosine'}]","[{'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0853360', 'cui_str': 'Blood electrolytes'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0232741', 'cui_str': 'Liver function'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0428460', 'cui_str': 'Lipid level - finding'}]",49.0,0.0359934,There were no significant differences between the initial and final measurements in renal and liver function.,"[{'ForeName': 'You-Shan', 'Initials': 'YS', 'LastName': 'Tsai', 'Affiliation': 'Biotech Research Institute, Grape King Bio Ltd, Taoyuan City, Taiwan.'}, {'ForeName': 'Jui-Hsia', 'Initials': 'JH', 'LastName': 'Hsu', 'Affiliation': 'Biotech Research Institute, Grape King Bio Ltd, Taoyuan City, Taiwan.'}, {'ForeName': 'David Pei-Cheng', 'Initials': 'DP', 'LastName': 'Lin', 'Affiliation': 'Department of Medical Laboratory Science and Biotechnology, Chung Shan Medical University, Taichung City, Taiwan.'}, {'ForeName': 'Han-Hsin', 'Initials': 'HH', 'LastName': 'Chang', 'Affiliation': 'Department of Nutrition, Chung Shan Medical University, Taichung City, Taiwan.'}, {'ForeName': 'Wen-Jui', 'Initials': 'WJ', 'LastName': 'Chang', 'Affiliation': 'Department of Ophthalmology, Landseed International Hospital, Taoyuan City, Taiwan.'}, {'ForeName': 'Yen-Lien', 'Initials': 'YL', 'LastName': 'Chen', 'Affiliation': 'Biotech Research Institute, Grape King Bio Ltd, Taoyuan City, Taiwan.'}, {'ForeName': 'Chin-Chu', 'Initials': 'CC', 'LastName': 'Chen', 'Affiliation': 'Institute of Food Science and Technology, National Taiwan University, Taipei City, Taiwan.'}]",Journal of the American College of Nutrition,['10.1080/07315724.2020.1743211'] 2908,32702255,"Re: Long-Term Effect of Community-Based Continence Promotion on Urinary Symptoms, Falls and Health Active Life Expectance among Older Women: Cluster Randomised Trial.",,2020,,['Older Women'],['Community-Based Continence Promotion'],"['Urinary Symptoms, Falls and Health Active Life Expectance']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}]","[{'cui': 'C0426359', 'cui_str': 'Urinary symptoms'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0376558', 'cui_str': 'Life'}]",,0.0837289,,"[{'ForeName': 'Tomas L', 'Initials': 'TL', 'LastName': 'Griebling', 'Affiliation': ''}]",The Journal of urology,['10.1097/JU.0000000000001207.01'] 2909,32702256,"Re: Testosterone for Androgen Deficiency-Like Symptoms in Men without Pathologic Hypogonadism: A Randomized, Placebo-Controlled Cross-Over with Masked Choice Extension Clinical Trial.",,2020,,['Men without Pathologic Hypogonadism'],"['Re: Testosterone', 'Placebo']",[],"[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0020619', 'cui_str': 'Hypogonadism'}]","[{'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.745346,,"[{'ForeName': 'Tomas L', 'Initials': 'TL', 'LastName': 'Griebling', 'Affiliation': ''}]",The Journal of urology,['10.1097/JU.0000000000001207.04'] 2910,32702258,"Re: A Group-Based Yoga Program for Urinary Incontinence in Ambulatory Women: Feasibility, Tolerability, and Change in Incontinence Frequency over 3 Months in a Single-Center Randomized Trial.",,2020,,['Ambulatory Women'],['Re: A Group-Based Yoga Program'],[],"[{'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]",[],,0.0157535,,"[{'ForeName': 'Tomas L', 'Initials': 'TL', 'LastName': 'Griebling', 'Affiliation': ''}]",The Journal of urology,['10.1097/JU.0000000000001207.02'] 2911,30485658,"From stem cells protection to skin microbiota balance: Orobanche rapum extract, a new natural strategy.","BACKGROUND Healthy skin is a delicate balance between skin renewal and microbiota homeostasis, and its imbalance promotes premature aging and dermatological disorders. Skin stem cells are key actors in this process but their sensitivity to aging and external stressors such as UV reduces the skin renewal power. The skin microbiota has been recently described as active in the healthy skin, and its imbalance could trigger some disorders. AIMS We hypothesized that reactivation of stem cells and maintenance of microbiota could be a disruptive strategy for younger and healthier skin. We thus developed a new plant extract that restores the entire skin renewal process by sequential activation from stem cells stimulation to microbiota protection. METHODS We studied stem cells comportment in the presence of Orobanche rapum extract by survivin immunocytochemistry and caspases 3 and 9 dosages. We also analyzed epidermal differentiation markers by immunohistochemistry and lipids organization by GC/MS At the clinical level, we investigated the impact of O. rapum extract on microbiota and on skin aspect. RESULTS We demonstrated an active protection of skin stem cells through the maintenance of their clone-forming capacity and resistance to UV through the overexpression of survivin coupled to caspases inhibition. Furthermore, we showed the restoration of epidermal differentiation markers and ceramide biosynthesis favorable to orthorhombic organization. Clinical studies, including microbiota analysis, showed an active skin surface renewal coupled with microbiota protection. CONCLUSION We evidenced that our active ingredient is able to stimulate skin rejuvenation while protecting the cutaneous microbiota, creating healthier skin and thereby beauty.",2019,We demonstrated an active protection of skin stem cells through the maintenance of their clone-forming capacity and resistance to UV through the overexpression of survivin coupled to caspases inhibition.,['younger and healthier skin'],[],[],"[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C1123023', 'cui_str': 'Skin'}]",[],[],,0.0349843,We demonstrated an active protection of skin stem cells through the maintenance of their clone-forming capacity and resistance to UV through the overexpression of survivin coupled to caspases inhibition.,"[{'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Meunier', 'Affiliation': 'Research and Development, Givaudan France SAS, Pomacle, France.'}, {'ForeName': 'Amandine', 'Initials': 'A', 'LastName': 'Scandolera', 'Affiliation': 'Research and Development, Givaudan France SAS, Pomacle, France.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Chapuis', 'Affiliation': 'Research and Development, Givaudan France SAS, Pomacle, France.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Lambert', 'Affiliation': 'Research and Development, Givaudan France SAS, Toulouse, France.'}, {'ForeName': 'Cyrille', 'Initials': 'C', 'LastName': 'Jarrin', 'Affiliation': 'Research and Development, Givaudan France SAS, Toulouse, France.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Robe', 'Affiliation': 'Research and Development, Givaudan France SAS, Toulouse, France.'}, {'ForeName': 'Hanane', 'Initials': 'H', 'LastName': 'Chajra', 'Affiliation': 'Research and Development, Givaudan France SAS, Toulouse, France.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Auriol', 'Affiliation': 'Research and Development, Givaudan France SAS, Toulouse, France.'}, {'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Reynaud', 'Affiliation': 'Research and Development, Givaudan France SAS, Pomacle, France.'}]",Journal of cosmetic dermatology,['10.1111/jocd.12804'] 2912,9882287,Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.,"Respiratory syncytial virus (RSV) cpts530/1030 is an attenuated, temperature-sensitive subgroup A vaccine candidate derived previously from cold-passaged RSV (cpRSV) by two sequential rounds of chemical mutagenesis and biological selection. Here, cpts530/1030 was shown to be highly attenuated in the upper and lower respiratory tracts of seronegative chimpanzees. However, evaluation in seropositive children showed that it retains sufficient replicative capacity and virulence to preclude its direct use as a live attenuated vaccine. Nucleotide sequence analysis of the genome of cpts530/1030 showed that it had acquired two nucleotide substitutions (compared to its cpts530 parent), both of which were in the L gene: a silent mutation at nucleotide position 8821 (amino acid 108) and a missense mutation at nucleotide position 12458 resulting in a tyrosine-to-asparagine change at amino acid 1321, herein referred to as the 1030 mutation. It also contained the previously identified 530 missense mutation at nucleotide 10060 in the L gene. The genetic basis of attenuation of cpts530/1030 was defined by the introduction of the 530 and 1030 mutations into a cDNA clone of cpRSV, from which recombinant RSV was derived and analyzed to determine the contribution of each mutation to the temperature sensitivity (ts) and attenuation (att) phenotypes of cpts530/1030. The 530 mutation, derived from cpts530, was previously shown to be responsible for the ts and att phenotypes of that virus. In the present study, the 1030 mutation was shown to be responsible for the increased temperature sensitivity of cpts530/1030. In addition, the 1030 mutation was shown to be responsible for the increased level of attenuation of cpts530/1030 in the upper and lower respiratory tracts of mice. The 530 and 1030 mutations were additive in their effects on the ts and att phenotypes. It was possible to introduce the 1030 mutation, but not the 530 mutation, into an attenuated vaccine candidate with residual reactogenicity in very young infants, namely, cpts248/404, by use of reverse genetics. The inability to introduce the 530 mutation into the cpts248/404 virus was shown to be due to its incompatibility with the 248 missense mutation at the level of L protein function. The resulting rA2cp248/404/1030 mutant virus was more temperature sensitive and more attenuated than the cpts248/404 parent virus, making it a promising new RSV vaccine candidate created by use of reverse genetics to improve upon an existing vaccine virus.",1999,"The 530 mutation, derived from cpts530, was previously shown to be responsible for the ts and att phenotypes of that virus.",['seropositive children'],[],[],"[{'cui': 'C0521143', 'cui_str': 'Seropositive (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",[],[],,0.0293051,"The 530 mutation, derived from cpts530, was previously shown to be responsible for the ts and att phenotypes of that virus.","[{'ForeName': 'S S', 'Initials': 'SS', 'LastName': 'Whitehead', 'Affiliation': 'Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA. sswhitehead@nih.gov'}, {'ForeName': 'C Y', 'Initials': 'CY', 'LastName': 'Firestone', 'Affiliation': ''}, {'ForeName': 'R A', 'Initials': 'RA', 'LastName': 'Karron', 'Affiliation': ''}, {'ForeName': 'J E', 'Initials': 'JE', 'LastName': 'Crowe', 'Affiliation': ''}, {'ForeName': 'W R', 'Initials': 'WR', 'LastName': 'Elkins', 'Affiliation': ''}, {'ForeName': 'P L', 'Initials': 'PL', 'LastName': 'Collins', 'Affiliation': ''}, {'ForeName': 'B R', 'Initials': 'BR', 'LastName': 'Murphy', 'Affiliation': ''}]",Journal of virology,[] 2913,31310839,How to improve the clinical experience for dermatology patients requiring a genital examination: A randomized trial of deodorizing wipes versus standard of care.,,2020,,['Dermatology Patients Requiring a Genital Examination'],['Deodorizing Wipes versus Standard of Care'],[],"[{'cui': 'C0011627', 'cui_str': 'Dermatology'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0017420', 'cui_str': 'Reproductive System'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}]","[{'cui': 'C2936643', 'cui_str': 'Standard of Care'}]",[],,0.02847,,"[{'ForeName': 'Susruthi', 'Initials': 'S', 'LastName': 'Rajanala', 'Affiliation': 'Department of Dermatology, Boston University School of Medicine, Boston, Masschusetts.'}, {'ForeName': 'Lauren K', 'Initials': 'LK', 'LastName': 'Burdine', 'Affiliation': 'Department of Dermatology, Boston University School of Medicine, Boston, Masschusetts.'}, {'ForeName': 'Mayra B C', 'Initials': 'MBC', 'LastName': 'Maymone', 'Affiliation': 'Department of Dermatology, Boston University School of Medicine, Boston, Masschusetts.'}, {'ForeName': 'Neelam A', 'Initials': 'NA', 'LastName': 'Vashi', 'Affiliation': 'Department of Dermatology, Boston University School of Medicine, Boston, Masschusetts; US Department of Veterans Affairs, Boston Health Care System, Boston, Massachusetts. Electronic address: nvashi@bu.edu.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2019.07.026'] 2914,31066722,Cerebral ischemic lesions on diffusion-weighted magnetic resonance imaging after carotid eversion endarterectomy vs carotid stenting with a proximal protection device: results of a randomized prospective trial.,,2019,,['comparison with carotid stenting under proximal protection'],[],[],"[{'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}]",[],[],,0.181456,,"[{'ForeName': 'Paweł', 'Initials': 'P', 'LastName': 'Latacz', 'Affiliation': 'Department of Neurology, University Hospital, Jagiellonian University Medical College, Kraków, Poland'}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Simka', 'Affiliation': 'Department of Anatomy, University of Opole, Opole, Poland'}, {'ForeName': 'Amira', 'Initials': 'A', 'LastName': 'Bryll', 'Affiliation': 'Department of Radiology, Jagiellonian University Medical College, Kraków, Poland'}, {'ForeName': 'Marek', 'Initials': 'M', 'LastName': 'Piwowarczyk', 'Affiliation': 'Department of Vascular Surgery, University Hospital, Kraków, Poland'}, {'ForeName': 'Grzegorz', 'Initials': 'G', 'LastName': 'Gajos', 'Affiliation': 'Department of Coronary Artery Disease and Heart Failure, John Paul II Hospital, Jagiellonian University Medical College, Kraków, Poland'}, {'ForeName': 'Tadeusz', 'Initials': 'T', 'LastName': 'Popiela', 'Affiliation': 'Department of Radiology, Jagiellonian University Medical College, Kraków, Poland'}]",Polish archives of internal medicine,['10.20452/pamw.14825'] 2915,31170036,Sound design for auditory biofeedback and motor performance in participants with stroke: a pilot study.,"Background : Although auditory biofeedback (ABF) has proved to be effective in stroke rehabilitation, there are a variety of means by which to present information through sound. Objectives : To examine if ABF sound design influences the motor performance of patients with stroke. Methods : A total of four people with chronic stroke participated . They were asked to track target signals by their paretic ankle dorsiflexion. Half of the participants were assigned to one of the two groups. Those in the Error ABF group heard ABF that alerted them to the error between the target and the joint angle. Those in the Full ABF group heard ABF that presented both the target and the angle separately by modulating the frequencies of two sounds. Therefore, when there was no error, no sound or two sounds with the identical frequency were heard in the Error and Full ABF sessions, respectively. The same visual BF (VBF) was always present regardless of the group. The accuracy of the task was quantified via an accuracy index (AI, ranging from -100 to 100). All participants were trained by repeating tracking, and the pre- and post-training AIs were obtained. Results : The AIs of all participants increased after training, but the increase was greater for the Error ABF group (mean increase = 8.9 and 14.9 for the Full and Error groups, respectively). Conclusions : The Full ABF was less effective than the Error ABF, probably because the VBF was present, and the information provided by the Full ABF was therefore redundant.",2019,"The AIs of all participants increased after training, but the increase was greater for the Error ABF group (mean increase = 8.9 and 14.9 for the Full and Error groups, respectively). ","['participants with stroke', 'four people with chronic stroke participated ', 'patients with stroke']","['auditory biofeedback and motor performance', ' ', 'auditory biofeedback (ABF']",['same visual BF (VBF'],"[{'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C3536593', 'cui_str': 'Chronic stroke'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C0678663', 'cui_str': 'Biofeedback, function (observable entity)'}]","[{'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}]",4.0,0.10595,"The AIs of all participants increased after training, but the increase was greater for the Error ABF group (mean increase = 8.9 and 14.9 for the Full and Error groups, respectively). ","[{'ForeName': 'Masaki', 'Initials': 'M', 'LastName': 'Iguchi', 'Affiliation': 'a Faculty of Health Sciences, Tsukuba University of Technology , Tsukuba , Japan.'}, {'ForeName': 'Ryosuke', 'Initials': 'R', 'LastName': 'Nakagawa', 'Affiliation': 'b Faculty of Library, Information and Media Science, University of Tsukuba , Tsukuba , Japan.'}, {'ForeName': 'Hiroko', 'Initials': 'H', 'LastName': 'Terasawa', 'Affiliation': 'b Faculty of Library, Information and Media Science, University of Tsukuba , Tsukuba , Japan.'}]",Topics in stroke rehabilitation,['10.1080/10749357.2019.1625546'] 2916,31686094,Alzheimer's Disease Composite Score: A Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease.,"As research evolves in prodromal AD, the need to validate sufficiently sensitive outcome measures, e.g. the Alzheimer's Disease Composite Score (ADCOMS) is clear. In the LipiDiDiet randomized trial in prodromal AD, cognitive decline in the study population was much less than expected in the timeframe studied. While the primary composite endpoint was insufficiently sensitive to detect a difference in the modified intention to treat population, the per-protocol population showed less decline in the active than the control group, indicating better treatment effects with regular product intake. These results were further strengthened by significant benefits on secondary endpoints of cognition and function, and brain atrophy. The present post-hoc analysis investigated whether ADCOMS could detect a difference between groups in the LipiDiDiet population (138 active, 140 control). The estimated mean change in ADCOMS from baseline (standard error) was 0.085 (0.018) in the active and 0.133 (0.018) in the control group; estimated mean treatment difference -0.048 (95% confidence intervals -0.090, -0.007; p=0.023), or 36% less decline in the active group. This suggests ADCOMS identified the cognitive and functional benefits observed previously, confirming the sensitivity of this composite measure.",2019,The estimated mean change in ADCOMS from baseline (standard error) was 0.085 (0.018) in the active and 0.133 (0.018) in the control group; estimated mean treatment difference -0.048,"[""Alzheimer's Disease Composite Score"", ""Prodromal Alzheimer's Disease""]",[],"['cognition and function, and brain atrophy']","[{'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3805054', 'cui_str': ""Prodromal Alzheimer's disease""}]",[],"[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0333641', 'cui_str': 'Atrophy'}]",,0.157408,The estimated mean change in ADCOMS from baseline (standard error) was 0.085 (0.018) in the active and 0.133 (0.018) in the control group; estimated mean treatment difference -0.048,"[{'ForeName': 'S B', 'Initials': 'SB', 'LastName': 'Hendrix', 'Affiliation': 'Suzanne B Hendrix, Pentara Corporation, 2180 Claybourne Avenue, Salt Lake City, UT 84109 USA. Email: shendrix@pentaracorp.com; Phone: +1 (801) 898-7241.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Soininen', 'Affiliation': ''}, {'ForeName': 'A M J', 'Initials': 'AMJ', 'LastName': 'van Hees', 'Affiliation': ''}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Ellison', 'Affiliation': ''}, {'ForeName': 'P J', 'Initials': 'PJ', 'LastName': 'Visser', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Solomon', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Attali', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Blennow', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kivipelto', 'Affiliation': ''}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Hartmann', 'Affiliation': ''}]",The journal of prevention of Alzheimer's disease,['10.14283/jpad.2019.33'] 2917,31632735,Treatment of at-level spinal cord injury pain with botulinum toxin A.,"Study design Randomized, double-blinded, placebo-controlled, cross-over study. Objective To explore whether botulinum toxin A (BoNTA) could be effective for treating at-level spinal cord injury (SCI) pain. Setting Outpatient SCI clinic, New York, USA. Methods Participants were randomized to receive subcutaneous injections of either placebo or BoNTA with follow-up (office visit, telephone, or e-mail) at 2, 4, 8, and 12 weeks to assess the magnitude of pain relief post injection. Crossover of participants was then performed. Those who received placebo received BoNTA, and vice versa, with follow-up at 2, 4, 8, and 12 weeks. Results Eight participants completed at least one of the two crossover study arms. Four completed both arms. The median age of the eight participants was 45 years (range 32-61 years) and 75% were male. All had traumatic, T1-L3 level, complete SCI. Although our data did not meet statistical significance, we noted a higher proportion of participants reporting a marked change in average pain intensity from baseline to 8 and 12 weeks post-BoNTA vs. post-placebo (33% vs. 0%). At 2 and 4 weeks post-BoNTA, almost all participants reported some degree of reduced pain, while the same was not seen post-placebo (83% vs. 0%). Conclusion The subcutaneous injection of BoNTA may be a feasible approach for the control of at-level SCI pain and is worthy of further study. Sponsorship The onabotulinumtoxinA (BOTOX) used in this study was provided by Allergan (Irvine, CA).",2019,"To explore whether botulinum toxin A (BoNTA) could be effective for treating at-level spinal cord injury (SCI) pain. ",['The median age of the eight participants was 45 years (range 32-61 years) and 75% were male'],"['placebo', 'botulinum toxin A (BoNTA', 'botulinum toxin A']","['degree of reduced pain', 'average pain intensity', 'traumatic, T1-L3 level, complete SCI']","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0006055', 'cui_str': 'Botulin'}]","[{'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0332663', 'cui_str': 'Traumatic (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]",8.0,0.484571,"To explore whether botulinum toxin A (BoNTA) could be effective for treating at-level spinal cord injury (SCI) pain. ","[{'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Chun', 'Affiliation': '1Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY USA.'}, {'ForeName': 'Isaiah', 'Initials': 'I', 'LastName': 'Levy', 'Affiliation': '2Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY USA.'}, {'ForeName': 'Ajax', 'Initials': 'A', 'LastName': 'Yang', 'Affiliation': 'The Spine and Pain Institute of New York, New York, NY USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Delgado', 'Affiliation': '1Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY USA.'}, {'ForeName': 'Chung-Ying', 'Initials': 'CY', 'LastName': 'Tsai', 'Affiliation': '1Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Leung', 'Affiliation': '5Department of Physical Medicine and Rehabilitation, Department of Pain Medicine, Northwell Health Physician Partners, Bay Shore, NY USA.'}, {'ForeName': 'Kristell', 'Initials': 'K', 'LastName': 'Taylor', 'Affiliation': '1Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Kolakowsky-Hayner', 'Affiliation': '1Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY USA.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Huang', 'Affiliation': '1Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY USA.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Escalon', 'Affiliation': '1Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY USA.'}, {'ForeName': 'Thomas N', 'Initials': 'TN', 'LastName': 'Bryce', 'Affiliation': '1Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY USA.'}]",Spinal cord series and cases,['10.1038/s41394-019-0221-9'] 2918,31557321,EBGene trial: patient preselection outcomes for the European GENEGRAFT ex vivo phase I/II gene therapy trial for recessive dystrophic epidermolysis bullosa.,,2020,,[],['European GENEGRAFT ex'],[],[],"[{'cui': 'C0239307', 'cui_str': 'European (ethnic group)'}]",[],,0.0200734,,"[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Gaucher', 'Affiliation': 'INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute, Paris, France.'}, {'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Lwin', 'Affiliation': ""St John's Institute of Dermatology, King's College London, London, U.K.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Titeux', 'Affiliation': 'INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute, Paris, France.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Abdul-Wahab', 'Affiliation': ""St John's Institute of Dermatology, King's College London, London, U.K.""}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Pironon', 'Affiliation': 'INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute, Paris, France.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Izmiryan', 'Affiliation': 'INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute, Paris, France.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Miskinyte', 'Affiliation': 'INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute, Paris, France.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Ganier', 'Affiliation': 'INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute, Paris, France.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Duchatelet', 'Affiliation': 'INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute, Paris, France.'}, {'ForeName': 'J E', 'Initials': 'JE', 'LastName': 'Mellerio', 'Affiliation': ""St John's Institute of Dermatology, King's College London, London, U.K.""}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Bourrat', 'Affiliation': 'Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.'}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'McGrath', 'Affiliation': ""St John's Institute of Dermatology, King's College London, London, U.K.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Hovnanian', 'Affiliation': 'INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute, Paris, France.'}]",The British journal of dermatology,['10.1111/bjd.18559'] 2919,31970581,"Stigma Related to HIV and Drug Use: Layers, Types, and Relations to Mental Health.","Stigma poses considerable challenges to the mental health of people living with HIV who use drugs (PLHWUD). In this study, we explored factors related to different types of stigma (perceived and internalized) attached to layered stigmatizing characters (HIV and drug use) and their mental health influences on PLHWUD. The study used baseline data of an ongoing randomized controlled trial among 241 PLHWUD recruited between March and December 2018 in Vietnam. A structural equation model was used to assess the relationships among different types and layers of stigma and mental health status. Both perceived and internalized drug-related stigma measures were significantly higher than their corresponding HIV-related stigma. HIV-related stigma was negatively associated with mental health status; however, we did not find a significant relationship between drug-related stigma and mental health. Tailored intervention strategies in consideration of types and layers of stigma are needed to address stigma-related challenges faced by PLHWUD.",2020,Both perceived and internalized drug-related stigma measures were significantly higher than their corresponding HIV-related stigma.,['241 PLHWUD recruited between March and December 2018 in Vietnam'],[],[],"[{'cui': 'C0042658', 'cui_str': 'Viet Nam'}]",[],[],241.0,0.0331404,Both perceived and internalized drug-related stigma measures were significantly higher than their corresponding HIV-related stigma.,"[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior - Center for Community Health, University of California, Los Angeles, CA, USA. lililili@ucla.edu.'}, {'ForeName': 'Chunqing', 'Initials': 'C', 'LastName': 'Lin', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior - Center for Community Health, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Feng', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior - Center for Community Health, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Diep Bich', 'Initials': 'DB', 'LastName': 'Nguyen', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior - Center for Community Health, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Cao', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior - Center for Community Health, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Anh Tuan', 'Initials': 'AT', 'LastName': 'Le', 'Affiliation': 'National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.'}, {'ForeName': 'Anh Tuan', 'Initials': 'AT', 'LastName': 'Nguyen', 'Affiliation': 'National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.'}]",AIDS and behavior,['10.1007/s10461-020-02794-5'] 2920,27461,Immuno-stimulation by a ribosomal vaccine associated with a bacterial cell wall adjuvant in humans.,"We have studied a new vaccine of ribosomal nature associated with glycoprotein cell walls from Klebsiella pneumoniae which served as an immunoadjuvant. Thus vaccine was administered by the aerosol route to working men free of any important disease, especially of respiratory disease. A total of 104 men working for the Commissariat à l'Energie Atomique, all volunteers, were randomly placed into two groups. During the first period, 51 patients (group I) were vaccinated three times a week during 5 weeks, and the second group was used as control. During the second period, which started on day 225, the control group received the vaccine, and the first group was revaccinated. Results of this experience show a significant difference in the immunity of the two groups. The specific antibodies increased with vaccination as illustrated by chi-square test (Yates correction), which corresponds to an independent probability equal to 0 (P = 0.5 X 10-4).",1978,"The specific antibodies increased with vaccination as illustrated by chi-square test (Yates correction), which corresponds to an independent probability equal to 0","[""104 men working for the Commissariat à l'Energie Atomique, all volunteers"", 'humans']",['vaccine'],['specific antibodies'],"[{'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0042210', 'cui_str': 'Vaccines'}]","[{'cui': 'C0443640', 'cui_str': 'Specific antibody (substance)'}]",104.0,0.0118887,"The specific antibodies increased with vaccination as illustrated by chi-square test (Yates correction), which corresponds to an independent probability equal to 0","[{'ForeName': 'F B', 'Initials': 'FB', 'LastName': 'Michel', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': ""Dussourd D'Hinterland"", 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Bousquet', 'Affiliation': ''}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Pinel', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Normier', 'Affiliation': ''}]",Infection and immunity,[] 2921,32088664,The Effects Of Slow Breathing Exercise On Heart Rate Dynamics And Cardiorespiratory Coherence In Preschool Children: A Prospective Clinical Study.,"Background Slow breathing has been used to improve psychophysiological regulation due to positive action on the autonomic nervous system. Primary Study Objective We evaluated the effects of slow breathing on heart rate autonomic control in preschool-aged children. Methods/Design Prospective clinical study. Setting Campinas, Brazil. Participants We included 42 children in the experimental group (age 5.7 ± 0.3) and 33 children in the control group (age 6.2 ± 0.3). Intervention Children received a daily training of eight weeks duration for practicing a slow breathing technique. Primary Outcome Measures • We analyzed heart rate variability (HRV) and cardiorespiratory coherence at rest under spontaneous breathing and during respiratory sinus arrhythmia (RSA) at the end of the 1st, 4th, and 8th weeks of training. Results The percentage of high coherence ratio increased (P < .0001), HRV reduced (SDNN, P = .0066; RMSSD, P = .0015; pNN50, P < .0001; SD1, P = .0015; SD2, P = .0166) and the complexity of HRV increased (ApEn, P = .0004; MSE area, P < .0001; DFAαl, P = .0001; ShanEnt, P = .0106; Lmean, P = .0066) during RSA compared to spontaneous breathing after slow breathing training period. Conclusion Slow breathing training exercise induced increased cardiorespiratory coherence and increased nonlinear behavior of heart rate dynamics suggesting improvements in health status. Increased cardiorespiratory coherence reinforces the importance of including respiratory exercises in strategies that aim to promote physical health and self-regulation skills in educational settings.",2020,"The percentage of high coherence ratio increased (P < .0001), HRV reduced (SDNN, P = .0066; RMSSD, P = .0015; pNN50, P < .0001; SD1, P = .0015; SD2, P = .0166) and the complexity of HRV increased (ApEn, P = .0004; MSE area, P < .0001; DFAαl, P = .0001;","['Participants\n\n\nWe included 42 children in the experimental group (age 5.7 ± 0.3) and 33 children in the control group (age 6.2 ± 0.3', 'preschool-aged children', 'Preschool Children']","['Slow Breathing Exercise', 'daily training of eight weeks duration for practicing a slow breathing technique', 'Slow breathing training exercise', 'slow breathing']","['heart rate variability (HRV) and cardiorespiratory coherence at rest under spontaneous breathing and during respiratory sinus arrhythmia (RSA', 'heart rate autonomic control', 'HRV', 'Heart Rate Dynamics And Cardiorespiratory Coherence', 'percentage of high coherence ratio', 'cardiorespiratory coherence', 'complexity of HRV']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517795', 'cui_str': 'Five point seven'}, {'cui': 'C4068885', 'cui_str': 'Zero point three'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517820', 'cui_str': '6.2'}, {'cui': 'C0008100', 'cui_str': 'Child, Preschool'}]","[{'cui': 'C0231837', 'cui_str': 'Slow respiration (finding)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0025664', 'cui_str': 'techniques'}]","[{'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0443144', 'cui_str': 'At rest (qualifier value)'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}, {'cui': 'C3812870', 'cui_str': 'Respiratory Sinus Arrhythmia'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",42.0,0.0420492,"The percentage of high coherence ratio increased (P < .0001), HRV reduced (SDNN, P = .0066; RMSSD, P = .0015; pNN50, P < .0001; SD1, P = .0015; SD2, P = .0166) and the complexity of HRV increased (ApEn, P = .0004; MSE area, P < .0001; DFAαl, P = .0001;","[{'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Zuanazzi Cruz', 'Affiliation': ''}, {'ForeName': 'Moacir', 'Initials': 'M', 'LastName': 'Fernandes de Godoy', 'Affiliation': ''}, {'ForeName': 'Vitor E', 'Initials': 'VE', 'LastName': 'Valenti', 'Affiliation': ''}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Pereira', 'Affiliation': ''}, {'ForeName': 'Roberto Antonio', 'Initials': 'RA', 'LastName': 'Dias Cardoso', 'Affiliation': ''}]",Alternative therapies in health and medicine,[] 2922,32107101,Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial.,,2020,,['patients with treatment-resistant schizophrenia'],[],['clozapine plasma levels'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3544321', 'cui_str': 'Treatment-resistant schizophrenia'}]",[],"[{'cui': 'C0009079', 'cui_str': 'Clozapine'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",,0.268407,,"[{'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Schoretsanitis', 'Affiliation': 'The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA. Electronic address: george.schor@gmail.com.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Mendelowitz', 'Affiliation': 'The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA; The Hofstra Northwell School of Medicine, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA.'}, {'ForeName': 'Chitra', 'Initials': 'C', 'LastName': 'Malur', 'Affiliation': 'The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA; The Hofstra Northwell School of Medicine, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA.'}, {'ForeName': 'Raphael J', 'Initials': 'RJ', 'LastName': 'Braga', 'Affiliation': 'The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA; The Hofstra Northwell School of Medicine, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA.'}, {'ForeName': 'Nina R', 'Initials': 'NR', 'LastName': 'Schooler', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, SUNY Downstate Medical Center, Brooklyn, NY, USA.'}, {'ForeName': 'Majnu', 'Initials': 'M', 'LastName': 'John', 'Affiliation': 'The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA; The Hofstra Northwell School of Medicine, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'de Leon', 'Affiliation': 'University of Kentucky Mental Health Research Center at Eastern State Hospital, Lexington, KY, USA; Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, Granada, Spain; Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apostol Hospital, University of the Basque Country, Vitoria, Spain.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Kane', 'Affiliation': 'The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA; The Hofstra Northwell School of Medicine, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA.'}, {'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Petrides', 'Affiliation': 'The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA; The Hofstra Northwell School of Medicine, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA.'}]",Schizophrenia research,['10.1016/j.schres.2020.02.008'] 2923,32198802,A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia.,"BACKGROUND IRL752 is a novel small-molecule compound that acts to regioselectively enhance norepinephrine, dopamine, and acetylcholine neurotransmission in the cerebral cortex. OBJECTIVE The primary objective of the trial was to investigate the safety and tolerability of IRL752 in patients with Parkinson's disease and dementia. METHODS Patients with Parkinson's disease and dementia were randomized to IRL752 or placebo treatment (3:1 ratio) for 28 days. The study drug was given as an adjunct treatment to the patients' regular stable antiparkinsonian medication. Dosing was individually titrated for 14 days after which the dose was kept stable for an additional 14 days. RESULTS A total of 32 patients were randomized to treatment, and 29 patients completed the 4-week treatment. Adverse events were generally mild and transient and were mostly reported during the dose titration phase. There were 2 serious adverse events, and none of them were related to the experimental treatment. The average dose achieved in the stable dose phase was 600 mg daily, yielding a 2-hour postdose plasma concentration of about 4 μM on day 28. Exploratory assessment of secondary outcomes indicated efficacy for symptoms and signs known to be poorly responsive to levodopa. CONCLUSIONS IRL752 appears to be safe and well tolerated for a 4-week treatment in patients with Parkinson's disease and dementia. © 2020 International Parkinson and Movement Disorder Society.",2020,"There were 2 serious adverse events, and none of them were related to the experimental treatment.","[""Parkinson's Disease Dementia"", ""patients with Parkinson's disease and dementia"", ""patients' regular stable antiparkinsonian medication"", ""Patients with Parkinson's disease and dementia"", '32 patients']","['Novel Cortical Enhancer IRL752', 'IRL752', 'IRL752 or placebo']","['Adverse events', 'safety and tolerability', 'Safety and Tolerability', 'serious adverse events', 'safe and well tolerated']","[{'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0003405', 'cui_str': 'Antiparkinsonians'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",32.0,0.0512868,"There were 2 serious adverse events, and none of them were related to the experimental treatment.","[{'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Svenningsson', 'Affiliation': 'Section of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Odin', 'Affiliation': 'Division of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.'}, {'ForeName': 'Nil', 'Initials': 'N', 'LastName': 'Dizdar', 'Affiliation': 'Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Johansson', 'Affiliation': 'Section of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Sotirios', 'Initials': 'S', 'LastName': 'Grigoriou', 'Affiliation': 'Division of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.'}, {'ForeName': 'Panagiota', 'Initials': 'P', 'LastName': 'Tsitsi', 'Affiliation': 'Section of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Klas', 'Initials': 'K', 'LastName': 'Wictorin', 'Affiliation': 'Department of Neurology, Helsingborg Hospital, Helsingborg, Sweden.'}, {'ForeName': 'Filip', 'Initials': 'F', 'LastName': 'Bergquist', 'Affiliation': 'Department of Pharmacology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Dag', 'Initials': 'D', 'LastName': 'Nyholm', 'Affiliation': 'Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Juha', 'Initials': 'J', 'LastName': 'Rinne', 'Affiliation': 'Clinical Research Services Turku Oy, Turku, Finland.'}, {'ForeName': 'Fredrik', 'Initials': 'F', 'LastName': 'Hansson', 'Affiliation': 'Clinical Trial Consultants, Uppsala, Sweden.'}, {'ForeName': 'Clas', 'Initials': 'C', 'LastName': 'Sonesson', 'Affiliation': 'Integrative Research Laboratories AB, Göteborg, Sweden.'}, {'ForeName': 'Joakim', 'Initials': 'J', 'LastName': 'Tedroff', 'Affiliation': 'Section of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Movement disorders : official journal of the Movement Disorder Society,['10.1002/mds.28020'] 2924,8837422,Specific detection and analysis of a probiotic Bifidobacterium strain in infant feces.,"For specific detection of the probiotic Bifidobacterium sp. strain LW420 in infant feces and for rapid quality control of this strain in culture, three strain-specific 16S rRNA gene-targeted primers have been developed. These primers allow specific detection of the organism via PCR. Specificity of the primers was determined in DNA samples isolated from single-strain and mixed cultures of bifidobacteria and in heterogenous fecal samples. The feasibility of this method for use in specific detection of probiotic strains was investigated through addition of Bifidobacterium sp. strain LW420 to infant instant milk formula (IMF) and PCR analyses of bacterial DNA isolated from feces of 17 newborn IMF-fed infants. In feces of all nine babies that had been fed with the probiotic IMF, the strain-specific PCR signal could be detected. No signal was found in feces of the eight infants that had been fed with a nonprobiotic IMF, demonstrating the specificity of the PCR method. All 17 infants developed a major fecal Bifidobacterium population already after 3 days, as determined through genus-specific and strain-specific PCR. Phenotypical screening of Bifidobacterium sp. strain LW420 and analysis of homology of the 16S rRNA gene sequence of this strain with that of other bifidobacteria deposited in databases do not allow positive classification of LW420 among the currently known species of Bifidobacterium.",1996,"All 17 infants developed a major fecal Bifidobacterium population already after 3 days, as determined through genus-specific and strain-specific PCR.","['17 newborn IMF-fed infants', 'infant feces']",[],[],"[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0015733', 'cui_str': 'Feces'}]",[],[],17.0,0.0423631,"All 17 infants developed a major fecal Bifidobacterium population already after 3 days, as determined through genus-specific and strain-specific PCR.","[{'ForeName': 'R G', 'Initials': 'RG', 'LastName': 'Kok', 'Affiliation': 'Department of Microbiology, E. C. Slater Institute, BioCentrum Amsterdam, The Netherlands.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'de Waal', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Schut', 'Affiliation': ''}, {'ForeName': 'G W', 'Initials': 'GW', 'LastName': 'Welling', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Weenk', 'Affiliation': ''}, {'ForeName': 'K J', 'Initials': 'KJ', 'LastName': 'Hellingwerf', 'Affiliation': ''}]",Applied and environmental microbiology,[] 2925,8878607,3-day course of ofloxacin versus cefalexin in the treatment of urinary tract infections in postmenopausal women.,,1996,,['postmenopausal women'],['ofloxacin versus cefalexin'],['urinary tract infections'],"[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0028902', 'cui_str': 'Ofloxacin'}, {'cui': 'C0007716', 'cui_str': 'Cephalexin'}]","[{'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}]",,0.0139358,,"[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Raz', 'Affiliation': 'Infectious Diseases Unit, Central Emek Hospital, Afula, Israel.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Rozenfeld', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 2926,31957638,Effects of a 12-week yoga versus a 12-week educational film intervention on symptoms of restless legs syndrome and related outcomes: an exploratory randomized controlled trial.,"STUDY OBJECTIVES To assess the effects of a yoga versus educational film (EF) program on restless legs syndrome (RLS) symptoms and related outcomes in adults with RLS. METHODS Forty-one community-dwelling, ambulatory nonpregnant adults with moderate to severe RLS were randomized to a 12-week yoga (n = 19) or EF program (n = 22). In addition to attending classes, all participants completed practice/treatment logs. Yoga group participants were asked to practice at home 30 minutes per day on nonclass days; EF participants were instructed to record any RLS treatments used on their daily logs. Core outcomes assessed pretreatment and posttreatment were RLS symptoms and symptom severity (International RLS Study Group Scale (IRLS) and RLS ordinal scale), sleep quality, mood, perceived stress, and quality of life (QOL). RESULTS Thirty adults (13 yoga, 17 EF), aged 24 to 73 (mean = 50.4 ± 2.4 years), completed the 12-week study (78% female, 80.5% white). Post-intervention, both groups showed significant improvement in RLS symptoms and severity, perceived stress, mood, and QOL-mental health (P ≤ .04). Relative to the EF group, yoga participants demonstrated significantly greater reductions in RLS symptoms and symptom severity (P ≤ .01), and greater improvements in perceived stress and mood (P ≤ .04), as well as sleep quality (P = .09); RLS symptoms decreased to minimal/mild in 77% of yoga group participants, with none scoring in the severe range by week 12, versus 24% and 12%, respectively, in EF participants. In the yoga group, IRLS and RLS severity scores declined with increasing minutes of homework practice (r = .7, P = .009 and r = .6, P = .03, respectively), suggesting a possible dose-response relationship. CONCLUSIONS Findings of this exploratory RCT suggest that yoga may be effective in reducing RLS symptoms and symptom severity, decreasing perceived stress, and improving mood and sleep in adults with RLS. CLINICAL TRIAL REGISTRATION Registry: Clinicaltrials.gov; Title: Yoga vs. Education for Restless Legs: a Feasibility Study; Identifier: NCT03570515; URL: https://clinicaltrials.gov/ct2/show/NCT03570515.",2020,"Post-intervention, both groups showed significant improvement in RLS symptoms and severity, perceived stress, mood, and QOL-mental health (P ≤ .04).","['Thirty adults (13 yoga, 17 EF), aged 24 to 73 (mean = 50.4 ± 2.4 years), completed the 12-week study (78% female, 80.5% white', 'adults with RLS', 'Forty-one community-dwelling, ambulatory nonpregnant adults with moderate to severe RLS']","['yoga versus educational film (EF) program', 'EF program', 'educational film intervention']","['RLS symptoms and symptom severity (International RLS Study Group Scale (IRLS) and RLS ordinal scale), sleep quality, mood, perceived stress, and quality of life (QOL', 'RLS symptoms and symptom severity', 'RLS symptoms', 'IRLS and RLS severity scores', 'symptoms of restless legs syndrome and related outcomes', 'perceived stress and mood', 'restless legs syndrome (RLS) symptoms', 'sleep quality', 'RLS symptoms and severity, perceived stress, mood, and QOL-mental health']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4517631', 'cui_str': '2.4 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C4045975', 'cui_str': 'Community Dwelling'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C4319646', 'cui_str': 'Film'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0034380'}, {'cui': 'C0457451', 'cui_str': 'Severity score (qualifier value)'}, {'cui': 'C0035258', 'cui_str': 'Wittmaack Ekbom Syndrome'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C3887611', 'cui_str': 'Restlessness (finding)'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]",30.0,0.153714,"Post-intervention, both groups showed significant improvement in RLS symptoms and severity, perceived stress, mood, and QOL-mental health (P ≤ .04).","[{'ForeName': 'Kim E', 'Initials': 'KE', 'LastName': 'Innes', 'Affiliation': 'Department of Epidemiology, West Virginia University School of Public Health, Morgantown, West Virginia.'}, {'ForeName': 'Terry Kit', 'Initials': 'TK', 'LastName': 'Selfe', 'Affiliation': 'Health Science Center Libraries, University of Florida, Gainesville, Florida.'}, {'ForeName': 'Caitlin', 'Initials': 'C', 'LastName': 'Montgomery', 'Affiliation': 'Department of Epidemiology, West Virginia University School of Public Health, Morgantown, West Virginia.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Hollingshead', 'Affiliation': 'Department of Family Medicine, The Ohio State University College of Medicine, Columbus, Ohio.'}, {'ForeName': 'Zenzi', 'Initials': 'Z', 'LastName': 'Huysmans', 'Affiliation': 'West Virginia University College of Physical Activity and Sport Sciences, Morgantown, West Virginia.'}, {'ForeName': 'Roshini', 'Initials': 'R', 'LastName': 'Srinivasan', 'Affiliation': 'Department of Family Medicine, The Ohio State University College of Medicine, Columbus, Ohio.'}, {'ForeName': 'Sijin', 'Initials': 'S', 'LastName': 'Wen', 'Affiliation': 'Department of Biostatistics, West Virginia University School of Public Health, Morgantown, West Virginia.'}, {'ForeName': 'Madeleine J', 'Initials': 'MJ', 'LastName': 'Hausmann', 'Affiliation': 'Department of Family Medicine, The Ohio State University College of Medicine, Columbus, Ohio.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Sherman', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute, Seattle, Washington.'}, {'ForeName': 'Maryanna', 'Initials': 'M', 'LastName': 'Klatt', 'Affiliation': 'Department of Family Medicine, The Ohio State University College of Medicine, Columbus, Ohio.'}]",Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine,['10.5664/jcsm.8134'] 2927,31957640,"The relationship between obesity and sleep timing behavior, television exposure, and dinnertime among elementary school-age children.","STUDY OBJECTIVES The daily lifestyle behaviors of children have been shown to be associated with obesity. There are limited studies on the association of sleep timing behavior and body mass index (BMI), specifically in elementary school-age children. This study aimed to investigate the relationship between obesity and sleep timing patterns, television exposure time, and dinnertime among elementary school-age children. METHODS Children (n = 169) aged 6 to 10 years who were residents of Alabama were recruited for this study. The questionnaires were used to determine the bedtime, wake-up time, television exposure time, and dinnertime of the participants. The participants were categorized into four groups depending on the bedtime and wake-up time behavior habits: early bed/early wake-up (EE); early bed/late wake-up (EL); late bed/early wake-up (LE); and late bed/late wake-up (LL) time. The BMI z-score, television exposure time, and dinnertime of these groups were compared. RESULTS The LL group had a significantly higher BMI z-score compared to the EE group. The higher BMI z-score in the LL group may be associated with late bedtime and not late wake-up time. Approximately 71% of children with late bedtime (8:48 pm), 75% of children who watch television for more than 1 hour, and 54% of children who have dinner after 7:00 pm have obesity. CONCLUSIONS Daily behavior habits such as late bedtime, increased television exposure, and late dinnertime are associated with obesity.",2020,The LL group had a significantly higher BMI z-score compared to the EE group.,"['Children (n = 169) aged 6 to 10 years who were residents of Alabama were recruited for this study', 'elementary school-age children']",[],"['BMI z-score, television exposure time, and dinnertime', 'higher BMI z-score', 'BMI z-score']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001895', 'cui_str': 'Alabama'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]",[],"[{'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0039461', 'cui_str': 'Television'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0585040', 'cui_str': 'Dinnertime'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]",,0.0314043,The LL group had a significantly higher BMI z-score compared to the EE group.,"[{'ForeName': 'Chandra M K', 'Initials': 'CMK', 'LastName': 'Venkatapoorna', 'Affiliation': 'Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, Alabama.'}, {'ForeName': 'Priscilla', 'Initials': 'P', 'LastName': 'Ayine', 'Affiliation': 'Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, Alabama.'}, {'ForeName': 'Vaithinathan', 'Initials': 'V', 'LastName': 'Selvaraju', 'Affiliation': 'Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, Alabama.'}, {'ForeName': 'Emily P', 'Initials': 'EP', 'LastName': 'Parra', 'Affiliation': 'Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, Alabama.'}, {'ForeName': 'Taylor', 'Initials': 'T', 'LastName': 'Koenigs', 'Affiliation': 'Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, Alabama.'}, {'ForeName': 'Jeganathan Ramesh', 'Initials': 'JR', 'LastName': 'Babu', 'Affiliation': 'Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, Alabama.'}, {'ForeName': 'Thangiah', 'Initials': 'T', 'LastName': 'Geetha', 'Affiliation': 'Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, Alabama.'}]",Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine,['10.5664/jcsm.8080'] 2928,32124456,Evaluation of a sterile surgical skin marker to indicate the optimal vein for venepuncture in the blood donation setting.,"BACKGROUND AND OBJECTIVES Phlebotomy is a central task for blood donation; however, not all blood donors have veins that are easy to see or feel. This study aimed to determine whether use of a surgical skin marker to highlight the donors' vein location and direction prior to venepuncture increased blood donation success. METHODS All blood donors who participated in this study were eligible to donate according to Australian guidelines. Ten donor centres with phlebotomy success rates <95% were selected. A randomized cluster trial design assigned five sites to test the skin marking device and five sites as controls. Single-use sterile Gentian violet skin marker pens were used to mark donors' veins. Phlebotomy site skin bacterial load after using the skin marking device was tested on a subset of 100 donors. Phlebotomy success rates and donor adverse events were recorded. RESULTS Of the control donors, 6993 had successful phlebotomies and 225 failed. Of the skin marker donors, 6998 had successful phlebotomies and 248 failed. No statistically significant differences in phlebotomy success were found between the two groups (OR: 0·91, 96·4% CI [96·0, 96·8], P-value 0·348). CONCLUSION The use of skin marker pens did not increase overall phlebotomy success rate. There was no increase in phlebotomy site skin bacterial load, and amendments to standard skin disinfection techniques were not required. Blood donors were not concerned about the pen mark on their arms. Generally, staff indicated that the markers may be valuable to assist with phlebotomies for donors with difficult or deep veins.",2020,"No statistically significant differences in phlebotomy success were found between the two groups (OR: 0·91, 96·4% CI [96·0, 96·8], P-value 0·348). ","['Of the skin marker donors, 6998 had successful phlebotomies and 248 failed', 'All blood donors who participated in this study were eligible to donate according to Australian guidelines', 'Ten donor centres with phlebotomy success rates <95% were selected']",['Single-use sterile Gentian violet skin marker pens'],"['Phlebotomy success rates and donor adverse events', 'phlebotomy site skin bacterial load, and amendments to standard skin disinfection techniques', 'overall phlebotomy success rate', 'phlebotomy success']","[{'cui': 'C0181740', 'cui_str': 'Skin marker (physical object)'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0190979', 'cui_str': 'Venesection'}, {'cui': 'C0005795', 'cui_str': 'Blood donor (person)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0220845', 'cui_str': 'guidelines'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0232920', 'cui_str': 'Sterile (qualifier value)'}, {'cui': 'C0017440', 'cui_str': 'Gentian Violet'}, {'cui': 'C0181740', 'cui_str': 'Skin marker (physical object)'}, {'cui': 'C4319659', 'cui_str': 'Pen (unit of presentation)'}]","[{'cui': 'C0190979', 'cui_str': 'Venesection'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C2936404', 'cui_str': 'Bacterial Load'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1698034', 'cui_str': 'Skin disinfection'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.0199904,"No statistically significant differences in phlebotomy success were found between the two groups (OR: 0·91, 96·4% CI [96·0, 96·8], P-value 0·348). ","[{'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Bell', 'Affiliation': 'Australian Red Cross Blood Service, Sydney, Australia.'}, {'ForeName': 'Justine', 'Initials': 'J', 'LastName': ""O'Donovan"", 'Affiliation': 'Australian Red Cross Blood Service, Sydney, Australia.'}, {'ForeName': 'Stephen T', 'Initials': 'ST', 'LastName': 'Wright', 'Affiliation': 'Australian Red Cross Blood Service, Sydney, Australia.'}, {'ForeName': 'Carley N', 'Initials': 'CN', 'LastName': 'Gemelli', 'Affiliation': 'Australian Red Cross Blood Service, Melbourne, Australia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Knight', 'Affiliation': 'Australian Red Cross Blood Service, Melbourne, Australia.'}, {'ForeName': 'Rena', 'Initials': 'R', 'LastName': 'Hirani', 'Affiliation': 'Australian Red Cross Blood Service, Sydney, Australia.'}]",Vox sanguinis,['10.1111/vox.12904'] 2929,4563983,Amino sugar assimilation by Escherichia coli.,"The carbon skeleton of glucose is extensively randomized during conversion to cell wall glucosamine by Escherichia coli K-12. Exogenous glucosamine-1-(14)C is selectively oxidized, and isotope incorporation into cellular glucosamine is greatly diluted during assimilation. A mutant unable to grow with N-acetylglucosamine as a carbon and energy source was isolated from E. coli K-12. This mutant was found to be defective in glucosamine-6-phosphate deaminase. Glucosamine-1-(14)C and N-acetylglucosamine-1-(14)C were assimilated during the growth of mutant cultures without degradation or carbon randomization. Assimilated isotopic carbon resided entirely in cell wall glucosamine and muramic acid. Some isotope dilution occurred from biosynthesis, but at high concentrations (0.2 mm) of added N-acetylglucosamine nearly all cellular amino sugar was derived from the exogenous source. Growth of the mutant was inhibited with 1 mmN-acetylglucosamine.",1972,Glucosamine-1-(14)C and N-acetylglucosamine-1-(14)C were assimilated during the growth of mutant cultures without degradation or carbon randomization.,[],"['Exogenous glucosamine-1-(14)C', 'Glucosamine-1-(14)C and N-acetylglucosamine-1-(14)C']",[],[],"[{'cui': 'C0205228', 'cui_str': 'Exogenous (qualifier value)'}, {'cui': 'C0017718', 'cui_str': 'Glucosamine'}, {'cui': 'C0001056', 'cui_str': 'N-Acetylglucosamine'}]",[],,0.0238557,Glucosamine-1-(14)C and N-acetylglucosamine-1-(14)C were assimilated during the growth of mutant cultures without degradation or carbon randomization.,"[{'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Rolls', 'Affiliation': ''}, {'ForeName': 'C W', 'Initials': 'CW', 'LastName': 'Shuster', 'Affiliation': ''}]",Journal of bacteriology,[] 2930,31935113,Skeletal muscle lipid droplets are resynthesized before being coated with perilipin proteins following prolonged exercise in elite male triathletes.,"Intramuscular triglycerides (IMTG) are a key substrate during prolonged exercise, but little is known about the rate of IMTG resynthesis in the postexercise period. We investigated the hypothesis that the distribution of the lipid droplet (LD)-associated perilipin (PLIN) proteins is linked to IMTG storage following exercise. Fourteen elite male triathletes (27 ± 1 yr, 66.5 ± 1.3 mL·kg -1 ·min -1 ) completed 4 h of moderate-intensity cycling. During the first 4 h of recovery, subjects received either carbohydrate or H 2 O, after which both groups received carbohydrate. Muscle biopsies collected pre- and postexercise and 4 and 24 h postexercise were analyzed using confocal immunofluorescence microscopy for fiber type-specific IMTG content and PLIN distribution with LDs. Exercise reduced IMTG content in type I fibers (-53%, P = 0.002), with no change in type IIa fibers. During the first 4 h of recovery, IMTG content increased in type I fibers ( P = 0.014), but was not increased more after 24 h, where it was similar to baseline levels in both conditions. During recovery the number of LDs labeled with PLIN2 (70%), PLIN3 (63%), and PLIN5 (62%; all P < 0.05) all increased in type I fibers. Importantly, the increase in LDs labeled with PLIN proteins only occurred at 24 h postexercise. In conclusion, IMTG resynthesis occurs rapidly in type I fibers following prolonged exercise in highly trained individuals. Furthermore, increases in IMTG content following exercise preceded an increase in the number of LDs labeled with PLIN proteins. These data, therefore, suggest that the PLIN proteins do not play a key role in postexercise IMTG resynthesis.",2020,"Exercise reduced IMTG content in type I fibers (-53%, P = 0.002), with no change in type IIa fibers.","['elite male triathletes', 'Fourteen elite male triathletes (27\u2009±\u20091 yr, 66.5\u2009±\u20091.3 mL·kg -1 ·min -1 ) completed 4 h of moderate-intensity cycling']","['Intramuscular triglycerides (IMTG', 'carbohydrate']","['IMTG content', 'LDs labeled with PLIN proteins']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C4517499', 'cui_str': '1.3 (qualifier value)'}, {'cui': 'C1301862', 'cui_str': 'Min 1'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}]","[{'cui': 'C0442117', 'cui_str': 'Intramuscular (qualifier value)'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}]","[{'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C4277675', 'cui_str': 'PAT Proteins'}]",14.0,0.123493,"Exercise reduced IMTG content in type I fibers (-53%, P = 0.002), with no change in type IIa fibers.","[{'ForeName': 'Emily F P', 'Initials': 'EFP', 'LastName': 'Jevons', 'Affiliation': 'Research Institute of Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Kasper D', 'Initials': 'KD', 'LastName': 'Gejl', 'Affiliation': 'Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Juliette A', 'Initials': 'JA', 'LastName': 'Strauss', 'Affiliation': 'Research Institute of Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Ørtenblad', 'Affiliation': 'Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Sam O', 'Initials': 'SO', 'LastName': 'Shepherd', 'Affiliation': 'Research Institute of Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}]",American journal of physiology. Endocrinology and metabolism,['10.1152/ajpendo.00399.2019'] 2931,31475941,Effect of adding whole-body vibration training to squat training on physical function and muscle strength in individuals with knee osteoarthritis.,"OBJECTIVES This study aims to investigate the effects of adding whole-body vibration (WBV) exercise to squat training (ST) on the physical function and muscle strength of patients with knee osteoarthritis (KOA). METHODS 41 participants completed the intervention and measurements (ST group; n=21, age=65.00±4.39 years, BMI=23.01±2.95 kg/m 2 ; WBV+ST group; n=20, age=64.10±4.95 years, BMI=24.79±3.12 kg/m 2 ). The supervised eight-week intervention was performed three times per week with the intensity and duration increased gradually. Visual analog scale, Timed Up and Go test (TUG), 6-min Walk Distance test, and isokinetic measurements were performed at baseline and post-intervention. RESULTS The peak torque (PT) of the extensors at 180°/s increased significantly in the WBV+ST group compared with the ST group (p = 0.046). The peak work of the extensors and the PT of the flexors at 180°/s improved only in the WBV+ST group (p<0.0125). However, no significant changes in these variables were found between groups (p>0.05). CONCLUSIONS Adding 8 weeks of WBV training to ST can more effectively improve the muscular strength of knee extensors compared with ST in patients with KOA.",2019,/s increased significantly in the WBV+ST group compared with the ST group (p = 0.046).,"['patients with KOA', 'individuals with knee osteoarthritis', 'patients with knee osteoarthritis (KOA']","['adding whole-body vibration (WBV) exercise to squat training (ST', 'adding whole-body vibration training to squat training', 'WBV+ST']","['peak torque (PT', 'muscular strength of knee extensors', 'physical function and muscle strength', 'Visual analog scale, Timed Up and Go test (TUG), 6-min Walk Distance test, and isokinetic measurements', 'peak work of the extensors and the PT of the flexors']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis, Knee'}]","[{'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}, {'cui': 'C0459800', 'cui_str': 'Vibration'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0241236', 'cui_str': 'Does squat (finding)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0376590', 'cui_str': 'Torque'}, {'cui': 'C0442025', 'cui_str': 'Muscular (qualifier value)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C3160837', 'cui_str': 'Walking distance test'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0043227', 'cui_str': 'Work'}]",41.0,0.0125917,/s increased significantly in the WBV+ST group compared with the ST group (p = 0.046).,"[{'ForeName': 'Zhangqi', 'Initials': 'Z', 'LastName': 'Lai', 'Affiliation': 'Key Laboratory of Exercise and Health Science of the Ministry of Education, Shanghai University of Sport, China.'}, {'ForeName': 'Seullee', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Key Laboratory of Exercise and Health Science of the Ministry of Education, Shanghai University of Sport, China.'}, {'ForeName': 'Xiaoyue', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'Key Laboratory of Exercise and Health Science of the Ministry of Education, Shanghai University of Sport, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Key Laboratory of Exercise and Health Science of the Ministry of Education, Shanghai University of Sport, China.'}]",Journal of musculoskeletal & neuronal interactions,[] 2932,30994312,High-flow nasal cannula oxygenation reduces postoperative hypoxemia in morbidly obese patients: a randomized controlled trial.,"BACKGROUND Postoperative pulmonary complications (PPCs) are common in high-risk surgical patients. Postoperative ventilatory management may improve their outcome. Supplemental oxygen through a high-flow nasal cannula (HFNC) has become an alternative to classical oxygenation techniques, although the results published for postoperative patients are contradictory. We examined the efficacy of HFNC in postoperative morbidly obese patients who were ventilated intraoperatively with an open-lung approach (OLA). METHODS We performed an open, two-arm, randomized controlled trial in 64 patients undergoing bariatric surgery (N.=32 in each arm) from May to November 2017 at the Hospital Clínico of Valencia. Patients were randomly assigned to receive HFNC oxygen therapy at the time of extubation or to receive conventional oxygen therapy, both applied during the first three postoperative hours. Intraoperatively, a recruitment maneuver and individualized positive end-expiratory pressure was applied in all patients. The primary outcome was postoperative hypoxemia. RESULTS All patients were included in the final analysis. There were no significant differences between the baseline characteristics. Postoperative hypoxemia was less frequent in the HFNC group compared to those who received standard care (28.6% vs. 80.0%, relative risk [RR]: 0.35; 95%CI: 0.150-0.849, P=0.009). Prevalence of atelectasis was lower in the HFNC group (31% vs. 77%, RR: 0.39; 95%CI: 0.166-0.925, P=0.013). No severe PPCs were reported in any patient. CONCLUSIONS Early application of HFNC in the operating room before extubation and during the immediate postoperative period decreases postoperative hypoxemia in obese patients after bariatric surgery who were intraoperatively ventilated using an OLA approach.",2019,"Postoperative hypoxemia was less frequent in the HFNC group compared to those who received standard care (28.6% vs. 80.0%, relative risk [RR]: 0.35; 95%CI: 0.150-0.849, p=0.009).","['64 patients undergoing bariatric surgery (N=32 in each arm) from May to November 2017 at the Hospital Clínico of Valencia', 'postoperative morbidly obese patients who were ventilated intraoperatively with an open-lung approach (OLA', 'obese patients after bariatric surgery who were intraoperatively ventilated using an OLA approach', 'morbidly obese patients', 'high-risk surgical patients']","['HFNC', 'High-flow nasal cannula oxygenation', 'HFNC oxygen therapy at the time of extubation or to receive conventional oxygen therapy', 'Supplemental oxygen through a high-flow nasal cannula (HFNC']","['postoperative hypoxemia', 'Postoperative hypoxemia', 'severe PPCs', 'Prevalence of atelectasis']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1456587', 'cui_str': 'Bariatric Surgery'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannula'}, {'cui': 'C0184633', 'cui_str': 'Oxygen Inhalation Therapy'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0004144', 'cui_str': 'Lung Collapse'}]",64.0,0.370149,"Postoperative hypoxemia was less frequent in the HFNC group compared to those who received standard care (28.6% vs. 80.0%, relative risk [RR]: 0.35; 95%CI: 0.150-0.849, p=0.009).","[{'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Ferrando', 'Affiliation': 'CIBER de Enfermedades Respiratorias, Carlos III Health Institute, Madrid, Spain - cafeoranestesia@gmail.com.'}, {'ForeName': 'Jaume', 'Initials': 'J', 'LastName': 'Puig', 'Affiliation': 'Department of Anesthesiology and Critical Care, General University Hospital, Valencia, Spain.'}, {'ForeName': 'Ferran', 'Initials': 'F', 'LastName': 'Serralta', 'Affiliation': 'Department of Anesthesiology and Critical Care, Clinical University Hospital, Valencia, Spain.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Carrizo', 'Affiliation': 'Department of Anesthesiology and Critical Care, Clinical University Hospital, Valencia, Spain.'}, {'ForeName': 'Natividad', 'Initials': 'N', 'LastName': 'Pozo', 'Affiliation': 'Department of Anesthesiology and Critical Care, Clinical University Hospital, Valencia, Spain.'}, {'ForeName': 'Blanca', 'Initials': 'B', 'LastName': 'Arocas', 'Affiliation': 'Department of Anesthesiology and Critical Care, Clinical University Hospital, Valencia, Spain.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Gutierrez', 'Affiliation': 'Department of Anesthesiology and Critical Care, Clinical University Hospital, Valencia, Spain.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Villar', 'Affiliation': 'CIBER de Enfermedades Respiratorias, Carlos III Health Institute, Madrid, Spain.'}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'Belda', 'Affiliation': 'Department of Anesthesiology and Critical Care, Clinical University Hospital, Valencia, Spain.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Soro', 'Affiliation': 'Department of Anesthesiology and Critical Care, Clinical University Hospital, Valencia, Spain.'}]",Minerva anestesiologica,['10.23736/S0375-9393.19.13364-0'] 2933,31394939,"The impact of pulsed electromagnetic field therapy on blood pressure and circulating nitric oxide levels: a double blind, randomized study in subjects with metabolic syndrome.","Purpose: Regulation of blood pressure (BP) is important in reducing the risk for cardiovascular disease. There is growing interest in non-pharmacological methods to treat BP including a novel approach using pulsed electromagnetic field therapy (PEMF). PEMF therapy has been proposed to impact physiological function at the cellular and tissue level and one possible mechanism is through an impact on endothelial function and nitric oxide (NO) related pathways. The focus of the present study was to evaluate the effect of PEMF on BP and NO in subjects with mild to moderate metabolic syndrome. Materials and methods: For 12 weeks, 23 subjects underwent PEMF therapy and 21 subjects underwent sham therapy. BP was measured at rest and near the end of submaximal exercise pre- and 12 week post-therapy. Additionally, plasma NO was measured at similar time points. Results: The PEMF demonstrated an increase in NO after therapy ( p =  .04) but SHAM did not ( p =  .37). For resting BP, there were no differences in systolic BP (SBP), diastolic BP (DBP) or mean arterial pressure (MAP) between groups ( p >  .05). During exercise, PEMF had a reduction in peak SBP ( p =  .04), but not SHAM ( p =  .57). PEMF demonstrated significant relationships between baseline SBP and change in SBP following therapy ( r = -0.71, p <  .01) and between MAP and change in MAP following therapy ( r = -0.60, p <  .01), but no such relationships were found in SHAM. Subjects with resting hypertension (SBP ≥140 mmHg) in PEMF (n = 11) had significant reductions in SBP, DBP and MAP when compared to SHAM with hypertension ( n  = 9) ( p <  .05). In this sub-group analysis, PEMF demonstrated lowered peak SBP ( p =  .04) at a given exercise load ( p =  .40) but SHAM did not ( p >  .05). Conclusion: PEMF may increase plasma NO availability and improve BP at rest and during exercise. However, this beneficial effect appears to be more pronounced in subjects with existing hypertension.",2020,"During exercise, PEMF had a reduction in peak SBP ( p =  .04), but not SHAM ( p =  .57).","['subjects with mild to moderate metabolic syndrome', 'subjects with metabolic syndrome', 'subjects with existing hypertension']","['pulsed electromagnetic field therapy (PEMF', 'PEMF therapy', 'PEMF', 'blood pressure (BP', 'pulsed electromagnetic field therapy']","['plasma NO availability and improve BP', 'baseline SBP and change in SBP', 'SBP, DBP and MAP', 'plasma NO', 'blood pressure and circulating nitric oxide levels', 'peak SBP', 'systolic BP (SBP), diastolic BP (DBP) or mean arterial pressure (MAP', 'BP']","[{'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0524620', 'cui_str': 'Metabolic Syndrome X'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}]","[{'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0013835', 'cui_str': 'Electromagnetic Fields'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0024779', 'cui_str': 'Map'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}]",23.0,0.106083,"During exercise, PEMF had a reduction in peak SBP ( p =  .04), but not SHAM ( p =  .57).","[{'ForeName': 'Chul-Ho', 'Initials': 'CH', 'LastName': 'Kim', 'Affiliation': 'Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Courtney M', 'Initials': 'CM', 'LastName': 'Wheatley-Guy', 'Affiliation': 'Department of Cardiovascular Diseases, Mayo Clinic, Phoenix, AZ, USA.'}, {'ForeName': 'Glenn M', 'Initials': 'GM', 'LastName': 'Stewart', 'Affiliation': 'Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Dongwook', 'Initials': 'D', 'LastName': 'Yeo', 'Affiliation': 'Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Win-Kuang', 'Initials': 'WK', 'LastName': 'Shen', 'Affiliation': 'Department of Cardiovascular Diseases, Mayo Clinic, Phoenix, AZ, USA.'}, {'ForeName': 'Bruce D', 'Initials': 'BD', 'LastName': 'Johnson', 'Affiliation': 'Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.'}]",Blood pressure,['10.1080/08037051.2019.1649591'] 2934,32112166,A Comparison of Intrathecal and Intravenous Morphine for Analgesia After Hepatectomy: A Randomized Controlled Trial.,"BACKGROUND Effective analgesia is essential for patient recovery after liver resection. This study aimed to evaluate the effects of the addition of preoperative intrathecal morphine to multimodal intravenous analgesia in patients undergoing liver resection. METHODS In this single-blind randomized controlled trial, patients undergoing liver resection were randomly assigned to the patient-controlled analgesia with (ITM-IV) or without (IV) preoperative intrathecal morphine groups. All patients received acetaminophen and dexketoprofen. The primary outcome was pain severity at rest over three postoperative days, assessed using the numerical rating scale (NRS). RESULTS The study included 36 patients (18 in each group). The mean maximum daily NRS scores over the first three postoperative days in the ITM-IV and IV groups were 1.3, 1.1, and 0.3 and 1.6, 1.1, and 0.7, respectively (p = 0.580). No differences were observed in pain severity while coughing, with corresponding scores of 2.8, 2.1, and 1.1, respectively, in the ITM-IV group and 2.3, 2.2, and 1.5, respectively, in the IV group (p = 0.963). Proportions of patients reporting clinically significant pain at rest and while coughing were 11.1% and 44.4%, respectively, in the ITM-IV group, and 16.7% and 44.4%, respectively, in the IV group (both p > 0.999). Cumulative morphine doses in the ITM-IV and IV groups were 26 mg and 17 mg, respectively (p = 0.257). Both groups also showed similar time to mobilization (p = 0.791) and solid food intake (p = 0.743), sedation grade (p = 0.584), and morbidity (p = 0.402). CONCLUSIONS Preoperative intrathecal morphine administration provides no benefits to multimodal analgesia in patients undergoing liver resection. TRIAL REGISTRATION NUMBER Clinicaltrial.gov Identifier: NCT03620916.",2020,"Both groups also showed similar time to mobilization (p = 0.791) and solid food intake (p = 0.743), sedation grade (p = 0.584), and morbidity (p = 0.402). ","['patients undergoing liver resection', 'patient recovery after liver resection', '36 patients (18 in each group']","['patient-controlled analgesia with (ITM-IV) or without (IV) preoperative intrathecal morphine', 'acetaminophen and dexketoprofen', 'morphine', 'Intrathecal and Intravenous Morphine', 'preoperative intrathecal morphine']","['pain severity while coughing', 'sedation grade', 'pain severity', 'time to mobilization', 'solid food intake', 'mean maximum daily NRS scores', 'morbidity', 'pain at rest and while coughing', 'Analgesia', 'numerical rating scale (NRS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019144', 'cui_str': 'Hepatectomy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0078944', 'cui_str': 'Patient-Controlled Analgesia'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0772505', 'cui_str': 'Dexketoprofen'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0300926', 'cui_str': 'mobilization'}, {'cui': 'C0453855', 'cui_str': 'Solid food (substance)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0234253', 'cui_str': 'Rest pain (finding)'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C0222045'}]",36.0,0.200098,"Both groups also showed similar time to mobilization (p = 0.791) and solid food intake (p = 0.743), sedation grade (p = 0.584), and morbidity (p = 0.402). ","[{'ForeName': 'Grzegorz', 'Initials': 'G', 'LastName': 'Niewiński', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Medical University of Warsaw, Warsaw, Poland.'}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Figiel', 'Affiliation': 'Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, 1A Banacha Street, 02-097, Warsaw, Poland. w.figiel@yahoo.es.'}, {'ForeName': 'Michał', 'Initials': 'M', 'LastName': 'Grąt', 'Affiliation': 'Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, 1A Banacha Street, 02-097, Warsaw, Poland.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Dec', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Medical University of Warsaw, Warsaw, Poland.'}, {'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Morawski', 'Affiliation': 'Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, 1A Banacha Street, 02-097, Warsaw, Poland.'}, {'ForeName': 'Waldemar', 'Initials': 'W', 'LastName': 'Patkowski', 'Affiliation': 'Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, 1A Banacha Street, 02-097, Warsaw, Poland.'}, {'ForeName': 'Krzysztof', 'Initials': 'K', 'LastName': 'Zieniewicz', 'Affiliation': 'Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, 1A Banacha Street, 02-097, Warsaw, Poland.'}]",World journal of surgery,['10.1007/s00268-020-05437-x'] 2935,9333066,Pharmacokinetic study of cefodizime and ceftriaxone in sera and bones of patients undergoing hip arthroplasty.,"The study was carried out to determine the concentrations of cefodizime (single 2-g intravenous [i.v.] dose) and ceftriaxone (single 2-g i.v. dose) in the sera and bones of 42 patients (18 women and 24 men) undergoing hip arthroplasty. The concentrations of cefodizime and ceftriaxone in cancellous and cortical bone appear to be related to the free levels in serum but not to the total levels in serum, so the concentrations of cephalosporins in bone must be compared with the free concentrations in serum. Both drugs diffuse well into bone, with concentrations exceeding the MIC at which 90% of the major pathogenic infecting organisms are inhibited.",1997,"Both drugs diffuse well into bone, with concentrations exceeding the MIC at which 90% of the major pathogenic infecting organisms are inhibited.","['sera and bones of patients undergoing hip arthroplasty', '42 patients (18 women and 24 men) undergoing hip arthroplasty']","['ceftriaxone', 'cefodizime and ceftriaxone']",[],"[{'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0186193', 'cui_str': 'Arthroplasty of coxofemoral joint'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0007561', 'cui_str': 'Ceftriaxone'}, {'cui': 'C0055007', 'cui_str': 'cefodizime'}]",[],,0.0192681,"Both drugs diffuse well into bone, with concentrations exceeding the MIC at which 90% of the major pathogenic infecting organisms are inhibited.","[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Scaglione', 'Affiliation': 'Department of Pharmacology, Chemotherapy and Toxicology, Faculty of Medicine, University of Milan, Italy. Chemio@imiucca.csi.unimi.it'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'De Martini', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Peretto', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Ghezzi', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Baratelli', 'Affiliation': ''}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Arcidiacono', 'Affiliation': ''}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Fraschini', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 2936,32122152,Integration of Mixed Methods in Community-Based Participatory Research: Development of a Disease Prevention Intervention for Ultra-Orthodox Jewish Women.,"PURPOSE To describe the development of the first disease prevention intervention with ultra-Orthodox Jewish (UOJ) women in Israel using mixed methods and community-based participatory research (CBPR). DESIGN This collaborative, 7-staged development process used an exploratory sequential mixed methods design integrated into a community-based participatory approach. SETTING The UOJ community in Israel, a high-risk, low socioeconomic, culturally insular minority that practices strict adherence to religious standards, maintains determined seclusion from mainstream culture and preserves traditional practices including extreme modesty and separation between the sexes. PARTICIPANTS Women from a targeted UOJ community in Israel with distinct geographic, religious, and cultural parameters. These included 5 key informant interviewees, 5 focus groups with 6 to 8 participants in each, a cluster randomized sample of 239 questionnaire respondents (an 87% response rate), and 11 steering committee participants. METHOD Qualitative data were analyzed through Interpretative Phenomenological Analysis by 2 researchers. Quantitative data were collected via questionnaire (designed based on qualitative findings) and analyzed utilizing descriptive statistics. RESULTS Barriers to health behavior engagement and intervention preferences were identified. The final intervention included walking programs, health newsletters, community leader trainings, teacher and student trainings, and health integration into schools. CONCLUSION Utilizing mixed methods in CBPR improved cultural tailoring, potentially serving as a model for intervention design in other difficult to access, low socioeconomic, and culturally insular populations.",2020,"To describe the development of the first disease prevention intervention with ultra-Orthodox Jewish (UOJ) women in Israel using mixed methods and community-based participatory research (CBPR). ","['239 questionnaire respondents (an 87% response rate), and 11 steering committee participants', 'Women from a targeted UOJ community in Israel with distinct geographic, religious, and cultural parameters', 'Ultra-Orthodox Jewish Women', 'The UOJ community in Israel, a high-risk, low socioeconomic, culturally insular minority that practices strict adherence to religious standards, maintains determined seclusion from mainstream culture and preserves traditional practices including extreme modesty and separation between the sexes']","['ultra-Orthodox Jewish (UOJ', 'walking programs, health newsletters, community leader trainings, teacher and student trainings, and health integration into schools']",[],"[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0022271', 'cui_str': 'Israel'}, {'cui': 'C0557075', 'cui_str': 'Has religious belief (finding)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0178443', 'cui_str': 'Jewish, follower of religion (person)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C0204742', 'cui_str': 'Secluding patient (procedure)'}, {'cui': 'C0220814', 'cui_str': 'culture'}, {'cui': 'C0728887', 'cui_str': 'Preserving (attribute)'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205403', 'cui_str': 'Extreme (qualifier value)'}, {'cui': 'C0237868', 'cui_str': 'Separation'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}]","[{'cui': 'C0178443', 'cui_str': 'Jewish, follower of religion (person)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0027988', 'cui_str': 'Newsletters'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0221457', 'cui_str': 'Teacher (occupation)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0036375', 'cui_str': 'School'}]",[],239.0,0.0465275,"To describe the development of the first disease prevention intervention with ultra-Orthodox Jewish (UOJ) women in Israel using mixed methods and community-based participatory research (CBPR). ","[{'ForeName': 'Elisheva', 'Initials': 'E', 'LastName': 'Leiter', 'Affiliation': 'Linda Joy Pollin Cardiovascular Wellness Center for Women, Hadassah University Medical Center, Jerusalem, Israel.'}, {'ForeName': 'Adi', 'Initials': 'A', 'LastName': 'Finkelstein', 'Affiliation': 'Program of Medical Humanities, Hebrew University Hadassah Medical School, Jerusalem, Israel.'}, {'ForeName': 'Milka', 'Initials': 'M', 'LastName': 'Donchin', 'Affiliation': 'Linda Joy Pollin Cardiovascular Wellness Center for Women, Hadassah University Medical Center, Jerusalem, Israel.'}, {'ForeName': 'Keren L', 'Initials': 'KL', 'LastName': 'Greenberg', 'Affiliation': 'Linda Joy Pollin Cardiovascular Wellness Center for Women, Hadassah University Medical Center, Jerusalem, Israel.'}, {'ForeName': 'Osnat', 'Initials': 'O', 'LastName': 'Keidar', 'Affiliation': 'Linda Joy Pollin Cardiovascular Wellness Center for Women, Hadassah University Medical Center, Jerusalem, Israel.'}, {'ForeName': 'Sima', 'Initials': 'S', 'LastName': 'Wetzler', 'Affiliation': 'Linda Joy Pollin Cardiovascular Wellness Center for Women, Hadassah University Medical Center, Jerusalem, Israel.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Siemiatycki', 'Affiliation': ""Bishvilaych, The Evelyne Barnett Women's Medical Center, Jerusalem, 9548311, Israel.""}, {'ForeName': 'Ronit', 'Initials': 'R', 'LastName': 'Calderon-Margalit', 'Affiliation': 'Hebrew University of Jerusalem, Braun School of Public Health and Community Medicine, Jerusalem, Israel.'}, {'ForeName': 'Donna R', 'Initials': 'DR', 'LastName': 'Zwas', 'Affiliation': 'Linda Joy Pollin Cardiovascular Wellness Center for Women, Hadassah University Medical Center, Jerusalem, Israel.'}]",American journal of health promotion : AJHP,['10.1177/0890117120906965'] 2937,4361353,Effect of induced interferon in experimental rhinovirus infections in volunteers.,"Nasal administration of an interferon inducer, CP-20,961 (N, N-dioctadecyl-N', N'-bis(2-hydroxyethyl)propanediamine), was evaluated in a double-blind, placebo-controlled study of experimental rhinovirus infection in 29 volunteers. Detectable nasal interferon developed in 10 of 15 subjects treated with CP-20,961, and 2 of 14 in the group receiving placebo (P < 0.006). Titers of CP-20,961-induced interferon ranged from 10 to 250 international units, concentrations similar to those observed in rhinovirus infections. Ten in the CP-20,961 group and eight in the placebo group became ill (P > 0.05). However, mean total sign scores were significantly diminished among CP-20,961-treated subjects as compared with placebo-treated subjects (P < 0.025). No significant effect was noted on quantitative virus shedding patterns or neutralizing antibody responses. These findings suggest that such concentrations of induced interferon do not protect against rhinovirus infection, and that factors other than interferon may be important in recovery from rhinovirus infection.",1974,"Ten in the CP-20,961 group and eight in the placebo group became ill (P > 0.05).","['volunteers', '29 volunteers']","['induced interferon', 'placebo', ""interferon inducer, CP-20,961 (N, N-dioctadecyl-N', N'-bis(2-hydroxyethyl)propanediamine""]","['quantitative virus shedding patterns or neutralizing antibody responses', 'mean total sign scores', 'Detectable nasal interferon']","[{'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0021747', 'cui_str': 'Interferons'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0021742', 'cui_str': 'Interferon Inducers'}, {'cui': 'C0110844', 'cui_str': 'CP 20961'}]","[{'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C0042776', 'cui_str': 'Virus'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C1142254', 'cui_str': 'Neutralising antibodies'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C0021747', 'cui_str': 'Interferons'}]",29.0,0.0709876,"Ten in the CP-20,961 group and eight in the placebo group became ill (P > 0.05).","[{'ForeName': 'R G', 'Initials': 'RG', 'LastName': 'Douglas', 'Affiliation': ''}, {'ForeName': 'R F', 'Initials': 'RF', 'LastName': 'Betts', 'Affiliation': ''}]",Infection and immunity,[] 2938,31790604,"Melatonin ingestion after exhaustive late-evening exercise attenuate muscle damage, oxidative stress, and inflammation during intense short term effort in the following day in teenage athletes.","The present study aimed to investigate whether nocturnal melatonin (MEL) ingestion has beneficial effects against exercise-induced oxidative stress and muscle damage in young athletes. Fourteen healthy-trained teenagers performed two-test sessions separated by at least, 1 week. During each session, participants completed the Running-Based Anaerobic Sprint Test (RAST) at 20:00 h. Then, they ingested a single 10-mg tablet of MEL or Placebo (PLA) in a double-blind randomized order at 22:00 h. The following morning (i.e., 07:30 h), participants performed the same test as the previous night. Blood samples were taken before and after exercise. MEL intake increased the peak power (P peak ) ( p < .01), mean power (P mean ) ( p < .001) and decreased the total time (TT) ( p < .001) and the fatigue index (FI) ( p < .05). Furthermore, MEL ingestion attenuated the hematologic parameters before and after exercise (White Blood Cells (WBC: p < .001 and p < .001, respectively); Neutrophiles (NE: p < .001 and p < .001, respectively); Lymphocytes (LY: p < .001 and p < .001, respectively)) and the ultra-sensitive C-reactive protein (us-CRP: p < .001 and p < .001; respectively) compared to PLA. Also, MEL reduced muscle and hepatic damage enzymes before and after exercise (creatine kinase (CK: p < .001 and p < .001; respectively), lactate dehydrogenase (LDH: p < .05 and p < .01; respectively), aspartate aminotransferase (ASAT: p < .01 and p < .001; respectively)), Malondialdehyde (MDA: p < .001 and p < .001; respectively) and Homocysteine (Hcy: p < .001 and p < .001; respectively)) from placebo. Plasma lactate [La] and glucose (GL) remained unchangeable during the two conditions. In summary, acute MEL ingestion after strenuous late-evening exercise attenuated transient leucocytosis and protected against lipid peroxidation and muscle damage induced by strenuous exercise the following morning in healthy male teenage athletes.",2020,"MEL intake increased the peak power (P peak ) ( p < .01), mean power (P mean ) ( p < .001) and decreased the total time (TT) ( p < .001) and the fatigue index (FI) ( p < .05).","['Fourteen healthy-trained teenagers', 'healthy male teenage athletes', 'young athletes']","['Melatonin ingestion', 'Homocysteine', 'placebo', 'nocturnal melatonin (MEL) ingestion', 'Running-Based Anaerobic Sprint Test (RAST', 'MEL or Placebo (PLA']","['lipid peroxidation and muscle damage', 'lactate dehydrogenase (LDH', 'total time (TT', 'MEL reduced muscle and hepatic damage enzymes', 'Plasma lactate [La] and glucose (GL', 'peak power', 'fatigue index (FI', 'hematologic parameters', 'muscle damage, oxidative stress, and inflammation', 'aspartate aminotransferase']","[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C1521910', 'cui_str': 'Teens'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}]","[{'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0019878', 'cui_str': '2-amino-4-mercaptobutyric acid'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0240526', 'cui_str': 'Night time (qualifier value)'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0034554', 'cui_str': 'Radioimmunosorbent Assay of Allergens'}]","[{'cui': 'C0023775', 'cui_str': 'Lipid Peroxidation'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage'}, {'cui': 'C0022917', 'cui_str': 'L-Lactate Dehydrogenase'}, {'cui': 'C0022922', 'cui_str': 'lactate dehydrogenase-K'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0151763', 'cui_str': 'Liver damage (disorder)'}, {'cui': 'C3541394', 'cui_str': 'Enzymes'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205488', 'cui_str': 'Hematologic (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0004002', 'cui_str': 'L-Aspartate-2-Oxoglutarate Aminotransferase'}]",14.0,0.204564,"MEL intake increased the peak power (P peak ) ( p < .01), mean power (P mean ) ( p < .001) and decreased the total time (TT) ( p < .001) and the fatigue index (FI) ( p < .05).","[{'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Cheikh', 'Affiliation': 'High institute of sport and physical education Ksar-Said, Manouba university, Manouba, Tunisia.'}, {'ForeName': 'Khouloud', 'Initials': 'K', 'LastName': 'Makhlouf', 'Affiliation': 'High institute of sport and physical education, Sfax university, Sfax, Tunisia.'}, {'ForeName': 'Kais', 'Initials': 'K', 'LastName': 'Ghattassi', 'Affiliation': 'High institute of sport and physical education, Sfax university, Sfax, Tunisia.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Graja', 'Affiliation': 'High institute of sport and physical education, Sfax university, Sfax, Tunisia.'}, {'ForeName': 'Salyma', 'Initials': 'S', 'LastName': 'Ferchichi', 'Affiliation': 'Biochemistry Laboratory, CHU Farhat Hached, Sousse, Tunisia.'}, {'ForeName': 'Choumous', 'Initials': 'C', 'LastName': 'Kallel', 'Affiliation': 'Hematology Laboratory, Hospital Habib Bourguiba, Sfax, Tunisia.'}, {'ForeName': 'Mallek', 'Initials': 'M', 'LastName': 'Houda', 'Affiliation': 'Hematology Laboratory, Hospital Slim Hadhri, Kerkennah, Sfax, Tunisia.'}, {'ForeName': 'Nizar', 'Initials': 'N', 'LastName': 'Souissi', 'Affiliation': 'High institute of sport and physical education Ksar-Said, Manouba university, Manouba, Tunisia.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Hammouda', 'Affiliation': 'Interdisciplinary Laboratory in Neurosciences, Physiology and Psychology: Physical Activity and Health (LINP2-AAPS), UPL, University Paris Nanterre, UFR STAPS, Nanterre, France.'}]",Chronobiology international,['10.1080/07420528.2019.1692348'] 2939,31402234,Randomized controlled trial to improve primary care follow-up among emergency department patients.,"STUDY OBJECTIVE Primary care (PC) follow-up for discharged emergency department (ED) patients provides patients with further medical attention. We conducted a pilot randomized controlled trial to determine whether using a freely-available physician appointment-booking website results in higher self-reported PC follow-up. METHODS We randomized discharged patients whom treating physicians determined PC follow-up was important and who possessed health insurance but had no PC provider to one of three groups: (1) a PC appointment booked through the booking website prior to ED discharge; (2) written information on how to use the booking website; or (3) usual care (i.e. standard follow-up instructions). We phoned subjects two weeks after the ED visit to determine whether they had completed a PC follow-up visit. We also asked subjects about their satisfaction with obtaining a PC appointment, satisfaction with the ED visit, symptom resolution and subsequent ED visits. The self-reported PCP follow-up rate was compared among the study groups by estimating the risk difference (RD) and 95% CI between usual care and each intervention group. RESULTS 272 subjects were enrolled and randomized and 68% completed the two-week telephone follow-up interview. The self-reported PCP follow-up rate was higher (52%) among subjects whose appointment was booked on the website before ED discharge (RD = 16%; 95% CI -1%, 34%) and lower (25%) for subjects who received booking website information (RD = 13%; 95% CI -32%, 7%) compared to subjects (36%) in the usual care group. A higher percentage of subjects in the booking group were more likely to report being extremely or very satisfied with obtaining a PC appointment (78%) compared to those who received booking website information (54%) or usual care (40%). CONCLUSION Among ED patients that providers judged PC follow-up is important, using a booking website to schedule an appointment before ED discharge resulted in a higher but not statistically significant self-reported PC follow-up rate. This intervention warrants further investigation in a study with a larger sample size and objective follow-up visit data.",2020,"The self-reported PCP follow-up rate was higher (52%) among subjects whose appointment was booked on the website before ED discharge (RD = 16%; 95% CI -1%, 34%) and lower (25%) for subjects who received booking website information (RD = 13%; 95% CI -32%, 7%) compared to subjects (36%) in the usual care group.","['Primary care (PC) follow-up for discharged emergency department (ED) patients provides patients with further medical attention', '272 subjects', 'patients whom treating physicians determined PC follow-up was important and who possessed health insurance but had no PC provider to one of three groups', 'emergency department patients']",[],['PCP follow-up rate'],"[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0021682', 'cui_str': 'Health Insurance'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]",[],"[{'cui': 'C0031381', 'cui_str': '1-(1-Phenylcyclohexyl)piperidine'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]",272.0,0.047437,"The self-reported PCP follow-up rate was higher (52%) among subjects whose appointment was booked on the website before ED discharge (RD = 16%; 95% CI -1%, 34%) and lower (25%) for subjects who received booking website information (RD = 13%; 95% CI -32%, 7%) compared to subjects (36%) in the usual care group.","[{'ForeName': 'Rory J', 'Initials': 'RJ', 'LastName': 'Merritt', 'Affiliation': 'Department of Emergency Medicine, Brown University, 55 Claverick Street, Providence, RI 02903, United States of America. Electronic address: Rory_Merritt@Brown.edu.'}, {'ForeName': 'Paige', 'Initials': 'P', 'LastName': 'Kulie', 'Affiliation': 'Department of Emergency Medicine, George Washington University, Washington, DC, United States of America.'}, {'ForeName': 'Andrew W', 'Initials': 'AW', 'LastName': 'Long', 'Affiliation': 'Department of Emergency Medicine, George Washington University, Washington, DC, United States of America.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Choudhri', 'Affiliation': 'University of Michigan, Ann Arbor, MI, United States of America.'}, {'ForeName': 'Melissa L', 'Initials': 'ML', 'LastName': 'McCarthy', 'Affiliation': 'Department of Health Policy and Management, Department of Emergency Medicine, George Washington University, Washington, DC, United States of America.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.158384'] 2940,31809394,"Autologous Iliac Bone Graft Compared with Biphasic Hydroxyapatite and Calcium Sulfate Cement for the Treatment of Bone Defects in Tibial Plateau Fractures: A Prospective, Randomized, Open-Label, Multicenter Study.","BACKGROUND Bone-graft substitutes are commonly used for the augmentation of traumatic bone defects in tibial plateau fractures. However, their clinical performance compared with that of autologous bone-grafting, the gold standard in bone defect reconstruction, still remains under debate. This study investigates the differences in quality of life, pain, and radiographic outcomes in the treatment of tibial plateau fracture-associated bone defects with either autologous bone grafts or a bioresorbable hydroxyapatite and calcium sulfate cement (CERAMENT BONE VOID FILLER [CBVF]; BONESUPPORT). METHODS In this study, 135 patients with acute depression and split-depression fractures of the proximal part of the tibia (OTA/AO types 41-B2 and 41-B3) were enrolled in a prospective, controlled, randomized, multicenter trial including 20 hospitals in Germany. Patients were randomized to receive either autologous iliac bone graft or CBVF for reconstruction of the bone defect. The primary outcome measures were the Short Form (SF)-12 version 2 Physical Component Summary (PCS) score at week 26 (the study was designed to show noninferiority of the CBVF with regard to the PCS with a prespecified margin of -5 points) and the pain level at 26 weeks postoperatively measured by a visual analog scale (VAS). The secondary outcomes were the SF-12 version 2 Mental Component Summary (MCS) and SF-12 PCS scores at weeks 1, 6, and 12 and bone-healing on radiographs. RESULTS Age, sex, fixation methods, and fracture pattern were comparable in both groups. There were no significant differences (p > 0.05) in the SF-12 PCS or VAS scores at postoperative week 26. There was a significant reduction of blood loss (p = 0.007) and pain levels (p = 0.008) at postoperative day 1 in the CBVF group. The rates of fracture-healing, defect remodeling, and articular subsidence were not significantly different (p > 0.05) in both groups. CONCLUSIONS Bioresorbable CBVF was noninferior to autologous bone graft with regard to both patient-reported and radiographic outcomes in tibial plateau fractures of OTA/AO types 41-B2 and 41-B3. LEVEL OF EVIDENCE Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.",2020,There was a significant reduction of blood loss (p = 0.007) and pain levels (p = 0.008) at postoperative day 1 in the CBVF group.,"['tibial plateau fractures', '135 patients with acute depression and split-depression fractures of the proximal part of the tibia (OTA/AO types 41-B2 and 41-B3', '20 hospitals in Germany', 'Tibial Plateau Fractures']","['Autologous Iliac Bone Graft Compared with Biphasic Hydroxyapatite and Calcium Sulfate Cement', 'autologous bone-grafting', 'autologous iliac bone graft or CBVF', 'autologous bone grafts or a bioresorbable hydroxyapatite and calcium sulfate cement (CERAMENT BONE VOID FILLER [CBVF]; BONESUPPORT']","['rates of fracture-healing, defect remodeling, and articular subsidence', 'SF-12 PCS or VAS scores', 'Bone Defects', 'pain level', 'quality of life, pain, and radiographic outcomes', 'Short Form (SF)-12 version 2 Physical Component Summary (PCS) score', 'SF-12 version 2 Mental Component Summary (MCS) and SF-12 PCS scores at weeks 1, 6, and 12 and bone-healing on radiographs', 'visual analog scale (VAS', 'blood loss', 'pain levels']","[{'cui': 'C0584640', 'cui_str': 'Tibial plateau structure (body structure)'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1386135', 'cui_str': 'Acute depression'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C1292711', 'cui_str': 'Part of (attribute)'}, {'cui': 'C0040184', 'cui_str': 'Tibia'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0017480', 'cui_str': 'Germany'}]","[{'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C0181075', 'cui_str': 'Bone graft material (product)'}, {'cui': 'C0205184', 'cui_str': 'Biphasic (qualifier value)'}, {'cui': 'C0115137', 'cui_str': 'Durapatite'}, {'cui': 'C0006720', 'cui_str': 'Calcium Sulfate'}, {'cui': 'C1704479', 'cui_str': 'Cement'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C1699650', 'cui_str': 'Autologous bone graft'}, {'cui': 'C3658778', 'cui_str': 'cerament'}, {'cui': 'C0729441', 'cui_str': 'Filler (substance)'}]","[{'cui': 'C0162542', 'cui_str': 'Fracture Healing'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0034380'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}]",135.0,0.067637,There was a significant reduction of blood loss (p = 0.007) and pain levels (p = 0.008) at postoperative day 1 in the CBVF group.,"[{'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Hofmann', 'Affiliation': 'Department of Traumatology and Orthopaedics 1, Academic Teaching Hospital of the Universities Mainz and Heidelberg, Westpfalz-Clinics, Kaiserslautern, Germany.'}, {'ForeName': 'Stanislav', 'Initials': 'S', 'LastName': 'Gorbulev', 'Affiliation': 'Interdisciplinary Center for Clinical Trials (IZKS), University Medical Center, Mainz, Germany.'}, {'ForeName': 'Thorsten', 'Initials': 'T', 'LastName': 'Guehring', 'Affiliation': 'Department for Traumatology and Orthopaedic Surgery, BG Traumacenter Ludwigshafen, Ludwigshafen, Germany.'}, {'ForeName': 'Arndt Peter', 'Initials': 'AP', 'LastName': 'Schulz', 'Affiliation': 'Department of Traumatology, Orthopaedics and Sports Traumatology, BG Trauma Hospital, Hamburg, Germany.'}, {'ForeName': 'Rupert', 'Initials': 'R', 'LastName': 'Schupfner', 'Affiliation': 'Department of Trauma Surgery, Clinical Center Bayreuth, Bayreuth, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Raschke', 'Affiliation': 'Department of Trauma Surgery, University of Muenster, Muenster, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Huber-Wagner', 'Affiliation': 'Department of Trauma Surgery, University of Munich, Munich, Germany.'}, {'ForeName': 'Pol Maria', 'Initials': 'PM', 'LastName': 'Rommens', 'Affiliation': 'Department of Orthopedics and Traumatology, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Journal of bone and joint surgery. American volume,['10.2106/JBJS.19.00680'] 2941,32109005,A well-tolerated new amino acid-based formula for cow's milk allergy.,"OBJECTIVES Infants with cow's milk allergy (CMA) are in need of a substitute formula up to 2 years. The are three requisites for a substitute of milk in CMA: tolerability, nutritional adequacy, and cost-effectiveness. We evaluate here the tolerability of a new amino acid-based infant formula for the management of CMA. METHODS In a phase III/IV prospective, multicentre, open-label, international study, infants and children with immunoglobulin E-mediated CMA were exposed to a diagnostic double-blinded, placebo-controlled food challenge with a new amino acid formula by Blemil Plus Elemental using Neocate as the placebo. If tolerant to it, the study formula was integrated into the patients' usual daily diet for 7 days. Efficacy on day 7 was assessed in terms of symptoms associated with CMA, amount of formula consumed, nutritional and energy intake, and anthropometric data. RESULTS Thirty children (17 M and 13 F; median age, 1.58; range, 0.08-12.83 years) completed the open challenge and were able to consume the study formula for at least 7 days. No signs or symptoms of allergic reactions were recorded among children assuming either the test or the control formula, with a lower 95% one-sided confidence interval for the proportion of subjects who did not experience allergic reactions above 90%. Sixteen patient under the age of two continued with the optional extension phase. CONCLUSIONS The study formula meets the American Academy of Pediatric criteria for hypoallergenicity and is well tolerated in short-term use. During optional phase, growth of the patients was not hindered by the study formula.",2020,"No signs or symptoms of allergic reactions were recorded among children assuming either the test or the control formula, with a lower 95% one-sided confidence interval for the proportion of subjects who did not experience allergic reactions above 90%.","['infants and children with immunoglobulin E-mediated CMA', 'Thirty children (17 M and 13 F; median age, 1.58; range, 0.08-12.83 years', 'Sixteen patient under the age of two continued with the optional extension phase', ""Infants with cow's milk allergy (CMA""]","['placebo-controlled food challenge with a new amino acid formula by Blemil Plus Elemental using Neocate as the placebo', 'new amino acid-based infant formula']","['symptoms associated with CMA, amount of formula consumed, nutritional and energy intake, and anthropometric data', 'signs or symptoms of allergic reactions']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0202086', 'cui_str': 'Immunoglobulin E measurement (procedure)'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C4517417', 'cui_str': 'Zero point zero eight'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0266815', 'cui_str': ""Cow's milk protein sensitivity (disorder)""}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C3539946', 'cui_str': 'Amino acids'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0379545', 'cui_str': 'Neocate'}, {'cui': 'C4074817', 'cui_str': 'Amino acid-based infant formula (finding)'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C1527304', 'cui_str': 'Allergic Reaction'}]",30.0,0.0326434,"No signs or symptoms of allergic reactions were recorded among children assuming either the test or the control formula, with a lower 95% one-sided confidence interval for the proportion of subjects who did not experience allergic reactions above 90%.","[{'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Fierro', 'Affiliation': 'Pediatric Allergy Unit, Bambino Gesù Hospital, Roma, Italy.'}, {'ForeName': 'Rocco L', 'Initials': 'RL', 'LastName': 'Valluzzi', 'Affiliation': 'Pediatric Allergy Unit, Bambino Gesù Hospital, Roma, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Banzato', 'Affiliation': 'Azienda Ospedaliera Universitaria Integrata, Verona, Italy.'}, {'ForeName': 'Ma A', 'Initials': 'MA', 'LastName': 'Plaza', 'Affiliation': 'Hospital Sant Joan de Deu, Barcelona, Spain.'}, {'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Bosque', 'Affiliation': 'Consorci Sanitari Parc Taulí, Sabadell, Spain.'}, {'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Íbero', 'Affiliation': 'Hospital de Terrassa, Terrassa, Spain.'}, {'ForeName': 'Luis A Z', 'Initials': 'LAZ', 'LastName': 'Echeverría', 'Affiliation': 'Hospital Severo Ochoa, Laganès, Spain.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Mennini', 'Affiliation': 'Pediatric Allergy Unit, Bambino Gesù Hospital, Roma, Italy.'}, {'ForeName': 'Lamia', 'Initials': 'L', 'LastName': 'Dahdah', 'Affiliation': 'Pediatric Allergy Unit, Bambino Gesù Hospital, Roma, Italy.'}, {'ForeName': 'Roser', 'Initials': 'R', 'LastName': 'de Castellar', 'Affiliation': 'Laboratorios Ordesa, Sant Boi de Llobregat, Spain.'}, {'ForeName': 'Gloria', 'Initials': 'G', 'LastName': 'Tort', 'Affiliation': 'Laboratorios Ordesa, Sant Boi de Llobregat, Spain.'}, {'ForeName': 'Jesus', 'Initials': 'J', 'LastName': 'Jiménez', 'Affiliation': 'Laboratorios Ordesa, Sant Boi de Llobregat, Spain.'}]","Immunity, inflammation and disease",['10.1002/iid3.286'] 2942,3891779,Effect of delay in processing on the performance of Directigen for the detection of group A streptococci in throat swabs.,"We compared a latex agglutination method, Directigen (Hynson, Westcott & Dunning) with a culture-based system for detection of group A streptococci in 964 throat swabs. Discordants were resolved by Lancefield typing of beta-hemolytic colonies. After culture, swabs were randomly assigned to be tested by Directigen within 4 h of sampling or after overnight storage. For swabs that yielded more than 50 beta-hemolytic colonies from culture, there was a highly significant difference (P less than 0.01) in sensitivity between the group tested early and the group tested after storage overnight. For swabs tested within 4 h of sampling, a trend (P = 0.07) existed between sensitivity and length of delay before testing.",1985,"For swabs tested within 4 h of sampling, a trend (P = 0.07) existed between sensitivity and length of delay before testing.","['964 throat swabs', 'throat swabs']","['latex agglutination method, Directigen (Hynson, Westcott & Dunning) with a culture-based system for detection of group A streptococci']",['sensitivity'],"[{'cui': 'C0439056', 'cui_str': 'Throat swab (specimen)'}]","[{'cui': 'C0023117', 'cui_str': 'Latex Agglutination Tests'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0220814', 'cui_str': 'culture'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0441835', 'cui_str': 'Group A (qualifier value)'}]","[{'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}]",964.0,0.129536,"For swabs tested within 4 h of sampling, a trend (P = 0.07) existed between sensitivity and length of delay before testing.","[{'ForeName': 'M L', 'Initials': 'ML', 'LastName': 'Matteson', 'Affiliation': ''}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Anhalt', 'Affiliation': ''}]",Journal of clinical microbiology,[] 2943,31389909,Effects of Exercise Training and Statin Use in People Living with HIV with Dyslipidemia.,"PURPOSE To evaluate the effects of the combination of ET and statins in people living with HIV. METHODS This was a randomized, double-blind, placebo-controlled clinical trial. Eighty-three people living with HIV were assigned to either placebo (PL), statins (STA), placebo + ET (PLET) or statins + ET (STAET) groups. Volunteers assigned to STA and STAET groups were administered 10 mg of rosuvastatin, whereas the PL and PLET groups were administered a placebo. PLET and STAET groups performed ET three times a week. Before and after the 12-week follow-up, the volunteers underwent to anthropometric assessment and blood collection to evaluate lipid profile, cardiovascular markers, inflammatory profile; a Doppler ultrasound examination, muscle strength (MS) and cardiorespiratory fitness (CF) tests were performed. RESULTS There was a decrease in total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-c), C-reactive protein, fibrinogen, interleukin (IL)-1β and right carotid intima-media thickness (cIMT) in the STA, PLET, and STAET groups compared to PL group (p<0.001). Furthermore, there was a decrease in TC, TG, LDL, IL-1β, IL-6, and IL-8 levels and in left and right cIMT and an increase in HDL-c levels in the STAET groups compared to the STA (p<0.001) and PLET groups (p<0.001). There was an increase in IL-10 levels, peak-systolic velocity, end-diastolic velocity, wall shear rate in the PLET and STAET groups compared to the PL (p<0.001) and STA groups (p<0.001). The PLET and STAET groups reduced body fat mass, body fat percentage and increased lean body mass, MS and CF compared to PL (p<0.001) and STA (p<0.001) groups. CONCLUSION The combination of ET and statins is useful to enhance lipid and inflammatory profiles, reduce CVD markers, and improve Doppler ultrasound findings, MS and CF in people living with HIV.",2019,"There was an increase in IL-10 levels, peak-systolic velocity, end-diastolic velocity, wall shear rate in the PLET and STAET groups compared to the PL (p<0.001) and STA groups (p<0.001).","['people living with HIV', 'People Living with HIV with Dyslipidemia', 'Eighty-three people living with HIV']","['STA', 'placebo (PL), statins (STA), placebo + ET (PLET) or statins + ET (STAET', 'rosuvastatin', 'Exercise Training and Statin Use', 'placebo', 'PLET', 'ET and statins']","['TC, TG, LDL, IL-1β, IL-6, and IL-8 levels and in left and right cIMT and an increase in HDL-c levels', 'lipid profile, cardiovascular markers, inflammatory profile; a Doppler ultrasound examination, muscle strength (MS) and cardiorespiratory fitness (CF) tests', 'IL-10 levels, peak-systolic velocity, end-diastolic velocity, wall shear rate', 'body fat mass, body fat percentage and increased lean body mass, MS and CF', 'total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-c), C-reactive protein, fibrinogen, interleukin (IL)-1β and right carotid intima-media thickness (cIMT']","[{'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemias'}, {'cui': 'C4517888', 'cui_str': '83'}]","[{'cui': 'C1529286', 'cui_str': 'stas'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C1947944', 'cui_str': 'Use'}]","[{'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0162481', 'cui_str': 'Doppler Ultrasound'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0442710', 'cui_str': 'Peak systolic, function (observable entity)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0205380', 'cui_str': 'Walled (qualifier value)'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass (observable entity)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0982156', 'cui_str': 'fibrinogen (125I)'}, {'cui': 'C0021764', 'cui_str': 'Interleukins'}, {'cui': 'C0162864', 'cui_str': 'Vascular Intima'}]",83.0,0.0940275,"There was an increase in IL-10 levels, peak-systolic velocity, end-diastolic velocity, wall shear rate in the PLET and STAET groups compared to the PL (p<0.001) and STA groups (p<0.001).","[{'ForeName': 'Hugo Ribeiro', 'Initials': 'HR', 'LastName': 'Zanetti', 'Affiliation': 'Postgraduate Program in Health Science, Faculty of Medicine, Federal University of Uberlândia, Uberlândia/MG, Brazil.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Gonçalves', 'Affiliation': 'Master Institute of Education President Antônio Carlos, Araguari/MG, Brazil.'}, {'ForeName': 'Leandro Teixeira', 'Initials': 'LT', 'LastName': 'Paranhos Lopes', 'Affiliation': 'Brazil University, Fernandópolis/SP, Brazil.'}, {'ForeName': 'Edmar Lacerda', 'Initials': 'EL', 'LastName': 'Mendes', 'Affiliation': 'Institute of Health Sciences, Department of Sport Sciences, Federal University of Triângulo Mineiro, Uberaba/MG, Brazil.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Roever', 'Affiliation': 'Postgraduate Program in Health Science, Faculty of Medicine, Federal University of Uberlândia, Uberlândia/MG, Brazil.'}, {'ForeName': 'Mário Leon', 'Initials': 'ML', 'LastName': 'Silva-Vergara', 'Affiliation': 'Institute of Health Sciences, Department of Medical Clinics, Clinics Hospital, Federal University of Triângulo Mineiro, Uberaba/MG, Brazil.'}, {'ForeName': 'Fernando Freitas', 'Initials': 'FF', 'LastName': 'Neves', 'Affiliation': 'Institute of Health Sciences, Department of Medical Clinics, Clinics Hospital, Federal University of Triângulo Mineiro, Uberaba/MG, Brazil.'}, {'ForeName': 'Elmiro Santos', 'Initials': 'ES', 'LastName': 'Resende', 'Affiliation': 'Postgraduate Program in Health Science, Faculty of Medicine, Federal University of Uberlândia, Uberlândia/MG, Brazil.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002120'] 2944,31530074,Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?,"ERA 223, a phase III, international, multicenter, double-blind study published in Lancet Oncology , was the first randomized controlled trial to investigate combined radium-223 (Ra-223) and abiraterone acetate plus prednisone or prednisolone (AAP) therapy. The data from ERA 223 demonstrated no increase in efficacy for this combination over AAP alone, and instead identified a significant safety concern due to the higher risk of fracture in the co-treatment group. The surprising results of this trial likely stem from the compounding osteoporotic effects of the different treatments, particularly the addition of prednisone, and supplementing therapy regimens with osteoprotective agents may aid in mitigating this safety risk.",2020,"The data from ERA 223 demonstrated no increase in efficacy for this combination over AAP alone, and instead identified a significant safety concern due to the higher risk of fracture in the co-treatment group.",['metastatic castration-resistant prostate cancer'],"['prednisone', 'combined radium-223 (Ra-223) and abiraterone acetate plus prednisone or prednisolone (AAP) therapy']",['efficacy'],"[{'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0303282', 'cui_str': 'Ra-223 radioisotope'}, {'cui': 'C2607886', 'cui_str': 'abiraterone acetate'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",[],223.0,0.159218,"The data from ERA 223 demonstrated no increase in efficacy for this combination over AAP alone, and instead identified a significant safety concern due to the higher risk of fracture in the co-treatment group.","[{'ForeName': 'Martina A', 'Initials': 'MA', 'LastName': 'Knechel', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Keith T', 'Initials': 'KT', 'LastName': 'Schmidt', 'Affiliation': 'Clinical Pharmacology Program, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'William D', 'Initials': 'WD', 'LastName': 'Figg', 'Affiliation': 'Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.'}]",Cancer biology & therapy,['10.1080/15384047.2019.1665395'] 2945,31925771,Limited Impact of Fetal Sex and Maternal Body Mass Index on Fetal and Maternal Insulin Resistance and Lipid Metabolism: Findings from the PEARs Study.,"The intrauterine environment can have a significant impact on fetal and maternal well-being, both during pregnancy and in later life. We aimed to identify how fetal sex and maternal body mass index (BMI) influence insulin resistance and metabolic function during pregnancy with maternal BMI > 25 kg/m 2 . This secondary analysis assessed data from the PEARS-randomized controlled trial that recruited pregnant women with body mass indexes 25-39.9 kg/m 2 . Longitudinal measurements of maternal and fetal insulin resistance and metabolic function were recorded throughout pregnancy. Regression models tested the effects of fetal sex and maternal BMI on markers of metabolic function and insulin regulation. A total of 484 women and their newborns (252 (52%) males vs. 232 (48%) females) were included in the analysis. A total of 333 (69%) women were overweight and 151 (31%) were obese. Male newborns were heavier and larger than females, and had a higher rate of instrumental delivery. Males had a lower LDL, but no other markers of insulin resistance or metabolic function were affected by fetal sex. Women with obesity had elevated markers of insulin resistance and metabolic dysfunction compared with women that were overweight, but maternal BMI did not impact these variables in the fetus. Fetal sex did not impact maternal and fetal metabolic parameters in women with BMI > 25 kg/m 2 . However, a higher BMI caused increasingly deranged maternal blood lipid concentrations and markers of insulin resistance as pregnancy progressed. Lipid monitoring and interventions to reduce lipids during pregnancy therefore require further evaluation.",2020,"Women with obesity had elevated markers of insulin resistance and metabolic dysfunction compared with women that were overweight, but maternal BMI did not impact these variables in the fetus.","['484 women and their newborns (252 (52%) males vs. 232 (48%) females', 'A total of 333 (69%) women were overweight and 151 (31%) were obese', 'women with BMI >\u200925\xa0kg/m 2 ', 'Male newborns', 'pregnancy with maternal BMI >\u200925\xa0kg', 'recruited pregnant women with body mass indexes 25-39.9\xa0kg/m 2 ']",[],"['insulin resistance and metabolic dysfunction', 'fetal sex and maternal body mass index (BMI) influence insulin resistance and metabolic function', 'maternal and fetal insulin resistance and metabolic function', 'insulin resistance or metabolic function']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4517724', 'cui_str': 'Three hundred and thirty-three'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",[],"[{'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0031843', 'cui_str': 'function'}]",484.0,0.121273,"Women with obesity had elevated markers of insulin resistance and metabolic dysfunction compared with women that were overweight, but maternal BMI did not impact these variables in the fetus.","[{'ForeName': 'Anthony R', 'Initials': 'AR', 'LastName': 'Rafferty', 'Affiliation': 'UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.'}, {'ForeName': 'Aisling A', 'Initials': 'AA', 'LastName': 'Geraghty', 'Affiliation': 'UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.'}, {'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Kennelly', 'Affiliation': 'UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.'}, {'ForeName': 'Eileen C', 'Initials': 'EC', 'LastName': ""O'Brien"", 'Affiliation': 'UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.'}, {'ForeName': 'Reshma Merin', 'Initials': 'RM', 'LastName': 'Reji', 'Affiliation': 'School of Public Health, Physiotherapy and Sports Science, Health Sciences Centre, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Mehegan', 'Affiliation': 'School of Public Health, Physiotherapy and Sports Science, Health Sciences Centre, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Segurado', 'Affiliation': 'Centre for Support and Training in Analysis and Research (CSTAR), School of Public Health, Physical & Sports Sciences, Health Sciences Centre, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Smith', 'Affiliation': ""Department of Endocrinology, St. Vincent's University Hospital, Dublin, Ireland.""}, {'ForeName': 'Orla', 'Initials': 'O', 'LastName': 'Maguire', 'Affiliation': ""Department of Endocrinology, St. Vincent's University Hospital, Dublin, Ireland.""}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Cronin', 'Affiliation': 'Department of Midwifery, National Maternity Hospital, Dublin, Ireland.'}, {'ForeName': 'Fionnuala M', 'Initials': 'FM', 'LastName': 'McAuliffe', 'Affiliation': 'UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland. fionnuala.mcauliffe@ucd.ie.'}]","Reproductive sciences (Thousand Oaks, Calif.)",['10.1007/s43032-019-00045-0'] 2946,30842038,Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.,"OBJECTIVES Pancreatic cancer is a highly lethal disease predominantly affecting older patients. Characterization of outcomes in these patients may help optimise treatment decisions. The global, phase 3 NAPOLI-1 trial (NCT01494506) demonstrated an overall survival (OS) benefit with liposomal irinotecan and 5-flurouracil/leucovorin (nal-IRI + 5-FU/LV) versus 5-FU/LV. This subgroup analysis explored impact of age on outcomes in NAPOLI-1 patients, and nal-IRI + 5-FU/LV efficacy and safety in older patients. MATERIALS AND METHODS This exploratory, post-hoc analysis of the NAPOLI-1 trial included patients aged ≥eighteen years (no upper limit) with metastatic pancreatic adenocarcinoma that had progressed on gemcitabine-based therapy. Patients were stratified by age (cut-offs at 65, 70, and 75 years); OS and progression-free survival (PFS) were estimated by Kaplan-Meier analysis. RESULTS Of 417 randomized patients, 192 (46%), 110 (26%) and 43 (10%) were aged ≥65, ≥70 and ≥ 75 years, respectively. Mortality risk and risk of disease progression were similar in older and younger patients independent of treatment (HRs for median [m]OS/mPFS comparisons were 0.88/0.95 [<65 versus ≥65 years], 0.89/0.88 [<70 versus ≥70 years] and 1.04/0.98 [<75 versus ≥75 years]; P > .25). Reduced mortality/morbidity risk with nal-IRI + 5-FU/LV in older subgroups was in line with the wider population. No additional toxicities with nal-IRI + 5-FU/LV were observed in older patients: 86% of patients ≥75 years versus 69% <75 years required a dose delay or reduction due to toxicities (43% versus 32% dose reductions). DISCUSSION Results suggest that older patients with metastatic pancreatic adenocarcinoma that progressed on prior gemcitabine-based treatment can benefit from second-line therapy, supporting nal-IRI + 5-FU/LV treatment in older patients.",2019,Mortality risk and risk of disease progression were similar in older and younger patients independent of treatment (HRs for median [m]OS/mPFS comparisons were 0.88/0.95 [,"['older patients with metastatic pancreatic adenocarcinoma', 'older patients: 86% of patients ≥75', 'Of 417 randomized patients, 192 (46%), 110 (26%) and 43 (10%) were aged ≥65, ≥70 and\u202f≥\u202f75\u202fyears, respectively', 'older patients with metastatic pancreatic cancer', 'patients aged ≥eighteen years (no upper limit) with metastatic pancreatic adenocarcinoma that had progressed on gemcitabine-based therapy', 'older patients']","['nal-IRI\u202f+\u202f5-FU/LV', '5-FU/LV', 'Liposomal irinotecan and 5-fluorouracil/leucovorin', 'liposomal irinotecan and 5-flurouracil/leucovorin (nal-IRI\u202f+\u202f5-FU/LV']","['mortality/morbidity risk', 'progression-free survival (PFS', 'Mortality risk and risk of disease progression', 'toxicities', 'overall survival (OS) benefit']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0281361', 'cui_str': 'Adenocarcinoma of pancreas'}, {'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0346647', 'cui_str': 'Cancer of Pancreas'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0439801', 'cui_str': 'Limited (qualifier value)'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C2721771', 'cui_str': 'levoleucovorin'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0242656', 'cui_str': 'Disease Progression'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",417.0,0.0596125,Mortality risk and risk of disease progression were similar in older and younger patients independent of treatment (HRs for median [m]OS/mPFS comparisons were 0.88/0.95 [,"[{'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Macarulla', 'Affiliation': ""Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address: tmacarulla@vhebron.net.""}, {'ForeName': 'Jean-Frédéric', 'Initials': 'JF', 'LastName': 'Blanc', 'Affiliation': 'Pôle ADEN, Hôpital Haut-Lévêque, CHU Bordeaux, Bordeaux, France.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Wang-Gillam', 'Affiliation': 'Division of Oncology, Washington University in St. Louis, MO, USA.'}, {'ForeName': 'Li-Tzong', 'Initials': 'LT', 'LastName': 'Chen', 'Affiliation': 'National Institute of Cancer Research, National Health Research Institutes, National Cheng Kung University, Tainan, Taiwan; Department of Internal Medicine, National Cheng Kung University, Tainan, Taiwan.'}, {'ForeName': 'Jens T', 'Initials': 'JT', 'LastName': 'Siveke', 'Affiliation': 'Division of Solid Tumor Translational Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany; Cancer Consortium (DKTK, partner site Essen), German Cancer Research Center, DKFZ, Heidelberg, Germany.'}, {'ForeName': 'Beloo', 'Initials': 'B', 'LastName': 'Mirakhur', 'Affiliation': 'Ipsen Biopharmaceuticals, Inc., Cambridge, MA, United States.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Shire plc, Cambridge, MA, United States.'}, {'ForeName': 'Floris A', 'Initials': 'FA', 'LastName': 'de Jong', 'Affiliation': 'Global Medical Affairs, Servier, Zurich, Switzerland.'}]",Journal of geriatric oncology,['10.1016/j.jgo.2019.02.011'] 2947,31991216,Impact of a Formal Advance Care Planning Program on End-of-Life Care for Patients With Heart Failure: Results From a Randomized Controlled Trial.,"BACKGROUND There is no evidence on effectiveness of advance care planning (ACP) among patients with heart failure (HF). We examined the effect of an ACP program in facilitating end of life (EOL) care consistent with the preferences of patients with HF (primary aim), and on their decisional conflict, discussion with surrogates, illness understanding, anxiety, depression, and quality of life (secondary aims). METHODS We randomized 282 patients with HF to receive ACP (n=93) or usual care (control arm, n=189). Primary outcomes were assessed among deceased (n=89) and secondary outcomes from baseline and 6 follow-ups conducted every 4 months. RESULTS Deceased patients in the ACP arm were no more likely than those in control arm to have wishes followed for EOL treatments (ACP: 35%, Control: 44%; P= .47), or place of death (ACP: 52%, Control: 51%; P = .1.00). A higher proportion in the ACP arm had wishes followed for cardiopulmonary resuscitation (ACP: 83%, Control: 62%; P = .12). At first follow-up, patients with ACP had lower decisional conflict (β = -10.8, P< .01) and were more likely to discuss preferences with surrogates (β = 1.3, P = .04). ACP did not influence other outcomes. CONCLUSION This trial did not confirm that our ACP program was effective in facilitating EOL care consistent with patient preferences. The program led to short-term improvements in the decision-making.",2020,"Deceased patients in ACP arm were no more likely than those in control arm to have wishes followed for EOL treatments (ACP: 35%, Control: 44%; p=0.47), or place of death (ACP: 52%, Control: 51%; p-value=1.00).","['heart failure (HF) patients', 'patients with heart failure', '282 HF patients to receive ACP (n=93) or usual care (control arm, n=189']","['formal advance care planning program', 'ACP program', 'Advance care planning (ACP', 'ACP']","['decisional conflict', 'anxiety, depression and quality of life (secondary aims']","[{'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517681', 'cui_str': '282'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}]","[{'cui': 'C0600371', 'cui_str': 'Advance Health Care Planning'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0231394', 'cui_str': 'Decisional conflict (finding)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0034380'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}]",282.0,0.0945932,"Deceased patients in ACP arm were no more likely than those in control arm to have wishes followed for EOL treatments (ACP: 35%, Control: 44%; p=0.47), or place of death (ACP: 52%, Control: 51%; p-value=1.00).","[{'ForeName': 'Chetna', 'Initials': 'C', 'LastName': 'Malhotra', 'Affiliation': 'Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore. Electronic address: chetna.malhotra@duke-nus.edu.sg.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Sim', 'Affiliation': 'National Heart Centre Singapore, Singapore.'}, {'ForeName': 'Fazlur Rehman', 'Initials': 'FR', 'LastName': 'Jaufeerally', 'Affiliation': 'Singapore General Hospital, Outram Road, Singapore.'}, {'ForeName': 'Meibo', 'Initials': 'M', 'LastName': 'Hu', 'Affiliation': 'Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore.'}, {'ForeName': 'Nivedita', 'Initials': 'N', 'LastName': 'Nadkarni', 'Affiliation': 'Duke-NUS Medical School, Singapore.'}, {'ForeName': 'Clarice Shu Hwa', 'Initials': 'CSH', 'LastName': 'Ng', 'Affiliation': 'National Heart Centre Singapore, Singapore.'}, {'ForeName': 'Genevieve', 'Initials': 'G', 'LastName': 'Wong', 'Affiliation': 'National Heart Centre Singapore, Singapore.'}, {'ForeName': 'Boon Cheng', 'Initials': 'BC', 'LastName': 'Tan', 'Affiliation': 'National Heart Centre Singapore, Singapore.'}, {'ForeName': 'Jing Fen', 'Initials': 'JF', 'LastName': 'Lim', 'Affiliation': 'Singapore General Hospital, Outram Road, Singapore.'}, {'ForeName': 'Claire Ya-Ting', 'Initials': 'CY', 'LastName': 'Chuang', 'Affiliation': 'Singapore General Hospital, Outram Road, Singapore.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Finkelstein', 'Affiliation': 'Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore.'}]",Journal of cardiac failure,['10.1016/j.cardfail.2020.01.015'] 2948,29907999,Memory-Based Deception Detection: Extending the Cognitive Signature of Lying From Instructed to Self-Initiated Cheating.,"From a cognitive perspective, lying can be regarded as a complex cognitive process requiring the interplay of several executive functions. Meta-analytic research on 114 studies encompassing 3,307 participants (Suchotzki, Verschuere, Van Bockstaele, Ben-Shakhar, & Crombez, 2017) suggests that computerized paradigms can reliably assess the cognitive burden of lying, with large reaction time differences between lying and truth telling. These studies, however, lack a key ingredient of real-life deception, namely self-initiated behavior. Research participants have typically been instructed to commit a mock crime and conceal critical information, whereas in real life, people freely choose whether or not to engage in antisocial behavior. In this study, participants (n = 433) engaged in a trivia quiz and were provided with a monetary incentive for high accuracy performance. Participants were randomly allocated to either a condition where they were instructed to cheat on the quiz (mimicking the typical laboratory set-up) or to a condition in which they were provided with the opportunity to cheat, yet without explicit instructions to do so. Assessments of their response times in a subsequent Concealed Information Test (CIT) revealed that both instructed cheaters (n = 107) and self-initiated cheaters (n = 142) showed the expected RT-slowing for concealed information. The data indicate that the cognitive signature of lying is not restricted to explicitly instructed cheating, but it can also be observed for self-initiated cheating. These findings are highly encouraging from an ecological validity perspective.",2020,Assessments of their response times in a subsequent Concealed Information Test (CIT) revealed that both instructed cheaters (n = 107) and self-initiated cheaters (n = 142) showed the expected RT-slowing for concealed information.,"['3,307 participants (Suchotzki, Verschuere, Van Bockstaele, Ben-Shakhar, & Crombez, ', 'participants (n\xa0=\xa0433) engaged in a trivia quiz and were provided with a monetary incentive for high accuracy performance']",['Memory-Based Deception Detection'],[],"[{'cui': 'C0557775', 'cui_str': 'Van (physical object)'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]","[{'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0024195', 'cui_str': 'Deception'}]",[],3307.0,0.0265244,Assessments of their response times in a subsequent Concealed Information Test (CIT) revealed that both instructed cheaters (n = 107) and self-initiated cheaters (n = 142) showed the expected RT-slowing for concealed information.,"[{'ForeName': 'Linda M', 'Initials': 'LM', 'LastName': 'Geven', 'Affiliation': 'Department of Clinical Psychology, University of Amsterdam.'}, {'ForeName': 'Gershon', 'Initials': 'G', 'LastName': 'Ben-Shakhar', 'Affiliation': 'Department of Psychology, Hebrew University of Jerusalem.'}, {'ForeName': 'Merel', 'Initials': 'M', 'LastName': 'Kindt', 'Affiliation': 'Department of Clinical Psychology, University of Amsterdam.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Verschuere', 'Affiliation': 'Department of Clinical Psychology, University of Amsterdam.'}]",Topics in cognitive science,['10.1111/tops.12353'] 2949,32268344,The role of dopamine in dynamic effort-reward integration.,"When deciding to act, the neurotransmitter dopamine is implicated in a valuation of prospective effort and reward. However, its role in dynamic effort-reward integration during action, a process central to everyday behaviour, remains unclear. In a placebo-controlled, within-subject, study, we probed the impact of increasing brain dopamine levels (150 mg of levodopa) and blocking dopamine receptors (1.5 mg of haloperidol) in the context of a novel dynamic effort task in healthy human subjects. We show that modulating homoeostatic dopamine balance distinctly alters implicit and explicit effort allocation as a function of instantaneous reward. Pharmacologically boosting dopamine enhanced motor vigour, reflected in an implicit increase in effort allocation for high rewards. Conversely, pharmacological blockade of dopamine attenuated sensitivity to differences in reward context, reflected in reduced strategic effort discounting. These findings implicate dopamine in an integration of momentary physical experience and instantaneous reward, suggesting a key role of dopamine in acting to maximise reward on the fly.",2020,"Pharmacologically boosting dopamine enhanced motor vigour, reflected in an implicit increase in effort allocation for high rewards.",['healthy human subjects'],"['dopamine', 'brain dopamine levels (150\u2009mg of levodopa) and blocking dopamine receptors (1.5\u2009mg of haloperidol']",[],"[{'cui': 'C0080105', 'cui_str': 'Human Subjects'}]","[{'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0034798', 'cui_str': 'Dopamine receptor'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0018546', 'cui_str': 'Haloperidol'}]",[],,0.0198057,"Pharmacologically boosting dopamine enhanced motor vigour, reflected in an implicit increase in effort allocation for high rewards.","[{'ForeName': 'Jochen', 'Initials': 'J', 'LastName': 'Michely', 'Affiliation': 'Wellcome Centre for Human Neuroimaging, University College London, London, WC1N 3BG, UK.'}, {'ForeName': 'Shivakumar', 'Initials': 'S', 'LastName': 'Viswanathan', 'Affiliation': 'Cognitive Neuroscience, Institute of Neuroscience & Medicine (INM-3), Research Centre Juelich, 52425, Juelich, Germany.'}, {'ForeName': 'Tobias U', 'Initials': 'TU', 'LastName': 'Hauser', 'Affiliation': 'Wellcome Centre for Human Neuroimaging, University College London, London, WC1N 3BG, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Delker', 'Affiliation': 'Medical Faculty, University of Cologne and Department of Neurology, University Hospital Cologne, 50937, Cologne, Germany.'}, {'ForeName': 'Raymond J', 'Initials': 'RJ', 'LastName': 'Dolan', 'Affiliation': 'Wellcome Centre for Human Neuroimaging, University College London, London, WC1N 3BG, UK.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Grefkes', 'Affiliation': 'Medical Faculty, University of Cologne and Department of Neurology, University Hospital Cologne, 50937, Cologne, Germany. christian.grefkes@uk-koeln.de.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0669-0'] 2950,32131641,"Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.","Introduction: Hereditary transthyretin-mediated (hATTR) amyloidosis is a rare, fatal, multisystem disease leading to deteriorating quality of life (QOL). The impact of patisiran on QOL in patients with hATTR amyloidosis with polyneuropathy from the phase 3 APOLLO study (NCT01960348) is evaluated. Methods: Patients received either patisiran 0.3 mg/kg ( n  = 148) or placebo ( n  = 77) intravenously once every three weeks for 18 months. Multiple measures were used to assess varying aspects of QOL. Results: At 18 months, compared with placebo, patisiran improved Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) score; (least squares [LS] mean difference: -21.1; p  = 1.10 × 10 -10 ; improved across all domains), EuroQoL 5-dimensions 5-levels (LS mean difference: 0.2; p  = 1.4 × 10 -12 ), EuroQoL-visual analog scale (LS mean difference: 9.5; p =.0004), Rasch-built Overall Disability Scale (LS mean difference: 9.0; p  = 4.07 × 10 -16 ) and Composite Autonomic Symptom Score-31(COMPASS-31; LS mean difference: -7.5; p =.0008). Placebo-treated patients experienced rapid QOL deterioration; treatment effects for patisiran were observed as early as 9 months. At 18 months, patisiran improved Norfolk QOL-DN total score and three individual domains as well as COMPASS-31 total scores relative to baseline. Consistent benefits were also observed in the cardiac subpopulation. Conclusion: The benefits of patisiran across all QOL measures and the rapid deterioration observed with placebo, highlight the urgency in early treatment for patients with hATTR amyloidosis with polyneuropathy.",2020,"At 18 months, patisiran improved Norfolk QOL-DN total score and three individual domains as well as COMPASS-31 total scores relative to baseline.","['patients with hereditary transthyretin-mediated amyloidosis', 'patients with hATTR amyloidosis with polyneuropathy']","['placebo', 'Placebo', 'patisiran 0.3\u2009mg/kg ( n \u2009=\u2009148) or placebo']","['Quality of life outcomes', 'EuroQoL 5-dimensions 5-levels', 'patisiran improved Norfolk QOL-DN total score', 'rapid QOL deterioration', 'Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) score', 'EuroQoL-visual analog scale', 'Rasch-built Overall Disability Scale']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439660', 'cui_str': 'Hereditary (qualifier value)'}, {'cui': 'C0032923', 'cui_str': 'Transthyretin'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C0002726', 'cui_str': 'Amyloidosis'}, {'cui': 'C0152025', 'cui_str': 'Polyneuropathy'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3896714', 'cui_str': 'patisiran'}, {'cui': 'C4068885', 'cui_str': 'Zero point three'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}]","[{'cui': 'C0034380'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C3896714', 'cui_str': 'patisiran'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0454866', 'cui_str': 'Norfolk (geographic location)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0011882', 'cui_str': 'Diabetic Neuropathies'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0222045'}]",,0.127037,"At 18 months, patisiran improved Norfolk QOL-DN total score and three individual domains as well as COMPASS-31 total scores relative to baseline.","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Obici', 'Affiliation': 'Amyloidosis Research and Treatment Centre, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.'}, {'ForeName': 'John L', 'Initials': 'JL', 'LastName': 'Berk', 'Affiliation': 'Amyloidosis Center, Boston Medical Center, Boston, MA, USA.'}, {'ForeName': 'Alejandra', 'Initials': 'A', 'LastName': 'González-Duarte', 'Affiliation': 'Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Coelho', 'Affiliation': 'Hospital de Santo António, Centro Hospitalar do Porto, Porto, Portugal.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Gillmore', 'Affiliation': 'Division of Medicine, National Amyloidosis Centre, University College London, London, UK.'}, {'ForeName': 'Hartmut H-J', 'Initials': 'HH', 'LastName': 'Schmidt', 'Affiliation': 'Medical Clinic for Gastroenterology and Hepatology, University of Münster, Münster, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Schilling', 'Affiliation': 'Department of Neurology, Institute of Translational Neurology, University Hospital Münster, Münster, Germany.'}, {'ForeName': 'Taro', 'Initials': 'T', 'LastName': 'Yamashita', 'Affiliation': 'Department of Neurology, Kumamoto University, Kumamoto, Japan.'}, {'ForeName': 'Céline', 'Initials': 'C', 'LastName': 'Labeyrie', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris (APHP), French National Reference Center for Familial Amyloidotic Polyneuropathy, Centre Hospitalier Universitaire Bicêtre, Universite Paris-Sud, INSERM Unite, Paris, France.'}, {'ForeName': 'Thomas H', 'Initials': 'TH', 'LastName': 'Brannagan', 'Affiliation': 'Department of Neurology, Columbia University Medical Center, New York, NY, USA.'}, {'ForeName': 'Senda', 'Initials': 'S', 'LastName': 'Ajroud-Driss', 'Affiliation': 'Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Gorevic', 'Affiliation': 'Department of Medicine, Mount Sinai Medical Center, New York, NY, USA.'}, {'ForeName': 'Arnt V', 'Initials': 'AV', 'LastName': 'Kristen', 'Affiliation': 'Department of Cardiology, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Jaclyn', 'Initials': 'J', 'LastName': 'Franklin', 'Affiliation': 'Alnylam Pharmaceuticals, Cambridge, MA, USA.'}, {'ForeName': 'Jihong', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Alnylam Pharmaceuticals, Cambridge, MA, USA.'}, {'ForeName': 'Marianne T', 'Initials': 'MT', 'LastName': 'Sweetser', 'Affiliation': 'Alnylam Pharmaceuticals, Cambridge, MA, USA.'}, {'ForeName': 'Jing Jing', 'Initials': 'JJ', 'LastName': 'Wang', 'Affiliation': 'Alnylam Pharmaceuticals, Cambridge, MA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Adams', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris (APHP), French National Reference Center for Familial Amyloidotic Polyneuropathy, Centre Hospitalier Universitaire Bicêtre, Universite Paris-Sud, INSERM Unite, Paris, France.'}]",Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis,['10.1080/13506129.2020.1730790'] 2951,31390464,Integrated specialized atrial fibrillation clinics reduce all-cause mortality: post hoc analysis of a randomized clinical trial.,"AIMS An integrated chronic care programme in terms of a specialized outpatient clinic for patients with atrial fibrillation (AF), has demonstrated improved clinical outcomes. The aim of this study is to assess all-cause mortality in patients in whom AF management was delivered through a specialized outpatient clinic offering an integrated chronic care programme. METHODS AND RESULTS Post hoc analysis of a Prospective Randomized Open Blinded Endpoint Clinical trial to assess all-cause mortality in AF patients. The study included 712 patients with newly diagnosed AF, who were referred for AF management to the outpatient service of a University hospital. In the specialized outpatient clinic (AF-Clinic), comprehensive, multidisciplinary, and patient-centred AF care was provided, i.e. nurse-driven, physician supervised AF treatment guided by software based on the latest guidelines. The control group received usual care by a cardiologist in the regular outpatient setting.After a mean follow-up of 22 months, all-cause mortality amounted 3.7% (13 patients) in the AF-Clinic arm and 8.1% (29 patients) in usual care [hazard ratio (HR) 0.44, 95% confidence interval (CI) 0.23-0.85; P = 0.014]. This included cardiovascular mortality in 4 AF-Clinic patients (1.1%) and 14 patients (3.9%) in usual care (HR 0.28; 95% CI 0.09-0.85; P = 0.025). Further, 9 patients (2.5%) died in the AF-Clinic arm due to a non-cardiovascular reason and 15 patients (4.2%) in the usual care arm (HR 0.59; 95% CI 0.26-1.34; P = 0.206). CONCLUSION An integrated specialized AF-Clinic reduces all-cause mortality compared with usual care. These findings provide compelling evidence that an integrated approach should be widely implemented in AF management.",2019,"After a mean follow-up of 22 months, all-cause mortality amounted 3.7% (13 patients) in the AF-Clinic arm and 8.1% (29 patients) in usual care [hazard ratio (HR) 0.44, 95% confidence interval (CI) 0.23-0.85; P = 0.014].","['patients with atrial fibrillation (AF', 'AF patients', '712 patients with newly diagnosed AF, who were referred for AF management to the outpatient service of a University hospital', 'patients in whom AF management was delivered through a specialized outpatient clinic offering an integrated chronic care programme']",['usual care by a cardiologist in the regular outpatient setting'],"['cause mortality', 'cardiovascular mortality']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}, {'cui': 'C0086751', 'cui_str': 'Outpatient Services'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}]","[{'cui': 'C0175906', 'cui_str': 'Cardiologists'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}]","[{'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",712.0,0.0512359,"After a mean follow-up of 22 months, all-cause mortality amounted 3.7% (13 patients) in the AF-Clinic arm and 8.1% (29 patients) in usual care [hazard ratio (HR) 0.44, 95% confidence interval (CI) 0.23-0.85; P = 0.014].","[{'ForeName': 'Jeroen M L', 'Initials': 'JML', 'LastName': 'Hendriks', 'Affiliation': 'Department of Cardiology, Maastricht University Medical Centre+, and Cardiovascular Research Institute Maastricht (CARIM), PO Box 5800, 6202 AZ, Maastricht, The Netherlands.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Tieleman', 'Affiliation': 'Department of Cardiology, Martini Hospital Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Hubertus J M', 'Initials': 'HJM', 'LastName': 'Vrijhoef', 'Affiliation': 'Department Patient and Care, Maastricht University Medical Centre+, Maastricht, The Netherlands.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Wijtvliet', 'Affiliation': 'Department of Cardiology, Maastricht University Medical Centre+, and Cardiovascular Research Institute Maastricht (CARIM), PO Box 5800, 6202 AZ, Maastricht, The Netherlands.'}, {'ForeName': 'Celine', 'Initials': 'C', 'LastName': 'Gallagher', 'Affiliation': 'Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia.'}, {'ForeName': 'Martin H', 'Initials': 'MH', 'LastName': 'Prins', 'Affiliation': 'Department of Epidemiology, Maastricht University Medical Centre+, Maastricht, The Netherlands.'}, {'ForeName': 'Prashanthan', 'Initials': 'P', 'LastName': 'Sanders', 'Affiliation': 'Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia.'}, {'ForeName': 'Harry J G M', 'Initials': 'HJGM', 'LastName': 'Crijns', 'Affiliation': 'Department of Cardiology, Maastricht University Medical Centre+, and Cardiovascular Research Institute Maastricht (CARIM), PO Box 5800, 6202 AZ, Maastricht, The Netherlands.'}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euz209'] 2952,32097261,"Comparison of Anterior Controllable Antedisplacement and Fusion With Posterior Laminoplasty in the Treatment of Multilevel Cervical Ossification of the Posterior Longitudinal Ligament: A Prospective, Randomized, and Control Study With at Least 1-Year Follow Up.","STUDY DESIGN A prospective, randomized, controlled study. OBJECTIVE To compare anterior controllable antidisplacement and fusion (ACAF) with laminoplasty in the treatment of multilevel ossification of the posterior longitudinal ligament (OPLL), and evaluate the efficacy and safety of this procedure. SUMMARY OF BACKGROUND DATA The optimal approach for the treatment of OPLL still remains controversial. Both anterior and posterior approaches have their advantages and disadvantages. METHODS Between September 2016 and April 2018, a total of 80 patients with multilevel OPLL were randomized in a 1:1 ratio to ACAF group and laminoplasty group. All patients were followed up at least 1 year. Clinical and radiological results were compared between ACAF group and laminoplasty group. RESULTS ACAF took a longer operation time. C5 palsy and axial pain occurred more commonly in laminoplasty group, whereas dysphagia and hoarseness appeared easily in ACAF group. At 1-year follow-up, the final Japanese Orthopedic Association (JOA) score and recovery rate were significant higher in ACAF group than those in laminoplasty group, when occupying rate (OR) was not less than 60%, or K-line was negative. ACAF was also good at preservation of cervical lordosis and sagittal balance, but range of movement of cervical spine in both groups decreased significantly. CONCLUSION Generally speaking, ACAF is a safe and effective alternative for multilevel OPLL. Compared with laminoplasty, ACAF is more effective in the cases when OR is not less than 60%, or K-line is negative. LEVEL OF EVIDENCE 2.",2020,"At one-year follow-up, the final JOA score and RR were significant higher in ACAF group than those in laminoplasty group, when OR was not less than 60%, or K-line was negative.","['Multilevel Cervical Ossification of the Posterior Longitudinal Ligament', '80 patients with multilevel OPLL', 'Between September 2016 and April 2018', 'multilevel ossification of the posterior longitudinal ligament (OPLL']","['Anterior Controllable Antedisplacement and Fusion (ACAF) with Posterior Laminoplasty', 'laminoplasty, ACAF', 'ACAF group and laminoplasty group', 'anterior controllable antidisplacement and fusion (ACAF) with laminoplasty', 'ACAF']","['efficacy and safety', 'final JOA score and RR', 'dysphagia and hoarseness', 'operation time', 'C5 palsy and axial pain', 'cervical lordosis and sagittal balance, but ROM of cervical spine']","[{'cui': 'C0205064', 'cui_str': 'Cervical (qualifier value)'}, {'cui': 'C0206366', 'cui_str': 'Calcification of Posterior Longitudinal Ligament'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C1293131', 'cui_str': 'Fusion procedure (procedure)'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C1535956', 'cui_str': 'Laminoplasty'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0019825', 'cui_str': 'Voice Hoarseness'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C4285911', 'cui_str': 'C5 palsy'}, {'cui': 'C0205131', 'cui_str': 'Axial (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205064', 'cui_str': 'Cervical (qualifier value)'}, {'cui': 'C0024004', 'cui_str': 'Acquired lordosis (disorder)'}, {'cui': 'C0205129', 'cui_str': 'Sagittal (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0728985', 'cui_str': 'Cervical spine'}]",80.0,0.0259923,"At one-year follow-up, the final JOA score and RR were significant higher in ACAF group than those in laminoplasty group, when OR was not less than 60%, or K-line was negative.","[{'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Spine Center, Department of Orthopaedics, Changzheng Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Jingchuan', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': ''}, {'ForeName': 'Xiaoqiu', 'Initials': 'X', 'LastName': 'Yuan', 'Affiliation': ''}, {'ForeName': 'Yongfei', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': ''}, {'ForeName': 'Haisong', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Deyu', 'Initials': 'D', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Jiangang', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': ''}]",Spine,['10.1097/BRS.0000000000003462'] 2953,31972380,Effect of remote ischaemic conditioning on coagulation function as measured by whole blood impedance aggregometry and rotational thromboelastometry in off-pump coronary artery bypass surgery: A randomised controlled trial.,"INTRODUCTION Remote ischaemic conditioning (RIC) has been shown to prevent platelet activation during ablation for atrial fibrillation. RIC has also been associated with more postoperative transfusion in the off-pump coronary artery bypass graft surgery (OPCAB) patients. We evaluated the effects of RIC on coagulation function in OPCAB patients. METHODS A total of 58 patients undergoing OPCAB were randomised to the RIC or control group. In the RIC group, four cycles of 5 min of ischaemia and 5 min of reperfusion were applied twice to the upper arm after the induction of anaesthesia (preconditioning), and after the completion of coronary anastomoses (postconditioning). Whole blood impedance aggregometry (Multiplate®) and rotational thromboelastometry (ROTEM®) were performed before the induction of anaesthesia, at the end of surgery, and at postoperative day 1. RESULTS The trend towards a decrease in adenosine diphosphate-induced whole blood aggregation at the end of surgery was greater in the RIC group than in the control group, but this effect was not statistically significant (-10.4 [18.1] vs. -5.7 [24.8] U, P = 0.424). In ROTEM® analysis, the EXTEM area under the velocity curve was lower in the RIC group than in the control group at the end of surgery (3567 [1399-5794] vs. 5693 [4718-6179] mm∗100, respectively; P = 0.030). A tendency of larger perioperative blood loss was identified in the RIC group. CONCLUSIONS Although some parameters indicated a tendency for hypocoagulation in the RIC group at the end of surgery, most effects were not statistically significant. RIC does not significantly affect perioperative platelet aggregability and coagulation in patients undergoing OPCAB.",2020,"In ROTEM® analysis, the EXTEM area under the velocity curve was lower in the RIC group than in the control group at the end of surgery (3567 [1399-5794] vs. 5693 [4718-6179] mm∗100, respectively; P = 0.030).","['58 patients undergoing OPCAB', 'pump coronary artery bypass surgery', 'OPCAB patients', 'patients undergoing OPCAB']","['Remote ischaemic conditioning (RIC', 'remote ischaemic conditioning', 'RIC']","['coagulation function', 'perioperative blood loss', 'adenosine diphosphate-induced whole blood aggregation', 'velocity curve', 'Whole blood impedance aggregometry (Multiplate®) and rotational thromboelastometry (ROTEM®', 'postoperative transfusion']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0010055', 'cui_str': 'Coronary Artery Bypass Grafting'}]","[{'cui': 'C0205157', 'cui_str': 'Remote (qualifier value)'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0441509', 'cui_str': 'Coagulation - action (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0001459', 'cui_str': ""Adenosine 5'-Pyrophosphate""}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0370231', 'cui_str': 'Whole blood (substance)'}, {'cui': 'C0332621', 'cui_str': 'Aggregation (finding)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0162537', 'cui_str': 'Electrical Impedance'}, {'cui': 'C0445237', 'cui_str': 'Rotational (qualifier value)'}, {'cui': 'C3661505', 'cui_str': 'Thromboelastometry'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0199960', 'cui_str': 'Transfusion - action (qualifier value)'}]",58.0,0.0343578,"In ROTEM® analysis, the EXTEM area under the velocity curve was lower in the RIC group than in the control group at the end of surgery (3567 [1399-5794] vs. 5693 [4718-6179] mm∗100, respectively; P = 0.030).","[{'ForeName': 'Tae Kyong', 'Initials': 'TK', 'LastName': 'Kim', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Anaesthesiology and Pain Medicine, SMG-SNU Boramae Medical Centre, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Karam', 'Initials': 'K', 'LastName': 'Nam', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Youn Joung', 'Initials': 'YJ', 'LastName': 'Cho', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Seungeun', 'Initials': 'S', 'LastName': 'Choi', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Anaesthesiology and Pain Medicine, SMG-SNU Boramae Medical Centre, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Hyung Sang', 'Initials': 'HS', 'LastName': 'Row', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Anaesthesiology and Pain Medicine, SMG-SNU Boramae Medical Centre, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Yunseok', 'Initials': 'Y', 'LastName': 'Jeon', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: jeonyunseok@gmail.com.'}]",Thrombosis research,['10.1016/j.thromres.2020.01.004'] 2954,32035035,Effectiveness and cost-effectiveness of group support psychotherapy delivered by trained lay health workers for depression treatment among people with HIV in Uganda: a cluster-randomised trial.,"BACKGROUND WHO recommends the use of psychological interventions as first-line treatment for depression in low-income and middle-income countries. However, evaluations of the effectiveness and cost-effectiveness of such interventions among people with HIV are scarce. Our aim was to establish the effectiveness of group support psychotherapy (GSP) delivered by lay health workers for depression treatment among people living with HIV in a rural area of Uganda on a large scale. METHODS In this cluster-randomised trial, we included 30 health centres offering HIV care. These were randomly assigned to deliver either GSP or group HIV education (GHE). Randomisation, in a ratio of 1:1, was achieved by health centre managers separately picking a paper containing the intervention allocation from a basket. Participants were people living with HIV, aged 19 years and older, with mild to moderate major depression assessed with the Mini International Neuropsychiatric Interview depression module, taking antiretroviral therapy, and antidepressant-naive. Group sessions were led by trained lay health workers once a week for 8 weeks. The primary outcomes were the proportion of participants with major depression and function scores at 6 months post-treatment, analysed by intention to treat by means of multilevel random effect regression analyses adjusting for clustering in health centres. This trial is registered with the Pan African Clinical Trials Registry, PACTR201608001738234. FINDINGS Between Sept 13 and Dec 15, 2016, we assessed 1473 individuals, of whom 1140 were recruited from health centres offering GSP (n=578 [51%]) or GHE (n=562 [49%]). Two (<1%) participants in the GSP group were diagnosed with major depression 6 months post-treatment compared with 160 (28%) in the GHE group (adjusted odds ratio=0·01, 95% CI 0·003-0·012, p<0·0001). The mean function scores 6 months post-treatment were 9·85 (SD 0·76) in the GSP group and 6·83 (2·85) in the GHE group (β=4·12; 95% CI 3·75-4·49, p<0·0001). 36 individuals had 63 serious adverse events, which included 25 suicide attempts and 22 hospital admissions for medical complications. The outcomes of these serious adverse events included 16 deaths, 4 of which were completed suicides (GSP=2; GHE=2), and 12 of which were HIV-related medical complications (GSP=8; GHE=4). Cost-effectiveness estimates showed an incremental cost-effectiveness ratio of US$13·0 per disability-adjusted life-year averted, which can be considered very cost-effective in Uganda. INTERPRETATION Integration of cost-effective psychological treatments such as group support psychotherapy into existing HIV interventions might improve the mental health of people living with HIV. FUNDING MQ Transforming Mental Health and Grand Challenges Canada.",2020,"The mean function scores 6 months post-treatment were 9·85 (SD 0·76) in the GSP group and 6·83 (2·85) in the GHE group (β=4·12; 95% CI 3·75-4·49, p<0·0001).","['people with HIV are scarce', 'Between Sept 13 and Dec 15, 2016', 'trained lay health workers for depression treatment among people with HIV in Uganda', 'people living with HIV in a rural area of Uganda on a large scale', '1473 individuals, of whom 1140 were recruited from health centres offering GSP (n=578 [51%]) or GHE (n=562 [49', 'people living with HIV', 'Participants were people living with HIV, aged 19 years and older, with mild to moderate major depression assessed with the Mini International Neuropsychiatric Interview depression module, taking antiretroviral therapy, and antidepressant-naive', '36 individuals had 63 serious adverse events, which included 25 suicide attempts and 22 hospital admissions for medical complications', '30 health centres offering HIV care']","['group support psychotherapy', 'GSP or group HIV education (GHE', 'group support psychotherapy (GSP']","['effectiveness and cost-effectiveness', 'Effectiveness and cost-effectiveness', 'proportion of participants with major depression and function scores', 'mean function scores']","[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0600261', 'cui_str': 'Lying'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0041573', 'cui_str': 'Republic of Uganda'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C4517539', 'cui_str': 'One thousand one hundred and forty'}, {'cui': 'C0475309', 'cui_str': 'Health center (environment)'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C4505426', 'cui_str': 'Mini International Neuropsychiatric Interview'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant Drugs'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0038663', 'cui_str': 'Suicide attempt (event)'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission (procedure)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C1273567', 'cui_str': 'Psychotherapy (specialty)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",1140.0,0.181347,"The mean function scores 6 months post-treatment were 9·85 (SD 0·76) in the GSP group and 6·83 (2·85) in the GHE group (β=4·12; 95% CI 3·75-4·49, p<0·0001).","[{'ForeName': 'Etheldreda', 'Initials': 'E', 'LastName': 'Nakimuli-Mpungu', 'Affiliation': 'Department of Psychiatry, College of Health Sciences, Makerere University, Kampala, Uganda. Electronic address: ethelnakimuli@chs.mak.ac.ug.'}, {'ForeName': 'Seggane', 'Initials': 'S', 'LastName': 'Musisi', 'Affiliation': 'Department of Psychiatry, College of Health Sciences, Makerere University, Kampala, Uganda.'}, {'ForeName': 'Kizito', 'Initials': 'K', 'LastName': 'Wamala', 'Affiliation': 'Department of Psychology, Center for Victims of Torture, Gulu, Uganda.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Okello', 'Affiliation': 'Department of Mental Health, Faculty of Medicine, Gulu University, Gulu, Uganda.'}, {'ForeName': 'Sheila', 'Initials': 'S', 'LastName': 'Ndyanabangi', 'Affiliation': 'Mental Health Program, Ministry of Health of Uganda, Kampala, Uganda.'}, {'ForeName': 'Josephine', 'Initials': 'J', 'LastName': 'Birungi', 'Affiliation': 'The AIDS Support Organization, Kampala, Uganda.'}, {'ForeName': 'Mastula', 'Initials': 'M', 'LastName': 'Nanfuka', 'Affiliation': 'The AIDS Support Organization, Kampala, Uganda.'}, {'ForeName': 'Micheal', 'Initials': 'M', 'LastName': 'Etukoit', 'Affiliation': 'The AIDS Support Organization, Kampala, Uganda.'}, {'ForeName': 'Chrispus', 'Initials': 'C', 'LastName': 'Mayora', 'Affiliation': 'Department of Health Policy Planning and Management, School of Public Health, Makerere University, Kampala, Uganda.'}, {'ForeName': 'Freddie', 'Initials': 'F', 'LastName': 'Ssengooba', 'Affiliation': 'Department of Health Policy Planning and Management, School of Public Health, Makerere University, Kampala, Uganda.'}, {'ForeName': 'Ramin', 'Initials': 'R', 'LastName': 'Mojtabai', 'Affiliation': 'Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Jean B', 'Initials': 'JB', 'LastName': 'Nachega', 'Affiliation': 'Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA; Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA; Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA; Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA; Center for Infectious Disease, Department of Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa.'}, {'ForeName': 'Ofir', 'Initials': 'O', 'LastName': 'Harari', 'Affiliation': 'MTEK Sciences, Vancouver, BC, Canada.'}, {'ForeName': 'Edward J', 'Initials': 'EJ', 'LastName': 'Mills', 'Affiliation': 'MTEK Sciences, Vancouver, BC, Canada; Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada.'}]",The Lancet. Global health,['10.1016/S2214-109X(19)30548-0'] 2955,9593172,"Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial.","The prophylactic efficacy of WR 238605, a primaquine analog, was studied with a human Plasmodium falciparum challenge model. A single oral dose of 600 mg, administered 1 day prior to challenge, successfully protected three of four subjects. The fourth subject developed mild, oligosymptomatic malaria on day 31, with drug concentrations one-half of those in the protected individuals. WR 238605 appears to be a promising prophylactic drug for P. falciparum malaria.",1998,"The prophylactic efficacy of WR 238605, a primaquine analog, was studied with a human Plasmodium falciparum challenge model.",[],['primaquine analog'],[],[],"[{'cui': 'C0033126', 'cui_str': 'Primaquine'}]",[],,0.0477541,"The prophylactic efficacy of WR 238605, a primaquine analog, was studied with a human Plasmodium falciparum challenge model.","[{'ForeName': 'R P', 'Initials': 'RP', 'LastName': 'Brueckner', 'Affiliation': 'Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Washington, DC 20307-5100, USA. LTC_Ralf_Brueckner@WRSMTP-ccMail.Army.Mil'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Coster', 'Affiliation': ''}, {'ForeName': 'D L', 'Initials': 'DL', 'LastName': 'Wesche', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Shmuklarsky', 'Affiliation': ''}, {'ForeName': 'B G', 'Initials': 'BG', 'LastName': 'Schuster', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 2956,32197915,Post-antibiotic Ocular Surface Microbiome in Children: A Cluster-Randomized Trial.,,2020,,['Children'],[],[],"[{'cui': 'C0008059', 'cui_str': 'Child'}]",[],[],,0.0653268,,"[{'ForeName': 'Thuy', 'Initials': 'T', 'LastName': 'Doan', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California. Electronic address: Thuy.Doan@ucsf.edu.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Hinterwirth', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Worden', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Arzika', 'Affiliation': 'The Carter Center, Niamey, Niger.'}, {'ForeName': 'Ramatou', 'Initials': 'R', 'LastName': 'Maliki', 'Affiliation': 'The Carter Center, Niamey, Niger.'}, {'ForeName': 'Cindi', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Zhong', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Zhaoxia', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Nisha R', 'Initials': 'NR', 'LastName': 'Acharya', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Travis C', 'Initials': 'TC', 'LastName': 'Porco', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California; Institute for Global Health Sciences, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Jeremy D', 'Initials': 'JD', 'LastName': 'Keenan', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Lietman', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California; Institute for Global Health Sciences, University of California San Francisco, San Francisco, California.'}]",Ophthalmology,['10.1016/j.ophtha.2020.02.014'] 2957,9145846,Suspicion of quinolone active metabolite following discrepancy between predicted and experimental urine bactericidal activities.,"The prediction of urine antibacterial activity from pharmacological and microbiological parameters was assessed by using experimental urine levels and urine bactericidal titers determined up to 72 h after a 400-mg single dose of two quinolones in a phase I study. The area under the bactericidal curve (AUBC) was accurately predicted for norfloxacin but significantly (P < 0.001) underestimated for rufloxacin (actual value was four times higher than the predicted value against Escherichia coli and two times higher against Staphylococcus aureus). In vitro susceptibility differences between the two strains predicted the ex vivo AUBC differences for norfloxacin but not for rufloxacin, where ex vivo differences were greater than expected. Urine bactericidal titers for up to 72 h were accurately predicted for norfloxacin against E. coli and S. aureus and for rufloxacin against S. aureus, but experimental activity for up to 48 h was four times higher (P < 0.001) than the predicted activity for rufloxacin against E. coli. In the case of norfloxacin, the duration of adequate urine antibacterial activity against S. aureus was overestimated. Inaccurate estimations of ex vivo antibacterial activity of a suspected active metabolite (as with rufloxacin) when an adequate cutoff is not established may have dosing implications.",1997,"Urine bactericidal titers for up to 72 h were accurately predicted for norfloxacin against E. coli and S. aureus and for rufloxacin against S. aureus, but experimental activity for up to 48 h was four times higher (P < 0.001) than the predicted activity for rufloxacin against E. coli.",[],['norfloxacin'],"['ex vivo AUBC differences', 'area under the bactericidal curve (AUBC', 'Urine bactericidal titers']",[],"[{'cui': 'C0028365', 'cui_str': 'Norfloxacin'}]","[{'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0042037'}, {'cui': 'C0475208', 'cui_str': 'TITR'}]",72.0,0.0453587,"Urine bactericidal titers for up to 72 h were accurately predicted for norfloxacin against E. coli and S. aureus and for rufloxacin against S. aureus, but experimental activity for up to 48 h was four times higher (P < 0.001) than the predicted activity for rufloxacin against E. coli.","[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Aguilar', 'Affiliation': 'Medical Department, SmithKline Beecham Pharmaceuticals, Madrid, Spain.'}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Giménez', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Costa', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Dal-Ré', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Prieto', 'Affiliation': ''}]",Antimicrobial agents and chemotherapy,[] 2958,31394314,A new approach to facilitating attentional disengagement from food cues in unsuccessful dieters: The bouncing image training task.,"This study tested the capacity of a modified Bouncing Image Training Task (BITT) to enhance unsuccessful dieters' attentional disengagement from food cues. Unsuccessful dieters were assigned to a training group performing daily BITT sessions for one week (n = 57) or a waitlist control group (n = 56). Change in attention was assessed using a visual search task and an odd-one-out task. Impact of the BITT on food craving and food intake were also assessed. Participants in the training group, compared to waitlist controls, showed reduced attention to food cues from pre-to post-training. Moreover, the reduction in AB to food cues exhibited by those who completed the BITT reflected the relative facilitation of attentional disengagement from food cues, rather than a reduction in attention engagement with food cues. The groups did not differ on food craving or intake post-training. It is concluded that the BITT is a promising procedure for directly manipulating individuals' attentional disengagement from food cues, though its capacity to enhance dieting success has not yet been established.",2019,"It is concluded that the BITT is a promising procedure for directly manipulating individuals' attentional disengagement from food cues, though its capacity to enhance dieting success has not yet been established.",[],"['waitlist control group', 'modified Bouncing Image Training Task (BITT']","['food craving and food intake', 'reduced attention to food cues']",[],"[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0872380', 'cui_str': 'Food craving'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0010439', 'cui_str': 'Cues'}]",,0.0216783,"It is concluded that the BITT is a promising procedure for directly manipulating individuals' attentional disengagement from food cues, though its capacity to enhance dieting success has not yet been established.","[{'ForeName': 'Nienke C', 'Initials': 'NC', 'LastName': 'Jonker', 'Affiliation': 'Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, the Netherlands. Electronic address: n.c.jonker@rug.nl.'}, {'ForeName': 'Janika', 'Initials': 'J', 'LastName': 'Heitmann', 'Affiliation': 'Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, the Netherlands; Verslavingszorg Noord-Nederland, Groningen, the Netherlands.'}, {'ForeName': 'Brian D', 'Initials': 'BD', 'LastName': 'Ostafin', 'Affiliation': 'Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, the Netherlands.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'MacLeod', 'Affiliation': 'School of Psychological Science, The University of Western Australia, Perth, Australia.'}, {'ForeName': 'Klaske A', 'Initials': 'KA', 'LastName': 'Glashouwer', 'Affiliation': 'Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, the Netherlands; Department of Eating Disorders, Accare Child and Adolescent Psychiatry, Groningen, the Netherlands.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'de Jong', 'Affiliation': 'Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, the Netherlands.'}]",Behaviour research and therapy,['10.1016/j.brat.2019.103445'] 2959,31958000,Effect of swimming program on glycemic control in male adolescents with type 1 diabetes mellitus.,"BACKGROUND Regular physical activity and exercise is the third management for the child with diabetes mellitus after diet regime and insulin therapy. The aim of the study is to evaluate the effect of swimming on glycemic control for a male adolescent with type 1 diabetes mellitus. The study evaluates the effect of swimming on glycemic control for a male adolescent with type 1 diabetes mellitus. METHODS The quasi-experimental design was conducted on 40 male adolescents with typ1 diabetes, then divided into two groups; study and control groups. 20 adolescents participated in the swimming program (study group) and other 20 did not expose to exercise program (control group) for 10 weeks. a venous blood sample was received to evaluate glycemic control (HbA1c %), in pre and post 10 weeks to compare HbA1c % for both groups. RESULTS Mean age 13.45±1.46 years (study group), while for control group age 13.55±1.5 years, and mean and standard deviation for Hba1c % was 9.61±1.15%, 9.65±2.23% in the study and control group respectively. The study showed that there was a high significant difference between pre and post-test HbA1c in the study group (P value<0.00) also the same result was observed in the control group but negatively (P value<0.00) it means the Hb1c % was raised. CONCLUSIONS The study concluded that regular physical activity (swimming) had a positive effect on lowering Glycosylated hemoglobin (HbA1c).",2020,The study concluded that regular physical activity (swimming) had a positive effect on lowering Glycosylated hemoglobin (HbA1c).,"['40 male adolescents with typ1 diabetes', 'child with diabetes mellitus after diet regime and insulin therapy', '20 adolescents participated in the', 'male adolescent with type 1 diabetes mellitus', 'male adolescents with Type 1 diabetes mellitus', 'Mean age 13.45 ±1.46 years (study group), while for control group age 13.55 ± 1.5 years, and mean and standard deviation for Hba1c % was 9.61 ± 1.15 %, 9.65 ± 2.23 % in the study and control group respectively']","['swimming program', 'regular physical activity (swimming', 'Regular physical activity and exercise', 'swimming program (study group) and other 20 did not expose to exercise program (control group']","['glycemic control', 'lowering Glycosylated hemoglobin (HbA1c']","[{'cui': 'C0001589', 'cui_str': 'Adolescents, Male'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C4517493', 'cui_str': '1.15'}]","[{'cui': 'C0039003', 'cui_str': 'Swimming'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}]",20.0,0.0181821,The study concluded that regular physical activity (swimming) had a positive effect on lowering Glycosylated hemoglobin (HbA1c).,"[{'ForeName': 'Kaify J', 'Initials': 'KJ', 'LastName': 'Qadir', 'Affiliation': 'Department of Pediatric Nursing Science, Hawler Medical University College of Nursing, Erbil, Iraq - Kaify.qadir@hmu.edu.krd.'}, {'ForeName': 'Kawes O', 'Initials': 'KO', 'LastName': 'Zangana', 'Affiliation': 'Departmeny of Pediatric Medicine, Hawler Medical University College of Medicine, Erbil, Iraq.'}]",The Journal of sports medicine and physical fitness,['10.23736/S0022-4707.19.10053-9'] 2960,32122717,Effects of spinal immobilization at 20° on end-tidal carbon dioxide.,"OBJECTIVE The aim was to determine the effect on end-tidal carbon dioxide (ETCO 2 ) of spinal immobilization (SI) at a conventional 0° angle and to investigate the usefulness of immobilization at a 20° angle for preventing possible hypoventilation. METHODS The study included 80 healthy volunteers, randomly divided into two groups. Spinal backboards and cervical collars were applied in Group 1 using a 0° angle and in Group 2 using a 20° angle, with the head up. SI was continued for 1 h, and ETCO 2 values were measured at the 0th, 30th and 60th minute. RESULTS There were no significant differences between the groups in 0th and 30th minute ETCO 2 . However, after 60th minute, results showed a statistically significant increase in ETCO 2 in Group 1 (35.5 mmHg [IQR 25-75:35-38]) compared to Group 2 (34 mmHg [IQR 25-75:33-36]) (p < 0.001). During SI, there was a statistically significant increase in ETCO 2 in Group 1 (35 mmHg [IQR 25-75:34-36], 35.5 mmHg [IQR 25-75:34-37] and 36 mmHg [IQR 25-75:35-38] respectively at the 0th, 30th and 60th minute after SI) (p < 0.001) and no change in Group 2. Also, we found statistically significant differences between ΔETCO 2 levels in Groups 1 and 2 at all 3 time intervals. CONCLUSION Conventional SI with an angle of 0° led to an increase in ETCO 2 while subjects immobilization at a 20° angle maintained their initial ETCO 2 values. Immobilization at 20° may prevent decompensation in patients who have thoracic trauma or lung diseases or those who are elderly, pregnant, or obese.",2020,"Also, we found statistically significant differences between ΔETCO 2 levels in Groups 1 and 2 at all 3 time intervals. ","['patients who have thoracic trauma or lung diseases or those who are elderly, pregnant, or obese', '80 healthy volunteers']","['tidal carbon dioxide (ETCO 2 ) of spinal immobilization (SI', 'Conventional SI', 'spinal immobilization']",['ETCO'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0024115', 'cui_str': 'Pulmonary Diseases'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0549206', 'cui_str': 'Pregnancy not delivered'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0020944', 'cui_str': 'Immobilization'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]",[],80.0,0.0267368,"Also, we found statistically significant differences between ΔETCO 2 levels in Groups 1 and 2 at all 3 time intervals. ","[{'ForeName': 'Seda', 'Initials': 'S', 'LastName': 'Dağar', 'Affiliation': 'Kecioren Training and Research Hospital, Department of Emergency Medicine, Ankara, Turkey. Electronic address: sedadagar@gmail.com.'}, {'ForeName': 'Şeref Kerem', 'Initials': 'ŞK', 'LastName': 'Çorbacıoğlu', 'Affiliation': 'Kecioren Training and Research Hospital, Department of Emergency Medicine, Ankara, Turkey.'}, {'ForeName': 'Emine', 'Initials': 'E', 'LastName': 'Emektar', 'Affiliation': 'Kecioren Training and Research Hospital, Department of Emergency Medicine, Ankara, Turkey.'}, {'ForeName': 'Hüseyin', 'Initials': 'H', 'LastName': 'Uzunosmanoğlu', 'Affiliation': 'Kecioren Training and Research Hospital, Department of Emergency Medicine, Ankara, Turkey.'}, {'ForeName': 'Yunsur', 'Initials': 'Y', 'LastName': 'Çevik', 'Affiliation': 'Kecioren Training and Research Hospital, Department of Emergency Medicine, Ankara, Turkey.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2020.02.042'] 2961,4564559,"Enteric immunization with live adenovirus type 21 vaccine. I. Tests for safety, infectivity, immunogenicity, and potency in volunteers.","Studies were undertaken in volunteers to determine whether living adenovirus type 21 (ADV-21) vaccine could be safely administered orally to susceptible young adults. In the first study, ten volunteers were fed 10(6.4) tissue culture infectious dose(50) (TCID(50)) of ADV-21 vaccine virus, and five received placebo tablets. Nine of ten infected volunteers shed ADV-21 in stools (mean duration, 10.1 days; range, 4 to 17 days). No pharyngeal excretion of ADV-21 was observed in any of these volunteers. Each of the nine developed type-specific neutralizing (N) antibodies to ADV-21. No evidence for person-to-person transmission of vaccine was observed. In a second study, volunteers were immunized with ADV-21 vaccines containing 10(6.8), 10(4.6), and 10(2.4) TCID(50). ADV-21 N antibody responses were detected in nine of eleven who received the highest dose, six of twelve who received the middle dose, and two of twelve who were fed the lowest dose. None of twelve susceptible volunteers receiving the placebo capsule developed ADV-21 N antibodies postimmunization. This study established that the human infectious dose(50) for these lots of ADV-21 vaccine was approximately 10(4.6) TCID(50) and that the dose response to ADV-21 vaccine was lower than those previously reported for live ADV-4 and ADV-7 enteric vaccines.",1972,None of twelve susceptible volunteers receiving the placebo capsule developed ADV-21 N antibodies postimmunization.,['volunteers'],"['ADV-21 vaccine virus, and five received placebo tablets', 'placebo', 'living adenovirus type 21 (ADV-21) vaccine', 'Enteric immunization with live adenovirus type 21 vaccine']","['ADV-21 in stools', 'pharyngeal excretion of ADV-21', 'ADV-21 N antibodies postimmunization', 'safety, infectivity, immunogenicity, and potency', 'ADV-21 N antibody responses']","[{'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0042776', 'cui_str': 'Virus'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0001483', 'cui_str': 'Adenoviruses'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0020971', 'cui_str': 'Sensitization, Immunologic'}]","[{'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030657', 'cui_str': 'infectivity'}, {'cui': 'C0003261', 'cui_str': 'Antibody Response'}]",10.0,0.0504493,None of twelve susceptible volunteers receiving the placebo capsule developed ADV-21 N antibodies postimmunization.,"[{'ForeName': 'B A', 'Initials': 'BA', 'LastName': 'Dudding', 'Affiliation': ''}, {'ForeName': 'P J', 'Initials': 'PJ', 'LastName': 'Bartelloni', 'Affiliation': ''}, {'ForeName': 'R M', 'Initials': 'RM', 'LastName': 'Scott', 'Affiliation': ''}, {'ForeName': 'F H', 'Initials': 'FH', 'LastName': 'Top', 'Affiliation': ''}, {'ForeName': 'P K', 'Initials': 'PK', 'LastName': 'Russell', 'Affiliation': ''}, {'ForeName': 'E L', 'Initials': 'EL', 'LastName': 'Buescher', 'Affiliation': ''}]",Infection and immunity,[] 2962,4218236,"Extracellular enzyme from Myxobacter AL-1 that exhibits both beta-1,4-glucanase and chitosanase activites.","An enzyme that has both beta-1,4-glucanase and chitosanase activities is characterized. Evidence for homogeneity was obtained from electrophoresis and sedimentation velocity studies; only one N-terminal amino acid, valine, was found. Results of denaturation studies showed that beta-1,4-glucanase and chitosanase activities decreased at equal rates. With carboxymethylcellulose as the substrate, a K(m) of 1.68 g of carboxymethylcellulose per liter of solution and a V(max) of 2.20 x 10(-9) mol/min were found. With chitosan (the beta-1,4-polymer of glucosamine) as the substrate, a K(m) of 0.30 g of chitosan per liter of solution and a V(max) of 0.75 x 10(-9) mol/min were found. A pH optimum of 5.0 was found for beta-1,4-glucanase activity, and pH optima of 5.0 and 6.8 were found for chitosanase activity. beta-1,4-Glucanase activity had a temperature optimum of 38 C, and chitosanase activity had a temperature optimum of 70 C. Chitosan stabilized both enzyme activities at 70 C. Cellotriose was the smallest polymer capable of hydrolysis. Glucosamine was released by action of the enzyme upon cell wall preparations of several fungi.",1974,"A pH optimum of 5.0 was found for beta-1,4-glucanase activity, and pH optima of 5.0 and 6.8 were found for chitosanase activity.",[],"['glucosamine', 'Glucosamine']","['beta-1,4-glucanase and chitosanase activities', 'beta-1,4-glucanase activity, and pH optima']",[],"[{'cui': 'C0017718', 'cui_str': 'Glucosamine'}]","[{'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0055320', 'cui_str': 'chitosanase'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",,0.0325754,"A pH optimum of 5.0 was found for beta-1,4-glucanase activity, and pH optima of 5.0 and 6.8 were found for chitosanase activity.","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Hedges', 'Affiliation': ''}, {'ForeName': 'R S', 'Initials': 'RS', 'LastName': 'Wolfe', 'Affiliation': ''}]",Journal of bacteriology,[] 2963,3771765,In vivo study of an antimicrobial surgical drape system.,"We performed a double-blind clinical study to determine the efficacy of nonwoven laparotomy drapes in which 3-(trimethoxysilyl)propyldimethyloctadecyl ammonium chloride, an antimicrobial agent, was chemically bonded to the absorbent reinforcement surrounding the fenestration. The reinforcement portion of the surgical drape that contained the fenestration was segmented into four identical-appearing sections, two on each side of the fenestration. One segment on each side was antimicrobial. The locations of the treated segments were randomly varied. At the end of each operation, test strips were removed. Bacteria were harvested from each segment by mechanical agitation. Bacterial CFU were counted. There were 110 surgical cases in the study, including clean, clean contaminated, and contaminated procedures. Data analysis divided the cases into two distinct groups. Group 1 was composed of 59 cases in which less than 30 total CFU was recovered from the four test samples. The average duration of surgery for this group was 1.8 h. Group 2 was composed of 51 cases in which bacterial recovery was in excess of 30 CFU per procedure (range, 30 to 25,000 bacterial CFU). The average duration of surgery was 3.3 h. Bacterial reduction in the treated strips was 84%. The most common organisms identified on the laparotomy drapes were Staphylococcus epidermidis, S. hominis, and Micrococcus luteus. This study demonstrated that the reinforcement of a laparotomy drape is a reservoir for potential pathogens. It demonstrated that an organosilicon quaternary ammonium antimicrobial agent covalently bonded to the reinforcement reduced the number of potential pathogens surrounding the surgical incision by 84%, independent of the size of the bacterial challenge.",1986,"The most common organisms identified on the laparotomy drapes were Staphylococcus epidermidis, S. hominis, and Micrococcus luteus.","['110 surgical cases in the study, including clean, clean contaminated, and contaminated procedures']",[],['average duration of surgery'],"[{'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0205279', 'cui_str': 'Contaminated (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}]",[],"[{'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]",,0.0231715,"The most common organisms identified on the laparotomy drapes were Staphylococcus epidermidis, S. hominis, and Micrococcus luteus.","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Conn', 'Affiliation': ''}, {'ForeName': 'J W', 'Initials': 'JW', 'LastName': 'Bornhoeft', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Almgren', 'Affiliation': ''}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Mucha', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Olderman', 'Affiliation': ''}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Patel', 'Affiliation': ''}, {'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Herring', 'Affiliation': ''}]",Journal of clinical microbiology,[] 2964,32098534,2-year results of an RCT of 2 uncemented isoelastic monoblock acetabular components: lower wear rate with vitamin E blended highly cross-linked polyethylene compared to ultra-high molecular weight polyethylene.,"Background and purpose - The long-term survival of arthroplasty components may be limited by polyethylene wear-related problems such as periprosthetic osteolysis and aseptic loosening. Highly cross-linked polyethylene (HXLPE) blended with vitamin E was introduced to improve oxidative stability and to avoid long-term embrittlement. This study clinically compares the tribological behavior and clinical outcome of vitamin E blended HXLPE with ultra-high molecular weight polyethylene (UHMWPE) in an isoelastic monoblock cup for uncemented total hip arthroplasty. Patients and methods - In this randomized controlled trial (RCT), 199 patients were included: 102 patients received the vitamin E blended HXLPE cup, 97 patients the UHMWPE cup. Clinical and radiographic parameters were obtained preoperatively, directly postoperative and at 3, 12, and 24 months. Wear rates were compared using the mean linear femoral head penetration (FHP) rate. Results - 188 patients (94%) completed the 2-year follow-up. Mean patient satisfaction was higher in the vitamin E blended HXLPE group (8.9 [1]) than in in the control group (8.5 [2], p = 0.03). The Harris Hip Score (HHS) was higher in the vitamin E blended HXLPE group (95 [8]) than in the control group (92 [11], p = 0.3). The FHP rate was lower in the vitamin E blended HXLPE group: 0.046 mm/year compared with 0.056 mm/year in the control group (p = 0.05). No adverse reactions associated with the clinical application of vitamin E blended HXLPE were observed during follow-up, with an excellent 2-year survival to revision rate of 98% for both cups. Interpretation - This study shows the superior performance of the HXLPE blended with vitamin E acetabular cup with lower linear femoral head penetration rates and better clinical results compared with the UHMWPE acetabular cup after 2 years.",2020,The FHP rate was lower in the vitamin E blended HXLPE group: 0.046 mm/year compared with 0.056 mm/year in the control group (p = 0.05).,"['199 patients were included: 102 patients received the', 'uncemented total hip arthroplasty']","['HXLPE blended with vitamin E acetabular cup', 'vitamin E blended HXLPE', 'Highly cross-linked polyethylene (HXLPE) blended with vitamin E', 'RCT', 'vitamin E blended HXLPE cup', 'vitamin E blended HXLPE with ultra-high molecular weight polyethylene (UHMWPE', 'vitamin E', 'UHMWPE acetabular cup']","['Mean patient satisfaction', '2-year survival to revision rate', 'FHP rate', 'oxidative stability', 'Harris Hip Score (HHS', 'Wear rates']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0186193', 'cui_str': 'Arthroplasty of coxofemoral joint'}]","[{'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C2949743', 'cui_str': 'Cup - unit of product usage'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0137914', 'cui_str': 'Polythene'}, {'cui': 'C0673477', 'cui_str': 'UHMWPE'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0439617', 'cui_str': 'Revision - value'}, {'cui': 'C2919875', 'cui_str': 'Harris hip score (observable entity)'}]",199.0,0.144797,The FHP rate was lower in the vitamin E blended HXLPE group: 0.046 mm/year compared with 0.056 mm/year in the control group (p = 0.05).,"[{'ForeName': 'Joost H J', 'Initials': 'JHJ', 'LastName': 'van Erp', 'Affiliation': 'Clinical Orthopedic Research Center-mN, Zeist, the Netherlands.'}, {'ForeName': 'Julie R A', 'Initials': 'JRA', 'LastName': 'Massier', 'Affiliation': 'Clinical Orthopedic Research Center-mN, Zeist, the Netherlands.'}, {'ForeName': 'Jelle J', 'Initials': 'JJ', 'LastName': 'Halma', 'Affiliation': 'Clinical Orthopedic Research Center-mN, Zeist, the Netherlands.'}, {'ForeName': 'Thom E', 'Initials': 'TE', 'LastName': 'Snijders', 'Affiliation': 'Clinical Orthopedic Research Center-mN, Zeist, the Netherlands.'}, {'ForeName': 'Arthur', 'Initials': 'A', 'LastName': 'de Gast', 'Affiliation': 'Clinical Orthopedic Research Center-mN, Zeist, the Netherlands.'}]",Acta orthopaedica,['10.1080/17453674.2020.1730073'] 2965,32092190,"Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease.","BACKGROUND Sleep dysfunction is common and disabling in persons with Parkinson's Disease (PD). Exercise improves motor symptoms and subjective sleep quality in PD, but there are no published studies evaluating the impact of exercise on objective sleep outcomes. The goal of this study was to to determine if high-intensity exercise rehabilitation combining resistance training and body-weight interval training, compared with a sleep hygiene control improved objective sleep outcomes in PD. METHODS Persons with PD (Hoehn & Yahr stages 2-3; aged ≥45 years, not in a regular exercise program) were randomized to exercise (supervised 3 times a week for 16 weeks; n = 27) or a sleep hygiene, no-exercise control (in-person discussion and monthly phone calls; n = 28). Participants underwent polysomnography at baseline and post-intervention. Change in sleep efficiency was the primary outcome, measured from baseline to post-intervention. Intervention effects were evaluated with general linear models with measurement of group × time interaction. As secondary outcomes, we evaluated changes in other aspects of sleep architecture and compared the effects of acute and chronic training on objective sleep outcomes. RESULTS The exercise group showed significant improvement in sleep efficiency compared with the sleep hygiene group (group × time interaction: F = 16.0, P < 0.001, d = 1.08). Other parameters of sleep architecture also improved in exercise compared with sleep hygiene, including total sleep time, wake after sleep onset, and slow-wave sleep. Chronic but not acute exercise improved sleep efficiency compared with baseline. CONCLUSIONS High-intensity exercise rehabilitation improves objective sleep outcomes in PD. Exercise is an effective nonpharmacological intervention to improve this disabling nonmotor symptom in PD. © 2020 International Parkinson and Movement Disorder Society.",2020,"Other parameters of sleep architecture also improved in exercise compared with sleep hygiene, including total sleep time, wake after sleep onset, and slow-wave sleep.","['Persons with PD (Hoehn & Yahr stages 2-3; aged ≥45\u2009years, not in a regular exercise program', ""Parkinson's Disease"", 'PD', ""persons with Parkinson's Disease (PD""]","['Exercise', 'High-intensity exercise rehabilitation', 'sleep hygiene, no-exercise control', 'high-intensity exercise rehabilitation combining resistance training and body-weight interval training']","['total sleep time, wake after sleep onset, and slow-wave sleep', 'Objective and Subjective Sleep', 'sleep efficiency', 'motor symptoms and subjective sleep quality', 'objective sleep outcomes']","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0582191', 'cui_str': 'Regular exercise (observable entity)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C4277672', 'cui_str': 'Sleep Hygiene'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0442696', 'cui_str': 'Waking (observable entity)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0234451', 'cui_str': 'Sleep, Slow-Wave'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}]",,0.070578,"Other parameters of sleep architecture also improved in exercise compared with sleep hygiene, including total sleep time, wake after sleep onset, and slow-wave sleep.","[{'ForeName': 'Amy W', 'Initials': 'AW', 'LastName': 'Amara', 'Affiliation': 'Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Kimberly H', 'Initials': 'KH', 'LastName': 'Wood', 'Affiliation': 'Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Allen', 'Initials': 'A', 'LastName': 'Joop', 'Affiliation': 'Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Raima A', 'Initials': 'RA', 'LastName': 'Memon', 'Affiliation': 'Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Pilkington', 'Affiliation': 'Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'S Craig', 'Initials': 'SC', 'LastName': 'Tuggle', 'Affiliation': 'UAB Center for Exercise Medicine. Birmingham, Alabama, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Reams', 'Affiliation': 'UAB Center for Exercise Medicine. Birmingham, Alabama, USA.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Barrett', 'Affiliation': 'Department of Neurology, University of Virginia, Charlottesville, Virginia, USA.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Edwards', 'Affiliation': 'Department of Kinesiology, University of Virginia, Charlottesville, Virginia, USA.'}, {'ForeName': 'Arthur L', 'Initials': 'AL', 'LastName': 'Weltman', 'Affiliation': 'Department of Kinesiology, University of Virginia, Charlottesville, Virginia, USA.'}, {'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Hurt', 'Affiliation': 'UAB Center for Exercise Medicine. Birmingham, Alabama, USA.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Cutter', 'Affiliation': 'UAB Center for Exercise Medicine. Birmingham, Alabama, USA.'}, {'ForeName': 'Marcas M', 'Initials': 'MM', 'LastName': 'Bamman', 'Affiliation': 'Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}]",Movement disorders : official journal of the Movement Disorder Society,['10.1002/mds.28009'] 2966,3417354,Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines.,"The clinical and immunological responses to typhoid vaccination with parenteral (TAB) and oral (Ty21a) vaccines in two groups of 30 adult male subjects were studied. Parameters monitored included specific anti-Salmonella typhi cell-mediated immunity and total and specific antilipopolysaccharide fecal immunoglobulin A (IgA) titers in Ty21a-vaccinated subjects. Peripheral blood lymphocytes antibacterial activity was significantly increased only in Ty21a-vaccinated subjects. Serum arming activity and results of human F(ab')2 anti-IgG and -IgA inhibition tests suggest antibody-dependent cellular cytotoxicity mediated by IgA in those vaccinated with Ty21a. Interestingly enough, the cells of TAB-vaccinated subjects were able to mediate IgG-dependent cellular cytotoxicity, as was observable from the results of blocking experiments. Moreover, total and specific antilipopolysaccharide fecal IgA levels were observed to be significantly increased with Ty21a, up to 8 months post-vaccination schedule. An early-onset, transitory increase in serum IgM rheumatoid factor was also found, exclusively in subjects treated with TAB, and was no longer detectable on day 240. Ty21a was well tolerated and free of side effects, whereas 65% of subjects administered TAB reported fever, headache, malaise, and local tenderness at the injection site. Our data show that the two typhoid vaccines induce different cell-mediated specific immune responses. The role of these responses in protection against Salmonella infection, however, requires further investigation.",1988,Parameters monitored included specific anti-Salmonella typhi cell-mediated immunity and total and specific antilipopolysaccharide fecal immunoglobulin A (IgA) titers in Ty21a-vaccinated subjects.,"['two groups of 30 adult male subjects', 'Ty21a-vaccinated subjects']","['typhoid vaccination with parenteral (TAB) and oral (Ty21a) vaccines', 'oral (Ty21a) and parenteral (TAB) typhoid vaccines']","['total and specific antilipopolysaccharide fecal IgA levels', 'tolerated and free of side effects', 'specific anti-Salmonella typhi cell-mediated immunity and total and specific antilipopolysaccharide fecal immunoglobulin A (IgA) titers', 'Peripheral blood lymphocytes antibacterial activity', 'fever, headache, malaise, and local tenderness', 'serum IgM rheumatoid factor']","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0199801', 'cui_str': 'Typhoid vaccination (procedure)'}, {'cui': 'C4522267', 'cui_str': 'Parenteral (intended site)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0041469', 'cui_str': 'Vaccines, Typhoid'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0332296', 'cui_str': 'Free of (attribute)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0036125', 'cui_str': 'Salmonella typhosa'}, {'cui': 'C0020966', 'cui_str': 'Cell-Mediated Immunity'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood (substance)'}, {'cui': 'C4018897', 'cui_str': 'Lymphocyte component of blood'}, {'cui': 'C0279516', 'cui_str': 'Anti-Bacterial Agents'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0231218', 'cui_str': 'Undifferentiated illness: Vague ill health'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0234233', 'cui_str': 'Tenderness (finding)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0020861', 'cui_str': 'IgM'}, {'cui': 'C0201660', 'cui_str': 'Rheumatoid factor measurement (procedure)'}]",30.0,0.0209773,Parameters monitored included specific anti-Salmonella typhi cell-mediated immunity and total and specific antilipopolysaccharide fecal immunoglobulin A (IgA) titers in Ty21a-vaccinated subjects.,"[{'ForeName': 'R', 'Initials': 'R', 'LastName': ""D'Amelio"", 'Affiliation': 'Aeronautica Militare, D.A.S.R.S., Rep. Medicina, Pratica di Mare, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Tagliabue', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Nencioni', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Di Addario', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Villa', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Manganaro', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Boraschi', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Le Moli', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Nisini', 'Affiliation': ''}, {'ForeName': 'P M', 'Initials': 'PM', 'LastName': 'Matricardi', 'Affiliation': ''}]",Infection and immunity,[] 2967,3497943,Commercial latex agglutination tests for detection of Haemophilus influenzae type b and Streptococcus pneumoniae antigens in patients with bacteremic pneumonia.,"The validity of commercial latex agglutination kits for detection of Haemophilus influenzae type b and Streptococcus pneumoniae antigens in serum and urine specimens was studied. We tested serum and urine specimens from 44 patients with bacteremic pneumonia (23 S. pneumoniae, 13 H. influenzae type b, 11 other) with commercial latex agglutination kits (Directigen, Bactigen) for S. pneumoniae and H. influenzae type b antigens. All specimen samples were randomized and read blindly by two readers. Interreader reproducibility was 100%. The sensitivity and specificity of both kits for H. influenzae type b antigens in serum and urine were greater than 90%. None of the 24 urine samples from S. pneumoniae bacteremic patients were positive by either kit, although 6 ng of type 3 polysaccharide could be detected in spiked urine. Sensitivity for S. pneumoniae antigens in serum was 27% for Directigen and 38% for Bactigen. Specificity for S. pneumoniae antigens in serum was 95% for Directigen and 74% for Bactigen. The results suggest that the kits are useful in diagnosing H. influenzae type b pneumonia. However, the commercially available S. pneumoniae reagents tested appear to have limited utility for diagnosing S. pneumoniae pneumonia because both kits lack sensitivity and Bactigen lacks specificity, as well.",1987,The sensitivity and specificity of both kits for H. influenzae type b antigens in serum and urine were greater than 90%.,"['44 patients with bacteremic pneumonia (23 S. pneumoniae, 13 H. influenzae type b, 11 other) with commercial latex agglutination kits (Directigen, Bactigen) for S. pneumoniae and H. influenzae type b antigens', 'patients with bacteremic pneumonia']","['commercial latex agglutination kits', 'Commercial latex agglutination tests']","['sensitivity and specificity', 'Interreader reproducibility']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0023117', 'cui_str': 'Latex Agglutination Tests'}, {'cui': 'C0368721', 'cui_str': 'Blood group antigen B (substance)'}]","[{'cui': 'C0023117', 'cui_str': 'Latex Agglutination Tests'}, {'cui': 'C1690540', 'cui_str': 'Kit'}]","[{'cui': 'C0036668', 'cui_str': 'Sensitivity and Specificity'}]",44.0,0.0385081,The sensitivity and specificity of both kits for H. influenzae type b antigens in serum and urine were greater than 90%.,"[{'ForeName': 'G W', 'Initials': 'GW', 'LastName': 'Ajello', 'Affiliation': ''}, {'ForeName': 'G A', 'Initials': 'GA', 'LastName': 'Bolan', 'Affiliation': ''}, {'ForeName': 'P S', 'Initials': 'PS', 'LastName': 'Hayes', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Lehmann', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Montgomery', 'Affiliation': ''}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Feeley', 'Affiliation': ''}, {'ForeName': 'C A', 'Initials': 'CA', 'LastName': 'Perlino', 'Affiliation': ''}, {'ForeName': 'C V', 'Initials': 'CV', 'LastName': 'Broome', 'Affiliation': ''}]",Journal of clinical microbiology,[] 2968,32077361,"Randomized phase 1 study of sequential (""primed"") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.",,2020,,['adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm'],"['sequential (""primed"") vs. concurrent decitabine', 'cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M']",[],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0023467', 'cui_str': 'Nonlymphoblastic Leukemia, Acute'}, {'cui': 'C1962917', 'cui_str': 'High grade (lymphoma)'}, {'cui': 'C2939461', 'cui_str': 'Myeloid neoplasm'}]","[{'cui': 'C0205420', 'cui_str': 'Concurrent (qualifier value)'}, {'cui': 'C0049065', 'cui_str': 'decitabine'}, {'cui': 'C0092801', 'cui_str': 'Cladribine'}, {'cui': 'C0010711', 'cui_str': 'Cytarabine'}, {'cui': 'C0079459', 'cui_str': 'G-CSF'}, {'cui': 'C0026259', 'cui_str': 'Mitoxantrone'}]",[],,0.0417158,,"[{'ForeName': 'Raffaele', 'Initials': 'R', 'LastName': 'Palmieri', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'Buckley', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Othus', 'Affiliation': 'Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Anna B', 'Initials': 'AB', 'LastName': 'Halpern', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Mary-Elizabeth M', 'Initials': 'MM', 'LastName': 'Percival', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Bart L', 'Initials': 'BL', 'LastName': 'Scott', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'Hendrie', 'Affiliation': 'Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Pamela S', 'Initials': 'PS', 'LastName': 'Becker', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Vivian G', 'Initials': 'VG', 'LastName': 'Oehler', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Elihu H', 'Initials': 'EH', 'LastName': 'Estey', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Roland B', 'Initials': 'RB', 'LastName': 'Walter', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}]",Leukemia & lymphoma,['10.1080/10428194.2020.1728754'] 2969,30964750,A strengths-based case management intervention to link HIV-positive people who inject drugs in Russia to HIV care.,"OBJECTIVE To determine whether the Linking Infectious and Narcology Care strengths-based case management intervention was more effective than usual care for linking people who inject drugs (PWID) to HIV care and improving HIV outcomes. DESIGN Two-armed randomized controlled trial. SETTING Participants recruited from a narcology hospital in St. Petersburg, Russia. PARTICIPANTS A total of 349 HIV-positive PWID not on antiretroviral therapy (ART). INTERVENTION Strengths-based case management over 6 months. MAIN OUTCOME MEASURES Primary outcomes were linkage to HIV care and improved CD4 cell count. We performed adjusted logistic and linear regression analyses controlling for past HIV care using the intention-to-treat approach. RESULTS Participants (N = 349) had the following baseline characteristics: 73% male, 12% any past ART use, and median values of 34.0 years of age and CD4 cell count 311 cells/μl. Within 6 months of enrollment 51% of the intervention group and 31% of controls linked to HIV care (adjusted odds ratio 2.34; 95% confidence interval: 1.49-3.67; P < 0.001). Mean CD4 cell count at 12 months was 343 and 354 cells/μl in the intervention and control groups, respectively (adjusted ratio of means 1.14; 95% confidence interval: 0.91, 1.42, P = 0.25). CONCLUSION The Linking Infectious and Narcology Care strengths-based case management intervention was more effective than usual care in linking Russian PWID to HIV care, but did not improve CD4 cell count, likely due to low overall ART initiation. Although case management can improve linkage to HIV care, specific approaches to initiate and adhere to ART are needed to improve clinical outcomes (e.g., increased CD4 cell count) in this population.",2019,"The Linking Infectious and Narcology Care strengths-based case management intervention was more effective than usual care in linking Russian PWID to HIV care, but did not improve CD4 cell count, likely due to low overall ART initiation.","['Participants (N\u200a=\u200a349) had the following baseline characteristics: 73% male, 12% any past ART use, and median values of 34.0 years of age and CD4 cell count 311\u200acells/μl', 'A total of 349 HIV-positive PWID not on antiretroviral therapy (ART', 'HIV-positive people who inject drugs in Russia to HIV care', 'Participants recruited from a narcology hospital in St. Petersburg, Russia']",['strengths-based case management intervention'],"['Mean CD4 cell count', 'linkage to HIV care and improved CD4 cell count', 'HIV care', 'CD4 cell count']","[{'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C4521936', 'cui_str': 'Inject (administration method)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0035970', 'cui_str': 'Russian Federation (Europe)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}]","[{'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0085971', 'cui_str': 'Case Management'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}]",349.0,0.160116,"The Linking Infectious and Narcology Care strengths-based case management intervention was more effective than usual care in linking Russian PWID to HIV care, but did not improve CD4 cell count, likely due to low overall ART initiation.","[{'ForeName': 'Jeffrey H', 'Initials': 'JH', 'LastName': 'Samet', 'Affiliation': 'Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine/Boston Medical Center.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Blokhina', 'Affiliation': 'First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation.'}, {'ForeName': 'Debbie M', 'Initials': 'DM', 'LastName': 'Cheng', 'Affiliation': 'Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.'}, {'ForeName': 'Alexander Y', 'Initials': 'AY', 'LastName': 'Walley', 'Affiliation': 'Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine/Boston Medical Center.'}, {'ForeName': 'Dmitry', 'Initials': 'D', 'LastName': 'Lioznov', 'Affiliation': 'First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Gnatienko', 'Affiliation': 'Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center.'}, {'ForeName': 'Emily K', 'Initials': 'EK', 'LastName': 'Quinn', 'Affiliation': 'Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health.'}, {'ForeName': 'Carly', 'Initials': 'C', 'LastName': 'Bridden', 'Affiliation': 'Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center.'}, {'ForeName': 'Christine E', 'Initials': 'CE', 'LastName': 'Chaisson', 'Affiliation': 'Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Toussova', 'Affiliation': 'First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation.'}, {'ForeName': 'Allen L', 'Initials': 'AL', 'LastName': 'Gifford', 'Affiliation': 'Boston University Schools of Medicine and Public Health.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Raj', 'Affiliation': 'Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine/Boston Medical Center.'}, {'ForeName': 'Evgeny', 'Initials': 'E', 'LastName': 'Krupitsky', 'Affiliation': 'First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation.'}]","AIDS (London, England)",['10.1097/QAD.0000000000002230'] 2970,32077300,Development of a Wellness Committee Implementation Index for Workplace Health Promotion Programs in Small Businesses.,"PURPOSE To construct a wellness committee (WC) implementation index and determine whether this index was associated with evidence-based intervention implementation in a workplace health promotion program. DESIGN Secondary data analysis of the HealthLinks randomized controlled trial. SETTING Small businesses assigned to the HealthLinks plus WC study arm. SAMPLE Small businesses (20-200 employees, n = 23) from 6 low-wage industries in King County, Washington. MEASURES Wellness committee implementation index (0%-100%) and evidence-based intervention implementation (0%-100%). ANALYSIS We used descriptive and bivariate statistics to describe worksites' organizational characteristics. For the primary analyses, we used generalized estimating equations with robust standard errors to assess the association between WC implementation index and evidence-based intervention implementation over time. RESULTS Average WC implementation index scores were 60% at 15 months and 38% at 24 months. Evidence-based intervention scores among worksites with WCs were 27% points higher at 15 months (64% vs 37%, P < .001) and 36% points higher at 24 months (55% vs 18%, P < .001). Higher WC implementation index scores were positively associated with evidence-based intervention implementation scores over time ( P < .001). CONCLUSION Wellness committees may play an essential role in supporting evidence-based intervention implementation among small businesses. Furthermore, the degree to which these WCs are engaged and have leadership support, a set plan or goals, and multilevel participation may influence evidence-based intervention implementation and maintenance over time.",2020,"Higher WC implementation index scores were positively associated with evidence-based intervention implementation scores over time ( P < .001). ","['Small Businesses', 'Small businesses assigned to the HealthLinks plus WC study arm', 'SAMPLE\n\n\nSmall businesses (20-200 employees, n = 23) from 6 low-wage industries in King County, Washington']",[],"['Average WC implementation index scores', 'Higher WC implementation index scores']","[{'cui': 'C2936313', 'cui_str': 'Microenterprise'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0599987', 'cui_str': 'Employee (person)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0036064', 'cui_str': 'Wages'}, {'cui': 'C0021267', 'cui_str': 'Industry'}, {'cui': 'C0454792', 'cui_str': 'Offaly (geographic location)'}, {'cui': 'C0043038', 'cui_str': 'Washington'}]",[],"[{'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]",,0.0927082,"Higher WC implementation index scores were positively associated with evidence-based intervention implementation scores over time ( P < .001). ","[{'ForeName': 'Meagan C', 'Initials': 'MC', 'LastName': 'Brown', 'Affiliation': 'Department of Health Services, School of Public Health, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Jeffrey R', 'Initials': 'JR', 'LastName': 'Harris', 'Affiliation': 'Department of Health Services, School of Public Health, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Hammerback', 'Affiliation': 'Department of Health Services, School of Public Health, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Marlana J', 'Initials': 'MJ', 'LastName': 'Kohn', 'Affiliation': 'Department of Health Services, School of Public Health, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Amanda T', 'Initials': 'AT', 'LastName': 'Parrish', 'Affiliation': 'Department of Health Services, School of Public Health, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Gary K', 'Initials': 'GK', 'LastName': 'Chan', 'Affiliation': 'Department of Health Services, School of Public Health, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'India J', 'Initials': 'IJ', 'LastName': 'Ornelas', 'Affiliation': 'Department of Health Services, School of Public Health, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Christian D', 'Initials': 'CD', 'LastName': 'Helfrich', 'Affiliation': 'Department of Health Services, School of Public Health, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Peggy A', 'Initials': 'PA', 'LastName': 'Hannon', 'Affiliation': 'Department of Health Services, School of Public Health, University of Washington, Seattle, WA, USA.'}]",American journal of health promotion : AJHP,['10.1177/0890117120906967'] 2971,32076564,Cost-utility analysis of learning and coping versus standard education in cardiac rehabilitation: a randomised controlled trial with 3 years of follow-up.,"Objectives To enhance adherence to cardiac rehabilitation (CR), a patient education programme called 'learning and coping' (LC-programme) was implemented in three hospitals in Denmark. The aim of this study was to investigate the cost-utility of the LC-programme compared with the standard CR-programme. Methods 825 patients with ischaemic heart disease or heart failure were randomised to the LC-programme or the standard CR-programme and were followed for 3 years.A societal cost perspective was applied and quality-adjusted life years (QALY) were based on SF-6D measurements. Multiple imputation technique was used to handle missing data on the SF-6D. The statistical analyses were based on means and bootstrapped SEs. Regression framework was employed to estimate the net benefit and to illustrate cost-effectiveness acceptability curves. Results No statistically significant differences were found between the two programmes in total societal costs (4353 Euros; 95% CI -3828 to 12 533) or in QALY (-0.006; 95% CI -0.053 to 0.042). At a threshold of 40 000 Euros, the LC-programme was found to be cost-effective at 15% probability; however, for patients with heart failure, due to increased cost savings, the probability of cost-effectiveness increased to 91%. Conclusions While the LC-programme did not appear to be cost-effective in CR, important heterogeneity was noted for subgroups of patients. The LC-programme was demonstrated to increase adherence to the rehabilitation programme and to be cost-effective among patients with heart failure. However, further research is needed to study the dynamic value of heterogeneity due to the small sample size in this subgroup.",2020,The LC-programme was demonstrated to increase adherence to the rehabilitation programme and to be cost-effective among patients with heart failure.,"['825 patients with ischaemic heart disease or heart failure', 'patients with heart failure', 'cardiac rehabilitation']","['learning and coping versus standard education', 'LC-programme or the standard CR-programme', ""cardiac rehabilitation (CR), a patient education programme called 'learning and coping' (LC-programme"", 'LC-programme']","['total societal costs', 'cost savings, the probability of cost-effectiveness', 'cost-utility']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0151744', 'cui_str': 'Ischemic Heart Disease'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0700431', 'cui_str': 'Cardiovascular Rehabilitation'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0700431', 'cui_str': 'Cardiovascular Rehabilitation'}, {'cui': 'C0030688', 'cui_str': 'Education of Patients'}, {'cui': 'C1720420', 'cui_str': 'Call'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0085550', 'cui_str': 'Saving, Cost'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",825.0,0.0314959,The LC-programme was demonstrated to increase adherence to the rehabilitation programme and to be cost-effective among patients with heart failure.,"[{'ForeName': 'Nasrin', 'Initials': 'N', 'LastName': 'Tayyari Dehbarez', 'Affiliation': 'DEFACTUM, Aarhus N, Denmark.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Palmhøj Nielsen', 'Affiliation': 'DEFACTUM, Aarhus N, Denmark.'}, {'ForeName': 'Bettine Wulff', 'Initials': 'BW', 'LastName': 'Risør', 'Affiliation': 'DEFACTUM, Aarhus N, Denmark.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Vinther Nielsen', 'Affiliation': 'DEFACTUM, Aarhus N, Denmark.'}, {'ForeName': 'Vibeke', 'Initials': 'V', 'LastName': 'Lynggaard', 'Affiliation': 'Department of Cardiology, Regional Hospital West Jutland, Herning, Denmark.'}]",Open heart,['10.1136/openhrt-2019-001184'] 2972,31213040,Is breakthrough pain better managed by adding programmed intermittent epidural bolus to a background infusion during labor epidural analgesia? A randomized controlled trial.,"BACKGROUND Breakthrough pain (BTP) is a common problem during labor analgesia. Programmed intermittent epidural bolus (PIEB) has demonstrated superior to background epidural infusion (BEI) concerning BTP, but the effect of combining both modes remains unknown. We hypothesized that this combination could reduce BTP incidence. METHODS Nulliparous parturients with early cervical dilation were randomized to receive 5 mL/h BEI of levobupivacaine 0.125% plus fentanyl 1.45 µg/mL (standard group) or 5 mL/h BEI + 10 mL/h PIEB (PIEB group). In case of BTP, patient-controlled epidural analgesia (PCEA) boluses of 10 mL (20-min lockout interval) were administered. If PCEA was insufficient, a 10-mL clinician bolus was delivered. The primary endpoint was the percentage of parturients who required supplementary epidural boluses. RESULTS One hundred and twenty women were recruited. Eighty-nine percent of parturients required supplementary boluses in standard group versus 30% in PIEB group (RR=3.07; 95% CI: 1.99-4.76; P<0.001). Adding PIEB prevented BTP in 70% of cases. Duration of effective analgesia was longer in PIEB than in standard group (P=0.003). Supplementary boluses were decreased (P<0.001), while local anesthetic consumption increased (P<0.001) by PIEB addition. Sensory-motor block, mode of delivery, maternal satisfaction and neonatal outcomes were equally distributed in both groups. CONCLUSIONS Adding PIEB to BEI+PCEA improved labor analgesia by significantly reducing the needs of rescue analgesia and prolonging the duration of effective analgesia. This combination provoked a higher consumption of local anesthetic with no detected clinical consequences.",2019,"Supplementary boluses were decreased (P<0.001), while local anesthetic consumption increased (P<0.001) by PIEB addition.","['120 women were recruited', 'Nulliparous parturients with early cervical dilation']",['5 mL/h BEI of levobupivacaine 0.125% plus fentanyl 1.45 μg/mL (standard group) or 5 mL/h BEI + 10 mL/h PIEB (PIEB'],"['Sensory-motor block, mode of delivery, maternal satisfaction and neonatal outcomes', 'duration of effective analgesia', 'percentage of parturients who required supplementary epidural boluses', 'local anesthetic consumption', 'BTP incidence', 'labor analgesia', 'Duration of effective analgesia']","[{'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0425979', 'cui_str': 'Nulliparous (finding)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0205064', 'cui_str': 'Cervical (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}]","[{'cui': 'C0439391', 'cui_str': 'mL/h'}, {'cui': 'C0873118', 'cui_str': 'Levobupivacaine'}, {'cui': 'C4517427', 'cui_str': '0.125 (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C4517505', 'cui_str': '1.45'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0445254', 'cui_str': 'Sensory (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia (procedure)'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0022864', 'cui_str': 'Labor, Obstetric'}]",120.0,0.379791,"Supplementary boluses were decreased (P<0.001), while local anesthetic consumption increased (P<0.001) by PIEB addition.","[{'ForeName': 'Luis D', 'Initials': 'LD', 'LastName': 'Diez-Picazo', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Treatment, La Paz University Hospital, Madrid, Spain - doclddp@gmail.com.'}, {'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Guasch', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Treatment, La Paz University Hospital, Madrid, Spain.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Brogly', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Treatment, La Paz University Hospital, Madrid, Spain.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Gilsanz', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Treatment, La Paz University Hospital, Madrid, Spain.'}]",Minerva anestesiologica,['10.23736/S0375-9393.19.13470-0'] 2973,31371795,Efficacy of novel small-quantity lipid-based nutrient supplements in improving long-chain polyunsaturated fatty acid status of South African infants: a randomised controlled trial.,"BACKGROUND/OBJECTIVES The objective of this study was to investigate the efficacy of small-quantity lipid-based nutrient supplements (SQ-LNS) containing essential fatty acids (EFAs) with or without long-chain polyunsaturated fatty acids (LCPUFAs) in improving LCPUFA status in South African infants fed complementary food. SUBJECTS/METHODS Six-month-old infants (n = 750) were randomised to receive SQ-LNS, SQ-LNS-plus, or no supplement. Both SQ-LNSs contained micronutrients and EFAs. SQ-LNS-plus additionally contained the LCPUFAs arachidonic acid (AA) and docosahexaenoic acid (DHA), lysine, phytase and other nutrients. Plasma total phospholipid FA composition (% of total FAs) was measured at baseline (n = 353) and at 12 months (n = 293). RESULTS At baseline, geometric mean (95% CI) plasma DHA and AA were 4.1 (4.0-4.3) and 11.5 (11.2-11.8)% respectively, with significantly higher plasma DHA and AA in breastfed than non-breastfed infants. Infants receiving the SQ-LNS-plus had significantly higher plasma DHA (4.52 (4.3-4.9)) at 12 months than the controls (3.8 (3.6-4.0)), with a higher effect size in infants who no longer received breast milk (β = 1.148 (95% CI = 0.597, 1.699)) than in infants who were still breastfeeding (β = 0.544 (95% CI = 0.179, 0.909)). There was no effect of either of the two SQ-LNSs on plasma AA. Consequently, infants receiving the SQ-LNS-plus had a significantly lower plasma n-6 to n-3 PUFA ratio at 12 months than control infants did. CONCLUSIONS Our study suggests that the provision of SQ-LNS-plus is efficacious in improving plasma DHA status. Particularly, infants who are no longer breastfed may benefit most from LCPUFA-enriched SQ-LNS.",2020,"Infants receiving the SQ-LNS-plus had significantly higher plasma DHA (4.52 (4.3-4.9)) at 12 months than the controls (3.8 (3.6-4.0)), with a higher effect size in infants who no longer received breast milk (β = 1.148 (95% CI = 0.597, 1.699)) than in infants who were still breastfeeding (β = 0.544 (95% CI = 0.179, 0.909)).","['Six-month-old infants (n\u2009=\u2009750', 'South African infants fed complementary food', 'South African infants']","['SQ-LNS, SQ-LNS-plus, or no supplement', 'SQ-LNS-plus additionally contained the LCPUFAs arachidonic acid (AA) and docosahexaenoic acid (DHA), lysine, phytase and other nutrients', 'small-quantity lipid-based nutrient supplements (SQ-LNS) containing essential fatty acids (EFAs) with or without long-chain polyunsaturated fatty acids (LCPUFAs', 'novel small-quantity lipid-based nutrient supplements']","['plasma AA', 'plasma n-6 to n-3 PUFA ratio', 'plasma DHA and AA', 'plasma DHA', 'Plasma total phospholipid FA composition']","[{'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C4517868', 'cui_str': '750 (qualifier value)'}, {'cui': 'C2987508', 'cui_str': 'Feeding (observable entity)'}, {'cui': 'C0016452', 'cui_str': 'Food'}]","[{'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0003701', 'cui_str': 'Arachidonic Acids'}, {'cui': 'C0556150', 'cui_str': 'docosahexaenoic acid'}, {'cui': 'C0024337', 'cui_str': 'L-lysine'}, {'cui': 'C0031853', 'cui_str': 'phytase'}, {'cui': 'C3653937', 'cui_str': 'OTHER NUTRIENTS'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C1265611', 'cui_str': 'Quantity finding'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0015686', 'cui_str': 'Fatty Acids, Essential'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0337112', 'cui_str': 'Chain, device (physical object)'}, {'cui': 'C0032615', 'cui_str': 'Polyunsaturated Fatty Acids'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1168488', 'cui_str': 'Total phospholipids'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}]",750.0,0.331143,"Infants receiving the SQ-LNS-plus had significantly higher plasma DHA (4.52 (4.3-4.9)) at 12 months than the controls (3.8 (3.6-4.0)), with a higher effect size in infants who no longer received breast milk (β = 1.148 (95% CI = 0.597, 1.699)) than in infants who were still breastfeeding (β = 0.544 (95% CI = 0.179, 0.909)).","[{'ForeName': 'Linda P', 'Initials': 'LP', 'LastName': 'Siziba', 'Affiliation': 'Centre of Excellence for Nutrition, North-West University, Private Bag X6001, 2520, Potchefstroom, South Africa.'}, {'ForeName': 'Jeannine', 'Initials': 'J', 'LastName': 'Baumgartner', 'Affiliation': 'Centre of Excellence for Nutrition, North-West University, Private Bag X6001, 2520, Potchefstroom, South Africa.'}, {'ForeName': 'Marinel', 'Initials': 'M', 'LastName': 'Rothman', 'Affiliation': 'Centre of Excellence for Nutrition, North-West University, Private Bag X6001, 2520, Potchefstroom, South Africa.'}, {'ForeName': 'Tonderayi M', 'Initials': 'TM', 'LastName': 'Matsungo', 'Affiliation': 'Centre of Excellence for Nutrition, North-West University, Private Bag X6001, 2520, Potchefstroom, South Africa.'}, {'ForeName': 'Mieke', 'Initials': 'M', 'LastName': 'Faber', 'Affiliation': 'Non-Communicable Disease Research Unit, South African Medical Research Council, Cape Town, South Africa.'}, {'ForeName': 'Cornelius M', 'Initials': 'CM', 'LastName': 'Smuts', 'Affiliation': 'Centre of Excellence for Nutrition, North-West University, Private Bag X6001, 2520, Potchefstroom, South Africa. corneliussmuts@gmail.com.'}]",European journal of clinical nutrition,['10.1038/s41430-019-0482-1'] 2974,32054899,"Effect of Scalp Nerve Block with Ropivacaine on Postoperative Pain in Patients Undergoing Craniotomy: A Randomized, Double Blinded Study.","Scalp nerve block with ropivacaine has been shown to provide perioperative analgesia. However, the best concentration of ropivacaine is still unknown for optimal analgesic effects. We performed a prospective study to evaluate the effects of scalp nerve block with varied concentration of ropivacaine on postoperative pain and intraoperative hemodynamic variables in patients undergoing craniotomy under general anesthesia. Eighty-five patients were randomly assigned to receive scalp block with either 0.2% ropivacaine, 0.33% ropivacaine, 0.5% ropivacaine, or normal saline. Intraoperative hemodynamics and post-operative pain scores at 2, 4, 6, 24 hours postoperatively were recorded. We found that scalp blockage with 0.2% and 0.33% ropivacaine provided adequate postoperative pain relief up to 2 h, while administration of 0.5% ropivacaine had a longer duration of action (up to 4 hour after craniotomy). Scalp nerve block with varied concentration of ropivacaine blunted the increase of mean arterial pressure in response to noxious stimuli during incision, drilling, and sawing skull bone. 0.2% and 0.5% ropivacaine decreased heart rate response to incision and drilling. We concluded that scalp block using 0.5% ropivacaine obtain preferable postoperative analgesia compared to lower concentrations. And scalp block with ropivacaine also reduced hemodynamic fluctuations in craniotomy operations.",2020,"Scalp nerve block with varied concentration of ropivacaine blunted the increase of mean arterial pressure in response to noxious stimuli during incision, drilling, and sawing skull bone.","['patients undergoing craniotomy under general anesthesia', 'Patients Undergoing Craniotomy', 'Eighty-five patients', 'craniotomy operations']","['ropivacaine', 'scalp block with either 0.2% ropivacaine, 0.33% ropivacaine, 0.5% ropivacaine, or normal saline', 'Scalp Nerve Block with Ropivacaine']","['mean arterial pressure', 'longer duration of action', 'heart rate response', 'Intraoperative hemodynamics and post-operative pain scores', 'scalp blockage', 'postoperative analgesia', 'postoperative pain and intraoperative hemodynamic variables', 'hemodynamic fluctuations', 'Postoperative Pain', 'adequate postoperative pain relief']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0010280', 'cui_str': 'Craniotomy'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C4517892', 'cui_str': '85'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}]","[{'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0036270', 'cui_str': 'Scalp'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C4517449', 'cui_str': 'Zero point three three'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C0027741', 'cui_str': 'Nerve Blockade'}]","[{'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C0439591', 'cui_str': 'Long duration (qualifier value)'}, {'cui': 'C0441472', 'cui_str': 'Action (qualifier value)'}, {'cui': 'C1997337', 'cui_str': 'Speed of heart rate response'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0036270', 'cui_str': 'Scalp'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0205411', 'cui_str': 'Adequate (qualifier value)'}]",85.0,0.161954,"Scalp nerve block with varied concentration of ropivacaine blunted the increase of mean arterial pressure in response to noxious stimuli during incision, drilling, and sawing skull bone.","[{'ForeName': 'Yaoxin', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan, P.R. China.'}, {'ForeName': 'Mengchan', 'Initials': 'M', 'LastName': 'Ou', 'Affiliation': 'Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan, P.R. China.'}, {'ForeName': 'Hongyu', 'Initials': 'H', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan, P.R. China.'}, {'ForeName': 'Lingcan', 'Initials': 'L', 'LastName': 'Tan', 'Affiliation': 'Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan, P.R. China.'}, {'ForeName': 'Yajiao', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan, P.R. China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan, P.R. China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Zhu', 'Affiliation': 'Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan, P.R. China. 739501155@qq.com.'}]",Scientific reports,['10.1038/s41598-020-59370-z'] 2975,3323227,Randomized trial interpreting sputum quality in a clinical laboratory.,"The role for laboratory interpretation of microbiologic results remains controversial, and many laboratories leave the interpretation of culture results entirely to physicians. We examined the effects of furnishing a laboratory interpretation of sputum quality on physician decision making. Quality of sputum was determined on Gram-stained smears by using a modification of the criteria of Bartlett (R. C. Bartlett, Medical Microbiology: Quality, Cost, and Clinical Relevance, p. 24-31, 1974). A total of 301 poor-quality specimens were randomized either to receive written interpretation of Gram stain results or to a control group for which Gram stain results were reported without interpretation. Physicians were more likely to follow up a poor-quality specimen with a second specimen if they had been furnished an interpretation of the results from the original Gram stain (22 versus 12%; P = 0.025). We conclude that laboratory-based interpretation of microbiologic results can improve physician decision making.",1987,A total of 301 poor-quality specimens were randomized either to receive written interpretation of Gram stain results or to a control group for which Gram stain results were reported without interpretation.,['A total of 301 poor-quality specimens'],[],['Quality of sputum'],"[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}]",[],"[{'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}]",,0.0286342,A total of 301 poor-quality specimens were randomized either to receive written interpretation of Gram stain results or to a control group for which Gram stain results were reported without interpretation.,"[{'ForeName': 'H H', 'Initials': 'HH', 'LastName': 'Mizrachi', 'Affiliation': 'Department of Pathology, State University of New York, Stony Brook 11794-8691.'}, {'ForeName': 'P N', 'Initials': 'PN', 'LastName': 'Valenstein', 'Affiliation': ''}]",Journal of clinical microbiology,[] 2976,32079428,"Shimian granules improve sleep, mood and performance of shift nurses in association changes in melatonin and cytokine biomarkers: a randomized, double-blind, placebo-controlled pilot study.","Shift nurses are prone to sleep problems and impaired nighttime alertness, with risk for reduced health status plus decreased performance, handling errors, and workplace accidents. Attention to and improvements in the situation of shift nurses are urgent. Shimian granules (SMG), an improved formula of Jieyuanshen with liver qingre and yangxin tranquilizing effects, for more than a decade has been used in China as a herbal treatment of sleep disorders in clinical practice. However, clinical data on SMG have rarely been reported. This double-blinded, randomized, placebo-controlled, pilot clinical trial (ChiCTR-IOR-17013031) aimed to explore whether Shimian granules (SMG) improves sleep and affective state in shift nurses and in association with changes in concentrations of salivary cytokines. Fifty-three rotating-shift female nurses with a Pittsburgh Sleep Quality Index (PSQI) score ≥8 were orally treated with 10.0 g SMG or placebo 2 times daily (30 min after breakfast and 30 min before bed) for 1 month. The Insomnia Severity Index (ISI), a psychomotor vigilance task, Hospital Anxiety and Depression Scale (HADS-A/HADS-D), and levels of four salivary cytokines were evaluated by single time-of-day sampling at baseline and after 1 month of treatment. Significantly lower ISI, HADS, HADS-A, and HADS-D scores, but higher 1/mean reaction time (1/mRT) score, were found in shift nurses treated with SMG than in those who received placebo, and these effects were associated with changes in salivary melatonin, TNF, IL-1β, and IL-6 levels. These latter findings suggest melatonin, TNF, and IL-6 levels may be suitable biomarkers of ISI score in shift nurses, whereas TNF level may be a suitable biomarker of 1/mRT score and IL-6 level a suitable biomarker of HADS score in response to SMG treatment. The results of this pilot study suggest SMG can effectively improve sleep, alertness, plus anxiety and depression symptoms in shift nurses in association with changes in salivary cytokine levels. The results of this study provide an experimental basis for the evaluation of traditional Chinese medicines for the treatment of insomnia and underlying mechanisms of their actions that require detailed future exploration.",2020,"The Insomnia Severity Index (ISI), a psychomotor vigilance task, Hospital Anxiety and Depression Scale (HADS-A/HADS-D), and levels of four salivary cytokines were evaluated by single time-of-day sampling at baseline and after 1 month of treatment.",['Fifty-three rotating-shift female nurses with a Pittsburgh Sleep Quality Index (PSQI) score ≥8'],"['placebo', 'SMG or placebo', 'SMG', 'Shimian granules (SMG']","['performance, handling errors, and workplace accidents', 'sleep, mood and performance of shift nurses', 'sleep and affective state', 'salivary melatonin, TNF, IL-1β, and IL-6 levels', 'ISI, HADS, HADS-A, and HADS-D scores', 'sleep, alertness, plus anxiety and depression symptoms', 'reaction time (1/mRT) score', 'Insomnia Severity Index (ISI), a psychomotor vigilance task, Hospital Anxiety and Depression Scale (HADS-A/HADS-D), and levels of four salivary cytokines']","[{'cui': 'C0231458', 'cui_str': 'Rotated (qualifier value)'}, {'cui': 'C0333051', 'cui_str': 'Shift (morphologic abnormality)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C4545801', 'cui_str': 'PSQI (Pittsburgh Sleep Quality Index) score'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3853573', 'cui_str': 'Granules'}]","[{'cui': 'C0018578', 'cui_str': 'Handling'}, {'cui': 'C0162579', 'cui_str': 'Job Site'}, {'cui': 'C1961149', 'cui_str': 'Accidental physical contact (event)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0333051', 'cui_str': 'Shift (morphologic abnormality)'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0048008', 'cui_str': 'Benzenamine, 4-((4-aminophenyl)sulfonyl)-N-hydroxy-'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C4520529', 'cui_str': 'Insomnia severity index (assessment scale)'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}]",53.0,0.225428,"The Insomnia Severity Index (ISI), a psychomotor vigilance task, Hospital Anxiety and Depression Scale (HADS-A/HADS-D), and levels of four salivary cytokines were evaluated by single time-of-day sampling at baseline and after 1 month of treatment.","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': ""Department of Pharmacy, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xi'an, China.""}, {'ForeName': 'Ruihuan', 'Initials': 'R', 'LastName': 'Zhang', 'Affiliation': 'Graduate School, Shaanxi University of Chinese Medicine, Xianyang, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Shen', 'Affiliation': ""Department of Encephalopathy, Traditional Chinese Medicine Hospital of Shaanxi Province, Xi'an, China.""}, {'ForeName': 'Shuzhen', 'Initials': 'S', 'LastName': 'Qiao', 'Affiliation': ""Department of Encephalopathy, Traditional Chinese Medicine Hospital of Shaanxi Province, Xi'an, China.""}, {'ForeName': 'Zhenliang', 'Initials': 'Z', 'LastName': 'Hui', 'Affiliation': ""Department of Encephalopathy, Traditional Chinese Medicine Hospital of Shaanxi Province, Xi'an, China.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ""Department of Encephalopathy, Traditional Chinese Medicine Hospital of Shaanxi Province, Xi'an, China.""}]",Chronobiology international,['10.1080/07420528.2020.1730880'] 2977,32071699,Effect of water-jet flossing on surface roughness and color stability of dental resin-based composites.,"Background The purpose of this in vitro study was to investigate the effects of water-jet flossing on the color stability and surface roughness of five resin-based composites. Material and Methods Five commercially available composite resins were studied. Nine disc-shaped specimens (6x2mm) were fabricated from each composite. The specimens were randomly allocated into three groups and three different treatments were performed on each group: storage in water (control group), water-jet flossing using 50 Psi water pressure, and water-jet flossing using 100 Psi water pressure. The water-jet flossing was performed in a standardized manner using a Waterpik® Aquarius® water flosser. Color and roughness were measured at baseline and at the end of 30 minutes of treatment, which is approximately equivalent to 5 years of simulated water-jet flossing for 1 minute once a day. The data were statistically analyzed using two-way analysis of variance (ANOVA) with Bonferroni and Tukey's post-hoc tests. Results No significant color change was found after 5 simulated years of water-jet flossing, irrespective of composite type and water-flossing pressure setting ( p > 0.05). Furthermore, none of composite specimens showed any significant surface roughness changes except for the two composites with spherical filler specimens in the 100 Psi treatment group. These composites exhibited a significant increase in surface roughness compared with the nano-filled composite ( p = 0.001 and p = 0.006). However, the differences were clinically acceptable (≈0.2 µm). Conclusions In terms of surface roughness and color, water-jet flossing is safe to be used on composite restorations within the settings of this study. Key words: Color difference (∆E), resin composites, surface roughness, water flosser.",2020,"In terms of surface roughness and color, water-jet flossing is safe to be used on composite restorations within the settings of this study. ",['dental resin-based composites'],"['storage in water (control group), water-jet flossing using 50 Psi water pressure, and water-jet flossing using 100 Psi water pressure', 'water-jet flossing']","['color stability and surface roughness', 'Key words: Color difference (∆E), resin composites, surface roughness, water flosser', 'surface roughness', 'surface roughness and color stability', 'Color and roughness']","[{'cui': 'C0598207', 'cui_str': 'Dental Resins'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}]","[{'cui': 'C1698986', 'cui_str': 'Storage (procedure)'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1706489', 'cui_str': 'Psi'}, {'cui': 'C0020309', 'cui_str': 'Hydrostatic Pressure'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]","[{'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0043047', 'cui_str': 'Water'}]",,0.022364,"In terms of surface roughness and color, water-jet flossing is safe to be used on composite restorations within the settings of this study. ","[{'ForeName': 'Mohammed', 'Initials': 'M', 'LastName': 'Alharbi', 'Affiliation': 'Dentist, Dentistry General Department, Ministry of Health, Qassim, Kingdom of Saudi Arabia.'}, {'ForeName': ""Ra'fat"", 'Initials': 'R', 'LastName': 'Farah', 'Affiliation': 'Assistant Professor, Department of Prosthodontics, College of dentistry, Qassim University, Kingdom of Saudi Arabia.'}]",Journal of clinical and experimental dentistry,['10.4317/jced.56153'] 2978,32073501,Implementation Lessons From a Randomized Trial Integrating Community Asthma Education for Children.,"This study characterized and compared the implementation of clinically integrated community health workers (CHWs) to a certified asthma educator (AE-C) for low-income children with asthma. In the AE-C arm (N = 115), 51.3% completed at least one in-clinic education session. In the CHW arm (N = 108), 722 home visits were completed. The median number of visits was 7 (range, 0-17). Scheduled in-clinic asthma education may not be the optimal intervention for this patient population. CHW visit completion rates suggest that the schedule, location, and content of CHW asthma services better met patients' needs. Seven to 10 visits seemed to be the preferred CHW dose.",2020,This study characterized and compared the implementation of clinically integrated community health workers (CHWs) to a certified asthma educator (AE-C) for low-income children with asthma.,"['clinically integrated community health workers (CHWs) to a certified asthma educator (AE-C) for low-income children with asthma', 'Children']",[],"['CHW visit completion rates', 'median number of visits']","[{'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",[],"[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}]",,0.0403265,This study characterized and compared the implementation of clinically integrated community health workers (CHWs) to a certified asthma educator (AE-C) for low-income children with asthma.,"[{'ForeName': 'Molly A', 'Initials': 'MA', 'LastName': 'Martin', 'Affiliation': 'University of Illinois at Chicago (Drs Martin, Bisarini, Weinstein, and Walton and Ms Rosales); Erie Family Health Center, Chicago, Illinois (Dr Roy); and Northshore University Health System, Evanston, Illinois (Dr Mosnaim).'}, {'ForeName': 'Reymundo', 'Initials': 'R', 'LastName': 'Bisarini', 'Affiliation': ''}, {'ForeName': 'Angkana', 'Initials': 'A', 'LastName': 'Roy', 'Affiliation': ''}, {'ForeName': 'Giselle', 'Initials': 'G', 'LastName': 'Mosnaim', 'Affiliation': ''}, {'ForeName': 'Genesis', 'Initials': 'G', 'LastName': 'Rosales', 'Affiliation': ''}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Weinstein', 'Affiliation': ''}, {'ForeName': 'Surrey M', 'Initials': 'SM', 'LastName': 'Walton', 'Affiliation': ''}]",The Journal of ambulatory care management,['10.1097/JAC.0000000000000326'] 2979,31834114,"A Prospective, Randomized Cross-over Trial of 2 Low-profile Gastrostomy Buttons to Determine Family Preference.","Low-profile gastrostomy balloon buttons are often used in the pediatric population. We conducted a prospective, randomized crossover trial to determine family preference comparing MIC-KEY (tube A) and MiniONE (tube B) buttons. Patients were randomized to tube A and tube B at placement. At 2 months, patients were given the opposite button. At 4 months, parents indicated their preferred button. A standardized assessment tool was used to assess gastrostomy site skin complications and device malfunction. One hundred fifty-eight patients were randomized, 79 each to receive tube A or tube B first. Sixty-eight with tube A and 60 with tube B completed their first follow-up. Sixty-five with tube A and 43 with tube B completed crossover, 69% of whom preferred tube B (P < 0.001). Including those who preferred their first button and declined to switch at 2 months, 91 of 127 (72%) kept tube B, demonstrating a strong preference for tube B.",2020,"Sixty-five with tube A and 43 with tube B completed crossover, 69% of whom preferred tube B (P < 0.001).",['One hundred fifty-eight patients'],"['MIC-KEY (tube A) and MiniONE (tube B) buttons', '2 Low-profile Gastrostomy Buttons', 'Low-profile gastrostomy balloon buttons']",[],"[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0427978', 'cui_str': 'Minimum Inhibitory Concentration'}, {'cui': 'C4318415', 'cui_str': 'Tube (unit of presentation)'}, {'cui': 'C0453985', 'cui_str': 'Button, device (physical object)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C3879280', 'cui_str': 'Gastrostomy button (physical object)'}, {'cui': 'C0017196', 'cui_str': 'Gastrostomy'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft (physical object)'}]",[],158.0,0.0263808,"Sixty-five with tube A and 43 with tube B completed crossover, 69% of whom preferred tube B (P < 0.001).","[{'ForeName': 'Ruba A', 'Initials': 'RA', 'LastName': 'Abdelhadi', 'Affiliation': 'Division of Gastroenterology.'}, {'ForeName': 'Charlene', 'Initials': 'C', 'LastName': 'Dekonenko', 'Affiliation': ""Department of Surgery, Children's Mercy Hospital, Kansas City, MO.""}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Dorman', 'Affiliation': ""Department of Surgery, Children's Mercy Hospital, Kansas City, MO.""}, {'ForeName': 'Tolulope A', 'Initials': 'TA', 'LastName': 'Oyetunji', 'Affiliation': ""Department of Surgery, Children's Mercy Hospital, Kansas City, MO.""}, {'ForeName': 'Shawn D', 'Initials': 'SD', 'LastName': 'St Peter', 'Affiliation': ""Department of Surgery, Children's Mercy Hospital, Kansas City, MO.""}]",Journal of pediatric gastroenterology and nutrition,['10.1097/MPG.0000000000002585'] 2980,31246553,How Providing Cervical Cancer Screening Results via Cell Phone Affects Patient Follow-Up Rates in Western Kenya.,"PURPOSE Human papillomavirus (HPV) testing is being more widely used in simplified cervical cancer screening protocols in low-resource settings. One challenge to successful implementation is the multiple visits necessary to provide results and follow-up. mHealth strategies may reduce visit burden by providing information through text message. METHODS As part of a cluster-randomized trial to compare HPV testing in clinics and community health campaigns in western Kenya, we carried out a mixed-methods study to assess women's preferences and experiences with different strategies to receive their results. Women could opt to receive their HPV results via text message, cell phone call, home visit, or return clinic visit. We examined overall receipt of results, follow-up rates, and acceptability by notification method. RESULTS Among the 4,947 women who underwent HPV-based cervical cancer screening, 1,596 (32%) received results via text message, 1,181 (24%) via cell phone call, 1,563 (32%) via clinic visit, and 605 (12%) via home visit. Women opting for texts or calls were younger and had higher rates of prior cervical cancer screening, HIV testing, and modern contraceptive use ( P < .001 for all). Home visits were associated with a significantly higher rate of treatment acquisition (45%) than texts (38%), cell phone calls (38%), and clinic visits (23%; P < .001). In a model controlling for age, prior screening, HIV testing, and contraceptive use, clinic visits remained significantly associated with decreased odds of treatment (adjusted odds ratio, 0.45; 95% CI, 0.29 to 0.69) compared with texts. Among treated women, there was no difference in time to treatment by notification method. CONCLUSION Cell phone-based results notification strategies were preferred by women with greater health-seeking behavior; however, HPV-positive women who received results via home visit were more likely to pursue for treatment.",2019,"Home visits were associated with a significantly higher rate of treatment acquisition (45%) than texts (38%), cell phone calls (38%), and clinic visits (23%; P < .001).","['4,947 women who underwent HPV-based cervical cancer screening, 1,596 (32', 'in clinics and community health campaigns in western Kenya']",['HPV testing'],"['cell phone calls', 'clinic visits', 'rate of treatment acquisition', 'rates of prior cervical cancer screening, HIV testing, and modern contraceptive use']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix (disorder)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0022558', 'cui_str': 'Republic of Kenya'}]",[],"[{'cui': 'C1136359', 'cui_str': 'Cell Phone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0008952', 'cui_str': 'Clinic Visits'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix (disorder)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0009871', 'cui_str': 'Contraceptives'}, {'cui': 'C1947944', 'cui_str': 'Use'}]",4947.0,0.0460339,"Home visits were associated with a significantly higher rate of treatment acquisition (45%) than texts (38%), cell phone calls (38%), and clinic visits (23%; P < .001).","[{'ForeName': 'Megan J', 'Initials': 'MJ', 'LastName': 'Huchko', 'Affiliation': 'Duke University, Durham, NC.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Saduma', 'Affiliation': 'Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Cinthia', 'Initials': 'C', 'LastName': 'Blat', 'Affiliation': 'University of California San Francisco, San Francisco, CA.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Oketch', 'Affiliation': 'Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Bukusi', 'Affiliation': 'Kenya Medical Research Institute, Nairobi, Kenya.'}]",Journal of global oncology,['10.1200/JGO.18.00264'] 2981,32076549,"Increasing the proportion of plasma MUFA, as a result of dietary intervention, is associated with a modest improvement in insulin sensitivity.","The effect of modifying dietary fatty acid (FA) composition on insulin sensitivity remains unclear. We aimed to investigate whether changes in plasma phospholipid (PL) FA composition, as a result of dietary intervention, correspond with changes in insulin sensitivity. The RISCK study was a 6-month randomised controlled dietary intervention study, which assessed the effect of modifying dietary fat and the glycaemic index (GI) of carbohydrates on insulin sensitivity. Total NEFA levels, fasting plasma PL FA profiles and an insulin sensitivity index (Si), derived from intravenous glucose tolerance minimal-model analysis, were available from 533 participants, all at elevated risk of type 2 diabetes. Bivariate correlations between changes in saturated PL FA (SFA), MUFA (as a percentage of total plasma NEFA) and changes in Si were assessed according to treatment group. Age, sex, ethnicity, percentage change in body mass and change in dietary GI were controlled for. Increasing total NEFA concentration was associated with worsening Si ( r - 0·152; P = 0·001). In the high-MUFA/low-GI diet group, change in PL-MUFA was positively and independently associated with change in Si ( r 0·297; P = 0·002). Among MUFA, change in oleic acid (18 : 1) was most strongly correlated with change in Si ( r 0·266 ; P = 0·005), as was change in minor FA 24 : 1 ( r 0·244; P = 0·011) and 17 : 1 ( r 0·196; P = 0·042). In the high-SFA/high-GI group, change in SFA concentration was not significantly associated with change in Si. In conclusion, increases in the proportion of plasma PL-MUFA following a high-MUFA dietary intervention were associated with improvements in insulin sensitivity.",2019,Increasing total NEFA concentration was associated with worsening Si ( r - 0·152; P = 0·001).,[],['modifying dietary fatty acid (FA) composition'],"['plasma phospholipid (PL) FA composition', 'insulin sensitivity', 'oleic acid', 'change in Si', 'total plasma NEFA) and changes in Si', 'proportion of plasma PL-MUFA', 'PL-MUFA', 'SFA concentration', 'Total NEFA levels, fasting plasma PL FA profiles and an insulin sensitivity index (Si', 'total NEFA concentration']",[],"[{'cui': 'C0015684', 'cui_str': 'Fatty Acids'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0031676', 'cui_str': 'Phospholipids'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0028929', 'cui_str': 'Oleic Acids'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0015688', 'cui_str': 'NEFA'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",533.0,0.0483951,Increasing total NEFA concentration was associated with worsening Si ( r - 0·152; P = 0·001).,"[{'ForeName': 'I', 'Initials': 'I', 'LastName': 'Johns', 'Affiliation': 'Nutrition and Dietetic Research Group, Imperial College London, London, UK.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Frost', 'Affiliation': 'Nutrition and Dietetic Research Group, Imperial College London, London, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Dornhorst', 'Affiliation': 'Nutrition and Dietetic Research Group, Imperial College London, London, UK.'}]",Journal of nutritional science,['10.1017/jns.2019.29'] 2982,31356985,Large Treatment Effect With Extended Home-Based Transcranial Direct Current Stimulation Over Dorsolateral Prefrontal Cortex in Fibromyalgia: A Proof of Concept Sham-Randomized Clinical Study.,"This randomized, double-blind controlled trial tested the hypothesis that 60 sessions of home-based anodal (a)-transcranial direct current stimulation (tDCS) over dorsolateral prefrontal cortex (DLPFC) would be better than home-based sham-tDCS to improve the widespread pain and the disability-related to pain. The anodal-tDCS (2 mA for 30 minutes) over the left DLPFC was self-administered with a specially developed device following in-person training. Twenty women, 18 to 65 years old were randomized into 2 groups [active-(a)-tDCS (n = 10) or sham-(s)-tDCS (n = 10)]. Post hoc analysis revealed that after the first 20 sessions of a-tDCS, the cumulative pain scores reduced by 45.65% [7.25 (1.43) vs 3.94 (1.14), active vs sham tDCS, respectively]. After 60 sessions, during the 12-week assessment, pain scores reduced by 62.06% in the actively group [visual analogue scale reduction, 7.25 (1.43) to 2.75 (.85)] compared to 24.92% in the s-tDCS group, [mean (SD) 7.10 (1.81) vs 5.33 (.90)], respectively. It reduced the risk for analgesic use in 55%. Higher serum levels of the brain-derived neurotrophic factor predicted higher decreases on the pain scores across of treatment. PERSPECTIVE: These findings bring 3 important insights: 1) show that an extended period of treatment (60 sessions, to date the largest number of tDCS sessions tested) for fibromyalgia induces large pain decreases (a large effect size of 1.59) and 2) support the feasibility of home-based tDCS as a method of intervention; 3) provide additional data on DLPFC target for the treatment of fibromyalgia. Finally, our findings also highlight that brain-derived neurotrophic factor to index neuroplasticity may be a valuable predictor of the tDCS effect on pain scores decreases across the treatment.",2020,"After 60 sessions, during the 12-week assessment, pain scores reduced by 62.06% in the actively group [visual analogue scale reduction, 7.25 (1.43) to 2.75 (.85)] compared to 24.92% in the s-tDCS group, [mean (SD) 7.10 (1.81) vs 5.33 (.90)], respectively.","['Fibromyalgia', 'Twenty women, 18 to 65 years old']","['anodal-tDCS', 'home-based anodal (a)-transcranial direct current stimulation (tDCS) over dorsolateral prefrontal cortex (DLPFC', 'Extended Home-Based Transcranial Direct Current Stimulation', 'sham-(s)-tDCS', 'active-(a)-tDCS']","['visual analogue scale reduction', 'cumulative pain scores', 'pain scores']","[{'cui': 'C0016053', 'cui_str': 'Fibrositis'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C4019080', 'cui_str': 'Dorsolateral Prefrontal Cortex'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}]","[{'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}]",20.0,0.213709,"After 60 sessions, during the 12-week assessment, pain scores reduced by 62.06% in the actively group [visual analogue scale reduction, 7.25 (1.43) to 2.75 (.85)] compared to 24.92% in the s-tDCS group, [mean (SD) 7.10 (1.81) vs 5.33 (.90)], respectively.","[{'ForeName': 'Aline P', 'Initials': 'AP', 'LastName': 'Brietzke', 'Affiliation': 'Post-Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Laboratory of Pain and Neuromodulation at Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil.'}, {'ForeName': 'Maxciel', 'Initials': 'M', 'LastName': 'Zortea', 'Affiliation': 'Post-Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Laboratory of Pain and Neuromodulation at Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil.'}, {'ForeName': 'Fabiana', 'Initials': 'F', 'LastName': 'Carvalho', 'Affiliation': 'Post-Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Laboratory of Pain and Neuromodulation at Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil.'}, {'ForeName': 'Paulo R S', 'Initials': 'PRS', 'LastName': 'Sanches', 'Affiliation': 'Laboratory of Biomedical Engineering at HCPA, Porto Alegre, Brazil.'}, {'ForeName': 'Danton P Jr', 'Initials': 'DPJ', 'LastName': 'Silva', 'Affiliation': 'Laboratory of Biomedical Engineering at HCPA, Porto Alegre, Brazil.'}, {'ForeName': 'Iraci Lucena da Silva', 'Initials': 'ILDS', 'LastName': 'Torres', 'Affiliation': 'Post-Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Laboratory of Pain and Neuromodulation at Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil; Laboratory of Biomedical Engineering at HCPA, Porto Alegre, Brazil; Laboratory of Neuromodulation and Center for Clinical Research Learning, Physics and Rehabilitation Department, Spaulding Rehabilitation Hospital, Boston, Massachusetts; Pain and Palliative Care Service at HCPA, Porto Alegre, Brazil; Department of Surgery, School of Medicine, UFRGS, Porto Alegre, Brazil.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Fregni', 'Affiliation': 'Laboratory of Neuromodulation and Center for Clinical Research Learning, Physics and Rehabilitation Department, Spaulding Rehabilitation Hospital, Boston, Massachusetts.'}, {'ForeName': 'Wolnei', 'Initials': 'W', 'LastName': 'Caumo', 'Affiliation': 'Post-Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Laboratory of Pain and Neuromodulation at Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil; Laboratory of Neuromodulation and Center for Clinical Research Learning, Physics and Rehabilitation Department, Spaulding Rehabilitation Hospital, Boston, Massachusetts; Pain and Palliative Care Service at HCPA, Porto Alegre, Brazil; Department of Surgery, School of Medicine, UFRGS, Porto Alegre, Brazil. Electronic address: wcaumo@hcpa.edu.br.'}]",The journal of pain : official journal of the American Pain Society,['10.1016/j.jpain.2019.06.013'] 2983,31229502,"Impact of Virtual Learning Environment on Students' Satisfaction, Engagement, Recall, and Retention.","BACKGROUND Virtual learning environments (VLEs) were introduced to progress students from passive to active learners. Active learning promotes the critical thinking skills essential for the transfer/use of classroom-acquired knowledge into the clinical setting. A VLE forms an increasingly vital component of clinical skills development in a range of disciplines. MATERIAL AND METHODS A randomized control trial was conducted with students randomly attending one of two teaching sessions about radiation therapy. Both sessions were identical except a VLE was used in the second talk with the first being solely didactic. Anonymous questionnaires were distributed. Two weeks after the talks, participants were required to complete the same knowledge questionnaire to determine retention. Mann-Whitney, means, standard deviations, and chi-squared tests were used according to data characteristics. Qualitative data (open-ended questions) were analysed thematically. RESULTS Virtual learning seemed to significantly improve students' satisfaction/engagement and recall. A total of 40 students attended the teaching sessions. The student group taught using the VLE had higher mean scores for retention than the didactic group; however, this was not statistically significant. Use of VLEs was associated with greater satisfaction/engagement than didactic information (P = .003). Students' learning styles seemed to have no effect on their satisfaction/engagement and ease of learning. Three key themes emerged from the qualitative data: (1) the visuals were good/helpful, (2) the talk was informative, and (3) more details/visuals were required. DISCUSSION AND CONCLUSION The key findings from this study suggest that there is a role for VLEs in the teaching of students. There is a need for the introduction of advanced technology into health care education as virtual reality, such as Virtual Environment of Radiotherapy, has shown improvement in students' satisfaction, engagement, and recall. Whether VLEs qualify students better than conventional didactic teaching is still undetermined, but these first results are encouraging.",2019,Use of VLEs was associated with greater satisfaction/engagement than didactic information (P = .003).,"['students randomly attending one of two', '40 students attended the teaching sessions']","['teaching sessions about radiation therapy', 'VLE', 'Active learning', 'Virtual Learning Environment']","['satisfaction/engagement and ease of learning', ""students' satisfaction/engagement and recall"", ""Students' Satisfaction, Engagement, Recall, and Retention""]","[{'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}]","[{'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0034619', 'cui_str': 'radiation therapy'}, {'cui': 'C0243012', 'cui_str': 'Experiential Learning'}, {'cui': 'C0014406', 'cui_str': 'Environment'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0035280', 'cui_str': 'Retention'}]",40.0,0.0367701,Use of VLEs was associated with greater satisfaction/engagement than didactic information (P = .003).,"[{'ForeName': 'Eimear', 'Initials': 'E', 'LastName': 'Ryan', 'Affiliation': 'Trinity College Dublin, Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, School of Medicine Dublin, Ireland.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Poole', 'Affiliation': 'Trinity College Dublin, Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, School of Medicine Dublin, Ireland. Electronic address: poolec@tcd.ie.'}]",Journal of medical imaging and radiation sciences,['10.1016/j.jmir.2019.04.005'] 2984,31356508,Physical Activity Is Higher in Patients with LVADs Compared to Chronic Heart Failure.,"PURPOSE Left ventricular assist devices (LVADs) are associated with an increased aerobic capacity in patients with chronic heart failure (CHF). However, studies evaluating the impact of LVAD implantation on physical activity (PA) are lacking. The aim of this study was to compare daily PA levels in participants with LVADs with well-matched CHF participants. METHODS Sixteen participants with an LVAD (age: 59.1 ± 10.8 years) were case-matched to 16 participants with advanced CHF (age: 58.3 ± 8.7 years), who were listed or being considered for cardiac transplantation. Participants underwent a cardiopulmonary exercise test to determine peak oxygen consumption (V[Combining Dot Above]O2 peak). PA was monitored continuously for seven consecutive days with an Actiheart monitor. RESULTS V[Combining Dot Above]O2 peak in the CHF group (12.3 ± 3.5 ml·kg·min) was not significantly different to the LVAD group prior to LVAD implantation (10.4 ± 2.1 ml·kg·min), but was lower than in the LVAD group following implantation (15.8 ± 4.3 ml·kg·min; p < 0.05). PA was higher in the LVAD (19.7 ± 6.4 kJ·kg·day) compared with the CHF group (11.6 ± 6.9 kJ·kg·day; p = 0.001). LVAD participants spent more time performing moderate intensity PA than their CHF counterparts, 26 (24-40) [median (IQR)] vs. 12 (9-16) min/day; p < 0.001. PA was correlated with V[Combining Dot Above]O2 peak (r = 0.582; p = 0.001) across participants in the CHF and LVAD groups. CONCLUSION Higher levels of PA were observed in participants with LVAD compared with patients with advanced CHF. This may be due to a higher V[Combining Dot Above]O2 peak, resulting in an improved capacity to perform activities of daily living with less symptoms.",2019,PA was higher in the LVAD (19.7 ± 6.4 kJ·kg·day) compared with the CHF group (11.6 ± 6.9 kJ·kg·day; p = 0.001).,"['Sixteen participants with an LVAD (age: 59.1 ± 10.8 years) were case-matched to 16 participants with advanced CHF (age: 58.3 ± 8.7 years), who were listed or being considered for cardiac transplantation', 'patients with chronic heart failure (CHF', 'participants with LVADs with well-matched CHF participants']","['LVAD implantation', 'Left ventricular assist devices (LVADs', 'cardiopulmonary exercise test', 'LVAD']","['Dot Above]O2 peak', 'time performing moderate intensity PA', 'V[Combining Dot Above]O2 peak', 'PA', 'peak oxygen consumption (V[Combining Dot Above]O2 peak', 'Physical Activity', 'aerobic capacity', 'daily PA levels', 'Higher levels of PA']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517523', 'cui_str': '10.8'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C4517880', 'cui_str': '8.7 (qualifier value)'}, {'cui': 'C0018823', 'cui_str': 'Transplantation, Cardiac'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0264716', 'cui_str': 'Chronic heart failure (disorder)'}]","[{'cui': 'C0021107', 'cui_str': 'Insertion procedure'}, {'cui': 'C0181598', 'cui_str': 'Left ventricular assist device'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary Exercise Test'}]","[{'cui': 'C1720485', 'cui_str': 'Corneal epithelial microcysts'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C1305742', 'cui_str': 'Oxygen consumption'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]",16.0,0.0464878,PA was higher in the LVAD (19.7 ± 6.4 kJ·kg·day) compared with the CHF group (11.6 ± 6.9 kJ·kg·day; p = 0.001).,"[{'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Moreno-Suarez', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia.'}, {'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Liew', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia.'}, {'ForeName': 'Lawrence G', 'Initials': 'LG', 'LastName': 'Dembo', 'Affiliation': 'Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Murdoch, Australia.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Larbalestier', 'Affiliation': 'Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Murdoch, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Maiorana', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002104'] 2985,31371154,Haemostasis in oral surgical procedures involving patients with a ventricular assist device.,"The purpose of this study was to determine whether tooth extraction for patients with ventricular assist devices (VADs) could be performed without interruption of anticoagulant and/or antiplatelet therapy and whether treatment with von Willebrand factor concentrates and desmopressin is required. The study consisted of three groups of patients undergoing oral surgery. The two experimental groups comprised patients with VADs, while the third group included cardiovascular patients without VADs who served as controls. All patients were treated intraoperatively with topical haemostatic agents (oxidized cellulose or collagen). The first group was additionally treated with fibrin glue. All 75 oral surgical procedures were performed under local anaesthesia without sedation. Three of 40 patients in the experimental groups and two of 20 patients in the control group suffered a haemorrhage, with no significant difference in the incidence of haemorrhage between the groups. The findings suggest that dental extraction can be performed without modification of oral anticoagulation or antiplatelet treatments, providing that INR is less than 3.5 on the day of the operation. It can further be hypothesized that an acquired coagulopathy in VAD patients does not influence the bleeding risk in dental extractions, and so the administration of desmopressin and/or von Willebrand factor concentrates is not required.",2019,"Three of 40 patients in the experimental groups and two of 20 patients in the control group suffered a haemorrhage, with no significant difference in the incidence of haemorrhage between the groups.","['patients with VADs, while the third group included cardiovascular patients without VADs who served as controls', 'patients undergoing oral surgery', 'patients with ventricular assist devices (VADs', 'patients with a ventricular assist device']","['local anaesthesia without sedation', 'topical haemostatic agents (oxidized cellulose or collagen', 'fibrin glue']","['incidence of haemorrhage', 'haemorrhage']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0038908', 'cui_str': 'Surgery, Maxillofacial'}, {'cui': 'C0085842', 'cui_str': 'Artificial Ventricle'}]","[{'cui': 'C0002921', 'cui_str': 'Local anesthesia (procedure)'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0019120', 'cui_str': 'Hemostatics'}, {'cui': 'C0007649', 'cui_str': 'Absorbable Cellulose'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0016004', 'cui_str': 'Fibrin Glue'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1869041', 'cui_str': 'Haemorrhages (SMQ)'}]",,0.0222906,"Three of 40 patients in the experimental groups and two of 20 patients in the control group suffered a haemorrhage, with no significant difference in the incidence of haemorrhage between the groups.","[{'ForeName': 'N A', 'Initials': 'NA', 'LastName': 'Hamzah', 'Affiliation': 'Department of Oral, Maxillofacial and Facial Plastic Surgery, University Hospital Leipzig, Leipzig, Germany. Electronic address: hamzah@medizin.uni-leipzig.de.'}, {'ForeName': 'H L', 'Initials': 'HL', 'LastName': 'Graf', 'Affiliation': 'Department of Oral, Maxillofacial and Facial Plastic Surgery, University Hospital Leipzig, Leipzig, Germany.'}, {'ForeName': 'M R', 'Initials': 'MR', 'LastName': 'Kaluđerović', 'Affiliation': 'Department of Oral, Maxillofacial and Facial Plastic Surgery, University Hospital Leipzig, Leipzig, Germany; Practice for Maxillofacial Surgery, Lepsiusstraße 2, 06618 Naumburg, Germany.'}, {'ForeName': 'A L', 'Initials': 'AL', 'LastName': 'Meyer', 'Affiliation': 'University Department for Cardiac Surgery, Leipzig Heart Centre, Leipzig, Germany.'}, {'ForeName': 'M T', 'Initials': 'MT', 'LastName': 'Dieterlen', 'Affiliation': 'University Department for Cardiac Surgery, Leipzig Heart Centre, Leipzig, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Hemprich', 'Affiliation': 'Department of Oral, Maxillofacial and Facial Plastic Surgery, University Hospital Leipzig, Leipzig, Germany.'}]",International journal of oral and maxillofacial surgery,['10.1016/j.ijom.2019.07.009'] 2986,32034202,Inhaled milrinone in cardiac surgical patients: a pilot randomized controlled trial of jet vs. mesh nebulization.,"Inhaled milrinone administered before cardiopulmonary bypass (CPB) reduces the severity of pulmonary hypertension during cardiac surgery. However, milrinone pharmacokinetics has not been determined for this route of administration. The objective of this study was to investigate inhaled milrinone dosing in vitro and early plasma concentrations in vivo after jet and mesh nebulization. Twelve pulmonary hypertensive patients scheduled for cardiac surgery were randomized to receive milrinone (5 mg) by inhalation before CPB using a jet or mesh nebulizer. In vitro experiments were conducted to determine the inhaled dose delivered with either jet or mesh nebulization. In vivo experiments involved hemodynamic monitoring and blood samples drawn from patients for the first 15 min after the end of inhalation to determine early plasma concentrations. After mesh nebulization, the mean in vitro inhaled dose was almost 3-fold higher compared to jet nebulization (46.4% vs 16.6% for mesh and jet, respectively; mean difference, 29.8%; 95% CI, 14.1 to 45.5; P = 0.006). Consistent with this, the early plasma concentrations in vivo were also 2-3 fold higher after mesh nebulization (P = 0.002-0.005). After inhalation (jet or mesh nebulization), milrinone early plasma concentrations remained within the therapeutic range. No systemic hypotension was reported in our patients.",2020,"After mesh nebulization, the mean in vitro inhaled dose was almost 3-fold higher compared to jet nebulization (46.4% vs 16.6% for mesh and jet, respectively; mean difference, 29.8%; 95% CI, 14.1 to 45.5; P = 0.006).","['cardiac surgical patients', 'Twelve pulmonary hypertensive patients scheduled for cardiac surgery']","['milrinone', 'Inhaled milrinone', 'jet or mesh nebulization', 'cardiopulmonary bypass (CPB', 'jet vs. mesh nebulization']","['severity of pulmonary hypertension', 'mean in vitro inhaled dose', 'early plasma concentrations', 'jet nebulization', 'hemodynamic monitoring and blood samples', 'systemic hypotension']","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}]","[{'cui': 'C0128513', 'cui_str': 'Milrinone'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0181805', 'cui_str': 'Mesh (physical object)'}, {'cui': 'C0007202', 'cui_str': 'Heart-Lung Bypass'}]","[{'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C1963999', 'cui_str': 'Pulmonary hypertension (SMQ)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0021135', 'cui_str': 'In Vitro'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C4082936', 'cui_str': 'Hemodynamic Monitoring'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0020649', 'cui_str': 'Blood Pressure, Low'}]",,0.0913442,"After mesh nebulization, the mean in vitro inhaled dose was almost 3-fold higher compared to jet nebulization (46.4% vs 16.6% for mesh and jet, respectively; mean difference, 29.8%; 95% CI, 14.1 to 45.5; P = 0.006).","[{'ForeName': 'Anne Quynh-Nhu', 'Initials': 'AQ', 'LastName': 'Nguyen', 'Affiliation': 'Faculty of Pharmacy, Université de Montréal, Montreal, Canada.'}, {'ForeName': 'André Y', 'Initials': 'AY', 'LastName': 'Denault', 'Affiliation': 'Department of Anesthesiology and Critical Care Division, Montreal Heart Institute, Université de Montréal, Montreal, Canada. andre.denault@umontreal.ca.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Théoret', 'Affiliation': 'Clinical Pharmacology Unit, CHU Sainte-Justine, Montreal, Canada.'}, {'ForeName': 'Louis P', 'Initials': 'LP', 'LastName': 'Perrault', 'Affiliation': 'Department of Cardiac Surgery, Montreal Heart Institute, Université de Montréal, Montreal, Canada.'}, {'ForeName': 'France', 'Initials': 'F', 'LastName': 'Varin', 'Affiliation': 'Faculty of Pharmacy, Université de Montréal, Montreal, Canada. france.varin@umontreal.ca.'}]",Scientific reports,['10.1038/s41598-020-58902-x'] 2987,30724574,Goal-Oriented Attention Self-Regulation (GOALS) training in older adults.,"Objectives: A common cognitive complaint of older adulthood is distractibility, or decline in ability to concentrate and maintain focus, yet few evidence-based interventions exist to address these deficits. We implemented s pilot trial of an evidence-based executive function training program, to investigate whether training in applied goal-directed attention regulation and problem solving would enhance executive control abilities in a sample of cognitively normal older adults with self-reported complaints of concentration problems. Method: Consecutively recruited participants were placed into small groups and randomized to either Goal-Oriented Attentional Self-Regulation training (GOALS; N  = 15) or a closely matched Brain Health Education program (BHE; N  = 15). Results: GOALS participants significantly improved on: neurocognitive measures of mental flexibility ( p  = 0.03, partial eta squared = 0.23); real-world setting functional performance measures of: task failures ( p  = 0.02, Cohen's d  = 0.88), task rule breaks ( p  = 0.02, Cohen's d  = 1.06), and execution ( p  = 0.04, Cohen's d = 0.76); and in-lab functional assessment of goal-directed behaviour divergent thinking scale ( p  = 0.03, Cohen's d  = 0.95). All participants improved on a neurocognitive measure of planning ( p  = 0.01, partial eta squared = 0.031). BHE participants' improvement over and above GOALS participants was limited to: rule adherence on the real world task ( p  = 0.04, Cohen's d  = 0.99), and evaluator rating ( p  = 0.03, Cohen's d  = 0.56), and average score ( p  = 0.02, Cohen's d  = 0.71) on the in-lab functional task. Conclusion: Participation in GOALS training can enhance executive control, and lead to real-world functional improvements, for cognitively normal older adults with self-reported attention difficulties.",2020,"RESULTS GOALS participants significantly improved on: neurocognitive measures of mental flexibility (p = 0.03, partial eta squared = 0.23); real-world setting functional performance measures of: task failures (p = 0.02, Cohen's d = 0.88), task rule breaks (p = 0.02, Cohen's d = 1.06), and execution (p = 0.04, Cohen's d = 0.76); and in-lab functional assessment of goal-directed behaviour divergent thinking scale (p = 0.03, Cohen's d = 0.95).","['cognitively normal older adults', 'Consecutively recruited participants', 'cognitively normal older adults with self-reported complaints of concentration problems', 'older adults']","['Goal-Oriented Attentional Self-Regulation training (GOALS; N\u2009=\u200915) or a closely matched Brain Health Education program (BHE; N\u2009=\u200915', 'Participation in GOALS training', 'evidence-based executive function training program', 'Goal-Oriented Attention Self-Regulation (GOALS) training']","['neurocognitive measures of mental flexibility', 'neurocognitive measure of planning', 'lab functional assessment of goal-directed behaviour divergent thinking scale', 'executive control abilities', 'evaluator rating', 'task rule breaks']","[{'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0277786', 'cui_str': 'Presenting complaint'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}]","[{'cui': 'C0018017', 'cui_str': 'Goals'}, {'cui': 'C0684274', 'cui_str': 'Self Regulation'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0018701'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0589092', 'cui_str': 'Executive functions training (regime/therapy)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]","[{'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning (observable entity)'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0018017', 'cui_str': 'Goals'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",,0.0515391,"RESULTS GOALS participants significantly improved on: neurocognitive measures of mental flexibility (p = 0.03, partial eta squared = 0.23); real-world setting functional performance measures of: task failures (p = 0.02, Cohen's d = 0.88), task rule breaks (p = 0.02, Cohen's d = 1.06), and execution (p = 0.04, Cohen's d = 0.76); and in-lab functional assessment of goal-directed behaviour divergent thinking scale (p = 0.03, Cohen's d = 0.95).","[{'ForeName': 'Gary R', 'Initials': 'GR', 'LastName': 'Turner', 'Affiliation': 'York University, Toronto, Canada.'}, {'ForeName': 'Tatjana', 'Initials': 'T', 'LastName': 'Novakovic-Agopian', 'Affiliation': 'University of California, San Francisco, USA.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Kornblith', 'Affiliation': 'San Francisco VA Medical Center, San Francisco, USA.'}, {'ForeName': 'Areeba', 'Initials': 'A', 'LastName': 'Adnan', 'Affiliation': 'York University, Toronto, Canada.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Madore', 'Affiliation': 'Palo Alto VA Medical Center, Palo Alto, USA.'}, {'ForeName': 'Anthony J W', 'Initials': 'AJW', 'LastName': 'Chen', 'Affiliation': 'University of California, Berkeley, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': ""D'Esposito"", 'Affiliation': 'University of California, Berkeley, USA.'}]",Aging & mental health,['10.1080/13607863.2018.1534080'] 2988,31630398,Effectiveness of nitrous oxide in external cephalic version on success rate: A randomized controlled trial.,"INTRODUCTION Approximately 4% of singleton pregnancies at term are in breech presentation. External cephalic version (ECV) can reduce the risks of noncephalic birth and cesarean delivery, but this maneuver can be painful. Our aim was to analyze the effect of administering inhaled nitrous oxide for analgesia on the ECV success rate. MATERIAL AND METHODS This prospective, randomized, single-blind, controlled trial included women with singleton pregnancies in breech presentation at term who were referred for ECV in a tertiary care center. Women were assigned according to a balanced (1:1) restricted randomization design to inhale either nitrous oxide (N 2 O) in a 50:50 mix with oxygen or medical air during the procedure. The main outcomes reported are the ECV success rate, degree of pain, adverse event rate, and women's satisfaction. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01948115. RESULTS The study included 150 women (nitrous oxide group: n = 74; medical air: n = 76). Inhaled nitrous oxide was not associated with a higher ECV success rate than medical air (24.3 vs 19.7%, P = 0.51). Among parous women (n = 34 in each group), the ECV success rate appeared higher in the nitrous oxide group, respectively 47.1% (n = 16) vs 23.5% (n = 8) (P = 0.042). Neither the median pain level nor adverse event rates differed significantly in women with inhaled nitrous oxide compared with medical air. CONCLUSIONS Use of an equimolar mixture of oxygen and nitrous oxide during ECV appears safe. Although it does not seem to change the overall success rate, it may increase success in parous women.",2020,"Inhaled nitrous oxide was not associated with a higher ECV success rate than medical air (24.3% vs. 19.7%, P=0.51).","['women with singleton pregnancies in breech presentation at term who were referred for ECV in a tertiary care center', 'parous women', '150 women (nitrous oxide group: n=74; medical air: n=76']","['nitrous oxide (N 2 O) in a 50:50 mix with oxygen or medical air during the procedure', 'Inhaled nitrous oxide', 'equimolar mixture of oxygen and nitrous oxide', 'nitrous oxide', 'External cephalic version (ECV', 'inhaled nitrous oxide']","['ECV success rate', ""ECV success rate, degree of pain, adverse event rate, and women's satisfaction"", 'success rate', 'median pain level nor adverse event rates']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0006157', 'cui_str': 'Labor Presentation, Breech'}, {'cui': 'C0587437', 'cui_str': 'Tertiary Hospital'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0028215', 'cui_str': 'Nitrous Oxide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C3536832', 'cui_str': 'medical air'}]","[{'cui': 'C0028215', 'cui_str': 'Nitrous Oxide'}, {'cui': 'C1720722', 'cui_str': 'Mix'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C3536832', 'cui_str': 'medical air'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0439962', 'cui_str': 'Mixture (qualifier value)'}, {'cui': 'C0410877', 'cui_str': 'Version, External Cephalic'}]","[{'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}]",150.0,0.14746,"Inhaled nitrous oxide was not associated with a higher ECV success rate than medical air (24.3% vs. 19.7%, P=0.51).","[{'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Dochez', 'Affiliation': 'Department of Gynecology and Obstetrics, University Hospital of Nantes, Nantes, France.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Esbelin', 'Affiliation': 'Department of Gynecology and Obstetrics, University Hospital of Nantes, Nantes, France.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Misbert', 'Affiliation': 'Department of Gynecology and Obstetrics, University Hospital of Nantes, Nantes, France.'}, {'ForeName': 'Chloé', 'Initials': 'C', 'LastName': 'Arthuis', 'Affiliation': 'Department of Gynecology and Obstetrics, University Hospital of Nantes, Nantes, France.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Drouard', 'Affiliation': 'Clinical Investigation Center (CIC), University Hospital of Nantes, Nantes, France.'}, {'ForeName': 'Virginie', 'Initials': 'V', 'LastName': 'Badon', 'Affiliation': 'Clinical Investigation Center (CIC), University Hospital of Nantes, Nantes, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Fenet', 'Affiliation': 'Biometrics and Biostatistics Platform, University Hospital of Nantes, Nantes, France.'}, {'ForeName': 'Thibault', 'Initials': 'T', 'LastName': 'Thubert', 'Affiliation': 'Department of Gynecology and Obstetrics, University Hospital of Nantes, Nantes, France.'}, {'ForeName': 'Norbert', 'Initials': 'N', 'LastName': 'Winer', 'Affiliation': 'Department of Gynecology and Obstetrics, University Hospital of Nantes, Nantes, France.'}]",Acta obstetricia et gynecologica Scandinavica,['10.1111/aogs.13753'] 2989,32072216,"A Randomized, Controlled Study Comparing Subbrow Blepharoplasty and Subbrow Blepharoplasty Combined with Periorbital Muscle Manipulation for Periorbital Aging Rejuvenation in Asians.","BACKGROUND Improving periorbital aging is, currently, of great concern. The previous literature has reported some surgical methods for periorbital aging. The purpose of this study was to compare subbrow blepharoplasty (SBB) with subbrow blepharoplasty combined with periorbital muscle manipulation (SBB-pm) with regard to improving periorbital aging. METHODS A prospective, randomized, controlled study was designed to evaluate and compare the effects of two different surgical techniques on upper lid relaxation, brow shape and periorbital wrinkles. Patients were divided into two groups. Group 1 underwent resection of excess skin; group 2 underwent a modified technique that involved resection of an elliptical island of skin, separation of the corrugator supercilii muscle and dissection of the orbicularis oculi muscle, followed by suturing it to the orbital periosteum and cross-fixation with itself. The upper eyelid and eyebrow height, periorbital wrinkle score and patient satisfaction were measured preoperatively and postoperatively. RESULTS This study included 70 patients (140 eyes). At 1 month, 3 months, 6 months and 12 months after surgery, group 2 was superior to group 1 with regard to the improvement in upper eyelid relaxation at the medial limbus, middle pupil and lateral canthus. The eyebrow assumed a low and flat appearance in group 1. The eyebrow showed a low and flat appearance and then returned to the preoperative level in group 2. When comparing the two surgical techniques, the authors found statistically significant differences in regard to changes in crow's feet and glabellar frown lines. Two patients in group 2 experienced forehead numbness after surgery, which resolved by the 6-month follow-up. Patients in group 2 were significantly more satisfied with their surgery than patients in group 1. CONCLUSION SBB-pm is more effective than SBB for improving upper eyelid relaxation and preventing secondary brow ptosis after surgery as well as for alleviating periorbital wrinkles, although it is accompanied by transient forehead numbness. LEVEL OF EVIDENCE II This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.",2020,"At 1 month, 3 months, 6 months and 12 months after surgery, group 2 was superior to group 1 with regard to the improvement in upper eyelid relaxation at the medial limbus, middle pupil and lateral canthus.","['Periorbital Aging Rejuvenation in Asians', '70 patients (140 eyes']","['Subbrow Blepharoplasty and Subbrow Blepharoplasty Combined with Periorbital Muscle Manipulation', 'subbrow blepharoplasty (SBB) with subbrow blepharoplasty combined with periorbital muscle manipulation (SBB-pm', 'SBB', 'resection of excess skin; group 2 underwent a modified technique that involved resection of an elliptical island of skin, separation of the corrugator supercilii muscle and dissection of the orbicularis oculi muscle, followed by suturing it to the orbital periosteum and cross-fixation with itself']","['forehead numbness', 'upper lid relaxation, brow shape and periorbital wrinkles', 'upper eyelid relaxation', 'upper eyelid and eyebrow height, periorbital wrinkle score and patient satisfaction', 'satisfied with their surgery']","[{'cui': 'C0230064', 'cui_str': 'Periorbital region structure'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0035016', 'cui_str': 'Rejuvenation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}]","[{'cui': 'C0197213', 'cui_str': 'Blepharoplasty'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0230064', 'cui_str': 'Periorbital region structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0947647', 'cui_str': 'Manipulation - action (qualifier value)'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0022130', 'cui_str': 'Islands'}, {'cui': 'C0237868', 'cui_str': 'Separation'}, {'cui': 'C0224127', 'cui_str': 'Structure of corrugator supercilii muscle'}, {'cui': 'C0012737', 'cui_str': 'Dissection'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture (procedure)'}, {'cui': 'C0459563', 'cui_str': 'Orbital periosteum (body structure)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0016540', 'cui_str': 'Forehead'}, {'cui': 'C0020580', 'cui_str': 'Reduced Sensation'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0522512', 'cui_str': 'With shape (attribute)'}, {'cui': 'C0230064', 'cui_str': 'Periorbital region structure'}, {'cui': 'C0037301', 'cui_str': 'Skin Wrinkling'}, {'cui': 'C0585636', 'cui_str': 'Upper eyelid structure (body structure)'}, {'cui': 'C0015420', 'cui_str': 'Eyebrows'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]",70.0,0.0269323,"At 1 month, 3 months, 6 months and 12 months after surgery, group 2 was superior to group 1 with regard to the improvement in upper eyelid relaxation at the medial limbus, middle pupil and lateral canthus.","[{'ForeName': 'Jianzhang', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""Department of Plastic and Reconstructive SurgeryXijing Hospital, Fourth Military Medical University, No. 127 Changle West Road, Xi'an, 710032, Shaanxi Province, China.""}, {'ForeName': 'Yingjun', 'Initials': 'Y', 'LastName': 'Su', 'Affiliation': ""Department of Plastic and Reconstructive SurgeryXijing Hospital, Fourth Military Medical University, No. 127 Changle West Road, Xi'an, 710032, Shaanxi Province, China.""}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Plastic and Reconstructive SurgeryXijing Hospital, Fourth Military Medical University, No. 127 Changle West Road, Xi'an, 710032, Shaanxi Province, China.""}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Guo', 'Affiliation': ""Department of Plastic and Reconstructive SurgeryXijing Hospital, Fourth Military Medical University, No. 127 Changle West Road, Xi'an, 710032, Shaanxi Province, China.""}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Huang', 'Affiliation': ""Department of Plastic and Reconstructive SurgeryXijing Hospital, Fourth Military Medical University, No. 127 Changle West Road, Xi'an, 710032, Shaanxi Province, China.""}, {'ForeName': 'Baoqiang', 'Initials': 'B', 'LastName': 'Song', 'Affiliation': ""Department of Plastic and Reconstructive SurgeryXijing Hospital, Fourth Military Medical University, No. 127 Changle West Road, Xi'an, 710032, Shaanxi Province, China. songbq@fmmu.edu.cn.""}]",Aesthetic plastic surgery,['10.1007/s00266-020-01630-4'] 2990,31014099,Glycaemic variation is a predictor of all-cause mortality in the Veteran Affairs Diabetes Trial.,"Diabetes is associated with substantially increased mortality. Classic risk factors explain a portion of the excess of mortality in type 2 diabetes. The aim of this study was to examine whether visit-to-visit variation in fasting glucose and haemoglobin A1c values in the Veteran Affairs Diabetes Trial were associated with all-cause mortality in patients with type 2 diabetes in addition to other comorbidity conditions, hypoglycaemic events and adverse lifestyle behaviours. The Veteran Affairs Diabetes Trial was a randomized trial that enrolled 1791 military veterans who had a suboptimal response to therapy for type 2 diabetes to receive either intensive or standard glucose control. During the Veteran Affairs Diabetes Trial, fasting glucose and haemoglobin A1c were measured quarterly for up to 84 months. Variability measures included coefficient of variation and average real variability. We found that variability measures (coefficient of variation and average real variability) of fasting glucose were predictors of all-cause mortality, even after adjusting for comorbidity index, mean fasting glucose and adverse lifestyle behaviour during the study. Accounting for severe hypoglycaemia did not weaken this association. Our analysis indicates that in the Veteran Affairs Diabetes Trial, longitudinal variation in fasting glucose was associated with all-cause mortality, even when accounting for standard measures of glucose control as well as comorbidity and lifestyle factors.",2019,"During the Veteran Affairs Diabetes Trial, fasting glucose and haemoglobin A1c were measured quarterly for up to 84 months.","['enrolled 1791 military veterans who had a suboptimal response to therapy for type 2 diabetes to receive either', 'patients with type 2 diabetes in addition to other comorbidity conditions, hypoglycaemic events and adverse lifestyle behaviours']",['intensive or standard glucose control'],"['coefficient of variation and average real variability', 'fasting glucose and haemoglobin A1c values', 'comorbidity index, mean fasting glucose and adverse lifestyle behaviour', 'severe hypoglycaemia', 'fasting glucose and haemoglobin A1c', 'mortality']","[{'cui': 'C0026126', 'cui_str': 'Armed Forces Personnel'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4521595', 'cui_str': 'Lcpl'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",1791.0,0.0223078,"During the Veteran Affairs Diabetes Trial, fasting glucose and haemoglobin A1c were measured quarterly for up to 84 months.","[{'ForeName': 'Jin J', 'Initials': 'JJ', 'LastName': 'Zhou', 'Affiliation': '1 Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, The University of Arizona, Tucson, AZ, USA.'}, {'ForeName': 'Juraj', 'Initials': 'J', 'LastName': 'Koska', 'Affiliation': '2 Carl T. Hayden Phoenix VA Health Care System, Phoenix, AZ, USA.'}, {'ForeName': 'Gideon', 'Initials': 'G', 'LastName': 'Bahn', 'Affiliation': '3 Edward Hines, Jr. VA Hospital, Hines, IL, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Reaven', 'Affiliation': '2 Carl T. Hayden Phoenix VA Health Care System, Phoenix, AZ, USA.'}]",Diabetes & vascular disease research,['10.1177/1479164119827598'] 2991,29267900,Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.,"Background Estimating prognosis on the basis of clinicopathologic factors can inform clinical practice and improve risk stratification for clinical trials. We constructed prognostic nomograms for one-year overall survival and six-month progression-free survival in metastatic colorectal carcinoma by using the ARCAD database. Methods Data from 22 674 patients in 26 randomized phase III clinical trials since 1997 were used to construct and validate Cox models, stratified by treatment arm within each study. Candidate variables included baseline age, sex, body mass index, performance status, colon vs rectal cancer, prior chemotherapy, number and location of metastatic sites, tumor mutation status (BRAF, KRAS), bilirubin, albumin, white blood cell count, hemoglobin, platelets, absolute neutrophil count, and derived neutrophil-to-lymphocyte ratio. Missing data (<11%) were imputed, continuous variables modeled with splines, and clinically relevant pairwise interactions tested if P values were less than .001. Final models were internally validated via bootstrapping to obtain optimism-corrected calibration and discrimination C-indices, and externally validated on a 10% holdout sample from each trial (n = 2257). Results In final models, all included variables were associated with overall survival except for lung metastases, and all but total white cell count associated with progression-free survival. No clinically relevant pairwise interactions were identified. Final nomogram calibration was good (C = 0.68 for overall and C = 0.62 for progression-free survival), as was external validity (concordance between predicted >50% vs < 50% probability) and actual (yes/no) survival (72.8% and 68.2% concordance, respectively, for one-year overall and six-month progression-free survival, between predicted [>50% vs < 50% probability] and actual [yes/no] overall and progression-free survival). Median survival predictions fell within the actual 95% Kaplan-Meier confidence intervals. Conclusions The nomograms are well calibrated and internally and externally valid. They have the potential to aid prognostication and patient-physician communication and balance risk in colorectal cancer trials.",2018,"We constructed prognostic nomograms for one-year overall survival and six-month progression-free survival in metastatic colorectal carcinoma by using the ARCAD database. ","['Advanced Colorectal Cancer', '22 674 patients in 26 randomized phase III clinical trials since 1997']",[],"['six-month progression-free survival', 'survival', 'Median survival predictions', 'baseline age, sex, body mass index, performance status, colon vs rectal cancer, prior chemotherapy, number and location of metastatic sites, tumor mutation status (BRAF, KRAS), bilirubin, albumin, white blood cell count, hemoglobin, platelets, absolute neutrophil count, and derived neutrophil-to-lymphocyte ratio', 'progression-free survival', 'overall survival except for lung metastases', 'external validity (concordance']","[{'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1096780', 'cui_str': 'Clinical Trial, Phase 3'}, {'cui': 'C0730225', 'cui_str': '1997 (qualifier value)'}]",[],"[{'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0009368', 'cui_str': 'Colon'}, {'cui': 'C0007113', 'cui_str': 'Cancer of Rectum'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0450429', 'cui_str': 'Location (attribute)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin IX alpha'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0023508', 'cui_str': 'Blood Cell Count, White'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0948762', 'cui_str': 'Absolute neutrophil count'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear Leukocytes'}, {'cui': 'C4018897', 'cui_str': 'Lymphocyte component of blood'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0332300', 'cui_str': 'Except for (attribute)'}, {'cui': 'C0153676', 'cui_str': 'Secondary malignant neoplasm of lung (disorder)'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0042283', 'cui_str': 'Validity (Epidemiology)'}]",22674.0,0.13348,"We constructed prognostic nomograms for one-year overall survival and six-month progression-free survival in metastatic colorectal carcinoma by using the ARCAD database. ","[{'ForeName': 'Katrin M', 'Initials': 'KM', 'LastName': 'Sjoquist', 'Affiliation': 'NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Lindsay A', 'Initials': 'LA', 'LastName': 'Renfro', 'Affiliation': 'Mayo Clinic, Rochester, MN.'}, {'ForeName': 'R John', 'Initials': 'RJ', 'LastName': 'Simes', 'Affiliation': 'NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Niall C', 'Initials': 'NC', 'LastName': 'Tebbutt', 'Affiliation': 'Austin Health, Heidelberg, Victoria, Australia.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Clarke', 'Affiliation': 'Royal North Shore Hospital, St Leonards, Australia.'}, {'ForeName': 'Matthew T', 'Initials': 'MT', 'LastName': 'Seymour', 'Affiliation': 'Cancer Research UK Clinical Centre, Leeds, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Adams', 'Affiliation': 'Cardiff University and Velindre Cancer Centre, Cardiff, UK.'}, {'ForeName': 'Timothy S', 'Initials': 'TS', 'LastName': 'Maughan', 'Affiliation': ""St James's Hospital and University of Leeds, Leeds, UK.""}, {'ForeName': 'Leonard', 'Initials': 'L', 'LastName': 'Saltz', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Goldberg', 'Affiliation': 'West Virginia University Cancer Institute, Morgantown, WV.'}, {'ForeName': 'Hans-Joachim', 'Initials': 'HJ', 'LastName': 'Schmoll', 'Affiliation': 'Martin-Luther-University, Halle, Germany.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Van Cutsem', 'Affiliation': 'University Hospital Leuven, Leuven, Belgium.'}, {'ForeName': 'Jean-Yves', 'Initials': 'JY', 'LastName': 'Douillard', 'Affiliation': ""European Society for Medical Oncology (ESMO) Chief Medical Officer (CMO), Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Saint-Herblain, France.""}, {'ForeName': 'Paulo M', 'Initials': 'PM', 'LastName': 'Hoff', 'Affiliation': 'Instituto do Cancer do Estado de Sao Paulo, Universidade de Sao Paolo, Sao Paolo, Brazil.'}, {'ForeName': 'Joel Randolph', 'Initials': 'JR', 'LastName': 'Hecht', 'Affiliation': 'David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Tournigand', 'Affiliation': 'University of Paris Est Creteil, Paris, France.'}, {'ForeName': 'Cornelis J A', 'Initials': 'CJA', 'LastName': 'Punt', 'Affiliation': 'Department of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Koopman', 'Affiliation': 'University Medical Center Utrecht, Utrecht University, the Netherlands.'}, {'ForeName': 'Herbert', 'Initials': 'H', 'LastName': 'Hurwitz', 'Affiliation': 'Duke University Medical Center, Durham, NC.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Heinemann', 'Affiliation': 'University of Munich, Department of Medical Oncology and Comprehensive Cancer Center, Munich, Germany.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Falcone', 'Affiliation': 'Department of Oncology, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Porschen', 'Affiliation': 'Klinikum Bremen-Ost Klinik fur Innere Medizin, Bremen, Germany.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Fuchs', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Diaz-Rubio', 'Affiliation': 'Department of Oncology, Hospital Clínico San Carlos, CIBERONC Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Aranda', 'Affiliation': 'Department of Medical Oncology IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC Instituto de Salud Carlos III, Córdoba, Spain.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Bokemeyer', 'Affiliation': 'University Hospital, Hamburg-Eppendorf, Germany.'}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Souglakos', 'Affiliation': 'University of Crete, Heraklion, Greece.'}, {'ForeName': 'Fairooz F', 'Initials': 'FF', 'LastName': 'Kabbinavar', 'Affiliation': 'David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA.'}, {'ForeName': 'Benoist', 'Initials': 'B', 'LastName': 'Chibaudel', 'Affiliation': 'Franco-British Institute, Levallois-Perret, France.'}, {'ForeName': 'Jeffrey P', 'Initials': 'JP', 'LastName': 'Meyers', 'Affiliation': 'Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Sargent', 'Affiliation': 'Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Aimery', 'Initials': 'A', 'LastName': 'de Gramont', 'Affiliation': 'Franco-British Institute, Levallois-Perret, France.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Zalcberg', 'Affiliation': 'School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of the National Cancer Institute,['10.1093/jnci/djx253'] 2992,31359374,Evaluating the Effect of a Video Education Curriculum for First Time Breast Cancer Patients: a Prospective RCT Feasibility Study.,"Newly diagnosed breast cancer patients seek information through a variety of sources. In this small pilot study, we evaluated the feasibility of providing personalizable breast cancer video education prior to the first oncology consultation and compared outcomes to patients receiving standard of care educational materials. Personalized videos included detailed information on a patient's specific grade, stage, and tumor subtype (e.g., grade 2, stage 3, triple negative breast cancer) in addition to general videos that defined the terms of grade, stage, and cancer subtype. Newly diagnosed breast cancer patients who were scheduled for an initial oncology appointment at two sites were enrolled in this prospective, randomized control trial. Twenty-eight patients were assigned to receive either video education (experimental group) with the possibility of personalization or a video explaining how to view cancer education materials at the cancer center website (control group). Sixteen oncologists at the two centers also participated in evaluating patient outcomes. Pre- and post-education surveys queried patient-perceived understanding of breast cancer and treatment, perceived ability for decision-making, confidence in providers, and anxiety and depression symptoms. We observed that patients given video education had greater improvements in some of these areas, with the biggest improvement seen in patients who received a personalized video on their specific tumor subtype (based on tumor receptor status). Overall, however, there were no statistically significant differences between the study groups. We conclude that providing personalized video education during the time prior to first oncologic consultation is feasible and may provide benefit for patients, especially for explaining complex components of a diagnosis, such as a cancer subtype. Further research is needed to determine how to optimally provide education tailored to a given patient and tumor type, and how to leverage patients' electronic devices as an education delivery vehicle.",2019,"Overall, however, there were no statistically significant differences between the study groups.","['Newly diagnosed breast cancer patients who were scheduled for an initial oncology appointment at two sites', 'Sixteen oncologists at the two centers also participated in evaluating patient outcomes', 'patients receiving standard of care educational materials', 'Newly diagnosed breast cancer patients', 'Twenty-eight patients', 'First Time Breast Cancer Patients']","['video education (experimental group) with the possibility of personalization or a video explaining how to view cancer education materials at the cancer center website (control group', 'personalizable breast cancer video education', 'Video Education Curriculum', 'personalized video']","['breast cancer and treatment, perceived ability for decision-making, confidence in providers, and anxiety and depression symptoms']","[{'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0259990', 'cui_str': 'Oncologists'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C1632851', 'cui_str': 'Times'}]","[{'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C0554794', 'cui_str': 'Cancer education'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0220815', 'cui_str': 'curriculum'}]","[{'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",28.0,0.035516,"Overall, however, there were no statistically significant differences between the study groups.","[{'ForeName': 'Nika', 'Initials': 'N', 'LastName': 'Sulakvelidze', 'Affiliation': 'University of Washington School of Medicine, Seattle, WA, USA. nsulakvelidze@gmail.com.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Burdick', 'Affiliation': 'University of Washington School of Medicine, Seattle, WA, USA.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Kaklamani', 'Affiliation': 'Department of Medicine, Division of Hematology and Oncology, University of Texas Health Science Center - San Antonio, San Antonio, TX, USA.'}, {'ForeName': 'Kay', 'Initials': 'K', 'LastName': 'Tilton', 'Affiliation': 'Division of Breast Oncology, Seattle Cancer Care Alliance, Seattle, WA, USA.'}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Baker', 'Affiliation': 'Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Janice', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Javid', 'Affiliation': 'Department of Surgery, Division of Oncology, University of Washington School of Medicine, Seattle, WA, USA.'}, {'ForeName': 'Julie R', 'Initials': 'JR', 'LastName': 'Gralow', 'Affiliation': 'Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA, USA.'}]",Journal of cancer education : the official journal of the American Association for Cancer Education,['10.1007/s13187-019-01578-3'] 2993,32053534,"Reply to: ""The Analgesic Effects of Liposomal Bupivacaine versus Bupivacaine Hydrochloride Administered as a Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction: A Prospective, Single-Blind, Randomized, Controlled Trial"".",,2020,,['Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction'],"['Bupivacaine Hydrochloride', 'Liposomal Bupivacaine']",[],"[{'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C0443258', 'cui_str': 'Microvascular (qualifier value)'}, {'cui': 'C0085076', 'cui_str': 'Breast Reconstruction'}]","[{'cui': 'C0887621', 'cui_str': 'Bupivacaine Hydrochloride'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]",[],,0.155102,,"[{'ForeName': 'Austin Y', 'Initials': 'AY', 'LastName': 'Ha', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Washington University School of Medicine, Saint Louis, MO.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Guffey', 'Affiliation': 'Department of Anesthesiology, Washington University School of Medicine, Saint Louis, MO.'}, {'ForeName': 'Terence M', 'Initials': 'TM', 'LastName': 'Myckatyn', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Washington University School of Medicine, Saint Louis, MO.'}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000006783'] 2994,31956037,Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.,"BACKGROUND The prognostic value of tumour-infiltrating lymphocytes (TILs) differs by breast cancer (BC) subtype. The aim of this study was to evaluate TILs in stage III BC in the context of BRCA1/2-like phenotypes and association with outcome and benefit of intensified platinum-based chemotherapy. PATIENTS AND METHODS Patients participated in a randomised controlled trial of adjuvant intensified platinum-based chemotherapy versus conventional anthracycline-based chemotherapy carried out between 1993 and 1999 in stage III BC. Stromal TILs were scored according to International guidelines in these human epidermal growth factor receptor 2 (HER2)-negative tumours. BRCA-profiles were determined using Comparative Genomic Hybridization. RESULTS TIL levels were evaluated in 248 BCs. High TILs were associated with Triple Negative BC (TNBC). BRCA-like tumours harboured higher TILs compared to non-BRCA-like tumours (median TILs of 20% versus 10%, p < 0.01). TIL levels in BRCA1-like tumours were higher compared to BRCA2-like tumours (median TILs of 20% versus 10%, p < 0.001). These correlations remained significant within the oestrogen (ER)-positive subgroup, however not within the TNBC subgroup. In this stage III BC cohort, high TIL level was associated with favourable outcome (TILs per 10% increment, recurrence-free survival (RFS): multivariate hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.71-0.94, p = 0.01; overall survival (OS): multivariate HR 0.80, 95% CI 0.68-0.94, p = 0.01). There was no significant interaction between TILs and benefit of intensified platinum-based chemotherapy. CONCLUSION In this high-risk breast cancer cohort, high TILs were associated with TNBC and BRCA1-like status. Within the ER-positive subgroup, TIL levels were higher in BRCA1-like compared to BRCA2-like tumours. When adjusted for clinical characteristics, TILs were significantly associated with a more favourable outcome in stage III BC patients.",2020,"BRCA-like tumours harboured higher TILs compared to non-BRCA-like tumours (median TILs of 20% versus 10%, p < 0.01).","['stage III breast cancer patients', 'stage III BC patients', 'Patients participated', 'carried out between 1993 and 1999 in stage III BC']","['adjuvant intensified platinum-based chemotherapy versus conventional anthracycline-based chemotherapy', 'intensified platinum-based chemotherapy', 'adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy']","['recurrence-free survival (RFS): multivariate hazard ratio', 'Tumour-infiltrating lymphocytes (TILs) and BRCA-like status', 'TIL levels', 'TIL levels in BRCA1-like tumours', 'Triple Negative BC (TNBC', 'overall survival']","[{'cui': 'C0441771', 'cui_str': 'Stage level 3 (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}]","[{'cui': 'C1098768', 'cui_str': '(diethylenetriamine)-platinum(II)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0282564', 'cui_str': 'Anthracyclines'}]","[{'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease (finding)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0332448', 'cui_str': 'Tissue infiltration'}, {'cui': 'C4018897', 'cui_str': 'Lymphocyte component of blood'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",,0.195327,"BRCA-like tumours harboured higher TILs compared to non-BRCA-like tumours (median TILs of 20% versus 10%, p < 0.01).","[{'ForeName': 'Leonora', 'Initials': 'L', 'LastName': 'de Boo', 'Affiliation': 'Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Cimino-Mathews', 'Affiliation': 'Departments of Pathology and Oncology, The Johns Hopkins Hospital, Baltimore, USA.'}, {'ForeName': 'Yoni', 'Initials': 'Y', 'LastName': 'Lubeck', 'Affiliation': 'Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Antonios', 'Initials': 'A', 'LastName': 'Daletzakis', 'Affiliation': 'Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Opdam', 'Affiliation': 'Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Sanders', 'Affiliation': 'Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Hooijberg', 'Affiliation': 'Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Annelot', 'Initials': 'A', 'LastName': 'van Rossum', 'Affiliation': 'Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Zuzana', 'Initials': 'Z', 'LastName': 'Loncova', 'Affiliation': 'Division of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Dietmar', 'Initials': 'D', 'LastName': 'Rieder', 'Affiliation': 'Division of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Zlatko', 'Initials': 'Z', 'LastName': 'Trajanoski', 'Affiliation': 'Division of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Marieke', 'Initials': 'M', 'LastName': 'Vollebergh', 'Affiliation': 'Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'Sobral-Leite', 'Affiliation': 'Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Coordenação de Pesquisa, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'van de Vijver', 'Affiliation': 'Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Annegien', 'Initials': 'A', 'LastName': 'Broeks', 'Affiliation': 'Core Facility Molecular Pathology and Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Rianne', 'Initials': 'R', 'LastName': 'van der Wiel', 'Affiliation': 'Core Facility Molecular Pathology and Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Harm', 'Initials': 'H', 'LastName': 'van Tinteren', 'Affiliation': 'Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Linn', 'Affiliation': 'Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, University Medical Centre, Utrecht, the Netherlands.'}, {'ForeName': 'Hugo Mark', 'Initials': 'HM', 'LastName': 'Horlings', 'Affiliation': 'Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Marleen', 'Initials': 'M', 'LastName': 'Kok', 'Affiliation': 'Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: m.kok@nki.nl.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.12.003'] 2995,32065485,Efficacy of chlorhexidine patches on central line-associated bloodstream infections in children.,"BACKGROUND Central line-associated bloodstream infections (CLABSIs) are important hospital-acquired infections. Chlorhexidine-impregnated dressings (also known as chlorhexidine patches, CHG patches) are reported to decrease CLABSIs in adults. This study aims to determine the efficacy of CHG patches in reducing CLABSIs in children. METHODS An open-label randomized controlled trial was conducted in children aged 2 months to 18 years, requiring a short-term catheter. Patients were randomized into two groups, allocated to receive CHG patches or standard transparent dressings. Care of the catheter was in accordance with Asia Pacific Society of Infection Control (APSIC) recommendations. Central-line-associated bloodstream infections were defined using National Healthcare Safety Network surveillance criteria. RESULTS From April 2017 to April 2018, 192 children were enrolled. There were 108 CHG patch catheters and 101 standard dressing catheters, contributing to 3,113 catheter days. The median duration of catheter dwelling was 13 days, with an interquartile range (IQR) of 8-20 days. Half were placed at the jugular vein and 22% at the femoral vein. There were 23 CLABSI events. Incidence rates for CHG patches and standard dressings were 7.98 (95% confidence interval (CI), 4.25-13.65) and 6.74 (95% CI, 3.23-12.39) per 1,000 catheter days, respectively (incidence rate ratio 1.18; 95% CI, 0.52-2.70). The CLABSI pathogens were 15 Gram-negative bacteria, six Gram-positive bacteria, and two Candida organisms. Catheter colonization of CHG patches and standard dressings were 2.02 (95% CI, 0.42-5.91) and 3.07 (95% CI, 1.00-7.16) per 1,000 catheter days, respectively. Only local adverse effects occurred in 6.8% of the participants. CONCLUSIONS In our setting, there was no difference in CLABSI rates when the chlorhexidine patch dressings were compared with the standard transparent dressings. Strengthening of CLABSI prevention bundles is mandatory.",2020,"Catheter colonization of CHG-patches and standard dressings were 2.02 (95% CI, 0.42-5.91) and 3.07 (95% CI, 1.00-7.16) per 1000 catheter-days, respectively.","['From April 2017 to April 2018, 192 children were enrolled', 'children aged 2 months to 18 years requiring a short-term catheter', 'children']","['Chlorhexidine-impregnated dressings', 'chlorhexidine patch', 'CHG-patches or standard transparent dressings', 'CHG-patches']","['central line-associated bloodstream infections', 'median duration of catheter dwelling', 'Incidence rates', 'CLABSI rates', 'Catheter colonization of CHG-patches and standard dressings', 'local adverse effects']","[{'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}]","[{'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C1272974', 'cui_str': 'Impregnated dressing'}, {'cui': 'C0445403', 'cui_str': 'Human patch'}, {'cui': 'C1527601', 'cui_str': '(alphaMe)Chg'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0770788', 'cui_str': 'Transparent dressing (physical object)'}]","[{'cui': 'C1145640', 'cui_str': 'Central Venous Catheters'}, {'cui': 'C2316160', 'cui_str': 'Infection of bloodstream'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1527601', 'cui_str': '(alphaMe)Chg'}, {'cui': 'C0445403', 'cui_str': 'Human patch'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013119', 'cui_str': 'Dressings'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}]",192.0,0.129444,"Catheter colonization of CHG-patches and standard dressings were 2.02 (95% CI, 0.42-5.91) and 3.07 (95% CI, 1.00-7.16) per 1000 catheter-days, respectively.","[{'ForeName': 'Nattapong', 'Initials': 'N', 'LastName': 'Jitrungruengnij', 'Affiliation': 'Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Suvaporn', 'Initials': 'S', 'LastName': 'Anugulruengkitt', 'Affiliation': 'Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Thanapoom', 'Initials': 'T', 'LastName': 'Rattananupong', 'Affiliation': 'Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Mayuree', 'Initials': 'M', 'LastName': 'Prinyawat', 'Affiliation': 'Infection Control Unit, Department of Nursing, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.'}, {'ForeName': 'Watsamon', 'Initials': 'W', 'LastName': 'Jantarabenjakul', 'Affiliation': 'Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Noppadol', 'Initials': 'N', 'LastName': 'Wacharachaisurapol', 'Affiliation': 'Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Tanittha', 'Initials': 'T', 'LastName': 'Chatsuwan', 'Affiliation': 'Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Pakpoom', 'Initials': 'P', 'LastName': 'Janewongwirot', 'Affiliation': 'Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Pintip', 'Initials': 'P', 'LastName': 'Suchartlikitwong', 'Affiliation': 'Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Monta', 'Initials': 'M', 'LastName': 'Tawan', 'Affiliation': 'Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Phavinee', 'Initials': 'P', 'LastName': 'Kanchanabutr', 'Affiliation': 'Department of Nursing, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.'}, {'ForeName': 'Chitsanu', 'Initials': 'C', 'LastName': 'Pancharoen', 'Affiliation': 'Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Thanyawee', 'Initials': 'T', 'LastName': 'Puthanakit', 'Affiliation': 'Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}]",Pediatrics international : official journal of the Japan Pediatric Society,['10.1111/ped.14200'] 2996,31944250,Effects of a Parent-Administered Exercise Program in the Neonatal Intensive Care Unit: Dose Does Matter-A Randomized Controlled Trial.,"BACKGROUND Despite the risk of delayed motor development in infants born preterm, knowledge about interventions in the neonatal intensive care unitt (NICU) and the effects of dosing is sparse. OBJECTIVE The objectives of this study were to examine the effectiveness of a parent-administered exercise program in the NICU on motor outcome at 3 months corrected age (CA) and the effect of dosing on motor performance. DESIGN This was a randomized clinical trial. SETTING The study was conducted at 3 university hospitals in Tromsø, Trondheim, and Oslo, Norway. PARTICIPANTS A total of 153 infants with gestational age <32 weeks at birth were randomly assigned to intervention or control groups. INTERVENTION A 3-week parent-administered intervention designed to facilitate movements in preterm infants was performed in the NICU. Parents were asked to administer the intervention 10 minutes twice a day. MEASUREMENTS Test of Infant Motor Performance (TIMP) was used to assess short-term outcome at 3 months CA. RESULTS No significant difference in the TIMP z-score was found between intervention and control groups at follow-up 3 months CA, but a significant positive relationship was found between total intervention dose and TIMP z-scores. The adjusted odds of having a clinical z-score < 0 at 3 months CA was about 6 times higher for infants with less than median intervention time than for infants with a longer intervention time. LIMITATIONS The number of infants born before 28 weeks was small. A spillover effect in favor of the control group was possible. We do not know if the infants received physical therapy after discharge from the hospital. CONCLUSIONS There was no difference in motor performance between the intervention group and the control group at 3 months CA. However, an increased intervention dose was positively associated with improved motor outcome.",2020,"No significant difference in the TIMP z-score was found between intervention and control groups at follow-up 3 months CA, but a significant positive relationship was found between total intervention dose and TIMP z-scores.","['3 university hospitals in Tromsø, Trondheim, and Oslo, Norway', 'A total of 153 infants with gestational age < 32 weeks at birth', 'infants born preterm', 'Neonatal Intensive Care Unit']","['parent-administered exercise program', 'physical therapy', 'Patient-Administered Exercise Program']","['TIMP z-score', 'motor outcome', 'Test of Infant Motor Performance (TIMP', 'motor performance', 'total intervention dose and TIMP z-scores']","[{'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0028423', 'cui_str': 'Kingdom of Norway'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1744681', 'cui_str': 'Congenital (qualifier value)'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0021709', 'cui_str': 'Newborn ICU'}]","[{'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]",153.0,0.132704,"No significant difference in the TIMP z-score was found between intervention and control groups at follow-up 3 months CA, but a significant positive relationship was found between total intervention dose and TIMP z-scores.","[{'ForeName': 'Gunn Kristin', 'Initials': 'GK', 'LastName': 'Øberg', 'Affiliation': 'Department of Health and Care Sciences, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, PB 6050 Langnes, Tromsø, 9037 Norway; and Department of Clinical Therapeutic Services, University Hospital North Norway, Tromsø, Norway.'}, {'ForeName': 'Gay L', 'Initials': 'GL', 'LastName': 'Girolami', 'Affiliation': 'Department of Physical Therapy, College of Applied Health Sciences, University of Illinois at Chicago, Chicago, Illinois.'}, {'ForeName': 'Suzann K', 'Initials': 'SK', 'LastName': 'Campbell', 'Affiliation': 'University of Illinois at Chicago.'}, {'ForeName': 'Tordis', 'Initials': 'T', 'LastName': 'Ustad', 'Affiliation': 'Department of Clinical Services, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.'}, {'ForeName': 'Ivar', 'Initials': 'I', 'LastName': 'Heuch', 'Affiliation': 'Department of Mathematics, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Bjarne K', 'Initials': 'BK', 'LastName': 'Jacobsen', 'Affiliation': 'Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway; and Centre for Sami Health Research, Department of Community Medicine, University of Tromsø, The Arctic University of Norway.'}, {'ForeName': 'Per Ivar', 'Initials': 'PI', 'LastName': 'Kaaresen', 'Affiliation': 'Pediatric and Adolescent Department, University Hospital North Norway; and Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway.'}, {'ForeName': 'Vibeke Smith', 'Initials': 'VS', 'LastName': 'Aulie', 'Affiliation': 'Section of Physiotherapy, Oslo University Hospital, Ullevål, Oslo, Norway.'}, {'ForeName': 'Lone', 'Initials': 'L', 'LastName': 'Jørgensen', 'Affiliation': 'Department of Health and Care Sciences, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway; and Department of Clinical Therapeutic Services, University Hospital North Norway.'}]",Physical therapy,['10.1093/ptj/pzaa014'] 2997,32049889,Does Circadian Rhythm Affect the Pharmacokinetics of Once-Daily Tobramycin in Adults With Cystic Fibrosis?,"BACKGROUND In the era of multiple daily dosing of systemic aminoglycosides, a circadian rhythm in the clearance of these vital antibiotics has been demonstrated in animals and healthy volunteers. Over the past decade, once-daily dosing regimens have been proved to be less nephrotoxic and were therefore adopted worldwide for most indications requiring treatment with an aminoglycoside. In this study, the effect of the time of administration on the pharmacokinetics of once-daily tobramycin in adults with cystic fibrosis (CF) experiencing a pulmonary exacerbation was investigated. METHODS In this open randomized study, patients with CF received intravenous tobramycin at 8:00 or 22:00 hours. Pharmacokinetic and kidney function parameters were compared between the 2 groups. RESULTS Twenty-five patients were included. The mean weight-corrected clearances of tobramycin were 1.46 versus 1.43 mL/h*kg (P = 0.50) and mean volumes of distribution were 0.25 versus 0.27 L/kg (P = 0.54) for the 8:00 and 22:00 groups, respectively. In addition, no significant differences were detected in changes in estimated clearances of creatinine or tobramycin on day 1 and day 8 in the 8:00 or 22:00 group, indicating that there was no decline in clearance over time. At day 8 of therapy, the increase in serum blood urea nitrogen in the 22:00 group was significantly higher than that in the 8:00 group (1.8 versus 0.2 mmol/L, P = 0.015). CONCLUSIONS The time of administration (8:00 versus 22:00) did not affect tobramycin pharmacokinetics in the adult CF population studied. The increase in serum blood urea nitrogen in the 22:00 group requires further investigation.",2020,"At day 8 of therapy, the increase in serum blood urea nitrogen in the 22:00 group was significantly higher than that in the 8:00 group (1.8 vs. 0.2 mmol/L, p=0.015). ","['animals and healthy volunteers', 'Twenty-five patients were included', 'Adults with Cystic Fibrosis', 'adults with cystic fibrosis (CF) experiencing a pulmonary exacerbation was investigated', 'patients with CF received']","['intravenous tobramycin', 'tobramycin', 'Tobramycin', 'aminoglycoside']","['serum blood urea nitrogen', 'tobramycin pharmacokinetics', 'mean weight-corrected clearances of tobramycin', 'estimated clearances of creatinine or tobramycin']","[{'cui': 'C0003062', 'cui_str': 'Animals'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0010674', 'cui_str': 'Mucoviscidosis'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0040341', 'cui_str': 'Tobramycin'}, {'cui': 'C0002556', 'cui_str': 'Aminoglycosides'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0600137', 'cui_str': 'Blood urea nitrogen (substance)'}, {'cui': 'C0040341', 'cui_str': 'Tobramycin'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}]",25.0,0.0258946,"At day 8 of therapy, the increase in serum blood urea nitrogen in the 22:00 group was significantly higher than that in the 8:00 group (1.8 vs. 0.2 mmol/L, p=0.015). ","[{'ForeName': 'Erik M', 'Initials': 'EM', 'LastName': 'van Maarseveen', 'Affiliation': '*University Medical Center Utrecht, Clinical Pharmacy, Utrecht; †Haga Teaching Hospital, Pulmonary Diseases, The Hague; ‡CAPHRI, Maastricht University Medical Center, Clinical Pharmacy, Maastricht; §CAPRI, Maastricht; and ¶Central Pharmacy, The Hague, Clinical Pharmacy, the Netherlands. Dr. TouW is now with the Department of Hospital and Clinical Pharmacy, University of Groningen, University Medical Center Groningen, Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Renske', 'Initials': 'R', 'LastName': 'van der Meer', 'Affiliation': ''}, {'ForeName': 'Cees', 'Initials': 'C', 'LastName': 'Neef', 'Affiliation': ''}, {'ForeName': 'Harry G M', 'Initials': 'HGM', 'LastName': 'Heijerman', 'Affiliation': ''}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Touw', 'Affiliation': ''}]",Therapeutic drug monitoring,['10.1097/FTD.0000000000000743'] 2998,31396891,Influence of Postoperative Posture on Macular Slippage after Macula-Off Retinal Detachment: A Randomized Controlled Trial.,"INTRODUCTION To evaluate the effect of postoperative posture on the retinal shift after retinal detachment repair. METHODS Patients who underwent pars plana vitrectomy (PPV) for macula-off rhegmatogenous retinal detachment (RRD) were included prospectively in the current study. Patients were randomized into two groups: group A included patients who did a log roll postoperatively, and group B included patients who had to lie flat on their backs for 6 h postoperatively before moving into the end position. Patients in group A and patients in group B were reviewed after 3 weeks and after 6 weeks, respectively, and fundus autofluorescence images (FAF) were obtained to visualize the retinal rotation. RESULTS The sample included 50 eyes from 49 patients. Retinal shift occurred after RRD repair in 17 patients (34%). There was no statistically significant difference between the two groups (p = 0.94). Postoperative macular shift occurred significantly less often (p  = 0.049) in participants in whom heavy fluid was used in the procedure. Metamorphopsia was reported postoperatively by 10 of 17 patients with retinal shift (p < 0.001). CONCLUSION In our study, postoperative posture did not significantly influence postoperative macular slippage after RRD repair. The use of intraoperative heavy liquid appears to be associated with a lower occurrence of retinal shift.",2019,Postoperative macular shift occurred significantly less often (p  = 0.049) in participants in whom heavy fluid was used in the procedure.,"['for macula-off rhegmatogenous retinal detachment (RRD', 'Patients who underwent', 'Macular Slippage after Macula-Off Retinal Detachment', 'The sample included 50 eyes from 49 patients']","['Postoperative Posture', 'postoperative posture', 'pars plana vitrectomy (PPV']","['Metamorphopsia', 'Retinal shift', 'Postoperative macular shift']","[{'cui': 'C0332573', 'cui_str': 'Macule (morphologic abnormality)'}, {'cui': 'C0271055', 'cui_str': 'Rhegmatogenous retinal detachment (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0035305', 'cui_str': 'Retinal Detachment'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C1262869', 'cui_str': 'Posture'}, {'cui': 'C0042903', 'cui_str': 'Vitrectomy'}]","[{'cui': 'C0271185', 'cui_str': 'Metamorphopsia'}, {'cui': 'C0035331', 'cui_str': 'Retinal'}, {'cui': 'C0333051', 'cui_str': 'Shift (morphologic abnormality)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}]",50.0,0.053386,Postoperative macular shift occurred significantly less often (p  = 0.049) in participants in whom heavy fluid was used in the procedure.,"[{'ForeName': 'Megir', 'Initials': 'M', 'LastName': 'Schawkat', 'Affiliation': 'Eye Clinic, Cantonal Hospital Sankt Gallen, St. Gallen, Switzerland.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Valmaggia', 'Affiliation': 'Eye Clinic, Cantonal Hospital Sankt Gallen, St. Gallen, Switzerland.'}, {'ForeName': 'Corina', 'Initials': 'C', 'LastName': 'Lang', 'Affiliation': 'Eye Clinic, Cantonal Hospital Sankt Gallen, St. Gallen, Switzerland.'}, {'ForeName': 'Hendrik P N', 'Initials': 'HPN', 'LastName': 'Scholl', 'Affiliation': 'Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Harsum', 'Affiliation': 'Epsom and St Helier University Hospitals, NHS Trust, London, UK.'}, {'ForeName': 'Ivo', 'Initials': 'I', 'LastName': 'Guber', 'Affiliation': 'Department of Ophthalmology, University of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Josef', 'Initials': 'J', 'LastName': 'Guber', 'Affiliation': 'Eye Clinic, Cantonal Hospital Sankt Gallen, St. Gallen, Switzerland. josef.guber@kssg.ch.'}]",Ophthalmology and therapy,['10.1007/s40123-019-0204-8'] 2999,32068572,Effect of an ultrasound-guided lung recruitment manoeuvre on postoperative atelectasis in children: A randomised controlled trial.,"BACKGROUND Ultrasound-guided alveolar recruitment, regardless of the technique, could be more effective because it facilitates real-time monitoring of the expansion of collapsed alveoli. OBJECTIVES To evaluate and compare the effects of an ultrasound-guided lung recruitment manoeuvre with those of a conventional recruitment manoeuvre on the occurrence of postoperative atelectasis and clinical outcomes in children. DESIGN A randomised controlled trial. SETTING Tertiary children's hospital. PATIENTS Children aged 6 years or less. INTERVENTION Children scheduled for simple, superficial procedures underwent lung ultrasound after tracheal intubation (T1), at the end of surgery (T2) and before discharge from the postanaesthesia care unit (T3). Following lung ultrasound evaluation at T1 and T2, the conventional recruitment manoeuvre with a maximal airway pressure of 30 cmH2O was performed in the control group, while an ultrasound-guided recruitment manoeuvre was performed in the ultrasound group. MAIN OUTCOME MEASURES The primary outcome was the incidence of significant atelectasis at T3. RESULTS The incidences of atelectasis at T3 were 20.9 and 11.6% in the control (n = 43) and ultrasound groups (n = 43), respectively (odds ratio [OR], 2.012; 95% confidence interval [CI], 0.614 to 6.594; P = 0.249). The lung ultrasound scores were better in the ultrasound group than in the control group at T2 and T3, and the incidence of postoperative desaturation was higher in the control group than in the ultrasound group (16.3 vs. 2.3%; OR, 0.12; 95% CI 0.01 to 1.04; P = 0.05). The median airway pressure required for full lung expansion in the ultrasound group was 35 cmH2O at T1 and T2. Other postoperative outcomes were similar between groups. CONCLUSION Ultrasound-guided lung recruitment may be more effective than the conventional procedure in terms of the prevention of intra-operative atelectasis and postoperative desaturation; however, its beneficial effects on postoperative atelectasis remain unclear. An inspiratory airway pressure of more than 30 cmH2O is required for full recruitment of alveoli in healthy children. CLINICAL TRIAL REGISTRY ClinicalTrials.gov (NCT03453762).",2020,"The lung ultrasound scores were better in the ultrasound group than in the control group at T2 and T3, and the incidence of postoperative desaturation was higher in the control group than in the ultrasound group (16.3 vs. 2.3%; OR, 0.12; 95% CI 0.01 to 1.04; P = 0.05).","['healthy children', 'Children aged 6 years or less', ""Tertiary children's hospital"", 'children']","['Children scheduled for simple, superficial procedures underwent lung ultrasound after tracheal intubation (T1', 'ultrasound-guided lung recruitment manoeuvre']","['incidences of atelectasis', 'lung ultrasound scores', 'incidence of significant atelectasis at T3', 'incidence of postoperative desaturation', 'median airway pressure required for full lung expansion']","[{'cui': 'C0686744', 'cui_str': 'Well child (finding)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0020017', 'cui_str': 'Hospitals, Pediatric'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0205352', 'cui_str': 'Simple (qualifier value)'}, {'cui': 'C0205124', 'cui_str': 'Superficial (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C4286019', 'cui_str': 'Lung ultrasound'}, {'cui': 'C0021932', 'cui_str': 'Intubation, Endotracheal'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0004144', 'cui_str': 'Lung Collapse'}, {'cui': 'C4286019', 'cui_str': 'Lung ultrasound'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}, {'cui': 'C0024109', 'cui_str': 'Lung'}]",,0.192551,"The lung ultrasound scores were better in the ultrasound group than in the control group at T2 and T3, and the incidence of postoperative desaturation was higher in the control group than in the ultrasound group (16.3 vs. 2.3%; OR, 0.12; 95% CI 0.01 to 1.04; P = 0.05).","[{'ForeName': 'Ji-Hyun', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'From the Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Seungeun', 'Initials': 'S', 'LastName': 'Choi', 'Affiliation': ''}, {'ForeName': 'Sang-Hwan', 'Initials': 'SH', 'LastName': 'Ji', 'Affiliation': ''}, {'ForeName': 'Young-Eun', 'Initials': 'YE', 'LastName': 'Jang', 'Affiliation': ''}, {'ForeName': 'Eun-Hee', 'Initials': 'EH', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Hee-Soo', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Jin-Tae', 'Initials': 'JT', 'LastName': 'Kim', 'Affiliation': ''}]",European journal of anaesthesiology,['10.1097/EJA.0000000000001175'] 3000,32014812,"Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.","BACKGROUND The RAINBOW trial showed that second-line ramucirumab with paclitaxel prolongs overall survival (OS) and progression-free survival (PFS) compared with placebo plus paclitaxel for treatment of advanced gastric/gastroesophageal junction cancer. Plasma samples were collected from patients during the trial and tested to identify predictive and prognostic biomarkers. PATIENTS AND METHODS Circulating factors in plasma samples from mutually exclusive subsets of RAINBOW patients were assayed using: Intertek assays (24 markers, 380 samples, 57% of patients) and Lilly-developed assay (LDA) platform (5 markers, 257 samples, 39% of patients). Time-trend plots were generated for each marker from the Intertek assays. Baseline patient data were dichotomized into low- and high-marker subgroups. Markers were analyzed for predictive effects using interaction models and for prognostic effects using main-effects models. RESULTS The Intertek and LDA populations were representative of the full trial population. Plasma levels of VEGF-D and PlGF increased from baseline levels during treatment, then declined after treatment discontinued. Angiopoietin-2 exhibited a decrease during treatment, then increased after treatment discontinuation. No clear time trend was evident with the other markers. Analyses of baseline biomarker expression and its relationship with efficacy variables found no biomarker was predictive for efficacy outcomes, including VEGF-D. However, CRP, HGF, ICAM-3, IL-8, SAA, and VCAM-1 were identified as potential prognostic markers with low baseline levels corresponding to longer OS and PFS. CONCLUSIONS Pharmacodynamic and prognostic relationships were found from the exploratory biomarker analyses in RAINBOW; however, no predictive markers for ramucirumab in gastric cancer were identified in this trial.",2020,"However, CRP, HGF, ICAM-3, IL-8, SAA, and VCAM-1 were identified as potential prognostic markers with low baseline levels corresponding to longer OS and PFS. ","['Circulating factors in plasma samples from mutually exclusive subsets of RAINBOW patients were assayed using: Intertek assays (24 markers, 380 samples, 57% of patients) and Lilly-developed assay (LDA) platform (5 markers, 257 samples, 39% of patients', 'advanced gastric/gastroesophageal junction cancer', 'patients with advanced gastric cancer']","['placebo plus paclitaxel', 'paclitaxel']","['Plasma samples', 'CRP, HGF, ICAM-3, IL-8, SAA, and VCAM-1', 'Plasma levels of VEGF-D and PlGF', 'overall survival (OS) and progression-free survival (PFS']","[{'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0444263', 'cui_str': 'Plasma specimen'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1510438', 'cui_str': 'Assay technique (qualifier value)'}, {'cui': 'C4319693', 'cui_str': 'Three hundred and eighty'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C0014871', 'cui_str': 'Gastroesophageal Junction'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0024623', 'cui_str': 'Cancer of Stomach'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}]","[{'cui': 'C0444263', 'cui_str': 'Plasma specimen'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C4319664', 'cui_str': 'ICAM3'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0078056', 'cui_str': 'CD106 Antigens'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0664390', 'cui_str': 'Vascular Endothelial Growth Factor D'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",,0.236128,"However, CRP, HGF, ICAM-3, IL-8, SAA, and VCAM-1 were identified as potential prognostic markers with low baseline levels corresponding to longer OS and PFS. ","[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Van Cutsem', 'Affiliation': 'Digestive Oncology, University Hospitals Gasthuisberg, Leuven and KULeuven, Leuven, Belgium. Electronic address: Eric.VanCutsem@uzleuven.be.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Muro', 'Affiliation': 'Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Cunningham', 'Affiliation': 'Royal Marsden Hospital, Sutton, UK.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Bodoky', 'Affiliation': 'Department of Oncology, St. László Hospital, Budapest, Hungary.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Sobrero', 'Affiliation': 'Medical Oncology, IRCCS Ospedale San Martino IST, Genova, Italy.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Cascinu', 'Affiliation': 'Department of Medical Oncology, Università Politecnica Delle Marche, Ancona, Italy.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ajani', 'Affiliation': 'Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'S C', 'Initials': 'SC', 'LastName': 'Oh', 'Affiliation': 'Korea University Guro Hospital, Seoul, South Korea.'}, {'ForeName': 'S E', 'Initials': 'SE', 'LastName': 'Al-Batran', 'Affiliation': 'Institute of Clinical Cancer Research (IKF), UCT- University Cancer Center, Frankfurt, Germany.'}, {'ForeName': 'Z A', 'Initials': 'ZA', 'LastName': 'Wainberg', 'Affiliation': 'Medical Hematology and Oncology, University of California Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'S R', 'Initials': 'SR', 'LastName': 'Wijayawardana', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Melemed', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Ferry', 'Affiliation': 'Eli Lilly and Company, Bridgewater, NJ, USA.'}, {'ForeName': 'R R', 'Initials': 'RR', 'LastName': 'Hozak', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ohtsu', 'Affiliation': 'Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.10.026'] 3001,2959623,Oral immunization of humans with Streptococcus sobrinus glucosyltransferase.,"The effect of oral administration of glucosyltransferase (GTF) from Streptococcus sobrinus 6715 on levels of immunoglobulin A (IgA) antibody to GTF in parotid saliva and on the number of indigenous Streptococcus mutans in the whole saliva was studied in young adult males. GTF combined with aluminum phosphate (AP) was administered in capsules to 14 subjects, while sodium phosphate buffer combined with AP was administered in the same way to 11 control subjects. Thirteen administrations were given during the first immunization regimen, and five administrations, approximately 3 months later, constituted the second immunization regimen. All subjects were given professional dental prophylaxis immediately prior to each immunization. Each subject served as his own control by using antibody and bacterial data collected prior to antigen administration for comparison. After the first immunization regimen, the GTF vaccine group exhibited a significantly higher distribution (P less than 0.05) of normalized parotid saliva IgA antibody elevations than observed in the placebo group. Between the first and second immunization regimens a significant increase (P less than 0.05) in parotid salivary anti-GTF activity also occurred in the GTF vaccine but not the placebo group. No significant differences between these two groups were observed on any occasion when serum IgG or IgA antibody to GTF was analyzed. Comparison of the group mean log ratios (post- to prevaccine administration) of S. mutans to total streptococci in whole saliva revealed that the GTF vaccine group values were always lower than those of the placebo group. These differences reached significance (P less than 0.01) on three of the last four sampling occasions (days 21, 35, and 42) following initiation of the first immunization regimen. The mean log ratios of the GTF vaccine group were also lower than those of the placebo group after the second immunization regimen but did not reach significance. These data indicate that oral administration of GTF from the mutans streptococci has the potential to elicit a salivary IgA antibody response when combined with an aluminum-based adjuvant and that this response can interfere with the reaccumulation of indigenous S. mutans following dental prophylaxis.",1987,No significant differences between these two groups were observed on any occasion when serum IgG or IgA antibody to GTF was analyzed.,"['young adult males', 'humans with Streptococcus sobrinus glucosyltransferase']","['glucosyltransferase (GTF', 'placebo', 'GTF', 'GTF combined with aluminum phosphate (AP', 'GTF vaccine', 'sodium phosphate buffer combined with AP']","['serum IgG or IgA antibody to GTF', 'mean log ratios', 'parotid salivary anti-GTF activity', 'normalized parotid saliva IgA antibody elevations']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0085497', 'cui_str': 'Streptococcus sobrinus'}, {'cui': 'C0017772', 'cui_str': 'Glucosyltransferases'}]","[{'cui': 'C0017772', 'cui_str': 'Glucosyltransferases'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0051519', 'cui_str': 'aluminium phosphate'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0074757', 'cui_str': 'sodium phosphate'}, {'cui': 'C0006353', 'cui_str': 'Buffers'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0030580', 'cui_str': 'Parotid Gland'}, {'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0036087', 'cui_str': 'Saliva (substance)'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}]",13.0,0.0221313,No significant differences between these two groups were observed on any occasion when serum IgG or IgA antibody to GTF was analyzed.,"[{'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Smith', 'Affiliation': 'Department of Immunology, Forsyth Dental Center, Boston, Massachusetts 02115.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Taubman', 'Affiliation': ''}]",Infection and immunity,[] 3002,32060605,Mastopexy with Autologous Augmentation in Women After Massive Weight Loss: A Randomized Clinical Trial.,"BACKGROUND Breast reshaping or mastopexy following massive weight loss can be challenging. The LOPOSAM (lower pole subglandular advancement mastoplasty) technique has shown promising results for correction of ptotic, wide, lateralized and deflated breasts following massive weight loss. MATERIALS AND METHODS We compared the LOPOSAM technique to the mastopexy technique after massive weight loss described by Rubin JP, in a randomized trial. The main outcome measure was the total operative time. Secondary outcomes measures were socio-economic factors; length of hospital stay, numbers of sutures used, secondary corrective procedures, post-operative sick leave and surgeon- and patient-reported appearance of the breasts. RESULTS We included 22 women: 11 operated on by the LOPOSAM technique and 11 by the technique described by Rubin JP. The total operative time was 84.8 (SD 12.2) minutes in the LOPOSAM group and 99.1 (SD 23.5) in the Rubin JP group (p = 0.074). There were no differences related to days with drains, length of hospital stay or sick leave between the two groups. The surgeon- and the patient-reported appearance of the breasts changed significantly between the pre-operative and the 12-month post-operative assessments. CONCLUSION The LOPOSAM technique is a safe and quick surgical procedure for correction of ptotic, wide, lateralized and deflated breasts following massive weight loss and seems to provide results comparable to the better-known Rubin JP's technique. There was a trend that the LOPOSAM technique was faster to perform, however, not significant. The breast appearance improved significantly using both techniques when assessed by both surgeons and patients. LEVEL OF EVIDENCE IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.",2020,"The LOPOSAM technique is a safe and quick surgical procedure for correction of ptotic, wide, lateralized and deflated breasts following massive weight loss and seems to provide results comparable to the better-known Rubin JP's technique.","['After Massive Weight Loss', '22 women: 11 operated on by the LOPOSAM technique and 11 by the technique described by Rubin JP', 'Women']","['Mastopexy with Autologous Augmentation', 'IV']","['days with drains, length of hospital stay or sick leave', 'total operative time', 'socio-economic factors; length of hospital stay, numbers of sutures used, secondary corrective procedures, post-operative sick leave and surgeon- and patient-reported appearance of the breasts', 'breast appearance']","[{'cui': 'C0522501', 'cui_str': 'Massive (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0025664', 'cui_str': 'techniques'}]","[{'cui': 'C0191918', 'cui_str': 'Fixation of pendulous breast (procedure)'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C1293122', 'cui_str': 'Augmentation procedure'}]","[{'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0180499', 'cui_str': 'Drain, device (physical object)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0242807', 'cui_str': 'Sick Leave'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0205749', 'cui_str': 'Factors, Economic'}, {'cui': 'C0457280', 'cui_str': 'Number of sutures (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0582175', 'cui_str': 'Surgeon (occupation)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0700364', 'cui_str': 'Appearances (qualifier value)'}, {'cui': 'C0006141', 'cui_str': 'Breast'}]",22.0,0.0838096,"The LOPOSAM technique is a safe and quick surgical procedure for correction of ptotic, wide, lateralized and deflated breasts following massive weight loss and seems to provide results comparable to the better-known Rubin JP's technique.","[{'ForeName': 'Peder', 'Initials': 'P', 'LastName': 'Ikander', 'Affiliation': 'Department of Plastic Surgery, Odense University Hospital and OPEN, Open Patient data Explorative Network, Odense University Hospital, Region of Southern Denmark, J. B. Winsløws Vej 4, 5000, Odense, Denmark. peder.ikander@gmail.com.'}, {'ForeName': 'Jens A', 'Initials': 'JA', 'LastName': 'Sørensen', 'Affiliation': 'Department of Plastic Surgery, Odense University Hospital and OPEN, Open Patient data Explorative Network, Odense University Hospital, Region of Southern Denmark, J. B. Winsløws Vej 4, 5000, Odense, Denmark.'}, {'ForeName': 'Jørn B', 'Initials': 'JB', 'LastName': 'Thomsen', 'Affiliation': 'Department of Plastic Surgery, Odense University Hospital and OPEN, Open Patient data Explorative Network, Odense University Hospital, Region of Southern Denmark, J. B. Winsløws Vej 4, 5000, Odense, Denmark.'}]",Aesthetic plastic surgery,['10.1007/s00266-020-01642-0'] 3003,31361019,"Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS).","OBJECTIVE To evaluate the long-term safety of NKTR-181, a novel mu-opioid receptor agonist that may have reduced human abuse potential, in patients with moderate to severe chronic low back pain (CLBP) or other chronic noncancer pain (CNP). DESIGN Uncontrolled, multicenter, open-label, long-term study of NKTR-181 comprised of three periods: screening (≤21 days), treatment (52 weeks), and safety follow-up (∼14 days after the last dose of NKTR-181). SETTING Multicenter, long-term clinical research study. METHODS NKTR-181 administered at doses of 100-600 mg twice daily (BID) was evaluated in opioid-naïve and opioid-experienced patients. Patients were enrolled de novo or following completion of the randomized, placebo-controlled phase 3 efficacy study (SUMMIT-07). Safety assessments included adverse event documentation, measurements of opioid withdrawal, and clinical laboratory tests. Effectiveness was assessed using the modified Brief Pain Inventory Short Form (mBPI-SF). RESULTS The study enrolled 638 patients. The most frequently reported treatment-emergent adverse events (TEAEs) were constipation (26%) and nausea (12%). Serious TEAEs, reported in 5% of patients, were deemed by investigators to be unrelated to NKTR-181. There were no deaths or reported cases of respiratory depression. A sustained reduction in mBPI-SF pain intensity and pain interference from baseline to study termination was observed throughout treatment. Only 2% of patients discontinued NKTR-181 due to lack of efficacy, and 11% discontinued due to treatment-related AEs. NKTR-181 doses of up to 600 mg BID were generally well tolerated, and patients experienced low rates of opioid-related adverse events. CONCLUSIONS The study results support the premise that NKTR-181 is a safe and effective option for patients with moderate to severe CLBP or CNP.",2020,"Serious TEAEs, reported in 5% of patients, were deemed by investigators to be unrelated to NKTR-181.","['patients with moderate to severe chronic low back pain (CLBP) or other chronic noncancer pain (CNP', 'Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain', 'patients with moderate to severe CLBP or CNP', '638 patients']","['placebo', 'NKTR-181']","['mBPI-SF pain intensity and pain interference', 'adverse event documentation, measurements of opioid withdrawal, and clinical laboratory tests', 'modified Brief Pain Inventory Short Form (mBPI-SF', 'respiratory depression', 'nausea']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain (finding)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4547855', 'cui_str': 'NKTR-181'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0920316', 'cui_str': 'Documentation'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0029104', 'cui_str': 'Opioid withdrawal (disorder)'}, {'cui': 'C4505474', 'cui_str': 'Clinical Laboratory Tests'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0235063', 'cui_str': 'Respiratory Depression'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",638.0,0.0753513,"Serious TEAEs, reported in 5% of patients, were deemed by investigators to be unrelated to NKTR-181.","[{'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Gudin', 'Affiliation': '*Department of Anesthesiology, Rutgers New Jersey Medical School, Newark, New Jersey.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Rauck', 'Affiliation': 'Carolinas Pain Institute and The Center for Clinical Research, Winston-Salem, North Carolina.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Argoff', 'Affiliation': 'Department of Neurology, Albany Medical Center, Albany, New York.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Agaiby', 'Affiliation': 'Clinical Investigation Specialists Inc, Kenosha, Wisconsin.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Gimbel', 'Affiliation': 'Arizona Research Center, Phoenix, Arizona.'}, {'ForeName': 'Nathaniel', 'Initials': 'N', 'LastName': 'Katz', 'Affiliation': 'Tufts University School of Medicine, Boston, Massachusetts.'}, {'ForeName': 'Stephen K', 'Initials': 'SK', 'LastName': 'Doberstein', 'Affiliation': 'Nektar Therapeutics, San Francisco, California.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Tagliaferri', 'Affiliation': 'Nektar Therapeutics, San Francisco, California.'}, {'ForeName': 'Margit', 'Initials': 'M', 'LastName': 'Tagliaferri', 'Affiliation': 'Nektar Therapeutics, San Francisco, California.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Potts', 'Affiliation': 'Great Lakes Research Group, Inc, Bay City, Michigan.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Wild', 'Affiliation': 'Upstate Clinical Research Associates, Williamsville, New York.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Lu', 'Affiliation': 'Nektar Therapeutics, San Francisco, California.'}, {'ForeName': 'Suresh', 'Initials': 'S', 'LastName': 'Siddhanti', 'Affiliation': 'Nektar Therapeutics, San Francisco, California.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hale', 'Affiliation': 'Gold Coast Research, LLC, Plantation, Florida.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Markman', 'Affiliation': 'Department of Neurosurgery, Translational Pain Research Program, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnz169'] 3004,29388802,Graphic and Arousing? Emotional and Cognitive Reactions to Tobacco Graphic Health Warnings and Associated Quit-Related Outcomes Among Low SEP Population Groups.,"Research on graphic health warnings (GHWs) indicates that beyond changing cognitions about the health effects of smoking, GHWs evoke emotional reactions that can influence quit-related outcomes. Emotions can be classified based on valence (positive or negative) and arousal (calm or excited). However, although considerable research has examined the differential effectiveness of positive versus negative GHW-evoked emotions, research investigating the role of arousal activation in quit-related behaviors is scarce. This study examined associations between quit-related outcomes (intention and attempt to quit) and GHWs-evoked negative emotions classified as high and low in arousal activation as well as cognitive reactions among smokers of low socioeconomic position (SEP). It also examined whether perceived health risks of smoking moderate the relationship between emotional and cognitive reactions to GHWs and quit-related outcomes. Data were collected from low SEP smokers in three Massachusetts communities. Participants were screened and randomized to view one of the nine GHWs initially proposed for use by the U.S. Food and Drug Administration (FDA) and answered pre- and post-exposure questions. Results showed that GHW-evoked negative emotions high in arousal activation and cognitive reactions were both significantly associated with intention to quit during immediate post-test, controlling for age, warning label difference, and prior quit intention. However, these associations did not hold for quit attempts at follow-up. Perceived health risks of smoking moderated the association between cognitive reactions to GHWs and quit attempts at follow-up. The findings suggest that not all negative emotions evoked by GHWs are effective. Negative emotions high in arousal activation may be more effective in influencing quit-related behavioral intentions in low SEP groups. Additionally, unlike emotional reactions, cognitive reactions to GHWs may have effects that last relatively longer, but only among smokers who had low levels of perceived health risks of smoking at baseline.",2019,"Results showed that GHW-evoked negative emotions high in arousal activation and cognitive reactions were both significantly associated with intention to quit during immediate post-test, controlling for age, warning label difference, and prior quit intention.","['smokers of low socioeconomic position (SEP', 'Low SEP Population Groups']",[],['GHW-evoked negative emotions high in arousal activation and cognitive reactions'],"[{'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C1561964', 'cui_str': 'Patient Positioning'}, {'cui': 'C1257890', 'cui_str': 'Population Group'}]",[],"[{'cui': 'C1444748', 'cui_str': 'Provoked by (attribute)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0013987', 'cui_str': 'Emotions'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}]",,0.0172644,"Results showed that GHW-evoked negative emotions high in arousal activation and cognitive reactions were both significantly associated with intention to quit during immediate post-test, controlling for age, warning label difference, and prior quit intention.","[{'ForeName': 'Mesfin Awoke', 'Initials': 'MA', 'LastName': 'Bekalu', 'Affiliation': 'a Department of Social and Behavioral Sciences , Harvard T.H. Chan School of Public Health; Center for Community-Based Research, Dana-Farber Cancer Institute.'}, {'ForeName': 'Shoba', 'Initials': 'S', 'LastName': 'Ramanadhan', 'Affiliation': 'a Department of Social and Behavioral Sciences , Harvard T.H. Chan School of Public Health; Center for Community-Based Research, Dana-Farber Cancer Institute.'}, {'ForeName': 'Cabral A', 'Initials': 'CA', 'LastName': 'Bigman', 'Affiliation': 'b Department of Communication , University of Illinois at Urbana-Champaign.'}, {'ForeName': 'Rebekah H', 'Initials': 'RH', 'LastName': 'Nagler', 'Affiliation': 'c School of Journalism & Mass Communication; School of Public Health , University of Minnesota.'}, {'ForeName': 'Kasisomayajula', 'Initials': 'K', 'LastName': 'Viswanath', 'Affiliation': 'a Department of Social and Behavioral Sciences , Harvard T.H. Chan School of Public Health; Center for Community-Based Research, Dana-Farber Cancer Institute.'}]",Health communication,['10.1080/10410236.2018.1434733'] 3005,32053538,"Reply to: ""The Analgesic Effects of Liposomal Bupivacaine versus Bupivacaine Hydrochloride Administered as a Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction: A Prospective, Single-Blind, Randomized, Controlled Trial"".",,2020,,['Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction'],"['Bupivacaine Hydrochloride', 'Liposomal Bupivacaine']",[],"[{'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C0443258', 'cui_str': 'Microvascular (qualifier value)'}, {'cui': 'C0085076', 'cui_str': 'Breast Reconstruction'}]","[{'cui': 'C0887621', 'cui_str': 'Bupivacaine Hydrochloride'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]",[],,0.155102,,"[{'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Knackstedt', 'Affiliation': ''}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Gatherwright', 'Affiliation': ''}, {'ForeName': 'Risal', 'Initials': 'R', 'LastName': 'Djohan', 'Affiliation': ''}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000006782'] 3006,32056119,Brief Report: Autistic Adults Assign Less Weight to Affective Cues When Judging Others' Ambiguous Emotional States.,"Understanding other people's emotional states involves integrating multiple sources of information, such as someone's smile (affective cue) with our knowledge that they have passed an exam (situational cue). We explored whether autistic adults display differences in how they integrate these cues by showing participants videos of students receiving their exams results. Our results suggest autistic adults generally perform as neurotypical participants when identifying and integrating affective and situational cues. It was only in certain unfamiliar and ambiguous social situations that autistic adults assigned less weight to affective cues compared to situational cues when judging other people's emotional states.",2020,It was only in certain unfamiliar and ambiguous social situations that autistic adults assigned less weight to affective cues compared to situational cues when judging other people's emotional states.,"['autistic adults', 'Autistic Adults']",[],['Weight to Affective Cues'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}]",[],"[{'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0010439', 'cui_str': 'Cues'}]",,0.0199498,It was only in certain unfamiliar and ambiguous social situations that autistic adults assigned less weight to affective cues compared to situational cues when judging other people's emotional states.,"[{'ForeName': 'Paul A G', 'Initials': 'PAG', 'LastName': 'Forbes', 'Affiliation': 'Social, Cognitive and Affective Neuroscience Unit, Department of Cognition, Emotion, and Methods in Psychology, Faculty of Psychology, University of Vienna, Vienna, Austria. paul.forbes@univie.ac.at.'}, {'ForeName': 'Antonia F de C', 'Initials': 'AFC', 'LastName': 'Hamilton', 'Affiliation': 'Institute of Cognitive Neuroscience, University College London, London, UK.'}]",Journal of autism and developmental disorders,['10.1007/s10803-020-04410-w'] 3007,31836450,Lymphoma Study Titles on ClinicalTrials.gov Lack Details Necessary for Study Identification.,"BACKGROUND ClinicalTrials.gov is used by clinicians and patients to identify clinical trials. We assessed the ease with which users could identify relevant trials related to lymphoma using the short and official titles. We hypothesized that lymphoma titles frequently lack important information. MATERIALS AND METHODS We performed 2 searches on ClinicalTrials.gov. The first search was performed before June 2017, when ClinicalTrials.gov underwent updates to improve usability. The second was performed after 2017. We assessed whether the short and official titles of each trial provided information on the study phase, eligible disease status, lymphoma histologic subtype, study intervention, primary objective, and the presence of randomization and placebo control. RESULTS Of the pre-overhaul lymphoma trials, the official versus short titles included information regarding study intervention (99% vs. 96%), study phase (82% vs. 14%), lymphoma histologic subtype (78% vs. 72%), disease status (46% vs. 35%), randomization (13% vs. 2%), presence of placebo (6% vs. 2%), and primary objective (38% vs. 26%). Of the post-overhaul trials, the official versus short titles included information regarding study intervention (97% vs. 96%), lymphoma histologic subtype (83% vs. 78%), study phase (78% vs. 8%), disease status (64% vs. 50%), primary objective (38% vs. 23%), presence of placebo (11% vs. 0%), and randomization (18% vs. 0%). CONCLUSION The official titles were more informative than were the short titles on ClinicalTrials.gov. However, the short and official titles both often lacked the basic information needed to understand a clinical trial. This has persisted despite updates to the platform. These results highlight the need for standardization of the format and content included in study titles.",2020,"Of the post-overhaul trials, the official versus short titles included information regarding study intervention (97% vs. 96%), lymphoma histologic subtype (83% vs. 78%), study phase (78% vs. 8%), disease status (64% vs. 50%), primary objective (38% vs. 23%), presence of placebo (11% vs. 0%), and randomization (18% vs. 0%). ",[],['placebo'],"['disease status', 'lymphoma histologic subtype']",[],"[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0024299', 'cui_str': 'Germinoblastoma'}, {'cui': 'C0205462', 'cui_str': 'Histologic (qualifier value)'}, {'cui': 'C0449560', 'cui_str': 'Subtype (attribute)'}]",,0.12841,"Of the post-overhaul trials, the official versus short titles included information regarding study intervention (97% vs. 96%), lymphoma histologic subtype (83% vs. 78%), study phase (78% vs. 8%), disease status (64% vs. 50%), primary objective (38% vs. 23%), presence of placebo (11% vs. 0%), and randomization (18% vs. 0%). ","[{'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Toure', 'Affiliation': 'Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Ghione', 'Affiliation': 'Molecular Biotechnologies and Health Sciences, Torino University, Torino, Italy.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Phillips', 'Affiliation': 'Weill Cornell/Rockefeller University/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY.'}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Klute', 'Affiliation': 'Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Leonard', 'Affiliation': 'Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Martin', 'Affiliation': 'Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY. Electronic address: pem9109@med.cornell.edu.'}]","Clinical lymphoma, myeloma & leukemia",['10.1016/j.clml.2019.11.011'] 3008,32054897,Machine Learning Algorithms for Predicting the Recurrence of Stage IV Colorectal Cancer After Tumor Resection.,"The aim of this study is to explore the feasibility of using machine learning (ML) technology to predict postoperative recurrence risk among stage IV colorectal cancer patients. Four basic ML algorithms were used for prediction-logistic regression, decision tree, GradientBoosting and lightGBM. The research samples were randomly divided into a training group and a testing group at a ratio of 8:2. 999 patients with stage 4 colorectal cancer were included in this study. In the training group, the GradientBoosting model's AUC value was the highest, at 0.881. The Logistic model's AUC value was the lowest, at 0.734. The GradientBoosting model had the highest F1_score (0.912). In the test group, the AUC Logistic model had the lowest AUC value (0.692). The GradientBoosting model's AUC value was 0.734, which can still predict cancer progress. However, the gbm model had the highest AUC value (0.761), and the gbm model had the highest F1_score (0.974). The GradientBoosting model and the gbm model performed better than the other two algorithms. The weight matrix diagram of the GradientBoosting algorithm shows that chemotherapy, age, LogCEA, CEA and anesthesia time were the five most influential risk factors for tumor recurrence. The four machine learning algorithms can each predict the risk of tumor recurrence in patients with stage IV colorectal cancer after surgery. Among them, GradientBoosting and gbm performed best. Moreover, the GradientBoosting weight matrix shows that the five most influential variables accounting for postoperative tumor recurrence are chemotherapy, age, LogCEA, CEA and anesthesia time.",2020,"In the training group, the GradientBoosting model's AUC value was the highest, at 0.881.","['patients with stage IV colorectal cancer after surgery', 'Stage IV Colorectal Cancer', 'stage IV colorectal cancer patients', '999 patients with stage 4 colorectal cancer']","['Machine Learning Algorithms', 'machine learning (ML) technology']",['weight matrix diagram'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4 (qualifier value)'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}]","[{'cui': 'C0376284', 'cui_str': 'Machine Learning'}, {'cui': 'C0002045'}, {'cui': 'C0039421', 'cui_str': 'Technology'}]","[{'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C4319583', 'cui_str': 'Matrix'}]",999.0,0.0140783,"In the training group, the GradientBoosting model's AUC value was the highest, at 0.881.","[{'ForeName': 'Yucan', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Henan, China.'}, {'ForeName': 'Lingsha', 'Initials': 'L', 'LastName': 'Ju', 'Affiliation': 'Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Henan, China.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Tong', 'Affiliation': 'Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Henan, China.'}, {'ForeName': 'Cheng-Mao', 'Initials': 'CM', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Henan, China. zhouchengmao187@foxmail.com.'}, {'ForeName': 'Jian-Jun', 'Initials': 'JJ', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Henan, China. yjyangjj@126.com.'}]",Scientific reports,['10.1038/s41598-020-59115-y'] 3009,32056148,"Impact of National Egyptian school feeding program on growth, development, and school achievement of school children.","BACKGROUND School feeding program (SFP) increases access to education and to better health. This study aims to evaluate the effects of SFP on physical growth, cognitive development, psychosocial behavior, and learning achievement of school children. METHODS A quasi-experimental study was conducted. The intervention group included 903 pupils in the fifth grade receiving the school meal, while the control group included 886 pupils, matched for age and sex, without meal. The meal consisted of a pie made of flour fortified with vitamins A, B6, B12, C, thiamin, riboflavin, niacin, folate, calcium, iron, zinc, and phosphorus. Socioeconomic position, nutritional status, and dietary behavior were evaluated. Neuropsychological tests were done. Psychosocial behavior was rated and educational achievement was recorded. Post hoc and independent sample t tests were used to detect the association of the studied parameters with the intake of school snack. RESULTS Children who took the meal had better scores on visual memory, auditory vigilance tests (9.71 ± 2.80 vs. 7.45 ± 3.25; 25.02 ± 3.36 vs. 10.82 ± 8.92, respectively, P < 0.001), the afternoon attention and working memory test (8.20 ± 2.21vs. 7.75 ± 3.05) (P < 0.001), but less score of externalizing behavior (P < 0.001) than the control group. No significant changes of children's nutritional status were detected between the two groups. School meal was the main predictor of visual memory and auditory vigilance (P < 0.001), and was the strongest predictor of academic achievements when combined with family size and meals' frequency (P < 0.001). CONCLUSION School meal improves academic achievements of school children.",2020,"RESULTS Children who took the meal had better scores on visual memory, auditory vigilance tests (9.71 ± 2.80 vs. 7.45 ± 3.25; 25.02 ± 3.36 vs. 10.82 ± 8.92, respectively, P < 0.001), the afternoon attention and working memory test (8.20 ± 2.21vs. 7.75 ± 3.05) (P < 0.001), but less score of externalizing behavior (P < 0.001) than the control group.","['school children', '903 pupils in the fifth grade receiving the school meal, while the control group included 886 pupils, matched for age and sex, without meal']","['flour fortified with vitamins A, B6, B12, C, thiamin, riboflavin, niacin, folate, calcium, iron, zinc, and phosphorus', 'School meal', 'National Egyptian school feeding program', 'SFP', 'School feeding program (SFP']","['visual memory, auditory vigilance tests', 'afternoon attention and working memory test', 'Psychosocial behavior was rated and educational achievement', 'Socioeconomic position, nutritional status, and dietary behavior', 'growth, development, and school achievement', ""children's nutritional status"", 'score of externalizing behavior', 'visual memory and auditory vigilance', 'physical growth, cognitive development, psychosocial behavior, and learning achievement']","[{'cui': 'C0260267', 'cui_str': 'School child (occupation)'}, {'cui': 'C0034121', 'cui_str': 'Pupil'}, {'cui': 'C0205439', 'cui_str': 'Fifth (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}]","[{'cui': 'C0016260', 'cui_str': 'Flour'}, {'cui': 'C0042839', 'cui_str': 'Vitamin A'}, {'cui': 'C0039840', 'cui_str': 'Thiamine'}, {'cui': 'C0373720', 'cui_str': 'Vitamin B2'}, {'cui': 'C0027996', 'cui_str': 'Niacin'}, {'cui': 'C0178638', 'cui_str': 'Folate'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0031705', 'cui_str': 'Phosphorus'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0337801', 'cui_str': 'Egyptians (ethnic group)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0075029', 'cui_str': 'spleen fibrinolytic proteinase (human)'}]","[{'cui': 'C0542316', 'cui_str': 'Visual memory (observable entity)'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0439550', 'cui_str': 'Afternoon (qualifier value)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0013658', 'cui_str': 'Educational Achievement'}, {'cui': 'C1561964', 'cui_str': 'Patient Positioning'}, {'cui': 'C0392209', 'cui_str': 'Nutrition Status'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}]",,0.0169019,"RESULTS Children who took the meal had better scores on visual memory, auditory vigilance tests (9.71 ± 2.80 vs. 7.45 ± 3.25; 25.02 ± 3.36 vs. 10.82 ± 8.92, respectively, P < 0.001), the afternoon attention and working memory test (8.20 ± 2.21vs. 7.75 ± 3.05) (P < 0.001), but less score of externalizing behavior (P < 0.001) than the control group.","[{'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Metwally', 'Affiliation': 'Medical Research Division, Community Medicine Department, National Research Centre, (Affiliation ID: 60014618), Dokki, Cairo, Egypt.'}, {'ForeName': 'Marwa M', 'Initials': 'MM', 'LastName': 'El-Sonbaty', 'Affiliation': 'Department of Pediatrics, College of Medicine, Taibah University, Madinah, Kingdom of Saudi Arabia. elsonbatymostafa@yahoo.com.'}, {'ForeName': 'L A', 'Initials': 'LA', 'LastName': 'El Etreby', 'Affiliation': 'Medical Research Division, Community Medicine Department, National Research Centre, (Affiliation ID: 60014618), Dokki, Cairo, Egypt.'}, {'ForeName': 'E M', 'Initials': 'EM', 'LastName': 'Salah El-Din', 'Affiliation': 'Medical Research Division, Child Health Department, National Research Centre, (Affiliation ID: 60014618), Dokki, Cairo, Egypt.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Abdel Hamid', 'Affiliation': 'Agricultural Research Centre, Giza, Egypt.'}, {'ForeName': 'H A', 'Initials': 'HA', 'LastName': 'Hussien', 'Affiliation': 'Agricultural Research Centre, Giza, Egypt.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Hassanin', 'Affiliation': 'Agricultural Research Centre, Giza, Egypt.'}, {'ForeName': 'Z M', 'Initials': 'ZM', 'LastName': 'Monir', 'Affiliation': 'Medical Research Division, Child Health Department, National Research Centre, (Affiliation ID: 60014618), Dokki, Cairo, Egypt.'}]",World journal of pediatrics : WJP,['10.1007/s12519-020-00342-8'] 3010,2454893,Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans.,"Healthy adult volunteers were vaccinated on day 0 and 28 and at 15 months with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine. Immunization resulted in mild, transient local reactions in less than 20% of the subjects. Maximal immunoglobulin G (IgG) antibody titers to both toxin A and lipopolysaccharide (LPS) as determined by enzyme-linked immunosorbent assay were seen at day 42, at which time 50% of the vaccinees showed a fourfold or greater rise in toxin A-neutralizing titers. By 15 months postvaccination, both antitoxin A and anti-LPS IgG antibodies had markedly declined. A booster dose of vaccine administered at 15 months evoked a vigorous anti-toxin A IgG antibody response with 100% of the volunteers showing a fourfold or greater rise in neutralizing antibody titer compared with preimmunization levels. In contrast, there was no significant elevation of anti-LPS IgG antibody levels. At 24 months postimmunization, only anti-toxin A antibody levels were significantly higher than preimmunization levels.",1988,"At 24 months postimmunization, only anti-toxin A antibody levels were significantly higher than preimmunization levels.","['Healthy adult volunteers', 'humans']","['toxin A and lipopolysaccharide (LPS', 'Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine', 'vaccine']","['Maximal immunoglobulin G (IgG) antibody titers', 'anti-LPS IgG antibody levels', 'neutralizing antibody titer', 'mild, transient local reactions', 'anti-toxin A antibody levels', 'antitoxin A and anti-LPS IgG antibodies']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0076851', 'cui_str': 'toxin A (Pseudomonas)'}, {'cui': 'C0023810', 'cui_str': 'Lipoglycans'}, {'cui': 'C0033808', 'cui_str': 'Flavimonas'}, {'cui': 'C0456570', 'cui_str': 'Immunotype (qualifier value)'}, {'cui': 'C0032594', 'cui_str': 'Glycans'}, {'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C1292065', 'cui_str': 'Antibody, immunoglobulin G class'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0052060', 'cui_str': 'Limulus anti-LPS factor'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1142254', 'cui_str': 'Neutralising antibodies'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}, {'cui': 'C0853813', 'cui_str': 'Local reaction'}, {'cui': 'C0076851', 'cui_str': 'toxin A (Pseudomonas)'}, {'cui': 'C0003445', 'cui_str': 'Antitoxins'}]",,0.0281203,"At 24 months postimmunization, only anti-toxin A antibody levels were significantly higher than preimmunization levels.","[{'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Cryz', 'Affiliation': 'Swiss Serum and Vaccine Institute, Berne.'}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Sadoff', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Fürer', 'Affiliation': ''}]",Infection and immunity,[] 3011,2365462,Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid.,"Conjugates of an uronic acid-containing capsular polysaccharide (CP), pneumococcous type 12F (Pn12F) bound to diphtheria toxoid (DT), were studied for safety and immunogenicity in adult volunteers. In mice, these conjugates, prepared with the same lot of DT and Pn12F-40234-006, a homogenous CP of high molecular weight, or Pn12-812408, a polydisperse CP with lower-molecular-weight material, were more immunogenic than the Pn12F alone and had T-cell dependent properties (A. Fattom, W. F. Vann, S.C. Szu, A. Sutton, X. Li, B. Bryla, G. Schiffman, J. B. Robbins, and R. Schneerson, Infect. Immun. 56:2292-2298, 1988). Adult volunteers, randomized into three groups, were injected either with one of these two conjugates or with Pnu-Imune, the 23 valent pneumococcus vaccine containing 25 micrograms of Pn12F as one of its components. Volunteers were injected two times, 4 weeks apart, with the Pn12F-DT conjugates and once with the Pnu-Imune. Side reactions following injection of the conjugates of Pnu-Imune were mild and short-lived. At 4 weeks and at 7 months after the first injection, higher levels of Pn12F antibodies were found in the volunteers injected with the conjugates than in the Pnu-Imune group (P less than 0.001). The conjugate prepared with the higher-molecular-weight Pn12F elicited higher levels of antibodies than the conjugate prepared with a lower-molecular-weight Pn12F preparation (P = 0.05). Both conjugates elicited about a 13-fold rise in DT antibodies.",1990,"At 4 weeks and at 7 months after the first injection, higher levels of Pn12F antibodies were found in the volunteers injected with the conjugates than in the Pnu-Imune group (P less than 0.001).","['pneumococcous type 12F', 'adult volunteers', 'Adult volunteers']","['uronic acid-containing capsular polysaccharide (CP', 'vaccine containing 25 micrograms of Pn12F', 'diphtheria toxoid (DT', 'Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid']","['Side reactions', 'higher levels of Pn12F antibodies', 'Serum antibody response', 'safety and immunogenicity']","[{'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0042081', 'cui_str': 'Uronic Acids'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0205151', 'cui_str': 'Capsular (qualifier value)'}, {'cui': 'C0032594', 'cui_str': 'Glycans'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0439211', 'cui_str': 'microgram'}, {'cui': 'C0084646', 'cui_str': 'Streptococcus pneumoniae type 12F polysaccharide'}, {'cui': 'C0012551', 'cui_str': 'diphtheria toxoid vaccine, inactivated'}, {'cui': 'C0301869', 'cui_str': 'Conjugate'}]","[{'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0084646', 'cui_str': 'Streptococcus pneumoniae type 12F polysaccharide'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0003261', 'cui_str': 'Antibody Response'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0216795,"At 4 weeks and at 7 months after the first injection, higher levels of Pn12F antibodies were found in the volunteers injected with the conjugates than in the Pnu-Imune group (P less than 0.001).","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Fattom', 'Affiliation': 'Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, Bethesda, Maryland 20892.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Lue', 'Affiliation': ''}, {'ForeName': 'S C', 'Initials': 'SC', 'LastName': 'Szu', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Mestecky', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Schiffman', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Bryla', 'Affiliation': ''}, {'ForeName': 'W F', 'Initials': 'WF', 'LastName': 'Vann', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Watson', 'Affiliation': ''}, {'ForeName': 'L M', 'Initials': 'LM', 'LastName': 'Kimzey', 'Affiliation': ''}, {'ForeName': 'J B', 'Initials': 'JB', 'LastName': 'Robbins', 'Affiliation': ''}]",Infection and immunity,[] 3012,32038628,Systemic β-Adrenergic Receptor Activation Augments the ex vivo Expansion and Anti-Tumor Activity of Vγ9Vδ2 T-Cells.,"TCR-gamma delta (γδ) T-cells are considered important players in the graft-vs.-tumor effect following allogeneic hematopoietic cell transplantation (alloHCT) and have emerged as candidates for adoptive transfer immunotherapy in the treatment of both solid and hematological tumors. Systemic β-adrenergic receptor (β-AR) activation has been shown to mobilize TCR-γδ T-cells to the blood, potentially serving as an adjuvant for alloHCT and TCR-γδ T-cell therapy. We investigated if systemic β-AR activation, using acute dynamic exercise as an experimental model, can increase the mobilization, ex vivo expansion, and anti-tumor activity of TCR-γδ T-cells isolated from the blood of healthy humans. We also sought to investigate the β-AR subtypes involved, by administering a preferential β 1 -AR antagonist (bisoprolol) and a non-preferential β 1 + β 2 -AR antagonist (nadolol) prior to exercise as part of a randomized placebo controlled cross-over experiment. We found that exercise mobilized TCR-γδ cells to blood and augmented their ex vivo expansion by ~182% compared to resting blood when stimulated with IL-2 and ZOL for 14-days. Exercise also increased the proportion of CD56+, NKG2D+/CD62L-, CD158a/b/e+ and NKG2A- cells among the expanded TCR-γδ cells, and increased their cytotoxic activity against several tumor target cells (K562, U266, 221.AEH) in vitro by 40-60%. Blocking NKG2D on TCR-γδ cells in vitro eliminated the augmented cytotoxic effects of exercise against U266 target cells. Furthermore, administering a β 1 + β 2 -AR (nadolol), but not a β 1 -AR (bisoprolol) antagonist prior to exercise abrogated the exercise-induced enhancement in TCR-γδ T-cell mobilization and ex vivo expansion. Furthermore, nadolol completely abrogated while bisoprolol partially inhibited the exercise-induced increase in the cytotoxic activity of the expanded TCR-γδ T-cells. We conclude that acute systemic β-AR activation in healthy donors markedly augments the mobilization, ex vivo expansion, and anti-tumor activity of TCR-γδ T-cells and that some of these effects are due to β 2 -AR signaling and phenotypic shifts that promote a dominant activating signal via NKG2D. These findings highlight β-ARs as potential targets to favorably alter the composition of allogeneic peripheral blood stem cell grafts and improve the potency of TCR-γδ T-cell immune cell therapeutics.",2019,"Exercise also increased the proportion of CD56+, NKG2D+/CD62L-, CD158a/b/e+ and NKG2A- cells among the expanded TCR-γδ cells, and increased their cytotoxic activity against several tumor target cells (K562, U266, 221.AEH) in vitro by 40-60%.","['healthy donors', 'healthy humans']","['allogeneic hematopoietic cell transplantation (alloHCT', 'nadolol', 'AR (nadolol', 'AR antagonist (nadolol']","['cytotoxic activity against several tumor target cells (K562, U266, 221.AEH) in vitro', 'cytotoxic activity of the expanded TCR-γδ T-cells', 'proportion of CD56+, NKG2D+/CD62L-, CD158a/b/e+ and NKG2A- cells', 'TCR-γδ T-cell mobilization and ex vivo expansion', 'TCR-gamma delta']","[{'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0206153', 'cui_str': 'Cell Transplantation'}, {'cui': 'C0027302', 'cui_str': 'Nadolol'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}]","[{'cui': 'C4521706', 'cui_str': 'Cytotoxic'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0221284', 'cui_str': 'Bell-shaped erythrocyte (in vivo)'}, {'cui': 'C0021135', 'cui_str': 'In Vitro'}, {'cui': 'C0205229', 'cui_str': 'Expanding (qualifier value)'}, {'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0300926', 'cui_str': 'mobilization'}, {'cui': 'C0085246', 'cui_str': 'TcR gamma-delta'}]",,0.0208792,"Exercise also increased the proportion of CD56+, NKG2D+/CD62L-, CD158a/b/e+ and NKG2A- cells among the expanded TCR-γδ cells, and increased their cytotoxic activity against several tumor target cells (K562, U266, 221.AEH) in vitro by 40-60%.","[{'ForeName': 'Forrest L', 'Initials': 'FL', 'LastName': 'Baker', 'Affiliation': 'Laboratory of Integrated Physiology, Department of Health and Human Performance, University of Houston, Houston, TX, United States.'}, {'ForeName': 'Austin B', 'Initials': 'AB', 'LastName': 'Bigley', 'Affiliation': 'Laboratory of Integrated Physiology, Department of Health and Human Performance, University of Houston, Houston, TX, United States.'}, {'ForeName': 'Nadia H', 'Initials': 'NH', 'LastName': 'Agha', 'Affiliation': 'Laboratory of Integrated Physiology, Department of Health and Human Performance, University of Houston, Houston, TX, United States.'}, {'ForeName': 'Charles R', 'Initials': 'CR', 'LastName': 'Pedlar', 'Affiliation': ""School of Sport, Health and Applied Science, St. Mary's University, London, United Kingdom.""}, {'ForeName': 'Daniel P', 'Initials': 'DP', 'LastName': ""O'Connor"", 'Affiliation': 'Laboratory of Integrated Physiology, Department of Health and Human Performance, University of Houston, Houston, TX, United States.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Bond', 'Affiliation': 'Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, TX, United States.'}, {'ForeName': 'Catherine M', 'Initials': 'CM', 'LastName': 'Bollard', 'Affiliation': ""Center for Cancer and Immunology Research, Children's National Health System and the George Washington University, Washington, DC, United States.""}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Katsanis', 'Affiliation': 'Department of Pediatrics, University of Arizona, Tucson, AZ, United States.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Simpson', 'Affiliation': 'Laboratory of Integrated Physiology, Department of Health and Human Performance, University of Houston, Houston, TX, United States.'}]",Frontiers in immunology,['10.3389/fimmu.2019.03082'] 3013,32053098,The effects of laparoscopic urologic surgery on cardiac functions: A pulse wave velocity study.,"OBJECTIVE The aim of this study is to evaluate the effects of laparoscopic urologic surgery on cardiac functions by the parameter pulse wave velocity (PWV), a noninvasive method. MATERIAL AND METHODS Between July 2012 and February 2013, a total of 47 patients were included in this prospective controlled study. Patients who have been scheduled for laparoscopic surgery (LS) (n=30) and open surgery (n=17) were enrolled in the study. Preoperative, perioperative, and postoperative cardiovascular parameters were measured by a PWV instrument, and the results were compared between laparoscopic (L) group and open (C) group. RESULTS In the L group, compared to preoperative values, perioperative systolic arterial pressure, diastolic arterial pressure, and mean arterial pressure increased considerably, by 2.6%, 7.9%, and 4.7%, respectively. This was in contrary to reductions in these parameters by 9.5%, 5.7%, and 10%, respectively, in the C group. For the L group, cardiac output (CO) and cardiac index (CI) were increased in the perioperative period and decreased in the postoperative period. For the C group, there were no changes in measurements of perioperative and postoperative CO and CI. However, these changes in CO and CI were not significantly different between the L and C groups. Postoperative large artery elasticity index decreased in both groups. However, these changes did not represent significant difference between groups. CONCLUSION Compared to open surgery, LS may cause increases in perioperative blood pressures. In addition, increased blood pressures may last even on the first postoperative day. These effects may be more important for patients with high cardiovascular risk.",2020,"In the L group, compared to preoperative values, perioperative systolic arterial pressure, diastolic arterial pressure, and mean arterial pressure increased considerably, by 2.6%, 7.9%, and 4.7%, respectively.","['Between July 2012 and February 2013, a total of 47 patients', 'n=30) and open surgery (n=17) were enrolled in the study', 'patients with high cardiovascular risk', 'Patients who have been scheduled for laparoscopic surgery (LS']",['laparoscopic urologic surgery'],"['Preoperative, perioperative, and postoperative cardiovascular parameters', 'CO and CI', 'preoperative values, perioperative systolic arterial pressure, diastolic arterial pressure, and mean arterial pressure', 'perioperative and postoperative CO and CI', 'perioperative blood pressures', 'blood pressures', 'Postoperative large artery elasticity index', 'cardiac output (CO) and cardiac index (CI', 'cardiac functions']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0348025', 'cui_str': 'Open approach - access (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0751429', 'cui_str': 'Surgical Procedures, Laparoscopic'}]","[{'cui': 'C0042077', 'cui_str': 'Urology'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic Pressure'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0226003', 'cui_str': 'Structure of large artery'}, {'cui': 'C0013764'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0007165', 'cui_str': 'Cardiac Output'}, {'cui': 'C0428776', 'cui_str': 'Cardiac index (observable entity)'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function (observable entity)'}]",47.0,0.0718779,"In the L group, compared to preoperative values, perioperative systolic arterial pressure, diastolic arterial pressure, and mean arterial pressure increased considerably, by 2.6%, 7.9%, and 4.7%, respectively.","[{'ForeName': 'Mehmet Çağatay', 'Initials': 'MÇ', 'LastName': 'Çiçek', 'Affiliation': 'Department of Urology, Uludağ University School of Medicine, Bursa, Turkey.'}, {'ForeName': 'Yurdaer', 'Initials': 'Y', 'LastName': 'Kaynak', 'Affiliation': 'Department of Urology, Eskişehir Ümit Hospital, Eskişehir, Turkey.'}, {'ForeName': 'Kadir Ömür', 'Initials': 'KÖ', 'LastName': 'Günseren', 'Affiliation': 'Department of Urology, Uludağ University School of Medicine, Bursa, Turkey.'}, {'ForeName': 'Onur', 'Initials': 'O', 'LastName': 'Kaygısız', 'Affiliation': 'Department of Urology, Uludağ University School of Medicine, Bursa, Turkey.'}, {'ForeName': 'Hakan', 'Initials': 'H', 'LastName': 'Vuruşkan', 'Affiliation': 'Department of Urology, Uludağ University School of Medicine, Bursa, Turkey.'}]",Turkish journal of urology,['10.5152/tud.2020.19094'] 3014,31757473,"Effect of Aspiration and Evaluation of Gastric Residuals on Intestinal Inflammation, Bleeding, and Gastrointestinal Peptide Level.","OBJECTIVE To determine the effect of gastric residual aspiration and evaluation on preterm very low birth weight infants' gastrointestinal function, intestinal inflammation, and gastrointestinal mucosal bleeding. STUDY DESIGN This single-center, randomized trial compared omission of gastric residuals vs prefeed gastric residuals in 143 infants ≤32 weeks of gestation with a birthweight of ≤1250 g for 6 weeks after birth. Serum levels of gastrin and motilin were collected between 14 and 21 days of life. Stools were collected at 3 and 6 weeks of age and analyzed for calprotectin and S100A12 levels. All stools were tested for occult blood for 6 weeks. RESULTS Means for gastrin (P = .999) and motilin (P = .694) were similar between groups and there were no statistically significant differences in adjusted means for transformed calprotectin (P = .580), and S100A12 (P = .212). Both calprotectin (P = .003) and S100A12 (P = .002) increased from week 3 to week 6. The mean percentage of stools positive for occult blood (P = .888) were similar between the groups. CONCLUSIONS Gastrointestinal function, intestinal inflammation, and gastrointestinal mucosal bleeding were similar whether aspiration and evaluation of gastric residuals were eliminated or not, suggesting routinely evaluating gastric residuals before every feeding may be unnecessary. TRIAL REGISTRATION CLINICALTRIALS.GOV:: NCT01863043.",2020,"The mean percentage of stools positive for occult blood (P = .888) were similar between the groups. ","['preterm very low birth weight infants', '143 infants ≤32']",['gastric residual aspiration and evaluation'],"['Intestinal Inflammation, Bleeding, and Gastrointestinal Peptide Level', 'transformed calprotectin', 'Gastrointestinal function, intestinal inflammation, and gastrointestinal mucosal bleeding', 'gastrointestinal function, intestinal inflammation, and gastrointestinal mucosal bleeding', 'mean percentage of stools positive for occult blood', 'Serum levels of gastrin and motilin']","[{'cui': 'C0282667', 'cui_str': 'Infant, Very Low Birth Weight'}, {'cui': 'C4517573', 'cui_str': 'One hundred and forty-three'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C3665864', 'cui_str': 'Gastric residuals'}, {'cui': 'C0349707', 'cui_str': 'Aspiration - action (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C3889047', 'cui_str': 'Intestinal inflammation'}, {'cui': 'C0030956', 'cui_str': 'Peptides'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0950624', 'cui_str': 'Calgranulin'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C2748540', 'cui_str': 'Mucosal bleeding'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0028792', 'cui_str': 'Occult Blood'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0376180', 'cui_str': 'Gastrin'}, {'cui': 'C0026594', 'cui_str': 'Motilin (substance)'}]",143.0,0.129509,"The mean percentage of stools positive for occult blood (P = .888) were similar between the groups. ","[{'ForeName': 'Leslie A', 'Initials': 'LA', 'LastName': 'Parker', 'Affiliation': 'College of Nursing, University of Florida, Gainesville, FL. Electronic address: Parkela@ufl.edu.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Weaver', 'Affiliation': 'College of Nursing, University of Florida, Gainesville, FL.'}, {'ForeName': 'Roberto J', 'Initials': 'RJ', 'LastName': 'Murgas Torrazza', 'Affiliation': 'Sistema Nacional de Investigacion de Panama, Secretaria Nacional de Ciencia Tecnologia e Innovacion, Panama City, Panama.'}, {'ForeName': 'Jonathon', 'Initials': 'J', 'LastName': 'Shuster', 'Affiliation': 'Department of Health Outcomes and Bioinformatics, University of Florida, Gainesville, FL.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Department of Pediatrics, University of Florida, Gainesville, FL.'}, {'ForeName': 'Charlene', 'Initials': 'C', 'LastName': 'Krueger', 'Affiliation': 'College of Nursing, University of Florida, Gainesville, FL.'}, {'ForeName': 'Josef', 'Initials': 'J', 'LastName': 'Neu', 'Affiliation': 'Department of Pediatrics, University of Florida, Gainesville, FL.'}]",The Journal of pediatrics,['10.1016/j.jpeds.2019.10.036'] 3015,2157737,Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants.,"Phase I studies of an oral quadrivalent rotavirus vaccine were conducted in 130 Venezuelan infants 10 to 20 weeks of age. The vaccine consists of a mixture of equal amounts of rhesus rotavirus (RRV) vaccine (serotype 3 [VP7]) and each of three human rotavirus-RRV reassortant strains: D x RRV (serotype 1 [VP7]), DS1 x RRV (serotype 2 [VP7]), and ST3 x RRV (serotype 4 [VP7]). Three different doses of the quadrivalent vaccine (0.25 x 10(4), 0.5 x 10(4), and 10(4) PFU of each component) were evaluated sequentially for safety and antigenicity in placebo-controlled, double-blind trials. Starting the day after vaccination, the infants were monitored by daily home visits for 7 days. Only minor reactions were observed during this period; these were limited to mild transient febrile episodes which began day 2 or 3 after vaccination and lasted 1 to 2 days in 15 to 30% of the infants. Serological studies demonstrated that 68 to 96% of the infants developed a rotavirus serum immunoglobulin A response following vaccination. However, when tested by plaque reduction neutralization assay against individual human rotavirus serotype 1, 2, 3, or 4, the response rates ranged from 4 to 23% with the low dose, 21 to 33% with the medium dose, and 32 to 58% with the high dose. Most (73 to 79%) infants developed neutralizing antibodies to RRV following administration of each dose schedule. Vaccine virus shedding was analyzed by utilizing tissue culture isolation of virus from stool. All of the infants who received the lower of medium dose and 89% of those fed the high dose shed one or more components of the vaccine. Analyses of rotavirus serotypes isolated from the stool of infants who received the 0.25 x 10(4) -PFU dose revealed that DS1 x RRV was the most commonly shed vaccine component, followed by RRV, D x RRV, and ST3 x RRV in that order.",1990,Only minor reactions were observed during this period; these were limited to mild transient febrile episodes which began day 2 or 3 after vaccination and lasted 1 to 2 days in 15 to 30% of the infants.,"['Venezuelan infants', '130 Venezuelan infants 10 to 20 weeks of age']","['mixture of equal amounts of rhesus rotavirus (RRV) vaccine (serotype 3 [VP7]) and each of three human rotavirus-RRV reassortant strains: D x RRV (serotype 1 [VP7]), DS1 x RRV (serotype 2 [VP7', 'oral quadrivalent rotavirus vaccine', 'quadrivalent vaccine', 'quadrivalent rotavirus vaccine']","['mild transient febrile episodes', 'rotavirus serum immunoglobulin A response', 'response rates', 'DS1 x RRV', 'neutralizing antibodies to RRV']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0439962', 'cui_str': 'Mixture (qualifier value)'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C1265611', 'cui_str': 'Quantity finding'}, {'cui': 'C0597418', 'cui_str': 'Rotavirus Vaccines'}, {'cui': 'C0449550', 'cui_str': 'Serotype (UK)'}, {'cui': 'C0318711', 'cui_str': 'Human rotavirus (organism)'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}]","[{'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0035870', 'cui_str': 'Rotavirus'}, {'cui': 'C0858451', 'cui_str': 'Serum immunoglobulin A'}, {'cui': 'C1142254', 'cui_str': 'Neutralising antibodies'}]",130.0,0.124031,Only minor reactions were observed during this period; these were limited to mild transient febrile episodes which began day 2 or 3 after vaccination and lasted 1 to 2 days in 15 to 30% of the infants.,"[{'ForeName': 'I', 'Initials': 'I', 'LastName': 'Perez-Schael', 'Affiliation': 'Instituto de Biomedicina, Universidad Central de Venezuela, Caracas.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Blanco', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Vilar', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Garcia', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'White', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Gonzalez', 'Affiliation': ''}, {'ForeName': 'A Z', 'Initials': 'AZ', 'LastName': 'Kapikian', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Flores', 'Affiliation': ''}]",Journal of clinical microbiology,[] 3016,31022007,Predictors of Exercise Training and Physical Activity Adherence in People Recently Hospitalized With Heart Failure: A BRIEF REPORT.,"PURPOSE For individuals with heart failure (HF), frequent attendance at exercise training programs and meeting physical activity (PA) guidelines are significantly associated with improvements in 6-min walk distance. Despite the evidence, adherence to exercise interventions remains poor. The aim of this study was to identify predictors of these 2 variables in patients recently hospitalized with HF. METHODS In this substudy of the Exercise Joins Education: Combined Therapy to Improve Outcomes in Newly-discharged Heart Failure (EJECTION-HF) trial, all participants were enrolled in a HF disease management program, including weekly review of a home exercise program for 12 wk. Intervention group participants additionally undertook twice weekly supervised exercise training. Primary outcomes were frequent exercise training program attendance (≥12 sessions) and attainment of PA guidelines (150 min/wk of moderate intensity exercise) at 12 wk. Participant and clinical characteristics were analyzed using a logistic regression model to identify significant predictors of each outcome. RESULTS A total of 278 participants provided PA data and 140 contributed attendance data. New diagnosis of HF was a significant predictor of frequent program attendance (OR = 2.3; 95% CI, 1.1-4.7; P = .03). Predictors of meeting PA guidelines at follow-up included new HF diagnosis (OR = 2.4; 95% CI, 1.2-4.8, P = .013), and being physically active at baseline (OR = 2.7; 95% CI, 1.3-5.6; P = .007). Gender, symptom severity, multimorbidity, and disability were not significantly associated with either outcome in multivariate analysis. CONCLUSION To improve adherence, specific strategies may be required for patients with decompensated HF and those physically inactive at time of referral.",2019,"New diagnosis of HF was a significant predictor of frequent program attendance (OR = 2.3; 95% CI, 1.1-4.7; P = .03).","['278 participants provided PA data and 140 contributed attendance data', 'Newly-discharged Heart Failure (EJECTION-HF) trial, all participants were enrolled in a HF disease management program, including weekly review of a home exercise program for 12 wk', 'individuals with heart failure (HF', 'patients with decompensated HF and those physically inactive at time of referral', 'People Recently Hospitalized With Heart Failure']","['Exercise Training and Physical Activity Adherence', 'supervised exercise training']","['Gender, symptom severity, multimorbidity, and disability', 'frequent exercise training program attendance (≥12 sessions) and attainment of PA guidelines', 'frequent program attendance']","[{'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0336969', 'cui_str': 'Ejection (qualifier value)'}, {'cui': 'C1303150', 'cui_str': 'Disease management program'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0699752', 'cui_str': 'Review of (contextual qualifier) (qualifier value)'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program (regime/therapy)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C1535889', 'cui_str': 'Multimorbidity'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C2728259', 'cui_str': 'Program'}]",278.0,0.0700865,"New diagnosis of HF was a significant predictor of frequent program attendance (OR = 2.3; 95% CI, 1.1-4.7; P = .03).","[{'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Adsett', 'Affiliation': ""Heart Support Service (Ms Adsett) and Departments of Physiotherapy (Ms Adsett) and Internal Medicine and Aged Care (Dr Mudge), Royal Brisbane and Women's Hospital, Brisbane, Australia; School of Allied Health Sciences, Griffith University, Gold Coast, Australia (Ms Adsett and Dr Morris); Menzies Health Institute, Queensland, Australia (Ms Adsett and Dr Morris); Metro North Hospital and Health Service, The Prince Charles Hospital, Allied Health Research Collaborative, Queensland, Australia (Dr Morris); and University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia (Dr Mudge).""}, {'ForeName': 'Norman R', 'Initials': 'NR', 'LastName': 'Morris', 'Affiliation': ''}, {'ForeName': 'Alison M', 'Initials': 'AM', 'LastName': 'Mudge', 'Affiliation': ''}]",Journal of cardiopulmonary rehabilitation and prevention,['10.1097/HCR.0000000000000407'] 3017,30892987,"Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.","PURPOSE To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial ( ClinicalTrials.gov identifier: NCT02928224; European Union Clinical Trials Register identifier: EudraCT2015-005805-35). PATIENTS AND METHODS Before initiation of the randomized portion of the BEACON Colorectal Cancer trial, 30 patients with BRAF V600E-mutant mCRC who had experienced treatment failure with one or two prior regimens were to be recruited to a safety lead-in of encorafenib 300 mg daily, binimetinib 45 mg twice daily, plus standard weekly cetuximab. The primary end point was safety, including the incidence of dose-limiting toxicities. Efficacy end points included overall response rate, progression-free survival, and overall survival. RESULTS Among the 30 treated patients, dose-limiting toxicities occurred in five patients and included serous retinopathy (n = 2), reversible decreased left ventricular ejection fraction (n = 1), and cetuximab-related infusion reactions (n = 2). The most common grade 3 or 4 adverse events were fatigue (13%), anemia (10%), increased creatine phosphokinase (10%), increased AST (10%), and urinary tract infections (10%). In 29 patients with BRAF V600E-mutant tumors (one patient had a non- BRAF V600E-mutant tumor and was not included in the efficacy analysis), the confirmed overall response rate was 48% (95% CI, 29.4% to 67.5%), median progression-free survival was 8.0 months (95% CI, 5.6 to 9.3 months), and median overall survival was 15.3 months (95% CI, 9.6 months to not reached), with median duration of follow-up of 18.2 months (range, 16.6 to 19.8 months). CONCLUSION In the safety lead-in, the safety and tolerability of the encorafenib, binimetinib, and cetuximab regimen is manageable and acceptable for initiation of the randomized portion of the study. The observed efficacy is promising compared with available therapies and, if confirmed in the randomized portion of the trial, could establish this regimen as a new standard of care for previously treated BRAF V600E-mutant mCRC.",2019,"The most common grade 3 or 4 adverse events were fatigue (13%), anemia (10%), increased creatine phosphokinase (10%), increased AST (10%), and urinary tract infections (10%).","['30 patients with BRAF V600E-mutant mCRC who had experienced treatment failure with one or two prior regimens were to be recruited to a safety lead-in of', 'Patients With BRAF', 'BRAF V600E-mutant metastatic colorectal cancer (mCRC', 'V600E-Mutant Metastatic Colorectal Cancer']","['Binimetinib, Encorafenib, and Cetuximab Triplet Therapy', 'encorafenib, binimetinib, and cetuximab regimen', 'encorafenib 300 mg daily, binimetinib 45 mg twice daily, plus standard weekly cetuximab', 'selective combination targeted therapy']","['safety and tolerability', 'overall response rate, progression-free survival, and overall survival', 'dose-limiting toxicities', 'median progression-free survival', 'left ventricular ejection fraction', 'incidence of dose-limiting toxicities', 'anemia', 'median overall survival', 'Safety Lead', 'creatine phosphokinase', 'overall response rate', 'urinary tract infections']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0162643'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0346973', 'cui_str': 'Secondary malignant neoplasm of large intestine'}]","[{'cui': 'C3899947', 'cui_str': 'Binimetinib'}, {'cui': 'C4079208', 'cui_str': 'encorafenib'}, {'cui': 'C0995188', 'cui_str': 'cetuximab'}, {'cui': 'C0041095', 'cui_str': 'Triplets'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0201973', 'cui_str': 'Creatine kinase measurement (procedure)'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}]",30.0,0.172122,"The most common grade 3 or 4 adverse events were fatigue (13%), anemia (10%), increased creatine phosphokinase (10%), increased AST (10%), and urinary tract infections (10%).","[{'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Van Cutsem', 'Affiliation': '1 University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Sanne', 'Initials': 'S', 'LastName': 'Huijberts', 'Affiliation': '2 Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Grothey', 'Affiliation': '3 West Cancer Center, Germantown, TN.'}, {'ForeName': 'Rona', 'Initials': 'R', 'LastName': 'Yaeger', 'Affiliation': '4 Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Pieter-Jan', 'Initials': 'PJ', 'LastName': 'Cuyle', 'Affiliation': '1 University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Elez', 'Affiliation': ""6 Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain.""}, {'ForeName': 'Marwan', 'Initials': 'M', 'LastName': 'Fakih', 'Affiliation': '7 City of Hope Comprehensive Cancer Center, Duarte, CA.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Montagut', 'Affiliation': ""8 Hospital del Mar-Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra, Barcelona, Spain.""}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Peeters', 'Affiliation': '9 Antwerp University Hospital, Edegem, Belgium.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Yoshino', 'Affiliation': '10 National Cancer Center Hospital East, Kashiwa, Japan.'}, {'ForeName': 'Harpreet', 'Initials': 'H', 'LastName': 'Wasan', 'Affiliation': '11 Hammersmith Hospital, Imperial College London, London, United Kingdom.'}, {'ForeName': 'Jayesh', 'Initials': 'J', 'LastName': 'Desai', 'Affiliation': '12 Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.'}, {'ForeName': 'Fortunato', 'Initials': 'F', 'LastName': 'Ciardiello', 'Affiliation': '13 University of Campania ""Luigi Vanvitelli,"" Naples, Italy.'}, {'ForeName': 'Ashwin', 'Initials': 'A', 'LastName': 'Gollerkeri', 'Affiliation': '14 Array BioPharma Inc, Boulder, CO.'}, {'ForeName': 'Janna', 'Initials': 'J', 'LastName': 'Christy-Bittel', 'Affiliation': '14 Array BioPharma Inc, Boulder, CO.'}, {'ForeName': 'Kati', 'Initials': 'K', 'LastName': 'Maharry', 'Affiliation': '14 Array BioPharma Inc, Boulder, CO.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Sandor', 'Affiliation': '14 Array BioPharma Inc, Boulder, CO.'}, {'ForeName': 'Jan H M', 'Initials': 'JHM', 'LastName': 'Schellens', 'Affiliation': '15 Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Kopetz', 'Affiliation': '16 The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Tabernero', 'Affiliation': ""6 Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain.""}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.18.02459'] 3018,31126174,Self-management Intervention Program Based on the Health Belief Model (HBM) among Women with Gestational Diabetes Mellitus: A Quazi-Experimental Study.,"BACKGROUND The Health Belief Model (HBM) as a conceptual framework in health behavior research was applied to improve self-management. This study aimed to determine the effect of theory-based intervention program among women with gestational diabetes mellitus (GDM). METHODS This quazi-experimental study was conducted on 110 women 17-41 years old which were divided randomly into intervention (n = 55) and control (n = 55) groups. The intervention group received a self-management education for four sessions lasting 35-40 minutes accompanied with a phone call as a booster. Both intervention and control groups attended a routine GDM education program at outpatient health centers. A multi-section instrument included demographics, 28 items in HBM (CVI and CVR were 0.83, 0.87, respectively) and self-management sections. All participants were invited to complete the questionnaire at baseline and at three and six months after intervention. SPSS version 21 was performed for data analysis using repeated measure ANOVA and paired t-test. P less than 0.05 was considered statistically significant. RESULTS At baseline, demographics and HBM constructs revealed no significant differences between two groups (P>0.05). After intervention, perceived susceptibility, severity, barriers, benefits and self-efficacy revealed significant differences in the intervention group compared with controls (P<0.001). Self-management and HbA1c indicated significant differences in the intervention group before and after three and six months (P<0.001) whereas in the control group no significant differences were revealed (P>0.05). CONCLUSION Implementing the HBM educational intervention program with focus on benefits of self-management has positive impact on pregnant women.",2019,"After intervention, perceived susceptibility, severity, barriers, benefits and self-efficacy revealed significant differences in the intervention group compared with controls (P<0.001).","['Women with Gestational Diabetes Mellitus', 'pregnant women', 'women with gestational diabetes mellitus (GDM', '110 women 17-41 years old which were divided randomly into intervention (n = 55) and control (n = 55) groups']","['Self-management Intervention Program', 'Health Belief Model (HBM', 'routine GDM education program', 'theory-based intervention program', 'self-management education for four sessions lasting 35-40 minutes accompanied with a phone call as a booster']","['HBM (CVI and CVR', 'perceived susceptibility, severity, barriers, benefits and self-efficacy']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0085207', 'cui_str': 'Diabetes, Pregnancy-Induced'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C3714363', 'cui_str': 'Health belief model (qualifier value)'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0085207', 'cui_str': 'Diabetes, Pregnancy-Induced'}, {'cui': 'C0729314', 'cui_str': 'Education provision (procedure)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C1697762', 'cui_str': 'Booster'}]","[{'cui': 'C1264642', 'cui_str': 'Susceptibility (property) (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",110.0,0.021432,"After intervention, perceived susceptibility, severity, barriers, benefits and self-efficacy revealed significant differences in the intervention group compared with controls (P<0.001).","[{'ForeName': 'Bahram', 'Initials': 'B', 'LastName': 'Mohebbi', 'Affiliation': 'Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Azar', 'Initials': 'A', 'LastName': 'Tol', 'Affiliation': 'Department of Health Education and Promotion, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Roya', 'Initials': 'R', 'LastName': 'Sadeghi', 'Affiliation': 'Department of Health Education and Promotion, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Seideh Fatemeh', 'Initials': 'SF', 'LastName': 'Mohtarami', 'Affiliation': 'Department of Health Education and Promotion, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ahmadreza', 'Initials': 'A', 'LastName': 'Shamshiri', 'Affiliation': 'School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran.'}]",Archives of Iranian medicine,[] 3019,32035487,"Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.","BACKGROUND Mixed dyslipidemia [elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), and decreased HDL-C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased cardiovascular risk. Non-HDL-C and apolipoprotein B (ApoB) are the preferred therapeutic targets for mixed dyslipidemia. Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) that effectively reduces low-density lipoprotein cholesterol (LDL-C), non-HDL-C, ApoB, and lipoprotein(a) (Lp[a]), and is well-tolerated in individuals with T2DM. METHODS The previously reported open-label ODYSSEY DM-DYSLIPIDEMIA trial data demonstrated the effects of alirocumab on individuals with non-HDL-C ≥ 100 mg/dL and TGs ≥ 150 and < 500 mg/dL receiving stable maximally tolerated statin (n = 413). This post hoc subgroup analysis of the primary trial investigated the effects of alirocumab [75 mg every 2 weeks (Q2W) with possible increase to 150 mg Q2W at Week 12] versus usual care [ezetimibe, fenofibrate, or no additional lipid-lowering therapy (LLT)] on non-HDL-C and other lipids in individuals with T2DM and baseline TGs ≥ 200 mg/dL and HDL-C < 40 mg/dL (men) or < 50 mg/dL (women). RESULTS Alirocumab significantly reduced non-HDL-C [LS mean difference (standard error (SE)), - 35.0% (3.9)], ApoB [LS mean difference (SE), - 34.7% (3.6)], LDL-C [LS mean difference (SE), - 47.3% (5.2)], LDL particle number [LS mean difference (SE), - 40.8% (4.1)], and Lp(a) [LS mean difference (SE), - 29.9% (5.4)] versus usual care from baseline to Week 24 (all P < 0.0001). Results were similar for alirocumab versus usual care. TG reductions were similar between alirocumab and usual care (no significant difference), but greater with fenofibrate versus alirocumab (P = 0.3371). Overall, alirocumab significantly increased HDL-C versus usual care [LS mean difference (SE), 7.9% (3.6); P < 0.05], although differences with alirocumab versus ezetimibe or fenofibrate were non-significant. Most individuals receiving alirocumab achieved ApoB < 80 mg/dL (67.9%) and non-HDL-C < 100 mg/dL (60.9%). Adverse event frequency was similar between alirocumab (67.2%) and usual care (70.7%). Additionally, no clinically relevant effect of alirocumab on change in glycemic parameters or use of antihyperglycemic agents was observed. CONCLUSIONS Alirocumab is an effective therapeutic option for individuals with T2DM, TGs ≥ 200 mg/dL, and HDL-C < 40 mg/dL (men) or < 50 mg/dL (women). Atherogenic lipid (ApoB and non-HDL) reductions were greater with alirocumab than ezetimibe, fenofibrate, or no LLT. Consistent with previous studies, alirocumab was generally well tolerated. Trial registration Clinicaltrials.gov, NCT02642159. Registered December 24, 2015, https://clinicaltrials.gov/ct2/show/NCT02642159.",2020,"Atherogenic lipid (ApoB and non-HDL) reductions were greater with alirocumab than ezetimibe, fenofibrate, or no LLT.","['individuals with T2DM, TGs\u2009≥', 'individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol', 'individuals with T2DM and baseline TGs\u2009≥\u2009200\xa0mg', 'individuals with T2DM']","['apolipoprotein B (ApoB', 'alirocumab', 'ezetimibe', 'fenofibrate versus alirocumab', 'alirocumab [75\xa0mg every 2\xa0weeks (Q2W) with possible increase to 150\xa0mg Q2W at Week 12] versus usual care [ezetimibe, fenofibrate, or no additional lipid-lowering therapy (LLT', 'ezetimibe, fenofibrate', 'Alirocumab', 'dL and HDL-C\u2009<\u200940\xa0mg/dL (men) or <\u200950\xa0mg/dL (women']","['low-density lipoprotein cholesterol (LDL-C), non-HDL-C, ApoB, and lipoprotein(a) (Lp[a', 'non-HDL-C [LS mean difference (standard error (SE', 'Atherogenic lipid (ApoB and non-HDL) reductions', 'Adverse event frequency', 'TG reductions', 'tolerated']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0023822', 'cui_str': 'High Density Lipoprotein Cholesterol'}, {'cui': 'C4319558', 'cui_str': '200'}]","[{'cui': 'C0003593', 'cui_str': 'ApoB'}, {'cui': 'C3491162', 'cui_str': 'alirocumab'}, {'cui': 'C1142985', 'cui_str': 'ezetimibe'}, {'cui': 'C0033228', 'cui_str': 'Fenofibrate'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0332149', 'cui_str': 'Possible (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0585943', 'cui_str': 'Lipid-lowering therapy (procedure)'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0003593', 'cui_str': 'ApoB'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]",,0.072325,"Atherogenic lipid (ApoB and non-HDL) reductions were greater with alirocumab than ezetimibe, fenofibrate, or no LLT.","[{'ForeName': 'Helen M', 'Initials': 'HM', 'LastName': 'Colhoun', 'Affiliation': 'The Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK. helen.colhoun@igmm.ed.ac.uk.'}, {'ForeName': 'Lawrence A', 'Initials': 'LA', 'LastName': 'Leiter', 'Affiliation': ""Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.""}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Müller-Wieland', 'Affiliation': 'Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Cariou', 'Affiliation': ""l'institut du thorax, CHU Nantes, INSERM, CNRS, UNIV Nantes, Nantes, France.""}, {'ForeName': 'Kausik K', 'Initials': 'KK', 'LastName': 'Ray', 'Affiliation': 'Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London, UK.'}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'Tinahones', 'Affiliation': 'Department of Clinical Endocrinology and Nutrition (IBIMA), Hospital Virgen de la Victoria, University of Málaga, CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Málaga, Spain.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Domenger', 'Affiliation': 'Sanofi, Gentilly, France.'}, {'ForeName': 'Alexia', 'Initials': 'A', 'LastName': 'Letierce', 'Affiliation': 'Biostatistics and Programming Department, Sanofi, Chilly-Mazarin, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Israel', 'Affiliation': 'Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Samuel', 'Affiliation': 'Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Del Prato', 'Affiliation': 'Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.'}]",Cardiovascular diabetology,['10.1186/s12933-020-0991-1'] 3020,2172288,Acyclovir treatment for varicella does not lower gpI and IE-62 (p170) antibody responses to varicella-zoster virus in normal children.,"The varicella-zoster virus (VZV) membrane glycoprotein gpI elicits a major immunoglobulin G antibody response after naturally acquired VZV infection; antibody to a nonglycosylated immediate-early protein, IE-62 (p170), represents a response to a nonmembrane VZV component. We evaluated antibody response to VZV gpI and IE-62 (p170) at 28 days and 1 year following infection in 34 children (ages 5 to 16 years) enrolled in a randomized placebo-controlled study of oral acyclovir for the treatment of varicella. All children were VZV antibody negative at enrollment, were previously healthy, and had laboratory-documented varicella. Compared with placebo recipients, acyclovir recipients had lower geometric mean titers by the fluorescent antibody to membrane antigen technique at 28 days (620 versus 836) but similar titers at 1 year (122 versus 122). All children had antibodies to gpI and IE-62 detectable by enzyme-linked immunosorbent assay at 28 days and 1 year. No difference in gpI at 28 days compared with 1 year was noted in acyclovir recipients. No difference in antibody to IE-62 (p170) was noted when acyclovir and placebo recipients were compared at either 28 days or 1 year. Antibody responses to gpI and IE were similar when children were stratified by age (5 to 6 years, 7 to 11 years, 12 to 16 years). A short course of oral acyclovir for the treatment of varicella did not affect antibody responses to gpI or IE-62 (p170) in healthy children at 28 days and 1 year following varicella.",1990,All children had antibodies to gpI and IE-62 detectable by enzyme-linked immunosorbent assay at 28 days and 1 year.,"['34 children (ages 5 to 16 years) enrolled in a randomized', 'All children were VZV antibody negative at enrollment, were previously healthy, and had laboratory-documented varicella']","['Acyclovir', 'oral acyclovir', 'acyclovir', 'placebo']","['geometric mean titers', 'antibody to IE-62 (p170', 'gpI and IE-62 (p170) antibody responses']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0855852', 'cui_str': 'Antibody NOS negative'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0008049', 'cui_str': 'Varicella'}]","[{'cui': 'C0001367', 'cui_str': 'Acyclovir'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0003261', 'cui_str': 'Antibody Response'}]",34.0,0.0450471,All children had antibodies to gpI and IE-62 detectable by enzyme-linked immunosorbent assay at 28 days and 1 year.,"[{'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Englund', 'Affiliation': 'Department of Laboratory Medicine, University of Minnesota Health Sciences Center, Minneapolis 55455.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Arvin', 'Affiliation': ''}, {'ForeName': 'H H', 'Initials': 'HH', 'LastName': 'Balfour', 'Affiliation': ''}]",Journal of clinical microbiology,[] 3021,31256606,Predictors of Depression and Anxiety in Family Members 3 Months After Child's Admission to a Pediatric ICU.,"OBJECTIVES Family members of children admitted to intensive care units (ICUs) suffer from severe stress, which sometimes results in long-term psychological problems. We aimed to identify associations between demographic and psychosocial variables at early stages of a child's admission to the ICU and depression and anxiety in family members at approximately 3 months after admission. We also explored predictive models for depression and anxiety at 3 months after admission. METHODS This study is a secondary analysis of data from a previous clinical trial of palliative care for family members in ICUs, in which 380 family members of 220 children reported demographic and psychosocial status at approximately 1 week after ICU admission (baseline), at discharge from the ICUs, and at 3 months after the child's admission to the ICU. Clinical data were extracted from the children's medical records. We used linear regression models and stepwise linear regression for the analyses. RESULTS After controlling for significant confounders of gender (female) and child mortality, worse psychological status at baseline, represented by reported depression, anxiety, and acute stress symptoms, was associated with more severe depression and anxiety at 3 months. Also, a better family relationship at baseline was associated with lower depression and anxiety at 3 months. CONCLUSION We suggest a need to screen family members of children admitted to the ICU with validated scales and intervening with those at high risk of depression and anxiety. CLINICAL TRIALS Registry number NCT02144779 on ClinicalTrials.gov . https://clinicaltrials.gov/ct2/show/NCT02144779?term=NCT02144779&rank=1 .",2019,"Also, a better family relationship at baseline was associated with lower depression and anxiety at 3 months. ","['Family Members 3 Months', 'Family members of children admitted to intensive care units (ICUs) suffer from severe stress', ""family members in ICUs, in which 380 family members of 220 children reported demographic and psychosocial status at approximately 1 week after ICU admission (baseline), at discharge from the ICUs, and at 3 months after the child's admission to the ICU""]",[],"['Depression and Anxiety', 'severe depression and anxiety', 'child mortality, worse psychological status', 'depression, anxiety, and acute stress symptoms']","[{'cui': 'C0086282', 'cui_str': 'Person in the family'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0583239', 'cui_str': 'Admission to intensive care unit (procedure)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C4319693', 'cui_str': 'Three hundred and eighty'}, {'cui': 'C4517650', 'cui_str': '220 (qualifier value)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0337459', 'cui_str': 'Psychosocial status (social concept)'}, {'cui': 'C0332232', 'cui_str': 'Approximate (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C3871203', 'cui_str': 'At discharge (qualifier value)'}]",[],"[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0588008', 'cui_str': 'Severe depression (disorder)'}, {'cui': 'C0008083', 'cui_str': 'Child Mortality'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress (finding)'}]",380.0,0.0434092,"Also, a better family relationship at baseline was associated with lower depression and anxiety at 3 months. ","[{'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Iwata', 'Affiliation': '1 Graduate School of Health Management, Keio University, Shinjuku, Japan.'}, {'ForeName': 'Soojeong', 'Initials': 'S', 'LastName': 'Han', 'Affiliation': '2 Department of Biobehavioral Nursing and Health Informatics, School of Nursing, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Hays', 'Affiliation': '3 Department of Pediatrics, School of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Ardith Z', 'Initials': 'AZ', 'LastName': 'Doorenbos', 'Affiliation': '2 Department of Biobehavioral Nursing and Health Informatics, School of Nursing, University of Washington, Seattle, WA, USA.'}]",The American journal of hospice & palliative care,['10.1177/1049909119859517'] 3022,30592553,"Novel immediate/sustained-release formulation of acetaminophen-ibuprofen combination (Paxerol®) for severe nocturia associated with overactive bladder: A multi-center, randomized, double blinded, placebo-controlled, 4-arm trial.","AIM To determine short-term efficacy and safety of Paxerol®, novel immediate:sustained (50%:50%) release tablets containing 325 mg acetaminophen and 150 mg ibuprofen per tablet. METHODS One of three dose levels, corresponding to the amounts in 1, 2, and 3 tablets, of Paxerol and placebo were administered for 14 consecutive days to patients with severe nocturia (defined in this study as an average nocturnal voids [NV] ≥2.5) associated with overactive bladder (OAB). Changes in NV, as well as Nocturia Quality of Life (NQOL), duration of first uninterrupted sleep (DFUS), and total hours of nightly sleep (THNS) associated with treatment were assessed. Short-term safety/tolerability was assessed throughout the study and for at least 30 days post-treatment. RESULTS Paxerol at all three doses reduced NV to a greater degree than placebo (average NV -1.1, -1.4, -1.3 voids for low, mid, and high doses, respectively, vs -0.3 void for placebo). NQOL and THNS were similar between baseline and treatment values in all four groups. There were also no between-group differences. Paxerol at high dose tended to (although not statistical significantly) increase DFUS to a greater degree than placebo (1.2 vs 0.4 h, P = 0.057). There were no treatment related adverse events in any of the four groups. CONCLUSIONS This study demonstrates short-term efficacy and short-term safety of Paxerol in patients with severe nocturia associated with OAB. The results warrant further investigation of the long-term efficacy and safety of Paxerol in larger patient populations.",2019,"Paxerol at all three doses reduced NV to a greater degree than placebo (average NV -1.1, -1.4, -1.3 voids for low, mid, and high doses, respectively, vs -0.3 void for placebo).","['severe nocturia associated with overactive bladder', 'patients with severe nocturia associated with OAB']","['ibuprofen', 'placebo', 'Paxerol', 'acetaminophen', 'Paxerol®', 'Paxerol and placebo', 'acetaminophen-ibuprofen combination (Paxerol®']","['Nocturia Quality of Life (NQOL), duration of first uninterrupted sleep (DFUS), and total hours of nightly sleep (THNS', 'severe nocturia', 'adverse events', 'NQOL and THNS', 'overactive bladder (OAB', 'Short-term safety/tolerability', 'DFUS']","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0028734', 'cui_str': 'Nycturia'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0878773', 'cui_str': 'Overactive Bladder'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}]","[{'cui': 'C0028734', 'cui_str': 'Nycturia'}, {'cui': 'C0034380'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0878773', 'cui_str': 'Overactive Bladder'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.153956,"Paxerol at all three doses reduced NV to a greater degree than placebo (average NV -1.1, -1.4, -1.3 voids for low, mid, and high doses, respectively, vs -0.3 void for placebo).","[{'ForeName': 'King C', 'Initials': 'KC', 'LastName': 'Lee', 'Affiliation': 'Quinnipiac University, Hamden, Connecticut.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Rauscher', 'Affiliation': 'WISTAR Institute, Department of Gene Expression and Regulation, Philadelphia, Pennsylvania.'}, {'ForeName': 'Jed', 'Initials': 'J', 'LastName': 'Kaminesky', 'Affiliation': 'Manhattan Medical Research, New York, New York.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Ryndin', 'Affiliation': 'A and I Medical PC, Brooklyn, New York.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Xie', 'Affiliation': 'Brightech International, Somerset, New Jersey.'}, {'ForeName': 'Yunzhu', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Brightech International, Somerset, New Jersey.'}, {'ForeName': 'Johnathan A', 'Initials': 'JA', 'LastName': 'Khusid', 'Affiliation': 'SUNY Downstate College of Medicine, Department of Urology, Brooklyn, New York.'}, {'ForeName': 'Jeffrey P', 'Initials': 'JP', 'LastName': 'Weiss', 'Affiliation': 'SUNY Downstate College of Medicine, Department of Urology, Brooklyn, New York.'}]",Neurourology and urodynamics,['10.1002/nau.23910'] 3023,31724291,Distraction-focused interventions on examination stress in nursing students: Effects on psychological stress and biomarker levels. A randomized controlled trial.,"BACKGROUND Nursing students all over the world experience high levels of stress with negative impacts on their health, emotional state and performance. AIM This study aimed to investigate the effects of distraction-focused interventions on examination stress and anxiety in nursing students. METHODS A randomized controlled, parallel trial design was conducted from January to June 2016. After baseline measurement, 72 participants were randomized to one of the following groups (n = 18 each): (i) animal-assisted therapy; (ii) music therapy; (iii) mandala painting; (iv) control group. Outcomes of all groups in terms of stress-reduction were compared by measuring self-reported perceived stress (STAI-State and visual analogue stress scale) and salivary biomarker levels (Cortisol and Immunoglobulin A). RESULTS Fifty-seven complete data sets (n = 12-16 for each group) were analysed. All distraction-focused interventions showed stress and anxiety reduction in everyday school situations. By contrast, on days with examinations, stress reductions did not reach statistical significance in regard to self-reported psychological stress. At the same time, interventions resulted in significantly decreased levels of stress biomarkers (P < .001). CONCLUSIONS Our preliminary findings suggest positive but situation-dependent effects of distraction-focused interventions in academic settings. Further research should investigate the complex relationship between physiological and psychological stress parameters.",2020,"By contrast, on days with examinations, stress reductions did not reach statistical significance in regard to self-reported psychological stress.","['nursing students', '72 participants']","['distraction-focused interventions', 'Distraction-focused interventions', 'animal-assisted therapy; (ii) music therapy; (iii) mandala painting; (iv) control group']","['stress-reduction', 'levels of stress biomarkers', 'stress and anxiety reduction', 'measuring self-reported perceived stress (STAI-State and visual analogue stress scale) and salivary biomarker levels (Cortisol and Immunoglobulin A']","[{'cui': 'C0038496', 'cui_str': 'Pupil Nurses'}]","[{'cui': 'C1369038', 'cui_str': 'Distraction (procedure)'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0150133', 'cui_str': 'Animal Facilitated Therapy'}, {'cui': 'C0026868', 'cui_str': 'Music Therapy'}, {'cui': 'C0030208', 'cui_str': 'Paintings'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0150135', 'cui_str': 'Reducing anxiety'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}]",72.0,0.0305037,"By contrast, on days with examinations, stress reductions did not reach statistical significance in regard to self-reported psychological stress.","[{'ForeName': 'Verena', 'Initials': 'V', 'LastName': 'Gebhart', 'Affiliation': 'FHG - Zentrum für Gesundheitsberufe Tirol GmbH, Innsbruck, Austria.'}, {'ForeName': 'Waltraud', 'Initials': 'W', 'LastName': 'Buchberger', 'Affiliation': 'FHG - Zentrum für Gesundheitsberufe Tirol GmbH, Innsbruck, Austria.'}, {'ForeName': 'Isabella', 'Initials': 'I', 'LastName': 'Klotz', 'Affiliation': 'Ausbildungszentrum West für Gesundheitsberufe der Tirol Kliniken GmbH, Innsbruck, Austria.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Neururer', 'Affiliation': 'Medizinische Universität Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Rungg', 'Affiliation': 'FHG - Zentrum für Gesundheitsberufe Tirol GmbH, Innsbruck, Austria.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Tucek', 'Affiliation': 'IMC Fachhochschule Krems, Krems, Austria.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Zenzmaier', 'Affiliation': 'FHG - Zentrum für Gesundheitsberufe Tirol GmbH, Innsbruck, Austria.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Perkhofer', 'Affiliation': 'FHG - Zentrum für Gesundheitsberufe Tirol GmbH, Innsbruck, Austria.'}]",International journal of nursing practice,['10.1111/ijn.12788'] 3024,31727415,"Evaluation of the efficacy, safety, and clinically recommended dose of dienogest in the treatment of primary dysmenorrhea: a randomized, double-blind, multicenter, placebo-controlled study.","OBJECTIVE To evaluate the efficacy, safety, and clinically recommended dose of dienogest (DNG; 0.5 mg/d, 1 mg/d, and 2 mg/d) in the treatment of primary dysmenorrhea. DESIGN A phase II, randomized, double-blind, multicenter, placebo-controlled study. SETTING Twenty study sites. PATIENTS A total of 235 patients with primary dysmenorrhea. INTERVENTION(S) Patients were randomized to receive orally a placebo, DNG (0.5 mg/d, 1 mg/d, or 2 mg/d) or ethinylestradiol 0.02 mg/drospirenone 3 mg (an open-label reference drug) for 12 weeks. MAIN OUTCOME MEASURE(S) The primary endpoint was the change from baseline in the dysmenorrhea score at week 12 of treatment. The secondary endpoint was the change from baseline in the visual analogue scale at week 12 of treatment. Subjects were assessed for lower abdominal pain and/or low back pain. RESULTS All DNG arms were superior to the placebo arm in terms of the change from baseline in the dysmenorrhea score. The results suggest an equal or greater effect of DNG 1 and 2 mg/d in relieving pain, when compared to the reference drug. In the safety profile of DNG, including irregular uterine bleeding, there was no obvious difference among the doses of DNG. A significant decrease in the serum estradiol concentration compared to that in the placebo arm was not observed in the DNG 1 mg/d arm but was observed in the DNG 2 mg/d arm. CONCLUSION(S) The results suggest that DNG at a dose of 1 mg/d is an effective and well-tolerated treatment for primary dysmenorrhea. TRIAL REGISTRATION JapicCTI-152977 (en).",2020,All DNG arms were superior to the placebo arm in terms of the change from baseline in the dysmenorrhea score.,"['235 patients with primary dysmenorrhea', 'primary dysmenorrhea', 'Twenty study sites']","['placebo, DNG', 'placebo', 'drospirenone', 'ethinylestradiol', 'DNG']","['dysmenorrhea score', 'serum estradiol concentration', 'efficacy, safety', 'irregular uterine bleeding', 'abdominal pain and/or low back pain', 'relieving pain', 'visual analogue scale']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0149875', 'cui_str': 'Primary dysmenorrhea (disorder)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0043822', 'cui_str': 'drospirenone'}, {'cui': 'C0015011', 'cui_str': 'Ethinyl Estradiol'}]","[{'cui': 'C0013390', 'cui_str': 'Pain, Menstrual'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0474672', 'cui_str': 'Serum estradiol measurement'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0156404', 'cui_str': 'Irregular Menses'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C0024031', 'cui_str': 'Low Back Ache'}, {'cui': 'C1304888', 'cui_str': 'Pain control (procedure)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",235.0,0.41021,All DNG arms were superior to the placebo arm in terms of the change from baseline in the dysmenorrhea score.,"[{'ForeName': 'Yutaka', 'Initials': 'Y', 'LastName': 'Osuga', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan. Electronic address: yutakaos-tky@umin.ac.jp.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Hayashi', 'Affiliation': 'Clinical Development Department, Mochida Pharmaceutical Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Shingo', 'Initials': 'S', 'LastName': 'Kanda', 'Affiliation': 'Clinical Development Department, Mochida Pharmaceutical Co., Ltd., Tokyo, Japan.'}]",Fertility and sterility,['10.1016/j.fertnstert.2019.09.014'] 3025,31926905,Longitudinal changes of resting-state functional connectivity of amygdala following fear learning and extinction.,"Altered functional connectivity of the amygdala has been observed in a resting state immediately after fear learning, even one day after aversive exposure. The persistence of increased resting-state functional connectivity (rsFC) of the amygdala has been a critical finding in patients with stress and anxiety disorders. However, longitudinal changes in amygdala rsFC have rarely been explored in healthy participants. To address this issue, we studied the rsFC of the amygdala in two groups of healthy volunteers. The control group participated in three fMRI scanning sessions of their resting state at the first visit, one day, and one week later. The experimental group participated in three fMRI sessions on the first day: a resting state before fear conditioning, a fear extinction session, and a resting state immediately after fear extinction. Furthermore, this group experienced scanning after one day and week. The fear-conditioning paradigm consisted of visual stimuli with a distinct rate of partial reinforcement by electric shock. During the extinction, we presented the same stimuli in another sequence without aversive pairing. In the control group, rsFC maps were statistically similar between sessions for the left and right amygdala. However, in the experimental group, the increased rsFC mainly of the left amygdala was observed after extinction, one day, and one week. The between-group comparison also demonstrated an increase in the left amygdala rsFC in the experimental group. Our results indicate that functional connections of the left amygdala influenced by fear learning may persist for several hours and days in the human brain.",2020,"In the control group, rsFC maps were statistically similar between sessions for the left and right amygdala.","['healthy participants', 'two groups of healthy volunteers', 'patients with stress and anxiety disorders']",[],"['left amygdala rsFC', 'increased rsFC mainly of the left amygdala']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0003469', 'cui_str': 'Anxiety Disorders'}]",[],"[{'cui': 'C0002708', 'cui_str': 'Amygdaloid Body'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}]",,0.0118251,"In the control group, rsFC maps were statistically similar between sessions for the left and right amygdala.","[{'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Martynova', 'Affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 5a Butlerova Str., Moscow 117485, Russia; Centre for Cognition and Decision Making, National Research University Higher School of Economics, 20 Myasnitskaya Str., Moscow 101000, Russia. Electronic address: omartynova@ihna.ru.'}, {'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Tetereva', 'Affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 5a Butlerova Str., Moscow 117485, Russia.'}, {'ForeName': 'Vladislav', 'Initials': 'V', 'LastName': 'Balaev', 'Affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 5a Butlerova Str., Moscow 117485, Russia.'}, {'ForeName': 'Galina', 'Initials': 'G', 'LastName': 'Portnova', 'Affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 5a Butlerova Str., Moscow 117485, Russia; Pushkin State Russian Language Institute,6 Ak. Volginа Str., Moscow 117485, Russia.'}, {'ForeName': 'Vadim', 'Initials': 'V', 'LastName': 'Ushakov', 'Affiliation': 'National Research Center Kurchatov Institute, 1 Ak. Kurchatova Pl., Moscow 123182, Russia.'}, {'ForeName': 'Alexey', 'Initials': 'A', 'LastName': 'Ivanitsky', 'Affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 5a Butlerova Str., Moscow 117485, Russia.'}]",International journal of psychophysiology : official journal of the International Organization of Psychophysiology,['10.1016/j.ijpsycho.2020.01.002'] 3026,31718828,Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial.,"OBJECTIVE To compare the effects of metformin, rosiglitazone, and their combination in obese polycystic ovary syndrome (PCOS) patients with insulin resistance. DESIGN Prospective randomized controlled trail. SETTING Tertiary teaching hospital. PATIENT(S) Obese Chinese women (body mass index [BMI] ≥25 kg/m 2 ) with insulin resistance who fulfilled the Rotterdam criteria of PCOS. INTERVENTION(S) In group 1, 68 patients administered metformin (1,500 mg/day); in group 2, 67 patients administered rosiglitazone (4 mg/day); in group 3, 69 patients administered metformin (1,000 mg/day) and rosiglitazone (4 mg/day) for 6 months, all with the same diet and regular exercise lifestyle recommendation. MAIN OUTCOME MEASURE(S) Average menstrual interval, anthropometric measurements, androgen-related parameters, and metabolic features of insulin, carbohydrates, and lipids, with intention-to-treat analysis. RESULT(S) The baseline parameters showed no statistically significant differences. After the 6-month treatment, most participants showed an improved menstrual pattern. There were statistically significant decreases in acne scores, weight, BMI, waist circumference, waist-to-hip ratio, and serum testosterone. The metabolic indexes of insulin, carbohydrates, and lipids were improved obviously compared with the baseline in each group. Among the three groups, the patients administered 1,500 mg/day metformin experienced greater reductions in weight. However, the rosiglitazone users (alone or combined with metformin) showed a more notable decline in total cholesterol and triglyceride levels. CONCLUSION(S) Considering the benefits of metformin on weight loss, high-dose metformin (1,500 mg/day) along with lifestyle modification should be recommended for obese, insulin-resistant women with PCOS. Rosiglitazone alone or combined with low-dosage metformin plus lifestyle modification should be considered for the women with abnormal lipid profiles. CLINICAL TRIAL REGISTRATION NUMBER ChiCTR-TRC-13003642 (Chinese Clinical Trial Registry).",2020,"There were statistically significant decreases in acne scores, weight, BMI, waist circumference, waist-to-hip ratio, and serum testosterone.","['obese women with polycystic ovary syndrome', 'obese polycystic ovary syndrome (PCOS) patients with insulin resistance', '\n\n\nObese Chinese women (body mass index [BMI] ≥25 kg/m 2 ) with insulin resistance who fulfilled the Rotterdam criteria of PCOS', 'Tertiary teaching hospital', 'women with abnormal lipid profiles', 'obese, insulin-resistant women with PCOS']","['Rosiglitazone alone or combined with low-dosage metformin', 'regular exercise lifestyle recommendation', 'metformin', 'metformin, rosiglitazone', 'metformin and rosiglitazone', 'rosiglitazone']","['menstrual pattern', 'total cholesterol and triglyceride levels', 'Average menstrual interval, anthropometric measurements, androgen-related parameters, and metabolic features of insulin, carbohydrates, and lipids, with intention-to-treat analysis', 'weight loss', 'weight', 'metabolic indexes of insulin, carbohydrates, and lipids', 'acne scores, weight, BMI, waist circumference, waist-to-hip ratio, and serum testosterone']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0032460', 'cui_str': 'Sclerocystic Ovary Syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0020027', 'cui_str': 'Teaching Hospitals'}, {'cui': 'C0740400', 'cui_str': 'Abnormal lipid profile'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}]","[{'cui': 'C0289313', 'cui_str': 'rosiglitazone'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0178602', 'cui_str': 'Dosages (qualifier value)'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0582191', 'cui_str': 'Regular exercise (observable entity)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C1620263', 'cui_str': 'Metformin / rosiglitazone'}]","[{'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0428475', 'cui_str': 'Triglyceride level - finding'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0002844', 'cui_str': 'Androgenic Compounds'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0702166', 'cui_str': 'Acne'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0205682', 'cui_str': 'Waist-Hip Ratio'}, {'cui': 'C0428413', 'cui_str': 'Serum testosterone measurement'}]",69.0,0.14659,"There were statistically significant decreases in acne scores, weight, BMI, waist circumference, waist-to-hip ratio, and serum testosterone.","[{'ForeName': 'Yujing', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ""Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, Sichuan, People's Republic of China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Tan', 'Affiliation': ""Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, Sichuan, People's Republic of China.""}, {'ForeName': 'Qiuyi', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': ""Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, Sichuan, People's Republic of China.""}, {'ForeName': 'Changling', 'Initials': 'C', 'LastName': 'Duan', 'Affiliation': ""Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, Sichuan, People's Republic of China.""}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': ""Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, Sichuan, People's Republic of China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Huang', 'Affiliation': ""Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, Sichuan, People's Republic of China. Electronic address: weihuang64@163.com.""}]",Fertility and sterility,['10.1016/j.fertnstert.2019.09.011'] 3027,30775982,Psychosocial Intervention in Couples Coping with Dementia Led by a Psychotherapist and a Social Worker: The DYADEM Trial.,"BACKGROUND Psychosocial interventions may improve the quality of life of both people with dementia (PWD) and their family caregivers. However, research is inconclusive and focused primarily on the quality of life of either the PWD or the caregiver, rather than on both. OBJECTIVE Our aim was to evaluate the effect of couple-based interdisciplinary psychosocial intervention in patients with mild-to-moderate dementia on quality of life of both partners. METHODS 108 community-dwelling PWD and their caregiving partners were enrolled in this pragmatic randomized controlled trial. The intervention consisted of 7 sessions at participants' homes led by a psychotherapist and a social worker. Quality of life was evaluated at baseline, one, and six-month follow-up for patients and their partners. Mixed effects models have been applied. RESULTS Intervention allocation was not associated with an improvement in quality of life in either the patients or their partners. In subgroup analyses, intervention was negatively associated with caregiver performance. However, this was only present in those reporting poor relationship quality. Patients in the intervention group who reported good relationship quality were found to have decreased cognitive decline. CONCLUSION A couple-based interdisciplinary intervention did not yield improvements in quality of life. This may be the result of a bias caused by an increased awareness due to the intervention. Relationship quality and support in the long-term should be considered when designing and implementing interventions for PWD and their partners.",2019,Relationship quality and support in the long-term should be considered when designing and implementing interventions for PWD and their partners.,"['people with dementia (PWD) and their family caregivers', 'patients with mild-to-moderate dementia on quality of life of both partners', '108 community-dwelling PWD and their caregiving partners', 'Couples Coping with Dementia Led by a Psychotherapist and a Social Worker']","['Psychosocial Intervention', 'couple-based interdisciplinary psychosocial intervention']","['good relationship quality', 'quality of life', 'cognitive decline', 'Quality of life']","[{'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0034380'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0557555', 'cui_str': 'Psychotherapists'}, {'cui': 'C0037444', 'cui_str': 'Social worker (occupation)'}]","[{'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0034380'}, {'cui': 'C0234985', 'cui_str': 'Cognitive Decline'}]",108.0,0.0412512,Relationship quality and support in the long-term should be considered when designing and implementing interventions for PWD and their partners.,"[{'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Nordheim', 'Affiliation': 'Institute for Medical Sociology and Rehabilitation Science, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Häusler', 'Affiliation': 'Social and Preventive Medicine, University of Potsdam, Potsdam, Germany.'}, {'ForeName': 'Sevil', 'Initials': 'S', 'LastName': 'Yasar', 'Affiliation': 'Johns Hopkins-Center on Aging and Health, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Suhr', 'Affiliation': 'ZQP-Centre for Quality in Care, Berlin, Germany.'}, {'ForeName': 'Adelheid', 'Initials': 'A', 'LastName': 'Kuhlmey', 'Affiliation': 'Institute for Medical Sociology and Rehabilitation Science, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Rapp', 'Affiliation': 'Social and Preventive Medicine, University of Potsdam, Potsdam, Germany.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Gellert', 'Affiliation': 'Institute for Medical Sociology and Rehabilitation Science, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-180812'] 3028,2037667,In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.,"In a double-blind, randomized trial, 102 healthy elderly subjects were inoculated with one of four preparations: (i) intranasal bivalent live attenuated influenza vaccine containing cold-adapted A/Kawasaki/86 (H1N1) and cold-adapted A/Bethesda/85 (H3N2) viruses; (ii) parenteral trivalent inactivated subvirion vaccine containing A/Taiwan/86 (H1N1), A/Leningrad/86 (H3N2), and B/Ann Arbor/86 antigens; (iii) both vaccines; or (iv) placebo. To determine whether local or systemic immunization augmented mucosal immunologic memory, all volunteers were challenged intranasally 12 weeks later with the inactivated virus vaccine. We used a hemagglutination inhibition assay to measure antibodies in sera and a kinetic enzyme-linked immunosorbent assay to measure immunoglobulin G (IgG) and IgA antibodies in sera and nasal washes, respectively. In comparison with the live virus vaccine, the inactivated virus vaccine elicited higher and more frequent rises of serum antibodies, while nasal wash antibody responses were similar. The vaccine combination induced serum and local antibodies slightly more often than the inactivated vaccine alone did. Coadministration of live influenza A virus vaccine did not alter the serum antibody response to the influenza B virus component of the inactivated vaccine. The anamnestic nasal antibody response elicited by intranasal inactivated virus challenge did not differ in the live, inactivated, or combined vaccine groups from that observed in the placebo group not previously immunized. These results suggest that in elderly persons cold-adapted influenza A virus vaccines offer little advantage over inactivated virus vaccines in terms of inducing serum or secretory antibody or local immunological memory. Studies are needed to determine whether both vaccines in combination are more efficacious than inactivated vaccine alone in people in this age group.",1991,"The anamnestic nasal antibody response elicited by intranasal inactivated virus challenge did not differ in the live, inactivated, or combined vaccine groups from that observed in the placebo group not previously immunized.","['elderly persons', '102 healthy elderly subjects']","['intranasal bivalent live attenuated influenza vaccine containing cold-adapted A/Kawasaki/86 (H1N1) and cold-adapted A/Bethesda/85 (H3N2) viruses; (ii) parenteral trivalent inactivated subvirion vaccine containing A/Taiwan/86 (H1N1), A/Leningrad/86 (H3N2), and B/Ann Arbor/86 antigens; (iii) both vaccines; or (iv) placebo', 'live influenza', 'placebo']","['serum antibody response', 'serum antibodies', 'anamnestic nasal antibody response', 'serum and local antibodies']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C3652556', 'cui_str': 'influenza, live attenuated'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0009443', 'cui_str': 'Common Cold'}, {'cui': 'C0042776', 'cui_str': 'Virus'}, {'cui': 'C4522267', 'cui_str': 'Parenteral (intended site)'}, {'cui': 'C0003320', 'cui_str': 'Antigens'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0021400', 'cui_str': 'Influenza, Human'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0003261', 'cui_str': 'Antibody Response'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}]",102.0,0.0170136,"The anamnestic nasal antibody response elicited by intranasal inactivated virus challenge did not differ in the live, inactivated, or combined vaccine groups from that observed in the placebo group not previously immunized.","[{'ForeName': 'D C', 'Initials': 'DC', 'LastName': 'Powers', 'Affiliation': 'Clinical Immunology Section, National Institute on Aging, Baltimore, Maryland 21224.'}, {'ForeName': 'L F', 'Initials': 'LF', 'LastName': 'Fries', 'Affiliation': ''}, {'ForeName': 'B R', 'Initials': 'BR', 'LastName': 'Murphy', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Thumar', 'Affiliation': ''}, {'ForeName': 'M L', 'Initials': 'ML', 'LastName': 'Clements', 'Affiliation': ''}]",Journal of clinical microbiology,[] 3029,32030990,Sociodemographic Correlates of Food Insecurity Among New York City Tobacco Users.,"PURPOSE To identify rates and sociodemographic correlates of food insecurity among low-income smokers. DESIGN Cross-sectional analysis of baseline survey data from a randomized controlled trial (N = 403) testing a smoking cessation intervention for low-income smokers. SETTING Two safety-net hospitals in New York City. SAMPLE Current smokers with annual household income <200% of the federal poverty level. MEASURES Food insecurity was measured using the United States Department of Agriculture 6-item food security module. Participant sociodemographics were assessed by self-reported survey responses. ANALYSIS We used frequencies to calculate the proportion of smokers experiencing food insecurity and multivariable logistic regression to identify factors associated with being food insecure. RESULTS Fifty-eight percent of participants were food insecure, with 29% reporting very high food insecurity. Compared to married participants, separated, widowed, or divorced participants were more likely to be food insecure (adjusted odds ratio [AOR] = 2.33, 95% confidence interval [CI]: 1.25-4.33), as were never married participants (AOR = 2.81, 95% CI: 1.54-5.14). CONCLUSIONS Health promotion approaches that target multiple health risks (eg, smoking and food access) may be needed for low-income populations. Interventions which seek to alleviate food insecurity may benefit from targeting socially isolated smokers.",2020,"Compared to married participants, separated, widowed, or divorced participants were more likely to be food insecure (adjusted odds ratio [AOR] =","['SAMPLE\n\n\nCurrent smokers with annual household income', 'low-income smokers', 'New York City Tobacco Users', 'Two safety-net hospitals in New York City']",['smoking cessation intervention'],['Sociodemographic Correlates of Food Insecurity'],"[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C3241966'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0557163', 'cui_str': 'Household income (observable entity)'}, {'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0027977', 'cui_str': 'New York City'}, {'cui': 'C3853727', 'cui_str': 'Tobacco user (finding)'}, {'cui': 'C3661443', 'cui_str': 'Safety-net Hospitals'}]","[{'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}]","[{'cui': 'C3494174', 'cui_str': 'Food Insecurity'}]",403.0,0.119324,"Compared to married participants, separated, widowed, or divorced participants were more likely to be food insecure (adjusted odds ratio [AOR] =","[{'ForeName': 'Christina N', 'Initials': 'CN', 'LastName': 'Wysota', 'Affiliation': 'New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Scott E', 'Initials': 'SE', 'LastName': 'Sherman', 'Affiliation': 'New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Vargas', 'Affiliation': 'New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Erin S', 'Initials': 'ES', 'LastName': 'Rogers', 'Affiliation': 'New York University Grossman School of Medicine, New York, NY, USA.'}]",American journal of health promotion : AJHP,['10.1177/0890117120904002'] 3030,32028209,"CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.","BACKGROUND CheckMate 171 (NCT02409368) is an open-label, multicentre, phase 2 trial of nivolumab in previously treated advanced squamous non-small cell lung cancer (NSCLC), conducted as part of a post-approval commitment to the European Medicines Agency (EMA). We report outcomes from this trial. METHODS Patients with Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2 and disease progression during/after ≥1 systemic treatment (≥1 being platinum-based chemotherapy) for advanced or metastatic disease were treated with nivolumab 3 mg/kg every 2 weeks until progression or unacceptable toxicity. The primary end-point was incidence of grade 3-4 treatment-related select adverse events (AEs). Other end-points included overall survival (OS) and safety. RESULTS Of 811 patients treated, 103 had ECOG PS 2; 278 were aged ≥70 years and 125 were ≥75 years of age. Minimum follow-up was ~18 months. Safety was similar across populations; the most frequent grade 3-4 treatment-related select AEs in all treated patients were diarrhoea (1%), increased alanine aminotransferase (ALT, 1%), pneumonitis (0.7%), colitis (0.6%) and increased aspartate aminotransferase (AST, 0.5%). Median OS was similar in all treated patients and those aged ≥70 and ≥75: 10.0 months, 10.0 months and 11.2 months, respectively. Median OS was 5.2 months in patients with ECOG PS 2. CONCLUSION These results suggest that nivolumab is well tolerated and active in patients with advanced, relapsed squamous NSCLC, including the elderly, with OS outcomes consistent with phase 3 data. In patients with ECOG PS 2, nivolumab had similar tolerability, but outcomes were worse, as expected in this difficult-to-treat, poor prognosis population. CLINICAL TRIAL REGISTRATION NCT02409368.",2020,"Median OS was similar in all treated patients and those aged ≥70 and ≥75: 10.0 months, 10.0 months and 11.2 months, respectively.","['patients with advanced, relapsed squamous NSCLC', '811 patients treated, 103 had ECOG PS 2; 278 were aged ≥70 years and 125 were ≥75\xa0years of age', 'patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations', 'Patients with Eastern Cooperative Oncology Group performance status (ECOG PS) 0', 'previously treated advanced squamous non-small cell lung cancer (NSCLC', 'CheckMate 171', 'advanced or metastatic disease']","['platinum-based chemotherapy', 'nivolumab']","['diarrhoea', 'tolerability', 'colitis', 'aspartate aminotransferase', 'Median OS', 'alanine aminotransferase (ALT, 1%), pneumonitis', 'overall survival (OS) and safety', 'Safety', 'incidence of grade 3-4 treatment-related select adverse events (AEs']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C4517526', 'cui_str': 'One hundred and three'}, {'cui': 'C0430797', 'cui_str': 'Intracranial EEG'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4319551', 'cui_str': 'One hundred and twenty-five'}, {'cui': 'C4509816', 'cui_str': 'Squamous non-small cell lung cancer'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1520224', 'cui_str': 'Eastern Cooperative Oncology Group performance status'}, {'cui': 'C2939420', 'cui_str': 'Metastatic disease'}]","[{'cui': 'C1098768', 'cui_str': '(diethylenetriamine)-platinum(II)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C3657270', 'cui_str': 'nivolumab'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0009319', 'cui_str': 'Colitis'}, {'cui': 'C0004002', 'cui_str': 'L-Aspartate-2-Oxoglutarate Aminotransferase'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0201836', 'cui_str': 'Alanine aminotransferase measurement (procedure)'}, {'cui': 'C3714636', 'cui_str': 'Pulmonary Inflammation'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",811.0,0.245196,"Median OS was similar in all treated patients and those aged ≥70 and ≥75: 10.0 months, 10.0 months and 11.2 months, respectively.","[{'ForeName': 'Enriqueta', 'Initials': 'E', 'LastName': 'Felip', 'Affiliation': ""Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, 8035, Spain. Electronic address: efelip@vhio.net.""}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Ardizzoni', 'Affiliation': 'Division of Medical Oncology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, 40138, Italy. Electronic address: andrea.ardizzoni@aosp.bo.it.'}, {'ForeName': 'Tudor', 'Initials': 'T', 'LastName': 'Ciuleanu', 'Affiliation': 'The Oncology Institute Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, RO-400015, Romania. Electronic address: tudor_ciuleanu@hotmail.com.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Cobo', 'Affiliation': 'Hospital Regional Universitario de Málaga and IBIMA, Malaga, 29010, Spain. Electronic address: manuelcobodols@yahoo.es.'}, {'ForeName': 'Konstantin', 'Initials': 'K', 'LastName': 'Laktionov', 'Affiliation': 'N.N. Blokhin Russian Cancer Research Center, Moscow, 115478, Russia. Electronic address: lkoskos@mail.ru.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Szilasi', 'Affiliation': 'University of Debrecen, Department for Pulmonology, Debrecen, H-4032, Hungary. Electronic address: mszilasi@med.unideb.hu.'}, {'ForeName': 'Raffaele', 'Initials': 'R', 'LastName': 'Califano', 'Affiliation': 'Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, M20 4BX, UK. Electronic address: Raffaele.Califano@christie.nhs.uk.'}, {'ForeName': 'Enric', 'Initials': 'E', 'LastName': 'Carcereny', 'Affiliation': 'Medical Oncology Department (B-ARGO Group) and Catalan Institute of Oncology-Badalona (Germans Trias I Pujol Hospital), Barcelona, 08916, Spain. Electronic address: ecarcereny@iconcologia.net.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Griffiths', 'Affiliation': 'The Clatterbridge Cancer Centre, Wirral, CH63 4JY, UK. Electronic address: richard.griffiths1@nhs.net.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Paz-Ares', 'Affiliation': 'Hospital Universitario 12 de Octubre, Madrid, 28041, Spain. Electronic address: lpazaresr@seom.org.'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Duchnowska', 'Affiliation': 'Military Institute of Medicine, Warsaw, 04-141, Poland. Electronic address: rduchnowska@wim.mil.pl.'}, {'ForeName': 'Miriam Alonso', 'Initials': 'MA', 'LastName': 'Garcia', 'Affiliation': 'Virgen Del Rocio University Hospital, Seville, 41013, Spain. Electronic address: miriamag3@hotmail.com.'}, {'ForeName': 'Dolores', 'Initials': 'D', 'LastName': 'Isla', 'Affiliation': 'University Hospital Lozano Blesa, Zaragoza, 50009, Spain. Electronic address: lola.isla@gmail.com.'}, {'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Jassem', 'Affiliation': 'Medical University of Gdańsk, Gdańsk, 80-210, Poland. Electronic address: jjassem@gumed.edu.pl.'}, {'ForeName': 'Wiebke', 'Initials': 'W', 'LastName': 'Appel', 'Affiliation': 'Rosemere Cancer Centre, Preston, PR2 9HT, UK. Electronic address: Wiebke.Appel@lthtr.nhs.uk.'}, {'ForeName': 'Janusz', 'Initials': 'J', 'LastName': 'Milanowski', 'Affiliation': 'Medical University of Lublin, Lublin, 20-059, Poland. Electronic address: janusz.milanowski@umlub.pl.'}, {'ForeName': 'Jan P', 'Initials': 'JP', 'LastName': 'Van Meerbeeck', 'Affiliation': 'Universitair Ziekenhuis Antwerpen, Antwerp-ERN Lung, 2650, Belgium. Electronic address: jan.van.meerbeeck@uza.be.'}, {'ForeName': 'Juergen', 'Initials': 'J', 'LastName': 'Wolf', 'Affiliation': 'Center for Integrated Oncology, University Hospital of Cologne, Cologne, 50937, Germany. Electronic address: juergen.wolf@uk-koeln.de.'}, {'ForeName': 'Ang', 'Initials': 'A', 'LastName': 'Li', 'Affiliation': 'Bristol-Myers Squibb, Princeton, NJ, 08540, USA. Electronic address: angus.lee@bms.com.'}, {'ForeName': 'Angelic', 'Initials': 'A', 'LastName': 'Acevedo', 'Affiliation': 'Bristol-Myers Squibb, Princeton, NJ, 08540, USA. Electronic address: angelic.acevedo@bms.com.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Popat', 'Affiliation': 'Royal Marsden Hospital, London, SW3 6JJ, UK; The Institute of Cancer Research, London, SW7 3RP, UK. Electronic address: Sanjay.Popat@rmh.nhs.uk.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.11.019'] 3031,1997425,Specific immune response in the human respiratory tract following oral immunization with live typhoid vaccine.,"Specific antibody responses in the lower respiratory tract of human subjects to orally administered Salmonella typhi Ty21a are reported. These responses, predominantly of the immunoglobulin G class, were determined to be a transudate from serum. These results were supported by the similarity in responses to parenteral administration of heat-killed typhoid vaccine. Specific immunoglobulin A antibody was a poor contributor to the respiratory antibody response to either vaccine.",1991,Specific immunoglobulin,[],"['live typhoid vaccine', 'Specific immunoglobulin']",['Specific antibody responses'],[],"[{'cui': 'C0875949', 'cui_str': 'Live typhoid vaccine'}, {'cui': 'C0358334', 'cui_str': 'Specific immunoglobulins'}]","[{'cui': 'C0443640', 'cui_str': 'Specific antibody (substance)'}]",,0.0181591,Specific immunoglobulin,"[{'ForeName': 'B D', 'Initials': 'BD', 'LastName': 'Forrest', 'Affiliation': 'Department of Medicine, University of Adelaide, Australia.'}, {'ForeName': 'J T', 'Initials': 'JT', 'LastName': 'LaBrooy', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Robinson', 'Affiliation': ''}, {'ForeName': 'C E', 'Initials': 'CE', 'LastName': 'Dearlove', 'Affiliation': ''}, {'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Shearman', 'Affiliation': ''}]",Infection and immunity,[] 3032,32024400,Inferior stabilization of cementless compared with cemented dual-mobility cups in elderly osteoarthrosis patients: a randomized controlled radiostereometry study on 60 patients with 2 years' follow-up.,"Background and purpose - Elderly patients may benefit from a dislocation low-risk dual-mobility (DM) articulation in total hip arthroplasty, but the best cup fixation method is unknown. We compared cup migration for cemented and cementless DM cups using radiostereometry.Patients and methods - In a patient-blinded randomized trial, 60 patients (33 female) with osteoarthritis were allocated to cemented (n = 30) or cementless (n = 30) Avantage DM cup fixation. Criteria were age above 70 years, and T-score above -4. We investigated cup migration, periprosthetic bone mineral density (BMD), and patient-reported outcome measures (PROMs) until 24 months postoperative follow-up.Results - At 24 months mean proximal cup migration was 0.11 mm (95% CI 0.00-0.23) for cemented cups and 0.09 mm (CI -0.09 to 0.28) for cementless cups. However, cementless cups generally migrated more than cemented cups at 12 and 24 months. Cemented cups had no measurable migration from 3 months' follow-up, while cementless cups had not yet stabilized at 24 months in all rotations. Cementless cups showed statistically significantly more maximum total point motion (MTPM) at 12- and 24-month follow-up compared with cemented cups in patients with low systemic BMD (p = 0.01). Periprosthetic BMD changes did not statisticially significantly correlate to proximal migration in either cup fixation group (p > 0.05). PROMs improved similarly in both groups.Interpretation - Cemented cups were well fixed at 3 months. The cementless cups migrated more in patients with low BMD, showed an inconsistent pattern of migration, and migrated in different directions during the first and second year without tendency to stabilization. Cemented fixation of the Avantage DM cup seems safer in elderly patients.",2020,Cementless cups showed statistically significantly more maximum total point motion (MTPM) at 12- and 24-month follow-up compared with cemented cups in patients with low systemic BMD (p = 0.01).,"['elderly osteoarthrosis patients', ""60 patients with 2 years' follow-up"", '60 patients (33 female) with osteoarthritis were allocated to cemented (n = 30) or cementless (n = 30', 'elderly patients']","['dislocation low-risk dual-mobility (DM) articulation', 'Avantage DM cup fixation', 'cemented dual-mobility cups', 'Cemented fixation of the Avantage DM cup']","['proximal migration', 'maximum total point motion (MTPM', 'cup migration, periprosthetic bone mineral density (BMD', 'proximal cup migration', 'Periprosthetic BMD changes']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0012691', 'cui_str': 'Joint Dislocations'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C2949743', 'cui_str': 'Cup - unit of product usage'}, {'cui': 'C0185023', 'cui_str': 'pexy'}]","[{'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C1533574', 'cui_str': 'Migration, function (observable entity)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0687704', 'cui_str': 'Motions (qualifier value)'}, {'cui': 'C2949743', 'cui_str': 'Cup - unit of product usage'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",60.0,0.154119,Cementless cups showed statistically significantly more maximum total point motion (MTPM) at 12- and 24-month follow-up compared with cemented cups in patients with low systemic BMD (p = 0.01).,"[{'ForeName': 'Steffan', 'Initials': 'S', 'LastName': 'Tabori-Jensen', 'Affiliation': 'University Clinic for Hand, Hip and Knee Surgery, Regional Hospital West Jutland, Holstebro;'}, {'ForeName': 'Sebastian Breddam', 'Initials': 'SB', 'LastName': 'Mosegaard', 'Affiliation': 'University Clinic for Hand, Hip and Knee Surgery, Regional Hospital West Jutland, Holstebro;'}, {'ForeName': 'Torben B', 'Initials': 'TB', 'LastName': 'Hansen', 'Affiliation': 'University Clinic for Hand, Hip and Knee Surgery, Regional Hospital West Jutland, Holstebro;'}, {'ForeName': 'Maiken', 'Initials': 'M', 'LastName': 'Stilling', 'Affiliation': 'University Clinic for Hand, Hip and Knee Surgery, Regional Hospital West Jutland, Holstebro;'}]",Acta orthopaedica,['10.1080/17453674.2020.1720978'] 3033,31742460,Development and Pretesting of Risk-Based Mobile Multimedia Message Content for Young Adult Hookah Use.,"Background . Hookah is one of the most commonly used tobacco products among U.S. young adults due in part to widespread misperceptions that it is not harmful or addictive. There is growing evidence that hookah tobacco is associated with health harms and can lead to addiction. Research on interventions to address these misperceptions by communicating the harms and addictiveness of hookah use is needed. Aims . This study developed and pretested mobile multimedia message service (MMS) message content communicating the risks of hookah tobacco use to young adult hookah smokers. Method . Message content, delivery, and pretesting were tailored to participants' risk beliefs, hookah use frequency, and responses to simulated text message prompts. Participants viewed 4 of 12 core MMS messages randomized within-subjects and completed postexposure measures of message receptivity and emotional response (e.g., worry). Results . The sample included 156 young adult (age 18-30 years) hookah smokers; 31% smoked hookah monthly and 69% weekly/daily. Prior to viewing messages, a majority endorsed beliefs reflecting misperceptions about the risks of hookah tobacco. Postexposure measures showed participants were receptive to the messages and the messages evoked emotional response. As anticipated, messages produced similar receptivity and there were few differences in emotional response between the messages tested. Discussion . Young adult hookah tobacco smokers were receptive to tailored mobile MMS messages and messages evoked emotional response, two critical precursors to behavior change. Conclusion . Findings indicate that research testing the efficacy of tailored MMS messaging as a strategy for reducing hookah tobacco use in young adults is warranted.",2019,"Young adult hookah tobacco smokers were receptive to tailored mobile MMS messages and messages evoked emotional response, two critical precursors to behavior change. ","['Young Adult Hookah Use', 'young adults', 'young adult hookah smokers', 'Young adult hookah tobacco smokers', '156 young adult (age 18-30 years) hookah smokers; 31% smoked hookah monthly and 69% weekly/daily']","['tailored MMS messaging', 'pretested mobile multimedia message service (MMS) message content communicating the risks of hookah tobacco']","['emotional response', 'message receptivity and emotional response (e.g., worry']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C4302493', 'cui_str': 'Smoking Water Pipes'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C4505132', 'cui_str': 'Hookah Tobacco'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}]","[{'cui': 'C0376478', 'cui_str': 'Multimedium'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0566001', 'cui_str': 'Does communicate (finding)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C4505132', 'cui_str': 'Hookah Tobacco'}]","[{'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0233481', 'cui_str': 'Worried (finding)'}]",156.0,0.040301,"Young adult hookah tobacco smokers were receptive to tailored mobile MMS messages and messages evoked emotional response, two critical precursors to behavior change. ","[{'ForeName': 'Andrea C', 'Initials': 'AC', 'LastName': 'Johnson', 'Affiliation': 'Georgetown University Medical Center, Washington, DC, USA.'}, {'ForeName': 'Isaac', 'Initials': 'I', 'LastName': 'Lipkus', 'Affiliation': 'Duke University School of Nursing, Durham, NC, USA.'}, {'ForeName': 'Kenneth P', 'Initials': 'KP', 'LastName': 'Tercyak', 'Affiliation': 'Georgetown University Medical Center, Washington, DC, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Luta', 'Affiliation': 'Georgetown University Medical Center, Washington, DC, USA.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Rehberg', 'Affiliation': 'Georgetown University Medical Center, Washington, DC, USA.'}, {'ForeName': 'Lilianna', 'Initials': 'L', 'LastName': 'Phan', 'Affiliation': 'Georgetown University Medical Center, Washington, DC, USA.'}, {'ForeName': 'Lorien C', 'Initials': 'LC', 'LastName': 'Abroms', 'Affiliation': 'George Washington University, Washington, DC, USA.'}, {'ForeName': 'Darren', 'Initials': 'D', 'LastName': 'Mays', 'Affiliation': 'Georgetown University Medical Center, Washington, DC, USA.'}]",Health education & behavior : the official publication of the Society for Public Health Education,['10.1177/1090198119874841'] 3034,1937790,Immunogenicity of Salmonella typhi Ty21a vaccine for young children.,"An attenuated Salmonella typhi Ty21a vaccine was administered to 18 infants and toddlers (less than or equal to 24 months old) to determine its safety and immunogenicity. The vaccination (10(9) CFU per dose, three doses) was well tolerated. However, after the vaccination there was no evidence of a humoral or cellular immune response to S. typhi. The vaccine used was known to be immunogenic for older children and adults. The results support the view that the immunogenicity of Ty21a is age dependent.",1991,"However, after the vaccination there was no evidence of a humoral or cellular immune response to S. typhi.","['young children', '18 infants and toddlers (less than or equal to 24 months old', 'older children and adults']",['Salmonella typhi Ty21a vaccine'],"['tolerated', 'Immunogenicity', 'humoral or cellular immune response', 'safety and immunogenicity']","[{'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0682053', 'cui_str': 'Toddler (qualifier value)'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0036125', 'cui_str': 'Salmonella typhosa'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}]","[{'cui': 'C1817908', 'cui_str': 'Cellular Immune Response'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0380835,"However, after the vaccination there was no evidence of a humoral or cellular immune response to S. typhi.","[{'ForeName': 'J R', 'Initials': 'JR', 'LastName': 'Murphy', 'Affiliation': 'Department of Medicine, University of Maryland School of Medicine, Baltimore 21201.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Grez', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Schlesinger', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Ferreccio', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Baqar', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Muñoz', 'Affiliation': ''}, {'ForeName': 'S S', 'Initials': 'SS', 'LastName': 'Wasserman', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Losonsky', 'Affiliation': ''}, {'ForeName': 'J G', 'Initials': 'JG', 'LastName': 'Olson', 'Affiliation': ''}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Levine', 'Affiliation': ''}]",Infection and immunity,[] 3035,31407108,Minimising recurrence after primary femoral hernia repair; is mesh mandatory?,"PURPOSE The recent international hernia guidelines advocate laparoscopic pre-peritoneal mesh repair for primary femoral hernias. However, no randomised trial has demonstrated a lower recurrence rate compared to suture repair. This study aimed to determine the 5-year recurrence rate following femoral hernia repair, in elective and emergency settings, according to surgical approach (open or laparoscopic) and method (suture, suture + mesh, or mesh alone). METHODS Consecutive patients undergoing primary femoral hernia repairs within a single health board, between 2007 and 2013, were identified from a prospective audit. Patients who had died or were uncontactable during the period of follow-up were excluded. Recurrence was defined as the clinical suspicion of an ipsilateral groin hernia at outpatient review or patient reported ipsilateral groin swelling. RESULTS A total of 297 patients underwent primary femoral hernia repairs in the time period. Of the 138 cases with complete follow-up, 25 patients experienced recurrence at 5 years (18%), with 60% of recurrences evident within the first post-operative year. The median follow-up of the remaining 113 patients was 93 months (range 63-127). No difference could be detected in recurrence rates (P = 0.372, P = 0.353), or time to recurrence (P = 0.421, P = 0.295), according to repair type (suture only, suture and mesh, or mesh only) or surgical approach (high open, low open and laparoscopic pre-peritoneal), respectively. CONCLUSIONS Use of different surgical approaches and types of repair for primary presentations of femoral hernia did not affect the recurrence rate or time to recurrence. Use of a pre-peritoneal mesh did not alter the recurrence rate or recurrence free survival, in either elective or emergency settings, compared to simple suture repair. Recurrence following primary femoral hernia repair tends to occur within the first post-operative year, suggesting that technical factors may be as important as suture or mesh failure.",2020,"Use of a pre-peritoneal mesh did not alter the recurrence rate or recurrence free survival, in either elective or emergency settings, compared to simple suture repair.","['Patients who had died or were uncontactable during the period of follow-up were excluded', 'Consecutive patients undergoing primary femoral hernia repairs within a single health board, between 2007 and 2013, were identified from a prospective audit', '297 patients underwent primary femoral hernia repairs in the time period', 'primary femoral hernias']","['femoral hernia repair', 'surgical approach (open or laparoscopic) and method (suture, suture\u2009+\u2009mesh, or mesh alone', 'laparoscopic pre-peritoneal mesh repair']","['recurrence rate', 'recurrence', 'recurrence rate or time to recurrence', 'Recurrence', 'recurrence rate or recurrence free survival', 'time to recurrence', 'recurrence rates', '5-year recurrence rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0015804', 'cui_str': 'Repair of femoral hernia (procedure)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0184820', 'cui_str': 'Prospective audit (procedure)'}, {'cui': 'C1948053', 'cui_str': 'Time periods (qualifier value)'}, {'cui': 'C0015811', 'cui_str': 'Femur'}]","[{'cui': 'C0015804', 'cui_str': 'Repair of femoral hernia (procedure)'}, {'cui': 'C0449446', 'cui_str': 'Surgical approach (attribute)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture (procedure)'}, {'cui': 'C0181805', 'cui_str': 'Mesh (physical object)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0442034', 'cui_str': 'Peritoneal (qualifier value)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}]","[{'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease (finding)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",297.0,0.194656,"Use of a pre-peritoneal mesh did not alter the recurrence rate or recurrence free survival, in either elective or emergency settings, compared to simple suture repair.","[{'ForeName': 'D R', 'Initials': 'DR', 'LastName': 'Clyde', 'Affiliation': 'Department of General Surgery, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4SA, UK. danielle.clyde@nhs.net.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'de Beaux', 'Affiliation': 'Department of General Surgery, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4SA, UK.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Tulloh', 'Affiliation': 'Department of General Surgery, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4SA, UK.'}, {'ForeName': 'J R', 'Initials': 'JR', 'LastName': ""O'Neill"", 'Affiliation': 'Department of General Surgery, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4SA, UK.'}]",Hernia : the journal of hernias and abdominal wall surgery,['10.1007/s10029-019-02007-6'] 3036,31919889,Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis.,"BACKGROUND Tildrakizumab is a high-affinity, anti-interleukin-23p19 monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis. OBJECTIVES To evaluate the effects of patient demographic and disease characteristics on tildrakizumab efficacy using phase 2b/3 trial data. METHODS Data from patients who received placebo, or tildrakizumab 100 or 200 mg, in P05495 [NCT01225731], reSURFACE 1 [NCT01722331] and reSURFACE 2 [NCT01729754] were analysed. Patient subgroups were defined by age, sex, race, weight, self-reported psoriatic arthritis, failure of ≥1 traditional systemic treatment and prior biologic use. Percentage of Psoriasis Area and Severity Index (PASI) 75 and 90 responders at Week 12 were compared across treatment arms in each subgroup. Absolute PASI at Weeks 0 and 12 was also determined for each subgroup. RESULTS Among patients randomized in P05495 (N = 355), reSURFACE 1 (N = 772) and 2 (N = 1090), percentage of PASI 75 and 90 responders were significantly greater for each tildrakizumab dose vs. placebo (P < 0.0001). PASI 75 and 90 responder percentages were numerically greater in patients <65 years of age, bodyweight ≤90 kg, without psoriatic arthritis and with no prior biologic exposure (only PASI 90), vs. their counterparts in corresponding subgroups. There were no clear or consistent differences in efficacy between the other subgroups. Absolute PASI scores were generally similar across subgroups. CONCLUSIONS Small numerical differences in tildrakizumab efficacy were observed between subgroups defined by patient age and weight, presence of psoriatic arthritis and prior biologic use. These differences were not clinically meaningful; however, analyses of long-term data may be of value. Tildrakizumab efficacy did not differ with respect to patient sex or race, or number of prior failed conventional systemic treatments. Overall, these results suggest tildrakizumab may be appropriate for treatment of moderate-to-severe plaque psoriasis in patients with a range of demographic and disease characteristics.",2020,"PASI 75 and 90 responder percentages were numerically greater in patients <65 years of age, body weight ≤90 kg, without psoriatic arthritis, and with no prior biologic exposure (only PASI 90), vs. their counterparts in corresponding subgroups.","['patients with a range of demographic and disease characteristics', 'patients with moderate to severe chronic plaque psoriasis']","['placebo, or tildrakizumab', 'tildrakizumab', 'tildrakizumab dose vs. placebo']","['Tildrakizumab efficacy', 'tildrakizumab efficacy', 'Absolute PASI', 'Percentage of Psoriasis Area and Severity Index (PASI', 'Absolute PASI scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0406317', 'cui_str': 'Plaque psoriasis (disorder)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4043954', 'cui_str': 'tildrakizumab'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C4043954', 'cui_str': 'tildrakizumab'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",1090.0,0.0713936,"PASI 75 and 90 responder percentages were numerically greater in patients <65 years of age, body weight ≤90 kg, without psoriatic arthritis, and with no prior biologic exposure (only PASI 90), vs. their counterparts in corresponding subgroups.","[{'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Poulin', 'Affiliation': 'Université Laval, Hôpital Hôtel-Dieu de Québec, Québec City, QC, Canada.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ramon', 'Affiliation': 'Department of Dermatology, Rambam Health Campus, Haifa, Israel.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Rosoph', 'Affiliation': 'North Bay Dermatology Centre, North Bay, ON, Canada.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Weisman', 'Affiliation': 'Medical Dermatology Specialists, Inc., Atlanta, GA, USA.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Mendelsohn', 'Affiliation': 'Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Parno', 'Affiliation': 'Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA.'}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Rozzo', 'Affiliation': 'Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Lee', 'Affiliation': 'Center for Clinical Studies, Webster, TX, USA.'}]",Journal of the European Academy of Dermatology and Venereology : JEADV,['10.1111/jdv.16187'] 3037,32037483,Can We Play Together? A Closer Look at the Peers of a Peer-Mediated Intervention to Improve Play in Children with Autism Spectrum Disorder.,"Peer-mediated interventions (PMIs) are often used to support children with autism spectrum disorder (ASD) to develop social skills. However, more investigation is needed to better understand the role of peers as both intervention recipients and models. Sixty-five typically developing peers who participated in a PMI for children with ASD were investigated using a randomised control trial. Play sessions of the dyads were scored using the Test of Playfulness. Results showed a significant moderate intervention effect for the peers from pre- to post-intervention; outcomes for children with ASD were not influenced by peer characteristics; and, the children demonstrated a similar pattern of play interaction. Implications for practice are discussed.Clinical Trials Registry Australian New Zealand Clinical Trials Registry, https://www.anzctr.org.au/ (ACTRN12615000008527; Universal Trial Number: U1111-1165-2708).",2020,Sixty-five typically developing peers who participated in a PMI for children with ASD were investigated using a randomised control trial.,"['children with autism spectrum disorder (ASD', 'Children with Autism Spectrum Disorder', 'Sixty-five typically developing peers who participated in a PMI for children with ASD']","['Peer-Mediated Intervention', 'Peer-mediated interventions (PMIs', 'https://www.anzctr.org.au']",[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C0450385', 'cui_str': '65 (qualifier value)'}]","[{'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}]",[],65.0,0.0625903,Sixty-five typically developing peers who participated in a PMI for children with ASD were investigated using a randomised control trial.,"[{'ForeName': 'Cally', 'Initials': 'C', 'LastName': 'Kent', 'Affiliation': 'School of Occupational Therapy, Speech Pathology and Social Work, Curtin University, Perth, WA, Australia. cally.smith@curtin.edu.au.'}, {'ForeName': 'Reinie', 'Initials': 'R', 'LastName': 'Cordier', 'Affiliation': 'School of Occupational Therapy, Speech Pathology and Social Work, Curtin University, Perth, WA, Australia.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Joosten', 'Affiliation': 'School of Allied Health, Australian Catholic University, Melbourne, VIC, Australia.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Wilkes-Gillan', 'Affiliation': 'Faculty of Health Sciences, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Bundy', 'Affiliation': 'Faculty of Health Sciences, University of Sydney, Sydney, NSW, Australia.'}]",Journal of autism and developmental disorders,['10.1007/s10803-020-04387-6'] 3038,32026820,Telerehabilitation is non-inferior to usual care following total hip replacement - a randomized controlled non-inferiority trial.,"OBJECTIVES Determine if outpatient physiotherapy care via telerehabilitation is as effective as in-person physiotherapy care after total hip replacement. DESIGN Randomised, single-blind, controlled, non-inferiority clinical trial. SETTING QEII Jubilee Hospital, Brisbane, Australia. PARTICIPANTS Seventy patients receiving a total hip replacement entered the study, sixty-nine completed the study. INTERVENTIONS The control group (n=35; x¯ age 67; female 60%) received in-person outpatient physiotherapy and a paper-based home exercise programme. The intervention group (n=35; x¯ age 62; female 66%) received remotely delivered telerehabilitation directly into their homes and a technology-based home exercise program using an iPad application. MAIN OUTCOME MEASURES The primary outcome was the quality of life subscale of the Hip disability and Osteoarthritis Outcome Score measured at six weeks post-operatively. Secondary outcomes included objective strength and balance outcomes, self-reported function and satisfaction outcomes, and home exercise program compliance. RESULTS No between group difference was detected in the Hip disability and Osteoarthritis Outcome Score quality of life subscale at the primary end point of six weeks (P=0.970). Strength, balance and self-reported function showed no between group differences. Overall satisfaction was high across both groups, with the intervention group scoring higher for ease of attending appointments (intervention 95 (10), control 86 (18), mean difference 9 (95% CI 2 to 16), P=0.017. The intervention group were more compliant with their home exercise programme (intervention 86% (20%), control 74% (26%), mean difference 12% (95% CI 1% to 23%), P=0.048). CONCLUSIONS Telerehabilitation programmes can be delivered to total hip replacement patients in their own homes, using readily available technology while maintaining high levels of satisfaction. More importantly, telerehabilitation patients appear to achieve non-inferior physical and functional outcomes as those receiving in-person rehabilitation programmes. TRIAL REGISTRATION ACTRN12615000824561. (Australian New Zealand Clinical Trials Registry).",2020,No between group difference was detected in the Hip disability and Osteoarthritis Outcome Score quality of life subscale at the primary end point of six weeks (P=0.970).,"['Seventy patients receiving a total hip replacement entered the study, sixty-nine completed the study', 'person physiotherapy care after total hip replacement', 'QEII Jubilee Hospital, Brisbane, Australia', 'The intervention group (n=35; x¯ age 62; female 66%) received']","['person outpatient physiotherapy and a paper-based home exercise programme', 'compliant with their home exercise programme', 'remotely delivered telerehabilitation directly into their homes and a technology-based home exercise program using an iPad application']","['Hip disability and Osteoarthritis Outcome Score quality of life subscale', 'Overall satisfaction', 'objective strength and balance outcomes, self-reported function and satisfaction outcomes, and home exercise program compliance', 'quality of life subscale of the Hip disability and Osteoarthritis Outcome Score', 'Strength, balance and self-reported function']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0040508', 'cui_str': 'Hip Replacement, Total'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0450388', 'cui_str': '69 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program (regime/therapy)'}, {'cui': 'C0566588', 'cui_str': 'Compliant (qualifier value)'}, {'cui': 'C4042802', 'cui_str': 'Tele-rehabilitation'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}]","[{'cui': 'C2960679', 'cui_str': 'Hip disability and osteoarthritis outcome score'}, {'cui': 'C0034380'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program (regime/therapy)'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}]",,0.126545,No between group difference was detected in the Hip disability and Osteoarthritis Outcome Score quality of life subscale at the primary end point of six weeks (P=0.970).,"[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Nelson', 'Affiliation': 'QEII Jubilee Hospital, Metro South Hospital and Health Service, Brisbane, Australia. Electronic address: mark.nelson@health.qld.gov.au.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bourke', 'Affiliation': 'Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, Australia. Electronic address: m.bourke@uq.edu.au.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Crossley', 'Affiliation': 'La Trobe Sport and Exercise Medicine Research Centre, College of Science, Health and Engineering, Melbourne, Australia. Electronic address: k.crossley@latrobe.edu.au.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Russell', 'Affiliation': 'Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, Australia. Electronic address: t.russell@uq.edu.au.'}]",Physiotherapy,['10.1016/j.physio.2019.06.006'] 3039,32026839,"Volume of water added to crushed ice affects the efficacy of cryotherapy: a randomised, single-blind, crossover trial.","OBJECTIVE To compare the effects of different cryotherapeutic preparations. DESIGN Randomised, single-blind, crossover trial. SETTING University laboratory. PARTICIPANTS Sixteen healthy women. INTERVENTIONS Participants were randomised to receive three cryotherapeutic preparations: pure ice (500g), watered ice (500g of ice in 500ml of water) and wetted ice (500g of ice in 50ml of water). MAIN OUTCOME MEASURES The primary outcome was skin surface temperature after cryotherapy, measured at the central point of application, and the minimum temperature of the region of interest (ROI). The secondary outcome was the surface area cooled to <13.6°C, which is the recommended temperature to achieve therapeutic effects. RESULTS After application of ice, mean skin surface temperature at the central point was 4.6 [standard deviation (SD) 1.9] °C for the pure ice preparation, 4.9 (SD 2.5) °C for the wetted ice preparation, and 9.6 (SD 1.8) °C for the watered ice preparation. When compared with the watered ice preparation, this represented a mean difference (MD) of 5.0°C for the pure ice preparation [95% confidence interval (CI) 4.0 to 6.0; P<0.001] and an MD of 4.7°C for the wetted ice preparation (95% CI 2.5 to 6.8; P<0.001). The minimum temperatures in the ROI were also lower for the pure ice preparation 3.0 (SD 0.9) °C and the wetted ice preparation 2.8 (SD 0.6) °C than the watered ice preparation 7.9 (SD 1.5) °C. This represented an MD of 4.8°C for the pure ice preparation (95% CI 4.0 to 5.7; P<0.001) and 5.1°C for the wetted ice preparation (95% CI 4.0 to 6.2; P<0.001]. CONCLUSIONS Application of pure ice or wetted ice led to a greater decrease in skin surface temperature compared with watered ice. For clinical purposes, combining equal parts of water and ice could decrease this effect. CLINICAL TRIAL REGISTRATION NUMBER Clinicaltrials.gov (NCT03414346).",2020,"CONCLUSIONS Application of pure ice or wetted ice led to a greater decrease in skin surface temperature compared with watered ice.","['University laboratory', 'Sixteen healthy women']","['cryotherapy', 'cryotherapeutic preparations: pure ice (500g), watered ice (500g of ice in 500ml of water) and wetted ice (500g of ice in 50ml of water']","['skin surface temperature after cryotherapy, measured at the central point of application, and the minimum temperature of the region of interest (ROI', 'skin surface temperature', 'mean skin surface temperature', 'therapeutic effects']","[{'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C4551716', 'cui_str': 'Cryotherapy'}, {'cui': 'C0349714', 'cui_str': 'Icing (substance)'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0205381', 'cui_str': 'Wet (qualifier value)'}]","[{'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}, {'cui': 'C4551716', 'cui_str': 'Cryotherapy'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1527144'}]",16.0,0.2698,"CONCLUSIONS Application of pure ice or wetted ice led to a greater decrease in skin surface temperature compared with watered ice.","[{'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'de Estéfani', 'Affiliation': 'Aging, Resources and Rheumatology Laboratory, Federal University of Santa Catarina, Araranguá, Santa Catarina, Brazil.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Ruschel', 'Affiliation': 'Health and Sports Science Centre, Santa Catarina State University, Florianópolis, Santa Catarina, Brazil.'}, {'ForeName': 'Inaihá Laureano', 'Initials': 'IL', 'LastName': 'Benincá', 'Affiliation': 'Aging, Resources and Rheumatology Laboratory, Federal University of Santa Catarina, Araranguá, Santa Catarina, Brazil.'}, {'ForeName': 'Daniela Pacheco', 'Initials': 'DP', 'LastName': 'Dos Santos Haupenthal', 'Affiliation': 'Laboratory of Cellular and Molecular Biology, University of the Extreme South of Santa Catarina, Criciuma, Santa Catarina, Brazil.'}, {'ForeName': 'Núbia Carelli Pereira', 'Initials': 'NCP', 'LastName': 'de Avelar', 'Affiliation': 'Aging, Resources and Rheumatology Laboratory, Federal University of Santa Catarina, Araranguá, Santa Catarina, Brazil.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Haupenthal', 'Affiliation': 'Aging, Resources and Rheumatology Laboratory, Federal University of Santa Catarina, Araranguá, Santa Catarina, Brazil. Electronic address: alessandro.haupenthal@ufsc.br.'}]",Physiotherapy,['10.1016/j.physio.2019.12.005'] 3040,32026836,Effects of land- and water-based exercise programmes on postural balance in individuals with COPD: additional results from a randomised clinical trial.,"OBJECTIVE To investigate the effects of water-based exercise training on postural balance in individuals with chronic obstructive pulmonary disease (COPD), and compare the effects of two similar protocols of land- and water-based exercise programmes on postural balance in this population. DESIGN Randomised clinical trial. SETTING University-based, outpatient, physical therapy clinic. SUBJECTS Fifty individuals with COPD. INTERVENTIONS Participants were assigned at random to the land group (LG; n=27) or the water group (WG; n=23), and underwent high-intensity endurance and strength training three times per week for 3months. MAIN OUTCOME MEASURES Functional balance was assessed by the timed up and go test (TUG), and static balance was assessed with a force platform in the following conditions: standing with feet hip-width apart and eyes open; standing with feet hip-width apart and eyes closed; standing on a short base; and one-legged stance. RESULTS Seventeen subjects completed the intervention in the LG {nine males, mean age 64 [standard deviation (SD) 8] years, mean forced expiratory volume in 1 second (FEV 1 ) 48 (SD 17) %predicted} compared with 14 subjects in the WG [nine males, mean age 65 (SD 8) years, FEV 1 51 (SD 15) %predicted]. Water-based exercise training had a positive effect on functional balance [TUG: mean difference -1.17 (-1.93 to -0.41 95% confidence interval) seconds; P=0.006], whereas static balance remained unaltered for both groups. There was no between-group difference in postural balance after exercise training; however, a higher proportion of participants who had a clinically relevant improvement in the TUG were in the WG (LG 35%, WG 64%; P<0.001). CONCLUSION Functional balance improved after 3months of high-intensity exercise training performed in water. Despite the environment, non-specific training seems to be insufficient to improve static balance. CLINICAL TRIAL REGISTRATION NUMBER clinicalTrials.gov NCT01691131.",2020,"Water-based exercise training had a positive effect on functional balance [TUG: mean difference -1.17 (-1.93 to -0.41 95% confidence interval) seconds; P=0.006], whereas static balance remained unaltered for both groups.","['Seventeen subjects completed the intervention in the LG {nine males, mean age 64 [standard deviation (SD) 8] years', 'individuals with chronic obstructive pulmonary disease (COPD', 'University-based, outpatient, physical therapy clinic', 'Fifty individuals with COPD', 'individuals with COPD']","['Water-based exercise training', 'high-intensity endurance and strength training three times per week for 3months', 'water-based exercise training', 'land- and water-based exercise programmes']","['static balance', 'functional balance', 'postural balance', 'mean forced expiratory volume', 'timed up and go test (TUG), and static balance']","[{'cui': 'C0450331', 'cui_str': '17 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}]","[{'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0518031', 'cui_str': 'Endurance capacity'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0441463', 'cui_str': 'Static (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C1256755', 'cui_str': 'Postural Equilibrium'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",50.0,0.102356,"Water-based exercise training had a positive effect on functional balance [TUG: mean difference -1.17 (-1.93 to -0.41 95% confidence interval) seconds; P=0.006], whereas static balance remained unaltered for both groups.","[{'ForeName': 'Larissa A', 'Initials': 'LA', 'LastName': 'de Castro', 'Affiliation': 'Research Centre in Health Sciences, University of North Parana, Londrina, Brazil; Centre of Research and Post-Graduation in Health Sciences, Londrina State University, Londrina, Brazil; Masters and Doctoral Programme in Rehabilitation Sciences, Physiotherapy Department, Londrina State University, Londrina, Brazil; University of North Parana, Londrina, Brazil; Laboratory of Research in Respiratory Physiotherapy, Physiotherapy Department, Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Josiane M', 'Initials': 'JM', 'LastName': 'Felcar', 'Affiliation': 'Research Centre in Health Sciences, University of North Parana, Londrina, Brazil; Centre of Research and Post-Graduation in Health Sciences, Londrina State University, Londrina, Brazil; Masters and Doctoral Programme in Rehabilitation Sciences, Physiotherapy Department, Londrina State University, Londrina, Brazil; University of North Parana, Londrina, Brazil; Laboratory of Research in Respiratory Physiotherapy, Physiotherapy Department, Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Débora R', 'Initials': 'DR', 'LastName': 'de Carvalho', 'Affiliation': 'Research Centre in Health Sciences, University of North Parana, Londrina, Brazil; Centre of Research and Post-Graduation in Health Sciences, Londrina State University, Londrina, Brazil; Masters and Doctoral Programme in Rehabilitation Sciences, Physiotherapy Department, Londrina State University, Londrina, Brazil; University of North Parana, Londrina, Brazil; Laboratory of Research in Respiratory Physiotherapy, Physiotherapy Department, Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Laís S', 'Initials': 'LS', 'LastName': 'Vidotto', 'Affiliation': 'Research Centre in Health Sciences, University of North Parana, Londrina, Brazil; Masters and Doctoral Programme in Rehabilitation Sciences, Physiotherapy Department, Londrina State University, Londrina, Brazil; University of North Parana, Londrina, Brazil.'}, {'ForeName': 'Rubens A', 'Initials': 'RA', 'LastName': 'da Silva', 'Affiliation': 'Research Centre in Health Sciences, University of North Parana, Londrina, Brazil; Masters and Doctoral Programme in Rehabilitation Sciences, Physiotherapy Department, Londrina State University, Londrina, Brazil; University of North Parana, Londrina, Brazil.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Pitta', 'Affiliation': 'Masters and Doctoral Programme in Rehabilitation Sciences, Physiotherapy Department, Londrina State University, Londrina, Brazil; Laboratory of Research in Respiratory Physiotherapy, Physiotherapy Department, Londrina State University, Londrina, Brazil.'}, {'ForeName': 'Vanessa S', 'Initials': 'VS', 'LastName': 'Probst', 'Affiliation': 'Research Centre in Health Sciences, University of North Parana, Londrina, Brazil; Centre of Research and Post-Graduation in Health Sciences, Londrina State University, Londrina, Brazil; Masters and Doctoral Programme in Rehabilitation Sciences, Physiotherapy Department, Londrina State University, Londrina, Brazil; University of North Parana, Londrina, Brazil. Electronic address: vanessaprobst@gmail.com.'}]",Physiotherapy,['10.1016/j.physio.2019.08.001'] 3041,32026838,Effectiveness of spinal manipulation and myofascial release compared with spinal manipulation alone on health-related outcomes in individuals with non-specific low back pain: randomized controlled trial.,"OBJECTIVE To investigate the effectiveness of spinal manipulation combined with myofascial release compared with spinal manipulation alone, in individuals with chronic non-specific low back pain (CNLBP). DESIGN Randomized controlled trial with three months follow-up. SETTING Rehabilitation clinic. PARTICIPANTS Seventy-two individuals (between 18 and 50 years of age; CNLBP ≥12 consecutive weeks) were enrolled and randomly allocated to one of two groups: (1) Spinal manipulation and myofascial release - SMMRG; n=36) or (2) Spinal manipulation alone (SMG; n=36). INTERVENTIONS Combined spinal manipulation (characterized by high velocity/low amplitude thrusts) of the sacroiliac and lumbar spine and myofascial release of lumbar and sacroiliac muscles vs manipulation of the sacroiliac and lumbar spine alone, twice a week, for three weeks. MAIN OUTCOME MEASURES Assessments were performed at baseline, three weeks post intervention and three months follow-up. Primary outcomes were pain intensity and disability. Secondary outcomes were quality of life, pressure pain-threshold and dynamic balance. RESULTS No significant differences were found between SMMRG vs SMG in pain intensity and disability post intervention and at follow-up. We found an overall significant difference between-groups for CNLBP disability (SMG-SMMRG: mean difference of 5.0; 95% confidence interval of difference 9.9; -0.1), though this effect was not clinically important and was not sustained at follow-up. CONCLUSIONS We demonstrated that spinal manipulation combined with myofascial release was not more effective compared to spinal manipulation alone for patients with CNLBP. CLINICAL TRIAL REGISTRATION NUMBER NCT03113292.",2020,No significant differences were found between SMMRG vs SMG in pain intensity and disability post intervention and at follow-up.,"['individuals with chronic non-specific low back pain (CNLBP', 'Seventy-two individuals (between 18 and 50 years of age; CNLBP ≥12 consecutive weeks', 'patients with CNLBP', 'individuals with non-specific low back pain', 'Rehabilitation clinic']","['spinal manipulation alone', 'spinal manipulation combined with myofascial release', 'Spinal manipulation and myofascial release - SMMRG; n=36) or (2) Spinal manipulation alone (SMG; n=36', 'SMMRG vs SMG', 'spinal manipulation and myofascial release', 'Combined spinal manipulation (characterized by high velocity/low amplitude thrusts) of the sacroiliac and lumbar spine and myofascial release of lumbar and sacroiliac muscles vs manipulation of the sacroiliac and lumbar spine alone']","['CNLBP disability', 'quality of life, pressure pain-threshold and dynamic balance', 'pain intensity and disability', 'health-related outcomes', 'pain intensity and disability post intervention']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0205370', 'cui_str': 'Non-specific (qualifier value)'}, {'cui': 'C0024031', 'cui_str': 'Low Back Ache'}, {'cui': 'C4319632', 'cui_str': 'Seventy-two'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3839785', 'cui_str': 'Rehabilitation clinic (environment)'}]","[{'cui': 'C0086586', 'cui_str': 'Manipulation, Spinal'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0695600', 'cui_str': 'Myofascial release (regime/therapy)'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0555898', 'cui_str': 'Sacroiliac (qualifier value)'}, {'cui': 'C3887615', 'cui_str': 'Lumbar spine structure (body structure)'}, {'cui': 'C0024090', 'cui_str': 'Lumbar Region'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0947647', 'cui_str': 'Manipulation - action (qualifier value)'}]","[{'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0162703', 'cui_str': 'Pain Threshold'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]",,0.152935,No significant differences were found between SMMRG vs SMG in pain intensity and disability post intervention and at follow-up.,"[{'ForeName': 'Taise Angeli', 'Initials': 'TA', 'LastName': 'Boff', 'Affiliation': 'Master in Rehabilitation Sciences, Universidade de Brasília (UnB), Campus UnB Ceilândia, Brasília, Brazil; Núcleo de Evidências e Tecnologias em Saúde (NETecS), Universidade de Brasília (UnB), Campus UnB Ceilândia, Brasília, Brazil.'}, {'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'Pasinato', 'Affiliation': 'Núcleo de Evidências e Tecnologias em Saúde (NETecS), Universidade de Brasília (UnB), Campus UnB Ceilândia, Brasília, Brazil; School of Physical Therapy, Universidade de Brasília (UnB), Campus UnB Ceilândia, Brasília, Brazil.'}, {'ForeName': 'Ângela Jornada', 'Initials': 'ÂJ', 'LastName': 'Ben', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, The Netherlands.'}, {'ForeName': 'Judith E', 'Initials': 'JE', 'LastName': 'Bosmans', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, The Netherlands.'}, {'ForeName': 'Maurits', 'Initials': 'M', 'LastName': 'van Tulder', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, The Netherlands; Department Physiotherapy & Occupational Therapy, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Rodrigo Luiz', 'Initials': 'RL', 'LastName': 'Carregaro', 'Affiliation': 'Master in Rehabilitation Sciences, Universidade de Brasília (UnB), Campus UnB Ceilândia, Brasília, Brazil; Núcleo de Evidências e Tecnologias em Saúde (NETecS), Universidade de Brasília (UnB), Campus UnB Ceilândia, Brasília, Brazil; School of Physical Therapy, Universidade de Brasília (UnB), Campus UnB Ceilândia, Brasília, Brazil. Electronic address: rodrigocarregaro@unb.br.'}]",Physiotherapy,['10.1016/j.physio.2019.11.002'] 3042,32026173,A Randomized Controlled Trial of an Intelligent Robotic Response to Joint Attention Intervention System.,"Although there has been growing interest in utilizing robots for intervention in autism spectrum disorder (ASD), there have been very few controlled trials to assess the actual impacts of such systems on social communication vulnerabilities. This study reports a randomized controlled trial to investigate a robot-mediated response to joint attention intervention in a small (23 recruited; 20 completed) group of young children (average age = 2.54 years) with ASD. Small and nonsignificant group differences were observed regarding improvements in response to joint attention skills within and beyond the intervention. The sample showed tremendous individual variability in response to the system. Results highlight the current challenges related to developing pragmatic, beneficial, and generalizable robotic intervention systems for the targeted population.",2020,Small and nonsignificant group differences were observed regarding improvements in response to joint attention skills within and beyond the intervention.,"['a small (23 recruited; 20 completed) group of young children (average age\u2009=\u20092.54\xa0years) with ASD', 'autism spectrum disorder (ASD']",['robot-mediated response to joint attention intervention'],['response to joint attention skills'],"[{'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}]","[{'cui': 'C0336537', 'cui_str': 'Robot, device (physical object)'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C0022417', 'cui_str': 'Joints'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]","[{'cui': 'C0022417', 'cui_str': 'Joints'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",,0.0678958,Small and nonsignificant group differences were observed regarding improvements in response to joint attention skills within and beyond the intervention.,"[{'ForeName': 'Zhi', 'Initials': 'Z', 'LastName': 'Zheng', 'Affiliation': 'Department of Biomedical Engineering, Rochester Institute of Technology, 160 Lomb Memorial Drive, Building 73, Rochester, NY, 14623, USA. zhzbme@rit.edu.'}, {'ForeName': 'Guangtao', 'Initials': 'G', 'LastName': 'Nie', 'Affiliation': 'Department of Electrical Engineering and Computer Science, Vanderbilt University, Olin Hall Room 101, 2400 Highland Avenue, Nashville, TN, 37212, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Swanson', 'Affiliation': 'Treatment and Research Institute of Autism Spectrum Disorders, Vanderbilt Kennedy Center, Vanderbilt University Medical Center, 110 Magnolia Circle, Nashville, TN, 37203, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Weitlauf', 'Affiliation': 'Treatment and Research Institute of Autism Spectrum Disorders, Vanderbilt Kennedy Center, Vanderbilt University Medical Center, 110 Magnolia Circle, Nashville, TN, 37203, USA.'}, {'ForeName': 'Zachary', 'Initials': 'Z', 'LastName': 'Warren', 'Affiliation': 'Treatment and Research Institute of Autism Spectrum Disorders, Vanderbilt Kennedy Center, Vanderbilt University Medical Center, 110 Magnolia Circle, Nashville, TN, 37203, USA.'}, {'ForeName': 'Nilanjan', 'Initials': 'N', 'LastName': 'Sarkar', 'Affiliation': 'Department of Electrical Engineering and Computer Science, Vanderbilt University, Olin Hall Room 101, 2400 Highland Avenue, Nashville, TN, 37212, USA.'}]",Journal of autism and developmental disorders,['10.1007/s10803-020-04388-5'] 3043,31704268,Do Splints Play a Role in the Management of Condylar Postfracture Syndrome After Mandibular Angle Fractures?-A Randomized Controlled Clinical Trial.,"PURPOSE Fractures of the mandibular angle can result in condylar postfracture syndrome (CPFS) due to indirect injury to the condylar region. Studies evaluating early intervention for CPFS are lacking. In the present study, we evaluated the efficacy of interocclusal splint therapy for the prevention and early management of CPFS. PATIENTS AND METHODS A prospective randomized controlled clinical trial was designed and included patients who required open reduction and internal fixation for a unilateral angle fracture. The patients were divided into 2 groups. The study group received interocclusal splints postoperatively and the control group did not receive such splints. The patients were followed up at 2 weeks and 1, 2, and 3 months. The primary outcome measure was the presence or absence of CPFS after 3 months. CPFS was defined as the presence of any 1 of the clinical signs of temporomandibular joint dysfunction. The secondary outcomes included the mean pain scores and degree of mouth opening, which were evaluated at each follow-up visit. RESULTS The study included 40 patients, with 20 patients each randomized to the study and control groups. At the end of 3 months, CPFS was present in 2 patients in the study group and in all 20 patients in the control group. The mean pain scores were significantly lower in the study group than in the control group, and the mean mouth opening was significantly greater. CONCLUSIONS The use of interocclusal splints was found to be effective in the prevention and early management of CPFS. The use of splints also resulted in decreased pain and an improved mandibular mouth opening.",2020,The use of interocclusal splints was found to be effective in the prevention and early management of CPFS.,"['patients who required open reduction and internal fixation for a unilateral angle fracture', 'Condylar Postfracture Syndrome', '40 patients, with 20 patients each randomized to the study and control groups']","['interocclusal splints postoperatively and the control group did not receive such splints', 'interocclusal splint therapy']","['decreased pain and an improved mandibular mouth opening', 'mean pain scores', 'CPFS', 'mean pain scores and degree of mouth opening', 'mean mouth opening', 'presence or absence of CPFS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2370853', 'cui_str': 'Open reduction (procedure)'}, {'cui': 'C0016642', 'cui_str': 'Osteosynthesis, Fracture'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0205143', 'cui_str': 'Angular (qualifier value)'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0204861', 'cui_str': 'Application of splint (procedure)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0230028', 'cui_str': 'Structure of oral region of face'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C3854307', 'cui_str': 'Presence'}, {'cui': 'C0332197', 'cui_str': 'Absent (qualifier value)'}]",40.0,0.0398079,The use of interocclusal splints was found to be effective in the prevention and early management of CPFS.,"[{'ForeName': 'Vikranth', 'Initials': 'V', 'LastName': 'Prathap', 'Affiliation': 'Consultant and Private Practitioner, Department of Oral and Maxillofacial Surgery, SRM Dental College and Hospital, Ramapuram, Chennai, India.'}, {'ForeName': 'Swetha', 'Initials': 'S', 'LastName': 'Tarun', 'Affiliation': 'Postgraduate Trainee, Department of Oral and Maxillofacial Surgery, SRM Dental College and Hospital, Ramapuram, Chennai, India.'}, {'ForeName': 'Logitha Sri', 'Initials': 'LS', 'LastName': 'S', 'Affiliation': 'Postgraduate Trainee, Department of Oral and Maxillofacial Surgery, SRM Dental College and Hospital, Ramapuram, Chennai, India.'}, {'ForeName': 'Sasikala', 'Initials': 'S', 'LastName': 'Balasubramanian', 'Affiliation': 'Reader, Department of Oral and Maxillofacial Surgery, SRM Dental College and Hospital, Ramapuram, Chennai, India. Electronic address: sasiomfs@gmail.com.'}, {'ForeName': 'Elavenil', 'Initials': 'E', 'LastName': 'Panneerselvam', 'Affiliation': 'Reader, Department of Oral and Maxillofacial Surgery, SRM Dental College and Hospital, Ramapuram, Chennai, India.'}, {'ForeName': 'Krishnakumar Raja', 'Initials': 'KR', 'LastName': 'Vb', 'Affiliation': 'Professor and Head, Department of Oral and Maxillofacial Surgery, SRM Dental College and Hospital, Ramapuram, Chennai, India.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.09.028'] 3044,32022890,An Open Trial of a Mind-Body Intervention for Young Women with Moderate to Severe Primary Dysmenorrhea.,"OBJECTIVE To evaluate the feasibility, acceptability, and preliminary efficacy of a mind-body intervention for moderate to severe primary dysmenorrhea (PD). DESIGN Open trial (single arm). SETTING Academic medical school. SUBJECTS A total of 20 young adult women with moderate to severe primary dysmenorrhea were included across four separate intervention groups. METHODS All participants received five 90-minute sessions of a mind-body intervention and completed self-report measures of menstrual pain, depression, anxiety, somatization, and pain catastrophizing at baseline, post-treatment, and at one-, two-, three-, and 12-month follow-up. Self-report of medication use and use of skills learned during the intervention were also collected at all follow-up points. RESULTS Participants reported significantly lower menstrual pain over time compared with baseline. No changes in anxiety, depression, or somatization were observed, although pain catastrophizing improved over time. Changes in menstrual pain were not associated with changes in medication use or reported use of skills. CONCLUSIONS A mind-body intervention is a promising nondrug intervention for primary dysmenorrhea, and future research should focus on testing the intervention further as part of a randomized clinical trial.",2020,"A total of 20 young adult women with moderate to severe primary dysmenorrhea were included across four separate intervention groups. ","['20 young adult women with moderate to severe primary dysmenorrhea', 'Academic medical school', 'Young Women with Moderate to Severe Primary Dysmenorrhea', 'moderate to severe primary dysmenorrhea (PD']","['mind-body intervention', 'Mind-Body Intervention']","['menstrual pain', 'pain catastrophizing', 'menstrual pain, depression, anxiety, somatization, and pain catastrophizing', 'anxiety, depression, or somatization']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0149875', 'cui_str': 'Primary dysmenorrhea (disorder)'}, {'cui': 'C0036378', 'cui_str': 'Schools, Medical'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}]",[],"[{'cui': 'C0013390', 'cui_str': 'Pain, Menstrual'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",20.0,0.0288666,"A total of 20 young adult women with moderate to severe primary dysmenorrhea were included across four separate intervention groups. ","[{'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Payne', 'Affiliation': 'McLean Hospital/Harvard Medical School, Belmont, Massachusetts.'}, {'ForeName': 'Laura C', 'Initials': 'LC', 'LastName': 'Seidman', 'Affiliation': 'McLean Hospital/Harvard Medical School, Belmont, Massachusetts.'}, {'ForeName': 'Tamineh', 'Initials': 'T', 'LastName': 'Romero', 'Affiliation': 'Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.'}, {'ForeName': 'Myung-Shin', 'Initials': 'MS', 'LastName': 'Sim', 'Affiliation': 'Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.'}]","Pain medicine (Malden, Mass.)",['10.1093/pm/pnz378'] 3045,30446250,Continuous Positive Airway Pressure Treatment Does not Reduce Uric Acid Levels in OSA Women.,"OBJECTIVES Although an association between uric acid (UA) levels and obstructive sleep apnea (OSA) has been reported, the effect of continuous positive airway pressure (CPAP) on this measure is yet unclear. We aimed to investigate the effect of CPAP therapy on serum UA levels in patients with OSA. METHODS We conducted a multicenter, open-label, randomized controlled trial in 307 women diagnosed with moderate-to-severe OSA (apnea-hypopnea index [AHI]≥15) in 19 Spanish Sleep Units. Women were randomized to CPAP (n=151) or conservative treatment (n=156) for 12 weeks. Changes in serum UA measures were assessed on an intention-to-treat basis. Additional analyses were conducted in the subgroup of women with CPAP adherence ≥4h/night and those with UA levels ≥6mg/dl. RESULTS Women had a mean (SD) age of 57.1 (10.1) years, median (first-third quartile) body mass index of 33.7 (29.0-38.5) mg/kg 2 and AHI of 32.0 (22.6-48.5). The average serum UA measure was 5.11 (1.26) mg/dl, and 80 (26.1%) participants had UA≥6mg/dl. Compared with the control group, the CPAP group did not achieve any reduction in UA levels (non-adjusted intergroup difference -0.03mg/dl, 95%CI -0.20 to 0.13; p=0.702) after 12 weeks of follow-up. These results did not change when the analysis was restricted to women with CPAP adherence ≥4h/night, or the subgroup of women with hyperuricemia. CONCLUSIONS Twelve weeks of CPAP therapy does not reduce UA levels compared to conservative treatment in women with moderate-to-severe OSA.",2019,"Compared with the control group, the CPAP group did not achieve any reduction in UA levels (non-adjusted intergroup difference -0.03mg/dl, 95%CI -0.20 to 0.13; p=0.702) after 12 weeks of follow-up.","['Women had a mean (SD) age of 57.1 (10.1) years, median (first-third quartile) body mass index of 33.7 (29.0-38.5) mg/kg 2 and AHI of 32.0 (22.6-48.5', 'OSA Women', '307 women diagnosed with moderate-to-severe OSA (apnea-hypopnea index [AHI]≥15) in 19 Spanish Sleep Units', 'patients with OSA', 'subgroup of women with CPAP adherence ≥4h/night and those with UA levels ≥6mg/dl']","['conservative treatment', 'continuous positive airway pressure (CPAP', 'CPAP therapy', 'CPAP']","['serum UA levels', 'uric acid (UA) levels and obstructive sleep apnea (OSA', 'UA levels', 'average serum UA measure', 'Uric Acid Levels', 'serum UA measures']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C2111846', 'cui_str': 'Apnea-hypopnea index'}, {'cui': 'C3161473', 'cui_str': 'Spaniards (ethnic group)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]","[{'cui': 'C0459914', 'cui_str': 'Conservative Management'}, {'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0041980', 'cui_str': 'Uric Acid'}, {'cui': 'C0520679', 'cui_str': 'Syndrome, Sleep Apnea, Obstructive'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",307.0,0.159244,"Compared with the control group, the CPAP group did not achieve any reduction in UA levels (non-adjusted intergroup difference -0.03mg/dl, 95%CI -0.20 to 0.13; p=0.702) after 12 weeks of follow-up.","[{'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Campos-Rodriguez', 'Affiliation': 'Respiratory Department, Hospital Universitario de Valme, Sevilla, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain. Electronic address: fracamrod@gmail.com.'}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Reyes-Nuñez', 'Affiliation': 'Respiratory Department, Hospital Universitario de Valme, Sevilla, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Queipo-Corona', 'Affiliation': 'Respiratory Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.'}, {'ForeName': 'Angeles', 'Initials': 'A', 'LastName': 'Sanchez-Armengol', 'Affiliation': 'Medical-Surgical Unit of Respiratory Diseases, Virgen del Rocio University Hospital, Sevilla, Spain.'}, {'ForeName': 'Bernabe', 'Initials': 'B', 'LastName': 'Jurado-Gamez', 'Affiliation': 'Department of Respiratory Medicine, Reina Sofia University Hospital, Institute of Biomedical Research Maimonides (IMIBIC), University of Cordoba, Spain.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Cordero-Guevara', 'Affiliation': 'Unidad de Metodología y Estadística, BioAraba, Vitoria, Spain.'}, {'ForeName': 'Maria F', 'Initials': 'MF', 'LastName': 'Troncoso', 'Affiliation': 'Respiratory Department, Fundación Jimenez Diaz, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.'}, {'ForeName': 'Araceli', 'Initials': 'A', 'LastName': 'Abad-Fernandez', 'Affiliation': 'Respiratory Department, Hospital Universitario de Getafe, Madrid, Spain.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Caballero-Rodriguez', 'Affiliation': 'Respiratory Department. Hospital Morales Meseguer, Murcia, Spain.'}, {'ForeName': 'Mercedes', 'Initials': 'M', 'LastName': 'Martin-Romero', 'Affiliation': 'Respiratory Department, Hospital Universitario Virgen de la Victoria, Malaga, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Encabo-Motiño', 'Affiliation': 'Respiratory Department, Hospital Severo Ochoa, Madrid, Spain.'}, {'ForeName': 'Lirios', 'Initials': 'L', 'LastName': 'Sacristan-Bou', 'Affiliation': 'Respiratory Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Navarro-Esteva', 'Affiliation': 'Respiratory Department, Hospital Dr. Negrin, Gran Canaria, Spain.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Somoza-Gonzalez', 'Affiliation': 'Respiratory Department, Consorcio Sanitario de Terrassa, Barcelona, Spain.'}, {'ForeName': 'Juan F', 'Initials': 'JF', 'LastName': 'Masa', 'Affiliation': 'Respiratory Department, Hospital San Pedro de Alcantara, Caceres, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.'}, {'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Sanchez-Quiroga', 'Affiliation': 'Respiratory Department, Hospital Virgen del Puerto, Caceres, Spain.'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Jara-Chinarro', 'Affiliation': 'Respiratory Department, Hospital Puerta de Hierro, Madrid, Spain.'}, {'ForeName': 'Belen', 'Initials': 'B', 'LastName': 'Orosa-Bertol', 'Affiliation': 'Respiratory Department, Hospital Dr Peset, Valencia, Spain.'}, {'ForeName': 'Miguel A', 'Initials': 'MA', 'LastName': 'Martinez-Garcia', 'Affiliation': 'Respiratory Department, Hospital Universitario y Politecnico La Fe, Valencia, Spain.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Archivos de bronconeumologia,['10.1016/j.arbres.2018.09.012'] 3046,31350643,PV isolation guided by esophageal visualization with a tailored ablation strategy for the avoidance of esophageal thermal injury: a randomized trial.,"PURPOSE Radiofrequency ablation along the posterior wall of the left atrium may lead to atrioesophageal fistula due to esophageal thermal injury. The purpose of our study was to prospectively investigate whether ablation guided by soluble contrast esophageal visualization (SCEV) reduces injury during atrial fibrillation (AF) ablation. METHODS Seventy-eight patients with paroxysmal AF undergoing circumferential pulmonary vein isolation (PVI) were randomized to a SCEV group (n = 39) and control group without visualization (n = 39). Cine imaging of the esophagus was performed during soluble contrast swallowing at the beginning of ablation, after adjacent ipsilateral PVI and at the end of the procedure. The ablation lesion set was modified to avoid radiofrequency delivery within the contrast esophagram boundaries. In the control group, a single final ingestion was performed at the end of the procedure. Esophageal injury was assessed by esophagogastroscopy within 24 h in all patients. RESULTS In the control group, the ablation lesion crossed over the esophagus in 46.2% of patients, whereas in SCEV group, the ablation line violated the boundaries of the esophagus unavoidably in 15.4% of patients (confidence interval (CI); 1.61-13.98, p = 0.003). The incidence of esophageal injury was significantly lower in patients that underwent ablation with SCEV (5.1% vs. 20.5%, CI; 0.04-1.06, p = 0.042). Regardless of randomization group, patients who received ablation which overlapped the esophagus had a higher incidence of esophageal injury compared with those without overlap (37.5 vs. 1.9%, CI; 3.73-271.37, p = 0.000). CONCLUSIONS Esophageal contrast visualization helps to reduce the potential for esophageal injury during paroxysmal AF ablation. This simple procedural adjunct has important implications to improve safety of paroxysmal AF ablation procedures globally.",2020,"Regardless of randomization group, patients who received ablation which overlapped the esophagus had a higher incidence of esophageal injury compared with those without overlap (37.5 vs. 1.9%, CI; 3.73-271.37, p = 0.000). ","['Seventy-eight patients with paroxysmal AF undergoing circumferential pulmonary vein isolation (PVI', 'esophageal thermal injury']","['SCEV', 'Radiofrequency ablation', 'control group without visualization', 'ablation guided by soluble contrast esophageal visualization (SCEV', 'PV isolation guided by esophageal visualization with a tailored ablation strategy']","['incidence of esophageal injury', 'ablation lesion', 'Esophageal injury']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205311', 'cui_str': 'Paroxysmal (qualifier value)'}, {'cui': 'C0205113', 'cui_str': 'Circumferential (qualifier value)'}, {'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}, {'cui': 'C0332685', 'cui_str': 'Thermal injury'}]","[{'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0220862', 'cui_str': 'isolation'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0267096', 'cui_str': 'Injury of esophagus (disorder)'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}]",78.0,0.0385633,"Regardless of randomization group, patients who received ablation which overlapped the esophagus had a higher incidence of esophageal injury compared with those without overlap (37.5 vs. 1.9%, CI; 3.73-271.37, p = 0.000). ","[{'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Ye', 'Affiliation': ""Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, People's Republic of China.""}, {'ForeName': 'Shi-Quan', 'Initials': 'SQ', 'LastName': 'Chen', 'Affiliation': ""Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, People's Republic of China.""}, {'ForeName': 'Yi-Fei', 'Initials': 'YF', 'LastName': 'Lu', 'Affiliation': ""Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, People's Republic of China.""}, {'ForeName': 'Ru-Hong', 'Initials': 'RH', 'LastName': 'Jiang', 'Affiliation': ""Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, People's Republic of China.""}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Liu', 'Affiliation': ""Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, People's Republic of China.""}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Sheng', 'Affiliation': ""Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, People's Republic of China.""}, {'ForeName': 'Zuwen', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': ""Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, People's Republic of China.""}, {'ForeName': 'Ya-Xun', 'Initials': 'YX', 'LastName': 'Sun', 'Affiliation': ""Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, People's Republic of China.""}, {'ForeName': 'Pei', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': ""Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, People's Republic of China.""}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Yu', 'Affiliation': ""Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, People's Republic of China.""}, {'ForeName': 'Meng-Meng', 'Initials': 'MM', 'LastName': 'Chen', 'Affiliation': ""Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, People's Republic of China.""}, {'ForeName': 'Guo-Sheng', 'Initials': 'GS', 'LastName': 'Fu', 'Affiliation': ""Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, People's Republic of China.""}, {'ForeName': 'Chen-Yang', 'Initials': 'CY', 'LastName': 'Jiang', 'Affiliation': ""Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang, People's Republic of China. cyjiang@zju.edu.cn.""}]",Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing,['10.1007/s10840-019-00572-5'] 3047,31901705,Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.,"BACKGROUND BRAF/MEK inhibitor combinations are established treatments for BRAF V600-mutant melanoma based on demonstrated benefits on progression-free survival (PFS) and overall survival (OS). Here, we report an updated analysis of the COLUMBUS (COmbined LGX818 [encorafenib] Used with MEK162 [binimetinib] in BRAF mutant Unresectable Skin cancer) trial with long-term follow-up. METHODS In part 1 of the COLUMBUS trial, 577 patients with advanced/metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomised 1:1:1 to 450 mg of encorafenib QD + 45 mg of binimetinib BID (COMBO450) vs 960 mg of vemurafenib BID (VEM) or 300 mg of encorafenib ENCO QD (ENCO300). An updated analysis was conducted that included PFS, OS, objective response rate, safety and tolerability and analyses of results by prognostic subgroups. RESULTS At data cutoff, there were 116, 113 and 138 deaths in the COMBO450, ENCO300 and VEM treatment arms, respectively. The median OS was 33.6 months (95% confidence interval [CI], 24.4-39.2) for COMBO450, 23.5 months (95% CI, 19.6-33.6) for ENCO300 and 16.9 months (95% CI, 14.0-24.5) for VEM. Compared with VEM, COMBO450 decreased the risk of death by 39% (hazard ratio [HR], 0.61; 95% CI, 0.48-0.79). The updated median PFS for COMBO450 was 14.9 months (95% CI, 11.0-20.2), ENCO300 was 9.6 months (95% CI, 7.4-14.8) and VEM was 7.3 months (95% CI, 5.6-7.9). PFS was longer for COMBO450 vs VEM (HR, 0.51; 95% CI, 0.39-0.67). Landmark OS and PFS results show consistent results for each year analysed. Subgroups all favoured COMBO450 vs VEM. CONCLUSIONS Updated PFS and OS results for COMBO450 from the COLUMBUS trial demonstrate a long-term benefit in patients with advanced BRAF V600-mutated melanoma.",2020,"PFS was longer for COMBO450 vs VEM (HR, 0.51; 95% CI, 0.39-0.67).","['patients with advanced BRAF V600-mutated melanoma', 'BRAF\xa0mutant Unresectable Skin cancer', 'patients with BRAF V600-mutant melanoma', '577 patients with advanced/metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy']","['encorafenib plus binimetinib vs vemurafenib or encorafenib', 'MEK162 [binimetinib', 'encorafenib QD\xa0+\xa045\xa0mg of binimetinib BID (COMBO450) vs 960\xa0mg of vemurafenib BID (VEM) or 300\xa0mg of encorafenib ENCO QD (ENCO300']","['PFS, OS, objective response rate, safety and tolerability', 'median OS', 'tolerability and overall survival', 'PFS', 'risk of death', 'median PFS for COMBO450', 'progression-free survival (PFS) and overall survival (OS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C0007114', 'cui_str': 'Cancer of Skin'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0021083', 'cui_str': 'Immunotherapy'}]","[{'cui': 'C4079208', 'cui_str': 'encorafenib'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C3899947', 'cui_str': 'Binimetinib'}, {'cui': 'C3192263', 'cui_str': 'Vemurafenib'}, {'cui': 'C2830125', 'cui_str': 'MEK162'}, {'cui': 'C0048106', 'cui_str': 'BIDS'}, {'cui': 'C4517908', 'cui_str': '960 (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}]","[{'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",577.0,0.531944,"PFS was longer for COMBO450 vs VEM (HR, 0.51; 95% CI, 0.39-0.67).","[{'ForeName': 'Paolo A', 'Initials': 'PA', 'LastName': 'Ascierto', 'Affiliation': 'Melanoma Unit, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy. Electronic address: paolo.ascierto@gmail.com.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Dummer', 'Affiliation': 'Department of Dermatology, University Hospital Zürich Skin Cancer Center and University Zürich, Zürich, Switzerland.'}, {'ForeName': 'Helen J', 'Initials': 'HJ', 'LastName': 'Gogas', 'Affiliation': 'Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece.'}, {'ForeName': 'Keith T', 'Initials': 'KT', 'LastName': 'Flaherty', 'Affiliation': 'Cancer Center, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Arance', 'Affiliation': 'Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Mandala', 'Affiliation': 'Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'Liszkay', 'Affiliation': 'Department of Dermatology, National Institute of Oncology, Budapest, Hungary.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Garbe', 'Affiliation': 'Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Schadendorf', 'Affiliation': 'Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.'}, {'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Krajsova', 'Affiliation': 'Department of Dermato-oncology, University Hospital Prague and Charles University First Medical Faculty, Prague, Czech Republic.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Gutzmer', 'Affiliation': 'Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Jan Willem B', 'Initials': 'JWB', 'LastName': 'de Groot', 'Affiliation': 'Department of Medical Oncology, Isala, Zwolle, Netherlands.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Loquai', 'Affiliation': 'Department of Dermatology, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Ashwin', 'Initials': 'A', 'LastName': 'Gollerkeri', 'Affiliation': 'Pfizer Inc., Boulder, CO, USA.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Pickard', 'Affiliation': 'Pfizer Inc., Boulder, CO, USA.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Robert', 'Affiliation': 'Service of Dermatology, Department of Medicine and Paris-Sud University, Gustave Roussy, Villejuif, France.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.11.016'] 3048,31931269,Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer.,"BACKGROUND Both peripherally inserted central catheters (PICCs) and implanted port catheters (PORTs) are used for adjuvant chemotherapy (ACT) administration in patients with early breast cancer (EBC). We aimed to compare the safety between PICCs and PORTs in this setting. PATIENTS AND METHODS This monocentric phase II randomised trial (NCT02095743) included patients with EBC who were eligible for ACT. Patients with curative anticoagulation therapy were excluded. The primary objective was to identify which device has a lower probability of catheter-related significant adverse events (CR-SAEs) within the 35 weeks after device implantation. The secondary objective was to evaluate quality of life (QoL) and patient satisfaction. RESULTS From February 2014 to May 2018, 256 patients were included, and 253 (99%) were analysed. Overall, 31 patients (12.2%) experienced CR-SAEs, which mainly included thromboembolic events. In an intention-to-treat analysis, the probability that a CR-SAE would occur was 7.8% (10 events) with PORTs versus 16.6% (21 events) with PICCs (hazard ratio [HR] = 2.2 [1.03-4.62], P = 0.036). In a per-protocol analysis, PICCs were also associated with a higher risk of CR-SAEs than PORTs (HR = 2.82 [1.26-6.25], P = 0.007). Regarding the secondary objectives, if there was no difference in QoL between the arms, then significantly more discomfort was reported among patients with PICCs than among patients with PORTs (P = 0.002 after implantation and P < 0.001 at mid-treatment or at the end of treatment). CONCLUSIONS CR-SAEs in patients with EBC are frequent but rarely impact the ACT process. Compared with PORTs, PICCs are associated with a significantly higher risk of CR-SAEs and more discomfort. PORTs should be preferred for ACT administration in patients with EBC.",2020,"In a per-protocol analysis, PICCs were also associated with a higher risk of CR-SAEs than PORTs (HR = 2.82 [1.26-6.25], P = 0.007).","['patients with early breast cancer (EBC', 'From February 2014 to May 2018, 256 patients were included, and 253 (99%) were analysed', 'patients with EBC', 'patients with early breast cancer', 'Patients with curative anticoagulation therapy were excluded', 'patients with EBC who were eligible for ACT']","['peripherally inserted central catheters (PICCs) and implanted port catheters (PORTs', 'adjuvant chemotherapy (ACT', 'peripherally inserted catheters versus implanted port catheters']","['higher risk of CR-SAEs', 'QoL', 'thromboembolic events', 'discomfort', 'risk of CR-SAEs and more discomfort', 'quality of life (QoL) and patient satisfaction', 'CR-SAEs']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1276305', 'cui_str': 'Curative procedure'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}]","[{'cui': 'C0179740', 'cui_str': 'Long line'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C3494350', 'cui_str': 'Port Catheters'}, {'cui': 'C0452253', 'cui_str': 'Port (substance)'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C1881217', 'cui_str': 'Insert - unit of product usage'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}]","[{'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolism'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0034380'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}]",256.0,0.113024,"In a per-protocol analysis, PICCs were also associated with a higher risk of CR-SAEs than PORTs (HR = 2.82 [1.26-6.25], P = 0.007).","[{'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Clatot', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France. Electronic address: florian.clatot@chb.unicancer.fr.'}, {'ForeName': 'Maxime', 'Initials': 'M', 'LastName': 'Fontanilles', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Laureline', 'Initials': 'L', 'LastName': 'Lefebvre', 'Affiliation': 'Department of Radiation Therapy, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Justine', 'Initials': 'J', 'LastName': 'Lequesne', 'Affiliation': 'Clinical Research Unit, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Veyret', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Alexandru', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Leheurteur', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Guillemet', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Gouérant', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Petrau', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Jean-Christophe', 'Initials': 'JC', 'LastName': 'Théry', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Rigal', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Moldovan', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Tennevet', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Rastelli', 'Affiliation': 'Clinical Research Unit, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Amélie', 'Initials': 'A', 'LastName': 'Poullain', 'Affiliation': 'Clinical Research Unit, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Laetitia', 'Initials': 'L', 'LastName': 'Savary', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Bubenheim', 'Affiliation': 'Department of Clinical Research and Innovation, Rouen University Hospital, Rouen, France.'}, {'ForeName': 'Dragos', 'Initials': 'D', 'LastName': 'Georgescu', 'Affiliation': 'Department of Surgery, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Gouérant', 'Affiliation': 'Department of Anaesthesia, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Gilles-Baray', 'Affiliation': 'Department of Anaesthesia, Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Di Fiore', 'Affiliation': 'Department of Medical Oncology, Centre Henri Becquerel, Rouen, France; Department of Digestive Oncology, Rouen University Hospital, Rouen, France.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.11.022'] 3049,32019388,Monitoring processes in extended emotion regulation.,"The extended process model of emotion regulation (ER) posits that dynamic ER processes monitor and adjust the implementation of ER strategies over time. When an initial ER strategy is ineffective, monitoring processes allow one to flexibly switch to a new, possibly more effective strategy. The present study employed a novel experimental task to explore these dynamic ER processes. Sixty-eight adult female participants each completed 40 trials. In each trial, participants first were assigned to use either distraction or reappraisal for the either low- or high-intensity negative image presented. Then, they were presented with a choice between continuing to use the assigned strategy or switching strategies before viewing the negative image again. Results showed that the combinations of ER strategies and image intensities generated different affect states for the choice context. The magnitude of intermediate negative affect was positively associated with a greater probability of choosing to switch strategies. Finally, for higher intermediate negative affect, negative affect was lower after choosing to switch strategies. For lower intermediate negative affect, negative affect remained low regardless of continuing or switching strategies. These findings support the extended process model and contribute to a growing body of empirical support for dynamic models of ER.",2020,The magnitude of intermediate negative affect was positively associated with a greater probability of choosing to switch strategies.,['Sixty-eight adult female participants each completed 40 trials'],['distraction or reappraisal for the either low- or high-intensity negative image presented'],[],"[{'cui': 'C0450387', 'cui_str': '68 (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C1369038', 'cui_str': 'Distraction (procedure)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}]",[],68.0,0.0260757,The magnitude of intermediate negative affect was positively associated with a greater probability of choosing to switch strategies.,"[{'ForeName': 'Jonathan W', 'Initials': 'JW', 'LastName': 'Murphy', 'Affiliation': 'Department of Psychology, Illinois Institute of Technology, Chicago, IL, USA.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Young', 'Affiliation': 'Department of Psychology, Illinois Institute of Technology, Chicago, IL, USA.'}]",Cognition & emotion,['10.1080/02699931.2020.1722614'] 3050,31961419,Effect of Early Surgery vs Endoscopy-First Approach on Pain in Patients With Chronic Pancreatitis: The ESCAPE Randomized Clinical Trial.,"Importance For patients with painful chronic pancreatitis, surgical treatment is postponed until medical and endoscopic treatment have failed. Observational studies have suggested that earlier surgery could mitigate disease progression, providing better pain control and preserving pancreatic function. Objective To determine whether early surgery is more effective than the endoscopy-first approach in terms of clinical outcomes. Design, Setting, and Participants The ESCAPE trial was an unblinded, multicenter, randomized clinical superiority trial involving 30 Dutch hospitals participating in the Dutch Pancreatitis Study Group. From April 2011 until September 2016, a total of 88 patients with chronic pancreatitis, a dilated main pancreatic duct, and who only recently started using prescribed opioids for severe pain (strong opioids for ≤2 months or weak opioids for ≤6 months) were included. The 18-month follow-up period ended in March 2018. Interventions There were 44 patients randomized to the early surgery group who underwent pancreatic drainage surgery within 6 weeks after randomization and 44 patients randomized to the endoscopy-first approach group who underwent medical treatment, endoscopy including lithotripsy if needed, and surgery if needed. Main Outcomes and Measures The primary outcome was pain, measured on the Izbicki pain score and integrated over 18 months (range, 0-100 [increasing score indicates more pain severity]). Secondary outcomes were pain relief at the end of follow-up; number of interventions, complications, hospital admissions; pancreatic function; quality of life (measured on the 36-Item Short Form Health Survey [SF-36]); and mortality. Results Among 88 patients who were randomized (mean age, 52 years; 21 (24%) women), 85 (97%) completed the trial. During 18 months of follow-up, patients in the early surgery group had a lower Izbicki pain score than patients in the group randomized to receive the endoscopy-first approach group (37 vs 49; between-group difference, -12 points [95% CI, -22 to -2]; P = .02). Complete or partial pain relief at end of follow-up was achieved in 23 of 40 patients (58%) in the early surgery vs 16 of 41 (39%)in the endoscopy-first approach group (P = .10). The total number of interventions was lower in the early surgery group (median, 1 vs 3; P < .001). Treatment complications (27% vs 25%), mortality (0% vs 0%), hospital admissions, pancreatic function, and quality of life were not significantly different between early surgery and the endoscopy-first approach. Conclusions and Relevance Among patients with chronic pancreatitis, early surgery compared with an endoscopy-first approach resulted in lower pain scores when integrated over 18 months. However, further research is needed to assess persistence of differences over time and to replicate the study findings. Trial Registration ISRCTN Identifier: ISRCTN45877994.",2020,Complete or partial pain relief at end of follow-up was achieved in 23 of 40 patients (58%) in the early surgery vs 16 of 41 (39%)in the endoscopy-first approach group (P = .10).,"['44 patients randomized to the early surgery group who underwent', 'patients with painful chronic pancreatitis', '30 Dutch hospitals participating in the Dutch Pancreatitis Study Group', 'Patients With Chronic Pancreatitis', 'From April 2011 until September 2016, a total of 88 patients with chronic pancreatitis, a dilated main pancreatic duct, and who only recently started using prescribed opioids for severe pain (strong opioids for ≤2 months or weak opioids for ≤6 months) were included', 'patients with chronic pancreatitis, early surgery', '88 patients who were randomized (mean age, 52 years; 21 (24%) women), 85 (97%) completed the trial']","['endoscopy-first approach group who underwent medical treatment, endoscopy including lithotripsy if needed, and surgery if needed', 'pancreatic drainage surgery', 'Early Surgery vs Endoscopy-First Approach']","['Pain', 'pain severity', 'pain relief at the end of follow-up; number of interventions, complications, hospital admissions; pancreatic function; quality of life (measured on the 36-Item Short Form Health Survey [SF-36]); and mortality', 'mortality', 'pain, measured on the Izbicki pain score', 'Complete or partial pain relief', 'Izbicki pain score', 'Treatment complications', 'pain scores', 'hospital admissions, pancreatic function, and quality of life', 'total number of interventions']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0149521', 'cui_str': 'Pancreatitis, Chronic'}, {'cui': 'C0013331', 'cui_str': 'Dutch (ethnic group)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0030305', 'cui_str': 'Pancreatitis'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0447557', 'cui_str': ""Wirsung's Duct""}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0278140', 'cui_str': 'Severe pain (finding)'}, {'cui': 'C0442821', 'cui_str': 'Strong (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1762617', 'cui_str': 'Weak (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0023878', 'cui_str': 'Litholapaxy'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0013103', 'cui_str': 'Drainage'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission (procedure)'}, {'cui': 'C0232786', 'cui_str': 'Pancreatic function'}, {'cui': 'C0034380'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",88.0,0.178325,Complete or partial pain relief at end of follow-up was achieved in 23 of 40 patients (58%) in the early surgery vs 16 of 41 (39%)in the endoscopy-first approach group (P = .10).,"[{'ForeName': 'Yama', 'Initials': 'Y', 'LastName': 'Issa', 'Affiliation': 'Department of Surgery, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Marinus A', 'Initials': 'MA', 'LastName': 'Kempeneers', 'Affiliation': 'Department of Surgery, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Marco J', 'Initials': 'MJ', 'LastName': 'Bruno', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Fockens', 'Affiliation': 'Department of Gastroenterology and Hepatology; Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Jan-Werner', 'Initials': 'JW', 'LastName': 'Poley', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Usama', 'Initials': 'U', 'LastName': 'Ahmed Ali', 'Affiliation': 'Department of Surgery, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Thomas L', 'Initials': 'TL', 'LastName': 'Bollen', 'Affiliation': 'Department of Radiology, St Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'Olivier R', 'Initials': 'OR', 'LastName': 'Busch', 'Affiliation': 'Department of Surgery, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Cees H', 'Initials': 'CH', 'LastName': 'Dejong', 'Affiliation': 'Department of Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'van Duijvendijk', 'Affiliation': 'Department of Surgery, Gelre Hospital, Apeldoorn, the Netherlands.'}, {'ForeName': 'Hendrik M', 'Initials': 'HM', 'LastName': 'van Dullemen', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Casper H', 'Initials': 'CH', 'LastName': 'van Eijck', 'Affiliation': 'Department of Surgery, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'van Goor', 'Affiliation': 'Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Muhammed', 'Initials': 'M', 'LastName': 'Hadithi', 'Affiliation': 'Department of Gastroenterology and Hepatology, Maasstad Hospital, Rotterdam, the Netherlands.'}, {'ForeName': 'Jan-Willem', 'Initials': 'JW', 'LastName': 'Haveman', 'Affiliation': 'Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Yolande', 'Initials': 'Y', 'LastName': 'Keulemans', 'Affiliation': 'Department of Gastroenterology and Hepatology, Zuyderland Hospital, Sittard/Heerlen, the Netherlands.'}, {'ForeName': 'Vincent B', 'Initials': 'VB', 'LastName': 'Nieuwenhuijs', 'Affiliation': 'Department of Surgery, Isala Hospital, Zwolle, the Netherlands.'}, {'ForeName': 'Alexander C', 'Initials': 'AC', 'LastName': 'Poen', 'Affiliation': 'Department of Gastroenterology and Hepatology, Isala Hospital, Zwolle, the Netherlands.'}, {'ForeName': 'Erik A', 'Initials': 'EA', 'LastName': 'Rauws', 'Affiliation': 'Department of Gastroenterology and Hepatology; Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Adriaan C', 'Initials': 'AC', 'LastName': 'Tan', 'Affiliation': 'Department of Gastroenterology and Hepatology, Canisius-Wilhemina Hospital, Nijmegen, the Netherlands.'}, {'ForeName': 'Willem', 'Initials': 'W', 'LastName': 'Thijs', 'Affiliation': 'Department of Gastroenterology and Hepatology, Martini Hospital, Groningen, the Netherlands.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Timmer', 'Affiliation': 'Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'Ben J', 'Initials': 'BJ', 'LastName': 'Witteman', 'Affiliation': 'Department of Gastroenterology and Hepatology, Gelderse Vallei Hospital, Ede, the Netherlands.'}, {'ForeName': 'Marc G', 'Initials': 'MG', 'LastName': 'Besselink', 'Affiliation': 'Department of Surgery, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Jeanin E', 'Initials': 'JE', 'LastName': 'van Hooft', 'Affiliation': 'Department of Gastroenterology and Hepatology; Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Hjalmar C', 'Initials': 'HC', 'LastName': 'van Santvoort', 'Affiliation': 'Department of Surgery, St Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'Marcel G', 'Initials': 'MG', 'LastName': 'Dijkgraaf', 'Affiliation': 'Department of Clinical Epidemiology, Biostatistics, and Bioinformatics, Amsterdam Public Health, Amsterdam UMC, University of Amsterdam, the Netherlands.'}, {'ForeName': 'Marja A', 'Initials': 'MA', 'LastName': 'Boermeester', 'Affiliation': 'Department of Surgery, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA,['10.1001/jama.2019.20967'] 3051,1482187,An uncooked vegan diet shifts the profile of human fecal microflora: computerized analysis of direct stool sample gas-liquid chromatography profiles of bacterial cellular fatty acids.,"The effect of an uncooked extreme vegan diet on fecal microflora was studied by direct stool sample gas-liquid chromatography (GLC) of bacterial cellular fatty acids and by quantitative bacterial culture by using classical microbiological techniques of isolation, identification, and enumeration of different bacterial species. Eighteen volunteers were divided randomly into two groups. The test group received an uncooked vegan diet for 1 month and a conventional diet of mixed Western type for the other month of the study. The control group consumed a conventional diet throughout the study period. Stool samples were collected. Bacterial cellular fatty acids were extracted directly from the stool samples and measured by GLC. Computerized analysis of the resulting fatty acid profiles was performed. Such a profile represents all bacterial cellular fatty acids in a sample and thus reflects its microflora and can be used to detect changes, differences, or similarities of bacterial flora between individual samples or sample groups. GLC profiles changed significantly in the test group after the induction and discontinuation of the vegan diet but not in the control group at any time, whereas quantitative bacterial culture did not detect any significant change in fecal bacteriology in either of the groups. The results suggest that an uncooked extreme vegan diet alters the fecal bacterial flora significantly when it is measured by direct stool sample GLC of bacterial fatty acids.",1992,"GLC profiles changed significantly in the test group after the induction and discontinuation of the vegan diet but not in the control group at any time, whereas quantitative bacterial culture did not detect any significant change in fecal bacteriology in either of the groups.","['Eighteen volunteers', 'human fecal microflora']","['uncooked extreme vegan diet', 'conventional diet', 'uncooked vegan diet']","['Bacterial cellular fatty acids', 'fecal bacteriology', 'GLC profiles', 'fecal bacterial flora']","[{'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0205403', 'cui_str': 'Extreme (qualifier value)'}, {'cui': 'C0344353', 'cui_str': 'Vegan dietary (finding)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}]","[{'cui': 'C0015684', 'cui_str': 'Fatty Acids'}, {'cui': 'C0004644', 'cui_str': 'Bacteriology'}]",18.0,0.0120291,"GLC profiles changed significantly in the test group after the induction and discontinuation of the vegan diet but not in the control group at any time, whereas quantitative bacterial culture did not detect any significant change in fecal bacteriology in either of the groups.","[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Peltonen', 'Affiliation': 'Department of Medical Microbiology, Turku University, Finland.'}, {'ForeName': 'W H', 'Initials': 'WH', 'LastName': 'Ling', 'Affiliation': ''}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Hänninen', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Eerola', 'Affiliation': ''}]",Applied and environmental microbiology,[] 3052,1398956,"Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial.","We conducted a double-blind, placebo-controlled, randomized crossover study to evaluate the safety and immunogenicity of a single 5 x 10(8)-CFU dose of live oral recombinant cholera vaccine CVD 103-HgR in 94 North American adults. The vaccine was well tolerated without associated adverse reactions. Despite minimal fecal excretion of vaccine, 97% of subjects exhibited serum vibriocidal antibody and 72% had antitoxin responses.",1992,"Despite minimal fecal excretion of vaccine, 97% of subjects exhibited serum vibriocidal antibody and 72% had antitoxin responses.","['North Americans', '94 North American adults']","['single 5 x 10(8)-CFU dose of live oral recombinant cholera vaccine CVD 103-HgR', 'placebo', 'live oral cholera vaccine CVD', '103-HgR']","['tolerated without associated adverse reactions', 'Safety and immunogenicity', 'antitoxin responses', 'safety and immunogenicity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0961644', 'cui_str': 'cholera vaccine CVD 103-HgR'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0008359', 'cui_str': 'Cholera Vaccine'}, {'cui': 'C4517526', 'cui_str': 'One hundred and three'}]","[{'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0003445', 'cui_str': 'Antitoxins'}]",,0.725333,"Despite minimal fecal excretion of vaccine, 97% of subjects exhibited serum vibriocidal antibody and 72% had antitoxin responses.","[{'ForeName': 'K L', 'Initials': 'KL', 'LastName': 'Kotloff', 'Affiliation': 'Department of Pediatrics, University of Maryland School of Medicine, Baltimore 21201.'}, {'ForeName': 'S S', 'Initials': 'SS', 'LastName': 'Wasserman', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': ""O'Donnell"", 'Affiliation': ''}, {'ForeName': 'G A', 'Initials': 'GA', 'LastName': 'Losonsky', 'Affiliation': ''}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Cryz', 'Affiliation': ''}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Levine', 'Affiliation': ''}]",Infection and immunity,[] 3053,32016500,Impact of Dorsal Preservation Rhinoplasty Versus Dorsal Hump Resection on the Internal Nasal Valve: a Quantitative Radiological Study.,"BACKGROUND This study evaluates the impact of different hump takedown techniques, namely the conventional hump resection with midvault reconstruction, the push-down (PD) and the let-down (LD) procedures, on the INV dimensions. METHODS In this cadaveric study, six heads were divided randomly into either the conventional hump resection technique (Group A; n = 6 sides) or DPR techniques (n = 6 sides). This latter group was subdivided such that initially a PD procedure was performed (Group B; n = 6 sides), followed by a LD procedure on the same heads (Group C; n = 6 sides). A validated radiological method was used to measure the INV angle and cross-sectional area (CSA) in a modified coronal plane both pre- and post-procedurally. RESULTS Group A did not show significant reduction in the INV angle nor in CSA (p = 0.068 and p = 0.156, respectively). In the push-down group (B), we observed a mean change of 2.05° in the angles and 0.3 cm 2 in the CSA (p = 0.0163 and p < 0.001, respectively). The LD group (C) did not show significant reduction in the INV angle nor in CSA (p = 0.437 and p = 0.331, respectively). CONCLUSION Neither the conventional hump resection nor the LD DPR technique reduced the INV dimensions. However, the PD preservation technique significantly reduced the INV dimensions. LEVEL OF EVIDENCE III This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.",2020,"RESULTS Group A did not show significant reduction in the INV angle nor in CSA (p = 0.068 and p = 0.156, respectively).",[],"['conventional hump resection technique (Group A; n\u2009=\u20096 sides) or DPR techniques', 'Dorsal Preservation Rhinoplasty', 'conventional hump resection with midvault reconstruction, the push-down (PD) and the let-down (LD) procedures', 'Dorsal Hump Resection']","['INV angle nor in CSA', 'INV angle and cross-sectional area (CSA', 'INV dimensions']",[],"[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0441835', 'cui_str': 'Group A (qualifier value)'}, {'cui': 'C0441987', 'cui_str': 'Side (qualifier value)'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0035467', 'cui_str': 'Plastic operation on nose'}, {'cui': 'C0524865', 'cui_str': 'Reconstructive Surgery'}, {'cui': 'C1719958', 'cui_str': 'Push'}, {'cui': 'C0086562', 'cui_str': 'LET'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}]","[{'cui': 'C0205143', 'cui_str': 'Angular (qualifier value)'}, {'cui': 'C0258591', 'cui_str': 'cyclosporin A, 4-(2-butenyl)-4,4,N-trimethylthreonine(1)-'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0205155', 'cui_str': 'Sectional (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439534', 'cui_str': 'Dimensions (qualifier value)'}]",6.0,0.0172006,"RESULTS Group A did not show significant reduction in the INV angle nor in CSA (p = 0.068 and p = 0.156, respectively).","[{'ForeName': 'Mohamed A', 'Initials': 'MA', 'LastName': 'Abdelwahab', 'Affiliation': 'Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head & Neck Surgery, Stanford University School of Medicine, 801 Welch Road, Stanford, CA, 94305, USA.'}, {'ForeName': 'Caio A', 'Initials': 'CA', 'LastName': 'Neves', 'Affiliation': 'Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head & Neck Surgery, Stanford University School of Medicine, 801 Welch Road, Stanford, CA, 94305, USA.'}, {'ForeName': 'Priyesh N', 'Initials': 'PN', 'LastName': 'Patel', 'Affiliation': 'Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head & Neck Surgery, Stanford University School of Medicine, 801 Welch Road, Stanford, CA, 94305, USA.'}, {'ForeName': 'Sam P', 'Initials': 'SP', 'LastName': 'Most', 'Affiliation': 'Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head & Neck Surgery, Stanford University School of Medicine, 801 Welch Road, Stanford, CA, 94305, USA. smost@stanford.edu.'}]",Aesthetic plastic surgery,['10.1007/s00266-020-01627-z'] 3054,31998949,"Surface Perturbation Training to Prevent Falls in Older Adults: A Highly Pragmatic, Randomized Controlled Trial.","BACKGROUND Falls are the leading cause of injuries among older adults, and trips and slips are major contributors to falls. OBJECTIVE The authors sought to compare the effectiveness of adding a component of surface perturbation training to usual gait/balance training for reducing falls and fall-related injury in high-risk older adults referred to physical therapy. DESIGN This was a multi-center, pragmatic, randomized, comparative effectiveness trial. SETTING Treatment took place within 8 outpatient physical therapy clinics. PATIENTS This study included 506 patients 65+ years of age at high fall risk referred for gait/balance training. INTERVENTION This trial evaluated surface perturbation treadmill training integrated into usual multimodal exercise-based balance training at the therapist's discretion versus usual multimodal exercise-based balance training alone. MEASUREMENTS Falls and injurious falls were assessed with a prospective daily fall diary, which was reviewed via telephone interview every 3 months for 1 year.A total of 211/253 (83%) patients randomized to perturbation training and 210/253 (83%) randomized to usual treatment provided data at 3-month follow-up. At 3 months, the perturbation training group had a significantly reduced chance of fall-related injury (5.7% versus 13.3%; relative risk 0.43) but no significant reduction in the risk of any fall (28% versus 37%, relative risk 0.78) compared with usual treatment. Time to first injurious fall showed reduced hazard in the first 3 months but no significant reduction when viewed over the entire first year. LIMITATIONS The limitations of this trial included lack of blinding and variable application of interventions across patients based on pragmatic study design. CONCLUSION The addition of some surface perturbation training to usual physical therapy significantly reduced injurious falls up to 3 months posttreatment. Further study is warranted to determine the optimal frequency, dose, progression, and duration of surface perturbation aimed at training postural responses for this population.",2020,"At 3 months, the perturbation-training group had significantly reduced chance of fall-related injury (5.7% vs. 13.3%; relative risk 0.43, p < 0.01) but no significant reduction in the risk of any fall (28% vs. 37% ST; relative risk 0.78 p<0.07) compared to usual treatment.","['high-risk older adults', 'Older Adults', 'Treatment took place within 8 outpatient physical therapy clinics', '506 patients aged 65+ at high fall risk referred for gait/balance training']","['surface-perturbation training to usual gait/balance training', 'Surface Perturbation Training', ""usual multimodal exercise-based balance training at the therapist's discretion versus usual multimodal exercise-based balance training alone""]","['injurious falls', 'Falls and injurious falls', 'chance of fall-related injury']","[{'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1268740', 'cui_str': 'Fall risk'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}]",506.0,0.0271618,"At 3 months, the perturbation-training group had significantly reduced chance of fall-related injury (5.7% vs. 13.3%; relative risk 0.43, p < 0.01) but no significant reduction in the risk of any fall (28% vs. 37% ST; relative risk 0.78 p<0.07) compared to usual treatment.","[{'ForeName': 'Jon D', 'Initials': 'JD', 'LastName': 'Lurie', 'Affiliation': 'Dartmouth-Hitchcock Medical Center, One Medical Center Dr, Lebanon, NH 03781 (USA), and Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.'}, {'ForeName': 'Alexandra B', 'Initials': 'AB', 'LastName': 'Zagaria', 'Affiliation': 'Geisel School of Medicine at Dartmouth.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Ellis', 'Affiliation': 'Elliot Hospital Senior Health Center Rehabilitation, Manchester, New Hampshire.'}, {'ForeName': 'Dawna', 'Initials': 'D', 'LastName': 'Pidgeon', 'Affiliation': 'Dartmouth-Hitchcock Medical Center.'}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Gill-Body', 'Affiliation': 'Newton-Wellesley Hospital, Newton, Massachusetts. Dr Gill-Body is a board-certified clinical specialist in neurologic physical therapy.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Burke', 'Affiliation': 'South Shore Neurologic Associates, Patchogue, New York. Dr Burke is a board-certified clinical specialist in neurologic physical therapy.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Armbrust', 'Affiliation': 'White River Junction Veterans Administration Hospital, White River Junction, Vermont.'}, {'ForeName': 'Sharil', 'Initials': 'S', 'LastName': 'Cass', 'Affiliation': 'Farnum Rehabilitation Center, Keene, New Hampshire.'}, {'ForeName': 'Kevin F', 'Initials': 'KF', 'LastName': 'Spratt', 'Affiliation': 'Geisel School of Medicine at Dartmouth.'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'McDonough', 'Affiliation': 'University of Pittsburgh, Pittsburgh, Pennsylvania.'}]",Physical therapy,['10.1093/ptj/pzaa023'] 3055,31942042,Exploring the receptor origin of vibration-induced reflexes.,"STUDY DESIGN An experimental design. OBJECTIVES The aim of this study was to determine the latencies of vibration-induced reflexes in individuals with and without spinal cord injury (SCI), and to compare these latencies to identify differences in reflex circuitries. SETTING A tertiary rehabilitation center in Istanbul. METHODS Seventeen individuals with chronic SCI (SCI group) and 23 participants without SCI (Control group) were included in this study. Latency of tonic vibration reflex (TVR) and whole-body vibration-induced muscular reflex (WBV-IMR) of the left soleus muscle was tested for estimating the reflex origins. The local tendon vibration was applied at six different vibration frequencies (50, 85, 140, 185, 235, and 265 Hz), each lasting for 15 s with 3-s rest intervals. The WBV was applied at six different vibration frequencies (35, 37, 39, 41, 43, and 45 Hz), each lasting for 15 s with 3-s rest intervals. RESULTS Mean (SD) TVR latency was 39.7 (5.3) ms in the SCI group and 35.9 (2.7) ms in the Control group with a mean (95% CI) difference of -3.8 (-6.7 to -0.9) ms. Mean (SD) WBV-IMR latency was 45.8 (7.4) ms in the SCI group and 43.3 (3.0) ms in the Control group with a mean (95% CI) difference of -2.5 (-6.5 to 1.4) ms. There were significant differences between TVR latency and WBV-IMR latency in both the groups (mean (95% CI) difference; -6.2 (-9.3 to -3.0) ms, p = 0.0001 for the SCI group and -7.4 (-9.3 to -5.6) ms, p = 0.011 for Control group). CONCLUSIONS The results suggest that the receptor of origin of TVR and WBV-IMR may be different.",2020,"There were significant differences between TVR latency and WBV-IMR latency in both the groups (mean (95% CI) difference; -6.2 (-9.3 to -3.0) ms, p = 0.0001 for the SCI group and -7.4 (-9.3 to -5.6) ms, p = 0.011 for Control group). ","['Seventeen individuals with chronic SCI (SCI group) and 23 participants without SCI (Control group', 'individuals with and without spinal cord injury (SCI', 'A tertiary rehabilitation center in Istanbul']",[],"['TVR latency and WBV-IMR latency', 'Latency of tonic vibration reflex (TVR) and whole-body vibration-induced muscular reflex (WBV-IMR', 'latencies of vibration-induced reflexes', 'Mean (SD) TVR latency', 'Mean (SD) WBV-IMR latency']","[{'cui': 'C0450331', 'cui_str': '17 (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0034993', 'cui_str': 'Rehabilitation Centers'}]",[],"[{'cui': 'C3543842', 'cui_str': 'TONICS'}, {'cui': 'C0459800', 'cui_str': 'Vibration'}, {'cui': 'C0034929', 'cui_str': 'Reflex'}, {'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0034943', 'cui_str': 'Reflex, Tendon'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",17.0,0.029,"There were significant differences between TVR latency and WBV-IMR latency in both the groups (mean (95% CI) difference; -6.2 (-9.3 to -3.0) ms, p = 0.0001 for the SCI group and -7.4 (-9.3 to -5.6) ms, p = 0.011 for Control group). ","[{'ForeName': 'Mustafa A', 'Initials': 'MA', 'LastName': 'Yildirim', 'Affiliation': 'İstanbul Physical Medicine Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Betilay', 'Initials': 'B', 'LastName': 'Topkara', 'Affiliation': 'Physiology Department, Koç University School of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Tugba', 'Initials': 'T', 'LastName': 'Aydin', 'Affiliation': 'İstanbul Physical Medicine Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Nurdan', 'Initials': 'N', 'LastName': 'Paker', 'Affiliation': 'İstanbul Physical Medicine Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Derya', 'Initials': 'D', 'LastName': 'Soy', 'Affiliation': 'İstanbul Physical Medicine Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Evrim', 'Initials': 'E', 'LastName': 'Coskun', 'Affiliation': 'İstanbul Physical Medicine Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Kadriye', 'Initials': 'K', 'LastName': 'Ones', 'Affiliation': 'İstanbul Physical Medicine Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Aysenur', 'Initials': 'A', 'LastName': 'Bardak', 'Affiliation': 'İstanbul Physical Medicine Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Nur', 'Initials': 'N', 'LastName': 'Kesiktas', 'Affiliation': 'İstanbul Physical Medicine Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Mustafa G', 'Initials': 'MG', 'LastName': 'Ozyurt', 'Affiliation': 'Physiology Department, Koç University School of Medicine, Istanbul, Turkey.'}, {'ForeName': 'Berna', 'Initials': 'B', 'LastName': 'Celik', 'Affiliation': 'İstanbul Physical Medicine Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Burcu', 'Initials': 'B', 'LastName': 'Onder', 'Affiliation': 'İstanbul Physical Medicine Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Aysegul', 'Initials': 'A', 'LastName': 'Kılıc', 'Affiliation': 'İstanbul Physical Medicine Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Habib C', 'Initials': 'HC', 'LastName': 'Kucuk', 'Affiliation': 'İstanbul Physical Medicine Rehabilitation Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Ilhan', 'Initials': 'I', 'LastName': 'Karacan', 'Affiliation': 'İstanbul Physical Medicine Rehabilitation Training and Research Hospital, Istanbul, Turkey. ilhankaracan@hotmail.com.'}, {'ForeName': 'Kemal S', 'Initials': 'KS', 'LastName': 'Türker', 'Affiliation': 'Physiology Department, Koç University School of Medicine, Istanbul, Turkey.'}]",Spinal cord,['10.1038/s41393-020-0419-5'] 3056,31557450,Does Including Dexmedetomidine Improve Outcomes After Intravenous Sedation for Outpatient Dentoalveolar Surgery?,"PURPOSE Dexmedetomidine represents an intriguing adjunct to outpatient intravenous (IV) sedation owing to its decreased risk of respiratory depression. The purpose of the present study was to measure the incremental effect of incorporating dexmedetomidine (DXM) into an established IV sedation regimen compared with control IV sedation without the DXM infusion. MATERIALS AND METHODS We designed a prospective, controlled trial in which American Society of Anesthesiologists Class 1 and 2 patients requiring both maxillary and mandibular dentoalveolar surgery would undergo 2 sedation appointments: 1 arch treated with surgery with control sedation (DXM-) using midazolam, fentanyl, and propofol as needed, and a second surgery on the opposite arch using the experimental sedation regimen (DXM+) of midazolam, fentanyl, and propofol, as needed, and a DXM infusion at 4 μg/kg/hr. The surgeon was the same for every appointment, and the patients were kept unaware regarding which sedation had included the experimental regimen. Whether the experimental sedation was used at the first or second surgery was randomized. The primary measured outcomes were efficiency in terms of anesthesia time for each sedation, the physiologic response in terms of vital signs, and the subjective patient experience. RESULTS A total of 12 patients completed the trial. With DXM-, the patients had significantly shorter total (∼15 minutes) and adjusted anesthesia (∼10 minutes) times. With DXM+, the patients had significantly lower average systolic blood pressure (SBP), SBP low values, diastolic blood pressure (DBP) low values, average heart rate (HR), and HR low values. None of the other continuous patient outcomes differed significantly between the 2 groups. Of the 12 patients, 10 (83.3%) reported that they preferred the experimental sedation experience with DXM (95% confidence interval, 0.52 to 0.98). CONCLUSIONS Using a DXM infusion with outpatient dentoalveolar surgery allowed for acceptable levels of sedation, greater patient satisfaction, and longer anesthesia and appointment times and often resulted in lower BP and heart rate.",2020,"With DXM-, the patients had significantly shorter total (∼15 minutes) and adjusted anesthesia (∼10 minutes) times.",['12 patients completed the trial'],"['midazolam, fentanyl, and propofol', 'surgery with control sedation (DXM-) using midazolam, fentanyl, and propofol', 'dexmedetomidine (DXM', 'Dexmedetomidine']","['average systolic blood pressure (SBP), SBP low values, diastolic blood pressure (DBP) low values, average heart rate (HR), and HR low values', 'lower BP and heart rate', 'efficiency in terms of anesthesia time for each sedation, the physiologic response in terms of vital signs, and the subjective patient experience']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}]","[{'cui': 'C1282151', 'cui_str': 'Average systolic blood pressure'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0020649', 'cui_str': 'Blood Pressure, Low'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0518766'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]",,0.0453159,"With DXM-, the patients had significantly shorter total (∼15 minutes) and adjusted anesthesia (∼10 minutes) times.","[{'ForeName': 'D Craig', 'Initials': 'DC', 'LastName': 'Taylor', 'Affiliation': 'Resident, Department of Oral and Maxillofacial Surgery, Augusta University, Augusta, GA. Electronic address: CraigTaylorDMD@gmail.com.'}, {'ForeName': 'Henry W', 'Initials': 'HW', 'LastName': 'Ferguson', 'Affiliation': 'Vice Chairman and Associate Professor, Department of Oral and Maxillofacial Surgery, Augusta University, Augusta, GA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Stevens', 'Affiliation': 'Chairman and Professor, Department of Oral and Maxillofacial Surgery, Augusta University, Augusta, GA.'}, {'ForeName': 'Solon', 'Initials': 'S', 'LastName': 'Kao', 'Affiliation': 'Vice Chairman and Associate Professor, Department of Oral Surgery and Hospital Dentistry, University of Missouri-Kansas City, Kansas City, MO.'}, {'ForeName': 'Frances M', 'Initials': 'FM', 'LastName': 'Yang', 'Affiliation': 'Associate Professor, Department of Occupational Therapy, School of Health Professions, University of Kansas Medical Center, Kansas City, KS.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Looney', 'Affiliation': 'Professor, Department of Biostatistics and Data Science, Augusta University, Augusta, GA.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.08.016'] 3057,31346900,"Comparison between two mathematical methods to estimate arterial occlusion pressure and tourniquet effectiveness in lower limb surgery: a prospective, randomized, double blind, comparative study.","The effectiveness of two different methods for calculating the arterial occlusion pressure (AOP) to set tourniquet inflation pressures were assessed in patients underwent knee arthroscopy. Eighty patients were included in this study. Tourniquet inflation pressure was set by adding 20 mmHg of safety margin above the AOP value which was calculated by either the Tuncali et al. formula or Hong-yun Liu et al. formula. Primary outcome measures were the initial and maximum SBP, initial and maximum tourniquet inflation pressure, the secondary outcomes were the surgeon rating of the bloodlessness of the surgical field and tourniquet associated complications. There was significant difference in the initial tourniquet pressure (mmHg); it was 208 ± 12 and 262 ± 18 for group (A) and (B) respectively; also there was significant difference in the maximum tourniquet pressure (mmHg), it was 229 ± 14 and 283 ± 19 for group (A) and (B) respectively. There was no significant difference in the initial SBP-to- tourniquet inflation time, the initial SBP or the maximum SBP between the groups. Also, there was no significant difference in surgeon rating of the bloodlessness of the surgical field, at the start, middle and end of surgery. Hong-yun Liu et al. mathematical formula was found to be less effective than Tuncali et al. formula to estimate the least effective tourniquet pressure in lower limb surgery and we might consider it invalid to be used in the lower limb.Clinical trials registration number: NCT03706859 (Clinicaltrials.gov) and registration date: January, 2019. https://clinicaltrials.gov/ct2/show/NCT03706859.",2020,"There was no significant difference in the initial SBP-to- tourniquet inflation time, the initial SBP or the maximum SBP between the groups.","['lower limb surgery', 'Eighty patients were included in this study', 'patients underwent knee arthroscopy']",['formula or Hong-yun'],"['arterial occlusion pressure (AOP', 'initial SBP-to- tourniquet inflation time, the initial SBP or the maximum SBP', 'maximum tourniquet pressure', 'Tourniquet inflation pressure', 'surgeon rating', 'initial tourniquet pressure', 'initial and maximum SBP, initial and maximum tourniquet inflation pressure, the secondary outcomes were the surgeon rating of the bloodlessness of the surgical field and tourniquet associated complications', 'arterial occlusion pressure and tourniquet effectiveness']","[{'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0187970', 'cui_str': 'Diagnostic arthroscopy of knee'}]",[],"[{'cui': 'C0264995', 'cui_str': 'Occlusion of artery (disorder)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C0040519', 'cui_str': 'Tourniquets'}, {'cui': 'C1318493', 'cui_str': 'Inflation'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0428725', 'cui_str': 'Tourniquet inflation pressure (observable entity)'}, {'cui': 'C0582175', 'cui_str': 'Surgeon (occupation)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0440042', 'cui_str': ""Field's""}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}]",80.0,0.0620154,"There was no significant difference in the initial SBP-to- tourniquet inflation time, the initial SBP or the maximum SBP between the groups.","[{'ForeName': 'Samaa A', 'Initials': 'SA', 'LastName': 'Kasem', 'Affiliation': 'Anesthesia Department, Faculty of Medicine, Beni Suef University, Street 10, Pyramids gardens, Giza, Egypt. sama.a.kasem@gmail.com.'}, {'ForeName': 'Tarek', 'Initials': 'T', 'LastName': 'Al Menesy', 'Affiliation': 'Anesthesia Department, Faculty of Medicine, Beni Suef University, Street 10, Pyramids gardens, Giza, Egypt.'}, {'ForeName': 'Ahmed A', 'Initials': 'AA', 'LastName': 'Badawy', 'Affiliation': 'Anesthesia Department, Faculty of Medicine, Cairo University, Giza, Egypt.'}, {'ForeName': 'Ashraf', 'Initials': 'A', 'LastName': 'Abd Elmawgoud', 'Affiliation': 'Anesthesia Department, Faculty of Medicine, Cairo University, Giza, Egypt.'}, {'ForeName': 'Ghada', 'Initials': 'G', 'LastName': 'Adel', 'Affiliation': 'Anesthesia Department, Faculty of Medicine, Cairo University, Giza, Egypt.'}, {'ForeName': 'Yasmin A', 'Initials': 'YA', 'LastName': 'Badawy', 'Affiliation': 'Faculty of Medicine, Cairo University, Giza, Egypt.'}]",Journal of clinical monitoring and computing,['10.1007/s10877-019-00366-0'] 3058,770329,Suppression of cell-mediated immunity after infection with attenuated rubella virus.,"The effects of attenuated rubella virus infection upon cell-mediated immunity of human volunteers were studied. The volunteers received the vaccine either by nose drops or by the subcutaneous route. Changes in cell-mediated immunity in terms of delayed cutaneous sensitivity to recall antigens, phytohemagglutination stimulation, and spontaneous migration inhibitory factor-like activity were studied at various time periods after infection. Spontaneous migration inhibitory factor-like activity was studied on supernatants of the lymphocytes obtained from the volunteers and incubated for 72 h in the absence of any antigens. A significant proportion of the volunteers showed suppression of one or more parameters of cell-medicated immunity tested by week 2 of infection compared to the control; however, there was no correlation between suppression of the various parameters studied. No difference was noticed in the incidence of cell-mediated immunity suppression between nose drops and subcutaneous route groups.",1976,"A significant proportion of the volunteers showed suppression of one or more parameters of cell-medicated immunity tested by week 2 of infection compared to the control; however, there was no correlation between suppression of the various parameters studied.",['human volunteers'],['vaccine either by nose drops or by the subcutaneous route'],"['incidence of cell-mediated immunity suppression', 'Spontaneous migration inhibitory factor-like activity']","[{'cui': 'C0020155', 'cui_str': 'Human Volunteers'}]","[{'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0991524', 'cui_str': 'Nasal drops'}, {'cui': 'C1522438', 'cui_str': 'SC use'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0020966', 'cui_str': 'Cell-Mediated Immunity'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression (disorder)'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C1533574', 'cui_str': 'Migration, function (observable entity)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",,0.0189958,"A significant proportion of the volunteers showed suppression of one or more parameters of cell-medicated immunity tested by week 2 of infection compared to the control; however, there was no correlation between suppression of the various parameters studied.","[{'ForeName': 'R', 'Initials': 'R', 'LastName': 'Ganguly', 'Affiliation': ''}, {'ForeName': 'C L', 'Initials': 'CL', 'LastName': 'Cusumano', 'Affiliation': ''}, {'ForeName': 'R H', 'Initials': 'RH', 'LastName': 'Waldman', 'Affiliation': ''}]",Infection and immunity,[] 3059,31973997,"Adjunctive sapropterin dihydrochloride treatment in schizophrenia: A positive proof-of-concept, rater-blind, randomized, multivitamin-controlled study.",,2020,,['schizophrenia'],['Adjunctive sapropterin dihydrochloride'],[],"[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}]","[{'cui': 'C1996349', 'cui_str': 'Sapropterin dihydrochloride'}]",[],,0.0833728,,"[{'ForeName': 'Catherine L', 'Initials': 'CL', 'LastName': 'Clelland', 'Affiliation': ""Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032, USA. Electronic address: cc2786@cumc.columbia.edu.""}, {'ForeName': 'Joshua T', 'Initials': 'JT', 'LastName': 'Kantrowitz', 'Affiliation': 'Department of Psychiatry, Columbia University Medical Center, 1051 Riverside Drive, New York, NY 10032, USA; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA; Schizophrenia Research Center, The Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA.'}, {'ForeName': 'Tse', 'Initials': 'T', 'LastName': 'Choo', 'Affiliation': 'New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA.'}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Clelland', 'Affiliation': 'Clinical Research Department, The Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA.'}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Lieberman', 'Affiliation': 'Department of Psychiatry, Columbia University Medical Center, 1051 Riverside Drive, New York, NY 10032, USA; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA.'}]",Schizophrenia research,['10.1016/j.schres.2019.12.039'] 3060,31596983,Efficacy of air cleaners in asthmatics allergic to cat in ALYATEC ® environmental exposure chamber.,"BACKGROUND Air cleaners have been promoted for respiratory allergic disease prevention, but there is no clear clinical proof of their efficacy in allergic asthma. OBJECTIVE To examine the efficacy of a new air cleaner on early and late asthmatic responses in cat-allergic patients. METHODS This randomized, cross-over, double-blind placebo-controlled study enrolled 24 cat-asthmatic patients with GINA 1 asthma. At baseline, participants were exposed to 40 ng/m 3 of airborne cat allergen for a maximum of 2 hours in ALYATEC ® environmental exposure chamber (EEC). All participants were subsequently randomized into two groups that were exposed to cat allergen, either with active then placebo air cleaners or with placebo then active air cleaners with a 3-week interval in the EEC. This study was registered under number (NCT03928561). RESULTS Fewer patients experienced an EAR with active air cleaners (seven patients; 29.17%) than placebo (21 patients; 87.50%). The response incidence was lower with active than with placebo air cleaners. A Cox model demonstrated a significant treatment effect (hazard ratio, 0.10; P = .002). Active air cleaners also prevented late asthmatic response: four patients (16.67%) had a late asthmatic response with active air cleaners compared to 11 patients (45.83%) with placebo (Prescott test P = .002). Active air cleaners also decreased the maximal severity of bronchial response (FEV1 decrease of 17.24% with active vs 25.62% with placebo air cleaners; P = .001). CONCLUSIONS Our present results demonstrated that Intense Pure Air XL ® air cleaners significantly prevented early and late asthmatic responses among cat-allergic asthmatics during cat allergen exposure in the ALYATEC ® EEC.",2020,Active air cleaners also decreased the maximal severity of bronchial response (FEV1 decrease of 17.24% with active vs 25.62% with placebo air cleaners; P = .001),"['cat-allergic patients', 'asthmatics allergic to cat in ALYATEC® Environmental Exposure Chamber', '24 cat-asthmatic patients with GINA 1 asthma']","['placebo', 'placebo air cleaners or with placebo', 'new air cleaner']","['EAR with active air cleaners', 'late asthmatic response with active air cleaners', 'response incidence', 'maximal severity of bronchial response (FEV1 decrease', 'late asthmatic responses', 'late asthmatic response']","[{'cui': 'C0524517', 'cui_str': 'Felis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0339805', 'cui_str': 'Allergy to cat dander'}, {'cui': 'C0014412', 'cui_str': 'Environmental Exposure'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0789995', 'cui_str': 'Air cleaner (physical object)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}]","[{'cui': 'C0013443', 'cui_str': 'Vestibulocochlear Apparatus'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0789995', 'cui_str': 'Air cleaner (physical object)'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0205039', 'cui_str': 'Bronchial (qualifier value)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}]",,0.361542,Active air cleaners also decreased the maximal severity of bronchial response (FEV1 decrease of 17.24% with active vs 25.62% with placebo air cleaners; P = .001),"[{'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Gherasim', 'Affiliation': ""ALYATEC® Environmental Exposure Chamber, 1 place de l'Hôpital, Strasbourg, France.""}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Jacob', 'Affiliation': ""ALYATEC® Environmental Exposure Chamber, 1 place de l'Hôpital, Strasbourg, France.""}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Schoettel', 'Affiliation': ""ALYATEC® Environmental Exposure Chamber, 1 place de l'Hôpital, Strasbourg, France.""}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Domis', 'Affiliation': ""ALYATEC® Environmental Exposure Chamber, 1 place de l'Hôpital, Strasbourg, France.""}, {'ForeName': 'Frederic', 'Initials': 'F', 'LastName': 'de Blay', 'Affiliation': ""ALYATEC® Environmental Exposure Chamber, 1 place de l'Hôpital, Strasbourg, France.""}]",Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,['10.1111/cea.13511'] 3061,31989151,Network Analysis Indicates That Avolition Is the Most Central Domain for the Successful Treatment of Negative Symptoms: Evidence From the Roluperidone Randomized Clinical Trial.,"A recent conceptual development in schizophrenia is to view its manifestations as interactive networks rather than individual symptoms. Negative symptoms, which are associated with poor functional outcome and reduced rates of recovery, represent a critical need in schizophrenia therapeutics. MIN101 (roluperidone), a compound in development, demonstrated efficacy in the treatment of negative symptoms in schizophrenia. However, it is unclear how the drug achieved its effect from a network perspective. The current study evaluated the efficacy of roluperidone from a network perspective. In this randomized clinical trial, participants with schizophrenia and moderate to severe negative symptoms were randomly assigned to roluperidone 32 mg (n = 78), 64 mg (n = 83), or placebo (N = 83). Macroscopic network properties were evaluated to determine whether roluperidone altered the overall density of the interconnections among symptoms. Microscopic properties were evaluated to examine which individual symptoms were most influential (ie, interconnected) on other symptoms in the network and are responsible for successful treatment effects. Participants receiving roluperidone did not differ from those randomized to placebo on macroscopic properties. However, microscopic properties (degree and closeness centrality) indicated that avolition was highly central in patients receiving placebo and that roluperidone reduced this level of centrality. These findings suggest that decoupling the influence of motivational processes from other negative symptom domains is essential for producing global improvements. The search for pathophysiological mechanisms and targeted treatment development should be focused on avolition, with the expectation of improvement in the entire constellation of negative symptoms if avolition is effectively treated.",2020,Macroscopic network properties were evaluated to determine whether roluperidone altered the overall density of the interconnections among symptoms.,['participants with schizophrenia and moderate to severe negative symptoms'],"['MIN101 (roluperidone', 'placebo', 'roluperidone']",[],"[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]",[],,0.241904,Macroscopic network properties were evaluated to determine whether roluperidone altered the overall density of the interconnections among symptoms.,"[{'ForeName': 'Gregory P', 'Initials': 'GP', 'LastName': 'Strauss', 'Affiliation': 'Department of Psychology, University of Georgia, Athens, GA.'}, {'ForeName': 'Farnaz', 'Initials': 'F', 'LastName': 'Zamani Esfahlani', 'Affiliation': 'Department of Systems Science and Industrial Engineering & Center for Collective Dynamics of Complex Systems, Binghamton University, Binghamton, NY.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Sayama', 'Affiliation': 'Department of Systems Science and Industrial Engineering & Center for Collective Dynamics of Complex Systems, Binghamton University, Binghamton, NY.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Kirkpatrick', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Reno School of Medicine, University of Nevada, Reno, NV.'}, {'ForeName': 'Mark G', 'Initials': 'MG', 'LastName': 'Opler', 'Affiliation': 'MedAvante-ProPhase, New York, NY.'}, {'ForeName': 'Jay B', 'Initials': 'JB', 'LastName': 'Saoud', 'Affiliation': 'Minerva Neurosciences, Waltham, MA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Davidson', 'Affiliation': 'Minerva Neurosciences, Waltham, MA.'}, {'ForeName': 'Remy', 'Initials': 'R', 'LastName': 'Luthringer', 'Affiliation': 'Minerva Neurosciences, Waltham, MA.'}]",Schizophrenia bulletin,['10.1093/schbul/sbz141'] 3062,31989155,"COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions.","AIMS Drug-coated balloons (DCBs) for femoropopliteal interventions have not been tested against each other. We aimed to directly compare efficacy and safety of a high-dose (In.Pact™) vs. low-dose (Ranger™) DCB with nominal paclitaxel densities of 3.5 vs. 2.0 μg/mm2. METHODS AND RESULTS Within a prospective, multicentre, non-inferiority, clinical trial 414 patients with symptomatic femoropopliteal lesions (Rutherford classification 2-4) were randomly assigned in a 1:1 ratio to endovascular treatment with either high- or low-dose DCB after stratification for lesion length. Primary efficacy and safety endpoints comprised primary patency and freedom from major adverse events (i.e. device and procedure-related deaths through 1 month, major amputations, and clinically driven target lesion revascularization through 12 months). We set a non-inferiority margin of -10% at 12 months. Total occlusions were observed frequently (>40%) and provisional stenting was performed in every fourth intervention. Non-inferiority was determined for both primary efficacy and safety endpoints at 12 months. Primary patency was 81.5% in the high-dose and 83.0% in low-dose DCB group {difference: 1.5% [lower bound of the 90% two-sided confidence interval (CI) -5.2%]; Pnon-inferiority < 0.01}. Freedom from major adverse events was determined in 92.6% in high-dose and in 91.0% in low-dose DCB group [difference -1.6% (lower bound of the 90% two-sided CI -6.5%); Pnon-inferiority < 0.01]. Overall death rate was low (2.0%) and no major amputation occurred. CONCLUSION Two DCBs with different coating characteristics exhibited comparable results with excellent effectiveness and safety through 12 months for femoropopliteal interventions including a wide range of lesion lengths. CLINICAL TRIAL REGISTRATION The trial is registered with ClinicalTrials.gov (NCT02701543).",2020,Primary patency was 81.5% in the high-dose and 83.0% in low-dose DCB group {difference: 1.5% [lower bound of the 90% two-sided confidence interval (CI) -5.2%]; Pnon-inferiority < 0.01}. Freedom from major adverse events was determined in 92.6% in high-dose and in 91.0% in low-dose DCB group [difference -1.6% (lower bound of the 90% two-sided CI -6.5%); Pnon-inferiority < 0.01].,['414 patients with symptomatic femoropopliteal lesions (Rutherford classification 2-4'],"['Drug-coated balloons (DCBs', 'high- vs. low-dose paclitaxel drug-coated balloons', 'endovascular treatment with either high- or low-dose DCB']","['Primary patency', 'efficacy and safety', 'Total occlusions', 'Overall death rate', 'primary patency and freedom from major adverse events (i.e. device and procedure-related deaths through 1\u2009month, major amputations, and clinically driven target lesion revascularization through 12\u2009months']","[{'cui': 'C4517771', 'cui_str': 'Four hundred and fourteen'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0008903', 'cui_str': 'taxonomy'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0453946', 'cui_str': 'Coat (physical object)'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft (physical object)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0441597', 'cui_str': 'Occlusion - action (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0014742', 'cui_str': 'Erythema Multiforme'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}]",414.0,0.322573,Primary patency was 81.5% in the high-dose and 83.0% in low-dose DCB group {difference: 1.5% [lower bound of the 90% two-sided confidence interval (CI) -5.2%]; Pnon-inferiority < 0.01}. Freedom from major adverse events was determined in 92.6% in high-dose and in 91.0% in low-dose DCB group [difference -1.6% (lower bound of the 90% two-sided CI -6.5%); Pnon-inferiority < 0.01].,"[{'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Steiner', 'Affiliation': 'Division of Angiology, Department of Internal Medicine, Neurology and Dermatology, University Hospital Leipzig, Liebigstraße 20, 04103 Leipzig, Germany.'}, {'ForeName': 'Andrej', 'Initials': 'A', 'LastName': 'Schmidt', 'Affiliation': 'Division of Angiology, Department of Internal Medicine, Neurology and Dermatology, University Hospital Leipzig, Liebigstraße 20, 04103 Leipzig, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Zeller', 'Affiliation': 'Department of Angiology, Universitäts-Herzzentrum Freiburg-Bad Krozingen, Südring 15, 79189 Bad Krozingen, Germany.'}, {'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Tepe', 'Affiliation': 'Department of Radiology, RoMed Clinic Rosenheim, Pettenkoferstraße 10, 83022 Rosenheim, Germany.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Thieme', 'Affiliation': 'Department of Angiology, Regiomed Gefäßzentrum Sonneberg, Neustadter Str. 61, 96515 Sonneberg, Germany.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Maiwald', 'Affiliation': 'Department of Angiology, Kreiskrankenhaus Torgau, Christianistraße 1, 04860 Torgau, Germany.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Schröder', 'Affiliation': 'Gemeinschaftspraxis für Radiologie, Neuroradiologie & Zentrum für Minimal Invasive Therapie, Jüdisches Krankenhaus Berlin, Heinz-Galinski-Straße 1, 13347 Berlin, Germany.'}, {'ForeName': 'Wulf', 'Initials': 'W', 'LastName': 'Euringer', 'Affiliation': 'Department of Radiology, Herz- und Gefäßzentrum Bad Bevensen, Römstedter Str. 25, 29549 Bad Bevensen, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Ulrich', 'Affiliation': 'Department of Angiology, Diakoniekrankenhaus Halle, Mühlweg 7, 06114 Halle (Saale), Germany.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Brechtel', 'Affiliation': 'Gemeinschaftspraxis für Radiologie, Franziskus-Krankenhaus, Budapester Str. 15-19, 10787 Berlin, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Brucks', 'Affiliation': 'Angiologikum Hamburg, Wördemanns Weg 25-27, 22527 Hamburg, Germany.'}, {'ForeName': 'Erwin', 'Initials': 'E', 'LastName': 'Blessing', 'Affiliation': 'Department of Angiology, SRH Klinikum Karlsbad Langensteinbach, Guttmannstraße 1, 76307 Karlsbad, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Schuster', 'Affiliation': 'Department of Angiology, Kreiskrankenhaus Delitzsch GmbH, Kliniken Delitzsch und Eilenburg, Dübener Straße 3-9, 04509 Delitzsch, Germany.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Langhoff', 'Affiliation': 'Department of Angiology, Sankt Gertrauden Krankenhaus GmbH, Paretzer Str. 12, 10713 Berlin, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Schellong', 'Affiliation': 'Department of Angiology, Medical Clinic 2, Municipal Hospital of Dresden, Heinrich-Cotta-Straße 12, 01324 Dresden, Germany.'}, {'ForeName': 'Norbert', 'Initials': 'N', 'LastName': 'Weiss', 'Affiliation': 'Division of Angiology, Department of Internal Medicine III, University Hospital Dresden, Fetscherstraße 74, 01307 Dresden, Germany.'}, {'ForeName': 'Dierk', 'Initials': 'D', 'LastName': 'Scheinert', 'Affiliation': 'Division of Angiology, Department of Internal Medicine, Neurology and Dermatology, University Hospital Leipzig, Liebigstraße 20, 04103 Leipzig, Germany.'}]",European heart journal,['10.1093/eurheartj/ehaa049'] 3063,31940109,"Transcarotid Artery Revascularization Results in Low Rates of Periprocedural Neurologic Events, Myocardial Infarction, and Death.","PURPOSE OF REVIEW Transcarotid artery revascularization (TCAR) is a novel hybrid procedure that reverses carotid flow and places a stent using surgical access of the carotid artery in the neck under local anesthesia. We discuss the indications for carotid revascularization, the clinical rationale for TCAR, and evidence for its potential role in the management of carotid stenosis. RECENT FINDINGS Results from pre-clinical studies, prospective single-arm studies, and comparative analyses of registry data indicate that TCAR results in low amounts of periprocedural microembolization, cerebral lesions detectable on magnetic resonance imaging, and neurologic events, myocardial infarctions (MIs), and death. Non-randomized comparisons suggest that TCAR may offer a novel solution to reducing periprocedural stroke, death, and MI in patients with carotid stenosis. A state of equipoise appears to have been reached with TCAR versus the traditional carotid revascularization procedures and a well-controlled randomized trial with careful oversight should be prioritized to obtain level 1 evidence.",2020,A state of equipoise appears to have been reached with TCAR versus the traditional carotid revascularization procedures and a well-controlled randomized trial with careful oversight should be prioritized to obtain level 1 evidence.,['patients with carotid stenosis'],"['TCAR', 'Transcarotid artery revascularization (TCAR']","['Periprocedural Neurologic Events, Myocardial Infarction, and Death', 'periprocedural stroke, death, and MI']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0007282', 'cui_str': 'Carotid Artery Narrowing'}]","[{'cui': 'C0003842', 'cui_str': 'Arteries'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}]","[{'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}]",,0.0724733,A state of equipoise appears to have been reached with TCAR versus the traditional carotid revascularization procedures and a well-controlled randomized trial with careful oversight should be prioritized to obtain level 1 evidence.,"[{'ForeName': 'Angelica R', 'Initials': 'AR', 'LastName': 'Lackey', 'Affiliation': 'Department of Vascular Surgery, University of Maryland, 22 South Greene Street, S10-B00, Baltimore, MD, 21201, USA.'}, {'ForeName': 'Young', 'Initials': 'Y', 'LastName': 'Erben', 'Affiliation': 'Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.'}, {'ForeName': 'Joao Antonio Da Rocha', 'Initials': 'JADR', 'LastName': 'Franco', 'Affiliation': 'Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.'}, {'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Meschia', 'Affiliation': 'Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.'}, {'ForeName': 'Brajesh K', 'Initials': 'BK', 'LastName': 'Lal', 'Affiliation': 'Department of Vascular Surgery, University of Maryland, 22 South Greene Street, S10-B00, Baltimore, MD, 21201, USA. blal@som.umaryland.edu.'}]",Current cardiology reports,['10.1007/s11886-020-1256-z'] 3064,31961418,Effect of Hydroxyethyl Starch vs Saline for Volume Replacement Therapy on Death or Postoperative Complications Among High-Risk Patients Undergoing Major Abdominal Surgery: The FLASH Randomized Clinical Trial.,"Importance It is not known if use of colloid solutions containing hydroxyethyl starch (HES) to correct for intravascular deficits in high-risk surgical patients is either effective or safe. Objective To evaluate the effect of HES 130/0.4 compared with 0.9% saline for intravascular volume expansion on mortality and postoperative complications after major abdominal surgery. Design, Setting, and Participants Multicenter, double-blind, parallel-group, randomized clinical trial of 775 adult patients at increased risk of postoperative kidney injury undergoing major abdominal surgery at 20 university hospitals in France from February 2016 to July 2018; final follow-up was in October 2018. Interventions Patients were randomized to receive fluid containing either 6% HES 130/0.4 diluted in 0.9% saline (n = 389) or 0.9% saline alone (n = 386) in 250-mL boluses using an individualized hemodynamic algorithm during surgery and for up to 24 hours on the first postoperative day, defined as ending at 7:59 am the following day. Main Outcomes and Measures The primary outcome was a composite of death or major postoperative complications at 14 days after surgery. Secondary outcomes included predefined postoperative complications within 14 days after surgery, durations of intensive care unit and hospital stays, and all-cause mortality at postoperative days 28 and 90. Results Among 826 patients enrolled (mean age, 68 [SD, 7] years; 91 women [12%]), 775 (94%) completed the trial. The primary outcome occurred in 139 of 389 patients (36%) in the HES group and 125 of 386 patients (32%) in the saline group (difference, 3.3% [95% CI, -3.3% to 10.0%]; relative risk, 1.10 [95% CI, 0.91-1.34]; P = .33). Among 12 prespecified secondary outcomes reported, 11 showed no significant difference, but a statistically significant difference was found in median volume of study fluid administered on day 1: 1250 mL (interquartile range, 750-2000 mL) in the HES group and 1500 mL (interquartile range, 750-2150 mL) in the saline group (median difference, 250 mL [95% CI, 83-417 mL]; P = .006). At 28 days after surgery, 4.1% and 2.3% of patients had died in the HES and saline groups, respectively (difference, 1.8% [95% CI, -0.7% to 4.3%]; relative risk, 1.76 [95% CI, 0.79-3.94]; P = .17). Conclusions and Relevance Among patients at risk of postoperative kidney injury undergoing major abdominal surgery, use of HES for volume replacement therapy compared with 0.9% saline resulted in no significant difference in a composite outcome of death or major postoperative complications within 14 days after surgery. These findings do not support the use of HES for volume replacement therapy in such patients. Trial Registration ClinicalTrials.gov Identifier: NCT02502773.",2020,"The primary outcome occurred in 139 of 389 patients (36%) in the HES group and 125 of 386 patients (32%) in the saline group (difference, 3.3% [95% CI, -3.3% to 10.0%]; relative risk, 1.10 [95% CI, 0.91-1.34]; P = .33).","['826 patients enrolled (mean age', 'after major abdominal surgery', 'Undergoing Major Abdominal Surgery', '775 adult patients at increased risk of postoperative kidney injury undergoing major abdominal surgery at 20 university hospitals in France from February 2016 to July 2018; final follow-up was in October 2018', '68 [SD, 7] years; 91 women [12%]), 775 (94%) completed the trial', 'High-Risk Patients', 'patients at risk of postoperative kidney injury undergoing major abdominal surgery']","['Hydroxyethyl Starch vs Saline', 'colloid solutions containing hydroxyethyl starch (HES', 'fluid containing either 6% HES 130/0.4 diluted in 0.9% saline (n\u2009=\u2009389) or 0.9% saline alone (n\u2009=\u2009386) in 250-mL boluses using an individualized hemodynamic algorithm', 'HES']","['mortality and postoperative complications', 'Death or Postoperative Complications', 'postoperative complications within 14 days after surgery, durations of intensive care unit and hospital stays, and all-cause mortality at postoperative days 28 and 90', 'composite outcome of death or major postoperative complications', 'median volume of study fluid', 'composite of death or major postoperative complications']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C4517874', 'cui_str': '775'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C1444641', 'cui_str': 'At risk'}]","[{'cui': 'C0020352', 'cui_str': 'hydroxyethylstarch'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0009361', 'cui_str': 'Colloids'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C1720119', 'cui_str': 'Dilute'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C4517752', 'cui_str': '389 (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0002045'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0032787', 'cui_str': 'Postoperative Complications'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}]",775.0,0.683203,"The primary outcome occurred in 139 of 389 patients (36%) in the HES group and 125 of 386 patients (32%) in the saline group (difference, 3.3% [95% CI, -3.3% to 10.0%]; relative risk, 1.10 [95% CI, 0.91-1.34]; P = .33).","[{'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Futier', 'Affiliation': 'Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Département Anesthésie et Réanimation, Hôpital Estaing, Université Clermont Auvergne, CNRS, Inserm U-1103, Clermont-Ferrand, France.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Garot', 'Affiliation': 'CHU de Lille, Pôle Anesthésie Réanimation, Hôpital Claude Huriez, Lille, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Godet', 'Affiliation': 'CHU de Clermont-Ferrand, Département Anesthésie et Réanimation, Hôpital Estaing, Clermont-Ferrand, France.'}, {'ForeName': 'Matthieu', 'Initials': 'M', 'LastName': 'Biais', 'Affiliation': 'CHU de Bordeaux, Département Anesthésie et Réanimation, Hôpital Pellegrin, Bordeaux, France.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Verzilli', 'Affiliation': 'CHU Montpellier, Département Anesthésie et Réanimation B (DAR B), Hôpital Saint-Eloi, and Inserm U-1046, Montpellier, France.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Ouattara', 'Affiliation': 'CHU de Bordeaux, Service Anesthésie et Réanimation, Centre Medico-chirugical Magellan, Bordeaux, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Huet', 'Affiliation': 'CHU de Brest, Département Anesthésie et Réanimation, Hôpital La cavale Blanche, Brest, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Lescot', 'Affiliation': 'Fresenius Kabi, Paris, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Lebuffe', 'Affiliation': 'CHU de Lille, Pôle Anesthésie Réanimation, Hôpital Claude Huriez, Lille, France.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Dewitte', 'Affiliation': 'CHU de Bordeaux, Service Anesthésie et Réanimation, Centre Medico-chirugical Magellan, Bordeaux, France.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Cadic', 'Affiliation': 'CHU de Brest, Département Anesthésie et Réanimation, Hôpital La cavale Blanche, Brest, France.'}, {'ForeName': 'Aymeric', 'Initials': 'A', 'LastName': 'Restoux', 'Affiliation': 'AP-HP, Département Anesthésie et Réanimation, Hôpital Beaujon, Clichy, Paris, France.'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Asehnoune', 'Affiliation': 'CHU de Nantes, Département Anesthésie et Réanimation, Hôpital Hôtel Dieu, Nantes, France.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Paugam-Burtz', 'Affiliation': 'AP-HP, Département Anesthésie et Réanimation, Hôpital Beaujon, Clichy, Paris, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Cuvillon', 'Affiliation': ""CHU de Nîmes, Section d'Anesthésie, Département Anesthésie et Réanimation, Nîmes, France.""}, {'ForeName': 'Marion', 'Initials': 'M', 'LastName': 'Faucher', 'Affiliation': 'Institut Paoli Calmettes, Département Anesthésie et Réanimation, Marseille, France.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Vaisse', 'Affiliation': 'Assistance Publique Hôpitaux de Marseille (AP-HM), Service Anesthésie et Réanimation, Hôpital Timone, Marseille, France.'}, {'ForeName': 'Younes', 'Initials': 'Y', 'LastName': 'El Amine', 'Affiliation': 'Centre Hospitalier de Valenciennes, Département Anesthésie et Réanimation, Valenciennes, France.'}, {'ForeName': 'Hélène', 'Initials': 'H', 'LastName': 'Beloeil', 'Affiliation': 'Université de Rennes, Inserm, INRA, CHU Rennes, CIC 1414, Numecan, Pôle Anesthésie et Réanimation, Rennes, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Leone', 'Affiliation': 'AP-HM, Service Anesthésie et Réanimation, Hôpital Nord, Université Aix Marseille, Marseille, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Noll', 'Affiliation': ""Hôpitaux Universitaires de Strasbourg, Service d'Anesthésie Réanimation Chirurgicale, Hôpital Hautepierre, Strasbourg, France.""}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Piriou', 'Affiliation': ""Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Service d'Anesthésie Réanimation, Centre Hospitalier Lyon Sud, Lyon, France.""}, {'ForeName': 'Sigismond', 'Initials': 'S', 'LastName': 'Lasocki', 'Affiliation': 'Département Anesthésie et Réanimation, CHU Angers, Angers, France.'}, {'ForeName': 'Jean-Etienne', 'Initials': 'JE', 'LastName': 'Bazin', 'Affiliation': 'CHU de Clermont-Ferrand, Département Anesthésie et Réanimation, Hôpital Estaing, Clermont-Ferrand, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Pereira', 'Affiliation': 'Biostatistics Unit, Direction de la Recherche Clinique (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France.'}, {'ForeName': 'Samir', 'Initials': 'S', 'LastName': 'Jaber', 'Affiliation': 'CHU Montpellier, Département Anesthésie et Réanimation B (DAR B), Hôpital Saint-Eloi, and Inserm U-1046, Montpellier, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Sigismond', 'Initials': '', 'LastName': 'Lasocki', 'Affiliation': ''}, {'ForeName': 'Olivier', 'Initials': '', 'LastName': 'Huet', 'Affiliation': ''}, {'ForeName': 'Anna', 'Initials': '', 'LastName': 'Cadic', 'Affiliation': ''}, {'ForeName': 'Christophe', 'Initials': '', 'LastName': 'Jacob', 'Affiliation': ''}, {'ForeName': 'Catherine', 'Initials': '', 'LastName': 'Paugam-Burtz', 'Affiliation': ''}, {'ForeName': 'Aymeric', 'Initials': '', 'LastName': 'Restoux', 'Affiliation': ''}, {'ForeName': 'Alexandre', 'Initials': '', 'LastName': 'Ouattara', 'Affiliation': ''}, {'ForeName': 'Ioana', 'Initials': '', 'LastName': 'Feitita', 'Affiliation': ''}, {'ForeName': 'Elsa', 'Initials': '', 'LastName': 'Deloge', 'Affiliation': ''}, {'ForeName': 'Mylène', 'Initials': '', 'LastName': 'Defaye', 'Affiliation': ''}, {'ForeName': 'Olivier', 'Initials': '', 'LastName': 'Joannes-Boyau', 'Affiliation': ''}, {'ForeName': 'Pauline', 'Initials': '', 'LastName': 'Carles', 'Affiliation': ''}, {'ForeName': 'Guya', 'Initials': '', 'LastName': 'Napolitano', 'Affiliation': ''}, {'ForeName': 'Simon', 'Initials': '', 'LastName': 'Monziols', 'Affiliation': ''}, {'ForeName': 'Emmanuel', 'Initials': '', 'LastName': 'Futier', 'Affiliation': ''}, {'ForeName': 'Marie', 'Initials': '', 'LastName': 'Vignaud', 'Affiliation': ''}, {'ForeName': 'Solène', 'Initials': '', 'LastName': 'Paul', 'Affiliation': ''}, {'ForeName': 'Karim', 'Initials': '', 'LastName': 'Gahbiche', 'Affiliation': ''}, {'ForeName': 'Julie', 'Initials': '', 'LastName': 'Fayon', 'Affiliation': ''}, {'ForeName': 'Erwan', 'Initials': '', 'LastName': 'Laroche', 'Affiliation': ''}, {'ForeName': 'Jean-Etienne', 'Initials': '', 'LastName': 'Bazin', 'Affiliation': ''}, {'ForeName': 'Antoine', 'Initials': '', 'LastName': 'Brandely', 'Affiliation': ''}, {'ForeName': 'Charlene', 'Initials': '', 'LastName': 'Le Moal', 'Affiliation': ''}, {'ForeName': 'Gilles', 'Initials': '', 'LastName': 'Lebuffe', 'Affiliation': ''}, {'ForeName': 'Matthias', 'Initials': '', 'LastName': 'Garot', 'Affiliation': ''}, {'ForeName': 'Vincent', 'Initials': '', 'LastName': 'Piriou', 'Affiliation': ''}, {'ForeName': 'Samir', 'Initials': '', 'LastName': 'Jaber', 'Affiliation': ''}, {'ForeName': 'Gérald', 'Initials': '', 'LastName': 'Chanques', 'Affiliation': ''}, {'ForeName': 'Daniel', 'Initials': '', 'LastName': 'Verzilli', 'Affiliation': ''}, {'ForeName': 'Audrey', 'Initials': '', 'LastName': 'De Jong', 'Affiliation': ''}, {'ForeName': 'Alice', 'Initials': '', 'LastName': 'Millot', 'Affiliation': ''}, {'ForeName': 'Anna', 'Initials': '', 'LastName': 'Castagnoli', 'Affiliation': ''}, {'ForeName': 'Marc', 'Initials': '', 'LastName': 'Leone', 'Affiliation': ''}, {'ForeName': 'Bruno', 'Initials': '', 'LastName': 'Pastene', 'Affiliation': ''}, {'ForeName': 'Caroline', 'Initials': '', 'LastName': 'Castelli', 'Affiliation': ''}, {'ForeName': 'Sophie', 'Initials': '', 'LastName': 'Medam', 'Affiliation': ''}, {'ForeName': 'Lionel', 'Initials': '', 'LastName': 'Velly', 'Affiliation': ''}, {'ForeName': 'Camille', 'Initials': '', 'LastName': 'Vaisse', 'Affiliation': ''}, {'ForeName': 'Marion', 'Initials': '', 'LastName': 'Faucher', 'Affiliation': ''}, {'ForeName': 'Karim', 'Initials': '', 'LastName': 'Asehnoune', 'Affiliation': ''}, {'ForeName': 'Esther', 'Initials': '', 'LastName': 'Samba', 'Affiliation': ''}, {'ForeName': 'Antoine', 'Initials': '', 'LastName': 'Roquilly', 'Affiliation': ''}, {'ForeName': 'Marguerite', 'Initials': '', 'LastName': 'Le Penndu', 'Affiliation': ''}, {'ForeName': 'Philippe', 'Initials': '', 'LastName': 'Cuvillon', 'Affiliation': ''}, {'ForeName': 'Jean', 'Initials': '', 'LastName': 'Yves Lefrant', 'Affiliation': ''}, {'ForeName': 'Olivier', 'Initials': '', 'LastName': 'Wira', 'Affiliation': ''}, {'ForeName': 'Elisabeth', 'Initials': '', 'LastName': 'Dubout', 'Affiliation': ''}, {'ForeName': 'Willy-Serge', 'Initials': '', 'LastName': 'Mfam', 'Affiliation': ''}, {'ForeName': 'Thomas', 'Initials': '', 'LastName': 'Lescot', 'Affiliation': ''}, {'ForeName': 'Emilie', 'Initials': '', 'LastName': 'Begneu', 'Affiliation': ''}, {'ForeName': 'Julien', 'Initials': '', 'LastName': 'Burey', 'Affiliation': ''}, {'ForeName': 'Teodora', 'Initials': '', 'LastName': 'Cirilovic', 'Affiliation': ''}, {'ForeName': 'Hélène', 'Initials': '', 'LastName': 'Beloeil', 'Affiliation': ''}, {'ForeName': 'Guillaume', 'Initials': '', 'LastName': 'Allo', 'Affiliation': ''}, {'ForeName': 'Julien', 'Initials': '', 'LastName': 'Pottecher', 'Affiliation': ''}, {'ForeName': 'Benjamin', 'Initials': '', 'LastName': 'Lebas', 'Affiliation': ''}, {'ForeName': 'Clementine', 'Initials': '', 'LastName': 'Venot', 'Affiliation': ''}, {'ForeName': 'Jean Pierre', 'Initials': '', 'LastName': 'Rameau', 'Affiliation': ''}, {'ForeName': 'Florin', 'Initials': '', 'LastName': 'Dimache', 'Affiliation': ''}, {'ForeName': 'Pierre Saint', 'Initials': '', 'LastName': 'Léger', 'Affiliation': ''}, {'ForeName': 'Younes', 'Initials': '', 'LastName': 'El Amine', 'Affiliation': ''}]",JAMA,['10.1001/jama.2019.20833'] 3065,31630182,"Comparing the Effect of Gabapentin, Ketamine, Dexmedetomidine, and Entonox on Pain Control in Burn Wound Dressing.","This study aimed to evaluate differences in the experience of pain, nausea, and vomiting, as well as the hemodynamic parameters including heart rate (HR) and blood pressure (BP) in burn patients across four pain treatment groups-i.e., gabapentin, ketamine, dexmedetomidine, and entonox. In a single blinded randomized comparative study, 25 burn patients with second- or third-degree burns between 20% and 50% of their body surface were assigned to different treatment groups by using block randomization, while keeping the investigator blind to the size of the block. We recorded demographics, the hemodynamics, adverse effects, and pain levels before the treatment and again 5, 10, 15, 30, 60, 120, 240, and 360 minutes postadministration of pain medication (after-treatment). Gabapentin ketamine, dexmedetomidine, and entonox had significant effects in treatment of pain in burn patients. Entonox had the best analgesic effect with the least adverse effects and hemodynamic changes. Gabapentin also had good pain management effects; however, it showed less desirable effects on hemodynamic variables. Entonox caused the least amount of hemodynamic changes and the least adverse reactions, but since the medication is delivered by a facemask it limited its application with our patients. Gabapentin offered good benefits but caused a gradual drop in BP and HR and had some unfavorable reactions. However, since it is administered orally and often is cheaper, it could be considered as the drug of choice.",2020,Entonox had the best analgesic effect with the least adverse effects and hemodynamic changes.,"['burn patients', 'burn patients across four pain treatment groups-i.e', '25 burn patients with second- or third-degree burns between 20% and 50% of their body surface', 'Burn Wound Dressing']","['gabapentin, ketamine, dexmedetomidine, and entonox', 'Entonox', 'Gabapentin, Ketamine, Dexmedetomidine, and Entonox', 'Gabapentin ketamine, dexmedetomidine, and entonox', 'Gabapentin']","['heart rate (HR) and blood pressure (BP', 'pain, nausea, and vomiting', 'hemodynamics, adverse effects, and pain levels', 'BP and HR', 'pain']","[{'cui': 'C0006434', 'cui_str': 'Burns'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0433445', 'cui_str': 'Third degree burn injury (morphologic abnormality)'}, {'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}, {'cui': 'C0178388', 'cui_str': 'Dressing of wound (procedure)'}]","[{'cui': 'C0060926', 'cui_str': 'gabapentin'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0059395', 'cui_str': 'Entonox'}]","[{'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}]",25.0,0.0262692,Entonox had the best analgesic effect with the least adverse effects and hemodynamic changes.,"[{'ForeName': 'Simin', 'Initials': 'S', 'LastName': 'Chaghazardi', 'Affiliation': 'Injury and Pain Management Research Center, Department of Anesthesiology Critical Care and Pain Management, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Mohammadbagher', 'Initials': 'M', 'LastName': 'Hedari', 'Affiliation': 'Injury and Pain Management Research Center, Department of Anesthesiology Critical Care and Pain Management, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Shahrzad', 'Initials': 'S', 'LastName': 'Bazargan-Hejazi', 'Affiliation': 'Department of Psychiatry, College of Medicine, Charles Drew University of Medicine and Science & David Geffen School of Medicine at University of California, Los Angeles (UCLA), CA.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Mohammadi', 'Affiliation': 'Department of Neurobiology, Care Sciences and Society (NVS), Division of Family Medicine and Primary Care, Karolinska Institutet, Huddinge, Sweden.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Ahmadi', 'Affiliation': 'Department of Anesthesiology Critical Care and Pain Management, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}]",Journal of burn care & research : official publication of the American Burn Association,['10.1093/jbcr/irz142'] 3066,31986899,Development and Evaluation of a Cancer Literacy Intervention to Promote Mammography Screening Among Navajo Women: A Pilot Study.,"PURPOSE Develop and evaluate a mammography intervention that provides hope about cancer prevention and treatment. DESIGN Pilot randomized controlled trial. SETTING Two communities on the Navajo Nation. PARTICIPANTS Navajo women and support persons. INTERVENTION Both groups received standard care: one home visit discussing mammography pros/cons and barriers. The treatment group received an intervention based on Navajo language via an additional home visit with health education materials (written and oral) in English and Navajo, including a Navajo Cancer Glossary with a new descriptive phrase for cancer. ANALYSIS Between control and intervention conditions, we compared baseline sociodemographics; changes from baseline to 3 months on mammography completion and breast cancer literacy scores. MEASURES (1) intervention feasibility; (2) self- and clinic-reported mammography screening completion; (3) breast cancer literacy. RESULTS A total of 25 participants were randomly assigned (13 treatment, 12 control), with 7 support persons in each arm. Mean age was 53 years, 90% had a high school degree or higher, 86% spoke Navajo and English. At 3 months, 44% had a clinically verified mammogram. Mammography completion was 57% among those with a support person and 27% among those without ( P = .14). Intervention women reported more breast cancer beliefs consistent with mammography ( P = .015). CONCLUSIONS Increases in breast cancer beliefs consistent with mammography show promise. Findings highlight a need to tailor education materials to Navajo culture/language and focus on enhancing support.",2020,Mammography completion was 57% among those with a support person and 27% among those without ( P = .14).,"['Two communities on the Navajo Nation', 'A total of 25 participants', 'Mean age was 53 years, 90% had a high school degree or higher, 86% spoke Navajo and English', 'Navajo Women', 'Navajo women and support persons']","['standard care: one home visit discussing mammography pros/cons and barriers', 'intervention based on Navajo language via an additional home visit with health education materials (written and oral) in English and Navajo, including a Navajo Cancer Glossary with a new descriptive phrase for cancer', 'Cancer Literacy Intervention', 'mammography intervention']","['1) intervention feasibility; (2) self- and clinic-reported mammography screening completion; (3) breast cancer literacy', 'Mammography completion', 'mammography completion and breast cancer literacy scores', 'breast cancer beliefs']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0027361', 'cui_str': 'Persons'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0020043', 'cui_str': 'Home Visits'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0574545', 'cui_str': 'Navajo language (qualifier value)'}, {'cui': 'C0018701'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0681470', 'cui_str': 'Glossary'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0600665', 'cui_str': 'Phrase'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}]",25.0,0.040073,Mammography completion was 57% among those with a support person and 27% among those without ( P = .14).,"[{'ForeName': 'Pamela S', 'Initials': 'PS', 'LastName': 'Sinicrope', 'Affiliation': 'Department of Psychiatry and Psychology and Behavioral Health Research Program, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Mark C', 'Initials': 'MC', 'LastName': 'Bauer', 'Affiliation': 'Diné College, Tsaile, AZ, USA.'}, {'ForeName': 'Christi A', 'Initials': 'CA', 'LastName': 'Patten', 'Affiliation': 'Department of Psychiatry and Psychology and Behavioral Health Research Program, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Austin-Garrison', 'Affiliation': 'Diné College, Tsaile, AZ, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Garcia', 'Affiliation': 'Diné College, Tsaile, AZ, USA.'}, {'ForeName': 'Christine A', 'Initials': 'CA', 'LastName': 'Hughes', 'Affiliation': 'Department of Psychiatry and Psychology and Behavioral Health Research Program, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Martha J', 'Initials': 'MJ', 'LastName': 'Bock', 'Affiliation': 'Department of Psychiatry and Psychology and Behavioral Health Research Program, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Decker', 'Affiliation': 'Department of Health Sciences Research, Biomedical Statistics and Behavioral Health Research Program, Rochester, MN, USA.'}, {'ForeName': 'Kathleen J', 'Initials': 'KJ', 'LastName': 'Yost', 'Affiliation': 'Department of Health Sciences Research, Survey Research Center, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Wesley O', 'Initials': 'WO', 'LastName': 'Petersen', 'Affiliation': 'Department of Psychiatry and Psychology and Behavioral Health Research Program, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Lydia P', 'Initials': 'LP', 'LastName': 'Buki', 'Affiliation': 'Department of Educational and Psychological Studies, University of Miami, Coral Gables, FL, USA.'}, {'ForeName': 'Edward R', 'Initials': 'ER', 'LastName': 'Garrison', 'Affiliation': 'Diné College, Tsaile, AZ, USA.'}]",American journal of health promotion : AJHP,['10.1177/0890117119900592'] 3067,31675102,Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine.,"OBJECTIVE To assess the onset of efficacy for fremanezumab in chronic migraine by evaluating pain-related clinical measures at different time points. BACKGROUND Faster onset of efficacy of preventive treatments could benefit patients with migraine. Fremanezumab is a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, a neuropeptide involved in the pathophysiology of migraine. In 12-week clinical trials, subcutaneous fremanezumab significantly reduced the frequency of migraine headaches, headache hours, and headaches in general, without serious treatment-related adverse events. New drug classes of migraine preventive treatment demonstrate markedly different clinical profiles from standard-of-care treatments. METHODS In this double-blind phase III study, eligible patients were randomized 1:1:1 to receive subcutaneous injections of fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8), fremanezumab monthly (675 mg at baseline, 225 mg at weeks 4 and 8), or placebo at each time point. This study included secondary, exploratory, and post hoc analyses of the primary trial, evaluating the change in headache days of at least moderate severity or migraine days during the first 4 weeks of the trial. RESULTS A total of 1130 patients were randomized (fremanezumab quarterly, n = 376; fremanezumab monthly, n = 379; or placebo, n = 375). During the 4-week period after the first dose, the mean number of monthly headache days of at least moderate severity was reduced for the all-fremanezumab group (mean reduction [95% confidence interval]: -4.6 days [-5.1, -4.1]) compared with the placebo group (-2.3 days [-2.9, -1.6]; P < .0001). Treatment effects were observed at Week 1 for the all-fremanezumab group (-1.1 days [-1.3, -1.0]) vs placebo (-0.5 days [-0.7, -0.3]; P < .0001), with separation from placebo by Day 2 (P = .003). Similar effects were observed for the monthly average number of migraine days and mean number of monthly headache hours. CONCLUSIONS The early onset of efficacy of fremanezumab may have the potential to improve patient compliance and clinical outcomes.",2019,"In 12-week clinical trials, subcutaneous fremanezumab significantly reduced the frequency of migraine headaches, headache hours, and headaches in general, without serious treatment-related adverse events.","['1130 patients were randomized (fremanezumab quarterly, n\xa0', 'patients with migraine', 'Chronic Migraine', 'eligible patients']","['fremanezumab', 'Fremanezumab', 'placebo', 'subcutaneous injections of fremanezumab quarterly (675\xa0mg at baseline, placebo', 'subcutaneous fremanezumab']","['headache days of at least moderate severity or migraine days', 'frequency of migraine headaches, headache hours, and headaches in general, without serious treatment-related adverse events', 'mean number of monthly headache days of at least moderate severity', 'migraine days and mean number of monthly headache hours']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4549503', 'cui_str': 'fremanezumab'}, {'cui': 'C0332179', 'cui_str': 'q3mo'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C1960870', 'cui_str': 'Chronic migraine'}]","[{'cui': 'C4549503', 'cui_str': 'fremanezumab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0021499', 'cui_str': 'Subcutaneous Injections'}, {'cui': 'C0332179', 'cui_str': 'q3mo'}, {'cui': 'C4517854', 'cui_str': '675 (qualifier value)'}, {'cui': 'C1522438', 'cui_str': 'SC use'}]","[{'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}]",1130.0,0.368358,"In 12-week clinical trials, subcutaneous fremanezumab significantly reduced the frequency of migraine headaches, headache hours, and headaches in general, without serious treatment-related adverse events.","[{'ForeName': 'Paul K', 'Initials': 'PK', 'LastName': 'Winner', 'Affiliation': 'Premiere Research Institute, West Palm Beach, FL, USA.'}, {'ForeName': 'Egilius L H', 'Initials': 'ELH', 'LastName': 'Spierings', 'Affiliation': 'MedVadis Research Corporation, Watertown, MA, USA.'}, {'ForeName': 'Paul P', 'Initials': 'PP', 'LastName': 'Yeung', 'Affiliation': 'Teva Pharmaceutical Industries Ltd., Frazer, PA, USA.'}, {'ForeName': 'Ernesto', 'Initials': 'E', 'LastName': 'Aycardi', 'Affiliation': 'Teva Pharmaceutical Industries Ltd., Frazer, PA, USA.'}, {'ForeName': 'Tricia', 'Initials': 'T', 'LastName': 'Blankenbiller', 'Affiliation': 'Teva Pharmaceutical Industries Ltd., Frazer, PA, USA.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Grozinski-Wolff', 'Affiliation': 'Teva Pharmaceutical Industries Ltd., Frazer, PA, USA.'}, {'ForeName': 'Ronghua', 'Initials': 'R', 'LastName': 'Yang', 'Affiliation': 'Teva Pharmaceutical Industries Ltd., Frazer, PA, USA.'}, {'ForeName': 'Yuju', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': 'Teva Pharmaceutical Industries Ltd., Frazer, PA, USA.'}]",Headache,['10.1111/head.13654'] 3068,32012217,Percutaneous Cordotomy for Pain Palliation in Advanced Cancer: A Randomized Clinical Trial Study Protocol.,"BACKGROUND Cancer pain, one of the most common symptoms for patients with advanced cancer, is often refractory to maximal medical therapy. A controlled clinical trial is needed to provide definitive evidence to support the use of ablative procedures such as cordotomy for patients with medically refractory cancer pain. OBJECTIVE To assess the efficacy of cordotomy for patients with unilateral advanced cancer pain using a controlled clinical trial study design. The secondary objectives are to define the patient experience of cordotomy for medically refractory cancer pain as well as to determine the utility of magnetic resonance imaging as a non-invasive biomarker for successful cordotomy. METHODS We will undertake a single-institution, double-blind, sham-controlled clinical trial of cordotomy in patients with refractory cancer pain. Patients in the cordotomy arm will undergo a percutaneous computed tomography-guided cordotomy at C1-C2, while patients in the control arm will undergo a similar procedure where the needle will not penetrate the thecal sac. The primary endpoint will be the reduction in pain intensity, as measured by the Edmonton Symptoms Assessment Scale. EXPECTED OUTCOMES We expect that patients randomized to cordotomy will have a significantly greater reduction in pain intensity than those patients randomized to the control surgical intervention. DISCUSSION This randomized clinical trial comparing cordotomy with a control intervention will provide the level of evidence necessary to determine whether cordotomy should be the standard of care intervention for patients with advanced cancer pain.",2020,"EXPECTED OUTCOMES We expect that patients randomized to cordotomy will have a significantly greater reduction in pain intensity than those patients randomized to the control surgical intervention. ","['patients with advanced cancer', 'patients with medically refractory cancer pain', 'Advanced Cancer', 'patients with advanced cancer pain', 'patients with unilateral advanced cancer pain', 'patients with refractory cancer pain']","['Percutaneous Cordotomy', 'cordotomy', 'control intervention', 'percutaneous computed tomography-guided cordotomy at C1-C2']","['reduction in pain intensity, as measured by the Edmonton Symptoms Assessment Scale', 'pain intensity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0677936', 'cui_str': 'Refractory cancer'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}]","[{'cui': 'C0196243', 'cui_str': 'Spinal percutaneous cordotomy (procedure)'}, {'cui': 'C0010009', 'cui_str': 'Cordotomy'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach - access (qualifier value)'}, {'cui': 'C0040395', 'cui_str': 'Tomographic imaging'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}]","[{'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C3494437', 'cui_str': 'Symptom Assessment'}, {'cui': 'C0222045'}]",,0.191581,"EXPECTED OUTCOMES We expect that patients randomized to cordotomy will have a significantly greater reduction in pain intensity than those patients randomized to the control surgical intervention. ","[{'ForeName': 'Ashwin', 'Initials': 'A', 'LastName': 'Viswanathan', 'Affiliation': 'Department of Neurosurgery, Baylor College of Medicine, Houston, Texas.'}, {'ForeName': 'Aditya', 'Initials': 'A', 'LastName': 'Vedantam', 'Affiliation': 'Department of Neurosurgery, Baylor College of Medicine, Houston, Texas.'}, {'ForeName': 'Loretta A', 'Initials': 'LA', 'LastName': 'Williams', 'Affiliation': 'Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Dhanalakshmi', 'Initials': 'D', 'LastName': 'Koyyalagunta', 'Affiliation': 'Department of Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Salahadin', 'Initials': 'S', 'LastName': 'Abdi', 'Affiliation': 'Department of Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Patrick M', 'Initials': 'PM', 'LastName': 'Dougherty', 'Affiliation': 'Department of Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Tito', 'Initials': 'T', 'LastName': 'Mendoza', 'Affiliation': 'Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Roland L', 'Initials': 'RL', 'LastName': 'Bassett', 'Affiliation': 'Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Hou', 'Affiliation': 'Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Bruera', 'Affiliation': 'Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.'}]",Neurosurgery,['10.1093/neuros/nyz527'] 3069,31989232,Prospective Analysis and Comparison of Periareolar Excision (Delivery) Technique and Pull-Through Technique for the Treatment of Gynecomastia.,"BACKGROUND Gynecomastia is one of the most common disorders affecting adolescent and adult males. It is a benign disorder but has severe psychological manifestations like low self-confidence, depression, anxiety and social phobia in patients suffering from gynecomastia. Different surgical techniques have been described utilizing a variety of incisions, excisions, lipectomy and liposuction methods. Very frequently, these methods are combined for the gynecomastia treatment with variable reported results. However, there is a lack of studies comparing these techniques. The present study was planned to compare cases of gynecomastia treated by liposuction with periareolar excision (delivery technique) and liposuction with a pull-through technique. METHOD A prospective randomized control study was conducted at a tertiary care hospital on 20 patients with gynecomastia. The patients were assigned to either liposuction with periareolar excision (delivery technique) or liposuction with pull-through technique. Anthropometric analysis and breast evaluation questionnaire (BEQ) scores were analyzed and compared before and after the surgery. RESULTS The majority of the study subjects were between 21 and 30 years of age. Low self-confidence was the main reason for surgery in most of the cases. Twelve patients had gynecomastia grade IIa and eight had grade IIb. Both groups had similar responses to BEQ scores before and after the surgery with no statistically significant difference. A statistically insignificant difference was observed between the groups on comparison of anthropometric analysis preoperatively and postoperatively. The mean lipoaspirate volume was 280 ml for the pull-through technique and 367 ml for the periareolar excision technique. No complications were observed in cases operated on by the pull-through technique, while two cases (10%) operated on by the periareolar excision had hematomas. CONCLUSION Both techniques provide excellent cosmetic results with low risk of complications in both small and moderate breast enlargement with skin excess. The pull-through technique combines the benefits of direct excision of glandular tissues along with the minimally invasive nature of liposuction. Thus, performing the procedure via a single incision without the use of drains is a safer alternative to traditional liposuction with the periareolar excision technique. LEVEL OF EVIDENCE III This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.",2020,Both groups had similar responses to BEQ scores before and after the surgery with no statistically significant difference.,"['patients suffering from gynecomastia', 'study subjects were between 21 and 30\xa0years of age', '20 patients with gynecomastia', 'Twelve patients had gynecomastia grade IIa and eight had grade IIb']","['liposuction with periareolar excision (delivery technique) or liposuction with pull-through technique', 'Periareolar Excision', 'liposuction with periareolar excision (delivery technique) and liposuction with a pull-through technique']","['hematomas', 'mean lipoaspirate volume', 'Anthropometric analysis and breast evaluation questionnaire (BEQ) scores', 'BEQ scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018418', 'cui_str': 'Male Breast Enlargement'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}]","[{'cui': 'C0038640', 'cui_str': 'Aspiration Lipectomy'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0457447', 'cui_str': 'Pull-through technique (qualifier value)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",20.0,0.0378695,Both groups had similar responses to BEQ scores before and after the surgery with no statistically significant difference.,"[{'ForeName': 'Satyaswarup', 'Initials': 'S', 'LastName': 'Tripathy', 'Affiliation': 'Department of Plastic Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.'}, {'ForeName': 'Abhinav', 'Initials': 'A', 'LastName': 'Likhyani', 'Affiliation': 'Department of Plastic Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.'}, {'ForeName': 'Raman', 'Initials': 'R', 'LastName': 'Sharma', 'Affiliation': 'Department of Plastic Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India. dr.sharma.raman@gmail.com.'}, {'ForeName': 'Ramesh Kumar', 'Initials': 'RK', 'LastName': 'Sharma', 'Affiliation': 'Department of Plastic Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.'}]",Aesthetic plastic surgery,['10.1007/s00266-020-01618-0'] 3070,1323576,"Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children.","Cold passage 18 (CP18) parainfluenza virus type 3 (PIV-3) vaccine was evaluated in a double-blind, randomized, placebo-controlled study of 95 infants and young children. None of 19 seropositive older children 41 to 124 months old became infected when 10(6) 50% tissue culture infective doses (TCID50) of vaccine virus was administered intranasally. Two of nine and seven of twenty-four young seropositive children given 10(5) or 10(6) TCID50 of CP18 PIV-3, respectively, became infected. Each of four seronegative young children became infected, as indicated by virus shedding and antibody response, when given 10(6) TCID50 of CP18 PIV-3 intranasally. Illness was not observed in seropositive children. Two of the four seronegative children developed a mild illness characterized by rhinorrhea and wheezing on auscultation; none had fever. In one case, vaccine virus spread from a vaccine to a sibling control but did not cause illness. The vaccine is attenuated relative to wild-type PIV-3, but additional attenuation will be required to achieve a satisfactory PIV-3 vaccine.",1992,"Each of four seronegative young children became infected, as indicated by virus shedding and antibody response, when given 10(6) TCID50 of CP18 PIV-3 intranasally.","['19 seropositive older children 41 to 124 months old became infected when 10(6', 'children', '95 infants and young children']","['Cold passage 18 (CP18) parainfluenza virus type 3 (PIV-3) vaccine', 'placebo']","['Illness', 'mild illness characterized by rhinorrhea and wheezing on auscultation; none had fever']","[{'cui': 'C0521143', 'cui_str': 'Seropositive (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}]","[{'cui': 'C0009443', 'cui_str': 'Common Cold'}, {'cui': 'C0520476', 'cui_str': 'Parainfluenza Virus Type 3'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C1260880', 'cui_str': 'Nasal catarrh'}, {'cui': 'C0043144', 'cui_str': 'Wheezing'}, {'cui': 'C0004339', 'cui_str': 'Auscultation'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}]",95.0,0.204641,"Each of four seronegative young children became infected, as indicated by virus shedding and antibody response, when given 10(6) TCID50 of CP18 PIV-3 intranasally.","[{'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Belshe', 'Affiliation': 'Department of Internal Medicine, St. Louis University School of Medicine, Missouri.'}, {'ForeName': 'R A', 'Initials': 'RA', 'LastName': 'Karron', 'Affiliation': ''}, {'ForeName': 'F K', 'Initials': 'FK', 'LastName': 'Newman', 'Affiliation': ''}, {'ForeName': 'E L', 'Initials': 'EL', 'LastName': 'Anderson', 'Affiliation': ''}, {'ForeName': 'S L', 'Initials': 'SL', 'LastName': 'Nugent', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Steinhoff', 'Affiliation': ''}, {'ForeName': 'M L', 'Initials': 'ML', 'LastName': 'Clements', 'Affiliation': ''}, {'ForeName': 'M H', 'Initials': 'MH', 'LastName': 'Wilson', 'Affiliation': ''}, {'ForeName': 'S L', 'Initials': 'SL', 'LastName': 'Hall', 'Affiliation': ''}, {'ForeName': 'E L', 'Initials': 'EL', 'LastName': 'Tierney', 'Affiliation': ''}]",Journal of clinical microbiology,[] 3071,31136927,Targeting quality of life in asthmatic children: The MyTEP pilot randomized trial.,"BACKGROUND Quality of life (QoL) is an important outcome in the management of children with asthma. Mobile Health (m-Health) and Therapeutic Education Programs (TEPs) are increasingly recognized as essential components of pediatric asthma management to improve disease outcomes. OBJECTIVE To evaluate the effect of an education program (MyTherapeutic Education Program, MyTEP) that couples multidisciplinary TEP intervention with an m-Health Program (mHP) in improving QoL in asthmatic children. METHODS This single-center study employed a nonblinded randomized clinical trial design. Italian-speaking children (6-11 years) with mild-moderate asthma were eligible for participation. Participants were randomly paired 1:1 with a control group that received mHP (smartphone app) or an intervention group that received MyTEP (TEP plus a smartphone app). Patients were followed up for 3 months. Descriptive statistics, Least Square (LS) mean change and Generalized Linear Mixed model were used for analysis. RESULTS Fifty patients were enrolled. The Pediatric Asthma Quality of Life Questionnaire (PAQLQ) score improved in both MyTEP (p = 0.014) and mHP (p = 0.046) with the minimally clinically significant difference of ⩾0.5 points reached in 23% of MyTEP and in 16% of mHP. Changes in PAQLQ scores were significantly greater in MyTEP than in mHP (LS mean difference: 0.269 p = 0.05). PAQLQ score was: positively associated with MyTEP (p = 0.023) and study time (p = 0.002); and inversely associated with current passive smoke exposure (p = 0.003). CONCLUSION Despite the small sample size and short observation period, this study demonstrated that implementing a multidisciplinary TEP with an m-Health program results in gains in QoL of children with asthma.",2019,Changes in PAQLQ scores were significantly greater in MyTEP than in mHP,"['Italian-speaking children (6-11 years) with mild-moderate asthma were eligible for participation', 'Fifty patients were enrolled', 'asthmatic children', 'children with asthma']","['education program (MyTherapeutic Education Program, MyTEP', 'MyTEP', 'multidisciplinary TEP with an m-Health program', 'TEP intervention with an m-Health Program (mHP', 'Mobile Health (m-Health) and Therapeutic Education Programs (TEPs', 'mHP', 'control group that received mHP (smartphone app) or an intervention group that received MyTEP (TEP plus a smartphone app']","['Pediatric Asthma Quality of Life Questionnaire (PAQLQ) score', 'current passive smoke exposure', 'PAQLQ scores', 'PAQLQ score', 'Targeting quality of life']","[{'cui': 'C0337810', 'cui_str': 'Italians (ethnic group)'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0581125', 'cui_str': 'Moderate asthma'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}]","[{'cui': 'C0729314', 'cui_str': 'Education provision (procedure)'}, {'cui': 'C0145334', 'cui_str': 'Pyrazine, tetraethyl-'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0034380'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}]",50.0,0.0853648,Changes in PAQLQ scores were significantly greater in MyTEP than in mHP,"[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Montalbano', 'Affiliation': 'Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR), Palermo, Italy.'}, {'ForeName': 'Giuliana', 'Initials': 'G', 'LastName': 'Ferrante', 'Affiliation': 'Dipartimento di Scienze per la Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza ""G. D\'Alessandro"", University of Palermo, Palermo, Italy.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Cilluffo', 'Affiliation': 'Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR), Palermo, Italy. Electronic address: giovanna.cilluffo@ibim.cnr.it.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Gentile', 'Affiliation': 'Istituto di Tecnologie Didattiche (ITD), National Research Council (CNR), Palermo, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Arrigo', 'Affiliation': 'Istituto di Tecnologie Didattiche (ITD), National Research Council (CNR), Palermo, Italy.'}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'La Guardia', 'Affiliation': 'Istituto di Tecnologie Didattiche (ITD), National Research Council (CNR), Palermo, Italy.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Allegra', 'Affiliation': 'Istituto di Tecnologie Didattiche (ITD), National Research Council (CNR), Palermo, Italy.'}, {'ForeName': 'Velia', 'Initials': 'V', 'LastName': 'Malizia', 'Affiliation': 'Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR), Palermo, Italy.'}, {'ForeName': 'Rosalia Paola', 'Initials': 'RP', 'LastName': 'Gagliardo', 'Affiliation': 'Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR), Palermo, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Bonini', 'Affiliation': 'Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'La Grutta', 'Affiliation': 'Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR), Palermo, Italy.'}]",Respiratory medicine,['10.1016/j.rmed.2019.05.008'] 3072,31150963,"Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.","BACKGROUND Prior replicate 12-week phase 3 trials demonstrated that once-daily doses of revefenacin inhalation solution at 88 μg and 175 μg produced significant bronchodilation over 24 h post dose in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). The objective was to characterize the safety profile of revefenacin 88 μg and 175 μg over 52 weeks of treatment. METHODS In this randomized, parallel-group, 52-week trial (NCT02518139), 1055 participants with moderate to very severe COPD received revefenacin 88 μg or 175 μg in a double-blind manner, or open-label active control tiotropium. RESULTS Treatment-emergent adverse events (AEs) were comparable across all treatment groups (n [%] patients; revefenacin 88 μg, 272 [74.7%]; 175 μg, 242 [72.2%]; tiotropium, 275 [77.2%]). Numerically fewer COPD exacerbations (n [%] patients) were observed with revefenacin 175 μg (73 [21.8%]) than with 88 μg (107 [29.4%]) or tiotropium (100 [28.1%]). Serious AEs were comparable with revefenacin 88 μg (58 [15.9%] and tiotropium (58 [16.3%]), but were lower with revefenacin 175 μg (43 [12.8%]), and mortality was low. In patients using revefenacin 88 μg or tiotropium with a concurrent long-acting β-agonist (LABA) product, the incidence of AEs was slightly higher than without concurrent LABA. LABA did not affect the incidence of AEs for patients who received revefenacin 175 μg. CONCLUSIONS Revefenacin was generally well tolerated over 52 weeks of treatment, and had a safety profile that supports its use as a long-term once-daily bronchodilator for the nebulized treatment of COPD.",2019,"Serious AEs were comparable with revefenacin 88 μg (58 [15.9%] and tiotropium (58 [16.3%]), but were lower with revefenacin 175 μg (43 [12.8%]), and mortality was low.","['patients with moderate to very severe chronic obstructive pulmonary disease (COPD', '1055 participants with moderate to very severe COPD received', 'moderate to very severe chronic obstructive pulmonary disease']","['Revefenacin', 'revefenacin inhalation solution', 'tiotropium', 'revefenacin 88\u202fμg or tiotropium', 'LABA', 'revefenacin 88\u202fμg or 175\u202fμg in a double-blind manner, or open-label active control tiotropium', 'revefenacin']","['COPD exacerbations', 'mortality']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C3641272', 'cui_str': 'Extreme'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}]","[{'cui': 'C1154181', 'cui_str': 'Inhalation Solution'}, {'cui': 'C0213771', 'cui_str': 'tiotropium'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0740304', 'cui_str': 'COPD exacerbation'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",1055.0,0.553082,"Serious AEs were comparable with revefenacin 88 μg (58 [15.9%] and tiotropium (58 [16.3%]), but were lower with revefenacin 175 μg (43 [12.8%]), and mortality was low.","[{'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Donohue', 'Affiliation': 'Pulmonary Medicine, UNC School of Medicine, Chapel Hill, NC, USA.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Kerwin', 'Affiliation': 'Clinical Research Institute of Southern Oregon, PC, Medford, OR, USA.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Sethi', 'Affiliation': 'University at Buffalo, State University of New York, Buffalo, NY, USA.'}, {'ForeName': 'Brett', 'Initials': 'B', 'LastName': 'Haumann', 'Affiliation': 'Theravance Biopharma US, Inc., 901 Gateway Boulevard, South San Francisco, CA, 94080, USA.'}, {'ForeName': 'Srikanth', 'Initials': 'S', 'LastName': 'Pendyala', 'Affiliation': 'Theravance Biopharma US, Inc., 901 Gateway Boulevard, South San Francisco, CA, 94080, USA.'}, {'ForeName': 'Lorna', 'Initials': 'L', 'LastName': 'Dean', 'Affiliation': 'Theravance Biopharma US, Inc., 901 Gateway Boulevard, South San Francisco, CA, 94080, USA.'}, {'ForeName': 'Chris N', 'Initials': 'CN', 'LastName': 'Barnes', 'Affiliation': 'Theravance Biopharma US, Inc., 901 Gateway Boulevard, South San Francisco, CA, 94080, USA.'}, {'ForeName': 'Edmund J', 'Initials': 'EJ', 'LastName': 'Moran', 'Affiliation': 'Theravance Biopharma US, Inc., 901 Gateway Boulevard, South San Francisco, CA, 94080, USA.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Crater', 'Affiliation': 'Theravance Biopharma US, Inc., 901 Gateway Boulevard, South San Francisco, CA, 94080, USA. Electronic address: gcrater@theravance.com.'}]",Respiratory medicine,['10.1016/j.rmed.2019.05.010'] 3073,31595772,Is Benzodiazepine Use Associated With the Risk of Dementia and Cognitive Impairment-Not Dementia in Older Persons? The Canadian Study of Health and Aging.,"Background: The use of benzodiazepines in relation to cognitive decline remains an area of controversy in aging populations. Objective: This study aims to evaluate the risk of cognitive impairment-not dementia (CIND), Alzheimer disease (AD), and all-cause dementia with benzodiazepine use. The effect modification by sex was also investigated. Methods: Data come from the Canadian Study of Health and Aging, a 10-year multicentric study involving 10 263 participants randomly selected, 65 years and older, living in the community and in institutions. Current exposure to benzodiazepines was assessed in a face-to-face interview or self-reported in a questionnaire. Cox proportional hazard regression models, using age as time scale, were conducted to estimate hazard ratios, with adjustment for sex, education, smoking, alcohol intake, depression, physical activity, nonsteroidal anti-inflammatory drug use, and vascular comorbidities. Results: Data sets included 5281 participants for dementia as the outcome, 5015 for AD, and 4187 for CIND. Compared with nonusers, current use of benzodiazepines was associated with an increased risk of CIND (hazard ratio = 1.36; 95% CI = 1.08-1.72) in the simplest model. Results remained similar in the fully adjusted model (hazard ratio = 1.32; 95% CI = 1.04-1.68). There was no association between benzodiazepine use and the risk of dementia or AD. All these effects were similar between men and women. Conclusion and Relevance: Benzodiazepine use in older people from the general population is related to subsequent occurrence of cognitive dysfunction but not implicated in the pathogenesis of dementia or AD. Caution should be exercised when prescribing benzodiazepines to preserve global cognitive function.",2020,Results remained similar in the fully adjusted model (hazard ratio = 1.32; 95% CI = 1.04-1.68).,"['older people from the general population', '10 263 participants randomly selected, 65 years and older, living in the community and in institutions', '5281 participants for dementia as the outcome, 5015 for AD, and 4187 for CIND']","['benzodiazepine', 'benzodiazepines', 'Benzodiazepine']","['sex, education, smoking, alcohol intake, depression, physical activity, nonsteroidal anti-inflammatory drug use, and vascular comorbidities', 'risk of CIND', 'risk of dementia or AD']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C4517671', 'cui_str': '263'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}]","[{'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}]","[{'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0449889', 'cui_str': 'Drug used (attribute)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}]",,0.0383974,Results remained similar in the fully adjusted model (hazard ratio = 1.32; 95% CI = 1.04-1.68).,"[{'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Nafti', 'Affiliation': ""Centre d'excellence sur le vieillissement de Québec, Centre de recherche du CHU de Québec-Université Laval, Centre de recherche sur les soins et les services de première ligne de l'Université Laval and Institut sur le vieillissement et la participation sociale des aînés de l'Université Laval, Quebec City, QC, Canada.""}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Sirois', 'Affiliation': ""Centre d'excellence sur le vieillissement de Québec, Centre de recherche du CHU de Québec-Université Laval, Centre de recherche sur les soins et les services de première ligne de l'Université Laval and Institut sur le vieillissement et la participation sociale des aînés de l'Université Laval, Quebec City, QC, Canada.""}, {'ForeName': 'Edeltraut', 'Initials': 'E', 'LastName': 'Kröger', 'Affiliation': ""Centre d'excellence sur le vieillissement de Québec, Centre de recherche du CHU de Québec-Université Laval, Centre de recherche sur les soins et les services de première ligne de l'Université Laval and Institut sur le vieillissement et la participation sociale des aînés de l'Université Laval, Quebec City, QC, Canada.""}, {'ForeName': 'Pierre-Hugues', 'Initials': 'PH', 'LastName': 'Carmichael', 'Affiliation': ""Centre d'excellence sur le vieillissement de Québec, Centre de recherche du CHU de Québec-Université Laval, Centre de recherche sur les soins et les services de première ligne de l'Université Laval and Institut sur le vieillissement et la participation sociale des aînés de l'Université Laval, Quebec City, QC, Canada.""}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Laurin', 'Affiliation': ""Centre d'excellence sur le vieillissement de Québec, Centre de recherche du CHU de Québec-Université Laval, Centre de recherche sur les soins et les services de première ligne de l'Université Laval and Institut sur le vieillissement et la participation sociale des aînés de l'Université Laval, Quebec City, QC, Canada.""}]",The Annals of pharmacotherapy,['10.1177/1060028019882037'] 3074,31602994,Impact of Pharmacist Involvement in Heart Failure Transition of Care.,"Background: Heart failure (HF) transition of care (TOC) programs may improve continuity of care and coordination and decrease hospital readmissions. Objective: This study evaluated the impact of pharmacy-led HF TOC on HF readmission rate. Methods: This was a single-center, pre-post quasi-experimental study. Pharmacy TOC comprised admission and discharge medication reconciliations and patient education. Patients were included if they had a primary HF diagnosis. Patients were excluded if they were admitted for a non-HF diagnosis, admitted for <24 hours, had a stage IV cancer or dementia diagnosis, or were transferred to hospice care. The primary outcome was HF 30-day readmission rate. Results: A total of 663 patients were included in the study: 330 in the control group and 333 in the intervention group. The average age for both groups was 67 ± 16 years; 48.1% were female; 56.9% were African American; and 51.4% of patients had an ejection fraction ≤40%. In the control group, 57 (17.3%) patients had a HF 30-day readmission compared with 35 (10.5%) patients in the intervention group. After adjusting for age, the intervention group continued to show a difference in readmission (odds ratio = 0.578; 95% CI = 0.367-0.911; P = 0.018). The most common interventions were medication addition (11%), dose titration (7.5%), medication discontinuation (6.6%), and duplication avoidance (2.7%). Conclusion and Relevance: Pharmacy-led HF TOC, as a component of a targeted hospital-based initiative, significantly decreased HF 30-day readmission rate. Results from this study warrant further research to explore which interventions in TOC are most effective.",2020,"After adjusting for age, the intervention group continued to show a difference in readmission (odds ratio = 0.578; 95% CI = 0.367-0.911; P = 0.018).","['A total of 663 patients were included in the study: 330 in the control group and 333 in the intervention group', 'Patients were included if they had a primary HF diagnosis', 'Patients were excluded if they were admitted for a non-HF diagnosis, admitted for <24 hours, had a stage IV cancer or dementia diagnosis, or were transferred to hospice care', 'average age for both groups was 67 ± 16 years; 48.1% were female; 56.9% were African American; and 51.4% of patients had an ejection fraction ≤40', 'Heart Failure Transition of Care']",['pharmacy-led HF TOC'],"['medication discontinuation', 'duplication avoidance', 'HF 30-day readmission', 'HF readmission rate', 'Heart failure (HF) transition of care', 'HF 30-day readmission rate', 'readmission']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4517719', 'cui_str': '330 (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517724', 'cui_str': 'Three hundred and thirty-three'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4 (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0085555', 'cui_str': 'Hospice Care'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C4019079', 'cui_str': 'Care Transition'}]","[{'cui': 'C0031322', 'cui_str': 'Pharmacies'}, {'cui': 'C0023175', 'cui_str': 'Lead'}]","[{'cui': 'C0332597', 'cui_str': 'Duplication (finding)'}, {'cui': 'C0030700', 'cui_str': 'Thirty Day Readmission'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C4019079', 'cui_str': 'Care Transition'}]",663.0,0.0800841,"After adjusting for age, the intervention group continued to show a difference in readmission (odds ratio = 0.578; 95% CI = 0.367-0.911; P = 0.018).","[{'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Neu', 'Affiliation': 'Ascension St John Hospital, Detroit, MI, USA.'}, {'ForeName': 'Melvin A', 'Initials': 'MA', 'LastName': 'Leonard', 'Affiliation': 'Ascension St John Hospital, Detroit, MI, USA.'}, {'ForeName': 'Michelle L', 'Initials': 'ML', 'LastName': 'Dehoorne', 'Affiliation': 'Ascension St John Hospital, Detroit, MI, USA.'}, {'ForeName': 'Samantha J', 'Initials': 'SJ', 'LastName': 'Scalia', 'Affiliation': 'Ascension St John Hospital, Detroit, MI, USA.'}, {'ForeName': 'Pramodini B', 'Initials': 'PB', 'LastName': 'Kale-Pradhan', 'Affiliation': 'Ascension St John Hospital, Detroit, MI, USA.'}, {'ForeName': 'Christopher A', 'Initials': 'CA', 'LastName': 'Giuliano', 'Affiliation': 'Ascension St John Hospital, Detroit, MI, USA.'}]",The Annals of pharmacotherapy,['10.1177/1060028019882685'] 3075,31340023,Text message alerts to emergency physicians identifying potential study candidates increase clinical trial enrollment.,"Prospective enrollment of research subjects in the fast-paced emergency department (ED) is challenging. We sought to develop a software application to increase real-time clinical trial enrollment during an ED visit. The Prospective Intelligence System for Clinical Emergency Services (PISCES) scans the electronic health record during ED encounters for preselected clinical characteristics of potentially eligible study participants and notifies the treating physician via mobile phone text alerts. PISCES alerts began 3 months into a cluster randomized trial of an electronic health record-based risk stratification tool for pediatric abdominal pain in 11 Northern California EDs. We compared aggregate enrollment before (2577 eligible patients, October 2016 to December 2016) and after (12 049 eligible patients, January 2017 to January 2018) PISCES implementation. Enrollment increased from 10.8% to 21.1% following PISCES implementations (P < .001). PISCES significantly increased study enrollment and can serve as a valuable tool to assist prospective research enrollment in the ED.",2019,Enrollment increased from 10.8% to 21.1% following PISCES implementations (P < .001).,"['2577 eligible patients, October 2016 to December 2016) and after (12\xa0049 eligible patients, January 2017 to January 2018) PISCES implementation', 'pediatric abdominal pain in 11 Northern California EDs']",['electronic health record-based risk stratification tool'],[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C0006754', 'cui_str': 'California'}]","[{'cui': 'C2362543', 'cui_str': 'Electronic Medical Record'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}]",[],2577.0,0.0650214,Enrollment increased from 10.8% to 21.1% following PISCES implementations (P < .001).,"[{'ForeName': 'Laura E', 'Initials': 'LE', 'LastName': 'Simon', 'Affiliation': 'Division of Research, Kaiser Permanente, Oakland, California, USA.'}, {'ForeName': 'Adina S', 'Initials': 'AS', 'LastName': 'Rauchwerger', 'Affiliation': 'Division of Research, Kaiser Permanente, Oakland, California, USA.'}, {'ForeName': 'Uli K', 'Initials': 'UK', 'LastName': 'Chettipally', 'Affiliation': 'Emergency Department, Kaiser Permanente South San Francisco Medical Center, South San Francisco, California, USA.'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Babakhanian', 'Affiliation': 'Asolva Inc, Pasadena, California, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Vinson', 'Affiliation': 'Division of Research, Kaiser Permanente, Oakland, California, USA.'}, {'ForeName': 'E Margaret', 'Initials': 'EM', 'LastName': 'Warton', 'Affiliation': 'Division of Research, Kaiser Permanente, Oakland, California, USA.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Reed', 'Affiliation': 'Division of Research, Kaiser Permanente, Oakland, California, USA.'}, {'ForeName': 'Anupam B', 'Initials': 'AB', 'LastName': 'Kharbanda', 'Affiliation': ""Emergency Department, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, USA.""}, {'ForeName': 'Elyse O', 'Initials': 'EO', 'LastName': 'Kharbanda', 'Affiliation': 'Division of Research, HealthPartners Institute, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Dustin W', 'Initials': 'DW', 'LastName': 'Ballard', 'Affiliation': 'Division of Research, Kaiser Permanente, Oakland, California, USA.'}]",Journal of the American Medical Informatics Association : JAMIA,['10.1093/jamia/ocz118'] 3076,30219843,Human Immunodeficiency Virus-associated Neurocognitive Impairment in Diverse Resource-limited Settings.,"BACKGROUND Neurocognitive impairment remains a common complication of human immunodeficiency virus (HIV) despite effective antiretroviral therapy (ART). We previously reported improved neurocognitive functioning with ART initiation in 7 resource-limited countries for HIV+ participants from the AIDS Clinical Trials Group (ACTG) 5199 International Neurological Study (INS). Here, we apply normative data from the International Neurocognitive Normative Study (INNS) to INS to provide previously unknown rates of neurocognitive impairment. METHODS The A5199 INS assessed neurocognitive and neurological performance within a randomized clinical trial with 3 arms containing World Health Organization first-line recommended ART regimens (ACTG 5175; PEARLS). The ACTG 5271 INNS collected normative comparison data on 2400 high-risk HIV-negative participants from 10 voluntary counseling and testing sites aligned with INS. Normative comparison data were used to create impairment ratings for HIV+ participants in INS; associations were estimated using generalized estimating equations. RESULTS Among 860 HIV+ adults enrolled in ACTG 5199, 55% had no neurocognitive impairment at baseline. Mild neurocognitive impairment was found in 25%, moderate in 17%, and severe in 3% of participants. With the initiation of ART, the estimated odds of impairment were reduced 12% (95% confidence interval, 9%, 14%) for every 24 weeks (P < .0001) on ART. Mild impairment dropped slightly and then remained at about 18% out to week 168. CONCLUSIONS Almost half of HIV+ participants had neurocognitive impairment at baseline before ART, based on local norms. With ART initiation, there were significant overall reductions in neurocognitive impairment over time, especially in those with moderate and severe impairments. CLINICAL TRIALS REGISTRATION NCT00096824.",2019,"With the initiation of ART, the estimated odds of impairment was reduced 12% (95% CI: 9%, 14%) for every 24 weeks (p<.0001) on ART.","['860 HIV+ adults enrolled in ACTG 5199, 55% had no neurocognitive impairment at baseline', 'HIV+ participants from AIDS Clinical Trials Group (ACTG) 5199 (International Neurological Study (INS']",[],"['neurocognitive and neurological performance', 'Mild neurocognitive impairment', 'Mild impairment', 'neurocognitive impairment']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C1320290', 'cui_str': 'Clinical trial group'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]",[],"[{'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}]",,0.664029,"With the initiation of ART, the estimated odds of impairment was reduced 12% (95% CI: 9%, 14%) for every 24 weeks (p<.0001) on ART.","[{'ForeName': 'Kevin R', 'Initials': 'KR', 'LastName': 'Robertson', 'Affiliation': 'University of North Carolina, Chapel Hill, Massachusetts.'}, {'ForeName': 'Hongyu', 'Initials': 'H', 'LastName': 'Jiang', 'Affiliation': 'Harvard Chan School of Public Health, Boston, Massachusetts.'}, {'ForeName': 'Johnstone', 'Initials': 'J', 'LastName': 'Kumwenda', 'Affiliation': 'Queen Elizabeth College of Medicine-Johns Hopkins Project, Blantyre, Malawi.'}, {'ForeName': 'Khuanchai', 'Initials': 'K', 'LastName': 'Supparatpinyo', 'Affiliation': 'Chiang Mai University, Thailand.'}, {'ForeName': 'Christina M', 'Initials': 'CM', 'LastName': 'Marra', 'Affiliation': 'University of Washington, Seattle.'}, {'ForeName': 'Baiba', 'Initials': 'B', 'LastName': 'Berzins', 'Affiliation': 'Northwestern University, Chicago, Illinois.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Hakim', 'Affiliation': 'University of Zimbabwe, Harare.'}, {'ForeName': 'Ned', 'Initials': 'N', 'LastName': 'Sacktor', 'Affiliation': 'Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Thomas B', 'Initials': 'TB', 'LastName': 'Campbell', 'Affiliation': 'University of Colorado Health Sciences Center, Denver.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Schouten', 'Affiliation': 'Fred Hutchinson Cancer Center and University of Washington, Seattle.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Mollan', 'Affiliation': 'University of North Carolina, Chapel Hill, Massachusetts.'}, {'ForeName': 'Srikanth', 'Initials': 'S', 'LastName': 'Tripathy', 'Affiliation': 'National AIDS Research Institute, Pune, India.'}, {'ForeName': 'Nagalingeswaran', 'Initials': 'N', 'LastName': 'Kumarasamy', 'Affiliation': 'Gaitonde Centre for AIDS Research and Education, Chennai, India.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'La Rosa', 'Affiliation': 'Asociacion Civil Impacta Salud y Educacion, Lima, Peru.'}, {'ForeName': 'Breno', 'Initials': 'B', 'LastName': 'Santos', 'Affiliation': 'Hospital Conceicao, Porto Alegre, Brazil.'}, {'ForeName': 'Marcus T', 'Initials': 'MT', 'LastName': 'Silva', 'Affiliation': 'Fiocruz, Rio De Janeiro, Brazil.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Kanyama', 'Affiliation': 'UNC Project-Malawi, Lilongwe, Malawi.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Firhnhaber', 'Affiliation': 'University of Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Murphy', 'Affiliation': 'Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Hall', 'Affiliation': 'University of North Carolina, Chapel Hill, Massachusetts.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Marcus', 'Affiliation': 'University of North Carolina, Chapel Hill, Massachusetts.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Naini', 'Affiliation': 'Social Scientific Systems, Silver Springs, Maryland.'}, {'ForeName': 'Reena', 'Initials': 'R', 'LastName': 'Masih', 'Affiliation': 'Social Scientific Systems, Silver Springs, Maryland.'}, {'ForeName': 'Mina C', 'Initials': 'MC', 'LastName': 'Hosseinipour', 'Affiliation': 'University of North Carolina, Chapel Hill, Massachusetts.'}, {'ForeName': 'Rosie', 'Initials': 'R', 'LastName': 'Mngqibisa', 'Affiliation': 'Durban International CRS, South Africa.'}, {'ForeName': 'Sharlaa', 'Initials': 'S', 'LastName': 'Badal-Faesen', 'Affiliation': 'University of Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Yosief', 'Affiliation': 'University of North Carolina, Chapel Hill, Massachusetts.'}, {'ForeName': 'Alyssa', 'Initials': 'A', 'LastName': 'Vecchio', 'Affiliation': 'Universita Vita - Salute San Raffaele, Milan, Italy.'}, {'ForeName': 'Apsara', 'Initials': 'A', 'LastName': 'Nair', 'Affiliation': 'Frontier Science & Technology Research Foundation, Buffalo, New York.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciy767'] 3077,31903588,Randomized clinical trial of intraoperative dexmedetomidine to prevent delirium in the elderly undergoing major non-cardiac surgery.,"BACKGROUND Delirium is common in elderly patients after surgery and is associated with poor outcomes. This study aimed to investigate the impact of intraoperative dexmedetomidine on the incidence of delirium in elderly patients undergoing major surgery. METHODS This was a randomized double-blind placebo-controlled trial. Elderly patients (aged 60 years or more) scheduled to undergo major non-cardiac surgery were randomized into two groups. Patients in the intervention group received a loading dose of dexmedetomidine 0·6 μg/kg 10 min before induction of anaesthesia followed by a continuous infusion (0·5 μg per kg per h) until 1 h before the end of surgery. Patients in the control group received volume-matched normal saline in the same schedule. The primary outcome was the incidence of delirium during the first 5 days after surgery. Delirium was assessed with the Confusion Assessment Method (CAM) for non-ventilated patients and CAM for the Intensive Care Unit for ventilated patients. RESULTS In total, 309 patients who received dexmedetomidine and 310 control patients were included in the intention-to-treat analysis. The incidence of delirium within 5 days of surgery was lower with dexmedetomidine treatment: 5·5 per cent (17 of 309) versus 10·3 per cent (32 of 310) in the control group (relative risk (RR) 0·53, 95 per cent c.i. 0·30 to 0·94; P = 0·026). The overall incidence of complications at 30 days was also lower after dexmedetomidine (19·4 per cent (60 of 309) versus 26·1 per cent (81 of 310) for controls; RR 0·74, 0·55 to 0·99, P = 0·047). CONCLUSION Intraoperative dexmedetomidine halved the risk of delirium in the elderly after major non-cardiac surgery. Registration number: ChiCTR-IPR-15007654 ( www.chictr.org.cn).",2020,The overall incidence of complications at 30 days was also lower after dexmedetomidine (19·4 per cent (60 of 309) versus 26·1 per cent (81 of 310) for controls;,"['Elderly patients (aged 60\u2009years or more) scheduled to undergo major non-cardiac surgery', 'elderly patients after surgery', 'and 310 control patients were included in the intention-to-treat analysis', 'elderly undergoing major non-cardiac surgery', '309 patients who received', 'elderly patients undergoing major surgery', 'elderly after major non-cardiac surgery']","['placebo', 'dexmedetomidine 0·6', 'dexmedetomidine', 'intraoperative dexmedetomidine', 'volume-matched normal saline']","['incidence of delirium', 'Delirium', 'overall incidence of complications', 'risk of delirium']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",309.0,0.639431,The overall incidence of complications at 30 days was also lower after dexmedetomidine (19·4 per cent (60 of 309) versus 26·1 per cent (81 of 310) for controls;,"[{'ForeName': 'C-J', 'Initials': 'CJ', 'LastName': 'Li', 'Affiliation': 'Department of Anaesthesiology and Critical Care Medicine, Beijing, China.'}, {'ForeName': 'B-J', 'Initials': 'BJ', 'LastName': 'Wang', 'Affiliation': 'Department of Anaesthesiology and Critical Care Medicine, Beijing, China.'}, {'ForeName': 'D-L', 'Initials': 'DL', 'LastName': 'Mu', 'Affiliation': 'Department of Anaesthesiology and Critical Care Medicine, Beijing, China.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': 'Department of Anaesthesiology and Critical Care Medicine, Beijing, China.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Guo', 'Affiliation': 'Department of Anaesthesiology and Critical Care Medicine, Beijing, China.'}, {'ForeName': 'X-Y', 'Initials': 'XY', 'LastName': 'Li', 'Affiliation': 'Department of Biostatistics, Peking University First Hospital, Beijing, China.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Ma', 'Affiliation': 'Section of Anaesthetics, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Imperial College London, Chelsea and Westminster Hospital, London, UK.'}, {'ForeName': 'D-X', 'Initials': 'DX', 'LastName': 'Wang', 'Affiliation': 'Department of Anaesthesiology and Critical Care Medicine, Beijing, China.'}]",The British journal of surgery,['10.1002/bjs.11354'] 3078,31903600,"Randomized clinical trial of continuous transversus abdominis plane block, epidural or patient-controlled analgesia for patients undergoing laparoscopic colorectal cancer surgery.","BACKGROUND The optimal analgesia regimen after laparoscopic colorectal cancer surgery is unclear. The aim of the study was to characterize the beneficial effects of continuous transversus abdominis plane (TAP) blocks initiated before operation on outcomes following laparoscopic colorectal cancer surgery. METHODS Patients undergoing surgery for colorectal cancer were divided randomly into three groups: combined general-TAP anaesthesia (TAP group), combined general-thoracic epidural anaesthesia (TEA group) and standard general anaesthesia (GA group). The primary endpoint was duration of hospital stay. Secondary endpoints included gastrointestinal motility, pain scores and plasma levels of cytokines. RESULTS In total, 180 patients were randomized and 165 completed the trial. The intention-to-treat analysis showed that duration of hospital stay was significantly longer in the TEA group than in the TAP and GA groups (median 4·1 (95 per cent c.i. 3·8 to 4·3) versus 3·1 (3·0 to 3·3) and versus 3·3 (3·2 to 3·6) days respectively; both P < 0·001). Time to first flatus was earlier in the TAP group (P < 0·001). Visual analogue scale (VAS) scores during coughing were lower in the TAP and TEA groups than the GA group (P < 0·001). Raised plasma levels of vascular endothelial growth factor C, interleukin 6, adrenaline and cortisol were attenuated significantly by continuous TAP block. CONCLUSION Continuous TAP analgesia not only improved gastrointestinal motility but also shortened duration of hospital stay. A decreased opioid requirement and attenuating surgical stress response may be potential mechanisms. Registration number: ChiCTR-TRC-1800015535 ( http://www.chictr.org.cn).",2020,"Raised plasma levels of vascular endothelial growth factor C, interleukin 6, adrenaline and cortisol were attenuated significantly by continuous TAP block. ","['laparoscopic colorectal cancer surgery', '3·8 to 4·3) versus 3·1', '180 patients were randomized and 165 completed the trial', 'Patients undergoing surgery for colorectal cancer', 'patients undergoing laparoscopic colorectal cancer surgery']","['continuous transversus abdominis plane (TAP) blocks', 'TEA', 'continuous transversus abdominis plane block, epidural or patient-controlled analgesia', 'combined general-TAP anaesthesia (TAP group), combined general-thoracic epidural anaesthesia (TEA group) and standard general anaesthesia (GA group']","['Visual analogue scale (VAS) scores during coughing', 'gastrointestinal motility, pain scores and plasma levels of cytokines', 'Time to first flatus', 'Raised plasma levels of vascular endothelial growth factor C, interleukin 6, adrenaline and cortisol', 'gastrointestinal motility', 'duration of hospital stay']","[{'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319555', 'cui_str': '165 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0039400', 'cui_str': 'Tea'}, {'cui': 'C0078944', 'cui_str': 'Patient-Controlled Analgesia'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0034115', 'cui_str': 'Puncture and Drainage'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0002913', 'cui_str': 'Anesthesia, Extradural'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0002915', 'cui_str': 'General Anesthesia'}]","[{'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0017184', 'cui_str': 'Gastrointestinal Motility'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0442818', 'cui_str': 'Raised (qualifier value)'}, {'cui': 'C0388911', 'cui_str': 'Vascular Endothelial Growth Factor C'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",180.0,0.143759,"Raised plasma levels of vascular endothelial growth factor C, interleukin 6, adrenaline and cortisol were attenuated significantly by continuous TAP block. ","[{'ForeName': 'Y J', 'Initials': 'YJ', 'LastName': 'Xu', 'Affiliation': 'Department of Anaesthesiology, Fudan University Shanghai Cancer Centre, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Sun', 'Affiliation': 'Department of Anaesthesiology, Fudan University Shanghai Cancer Centre, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Jiang', 'Affiliation': 'Department of Anaesthesiology, Fudan University Shanghai Cancer Centre, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.'}, {'ForeName': 'Y H', 'Initials': 'YH', 'LastName': 'Yin', 'Affiliation': 'Department of Anaesthesiology, Fudan University Shanghai Cancer Centre, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.'}, {'ForeName': 'M L', 'Initials': 'ML', 'LastName': 'Weng', 'Affiliation': 'Department of Anaesthesiology, Fudan University Shanghai Cancer Centre, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.'}, {'ForeName': 'Z R', 'Initials': 'ZR', 'LastName': 'Sun', 'Affiliation': 'Department of Anaesthesiology, Fudan University Shanghai Cancer Centre, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.'}, {'ForeName': 'W K', 'Initials': 'WK', 'LastName': 'Chen', 'Affiliation': 'Department of Anaesthesiology, Fudan University Shanghai Cancer Centre, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.'}, {'ForeName': 'C H', 'Initials': 'CH', 'LastName': 'Miao', 'Affiliation': 'Department of Anaesthesiology, Fudan University Shanghai Cancer Centre, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.'}]",The British journal of surgery,['10.1002/bjs.11403'] 3079,30565955,A School-Based Comprehensive Intervention for Childhood Obesity in China: A Cluster Randomized Controlled Trial.,"BACKGROUND A comprehensive approach involving both environmental and individual strategies offers opportunities to strengthen school-based interventions for childhood obesity. OBJECTIVES To evaluate a theory-based comprehensive intervention implemented within primary schools for childhood obesity in China. METHODS A 1-year, cluster randomized controlled trial was conducted in twelve primary schools (7-11 years old) in Beijing, China. Environmental and individual factors were improved in the intervention group (6 schools, 930 children) to promote knowledge and behaviors related to energy balance. The control group (6 schools, 959 children) did not receive any intervention. The primary outcome was body mass index (BMI) and its Z-score at 12 months. Generalized linear mixed models were used controlling for the cluster effect of school. RESULTS No significant differences were found between groups on BMI (0.07 kg/m 2 [95% confidence interval (CI) -0.16 to 0.31, p = 0.54]) and its Z-score (0.02 [95% CI: -0.08 to 0.11, p = 0.73]) at 12 months. Self-reported knowledge, daily consumption of sugar-sweetened beverage, and frequency of moderate to vigorous physical activity improved at 12 months. CONCLUSIONS The intervention did not mitigate excess weight gain, but did improve children's knowledge and several behaviors related to energy balance.",2019,"The intervention did not mitigate excess weight gain, but did improve children's knowledge and several behaviors related to energy balance.","['Childhood Obesity in China', 'primary schools for childhood obesity in China', 'twelve primary schools (7-11 years old) in Beijing, China']",['School-Based Comprehensive Intervention'],"['BMI', ""children's knowledge and several behaviors related to energy balance"", 'Self-reported knowledge, daily consumption of sugar-sweetened beverage, and frequency of moderate to vigorous physical activity', 'body mass index (BMI) and its Z-score']","[{'cui': 'C2362324', 'cui_str': 'Childhood Onset Obesity'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0033145', 'cui_str': 'Primary Schools'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C4042832', 'cui_str': 'Peking'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0242209', 'cui_str': 'Sugars'}, {'cui': 'C0005329', 'cui_str': 'Beverages'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}]",959.0,0.0683128,"The intervention did not mitigate excess weight gain, but did improve children's knowledge and several behaviors related to energy balance.","[{'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': '1 Department of Maternal and Child Health, School of Public Health, Peking University, Beijing, China.'}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': '1 Department of Maternal and Child Health, School of Public Health, Peking University, Beijing, China.'}, {'ForeName': 'Ralph', 'Initials': 'R', 'LastName': 'Maddison', 'Affiliation': '2 Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Burwood, Australia.'}, {'ForeName': 'Cliona', 'Initials': 'C', 'LastName': 'Ni Mhurchu', 'Affiliation': '3 National Institute for Health Innovation, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Yannan', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': '3 National Institute for Health Innovation, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Dong-Mei', 'Initials': 'DM', 'LastName': 'Wei', 'Affiliation': '1 Department of Maternal and Child Health, School of Public Health, Peking University, Beijing, China.'}, {'ForeName': 'Lan', 'Initials': 'L', 'LastName': 'Cheng', 'Affiliation': '1 Department of Maternal and Child Health, School of Public Health, Peking University, Beijing, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Cheng', 'Affiliation': '1 Department of Maternal and Child Health, School of Public Health, Peking University, Beijing, China.'}, {'ForeName': 'Di', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': '1 Department of Maternal and Child Health, School of Public Health, Peking University, Beijing, China.'}, {'ForeName': 'Hai-Jun', 'Initials': 'HJ', 'LastName': 'Wang', 'Affiliation': '1 Department of Maternal and Child Health, School of Public Health, Peking University, Beijing, China.'}]",Childhood obesity (Print),['10.1089/chi.2018.0251'] 3080,32036693,"Secretin effects on gastric functions, hormones and symptoms in functional dyspepsia and health: randomized crossover trial.","Abnormal gastric accommodation (GA) and gastric emptying contribute to pathophysiology in functional dyspepsia (FD). Secretin is a key regulator of GA in animal studies. Our aim was to study the effects of secretin on gastric motility, satiation, postprandial symptoms, and key hormones. We performed two double-blind, randomized, saline-controlled crossover trials in 10 healthy volunteers and 10 patients with FD by Rome IV criteria. We used measured GA (by validated SPECT method) after a 111 In radiolabeled Ensure 300-mL meal and quantified gastric emptying for 30 min by scintigraphy. Satiation was measured by volume to fullness (VTF) and maximum tolerated volume (MTV) on an Ensure nutrient drink test and postprandial symptoms 30 min post-MTV. Fasting and postprandial GLP-1, GIP, and HPP were measured. The ages and sex distribution of healthy controls and patients with FD were similar. Compared with placebo, secretin delayed gastric emptying at 30 min in both health [-11% (-16, -4), P = 0.004]; and FD [-8% (-9, 0), P = 0.03]. Satiation (VTF and MTV), GA, and plasma levels of GLP-1, GIP, and HPP did not differ between treatment arms in health or FD. On ANCOVA analysis (adjusting for age and sex), secretin did not consistently increase postprandial symptoms in health or FD. Secretin delayed gastric emptying in both health and FD without significantly altering GA, VTF, or MTV or selected hormones. Thus, secretin receptor activation may provide a novel therapeutic mechanism for patients with FD and rapid gastric emptying. NEW & NOTEWORTHY The naturally occurring hormone secretin retards gastric emptying of solids without deleteriously affecting gastric accommodation, satiation, other upper gastrointestinal hormones, or postprandial symptoms. Given these findings, a subset of patients with rapid gastric emptying (e.g., the estimated 20% of patients with functional dyspepsia) could be candidates for treatments that stimulate a secretin receptor such as sacubitril, which inhibits neprilysin, an enzyme that degrades secretin.",2020,"Compared to placebo, secretin delayed gastric emptying at 30 minutes in both health [-11% (-16, -4); P=0.004] and FD [-8% (-9, 0); P=0.03].","['patients with FD and rapid gastric emptying', '10 healthy volunteers and 10 patients with FD by Rome IV criteria', 'DYSPEPSIA AND HEALTH', 'functional dyspepsia (FD']","['placebo', 'Secretin', 'secretin']","['postprandial symptoms in health or FD', 'Satiation (VTF and MTV), GA as well as plasma levels of GLP1, GIP and HPP', 'Abnormal gastric accommodation (GA) and gastric emptying', 'Fasting and postprandial GLP-1, GIP and HPP', 'secretin delayed gastric emptying', 'Secretin delayed gastric emptying', 'volume to fullness (VTF) and maximum tolerated volume (MTV', 'gastric motility, satiation, postprandial symptoms and key hormones']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0232584', 'cui_str': 'Rapid gastric emptying (finding)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0035831', 'cui_str': 'Rome'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0013395', 'cui_str': 'Indigestion'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0267167', 'cui_str': 'Nonulcer dyspepsia (disorder)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0036534', 'cui_str': 'Secretin'}]","[{'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036239', 'cui_str': 'Satiations'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1702020', 'cui_str': '37-epsilon-palmitoyl-Lys-GIP'}, {'cui': 'C0068293', 'cui_str': 'N-succinimidyl-3-(4-hydroxyphenyl)propionate'}, {'cui': 'C0205161', 'cui_str': 'Abnormal (qualifier value)'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C0000936', 'cui_str': 'Ocular Distance Accommodation'}, {'cui': 'C0017127', 'cui_str': 'Gastric Emptyings'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-Like Peptide 1'}, {'cui': 'C0036534', 'cui_str': 'Secretin'}, {'cui': 'C0740411', 'cui_str': 'Delayed gastric emptying (disorder)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0439650', 'cui_str': 'Fullness (qualifier value)'}, {'cui': 'C0232572', 'cui_str': 'Gastric motility, function (observable entity)'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}]",10.0,0.0959755,"Compared to placebo, secretin delayed gastric emptying at 30 minutes in both health [-11% (-16, -4); P=0.004] and FD [-8% (-9, 0); P=0.03].","[{'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Brandler', 'Affiliation': 'Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Laurence J', 'Initials': 'LJ', 'LastName': 'Miller', 'Affiliation': 'Mayo Clinic, Scottsdale, Arizona.'}, {'ForeName': 'Xiao Jing', 'Initials': 'XJ', 'LastName': 'Wang', 'Affiliation': 'Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Duane', 'Initials': 'D', 'LastName': 'Burton', 'Affiliation': 'Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Busciglio', 'Affiliation': 'Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Kayla', 'Initials': 'K', 'LastName': 'Arndt', 'Affiliation': 'Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'William S', 'Initials': 'WS', 'LastName': 'Harmsen', 'Affiliation': 'Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Camilleri', 'Affiliation': 'Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.'}]",American journal of physiology. Gastrointestinal and liver physiology,['10.1152/ajpgi.00371.2019'] 3081,32183783,"The impact of the Adolescent Girls Empowerment Program (AGEP) on short and long term social, economic, education and fertility outcomes: a cluster randomized controlled trial in Zambia.","BACKGROUND Adolescent girls in Zambia face risks and vulnerabilities that challenge their healthy development into young women: early marriage and childbearing, sexual and gender-based violence, unintended pregnancy and HIV. The Adolescent Girls Empowerment Program (AGEP) was designed to address these challenges by building girls' social, health and economic assets in the short term and improving sexual behavior, early marriage, pregnancy and education in the longer term. The two-year intervention included weekly, mentor-led, girls group meetings on health, life skills and financial education. Additional intervention components included a health voucher redeemable for general wellness and reproductive health services and an adolescent-friendly savings account. METHODS A cluster-randomized-controlled trial with longitudinal observations evaluated the impact of AGEP on key indicators immediately and two years after program end. Baseline data were collected from never-married adolescent girls in 120 intervention clusters (3515 girls) and 40 control clusters (1146 girls) and again two and four years later. An intent-to-treat analysis assessed the impact of AGEP on girls' social, health and economic assets, sexual behaviors, education and fertility outcomes. A treatment-on-the-treated analysis using two-stage, instrumental variables regression was also conducted to assess program impact for those who participated. RESULTS The intervention had modest, positive impacts on sexual and reproductive health knowledge after two and four years, financial literacy after two years, savings behavior after two and four years, self-efficacy after four years and transactional sex after two and four years. There was no effect of AGEP on the primary education or fertility outcomes, nor on norms regarding gender equity, acceptability of intimate partner violence and HIV knowledge. CONCLUSIONS Although the intervention led to sustained change in a small number of individual outcomes, overall, the intervention did not lead to girls acquiring a comprehensive set of social, health and economic assets, or change their educational and fertility outcomes. It is important to explore additional interventions that may be needed for the most vulnerable girls, particularly those that address household economic conditions. Additional attention should be given to the social and economic environment in which girls are living. TRIAL REGISTRATION ISRCTN29322231. Trial Registration Date: March 04, 2016; retrospectively registered.",2020,"There was no effect of AGEP on the primary education or fertility outcomes, nor on norms regarding gender equity, acceptability of intimate partner violence and HIV knowledge. ","['never-married adolescent girls in 120 intervention clusters (3515 girls) and 40 control clusters (1146 girls) and again two and four years later', 'Zambia', 'Adolescent girls']","['Adolescent Girls Empowerment Program (AGEP', 'AGEP', 'mentor-led, girls group meetings on health, life skills and financial education', 'health voucher redeemable for general wellness and reproductive health services and an adolescent-friendly savings account']","['gender equity, acceptability of intimate partner violence and HIV knowledge', ""girls' social, health and economic assets, sexual behaviors, education and fertility outcomes"", 'sexual and reproductive health knowledge', 'savings behavior']","[{'cui': 'C0027952', 'cui_str': 'Never Married'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043445', 'cui_str': 'Republic of Zambia'}]","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0863129', 'cui_str': 'AGEP'}, {'cui': 'C0025369', 'cui_str': 'Mentors'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0018261', 'cui_str': 'Group Meetings'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1136000', 'cui_str': 'Reproductive Health Services'}, {'cui': 'C4046102', 'cui_str': 'Savings Accounts'}]","[{'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013557', 'cui_str': 'economics'}, {'cui': 'C0036864', 'cui_str': 'Sexual Behavior'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0015895', 'cui_str': 'Fecundity'}, {'cui': 'C0242667', 'cui_str': 'Reproductive Health'}, {'cui': 'C0036245', 'cui_str': 'Savings'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]",,0.0562796,"There was no effect of AGEP on the primary education or fertility outcomes, nor on norms regarding gender equity, acceptability of intimate partner violence and HIV knowledge. ","[{'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Austrian', 'Affiliation': 'Population Council, Nairobi, Kenya. kaustrian@popcouncil.org.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Soler-Hampejsek', 'Affiliation': 'Independent Consultant, Barcelona, Spain.'}, {'ForeName': 'Jere R', 'Initials': 'JR', 'LastName': 'Behrman', 'Affiliation': 'University of Pennsylvania, Department of Economics, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Digitale', 'Affiliation': 'University of California, San Francisco, Deparment of Epidemiology and Biostatistics, San Francisco, California, USA.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Jackson Hachonda', 'Affiliation': 'Population Council, Lusaka, Zambia.'}, {'ForeName': 'Maximillian', 'Initials': 'M', 'LastName': 'Bweupe', 'Affiliation': 'Ministry of Health, Government of Republic of Zambia, Lusaka, Zambia.'}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'Hewett', 'Affiliation': 'Population Council, Washington, D.C., USA.'}]",BMC public health,['10.1186/s12889-020-08468-0'] 3082,32135136,Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.,"BACKGROUND Microalbuminuria is an early sign of kidney disease in people with diabetes and indicates increased risk of cardiovascular disease. We tested whether a urinary proteomic risk classifier (CKD273) score was associated with development of microalbuminuria and whether progression to microalbuminuria could be prevented with the mineralocorticoid receptor antagonist spironolactone. METHODS In this multicentre, prospective, observational study with embedded randomised controlled trial (PRIORITY), we recruited people with type 2 diabetes, normal urinary albumin excretion, and preserved renal function from 15 specialist centres in ten European countries. All participants (observational cohort) were tested with the CKD273 classifier and classified as high risk (CKD273 classifier score >0·154) or low risk (≤0·154). Participants who were classified as high risk were entered into a randomised controlled trial and randomly assigned (1:1), by use of an interactive web-response system, to receive spironolactone 25 mg once daily or matched placebo (trial cohort). The primary endpoint was development of confirmed microalbuminuria in all individuals with available data (observational cohort). Secondary endpoints included reduction in incidence of microalbuminuria with spironolactone (trial cohort, intention-to-treat population) and association between CKD273 risk score and measures of impaired renal function based on estimated glomerular filtration rate (eGFR; observational cohort). Adverse events (particularly gynaecomastia and hyperkalaemia) and serious adverse events were recorded for the intention-to-treat population (trial cohort). This study is registered with the EU Clinical Trials Register (EudraCT 20120-004523-4) and ClinicalTrials.gov (NCT02040441) and is completed. FINDINGS Between March 25, 2014, and Sept 30, 2018, we enrolled and followed-up 1775 participants (observational cohort), 1559 (88%) of 1775 participants had a low-risk urinary proteomic pattern and 216 (12%) had a high-risk pattern, of whom 209 were included in the trial cohort and assigned to spironolactone (n=102) or placebo (n=107). The overall median follow-up time was 2·51 years (IQR 2·0-3·0). Progression to microalbuminuria was seen in 61 (28%) of 216 high-risk participants and 139 (9%) of 1559 low-risk participants (hazard ratio [HR] 2·48, 95% CI 1·80-3·42; p<0·0001, after adjustment for baseline variables of age, sex, HbA 1c , systolic blood pressure, retinopathy, urine albumin-to-creatinine ratio [UACR], and eGFR). Development of impaired renal function (eGFR <60 mL/min per 1·73 m 2 ) was seen in 48 (26%) of 184 high-risk participants and 119 (8%) of 1423 low-risk participants (HR 3·50; 95% CI 2·50-4·90, after adjustment for baseline variables). A 30% decrease in eGFR from baseline (post-hoc endpoint) was seen in 42 (19%) of 216 high-risk participants and 62 (4%) of 1559 low-risk participants (HR 5·15, 95% CI 3·41-7·76; p<0·0001, after adjustment for basline eGFR and UACR). In the intention-to-treat trial cohort, development of microalbuminuria was seen in 35 (33%) of 107 in the placebo group and 26 (25%) of 102 in the spironolactone group (HR 0·81, 95% CI 0·49-1·34; p=0·41). In the safety analysis (intention-to-treat trial cohort), events of plasma potassium concentrations of more than 5·5 mmol/L were seen in 13 (13%) of 102 participants in the spironolactone group and four (4%) of 107 participants in the placebo group, and gynaecomastia was seen in three (3%) participants in the spironolactone group and none in the placebo group. One patient died in the placebo group due to a cardiac event (considered possibly related to study drug) and one patient died in the spironolactone group due to cancer, deemed unrelated to study drug. INTERPRETATION In people with type 2 diabetes and normoalbuminuria, a high-risk score from the urinary proteomic classifier CKD273 was associated with an increased risk of progression to microalbuminuria over a median of 2·5 years, independent of clinical characteristics. However, spironolactone did not prevent progression to microalbuminuria in high-risk patients. FUNDING European Union Seventh Framework Programme.",2020,"Development of impaired renal function (eGFR <60 mL/min per 1·73 m 2 ) was seen in 48 (26%) of 184 high-risk participants and 119 (8%) of 1423 low-risk participants (HR 3·50; 95% CI 2·50-4·90, after adjustment for baseline variables).","['Participants who were classified as high risk', 'recruited people with type 2 diabetes, normal urinary albumin excretion, and preserved renal function from 15 specialist centres in ten European countries', 'Between March 25, 2014, and Sept 30, 2018, we enrolled and followed-up 1775 participants (observational cohort), 1559 (88%) of 1775 participants had a low-risk urinary proteomic pattern and 216 (12%) had a high-risk pattern, of whom 209 were included in the trial cohort and assigned to', 'people with diabetes']","['placebo', 'spironolactone 25 mg once daily or matched placebo', 'spironolactone']","['development of confirmed microalbuminuria', 'Progression to microalbuminuria', 'reduction in incidence of microalbuminuria with spironolactone (trial cohort, intention-to-treat population) and association between CKD273 risk score and measures of impaired renal function', 'cardiac event', 'eGFR', 'urinary proteomic risk classifier (CKD273) score', 'Adverse events (particularly gynaecomastia and hyperkalaemia) and serious adverse events', 'gynaecomastia', 'systolic blood pressure, retinopathy, urine albumin-to-creatinine ratio [UACR], and eGFR', 'plasma potassium concentrations', 'progression to microalbuminuria']","[{'cui': 'C0008902', 'cui_str': 'Systematics'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0728887', 'cui_str': 'Preserving (attribute)'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0087009', 'cui_str': 'Specialists'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0454713', 'cui_str': 'European country (geographic location)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}, {'cui': 'C0872252', 'cui_str': 'Proteomics'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0990353', 'cui_str': 'Spironolactone 25 MG'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0037982', 'cui_str': 'Spironolactone'}]","[{'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0730345', 'cui_str': 'Microalbuminuria (finding)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0037982', 'cui_str': 'Spironolactone'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1565489', 'cui_str': 'Renal Insufficiency'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0872252', 'cui_str': 'Proteomics'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0018418', 'cui_str': 'Male Breast Enlargement'}, {'cui': 'C0020461', 'cui_str': 'Hyperpotassemia'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0035309', 'cui_str': 'Retinal Diseases'}, {'cui': 'C0042037'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0858155', 'cui_str': 'Plasma potassium'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",,0.573791,"Development of impaired renal function (eGFR <60 mL/min per 1·73 m 2 ) was seen in 48 (26%) of 184 high-risk participants and 119 (8%) of 1423 low-risk participants (HR 3·50; 95% CI 2·50-4·90, after adjustment for baseline variables).","[{'ForeName': 'Nete', 'Initials': 'N', 'LastName': 'Tofte', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Morten', 'Initials': 'M', 'LastName': 'Lindhardt', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Katarina', 'Initials': 'K', 'LastName': 'Adamova', 'Affiliation': 'University Clinic of Endocrinology, Diabetes and Metabolic Disorders, Skopje, Macedonia.'}, {'ForeName': 'Stephan J L', 'Initials': 'SJL', 'LastName': 'Bakker', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Beige', 'Affiliation': 'Division of Nephrology and KfH Renal Unit, Hospital St Georg, Leipzig, Germany; Martin-Luther University Halle, Wittenberg, Germany.'}, {'ForeName': 'Joline W J', 'Initials': 'JWJ', 'LastName': 'Beulens', 'Affiliation': 'Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Andreas L', 'Initials': 'AL', 'LastName': 'Birkenfeld', 'Affiliation': 'Department of Internal Medicine IV, Division of Endocrinology, Diabetology, and Nephrology, University Hospital Tübingen, Tübingen, Germany; Institute for Diabetes Research and Metabolic Diseases, Helmholtz Center Munich at Eberhard Karls University of Tübingen, Tübingen, Germany; German Center for Diabetes Research, Neuherberg, Germany.'}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Currie', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Delles', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Ingo', 'Initials': 'I', 'LastName': 'Dimos', 'Affiliation': 'Diabetespraxis, Leipzig, Germany.'}, {'ForeName': 'Lidmila', 'Initials': 'L', 'LastName': 'Francová', 'Affiliation': '1st Department, Charles University, Third Faculty of Medicine, Prague, Czech Republic.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Frimodt-Møller', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Girman', 'Affiliation': 'Diabetes Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.'}, {'ForeName': 'Rüdiger', 'Initials': 'R', 'LastName': 'Göke', 'Affiliation': 'Diabetologische Schwerpunktpraxis, Diabetologen Hessen, Marburg, Germany.'}, {'ForeName': 'Tereza', 'Initials': 'T', 'LastName': 'Havrdova', 'Affiliation': 'Diabetes Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.'}, {'ForeName': 'Hiddo J L', 'Initials': 'HJL', 'LastName': 'Heerspink', 'Affiliation': 'Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.'}, {'ForeName': 'Adriaan', 'Initials': 'A', 'LastName': 'Kooy', 'Affiliation': 'Bethesda Diabetes Research Center, Hoogeveen, Netherlands; Diabetes Vascular Research Foundation (DVRF), Hoogeveen, Netherlands; University Medical Center Groningen, Groningen, Netherlands.'}, {'ForeName': 'Gozewijn D', 'Initials': 'GD', 'LastName': 'Laverman', 'Affiliation': 'Department of Internal Medicine/Nephrology, Ziekenhuisgroep Twente Hospital, Almelo, Netherlands.'}, {'ForeName': 'Harald', 'Initials': 'H', 'LastName': 'Mischak', 'Affiliation': 'Mosaiques Diagnostics, Hannover, Germany.'}, {'ForeName': 'Gerjan', 'Initials': 'G', 'LastName': 'Navis', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.'}, {'ForeName': 'Giel', 'Initials': 'G', 'LastName': 'Nijpels', 'Affiliation': 'Department General Practice and Elderly Care, Amsterdam, Netherlands.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Noutsou', 'Affiliation': 'Diabetes Center, 2nd Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Hippokratio General Hospital, Athens, Greece.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Ortiz', 'Affiliation': 'Instituto de Investigacion Sanitaria de la Fundacion Jiménez Díaz UAM, Madrid, Spain.'}, {'ForeName': 'Aneliya', 'Initials': 'A', 'LastName': 'Parvanova', 'Affiliation': 'Department of Renal Medicine, Clinical Research Centre for Rare Diseases ""Aldo e CeleDaccò"": Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Bergamo, Italy.'}, {'ForeName': 'Frederik', 'Initials': 'F', 'LastName': 'Persson', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Petrie', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Piero L', 'Initials': 'PL', 'LastName': 'Ruggenenti', 'Affiliation': 'Department of Renal Medicine, Clinical Research Centre for Rare Diseases ""Aldo e CeleDaccò"": Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Bergamo, Italy.'}, {'ForeName': 'Femke', 'Initials': 'F', 'LastName': 'Rutters', 'Affiliation': 'Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, Netherlands.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Rychlík', 'Affiliation': '1st Department, Charles University, Third Faculty of Medicine, Prague, Czech Republic; Faculty Hospital Královské Vinohrady, Prague, Czech Republic.'}, {'ForeName': 'Justyna', 'Initials': 'J', 'LastName': 'Siwy', 'Affiliation': 'Mosaiques Diagnostics, Hannover, Germany.'}, {'ForeName': 'Goce', 'Initials': 'G', 'LastName': 'Spasovski', 'Affiliation': 'Department of Nephrology, Cyril and Methodius University in Skopje, Skopje, North Macedonia.'}, {'ForeName': 'Marijn', 'Initials': 'M', 'LastName': 'Speeckaert', 'Affiliation': 'Department of Nephrology, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Matias', 'Initials': 'M', 'LastName': 'Trillini', 'Affiliation': 'Department of Renal Medicine, Clinical Research Centre for Rare Diseases ""Aldo e CeleDaccò"": Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Bergamo, Italy.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Zürbig', 'Affiliation': 'Mosaiques Diagnostics, Hannover, Germany.'}, {'ForeName': 'Heiko', 'Initials': 'H', 'LastName': 'von der Leyen', 'Affiliation': 'Hannover Clinical Trial Center, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Rossing', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark; University of Copenhagen, Copenhagen, Denmark. Electronic address: peter.rossing@regionh.dk.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The lancet. Diabetes & endocrinology,['10.1016/S2213-8587(20)30026-7'] 3083,32004636,"Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.","BACKGROUND OLZ/SAM is a combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist, and is in development for the treatment of schizophrenia and bipolar I disorder. OLZ/SAM is under development with the intent to provide the established antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. This thorough QT study assessed the effects of therapeutic and supratherapeutic doses of OLZ/SAM on cardiac repolarization in patients with schizophrenia. METHODS In this randomized, double-blind, placebo- and positive (moxifloxacin)-controlled, parallel-group study, 100 patients aged 18 to 60 years with stable schizophrenia were randomized 3:2 to the active arm and control arm. Subjects in the active arm received a therapeutic dose of 10/10 mg (10 mg olanzapine/10 mg samidorphan) on days 2-4, 20/20 mg on days 5-8, and a supratherapeutic dose of 30/30 mg (1.5 times and 3 times the maximum recommended daily dose of olanzapine and samidorphan, respectively) on days 9-13, and moxifloxacin-matched placebo on days 1 and 14. Subjects in the control arm received a single oral dose of moxifloxacin 400 mg and moxifloxacin-matched placebo on days 1 and 14 in a nested crossover fashion, along with OLZ/SAM-matched placebo on days 2-13. Serial electrocardiograms (ECGs) and simultaneous plasma drug concentrations were determined pre- and post-dose. The effects of OLZ/SAM on heart rate and ECG parameters (QT interval with Fridericia's correction [QTcF], PR and QRS interval, and T-wave morphology) were evaluated, and the primary endpoint was change from baseline in QTcF (ΔQTcF). The relationship between drug concentration and ΔQTcF (C-QTc) was evaluated using a linear mixed-effects model. Safety monitoring included adverse events reporting and clinical laboratory assessments. RESULTS Based on primary analysis using C-QTc modeling, no clinically concerning QTc effect (ie, placebo-corrected ΔQTcF [ΔΔQTcF] ≥10 msec) was observed across the OLZ/SAM dose range tested (10/10 to 30/30 mg), up to olanzapine and samidorphan concentrations of approximately 110 and 160 ng/mL, respectively. The slope (90% confidence interval [CI]) of the C-QTc relationship was shallow and not significant for either olanzapine or samidorphan (0.03 [-0.01, 0.08] and 0.01 [-0.01, 0.04] msec per ng/mL, respectively). The predicted ΔΔQTcF (90% CI) was 2.33 (-2.72, 7.38) and 1.38 (-3.37, 6.12) msec at the observed geometric mean maximal concentration (C max ) of olanzapine (62.6 ng/mL) and samidorphan (75.1 ng/mL) on day 13, respectively. The study's assay sensitivity was confirmed by the C-QTc relationship of moxifloxacin. OLZ/SAM was well tolerated at all doses; adverse events occurring in >5% of subjects treated with OLZ/SAM were somnolence, weight increased, nausea, and dizziness. CONCLUSIONS This thorough QT study in patients with stable schizophrenia demonstrated that OLZ/SAM, in doses and plasma concentrations up to supratherapeutic levels, does not have a clinically relevant effect on ECG parameters, including QT/QTc prolongation.",2020,"OLZ/SAM was well tolerated at all doses; adverse events occurring in >5% of subjects treated with OLZ/SAM were somnolence, weight increased, nausea, and dizziness. ","['patients with stable schizophrenia', 'patients with schizophrenia', '100 patients aged 18 to 60\u202fyears with stable schizophrenia']","['olanzapine', 'OLZ/SAM', 'placebo-corrected ΔQTcF [ΔΔQTcF', 'olanzapine/10\u202fmg samidorphan', 'olanzapine and samidorphan, respectively) on days 9-13, and moxifloxacin-matched placebo', 'samidorphan', 'OLZ/SAM-matched placebo', 'olanzapine and samidorphan', 'moxifloxacin', 'moxifloxacin 400\u202fmg and moxifloxacin-matched placebo', 'placebo- and positive (moxifloxacin)-controlled']","['QTcF (ΔQTcF', 'drug concentration and ΔQTcF (C-QTc', 'assay sensitivity', 'somnolence, weight increased, nausea, and dizziness', ""heart rate and ECG parameters (QT interval with Fridericia's correction [QTcF], PR and QRS interval, and T-wave morphology"", 'QTc effect', 'cardiac repolarization', 'Serial electrocardiograms (ECGs) and simultaneous plasma drug concentrations', 'geometric mean maximal concentration (C max ']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C1563296', 'cui_str': 'Systolic anterior movement of mitral valve'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C4277369', 'cui_str': '3-carboxamido-4-hydroxynaltrexone'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1592286', 'cui_str': 'moxifloxacin 400 MG [Avelox]'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0860814', 'cui_str': 'QTc'}, {'cui': 'C1510438', 'cui_str': 'Assay technique (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C2830004', 'cui_str': 'Somnolence'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C1623258', 'cui_str': 'ECG'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0429028', 'cui_str': 'QT interval feature'}, {'cui': 'C0520880', 'cui_str': 'QRS interval'}, {'cui': 'C0429103', 'cui_str': 'T wave feature'}, {'cui': 'C0543482', 'cui_str': 'morphology'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0806909', 'cui_str': 'Max'}]",100.0,0.17629,"OLZ/SAM was well tolerated at all doses; adverse events occurring in >5% of subjects treated with OLZ/SAM were somnolence, weight increased, nausea, and dizziness. ","[{'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Sun', 'Affiliation': 'Alkermes, Inc., 852 Winter Street, Waltham, MA 02451, USA. Electronic address: lei.sun@alkermes.com.'}, {'ForeName': 'Sergey', 'Initials': 'S', 'LastName': 'Yagoda', 'Affiliation': 'Alkermes, Inc., 852 Winter Street, Waltham, MA 02451, USA.'}, {'ForeName': 'Hongqi', 'Initials': 'H', 'LastName': 'Xue', 'Affiliation': 'ERT, 150 Allens Creek Road, Rochester, NY 14618, USA.'}, {'ForeName': 'Randy', 'Initials': 'R', 'LastName': 'Brown', 'Affiliation': 'ERT, 150 Allens Creek Road, Rochester, NY 14618, USA.'}, {'ForeName': 'Narinder', 'Initials': 'N', 'LastName': 'Nangia', 'Affiliation': 'Alkermes, Inc., 852 Winter Street, Waltham, MA 02451, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'McDonnell', 'Affiliation': 'Alkermes Pharma Ireland Limited, Connaught House, 1 Burlington Road, Dublin 4 D04 C5Y6, Ireland.'}, {'ForeName': 'Bhaskar', 'Initials': 'B', 'LastName': 'Rege', 'Affiliation': 'Alkermes, Inc., 852 Winter Street, Waltham, MA 02451, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'von Moltke', 'Affiliation': 'Alkermes, Inc., 852 Winter Street, Waltham, MA 02451, USA.'}, {'ForeName': 'Borje', 'Initials': 'B', 'LastName': 'Darpo', 'Affiliation': 'ERT, 150 Allens Creek Road, Rochester, NY 14618, USA.'}]",Progress in neuro-psychopharmacology & biological psychiatry,['10.1016/j.pnpbp.2020.109881'] 3084,32069071,"Probiotic supplementation increases carbohydrate metabolism in trained male cyclists: a randomized, double-blind, placebo-controlled crossover trial.","We hypothesized that probiotic supplementation (PRO) increases the absorption and oxidation of orally ingested maltodextrin during 2 h endurance cycling, thereby sparing muscle glycogen for a subsequent time trial (simulating a road race). Measurements were made of lipid and carbohydrate oxidation, plasma metabolites and insulin, gastrointestinal (GI) permeability, and subjective symptoms of discomfort. Seven male cyclists were randomized to PRO (bacterial composition given in methods) or placebo for 4 wk, separated by a 14-day washout period. After each period, cyclists consumed a 10% maltodextrin solution (initial 8 mL/kg bolus and 2 mL/kg every 15 min) while exercising for 2 h at 55% maximal aerobic power output, followed by a 100-kJ time trial. PRO resulted in small increases in peak oxidation rates of the ingested maltodextrin (0.84 ± 0.10 vs. 0.77 ± 0.09 g/min; P = 0.016) and mean total carbohydrate oxidation (2.20 ± 0.25 vs. 1.87 ± 0.39 g/min; P = 0.038), whereas fat oxidation was reduced (0.40 ± 0.11 vs. 0.55 ± 0.10 g/min; P = 0.021). During PRO, small but significant increases were seen in glucose absorption, plasma glucose, and insulin concentration and decreases in nonesterified fatty acid and glycerol. Differences between markers of GI damage and permeability and time-trial performance were not significant ( P > 0.05). In contrast to the hypothesis, PRO led to minimal increases in absorption and oxidation of the ingested maltodextrin and small reductions in fat oxidation, whereas having no effect on subsequent time-trial performance.",2020,"During PRO small but significant increases were seen in glucose absorption, plasma glucose and insulin concentration and decreases in NEFA and glycerol.","['trained male cyclists', 'Seven male cyclists']","['PRO (bacterial composition given in methods) or placebo (PLC', 'maltodextrin solution', 'placebo', 'PRO', 'Probiotic supplementation', 'probiotic supplementation (PRO']","['carbohydrate metabolism', 'subsequent time trial performance', 'mean total carbohydrate oxidation', 'glucose absorption, plasma glucose and insulin concentration and decreases in NEFA and glycerol', 'fat oxidation', 'absorption and oxidation', 'GI damage and permeability and time trial performance', 'lipid and carbohydrate oxidation, plasma metabolites and insulin, gastrointestinal permeability, and subjective symptoms of discomfort', 'peak oxidation rates']","[{'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0205453', 'cui_str': '7'}]","[{'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}]","[{'cui': 'C0302820', 'cui_str': 'Carbohydrate Metabolism'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0030011', 'cui_str': 'Oxidation, function (observable entity)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0015688', 'cui_str': 'NEFA'}, {'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0010957', 'cui_str': 'Damage (morphologic abnormality)'}, {'cui': 'C0031164', 'cui_str': 'Permeability'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}]",,0.515573,"During PRO small but significant increases were seen in glucose absorption, plasma glucose and insulin concentration and decreases in NEFA and glycerol.","[{'ForeName': 'Jamie N', 'Initials': 'JN', 'LastName': 'Pugh', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Anton J M', 'Initials': 'AJM', 'LastName': 'Wagenmakers', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Dominic A', 'Initials': 'DA', 'LastName': 'Doran', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Simon C', 'Initials': 'SC', 'LastName': 'Fleming', 'Affiliation': 'Royal Cornwall Hospital, Truro, United Kingdom.'}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Fielding', 'Affiliation': 'Department of Nutritional Sciences, University of Surrey, Guildford, Surrey, United Kingdom.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Morton', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Graeme L', 'Initials': 'GL', 'LastName': 'Close', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}]",American journal of physiology. Endocrinology and metabolism,['10.1152/ajpendo.00452.2019'] 3085,32135135,Glycaemic status during pregnancy and longitudinal measures of fetal growth in a multi-racial US population: a prospective cohort study.,"BACKGROUND The timepoint at which fetal growth begins to differ by maternal glycaemic status is not well understood. To address this lack of data, we examined gestational diabetes, impaired glucose tolerance, and early pregnancy glucose concentrations in relation to fetal growth trajectories. METHODS This cohort study included 2458 pregnant women from the NICHD Fetal Growth Studies-Singletons study, which took place between 2009 and 2013. Women were recruited from 12 clinical centres in the USA. Women aged 18-40 years without major chronic conditions when entering pregnancy were included and those with records of neither glucose screening test or glucose tolerance test were excluded from the study. Women were enrolled at gestational weeks 8-13 and randomly assigned to four ultrasonogram schedules (Group A; weeks 16, 24, 30, 34; Group B: weeks 18, 26, 31, 35, 39; Group C: weeks 20, 28, 32, 36; Group D: weeks 22, 29, 33, 37, 41) to capture weekly fetal growth. Gestational diabetes, impaired glucose tolerance, and normal glucose tolerance were defined by medical record review. Glucose was measured in a subsample of women at weeks 10-14. We modelled fetal growth trajectories using linear mixed models with cubic splines. This study is registered with ClinicalTrials.gov, NCT00912132. FINDINGS Of the 2458 women included in this study, 107 (4·4%) had gestational diabetes, 118 (4·8%) had impaired glucose tolerance, and 2020 (82·2%) had NGT. 213 women were excluded from the main analysis. The cohort with gestational diabetes was associated with a larger estimated fetal weight that started at week 20 and was significant at week 28-40 (at week 37: 3061 g [95% CI 2967-3164] for women with gestational diabetes vs 2943 g [2924-2962] for women with normal glucose tolerance, adjusted p=0·02). In addition, glucose levels at weeks 10-14 were positively associated with estimated fetal weight starting at week 23 and the association became significant at week 27 (at week 37: 3073 g [2983-3167] in the highest tertile vs 2853 g [2755-2955] in the lowest tertile, adjusted p=0·0009. INTERPRETATION Gestational diabetes was associated with a larger fetal size that started at week 20 and became significant at gestational week 28. Efforts to mitigate gestational diabetes-related fetal overgrowth should start before 24-28 gestational weeks, when gestational diabetes is typically screened for in the USA. FUNDING National Institutes of Health.",2020,The cohort with gestational diabetes was associated with a larger estimated fetal weight that started at week 20 and was significant at week 28-40 (at week 37: 3061,"['Women were enrolled at gestational weeks 8-13', 'women with gestational diabetes vs 2943 g', '2458 women included in this study, 107 (4·4%) had gestational diabetes, 118 (4·8%) had impaired glucose tolerance, and 2020 (82·2%) had NGT', '2924-2962] for women with normal glucose tolerance, adjusted p=0·02', 'Women aged 18-40 years without major chronic conditions when entering pregnancy were included and those with records of neither glucose screening test or glucose tolerance test were excluded from the study', '213 women were excluded from the main analysis', '2458 pregnant women from the NICHD Fetal Growth Studies-Singletons study, which took place between 2009 and 2013', 'Women were recruited from 12 clinical centres in the USA']",[],"['glucose levels', 'Glucose', 'estimated fetal weight starting', 'Gestational diabetes, impaired glucose tolerance, and normal glucose tolerance', 'Glycaemic status']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439671', 'cui_str': 'Gestational (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4517529', 'cui_str': 'One hundred and seven'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C2355580', 'cui_str': 'Record of (contextual qualifier) (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0017741', 'cui_str': 'Glucose tolerance test (procedure)'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0205225', 'cui_str': 'Principal (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C1513896', 'cui_str': 'National Institute of Child Health and Human Development'}, {'cui': 'C0743925', 'cui_str': 'Fetal Growth'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]",[],"[{'cui': 'C0428548', 'cui_str': 'Glucose level - finding'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0751992', 'cui_str': 'Body Weight, Fetal'}, {'cui': 'C0439671', 'cui_str': 'Gestational (qualifier value)'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]",2458.0,0.105319,The cohort with gestational diabetes was associated with a larger estimated fetal weight that started at week 20 and was significant at week 28-40 (at week 37: 3061,"[{'ForeName': 'Mengying', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Stefanie N', 'Initials': 'SN', 'LastName': 'Hinkle', 'Affiliation': 'Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Grantz', 'Affiliation': 'Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Sungduk', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Jagteshwar', 'Initials': 'J', 'LastName': 'Grewal', 'Affiliation': 'Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'William A', 'Initials': 'WA', 'LastName': 'Grobman', 'Affiliation': 'Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.'}, {'ForeName': 'Daniel W', 'Initials': 'DW', 'LastName': 'Skupski', 'Affiliation': 'Department of Obstetrics and Gynecology, New York-Presbyterian Hospital Queens, Flushing, NY, USA.'}, {'ForeName': 'Roger B', 'Initials': 'RB', 'LastName': 'Newman', 'Affiliation': 'Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Edward K', 'Initials': 'EK', 'LastName': 'Chien', 'Affiliation': 'Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island, Providence, RI, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Sciscione', 'Affiliation': 'Christiana Care Health System, Newark, DE, USA.'}, {'ForeName': 'Noelia', 'Initials': 'N', 'LastName': 'Zork', 'Affiliation': 'Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY, USA.'}, {'ForeName': 'Deborah A', 'Initials': 'DA', 'LastName': 'Wing', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics-Gynecology, University of California School of Medicine, Irvine, CA, USA; Fountain Valley Regional Hospital and Medical Center, Fountain Valley, CA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Nageotte', 'Affiliation': 'Long Beach Memorial Medical Center, Long Beach, CA, USA.'}, {'ForeName': 'Fasil', 'Initials': 'F', 'LastName': 'Tekola-Ayele', 'Affiliation': 'Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Germaine M Buck', 'Initials': 'GMB', 'LastName': 'Louis', 'Affiliation': 'College of Health and Human Services, George Mason University, VA, USA.'}, {'ForeName': 'Paul S', 'Initials': 'PS', 'LastName': 'Albert', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Cuilin', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': 'Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. Electronic address: zhangcu@mail.nih.gov.'}]",The lancet. Diabetes & endocrinology,['10.1016/S2213-8587(20)30024-3'] 3086,32135138,"Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.","BACKGROUND In type 2 diabetes, long-acting GLP-1 receptor agonists lower fasting plasma glucose and improve glycaemic control via their insulinotropic and glucagonostatic effects. In type 1 diabetes, their efficacy as an add-on treatment to insulin therapy is modest. Short-acting GLP-1 receptor agonists also lower postprandial glucose excursions in type 2 diabetes by decelerating gastric emptying rate. We aimed to test the efficacy of a short-acting GLP-1 receptor agonist in type 1 diabetes. METHODS In the single-centre, parallel-group, randomised, double-blind, placebo-controlled MAG1C trial, patients with type 1 diabetes on multiple daily injection therapy aged 18 years and older with HbA 1c 59-88 mmol/mol (7·5-10·0%) and a BMI of more than 22·0 kg/m 2 were randomly assigned (1:1) through a computer-generated randomisation list to preprandial subcutaneous injection of 10 μg exenatide (Byetta) or placebo three times daily for 26 weeks as an add-on treatment to usual insulin therapy. Clinically assessed insulin titration was done by study staff. Participants and investigators were masked to treatment allocation. The primary endpoint was between-group difference in HbA 1c after 26 weeks. Data were analysed with a baseline-adjusted linear mixed model in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03017352, and is completed. FINDINGS Between Jan 4, 2017, and Jan 16, 2019, 108 participants were randomly assigned, 54 to exenatide and 54 to placebo; 23 participants discontinued treatment (17 in the exenatide group and six in the placebo group). From a baseline-adjusted mean of 66·4 mmol/mol (95% CI 64·9-67·8 [8·2%, 8·1-8·4]), HbA 1c changed by -3·2 mmol/mol (-5·0 to -1·4 [-0·3%, -0·5 to -0·1]) with exenatide and -2·1 mmol/mol (-3·7 to -0·6 [-0·2%, -0·3 to -0·1]) with placebo after 26 weeks (estimated treatment difference of -1·1 mmol/mol (-3·4 to 1·2 [-0·1%, -0·3 to 0·1]; p=0·36). Exenatide increased the number of self-reported gastrointestinal adverse events (primarily nausea [48 events among 37 patients with exenatide, nine with placebo among 9 patients]). Two serious adverse events occurred in the exenatide group, and six occurred in the placebo group (none were considered to be related to the study drug). INTERPRETATION Short-acting exenatide does not seem to have a future as a standard add-on treatment to insulin therapy in type 1 diabetes. FUNDING AstraZeneca.",2020,"Exenatide increased the number of self-reported gastrointestinal adverse events (primarily nausea [48 events among 37 patients with exenatide, nine with placebo among 9 patients]).","['Between Jan 4, 2017, and Jan 16, 2019', '108 participants', 'patients with type 1 diabetes on multiple daily injection therapy aged 18 years and older with HbA 1c 59-88 mmol/mol (7·5-10·0%) and a BMI of more than 22·0 kg/m 2', 'type 1 diabetes (MAG1C', '37 patients with']","['Short-acting GLP-1 receptor agonists', 'placebo-controlled MAG1C', 'placebo', 'exenatide (Byetta) or placebo three times daily for 26 weeks as an add-on treatment to usual insulin therapy', 'exenatide', 'Exenatide', 'exenatide and -2·1 mmol/mol (-3·7 to -0·6', 'short-acting GLP-1 receptor agonist', 'meal-time administration of short-acting exenatide', 'exenatide group and six in the placebo']","['Efficacy and safety', 'postprandial glucose excursions', 'number of self-reported gastrointestinal adverse events', 'adverse events']","[{'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mole - unit'}, {'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}]","[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0378073', 'cui_str': 'GLP-1 Receptor'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0167117', 'cui_str': 'exenatide'}, {'cui': 'C0556984', 'cui_str': 'Three times daily (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mole - unit'}, {'cui': 'C0587119', 'cui_str': 'Meal Times'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",108.0,0.568872,"Exenatide increased the number of self-reported gastrointestinal adverse events (primarily nausea [48 events among 37 patients with exenatide, nine with placebo among 9 patients]).","[{'ForeName': 'Nicklas J', 'Initials': 'NJ', 'LastName': 'Johansen', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Thomas F', 'Initials': 'TF', 'LastName': 'Dejgaard', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Denmark; Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.'}, {'ForeName': 'Asger', 'Initials': 'A', 'LastName': 'Lund', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Schlüntz', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.'}, {'ForeName': 'Christian S', 'Initials': 'CS', 'LastName': 'Frandsen', 'Affiliation': 'Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.'}, {'ForeName': 'Julie L', 'Initials': 'JL', 'LastName': 'Forman', 'Affiliation': 'Section of Biostatistics, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Nicolai J', 'Initials': 'NJ', 'LastName': 'Wewer Albrechtsen', 'Affiliation': 'Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jens J', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Ulrik', 'Initials': 'U', 'LastName': 'Pedersen-Bjergaard', 'Affiliation': 'Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Endocrinology and Nephrology, Nordsjællands Hospital Hillerød, University of Copenhagen, Hillerød, Denmark.'}, {'ForeName': 'Sten', 'Initials': 'S', 'LastName': 'Madsbad', 'Affiliation': 'Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Vilsbøll', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Henrik U', 'Initials': 'HU', 'LastName': 'Andersen', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Filip K', 'Initials': 'FK', 'LastName': 'Knop', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: filip.krag.knop.01@regionh.dk.'}]",The lancet. Diabetes & endocrinology,['10.1016/S2213-8587(20)30030-9'] 3087,31218661,Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.,"BACKGROUND Tildrakizumab is a specific anti-interleukin-23p19 monoclonal antibody approved for the treatment of plaque psoriasis. OBJECTIVES To evaluate the long-term efficacy and safety of tildrakizumab treatment for patients with moderate-to-severe psoriasis for up to 148 weeks. METHODS Pooled analysis from two double-blind, randomized controlled trials: reSURFACE 1 and reSURFACE 2. Efficacy was assessed for responders (≥ 75% improvement in Psoriasis Area and Severity Index; PASI 75) and partial responders (PASI 50-75) to tildrakizumab 100 mg and 200 mg at week 28 who were maintained on the same dose (administered every 12 weeks), and for partial responders or nonresponders (PASI < 50) to etanercept 50 mg at week 28 who, after a 4-week washout, were switched to tildrakizumab 200 mg (administered at weeks 32 and 36, and every 12 weeks thereafter). Safety was assessed in the all-patients-as-treated population. Three different methods of imputing missing data were used: nonresponder imputation (NRI), multiple imputation and observed cases. The Clinicaltrials.gov numbers are NCT01722331 (reSURFACE 1) and NCT01729754 (reSURFACE 2). RESULTS At week 148 (NRI), 72·6%, 53·8% and 28·9% of tildrakizumab 100-mg responders and 80·2%, 59·9% and 32·6% of tildrakizumab 200-mg responders had PASI 75, 90 and 100 responses, respectively. For partial responders to tildrakizumab 100 mg and 200 mg, the proportions of patients achieving PASI 75, 90 and 100 responses were 32·5%, 25·0% and 10·0%; and 47·1%, 27·5% and 12·8%, respectively. For patients who were partial responders or nonresponders to etanercept, the proportions of patients achieving PASI 75, 90 and 100 responses were 66·9%, 43·8% and 14·9% at week 148. Rates of discontinuations due to adverse events [tildrakizumab 100 mg: 1·7 per 100 patient-years (PYs); tildrakizumab 200 mg: 1·2 per 100 PYs] and exposure-adjusted rates of serious adverse events (5·9 per 100 PYs; 5·5 per 100 PYs), severe infections (1·1 per 100 PYs; 1·1 per 100 PYs), malignancies (0·6 per 100 PYs; 0·4 per 100 PYs) and major adverse cardiovascular events (0·4 per 100 PYs; 0·5 per 100 PYs) were low. CONCLUSIONS Tildrakizumab was well tolerated and efficacy was well maintained in week 28 responders who continued tildrakizumab treatment through 3 years, or improved among etanercept partial responders or nonresponders who switched to tildrakizumab. What's already known about this topic? Tildrakizumab 100 mg and 200 mg are efficacious and well tolerated with short-term use in the treatment of patients with moderate-to-severe plaque psoriasis. What does this study add? High levels of efficacy are maintained for up to 3 years of psoriasis treatment with tildrakizumab. There is a favourable long-term safety profile with both tildrakizumab 100 mg and 200 mg, with a low incidence of adverse events of special interest through 3 years.",2020,Tildrakizumab was well-tolerated and efficacy was well-maintained in week 28 responders who continued tildrakizumab treatment through three years or improved among etanercept partial responders/non-responders who switched to tildrakizumab.,"['moderate-to-severe psoriasis', 'moderate-to-severe psoriasis for up to 148 weeks']","['tildrakizumab', 'Tildrakizumab', 'etanercept']","['Efficacy', 'severe infections', 'tolerated and efficacy', 'major adverse cardiovascular events', 'exposure-adjusted rates of serious adverse events', 'PASI 75/PASI 90/PASI 100 responses', 'Safety']","[{'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C4043954', 'cui_str': 'tildrakizumab'}, {'cui': 'C0717758', 'cui_str': 'Etanercept'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0585901,Tildrakizumab was well-tolerated and efficacy was well-maintained in week 28 responders who continued tildrakizumab treatment through three years or improved among etanercept partial responders/non-responders who switched to tildrakizumab.,"[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Reich', 'Affiliation': 'Centre for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Skinflammation® Center, Hamburg, Germany.'}, {'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Warren', 'Affiliation': 'Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, U.K.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Iversen', 'Affiliation': 'Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Puig', 'Affiliation': 'Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Pau-Charles', 'Affiliation': 'Almirall R&D, Barcelona, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Igarashi', 'Affiliation': 'NTT Medical Center Tokyo, Tokyo, Japan.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ohtsuki', 'Affiliation': 'Department of Dermatology, Jichi Medical University, Tochigi, Japan.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Falqués', 'Affiliation': 'Almirall R&D, Barcelona, Spain.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Harmut', 'Affiliation': 'Almirall R&D, Barcelona, Spain.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Rozzo', 'Affiliation': 'Sun Pharmaceuticals, Princeton, NJ, U.S.A.'}, {'ForeName': 'M G', 'Initials': 'MG', 'LastName': 'Lebwohl', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Cantrell', 'Affiliation': 'Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, U.S.A.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Blauvelt', 'Affiliation': 'Oregon Medical Research Center, Portland, OR, U.S.A.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Thaçi', 'Affiliation': 'Institute and Comprehensive Centre for Inflammation Medicine, University of Lübeck, Lübeck, Germany.'}]",The British journal of dermatology,['10.1111/bjd.18232'] 3088,31403610,Can Creatine Combat the Mental Fatigue-associated Decrease in Visuomotor Skills?,"PURPOSE The importance of the brain in sports was recently confirmed by the negative effect of mental fatigue (MF) on sport-specific psychomotor skills. Creatine supplementation improves strength but can also improve cognitive functioning. To explore the role of creatine in combating MF, we evaluated whether creatine supplementation counteracts the MF-associated impairment in sport-specific psychomotor skills. METHODS In 23°C, 14 healthy participants (4 females, 10 males; mean ± SD, age = 24 ± 3 yr, mass = 74 ± 13 kg, height = 179 ± 9 cm) performed a 90-min mentally fatiguing task (counterbalanced, crossover, and double-blinded; i.e., Stroop task) in two different conditions: after a 7-d creatine supplementation (CR; 20 g·d) and after a 7-d calcium lactate supplementation (placebo [PLAC]), separated by a 5-wk washout. In both conditions, a 7-min sport-specific visuomotor task, a dynamic handgrip strength endurance task, and a 3-min Flanker task was performed before and after the mentally fatiguing task. Physiological and perceptual responses were measured throughout the protocol. RESULTS Handgrip strength endurance was higher in CR compared with PLAC (P = 0.022). MF impaired visuomotor response time (+4.4%; P = 0.022) and Flanker accuracy (-5.0%; P = 0.009) in both conditions. Accuracy on the Stroop task was higher in CR compared with PLAC (+4.9%; P = 0.026). Within the perceptual and physiological parameters, only motivation and vigor (P ≤ 0.027) were lower in CR compared with PLAC. CONCLUSION Creatine supplementation improved physical (strength endurance) and prolonged cognitive (Stroop accuracy) performance, yet it did not combat MF-induced impairments in short sport-specific psychomotor or cognitive (Flanker) performance. These results warrant further investigation in the potential role of creatine in combating the MF-associated decrements in prolonged (e.g., 90-min soccer game) sport performance and suggest a role of brain phosphocreatine in MF.",2020,Accuracy on the Stroop task was higher in CR compared to PLAC (+4.9%; p=0.026).,"['14 healthy participants (4F 10M; mean ± SD; age:24 ± 3 y; mass:74 ± 13 kg; height:179 ± 9 cm) performed -counterbalanced, crossover and double blinded- a 90-min mentally fatiguing task (i.e. Stroop task) in two different conditions: after a']","['7-day calcium lactate supplementation (PLAC; placebo', 'Creatine supplementation', '7-day creatine supplementation']","['Stroop task', 'Flanker accuracy', 'Visuomotor Skills', 'Physiological and perceptual responses', 'physical (strength endurance) and prolonged cognitive (Stroop accuracy) performance', 'cognitive functioning', 'Handgrip strength endurance', 'MF impaired visuomotor response time']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C2718024', 'cui_str': 'Stroop Task'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0108121', 'cui_str': 'calcium 2-hydroxypropanoate'}, {'cui': 'C0048838', 'cui_str': 'PLAC'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0010286', 'cui_str': 'Creatine'}]","[{'cui': 'C2718024', 'cui_str': 'Stroop Task'}, {'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0518031', 'cui_str': 'Endurance capacity'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}]",14.0,0.0776301,Accuracy on the Stroop task was higher in CR compared to PLAC (+4.9%; p=0.026).,"[{'ForeName': 'Jeroen', 'Initials': 'J', 'LastName': 'VAN Cutsem', 'Affiliation': 'Human Physiology and Sports Physiotherapy Research Group, Vrije Universiteit Brussel, Brussels, BELGIUM.'}, {'ForeName': 'Bart', 'Initials': 'B', 'LastName': 'Roelands', 'Affiliation': ''}, {'ForeName': 'Bert', 'Initials': 'B', 'LastName': 'Pluym', 'Affiliation': ''}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Tassignon', 'Affiliation': ''}, {'ForeName': 'J O', 'Initials': 'JO', 'LastName': 'Verschueren', 'Affiliation': ''}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'DE Pauw', 'Affiliation': ''}, {'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Meeusen', 'Affiliation': ''}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002122'] 3089,31425383,Exercise Training Modulates Gut Microbiota Profile and Improves Endotoxemia.,"INTRODUCTION Intestinal metabolism and microbiota profiles are impaired in obesity and insulin resistance. Moreover, dysbiotic gut microbiota has been suggested to promote systemic low-grade inflammation and insulin resistance through the release of endotoxins particularly lipopolysaccharides. We have previously shown that exercise training improves intestinal metabolism in healthy men. To understand whether changes in intestinal metabolism interact with gut microbiota and its release of inflammatory markers, we studied the effects of sprint interval (SIT) and moderate-intensity continuous training (MICT) on intestinal metabolism and microbiota in subjects with insulin resistance. METHODS Twenty-six, sedentary subjects (prediabetic, n = 9; type 2 diabetes, n = 17; age, 49 [SD, 4] yr; body mass index, 30.5 [SD, 3]) were randomized into SIT or MICT. Intestinal insulin-stimulated glucose uptake (GU) and fatty acid uptake (FAU) from circulation were measured using positron emission tomography. Gut microbiota composition was analyzed by 16S rRNA gene sequencing and serum inflammatory markers with multiplex assays and enzyme-linked immunoassay kit. RESULTS V˙O2peak improved only after SIT (P = 0.01). Both training modes reduced systematic and intestinal inflammatory markers (tumor necrosis factor-α, lipopolysaccharide binding protein) (time P < 0.05). Training modified microbiota profile by increasing Bacteroidetes phylum (time P = 0.03) and decreasing Firmicutes/Bacteroidetes ratio (time P = 0.04). Moreover, there was a decrease in Clostridium genus (time P = 0.04) and Blautia (time P = 0.051). Only MICT decreased jejunal FAU (P = 0.02). Training had no significant effect on intestinal GU. Colonic GU associated positively with Bacteroidetes and inversely with Firmicutes phylum, ratio Firmicutes/Bacteroidetes and Blautia genus. CONCLUSIONS Intestinal substrate uptake associates with gut microbiota composition and whole-body insulin sensitivity. Exercise training improves gut microbiota profiles and reduces endotoxemia.",2020,"Both training modes reduced systematic and intestinal inflammatory markers (TNF α, LBP) (time p<0.05).","['Twenty-six, sedentary subjects (prediabetic n=9, T2D n=17; age 49[SD 4] years; BMI 30.5[SD 3', 'healthy men']","['Exercise Training', 'sprint interval (SIT) and moderate intensity continuous training (MICT', 'exercise training', 'Exercise training', 'SIT or MICT']","['Gut Microbiota Profile and Improves Endotoxemia', 'intestinal GU', 'intestinal metabolism', 'Gut microbiota composition', 'jejunal FAU', 'Firmicutes/Bacteroidetes ratio', 'Clostridium genus', 'gut microbiota profiles and reduces endotoxemia', 'Intestinal insulin-stimulated glucose uptake (GU) and fatty acid uptake (FAU', 'systematic and intestinal inflammatory markers (TNF α, LBP']","[{'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}]","[{'cui': 'C4018878', 'cui_str': 'Gastrointestinal Microbial Community'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0376618', 'cui_str': 'Endotoxemia'}, {'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0022378', 'cui_str': 'Jejunum'}, {'cui': 'C0995456', 'cui_str': 'Bacteroidetes'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0009054', 'cui_str': 'Clostridium'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0015684', 'cui_str': 'Fatty Acids'}, {'cui': 'C0220922', 'cui_str': 'systematics'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}]",,0.0407134,"Both training modes reduced systematic and intestinal inflammatory markers (TNF α, LBP) (time p<0.05).","[{'ForeName': 'Kumail K', 'Initials': 'KK', 'LastName': 'Motiani', 'Affiliation': 'Turku PET Centre, University of Turku, Turku, FINLAND.'}, {'ForeName': 'M Carmen', 'Initials': 'MC', 'LastName': 'Collado', 'Affiliation': 'Institute of Agrochemistry and Food Technology-National Research Council (IATA-CSIC), Valencia, SPAIN.'}, {'ForeName': 'Jari-Joonas', 'Initials': 'JJ', 'LastName': 'Eskelinen', 'Affiliation': 'Turku PET Centre, University of Turku, Turku, FINLAND.'}, {'ForeName': 'Kirsi A', 'Initials': 'KA', 'LastName': 'Virtanen', 'Affiliation': 'Turku PET Centre, Turku University Hospital, Turku, FINLAND.'}, {'ForeName': 'Eliisa', 'Initials': 'E', 'LastName': 'Löyttyniemi', 'Affiliation': 'Department of Biostatistics, University of Turku, FINLAND.'}, {'ForeName': 'Seppo', 'Initials': 'S', 'LastName': 'Salminen', 'Affiliation': 'Functional Food Forum, University of Turku, FINLAND.'}, {'ForeName': 'Pirjo', 'Initials': 'P', 'LastName': 'Nuutila', 'Affiliation': 'Turku PET Centre, University of Turku, Turku, FINLAND.'}, {'ForeName': 'Kari K', 'Initials': 'KK', 'LastName': 'Kalliokoski', 'Affiliation': 'Turku PET Centre, University of Turku, Turku, FINLAND.'}, {'ForeName': 'Jarna C', 'Initials': 'JC', 'LastName': 'Hannukainen', 'Affiliation': 'Turku PET Centre, University of Turku, Turku, FINLAND.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002112'] 3090,32189314,[Bioavailability of natural versus synthetic B vitamins and their effects on metabolic processes].,"BACKGROUND Owing to the widespread use of vitamin supplements to prevent and compensate for deficiencies, the equivalence of natural versus synthetic vitamins with respect to their bioavailability and metabolic influence is discussed controversially. METHOD Thirty healthy female (n=22) and male participants (n=8) were investigated in a randomized, double-blind, cross-over study over a supplementation period of 6 weeks for each condition. The participants received a daily dose of a complex of the 8 natural B vitamins (group N), determined by the natural composition of quinoa seedlings, resp. synthetic B vitamins (group S), both corresponding to about 2.5 times the Recommended Dietary Allowance (RDA) of the national nutrition board. The primary criterion under investigation was changes in the blood levels of the individual B vitamins. Secondary criteria were the influence of both B complexes on homocysteine, antioxidant status, polyphenols, peroxide loading and peroxidase activity. RESULTS Compared to baseline values, serum levels of all B vitamins measured increased: Vitamins B1 (N +23%; S +27%), B2 (N +14%; S +13%), B6 (N +101%; S +101%), B9 (N +86%; S +153%) and B12 (N +16%) were elevated at the end of the first supplementation period (p < 0.05), while serum levels of vitamins B1, B9 and B12 remained elevated compared to baseline even after the 2-week washout phase. During the second supplementation period, the vitamin concentrations in group N, with the exception of vitamin B1, could be increased once again (p < 0.05). In contrast, in group S only for vitamins B2 and B12 substantial increases (p < 0.05) were found. The influence of B vitamins on metabolic parameters such as homocysteine and polyphenols, which were markedly reduced, was also clearly measurable; however, total antioxidant capacity and peroxidase activity increased. The peroxide concentration remained almost unchanged in both groups. CONCLUSION This clinical pilot study showed comparable bioavailability for both natural and synthetic B vitamins, with a 2.5-fold concentration of the RDA. Both vitamin B preparations showed a clear influence on metabolic parameters, whereas that of the natural B vitamins tended to have a slightly stronger effect than the synthetic analogues.",2020,"In contrast, in group S only for vitamins B2 and B12 substantial increases (p < 0.05) were found.",['Thirty healthy female (n=22) and male participants (n=8'],"['natural versus synthetic B vitamins', 'vitamin B preparations', 'B vitamins', 'complex of the 8 natural B vitamins', 'synthetic B vitamins', 'vitamin supplements']","['total antioxidant capacity and peroxidase activity', 'metabolic parameters', 'serum levels of all B vitamins measured increased: Vitamins B1', 'peroxide concentration', 'vitamin concentrations', 'homocysteine, antioxidant status, polyphenols, peroxide loading and peroxidase activity', 'blood levels of the individual B vitamins', 'serum levels of vitamins B1, B9 and B12']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0205296', 'cui_str': 'Natural (qualifier value)'}, {'cui': 'C3714647', 'cui_str': 'B Vitamins'}, {'cui': 'C0042849', 'cui_str': 'Vitamin B Complex'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0681579', 'cui_str': 'Vitamin supplement'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0031179', 'cui_str': 'Peroxidases'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C3714647', 'cui_str': 'B Vitamins'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0373727', 'cui_str': 'Vitamin B-1 measurement'}, {'cui': 'C0031180', 'cui_str': 'Peroxides'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0042890', 'cui_str': 'Vitamins'}, {'cui': 'C0019878', 'cui_str': '2-amino-4-mercaptobutyric acid'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0071649', 'cui_str': 'Polyphenol (substance)'}, {'cui': 'C0005768'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]",8.0,0.0702744,"In contrast, in group S only for vitamins B2 and B12 substantial increases (p < 0.05) were found.","[{'ForeName': 'Meinrad', 'Initials': 'M', 'LastName': 'Lindschinger', 'Affiliation': 'Institut für Ernährung und Stoffwechselerkrankungen, Laßnitzhöhe, Austria.'}, {'ForeName': 'Franz', 'Initials': 'F', 'LastName': 'Tatzber', 'Affiliation': 'Otto Loewi Forschungszentrum, Lehrstuhl für Immunologie und Pathophysiologie, Medizinische Universität Graz, Graz, Austria.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Schimetta', 'Affiliation': 'Abteilung für Angewandte Systemforschung und Statistik, Johannes Kepler Universität Linz, Linz, Austria.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Schmid', 'Affiliation': 'Institut für Ernährung und Stoffwechselerkrankungen, Laßnitzhöhe, Austria.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Lindschinger', 'Affiliation': 'Institut für Ernährung und Stoffwechselerkrankungen, Laßnitzhöhe, Austria.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Cvirn', 'Affiliation': 'Otto Loewi Forschungszentrum, Lehrstuhl für Physiologische Chemie, Medizinische Universität Graz, Neue Stiftingtalstraße 6 M1/D3, A-8010, Graz, Austria.'}, {'ForeName': 'Norbert', 'Initials': 'N', 'LastName': 'Fuchs', 'Affiliation': 'Institut für Nährstofftherapie, Lungau, Austria.'}, {'ForeName': 'Gertrude', 'Initials': 'G', 'LastName': 'Markolin', 'Affiliation': 'Institut für Nährstofftherapie, Lungau, Austria.'}, {'ForeName': 'Eugenia', 'Initials': 'E', 'LastName': 'Lamont', 'Affiliation': 'Klinische Abteilung für Gefäßforschung, Universitätsklinik für Chirurgie, Medizinische Universität Graz, Graz, Austria.'}, {'ForeName': 'Willibald', 'Initials': 'W', 'LastName': 'Wonisch', 'Affiliation': 'Otto Loewi Forschungszentrum, Lehrstuhl für Physiologische Chemie, Medizinische Universität Graz, Neue Stiftingtalstraße 6 M1/D3, A-8010, Graz, Austria. willibald.wonisch@medunigraz.at.'}]",MMW Fortschritte der Medizin,['10.1007/s15006-020-0230-4'] 3091,32186014,Effect of Jiawei Shenfu decoction on tumor necrosis factor-alpha and nuclear factor-kappa B in patients who have chronic heart failure with syndromes of deficiency of heart Yang.,"OBJECTIVE To examine the clinical efficacy of Jiawei Shenfu decoction on tumor necrosis factor-al- pha (TNF-α) and nuclear factor-kappa B (NF-κB) levels in patients who have chronic heart failure with syndromes of deficiency of heart Yang. METHODS A total of 63 patients with syndromes of deficiency of heart Yang (chronic heart failure) were enrolled. Patients were randomly divided into the control group and Jiawei Shenfu group. All patients received standard medications for treatment of chronic heart failure. Patients in the Jiawei Shenfu group were additionally provided Jiawei Shenfu decoction one dose daily. Treatments continued for 4 consecutive weeks. The primary endpoint was the change in plasma B-type natriuretic peptide (BNP), NF-κB, and TNF-α levels during 4 weeks of treatment. RESULTS At the 4-week follow-up, a significant reduction in BNP levels compared with baseline was observed in both groups, but the Jiawei Shenfu decoction group showed a significantly greater reduction than did the control group. The Jiawei Shenfu group also showed superior performance regarding the Minnesota Living with Heart Failure Questionnaire score, the Chinese medicine syndrome score, heart rate, left ventricular ejection fraction, and 6-min walking distance compared with the control group. The degree of changes in NF-κB and TNF-α levels in the Jiawei Shenfu group was more significant than that in the control group. CONCLUSION Routine medicine combined with Jiawei Shenfu decoction for patients with heart Yang deficiency syndrome in chronic heart failure can improve the left ventricular ejection fraction and cardiac function, and reduce BNP levels. The mechanism may be related to inhibition of pro-inflamma- tory cytokines and the NF-κB-induced kinase pathway, leading to amelioration of the inflammatory response.",2019,"The degree of changes in NF-κB and TNF-α levels in the Jiawei Shenfu group was more significant than that in the control group. ","['63 patients with syndromes of deficiency of heart Yang (chronic heart failure', 'patients who have chronic heart failure with syndromes of deficiency of heart Yang', 'patients with heart Yang deficiency syndrome in chronic heart failure']","['control group and Jiawei Shenfu group', 'standard medications', 'Routine medicine combined with Jiawei Shenfu decoction', 'Jiawei Shenfu decoction']","['Minnesota Living with Heart Failure Questionnaire score, the Chinese medicine syndrome score, heart rate, left ventricular ejection fraction, and 6-min walking distance', 'tumor necrosis factor-al- pha (TNF-α) and nuclear factor-kappa B (NF-κB) levels', 'BNP levels', 'tumor necrosis factor-alpha and nuclear factor-kappa B', 'change in plasma B-type natriuretic peptide (BNP), NF-κB, and TNF-α levels', 'NF-κB and TNF-α levels']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0011155', 'cui_str': 'Deficient (qualifier value)'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0264716', 'cui_str': 'Chronic heart failure (disorder)'}, {'cui': 'C0085258', 'cui_str': 'Yang Xu'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1528398', 'cui_str': 'Shen-Fu'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0026183', 'cui_str': 'Minnesota'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction (observable entity)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0429886', 'cui_str': 'Walking distance (observable entity)'}, {'cui': 'C0041368', 'cui_str': 'Tumor Necrosis Factors'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0079904', 'cui_str': 'Nuclear Factor-Kappab'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1095989', 'cui_str': 'Brain natriuretic peptide measurement (procedure)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0054015', 'cui_str': 'Nesiritide'}]",63.0,0.0184632,"The degree of changes in NF-κB and TNF-α levels in the Jiawei Shenfu group was more significant than that in the control group. ","[{'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Yu', 'Affiliation': 'Department of Cardiology, Shaoxing Traditional Chinese Medicine Hospital, The Affiliated Shaoxing Hospital of Zhejiang Chinese Medical University, Shaoxing 312000, China.'}, {'ForeName': 'Lingling', 'Initials': 'L', 'LastName': 'Ye', 'Affiliation': 'Department of Cardiology, Shaoxing Traditional Chinese Medicine Hospital, The Affiliated Shaoxing Hospital of Zhejiang Chinese Medical University, Shaoxing 312000, China.'}, {'ForeName': 'Jiaping', 'Initials': 'J', 'LastName': 'Bian', 'Affiliation': 'Department of Cardiology, Shaoxing Traditional Chinese Medicine Hospital, The Affiliated Shaoxing Hospital of Zhejiang Chinese Medical University, Shaoxing 312000, China.'}, {'ForeName': 'Lijuan', 'Initials': 'L', 'LastName': 'Ma', 'Affiliation': 'Department of Cardiology, Shaoxing Traditional Chinese Medicine Hospital, The Affiliated Shaoxing Hospital of Zhejiang Chinese Medical University, Shaoxing 312000, China.'}, {'ForeName': 'Chunli', 'Initials': 'C', 'LastName': 'Zheng', 'Affiliation': 'Department of Cardiology, Shaoxing Traditional Chinese Medicine Hospital, The Affiliated Shaoxing Hospital of Zhejiang Chinese Medical University, Shaoxing 312000, China.'}, {'ForeName': 'Hangyuan', 'Initials': 'H', 'LastName': 'Guo', 'Affiliation': ""Department of Cardiology, Shaoxing People's Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing 312000, China.""}]",Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan,[] 3092,31609301,Oral L-Tyrosine Supplementation Improves Core Temperature Maintenance in Older Adults.,"INTRODUCTION During cold exposure, an increase in sympathetic nerve activity evokes vasoconstriction (VC) of cutaneous vessels to minimize heat loss. In older adults, this reflex VC response is impaired thereby increasing their susceptibility to excess heat loss and hypothermia. Because L-tyrosine, the amino acid substrate necessary for catecholamine production, has been shown to augment reflex VC in age skin, we hypothesize that oral ingestion of L-tyrosine will attenuate the decline in core temperature (Tc) during whole-body cooling in older adults. METHODS In a randomized, double-blind design, nine young (25 ± 3 yr) and nine older (72 ± 8 yr) participants ingested either 150 mg·kg of L-tyrosine or placebo before commencing 90 min of whole-body cooling to decrease skin temperature to approximately 29.5°C. Esophageal temperature and forearm laser Doppler flux (LDF) were measured continuously throughout the protocol to provide an index of Tc and skin blood flow, respectively. The change in esophageal temperature (ΔTES) was the difference in temperature at the end of cooling subtracted from baseline. Cutaneous vascular conductance (CVC) was calculated as CVC = LDF/mean arterial pressure and expressed as a percent change from baseline (%ΔCVCBASELINE). RESULTS Oral tyrosine ingestion augmented the cutaneous VC response to cooling in older adults (placebo, 14.4 ± 2.0; tyrosine, 32.7% ± 1.7% ΔCVCBASELINE; P < 0.05). Additionally, tyrosine improved Tc maintenance throughout cooling in older adults (placebo, -0.29 ± 0.07; tyrosine, -0.07 ± 0.07 ΔTES; P < 0.05). Both the cutaneous VC and Tc during cooling were similar between young and older adults supplemented with tyrosine (P > 0.05). CONCLUSIONS These results indicate that L-tyrosine supplementation improves Tc maintenance in response to acute cold exposure in an older population.",2020,"Both the cutaneous VC and Tc during cooling were similar between young and older adults supplemented with tyrosine (p>0.05). ","['Older Adults', 'nine young (25 ± 3 years) and nine older (72 ± 8 years) participants', 'older adults']","['L-tyrosine supplementation', 'ingested either 150 mg/kg of L-tyrosine or placebo', 'Oral L-Tyrosine Supplementation']","['Cutaneous vascular conductance (CVC', 'cutaneous VC response', 'tyrosine improved Tc maintenance', 'change in esophageal temperature (ΔTES', 'skin temperature to ~29.5C. Esophageal temperature and forearm laser Doppler flux (LDF', 'Tc maintenance']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0041485', 'cui_str': 'L-tyrosine'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C4521174', 'cui_str': 'Cutaneous'}, {'cui': 'C0041485', 'cui_str': 'L-tyrosine'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}, {'cui': 'C0037294', 'cui_str': 'Skin Temperature'}, {'cui': 'C0016536', 'cui_str': 'Antebrachiums'}, {'cui': 'C0430489', 'cui_str': 'Laser doppler (procedure)'}]",,0.100166,"Both the cutaneous VC and Tc during cooling were similar between young and older adults supplemented with tyrosine (p>0.05). ","[{'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Lang', 'Affiliation': 'Department of Kinesiology, Iowa State University, Ames, IA.'}, {'ForeName': 'Alex C', 'Initials': 'AC', 'LastName': 'Krajek', 'Affiliation': 'Department of Physical Therapy, Des Moines University, Des Moines, IA.'}, {'ForeName': 'Kelsey S', 'Initials': 'KS', 'LastName': 'Schwartz', 'Affiliation': 'Department of Kinesiology, Iowa State University, Ames, IA.'}, {'ForeName': 'Joel E', 'Initials': 'JE', 'LastName': 'Rand', 'Affiliation': 'Department of Physical Therapy, Des Moines University, Des Moines, IA.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002188'] 3093,32164679,Bouldering psychotherapy is more effective in the treatment of depression than physical exercise alone: results of a multicentre randomised controlled intervention study.,"BACKGROUND Recent scientific studies have suggested that climbing/bouldering is effective in alleviating depression when the comparison group was a waitlist control group, even when physical activity and other therapeutic approaches were controlled for. In the present study, we aimed to investigate the effectiveness of a manualised psychotherapeutic bouldering intervention for depressed individuals, compared with an active control group performing physical exercise alone. METHODS In a multicentre randomised controlled intervention trial, 133 outpatients with depression were assigned to either a bouldering psychotherapy (BPT) group or a home-based supervised exercise programme (EP). Severity of depression as the primary outcome was assessed at baseline and directly after a ten-week intervention period using the Montgomery-Åsberg Depression Rating Scale (MADRS). Secondary outcomes included anxiety, coping skills, self-esteem, body image, and interpersonal sensitivity. We applied t-tests to test for differences within the groups (t0 vs. t1) and between the BPT and the EP and a multiple regression analysis with the post-intervention MADRS score as the dependent variable. The robustness of estimates was investigated with a sensitivity analyses. RESULTS Patients in the BPT group showed a significantly larger decrease in depression scores compared with the EP on the MADRS (drop of 8.4 vs. 3.0 points, p = .002, Cohen's d = 0.55). In the confounder-adjusted regression analyses, group allocation was found to be the only significant predictor of the post-intervention MADRS score (β = - 5.60, p = .001) besides the baseline MADRS score. Further significant differences in change scores between the BPT and the EP were found for anxiety (p = .046, d = 0.35), body image (p = .018, d = 0.42), and global self-esteem (p = .011, d = 0.45). CONCLUSIONS The study provides evidence that the manualised BPT is not only effective in alleviating depressive symptoms but even goes beyond the effect of mere physical exercise. Based on these findings, the BPT should be considered as a complementary therapeutic approach. TRIAL REGISTRATION Trial identification number: ISRCTN12457760: Study KuS (Klettern und Stimmung - Climbing and Mood) combined boulder and psychotherapy against depression, registered retrospectively on July 26th, 2017.",2020,"Further significant differences in change scores between the BPT and the EP were found for anxiety (p = .046, d = 0.35), body image (p = .018, d = 0.42), and global self-esteem (p = .011, d = 0.45). ",['133 outpatients with depression'],"['bouldering psychotherapy (BPT) group or a home-based supervised exercise programme (EP', 'BPT', 'active control group performing physical exercise alone', 'manualised psychotherapeutic bouldering intervention']","['Montgomery-Åsberg Depression Rating Scale (MADRS', 'baseline MADRS score', 'anxiety', 'MADRS', 'depression scores', 'global self-esteem', 'anxiety, coping skills, self-esteem, body image, and interpersonal sensitivity', 'change scores', 'post-intervention MADRS score']","[{'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]","[{'cui': 'C1273567', 'cui_str': 'Psychotherapy (specialty)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0036597', 'cui_str': 'Self Esteem'}, {'cui': 'C0086059', 'cui_str': 'Coping Skills'}, {'cui': 'C0005891', 'cui_str': 'Body Image'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]",133.0,0.07352,"Further significant differences in change scores between the BPT and the EP were found for anxiety (p = .046, d = 0.35), body image (p = .018, d = 0.42), and global self-esteem (p = .011, d = 0.45). ","[{'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Karg', 'Affiliation': 'Centre for Health Services Research in Medicine, Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany. nina.karg@uk-erlangen.de.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Dorscht', 'Affiliation': 'Centre for Health Services Research in Medicine, Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Kornhuber', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany.'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Luttenberger', 'Affiliation': 'Centre for Health Services Research in Medicine, Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany.'}]",BMC psychiatry,['10.1186/s12888-020-02518-y'] 3094,32056501,"Laser Ablation Versus Radiofrequency Ablation for Benign Non-Functioning Thyroid Nodules: Six-Month Results of a Randomized, Parallel, Open-Label, Trial (LARA Trial).","Background: No direct prospective studies comparing laser ablation (LA) and radiofrequency ablation (RFA) for debulking benign non-functioning thyroid nodules (BNTNs) exist. We aimed at comparing the efficacy and safety of both techniques in patients with solid or predominantly solid BNTN. Methods: This six-month, single-use, randomized, open-label, parallel trial compared the following primary endpoints between the RFA and LA groups six months after treatment: (i) nodule volume reduction expressed as a percentage of nodule volume at baseline; (ii) proportion of nodules with more than 50% reduction (successful rate). We enrolled subjects with a solitary BNTN or dominant nodule characterized by pressure symptoms/cosmetic problems or patients without symptoms who experienced a volume increase >20% in one year. Nodules underwent core needle biopsy for diagnosis. Patients were randomly assigned (1:1) to receive LA or RFA. Safety was assessed in all randomly assigned participants. Results: Sixty patients were randomly assigned to receive either RFA or LA (1:1) between January 2016 and November 2018. Both groups were similar in basal nodule volume, thyroid function, histology, symptoms/cosmetic score, and procedure time. At six months, the nodule volume reduction was 64.3% (95% confidence interval, CI 57.5-71.2) in the RFA group and 53.2% ([CI 47.2-95.2]; p  = 0.02) in the LA group. This effect was also confirmed in the linear regression model adjusted for age, baseline volume, and proportion of cellular component (LA vs. RFA percent change Delta = -12.8, p  = 0.02). No significant difference was observed in success rate six months after treatment (RFA vs. LA: 86.7% vs. 66.7%, p  = 0.13) or in thyrotropin level between the groups. Although improved, no significant difference was observed between RFA and LA for compressive symptoms (RFA: 2.13 vs. 3.9, p  < 0 · 001; LA: 2.4 vs. 3.87, p  < 0.001) and cosmetic score (RFA: 1.65 vs. 2.2, p  < 0.001; LA: 1.85 vs. 2.2, p  < 0.001). The adverse event rates (local pain, dysphonia, thyrotoxicosis, fever, hematoma) were 37% ( n  = 11) and 43% ( n  = 13) for RFA and LA, respectively, with no requirement for hospitalization. Conclusion: Although the success rate was similar in the RFA and LA groups, RFA achieved a significantly larger nodule volume reduction at six months.",2020,"No significant difference was observed in success rate 6-month after treatment (RFA vs LA: 86·7% vs 66·7%, p=0·13) or in thyrotropin level between the groups.","['enrolled subjects with a solitary BNTN or dominant nodule characterized by pressure symptoms/cosmetic problems or patients without symptoms who experienced a volume increase >20% in one year', 'patients with solid or predominantly solid BNTN', 'Sixty patients', 'benign non-functioning thyroid nodules']","['Laser Ablation versus Radiofrequency Ablation', 'RFA and LA', 'RFA or LA', 'laser ablation (LA) and radiofrequency ablation (RFA', 'Nodules underwent core needle biopsy (CNB', 'LA or RFA']","['efficacy and safety', 'cosmetic score', 'nodule volume reduction', 'basal nodule volume, thyroid function, histology, symptoms/cosmetic score, and procedure time', 'success rate', 'success rate 6-month', 'adverse event rates (local pain, dysphonia, thyrotoxicosis, fever, hematoma', 'thyrotropin level', 'RFA and LA for compressive symptoms', 'Safety']","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0028259', 'cui_str': 'Nodule (morphologic abnormality)'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0442965', 'cui_str': 'Cosmetic procedure (qualifier value)'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0302909', 'cui_str': 'Solid substance (substance)'}, {'cui': 'C0205183', 'cui_str': 'Benign (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0154141', 'cui_str': 'Toxic uninodular goiter with thyrotoxic crisis (disorder)'}]","[{'cui': 'C0348007', 'cui_str': 'Pulsed Laser Tissue Ablation'}, {'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C1318309', 'cui_str': 'Biopsy, Large-Core Needle'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0442965', 'cui_str': 'Cosmetic procedure (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0028259', 'cui_str': 'Nodule (morphologic abnormality)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C0040134', 'cui_str': 'thyroid (USP)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0344441', 'cui_str': 'Histologic test (procedure)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1527344', 'cui_str': 'Phonation Disorders'}, {'cui': 'C0040156', 'cui_str': 'Thyrotoxicosis'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0202230', 'cui_str': 'Thyroid stimulating hormone measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",60.0,0.111993,"No significant difference was observed in success rate 6-month after treatment (RFA vs LA: 86·7% vs 66·7%, p=0·13) or in thyrotropin level between the groups.","[{'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Cesareo', 'Affiliation': 'Unit of Metabolic Diseases, ""S.M. Goretti"" Hospital, Latina, Italy.'}, {'ForeName': 'Claudio Maurizio', 'Initials': 'CM', 'LastName': 'Pacella', 'Affiliation': 'Department of Diagnostic Imaging and Interventional Radiology, Regina Apostolorum Hospital, Albano Laziale, Italy.'}, {'ForeName': 'Valerio', 'Initials': 'V', 'LastName': 'Pasqualini', 'Affiliation': 'Department of Radiology and ""S.M. Goretti"" Hospital, Latina, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Campagna', 'Affiliation': 'Department of Internal Medicine, ""S.M. Goretti"" Hospital, Latina, Italy.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Iozzino', 'Affiliation': 'Department of Diagnostic Imaging and Interventional Radiology, Regina Apostolorum Hospital, Albano Laziale, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Gallo', 'Affiliation': 'Department of Sense Organs, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Lauria Pantano', 'Affiliation': 'Department of Internal Medicine, University Hospital Campus Bio-Medico, Rome, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Cianni', 'Affiliation': 'Department of Interventional Radiology, S. Camillo Hospital, Rome, Italy.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Pedone', 'Affiliation': 'Geriatric Unit, Campus Bio-Medico University, Rome, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Pozzilli', 'Affiliation': 'Unit of Endocrinology and Diabetes, Campus Bio-Medico University, Rome, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Taffon', 'Affiliation': 'Pathology Unit, University Hospital Campus Bio-Medico, Rome, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Crescenzi', 'Affiliation': 'Pathology Unit, University Hospital Campus Bio-Medico, Rome, Italy.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Manfrini', 'Affiliation': 'Unit of Endocrinology and Diabetes, Campus Bio-Medico University, Rome, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Palermo', 'Affiliation': 'Unit of Endocrinology and Diabetes, Campus Bio-Medico University, Rome, Italy.'}]",Thyroid : official journal of the American Thyroid Association,['10.1089/thy.2019.0660'] 3095,31639063,Multi-compositional MRI evaluation of repair cartilage in knee osteoarthritis with treatment of allogeneic human adipose-derived mesenchymal progenitor cells.,"BACKGROUND We used multimodal compositional magnetic resonance imaging (MRI) techniques, combined with clinical outcomes, to differentiate the alternations of composition in repair cartilage with allogeneic human adipose-derived mesenchymal progenitor cells (haMPCs) in knee osteoarthritis (KOA) patients. METHODS Eighteen patients participated a phase I/IIa clinical trial. All patients were divided randomly into three groups with intra-articular injections of haMPCs: the low-dose (1.0 × 10 7 cells), mid-dose (2.0 × 10 7 ), and high-dose (5.0 × 10 7 ) groups with six patients each. Compositional MRI examinations and clinical evaluations were performed at different time points. RESULTS Significant differences were observed in quantitative T1rho, T2, T2star, R2star, and ADC measurements in patients of three dose groups, suggesting a possible compositional changes of cartilage with the treatment of allogeneic haMPCs. Also significant reduction in WOMAC and SF-36 scores showed the symptoms might be alleviated to some extent with this new treatment. As regards sensibilities of multi-parametric mappings to detect compositional or structural changes of cartilage, T1rho mapping was most sensitive to differentiate difference between three dose groups. CONCLUSIONS These results showed that multi-compositional MRI sequences might be an effective tool to evaluate the promotion of the repair of cartilage with allogeneic haMPCs by providing information of compositional alterations of cartilage. TRIAL REGISTRATION Clinicaltrials, NCT02641860 . Registered 3 December 2015.",2019,"RESULTS Significant differences were observed in quantitative T1rho, T2, T2star, R2star, and ADC measurements in patients of three dose groups, suggesting a possible compositional changes of cartilage with the treatment of allogeneic haMPCs.","['Eighteen patients participated a phase I/IIa clinical trial', 'knee osteoarthritis (KOA) patients']","['multimodal compositional magnetic resonance imaging (MRI) techniques', 'allogeneic human adipose-derived mesenchymal progenitor cells', 'Multi-compositional MRI evaluation of repair cartilage', 'intra-articular injections of haMPCs', 'allogeneic human adipose-derived mesenchymal progenitor cells (haMPCs']","['quantitative T1rho, T2, T2star, R2star, and ADC measurements', 'WOMAC and SF-36 scores']","[{'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis, Knee'}]","[{'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C4552764', 'cui_str': 'Mesenchymal Progenitor Cell'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C0007301', 'cui_str': 'Cartilage'}, {'cui': 'C0021488', 'cui_str': 'Intra-Articular Injections'}]","[{'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0349639,"RESULTS Significant differences were observed in quantitative T1rho, T2, T2star, R2star, and ADC measurements in patients of three dose groups, suggesting a possible compositional changes of cartilage with the treatment of allogeneic haMPCs.","[{'ForeName': 'Xinxin', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 160, Pujian Road, Shanghai, 200127, China.'}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Ruan', 'Affiliation': 'Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 160, Pujian Road, Shanghai, 200127, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Tang', 'Affiliation': 'Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 160, Pujian Road, Shanghai, 200127, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 160, Pujian Road, Shanghai, 200127, China.'}, {'ForeName': 'Yingxuan', 'Initials': 'Y', 'LastName': 'Shi', 'Affiliation': 'Cellular Biomedicine Group, Inc., No. 85 Faladi Road, Building 3, Zhangjiang, Pudong New Area, Shanghai, 201210, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Cellular Biomedicine Group, Inc., No. 85 Faladi Road, Building 3, Zhangjiang, Pudong New Area, Shanghai, 201210, China.'}, {'ForeName': 'Suke', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Cellular Biomedicine Group, Inc., No. 85 Faladi Road, Building 3, Zhangjiang, Pudong New Area, Shanghai, 201210, China.'}, {'ForeName': 'Cuili', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': 'Cellular Biomedicine Group, Inc., No. 85 Faladi Road, Building 3, Zhangjiang, Pudong New Area, Shanghai, 201210, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Lu', 'Affiliation': 'Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 160, Pujian Road, Shanghai, 200127, China. drluqingsjtu@163.com.'}, {'ForeName': 'Chengxiang', 'Initials': 'C', 'LastName': 'Dai', 'Affiliation': 'Cellular Biomedicine Group, Inc., No. 85 Faladi Road, Building 3, Zhangjiang, Pudong New Area, Shanghai, 201210, China. chase.dai@cellbiomedgroup.com.'}]",Stem cell research & therapy,['10.1186/s13287-019-1406-7'] 3096,32169003,Randomized controlled trial of a sibling support group: Mental health outcomes for siblings of children with autism.,"LAY ABSTRACT Typically developing siblings of a child with autism spectrum disorder may show mental health difficulties. A support group is one approach to help typically developing siblings. During support groups, typically developing siblings discuss their feelings, learn coping strategies and problem-solving skills, and develop a peer network. We compared a support group to participation in a similar group without a focus on the sibling with autism spectrum disorder. Some areas of mental health improved. Improvements were also impacted by autism spectrum disorder symptom severity in the sibling with autism spectrum disorder. Findings suggest continuing to examine how support groups can help typically developing siblings and for which siblings support groups might be particularly effective.",2020,Findings suggest continuing to examine how support groups can help typically developing siblings and for which siblings support groups might be particularly effective.,['siblings of children with autism'],['sibling support group: Mental health outcomes'],['autism spectrum disorder symptom severity'],"[{'cui': 'C0037047', 'cui_str': 'Sibling'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}]","[{'cui': 'C0150345', 'cui_str': 'Sibling support (regime/therapy)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]","[{'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}]",,0.0316823,Findings suggest continuing to examine how support groups can help typically developing siblings and for which siblings support groups might be particularly effective.,"[{'ForeName': 'Emily A', 'Initials': 'EA', 'LastName': 'Jones', 'Affiliation': 'The City University of New York, USA.'}, {'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Fiani', 'Affiliation': 'The City University of New York, USA.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Stewart', 'Affiliation': 'Laureate Institute for Brain Research, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Neil', 'Affiliation': 'Western University, Canada.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'McHugh', 'Affiliation': 'The City University of New York, USA.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Fienup', 'Affiliation': 'The City University of New York, USA.'}]",Autism : the international journal of research and practice,['10.1177/1362361320908979'] 3097,32128909,Cancer worry and empathy moderate the effect of a survivorship-focused intervention on quality of life.,"OBJECTIVE This study examined the impact of a survivorship planning consultation (SPC) for patients with Hodgkin's lymphoma and diffuses large B-cell lymphoma on quality of life (QOL). We specifically assessed two potential moderators, cancer worry and perceived empathy, of the intervention effects on QOL. METHODS This cluster randomized, four-site trial examined the efficacy of a SPC; physicians received communication skills training and applied these skills in a survivorship-focused office visit using a care plan vs a control arm in which physicians were trained to and subsequently provided a time-controlled, manualized wellness rehabilitation consultation focused only on discussion of healthy nutrition and exercise. We examined the effect of the intervention on patients' QOL and examined potential moderators-cancer worry and perceived physician empathy. RESULTS Forty-two physicians and 198 patients participated. There was no main effect of the intervention on any of the QOL dimensions (ps > 0.10). However, cancer worry was a significant moderator of the effects of the intervention on three QOL domains (physical P = .04; social P = .04; spiritual P = .01) and perceived empathy was a significant moderator of QOL (physical P = .004; psychological P = .04; social P = .01). Specifically, the beneficial effects of the intervention were more pronounced among patients who initially reported higher levels of cancer worry and lower levels of physician empathy. CONCLUSIONS This study identified two factors, perceived empathy and cancer worry, that were found to impact the QOL of patients who participated in this communication-based survivorship intervention.",2020,There was no main effect of the intervention on any of the QOL dimensions (ps > 0.10).,"['Forty-two physicians and 198 patients participated', ""patients with Hodgkin's lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL"", 'patients who participated in this communication-based survivorship intervention']","['manualized Wellness Rehabilitation Consultation (WRC) focused only on discussion of healthy nutrition and exercise', 'survivorship planning consultation (SPC', 'communication skills training']","['QOL dimensions', 'quality of life', 'cancer worry and lower levels of physician empathy', 'quality of life (QOL']","[{'cui': 'C4319566', 'cui_str': 'Forty-two'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1266193', 'cui_str': 'Hodgkin lymphoma - category (morphologic abnormality)'}, {'cui': 'C0079744', 'cui_str': 'Diffuse Large-Cell Lymphoma'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0038955'}]","[{'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0557061', 'cui_str': 'Discussion (procedure)'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0038955'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning (observable entity)'}, {'cui': 'C4521398', 'cui_str': 'US Military enlisted E4'}, {'cui': 'C0588407', 'cui_str': 'Communication skills training (procedure)'}]","[{'cui': 'C0439534', 'cui_str': 'Dimensions (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0233481', 'cui_str': 'Worried (finding)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}]",198.0,0.0188331,There was no main effect of the intervention on any of the QOL dimensions (ps > 0.10).,"[{'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Parker', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Smita C', 'Initials': 'SC', 'LastName': 'Banerjee', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Matasar', 'Affiliation': 'Department of Medicine, Weill Cornell Medical College, New York, New York, USA.'}, {'ForeName': 'Carma L', 'Initials': 'CL', 'LastName': 'Bylund', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Schofield', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Yuelin', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Paul B', 'Initials': 'PB', 'LastName': 'Jacobsen', 'Affiliation': 'Division of Cancer Control & Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.'}, {'ForeName': 'Alan B', 'Initials': 'AB', 'LastName': 'Astrow', 'Affiliation': 'Department of Medicine, New York Methodist Hospital, Hematology and Oncology, Weill Cornell Medical College, New York, New York, USA.'}, {'ForeName': 'Howard', 'Initials': 'H', 'LastName': 'Leventhal', 'Affiliation': 'Department of Psychology, Rutgers University, New Brunswick, New Jersey, USA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Horwitz', 'Affiliation': 'Department of Medicine, Weill Cornell Medical College, New York, New York, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kissane', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.'}]",Psycho-oncology,['10.1002/pon.5371'] 3098,32156544,"Efficacy and safety of intravenous lidocaine in propofol-based sedation for ERCP procedures: a prospective, randomized, double-blinded, controlled trial.","BACKGROUND AND AIMS Propofol-based sedation is widely used in ERCP procedures, but adverse respiratory or cardiovascular events commonly occur. Intravenous injection of lidocaine has an analgesic effect and can reduce the requirements of fentanyl and propofol during abdominal surgery. The objective of this study was to assess the efficacy and safety of intravenous lidocaine on propofol requirements during ERCP procedures. METHODS Forty-eight patients scheduled for ERCP were randomly divided into 2 groups, the lidocaine group and the control group. All patients received .02 mg/kg midazolam and .1 μg/kg sufentanil intravenously as premedication. A bolus of propofol was applied for induction of sedation, and perfusion of propofol was applied for maintenance. Patients in the lidocaine group received a bolus of 1.5 mg/kg lidocaine intravenously followed by continuous infusion of 2 mg/kg/h, whereas the control group received the same volumes of saline solution. The primary outcome was the propofol requirement during ERCP. RESULTS Compared with the control group, propofol requirements were reduced by 33.8% in the lidocaine group (212.0 ± 118.2 mg vs 320.0 ± 189.6 mg, P = .023). Involuntary movement was less common in the lidocaine group than in the control group (12.5% vs 41.7%, P = .049). In the lidocaine group, postprocedure pain and fatigue, as measured by the visual analog scale, were significantly reduced (0 [range, 0-4] vs 3 [range, 0-5], P = .005; 2 [range, 0-4] vs 5 [range, 2-8], P < .001).The incidence of oxygen desaturation, hypotension, and bradycardia tended to be lower in the lidocaine group. CONCLUSIONS Intravenous lidocaine can significantly decrease propofol requirements during ERCP, with higher sedation quality and endoscopist satisfaction. (Clinical trial registration number: NCT03996577.).",2020,"Involuntary movement was less common in the lidocaine group than in the control group (12.5% vs 41.7%, p=0.049).",['Forty-eight patients scheduled for ERCP'],"['midazolam', 'propofol', 'propofol-based sedation', 'sufentanil', 'saline solution', 'lidocaine']","['propofol requirement during ERCP', 'Efficacy and safety', 'oxygen desaturation, hypotension, and bradycardia', 'efficacy and safety', 'Involuntary movement', 'sedation quality and endoscopist satisfaction', 'propofol requirements', 'postprocedure pain and fatigue']","[{'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C0008310', 'cui_str': 'ERCP'}]","[{'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}]","[{'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0008310', 'cui_str': 'ERCP'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0020649', 'cui_str': 'Blood Pressure, Low'}, {'cui': 'C0428977', 'cui_str': 'Bradyarrhythmia'}, {'cui': 'C0427086', 'cui_str': 'Involuntary Movements'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}]",48.0,0.0527241,"Involuntary movement was less common in the lidocaine group than in the control group (12.5% vs 41.7%, p=0.049).","[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China; Department of Anesthesiology, Qilu Hospital of Shandong University, Jinan, Shandong, China.'}, {'ForeName': 'Xiaoping', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, Qilu Hospital of Shandong University, Jinan, Shandong, China.'}, {'ForeName': 'Li-Ping', 'Initials': 'LP', 'LastName': 'Peng', 'Affiliation': 'Department of Anesthesiology, Qilu Hospital of Shandong University, Jinan, Shandong, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Ji', 'Affiliation': 'Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.'}, {'ForeName': 'Yan-Qing', 'Initials': 'YQ', 'LastName': 'Li', 'Affiliation': 'Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China; Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China; Robot Engineering Laboratory for Precise Diagnosis and Therapy of GI Tumor, Qilu Hospital of Shandong University, Jinan, Shandong, China.'}]",Gastrointestinal endoscopy,['10.1016/j.gie.2020.02.050'] 3099,32044339,The effects of a brief motivation manipulation on reward responsiveness: A multi-method study with implications for depression.,"Individual differences in reward responsiveness can be reliably measured at the neurophysiological level using the reward positivity (RewP) event-related potential (ERP). Alterations in reward responsiveness impact physical and psychological health. In particular, prior research indicates that a reduced RewP prospectively predicts depressive symptoms. However, it remains unclear whether RewP can be modified through intervention or prevention. The present study examined the effects of a brief motivation manipulation on behavioral, neural, and self-report indicators of reward responsiveness in an unselected sample of young adults (N = 98). Participants completed a monetary incentive delay task twice while ERPs to monetary reward and loss feedback were recorded. Before the first round, all participants were read standard instructions. For the second round, participants were randomized to either a motivation manipulation, in which the experimenter prompted the participant to focus on the positive outcomes of winning, or to a neutral condition. Participants completed a self-report questionnaire assessing motivation to win/not lose money following both rounds. Reaction time for incentive trials decreased, while RewP to wins and self-reported motivation increased, from the first to the second round only in the motivation group. These results provide the first evidence that a brief motivation manipulation can enhance multiple indicators of reward responsiveness, including RewP. Longitudinal research is needed to test whether effects persist across time and generalize to clinically depressed samples and those at high risk for depression.",2020,Individual differences in reward responsiveness can be reliably measured at the neurophysiological level using the reward positivity (RewP) event-related potential (ERP).,['unselected sample of young adults (N\u202f=\u202f98'],"['brief motivation manipulation', 'motivation manipulation']","['RewP to wins and self-reported motivation', 'reward responsiveness', 'monetary incentive delay task twice while ERPs to monetary reward and loss feedback', 'behavioral, neural, and self-report indicators of reward responsiveness', 'Reaction time', 'self-report questionnaire assessing motivation']","[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0947647', 'cui_str': 'Manipulation - action (qualifier value)'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",98.0,0.0465817,Individual differences in reward responsiveness can be reliably measured at the neurophysiological level using the reward positivity (RewP) event-related potential (ERP).,"[{'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Pegg', 'Affiliation': 'Vanderbilt University, Department of Psychology and Human Development, Peabody #552, 230 Appleton Place, Nashville, TN 37203, United States. Electronic address: samantha.l.pegg@vanderbilt.edu.'}, {'ForeName': 'Autumn', 'Initials': 'A', 'LastName': 'Kujawa', 'Affiliation': 'Vanderbilt University, Department of Psychology and Human Development, Peabody #552, 230 Appleton Place, Nashville, TN 37203, United States. Electronic address: autumn.kujawa@vanderbilt.edu.'}]",International journal of psychophysiology : official journal of the International Organization of Psychophysiology,['10.1016/j.ijpsycho.2020.02.004'] 3100,32146440,"The effects of circuit resistance training on plasma progranulin level, insulin resistance and body composition in obese men.","Background Progranulin (PGRN) is implicated in obesity and insulin resistance (IR). The aim of this study was to evaluate the effects of 8 weeks of circuit resistance training (CRT) on plasma PGRN, IR and body composition in obese men. Materials and methods Twenty-eight healthy obese men [age: 36 ± 7.7 years, body weight (BW): 96.4 ± 15.6 kg, body mass index (BMI): 32.4 ± 4.5 kg/m2] completed the study. Subjects were randomly assigned to two groups of control and training. Subjects in the training group underwent training for 8 weeks, 3 times a week. Blood samples and anthropometric characteristics were taken before the commencement of the exercise protocol and 72 h after the last training session. The homeostatic model assessment of insulin resistance (HOMA-IR) was used to measure IR. Results BW, BF%, BMI, waist-hip ratio (WHR), HOMA-IR and plasma PGRN levels except lean body mass (LBM) were significantly reduced in the training group (p < 0.05). Additionally, except for LBM, subjects in the training group had significantly decreased BW, BF%, BMI, WHR, HOMA-IR and plasma PGRN levels compared to changes in those in the control group (p < 0.05). Significant correlations were found between the changes in plasma PGRN and the changes in insulin, HOMA-IR and BMI (p < 0.05). Conclusions The findings showed that 8 weeks of CRT improved body composition and IR which were accompanied by reduced plasma PGRN levels. This study suggests that CRT has the potential for obese individuals to counteract obesity-associated health impairments.",2020,"Significant correlations were found between the changes in plasma PGRN and the changes in insulin, HOMA-IR and BMI (p < 0.05).","['obese men', 'obese individuals', 'Materials and methods Twenty-eight healthy obese men [age: 36 ± 7.7 years, body weight (BW): 96.4 ± 15.6 kg, body mass index (BMI): 32.4 ± 4.5 kg/m2] completed the study']","[' Progranulin (PGRN', 'circuit resistance training (CRT', 'circuit resistance training', 'CRT']","['plasma PGRN levels', 'plasma PGRN and the changes in insulin, HOMA-IR and BMI', 'Results BW, BF%, BMI, waist-hip ratio (WHR), HOMA-IR and plasma PGRN levels except lean body mass (LBM', 'body composition and IR', 'Blood samples and anthropometric characteristics', 'plasma PGRN, IR and body composition', 'homeostatic model assessment of insulin resistance (HOMA-IR', 'BW, BF%, BMI, WHR, HOMA-IR and plasma PGRN levels', 'plasma progranulin level, insulin resistance and body composition']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517860', 'cui_str': '7.7 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517709', 'cui_str': '32.4 (qualifier value)'}, {'cui': 'C3844009', 'cui_str': 'Four point five'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0168913', 'cui_str': 'Granulin Precursor Protein'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0025320', 'cui_str': 'Change of Life, Female'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205682', 'cui_str': 'Waist-Hip Ratio'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass (observable entity)'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0168913', 'cui_str': 'Granulin Precursor Protein'}]",28.0,0.0121934,"Significant correlations were found between the changes in plasma PGRN and the changes in insulin, HOMA-IR and BMI (p < 0.05).","[{'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Safarzade', 'Affiliation': 'Department of Exercise Physiology, Faculty of Sport Sciences, University of Mazandaran, Babolsar, Iran.'}, {'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Alizadeh', 'Affiliation': 'Department of Exercise Physiology, Faculty of Sport Sciences, University of Mazandaran, Babolsar, Iran.'}, {'ForeName': 'Zainab', 'Initials': 'Z', 'LastName': 'Bastani', 'Affiliation': 'Department of Exercise Physiology, Faculty of Sport Sciences, Islamic Azad University of Sari Branch, Sari, Iran.'}]",Hormone molecular biology and clinical investigation,['10.1515/hmbci-2019-0050'] 3101,31762155,Coronally advanced flap with connective tissue graft or xenogeneic acellular dermal matrix in the treatment of multiple gingival recessions: A split-mouth randomized clinical trial.,"OBJECTIVE To evaluate the clinical efficacy of xenogeneic acellular dermal matrix (XADM) or connective tissue graft (CTG) combined with modified-coronally advanced flap (M-CAF) in the treatment of multiple gingival recessions. MATERIALS AND METHODS Twelve participants with bilateral MGRs (multiple gingival recession) (82 gingival recessions) randomly received XADM (test group, 41 teeth) on one side and subepithelial CTG (control group, 41 teeth) on the other side in conjunction with M-CAF in the same session and completed the 18-months study period. Recession depth (RD), recession width (RW), keratinized tissue width (KTW), probing depth (PD), and clinical attachment level (CAL) were recorded at baseline, and 6-, 18-months postoperatively. RESULTS PD was significantly higher in the test group at 18-months (P < .05). PD in the test group was also significantly higher at 6- and 18-months compared to baseline (P < .05). RD and RW were significantly lower at 6- and 18-months compared to baseline in both groups (P < .05) and both parameters were significantly higher in the test group at 18-months (P < .05). Percentage of teeth with complete root coverage in the test and control groups were similar at 6-months (78% and 70.7%, respectively) and at 18-months (both 87.8%) (P > .05). CONCLUSION Within the limits of the study, M-CAF combined with XADM or CTG seems to be similarly effective in RD reduction of class I and II MGRs at least in the short term. Soft tissue shrinkage and increase in PD may be observed with XADM, while; CTG seems to provide stable clinical outcomes for 18-months follow-up. CLINICAL SIGNIFICANCE Even though the CTG and XADM in conjunction with M-CAF may provide similar RD reduction in class I and II multiple gingival recessions in the short term. CTGs may be superior in terms of soft tissue shrinkage and PD values.",2020,RD and RW were significantly lower at 6- and 18-months compared to baseline in both groups (P < .05) and both parameters were significantly higher in the test group at 18-months (P < .05).,"['Twelve participants with bilateral MGRs (multiple gingival recession) (82 gingival recessions) randomly received', 'multiple gingival recessions']","['xenogeneic acellular dermal matrix (XADM) or connective tissue graft (CTG) combined with modified-coronally advanced flap (M-CAF', 'XADM or CTG', 'side and subepithelial CTG (control group, 41 teeth) on the other side in conjunction with M-CAF', 'Coronally advanced flap with connective tissue graft or xenogeneic acellular dermal matrix', 'XADM']","['RD reduction of class', 'RD and RW', 'Recession depth (RD), recession width (RW), keratinized tissue width (KTW), probing depth (PD), and clinical attachment level (CAL', 'PD', 'Percentage of teeth with complete root coverage', 'Soft tissue shrinkage and increase in PD']","[{'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0017572', 'cui_str': 'Gingival Recession'}]","[{'cui': 'C3494272', 'cui_str': 'Acellular Dermal Matrix'}, {'cui': 'C0009780', 'cui_str': 'Connective Tissue'}, {'cui': 'C1527362', 'cui_str': 'grafts'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0038925', 'cui_str': 'Surgical Flaps'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}]","[{'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C0333047', 'cui_str': 'Recession (morphologic abnormality)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0487742', 'cui_str': 'Width (qualifier value)'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C3179165', 'cui_str': 'Probe (methazole)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0563017', 'cui_str': 'Anal penetration using finger (finding)'}, {'cui': 'C0225317', 'cui_str': 'Soft tissues (body structure)'}, {'cui': 'C0332513', 'cui_str': 'Shrinkage (finding)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}]",12.0,0.0226828,RD and RW were significantly lower at 6- and 18-months compared to baseline in both groups (P < .05) and both parameters were significantly higher in the test group at 18-months (P < .05).,"[{'ForeName': 'Önder', 'Initials': 'Ö', 'LastName': 'Gürlek', 'Affiliation': 'Department of Periodontology, School of Dentistry, Ege University, İzmir, Turkey.'}, {'ForeName': 'Pınar', 'Initials': 'P', 'LastName': 'Gümüş', 'Affiliation': 'Department of Periodontology, School of Dentistry, Ege University, İzmir, Turkey.'}, {'ForeName': 'Nejat', 'Initials': 'N', 'LastName': 'Nizam', 'Affiliation': 'Department of Periodontology, School of Dentistry, Ege University, İzmir, Turkey.'}, {'ForeName': 'Nurcan', 'Initials': 'N', 'LastName': 'Buduneli', 'Affiliation': 'Department of Periodontology, School of Dentistry, Ege University, İzmir, Turkey.'}]",Journal of esthetic and restorative dentistry : official publication of the American Academy of Esthetic Dentistry ... [et al.],['10.1111/jerd.12547'] 3102,31999862,An algorithm for diagnosing IgE-mediated food allergy in study participants who do not undergo food challenge.,"BACKGROUND Food allergy diagnosis in clinical studies can be challenging. Oral food challenges (OFC) are time-consuming, carry some risk and may, therefore, not be acceptable to all study participants. OBJECTIVE To design and evaluate an algorithm for detecting IgE-mediated food allergy in clinical study participants who do not undergo OFC. METHODS An algorithm for trial participants in the Barrier Enhancement for Eczema Prevention (BEEP) study who were unwilling or unable to attend OFC was developed. BEEP is a pragmatic, multi-centre, randomized-controlled trial of daily emollient for the first year of life for primary prevention of eczema and food allergy in high-risk infants (ISRCTN21528841). We built on the European iFAAM consensus guidance to develop a novel food allergy diagnosis algorithm using available information on previous allergenic food ingestion, food reaction(s) and sensitization status. This was implemented by a panel of food allergy experts blind to treatment allocation and OFC outcome. We then evaluated the algorithm's performance in both BEEP and Enquiring About Tolerance (EAT) study participants who did undergo OFC. RESULTS In 31/69 (45%) BEEP and 44/55 (80%) EAT study control group participants who had an OFC the panel felt confident enough to categorize children as ""probable food allergy"" or ""probable no food allergy"". Algorithm-derived panel decisions showed high sensitivity 94% (95%CI 68, 100) BEEP; 90% (95%CI 72, 97) EAT and moderate specificity 67% (95%CI 39, 87) BEEP; 67% (95%CI 39, 87) EAT. Sensitivity and specificity were similar when all BEEP and EAT participants with OFC outcome were included. CONCLUSION We describe a new algorithm with high sensitivity for IgE-mediated food allergy in clinical study participants who do not undergo OFC. CLINICAL RELEVANCE This may be a useful tool for excluding food allergy in future clinical studies where OFC is not conducted.",2020,"Algorithm-derived panel decisions showed high sensitivity 94% (95%CI 68, 100) BEEP; 90% (95%CI 72, 97) EAT and moderate specificity 67% (95%CI 39, 87) BEEP; 67% (95%CI 39, 87) EAT.","['study participants who do not undergo food challenge', 'clinical study participants who do not undergo OFC', ""clinical study participants who don't undergo OFC"", 'study participants who did undergo OFC']","['BEEP', 'BEEP and Enquiring About Tolerance (EAT']",['Sensitivity and specificity'],"[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}]","[{'cui': 'C0036668', 'cui_str': 'Sensitivity and Specificity'}]",,0.249941,"Algorithm-derived panel decisions showed high sensitivity 94% (95%CI 68, 100) BEEP; 90% (95%CI 72, 97) EAT and moderate specificity 67% (95%CI 39, 87) BEEP; 67% (95%CI 39, 87) EAT.","[{'ForeName': 'Maeve M', 'Initials': 'MM', 'LastName': 'Kelleher', 'Affiliation': 'Section of Inflammation, Repair & Development, National Heart & Lung Institute, Imperial College London, London, UK.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Jay', 'Affiliation': ""Children's Allergy Dept., Sheffield Children's NHS Foundation Trust, Sheffield, UK.""}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Perkin', 'Affiliation': ""Population Health Research Institute, St George's University of London, London, UK.""}, {'ForeName': 'Rachel H', 'Initials': 'RH', 'LastName': 'Haines', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Batt', 'Affiliation': ""Children's Allergy Service, Evelina Children's Hospital London, London, UK.""}, {'ForeName': 'Lucy E', 'Initials': 'LE', 'LastName': 'Bradshaw', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Alan A', 'Initials': 'AA', 'LastName': 'Montgomery', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Joanne R', 'Initials': 'JR', 'LastName': 'Chalmers', 'Affiliation': 'Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Hywel C', 'Initials': 'HC', 'LastName': 'Williams', 'Affiliation': 'Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Boyle', 'Affiliation': 'Section of Inflammation, Repair & Development, National Heart & Lung Institute, Imperial College London, London, UK.'}]",Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,['10.1111/cea.13577'] 3103,31982831,Group-based cognitive behavioral therapy program for improving poor sleep quality and quality of life in people with epilepsy: A pilot study.,"Sleep difficulties are commonly reported by patients with epilepsy and can have a detrimental impact on overall quality of life. The purpose of this pilot study was to assess the efficacy of a psychotherapeutic approach, namely Cognitive Behavioral Therapy for Insomnia (CBT-I), in improving sleep quality in patients with epilepsy. Twenty outpatients with epilepsy who reported poor sleep quality were randomized to either a control or CBT-I treatment group, which involved four group-based CBT-I sessions, delivered on a weekly basis. In addition to completing a range of standardized measures related to sleep quality and quality of life, participants also monitored their sleep with a self-completed sleep diary over a two-week period, on two separate occasions. Following CBT-I treatment, no between-group difference was found on any sleep or quality of life measure. However, both the treatment and control groups improved on measures of sleep quality, quality of life, sleep hygiene behaviors, and dysfunctional beliefs about sleep. These findings suggest that sleep monitoring alone may have the potential for prompting healthy behavior change in this clinical population.",2020,"However, both the treatment and control groups improved on measures of sleep quality, quality of life, sleep hygiene behaviors, and dysfunctional beliefs about sleep.","['Twenty outpatients with epilepsy who reported poor sleep quality', 'people with epilepsy', 'patients with epilepsy']","['psychotherapeutic approach, namely Cognitive Behavioral Therapy', 'cognitive behavioral therapy program', 'control or CBT']","['poor sleep quality and quality of life', 'sleep quality and quality of life, participants also monitored their sleep with a self-completed sleep diary', 'sleep or quality of life measure', 'sleep quality', 'sleep quality, quality of life, sleep hygiene behaviors, and dysfunctional beliefs about sleep']","[{'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0235162', 'cui_str': 'Difficulty sleeping (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0235162', 'cui_str': 'Difficulty sleeping (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0034380'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0376660', 'cui_str': 'Diary'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C4277672', 'cui_str': 'Sleep Hygiene'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}]",20.0,0.0202449,"However, both the treatment and control groups improved on measures of sleep quality, quality of life, sleep hygiene behaviors, and dysfunctional beliefs about sleep.","[{'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Paardekooper', 'Affiliation': 'School of Psychological Sciences, Australian College of Applied Psychology, Sydney, Australia.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Thayer', 'Affiliation': 'Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, Australia.'}, {'ForeName': 'Laurie', 'Initials': 'L', 'LastName': 'Miller', 'Affiliation': 'Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, Australia.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Nikpour', 'Affiliation': 'Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, Australia.'}, {'ForeName': 'Michael B', 'Initials': 'MB', 'LastName': 'Gascoigne', 'Affiliation': 'School of Psychological Sciences, Australian College of Applied Psychology, Sydney, Australia; School of Psychology, The University of Sydney, Australia. Electronic address: michael.gascoigne@acap.edu.au.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2019.106884'] 3104,31961420,Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial.,"Importance Renal denervation can reduce cardiac sympathetic activity that may result in an antiarrhythmic effect on atrial fibrillation. Objective To determine whether renal denervation when added to pulmonary vein isolation enhances long-term antiarrhythmic efficacy. Design, Setting, and Participants The Evaluate Renal Denervation in Addition to Catheter Ablation to Eliminate Atrial Fibrillation (ERADICATE-AF) trial was an investigator-initiated, multicenter, single-blind, randomized clinical trial conducted at 5 referral centers for catheter ablation of atrial fibrillation in the Russian Federation, Poland, and Germany. A total of 302 patients with hypertension despite taking at least 1 antihypertensive medication, paroxysmal atrial fibrillation, and plans for ablation were enrolled from April 2013 to March 2018. Follow-up concluded in March 2019. Interventions Patients were randomized to either pulmonary vein isolation alone (n = 148) or pulmonary vein isolation plus renal denervation (n = 154). Complete pulmonary vein isolation to v an end point of elimination of all pulmonary vein potentials; renal denervation using an irrigated-tip ablation catheter delivering radiofrequency energy to discrete sites in a spiral pattern from distal to proximal in both renal arteries. Main Outcomes and Measures The primary end point was freedom from atrial fibrillation, atrial flutter, or atrial tachycardia at 12 months. Secondary end points included procedural complications within 30 days and blood pressure control at 6 and 12 months. Results Of the 302 randomized patients (median age, 60 years [interquartile range, 55-65 years]; 182 men [60.3%]), 283 (93.7%) completed the trial. All successfully underwent their assigned procedures. Freedom from atrial fibrillation, flutter, or tachycardia at 12 months was observed in 84 of 148 (56.5%) of those undergoing pulmonary vein isolation alone and in 111 of 154 (72.1%) of those undergoing pulmonary vein isolation plus renal denervation (hazard ratio, 0.57; 95% CI, 0.38 to 0.85; P = .006). Of 5 prespecified secondary end points, 4 are reported and 3 differed between groups. Mean systolic blood pressure from baseline to 12 months decreased from 151 mm Hg to 147 mm Hg in the isolation-only group and from 150 mm Hg to 135 mm Hg in the renal denervation group (between-group difference, -13 mm Hg; 95% CI, -15 to -11 mm Hg; P < .001). Procedural complications occurred in 7 patients (4.7%) in the isolation-only group and 7 (4.5%) of the renal denervation group. Conclusions and Relevance Among patients with paroxysmal atrial fibrillation and hypertension, renal denervation added to catheter ablation, compared with catheter ablation alone, significantly increased the likelihood of freedom from atrial fibrillation at 12 months. The lack of a formal sham-control renal denervation procedure should be considered in interpreting the results of this trial. Trial Registration ClinicalTrials.gov Identifier: NCT01873352.",2020,"Mean systolic blood pressure from baseline to 12 months decreased from 151 mm Hg to 147 mm Hg in the isolation-only group and from 150 mm Hg to 135 mm Hg in the renal denervation group (between-group difference, -13 mm Hg; 95% CI, -15 to -11 mm Hg; P < .001).","[' 182 men [60.3%]), 283 (93.7%) completed the trial', '5 referral centers for catheter ablation of atrial fibrillation in the Russian Federation, Poland, and Germany', 'Patients With Paroxysmal Atrial Fibrillation and Hypertension', '302 patients with hypertension despite taking at least 1 antihypertensive medication, paroxysmal atrial fibrillation, and plans for ablation were enrolled from April 2013 to March 2018', '302 randomized patients (median age, 60 years [interquartile range, 55-65 years', 'patients with paroxysmal atrial fibrillation and hypertension']","['irrigated-tip ablation catheter delivering radiofrequency energy', 'pulmonary vein isolation alone (n\u2009=\u2009148) or pulmonary vein isolation plus renal denervation', 'catheter ablation alone', 'Renal Denervation and Catheter Ablation vs Catheter Ablation Alone', 'Catheter Ablation to Eliminate Atrial Fibrillation']","['Mean systolic blood pressure', 'freedom from atrial fibrillation, atrial flutter, or atrial tachycardia at 12 months', 'Atrial Fibrillation Recurrence', 'likelihood of freedom from atrial fibrillation', 'Procedural complications', 'Freedom from atrial fibrillation, flutter, or tachycardia', 'procedural complications within 30 days and blood pressure control']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C4708786', 'cui_str': 'Two hundred and eighty-three'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0162563', 'cui_str': 'Catheter Ablation'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}, {'cui': 'C0037045', 'cui_str': 'Russian S.F.S.R., Asian'}, {'cui': 'C0032356', 'cui_str': 'Republic of Poland'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0235480', 'cui_str': 'Paroxysmal atrial fibrillation (disorder)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0003364', 'cui_str': 'Anti-Hypertensive Drugs'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}]","[{'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1321798', 'cui_str': 'Muscle denervation'}, {'cui': 'C0162563', 'cui_str': 'Catheter Ablation'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}, {'cui': 'C0004239', 'cui_str': 'Auricular Flutter'}, {'cui': 'C0546959', 'cui_str': 'Atrial tachycardia (disorder)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C1141861', 'cui_str': 'Periprocedural complication'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",302.0,0.123224,"Mean systolic blood pressure from baseline to 12 months decreased from 151 mm Hg to 147 mm Hg in the isolation-only group and from 150 mm Hg to 135 mm Hg in the renal denervation group (between-group difference, -13 mm Hg; 95% CI, -15 to -11 mm Hg; P < .001).","[{'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Steinberg', 'Affiliation': 'University of Rochester School of Medicine & Dentistry, Heart Research Follow-up Program, Rochester, New York.'}, {'ForeName': 'Vitaliy', 'Initials': 'V', 'LastName': 'Shabanov', 'Affiliation': 'E. Meshalkin National Medical Research Center, Novosibirsk, Russian Federation.'}, {'ForeName': 'Dmitry', 'Initials': 'D', 'LastName': 'Ponomarev', 'Affiliation': 'E. Meshalkin National Medical Research Center, Novosibirsk, Russian Federation.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Losik', 'Affiliation': 'E. Meshalkin National Medical Research Center, Novosibirsk, Russian Federation.'}, {'ForeName': 'Eduard', 'Initials': 'E', 'LastName': 'Ivanickiy', 'Affiliation': 'E. Meshalkin National Medical Research Center, Novosibirsk, Russian Federation.'}, {'ForeName': 'Evgeny', 'Initials': 'E', 'LastName': 'Kropotkin', 'Affiliation': 'Federal Center of Cardiovascular Surgery, Krasnoyarsk, Russian Federation.'}, {'ForeName': 'Konstantin', 'Initials': 'K', 'LastName': 'Polyakov', 'Affiliation': 'Federal Center of Cardiovascular Surgery, Khabarovosk, Russian Federation.'}, {'ForeName': 'Pawel', 'Initials': 'P', 'LastName': 'Ptaszynski', 'Affiliation': 'Medical University Lodz, Lodz, Poland.'}, {'ForeName': 'Boris', 'Initials': 'B', 'LastName': 'Keweloh', 'Affiliation': 'Unfallkrankenhaus Berlin, Berlin, Germany.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Yao', 'Affiliation': 'University of Rochester School of Medicine & Dentistry, Heart Research Follow-up Program, Rochester, New York.'}, {'ForeName': 'Evgeny A', 'Initials': 'EA', 'LastName': 'Pokushalov', 'Affiliation': 'E. Meshalkin National Medical Research Center, Novosibirsk, Russian Federation.'}, {'ForeName': 'Alexander B', 'Initials': 'AB', 'LastName': 'Romanov', 'Affiliation': 'E. Meshalkin National Medical Research Center, Novosibirsk, Russian Federation.'}]",JAMA,['10.1001/jama.2019.21187'] 3105,31326924,Protocol for a non-randomised pilot and feasibility study evaluating a multicomponent intervention to simplify medication regimens for people receiving community-based home care services.,"INTRODUCTION Managing medication regimens is one of the most complex and burdensome tasks performed by older people, and can be prone to errors. People living with dementia may require medication administration assistance from formal and informal caregivers. Simplified medication regimens maintain the same therapeutic intent, but have less complex instructions and administration schedules. This protocol paper outlines a study to determine the feasibility of a multicomponent intervention to simplify medication regimens for people receiving community-based home care services. METHODS AND ANALYSIS This is a non-randomised pilot and feasibility study. Research nurses will recruit 50 people receiving community-based home care services. All participants will receive the intervention from a clinical pharmacist, who will undertake medication reconciliation, assess each participant's capacity to self-manage their medication regimen and apply a structured tool to identify opportunities for medication simplification. The pharmacist will communicate recommendations regarding medication simplification to registered nurses at the community-based home care provider organisation. The primary outcome will be a description of study feasibility (recruitment and retention rates, protocol adherence and stakeholder acceptability). Secondary outcomes include the change in number of medication administration times per day, medication adherence, quality of life, participant satisfaction, medication incidents, falls and healthcare utilisation at 4 months. ETHICS AND DISSEMINATION Ethical approval was obtained from the Monash University Human Research Ethics Committee and the community-based home care provider organisation's ethical review panel. Research findings will be disseminated to consumers and caregivers, health professionals, researchers and healthcare providers through the National Health and Medical Research Council Cognitive Decline Partnership Centre and through conference presentations, lay summaries and peer-reviewed publications. This study will enable an improved understanding of medication management and administration among people receiving community-based home care services. This study will inform the decision to proceed with a randomised controlled trial to assess the effect of this intervention. TRIAL REGISTRATION NUMBER ACTRN12618001130257; Pre-results.",2019,"Secondary outcomes include the change in number of medication administration times per day, medication adherence, quality of life, participant satisfaction, medication incidents, falls and healthcare utilisation at 4 months. ","['50 people receiving community-based home care services', 'people receiving community-based home care services', 'People living with dementia may require medication administration assistance from formal and informal caregivers']",['multicomponent intervention'],"['description of study feasibility (recruitment and retention rates, protocol adherence and stakeholder acceptability', 'change in number of medication administration times per day, medication adherence, quality of life, participant satisfaction, medication incidents, falls and healthcare utilisation at 4\u2009months']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0019855', 'cui_str': 'Domiciliary Care'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C3469597', 'cui_str': 'Medication treatment'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}]",[],"[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C3469597', 'cui_str': 'Medication treatment'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C2364172', 'cui_str': 'Medication Adherence'}, {'cui': 'C0034380'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]",,0.10118,"Secondary outcomes include the change in number of medication administration times per day, medication adherence, quality of life, participant satisfaction, medication incidents, falls and healthcare utilisation at 4 months. ","[{'ForeName': 'Janet Kathleen', 'Initials': 'JK', 'LastName': 'Sluggett', 'Affiliation': 'Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.'}, {'ForeName': 'Amy Theresa', 'Initials': 'AT', 'LastName': 'Page', 'Affiliation': 'Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.'}, {'ForeName': 'Esa Y H', 'Initials': 'EYH', 'LastName': 'Chen', 'Affiliation': 'Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.'}, {'ForeName': 'Jenni', 'Initials': 'J', 'LastName': 'Ilomäki', 'Affiliation': 'Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Corlis', 'Affiliation': 'National Health and Medical Research Council (NHMRC) Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Van Emden', 'Affiliation': 'National Health and Medical Research Council (NHMRC) Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Hogan', 'Affiliation': 'National Health and Medical Research Council (NHMRC) Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia.'}, {'ForeName': 'Tessa', 'Initials': 'T', 'LastName': 'Caporale', 'Affiliation': 'Research and Development, Helping Hand Aged Care, North Adelaide, South Australia, Australia.'}, {'ForeName': 'Manya', 'Initials': 'M', 'LastName': 'Angley', 'Affiliation': 'School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Sarah N', 'Initials': 'SN', 'LastName': 'Hilmer', 'Affiliation': 'National Health and Medical Research Council (NHMRC) Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia.'}, {'ForeName': 'Choon Ean', 'Initials': 'CE', 'LastName': 'Ooi', 'Affiliation': 'Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.'}, {'ForeName': 'J Simon', 'Initials': 'JS', 'LastName': 'Bell', 'Affiliation': 'Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.'}]",BMJ open,['10.1136/bmjopen-2018-025345'] 3106,32149427,Aromatic L-Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease.,"BACKGROUND As Parkinson's disease progresses, levodopa treatment loses efficacy, partly through the loss of the endogenous dopamine-synthesizing enzyme L-amino acid decarboxylase (AADC). In the phase I PD-1101 study, putaminal administration of VY-AADC01, an investigational adeno-associated virus serotype-2 vector for delivery of the AADC gene in patients with advanced Parkinson's disease, was well tolerated, improved motor function, and reduced antiparkinsonian medication requirements. OBJECTIVES This substudy aimed to determine whether the timing and magnitude of motor response to intravenous levodopa changed in PD-1101 patients after VY-AADC01 administration. METHODS Participants received 2-hour threshold (0.6 mg/kg/h) and suprathreshold (1.2 mg/kg/h) levodopa infusions on each of 2 days, both before and approximately 6 months after VY-AADC01. Infusion order was randomized and double blinded. Unified Parkinson's Disease Rating Scale motor scores, finger-tapping speeds, and dyskinesia rating scores were assessed every 30 minutes for 1 hour before and ≥3 hours after start of levodopa infusion. RESULTS Of 15 PD-1101 patients, 13 participated in the substudy. Unified Parkinson's Disease Rating Scale motor score area under the curve responses to threshold and suprathreshold levodopa infusions increased by 168% and 67%, respectively, after VY-AADC01; finger-tapping speeds improved by 162% and 113%, and dyskinesia scores increased by 208% and 72%, respectively, after VY-AADC01. Adverse events (mild/moderate severity) were reported in 5 participants during levodopa infusions pre-VY-AADC01 and 2 participants post-VY-AADC01 administration. CONCLUSIONS VY-AADC01 improved motor responses to intravenous levodopa given under controlled conditions. These data and findings from the parent study support further clinical development of AADC gene therapy for people with Parkinson's disease. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.",2020,"Unified Parkinson's Disease Rating Scale motor score area under the curve responses to threshold and suprathreshold levodopa infusions increased by 168% and 67%, respectively, after VY-AADC01; finger-tapping speeds improved by 162% and 113%, and dyskinesia scores increased by 208% and 72%, respectively, after VY-AADC01.","['2020', ""patients with advanced Parkinson's disease"", ""people with Parkinson's disease"", 'PD-1101 patients after VY-AADC01 administration', ""Parkinson's Disease"", 'Of 15 PD-1101 patients, 13 participated in the substudy']","['levodopa', 'Aromatic L-Amino Acid Decarboxylase Gene Therapy', 'levodopa infusions']","['dyskinesia scores', 'Adverse events', 'tapping speeds', 'Levodopa Response', ""Unified Parkinson's Disease Rating Scale motor score area under the curve responses to threshold and suprathreshold levodopa infusions"", 'motor responses', ""Unified Parkinson's Disease Rating Scale motor scores, finger-tapping speeds, and dyskinesia rating scores""]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C1533734', 'cui_str': 'Administration'}]","[{'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C1412028', 'cui_str': '5-Hydroxytryptophan Decarboxylase'}, {'cui': 'C0017296', 'cui_str': 'Gene therapy (procedure)'}]","[{'cui': 'C1869094', 'cui_str': 'Dyskinesia (SMQ)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0034115', 'cui_str': 'Puncture and Drainage'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C0222045'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0449864', 'cui_str': 'Threshold (property) (qualifier value)'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C1285623', 'cui_str': 'Motor response'}, {'cui': 'C0016129', 'cui_str': 'Fingers'}]",,0.114359,"Unified Parkinson's Disease Rating Scale motor score area under the curve responses to threshold and suprathreshold levodopa infusions increased by 168% and 67%, respectively, after VY-AADC01; finger-tapping speeds improved by 162% and 113%, and dyskinesia scores increased by 208% and 72%, respectively, after VY-AADC01.","[{'ForeName': 'John G', 'Initials': 'JG', 'LastName': 'Nutt', 'Affiliation': 'Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.'}, {'ForeName': 'Carolin', 'Initials': 'C', 'LastName': 'Curtze', 'Affiliation': 'Department of Biomechanics, University of Nebraska at Omaha, Omaha, Nebraska, USA.'}, {'ForeName': 'Amie', 'Initials': 'A', 'LastName': 'Hiller', 'Affiliation': 'Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Anderson', 'Affiliation': 'Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.'}, {'ForeName': 'Paul S', 'Initials': 'PS', 'LastName': 'Larson', 'Affiliation': 'Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Amber D', 'Initials': 'AD', 'LastName': 'Van Laar', 'Affiliation': 'Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'R Mark', 'Initials': 'RM', 'LastName': 'Richardson', 'Affiliation': 'Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Marin E', 'Initials': 'ME', 'LastName': 'Thompson', 'Affiliation': 'Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Sedkov', 'Affiliation': 'Voyager Therapeutics, Inc., Cambridge, Massachusetts, USA.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Leinonen', 'Affiliation': 'Clinical Data Science GmbH, Basel, Switzerland.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Ravina', 'Affiliation': 'Voyager Therapeutics, Inc., Cambridge, Massachusetts, USA.'}, {'ForeName': 'Krystof S', 'Initials': 'KS', 'LastName': 'Bankiewicz', 'Affiliation': 'Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Chadwick W', 'Initials': 'CW', 'LastName': 'Christine', 'Affiliation': 'Department of Neurology, University of California San Francisco, San Francisco, California, USA.'}]",Movement disorders : official journal of the Movement Disorder Society,['10.1002/mds.27993'] 3107,31310775,"Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: Results from a double-blind, placebo-controlled human laboratory study.","Increasing evidence supports the role of appetite-regulating hormones, including ghrelin, in alcohol use disorder (AUD). Effects of ghrelin administration on cortisol and aldosterone, two hormones known to influence the development and maintenance of AUD, have been observed in ghrelin-exposed tissues or cells, as well as rodents and healthy volunteers, however whether these effects replicate in individuals with AUD is unknown. Here, we tested the hypothesis that intravenous administration of ghrelin leads to increase in endogenous serum cortisol and aldosterone concentrations in alcohol-dependent, heavy drinking individuals, and that these changes may predict ghrelin-induced alcohol craving. This was a double-blind, placebo-controlled human laboratory study in non-treatment-seeking, heavy-drinking, alcohol-dependent individuals randomized to receive either placebo, 1 mcg/kg or 3 mcg/kg of intravenous ghrelin. Then, participants underwent a cue-reactivity procedure in a bar-like setting, which included exposure to both neutral (juice) and alcohol cues. Repeated blood samples were collected and used to measure endogenous cortisol and aldosterone serum concentrations, in response to exogenous ghrelin administration. Furthermore, cortisol and aldosterone serum concentrations were used to develop a model to predict the effect of exogenous ghrelin administration on alcohol craving. Intravenous ghrelin administration increased endogenous cortisol and aldosterone serum concentrations. While the effects on cortisol were greater than those on aldosterone, only the ghrelin-induced changes in aldosterone serum concentrations predicted craving. These findings provide initial evidence of ghrelin effects on glucocorticoids and mineralocorticoids in individuals with AUD, thereby providing additional information on the potential mechanisms by which the ghrelin system may play a role in alcohol craving and seeking in AUD.",2019,"While the effects on cortisol were greater than those on aldosterone, only the ghrelin-induced changes in aldosterone serum concentrations predicted craving.","['individuals with AUD', 'heavy-drinking alcohol-dependent individuals', 'healthy volunteers', 'non-treatment-seeking, heavy-drinking, alcohol-dependent individuals']","['placebo, 1 mcg/kg or 3 mcg/kg of intravenous ghrelin', 'cue-reactivity procedure in a bar-like setting, which included exposure to both neutral (juice) and alcohol cues', 'placebo', 'ghrelin']","['endogenous cortisol and aldosterone serum concentrations', 'alcohol craving', 'endogenous serum cortisol and aldosterone concentrations', 'serum cortisol and aldosterone concentrations']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1627892', 'cui_str': 'ng/g'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0911014', 'cui_str': 'Ghrelin (substance)'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0993613', 'cui_str': 'Bar (basic dose form)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}]","[{'cui': 'C0205227', 'cui_str': 'Endogenous (qualifier value)'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0373535', 'cui_str': 'Aldosterone measurement (procedure)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0556385', 'cui_str': 'Craving for alcohol (finding)'}, {'cui': 'C0729349', 'cui_str': 'Serum cortisol (substance)'}]",,0.0591482,"While the effects on cortisol were greater than those on aldosterone, only the ghrelin-induced changes in aldosterone serum concentrations predicted craving.","[{'ForeName': 'Carolina L', 'Initials': 'CL', 'LastName': 'Haass-Koffler', 'Affiliation': 'Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA; Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, RI, USA; Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research and National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Bethesda, MD, USA. Electronic address: carolina_haass-koffler@brown.edu.'}, {'ForeName': 'Victoria M', 'Initials': 'VM', 'LastName': 'Long', 'Affiliation': 'Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, RI, USA.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Farokhnia', 'Affiliation': 'Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research and National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Bethesda, MD, USA. Electronic address: mehdi.farokhnia@nih.gov.'}, {'ForeName': 'Molly', 'Initials': 'M', 'LastName': 'Magill', 'Affiliation': 'Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, RI, USA.'}, {'ForeName': 'George A', 'Initials': 'GA', 'LastName': 'Kenna', 'Affiliation': 'Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Swift', 'Affiliation': 'Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA; Veterans Affairs Medical Center, Providence, RI, USA.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Leggio', 'Affiliation': 'Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, RI, USA; Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research and National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Bethesda, MD, USA; Medication Development Program, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA. Electronic address: lorenzo.leggio@nih.gov.'}]",Neuropharmacology,['10.1016/j.neuropharm.2019.107711'] 3108,31771385,Child Caries Management: A Randomized Controlled Trial in Dental Practice.,"This multicenter 3-arm, parallel-group, patient-randomized controlled trial compared clinical effectiveness of 3 treatment strategies over 3 y for managing dental caries in primary teeth in UK primary dental care. Participants aged 3 to 7 y with at least 1 primary molar with dentinal carious lesion were randomized across 3 arms (1:1:1 via centrally administered system with variable-length random permuted blocks): C+P, conventional carious lesion management (complete carious tooth tissue removal and restoration placement) with prevention; B+P, biological management (sealing in carious tooth tissue restoratively) with prevention; and PA, prevention alone (diet, plaque removal, fluorides, and fissure sealants). Parents, children, and dentists were not blind to allocated arm. Co-primary outcomes were 1) the proportion of participants with at least 1 episode of dental pain and/or infection and 2) the number of episodes of dental pain and/or infection during follow-up (minimum, 23 mo). In sum, 1,144 participants were randomized (C+P, n = 386; B+P, n = 381; PA, n = 377) by 72 general dental practitioners, of whom 1,058 (C+P, n = 352; B+P, n = 352; PA, n = 354) attended at least 1 study visit and were included in the primary analysis. The median follow-up was 33.8 mo (interquartile range, 23.8 to 36.7). Proportions of participants with at least 1 episode of dental pain and/or infection were as follows: C+P, 42%; B+P, 40%; PA, 45%. There was no evidence of a difference in incidence of dental pain and/or infection when B+P (adjusted risk difference [97.5% CI]: -2% [-10% to 6%]) or PA (4% [-4% to 12%]) was compared with C+P. The mean (SD) number of episodes of dental pain and/or infection were as follows: C+P, 0.62 (0.95); B+P, 0.58 (0.87); and PA, 0.72 (0.98). Superiority could not be concluded for number of episodes between B+P (adjusted incident rate ratio (97.5% CI): 0.95 [0.75 to 1.21]) or PA (1.18 [0.94 to 1.48]) and C+P. In conclusion, there was no evidence of a difference among the 3 treatment approaches for incidence or number of episodes of dental pain and/or infection experienced by these participants with high caries risk and established disease (trial registration: ISRCTN77044005).",2020,There was no evidence of a difference in incidence of dental pain and/or infection when B+P (adjusted risk difference [97.5% CI]: -2% [-10% to 6%]) or PA (4% [-4% to 12%]) was compared with C+P.,"['1,144 participants were randomized (C+P, n = 386; B+P, n = 381; PA, n = 377) by 72 general dental practitioners, of whom 1,058 (C+P, n = 352; B+P, n = 352; PA, n = 354) attended at least 1 study visit and were included in the primary analysis', 'Participants aged 3 to 7 y with at least 1 primary molar with dentinal carious lesion', 'Child Caries Management', '3 y for managing dental caries in primary teeth in UK primary dental care', 'participants with at least 1 episode of dental pain and/or infection were as follows']","['centrally administered system with variable-length random permuted blocks): C+P, conventional carious lesion management (complete carious tooth tissue removal and restoration placement) with prevention; B+P, biological management (sealing in carious tooth tissue restoratively) with prevention; and PA, prevention alone (diet, plaque removal, fluorides, and fissure sealants', 'C+P']","['incidence or number of episodes of dental pain and/or infection', 'incidence of dental pain and/or infection', 'proportion of participants with at least 1 episode of dental pain and/or infection and 2) the number of episodes of dental pain and/or infection', 'mean (SD) number of episodes of dental pain and/or infection']","[{'cui': 'C4708787', 'cui_str': '381 (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0011441', 'cui_str': 'Dentist'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0026367', 'cui_str': 'Molar'}, {'cui': 'C0011334', 'cui_str': 'Dental Decay'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C3266841', 'cui_str': 'Baby Teeth'}, {'cui': 'C0011331', 'cui_str': 'Dental Care'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}]","[{'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0011334', 'cui_str': 'Dental Decay'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration (attribute)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C4553887', 'cui_str': 'Biologic Drugs'}, {'cui': 'C0036492', 'cui_str': 'Seal (organism)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0016327', 'cui_str': 'Fluorides'}, {'cui': 'C0016168', 'cui_str': 'Fissure Sealants'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",1144.0,0.369859,There was no evidence of a difference in incidence of dental pain and/or infection when B+P (adjusted risk difference [97.5% CI]: -2% [-10% to 6%]) or PA (4% [-4% to 12%]) was compared with C+P.,"[{'ForeName': 'N P', 'Initials': 'NP', 'LastName': 'Innes', 'Affiliation': 'School of Dentistry, University of Dundee, Dundee, UK.'}, {'ForeName': 'J E', 'Initials': 'JE', 'LastName': 'Clarkson', 'Affiliation': 'Dental Health Services Research Unit, University of Dundee, Dundee, UK.'}, {'ForeName': 'G V A', 'Initials': 'GVA', 'LastName': 'Douglas', 'Affiliation': 'School of Dentistry, University of Leeds, Leeds, UK.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Ryan', 'Affiliation': 'Institute of Health and Society, Newcastle University, Newcastle, UK.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Wilson', 'Affiliation': 'Institute of Health and Society, Newcastle University, Newcastle, UK.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Homer', 'Affiliation': 'Institute of Health and Society, Newcastle University, Newcastle, UK.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Marshman', 'Affiliation': 'School of Clinical Dentistry, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'McColl', 'Affiliation': 'Institute of Health and Society, Newcastle University, Newcastle, UK.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Vale', 'Affiliation': 'Institute of Health and Society, Newcastle University, Newcastle, UK.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Robertson', 'Affiliation': 'School of Dentistry, University of Dundee, Dundee, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Abouhajar', 'Affiliation': 'Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'R D', 'Initials': 'RD', 'LastName': 'Holmes', 'Affiliation': 'School of Dental Sciences, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Freeman', 'Affiliation': 'Dental Health Services Research Unit, University of Dundee, Dundee, UK.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Chadwick', 'Affiliation': 'School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Deery', 'Affiliation': 'School of Clinical Dentistry, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Wong', 'Affiliation': 'Institute of Dentistry, Queen Mary University of London, London, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Maguire', 'Affiliation': 'School of Dental Sciences, Newcastle University, Newcastle upon Tyne, UK.'}]",Journal of dental research,['10.1177/0022034519888882'] 3109,32007714,"Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).","BACKGROUND Up to 50% of men with poor prognosis, non-seminoma germ cell tumours (GCTs) die with standard BEP (bleomycin, etoposide and cisplatin) chemotherapy. An intensive regimen, CBOP/BEP (carboplatin, bleomycin, vincristine and cisplatin/BEP), met response targets in a randomised, phase II trial (74% complete response or partial response marker negative, 90% confidence interval (CI) 61%-85%). AIM To assess long-term outcomes and late toxicity associated with CBOP/BEP. METHODS Patients with poor prognosis extracranial GCT were randomised to 4xBEP or CBOP/BEP (2xCBOP, 2xBO, 3xBEP with 15,000iu of bleomycin). Low-dose, stabilising chemotherapy before entry was permitted. Response rates (primary outcome) were reported previously. Here, we report secondary outcomes: progression-free survival (PFS), overall survival (OS) and late toxicity. Prognostic factors and the impact of marker decline are assessed in exploratory analysis. RESULTS Eighty-nine patients (43 CBOP/BEP) were randomised. After median 63 months follow-up, 3-year PFS is 55.7% (95% CI: 39.7%, 69.0%) for CBOP/BEP and 38.7% (95% CI: 24.7%, 52.4%) for BEP (hazard ratio [HR]: 0.59 (0.33, 1.06), p = 0.079). Three-year OS is 65.0% (48.8%, 77.2%) and 58.5% (43.0%, 71.2%), respectively (HR: 0.79 (0.41, 1.52), p = 0.49). Twelve-month toxicity was affected by subsequent treatments, with no clear differences between arms. Stabilising chemotherapy was associated with poorer PFS (HR: 2.09 (1.14, 3.81), p = 0.017), whereas unfavourable marker decline, in 60 (70%) patients, was not. CONCLUSION Although not powered for PFS, results for CBOP/BEP are promising. Impact on OS was less clear (and will be affected by subsequent therapy). Further study in an international phase III trial is warranted. TRIAL REGISTRATION ISRCTN 53643604.",2020,"Stabilising chemotherapy was associated with poorer PFS (HR: 2.09 (1.14, 3.81), p = 0.017), whereas unfavourable marker decline, in 60 (70%) patients, was not. ","['poor prognosis germ cell tumours', 'men with poor prognosis, non-seminoma germ cell tumours (GCTs) die with', 'Patients with poor prognosis extracranial GCT', 'Eighty-nine patients (43 CBOP/BEP']","['Stabilising chemotherapy', 'intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin', 'CBOP/BEP (carboplatin, bleomycin, vincristine and cisplatin/BEP', 'standard BEP (bleomycin, etoposide and cisplatin) chemotherapy', 'CBOP/BEP', '4xBEP or CBOP/BEP (2xCBOP, 2xBO, 3xBEP with 15,000iu of bleomycin']","['progression-free survival (PFS), overall survival (OS) and late toxicity', 'Response rates', 'toxicity', '3-year PFS']","[{'cui': 'C0278252', 'cui_str': 'Prognosis bad (finding)'}, {'cui': 'C0205851', 'cui_str': 'Neoplasms, Germ Cell'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0036631', 'cui_str': 'Seminoma'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0580586', 'cui_str': 'Extracranial (qualifier value)'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}]","[{'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C3179010', 'cui_str': 'Induction Chemotherapy'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0005740', 'cui_str': 'Bleomycin'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0015133', 'cui_str': 'Etoposide'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",,0.300647,"Stabilising chemotherapy was associated with poorer PFS (HR: 2.09 (1.14, 3.81), p = 0.017), whereas unfavourable marker decline, in 60 (70%) patients, was not. ","[{'ForeName': 'Fay H', 'Initials': 'FH', 'LastName': 'Cafferty', 'Affiliation': 'MRC Clinical Trials Unit at UCL, 90 High Holborn, London, WC1V 6LJ, UK. Electronic address: f.cafferty@ucl.ac.uk.'}, {'ForeName': 'Jeff D', 'Initials': 'JD', 'LastName': 'White', 'Affiliation': 'Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 0YN, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Shamash', 'Affiliation': ""St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK.""}, {'ForeName': 'Ivo', 'Initials': 'I', 'LastName': 'Hennig', 'Affiliation': 'Nottingham University Hospitals NHS Trust, Hucknall Road, Nottingham, NG5 1PB, UK.'}, {'ForeName': 'Sally P', 'Initials': 'SP', 'LastName': 'Stenning', 'Affiliation': 'MRC Clinical Trials Unit at UCL, 90 High Holborn, London, WC1V 6LJ, UK.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Huddart', 'Affiliation': 'The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Downs Road, Sutton, SM2 5PT, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.12.028'] 3110,31793890,"Comparison of YouthCHAT, an Electronic Composite Psychosocial Screener, With a Clinician Interview Assessment for Young People: Randomized Controlled Trial.","BACKGROUND Psychosocial problems such as depression, anxiety, and substance abuse are common and burdensome in young people. In New Zealand, screening for such problems is undertaken routinely only with year 9 students in low-decile schools and opportunistically in pediatric settings using a nonvalidated and time-consuming clinician-administered Home, Education, Eating, Activities, Drugs and Alcohol, Sexuality, Suicide and Depression, Safety (HEEADSSS) interview. The Youth version, Case-finding and Help Assessment Tool (YouthCHAT) is a relatively new, locally developed, electronic tablet-based composite screener for identifying similar psychosocial issues to HEEADSSS. OBJECTIVE This study aimed to compare the performance and acceptability of YouthCHAT with face-to-face HEEADSSS assessment among 13-year-old high school students. METHODS A counterbalanced randomized trial of YouthCHAT screening either before or after face-to-face HEEADSSS assessment was undertaken with 129 13-year-old New Zealand high school students of predominantly Māori and Pacific Island ethnicity. Main outcome measures were comparability of YouthCHAT and HEEADSSS completion times, detection rates, and acceptability to students and school nurses. RESULTS YouthCHAT screening was more than twice as fast as HEEADSSS assessment (mean 8.57 min vs mean 17.22 min; mean difference 8 min 25 seconds [range 6 min 20 seconds to 11 min 10 seconds]; P<.01) and detected more issues overall on comparable domains. For substance misuse and problems at home, both instruments were roughly comparable. YouthCHAT detected significantly more problems with eating or body image perception (70/110, 63.6% vs 25/110, 22.7%; P<.01), sexual health (24/110, 21.8% vs 10/110, 9.1%; P=.01), safety (65/110, 59.1% vs 17/110, 15.5%; P<.01), and physical inactivity (43/110, 39.1% vs 21/110, 19.1%; P<.01). HEEADSSS had a greater rate of detection for a broader set of mental health issues (30/110, 27%) than YouthCHAT (11/110, 10%; P=.001), which only assessed clinically relevant anxiety and depression. Assessment order made no significant difference to the duration of assessment or to the rates of YouthCHAT-detected positive screens for anxiety and depression. There were no significant differences in student acceptability survey results between the two assessments. Nurses identified that students found YouthCHAT easy to answer and that it helped students answer face-to-face questions, especially those of a sensitive nature. Difficulties encountered with YouthCHAT included occasional Wi-Fi connectivity and student literacy issues. CONCLUSIONS This study provides preliminary evidence regarding the shorter administration time, detection rates, and acceptability of YouthCHAT as a school-based psychosocial screener for young people. Although further research is needed to confirm its effectiveness in other age and ethnic groups, YouthCHAT shows promise for aiding earlier identification and treatment of common psychosocial problems in young people, including possible use as part of an annual, school-based, holistic health check. TRIAL REGISTRATION Australian New Zealand Clinical Trials Network Registry (ACTRN) ACTRN12616001243404p; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371422.",2019,Assessment order made no significant difference to the duration of assessment or to the rates of YouthCHAT-detected positive screens for anxiety and depression.,"['129 13-year-old New Zealand high school students of predominantly Māori and Pacific Island ethnicity', 'Young People', '13-year-old high school students', 'young people']","['YouthCHAT', 'YouthCHAT screening either before or after face-to-face HEEADSSS assessment']","['safety', 'rate of detection for a broader set of mental health issues', 'problems with eating or body image perception', 'sexual health', 'student acceptability survey', 'physical inactivity', 'shorter administration time, detection rates, and acceptability of YouthCHAT', 'comparability of YouthCHAT and HEEADSSS completion times, detection rates, and acceptability to students and school nurses']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0030168', 'cui_str': 'Pacific Islands'}, {'cui': 'C0243103', 'cui_str': 'ethnicity'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}]","[{'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0005891', 'cui_str': 'Body Image'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C2362326', 'cui_str': 'Sexual Health'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0302833', 'cui_str': 'School nurse (occupation)'}]",,0.0858498,Assessment order made no significant difference to the duration of assessment or to the rates of YouthCHAT-detected positive screens for anxiety and depression.,"[{'ForeName': 'Hiran', 'Initials': 'H', 'LastName': 'Thabrew', 'Affiliation': 'Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': ""D'Silva"", 'Affiliation': 'Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Margot', 'Initials': 'M', 'LastName': 'Darragh', 'Affiliation': 'Department of General Practice, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Goldfinch', 'Affiliation': 'Tamaki College, Auckland, New Zealand.'}, {'ForeName': 'Jake', 'Initials': 'J', 'LastName': 'Meads', 'Affiliation': 'School of Health Science, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand.'}, {'ForeName': 'Felicity', 'Initials': 'F', 'LastName': 'Goodyear-Smith', 'Affiliation': 'Department of General Practice, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.'}]",Journal of medical Internet research,['10.2196/13911'] 3111,32036242,Abrupt withdrawal of cannabidiol (CBD): A randomized trial.,"RATIONALE The rationale of this study was to assess occurrence of withdrawal symptoms induced by abrupt cessation of cannabidiol (CBD) after prolonged administration in healthy volunteers. METHODS Thirty volunteers were randomized to receive 750 mg of a plant-derived pharmaceutical formulation of highly purified CBD in oral solution (100 mg/mL; Epidiolex® in the United States and Epidyolex® in Europe) twice daily (b.i.d.) for 4 weeks (Part 1) followed by 2 weeks of 750 mg b.i.d. CBD (Part 2, Arm 1) or matched placebo (Part 2, Arm 2). All volunteers completed the Cannabis Withdrawal Scale (CWS) and the 20-item Penn Physician Withdrawal Checklist (PWC-20) on days -1, 21, 28, 31, 35, 42, and at follow-up. RESULTS Median CWS and PWC-20 scores slightly decreased from Part 1 to Part 2. Median CWS scores ranged from 0.0 to 4.0 (out of a possible 190) in Arm 1 and 0.0 to 0.5 in Arm 2. Median PWC-20 scores were 0.0 (out of a possible 60) in both arms. Twenty-nine (97%) volunteers in Part 1 reported all-causality treatment-emergent adverse events (AEs); the most commonly reported was diarrhea (63%). In Part 2, Arm 1, 6 (67%) volunteers reported all-causality AEs; the most commonly reported was diarrhea (44%). In Part 2, Arm 2, 9 (75%) volunteers reported all-causality AEs; the most commonly reported was headache (58%). Nine volunteers withdrew because of AEs in Part 1; 1 withdrew in Part 2, Arm 2, because of an AE that began in Part 1. Four severe AEs were reported in Part 1; the remainder were mild or moderate. No serious AEs were reported. CONCLUSION In healthy volunteers, no evidence of withdrawal syndrome was found with abrupt discontinuation of short-term treatment with CBD.",2020,Median CWS scores ranged from 0.0 to 4.0 (out of a possible 190) in Arm 1 and 0.0 to 0.5 in Arm 2.,"['Thirty volunteers', 'Abrupt withdrawal of cannabidiol (CBD', 'healthy volunteers']","['cannabidiol (CBD', 'placebo', '750\u202fmg of a plant-derived pharmaceutical formulation of highly purified CBD in oral solution (100\u202fmg/mL; Epidiolex® in the United States and Epidyolex®']","['diarrhea', 'Median CWS and PWC-20 scores', 'Median PWC-20 scores', 'withdrawal syndrome', 'Median CWS scores', 'headache', 'Cannabis Withdrawal Scale (CWS) and the 20-item Penn Physician Withdrawal Checklist (PWC-20']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0006863', 'cui_str': '1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0006863', 'cui_str': '1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4517868', 'cui_str': '750 (qualifier value)'}, {'cui': 'C0032098', 'cui_str': 'Plants'}, {'cui': 'C0524527', 'cui_str': 'Drug Formulation'}, {'cui': 'C0991536', 'cui_str': 'Oral Solution'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0439294', 'cui_str': 'mcg/mcL'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0038587', 'cui_str': 'Substance Withdrawal Syndrome'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C3840212', 'cui_str': 'Cannabis withdrawal (disorder)'}, {'cui': 'C0222045'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}]",30.0,0.0462395,Median CWS scores ranged from 0.0 to 4.0 (out of a possible 190) in Arm 1 and 0.0 to 0.5 in Arm 2.,"[{'ForeName': 'Lesley', 'Initials': 'L', 'LastName': 'Taylor', 'Affiliation': 'GW Research Ltd., Sovereign House, Vision Park, Histon, Cambridge CB24 9BZ, UK. Electronic address: lesley@alchemymedicalwriting.com.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Crockett', 'Affiliation': 'GW Research Ltd., Sovereign House, Vision Park, Histon, Cambridge CB24 9BZ, UK. Electronic address: JCrockett@gwpharm.com.'}, {'ForeName': 'Bola', 'Initials': 'B', 'LastName': 'Tayo', 'Affiliation': 'GW Research Ltd., Sovereign House, Vision Park, Histon, Cambridge CB24 9BZ, UK. Electronic address: BTayo@gwpharm.com.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Checketts', 'Affiliation': 'GW Research Ltd., Sovereign House, Vision Park, Histon, Cambridge CB24 9BZ, UK. Electronic address: Dchecketts@gwpharm.com.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Sommerville', 'Affiliation': 'Greenwich Biosciences, Inc., 5750 Fleet Street, Suite 200, Carlsbad, CA 92008, USA. Electronic address: kwsommerville@gmail.com.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2020.106938'] 3112,31134713,The academic outcomes of working memory and metacognitive strategy training in children: A double-blind randomized controlled trial.,"Working memory training has been shown to improve performance on untrained working memory tasks in typically developing children, at least when compared to non-adaptive training; however, there is little evidence that it improves academic outcomes. The lack of transfer to academic outcomes may be because children are only learning skills and strategies in a very narrow context, which they are unable to apply to other tasks. Metacognitive strategy interventions, which promote metacognitive awareness and teach children general strategies that can be used on a variety of tasks, may be a crucial missing link in this regard. In this double-blind randomized controlled trial, 95 typically developing children aged 9-14 years were allocated to three cognitive training programmes that were conducted daily after-school. One group received Cogmed working memory training, another group received concurrent Cogmed and metacognitive strategy training, and the control group received adaptive visual search training, which better controls for expectancy and motivation than non-adaptive training. Children were assessed on four working memory tasks, reading comprehension, and mathematical reasoning before, immediately after, and 3 months after training. Working memory training improved working memory and mathematical reasoning relative to the control group. The improvements in working memory were maintained 3 months later, and these were significantly greater for the group that received metacognitive strategy training, compared to working memory training alone. Working memory training is a potentially effective educational intervention when provided in addition to school; however, future research will need to investigate ways to maintain academic improvements long term and to optimize metacognitive strategy training to promote far-transfer. A video abstract of this article can be viewed at https://youtu.be/-7MML48ZFgw.",2020,"The improvements in working memory were maintained 3 months later, and these were significantly greater for the group that received metacognitive strategy training, compared to working memory training alone.","['children', '95 typically developing children aged 9-14\xa0years']","['cognitive training programmes', 'metacognitive strategy training', 'Cogmed working memory training, another group received concurrent Cogmed and metacognitive strategy training, and the control group received adaptive visual search training, which better controls for expectancy and motivation than non-adaptive training', 'Metacognitive strategy interventions', 'working memory and metacognitive strategy training', 'Working memory training']","['working memory and mathematical reasoning relative', 'working memory', 'working memory tasks, reading comprehension, and mathematical reasoning']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0589105', 'cui_str': 'Strategy training (regime/therapy)'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205420', 'cui_str': 'Concurrent (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C3853142', 'cui_str': 'Well controlled'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}]","[{'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}]",95.0,0.0643129,"The improvements in working memory were maintained 3 months later, and these were significantly greater for the group that received metacognitive strategy training, compared to working memory training alone.","[{'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Jones', 'Affiliation': 'School of Psychology, College of Life and Environmental Sciences, University of Exeter, Exeter, UK.'}, {'ForeName': 'Fraser', 'Initials': 'F', 'LastName': 'Milton', 'Affiliation': 'School of Psychology, College of Life and Environmental Sciences, University of Exeter, Exeter, UK.'}, {'ForeName': 'Mohammod', 'Initials': 'M', 'LastName': 'Mostazir', 'Affiliation': 'School of Psychology, College of Life and Environmental Sciences, University of Exeter, Exeter, UK.'}, {'ForeName': 'Anna R', 'Initials': 'AR', 'LastName': 'Adlam', 'Affiliation': 'School of Psychology, College of Life and Environmental Sciences, University of Exeter, Exeter, UK.'}]",Developmental science,['10.1111/desc.12870'] 3113,30202872,"The Impact of Intensive Versus Standard Anthelminthic Treatment on Allergy-related Outcomes, Helminth Infection Intensity, and Helminth-related Morbidity in Lake Victoria Fishing Communities, Uganda: Results From the LaVIISWA Cluster-randomized Trial.","BACKGROUND The prevalence of allergy-related diseases is increasing in low-income countries. Parasitic helminths, common in these settings, may be protective. We hypothesized that intensive, community-wide, anthelminthic mass drug administration (MDA) would increase allergy-related diseases, while reducing helminth-related morbidity. METHODS In an open, cluster-randomized trial (ISRCTN47196031), we randomized 26 high-schistosomiasis-transmission fishing villages in Lake Victoria, Uganda, in a 1:1 ratio to receive community-wide intensive (quarterly single-dose praziquantel plus albendazole daily for 3 days) or standard (annual praziquantel plus 6 monthly single-dose albendazole) MDA. Primary outcomes were recent wheezing, skin prick test positivity (SPT), and allergen-specific immunoglobulin E (asIgE) after 3 years of intervention. Secondary outcomes included helminths, haemoglobin, and hepatosplenomegaly. RESULTS The outcome survey comprised 3350 individuals. Intensive MDA had no effect on wheezing (risk ratio [RR] 1.11, 95% confidence interval [CI] 0.64-1.93), SPT (RR 1.10, 95% CI 0.85-1.42), or asIgE (RR 0.96, 95% CI 0.82-1.12). Intensive MDA reduced Schistosoma mansoni infection intensity: the prevalence from Kato Katz examinations of single stool samples from each patient was 23% versus 39% (RR 0.70, 95% CI 0.55-0.88), but the urine circulating cathodic antigen test remained positive in 85% participants in both trial arms. Hookworm prevalence was 8% versus 11% (RR 0.55, 95% CI 0.31-1.00). There were no differences in anemia or hepatospenomegaly between trial arms. CONCLUSIONS Despite reductions in S. mansoni intensity and hookworm prevalence, intensive MDA had no effect on atopy, allergy-related diseases, or helminth-related pathology. This could be due to sustained low-intensity infections; thus, a causal link between helminths and allergy outcomes cannot be discounted. Intensive community-based MDA has a limited impact in high-schistosomiasis-transmission fishing communities, in the absence of other interventions. CLINICAL TRIALS REGISTRATION ISRCTN47196031.",2019,"Intensive MDA reduced S. mansoni infection intensity: prevalence from Kato-Katz examination of one stool sample was 23% versus 39% (RR 0.70 (0.55,0.88)), but the more-sensitive urine circulating cathodic antigen test remained positive in 85% participants in both trial arms.","['3350 individuals', 'Lake Victoria fishing communities, Uganda', '26 high-schistosomiasis-transmission fishing villages, Lake Victoria, Uganda, in a 1:1 ratio to receive']","['Intensive community-based MDA', 'intensive community-wide anthelminthic mass drug administration (MDA', 'community-wide intensive (quarterly single-dose praziquantel plus albendazole daily for three days) or standard (annual praziquantel plus six-monthly single-dose albendazole) MDA', 'intensive versus standard anthelminthic treatment']","['anaemia', 'helminths, haemoglobin and hepatosplenomegaly', 'recent wheeze, skin prick test positivity (SPT) and allergen-specific immunoglobulin E (asIgE', 'Hookworm prevalence', 'wheeze, SPT or asIgE (risk ratios']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0337049', 'cui_str': 'Lakes'}, {'cui': 'C0042645', 'cui_str': 'Victoria'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0041573', 'cui_str': 'Republic of Uganda'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0036323', 'cui_str': 'Schistoma Infection'}, {'cui': 'C0040722', 'cui_str': 'transmission'}, {'cui': 'C0562518', 'cui_str': 'Village environment (environment)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0000379', 'cui_str': '1,3-Benzodioxole-5-ethanamine, alpha-methyl-'}, {'cui': 'C4505223', 'cui_str': 'Mass Drug Administration'}, {'cui': 'C0332179', 'cui_str': 'q3mo'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0032911', 'cui_str': 'Praziquantel'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0001911', 'cui_str': 'Albendazole'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0585339', 'cui_str': 'q6mo'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0018893', 'cui_str': 'Worms, Parasitic'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0019214', 'cui_str': 'Hepatosplenomegaly (disorder)'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0043144', 'cui_str': 'Wheezing'}, {'cui': 'C0430561', 'cui_str': 'Prick test (procedure)'}, {'cui': 'C0443736', 'cui_str': 'Allergen specific immunoglobulin E'}, {'cui': 'C1265425', 'cui_str': 'Family Ancylostomatidae (organism)'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}]",,0.58775,"Intensive MDA reduced S. mansoni infection intensity: prevalence from Kato-Katz examination of one stool sample was 23% versus 39% (RR 0.70 (0.55,0.88)), but the more-sensitive urine circulating cathodic antigen test remained positive in 85% participants in both trial arms.","[{'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Sanya', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.'}, {'ForeName': 'Gyaviira', 'Initials': 'G', 'LastName': 'Nkurunungi', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.'}, {'ForeName': 'Remy', 'Initials': 'R', 'LastName': 'Hoek Spaans', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Nampijja', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.'}, {'ForeName': 'Geraldine', 'Initials': 'G', 'LastName': ""O'Hara"", 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Kizindo', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.'}, {'ForeName': 'Gloria', 'Initials': 'G', 'LastName': 'Oduru', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.'}, {'ForeName': 'Prossy', 'Initials': 'P', 'LastName': 'Kabuubi Nakawungu', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Niwagaba', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.'}, {'ForeName': 'Elson', 'Initials': 'E', 'LastName': 'Abayo', 'Affiliation': 'Entebbe Hospital, Wakiso District Local Government, Uganda.'}, {'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Kabagenyi', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Zziwa', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.'}, {'ForeName': 'Josephine', 'Initials': 'J', 'LastName': 'Tumusiime', 'Affiliation': 'Entebbe Hospital, Wakiso District Local Government, Uganda.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Nakazibwe', 'Affiliation': 'Entebbe Hospital, Wakiso District Local Government, Uganda.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Kaweesa', 'Affiliation': 'Vector Control Division, Ministry of Health, Kampala, Uganda.'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Muwonge Kakooza', 'Affiliation': 'Koome Health Centre III, Mukono District Local Government, Uganda.'}, {'ForeName': 'Mirriam', 'Initials': 'M', 'LastName': 'Akello', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Lubyayi', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.'}, {'ForeName': 'Jaco', 'Initials': 'J', 'LastName': 'Verweij', 'Affiliation': 'Laboratory for Medical Microbiology and Immunology, St Elisabeth Hospital, Tilburg, The Netherlands.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Nash', 'Affiliation': 'Medical Research Council Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, United Kingdom.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'van Ree', 'Affiliation': 'Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'Mpairwe', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.'}, {'ForeName': 'Edridah', 'Initials': 'E', 'LastName': 'Tukahebwa', 'Affiliation': 'Vector Control Division, Ministry of Health, Kampala, Uganda.'}, {'ForeName': 'Emily L', 'Initials': 'EL', 'LastName': 'Webb', 'Affiliation': 'Medical Research Council Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, United Kingdom.'}, {'ForeName': 'Alison M', 'Initials': 'AM', 'LastName': 'Elliott', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciy761'] 3114,30948365,Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML.,"Here we evaluated whether sequential high-dose chemotherapy (sHD) increased the early complete remission (CR) rate in acute myelogenous leukemia (AML) compared with standard-intensity idarubicin-cytarabine-etoposide (ICE) chemotherapy. This study enrolled 574 patients (age, 16-73 years; median, 52 years) who were randomly assigned to ICE (n = 286 evaluable) or sHD (2 weekly 3-day blocks with cytarabine 2 g/m 2 twice a day for 2 days plus idarubicin; n = 286 evaluable). Responsive patients were risk-stratified for a second randomization. Standard-risk patients received autograft or repetitive blood stem cell-supported high-dose courses. High-risk patients (and standard-risk patients not mobilizing stem cells) underwent allotransplantation. CR rates after 2 induction courses were comparable between ICE (80.8%) and sHD (83.6%; P = . 38). sHD yielded a higher single-induction CR rate (69.2% vs 81.5%; P = . 0007) with lower resistance risk ( P < .0001), comparable mortality ( P = . 39), and improved 5-year overall survival (39% vs 49%; P = . 045) and relapse-free survival (36% vs 48%; P = . 028), despite greater hematotoxicity delaying or reducing consolidation blocks. sHD improved the early CR rate in high-risk AML (odds ratio, 0.48; 95% confidence interval [CI], 0.31-0.74; P = . 0008) and in patients aged 60 years and less with de novo AML (odds ratio, 0.46; 95% CI, 0.27-0.78; P = . 003), and also improved overall/relapse-free survival in the latter group (hazard ratio, 0.70; 95% CI, 0.52-0.94; P = . 01), in standard-risk AML, and postallograft (hazard ratio, 0.61; 95% CI, 0.39-0.96; P = . 03). sHD was feasible, effectively achieved rapid CR, and improved outcomes in AML subsets. This study is registered at www.clinicaltrials.gov as #NCT00495287.",2019,"sHD improved the early CR rate in high-risk AML (odds ratio, 0.48; 95% confidence interval [CI], 0.31-0.74; P = .","['High-risk patients (and standard-risk patients not mobilizing stem cells) underwent allotransplantation', '574 patients (age, 16-73 years; median, 52 years', 'acute myelogenous leukemia (AML', 'adult AML', '0008']","['sequential high-dose chemotherapy (sHD', 'cytarabine 2 g/m 2 twice a day for 2 days plus idarubicin', 'ICE', 'sHD', 'standard-intensity idarubicin-cytarabine-etoposide (ICE) chemotherapy', 'standard vs sequential high-dose chemotherapy', 'autograft or repetitive blood stem cell-supported high-dose courses']","['hematotoxicity delaying or reducing consolidation blocks', 'early CR rate', 'comparable mortality', '5-year overall survival', 'early complete remission (CR) rate', 'relapse-free survival', 'overall/relapse-free survival', 'single-induction CR rate', 'CR rates']","[{'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0578718', 'cui_str': 'Mobilizes'}, {'cui': 'C0038250', 'cui_str': 'Mother Cells'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0023467', 'cui_str': 'Nonlymphoblastic Leukemia, Acute'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0010711', 'cui_str': 'Cytarabine'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0020789', 'cui_str': 'Idarubicin'}, {'cui': 'C0349714', 'cui_str': 'Icing (substance)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0015133', 'cui_str': 'Etoposide'}, {'cui': 'C0040736', 'cui_str': 'Autotransplantation'}, {'cui': 'C0005768'}, {'cui': 'C0038250', 'cui_str': 'Mother Cells'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}]","[{'cui': 'C0920103', 'cui_str': 'Haematotoxicity'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0702116', 'cui_str': 'Consolidation (morphologic abnormality)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}]",574.0,0.413479,"sHD improved the early CR rate in high-risk AML (odds ratio, 0.48; 95% confidence interval [CI], 0.31-0.74; P = .","[{'ForeName': 'Renato', 'Initials': 'R', 'LastName': 'Bassan', 'Affiliation': ""Ospedale dell'Angelo and SS. Giovanni e Paolo, Venezia-Mestre, Italy.""}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Intermesoli', 'Affiliation': 'Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Arianna', 'Initials': 'A', 'LastName': 'Masciulli', 'Affiliation': 'Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Pavoni', 'Affiliation': 'Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Boschini', 'Affiliation': 'Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Gianfaldoni', 'Affiliation': 'Azienda Ospedaliera Universitaria Careggi, Firenze, Italy.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Marmont', 'Affiliation': 'Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Cavattoni', 'Affiliation': 'Ospedale S. Maurizio, Bolzano, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Mattei', 'Affiliation': 'Azienda Ospedaliera S. Croce e Carle di Cuneo, Cuneo, Italy.'}, {'ForeName': 'Elisabetta', 'Initials': 'E', 'LastName': 'Terruzzi', 'Affiliation': 'Azienda Ospedaliera San Gerardo, Monza, Italy.'}, {'ForeName': 'Lorella', 'Initials': 'L', 'LastName': 'De Paoli', 'Affiliation': 'Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Cattaneo', 'Affiliation': 'ASST-Spedali Civili, Brescia, Italy.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Borlenghi', 'Affiliation': 'ASST-Spedali Civili, Brescia, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Ciceri', 'Affiliation': 'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Bernardi', 'Affiliation': 'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.'}, {'ForeName': 'Anna M', 'Initials': 'AM', 'LastName': 'Scattolin', 'Affiliation': ""Ospedale dell'Angelo and SS. Giovanni e Paolo, Venezia-Mestre, Italy.""}, {'ForeName': 'Elisabetta', 'Initials': 'E', 'LastName': 'Todisco', 'Affiliation': 'IRCCS Istituto Clinico Humanitas di Rozzano, Rozzano, Italy.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Campiotti', 'Affiliation': 'Department of Medicine and Surgery, University of Insubria, Varese, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Corradini', 'Affiliation': 'Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Agostino', 'Initials': 'A', 'LastName': 'Cortelezzi', 'Affiliation': ""Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Ferrero', 'Affiliation': 'Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Zanghì', 'Affiliation': 'Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Oldani', 'Affiliation': 'Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Orietta', 'Initials': 'O', 'LastName': 'Spinelli', 'Affiliation': 'Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Ernesta', 'Initials': 'E', 'LastName': 'Audisio', 'Affiliation': 'Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Cortelazzo', 'Affiliation': 'Ospedale S. Maurizio, Bolzano, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Bosi', 'Affiliation': 'Azienda Ospedaliera Universitaria Careggi, Firenze, Italy.'}, {'ForeName': 'Brunangelo', 'Initials': 'B', 'LastName': 'Falini', 'Affiliation': 'Section of Hematology and Clinical Immunology, Department of Medicine, University of Perugia, Perugia, Italy; and.'}, {'ForeName': 'Enrico M', 'Initials': 'EM', 'LastName': 'Pogliani', 'Affiliation': 'Azienda Ospedaliera San Gerardo, Monza, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Rambaldi', 'Affiliation': 'Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy.'}]",Blood advances,['10.1182/bloodadvances.2018026625'] 3115,31350236,"Clinical benefit of two-times-per-day aclidinium bromide compared with once-a-day tiotropium bromide hydrate in COPD: a multicentre, open-label, randomised study.","OBJECTIVE Chronic obstructive pulmonary disease (COPD) is mainly treated pharmaceutically with bronchodilators. The purpose of this study was to evaluate the clinical benefits of two-times-per-day aclidinium bromide (Acli-BID) compared with once-a-day tiotropium bromide hydrate (Tio-QD) in patients with COPD. DESIGN This study was a multicentre, open-label, randomised study. SETTING Fourcentres in Kagawa prefecture, Japan. PARTICIPANT Patients who were diagnosed to have COPD Grade 2-3 according to the Global Initiative for Chronic Obstructive Lung Disease 2015 criteria were enrolled. INTERVENTIONS Patients were randomly assigned to receive Acli-BID or Tio-QD at a 1:1 ratio, and followed for 8 weeks. Acli-BID was administered in the morning and night, and Tio-QD was administered in the night. PRIMARY AND SECONDARY OUTCOME MEASURES Primary outcome was forced expiratory volume in one second area under the curve (FEV 1 AUC 0-3 ), and secondary outcomes were pulmonary function, physical activity, St George's Respiratory Questionnaire (SGRQ), modified Medical Research Council (mMRC), the 8-item Short-Form Health Survey (SF-8) and COPD exacerbations. Adverse events were evaluated during the study. RESULTS 44 patients were included in this study. FEV 1 AUC 0-3 at week 8 was 4.62±1.43 L·hour in Acli-BID and 4.73±1.60 L·hour in Tio-QD (mean difference (MD) -0.11 L·hour; 95% CI), -1.04 to 0.83). Significant improvement was observed in activity-related subscales of SGRQ (MD -7.78; 95% CI -14.61 to -0.94) and SF-8 (MD 4.01; 95% CI 0.37 to 7.65), mMRC (MD -0.66; 95% CI -1.19 to -0.13) and rate ratio (0.52, 95% CI 0.27 to 0.99) of exacerbations in the Acli-BID compared with the Tio-QD. Acli-BID and Tio-QD significantly improved sedentary behaviour (MD -35.20 min; 95% CI -67.41 to -2.94 and MD -55.40 min; 95% CI -98.15 to -12.77) within each group, but there was no significant difference between the two groups. CONCLUSION Acli-BID as with Tio-QD could be one of the therapeutic options for patients with COPD to improve pulmonary function. Also, our results suggest that intervention with bronchodilators enhanced physical activity in patients with COPD. TRIAL REGISTRATION NUMBER UMIN 000020020.",2019,"Acli-BID and Tio-QD significantly improved sedentary behaviour (MD -35.20 min; 95% CI -67.41 to -2.94 and MD -55.40 min; 95% CI -98.15 to -12.77) within each group, but there was no significant difference between the two groups. ","['patients with COPD', '44 patients were included in this study', 'COPD', 'Patients who were diagnosed to have COPD Grade 2-3 according to the Global Initiative for Chronic Obstructive Lung Disease 2015 criteria were enrolled', 'Fourcentres in Kagawa prefecture, Japan', 'Chronic obstructive pulmonary disease (COPD']","['tiotropium bromide hydrate (Tio-QD', 'tiotropium bromide hydrate', 'aclidinium bromide', 'times-per-day aclidinium bromide (Acli-BID', 'Acli-BID and Tio-QD', 'Acli-BID or Tio-QD']","['rate ratio', 'Adverse events', 'activity-related subscales of SGRQ', ""forced expiratory volume in one second area under the curve (FEV 1 AUC 0-3 ), and secondary outcomes were pulmonary function, physical activity, St George's Respiratory Questionnaire (SGRQ), modified Medical Research Council (mMRC), the 8-item Short-Form Health Survey (SF-8) and COPD exacerbations"", 'physical activity', 'sedentary behaviour']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0424093', 'cui_str': 'Initiative (observable entity)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C1306772', 'cui_str': 'tiotropium bromide'}, {'cui': 'C2355432', 'cui_str': 'TiO(tpyp)'}, {'cui': 'C2699758', 'cui_str': 'aclidinium bromide'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C0048106', 'cui_str': 'BIDS'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0079816', 'cui_str': 'Medical Research'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0740304', 'cui_str': 'COPD exacerbation'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}]",44.0,0.151494,"Acli-BID and Tio-QD significantly improved sedentary behaviour (MD -35.20 min; 95% CI -67.41 to -2.94 and MD -55.40 min; 95% CI -98.15 to -12.77) within each group, but there was no significant difference between the two groups. ","[{'ForeName': 'Tadashi', 'Initials': 'T', 'LastName': 'Kamei', 'Affiliation': 'Department of Respiratory Medicine, Kamei Internal medicine and Respiratory Clinic, Takamatsu, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Nakamura', 'Affiliation': 'Department of Pulmonary Medicine, Sakaide City Hospital, Sakaide, Kagawa, Japan.'}, {'ForeName': 'Nobuki', 'Initials': 'N', 'LastName': 'Nanki', 'Affiliation': 'Department of Respiratory Medicine, Sanuki Municipal Hospital, Sanuki, Kagawa, Japan.'}, {'ForeName': 'Yoshiaki', 'Initials': 'Y', 'LastName': 'Minakata', 'Affiliation': 'Department of Respiratory Medicine, National Hospital Organization Wakayama Hospital, Wakayama, Japan.'}, {'ForeName': 'Kazuto', 'Initials': 'K', 'LastName': 'Matsunaga', 'Affiliation': 'Department of Respiratory Medicine and Infectious Disease, Graduate school of Medicine, Yamaguchi University, Ube, Japan.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Mori', 'Affiliation': 'Sleep and Respiratory Disease Center, KKR Takamatsu Hospital, Takamatsu, Kagawa, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2018-024114'] 3116,31745762,Transcriptome sequencing of endometrium revealed alterations in mRNAs and lncRNAs after ovarian stimulation.,"RESEARCH QUESTION Using RNA-sequencing analysis, we investigated the relationship between ovarian stimulation and endometrial transcriptome profiles during the window of implantation (WOI) to identify candidate predictive factors for the WOI and to optimize timing for embryo transfer. METHODS Twelve women with normal basal hormone levels and regular ovulation were randomly assigned into three groups based on sampling time: late-proliferate phase (P group), and receptive phase in natural cycles (LH+7, N group) and stimulated cycles (hCG+7, S group). Transcriptome profiles of mRNAs and long non-coding RNAs (lncRNAs) were then compared among the three groups. Validation was performed using real-time qPCR. RESULTS Comparison of transcriptome profiles between the natural and stimulated endometrium revealed 173 differentially expressed genes (DEGs), with a > 2-fold change (FC) and p < 0.05, under the influence of supraphysiological estradiol (E 2 ) induced by ovarian stimulation. By clustering and KEGG pathway analysis, molecules and pathways associated with endometrial receptivity were identified. Of the 39 DEGs common to the three groups, eight genes were validated using real-time PCR. ESR1, MMP10, and HPSE were previously reported to be associated with endometrial receptivity. In addition, three novel genes (IL13RA2, ZCCHC12, SRARP) and two lncRNAs (LINC01060, LINC01104) were new potential endometrial receptivity-related markers. CONCLUSION Using mRNA and lncRNA sequencing, we found that supraphysiological E 2 levels from ovarian stimulation had a marked impact upon endometrial transcriptome profiles and may result in a shift of the WOI. The precise mechanisms underlying the supraphysiological hormone-induced shift of the WOI require further research. REGISTRATION NUMBER ChiCTR180001453.",2020,"In addition, three novel genes (IL13RA2, ZCCHC12, SRARP) and two lncRNAs (LINC01060, LINC01104) were new potential endometrial receptivity-related markers. ",['Twelve women with normal basal hormone levels and regular ovulation'],"['sampling time: late-proliferate phase (P group), and receptive phase in natural cycles']",['Transcriptome profiles of mRNAs and long non-coding RNAs (lncRNAs'],"[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C1287355', 'cui_str': 'Finding of hormone level (finding)'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0029965', 'cui_str': 'Ovulation'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205296', 'cui_str': 'Natural (qualifier value)'}]","[{'cui': 'C1956267', 'cui_str': 'Transcriptome Profiles'}, {'cui': 'C0035696', 'cui_str': 'mRNA'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0009219', 'cui_str': 'Coding'}, {'cui': 'C0035668', 'cui_str': 'RNA'}]",12.0,0.0467323,"In addition, three novel genes (IL13RA2, ZCCHC12, SRARP) and two lncRNAs (LINC01060, LINC01104) were new potential endometrial receptivity-related markers. ","[{'ForeName': 'Lingxiu', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Medical Center for Human Reproduction, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Wang', 'Affiliation': 'Medical Center for Human Reproduction, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Shan', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Medical Center for Human Reproduction, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Xueyan', 'Initials': 'X', 'LastName': 'Bai', 'Affiliation': 'Medical Center for Human Reproduction, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Binbin', 'Initials': 'B', 'LastName': 'Zou', 'Affiliation': 'Beijing NeoAntigen Biotechnology Co. Ltd, Beijing, China.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Medical Center for Human Reproduction, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. cyliyuan@126.com.'}]",Journal of assisted reproduction and genetics,['10.1007/s10815-019-01616-5'] 3117,31292181,"Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial).","INTRODUCTION The The BIOlogical Dose OPTimisation (BIODOPT) trial is a pragmatic, multicentre, randomised controlled, open-label, parallel-group, equivalence study designed to evaluate tapering of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) in sustained clinical remission or low disease activity (LDA). Traditionally, these patients maintain standard dosage of bDMARD lifelong; however, recent studies indicate that a significant proportion of patients in sustained remission or LDA can taper their bDMARD and maintain stable disease activity. Thus, this trial aims to evaluate whether a disease activity-guided tapering strategy for bDMARDs will enable a significant dosage reduction while maintaining disease activity compared with usual care. From the individual patient's standpoint as well as from a societal perspective, it would be advantageous if bDMARDs could be reduced or even discontinued while maintaining disease activity. METHODS AND ANALYSIS A total of 180 patients with RA, PsA or axSpA treated with bDMARDs and in clinical remission/LDA during the past 12 months will be enrolled from four centres in Denmark. Patients will be randomised in a ratio of 2:1 to either disease activity-guided tapering of bDMARDs (intervention group) or continuation of bDMARDs as usual care (control group).The primary objective is the difference between the two groups in the proportion of patients who have reduced their inclusion dosage of bDMARDs to 50% or less while maintaining stable disease activity at 18 months follow-up. ETHICS AND DISSEMINATION The study is approved by the ethics committee of Northern Jutland, Denmark (N-20170073) and by the Danish Medicine Agency. Patient research partner KHH contributed to refinement of the protocol and approved the final manuscript. Results will be disseminated through publication in international peer-reviewed journals. TRIAL REGISTRATION NUMBER 2017-001970-41; Pre-results.",2019,"The The BIOlogical Dose OPTimisation (BIODOPT) trial is a pragmatic, multicentre, randomised controlled, open-label, parallel-group, equivalence study designed to evaluate tapering of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) in sustained clinical remission or low disease activity (LDA).","['patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) in sustained clinical remission or low disease activity (LDA', '180 patients with RA, PsA or axSpA treated with bDMARDs and in clinical remission/LDA during the past 12 months will be enrolled from four centres in Denmark', 'patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis']","['biological disease-modifying antirheumatic drugs (bDMARDs', 'disease activity-guided tapering of bDMARDs (intervention group) or continuation of bDMARDs', 'biological disease-modifying antirheumatic drugs']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid Arthritis'}, {'cui': 'C0003872', 'cui_str': 'Psoriatic Arthropathy'}, {'cui': 'C3203547', 'cui_str': 'Axial spondyloarthritis (disorder)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0201544', 'cui_str': 'Prostate specific antigen measurement (procedure)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}]","[{'cui': 'C4553887', 'cui_str': 'Biologic Drugs'}, {'cui': 'C0242708', 'cui_str': 'Antirheumatic Drugs, Disease-Modifying'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0441640', 'cui_str': 'Tapering - action (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]",[],180.0,0.130415,"The The BIOlogical Dose OPTimisation (BIODOPT) trial is a pragmatic, multicentre, randomised controlled, open-label, parallel-group, equivalence study designed to evaluate tapering of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) in sustained clinical remission or low disease activity (LDA).","[{'ForeName': 'Line', 'Initials': 'L', 'LastName': 'Uhrenholt', 'Affiliation': 'Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Schlemmer', 'Affiliation': 'Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Ellen-Margrethe', 'Initials': 'EM', 'LastName': 'Hauge', 'Affiliation': 'Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Christensen', 'Affiliation': 'Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Lene', 'Initials': 'L', 'LastName': 'Dreyer', 'Affiliation': 'Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Maria E', 'Initials': 'ME', 'LastName': 'Suarez-Almazor', 'Affiliation': 'Department of General Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Salome', 'Initials': 'S', 'LastName': 'Kristensen', 'Affiliation': 'Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark.'}]",BMJ open,['10.1136/bmjopen-2018-028517'] 3118,30916463,Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.,"AIMS To compare long-term criminal justice outcomes among opioid-dependent individuals randomized to receive buprenorphine or methadone. DESIGN, SETTING AND PARTICIPANTS A 5-year follow-up was conducted in 2011-14 of 303 opioid-dependent participants entering three opioid treatment programs in California, USA in 2006-09 and randomized to receive either buprenorphine/naloxone or methadone. INTERVENTION AND COMPARATOR Participants received buprenorphine/naloxone (BUP; n = 179) or methadone (MET; n = 124) for 24 weeks and then were tapered off their treatment over ≤ 8 weeks or referred for ongoing clinical treatment. Midway through the study, the randomization scheme was switched from 1 : 1 BUP : MET to 2 : 1 because of higher dropout in the BUP arm. MEASUREMENTS Study outcomes included arrests and self-reported incarceration. Predictors included randomization condition (buprenorphine versus methadone), age, gender, race/ethnicity, use of cocaine, drug injection in the 30 days prior to baseline and study site. Treatment status (buprenorphine, methadone, none) during follow-up was included as a time-varying covariate. FINDINGS There was no significant difference by randomization condition in the proportion arrested (buprenorphine: 55.3%, methadone: 54.0%) or incarcerated (40.9%, 47.3%) during follow-up. Among methadone-randomized individuals, arrest was less likely with methadone treatment (0.50, 0.35-0.72) during follow-up (relative to no treatment) and switching to buprenorphine had a lower likelihood of arrest than those receiving no treatment (0.39, 0.18-0.87). Among buprenorphine-randomized individuals, arrest was less likely with receipt of buprenorphine (0.49, 0.33-0.75) during follow-up and switching to methadone had a similar likelihood of arrest as methadone-randomized individuals receiving no treatment. Likelihood of arrest was also negatively associated with older age (0.98, 0.96-1.00); it was positively associated with Hispanic ethnicity (1.63, 1.04-2.56), cocaine use (2.00, 1.33-3.03), injection drug use (2.19, 1.26-3.83), and study site. CONCLUSIONS In a US sample of people treated for opioid use disorder, continued treatment with either buprenorphine or methadone was associated with a reduction in arrests relative to no treatment. Cocaine use, injection drug use, Hispanic ethnicity and younger age were associated with higher likelihood of arrest.",2019,"There was no significant difference by randomization condition in the proportion arrested (buprenorphine: 55.3%, methadone: 54.0%) or incarcerated (40.9%, 47.3%) during follow-up.","['A 5-year follow-up was conducted in 2011-14 of 303 opioid-dependent participants entering three opioid treatment programs in California, USA in 2006-09 and randomized to receive either']","['buprenorphine or methadone', 'buprenorphine/naloxone or methadone', 'buprenorphine/naloxone (BUP; n\xa0=\xa0179) or methadone', 'Cocaine', 'buprenorphine', 'buprenorphine-naloxone', 'methadone', 'buprenorphine, methadone']","['arrests and self-reported incarceration', 'likelihood of arrest', 'randomization condition (buprenorphine versus methadone), age, gender, race/ethnicity, use of cocaine, drug injection', 'Hispanic ethnicity', 'Criminal justice outcomes']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0006754', 'cui_str': 'California'}]","[{'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C0025605', 'cui_str': 'Methadone'}, {'cui': 'C1169989', 'cui_str': 'Buprenorphine / Naloxone'}, {'cui': 'C4517609', 'cui_str': '179 (qualifier value)'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}]","[{'cui': 'C0237477', 'cui_str': 'Arrested (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0205255', 'cui_str': 'Imprisonment (finding)'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C0025605', 'cui_str': 'Methadone'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}, {'cui': 'C0243103', 'cui_str': 'ethnicity'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0086072', 'cui_str': 'Criminal Justice'}]",3.0,0.0573535,"There was no significant difference by randomization condition in the proportion arrested (buprenorphine: 55.3%, methadone: 54.0%) or incarcerated (40.9%, 47.3%) during follow-up.","[{'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Evans', 'Affiliation': 'Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA, USA.'}, {'ForeName': 'Yuhui', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'UCLA Integrated Substance Abuse Programs, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Yoo', 'Affiliation': 'UCLA Integrated Substance Abuse Programs, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Huang', 'Affiliation': 'UCLA Integrated Substance Abuse Programs, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA.'}, {'ForeName': 'Yih-Ing', 'Initials': 'YI', 'LastName': 'Hser', 'Affiliation': 'UCLA Integrated Substance Abuse Programs, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA.'}]","Addiction (Abingdon, England)",['10.1111/add.14620'] 3119,30804464,Association of orthostatic hypertension with mortality in the Systolic Hypertension in the Elderly Program.,"We examined the association of orthostatic hypertension with all-cause mortality in the active treatment and placebo randomized groups of the Systolic Hypertension in the Elderly Program (SHEP). SHEP was a multicenter, randomized, double-blind, placebo-controlled clinical trial of the effect of chlorthalidone-based antihypertensive treatment on the rate of occurrence of stroke among older persons with isolated systolic hypertension (ISH). Men and women aged 60 years and above with ISH defined by a systolic blood pressure (SBP) of 160 mm Hg or higher and diastolic blood pressure lower than 90 mm Hg were randomized to chlorthalidone-based stepped care therapy or matching placebo. Among 4736 SHEP participants, 4073 had a normal orthostatic response, 203 had orthostatic hypertension, and 438 had orthostatic hypotension. Compared with normal response, orthostatic hypertension was associated with higher all-cause mortality at 4.5 and 17 years in analyses adjusted for age, gender, treatment, SBP, and pulse pressure (PP, HR 1.87, 95% CI 1.30-2.69, p = 0.0007; HR 1.40, 95% CI 1.17-1.68, p = 0.0003, respectively). These associations remained significant after additional adjustment for risk factors and comorbidities (HR 1.43, 95% CI 0.99-0.08, p = 0.0566 at 4.5 years, and HR 1.27, 95% CI 1.06-1.53, p = 0.0096 at 17 years). The increased risk of all-cause mortality associated with orthostatic hypertension was observed in both the active and placebo groups without significant interaction between randomization group and the effect on mortality. Orthostatic hypertension is associated with future mortality risk, is easily detected, and can be used in refining cardiovascular risk assessment.",2019,"Compared with normal response, orthostatic hypertension was associated with higher all-cause mortality at 4.5 and 17 years in analyses adjusted for age, gender, treatment, SBP, and pulse pressure (PP, HR 1.87, 95% CI 1.30-2.69, p = 0.0007; HR 1.40, 95% CI 1.17-1.68, p = 0.0003, respectively).","['randomized groups of the Systolic Hypertension in the Elderly Program (SHEP', 'Men and women aged 60 years and above with ISH defined by a systolic blood pressure (SBP) of 160\u2009mm Hg or higher and diastolic blood pressure lower than 90\u2009mm Hg', '4736 SHEP participants, 4073 had a normal orthostatic response, 203 had orthostatic hypertension, and 438 had orthostatic hypotension', 'older persons with isolated systolic hypertension (ISH']","['SHEP', 'chlorthalidone-based antihypertensive treatment', 'chlorthalidone-based stepped care therapy or matching placebo', 'placebo']","['Orthostatic hypertension', 'orthostatic hypertension', 'SBP, and pulse pressure', 'rate of occurrence of stroke', 'mortality']","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0221155', 'cui_str': 'Systolic hypertension (disorder)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0544618', 'cui_str': 'Orthostatic hypertension'}, {'cui': 'C0020651', 'cui_str': 'Hypotension, Postural'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0745133', 'cui_str': 'Isolated systolic hypertension'}]","[{'cui': 'C0008294', 'cui_str': 'Chlorthalidone'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0003364', 'cui_str': 'Anti-Hypertensive Drugs'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0544618', 'cui_str': 'Orthostatic hypertension'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C0949236', 'cui_str': 'Pulse Pressure'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",4736.0,0.348896,"Compared with normal response, orthostatic hypertension was associated with higher all-cause mortality at 4.5 and 17 years in analyses adjusted for age, gender, treatment, SBP, and pulse pressure (PP, HR 1.87, 95% CI 1.30-2.69, p = 0.0007; HR 1.40, 95% CI 1.17-1.68, p = 0.0003, respectively).","[{'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Kostis', 'Affiliation': 'Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. wkostis@rutgers.edu.'}, {'ForeName': 'Davit', 'Initials': 'D', 'LastName': 'Sargsyan', 'Affiliation': 'Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'Choukri', 'Initials': 'C', 'LastName': 'Mekkaoui', 'Affiliation': 'Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Abel E', 'Initials': 'AE', 'LastName': 'Moreyra', 'Affiliation': 'Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Cabrera', 'Affiliation': 'Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'Nora M', 'Initials': 'NM', 'LastName': 'Cosgrove', 'Affiliation': 'Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'Jeanine E', 'Initials': 'JE', 'LastName': 'Sedjro', 'Affiliation': 'Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Kostis', 'Affiliation': 'Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Cushman', 'Affiliation': 'Memphis Veterans Affairs Medical Center, Memphis, TN, USA.'}, {'ForeName': 'John S', 'Initials': 'JS', 'LastName': 'Pantazopoulos', 'Affiliation': 'Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'Sara L', 'Initials': 'SL', 'LastName': 'Pressel', 'Affiliation': 'University of Texas Health Science Center, Houston, TX, USA.'}, {'ForeName': 'Barry R', 'Initials': 'BR', 'LastName': 'Davis', 'Affiliation': 'University of Texas Health Science Center, Houston, TX, USA.'}]",Journal of human hypertension,['10.1038/s41371-019-0180-4'] 3120,31994003,"Effect of Group Embryo Culture under Low-Oxygen Tension in Benchtop Incubators on Human Embryo Culture: Prospective, Randomized, Controlled Trial.","To evaluate the efficacy of group embryo culture under low-oxygen tension in benchtop incubators on human embryo development in vitro. The study was designed as a prospective, patient blind, randomized, controlled trial of a complex intervention. One hundred forty-eight women undergoing IVF were recruited in our fertility practice and randomized into two groups: intervention group (study culture strategy) or control group (control culture strategy). Intervention group embryos were cultured grouped under low-oxygen tension in benchtop incubators while control group embryos were cultured individually under atmospheric oxygen tension in large-box incubators. Using the study culture strategy, there were a significantly higher implantation rate (65.1% vs 49.2%; RR, 1.42; 95% CI, 1.17-1.73) and live birth delivery rate per embryo transfer (52.7% vs 39.5%; RR, 1.33; 95% CI, 1.02-1.75) with the first fresh embryo transfer. Cumulative implantation rate (56.7% vs 43.6%; RR, 1.30; 95% CI, 1.05-1.62) and cumulative live birth rate per embryo transfer (47.4% vs 36.2%; RR, 1.31; 95% CI, 1.01-1.69) were also statistically significantly increased in the study culture strategy. Human embryos exposed to our study culture condition strategy had statistically significant increased cumulative implantation rate and cumulative live birth rate per embryo transferred. Our findings suggest that this strategy specially favours poor quality embryos. Clinical Trial Registration Number: NCT01904006.",2020,Human embryos exposed to our study culture condition strategy had statistically significant increased cumulative implantation rate and cumulative live birth rate per embryo transferred.,"['benchtop incubators on human embryo development in vitro', 'Benchtop Incubators on Human Embryo Culture', 'One hundred forty-eight women undergoing IVF were recruited in our fertility practice']","['Group Embryo Culture under Low-Oxygen Tension', 'group embryo culture under low-oxygen tension', 'intervention group (study culture strategy) or control group (control culture strategy', 'Intervention group embryos were cultured grouped under low-oxygen tension in benchtop incubators while control group embryos were cultured individually under atmospheric oxygen tension in large-box incubators']","['Cumulative implantation rate', 'implantation rate', 'cumulative implantation rate and cumulative live birth rate per embryo transferred', 'live birth delivery rate per embryo transfer', 'cumulative live birth rate per embryo transfer']","[{'cui': 'C0021178', 'cui_str': 'Incubators'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0013936', 'cui_str': 'Embryonic Development'}, {'cui': 'C0021135', 'cui_str': 'In Vitro'}, {'cui': 'C0013935', 'cui_str': 'Embryo'}, {'cui': 'C0220814', 'cui_str': 'culture'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0015915', 'cui_str': 'Test-Tube Fertilization'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0013935', 'cui_str': 'Embryo'}, {'cui': 'C0220814', 'cui_str': 'culture'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0202155', 'cui_str': 'Oxygen measurement, partial pressure, arterial (procedure)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0021178', 'cui_str': 'Incubators'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C1638312', 'cui_str': 'Boxes'}]","[{'cui': 'C0021107', 'cui_str': 'Insertion procedure'}, {'cui': 'C0481667', 'cui_str': 'Live Birth'}, {'cui': 'C0013938', 'cui_str': 'Embryo Transfer'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}]",148.0,0.172007,Human embryos exposed to our study culture condition strategy had statistically significant increased cumulative implantation rate and cumulative live birth rate per embryo transferred.,"[{'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Ruíz', 'Affiliation': 'IVI-RMA Seville, Avda. República Argentina 58, ES-41011, Seville, Spain.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Santamaría-López', 'Affiliation': 'IVI-RMA Seville, Avda. República Argentina 58, ES-41011, Seville, Spain.'}, {'ForeName': 'Víctor', 'Initials': 'V', 'LastName': 'Blasco', 'Affiliation': 'IVI-RMA Seville, Avda. República Argentina 58, ES-41011, Seville, Spain.'}, {'ForeName': 'María José', 'Initials': 'MJ', 'LastName': 'Hernáez', 'Affiliation': 'IVI-RMA Seville, Avda. República Argentina 58, ES-41011, Seville, Spain.'}, {'ForeName': 'Cinzia', 'Initials': 'C', 'LastName': 'Caligara', 'Affiliation': 'IVI-RMA Seville, Avda. República Argentina 58, ES-41011, Seville, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Pellicer', 'Affiliation': 'IVI Foundation, Instituto de Investigación Sanitaria La Fe (IIS La Fe), ES-46026, Valencia, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Fernández-Sánchez', 'Affiliation': 'IVI-RMA Seville, Avda. República Argentina 58, ES-41011, Seville, Spain. mfernandez57@us.es.'}, {'ForeName': 'Nicolás', 'Initials': 'N', 'LastName': 'Prados', 'Affiliation': 'IVI-RMA Seville, Avda. República Argentina 58, ES-41011, Seville, Spain.'}]","Reproductive sciences (Thousand Oaks, Calif.)",['10.1007/s43032-020-00150-5'] 3121,31343675,Comparison of 3- vs 2-Dimensional Endoscopy Using Eye Tracking and Assessment of Cognitive Load Among Surgeons Performing Endoscopic Ear Surgery.,"Importance Endoscopic ear surgery (EES) is an emerging technique to treat middle ear diseases; however, the interventions are performed in 2-dimensional (2D) endoscopic views, which do not provide depth perception. Recent technical developments now allow the application of 3-dimensional (3D) endoscopy in EES. Objective To investigate the usability, advantages, and disadvantages of 3D vs 2D endoscopy in EES under standardized conditions. Design, Setting, and Participants This cohort study conducted at a tertiary academic medical center in Bern, Switzerland, included 16 residents and consultants of the Department of Otorhinolaryngology, Head & Neck Surgery, Inselspital, Bern. Interventions Each participant performed selected steps of a type I tympanoplasty and stapedotomy in 3D and 2D views in a cadaveric model using a randomized, Latin-square crossover design. Main Outcomes and Measures Time taken to perform the EES, number of attempts, and accidental damage during the dissections were compared between 3D and 2D endoscopy. Eye tracking was performed throughout the interventions. Cognitive load and subjective feedback were measured by standardized questionnaires. Results Of the 16 surgeons included in the study (11 inexperienced residents; 5 experienced consultants), 8 were women (50%); mean age was 36 years (range, 27-57 years). Assessment of surgical time revealed similar operating times for both techniques (181 seconds in 2D vs 174 seconds in 3D). A total of 64 surgical interventions were performed. Most surgeons preferred the 3D technique (10 for 3D vs 6 for 2D), even though a higher incidence of eye strain, measured on a 7-point Likert scale, was observed (3D, 2.19 points vs 2D, 1.44 points; mean difference , 0.74; 95% CI, 0.29-1.20; r = 0.67). Eye movement assessment revealed a higher duration of fixation for consultants in 2D (0.79 seconds) compared with 3D endoscopy (0.54 seconds), indicating a less-efficient application of previously acquired experiences using the new technique. Residents (mean [SD], 49.02 [16.4]) had a significantly higher workload than consultants (mean [SD], 27.21 [12.20]), independent of the used technique or task. Conclusions and Relevance Three-dimensional endoscopy is suitable for EES, especially for inexperienced surgeons whose mental model of the intervention has yet to be consolidated. The application of 3D endoscopy in clinical routines and for educational purposes may be feasible and beneficial.",2019,Assessment of surgical time revealed similar operating times for both techniques (181 seconds in 2D vs 174 seconds in 3D).,"['8 were women (50%); mean age was 36 years (range, 27-57 years', 'Surgeons Performing Endoscopic Ear Surgery', '16 surgeons included in the study (11 inexperienced residents; 5 experienced consultants', 'tertiary academic medical center in Bern, Switzerland, included 16 residents and consultants of the Department of Otorhinolaryngology, Head & Neck Surgery, Inselspital, Bern.\nInterventions']","['2-Dimensional Endoscopy', 'Endoscopic ear surgery (EES']","['Cognitive load and subjective feedback', 'Measures\n\n\nTime taken to perform the EES, number of attempts, and accidental damage during the dissections', 'Cognitive Load', '7-point Likert scale']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0910435', 'cui_str': 'AM 36'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0582175', 'cui_str': 'Surgeon (occupation)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0013443', 'cui_str': 'Vestibulocochlear Apparatus'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0009817', 'cui_str': 'Consultant'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0000872', 'cui_str': 'University Medical Centers'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}, {'cui': 'C0029892', 'cui_str': 'Otorhinolaryngology'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0185773', 'cui_str': 'Operation on neck'}]","[{'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0013443', 'cui_str': 'Vestibulocochlear Apparatus'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0521129', 'cui_str': 'Accidental (qualifier value)'}, {'cui': 'C0010957', 'cui_str': 'Damage (morphologic abnormality)'}, {'cui': 'C0012737', 'cui_str': 'Dissection'}, {'cui': 'C0451267', 'cui_str': 'Likert scale (assessment scale)'}]",16.0,0.0423577,Assessment of surgical time revealed similar operating times for both techniques (181 seconds in 2D vs 174 seconds in 3D).,"[{'ForeName': 'Lukas', 'Initials': 'L', 'LastName': 'Anschuetz', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital, University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Niederhauser', 'Affiliation': 'Department of Psychology, Swiss University of Distance Education, Bern, Switzerland.'}, {'ForeName': 'Wilhelm', 'Initials': 'W', 'LastName': 'Wimmer', 'Affiliation': 'Artificial Organ Center for Biomedical Engineering, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Abraam', 'Initials': 'A', 'LastName': 'Yacoub', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital, University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Weibel', 'Affiliation': 'Department of Psychology, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Fred W', 'Initials': 'FW', 'LastName': 'Mast', 'Affiliation': 'Department of Psychology, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Caversaccio', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital, University Hospital, University of Bern, Bern, Switzerland.'}]",JAMA otolaryngology-- head & neck surgery,['10.1001/jamaoto.2019.1765'] 3122,2807523,Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.,"A single dose (5 x 10(8) organisms) of attenuated A- B+ Vibrio cholerae classical Inaba recombinant vaccine strain CVD 103-HgR or placebo was administered to 24 healthy young Thai adults in a randomized, placebo-controlled, double-blind trial of safety and immunogenicity. None of the volunteers experienced untoward reactions. The vaccine strain was recovered from 2 of 12 vaccines. The vibriocidal antibody response (the best immunological correlate of protection) was good: 11 of 12 vaccinees (92%) manifested significant serotype-homologous Inaba antibody rises with a peak reciprocal geometric mean titer (RGMT) postvaccination of 3,417; 9 of 12 exhibited significant serotype-heterologous Ogawa antibody rises (prevaccination RGMT, 180; peak RGMT, 2,874). Nine of 12 vaccinees had significant rises in serum antitoxin. None of the controls exhibited rises in vibriocidal or antitoxic antibody. This preliminary study further confirms the safety and immunogenicity of CVD 103-HgR live oral cholera vaccine and paves the way for larger community studies of this candidate cholera vaccine.",1989,"The vibriocidal antibody response (the best immunological correlate of protection) was good: 11 of 12 vaccinees (92%) manifested significant serotype-homologous Inaba antibody rises with a peak reciprocal geometric mean titer (RGMT) postvaccination of 3,417; 9 of 12 exhibited significant serotype-heterologous Ogawa antibody rises (","['healthy Thai adults', '24 healthy young Thai adults']","['attenuated A', 'placebo', '103-HgR or placebo', 'live oral cholera vaccine strain CVD 103-HgR', 'CVD 103-HgR live oral cholera vaccine', 'recombinant vaccine strain CVD']","['untoward reactions', 'vibriocidal antibody response', 'serum antitoxin', 'vibriocidal or antitoxic antibody']","[{'cui': 'C0337910', 'cui_str': 'Thai'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}]","[{'cui': 'C0332161', 'cui_str': 'Attenuated by (contextual qualifier) (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4517526', 'cui_str': 'One hundred and three'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0008359', 'cui_str': 'Cholera Vaccine'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C0961644', 'cui_str': 'cholera vaccine CVD 103-HgR'}, {'cui': 'C0034862', 'cui_str': 'Vaccines, Recombinant'}]","[{'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}, {'cui': 'C0003261', 'cui_str': 'Antibody Response'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0003445', 'cui_str': 'Antitoxins'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}]",24.0,0.318904,"The vibriocidal antibody response (the best immunological correlate of protection) was good: 11 of 12 vaccinees (92%) manifested significant serotype-homologous Inaba antibody rises with a peak reciprocal geometric mean titer (RGMT) postvaccination of 3,417; 9 of 12 exhibited significant serotype-heterologous Ogawa antibody rises (","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Migasena', 'Affiliation': 'Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Pitisuttitham', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Prayurahong', 'Affiliation': ''}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Suntharasamai', 'Affiliation': ''}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Supanaranond', 'Affiliation': ''}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Desakorn', 'Affiliation': ''}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Vongsthongsri', 'Affiliation': ''}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Tall', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ketley', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Losonsky', 'Affiliation': ''}]",Infection and immunity,[] 3123,32115311,Aggression Prevention Training for Individuals With Dementia and Their Caregivers: A Randomized Controlled Trial.,"OBJECTIVE International appeals call for interventions to prevent aggression and other behavioral problems in individuals with dementia (IWD). Aggression Prevention Training (APT), based on intervening in three contributors to development of aggression (IWD pain, IWD depression, and caregiver-IWD relationship problems) aims to reduce incidence of aggression in IWD over 1 year. DESIGN Randomized, controlled trial. SETTING Three clinics that assess, diagnose, and treat dementia. PARTICIPANTS Two hundred twenty-eight caregiver-IWD dyads who screened positive for IWD pain, IWD depression, or caregiver-IWD relationship problems randomized to APT or Enhanced Usual Primary Care (EU-PC). INTERVENTION APT, a skills-based intervention delivered over 3 months to address pain/depression/caregiver-IWD relationship issues. EU-PC included printed material on dementia and community resources; and eight brief, weekly support calls. MEASUREMENTS The primary outcome was incidence of aggression over 1 year, determined by the Cohen Mansfield Agitation Inventory-Aggression Subscale. Secondary outcomes included pain, depression, caregiver-IWD relationship, caregiver burden, positive caregiving, behavior problems, and anxiety. RESULTS Aggression incidence and secondary outcomes did not differ between groups. However, in those screening positive for IWD depression or caregiver-IWD relationship problems, those receiving EU-PC had significant increases in depression and significant decreases in quality of the caregiver-IWD relationship, whereas those receiving APT showed no changes in these outcomes over time. CONCLUSION The cost to patients, family, and society of behavioral problems in IWD, along with modest efficacy of most pharmacologic and nonpharmacologic interventions, calls for more study of novel preventive approaches.",2020,"RESULTS Aggression incidence and secondary outcomes did not differ between groups.","['Two hundred twenty-eight caregiver-IWD dyads who screened positive for IWD pain, IWD depression, or caregiver-IWD relationship problems randomized to APT or Enhanced Usual Primary Care (EU-PC', 'Three clinics that assess, diagnose, and treat dementia', 'individuals with dementia (IWD', 'Individuals With Dementia and Their Caregivers']","['Aggression Prevention Training', 'Aggression Prevention Training (APT']","['incidence of aggression over 1 year, determined by the Cohen Mansfield Agitation Inventory-Aggression Subscale', 'IWD pain, IWD depression, and caregiver-IWD relationship problems', 'depression', 'quality of the caregiver-IWD relationship', 'pain, depression, caregiver-IWD relationship, caregiver burden, positive caregiving, behavior problems, and anxiety']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0425168', 'cui_str': 'Relationship problems (finding)'}, {'cui': 'C0003645', 'cui_str': 'APT'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0001807', 'cui_str': 'Aggression'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0003645', 'cui_str': 'APT'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0001807', 'cui_str': 'Aggression'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0521095', 'cui_str': 'Determined by (contextual qualifier) (qualifier value)'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated (finding)'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0425168', 'cui_str': 'Relationship problems (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",228.0,0.24421,"RESULTS Aggression incidence and secondary outcomes did not differ between groups.","[{'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Kunik', 'Affiliation': 'Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (MEK, DR, TE, ABA), Houston, TX; VA South Central Mental Illness Research, Education and Clinical Center (a virtual center) (MEK, DR, TE, ABA); Baylor College of Medicine (MEK, MAS, SS, DR, SR, TE, MN, SW, NW, ABA), Houston, TX; Michael E. DeBakey VA Medical Center (MEK, SR, JF), Houston, TX. Electronic address: mkunik@bcm.edu.'}, {'ForeName': 'Melinda A', 'Initials': 'MA', 'LastName': 'Stanley', 'Affiliation': 'Baylor College of Medicine (MEK, MAS, SS, DR, SR, TE, MN, SW, NW, ABA), Houston, TX.'}, {'ForeName': 'Srijana', 'Initials': 'S', 'LastName': 'Shrestha', 'Affiliation': 'Baylor College of Medicine (MEK, MAS, SS, DR, SR, TE, MN, SW, NW, ABA), Houston, TX; Wheaton College (SS), Norton, MA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Ramsey', 'Affiliation': 'Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (MEK, DR, TE, ABA), Houston, TX; VA South Central Mental Illness Research, Education and Clinical Center (a virtual center) (MEK, DR, TE, ABA); Baylor College of Medicine (MEK, MAS, SS, DR, SR, TE, MN, SW, NW, ABA), Houston, TX.'}, {'ForeName': 'Sheila', 'Initials': 'S', 'LastName': 'Richey', 'Affiliation': 'Baylor College of Medicine (MEK, MAS, SS, DR, SR, TE, MN, SW, NW, ABA), Houston, TX; Michael E. DeBakey VA Medical Center (MEK, SR, JF), Houston, TX.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Snow', 'Affiliation': 'Tuscaloosa VA Medical Center (LS), Tuscaloosa, AL; The University of Alabama Center for Mental Health and Aging (LS), Tuscaloosa, AL.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Freshour', 'Affiliation': 'Michael E. DeBakey VA Medical Center (MEK, SR, JF), Houston, TX.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Evans', 'Affiliation': 'Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (MEK, DR, TE, ABA), Houston, TX; VA South Central Mental Illness Research, Education and Clinical Center (a virtual center) (MEK, DR, TE, ABA); Baylor College of Medicine (MEK, MAS, SS, DR, SR, TE, MN, SW, NW, ABA), Houston, TX.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Newmark', 'Affiliation': 'Baylor College of Medicine (MEK, MAS, SS, DR, SR, TE, MN, SW, NW, ABA), Houston, TX; Kelsey Seybold Research Foundation (MN), West University Place, TX.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Williams', 'Affiliation': 'Baylor College of Medicine (MEK, MAS, SS, DR, SR, TE, MN, SW, NW, ABA), Houston, TX.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Wilson', 'Affiliation': 'Baylor College of Medicine (MEK, MAS, SS, DR, SR, TE, MN, SW, NW, ABA), Houston, TX.'}, {'ForeName': 'Amber B', 'Initials': 'AB', 'LastName': 'Amspoker', 'Affiliation': 'Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (MEK, DR, TE, ABA), Houston, TX; VA South Central Mental Illness Research, Education and Clinical Center (a virtual center) (MEK, DR, TE, ABA); Baylor College of Medicine (MEK, MAS, SS, DR, SR, TE, MN, SW, NW, ABA), Houston, TX.'}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2020.01.190'] 3124,31918233,A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.,"BACKGROUND Metastatic soft tissue sarcomas (STSs) management remains an unmet medical need. We assessed the activity and safety of regorafenib in patients with metastatic non-adipocytic STS who were previously treated with both chemotherapy and pazopanib. PATIENTS AND METHODS This double-blind, placebo-controlled, multicenter comparative randomized phase II trial included patients with histologically proven advanced and inoperable STS. Patients receiving placebo were offered optional cross-over for centrally confirmed disease progression. Primary end-point was centrally reviewed Response Evaluation Criteria in Solid Tumours-based progression-free survival (PFS), analysed on the intent-to-treat data set. In total, 24 events were required for 90% power, hazard ratio (HR) = 0.33 (median PFS, 3.6 versus 1.2 months), and 1-sided α = 0.1 (ClinicalTrials.gov, NCT01900743). RESULTS From December 2015 to October 2017, 37 patients were randomized; 18 to regorafenib and 19 to placebo. Thirteen patients assigned to placebo switched to regorafenib after progression. Median follow-up was 27.2 months (95% confidence interval [CI]: 24.4-not reached). We observed a significant PFS benefit of regorafenib compared with placebo (adjusted HR = 0.33; 95% CI: 0.15-0.74; p = 0.0007 median PFS = 2.1 versus 1.1 months, respectively), and a large and nearly significant overall survival (OS) benefit despite the cross-over (adjusted HR = 0.49; 95% CI: 0.23-1.06; p = 0.007; median OS = 17.8 versus 8.2 months). Before cross-over, the most common grade III or higher adverse events were lymphopenia (5 versus 1, respectively), diarrhoea (4 versus 0), dyspnoea (3 versus 1), skin toxicity (3 versus 0), arterial hypertension (2 versus 0), and increased transaminases (2 versus 0). CONCLUSION The present study demonstrated a meaningful clinical anti-tumour activity with regorafenib in heavily pre-treated patients with non-adipocytic STS.",2020,"In total, 24 events were required for 90% power, hazard ratio (HR) = 0.33","['non-adipocytic patients previously treated with both', 'From December 2015 to October 2017, 37 patients were randomized; 18 to', 'patients with metastatic non-adipocytic STS who were previously treated with both chemotherapy and pazopanib', 'heavily pre-treated patients with non-adipocytic STS', 'patients with histologically proven advanced and inoperable STS']","['placebo', 'chemotherapy and pazopanib', 'regorafenib']","['PFS benefit of regorafenib', 'dyspnoea', 'diarrhoea', 'Response Evaluation Criteria in Solid Tumours-based progression-free survival (PFS', 'activity and safety', 'overall survival', 'arterial hypertension', 'skin toxicity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1831796', 'cui_str': 'pazopanib'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0456369', 'cui_str': 'Proven (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0205187', 'cui_str': 'Inoperable (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1831796', 'cui_str': 'pazopanib'}, {'cui': 'C2980094', 'cui_str': 'regorafenib'}]","[{'cui': 'C2980094', 'cui_str': 'regorafenib'}, {'cui': 'C0013404', 'cui_str': 'Breathlessness'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C1167791', 'cui_str': 'Skin toxicity'}]",,0.621386,"In total, 24 events were required for 90% power, hazard ratio (HR) = 0.33","[{'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Penel', 'Affiliation': 'Medical Oncology Department, Centre Oscar Lambret, Lille and Lille University Hospital, Lille University, Lille, France. Electronic address: n-penel@o-lambret.fr.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Mir', 'Affiliation': 'Medical Oncology Department, Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Wallet', 'Affiliation': 'Clinical Research and Innovation Department, Centre Oscar Lambret, Lille, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Ray-Coquard', 'Affiliation': 'Medical Oncology Department, Centre Léon Bérard, Lyon, France.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Le Cesne', 'Affiliation': 'Medical Oncology Department, Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Italiano', 'Affiliation': 'Medical Oncology Department, Institut Bergonié, Bordeaux, France.'}, {'ForeName': 'Sebastien', 'Initials': 'S', 'LastName': 'Salas', 'Affiliation': 'Medical Oncology Department, CH La Timone, Marseille, France.'}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Delcambre', 'Affiliation': 'Medical Oncology Department, Centre François Baclesse, Caen, France.'}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Bompas', 'Affiliation': 'Medical Oncology Department, René Gauducheau, Saint-Herblain, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Bertucci', 'Affiliation': 'Medical Oncology Department, Institut Paoli-Calmette, Marseille, France.'}, {'ForeName': 'Esma', 'Initials': 'E', 'LastName': 'Saada-Bouzid', 'Affiliation': 'Medical Oncology Department, Centre Antoine Lacassagne, Nice, France.'}, {'ForeName': 'Loïc', 'Initials': 'L', 'LastName': 'Chaigneau', 'Affiliation': 'Medical Oncology Department, Hopital Saint-Jacques, Besançon, France.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Chevreau', 'Affiliation': 'Medical Oncology Department, Institut Universitaire de Cancérologie de Toulouse, Oncopôle, Toulouse, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Brodowicz', 'Affiliation': 'Medical University Vienna - General Hospital, Vienna, Austria.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Decoupigny', 'Affiliation': 'Clinical Research and Innovation Department, Centre Oscar Lambret, Lille, France.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Vanseymortier', 'Affiliation': 'Clinical Research and Innovation Department, Centre Oscar Lambret, Lille, France.'}, {'ForeName': 'Lucie', 'Initials': 'L', 'LastName': 'Laroche', 'Affiliation': 'Labeled Datacenter, Caen, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Taieb', 'Affiliation': 'Radiology Department, Centre Oscar Lambret, Lille, France.'}, {'ForeName': 'Marie-Cécile', 'Initials': 'MC', 'LastName': 'Le Deley', 'Affiliation': 'Clinical Research and Innovation Department, Centre Oscar Lambret, Lille, France; Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France.'}, {'ForeName': 'Jean-Yves', 'Initials': 'JY', 'LastName': 'Blay', 'Affiliation': 'Medical Oncology Department, Centre Léon Bérard, Lyon, France.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.12.001'] 3125,31209720,Effectiveness of Sterilized Symbiotic Drink Containing Lactobacillus helveticus Comparable to Probiotic Alone in Patients with Constipation-Predominant Irritable Bowel Syndrome.,"BACKGROUND This study aimed to objectively investigate whether the addition of polydextrose to sterilized probiotic containing Lactobacillus helveticus will confer benefits to constipation-predominant irritable bowel syndrome patients. METHODS A total of 163 patients were randomized into two groups: Group A to consume 350 mL of sterilized probiotic with 5.85 g polydextrose daily for 1 week and Group B without polydextrose. Intestinal transit time, fecal pH, fecal weight, and modified Garrigues questionnaires for pre- and post-consumption were assessed. RESULTS Median intestinal transit time was significantly reduced from 58 (IQR 43-72) to 45 (IQR 24-59) hours and 48 (IQR 31-72) to 30 (IQR 24-49) hours for Groups A and B, respectively (p < 0.01). Fecal pH for Groups A and B was significantly reduced from 6.57 ± 0.96 to 6.13 ± 0.95 (p = 0.003) and 6.58 ± 1.0 to 5.87 ± 0.83 (p < 0.001), respectively. Fecal weight for Group A was significantly increased from 8 g ± 6.4 g to 9.8 g ± 7.6 g (p = 0.003), but it was reduced for Group B from 13.3 g ± 19.4 g to 11.2 g ± 6.6 g (p = 0.308). Constipation-related symptoms were significantly improved for both groups. CONCLUSIONS The addition of polydextrose to sterilized probiotic containing L. helveticus did not show significant benefits to constipation-predominant irritable bowel syndrome patients. However, daily consumption of sterilized probiotic containing L. helveticus with or without polydextrose for a week alleviated constipation-related symptoms and objectively reduced both fecal pH and intestinal transit time.",2020,The addition of polydextrose to sterilized probiotic containing L. helveticus did not show significant benefits to constipation-predominant irritable bowel syndrome patients.,"['constipation-predominant irritable bowel syndrome patients', 'Patients with Constipation-Predominant Irritable Bowel Syndrome', '163 patients']","['Sterilized Symbiotic Drink Containing Lactobacillus helveticus', 'Probiotic Alone', 'Group A to consume 350\xa0mL of sterilized probiotic with 5.85', 'polydextrose to sterilized probiotic containing Lactobacillus helveticus']","['Median intestinal transit time', 'Intestinal transit time, fecal pH, fecal weight, and modified Garrigues questionnaires for pre- and post-consumption', 'Fecal pH', 'Fecal weight', 'fecal pH and intestinal transit time', 'Constipation-related symptoms']","[{'cui': 'C1868889', 'cui_str': 'Irritable bowel syndrome characterized by constipation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0317592', 'cui_str': 'Lactobacillus helveticus'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}, {'cui': 'C0441835', 'cui_str': 'Group A (qualifier value)'}, {'cui': 'C4517735', 'cui_str': '350'}, {'cui': 'C0071545', 'cui_str': 'polydextrose'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3665877', 'cui_str': 'Intestinal transit time'}, {'cui': 'C2711455', 'cui_str': 'pH of stool'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",163.0,0.0475529,The addition of polydextrose to sterilized probiotic containing L. helveticus did not show significant benefits to constipation-predominant irritable bowel syndrome patients.,"[{'ForeName': 'Mohd Fyzal', 'Initials': 'MF', 'LastName': 'Bahrudin', 'Affiliation': 'Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, 56000, Cheras, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Rafiz', 'Initials': 'R', 'LastName': 'Abdul Rani', 'Affiliation': 'Gastroenterology Unit, Faculty of Medicine, Universiti Teknologi MARA, 47000, Sungai Buloh, Selangor, Malaysia.'}, {'ForeName': 'Azmi Mohd', 'Initials': 'AM', 'LastName': 'Tamil', 'Affiliation': 'Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, 56000, Cheras, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Norfilza Mohd', 'Initials': 'NM', 'LastName': 'Mokhtar', 'Affiliation': 'Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, 56000, Cheras, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Raja Affendi', 'Initials': 'RA', 'LastName': 'Raja Ali', 'Affiliation': 'Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, 56000, Cheras, Kuala Lumpur, Malaysia. draffendi@ppukm.ukm.edu.my.'}]",Digestive diseases and sciences,['10.1007/s10620-019-05695-3'] 3126,31550354,Cell-Mediated Immune Responses After Influenza Vaccination of Solid Organ Transplant Recipients: Secondary Outcomes Analyses of a Randomized Controlled Trial.,"BACKGROUND Despite annual immunization, solid organ transplant (SOT) patients remain at increased risk for severe influenza infection because of suboptimal vaccine immunogenicity. We aimed to compare the CD4+ and CD8+ T-cell responses of the high-dose (HD) and the standard-dose (SD) trivalent inactivated vaccine. METHODS We collected peripheral blood mononuclear cells pre- and postimmunization from 60 patients enrolled in a randomized trial of HD versus SD vaccine (30 HD; 30 SD) during the 2016-2017 influenza season. RESULTS The HD vaccine elicited significantly greater monofunctional and polyfunctional CD4+ and CD8+ T-cell responses against influenza A/H1N1, A/H3N2, and B. For example, median vaccine-elicited influenza-specific polyfunctional CD4+ T cells were higher in recipients of the HD than SD vaccine after stimulation with influenza A/H1N1 (1193 vs 0 per 106 CD4+ T cells; P = .003), A/H3N2 (1154 vs 51; P = .008), and B (1102 vs 0; P = .001). Likewise, vaccine-elicited influenza-specific polyfunctional CD8+ T cells were higher in recipients of the HD than SD vaccine after stimulation with influenza B (367 vs 0; P = .002). CONCLUSIONS Our study provides novel evidence that HD vaccine elicits greater cellular responses compared with the SD vaccine in SOT recipients, which provides support to preferentially consider use of HD vaccination in the SOT setting.",2020,"The HD vaccine elicited significantly greater monofunctional and polyfunctional CD4+ and CD8+ T-cell responses against influenza A/H1N1, A/H3N2 and B.","['60 patients enrolled', 'Solid Organ Transplant Recipients', '30 HD; 30 SD) during the 2016-2017 influenza season', 'SOT recipients']","['HD vs. SD vaccine', 'H3N2 ', 'standard-dose (SD) trivalent inactivated vaccine']","['CD4+ and CD8+ T-cell responses', 'monofunctional and polyfunctional CD4+ and CD8+ T-cell responses against influenza A/H1N1, A/H3N2 and B']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0730400', 'cui_str': 'Solid organ transplant (procedure)'}, {'cui': 'C0021400', 'cui_str': 'Influenza, Human'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}]","[{'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0580267', 'cui_str': 'H3N2'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0042212', 'cui_str': 'Vaccines, Killed'}]","[{'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C2076600', 'cui_str': 'Influenza caused by Influenza A virus subtype H1N1'}, {'cui': 'C0580264', 'cui_str': 'H1N1'}, {'cui': 'C0580267', 'cui_str': 'H3N2'}]",,0.213913,"The HD vaccine elicited significantly greater monofunctional and polyfunctional CD4+ and CD8+ T-cell responses against influenza A/H1N1, A/H3N2 and B.","[{'ForeName': 'Arnaud G', 'Initials': 'AG', 'LastName': ""L'huillier"", 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Victor H', 'Initials': 'VH', 'LastName': 'Ferreira', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Cedric', 'Initials': 'C', 'LastName': 'Hirzel', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Yoichiro', 'Initials': 'Y', 'LastName': 'Natori', 'Affiliation': 'Division of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine and Miami Transplant Institute, Miami, Florida, USA.'}, {'ForeName': 'Jaclyn', 'Initials': 'J', 'LastName': 'Slomovic', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Terrance', 'Initials': 'T', 'LastName': 'Ku', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Hoschler', 'Affiliation': 'Public Health England, London, United Kingdom.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Ierullo', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Nazia', 'Initials': 'N', 'LastName': 'Selzner', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Schiff', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Lianne G', 'Initials': 'LG', 'LastName': 'Singer', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Atul', 'Initials': 'A', 'LastName': 'Humar', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}, {'ForeName': 'Deepali', 'Initials': 'D', 'LastName': 'Kumar', 'Affiliation': 'Multi-Organ Transplant Program, University Health Network, Toronto, Canada.'}]",The Journal of infectious diseases,['10.1093/infdis/jiz471'] 3127,31882151,"The Effect of Corticosteroid Local Injection Versus Platelet-Rich Plasma for the Treatment of Plantar Fasciitis in Obese Patients: A Single-Blind, Randomized Clinical Trial.","Chronic plantar heel pain (CPHP) is one of the most common painful and disabling foot conditions, for which various treatments have been proposed. We aimed to investigate the efficacy of local injection of platelet-rich plasma (PRP) compared with the conventional method of local corticosteroid injection in obese patients who were resistant to other nonsurgical treatments. In this single-blind, randomized clinical trial, 32 obese patients with chronic plantar heel pain were randomly allocated to 2 groups of 16 participants each. In 1 group, 40 mg of dimethylprednisolone was injected once into the painful heel, whereas the other group received 3 separate injections of PRP, with each injection administered 1 week apart. The groups were compared at baseline and at 24 weeks after the injection, or course of injections, was administered. Exposures, total morning pain, and foot function index were not statistically significantly different between the groups at baseline; however, at 24 weeks after the treatment, final pain and morning pain scores were statistically significantly (p < .001) better in the corticosteroid group, and the mean foot function index scores were 65.4 ± 3.2 and 58.3 ± 2.9 (p < .001) in patients treated with corticosteroid and PRP, respectively. In obese patients with plantar fasciitis, injection with corticosteroid was more effective than PRP at reducing pain and improving function.",2020,"In obese patients with plantar fasciitis, injection with corticosteroid was more effective than PRP at reducing pain and improving function.","['Chronic plantar heel pain (CPHP', '32 obese patients with chronic plantar heel pain', 'Plantar Fasciitis in Obese Patients', 'obese patients with plantar fasciitis', 'obese patients who were resistant to other nonsurgical treatments']","['dimethylprednisolone', 'platelet-rich plasma (PRP', 'corticosteroid', 'local corticosteroid injection', 'Corticosteroid Local Injection Versus Platelet-Rich Plasma']","['final pain and morning pain scores', 'mean foot function index scores', 'Exposures, total morning pain, and foot function index', 'pain and improving function']","[{'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0231786', 'cui_str': 'Plantar heel pain (finding)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0149756', 'cui_str': ""Policeman's Heel""}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma (substance)'}, {'cui': 'C0242848', 'cui_str': 'PrP (GSS)'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]","[{'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332170', 'cui_str': 'Morning (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4706287', 'cui_str': 'Foot Function Index (assessment scale)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}]",32.0,0.202505,"In obese patients with plantar fasciitis, injection with corticosteroid was more effective than PRP at reducing pain and improving function.","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Tabrizi', 'Affiliation': 'Assistant Professor, Department of Orthopedics, Clinical Research Development Unit of Imam Khomeini Hospital, Urmia University of Medical Sciences, Urmia, Iran. Electronic address: Ali.tab.ms@gmail.com.'}, {'ForeName': 'Sina', 'Initials': 'S', 'LastName': 'Dindarian', 'Affiliation': 'Medical Student and Researcher, Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Sedra', 'Initials': 'S', 'LastName': 'Mohammadi', 'Affiliation': 'Medical Student and Researcher, Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.'}]",The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons,['10.1053/j.jfas.2019.07.004'] 3128,8408569,Reactogenicity and immunogenicity of a high-titer rhesus rotavirus-based quadrivalent rotavirus vaccine.,"We evaluated the reactogenicity and antigenicity of a quadrivalent rotavirus vaccine composed of serotype 3 rhesus rotavirus (RRV) and three single-gene-substitution reassortants of RRV and human strain D (D x RRV, serotype 1), DS1 (DS1 x RRV, serotype 2), or ST3 (ST3 x RRV, serotype 4) in a double-masked study with 302 infants in Caracas, Venezuela. Three doses of the quadrivalent vaccine composed of either 10(5) PFU (low titer) or 10(6) PFU (high titer) of each component were administered to 99 and 101 infants, respectively, at 4-week intervals starting at the second month of age; 102 infants received a placebo. Postvaccination reactions were monitored by home visits every other day during the week postvaccination. The vaccine was associated with the occurrence of mild, short-lived febrile episodes in 26 and 23% of the recipients after the first doses of high- or low-titer vaccine, respectively, in comparison with 13% of the infants receiving the placebo. Febrile reactions occurred less frequently in vaccinees after the second or third dose than after the initial dose. The vaccine was not significantly associated with diarrhea or any additional symptom or sign. Serum specimens obtained shortly before the first, 4 weeks after the first, and 4 weeks after the third dose of vaccine or placebo were tested by an immunoglobulin A enzyme-linked immunosorbent assay and by neutralization assays. Seroresponses occurred significantly more often after 3 doses than after a single dose of either vaccine. Immunoglobulin A responses were observed in 80 and 79% of the infants after 3 doses of high- or low-titer vaccine, respectively. Most of the infants tested developed a neutralization response to RRV after 3 doses of the high- (90%) or low-(88%) titer vaccine. Neutralization response rates to human rotavirus serotypes 1 to 4 after 3 doses were similar in both vaccine and 87 of 90 receiving the high-titer vaccine developed seroresponses, as detected by any of the assays employed. The study indicates that 3 doses of quadrivalent vaccine at a titer of 10(6) PFU of each component offered no advantage over the lower-titer preparation for use in efficacy trials.",1993,"Neutralization response rates to human rotavirus serotypes 1 to 4 after 3 doses were similar in both vaccine and 87 of 90 receiving the high-titer vaccine developed seroresponses, as detected by any of the assays employed.","['302 infants in Caracas, Venezuela']","['placebo', 'high-titer rhesus rotavirus-based quadrivalent rotavirus vaccine', 'vaccine', 'vaccine or placebo', 'quadrivalent vaccine composed of either 10(5) PFU (low titer) or 10(6) PFU', 'quadrivalent vaccine']","['Febrile reactions', 'occurrence of mild, short-lived febrile episodes', 'diarrhea', 'Seroresponses', 'reactogenicity and antigenicity', 'Postvaccination reactions', 'neutralization response to RRV', 'Reactogenicity and immunogenicity', 'Immunoglobulin A responses', 'Neutralization response rates']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0042469', 'cui_str': 'Venezuela'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0035870', 'cui_str': 'Rotavirus'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0597418', 'cui_str': 'Rotavirus Vaccines'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}]","[{'cui': 'C0235723', 'cui_str': 'Reaction febrile'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}]",302.0,0.215844,"Neutralization response rates to human rotavirus serotypes 1 to 4 after 3 doses were similar in both vaccine and 87 of 90 receiving the high-titer vaccine developed seroresponses, as detected by any of the assays employed.","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Flores', 'Affiliation': 'Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Perez-Schael', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Blanco', 'Affiliation': ''}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Rojas', 'Affiliation': ''}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Alfonzo', 'Affiliation': ''}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Crespo', 'Affiliation': ''}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Cunto', 'Affiliation': ''}, {'ForeName': 'A L', 'Initials': 'AL', 'LastName': 'Pittman', 'Affiliation': ''}, {'ForeName': 'A Z', 'Initials': 'AZ', 'LastName': 'Kapikian', 'Affiliation': ''}]",Journal of clinical microbiology,[] 3129,31689378,Assessment of Effect of Submucosal Injection of Dexmedetomidine on Postoperative Symptoms.,"PURPOSE Embedded third molar surgery is the most frequent oral-maxillofacial surgical procedure performed. The purpose of this study was to assess the clinical effect of submucosal dexmedetomidine (dex) on decreasing postoperative edema, trismus, and pain after surgical molar extraction. MATERIALS AND METHODS We carried out a double-blind, randomized, prospective study including patients undergoing surgical bilateral embedded mandibular molar extraction. Patients were divided into 2 groups: those receiving saline solution and those receiving dex. The main outcome measures of pain, facial swelling, and trismus were assessed on days 2 and 7 after surgery. In addition, patients were requested to record the time rescue analgesics were taken, as well as the total number taken. The variables were analyzed using the Student t test and a repeated-measures general linear model. P < .05 was considered statistically significant. RESULTS The study included 40 patients (9 women and 11 men per group; mean age, 23.40 years) undergoing surgical bilateral embedded mandibular molar extraction. On day 2, a statistically significant difference in edema was found between the groups (P = .004). On days 2 and 7, statistically significant differences in the severity of trismus were found between the groups (P = .001 and P < .001, respectively). In addition, statistically significant differences were found between the groups in visual analog scale pain scores at 1, 6, 12, 24, and 48 hours (P = .161, P = .038, P = .110, P = .136, and P = .007, respectively) and in the number of analgesic tablets taken (P < .001). CONCLUSIONS Preoperative submucosal dex is an efficient, safe, and beneficial therapeutic strategy to decrease edema, trismus, and pain after surgical molar extraction.",2020,"On day 2, a statistically significant difference in edema was found between the groups (P = .004).","['patients undergoing surgical bilateral embedded mandibular molar extraction', '40 patients (9 women and 11 men per group; mean age, 23.40\xa0years) undergoing surgical bilateral embedded mandibular molar extraction']","['saline solution and those receiving dex', 'submucosal dexmedetomidine (dex', 'Dexmedetomidine']","['Postoperative Symptoms', 'edema', 'edema, trismus, and pain', 'pain, facial swelling, and trismus', 'visual analog scale pain scores', 'severity of trismus', 'postoperative edema, trismus, and pain']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0026367', 'cui_str': 'Molar'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0013604', 'cui_str': 'Hydrops'}, {'cui': 'C0041105', 'cui_str': 'Trismus'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0151602', 'cui_str': 'Facial swelling (finding)'}, {'cui': 'C2732809', 'cui_str': 'Visual analog scale pain score (observable entity)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",40.0,0.113759,"On day 2, a statistically significant difference in edema was found between the groups (P = .004).","[{'ForeName': 'Burcu', 'Initials': 'B', 'LastName': 'Gursoytrak', 'Affiliation': 'Assistant Professor, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Adnan Menderes University, Aydın, Turkey. Electronic address: dt_burcupoyraz@hotmail.com.'}, {'ForeName': 'Ozlem', 'Initials': 'O', 'LastName': 'Kocaturk', 'Affiliation': 'Associate Professor, Department of Oral and Maxillofacial Surgery, Division of Anesthesiology, Faculty of Dentistry, Adnan Menderes University, Aydın, Turkey.'}, {'ForeName': 'Mahmut', 'Initials': 'M', 'LastName': 'Koparal', 'Affiliation': 'Associate Professor, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Adıyaman University, Adıyaman, Turkey.'}, {'ForeName': 'Belgin', 'Initials': 'B', 'LastName': 'Gulsun', 'Affiliation': 'Professor, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Dicle University, Diyarbakır, Turkey.'}]",Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,['10.1016/j.joms.2019.09.024'] 3130,28454014,"Reduced mouse allergen is associated with epigenetic changes in regulatory genes, but not mouse sensitization, in asthmatic children.","Chronic exposure to mouse allergen may contribute greatly to the inner-city asthma burden. We hypothesized that reducing mouse allergen exposure may modulate the immunopathology underlying symptomatic pediatric allergic asthma, and that this occurs through epigenetic regulation. To test this hypothesis, we studied a cohort of mouse sensitized, persistent asthmatic inner-city children undergoing mouse allergen-targeted integrated pest management (IPM) vs education in a randomized controlled intervention trial. We found that decreasing mouse allergen exposure, but not cockroach, was associated with reduced FOXP3 buccal DNA promoter methylation, but this was unrelated to mouse specific IgE production. This finding suggests that the environmental epigenetic regulation of an immunomodulatory gene may occur following changing allergen exposures in some highly exposed cohorts. Given the clinical and public health importance of inner-city pediatric asthma and the potential impact of environmental interventions, further studies will be needed to corroborate changes in epigenetic regulation following changing exposures over time, and determine their impact on asthma morbidity in susceptible children.",2017,"We found that decreasing mouse allergen exposure, but not cockroach, was associated with reduced FOXP3 buccal DNA promoter methylation, but this was unrelated to mouse specific IgE production.","['cohort of mouse sensitized, persistent asthmatic inner-city children undergoing', 'susceptible children', 'asthmatic children']",['mouse allergen-targeted integrated pest management (IPM) vs education'],['FOXP3 buccal DNA promoter methylation'],"[{'cui': 'C0026809', 'cui_str': 'Mice'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0557849', 'cui_str': 'Inner city environment (environment)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0231204', 'cui_str': 'Susceptible (qualifier value)'}]","[{'cui': 'C0026809', 'cui_str': 'Mice'}, {'cui': 'C0002092', 'cui_str': 'Allergens'}, {'cui': 'C0031249', 'cui_str': 'Pest Management'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0442010', 'cui_str': 'Buccal (qualifier value)'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C0025723', 'cui_str': 'Methylation'}]",,0.108617,"We found that decreasing mouse allergen exposure, but not cockroach, was associated with reduced FOXP3 buccal DNA promoter methylation, but this was unrelated to mouse specific IgE production.","[{'ForeName': 'Rachel L', 'Initials': 'RL', 'LastName': 'Miller', 'Affiliation': 'Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Columbia University Medical Center, PH8E-101B, 630 W. 168th St., New York City, NY 10032, USA; Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Columbia University Medical Center, PH8E-101B, 630 W. 168th St., New York City, NY 10032, USA; Department of Environmental Health Sciences, Columbia University, 722 W 168th St, 11th Floor, New York City, NY, 10032, USA. Electronic address: rlm14@cumc.columbia.edu.'}, {'ForeName': 'Hanjie', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Columbia University Medical Center, PH8E-101B, 630 W. 168th St., New York City, NY 10032, USA.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Jezioro', 'Affiliation': 'Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Columbia University Medical Center, PH8E-101B, 630 W. 168th St., New York City, NY 10032, USA.'}, {'ForeName': 'Mariangels', 'Initials': 'M', 'LastName': 'De Planell Saguer', 'Affiliation': 'Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Columbia University Medical Center, PH8E-101B, 630 W. 168th St., New York City, NY 10032, USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Lovinsky-Desir', 'Affiliation': 'Division of Pulmonary, Department of Pediatrics, Columbia University Medical Center, 3959 Broadway, CHC 7-701, New York City, NY 10032, USA.'}, {'ForeName': 'Xinhua', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Biostatistics, Columbia University Medical Center, 722 W 168 St, 6 Floor, New York City, NY, 10032, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Perzanowski', 'Affiliation': 'Department of Environmental Health Sciences, Columbia University, 722 W 168th St, 11th Floor, New York City, NY, 10032, USA.'}, {'ForeName': 'Adnan', 'Initials': 'A', 'LastName': 'Divjan', 'Affiliation': 'Department of Environmental Health Sciences, Columbia University, 722 W 168th St, 11th Floor, New York City, NY, 10032, USA.'}, {'ForeName': 'Wanda', 'Initials': 'W', 'LastName': 'Phipatanakul', 'Affiliation': ""Division of Pediatric Allergy/Immunology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Boston, MA 02115, USA.""}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Matsui', 'Affiliation': 'Division of Pediatric Allergy/Immunology, Johns Hopkins School of Medicine, CMSC 1102, 600 N. Wolfe Street, Baltimore, MD 21287, USA.'}]",Environmental research,['10.1016/j.envres.2017.04.025'] 3131,28990665,Transcutaneous electrical nerve stimulation (TENS) for fibromyalgia in adults.,"BACKGROUND Fibromyalgia is characterised by persistent, widespread pain; sleep problems; and fatigue. Transcutaneous electrical nerve stimulation (TENS) is the delivery of pulsed electrical currents across the intact surface of the skin to stimulate peripheral nerves and is used extensively to manage painful conditions. TENS is inexpensive, safe, and can be self-administered. TENS reduces pain during movement in some people so it may be a useful adjunct to assist participation in exercise and activities of daily living. To date, there has been only one systematic review in 2012 which included TENS, amongst other treatments, for fibromyalgia, and the authors concluded that TENS was not effective. OBJECTIVES To assess the analgesic efficacy and adverse events of TENS alone or added to usual care (including exercise) compared with placebo (sham) TENS; no treatment; exercise alone; or other treatment including medication, electroacupuncture, warmth therapy, or hydrotherapy for fibromyalgia in adults. SEARCH METHODS We searched the following electronic databases up to 18 January 2017: CENTRAL (CRSO); MEDLINE (Ovid); Embase (Ovid); CINAHL (EBSCO); PsycINFO (Ovid); LILACS; PEDRO; Web of Science (ISI); AMED (Ovid); and SPORTDiscus (EBSCO). We also searched three trial registries. There were no language restrictions. SELECTION CRITERIA We included randomised controlled trials (RCTs) or quasi-randomised trials of TENS treatment for pain associated with fibromyalgia in adults. We included cross-over and parallel-group trial designs. We included studies that evaluated TENS administered using non-invasive techniques at intensities that produced perceptible TENS sensations during stimulation at either the site of pain or over nerve bundles proximal (or near) to the site of pain. We included TENS administered as a sole treatment or TENS in combination with other treatments, and TENS given as a single treatment or as a course of treatments. DATA COLLECTION AND ANALYSIS Two review authors independently determined study eligibility by assessing each record and reaching agreement by discussion. A third review author acted as arbiter. We did not anonymise the records of studies before assessment. Two review authors independently extracted data and assessed risk of bias of included studies before entering information into a 'Characteristics of included studies' table. Primary outcomes were participant-reported pain relief from baseline of 30% or greater or 50% or greater, and Patient Global Impression of Change (PGIC). We assessed the evidence using GRADE and added 'Summary of findings' tables. MAIN RESULTS We included eight studies (seven RCTs, one quasi-RCT, 315 adults (299 women), aged 18 to 75 years): six used a parallel-group design and two used a cross-over design. Sample sizes of intervention arms were five to 43 participants.Two studies, one of which was a cross-over design, compared TENS with placebo TENS (82 participants), one study compared TENS with no treatment (43 participants), and four studies compared TENS with other treatments (medication (two studies, 74 participants), electroacupuncture (one study, 44 participants), superficial warmth (one cross-over study, 32 participants), and hydrotherapy (one study, 10 participants)). Two studies compared TENS plus exercise with exercise alone (98 participants, 49 per treatment arm). None of the studies measured participant-reported pain relief of 50% or greater or PGIC. Overall, the studies were at unclear or high risk of bias, and in particular all were at high risk of bias for sample size.Only one study (14 participants) measured the primary outcome participant-reported pain relief of 30% or greater. Thirty percent achieved 30% or greater reduction in pain with TENS and exercise compared with 13% with exercise alone. One study found 10/28 participants reported pain relief of 25% or greater with TENS compared with 10/24 participants using superficial warmth (42 °C). We judged that statistical pooling was not possible because there were insufficient data and outcomes were not homogeneous.There were no data for the primary outcomes participant-reported pain relief from baseline of 50% or greater and PGIC.There was a paucity of data for secondary outcomes. One pilot cross-over study of 43 participants found that the mean (95% confidence intervals (CI)) decrease in pain intensity on movement (100-mm visual analogue scale (VAS)) during one 30-minute treatment was 11.1 mm (95% CI 5.9 to 16.3) for TENS and 2.3 mm (95% CI 2.4 to 7.7) for placebo TENS. There were no significant differences between TENS and placebo for pain at rest. One parallel group study of 39 participants found that mean ± standard deviation (SD) pain intensity (100-mm VAS) decreased from 85 ± 20 mm at baseline to 43 ± 20 mm after one week of dual-site TENS; decreased from 85 ± 10 mm at baseline to 60 ± 10 mm after single-site TENS; and decreased from 82 ± 20 mm at baseline to 80 ± 20 mm after one week of placebo TENS. The authors of seven studies concluded that TENS relieved pain but the findings of single small studies are unlikely to be correct.One study found clinically important improvements in Fibromyalgia Impact Questionnaire (FIQ) subscales for work performance, fatigue, stiffness, anxiety, and depression for TENS with exercise compared with exercise alone. One study found no additional improvements in FIQ scores when TENS was added to the first three weeks of a 12-week supervised exercise programme.No serious adverse events were reported in any of the studies although there were reports of TENS causing minor discomfort in a total of 3 participants.The quality of evidence was very low. We downgraded the GRADE rating mostly due to a lack of data; therefore, we have little confidence in the effect estimates where available. AUTHORS' CONCLUSIONS There was insufficient high-quality evidence to support or refute the use of TENS for fibromyalgia. We found a small number of inadequately powered studies with incomplete reporting of methodologies and treatment interventions.",2017,"One study found clinically important improvements in Fibromyalgia Impact Questionnaire (FIQ) subscales for work performance, fatigue, stiffness, anxiety, and depression for TENS with exercise compared with exercise alone.","['315 adults (299 women), aged 18 to 75 years', 'for fibromyalgia in adults', 'one study, 44 participants), superficial warmth (one cross-over study, 32 participants), and hydrotherapy (one study, 10 participants', '43 participants', '39 participants found that', 'fibromyalgia in adults', 'pain associated with fibromyalgia in adults']","['electroacupuncture', 'electroacupuncture, warmth therapy, or hydrotherapy', 'TENS and placebo', 'TENS', 'TENS plus exercise with exercise alone', 'TENS with placebo TENS', 'TENS alone or added to usual care (including exercise', 'placebo (sham) TENS', 'Transcutaneous electrical nerve stimulation (TENS', 'TENS in combination with other treatments, and TENS', 'placebo TENS']","['Fibromyalgia Impact Questionnaire (FIQ) subscales for work performance, fatigue, stiffness, anxiety, and depression for TENS with exercise', 'pain', 'mean ± standard deviation (SD) pain intensity (100-mm VAS', 'analgesic efficacy and adverse events', 'pain with TENS and exercise', 'pain intensity on movement (100-mm visual analogue scale (VAS', 'serious adverse events', 'Patient Global Impression of Change (PGIC', 'FIQ scores', 'pain relief']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0016053', 'cui_str': 'Fibrositis'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205124', 'cui_str': 'Superficial (qualifier value)'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}]","[{'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0014518', 'cui_str': ""Lyell's Syndrome""}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0040654', 'cui_str': 'Electric Stimulation, Transcutaneous'}]","[{'cui': 'C0016053', 'cui_str': 'Fibrositis'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1286385', 'cui_str': 'Performance at Work'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0427008', 'cui_str': 'Stiffness (finding)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0014518', 'cui_str': ""Lyell's Syndrome""}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}]",44.0,0.445202,"One study found clinically important improvements in Fibromyalgia Impact Questionnaire (FIQ) subscales for work performance, fatigue, stiffness, anxiety, and depression for TENS with exercise compared with exercise alone.","[{'ForeName': 'Mark I', 'Initials': 'MI', 'LastName': 'Johnson', 'Affiliation': 'Faculty of Health and Social Sciences, Leeds Beckett University, City Campus, Calverley Street, Leeds, UK, LS1 3HE.'}, {'ForeName': 'Leica S', 'Initials': 'LS', 'LastName': 'Claydon', 'Affiliation': ''}, {'ForeName': 'G Peter', 'Initials': 'GP', 'LastName': 'Herbison', 'Affiliation': ''}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Jones', 'Affiliation': ''}, {'ForeName': 'Carole A', 'Initials': 'CA', 'LastName': 'Paley', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD012172.pub2'] 3132,30460734,The Experience Sampling Method-Evaluation of treatment effect of escitalopram in IBS with comorbid panic disorder.,"BACKGROUND Confirming treatment response in clinical trials for irritable bowel syndrome (IBS) is challenging, due to the lack of biomarkers and limitations of the currently available symptom assessment tools. The Experience Sampling Method (ESM) might overcome these limitations by collecting digital assessments randomly and repeatedly during daily life. This study evaluated differences in change in abdominal pain between real-time (ie, ESM) and retrospective (ie, Gastrointestinal Symptom Rating Scale [GSRS] and an end-of-day symptom diary) measurements, using data of an RCT on escitalopram vs placebo in patients with IBS and comorbid panic disorder. METHODS Twenty-nine IBS patients with comorbid panic disorder were included in a 6-month RCT. The GSRS, diary, and ESM were completed at baseline (t = 0) and after 3 (t = 3) and 6 months (t = 6). Linear mixed models were used. KEY RESULTS Experience Sampling Method analyses revealed a significant interaction between escitalopram and time, and ESM abdominal pain scores were 1.4 points lower in the escitalopram group compared to placebo at t = 6 (on a 1-to-7 scale; P = 0.021). When including the interaction with momentary anxiety, the reduction in abdominal pain scores in escitalopram vs placebo was even more pronounced for higher levels of anxiety. Average GSRS- and end-of-day abdominal pain scores were not significantly different between escitalopram and placebo at t = 3 and 6. CONCLUSIONS & INFERENCES Real-time ESM has the potential to capture treatment response more sensitively compared to a retrospective end-of-day GI symptom diary and the GSRS, by taking into account day-to-day symptom variability as well as momentary factors that might moderate treatment effect, such as anxiety.",2019,"Average GSRS- and end-of-day abdominal pain scores were not significantly different between escitalopram and placebo at t = 3 and 6. ","['irritable bowel syndrome (IBS', 'Twenty-nine IBS patients with comorbid panic disorder', 'patients with IBS and comorbid panic disorder', 'IBS with comorbid panic disorder']","['escitalopram', 'placebo']","['Average GSRS- and end-of-day abdominal pain scores', 'escitalopram and time, and ESM abdominal pain scores', 'abdominal pain between real-time (ie, ESM) and retrospective (ie, Gastrointestinal Symptom Rating Scale [GSRS] and an end-of-day symptom diary) measurements', 'GSRS, diary, and ESM', 'abdominal pain scores']","[{'cui': 'C0022104', 'cui_str': 'Irritable Bowel Syndrome'}, {'cui': 'C0450351', 'cui_str': '29 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030319', 'cui_str': 'Panic Disorder'}]","[{'cui': 'C1099456', 'cui_str': 'Escitalopram'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1099456', 'cui_str': 'Escitalopram'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0222045'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0376660', 'cui_str': 'Diary'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}]",29.0,0.0993698,"Average GSRS- and end-of-day abdominal pain scores were not significantly different between escitalopram and placebo at t = 3 and 6. ","[{'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Vork', 'Affiliation': 'Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Zlatan', 'Initials': 'Z', 'LastName': 'Mujagic', 'Affiliation': 'Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Marjan', 'Initials': 'M', 'LastName': 'Drukker', 'Affiliation': 'Department of Psychiatry and Psychology, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Keszthelyi', 'Affiliation': 'Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'José M', 'Initials': 'JM', 'LastName': 'Conchillo', 'Affiliation': 'Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Martine A M', 'Initials': 'MAM', 'LastName': 'Hesselink', 'Affiliation': 'Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'van Os', 'Affiliation': 'Department of Psychiatry and Psychology, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Ad A M', 'Initials': 'AAM', 'LastName': 'Masclee', 'Affiliation': 'Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Leue', 'Affiliation': 'Department of Psychiatry and Psychology, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'Joanna W', 'Initials': 'JW', 'LastName': 'Kruimel', 'Affiliation': 'Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands.'}]",Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,['10.1111/nmo.13515'] 3133,30286418,Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004).,"PURPOSE About 40-60% of patients treated with post-operative radiotherapy for parotid cancer experience ipsilateral sensorineural hearing loss. Intensity-modulated radiotherapy (IMRT) can reduce radiation dose to the cochlea. COSTAR, a phase III trial, investigated the role of cochlear-sparing IMRT (CS-IMRT) in reducing hearing loss. METHODS Patients (pT1-4 N0-3 M0) were randomly assigned (1:1) to 3-dimensional conformal radiotherapy (3DCRT) or CS-IMRT by minimisation, balancing for centre and radiation dose of 60Gy or 65Gy in 30 daily fractions. The primary end-point was proportion of patients with sensorineural hearing loss in the ipsilateral cochlea of ≥10 dB bone conduction at 4000 Hz 12 months after radiotherapy compared using Fisher's exact test. Secondary end-points included hearing loss at 6 and 24 months, balance assessment, acute and late toxicity, patient-reported quality of life, time to recurrence and survival. RESULTS From Aug 2008 to Feb 2013, 110 patients (54 3DCRT; 56 CS-IMRT) were enrolled from 22 UK centres. Median doses to the ipsilateral cochlea were 3DCRT: 56.2Gy and CS-IMRT: 35.7Gy (p < 0.0001). 67/110 (61%) patients were evaluable for the primary end-point; main reasons for non-evaluability were non-attendance at follow-up or incomplete audiology assessment. At 12 months, 14/36 (39%) 3DCRT and 11/31 (36%) CS-IMRT patients had ≥10 dB loss (p = 0.81). No statistically significant differences were observed in hearing loss at 6 or 24 months or in other secondary end-points including patient-reported hearing outcomes. CONCLUSION CS-IMRT reduced the radiation dose below the accepted tolerance of the cochlea, but this did not lead to a reduction in the proportion of patients with clinically relevant hearing loss.",2018,"No statistically significant differences were observed in hearing loss at 6 or 24 months or in other secondary end-points including patient-reported hearing outcomes. ","['Patients (pT1-4 N0-3 M0', 'parotid cancer experience ipsilateral sensorineural hearing loss', 'patients with parotid cancer (COSTAR; CRUK/08/004', 'From Aug 2008 to Feb 2013, 110 patients (54 3DCRT; 56 CS-IMRT) were enrolled from 22 UK centres']","['3-dimensional conformal radiotherapy (3DCRT) or CS-IMRT by minimisation, balancing for centre and radiation dose of 60Gy or 65Gy in 30 daily fractions', 'cochlear-sparing IMRT (CS-IMRT', 'radiotherapy', 'cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy', 'post-operative radiotherapy', '3DCRT', 'CS-IMRT', 'Intensity-modulated radiotherapy (IMRT']","['hearing loss at 6 and 24 months, balance assessment, acute and late toxicity, patient-reported quality of life, time to recurrence and survival', 'proportion of patients with sensorineural hearing loss', '≥10\xa0dB loss', 'hearing loss']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0747273', 'cui_str': 'Cancer of Parotid'}, {'cui': 'C0441989', 'cui_str': 'Ipsilateral (qualifier value)'}, {'cui': 'C0018784', 'cui_str': 'Hearing Loss, Sensorineural'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0450363', 'cui_str': 'Three-dimensional (qualifier value)'}, {'cui': 'C0600521', 'cui_str': 'Three-Dimensional Conformal Radiotherapy'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C1512814', 'cui_str': 'Radiotherapy, Intensity-Modulated'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}]","[{'cui': 'C1384666', 'cui_str': 'Hypoacusis'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1960377', 'cui_str': 'Assessment of sense of balance (procedure)'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0034380'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0018784', 'cui_str': 'Hearing Loss, Sensorineural'}]",,0.116361,"No statistically significant differences were observed in hearing loss at 6 or 24 months or in other secondary end-points including patient-reported hearing outcomes. ","[{'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Nutting', 'Affiliation': 'Head and Neck Unit, Royal Marsden Hospital, London, United Kingdom. Electronic address: Chris.Nutting@rmh.nhs.uk.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Morden', 'Affiliation': 'The Institute of Cancer Research Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Beasley', 'Affiliation': 'Bristol Cancer Institute, Bristol Haematology and Oncology Centre, United Kingdom.'}, {'ForeName': 'Shreerang', 'Initials': 'S', 'LastName': 'Bhide', 'Affiliation': 'Head and Neck Unit, Royal Marsden Hospital, London, United Kingdom.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Cook', 'Affiliation': 'Gloucestershire Oncology Centre, Cheltenham General Hospital, United Kingdom.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'De Winton', 'Affiliation': 'Department of Oncology, Royal United Hospital, Bath, United Kingdom.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Emson', 'Affiliation': 'The Institute of Cancer Research Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.'}, {'ForeName': 'Mererid', 'Initials': 'M', 'LastName': 'Evans', 'Affiliation': 'Clinical Oncology, Velindre NHS Trust, United Kingdom.'}, {'ForeName': 'Lydia', 'Initials': 'L', 'LastName': 'Fresco', 'Affiliation': 'Department of Oncology, University Hospitals of Coventry and Warwickshire, United Kingdom.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Gollins', 'Affiliation': 'Department of Oncology, Glan Clwyd Hospital, Rhyl, United Kingdom.'}, {'ForeName': 'Dorothy', 'Initials': 'D', 'LastName': 'Gujral', 'Affiliation': 'Head and Neck Department, Imperial College Healthcare NHS Trust, United Kingdom; Sarcoma Unit, Royal Marsden Hospital, Sutton, United Kingdom.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Harrington', 'Affiliation': 'Head and Neck Unit, Royal Marsden Hospital, London, United Kingdom.'}, {'ForeName': 'Mano', 'Initials': 'M', 'LastName': 'Joseph', 'Affiliation': 'Oncology and Haematology Directorate, The Royal Wolverhampton NHS Trust, United Kingdom.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Lemon', 'Affiliation': 'Department of Oncology, Mount Vernon Hospital, United Kingdom.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Luxon', 'Affiliation': 'University College London Ear Institute, United Kingdom.'}, {'ForeName': 'Qurrat', 'Initials': 'Q', 'LastName': 'van den Blink', 'Affiliation': 'Department of Oncology, Northampton General Hospital, United Kingdom.'}, {'ForeName': 'Ruheena', 'Initials': 'R', 'LastName': 'Mendes', 'Affiliation': 'Department of Oncology, University College Hospital, London, United Kingdom.'}, {'ForeName': 'Aisha', 'Initials': 'A', 'LastName': 'Miah', 'Affiliation': 'Head and Neck Department, Imperial College Healthcare NHS Trust, United Kingdom; Sarcoma Unit, Royal Marsden Hospital, Sutton, United Kingdom.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Newbold', 'Affiliation': 'Head and Neck Unit, Royal Marsden Hospital, London, United Kingdom.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Prestwich', 'Affiliation': ""Department of Clinical Oncology, St James's University Hospital, Leeds, United Kingdom.""}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Robinson', 'Affiliation': 'Department of Clinical Oncology, Weston Park Hospital, Sheffield, United Kingdom.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Sanghera', 'Affiliation': 'Department of Oncology, University Hospitals Birmingham NHS Foundation Trust, United Kingdom.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Simpson', 'Affiliation': 'Department of Oncology, Royal Sussex County Hospital, United Kingdom.'}, {'ForeName': 'Muthiah', 'Initials': 'M', 'LastName': 'Sivaramalingam', 'Affiliation': 'Department of Oncology, Royal Preston Hospital, United Kingdom.'}, {'ForeName': 'Narayanan Nair', 'Initials': 'NN', 'LastName': 'Srihari', 'Affiliation': 'Department of Oncology, Royal Shrewsbury Hospital, United Kingdom.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Sydenham', 'Affiliation': 'The Institute of Cancer Research Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Wells', 'Affiliation': 'QA Physics, Royal Marsden Hospital, London, United Kingdom.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Witts', 'Affiliation': 'The Institute of Cancer Research Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Hall', 'Affiliation': 'The Institute of Cancer Research Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2018.08.006'] 3134,30461025,Washing or filtering of blood products does not improve outcome in a rat model of trauma and multiple transfusion.,"BACKGROUND Transfusion is associated with organ failure and nosocomial infection in trauma patients, which may be mediated by soluble bioactive substances in blood products, including extracellular vesicles (EVs). We hypothesize that removing EVs, by washing or filtering of blood products, reduces organ failure and improves host immune response. MATERIALS AND METHODS Blood products were prepared from syngeneic rat blood. EVs were removed from RBCs and platelets by washing. Plasma was filtered through a 0.22-μm filter. Rats were traumatized by crush injury to the intestines and liver, and a femur was fractured. Rats were hemorrhaged until a mean arterial pressure of 40 mm Hg and randomized to receive resuscitation with standard or washed/filtered blood products, in a 1:1:1 ratio. Sham controls were not resuscitated. Ex vivo whole blood stimulation tests were performed and histopathology was done. RESULTS Washing of blood products improved quality metrics compared to standard products. Also, EV levels reduced by 12% to 77%. The coagulation status, as assessed by thromboelastometry, was deranged in both groups and normalized during transfusion, without significant differences. Use of washed/filtered products did not reduce organ failure, as assessed by histopathologic score and biochemical measurements. Immune response ex vivo was decreased following transfusion compared to sham but did not differ between transfusion groups. CONCLUSION Filtering or washing of blood products improved biochemical properties and reduced EV counts, while maintaining coagulation abilities. However, in this trauma and transfusion model, the use of optimized blood components did not attenuate organ injury or immune suppression.",2019,"Use of washed/filtered products did not reduce organ failure, as assessed by histopathologic score and biochemical measurements.","['trauma patients', 'Blood products were prepared from syngeneic rat blood']",[],"['organ failure', 'coagulation status', 'EV levels', 'biochemical properties and reduced EV counts', 'histopathologic score and biochemical measurements', 'Immune response ex vivo', 'organ failure and improves host immune response', 'quality metrics']","[{'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0456388', 'cui_str': 'Blood product (product)'}, {'cui': 'C4082130', 'cui_str': 'Prepared (qualifier value)'}, {'cui': 'C0034721', 'cui_str': 'Rats'}, {'cui': 'C0005768'}]",[],"[{'cui': 'C0349410', 'cui_str': 'Single organ dysfunction (disorder)'}, {'cui': 'C0441509', 'cui_str': 'Coagulation - action (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205474', 'cui_str': 'Biochemical (qualifier value)'}, {'cui': 'C0871161', 'cui_str': 'Property (attribute)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0301872', 'cui_str': 'Immune response, function (observable entity)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}]",,0.0988275,"Use of washed/filtered products did not reduce organ failure, as assessed by histopathologic score and biochemical measurements.","[{'ForeName': 'Mathijs R', 'Initials': 'MR', 'LastName': 'Wirtz', 'Affiliation': 'Department of Intensive Care Medicine, Academic Medical Center, Amsterdam, The Netherlands.'}, {'ForeName': 'Jordy', 'Initials': 'J', 'LastName': 'Jurgens', 'Affiliation': 'Department of Intensive Care Medicine, Academic Medical Center, Amsterdam, The Netherlands.'}, {'ForeName': 'Coert J', 'Initials': 'CJ', 'LastName': 'Zuurbier', 'Affiliation': 'Laboratory of Experimental Intensive Care and Anesthesiology, Academic Medical Center, Amsterdam, The Netherlands.'}, {'ForeName': 'Joris J T H', 'Initials': 'JJTH', 'LastName': 'Roelofs', 'Affiliation': 'Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands.'}, {'ForeName': 'Philip C', 'Initials': 'PC', 'LastName': 'Spinella', 'Affiliation': 'Department of Pediatrics, Division of Critical Care, Washington University in St Louis, St Louis, Missouri.'}, {'ForeName': 'Jennifer A', 'Initials': 'JA', 'LastName': 'Muszynski', 'Affiliation': ""Department of Pediatrics, Division of Critical Care Medicine, Nationwide Children's Hospital, Columbus, Ohio.""}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Carel Goslings', 'Affiliation': 'Department of Trauma Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.'}, {'ForeName': 'Nicole P', 'Initials': 'NP', 'LastName': 'Juffermans', 'Affiliation': 'Department of Intensive Care Medicine, Academic Medical Center, Amsterdam, The Netherlands.'}]",Transfusion,['10.1111/trf.15039'] 3135,31102938,Immune function testing in sepsis patients receiving sodium selenite.,"PURPOSE We examined in a longitudinal study the role of sodium selenite in sepsis patients in strengthening the immune performance in whole blood samples using immune functional assays. MATERIALS AND METHODS This was a sub-study from a randomized, double blinded multicenter clinical trial (SISPCT) registered with www.clinicaltrials.gov (NCT00832039) and with data collected at our center. Full blood samples were incubated with various recall antigens and the supernatants were measured for their cytokine concentrations as markers for immune response. Data from days 0, 4, 7, 14, and 21 (from sepsis onset) were analyzed using a generalized least squares model in R to appropriately take the longitudinal structure and the missing values into account. RESULTS From the 76 patients enrolled in the study at our center, 40 were randomized to selenium therapy and 36 to placebo. The analyses of immune response assay data showed no statistical difference between the selenium and placebo groups at each of the time points. There was however an overall dampening of cytokine release, which tended to recover over time in both groups. CONCLUSION Selenium has long been an adjuvant therapy in treating sepsis. Recently, it was proven to not have beneficial effects on the mortality outcome. Using data from our center in this sub-cohort study, we identified no relative improvement in cytokine release of stimulated blood immune cells ex vivo from patients with selenium therapy over a three-week period. This offers a potential explanation for the lack of beneficial effects of selenium in sepsis patients.",2019,The analyses of immune response assay data showed no statistical difference between the selenium and placebo groups at each of the time points.,"['76 patients enrolled in the study at our center, 40 were randomized to', 'sepsis patients', 'sepsis patients receiving']","['selenium and placebo', 'placebo', 'Selenium', 'sodium selenite', 'selenium therapy']",['cytokine release'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}]","[{'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0142923', 'cui_str': 'Sodium Selenite'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}]",76.0,0.177321,The analyses of immune response assay data showed no statistical difference between the selenium and placebo groups at each of the time points.,"[{'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Guo', 'Affiliation': 'Department of Anaesthesiology, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Jyotsna', 'Initials': 'J', 'LastName': 'Srinath', 'Affiliation': 'Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Feuerecker', 'Affiliation': 'Department of Anaesthesiology, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Crucian', 'Affiliation': 'Johnson Space Center (JSC), NASA, 1601 NASA Parkway, Houston, TX 77058, USA.'}, {'ForeName': 'Josef', 'Initials': 'J', 'LastName': 'Briegel', 'Affiliation': 'Department of Anaesthesiology, University Hospital, LMU Munich, Munich, Germany.'}, {'ForeName': 'Anne-Laure', 'Initials': 'AL', 'LastName': 'Boulesteix', 'Affiliation': 'Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany.'}, {'ForeName': 'Ines', 'Initials': 'I', 'LastName': 'Kaufmann', 'Affiliation': 'Department of Anaesthesiology, Munich-Neuperlach Hospital, Munich, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Choukèr', 'Affiliation': 'Department of Anaesthesiology, University Hospital, LMU Munich, Munich, Germany. Electronic address: achouker@med.uni-muenchen.de.'}]",Journal of critical care,['10.1016/j.jcrc.2019.05.001'] 3136,29792519,Effects of Online Physician Reviews and Physician Gender on Perceptions of Physician Skills and Primary Care Physician (PCP) Selection.,"Physician review websites have become more relevant and important in people's selection of physicians. The current study experimentally examined how online physician reviews endorsing a primary care physician's (PCP's) technical or interpersonal skills, along with a physician's gender, may influence people's perceptions of the physician's skills and their willingness to choose the physician. Participants were randomly assigned to view a mockup physician review web page and to imagine that they needed to find a new PCP in a new city. They were then asked to report their perceptions of the physician and willingness to choose the physician as their PCP. The results suggested that people's willingness to choose a PCP was affected by physician reviews through their influence on people's perceptions of the PCP's technical and interpersonal skills. More importantly, this study found that when physician reviews endorsed a PCP's technical skills people perceived a female PCP to be more interpersonally competent than a male PCP and thus were more likely to choose the female PCP. The gendered perception, however, was not extended to a PCP's technical skills. Practical implications for health providers and consumers are discussed.",2019,The results suggested that people's willingness to choose a PCP was affected by physician reviews through their influence on people's perceptions of the PCP's technical and interpersonal skills.,[],[],[],[],[],[],,0.0150788,The results suggested that people's willingness to choose a PCP was affected by physician reviews through their influence on people's perceptions of the PCP's technical and interpersonal skills.,"[{'ForeName': 'Siyue', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'School of Communication, The Ohio State University.'}, {'ForeName': 'Roselyn J', 'Initials': 'RJ', 'LastName': 'Lee-Won', 'Affiliation': 'School of Communication, The Ohio State University.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'McKnight', 'Affiliation': 'School of Communication, The Ohio State University.'}]",Health communication,['10.1080/10410236.2018.1475192'] 3137,31964203,Contribution of diet to gut microbiota and related host cardiometabolic health: diet-gut interaction in human health.,"Obesity and cardiometabolic diseases in both developed and developing counties in a state of nutrition transition are often related to diet, which also play a major role in shaping human gut microbiota. The human gut harbors diverse microbes that play an essential role in the well-being of their host. Complex interactions between diet and microorganisms may lead to beneficial or detrimental outcomes to host cardiometabolic health. Despite numerous studies using rodent models indicated that high-fat diet may disrupt protective functions of the intestinal barrier and contribute to inflammatory processes, evidence from population-based study is still limited. In our recent study of a 6-month randomized controlled-feeding trial, we showed that high-fat, low-carbohydrate diet was associated with unfavorable changes in gut microbiota, fecal microbial metabolites, and plasma proinflammatory factors in healthy young adults. Here, we provide an overview and extended discussion of our key findings, and outline important future directions.",2020,"Obesity and cardiometabolic diseases in both developed and developing counties in a state of nutrition transition are often related to diet, which also play a major role in shaping human gut microbiota.","['human health', 'healthy young adults']","['high-fat, low-carbohydrate diet']","['gut microbiota, fecal microbial metabolites, and plasma proinflammatory factors', 'Obesity and cardiometabolic diseases']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0259836', 'cui_str': 'Diet, Carbohydrate-Restricted'}]","[{'cui': 'C4018878', 'cui_str': 'Gastrointestinal Microbial Community'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",,0.0199388,"Obesity and cardiometabolic diseases in both developed and developing counties in a state of nutrition transition are often related to diet, which also play a major role in shaping human gut microbiota.","[{'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Wan', 'Affiliation': 'Department of Food Science and Nutrition, Zhejiang University , Hangzhou, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': 'Department of Food Science and Nutrition, Zhejiang University , Hangzhou, China.'}, {'ForeName': 'Jiaomei', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Institute of Nutrition and Health, Qingdao University , Qingdao, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ""No. 1 Department of Nutrition, Chinese People's Liberation Army General Hospital , Beijing, China.""}, {'ForeName': 'Jihong', 'Initials': 'J', 'LastName': 'Yuan', 'Affiliation': ""No. 1 Department of Nutrition, Chinese People's Liberation Army General Hospital , Beijing, China.""}, {'ForeName': 'Fenglei', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': 'Department of Food Science and Nutrition, Zhejiang University , Hangzhou, China.'}, {'ForeName': 'Duo', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Institute of Nutrition and Health, Qingdao University , Qingdao, China.'}]",Gut microbes,['10.1080/19490976.2019.1697149'] 3138,31972249,Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.,"The IL-23/T helper type 17 cell axis is a target for psoriasis. The TYK2/Janus kinase 1 inhibitor PF-06700841 will directly suppress TYK2-dependent IL-12 and IL-23 signaling and Janus kinase 1-dependent signaling in cells expressing these signaling molecules, including T cells and keratinocytes. This clinical study sought to define the inflammatory gene and cellular pathways through which PF-06700841 improves the clinical manifestations of psoriasis. Patients (n = 30) with moderate-to-severe psoriasis were randomized to once-daily 30 mg (n = 14) or 100 mg (n = 7) PF-06700841 or placebo (n = 9) for 28 days. Biopsies were taken from nonlesional and lesional skin at baseline and weeks 2 and 4. Changes in the psoriasis transcriptome and genes induced by IL-17 in keratinocytes were evaluated with microarray profiling and reverse transcriptase-PCR. Reductions in IL-17A, IL-17F, and IL-12B mRNA were observed as early as 2 weeks and approximately 70% normalization of lesional gene expression after 4 weeks. Immunohistochemistry showed significant decreases in markers of keratinocyte activation, epidermal thickness, KRT16 and Ki-67 expression, and immune cell infiltrates CD3 + /CD8 + (T cells) and CD11c (dendritic cells) after 2 weeks of treatment, corresponding with improvement in histologic score. PF-06700841 improves clinical symptoms of chronic plaque psoriasis by inhibition of proinflammatory cytokines that require TYK2 and Janus kinase 1 for signal transduction.",2020,"Immunohistochemistry showed significant decreases in markers of keratinocyte activation, epidermal thickness, KRT16 and Ki-67 expression, and immune cell infiltrates CD3+/CD8+ (T cells) and CD11c (dendritic cells) after 2 weeks of treatment, corresponding with improvement in histologic score.",['Patients (n=30) with moderate-to-severe psoriasis'],"['interleukin (IL)-23/T-helper type 17 cell axis', 'placebo']","['markers of keratinocyte activation, epidermal thickness, KRT16 and Ki-67 expression, and immune cell infiltrates CD3+/CD8+ (T cells) and CD11c (dendritic cells', 'lesional gene expression', 'histologic score', 'IL-17A, IL-17F, and IL-12B mRNA']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}]","[{'cui': 'C0963088', 'cui_str': 'IL-23'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0004457', 'cui_str': 'C2 Vertebra'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0022567', 'cui_str': 'Keratinocyte (cell)'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0439662', 'cui_str': 'Immune (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0332448', 'cui_str': 'Tissue infiltration'}, {'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0011306', 'cui_str': 'Dendritic Cells'}, {'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C0205462', 'cui_str': 'Histologic (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1705947', 'cui_str': 'CTLA8'}, {'cui': 'C1705097', 'cui_str': 'Interleukin-17F'}, {'cui': 'C0035696', 'cui_str': 'mRNA'}]",,0.0954999,"Immunohistochemistry showed significant decreases in markers of keratinocyte activation, epidermal thickness, KRT16 and Ki-67 expression, and immune cell infiltrates CD3+/CD8+ (T cells) and CD11c (dendritic cells) after 2 weeks of treatment, corresponding with improvement in histologic score.","[{'ForeName': 'Karen M', 'Initials': 'KM', 'LastName': 'Page', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Mayte', 'Initials': 'M', 'LastName': 'Suarez-Farinas', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Suprun', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Weidong', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Garcet', 'Affiliation': 'Rockefeller University, New York, New York, USA.'}, {'ForeName': 'Judilyn', 'Initials': 'J', 'LastName': 'Fuentes-Duculan', 'Affiliation': 'Rockefeller University, New York, New York, USA.'}, {'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Rockefeller University, New York, New York, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Scaramozza', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Kieras', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Banfield', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA.'}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Clark', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Fensome', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA.'}, {'ForeName': 'James G', 'Initials': 'JG', 'LastName': 'Krueger', 'Affiliation': 'Rockefeller University, New York, New York, USA.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Peeva', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA. Electronic address: Elena.Peeva@pfizer.com.'}]",The Journal of investigative dermatology,['10.1016/j.jid.2019.11.027'] 3139,31122860,Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older.,"A multi-centre, randomised, double-blinded, active-controlled, parallel-group clinical trial was carried out to assess the immunogenicity and safety of NBP608-a newly developed live-attenuated zoster vaccine in Korea-relative to Zostavax® in healthy adults aged 50 years or older. Immune responses to the vaccine were evaluated by glycoprotein enzyme-linked immunosorbent assay (gpELISA) and enzyme-linked immunosorbent spot (ELISPOT) assays using the interferon (IFN)-γ and interleukin (IL)-2 FluoroSpot kit 6 weeks after vaccination. Safety was monitored for 26 weeks based on subjects' diaries, spontaneous reports from subjects, and history taking by the investigators. A total of 845 subjects participated in the screening, and 823 received the vaccination (413 in the NBP608 group and 411 in the comparator group). The gpELISA-determined geometric mean fold rise from baseline to post NBP608 vaccination was 2.75 [95% confidence interval, CI (2.57, 2.94)]. The gpELISA-determined adjusted geometric mean titers (GMTs) of NBP608 and the comparator were 1346.37 [95% CI (1273.99, 1422.87)] and 1674.94 [95% CI (1585.35, 1769.58)], respectively. The adjusted GMT ratio of NBP608 to the comparator was 0.80 [95% CI (0.75, 0.87)]. There was no statistically significant difference between two groups in terms of the geometric mean spot numbers determined by IFN-γ and IL-2 ELISPOT assays at 6 weeks post vaccination (P = 0.7232, 0.3844). The incidence of adverse events (AEs) within 6 weeks post vaccination was 49.82% overall (410/823, 941 cases), 50.73% (209/412, 474 cases) in the NBP608 group, and 48.91% (201/411, 467 cases) in the comparator group. The difference in AE rate between the two groups was not statistically significant (P = 0.6010). Most AEs were mild, with a rate of 83.12% in the NBP608 group and 75.37% in the comparator group. Thus, NBP608 is non-inferior to Zostavax® in terms of inducing the immune response and can be safely administered to adults aged 50 years or older. ClinicalTrials.gov Identifier: NCT03120364.",2019,"The incidence of adverse events (AEs) within 6 weeks post vaccination was 49.82% overall (410/823, 941 cases), 50.73% (209/412, 474 cases) in the NBP608 group, and 48.91% (201/411, 467 cases) in the comparator group.","['845 subjects participated in the screening, and 823 received the vaccination (413 in the NBP608 group and 411 in the comparator group', 'healthy adults aged 50 years and older', 'healthy adults aged 50\u202fyears or older', 'adults aged 50\u202fyears or older']","['interferon (IFN)-γ and interleukin (IL)-2 FluoroSpot', 'Zostavax®', 'NBP608-a newly developed live-attenuated zoster vaccine', 'new live attenuated herpes zoster vaccine (NBP608']","['geometric mean spot numbers determined by IFN-γ and IL-2 ELISPOT assays', 'AE rate', 'glycoprotein enzyme-linked immunosorbent assay (gpELISA) and enzyme-linked immunosorbent spot (ELISPOT) assays', 'incidence of adverse events (AEs', 'adjusted GMT ratio of NBP608', 'immunogenicity and safety', 'Immunogenicity and safety', 'Safety']","[{'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0021747', 'cui_str': 'Interferons'}, {'cui': 'C0021756', 'cui_str': 'TCGF'}, {'cui': 'C1720919', 'cui_str': 'Zostavax'}, {'cui': 'C1720918', 'cui_str': 'Zoster Vaccine'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0019360', 'cui_str': 'Shingles'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0848332', 'cui_str': 'Spots on skin (disorder)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0521095', 'cui_str': 'Determined by (contextual qualifier) (qualifier value)'}, {'cui': 'C0021756', 'cui_str': 'TCGF'}, {'cui': 'C0920508', 'cui_str': 'ELISPOT'}, {'cui': 'C1510438', 'cui_str': 'Assay technique (qualifier value)'}, {'cui': 'C0017968', 'cui_str': 'Glycoproteins'}, {'cui': 'C0014441', 'cui_str': 'ELISA'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",845.0,0.380719,"The incidence of adverse events (AEs) within 6 weeks post vaccination was 49.82% overall (410/823, 941 cases), 50.73% (209/412, 474 cases) in the NBP608 group, and 48.91% (201/411, 467 cases) in the comparator group.","[{'ForeName': 'Won Suk', 'Initials': 'WS', 'LastName': 'Choi', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jung Hyun', 'Initials': 'JH', 'LastName': 'Choi', 'Affiliation': ""Division of Infectious Diseases, Department of Internal Medicine, The Catholic University of Korea, Incheon St. Mary's Hospital, Incheon, Republic of Korea.""}, {'ForeName': 'Dong Sik', 'Initials': 'DS', 'LastName': 'Jung', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Dong-A University Hospital, Busan, Republic of Korea.'}, {'ForeName': 'Hee Jung', 'Initials': 'HJ', 'LastName': 'Choi', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Yeon-Sook', 'Initials': 'YS', 'LastName': 'Kim', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine, Daejon, Republic of Korea.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Republic of Korea.'}, {'ForeName': 'Hee-Chang', 'Initials': 'HC', 'LastName': 'Jang', 'Affiliation': 'Department of Infectious Diseases, Chonnam National University Medical School, Gwangju, Republic of Korea.'}, {'ForeName': 'Eui-Cheol', 'Initials': 'EC', 'LastName': 'Shin', 'Affiliation': 'Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science & Engineering, KAIST, Daejeon, Republic of Korea.'}, {'ForeName': 'Jun-Sik', 'Initials': 'JS', 'LastName': 'Park', 'Affiliation': 'Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science & Engineering, KAIST, Daejeon, Republic of Korea.'}, {'ForeName': 'Hun', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Life Science Research Institute, SK Bioscience, Seongnam, Gyeonggi-do, Republic of Korea.'}, {'ForeName': 'Hee Jin', 'Initials': 'HJ', 'LastName': 'Cheong', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea. Electronic address: heejinmd@korea.ac.kr.'}]",Vaccine,['10.1016/j.vaccine.2019.04.046'] 3140,29389542,Tranexamic acid for treatment of women with post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of data from the WOMAN trial.,"BACKGROUND Sub-Saharan Africa and southern Asia account for almost 85% of global maternal deaths from post-partum haemorrhage. Early administration of tranexamic acid, within 3 h of giving birth, was shown to reduce the risk of death due to bleeding in women with post-partum haemorrhage in the World Maternal Antifibrinolytic (WOMAN) trial. We aimed to assess the cost-effectiveness of early administration of tranexamic acid for treatment of post-partum haemorrhage. METHODS For this economic evaluation we developed a decision model to assess the cost-effectiveness of the addition of tranexamic acid to usual care for treatment of women with post-partum haemorrhage in Nigeria and Pakistan. We used data from the WOMAN trial to inform model parameters, supplemented by estimates from the literature. We estimated costs (calculated in 2016 US$), life-years, and quality-adjusted life-years (QALYs) with and without tranexamic acid, calculated incremental cost-effectiveness ratios (ICERs), and compared these to threshold values in each country. Costs were assessed from the health-care provider perspective and discounted at 3% per year in the base case analysis. We did a series of one-way sensitivity analyses and probabilistic sensitivity analysis to assess the robustness of the results to parameter uncertainty. FINDINGS Early treatment of post-partum haemorrhage with tranexamic acid generated an average gain of 0·18 QALYs at an additional cost of $37·12 per patient in Nigeria and an average gain of 0·08 QALYs at an additional cost of $6·55 per patient in Pakistan. The base case ICER results were $208 per QALY in Nigeria and $83 per QALY in Pakistan. These ICERs were below the lower bound of the cost-effectiveness threshold range in both countries. The ICERs were most sensitive to uncertainty in parameter inputs for the relative risk of death due to bleeding with tranexamic acid, the discount rate, the cost of the drug, and the baseline probability of death due to bleeding. INTERPRETATION Early treatment of post-partum haemorrhage with tranexamic acid is highly cost-effective in Nigeria and Pakistan, and is likely to be cost-effective in countries in sub-Saharan Africa and southern Asia with a similar baseline risk of death due to bleeding. FUNDING London School of Hygiene & Tropical Medicine, Pfizer, UK Department of Health, Wellcome Trust, and Bill & Melinda Gates Foundation.",2018,"INTERPRETATION Early treatment of post-partum haemorrhage with tranexamic acid is highly cost-effective in Nigeria and Pakistan, and is likely to be cost-effective in countries in sub-Saharan Africa and southern Asia with a similar baseline risk of death due to bleeding. ","['women with post-partum haemorrhage in the World Maternal Antifibrinolytic (WOMAN) trial', 'women with post-partum haemorrhage in Nigeria and Pakistan']","['Tranexamic acid', 'tranexamic acid']","['cost-effectiveness', 'average gain of 0·18 QALYs', 'estimated costs (calculated in 2016 US$), life-years, and quality-adjusted life-years (QALYs) with and without tranexamic acid, calculated incremental cost-effectiveness ratios (ICERs', 'risk of death due to bleeding']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C1869041', 'cui_str': 'Haemorrhages (SMQ)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0003304', 'cui_str': 'Antifibrinolysins'}, {'cui': 'C0028075', 'cui_str': 'Federal Republic of Nigeria'}, {'cui': 'C0030211', 'cui_str': 'Islamic Republic of Pakistan'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0080071', 'cui_str': 'QALY'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0444686', 'cui_str': 'Calculated (qualifier value)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}]",,0.319762,"INTERPRETATION Early treatment of post-partum haemorrhage with tranexamic acid is highly cost-effective in Nigeria and Pakistan, and is likely to be cost-effective in countries in sub-Saharan Africa and southern Asia with a similar baseline risk of death due to bleeding. ","[{'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'Li', 'Affiliation': 'Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: bernadette.li@lshtm.ac.uk.'}, {'ForeName': 'Alec', 'Initials': 'A', 'LastName': 'Miners', 'Affiliation': 'Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Haleema', 'Initials': 'H', 'LastName': 'Shakur', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Roberts', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Global health,['10.1016/S2214-109X(17)30467-9'] 3141,31908205,"Assessing the Potential Impact of Cigarette Packs Designed for Lesbian, Gay, Bisexual, and Transgender Adults: A Randomized Experiment to Inform U.S. Regulation, 2018.","The Food and Drug Administration (FDA) can regulate the introduction of new tobacco products and some changes to existing products. Cigarette packs have been used as a marketing tool to target specific groups and priority populations. Research has shown that sexual and gender minority (SGM) adults are substantially more likely to use tobacco products than their straight and cisgender counterparts. However, research to inform the FDA's regulatory decisions regarding cigarette packs targeting priority populations is nascent. To fill this gap, we conducted an online experiment in 2018, randomizing U.S. adults who reported current smoking ( N = 954, 52% were SGM) to view one of three cigarette packs. A graphic designer developed ""Glacier"" branded packs with three levels of SGM imagery: (1) no targeting, (2) subtle targeting, and (3) a rainbow ""pride edition."" Participants viewed and rated the pack using cognitive, affective, and behavioral measures informed by theory. We used a linear model framework to compare the two SGM-targeted packs with the not targeted version and tested interactions between pack and SGM identity for the dependent variables. We stratified results by SGM status. SGM status was a significant moderator of the relationship between the pack and ratings of appeal, positive affect, feeling shocked, and intent to try with a coupon. Findings from this study revealed that packs designed for SGM populations can disproportionately change cognitive, affective, and behavioral intention responses for SGM smokers. Products entering the market should be assessed by FDA for the appeal of their packs to vulnerable populations.",2020,"SGM status was a significant moderator of the relationship between the pack and ratings of appeal, positive affect, feeling shocked, and intent to try with a coupon.","['2018, randomizing U.S. adults who reported current smoking ( N = 954, 52% were SGM) to view one of three cigarette packs', 'Lesbian, Gay, Bisexual, and Transgender Adults']",[],"['cognitive, affective, and behavioral intention responses']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C4521841', 'cui_str': 'MGySgt'}, {'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C1968515', 'cui_str': 'Pack (physical object)'}, {'cui': 'C1533642', 'cui_str': 'Women Who Have Sex With Women'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C2129310', 'cui_str': 'Bisexual (finding)'}]",[],"[{'cui': 'C0162425', 'cui_str': 'Intention'}]",,0.0169502,"SGM status was a significant moderator of the relationship between the pack and ratings of appeal, positive affect, feeling shocked, and intent to try with a coupon.","[{'ForeName': 'Joseph G L', 'Initials': 'JGL', 'LastName': 'Lee', 'Affiliation': 'East Carolina University, Greenville, NC, USA.'}, {'ForeName': 'Tiffany M', 'Initials': 'TM', 'LastName': 'Blanchflower', 'Affiliation': 'East Carolina University, Greenville, NC, USA.'}, {'ForeName': 'Kevin F', 'Initials': 'KF', 'LastName': ""O'Brien"", 'Affiliation': 'East Carolina University, Greenville, NC, USA.'}, {'ForeName': 'Leslie E', 'Initials': 'LE', 'LastName': 'Cofie', 'Affiliation': 'East Carolina University, Greenville, NC, USA.'}, {'ForeName': 'Kyle R', 'Initials': 'KR', 'LastName': 'Gregory', 'Affiliation': 'East Carolina University, Greenville, NC, USA.'}, {'ForeName': 'Paige E', 'Initials': 'PE', 'LastName': 'Averett', 'Affiliation': 'East Carolina University, Greenville, NC, USA.'}]",Health promotion practice,['10.1177/1524839919879923'] 3142,31935118,Oral supplementation with omega-3 fatty acids and inflammation markers in patients with chronic kidney disease in hemodialysis.,"Chronic kidney disease (CKD) is an increasingly common public health problem that increases the risk of death because of cardiovascular complications by 2-3 times compared with the general population. This research concerns a prospective, randomized, double-blind study in patients with CKD undergoing hemodialysis. The participants were assigned to 1 of 2 groups: the study group (group A; 46 patients) received 4 capsules (2.4 g) of omega-3 fatty acids daily during the 12-week intervention, while patients in the control group (group B; 47 patients) received 4 capsules of paraffin oil. The patients' general characteristics, nutritional indicators, renal disease markers and inflammatory markers (C-reactive protein, interleukin (IL)-6, IL-10, and tumour necrosis factor alpha (TNF-α)) were evaluated. No differences were found between the general characteristics of the patients ( P < 0.05), and no differences were shown in the nutritional indicators and markers of kidney disease ( P < 0.05). Patients in group A showed significant decreases in levels of C-reactive protein, IL-6, TNF-α, and the IL-10/IL-6 ratio after 12 weeks of supplementation ( P < 0.05). Patients in group B did not show any significant changes in concentrations of inflammatory markers during the intervention ( P < 0.05). In conclusion, oral supplementation with omega-3 fatty acids produces a significant decrease in the concentrations of inflammation markers in patients with chronic kidney disease on hemodialysis. Novelty Oral supplementation with omega-3 fatty acids produced significant decreases in the concentrations of inflammation markers. This supplementation could be given to patients with uremic syndrome and coronary heart disease to reduce cardiovascular risk.",2020,"Patients in group A showed significant decreases in levels of C-reactive protein, interleukin-6, tumour necrosis factor alpha and the interleukin-10/interleukin-6 ratio after 12 weeks of supplementation (P <0.05).","['patients with uremic syndrome and coronary heart disease to reduce cardiovascular risk', 'Chronic kidney disease (CKD', 'patients with CKD undergoing hemodialysis', 'patients with chronic kidney disease in hemodialysis', 'patients with chronic kidney disease on hemodialysis']","['Oral supplementation with omega-3 fatty acids', 'omega-3 fatty acids', 'paraffin oil']","['nutritional indicators and markers of kidney disease', 'levels of C-reactive protein, interleukin-6, tumour necrosis factor alpha and the interleukin-10/interleukin-6 ratio', 'concentrations of inflammation markers', 'concentrations of inflammatory markers', 'general characteristics, nutritional indicators, renal disease markers and inflammatory markers (C-reactive protein, interleukin-6, interleukin-10 and tumour necrosis factor alpha']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0302810', 'cui_str': 'Uraemic syndrome'}, {'cui': 'C0010068', 'cui_str': 'Coronary Disease'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0070062', 'cui_str': 'paraffin oils'}]","[{'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0022658', 'cui_str': 'Kidney Diseases'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}]",47.0,0.0360031,"Patients in group A showed significant decreases in levels of C-reactive protein, interleukin-6, tumour necrosis factor alpha and the interleukin-10/interleukin-6 ratio after 12 weeks of supplementation (P <0.05).","[{'ForeName': 'José A', 'Initials': 'JA', 'LastName': 'Valle Flores', 'Affiliation': 'Nutrition and Food Science Program, University of Granada, Spain.'}, {'ForeName': 'Juan E', 'Initials': 'JE', 'LastName': 'Fariño Cortéz', 'Affiliation': 'Carrera de Enfermería, Facultad de Ciencias Sociales y de la Salud, Universidad Estatal de Santa Elena, Santa Elena, Ecuador, 241702.'}, {'ForeName': 'Gabriel A', 'Initials': 'GA', 'LastName': 'Mayner Tresol', 'Affiliation': 'Carrera de Medicina, Facultad de Ciencias Médicas, Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, 150950.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Perozo Romero', 'Affiliation': 'Servicio de Nefrología, Hospital Central Dr. Urquinaona, Facultad de Medicina, Universidad de Zulia, Maracaibo, Venezuela, 4001.'}, {'ForeName': 'Miquel', 'Initials': 'M', 'LastName': 'Blasco Carlos', 'Affiliation': 'Instituto de Investigación e Innovación de Salud Integral, Universidad Católica de Santiago de Guayaquil, Avenue Carlos Julio Arosemena Tola, Guayaquil, Ecuador.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Nestares', 'Affiliation': 'Department of Physiology, Institute of Nutrition and Food Technology, University of Granada, Granada, Spain, 18010.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2019-0729'] 3143,31743507,Feasibility of Resistance Exercise for Posttraumatic Stress and Anxiety Symptoms: A Randomized Controlled Pilot Study.,"Emerging evidence suggests that exercise may beneficially affect posttraumatic stress symptoms (PTSS), but few randomized trials exist. Additionally, the effects of resistance exercise (i.e., weight lifting or strength training) on PTSS have not been thoroughly examined. This study aimed to explore the feasibility of a brief high-intensity resistance exercise intervention for PTSS and related issues, such as anxiety, sleep, alcohol use, and depression, in non-treatment-seeking adults who screened positive for posttraumatic stress disorder (PTSD) and anxiety. The sample included 30 non-treatment-seeking, urban-dwelling adults (M age = 29.10 years, SD = 7.38; 73.3% female) who screened positive for PTSD and anxiety and were randomly assigned to either a 3-week resistance exercise intervention or a time-matched contact control condition. The results suggest the intervention was feasible, with 80.0% (n = 24) of participants completing the study, 88.9% of the resistance exercise sessions attended, and no adverse effects reported. Additionally, resistance exercise had large beneficial effects on symptoms of avoidance, d = 1.26, 95% CI [0.39, 2.14]; and hyperarousal, d = 0.90, 95% CI [0.06, 1.74], relative to the control condition. Resistance exercise also produced large improvements concerning sleep quality, d = 1.31, 95% CI [0.41, 2.21], and hazardous alcohol use, d = 0.99, 95% CI [0.13, 1.86], compared to the control condition. Overall, the findings suggest that 3 weeks of high-intensity resistance exercise is a feasible intervention for PTSS reduction in non-treatment-seeking adults who screen positive for PTSD and anxiety; additional research is needed to verify these preliminary findings.",2019,"Resistance exercise also produced large improvements concerning sleep quality, d = 1.31, 95% CI [0.41, 2.21], and hazardous alcohol use, d = 0.99, 95% CI [0.13, 1.86], compared to the control condition.","['non-treatment-seeking adults who screened positive for posttraumatic stress disorder (PTSD) and anxiety', 'The sample included 30 non-treatment-seeking, urban-dwelling adults (M age = 29.10 years, SD = 7.38; 73.3% female) who screened positive for PTSD and anxiety', 'Posttraumatic Stress and Anxiety Symptoms']","['resistance exercise (i.e., weight lifting or strength training', 'resistance exercise intervention or a time-matched contact control condition', 'brief high-intensity resistance exercise intervention', 'Resistance Exercise']",[],"[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0043095', 'cui_str': 'Weight Liftings'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}]",[],,0.0706585,"Resistance exercise also produced large improvements concerning sleep quality, d = 1.31, 95% CI [0.41, 2.21], and hazardous alcohol use, d = 0.99, 95% CI [0.13, 1.86], compared to the control condition.","[{'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'Whitworth', 'Affiliation': 'Department of Biobehavioral Sciences, Teachers College, Columbia University, New York, NY, USA.'}, {'ForeName': 'Sanaz', 'Initials': 'S', 'LastName': 'Nosrat', 'Affiliation': 'Department of Biobehavioral Sciences, Teachers College, Columbia University, New York, NY, USA.'}, {'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'SantaBarbara', 'Affiliation': 'Department of Biobehavioral Sciences, Teachers College, Columbia University, New York, NY, USA.'}, {'ForeName': 'Joseph T', 'Initials': 'JT', 'LastName': 'Ciccolo', 'Affiliation': 'Department of Biobehavioral Sciences, Teachers College, Columbia University, New York, NY, USA.'}]",Journal of traumatic stress,['10.1002/jts.22464'] 3144,31249395,Effects of a diet naturally rich in polyphenols on lipid composition of postprandial lipoproteins in high cardiometabolic risk individuals: an ancillary analysis of a randomized controlled trial.,"BACKGROUND/OBJECTIVES Plasma lipoprotein composition, especially in the postprandial state, could be relevant for cardiovascular risk and could be influenced by eating habits. This study evaluated the effects of a polyphenol-rich diet on postprandial lipoprotein composition in individuals at high cardiometabolic risk. SUBJECTS/METHODS Seventy-eight individuals with high waist circumference and at least another component of the metabolic syndrome were randomized to either a high-polyphenol (HighP) or low-polyphenol (LowP) diet. Before and after the 8-week intervention, chylomicrons, VLDL1, VLDL2, IDL, LDL, HDL particles, and their lipid concentrations were determined over a 6-h high-fat test meal with high or low-polyphenol content, according to the diet assigned. RESULTS VLDL1 postprandial areas under the curve (AUCs) were lower for cholesterol (Chol) (1.48 ± 0.98 vs. 1.91 ± 1.13 mmol/L × 6 h, M ± SD, p = 0.014) and triglycerides (Tg) (4.70 ± 2.70 vs. 6.02 ± 3.07 mmol/L × 6 h, p = 0.005) after the HighP than after the LowP diet, with no changes in Chol/Tg ratio. IDL Chol AUCs were higher after the HighP than after the LowP diet (1.29 ± 0.77 vs. 1.01 ± 0.51 mmol/L × 6 h, p = 0.037). LDL Tg AUCs were higher after the HighP than after the LowP diet (1.15 ± 0.33 vs. 1.02 ± 0.35 mmol/L × 6 h, p < 0.001), with a lower Chol/Tg ratio (14.6 ± 4.0 vs. 16.0 ± 3.8, p = 0.007). HDL Tg AUCs were lower after the HighP than after the LowP diet (1.20 ± 0.41 vs. 1.34 ± 0.37 mmol/L × 6 h, p = 0.013). CONCLUSIONS A high-polyphenol diet reduces the postprandial lipid content of large VLDL and increases IDL cholesterol; it modifies the composition of LDL particles-which become richer in triglycerides, and of HDL-which become instead triglyceride poor. The overall changes in atherogenicity by these effects warrant further investigation on clinical cardiovascular outcomes.",2020,"h, p = 0.005) after the HighP than after the LowP diet, with no changes in Chol/Tg ratio.","['Seventy-eight individuals with high waist circumference and at least another component of the metabolic syndrome', 'high cardiometabolic risk individuals', 'individuals at high cardiometabolic risk']","['high-polyphenol (HighP) or low-polyphenol (LowP) diet', 'polyphenol diet', 'diet naturally rich in polyphenols', 'polyphenol-rich diet']","['HDL Tg AUCs', 'VLDL1 postprandial areas under the curve (AUCs', 'lipid composition of postprandial lipoproteins', 'postprandial lipid content of large VLDL and increases IDL cholesterol', 'LDL Tg AUCs', 'chylomicrons, VLDL1, VLDL2, IDL, LDL, HDL particles, and their lipid concentrations', 'postprandial lipoprotein composition', 'IDL Chol AUCs']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0524620', 'cui_str': 'Metabolic Syndrome X'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0071649', 'cui_str': 'Polyphenol (substance)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}]","[{'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0523560', 'cui_str': 'VLDL cholesterol measurement'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0123167', 'cui_str': 'IDL cholesterol'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0008731', 'cui_str': 'Chylomicrons'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",78.0,0.0231524,"h, p = 0.005) after the HighP than after the LowP diet, with no changes in Chol/Tg ratio.","[{'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Della Pepa', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University, 80131, Naples, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Vetrani', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University, 80131, Naples, Italy.'}, {'ForeName': 'Marilena', 'Initials': 'M', 'LastName': 'Vitale', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University, 80131, Naples, Italy.'}, {'ForeName': 'Lutgarda', 'Initials': 'L', 'LastName': 'Bozzetto', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University, 80131, Naples, Italy.'}, {'ForeName': 'Giuseppina', 'Initials': 'G', 'LastName': 'Costabile', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University, 80131, Naples, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Cipriano', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University, 80131, Naples, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Mangione', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University, 80131, Naples, Italy.'}, {'ForeName': 'Lidia', 'Initials': 'L', 'LastName': 'Patti', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University, 80131, Naples, Italy.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Riccardi', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University, 80131, Naples, Italy.'}, {'ForeName': 'Angela Albarosa', 'Initials': 'AA', 'LastName': 'Rivellese', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University, 80131, Naples, Italy. rivelles@unina.it.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Annuzzi', 'Affiliation': 'Department of Clinical Medicine and Surgery, Federico II University, 80131, Naples, Italy.'}]",European journal of clinical nutrition,['10.1038/s41430-019-0459-0'] 3145,31962350,Evaluation of Graft Tensioning Effects in Anterior Cruciate Ligament Reconstruction between Hamstring and Bone-Patellar Tendon Bone Autografts.,"This article investigates the clinical, functional, and radiographic outcomes in anterior cruciate ligament (ACL) reconstruction patients over 7 years to determine the effects of initial graft tension on outcomes when using patellar tendon (bone-tendon-bone [BTB]) and hamstring tendon (HS) autografts. Ninety patients, reconstructed with BTB or HS, were randomized using two initial graft tension protocols: (1) normal anteroposterior (AP) laxity (""low-tension""; n  = 46) and (2) AP laxity overconstrained by 2 mm (""high-tension""; n  = 44). Seventy-two patients had data available at 7 years, with 9 excluded for graft failure. Outcomes included the Knee Injury and Osteoarthritis Outcome Score, Short-Form-36 (SF-36), and Tegner activity scale. Clinical outcomes included KT-1000S and International Knee Documentation Committee examination score; and functional outcomes included 1-leg hop distance and peak knee extensor torque. Imaging outcomes included medial joint space width, Osteoarthritis Research Society International radiographic score, and Whole-Organ Magnetic Resonance Score. There were significantly improved outcomes in the high-tension compared with the low-tension HS group for SF-36 subset scores for bodily pain ( p  = 0.012), social functioning ( p  = 0.004), and mental health ( p  = 0.014) 84 months postsurgery. No significant differences in any outcome were found within the BTB groups. Tegner activity scores were also significantly higher for the high-tension HS group compared with the low-tension (6.0 vs. 3.8, p  = 0.016). Patients with HS autografts placed in high tension had better outcomes relative to low tension for Tegner activity score and SF-36 subset scores for bodily pain, social functioning, and mental health. For this reason, we recommend that graft fixation be performed with the knee at 30-degree flexion (""high-tension"" condition) when reconstructing the ACL with HS autograft.",2020,"There were significantly improved outcomes in the high-tension compared with the low-tension HS group for SF-36 subset scores for bodily pain ( p  = 0.012), social functioning ( p  = 0.004), and mental health ( p  = 0.014) 84 months postsurgery.","['Ninety patients, reconstructed with BTB or HS', 'Seventy-two patients had data available at 7 years, with 9 excluded for graft failure', 'anterior cruciate ligament (ACL) reconstruction patients over 7 years', 'Anterior Cruciate Ligament Reconstruction between Hamstring and Bone-Patellar Tendon Bone Autografts']","['initial graft tension', 'initial graft tension protocols: (1) normal anteroposterior (AP) laxity (""low-tension""; n \u2009=\u200946) and (2) AP laxity overconstrained by 2\u2009mm (""high-tension""; n \u2009=\u200944', 'patellar tendon (bone-tendon-bone [BTB]) and hamstring tendon (HS) autografts']","['Tegner activity scores', 'bodily pain', 'social functioning', 'medial joint space width, Osteoarthritis Research Society International radiographic score, and Whole-Organ Magnetic Resonance Score', 'high-tension', 'mental health', 'Knee Injury and Osteoarthritis Outcome Score, Short-Form-36 (SF-36), and Tegner activity scale', 'Tegner activity score and SF-36 subset scores for bodily pain, social functioning, and mental health', 'KT-1000S and International Knee Documentation Committee examination score; and functional outcomes included 1-leg hop distance and peak knee extensor torque']","[{'cui': 'C3816959', 'cui_str': 'Ninety'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319632', 'cui_str': 'Seventy-two'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C1262018', 'cui_str': 'Transplant failure'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0206332', 'cui_str': 'Ligamentum Patellae'}, {'cui': 'C1444862', 'cui_str': 'Autogenous bone graft material'}]","[{'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C1527362', 'cui_str': 'grafts'}, {'cui': 'C0233494', 'cui_str': 'Tension (finding)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0332536', 'cui_str': 'Laxness'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0206332', 'cui_str': 'Ligamentum Patellae'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0039508', 'cui_str': 'Tendons'}, {'cui': 'C1267157', 'cui_str': 'Hamstring Tendons'}, {'cui': 'C0040736', 'cui_str': 'Autotransplantation'}]","[{'cui': 'C3850078', 'cui_str': 'Tegner Activity Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205098', 'cui_str': 'Medial (qualifier value)'}, {'cui': 'C0224497', 'cui_str': 'Articular space (body structure)'}, {'cui': 'C0487742', 'cui_str': 'Width (qualifier value)'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}, {'cui': 'C0035168'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0917874', 'cui_str': 'Magnetic Resonance'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0233494', 'cui_str': 'Tension (finding)'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0022744', 'cui_str': 'Knee Injuries'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0920316', 'cui_str': 'Documentation'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C4018995', 'cui_str': 'Hop'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0376590', 'cui_str': 'Torque'}]",90.0,0.107033,"There were significantly improved outcomes in the high-tension compared with the low-tension HS group for SF-36 subset scores for bodily pain ( p  = 0.012), social functioning ( p  = 0.004), and mental health ( p  = 0.014) 84 months postsurgery.","[{'ForeName': 'Steven F', 'Initials': 'SF', 'LastName': 'DeFroda', 'Affiliation': 'Department of Orthopedic Surgery, Brown University, Providence, Rhode Island.'}, {'ForeName': 'Naga Padmini', 'Initials': 'NP', 'LastName': 'Karamchedu', 'Affiliation': 'Department of Orthopedic Surgery, Brown University, Providence, Rhode Island.'}, {'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Budacki', 'Affiliation': 'Department of Orthopedic Surgery, Brown University, Providence, Rhode Island.'}, {'ForeName': 'Taylor', 'Initials': 'T', 'LastName': 'Wiley', 'Affiliation': 'Department of Orthopedic Surgery, Brown University, Providence, Rhode Island.'}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Fadale', 'Affiliation': 'Department of Orthopedic Surgery, Brown University, Providence, Rhode Island.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Hulstyn', 'Affiliation': 'Department of Orthopedic Surgery, Brown University, Providence, Rhode Island.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Shalvoy', 'Affiliation': 'Department of Orthopedic Surgery, Brown University, Providence, Rhode Island.'}, {'ForeName': 'Gary J', 'Initials': 'GJ', 'LastName': 'Badger', 'Affiliation': 'Department Medical Biostatistics, University of Vermont, Burlington, Vermont.'}, {'ForeName': 'Braden C', 'Initials': 'BC', 'LastName': 'Fleming', 'Affiliation': 'Department of Orthopedic Surgery, Brown University, Providence, Rhode Island.'}, {'ForeName': 'Brett D', 'Initials': 'BD', 'LastName': 'Owens', 'Affiliation': 'Department of Orthopedic Surgery, Brown University, Providence, Rhode Island.'}]",The journal of knee surgery,['10.1055/s-0039-3402046'] 3146,31962198,Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial.,"PURPOSE To investigate long-term results of patients with hormonal receptor-positive breast cancer treated with breast-conserving surgery (BCS) and consecutive endocrine therapy (ET) with or without whole breast irradiation (WBI). METHODS AND MATERIALS Within the 8 A trial of the Austrian Breast and Colorectal Cancer Study Group, a total of 869 patients received ET after BCS which was randomly followed by WBI (n = 439, group 1) or observation (n = 430, group 2). WBI was applied up to a mean total dosage of 50 Gy (+/- 10 Gy boost) in conventional fractionation. RESULTS After a median follow-up of 9.89 years, 10 in-breast recurrences (IBRs) were observed in group 1 and 31 in group 2, resulting in a 10-year local recurrence-free survival (LRFS) of 97.5% and 92.4%, respectively (p = 0.004). This translated into significantly higher rates for disease-free survival (DFS): 94.5% group 1 vs 88.4% group 2, p = 0.0156. For distant metastases-free survival (DMFS) and overall survival (OS), respective 10-year rates amounted 96.7% and 86.6% for group 1 versus 96.4% and 87.6%, for group 2 (ns). WBI (hazard ratio [HR]: 0.27, p < 0.01) and tumour grading (HR: 3.76, p = 0.03) were found as significant predictors for IBR in multiple cox regression analysis. CONCLUSIONS After a median follow-up of 10 years, WBI resulted in a better local control and DFS compared with ET alone. The omission of WBI and tumour grading, respectively, were the only negative predictors for LRFS.",2020,"After a median follow-up of 10 years, WBI resulted in a better local control and DFS compared with ET alone.","['low-risk breast cancer patients after breast-conserving surgery', 'Austrian Breast and Colorectal Cancer Study Group, a total of 869 patients received ET after BCS', '10', 'patients with hormonal receptor-positive breast cancer treated with']","['breast-conserving surgery (BCS) and consecutive endocrine therapy (ET) with or without whole breast irradiation (WBI', 'Endocrine therapy with or without whole breast irradiation']","['10-year local recurrence-free survival (LRFS', 'distant metastases-free survival (DMFS) and overall survival (OS), respective 10-year rates']","[{'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0917927', 'cui_str': 'Breast-Conserving Surgery'}, {'cui': 'C0337795', 'cui_str': 'Austrians (ethnic group)'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0458083', 'cui_str': 'Hormonal (qualifier value)'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0917927', 'cui_str': 'Breast-Conserving Surgery'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy (procedure)'}, {'cui': 'C0457102', 'cui_str': 'Whole breast (qualifier value)'}, {'cui': 'C1282930', 'cui_str': 'Irradiation (physical force)'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease (finding)'}, {'cui': 'C0443203', 'cui_str': 'Distant (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",869.0,0.0432399,"After a median follow-up of 10 years, WBI resulted in a better local control and DFS compared with ET alone.","[{'ForeName': 'Gerd', 'Initials': 'G', 'LastName': 'Fastner', 'Affiliation': 'Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University, University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria. Electronic address: g.fastner@salk.at.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Sedlmayer', 'Affiliation': 'Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University, University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria. Electronic address: f.sedlmayer@salk.at.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Widder', 'Affiliation': 'Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: joachim.widder@meduniwien.ac.at.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Metz', 'Affiliation': 'Department of Radiooncology and Radiotherapy, Wiener Neustadt Hospital, Wiener Neustadt, Austria. Electronic address: martina.metz@wienerneustadt.lknoe.at.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Geinitz', 'Affiliation': 'Department of Radiation Oncology, Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria. Electronic address: hans.geinitz@ordensklinikum.at.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Kapp', 'Affiliation': 'Department of Therapeutic Radiology and Oncology, Comprehensive Cancer Center (CCC), Medical University of Graz, Graz, Austria. Electronic address: karin.kapp@medunigraz.at.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Fesl', 'Affiliation': 'Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Electronic address: Christian.Fesl@abcsg.at.'}, {'ForeName': 'Lidija', 'Initials': 'L', 'LastName': 'Sölkner', 'Affiliation': 'Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Electronic address: Lidija.Soelkner@abcsg.at.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Greil', 'Affiliation': 'Department of Medical Oncology, Paracelsus Medical University, Salzburg, Austria. Electronic address: r.greil@salk.at.'}, {'ForeName': 'Raimund', 'Initials': 'R', 'LastName': 'Jakesz', 'Affiliation': 'Department of Medical Oncology, Paracelsus Medical University, Salzburg, Austria. Electronic address: raimund.jakesz@meduniwien.ac.at.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Kwasny', 'Affiliation': 'Department of Surgery, Wiener Neustadt Hospital, Wiener Neustadt, Austria. Electronic address: werner.kwasny@wienerneustadt.lknoe.at.'}, {'ForeName': 'Dietmar', 'Initials': 'D', 'LastName': 'Heck', 'Affiliation': 'Department of Surgery, Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria. Electronic address: dietmar.heck@ordensklinikum.at.'}, {'ForeName': 'Vesna', 'Initials': 'V', 'LastName': 'Bjelic-Radisic', 'Affiliation': 'Breast Unit, Universtiy Hospital Wuppertal, University Witten/Herdecke, Witten, Germany. Electronic address: vesna.bjelic-radisic@helios-gesundheit.de.'}, {'ForeName': 'Marija', 'Initials': 'M', 'LastName': 'Balic', 'Affiliation': 'Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria. Electronic address: marija.balic@medunigraz.at.'}, {'ForeName': 'Herbert', 'Initials': 'H', 'LastName': 'Stöger', 'Affiliation': 'Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria. Electronic address: herbert.stoeger@klinikum-graz.at.'}, {'ForeName': 'Ursula', 'Initials': 'U', 'LastName': 'Wieder', 'Affiliation': 'Department of Surgery, Hanusch Spital, Vienna, Austria. Electronic address: ursula.wieder@wgkk.at.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Zwrtek', 'Affiliation': 'Department of Surgery, Mistelbach Hospital, Mistelbach, Austria. Electronic address: ronald.zwrtek@mistelbach.lknoe.at.'}, {'ForeName': 'Dagmar', 'Initials': 'D', 'LastName': 'Semmler', 'Affiliation': 'Department of Surgery, Mistelbach Hospital, Mistelbach, Austria. Electronic address: dagmar.semmler@mistelbach.lknoe.at.'}, {'ForeName': 'Wilfried', 'Initials': 'W', 'LastName': 'Horvath', 'Affiliation': 'Department of Surgery, Guessing Hospital, Guessing, Austria. Electronic address: wilfried.horvath@krages.at.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Melbinger-Zeinitzer', 'Affiliation': 'Department of Gynecology, Wolfsberg Hospital, Wolfsberg, Austria. Electronic address: elisabeth.melbinger-zeinitzer@lkh-wo.at.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Wiesholzer', 'Affiliation': 'Department of Internal Medicine I, Division of Nephrology and Hematology, University Hospital St. Poelten, Karl Landsteiner University of Health Sciences, St. Pölten, Austria. Electronic address: martin.wiesholzer@stpoelten.lknoe.at.'}, {'ForeName': 'Viktor', 'Initials': 'V', 'LastName': 'Wette', 'Affiliation': 'Department of Surgery, Krankenhaus der Barmherzigen Brüder St Veit an der Glan, St. Veit an der Glan, Austria. Electronic address: wetteviktor@aon.at.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Gnant', 'Affiliation': 'Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: michael.gnant@abcsg.at.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.11.024'] 3147,31887277,Magnetic Resonance-Based Diagnostics for Bleeding Assessment in Neonatal Cardiac Surgery.,"PURPOSE Infants undergoing a cardiac operation are at high risk for postsurgical bleeding. To date, there are no highly predictive models for postsurgical bleeding in this population. This study's objective was to assess the predictive ability of T2 magnetic resonance (T2MR). DESCRIPTION T2MR uses magnetic resonance to detect clot formation characteristics on a small blood sample and provides hemostatic indicators that can assess bleeding risk. EVALUATION This prospective, single-institution study enrolled 100 patients younger than 12 months old undergoing a cardiac operation from April 27, 2015, to September 21, 2016. The primary end point was postsurgical bleeding within 24 hours after the procedure. T2MR data were modeled with a binary recursive partitioning algorithm with randomized cross-validation. The tight clot metric produced the highest univariate discrimination of bleeding (receiver operator characteristic curve, 0.64; classification accuracy, 72%), and along with the platelet function metric, demonstrated highest relative importance based on Gini index splitting (Salford Systems, San Diego, CA). Multivariate modeling with cross-validation showed mean receiver operator characteristic curve area of 0.74 and classification accuracy of 82%. CONCLUSIONS T2MR tight clot and platelet function metrics were associated with bleeding events.",2020,"The tight clot metric produced the highest univariate discrimination of bleeding (receiver operator curve = 0.64, classification accuracy = 72%), and along with the platelet function metric, demonstrated highest relative importance based on Gini index splitting.","['Infants undergoing cardiac surgery', '100 patients less than 12 months old undergoing cardiac surgery from 4/27/2015 and 9/21/2016', 'Neonatal Cardiac Surgery']","['Magnetic Resonance-Based Diagnostics', 'T2 magnetic resonance (T2MR']",['post-surgical bleeding'],"[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}]","[{'cui': 'C0917874', 'cui_str': 'Magnetic Resonance'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}]","[{'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}]",100.0,0.0527928,"The tight clot metric produced the highest univariate discrimination of bleeding (receiver operator curve = 0.64, classification accuracy = 72%), and along with the platelet function metric, demonstrated highest relative importance based on Gini index splitting.","[{'ForeName': 'Perry S', 'Initials': 'PS', 'LastName': 'Choi', 'Affiliation': ""Department of Cardiovascular Surgery, Boston Children's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Sirisha', 'Initials': 'S', 'LastName': 'Emani', 'Affiliation': ""Department of Cardiovascular Surgery, Boston Children's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Juan C', 'Initials': 'JC', 'LastName': 'Ibla', 'Affiliation': ""Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Joseph E', 'Initials': 'JE', 'LastName': 'Marturano', 'Affiliation': 'T2 Biosystems, Lexington, Massachusetts.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Lowery', 'Affiliation': 'T2 Biosystems, Lexington, Massachusetts.'}, {'ForeName': 'Sitaram', 'Initials': 'S', 'LastName': 'Emani', 'Affiliation': ""Department of Cardiovascular Surgery, Boston Children's Hospital, Boston, Massachusetts. Electronic address: sitaram.emani@cardio.chboston.org.""}]",The Annals of thoracic surgery,['10.1016/j.athoracsur.2019.11.010'] 3148,31468682,"Effects of a posttonsillectomy management program using a mobile instant messenger on parents' knowledge and anxiety, and their children's compliance, bleeding, and pain.","PURPOSE Pediatric tonsillectomy is a highly common surgery for children. The inclusion of tonsillectomy in the diagnosis-related group payment system in Korea has resulted in a shorter hospital stay for patients who undergo tonsillectomy. This, in turn, provides parents with additional caregiver roles in the home. OBJECTIVES This study aimed to investigate the effects of a postdischarge management program (PDMP) using Mobile Instant Messenger (MIM) on parents' knowledge and state anxiety about postoperative care, and their children's compliance with care instructions at home, frequency of bleeding, and pain intensity after tonsillectomy. DESIGN AND METHODS A nonequivalent control group nonsynchronized design. SETTINGS AND PARTICIPANTS Participants were 52 tonsillectomy children aged 3-7 years and their 52 parents (27 for the experimental group and 25 for the control group) from a hospital, in Korea. The control group received a routine written and oral predischarge education, while the experimental group received a predischarge education and a daily MIM for 7 days. For the experimental group, bidirectional communication between the nurse and parent when necessary using MIM are available during the intervention period. RESULTS Parents in the experimental group reported a significantly higher knowledge about postdischarge management and lower state anxiety than the control group. Children in the experimental group showed a significantly greater improvement in compliance with the care instructions at home than the control group. However, bleeding frequency and pain intensity were not significantly lower in the experimental group than that in the control group. PRACTICAL IMPLICATIONS Nurses play a critical role in preventing and managing the complications of tonsillectomy. Providing proper parental education about pediatric posttonsillectomy care at home is critical for a successful recovery. With the explosion of smartphone technology, the MIM-based PDMP is a useful and effective strategy in helping parents and children in posttonsillectomy care at home.",2019,"RESULTS Parents in the experimental group reported a significantly higher knowledge about postdischarge management and lower state anxiety than the control group.","['children', 'patients who undergo tonsillectomy', 'Participants were 52 tonsillectomy children aged 3-7 years and their 52 parents (27 for the experimental group and 25 for the control group) from a hospital, in Korea', ""parents' knowledge and state anxiety about postoperative care, and their children's compliance with care instructions at home, frequency of bleeding, and pain intensity after tonsillectomy""]","['routine written and oral predischarge education, while the experimental group received a predischarge education and a daily MIM', 'postdischarge management program (PDMP) using Mobile Instant Messenger (MIM', 'posttonsillectomy management program']","[""parents' knowledge and anxiety, and their children's compliance, bleeding, and pain"", 'knowledge about postdischarge management and lower state anxiety', 'bleeding frequency and pain intensity', 'compliance with the care instructions']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0040423', 'cui_str': 'Tonsillectomy'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0022771', 'cui_str': 'Korea'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0032786', 'cui_str': 'Postoperative Care'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0231290', 'cui_str': 'Status post (contextual qualifier) (qualifier value)'}]","[{'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0335218', 'cui_str': 'Messenger'}]","[{'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}]",52.0,0.0269931,"RESULTS Parents in the experimental group reported a significantly higher knowledge about postdischarge management and lower state anxiety than the control group.","[{'ForeName': 'Kyoung Eun', 'Initials': 'KE', 'LastName': 'Yu', 'Affiliation': 'Department of Nursing, Donggang University, Gwangju, Korea.'}, {'ForeName': 'Jin Sun', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': 'Department of Nursing, Chosun University, Gwangju, Korea.'}]",Journal for specialists in pediatric nursing : JSPN,['10.1111/jspn.12270'] 3149,30353619,"High-dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan.","BACKGROUND A previous phase II dose-ranging study of linaclotide in a Japanese chronic constipation (CC) population showed that 0.5 mg was the most effective dose. This study aimed to verify the hypothesis that 0.5 mg of linaclotide is effective and safe in Japanese CC patients. METHODS This was a Japanese phase III randomized, double-blind, placebo-controlled (part 1), and long-term, open-label extension (part 2) study of linaclotide. CC patients (n = 186) diagnosed using the Rome III criteria were randomly assigned to linaclotide 0.5 mg (n = 95) or placebo (n = 91) for a 4-week double-blind treatment period in part 1, followed by an additional 52 weeks of open-label treatment with linaclotide in part 2. The primary efficacy endpoint was the change from baseline in weekly spontaneous bowel movement (SBM) frequency at the first week. Secondary endpoints included responder rate for complete SBM (CSBM), changes in stool consistency, and severity of straining. KEY RESULTS Part 1: Change in weekly mean SBM frequency in the first week of treatment with linaclotide (4.02) was significantly greater than that with placebo (1.48, P < 0.001). Linaclotide produced a higher CSBM responder rate (52.7%) compared to placebo (26.1%, P < 0.001). Part 2: Patients continued to show improved SBM frequency with linaclotide. Through parts 1 and 2, the most common drug-related adverse event was mild and occasionally moderate diarrhea. CONCLUSIONS AND INFERENCES The results of this study indicate that a linaclotide dose of 0.5 mg/day is effective and safe in Japanese CC patients.",2019,"Linaclotide produced a higher CSBM responder rate (52.7%) compared to placebo (26.1%, P < 0.001).","['CC patients (n\xa0=\xa0186) diagnosed using the Rome III criteria', 'Japanese CC patients', 'patients with chronic constipation']","['linaclotide 0.5\xa0mg (n\xa0=\xa095) or placebo', 'High-dose linaclotide', 'placebo', 'linaclotide']","['responder rate for complete SBM (CSBM), changes in stool consistency, and severity of straining', 'SBM frequency', 'mean SBM frequency', 'weekly spontaneous bowel movement (SBM) frequency', 'CSBM responder rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0035831', 'cui_str': 'Rome'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0401149', 'cui_str': 'Chronic constipation (disorder)'}]","[{'cui': 'C2000261', 'cui_str': 'linaclotide'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}]","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0278015', 'cui_str': 'Change in stool consistency'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}]",186.0,0.242971,"Linaclotide produced a higher CSBM responder rate (52.7%) compared to placebo (26.1%, P < 0.001).","[{'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Fukudo', 'Affiliation': 'Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Hiroto', 'Initials': 'H', 'LastName': 'Miwa', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Nakajima', 'Affiliation': 'Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan.'}, {'ForeName': 'Yoshikazu', 'Initials': 'Y', 'LastName': 'Kinoshita', 'Affiliation': 'Department of Gastroenterology, Faculty of Medicine, Shimane University, Izumo, Japan.'}, {'ForeName': 'Masanori', 'Initials': 'M', 'LastName': 'Kosako', 'Affiliation': 'Japan-Asia Clinical Development 1, Development, Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Kenta', 'Initials': 'K', 'LastName': 'Hayashi', 'Affiliation': 'Regulatory Affairs-Japan, Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Hiraku', 'Initials': 'H', 'LastName': 'Akiho', 'Affiliation': 'Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Kuroishi', 'Affiliation': 'Japan-Asia Data Science, Development, Astellas Pharma Inc., Tokyo, Japan.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Johnston', 'Affiliation': 'Ironwood Pharmaceuticals Inc., Cambridge, Massachusetts.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Currie', 'Affiliation': 'Ironwood Pharmaceuticals Inc., Cambridge, Massachusetts.'}, {'ForeName': 'Toshifumi', 'Initials': 'T', 'LastName': 'Ohkusa', 'Affiliation': 'Department of Internal Medicine, Kashiwa Hospital, Jikei University School of Medicine, Kashiwa, Japan.'}]",Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,['10.1111/nmo.13487'] 3150,31173921,Physical Therapy Informed by Acceptance and Commitment Therapy (PACT) Versus Usual Care Physical Therapy for Adults With Chronic Low Back Pain: A Randomized Controlled Trial.,"Chronic low back pain (CLBP) is a major cause of global disability and improving management is essential. Acceptance and commitment therapy (ACT) is a promising treatment for chronic pain but has not been modified for physical therapy. This randomized controlled trial (RCT) compared physical therapy informed by ACT (PACT) against standard care physical therapy for patients with CLBP. Patients with CLBP (duration ≥12 weeks, mean 3 years) were recruited from physical therapy clinics in 4 UK public hospitals. The Roland-Morris Disability Questionnaire (RMDQ) at 3 months' post-randomization was the primary outcome. Two hundred forty-eight participants (59% female, mean age = 48) were recruited and 219 (88.3%) completed measures at 3 and/or 12 months' follow-up. At 3 months, PACT participants reported better outcomes for disability (RMDQ mean difference = 1.07, p = .037, 95% CI = -2.08 to -.07, d = .2), Patient Specific Functioning (p = .008), SF12 physical health (p = .032), and treatment credibility (p < .001). At 12 months' follow-up, there were no significant differences between groups. PACT was acceptable to patients and clinicians and feasible to deliver. Physical therapists incorporated psychological principles successfully and treatment was delivered with high (≥80%) fidelity. Our results may inform the management of CLBP, with potential benefits for patients, health care providers, and society. PERSPECTIVE: Psychologically informed physical therapy has great potential but there are challenges in implementation. The training and support included in the PACT trial enabled the intervention to be delivered as planned. This successfully reduced disability in the short but not long term. Findings could inform physical therapists' treatment of CLBP.",2020,"At 3 months, PACT participants reported better outcomes for disability (RMDQ mean difference =1•07, p=0•037, 95%CI -2•08 to -0•07, d=0•2), Patient Specific Functioning (p=0.008), SF12 physical health (p=0.032), and treatment credibility (p<0.001).","['Patients with CLBP (duration ≥12 weeks, mean 3 years) were recruited from physical therapy clinics in four UK public hospitals', ""248 participants (59% female, mean age=48) were recruited and 219 (88•3%) completed measures at 3 and/or 12 months' follow-up"", 'Chronic low back pain (CLBP', 'adults with chronic low back pain', 'patients with CLBP']","['usual care physical therapy', 'PACT', 'physical therapy informed by Acceptance and Commitment Therapy (PACT) against standard care physical therapy', 'Physical therapy informed by Acceptance and Commitment Therapy (PACT', 'Acceptance and Commitment Therapy (ACT']","['Patient Specific Functioning', 'SF12 physical health', 'Roland-Morris Disability Questionnaire (RMDQ']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0020022', 'cui_str': 'Hospitals, Public'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C4517648', 'cui_str': '219 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain (finding)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0700287', 'cui_str': 'Informing (procedure)'}, {'cui': 'C3658321', 'cui_str': 'Acceptance and Commitment Therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",248.0,0.108932,"At 3 months, PACT participants reported better outcomes for disability (RMDQ mean difference =1•07, p=0•037, 95%CI -2•08 to -0•07, d=0•2), Patient Specific Functioning (p=0.008), SF12 physical health (p=0.032), and treatment credibility (p<0.001).","[{'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Godfrey', 'Affiliation': ""Health Psychology Section, Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Department of Physiotherapy, School of Population Health and Environmental Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. Electronic address: emma.l.godfrey@kcl.ac.uk.""}, {'ForeName': 'Vari', 'Initials': 'V', 'LastName': 'Wileman', 'Affiliation': ""Health Psychology Section, Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Galea Holmes', 'Affiliation': ""Health Psychology Section, Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Lance M', 'Initials': 'LM', 'LastName': 'McCracken', 'Affiliation': ""Health Psychology Section, Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Norton', 'Affiliation': ""Health Psychology Section, Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Rona', 'Initials': 'R', 'LastName': 'Moss-Morris', 'Affiliation': ""Health Psychology Section, Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Noonan', 'Affiliation': ""Guy's and St Thomas' Hospital NHS, St Thomas' Hospital, London, UK.""}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Barcellona', 'Affiliation': ""King's College Hospital NHS Foundation Trust, London, UK.""}, {'ForeName': 'Duncan', 'Initials': 'D', 'LastName': 'Critchley', 'Affiliation': ""Department of Physiotherapy, School of Population Health and Environmental Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.""}]",The journal of pain : official journal of the American Pain Society,['10.1016/j.jpain.2019.05.012'] 3151,31236731,Mesh fixation in open IPOM procedure with tackers or sutures? A randomized clinical trial with preliminary results.,"PURPOSE In open intra-peritoneal onlay mesh (IPOM) hernia repair, mesh fixation can be done by tacks, sutures or fibrin glue. There are randomized controlled trials (RCTs) on laparoscopic IPOM procedure, but no RCT so far has examined mesh fixation techniques in open IPOM repair. METHODS In a single-center RCT, 48 patients undergoing open IPOM repair of an abdominal wall hernia were included. After randomization, surgery was performed in a standardized fashion. Hernia size, extent of mesh fixation, and duration of surgery were documented. The primary endpoint was postoperative pain intensity. Secondary endpoints were: complications, length of stay, quality of life, return to work, hernia recurrence. Follow-up was 1 year in all 48 patients. RESULTS After using tacks, mean pain intensity was 16.9, which is slightly lower than after suture fixation (19.6, p = 0.20). The duration of surgery was about the same (83 vs. 85 min). When using tack fixation, significantly more fixation points were applied as compared to sutures (19 vs. 12; p = 0.02), although mesh size was similar. The complication rate was similar (tacks: 6/28 vs. sutures: 3/20). Cost of suture fixation was about 26 €, which is markedly lower than the 180 € associated with tacks. However, surgeons clearly preferred mesh fixation with tacks, because it is more comfortable especially in small hernias. CONCLUSIONS The present study failed to show an advantage of tacks over suture fixation and even there are more severe adverse events. Using tacks significantly increases the costs of hernia repair.",2020,"When using tack fixation, significantly more fixation points were applied as compared to sutures (19 vs. 12; p = 0.02), although mesh size was similar.",['48 patients undergoing open IPOM repair of an abdominal wall hernia were included'],"['open intra-peritoneal onlay mesh (IPOM) hernia repair, mesh fixation', 'sutures or fibrin glue', 'Mesh fixation']","['mean pain intensity', 'postoperative pain intensity', 'Hernia size, extent of mesh fixation, and duration of surgery', 'duration of surgery', 'complication rate', 'costs of hernia repair', 'Cost of suture fixation', 'complications, length of stay, quality of life, return to work, hernia recurrence', 'fixation points']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C0836916', 'cui_str': 'Abdominal Wall'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C0442034', 'cui_str': 'Peritoneal (qualifier value)'}, {'cui': 'C0677511', 'cui_str': 'Onlay (qualifier value)'}, {'cui': 'C0181805', 'cui_str': 'Mesh (physical object)'}, {'cui': 'C0019328', 'cui_str': 'Hernia Repair'}, {'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture (procedure)'}, {'cui': 'C0016004', 'cui_str': 'Fibrin Glue'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0439792', 'cui_str': 'Extents (qualifier value)'}, {'cui': 'C0181805', 'cui_str': 'Mesh (physical object)'}, {'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0019328', 'cui_str': 'Hernia Repair'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture (procedure)'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0034380'}, {'cui': 'C0425105', 'cui_str': 'Back to Work'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}]",48.0,0.202162,"When using tack fixation, significantly more fixation points were applied as compared to sutures (19 vs. 12; p = 0.02), although mesh size was similar.","[{'ForeName': 'M R', 'Initials': 'MR', 'LastName': 'Langenbach', 'Affiliation': 'Department of Surgery II, Helios St. Elisabeth Klinik Oberhausen, University of Witten/Herdecke, Josefstr. 3, 46045, Oberhausen, Germany. MRLangenbach@aol.com.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Enz', 'Affiliation': 'Department of Surgery II, Helios St. Elisabeth Klinik Oberhausen, University of Witten/Herdecke, Josefstr. 3, 46045, Oberhausen, Germany.'}]",Hernia : the journal of hernias and abdominal wall surgery,['10.1007/s10029-019-01991-z'] 3152,31609707,A randomized controlled trial on the use of magnesium sulfate and melatonin in neonatal hypoxic ischemic encephalopathy.,"BACKGROUND Birth asphyxia is a leading case of neonatal morbidity and mortality especially in developing countries. Hypoxic-ischemic encephalopathy (HIE) attributed to asphyxia can be ameliorated with several remedies, although full recovery is currently not feasible. The aim of this trial on infants with HIE who are receiving melatonin therapy, is to assess the added effect of magnesium sulfate (MgSO4) on the expression of S100-B, a marker of brain injury. METHODS This study is a randomized controlled trial on neonates with moderate HIE (Sarnat grade II). Infants were randomized into 2 groups; group1 who received MgSO4 and melatonin; and group 2 who received melatonin only. Serum concentrations of S100-B were measured at baseline, and at days 2 and 6 of therapy. RESULTS The study included 60 neonates of them 30 infants in group 1 and 30 infants in group 2. S100-B did not differ between groups 1 and 2 at enrollment (median = 13.5 vs 13.2, p = 0.381). However, group 1 had lower concentrations of S100-B at 2 days (median = 8 vs 12, p = 0.001) and at 6 days (median = 3 vs 10.5, p < 0.001), respectively. Compared to baseline, S100-B decreased in in group 2 at day 6 (13.2 vs 10.5, p = 0.011) but did not decrease at day 2 (13.2 vs 12, p = 0.478). CONCLUSIONS MgSO4 may have an added effect for the reduction in brain injury in infants with HIE who are receiving melatonin.",2019,"However, group 1 had lower concentrations of S100-B at 2 days (median = 8 vs 12, p = 0.001) and at 6 days (median = 3 vs 10.5, p < 0.001), respectively.","['60 neonates of them 30 infants in group 1 and 30 infants in group 2', 'neonatal hypoxic ischemic encephalopathy', 'neonates with moderate HIE (Sarnat grade II', 'infants with HIE who are receiving']","['magnesium sulfate (MgSO4', 'melatonin only', 'magnesium sulfate and melatonin', 'melatonin', 'MgSO4 and melatonin', 'melatonin therapy']","['Serum concentrations of S100-B', 'lower concentrations of S100-B']","[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0752304', 'cui_str': 'Hypoxic-Ischemic Encephalopathy'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}]","[{'cui': 'C0024480', 'cui_str': 'Magnesium Sulfate'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}]",60.0,0.281288,"However, group 1 had lower concentrations of S100-B at 2 days (median = 8 vs 12, p = 0.001) and at 6 days (median = 3 vs 10.5, p < 0.001), respectively.","[{'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'El Farargy', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Tanta University, Tanta, Egypt.'}, {'ForeName': 'N A', 'Initials': 'NA', 'LastName': 'Soliman', 'Affiliation': 'Department of Medical Biochemistry, Faculty of Medicine, Tanta University, Tanta, Egypt.'}]",Journal of neonatal-perinatal medicine,['10.3233/NPM-181830'] 3153,31587431,Er:YAG laser vs. sharp debridement in management of chronic wounds: Effects on pain and bacterial load.,"Chronic wounds affect roughly 6.5 million patients in the US annually. Current standard of therapy entails weekly sharp debridement. However, the sharp technique is associated with significant pain, while having minimal impact on the bioburden. Our study proposes the Er:YAG laser as an alternative method of debridement that may decrease procedural pain, reduce bioburden, and potentially improve overall healing. This pilot study was performed as a prospective, randomized, controlled, crossover clinical trial, containing two groups: (1) one group underwent single laser debridement session first, followed by single sharp debridement session one week later; and (2) the other group underwent single sharp debridement session first, followed by single laser debridement session one week later. Variables analyzed included pain during debridement, pre- and post-debridement wound sizes, pre- and post-debridement bacterial loads and patient preference. Twenty-two patients were enrolled (12 patients in Group 1, plus 10 patients in Group 2). The mean pain score for patients undergoing laser debridement was 3.0 ± 1.7 vs. 4.8 ± 2.6 for those undergoing sharp debridement (p = 0.003). The mean percent change in wound size 1-week post-laser debridement was -20.8% ± 80.1%, as compared with -36.7% ± 54.3% 1-week post-sharp debridement (p = 0.6). The percentage of patients who had a bacterial load in the low/negative category increased from 27.3% to 59.1% immediately after laser debridement (p = 0.04), vs. 54.5% to 68.2% immediately after sharp debridement (p = 0.38). Moreover, there was a sustained decrease in bacterial load 1-week post-laser debridement, as compared with no sustained decrease 1-week post-sharp debridement (p < 0.02). Overall, 52.9% of patients preferred laser debridement vs. 35.3% for sharp debridement. We believe that Er:YAG laser serves as a promising technology in chronic wounds, functioning as a potentially superior alternative to sharp debridement, the current standard of therapy.",2020,"Overall, 52.9% of patients preferred laser debridement versus 35.3% for sharp debridement.",['Chronic wounds affect roughly 6.5 million patients in the United States annually'],"['laser debridement', 'Er:YAG Laser versus Sharp Debridement']","['pain during debridement, pre- and post-debridement wound sizes, pre- and post-debridement bacterial loads and patient preference', 'mean pain score', 'bacterial load']","[{'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C3844007', 'cui_str': '6.5'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}]","[{'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0457903', 'cui_str': 'Erbium YAG Lasers'}, {'cui': 'C1444775', 'cui_str': 'Sharp'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C2936404', 'cui_str': 'Bacterial Load'}, {'cui': 'C0376409', 'cui_str': 'Patient Preference'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}]",22.0,0.0259278,"Overall, 52.9% of patients preferred laser debridement versus 35.3% for sharp debridement.","[{'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Hajhosseini', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Grace J', 'Initials': 'GJ', 'LastName': 'Chiou', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Gretchen', 'Initials': 'G', 'LastName': 'Dori', 'Affiliation': 'Advanced Wound Care Center, Stanford University School of Medicine, Redwood City, California.'}, {'ForeName': 'Eri', 'Initials': 'E', 'LastName': 'Fukaya', 'Affiliation': 'Advanced Wound Care Center, Stanford University School of Medicine, Redwood City, California.'}, {'ForeName': 'Venita', 'Initials': 'V', 'LastName': 'Chandra', 'Affiliation': 'Advanced Wound Care Center, Stanford University School of Medicine, Redwood City, California.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Meyer', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Geoffrey C', 'Initials': 'GC', 'LastName': 'Gurtner', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, California.'}]",Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society,['10.1111/wrr.12764']